ISSN: 0090-1423

National Library of Medicine

CUMULATED INDEX MEDICUS

Volume 37, 1996

Bibliography of
Medical Reviews

U.S. DEPARTMENT OF HEALTH
AND HUMAN SERVICES
Public Health Service
National Institutes of Health

NATIONAL LIBRARY OF MEDICINE
8600 Rockville Pike
Bethesda, Maryland 20894

NIH Publication No. 97-259

Book 17

© All or portions of this publication are protected against copying or other reproduction outside of the United States in accordance with the provisions of Article II of the Universal Copyright Convention.

National Library of Medicine Cataloging in Publication

Cumulated Index medicus.
Vol. 1 (Jan.-Dec. 1960)-
--Chicago : American Medical Association ; Washington, D.C. : Supt. of Docs., U.S. G.P.O. [distributor], 1961-
v.

Vols. for 1971-1978 issued as DHEW publication ; no. (NIH) 72-259, etc.; for 1979- as NIH publication ; no. 80-259, etc.
Annual cumulation of the monthly issues of Index medicus.
Continues: Quarterly cumulative Index medicus.
Issues for 1967- include Bibliography of medical reviews.
Vols. for 1965- issued by the National Library of Medicine.

1. Bibliography of Medicine 2. Medicine - indexes I. American Medical Association II. National Library of Medicine (U.S.). III. Bibliography of medical reviews IV. Index medicus V. Series: DHEW publication ; no. (NIH) 72-259, etc. VI. Series: NIH publication ; no. 80-259, etc.

ISSN 0090-1423 = Cumulated Index medicus.

ZW 1 I384

This book is printed on acid-free paper for permanence.

Use of funds for printing this periodical has been approved by the Director of the Office of Management and Budget through September 30, 1997.

For sale by the U.S. Government Printing Office
Superintendent of Documents, Mail Stop: SSOP, Washington, DC 20402-9328
ISBN 0-16-048940-7

CUMULATED INDEX MEDICUS 1996

CONTENTS

BOOK 1

Preface v
Index Medicus Citation Format vii
Introduction viii
Materials Indexed viii
The Indexing Operation viii
Subject Heading Changes ix
Arrangement ix
Subject Section ix
Author Section xi
Bibliography of Medical Reviews xi
Access to Articles Cited xii
Interlibrary Loan Policy xii
Other Resources xiv
National Network of Libraries of Medicine xiv
International MEDLARS/MEDLINE Centers xv

MEDICAL SUBJECT HEADINGS (Contents) I-3
Medical Subject Headings 1

JOURNALS INDEXED Abbreviation Listing 1393
Full Title Listing 1489

BOOK 2 Subject Index **A** 1565

BOOK 3 Subject Index **B-Chi** 2972

BOOK 4 Subject Index **Chl-Do** 4295

BOOK 5 Subject Index **Dr-Geo** 5591

BOOK 6 Subject Index **Ger-Ino** 6929

BOOK 7 Subject Index **Inp-Mei** 8260

BOOK 8 Subject Index **Mel-Or** 9583

BOOK 9 Subject Index **Os-Psi** 10915

BOOK 10 Subject Index **Pso-Sr** 12241

BOOK 11 Subject Index **St-Z** 13570

BOOK 12 Author Index **A-Dh** 14907

BOOK 13 Author Index **Di-Jd** 16222

BOOK 14 Author Index **Je-Mor** 17550

BOOK 15 Author Index **Mos-She** 18896

BOOK 16 Author Index **Shi-Z** 20223

BOOK 17 Bibliography of Medical Reviews 21539

BIBLIOGRAPHY OF MEDICAL REVIEWS

From 1955 through 1987, the Library defined medical reviews as well-documented surveys of the recent biomedical literature. In response to user requests, the library broadened this definition in 1988 to encompass reviews of current thinking on a given subject, regardless of the age of the literature cited, and to include categories of material previously excluded. Types of articles now considered to be reviews include academic, or classical, reviews; tutorial, or didactic or subject, reviews; multicase, or epidemiologic, reviews; consensus conferences; reviews of known or published cases; and state of the art reviews.

Materials with the following characteristics are not considered as reviews: case reports or original research articles containing a review of the literature as an adjunct; statistical and epidemiological surveys; bibliographies which comprise only a list of references; historical articles; monthly summaries of a subject area which appear as a regular feature in journals; and theses.

Citations to reviews are included in the "Bibliography of Medical Reviews" section of the monthly INDEX MEDICUS and CUMULATED INDEX MEDICUS, as well as in the Subject Section and Author Section of each. In the latter sections, users will be able to distinguish review articles from standard citations by the number of references shown in parentheses at the end of the source. "0 ref." will indicate that the bibliographic references were not printed in the article.

A FIBERS see NERVE FIBERS, MYELINATED

ABATTOIRS

STANDARDS

Use of antimicrobial agents in official abattoirs under meat inspection in the United States of America. Patch MA. **Rev Sci Tech** 1995 Jun;14(2):309–12 (4 ref.)

ABC TRANSPORTERS

ANALYSIS

How to probe clinical tumour samples for P-glycoprotein and multidrug resistance-associated protein. Broxterman HJ, et al. **Eur J Cancer** 1996 Jun;32A(6):1024–33 (86 ref.)

CLASSIFICATION

Phylogenetic analyses of the ATP-binding constituents of bacterial extracytoplasmic receptor-dependent ABC-type nutrient uptake permeases. Kuan G, et al. **Res Microbiol** 1995 May;146(4):271–8 (16 ref.)

GENETICS

MHC-encoded TAP genes in rheumatic diseases [editorial] Coakley G, et al. **Br J Rheumatol** 1996 Jun;35(6):501–3 (20 ref.)

Evolution of ATP-binding cassette transporter genes. Dean M, et al. **Curr Opin Genet Dev** 1995 Dec;5(6):779–85 (42 ref.)

Locoregional immuno-chemotherapy transplenic and transtumoral in vivo immunostimulation. Lygidakis NJ, et al. **Hepatogastroenterology** 1996 Mar-Apr;43(8):440–7 (38 ref.)

IMMUNOLOGY

How selective is the transporter associated with antigen processing? Androlewicz MJ, et al. **Immunity** 1996 Jul; 5(1):1–5 (41 ref.)

METABOLISM

Multidrug resistance proteins and other drug transport-related resistance to natural product agents. Broxterman HJ, et al. **Curr Opin Oncol** 1995 Nov; 7(6):532–40 (78 ref.)

Biology of membrane transport proteins. Sadée W, et al. **Pharm Res** 1995 Dec;12(12):1823–37 (105 ref.)

PHYSIOLOGY

Experimental modulation of MRP (multidrug resistance-associated protein)-mediated resistance. Twentyman PR, et al. **Eur J Cancer** 1996 Jun; 32A(6):1002–9 (61 ref.)

Neurotransmitter transporters: molecular biology, function, and regulation. Borowsky B, et al. **Int Rev Neurobiol** 1995; 38:139–99 (250 ref.)

The role of mdr2 P-glycoprotein in biliary lipid secretion. Cross-talk between cancer research and biliary physiology. Oude Elferink RP, et al. **J Hepatol** 1995 Nov;23(5):617–25 (62 ref.)

ABDOMEN

Cephalosporin-metronidazole combinations in the management of intra-abdominal infections. Nicolau DP, et al. **Diagn Microbiol Infect Dis** 1995 May-Jun; 22(1-2):189–94 (28 ref.)

Bilateral giant abdominoscrotal hydroceles in childhood. Serels S, et al. **Urology** 1996 May;47(5):763–5 (15 ref.)

[Abdominal pseudotumor and Whipple's disease] Guilera M, et al. **Gastroenterol Hepatol** 1996 May;19(5):247–9 (16 ref.) (Eng. Abstr.) **(Spa)**

BLOOD SUPPLY

MR angiography of abdominal and peripheral arteries. Techniques and clinical applications. Ekelund L, et al. **Acta Radiol** 1996 Jan;37(1):3–13 (109 ref.)

Vascular abdominal emergencies. Walker JS, et al. **Emerg Med Clin North Am** 1996 Aug;14(3):571–92 (85 ref.)

Magnetic resonance angiography of systemic thoracic and abdominal veins. Hartnell GG. **Magn Reson Imaging Clin N Am** 1993 Dec;1(2):281–94 (49 ref.)

Phase-contrast magnetic resonance angiography in the abdomen and thorax. Yuasa Y. **Magn Reson Imaging Clin N Am** 1993 Dec;1(2):327–38 (25 ref.)

PATHOLOGY

The female pelvic mass. Diagnosis and management. Russell DJ. **Med Clin North Am** 1995 Nov;79(6):1481–93 (19 ref.)

PHYSIOPATHOLOGY

The abdominal compartment syndrome. Burch JM, et al. **Surg Clin North Am** 1996 Aug;76(4):833–42 (35 ref.)

SURGERY

A "bicycle-handlebar" type of incision for primary and secondary abdominoplasty. Baroudi R, et al. **Aesthetic Plast Surg** 1995 Jul-Aug;19(4):307–20 (27 ref.)

Acute ventilatory complications during laparoscopic upper abdominal surgery. Wahba RW, et al. **Can J Anaesth** 1996 Jan;43(1):77–83 (35 ref.)

Endoscopic abdominoplasty with repair of diastasis recti and abdominal wall hernia. Core GB, et al. **Clin Plast Surg** 1995 Oct;22(4):707–22 (14 ref.)

Endoscopic abdominoplasty, mastopexy, and breast reduction. Faria-Correa MA. **Clin Plast Surg** 1995 Oct; 22(4):723–45 (9 ref.)

The trauma celiotomy: the evolving concepts of damage control. Morris JA Jr, et al. **Curr Probl Surg** 1996 Aug; 33(8):611–700 (341 ref.)

[Cardiovascular function during laparoscopic interventions in surgery and gynecology] Berg K, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Nov; 30(7):446–50 (28 ref.) **(Ger)**

ULTRASONOGRAPHY

Areas of increased echogenicity in the fetal abdomen: diagnosis and significance. Rypens FF, et al. **Radiographics** 1995 Nov;15(6):1329–44; discussion 1344–5 (58 ref.)

Ultrasonography of the acute pediatric abdomen. Hayden CK Jr. **Radiol Clin North Am** 1996 Jul;34(4):791–806 (86 ref.)

The significance of echogenic areas in the fetal abdomen. Carroll SG, et al. **Ultrasound Obstet Gynecol** 1996 Apr; 7(4):293–8 (58 ref.)

[Ultrasound findings in HIV patients] Lüthen R, et al. **Bildgebung** 1995 Dec;62(4):271–80 (45 ref.) (Eng. Abstr.) **(Ger)**

ABDOMEN, ACUTE

DIAGNOSIS

Cost-effective evaluation and management of the acute abdomen. Gill BD, et al. **Surg Clin North Am** 1996 Feb; 76(1):71–82 (13 ref.)

ECONOMICS

Cost-effective evaluation and management of the acute abdomen. Gill BD, et al. **Surg Clin North Am** 1996 Feb; 76(1):71–82 (13 ref.)

ETIOLOGY

Acute abdomen from pedicle torsion ectopic pelvic spleen. A case report and review of the literature. Pizzo A, et al. **Clin Exp Obstet Gynecol** 1996;23(1):37–8 (5 ref.)

Vascular abdominal emergencies. Walker JS, et al. **Emerg Med Clin North Am** 1996 Aug;14(3):571–92 (85 ref.)

Spontaneous hemoperitoneum. Lucha PA Jr. **J Am Osteopath Assoc** 1996 Jun;96(6):364–5 (7 ref.)

[Abdominal emergencies of infectious origin] Porcel A, et al. **Ann Radiol (Paris)** 1996;39(1):15–36 (20 ref.) (Eng. Abstr.) **(Fre)**

[Acute solitary diverticulitis of the cecum, a rare cause of acute abdomen. Apropos of 9 cases and review of the literature] Villalba Caballero R, et al. **J Chir (Paris)** 1995 Jun-Jul;132(6-7):299–304 (25 ref.) (Eng. Abstr.) **(Fre)**

[The torsion of an accessory liver lobe as the rare cause of acute abdomen] Betge L. **Dtsch Med Wochenschr** 1995 Sep 29;120(39):1318–20 (11 ref.) (Eng. Abstr.) **(Ger)**

[Peritoneal mesothelioma as a rare case of acute abdomen. Review of the literature] Cipollone G, et al. **Chir Ital** 1994; 46(6):73–9 (86 ref.) (Eng. Abstr.) **(Ita)**

[Spontaneous bladder perforation secondary to bacterial cystitis. Cause of acute abdomen in diabetic elderly] Rodríguez Rodríguez A, et al. **Actas Urol Esp** 1995 May; 19(5):393–7 (14 ref.) (Eng. Abstr.) **(Spa)**

RADIOGRAPHY

[Interventional radiology and aodominal emergencies] Rotenberg L, et al. **Ann Radiol (Paris)** 1996;39(2):89–103 (35 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

[Surgery in childhood at the hospital for basic and routine general management] Willital GH. **Chirurg** 1996 Jun; 67(6):567–75 (28 ref.) (Eng. Abstr.) **(Ger)**

ULTRASONOGRAPHY

Ultrasonography of the acute pediatric abdomen. Hayden CK Jr. **Radiol Clin North Am** 1996 Jul;34(4):791–806 (86 ref.)

ABDOMINAL ABSCESS

DIAGNOSIS

Abdominal actinomycosis. Cintron JR, et al. **Dis Colon Rectum** 1996 Jan;39(1):105–8 (10 ref.)

[Diagnosis and therapy of intra-abdominal abscesses] Rieber A. **Rontgenpraxis** 1995 Dec;48(12):335–9 (18 ref.) **(Ger)**

ETIOLOGY

Jejunal diverticulitis manifesting with abdominal wall abscess. Alvarez OA, et al. **Am J Gastroenterol** 1995 Nov; 90(11):2060–2 (10 ref.)

MICROBIOLOGY

Structure and function of Bacteroides fragilis capsular polysaccharides: relationship to induction and prevention of abscesses. Tzianabos AO, et al. **Clin Infect Dis** 1995 Jun; 20 Suppl 2:S132–40 (35 ref.)

RADIOGRAPHY

Clostridial infection of the abdomen: CT findings in two successfully treated patients. Spencer JA, et al. **AJR Am J Roentgenol** 1996 May;166(5):1094–6 (8 ref.)

SURGERY

Abdominal actinomycosis. Cintron JR, et al. **Dis Colon Rectum** 1996 Jan;39(1):105–8 (10 ref.)

ABDOMINAL CRAMPS see **COLIC**

ABDOMINAL INJURIES

Blunt trauma to the abdomen. Haller JA Jr. **Pediatr Rev** 1996 Jan;17(1):29–31 (8 ref.)

COMPLICATIONS

Traumatic lumbar hernia: a seat belt injury. McCarthy MC, et al. **J Trauma** 1996 Jan;40(1):121–2 (10 ref.)

Renal artery pseudoaneurysm after blunt abdominal trauma: case report and literature review. Swana HS, et al. **J Trauma** 1996 Mar;40(3):459–61 (15 ref.)

Intra-abdominal injury with handlebar hernia: case report and literature review. Yarbrough DR 3rd. **J Trauma** 1996 Jan;40(1):116–8 (21 ref.)

Intravascular stenting of traumatic abdominal aortic dissection. Marty-Ané CH, et al. **J Vasc Surg** 1996 Jan; 23(1):156–61 (13 ref.)

Splenic Injuries in children after blunt abdominal trauma. Benya EC, et al. **Semin Ultrasound CT MR** 1996 Apr; 17(2):170–6 (31 ref.)

Diagnosis of pancreatic injury after blunt abdominal trauma. Lane MJ, et al. **Semin Ultrasound CT MR** 1996 Apr; 17(2):177–82 (29 ref.)

Gastric bezoar following penetrating abdominal injury. Diagnosis and endoscopic therapy. Kaplan LJ, et al. **Surg Endosc** 1996 Jan;10(1):62–4 (16 ref.)

[Atrio-caval shunt in injury to the suprahepatic vena cava. Apropos of a case and review of the literature] Orsoni P, et al. **J Chir (Paris)** 1995 Nov;132(11):438–41 (24 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Blunt abdominal injuries. Diagnostic peritoneal lavage, ultrasonography and computed tomography scanning. Chiquito PE. **Injury** 1996 Mar;27(2):117–24 (92 ref.)

[Abdominal injuries] Monnier-Cholley L, et al. **Ann Radiol (Paris)** 1996;39(1):45–56 (26 ref.) (Eng. Abstr.) **(Fre)**

[Blunt and penetrating abdominal trauma. Patient assessment algorithm and principles for management] Ertel W, et al. **Unfallchirurg** 1996 Apr;99(4):288–303 (28 ref.) **(Ger)**

EPIDEMIOLOGY

A review of intestinal injury from blunt abdominal trauma. Munns J, et al. **Aust N Z J Surg** 1995 Dec;65(12):857–60 (15 ref.)

ETIOLOGY

Lumbar compression fractures secondary to lap-belt use in children. Sturm PF, et al. **J Pediatr Orthop** 1995 Jul–Aug; 15(4):521–3 (27 ref.)

Shotgun slug injuries: case report and literature review. Gestring ML, et al. **J Trauma** 1996 Apr;40(4):650–3 (23 ref.)

[Urogenital injuries caused by projectiles. Data on recent conflicts and the North-American civilian experience] Houdelette P. **J Chir (Paris)** 1995 Oct;132(10):375–81 (19 ref.) (Eng. Abstr.) **(Fre)**

NURSING

Management of upper abdominal solid organ injuries. Richardson JD, et al. **AORN J** 1996 May;63(5):907–16 (15 ref.)

PHYSIOPATHOLOGY

Blunt abdominal trauma. Boulanger BR, et al. **Emerg Med Clin North Am** 1996 Feb;14(1):151–71 (89 ref.)

RADIOGRAPHY

Radiologic management of abdominal trauma in pregnancy. Goldman SM, et al. **AJR Am J Roentgenol** 1996 Apr; 166(4):763–7 (33 ref.)

Diagnostic imaging in the evaluation of blunt abdominal trauma. Barloon TJ, et al. **Am Fam Physician** 1996 Jul; 54(1):205–9 (20 ref.)

CT of abdominal and pelvic trauma. Roberts JL. **Semin Ultrasound CT MR** 1996 Apr;17(2):142–69 (71 ref.)

SURGERY

Management of upper abdominal solid organ injuries. Richardson JD, et al. **AORN J** 1996 May;63(5):907–16 (15 ref.)

Visceral injury. Porter JM, et al. **Curr Opin Gen Surg** 1993; :62–8 (31 ref.)

The trauma celiotomy: the evolving concepts of damage control. Morris JA Jr, et al. **Curr Probl Surg** 1996 Aug; 33(8):611–700 (341 ref.)

Abdominal vascular injuries. Mullins RJ, et al. **Surg Clin North Am** 1996 Aug;76(4):813–32 (45 ref.)

Laparoscopy in trauma. Poole GV, et al. **Surg Clin North Am** 1996 Jun;76(3):547–56 (48 ref.)

Polypropylene mesh closure after emergency laparotomy: morbidity and outcome. Brandt CP, et al. **Surgery** 1995 Oct;118(4):736–40; discussion 740–1 (17 ref.)

[Surgery in childhood at the hospital for basic and routine general management] Willital GH. **Chirurg** 1996 Jun; 67(6):567–75 (28 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

[Resuscitation in severe hepatic injuries] Wodey E, et al. **Cah Anesthesiol** 1996;44(1):55–69 (131 ref.) (Eng. Abstr.) **(Fre)**

ULTRASONOGRAPHY

Ultrasonography for the initial evaluation of blunt abdominal trauma: A review of prospective trials. Pearl WS, et al. **Ann Emerg Med** 1996 Mar;27(3):353–61 (36 ref.)

ABDOMINAL MUSCLES

Jejunal diverticulitis manifesting with abdominal wall abscess. Alvarez OA, et al. **Am J Gastroenterol** 1995 Nov; 90(11):2060–2 (10 ref.)

Retroperitoneal and abdominal wall emphysema after transanal excision of a rectal carcinoma. Petros JG, et al. **Am Surg** 1996 Sep;62(9):759–61 (8 ref.)

Heterotopic ossification in adenocarcinoma of the colon. Hui Y, et al. **Chin Med J (Engl)** 1995 Oct;108(10):798–800 (2 ref.)

Abdominal wall metastasis and peritoneal carcinomatosis after laparoscopic-assisted colectomy for colon cancer. Jacquet P, et al. **Eur J Surg Oncol** 1995 Oct;21(5):568–70 (25 ref.)

Chondroid syringoma of the abdominal wall. A case report and review of the literature. Sliwa-Hähnle K, et al. **S Afr J Surg** 1996 Feb;34(1):46–8 (15 ref.)

Abdominal wall metastasis following percutaneous endoscopic gastrostomy. Becker G, et al. **Support Care Cancer** 1995 Sep;3(5):313–6 (18 ref.)

[Endometriosis of the abdominal wall. A report of a case secondary to cesarean section] Capanna A, et al. **G Chir** 1995 Aug–Sep;16(8–9):352–6 (19 ref.) (Eng. Abstr.) **(Ita)**

ABNORMALITIES

[Diagnostic-therapeutic concept in abnormalities of the abdominal wall and diaphragm] Terinde R, et al. **Gynakologe** 1995 Oct;28(5):368–83 (84 ref.) **(Ger)**

RADIOGRAPHY

[Imaging of connective tissue formations of the sub-umbilical anterior abdominal wall] Roy C, et al. **Ann Radiol (Paris)** 1995;38(7–8):389–95 (20 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Necrotizing fasciitis following laparoscopic surgery. Case report and review of the literature. Golshani S, et al. **Surg Endosc** 1996 Jul;10(7):751–4 (20 ref.)

Polypropylene mesh closure after emergency laparotomy: morbidity and outcome. Brandt CP, et al. **Surgery** 1995 Oct;118(4):736–40; discussion 740–1 (17 ref.)

[Pathophysiology of the abdominal wall] Klinge U, et al. **Chirurg** 1996 Mar;67(3):229–33 (12 ref.) (Eng. Abstr.) **(Ger)**

[Reconstructive surgery using the flaps pedicled by rectus abdominis muscle or deep inferior epigastric artery] Hyakusoku H. **Nippon Ika Daigaku Zasshi** 1995 Dec; 62(6):567–73 (22 ref.) **(Jpn)**

ABDOMINAL NEOPLASMS

COMPLICATIONS

Malignant ascites. Parsons SL, et al. **Br J Surg** 1996 Jan; 83(1):6–14 (92 ref.)

Intestinal obstruction. Baines MJ. **Cancer Surv** 1994;21:147–56 (32 ref.)

A child with an intra-abdominal testicular teratoma: a case report and review of prepubertal cryptorchid germ cell tumors. Brown IR, et al. **Urology** 1995 Dec;46(6):863–6 (27 ref.)

DIAGNOSIS

Desmoplastic small cell tumor: a report of three cases and a review of the literature. Kretschmar CS, et al. **J Pediatr Hematol Oncol** 1996 Aug;18(3):293–8 (29 ref.)

[Desmoplastic small round cell tumors in adults: a new entity] Farhat F, et al. **Bull Cancer (Paris)** 1995 Aug;82(8):665–73 (39 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Abdominal wall metastasis and peritoneal carcinomatosis after laparoscopic-assisted colectomy for colon cancer. Jacquet P, et al. **Eur J Surg Oncol** 1995 Oct;21(5):568–70 (25 ref.)

Basal cell carcinoma due to radiotherapy for carcinoma of the cervix. Copas P, et al. **South Med J** 1995 Nov; 88(11):1161–2 (12 ref.)

Abdominal wall metastasis following percutaneous endoscopic gastrostomy. Becker G, et al. **Support Care Cancer** 1995 Sep;3(5):313–6 (18 ref.)

GENETICS

[Identification of the breakpoint-flanking markers on chromosomes 1 and 17 of a constitutional translocation T(1;17)(P36;Q12–21) in a patient with neuroblastoma] Laureys GG. **Verh K Acad Geneeskd Belg** 1995; 57(5):389–422 (65 ref.) (Eng. Abstr.) **(Dut)**

PATHOLOGY

Adult extrarenal Wilms' tumor. A case report. Gürsoy R, et al. **Gynecol Obstet Invest** 1995;40(2):141–4 (7 ref.)

Extrarenal Wilms' tumour--a case report and review of literature. Waingankar VS, et al. **Indian J Cancer** 1995 Sep; 32(3):135–40 (33 ref.)

RADIOTHERAPY

[Radiation injury of the small intestine. Radiobiological, radiopathological aspects; risk factors and prevention] Touboul E, et al. **Ann Chir** 1996;50(1):58–71 (95 ref.) (Eng. Abstr.) **(Fre)**

SECONDARY

Strategies to decrease the incidence of intra-abdominal recurrence in resectable gastric cancer. Averbach AM, et al. **Br J Surg** 1996 Jun;83(6):726–33 (103 ref.)

Imaging of abdominal nodal spread in malignant disease. Delorme S, et al. **Eur Radiol** 1996;6(3):262–74 (47 ref.)

Abdominal wall metastasis following percutaneous endoscopic gastrostomy. Becker G, et al. **Support Care Cancer** 1995 Sep;3(5):313–6 (18 ref.)

[Implantation metastases following laparoscopic cholecystectomy in gallbladder carcinoma] Buhr J, et al. **Dtsch Med Wochenschr** 1996 Jan 19;121(3):57–61; discussion 61–2 (36 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

[Surgical therapy of soft tissue sarcoma. I. General principles and resections of the trunk] Karakousis CP. **Chirurg** 1995 Sep;66(9):905–13 (17 ref.) (Eng. Abstr.) **(Ger)**

VETERINARY

Radiation therapy of thoracic and abdominal tumors. LaRue SM, et al. **Semin Vet Med Surg (Small Anim)** 1995 Aug; 10(3):190–6 (32 ref.)

ABDOMINAL PAIN

see related
COLIC

Noncardiac chest pain and abdominal pain. Ho K. **Ann Emerg Med** 1996 Apr;27(4):457–60 (24 ref.)

Acute abdominal pain in children. Davenport M. **BMJ** 1996 Feb 24;312(7029):498–501 (0 ref.)

Abdominal migraine as a cause of vomiting in children: a clinician's view. Bentley D, et al. **J Pediatr Gastroenterol Nutr** 1995;21 Suppl 1:S49–51 (15 ref.)

DIAGNOSIS

Abdominal pain in the postpartum: role of imaging. Van Hoe L, et al. **J Belge Radiol** 1995 Jun;78(3):186–9 (17 ref.)

ETIOLOGY

Boerhaave's syndrome presenting with abdominal pain and right hydropneumothorax. Jagminas L, et al. **Am J Emerg Med** 1996 Jan;14(1):53–6 (46 ref.)

Recurrent abdominal pain in children. Hyams JS. **Curr Opin Pediatr** 1995 Oct;7(5):529–32 (19 ref.)

The evaluation of acute abdominal pain in children. Mason JD. **Emerg Med Clin North Am** 1996 Aug;14(3):629–43 (73 ref.)

Unusual causes of abdominal pain. Pearigen PD. **Emerg Med Clin North Am** 1996 Aug;14(3):593–613 (75

ref.)
Evaluation of abdominal pain in the elderly. Sanson TG, et al. **Emerg Med Clin North Am** 1996 Aug;14(3):615–27 (68 ref.)
Foreign bodies of dental origin in the appendix. Mellor TK, et al. **J R Army Med Corps** 1995 Oct;141(3):174–6 (25 ref.)

PATHOLOGY

[A 27-year-old woman with abdominal pain, vomiting, dark urine and hyponatremia (clinical conference)] **Rev Clin Esp** 1995 Oct;195(10):726–36 (74 ref.) **(Spa)**

PSYCHOLOGY

A frequent attender. Crossley N, et al. **Practitioner** 1995 Nov; 239(1556):631–2, 635–8 (3 ref.)

ABDOMINAL WALL see **ABDOMINAL MUSCLES**

ABDUCENS NERVE

Simultaneous, multiple cranial neuropathies in diabetes mellitus. Eshbaugh CG, et al. **J Neuroophthalmol** 1995 Dec; 15(4):219–24 (23 ref.)

ABERRANT TISSUE see **CHORISTOMA**

ABH BLOOD GROUP see **ABO BLOOD-GROUP SYSTEM**

ABL GENES see **GENES, ABL**

ABL PROTO-ONCOGENE PROTEINS see **PROTO-ONCOGENE PROTEINS C-ABL**

ABLATION, TRANSVENOUS ELECTRIC see **CATHETER ABLATION**

ABNORMAL FIBRINOGENS see **FIBRINOGENS, ABNORMAL**

ABNORMALITIES

Telling parents their child has severe congenital anomalies. Ryan S. **Postgrad Med J** 1995 Sep;71(839):529–33 (14 ref.)

DIAGNOSIS

Mild errors of morphogenesis. Frias JL, et al. **Adv Pediatr** 1996;43:27–75 (194 ref.)
Assessing congenital anomalies after preimplantation genetic diagnosis. Simpson JL, et al. **J Assist Reprod Genet** 1996 Feb;13(2):170–6 (30 ref.)
Genetic and congenital defect conditions that mimic child abuse. Wardinsky TD. **J Fam Pract** 1995 Oct;41(4):377–83 (26 ref.)
[Improved prenatal diagnostic possibilities for congenital abnormalities and chromosomal disorders. Advantages and disadvantages of screening and diagnostic methods] Nørgaard-Pedersen B, et al. **Ugeskr Laeger** 1996 Feb 26; 158(9):1201–7 (29 ref.) (Eng. Abstr.) **(Dan)**
[Applications of magnetic resonance tomography (MRT) in obstetrics] Wischnik A, et al. **Gynäkologe** 1995 Oct; 28(5):321–8 (18 ref.) **(Ger)**

EMBRYOLOGY

[Uterine malformations. Diagnosis, prognosis and treatment] Brun JL, et al. **Presse Med** 1995 Nov 18;24(35):1658–62 (25 ref.) (Eng. Abstr.) **(Fre)**

EPIDEMIOLOGY

Pre-conception care of diabetes, congenital malformations, and spontaneous abortions. Kitzmiller JL, et al. **Diabetes Care** 1996 May;19(5):514–41 (324 ref.)
The prevalence of genetic disorders, birth defects and syndromes in central and eastern Kentucky. Cadle RG, et al. **J Ky Med Assoc** 1996 Jun;94(6):237–41 (15 ref.)
Maternal obesity increases congenital malformations. Prentice A, et al. **Nutr Rev** 1996 May;54(5):146–50 (19 ref.)

ETIOLOGY

Genetic risk in micromanipulative assisted reproduction. Meschede D, et al. **Hum Reprod** 1995 Nov;10(11):2880–6 (72 ref.)
Congenital defects, folic-acid, and homoeobox genes. Milunsky A. **Lancet** 1996 Aug 17;348(9025):419–20 (8 ref.)
Maternal obesity increases congenital malformations. Prentice A, et al. **Nutr Rev** 1996 May;54(5):146–50 (19 ref.)
The pathogenesis of diabetes-associated congenital malformations. Reece EA, et al. **Obstet Gynecol Clin North Am** 1996 Mar;23(1):29–45 (144 ref.)
The new dysmorphology: application of insights from basic developmental biology to the understanding of human birth defects. Epstein CJ. **Proc Natl Acad Sci U S A** 1995 Sep 12;92(19):8566–73 (92 ref.)
Heat shock proteins and teratogenesis. Buckiová D, et al. **Reprod Toxicol** 1995 Nov-Dec;9(6):501–11 (120 ref.)
Hyperthermia and birth defects. Edwards MJ, et al. **Reprod Toxicol** 1995 Sep-Oct;9(5):411–25 (109 ref.)
[Smoking and pregnancy] Wenderlein JM. **Z Arztl Fortbild (Jena)** 1995 Oct;89(5):467–71 (15 ref.) (Eng. Abstr.) **(Ger)**
[European study of working mothers and congenital malformations] Candela S, et al. **Epidemiol Prev** 1996 Apr-Sep;20(2-3):183–5 (17 ref.) **(Ita)**
[Folate deficiency, cancer and congenital abnormalities. Is there a connection?] Christensen B. **Tidsskr Nor Laegeforen** 1996 Jan 20;116(2):250–4 (45 ref.) (Eng. Abstr.) **(Nor)**

GENETICS

Finding genes involved in human developmental disorders. Muenke M. **Curr Opin Genet Dev** 1995 Jun;5(3):354–61 (80 ref.)
Recent molecular advances in dysmorphology. Winter RM. **Hum Mol Genet** 1995;4 Spec No:1699–704 (87 ref.)
Genetic risk in micromanipulative assisted reproduction. Meschede D, et al. **Hum Reprod** 1995 Nov;10(11):2880–6 (72 ref.)
Prenatal diagnosis of genetic disorders. Kulkarni ML, et al. **Indian Pediatr** 1995 Nov;32(11):1229–38 (28 ref.)
Mutations, malformations and mortality. Suthers G. **J Paediatr Child Health** 1996 Feb;32(1):10–5 (67 ref.)

PHYSIOPATHOLOGY

Cell death in normo- and teratogenesis. I. Cell death in normogenesis. Sandor S, et al. **Rom J Morphol Embryol** 1994 Jul-Dec;40(3-4):69–81 (79 ref.)
Cell death in normo- and teratogenesis. II. Cell death in teratogenesis. Sandor S, et al. **Rom J Morphol Embryol** 1994 Jul-Dec;40(3-4):83–91 (67 ref.)

PREVENTION & CONTROL

Prevention of birth defects: a task for a world alliance. Wertelecki W, et al. **Acta Paediatr Sin** 1996 May-Jun; 37(3):168–72 (57 ref.)
Primary prevention of birth defects by periconceptional care, including multivitamin supplementation. Czeizel AE. **Baillieres Clin Obstet Gynaecol** 1995 Sep;9(3):417–30 (26 ref.)
Diabetes. Oats JN. **Baillieres Clin Obstet Gynaecol** 1995 Sep; 9(3):481–95 (67 ref.)
A multiple-level, comprehensive approach to the prevention of fetal alcohol syndrome (FAS) and other alcohol-related birth defects (ARBD). May PA. **Int J Addict** 1995; 30(12):1549–602 (160 ref.)

THERAPY

[Induced delivery in fetal malformations] Boog G. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24 Suppl 1:54–6 (22 ref.) **(Fre)**

ULTRASONOGRAPHY

Comprehensive ultrasound examination in a private perinatal practice. Ott WJ, et al. **Am J Perinatol** 1995 Nov; 12(6):385–91 (14 ref.)
Ultrasound screening for fetal abnormalities [see comments] Chitty LS. **Prenat Diagn** 1995 Dec;15(13):1241–57 (74 ref.) Comment in: Prenat Diagn 1995 Dec;15(13):1209–13.
Fetal structural disorders—the large series are emerging [comment] Eik-Nes SH. **Ultrasound Obstet Gynecol** 1995 Jun;5(6):364–5 (10 ref.) Comment on: Ultrasound Obstet Gynecol 1995 Jun;5(6):366–71. Comment on: Ultrasound Obstet Gynecol 1995 Jun;5(6):372–80.
IRONFAN—a sonographic window into the natural history of fetal anomalies. International Registry of the Onset of Fetal Anomalies [editorial] Rottem S. **Ultrasound Obstet Gynecol** 1995 Jun;5(6):361–3 (6 ref.)
[Potential 3-dimensional (3D-)ultrasound in the diagnosis of fetal abnormalities] Steiner H. **Gynakologe** 1995 Oct; 28(5):315–20 (31 ref.) **(Ger)**
[Use of 3D ultrasound technique in prenatal diagnosis] Merz E. **Ultraschall Med** 1995 Aug;16(4):154–61 (28 ref.) (Eng. Abstr.) **(Ger)**
[Polyhydramnios and its relationship with congenital malformations: ultrasonographic diagnosis] Gaxiola Castro R, et al. **Ginecol Obstet Mex** 1995 Dec;63:505–8 (12 ref.) (Eng. Abstr.) **(Spa)**

ABNORMALITIES, DRUG-INDUCED

see related
TERATOGENS

Prenatal exposure to phenytoin, facial development, and a possible role for vitamin K. Howe AM, et al. **Am J Med Genet** 1995 Sep 11;58(3):238–44 (52 ref.)
Hand anomalies in fetal-hydantoin syndrome: from nail/phalangeal hypoplasia to unilateral acheiria [letter] Sabry MA, et al. **Am J Med Genet** 1996 Apr 24;62(4):410–2 (34 ref.)
Considerations of prescription medications for the pregnant podiatric patient. Haverstock BD, et al. **J Am Podiatr Med Assoc** 1996 Jul;86(7):334–46 (108 ref.)
Pharmacologic treatment of psychiatric disease in pregnancy and lactation: fetal and neonatal effects. Kuller JA, et al. **Obstet Gynecol** 1996 May;87(5 Pt 1):789–94 (38 ref.)
Reactive oxygen species in developmental toxicity: review and hypothesis. Fantel AG. **Teratology** 1996 Mar; 53(3):196–217 (123 ref.)
Teratogen update: ergot and ergotamine. Raymond GV. **Teratology** 1995 May;51(5):344–7 (19 ref.)
Developmental effects of dioxins and related endocrine disrupting chemicals. Birnbaum LS. **Toxicol Lett** 1995 Dec; 82-83:743–50 (60 ref.)
[Teratogenic effects of exogenous agents] Graça LM, et al. **Acta Med Port** 1995 Jul-Aug;8(7-8):441–9 (70 ref.) (Eng. Abstr.) **(Por)**

EMBRYOLOGY

Cocaine during pregnancy: a critical review of the literature. Offidani C, et al. **Minerva Ginecol** 1995 Sep;47(9):381–90 (40 ref.)

ETIOLOGY

Biochemical toxicology of chemical teratogenesis. Wells PG, et al. **Crit Rev Biochem Mol Biol** 1996 Feb;31(1):1–40 (200 ref.)
The road to embryologically based dose-response models. Kavlock RJ, et al. **Environ Health Perspect** 1996 Mar;104 Suppl 1:107–21 (88 ref.)
Anticoagulation and pregnancy. Oakley CM. **Eur Heart J** 1995 Oct;16(10):1317–9 (22 ref.)
Mutagenicity, carcinogenicity and teratogenicity of lithium compounds. Léonard A, et al. **Mutat Res** 1995 Oct; 339(3):131–7 (69 ref.)
Reproductive disorders due to chemical exposure among hairdressers. Kersemaekers WM, et al. **Scand J Work Environ Health** 1995 Oct;21(5):325–34 (85 ref.)
Antenatal drugs affecting vitamin K status of the fetus and the newborn. Astedt B. **Semin Thromb Hemost** 1995; 21(4):364–70 (84 ref.)
Review of the interaction between TCDD and glucocorticoids in embryonic palate. Abbott BD. **Toxicology** 1995 Dec 28;105(2-3):365–73 (86 ref.)
Agents that cause birth defects. Shepard TH. **Yonsei Med J** 1995 Nov;36(5):393–6 (13 ref.)
[Tumor therapy and family planning] Theile U, et al. **Med Klin** 1996 Jun 15;91(6):402–9 (43 ref.) **(Ger)**
[Retinoids—drugs with a strong teratogenic side effect] Jendryczko A, et al. **Ginekol Pol** 1995 Jun;66(6):351–3 (17 ref.) (Eng. Abstr.) **(Pol)**

IMMUNOLOGY

Immunoteratology: I. MHC involvement in the embryo response to teratogens in mice. Torchinsky A, et al. **Am J Reprod Immunol** 1995 Nov;34(5):288–98 (27 ref.)

PHYSIOPATHOLOGY

Introduction to functional teratology. Dencker L. **Arch Toxicol Suppl** 1996;18:51–6 (10 ref.)

PREVENTION & CONTROL

Oral retinoids and pregnancy. Chan A, et al. **Med J Aust** 1996 Aug 5;165(3):164–7 (20 ref.)

ABNORMALITIES, MULTIPLE

"New" ectodermal dysplasia with mental retardation and syndactyly. Ilyina HG, et al. **Am J Med Genet** 1995 Sep 25;58(4):345–7 (15 ref.)
LEOPARD syndrome (cardiocutaneous lentiginosis syndrome). Józwiak S, et al. **Cutis** 1996 Apr;57(4):208–14 (129 ref.)
Frontonasal dysplasia: analysis of 21 cases and literature review. Guion-Almeida ML, et al. **Int J Oral Maxillofac Surg** 1996 Apr;25(2):91–7 (62 ref.)
Complete duplication of the bladder and urethra: a case report and review of the literature. Ciftci AO, et al. **J Pediatr Surg** 1995 Nov;30(11):1605–6 (10 ref.)
Fraser syndrome (cryptophthalmos [hidden eye]-syndactyly syndrome). Sarman G, et al. **J Perinatol** 1995 Nov-Dec; 15(6):503–6 (12 ref.)
Splenogonadal fusion. Balaji KC, et al. **J Urol** 1996 Aug;156(2 Pt 2):854–6 (20 ref.)
Bilateral ulnar agenesis: case report and review of the literature. Bozner P, et al. **Pediatr Pathol Lab Med** 1995 Nov-Dec;15(6):895–913 (84 ref.)
[Bird headed dwarfism in Seckel syndrome. Nosologic difficulties] Parent P, et al. **Arch Pediatr** 1996 Jan;3(1):55–62 (47 ref.) (Eng. Abstr.) **(Fre)**

CHEMICALLY INDUCED

[Isotretinoin (RoAccutane) embryopathy. A case report] Pilorget H, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(5):511–5 (14 ref.) (Eng. Abstr.) **(Fre)**

CLASSIFICATION

Oral-facial-skeletal syndromes [editorial; comment] Neri G, et al. **Am J Med Genet** 1995 Nov 20;59(3):365–8 (29 ref.) Comment on: Am J Med Genet 1995 Nov 20;59(3):359–64.
DiGeorge syndrome and related syndromes associated with 22q11.2 deletions. A review. Demczuk S, et al. **Ann Genet** 1995;38(2):59–76 (183 ref.)
Schinzel-Giedion syndrome: further delineation of the phenotype. Elliott AM, et al. **Clin Dysmorphol** 1996 Apr; 5(2):135–42 (18 ref.)
The EEC syndrome: a literature study. Roelfsema NM, et al. **Clin Dysmorphol** 1996 Apr;5(2):115–27 (124 ref.)
Congenital posterior urethral perineal fistulae: a unique form

of urethral duplication. Wagner JR, et al. **Urology** 1996 Aug;48(2):277–80 (12 ref.)

DIAGNOSIS

Occipital encephalocele and MURCS association: case report and review of central nervous system anomalies in MURCS patients. Lin HJ, et al. **Am J Med Genet** 1996 Jan 2; 61(1):59–62 (23 ref.)

Oculoauriculofrontonasal syndrome: report of another case and review of differential diagnosis. Toriello HV, et al. **Clin Dysmorphol** 1995 Oct;4(4):338–46 (25 ref.)

Absent meibomian glands: a marker for EEC syndrome. Bonnar E, et al. **Eye** 1996;10 (Pt 3):355–61 (34 ref.)

Ebstein's anomaly with coarctation of the aorta—an unusual association. Salkar HR, et al. **Indian Heart J** 1996 May-Jun; 48(3):283–4 (7 ref.)

Complicated anophthalmos. Bajwa GS, et al. **Indian Pediatr** 1995 Apr;32(4):480–2 (5 ref.)

Agenesis of bladder associated with multiple organ anomalies. Sarica K, et al. **Int Urol Nephrol** 1995; 27(6):697–703 (10 ref.)

[The Tel Hashomer camptodactyly syndrome] Rogovina EG, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995; 95(4):83–6 (6 ref.) (Eng. Abstr.) **(Rus)**

[The Townes–Brocks syndrome] Arroyo Carrera I, et al. **An Esp Pediatr** 1996 Apr;44(4):364–6 (18 ref.) **(Spa)**

[The cerebrocostomandibular syndrome] Casas Gómez J, et al. **An Esp Pediatr** 1996 Apr;44(4):369–72 (25 ref.) **(Spa)**

[The Camak syndrome] Maldonado Lozano J, et al. **An Esp Pediatr** 1996 Apr;44(4):377–80 (10 ref.) **(Spa)**

[The MMT syndrome (microcephaly, mesobrachyphalangy and tracheoesophageal fistula). The first case described in Spain and a review of the literature] Martínez-Frías ML, et al. **An Esp Pediatr** 1996 Jul;45(1):87–9 (7 ref.) **(Spa)**

[Epilepsy and psychomotor retardation in a child with aplasia cutis and brachydactyly (Adams–Oliver syndrome)] Verdú Pérez A, et al. **An Esp Pediatr** 1996 Mar;44(3):289–91 (15 ref.) **(Spa)**

DRUG THERAPY

Growth hormone and dysmorphic syndromes. Galasso C, et al. **Horm Res** 1995;44 Suppl 3:42–8 (73 ref.)

ETHNOLOGY

The Finnish disease heritage: a personal look. Perheentupa J. **Acta Paediatr** 1995 Oct;84(10):1094–9 (26 ref.)

ETIOLOGY

Thalasselis syndrome and genetic theories on keratoconus. Thalasselis A. **J Am Optom Assoc** 1995 Aug;66(8):495–9 (64 ref.)

Maternal phenylketonuria: a metabolic teratogen. Levy HL, et al. **Teratology** 1996 Mar;53(3):176–84 (54 ref.)

GENETICS

Cytogenetic and molecular analysis in trisomy 12p. Allen TL, et al. **Am J Med Genet** 1996 May 3;63(1):250–6 (33 ref.)

Monozygotic twins discordant for the Russell-Silver syndrome. Bailey W, et al. **Am J Med Genet** 1995 Aug 28;58(2):101–5 (3 ref.)

Detection of a subtle rearrangement of chromosome 22 using molecular techniques. Biesecker LG, et al. **Am J Med Genet** 1995 Sep 25;58(4):389–94 (15 ref.)

Kaufman oculocerebrofacial syndrome in a girl of 15 years. Briscioli V, et al. **Am J Med Genet** 1995 Jul 31;58(1):21–3 (6 ref.)

Mosaic vs. nonmosaic trisomy 9: report of a liveborn infant evaluated by fluorescence in situ hybridization and review of the literature. Cantú ES, et al. **Am J Med Genet** 1996 Apr 24;62(4):330–5 (39 ref.)

Terminal deletion of the long arm of chromosome 3 [46,XX,del(3)(q27-->qter)]. Chitayat D, et al. **Am J Med Genet** 1996 Jan 2;61(1):45–8 (8 ref.)

Is there a Baller–Gerold syndrome? [editorial; comment] Cohen MM Jr, et al. **Am J Med Genet** 1996 Jan 2;61(1):63–4 (38 ref.) Comment on: Am J Med Genet 1996 Jan 2;61(1):65–7.

Inversion duplication of the short arm of chromosome 8: clinical data on seven patients and review of the literature. de Die-Smulders CE, et al. **Am J Med Genet** 1995 Nov 20;59(3):369–74 (16 ref.)

Kabuki make-up (Niikawa-Kuroki) syndrome in five Spanish children. Galán-Gómez E, et al. **Am J Med Genet** 1995 Nov 20;59(3):276–82 (30 ref.)

Interstitial deletion (6)q13q15. Gershoni-Baruch R, et al. **Am J Med Genet** 1996 Apr 24;62(4):345–7 (18 ref.)

Clinical and cytogenetic findings in seven cases of inverted duplication of 8p with evidence of a telomeric deletion using fluorescence in situ hybridization [see comments] Guo WJ, et al. **Am J Med Genet** 1995 Sep 11;58(3):230–6 (20 ref.) Comment in: Am J Med Genet 1995 Sep 11;58(3):237.

Mirror image duplication of the hands and feet: report of a sporadic case with multiple congenital anomalies. Hersh JH, et al. **Am J Med Genet** 1995 Nov 20;59(3):341–5 (14 ref.)

Familial partial duplication (1)(p21p31). Hoechstetter L, et al. **Am J Med Genet** 1995 Nov 20;59(3):291–4 (8 ref.)

Neuroblastoma in a boy with MCA/MR syndrome, deletion 11q, and duplication 12q. Koiffmann CP, et al. **Am J Med Genet** 1995 Jul 31;58(1):46–9 (18 ref.)

Uniparental isodisomy of chromosome 14 in two cases: an abnormal child and a normal adult. Papenhausen PR, et al. **Am J Med Genet** 1995 Nov 20;59(3):271–5 (30 ref.)

Clinical and molecular cytogenetic observations in three cases of "trisomy 12p syndrome". Rauch A, et al. **Am J Med Genet** 1996 May 3;63(1):243–9 (26 ref.)

Duplication of 7p: further delineation of the phenotype and restriction of the critical region to the distal part of the short arm. Reish O, et al. **Am J Med Genet** 1996 Jan 2; 61(1):21–5 (33 ref.)

Hunter–McAlpine craniosynostosis phenotype associated with skeletal anomalies and interstitial deletion of chromosome 17q. Thomas JA, et al. **Am J Med Genet** 1996 Apr 24;62(4):372–5 (8 ref.)

Juberg–Marsidi syndrome: report of an additional case. Tsukahara M, et al. **Am J Med Genet** 1995 Sep 25; 58(4):353–5 (7 ref.)

Fryns syndrome survivors and neurologic outcome. Van Hove JL, et al. **Am J Med Genet** 1995 Nov 20;59(3):334–40 (39 ref.)

Autosomal recessive omodysplasia. Stoll C, et al. **Ann Genet** 1995;38(2):97–101 (8 ref.)

The genetic basis of paediatric heart disease. Johnson MC, et al. **Ann Med** 1995 Jun;27(3):289–300 (126 ref.)

Campomelic dysplasia with XY sex reversal: diverse phenotypes resulting from mutations in a single gene. Schafer AJ, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:137–49 (46 ref.)

Happenstance, circumstance or enemy action: cyclin D1 in breast, eye and brain. Schmidt EV. **Bioessays** 1996 Jan; 18(1):6–8 (29 ref.)

Serpentine fibula syndrome: expansion of the phenotype with three affected siblings. Rosser EM, et al. **Clin Dysmorphol** 1996 Apr;5(2):105–13 (12 ref.)

Clinical phenotype associated with terminal 2q37 deletion. Conrad B, et al. **Clin Genet** 1995 Sep;48(3):134–9 (16 ref.)

Joint dislocation and cerebral anomalies are consistently associated with oral–facial–digital syndrome type IV. Digilio MC, et al. **Clin Genet** 1995 Sep;48(3):156–9 (11 ref.)

Molecular cytogenetic studies of duplication 9q32-->q34.3 inserted into 9q13. Hou JW, et al. **Clin Genet** 1995 Sep; 48(3):148–50 (9 ref.)

Cytogenetic and molecular cytogenetic studies of a case of interstitial deletion of proximal 15q. Tonk V, et al. **Clin Genet** 1995 Sep;48(3):151–5 (15 ref.)

Mosaic "tetrasomy" 8p: case report and review of the literature. Winters J, et al. **Clin Genet** 1995 Oct;48(4):195–8 (9 ref.)

CRASH syndrome: clinical spectrum of corpus callosum hypoplasia, retardation, adducted thumbs, spastic paraparesis and hydrocephalus due to mutations in one single gene, L1. Fransen E, et al. **Eur J Hum Genet** 1995; 3(5):273–84 (49 ref.)

The Currarino syndrome—hereditary transmitted syndrome of anorectal, sacral and presacral anomalies. Case report and review of the literature. Köchling J, et al. **Eur J Pediatr Surg** 1996 Apr;6(2):114–9 (35 ref.)

A distinct phenotype associated with partial trisomy 10q due to proximal direct duplication 10q11 --> q223? van Buggenhout G, et al. **Genet Couns** 1996;7(1):53–9 (14 ref.)

Zimmermann–Laband syndrome in a patient with severe mental retardation. Van Buggenhout GJ, et al. **Genet Couns** 1995;6(4):321–7 (15 ref.)

A nine-month-old boy with microcephaly, cataracts, intracerebral calcifications and dysmorphic signs: an additional observation of an autosomal recessive congenital infection-like syndrome? Wieczorek D, et al. **Genet Couns** 1995;6(4):297–302 (18 ref.)

Xp-duplications with and without sex reversal. Baumstark A, et al. **Hum Genet** 1996 Jan;97(1):79–86 (32 ref.)

ICF syndrome (immunodeficiency, centromeric instability and facial anomalies): investigation of heterochromatin abnormalities and review of clinical outcome. Brown DC, et al. **Hum Genet** 1995 Oct;96(4):411–6 (15 ref.)

Small extra ring chromosome derived from chromosome 10p: clinical report and characterisation by FISH. Blennow E, et al. **J Med Genet** 1996 May;33(5):399–402 (30 ref.)

Filippi syndrome: a new case with skeletal abnormalities. Héron D, et al. **J Med Genet** 1995 Aug;32(8):659–61 (6 ref.)

Absence/hypoplasia of tibia, polydactyly, retrocerebellar arachnoid cyst, and other anomalies: an autosomal recessive disorder. Holmes LB, et al. **J Med Genet** 1995 Nov; 32(11):896–900 (29 ref.)

Microcephaly, characteristic facies, joint abnormalities, and deficient leucocyte chemotaxis: a further case of the syndrome of Say et al. Perandones C, et al. **J Med Genet** 1996 Mar;33(3):227–9 (7 ref.)

The Aicardi–Goutières syndrome (familial, early onset encephalopathy with calcifications of the basal ganglia and chronic cerebrospinal fluid lymphocytosis). Tolmie JL, et al. **J Med Genet** 1995 Nov;32(11):881–4 (26 ref.)

Pfeiffer type cardiocranial syndrome: a third case report. Williamson-Kruse L, et al. **J Med Genet** 1995 Nov; 32(11):901–3 (5 ref.)

What's in a face? [see comments] Winter RM. **Nat Genet** 1996 Feb;12(2):124–9 (40 ref.) Comment in: Nat Genet 1996 Feb;12(2):130–6.

Ophthalmic manifestations of Smith–Magenis syndrome. Chen RM, et al. **Ophthalmology** 1996 Jul;103(7):1084–91 (29 ref.)

Partial deletion of chromosome 6p: autopsy findings in a premature infant and review of the literature. Alashari M, et al. **Pediatr Pathol Lab Med** 1995 Nov-Dec;15(6):941–7 (20 ref.)

[Genetics of hereditary cardiopathies] Debrus S, et al. **Arch Mal Coeur Vaiss** 1996 May;89(5):619–27 (56 ref.) (Eng. Abstr.) **(Fre)**

[Molecular basis of cystic fibrosis and congenital bilateral agenesis of vas deferens] Bienvenu T, et al. **Contracept Fertil Sex** 1996 Jun;24(6):495–500 (31 ref.) (Eng. Abstr.) **(Fre)**

[Schimmelpenning–Feuerstein–Mims syndrome and its neurologic manifestations. 6 personal cases and review of the literature] Fritzsch C, et al. **Klin Padiatr** 1995 Sep–Oct; 207(5):288–97 (40 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

Distinct skeletal abnormalities in four girls with Shprintzen–Goldberg syndrome. Adès LC, et al. **Am J Med Genet** 1995 Jul 17;57(4):565–72 (13 ref.)

Penoscrotal transposition and associated anomalies: report of five new cases and review of the literature. Parida SK, et al. **Am J Med Genet** 1995 Oct 23;59(1):68–75 (35 ref.)

Patient with craniosynostosis and marfanoid phenotype (Shprintzen–Goldberg syndrome) and cloverleaf skull. Saal HM, et al. **Am J Med Genet** 1995 Jul 17;57(4):573–8 (16 ref.)

[Cerebro–oculofacial dysplasia associated with vertebral changes] Munteanu G, et al. **Oftalmologia** 1995 Oct–Dec; 39(4):316–21 (10 ref.) (Eng. Abstr.) **(Rum)**

[The Hay–Wells syndrome, its incidence in Spain and a review of the literature] Martínez-Frías ML, et al. **An Esp Pediatr** 1996 Jul;45(1):101–4 (24 ref.) **(Spa)**

RADIOGRAPHY

[Polysplenia syndrome in adults. Report of an atypical case] Catalano O, et al. **Radiol Med (Torino)** 1995 Dec; 90(6):837–9 (20 ref.) **(Ita)**

SURGERY

Hernia uteri (correction of: uterus) inguinale associated with unilateral renal agenesis. Keating JP, et al. **Aust N Z J Surg** 1995 Sep;65(9):688–90 (10 ref.)

Rehabilitation of a child with partial unilateral cryptophthalmos and multiple congenital anomalies. Konrad H, et al. **Trans Am Ophthalmol Soc** 1995;93:219–40; discussion 241–4 (121 ref.)

ULTRASONOGRAPHY

The Ivemark syndrome: prenatal diagnosis of an uncommon cystic renal lesion with heterogeneous associations. Larson RS, et al. **Pediatr Nephrol** 1995 Oct;9(5):594–8 (16 ref.)

[Potential 3-dimensional (3D-)ultrasound in the diagnosis of fetal abnormalities] Steiner H. **Gynakologe** 1995 Oct; 28(5):315–20 (31 ref.) **(Ger)**

[Diagnostic-therapeutic concept in abnormalities of the abdominal wall and diaphragm] Terinde R, et al. **Gynakologe** 1995 Oct;28(5):368–83 (84 ref.) **(Ger)**

[Prenatal diagnosis of left cardiac abnormality] Hajdú J, et al. **Orv Hetil** 1995 Oct 22;136(43):2333–7 (22 ref.) (Eng. Abstr.) **(Hun)**

VIROLOGY

Chickenpox in pregnancy: how dangerous? Venkatesan P. **Practitioner** 1996 Apr;240(1561):256–9 (5 ref.)

ABNORMALITIES, RADIATION-INDUCED

EPIDEMIOLOGY

What can we infer from findings in subgroups? [editorial; comment] Hatch M. **Epidemiology** 1995 Sep;6(5):473–5 (4 ref.) Comment on: Epidemiology 1995 Sep;6(5):485–9.

ETIOLOGY

[Tumor therapy and family planning] Theile U, et al. **Med Klin** 1996 Jun 15;91(6):402–9 (43 ref.) **(Ger)**

ABO BLOOD-GROUP SYSTEM

GENETICS

Molecular genetics of the ABO histo-blood group system. Yamamoto F. **Vox Sang** 1995;69(1):1–7 (38 ref.)

ABO FACTORS see **ABO BLOOD-GROUP SYSTEM**

ABOMASUM

Abomasal displacement in the bovine—a review on character, occurrence, aetiology and pathogenesis. Geishauser T. **Zentralbl Veterinarmed A** 1995 Jun; 42(4):229–51 (253 ref.)

[Right displacement of the abomasum in cattle. 1. Pathogenesis, clinical course and prognosis] Kümper H. **Tierarztl Prax** 1995 Aug;23(4):351–9 (30 ref.) (Eng. Abstr.) **(Ger)**

ABORIGINES

see related

AUSTRALOID RACE

Evaluating government health and substance abuse programs for indigenous peoples: a comparative review. Gray D, et al. **Aust J Public Health** 1995 Dec;19(6):567–72 (62 ref.)

Is there a role for prevention in aboriginal mental health? Hunter E. **Aust J Public Health** 1995 Dec;19(6):573–9 (50 ref.)

Malignant mesothelioma in Pilbara Aborigines. Musk AW, et al. **Aust J Public Health** 1995 Oct;19(5):520–2 (10 ref.)

New World syndrome in Western Australian aborigines. Gracey M. **Clin Exp Pharmacol Physiol** 1995 Mar; 22(3):220–5 (38 ref.)

Culture in treatment, culture as treatment. A critical appraisal of developments in addictions programs for indigenous North Americans and Australians. Brady M. **Soc Sci Med** 1995 Dec;41(11):1487–98 (78 ref.)

Breastfeeding in Australia. Lund-Adams M, et al. **World Rev Nutr Diet** 1995;78:74–113 (100 ref.)

PSYCHOLOGY

"Freedom's just another word": aboriginal youth and mental health. Hunter E. **Aust N Z J Psychiatry** 1995 Sep; 29(3):374–84 (64 ref.)

ABORTIFACIENT AGENTS

see related

OXYTOCICS

The combined use of prostaglandin and antiprogestin in human fertility control. Baulieu EE. **Eur J Obstet Gynecol Reprod Biol** 1996 Mar;65(1):115–9 (42 ref.)

Acceptability of medical abortion in early pregnancy. Winikoff B. **Fam Plann Perspect** 1995 Jul–Aug;27(4):142–8, 185 (36 ref.)

ABORTIFACIENT AGENTS, NON-STEROIDAL

[Mifepristone and misoprostol in therapeutic abortions] Jannet D, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996; 25(3):277–82 (24 ref.) (Eng. Abstr.) **(Fre)**

ADVERSE EFFECTS

[Uterine rupture during induced abortion with prostaglandins in the second trimester] Zieger W, et al. **Geburtshilfe Frauenheilkd** 1995 Oct;55(10):592–8 (43 ref.) (Eng. Abstr.) **(Ger)**

ABORTIFACIENT AGENTS, STEROIDAL

Mifepristone and first trimester abortion. Murray S, et al. **Clin Obstet Gynecol** 1996 Jun;39(2):474–85 (59 ref.)

[Advances in the study of mifepristone] Wong L. **Chung Hua Fu Chan Ko Tsa Chih** 1995 Sep;30(9):565–8 (22 ref.) **(Chi)**

[Mifepristone and misoprostol in therapeutic abortions] Jannet D, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996; 25(3):277–82 (24 ref.) (Eng. Abstr.) **(Fre)**

PHARMACOLOGY

Clinical applications of the antiprogestins. Kettel LM. **Clin Obstet Gynecol** 1995 Dec;38(4):921–34 (56 ref.)

ABORTION

see related

ABORTIFACIENT AGENTS

Quo vadis? Fetal tissue transplantation. Michejda M. **J Hematother** 1996 Apr;5(2):185–8 (31 ref.)

CHEMICALLY INDUCED

Reproductive disorders due to chemical exposure among hairdressers. Kersemaekers WM, et al. **Scand J Work Environ Health** 1995 Oct;21(5):325–34 (85 ref.)

EPIDEMIOLOGY

Hypothyroidism and spontaneous abortions among Hanford, Washington, downwinders. Grossman CM, et al. **Arch Environ Health** 1996 May–Jun;51(3):175–6 (8 ref.)

Pre-conception care of diabetes, congenital malformations, and spontaneous abortions. Kitzmiller JL, et al. **Diabetes Care** 1996 May;19(5):514–41 (324 ref.)

Assessing congenital anomalies after preimplantation genetic diagnosis. Simpson JL, et al. **J Assist Reprod Genet** 1996 Feb;13(2):170–6 (30 ref.)

Effects of parental occupational exposure to lead and other metals on spontaneous abortion. Anttila A, et al. **J Occup Environ Med** 1995 Aug;37(8):915–21 (36 ref.)

ETIOLOGY

[Ectopic pregnancy: factors related to ovum anomalies?] Bouyer J, et al. **Rev Epidemiol Sante Publique** 1996 Apr; 44(2):101–10 (48 ref.) (Eng. Abstr.) **(Fre)**

[Smoking and pregnancy] Wenderlein JM. **Z Arztl Fortbild (Jena)** 1995 Oct;89(5):467–71 (15 ref.) (Eng. Abstr.) **(Ger)**

[Genital infections as a cause of abortion in the first trimester of pregnancy. Review of the literature] Capuzzo E, et al. **Minerva Ginecol** 1995 Dec;47(12):557–60 (15 ref.) (Eng. Abstr.) **(Ita)**

GENETICS

Mutations, malformations and mortality. Suthers G. **J Paediatr Child Health** 1996 Feb;32(1):10–5 (67 ref.)

ABORTION, EUGENIC

Justifying prenatal screening and genetic amniocentesis programs by cost-effectiveness analyses: a re-evaluation. Ganiats TG. **Med Decis Making** 1996 Jan–Mar;16(1):45–50 (61 ref.)

ABORTION, HABITUAL

Habitual abortion: endocrinological aspects. Fedele L, et al. **Curr Opin Obstet Gynecol** 1995 Oct;7(5):351–6 (45 ref.)

Early pregnancy loss. **Int J Gynaecol Obstet** 1995 Dec; 51(3):278–85 (45 ref.)

ETIOLOGY

Recurrent pregnancy loss. Cook CL, et al. **Curr Opin Obstet Gynecol** 1995 Oct;7(5):357–66 (46 ref.)

Recurrent miscarriage: causes and management. Chung PH, et al. **Hosp Pract (Off Ed)** 1996 May 15;31(5):157–64 (11 ref.)

GENETICS

Uniparental isodisomy of chromosome 14 in two cases: an abnormal child and a normal adult. Papenhausen PR, et al. **Am J Med Genet** 1995 Nov 20;59(3):271–5 (30 ref.)

IMMUNOLOGY

T-helper 1-type immunity to trophoblast: evidence for a new immunological mechanism for recurrent abortion in women. Hill JA. **Hum Reprod** 1995 Dec;10 Suppl 2:114–20 (75 ref.)

Materno-fetal immunobiology in normal pregnancy and its possible failure in recurrent spontaneous abortion? Vince GS, et al. **Hum Reprod** 1995 Dec;10 Suppl 2:107–13 (50 ref.)

PREVENTION & CONTROL

The modern preventative treatment of recurrent miscarriage [see comments] Rai R, et al. **Br J Obstet Gynaecol** 1996 Feb;103(2):106–10 (41 ref.) Comment in: Br J Obstet Gynaecol 1996 Jul;103(7):723. Comment in: Br J Obstet Gynaecol 1996 Jul;103(7):723–4.

THERAPY

Recurrent miscarriage: causes and management. Chung PH, et al. **Hosp Pract (Off Ed)** 1996 May 15;31(5):157–64 (11 ref.)

The Euro-Team Early Pregnancy (ETEP) protocol for recurrent miscarriage. Berry CW, et al. **Hum Reprod** 1995 Jun;10(6):1516–20 (42 ref.)

ABORTION, INCOMPLETE

Arthrogryposis associated with unsuccessful attempts at termination of pregnancy. Hall JG. **Am J Med Genet** 1996 May 3;63(1):293–300 (40 ref.)

ABORTION, INDUCED

Arthrogryposis associated with unsuccessful attempts at termination of pregnancy. Hall JG. **Am J Med Genet** 1996 May 3;63(1):293–300 (40 ref.)

Mifepristone and first trimester abortion. Murray S, et al. **Clin Obstet Gynecol** 1996 Jun;39(2):474–85 (59 ref.)

Quo vadis? Fetal tissue transplantation. Michejda M. **J Hematother** 1996 Apr;5(2):185–8 (31 ref.)

[Uterine rupture during induced abortion with prostaglandins in the second trimester] Zieger W, et al. **Geburtshilfe Frauenheilkd** 1995 Oct;55(10):592–8 (43 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Gas embolism complicating obstetric or gynecologic procedures. Case reports and review of the literature. Mushkat Y, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Nov;63(1):97–103 (54 ref.)

Selections from current literature: abortion, breast cancer and causal inferences. Rahman MI, et al. **Fam Pract** 1996 Apr; 13(2):194–200 (11 ref.)

Induced midtrimester abortion and future fertility--where are we today? Lurie S, et al. **Int J Fertil Menopausal Stud** 1995 Nov–Dec;40(6):311–5 (39 ref.)

Midtrimester uterine rupture. A case report. Levrant SG, et al. **J Reprod Med** 1996 Mar;41(3):186–90 (28 ref.)

METHODS

Acceptability of medical abortion in early pregnancy. Winikoff B. **Fam Plann Perspect** 1995 Jul–Aug;27(4):142–8, 185 (36 ref.)

[Induced delivery in fetal malformations] Boog G. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24 Suppl 1:54–6 (22 ref.) **(Fre)**

STANDARDS

[Indications for pregnancy termination in cases of pre-eclampsia, hypertension, intrauterine growth retardation, liver and heart disease] Uzan S, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24 Suppl 1:33–40 (54 ref.) **(Fre)**

STATISTICS & NUMERICAL DATA

Abortion and fertility regulation [see comments] Kulczycki A, et al. **Lancet** 1996 Jun 15;347(9016):1663–8 (41 ref.) Comment in: Lancet 1996 Aug 17;348(9025):478; discussion 478–9.

ABORTION, LEGAL

Emergency contraception in the United Kingdom and The Netherlands. Glasier A, et al. **Fam Plann Perspect** 1996 Mar–Apr;28(2):49–51 (17 ref.)

Abortion: the antithesis of womanhood? Timpson J. **J Adv Nurs** 1996 Apr;23(4):776–85 (121 ref.)

Teenage abortion in Germany: with reference to the legal system in the United States. Belling DW, et al. **J Contemp Health Law Policy** 1996 Spring;12(2):475–502 (128 ref.)

ADVERSE EFFECTS

Preventing pelvic infection after abortion [editorial] Stevenson MM, et al. **Int J STD AIDS** 1995 Sep–Oct; 6(5):305–12 (61 ref.)

[Legal abortion--different methods and complications] Stefanov B. **Akush Ginekol (Sofiia)** 1995;34(1):27–30 (29 ref.) **(Bul)**

METHODS

[Legal abortion--different methods and complications] Stefanov B. **Akush Ginekol (Sofiia)** 1995;34(1):27–30 (29 ref.) **(Bul)**

TRENDS

Abortion law and practice in China: an overview with comparisons to the United States. Rigdon SM. **Soc Sci Med** 1996 Feb;42(4):543–60 (96 ref.)

ABORTION, MISSED

PATHOLOGY

Placental changes in a first trimester missed abortion in maternal systemic lupus erythematosus with antiphospholipid syndrome; a case report and review of the literature. Nayar R, et al. **Hum Pathol** 1996 Feb; 27(2):201–6 (36 ref.)

ABORTION ON DEMAND see **ABORTION, LEGAL**

ABORTION, SEPTIC

DIAGNOSIS

[Septic abortion in Campylobacter jejuni infection] Abderhalden R, et al. **Geburtshilfe Frauenheilkd** 1995 Oct; 55(10):599–601 (14 ref.) (Eng. Abstr.) **(Ger)**

ABORTION, SPONTANEOUS see **ABORTION**

ABORTION, THERAPEUTIC

Arthrogryposis associated with unsuccessful attempts at termination of pregnancy. Hall JG. **Am J Med Genet** 1996 May 3;63(1):293–300 (40 ref.)

METHODS

[Mifepristone and misoprostol in therapeutic abortions] Jannet D, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996; 25(3):277–82 (24 ref.) (Eng. Abstr.) **(Fre)**

ABRUPTIO PLACENTAE

COMPLICATIONS

[Consumption coagulopathy during pregnancy: a case of afibrinogenemia during the second trimester] Debiève F, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(8):860–2 (9 ref.) (Eng. Abstr.) **(Fre)**

EPIDEMIOLOGY

The occurrence of placental abruption in Norway 1967–1991. Rasmussen S, et al. **Acta Obstet Gynecol Scand** 1996 Mar; 75(3):222–8 (41 ref.)

ABSCESS

see related
EMPYEMA

[Pericholecystic abscess] Kogure K.
Ryoikibetsu Shokogun Shirizu 1996;(9):225–7 (6 ref.) **(Jpn)**

COMPLICATIONS

Coronary artery obstruction caused by perivalvular abscess in aortic valve endocarditis. Schlaifer JD, et al.
Am Heart J 1996 Feb;131(2):413–6 (8 ref.)
[Tuberculous prostatic abscess in a patient with AIDS] Duarte Ojeda JM, et al. **Actas Urol Esp** 1995 Sep; 19(8):655–61 (22 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Tuberculous inguinal lymphadenitis. Challapalli M, et al.
Pediatr Infect Dis J 1995 Aug;14(8):723–4 (5 ref.)
Seminal vesicle abscess: a case report and review of literature. Pandey P, et al. **Scand J Urol Nephrol** 1995 Dec;29(4):521–4 (14 ref.)
[Diagnosis of perianal and perirectal fistulas and abscesses] Rieber A, et al. **Rontgenpraxis** 1996 May;49(5):110–4 (20 ref.) **(Ger)**

ETIOLOGY

Spinal epidural abscess in hemodialysis patients: report of three cases and review of the literature. Obrador GT, et al. **Am J Kidney Dis** 1996 Jan;27(1):75–83 (34 ref.)
Chronic otitis media after tympanostomy tube placement caused by Mycobacterium abscessus: a new clinical entity? Franklin DJ, et al. **Am J Otol** 1994 May;15(3):313–20 (21 ref.)
The risk of extradural abscess [editorial] Carson D, et al. **Br J Anaesth** 1995 Nov;75(5):520–1 (13 ref.)
Infections complicating tunneled intraspinal catheter systems used to treat chronic pain. Byers K, et al.
Clin Infect Dis 1995 Aug;21(2):403–8 (30 ref.)
Intrauterine contraceptive device–associated actinomycotic abscess and Actinomyces detection on cervical smear. Fiorino AS. **Obstet Gynecol** 1996 Jan;87(1):142–9 (107 ref.)
[Retroperitoneal abscess formation accompanied by intraabdominal free air, a rare complication of transcatheter arterial embolization of renal tumor: a case report] Koga F, et al. **Hinyokika Kiyo** 1996 Jun;42(6):443–6 (7 ref.) (Eng. Abstr.) **(Jpn)**

MICROBIOLOGY

Chronic otitis media after tympanostomy tube placement caused by Mycobacterium abscessus: a new clinical entity? Franklin DJ, et al. **Am J Otol** 1994 May;15(3):313–20 (21 ref.)
Spinal epidural abscess caused by Brucella: case report. Paz JF, et al. **J Neurosurg Sci** 1994 Dec;38(4):245–9 (22 ref.)
Primary cutaneous nocardiosis caused by Nocardia otitidiscaviarum: two cases and a review of the literature. Freland C, et al. **J Trop Med Hyg** 1995 Dec;98(6):395–403 (26 ref.)
Microbiology and antimicrobial therapy of spinal infections. Sapico FL. **Orthop Clin North Am** 1996 Jan;27(1):9–13 (22 ref.)

RADIOGRAPHY

CT evaluation of soft tissue and muscle infection and inflammation: a systematic compartmental approach. Beauchamp NJ Jr, et al. **Skeletal Radiol** 1995 Jul; 24(5):317–24 (8 ref.)

SURGERY

Abscess drainage techniques. Grant DS. **Br J Hosp Med** 1995 Nov 1–14;54(9):435–8 (14 ref.)
Perianal inflammatory conditions in inflammatory bowel disease. Stein BL, et al. **Curr Opin Gen Surg** 1993;:141–6 (17 ref.)
Intramedullary spinal cord abscess: case report. Tacconi L, et al. **Neurosurgery** 1995 Oct;37(4):817–9 (25 ref.)
[Peritonsillar abscess. Emergency tonsillectomy?] Marchal F, et al. **Ann Otolaryngol Chir Cervicofac** 1995;112(8):393–8 (26 ref.) (Eng. Abstr.) **(Fre)**
[Fistula, fissure, abscess] Girona J, et al. **Chirurg** 1996 Mar; 67(3):222–8 (28 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Successful management of breast abscess with ongoing breastfeeding. Banapurmath CR, et al. **Indian Pediatr** 1995 Apr;32(4):488–91 (10 ref.)
Neurosurgical care of spinal epidural, subdural, and intramedullary abscesses and arachnoiditis. Martin RJ, et al. **Orthop Clin North Am** 1996 Jan;27(1):125–36 (72 ref.)
Multifocal metachronous epidural abscesses of the spine. A case report. Chow GH, et al. **Spine** 1996 May 1; 21(9):1094–7 (11 ref.)

VETERINARY

Nodules and draining tracts. Beale KM.
Vet Clin North Am Small Anim Pract 1995 Jul; 25(4):887–900 (50 ref.)

ABSCESS, ABDOMINAL see **ABDOMINAL ABSCESS**

ABSCESS, AMEBIC, HEPATIC see **LIVER ABSCESS, AMEBIC**

ABSCESS, CEREBRAL see **BRAIN ABSCESS**

ABSCESS, HEPATIC see **LIVER ABSCESS**

ABSCESS, HEPATIC, AMEBIC see **LIVER ABSCESS, AMEBIC**

ABSCESS, INTRA-ABDOMINAL see **ABDOMINAL ABSCESS**

ABSCESS, LIVER, AMEBIC see **LIVER ABSCESS, AMEBIC**

ABSCESS, PERIAPICAL see **PERIAPICAL ABSCESS**

ABSCESS, PERIODONTAL see **PERIODONTAL ABSCESS**

ABSCESS, PERITONSILLAR see **PERITONSILLAR ABSCESS**

ABSCESS, PSOAS see **PSOAS ABSCESS**

ABSCESS, PULMONARY see **LUNG ABSCESS**

ABSCESS, RETROPHARYNGEAL see **RETROPHARYNGEAL ABSCESS**

ABSCESS, SUBDURAL see **EMPYEMA, SUBDURAL**

ABSENCE SEIZURES see **EPILEPSY, ABSENCE**

ABSENTEEISM

Effects of smog on absenteeism in forestry workers. Moll Van Charante AW, et al. **Arch Environ Health** 1996 Jan–Feb;51(1):34–41 (39 ref.)
Factors relating to return to work after burn injury. Wrigley M, et al. **J Burn Care Rehabil** 1995 Jul–Aug;16(4):445–50; discussion 444 (19 ref.)
[Management and monitoring of transient work incapacity. Is the primary care model effective?] Alberquilla Menéndez-Asenjo A, et al. **Aten Primaria** 1996 Jan; 17(1):40–6 (33 ref.) (Eng. Abstr.) **(Spa)**

ABSORPTIOMETRY, DUAL-ENERGY X-RAY see **DENSITOMETRY, X-RAY**

ABSORPTIOMETRY, PHOTON

[Dual photon absorptiometry, dual energy X-ray absorptiometry for analysis of body fat mass] Itabashi A. **Nippon Rinsho** 1995 Jun;53 Suppl:174–8 (11 ref.) **(Jpn)**

METHODS

Bone absorptiometry: a critical appraisal of various methods. Slosman DO, et al. **Acta Paediatr Suppl** 1995 Sep;411:9–11 (7 ref.)
The state of the art of non-invasive diagnostics for bone densitometry. Methods of photonic absorption. Baruffaldi F, et al. **Chir Organi Mov** 1995 Oct–Dec;80(4):427–48 (71 ref.) **(Eng, Ita)**

ABSORPTION, INTESTINAL see **INTESTINAL ABSORPTION**

ABSORPTION, SKIN see **SKIN ABSORPTION**

ABSTINENCE SYNDROME, NEONATAL see **NEONATAL ABSTINENCE SYNDROME**

ABSTRACTING AND INDEXING

STANDARDS

Quantitative analyses of scientific literature and their validity for judging Latin American production [comment] Spinak E. **Bull Pan Am Health Organ** 1995 Dec;29(4):352–9; discussion 359–60 (25 ref.) Comment on: Bull Pan Am Health Organ 1995 Mar;29(1):87–95.

ABUSE OF HEALTH SERVICES see **HEALTH SERVICES MISUSE**

ABUSED WOMEN see **BATTERED WOMEN**

ACADEMIC MEDICAL CENTERS

Academic research and HIV/AIDS in South Africa. Campbell CM, et al. **S Afr Med J** 1996 Jan;86(1):55–60 (63 ref.)

ECONOMICS

Academic medical centers and the fight for survival in the new era of managed care. Nauert RC.
J Health Care Finance 1995 Summer;21(4):47–59 (15 ref.)

ORGANIZATION & ADMINISTRATION

The effect of health care reform on academic medicine in Canada. Editorial Committee of the Canadian Institute for Academic Medicine. Hollenberg CH. **Can Med Assoc J** 1996 May 15;154(10):1483–9 (0 ref.)
Academics and the nursing home. Katz PR, et al.
Clin Geriatr Med 1995 Aug;11(3):503–16 (36 ref.)

STATISTICS & NUMERICAL DATA

High autopsy rates at a university medical center. What has gone right? Haque AK, et al. **Arch Pathol Lab Med** 1996 Aug;120(8):727–32 (19 ref.)

ACADEMIES AND INSTITUTES

HISTORY

Antitumor antibiotics discovered and studied at the Institute of Microbial Chemistry. Takeuchi T.
J Cancer Res Clin Oncol 1995;121(9–10):505–10 (52 ref.)

ACANTHAMOEBA

CHEMISTRY

Thermal unfolding of Acanthamoeba myosin II and skeletal muscle myosin. Zolkiewski M, et al. **Biophys Chem** 1996 Apr 16;59(3):365–71 (45 ref.)

PATHOGENICITY

Acanthamoeba: ecology, pathogenicity and laboratory detection. Walker CW. **Br J Biomed Sci** 1996 Jun; 53(2):146–51 (30 ref.)

ACANTHOCYTES

[Choreoacanthocytosis. A neurologic–hematologic syndrome] Hiersemenzel LP, et al. **Nervenarzt** 1996 Jun; 67(6):490–5 (39 ref.) (Eng. Abstr.) **(Ger)**

ACANTHOLYSIS BULLOSA see **EPIDERMOLYSIS BULLOSA**

ACARIASIS see **MITE INFESTATIONS**

ACARUS see **MITES**

ACCELERATION

The study of kinematic transients in locomotion using the integrated kinematic sensor. Wu G, et al.
IEEE Trans Rehabil Eng 1996 Sep;4(3):193–200 (18 ref.)

ACCEPTABILITY OF HEALTH CARE see **PATIENT ACCEPTANCE OF HEALTH CARE**

ACCESS TO HEALTH CARE see **HEALTH SERVICES ACCESSIBILITY**

ACCESSIBILITY OF HEALTH SERVICES see **HEALTH SERVICES ACCESSIBILITY**

ACCESSORY CELLS, IMMUNOLOGIC see **ANTIGEN-PRESENTING CELLS**

ACCIDENT INSURANCE see **INSURANCE, ACCIDENT**

ACCIDENT PREVENTION

see related
PROTECTIVE DEVICES

On the prevention of accidents and injuries. A comparative analysis of conceptual frameworks. Andersson R, et al.
Accid Anal Prev 1995 Dec;27(6):757–68 (30 ref.)

ACCIDENTAL FALLS

Etiology and prevention of age-related hip fracture Hayes WC, et al. **Bone** 1996 Jan;18(1 Suppl):77S–86S (110 ref.)
Fetal complications related to minor maternal trauma. Huzel PS, et al. **J Obstet Gynecol Neonatal Nurs** 1996 Feb; 25(2):121–4 (9 ref.)
Peripheral neuropathy: an often-overlooked cause of falls in the elderly. Richardson JK, et al. **Postgrad Med** 1996 Jun;99(6):161–72 (20 ref.)

ECONOMICS

Economic dimensions of slip and fall injuries. Englander F, et al. **J Forensic Sci** 1996 Sep;41(5):733–46 (42 ref.)

PREVENTION & CONTROL

Elderly people who fall: identifying and managing the causes. Campbell AJ, et al. **Br J Hosp Med** 1995 Nov 15–Dec 12;54(10):520–3 (21 ref.)
Preventing falls: how to identify risk factors, reduce complications. Tideiksaar R. **Geriatrics** 1996 Feb; 51(2):43–6, 49–50, 53, quiz 54–5 (5 ref.)

STATISTICS & NUMERICAL DATA

Falls in community-dwelling older persons. King MB, et

al. **J Am Geriatr Soc** 1995 Oct;43(10):1146–54 (97 ref.)
Neurologic antecedents to patient falls. Benson C, et al. **J Neurosci Nurs** 1995 Dec;27(6):331–7 (25 ref.)
[Iatrogenic falls] Stäubli M. **Schweiz Med Wochenschr** 1996 Apr 6;126(14):576–83 (33 ref.) (Eng. Abstr.) **(Ger)**

ACCIDENTS

MORTALITY

Accidents involving older people: a review of the literature. Lilley JM, et al. **Age Ageing** 1995 Jul;24(4):346–65 (153 ref.)

PSYCHOLOGY

Accident neurosis revisited [editorial] Mayou R. **Br J Psychiatry** 1996 Apr;168(4):399–403 (26 ref.)
Transportation disasters—a review. Lundin T. **J Trauma Stress** 1995 Jul;8(3):381–9 (27 ref.)
Psychosocial aspects of accidental injuries—an overview [see comments] Schnyder U, et al. **Langenbecks Arch Chir** 1996; 381(3):125–31 (67 ref.) Comment in: Langenbecks Arch Chir 1996;381(3):123–4.

ACCIDENTS, AVIATION

PREVENTION & CONTROL

[The importance of the human factor in the medical support for flight safety] Lapa VV, et al. **Voen Med Zh** 1996 Apr; 317(4):41–4, 79 (16 ref.) (Eng. Abstr.) **(Rus)**

PSYCHOLOGY

Transportation disasters—a review. Lundin T. **J Trauma Stress** 1995 Jul;8(3):381–9 (27 ref.)

ACCIDENTS, INDUSTRIAL see **ACCIDENTS, OCCUPATIONAL**

ACCIDENTS, NUCLEAR see **ACCIDENTS, RADIATION**

ACCIDENTS, NUCLEAR REACTOR see **ACCIDENTS, RADIATION**

ACCIDENTS, OCCUPATIONAL

The injured worker: assessing "return-to-work" status. Mazanec DJ. **Cleve Clin J Med** 1996 May–Jun;63(3):166–71 (27 ref.)
Interactions of aniline with soil and groundwater at an industrial spill site. Kosson DS, et al. **Environ Health Perspect** 1995 Jun;103 Suppl 5:71–3 (13 ref.)
Occupational injury and stress. Johnston JJ. **J Occup Environ Med** 1995 Oct;37(10):1199–203 (25 ref.)
Respiratory irritants encountered at work. Taylor AJ. **Thorax** 1996 May;51(5):541–5 (17 ref.)
[Chronic obstructive bronchopneumopathy after acute inhalation of sulfur anhydride. Apropos of a case] Ramakers M, et al. **Rev Pneumol Clin** 1995;51(6):343–7 (31 ref.) (Eng. Abstr.) **(Fre)**

LEGISLATION & JURISPRUDENCE

Regional harmonization of occupational health rules: the European example. Raworth P. **Am J Law Med** 1995; 21(1):7–44 (339 ref.)

PREVENTION & CONTROL

The integrated model: implications for worksite health promotion and occupational health and safety practice. Baker E, et al. **Health Educ Q** 1996 May;23(2):175–90 (61 ref.)
Worksite health programs: working together to advance employee health. Heaney CA, et al. **Health Educ Q** 1996 May;23(2):133–6 (18 ref.)
The ecology of work and health: research and policy directions for the promotion of employee health. Stokols D, et al. **Health Educ Q** 1996 May;23(2):137–58 (162 ref.)
Prevention of occupational musculo-skeletal injuries. Labour Inspectorate investigation. Kemmlert K. **Scand J Rehabil Med Suppl** 1996;35:1–34 (124 ref.)
Injury prevention in anesthesiology. Berry AJ. **Surg Clin North Am** 1995 Dec;75(6):1123–32 (21 ref.)

STATISTICS & NUMERICAL DATA

Epidemiology of injuries by needles and other sharp instruments. Minimizing sharp injuries in gynecologic and obstetric operations. Lewis FR Jr, et al. **Surg Clin North Am** 1995 Dec;75(6):1105–21 (34 ref.)

ACCIDENTS, RADIATION

see related
RADIATION INJURIES

Is blood a better source of allogeneic hematopoietic stem cells for use after radiation accidents? Frickhofen N, et al. **Bone Marrow Transplant** 1996 Feb;17(2):131–5 (48 ref.)
Radiation disasters and emergency department preparedness. Fong F, et al. **Emerg Med Clin North Am** 1996 May; 14(2):349–70 (18 ref.)
Cancer consequences of the Chernobyl accident in Europe outside the former USSR: a review. Sali D, et al. **Int J Cancer** 1996 Jul 29;67(3):343–52 (33 ref.)
Cytogenetic research after accidental radiation exposure. Bauchinger M. **Stem Cells (Dayt)** 1995 May;13 Suppl 1:182–90 (36 ref.)
[Therapeutic approaches of hematopoietic syndrome following accidental total whole body irradiation] Thierry D, et al. **Bull Cancer (Paris)** 1996 May;83(5):361–70 (40 ref.) (Eng. Abstr.) **(Fre)**
[Medical management of radiation casualties] Dushnitsky T, et al. **Harefuah** 1995 Dec 1;129(11):481–4 (28 ref.) **(Heb)**
[Endocrine function of the thymus and ionizing radiation] Grinevich IuA, et al. **Radiats Biol Radioecol** 1995 May–Jun; 35(3):391–404 (126 ref.) (Eng. Abstr.) **(Rus)**
[The sequelae of the Kyshtym and Chernobyl accidents for hydrobionts] Polikarpov GG, et al. **Radiats Biol Radioecol** 1995 Jul–Aug;35(4):536–49 (79 ref.) (Eng. Abstr.) **(Rus)**
[From Hiroshima to Chernobyl. Increasing number of late fatal cases of cancer] Drottz-Sjöberg BM, et al. **Lakartidningen** 1995 Nov 1;92(44):4100–2, 4105 (18 ref.) **(Swe)**

ACCIDENTS, TRAFFIC

see related
AIR BAGS
SEAT BELTS

Lumbar compression fractures secondary to lap-belt use in children. Sturm PF, et al. **J Pediatr Orthop** 1995 Jul–Aug; 15(4):521–3 (27 ref.)
Traumatic lumbar hernia: a seat belt injury. McCarthy MC, et al. **J Trauma** 1996 Jan;40(1):121–2 (10 ref.)
Intra-abdominal injury with handlebar hernia: case report and literature review. Yarbrough DR 3rd. **J Trauma** 1996 Jan;40(1):116–8 (21 ref.)
Long-term outcome after whiplash injury. A 2-year follow-up considering features of injury mechanism and somatic, radiologic, and psychosocial findings. Radanov BP, et al. **Medicine (Baltimore)** 1995 Sep;74(5):281–97 (61 ref.)
[Neurological diseases and driving] Mola S. **Rev Neurol** 1995 Mar–Apr;23(120):334–50 (139 ref.) (Eng. Abstr.) **(Spa)**

LEGISLATION & JURISPRUDENCE

Medico-legal aspects of road traffic accidents. Mayou R. **J Psychosom Res** 1995 Aug;39(6):789–98 (13 ref.)
[Revoking the right to drive—a blunt weapon against alcohol intoxicated drivers, hit-and-run drivers and speed limit and red light offenders? (see comments)] Zabel GE. **Blutalkohol** 1995 Sep;32(5):254–67 (56 ref.) (Eng. Abstr.) Comment in: Blutalkohol 1995 Nov;32(6):314–6. **(Ger)**

PREVENTION & CONTROL

Drink driving legislation: medicine and the law. Marks P. **Med Leg J** 1995;63 (Pt 3):119–27 (17 ref.)
Diabetes mellitus and traffic incidents. Veneman TF. **Neth J Med** 1996 Jan;48(1):24–8 (27 ref.)
[Air bags: benefits and risks] Haddad R, et al. **Harefuah** 1996 Jan 15;130(2):120–2 (25 ref.) **(Heb)**

PSYCHOLOGY

Psychosocial factors in childhood pedestrian injury: a matched case-control study. Kid's'n Cars Team. Christoffel KK, et al. **Pediatrics** 1996 Jan;97(1):33–42 (49 ref.)

STATISTICS & NUMERICAL DATA

Psychosocial factors in childhood pedestrian injury: a matched case-control study. Kid's'n Cars Team. Christoffel KK, et al. **Pediatrics** 1996 Jan;97(1):33–42 (49 ref.)
[Abuse of psychotropic drugs during driving] Lemoine P, et al. **Encephale** 1996 Jan–Feb;22(1):1–6 (39 ref.) (Eng. Abstr.) **(Fre)**

TRENDS

The older driver—a review. Morgan R, et al. **Postgrad Med J** 1995 Sep;71(839):525–8 (30 ref.)

ACCLIMATION see **ACCLIMATIZATION**

ACCLIMATIZATION

PHYSIOLOGY

Adaptation to heat. Hori S. **Jpn J Physiol** 1995;45(6):921–46 (82 ref.)

ACCOMMODATION, OCULAR

Spasm of the near reflex: a spectrum of anomalies. Goldstein JH, et al. **Surv Ophthalmol** 1996 Jan–Feb;40(4):269–78 (50 ref.)
[Measuring the level of tonic accomodation as a function of wavelength] Dechriste S, et al. **J Fr Ophtalmol** 1995; 18(6–7):439–46 (26 ref.) (Eng. Abstr.) **(Fre)**

DRUG EFFECTS

Dapiprazole's effect upon accommodative recovery: is it due entirely to changes in depth of field? Molinari JF, et al. **Optom Vis Sci** 1995 Aug;72(8):552–6 (18 ref.)

PHYSIOLOGY

Neuronal circuitry controlling the near response. Mays LE, et al. **Curr Opin Neurobiol** 1995 Dec;5(6):763–8 (29 ref.)
Evolution of control system models of ocular accommodation, vergence and their interaction. Eadie AS, et al. **Med Biol Eng Comput** 1995 Jul;33(4):517–24 (84 ref.)

ACCREDITATION

see related
CERTIFICATION

Accreditation of postdoctoral general dentistry programs. Glassman P. **J Am Coll Dent** 1995 Fall;62(3):27–30 (33 ref.)
The 1995 JCAHO mental health manual—an overview for dietetics professionals. Foiles RA. **J Am Diet Assoc** 1996 Apr;96(4):403–4 (6 ref.)
Applying the 1996 JCAHO nutrition care standards in a long-term-care setting. Robinson GE. **J Am Diet Assoc** 1996 Apr;96(4):400–3 (8 ref.)
Applying the 1995 JCAHO standards to dietetics practice in home care. Westbrook NH. **J Am Diet Assoc** 1996 Apr; 96(4):404–6 (5 ref.)
Accreditation in the UK for pesticide residue analysis in foods. Thorpe SA, et al. **J Chromatogr A** 1996 Jun 14; 737(1):3–7 (4 ref.)
[Accreditation. Priority and challenge] Imperatori E. **Acta Med Port** 1996 Jan;9(1):59–66 (16 ref.) (Eng. Abstr.) **(Por)**

LEGISLATION & JURISPRUDENCE

Accreditation of those who arrange adoptions under the Hague Convention on intercountry adoption as a means of protecting, through private international law, the rights of children. Pierce WL. **J Contemp Health Law Policy** 1996 Spring;12(2):535–61 (31 ref.)

ORGANIZATION & ADMINISTRATION

Can educational accreditation drive interdisciplinary learning in the health professions? Gelmon SB. **Jt Comm J Qual Improv** 1996 Mar;22(3):213–22 (27 ref.)

STANDARDS

Relating autopsy requirements to the contemporary accreditation process. O'Leary DS. **Arch Pathol Lab Med** 1996 Aug;120(8):763–6 (5 ref.)

ACE INHIBITORS see **ANGIOTENSIN-CONVERTING ENZYME INHIBITORS**

ACEBUTOLOL

POISONING

[Acute voluntary poisoning with acebutolol (letter)] Darmanaden R, et al. **Therapie** 1995 Nov–Dec;50(6):591–3 (18 ref.) **(Fre)**

ACEMETHADONE see **METHADYL ACETATE**

ACETABULUM

ANATOMY & HISTOLOGY

[Anatomy and development of the hip joint during growth. I. anatomy and development of the acetabulum] Wierusz-Kozłowska M. **Chir Narzadow Ruchu Ortop Pol** 1995;60(6):477–83 (59 ref.) (Eng. Abstr.) **(Pol)**

GROWTH & DEVELOPMENT

[Anatomy and development of the hip joint during growth. I. anatomy and development of the acetabulum] Wierusz-Kozłowska M. **Chir Narzadow Ruchu Ortop Pol** 1995;60(6):477–83 (59 ref.) (Eng. Abstr.) **(Pol)**

INJURIES

[clinical application of multiplanar and 3D reconstruction of spiral CT in diagnosis of acetabulum fractures] Stroszczynski C, et al. **Aktuelle Radiol** 1996 Mar;6(2):91–5 (23 ref.) (Eng. Abstr.) **(Ger)**

RADIOGRAPHY

Idiopathic osteolysis of the acetabulum: a case report. Nemec B, et al. **J Bone Joint Surg Br** 1996 Jul;78(4):666–7 (8 ref.)

SURGERY

Radiographic course after acetabuloplasty and femoral osteotomy in hip dysplasia. Fritsch EW, et al. **Clin Orthop** 1996 Feb;(323):215–25 (52 ref.)
Acetabular allografts for restoration of bone stock in revision arthroplasty of the hip. Gross AE, et al. **Instr Course Lect** 1996;45:135–42 (41 ref.)
[Acetabular implant in Charnley's total arthroplasty. Review of 309 cases with a minimum of 15 years follow-up] Avedikian J, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1996;82(2):116–24

ACETABULUM

(40 ref.) (Eng. Abstr.) **(Fre)**

ACETALDEHYDE

PHARMACOKINETICS

Measuring and reporting the concentration of acetaldehyde in human breath. Jones AW. **Alcohol Alcohol** 1995 May; 30(3):271–85 (45 ref.)

PHARMACOLOGY

Role of acetaldehyde in the actions of ethanol on the brain--a review. Hunt WA. **Alcohol** 1996 Mar–Apr;13(2):147–51 (66 ref.)

ACETAMIDES

PHARMACOLOGY

Neuroprotective properties of the uncompetitive NMDA receptor antagonist remacemide hydrochloride. Palmer GC, et al. **Ann N Y Acad Sci** 1995 Sep 15;765:236–47; discussion 248 (38 ref.)

Cell cycle regulatory proteins are targets for induced differentiation of transformed cells: Molecular and clinical studies employing hybrid polar compounds. Marks PA, et al. **Int J Hematol** 1996 Jan;63(1):1–17 (152 ref.)

2-ACETAMIDOFLUORENE see **2-ACETYLAMINOFLUORENE**

ACETAMIDOPHENOL see **ACETAMINOPHEN**

ACETAMINOPHEN

ADVERSE EFFECTS

Acetaminophen and adverse chronic renal outcomes: an appraisal of the epidemiologic evidence. Barrett BJ. **Am J Kidney Dis** 1996 Jul;28(1 Suppl 1):S14–9 (15 ref.)

Acetaminophen: acute and chronic effects on renal function. Blantz RC. **Am J Kidney Dis** 1996 Jul;28(1 Suppl 1):S3–6 (23 ref.)

Habitual use of acetaminophen as a risk factor for chronic renal failure: a comparison with phenacetin. Buckalew VM Jr. **Am J Kidney Dis** 1996 Jul;28(1 Suppl 1):S7–13 (31 ref.)

Nonrenal toxicities of acetaminophen, aspirin, and nonsteroidal anti-inflammatory agents. Matzke GR. **Am J Kidney Dis** 1996 Jul;28(1 Suppl 1):S63–70 (38 ref.)

Does acetaminophen damage the heart? [see comments] Lip GY, et al. **J Toxicol Clin Toxicol** 1996;34(2):145–7 (23 ref.) Comment in: J Toxicol Clin Toxicol 1996;34(2):149–53. Comment in: J Toxicol Clin Toxicol 1996;34(2):155–6.

[Amidazophen. Yes or no?] Jákó J, et al. **Orv Hetil** 1995 Sep 24;136(39):2121–4 (50 ref.) (Eng. Abstr.) **(Hun)**

POISONING

Paracetamol intoxication and N-acetyl-cysteine treatment. De Groote J, et al. **Acta Gastroenterol Belg** 1995 May–Aug; 58(3–4):326–34 (78 ref.)

Management of acetaminophen toxicity. Larsen LC, et al. **Am Fam Physician** 1996 Jan;53(1):185–90 (25 ref.)

Acute renal failure due to acetaminophen ingestion: a case report and review of the literature. Blakely P, et al. **J Am Soc Nephrol** 1995 Jul;6(1):48–53 (21 ref.)

Acetaminophen toxicity: report of case and review of the literature. Schueler L, et al. **J Oral Maxillofac Surg** 1995 Oct;53(10):1208–12 (13 ref.)

[Clinical-toxicological case (1). Dosage of N-acetylcysteine in acute paracetamol poisoning] Kind B, et al. **Schweiz Rundsch Med Prax** 1996 Aug 2;85(31–32):935–8 (33 ref.) (Eng. Abstr.) **(Ger)**

THERAPEUTIC USE

[Effectiveness of fixed analgesic combinations exemplified by thomapyrin] Aicher B, et al. **Wien Klin Wochenschr** 1996;108(8):219–33 (104 ref.) (Eng. Abstr.) **(Ger)**

TOXICITY

Acetaminophen/aspirin mixtures: experimental data. Porter GA. **Am J Kidney Dis** 1996 Jul;28(1 Suppl 1):S30–3 (11 ref.)

Comparative methods of toxicity testing. Consensus document following an International Life Sciences Institute-ILSI Europe Workshop held in May 1995. Huggett AC, et al. **Food Chem Toxicol** 1996 Feb; 34(2):183–92 (34 ref.)

Series: current issues in mutagenesis and carcinogenesis, No. 65. The genotoxicity and carcinogenicity of paracetamol: a regulatory (re)view. Bergman K, et al. **Mutat Res** 1996 Feb 1;349(2):263–88 (103 ref.)

ACETATE-FREE BIOFILTRATION see **HEMODIAFILTRATION**

ACETATES

BLOOD

[Acetate] Shimizu T. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:590–2 (16 ref.) **(Jpn)**

ACETAZOLAMIDE

THERAPEUTIC USE

Acetazolamide in the treatment of seizures. Reiss WG, et al. **Ann Pharmacother** 1996 May;30(5):514–9 (68 ref.)

ACETIC ACIDS

[Prostacyclin mimetics with non-prostanoid structures] Kondo K, et al. **Nippon Yakurigaku Zasshi** 1995 Sep; 106(3):181–91 (21 ref.) (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Gabapentin: pharmacokinetics, efficacy, and safety. Beydoun A, et al. **Clin Neuropharmacol** 1995 Dec;18(6):469–81 (61 ref.)

PHARMACOLOGY

Gabapentin: pharmacokinetics, efficacy, and safety. Beydoun A, et al. **Clin Neuropharmacol** 1995 Dec;18(6):469–81 (61 ref.)

THERAPEUTIC USE

Potential use of gabapentin and lamotrigine. Cory PR, et al. **Ann Pharmacother** 1995 Nov;29(11):1160–1 (10 ref.)

Gabapentin. McLean MJ. **Epilepsia** 1995;36 Suppl 2:S73–86 (70 ref.)

[Gabapentin (Neurontin): a new possibility in the add-on therapy of partial epilepsies] Krämer G. **Schweiz Rundsch Med Prax** 1996 Jan 23;85(4):84–93 (106 ref.) (Eng. Abstr.) **(Ger)**

[Refractory epilepsy in adults and the new antiepileptic drugs: the role of gabapentin] Galdames D, et al. **Rev Med Chil** 1995 Apr;123(4):500–8 (34 ref.) (Eng. Abstr.) **(Spa)**

[Advances in the diagnostic and treatment of infantile epilepsy] Legido A. **Rev Neurol** 1996 Jun;24(130):688–93 (25 ref.) **(Spa)**

ACETONE

ADMINISTRATION & DOSAGE

Removal of superglue from the external ear using acetone: case report and literature review. Abadir WF, et al. **J Laryngol Otol** 1995 Dec;109(12):1219–21 (5 ref.)

ACETONE BODIES see **KETONE BODIES**

ACETOPHENETIDIN see **PHENACETIN**

N-ACETYL-BETA-D-GLUCOSAMINIDASE see **ACETYLGLUCOSAMINIDASE**

ACETYL COA see **ACETYL COENZYME A**

ACETYL COA ACYLTRANSFERASE

DEFICIENCY

[Ketoacidotic coma in an infant as the form of onset of a mitochondrial 2-methylacetoacetyl-CoA thiolase deficiency] Yeste Fernández D, et al. **An Esp Pediatr** 1996 Jun;44(6):620–2 (9 ref.) **(Spa)**

ACETYL COENZYME A

METABOLISM

Disturbances of acetyl-CoA, energy and acetylcholine metabolism in some encephalopathies. Szutowicz A, et al. **Acta Neurobiol Exp (Warsz)** 1996;56(1):323–39 (110 ref.)

ACETYL COENZYME A ACYLTRANSFERASE see **ACETYL COA ACYLTRANSFERASE**

ACETYL GLYCERYL ETHER PHOSPHORYLCHOLINE see **PLATELET ACTIVATING FACTOR**

2-ACETYLAMINOFLUORENE

TOXICITY

Relationship of DNA adducts derived from 2-acetylaminofluorene to cell proliferation and the induction of rodent liver and bladder tumors. Cohen SM, et al. **Toxicol Pathol** 1995 Mar–Apr;23(2):136–42 (21 ref.)

ACETYLCHOLINE

see related
CHOLINERGIC AGENTS
RECEPTORS, CHOLINERGIC

The emerging three-dimensional structure of a receptor. The nicotinic acetylcholine receptor. Hucho F, et al. **Eur J Biochem** 1996 Aug 1;239(3):539–57 (180 ref.)

METABOLISM

Disturbances of acetyl-CoA, energy and acetylcholine metabolism in some encephalopathies. Szutowicz A, et al. **Acta Neurobiol Exp (Warsz)** 1996;56(1):323–39 (110 ref.)

Overexpression of choline acetyltransferase reconstitutes discrete acetylcholine release in some but not all synapse formation-defective neuroblastoma cells. Zhong ZG, et al. **J Physiol Paris** 1995;89(3):137–45 (40 ref.)

Minireview. Galanin-acetylcholine interactions: relevance to memory and Alzheimer's disease. Crawley JN. **Life Sci** 1996;58(24):2185–99 (112 ref.)

A unifying hypothesis for acetylcholine release. Israël M, et al. **Neurochem Int** 1996 Jan;28(1):1–9 (88 ref.)

PHYSIOLOGY

Acetylcholine and hallucinations: disease-related compared to drug-induced alterations in human consciousness. Perry EK, et al. **Brain Cogn** 1995 Aug;28(3):240–58 (65 ref.)

Involvement of brain catecholamines and acetylcholine in growth hormone hypersecretory states. Pathophysiological, diagnostic and therapeutic implications. Müller EE, et al. **Drugs** 1995 Nov; 50(5):805–37 (285 ref.)

Optimal physical performance in athletes: key roles of dopamine in a specific neurotransmitter/hormonal mechanism. Gilbert C. **Mech Ageing Dev** 1995 Oct 13; 84(2):83–102 (85 ref.)

Cholinergic and vasoactive intestinal polypeptidergic innervation of the cerebral arteries. Dauphin F, et al. **Pharmacol Ther** 1995;67(3):385–417 (274 ref.)

ACETYLCHOLINE AGENTS see **CHOLINERGIC AGENTS**

ACETYLCHOLINE AGONISTS see **CHOLINERGIC AGONISTS**

ACETYLCHOLINE ANTAGONISTS see **CHOLINERGIC ANTAGONISTS**

ACETYLCHOLINE RECEPTORS see **RECEPTORS, CHOLINERGIC**

ACETYLCHOLINESTERASE

BLOOD

Cholinesterase inhibition: complexities in interpretation. Lotti M. **Clin Chem** 1995 Dec;41(12 Pt 2):1814–8 (22 ref.)

METABOLISM

Cholinergic signaling in the rat pineal gland. Laitinen JT, et al. **Cell Mol Neurobiol** 1995 Apr;15(2):177–92 (72 ref.)

PHYSIOLOGY

Tetrameric (G4) acetylcholinesterase: structure, localization, and physiological regulation. Fernandez HL, et al. **J Neurochem** 1996 Apr;66(4):1335–46 (120 ref.)

ACETYLCHOLINESTERASE INHIBITORS see **CHOLINESTERASE INHIBITORS**

ACETYLCYSTEINE

ADMINISTRATION & DOSAGE

[Clinical-toxicological case (1). Dosage of N-acetylcysteine in acute paracetamol poisoning] Kind B, et al. **Schweiz Rundsch Med Prax** 1996 Aug 2;85(31–32):935–8 (33 ref.) (Eng. Abstr.) **(Ger)**

[The dissolution of cystine lithiasis with n-acetylcysteine] Benítez Navio J, et al. **Arch Esp Urol** 1995 Nov;48(9):944–8 (13 ref.) (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Antidotes: benefits and risks. Proudfoot AT. **Toxicol Lett** 1995 Dec;82–83:779–83 (20 ref.)

ANALOGS & DERIVATIVES

[Lactacystin: a tool for elucidation of proteasome functions] Omura S, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr; 41(4):327–36 (57 ref.) **(Jpn)**

PHARMACOLOGY

Activity profiles of antimutagens: in vitro and in vivo data. Waters MD, et al. **Mutat Res** 1996 Feb 19;350(1):109–29 (117 ref.)

THERAPEUTIC USE

Paracetamol intoxication and N-acetyl-cysteine treatment. De Groote J, et al. **Acta Gastroenterol Belg** 1995 May–Aug; 58(3–4):326–34 (78 ref.)

Chemopreventive properties and mechanisms of N-Acetylcysteine. The experimental background. De Flora S, et al. **J Cell Biochem Suppl** 1995;22:33–41 (37 ref.)

N-acetylcysteine (NAC) and glutathione (GSH): antioxidant and chemopreventive properties, with special reference to lung cancer. van Zandwijk N. **J Cell Biochem Suppl** 1995; 22:24–32 (48 ref.)

The role of N-acetylcysteine in the treatment of chronic obstructive pulmonary disease [editorial] van Herwaarden CL, et al. **Neth J Med** 1995 Aug;47(2):45–8 (21 ref.)

ACETYLFORMALDEHYDE see PYRUVALDEHYDE

ACETYLGALACTOSAMINE

METABOLISM

Oligosaccharides containing beta 1,4-linked N-acetylgalactosamine, a paradigm for protein-specific glycosylation. Manzella SM, et al. **J Biol Chem** 1996 May 24;271(21):12117-20 (54 ref.)

ACETYLGLUCOSAMINE

METABOLISM

O-linked N-acetylglucosamine: the "yin-yang" of Ser/Thr phosphorylation? Nuclear and cytoplasmic glycosylation. Hart GW, et al. **Adv Exp Med Biol** 1995;376:115-23 (45 ref.)

ACETYLGLUCOSAMINIDASE

METABOLISM

Are there biological functions for bacterial endo-N-acetyl-beta-D-glucosaminidases? Karamanos Y, et al. **Res Microbiol** 1995 Jul-Aug;146(6):437-43 (42 ref.)

URINE

Urinary N-acetyl-beta-D-glucosaminidase determination in newborns and children: methods and diagnostic applications. Csáthy L, et al. **Eur J Clin Chem Clin Biochem** 1995 Sep;33(9):575-87 (188 ref.)

[Urinary N-acetyl-beta-D-glucosaminidase] Sugita O. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:447-9 (20 ref.) **(Jpn)**

N-ACETYLLACTOSAMINE SYNTHASE

GENETICS

Murine beta 1,4-galactosyltransferase. Analysis of a gene that serves both a housekeeping and a cell specific function. Shaper JH, et al. **Adv Exp Med Biol** 1995;376:95-104 (33 ref.)

METABOLISM

Beta 1,4-galactosyltransferase variations in rheumatoid arthritis. Alavi A, et al. **Adv Exp Med Biol** 1995;376:185-92 (35 ref.)

Cell surface beta 1,4-galactosyltransferase. A signal transducing receptor? Dubois DH, et al. **Adv Exp Med Biol** 1995;376:105-14 (72 ref.)

PHYSIOLOGY

Evaluation of beta 1,4-galactosyltransferase in rheumatoid arthritis and its role in the glycosylation network associated with this disease. Alavi A, et al. **Glycoconj J** 1995 Jun; 12(3):206-10 (35 ref.)

N-ACETYLLACTOSAMINE SYNTHETASE see N-ACETYLLACTOSAMINE SYNTHASE

ACETYLMETHADOL see METHADYL ACETATE

N-ACETYLMURAMOYL-L-ALANINE AMIDASE

METABOLISM

From growth to autolysis: the murein hydrolases in Escherichia coli. Höltje JV. **Arch Microbiol** 1995 Oct; 164(4):243-54 (94 ref.)

ACETYLMURAMYL-ALANYL-ISOGLUTAMINE

ANALOGS & DERIVATIVES

Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide. Kleinerman ES. **Hematol Oncol Clin North Am** 1995 Aug;9(4):927-38 (37 ref.)

CHEMICAL SYNTHESIS

Development of an emulsion-based muramyl dipeptide adjuvant formulation for vaccines. Lidgate DM, et al. **Pharm Biotechnol** 1995;6:313-24 (34 ref.)

N-ACETYLNEURAMINIC ACIDS see SIALIC ACIDS

ACETYLSALICYLIC ACID see ASPIRIN

ACETYLTRANSFERASES

GENETICS

Genetic predisposition in occupational toxicology. Bolt HM. **Arch Toxicol Suppl** 1996;18:362-6 (32 ref.)

PHYSIOLOGY

Special HATs for special occasions: linking histone acetylation to chromatin assembly and gene activation. Brownell JE, et al. **Curr Opin Genet Dev** 1996 Apr; 6(2):176-84 (83 ref.)

ACHALASIA, ESOPHAGEAL see ESOPHAGEAL ACHALASIA

ACHIEVEMENT

Predicting antisocial behavior in youngsters displaying poor academic achievement: a review of risk factors. Brier N. **J Dev Behav Pediatr** 1995 Aug;16(4):271-6 (90 ref.)

Children who have difficulty in school: a primary pediatrician's approach. McInerny TK. **Pediatr Rev** 1995 Sep;16(9):325-32; quiz 332 (18 ref.)

ACHILLES TENDON

Lower leg overuse injuries in athletes. Järvinen M. **Knee Surg Sports Traumatol Arthrosc** 1993;1(2):126-30 (33 ref.)

INJURIES

Diagnosis and treatment of Achilles tendon rupture. Kuwada GT. **Clin Podiatr Med Surg** 1995 Oct;12(4):633-52 (75 ref.)

[Fracture of an ossified Achilles tendon] Krause K, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Feb;164(2):171-2 (9 ref.) **(Ger)**

TRANSPLANTATION

Subcutaneous pretibial cyst formation associated with anterior cruciate ligament allografts: a report of four cases and literature review. Victoroff BN, et al. **Arthroscopy** 1995 Aug;11(4):486-94 (25 ref.)

ACHLORHYDRIA

COMPLICATIONS

Bacteria in the aetio-pathogenesis of gastric cancer: a review. Houben GM, et al. **Scand J Gastroenterol Suppl** 1995; 212:13-8 (61 ref.)

ACHONDROPLASIA

GENETICS

Cardiac malformation in two infants with hypochondrogenesis. Potocki L, et al. **Am J Med Genet** 1995 Nov 20;59(3):295-9 (17 ref.)

Mutations of the fibroblast growth factor receptor-3 gene in achondroplasia. Rousseau F, et al. **Horm Res** 1996; 45(1-2):108-10 (18 ref.)

ACHROMOBACTER see ALCALIGENES

ACHROMOBACTERIACEAE see GRAM-NEGATIVE AEROBIC BACTERIA

ACHYLIA GASTRICA see ACHLORHYDRIA

ACID ANHYDRIDE HYDROLASES

METABOLISM

[Organelle specificity of yeast cell polyphosphatases] Kulaev IS, et al. **Biokhimiia** 1995 Sep;60(9):1396-402 (34 ref.) (Eng. Abstr.) **(Rus)**

ACID ASPIRATION SYNDROME see PNEUMONIA, ASPIRATION

ACID-BASE EQUILIBRIUM

see related
ACIDOSIS
ALKALOSIS

Moving more closely to acid-base relationships in the body as a whole. Gamble JL Jr. **Perspect Biol Med** 1996 Summer; 39(4):593-600 (9 ref.)

[Base excess and buffer base] Matsuzaki K. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:782-6 (4 ref.) **(Jpn)**

[Arterial pH] Matsuzaki K. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:800-3 (5 ref.) **(Jpn)**

DRUG EFFECTS

Effect of different buffers on the biocompatibility of CAPD solutions. Schambye HT. **Perit Dial Int** 1996;16 Suppl 1:S130-6 (48 ref.)

Gastric alkalinization, pneumonia, and systemic infections: the controversy. Tryba M, et al. **Scand J Gastroenterol Suppl** 1995;210:53-9 (69 ref.)

PHYSIOLOGY

Extreme derangements of acid-base balance in exercise: advantages and limitations of the Stewart analysis. Fedde MR, et al. **Can J Appl Physiol** 1995 Sep;20(3):369-79 (10 ref.)

Contribution of acid-base changes to control of breathing during exercise. Forster HV, et al. **Can J Appl Physiol** 1995 Sep;20(3):380-94 (97 ref.)

A quantitative approach to acid-base chemistry. Heigenhauser GJ. **Can J Appl Physiol** 1995 Sep; 20(3):333-40 (20 ref.)

Acid-base balance: origin of plasma [H+] during exercise. Kowalchuk JM, et al. **Can J Appl Physiol** 1995 Sep; 20(3):341-56 (33 ref.)

Origins of [H+] changes in exercising skeletal muscle. Lindinger MI. **Can J Appl Physiol** 1995 Sep;20(3):357-68 (38 ref.)

Ontogeny of proximal tubule acidification [editorial] Baum M, et al. **Kidney Int** 1995 Dec;48(6):1697-704 (90 ref.)

Liver and kidney in acid-base regulation. Hüssinger D. **Nephrol Dial Transplant** 1995;10(9):1536 (5 ref.)

The kidney in acid-base balance. Hanna JD, et al. **Pediatr Clin North Am** 1995 Dec;42(6):1365-95 (85 ref.)

[Lactate versus intramucosal pCO2 or pH?] Mertzlufft F. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Oct; 30 Suppl 1:S27-33 (41 ref.) **(Ger)**

[Effect of organ preservation conditions on reperfusion after liver transplantation] Walcher F, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Oct; 30 Suppl 1:S55-7 (27 ref.) **(Ger)**

[Liver metabolism and acid-base balance] Zander R. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Oct; 30 Suppl 1:S48-51 (26 ref.) **(Ger)**

ACID-BASE IMBALANCE

Acid-base disorders in medicine. Laski ME, et al. **Dis Mon** 1996 Feb;42(2):51-125 (200 ref.)

BLOOD

[Disorders of acid-base balance caused by blood products] Schmitt HJ. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Oct; 30 Suppl 1:S62-4 (20 ref.) **(Ger)**

[Base excess and buffer base] Matsuzaki K. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:782-6 (4 ref.) **(Jpn)**

METABOLISM

The skeleton as an ion exchange system: implications for the role of acid-base imbalance in the genesis of osteoporosis. Barzel US. **J Bone Miner Res** 1995 Oct;10(10):1431-6 (31 ref.)

Tubular function and acid-base disturbances. Bleich M. **Nephrol Dial Transplant** 1995;10(9):1540-1 (13 ref.)

ACID ETCHING, DENTAL

METHODS

Effect of varying etching times on the bond strength of ceramic brackets. Olsen ME, et al. **Am J Orthod Dentofacial Orthop** 1996 Apr;109(4):403-9 (49 ref.)

ACID MALTASE see GLUCAN 1,4-ALPHA-GLUCOSIDASE

ACID PHOSPHATASE

BLOOD

Neuroendocrine tumors of the liver and pancreas associated with elevated serum prostatic acid phosphatase. Kaneko Y, et al. **Intern Med** 1995 Sep;34(9):886-91 (35 ref.)

[Acid phosphatase] Kishi H, et al. **Nippon Rinsho** 1995 Feb; 53 Su Pt 1:338-41 (13 ref.) **(Jpn)**

[Acid phosphatase] Otani K, et al. **Nippon Rinsho** 1995 Mar; 53 Su Pt 2:247-50 (8 ref.) **(Jpn)**

[Myeloperoxidase] Saito K, et al. **Nippon Rinsho** 1995 Mar; 53 Su Pt 2:251-3 (6 ref.) **(Jpn)**

METABOLISM

The tartrate-resistant purple acid phosphatase of bone osteoclasts--a protein phosphatase with multivalent substrate specificity and regulation. Andersson G, et al. **Acta Orthop Scand Suppl** 1995 Oct;266:189-94 (28 ref.)

Clinical and biological aspects of acid phosphatase. Moss DW, et al. **Crit Rev Clin Lab Sci** 1995;32(4):431-67 (285 ref.)

[Biosynthesis, processing, and lysosome targeting of acid phosphatase] Himeno M, et al. **Nippon Rinsho** 1995 Dec; 53(12):2898-903 (17 ref.) (Eng. Abstr.) **(Jpn)**

ACID RAIN

[Atmospheric pollution: acid depositions] De Luca D'Alessandro E. **Ann Ig** 1994 Jul-Dec;6(4-6):793-802 (27 ref.) (Eng. Abstr.) **(Ita)**

ACID SEROMUCOID see OROSOMUCOID

ACIDIC FIBROBLAST GROWTH FACTOR see FIBROBLAST GROWTH FACTOR, ACIDIC

ACIDIC PANCREATIC TRYPSIN INHIBITOR see

ACIDIC PANCREATIC TRYPSIN INHIBITOR

TRYPSIN INHIBITOR, KAZAL PANCREATIC

ACIDOSIS

Metabolic acidosis stimulates protein metabolism in uremia. Mitch WE. **Miner Electrolyte Metab** 1996;22(1-3):62-5 (20 ref.)

BLOOD

[Diagnosis of organic aciduria] García L, et al. **Rev Neurol** 1995;23 Suppl 3:S325-9 (16 ref.) **(Spa)**

CHEMICALLY INDUCED

Salicylism from topical salicylates: review of the literature. Brubacher JR, et al. **J Toxicol Clin Toxicol** 1996; 34(4):431-6 (31 ref.)

COMPLICATIONS

Follow-up of children born with an umbilical arterial blood pH < 7 [see comments] Nagel HT, et al. **Am J Obstet Gynecol** 1995 Dec;173(6):1758-64 (26 ref.) Comment in: Am J Obstet Gynecol 1996 Jul;175(1):229.

Is it necessary to treat metabolic acidosis in chronic renal insufficiency? Hörl WH. **Nephrol Dial Transplant** 1995; 10(9):1542-3 (27 ref.)

Methemoglobinemia in an infant: case report and review of the literature. Jolly BT, et al. **Pediatr Emerg Care** 1995 Oct;11(5):294-7 (22 ref.)

Metabolic acidosis as a uremic toxin. Bailey JL, et al. **Semin Nephrol** 1996 May;16(3):160-6 (37 ref.)

ENZYMOLOGY

The role of H(+)-ATPases in urinary acidification. Constantinescu A. **Pediatr Nephrol** 1995 Aug;9(4):510-3 (24 ref.)

ETIOLOGY

[Methemoglobinemia, acidemia and diarrhea induced by hypersensitivity to cow's milk proteins] Catalán Muñoz M, et al. **An Esp Pediatr** 1996 Mar;44(3):295-6 (6 ref.) **(Spa)**

[Ketoacidotic coma in an infant as the form of onset of a mitochondrial 2-methylacetoacetyl-CoA thiolase deficiency] Yeste Fernández D, et al. **An Esp Pediatr** 1996 Jun;44(6):620-2 (9 ref.) **(Spa)**

METABOLISM

Uremic acidosis and protein metabolism. Mitch WE. **Curr Opin Nephrol Hypertens** 1995 Nov;4(6):488-92 (41 ref.)

Acidosis and glucocorticoids induce branched-chain amino acid catabolism. England BK, et al. **Miner Electrolyte Metab** 1996;22(1-3):69-71 (26 ref.)

Necessary but not sufficient: the role of glucocorticoids in the acidosis-induced increase in levels of mRNAs encoding proteins of the ATP-dependent proteolytic pathway in rat muscle. Price SR, et al. **Miner Electrolyte Metab** 1996; 22(1-3):72-5 (14 ref.)

Influence of acidosis on protein metabolism. Ballmer PE, et al. **Nutrition** 1995 Sep-Oct;11(5):462-8; discussion 470 (66 ref.)

PHYSIOPATHOLOGY

The role of intracellular acidosis in muscle fatigue. Allen DG, et al. **Adv Exp Med Biol** 1995;384:57-68 (54 ref.)

THERAPY

Is it necessary to treat metabolic acidosis in chronic renal insufficiency? Hörl WH. **Nephrol Dial Transplant** 1995; 10(9):1542-3 (27 ref.)

URINE

The role of H(+)-ATPases in urinary acidification. Constantinescu A. **Pediatr Nephrol** 1995 Aug;9(4):510-3 (24 ref.)

[Diagnosis of organic aciduria] García L, et al. **Rev Neurol** 1995;23 Suppl 3:S325-9 (16 ref.) **(Spa)**

ACIDOSIS, DIABETIC see **DIABETIC KETOACIDOSIS**

ACIDOSIS, LACTIC

CHEMICALLY INDUCED

[Lactic acidosis associated with biguanides] Safadi R, et al. **Harefuah** 1996 Feb 15;130(4):280-3 (40 ref.) **(Heb)**

PHYSIOPATHOLOGY

[Is sepsis and septic shock due to a global oxygen insufficiency? A review in 2 parts. 2: Sepsis and lactate] Ensinger H, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May; 31(4):205-15 (175 ref.) **(Ger)**

ACIDOSIS, RENAL TUBULAR

CHEMICALLY INDUCED

Nephrogenic diabetes insipidus and renal tubular acidosis secondary to foscarnet therapy. Navarro JF, et al. **Am J Kidney Dis** 1996 Mar;27(3):431-4 (16 ref.)

COMPLICATIONS

Osteomalacia as a presenting manifestation of Sjögren's syndrome. Hajjaj-Hassouni N, et al. **Rev Rhum Engl Ed** 1995 Jul-Sep;62(7-8):529-32 (30 ref.)

DIAGNOSIS

Renal tubular acidosis. Pathophysiology and diagnosis. Smulders YM, et al. **Arch Intern Med** 1996 Aug 12-26; 156(15):1629-36 (63 ref.)

ETIOLOGY

Primary distal renal tubular acidosis as a result of a gradient defect. Bonilla-Felix M. **Am J Kidney Dis** 1996 Mar; 27(3):428-30 (10 ref.)

Renal tubular dysfunction and acidosis. Sharma AM. **Nephrol Dial Transplant** 1995;10(9):1544-45 (4 ref.)

[Renal tubular acidosis] Zawadzki J. **Pediatr Pol** 1995 Dec; 70(12):1059-64 (36 ref.) (Eng. Abstr.) **(Pol)**

GENETICS

Arthrogryposis, renal dysfunction and cholestasis syndrome: report of five patients from three Italian families. Di Rocco M, et al. **Eur J Pediatr** 1995 Oct;154(10):835-9 (8 ref.)

PHYSIOPATHOLOGY

Underlying defects in distal renal tubular acidosis: new understandings. Batlle D, et al. **Am J Kidney Dis** 1996 Jun; 27(6):896-915 (120 ref.)

Renal tubular acidosis. Pathophysiology and diagnosis. Smulders YM, et al. **Arch Intern Med** 1996 Aug 12-26; 156(15):1629-36 (63 ref.)

ACIDS

[Stereochemistry of highly selective transition metal or Lewis acid-catalyzed asymmetric reactions] Hiroi K. **Yakugaku Zasshi** 1995 Aug;115(8):553-69 (63 ref.) (Eng. Abstr.) **(Jpn)**

CEREBROSPINAL FLUID

[The acid-base balance of cerebrospinal fluid] Kępa L. **Neurol Neurochir Pol** 1996 Jan-Feb;30(1):113-21 (27 ref.) (Eng. Abstr.) **(Pol)**

PHARMACOLOGY

Low pH adaptation and the acid tolerance response of Salmonella typhimurium. Foster JW. **Crit Rev Microbiol** 1995;21(4):215-37 (90 ref.)

POISONING

Corrosive injuries of the oesophagus and stomach: experience in management at a regional paediatric centre. Stiff G, et al. **Ann R Coll Surg Engl** 1996 Mar;78(2):119-23 (68 ref.)

URINE

Organic acidurias and related abnormalities. Lehotay DC, et al. **Crit Rev Clin Lab Sci** 1995;32(4):377-429 (262 ref.)

ACINETOBACTER

Resistant nosocomial gram-negative bacillary pathogens: Acinetobacter baumannii, Xanthomonas maltophilia, and Pseudomonas cepacia. Fang FC, et al. **Curr Clin Top Infect Dis** 1996;16:52-83 (363 ref.)

ACINETOBACTER CALCOACETICUS

Acinetobacter endocarditis in children: a case report and review of the literature. Malik AS. **Infection** 1995 Sep-Oct; 23(5):306-8 (18 ref.)

Nosocomial bacteremia due to Acinetobacter baumannii. Clinical features, epidemiology, and predictors of mortality. Seifert H, et al. **Medicine (Baltimore)** 1995 Nov;74(6):340-9 (46 ref.)

ACINETOBACTER INFECTIONS

COMPLICATIONS

Acinetobacter endocarditis in children: a case report and review of the literature. Malik AS. **Infection** 1995 Sep-Oct; 23(5):306-8 (18 ref.)

MICROBIOLOGY

Nosocomial bacteremia due to Acinetobacter baumannii. Clinical features, epidemiology, and predictors of mortality. Seifert H, et al. **Medicine (Baltimore)** 1995 Nov;74(6):340-9 (46 ref.)

ACITRETIN

ADVERSE EFFECTS

Prolonged treatment with oral retinoids in adults: no influence on the frequency and severity of spinal abnormalities. Van Dooren-Greebe RJ, et al. **Br J Dermatol** 1996 Jan;134(1):71-6 (30 ref.)

PHARMACOKINETICS

[Trans-acitretin is metabolized back to etretinate. Importance for oral retinoid therapy] Almond-Roesler B, et al. **Hautarzt** 1996 Mar;47(3):173-7 (29 ref.) (Eng. Abstr.) **(Ger)**

13-CIS-ACITRETIN see **ACITRETIN**

ACNE see **ACNE VULGARIS**

ACNE ROSACEA

DRUG THERAPY

[Pharma-clinics. How I treat... rosacea] Piérard-Franchimont C, et al. **Rev Med Liege** 1996 Jun; 51(6):393-5 (25 ref.) **(Fre)**

[The oral treatment of rosacea with isotretinoin] Jansen T, et al. **Dtsch Med Wochenschr** 1995 Dec 15;120(50):1745-7 (32 ref.) **(Ger)**

PARASITOLOGY

Rosacea-like demodicosis in an HIV-positive child. Barrio J, et al. **Dermatology** 1996;192(2):143-5 (23 ref.)

ACNE VULGARIS

Why the "SAPHO" syndrome? [editorial] Kahn MF. **J Rheumatol** 1995 Nov;22(11):2017-9 (20 ref.)

DRUG THERAPY

Rationale for the development of new topical treatments for acne vulgaris. Gibson JR. **Cutis** 1996 Jan;57(1 Suppl):13-9 (47 ref.)

Benzamycin gel for acne. **Drug Ther Bull** 1995 Aug; 33(8):62-4 (13 ref.)

Bacteria and antimicrobial agents in the treatment of acne. Parry EJ, et al. **Int J Dermatol** 1996 Apr;35(4):249-51 (15 ref.)

THERAPY

An overview of acne and its treatment. Thiboutot DM. **Cutis** 1996 Jan;57(1 Suppl):8-12 (16 ref.)

[A survey on the treatment of acne] Huang ZM. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Jun; 15(6):379-81 (20 ref.) **(Chi)**

ACOCANTHERIN see **OUABAIN**

ACOUSTIC EVOKED BRAIN STEM POTENTIALS see **EVOKED POTENTIALS, AUDITORY, BRAIN STEM**

ACOUSTIC NERVE

Pineal germinoma with cranial nerve metastasis. Incesu L, et al. **Radiol Med (Torino)** 1996 Apr;91(4):471-2 (11 ref.)

ANATOMY & HISTOLOGY

Structural diversity in the inner ear of teleost fishes: implications for connections to the Mauthner cell. Popper AN, et al. **Brain Behav Evol** 1995;46(3):131-40 (70 ref.)

PHYSIOLOGY

The octavolateralis system and Mauthner cell: interactions and questions. Eaton RC, et al. **Brain Behav Evol** 1995; 46(3):124-30 (60 ref.)

Physiology of primary saccular afferents of goldfish: implications for Mauthner cell response. Fay RR. **Brain Behav Evol** 1995;46(3):141-50 (54 ref.)

Comparative studies on the Mauthner cell of teleost fish in relation to sensory input. Zottoli SJ, et al. **Brain Behav Evol** 1995;46(3):151-64 (115 ref.)

ACOUSTIC NERVE DISEASES

ETIOLOGY

Pineal germinoma with cranial nerve metastasis. Incesu L, et al. **Radiol Med (Torino)** 1996 Apr;91(4):471-2 (11 ref.)

ACOUSTIC NEUROMA see **NEUROMA, ACOUSTIC**

ACOUSTIC STIMULATION

see related
EVOKED POTENTIALS, AUDITORY

Tinnitus and otoacoustic emissions. Ceranic BJ, et al. **Clin Otolaryngol** 1995 Jun;20(3):192-200 (89 ref.)

ACOUSTIC TRAUMA see **HEARING LOSS, NOISE-INDUCED**

ACOUSTICS

see related
SPEECH ACOUSTICS

Bio-acoustic signals from stenotic tube flow: state of the art and perspectives for future methodological development. Ask P, et al. **Med Biol Eng Comput** 1995 Sep;33(5):669–75 (29 ref.)

Magnetic resonance elastography. Muthupillai R, et al. **Nat Med** 1996 May;2(5):601–3 (16 ref.)

ACOUSTICS, SPEECH see **SPEECH ACOUSTICS**

ACQUIRED IMMUNODEFICIENCY SYNDROME

see related
AIDS SERODIAGNOSIS
HIV SEROPOSITIVITY
HIV SEROPREVALENCE
LYMPHOMA, AIDS-RELATED

AIDS phobia, public health warnings, and lawsuits: deterring harm or rewarding ignorance? Mariner WK. **Am J Public Health** 1995 Nov;85(11):1562–8 (42 ref.)

The risk of domestic violence and women with HIV infection: implications for partner notification, public policy, and the law. Rothenberg KH, et al. **Am J Public Health** 1995 Nov;85(11):1569–76 (98 ref.)

Historical and analytical overview of policy issues affecting women living with AIDS: a blueprint for learning from our past. Cooper EB. **Bull N Y Acad Med** 1995 Summer; 72(1 Suppl):283–99 (59 ref.)

The role of the dentist in the era of AIDS. Glick M. **Dent Clin North Am** 1996 Apr;40(2):343–57 (52 ref.)

Immunologic and virologic markers determining progression to AIDS. Schellekens PT, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995;10 Suppl 2:S62–6 (30 ref.)

The mythology of modern medicine—IV. HIV: heuristically important virus. AIDS: advances induced deficiency syndromes. Kothari MV, et al. **J Postgrad Med** 1994 Jan–Mar;40(1):42–5 (31 ref.)

AIDS: newer concepts in the immunopathogenic mechanisms of human immunodeficiency virus disease. Fauci AS. **Proc Assoc Am Physicians** 1995 Apr;107(1):1–7 (25 ref.)

AIDS: clinical and scientific issues past, present and future. Dalgleish AG, et al. **Q J Nucl Med** 1995 Sep;39(3):156–62 (44 ref.)

Human immunodeficiency virus and acquired immunodeficiency syndrome: recent developments and their implications for pediatric surgeons. Cooper A. **Semin Pediatr Surg** 1995 Nov;4(4):252–61 (88 ref.)

[Acquired immunodeficiency syndrome—1995 (Part [illegible])] Lasry Y, et al. **Harefuah** 1995 Dec 15;129(12):596–602 [illegible] ref.) **(Heb)**

[New anti-HIV drug which binds the oligosaccharides of HIV envelope glycoprotein] Mizuochi T, et al. **Nippon Rinsho** 1995 Sep;53(9):2340–9 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Hepatitis induced by HIV (human immunodeficiency virus)] Fujii T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):141–3 (14 ref.) **(Jpn)**

[Basic results of studies on AIDS from 1994] Pokrovskiĭ VI, et al. **Vopr Virusol** 1995 Nov–Dec;40(6):242–6 (0 ref.) **(Rus)**

[AIDS: the Spanish view] Schüller DA. **An R Acad Nac Med (Madr)** 1996;Spec No:157–81; discussion 181–2 (73 ref.) **(Spa)**

[Two different HIV types are known. The differences may explain mechanisms of the infection] Andersson S, et al. **Lakartidningen** 1996 Jun 5;93(23):2230, 2235–6 (37 ref.) **(Swe)**

COMPLICATIONS

AIDS behind bars: preventing HIV spread among incarcerated drug injectors [editorial] Dolan K, et al. **AIDS** 1995 Aug;9(8):825–32 (72 ref.)

Tuberculous brain abscess should be considered in HIV/AIDS patients [letter] Velasco-Martínez JJ, et al. **AIDS** 1995 Oct;9(10):1197–9 (16 ref.)

Pathophysiology and treatment of the AIDS wasting syndrome. Kotler DP, et al. **AIDS Clin Rev** 1995–96; :229–75 (211 ref.)

Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration. Guillaume MP, et al. **Am J Gastroenterol** 1996 Jan;91(1):165–8 (14 ref.)

Concurrent thrombotic thrombocytopenic purpura and immune thrombocytopenic purpura in an HIV-positive patient: case report and review of the literature. Yospur LS, et al. **Am J Hematol** 1996 Jan;51(1):73–8 (29 ref.)

Charting a new course through the chaos of KS (Kaposi's sarcoma) [comment] Nickoloff BJ, et al. **Am J Pathol** 1996 May;148(5):1323–9 (82 ref.) Comment on: Am J Pathol 1996 May;148(5):1387–96.

Fifth Seah Cheng Siang Memorial Lecture. Human immunodeficiency virus and the respiratory system—pulmonary manifestations of acquired immunodeficiency syndrome. Dudley A, et al. **Ann Acad Med Singapore** 1995 May;24(3):482–9 (35 ref.)

Visceral leishmaniasis emerging as an important opportunistic infection in HIV-infected persons living in areas nonendemic for Leishmania donovani. Albrecht H, et al. **Arch Pathol Lab Med** 1996 Feb;120(2):189–98 (53 ref.)

Pathology of microsporidiosis: emerging parasitic infections in patients with acquired immunodeficiency syndrome. Schwartz DA, et al. **Arch Pathol Lab Med** 1996 Feb; 120(2):173–88 (72 ref.)

Primary adrenal leiomyosarcoma in a man with acquired immunodeficiency syndrome (AIDS). Further evidence for an increase in smooth muscle tumors related to Epstein–Barr infection in AIDS. Zetler PJ, et al. **Arch Pathol Lab Med** 1995 Dec;119(12):1164–7 (19 ref.)

AIDS and the eye. A 10-year experience. Maclean H, et al. **Aust N Z J Ophthalmol** 1996 Feb;24(1):61–7 (18 ref.)

Recent insights into the pathogenesis of Kaposi's sarcoma. Fife K, et al. **Br J Cancer** 1996 Jun;73(11):1317–22 (68 ref.)

AIDS-associated malignancies. Krown SE. **Cancer Chemother Biol Response Modif** 1996;16:441–61 (141 ref.)

Kaposi's sarcoma in patients infected with human virus (HIV): an overview. Hermans P, et al. **Cell Mol Biol (Noisy-le-grand)** 1995 May;41(3):357–64 (43 ref.)

Spontaneous pneumothorax in children with AIDS. Schroeder SA, et al. **Chest** 1995 Oct;108(4):1173–6 (25 ref.)

Cryptococcosis in the era of AIDS—100 years after the discovery of Cryptococcus neoformans. Mitchell TG, et al. **Clin Microbiol Rev** 1995 Oct;8(4):515–48 (529 ref.)

Verruga peruana: an infectious endemic angiomatosis. Cáceres-Ríos H, et al. **Crit Rev Oncog** 1995;6(1):47–56 (96 ref.)

An integrated approach to the epidemiology of Kaposi's sarcoma. Jacobson LP, et al. **Curr Opin Oncol** 1995 Sep; 7(5):450–5 (71 ref.)

Malignancies in pediatric AIDS. Mueller BU, et al. **Curr Opin Pediatr** 1996 Feb;8(1):45–9 (42 ref.)

Ofuji papulоerythroderma in a patient with the acquired immunodeficiency syndrome. García-Patos V, et al. **Dermatology** 1996;192(2):164–6 (23 ref.)

Rahnella aquatilis bacteremia in an HIV-infected intravenous drug abuser. Funke G, et al. **Diagn Microbiol Infect Dis** 1995 Jul;22(3):293–6 (8 ref.)

Posterior uveitis in the acquired immunodeficiency syndrome. McCluskey PJ, et al. **Int Ophthalmol Clin** 1995 Spring;35(2):1–14 (20 ref.)

A hemophiliac with human immunodeficiency virus (HIV)–1–associated dementia complex [see comments] Arimura H, et al. **Intern Med** 1995 Oct;34(10):995–9 (12 ref.) Comment in: Intern Med 1995 Oct;34(10):935.

Human immunodeficiency virus and acquired immune deficiency syndrome AIDS-related hearing disorders. Madriz JJ, et al. **J Am Acad Audiol** 1995 Sep;6(5):358–64 (48 ref.)

Liposomal doxorubicin (Doxil). Porche DJ. **J Assoc Nurses AIDS Care** 1996 Mar–Apr;7(2):55–9 (6 ref.)

The spectrum of non-AIDS-defining neoplastic disease in HIV infection. Remick SC. **J Investig Med** 1996 Jun; 44(5):205–15 (183 ref.)

AIDS-related malignancies. Spittle MF. **J R Soc Med** 1996 Jan;89(1):35P–6P (0 ref.)

HIV-related oral disease. Greenspan D, et al. **Lancet** 1996 Sep 14;348(9029):729–33 (38 ref.)

HIV infection and neoplasia. Schulz TF, et al. **Lancet** 1996 Aug 31;348(9027):587–91 (50 ref.)

Hodgkin's disease as an indicator of AIDS. Gerold M, et al. **Med Hypotheses** 1995 Jul;45(1):76–82 (113 ref.)

Manaing HIV. Part 5: Treating secondary outcomes. 5.17 HIV, weight loss and wasting syndrome. Kelly MD, et al. **Med J Aust** 1996 May 6;164(9):549–50 (9 ref.)

Managing HIV. Part 5: Treating secondary outcomes. 5.14 HIV and Kaposi's sarcoma. Millar JL, et al. **Med J Aust** 1996 May 6;164(9):539–42 (16 ref.)

Sulfadiazine-associated nephrotoxicity in patients with the acquired immunodeficiency syndrome. Becker K, et al. **Medicine (Baltimore)** 1996 Jul;75(4):185–94 (56 ref.)

The lung in HIV infection: can pulmonary function testing help? Mitchell DM, et al. **Monaldi Arch Chest Dis** 1996 Jun;51(3):214–22 (30 ref.)

AIDS, drugs, and the adolescent. Steel E. **NIDA Res Monogr** 1995;156:130–45 (34 ref.)

Acquired immunodeficiency syndrome (AIDS) and the eye. Armstrong RA. **Ophthalmic Physiol Opt** 1995 Sep;15 Suppl 2:S42–8 (25 ref.)

Gastrointestinal and nutritional problems in children with immunodeficiency and AIDS. Winter H, et al. **Pediatr Clin North Am** 1996 Apr;43(2):573–90 (40 ref.)

Adrenal gland leiomyoma in a child with acquired immunodeficiency syndrome. Jimenez-Heffernan JA, et al. **Pediatr Pathol Lab Med** 1995 Nov–Dec;15(6):923–9 (22 ref.)

AIDS-associated Kaposi's sarcoma: a new perspective of its pathogenesis and treatment. Ensoli B, et al. **Proc Assoc Am Physicians** 1995 Apr;107(1):8–18 (90 ref.)

Gastrointestinal manifestations of acquired immunodeficiency syndrome: radiologic-pathologic correlation. Pantongrag-Brown L, et al. **Radiographics** 1995 Sep; 15(5):1155–78 (105 ref.)

Treatment of disseminated Mycobacterium avium complex disease: a clinician's perspective. Benson CA. **Res Microbiol** 1996 Jan–Feb;147(1–2):16–24 (43 ref.)

Current problems with tuberculosis treatment. Grosset J. **Res Microbiol** 1996 Jan–Feb;147(1–2):10–6 (32 ref.)

Solving the dilemma of antimycobacterial chemotherapy. Rastogi N, et al. **Res Microbiol** 1996 Jan–Feb;147(1–2):7–10 (30 ref.)

CT/MRI of musculoskeletal complications of AIDS. Wyatt SH, et al. **Skeletal Radiol** 1995 Oct;24(7):481–8 (21 ref.)

AIDS and cerebrovascular disease. Pinto AN. **Stroke** 1996 Mar;27(3):538–43 (61 ref.)

AIDS and hemophilia—current issues. Evatt BL. **Thromb Haemost** 1995 Jul;74(1):36–9 (46 ref.)

Epididymocutaneous fistula in a patient with the acquired immunodeficiency syndrome and Marfan's syndrome. Weiner DM, et al. **Urology** 1996 May;47(5):766–8 (14 ref.)

[What to do in a 60-year-old HIV-positive woman with a cerebral arteriovenous malformation? Decision analysis (see comments)] Dippel DW, et al. **Ned Tijdschr Geneeskd** 1995 Nov 18;139(46):2362–9 (52 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1996 Feb 17;140(7):386–7. **(Dut)**

[Local treatments of AIDS-related Kaposi disease] Saiag P, et al. **Ann Dermatol Venereol** 1995;122(8):551–7 (56 ref.) **(Fre)**

[Helicobacter pylori, gastric acid secretion, ulcer disease and HIV infection] Blondon H, et al. **Gastroenterol Clin Biol** 1996;20(3):248–53 (49 ref.) **(Fre)**

[Primary non-Hodgkin's lymphomas of the liver in human immunodeficiency virus infected patients. Three cases] Brugière O, et al. **Gastroenterol Clin Biol** 1996;20(3):307–11 (18 ref.) (Eng. Abstr.) **(Fre)**

[Liver, biliary tracts and human immunodeficiency virus infection. 1: liver, HIV and hepatitis B, C and D viruses] Vuitton DA, et al. **Gastroenterol Clin Biol** 1996; 20(3):269–80 (146 ref.) **(Fre)**

[Liver, biliary tracts and human immunodeficiency virus infection. 2: hepatobiliary complications of AIDS] Vuitton DA, et al. **Gastroenterol Clin Biol** 1996;20(3):281–93 (146 ref.) **(Fre)**

[Bilateral acute retinal necrosis in a patient with acquired immunodeficiency syndrome] Menerath JM, et al. **J Fr Ophtalmol** 1995;18(10):625–33 (39 ref.) (Eng. Abstr.) **(Fre)**

[Parvovirus B19 infection. New physiopathological approaches] Labau E, et al. **Presse Med** 1996 Feb 3; 25(4):162–6 (26 ref.) (Eng. Abstr.) **(Fre)**

[Prevention of opportunistic infections in HIV infection] Pesce A. **Rev Med Interne** 1995;16 Suppl 3:315s–319s (20 ref.) **(Fre)**

[AIDS and diabetes] Blanc MH. **Rev Med Suisse Romande** 1995 Sep;115(9):667–70 (29 ref.) **(Fre)**

[Kaposi sarcoma of the glans penis with meatal obstruction. Case report and literature review] John H, et al. **Swiss Surg** 1996;(3):134–6 (3 ref.) (Eng. Abstr.) **(Ger)**

[Why are AIDS patients frequently visually impaired?] Fabricius EM. **Ther Umsch** 1996 Jan;53(1):49–57 (13 ref.) (Eng. Abstr.) **(Ger)**

[Diseases of the gallbladder and biliary tract in patients with AIDS] Regev A, et al. **Harefuah** 1996 Mar 1;130(5):330–2 (15 ref.) **(Heb)**

[Magnetic resonance in AIDS-related encephalopathy] Gualdi GF, et al. **Clin Ter** 1995 Dec;146(12):843–56 (42 ref.) (Eng. Abstr.) **(Ita)**

[Oral lesions in Kaposi sarcoma: clinical and radiotherapeutic considerations] Barberis M, et al. **Minerva Stomatol** 1996 Jan–Feb;45(1–2):17–27 (62 ref.) (Eng. Abstr.) **(Ita)**

[Two cases of sensory neural hearing loss as a manifestation of HIV infection] Ohashi S, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1995 Sep;98(9):1399–406 (25 ref.) (Eng. Abstr.) **(Jpn)**

[HIV (human immunodeficiency virus) disease and AIDS (acquired immunodeficiency syndrome)] Fujii T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):255–7 (10 ref.) **(Jpn)**

[Facial and cervical manifestations of AIDS] Gebrim EM, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1995 Jul–Aug; 50(4):222–6 (22 ref.) (Eng. Abstr.) **(Por)**

[Central nervous system involvement in the acquired immunodeficiency syndrome] Gavura VV. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995; 95(2):96–100 (87 ref.) **(Rus)**

[Tuberculous prostatic abscess in a patient with AIDS] Duarte Ojeda JM, et al. **Actas Urol Esp** 1995 Sep; 19(8):655–61 (22 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Laboratory tests for detection of human immunodeficiency virus type 1 infection. Nuwayhid NF. **Clin Diagn Lab Immunol** 1995 Nov;2(6):637–45 (126 ref.)

Correlative morphologic and functional imaging for diagnosis, staging and follow up in AIDS: an overview. Brunetti A, et al. **Q J Nucl Med** 1995 Sep;39(3):201–11 (90 ref.)

[AIDS: infections of the retina and choroid] Schimkat M, et al. **Bildgebung** 1995 Dec;62(4):288–301 (100 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Discovery and in vitro development of AIDS antiviral drugs as biopharmaceuticals. Rice WG, et al. **Adv Pharmacol** 1995;33:389–438 (204 ref.)

Drug-resistance patterns of saquinavir and other HIV proteinase inhibitors. Roberts NA. **AIDS** 1995 Dec;9 Suppl

2:27–S32 (34 ref.)
New developments in antiretroviral drug therapy for HIV–1 infections. Johnson VA. **AIDS Clin Rev** 1995–96;:305–46 (106 ref.)
Survivor treatment selection bias in observational studies: examples from the AIDS literature. Glesby MJ, et al. **Ann Intern Med** 1996 Jun 1;124(11):999–1005 (46 ref.)
Recombinant erythropoietin for zidovudine–induced anemia in AIDS. Kuehl AK, et al. **Ann Pharmacother** 1995 Jul–Aug;29(7–8):778–9 (15 ref.)
New strategies for treating AIDS. Sandstrom PA, et al. **Bioessays** 1996 May;18(5):343–6 (20 ref.)
Clinical significance of drug resistance in human immunodeficiency virus. Richman DD. **Clin Infect Dis** 1995 Oct;21 Suppl 2:S166–9 (26 ref.)
Treatment of AIDS and HIV–related conditions—1996. Goldschmidt RH, et al. **J Am Board Fam Pract** 1996 Mar–Apr;9(2):125–48 (88 ref.)
Non–nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of human immunodeficiency virus type 1 (HIV–1) infections: strategies to overcome drug resistance development. de Clercq E. **Med Res Rev** 1996 Mar;16(2):125–57 (180 ref.)
[New treatments in HIV] Turner D, et al. **Harefuah** 1996 Apr 1;130(7):467–70 (32 ref.) **(Heb)**
[Care for the patient with AIDS] Ponce–de León S, et al. **Salud Publica Mex** 1995 Nov–Dec;37(6):525–32 (30 ref.) (Eng. Abstr.) **(Spa)**

ECONOMICS

Specific considerations for cost–effectiveness studies in AIDS. Bozzette SA.
J Acquir Immune Defic Syndr Hum Retrovirol 1995;10 Suppl 4:S23–7 (14 ref.)
Design and assessment of cost–effectiveness studies in AIDS populations. Simpson KN.
J Acquir Immune Defic Syndr Hum Retrovirol 1995;10 Suppl 4:S28–32 (17 ref.)

EPIDEMIOLOGY

Responding to the AIDS epidemic in Asia and the Pacific: report on the Third International Conference on AIDS in Asia and the Pacific, Chiang Mai, Thailand, 17–21 September, 1995. Ford NJ. **AIDS Care** 1996 Feb; 8(1):117–24 (7 ref.)
Update on epidemiology of AIDS in Asia. Li PC, et al. **AIDS Clin Rev** 1995–96;:347–86 (151 ref.)
HIV–1 subtype O: epidemiology, pathogenesis, diagnosis, and perspectives of the evolution of HIV. Gürtler LG, et al. **Arch Virol Suppl** 1996;11:195–202 (15 ref.)
Pediatric AIDS epidemic reflects the first half million AIDS cases in the U.S. Waldman HB. **ASDC J Dent Child** 1996 Mar–Apr;63(2):89–94 (6 ref.)
AIDS–related lymphoma: an emerging epidemic. Denton AS, et al. **Br J Hosp Med** 1996 Mar 6–19;55(5):282–8 (27 ref.)
Pending problem of "silent" human immunodeficiency virus infection. Bentwich Z, et al.
Cell Mol Biol (Noisy–le–grand) 1995 May;41(3):345–50 (42 ref.)
Patterns and predictability in emerging infections. Morse SS. **Hosp Pract (Off Ed)** 1996 Apr 15;31(4):85–91, 96–101, 104 passim (11 ref.)
Global burden of the HIV pandemic [see comments] Quinn TC. **Lancet** 1996 Jul 13;348(9020):99–106 (50 ref.) Comment in: Lancet 1996 Aug 17;348(9025):480–1.
Hodgkin's disease as an indicator of AIDS. Gerold M, et al. **Med Hypotheses** 1995 Jul;45(1):76–82 (113 ref.)
Bringing the context in from the cold: substantive, technical, and statistical issues for AIDS research in the second decade. Brunswick AF. **NIDA Res Monogr** 1994; 143:187–201 (21 ref.)
HIV/AIDS in South Africa—a relentless progression? [editorial] McIntyre J. **S Afr Med J** 1996 Jan;86(1):27–8 (12 ref.)
The epidemiology of HIV/AIDS. Hughes MJ, et al. **Semin Dermatol** 1995 Sep;14(3):191–201 (123 ref.)
[AIDS and childhood] Courpotin C, et al.
Bull Acad Natl Med 1996 Mar;180(3):709–25 (27 ref.) **(Fre)**
[The AIDS epidemic in Norway—where did it go?] Eskild A, et al. **Tidsskr Nor Laegeforen** 1996 Jan 30;116(3):382–6 (26 ref.) (Eng. Abstr.) **(Nor)**
[The social geography of AIDS in Brazil] Bastos FI, et al. **Rev Saude Publica** 1995 Feb;29(1):52–62 (38 ref.) (Eng. Abstr.) **(Por)**

ETHNOLOGY

HIV/AIDS in the context of culture: selection of ethnocultural communities for study in Canada. Cappon P, et al. **Can J Public Health** 1996 May–Jun;87 Suppl 1:S11–4, S11–5 (50 ref.) **(Eng, Fre)**

ETIOLOGY

Network between main protagonists and events leading to AIDS. Larralde C, et al. **Arch Med Res** 1996 Summer; 27(2):107–13 (87 ref.)
AIDS pathogenesis: from models to viral dynamics in patients. Nowak MA.
J Acquir Immune Defic Syndr Hum Retrovirol 1995;10 Suppl 1:S1–5 (14 ref.)
Risk of acquiring AIDS from salivary exchange through cardiopulmonary resuscitation courses and mouth–to–mouth resuscitation. Sun D, et al.
Semin Dermatol 1995 Sep;14(3):205–11 (76 ref.)

GENETICS

Genetic predisposition to HIV–1 infection and acquired immune deficiency virus syndrome A review of the literature examining associations with HLA. Just JJ.
Hum Immunol 1995 Nov;44(3):156–69 (92 ref.)

IMMUNOLOGY

From cell activation to cell depletion. The programmed cell death hypothesis of AIDS pathogenesis. Ameisen JC.
Adv Exp Med Biol 1995;374:139–63 (159 ref.)
AIDS as immune system activation. Key questions that remain. Ascher MS, et al. **Adv Exp Med Biol** 1995; 374:203–10 (89 ref.)
Immunosuppression by a noncytolytic virus via T cell mediated immunopathology. Implication for AIDS. Zinkernagel RM. **Adv Exp Med Biol** 1995;374:165–71 (78 ref.)
Molecular mechanisms of APO–1/Fas(CD95)–mediated apoptosis in tolerance and AIDS. Dhein J, et al.
Behring Inst Mitt 1995 Jun;(96):13–20 (37 ref.)
Genetic predisposition to HIV–1 infection and acquired immune deficiency virus syndrome A review of the literature examining associations with HLA. Just JJ.
Hum Immunol 1995 Nov;44(3):156–69 (92 ref.)
AIDS: a disease of impaired Th–cell renewal? Heeney JL. **Immunol Today** 1995 Nov;16(11):515–20 (44 ref.)
Cytokines in the acquired immunodeficiency syndrome and other infectious diseases. Poli G, et al.
Int J Clin Lab Res 1995;25(3):128–34 (58 ref.)
Human studies in the development of human immunodeficiency virus vaccines. Dolin R. **J Infect Dis** 1995 Nov;172(5):1175–83 (91 ref.)
Malignant testicular neoplasms in immunosuppressed patients. Leibovitch I, et al. **J Urol** 1996 Jun;155(6):1938–42 (41 ref.)
TNF and AIDS: two sides of the same coin? Pallarés–Trujillo J, et al. **Med Res Rev** 1995 Nov;15(6):533–46 (128 ref.)
Molecular biological bases of resistance to HIV/AIDS (the hypothesis with elements of the theory). Skripal IG.
Mikrobiol Z 1995 Jul–Aug;57(4):89–105 (45 ref.)
Directions in HIV/AIDS research. A Minnesota perspective. Henry K, et al. **Minn Med** 1995 Nov;78(11):26–34 (17 ref.)
Toward an understanding of the correlates of protective immunity to HIV infection [see comments] Haynes BF, et al. **Science** 1996 Jan 19;271(5247):324–8 (73 ref.) Comment in: Science 1996 Feb 23;371(5252):1043. Comment in: Science 1996 May 31;272(5266):1362. Comment in: Science 1996 Jul 26;273(5274):415–6.
AIDS pathogenesis: a finite immune response to blame? [comment] Miedema F, et al. **Science** 1996 Apr 26; 272(5261):505–6 (18 ref.) Comment on: Science 1996 Apr 26;272(5261):537–42.
Overview: practical insights from comparative immunology and pathogenesis of AIDS, hepatitis B, and measles for developing an HIV vaccine. Hilleman MR. **Vaccine** 1995 Dec;13(18):1733–40 (41 ref.)
[Self–defence power fighting against AIDS. Cellular immunity and its activation] Takahashi H.
Nippon Ika Daigaku Zasshi 1995 Oct;62(5):539–46 (23 ref.) **(Jpn)**

METABOLISM

Histological study of oxalosis in the eye and adnexa of AIDS patients. Pecorella I, et al. **Histopathology** 1995 Nov; 27(5):431–8 (22 ref.)
[Thyroid and AIDS] Bonnyns M, et al. **Rev Med Brux** 1995 Nov;16(5):361–3 (16 ref.) (Eng. Abstr.) **(Fre)**

NURSING

Nurses' attitudes about acquired immunodeficiency syndrome care: what research tells us. Bennett JA. **J Prof Nurs** 1995 Nov–Dec;11(6):339–50 (67 ref.)

PATHOLOGY

The role of the cell cycle in HIV–1 infection. Zack JA. **Adv Exp Med Biol** 1995;374:27–31 (26 ref.)
Primary brain tumors in the acquired immunodeficiency syndrome. DeAngelis LM. **Curr Opin Neurol** 1995 Dec; 8(6):419–23 (35 ref.)
Histological study of oxalosis in the eye and adnexa of AIDS patients. Pecorella I, et al. **Histopathology** 1995 Nov; 27(5):431–8 (22 ref.)
AIDS: a disease of impaired Th–cell renewal? Heeney JL. **Immunol Today** 1995 Nov;16(11):515–20 (44 ref.)
[Disseminated Kaposi's sarcoma with hepatosplenic involvement in AIDS] González–López A, et al.
Med Clin (Barc) 1996 Apr 27;106(16):622–3 (15 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

Molecular basis of cell cycle dependent HIV–1 replication. Implications for control of virus burden. Stevenson M, et al. **Adv Exp Med Biol** 1995;374:33–45 (56 ref.)
Clinical profile of AIDS in India: a review of 61 cases. Chacko S, et al. **J Assoc Physicians India** 1995 Aug; 43(8):535–8 (25 ref.)
Catabolic hormones and growth hormone resistance in acquired immunodeficiency syndrome and other catabolic states. Rodgers BD. **Proc Soc Exp Biol Med** 1996 Sep; 212(4):324–31 (106 ref.)
[Cofactors in the course of HIV infection] Meyer L, et al. **Presse Med** 1996 Mar 2–9;25(8):379–80, 382–4 (35 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

AIDS behind bars: preventing HIV spread among incarcerated drug injectors [editorial] Dolan K, et al.
AIDS 1995 Aug;9(8):825–32 (72 ref.)
Responding to the AIDS epidemic in Asia and the Pacific: report on the Third International Conference on AIDS in Asia and the Pacific, Chiang Mai, Thailand, 17–21 September, 1995. Ford NJ. **AIDS Care** 1996 Feb; 8(1):117–24 (7 ref.)
AIDS education for college students: review and proposal for a research–based curriculum. Mulvihill CK.
AIDS Educ Prev 1996 Feb;8(1):11–25 (72 ref.)
AIDS prevention with adolescents. Rotheram–Borus MJ, et al. **AIDS Educ Prev** 1995 Aug;7(4):320–36 (125 ref.)
Regulating controversial programs for unpopular people: methadone maintenance and syringe exchange programs [see comments] Des Jarlais DC, et al.
Am J Public Health 1995 Nov;85(11):1577–84 (39 ref.) Comment in: Am J Public Health 1995 Nov;85(11):1490–1.
Progress in AIDS vaccine development. Johnston MI.
Int Arch Allergy Immunol 1995 Dec;108(4):313–7 (29 ref.)
Increased attention to human sexuality can improve HIV–AIDS prevention efforts: key research issues and directions. Kelly JA, et al. **J Consult Clin Psychol** 1995 Dec;63(6):907–18 (120 ref.)
Candidate AIDS vaccines. Graham BS, et al.
N Engl J Med 1995 Nov 16;333(20):1331–9 (100 ref.)
HIV–1 Tat protein as a potential AIDS vaccine. Goldstein G. **Nat Med** 1996 Sep;2(9):960–4 (34 ref.)
Qualitative research methods in drug abuse and AIDS prevention research: an overview. Carlson RG, et al.
NIDA Res Monogr 1995;157:6–26 (75 ref.)
The role of qualitative research in the Global Programme on AIDS at the World Health Organization. O'Reilly KR.
NIDA Res Monogr 1995;157:27–37 (17 ref.)
Academic research and HIV/AIDS in South Africa. Campbell CM, et al. **S Afr Med J** 1996 Jan;86(1):55–60 (63 ref.)
[Acquired immunodeficiency syndrome—1995 (Part I)] Lasry Y, et al. **Harefuah** 1995 Dec 1;129(11):520–5 (50 ref.) **(Heb)**
[AIDS–related knowledge and sex behavior: a review of Italian studies of young people] Aloisi MS, et al.
Ann Ig 1995 Sep–Oct;7(5):349–58 (38 ref.) (Eng. Abstr.) **(Ita)**

PSYCHOLOGY

Fear of AIDS and suicide in Finland: a review. Aro AR, et al. **AIDS Care** 1995;7 Suppl 2:S187–97 (60 ref.)
Epidemiology of suicide among persons with AIDS. Starace F. **AIDS Care** 1995;7 Suppl 2:S123–8 (15 ref.)
Gay men with AIDS and their families of origin: an analysis of social support. Kadushin G. **Health Soc Work** 1996 May; 21(2):141–9 (100 ref.)
Anticipatory grief and AIDS: strategies for intervening with caregivers. Walker RJ, et al. **Health Soc Work** 1996 Feb; 21(1):49–57 (43 ref.)
Patients misrepresenting their risk factors for AIDS [editorial] Brody S. **Int J STD AIDS** 1995 Nov–Dec; 6(6):392–8 (75 ref.)
AIDS and suicide. Kirchner JT. **J Fam Pract** 1995 Nov; 41(5):493–6 (19 ref.)
Assessing the reliability and validity of self–reported risk behavior. Gibson DR, et al. **NIDA Res Monogr** 1994; 143:218–36 (13 ref.)
Using focus groups in drug abuse and HIV/AIDS research. Shedlin MG, et al. **NIDA Res Monogr** 1995;157:136–55 (13 ref.)
Stigma, HIV and AIDS: an exploration and elaboration of a stigma trajectory. Alonzo AA, et al. **Soc Sci Med** 1995 Aug;41(3):303–15 (79 ref.)
Fear of AIDS and homophobia: implications for direct practice and advocacy. O'Hare T, et al. **Soc Work** 1996 Jan;41(1):51–8 (22 ref.)

RADIOGRAPHY

Radiographic evaluation of AIDS patients. Le Blang SD, et al. **Q J Nucl Med** 1995 Sep;39(3):187–200 (101 ref.)
The gastrointestinal manifestations of pediatric AIDS. Stoane JM, et al. **Radiol Clin North Am** 1996 Jul;34(4):779–90 (44 ref.)
[Standard radiological characteristics of thoracic sites of tuberculosis in patients with AIDS in a Tunisian population] Tiouiri H, et al. **Rev Pneumol Clin** 1995; 51(6):321–4 (12 ref.) (Eng. Abstr.) **(Fre)**

RADIONUCLIDE IMAGING

Role of nuclear medicine and AIDS: overview and perspective for the future. Ganz WI, et al.

Q J Nucl Med 1995 Sep;39(3):169–86 (51 ref.)

THERAPY

Idiotype manipulation in disease management. Kohler H, et al. **Adv Exp Med Biol** 1995;383:117–22 (38 ref.)
Enhancing HIV-1 specific immunity as a therapeutic strategy in AIDS. Schooley RT. **Adv Exp Med Biol** 1996;394:405–10 (24 ref.)
"Kinoids": the basis for anticytokine immunization and their use in HIV infection. Bizzini B, et al. **Cell Mol Biol (Noisy-le-grand)** 1995 May;41(3):351–6 (38 ref.)
Steps toward gene therapy: 2. Cancer and AIDS. Blaese RM. **Hosp Pract (Off Ed)** 1995 Dec 15;30(12):37–45 (6 ref.)
Gene therapy against retroviral diseases. Essex M, et al. **Leukemia** 1995 Oct;9 Suppl 1:S71–4 (13 ref.)
Update of HIV and AIDS in North America. Flanigan TP, et al. **Med Health R I** 1996 May;79(5):180–7 (18 ref.)
HIV accessory proteins: emerging therapeutic targets. Miller RH, et al. **Mol Med** 1995 Jul;1(5):479–85 (11 ref.)
Xenotransplantation at a crossroads: prevention versus progress. Allan JS. **Nat Med** 1996 Jan;2(1):18–21 (19 ref.)
A magnetic approach to AIDS. Jacobson JI. **Panminerva Med** 1995 Mar;37(1):22–7 (21 ref.)
Therapeutic applications of ribozymes. Kijima H, et al. **Pharmacol Ther** 1995;68(2):247–67 (200 ref.)
[Gene therapy for hereditary and acquired human diseases] Mehtali M, et al. **Ann Endocrinol (Paris)** 1995;56(6):571–4 (15 ref.) (Eng. Abstr.) **(Fre)**
[Safer trials of vaccine and gene therapy against HIV] Ikuta K. **Hokkaido Igaku Zasshi** 1996 Jan;71(1):21–6 (31 ref.) (Eng. Abstr.) **(Jpn)**
[Gene therapy for AIDS: current trends] Takatsuki K, et al. **Nippon Rinsho** 1996 Jan;54(1):233–41 (9 ref.) (Eng. Abstr.) **(Jpn)**
[Gene therapy of AIDS by a Rev mutant without nucleolar dysfunction] Hatanaka M. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2753–8 (8 ref.) **(Jpn)**

TRANSMISSION

Women and AIDS in Zambia: a review of the psychosocial factors implicated in the transmission of HIV. Campbell T, et al. **AIDS Care** 1995;7(3):365–73 (26 ref.)
AIDS and the contact lens practice. Slonim CB. **CLAO J** 1995 Oct;21(4):233–5 (19 ref.)
Transmission of HIV-1 in the breast-feeding process. Black RF. **J Am Diet Assoc** 1996 Mar;96(3):267–74; quiz 275–6 (61 ref.)
Global burden of the HIV pandemic [see comments] Quinn TC. **Lancet** 1996 Jul 13;348(9020):99–106 (50 ref.) Comment in: Lancet 1996 Aug 17;348(9025):480–1.
Assessing the reliability and validity of self-reported risk behavior. Gibson DR, et al. **NIDA Res Monogr** 1994; 143:218–36 (13 ref.)
HIV/AIDS risks among male, heterosexual noninjecting drug users who exchange crack for sex. Inciardi JA. **NIDA Res Monogr** 1994;143:26–40 (66 ref.)
Factors associated with sexual risk of AIDS in women. O'Leary A. **NIDA Res Monogr** 1994;143:64–81 (82 ref.)
Dermatologic surgery personnel with AIDS. Resnik SS, et al. **Semin Dermatol** 1995 Sep;14(3):240–2 (22 ref.)
Syringe-mediated drug sharing among injecting drug users: patterns, social context and implications for transmission of blood-borne pathogens. Grund JP, et al. **Soc Sci Med** 1996 Mar;42(5):691–703 (89 ref.)
[Infection with human immunodeficiency virus type 2—HIV-2] Christiansen CB. **Ugeskr Laeger** 1996 Mar 18; 158(12):1662–6 (37 ref.) (Eng. Abstr.) **(Dan)**
[Perforations and porosity of surgical gloves. Frequency, mechanism, risk] Johanet H, et al. **Ann Chir** 1996; 50(4):352–5 (35 ref.) (Eng. Abstr.) **(Fre)**
[In the name of Commission VII (Sexually transmissible diseases and AIDS). Heterosexual transmission of HIV in France] Montagnier L. **Bull Acad Natl Med** 1995 Jun; 179(6):1209–24 (22 ref.) **(Fre)**
[The sexual transmission of the acquired immunodeficiency virus: the reasons for greater male-to-female than female-to-male transmission efficiency] Nicolosi A, et al. **Ann Ig** 1994 Jul–Dec;6(4–6):641–8 (88 ref.) (Eng. Abstr.) **(Ita)**
[Salivary HIV antibodies. Review of current data and future prospectives] Polimeni A, et al. **Minerva Stomatol** 1995 Dec;44(12):583–90 (20 ref.) (Eng. Abstr.) **(Ita)**
[Human immunodeficiency virus (HIV) infection in obstetrics and gynaecology] Balsdon MJ. **Rev Chil Obstet Ginecol** 1994;59(6):476–84 (0 ref.) (Eng. Abstr.) **(Spa)**

VIROLOGY

JCV-DNA and BKV-DNA in the CNS tissue and CSF of AIDS patients and normal subjects. Study of 41 cases and review of the literature. Vago L, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Jun 1;12(2):139–46 (43 ref.)
HIV as the cause of AIDS. Barré-Sinoussi F. **Lancet** 1996 Jul 6;348(9019):31–5 (50 ref.)
Can evolutionary principles help resolve the acquired immune deficiency syndrome crisis? Powell PD. **Med Hypotheses** 1996 Feb;46(2):130–4 (40 ref.)
Viral counts count in HIV infection [see comments] Ho DD. **Science** 1996 May 24;272(5265):1124–5 (13 ref.) Comment in: Science 1996 May 24;272(5265):1167–70.
[Epithelial dendritic cells and HIV-1 infection in vivo and in vitro] Dezutter-Dambuyant C, et al. **Pathol Biol (Paris)** 1995 Dec;43(10):882–8 (71 ref.) (Eng. Abstr.) **(Fre)**
[Dendritic cells of spleen and blood and HIV-1 infection] Hosmalin A. **Pathol Biol (Paris)** 1995 Dec;43(10):889–96 (54 ref.) (Eng. Abstr.) **(Fre)**
[Nervous system infections by retroviruses] Román GC. **Rev Neurol** 1996 Jun;24(130):703–7 (9 ref.) **(Spa)**

ACQUISITION, HEALTH FACILITY see **HEALTH FACILITY MERGER**

ACREMONIUM

Pulmonary acremonium abscesses and gastrointestinal tuberculosis manifested as massive upper gastrointestinal bleeding. Miró O, et al. **Nephrol Dial Transplant** 1995; 10(8):1444–6 (17 ref.)

PATHOGENICITY

Fatal, disseminated Acremonium strictum infection in a neutropenic host. Schell WA, et al. **J Clin Microbiol** 1996 May;34(5):1333–6 (27 ref.)

ACRIDINE ORANGE

Comparison of acridine orange and giemsa stains for malaria diagnosis. Kong HH, et al. **Korean J Parasitol** 1995 Dec; 33(4):391–4 (18 ref.)

ACRIDINES

PHARMACOLOGY

Status of new anthrapyrazole and pyrazoloacridine derivatives. Berg SL. **Crit Rev Oncol Hematol** 1996 Mar; 22(2):79–87 (57 ref.)

TOXICITY

Comparative carcinogenicity, metabolism, mutagenicity, and DNA binding of 7H-dibenzo[c,g]carbazole and dibenz[a,j]acridine. Warshawsky D, et al. **Crit Rev Toxicol** 1996;26(2):213–49 (101 ref.)

ACRO-OSTEOLYSIS SYNDROMES see **OSTEOLYSIS, ESSENTIAL**

ACROCEPHALY see **CRANIOSYNOSTOSES**

ACRODERMATITIS

[Gianotti disease and Gianotti-Crosti syndrome] Toda G. **Ryoikibetsu Shokogun Shirizu** 1995;(7):24–6 (11 ref.) **(Jpn)**

DIAGNOSIS

Acro-angiodermatitis: review of the literature and report of a case. Rashkovsky I, et al. **Acta Derm Venereol** 1995 Nov; 75(6):475–8 (55 ref.)

ETIOLOGY

[Gianotti-Crosti syndrome due to a mixed infection produced by the mumps virus and the parainfluenza virus type 2] Hergueta Lendínez R, et al. **An Esp Pediatr** 1996 Jan; 44(1):65–6 (17 ref.) **(Spa)**

ACROLEIN

Fate and effects of acrolein. Ghilarducci DP, et al. **Rev Environ Contam Toxicol** 1995;144:95–146 (222 ref.)

ACROMEGALY

Acromegaly: unravelling a complex disease. O'Halloran DJ, et al. **Growth Regul** 1995 Sep;5(3):119–24 (60 ref.)

DIAGNOSIS

Clinical review 75: Recent advances in pathogenesis, diagnosis, and management of acromegaly. Melmed S, et al. **J Clin Endocrinol Metab** 1995 Dec;80(12):3395–402 (69 ref.)
[Acromegaly; diagnosis and treatment] van der Lely AJ, et al. **Ned Tijdschr Geneeskd** 1996 Jul 13;140(28):1436–40 (52 ref.) **(Dut)**

THERAPY

Acromegaly: what constitutes optimal therapy? [editorial] Frohman LA. **J Clin Endocrinol Metab** 1996 Feb; 81(2):443–5 (22 ref.)
Remission of acromegaly caused by pituitary carcinoma after surgical excision of growth hormone-secreting metastasis detected by 111-indium pentetreotide scan. Greenman Y, et al. **J Clin Endocrinol Metab** 1996 Apr;81(4):1628–33 (29 ref.)
Clinical review 75: Recent advances in pathogenesis, diagnosis, and management of acromegaly. Melmed S, et al. **J Clin Endocrinol Metab** 1995 Dec;80(12):3395–402 (69 ref.)
[Acromegaly; diagnosis and treatment] van der Lely AJ, et al. **Ned Tijdschr Geneeskd** 1996 Jul 13;140(28):1436–40 (52 ref.) **(Dut)**

ACROSOME

PHYSIOLOGY

Cellular biology of capacitation and the acrosome reaction. Fraser LR. **Hum Reprod** 1995 Oct;10 Suppl 1:22–30 (50 ref.)

ACROSPIROMA, ECCRINE

PATHOLOGY

Porocarcinoma of the heel. A case report with unusual histologic features. D'Amato MS, et al. **Cancer** 1996 Aug 15;78(4):751–7 (27 ref.)

ACRYLAMIDES

ADMINISTRATION & DOSAGE

Antibody-targeted polymer-bound drugs. Říhová B. **Folia Microbiol (Praha)** 1995;40(4):367–84 (121 ref.)

CHEMISTRY

Lophozozymus pictor toxin: a fluorescent structural isomer of palytoxin. Lau CO, et al. **Toxicon** 1995 Oct;33(10):1373–7 (18 ref.)

ACRYLATES

ADVERSE EFFECTS

Adverse contact reactions to sculptured acrylic nails: 4 case reports and a literature review. Freeman S, et al. **Contact Dermatitis** 1995 Dec;33(6):381–5 (48 ref.)

ACRYLIC RESINS

see related
DENTAL MATERIALS

Prevention of dialysis-related amyloidosis using the polyacrylonitrile AN69 membrane. Chanard J. **Contrib Nephrol** 1995;112:137–44 (23 ref.)

ACTH see **CORTICOTROPIN**

ACTH RECEPTORS see **RECEPTORS, CORTICOTROPIN**

ACTH-RELEASING FACTOR see **CORTICOTROPIN-RELEASING HORMONE**

ACTH SYNDROME, ECTOPIC

PATHOLOGY

Ectopic adrenocorticotropin syndrome associated with undifferentiated carcinoma of the colon showing multidirectional neuroendocrine, exocrine, and squamous differentiation. Onishi R, et al. **Virchows Arch** 1996 Feb; 427(5):537–41 (14 ref.)

ACTIN-BINDING PROTEINS see **MICROFILAMENT PROTEINS**

ACTING OUT

Enactments: an evolving dyadic concept of acting out. Frayn DH. **Am J Psychother** 1996 Spring;50(2):194–207 (35 ref.)

ACTINIC RAYS see **ULTRAVIOLET RAYS**

ACTINIC RETICULOID SYNDROME see **PHOTOSENSITIVITY DISORDERS**

ACTINIDES see **METALS, ACTINOID**

ACTINOBACILLUS ACTINOMYCETEMCOMITANS

Cerebral abscess complicating dental treatment. Case report and review of the literature. Renton TF, et al. **Aust Dent J** 1996 Feb;41(1):12–5 (32 ref.)

PATHOGENICITY

Virulence factors of Actinobacillus actinomycetemcomitans relevant to the pathogenesis of inflammatory periodontal diseases. Wilson M, et al. **FEMS Microbiol Rev** 1995 Dec; 17(4):365–79 (108 ref.)

ACTINOBACILLUS INFECTIONS

Cerebral abscess complicating dental treatment. Case report and review of the literature. Renton TF, et al. **Aust Dent J** 1996 Feb;41(1):12–5 (32 ref.)
Actinobacillus ureae meningitis: case report and review of the literature. Kingsland RC, et al. **J Emerg Med** 1995 Sep–Oct;13(5):623–7 (37 ref.)

ACTINOBACILLUS INFECTIONS

MICROBIOLOGY

Virulence factors of Actinobacillus actinomycetemcomitans relevant to the pathogenesis of inflammatory periodontal diseases. Wilson M, et al. **FEMS Microbiol Rev** 1995 Dec; 17(4):365–79 (108 ref.)

ACTINOBACILLUS PLEUROPNEUMONIAE

PATHOGENICITY

Virulence in Actinobacillus pleuropneumoniae and RTX toxins. Frey J. **Trends Microbiol** 1995 Jul;3(7):257–61 (50 ref.)

ACTINOIDS see METALS, ACTINOID

ACTINOMYCES INFECTIONS see ACTINOMYCOSIS

ACTINOMYCES VISCOSUS

Cervicofacial Actinomyces viscosus infection in a Brazilian fila: a case report and literature review. Donohue DE, et al. **J Am Anim Hosp Assoc** 1995 Nov–Dec;31(6):501–5 (20 ref.)

ACTINOMYCETALES

Treatment of eumycetoma and actinomycetoma. Welsh O, et al. **Curr Top Med Mycol** 1995;6:47–71 (105 ref.)

CLASSIFICATION

[Importance of taxonomic and immunologic lipid markers of actinomycetes and similar bacteria] Szponar B. **Postepy Hig Med Dosw** 1995;49(1):161–70 (25 ref.) (Eng. Abstr.) **(Pol)**

GENETICS

Rifamycins: strain improvement program. Lal R, et al. **Crit Rev Microbiol** 1995;21(1):19–30 (42 ref.)

METABOLISM

Tetracyclines. Bëhal V, et al. **Biotechnology** 1995;28:359–84 (99 ref.)

Aminoglycosides and aminocyclitols (other than streptomycin). Hotta K, et al. **Biotechnology** 1995;28:571–95 (82 ref.)

Macrolides. Katz L, et al. **Biotechnology** 1995;28:385–420 (136 ref.)

Streptomycin and related aminoglycosides. Piepersberg W. **Biotechnology** 1995;28:531–70 (179 ref.)

Rifamycins: strain improvement program. Lal R, et al. **Crit Rev Microbiol** 1995;21(1):19–30 (42 ref.)

ACTINOMYCETALES INFECTIONS

COMPLICATIONS

[Rhodococcus equi pneumonia in patients with HIV infection: report of 2 cases and review of the literature] Berna JD, et al. **Enferm Infecc Microbiol Clin** 1996 Mar; 14(3):177–80 (57 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

[Rhodococcus equi pulmonary abscess in HIV infection] About I, et al. **Rev Med Interne** 1996;17(5):410–4 (25 ref.) (Eng. Abstr.) **(Fre)**

RADIOGRAPHY

[Rhodococcus equi lung infection in AIDS patients. A report of 4 cases] Carli Moretti C, et al. **Radiol Med (Torino)** 1996 Apr;91(4):477–80 (13 ref.) **(Ita)**

ACTINOMYCETE INFECTIONS see ACTINOMYCETALES INFECTIONS

ACTINOMYCOSIS

Colonic actinomycosis: report of a case and review of the literature. Kaya E, et al. **Surg Today** 1995;25(10):923–6 (12 ref.)

[Hepatic actinomycosis] Ito A. **Ryoikibetsu Shokogun Shirizu** 1995;(7):104–5 (8 ref.) **(Jpn)**

DIAGNOSIS

Actinomyces odontolyticus thoracopulmonary infections. Two cases in lung and heart–lung transplant recipients and a review of the literature. Bassiri AG, et al. **Chest** 1996 Apr;109(4):1109–11 (10 ref.)

Disseminated infection due to Actinomyces meyeri: case report and review. Apothéloz C, et al. **Clin Infect Dis** 1996 Apr;22(4):621–5 (32 ref.)

Abdominal actinomycosis. Cintron JR, et al. **Dis Colon Rectum** 1996 Jan;39(1):105–8 (10 ref.)

[Pulmonary actinomycosis. The difficulties in its diagnosis and treatment] Márquez Rivas FJ, et al. **An Esp Pediatr** 1996 Jun;44(6):588–90 (12 ref.) **(Spa)**

DRUG THERAPY

[Pulmonary actinomycosis. The difficulties in its diagnosis and treatment] Márquez Rivas FJ, et al. **An Esp Pediatr** 1996 Jun;44(6):588–90 (12 ref.) **(Spa)**

ETIOLOGY

Intrauterine contraceptive device–associated actinomycotic abscess and Actinomyces detection on cervical smear. Fiorino AS. **Obstet Gynecol** 1996 Jan;87(1):142–9 (107 ref.)

SURGERY

Abdominal actinomycosis. Cintron JR, et al. **Dis Colon Rectum** 1996 Jan;39(1):105–8 (10 ref.)

VETERINARY

Cervicofacial Actinomyces viscosus infection in a Brazilian fila: a case report and literature review. Donohue DE, et al. **J Am Anim Hosp Assoc** 1995 Nov–Dec;31(6):501–5 (20 ref.)

ACTINOTHERAPY see ULTRAVIOLET THERAPY

ACTINS

Evolution of a dynamic cytoskeleton. Mitchison TJ. **Philos Trans R Soc Lond B Biol Sci** 1995 Sep 29; 349(1329):299–304 (18 ref.)

Actin. Sheterline P, et al. **Protein Profile** 1994;1(1):1–121 (1838 ref.)

CHEMISTRY

Allostery, cooperativity, and different structural states in F-actin. Egleman EH, et al. **J Struct Biol** 1995 Sep–Oct; 115(2):159–62 (16 ref.)

A discourse on modeling F-actin. Schutt CE, et al. **J Struct Biol** 1995 Sep–Oct;115(2):186–98 (69 ref.)

The ADF/cofilin proteins: stimulus–responsive modulators of actin dynamics. Moon A, et al. **Mol Biol Cell** 1995 Nov; 6(11):1423–31 (84 ref.)

Protein–protein interactions in the rigor actomyosin complex. Milligan RA. **Proc Natl Acad Sci U S A** 1996 Jan 9; 93(1):21–6 (31 ref.)

Actin. Sheterline P, et al. **Protein Profile** 1995;2(1):1–103 (2085 ref.)

GENETICS

Modular cis-regulatory organization of developmentally expressed genes: two genes transcribed territorially in the sea urchin embryo, and additional examples. Kirchhamer CV, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3; 93(18):9322–8 (67 ref.)

METABOLISM

Microfilament dynamics: regulation of actin polymerization by actin–fragmin kinase and phosphatases. Waelkens E, et al. **Adv Enzyme Regul** 1995;35:199–227 (60 ref.)

Control of actin assembly at filament ends. Schafer DA, et al. **Ann Rev Cell Dev Biol** 1995;11:497–518 (143 ref.)

Modulation of actin dynamics during stress and physiological stimulation by a signaling pathway involving p38 MAP kinase and heat-shock protein 27. Landry J, et al. **Biochem Cell Biol** 1995 Sep–Oct;73(9–10):703–7 (42 ref.)

Rho, rac and cdc42 GTPases: regulators of actin structures, cell adhesion and motility. Nobes CD, et al. **Biochem Soc Trans** 1995 Aug;23(3):456–9 (16 ref.)

Microvillus assembly. Not actin alone. Fath KR, et al. **Curr Biol** 1995 Jun 1;5(6):591–3 (22 ref.)

Actin–membrane cytoskeletal dynamics in early sea urchin development. Bonder EM, et al. **Curr Top Dev Biol** 1995; 31:101–37 (131 ref.)

The Dictyostelium cytoskeleton. Noegel AA, et al. **Experientia** 1995 Dec 18;51(12):1135–43 (135 ref.)

Chaperonin-mediated folding of actin and tubulin. Lewis SA, et al. **J Cell Biol** 1996 Jan;132(1–2):1–4 (32 ref.)

Role of the actin cytoskeleton on epithelial Na+ channel regulation. Cantiello HF. **Kidney Int** 1995 Oct;48(4):970–84 (91 ref.)

Actin. Sheterline P, et al. **Protein Profile** 1995;2(1):1–103 (2085 ref.)

Cellular microbiology emerging. Cossart P, et al. **Science** 1996 Jan 19;271(5247):315–6 (22 ref.)

Regulation of the actin cytoskeleton by inositol phospholipid pathways. Kandzari DE, et al. **Subcell Biochem** 1996; 26:97–114 (91 ref.)

PHYSIOLOGY

Growth factors and the glomerulus: relationships between development and injury. Alpers CE, et al. **Adv Nephrol Necker Hosp** 1995;24:33–52 (85 ref.)

The role of actin filament barbed-end exposure in cytoskeletal dynamics and cell motility. Barkalow K, et al. **Biochem Soc Trans** 1995 Aug;23(3):451–6 (40 ref.)

Actin-based cell motility and cell locomotion. Mitchison TJ, et al. **Cell** 1996 Feb 9;84(3):371–9 (76 ref.)

Actin cytoskeleton. Setting the pace of cell movement. Barkalow K, et al. **Curr Biol** 1995 Sep 1;5(9):1000–2 (11 ref.)

Molecular motors, membrane movements and physiology: emerging roles for myosins. Hasson T, et al. **Curr Opin Cell Biol** 1995 Aug;7(4):587–94 (49 ref.)

Role of the actin cytoskeleton in early Drosophila development. Miller KG. **Curr Top Dev Biol** 1995; 31:167–96 (59 ref.)

The ADF/cofilin proteins: stimulus–responsive modulators of actin dynamics. Moon A, et al. **Mol Biol Cell** 1995 Nov; 6(11):1423–31 (84 ref.)

ULTRASTRUCTURE

Control of actin assembly at filament ends. Schafer DA, et al. **Ann Rev Cell Dev Biol** 1995;11:497–518 (143 ref.)

Role of the cytoskeleton in the generation of spatial patterns in Tubifex eggs. Shimizu T. **Curr Top Dev Biol** 1995; 31:197–235 (57 ref.)

ACTION POTENTIALS

Repolarization gradients derived by subtraction of monophasic action potential recordings in the human heart. Studies incorporating altered mechanical loading and ischemia. Taggart P, et al. **J Electrocardiol** 1995;28 Suppl:156–61 (25 ref.)

DRUG EFFECTS

[Variability of antiarrhythmic drug action in prolonging action potential duration during various rates of heart action] Zakrzewski D, et al. **Pol Arch Med Wewn** 1996 Apr;95(4):383–7 (20 ref.) **(Pol)**

PHYSIOLOGY

The role of the sarcolemma action potential in fatigue. Fuglevand AJ. **Adv Exp Med Biol** 1995;384:101–8 (56 ref.)

Human motor units studied by spike–triggered averaging and intraneural motor axon stimulation. Thomas CK. **Adv Exp Med Biol** 1995;384:147–60 (75 ref.)

Backpropagation of action potentials generated at ectopic axonal loci: hypothesis that axon terminals integrate local environmental signals. Pinault D. **Brain Res Brain Res Rev** 1995 Jul;21(1):42–92 (484 ref.)

Mechano–electrical feedback in ventricular myocardium. Franz MR. **Cardiovasc Res** 1996 Jul;32(1):15–24 (40 ref.)

The role of Na–Ca exchange current in the cardiac action potential. Janvier NC, et al. **Cardiovasc Res** 1996 Jul; 32(1):69–84 (74 ref.)

Presynaptic excitability. Jackson MB. **Int Rev Neurobiol** 1995; 38:201–51 (296 ref.)

Calcium–dependent afterhyperpolarization and learning in young and aging hippocampus. Disterhoft JF, et al. **Life Sci** 1996;59(5–6):413–20 (54 ref.)

Encoding with bursting, subthreshold oscillations, and noise in mammalian cold receptors. Longtin A, et al. **Neural Comput** 1996 Feb 15;8(2):215–55 (75 ref.)

Basic concepts in cellular cardiac electrophysiology: Part I: Ion channels, membrane currents, and the action potential. Whalley DW, et al. **Pacing Clin Electrophysiol** 1995 Aug; 18(8):1556–74 (72 ref.)

[Developmental changes in the pacemaker current and membrane currents of the guinea pig myocardium] Shigenobu K, et al. **Nippon Yakurigaku Zasshi** 1996 Jun; 107(6):259–72 (48 ref.) (Eng. Abstr.) **(Jpn)**

ACTIVATED CHARCOAL see CHARCOAL

ACTIVATED COAGULATION TIME, WHOLE BLOOD see WHOLE BLOOD COAGULATION TIME

ACTIVATED PARTIAL THROMBOPLASTIN TIME see PARTIAL THROMBOPLASTIN TIME

ACTIVE LEARNING see PROBLEM-BASED LEARNING

ACTIVE SITE see BINDING SITES

ACTIVE TRANSPORT see BIOLOGICAL TRANSPORT, ACTIVE

ACTIVITIES OF DAILY LIVING

see related
SICKNESS IMPACT PROFILE

Low vision: physician screening helps to improve patient function. Castor TD, et al. **Geriatrics** 1995 Dec;50(12):51–2, 55–7; quiz 58–9 (5 ref.)

The economics of independent living: efficiency, equity and ethics. O'Shea E, et al. **Int J Rehabil Res** 1996 Mar; 19(1):13–26 (28 ref.)

Effects of exercise on body composition and functional capacity of the elderly. Evans WJ. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:147–50 (23 ref.)

Functional ability and nutritional status of free–living elderly people. Manandhar MC. **Proc Nutr Soc** 1996 Nov; 54(3):677–91 (99 ref.)

Longitudinal studies of dependence in daily life activities among elderly persons. Sonn U. **Scand J Rehabil Med Suppl** 1996;34:1–35 (168 ref.)

[Rheumatoid arthritis and quality of life] Kawai S. **Ryumachi** 1995 Jun;35(3):609–20 (43 ref.) **(Jpn)**

CLASSIFICATION

Migraine impact and functional disability. Lipton RB, et al. **Cephalalgia** 1995 Oct;15 Suppl 15:4–9 (33 ref.)
Interventionalists' guide to the patient's experience of lower extremity arterial occlusive disease. McDaniel MD, et al. **J Vasc Interv Radiol** 1995 Nov–Dec;6(6 Pt 2 Su):30S–35S (27 ref.)

PSYCHOLOGY

[Evaluation of autonomy in chronic mental patients. Problems, assessment tools, results] Leguay D. **Encephale** 1995 Nov–Dec;21(6):425–35 (98 ref.) (Eng. Abstr.) **(Fre)**

ACTOMYOSIN

CHEMISTRY

Protein–protein interactions in the rigor actomyosin complex. Milligan RA. **Proc Natl Acad Sci U S A** 1996 Jan 9; 93(1):21–6 (31 ref.)

ACTOMYOSIN ADENOSINETRIPHOSPHATASE see **MYOSIN ATPASE**

ACTOMYOSIN SUBFRAGMENTS see **MYOSIN SUBFRAGMENTS**

ACUPOINTS see **ACUPUNCTURE POINTS**

ACUPUNCTURE

Acupuncture—from empiricism to science: functional background to acupuncture effects in pain and disease. Andersson S, et al. **Med Hypotheses** 1995 Sep;45(3):271–81 (96 ref.)
The language of acupuncture: should Western physicians learn it? Erickson JK. **Pharos** 1995 Fall;58(4):21–5 (14 ref.)

ACUPUNCTURE ANALGESIA

A concept in analgesic mechanisms of acupuncture. Lin JG. **Chin Med J (Engl)** 1996 Mar;109(3):185–8 (8 ref.)

ACUPUNCTURE POINTS

[The clinico–physiological characteristics of biologically active points] Panasiuk IeM, et al. **Fiziol Zh** 1995 Jan–Apr; 41(1–2):117–21 (19 ref.) (Eng. Abstr.) **(Ukr)**

ACUPUNCTURE THERAPY

Second-line and 'alternative' treatments for alcohol withdrawal: alpha-agonists, beta-blockers, anticonvulsants, acupuncture and neuro-electric therapy. Brewer C. **Alcohol Alcohol** 1995 Nov;30(6):799–803 (25 ref.)
Conditioned healing with electroacupuncture. Ulett GA. **Altern Ther Health Med** 1996 Sep;2(5):56–60 (52 ref.)
Can acupuncture have specific effects on health? A systematic review of acupuncture antiemesis trials. Vickers AJ. **J R Soc Med** 1996 Jun;89(6):303–11 (49 ref.)
Advanced in studies on acupuncture abstinence. Cui M. **J Tradit Chin Med** 1996 Mar;16(1):65–9 concl (38 ref.)
Advances in studies on acupuncture abstinence. Cui M. **J Tradit Chin Med** 1995 Dec;15(4):301–7, contd (32 ref.)
Recent progress in the studies on weight reduction by acupuncture and moxibustion. Liu Z, et al. **J Tradit Chin Med** 1995 Sep;15(3):224–30 (42 ref.)
[Progress in the treatment of opiate dependence] Wu LZ, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Sep;15(9):569–73 (38 ref.) **(Chi)**
[Value of acupuncture in treatment of migraine] Chrubasik S, et al. **Anaesthesiol Reanim** 1995;20(6):150–2 (25 ref.) (Eng. Abstr.) **(Ger)**

ACUTE DISEASE

Strategies for potential manipulation of anorexia during acute and chronic disease. Plata-Salamán CR. **Nutrition** 1995 Sep–Oct;11(5 Suppl):702–4 (39 ref.)
Anorexia during acute and chronic disease. Plata-Salamán CR. **Nutrition** 1996 Feb;12(2):69–78 (147 ref.)

NURSING

The changing profile of acute childhood illness: a need for the development of family nursing knowledge. Rennick JE. **J Adv Nurs** 1995 Aug;22(2):258–66 (57 ref.)

THERAPY

Gene therapy in acute critical illness. Brigham KL, et al. **New Horiz** 1995 May;3(2):321–9 (34 ref.)

ACUTE LARYNGOTRACHEOBRONCHITIS VIRUS see **PARAINFLUENZA VIRUS TYPE 2**

ACUTE LUNG INJURY see **RESPIRATORY DISTRESS SYNDROME, ADULT**

ACUTE PAIN SERVICE see **PAIN CLINICS**

ACUTE-PHASE PROTEINS

ANALYSIS

Acute-phase proteins in osteoarthritis. Sipe JD. **Semin Arthritis Rheum** 1995 Oct;25(2):75–86 (115 ref.)
[Usefulness of the determination of C reactive protein and other acute phase proteins in rheumatoid arthritis] Galeazzi M, et al. **Recenti Prog Med** 1995 Nov;86(11):456–62 (40 ref.) (Eng. Abstr.) **(Ita)**

METABOLISM

[Acute-phase proteins in inflammation] Engler R. **C R Seances Soc Biol Fil** 1995;189(4):563–78 (20 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

The acute-phase response. Pannen BH, et al. **New Horiz** 1995 May;3(2):183–97 (84 ref.)

ACUTE-PHASE REACTANTS see **ACUTE-PHASE PROTEINS**

ACUTE-PHASE REACTION

The acute-phase response. Pannen BH, et al. **New Horiz** 1995 May;3(2):183–97 (84 ref.)

METABOLISM

Haptoglobin. A potential reporter molecule for glycosylation changes in disease. Turner GA. **Adv Exp Med Biol** 1995; 376:231–8 (26 ref.)

PHYSIOPATHOLOGY

Inflammatory cell response to acute muscle injury. Tidball JG. **Med Sci Sports Exerc** 1995 Jul;27(7):1022–32 (118 ref.)

ACUTE-PHASE STATE see **ACUTE-PHASE REACTION**

ACUTE RESPIRATORY DISEASE VIRUSES see **ADENOVIRUSES, HUMAN**

ACUTE RETINAL NECROSIS see **RETINAL NECROSIS SYNDROME, ACUTE**

ACYCLOGUANOSINE see **ACYCLOVIR**

ACYCLOVIR

ADVERSE EFFECTS

Delirium associated with acyclovir treatment in a patient with renal failure. Revankar SG, et al. **Clin Infect Dis** 1995 Aug;21(2):435–6 (14 ref.)

ANALOGS & DERIVATIVES

Valacyclovir HCl (Valtrex): an acyclovir prodrug with improved pharmacokinetics and better efficacy for treatment of zoster. Smiley ML, et al. **Adv Exp Med Biol** 1996;394:33–9 (23 ref.)
Valacyclovir: a review of its antiviral activity, pharmacokinetic properties, and clinical efficacy. Beutner KR. **Antiviral Res** 1995 Dec;28(4):281–90 (29 ref.)
Use of penciclovir and famciclovir in the management of genital herpes. Sacks SL. **Curr Probl Dermatol** 1996; 24:219–26 (34 ref.)
Aciclovir and its l-valyl ester, valaciclovir. Smiley ML, et al. **Curr Probl Dermatol** 1996;24:209–18 (56 ref.)

PHARMACOLOGY

Treatment of acyclovir-resistant herpes simplex and varicella zoster virus infections. Safrin S. **Adv Exp Med Biol** 1996; 394:59–66 (44 ref.)

THERAPEUTIC USE

Treatment of acyclovir-resistant herpes simplex and varicella zoster virus infections. Safrin S. **Adv Exp Med Biol** 1996; 394:59–66 (44 ref.)
Herpetic eye disease study. You can help [editorial] Dawson CR, et al. **Arch Ophthalmol** 1996 Jan;114(1):89–90 (8 ref.)
Aciclovir and its l-valyl ester, valaciclovir. Smiley ML, et al. **Curr Probl Dermatol** 1996;24:209–18 (56 ref.)
Herpes simplex virus resistance to acyclovir: clinical relevance. Pottage JC Jr, et al. **Infect Agents Dis** 1995 Sep; 4(3):115–24 (111 ref.)
Antiviral chemotherapy in genital herpes simplex virus infections. Patel R, et al. **Int J STD AIDS** 1995 Sep–Oct; 6(5):320–8 (78 ref.)
Perinatal herpes: current status and obstetric management strategies. Scott LL. **Pediatr Infect Dis J** 1995 Oct; 14(10):827–32; discussion 832–5 (73 ref.)

ACYL COA see **ACYL COENZYME A**

ACYL-COA-CHOLESTEROL ACYLTRANSFERASE see **CHOLESTEROL ACYLTRANSFERASE**

ACYL COA DEHYDROGENASES see **FATTY ACID DESATURASES**

ACYL COA DESATURASES see **FATTY ACID DESATURASES**

ACYL COA SYNTHETASES see **COENZYME A SYNTHETASES**

ACYL COENZYME A

METABOLISM

Are the beta-cell signaling molecules malonyl-CoA and cystolic long-chain acyl-CoA implicated in multiple tissue defects of obesity and NIDDM? Prentki M, et al. **Diabetes** 1996 Mar;45(3):273–83 (163 ref.)
Unusual dehydrations in anaerobic bacteria: considering ketyls (radical anions) as reactive intermediates in enzymatic reactions. Buckel W. **FEBS Lett** 1996 Jun 24; 389(1):20–4 (43 ref.)

ACYL COENZYME A SYNTHETASES see **COENZYME A SYNTHETASES**

ACYLATION

Mechanisms of phosphoryl and acyl transfer. Cleland WW, et al. **FASEB J** 1995 Dec;9(15):1585–94 (50 ref.)

ACYLTRANSFERASES

DEFICIENCY

[Biotinidase deficiency. Its form of presentation and response to treatment] Campistol J, et al. **An Esp Pediatr** 1996 Apr; 44(4):389–92 (22 ref.) **(Spa)**

GENETICS

Suppression of flavonoid flower pigmentation genes in Petunia hybrida by the introduction of antisense and sense genes. de Lange P, et al. **Curr Top Microbiol Immunol** 1995; 197:57–75 (88 ref.)
Developmental regulation of co-suppression in Petunia hybrida. Flavell RB, et al. **Curr Top Microbiol Immunol** 1995;197:43–56 (63 ref.)

METABOLISM

Production of poly(hydroxyalkanoic acid). Lee SY, et al. **Adv Biochem Eng Biotechnol** 1995;52:27–58 (131 ref.)
Mammalian myristoyl CoA: protein N-myristoyltransferase. Raju RV, et al. **Mol Cell Biochem** 1995 Aug–Sep; 149–150:191–202 (89 ref.)

ADAMANTINOMA see **AMELOBLASTOMA**

ADAPTATION, BIOLOGICAL

The Leeuwenhoek Lecture, 1995. Adaptation to life without oxygen. Guest JR. **Philos Trans R Soc Lond B Biol Sci** 1995 Nov 29;350(1332):189–202 (61 ref.)
Sexual potency and adaptive mutation in bacteria. Bridges BA. **Trends Microbiol** 1995 Aug;3(8):291–2; discussion 292–4 (16 ref.)

ADAPTATION, PHYSIOLOGICAL

Is the slow component of exercise VO2 a respiratory adaptation to anaerobiosis? Wasserman K, et al. **Adv Exp Med Biol** 1995;393:187–94 (11 ref.)
Extrarenal potassium adaptation: review of a concept [editorial] Spital A, et al. **Am J Nephrol** 1995;15(5):367–73 (29 ref.)
Involvement of heat shock proteins and cellular membranes in the development of thermotolerance. Jóźwiak Z. **Arch Immunol Ther Exp (Warsz)** 1994;42(4):247–52 (70 ref.)
Role of membrane lipids in temperature acclimatization of carp. Buda C, et al. **Arch Tierernahr** 1996;49(1):61–2 (7 ref.)
The economy of winter: phenotypic plasticity in behavior and brain structure. Jacobs LF. **Biol Bull** 1996 Aug; 191(1):92–100 (61 ref.)
Skeletal adaptations to mechanical usage: results from tibial loading studies in rats. Forwood MR, et al. **Bone** 1995 Oct; 17(4 Suppl):197S–205S (56 ref.)
Using functional loading to influence bone mass and architecture: objectives, mechanisms, and relationship with estrogen of the mechanically adaptive process in bone. Lanyon LE. **Bone** 1996 Jan;18(1 Suppl):37S–43S (74 ref.)
Adaptation in the oculomotor response to caloric irrigation and the merits of bithermal stimulation [see comments] Barnes G. **Br J Audiol** 1995 Apr;29(2):95–106 (22 ref.) Comment in: Br J Audiol 1995 Apr;29(2):83–6.
On the mechanism and possible therapeutic application of delayed cardiac adaptation to stress. Szekeres L. **Can J Cardiol** 1996 Feb;12(2):177–85 (49 ref.)
Biophysical modulation of cell and tissue structure and function. Rubin J, et al. **Crit Rev Eukaryot Gene Expr** 1995; 5(2):177–91 (81 ref.)
Maternal adaptation to pregnancy. Sibai BM, et al. **Curr Opin Obstet Gynecol** 1995 Dec;7(6):420–6 (55 ref.)
Towards understanding the process of intestinal adaptation. Wolvekamp MC, et al. **Dig Dis** 1996 Jan–Feb;14(1):59–72 (106 ref.)
Biological adaptation of the myocardium to chronic mechanical overload. Molecular determinants of the

autonomic nervous system. Mondry A, et al. **Eur Heart J** 1995 Aug;16 Suppl I:64–73 (96 ref.)

Thyroid hormone: modulation of muscle structure, function, and adaptive responses to mechanical loading. Caiozzo VJ, et al. **Exerc Sport Sci Rev** 1996;24:321–61 (159 ref.)

Muscle mechanics: adaptations with exercise–training. Fitts RH, et al. **Exerc Sport Sci Rev** 1996;24:427–73 (139 ref.)

Strength and power training: physiological mechanisms of adaptation. Kraemer WJ, et al. **Exerc Sport Sci Rev** 1996; 24:363–97 (158 ref.)

Exercise training and the cross–stressor adaptation hypothesis. Sothmann MS, et al. **Exerc Sport Sci Rev** 1996; 24:267–87 (89 ref.)

Specialized surface adaptations of Giardia lamblia. Aley SB, et al. **Infect Agents Dis** 1995 Sep;4(3):161–6 (32 ref.)

The adaptive value of fever. Kluger MJ, et al. **Infect Dis Clin North Am** 1996 Mar;10(1):1–20 (96 ref.)

The role of protein kinases in adaptational growth of the heart. Bogoyevitch MA, et al. **Int J Biochem Cell Biol** 1996 Jan;28(1):1–12 (101 ref.)

The significance of bacteria in stationary phase to food microbiology. Rees CE, et al. **Int J Food Microbiol** 1995 Dec;28(2):263–75 (74 ref.)

Gravity, blood circulation, and the adaptation of form and function in lower vertebrates. Lillywhite HB. **J Exp Zool** 1996 Jun 1–15;275(2–3):217–25 (37 ref.)

Transduction and adaptation in sensory receptor cells. Torre V, et al. **J Neurosci** 1995 Dec;15(12):7757–68 (105 ref.)

Skin response to mechanical stress: adaptation rather than breakdown—a review of the literature. Sanders JE, et al. **J Rehabil Res Dev** 1995 Oct;32(3):214–26 (71 ref.)

Alzheimer's disease: maladaptive synaptoplasticity hypothesis. Neill D. **Neurodegeneration** 1995 Jun; 4(2):217–32 (250 ref.)

Perinatal benzodiazepine modulation of GABAA receptor function: influence on adaptive responses. Kellogg CK. **NIDA Res Monogr** 1995;158:202–26 (78 ref.)

Fuel selection by the kidney: adaptation to starvation. Baverel G, et al. **Proc Nutr Soc** 1995 Mar;54(1):197–212 (116 ref.)

Correlation between proto–oncogene, fibroblast growth factor and adaptive response in brain iiifarct. Liu HM. **Prog Brain Res** 1995;105:239–44 (44 ref.)

Aging of human muscle: structure, function and adaptability [see comments] Porter MM, et al. **Scand J Med Sci Sports** 1995 Jun;5(3):129–42 (122 ref.) Comment in: Scand J Med Sci Sports 1995 Jun;5(3):127–8.

[Post–polio syndrome; the limit of neuromuscular adaptation?] Nollet F, et al. **Ned Tijdschr Geneeskd** 1996 Jun 1;140(22):1169–73 (39 ref.) **(Dut)**

[Adaptation and protection systems against chemical substances in living body] Ariyoshi T. **Yakugaku Zasshi** 1996 Mar;116(3):192–208 (30 ref.) (Eng. Abstr.) **(Jpn)**

[Ecology, adaptation and biorhythms] Agadzhanian NA, et al. **Aviakosm Ekolog Med** 1995;29(3):16–9 (17 ref.) (Eng. Abstr.) **(Rus)**

[Immunophysiologic mechanisms of adaptation to extreme conditions] Novikov VS. **Fiziol Cheloveka** 1996 Mar–Apr; 22(2):25–34 (44 ref.) **(Rus)**

[Cardiorespiratory system adaptation after surgical correction of intracardiac hemodynamics] Shevchenko IuL. **Fiziol Cheloveka** 1996 Mar–Apr;22(2):20–4 (14 ref.) **(Rus)**

[The basic molecular cellular mechanisms of adaptive reactions in the brain] Samoilov MO. **Fiziol Zh Im I M Sechenova** 1995 Aug;81(8):3–11 (32 ref.) **(Rus)**

[Neuroendocrine mechanisms in the shaping of adaptive behavior] Shaliapina VG, et al. **Fiziol Zh Im I M Sechenova** 1995 Aug;81(8):94–100 (25 ref.) (Eng. Abstr.) **(Rus)**

[Intestinal adaptation in the short and ultrashort bowel syndrome. Nutritional support] Galiano Segovia MJ, et al. **An Esp Pediatr** 1996 Jun;44(6):605–8 (16 ref.) **(Spa)**

[The functional organization of the adaptive and compensatory reactions of the endocrine glands] Reznikov OH. **Fiziol Zh** 1994 Sep–Dec;40(5–6):121–7 (22 ref.) (Eng. Abstr.) **(Ukr)**

DRUG EFFECTS

Contingent tolerance to the anticonvulsant effects of carbamazepine: relationship to loss of endogenous adaptive mechanisms. Weiss SR, et al. **Brain Res Brain Res Rev** 1995 Mar;20(3):305–25 (96 ref.)

Hypothalamic neuronal histamine modulates adaptive behavior and thermogenesis in response to endogenous pyrogen. Sakata T, et al. **Obes Res** 1995 Dec;3 Suppl 5:707S–712S (26 ref.)

IMMUNOLOGY

Natural killer cells wear different hats: effector cells of innate resistance and regulatory cells of adaptive immunity and of hematopoiesis. Trinchieri G. **Semin Immunol** 1995 Apr; 7(2):83–8 (43 ref.)

PHYSIOLOGY

A hot topic: the origin of hyperthermophiles. Forterre P. **Cell** 1996 Jun 14;85(6):789–92 (20 ref.)

Low pH adaptation and the acid tolerance response of Salmonella typhimurium. Foster JW. **Crit Rev Microbiol** 1995;21(4):215–37 (90 ref.)

Role of the cerebellum in movement control and adaptation. Robinson FR. **Curr Opin Neurobiol** 1995 Dec;5(6):755–62 (49 ref.)

Adaptation to life at micromolar nutrient levels: the regulation of Escherichia coli glucose transport by endoinduction and cAMP. Ferenci T. **FEMS Microbiol Rev** 1996 Jul;18(4):301–17 (92 ref.)

Adaptation of human skeletal muscle to exercise–training. Simoneau JA. **Int J Obes Relat Metab Disord** 1995 Oct; 19 Suppl 4:S9–13 (47 ref.)

Di...cte, patterned and purposeful adaptive physiological adjustments integrated by forebrain influences. Wolf S. **Integr Physiol Behav Sci** 1995 Jul–Sep;30(3):190–9 (21 ref.)

Signal transduction in ischemic preconditioning. Downey JM, et al. **Z Kardiol** 1995;84 Suppl 4:77–86 (68 ref.)

[Morphologic adaptation of the vertebrate eye to the environment] Puzzolo D. **Arch Ital Anat Embriol** 1994 Oct–Dec;99(4):17–100 (250 ref.) **(Ita)**

ADAPTATION, PSYCHOLOGICAL

see related

SOCIAL ADJUSTMENT

Impact of aborted sudden cardiac death on survivors and their spouses: the phenomenon of different reference points. Doolittle ND, et al. **Am J Crit Care** 1995 Sep;4(5):389–96 (24 ref.)

Transformative narratives: from victimic to agentic life plots. Polkinghorne DE. **Am J Occup Ther** 1996 Apr; 50(4):299–305 (34 ref.)

Research update on the psychosocial treatment of schizophrenia. Penn DL, et al. **Am J Psychiatry** 1996 May; 153(5):607–17 (89 ref.)

Dissociation, somatization, and affect dysregulation: the complexity of adaptation of trauma. van der Kolk BA, et al. **Am J Psychiatry** 1996 Jul;153(7 Suppl):83–93 (90 ref.)

Basic behavioral science research for mental health. Vulnerability and resilience. Basic Behavioral Science Task Force of the National Advisory Mental Health Council. **Am Psychol** 1996 Jan;51(1):22–8 (7 ref.)

Violence in the health care environment. Gregg CM, et al. **Arch Otolaryngol Head Neck Surg** 1996 Jan;122(1):11–6 (19 ref.)

Psychological first–aid: a practical aide–memoire. Leach J. **Aviat Space Environ Med** 1995 Jul;66(7):668–74 (22 ref.)

Computer modeling of adaptive depression. Webster C. **Behav Sci** 1995 Oct;40(4):314–30 (52 ref.)

Psychological interventions in infection with the human immunodeficiency virus. Catalan J. **Br J Psychiatry** 1995 Jul;167(1):104–11 (65 ref.)

Self–esteem and cancer: theory and research. Katz MR, et al. **Can J Psychiatry** 1995 Dec;40(10):608–15 (120 ref.)

Managing erotic feelings in the physician–patient relationship [see comments] Golden GA, et al. **Can Med Assoc J** 1995 Nov 1;153(9):1241–5 (52 ref.) Comment in: Can Med Assoc J 1996 Apr 15;154(8):1149; discussion 1150. Comment in: Can Med Assoc J 1996 Apr 15;154(8):1149–50.

Illness and family functioning: theoretical and practical considerations from the primary care point of view. Tansella CZ. **Fam Pract** 1995 Jun;12(2):214–20 (14 ref.)

The effects of poverty environments on elders' subjective well–being: a conceptual model. Brown V. **Gerontologist** 1995 Aug;35(4):541–8 (48 ref.)

Social support and adjustment to cancer: reconciling descriptive, correlational, and intervention research. Helgeson VS, et al. **Health Psychol** 1996 Mar;15(2):135–48 (80 ref.)

Links between growth hormone deficiency, adaptation and social phobia. Stabler B, et al. **Horm Res** 1996;45(1–2):30–3 (27 ref.)

The Pinwheel Model of Bereavement. Solari–Twadell PA, et al. **Image J Nurs Sch** 1995 Winter;27(4):323–6 (21 ref.)

Smoking cessation leads to reduced stress, but why? Parrott AC. **Int J Addict** 1995 Sep;30(11):1509–16 (17 ref.)

Psychological and hypnotic preparation for anesthesia and surgery: an individual differences perspective. Kessler R, et al. **Int J Clin Exp Hypn** 1996 Jul;44(3):189–207 (60 ref.)

Wellness and HIV: developing a model for progression from theoretical knowledge about psychosocial factors to application. Rayner–Brosnan D. **Int J Immunopharmacol** 1995 Aug;17(8):663–76 (95 ref.)

The spiritual dimension: its importance to patients' health, well–being and quality of life and its implications for nursing practice. Ross L. **Int J Nurs Stud** 1995 Oct; 32(5):457–68 (66 ref.)

"Adaptive" changes in the behaviour of parasitized animals: a critical review. Poulin R. **Int J Parasitol** 1995 Dec; 25(12):1371–83 (102 ref.)

Social support and the patient with cancer: a consideration of the literature. Krishnasamy M. **J Adv Nurs** 1996 Apr; 23(4):757–62 (29 ref.)

Chronic illness and the family life–cycle. Newby NM. **J Adv Nurs** 1996 Apr;23(4):786–91 (29 ref.)

Management of conflict: do nurses/women handle it differently? Valentine PE. **J Adv Nurs** 1995 Jul;22(1):142–9 (77 ref.)

Caring, curing, coping: towards an integrated model. Webb C. **J Adv Nurs** 1996 May;23(5):960–8 (44 ref.)

Stress, coping, and social support processes: where are we? What next? Thoits PA. **J Health Soc Behav** 1995;Spec No:53–79 (220 ref.)

A model of family adaptation to new–onset childhood epilepsy. Austin JK. **J Neurosci Nurs** 1996 Apr;28(2):82–92 (55 ref.)

Spiritual care of the school–age child with a chronic condition. Fulton RA, et al. **J Pediatr Nurs** 1995 Aug; 10(4):224–31 (56 ref.)

Evolution of parental stress and coping processes: a framework for critical care practice. LaMontagne LL, et al. **J Pediatr Nurs** 1995 Aug;10(4):212–8 (13 ref.)

Hardiness and stress: a critical review. Huang C. **Matern Child Nurs J** 1995 Jul–Sep;23(3):82–9 (36 ref.)

Managing HIV. Part 3: Mechanisms of disease. 3.8 How psychosocial aspects of HIV infection can affect health. Ross MW. **Med J Aust** 1996 Feb 19;164(4):235–7 (5 ref.)

African American families, religion, and disability: a conceptual framework. Rogers–Dulan J, et al. **Ment Retard** 1995 Aug;33(4):226–38 (65 ref.)

Pediatric and family HIV. Psychosocial concerns across the continuum of disease. Lewis SL, et al. **Nurs Clin North Am** 1996 Mar;31(1):221–30 (29 ref.)

The attentional control of pain: methodological and theoretical concerns. Eccleston C. **Pain** 1995 Oct; 63(1):3–10 (45 ref.)

Divorce: consequences for children. Emery RE, et al. **Pediatr Rev** 1995 Aug;16(8):306–10 (8 ref.)

Trends in research on temperament. Bates JE, et al. **Psychiatr Serv** 1995 Jul;46(7):661–3 (21 ref.)

Determinants and consequences of children's coping in the medical setting: conceptualization, review, and critique. Rudolph KD, et al. **Psychol Bull** 1995 Nov;118(3):328–57 (130 ref.)

Coping with laryngeal cancer. Shanks JC. **Semin Speech Lang** 1995 Aug;16(3):180–90 (37 ref.)

Sociological dimensions of illness behavior. Mechanic D. **Soc Sci Med** 1995 Nov;41(9):1207–16 (54 ref.)

[Psychological factors associated with organ transplantation] Kronqvist K, et al. **Duodecim** 1994;110(19):1771–5 (13 ref.) **(Fin)**

[Systemic approach to families dealing with cancer diagnosis, its treatment and its prognosis] Bodart A, et al. **Acta Psychiatr Belg** 1996 Jan–Feb;96(1):30–57 (73 ref.) (Eng. Abstr.) **(Fre)**

[Psycho–oncology in gynecology] **Arch Gynecol Obstet** 1995; 257(1–4):270–7 (28 ref.) **(Ger)**

[Psychiatric manifestations in climacteric. Diagnostic difficulties and therapeutic possibilities] Nijs P, et al. **Gynakologe** 1995 Dec;28(6):420–5 (22 ref.) **(Ger)**

[Therapists' coping with his own abilities] Joss R. **Schweiz Rundsch Med Prax** 1996 Jul 16;85(29–30):904–10 (25 ref.) (Eng. Abstr.) **(Ger)**

[Life review: promoting the developmental potentials in aging] Lohmann R, et al. **Z Gerontol Geriatr** 1995 Jul–Aug; 28(4):236–41 (35 ref.) (Eng. Abstr.) **(Ger)**

[Pain and psychological disorders in the elderly] Wojnar J, et al. **Z Gerontol Geriatr** 1995 Sep–Oct;28(5):369–73 (22 ref.) (Eng. Abstr.) **(Ger)**

[Measuring scales for assessment of coping behavior: a critical evaluation] Wendt A, et al. **Z Klin Psychol Psychopathol Psychother** 1996;44(1):3–32 (90 ref.) (Eng. Abstr.) **(Ger)**

DRUG EFFECTS

Psychological and sexual symptoms associated with the menopause and the effects of hormone replacement therapy. Pearce J, et al. **Br J Psychiatry** 1995 Aug; 167(2):163–73 (60 ref.)

PHYSIOLOGY

Cholesterol and psychological well–being. Wardle J. **J Psychosom Res** 1995 Jul;39(5):549–62 (72 ref.)

NGF regulatory role in stress and coping of rodents and humans. Alleva E, et al. **Pharmacol Biochem Behav** 1996 May;54(1):65–72 (110 ref.)

Stress management for the cardiovascular patient: a look at current treatment and trends. Ulmer D. **Prog Cardiovasc Nurs** 1996 Winter;11(1):21–9 (31 ref.)

[Ontogenesis of affect regulation] Beckmann D, et al. **Psychother Psychosom Med Psychol** 1995 Dec; 45(12):427–35 (60 ref.) (Eng. Abstr.) **(Ger)**

ADCC see **ANTIBODY–DEPENDENT CELL CYTOTOXICITY**

ADDICTIVE BEHAVIOR see **BEHAVIOR, ADDICTIVE**

ADDISON'S ANEMIA see **ANEMIA, PERNICIOUS**

ADDISON'S DISEASE

IMMUNOLOGY

[Autoimmune Addison's disease. Current knowledge and prospects] De Bellis A, et al. **Minerva Endocrinol** 1996 Mar; 21(1):1–6 (35 ref.) (Eng. Abstr.) **(Ita)**

ADENINE

CHEMISTRY

What is the basis of sequence–directed curvature in DNAs containing A tracts? Harvey SC, et al. **J Biomol Struct Dyn** 1995 Oct;13(2):301–7 (55 ref.)

AU-rich elements: characterization and importance in mRNA degradation. Chen CY, et al. **Trends Biochem Sci** 1995 Nov;20(11):465–70 (42 ref.)
[Oxidative reactions of the base moiety in purine nucleosides and their applications] Maki Y, et al. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1211–8 (30 ref.) **(Jpn)**

ADENINE ARABINOSIDE see **VIDARABINE**

ADENINE ARABINOSIDE MONOPHOSPHATE see **VIDARABINE PHOSPHATE**

ADENINE NUCLEOTIDE TRANSLOCASE

CHEMISTRY

The yeast ADP/ATP carrier. Mutagenesis and second-site revertants. Nelson DR. **Biochim Biophys Acta** 1996 Jul 18; 1275(1–2):133–7 (27 ref.)

ADENINE NUCLEOTIDES

BIOSYNTHESIS

Agrocins. Clare BG. **Biotechnology** 1995;28:619–32 (53 ref.)

CHEMISTRY

Agrocins. Clare BG. **Biotechnology** 1995;28:619–32 (53 ref.)

METABOLISM

Control of adenine nucleotide metabolism and glycolysis in vertebrate skeletal muscle during exercise. Krause U, et al. **Experientia** 1996 May 15;52(5):396–403 (51 ref.)
Is there a critical tissue oxygen tension for bioenergetic status and cellular pH regulation in solid tumors? Vaupel P. **Experientia** 1996 May 15;52(5):464–8 (33 ref.)

ADENITIS see **LYMPHADENITIS**

ADENO-ASSOCIATED VIRUSES see **DEPENDOVIRUS**

ADENOCARCINOMA

ABC of Urology. Urological malignancy—II: Urothelial tumours. Dawson C, et al. **BMJ** 1996 Apr 27; 312(7038):1090–4 (0 ref.)
Periampullary tumours: report of two cases. Kassa E. **East Afr Med J** 1996 May;73(5):333–5 (17 ref.)
Mixed adenocarcinoma and neuroendocrine carcinoma arising in the urachus. A case report and review of the literature. Munichor M, et al. **Eur Urol** 1995;28(4):345–7 (22 ref.)
Adenocarcinoma of the rete testis. Sánchez-Chapado M, et al. **Urology** 1995 Oct;46(4):468–75 (48 ref.)
[Cancer of the anal canal] Gérard JP, et al. **Bull Cancer Radiother** 1990;77(1):23–31 (41 ref.) **(Fre)**
[Muscular metastasis of cancer of the pancreas. A propos of a case] Wafflart E, et al. **J Chir (Paris)** 1996 Jun; 133(4):167–70 (16 ref.) (Eng. Abstr.) **(Fre)**
[Urachal adenocarcinoma associated with urothelial tumor of the bladder. Report of a case] Payen E, et al. **Prog Urol** 1996 Apr;6(2):288–91 (13 ref.) (Eng. Abstr.) **(Fre)**
[Appearance in 2 brothers of double primary neoplasms: right renal carcinoma and gastric adenocarcinoma] Casetta G, et al. **Minerva Urol Nefrol** 1995 Mar;47(1):49–51 (11 ref.) (Eng. Abstr.) **(Ita)**
[Natural history of prostatic adenocarcinoma. Recent advances in prognostic parameters and biological behavior] Mirone V, et al. **Minerva Urol Nefrol** 1995 Dec;47(4):171–5 (11 ref.) (Eng. Abstr.) **(Ita)**
[Adenoacanthoma] Honda K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):303–4 (17 ref.) **(Jpn)**
[Carcinoma in adenoma of the gallbladder] Itoi T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):311–3 (6 ref.) **(Jpn)**
[Adenoacanthoma, adenosquamous carcinoma of the extrahepatic bile duct] Kimoto E, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):47–9 (36 ref.) **(Jpn)**
[Adenocarcinoma of the gallbladder] Nakamura S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):299–302 (16 ref.) **(Jpn)**
[Diffuse bile duct carcinoma] Nakao A. **Ryoikibetsu Shokogun Shirizu** 1996;(9):74–6 (14 ref.) **(Jpn)**
[Adenocarcinoma of the extra bile duct] Noguchi T. **Ryoikibetsu Shokogun Shirizu** 1996;(9):43–6 (8 ref.) **(Jpn)**
[Pleomorphic giant cell adenocarcinoma (PGCA–Ca)] Seki S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):318–20 (20 ref.) **(Jpn)**
[Intrahepatic bile duct adenocarcinoma] Terada T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):402–4 (7 ref.) **(Jpn)**
[Anal cancer. A review] Tanum G. **Tidsskr Nor Laegeforen** 1996 May 20;116(13):1567–70 (31 ref.) (Eng. Abstr.) **(Nor)**
[Gastric cancer in children: report of a case] Berrospi Espinoza F, et al. **Rev Gastroenterol Peru** 1995 Sep–Dec; 15(3):296–8 (16 ref.) (Eng. Abstr.) **(Spa)**

BLOOD

Marked elevation of plasma carcinoembryonic antigen and stomach carcinoma. Horie Y, et al. **Cancer** 1996 May 15; 77(10):1991–7 (21 ref.)

CLASSIFICATION

[A new histological classification of cancers of the stomach] Paraf F. **Gastroenterol Clin Biol** 1995 Oct;19(10):858–60 (12 ref.) **(Fre)**

COMPLICATIONS

Nontraumatic subcutaneous emphysema in association with rectal carcinoma. Chow E, et al. **Can Assoc Radiol J** 1996 Apr;47(2):94–7 (12 ref.)
A case of pancreatic carcinoma causing massive bronchial fluid production and electrolyte abnormalities. Lembo T, et al. **Chest** 1995 Oct;108(4):1161–3 (8 ref.)
Facial pain as a symptom of nonmetastatic lung cancer. Capobianco DJ. **Headache** 1995 Nov–Dec;35(10):581–5 (18 ref.)
Barrett's esophagus: a review. Sawyer DR, et al. **Mo Med** 1995 Oct;92(10):645–7 (13 ref.)
Non-islet-cell tumour induced hypoglycaemia: a case report and review of literature. Kuenen BC, et al. **Neth J Med** 1996 May;48(5):175–9 (16 ref.)
Adenocarcinoma of the prostate and Eaton-Lambert syndrome. A previously unreported association. Agarawal SK, et al. **Scand J Urol Nephrol** 1995 Sep;29(3):351–3 (8 ref.)
[Clinical analysis of lung cancer in patients with chondromatous hamartoma] Umemori Y, et al. **Kyobu Geka** 1995 Nov;48(12):1061–4 (11 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Multicentric primary adenocarcinomas of the midgut: the first case report. Liu KJ, et al. **Am J Gastroenterol** 1996 Jun;91(6):1239–43 (48 ref.)
Pyogenic liver abscess: warning indicator of silent colonic cancer. Report of a case and review of the literature. Teitz S, et al. **Dis Colon Rectum** 1995 Nov;38(11):1220–3 (18 ref.)
Cytogenetic analysis of prostate carcinoma by fluorescence in situ hybridization. Takahashi S, et al. **Int J Urol** 1995 Sep;2(4):215–23 (49 ref.)
Hysteroscopy and adenocarcinoma. Mencaglia L. **Obstet Gynecol Clin North Am** 1995 Sep;22(3):573–9 (30 ref.)
Adenosis (atypical adenomatous hyperplasia): histopathology and relationship to carcinoma. Epstein JI. **Pathol Res Pract** 1995 Sep;191(9):888–98 (21 ref.)
Colorectal neoplasms. Screening can save lives. Truszkowski JA, et al. **Postgrad Med** 1995 Nov;98(5):97–9, 103–6, 109–12 (20 ref.)
Gastric cancer and pernicious anemia appearing as pseudoachalasia. el-Newihi HM, et al. **South Med J** 1996 Sep;89(9):906–10 (30 ref.)
[Choroid metastasis in a patient with adenocarcinoma of the cervix. A case report] Wiegel T, et al. **Strahlenther Onkol** 1995 Sep;171(9):539–42 (16 ref.) (Eng. Abstr.) **(Ger)**
[Is it possible to screen for endometrial carcinoma? Incidence and risk factors] Broso PR, et al. **Minerva Ginecol** 1995 Dec;47(12):539–52 (70 ref.) (Eng. Abstr.) **(Ita)**
[The imaging diagnosis of primary hyperparathyroidism due to parathyroid adenocarcinoma. A case report] Prato N, et al. **Radiol Med (Torino)** 1995 Sep;90(3):323–6 (11 ref.) **(Ita)**
[A case of genitourinary double cancers detected by health screening] Ito T, et al. **Hinyokika Kiyo** 1996 Jun; 42(6):461–4 (20 ref.) (Eng. Abstr.) **(Jpn)**
[Bronchogenic carcinoma and human immunodeficiency virus infection] Carrasquer C, et al. **Arch Bronconeumol** 1995 Aug–Sep;31(7):362–4 (15 ref.) (Eng. Abstr.) **(Spa)**
[Clinical study of incidentally diagnosed renal adenocarcinoma] Herranz Amo F, et al. **Arch Esp Urol** 1995 Dec;48(10):991–8; discussion 998–9 (24 ref.) (Eng. Abstr.) **(Spa)**
[Adenoma of Vater's ampulla without clinical or analytical expression (letter)] Moreira VF, et al. **Rev Clin Esp** 1996 May;196(5):343–4 (11 ref.) **(Spa)**

DRUG THERAPY

Locoregional chemotherapy for adjuvant treatment of colorectal adenocarcinoma. Penna C, et al. **Eur J Cancer** 1996 Jun;32A(7):1117–22 (47 ref.)
The role of chemotherapy in the treatment of adenocarcinoma of the pancreas. Fennelly D, et al. **Hepatogastroenterology** 1996 Mar–Apr;43(8):356–62 (30 ref.)
Preoperative chemoradiation for adenocarcinoma of the pancreas: excessive toxicity of prophylactic hepatic irradiation [see comments] Evans DB, et al. **Int J Radiat Oncol Biol Phys** 1995 Nov 1;33(4):913–8 (35 ref.) Comment in: Int J Radiat Oncol Biol Phys 1995 Nov 1;33(4):969–70.
Adjuvant therapy for resectable gastric adenocarcinoma: preoperative and postoperative chemotherapy trials. Leach SD, et al. **J Infus Chemother** 1995 Summer;5(3):104–11 (46 ref.)
P450-dependent enzymes as targets for prostate cancer therapy. De Coster R, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1–6 Spec No):133–43 (101 ref.)
Chemotherapy of adenocarcinoma of the pancreas. Schnall SF, et al. **Semin Oncol** 1996 Apr;23(2):220–8 (81 ref.)
[Chemotherapy of metastatic endometrial carcinoma. Review of the literature] Pierga JY, et al. **Bull Cancer (Paris)** 1995 Dec;82(12):1005–18 (110 ref.) (Eng. Abstr.) **(Fre)**

EPIDEMIOLOGY

The changing epidemiology of smoking and lung cancer histology. Wynder EL, et al. **Environ Health Perspect** 1995 Nov;103 Suppl 8:143–8 (67 ref.)
[7 cases of carcinoma of the distal choledochus] Gómez-Méndez TJ, et al. **Rev Invest Clin** 1995 Jul–Aug; 47(4):291–5 (11 ref.) (Eng. Abstr.) **(Spa)**

ETHNOLOGY

Molecular changes of colorectal cancer in Singapore. Goh HS, et al. **Ann Acad Med Singapore** 1996 Jan;25(1):3–10 (93 ref.)

ETIOLOGY

Barrett's esophagus: a model of human neoplastic progression. Neshat K, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:577–83 (58 ref.)
The biological significance of tobacco-specific N-nitrosamines: smoking and adenocarcinoma of the lung. Hoffmann D, et al. **Crit Rev Toxicol** 1996;26(2):199–211 (76 ref.)
Malignant tumor developed in colon-esophagus. Altorjay A, et al. **Hepatogastroenterology** 1995 Nov–Dec;42(6):797–9 (19 ref.)
Helicobacter pylori and gastric neoplasia: evolving concepts. Bolin TD, et al. **Med J Aust** 1995 Sep 4;163(5):253–5 (18 ref.)
[From Barrett esophagus to adenocarcinoma: can the dangers of natural history be overcome?] Robaszkiewicz M. **Gastroenterol Clin Biol** 1996;20(5 Pt 2):B89–97 (111 ref.) **(Fre)**
[Two complications of bullous emphysema. Apropos of a case] Guichenez P, et al. **Rev Pneumol Clin** 1995; 51(4):250–2 (14 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Pathways of chromosome alteration in human epithelial cancers. Dutrillaux B. **Adv Cancer Res** 1995;67:59–82 (80 ref.)
Molecular changes of colorectal cancer in Singapore. Goh HS, et al. **Ann Acad Med Singapore** 1996 Jan;25(1):3–10 (93 ref.)
p53 and prognosis in colorectal cancer. Smith DR, et al. **Ann Acad Med Singapore** 1996 Jan;25(1):107–12 (97 ref.)
Colorectal adenoma progression and genetic change: is there a link? Jass JR. **Ann Med** 1995 Jun;27(3):301–6 (40 ref.)
Genetic characteristics of prostate cancer. Huncharek M, et al. **Cancer Epidemiol Biomarkers Prev** 1995 Sep;4(6):681–7 (65 ref.)
Genetic alterations in esophageal cancer and their relevance to etiology and pathogenesis: a review. Montesano R, et al. **Int J Cancer** 1996 Jun 21;69(3):225–35 (120 ref.)
K-ras mutation and pancreatic adenocarcinoma. Caldas C, et al. **Int J Pancreatol** 1995 Aug;18(1):1–6 (66 ref.)
Alternative splicing of the estrogen receptor primary transcript normally occurs in estrogen receptor positive tissues and cell lines. Pfeffer U, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1–6 Spec No):99–105 (37 ref.)
[Genetics of colorectal cancers (editorial)] Pocard M, et al. **Ann Chir** 1996;50(3):211–6 (19 ref.) **(Fre)**
[Genetic alterations in stomach cancer] Tahara E, et al. **Nippon Geka Gakkai Zasshi** 1996 Apr;97(4):252–6 (23 ref.) (Eng. Abstr.) **(Jpn)**

MORTALITY

Carcinoma of the pancreas: critical analysis of costs, results of resections, and the need for standardized reporting [see comments] Gudjonsson B. **J Am Coll Surg** 1995 Dec; 181(6):483–503 (350 ref.) Comment in: J Am Coll Surg 1995 Dec;181(6):558–60.
[Possibilities and limitations of curative resections in cancers of the pancreas] Klempnauer J, et al. **J Chir (Paris)** 1996 May;133(3):117–22 (27 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Barrett's esophagus and esophageal adenocarcinoma: the scope of the problem. Levine MS, et al. **Abdom Imaging** 1995 Jul–Aug;20(4):291–8 (69 ref.)
Intraoral salivary duct carcinoma: a clinicopathological study of four cases and review of the literature. Epivatianos A, et al. **Ann Dent** 1995 Summer–Fall;54(1–2):36–40 (21 ref.)
Tubular carcinoma of the breast. Predicting axillary nodal metastases and recurrence. Winchester DJ, et al. **Ann Surg** 1996 Mar;223(3):342–7 (20 ref.)
Outpatient endometrial biopsy: the pipelle. Youssif SN, et al. **Br J Hosp Med** 1995 Sep 6–19;54(5):198–201 (23 ref.)

ADENOCARCINOMA

The diagnosis and reporting of adenocarcinoma of the prostate in core needle biopsy specimens. Epstein JI. **Cancer** 1996 Jul 15;78(2):350–6 (39 ref.)

Early gastric lymphoma: a clinicopathologic study of ten patients, literature review, and comparison with early gastric adenocarcinoma. Kitamura K, et al. **Cancer** 1996 Mar 1;77(5):850–7 (70 ref.)

The pathology of cervical cancer. Walsh CB, et al. **Clin Obstet Gynecol** 1995 Sep;38(3):653–61 (16 ref.)

Benign to malignant progression in cervical squamous epithelium. Ehrmann RL. **Compr Ther** 1996 Feb; 22(2):67–75 (43 ref.)

Prognostic factors in endometrial neoplasia: old and new. Nogales FF. **Curr Opin Obstet Gynecol** 1996 Feb;8(1):74–8 (34 ref.)

Adequacy of conization margins in adenocarcinoma in situ of the cervix as a predictor of residual disease. Im DD, et al. **Gynecol Oncol** 1995 Nov;59(2):179–82 (20 ref.)

Vulvar Merkel cell tumor with glandular and squamous differentiation. Scurry J, et al. **Gynecol Oncol** 1996 Aug; 62(2):292–7 (15 ref.)

Synchronous adenocarcinoma and low grade B-cell lymphoma of mucosa associated lymphoid tissue (MALT) of the stomach. Wotherspoon AC, et al. **Histopathology** 1995 Oct;27(4):325–31 (45 ref.)

Tumor embolism to LAD during pneumonectomy. A case report. Shah R, et al. **J Cardiovasc Surg (Torino)** 1996 Jun; 37(3):319–21 (13 ref.)

Basal cell adenocarcinoma of the sublingual gland: report of a case. Mima T, et al. **J Oral Maxillofac Surg** 1996 Sep; 54(9):1121–3 (6 ref.)

Controversies in the diagnosis and management of thyroid cancer. Thomas MJ. **J Otolaryngol** 1996 Feb;25(1):20–2 (11 ref.)

Gallbladder adenocarcinoma, acalculous chronic lymphoplasmacytic cholecystitis, ulcerative colitis. Herzog K, et al. **Mod Pathol** 1996 Mar;9(3):194–8 (26 ref.)

Low-grade papillary adenomatous tumors of the temporal bone: report of two cases and review of the literature. Lavoie M, et al. **Mod Pathol** 1995 Aug;8(6):603–8 (17 ref.)

Pathologic evaluation of prostatic carcinoma: critical information for the oncologist. Epstein JI. **Oncology (Huntingt)** 1996 Apr;10(4):527–34; discussion 539, 541–3 (50 ref.)

Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model. Bonkhoff H, et al. **Prostate** 1996 Feb;28(2):98–106 (52 ref.)

Molecular biology of prostatic intraepithelial neoplasia. Bostwick DG, et al. **Prostate** 1996 Aug;29(2):117–34 (157 ref.)

Basal cell adenocarcinoma of minor salivary and seromucous glands of the head and neck region. Fonseca I, et al. **Semin Diagn Pathol** 1996 May;13(2):128–37 (30 ref.)

Colorectal adenocarcinoma: staging and histopathology. Johnson RD, et al. **Semin Roentgenol** 1996 Apr; 31(2):94–102 (36 ref.)

Observations of aggressive, small, flat, and depressed colon cancer. Report of three cases. Kasumi A, et al. **Surg Endosc** 1995 Jun;9(6):690–4 (19 ref.)

Simultaneous gastric adenocarcinoma and MALT-type lymphoma in Helicobacter pylori infection. von Herbay A, et al. **Virchows Arch** 1995;427(4):445–50 (62 ref.)

Gastric carcinoma arising from a hyperplasiogenic polyp with a diameter of less than 2 centimeters. Gschwantler M, et al. **Z Gastroenterol** 1995 Oct;33(10):610–2 (15 ref.)

[Anatomopathologic reassessment of prostatic tumors exclusively affecting the organ with biologic progression and survival study of prostatectomized patients, in terms of the histologic characteristics of the tumor] Ravery V, et al. **Prog Urol** 1995 Dec;5(6):968–73 (17 ref.) (Eng. Abstr.) **(Fre)**

[A case report of prostate cancer with Paneth cell-like change] Soga N, et al. **Hinyokika Kiyo** 1995 Nov; 41(11):891–4 (9 ref.) (Eng. Abstr.) **(Jpn)**

[Comparative study on biological difference between gastric cancer and colorectal cancer] Mai M, et al. **Nippon Geka Gakkai Zasshi** 1996 Apr;97(4):263–8 (24 ref.) (Eng. Abstr.) **(Jpn)**

[Streptococcus bovis in a surgical wound and a colonic neoplasm] Martínez Mas E, et al. **Gastroenterol Hepatol** 1995 Nov;18(9):474–6 (19 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

Salivary duct carcinoma. Clinicopathologic and immunohistochemical review of 26 cases. Lewis JE, et al. **Cancer** 1996 Jan 15;77(2):223–30 (35 ref.)

PREVENTION & CONTROL

Potential criteria for cohort selection in chemoprevention trials of uterine adenocarcinoma. Baker VV. **J Cell Biochem Suppl** 1995;23:184–8 (32 ref.)

Chemoprevention of colon cancer by minor dietary constituents and their synthetic analogues. Reddy BS. **Prev Med** 1996 Jan–Feb;25(1):48–50 (13 ref.)

RADIOGRAPHY

[Acute respiratory failure and multiple pulmonary nodules. Pulmonary metastases of colonic adenocarcinoma] Cordero PJ, et al. **Rev Clin Esp** 1995 Dec;195(12):845–6 (7 ref.) **(Spa)**

RADIOTHERAPY

Preoperative chemoradiation for adenocarcinoma of the pancreas: excessive toxicity of prophylactic hepatic irradiation [see comments] Evans DB, et al. **Int J Radiat Oncol Biol Phys** 1995 Nov 1;33(4):913–8 (35 ref.) Comment in: Int J Radiat Oncol Biol Phys 1995 Nov 1;33(4):969–70.

Radiotherapy in rectal cancer: stage of the disease and therapeutic approach. Cellini N, et al. **Rays** 1995 Apr–Jun; 20(2):132–44 (72 ref.) **(Eng, Ita)**

Prevention of radiation related complications in the treatment of rectal adenocarcinoma. The importance of the dose volume relationship. Gerard JP, et al. **Tumori** 1995 May–Jun;81(3 Suppl):114–6 (20 ref.)

SECONDARY

Carcinoma of the prostate: treatment of bone metastasis. Scalliet P. **Acta Urol Belg** 1996 May;64(2):87–90 (13 ref.)

Cutaneous metastasis from a parotid adenocarcinoma. Report of a case with immunohistochemical findings and review of the literature. Tok J, et al. **Am J Dermatopathol** 1995 Jun;17(3):303–6 (9 ref.)

Heterotopic ossification in adenocarcinoma of the colon. Hui Y, et al. **Chin Med J (Engl)** 1995 Oct;108(10):798–800 (2 ref.)

Abdominal wall metastasis and peritoneal carcinomatosis after laparoscopic-assisted colectomy for colon cancer. Jacquet P, et al. **Eur J Surg Oncol** 1995 Oct;21(5):568–70 (25 ref.)

Carcinomatous meningitis complicating cervical cancer: a clinicopathologic study and literature review. Aboulafia DM, et al. **Gynecol Oncol** 1996 Feb;60(2):313–8 (19 ref.)

Recurrent endometrial adenocarcinoma presenting as a solitary humeral metastasis. Schöls WA, et al. **Gynecol Oncol** 1995 Oct;59(1):148–50 (14 ref.)

Diffuse spinal leptomeningeal metastases from prostatic cancer. A case report. Matsui H, et al. **Int Orthop** 1995; 19(5):315–8 (18 ref.)

Metastatic breast cancer to the bladder: a case report. Schneidau T, et al. **Int Urol Nephrol** 1995;27(3):297–300 (11 ref.)

Metastatic endometrial carcinoma of the foot. A case report. Clarke SJ, et al. **J Am Podiatr Med Assoc** 1996 Jul; 86(7):331–3 (6 ref.)

Bilateral patellar metastases as the clinical presentation of bronchogenic adenocarcinoma. Pauzner R, et al. **J Rheumatol** 1996 May;23(5):939–41 (22 ref.)

[Report of a case of penile metastasis. Review of the literature] Cuvillier X, et al. **Prog Urol** 1995 Dec; 5(6):1009–11 (17 ref.) (Eng. Abstr.) **(Fre)**

[Implantation metastases following laparoscopic cholecystectomy in gallbladder carcinoma] Buhr J, et al. **Dtsch Med Wochenschr** 1996 Jan 19;121(3):57–61; discussion 61–2 (36 ref.) (Eng. Abstr.) **(Ger)**

[Splenic metastases] Tiszlavicz L. **Orv Hetil** 1996 Feb 11; 137(6):295–8 (25 ref.) (Eng. Abstr.) **(Hun)**

[Meningeal carcinomatosis from pulmonary adenocarcinoma: two clinical cases with review of the literature] Rostagno C, et al. **Ann Ital Med Int** 1995 Oct–Dec;10(4):253–6 (11 ref.) (Eng. Abstr.) **(Ita)**

[Single metastasis of renal adenocarcinoma in contralateral adrenal gland] Diego García A, et al. **Actas Urol Esp** 1995 Apr;19(4):314–8; discussion 318–9 (20 ref.) (Eng. Abstr.) **(Spa)**

[Renal adenocarcinoma with venous tumor extension to the right atrium: diagnostic and therapeutic considerations] Herranz Amo F, et al. **Arch Esp Urol** 1996 Jan–Feb; 49(1):17–25 (61 ref.) (Eng. Abstr.) **(Spa)**

[Acute respiratory failure and multiple pulmonary nodules. Pulmonary metastases of colonic adenocarcinoma] Cordero PJ, et al. **Rev Clin Esp** 1995 Dec;195(12):845–6 (7 ref.) **(Spa)**

SURGERY

Total androgenic blockade: a review. Bianchi G, et al. **Acta Urol Belg** 1995 Sep;63(3):11–9 (54 ref.)

Vascular resection and intraoperative radiation therapy during pancreaticoduodenectomy: rationale and technique. Evans DB, et al. **Adv Surg** 1996;29:235–62 (87 ref.)

Retroperitoneal and abdominal wall emphysema after transanal excision of a rectal carcinoma. Petros JG, et al. **Am Surg** 1996 Sep;62(9):759–61 (8 ref.)

Surgical management of Barrett's esophagus. Clark GW, et al. **Ann Chir Gynaecol** 1995;84(2):139–44 (30 ref.)

1995 Roussel Lecture. Management of adenocarcinoma of the head of the pancreas: 10 questions for the 1990s [see comments] Taylor B. **Can J Surg** 1996 Aug;39(4):271–83 (129 ref.) Comment in: Can J Surg 1996 Aug;39(4):265–6.

Progress in the management of gastric cancer. Karpeh MS Jr, et al. **Curr Opin Gen Surg** 1994;:125–30 (47 ref.)

Vater's papilla and periampullary area villous adenoma: personal experience about nine cases and review of the literature. Motton G, et al. **Hepatogastroenterology** 1996 Mar–Apr;43(8):448–55 (77 ref.)

Carcinoma of the pancreas: critical analysis of costs, results of resections, and the need for standardized reporting [see comments] Gudjonsson B. **J Am Coll Surg** 1995 Dec; 181(6):483–503 (350 ref.) Comment in: J Am Coll Surg 1995 Dec;181(6):558–60.

Pancreatic adenocarcinoma: an update. Tan HP, et al. **J Am Coll Surg** 1996 Aug;183(2):164–84 (159 ref.)

Tumor embolism to LAD during pneumonectomy. A case report. Shah R, et al. **J Cardiovasc Surg (Torino)** 1996 Jun; 37(3):319–21 (13 ref.)

Evolving strategies for the treatment of adenocarcinoma of the pancreas. A review. Ettinghausen SE, et al. **J Clin Gastroenterol** 1995 Jul;21(1):48–60 (123 ref.)

Adjuvant therapy for resectable gastric adenocarcinoma: preoperative and postoperative chemotherapy trials. Leach SD, et al. **J Infus Chemother** 1995 Summer;5(3):104–11 (46 ref.)

Trocar site tumor recurrence after laparoscopic-assisted colectomy. Fodera M, et al. **J Laparoendosc Surg** 1995 Aug; 5(4):259–62 (12 ref.)

Surgery for gastric cancer: the American view. Brennan MF, et al. **Semin Oncol** 1996 Jun;23(3):352–9 (31 ref.)

Radioimmunoguided Surgery system improves survival for patients with recurrent colorectal cancer. Bertsch DJ, et al. **Surgery** 1995 Oct;118(4):634–8; discussion 638–9 (9 ref.)

[Primary adenocarcinoma of the duodenum. Study of three cases and review of the literature] Lachachi F, et al. **Ann Chir** 1996;50(4):333–9 (30 ref.) (Eng. Abstr.) **(Fre)**

[Oncocytic cancers of the thyroid. Hürthle cell cancers] Janser JC, et al. **Chirurgie** 1996;121(1):28–36 (40 ref.) (Eng. Abstr.) **(Fre)**

[Anatomopathologic reassessment of prostatic tumors exclusively affecting the organ with biologic progression and survival study of prostatectomized patients, in terms of the histologic characteristics of the tumor] Ravery V, et al. **Prog Urol** 1995 Dec;5(6):968–73 (17 ref.) (Eng. Abstr.) **(Fre)**

[A case of resected small-sized (4 mm in diameter) lung cancer and its way of surgical treatment] Morita H. **Kyobu Geka** 1996 Mar;49(3):175–8; discussion 179–81 (15 ref.) (Eng. Abstr.) **(Jpn)**

[A case of resected lung cancer associated with bullous pemphigoid] Sato Y, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Apr;44(4):524–8 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Cancer of the gastric stump] Pinatel Lopasso F. **Rev Gastroenterol Peru** 1996 Jan–Apr;16(1):57–63 (69 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

Carcinoma of the prostate: treatment of bone metastasis. Scalliet P. **Acta Urol Belg** 1996 May;64(2):87–90 (13 ref.)

Isolated incisional recurrence after curative resection for primary lung cancer. Yokoi K, et al. **Ann Thorac Surg** 1996 Apr;61(4):1236–7 (9 ref.)

Preoperative chemoradiotherapy for localized pancreatic carcinoma. A perspective. Hoffman JP, et al. **Cancer** 1996 Aug 1;78(3 Suppl):592–7 (36 ref.)

A phase I study of intraperitoneal interferon-alpha 2b and intravenous cis-platinum plus cyclophosphamide chemotherapy in patients with untreated stage III epithelial ovarian cancer: a Gynecologic Oncology Group pilot study. Moore DH, et al. **Gynecol Oncol** 1995 Nov; 59(2):267–72 (25 ref.)

Concurrent radiation therapy and chemotherapy followed by esophagectomy for localized esophageal carcinoma. Bates BA, et al. **J Clin Oncol** 1996 Jan;14(1):156–63 (48 ref.)

Inflammatory breast cancer. Lopez MJ, et al. **Surg Clin North Am** 1996 Apr;76(2):411–29 (88 ref.)

The role of bone marrow transplantation in the management of advanced local disease. Safah H, et al. **Surg Oncol Clin N Am** 1995 Oct;4(4):735–49 (83 ref.)

[Statistical study of a series of 672 cases of carcinoma of the uterine cervix. Results and complications according to age and modalities of treatment] Pernot M, et al. **Bull Cancer (Paris)** 1995 Jul;82(7):568–81 (66 ref.) (Eng. Abstr.) **(Fre)**

[The use of self-expanding stents in the recanalization of gastric antrum neoplastic obstructions. The experience of a case] Profili S, et al. **Radiol Med (Torino)** 1995 Sep; 90(3):330–3 (23 ref.) **(Ita)**

ULTRASONOGRAPHY

[A case of early carcinoma of the gall-bladder arising in adenomyomatosis detected by endoscopic ultrasonography] Sakurai T, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Sep;92(9):1304–8 (18 ref.) **(Jpn)**

ULTRASTRUCTURE

Basal cell adenocarcinoma of the parotid gland: a case report with immunohistochemical, ultrastructural findings and review of the literature. Raslan WF, et al. **J Oral Maxillofac Surg** 1995 Dec;53(12):1457–62 (15 ref.)

VETERINARY

Intestinal adenocarcinomas in two beluga whales (Delphinapterus leucas) from the estuary of the St. Lawrence River. Martineau D, et al. **Can Vet J** 1995 Sep; 36(9):563–5 (14 ref.)

ADENOCARCINOMA, BASAL CELL see **ADENOCARCINOMA**

ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR

Bronchioloalveolar carcinoma. Barkley JE, et al. **J Clin Oncol** 1996 Aug;14(8):2377–86 (96 ref.)

DIAGNOSIS

Cardiac tamponade as the initial presentation of bronchioloalveolar cell carcinoma. Hourany J, et al. **Tenn Med** 1996 Jul;89(7):247–8 (12 ref.)

[Choroidal metastases as the form of presentation of 2 bronchiolo-alveolar carcinomas] de Frutos Arribas JF, et al. **Rev Clin Esp** 1995 Dec;195(12):853–5 (19 ref.) (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

[A case of bronchiolo-alveolar carcinoma with high production of carbohydrate antigen (CA19-9)] Shioji Y, et al. **Nippon Geka Gakkai Zasshi** 1996 Apr;97(4):325–9 (20 ref.) (Eng. Abstr.) **(Jpn)**

SECONDARY

[Choroidal metastases as the form of presentation of 2 bronchiolo-alveolar carcinomas] de Frutos Arribas JF, et al. **Rev Clin Esp** 1995 Dec;195(12):853–5 (19 ref.) (Eng. Abstr.) **(Spa)**

ADENOCARCINOMA, CLEAR CELL

[Appearance in 2 brothers of double primary neoplasms: right renal carcinoma and gastric adenocarcinoma] Casetta G, et al. **Minerva Urol Nefrol** 1995 Mar;47(1):49–51 (11 ref.) (Eng. Abstr.) **(Ita)**

[Clear cell carcinoma of the gallbladder] Nomura S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):345–7 (8 ref.) **(Jpn)**

COMPLICATIONS

[Favorable prognosis in a case of recurrent cerebral infarctions caused by chronic disseminated intravascular coagulation due to ovarian carcinoma] Izumi M, et al. **No To Shinkei** 1996 Jun;48(6):581–5 (16 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Familial renal cell carcinoma: review of recent molecular genetics. Yao M, et al. **Int J Urol** 1995 May;2(2):61–70 (134 ref.)

PATHOLOGY

Malignant transformation in endometriosis of the urinary bladder: case report of clear cell adenocarcinoma. Balat O, et al. **Eur J Gynaecol Oncol** 1996;17(1):13–6 (14 ref.)

The histogenesis of clear cell adenocarcinoma of the lower urinary tract. Case series and review of the literature. Drew PA, et al. **Hum Pathol** 1996 Mar;27(3):248–52 (32 ref.)

[Hyalinizing clear cell carcinoma of the salivary glands] Seifert G, et al. **Pathologe** 1996 Mar;17(2):110–5 (26 ref.) (Eng. Abstr.) **(Ger)**

SECONDARY

[Metachronous metastasis in ureteral stump secondary to ipsilateral renal adenocarcinoma] Pereira Arias JG, et al. **Arch Esp Urol** 1995 Sep;48(7):746–8 (9 ref.) (Eng. Abstr.) **(Spa)**

ADENOCARCINOMA, FOLLICULAR

Follicular thyroid cancer. Grebe SK, et al. **Endocrinol Metab Clin North Am** 1995 Dec;24(4):761–801 (184 ref.)

CHEMICALLY INDUCED

Mechanisms of chemically induced thyroid follicular carcinogenesis. Kanno J, et al. **Prog Clin Biol Res** 1996; 394:353–98 (176 ref.)

GENETICS

Genetics of follicular thyroid cancer. Farid NR, et al. **Endocrinol Metab Clin North Am** 1995 Dec;24(4):865–83 (87 ref.)

Molecular analysis of mutations in thyroid tumors with TGGE. Simon D, et al. **Exp Clin Endocrinol Diabetes** 1995; 103(5):275–9 (36 ref.)

PATHOLOGY

[Papillary carcinoma arising in thyroglossal duct cyst: a case report and review of the literature] Sorrenti G, et al. **Acta Otorhinolaryngol Ital** 1995 Dec;15(6):460–4 (40 ref.) (Eng. Abstr.) **(Ita)**

SURGERY

The role of total thyroidectomy in the management of differentiated thyroid cancer. Stephenson BM, et al. **Curr Opin Gen Surg** 1994;:53–9 (61 ref.)

[Prospective therapy study in differentiated thyroid carcinoma] Gemsenjäger E, et al. **Schweiz Med Wochenschr** 1995 Nov 18;125(46):2226–36 (41 ref.) (Eng. Abstr.) **(Ger)**

[Thyroid carcinoma in hyperthyroid syndromes] Ragni F, et al. **G Chir** 1996 Apr;17(4):158–65 (26 ref.) (Eng. Abstr.) **(Ita)**

ADENOCARCINOMA, GRANULAR CELL see **ADENOCARCINOMA**

ADENOCARCINOMA, MUCINOUS

[Adenocarcinoma of the appendix. A propos of a case complicated by double local and parietal recurrence] de Souza N, et al. **J Chir (Paris)** 1996 Jun;133(4):159–61 (10 ref.) (Eng. Abstr.) **(Fre)**

[Mucin producing gallbladder cancer] Araida T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):352–5 (15 ref.) **(Jpn)**

[Mucinous cholangiocarcinoma, mucus producing carcinoma] Sakamoto H, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):414–6 (17 ref.) **(Jpn)**

[Mucinous cholangiocarcinoma] Sasaki M, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):423–5 (15 ref.) **(Jpn)**

[Mucin producing extrahepatic bile duct carcinoma] Yamanaka T. **Ryoikibetsu Shokogun Shirizu** 1996;(9):92–4 (9 ref.) **(Jpn)**

[Primary mucinous adenocarcinoma of the prostate] Gomiz Léon JJ, et al. **Actas Urol Esp** 1995 Jun;19(6):473–5 (16 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

Is mucinous carcinoma of the colorectum a distinct genetic entity? Hanski C. **Br J Cancer** 1995 Dec;72(6):1350–6 (124 ref.)

PATHOLOGY

Increased incidence of second primary malignancy in patients with carcinoid tumors: case report and literature review. Rivadeneira DE, et al. **J Natl Med Assoc** 1996 May; 88(5):310–2 (12 ref.)

Mucinous adenocarcinoma of the prostate: a report of a case of long-term survival. Olivas TP, et al. **Urology** 1996 Feb; 47(2):256–8 (7 ref.)

SECRETION

[Mucinous pancreatic ductal ectasia: mucus secreting tumor of malignant potential] Michelin T, et al. **Presse Med** 1996 Apr 13;25(13):625–7 (10 ref.) (Eng. Abstr.) **(Fre)**

ADENOCARCINOMA, OXYPHILIC see **ADENOCARCINOMA**

ADENOCARCINOMA, PAPILLARY

[Intrahepatic bile duct adenocarcinoma] Terada T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):402–4 (7 ref.) **(Jpn)**

PATHOLOGY

Familial adenomatous polyposis and lung cancer. Wong RP, et al. **J Surg Oncol** 1995 Nov;60(3):213–4 (11 ref.)

SECRETION

Mucin-producing neoplasms of the pancreas. Intraductal papillary and mucinous cystic neoplasms. Shyr YM, et al. **Ann Surg** 1996 Feb;223(2):141–6 (27 ref.)

ADENOCARCINOMA, RENAL CELL see **CARCINOMA, RENAL CELL**

ADENOCARCINOMA, SEBACEOUS

PATHOLOGY

Sebaceous carcinoma of the vulva. Kawamoto M, et al. **Pathol Int** 1995 Oct;45(10):767–73 (32 ref.)

ADENOCARCINOMA, TUBULAR see **ADENOCARCINOMA**

ADENOHYPOPHYSIS see **PITUITARY GLAND, ANTERIOR**

ADENOIDECTOMY

ADVERSE EFFECTS

Atlanto-axial subluxation and cervical osteomyelitis: two unusual complications of adenoidectomy. Baker LL, et al. **Ann Otol Rhinol Laryngol** 1996 Apr;105(4):295–9 (12 ref.)

Meningitis after adenoidectomy: an anatomic explanation. Isaacson G, et al. **Ann Otol Rhinol Laryngol** 1996 Sep; 105(9):684–8 (18 ref.)

ADENOIDS

see related
ADENOIDECTOMY

PATHOLOGY

Obstructive sleep apnea syndrome in children: an overview. Boudewyns AN, et al. **Acta Otorhinolaryngol Belg** 1995; 49(3):275–9 (15 ref.)

Lymphoid changes of the nasopharyngeal and palatine tonsils that are indicative of human immunodeficiency virus infection. A clinicopathologic study of 12 cases. Wenig BM, et al. **Am J Surg Pathol** 1996 May;20(5):572–87 (76 ref.)

Adenotonsillar disease. Zalzal GH. **J Med Liban** 1994; 42(4):230–4 (18 ref.)

PHYSIOLOGY

The functional role of the adenoids in speech. Finkelstein Y, et al. **Int J Pediatr Otorhinolaryngol** 1996 Jan; 34(1-2):61–74 (73 ref.)

ADENOLYMPHOMA

CLASSIFICATION

Multiple tumours of the salivary glands—terminology and nomenclature. Seifert G, et al. **Eur J Cancer B Oral Oncol** 1996 Jan;32B(1):3–7 (105 ref.)

ETIOLOGY

New insights into the pathogenesis of Warthin's tumour. Gallo O. **Eur J Cancer B Oral Oncol** 1995 Jul;31B(4):211–5 (54 ref.)

PATHOLOGY

[Bilateral Warthin tumors. Case report and review of literature] Sancipriano JA, et al. **Acta Otorrinolaringol Esp** 1996 Mar-Apr;47(2):157–9 (21 ref.) (Eng. Abstr.) **(Spa)**

SURGERY

[Bilateral Warthin tumors. Case report and review of literature] Sancipriano JA, et al. **Acta Otorrinolaringol Esp** 1996 Mar-Apr;47(2):157–9 (21 ref.) (Eng. Abstr.) **(Spa)**

ADENOMA

[Carcinoma in adenoma of the gallbladder] Itoi T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):311–3 (6 ref.) **(Jpn)**

[Adenoma, cyst adenoma of the extrahepatic bile duct] Shiga J. **Ryoikibetsu Shokogun Shirizu** 1996;(9):53–6 (21 ref.) **(Jpn)**

[Liver adenoma and hepatobiliary cystadenoma] Takahama T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):387–91 (7 ref.) **(Jpn)**

BLOOD SUPPLY

Blood supply, blood flow and autoregulation in the adenohypophysis, and altered patterns in oestrogen-induced adenomatous hyperplasia. Jakubowski J. **Br J Neurosurg** 1995;9(3):331–46 (103 ref.)

CHEMICALLY INDUCED

Synthesis of tobacco-specific N-nitrosamines and their metabolites and results of related bioassays. Amin S, et al. **Crit Rev Toxicol** 1996;26(2):139–47 (32 ref.)

CLASSIFICATION

[Gallbladder adenoma (pyloric gland type, intestinal type, proper epithelial type, papillary type, mucinous cystic type] Ono T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):308–10 (16 ref.) **(Jpn)**

COMPLICATIONS

Conn syndrome in a child, caused by adrenal adenoma. Abasiyanik A, et al. **J Pediatr Surg** 1996 Mar;31(3):430–2 (15 ref.)

Aldosteronoma in childhood [letter; comment] Etker S. **J Pediatr Surg** 1995 Jul;30(7):1113 (15 ref.) Comment on: J Pediatr Surg 1994 Oct;29(10):1388–91.

Unusual cases of hyperparathyroidism [see comments] Vázquez-Quintana E, et al. **P R Health Sci J** 1995 Sep; 14(3):227–32 (8 ref.) Comment in: P R Health Sci J 1995 Sep;14(3):191–3.

[Apropos of a case of nephrogenic adenoma in a urethral diverticulum in a woman] Materne R, et al. **Acta Urol Belg** 1995 Dec;63(4):13–8 (59 ref.) (Eng. Abstr.) **(Fre)**

[Adenoma of Brunner's gland: a rare cause of duodenal obstruction] Rey P, et al. **J Chir (Paris)** 1996 Jun; 133(4):162–6 (41 ref.) (Eng. Abstr.) **(Fre)**

[A case of pituitary adenoma progressing to pituitary apoplexy on the occasion of cerebral angiography] Suga T, et al. **No Shinkei Geka** 1996 May;24(5):475–9 (12 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Basal cell (monomorphic) and minimally pleomorphic adenomas of the salivary glands. Distinction from the solid (anaplastic) type of adenoid cystic carcinoma in fine-needle aspiration. Stanley MW, et al. **Am J Clin Pathol** 1996 Jul;

106(1):35–41 (35 ref.)
Diagnosis and management of nonfunctioning pituitary tumors. Greenman Y, et al. **Annu Rev Med** 1996;47:95–106 (51 ref.)
Preoperative endocrine tumor localization utilizing a cost-effective approach. Leight GS Jr, et al. **Curr Opin Gen Surg** 1993;:108–14 (19 ref.)
The characteristics of nine patients with adrenal incidentalomas. Kamel N, et al. **Endocr J** 1995 Aug; 42(4):497–503 (21 ref.)
Differential diagnosis and treatment of steroid-induced affective syndromes. Pies R. **Gen Hosp Psychiatry** 1995 Sep;17(5):353–61 (27 ref.)
Colorectal neoplasms. Screening can save lives. Truszkowski JA, et al. **Postgrad Med** 1995 Nov;98(5):97–9, 103–6, 109–12 (20 ref.)
Renal adenoma and oncocytoma. Licht MR. **Semin Urol Oncol** 1995 Nov;13(4):262–6 (60 ref.)
[Endoscopic diagnosis and treatment of flat colorectal neoplastic lesions] Saurin JC. **Gastroenterol Clin Biol** 1996; 20(5 Pt 2):B152–8 (44 ref.) **(Fre)**

DRUG THERAPY

Adjuvant therapy for pituitary adenomas: the possible role of photodynamic therapy. Marks PV. **Ann R Coll Surg Engl** 1995 Jul;77(4):308–12 (25 ref.)

EPIDEMIOLOGY

Pituitary adenomas in childhood and adolescence. Mindermann T, et al. **J Pediatr Endocrinol Metab** 1995 Apr–Jun;8(2):79–83 (39 ref.)

ETIOLOGY

The causes of ordinary colorectal adenomas: the key to the control of colorectal cancer? [see comments] Kune GA, et al. **J R Soc Med** 1995 Nov;88(11):625–8 (32 ref.) Comment in: J R Soc Med 1996 Apr;89(4):237.

GENETICS

The classification and molecular biology of pituitary adenomas. Thapar K, et al. **Adv Tech Stand Neurosurg** 1995; 22:3–53 (130 ref.)
K-ras mutation in a tubular adenoma originating at an ileostomy in a familial adenomatous polyposis patient. Herring JA, et al. **Am J Gastroenterol** 1996 Mar; 91(3):587–91 (38 ref.)
The cyclin D1/PRAD1 oncogene in human neoplasia. Arnold A. **J Investig Med** 1995 Dec;43(6):543–9 (44 ref.)
Nephrogenic adenoma of the bladder in renal transplant recipients: a report of 9 cases with assessment of deoxyribonucleic acid ploidy and long-term followup. Fournier G, et al. **J Urol** 1996 Jul;156(1):41–4 (21 ref.)
[Familial pituitary tumors] Yoshimoto K, et al. **Nippon Rinsho** 1995 Nov;53(11):2691–6 (21 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Hyalinizing trabecular adenoma of the thyroid—morphology and differential diagnosis. Schmid KW, et al. **Acta Med Austriaca** 1996;23(1–2):65–8 (23 ref.)
Flat adenoma, flat carcinoma, and de novo carcinoma of the colon [editorial; comment] Owen DA. **Cancer** 1996 Jan 1;77(1):3–6 (40 ref.) Comment on: Cancer 1996 Jan 1;77(1):44–50.
Carcinomas of the pituitary: definition and review of the literature. Lübke D, et al. **Gen Diagn Pathol** 1995 Oct; 141(2):81–92 (83 ref.)
Superficial papillary adenomatosis of the nipple: a case report and review of the literature. Montemarano AD, et al. **J Am Acad Dermatol** 1995 Nov;33(5 Pt 2):871–5 (24 ref.)
Mucin-producing adenoma associated with pancreas divisum and hepatic hilar carcinoma: an autopsy case. Origuchi N, et al. **J Gastroenterol** 1996 Jun;31(3):455–9 (40 ref.)
Coexistence of nipple duct adenoma and breast carcinoma: a clinicopathologic study of five cases and review of the literature. Jones MW, et al. **Mod Pathol** 1995 Aug; 8(6):633–6 (13 ref.)
Low-grade papillary adenomatous tumors of the temporal bone: report of two cases and review of the literature. Lavoie M, et al. **Mod Pathol** 1995 Aug;8(6):603–8 (17 ref.)
Nephrogenic adenoma of the urinary tract: a review of the microscopic appearance of 80 cases with emphasis on unusual features. Oliva E, et al. **Mod Pathol** 1995 Sep; 8(7):722–30 (27 ref.)
Parathyroid lipoadenoma: case report and review of the literature. Turner WJ, et al. **Otolaryngol Head Neck Surg** 1996 Feb;114(2):313–6 (19 ref.)
Pituitary lesions in multiple endocrine neoplasia syndrome (MENS) type 1. Capella C, et al. **Pathol Res Pract** 1995 May;191(4):345–7 (27 ref.)
Null cell adenomas and oncocytomas of the pituitary gland. Holm R. **Pathol Res Pract** 1995 May;191(4):348–52 (38 ref.)
Hereditary nonpolyposis colorectal cancer and colonic adenomas: aggressive adenomas? Lynch HT, et al. **Semin Surg Oncol** 1995 Nov–Dec;11(6):406–10 (24 ref.)
Observations of aggressive, small, flat, and depressed colon cancer. Report of three cases. Kasumi A, et al. **Surg Endosc** 1995 Jun;9(6):690–4 (19 ref.)
[Current anatomopathological aspects of differentiated thyroid cancers of follicular (vesicular) origin: value and necessity of a common language] Franc B. **Ann Chir** 1995; 49(10):909–21 (65 ref.) (Eng. Abstr.) **(Fre)**
[Intraductal pancreatic adenomatosis. Apropos of a new case] Brassier D, et al. **Ann Gastroenterol Hepatol (Paris)** 1996 Jan–Feb;32(1):19–23 (21 ref.) (Eng. Abstr.) **(Fre)**
[Hepatocellular nodular hyperplasias, adenomas and carcinomas] Altmann HW. **Verh Dtsch Ges Pathol** 1995; 79:84–108 (144 ref.) (Eng. Abstr.) **(Ger)**
[Adenomatoid hyperplasia of the minor salivary glands. Report of a clinical case] Tucci E, et al. **Minerva Stomatol** 1996 Jan–Feb;45(1–2):49–52 (9 ref.) (Eng. Abstr.) **(Ita)**

PREVENTION & CONTROL

Screening high-risk groups for colorectal neoplasia. Hardcastle JD, et al. **Am J Gastroenterol** 1996 May; 91(5):850–2 (34 ref.)
Lessons from the follow-up of patients with large colorectal adenomas: be or not be, that is the question [editorial; comment] Neugut AI, et al. **Am J Gastroenterol** 1996 Mar; 91(3):420–2 (45 ref.) Comment on: Am J Gastroenterol 1996 Mar;91(3):448–54.

RADIOGRAPHY

Incidentally discovered adrenal tumors. Saxe A. **Curr Opin Gen Surg** 1993;:121–9 (50 ref.)

RADIONUCLIDE IMAGING

Sestamibi parathyroid imaging. McBiles M, et al. **Semin Nucl Med** 1995 Jul;25(3):221–34 (62 ref.)

SECRETION

Thyrotropin-secreting pituitary tumors in hyper- and hypothyroidism. Beck-Peccoz P, et al. **Acta Med Austriaca** 1996;23(1–2):41–6 (45 ref.)

SURGERY

Recovery of vision following transsphenoidal surgery for pituitary adenomas. Powell M. **Br J Neurosurg** 1995; 9(3):367–73 (7 ref.)
Follow-up after polypectomy: consensus? Bond JH. **Eur J Cancer** 1995 Jul–Aug;31A(7–8):1141–4 (28 ref.)
Interference with the adenoma–carcinoma sequence. Bond JH. **Eur J Cancer** 1995 Jul–Aug;31A(7–8):1115–7 (30 ref.)
Primary aldosteronism in pregnancy—should it be treated surgically? Aboud E, et al. **Ir J Med Sci** 1995 Oct–Dec; 164(4):279–80 (12 ref.)
Delayed onset of hyponatremia after transsphenoidal surgery for pituitary adenomas. Taylor SL, et al. **Neurosurgery** 1995 Oct;37(4):649–53; discussion 653–4 (26 ref.)
Gamma Knife treatment of pituitary adenomas. Ganz JC. **Stereotact Funct Neurosurg** 1995;64 Suppl 1:3–10 (38 ref.)
Laparoscopic resection of a large hepatic tumor. Ferzli G, et al. **Surg Endosc** 1995 Jun;9(6):733–5 (9 ref.)

THERAPY

Treatment and follow-up of large bowel adenoma. Rossini FP, et al. **Tumori** 1995 May–Jun;81(3 Suppl):38–44 (61 ref.)
[Treatment of hypothalamic-pituitary tumors—experiences at Hiroshima University School of Medicine] Uozumi T. **Nippon Naibunpi Gakkai Zasshi** 1995 Nov 20;71(7):1019–36 (43 ref.) (Eng. Abstr.) **(Jpn)**

ADENOMA, ACIDOPHIL

see related
ACROMEGALY
GIGANTISM

ADENOMA, ADRENAL CORTICAL

SECRETION

A case of deoxycorticosterone-producing adrenal adenoma. Wada N, et al. **Endocr J** 1995 Oct;42(5):637–42 (29 ref.)

ADENOMA, BASAL CELL see **ADENOMA**

ADENOMA, BASOPHIL

see related
CUSHING'S SYNDROME

ADENOMA, BETA-CELL see **INSULINOMA**

ADENOMA, BILE DUCT

Extrahepatic biliary cystadenomas and cystadenocarcinoma. Report of seven cases and review of the literature. Davies W, et al. **Ann Surg** 1995 Nov;222(5):619–25 (20 ref.)

DIAGNOSIS

[A giant unifocal biliary cystadenoma: a chance finding in a young asymptomatic athlete] Busoni F, et al. **Radiol Med (Torino)** 1996 Apr;91(4):480–2 (12 ref.) **(Ita)**

VETERINARY

Biliary cystadenoma of cats. Adler R, et al. **Vet Pathol** 1995 Jul;32(4):415–8 (23 ref.)

ADENOMA, CHROMOPHOBE

DIAGNOSIS

[Cystic ectopic pituitary adenoma: report of a case] Akimoto J, et al. **No To Shinkei** 1995 Nov;47(11):1092–7 (12 ref.) (Eng. Abstr.) **(Jpn)**

SURGERY

Expanding intracerebral hematoma from pituitary adenoma: case report. Wakai S, et al. **Neurosurgery** 1995 Oct; 37(4):807–8; discussion 808–9 (2 ref.)

ADENOMA, FOLLICULAR see **ADENOMA**

ADENOMA, HEPATOCELLULAR see **ADENOMA, LIVER CELL**

ADENOMA, ISLET CELL

COMPLICATIONS

Pancreatic duct stricture caused by islet cell tumors. Heller SJ, et al. **Am J Gastroenterol** 1996 Jan;91(1):147–9 (15 ref.)

DIAGNOSIS

[Endocrine pancreatic tumors] Goretzki PE, et al. **Ther Umsch** 1996 May;53(5):408–12 (18 ref.) (Eng. Abstr.) **(Ger)**
[A case study of nonfunctioning islet cell tumor in patient with splenic tumor and increased AFP] Zeki S, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 May;93(5):382–7 (20 ref.) **(Jpn)**

SURGERY

[Is preoperative site diagnosis in organic hyperinsulinism from the viewpoint of the surgeon still necessary today? Results of a consecutive series and analysis of the literature] Böttger T, et al. **Chirurg** 1996 Mar;67(3):268–72 (17 ref.) (Eng. Abstr.) **(Ger)**
[Progress in pancreatic endocrine tumor surgery: with special reference to the Zollinger–Ellison syndrome] Imamura M. **Nippon Shokakibyo Gakkai Zasshi** 1995 Dec;92(12):1905–10 (10 ref.) **(Jpn)**

ADENOMA, LIVER CELL

[Hepatic tumors resembling hepatocellular carcinoma] Kojiro M. **Ryoikibetsu Shokogun Shirizu** 1995;(7):374–7 (14 ref.) **(Jpn)**

CHEMICALLY INDUCED

[The regression of a hepatocellular adenoma after the withdrawal of hormonal contraception] Daldrup HE, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1995 Nov;163(5):449–51 (12 ref.) **(Ger)**

RADIOGRAPHY

Hepatocellular adenoma. al-Otaibi L, et al. **AJR Am J Roentgenol** 1995 Dec;165(6):1426 (6 ref.)

ADENOMA, MICROCYSTIC see **ADENOMA**

ADENOMA, MONOMORPHIC see **ADENOMA**

ADENOMA, OXYPHILIC

COMPLICATIONS

Bilateral renal oncocytomatosis in a patient with renal failure. Israeli RS, et al. **Urology** 1995 Dec;46(6):873–5 (15 ref.)

DIAGNOSIS

Renal oncocytomatosis. Katz DS, et al. **Am J Kidney Dis** 1996 Apr;27(4):579–82 (19 ref.)
Renal adenoma and oncocytoma. Licht MR. **Semin Urol Oncol** 1995 Nov;13(4):262–6 (60 ref.)

PATHOLOGY

Pathologic quiz case 2. Oncocytic cyst of the larynx. Kleidermacher P, et al. **Arch Otolaryngol Head Neck Surg** 1995 Dec; 121(12):1430–1, 1433 (5 ref.)
Fine needle aspiration (FNA)-induced necrosis of tumours of the thyroid. Ramp U, et al. **Cytopathology** 1995 Aug; 6(4):248–54 (13 ref.)
Null cell adenomas and oncocytomas of the pituitary gland. Holm R. **Pathol Res Pract** 1995 May;191(4):348–52 (38 ref.)
[Oncocytoma of the nose. A case report and review of the literature] Förster C, et al. **Pathologe** 1995 Nov;16(6):431–3 (12 ref.) (Eng. Abstr.) **(Ger)**
[Synchronous bilateral renal oncocytoma] Sánchez-Chapado M, et al. **Arch Esp Urol** 1995 Nov;48(9):909–13 (35 ref.) (Eng. Abstr.) **(Spa)**

SURGERY

Management considerations in Hürthle cell carcinoma.

Azadian A, et al. **Surgery** 1995 Oct;118(4):711–4; discussion 714–5 (23 ref.)

ADENOMA, PAPILLARY see **ADENOMA**

ADENOMA, PLEOMORPHIC

Chondroid syringoma of the abdominal wall. A case report and review of the literature. Sliwa-Hähnle K, et al. **S Afr J Surg** 1996 Feb;34(1):46–8 (15 ref.)

CLASSIFICATION

Multiple tumours of the salivary glands—terminology and nomenclature. Seifert G, et al. **Eur J Cancer B Oral Oncol** 1996 Jan;32B(1):3–7 (105 ref.)

DIAGNOSIS

Basal cell (monomorphic) and minimally pleomorphic adenomas of the salivary glands. Distinction from the solid (anaplastic) type of adenoid cystic carcinoma in fine-needle aspiration. Stanley MW, et al. **Am J Clin Pathol** 1996 Jul; 106(1):35–41 (35 ref.)

PATHOLOGY

Pleomorphic adenoma of the external auditory canal: a case report and review of the literature. Haraguchi H, et al. **J Laryngol Otol** 1996 Jan;110(1):52–6 (24 ref.)

Pleomorphic adenoma of the breast: case report and review of the literature. Narita T, et al. **Pathol Int** 1995 Jun; 45(6):441–7 (40 ref.)

SURGERY

[Iatrogenic lesions of the facial nerve during parotid surgery for pleomorphic adenoma] Colella G, et al. **Minerva Stomatol** 1995 Dec;44(12):591–6 (40 ref.) (Eng. Abstr.) **(Ita)**

ADENOMA, PROLACTIN-SECRETING, PITUITARY see **PROLACTINOMA**

ADENOMA, PROSTATIC see **PROSTATIC HYPERPLASIA**

ADENOMA, SWEAT GLAND

PATHOLOGY

Carcinosarcoma arising in eccrine spiradenoma of the breast. Report of a case and review of the literature. Saboorian MH, et al. **Arch Pathol Lab Med** 1996 May;120(5):501–4 (19 ref.)

ADENOMA, TRABECULAR see **ADENOMA**

ADENOMA, VILLOUS

SURGERY

Vater's papilla and periampullary area villous adenoma: personal experience about nine cases and review of the literature. Motton G, et al. **Hepatogastroenterology** 1996 Mar-Apr;43(8):448–55 (77 ref.)

ADENOMATOSIS, FAMILIAL ENDOCRINE see **MULTIPLE ENDOCRINE NEOPLASIA**

ADENOMATOUS POLYPOSIS COLI

see related
GENES, APC

[Hamartomatous polyposis syndrome] Tamura K, et al. **Nippon Rinsho** 1995 Nov;53(11):2728–33 (24 ref.) (Eng. Abstr.) **(Jpn)**

[Mouse model for familial adenomatous polyposis coli] Ito M, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec; 40(17):2668–73 (22 ref.) **(Jpn)**

COMPLICATIONS

Chemotherapy for desmoid tumours in association with familial adenomatous polyposis: a report of three cases. Hamilton L, et al. **Can J Surg** 1996 Jun;39(3):247–52 (21 ref.)

DIAGNOSIS

Use of molecular methods in the early diagnosis of familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer. Khine K, et al. **Ann Acad Med Singapore** 1996 Jan;25(1):64–70 (88 ref.)

EPIDEMIOLOGY

Triple primary malignant neoplasms including a malignant brain tumor: report of two cases and review of the literature. Nagane M, et al. **Surg Neurol** 1996 Mar; 45(3):219–29 (44 ref.)

GENETICS

The genetic background of familial adenomatous polyposis. Linkage analysis, the APC gene identification and mutation screening. Kartheuser A, et al. **Acta Gastroenterol Belg** 1995 Sep-Dec;58(5–6):433–51 (112 ref.)

The technical background of familial adenomatous polyposis. History, epidemiology, diagnosis and treatment. Kartheuser A, et al. **Acta Gastroenterol Belg** 1995 Mar-Apr; 58(2):252–66 (136 ref.)

K-ras mutation in a tubular adenoma originating at an ileostomy in a familial adenomatous polyposis patient. Herring JA, et al. **Am J Gastroenterol** 1996 Mar; 91(3):587–91 (38 ref.)

Emergent issues in the genetics of intestinal neoplasia. Dove WF, et al. **Cancer Surv** 1995;25:335–55 (98 ref.)

The adenomatous polyposis coli gene of the mouse in development and neoplasia. Dove WF, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:501–8 (43 ref.)

ApcMin: a mouse model for intestinal and mammary tumorigenesis. Moser AR, et al. **Eur J Cancer** 1995 Jul-Aug;31A(7–8):1061–4 (30 ref.)

The adenomatous polyposis coli gene and human cancers. Nakamura Y. **J Cancer Res Clin Oncol** 1995; 121(9–10):529–34 (63 ref.)

The Canadian Familial Adenomatous Polyposis Registry: past, present and future. Stern HS. **J R Soc Med** 1996 Mar; 89(3):153P–4P (10 ref.)

Familial adenomatous polyposis: an update. Wyman A, et al. **J R Soc Med** 1996 Apr;89(4):224P–8P (26 ref.)

Impact of molecular genetics on the management of familial adenomatous polyposis. Jass JR, et al. **N Z Med J** 1996 Aug 9;109(1027):285–6 (32 ref.)

Multistep carcinogenesis in colorectal cancers. Takami K, et al. **Southeast Asian J Trop Med Public Health** 1995;26 Suppl 1:190–6 (28 ref.)

[Genetics of colorectal cancers (editorial)] Pocard M, et al. **Ann Chir** 1996;50(3):211–6 (19 ref.) **(Fre)**

[Familial adenomatous polyposis] Constanda MT, et al. **Schweiz Rundsch Med Prax** 1996 Aug 27;85(35):1052–7 (61 ref.) (Eng. Abstr.) **(Fre)**

[Familial polyposis coli] Watanabe T, et al. **Nippon Rinsho** 1995 Nov;53(11):2722–7 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Mouse model for familial adenomatous polyposis coli and APC gene] Ito M, et al. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2035–44 (22 ref.) **(Jpn)**

PATHOLOGY

Familial adenomatous polyposis and lung cancer. Wong RP, et al. **J Surg Oncol** 1995 Nov;60(3):213–4 (11 ref.)

SURGERY

Colorectal cancer: surgical prophylaxis and chemoprevention [see comments] Nugent KP. **Ann R Coll Surg Engl** 1995 Sep;77(5):372–6 (55 ref.) Comment in: Ann R Coll Surg Engl 1996 Mar;78(2):154–5.

Choice of prophylactic surgery for the large bowel component of familial adenomatous polyposis. Setti-Carraro P, et al. **Br J Surg** 1996 Jul;83(7):885–92 (88 ref.)

Recurrent polyps in the ileo-anal pouch or rectum in familial adenomatous polyposis. Tytgat GN, et al. **Eur J Cancer** 1995 Jul-Aug;31A(7–8):1154–9 (45 ref.)

Surgical options for familial adenomatous polyposis. Ambroze WL Jr, et al. **Semin Surg Oncol** 1995 Nov-Dec; 11(6):423–7 (27 ref.)

THERAPY

Impact of molecular genetics on the management of familial adenomatous polyposis. Jass JR, et al. **N Z Med J** 1996 Aug 9;109(1027):285–6 (32 ref.)

ADENOMATOUS POLYPS

DIAGNOSIS

Endoscopic evaluation of colon polyps. VanDerWerken BS, et al. **Semin Roentgenol** 1996 Apr;31(2):118–24 (43 ref.)

ETIOLOGY

Malignant tumor developed in colon-esophagus. Altorjay A, et al. **Hepatogastroenterology** 1995 Nov-Dec;42(6):797–9 (19 ref.)

GENETICS

Colorectal adenoma progression and genetic change: is there a link? Jass JR. **Ann Med** 1995 Jun;27(3):301–6 (40 ref.)

[Hereditary solitary adenoma] Yoshikawa R, et al. **Nippon Rinsho** 1995 Nov;53(11):2734–6 (12 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Gastrointestinal adenomatous polyps. Itzkowitz SH. **Semin Gastrointest Dis** 1996 Apr;7(2):105–16 (85 ref.)

ADENOMYOMA

[Adenomyoma of the extrahepatic bile duct] Hoso M, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):50–2 (19 ref.) **(Jpn)**

[Adenomyomatosis of the gallbladder] Yamaguchi T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):305–7 (18 ref.) **(Jpn)**

PATHOLOGY

Atypical polypoid adenomyomas of the uterus. Fukunaga M, et al. **Histopathology** 1995 Jul;27(1):35–42 (18 ref.)

ULTRASONOGRAPHY

[A case of early carcinoma of the gall-bladder arising in adenomyomatosis detected by endoscopic ultrasonography] Sakurai T, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Sep;92(9):1304–8 (18 ref.) **(Jpn)**

ADENOMYOSIS see **ENDOMETRIOSIS**

ADENOSARCOMA

PATHOLOGY

Two unusual presentations of müllerian adenosarcoma: case reports, literature review, and treatment considerations. Gollard R, et al. **Gynecol Oncol** 1995 Dec;59(3):412–22 (26 ref.)

Müllerian adenosarcoma of the cervix: differential diagnosis, histogenesis and review of the literature. García-Rostán y P erez GM, et al. **Pathol Int** 1995 Nov;45(11):890–4 (30 ref.)

SURGERY

[Heterologous adenosarcoma of the Müllerian ducts in adolescence. Presentation of clinical case and review of the literature] Juárez Azpilcueta A, et al. **Ginecol Obstet Mex** 1995 Sep;63:398–400 (15 ref.) (Eng. Abstr.) **(Spa)**

ADENOSINE

ANALOGS & DERIVATIVES

Rationale and hurdles of inhibitors of hepatic gluconeogenesis in treatment of diabetes mellitus. Kashiwagi A. **Diabetes Res Clin Pract** 1995 Aug;28 Suppl:S195–200 (30 ref.)

[Phosphodiesterase inhibitor: griseolic acid, its' derivatives and their biological activities] Kaneko M, et al. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1268–76 (23 ref.) **(Jpn)**

[Design of S-adenosylhomocystein hydrolase (SHAase) inhibitors as potent anti-RNA viral agents] Shuto S. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1261–7 (27 ref.) **(Jpn)**

METABOLISM

Activation of ecto-5'-nucleotidase and cardioprotection by ischemic preconditioning. Kitakaze M, et al. **Basic Res Cardiol** 1996 Jan-Feb;91(1):23–6 (8 ref.)

Adenosine and bradykinin: are they independent triggers of preconditioning? Miura T. **Basic Res Cardiol** 1996 Jan-Feb; 91(1):20–2 (14 ref.)

The role of intracellular pH in the control of adenosine output from red skeletal muscle. Ballard HJ. **Biol Signals** 1995 May-Jun;4(3):168–73 (21 ref.)

PHARMACOLOGY

Adenosine: a prototherapeutic concept in neurodegeneration. von Lubitz DK, et al. **Ann N Y Acad Sci** 1995 Sep 15; 765:163–78; discussion 196–7 (123 ref.)

Glyceryl trinitrate enhances the adenosine-induced inhibition of platelet responses: a mechanism potentially involved in the in vivo anti-aggregating effects of organic nitrates. Anfossi G, et al. **Clin Exp Pharmacol Physiol** 1995 Nov; 22(11):803–11 (57 ref.)

Adenosine, antioxidant enzymes and cytoprotection. Ramkumar V, et al. **Trends Pharmacol Sci** 1995 Sep; 16(9):283–5 (31 ref.)

PHYSIOLOGY

Adenosine: a prototherapeutic concept in neurodegeneration. von Lubitz DK, et al. **Ann N Y Acad Sci** 1995 Sep 15; 765:163–78; discussion 196–7 (123 ref.)

Harnessing an endogenous cardioprotective mechanism: cellular sources and sites of action of adenosine. Mullane K, et al. **J Mol Cell Cardiol** 1995 Apr;27(4):1041–54 (145 ref.)

Modulation of protein kinase C by adenosine: involvement of adenosine A1 receptor-pertussis toxin sensitive nucleotide binding protein system. Marala RB, et al. **Mol Cell Biochem** 1995 Aug-Sep;149–150:51–8 (56 ref.)

Purinergic inhibition of neurotransmitter release in the central nervous system. Ribeiro JA. **Pharmacol Toxicol** 1995 Nov; 77(5):299–305 (68 ref.)

THERAPEUTIC USE

[Adenosine in the treatment of supraventricular arrhythmias] Lommi J, et al. **Duodecim** 1994;110(5):473–7 (27 ref.) **(Fin)**

[Effects of adenosine on the heart—therapeutic and diagnostic possibilities] Stark U, et al. **Wien Klin Wochenschr** 1996;108(12):343–51 (61 ref.) (Eng. Abstr.) **(Ger)**

ADENOSINE AMINOHYDROLASE see **ADENOSINE**

ADENOSINE AMINOHYDROLASE

DEAMINASE

ADENOSINE CYCLIC MONOPHOSPHATE-DEPENDENT PROTEIN KINASES see **CYCLIC AMP-DEPENDENT PROTEIN KINASES**

ADENOSINE CYCLIC 3',5'-MONOPHOSPHATE see **CYCLIC AMP**

ADENOSINE DEAMINASE

BLOOD

[Adenosine deaminase] Sakura N. **Nippon Rinsho** 1995 Feb; 53 Su Pt 1:299–302 (20 ref.) **(Jpn)**

DEFICIENCY

Adenosine deaminase deficiency: molecular basis and recent developments. Hirschhorn R. **Clin Immunol Immunopathol** 1995 Sep;76(3 Pt 2):S219–27 (66 ref.)

Steps toward gene therapy: 1. The initial trials. Blaese RM. **Hosp Pract (Off Ed)** 1995 Nov 15;30(11):33–40 (7 ref.)

[Gene therapy for adenosine deaminase deficiency] Sakiyama Y. **Hokkaido Igaku Zasshi** 1996 Jan;71(1):27–32 (9 ref.) (Eng. Abstr.) **(Jpn)**

[Gene therapy for ADA deficiency] Ariga T, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2772–80 (13 ref.) **(Jpn)**

GENETICS

Adenosine deaminase deficiency: molecular basis and recent developments. Hirschhorn R. **Clin Immunol Immunopathol** 1995 Sep;76(3 Pt 2):S219–27 (66 ref.)

PHYSIOLOGY

RNA editing. An I for editing. Bass BL. **Curr Biol** 1995 Jun 1;5(6):598–600 (15 ref.)

ADENOSINE DEAMINASE-BINDING PROTEINS see **ANTIGENS, CD26**

ADENOSINE DIPHOSPHATASE see **APYRASE**

ADENOSINE DIPHOSPHATE

ANALOGS & DERIVATIVES

[Calorimetric study of stable complexes of myosin subfragment I with adenosine diphosphate and phosphate analogs] Levitskiĭ DI, et al. **Biofizika** 1996 Jan–Feb; 41(1):64–72 (29 ref.) (Eng. Abstr.) **(Rus)**

BLOOD

[Nucleotides] Fujii H. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:243–6 (5 ref.) **(Jpn)**

ADENOSINE DIPHOSPHATE RIBOSE

ANALOGS & DERIVATIVES

NAD glycohydrolases and the metabolism of cyclic ADP-ribose. Jacobson MK, et al. **Biochimie** 1995; 77(5):341–4 (15 ref.)

Cyclic ADP-ribose and its metabolic enzymes. Lee HC, et al. **Biochimie** 1995;77(5):345–55 (42 ref.)

New aspects of the physiological significance of NAD, poly ADP-ribose and cyclic ADP-ribose. Okamoto H, et al. **Biochimie** 1995;77(5):356–63 (41 ref.)

Inositol trisphosphate and cyclic ADP ribose as long range messengers generating local subcellular calcium signals. Petersen OH. **J Physiol Paris** 1995;89(3):125–7 (16 ref.)

Modulator and messenger functions of cyclic ADP-ribose in calcium signaling. Lee HC. **Recent Prog Horm Res** 1996; 51:355–88; discussion 389 (86 ref.)

Cyclic ADP-ribose, the ryanodine receptor and Ca2+ release. Sitsapesan R, et al. **Trends Pharmacol Sci** 1995 Nov; 16(11):386–91 (50 ref.)

METABOLISM

Studies on the active-site structure of C3-like exoenzymes: involvement of glutamic acid in catalysis of ADP-ribosylation. Aktories K, et al. **Biochimie** 1995; 77(5):326–32 (62 ref.)

A proposed mechanism of ADP-ribosylation catalyzed by the pertussis toxin S1 subunit. Locht C, et al. **Biochimie** 1995;77(5):333–40 (56 ref.)

Characterization of mammalian ADP-ribosylation cycles. Okazaki IJ, et al. **Biochimie** 1995;77(5):319–25 (43 ref.)

ADP-ribosylation reactions. Shall S. **Biochimie** 1995; 77(5):313–8 (21 ref.)

ADENOSINE DIPHOSPHORIBOSE see **ADENOSINE DIPHOSPHATE RIBOSE**

ADENOSINE MONOPHOSPHATE

BLOOD

[Nucleotides] Fujii H. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:243–6 (5 ref.) **(Jpn)**

ADENOSINE PHOSPHATES see **ADENINE NUCLEOTIDES**

ADENOSINE PYROPHOSPHATE see **ADENOSINE DIPHOSPHATE**

ADENOSINE RECEPTORS see **RECEPTORS, PURINERGIC P1**

ADENOSINE TRIPHOSPHATE

Clinical relevance of ATP-dependent potassium channels. Ligtenberg JJ, et al. **Neth J Med** 1995 Nov;47(5):241–51 (82 ref.)

BLOOD

[Nucleotides] Fujii H. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:243–6 (5 ref.) **(Jpn)**

METABOLISM

A new splicing variant in the frog heart sarcolemmal Na–Ca exchanger creates a putative ATP-binding site. Iwata T, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:37–45 (34 ref.)

Regulation of ATP-sensitive potassium channels by phosphorylation. Light P. **Biochim Biophys Acta** 1996 May 6;1286(1):65–73 (139 ref.)

ATP hydrolysis by membrane-bound Escherichia coli F0F1 causes rotation of the gamma subunit relative to the beta subunits. Zhou Y, et al. **Biochim Biophys Acta** 1996 Jul 18;1275(1–2):96–100 (23 ref.)

Activation of ATP-sensitive potassium channels: a novel pharmacological approach to myocardial protection? Hearse DJ. **Cardiovasc Res** 1995 Jul;30(1):1–17 (94 ref.)

Control of apoptosis by the cellular ATP level. Richter C, et al. **FEBS Lett** 1996 Jan 8;378(2):107–10 (62 ref.)

The catalytic cycle of P-glycoprotein. Senior AE, et al. **FEBS Lett** 1995 Dec 27;377(3):285–9 (42 ref.)

Role of translocases in the generation of phosphatidylserine asymmetry. Diaz C, et al. **J Membr Biol** 1996 May; 151(1):1–9 (99 ref.)

An ATP-regulated, inwardly rectifying potassium channel from rat kidney (ROMK). Hebert SC. **Kidney Int** 1995 Oct; 48(4):1010–6 (66 ref.)

Cross-talk and the role of KATP channels in the proximal tubule. Welling PA. **Kidney Int** 1995 Oct;48(4):1017–23 (79 ref.)

Necessary but not sufficient: the role of glucocorticoids in the acidosis-induced increase in levels of mRNAs encoding proteins of the ATP-dependent proteolytic pathway in rat muscle. Price SR, et al. **Miner Electrolyte Metab** 1996; 22(1–3):72–5 (14 ref.)

PHARMACOLOGY

Regulation of sodium–calcium exchange in intact myocytes by ATP and calcium. Haworth RA, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:464–79 (42 ref.)

Regulation of postsynaptic responses by calcitonin gene related peptide and ATP at developing neuromuscular junctions. Lu B, et al. **Can J Physiol Pharmacol** 1995 Jul; 73(7):1050–6 (42 ref.)

The beta-cell response to oral hypoglycemic agents. Cook DL. **Diabetes Res Clin Pract** 1995 Aug;28 Suppl:S81–9 (72 ref.)

The molecular interaction of sulfonylureas with beta-cell ATP-sensitive K(+)-channels. Kramer W, et al. **Diabetes Res Clin Pract** 1995 Aug;28 Suppl:S67–80 (25 ref.)

PHYSIOLOGY

Extracellular ATP as a neurotransmitter: its role in synaptic plasticity in the hippocampus. Wieraszko A. **Acta Neurobiol Exp (Warsz)** 1996;56(2):637–48 (85 ref.)

Modulation of muscle contractility during fatigue and recovery by ATP sensitive potassium channel. Renaud JM, et al. **Acta Physiol Scand** 1996 Mar;156(3):203–12 (50 ref.)

Cardiac ATP-sensitive K+ channels: regulation by intracellular nucleotides and K+ channel-opening drugs. Terzic A, et al. **Am J Physiol** 1995 Sep;269(3 Pt 1):C525–45 (196 ref.)

Do ATP-sensitive potassium channels play a role in myocardial stunning? Gross GJ. **Basic Res Cardiol** 1995 Jul–Aug;90(4):266–8 (10 ref.)

Potassium channels in the cardiovascular system. Pogátsa G. **Diabetes Res Clin Pract** 1995 Aug;28 Suppl:S91–8 (48 ref.)

Role of extracellular ATP and P1 and P2 classes of purinergic receptors in T-cell development and cytotoxic T lymphocyte effector functions. Apasov S, et al. **Immunol Rev** 1995 Aug;146:5–19 (40 ref.)

The role of ATP sensitive potassium channels in myocardial protection. Cason BA, et al. **J Card Surg** 1995 Jul;10(4 Suppl):441–4 (32 ref.)

Noradrenaline and ATP: cotransmitters and neuromodulators. Burnstock G. **J Physiol Pharmacol** 1995 Dec;46(4):365–84 (195 ref.)

Regulatory role of ATP at developing neuromuscular junctions. Fu WM. **Prog Neurobiol** 1995 Sep;47(1):31–44 (101 ref.)

Geometry, kinetics and plasticity of release and clearance of ATP and noradrenaline as sympathetic cotransmitters: roles for the neurogenic contraction. Stjärne L, et al. **Prog Neurobiol** 1995 Sep;47(1):45–94 (145 ref.)

ADENOSINETRIPHOSPHATASE

CHEMISTRY

Organization of P-type ATPases: significance of structural diversity. Lutsenko S, et al. **Biochemistry** 1995 Dec 5; 34(48):15607–13 (54 ref.)

METABOLISM

The ATPase module and the process of cellular immortalization. Krøll J. **Ann N Y Acad Sci** 1996 Jun 15;786:57–61 (36 ref.)

SecA, a novel ATPase that converts chemical energy into a mechanical force to drive precursor protein translocation. Driessen AJ, et al. **Biochem Soc Trans** 1995 Nov; 23(4):981–5 (32 ref.)

Structural organization, ion transport, and energy transduction of P-type ATPases. Møller JV, et al. **Biochim Biophys Acta** 1996 May 6;1286(1):1–51 (527 ref.)

The catalytic cycle of P-glycoprotein. Senior AE, et al. **FEBS Lett** 1995 Dec 27;377(3):285–9 (42 ref.)

[Oligomeric assemblies of transport adenosine triphosphatases in a membrane bilayer] Boldyrev AA. **Zh Evol Biokhim Fiziol** 1995 Jul–Aug;31(4):375–86 (45 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Sec-dependent preprotein translocation in bacteria. den Blaauwen T, et al. **Arch Microbiol** 1996 Jan;165(1):1–8 (73 ref.)

Factors limiting adenosine triphosphatase function during high intensity exercise. Thermodynamic and regulatory considerations. Korge P. **Sports Med** 1995 Oct;20(4):215–25 (31 ref.)

ADENOSINETRIPHOSPHATASE, ACTOMYOSIN see **MYOSIN ATPASE**

ADENOSINETRIPHOSPHATASE, CALCIUM see **CA(2+)-TRANSPORTING ATPASE**

ADENOSINETRIPHOSPHATASE, DYNEIN see **DYNEIN ATPASE**

ADENOSINETRIPHOSPHATASE F1 see **H(+)-TRANSPORTING ATP SYNTHASE**

ADENOSINETRIPHOSPHATASE, HYDROGEN, POTASSIUM see **H(+)-K(+)-EXCHANGING ATPASE**

ADENOSINETRIPHOSPHATASE, MYOSIN see **MYOSIN ATPASE**

ADENOSINETRIPHOSPHATASE, SODIUM, POTASSIUM see **NA(+)-K(+)-EXCHANGING ATPASE**

ADENOSIS OF BREAST see **FIBROCYSTIC DISEASE OF BREAST**

S-ADENOSYLMETHIONINE

ANALYSIS

Thiopeptides. Strohl WR, et al. **Biotechnology** 1995;28:223–38 (50 ref.)

METABOLISM

S-Adenosylmethionine and methylation. Chiang PK, et al. **FASEB J** 1996 Mar;10(4):471–80 (99 ref.)

ADENOVIRIDAE

Adenovirus fiber. Chroboczek J, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 1):163–200 (125 ref.)

Non-replicating expression vectors: applications in vaccine development and gene therapy. Limbach KJ, et al. **Epidemiol Infect** 1996 Jun;116(3):241–56 (87 ref.)

ENZYMOLOGY

Transcription of adenovirus RNA polymerase III genes. Pruzan R, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 1):201–26 (116 ref.)

Adenovirus endopeptidase and its role in virus infection. Weber JM. **Curr Top Microbiol Immunol** 1995;199 (Pt 1):227–35 (36 ref.)

GENETICS

Adenovirus and adeno-associated virus as vectors for gene therapy. Berns KI, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:95–104 (48 ref.)

Prospects for gene therapy with direct injection of

polynucleotides. Kass-Eisler A, et al.
Ann N Y Acad Sci 1995 Nov 27;772:232–40 (33 ref.)
Recombinant adenoviruses as vaccines.
Randrianarison-Jewtoukoff V, et al. **Biologicals** 1995 Jun; 23(2):145–57 (82 ref.)
The use of adenoviral vectors for gene therapy and gene transfer in vivo. Bramson JL, et al.
Curr Opin Biotechnol 1995 Oct;6(5):590–5 (49 ref.)
Adenovirus-augmented, receptor-mediated gene delivery and some solutions to the common toxicity problems. Cotten M. **Curr Top Microbiol Immunol** 1995;199 (Pt 3):283–95 (70 ref.)
The mechanism of adenovirus DNA integration: studies in a cell-free system. Fechteler K, et al.
Curr Top Microbiol Immunol 1995;199 (Pt 2):109–37 (122 ref.)
Gene therapy using adenovirus vectors. Haddada H, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 3):297–306 (35 ref.)
Molecular interactions during adenovirus DNA replication. Hay RT, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 2):31–48 (114 ref.)
Post-transcriptional control of adenovirus gene expression. Imperiale MJ, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 2):139–71 (143 ref.)
Structure, function, and evolution of adenovirus virus-associated RNAs. Mathews MB.
Curr Top Microbiol Immunol 1995;199 (Pt 2):173–87 (35 ref.)
Expression, nuclear transport, and phosphorylation of adenovirus DNA replication proteins. Ramachandra M, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 2):50–88 (262 ref.)
Cap-independent translation in adenovirus infected cells. Schneider RJ. **Curr Top Microbiol Immunol** 1995; 203:117–29 (61 ref.)
Adenovirus DNA replication. Van der Vliet PC.
Curr Top Microbiol Immunol 1995;199 (Pt 2):1–30 (147 ref.)
Homologous recombination in the replicative cycle of adenovirus and its relationship to DNA replication. Young CS. **Curr Top Microbiol Immunol** 1995;199 (Pt 2):89–108 (75 ref.)
Strategies for cancer gene therapy using adenoviral vectors. Descamps V, et al. **J Mol Med** 1996 Apr;74(4):183–9 (80 ref.)
Gene transfer using replication-defective retroviral and adenoviral vectors. Leber SM, et al. **Methods Cell Biol** 1996;51:161–83 (42 ref.)
Second-generation adenovirus vectors. Wang Q, et al.
Nat Med 1996 Jun;2(6):714–6 (36 ref.)
Adenovirus vectors as recombinant viral vaccines. Imler JL.
Vaccine 1995 Sep;13(13):1143–51 (72 ref.)
[Expression of HCV genes using adenovirus vector with CAG promoter] Makimura M, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:91–4 (9 ref.) **(Jpn)**
[Gene expression using adenovirus vector] Kanegae Y, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2525–31 (11 ref.) **(Jpn)**

PATHOGENICITY

Model systems for studying the effects of adenovirus E3 genes on virulence in vivo. Horwitz MS, et al.
Curr Top Microbiol Immunol 1995;199 (Pt 3):195–211 (63 ref.)
Adenovirus and Epstein-Barr virus in lung disease. Hogg JC, et al. **Semin Respir Infect** 1995 Dec;10(4):244–53 (34 ref.)

PHYSIOLOGY

Nuclear organization of replication and gene expression in adenovirus-infected cells. Bridge E, et al.
Curr Top Microbiol Immunol 1995;199 (Pt 1):99–117 (86 ref.)
Virus assembly. D'Halluin JC.
Curr Top Microbiol Immunol 1995;199 (Pt 1):47–66 (145 ref.)
Adenovirus—an eternal archetype. Philipson L.
Curr Top Microbiol Immunol 1995;199 (Pt 1):1–24 (138 ref.)
Selective encapsidation of adenovirus DNA. Schmid SI, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 1):67–80 (45 ref.)

ULTRASTRUCTURE

Adenovirus structure by X-ray crystallography and electron microscopy. Stewart PL, et al.
Curr Top Microbiol Immunol 1995;199 (Pt 1):25–38 (51 ref.)

ADENOVIRIDAE INFECTIONS

Fulminant adenovirus hepatitis after allogeneic bone marrow transplantation. Bertheau P, et al.
Bone Marrow Transplant 1996 Feb;17(2):295–8 (14 ref.)

ENZYMOLOGY

Adenovirus endopeptidase and its role in virus infection. Weber JM. **Curr Top Microbiol Immunol** 1995;199 (Pt 1):227–35 (36 ref.)

VIROLOGY

Nuclear organization of replication and gene expression in adenovirus-infected cells. Bridge E, et al.
Curr Top Microbiol Immunol 1995;199 (Pt 1):99–117 (86 ref.)
Enteric adenoviruses. Mautner V, et al.
Curr Top Microbiol Immunol 1995;199 (Pt 3):229–82 (189 ref.)
Role of adenovirus structural components in the regulation of adenovirus infection. Russell WC, et al.
Curr Top Microbiol Immunol 1995;199 (Pt 1):81–98 (78 ref.)

ADENOVIRUS E1 PROTEINS

GENETICS

Second-generation adenovirus vectors. Wang Q, et al.
Nat Med 1996 Jun;2(6):714–6 (36 ref.)

ADENOVIRUS E1A PROTEIN DOMAIN 3 see **ADENOVIRUS E1A PROTEINS**

ADENOVIRUS E1A PROTEINS

GENETICS

Transcriptional modulation by the adenovirus E1A gene. Jones N. **Curr Top Microbiol Immunol** 1995;199 (Pt 3):59–80 (118 ref.)
Functional domains of adenovirus E1A oncogenes which control interactions with effectors of cellular immunity. Raška K Jr. **Curr Top Microbiol Immunol** 1995;199 (Pt 3):131–48 (85 ref.)
Transcriptional regulation of the adenovirus E1A gene. Yoshida K, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 3):113–30 (107 ref.)
Reversal of malignancy by the adenovirus E1a gene. Frisch SM. **Mutat Res** 1996 Feb 19;350(1):261–6 (31 ref.)

PHYSIOLOGY

Regulation of viral and cellular gene expression by E1A proteins encoded by the oncogenic adenovirus type 12. Brockmann D, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 3):81–112 (221 ref.)
Adenovirus E1A: transcription regulation and alteration of cell growth control. Nevins JR.
Curr Top Microbiol Immunol 1995;199 (Pt 3):25–32 (39 ref.)
Regulation of p53-dependent apoptosis by E1A and E1B. White E. **Curr Top Microbiol Immunol** 1995;199 (Pt 3):34–58 (103 ref.)
Assessing the role of E1A in the differential oncogenicity of group A and group C human adenoviruses. Williams J, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 3):149–75 (134 ref.)

ADENOVIRUS E1B 19K PROTEIN see **ADENOVIRUS E1B PROTEINS**

ADENOVIRUS E1B PROTEINS

PHYSIOLOGY

Functional similarity between adenovirus E1B 19-kDa protein and proteins encoded by Bcl-2 proto-oncogene and Epstein-Barr virus BHRF1 gene. Subramanian T, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 1):153–61 (52 ref.)
Regulation of p53-dependent apoptosis by E1A and E1B. White E. **Curr Top Microbiol Immunol** 1995;199 (Pt 3):34–58 (103 ref.)

ADENOVIRUS E2 PROTEINS

GENETICS

Regulation of adenovirus E2 transcription unit. Swaminathan S, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 3):177–94 (46 ref.)
Second-generation adenovirus vectors. Wang Q, et al.
Nat Med 1996 Jun;2(6):714–6 (36 ref.)

ADENOVIRUS E2A DNA-BINDING PROTEINS see **ADENOVIRUS E2 PROTEINS**

ADENOVIRUS E2A 72K PROTEIN see **ADENOVIRUS E2 PROTEINS**

ADENOVIRUS E2A PROTEINS see **ADENOVIRUS E2 PROTEINS**

ADENOVIRUS E2F PROTEINS see **ADENOVIRUS E2 PROTEINS**

ADENOVIRUS E3 19K PROTEIN see **ADENOVIRUS E3 PROTEINS**

ADENOVIRUS E3 PROTEINS

BIOSYNTHESIS

Tumor necrosis factor alpha increases expression of adenovirus E3 proteins. Deryckere F, et al.
Immunobiology 1995 Jul;193(2–4):186–92 (16 ref.)

DRUG EFFECTS

Tumor necrosis factor alpha increases expression of adenovirus E3 proteins. Deryckere F, et al.
Immunobiology 1995 Jul;193(2–4):186–92 (16 ref.)

GENETICS

Model systems for studying the effects of adenovirus E3 genes on virulence in vivo. Horwitz MS, et al.
Curr Top Microbiol Immunol 1995;199 (Pt 3):195–211 (63 ref.)
E3 transcription unit of adenovirus. Wold WS, et al.
Curr Top Microbiol Immunol 1995;199 (Pt 1):237–74 (196 ref.)

ADENOVIRUS 2, HUMAN see **ADENOVIRUSES, HUMAN**

ADENOVIRUS INFECTIONS see **ADENOVIRIDAE INFECTIONS**

ADENOVIRUS INFECTIONS, HUMAN

[Adenovirus hepatitis] Nishiyama Y, et al.
Ryoikibetsu Shokogun Shirizu 1995;(7):27–9 (3 ref.) **(Jpn)**

COMPLICATIONS

Adenoviral infections in children. Singh-Naz N, et al.
Adv Pediatr Infect Dis 1996;11:365–88 (106 ref.)

EPIDEMIOLOGY

[Adenoviruses from stool samples in hospital units. Comparison with main pathogens in gastroenteritis (rotavirus, Campylobacter, Salmonella)] Durepaire N, et al. **Pathol Biol (Paris)** 1995 Sep;43(7):601–10 (22 ref.) (Eng. Abstr.) **(Fre)**

VIROLOGY

[Adenoviruses as causative agents in gastroenteritis] de Jong JC. **Ned Tijdschr Geneeskd** 1996 Mar 9;140(10):536–41 (48 ref.) **(Dut)**

ADENOVIRUSES, HUMAN

Enteric adenoviruses. Mautner V, et al.
Curr Top Microbiol Immunol 1995;199 (Pt 3):229–82 (189 ref.)
Adenoviruses as gene-delivery vehicles. Wilson JM.
N Engl J Med 1996 May 2;334(18):1185–7 (0 ref.)

CHEMISTRY

Structure of the receptor binding domain of adenovirus type 5 fiber protein. Xia D, et al.
Curr Top Microbiol Immunol 1995;199 (Pt 1):39–46 (17 ref.)

GENETICS

The complete nucleotide sequence of the DNA of human adenovirus type 12. Sprengel J, et al.
Curr Top Microbiol Immunol 1995;199 (Pt 2):189–274 (45 ref.)
E3 transcription unit of adenovirus. Wold WS, et al.
Curr Top Microbiol Immunol 1995;199 (Pt 1):237–74 (196 ref.)
Modulation of gene expression by adenovirus transformation. Zantema A, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 3):1–23 (158 ref.)

ISOLATION & PURIFICATION

Fulminant adenovirus hepatitis after allogeneic bone marrow transplantation. Bertheau P, et al.
Bone Marrow Transplant 1996 Feb;17(2):295–8 (14 ref.)

PHYSIOLOGY

Regulation of viral and cellular gene expression by E1A proteins encoded by the oncogenic adenovirus type 12. Brockmann D, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 3):81–112 (221 ref.)
Abortive adenovirus infection and host range determinants. Lucher LA. **Curr Top Microbiol Immunol** 1995;199 (Pt 1):119–52 (148 ref.)
Molecular determinants of adenovirus tropism. Mei YF, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 3):213–28 (55 ref.)
Role of adenovirus structural components in the regulation of adenovirus infection. Russell WC, et al.
Curr Top Microbiol Immunol 1995;199 (Pt 1):81–98 (78 ref.)
Assessing the role of E1A in the differential oncogenicity of group A and group C human adenoviruses. Williams J, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 3):149–75 (134 ref.)

ADENOVIRUSES, HUMAN

ULTRASTRUCTURE

[Adenoviruses as causative agents in gastroenteritis] de Jong JC. **Ned Tijdschr Geneeskd** 1996 Mar 9;140(10):536–41 (48 ref.) **(Dut)**

ADENYL CYCLASE

CHEMISTRY

The stoichiometry of expression of protein components of the stimulatory adenylyl cyclase cascade and the regulation of information transfer. Milligan G. **Cell Signal** 1996 Feb; 8(2):87–95 (81 ref.)

GENETICS

The stoichiometry of expression of protein components of the stimulatory adenylyl cyclase cascade and the regulation of information transfer. Milligan G. **Cell Signal** 1996 Feb; 8(2):87–95 (81 ref.)

METABOLISM

Complexity and diversity of mammalian adenylyl cyclases. Sunahara RK, et al. **Annu Rev Pharmacol Toxicol** 1996; 36:461–80 (95 ref.)

Dopamine receptor multiplicity: "D1-like"-"D2-like" interactions and " D1-like" receptors not linked to adenylate cyclase. Waddington JL, et al. **Biochem Soc Trans** 1996 Feb;24(1):177–82 (77 ref.)

Nobel Lecture. G proteins and regulation of adenylyl cyclase. Gilman AG. **Biosci Rep** 1995 Apr;15(2):65–97 (154 ref.)

Alterations of beta-adrenoceptor–G-protein–regulated adenylyl cyclase in heart failure. Böhm M. **Mol Cell Biochem** 1995 Jun 7–21;147(1–2):147–60 (84 ref.)

PHYSIOLOGY

The Gs alpha/Gi alpha 2 axis controls adipogenesis independently of adenylylcyclase. Wang HY, et al. **Int J Obes Relat Metab Disord** 1996 Mar;20 Suppl 3:S26–31 (62 ref.)

Adenylate cyclases: critical foci in neuronal signaling. Mons N, et al. **Trends Neurosci** 1995 Dec;18(12):536–42 (60 ref.)

ADENYLATE CYCLASE see **ADENYL CYCLASE**

ADENYLATE DEAMINASE see **AMP DEAMINASE**

ADENYLATE PHOSPHATASE see **5'-NUCLEOTIDASE**

ADENYLIC ACID see **ADENOSINE MONOPHOSPHATE**

ADENYLPYROPHOSPHATE see **ADENOSINE TRIPHOSPHATE**

ADHESINS, BACTERIAL

see related
BACTERIAL ADHESION

GENETICS

[Adhesins from Vibrio cholerae: phenotypic analysis and genetic control of synthesis] Smirnova NI. **Mol Gen Mikrobiol Virusol** 1995 Jul–Sep;(3):18–26 (80 ref.) (Eng. Abstr.) **(Rus)**

METABOLISM

Isolation and structural characterization of adhesin polysaccharide receptors. Cassels FJ, et al. **Methods Enzymol** 1995;253:69–91 (44 ref.)

PHARMACOLOGY

Erythrocytes as target cells for testing bacterial adhesins. Goldhar J. **Methods Enzymol** 1995;253:43–50 (32 ref.)

ADHESINS, ESCHERICHIA COLI

GENETICS

Strategies for employing molecular genetics to study tip adhesions. Vetter V, et al. **Methods Enzymol** 1995; 253:229–41 (48 ref.)

ADHESINS, FIMBRIAL see **ADHESINS, BACTERIAL**

ADHESION, BACTERIAL see **BACTERIAL ADHESION**

ADHESIONS

ETIOLOGY

Etiology of and therapeutic approach to synechia uteri. Schenker JG. **Eur J Obstet Gynecol Reprod Biol** 1996 Mar; 65(1):109–13 (20 ref.)

THERAPY

Etiology of and therapeutic approach to synechia uteri. Schenker JG. **Eur J Obstet Gynecol Reprod Biol** 1996 Mar; 65(1):109–13 (20 ref.)

ADHESIVE CAPSULITIS see **BURSITIS**

ADHESIVENESS

see related
PLATELET ADHESIVENESS

ADHESIVES

see related
TISSUE ADHESIVES

Denture fixatives—an update for general dental practice. Jagger DC, et al. **Br Dent J** 1996 Apr 20;180(8):311–3 (18 ref.)

Denture adhesives: changing attitudes. Grasso JE. **J Am Dent Assoc** 1996 Jan;127(1):90–6 (36 ref.)

CHEMISTRY

Wresting the muscle from mussel beards: research and applications. Rzepecki LM, et al. **Mol Mar Biol Biotechnol** 1995 Dec;4(4):313–22 (45 ref.)

ADIPOCERE see **POSTMORTEM CHANGES**

ADIPOCYTES

CYTOLOGY

The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation. Schoonjans K, et al. **Biochim Biophys Acta** 1996 Jul 26;1302(2):93–109 (259 ref.)

Regulation of adipocyte gene expression and differentiation by peroxisome proliferator activated receptor gamma. Tontonoz P, et al. **Curr Opin Genet Dev** 1995 Oct; 5(5):571–6 (51 ref.)

The possibility of active form of vitamins A and D as suppressors on adipocyte development via ligand-dependent transcriptional regulators. Kawada T, et al. **Int J Obes Relat Metab Disord** 1996 Mar;20 Suppl 3:S52–7 (22 ref.)

Control of adipocyte differentiation by CCAAT/enhancer binding protein alpha (C/EBP alpha). Lane MD, et al. **Int J Obes Relat Metab Disord** 1996 Mar;20 Suppl 3:S91–6 (16 ref.)

The insulin/Ras pathway of adipocytic differentiation of 3T3 L1 cells: dissociation between Raf-1 kinase and the MAPK/RSK cascade. Porras A, et al. **Int J Obes Relat Metab Disord** 1996 Mar;20 Suppl 3:S43–51 (47 ref.)

Endocrine and paracrine negative regulators of adipose differentiation. Serrero G, et al. **Int J Obes Relat Metab Disord** 1996 Mar;20 Suppl 3:S58–64 (33 ref.)

Characterization of Pref-1 and its inhibitory role in adipocyte differentiation. Smas CM, et al. **Int J Obes Relat Metab Disord** 1996 Mar;20 Suppl 3:S65–72 (44 ref.)

The Gs alpha/Gi alpha 2 axis controls adipogenesis independently of adenylylcyclase. Wang HY, et al. **Int J Obes Relat Metab Disord** 1996 Mar;20 Suppl 3:S26–31 (62 ref.)

The role of growth hormone/insulin-like growth factors in adipocyte differentiation. Wabitsch M, et al. **Metabolism** 1995 Oct;44(10 Suppl 4):45–9 (58 ref.)

[Proliferation and differentiation of fat cells] Sugihara H, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:115–20 (9 ref.) **(Jpn)**

DRUG EFFECTS

Differential activation of beta 1-, beta 2- and beta 3-adrenoceptors by catecholamines in white and brown adipocytes. Galitzky J, et al. **Fundam Clin Pharmacol** 1995; 9(4):324–31 (54 ref.)

The possibility of active form of vitamins A and D as suppressors on adipocyte development via ligand-dependent transcriptional regulators. Kawada T, et al. **Int J Obes Relat Metab Disord** 1996 Mar;20 Suppl 3:S52–7 (22 ref.)

METABOLISM

Membrane permeation and intracellular trafficking of long chain fatty acids: insights from Escherichia coli and 3T3-L1 adipocytes. Mangroo D, et al. **Biochem Cell Biol** 1995 May-Jun;73(5–6):223–34 (98 ref.)

Regulation of adipocyte gene expression and differentiation by peroxisome proliferator activated receptor gamma. Tontonoz P, et al. **Curr Opin Genet Dev** 1995 Oct; 5(5):571–6 (51 ref.)

Perilipin: possible roles in structure and metabolism of intracellular neutral lipids in adipocytes and steroidogenic cells. Londos C, et al. **Int J Obes Relat Metab Disord** 1996 Mar;20 Suppl 3:S97–101 (13 ref.)

Metabolic disruptions in the adipocyte–hepatocyte fatty acid axis as causes of HyperapoB. Sniderman AD, et al. **Int J Obes Relat Metab Disord** 1995 May;19 Suppl 1:S27–33 (68 ref.)

Cellular aspects of fuel mobilization and selection in white adipocytes. Lafontan M, et al. **Proc Nutr Soc** 1995 Mar; 54(1):49–63 (81 ref.)

[Molecular biology of adipocyte metabolism and obese gene] Kagawa Y. **Nippon Rinsho** 1995 Jun;53 Suppl:93–9 (16 ref.) **(Jpn)**

[Role of peptide hormones in adipocyte metabolism] Kaneko T, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:100–5 (20 ref.) **(Jpn)**

[Role of catecholamines in adipocyte metabolism] Nagasaka Y, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:106–10 (13 ref.) **(Jpn)**

[Role of steroid hormone in adipocyte metabolism] Nagasaka Y, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:111–4 (9 ref.) **(Jpn)**

PATHOLOGY

Molecular mechanisms of liver fibrogenesis—a homage to the role of activated fat-storing cells. Gressner AM, et al. **Digestion** 1995;56(5):335–46 (99 ref.)

PHYSIOLOGY

Fat cell alpha 2-adrenoceptors: the regulation of fat cell function and lipolysis. Lafontan M, et al. **Endocr Rev** 1995 Dec;16(6):716–38 (234 ref.)

Mediators of hepatic fibrogenesis. Gressner AM. **Hepatogastroenterology** 1996 Jan–Feb;43(7):92–103 (84 ref.)

Pathobiology of hepatic stellate cells. Mathew J, et al. **Hepatogastroenterology** 1996 Jan–Feb;43(7):72–91 (201 ref.)

Adrenergic receptors and fat cells: differential recruitment by physiological amines and homologous regulation. Lafontan M, et al. **Obes Res** 1995 Nov;3 Suppl 4:507S–514S (56 ref.)

A cascade-mechanism of fat storing cell activation forms the basis of the fibrogenic reaction of the liver. Gressner AM, et al. **Verh Dtsch Ges Pathol** 1995;79:1–14 (80 ref.)

[Leptin—a peptide hormone from adipocytes. Sensation of the 23rd FEBS Meeting] Pankov IuA. **Bioorg Khim** 1996 Mar;22(3):228–33 (13 ref.) (Eng. Abstr.) **(Rus)**

ADIPOGENESIS INHIBITORY FACTOR see **INTERLEUKIN-11**

ADIPOSE TISSUE

see related
ADIPOCYTES
BROWN FAT
LIPECTOMY
SKINFOLD THICKNESS

The buccal pad of fat: a review. Tostevin PM, et al. **Clin Anat** 1995;8(6):403–6 (35 ref.)

The regulation of adipose tissue distribution in humans. Björntorp P. **Int J Obes Relat Metab Disord** 1996 Apr; 20(4):291–302 (117 ref.)

High-density lipoprotein-cholesterol: determining hygienic factors for intervention [published erratum appears in J Occup Environ Med 1995 Sep;37(9):1121] Anzalone DA, et al. **J Occup Environ Med** 1995 Jul;37(7):856–61 (32 ref.)

Dehydroepiandrosterone and body fat. Clore JN. **Obes Res** 1995 Nov;3 Suppl 4:613S–616S (46 ref.)

Visceral fat accumulation and cardiovascular disease. Matsuzawa Y, et al. **Obes Res** 1995 Dec;3 Suppl 5:645S–647S (11 ref.)

[Lipedema] Herpertz U. **Z Lymphol** 1995 Aug;19(1):1–11 (5 ref.) (Eng. Abstr.) **(Ger)**

ANATOMY & HISTOLOGY

The importance of body fat distribution in early life. Freedman DS. **Am J Med Sci** 1995 Dec;310 Suppl 1:S72–6 (47 ref.)

Lymphatics and adipose tissue. Ryan TJ. **Clin Dermatol** 1995 Sep-Oct;13(5):493–8 (38 ref.)

Insulin resistance and obesity. The role of fat distribution pattern. Abate N. **Diabetes Care** 1996 Mar;19(3):292–4 (25 ref.)

The interrelationships of body fat, exercise, and hormonal status and their impact on reproduction and bone health. Ramos RH, et al. **Semin Perinatol** 1995 Jun;19(3):163–70 (53 ref.)

[Waist to hip circumference ratio] Abe T, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:221–6 (16 ref.) **(Jpn)**

[Dual photon absorptiometry, dual energy X-ray absorptiometry for analysis of body fat mass] Itabashi A. **Nippon Rinsho** 1995 Jun;53 Suppl:174–8 (11 ref.) **(Jpn)**

[Techniques of measurement of human body fat mass: overview] Kataoka K. **Nippon Rinsho** 1995 Jun;53 Suppl:157–64 (42 ref.) **(Jpn)**

[Densitometry (hydrostatic weighing) for measurement of human body fat mass] Koda M, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:165–9 (11 ref.) **(Jpn)**

[Total body water by D2O dilution] Koda M, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:170–3 (10 ref.) **(Jpn)**

[Skinfold thickness for analysis of body fat mass] Koda M, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:189–93 (21 ref.) **(Jpn)**

[Bio-electrical impedance analysis method for body fat mass] Sato T. **Nippon Rinsho** 1995 Jun;53 Suppl:179–82 (10 ref.) **(Jpn)**

[Near infrared interactance for measurement of body fat mass] Sawai S, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:183–8 (11 ref.) **(Jpn)**

[Fat measurement using MRI] Yamaguchi K, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:215–20 (9 ref.) **(Jpn)**

CHEMISTRY

Fatty acid composition of adipose tissue in humans. Implications for the dietary fat–serum cholesterol–CHD issue. Seidelin KN. **Prog Lipid Res** 1995;34(3):199–217 (158 ref.)

Diagnosing amyloidosis [editorial] Westermark P. **Scand J Rheumatol** 1995;24(6):327–9 (12 ref.)

CYTOLOGY

Transcriptional regulation of gene expression during adipocyte differentiation. MacDougald OA, et al. **Annu Rev Biochem** 1995;64:345–73 (164 ref.)

Adipocyte differentiation. When precursors are also regulators. MacDougald OA, et al. **Curr Biol** 1995 Jun 1; 5(6):618–21 (16 ref.)

Regulation of adipose maturation and energy homeostasis. Yeh WC, et al. **Curr Opin Cell Biol** 1995 Dec;7(6):885–90 (57 ref.)

Cellular aspects of fuel mobilization and selection in white adipocytes. Lafontan M, et al. **Proc Nutr Soc** 1995 Mar; 54(1):49–63 (81 ref.)

[Toward the treatment of obesity: role of PPAR gamma in adipogenesis] Motojima K. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(13):1936–41 (32 ref.) **(Jpn)**

GROWTH & DEVELOPMENT

Paracrine interactions in adipose tissue development and growth. Lau DC, et al. **Int J Obes Relat Metab Disord** 1996 Mar;20 Suppl 3:S16–25 (57 ref.)

METABOLISM

Ethnicity and energy stores. Conway JM. **Am J Clin Nutr** 1995 Nov;62(5 Suppl):1067S–1071S (35 ref.)

Differences in lipolysis between human subcutaneous and omental adipose tissues. Arner P. **Ann Med** 1995 Aug; 27(4):435–8 (27 ref.)

Estrogen biosynthesis in adipose. Significance in breast cancer development. Simpson ER, et al. **Ann N Y Acad Sci** 1996 Apr 30;784:18–26 (60 ref.)

Transcriptional regulation of gene expression during adipocyte differentiation. MacDougald OA, et al. **Annu Rev Biochem** 1995;64:345–73 (164 ref.)

Regulation of adipose maturation and energy homeostasis. Yeh WC, et al. **Curr Opin Cell Biol** 1995 Dec;7(6):885–90 (57 ref.)

Investigations on the mechanism of adipocere formation and its relation to other biochemical reactions. Takatori T. **Forensic Sci Int** 1996 Jun 28;80(1–2):49–61 (25 ref.)

The role of angiotensin II and its receptors in regulation of adipose tissue metabolism and cellularity. Zorad S, et al. **Gen Physiol Biophys** 1995 Oct;14(5):383–91 (43 ref.)

Impact of exercise on adipose tissue metabolism in humans. Arner P. **Int J Obes Relat Metab Disord** 1995 Oct;19 Suppl 4:S18–21 (25 ref.)

Techniques for the measurement of white adipose tissue metabolism: a practical guide. Arner P. **Int J Obes Relat Metab Disord** 1995 Jul;19(7):435–42 (50 ref.)

Beta-adrenergic receptors and G-proteins in the ob/ob mouse. Bégin-Heick N. **Int J Obes Relat Metab Disord** 1996 Mar;20 Suppl 3:S32–5 (21 ref.)

Fuel selection in white adipose tissue. Frayn KN, et al. **Proc Nutr Soc** 1995 Mar;54(1):177–89 (50 ref.)

[Pathogenesis of visceral fat accumulation] Keno Y, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:121–6 (20 ref.) **(Jpn)**

[Characteristics of adipose] Yamamura M, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:133–7 (7 ref.) **(Jpn)**

PATHOLOGY

Lipomatous medulloblastoma in adults. A distinct clinicopathological entity Soylemezoglu F, et al. **Am J Surg Pathol** 1996 Apr;20(4):413–8 (33 ref.)

Pathophysiology and pathogenesis of visceral fat obesity. Matsuzawa Y, et al. **Obes Res** 1995 Sep;3 Suppl 2:187S–194S (14 ref.)

PHYSIOLOGY

New model for the regulation of energy balance and adiposity by the central nervous system. Kaiyala KJ, et al. **Am J Clin Nutr** 1995 Nov;62(5 Suppl):1123S–1134S (130 ref.)

Steroid hormones and adipose tissue [comment] Prins JB, et al. **Eur J Clin Invest** 1996 Apr;26(4):259–61 (24 ref.) Comment on: Eur J Clin Invest 1996 Apr;26(4):262–9.

[The role of muscle, adipose tissue and liver in development of metabolic syndrome] Krotkiewski M. **Pol Tyg Lek** 1996 Jan;51(1–5):40–5 (55 ref.) **(Pol)**

PHYSIOPATHOLOGY

Changes in autonomic nervous system activity and consecutive hyperinsulinaemia: respective roles in the development of obesity in rodents. Pénicaud L, et al. **Diabetes Metab** 1996 Feb;22(1):15–24 (67 ref.)

RADIOGRAPHY

[The measurement of fat distribution by computed tomography] Nakamura T, et al. **Nippon Rinsho** 1995 Jun; 53 Suppl:209–14 (10 ref.) **(Jpn)**

SECRETION

[Leptin—a new way to diet?] Holst JJ. **Ugeskr Laeger** 1996 Aug 5;158(32):4505–8 (25 ref.) (Eng. Abstr.) **(Dan)**

TRANSPLANTATION

[Injected fat for correction of soft tissue defects] Shoshani O, et al. **Harefuah** 1995 Dec 1;129(11):489–93 (40 ref.) **(Heb)**

ULTRASONOGRAPHY

[Ultrasonic diagnosis of visceral type obesity] Murano S, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:203–8 (10 ref.) **(Jpn)**

ADIPOSE TISSUE, BROWN see **BROWN FAT**

ADJUSTMENT, SOCIAL see **SOCIAL ADJUSTMENT**

ADJUVANT ARTHRITIS see **ARTHRITIS, ADJUVANT**

ADJUVANTS, IMMUNOLOGIC

Copolymer adjuvants. Brey RN. **Adv Exp Med Biol** 1995; 383:23–34 (47 ref.)

Myelopeptides: new immunoregulatory peptides. Petrov R. **Allergy Proc** 1995 Jul–Aug;16(4):177–84 (14 ref.)

A genetic approach to idiotypic vaccination for B cell lymphoma. Stevenson FK, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:212–26 (23 ref.)

Immunomodulatory effects of donor lymphocyte infusions following allogeneic bone marrow transplantation. Soiffer RJ, et al. **J Clin Apheresis** 1995;10(3):139–43 (36 ref.)

Alpha interferon as an immunomodulator in the treatment of patients with tumors. Alvarez-Mon M, et al. **Med Oncol** 1995 Mar;12(1):15–21 (45 ref.)

Vaccine adjuvants based on gamma inulin. Cooper PD. **Pharm Biotechnol** 1995;6:559–80 (73 ref.)

Adjuvant properties of aluminum and calcium compounds. Gupta RK, et al. **Pharm Biotechnol** 1995;6:229–48 (126 ref.)

Structural and immunological characterization of the vaccine adjuvant QS-21. Kensil CR, et al. **Pharm Biotechnol** 1995; 6:525–41 (41 ref.)

Nanoparticles as adjuvants for vaccines. Kreuter J. **Pharm Biotechnol** 1995;6:463–72 (32 ref.)

Monophosphoryl lipid A as an adjuvant. Past experiences and new directions. Ulrich JT, et al. **Pharm Biotechnol** 1995;6:495–524 (150 ref.)

A compendium of vaccine adjuvants and excipients. Vogel FR, et al. **Pharm Biotechnol** 1995;6:141–228 (284 ref.)

ADMINISTRATION & DOSAGE

Vaccine adjuvancy: a new potential area of development for GM-CSF. Taglietti M. **Adv Exp Med Biol** 1995;378:565–9 (22 ref.)

[Therapy of multiple sclerosis with interferon-beta-1b. Educating the patient and managing side-effects] Walther EU, et al. **Nervenarzt** 1996 Jun;67(6):452–6 (16 ref.) (Eng. Abstr.) **(Ger)**

CHEMICAL SYNTHESIS

Development of an emulsion-based muramyl dipeptide adjuvant formulation for vaccines. Lidgate DM, et al. **Pharm Biotechnol** 1995;6:313–24 (34 ref.)

MF59. Design and evaluation of a safe and potent adjuvant for human vaccines. Ott G, et al. **Pharm Biotechnol** 1995; 6:277–96 (36 ref.)

CHEMISTRY

Antibacterial and immunostimulating casein-derived substances from milk: casecidin, isracidin peptides. Lahov E, et al. **Food Chem Toxicol** 1996 Jan;34(1):131–45 (49 ref.)

Structure and properties of aluminum-containing adjuvants. Hem SL, et al. **Pharm Biotechnol** 1995;6:249–76 (36 ref.)

Water-soluble phosphazene polymers for parenteral and mucosal vaccine delivery. Payne LG, et al. **Pharm Biotechnol** 1995;6:473–93 (15 ref.)

PHARMACOLOGY

Calcium uptake by ACTH-stimulated lymphocytes: what is the physiological significance? Clarke BL. **Adv Neuroimmunol** 1995;5(3):271–81 (48 ref.)

Mechanisms of action of intravenous immune globulin in immune-mediated diseases. Mouthon L, et al. **Clin Exp Immunol** 1996 May;104 Suppl 1:3–9 (63 ref.)

Modulation of B-cell immunoglobulin synthesis by retinoic acid. Ballow M, et al. **Clin Immunol Immunopathol** 1996 Sep;80(3 Pt 2):S73–81 (37 ref.)

Immunomodulatory effects of 1,25-dihydroxyvitamin D3. Casteels K, et al. **Curr Opin Nephrol Hypertens** 1995 Jul; 4(4):313–8 (75 ref.)

Exogenous and endogenous opioids as biological response modifiers. Carr DJJ, et al. **Immunopharmacology** 1995 Nov; 31(1):59–71 (118 ref.)

Histogranin, a modified histone H4 fragment endowed with N-methyl-D-aspartate antagonist and immunostimulatory activities. Lemaire S, et al. **Life Sci** 1995 Mar 3; 56(15):1233–41 (34 ref.)

Immunomodulatory actions of xanthines and isoenzyme selective phosphodiesterase inhibitors. Banner KH, et al. **Monaldi Arch Chest Dis** 1995 Aug;50(4):286–92 (96 ref.)

Lyme vaccine enhancement. N-terminal acylation of a protein antigen and inclusion of a saponin adjuvant. Coughlin RT, et al. **Pharm Biotechnol** 1995;6:719–35 (126 ref.)

Cytokines as vaccine adjuvants. Current status and potential applications. Dong P, et al. **Pharm Biotechnol** 1995;6:625–43 (122 ref.)

A new approach to vaccine adjuvants. Immunopotentiation by intracellular T-helper-like signals transmitted by loxoribine. Goodman MG. **Pharm Biotechnol** 1995; 6:581–609 (73 ref.)

Cytokines as immunological adjuvants. Heath AW. **Pharm Biotechnol** 1995;6:645–58 (66 ref.)

Cytokine-containing liposomes as adjuvants for subunit vaccines. Lachman LB, et al. **Pharm Biotechnol** 1995; 6:659–71 (37 ref.)

Stearyl tyrosine. An organic equivalent of aluminum-based immunoadjuvants. Penney C. **Pharm Biotechnol** 1995; 6:611–24 (26 ref.)

Immunopharmacological and biochemical bases of Chinese herbal medicine. Lien EJ, et al. **Prog Drug Res** 1996; 46:263–80 (29 ref.)

Adjuvants for human vaccines—current status, problems and future prospects. Gupta RK, et al. **Vaccine** 1995 Oct; 13(14):1263–76 (123 ref.)

PHYSIOLOGY

The heterogeneity of the osteopetroses reflects the diversity of cellular influences during skeletal development. Popoff SN, et al. **Bone** 1995 Nov;17(5):437–45 (131 ref.)

Exogenous and endogenous opioids as biological response modifiers. Carr DJJ, et al. **Immunopharmacology** 1995 Nov; 31(1):59–71 (118 ref.)

[Food-acquisition and avoidance behaviors: the role of immunomodulators in their systemic organization] Zhuravlev BV, et al. **Usp Fiziol Nauk** 1996 Apr–Jun; 27(2):90–106 (107 ref.) (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Assessment of the clinical value of using an immunomodulator in recurrent respiratory infections. Bergmann KC. **Adv Exp Med Biol** 1995;371B:795–7 (15 ref.)

Melatonin: implications at the oral level. Cutando A, et al. **Bull Group Int Rech Sci Stomatol Odontol** 1995 Sep–Oct; 38(3–4):81–6 (29 ref.)

Kawasaki syndrome: immunomodulatory benefit and potential toxin neutralization by intravenous immune globulin. Leung DY. **Clin Exp Immunol** 1996 May;104 Suppl 1:49–54 (41 ref.)

The treatment of multiple sclerosis: current and future. Polman CH, et al. **Curr Opin Neurol** 1995 Jun;8(3):200–9 (87 ref.)

Immunomodulating agents for the management of heart failure with myocarditis and cardiomyopathy—lessons from animal experiments. Matsumori A, et al. **Eur Heart J** 1995 Dec;16 Suppl O:140–3 (10 ref.)

Pharmacological aspects and therapeutic applications of lysozymes. Sava G. **EXS** 1996;75:433–49 (79 ref.)

Approaches to augmenting the immunogenicity of melanoma gangliosides: from whole melanoma cells to ganglioside-KLH conjugate vaccines. Livingston PO. **Immunol Rev** 1995 Jun;145:147–66 (68 ref.)

The role of interferons in the treatment of multiple sclerosis. Kelley CL. **J Neurosci Nurs** 1996 Apr;28(2):114–20 (21 ref.)

Biologic interventions in rheumatoid arthritis. Cush JJ, et al. **Rheum Dis Clin North Am** 1995 Aug;21(3):797–816 (74 ref.)

Marine and botanical lipids as immunomodulatory and therapeutic agents in the treatment of rheumatoid arthritis. DeLuca P, et al. **Rheum Dis Clin North Am** 1995 Aug; 21(3):759–77 (91 ref.)

[Immunomodulator treatments in HIV infection: rational bases and therapeutic prospects] Durant J, et al. **Rev Med Interne** 1995;16 Suppl 3:308s–312s (30 ref.) **(Fre)**

[Echinacea drugs—effects and active ingredients] Bauer R. **Z Arztl Fortbild (Jena)** 1996 Apr;90(2):111–5 (23 ref.) (Eng. Abstr.) **(Ger)**

[Clinical application of extracts of Echinacea purpurea or Echinacea pallida. Critical evaluation of controlled clinical studies] Dorsch W. **Z Arztl Fortbild (Jena)** 1996 Apr; 90(2):117–22 (20 ref.) (Eng. Abstr.) **(Ger)**

[The characteristics of the immunogenesis and immunocorrection of diabetes mellitus] Galenok VA, et al. Ter Arkh 1995;67(10):7–12 (61 ref.) (Eng. Abstr.) **(Rus)**

ADL see **ACTIVITIES OF DAILY LIVING**

ADMINISTRATION, CUTANEOUS

see related
SKIN ABSORPTION

ADMINISTRATION, INHALATION

see related
ANESTHESIA, INHALATION
RESPIRATORY THERAPY

ADMINISTRATION, INHALATION

Molecular toxicology endpoints in rodent inhalation studies. Brown BG, et al. **Exp Toxicol Pathol** 1995 May; 47(2-3):183-91 (29 ref.)
[Inhalation techniques] Huchon GJ.
Rev Med Suisse Romande 1996 May;116(5):319-23 (32 ref.) **(Fre)**

ADMINISTRATION, INTRANASAL

see related
NEBULIZERS AND VAPORIZERS

ADMINISTRATION, RECTAL

see related
ANESTHESIA, RECTAL
SUPPOSITORIES

ADMINISTRATION RESEARCH, NURSING see **NURSING ADMINISTRATION RESEARCH**

ADMINISTRATION SCHEDULE, DRUG see **DRUG ADMINISTRATION SCHEDULE**

ADMINISTRATIVE PERSONNEL

The budget process in schools of nursing: a primer for the novice administrator. Starck PL, et al. **J Prof Nurs** 1996 Mar-Apr;12(2):69-75 (7 ref.)

ADMINISTRATORS see **ADMINISTRATIVE PERSONNEL**

ADMISSION TESTS, ROUTINE see **DIAGNOSTIC TESTS, ROUTINE**

ADNEXAL DISEASES

The female pelvic mass. Diagnosis and management. Russell DJ. **Med Clin North Am** 1995 Nov;79(6):1481-93 (19 ref.)

DIAGNOSIS

Magnetic resonance imaging of benign adnexal conditions. Thickman D, et al. **Magn Reson Imaging Clin N Am** 1994 May;2(2):275-89 (30 ref.)
[Aspiration of the adnexal mass--is it reliable?] Lavie O, et al. **Harefuah** 1995 Dec 1;129(11):502-7 (45 ref.) **(Heb)**

HISTORY

[The historical stages in the conservative treatment of endometriosis] Karag'ozov I, et al.
Akush Ginekol (Sofiia) 1995;34(1):30-2 (12 ref.) **(Bul)**

SURGERY

The case for laparoscopic management of the adnexal mass. Parker WH. **Clin Obstet Gynecol** 1995 Jun;38(2):362-9 (32 ref.)
Laparoscopic oophorectomy. Russell JB.
Curr Opin Obstet Gynecol 1995 Aug;7(4):295-8 (20 ref.)
[Indications for celioscopic surgery in children (editorial)] Heloury Y. **Presse Med** 1995 Oct 14;24(30):1374-5 (9 ref.) **(Fre)**

THERAPY

[Aspiration of the adnexal mass--is it reliable?] Lavie O, et al. **Harefuah** 1995 Dec 1;129(11):502-7 (45 ref.) **(Heb)**

ULTRASONOGRAPHY

[Transvaginal diagnosis of adnexal diseases] Osmers R.
Gynakologe 1995 Aug;28(4):233-9 (52 ref.) **(Ger)**

ADNEXITIS

Pelvic inflammatory disease in adolescents. Wald ER.
Curr Probl Pediatr 1996 Mar;26(3):86-97 (78 ref.)
Pelvic inflammatory disease: clinical overview. Kottmann LM. **J Obstet Gynecol Neonatal Nurs** 1995 Oct; 24(8):759-67 (33 ref.)
[Upper genital tract infections in women infected with HIV: epidemiologic, diagnostic and therapeutic aspects] Panel P, et al. **Contracept Fertil Sex** 1996 Jun;24(6):488-94 (22 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

[Fitz-Hugh-Curtis syndrome] Sakai H, et al.
Ryoikibetsu Shokogun Shirizu 1995;(8):430-3 (7 ref.) **(Jpn)**

DIAGNOSIS

Pelvic inflammatory disease: an ongoing epidemic. Augenbraun MH, et al. **Hosp Pract (Off Ed)** 1995 Sep 15; 30(9):61-6 (6 ref.)
[Current concepts in the diagnosis and treatment of pelvic inflammatory disease] Borisov I. **Akush Ginekol (Sofiia)** 1995;34(2):47-51 (10 ref.) **(Bul)**
[Chlamydia infections in gynecology and obstetrics] Dieterle S. **Geburtshilfe Frauenheilkd** 1995 Sep;55(9):510-7 (65 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Chlamydia trachomatis: a major cause of mucopurulent cervicitis and pelvic inflammatory disease in women. Paavonen J. **Curr Probl Dermatol** 1996;24:110-22 (78 ref.)
Pelvic inflammatory disease: an ongoing epidemic. Augenbraun MH, et al. **Hosp Pract (Off Ed)** 1995 Sep 15; 30(9):61-6 (6 ref.)
[Current concepts in the diagnosis and treatment of pelvic inflammatory disease] Borisov I. **Akush Ginekol (Sofiia)** 1995;34(2):47-51 (10 ref.) **(Bul)**

EPIDEMIOLOGY

Pelvic inflammatory disease: a contemporary approach. Newkirk GR. **Am Fam Physician** 1996 Mar;53(4):1127-35 (49 ref.)

MICROBIOLOGY

Role of bacterial vaginosis in pelvic inflammatory disease. Sweet RL. **Clin Infect Dis** 1995 Jun;20 Suppl 2:S271-5 (46 ref.)

PREVENTION & CONTROL

Prevention of recurrent pelvic infection by contact tracing: a commonsense approach. Robinson AJ, et al.
Br J Obstet Gynaecol 1996 Sep;103(9):859-61 (21 ref.)
Preventing pelvic infection after abortion [editorial] Stevenson MM, et al. **Int J STD AIDS** 1995 Sep-Oct; 6(5):305-12 (61 ref.)

ADOLESCENCE

Effects of welfare reform on teenage parents and their children. Aber JL, et al. **Future Child** 1995 Summer-Fall; 5(2):53-71 (60 ref.)

ADOLESCENT BEHAVIOR

Effectiveness in adolescent health. Macfarlane A.
Acta Paediatr 1995 Oct;84(10):1089-93 (19 ref.)
In search of effective programs to address students' emotional distress and behavioral problems. Part I: Defining the problem. Wassef A, et al. **Adolescence** 1995 Fall; 30(119):523-38 (22 ref.)
In search of effective programs to address students' emotional distress and behavioral problems. Part II: Critique of school- and community-based programs. Wassef A, et al. **Adolescence** 1995 Winter;30(120):757-77 (29 ref.)
Adolescent sexuality and its problems. Yang M.
Ann Acad Med Singapore 1995 Sep;24(5):736-40 (40 ref.)
Violence among children and adolescents and the role of the pediatrician. Dukarm CP, et al.
Bull N Y Acad Med 1995 Summer;72(1):5-15 (38 ref.)
The effects of family structure and family relations on adolescent marijuana use. Hoffmann JP. **Int J Addict** 1995 Aug;30(10):1207-41 (106 ref.)
STDs: Screening, therapy, and long-term implications for the adolescent patient. Bishop-Townsend V.
Int J Fertil Menopausal Stud 1996 Mar-Apr;41(2):109-14 (41 ref.)
Reexamination of the paradigm of HIV risk reduction in adolescents. Earl DT. **J Am Osteopath Assoc** 1995 Dec; 95(12):725-8 (32 ref.)
Adolescent substance use disorder with conduct disorder and comorbid conditions. Crowley TJ, et al.
NIDA Res Monogr 1995;156:49-111 (178 ref.)
Youth Evaluation Services (YES): assessment, systems of referral, and treatment effects. Del Boca FK, et al.
NIDA Res Monogr 1995;156:325-40 (11 ref.)
Service delivery strategies for treating high-risk youth: delinquents, homeless, runaways, and sexual minorities. Farrow JA. **NIDA Res Monogr** 1995;156:39-48 (23 ref.)
Skills training for pregnant and parenting adolescents. Hall JA. **NIDA Res Monogr** 1995;156:255-90 (70 ref.)
Therapeutic communities for adolescents. Jainchill N, et al.
NIDA Res Monogr 1995;156:190-217 (19 ref.)
Pharmacotherapy for adolescents with psychoactive substance use disorders. Kaminer Y. **NIDA Res Monogr** 1995;156:291-324 (101 ref.)
Physical health problems associated with adolescent substance abuse. Kokotailo P. **NIDA Res Monogr** 1995; 156:112-29 (52 ref.)
Cultural competence in assessing Hispanic youths and families: challenges in the assessment of treatment needs and treatment evaluation for Hispanic drug-abusing adolescents. Kurtines WM, et al. **NIDA Res Monogr** 1995; 156:172-89 (30 ref.)
Family-based treatment for adolescent drug use: state of the science. Liddle HA, et al. **NIDA Res Monogr** 1995; 156:218-54 (153 ref.)
Identifying high-risk youth: prevalence and patterns of adolescent drug abuse. Newcomb MD.
NIDA Res Monogr 1995;156:7-38 (68 ref.)
Advances in adolescent drug abuse treatment. Rahdert E, et al. **NIDA Res Monogr** 1995;156:1-6 (5 ref.)
Posttreatment services for chemically dependent adolescents. Spear SF, et al. **NIDA Res Monogr** 1995;156:341-64 (73 ref.)
AIDS, drugs, and the adolescent. Steel E.
NIDA Res Monogr 1995;156:130-45 (34 ref.)
Current issues and future needs in the assessment of adolescent drug abuse. Winters KC, et al.
NIDA Res Monogr 1995;156:146-71 (60 ref.)
Adolescent contraceptive behavior: the impact of the provider and the structure of clinic-based programs. Jaccard J. **Obstet Gynecol** 1996 Sep;88(3 Suppl):57S-64S (68 ref.)
Pathways of influence on fifth and eighth graders' reports about having had sexual intercourse. Porter CP, et al.
Res Nurs Health 1996 Jun;19(3):193-204 (55 ref.)
Anabolic steroid use and associated health risk behaviours. Middleman AB, et al. **Sports Med** 1996 Apr;21(4):251-5 (26 ref.)
[Design of a program to prevent adolescent suicide] González-Seijo JC, et al.
Actas Luso Esp Neurol Psiquiatr Cienc Afines 1994 May-Jun;22(3):100-8 (59 ref.) (Eng. Abstr.) **(Spa)**

ADOLESCENT HEALTH SERVICES

In search of effective programs to address students' emotional distress and behavioral problems. Part II: Critique of school- and community-based programs. Wassef A, et al. **Adolescence** 1995 Winter;30(120):757-77 (29 ref.)
School-based health clinics in the mid-1990s. Klein JD, et al. **Curr Opin Pediatr** 1995 Aug;7(4):353-9 (31 ref.)
Condom availability and prevention issues for adolescents. Spingarn RW. **Curr Opin Pediatr** 1995 Aug;7(4):360-5 (53 ref.)
Transferring to adult health care: experiences of adolescents with cystic fibrosis. Russell MT, et al. **J Pediatr Nurs** 1996 Aug;11(4):262-8 (44 ref.)
Adolescent contraceptive behavior: the impact of the provider and the structure of clinic-based programs. Jaccard J. **Obstet Gynecol** 1996 Sep;88(3 Suppl):57S-64S (68 ref.)
Meeting the needs of young adults. McCauley AP, et al.
Popul Rep J 1995 Oct;(41):1-43 (595 ref.)
Preventive health care for teenagers and young adults. Schaff EA, et al. **Prim Care** 1995 Dec;22(4):637-52 (27 ref.)

ORGANIZATION & ADMINISTRATION

Review of teenage health: time for a new direction. Jacobson LD, et al. **Br J Gen Pract** 1994 Sep;44(386):420-4 (64 ref.)

SUPPLY & DISTRIBUTION

[Adolescents and rehabilitation] Kokkonen J, et al.
Duodecim 1994;110(15):1410-6 (20 ref.) **(Fin)**

ADOLESCENT MEDICINE

ECONOMICS

The cost of comprehensive preventive medical services for adolescents. Gans JE, et al. **Arch Pediatr Adolesc Med** 1995 Nov;149(11):1226-34 (52 ref.)

ADOLESCENT NUTRITION

Eating disorders in adolescents: a model for broadening our perspective. Rees JM. **J Am Diet Assoc** 1996 Jan;96(1):22-3 (4 ref.)

ADOLESCENT PREGNANCY see **PREGNANCY IN ADOLESCENCE**

ADOLESCENT PSYCHIATRY

Psychopharmacology in child and adolescent psychiatry: a review of the past seven years. Part I. Campbell M, et al. **J Am Acad Child Adolesc Psychiatry** 1995 Sep; 34(9):1124-32 (132 ref.)
[Reflections on transference, countertransference, session frequency and the analytic process] Holder A.
Psychiatr Enfant 1995;38(2):703-23 (5 ref.) (Eng. Abstr.) **(Fre)**

ADOLESCENT PSYCHOLOGY

Constructivist developmental theory and therapy: implications for counseling adolescents. Crespi TD, et al. **Adolescence** 1995 Fall;30(119):735-43 (20 ref.)
Sexuality and related issues in the preadolescent and adolescent female with epilepsy. Mims J.
J Neurosci Nurs 1996 Apr;28(2):102-6 (34 ref.)
Adolescent condom use, the health belief model, and the prevention of sexually transmitted disease. Hiltabiddle SJ. **J Obstet Gynecol Neonatal Nurs** 1996 Jan;25(1):61-6 (36 ref.)
Marketing adolescent tobacco addiction. Tye J, et al.
Md Med J 1995 Oct;44(10):767-73 (29 ref.)
[Depression amd depressive feelings in childhood and adolescence--problems in diagnosis and assessment] Solantaus T. **Duodecim** 1994;110(3):239-51 (69 ref.) **(Fin)**
[White walls for black holes: essay on graffiti psychopathology] Catheline-Antipoff N, et al.
Psychiatr Enfant 1995;38(2):625-53 (16 ref.) (Eng. Abstr.) **(Fre)**
[Modern family and adolescence] Takikawa K.
Seishin Shinkeigaku Zasshi 1995;97(8):586-98 (7 ref.) **(Jpn)**

ADOPTION

The role of the perinatal nurse in open adoption. Fister S, et al. **MCN Am J Matern Child Nurs** 1995 Jan–Feb; 20(1):9–12 (11 ref.)

LEGISLATION & JURISPRUDENCE

Accreditation of those who arrange adoptions under the Hague Convention on intercountry adoption as a means of protecting, through private international law, the rights of children. Pierce WL. **J Contemp Health Law Policy** 1996 Spring;12(2):535–61 (31 ref.)

PSYCHOLOGY

Adoption and mental health: a theoretical critique of the psychopathological model. Wegar K.
Am J Orthopsychiatry 1995 Oct;65(4):540–8 (55 ref.)

[Reflections on international adoption] Laurent A, et al.
Ann Med Psychol (Paris) 1995 Oct;153(8):528–30; discussion 531 (2 ref.) (Eng. Abstr.) **(Fre)**

ADOPTIVE CELL TRANSFER see **IMMUNOTHERAPY, ADOPTIVE**

ADOPTIVE CELLULAR IMMUNOTHERAPY see **IMMUNOTHERAPY, ADOPTIVE**

ADP see **ADENOSINE DIPHOSPHATE**

ADP,ATP CARRIER see **ADENINE NUCLEOTIDE TRANSLOCASE**

ADP,ATP TRANSLOCATOR PROTEIN see **ADENINE NUCLEOTIDE TRANSLOCASE**

ADP RECEPTORS see **RECEPTORS, PURINERGIC P2**

ADP RIBOSE see **ADENOSINE DIPHOSPHATE RIBOSE**

ADP-RIBOSYLTRANSFERASE (POLYMERIZING) see **NAD+ ADP-RIBOSYLTRANSFERASE**

ADPASE see **APYRASE**

ADRENAL CORTEX

METABOLISM

Biosynthesis of DHEAS by the human adrenal cortex and its age-related decline. Hornsby PJ. **Ann N Y Acad Sci** 1995 Dec 29;774:29–46 (64 ref.)

PATHOLOGY

[Morphological typing, evaluation of tumor dignity and prognosis and etiologic classification of adrenomedullary and adrenocortical neoplasias] Schröder S, et al.
Pathologe 1995 Sep;16(5):307–14 (57 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Potential interactions between nimodipine and adrenal hormones. Isaacson RL, et al. **Ann N Y Acad Sci** 1995 Sep 15;765:134–42; discussion 160–2 (29 ref.)

The 1994 Upjohn Award Lecture. Molecular and genetic approaches to the study of signal transduction in the adrenal cortex. Schimmer BP. **Can J Physiol Pharmacol** 1995 Aug;73(8):1097–107 (83 ref.)

Serotonin and the regulation of hypothalamic-pituitary-adrenal axis function. Dinan TG. **Life Sci** 1996;58(20):1683–94 (146 ref.)

PHYSIOPATHOLOGY

Antidepressants and hypothalamic-pituitary-adrenocortical regulation. Holsboer F, et al. **Endocr Rev** 1996 Apr; 17(2):187–205 (237 ref.)

TRANSPLANTATION

Update on cellular transplantation into the CNS as a novel therapy for chronic pain. Czech KA, et al.
Prog Neurobiol 1995 Aug;46(5):507–29 (126 ref.)

ADRENAL CORTEX DISEASES

DIAGNOSIS

Adrenal cortical and medullary imaging. Freitas JE.
Semin Nucl Med 1995 Jul;25(3):235–30 (63 ref.)

ADRENAL CORTEX HORMONES

see related
ADRENAL GLAND HYPERFUNCTION
ADRENAL GLAND HYPOFUNCTION
RECEPTORS, GLUCOCORTICOID

Four decades of topical corticosteroid assessment. Smith EW.
Curr Probl Dermatol 1995;22:124–31 (10 ref.)

[Corticoid resistance in asthma] Perrin-Fayolle M, et al.
Rev Pneumol Clin 1996;52(2):150–8 (43 ref.) (Eng. Abstr.) **(Fre)**

ADMINISTRATION & DOSAGE

Benefits and risks of intralesional corticosteroid injection in the treatment of dermatological diseases. Firooz A, et al.
Clin Exp Dermatol 1995 Sep;20(5):363–70 (79 ref.)

Use of antenatal corticosteroids for fetal maturation. Gardner MO, et al. **Curr Opin Obstet Gynecol** 1996 Apr;8(2):106–9 (37 ref.)

Articular and periarticular corticosteroid injections.
Drug Ther Bull 1995 Sep;33(9):67–70 (31 ref.)

Counseling patients about allergic rhinitis. Swanson KA.
J Am Pharm Assoc (Wash) 1996 May;NS36(5):300–7 (40 ref.)

Lumbar and caudal epidural corticosteroid injections. Spaccarelli KC. **Mayo Clin Proc** 1996 Feb;71(2):169–78 (109 ref.)

Prenatal and postnatal: use of corticosteroids. Corbett JV, et al. **MCN Am J Matern Child Nurs** 1995 Nov–Dec; 20(6):346 (9 ref.)

Contemporary concepts in spine care. Epidural steroid injections. Weinstein SM, et al. **Spine** 1995 Aug 15; 20(16):1842–6 (46 ref.)

ADVERSE EFFECTS

Chronic finger dermatitis after trauma. Diagnosis: posttraumatic eczema with allergic contact dermatitis to neomycin, bacitracin, and topical corticosteroids. Sherertz EF. **Arch Dermatol** 1996 Apr;132(4):461, 464 (11 ref.)

Side-effects of drugs used in the treatment of rheumatoid arthritis. Evans PJ, et al. **Biochem Soc Symp** 1995; 61:195–207 (49 ref.)

Controversies involving inhaled beta-agonists and inhaled corticosteroids in the treatment of asthma. Fahy JV, et al. **Clin Chest Med** 1995 Dec;16(4):715–33 (145 ref.)

Benefits and risks of intralesional corticosteroid injection in the treatment of dermatological diseases. Firooz A, et al. **Clin Exp Dermatol** 1995 Sep;20(5):363–70 (79 ref.)

The neuropsychiatric complications of corticosteroid therapy. Vincent FM. **Compr Ther** 1995 Sep;21(9):524–8 (22 ref.)

Sensitisation to corticosteroids. Consequences for anti-inflammatory therapy. Dooms-Goossens A.
Drug Saf 1995 Aug;13(2):123–9 (47 ref.)

Corticosteroids in kidney transplant recipients. Safety issues and timing of discontinuation. Tarantino A, et al.
Drug Saf 1995 Sep;13(3):145–56 (120 ref.)

Aortic aneurysms in patients with autoimmune disorders treated with corticosteroids. Sato O, et al.
Eur J Vasc Endovasc Surg 1995 Oct;10(3):366–9 (17 ref.)

Physiologic basis of steroid-induced immunosuppression. Effects on lymphocyte migration to lymph nodes. Sackstein R. **J Fla Med Assoc** 1995 Sep;82(9):613–5 (22 ref.)

Spinal epidural lipomatosis as a complication of prolonged corticosteroid therapy. Zentner J, et al.
J Neurosurg Sci 1995 Mar;39(1):81–5 (23 ref.)

Peracute disseminated fatal Aspergillus fumigatus sepsis as a complication of corticoid-treated systemic lupus erythematosus. Nenoff P, et al. **Mycoses** 1995 Nov–Dec; 38(11–12):467–71 (21 ref.)

[Maternal corticotherapy . Pharmacology and effect on the fetus] Guillonneau M, et al.
J Gynecol Obstet Biol Reprod (Paris) 1996;25(2):160–7 (53 ref.) (Eng. Abstr.) **(Fre)**

[Steroid-induced psychoses] Whitworth AB, et al.
Hautarzt 1995 Sep;46(9):666–73; quiz 672 (34 ref.) **(Ger)**

[Drug induced obesity] Murakami T, et al.
Nippon Rinsho 1995 Jun;53 Suppl:425–9 (16 ref.) **(Jpn)**

[Dysphonia produced by corticoid inhalation: truth or myth?] Bonet Agustí M, et al. **Arch Bronconeumol** 1995 Oct; 31(8):415–7 (10 ref.) (Eng. Abstr.) **(Spa)**

ANALYSIS

High-performance liquid chromatographic analysis of corticosteroids. Volin P. **J Chromatogr B Biomed Appl** 1995 Sep 15;671(1–2):319–40 (162 ref.)

ANTAGONISTS & INHIBITORS

[Corticoid-resistant rejection and humoral rejection. The diagnostic criteria and therapeutic management] Crespo Leiro MG, et al. **Rev Esp Cardiol** 1995;48 Suppl 7:77–85 (29 ref.) (Eng. Abstr.) **(Spa)**

BLOOD

Do the salutary effects of food restriction occur because of or despite of the accompanying hyperadrenocorticism? Sapolsky RM. **Neurobiol Aging** 1995 Sep–Oct;16(5):849–50; discussion 855–6 (5 ref.)

GENETICS

Genetic disorders of steroid hormone synthesis and metabolism. New MI, et al.
Baillieres Clin Endocrinol Metab 1995 Jul;9(3):525–54 (127 ref.)

Molecular biology in reproductive endocrinology. Layman LC. **Curr Opin Obstet Gynecol** 1995 Oct;7(5):328–39 (104 ref.)

METABOLISM

Corticosteroid metabolism in isolated perfused rat liver and kidney. Experimental studies with emphasis on aldosterone. Egfjord M. **Acta Physiol Scand Suppl** 1995;627:1–42 (226 ref.)

Corticosteroid hypertension. Funder JW.
Curr Opin Nephrol Hypertens 1995 Sep;4(5):432–7 (39 ref.)

PHARMACOLOGY

Effects of K+, Mg2+ deficiency and adrenal steroids on Na+, K(+)-pump concentration in skeletal muscle. Dørup I. **Acta Physiol Scand** 1996 Mar;156(3):305–11 (51 ref.)

PHYSIOLOGY

Actions of placental and fetal adrenal steroid hormones in primate pregnancy. Pepe GJ, et al. **Endocr Rev** 1995 Oct; 16(5):608–48 (617 ref.)

Steroids, stability and stress. de Kloet ER.
Front Neuroendocrinol 1995 Oct;16(4):416–25 (41 ref.)

Regulation of 5-HT receptors by corticosteroids: where do we stand? Chaouloff F. **Fundam Clin Pharmacol** 1995; 9(3):219–33 (82 ref.)

Stress and the brain: a paradoxical role for adrenal steroids. McEwen BS, et al. **Vitam Horm** 1995;51:371–402 (113 ref.)

[Gastric stress ulcers: the protective role of hormones of the hypothalamo-hypophyseal-adrenocortical system] Filaretova LP. **Fiziol Zh Im I M Sechenova** 1995 Mar; 81(3):50–60 (80 ref.) (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Corticosteroid injection therapy for overuse injuries. Nelson KH, et al. **Am Fam Physician** 1995 Nov 1;52(6):1811–6 (31 ref.)

The adjuvant therapy of pemphigus. An update. Bystryn JC, et al. **Arch Dermatol** 1996 Feb;132(2):203–12 (89 ref.)

Prevention of preterm birth. Owen P, et al.
Baillieres Clin Obstet Gynaecol 1995 Sep;9(3):465–79 (96 ref.)

Intravenous immune globulin: an alternative therapy in steroid-dependent allergic diseases. Gelfand EW, et al.
Clin Exp Immunol 1996 May;104 Suppl 1:61–6 (56 ref.)

The clinical use of antenatal corticosteroids. Gardner MO, et al. **Clin Obstet Gynecol** 1995 Dec;38(4):746–54 (39 ref.)

Treatment of scleroderma. Gelber AC, et al.
Curr Opin Rheumatol 1995 Nov;7(6):551–9 (66 ref.)

Articular and periarticular corticosteroid injections.
Drug Ther Bull 1995 Sep;33(9):67–70 (31 ref.)

What is the role of corticosteroids in meningitis? Harvey DR, et al. **Drugs** 1995 Dec;50(6):945–50 (58 ref.)

Alternative epilepsy therapies: the ketogenic diet, immunoglobulins, and steroids. Prasad AN, et al.
Epilepsia 1996;37 Suppl 1:S81–95 (106 ref.)

Allergic rhinoconjunctivitis: current therapy. Hollingsworth HM. **Hosp Pract (Off Ed)** 1996 Jun 15;31(6):61–2, 65–7, 71–3 (12 ref.)

Adjuncts to antibacterial therapy. Frank MO, et al.
Infect Dis Clin North Am 1995 Sep;9(3):769–81 (63 ref.)

New therapeutic approaches in sepsis: a critical review. Eidelman LA, et al. **Intensive Care Med** 1995 Nov;21 Suppl 2:S269–72 (18 ref.)

Inhaled corticosteroids: benefits and risks [see comments] Robinson DS, et al. **J Asthma** 1996;33(1):5–16 (103 ref.) Comment in: J Asthma 1996;33(1):1–3.

Role of corticosteroids in cystic fibrosis lung disease. Balfour-Lynn IM, et al. **J R Soc Med** 1996;89 Suppl 27:8–13 (37 ref.)

Are corticosteroids really necessary in renal transplantation? Ponticelli C, et al. **Nephrol Dial Transplant** 1995; 10(9):1587–91 (36 ref.)

Does the treatment of cryptogenic fibrosing alveolitis influence prognosis? Egan JJ, et al. **Respir Med** 1996 Mar; 90(3):127–30 (26 ref.)

Adjunctive corticosteroid therapy in bacterial meningitis. Lauritsen A, et al. **Scand J Infect Dis** 1995;27(5):431–4 (25 ref.)

[Indication of corticotherapy for fetal pulmonary maturation] Tchobroutsky C. **Contracept Fertil Sex** 1996 May; 24(5):413–6 (11 ref.) (Eng. Abstr.) **(Fre)**

[Value of corticoids in hematology/oncology in adulthood] Schlimok G, et al. **Med Klin** 1995 Oct 15;90(10):579–84 (23 ref.) **(Ger)**

[Pemphigus vulgaris. Clinical aspects, pathophysiology and therapy of a bullous autoimmune dermatosis] Sunderkötter CH, et al. **Med Monatsschr Pharm** 1995 Sep;18(9):255–63 (39 ref.) **(Ger)**

[Immunosuppressive therapy of vasculitis: current aspects and perspectives] Giacomelli R, et al.
Recenti Prog Med 1996 Mar;87(3):124–34 (74 ref.) (Eng. Abstr.) **(Ita)**

[Pharmacological treatment of migraine: other treatments] Gómez Aranda F, et al. **Rev Neurol** 1995;23 Suppl 2:S198–200 (43 ref.) **(Spa)**

[Approach to the diagnosis and therapy of vascular neuropathy] Hernández MA, et al. **Rev Neurol** 1995 Sep–Oct;23(123):1008–12 (40 ref.) (Eng. Abstr.) **(Spa)**

[Prophylactic treatment of episodic forms of cluster headache] Liaño H, et al. **Rev Neurol** 1995;23 Suppl 4:S525–9 (29 ref.) **(Spa)**

ADRENAL CORTEX NEOPLASMS

COMPLICATIONS

Isolated clinical syndrome of primary aldosteronism in a

patient with adrenocortical carcinoma. Case report and review of the literature. Weingärtner K, et al. **Urol Int** 1995;55(4):232–5 (15 ref.)

DIAGNOSIS

Adrenal carcinoma in a patient with Gardner's syndrome: imaging findings. Traill Z, et al. **AJR Am J Roentgenol** 1995 Dec;165(6):1460–1 (8 ref.)

[Adrenal cortex carcinoma—progress in diagnosis and therapy] Lizakowska-Kmieć M, et al. **Pol Arch Med Wewn** 1995 Dec;94(6):525–32 (32 ref.) **(Pol)**

PATHOLOGY

[Morphological typing, evaluation of tumor dignity and prognosis and etiologic classification of adrenomedullary and adrenocortical neoplasias] Schröder S, et al. **Pathologe** 1995 Sep;16(5):307–14 (57 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

[Role of hormonal receptor abnormalities in the physiopathology of adrenocortical tumors] Lacroix A. **Ann Endocrinol (Paris)** 1995;56(6):614–6 (21 ref.) **(Fre)**

SECRETION

A case of deoxycorticosterone-producing adrenal adenoma. Wada N, et al. **Endocr J** 1995 Oct;42(5):637–42 (29 ref.)

THERAPY

[Adrenal cortex carcinoma—progress in diagnosis and therapy] Lizakowska-Kmieć M, et al. **Pol Arch Med Wewn** 1995 Dec;94(6):525–32 (32 ref.) **(Pol)**

ADRENAL CORTICAL REST TUMOR see **ADRENAL REST TUMOR**

ADRENAL GLAND DISEASES

COMPLICATIONS

[Unilateral spontaneous adrenal hematoma: an unusual cause of retroperitoneal hemorrhage] Vendrell JR, et al. **Actas Urol Esp** 1996 Jan;20(1):59–62 (12 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Incidentally discovered adrenal masses. Kloos RT, et al. **Endocr Rev** 1995 Aug;16(4):460–84 (253 ref.)

Spontaneous unilateral adrenal hemorrhage: computerized tomography and magnetic resonance imaging findings in 8 cases. Hoeffel C, et al. **J Urol** 1995 Nov;154(5):1647–51 (24 ref.)

Contrast-enhanced MR imaging of the kidneys and adrenal glands. Huch Böni RA, et al. **Magn Reson Imaging Clin N Am** 1996 Feb;4(1):101–31 (61 ref.)

The incidental adrenal mass. Korobkin M, et al. **Radiol Clin North Am** 1996 Sep;34(5):1037–54 (54 ref.)

Adrenal imaging. Korobkin M, et al. **Semin Ultrasound CT MR** 1995 Aug;16(4):317–30 (45 ref.)

[Imaging of adrenal gland diseases] Taillefer R, et al. **Ann Endocrinol (Paris)** 1995;56(5):507–8 (4 ref.) **(Fre)**

PATHOLOGY

[A giant adrenal mass: the anatomicopathological surprise finding] Mármol Navarro S, et al. **Arch Esp Urol** 1995 Nov; 48(9):949–51 (8 ref.) (Eng. Abstr.) **(Spa)**

SURGERY

Laparoscopic surgery for adrenal lesions. Brown JP, et al. **Semin Surg Oncol** 1996 Mar–Apr;12(2):96–9 (12 ref.)

ADRENAL GLAND HYPERFUNCTION

see related
HYPERANDROGENISM

COMPLICATIONS

Do the salutary effects of food restriction occur because of or despite of the accompanying hyperadrenocorticism? Sapolsky RM. **Neurobiol Aging** 1995 Sep–Oct;16(5):849–50; discussion 855–6 (5 ref.)

DRUG THERAPY

Canine pituitary-dependent hyperadrenocorticism: a spontaneous animal model for neurodegenerative disorders and their treatment with l-deprenyl. Bruyette DS, et al. **Prog Brain Res** 1995;106:207–15 (30 ref.)

ETIOLOGY

[Food-dependent Cushing syndrome: a new entity of organic hypercorticism] Matejka G, et al. **Rev Med Interne** 1996; 17(6):461–6 (23 ref.) (Eng. Abstr.) **(Fre)**

ADRENAL GLAND HYPOFUNCTION

COMPLICATIONS

Adrenal insufficiency in the antiphospholipid antibody syndrome. Arnason JA, et al. **Semin Arthritis Rheum** 1995 Oct;25(2):109–16 (27 ref.)

CONGENITAL

The gene responsible for adrenal hypoplasia congenita, DAX-1, encodes a nuclear hormone receptor that defines a new class within the superfamily. Burris TP, et al. **Recent Prog Horm Res** 1996;51:241–59; discussion 259–60 (94 ref.)

DIAGNOSIS

Diagnostic significance of dopamine estimation using plasma and urine in patients with adrenal and renal insufficiency, renal transplantation and hypertension. Yoshimura M, et al. **Hypertens Res** 1995 Jun;18 Suppl 1:S87–92 (31 ref.)

DRUG THERAPY

[Glucocorticoid treatment] Kauppinen-Mäkelin R. **Duodecim** 1995;111(8):725–31 (28 ref.) **(Fin)**

GENETICS

The gene responsible for adrenal hypoplasia congenita, DAX-1, encodes a nuclear hormone receptor that defines a new class within the superfamily. Burris TP, et al. **Recent Prog Horm Res** 1996;51:241–59; discussion 259–60 (94 ref.)

PATHOLOGY

Angiotropic large cell lymphoma presenting as primary adrenal insufficiency. Chu P, et al. **Hum Pathol** 1996 Feb; 27(2):209–11 (24 ref.)

ADRENAL GLAND NEOPLASMS

[Pheochromocytoma and pregnancy. Two case reports] Barhmi R, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995; 24(5):543–8 (24 ref.) (Eng. Abstr.) **(Fre)**

[Adrenal hemangioma: review of the literature] Llado Carbonell C, et al. **Prog Urol** 1996 Apr;6(2):292–6 (38 ref.) (Eng. Abstr.) **(Fre)**

[Adrenal myelolipoma. Report of a case and review of the literature] Bordallo Cortina A, et al. **Arch Esp Urol** 1996 Mar;49(2):184–7 (18 ref.) (Eng. Abstr.) **(Spa)**

COMPLICATIONS

Acute reversal of pheochromocytoma-induced catecholamine cardiomyopathy. Nanda AS, et al. **Clin Cardiol** 1995 Jul;18(7):421–3 (8 ref.)

Conn syndrome in a child, caused by adrenal adenoma. Abasiyanik A, et al. **J Pediatr Surg** 1996 Mar;31(3):430–2 (15 ref.)

Aldosteronoma in childhood [letter; comment] Etker S. **J Pediatr Surg** 1995 Jul;30(7):1113 (15 ref.) Comment on: J Pediatr Surg 1994 Oct;29(10):1388–91.

[Tumors outside of the central nervous system in Von Hippel-Lindau disease] Veltman GA, et al. **Ned Tijdschr Geneeskd** 1996 Apr 13;140(15):823–6 (33 ref.) **(Dut)**

DIAGNOSIS

The incidental adrenal mass. Cook DM, et al. **Am J Med** 1996 Jul;101(1):88–94 (03 ref.)

Investigation of phaeochromocytoma. Bouloux PG, et al. **Clin Endocrinol (Oxf)** 1995 Dec;43(6):657–64 (31 ref.)

Preoperative endocrine tumor localization utilizing a cost-effective approach. Leight GS Jr, et al. **Curr Opin Gen Surg** 1993;:108–14 (19 ref.)

Incidentally discovered adrenal tumors. Saxe A. **Curr Opin Gen Surg** 1993;:121–9 (50 ref.)

The characteristics of nine patients with adrenal incidentalomas. Kamel N, et al. **Endocr J** 1995 Aug; 42(4):497–503 (21 ref.)

Incidentally discovered adrenal masses. Kloos RT, et al. **Endocr Rev** 1995 Aug;16(4):460–84 (253 ref.)

Contrast-enhanced MR imaging of the kidneys and adrenal glands. Huch Böni RA, et al. **Magn Reson Imaging Clin N Am** 1996 Feb;4(1):101–31 (61 ref.)

Adrenal incidentaloma: subclinical Cushing's syndrome. Newell-Price J, et al. **Postgrad Med J** 1996 Apr; 72(846):207–10 (27 ref.)

[Adrenal gland carcinoma—status of diagnostic and therapeutic possibilities] Wunderlich H, et al. **Z Arztl Fortbild (Jena)** 1996 May;90(3):221–6 (16 ref.) (Eng. Abstr.) **(Ger)**

[Imaging diagnosis in a case of adrenal cystic ganglioneuroblastoma in a child] Miele V, et al. **Radiol Med (Torino)** 1996 Apr;91(4):485–8 (11 ref.) **(Ita)**

[Cystic lymphangioma of the adrenal gland] Duca S, et al. **Chirurgia (Bucur)** 1995;44(1):43–7 (8 ref.) **(Rum)**

[Adrenal myelolipoma: apropos a case with urologic symptomatology. A review of the literature] Pérez Arbej JA, et al. **Actas Urol Esp** 1995 Mar;19(3):243–6 (27 ref.) (Eng. Abstr.) **(Spa)**

[Pheochromocytoma in children: 2 cases] Fernández Córdoba MS, et al. **An Esp Pediatr** 1996 Mar;44(3):277–8 (6 ref.) **(Spa)**

[Laboratory contribution to the diagnosis of pheochromocytoma] Rivero Marcotegui A, et al. **An Med Interna** 1996 Jan;13(1):40–4 (60 ref.) **(Spa)**

[Incidental adrenal masses] López Hernández E, et al. **Rev Clin Esp** 1995 Dec;195(12):873–81 (85 ref.) **(Spa)**

ETIOLOGY

Primary adrenal leiomyosarcoma in a man with acquired immunodeficiency syndrome (AIDS). Further evidence for an increase in smooth muscle tumors related to Epstein-Barr infection in AIDS. Zetler PJ, et al. **Arch Pathol Lab Med** 1995 Dec;119(12):1164–7 (19 ref.)

GENETICS

Primary adrenal lymphoma with chromosomal abnormalities. Sasagawa I, et al. **Acta Haematol** 1995;94(3):156–62 (34 ref.)

[Familial neuroblastoma] Nakamura M, et al. **Nippon Rinsho** 1995 Nov;53(11):2684–7 (12 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Radiation therapy of metastatic pheochromocytoma: case report and review of the literature. Yu L, et al. **Am J Clin Oncol** 1996 Aug;19(4):389–93 (29 ref.)

Histologic, flow cytometric, and genetic criteria in endocrine surgery. Flynn SD, et al. **Curr Opin Gen Surg** 1993;:115–20 (45 ref.)

Two cases of pheochromocytoma diagnosed histopathologically as mixed neuroendocrine-neural tumor. Watanabe T, et al. **Intern Med** 1995 Jul;34(7):683–7 (47 ref.)

Adrenal gland leiomyoma in a child with acquired immunodeficiency syndrome. Jimenez-Heffernan JA, et al. **Pediatr Pathol Lab Med** 1995 Nov–Dec;15(6):923–9 (22 ref.)

[Morphological typing, evaluation of tumor dignity and prognosis and etiologic classification of adrenomedullary and adrenocortical neoplasias] Schröder S, et al. **Pathologe** 1995 Sep;16(5):307–14 (57 ref.) (Eng. Abstr.) **(Ger)**

[A giant adrenal mass: the anatomicopathological surprise finding] Mármol Navarro S, et al. **Arch Esp Urol** 1995 Nov; 48(9):949–51 (8 ref.) (Eng. Abstr.) **(Spa)**

RADIOGRAPHY

[Giant myelolipoma of the adrenals. A report of 3 cases studied by CT and a review of the literature] Catalano O, et al. **Radiol Med (Torino)** 1995 Dec;90(6):842–6 (53 ref.) **(Ita)**

[A woman with a unilateral adrenal mass. The adrenal metastasis of a medullary carcinoma of the thyroid] Maroto P, et al. **Rev Clin Esp** 1995 Dec;195(12):847–8 (5 ref.) **(Spa)**

SECONDARY

[Renal cell carcinoma with solitary asynchronous adrenal metastasis] Maeda Y, et al. **Hinyokika Kiyo** 1996 Jan; 42(1):39–42 (22 ref.) (Eng. Abstr.) **(Jpn)**

[Asynchronous metastases solely to the bilateral adrenal glands from bladder cancer: a case report] Watanabe J, et al. **Hinyokika Kiyo** 1996 Jan;42(1):63–6 (7 ref.) (Eng. Abstr.) **(Jpn)**

[Single metastasis of renal adenocarcinoma in contralateral adrenal gland] Diego García A, et al. **Actas Urol Esp** 1995 Apr;19(4):314–8; discussion 318–9 (20 ref.) (Eng. Abstr.) **(Spa)**

[A woman with a unilateral adrenal mass. The adrenal metastasis of a medullary carcinoma of the thyroid] Maroto P, et al. **Rev Clin Esp** 1995 Dec;195(12):847–8 (5 ref.) **(Spa)**

SECRETION

Pheochromocytoma and secondary erythrocytosis: role of tumour erythropoietin secretion. Drénou B, et al. **Nouv Rev Fr Hematol** 1995;37(3):197–9 (18 ref.)

SURGERY

Primary aldosteronism in pregnancy—should it be treated surgically? Aboud E, et al. **Ir J Med Sci** 1995 Oct–Dec; 164(4):279–80 (12 ref.)

Cystic neuroblastoma of infancy. Richards ML, et al. **J Pediatr Surg** 1995 Sep;30(9):1354–7 (16 ref.)

[Laparoscopic adrenalectomy in pheochromocytoma] Vogelbach P, et al. **Schweiz Med Wochenschr** 1995 Sep 16;125(37):1735–9 (25 ref.) (Eng. Abstr.) **(Ger)**

URINE

The clinical and laboratory correlates of an increased urinary 5-hydroxyindoleacetic acid. Tormey WP, et al. **Postgrad Med J** 1995 Sep;71(839):542–5 (16 ref.)

ADRENAL GLANDS

see related
ADRENALECTOMY

BLOOD SUPPLY

[Opening of the left V. spermatica interna into the left V. suprarenalis] Risse JH, et al.
Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1995 Oct;163(4):364–6 (9 ref.) **(Ger)**

EMBRYOLOGY

Hypothalamic pituitary adrenal function in the sheep fetus. Matthews SG, et al. **Reprod Fertil Dev** 1995;7(3):509–16 (52 ref.)

METABOLISM

Adrenal androgen production in polycystic ovary syndrome. McKenna TJ, et al. **Eur J Endocrinol** 1995 Oct;133(4):383–9 (35 ref.)
The adrenal renin-angiotensin system: a local hormonal regulator of aldosterone production. Mulrow PJ, et al. **J Hypertens** 1996 Feb;14(2):173–6 (41 ref.)

PATHOLOGY

Til death do us part: a case of failed affection. Weber KT, et al. **Cardiovasc Res** 1995 Jul;30(1):26–30 (32 ref.)
Angiotropic large cell lymphoma presenting as primary adrenal insufficiency. Chu P, et al. **Hum Pathol** 1996 Feb; 27(2):209–11 (24 ref.)
Contrast-enhanced MR imaging of the kidneys and adrenal glands. Huch Böni RA, et al.
Magn Reson Imaging Clin N Am 1996 Feb;4(1):101–31 (61 ref.)

PHYSIOLOGY

The adrenal renin/angiotensin system. Vinson GP. **Adv Exp Med Biol** 1995;377:237–51 (135 ref.)
Dynamics of the regulation of the hypothalamo-pituitary-adrenal (HPA) axis determined using a nonsurgical method for collecting pituitary venous blood from horses. Alexander SL, et al.
Front Neuroendocrinol 1996 Jan;17(1):1–50 (220 ref.)
Comparative aspects of regulation and function of the adrenal complex in different groups of vertebrates. Hanke W, et al. **Horm Metab Res** 1995 Sep;27(9):389–97 (29 ref.)
Role for endogenous dopamine in modulating sympathetic-adrenal activity in humans. Mannelli M, et al. **Hypertens Res** 1995 Jun;18 Suppl 1:S79–86 (92 ref.)
Mechanisms of catecholamine secretion from adrenal chromaffin cells. Burgoyne RD. **J Physiol Pharmacol** 1995 Sep;46(3):273–83 (45 ref.)
[The participation of enteral mechanisms in the sympathetic-adrenal inhibition of gastric secretion] Trefilov AB. **Usp Fiziol Nauk** 1995 Jan-Mar;26(1):76–92 (79 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

[Endocrine function (pituitary, thyroid, adrenal gland) of obesity] Ogino Y, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:316–9 (13 ref.) **(Jpn)**

SECRETION

Adrenal androgen action in breast cancer. Boccuzzi G, et al. **Ann N Y Acad Sci** 1996 Apr 30;784:349–61 (55 ref.)

ULTRASONOGRAPHY

[Ultrasound in the study of the adrenal glands] Kuznetsov NS, et al. **Khirurgiia (Mosk)** 1996;(1):75–6 (44 ref.) **(Rus)**

ULTRASTRUCTURE

Na-Ca exchange in Ca2+ signaling and neurohormone secretion. Secretory vesicle contributions in adrenal chromaffin cells. Schneider AS, et al.
Ann N Y Acad Sci 1996 Apr 15;779:356–65 (17 ref.)

ADRENAL GLOMERULOSA see **ZONA GLOMERULOSA**

ADRENAL HYPERPLASIA, CONGENITAL

see related
PUBERTY, PRECOCIOUS
VIRILISM

COMPLICATIONS

[Congenital adrenal hyperplasia and testicular hypertrophy] Dieckmann K, et al. **Arch Pediatr** 1995 Dec;2(12):1167–72 (20 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Congenital adrenal hyperplasia: molecular genetics and alternative approaches to treatment. Laue L, et al.
Adv Pediatr 1995;42:113–43 (55 ref.)
[21-hydroxylase deficiency. Review of the biochemical characteristics and their diagnostic implications] Campos López-Carrión M, et al. **Rev Clin Esp** 1995 Aug; 195(8):571–7 (81 ref.) **(Spa)**

GENETICS

Congenital adrenal hyperplasia: molecular genetics and alternative approaches to treatment. Laue L, et al.
Adv Pediatr 1995;42:113–43 (55 ref.)

ADRENAL MEDULLA

Adrenal cortical and medullary imaging. Freitas JE. **Semin Nucl Med** 1995 Jul;25(3):235–30 (63 ref.)

PATHOLOGY

[Morphological typing, evaluation of tumor dignity and prognosis and etiologic classification of adrenomedullary and adrenocortical neoplasias] Schröder S, et al.
Pathologe 1995 Sep;16(5):307–14 (57 ref.) (Eng. Abstr.) **(Ger)**

TRANSPLANTATION

Chromaffin cell survival and host dopaminergic fiber recovery in a patient with Parkinson's disease treated by cografts of adrenal medulla and pretransected peripheral nerve. Case report. Date I, et al. **J Neurosurg** 1996 Apr; 84(4):685–9 (33 ref.)

ADRENAL REST TUMOR

[Adrenal rest tumor of the liver] Miyazaki I, et al.
Ryoikibetsu Shokogun Shirizu 1995;(7):285–7 (10 ref.) **(Jpn)**

ADRENALECTOMY

Laparoscopic adrenalectomy [editorial; comment] Prinz RA. **J Am Coll Surg** 1996 Jul;183(1):71–3 (9 ref.) Comment on: J Am Coll Surg 1996 Jul;183(1):1–10.
Laparoscopic adrenalectomy. Gagner M.
Surg Clin North Am 1996 Jun;76(3):523–37 (25 ref.)

ADVERSE EFFECTS

Primary aldosteronism. Results of surgical treatment. Lo CY, et al. **Ann Surg** 1996 Aug;224(2):125–30 (23 ref.)

METHODS

[Laparoscopic adrenalectomy in pheochromocytoma] Vogelbach P, et al. **Schweiz Med Wochenschr** 1995 Sep 16;125(37):1735–9 (25 ref.) (Eng. Abstr.) **(Ger)**

ADRENALINE see **EPINEPHRINE**

ADRENERGIC AGENTS

see related
SYMPATHOLYTICS
SYMPATHOMIMETICS

PHARMACOLOGY

Autonomic receptor--effector coupling during post-natal development. Robinson RB. **Cardiovasc Res** 1996 Feb;31 Spec No:E68–76 (68 ref.)

THERAPEUTIC USE

[Drug treatment of obesity] Yoshida T. **Nippon Rinsho** 1995 Jun;53 Suppl:481–6 (20 ref.) **(Jpn)**

ADRENERGIC ALPHA-AGONISTS

Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. Ruffolo RR Jr, et al. **J Med Chem** 1995 Sep 15;38(19):3681–716 (317 ref.)

ADVERSE EFFECTS

Medications used to prevent migraine headaches and their potential ocular adverse effects. Doughty MJ, et al.
Optom Vis Sci 1995 Dec;72(12):879–91 (176 ref.)

METABOLISM

Imidazoline receptors and their endogenous ligands. Regunathan S, et al. **Annu Rev Pharmacol Toxicol** 1996; 36:511–44 (168 ref.)

PHARMACOLOGY

Nitric oxide synthase inhibitors. Preclinical studies of potential use for treatment of opioid withdrawal. Vaupel DB, et al. **Neuropsychopharmacology** 1995 Dec; 13(4):315–22 (27 ref.)

THERAPEUTIC USE

Second-line and 'alternative' treatments for alcohol withdrawal: alpha-agonists, beta-blockers, anticonvulsants, acupuncture and neuro-electric therapy. Brewer C.
Alcohol Alcohol 1995 Nov;30(6):799–803 (25 ref.)
Is clonidine an effective smoking cessation therapy? Gourlay SG, et al. **Drugs** 1995 Aug;50(2):197–207 (83 ref.)

ADRENERGIC ALPHA-ANTAGONISTS

Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. Ruffolo RR Jr, et al. **J Med Chem** 1995 Sep 15;38(19):3681–716 (317 ref.)
[Discovery and development of tamsulosin hydrochloride, a new alpha 1-adrenoceptor antagonist] Takenaka T, et al. **Yakugaku Zasshi** 1995 Oct;115(10):773–89 (42 ref.) (Eng. Abstr.) **(Jpn)**

BLOOD

[Alpha-blocker] Mikami H. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:974–7 (19 ref.) **(Jpn)**

CLASSIFICATION

Alpha 1-adrenoceptors: pharmacological classification and newer therapeutic applications. Ruffolo RR Jr, et al.
Proc West Pharmacol Soc 1995;38:121–6 (59 ref.)

METABOLISM

Imidazoline receptors and their endogenous ligands. Regunathan S, et al. **Annu Rev Pharmacol Toxicol** 1996; 36:511–44 (168 ref.)

POISONING

Poisoning with anti-hypertensive drugs: alpha-adrenoceptor antagonists. Lip GY, et al. **J Hum Hypertens** 1995 Jul; 9(7):523–6 (21 ref.)

THERAPEUTIC USE

Alpha blockers: a reassessment of their role in therapy. Cauffield JS, et al. **Am Fam Physician** 1996 Jul;54(1):263–6, 269–70 (22 ref.)
Blood pressure-lowering effect of adding grapefruit juice to nifedipine and terazosin in a patient with severe renovascular hypertension. Pisarik P. **Arch Fam Med** 1996 Jul-Aug;5(7):413–6 (17 ref.)
Doxazosin: a new approach to hypertension and benign prostatic hyperplasia. Pool JL. **Br J Clin Pract** 1996 Apr-May;50(3):154–63 (70 ref.)
Benign prostatic hyperplasia: pathophysiology and pharmacological treatment. Madsen FA, et al.
Curr Opin Nephrol Hypertens 1995 Sep;4(5):455–9 (23 ref.)
Consensus meeting on new approaches in the pharmacotherapy of benign prostatic hyperplasia (BPH). Proceedings of the meeting held on the 8th and 9th October 1994 in St. Tropez, France, under the patronage of the International Academy of Biomedical and Drug Research. **Eur Urol** 1996;29(3):374–84 (52 ref.)
Selective alpha 1-adrenoceptor antagonists in benign prostatic hyperplasia: rationale and clinical experience. Chapple CR. **Eur Urol** 1996;29(2):129–44 (67 ref.)
Hypertension and CHD risk: whither alpha-1 blockers? Pandit RB. **Indian Heart J** 1996 May-Jun;48(3):265–71 (41 ref.)
Benign prostatic hyperplasia. Current strategy and pharmacotherapeutical potential. Dutkiewicz S. **Mater Med Pol** 1995 Jan-Mar;27(1):3–6 (41 ref.)
Alpha 1-adrenoceptors: pharmacological classification and newer therapeutic applications. Ruffolo RR Jr, et al.
Proc West Pharmacol Soc 1995;38:121–6 (59 ref.)
[Medical treatment of benign hypertrophy of the prostate] Bensadoun H. **Presse Med** 1995 Oct 28;24(32):1485–9 (16 ref.) (Eng. Abstr.) **(Fre)**
[Current drug therapy of benign prostatic hyperplasia] Schmidbauer CP, et al. **Wien Med Wochenschr** 1996; 146(8):161–4 (12 ref.) (Eng. Abstr.) **(Ger)**
[Controversies in the treatment of arterial hypertension: other drugs as the first step (calcium antagonists, ACE inhibitors and alpha-blockers)] Castro Beiras A, et al.
Rev Esp Cardiol 1995;48 Suppl 4:72–80 (31 ref.) (Eng. Abstr.) **(Spa)**

ADRENERGIC ALPHA-RECEPTOR AGONISTS see **ADRENERGIC ALPHA-AGONISTS**

ADRENERGIC ALPHA RECEPTOR BLOCKADERS see **ADRENERGIC ALPHA-ANTAGONISTS**

ADRENERGIC ALPHA-RECEPTORS see **RECEPTORS, ADRENERGIC, ALPHA**

ADRENERGIC ALPHA-1 RECEPTORS see **RECEPTORS, ADRENERGIC, ALPHA-1**

ADRENERGIC ALPHA-2 RECEPTORS see **RECEPTORS, ADRENERGIC, ALPHA-2**

ADRENERGIC ANTAGONISTS

see related
SYMPATHOLYTICS

ADRENERGIC BETA-AGONISTS

Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. Ruffolo RR Jr, et al. **J Med Chem** 1995 Sep

15;38(19):3681–716 (317 ref.)
[Evaluation of the beta-adrenergic receptor agonists] Liang B, et al. **Chung Hua Chieh Ho Ho Hu Hsi Tsa Chih** 1995 Jun;18(3):133–5 (17 ref.) **(Chi)**

ADMINISTRATION & DOSAGE

[Modes of administration of beta agonists in asthma] Salmeron S, et al. **Rev Pneumol Clin** 1996;52(2):119–27 (76 ref.) (Eng. Abstr.) **(Fre)**
[Therapy of asthma using bronchodilator agents—special reference to adrenergic beta 2-receptor agonists] Kurosawa M, et al. **Nippon Naika Gakkai Zasshi** 1996 Feb 10; 85(2):210–5 (5 ref.) **(Jpn)**

ADVERSE EFFECTS

B2 agonists and their safety in the treatment of asthma. Fireman P. **Allergy Proc** 1995 Sep–Oct;16(5):235–9 (22 ref.)
Controversies involving inhaled beta-agonists and inhaled corticosteroids in the treatment of asthma. Fahy JV, et al. **Clin Chest Med** 1995 Dec;16(4):715–33 (145 ref.)
Asthma and the beta 2-agonist controversy: much ado about something. Lieberman JS, et al. **Del Med J** 1995 Dec; 67(12):624–8 (28 ref.)
Asthma and the beta agonist debate. Crane J, et al. **Thorax** 1995 Sep;50 Suppl 1:S5–10 (37 ref.)

ANALYSIS

Methods for the determination of beta-agonists in biological matrices. A review. Boyd D, et al. **Analyst** 1996 Jan; 121(1):1R–10R (115 ref.)

DIAGNOSTIC USE

[Echocardiography with pharmacological stress: dobutamine or dipyridamole?] Salustri A, et al. **G Ital Cardiol** 1996 Apr;26(4):447–53 (45 ref.) **(Ita)**

METABOLISM

[Role of hormonal receptor abnormalities in the physiopathology of adrenocortical tumors] Lacroix A. **Ann Endocrinol (Paris)** 1995;56(6):614–6 (21 ref.) **(Fre)**

PHARMACOLOGY

Long-and short-acting beta 2-adrenergic agonists. Effects on airway function in patients with asthma. Busse WW. **Arch Intern Med** 1996 Jul 22;156(14):1514–20 (63 ref.)
Beta 3-adrenoceptors and intestinal motility. Manara L, et al. **Fundam Clin Pharmacol** 1995;9(4):332–42 (70 ref.)
Pharmacological basis for duration of effect: formoterol and salmeterol versus short-acting beta 2-adrenoceptor agonists. Lindén A, et al. **Lung** 1996;174(1):1–22 (52 ref.)

THERAPEUTIC USE

Salmeterol for the treatment of asthma [editorial; comment] Weinberger M. **Ann Allergy Asthma Immunol** 1995 Sep; 75(3):209–11 (26 ref.) Comment on: Ann Allergy Asthma Immunol 1995 Sep;75(3):243–8.
Beta-2 agonists in asthma—the Thoracic Society of Australia and New Zealand. Wilson J, et al. **Aust N Z J Med** 1995 Aug;25(4):358–61 (39 ref.)
Anti-inflammatory effects of long-acting beta-agonists in asthma [editorial] Bradding P. **Clin Exp Allergy** 1995 Oct; 25(10):912–4 (36 ref.)
Beta-adrenergic agonists. Boyle JG. **Clin Obstet Gynecol** 1995 Dec;38(4):688–96 (36 ref.)
Bronchodilator therapy in the management of acute asthma. Moan MJ, et al. **Compr Ther** 1995 Aug;21(8):421–7 (39 ref.)
Dopexamine after cardiac surgery. **Drug Ther Bull** 1995 Apr; 33(4):30–2 (17 ref.)
Prospects for beta 3-adrenoceptor agonists in the treatment of obesity and diabetes. Arch JR, et al. **Int J Obes Relat Metab Disord** 1996 Mar;20(3):191–9 (90 ref.)
Long-acting inhaled beta agonists [see comments] Tilles SA, et al. **J Asthma** 1995;32(6):397–404 (51 ref.) Comment in: J Asthma 1995;32(6):395–6.
The beta-agonist controversy. Taylor DR, et al. **Med Clin North Am** 1996 Jul;80(4):719–48 (126 ref.)
Beta-agonists as antiobesity, antidiabetic and nutrient partitioning agents. Yen TT. **Obes Res** 1995 Nov;3 Suppl 4:531S–536S (57 ref.)
The use of beta 2-adrenoceptor agonists in the treatment of bronchial asthma. Svedmyr N, et al. **Pharmacol Toxicol** 1996 Jan;78(1):3–11 (94 ref.)
[Beta-2 adrenergic receptor agonists in asthma treatment] Haahtela T, et al. **Duodecim** 1995;111(8):744–8 (28 ref.) **(Fin)**
[Beta 2-sympathomimetic drugs] Criée CP, et al. **Internist (Berl)** 1995 Sep;36(9):918–23 (28 ref.) **(Ger)**
[The role of long-acting beta-mimetics in patients with chronic bronchial spasm and bronchial asthma] Chazan R, et al. **Pol Arch Med Wewn** 1995 Jul;94(1):59–63 (47 ref.) **(Pol)**

TOXICITY

Structural and biochemical remodelling in catecholamine-induced cardiomyopathy: comparative and ontogenetic aspects. Oštádal B, et al. **Mol Cell Biochem** 1995 Jun 7–21;147(1–2):83–8 (49 ref.)

ADRENERGIC BETA-ANTAGONISTS

beta-blockers. Drug interactions of clinical significance. Blaufarb I, et al. **Drug Saf** 1995 Dec;13(6):359–70 (114 ref.)
Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. Ruffolo RR Jr, et al. **J Med Chem** 1995 Sep 15;38(19):3681–716 (317 ref.)

ADVERSE EFFECTS

Medical treatment of glaucoma—a reappraisal of the risks. Diggory P, et al. **Br J Ophthalmol** 1996 Jan;80(1):85–9 (38 ref.)
Beta blockers and the elderly with glaucoma: are we adding insult to injury? O'Donoghue E. **Br J Ophthalmol** 1995 Sep;79(9):794–6 (48 ref.)
Beta-blockers and their effects on protein metabolism and resting energy expenditure. Lamont LS. **J Cardpulm Rehabil** 1995 May–Jun;15(3):183–5 (21 ref.)
Risk assessment of adverse pulmonary effects induced by adrenaline beta-receptor antagonists and rational drug dosage regimen based on receptor occupancy. Yamada Y, et al. **J Pharmacokinet Biopharm** 1995 Oct;23(5):463–78 (30 ref.)
Medications used to prevent migraine headaches and their potential ocular adverse effects. Doughty MJ, et al. **Optom Vis Sci** 1995 Dec;72(12):879–91 (176 ref.)
[Are beta-blockers really depressogenic?] Pélissolo A, et al. **Ann Med Psychol (Paris)** 1995 Aug–Sep;153(7):441–7 (26 ref.) (Eng. Abstr.) **(Fre)**

BLOOD

[Beta-blocking agents] Suzuki M. **Nippon Rinsho** 1995 Feb; 53 Su Pt 1:978–82 (16 ref.) **(Jpn)**

PHARMACOKINETICS

[Adrenergic betablockers] Alvarez Sabín J. **Rev Neurol** 1995; 23 Suppl 2:S185–9 (23 ref.) **(Spa)**

PHARMACOLOGY

Topical beta-adrenergic antagonists and quinidine. A risky interaction [editorial] Higginbotham EJ. **Arch Ophthalmol** 1996 Jun;114(6):745–6 (7 ref.)
Too many beta-blockers. **Drug Ther Bull** 1996 Jul;34(7):49–52 (37 ref.)
Carvedilol, a novel vasodilating beta-blocker with the potential for cardiovascular organ protection. Feuerstein GZ, et al. **Eur Heart J** 1996 Apr;17 Suppl B:24–9 (24 ref.)
Cardiac adrenergic receptor effects of carvedilol. Yoshikawa T, et al. **Eur Heart J** 1996 Apr;17 Suppl B:8–16 (37 ref.)
Beta 3-adrenoceptors and intestinal motility. Manara L, et al. **Fundam Clin Pharmacol** 1995;9(4):332–42 (70 ref.)
Adrenergic and muscarinic receptor regulation and therapeutic implications in heart failure. Schmitz W, et al. **Mol Cell Biochem** 1996 Apr 12–26;157(1–2):251–8 (91 ref.)
[The effect of beta-adrenoblockaders on the lipid composition of the blood] Velkin AK, et al. **Ter Arkh** 1995; 67(8):30–3 (28 ref.) **(Rus)**
[Adrenergic betablockers] Alvarez Sabín J. **Rev Neurol** 1995; 23 Suppl 2:S185–9 (23 ref.) **(Spa)**

THERAPEUTIC USE

Second-line and 'alternative' treatments for alcohol withdrawal: alpha-agonists, beta-blockers, anticonvulsants, acupuncture and neuro-electric therapy. Brewer C. **Alcohol Alcohol** 1995 Nov;30(6):799–803 (25 ref.)
Comparison of the ocular beta-blockers. Sorensen SJ, et al. **Ann Pharmacother** 1996 Jan;30(1):43–54 (85 ref.)
Beta-blockers in hypertensive and coronary heart disease. Goldstein S. **Arch Intern Med** 1996 Jun 24;156(12):1267–76 (89 ref.)
The place of beta-blockers in cardiovascular medicine. Cruickshank JM. **Cardiologia** 1995 Nov;40(11):829–43 (81 ref.)
Prophylactic treatment of migraine: evaluation of clinical trials and choice among drugs. Tfelt-Hansen P. **Cephalalgia** 1995 Oct;15 Suppl 15:29–32 (15 ref.)
The actions of talinolol, a beta 1-selective beta blocker, in cardiac arrhythmia and acute myocardial infarction. Assmann I. **Curr Med Res Opin** 1995;13(6):325–42 (43 ref.)
Too many beta-blockers. **Drug Ther Bull** 1996 Jul;34(7):49–52 (37 ref.)
Drug treatment of esophageal variceal bleeding: alternative or supplement to endoscopic therapy? Zoller WG, et al. **Endoscopy** 1995 Oct;27(8):616–21 (65 ref.)
Improvement in cardiac myocyte function by biological effects of medical therapy: a new concept in the treatment of heart failure. Bristow MR, et al. **Eur Heart J** 1995 Jul; 16 Suppl F:20–31 (93 ref.)
Beta-blockers in heart failure—the evidence from clinical trials. Hampton JR. **Eur Heart J** 1996 Apr;17 Suppl B:17–20 (23 ref.)
Beta-blockade in the management of chronic heart failure. Another step in the conceptual evolution of a neurohormonal model of the disease. Packer M. **Eur Heart J** 1996 Apr;17 Suppl B:21–3 (23 ref.)
Beta-blockers in heart failure. Future directions. Sharpe N. **Eur Heart J** 1996 Apr;17 Suppl B:39–42 (23 ref.)
Adrenergic beta-blocking agents in congestive heart failure due to idiopathic dilated cardiomyopathy. Waagstein F. **Eur Heart J** 1995 Dec;16 Suppl O:128–32 (37 ref.)
Treatment of hypertension in the elderly. Lever AF, et al. **J Hypertens** 1995 Jun;13(6):571–9 (44 ref.)
Rationale for treatment of patients with chronic heart failure with adrenergic blockade. Sackner-Bernstein JD, et al. **JAMA** 1995 Nov 8;274(18):1462–7 (71 ref.)
Adrenergic and muscarinic receptor regulation and therapeutic implications in heart failure. Schmitz W, et al. **Mol Cell Biochem** 1996 Apr 12–26;157(1–2):251–8 (91 ref.)
Current perspectives on beta-receptor antagonists in the treatment of symptomatic ventricular dysfunction. Adams KF Jr. **Pharmacotherapy** 1996 Mar–Apr;16(2 Pt 2):69S–77S (46 ref.)
Pharmacological therapy for portal hypertension: rationale and results. Burroughs AK, et al. **Semin Gastrointest Dis** 1995 Jul;6(3):148–64 (148 ref.)
[Should beta-adrenergic blockade be part of drug therapy for heart failure? (editorial)] Leinonen H. **Duodecim** 1995; 111(3):209–13 (18 ref.) **(Fin)**
[Beta blockers, calcium channel blockers and psyche] Strandberg T, et al. **Duodecim** 1994;110(4):397–402 (29 ref.) **(Fin)**
[Medical treatment of aortic abdominal aneurysms. Outstanding questions] Cacoub P, et al. **Presse Med** 1996 Apr 20;25(14):683–5 (15 ref.) (Eng. Abstr.) **(Fre)**
[Beta-blockers in cardiac insufficiency. Time to reconsider? (editorial)] Follath F. **Schweiz Med Wochenschr** 1996 May 4;126(18):747–9 (12 ref.) **(Ger)**
[Beta blockers and diuretics: therapeutic drugs of first choice in diabetes mellitus and hypertension] Sawicki PT. **Wien Klin Wochenschr** 1995;107(21):629–39 (98 ref.) (Eng. Abstr.) **(Ger)**
[Beta receptor blockers in chronic heart failure] Sigmund M, et al. **Z Kardiol** 1995 Oct;84(10):820–6 (74 ref.) (Eng. Abstr.) **(Ger)**
[Beta-blockers in congestive heart failure—a therapeutic paradox] Jonas M, et al. **Harefuah** 1995 Sep;129(5–6):192–7 (44 ref.) **(Heb)**
[Use of beta-blockers in the treatment of chronic heart failure] Sutka J, et al. **Vnitr Lek** 1996 Jan;42(1):37–42 (30 ref.) (Eng. Abstr.) **(Slo)**
[Diuretics and beta-blockers as the first option in the treatment of arterial hypertension] Ferreira Montero IJ, et al. **Rev Esp Cardiol** 1995;48 Suppl 4:66–71 (41 ref.) (Eng. Abstr.) **(Spa)**

ADRENERGIC BETA-RECEPTOR AGONISTS see **ADRENERGIC BETA-AGONISTS**

ADRENERGIC BETA-RECEPTOR BLOCKADERS see **ADRENERGIC BETA-ANTAGONISTS**

ADRENERGIC BETA-RECEPTORS see **RECEPTORS, ADRENERGIC, BETA**

ADRENERGIC BETA-1 RECEPTORS see **RECEPTORS, ADRENERGIC, BETA-1**

ADRENERGIC BETA-2 RECEPTORS see **RECEPTORS, ADRENERGIC, BETA-2**

ADRENERGIC FIBERS

PHYSIOLOGY

Neuroendocrine insights from the laboratory to the clinic. Ahlman H, et al. **Am J Surg** 1996 Jul;172(1):61–7 (40 ref.)

ADRENERGIC NEURON AGENTS see **ADRENERGIC AGENTS**

ADRENERGIC RECEPTORS see **RECEPTORS, ADRENERGIC**

ADRENERGIC SYNTHESIS INHIBITORS see **ADRENERGIC AGENTS**

ADRENERGIC UPTAKE INHIBITORS

see related
AMPHETAMINES
ANTIDEPRESSIVE AGENTS, TRICYCLIC
DOPAMINE UPTAKE INHIBITORS

ADRENOCEPTORS see **RECEPTORS, ADRENERGIC**

ADRENOCORTICOTROPIC HORMONE see **CORTICOTROPIN**

ADRENOCORTICOTROPIC HORMONE RECEPTORS see **RECEPTORS, CORTICOTROPIN**

ADRENOCORTICOTROPIN see **CORTICOTROPIN**

ADRENODOXIN REDUCTASE see **FERREDOXIN-NADP REDUCTASE**

ADRENOGENITAL SYNDROME see **ADRENAL HYPERPLASIA, CONGENITAL**

ADRENOLEUKODYSTROPHY

DIET THERAPY

Dietary management of X-linked adrenoleukodystrophy. Moser HW, et al. **Annu Rev Nutr** 1995;15:379–97 (77 ref.)

GENETICS

Dietary management of X-linked adrenoleukodystrophy. Moser HW, et al. **Annu Rev Nutr** 1995;15:379–97 (77 ref.)
Adrenoleukodystrophy. Moser HW. **Curr Opin Neurol** 1995 Jun;8(3):221–6 (37 ref.)

PHYSIOPATHOLOGY

Komrower Lecture. Adrenoleukodystrophy: natural history, treatment and outcome. Moser HW.
J Inherit Metab Dis 1995;18(4):435–47 (47 ref.)

PSYCHOLOGY

Neuropsychological outcomes of several storage diseases with and without bone marrow transplantation. Shapiro EG, et al. **J Inherit Metab Dis** 1995;18(4):413–29 (29 ref.)

SURGERY

The future for treatment by bone marrow transplantation for adrenoleukodystrophy, metachromatic leukodystrophy, globoid cell leukodystrophy and Hurler syndrome. Krivit W, et al. **J Inherit Metab Dis** 1995;18(4):398–412 (23 ref.)
Neuropsychological outcomes of several storage diseases with and without bone marrow transplantation. Shapiro EG, et al. **J Inherit Metab Dis** 1995;18(4):413–29 (29 ref.)

THERAPY

Bone marrow transplantation for metabolic diseases. Parkman R, et al. **Cancer Treat Res** 1995;76:87–96 (33 ref.)
Komrower Lecture. Adrenoleukodystrophy: natural history, treatment and outcome. Moser HW.
J Inherit Metab Dis 1995;18(4):435–47 (47 ref.)
[Gene therapy of adrenoleukodystrophy] Cartier N, et al. **Arch Pediatr** 1996;3 Suppl 1:77s–81s (18 ref.) **(Fre)**

ADRENOLEUKODYSTROPHY, NEONATAL see **PEROXISOMAL DISORDERS**

ADRENOLYTICS see **ADRENERGIC AGENTS**

ADRENOMIMETICS see **ADRENERGIC AGENTS**

ADRENOMYELONEUROPATHY see **ADRENOLEUKODYSTROPHY**

ADRENRGIC RELEASE INHIBITORS see **ADRENERGIC AGENTS**

ADRIAMYCIN see **DOXORUBICIN**

ADULT RESPIRATORY DISTRESS SYNDROME see **RESPIRATORY DISTRESS SYNDROME, ADULT**

ADULT T-CELL LEUKEMIA-LYMPHOMA VIRUS I see **HTLV-I**

ADVANCE DIRECTIVES

see related
RESUSCITATION ORDERS
RIGHT TO DIE

Advance directives. Most patients don't have one. Do yours? Berrio MW, et al. **Am J Nurs** 1996 Aug;96(8):24–8; quiz 29 (7 ref.)
On advancing advance directives. Why should we believe the promise? [editorial; comment] McIntyre KM.
Arch Intern Med 1995 Nov 27;155(21):2271–3 (12 ref.)
Comment on: Arch Intern Med 1994 Oct 24;154(20):2299–308.
Advance end-of-life treatment planning. A research review. Miles SH, et al. **Arch Intern Med** 1996 May 27; 156(10):1062–8 (120 ref.)
Dworkin on dementia. Elegant theory, questionable policy. Dresser R. **Hastings Cent Rep** 1995 Nov–Dec;25(6):32–8 (17 ref.)
Advance directives and opportunities for nurses. Johns JL. **Image J Nurs Sch** 1996 Summer;28(2):149–53 (52 ref.)

ECONOMICS

Cost savings at the end of life. What do the data show? Emanuel EJ. **JAMA** 1996 Jun 26;275(24):1907–14 (42 ref.)

LEGISLATION & JURISPRUDENCE

Social work and end-of-life decisions: self-determination and the common good. Wesley CA. **Health Soc Work** 1996 May;21(2):115–21 (52 ref.)

ADVERSE DRUG REACTION REPORTING SYSTEMS

Medication-related adverse reactions and the elderly: a literature review. Atkin PA, et al.
Adverse Drug React Toxicol Rev 1995 Autumn;14(3):175–91 (125 ref.)
Case series analysis of adverse reactions to vaccines: a comparative evaluation. Farrington CP, et al.
Am J Epidemiol 1996 Jun 1;143(11):1165–73 (18 ref.)
Methods for monitoring and documenting adverse drug reactions. Venulet J, et al. **Int J Clin Pharmacol Ther** 1996 Mar;34(3):112–29 (48 ref.)
Epidemiological identification and evaluation of hepatic adverse drug reactions. Bruppacher R. **Semin Liver Dis** 1995 Aug;15(3):301–8 (40 ref.)
[Drug side-effects of the eye—a contribution to quality assurance in ophthalmology] Dangelmaier S, et al.
Klin Monatsbl Augenheilkd 1996 May;208(5):385–8 (4 ref.) (Eng. Abstr.) **(Ger)**

ADVERTISING

Harry and Louise go to Washington: political advertising and health care reform. West DM, et al.
J Health Polit Policy Law 1996 Spring;21(1):35–68 (57 ref.)
The role of UK tobacco advertising: no effect on the nation's health? Kinman BF, et al. **J R Soc Health** 1995 Oct; 115(5):296–302 (27 ref.)
Marketing adolescent tobacco addiction. Tye J, et al.
Md Med J 1995 Oct;44(10):767–73 (29 ref.)

AEDES

Community involvement in the control of Aedes aegypti. Gubler DJ, et al. **Acta Trop** 1996 Apr;61(2):169–79 (21 ref.)
Global distribution and continuing spread of Aedes albopictus. Knudsen AB. **Parassitologia** 1995 Dec; 37(2–3):91–7 (44 ref.)
The role of Aedes albopictus as an arbovirus vector. Mitchell CJ. **Parassitologia** 1995 Dec;37(2–3):109–13 (17 ref.)
Control of Aedes albopictus from the perspective of North America. Nasci RS. **Parassitologia** 1995 Dec;37(2–3):123–7 (6 ref.)
A North American model to contain the spread of Aedes albopictus through tire legislation. Novak RJ.
Parassitologia 1995 Dec;37(2–3):129–39 (17 ref.)
Aedes albopictus: a potential problem in France. Rodhain F. **Parassitologia** 1995 Dec;37(2–3):115–9 (31 ref.)
History and updating on the spread of Aedes albopictus in Italy. Romi R. **Parassitologia** 1995 Dec;37(2–3):99–103 (16 ref.)
[The role of the Aedes aegypti vector in the epidemiology of dengue in Mexico] Fernández-Salas I, et al.
Salud Publica Mex 1995;37 Suppl:S45–52 (17 ref.) (Eng. Abstr.) **(Spa)**
[Vectors of dengue in Mexico: a critical review)] Ibáñez-Bernal S, et al. **Salud Publica Mex** 1995;37 Suppl:S53–63 (34 ref.) (Eng. Abstr.) **(Spa)**

PARASITOLOGY

Interactions between parasites and insects vectors. Hurd H. **Mem Inst Oswaldo Cruz** 1994;89 Suppl 2:27–30 (20 ref.)
Development of Dirofilaria and Setaria nematodes in Aedes albopictus. Cancrini G, et al. **Parassitologia** 1995 Dec; 37(2–3):141–5 (24 ref.)

AEQUORIN

Recombinant aequorin methods for intracellular calcium measurement in plants. Knight H, et al.
Methods Cell Biol 1995;49:201–16 (29 ref.)

AEROBACTER see **ENTEROBACTER**

AEROBACTER AEROGENES see **KLEBSIELLA PNEUMONIAE**

AEROBIC BACTERIA see **BACTERIA, AEROBIC**

AEROBIC EXERCISE see **EXERCISE**

AEROMONAS

Indications and complications of medicinal leech therapy. Haycox CL, et al. **J Am Acad Dermatol** 1995 Dec; 33(6):1053–5 (10 ref.)
Motile Aeromonas as agent of infections of the foot. Wakabongo M. **J Am Podiatr Med Assoc** 1995 Sep; 85(9):505–8 (53 ref.)

AEROMONAS HYDROPHILA

ISOLATION & PURIFICATION

[Soft-tissue infection caused by Aeromonas hydrophila] Ramos JM, et al. **Enferm Infecc Microbiol Clin** 1995 Oct; 13(8):469–72 (27 ref.) (Eng. Abstr.) **(Spa)**

AEROSOL PROPELLANTS

TOXICITY

An overview of the toxicology of HFA-134a (1,1,1,2-tetrafluoroethane). Alexander DJ, et al.
Hum Exp Toxicol 1995 Sep;14(9):715–20 (8 ref.)

AEROSPACE MEDICINE

see related
ACCIDENTS, AVIATION
ALTITUDE
DECOMPRESSION SICKNESS
SPACE FLIGHT

The hazards of reproduction in space. Sullivan R.
Acta Obstet Gynecol Scand 1996 Apr;75(4):372–7 (72 ref.)
A review of articles published in Aviation, Space, and Environmental Medicine, 1975–94. Rudge FW.
Aviat Space Environ Med 1995 Oct;66(10):1005–9 (4 ref.)
Implications of automation surprises in aviation for the future of total intravenous anesthesia (TIVA). Cook RI, et al.
J Clin Anesth 1996 May;8(3 Suppl):29S–37S (49 ref.)
Noise induced hearing loss in military helicopter aircrew—a review of the evidence. Owen JP.
J R Army Med Corps 1995 Jun;141(2):98–101 (19 ref.)
[Aviation medicine] Liu G.
Chung Hua I Hsueh Tsa Chih 1996 Jan;76(1):72–3 (0 ref.) **(Chi)**
[The contribution of space biology and medicine to the solution of ecological problems] Grigor'ev AI, et al.
Aviakosm Ekolog Med 1995;29(3):21–4 (14 ref.) (Eng. Abstr.) **(Rus)**
[The concept of risk factors and flight certificate examination] Vlasov VV. **Aviakosm Ekolog Med** 1995;29(5):4–9 (60 ref.) (Eng. Abstr.) **(Rus)**
[The problem of myopia in pilots (causes and characteristics of development and comprehensive correction)] Ovechkin IG, et al. **Vestn Oftalmol** 1995 Oct–Dec;111(4):38–40 (45 ref.) **(Rus)**
[The lung and trips by plane] Ibáñez Cuerda MD, et al.
Arch Bronconeumol 1995 Dec;31(10):526–33 (65 ref.) **(Spa)**

ORGANIZATION & ADMINISTRATION

Increased flight surgeon role in military aeromedical evacuation. Lyons TJ, et al. **Aviat Space Environ Med** 1995 Oct;66(10):927–9 (16 ref.)

STANDARDS

Excimer laser photorefractive keratectomy (PRK) for myopia—present status: aerospace considerations. Diamond S. **Aviat Space Environ Med** 1995 Jul;66(7):690–3 (38 ref.)

AFFECT

Dissociation, somatization, and affect dysregulation: the complexity of adaptation of trauma. van der Kolk BA, et al. **Am J Psychiatry** 1996 Jul;153(7 Suppl):83–93 (90 ref.)
Understanding and differentiating clients' positive feelings in psychotherapy. Chance SE, et al. **Am J Psychother** 1995 Fall;49(4):514–25 (23 ref.)
Chaos and complexity. Can it help us to understand mood and behavior? Ehlers CL. **Arch Gen Psychiatry** 1995 Nov; 52(11):960–4 (57 ref.)
The role of affects in the process of change in psychotherapy. Stein R. **Isr J Psychiatry Relat Sci** 1995;32(3):174–83 (26 ref.)
The acute effects of exercise on mood state. Yeung RR.
J Psychosom Res 1996 Feb;40(2):123–41 (108 ref.)
Depot medroxyprogesterone acetate contraception. Metabolic parameters and mood changes. Westhoff C.
J Reprod Med 1996 May;41(5 Suppl):401–6 (28 ref.)
Expression of emotion in voice and music. Scherer KR.
J Voice 1995 Sep;9(3):235–48 (89 ref.)
Well-being, symptoms and the menopausal transition. Dennerstein L. **Maturitas** 1996 Mar;23(2):147–57 (51 ref.)
[Development of the affect system] Moser U, et al.
Psyche (Stuttg) 1996 Jan;50(1):32–84 (110 ref.) (Eng. Abstr.) **(Ger)**

DRUG EFFECTS

[Delay in the effect of antidepressive agents: pharmacologic approach] Allain H, et al. **Encephale** 1995 Mar;21 Spec No 2:9–15 (39 ref.) (Eng. Abstr.) **(Fre)**
[Delay of the antidepressant effect: clinical studies] Escande M, et al. **Encephale** 1995 Mar;21 Spec No 2:3–8 (30 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

The neuroendocrinology of menstrual cycle mood disorders. Rubinow DR, et al. **Ann N Y Acad Sci** 1995 Dec 29; 771:648–59 (51 ref.)
Cerebral laterality in affect and affective illness: a review. Mandal MK, et al. **J Psychol** 1996 Jul;130(4):447–59 (80 ref.)
Cholesterol and psychological well-being. Wardle J.
J Psychosom Res 1995 Jul;39(5):549–62 (72 ref.)
[Ontogenesis of affect regulation] Beckmann D, et al.
Psychother Psychosom Med Psychol 1995 Dec; 45(12):427–35 (60 ref.) (Eng. Abstr.) **(Ger)**

AFFECTIVE DISORDERS

CLASSIFICATION

[Classification of mood disorders in adults] Guelfi JD.
Encephale 1995 Dec;21 Spec No 5:21–9 (4 ref.) (Eng. Abstr.) **(Fre)**

AFFECTIVE DISORDERS

DIAGNOSIS

Demography of DSM-III borderline personality disorder (PD): a comparison with Axis II PDs, affective illness and schizophrenia convergent and discriminant validation. Taub JM. **Int J Neurosci** 1995 Jun;82(3–4):191–214 (96 ref.)

Chronic mood disorder and depressive personality. Shea MT, et al. **Psychiatr Clin North Am** 1996 Mar;19(1):103–20 (42 ref.)

ETIOLOGY

GABA and mood disorders: a brief review and hypothesis. Petty F. **J Affect Disord** 1995 Aug 18;34(4):275–81 (60 ref.)

Anatomic correlates of psychological events related to temporolimbic epilepsy. Tackenberg JN, et al. **J Neurosci Nurs** 1996 Apr;28(2):73–81 (51 ref.)

GENETICS

[Severe mood disorders and heredity] Bredbacka PE. **Duodecim** 1994;110(3):252–9 (44 ref.) **(Fin)**

METABOLISM

Recent advances in the GABA-A-benzodiazepine receptor pharmacology. Kostowski W. **Pol J Pharmacol** 1995 May–Jun;47(3):237–46 (57 ref.)

PHYSIOPATHOLOGY

Stress, conditioning, and the temporal aspects of affective disorders. Post RM, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:677–96 (42 ref.)

Cerebral laterality in affect and affective illness: a review. Mandal MK, et al. **J Psychol** 1996 Jul;130(4):447–59 (80 ref.)

PSYCHOLOGY

Pathways linking affective disturbances and physical disorders. Cohen S, et al. **Health Psychol** 1995 Sep; 14(5):374–80 (50 ref.)

THERAPY

Practical management of treatment-resistant affective disorders. Bridges PK, et al. **Br J Hosp Med** 1995 Nov 15–Dec 12;54(10):501–6 (58 ref.)

The clinical research of affective disorders. A personal perspective. Angst J. **Pharmacopsychiatry** 1995 Sep;28 Suppl 1:38–44 (0 ref.) **(Eng, Ger)**

AFFECTIVE DISORDERS, PSYCHOTIC

DRUG THERAPY

Management of psychotic, treatment-resistant depression. Rothschild AJ. **Psychiatr Clin North Am** 1996 Jun; 19(2):237–52 (119 ref.)

GENETICS

[Severe mood disorders and heredity] Bredbacka PE. **Duodecim** 1994;110(3):252–9 (44 ref.) **(Fin)**

AFFECTIVE PSYCHOSIS, BIPOLAR see **BIPOLAR DISORDER**

AFFECTIVE SYMPTOMS

DIAGNOSIS

Alexithymia: past and present. Sifneos PE. **Am J Psychiatry** 1996 Jul;153(7 Suppl):137–42 (72 ref.)

Negative symptoms and affective disturbance in schizophrenia and related disorders. Malla AK. **Can J Psychiatry** 1995 Sep;40(7 Suppl 2):S55–9 (49 ref.)

DRUG THERAPY

Managing agitation in critically ill patients. Harvey MA. **Am J Crit Care** 1996 Jan;5(1):7–16; quiz 17–8 (72 ref.)

EPIDEMIOLOGY

Developmental epidemiology. Angold A, et al. **Epidemiol Rev** 1995;17(1):74–82 (126 ref.)

[Gender and emotional disorders: the importance of the difference] Ferrara M, et al. **Epidemiol Prev** 1996 Apr–Sep; 20(2–3):246–50 (19 ref.) **(Ita)**

ETIOLOGY

Modifiers of non-specific symptoms in occupational and environmental syndromes. Spurgeon A, et al. **Occup Environ Med** 1996 Jun;53(6):361–6 (61 ref.)

–Psychosomatic aspects around the period of menopause– Czubalski K. **Ginekol Pol** 1995 Dec;66(12):692–6 (22 ref.) **(Pol)**

PREVENTION & CONTROL

Developmental and behavioral issues in childhood injury prevention. Rivara FP. **J Dev Behav Pediatr** 1995 Oct; 16(5):362–70 (79 ref.)

PSYCHOLOGY

Traumatic brain injury, cognitive and emotional dysfunction. Impact of clinical neuropsychology research. Emilien G, et al. **Acta Neurol Belg** 1996 Jun;96(2):89–101 (73 ref.)

Negligent infliction of emotional distress: a focus on relationships. Appleberry JM. **Am J Law Med** 1995; 21(2–3):301–22 (190 ref.)

Adoption and mental health: a theoretical critique of the psychopathological model. Wegar K. **Am J Orthopsychiatry** 1995 Oct;65(4):540–8 (55 ref.)

THERAPY

[Therapy of emotional disturbance by manipulation of the biological clocks] Nagayama H. **Seishin Shinkeigaku Zasshi** 1995;97(8):575–85 (61 ref.) **(Jpn)**

AFFERENT PATHWAYS

PHYSIOLOGY

Role of muscle afferents in the inhibition of motoneurons during fatigue. Garland SJ, et al. **Adv Exp Med Biol** 1995; 384:271–8 (50 ref.)

Sub-diaphragmatic vagal afferent integration of meal-related gastrointestinal signals. Schwartz GJ, et al. **Neurosci Biobehav Rev** 1996;20(1):47–56 (31 ref.)

AFFINITY, ANTIBODY see **ANTIBODY AFFINITY**

AFFINITY LABELING REAGENTS see **AFFINITY LABELS**

AFFINITY LABELS

Exploring the nucleotide-binding site in proteins by affinity labeling and site-directed mutagenesis. Fukui T. **J Biochem (Tokyo)** 1995 Jun;117(6):1139–44 (45 ref.)

[Analysis of GTP-binding protein function with a photoaffinity GTP analog] Hatta S, et al. **Nippon Yakurigaku Zasshi** 1995 Jun;105(6):431–6 (18 ref.) (Eng. Abstr.) **(Jpn)**

[Structural studies of phorbol ester-binding domain of protein kinase C by photoaffinity labeling] Irie K. **Seikagaku** 1996 Feb;68(2):129–32 (16 ref.) **(Jpn)**

AFIBRINOGENEMIA

COMPLICATIONS

[Consumption coagulopathy during pregnancy: a case of afibrinogenemia during the second trimester] Debiéve F, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(8):860–2 (9 ref.) (Eng. Abstr.) **(Fre)**

AFLATOXIN B1

p53 proteins and aflatoxin b1: the good, the bad, and the ugly [editorial] Liang TJ. **Hepatology** 1995 Oct;22(4 Pt 1):1330–2 (21 ref.)

TOXICITY

Comparative methods of toxicity testing. Consensus document following an International Life Sciences Institute-ILSI Europe Workshop held in May 1995. Huggett AC, et al. **Food Chem Toxicol** 1996 Feb; 34(2):183–92 (34 ref.)

AFLATOXINS

METABOLISM

Selective chemisorption and detoxification of aflatoxins by phyllosilicate clay. Phillips TD, et al. **Nat Toxins** 1995; 3(4):204–13; discussion 221 (59 ref.)

TOXICITY

Molecular biomarkers for aflatoxins and their application to human liver cancer. Scholl P, et al. **Pharmacogenetics** 1995; 5 Spec No:S171–6 (33 ref.)

AFP see **ALPHA-FETOPROTEINS**

AFRICAN AMERICANS see **BLACKS**

AFRICAN LYMPHOMA see **BURKITT'S LYMPHOMA**

AFRICAN MEDICINE, TRADITIONAL see **MEDICINE, AFRICAN TRADITIONAL**

AFRICAN SLEEPING SICKNESS see **TRYPANOSOMIASIS, AFRICAN**

AFRICAN SWINE FEVER

PATHOLOGY

The lesional changes and pathogenesis in the kidney in African swine fever. Hervás J, et al. **Vet Res Commun** 1996; 20(3):285–99 (44 ref.)

AFRICAN SWINE FEVER VIRUS

ISOLATION & PURIFICATION

The lesional changes and pathogenesis in the kidney in African swine fever. Hervás J, et al. **Vet Res Commun** 1996; 20(3):285–99 (44 ref.)

AFTERCARE

Posttreatment services for chemically dependent adolescents. Spear SF, et al. **NIDA Res Monogr** 1995;156:341–64 (73 ref.)

Follow-up after therapy for prostate cancer. Treating the problems and caring for the man. Freedman A, et al. **Postgrad Med** 1996 Sep;100(3):125–9, 133–4, 136 (18 ref.)

Follow-up of colorectal cancer. Sugarbaker PH. **Tumori** 1995 May–Jun;81(3 Suppl):126–34 (64 ref.)

[Oncologic after-care and rehabilitation--physician-patient interaction in gynecologic oncology] Schünemann H, et al. **Arch Gynecol Obstet** 1995;257(1–4):277–83 (14 ref.) **(Ger)**

[Aftercare in patients with colorectal carcinomas] Mezger J, et al. **Dtsch Med Wochenschr** 1995 Nov 10; 120(45):1549–54 (44 ref.) **(Ger)**

[Oncologic after-care--a patient-oriented concept. Basic diagnostic plan for pediatric oncology patients] Duffner U, et al. **Klin Padiatr** 1995 Jul–Aug;207(4):193–203 (55 ref.) (Eng. Abstr.) **(Ger)**

[Short-bowel syndrome] Koblitz DK. **Z Gastroenterol** 1996 Jun;34 Suppl 2:41–6 (71 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Emergency and long-term management of bleeding oesophageal varices. Parks RW, et al. **Br J Hosp Med** 1995 Aug 16–Sep 5;54(4):161–8 (10 ref.)

[Sense and nonsense in after-care of colorectal carcinoma] Schölmerich J. **Med Klin** 1996 Jun 15;91(6):420–7 (53 ref.) **(Ger)**

ORGANIZATION & ADMINISTRATION

Infants with bronchopulmonary dysplasia: a developmental perspective. Mitchell SH. **J Pediatr Nurs** 1996 Jun; 11(3):145–51 (18 ref.)

AGAMMAGLOBULINEMIA

Molecular and cellular aspects of X-linked agammaglobulinemia. Sideras P, et al. **Adv Immunol** 1995; 59:135–223 (445 ref.)

ENZYMOLOGY

The Btk subfamily of cytoplasmic tyrosine kinases: structure, regulation and function. Rawlings DJ, et al. **Semin Immunol** 1995 Aug;7(4):237–46 (81 ref.)

GENETICS

BTKbase: a database of XLA-causing mutations. International Study Group. Vihinen M, et al. **Immunol Today** 1995 Oct;16(10):460–5 (39 ref.)

AGANGLIONOSIS, COLONIC see **HIRSCHSPRUNG DISEASE**

AGARICACEAE see **AGARICALES**

AGARICALES

[An outbreak of poisoning by mushrooms of the genus Omphalotus (letter)] Alguacil García GF, et al. **Med Clin (Barc)** 1996 Jun 8;107(2):75 (8 ref.) **(Spa)**

AGE-RELATED OSTEOPOROSIS see **OSTEOPOROSIS**

AGED

see related
HEALTH SERVICES FOR THE AGED
HOMES FOR THE AGED
HOUSING FOR THE ELDERLY
PENSIONS

Disability as a public health outcome in the aging population. Guralnik JM, et al. **Annu Rev Public Health** 1996;17:25–46 (98 ref.)

Cobalamin and folate deficiency in the elderly. Matthews JH. **Baillieres Clin Haematol** 1995 Sep;8(3):679–97 (96 ref.)

When drug treatment in the elderly is not cost effective. An ethical dilemma in an environment of healthcare rationing. Chadwick R, et al. **Drugs Aging** 1995 Dec;7(6):416–9 (25 ref.)

Antiviral therapy of acute herpes zoster in older patients. Herne K, et al. **Drugs Aging** 1996 Feb;8(2):97–112 (89 ref.)

Fungal urinary tract infections in the elderly: treatment guidelines. Jacobs LG. **Drugs Aging** 1996 Feb;8(2):89–96 (32 ref.)

Bisphosphonates and the treatment of bone disease in the elderly. Johansen A, et al. **Drugs Aging** 1996 Feb; 8(2):113–26 (133 ref.)

ACE inhibitors in elderly patients with hypertension. Special considerations. Ravid M, et al. **Drugs Aging** 1996 Jan; 8(1):29–37 (89 ref.)

Use of misoprostol in the elderly: is the expense justified? Stucki G, et al. **Drugs Aging** 1996 Feb;8(2):84–8 (24 ref.)
Optimising thrombolytic therapy in elderly patients with acute myocardial infarction. Verstraete M, et al. **Drugs Aging** 1996 Jan;8(1):17–22 (32 ref.)
Nutrition in minority elders: current problems and future directions. Buchowski MS, et al. **J Health Care Poor Underserved** 1996 Aug;7(3):184–209 (158 ref.)
The older driver—a review. Morgan R, et al. **Postgrad Med J** 1995 Sep;71(839):525–8 (30 ref.)
Longitudinal studies of dependence in daily life activities among elderly persons. Sonn U. **Scand J Rehabil Med Suppl** 1996;34:1–35 (168 ref.)
Is sleep apnea syndrome in the elderly a specific entity? Lévy P, et al. **Sleep** 1996 Apr;19(3 Suppl):S29–38 (78 ref.)
[Pharmacology in the elderly. Changes in the pharmacodynamic response to a given drug concentration and changes in mechanisms of regulation] Jolliet P, et al. **Ann Med Interne (Paris)** 1995;146(5):328–34 (71 ref.) **(Fre)**
[[Wallonian general physicians. Which prescriptions should be given to elderly persons over 75 years?] Franck J, et al. **Rev Med Liege** 1996 Feb;51(2):163–74 (47 ref.) **(Fre)**
[Changes in patterns of medication as function of age of the aging patient (review of the literature) (editorial)] Rosario Burgos EN. **Bol Asoc Med P R** 1995 Jul–Sep;87(7–9):121–3 (8 ref.) **(Spa)**
[Thrombolytic treatment in acute myocardial infarction in the aged: arguments in favor] Alonso-Orcajo N, et al. **Rev Esp Cardiol** 1995 Sep;48(9):589–93 (43 ref.) **(Spa)**
[Thrombolytic treatment in acute myocardial infarction in the aged: arguments against] Pabón Osuna P, et al. **Rev Esp Cardiol** 1995 Sep;48(9):581–8 (36 ref.) **(Spa)**
[Clinical aspects of vascular epilepsy in aging] Carod FJ, et al. **Rev Neurol** 1995 Nov–Dec;23(124):1314–7 (11 ref.) **(Spa)**
[Status epilepticus in the elderly] Cid MA. **Rev Neurol** 1995 Nov–Dec;23(124):1310–3 (27 ref.) **(Spa)**

PHYSIOLOGY

Protein requirements of elderly people. Campbell WW, et al. **Eur J Clin Nutr** 1996 Feb;50 Suppl 1:S180–3; discussion S183–5 (8 ref.)
Energy requirements of older individuals. Roberts SB. **Eur J Clin Nutr** 1996 Feb;50 Suppl 1:S112–7; discussion S117–8 (20 ref.)
Renal reserve in the elderly. Fliser D, et al. **Semin Nephrol** 1995 Sep;15(5):463–7 (47 ref.)
Anesthetic considerations in the geriatric patient. Burney TL, et al. **Urol Clin North Am** 1996 Feb;23(1):19–26 (20 ref.)
Sexuality in the elderly. Kaiser FE. **Urol Clin North Am** 1996 Feb;23(1):99–109 (76 ref.)

PSYCHOLOGY

Review: diogenes syndrome. Cooney C, et al. **Age Ageing** 1995 Sep;24(5):451–3 (14 ref.)
Caring for older people. Loneliness. Forbes A. **BMJ** 1996 Aug 10;313(7053):352–4 (0 ref.)
Anorexia in older persons: epidemiology and optimal treatment. Morley JE. **Drugs Aging** 1996 Feb;8(2):134–55 (205 ref.)
The effects of poverty environments on elders' subjective well-being: a conceptual model. Brown V. **Gerontologist** 1995 Aug;35(4):541–8 (48 ref.)
Reminiscence: a continuity theory framework. Parker RG. **Gerontologist** 1995 Aug;35(4):515–25 (81 ref.)
Psychosocial issues in geriatric urology: problems in treatment and treatment seeking. Umlauf MG, et al. **Urol Clin North Am** 1996 Feb;23(1):127–36 (35 ref.)

STATISTICS & NUMERICAL DATA

Changing demographics and neurologic disease in the elderly. Riggs JE. **Neurol Clin** 1996 May;14(2):477–86 (41 ref.)

AGED ABUSE see **ELDER ABUSE**

AGED, 80 AND OVER

PHYSIOLOGY

Immunosenescence in humans: deterioration or remodelling? Franceschi C, et al. **Int Rev Immunol** 1995;12(1):57–74 (100 ref.)

AGEISM see **PREJUDICE**

AGEPC see **PLATELET ACTIVATING FACTOR**

AGGLUTININS

PHYSIOLOGY

Cardiac surgery and cold-reactive proteins. Agarwal SK, et al. **Ann Thorac Surg** 1995 Oct;60(4):1143–50 (47 ref.)

AGGLUTININS, PLANT see **LECTINS**

AGGREGATION BIAS see **BIAS (EPIDEMIOLOGY)**

AGGRESSION

Neuroanatomical and neurochemical mechanisms underlying amygdaloid control of defensive rage behavior in the cat. Shaikh MB, et al. **Braz J Med Biol Res** 1994 Dec; 27(12):2759–79 (43 ref.)
Aggression against doctors: a review. Hobbs FD, et al. **J R Soc Med** 1996 Feb;89(2):69–72 (38 ref.)
Aggression, anxiety and vocalizations in animals: GABAA and 5-HT anxiolytics. Miczek KA, et al. **Psychopharmacology (Berl)** 1995 Sep;121(1):38–56 (161 ref.)
Aggressive behavior in childhood and early adolescence: an ecological-developmental perspective on youth violence. Fraser MW. **Soc Work** 1996 Jul;41(4):347–61 (120 ref.)
[Threats and physical violence at work] Laakkonen A, et al. **Duodecim** 1994;110(16):1510–6 (33 ref.) **(Fin)**
[Low concentration level of total serum cholesterol as a risk factor for suicidal and aggressive behavior] Ainiyet J, et al. **Psychiatr Pol** 1996 May–Jun;30(3):499–509 (31 ref.) (Eng. Abstr.) **(Pol)**

DRUG EFFECTS

Anabolic steroids and the mind. Corrigan B. **Med J Aust** 1996 Aug 19;165(4):222–6 (51 ref.)

PHYSIOLOGY

Mean genes. Hen R. **Neuron** 1996 Jan;16(1):17–21 (50 ref.)
Biochemical background for an analysis of cost–benefit interrelations in aggression. Haller J. **Neurosci Biobehav Rev** 1995 Winter;19(4):599–604 (52 ref.)
Serotonin receptors and animal models of aggressive behavior. Olivier B, et al. **Pharmacopsychiatry** 1995 Oct; 28 Suppl 2:80–90 (92 ref.)

PSYCHOLOGY

Working with noncompliant and abusive dialysis patients: practical strategies based on ethics and the law. Johnson CC, et al. **Adv Ren Replace Ther** 1996 Jan;3(1):77–86 (40 ref.)
The acute management of aggressive behaviour in hospitalized children and adolescents. Measham TJ. **Can J Psychiatry** 1995 Aug;40(6):330–6 (30 ref.)
Experimental models for aggression and inventories for the assessment of aggressive and autoaggressive behavior. Netter P, et al. **Pharmacopsychiatry** 1995 Oct;28 Suppl 2:58–63 (21 ref.)
Outward and inward directed aggressiveness: the interaction between violence and suicidality. Plutchik R. **Pharmacopsychiatry** 1995 Oct;28 Suppl 2:47–57 (58 ref.)
Clinical research in aggressive patients, pitfalls in study design and measurement of aggression. Mak M, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1995 Oct; 19(6):993–1017 (48 ref.)
Relation of threatened egotism to violence and aggression: the dark side of high self-esteem. Baumeister RF, et al. **Psychol Rev** 1996 Jan;103(1):5–33 (175 ref.)

AGING

Mivacurium in special patient groups. Jones RM. **Acta Anaesthesiol Scand Suppl** 1995;106:47–54 (57 ref.)
Evidence for protection against age-related macular degeneration by carotenoids and antioxidant vitamins. Snodderly DM. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1448S–1461S (153 ref.)
Aging is associated in the 344/N Fischer rat with decreased stress responsivity of central and peripheral catecholaminergic systems and impairment of the hypothalamic-pituitary-adrenal axis. Cizza G, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:491–511 (68 ref.)
Biosynthesis of DHEAS by the human adrenal cortex and its age-related decline. Hornsby PJ. **Ann N Y Acad Sci** 1995 Dec 29;774:29–46 (64 ref.)
Stress, aging, and memory. Involvement of peripheral catecholamines. Mabry TR, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:512–22 (53 ref.)
Sympathetic nervous system—immune system interactions in young and old Fischer 344 rats. Madden KS, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:523–34 (36 ref.)
Neuronal actions of dehydroepiandrosterone. Possible roles in brain development, aging, memory, and affect. Majewska MD. **Ann N Y Acad Sci** 1995 Dec 29;774:111–20 (86 ref.)
The sodium-calcium exchanger and glutamate-induced calcium loads in aged hippocampal neurons in vitro. Mills LR. **Ann N Y Acad Sci** 1996 Apr 15;779:379–90 (39 ref.)
On the possible role of nootropica in geriatric prevention and therapy. Nagy IZ. **Ann N Y Acad Sci** 1996 Jun 15; 786:444–52 (45 ref.)
Does DHEAS restore immune competence in aged animals through its capacity to function as a natural modulator of peroxisome activities? Spencer NF, et al. **Ann N Y Acad Sci** 1995 Dec 29;774:200–16 (129 ref.)
Dehydroepiandrosterone sulfate and aging. Vermeulen A. **Ann N Y Acad Sci** 1995 Dec 29;774:121–7 (54 ref.)
The requirement for vitamins in aging and age-associated degenerative conditions. Blumberg J. **Bibl Nutr Dieta** 1995; (52):108–15 (44 ref.)
Mitochondrial damage as a source of diseases and aging: a strategy of how to fight these. Zorov DB. **Biochim Biophys Acta** 1996 Jul 18;1275(1–2):10–5 (48 ref.)
Arterial and cardiac changes in hypertension in the elderly. Asmar R, et al. **Blood Press Suppl** 1995;3:31–7 (48 ref.)
Review of studies with urapidil in elderly hypertensives. Hansson L, et al. **Blood Press Suppl** 1995;3:21–5 (21 ref.)
Pharmacological backgrounds of the drug treatment of hypertension in the elderly. Van Zwieten PA. **Blood Press Suppl** 1995;3:15–20 (33 ref.)
Age and reversible lung disease. Let's grow old, but not be forgotten or ignored! [editorial] Berger R. **Chest** 1995 Oct; 108(4):897–8 (10 ref.)
Elastase in the prevention of arterial aging and the treatment of atherosclerosis. Ooyama T, et al. **Ciba Found Symp** 1995; 192:307–17; discussion 318–20 (36 ref.)
The immature athlete. Common injuries and overuse syndromes of the elbow and wrist. Gill TJ 4th, et al. **Clin Sports Med** 1996 Apr;15(2):401–23 (49 ref.)
Effect of age and sex on the induction and elicitation of allergic contact dermatitis. Kwangsukstith C, et al. **Contact Dermatitis** 1995 Nov;33(5):289–98 (85 ref.)
Diabetic neuropathy in elderly patients. What can be done? Belmin J, et al. **Drugs Aging** 1996 Jun;8(6):416–29 (97 ref.)
Risk factors for age-related cataracts. Hodge WG, et al. **Epidemiol Rev** 1995;17(2):336–46 (62 ref.)
Depression in old age. Is there a real decrease in prevalence? A review. Ernst C, et al. **Eur Arch Psychiatry Clin Neurosci** 1995;245(6):272–87 (199 ref.)
Age-dependency of surfactant phospholipids and surfactant protein A in bronchoalveolar lavage fluid of children without bronchopulmonary disease. Ratjen F, et al. **Eur Respir J** 1996 Feb;9(2):328–33 (34 ref.)
Changes in movement capabilities with aging. Grabiner MD, et al. **Exerc Sport Sci Rev** 1995;23:65–104 (230 ref.)
Age-related changes in visual function and visual organs of rats. Kiyosawa I. **Exp Anim** 1996 Apr;45(2):103–14 (34 ref.)
Nutrition and its relationship to aging. Casper RC. **Exp Gerontol** 1995 May–Aug;30(3–4):299–314 (93 ref.)
Dietary restriction. Masoro EJ. **Exp Gerontol** 1995 May–Aug; 30(3–4):291–8 (27 ref.)
The evolutionary tangle of aging, sex, and reproduction and an experimental approach to its molecular dissection. Roy AK, et al. **Exp Gerontol** 1996 Jan–Apr;31(1–2):83–94 (36 ref.)
Role of calcium in brain aging. Gareri P, et al. **Gen Pharmacol** 1995 Dec;26(8):1651–7 (64 ref.)
Effects of ageism on individual and health care providers' responses to healthy aging. Grant LD. **Health Soc Work** 1996 Feb;21(1):9–15 (46 ref.)
Physical workload and the aging worker: a review of the literature. de Zwart BC, et al. **Int Arch Occup Environ Health** 1995;68(1):1–12 (123 ref.)
Aging and performance on implicit memory tasks: a brief review. Jelicic M. **Int J Neurosci** 1995 Jun;82(3–4):155–61 (46 ref.)
The role of progressive resistance training and nutrition in the preservation of lean body mass in the elderly. Fielding RA. **J Am Coll Nutr** 1995 Dec;14(6):587–94 (51 ref.)
Geriatric oral health and its impact on eating. Ship JA, et al. **J Am Geriatr Soc** 1996 Apr;44(4):456–64 (105 ref.)
Self-ratings of health: do they also predict change in functional ability? Idler EL, et al. **J Gerontol B Psychol Sci Soc Sci** 1995 Nov;50(6):S344–53 (49 ref.)
Mitochondrial medicine. Luft R, et al. **J Intern Med** 1995 Nov;238(5):405–21 (119 ref.)
Benign aging or Alzheimer disease? Gorman WF. **J Okla State Med Assoc** 1995 Sep;88(9):383–91 (51 ref.)
A morphologist's approach to the vagina—age-related changes and estrogen sensitivity. Forsberg JG. **Maturitas** 1995 Dec;22 Suppl:S7–S15 (82 ref.)
Ageing—a biological perspective. Rattan SI. **Mol Aspects Med** 1995;16(5):439–508 (217 ref.)
Replicative senescence: implications for in vivo aging and tumor suppression. Smith JR, et al. **Science** 1996 Jul 5; 273(5271):63–7 (52 ref.)
Oxidative stress, caloric restriction, and aging. Sohal RS, et al. **Science** 1996 Jul 5;273(5271):59–63 (59 ref.)
Aging, physical activity and sports injuries. An overview of common sports injuries in the elderly. Kallinen M, et al. **Sports Med** 1995 Jul;20(1):41–52 (76 ref.)
[Progresses in geriatrics in China, 1995] Wang S, et al. **Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):768–70 (0 ref.) **(Chi)**
[Cytotoxic chemotherapy in elderly patients: present and future] Freyer G, et al. **Bull Cancer (Paris)** 1995 Jul; 82(7):531–40 (66 ref.) (Eng. Abstr.) **(Fre)**
[Aging and sexuality in the male] Tordjman G. **Contracept Fertil Sex** 1996 Jun;24(6):501–4 (14 ref.) (Eng. Abstr.) **(Fre)**
[Most frequent causes for hand tremor in clinical practice] Málly J. **Orv Hetil** 1995 Oct 8;136(41):2211–6 (53 ref.) (Eng. Abstr.) **(Hun)**
[RS3PE syndrome. A new rheumatic inflammatory syndrome in advanced age] Pittau E, et al. **Clin Ter** 1995 Nov; 146(11):663–73 (35 ref.) (Eng. Abstr.) **(Ita)**
[Treatment of chronic insomnia. A recommendation with special emphasis on problems of the elderly] Neckelmann D. **Tidsskr Nor Laegeforen** 1996 Mar 10;116(7):854–9 (40 ref.) (Eng. Abstr.) **(Nor)**
[Medicine and the aging process at the end of the 20th century] Schüller Pérez A. **An R Acad Nac Med (Madr)** 1996;Spec No:31–49 (73 ref.) **(Spa)**

AGING

[Status epilepticus in the elderly] Cid MA. **Rev Neurol** 1995 Nov-Dec;23(124):1310-3 (27 ref.) **(Spa)**

[Epileptogenesis. Epilepsy and aging] Olaskoaga J, et al. **Rev Neurol** 1995 Nov-Dec;23(124):1297-306 (87 ref.) **(Spa)**

[Epileptogenesis in the elderly. Part II. Spike-wave confusional states. Myoclonic seizure in Alzheimer's disease] Urcola J, et al. **Rev Neurol** 1995 Nov-Dec; 23(124):1307-9 (18 ref.) **(Spa)**

[Future drugs against aging? New research on molecular background of aging] Nordstedt C, et al. **Lakartidningen** 1995 Oct 18;92(42):3881-4 (20 ref.) **(Swe)**

BLOOD

The effect of age on hemopoiesis. Quaglino D, et al. **Aging (Milano)** 1996 Feb;8(1):1-12 (83 ref.)

Impact of apolipoprotein E genotype variation on means, variances, and correlations of plasma lipid, lipoprotein, and apolipoprotein traits in octogenarians. Haviland MB, et al. **Am J Med Genet** 1995 Sep 25;58(4):315-31 (64 ref.)

Developmental hemostasis: relevance to thromboembolic complications in pediatric patients. Andrew M. **Thromb Haemost** 1995 Jul;74(1):415-25 (141 ref.)

[Pineal functioning (melatonin levels) in healthy children of different ages. An update and the value of pineal gland study in pediatrics] Molina Carballo A, et al. **An Esp Pediatr** 1996 Jul;45(1):33-44 (124 ref.) (Eng. Abstr.) **(Spa)**

DRUG EFFECTS

The changing face of hypertension and antihypertensive agents. Kitler ME. **Drugs Aging** 1996 Jan;8(1):5-11 (43 ref.)

Trophic factor supplementation: effect on the age-associated changes in body composition. Schwartz RS. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:151-6 (53 ref.)

[Pharmacodynamic changes in the elderly subject] Beltrami G, et al. **Clin Ter** 1996 Apr;147(4):181-91 (98 ref.) (Eng. Abstr.) **(Ita)**

GENETICS

Do changes in chromosomes cause aging? Guarente L. **Cell** 1996 Jul 12;86(1):9-12 (21 ref.)

Ponce d'elegans: genetic quest for the fountain of youth. Kenyon C. **Cell** 1996 Feb 23;84(4):501-4 (17 ref.)

Genetic modulation of the senescent phenotype of Homo sapiens. Martin GM. **Exp Gerontol** 1996 Jan-Apr; 31(1-2):49-59 (57 ref.)

Mitochondrial DNA mutations associated with aging and degenerative diseases. Ozawa T. **Exp Gerontol** 1995 May-Aug;30(3-4):269-90 (55 ref.)

Genetics of aging: current animal models. Shmookler Reis RJ, et al. **Exp Gerontol** 1996 Jan-Apr;31(1-2):69-81 (67 ref.)

Aetiology of age-associated aneuploidy: a mechanism based on the 'free radical theory of ageing'. Tarín JJ. **Hum Reprod** 1995 Jun;10(6):1563-5 (25 ref.)

Cellular and molecular determinants of ageing. Rattan SI. **Indian J Exp Biol** 1996 Jan;34(1):1-6 (30 ref.)

T cell repertoire usage in humans, from newborns to centenarians. Cossarizza A, et al. **Int Rev Immunol** 1995; 12(1):41-55 (71 ref.)

V beta gene repertoire in the aging mouse: a developmental perspective. González-Quintial R, et al. **Int Rev Immunol** 1995;12(1):27-40 (81 ref.)

DNA damage, mutation and fine structure DNA repair in aging. Bohr VA et al. **Mutat Res** 1995 Oct;338(1-6):25-34 (100 ref.)

Genotypic selection of mitochondrial and oncogenic mutations in human tissue suggests mechanisms of age-related pathophysiology. Cortopassi G, et al. **Mutat Res** 1995 Oct;338(1-6):151-9 (43 ref.)

Somatic mutations in the brain: relationship to aging? Evans DA, et al. **Mutat Res** 1995 Oct;338(1-6):173-82 (47 ref.)

Human aging is associated with stochastic somatic mutations of mitochondrial DNA. Kadenbach B, et al. **Mutat Res** 1995 Oct;338(1-6):161-72 (112 ref.)

Somatic mutagenesis and antimutagenesis in aging research. Martin GM. **Mutat Res** 1996 Feb 19;350(1):35-41 (55 ref.)

Use of transgenic mouse models for studying somatic mutations in aging. Martus HJ, et al. **Mutat Res** 1995 Oct; 338(1-6):203-13 (46 ref.)

The somatic mutation theory of ageing. Morley AA. **Mutat Res** 1995 Oct;338(1-6):19-23 (49 ref.)

Sex chromosome aneuploidy and aging. Stone JF, et al. **Mutat Res** 1995 Oct;338(1-6):107-13 (51 ref.)

Nucleic acid fingerprinting by PCR-based methods: applications to problems in aging and mutagenesis. Welsh J, et al. **Mutat Res** 1995 Oct;338(1-6):215-29 (72 ref.)

Genetic analysis of ageing: role of oxidative damage and environmental stresses. Martin GM, et al. **Nat Genet** 1996 May;13(1):25-34 (151 ref.)

Genetic and aging epidemiology. The merging of two disciplines. Cauley JA, et al. **Neurol Clin** 1996 May; 14(2):467-75 (53 ref.)

Longevity, genes, and aging. Jazwinski SM. **Science** 1996 Jul 5;273(5271):54-9 (73 ref.)

Mechanisms and evolution of aging. Lithgow GJ, et al. **Science** 1996 Jul 5;273(5271):80 (14 ref.)

IMMUNOLOGY

Antioxidants and immune response in aged persons: overview of present evidence. Meydani SN, et al. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1462S-1476S (146 ref.)

Vitamin E and aging immune response. Meydani SN, et al. **Clin Geriatr Med** 1995 Nov;11(4):567-76 (52 ref.)

Immune dysfunction in Down's syndrome: primary immune deficiency or early senescence of the immune system? Cuadrado E, et al. **Clin Immunol Immunopathol** 1996 Mar; 78(3):209-14 (61 ref.)

Impact of aging on gastrointestinal mucosal immunity. Schmucker DL, et al. **Dig Dis Sci** 1996 Jun;41(6):1183-93 (76 ref.)

Aging and immune function: a possible role for growth hormone. Gelato MC. **Horm Res** 1996;45(1-2):46-9 (25 ref.)

Cytokine production pathway in the elderly. Caruso C, et al. **Immunol Res** 1996;15(1):84-90 (52 ref.)

T cell repertoire usage in humans, from newborns to centenarians. Cossarizza A, et al. **Int Rev Immunol** 1995; 12(1):41-55 (71 ref.)

Immunosenescence in humans: deterioration or remodelling? Franceschi C, et al. **Int Rev Immunol** 1995;12(1):57-74 (100 ref.)

Introduction: the reshaping of the immune system with age. Franceschi C, et al. **Int Rev Immunol** 1995;12(1):1-4 (19 ref.)

V beta gene repertoire in the aging mouse: a developmental perspective. González-Quintial R, et al. **Int Rev Immunol** 1995;12(1):27-40 (81 ref.)

Aging associated changes in the generation and development of B cell memory. Klinman NR, et al. **Int Rev Immunol** 1995;12(1):5-12 (60 ref.)

Immunoendocrine reshaping with age. Panerai AE, et al. **Int Rev Immunol** 1995;12(1):75-84 (73 ref.)

Changes in the intestinal lymphoid compartment throughout life: implications for the local generation of intestinal T cells. Rozing J, et al. **Int Rev Immunol** 1995;12(1):13-25 (45 ref.)

The aging immune system: primer and prospectus. Miller RA. **Science** 1996 Jul 5;273(5271):70-4 (77 ref.)

[The immune system characteristics during normal aging and in Alzheimer's disease] Koliaskina GI, et al. **Vestn Ross Akad Med Nauk** 1996;(4):19-23 (32 ref.) (Eng. Abstr.) **(Rus)**

METABOLISM

Zinc, human diseases and aging. Fabris N, et al. **Aging (Milano)** 1995 Apr;7(2):77-93 (172 ref.)

Relations among aging, antioxidant status, and cataract. Taylor A, et al. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1439S-1447S (80 ref.)

Concerns with chronic analgesic therapy in elderly patients. Gloth FM 3rd. **Am J Med** 1996 Jul 31;101(1A):19S-24S (39 ref.)

Increased sensitivity to oxidative stress and the loss of muscarinic receptor responsiveness in senescence. Joseph JA, et al. **Ann N Y Acad Sci** 1996 Jun 15;786:112-9 (47 ref.)

The ATPase module and the process of cellular immortalization. Krsoll J. **Ann N Y Acad Sci** 1996 Jun 15;786:57-61 (36 ref.)

Free intracellular calcium in aging and Alzheimer's disease. Müller WE, et al. **Ann N Y Acad Sci** 1996 Jun 15;786:305-20 (55 ref.)

Melatonin in the context of the free radical theory of aging. Reiter RJ, et al. **Ann N Y Acad Sci** 1996 Jun 15;786:362-78 (73 ref.)

Critical evaluation of the free radical theory of aging. A proposal for the oxidative stress hypothesis. Yu BP, et al. **Ann N Y Acad Sci** 1996 Jun 15;786:1-11 (44 ref.)

Angiotensin II receptor antagonists in heart failure: rationale and design of the evaluation of losartan in the elderly (ELITE) trial. Pitt B, et al. **Cardiovasc Drugs Ther** 1995 Oct;9(5):693-700 (80 ref.)

Drug therapy of non-insulin-dependent diabetes mellitus in the elderly. Mooradian AD. **Drugs** 1996 Jun;51(6):931-41 (57 ref.)

P-glycoprotein expression and regulation. Age-related changes and potential effects on drug therapy. Gupta S. **Drugs Aging** 1995 Jul;7(1):19-29 (81 ref.)

ACE inhibitors. Differential use in elderly patients with hypertension. Israili ZH, et al. **Drugs Aging** 1995 Nov; 7(5):355-71 (225 ref.)

Recent advances in geriatric psychopharmacology. Naranjo CA, et al. **Drugs Aging** 1995 Sep;7(3):184-202 (85 ref.)

Pharmacokinetic optimisation of drug therapy in elderly patients. Parker BM, et al. **Drugs Aging** 1995 Jul;7(1):10-8 (38 ref.)

Protein requirements of elderly people. Campbell WW, et al. **Eur J Clin Nutr** 1996 Feb;50 Suppl 1:S180-3; discussion S183-5 (8 ref.)

Oxygen free radicals, melatonin, and aging. Pierrefiche G, et al. **Exp Gerontol** 1995 May-Aug;30(3-4):213-27 (75 ref.)

Synthesis, modifications, and turnover of proteins during aging. Rattan SI. **Exp Gerontol** 1996 Jan-Apr;31(1-2):33-47 (88 ref.)

Principles to optimize drug treatment in the depressed elderly: practical pharmacokinetics and drug interactions. Cohen LJ. **Geriatrics** 1995 Oct;50 Suppl 1:S32-40 (33 ref.)

Oxidative stress and aging: still a hypothesis [editorial; comment] Kritchevsky SB, et al. **J Am Geriatr Soc** 1996 Jul;44(7):873-5 (25 ref.) Comment on: J Am Geriatr Soc 1996 Jul;44(7):823-7.

Screening the older population for cobalamin (vitamin B12) deficiency. Stabler SP. **J Am Geriatr Soc** 1995 Nov; 43(11):1290-7 (47 ref.)

The age related amyloids: a growing family of unique biochemical substances. Cornwell GG 3rd, et al. **J Clin Pathol** 1995 Nov;48(11):984-9 (41 ref.)

Age-related endocrine deficiencies and fractures of the proximal femur. II implications of vitamin D deficiency in the elderly. Boonen S, et al. **J Endocrinol** 1996 Apr; 149(1):13-7 (57 ref.)

Age-related endocrine deficiencies and fractures of the proximal femur. I implications of growth hormone deficiency in the elderly. Boonen S, et al. **J Endocrinol** 1996 Apr;149(1):7-12 (72 ref.)

Muscle protein turnover: methodological issues and the effect of aging. Nair KS. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:107-12 (26 ref.)

Effects of aging on energy requirements and the control of food intake in men. Roberts SB. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:101-6 (29 ref.)

The calcium hypothesis of brain aging and neurodegenerative disorders: significance in diabetic neuropathy. Biessels G, et al. **Life Sci** 1996;59(5-6):379-87 (67 ref.)

Aging-related increase in hippocampal calcium channels. Landfield PW. **Life Sci** 1996;59(5-6):399-404 (17 ref.)

Decreased plasma membrane calcium transport activity in aging brain. Michaelis ML, et al. **Life Sci** 1996; 59(5-6):405-12 (16 ref.)

Calcium signals in T lymphocytes from old mice. Miller RA. **Life Sci** 1996;59(5-6):469-75 (22 ref.)

Cytosolic and mitochondrial calcium in synaptosomes during aging. Satrústegui J, et al. **Life Sci** 1996;59(5-6):429-34 (33 ref.)

On the role of the peroxisome in ontogeny, ageing and degenerative disease. Masters CJ, et al. **Mech Ageing Dev** 1995 May 12;80(2):69-83 (31 ref.)

Free radicals and aging of anterior segment tissues of the eye: a hypothesis. Green K. **Ophthalmic Res** 1995;27 Suppl 1:143-9 (41 ref.)

Lipofuscin and ceroid pigments in aging and brain pathology. A review. I. Biochemical and morphological properties. Riga D, et al. **Rom J Neurol Psychiatry** 1995 Apr-Jun; 33(2):121-36 (107 ref.)

PATHOLOGY

Medication-related adverse reactions and the elderly: a literature review. Atkin PA, et al. **Adverse Drug React Toxicol Rev** 1995 Autumn;14(3):175-91 (125 ref.)

Molecular and cellular biology of the senescent hypertrophied and failing heart. Swynghedauw B, et al. **Am J Cardiol** 1995 Nov 2;76(13):2D-7D (21 ref.)

Nutritional aspects of hip fractures. Bonjour JP, et al. **Bone** 1996 Mar;18(3 Suppl):139S-144S (87 ref.)

Epidemiology of hip fractures: implications of the exponential increase with age. Melton LJ 3rd. **Bone** 1996 Mar;18(3 Suppl):121S-125S (53 ref.)

Management of cancer in the aged. Balducci L, et al. **Compr Ther** 1996 Feb;22(2):88-93 (28 ref.)

Drug-induced seizures in the elderly. Causative agents and optimal management. Franson KL, et al. **Drugs Aging** 1995 Jul;7(1):38-48 (78 ref.)

Rheumatoid arthritis in the elderly. Prevalence and optimal management. van Schaardenburg D. **Drugs Aging** 1995 Jul; 7(1):30-7 (57 ref.)

Vascular pathology in the elderly. Hsu CY, et al. **Eur Neurol** 1995;35 Suppl 1:2-4 (20 ref.)

Incidence of prostate cancer will double by the year 2030: the argument against. George NJ. **Eur Urol** 1996;29 Suppl 2:10-2 (7 ref.)

Degeneration of human oncogenes and mitochondrial genes occurs in cells that exhibit age-related pathology. Cortopassi G, et al. **Exp Gerontol** 1996 Jan-Apr; 31(1-2):253-65 (43 ref.)

Cellular and molecular determinants of ageing. Rattan SI. **Indian J Exp Biol** 1996 Jan;34(1):1-6 (30 ref.)

Hippocampal and neocortical involvement in normal brain aging and dementia: morphological and neurochemical profile of the vulnerable circuits. Hof PR, et al. **J Am Geriatr Soc** 1996 Jul;44(7):857-64 (83 ref.)

Factors influencing the repair and adaptation of muscles in aged individuals: satellite cells and innervation. Carlson BM. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:96-100 (34 ref.)

Muscle biopsy as a tool in the study of aging. Coggan AR. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:30-4 (38 ref.)

From muscle properties to human performance, using magnetic resonance. Conley KE, et al. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:35-40 (30 ref.)

Muscle performance and structure in the elderly as studied cross-sectionally and longitudinally. Grimby G. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:17-22 (22 ref.)

Loss of skeletal muscle mass with aging: effect on glucose tolerance. Kohrt WM, et al. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:68-72

(43 ref.)
Human aging, muscle mass, and fiber type composition. Lexell J. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:11–6 (55 ref.)
The application of blood flow measurements to the study of aging muscle. McCully KK, et al. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:130–6 (80 ref.)
Relationship of age-related decreases in muscle mass and strength to skeletal status. Marcus R. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:86–7 (12 ref.)
Quantitative computed tomography and magnetic resonance imaging in aging and Alzheimer's disease. A review. Smith CD. **J Neuroimaging** 1996 Jan;6(1):44–53 (122 ref.)
The canine as an animal model of human aging and dementia. Cummings BJ, et al. **Neurobiol Aging** 1996 Mar–Apr; 17(2):259–68 (106 ref.)
Magnetic resonance imaging of the aging brain in Down syndrome. Emerson JF, et al. **Prog Clin Biol Res** 1995; 393:123–38 (28 ref.)
GABAergic deafferentation hypothesis of brain aging and Alzheimer's disease; pharmacologic profile of the benzodiazepine antagonist, flumazenil. Marczynski TJ. **Rev Neurosci** 1995 Jul–Sep;6(3):221–58 (164 ref.)
Pruritus in the elderly. Gilchrest BA. **Semin Dermatol** 1995 Dec;14(4):317–9 (22 ref.)

PHYSIOLOGY

Evolutionary ancient roles of serotonin: long-lasting regulation of activity and development. Turlejski K. **Acta Neurobiol Exp (Warsz)** 1996;56(2):619–36 (138 ref.)
Molecular biology of brain aging and neurodegenerative disorders. Wisniewski T, et al. **Acta Neurobiol Exp (Warsz)** 1996;56(1):267–79 (93 ref.)
Muscle fatigue in old animals. Unique aspects of fatigue in elderly humans. Faulkner JA, et al. **Adv Exp Med Biol** 1995;384:471–80 (35 ref.)
Matrix changes in the bladder associated with normal aging. Shapiro E, et al. **Adv Exp Med Biol** 1995;385:187–90; discussion 223–8 (23 ref.)
Biologic differences between early- and late-onset Alzheimer disease. Terry RD. **Alzheimer Dis Assoc Disord** 1995;9 Suppl 1:S26–7 (7 ref.)
Transcription factors and pattern formation in the developing lung. Cardoso WV. **Am J Physiol** 1995 Oct;269(4 Pt 1):L429–42 (185 ref.)
Aging and disease: extending functional life span. Harman D. **Ann N Y Acad Sci** 1996 Jun 15;786:321–36 (87 ref.)
Cellular and molecular mechanisms of cardiovascular aging. Molecular pharmacological implications. Miyamoto A, et al. **Ann N Y Acad Sci** 1996 Jun 15;786:283–93 (58 ref.)
Frontal lobes, memory, and aging. Moscovitch M, et al. **Ann N Y Acad Sci** 1995 Dec 15;769:119–50 (228 ref.)
Age-associated problems in nutrition. Sone Y. **Appl Human Sci** 1995 Sep;14(5):201–10 (85 ref.)
Ageing, oscillations and efficiency. Gilbert DA. **Biosystems** 1995;36(1):1–5 (30 ref.)
Arterial and cardiac changes in hypertension in the elderly. Asmar R, et al. **Blood Press** 1995;Suppl 3:31–7 (48 ref.)
Hypertension in the elderly: benefits of treatment. Chalmers J. **Blood Press** 1995;Suppl 3:6–10 (24 ref.)
Review of studies with urapidil in elderly hypertensives. Hansson L, et al. **Blood Press** 1995;Suppl 3:21–5 (21 ref.)
Characteristics of an ideal antihypertensive therapy for elderly hypertensives. Hansson L, et al. **Blood Press** 1995; Suppl 3:68–72 (25 ref.)
Pharmacological backgrounds of the drug treatment of hypertension in the elderly. van Zwieten PA. **Blood Press** 1995;Suppl 3:15–20 (33 ref.)
Etiology and prevention of age-related hip fractures. Hayes WC, et al. **Bone** 1996 Jan;18(1 Suppl):77S–86S (110 ref.)
Epidemiology of hip fractures. Kannus P, et al. **Bone** 1996 Jan;18(1 Suppl):57S–63S (59 ref.)
Concentric and eccentric knee extension strength in older and younger men and women. Porter MM, et al. **Can J Appl Physiol** 1995 Dec;20(4):429–39 (38 ref.)
Oestrogens and the structural and functional plasticity of neurons: implications for memory, ageing and neurodegenerative processes. McEwen BS, et al. **Ciba Found Symp** 1995;191:52–66; discussion 66–73 (43 ref.)
Effects of age on nutrient requirements. Chernoff R. **Clin Geriatr Med** 1995 Nov;11(4):641–51 (81 ref.)
Exercise, nutrition, and aging. Evans WJ. **Clin Geriatr Med** 1995 Nov;11(4):725–34 (49 ref.)
Syndromes of language dissolution in aging and dementia. Kirshner HS, et al. **Compr Ther** 1995 Sep;21(9):519–23 (30 ref.)
Clinical evaluation of voiding symptoms and uroflowmetry in elderly men. A prospective study. Jørgensen JB. **Dan Med Bull** 1995 Jun;42(3):244–56 (113 ref.)
The optics of the eye–lens and lenticular senescence. A review. Pierscionek BK, et al. **Doc Ophthalmol** 1995; 89(4):321–35 (96 ref.)
Osteoarthritis in older patients. Optimum treatment. Bagge E, et al. **Drugs Aging** 1995 Sep;7(3):176–83 (47 ref.)
Switching drug availability from prescription only to over-the-counter status. Are elderly patients at increased risk? Benrimoj SI, et al. **Drugs Aging** 1995 Oct;7(4):255–65 (152 ref.)
Potential of antineoplastons in diseases of old age. Burzynski SR. **Drugs Aging** 1995 Sep;7(3):157–67 (175 ref.)
Age-related changes in vascular smooth muscle and endothelium. Dohi Y, et al. **Drugs Aging** 1995 Oct; 7(4):278–91 (141 ref.)
Drug poisoning in older patients. Preventative and management strategies. Haselberger MB, et al. **Drugs Aging** 1995 Oct;7(4):292–7 (32 ref.)
Anti-amyloid drugs: potential in the treatment of diseases associated with aging. Kisilevsky R. **Drugs Aging** 1996 Feb; 8(2):75–83 (70 ref.)
Sinusitis in the aged. Optimal management strategies. Knutson JW, et al. **Drugs Aging** 1995 Oct;7(4):310–6 (24 ref.)
Physiological aspects of aging. Implications for the treatment of cancer. Lichtman SM. **Drugs Aging** 1995 Sep;7(3):212–25 (173 ref.)
Epidemiology of adverse drug events in the nursing home setting. Monette J, et al. **Drugs Aging** 1995 Sep;7(3):203–11 (57 ref.)
Optimum treatment of rhinitis in the elderly. Tan R, et al. **Drugs Aging** 1995 Sep;7(3):168–75 (21 ref.)
The aging thyroid. Mariotti S, et al. **Endocr Rev** 1995 Dec; 16(6):686–715 (403 ref.)
Quantitative electroencephalography in aging brain and cerebrovascular disease: the effects of almitrine-raubasine. Sebban C. **Eur Neurol** 1995;35 Suppl 1:37–42 (16 ref.)
Aging and body composition: biological changes and methodological issues. Going S, et al. **Exerc Sport Sci Rev** 1995;23:411–58 (173 ref.)
The evolution of research on motor development: new approaches bringing new insights. Whitall J. **Exerc Sport Sci Rev** 1995;23:243–73 (116 ref.)
Central auditory aging: GABA changes in the inferior colliculus. Caspary DM, et al. **Exp Gerontol** 1995 May–Aug;30(3–4):349–60 (85 ref.)
Estrogen-induced hypothalamic beta-endorphin neuron loss: a possible model of hypothalamic aging. Desjardins GC, et al. **Exp Gerontol** 1995 May–Aug;30(3–4):253–67 (143 ref.)
The role of aging in the clinical expression of essential tremor. Elble RJ. **Exp Gerontol** 1995 May–Aug;30(3–4):337–47 (43 ref.)
Prohibitin: potential role in senescence, development, and tumor suppression. McClung JK, et al. **Exp Gerontol** 1995 Mar–Apr;30(2):99–124 (90 ref.)
Individual differences in hypothalamic–pituitary–adrenal activity in later life and hippocampal aging. Meaney MJ, et al. **Exp Gerontol** 1995 May–Aug;30(3–4):229–51 (125 ref.)
The pineal gland and melatonin in relation to aging: a summary of the theories and of the data. Reiter RJ. **Exp Gerontol** 1995 May–Aug;30(3–4):199–212 (73 ref.)
Gonadotropin secretion during aging in women: review article. Rossmanith WG. **Exp Gerontol** 1995 May–Aug; 30(3–4):369–81 (38 ref.)
Changes in tissue responsiveness to hormones and neurotransmitters during aging. Roth GS. **Exp Gerontol** 1995 May–Aug;30(3–4):361–8 (30 ref.)
Rapid development and a long life: an association expected under a stress theory of aging. Parsons PA. **Experientia** 1996 Jul 15;52(7):643–6 (54 ref.)
Morphological study of microglia in human mesencephalon during the development and aging. Wierzba-Bobrowicz T, et al. **Folia Neuropathol** 1995;33(2):77–83 (46 ref.)
Reversing sarcopenia: how weight training can build strength and vitality. Evans WJ. **Geriatrics** 1996 May;51(5):46–7, 51–3; quiz 54 (18 ref.)
Assessing biological age: reality? Bellamy D. **Gerontology** 1995;41(6):322–4 (2 ref.)
Assessing biological age: practicality? Bulpitt CJ. **Gerontology** 1995;41(6):315–21 (20 ref.)
Effects of aging on the female reproductive system. Pellicer A, et al. **Hum Reprod** 1995 Dec;10 Suppl 2:77–83 (37 ref.)
Structure and function of basement membranes. Engvall E. **Int J Dev Biol** 1995 Oct;39(5):781–7 (71 ref.)
Normal development and neoplasia: the imprinting connection. Ohlsson R, et al. **Int J Dev Biol** 1995 Oct; 39(5):869–76 (54 ref.)
Vernier acuity and aging. Lakshminarayanan V, et al. **Int Ophthalmol** 1995;19(2):109–15 (61 ref.)
The effects of ageing on cutaneous wound healing in mammals. Ashcroft GS, et al. **J Anat** 1995 Aug;187 (Pt 1):1–26 (287 ref.)
Can the neurotrophic hypothesis explain degeneration and loss of plasticity in mature and ageing autonomic nerves? Gavazzi I, et al. **J Auton Nerv Syst** 1996 Apr 20; 58(1–2):1–10 (79 ref.)
Dehydroepiandrosterone (DHEA): a fountain of youth? [editorial] Baulieu EE. **J Clin Endocrinol Metab** 1996 Sep; 81(9):3147–51 (14 ref.)
Cytokines in aging and muscle homeostasis. Cannon JG. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:120–3 (39 ref.)
Factors influencing the repair and adaptation of muscles in aged individuals: satellite cells and innervation. Carlson BM. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:96–100 (34 ref.)
What insights into age-related changes in skeletal muscle are provided by animal models? Cartee GD. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:137–41 (43 ref.)
From muscle properties to human performance, using magnetic resonance. Conley KE, et al. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:35–40 (30 ref.)
What is sarcopenia? Evans WJ. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:5–8 (36 ref.)
Muscle atrophy and weakness with aging: contraction-induced injury as an underlying mechanism. Faulkner JA, et al. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:124–9 (36 ref.)
Muscle performance and structure in the elderly as studied cross-sectionally and longitudinally. Grimby G. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:17–22 (22 ref.)
Age, gender, and muscular strength. Hurley BF. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:41–4 (50 ref.)
Functional consequences of sarcopenia: effects on thermoregulation. Kenney WL, et al. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:78–85 (73 ref.)
Motor units: remodeling in aged animals. Larsson L. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:91–5 (15 ref.)
Sarcopenia in aging humans: the impact of menopause and disease. Poehlman ET, et al. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:73–7 (25 ref.)
Muscle function and mobility biomechanics in the elderly: an overview of some recent research. Schultz AB. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:60–3 (29 ref.)
Trophic factor supplementation: effect on the age-associated changes in body composition. Schwartz RS. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:151–6 (53 ref.)
Strength and aerobic training attenuate muscle wasting and improve resistance to the development of disability with aging. Tseng BS, et al. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:113–9 (49 ref.)
Interventions based on the possibility that oxidative stress contributes to sarcopenia. Weindruch R. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:157–61 (54 ref.)
General and specific speed mediation of adult age differences in memory. Salthouse TA. **J Gerontol B Psychol Sci Soc Sci** 1996 Jan;51(1):P30–42 (32 ref.)
Fetal influences on adult hypertension. Law C. **J Hum Hypertens** 1995 Aug;9(8):649–51 (30 ref.)
Neuroendocrine ageing. Björntorp P. **J Intern Med** 1995 Nov;238(5):401–4 (19 ref.)
Role of proteoglycans in neural development, regeneration, and the aging brain. Small DH, et al. **J Neurochem** 1996 Sep;67(3):889–99 (140 ref.)
Pattern of amino acid requirements in humans: an interspecies comparison using published amino acid requirement recommendations. McLarney MJ, et al. **J Nutr** 1996 Jul; 126(7):1871–82 (55 ref.)
Calcium-dependent afterhyperpolarization and learning in young and aging hippocampus. Disterhoft JF, et al. **Life Sci** 1996;59(5–6):413–20 (54 ref.)
Age-related changes before and after imposition of hemodynamic stress in the mammalian heart. Isoyama S. **Life Sci** 1996;58(19):1601–14 (112 ref.)
Induction and repair of benzo[a]pyrene-DNA adducts in C57BL/6 and BALB/c mice: association with aging and longevity. Boerrigter ME, et al. **Mech Ageing Dev** 1995 Jul 28;82(1):31–50 (50 ref.)
The last mitoses of the human fibroblast proliferative life span, physiopathologic implications. Macieira-Coelho A. **Mech Ageing Dev** 1995 Aug 8;82(2–3):91–104 (22 ref.)
Neurotrophin-3 as an essential signal for the developing nervous system. Chalazonitis A. **Mol Neurobiol** 1996 Feb; 12(1):39–53 (90 ref.)
Aging and caloric restriction: human effects and mode of action. Austad SN. **Neurobiol Aging** 1995 Sep–Oct; 16(5):851–2; discussion 855–6 (19 ref.)
Neuroendocrine involvement in aging: evidence from studies of reproductive aging and caloric restriction. Nelson JF, et al. **Neurobiol Aging** 1995 Sep–Oct;16(5):837–43; discussion 855–6 (50 ref.)
Use of caloric restriction to investigate neuroendocrine involvement in aging. Weindruch R, et al. **Neurobiol Aging** 1995 Sep–Oct;16(5):845–7; discussion 855–6 (30 ref.)
Changes in circadian rhythms and sleep quality with aging: mechanisms and interventions. Myers BL, et al. **Neurosci Biobehav Rev** 1995 Winter;19(4):553–71 (318 ref.)
Habitual physical activity, psychomotor performance, and older workers. Ilmarinen J, et al. **Nutr Rev** 1996 Apr;54(4 Pt 2):S44–52 (39 ref.)
Do dairy products improve bone density in adolescent girls? Kerstetter JE. **Nutr Rev** 1995 Nov;53(11):328–32 (26 ref.)
Micronutrient status and aging. Tucker K. **Nutr Rev** 1995 Sep;53(9 Pt 2):S9–15 (47 ref.)
Antiaging action of caloric restriction: endocrine and metabolic aspects. Masoro EJ. **Obes Res** 1995 Sep;3 Suppl 2:241s–247s (30 ref.)
Effects of noise and age on the auditory system. Boettcher FA, et al. **Occup Med** 1995 Jul–Aug;10(3):577–91 (41 ref.)
Presbycusis and occupational hearing loss. Rosenhall U, et al. **Occup Med** 1995 Jul–Aug;10(3):593–607 (73 ref.)
Developmental renal hemodynamics. Yao LP, et al. **Pediatr Nephrol** 1995 Oct;9(5):632–7 (59 ref.)

Aging and the hypothalamus: research perspectives. Bernardis LL, et al. **Physiol Behav** 1996 Mar;59(3):523–36 (220 ref.)

The older driver—a review. Morgan R, et al. **Postgrad Med J** 1995 Sep;71(839):525–8 (30 ref.)

Effects of exercise training in the elderly: impact of progressive- resistance training on skeletal muscle and whole-body protein metabolism. Fielding RA. **Proc Nutr Soc** 1996 Nov;54(3):665–75 (58 ref.)

Functional ability and nutritional status of free-living elderly people. Manandhar MC. **Proc Nutr Soc** 1996 Nov; 54(3):677–91 (99 ref.)

Hypertrophic cardiomyopathy in old agers. Definitions and general considerations. Stănescu C. **Rom J Intern Med** 1995 Jul–Dec;33(3–4):133–9 (16 ref.)

Aging of human muscle: structure, function and adaptability [see comments] Porter MM, et al. **Scand J Med Sci Sports** 1995 Jun;5(3):129–42 (122 ref.) Comment in: Scand J Med Sci Sports 1995 Jun;5(3):127–8.

General medicine and geriatrics, where is the difference? The example of infective disease. Evans JG. **Schweiz Med Wochenschr** 1995 Oct 7;125(40):1847–54 (34 ref.)

Age, altitude, and arrhythmia. Alexander JK. **Tex Heart Inst J** 1995;22(4):308–16 (69 ref.)

Sexuality and aging. Schiavi RC, et al. **Urol Clin North Am** 1995 Nov;22(4):711–26 (126 ref.)

Nutrition and ageing at the population level. Kesteloot H. **Verh K Acad Geneeskd Belg** 1996;58(2):117–38; discussion 138–9 (24 ref.)

Healthy aging and the quality of life. Darnton-Hill I. **World Health Forum** 1995;16(4):335–43; discussion 344–72 (13 ref.)

[Current viewpoints in the pathophysiology and treatment of muscle weakness in elderly men] Lamberts SW. **Ned Tijdschr Geneeskd** 1996 Jan 13;140(2):68–72 (51 ref.) **(Dut)**

[Pharmacology in the elderly. Changes in the pharmacodynamic response to a given drug concentration and changes in mechanisms of regulation] Jolliet P, et al. **Ann Med Interne (Paris)** 1995;146(5):328–34 (71 ref.) **(Fre)**

[Degeneration of catecholaminergic neurons (editorial)] Chatellard-Causse C, et al. **Pathol Biol (Paris)** 1995 Sep; 43(7):577–80 (13 ref.) **(Fre)**

[Which problems arise in the hydration of elderly persons?] Mutsers A. **Rev Med Liege** 1996 Mar;51(3):249–53 (25 ref.) **(Fre)**

[Orthostatic hypotension in the elderly] Büla C. **Schweiz Rundsch Med Prax** 1996 Feb 6;85(6):145–9 (31 ref.) (Eng. Abstr.) **(Fre)**

[The calcium hypothesis of brain aging] Müller WE, et al. **Nervenarzt** 1996 Jan;67(1):15–24 (59 ref.) (Eng. Abstr.) **(Ger)**

[Heart failure in elderly patients] Hunziker P, et al. **Schweiz Rundsch Med Prax** 1995 Oct 31;84(44):1272–6 (34 ref.) (Eng. Abstr.) **(Ger)**

[Sports and rehabilitation in old age] Niederhauser HU. **Schweiz Rundsch Med Prax** 1995 Oct 31;84(44):1259–64 (30 ref.) (Eng. Abstr.) **(Ger)**

[Andropause: myth or reality?] Tomer Y, et al. **Harefuah** 1995 Jun 15;128(12):785–8 (51 ref.) **(Heb)**

[Characteristic and therapy of hypertension in the aged] Ogihara T. **Nippon Naika Gakkai Zasshi** 1996 Mar 10; 85(3):423–7 (8 ref.) **(Jpn)**

[Calcium metabolism in bone] Lorenc RS. **Pol Tyg Lek** 1995 Nov;50(44–47):48–52 (28 ref.) **(Pol)**

[Enterosorption as a method for prolonging life] Mamal AV, et al. **Fiziol Cheloveka** 1996 May–Jun;22(3):131–5 (32 ref.) **(Rus)**

[Modern concepts on the mechanisms of aging] Titov SA, et al. **Fiziol Cheloveka** 1996 Mar–Apr;22(2):118–23 (47 ref.) **(Rus)**

[Aging as the final stage of differentiation: an approach to an aperiodic state?] Gilbert DA. **Ontogenez** 1996 Jan–Feb; 27(1):3–16 (75 ref.) **(Rus)**

[The development of the active sleep phase in phylogeny and ontogeny] Aristakesian EA, et al. **Zh Evol Biokhim Fiziol** 1995 May–Jun;31(3):346–65 (85 ref.) **(Rus)**

[Aging and the morphofunctional changes in the hypothalamo-hypophyseal-adrenal cortical system] Bazhanova ED. **Zh Evol Biokhim Fiziol** 1995 Jan–Feb; 31(1):92–102 (74 ref.) **(Rus)**

[Degeneration and regeneration of the peripheral nervous system with aging] Verdú E, et al. **Rev Neurol** 1995 May–Jun;23(121):648–55 (98 ref.) (Eng. Abstr.) **(Spa)**

PSYCHOLOGY

On the importance of evolution to developmental psychobiology. Hill WL. **Dev Psychobiol** 1995 Mar; 28(2):117–29 (70 ref.)

Cognitive impairment in elderly people. Predisposing factors and implications for experimental drug studies. Jolles J, et al. **Drugs Aging** 1995 Dec;7(6):459–79 (176 ref.)

The neuropsychology of aging. Zec RF. **Exp Gerontol** 1995 May–Aug;30(3–4):431–42 (79 ref.)

Embodiment and emplacement: identities, representation and landscape in Sun City retirement communities. Laws G. **Int J Aging Hum Dev** 1995;40(4):253–80 (60 ref.)

Human development in the context of aging and chronic illness: the role of attachment in Alzheimer's disease and stroke. Wright LK, et al. **Int J Aging Hum Dev** 1995; 41(2):133–50 (82 ref.)

Relationship between elderly carers and the older adult with learning disabilities: an overview of the literature. Maggs C, et al. **J Adv Nurs** 1996 Feb;23(2):243–51 (56 ref.)

Does job-related training performance decline with age? Kubeck JE, et al. **Psychol Aging** 1996 Mar;11(1):92–107 (100 ref.)

The processing-speed theory of adult age differences in cognition. Salthouse TA. **Psychol Rev** 1996 Jul; 103(3):403–28 (110 ref.)

Healthy aging and the quality of life. Darnton-Hill I. **World Health Forum** 1995;16(4):335–43; discussion 344–72 (13 ref.)

[Life review: promoting the developmental potentials in aging] Lohmann R, et al. **Z Gerontol Geriatr** 1995 Jul–Aug; 28(4):236–41 (35 ref.) (Eng. Abstr.) **(Ger)**

[Quality of attachment representation, social integration and use of social network resources in advanced age] Wensauer M, et al. **Z Gerontol Geriatr** 1995 Nov–Dec;28(6):444–56 (89 ref.) (Eng. Abstr.) **(Ger)**

AGING, CELL see **CELL AGING**

AGITATION, PSYCHOMOTOR see **PSYCHOMOTOR AGITATION**

AGMATINE

PHARMACOLOGY

Effects of agmatine, an active metabolite of arginine metabolism, on the kidney [editorial] Morrissey JJ, et al. **Nephrol Dial Transplant** 1996 Jul;11(7):1217–9 (25 ref.)

AGNOGENIC MYELOID METAPLASIA see **MYELOID METAPLASIA**

AGNOSIA

DIAGNOSIS

Acquired epileptiform opercular syndrome: a second case report, review of the literature, and comparison to the Landau-Kleffner syndrome. Shafrir Y, et al. **Epilepsia** 1995 Oct;36(10):1050–7 (32 ref.)

PSYCHOLOGY

Is face recognition 'special'? Evidence from neuropsychology. Farah MJ. **Behav Brain Res** 1996 Apr; 76(1–2):181–9 (18 ref.)

AGORAPHOBIA

DIAGNOSIS

The panic-agoraphobic syndrome: a paradigm of the anxiety group of disorders and its implications for psychiatric practice and theory. Roth M. **Am J Psychiatry** 1996 Jul; 153(7 Suppl):111–24 (90 ref.)

DRUG THERAPY

[Panic disorder and agoraphobia: what is effective?] Bandelow B, et al. **Fortschr Neurol Psychiatr** 1995 Nov; 63(11):451–64 (120 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Panic disorder and agoraphobia: hypothesis hothouse. Klein DF. **J Clin Psychiatry** 1996;57 Suppl 6:21–7 (38 ref.)

AGRAMMATISM see **APHASIA, BROCA**

AGRANULOCYTOSIS

CHEMICALLY INDUCED

Vesnarinone-induced granulocytopenia: incidence in Japan and recommendations for safety. Furusawa S, et al. **J Clin Pharmacol** 1996 May;36(5):477–81 (13 ref.)

[Agranulocytosis caused by clozapine: the importance of leukocyte monitoring and efficacy of hematopoietic growth factors] van Melick EJ, et al. **Ned Tijdschr Geneeskd** 1995 Nov 25;139(47):2437–40 (18 ref.) (Eng. Abstr.) **(Dut)**

[Adverse hematologic effects of ticlopidine (letter)] Lesesve JF, et al. **Therapie** 1995 Sep–Oct;50(5):468–70 (11 ref.) **(Fre)**

CLASSIFICATION

Dapsone toxicity: some current perspectives. Coleman MD. **Gen Pharmacol** 1995 Nov;26(7):1461–7 (51 ref.)

COMPLICATIONS

The use of quinolones as therapy in granulocytopenic cancer patients. Comparison with other antimicrobials. Krcméry V Jr. **Drugs** 1995;49 Suppl 2:139–43 (30 ref.)

DIAGNOSIS

[Acute agranulocytosis—pathogenesis, diagnosis and treatment] Kuratowska Z. **Pol Arch Med Wewn** 1995 May; 93(5):384–9 (15 ref.) **(Pol)**

PREVENTION & CONTROL

[Agranulocytosis caused by clozapine: the importance of leukocyte monitoring and efficacy of hematopoietic growth factors] van Melick EJ, et al. **Ned Tijdschr Geneeskd** 1995 Nov 25;139(47):2437–40 (18 ref.) (Eng. Abstr.) **(Dut)**

SURGERY

The effect of thymectomy on myasthenia gravis, thrombocytopenia, and granulocytopenia associated with thymoma: report of a case. Kobayashi M, et al. **Surg Today** 1995;25(12):1061–5 (14 ref.)

THERAPY

[Use of hematopoietic growth factors] Elonen E. **Duodecim** 1995;111(8):733–40 (38 ref.) **(Fin)**

[Emergency drug therapy of thyroid disease] Tsushima T. **Nippon Naika Gakkai Zasshi** 1995 Nov 10;84(11):1848–51 (0 ref.) **(Jpn)**

[Acute agranulocytosis—pathogenesis, diagnosis and treatment] Kuratowska Z. **Pol Arch Med Wewn** 1995 May; 93(5):384–9 (15 ref.) **(Pol)**

AGRICULTURAL CHEMICALS see **AGROCHEMICALS**

AGRICULTURAL CROPS see **CROPS, AGRICULTURAL**

AGRICULTURAL WORKERS' DISEASES

DIAGNOSIS

A case of Trichuris trichiura infection diagnosed by colonoscopy. Yoshida M, et al. **Am J Gastroenterol** 1996 Jan;91(1):161–2 (7 ref.)

EPIDEMIOLOGY

Agricultural exposures and cancer. Blair A, et al. **Environ Health Perspect** 1995 Nov;103 Suppl 8:205–8 (39 ref.)

ETIOLOGY

Creutzfeldt-Jakob disease and bovine spongiform encephalopathy: any connection? [see comments] Almond JW, et al. **BMJ** 1995 Nov 25;311(7017):1415–21 (14 ref.) Comment in: BMJ 1996 Jan 20;312(7024):180. Comment in: BMJ 1996 Jan 20;312(7024):181. Comment in: BMJ 1996 Jul 20;313(7050):171–2.

Farmers at risk for prostate cancer. Van Der Gulden JW, et al. **Br J Urol** 1996 Jan;77(1):6–14 (98 ref.)

[Allergies in agriculture] Gassner M. **Schweiz Rundsch Med Prax** 1996 Aug 13;85(33):950–60 (37 ref.) (Eng. Abstr.) **(Ger)**

AGRICULTURE

Endectocidal drugs: ecological risks and counter-measures. Herd R. **Int J Parasitol** 1995 Aug;25(8):875–85 (82 ref.)

The need for ergonomics considerations for the design and development of agricultural machinery in Thailand. Mamansari DU, et al. **J Hum Ergol (Tokyo)** 1995 Jun; 24(1):61–72 (11 ref.)

The commercial and agricultural applications of animal transgenesis. Ward KA, et al. **Mol Biotechnol** 1995 Oct; 4(2):167–78 (63 ref.)

Hazard to man and the environment posed by the use of urban waste compost: a review. Déportes I, et al. **Sci Total Environ** 1995 Nov 30;172(2–3):197–22 (182 ref.)

[Occupational asthma in an agricultural setting] Bessot JC, et al. **Rev Mal Respir** 1996 Jul;13(3):205–15 (103 ref.) (Eng. Abstr.) **(Fre)**

[The effect of economic activities altering water resources on the parasitological situation] Artamoshin AS, et al. **Med Parazitol (Mosk)** 1995 Apr–Jun;(2):51–7 (50 ref.) (Eng. Abstr.) **(Rus)**

ECONOMICS

Measuring financial performance: an overview of financial statements. Dalsted NL. **Vet Clin North Am Food Anim Pract** 1995 Jul;11(2):293–311 (2 ref.)

SPA: marketing and financial performance measures for the cow-calf enterprise. Gutierrez PH. **Vet Clin North Am Food Anim Pract** 1995 Jul;11(2):313–60 (3 ref.)

Stocker/feeder cattle standardized performance analysis. McGrann JM, et al. **Vet Clin North Am Food Anim Pract** 1995 Jul;11(2):361–73 (3 ref.)

Farm Financial Standards. McGrann JM. **Vet Clin North Am Food Anim Pract** 1995 Jul;11(2):279–91 (3 ref.)

EDUCATION

Consumer concerns about modern technology in agriculture: considerations for undergraduate and graduate teaching. Weber GM, et al. **J Anim Sci** 1995 Sep;73(9):2727–32 (16 ref.)

METHODS

Regulation of Agrobacterium gene manipulation. Dewhurst F. **Methods Mol Biol** 1995;44:369-91 (33 ref.)

STANDARDS

Environmental considerations of disinfectants used in agriculture. Bruins G, et al. **Rev Sci Tech** 1995 Mar; 14(1):81-94 (15 ref.)

Stocker/feeder cattle standardized performance analysis. McGrann JM, et al. **Vet Clin North Am Food Anim Pract** 1995 Jul;11(2):361-73 (3 ref.)

AGRIN

PHARMACOLOGY

Acetylcholine receptors and the cytoskeletal connection. Phillips WD. **Clin Exp Pharmacol Physiol** 1995 Dec; 22(12):961-5 (40 ref.)

PHYSIOLOGY

Testing the agrin hypothesis. Kleiman RJ, et al. **Cell** 1996 May 17;85(4):461-4 (16 ref.)

Agrin: toward a molecular understanding of synapse regeneration. Deyst KA, et al. **Neurosurgery** 1995 Jul; 37(1):71-7 (81 ref.)

AGROBACTERIUM

GENETICS

Agrobacterium-mediated transfer of geminiviruses to plant tissues. Boulton MI. **Methods Mol Biol** 1995;49:77-93 (47 ref.)

Agrobacterium rhizogenes as a vector for transforming higher plants. Application in Lotus corniculatus transformation. Stougaard J. **Methods Mol Biol** 1995; 49:49-61 (18 ref.)

Agrobacterium-mediated transformation of Arabidopsis thaliana. Application in T-DNA tagging. Topping JF, et al. **Methods Mol Biol** 1995;49:63-76 (26 ref.)

METABOLISM

Agrocins. Clare BG. **Biotechnology** 1995;28:619-32 (53 ref.)

AGROBACTERIUM TUMEFACIENS

GENETICS

Regulation of Agrobacterium gene manipulation. Dewhurst F. **Methods Mol Biol** 1995;44:369-91 (33 ref.)

Leaf disk transformation using Agrobacterium tumefaciens-expression of heterologous genes in tobacco. Gallois P, et al. **Methods Mol Biol** 1995;49:39-48 (32 ref.)

Introduction of cloning plasmids into Agrobacterium tumefaciens. Shaw CH. **Methods Mol Biol** 1995;49:33-7 (14 ref.)

AGROCHEMICALS

see related
PESTICIDES

ADVERSE EFFECTS

Agricultural exposures and cancer. Blair A, et al. **Environ Health Perspect** 1995 Nov;103 Suppl 8:205-8 (39 ref.)

[Occupational asthma in an agricultural setting] Bessot JC, et al. **Rev Mal Respir** 1996 Jul;13(3):205-15 (103 ref.) (Eng. Abstr.) **(Fre)**

AH RECEPTORS see **RECEPTORS, ARYL HYDROCARBON**

AHG-CDC TESTS see **CYTOTOXICITY TESTS, IMMUNOLOGIC**

AID TO FAMILIES WITH DEPENDENT CHILDREN

ECONOMICS

The family cap: a popular but unproven method of welfare reform. Donovan P. **Fam Plann Perspect** 1995 Jul-Aug; 27(4):166-71 (41 ref.)

LEGISLATION & JURISPRUDENCE

The family cap: a popular but unproven method of welfare reform. Donovan P. **Fam Plann Perspect** 1995 Jul-Aug; 27(4):166-71 (41 ref.)

Fashioning a work-based strategy for welfare reform based on international human rights doctrine. Harvey P. **J Public Health Policy** 1995;16(3):269-85 (22 ref.)

AID TO THE BLIND see **SOCIAL SECURITY**

AID TO THE TOTALLY DISABLED see **SOCIAL SECURITY**

AIDS see **ACQUIRED IMMUNODEFICIENCY SYNDROME**

AIDS ANTIBODIES see **HIV ANTIBODIES**

AIDS ANTIGENS see **HIV ANTIGENS**

AIDS-ASSOCIATED ENTEROPATHY see **HIV ENTEROPATHY**

AIDS-ASSOCIATED LYMPHOMA see **LYMPHOMA, AIDS-RELATED**

AIDS-ASSOCIATED NEPHROPATHY

Human immunodeficiency virus-associated glomerulosclerosis. Humphreys MH. **Kidney Int** 1995 Aug; 48(2):311-20 (96 ref.)

DIAGNOSIS

HIV nephropathy in children. Zilleruelo G, et al. **Pediatr Clin North Am** 1995 Dec;42(6):1469-85 (52 ref.)

PHYSIOPATHOLOGY

HIV nephropathy in children. Zilleruelo G, et al. **Pediatr Clin North Am** 1995 Dec;42(6):1469-85 (52 ref.)

AIDS DEMENTIA COMPLEX

Feline immunodeficiency virus as a model for study of lentivirus infection of the central nervous system. Henriksen SJ, et al. **Curr Top Microbiol Immunol** 1995; 202:167-86 (88 ref.)

Transgenic models to assess the neuropathogenic potential of HIV-1 proteins and cytokines. Mucke L, et al. **Curr Top Microbiol Immunol** 1995;202:187-205 (98 ref.)

Selected models of HIV-induced neurological disease. Narayan O, et al. **Curr Top Microbiol Immunol** 1995; 202:151-66 (61 ref.)

Neurological complications of HIV infection. Price RW. **Lancet** 1996 Aug 17;348(9025):445-52 (50 ref.)

COMPLICATIONS

Cytotoxic T lymphocytes and HIV-1 related neurologic disorders. Kalams SA, et al. **Curr Top Microbiol Immunol** 1995;202:79-88 (51 ref.)

DIAGNOSIS

The overlooked epidemic: HIV in older adults [see comments] Whipple B, et al. **Am J Nurs** 1996 Feb; 96(2):22-8; quiz 29 (9 ref.) Comment in: Am J Nurs 1996 May;96(5):18.

Imaging methods as a diagnostic tool in neuro-AIDS. A review. Arendt G. **Bildgebung** 1995 Dec;62(4):310-9 (51 ref.)

A hemophiliac with human immunodeficiency virus (HIV)-1-associated dementia complex [see comments] Arimura H, et al. **Intern Med** 1995 Oct;34(10):995-9 (12 ref.) Comment in: Intern Med 1995 Oct;34(10):935.

[Clinical and paraclinical diagnosis of AIDS neurologic lesions] Bossi P, et al. **J Neuroradiol** 1995 Sep;22(3):142-7 (62 ref.) (Eng. Abstr.) **(Fre)**

[Magnetic resonance in AIDS-related encephalopathy] Gualdi GF, et al. **Clin Ter** 1995 Dec;146(12):843-56 (42 ref.) (Eng. Abstr.) **(Ita)**

DRUG THERAPY

[New strategies in anti-HIV therapy--consequences for the neurologist?] Enzensberger W, et al. **Nervenarzt** 1996 Jun; 67(6):506-8 (2 ref.) **(Ger)**

EPIDEMIOLOGY

Psychiatric disorders and HIV infection: impact on one another. Lyketsos CG, et al. **Epidemiol Rev** 1995; 17(1):152-64 (82 ref.)

ETIOLOGY

The pathogenesis of HIV infections of the brain. Johnson RT. **Curr Top Microbiol Immunol** 1995;202:3-10 (38 ref.)

AIDS dementia complex and HIV-1 brain infection: a pathogenetic framework for treatment and evaluation. Price RW. **Curr Top Microbiol Immunol** 1995;202:33-54 (68 ref.)

Transgenic models in the study of AIDS dementia complex. Toggas SM, et al. **Curr Top Microbiol Immunol** 1996; 206:223-41 (89 ref.)

[Biochemical studies on AIDS dementia complex--possible contribution of quinolinic acid during brain damage] Saito K. **Rinsho Byori** 1995 Sep;43(9):891-901 (36 ref.) (Eng. Abstr.) **(Jpn)**

[Organic mental disorders and AIDS] Kasparas GG. **Acta Psiquiatr Psicol Am Lat** 1994 Dec;40(4):330-4 (14 ref.) (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

Role of immune activation and cytokine expression in HIV-1-associated neurologic diseases. Yoshioka M, et al. **Adv Neuroimmunol** 1995;5(3):335-58 (190 ref.)

Unraveling the neuroimmune mechanisms for the HIV-1-associated cognitive/motor complex. Nottet HS, et al. **Immunol Today** 1995 Sep;16(9):441-8 (85 ref.)

Managing HIV. Part 3: Mechanisms of diseases. 3.7 How HIV leads to neurological disease. Brew BJ, et al. **Med J Aust** 1996 Feb 19;164(4):233-4 (19 ref.)

NURSING

The overlooked epidemic: HIV in older adults [see comments] Whipple B, et al. **Am J Nurs** 1996 Feb; 96(2):22-8; quiz 29 (9 ref.) Comment in: Am J Nurs 1996 May;96(5):18.

The role of the consultation-liaison nurse. Caring for patients with AIDS dementia complex. Price N. **J Psychosoc Nurs Ment Health Serv** 1995 Dec;33(12):31-4 (14 ref.)

PATHOLOGY

Role for astrocytosis in HIV-1-associated dementia. Vitkovic L, et al. **Curr Top Microbiol Immunol** 1995;202:105-16 (49 ref.)

Quantitative neuropathologic assessment of HIV-1 encephalitis. Wiley CA. **Curr Top Microbiol Immunol** 1995; 202:55-61 (32 ref.)

Neuropathology of human immunodeficiency virus: questions and answers [editorial] Petito CK. **Hum Pathol** 1996 Jul; 27(7):623-4 (24 ref.)

In vivo magnetic resonance spectroscopy in HIV and HIV-related brain diseases. Chang L. **Rev Neurosci** 1995 Oct-Dec;6(4):365-78 (63 ref.)

PHYSIOPATHOLOGY

In vivo modeling of HIV-1 mediated neurodegeneration [comment] Masliah E. **Am J Pathol** 1996 Sep;149(3):745-50 (68 ref.) Comment on: Am J Pathol 1996 Sep;149(3):1027-53.

Trypsin inhibition: a potential cause of cobalamin deficiency common to the pathogenesis of Alzheimer-type dementia and AIDS dementia complex? McCaddon A, et al. **Med Hypotheses** 1995 Aug;45(2):200-4 (49 ref.)

PSYCHOLOGY

Neurocognitive disorders in HIV-1 infection. HNRC Group. HIV Neurobehavioral Research Center. Grant I, et al. **Curr Top Microbiol Immunol** 1995;202:11-32 (77 ref.)

THERAPY

[AIDS dementia. Prognosis and therapeutic perspectives] Lubetzki C. **J Neuroradiol** 1995 Sep;22(3):169-71 (15 ref.) (Eng. Abstr.) **(Fre)**

AIDS ENCEPHALOPATHY see **AIDS DEMENTIA COMPLEX**

AIDS ENTEROPATHY see **HIV ENTEROPATHY**

AIDS, FELINE see **FELINE ACQUIRED IMMUNODEFICIENCY SYNDROME**

AIDS, MURINE see **MURINE ACQUIRED IMMUNODEFICIENCY SYNDROME**

AIDS-RELATED LYMPHOMA see **LYMPHOMA, AIDS-RELATED**

AIDS-RELATED OPPORTUNISTIC INFECTIONS

Advances in the management of AIDS-related cytomegalovirus retinitis [see comments] Masur H, et al. **Ann Intern Med** 1996 Jul 15;125(2):126-36 (69 ref.) Comment in: Ann Intern Med 1996 Jul 15;125(2):144-5.

Cryptococcal meningitis. Jones GA, et al. **Br J Hosp Med** 1995 Nov 1-14;54(9):439-45 (38 ref.)

Mycocutaneous atypical mycobacterial infections in acquired immunodeficiency syndrome. Zanelli G, et al. **Clin Dermatol** 1995 May-Jun;13(3):281-8 (68 ref.)

Oral candidiasis in HIV-infected patients. Brawner DL, et al. **Curr Top Med Mycol** 1995;6:113-25 (68 ref.)

HIV-associated lesions. Greenberg MS. **Dermatol Clin** 1996 Apr;14(2):319-26 (39 ref.)

Management of protozoan infections in AIDS. The Jefferiss Wing Therapeutics and Protocols Group. Tomlinson DR, et al. **Int J STD AIDS** 1995 Jul-Aug;6(4):237-40 (7 ref.)

Mycobacterium avium complex infection in AIDS: clinical features, treatment, and prevention. Eccles E, et al. **J Assoc Nurses AIDS Care** 1995 Sep-Oct;6(5):37-47; quiz 48-9 (23 ref.)

Opportunistic infections in HIV seropositive individuals. Gazzard BG. **J R Coll Physicians Lond** 1995 Jul-Aug; 29(4):335-9 (21 ref.)

HIV-associated respiratory diseases. Miller R. **Lancet** 1996 Aug 3;348(9023):307-12 (50 ref.)

Neurological complications of HIV infection. Price RW. **Lancet** 1996 Aug 17;348(9025):445-52 (50 ref.)

AIDS and the eyes. Sarraf D, et al. **Lancet** 1996 Aug 24; 348(9026):525-8 (30 ref.)

Gastrointestinal manifestations of HIV infection. Sharpstone D, et al. **Lancet** 1996 Aug 10;348(9024):379-83 (50 ref.)

Cytomegalovirus retinitis in patients with AIDS: current status. Luckie AP. **Med J Aust** 1995 Nov 6;163(9):489-92

(24 ref.)
Pediatric HIV infection and its oral manifestations: a review. Chigurupati R, et al. **Pediatr Dent** 1996 Mar-Apr; 18(2):106-13 (68 ref.)
Mycobacterium avium intracellulare infection in children with AIDS. Gershon AA. **Pediatr Pulmonol Suppl** 1995; 11:7-9 (14 ref.)
Opportunistic fungal infections in patients with HIV disease: combating cryptococcosis and histoplasmosis. Kirchner JT. **Postgrad Med** 1996 Jun;99(6):209-16 (34 ref.)
Tuberculous pericarditis in an HIV-infected patient. Antony SJ, et al. **Scand J Infect Dis** 1995;27(4):411-3 (26 ref.)
Severe pulmonary infections in AIDS patients. Gatell JM, et al. **Semin Respir Infect** 1996 Jun;11(2):119-28 (57 ref.)
[Upper genital tract infections in women infected with HIV: epidemiologic, diagnostic and therapeutic aspects] Panel P, et al. **Contracept Fertil Sex** 1996 Jun;24(6):488-94 (22 ref.) (Eng. Abstr.) **(Fre)**
[Chorioretinal manifestations in AIDS] Snyers B, et al. **J Fr Ophtalmol** 1995;18(10):634-44 (76 ref.) **(Fre)**
[Mycobacterium gordonae infections in human immunodeficiency virus infection] Maslo C, et al. **Presse Med** 1995 Sep 2-9;24(25):1157-60 (15 ref.) (Eng. Abstr.) **(Fre)**
[Rhodococcus equi pulmonary abscess in HIV infection] About I, et al. **Rev Med Interne** 1996;17(5):410-4 (25 ref.) (Eng. Abstr.) **(Fre)**
[Respiratory system changes in persons infected with the HIV virus] Niemirowska H. **Pneumonol Pol** 1990 Sep-Oct; 58(9-10):549-58 (42 ref.) **(Pol)**
[Update on microsporidiosis in humans] Atías A. **Rev Med Chil** 1995 Jun;123(6):762-72 (40 ref.) (Eng. Abstr.) **(Spa)**

COMPLICATIONS

Ocular complication in HIV infected individuals. Harrison TJ. **Alaska Med** 1995 Jul-Sep;37(3):91-100 (78 ref.)
Mucocutaneous histoplasmosis in AIDS. Souza Filho FJ, et al. **Br J Dermatol** 1995 Sep;133(3):472-4 (26 ref.)
Common superficial fungal infections in patients with AIDS. Aly R, et al. **Clin Infect Dis** 1996 May;22 Suppl 2:S128-32 (24 ref.)
Paracoccidioidomycosis and AIDS: an overview. Goldani LZ, et al. **Clin Infect Dis** 1995 Nov;21(5):1275-81 (41 ref.)
Aspergillus sinusitis in patients with AIDS: report of three cases and review. Teh W, et al. **Clin Infect Dis** 1995 Sep; 21(3):529-35 (46 ref.)
Clinical manifestations and implications of coinfection with Mycobacterium kansasii and human immunodeficiency virus type 1. Witzig RS, et al. **Clin Infect Dis** 1995 Jul; 21(1):77-85 (69 ref.)
Cryptococcosis in the era of AIDS--100 years after the discovery of Cryptococcus neoformans. Mitchell TG, et al. **Clin Microbiol Rev** 1995 Oct;8(4):515-48 (529 ref.)
Cutaneous manifestations of opportunistic infections in patients infected with human immunodeficiency virus. Tappero JW, et al. **Clin Microbiol Rev** 1995 Jul;8(3):440-50 (68 ref.)
Myopathy and HIV infection. Chariot P, et al. **Curr Opin Rheumatol** 1995 Nov;7(6):497-502 (72 ref.)
Zygomycosis (mucormycosis) and HIV infection: report of three cases and review. Nagy-Agren SE, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995 Dec 1;10(4):441-9 (27 ref.)
Anergy, AIDS and tuberculosis. Hegde HR. **Med Hypotheses** 1995 Nov;45(5):433-40 (48 ref.)
Acquired immunodeficiency syndrome (AIDS) and the eye. Armstrong RA. **Ophthalmic Physiol Opt** 1995 Sep;15 Suppl 2:S42-8 (25 ref.)
Gastrointestinal manifestations of acquired immunodeficiency syndrome: radiologic-pathologic correlation. Pantongrag-Brown L, et al. **Radiographics** 1995 Sep; 15(5):1155-78 (105 ref.)
[Left vocal cord paralysis in cytomegalovirus multifocal neuropathy in a patient with HIV infection] de La Blanchardiere A, et al. **Presse Med** 1996 Jan 27;25(3):106-7 (7 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Pulmonary complications of HIV infection. Murray JF. **Annu Rev Med** 1996;47:117-26 (30 ref.)
Cytomegalovirus sinusitis. A new manifestation of AIDS. Marks SC, et al. **Arch Otolaryngol Head Neck Surg** 1996 Jul;122(7):789-91 (11 ref.)
Imaging methods as a diagnostic tool in neuro-AIDS. A review. Arendt G. **Bildgebung** 1995 Dec;62(4):310-9 (51 ref.)
Bacillary angiomatosis and parenchymal peliosis: frequent absence of mucocutaneous lesions [editorial] Schwartzman WA. **Clin Infect Dis** 1996 May;22(5):801-2 (14 ref.)
Radiologic and laboratory evaluation of enhancing brain lesions in patients with AIDS. Johnson MD, et al. **Compr Ther** 1995 Nov;21(11):645-52 (45 ref.)
Neurologic opportunistic infections. Clifford DB. **Curr Opin Neurol** 1995 Jun;8(3):175-8 (32 ref.)
Progressive multifocal leukoencephalopathy: clinical and laboratory observations on a viral induced demyelinating disease in the immunodeficient patient. Major EO, et al. **Curr Opin Neurol** 1995 Jun;8(3):184-90 (58 ref.)
Serological diagnosis of tuberculosis. Bothamley GH. **Eur Respir J Suppl** 1995 Sep;20:676s-688s (114 ref.)
Molecular diagnosis of tuberculosis. Richeldi L, et al. **Eur Respir J Suppl** 1995 Sep;20:689s-700s (95 ref.)
Bacillus piliformis infection (Tyzzer's disease) in a patient infected with HIV-1: confirmation with 16S ribosomal RNA sequence analysis. Smith KJ, et al. **J Am Acad Dermatol** 1996 Feb;34(2 Pt 2):343-8 (18 ref.)
AIDS and the lung. Huang L, et al. **Med Clin North Am** 1996 Jul;80(4):775-801 (114 ref.)
Managing HIV. Part 5: Treating secondary outcomes. 5.5 HIV and opportunistic neurological infections. Jones PD, et al. **Med J Aust** 1996 Apr 1;164(7):418-21 (22 ref.)
Managing HIV. Part 5: Treating secondary outcomes. 5.7 HIV and respiratory disease. Smith AI, et al. **Med J Aust** 1996 Apr 1;164(7):425-8 (33 ref.)
The lung in HIV infection: can pulmonary function testing help? Mitchell DM, et al. **Monaldi Arch Chest Dis** 1996 Jun;51(3):214-22 (30 ref.)
HIV-related Pneumocystis carinii thyroiditis: a unique case and literature review. Danahey DG, et al. **Otolaryngol Head Neck Surg** 1996 Jan;114(1):158-61 (15 ref.)
Assessment of fever in HIV-infected patients. Gleckman R, et al. **Postgrad Med** 1996 Mar;99(3):78-80, 87-9, 93-4 passim (37 ref.)
Use of polyclonal IgG in HIV infection and AIDS. Buscombe JR, et al. **Q J Nucl Med** 1995 Sep;39(3):212-20 (34 ref.)
Radiology's role in diagnosis of AIDS-related pathologies. Vedda RA. **Radiol Technol** 1995 Jul-Aug;66(6):365-9; quiz 370-2 (25 ref.)
Pneumocystic infections: the radiologist's perspective. Kuhlman JE. **Radiology** 1996 Mar;198(3):623-35 (96 ref.)
Seminal vesicle abscess: a case report and review of literature. Pandey P, et al. **Scand J Urol Nephrol** 1995 Dec;29(4):521-4 (14 ref.)
[Cerebral toxoplasmosis. Neuroradiologic diagnosis and prognostic monitoring] Martin-Duverneuil N, et al. **J Neuroradiol** 1995 Sep;22(3):196-203 (28 ref.) (Eng. Abstr.) **(Fre)**
[Bacteriological diagnosis of tuberculosis: current hieratic classification of methods] Carbonnelle B, et al. **Rev Med Interne** 1995;16(7):518-23 (45 ref.) (Eng. Abstr.) **(Fre)**
[Endoscopy of the upper gastrointestinal tract in HIV disease] Caca K, et al. **Bildgebung** 1995 Dec;62(4):244-51 (56 ref.) (Eng. Abstr.) **(Ger)**
[HIV infection: findings in liver and bile ducts] Jablonowski H. **Bildgebung** 1995 Dec;62(4):260-70 (89 ref.) (Eng. Abstr.) **(Ger)**
[HIV infection and the lower gastrointestinal tract--characteristics of endoscopic diagnosis] Mauss S, et al. **Bildgebung** 1995 Dec;62(4):252-8 (46 ref.) (Eng. Abstr.) **(Ger)**
[AIDS: infections of the retina and choroid] Schimkat M, et al. **Bildgebung** 1995 Dec;62(4):288-301 (100 ref.) (Eng. Abstr.) **(Ger)**
[Clinical aspects and therapy of ubiquitous mycobacterioses] Fätkenheuer G, et al. **Internist (Berl)** 1995 Oct; 36(10):987-94 (52 ref.) **(Ger)**
[Clinical aspects and therapy of tuberculosis] Höffken G, et al. **Internist (Berl)** 1995 Oct;36(10):961-9 (61 ref.) **(Ger)**
[Magnetic resonance in AIDS-related encephalopathy] Gualdi GF, et al. **Clin Ter** 1995 Dec;146(12):843-56 (42 ref.) (Eng. Abstr.) **(Ita)**
[The influence of HIV infection on development of tuberculosis] Kwiatkowska S. **Pol Arch Med Wewn** 1995 May;93(5):421-6 (39 ref.) **(Pol)**
[Facial and cervical manifestations of AIDS] Gebrim EM, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1995 Jul-Aug; 50(4):222-6 (22 ref.) (Eng. Abstr.) **(Por)**
[Applications of the polymerase chain reaction (PCR) to the diagnosis of central nervous system infections] Querol JM, et al. **An Med Interna** 1996 May;13(5):235-8 (20 ref.) (Eng. Abstr.) **(Spa)**
[Hospital pneumonia due to Xanthomonas maltophilia and AIDS (letter)] Sitges M, et al. **Arch Bronconeumol** 1996 May;32(5):259-60 (6 ref.) **(Spa)**

DRUG THERAPY

Current management of cytomegalovirus retinitis in AIDS update on ganciclovir and foscarnet for CMV infections. Jacobson MA. **Adv Exp Med Biol** 1996;394:85-92 (28 ref.)
Cytomegalovirus retinitis in AIDS: natural history, diagnosis, and treatment. Dunn JP, et al. **AIDS Clin Rev** 1995-96; :99-129 (120 ref.)
Therapeutic approaches for AIDS-related toxoplasmosis [see comments] Behbahani R, et al. **Ann Pharmacother** 1995 Jul-Aug;29(7-8):760-8 (52 ref.) Comment in: Ann Pharmacother 1995 Dec;29(12):1303-4.
Use of rifabutin in the treatment of pulmonary tuberculosis. Grassi C, et al. **Clin Infect Dis** 1996 Apr;22 Suppl 1:S50-4 (21 ref.)
Mycobacterium avium complex infection, rifabutin, and uveitis--is there a connection? Nichols CW. **Clin Infect Dis** 1996 Apr;22 Suppl 1:S43-7; discussion S47-9 (21 ref.)
Recent advances in the management of cryptococcal meningitis in patients with AIDS. Powderly WG. **Clin Infect Dis** 1996 May;22 Suppl 2:S119-23 (32 ref.)
Rifabutin prophylaxis for Mycobacterium avium complex infection in patients with AIDS. Siegal FP. **Clin Infect Dis** 1996 Apr;22 Suppl 1:S23-30; discussion S30-2 (38 ref.)
Cryptococcosis in the era of AIDS--100 years after the discovery of Cryptococcus neoformans. Mitchell TG, et al. **Clin Microbiol Rev** 1995 Oct;8(4):515-48 (529 ref.)
Atovaquone. A review of its pharmacological properties and therapeutic efficacy in opportunistic infections. Spencer CM, et al. **Drugs** 1995 Jul;50(1):176-96 (64 ref.)
Drug resistance in Mycobacterium tuberculosis. Cole ST, et al. **Eur Respir J Suppl** 1995 Sep;20:701s-713s (116 ref.)
Controversies in the treatment of cytomegalovirus retinitis: foscarnet versus ganciclovir. Jabs DA. **Infect Agents Dis** 1995 Sep;4(3):131-42 (63 ref.)
Management of cytomegalovirus infection. The Jefferiss Wing Therapeutics and Protocols Group. Fisher M, et al. **Int J STD AIDS** 1995 Sep-Oct;6(5):313-9 (28 ref.)
Treatment of AIDS and HIV-related conditions--1996. Goldschmidt RH, et al. **J Am Board Fam Pract** 1996 Mar-Apr;9(2):125-48 (88 ref.)
Managing HIV. Part 5: Treating secondary outcomes. 5.16 HIV and bacterial infections. Allworth AM, et al. **Med J Aust** 1996 May 6;164(9):546-8 (5 ref.)
Managing HIV. Part 5: Treating secondary outcomes. 5.15 HIV and non-tuberculous mycobacterial infection. Hoy JF, et al. **Med J Aust** 1996 May 6;164(9):543-5 (29 ref.)
Management of HIV infection. A 1995-96 overview for the clinician. Henry K. **Minn Med** 1995 Nov;78(11):17-24 (25 ref.)
Treatment of disseminated Mycobacterium avium complex disease: a clinician's perspective. Benson CA. **Res Microbiol** 1996 Jan-Feb;147(1-2):16-24 (43 ref.)
Solving the dilemma of antimycobacterial chemotherapy. Rastogi N, et al. **Res Microbiol** 1996 Jan-Feb;147(1-2):7-10 (30 ref.)
Update (1995) on clinical trials of antiviral therapy and prophylaxis for AIDS-related cytomegalovirus disease. Jacobson MA. **Scand J Infect Dis Suppl** 1995;99:96-9 (25 ref.)
Options in the management of pneumonia caused by Pneumocystis carinii in patients with acquired immune deficiency syndrome and intolerance to trimethoprim/sulfamethoxazole. Korraa H, et al. **South Med J** 1996 Mar;89(3):272-7 (38 ref.)
Clarithromycin against Mycobacterium avium complex infections. Heifets LB. **Tuber Lung Dis** 1996 Feb; 77(1):19-26 (105 ref.)
[Intolerance to trimethoprim-sulfamethoxazole in Pneumocystis carinii pneumonia in AIDS. Search for predictive factors] Pinzani V, et al. **Ann Med Interne (Paris)** 1995;146(7):505-9 (25 ref.) (Eng. Abstr.) **(Fre)**
[Cotrimoxazole induced dermatitis and curative treatment of AIDS pneumocystosis] Caumes E. **Rev Mal Respir** 1996; 13(2):101-6 (45 ref.) (Eng. Abstr.) **(Fre)**
[Treatment of non-tuberculous mycobacterial infections] Dautzenberg B. **Rev Mal Respir** 1996;13(1):81-3 (17 ref.) **(Fre)**
[Multiple digestive involvement in visceral leishmaniasis in a patient with HIV infection: favourable course with itraconazole] Béchade D, et al. **Rev Med Interne** 1996; 17(3):234-7 (20 ref.) (Eng. Abstr.) **(Fre)**
[Cytomegalovirus disease in the AIDS patient. The current status of therapy and the outlook] Stoehr A, et al. **Dtsch Med Wochenschr** 1995 Dec 22;120(51-52):1785-8 (39 ref.) **(Ger)**
[Therapy and prevention of pneumocystis carinii pneumonia] Goebel FD, et al. **Internist (Berl)** 1995 Dec;36(12):1150-5 (31 ref.) **(Ger)**
[Renaissance of tuberculosis?] Meyer FJ, et al. **Internist (Berl)** 1995 Dec;36(12):1162-73 (80 ref.) **(Ger)**
[Therapeutic approaches in diseases caused by mycobacteria] Urbanczik R. **Pneumologie** 1995 Dec;49 Suppl 3:649-52 (32 ref.) (Eng. Abstr.) **(Ger)**
[The role of aminoglycosides in HIV-infected patients] Opravil M. **Schweiz Med Wochenschr Suppl** 1996; 76:49S-53S (27 ref.) (Eng. Abstr.) **(Ger)**
[Clarithromycin combined with pyrimethamine in cerebral toxoplasmosis--a report of 2 cases] Dalston MO, et al. **Rev Soc Bras Med Trop** 1995 Oct-Dec;28(4):409-13 (11 ref.) (Eng. Abstr.) **(Por)**

EPIDEMIOLOGY

Duodenal and hepatic toxoplasmosis in a patient with HIV infection: review of the literature. Bonacini M, et al. **Am J Gastroenterol** 1996 Sep;91(9):1838-40 (13 ref.)
Tuberculosis as an opportunistic disease in persons infected with human immunodeficiency virus. Castro KG. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S66-71 (71 ref.)
Disseminated histoplasmosis in persons infected with human immunodeficiency virus. Hajjeh RA. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S108-10 (27 ref.)
Human immunodeficiency virus and AIDS in Uganda. Mugerwa RD, et al. **East Afr Med J** 1996 Jan;73(1):20-6 (56 ref.)
Intestinal histoplasmosis in AIDS patients: report of three cases observed in France and review of the literature. Trylesinski A, et al. **Eur J Gastroenterol Hepatol** 1995 Jul; 7(7):679-83 (23 ref.)
Epidemiology of tuberculosis in Europe. Rieder HL. **Eur Respir J Suppl** 1995 Sep;20:620s-632s (157 ref.)
Zygomycosis in HIV-positive patients: a review of the literature. Van den Saffele JK, et al. **Mycoses** 1996 Mar-Apr;39(3-4):77-84 (51 ref.)

Tuberculosis and HIV infection worldwide. Murray JF. **Pneumologie** 1995 Dec;49 Suppl 3:653–6 (22 ref.)
Current problems with tuberculosis treatment. Grosset J. **Res Microbiol** 1996 Jan–Feb;147(1–2):10–6 (32 ref.)
Human immunodeficiency virus–associated atypical mycobacterial skeletal infections. Hirsch R, et al. **Semin Arthritis Rheum** 1996 Apr;25(5):347–56 (46 ref.)
Endemic mycosis complicating human immunodeficiency virus infection. Sarosi GA, et al. **West J Med** 1996 Apr; 164(4):335–40 (43 ref.)
[HIV infection and tuberculosis] Brodt HR. **Internist (Berl)** 1995 Oct;36(10):970–9 (63 ref.) **(Ger)**
[Epidemiology of tuberculosis] Schlegel J, et al. **Internist (Berl)** 1995 Oct;36(10):951–6 (9 ref.) **(Ger)**
[Does AIDS influence the epidemiology of tuberculosis?] Ferlinz R, et al. **Pneumologie** 1995 Aug;49(8):449–54 (7 ref.) **(Ger)**

ETIOLOGY

Mycobacterium avium complex infection in AIDS. Kemper CA, et al. **AIDS Clin Rev** 1995–96;:153–228 (271 ref.)
Acquired immunodeficiency syndrome and the eye—1996 [editorial] Jabs DA. **Arch Ophthalmol** 1996 Jul;114(7):863–6 (61 ref.)
Is vulvovaginal candidiasis an AIDS-related illness? White MH. **Clin Infect Dis** 1996 May;22 Suppl 2:S124–7 (29 ref.)
Nosocomial colonization and infection in persons infected with human immunodeficiency virus. Craven DE, et al. **Infect Control Hosp Epidemiol** 1996 May;17(5):304–18 (90 ref.)
Catheter–associated fungemia due to Wangiella (Exophiala) dermatitidis. Nachman S, et al. **J Clin Microbiol** 1996 Apr; 34(4):1011–3 (10 ref.)
HIV–related oral disease. Greenspan D, et al. **Lancet** 1996 Sep 14;348(9029):729–33 (38 ref.)

IMMUNOLOGY

Anergy, AIDS and tuberculosis. Hegde HR. **Med Hypotheses** 1995 Nov;45(5):433–40 (48 ref.)
[The influence of HIV infection on development of tuberculosis] Kwiatkowska S. **Pol Arch Med Wewn** 1995 May;93(5):421–6 (39 ref.) **(Pol)**

MICROBIOLOGY

Lung abscess due to nontyphoid Salmonella in an immunocompromised host. Case report with review of the literature. Ridha AG, et al. **Acta Clin Belg** 1996; 51(3):175–83 (41 ref.)
Cutaneous Cryptococcus infection and AIDS. Report of 12 cases and review of the literature. Murakawa GJ, et al. **Arch Dermatol** 1996 May;132(5):545–8 (36 ref.)
Infectious endocarditis due to non–typhi Salmonella in patients infected with human immunodeficiency virus: report of two cases and review. Fernández Guerrero ML, et al. **Clin Infect Dis** 1996 May;22(5):853–5 (10 ref.)
Cavitary pulmonary lesions in patients infected with human immunodeficiency virus. Gallant JE, et al. **Clin Infect Dis** 1996 Apr;22(4):671–82 (208 ref.)
Oral manifestation of disseminated Mycobacterium kansasii infection in a patient with AIDS. Nüesch R, et al. **Dermatology** 1996;192(2):183–4 (10 ref.)
Infectious colitides in patients with acquired immunodeficiency syndrome. Mosenkis BN, et al. **Gastroenterologist** 1995 Sep;3(3):241–8 (72 ref.)
Isolated renal mucormycosis: case report and review. Levy E, et al. **J Am Soc Nephrol** 1995 Jun;5(12):2014–9 (25 ref.)
Central venous catheter infection with Rhodotorula minuta in a patient with AIDS taking suppressive doses of fluconazole. Goldani LZ, et al. **J Med Vet Mycol** 1995 Jul–Aug;33(4):267–70 (22 ref.)
[Disseminated Histoplasma capsulatum histoplasmosis in African AIDS patients (3 cases)] Imbert P, et al. **Med Trop (Mars)** 1995;55(2):151–3 (12 ref.) (Eng. Abstr.) **(Fre)**
[New opportunistic pathogens in AIDS] Morillon M. **Med Trop (Mars)** 1996;56(1):17–20 (20 ref.) **(Fre)**

PARASITOLOGY

Multiorgan microsporidiosis: report of five cases and review. Gunnarsson G, et al. **Clin Infect Dis** 1995 Jul;21(1):37–44 (46 ref.)
Rosacea–like demodicosis in an HIV–positive child. Barrio J, et al. **Dermatology** 1996;192(2):143–5 (23 ref.)
Microsporidium in AIDS patients: a perspective. Chukwuma C Sr. **East Afr Med J** 1996 Jan;73(1):72–5 (35 ref.)
Human microsporidioses and AIDS: recent advances. Desportes–Livage I. **Parasite** 1996 Jun;3(2):107–13 (12 ref.)
[Extracerebral toxoplasmosis in immunodepressed subjects. Case report of a case of pulmonary toxoplasmosis in an HIV–positive patient and literature review] Kamm W, et al. **Rev Med Suisse Romande** 1996 May;116(5):385–90 (23 ref.) **(Fre)**

PATHOLOGY

A foveal–sparing pattern of cytomegalovirus retinitis in the acquired immunodeficiency syndrome. Luckie AP, et al. **Aust N Z J Ophthalmol** 1996 Feb;24(1):53–9 (23 ref.)
HIV–associated eosinophilic folliculitis: case report and review of the literature. Basarab T, et al. **Br J Dermatol** 1996 Mar;134(3):499–503 (16 ref.)
Opportunistic infections of the central nervous system in children with HIV infection: report of 9 autopsy cases and review of literature. Wrzolek MA, et al. **Clin Neuropathol** 1995 Jul–Aug;14(4):187–96 (41 ref.)
Disseminated cutaneous Cryptococcus clinically mimicking basal cell carcinoma [letter] Murakawa GJ, et al. **Dermatol Surg** 1995 Nov;21(11):992–3 (8 ref.)
Penile mass caused by the newly described organism Mycobacterium celatum. Dahl DM, et al. **Urology** 1996 Feb;47(2):266–8 (13 ref.)
[Pathologic anatomy of cytomegalovirus encephalomyelitis and varicella–zona virus encephalomyelitis] Henin D, et al. **J Neuroradiol** 1995 Sep;22(3):180–3 (14 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Clinical impact of cytomegalovirus infections of the nervous system in patients with AIDS. McCutchan JA. **Clin Infect Dis** 1995 Oct;21 Suppl 2:S196–201 (42 ref.)
[Parvovirus B19 infection. New physiopathological approaches] Labau E, et al. **Presse Med** 1996 Feb 3; 25(4):162–6 (26 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

Preventive therapy for tuberculosis in HIV infection: the promise and the reality [editorial] O'Brien RJ, et al. **AIDS** 1995 Jul;9(7):665–73 (83 ref.)
Multiple opportunistic pathogen prophylaxis for patients with advanced HIV disease: an overview. Jacobson MA. **AIDS Clin Rev** 1995–96;:47–63 (24 ref.)
Preventing opportunistic infections in human immunodeficiency virus–infected persons: implications for the developing world. Kaplan JE, et al. **Am J Trop Med Hyg** 1996 Jul;55(1):1–11 (113 ref.)
Microsporidiosis as an AIDS–related opportunistic infection. Bryan RT. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S62–5 (57 ref.)
Prophylaxis for tuberculosis in Europe—ongoing research. Carosi G, et al. **Clin Infect Dis** 1996 Apr;22 Suppl 1:S55–60 (31 ref.)
Potential role of rifabutin in prophylaxis for tuberculosis and infections due to multiple opportunistic pathogens. Chaisson RE. **Clin Infect Dis** 1996 Apr;22 Suppl 1:S61–6; discussion S66–9 (51 ref.)
Indicators for assessment of compliance with quality standards for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. Gross PA, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S138–41 (0 ref.)
Cryptosporidiosis: sources of infection and guidelines for prevention. Juranek DD. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S57–61 (52 ref.)
Opportunistic coccidioidomycosis in patients infected with human immunodeficiency virus: prevention issues and priorities. McNeil MM, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S111–3 (19 ref.)
Preventing disseminated Mycobacterium avium complex disease in patients infected with human immunodeficiency virus. Ostroff SM, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S72–6 (27 ref.)
Quality standard for the prophylaxis of Pneumocystis carinii pneumonia in adults and adolescents infected with human immunodeficiency virus. Phair JP, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S128–9 (8 ref.)
Opportunistic candidal infections in patients infected with human immunodeficiency virus: prevention issues and priorities. Reef SE, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S99–102 (24 ref.)
Preventing toxoplasmic encephalitis in persons infected with human immunodeficiency virus. Richards FO Jr, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S49–56 (44 ref.)
Preventing Pneumocystis carinii pneumonia in persons infected with human immunodeficiency virus. Simonds RJ, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S44–8 (41 ref.)
Quality standard for the prophylaxis of Pneumocystis carinii pneumonia in infants and children born to women infected with human immunodeficiency virus. Wilfert CM, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S132–3 (4 ref.)
The diagnosis and management of perinatal HIV infection. Nesheim SR. **Clin Obstet Gynecol** 1996 Jun;39(2):396–410 (84 ref.)
Treatment and prophylaxis of Mycobacterium avium complex. Young LS. **Int J STD AIDS** 1996;7 Suppl 1:23–7 (15 ref.)
Infection prevention strategies for children with cancer and AIDS: contrasting dilemmas. Chanock SJ, et al. **J Hosp Infect** 1995 Jun;30 Suppl:197–208 (69 ref.)
Use of BCG in high prevalence areas for HIV. Felten MK, et al. **Trop Med Parasitol** 1995 Jun;46(2):69–71 (30 ref.)
[Prevention of opportunistic infections in HIV infection] Pesce A. **Rev Med Interne** 1995;16 Suppl 3:315s–319s (20 ref.) **(Fre)**

RADIOGRAPHY

[Standard radiological characteristics of thoracic sites of tuberculosis in patients with AIDS in a Tunisian population] Tiouiri H, et al. **Rev Pneumol Clin** 1995; 51(6):321–4 (12 ref.) (Eng. Abstr.) **(Fre)**
[Pneumococcal pneumonia in a patient with HIV infection. Development to excavation. Apropos of a case] Venot P, et al. **Rev Pneumol Clin** 1996;52(1):29–32 (11 ref.) (Eng. Abstr.) **(Fre)**
[Differential radiologic diagnosis of HIV–associated lung diseases] Becker–Gaab C, et al. **Bildgebung** 1995 Dec; 62(4):302–9 (16 ref.) (Eng. Abstr.) **(Ger)**
[Rhodococcus equi lung infection in AIDS patients. A report of 4 cases] Carli Moretti C, et al. **Radiol Med (Torino)** 1996 Apr;91(4):477–80 (13 ref.) **(Ita)**

THERAPY

The potential role of azithromycin in the treatment of prophylaxis of toxoplasmosis. Chang HR. **Int J STD AIDS** 1996;7 Suppl 1:18–22 (34 ref.)
[The therapy of viral hepatitis in HIV–infected patients] Rockstroh JK, et al. **Dtsch Med Wochenschr** 1995 Dec 8; 120(49):1705–8 (29 ref.) **(Ger)**

TRANSMISSION

Sexually transmissible agent and African Kaposi's sarcoma [editorial] Matondo P, et al. **Int J STD AIDS** 1996 Jan–Feb; 7(1):4–6 (35 ref.)

ULTRASONOGRAPHY

[Ultrasound skin findings in HIV infection by imaging with 7.5 MHz linear transducers] Bogner JR, et al. **Bildgebung** 1995 Dec;62(4):281–6 (14 ref.) (Eng. Abstr.) **(Ger)**
[Ultrasound findings in HIV patients] Lüthen R, et al. **Bildgebung** 1995 Dec;62(4):271–80 (45 ref.) (Eng. Abstr.) **(Ger)**

VIROLOGY

[Cytomegalovirus pneumopathies. What role should be given to cytomegaloviruses isolated from blood and bronchoalveolar lavage fluid in AIDS and from organ and bone marrow grafts?] Blot F, et al. **Rev Pneumol Clin** 1995; 51(6):309–20 (102 ref.) (Eng. Abstr.) **(Fre)**

AIDS SEROCONVERSION see HIV SEROPOSITIVITY

AIDS SERODIAGNOSIS

see related
HIV SEROPREVALENCE

Difficulties and strategies of HIV diagnosis. Gürtler L. **Lancet** 1996 Jul 20;348(9021):176–9 (30 ref.)
A review of research on the nature and quality of HIV testing services: a proposal for process–based studies. Beardsell S, et al. **Soc Sci Med** 1996 Mar;42(5):733–43 (112 ref.)

LEGISLATION & JURISPRUDENCE

Home HIV testing and conflicts with state HIV testing regulations. Fabbri WO. **Am J Law Med** 1995;21(4):419–44 (230 ref.)

METHODS

Application of laboratory diagnostics in HIV nursing. Barrick B, et al. **Nurs Clin North Am** 1996 Mar;31(1):41–56 (47 ref.)

NURSING

Application of laboratory diagnostics in HIV nursing. Barrick B, et al. **Nurs Clin North Am** 1996 Mar;31(1):41–56 (47 ref.)

STANDARDS

Pitfalls in HIV testing. Application and limitations of current tests. Cordes RJ, et al. **Postgrad Med** 1995 Nov; 98(5):177–80, 185–6, 189 (22 ref.)

AIDS SEROLOGY see AIDS SERODIAGNOSIS

AIDS SEROPOSITIVITY see HIV SEROPOSITIVITY

AIDS, SIMIAN see SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME

AIDS VACCINES

HIV preventive vaccines. Progress to date. Esparza J, et al. **Drugs** 1995 Nov;50(5):792–804 (153 ref.)
Candidate AIDS vaccines. Graham BS, et al. **N Engl J Med** 1995 Nov 16;333(20):1331–9 (100 ref.)
A "complement–ary" AIDS vaccine. Dierich MP, et al. **Nat Med** 1996 Feb;2(2):153–5 (26 ref.)
Modelling HIV vaccination. McLean AR, et al. **Trends Microbiol** 1995 Dec;3(12):458–62 (18 ref.)

IMMUNOLOGY

Progress in AIDS vaccine development. Johnston MI. **Int Arch Allergy Immunol** 1995 Dec;108(4):313–7 (29 ref.)
Human studies in the development of human immunodeficiency virus vaccines. Dolin R. **J Infect Dis** 1995 Nov;172(5):1175–83 (91 ref.)
HIV–1 Tat protein as a potential AIDS vaccine. Goldstein G. **Nat Med** 1996 Sep;2(9):960–4 (34 ref.)
Overview: practical insights from comparative immunology and pathogenesis of AIDS, hepatitis B, and measles for developing an HIV vaccine. Hilleman MR. **Vaccine** 1995

AIDS VACCINES

Dec;13(18):1733–40 (41 ref.)

THERAPEUTIC USE

Retroviral vectors for HIV immunotherapy. Warner JF, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:105–16 (36 ref.)
State of the science. HIV vaccine development. Grady C, et al. **Nurs Clin North Am** 1996 Mar;31(1):25–39 (44 ref.)
Clinical considerations in vaccine trials with special reference to candidate HIV vaccines. Fast PE, et al. **Pharm Biotechnol** 1995;6:97–134 (255 ref.)
[Safer trials of vaccine and gene therapy against HIV] Ikuta K. **Hokkaido Igaku Zasshi** 1996 Jan;71(1):21–6 (31 ref.) (Eng. Abstr.) **(Jpn)**

AIDS VIRUS see **HIV-1**

AIDS VIRUS RECEPTORS see **RECEPTORS, HIV**

AIR

Self-induced pneumoparotitis. Goguen LA, et al. **Arch Otolaryngol Head Neck Surg** 1995 Dec;121(12):1426–9 (28 ref.)

ANALYSIS

The novel selected-ion flow tube approach to trace gas analysis of air and breath. Smith D, et al. **Rapid Commun Mass Spectrom** 1996;10(10):1183–98 (37 ref.)

AIR AMBULANCES

Increased flight surgeon role in military aeromedical evacuation. Lyons TJ, et al. **Aviat Space Environ Med** 1995 Oct;66(10):927–9 (16 ref.)
Prehospital monitoring of trauma patients: experience of a helicopter emergency medical service. Morley AP. **Br J Anaesth** 1996 May;76(5):726–30 (56 ref.)

AIR BAGS

see related
SEAT BELTS
[Air bags: benefits and risks] Haddad R, et al. **Harefuah** 1996 Jan 15;130(2):120–2 (25 ref.) **(Heb)**

AIR-BLOOD BARRIER see **BLOOD-AIR BARRIER**

AIR EMBOLISM see **EMBOLISM, AIR**

AIR MICROBIOLOGY

Molecular techniques and their potential application in monitoring the microbiological quality of indoor air. MacNeil L, et al. **Can J Microbiol** 1995 Aug;41(8):657–65 (69 ref.)
Hazard to man and the environment posed by the use of urban waste compost: a review. Déportes I, et al. **Sci Total Environ** 1995 Nov 30;172(2–3):197–22 (182 ref.)
Microbiologic considerations. Disinfection and sterilization strategies and the potential for airborne transmission of bloodborne pathogens. Favero MS, et al. **Surg Clin North Am** 1995 Dec;75(6):1071–89 (40 ref.)

AIR POLLUTANTS

Monitoring of exposure to air pollution. Williams ML. **Sci Total Environ** 1995 Jun 16;168(2):169–74 (6 ref.)
[Regional and local problems of chemical environmental pollution and health of the population (review of the literature)] Revich BA, et al. **Med Tr Prom Ekol** 1995; (9):23–9 (12 ref.) **(Rus)**

ADVERSE EFFECTS

Health effects of outdoor air pollution. Part 2. Committee of the Enviroamental and Occupational Health Assembly of the American Thoracic Society. **Am J Respir Crit Care Med** 1996 Feb;153(2):477–98 (226 ref.)
Persistent organic pollutants—the state of contamination of ambient air in central Europe. Possible sources and effects. Holoubek I. **Arch Toxicol Suppl** 1996;18:381–90 (10 ref.)
Long-term canine exposure studies with ambient air pollutants. Heyder J, et al. **Eur Respir J** 1996 Mar; 9(3):571–84 (101 ref.)
Risk factors for lung cancer among nonsmokers with emphasis on lifestyle factors. Gao YT. **Lung Cancer** 1996 Mar;14 Suppl 1:S39–45 (24 ref.)
Air pollution: brown skies research. Tattersfield AE. **Thorax** 1996 Jan;51(1):13–22 (43 ref.)
Air pollutants and respiratory hypersensitivity. Devalia JL, et al. **Toxicol Lett** 1996 Aug;86(2–3):169–76 (55 ref.)
Exposure to environmental chemicals relevant for respiratory hypersensitivity: global aspects. Schwela D. **Toxicol Lett** 1996 Aug;86(2–3):131–42 (13 ref.)
Interaction of environmental chemicals with respiratory sensitization. Van Loveren H, et al. **Toxicol Lett** 1996 Aug; 86(2–3):163–7 (12 ref.)
Adverse health effects of air pollutants in a nonsmoking population. Pope CA 3rd. **Toxicology** 1996 Jul 17; 111(1–3):149–55 (19 ref.)

TOXICITY

Biological and biochemical effects of air pollutants: synergistic effects of sulphite. Hippeli S, et al. **Biochem Soc Symp** 1995;61:153–61 (43 ref.)
Interaction of air pollutants and pulmonary allergic responses in experimental animals. Gilmour MI. **Toxicology** 1995 Dec 28;105(2–3):335–42 (48 ref.)

AIR POLLUTANTS, ENVIRONMENTAL

Respiratory effects of air pollutants: experimental studies in humans [see comments] Sandström T. **Eur Respir J** 1995 Jun;8(6):976–95 (221 ref.) Comment in: Eur Respir J 1995 Jun;8(6):883–4.
[Role of atmospheric pollutants in asthma] Charpin D, et al. **Rev Pneumol Clin** 1996;52(2):70–8 (54 ref.) (Eng. Abstr.) **(Fre)**
[Disorders of clearance of pollutants from the lung] Mustajbegović J, et al. **Lijec Vjesn** 1996 Jan–Feb; 118(1–2):39–43 (88 ref.) (Eng. Abstr.) **(Scr)**

ADVERSE EFFECTS

Abatement of tropospheric ozone: effects of strategies to improve air quality on public health and other sectors. Guest CS, et al. **Aust N Z J Public Health** 1996 Jun; 20(3):301–8 (55 ref.)
Usefulness of animal models for predicting human responses to long-term inhalation of particles. Mauderly JL. **Chest** 1996 Mar;109(3 Suppl):65S–68S (24 ref.)
The effects of air pollution on children. Bates DV. **Environ Health Perspect** 1995 Sep;103 Suppl 6:49–53 (49 ref.)
Lung cancer and air pollution. Cohen AJ, et al. **Environ Health Perspect** 1995 Nov;103 Suppl 8:219–24 (50 ref.)
Rubber latex in the air: an occupational and environmental cause of asthma? Hopkins J. **Food Chem Toxicol** 1995 Oct; 33(10):895–9 (23 ref.)
Particulate pollution and health: a review of the Utah valley experience. Pope CA 3rd. **J Expo Anal Environ Epidemiol** 1996 Jan–Mar;6(1):23–34 (19 ref.)
A critical review of PM10-mortality time-series studies. Thurston GD. **J Expo Anal Environ Epidemiol** 1996 Jan–Mar;6(1):3–21 (33 ref.)
Airborne pollutants and the immune system. Albright JF, et al. **Otolaryngol Head Neck Surg** 1996 Feb;114(2):232–8 (35 ref.)
Bone: target and source of environmental pollutant exposure. McGowan JA. **Otolaryngol Head Neck Surg** 1996 Feb; 114(2):220–3 (14 ref.)
Exposure of children to pollutants in house dust and indoor air. Roberts JW, et al. **Rev Environ Contam Toxicol** 1995; 143:59–78 (74 ref.)
Review of the Wisconsin DHSS report on health concerns attributed to reformulated gasoline use in southeastern Wisconsin [editorial] Rudo K. **Toxicol Ind Health** 1995 Sep–Oct;11(5):463–6 (3 ref.)
Exposure to environmental chemicals relevant for respiratory hypersensitivity: European aspects. Sivertsen B, et al. **Toxicol Lett** 1996 Aug;86(2–3):143–53 (23 ref.)
[Advances in the study on biological effects of diesel exhaust] Lu Y, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1995 Sep;29(5):305–6 (15 ref.) **(Chi)**

ANALYSIS

The ozone hole. Lehmann P. **Med J Aust** 1995 Dec 4–18; 163(11–12):576–8 (7 ref.)

IMMUNOLOGY

Environmental factors and primary T-cell sensitisation to inhalant allergens in infancy: reappraisal of the role of infections and air pollution. Holt PG. **Pediatr Allergy Immunol** 1995 Feb;6(1):1–10 (85 ref.)

METABOLISM

Environmental hazard assessment of chemicals and products. Part VI. Abiotic degradation in the troposphere. Klöpffer W. **Chemosphere** 1996 Sep;33(6):1083–99 (71 ref.)
Disposition, metabolism, and toxicity of methyl tertiary butyl ether, an oxygenate for reformulated gasoline. Hutcheon DE, et al. **J Toxicol Environ Health** 1996 Apr 5; 47(5):453–64 (40 ref.)

PHARMACOKINETICS

Pharmacokinetic modeling approaches for describing the uptake, systemic distribution, and disposition of inhaled chemicals. Gargas ML, et al. **Crit Rev Toxicol** 1995; 25(3):237–54 (70 ref.)

TOXICITY

Pharmacokinetic modeling approaches for describing the uptake, systemic distribution, and disposition of inhaled chemicals. Gargas ML, et al. **Crit Rev Toxicol** 1995; 25(3):237–54 (70 ref.)
Observations on asthma. Bates DV. **Environ Health Perspect** 1995 Sep;103 Suppl 6:243–7 (49 ref.)
Associations between criteria air pollutants and asthma. Koren HS. **Environ Health Perspect** 1995 Sep;103 Suppl 6:235–42 (106 ref.)
Evaluation of a possible association of urban air toxics and asthma. Leikauf GD, et al. **Environ Health Perspect** 1995 Sep;103 Suppl 6:253–71 (179 ref.)
Disposition, metabolism, and toxicity of methyl tertiary butyl ether, an oxygenate for reformulated gasoline. Hutcheon DE, et al. **J Toxicol Environ Health** 1996 Apr 5; 47(5):453–64 (40 ref.)
Methyl tertiary butyl ether (MTBE)—evaluation of MTBE carcinogenicity studies. Rudo KM. **Toxicol Ind Health** 1995 Mar–Apr;11(2):167–73 (14 ref.)

AIR POLLUTANTS, OCCUPATIONAL

ADVERSE EFFECTS

Wood dust. **IARC Monogr Eval Carcinog Risks Hum** 1995; 62:35–215 (383 ref.)
Respiratory irritants encountered at work. Taylor AJ. **Thorax** 1996 May;51(5):541–5 (17 ref.)
Exposure-response functions in Air Force toxic risk modeling. Philipson LL, et al. **Toxicology** 1996 Jul 17; 111(1–3):239–49 (22 ref.)
[Occupational asthma: definition—epidemiology—etiologic substances—prognosis—prevention—diagnosis—expert assessment aspects] Merget R, et al. **Pneumologie** 1996 May; 50(5):356–63 (83 ref.) **(Ger)**
[The first case of severe pneumopathy due to hard metals successfully undergoing a lung transplant] Tomasini M, et al. **Med Lav** 1995 Jul–Aug;86(4):325–31 (6 ref.) (Eng. Abstr.) **(Ita)**

ANALYSIS

[Refractory ceramic fibers, kinds, health effects after exposure, TLVs] Woźniak H, et al. **Med Pr** 1996; 47(4):393–9 (17 ref.) (Eng. Abstr.) **(Pol)**

POISONING

Arsine toxicity: chemical and mechanistic implications. Klimecki WT, et al. **J Toxicol Environ Health** 1995 Dec; 46(4):399–409 (49 ref.)

TOXICITY

Toxicity of combustion products of polymeric materials. Cempel M. **Bull Inst Marit Trop Med Gdynia** 1993–94; 44–45(1–4):75–81 (21 ref.)
Occupational asthma. Chan-Yeung M. **Environ Health Perspect** 1995 Sep;103 Suppl 6:249–52 (40 ref.)
Respiratory health effects of man-made vitreous (mineral) fibres. De Vuyst P, et al. **Eur Respir J** 1995 Dec; 8(12):2149–73 (169 ref.)

AIR POLLUTANTS, RADIOACTIVE

ADVERSE EFFECTS

Importance of radon as a threat to public health. Donohoe K, et al. **Otolaryngol Head Neck Surg** 1996 Feb; 114(2):271–6 (23 ref.)

TOXICITY

Biokinetics of nuclear fuel compounds and biological effects of nonuniform radiation. Lang S, et al. **Environ Health Perspect** 1995 Oct;103(10):920–34 (191 ref.)

AIR POLLUTION

Direct and indirect exposure to air pollution. Thron RW. **Otolaryngol Head Neck Surg** 1996 Feb;114(2):281–5 (24 ref.)
[Atmospheric pollution: acid depositions] De Luca D'Alessandro E. **Ann Ig** 1994 Jul–Dec;6(4–6):793–802 (27 ref.) (Eng. Abstr.) **(Ita)**
[Association of air pollution and mortality: a review of recent epidemiological studies] Ballester Diez F, et al. **Rev Esp Salud Publica** 1995 Mar–Apr;69(2):177–88 (38 ref.) (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Health effects of outdoor air pollution. Committee of the Environmental and Occupational Health Assembly of the American Thoracic Society. **Am J Respir Crit Care Med** 1996 Jan;153(1):3–50 (578 ref.)
Particulate air pollution and mortality: the Philadelphia story [editorial; comment] [see comments] Samet JM. **Epidemiology** 1995 Sep;6(5):471–3 (14 ref.) Comment on: Epidemiology 1995 Sep;6(5):476–84. Comment in: Epidemiology 1995 Nov;6(6):629–32.
Air pollution and mortality: issues and uncertainties. Lipfert FW, et al. **J Air Waste Manag Assoc** 1995 Dec; 45(12):949–66 (54 ref.)
Hispanic environmental health: ambient and indoor air pollution. National Coalition of Hispanic Health and Human Services Organizations (COSSMHO). **Otolaryngol Head Neck Surg** 1996 Feb;114(2):256–64 (27 ref.)
Blood and air pollution: state of knowledge and research

needs. Badman DG, et al. **Otolaryngol Head Neck Surg** 1996 Feb;114(2):205–8 (16 ref.)
Psychiatric aspects of air pollution. Lundberg A. **Otolaryngol Head Neck Surg** 1996 Feb;114(2):227–31 (39 ref.)
Effect of air pollution in asthma and respiratory allergy. Peden DB. **Otolaryngol Head Neck Surg** 1996 Feb; 114(2):242–7 (33 ref.)
The free radical basis of air pollution: focus on ozone. Kelly FJ, et al. **Respir Med** 1995 Nov;89(10):647–56 (77 ref.)
Air pollution: brown skies research. Tattersfield AE. **Thorax** 1996 Jan;51(1):13–22 (43 ref.)
Asthma and the environment: do environmental factors affect the incidence and prognosis of asthma? Samet JM. **Toxicol Lett** 1995 Dec;82–83:33–8 (15 ref.)
Environmentally induced asthma. Utell MJ, et al. **Toxicol Lett** 1995 Dec;82–83:47–53 (21 ref.)

ANALYSIS

Allergen levels causing sensitisation, bronchial hyperreactivity and asthma. Dreborg S. **Pediatr Allergy Immunol** 1995;6 Suppl 7:22–6 (44 ref.)

PREVENTION & CONTROL

Abatement of tropospheric ozone: effects of strategies to improve air quality on public health and other sectors. Guest CS, et al. **Aust N Z J Public Health** 1996 Jun; 20(3):301–8 (55 ref.)

STATISTICS & NUMERICAL DATA

A population-based exposure model for benzene. MacIntosh DL, et al. **J Expo Anal Environ Epidemiol** 1995 Jul–Sep; 5(3):375–403 (73 ref.)

AIR POLLUTION, INDOOR

see related
ENVIRONMENTAL ILLNESS

Molecular techniques and their potential application in monitoring the microbiological quality of indoor air. MacNeil L, et al. **Can J Microbiol** 1995 Aug;41(8):657–65 (69 ref.)
Indoor particles: a review. Wallace L. **J Air Waste Manag Assoc** 1996 Feb;46(2):98–126 (106 ref.)
Is there a dose-response relationship between exposure to indoor allergens and symptoms of asthma? [editorial] Platts-Mills TA, et al. **J Allergy Clin Immunol** 1995 Oct; 96(4):435–40 (44 ref.)
[Allergic diseases in the indoor environment] Schata M. **Zentralbl Hyg Umweltmed** 1995 Apr;197(1–3):196–211 (8 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Indoor air pollution and childhood asthma: effective environmental interventions. Etzel RA. **Environ Health Perspect** 1995 Sep;103 Suppl 6:55–8 (43 ref.)
Environmental risk factors of childhood asthma in urban centers. Malveaux FJ, et al. **Environ Health Perspect** 1995 Sep;103 Suppl 6:59–62 (30 ref.)
Risk factors for lung cancer among nonsmokers with emphasis on lifestyle factors. Gao YT. **Lung Cancer** 1996 Mar;14 Suppl 1:S39–45 (24 ref.)
Diet as a confounder of the association between air pollution and female lung cancer: Hong Kong studies on exposures to environmental tobacco smoke, incense, and cooking fumes as examples. Koo LC, et al. **Lung Cancer** 1996 Mar; 14 Suppl 1:S47–61 (21 ref.)
Hispanic environmental health: ambient and indoor air pollution. National Coalition of Hispanic Health and Human Services Organizations (COSSMHO). **Otolaryngol Head Neck Surg** 1996 Feb;114(2):256–64 (27 ref.)
Environmental factors influencing the levels of indoor allergens. Munir AK. **Pediatr Allergy Immunol** 1995;6 Suppl 7:13–21 (91 ref.)
Possible mechanisms for the respiratory tract effects of noncarcinogenic indoor-climate pollutants and bases for their risk assessment. Damgård Nielsen G, et al. **Scand J Work Environ Health** 1995 Jun;21(3):165–78 (113 ref.)
Health effects of indoor-air microorganisms [see comments] Husman T. **Scand J Work Environ Health** 1996 Feb; 22(1):5–13 (95 ref.) Comment in: Scand J Work Environ Health 1996 Feb;22(1):1–3.
Environmental chemicals relevant for respiratory hypersensitivity: the indoor environment. Becher R, et al. **Toxicol Lett** 1996 Aug;86(2–3):155–62 (47 ref.)

ANALYSIS

Immunochemical and molecular methods for defining and measuring indoor allergens: in dust and air. Chapman MD, et al. **Pediatr Allergy Immunol** 1995;6 Suppl 7:8–12 (32 ref.)

PREVENTION & CONTROL

Condensation and mould: the Canadian experience. Rayner KF. **J R Soc Health** 1996 Apr;116(2):83–6 (19 ref.)
Strategies for indoor allergen elimination. Wahn U, et al. **Pediatr Allergy Immunol** 1995;6 Suppl 7:42–6 (41 ref.)
[Prevention during building construction against electromagnetic fields caused by high voltage electric lines--principles and risk evaluation] Boikat U, et al. **Gesundheitswesen** 1996 Mar;58(3):147–53 (50 ref.) (Eng. Abstr.) **(Ger)**

AIR POLLUTION, TOBACCO SMOKE see **TOBACCO SMOKE POLLUTION**

AIR QUALITY, INDOOR see **AIR POLLUTION, INDOOR**

AIRCRAFT

Air travel induced meningitis following vestibular schwannoma (acoustic neuroma) surgery. Callanan V, et al. **J Laryngol Otol** 1996 Mar;110(3):258–60 (18 ref.)
Noise induced hearing loss in military helicopter aircrew—a review of the evidence. Owen JP. **J R Army Med Corps** 1995 Jun;141(2):98–101 (19 ref.)

STANDARDS

Aircraft and ship disinfection. Cancellotti FM. **Rev Sci Tech** 1995 Mar;14(1):177–89 (20 ref.)

AIRSICKNESS see **MOTION SICKNESS**

AIRWAY OBSTRUCTION

Pediatric stridor and airway compromise. Zalzal GH. **J Med Liban** 1994;42(4):221–6 (15 ref.)

COMPLICATIONS

Relationship of acute obstructive airway change to chronic (fixed) obstruction. Becklake MR. **Thorax** 1995 Sep;50 Suppl 1:S16–21 (57 ref.)

CONGENITAL

Prenatal sonographic diagnosis of upper airway obstruction: a challenge that can be achieved. Golan-Porat N, et al. **J Laryngol Otol** 1996 Jun;110(6):583–5 (16 ref.)

DIAGNOSIS

Obstructive sleep apnea in infants and young children. Ward SL, et al. **J Clin Neurophysiol** 1996 May;13(3):198–207 (40 ref.)
Flow volume loops in the evaluation of upper airway obstruction. Lunn WW, et al. **Otolaryngol Clin North Am** 1995 Aug;28(4):721–9 (13 ref.)
[Functional laryngeal obstruction] Alonso Peces ME, et al. **Arch Bronconeumol** 1995 Dec;31(10):543–5 (12 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

[Bronchodilator drugs] Tschopp JM. **Rev Med Suisse Romande** 1996 May;116(5):325–7 (27 ref.) **(Fre)**
[Chronopharmacology of reversible airway obstruction] Haen E. **Wien Med Wochenschr** 1995;145(17–18):439–45 (38 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Grain dust, endotoxin, and airflow obstruction. Schwartz DA. **Chest** 1996 Mar;109(3 Suppl):57S–63S (51 ref.)
Mechanisms of increased airway microvascular permeability: role in airway inflammation and obstruction. Goldie RG, et al. **Clin Exp Pharmacol Physiol** 1995 Jun–Jul; 22(6–7):387–96 (88 ref.)
Airway obstruction secondary to rhinoscleroma during pregnancy. Armstrong WB, et al. **Ear Nose Throat J** 1995 Nov;74(11):768–73 (40 ref.)
Airway foreign bodies in children. Somanath BP, et al. **Indian Pediatr** 1995 Aug;32(8):890–7 (26 ref.)
Airway obstruction. The problem and its causes. Courey MS. **Otolaryngol Clin North Am** 1995 Aug;28(4):673–84 (15 ref.)
[Medical ENT diagnosis and therapy of sleep-associated respiratory disorders with obstruction of the upper airways] Riechelmann H, et al. **Pneumologie** 1995 Oct;49(10):523–7 (33 ref.) **(Ger)**

NURSING

Mastering emergency airway management. Somerson SJ, et al. **Am J Nurs** 1996 May;96(5):24–30; quiz 31 (11 ref.)

PHYSIOPATHOLOGY

Leukotrienes as mediators of airway obstruction and inflammation in asthma. Dahlén B, et al. **Clin Exp Allergy** 1995 Nov;25 Suppl 2:50–4 (42 ref.)
Postnatal development of responses to airflow obstruction. Harding R, et al. **Clin Exp Pharmacol Physiol** 1995 Aug; 22(8):537–43 (33 ref.)
Esophago/pharyngo/laryngeal interrelationships: airway protection mechanisms. Kidder TM. **Dysphagia** 1995 Fall; 10(4):228–31 (21 ref.)

RADIOGRAPHY

Evidence of expiratory CT scans of small-airway obstruction in sarcoidosis. Gleeson FV, et al. **AJR Am J Roentgenol** 1996 May;166(5):1052–4 (12 ref.)
Radiology of the central airways. Worrell JA. **Otolaryngol Clin North Am** 1995 Aug;28(4):701–20 (23 ref.)
Thin-section CT, emphysema, air trapping, and airway obstruction [editorial; comment] Müller NL, et al. **Radiology** 1996 Jun;199(3):621–2 (22 ref.) Comment on: Radiology 1996 Jun;199(3):825–9.

RADIONUCLIDE IMAGING

Pulmonary studies using positron emission tomography. Rhodes CG, et al. **Eur Respir J** 1995 Jun;8(6):1001–17 (80 ref.)

SURGERY

Operative evaluation of airway obstruction. Gardner GM, et al. **Otolaryngol Clin North Am** 1995 Aug;28(4):737–50 (12 ref.)

THERAPY

Mastering emergency airway management. Somerson SJ, et al. **Am J Nurs** 1996 May;96(5):24–30; quiz 31 (11 ref.)
Rapid-sequence intubation of the pediatric patient. Pediatric Emergency Medicine Committee of the American College of Emergency Physicians [see comments] Gerardi MJ, et al. **Ann Emerg Med** 1996 Jul;28(1):55–74 (200 ref.) Comment in: Ann Emerg Med 1996 Jul;28(1):79–81.
Management of upper airway obstruction: intubation vs tracheotomy. Bu Saba NY, et al. **J Med Liban** 1994; 42(4):235–9 (18 ref.)
Current concepts in airway management for cardiopulmonary resuscitation. Reed AP. **Mayo Clin Proc** 1995 Dec;70(12):1172–84 (111 ref.)
Endoscopic management of acute respiratory failure related to tracheobronchial malignancies. Ninane V. **Support Care Cancer** 1995 Nov;3(6):418–21 (40 ref.)
[Airway occlusion as an emergency. Recognition and treatment] Lipp M, et al. **Internist (Berl)** 1995 Aug; 36(8):765–8 (15 ref.) **(Ger)**

ULTRASONOGRAPHY

Prenatal sonographic diagnosis of upper airway obstruction: a challenge that can be achieved. Golan-Porat N, et al. **J Laryngol Otol** 1996 Jun;110(6):583–5 (16 ref.)

AIRWAY RESISTANCE

Rhinomanometric study in China. Li X, et al. **Chin Med J (Engl)** 1995 Jul;108(7):557–60 (15 ref.)
Effect of partial middle turbinectomy on nasal airflow and resistance. Cook PR, et al. **Otolaryngol Head Neck Surg** 1995 Oct;113(4):413–9 (32 ref.)

DRUG EFFECTS

[Chronopharmacology of reversible airway obstruction] Haen E. **Wien Med Wochenschr** 1995;145(17–18):439–45 (38 ref.) (Eng. Abstr.) **(Ger)**

AKATHISIA see **PSYCHOMOTOR AGITATION**

AKATHISIA, DRUG-INDUCED

see related
DYSKINESIA, DRUG-INDUCED

Drug-induced akathisia revisited. Chung WS, et al. **Br J Clin Pract** 1996 Jul–Aug;50(5):270–8 (101 ref.)

CLASSIFICATION

[Deficit: the value and difficulty of defining the primary or secondary character of observed symptoms] Petit M, et al. **Encephale** 1996 Jun;22 Spec No 2:13–8 (20 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

[The serotonin syndrome: review of the literature and description of an original study] Lejoyeux M, et al. **Encephale** 1995 Sep–Oct;21(5):537–43 (45 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

Is there a rationale for iron supplementation in the treatment of akathisia? A review of the evidence. Gold R, et al. **J Clin Psychiatry** 1995 Oct;56(10):476–83 (63 ref.)

EPIDEMIOLOGY

The epidemiology of drug-induced akathisia: Part I. Acute akathisia. Sachdev P. **Schizophr Bull** 1995;21(3):431–49 (130 ref.)
The epidemiology of drug-induced akathisia: Part II. Chronic, tardive, and withdrawal akathisias. Sachdev P. **Schizophr Bull** 1995;21(3):451–61 (70 ref.)

ETIOLOGY

Akathisia: a review and case report following paroxetine treatment. Baldassano CF, et al. **Compr Psychiatry** 1996 Mar–Apr;37(2):122–4 (40 ref.)

AKATHISIA, TARDIVE see **AKATHISIA, DRUG-INDUCED**

AKINETIC MUTISM

AKINETIC MUTISM

ETIOLOGY

[Akinetic mutism with right hemiplegia caused by infarction in the territory of the left anterior cerebral artery] Lechevalier B, et al. **Rev Neurol (Paris)** 1996 Mar; 152(3):181–9 (27 ref.) (Eng. Abstr.) **(Fre)**

AKINETIC PETIT MAL see **EPILEPSY, ABSENCE**

ALAGILLE SYNDROME

[Alagille syndrome] Hata K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):523–6 (15 ref.) **(Jpn)**

[Dysmorphogenesis of intrahepatic bile duct] Okanoue T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):553–4 (12 ref.) **(Jpn)**

COMPLICATIONS

Alagille's syndrome associated with cystic renal disease. Martin SR, et al. **Arch Dis Child** 1996 Mar;74(3):232–5 (14 ref.)

[Dermatological manifestations of Alagille syndrome] Doutre MS, et al. **Gastroenterol Clin Biol** 1996 Mar;20(2):207–8 (7 ref.) **(Fre)**

ETIOLOGY

[Alagille syndrome in 1995. Clinical and genetic data] Deleuze JF, et al. **Gastroenterol Clin Biol** 1995 Jun–Jul; 19(6–7):587–96 (103 ref.) (Eng. Abstr.) **(Fre)**

ALANINE

ANALOGS & DERIVATIVES

The genetics of lantibiotic biosynthesis. Jack R, et al. **Bioessays** 1995 Sep;17(9):793–802 (69 ref.)

Lantibiotics. Gasson MJ. **Biotechnology** 1995;28:283–306 (78 ref.)

ALANINE AMINOTRANSFERASE

BLOOD

[Interactions between chronic viral hepatitis C and pregnancy] Grangé JD, et al. **Gastroenterol Clin Biol** 1995 May;19(5):520–4 (29 ref.) (Eng. Abstr.) **(Fre)**

[Aspartate aminotransferase (AST) and alanine aminotransferase (ALT)] Miura Y. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:266–71 (12 ref.) **(Jpn)**

D-ALANINE CARBOXYPEPTIDASE see **CARBOXYPEPTIDASE TRANSPEPTIDASE**

ALBENDAZOLE

ADVERSE EFFECTS

Albendazole-induced pseudomembranous colitis. Shah V, et al. **Am J Gastroenterol** 1996 Jul;91(7):1453–4 (11 ref.)

ALBERS-SCHOENBERG DISEASE see **OSTEOPETROSIS**

ALBINISM, OCULAR

PATHOLOGY

Albinism and the associated ocular defects. Oetting WS, et al. **Metab Pediatr Syst Ophthalmol** 1994;17(1–4):5–9 (19 ref.)

ALBINISM, OCULOCUTANEOUS

PATHOLOGY

Albinism and the associated ocular defects. Oetting WS, et al. **Metab Pediatr Syst Ophthalmol** 1994;17(1–4):5–9 (19 ref.)

ALBINISM, TYROSINASE-NEGATIVE see **ALBINISM, OCULOCUTANEOUS**

ALBINISM, TYROSINASE-POSITIVE see **ALBINISM, OCULOCUTANEOUS**

ALBINISM, YELLOW-MUTANT see **ALBINISM, OCULOCUTANEOUS**

ALBRIGHT'S SYNDROME see **FIBROUS DYSPLASIA, POLYOSTOTIC**

ALBUMIN RECEPTORS see **RECEPTORS, ALBUMIN**

ALBUMINS

see related
PREALBUMIN
RECEPTORS, ALBUMIN

ADMINISTRATION & DOSAGE

Does it make sense to administer albumin to the patient with nephrotic oedema? [editorial] Dorhout Mees EJ. **Nephrol Dial Transplant** 1996 Jul;11(7):1224–6 (17 ref.)

BIOSYNTHESIS

[The study of the biological activation induced by the lymphocyte transfusion—the induction of the bio-reproducing protein (BRP)] Sato I. **Hum Cell** 1995 Sep; 8(3):77–84 (18 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Nucleoprotein architecture of the albumin transcriptional enhancer. Zaret KS. **Semin Cell Biol** 1995 Aug;6(4):209–18 (56 ref.)

THERAPEUTIC USE

Therapeutic use of albumin. De Gaudio AR. **Int J Artif Organs** 1995 Apr;18(4):216–24 (60 ref.)

[The study of the biological activation induced by the lymphocyte transfusion—the induction of the bio-reproducing protein (BRP)] Sato I. **Hum Cell** 1995 Sep; 8(3):77–84 (18 ref.) (Eng. Abstr.) **(Jpn)**

TOXICITY

Renal toxicity of albumin and other lipoproteins. Schreiner GF. **Curr Opin Nephrol Hypertens** 1995 Jul;4(4):369–73 (33 ref.)

ALBUMINURIA

Microalbuminuria: prognostic and therapeutic implications in diabetic and hypertensive pregnancy. Bar J, et al. **Diabet Med** 1995 Aug;12(8):649–56 (110 ref.)

Microalbuminuria in non-insulin dependent diabetes mellitus [editorial; comment] Kumar S. **Diabet Med** 1995 Aug; 12(8):647–8 (11 ref.) Comment on: Diabet Med 1995 Aug;12(8):657–63.

Microalbuminuria and potential confounders. A review and some observations on variability of urinary albumin excretion. Mogensen CE, et al. **Diabetes Care** 1995 Apr; 18(4):572–81 (85 ref.)

Microalbuminuria in prediction and prevention of diabetic nephropathy in insulin-dependent diabetes mellitus patients. Mogensen CE. **J Diabetes Complications** 1995 Oct-Dec;9(4):337–49 (99 ref.)

[Microalbuminuria and non-insulin-dependent diabetes: practical interpretation and therapeutic consequences] Bouhanick B, et al. **Diabete Metab** 1995 Oct;21(4):295–8 (20 ref.) **(Fre)**

[Microalbuminuria in clinical practice] Bar J, et al. **Harefuah** 1995 Jun 15;128(12):797–800 (40 ref.) **(Heb)**

COMPLICATIONS

Microalbuminuria as a marker of cardiovascular and renal disease in essential hypertension. Bigazzi R, et al. **Nephrol Dial Transplant** 1995;10 Suppl 6:10–4 (58 ref.)

DIAGNOSIS

Surveillance for complications of diabetes: don't wait for symptoms before intervening. Hirsch IB. **Postgrad Med** 1996 Mar;99(3):147–55, 159–62 (24 ref.)

DRUG THERAPY

Comparative effects of indapamide and captopril on blood pressure and albumin excretion rate in diabetic microalbuminuria. Donnelly R, et al. **Am J Cardiol** 1996 Feb 22;77(6):26B–30B (33 ref.)

EPIDEMIOLOGY

Microalbuminuria in patients with NIDDM: an overview. Alzaid AA. **Diabetes Care** 1996 Jan;19(1):79–89 (136 ref.)

ETIOLOGY

Microalbuminuria: a marker of systemic disease. Gosling P. **Br J Hosp Med** 1995 Sep 20–Oct 3;54(6):285–90 (20 ref.)

Diabetic renal disease: microalbuminuria, implications and intervention. Savage MW, et al. **Nutrition** 1995 Nov–Dec; 11(6):761–4 (57 ref.)

[Microalbuminuria in diabetes mellitus] van Etten RW, et al. **Ned Tijdschr Geneeskd** 1995 Sep 9;139(36):1823–8 (72 ref.) **(Dut)**

[Microalbuminuria in diabetes mellitus—illness or symptom?] Müller WA. **Versicherungsmedizin** 1996 Jun 1;48(3):70–6 (84 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Prognostic significance of albuminuria for the development of nephropathy. Viberti GF. **J Hypertens Suppl** 1995 Aug; 13(2):S87–9 (15 ref.)

PREVENTION & CONTROL

Differing effects of antihypertensive agents on urinary albumin excretion. Weir MR. **Am J Nephrol** 1996; 16(3):237–45 (69 ref.)

Prevention of diabetic renal disease with special reference to microalbuminuria [see comments] Mogensen CE, et al. **Lancet** 1995 Oct 21;346(8982):1080–4 (49 ref.) Comment in: Lancet 1995 Dec 16;346(8990):1638.

URINE

Renal function (microalbuminuria). Ward KM. **Anal Chem** 1995 Jun 15;67(12):383R–391R (144 ref.)

[Diabetic nephropathy: significance of microalbuminuria and proteinuria in Type I and Type II diabetes mellitus] Lehmann R, et al. **Schweiz Rundsch Med Prax** 1995 Oct 31;84(44):1265–71 (53 ref.) (Eng. Abstr.) **(Ger)**

[Microalbuminuria—laboratory methods and implications] Kumasaka K. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:129–32 (12 ref.) **(Jpn)**

ALBUTEROL

ANALOGS & DERIVATIVES

Salmeterol for the treatment of asthma [editorial; comment] Weinberger M. **Ann Allergy Asthma Immunol** 1995 Sep; 75(3):209–11 (26 ref.) Comment on: Ann Allergy Asthma Immunol 1995 Sep;75(3):243–8.

Pharmacological basis for duration of effect: formoterol and salmeterol versus short-acting beta 2-adrenoceptor agonists. Lindén A, et al. **Lung** 1996;174(1):1–22 (52 ref.)

PHARMACOLOGY

Pharmacological basis for duration of effect: formoterol and salmeterol versus short-acting beta 2-adrenoceptor agonists. Lindén A, et al. **Lung** 1996;174(1):1–22 (52 ref.)

ALCALIGENES

Alcaligenes xylosoxidans subsp xylosoxidans in children with chronic otorrhea. Wintermeyer SM, et al. **Otolaryngol Head Neck Surg** 1996 Feb;114(2):332–4 (15 ref.)

ENZYMOLOGY

Characterization of the first enzyme in 2,4-dichlorophenoxyacetic acid metabolism. Hausinger RP, et al. **Environ Health Perspect** 1995 Jun;103 Suppl 5:37–9 (8 ref.)

ALCIAN BLUE

CHEMISTRY

Alcian blue. Now you see it, now you don't. Scott JE. **Eur J Oral Sci** 1996 Feb;104(1):2–9 (17 ref.)

ALCOHOL ABUSE see **ALCOHOLISM**

ALCOHOL AMNESTIC DISORDER

DIAGNOSIS

The Autobiographical Memory Interview (AMI) in organic and psychogenic amnesia. Kopelman MD. **Memory** 1994 Jun;2(2):211–35 (66 ref.)

ALCOHOL CONSUMPTION see **ALCOHOL DRINKING**

ALCOHOL DEHYDROGENASE

BLOOD

[Alcohol dehydrogenase (ADH)] Matsushima T. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:419–22 (10 ref.) **(Jpn)**

GENETICS

Class I and class IV alcohol dehydrogenase (retinol dehydrogenase) gene expression in mouse embryos. Duester G, et al. **Adv Exp Med Biol** 1995;372:301–13 (42 ref.)

The alcohol dehydrogenase system. Jörnvall H, et al. **Adv Exp Med Biol** 1995;372:281–94 (51 ref.)

METABOLISM

Alcohol dehydrogenase: multiplicity and relatedness in the solvent-producing clostridia. Chen JS. **FEMS Microbiol Rev** 1995 Oct;17(3):263–73 (44 ref.)

[Human alcohol dehydrogenase] Chrostek L, et al. **Postepy Hig Med Dosw** 1996;50(1):95–107 (65 ref.) (Eng. Abstr.) **(Pol)**

ALCOHOL DETERRENTS

THERAPEUTIC USE

Acamprosate in alcohol dependence: how does it work? Littleton J. **Addiction** 1995 Sep;90(9):1179–88 (42 ref.)

How to get the best out of antabuse. Kristenson H. **Alcohol Alcohol** 1995 Nov;30(6):775–83 (47 ref.)

Conference summary: Consensus Conference on Alcohol Dependence and the Role of Pharmacotherapy in its Treatment. Chick J, et al. **Alcohol Clin Exp Res** 1996 Apr; 20(2):391–402 (82 ref.)

Pharmacotherapy and psychotherapy for the treatment of alcoholism in Germany. Soyka M.

Drug Alcohol Depend 1995 Sep;39 Suppl 1:S9–13 (40 ref.)
[What is used as a drug for problem drinking?] Heinälä P, et al. **Duodecim** 1995;111(8):761–8 (30 ref.) **(Fin)**
[Disulfiram therapy] Widenius T, et al. **Duodecim** 1994; 110(2):153–8 (10 ref.) **(Fin)**

ALCOHOL DRINKING

see related
ALCOHOLISM
TEMPERANCE

Barriers to help-seeking for change in drinking: a gender-focused review of the literature. Schober R, et al. **Addict Behav** 1996 Jan–Feb;21(1):81–92 (96 ref.)
Review of moderate alcohol consumption and reduced risk of coronary heart disease: is the effect due to beer, wine, or spirits. Rimm EB, et al. **BMJ** 1996 Mar 23; 312(7033):731–6 (57 ref.)
Alcohol and the NIDDM patient. Bell DS. **Diabetes Care** 1996 May;19(5):509–13 (60 ref.)
Ought low alcohol intake to be promoted for health reasons? Holman CD, et al. **J R Soc Med** 1996 Mar;89(3):123–9 (36 ref.)
[How much does my patient drink?] Poikolainen K. **Duodecim** 1994;110(9):870–6 (34 ref.) **(Fin)**
[A wine pitcher, cause of lead poisoning] Jouglard J, et al. **Presse Med** 1996 Feb 17;25(6):243–6 (8 ref.) (Eng. Abstr.) **(Fre)**
[Alcohol and diabetes] Georgescu M, et al. **Rev Med Suisse Romande** 1995 Sep;115(9):707–11 (17 ref.) **(Fre)**
[Present status and future of alcohol studies in the field of public health] Kamishima H. **Nihon Arukoru Yakubutsu Igakkai Zasshi** 1996 Feb; 31(1):33–53 (28 ref.) **(Jpn)**
[Abuse of alcohol and central nervous system stimulants. A growing problem in developing countries] Eide AH, et al. **Lakartidningen** 1995 Nov 29;92(48):4569–71 (31 ref.) **(Swe)**

ADVERSE EFFECTS

Investigations into the toxic effects of alcohol on skeletal muscle. Reilly ME, et al. **Adverse Drug React Toxicol Rev** 1995 Summer;14(2):117–50 (141 ref.)
Alcohol, hepatotropic viruses, and hepatocellular carcinoma [editorial] Nalpas B, et al. **Alcohol Clin Exp Res** 1995 Oct; 19(5):1089–95 (96 ref.)
Lipid vs protein theories of alcohol action in the nervous system. Peoples RW, et al. **Annu Rev Pharmacol Toxicol** 1996;36:185–201 (112 ref.)
Alcohol-related problems in older persons. Determinants, consequences, and screening. Fink A, et al. **Arch Intern Med** 1996 Jun 10;156(11):1150–6 (76 ref.)
"Moderate" drinking during pregnancy: cause for concern? Abel EL. **Clin Chim Acta** 1996 Mar 15;246(1–2):149–54 (15 ref.)
Alcohol and hypertension. Klatsky AL. **Clin Chim Acta** 1996 Mar 15;246(1–2):91–105 (28 ref.)
The questionable link between alcohol intake and cancer. Rubin E. **Clin Chim Acta** 1996 Mar 15;246(1–2):143–8 (14 ref.)
Assessing moderate alcohol consumption as a personal risk factor. Werner M. **Clin Chim Acta** 1996 Mar 15; 246(1–2):5–20 (45 ref.)
Alcohol and hypertension. Beilin LJ. **Clin Exp Pharmacol Physiol** 1995 Mar;22(3):185–8 (35 ref.)
Alcohol, hypertension, coronary disease and stroke. Lip GY, et al. **Clin Exp Pharmacol Physiol** 1995 Mar;22(3):189–94 (66 ref.)
Beer potomania: two cases and review of the literature. Fenves AZ, et al. **Clin Nephrol** 1996 Jan;45(1):61–4 (14 ref.)
Toxicological effects of ethanol on human health. Ahmed FE. **Crit Rev Toxicol** 1995;25(4):347–67 (113 ref.)
Alcohol as a cause of cancer. Thomas DB. **Environ Health Perspect** 1995 Nov;103 Suppl 8:153–60 (65 ref.)
A multiple-level, comprehensive approach to the prevention of fetal alcohol syndrome (FAS) and other alcohol-related birth defects (ARBD). May PA. **Int J Addict** 1995; 30(12):1549–602 (160 ref.)
A review of the effects of moderate alcohol intake on the treatment of anxiety and mood disorders. Castaneda R, et al. **J Clin Psychiatry** 1996 May;57(5):207–12 (82 ref.)
[Obesity due to alcohol intake] Nakamura H, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:430–5 (8 ref.) **(Jpn)**

BLOOD

Effects of alcohol on plasma lipoprotein metabolism. Frohlich JJ. **Clin Chim Acta** 1996 Mar 15;246(1–2):39–49 (30 ref.)

EPIDEMIOLOGY

Alcohol consumption and coronary heart disease: good habits may be more important than just good wine [see comments] Rimm EB. **Am J Epidemiol** 1996 Jun 1;143(11):1094–8; discussion 1099 (39 ref.) Comment in: Am J Epidemiol 1996 Jun 1;143(1):1089–93.
Case-control and cohort studies of moderate alcohol consumption and stroke. Camargo CA Jr. **Clin Chim Acta** 1996 Mar 15;246(1–2):107–19 (41 ref.)
Alcohol and coronary heart disease: consistent relationship and public health implications. Criqui MH. **Clin Chim Acta** 1996 Mar 15;246(1–2):51–7 (27 ref.)
Epidemiologic data on alcoholic beverage consumption and risk of cancer. Longnecker MP, et al. **Clin Chim Acta** 1996 Mar 15;246(1–2):121–41 (130 ref.)

GENETICS

Strategies for mapping and identifying quantitative trait loci specifying behavioral responses to alcohol. Buck KJ. **Alcohol Clin Exp Res** 1995 Aug;19(4):795–801 (57 ref.)
Molecular genetic analysis of the role of GABAergic systems in the behavioral and cellular actions of alcohol. Buck KJ. **Behav Genet** 1996 May;26(3):313–23 (72 ref.)

LEGISLATION & JURISPRUDENCE

Interpretations of risk: the use of scientific information in the development of the alcohol warning label policy. Kaskutas LA. **Int J Addict** 1995;30(12):1519–48 (70 ref.)
[Revoking the right to drive—a blunt weapon against alcohol intoxicated drivers, hit-and-run drivers and speed limit and red light offenders? (see comments)] Zabel GE. **Blutalkohol** 1995 Sep;32(5):254–67 (56 ref.) (Eng. Abstr.) Comment in: Blutalkohol 1995 Nov;32(6):314–6. **(Ger)**

METABOLISM

Fundamental studies on alcohol dependence and disposition. Komura S, et al. **Forensic Sci Int** 1996 Jun 28; 80(1–2):99–107 (37 ref.)

PHYSIOPATHOLOGY

Alcohol stimulates ACTH secretion in the rat: mechanisms of action and interactions with other stimuli. Rivier C. **Alcohol Clin Exp Res** 1996 Apr;20(2):240–54 (207 ref.)
Alcohol, coronary disease, and hypertension. Klatsky AL. **Annu Rev Med** 1996;47:149–60 (95 ref.)
Alcohol and coronary heart disease. Shaper AG. **Eur Heart J** 1995 Dec;16(12):1760–4 (20 ref.)
Alcohol and obesity. Prentice AM. **Int J Obes Relat Metab Disord** 1995 Nov;19 Suppl 5:S44–50 (31 ref.)

PREVENTION & CONTROL

Identification and care of problems associated with alcohol ingestion in pregnancy. Hankin JR, et al. **Semin Perinatol** 1995 Aug;19(4):286–92 (24 ref.)
Young people and alcohol, drugs and tobacco. Anderson K. **WHO Reg Publ Eur Ser** 1995;66:1–83 (59 ref.)

PSYCHOLOGY

Controlled drinking after 25 years: how important was the great debate? [editorial] Sobell MB, et al. **Addiction** 1995 Sep;90(9):1149–53; discussion 1157–77 (28 ref.)
Behavioral and social consequences related to the consumption of different beverage types. Smart RG. **J Stud Alcohol** 1996 Jan;57(1):77–84 (60 ref.)

THERAPY

Advanced in studies on acupuncture abstinence. Cui M. **J Tradit Chin Med** 1996 Mar;16(1):65–9 concl (38 ref.)
Advances in studies on acupuncture abstinence. Cui M. **J Tradit Chin Med** 1995 Dec;15(4):301–7, contd (32 ref.)
Treatment of adolescent substance abusers: issues for practice and research. Jenson JM, et al. **Soc Work Health Care** 1995; 21(2):1–18 (58 ref.)

ALCOHOL, ETHYL

see related
ALCOHOLIC BEVERAGES

Ambulatory medical detoxification for alcohol. Abbott PJ, et al. **Am J Drug Alcohol Abuse** 1995 Nov;21(4):549–63 (30 ref.)
Aggregated DNA in ethanol solution. Piškur J, et al. **FEBS Lett** 1995 Nov 20;375(3):174–8 (38 ref.)
Recent changes in the etiology of hearing disorders: perinatal drug exposure. Gerber SE, et al. **J Am Acad Audiol** 1995 Sep;6(5):371–7 (50 ref.)
[The present and the future of alcohol study in the field of Pharmacology] Suzuki T. **Arukoru Kenkyuto Yakubutsu Ison** 1996 Apr;31(2):135–45 (24 ref.) **(Jpn)**

ADMINISTRATION & DOSAGE

Non-invasive loco-regional therapy for hepatocellular carcinoma. Tanikawa K. **Semin Surg Oncol** 1996 May–Jun; 12(3):189–92 (15 ref.)
[Percutaneous ethanol injection therapy of hepatoma] Shiina S, et al. **Nippon Naika Gakkai Zasshi** 1995 Dec 10; 84(12):2008–11 (5 ref.) **(Jpn)**

ADVERSE EFFECTS

CNS effects and abuse liability of anabolic-androgenic steroids. Lukas SE. **Annu Rev Pharmacol Toxicol** 1996; 36:333–57 (125 ref.)
Lipid vs protein theories of alcohol action in the nervous system. Peoples RW, et al. **Annu Rev Pharmacol Toxicol** 1996;36:185–201 (112 ref.)
Ethanol- and threonine-induced hypertension in rats: a common mechanism. Vasdev S, et al. **Can J Cardiol** 1995 Oct;11(9):807–15 (56 ref.)
Alcohol and hypertension. Beilin LJ. **Clin Exp Pharmacol Physiol** 1995 Mar;22(3):185–8 (35 ref.)
Alcohol, hypertension, coronary disease and stroke. Lip GY, et al. **Clin Exp Pharmacol Physiol** 1995 Mar;22(3):189–94 (66 ref.)
Parkinsonism in alcohol withdrawal: case report and review of the literature. Luijckx GJ, et al. **Clin Neurol Neurosurg** 1995 Nov;97(4):336–9 (18 ref.)
Therapy of alcohol withdrawal syndrome in intensive care unit patients following trauma: results of a prospective, randomized trial. Spies CD, et al. **Crit Care Med** 1996 Mar; 24(3):414–22 (64 ref.)
Drugs and alcohol: harmful cocktails? **Drug Ther Bull** 1996 May;34(5):36–8 (22 ref.)
A review of the effects of moderate alcohol intake on the treatment of anxiety and mood disorders. Castaneda R, et al. **J Clin Psychiatry** 1996 May;57(5):207–12 (82 ref.)
Benzodiazepines for alcohol withdrawal in the elderly and in patients with liver disease. Peppers MP. **Pharmacotherapy** 1996 Jan–Feb;16(1):49–57 (49 ref.)
[The cardiovascular effects of alcohol] Estruch R. **Med Clin (Barc)** 1995 Nov 11;105(16):628–35 (80 ref.) **(Spa)**

ANALYSIS

Medicolegal alcohol determination: variability of the blood- to breath-alcohol ratio and its effect on reported breath-alcohol concentrations. Labianca DA, et al. **Eur J Clin Chem Clin Biochem** 1995 Dec;33(12):919–25 (17 ref.)

DIAGNOSTIC USE

Ethanol monitoring of irrigating fluid absorption. Hahn RG. **Eur J Anaesthesiol** 1996 Mar;13(2):102–15 (60 ref.)

ISOLATION & PURIFICATION

Membrane based ethanol separation process. Choudhury JP, et al. **Hindustan Antibiot Bull** 1994 Aug–Nov; 36(3–4):135–40 (32 ref.)

METABOLISM

Alcohol and energy intake. Lands WE. **Am J Clin Nutr** 1995 Nov;62(5 Suppl):1101S–1106S (55 ref.)
Fundamental studies on alcohol dependence and disposition. Komura S, et al. **Forensic Sci Int** 1996 Jun 28; 80(1–2):99–107 (37 ref.)

PHARMACOKINETICS

Cellular signals in alcohol-induced liver injury: a review. Lands WE. **Alcohol Clin Exp Res** 1995 Aug;19(4):928–38 (112 ref.)
Alcohol and endotoxin: another path to alcoholic liver injury? Schenker S, et al. **Alcohol Clin Exp Res** 1995 Oct; 19(5):1364–6 (40 ref.)
Medicolegal alcohol determination: variability of the blood- to breath-alcohol ratio and its effect on reported breath-alcohol concentrations. Labianca DA, et al. **Eur J Clin Chem Clin Biochem** 1995 Dec;33(12):919–25 (17 ref.)
[Formation of so-called byproducts (propanols, butanols et al.) from ethanol by microorganisms] Stöhlmacher P. **Blutalkohol** 1996 May;33(3):113–41 (200 ref.) (Eng. Abstr.) **(Ger)**

PHARMACOLOGY

Addictive drugs as reinforcers: multiple partial actions on memory systems. White NM. **Addiction** 1996 Jul; 91(7):921–49; discussion 951–65 (304 ref.)
Role of acetaldehyde in the actions of ethanol on the brain—a review. Hunt WA. **Alcohol** 1996 Mar–Apr;13(2):147–51 (66 ref.)
ESBRA 1994 Award Lecture. Phosphatidylethanol formation: specific effects of ethanol mediated via phospholipase D. Gustavsson L. **Alcohol Alcohol** 1995 Jul; 30(4):391–406 (84 ref.)
Alcohol stimulates ACTH secretion in the rat: mechanisms of action and interactions with other stimuli. Rivier C. **Alcohol Clin Exp Res** 1996 Apr;20(2):240–54 (207 ref.)
Alcohol and energy intake. Lands WE. **Am J Clin Nutr** 1995 Nov;62(5 Suppl):1101S–1106S (55 ref.)
Effects of alcohol on plasma lipoprotein metabolism. Frohlich JJ. **Clin Chim Acta** 1996 Mar 15;246(1–2):39–49 (30 ref.)
Effects of alcohol on platelet functions. Renaud SC, et al. **Clin Chim Acta** 1996 Mar 15;246(1–2):77–89 (50 ref.)
Molecular and cellular adaptations in signal transduction pathways following ethanol exposure. Fitzgerald LW, et al. **Clin Neurosci** 1995;3(3):165–73 (98 ref.)
Cellular and behavioral neurobiology of alcohol: receptor-mediated neuronal processes. Grant KA, et al. **Clin Neurosci** 1995;3(3):155–64 (98 ref.)
Alcohol addiction: an enigma among us. Tabakoff B, et al. **Neuron** 1996 May;16(5):909–12 (25 ref.)
[Alcohol and free radicals: from basic research to clinical prospects] Nordmann R, et al. **Bull Acad Natl Med** 1995

Dec;179(9):1839-50; discussion 1850-3 (41 ref.) (Eng. Abstr.) **(Fre)**

[Alcohol and diabetes] Georgescu M, et al. **Rev Med Suisse Romande** 1995 Sep;115(9):707-11 (17 ref.) **(Fre)**

[Is alcohol healthy? (editorial)] Sieber C. **Schweiz Rundsch Med Prax** 1996 May 7;85(19):615-6 (21 ref.) **(Ger)**

[Ethanol mechanism(s) of action on LHRH secretion] Canteros MG, et al. **Acta Physiol Pharmacol Ther Latinoam** 1995;45(1):55-63 (18 ref.) **(Spa)**

POISONING

Alcoholic rhabdomyolysis: a review. Bessa O Jr. **Conn Med** 1995 Sep;59(9):519-21 (19 ref.)

THERAPEUTIC USE

Alcohol and coronary heart disease: the evidence for a protective effect. Kannel WB, et al. **Clin Chim Acta** 1996 Mar 15;246(1-2):59-76 (44 ref.)

TOXICITY

Investigations into the toxic effects of alcohol on skeletal muscle. Reilly ME, et al. **Adverse Drug React Toxicol Rev** 1995 Summer;14(2):117-50 (141 ref.)

Ethanol-induced oxidative stress in the liver. Kurose I, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1 Suppl):77A-85A (88 ref.)

Teratogenic effects of alcohol: current status of animal research and in vitro models. Guerri C. **Arch Toxicol Suppl** 1996;18:71-80 (55 ref.)

Ethanol neurobehavioural teratogenesis and the role of L-glutamate in the fetal hippocampus. Reynolds JD, et al. **Can J Physiol Pharmacol** 1995 Sep;73(9):1209-23 (175 ref.)

Toxicological effects of ethanol on human health. Ahmed FE. **Crit Rev Toxicol** 1995;25(4):347-67 (113 ref.)

The heat shock and ethanol stress responses of yeast exhibit extensive similarity and functional overlap. Piper PW. **FEMS Microbiol Lett** 1995 Dec 15;134(2-3):121-7 (38 ref.)

[Alcohol and mortality] Blanc MH. **Rev Med Suisse Romande** 1995 Nov;115(11):905-14 (65 ref.) **(Fre)**

ALCOHOL, METHYL

METABOLISM

Review: methylotrophic yeasts as factories for the production of foreign proteins. Faber KN, et al. **Yeast** 1995 Nov; 11(14):1331-44 (111 ref.)

TOXICITY

Recent developments in methanol toxicity. Medinsky MA, et al. **Toxicol Lett** 1995 Dec;82-83:707-11 (17 ref.)

ALCOHOL OXIDOREDUCTASES

CHEMISTRY

[Structure-activity relationships in multienzyme complexes] Gol'dshtein BN, et al. **Mol Biol (Mosk)** 1995 May-Jun; 29(3):603-11 (35 ref.) (Eng. Abstr.) **(Rus)**

GENETICS

Unusual evolution of 11beta- and 17beta-hydroxysteroid and retinol dehydrogenases. Baker ME. **Bioessays** 1996 Jan; 18(1):63-70 (47 ref.)

Suppression of flavonoid flower pigmentation genes in Petunia hybrida by the introduction of antisense and sense genes. de Lange P, et al. **Curr Top Microbiol Immunol** 1995; 197:57-75 (88 ref.)

METABOLISM

Prostaglandin-metabolizing enzymes during pregnancy: characterization of NAD(+)-dependent prostaglandin dehydrogenase, carbonyl reductase, and cytochrome P450-dependent prostaglandin omega-hydroxylase. Okita RT, et al. **Crit Rev Biochem Mol Biol** 1996 Apr; 31(2):101-26 (100 ref.)

ALCOHOL, PROPYL

PHARMACOKINETICS

[Formation of so-called byproducts (propanols, butanols et al.) from ethanol by microorganisms] Stöhlmacher P. **Blutalkohol** 1996 May;33(3):113-41 (200 ref.) (Eng. Abstr.) **(Ger)**

ALCOHOL WITHDRAWAL DELIRIUM

DRUG THERAPY

The management of alcohol withdrawal using chlormethiazole. Morgan MY. **Alcohol Alcohol** 1995 Nov; 30(6):771-4 (21 ref.)

Management of delirium tremens on the head and neck service. Alvi A, et al. **Am J Otolaryngol** 1995 Jul-Aug; 16(4):224-31 (25 ref.)

THERAPY

Second-line and 'alternative' treatments for alcohol withdrawal: alpha-agonists, beta-blockers, anticonvulsants, acupuncture and neuro-electric therapy. Brewer C. **Alcohol Alcohol** 1995 Nov;30(6):799-803 (25 ref.)

ALCOHOLIC BEVERAGES

Behavioral and social consequences related to the consumption of different beverage types. Smart RG. **J Stud Alcohol** 1996 Jan;57(1):77-84 (60 ref.)

[Is alcohol healthy? (editorial)] Sieber C. **Schweiz Rundsch Med Prax** 1996 May 7;85(19):615-6 (21 ref.) **(Ger)**

ADVERSE EFFECTS

Interpretations of risk: the use of scientific information in the development of the alcohol warning label policy. Kaskutas LA. **Int J Addict** 1995;30(12):1519-48 (70 ref.)

ALCOHOLIC CARDIOMYOPATHY see **CARDIOMYOPATHY, ALCOHOLIC**

ALCOHOLIC CIRRHOSIS see **LIVER CIRRHOSIS, ALCOHOLIC**

ALCOHOLIC HEPATITIS see **HEPATITIS, ALCOHOLIC**

ALCOHOLIC INTOXICATION

COMPLICATIONS

Alcoholic rhabdomyolysis: a review. Bessa O Jr. **Conn Med** 1995 Sep;59(9):519-21 (19 ref.)

DIAGNOSIS

Measuring and reporting the concentration of acetaldehyde in human breath. Jones AW. **Alcohol Alcohol** 1995 May; 30(3):271-85 (45 ref.)

DRUG THERAPY

Detoxification: the use of benzodiazepines. Shaw GK. **Alcohol Alcohol** 1995 Nov;30(6):765-70 (20 ref.)

METABOLISM

Drink driving legislation: medicine and the law. Marks P. **Med Leg J** 1995;63 (Pt 3):119-27 (17 ref.)

PHYSIOPATHOLOGY

Alcohol and head injury: an issue revisited. Kelly DF. **J Neurotrauma** 1995 Oct;12(5):883-90 (62 ref.)

THERAPY

Treatment approaches to alcohol problems. Heather N. **WHO Reg Publ Eur Ser** 1995;65:1-201 (262 ref.)

ALCOHOLIC LIVER DISEASES see **LIVER DISEASES, ALCOHOLIC**

ALCOHOLISM

see related
ALCOHOL DETERRENTS
FETAL ALCOHOL SYNDROME
PSYCHOSES, ALCOHOLIC
TEMPERANCE

Medical education about alcohol: review of its role and effectiveness. Walsh RA. **Alcohol Alcohol** 1995 Nov; 30(6):689-702 (126 ref.)

Neurobehavioral aspects of the pharmacotherapy of alcohol dependence. Anton RF, et al. **Clin Neurosci** 1995; 3(3):145-54 (105 ref.)

Inconsistencies in the literature on collegiate adult children of alcoholics: factors to consider for African Americans. Rodney HE. **J Am Coll Health** 1996 Jul;45(1):19-25 (58 ref.)

The disease called addiction: emerging evidence in a 200-year debate. Meyer RE. **Lancet** 1996 Jan 20; 347(8995):162-6 (62 ref.)

[Psychiatric studies on alcoholism in Japan] Saito T. **Arukoru Kenkyuto Yakubutsu Ison** 1995 Dec;30(6):411-25 (137 ref.) **(Jpn)**

[The present and the future of alcohol study in the field of Pharmacology] Suzuki T. **Arukoru Kenkyuto Yakubutsu Ison** 1996 Apr;31(2):135-45 (24 ref.) **(Jpn)**

[Pathologic states related to alcoholism] Manso CF. **Acta Med Port** 1995 Dec;8(12):711-7 (107 ref.) (Eng. Abstr.) **(Por)**

BLOOD

[Formation of so-called byproducts (propanols, butanols et al.) from ethanol by microorganisms] Stöhlmacher P. **Blutalkohol** 1996 May;33(3):113-41 (200 ref.) (Eng. Abstr.) **(Ger)**

CLASSIFICATION

Essential and reactive alcoholism: a review. Walker RD, et al. **J Clin Psychol** 1996 Jan;52(1):80-95 (39 ref.)

COMPLICATIONS

Evaluation of hypotheses on pathogenesis of alcoholic pancreatitis. Pitchumoni CS, et al. **Am J Gastroenterol** 1996 Apr;91(4):637-47 (121 ref.)

Alcoholism is associated with hepatitis C but not hepatitis B in an urban population. Rosman AS, et al. **Am J Gastroenterol** 1996 Mar;91(3):498-505 (67 ref.)

Alcohol-related problems in older persons. Determinants, consequences, and screening. Fink A, et al. **Arch Intern Med** 1996 Jun 10;156(11):1150-6 (76 ref.)

Alcohol, hypertension, coronary disease and stroke. Lip GY, et al. **Clin Exp Pharmacol Physiol** 1995 Mar;22(3):189-94 (66 ref.)

Hypocalcaemia and chronic alcohol intoxication: transient hypoparathyroidism secondary to magnesium deficiency. Hermans C, et al. **Clin Rheumatol** 1996 Mar;15(2):193-6 (31 ref.)

Chronic alcoholism: an important condition in the dentist-patient relationship. Robb ND, et al. **J Dent** 1996 Jan-Mar;24(1-2):17-24 (45 ref.)

An update on incidence of FAS: FAS is not an equal opportunity birth defect. Abel EL. **Neurotoxicol Teratol** 1995 Jul-Aug;17(4):437-43 (80 ref.)

Multiple hepatic abscesses due to Yersinia enterocolitica. Strungs I, et al. **Pathology** 1995 Oct;27(4):374-7 (14 ref.)

[Influence of heavy drinking for the development of hepatocellular carcinoma in type C cirrhosis] Chiba T, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:731-5 (23 ref.) **(Jpn)**

[Cardiovascular impact of alcoholism] Faintuch JJ. **Rev Hosp Clin Fac Med Sao Paulo** 1995 Jan-Feb;50(1):76-9 (47 ref.) (Eng. Abstr.) **(Por)**

[Toxic lesions of the optic nerve] Mozherenkov VP, et al. **Vestn Oftalmol** 1996 Jan-Mar;112(1):54-5 (32 ref.) **(Rus)**

DIAGNOSIS

Measuring and reporting the concentration of acetaldehyde in human breath. Jones AW. **Alcohol Alcohol** 1995 May; 30(3):271-85 (45 ref.)

Gamma-glutamyltranspeptidase and carbohydrate deficient transferrin: alternative measures of excessive alcohol consumption. Litten RZ, et al. **Alcohol Clin Exp Res** 1995 Dec;19(6):1541-6 (37 ref.)

Diagnosis and treatment of drug and alcohol abuse in women. Kaufman E. **Am J Obstet Gynecol** 1996 Jan;174(1 Pt 1):21-7 (27 ref.)

Alcohol-related problems in older persons. Determinants, consequences, and screening. Fink A, et al. **Arch Intern Med** 1996 Jun 10;156(11):1150-6 (76 ref.)

Early identification, screening, and brief intervention for adolescent alcohol use. Werner MJ, et al. **Arch Pediatr Adolesc Med** 1995 Nov;149(11):1241-8 (73 ref.)

Identifying and managing problem drinkers. Kahan M. **Can Fam Physician** 1996 Apr;42:661-71 (59 ref.)

Alcohol risk assessment and intervention for family physicians. Project of the College of Family Physicians of Canada. Peters C, et al. **Can Fam Physician** 1996 Apr; 42:681-9 (31 ref.)

Evaluation and treatment of anxiety symptoms and disorders in alcoholics. Kranzler HR. **J Clin Psychiatry** 1996;57 Suppl 7:15-21; discussion 22-4 (60 ref.)

[How much does my patient drink?] Poikolainen K. **Duodecim** 1994;110(9):870-6 (34 ref.) **(Fin)**

[Who has alcoholic liver disease?] Salaspuro M. **Duodecim** 1994;110(20):1895-900 (22 ref.) **(Fin)**

DRUG THERAPY

Acamprosate as an aid in the treatment of alcoholism. Chick J. **Alcohol Alcohol** 1995 Nov;30(6):785-7 (17 ref.)

How to get the best out of antabuse. Kristenson H. **Alcohol Alcohol** 1995 Nov;30(6):775-83 (47 ref.)

The pharmacological treatment of alcoholism: from basic science to clinical medicine. Verbanck PM. **Alcohol Alcohol** 1995 Nov;30(6):757-64 (81 ref.)

Medical management of alcohol dependence: clinical use and limitations of naltrexone treatment. Volpicelli JR, et al. **Alcohol Alcohol** 1995 Nov;30(6):789-98 (42 ref.)

Evaluation and treatment of anxiety symptoms and disorders in alcoholics. Kranzler HR. **J Clin Psychiatry** 1996;57 Suppl 7:15-21; discussion 22-4 (60 ref.)

[What is used as a drug for problem drinking?] Heinälä P, et al. **Duodecim** 1995;111(8):761-8 (30 ref.) **(Fin)**

[Disulfiram therapy] Widenius T, et al. **Duodecim** 1994; 110(2):153-8 (10 ref.) **(Fin)**

EPIDEMIOLOGY

Substance misuse in individuals with spinal cord injury. Radnitz CL, et al. **Int J Addict** 1995 Jul;30(9):1117-40 (50 ref.)

[Abuse of alcohol and central nervous system stimulants. A growing problem in developing countries] Eide AH, et al. **Lakartidningen** 1995 Nov 29;92(48):4569-71 (31 ref.) **(Swe)**

ETIOLOGY

Alcoholism: the role of different motivational systems. Pihl RO, et al. **J Psychiatry Neurosci** 1995 Nov;20(5):372–96 (205 ref.)

[Functional significance of diazepam binding inhibitor (DBI) in establishment of alcohol dependence] Katsura M, et al. **Nippon Yakurigaku Zasshi** 1995 Sep;106(3):217–27 (50 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Strategies for mapping and identifying quantitative trait loci specifying behavioral responses to alcohol. Buck KJ. **Alcohol Clin Exp Res** 1995 Aug;19(4):795–801 (57 ref.)

Identifying alcoholism vulnerability alleles. Goldman D. **Alcohol Clin Exp Res** 1995 Aug;19(4):824–31 (71 ref.)

Use of transgenics, null mutants, and antisense approaches to study ethanol's actions. Wehner JM, et al. **Alcohol Clin Exp Res** 1995 Aug;19(4):811–20 (79 ref.)

Molecular genetic analysis of the role of GABAergic systems in the behavioral and cellular actions of alcohol. Buck KJ. **Behav Genet** 1996 May;26(3):313–23 (72 ref.)

Candidate genes in alcoholism. Goldman D. **Clin Neurosci** 1995;3(3):174–81 (76 ref.)

Genetics and primary prevention of drug and alcohol abuse. Tarter RE. **Int J Addict** 1995 Sep;30(11):1479–84 (14 ref.)

[Depression and alcoholism: a potential familial–genetic relationship] Kasperowicz–Dąbrowiecka A, et al. **Psychiatr Pol** 1996 Mar–Apr;30(2):281–96 (45 ref.) (Eng. Abstr.) **(Pol)**

METABOLISM

Medicolegal alcohol determination: variability of the blood–to breath–alcohol ratio and its effect on reported breath–alcohol concentrations. Labianca DA, et al. **Eur J Clin Chem Clin Biochem** 1995 Dec;33(12):919–25 (17 ref.)

Fundamental studies on alcohol dependence and disposition. Komura S, et al. **Forensic Sci Int** 1996 Jun 28; 80(1–2):99–107 (37 ref.)

[Functional significance of diazepam binding inhibitor (DBI) in establishment of alcohol dependence] Katsura M, et al. **Nippon Yakurigaku Zasshi** 1995 Sep;106(3):217–27 (50 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Noradrenergic locus coeruleus neurons [letter] Halliday G, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1):191–2 (15 ref.)

Neuroimaging in alcoholism: CT and MRI results and clinical correlates. Mann K, et al. **J Neural Transm Gen Sect** 1995; 99(1–3):145–55 (76 ref.)

PHYSIOPATHOLOGY

The neurology of alcoholic denial: implications for assessment and treatment. Duffy JD. **Can J Psychiatry** 1995 Jun;40(5):257–63 (30 ref.)

Alcoholism: the clinical/basic science interface. Meyer RE. **Clin Neurosci** 1995;3(3):141–4 (24 ref.)

A proposed sequence of reactions leading to collagen biosynthesis, fibrosis, and hypertension in alcoholics. Brecher AS, et al. **J Investig Med** 1996 Feb;44(2):36–41 (107 ref.)

The psychobiological regulation of social cooperation [comment] Cloninger CR. **Nat Med** 1995 Jul;1(7):623–5 (21 ref.) Comment on: Nat Med 1995 Jul;1(7):654–7.

Alcohol addiction: an enigma among us. Tabakoff B, et al. **Neuron** 1996 May;16(5):909–12 (25 ref.)

PREVENTION & CONTROL

Contrasting self–report screens for alcohol problems: a review. Maisto SA, et al. **Alcohol Clin Exp Res** 1995 Dec; 19(6):1510–6 (24 ref.)

Community–based approaches for the prevention of alcohol, tobacco, and other drug use. Aguirre–Molina M, et al. **Annu Rev Public Health** 1996;17:337–58 (121 ref.)

Early identification, screening, and brief intervention for adolescent alcohol use. Werner MJ, et al. **Arch Pediatr Adolesc Med** 1995 Nov;149(11):1241–8 (73 ref.)

Secondary prevention of excessive alcohol use: assessing the prospects of implementation. Botelho RJ, et al. **Fam Pract** 1996 Apr;13(2):182–93 (139 ref.)

Alcohol–problem prevention research policy: the need for a phases research model. Holder H, et al. **J Public Health Policy** 1995;16(3):324–46 (43 ref.)

Alcoholism. Taking a preventive, public health approach. Blondell RD, et al. **Postgrad Med** 1996 Jul;100(1):69–72, 78–80 (16 ref.)

PSYCHOLOGY

Pharmacogenetic models of alcoholism. Li TK, et al. **Clin Neurosci** 1995;3(3):182–8 (62 ref.)

Children of alcoholic parents. A review. Steinhausen HC. **Eur Child Adolesc Psychiatry** 1995 Jul;4(3):143–52 (55 ref.)

Alcoholism: the role of different motivational systems. Pihl RO, et al. **J Psychiatry Neurosci** 1995 Nov;20(5):372–96 (205 ref.)

Cultural aspects of substance abuse and alcoholism. Assessment and management. Westermeyer J. **Psychiatr Clin North Am** 1995 Sep;18(3):589–605 (68 ref.)

Alcohol abuse in individuals exposed to trauma: a critical review. Stewart SH. **Psychol Bull** 1996 Jul;120(1):83–112 (280 ref.)

[Alcoholism from the psychiatric viewpoint. Diagnosis, neurobiology, pathophysiology and clinical manifestations] Wiesbeck GA, et al. **Internist (Berl)** 1996 Jul;37(7):761–72 (10 ref.) **(Ger)**

RADIOGRAPHY

Neuroimaging in alcoholism: CT and MRI results and clinical correlates. Mann K, et al. **J Neural Transm Gen Sect** 1995; 99(1–3):145–55 (76 ref.)

REHABILITATION

Acamprosate in alcohol dependence: how does it work? Littleton J. **Addiction** 1995 Sep;90(9):1179–88 (42 ref.)

Controlled drinking after 25 years: how important was the great debate? [editorial] Sobell MB, et al. **Addiction** 1995 Sep;90(9):1149–53; discussion 1157–77 (28 ref.)

Interpreting the evidence on brief interventions for excessive drinkers: the need for caution. Heather N. **Alcohol Alcohol** 1995 May;30(3):287–96 (35 ref.)

Conference summary: Consensus Conference on Alcohol Dependence and the Role of Pharmacotherapy in its Treatment. Chick J, et al. **Alcohol Clin Exp Res** 1996 Apr; 20(2):391–402 (82 ref.)

Elevated rates of early discontinuation from pharmacotherapy trials in alcoholics and drug abusers. Kranzler HR, et al. **Alcohol Clin Exp Res** 1996 Feb; 20(1):16–20 (20 ref.)

Pharmacotherapy and psychotherapy for the treatment of alcoholism in Germany. Soyka M. **Drug Alcohol Depend** 1995 Sep;39 Suppl 1:S9–13 (40 ref.)

[The alcoholic patient in general practice. From initial contact to implementing therapy] Luderer HJ. **Fortschr Med** 1995 Nov 30;113(33):469–72 (17 ref.) (Eng. Abstr.) **(Ger)**

[Craving—an adequately defined concept?] Wetterling T, et al. **Fortschr Neurol Psychiatr** 1996 Apr;64(4):142–52 (136 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Diagnosis and treatment of drug and alcohol abuse in women. Kaufman E. **Am J Obstet Gynecol** 1996 Jan;174(1 Pt 1):21–7 (27 ref.)

Alcohol treatment and health care system reform. McCrady BS, et al. **Arch Gen Psychiatry** 1996 Aug;53(8):737–46 (109 ref.)

Identifying and managing problem drinkers. Kahan M. **Can Fam Physician** 1996 Apr;42:661–71 (59 ref.)

Alcohol risk assessment and intervention for family physicians. Project of the College of Family Physicians of Canada. Peters C, et al. **Can Fam Physician** 1996 Apr; 42:681–9 (31 ref.)

Alcoholism: the role of different motivational systems. Pihl RO, et al. **J Psychiatry Neurosci** 1995 Nov;20(5):372–96 (205 ref.)

Treatment approaches to alcohol problems. Heather N. **WHO Reg Publ Eur Ser** 1995;65:1–201 (262 ref.)

ALCOHOLS

PHARMACOKINETICS

[Formation of so–called byproducts (propanols, butanols et al.) from ethanol by microorganisms] Stöhlmacher P. **Blutalkohol** 1996 May;33(3):113–41 (200 ref.) (Eng. Abstr.) **(Ger)**

ALCOHOLS, BUTYL

PHARMACOKINETICS

[Formation of so–called byproducts (propanols, butanols et al.) from ethanol by microorganisms] Stöhlmacher P. **Blutalkohol** 1996 May;33(3):113–41 (200 ref.) (Eng. Abstr.) **(Ger)**

ALCOHOLS, SUGAR see **SUGAR ALCOHOLS**

ALDEHYDE DEHYDROGENASE

BIOSYNTHESIS

Studies on the induction of rat class 3 aldehyde dehydrogenase. Pappas P, et al. **Adv Exp Med Biol** 1995; 372:143–9 (37 ref.)

Constitutive and overexpressed human cytosolic class–3 aldehyde dehydrogenases in normal and neoplastic cells/secretions. Sladek NE, et al. **Adv Exp Med Biol** 1995; 372:103–14 (41 ref.)

GENETICS

Class 3 aldehyde dehydrogenase. A northern perspective in the land down under. Feimer J, et al. **Adv Exp Med Biol** 1995;372:137–41 (12 ref.)

Site directed mutagenesis to probe for active site components of liver mitochondrial aldehyde dehydrogenase. Weiner H, et al. **Adv Exp Med Biol** 1995;372:1–7 (17 ref.)

Infertility treatment: a nuclear restorer gene in maize [comment] Levings CS 3rd. **Science** 1996 May 31; 272(5266):1279–80 (16 ref.) Comment on: Science 1996 May 31;272(5266):1334–6.

METABOLISM

Substrate binding pocket structure of human aldehyde dehydrogenases. A substrate specificity approach. Yin SJ, et al. **Adv Exp Med Biol** 1995;372:9–16 (48 ref.)

ALDEHYDE OXIDOREDUCTASES

ANALYSIS

Retinoic acid synthesis in the developing spinal cord. Dräger UC, et al. **Adv Exp Med Biol** 1995;372:185–92 (26 ref.)

CHEMISTRY

Metal–carbon bonds in nature [comment] Kovacs JA, et al. **Science** 1995 Oct 27;270(5236):587–8 (22 ref.) Comment on: Science 1995 Oct 27;270(5236):628–30.

METABOLISM

Retinoic acid synthesizing enzymes in the embryonic and adult vertebrate. McCaffery P, et al. **Adv Exp Med Biol** 1995;372:173–83 (45 ref.)

CO dehydrogenase. Ferry JG. **Annu Rev Microbiol** 1995; 49:305–33 (132 ref.)

Role of aldehyde oxidase in biogenic amine metabolism. Beedham C, et al. **Prog Brain Res** 1995;106:345–53 (52 ref.)

ALDEHYDE REDUCTASE

ANTAGONISTS & INHIBITORS

New approaches for treatment in diabetes: aldose reductase inhibitors. Hotta N. **Biomed Pharmacother** 1995; 49(5):232–43 (168 ref.)

THERAPEUTIC USE

Drug trials in neuropathy. Hughes RA, et al. **Baillieres Clin Neurol** 1995 Nov;4(3):607–27 (87 ref.)

New approaches for treatment in diabetes: aldose reductase inhibitors. Hotta N. **Biomed Pharmacother** 1995; 49(5):232–43 (168 ref.)

ALDOLASE see **FRUCTOSEDIPHOSPHATE ALDOLASE**

ALDOSE REDUCTASE see **ALDEHYDE REDUCTASE**

ALDOSTERONE

see related
HYPERALDOSTERONISM
RECEPTORS, ALDOSTERONE
RENIN–ANGIOTENSIN SYSTEM

ANALYSIS

[Aldosterone] Tanaka K, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:483–6 (8 ref.) **(Jpn)**

BIOSYNTHESIS

Neuropeptides in the adrenal gland: distribution, localization of receptors, and effects on steroid hormone synthesis. Tóth IE, et al. **Endocr Res** 1995 Feb–May;21(1–2):39–51 (135 ref.)

The adrenal renin–angiotensin system: a local hormonal regulator of aldosterone production. Mulrow PJ, et al. **J Hypertens** 1996 Feb;14(2):173–6 (41 ref.)

BLOOD

Aldosterone escape during ACE inhibitor therapy in chronic heart failure. Struthers AD. **Eur Heart J** 1995 Dec;16 Suppl N:103–6 (26 ref.)

Aldosterone escape during angiotensin–converting enzyme inhibitor therapy in chronic heart failure. Struthers AD. **J Card Fail** 1996 Mar;2(1):47–54 (56 ref.)

METABOLISM

Corticosteroid metabolism in isolated perfused rat liver and kidney. Experimental studies with emphasis on aldosterone. Egfjord M. **Acta Physiol Scand Suppl** 1995;627:1–42 (226 ref.)

The promiscuous receptor: a case for the guardian enzyme. Weber KT, et al. **Cardiovasc Res** 1995 Aug;30(2):176–80 (34 ref.)

PHARMACOLOGY

Guanine nucleotide–dependent carboxymethylation: a pathway for aldosterone modulation of apical Na+ permeability in epithelia. Sariban–Sohraby S, et al. **Kidney Int** 1995 Oct;48(4):965–9 (66 ref.)

PHYSIOLOGY

Aldosterone and its mechanism of action: more questions than answers. Fuller PJ. **Aust N Z J Med** 1995 Dec;25(6):800–7 (57 ref.)

The renin–angiotensin–aldosterone system and myocardial collagen matrix remodelling in congestive heart failure. Brilla CG, et al. **Eur Heart J** 1995 Dec;16 Suppl O:107–9

ALDOSTERONE

(24 ref.)
Structural remodelling of the heart by fibrous tissue: role of circulating hormones and locally produced peptides. Weber KT, et al. **Eur Heart J** 1995 Dec;16 Suppl N:12–8 (83 ref.)
Aldosterone and heart failure. Zannad F. **Eur Heart J** 1995 Dec;16 Suppl N:98–102 (33 ref.)
Renin–angiotensin–aldosterone system for blood pressure and electrolyte homeostasis and its involvement in hypertension, in congestive heart failure and in associated cardiovascular damage (myocardial infarction and stroke). Laragh JH. **J Hum Hypertens** 1995 Jun;9(6):385–90 (47 ref.)
Two new culprits in cardiovascular disease: QT dispersion and aldosterone. Struthers AD. **J Hum Hypertens** 1995 Aug;9(8):659–61 (19 ref.)
[New data on mineralocorticoid hormones. Physiopathological implications (editorial)] Corvol P, et al. **Presse Med** 1995 Sep 23;24(27):1235–7 (12 ref.) (Eng. Abstr.) **(Fre)**

ALDOSTERONE RECEPTORS see **RECEPTORS, ALDOSTERONE**

ALDOSTERONISM see **HYPERALDOSTERONISM**

ALDRICH SYNDROME see **WISKOTT–ALDRICH SYNDROME**

ALEXITHYMIA see **AFFECTIVE SYMPTOMS**

ALGAE

ENZYMOLOGY

Vanadium–dependent haloperoxidases. Vilter H. **Met Ions Biol Syst** 1995;31:325–62 (192 ref.)

PHYSIOLOGY

Phosphoinositide signalling in plant and algal responses to physiological stimuli. Crain RC, et al. **Biochem Soc Trans** 1995 Nov;23(4):853–6 (28 ref.)

ALGAE, BLUE–GREEN see **CYANOBACTERIA**

ALGAE, GREEN

ULTRASTRUCTURE

Lipids and membrane function in green algae. Thompson GA Jr. **Biochim Biophys Acta** 1996 Jul 12;1302(1):17–45 (183 ref.)

ALGINATES

[Immobilization in alginate gels] Jankovský M, et al. **Vet Med (Praha)** 1996 May;41(5):159–64 (60 ref.) (Eng. Abstr.) **(Cze)**

METABOLISM

Exopolysaccharide alginate synthesis in Pseudomonas aeruginosa: enzymology and regulation of gene expression. Shankar S, et al. **Adv Enzymol Relat Areas Mol Biol** 1995; 70:221–55 (84 ref.)
[Alginates of Pseudomonas aeruginosa: a complex regulation of the pathway of biosynthesis] Schmitt–Andrieu L, et al. **C R Acad Sci III** 1996 Mar;319(3):153–60 (62 ref.) (Eng. Abstr.) **(Fre)**

ALGODYSTROPHIC SYNDROME see **REFLEX SYMPATHETIC DYSTROPHY**

ALGOR MORTIS see **POSTMORTEM CHANGES**

ALGORITHMS

Homeostatic control of plasma calcium concentration. Hurwitz S. **Crit Rev Biochem Mol Biol** 1996 Feb; 31(1):41–100 (500 ref.)
Current computational tools for de novo ligand design. Böhm HJ. **Curr Opin Biotechnol** 1996 Aug;7(4):433–6 (61 ref.)
Genetic algorithms for protein structure prediction. Pedersen JT, et al. **Curr Opin Struct Biol** 1996 Apr;6(2):227–31 (40 ref.)
Management after a first myocardial infarction. Flapan AD. **Hosp Pract (Off Ed)** 1996 May 15;31(5):133–7, 141–6 (11 ref.)
Intravenous drug delivery systems: toward an intravenous "vaporizer". Egan TD. **J Clin Anesth** 1996 May;8(3 Suppl):8S–14S (38 ref.)
Using cluster analysis for medical resource decision making. Dilts D, et al. **Med Decis Making** 1995 Oct–Dec; 15(4):333–47 (72 ref.)
Hints. Abu–Mostafa YS. **Neural Comput** 1995 Jul;7(4):639–71 (34 ref.)
Medical management of severe head injury: present and future. Chesnut RM. **New Horiz** 1995 Aug;3(3):581–93 (45 ref.)
An algorithmic approach to cancer pain management. Hudzinski DM. **Nurs Clin North Am** 1995 Dec;30(4):711–23 (11 ref.)
Treatment algorithms in treatment–resistant depression. Amsterdam JD, et al. **Psychiatr Clin North Am** 1996 Jun; 19(2):371–86 (72 ref.)
Stress fractures. Anderson MW, et al. **Radiology** 1996 Apr; 199(1):1–12 (105 ref.)
Mapping the protein universe. Holm L, et al. **Science** 1996 Aug 2;273(5275):595–603 (36 ref.)
Planning and revising the sample size for a trial. Gould AL. **Stat Med** 1995 May 15–30;14(9–10):1039–51; discussion 1053–5 (15 ref.)
[Consensus inflammatory intestinal diseases in children: ulcerative colitis and Crohn disease. Work Group Academic Medical Center, Amsterdam] Büller HA, et al. **Ned Tijdschr Geneeskd** 1996 Mar 9;140(10):544–50 (6 ref.) (Eng. Abstr.) **(Dut)**
[What to do in a 60–year–old HIV–positive woman with a cerebral arteriovenous malformation? Decision analysis (see comments)] Dippel DW, et al. **Ned Tijdschr Geneeskd** 1995 Nov 18;139(46):2362–9 (52 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1996 Feb 17;140(7):386–7. **(Dut)**
[Treatment strategies in mechanical and electrical cardiovascular failure] Oechslin E. **Ther Umsch** 1996 Aug; 53(8):646–57 (21 ref.) (Eng. Abstr.) **(Ger)**
[Blunt and penetrating abdominal trauma. Patient assessment algorithm and principles for management] Ertel W, et al. **Unfallchirurg** 1996 Apr;99(4):288–303 (28 ref.) **(Ger)**
[Potential of ultrasonography in urologic diagnostic algorithms] Mayayo Dehesa T, et al. **Arch Esp Urol** 1995 Sep;48(7):665–77; discussion 678 (35 ref.) (Eng. Abstr.) **(Spa)**

ALKALI see **ALKALIES**

ALKALIES

see related
HYPERCALCEMIA

POISONING

Corrosive injuries of the oesophagus and stomach: experience in management at a regional paediatric centre. Stiff G, et al. **Ann R Coll Surg Engl** 1996 Mar;78(2):119–23 (68 ref.)

ALKALINE PHOSPHATASE

see related
HYPOPHOSPHATASIA

[Properties of enzymes for enzyme immunoassay] Maekawa M. **Nippon Rinsho** 1995 Sep;53(9):2154–9 (11 ref.) (Eng. Abstr.) **(Jpn)**

ANALYSIS

[Isoenzyme] Ohta H, et al. **Nippon Rinsho** 1996 Jun; 54(6):1505–9 (16 ref.) (Eng. Abstr.) **(Jpn)**

BLOOD

[Neutrophil alkaline phosphatase (NAP) score] Aoyagi M, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:221–4 (17 ref.) **(Jpn)**

[Alkaline phosphatase and its isozyme] Iino S. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:276–9 (6 ref.) **(Jpn)**

URINE

[Urinary alkaline phosphatases] Komoda T, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:454–9 (20 ref.) **(Jpn)**

ALKALOIDS

Benzo[c]phenanthridine alkaloids sanguinarine and chelerythrine: biological activities and dental care applications. Walterová D, et al. **Acta Univ Palacki Olomuc Fac Med** 1995;139:7–16 (110 ref.)

ANALYSIS

Determination of datura alkaloids by using chromatographic techniques: a review. Papadoyannis IN. **Nat Toxins** 1995; 3(4):310–6; discussion 317 (17 ref.)

CHEMICAL SYNTHESIS

Strategies for the synthesis of some complex antitumor alkaloids. Pandit UK. **Farmaco** 1995 Nov;50(11):749–54 (32 ref.)

HISTORY

Psychoactive constituents of the genus Sceletium N.E.Br. and other Mesembryanthemaceae: a review. Smith MT, et al. **J Ethnopharmacol** 1996 Mar;50(3):119–30 (67 ref.)

METABOLISM

Alkaloids from frog skins: selective probes for ion channels and nicotinic receptors. Daly JW. **Braz J Med Biol Res** 1995 Oct;28(10):1033–42 (28 ref.)
Some ethnopharmacological notes on African hallucinogens. De Smet PA. **J Ethnopharmacol** 1996 Mar;50(3):141–6 (50 ref.)

THERAPEUTIC USE

[Prophylactic treatment of episodic forms of cluster headache] Liaño H, et al. **Rev Neurol** 1995;23 Suppl 4:S525–9 (29 ref.) **(Spa)**

TOXICITY

Anti–nutritional factors of Datura in feedstuffs. Piva G, et al. **Nat Toxins** 1995;3(4):238–41; discussion 242 (24 ref.)
Directly toxic effects of plant chemicals which may occur in human and animal foods. Seawright AA. **Nat Toxins** 1995;3(4):227–32; discussion 242 (54 ref.)

ALKALOSIS

COMPLICATIONS

Apparent mineralocorticoid excess due to 11 beta–hydroxysteroid dehydrogenase deficiency: a possible cause of intrauterine growth retardation. Kitanaka S, et al. **Clin Endocrinol (Oxf)** 1996 Mar;44(3):353–9 (33 ref.)
[Severe metabolic alkalosis with a consciousness disorder] Niederstadt C, et al. **Dtsch Med Wochenschr** 1996 Aug 2; 121(31–32):978–82 (19 ref.) (Eng. Abstr.) **(Ger)**

METABOLISM

The cellular basis of metabolic alkalosis. Sabatini S. **Kidney Int** 1996 Mar;49(3):906–17 (88 ref.)

ULTRASONOGRAPHY

[Renovascular hypertension due to unilateral renal artery stenosis with hypokalemic alkalosis, the salt–losing syndrome and reversible hyperechogenicity of the contralateral kidney. A study of 2 infants] Castelló Girona F, et al. **An Esp Pediatr** 1996 Jul;45(1):49–52 (14 ref.) (Eng. Abstr.) **(Spa)**

ALKALOSIS, RESPIRATORY

ETIOLOGY

Urea cycle disorders: diagnosis, pathophysiology, and therapy. Brusilow SW, et al. **Adv Pediatr** 1996;43:127–70 (59 ref.)

ALKANES

ANALYSIS

Plant wax components: a new approach to estimating intake and diet composition in herbivores. Dove H, et al. **J Nutr** 1996 Jan;126(1):13–26 (62 ref.)

ALKAPTONURIA

COMPLICATIONS

Ochronosis and alkaptonuria. Case report and literature review. Kneebone TS, et al. **J Am Podiatr Med Assoc** 1995 Oct;85(10):554–5 (7 ref.)

ALKYLATING AGENTS

ADVERSE EFFECTS

Mutagenic damage to mammalian cells by therapeutic alkylating agents. Sanderson BJ, et al. **Mutat Res** 1996 Aug 17;355(1–2):41–57 (118 ref.)

THERAPEUTIC USE

Innovative treatment approaches for rheumatoid arthritis. Cyclosporin, leflunomide and nitrogen mustard. Furst DE. **Baillieres Clin Rheumatol** 1995 Nov;9(4):711–29 (41 ref.)

TOXICITY

Alkylation of DNA and its aftermath. Lawley PD. **Bioessays** 1995 Jun;17(6):561–8 (54 ref.)
Role of induced genetic instability in the mutagenic effects of chemicals and radiation. Murnane JP. **Mutat Res** 1996 Jan;367(1):11–23 (160 ref.)

ALKYLATING AGENTS, ANTINEOPLASTIC see **ANTINEOPLASTIC AGENTS, ALKYLATING**

ALL, ADULT see **LEUKEMIA, LYMPHOCYTIC, ACUTE, L2**

ALL, CHILDHOOD see **LEUKEMIA, LYMPHOCYTIC, ACUTE, L1**

ALLANTOIN

ANALYSIS

Determination of allantoin in biological, cosmetic, and pharmaceutical samples. Chen XB, et al. **J AOAC Int** 1996 May–Jun;79(3):628–35 (56 ref.)

ALLELES

Identifying alcoholism vulnerability alleles. Goldman D.

Alcohol Clin Exp Res 1995 Aug;19(4):824–31 (71 ref.)
Apolipoprotein E alleles as risk factors in Alzheimer's disease. Roses AD. **Annu Rev Med** 1996;47:387–400 (66 ref.)
Quantitative genetics. Loci with large effects. Keightley PD. **Curr Biol** 1995 May 1;5(5):485–7 (7 ref.)
Paramutation in maize and related allelic interactions. Patterson GI, et al. **Curr Top Microbiol Immunol** 1995; 197:121–41 (94 ref.)
Evolution of MHC class II allelic diversity. McDevitt H. **Immunol Rev** 1995 Feb;143:113–22 (25 ref.)
Quantifying the degree of convergence in primate Mhc-DRB genes. O'hUigin C. **Immunol Rev** 1995 Feb;143:123–40 (24 ref.)
[Mutant allele specific amplification (MASA)] Sugai S, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):546–8 (11 ref.) **(Jpn)**

ALLERGEN BRONCHIAL PROVOCATION TESTS see **BRONCHIAL PROVOCATION TESTS**

ALLERGEN IMMUNOTHERAPY see **DESENSITIZATION, IMMUNOLOGIC**

ALLERGENS

see related
BITES AND STINGS
DUST
FUNGI

What the pulmonologist needs to know about allergy. Hoover GE, et al. **Clin Chest Med** 1995 Dec;16(4):603–20 (129 ref.)
Contact allergy testing alternatives: 1996. Scheman A. **Cutis** 1996 Apr;57(4):235–40 (22 ref.)
Environmental factors and respiratory hypersensitivity: experiences from studies in Eastern and Western Europe. Björkstén B. **Toxicol Lett** 1996 Aug;86(2–3):93–8 (17 ref.)
[Natural allergens and recombinant allergens] Deviller P. **Allerg Immunol (Paris)** 1995 Nov;27(9):316–9 (6 ref.) (Eng. Abstr.) **(Fre)**
[New aero-allergens] De Blay F, et al. **Rev Pneumol Clin** 1996;52(2):79–87 (84 ref.) (Eng. Abstr.) **(Fre)**
[Latex allergy: from contact urticaria to asthma] Helbling A. **Schweiz Rundsch Med Prax** 1996 Aug 13;85(33):978–82 (22 ref.) (Eng. Abstr.) **(Ger)**
[Allergic diseases in the indoor environment] Schata M. **Zentralbl Hyg Umweltmed** 1995 Apr;197(1–3):196–211 (8 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Aerobiologic and clinical aspects of mould allergy in Europe. D'Amato G, et al. **Allergy** 1995 Nov;50(11):870–7 (62 ref.)
Specific immunotherapy in house dust mite allergy. Bousquet J, et al. **Clin Rev Allergy Immunol** 1995 Summer;13(2):151–9 (57 ref.)
Atopic dermatitis and delayed hypersensitivity to dust mites. Castelain M. **Clin Rev Allergy Immunol** 1995 Summer; 13(2):161–72 (53 ref.)
Introduction. House dust mite allergy. Guérin B. **Clin Rev Allergy Immunol** 1995 Summer;13(2):107–13 (57 ref.)
Contact allergens in toothpastes and a review of their hypersensitivity. Sainio EL, et al. **Contact Dermatitis** 1995 Aug;33(2):100–5 (74 ref.)
Atopic dermatitis: new knowledge and new approaches. Kolmer HL, et al. **Hosp Pract (Off Ed)** 1995 Oct 15; 30(10):63–72 (9 ref.)
"Hidden" allergens in foods. Steinman HA. **J Allergy Clin Immunol** 1996 Aug;98(2):241–50 (93 ref.)
Environmental factors influencing the levels of indoor allergens. Munir AK. **Pediatr Allergy Immunol** 1995;6 Suppl 7:13–21 (91 ref.)
[Contact dermatoses: new antigens and current events] Castelain M. **Allerg Immunol (Paris)** 1995 Dec;27(10):363–9 (37 ref.) (Eng. Abstr.) **(Fre)**

ANALYSIS

Immunochemical and molecular methods for defining and measuring indoor allergens: in dust and air. Chapman MD, et al. **Pediatr Allergy Immunol** 1995;6 Suppl 7:8–12 (32 ref.)
Allergen levels causing sensitisation, bronchial hyperreactivity and asthma. Dreborg S. **Pediatr Allergy Immunol** 1995;6 Suppl 7:22–6 (44 ref.)
Strategies for indoor allergen elimination. Wahn U, et al. **Pediatr Allergy Immunol** 1995;6 Suppl 7:42–6 (41 ref.)

BIOSYNTHESIS

The biology of allergenic domestic mites. An update. Hart BJ. **Clin Rev Allergy Immunol** 1995 Summer;13(2):115–33 (134 ref.)

CHEMISTRY

Allergenic cross-reactivity of foods and characterization of food allergens and extracts. Bernhisel-Broadbent J. **Ann Allergy Asthma Immunol** 1995 Oct;75(4):295–303; quiz 304–7 (80 ref.)
Structure-activity relationships and computer-assisted analysis of respiratory sensitization potential. Karol MH, et al. **Toxicol Lett** 1996 Aug;86(2–3):187–91 (10 ref.)

DIAGNOSTIC USE

Basic and practical aspects of recombinant allergens. Scheiner O, et al. **Allergy** 1995 May;50(5):384–91 (94 ref.)
The European standard series. European Environmental and Contact Dermatitis Research Group (EECDRG). Bruynzeel DP, et al. **Contact Dermatitis** 1995 Sep; 33(3):145–8 (16 ref.)

GENETICS

Recombinant allergens for diagnosis and therapy of allergic diseases. Valenta R, et al. **Curr Opin Immunol** 1995 Dec; 7(6):751–6 (68 ref.)

IMMUNOLOGY

Bronchial inhalation challenge procedures with allergens and other bronchoconstrictor substances. Spector S. **Allerg Immunol (Paris)** 1996 Apr;28(4):112, 115–8 (38 ref.)
Modulation of immune responses to allergens of house dust mite. Hawrylowicz C, et al. **Biochem Soc Trans** 1995 Aug; 23(3):660–4 (29 ref.)
Dust mite allergens. Stewart GA. **Clin Rev Allergy Immunol** 1995 Summer;13(2):135–50 (65 ref.)
Allergen testing in patients with type I hypersensitivity. **Drug Ther Bull** 1995 Jun;33(6):45–7 (17 ref.)
Is there a dose–response relationship between exposure to indoor allergens and symptoms of asthma? [editorial] Platts-Mills TA, et al. **J Allergy Clin Immunol** 1995 Oct; 96(4):435–40 (44 ref.)
Type 1 allergic reactions to plant-derived food: a consequence of primary sensitization to pollen allergens. Valenta R, et al. **J Allergy Clin Immunol** 1996 Apr; 97(4):893–5 (29 ref.)
Biochemical features of grain legume allergens in humans and animals. Lallès JP, et al. **Nutr Rev** 1996 Apr;54(4 Pt 1):101–7 (65 ref.)
Environmental factors and primary T-cell sensitisation to inhalant allergens in infancy: reappraisal of the role of infections and air pollution. Holt PG. **Pediatr Allergy Immunol** 1995 Feb;6(1):1–10 (85 ref.)
[Cockroach allergy: a study of its prevalence using skin tests with commercial extracts] Cuesta C, et al. **Allergol Immunopathol (Madr)** 1995 Nov-Dec; 23(6):295–300 (34 ref.) (Eng. Abstr.) **(Spa)**

PHARMACOLOGY

The kinetics of the cytologic and rhinomanometric changes in the nose after challenge with allergen. Bernheim N, et al. **Acta Otorhinolaryngol Belg** 1995;49(3):229–33 (20 ref.)
Chemicals and proteins as allergens and adjuvants. Kapsenberg ML. **Toxicol Lett** 1996 Aug;86(2–3):79–83 (30 ref.)

THERAPEUTIC USE

Basic and practical aspects of recombinant allergens. Scheiner O, et al. **Allergy** 1995 May;50(5):384–91 (94 ref.)
Modified allergen immunotherapy: effect on immunoglobulin E production. Babakhin AA, et al. **Allergy Proc** 1995 Jul-Aug;16(4):195–202 (46 ref.)

TOXICITY

Predictive testing for respiratory sensitization in the mouse. Kimber I, et al. **Toxicol Lett** 1996 Aug;86(2–3):193–8 (31 ref.)

ALLERGIC ALVEOLITIS, EXTRINSIC see **ALVEOLITIS, EXTRINSIC ALLERGIC**

ALLERGIC ANGIITIS see **CHURG-STRAUSS SYNDROME**

ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS see **ASPERGILLOSIS, ALLERGIC BRONCHOPULMONARY**

ALLERGIC CONJUNCTIVITIS see **CONJUNCTIVITIS, ALLERGIC**

ALLERGIC CONTACT DERMATITIS see **DERMATITIS, ALLERGIC CONTACT**

ALLERGIC CUTANEOUS ANGIITIS see **VASCULITIS, ALLERGIC CUTANEOUS**

ALLERGIC CUTANEOUS VASCULITIS see **VASCULITIS, ALLERGIC CUTANEOUS**

ALLERGIC GRANULOMATOUS ANGIITIS see **CHURG-STRAUSS SYNDROME**

ALLERGIC PURPURA see **PURPURA, SCHOENLEIN-HENOCH**

ALLERGY see **HYPERSENSITIVITY**

ALLERGY (SPECIALTY) see **ALLERGY AND IMMUNOLOGY**

ALLERGY AND IMMUNOLOGY

Bela Schick Lecture, 1995. The three Ps: unabridged [editorial] Wray BB. **Ann Allergy Asthma Immunol** 1996 May;76(5):412–5 (18 ref.)
Clinical immunology. Mollnes TE, et al. **BMJ** 1996 Jun 8; 312(7044):1465–9 (35 ref.)
Internet for the allergist. Bell T. **J Asthma** 1996;33(3):143–8 (6 ref.)
[Progresses in microbiology and immunology in China, 1995] Wen Y. **Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):781 (0 ref.) **(Chi)**

TRENDS

Dendritic cells: a major story unfolds. Stingl G, et al. **Immunol Today** 1995 Jul;16(7):330–3 (32 ref.)
Antigen presentation--recent developments. Rammensee HG. **Int Arch Allergy Immunol** 1996 Aug;110(4):299–307 (63 ref.)
The impact of recent advances in microbiology and immunology on perinatal and women's health care. Munro CL. **J Obstet Gynecol Neonatal Nurs** 1995 Jul-Aug; 24(6):525–31 (32 ref.)
[Immunological novelties for clinicians] Meri S, et al. **Duodecim** 1994;110(2):175–7 (8 ref.) **(Fin)**

ALLESCHERIA see **PSEUDALLESCHERIA**

ALLIED HEALTH PERSONNEL

[Significance of initial defibrillation by paramedics] Mauer D, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Aug; 30(5):303–6 (30 ref.) **(Ger)**

ALLIUM SATIVUM see **GARLIC**

ALLOANTIBODIES see **ISOANTIBODIES**

ALLOANTIGENS see **ISOANTIGENS**

ALLOGRAFT see **TRANSPLANTATION, HOMOLOGOUS**

ALLOGRAFT DRESSINGS see **BIOLOGICAL DRESSINGS**

ALLOTYPES, IMMUNOGLOBULIN see **IMMUNOGLOBULIN ALLOTYPES**

ALLOTYPES, IMMUNOGLOBULIN GM see **IMMUNOGLOBULIN GM ALLOTYPES**

ALLOTYPIC ANTIBODIES see **IMMUNOGLOBULIN ALLOTYPES**

ALLOWING TO DIE see **EUTHANASIA, PASSIVE**

ALLOXAN DIABETES see **DIABETES MELLITUS, EXPERIMENTAL**

ALLOYS

Metallic implants used in foot surgery. Chang TJ, et al. **Clin Podiatr Med Surg** 1995 Jul;12(3):457–74 (57 ref.)

STANDARDS

Corrosion and other electrochemical aspects of biomaterials. Bundy KJ. **Crit Rev Biomed Eng** 1994;22(3–4):139–251 (1712 ref.)

TOXICITY

Metal carcinogenesis in total joint arthroplasty. Animal models. Lewis CG, et al. **Clin Orthop** 1996 Aug;(329 Suppl):S264–8 (37 ref.)

ALMITRINE

THERAPEUTIC USE

Pathophysiology of postischemic hypoxia and cerebral protection: implications of the almitrine and raubasine combination. Chan P. **Eur Neurol** 1995;35 Suppl 1:23–7 (41 ref.)
Quantitative electroencephalography in aging brain and cerebrovascular disease: the effects of almitrine-raubasine. Sebban C. **Eur Neurol** 1995;35 Suppl 1:37–42 (16 ref.)

ALMITRINE BISMESYLATE see **ALMITRINE**

ALOPECIA

The symptom experience of alopecia. Pickard-Holley S. **Semin Oncol Nurs** 1995 Nov;11(4):235–8 (16 ref.)

DIAGNOSIS

[Meralgia paresthetica. A rare differential diagnosis of circumscribed alopecia] Nabavi DG, et al. **Dtsch Med Wochenschr** 1996 Jun 21;121(25–26):834–8 (25 ref.) (Eng. Abstr.) **(Ger)**

ALOPECIA

ETIOLOGY

The moth-eaten alopecia of secondary syphilis. A histopathological study of 12 patients. Jordaan HF, et al. **Am J Dermatopathol** 1995 Apr;17(2):158–62 (16 ref.)

GENETICS

Alopecia/mental retardation syndrome. Hannig VL, et al. **Am J Med Genet** 1995 Aug 28;58(2):123–4 (13 ref.)

GAPO syndrome: a new case. Sandgren G. **Am J Med Genet** 1995 Jul 31;58(1):87–90 (16 ref.)

PATHOLOGY

The moth-eaten alopecia of secondary syphilis. A histopathological study of 12 patients. Jordaan HF, et al. **Am J Dermatopathol** 1995 Apr;17(2):158–62 (16 ref.)

Histopathology of non-scarring alopecia. Sperling LC, et al. **J Cutan Pathol** 1995 Apr;22(2):97–114 (47 ref.)

PHYSIOPATHOLOGY

Hair growth and the fluid factor. Foote SI. **Med Hypotheses** 1995 Jun;44(6):475–8 (18 ref.)

VETERINARY

Focal and generalized alopecia. O'Dair HA, et al. **Vet Clin North Am Small Anim Pract** 1995 Jul;25(4):851–70 (87 ref.)

ALOPECIA, ANDROGENETIC see **ALOPECIA**

ALOPECIA AREATA

ETIOLOGY

Does interleukin-1 induce hair loss? Hoffmann R, et al. **Dermatology** 1995;191(4):273–5 (17 ref.)

Clinical-epidemiologic study of alopecia areata. Roselino AM, et al. **Int J Dermatol** 1996 Mar;35(3):181–4 (8 ref.)

PATHOLOGY

Histopathology of non-scarring alopecia. Sperling LC, et al. **J Cutan Pathol** 1995 Apr;22(2):97–114 (47 ref.)

ALOPECIA, MALE PATTERN see **ALOPECIA**

ALPERS SYNDROME see **CEREBRAL SCLEROSIS, DIFFUSE**

ALPHA 1-ACID GLYCOPROTEIN see **OROSOMUCOID**

ALPHA 1-ACID SEROMUCOID see **OROSOMUCOID**

ALPHA 2-ACUTE PHASE GLOBULINS see **ALPHA-MACROGLOBULINS**

ALPHA-ADRENERGIC BLOCKING AGENTS see **ADRENERGIC ALPHA-ANTAGONISTS**

ALPHA-ADRENERGIC RECEPTOR AGONISTS see **ADRENERGIC ALPHA-AGONISTS**

ALPHA-ADRENERGIC RECEPTOR BLOCKADERS see **ADRENERGIC ALPHA-ANTAGONISTS**

ALPHA-ADRENERGIC RECEPTORS see **RECEPTORS, ADRENERGIC, ALPHA**

ALPHA-1 ADRENERGIC RECEPTORS see **RECEPTORS, ADRENERGIC, ALPHA-1**

ALPHA-2 ADRENERGIC RECEPTORS see **RECEPTORS, ADRENERGIC, ALPHA-2**

ALPHA-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID

see related
RECEPTORS, AMPA

ALPHA 1-ANTICHYMOTRYPSIN

BLOOD

[Alpha 1-antichymotrypsin (ACT)] Mashige F, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:198–202 (20 ref.) **(Jpn)**

ALPHA 1-ANTITRYPSIN

ANALYSIS

[alpha 1-Antitrypsin (alpha 1-AT)] Miyake K, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:193–7 (18 ref.) **(Jpn)**

CHEMISTRY

Glycosylation of alpha-1-proteinase inhibitor and haptoglobin in ovarian cancer: evidence for two different mechanisms. Turner GA, et al. **Glycoconj J** 1995 Jun; 12(3):211–8 (62 ref.)

DEFICIENCY

Recent pulmonary observations in alpha 1-antitrypsin deficiency, primary biliary cirrhosis, chronic hepatitis C, and other hepatic problems. Krowka MJ. **Clin Chest Med** 1996 Mar;17(1):67–82 (90 ref.)

Inherited liver diseases in adults. Kumar A, et al. **West J Med** 1995 Oct;163(4):382–6 (20 ref.)

[Gene therapy for alpha 1-antitrypsin deficiency. Hopes, realities and perspectives] LeMarchand P. **Rev Mal Respir** 1996;13(1):7–12 (24 ref.) (Eng. Abstr.) **(Fre)**

[Liver cirrhosis associated with metabolic disorders] Ono M, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):191–6 (26 ref.) **(Jpn)**

PHYSIOLOGY

[Serpins, a functionally important class of proteins: the paradigm of alpha-1-antitrypsin] Emmerich J. **Rev Med Interne** 1996;17(2):176–9 (27 ref.) **(Fre)**

ALPHA-BLOCKERS, ADRENERGIC see **ADRENERGIC ALPHA-ANTAGONISTS**

5 ALPHA-DIHYDROTESTOSTERONE see **STANOLONE**

ALPHA-ENDOTHELIAL GROWTH FACTOR see **ENDOTHELIAL GROWTH FACTORS**

ALPHA-FETOPROTEINS

ANALYSIS

Carbohydrate-based measurements on alpha-fetoprotein in the early diagnosis of hepatocellular carcinoma. Aoyagi Y. **Glycoconj J** 1995 Jun;12(3):194–9 (66 ref.)

Family care related to alpha-fetoprotein screening. Covington C, et al. **J Obstet Gynecol Neonatal Nurs** 1996 Feb;25(2):125–30 (28 ref.)

[Early diagnosis of hepatocellular carcinoma by serum AFP and PIVKA-II analysis] Aoyagi Y, et al. **Nippon Naika Gakkai Zasshi** 1995 Dec 10;84(12):2003–7 (5 ref.) **(Jpn)**

[Carcino-fetal antigens] Endo Y. **Nippon Rinsho** 1996 Jun; 54(6):1499–504 (17 ref.) (Eng. Abstr.) **(Jpn)**

BIOSYNTHESIS

Expression of alpha-fetoprotein by ovarian Sertoli-Leydig cell tumors. Case report and review of the literature. Hammad A, et al. **Arch Pathol Lab Med** 1995 Nov; 119(11):1075–9 (29 ref.)

AFP-producing squamous cell carcinoma of the lung in an adolescent. Asamura H, et al. **Jpn J Clin Oncol** 1996 Apr; 26(2):103–6 (12 ref.)

[Alpha-fetoprotein producing hepatocellular carcinoma, AT-III producing hepatocellular carcinoma] Nakamura K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):265–8 (11 ref.) **(Jpn)**

GENETICS

[Several transcription factors participate in the functioning of the alpha-fetoprotein gene promoter] Bois-Joyeux B, et al. **Bull Cancer (Paris)** 1995 Jul;82(7):541–50 (51 ref.) (Eng. Abstr.) **(Fre)**

[Human alpha-fetoprotein transcriptional regulatory regions: application to gene therapy] Tamaoki T, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2613–7 (25 ref.) **(Jpn)**

METABOLISM

Primary mediastinal malignant germ cell tumour. Single institution experience in Chinese patients and correlation with specific alpha-fetoprotein bends. Chan AT, et al. **Acta Oncol** 1996;35(2):221–7 (29 ref.)

[Maternal serum screening for detection of fetal chromosome abnormalities] Holzgreve W, et al. **Gynakologe** 1995 Oct; 28(5):280–8 (44 ref.) **(Ger)**

[A case study of nonfunctioning islet cell tumor in patient with splenic tumor and increased AFP] Zeki S, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 May;93(5):382–7 (20 ref.) **(Jpn)**

ALPHA-GALACTOSIDASE

DEFICIENCY

[Fabry disease (alpha-galactosidase deficiency)] Okumiya T, et al. **Nippon Rinsho** 1995 Dec;53(12):2952–9 (21 ref.) (Eng. Abstr.) **(Jpn)**

ALPHA-GLOBIN see **GLOBIN**

ALPHA-GLOBULINS

ANALYSIS

[alpha 1-Microglobulin (protein HC)] Itoh Y. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:189–92 (18 ref.) **(Jpn)**

PHYSIOLOGY

The inter-alpha-inhibitor family: from structure to regulation. Salier JP, et al. **Biochem J** 1996 Apr 1;315 (Pt 1):1–9 (68 ref.)

ALPHA 2-GLUCOPROTEINS see **ALPHA-MACROGLOBULINS**

1,4-ALPHA-GLUCOSIDASE, EXO see **GLUCAN 1,4-ALPHA-GLUCOSIDASE**

ALPHA-GLUCOSIDASES

ANTAGONISTS & INHIBITORS

The mechanism of alpha-glucosidase inhibition in the management of diabetes. Bischoff H. **Clin Invest Med** 1995 Aug;18(4):303–11 (31 ref.)

[alpha-Glucosidase inhibitors in the therapy of diabetes mellitus] Giorgino R, et al. **Ann Ital Med Int** 1995 Oct;10 Suppl:61S–65S (45 ref.) (Eng. Abstr.) **(Ita)**

ALPHA-HELICAL CONFORMATION, PROTEIN see **PROTEIN STRUCTURE, SECONDARY**

ALPHA-HEPARIN see **HEPARIN**

ALPHA-INTERFERON see **INTERFERON-ALPHA**

ALPHA-LINOLENIC ACID

STANDARDS

alpha-Linolenic acid: a preventive in secondary coronary events? Hartman IS. **Nutr Rev** 1995 Jul;53(7):194–7 (13 ref.)

ALPHA-LIPOPROTEINS see **LIPOPROTEINS, HDL**

ALPHA-MACROFETOPROTEINS see **ALPHA-MACROGLOBULINS**

ALPHA-MACROGLOBULINS

[From the Smart alpha 2-macroglobulin to single molecule biochemistry] Ikai A. **Seikagaku** 1996 Mar;68(3):179–95 (47 ref.) **(Jpn)**

[Direct analysis of the peptide bond cleavage by rapid quenching method] Shibuya N, et al. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(13):1959–62 (3 ref.) **(Jpn)**

ANALYSIS

[alpha 2-Macroglobulin] Ohtani H. **Nippon Rinsho** 1995 Feb; 53 Su Pt 1:210–2 (10 ref.) **(Jpn)**

ALPHA-METHYLDOPA see **METHYLDOPA**

ALPHA-MSH

PHYSIOLOGY

The neuropeptide alpha-melanocyte-stimulating hormone: a key component of neuroimmunomodulation. Catania A, et al. **Neuroimmunomodulation** 1994 Mar-Apr;1(2):93–9 (65 ref.)

ALPHA-NAPHTHYLAMINE see **1-NAPHTHYLAMINE**

ALPHA PARTICLES

THERAPEUTIC USE

Radioimmunotherapy with alpha-particle emitting radioimmunoconjugates. Zalutsky MR, et al. **Acta Oncol** 1996;35(3):373–9 (36 ref.)

Two approaches for enhancing radioimmunotherapy: alpha emitters and hyperthermia. Zalutsky MR, et al. **Recent Results Cancer Res** 1996;141:101–22 (41 ref.)

ALPHA 2-PLASMIN INHIBITOR see **ANTIPLASMIN**

ALPHA 1-PROTEASE INHIBITOR see **ALPHA 1-ANTITRYPSIN**

ALPHA 1-PROTEINASE INHIBITOR see **ALPHA 1-ANTITRYPSIN**

ALPHA RAYS see **ALPHA PARTICLES**

5-ALPHA-REDUCTASE, TESTOSTERONE see **TESTOSTERONE 5-ALPHA-REDUCTASE**

ALPHA-THALASSEMIA

DIAGNOSIS

[Thalassemia] Hattori Y. **Rinsho Byori** 1995 Aug;43(8):776–80 (8 ref.) (Eng. Abstr.) **(Jpn)**

EPIDEMIOLOGY

Hematologic disorders in children from southeast Asia. Glader BE, et al. **Pediatr Clin North Am** 1996 Jun;

43(3):665–81 (48 ref.)

GENETICS

Syndromal mental retardation due to mutations in a regulator of gene expression. Gibbons RJ, et al. **Hum Mol Genet** 1995;4 Spec No:1705–9 (24 ref.)
The alpha-thalassemia/mental retardation syndromes. Gibbons RJ, et al. **Medicine (Baltimore)** 1996 Mar; 75(2):45–52 (32 ref.)
The thalassemia syndromes lessons from molecular medicines index case. Benz EJ Jr. **Trans Am Clin Climatol Assoc** 1995; 107:20–36; discussion 35–6 (15 ref.)

ALPHA-TOXIN see PHOSPHOLIPASE C

ALPHACETYLMETHADOL see METHADYL ACETATE

ALPHAVIRUS

Mosquito-borne viruses and epidemic polyarthritis. Mackenzie JS, et al. **Med J Aust** 1996 Jan 15;164(2):90–3 (21 ref.)

GROWTH & DEVELOPMENT

Budding of alphaviruses. Strauss JH, et al. **Trends Microbiol** 1995 Sep;3(9):346–50 (34 ref.)

ALPHAVIRUS INFECTIONS

Mosquito-borne viruses and epidemic polyarthritis. Mackenzie JS, et al. **Med J Aust** 1996 Jan 15;164(2):90–3 (21 ref.)

EPIDEMIOLOGY

What is the potential for future outbreaks of chikungunya, dengue and yellow fever in southern Africa? [editorial] Jupp PG, et al. **S Afr Med J** 1996 Jan;86(1):35–7 (20 ref.)

ALPORT'S SYNDROME see NEPHRITIS, HEREDITARY

ALPROSTADIL

ADMINISTRATION & DOSAGE

[Long-term results of the treatment with intracavernous injection of vasoactive drugs] Rodríguez Vela L, et al. **Arch Esp Urol** 1996 Apr;49(3):257–69 (25 ref.) (Eng. Abstr.) **(Spa)**

BLOOD

[Prostaglandin E1 and its metabolites] Shio H, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:702–5 (9 ref.) **(Jpn)**

METABOLISM

[Prostaglandin E1 and its metabolites] Shio H, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:702–5 (9 ref.) **(Jpn)**

PHARMACOKINETICS

Intracavernous alprostadil. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in erectile dysfunction. Lea AP, et al. **Drugs Aging** 1996 Jan;8(1):56–74 (123 ref.)

PHARMACOLOGY

Intracavernous alprostadil. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in erectile dysfunction. Lea AP, et al. **Drugs Aging** 1996 Jan;8(1):56–74 (123 ref.)

THERAPEUTIC USE

Alprostadil for erectile impotence. **Drug Ther Bull** 1995 Aug; 33(8):61–2 (13 ref.)
The rationale for prostaglandin E1 in erectile failure: a survey of worldwide experience. Porst H. **J Urol** 1996 Mar; 155(3):802–15 (219 ref.)
[Use of PGE1 in severe ischemia of the lower extremities. Clinical study] Occhionorelli S, et al. **Minerva Cardioangiol** 1995 Jun;43(6):247–56 (73 ref.) (Eng. Abstr.) **(Ita)**

ALTEPLASE

ADMINISTRATION & DOSAGE

[Thrombolytic therapy of renal artery embolism. An expanded case report with review of the literature] Gulba DC, et al. **Internist (Berl)** 1996 Jun;37(6):623–7 (51 ref.) **(Ger)**

ANALYSIS

[Tissue-plasminogen activator (t-PA)] Sakuragawa N. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:59–63 (20 ref.) **(Jpn)**

GENETICS

The promise of new genetically engineered plasminogen activators. Cutler D, et al. **J Vasc Interv Radiol** 1995 Nov-Dec;6(6 Pt 2 Su):3S–7S (16 ref.)

THERAPEUTIC USE

Use of tissue type plasminogen activator in neonates: case reports and review of the literature. Smets K, et al. **Am J Perinatol** 1996 May;13(4):217–22 (21 ref.)
Interpreting results from thrombolytic megatrials: distinguishing fact from fiction. Brophy JM. **Can J Cardiol** 1996 Jan;12(1):89–92 (22 ref.)
Fibrin-selective thrombolytic therapy for acute myocardial infarction. Collen D. **Circulation** 1996 Mar 1;93(5):857–65 (90 ref.)
Thrombolysis in ischemic stroke: double or quits? [editorial] van Gijn J. **Circulation** 1996 May 1;93(9):1616–7 (21 ref.)
Alteplase. A reappraisal of its pharmacological properties and therapeutic use in acute myocardial infarction. Gillis JC, et al. **Drugs** 1995 Jul;50(1):102–36 (154 ref.)
Alteplase. A reappraisal of its pharmacology and therapeutic use in vascular disorders other than acute myocardial infarction. Wagstaff AJ, et al. **Drugs** 1995 Aug; 50(2):289–316 (185 ref.)
Innovations in aneurysmal subarachnoid hemorrhage: intracisternal t-PA for the prevention of vasospasm. Bell TE, et al. **J Neurosci Nurs** 1996 Apr;28(2):107–13 (37 ref.)
Comparison of "accelerated" tissue plasminogen activator with streptokinase for treatment of suspected myocardial infarction [see comments] Kellett J, et al. **Med Decis Making** 1995 Oct-Dec;15(4):297–310 (145 ref.)
Comment in: Med Decis Making 1995 Oct-Dec;15(4):395–6.

ALTERNARIA

Cutaneous alternariosis in a nonimmunocompromised patient. Saenz-Santamaria MC, et al. **Int J Dermatol** 1995 Aug; 34(8):556–7 (10 ref.)

ISOLATION & PURIFICATION

Cutaneous alternariosis in an immunocompromised patient. Chaidemenos GC, et al. **Cutis** 1995 Sep;56(3):145–50 (40 ref.)

ALTERNATIVE MEDICINE

Alternative medicine in the workplace. Lippin RA. **Altern Ther Health Med** 1996 Jan;2(1):47–51 (28 ref.)
Antiscience trends in the rise of the "alternative medicine" movement. Sampson W. **Ann N Y Acad Sci** 1996 Jun 24; 775:188–97 (34 ref.)
"Sucking with vampires". The medicine of unreason. Weissmann G. **Ann N Y Acad Sci** 1996 Jun 24;775:179–87 (26 ref.)
Alternative and complementary cancer therapies. Cassileth BR, et al. **Cancer** 1996 Mar 15;77(6):1026–34 (61 ref.)
Alternative cancer medicine: a ten-year update. Cassileth BR, et al. **Cancer Invest** 1996;14(4):396–404 (46 ref.)
Complementary cancer treatments: hope or hazard? Ernst E. **Clin Oncol (R Coll Radiol)** 1995;7(4):259–63 (34 ref.)
Brief report: alternative approaches to the development of effective treatments for autism. Rimland B, et al. **J Autism Dev Disord** 1996 Apr;26(2):237–41 (7 ref.)
Alternative cancer treatments. Aulas JJ. **Sci Am** 1996 Sep; 275(3):162–3 (0 ref.)
Unproven (questionable) cancer therapies. Brigden ML. **West J Med** 1995 Nov;163(5):463–9 (39 ref.)
[Alternative medicine] Saano V. **Duodecim** 1995;111(1):78–84 (41 ref.) **(Fin)**
[The cancer patient between academic medicine and alternative medicine--therapeutic concepts] Nagel GA. **Arch Gynecol Obstet** 1995;257(1–4):283–94 (13 ref.) **(Ger)**
[Alternative treatment methods in cancer] Jungi WF, et al. **Med Monatsschr Pharm** 1996 Jan;19(1):6–16 (8 ref.) **(Ger)**
[Smoking cessation with alternative methods] Stumpfe KD. **Z Arztl Fortbild (Jena)** 1995 Oct;89(5):511–4 (27 ref.) (Eng. Abstr.) **(Ger)**
[The challenge of alternative medicine] Leibovici L. **Harefuah** 1996 Jan 15;130(2):109–13 (20 ref.) **(Heb)**
[The "kangaroo mother" method (editorial)] Mosseri R, et al. **Harefuah** 1996 Jan 15;130(2):95–7 (15 ref.) **(Heb)**

ECONOMICS

The development and dissemination of non-patentable therapies (NPTs). Root-Bernstein RS. **Perspect Biol Med** 1995 Autumn;39(1):110–7 (26 ref.)

HISTORY

The efficacy, history, and politics of medicinal plants. Lipp FJ. **Altern Ther Health Med** 1996 Jul;2(4):36–41 (40 ref.)

UTILIZATION

Alternative medicine: should it be used by children? Spigelblatt LS. **Curr Probl Pediatr** 1995 Jul;25(6):180–8 (67 ref.)

ALTERNATIVE SPLICING

Alternative splicing of the Na(+)-Ca2+ exchanger gene, NCX1. Schulze DH, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:46–57 (32 ref.)
Developmental role of transcription factor isoforms generated by alternative splicing. López AJ. **Dev Biol** 1995 Dec;172(2):396–411 (118 ref.)
The developmental consequences of alternate splicing in sex determination and differentiation in Drosophila. MacDougall C, et al. **Dev Biol** 1995 Dec;172(2):353–76 (144 ref.)
Alternative splicing of fibronectin--many different proteins but few different functions. french-Constant C. **Exp Cell Res** 1995 Dec;221(2):261–71 (111 ref.)
The fibronectin gene as a model for splicing and transcription studies. Kornblihtt AR, et al. **FASEB J** 1996 Feb; 10(2):248–57 (76 ref.)
Schwann cell tumors express characteristic patterns of CD44 splice variants. Sherman L, et al. **J Neurooncol** 1995 Dec; 26(3):171–84 (57 ref.)
Retention of CD44 introns in bladder cancer: understanding the alternative splicing of pre-mRNA opens new insights into the pathogenesis of human cancers [editorial] Cooper DL. **J Pathol** 1995 Sep;177(1):1–3 (28 ref.)

ALTERNATIVES TO ANIMAL TESTING see ANIMAL TESTING ALTERNATIVES

ALTITUDE

see related MOUNTAINEERING

Exposure to moderate altitude and cardiorespiratory diseases. Gong H Jr. **Cardiologia** 1995 Jul;40(7):477–88 (98 ref.)
Age, altitude, and arrhythmia. Alexander JK. **Tex Heart Inst J** 1995;22(4):308–16 (69 ref.)
[Lung problems in acute to subacute exposure to medium altitudes] Marugg D. **Schweiz Rundsch Med Prax** 1995 Oct 3;84(40):1101–7 (41 ref.) (Eng. Abstr.) **(Ger)**

ALTITUDE SICKNESS

Selections from current literature: the traveller to high altitude. Fahrenwald R. **Fam Pract** 1995 Jun;12(2):237–41 (0 ref.)
A trek to the top: a review of acute mountain sickness. Porcelli MJ, et al. **J Am Osteopath Assoc** 1995 Dec; 95(12):718–20 (15 ref.)
Medicine and mechanisms in altitude sickness. Recommendations. Coote JH. **Sports Med** 1995 Sep; 20(3):148–59 (67 ref.)
[Altitude medicine] Wu T. **Chung Hua I Hsueh Tsa Chih** 1996 Jan;76(1):71–2 (0 ref.) **(Chi)**

COMPLICATIONS

High altitude pulmonary oedema: still a place for controversy? [editorial] Richalet JP. **Thorax** 1995 Sep; 50(9):923–9 (133 ref.)

PHYSIOPATHOLOGY

High-altitude pulmonary edema: current concepts. Hultgren HN. **Annu Rev Med** 1996;47:267–84 (71 ref.)
Hypothetical roles of angiogenesis, osmotic swelling, and ischemia in high-altitude cerebral edema. Severinghaus JW. **J Appl Physiol** 1995 Aug;79(2):375–9 (68 ref.)

ALTRETAMINE

ADMINISTRATION & DOSAGE

Oral therapy for small cell lung cancer. Postmus PE, et al. **Lung Cancer** 1995 Jun;12 Suppl 3:S63–70 (29 ref.)

ALTRUISM

The proper focus of nursing: a critique of the "caring" ideology. Barker PJ, et al. **Int J Nurs Stud** 1995 Aug; 32(4):386–97 (44 ref.)
An analysis of altruism: a concept of caring. Smith A. **J Adv Nurs** 1995 Oct;22(4):785–90 (22 ref.)
Beneficence re-examined: protective intervention in mental health. Murdach AD. **Soc Work** 1996 Jan;41(1):26–32 (43 ref.)
[Humanitarianism: the gardener, the truck driver and the "shrink"] Maqueda F. **Psychiatr Enfant** 1995;38(1):311–43 (4 ref.) (Eng. Abstr.) **(Fre)**

ALU REPETITIVE SEQUENCE see REPETITIVE SEQUENCES, NUCLEIC ACID

ALUMINUM

ADVERSE EFFECTS

Status and future concerns of clinical and environmental aluminum toxicology. Flaten TP, et al. **J Toxicol Environ Health** 1996 Aug 30;48(6):527–41 (97 ref.)
What we know and what we need to know about developmental aluminum toxicity. Golub MS, et al. **J Toxicol Environ Health** 1996 Aug 30;48(6):585–97 (74 ref.)
Speciation of aluminum in biological systems. Harris WR, et al. **J Toxicol Environ Health** 1996 Aug 30;48(6):543–68 (132 ref.)
Systemic aluminum toxicity: effects on bone, hematopoietic tissue, and kidney. Jeffery EH, et al.

ALUMINUM

J Toxicol Environ Health 1996 Aug 30;48(6):649–65 (80 ref.)

Can the controversy of the role of aluminum in Alzheimer's disease be resolved? What are the suggested approaches to this controversy and methodological issues to be considered? Savory J, et al. **J Toxicol Environ Health** 1996 Aug 30;48(6):615–35 (96 ref.)

Prevention and treatment of aluminum toxicity including chelation therapy: status and research needs. Yokel RA, et al. **J Toxicol Environ Health** 1996 Aug 30;48(6):667–83 (90 ref.)

Amyloid, aluminium and the aetiology of Alzheimer's disease [see comments] Storey E, et al. **Med J Aust** 1995 Sep 4; 163(5):256–9 (49 ref.) Comment in: Med J Aust 1996 Feb 19;164(4):252–3. Comment in: Med J Aust 1996 Mar 18;164(6):382–3.

ANALYSIS

[Aluminium] Manabe S. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:823–5 (13 ref.) **(Jpn)**

BLOOD

[Reversed-phase high-performance liquid chromatograph—application to serum aluminium monitoring] Hoshino H, et al. **Nippon Rinsho** 1996 Jan; 54(1):215–20 (9 ref.) (Eng. Abstr.) **(Jpn)**

CHEMISTRY

Standardization in biological analyses of aluminum: what are the needs? Lovell MA, et al. **J Toxicol Environ Health** 1996 Aug 30;48(6):637–48 (45 ref.)

IMMUNOLOGY

Vaccine adjuvants based on gamma inulin. Cooper PD. **Pharm Biotechnol** 1995;6:559–80 (73 ref.)

METABOLISM

Neurofibrillary pathology and aluminum in Alzheimer's disease. Shin RW, et al. **Histol Histopathol** 1995 Oct; 10(4):969–78 (168 ref.)

PHARMACOKINETICS

Aluminum toxicokinetics. Exley C, et al. **J Toxicol Environ Health** 1996 Aug 30;48(6):569–84 (64 ref.)

PHARMACOLOGY

Effects of aluminum on neuronal signal transduction: mechanisms underlying disruption of phosphoinositide hydrolysis. Shafer TJ, et al. **Gen Pharmacol** 1995 Sep; 26(5):889–95 (46 ref.)

POISONING

Chemical, pharmacological, toxicological and therapeutic advances of deferiprone (L1) and other iron and aluminium chelators. Kontoghiorghes GJ. **Arch Toxicol Suppl** 1996; 18:202–14 (56 ref.)

TOXICITY

Microbial interactions with aluminium. Piña RG, et al. **Biometals** 1996 Jul;9(3):311–6 (63 ref.)

Neurofibrillary pathology and aluminum in Alzheimer's disease. Shin RW, et al. **Histol Histopathol** 1995 Oct; 10(4):969–78 (168 ref.)

Developing a workshop to address unresolved research issues. Brandt BF. **J Toxicol Environ Health** 1996 Aug 30; 48(6):ix–xii (6 ref.)

Reproductive and developmental toxicity of aluminum: a review. Domingo JL. **Neurotoxicol Teratol** 1995 Jul–Aug; 17(4):515–21 (59 ref.)

Environmental hazards of aluminum to plants, invertebrates, fish, and wildlife. Sparling DW, et al. **Rev Environ Contam Toxicol** 1996;145:1–127 (242 ref.)

ALUMINUM COMPOUNDS

CHEMISTRY

Structure and properties of aluminum-containing adjuvants. Hem SL, et al. **Pharm Biotechnol** 1995;6:249–76 (36 ref.)

PHARMACOLOGY

Adjuvant properties of aluminum and calcium compounds. Gupta RK, et al. **Pharm Biotechnol** 1995;6:229–48 (126 ref.)

Stearyl tyrosine. An organic equivalent of aluminum-based immunoadjuvants. Penney C. **Pharm Biotechnol** 1995; 6:611–24 (26 ref.)

POISONING

Oral aluminium phosphide poisoning. Sharma A. **Indian Pediatr** 1995 Mar;32(3):339–42 (17 ref.)

ALUMINUM L-GLUTAMATE see **GLUTAMATES**

ALUMINUM HYDROXIDE

PHARMACOLOGY

Pharmacokinetic interactions related to the chemical structures of fluoroquinolones. Mizuki Y, et al. **J Antimicrob Chemother** 1996 May;37 Suppl A:41–55 (46 ref.)

ALUMINUM HYDROXIDE GEL see **ALUMINUM HYDROXIDE**

ALUMINUM SILICATES

ADVERSE EFFECTS

Vermiculite: a review of the mineralogy and health effects of vermiculite exploitation. Addison J. **Regul Toxicol Pharmacol** 1995 Jun;21(3):397–405 (74 ref.)

CHEMISTRY

Vermiculite: a review of the mineralogy and health effects of vermiculite exploitation. Addison J. **Regul Toxicol Pharmacol** 1995 Jun;21(3):397–405 (74 ref.)

PHARMACOLOGY

Selective chemisorption and detoxification of aflatoxins by phyllosilicate clay. Phillips TD, et al. **Nat Toxins** 1995; 3(4):204–13; discussion 221 (59 ref.)

ALUMINUM SUCROSE SULFATE see **SUCRALFATE**

ALVEOLAR ABSCESS, APICAL see **PERIAPICAL ABSCESS**

ALVEOLAR BONE LOSS

PHYSIOPATHOLOGY

A review of residual ridge resorption and bone density. Klemetti E. **J Prosthet Dent** 1996 May;75(5):512–4 (32 ref.)

ALVEOLAR ECHINOCOCCIS, HEPATIC see **ECHINOCOCCOSIS, HEPATIC**

ALVEOLAR LAVAGE FLUID see **BRONCHOALVEOLAR LAVAGE FLUID**

ALVEOLAR MACROPHAGES see **MACROPHAGES, ALVEOLAR**

ALVEOLAR NERVE, INFERIOR see **MANDIBULAR NERVE**

ALVEOLAR PROCESS

see related
ALVEOLOPLASTY
DENTAL ARCH

PHYSIOLOGY

Devices for dentoalveolar regeneration: an up-to-date literature review. Hardwick R, et al. **J Periodontol** 1995 Jun;66(6):495–505 (58 ref.)

SURGERY

Alveolar cleft bone grafting (Part II): Secondary bone grafting. Ochs MW. **J Oral Maxillofac Surg** 1996 Jan; 54(1):83–8 (37 ref.)

ALVEOLAR RESORPTION see **ALVEOLAR BONE LOSS**

ALVEOLITIS, EXTRINSIC ALLERGIC

Summer-type hypersensitivity pneumonitis. Ando M, et al. **Intern Med** 1995 Aug;34(8):707–12 (37 ref.)

DIAGNOSIS

Hypersensitivity pneumonitis: a noninfectious granulomatosis. Sharma OP, et al. **Semin Respir Infect** 1995 Jun;10(2):96–106 (32 ref.)

EPIDEMIOLOGY

[Extrinsic allergic alveolitis of occupational origin] Toubas D, et al. **Presse Med** 1995 Oct 14;24(30):1391–6 (42 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

[Hypersensitivity pneumonitis caused by a home humidifier] Hagiwara S, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Sep; 33(9):1024–9 (10 ref.) (Eng. Abstr.) **(Jpn)**

RADIOGRAPHY

[Hypersensitivity pneumopathies: x-ray computed tomographic aspects] Moysan P, et al. **J Radiol** 1995 Jul; 76(7):435–40 (27 ref.) (Eng. Abstr.) **(Fre)**

ALVEOLITIS, FIBROSING see **PULMONARY FIBROSIS**

ALVEOLOCAPILLARY MEMBRANE see **BLOOD-AIR BARRIER**

ALVEOLOPLASTY

METHODS

Alternative donor site for alveolar bone grafting in adults with cleft lip and palate. So LL, et al. **Angle Orthod** 1996; 66(1):9–16 (64 ref.)

ALZHEIMER BETA-PROTEIN see **AMYLOID BETA-PROTEIN**

ALZHEIMER'S DISEASE

see related
AMYLOID BETA-PROTEIN
AMYLOID BETA-PROTEIN PRECURSOR
APHASIA, PRIMARY PROGRESSIVE
NEUROFIBRILLARY TANGLES
NEUROFILAMENT PROTEINS
TAU PROTEINS

Is there a role for estrogen replacement therapy in the prevention and treatment of dementia? [see comments] Birge SJ. **J Am Geriatr Soc** 1996 Jul;44(7):865–70 (79 ref.) Comment in: J Am Geriatr Soc 1996 Jul;44(7):878–80.

[Trial to produce animal model of Alzheimer's disease by continuous infusion of beta-amyloid protein into the rat cerebral ventricle] Nabeshima T. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1995 Oct; 15(5):411–8 (27 ref.) (Eng. Abstr.) **(Jpn)**

[Methodological aspects and discrepancies in the clinical trials in Alzheimer's disease] Borja J, et al. **Rev Neurol** 1995 Jan–Feb;23(119):125–8 (30 ref.) (Eng. Abstr.) **(Spa)**

CLASSIFICATION

A comment on age at onset as a subtype of Alzheimer disease. Brooks JO 3rd. **Alzheimer Dis Assoc Disord** 1995;9 Suppl 1:S28–9 (9 ref.)

Is early-onset Alzheimer disease a distinct subgroup within the Alzheimer disease population? Raskind MA, et al. **Alzheimer Dis Assoc Disord** 1995;9 Suppl 1:S2–6 (41 ref.)

COMPLICATIONS

Adverse effects of potential agents for the treatment of Alzheimer's disease: a review. Domingo JL. **Adverse Drug React Toxicol Rev** 1995 Summer;14(2):101–15 (91 ref.)

Making the diagnosis of mixed and non-Alzheimer's dementias. Hansen LA, et al. **Arch Pathol Lab Med** 1995 Nov;119(11):1023–31 (34 ref.)

Alzheimer's disease and the eye. Armstrong RA, et al. **Ophthalmic Physiol Opt** 1996 Mar;16 Suppl 1:S2–8 (32 ref.)

[Progressive severity of left unilateral apraxia in 2 cases of Alzheimer disease] Ceccaldi M, et al. **Rev Neurol (Paris)** 1995 Apr;151(4):240–6 (36 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Review: Binswanger's disease, leukoaraiosis and dementia [letter; comment] Hasan M, et al. **Age Ageing** 1995 Sep; 24(5):454 (4 ref.) Comment on: Age Ageing 1994 Jan;23(1):75–81.

A flexible system of detection for Alzheimer's disease and related dementias. Gurland BJ, et al. **Aging (Milano)** 1995 Jun;7(3):165–72 (18 ref.)

Identification of fast and slow decliners in Alzheimer disease: a different approach. Brooks JO 3rd, et al. **Alzheimer Dis Assoc Disord** 1995;9 Suppl 1:S19–25 (23 ref.)

A comment on age at onset as a subtype of Alzheimer disease. Brooks JO 3rd. **Alzheimer Dis Assoc Disord** 1995;9 Suppl 1:S28–9 (9 ref.)

Is early-onset Alzheimer disease a distinct subgroup within the Alzheimer disease population? Raskind MA, et al. **Alzheimer Dis Assoc Disord** 1995;9 Suppl 1:S2–6 (41 ref.)

Preliminary findings from the predictors study: utility of clinical signs for predicting disease course. Stern Y, et al. **Alzheimer Dis Assoc Disord** 1995;9 Suppl 1:S14–8 (30 ref.)

Biologic differences between early- and late-onset Alzheimer disease. Terry RD. **Alzheimer Dis Assoc Disord** 1995;9 Suppl 1:S26–7 (7 ref.)

Near infrared spectroscopy in the diagnosis of Alzheimer's disease. Hock C, et al. **Ann N Y Acad Sci** 1996 Jan 17; 777:22–9 (20 ref.)

Neurodegenerative disorders with extensive tau pathology: a comparative study and review. Feany MB, et al. **Ann Neurol** 1996 Aug;40(2):139–48 (93 ref.)

Lewy body diseases with dementia: pathophysiology and treatment. Cummings JL. **Brain Cogn** 1995 Aug; 28(3):266–80 (64 ref.)

Genetic evidence that the Lewy body variant is indeed a phenotypic variant of Alzheimer's disease. Katzman R, et al. **Brain Cogn** 1995 Aug;28(3):259–65 (43 ref.)

Alzheimer's disease: an update. Sandson TA, et al. **Compr Ther** 1995 Sep;21(9):480–5 (41 ref.)

Non-Alzheimer's disease amyloidoses of the nervous system. Castaño EM, et al. **Curr Opin Neurol** 1995 Aug;8(4):279–85 (57 ref.)

Brain electrical activity (quantitative EEG and bit-mapping neurocognitive CNV components), psychometrics and

clinical findings in presenile subjects with initial mild cognitive decline or probable Alzheimer-type dementia. Zappoli R, et al. **Ital J Neurol Sci** 1995 Sep;16(6):341–76 (177 ref.)

Quantitative computed tomography and magnetic resonance imaging in aging and Alzheimer's disease. A review. Smith CD. **J Neuroimaging** 1996 Jan;6(1):44–53 (122 ref.)

Benign aging or Alzheimer disease? Gorman WF. **J Okla State Med Assoc** 1995 Sep;88(9):383–91 (51 ref.)

Vascular risk factors and atherosclerosis as risk factors for cognitive decline and dementia [editorial] Prince MJ. **J Psychosom Res** 1995 Jul;39(5):525–30 (31 ref.)

Apolipoprotein E genotyping in Alzheimer's disease. National Institute on Aging/Alzheimer's Association Working Group [see comments] **Lancet** 1996 Apr 20; 347(9008):1091–5 (77 ref.) Comment in: Lancet 1996 Apr 27;347(9009):1184–5. Comment in: Lancet 1996 Aug 3;348(9023):334.

The Autobiographical Memory Interview (AMI) in organic and psychogenic amnesia. Kopelman MD. **Memory** 1994 Jun;2(2):211–35 (66 ref.)

Assessing cognitive function in schizophrenics and patients with Alzheimer's disease. Mohs RC. **Schizophr Res** 1995 Sep;17(1):115–21 (65 ref.)

[Presentation by the GRECO group of the French adaptation of a cognitive assessment scale used in Alzheimer type dementia] Puel M, et al. **Presse Med** 1996 Jun 22; 25(22):1028–32 (14 ref.) (Eng. Abstr.) **(Fre)**

[Patchy changes in white matter in cranial computerized and magnetic resonance tomography--significance for (differential) diagnosis of dementia of the Alzheimer type and vascular dementia] Stoppe G, et al. **Fortschr Neurol Psychiatr** 1995 Nov;63(11):425–40 (150 ref.) (Eng. Abstr.) **(Ger)**

[Some problems in giving notice of the name of a disease: with special reference to Alzheimer's disease and vascular dementia] Hirai S. **No To Shinkei** 1996 May;48(5):431–5 (3 ref.) **(Jpn)**

[Differential diagnosis and diagnostic markers of Alzheimer's disease] Takeda M. **Seishin Shinkeigaku Zasshi** 1995; 97(8):557–66 (4 ref.) **(Jpn)**

[Clinical picture of dementia] Parnowski T. **Psychiatr Pol** 1995 Sep–Oct;29(5):593–605 (50 ref.) (Eng. Abstr.) **(Pol)**

[Alzheimer's disease. Considerations for its clinical diagnosis] Vasconcelos D. **Gac Med Mex** 1995 Jan–Feb;131(1):64–71 (20 ref.) (Eng. Abstr.) **(Spa)**

[Prion-type pathologies: from scrapie to prion-related dementias. On the borderline between veterinary and human pathology] Domich L. **Rev Neurol** 1996 Jul; 24(131):785–802 (250 ref.) **(Spa)**

[Dementias: current situation and future perspectives] Espert R, et al. **Rev Neurol** 1995 Jan–Feb;23(119):70–6 (90 ref.) (Eng. Abstr.) **(Spa)**

[Clinical trials in the Alzheimer's disease: evaluation of the therapeutic response] Frank A, et al. **Rev Neurol** 1995 Jan–Feb;23(119):111–7 (41 ref.) (Eng. Abstr.) **(Spa)**

[Alzheimer's disease] Giménez-Roldán S. **Rev Neurol** 1995 Jan–Feb;23(119):96–102 (62 ref.) **(Spa)**

[A model system in cell culture shows pathogenic processes. Biochemical diagnosis in Alzheimer dementia] Lannfelt L, et al. **Lakartidningen** 1996 Jun 12;93(24):2326–31 (46 ref.) **(Swe)**

DRUG THERAPY

Adverse effects of potential agents for the treatment of Alzheimer's disease: a review. Domingo JL. **Adverse Drug React Toxicol Rev** 1995 Summer;14(2):101–15 (91 ref.)

Clinical heterogeneity: responders to cholinergic therapy. Eagger SA, et al. **Alzheimer Dis Assoc Disord** 1995;9 Suppl 2:37–42 (72 ref.)

M1 agonists for the treatment of Alzheimer's disease. Novel properties and clinical update. Fisher A, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:189–96 (21 ref.)

Anti-inflammatory drugs in the fight against Alzheimer's disease. McGeer PL, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:213–20 (16 ref.)

HWA 285 (propentofylline)--a new compound for the treatment of both vascular dementia and dementia of the Alzheimer type. Rother M, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:404–9 (23 ref.)

The role of anti-inflammatory drugs in the prevention and treatment of Alzheimer's disease. Breitner JC. **Annu Rev Med** 1996;47:401–11 (81 ref.)

Psychopharmacology of Alzheimer's disease. Procter AW. **Br J Hosp Med** 1996 Feb 21–Mar 5;55(4):191–4 (20 ref.)

Clinical pharmacokinetics of drugs for Alzheimer's disease. Parnetti L. **Clin Pharmacokinet** 1995 Aug;29(2):110–29 (111 ref.)

Therapeutic trials in Alzheimer's disease. Whitehouse PJ, et al. **Curr Opin Neurol** 1995 Aug;8(4):275–8 (25 ref.)

THA--historical aspects, review of pharmacological properties and therapeutic effects. Soares JC, et al. **Dementia** 1995 Jul–Aug;6(4):225–34 (73 ref.)

Adjunctive therapy in patients with Alzheimer's disease. A practical approach. Corey-Bloom J, et al. **Drugs Aging** 1995 Aug;7(2):79–87 (46 ref.)

Drug treatment of Alzheimer's disease. Effects on caregiver burden and patient quality of life. Hollister L, et al. **Drugs Aging** 1996 Jan;8(1):47–55 (58 ref.)

Alzheimer's disease: the role of tacrine therapy. Jogerst G. **Iowa Med** 1995 Oct;85(10):409–11 (0 ref.)

Neuroleptic treatment of agitation and psychosis in dementia. Devanand DP, et al. **J Geriatr Psychiatry Neurol** 1995 Oct; 8 Suppl 1:S18–27 (141 ref.)

Therapeutic approaches related to amyloid-beta peptide and Alzheimer's disease. Schenk DB, et al. **J Med Chem** 1995 Oct 13;38(21):4141–54 (181 ref.)

The pharmacotherapy of Alzheimer's disease based on the cholinergic hypothesis: an update. Weinstock M. **Neurodegeneration** 1995 Dec;4(4):349–56 (82 ref.)

Noncompetitive NMDA receptor antagonists with fast open-channel blocking kinetics and strong voltage-dependency as potential therapeutic agents for Alzheimer's dementia. Müller WE, et al. **Pharmacopsychiatry** 1995 Jul;28(4):113–24 (90 ref.)

Treating Alzheimer's disease. Wilcock GK, et al. **QJM** 1995 Sep;88(9):673–6 (16 ref.)

[New therapeutic possibilities with low-affinity NMDA receptor antagonists] Kornhuber J, et al. **Nervenarzt** 1996 Jan;67(1):77–82 (22 ref.) (Eng. Abstr.) **(Ger)**

[Possibilities and limits of therapy of cognition disorders in the elderly] Hoyer S. **Z Gerontol Geriatr** 1995 Nov–Dec; 28(6):457–62 (56 ref.) (Eng. Abstr.) **(Ger)**

[New strategies in the acute and chronic treatment of the patient with Alzheimer's dementia] Rocco PL. **Minerva Med** 1996 Apr;87(4):171–7 (14 ref.) **(Ita)**

[Nerve growth factor strategy and preparation of animal model for Alzheimer-type senile dementia] Nabeshima T. **Yakugaku Zasshi** 1995 Jul;115(7):499–512 (59 ref.) (Eng. Abstr.) **(Jpn)**

[Pharmacological treatment of Alzheimer's disease: present situation and perspectives] Jané F. **Rev Neurol** 1995 Jan–Feb;23(119):103–7 (43 ref.) (Eng. Abstr.) **(Spa)**

EPIDEMIOLOGY

Sources of variability in prevalence rates of Alzheimer's disease. Corrada M, et al. **Int J Epidemiol** 1995 Oct; 24(5):1000–5 (37 ref.)

The clinical epidemiology of Alzheimer's disease. Keefover RW. **Neurol Clin** 1996 May;14(2):337–51 (194 ref.)

The "protective" influence of cigarette smoking on Alzheimer's and Parkinson's diseases. Quagmire or opportunity for neuroepidemiology? Riggs JE. **Neurol Clin** 1996 May;14(2):353–8 (24 ref.)

[Dementias: current situation and future perspectives] Espert R, et al. **Rev Neurol** 1995 Jan–Feb;23(119):70–6 (90 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

The Golgi apparatus and the pathogenesis of Alzheimer's disease [comment] Dal Canto MC. **Am J Pathol** 1996 Feb; 148(2):355–60 (40 ref.) Comment on: Am J Pathol 1996 Feb;148(2):415–26.

The role of heparan sulfate proteoglycans in the pathogenesis of Alzheimer's disease. Small DH, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:316–21 (18 ref.)

Molecular physiology, biochemistry, and pharmacology of Alzheimer's amyloid precursor protein (APP). Suh YH, et al. **Ann N Y Acad Sci** 1996 Jun 15;786:169–83 (59 ref.)

Cognitive problems in the elderly. Dal Forno G, et al. **Curr Opin Neurol** 1995 Aug;8(4):256–61 (44 ref.)

The cortical neuritic dystrophy of Alzheimer's disease: nature, significance, and possible pathogenesis. Larner AJ. **Dementia** 1995 Jul–Aug;6(4):218–24 (84 ref.)

Can the controversy of the role of aluminum in Alzheimer's disease be resolved? What are the suggested approaches to this controversy and methodological issues to be considered? Savory J, et al. **J Toxicol Environ Health** 1996 Aug 30;48(6):615–35 (96 ref.)

Amyloid, aluminium and the aetiology of Alzheimer's disease [see comments] Storey E, et al. **Med J Aust** 1995 Sep 4; 163(5):256–9 (49 ref.) Comment in: Med J Aust 1996 Feb 19;164(4):252–3. Comment in: Med J Aust 1996 Mar 18;164(6):382–3.

New clues to Alzheimer's disease: unraveling the roles of amyloid and tau [comment] Yankner BA. **Nat Med** 1996 Aug;2(8):850–2 (22 ref.) Comment on: Nat Med 1996 Aug;2(8):864–70.

Genetic dissection of Alzheimer disease, a heterogeneous disorder. Schellenberg GD. **Proc Natl Acad Sci U S A** 1995 Sep 12;92(19):8552–9 (144 ref.)

[Alzheimer's disease and trace elements] Yoshida H, et al. **Nippon Rinsho** 1996 Jan;54(1):111–6 (20 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

The amyloid peptide precursor in Alzheimer's disease. Octave JN. **Acta Neurol Belg** 1995 Dec;95(4):197–209 (70 ref.)

Does early-onset Alzheimer disease constitute a distinct subtype? The contribution of molecular genetics. Harvey RJ, et al. **Alzheimer Dis Assoc Disord** 1995;9 Suppl 1:S7–13 (70 ref.)

Clinical and neuropathological correlates of apolipoprotein E genotype in Alzheimer's disease. Window on molecular epidemiology. Hyman BT, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:158–65 (27 ref.)

Clinical and neuroimaging features of familial Alzheimer's disease. Rossor MN, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:49–56 (18 ref.)

Apolipoprotein E alleles as risk factors in Alzheimer's disease. Roses AD. **Annu Rev Med** 1996;47:387–400 (66 ref.)

Alzheimer's disease: genetics or environment? Mera SL. **Br J Biomed Sci** 1996 Jun;53(2):91–2 (8 ref.)

Genetic evidence that the Lewy body variant is indeed a phenotypic variant of Alzheimer's disease. Katzman R, et al. **Brain Cogn** 1995 Aug;28(3):259–65 (43 ref.)

Amyloid beta amyloidosis in Alzheimer's disease. Price DL, et al. **Curr Opin Neurol** 1995 Aug;8(4):268–74 (71 ref.)

Progress in Alzheimer's disease genetics. Schellenberg GD. **Curr Opin Neurol** 1995 Aug;8(4):262–7 (68 ref.)

Genes and recent developments in the epidemiology of Alzheimer's disease and related dementia. Breitner JC, et al. **Epidemiol Rev** 1995;17(1):39–47 (99 ref.)

A mechanism for beta-amyloid overproduction in Alzheimer's disease: precursor-independent generation of beta-amyloid via antisense RNA-primed mRNA synthesis. Volloch V. **FEBS Lett** 1996 Jul 22;390(2):124–8 (31 ref.)

Amyloid beta-protein and the genetics of Alzheimer's disease. Selkoe DJ. **J Biol Chem** 1996 Aug 2; 271(31):18295–8 (93 ref.)

Catastrophe, chaos and Alzheimer's disease. The F E Williams Lecture. Rossor MN. **J R Coll Physicians Lond** 1995 Sep–Oct;29(5):412–8 (60 ref.)

Apolipoprotein E and Alzheimer's disease. Stephens D. **J R Soc Health** 1996 Feb;116(1):41–3 (7 ref.)

Statement on use of apolipoprotein E testing for Alzheimer disease. American College of Medical Genetics/American Society of Human Genetics Working Group on ApoE and Alzheimer disease. **JAMA** 1995 Nov 22–29;274(20):1627–9 (55 ref.)

Apolipoprotein E genotyping in Alzheimer's disease. National Institute on Aging/Alzheimer's Association Working Group [see comments] **Lancet** 1996 Apr 20; 347(9008):1091–5 (77 ref.) Comment in: Lancet 1996 Apr 27;347(9009):1184–5. Comment in: Lancet 1996 Aug 3;348(9023):334.

Genetic dissection of Alzheimer disease, a heterogeneous disorder. Schellenberg GD. **Proc Natl Acad Sci U S A** 1995 Sep 12;92(19):8552–9 (144 ref.)

Genetic determinants of Alzheimer disease. St George-Hyslop P. **Prog Clin Biol Res** 1995;393:139–45 (23 ref.)

Genetic susceptibility to Alzheimer disease. Pericak-Vance MA, et al. **Trends Genet** 1995 Dec;11(12):504–8 (66 ref.)

[Phenotype of familial forms of early-onset Alzheimer's disease linked to chromosome 14. Clinical and neuropsychological characteristics of a large group] Hannequin D, et al. **Rev Neurol (Paris)** 1995 Dec; 151(12):682–90 (74 ref.) (Eng. Abstr.) **(Fre)**

[Genetic predisposition for Alzheimer's disease] Staufenbiel M, et al. **Ther Umsch** 1995 Dec;52(12):821–5 (28 ref.) (Eng. Abstr.) **(Ger)**

[Positional cloning of the genes for progeroid syndromes] Miki T, et al. **Tanpakushitsu Kakusan Koso** 1996 Mar; 41(3):245–54 (41 ref.) **(Jpn)**

IMMUNOLOGY

[The immune system characteristics during normal aging and in Alzheimer's disease] Koliaskina GI, et al. **Vestn Ross Akad Med Nauk** 1996;(4):19–23 (32 ref.) (Eng. Abstr.) **(Rus)**

METABOLISM

High affinity choline transporter status in Alzheimer's disease tissue from rapid autopsy. Bissette G, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:197–204 (12 ref.)

Reactive oxygen species as causal agents in the neurotoxicity of the Alzheimer's disease-associated amyloid beta peptide. Hensley K, et al. **Ann N Y Acad Sci** 1996 Jun 15;786:120–34 (49 ref.)

Regulation of tau phosphorylation in Alzheimer's disease. Lee VM. **Ann N Y Acad Sci** 1996 Jan 17;777:107–13 (37 ref.)

Free intracellular calcium in aging and Alzheimer's disease. Müller WE, et al. **Ann N Y Acad Sci** 1996 Jun 15;786:305–20 (55 ref.)

Clinical and neuroimaging features of familial Alzheimer's disease. Rossor MN, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:49–56 (18 ref.)

Molecular physiology, biochemistry, and pharmacology of Alzheimer's amyloid precursor protein (APP). Suh YH, et al. **Ann N Y Acad Sci** 1996 Jun 15;786:169–83 (59 ref.)

Glucose regulation and cognitive functions: relation to Alzheimer's disease and diabetes. Messier C, et al. **Behav Brain Res** 1996 Feb;75(1–2):1–11 (127 ref.)

Clinical pharmacokinetics of drugs for Alzheimer's disease. Parnetti L. **Clin Pharmacokinet** 1995 Aug;29(2):110–29 (111 ref.)

Disruption of the cytoskeleton in Alzheimer's disease. Lee VM. **Curr Opin Neurobiol** 1995 Oct;5(5):663–8 (43 ref.)

Cytokines in Alzheimer's disease and multiple sclerosis. Patterson PH. **Curr Opin Neurobiol** 1995 Oct;5(5):642–6 (44 ref.)

The role of beta-amyloid in the development of Alzheimer's disease. Ii K. **Drugs Aging** 1995 Aug;7(2):97–109 (154 ref.)

The molecular significance of amyloid beta-peptide for Alzheimer's disease. Haass C. **Eur Arch Psychiatry Clin Neurosci** 1996;246(3):118–23 (54 ref.)

A beta A4 amyloid precursor protein gene and Alzheimer's disease. Hendriks L, et al. **Eur J Biochem** 1996 Apr 1;

237(1):6–15 (123 ref.)
Phosphorylation of paired helical filament tau in Alzheimer's disease neurofibrillary lesions: focusing on phosphatases. Trojanowski JQ, et al. **FASEB J** 1995 Dec;9(15):1570–6 (77 ref.)
A mechanism for beta-amyloid overproduction in Alzheimer's disease: precursor-independent generation of beta-amyloid via antisense RNA-primed mRNA synthesis. Volloch V. **FEBS Lett** 1996 Jul 22;390(2):124–8 (31 ref.)
Neurofibrillary pathology and aluminum in Alzheimer's disease. Shin RW, et al. **Histol Histopathol** 1995 Oct; 10(4):969–78 (168 ref.)
Heparan sulfate proteoglycan/low density lipoprotein receptor-related protein pathway involved in type III hyperlipoproteinemia and Alzheimer's disease. Mahley RW. **Isr J Med Sci** 1996 Jun;32(6):414–29 (72 ref.)
Processing of the beta-amyloid precursor protein and its regulation in Alzheimer's disease. Checler F. **J Neurochem** 1995 Oct;65(4):1431–44 (101 ref.)
Minireview. Galanin–acetylcholine interactions: relevance to memory and Alzheimer's disease. Crawley JN. **Life Sci** 1996;58(24):2185–99 (112 ref.)
Lymphocytes and neutrophils as peripheral models to study the effect of beta-amyloid on cellular calcium signalling in Alzheimer's disease. Eckert A, et al. **Life Sci** 1996; 59(5–6):499–510 (47 ref.)
Soluble beta-amyloid induces Alzheimer's disease features in human fibroblasts and in neuronal tissues. Etcheberrigaray R, et al. **Life Sci** 1996;59(5–6):491–8 (42 ref.)
Altered oxidation and signal transduction systems in fibroblasts from Alzheimer patients. Gibson G, et al. **Life Sci** 1996;59(5–6):477–89 (81 ref.)
Peripheral cells as an investigational tool for Alzheimer's disease. Govoni S, et al. **Life Sci** 1996;59(5–6):461–8 (68 ref.)
Neurotrophins and Alzheimer's disease: beyond the cholinergic neurons. Knusel B, et al. **Life Sci** 1996; 58(22):2019–27 (38 ref.)
Alterations of thiamine phosphorylation and of thiamine-dependent enzymes in Alzheimer's disease. Héroux M, et al. **Metab Brain Dis** 1996 Mar;11(1):81–8 (35 ref.)
Breakdown of membrane phospholipids in Alzheimer disease. Involvement of excitatory amino acid receptors. Farooqui AA, et al. **Mol Chem Neuropathol** 1995 Jun–Aug; 25(2–3):155–73 (94 ref.)
Are reactive oxygen species involved in Alzheimer's disease? [see comments] Benzi G, et al. **Neurobiol Aging** 1995 Jul–Aug;16(4):661–74 (201 ref.) Comment in: Neurobiol Aging 1995 Jul–Aug;16(4):675–8. Comment in: Neurobiol Aging 1995 Jul–Aug;16(4):667–82; discussion 683. Comment in: Neurobiol Aging 1995 Jul–Aug;16(4):679–82; discussion 683.
Oxidative stress and Alzheimer's disease [comment] Choi BH. **Neurobiol Aging** 1995 Jul–Aug;16(4):675–8 (49 ref.) Comment on: Neurobiol Aging 1995 Jul–Aug;16(4):661–74.
Free radicals and disruption of neuronal ion homeostasis in AD: a role for amyloid beta-peptide? [comment] Mattson MP. **Neurobiol Aging** 1995 Jul–Aug;16(4):679–82; discussion 683 (40 ref.) Comment on: Neurobiol Aging 1995 Jul–Aug;16(4):661–74.
Hyperphosphorylation of tau in PHF. Morishima-Kawashima M, et al. **Neurobiol Aging** 1995 May–Jun;16(3):365–71; discussion 371–80 (56 ref.)
The amyloid peptide and its precursor in Alzheimer's disease. Octave JN. **Rev Neurosci** 1995 Oct–Dec;6(4):287–316 (289 ref.)
Neuropeptide changes in cortical and deep gray structures in Alzheimer's disease. Roeske LC, et al. **Rev Neurosci** 1995 Oct–Dec;6(4):317–28 (156 ref.)
[Alzheimer disease: hypotheses implicating apolipoproteins E] Blain H, et al. **Presse Med** 1996 May 4–11;25(16):763–8 (35 ref.) (Eng. Abstr.) **(Fre)**
[Abnormality of cytoskeletons and their phosphorylation in Alzheimer's disease] Nakamura Y, et al. **Seikagaku** 1996 Feb;68(2):133–6 (25 ref.) **(Jpn)**
[The neurochemical aspects of Alzheimer's disease] Almeida R, et al. **Acta Med Port** 1995 Oct;8(10):567–72 (46 ref.) (Eng. Abstr.) **(Por)**
[Protein phosphorylation in the normal nervous system and in Alzheimer's disease] Burbaeva GSh, et al. **Vestn Ross Akad Med Nauk** 1996;(4):13–8 (43 ref.) (Eng. Abstr.) **(Rus)**

NURSING

Kitwood's approach to dementia and dementia care: a critical but appreciative review. Adams T. **J Adv Nurs** 1996 May; 23(5):948–53 (32 ref.)

PATHOLOGY

The neurobiology of Alzheimer's disease. Brion JP. **Acta Clin Belg** 1996;51(2):80–90 (76 ref.)
Tau protein and the neurofibrillary pathology of Alzheimer's disease. Goedert M. **Ann N Y Acad Sci** 1996 Jan 17; 777:121–31 (26 ref.)
A hypothesis on the pathogenesis of Alzheimer's disease. Harman D. **Ann N Y Acad Sci** 1996 Jun 15;786:152–68 (100 ref.)
Molecular mechanism of Alzheimer's neurofibrillary degeneration and therapeutic intervention. Iqbal K, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:132–8 (22 ref.)
Amyloid beta-protein induces the cerebrovascular cellular pathology of Alzheimer's disease and related disorders. Van Nostrand WE, et al. **Ann N Y Acad Sci** 1996 Jan 17; 777:297–302 (19 ref.)
Incorrect diagnosis of Alzheimer's disease. A clinicopathologic study. Klatka LA, et al. **Arch Neurol** 1996 Jan;53(1):35–42 (57 ref.)
Making the diagnosis of mixed and non-Alzheimer's dementias. Hansen LA, et al. **Arch Pathol Lab Med** 1995 Nov;119(11):1023–31 (34 ref.)
The cortical neuritic dystrophy of Alzheimer's disease: nature, significance, and possible pathogenesis. Larner AJ. **Dementia** 1995 Jul–Aug;6(4):218–24 (84 ref.)
Inflammatory mechanisms in Alzheimer's disease. Hüll M, et al. **Eur Arch Psychiatry Clin Neurosci** 1996;246(3):124–8 (36 ref.)
Neurofibrillary pathology and aluminum in Alzheimer's disease. Shin RW, et al. **Histol Histopathol** 1995 Oct; 10(4):969–78 (168 ref.)
Hippocampal and neocortical involvement in normal brain aging and dementia: morphological and neurochemical profile of the vulnerable circuits. Hof PR, et al. **J Am Geriatr Soc** 1996 Jul;44(7):857–64 (83 ref.)
Methodological problems and clinical relevance of structural neuroimaging in dementia research. Lang CJ. **J Neural Transm Gen Sect** 1995;99(1–3):131–43 (45 ref.)
Free radical damage, iron, and Alzheimer's disease. Smith MA, et al. **J Neurol Sci** 1995 Dec;134 Suppl:92–4 (21 ref.)
Peripheral cells as an investigational tool for Alzheimer's disease. Govoni S, et al. **Life Sci** 1996;59(5–6):461–8 (68 ref.)
Staging of Alzheimer's disease-related neurofibrillary changes. Braak H, et al. **Neurobiol Aging** 1995 May–Jun; 16(3):271–8; discussion 278–84 (45 ref.)
APP transgenesis: approaches toward the development of animal models for Alzheimer disease neuropathology. Greenberg BD, et al. **Neurobiol Aging** 1996 Mar–Apr; 17(2):153–71 (323 ref.)
Relationship between plaques, tangles, and dystrophic processes in Alzheimer's disease. Trojanowski JQ, et al. **Neurobiol Aging** 1995 May–Jun;16(3):335–40; discussion 341–5 (47 ref.)
The older rabbit as an animal model: implications for Alzheimer's disease. Woodruff-Pak DS, et al. **Neurobiol Aging** 1996 Mar–Apr;17(2):283–90 (87 ref.)
Alzheimer neurofibrillary lesions: molecular nature and potential roles of different components. Yen SH, et al. **Neurobiol Aging** 1995 May–Jun;16(3):381–7 (92 ref.)
Mechanisms of neuronal degeneration in Alzheimer's disease. Yankner BA. **Neuron** 1996 May;16(5):921–32 (172 ref.)
Transgenic mice and modeling Alzheimer's disease. Higgins LS, et al. **Rev Neurosci** 1995 Apr–Jun;6(2):87–96 (91 ref.)
GABAergic deafferentation hypothesis of brain aging and Alzheimer's disease; pharmacologic profile of the benzodiazepine antagonist, flumazenil. Marczynski TJ. **Rev Neurosci** 1995 Jul–Sep;6(3):221–58 (164 ref.)

PHYSIOPATHOLOGY

Apolipoprotein E, synaptic plasticity and Alzheimer's disease. Poirier J, et al. **Ann Med** 1995 Dec;27(6):663–70 (89 ref.)
Receptor–effector coupling dysfunctions in Alzheimer's disease. Fowler CJ, et al. **Ann N Y Acad Sci** 1996 Jun 15;786:294–304 (72 ref.)
Tau protein and the neurofibrillary pathology of Alzheimer's disease. Goedert M. **Ann N Y Acad Sci** 1996 Jan 17; 777:121–31 (26 ref.)
Amyloid fibril toxicity in Alzheimer's disease and diabetes. Lorenzo A, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:89–95 (12 ref.)
Apolipoprotein E. Structure, function, and possible roles in Alzheimer's disease. Mahley RW, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:139–45 (24 ref.)
Ion channel hypothesis for Alzheimer amyloid peptide neurotoxicity. Pollard HB, et al. **Cell Mol Neurobiol** 1995 Oct;15(5):513–26 (67 ref.)
Biologic markers and neurochemical correlates of agitation and psychosis in dementia. Kirby M, et al. **J Geriatr Psychiatry Neurol** 1995 Oct;8 Suppl 1:S2–7 (63 ref.)
The basis for behavioural disturbances in dementia [editorial] Esiri MM. **J Neurol Neurosurg Psychiatry** 1996 Aug; 61(2):127–30 (57 ref.)
Trypsin inhibition: a potential cause of cobalamin deficiency common to the pathogenesis of Alzheimer-type dementia and AIDS dementia complex? McCaddon A, et al. **Med Hypotheses** 1995 Aug;45(2):200–4 (49 ref.)
Disturbances in signal transduction mechanisms in Alzheimer's disease. Fowler CJ, et al. **Mol Cell Biochem** 1995 Aug–Sep;149–150:287–92 (34 ref.)
Degenerative and protective signaling mechanisms in the neurofibrillary pathology of AD. Mattson MP. **Neurobiol Aging** 1995 May–Jun;16(3):447–57; discussion 458–63 (99 ref.)
Functional alterations in neural circuits in Alzheimer's disease. Simonian NA, et al. **Neurobiol Aging** 1995 May–Jun;16(3):305–9 (38 ref.)
Alzheimer's disease: maladaptive synaptoplasticity hypothesis. Neill D. **Neurodegeneration** 1995 Jun; 4(2):217–32 (250 ref.)
Mechanisms of neuronal degeneration in Alzheimer's disease. Yankner BA. **Neuron** 1996 May;16(5):921–32 (172 ref.)
Canine cognitive dysfunction as a model for human age-related cognitive decline, dementia and Alzheimer's disease: clinical presentation, cognitive testing, pathology and response to 1-deprenyl therapy. Ruehl WW, et al. **Prog Brain Res** 1995;106:217–25 (32 ref.)
[Alzheimer's disease in 1995] Mavroudakis N. **Rev Med Brux** 1996 Apr;17(2):57–60 (17 ref.) (Eng. Abstr.) **(Fre)**
[Isoform 4 of apolipoprotein E and Alzheimer disease. Specificity and clinical study] Mahieux F, et al. **Rev Neurol (Paris)** 1995 Apr;151(4):231–9 (71 ref.) (Eng. Abstr.) **(Fre)**
[Dementias: present situation and future perspectives (II). Biological markers] Espert R, et al. **Rev Neurol** 1995 Jan–Feb;23(119):77–85 (107 ref.) (Eng. Abstr.) **(Spa)**

PREVENTION & CONTROL

Oestrogen replacement therapy and Alzheimer's disease. Paganini-Hill A. **Br J Obstet Gynaecol** 1996 May;103 Suppl 13:80–6 (49 ref.)
Schizophrenia, Alzheimer's disease, and anti-inflammatory agents. Oken RJ, et al. **Schizophr Bull** 1996;22(1):1–4 (24 ref.)
Estrogen replacement therapy in the elderly. Paganini-Hill A. **Zentralbl Gynakol** 1996;118(5):255–61 (41 ref.)

PSYCHOLOGY

Human development in the context of aging and chronic illness: the role of attachment in Alzheimer's disease and stroke. Wright LK, et al. **Int J Aging Hum Dev** 1995; 41(2):133–50 (82 ref.)
Kitwood's approach to dementia and dementia care: a critical but appreciative review. Adams T. **J Adv Nurs** 1996 May; 23(5):948–53 (32 ref.)
Dementia and guns [see comments] Mendez MF. **J Am Geriatr Soc** 1996 Apr;44(4):409–10 (10 ref.) Comment in: J Am Geriatr Soc 1996 Apr;44(4):467–9.
Neuroleptic treatment of agitation and psychosis in dementia. Devanand DP, et al. **J Geriatr Psychiatry Neurol** 1995 Oct; 8 Suppl 1:S18–27 (141 ref.)
The depressions of Alzheimer's disease: sorting, pharmacotherapy, and clinical advice. Knesper DJ. **J Geriatr Psychiatry Neurol** 1995 Oct;8 Suppl 1:S40–51 (147 ref.)
[Concomitant therapies in the clinical trial in Alzheimer's disease] Bermejo F, et al. **Rev Neurol** 1995 Jan–Feb; 23(119):118–24 (81 ref.) (Eng. Abstr.) **(Spa)**
[Dementias: present situation and future perspectives (III). Neurological, therapeutic, psychosocial aspects and patient care] Espert R, et al. **Rev Neurol** 1995 Jan–Feb; 23(119):86–95 (138 ref.) (Eng. Abstr.) **(Spa)**

RADIOGRAPHY

Methodological problems and clinical relevance of structural neuroimaging in dementia research. Lang CJ. **J Neural Transm Gen Sect** 1995;99(1–3):131–43 (45 ref.)

RADIONUCLIDE IMAGING

Functional imaging patterns in Alzheimer's disease. Relationships to neurobiology. Jagust WJ. **Ann N Y Acad Sci** 1996 Jan 17;777:30–6 (20 ref.)

THERAPY

[New therapeutic prospects in Alzheimer disease] Rouhart F. **Rev Med Interne** 1995;16(11):860–3 (28 ref.) (Eng. Abstr.) **(Fre)**
[Toward a treatment for dementia] Ghika J. **Schweiz Rundsch Med Prax** 1995 Sep 19;84(38):1050–3 (47 ref.) (Eng. Abstr.) **(Fre)**
[Dementias: present situation and future perspectives (III). Neurological, therapeutic, psychosocial aspects and patient care] Espert R, et al. **Rev Neurol** 1995 Jan–Feb; 23(119):86–95 (138 ref.) (Eng. Abstr.) **(Spa)**

AMANITINS

PHARMACOLOGY

[Phallotoxins as modifiers in the study of muscles] Bukatina AE. **Biofizika** 1996 Jan–Feb;41(1):95–102 (38 ref.) (Eng. Abstr.) **(Rus)**

AMANTADINE

THERAPEUTIC USE

[New therapeutic possibilities with low-affinity NMDA receptor antagonists] Kornhuber J, et al. **Nervenarzt** 1996 Jan;67(1):77–82 (22 ref.) (Eng. Abstr.) **(Ger)**

AMAUROSIS see **BLINDNESS**

AMBIDEXTERITY see **LATERALITY**

AMBLYOPIA

Update on strabismus and amblyopia. Campos EC. **Acta Ophthalmol Scand** 1995;73 Suppl 214:17–24; discussion 24–5 (88 ref.)

Update on strabismus and amblyopia. Campos EC. **Acta Ophthalmol Scand Suppl** 1995;(214):17–24; discussion 24–5 (90 ref.)

ETIOLOGY

Amblyopia. Campos E. **Surv Ophthalmol** 1995 Jul–Aug; 40(1):23–39 (177 ref.)

PHYSIOPATHOLOGY

Physiology of suppression in strabismic amblyopia. Harrad R, et al. **Br J Ophthalmol** 1996 Apr;80(4):373–7 (63 ref.)

AMBLYSTOMA see **AMBYSTOMA**

AMBROXOL

THERAPEUTIC USE

Antenatal ambroxol usage in the prevention of infant respiratory distress syndrome. Beneficial and adverse effects. Kimya Y, et al. **Clin Exp Obstet Gynecol** 1995; 22(3):204–11 (39 ref.)

AMBULANCES

The revolution and evolution of prehospital cardiac care. Eisenberg MS, et al. **Arch Intern Med** 1996 Aug 12–26; 156(15):1611–9 (43 ref.)

AMBULANCES, AIR see **AIR AMBULANCES**

AMBULATORY BLOOD PRESSURE MONITORING see **BLOOD PRESSURE MONITORING, AMBULATORY**

AMBULATORY CARE

Teaching and learning in ambulatory care settings: a thematic review of the literature. Irby DM. **Acad Med** 1995 Oct; 70(10):898–931 (152 ref.)

Outpatient management of tuberculosis [see comments] McColloster P, et al. **Am Fam Physician** 1996 Apr; 53(5):1579–94 (12 ref.) Comment in: Am Fam Physician 1996 Apr;53(5):1511–2.

Ambulatory medical detoxification for alcohol. Abbott PJ, et al. **Am J Drug Alcohol Abuse** 1995 Nov;21(4):549–63 (30 ref.)

Guidelines for the use of nebulizers in the home and at domiciliary sites. Report of a consensus conference. National Association for Medical Direction of Respiratory Care (NAMDRC) Consensus Group. O'Donohue WJ Jr. **Chest** 1996 Mar;109(3):814–20 (32 ref.)

Outpatient cervical ripening. Sawai SK, et al. **Clin Obstet Gynecol** 1995 Jun;38(2):301–9 (23 ref.)

Office management of common neurologic problems. Moe PG. **Compr Ther** 1995 Sep;21(9):513–8 (16 ref.)

Outpatient management of HIV infection in the adult: an update. Boswell SL. **Curr Clin Top Infect Dis** 1995; 15:301–43 (189 ref.)

Benzodiazepines for insomnia in community-dwelling elderly: a review of benefit and risk. Grad RM. **J Fam Pract** 1995 Nov;41(5):473–81 (41 ref.)

Diagnosis and outpatient management of congestive heart failure. Karon BL. **Mayo Clin Proc** 1995 Nov;70(11):1080–5 (00 ref.)

Management of depression in the outpatient office. Salazar WH. **Med Clin North Am** 1996 Mar;80(2):431–55 (95 ref.)

Radiation protection issues associated with nuclear medicine out-patients [see comments] Thomson WH, et al. **Nucl Med Commun** 1995 Nov;16(11):879–92 (43 ref.) Comment in: Nucl Med Commun 1995 Nov;16(11):877–8.

Office hysteroscopy. Siegler AM. **Obstet Gynecol Clin North Am** 1995 Sep;22(3):457–71 (34 ref.)

[Nosocomial infections: a problem in ambulatory practice] Francioli P. **Rev Med Suisse Romande** 1996 May; 116(5):371–7 (5 ref.) **(Fre)**

[Ambulatory therapy in varicose veins] Eichlisberger R, et al. **Ther Umsch** 1996 Apr;53(4):295–303 (24 ref.) (Eng. Abstr.) **(Ger)**

[Classification systems in case-mix groups in ambulatory care. Perspectives for our primary health care] Juncosa S, et al. **Aten Primaria** 1996 Jan;17(1):76–82 (34 ref.) **(Spa)**

ECONOMICS

An economic evaluation of schizophrenia—1991. Wyatt RJ, et al. **Soc Psychiatry Psychiatr Epidemiol** 1995 Aug; 30(5):196–205 (49 ref.)

LEGISLATION & JURISPRUDENCE

[Social legislative and structural deficits of ambulatory management of chronic psychiatric and handicapped patients] Rössler W, et al. **Nervenarzt** 1995 Nov; 66(11):802–10 (34 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Outpatient endometrial assessment. Read MD. **Br J Hosp Med** 1995 Aug 16–Sep 5;54(4):150–3 (45 ref.)

Office laparoscopy as a screening tool for early detection of ovarian cancer. Runowicz CD. **J Cell Biochem Suppl** 1995;23:238–42 (12 ref.)

Implementation of a formal treatment agreement for outpatient management of chronic nonmalignant pain with opioid analgesics. Burchman SL, et al. **J Pain Symptom Manage** 1995 Oct;10(7):556–63 (19 ref.)

Outpatient asthma management. Cockcroft DW, et al. **Med Clin North Am** 1996 Jul;80(4):701–18 (60 ref.)

The outpatient management of febrile neutropenia in cancer patients. Freifeld AG, et al. **Oncology (Huntingt)** 1996 Apr; 10(4):599–606, 611–2; discussion 615–6 (31 ref.)

ORGANIZATION & ADMINISTRATION

Ambulatory care of the HIV-infected child. O'Hara MJ, et al. **Nurs Clin North Am** 1996 Mar;31(1):179–205 (46 ref.)

STATISTICS & NUMERICAL DATA

Evaluation of 2-week doctor visit reporting in the national health interview survey. Edwards WS, et al. **Vital Health Stat 2** 1996 Aug;(122):1–46 (17 ref.)

TRENDS

Recent advances: ambulatory care and family medicine. Gums JG. **Ann Pharmacother** 1995 Jul–Aug;29(7–8):716–8 (10 ref.)

AMBULATORY CARE FACILITIES

[Valuable methods for lung function measurements. Spirometry at ambulatory centers is excellent for early diagnosis] Larsson M. **Lakartidningen** 1995 Nov 22; 92(47):4427–30, 4435–7 (27 ref.) **(Swe)**

HISTORY

Evolution of undergraduate education in ambulatory settings: historical models. Greenberg LW. **Pharos** 1995 Fall; 58(4):13–7 (20 ref.)

AMBULATORY CARE FACILITIES, HOSPITAL see **OUTPATIENT CLINICS, HOSPITAL**

AMBULATORY CARE INFORMATION SYSTEMS

UTILIZATION

Has general practitioner computing made a difference to patient care? A systematic review of published reports. Sullivan F, et al. **BMJ** 1995 Sep 30;311(7009):848–52 (56 ref.)

AMBULATORY ELECTROCARDIOGRAPHY see **ELECTROCARDIOGRAPHY, AMBULATORY**

AMBULATORY MONITORING see **MONITORING, AMBULATORY**

AMBULATORY SURGERY

see related
SURGICENTERS

Ambulatory phlebectomy compared to sclerotherapy for varicose and telangiectatic veins: indications and complications. Weiss RA, et al. **Adv Dermatol** 1996;11:3–16; discussion 17 (37 ref.)

Recovery from outpatient anaesthesia. Factors affecting outcome. Korttila K. **Anaesthesia** 1995 Oct;50 Suppl:22–8 (63 ref.)

The role of sevoflurane in outpatient anesthesia. Smith I, et al. **Anesth Analg** 1995 Dec;81(6 Suppl):S67–72 (24 ref.)

Day surgery—the future. Jarrett PE. **Ann Chir Gynaecol** 1995;84(4):379–83 (37 ref.)

Anaesthesia for day-case surgery. Hitchcock M, et al. **Br J Hosp Med** 1995 Sep 6–19;54(5):202–6 (20 ref.)

Ambulatory phlebectomy. A rare complication of local anesthetic: case report and literature review. Olivencia JA. **Dermatol Surg** 1996 Jan;22(1):53–5 (15 ref.)

Intraoperative radiation therapy and Mohs micrographic surgery on an outpatient basis. Siegle RJ, et al. **Dermatol Surg** 1995 Nov;21(11):975–8 (16 ref.)

Co-induction of anaesthesia: day-case surgery. Whitwam JG. **Eur J Anaesthesiol Suppl** 1995 Nov;12:25–34 (50 ref.)

Pediatric ambulatory anesthesia: NPO—before or after surgery? Schreiner MS, et al. **J Clin Anesth** 1995 Nov; 7(7):589–96 (41 ref.)

An overview of consumer-driven ambulatory surgery: operative laparoscopy. Geier WS. **Nurse Pract** 1995 Nov; 20(11 Pt 1):36, 46–51 (61 ref.)

Arguments for day case surgery [see comments] Alexander-Williams J. **Practitioner** 1996 Mar; 240(1560):152–60 (10 ref.) Comment in: Practitioner 1996 Mar;240(1560):131.

[General ambulatory anesthesia in oral medicine and maxillofacial surgery] Boufflers E, et al. **Rev Stomatol Chir Maxillofac** 1995;96(4):247–58 (22 ref.) **(Fre)**

ECONOMICS

Practical, cost-effective regional anesthesia for ambulatory surgery. Greenberg CP. **J Clin Anesth** 1995 Nov; 7(7):614–21 (32 ref.)

Practical cost-effective choices: ambulatory general anesthesia. Philip BK. **J Clin Anesth** 1995 Nov;7(7):606–13 (31 ref.)

AMBYSTOMA

EMBRYOLOGY

The cardiac mutant gene c in axolotls: cellular, developmental, and molecular studies. Lemanski LF, et al. **Cell Mol Biol Res** 1995;41(4):293–305 (28 ref.)

GENETICS

The cardiac mutant gene c in axolotls: cellular, developmental, and molecular studies. Lemanski LF, et al. **Cell Mol Biol Res** 1995;41(4):293–305 (28 ref.)

AMEBA see **AMOEBA**

AMEBIASIS

see related
AMEBICIDES

DIAGNOSIS

Acanthamoeba: ecology, pathogenicity and laboratory detection. Walker CW. **Br J Biomed Sci** 1996 Jun; 53(2):146–51 (30 ref.)

Balamuthia mandrillaris: a newly recognized agent for amebic meningoencephalitis. Rowen JL, et al. **Pediatr Infect Dis J** 1995 Aug;14(8):705–10 (30 ref.)

AMEBIASIS, HEPATIC see **LIVER ABSCESS, AMEBIC**

AMEBIASIS, INTESTINAL see **DYSENTERY, AMEBIC**

AMEBIC DYSENTERY see **DYSENTERY, AMEBIC**

AMEBICIDES

ISOLATION & PURIFICATION

Amoebicidal compounds from medicinal plants. Di Stasi LC. **Parassitologia** 1995 Apr;37(1):29–39 (56 ref.)

THERAPEUTIC USE

Is there any reason to continue treating Blastocystis infections? [editorial; comment] Markell EK. **Clin Infect Dis** 1995 Jul;21(1):104–5 (11 ref.) Comment on: Clin Infect Dis 1995 Jul;21(1):97–101.

AMEBOMA see **AMEBIASIS**

AMEIURUS see **ICTALURIDAE**

AMELIA see **ECTROMELIA**

AMELOBLASTOMA

SURGERY

Le Fort I downfracture approach for the treatment of a posterior maxillary ameloblastoma. Symington OG, et al. **J Can Dent Assoc** 1995 Dec;61(12):1048–52 (24 ref.)

Surgical management of ameloblastoma. Current status of the literature. Feinberg SE, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Apr;81(4):383–8 (31 ref.)

AMELOBLASTS

METABOLISM

Enamel mineralization and the role of ameloblasts in calcium transport. Takano Y. **Connect Tissue Res** 1995; 33(1–3):127–37 (74 ref.)

PHYSIOLOGY

Enamel matrix proteins and ameloblast biology. Deutsch D, et al. **Connect Tissue Res** 1995;32(1–4):97–107 (123 ref.)

AMELOGENESIS

Enamel matrix proteins and ameloblast biology. Deutsch D, et al. **Connect Tissue Res** 1995;32(1–4):97–107 (123 ref.)

Molecular mechanisms of dental enamel formation. Simmer JP, et al. **Crit Rev Oral Biol Med** 1995;6(2):84–108 (194 ref.)

GENETICS

Understanding enamel formation from mutations causing X-linked amelogenesis imperfecta. Lagerström-Fermér M, et al. **Connect Tissue Res** 1995;32(1–4):241–6 (40 ref.)

PHYSIOLOGY

Recent observations on enamel crystal formation during mammalian amelogenesis. Aoba T. **Anat Rec** 1996 Jun; 245(2):208–18 (74 ref.)

AMELOGENESIS IMPERFECTA

GENETICS

Understanding enamel formation from mutations causing X-linked amelogenesis imperfecta. Lagerström-Fermér M, et al. **Connect Tissue Res** 1995;32(1-4):241-6 (40 ref.)
[Incidence of structural disorders of teeth in hereditary epidermolysis bullosa] Gábris K, et al. **Fogorv Sz** 1996 Jan; 89(1):7-10 (25 ref.) (Eng. Abstr.) **(Hun)**

AMENORRHEA

[Lactational amenorrhea as a method of family planning] Canto-de Cetina T, et al. **Salud Publica Mex** 1996 Jan-Feb; 38(1):58-63 (38 ref.) (Eng. Abstr.) **(Spa)**

COMPLICATIONS

[Sports, bones and hormones. Multiple interactions (editorial)] Maugars Y, et al. **Presse Med** 1995 Sep 30; 24(28):1284-6 (15 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Evaluation of amenorrhea. Kiningham RB, et al. **Am Fam Physician** 1996 Mar;53(4):1185-94 (44 ref.)

ETIOLOGY

Distress amenorrhea. Tolis G, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:660-4 (35 ref.)
Evaluation of amenorrhea. Aloi JA. **Compr Ther** 1995 Oct; 21(10):575-8 (7 ref.)
Clinical review 77: evaluation of secondary amenorrhea. Warren MP. **J Clin Endocrinol Metab** 1996 Feb; 81(2):437-42 (20 ref.)

PHYSIOPATHOLOGY

Spontaneous episodic release of adenohypophyseal hormones in hypothalamic amenorrhea. Genazzani AD, et al. **Gynecol Endocrinol** 1995 Dec;9(4):325-34 (63 ref.)

THERAPY

From physiology to clinics--20 years of experience with pulsatile GnRH. Leyendecker G, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Apr;65 Suppl:S3-12 (107 ref.)

AMERICAN MEDICAL ASSOCIATION

HISTORY

The evolution of American Medical Association policies concerning health care of veterans. Kendall JW. **Mil Med** 1995 Oct;160(10):518-21 (10 ref.)

AMERINDS, NORTH AMERICAN see **INDIANS, NORTH AMERICAN**

AMERINDS, SOUTH AMERICAN see **INDIANS, SOUTH AMERICAN**

AMETHOPTERIN see **METHOTREXATE**

AMETROPIA see **REFRACTIVE ERRORS**

AMIDASES see **AMIDOHYDROLASES**

AMIDES

Ropivacaine. McClure JH. **Br J Anaesth** 1996 Feb; 76(2):300-7 (88 ref.)

ADVERSE EFFECTS

1995 Gaston Labat Lecture. Ropivacaine. White knight or dark horse? de Jong RH. **Reg Anesth** 1995 Nov-Dec; 20(6):474-81 (37 ref.)

CHEMISTRY

Nonenzymatic deamidation of food proteins. Riha WE 3rd, et al. **Crit Rev Food Sci Nutr** 1996 Feb;36(3):225-55 (102 ref.)

THERAPEUTIC USE

1995 Gaston Labat Lecture. Ropivacaine. White knight or dark horse? de Jong RH. **Reg Anesth** 1995 Nov-Dec; 20(6):474-81 (37 ref.)

AMIDOHYDROLASES

DEFICIENCY

[Farber's lipogranulomatosis] Koga M. **Nippon Rinsho** 1995 Dec;53(12):3009-13 (21 ref.) (Eng. Abstr.) **(Jpn)**
[Biotinidase deficiency. Its form of presentation and response to treatment] Campistol J, et al. **An Esp Pediatr** 1996 Apr; 44(4):389-92 (22 ref.) **(Spa)**

METABOLISM

Enzymatic release of oligosaccharides from glycoproteins for chromatographic and electrophoretic analysis. O'Neill RA. **J Chromatogr A** 1996 Jan 12;720(1-2):201-15 (101 ref.)

PHYSIOLOGY

Do de-N-glycosylation enzymes have an important role in plant cells? Berger S, et al. **Biochimie** 1995;77(9):751-60 (98 ref.)

AMIDOLACETATE see **METHADYL ACETATE**

AMIDONE see **METHADONE**

AMIDOPHENAZON see **AMINOPYRINE**

AMIDOTREZOATE see **DIATRIZOATE**

AMIFOSTINE

PHARMACOKINETICS

Amifostine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as a radioprotector and cytotoxic chemoprotector. Spencer CM, et al. **Drugs** 1995 Dec;50(6):1001-31 (176 ref.)
Pharmacokinetic profile of amifostine. Shaw LM, et al. **Semin Oncol** 1996 Aug;23(4 Suppl 8):18-22 (19 ref.)

PHARMACOLOGY

Amifostine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as a radioprotector and cytotoxic chemoprotector. Spencer CM, et al. **Drugs** 1995 Dec;50(6):1001-31 (176 ref.)
Amifostine: the preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies. Capizzi R. **Semin Oncol** 1996 Aug;23(4 Suppl 8):2-17 (99 ref.)

THERAPEUTIC USE

Protection of normal tissue from the cytotoxic effects of chemotherapy and radiation by amifostine: clinical experiences. Capizzi RL, et al. **Eur J Cancer** 1995;31A Suppl 1:S8-13 (11 ref.)
Protection of normal tissues from the cytotoxic effects of chemotherapy and radiation by amifostine (WR-2721): preclinical aspects. Peters GJ, et al. **Eur J Cancer** 1995;31A Suppl 1:S1-7 (45 ref.)
Future development of amifostine in cancer treatment. Alberts DS, et al. **Semin Oncol** 1996 Aug;23(4 Suppl 8):90-9 (61 ref.)
Amifostine and chemotherapy-related thrombocytopenia. Budd GT. **Semin Oncol** 1996 Aug;23(4 Suppl 8):49-52 (31 ref.)
Cytoprotective agents for anthracyclines. Dorr RT. **Semin Oncol** 1996 Aug;23(4 Suppl 8):23-34 (122 ref.)
Amifostine and radiation therapy: past, present, and future. Tannehill SP, et al. **Semin Oncol** 1996 Aug;23(4 Suppl 8):69-77 (40 ref.)
The potential role of amifostine in conjunction with cisplatin in the treatment of locally advanced carcinoma of the cervix. Wadler S, et al. **Semin Oncol** 1996 Aug;23(4 Suppl 8):64-8 (33 ref.)

AMILORIDE

PHARMACOLOGY

[Distribution of amiloride-sensitive sodium channel in epithelial tissue] Bonvalet JP, et al. **C R Seances Soc Biol Fil** 1995;189(2):169-77 (14 ref.) (Eng. Abstr.) **(Fre)**

AMINE OXIDASE (COPPER-CONTAINING)

CHEMISTRY

Copper amine oxidase: a novel use for a tyrosine [comment] Fontecave M, et al. **Structure** 1995 Nov 15;3(11):1127-9 (22 ref.) Comment on: Structure 1995 Nov 15;3(11):1171-84.

METABOLISM

Biogenesis of novel quinone coenzymes. Tanizawa K. **J Biochem (Tokyo)** 1995 Oct;118(4):671-8 (52 ref.)

AMINE OXIDASE (FLAVIN-CONTAINING) see **MONOAMINE OXIDASE**

AMINE OXIDOREDUCTASES

CHEMISTRY

Stereochemistry and cofactor identity status of semicarbazide-sensitive amine oxidases. Palcic MM, et al. **Prog Brain Res** 1995;106:41-7 (28 ref.)
Polyamine oxidase, properties and functions. Seiler N. **Prog Brain Res** 1995;106:333-44 (51 ref.)

DEFICIENCY

Molecular genetic aspects of hyperhomocysteinemia and its relation to folic acid. Rozen R. **Clin Invest Med** 1996 Jun; 19(3):171-8 (18 ref.)

GENETICS

Molecular genetic aspects of hyperhomocysteinemia and its relation to folic acid. Rozen R. **Clin Invest Med** 1996 Jun; 19(3):171-8 (18 ref.)

METABOLISM

Biogenesis of novel quinone coenzymes. Tanizawa K. **J Biochem (Tokyo)** 1995 Oct;118(4):671-8 (52 ref.)
Semicarbazide-sensitive amine oxidases: some biochemical properties and general considerations. Buffoni F. **Prog Brain Res** 1995;106:323-31 (62 ref.)
Some aspects of the pathophysiology of semicarbazide-sensitive amine oxidase enzymes. Callingham BA, et al. **Prog Brain Res** 1995;106:305-21 (109 ref.)
Substrate-specificity of mammalian tissue-bound semicarbazide-sensitive amine oxidase. Lyles GA. **Prog Brain Res** 1995;106:293-303 (82 ref.)
Polyamine oxidase, properties and functions. Seiler N. **Prog Brain Res** 1995;106:333-44 (51 ref.)

AMINES

ADVERSE EFFECTS

The food-derived heterocyclic amines and breast cancer: a 1995 perspective. Synderwine EG. **Recent Results Cancer Res** 1996;140:17-25 (54 ref.)

ANALYSIS

Derivatization reactions for the determination of amines by gas chromatography and their applications in environmental analysis. Kataoka H. **J Chromatogr A** 1996 May 10;733(1-2):19-34 (178 ref.)

METABOLISM

Some aspects of the role of cytochrome P-450 isozymes in the N-oxidative transformation of secondary and tertiary amine compounds. Hlavica P, et al. **J Biochem Toxicol** 1995 Oct;10(5):275-285 (86 ref.)
The role of peroxidase-catalyzed activation of aromatic amines in breast cancer. Josephy PD. **Mutagenesis** 1996 Jan;11(1):3-7 (65 ref.)
Trace amines in hepatic encephalopathy. Mousseau DD, et al. **Prog Brain Res** 1995;106:277-84 (43 ref.)
An evolutionary view of drug-receptor interaction: the bioamine receptor family. Vernier P, et al. **Trends Pharmacol Sci** 1995 Nov;16(11):375-81 (56 ref.)
Aminium cation radical mechanism proposed for monoamine oxidase B catalysis: are there alternatives? Edmondson DE. **Xenobiotica** 1995 Jul;25(7):735-53 (53 ref.)
On the mechanism of amine oxidations by P450. Karki SB, et al. **Xenobiotica** 1995 Jul;25(7):711-24 (55 ref.)

PHARMACOKINETICS

Some aspects of the role of cytochrome P-450 isozymes in the N-oxidative transformation of secondary and tertiary amine compounds. Hlavica P, et al. **J Biochem Toxicol** 1995 Oct;10(5):275-285 (86 ref.)

THERAPEUTIC USE

A rationale for the selection of nasal decongestants in lacrimal drainage surgery. Hosal BM, et al. **Ophthal Plast Reconstr Surg** 1995 Sep;11(3):215-20 (29 ref.)

TOXICITY

Extrapolation of heterocyclic amine carcinogenesis data from rodents and nonhuman primates to humans. Adamson RH, et al. **Arch Toxicol Suppl** 1996;18:303-18 (56 ref.)
Induction of cytochrome P450 isoforms by carcinogenic aromatic amines and carcinogenic susceptibility of rodent animals. Hashimoto Y, et al. **Pharmacogenetics** 1995;5 Spec No:S80-3 (22 ref.)

AMINES, BIOGENIC see **BIOGENIC AMINES**

AMINES, SYMPATHOMIMETIC see **SYMPATHOMIMETICS**

AMINO ACID ACTIVATING ENZYMES see **AMINO ACYL T RNA SYNTHETASES**

AMINO ACID ACTIVATION

see related
AMINO ACYL T RNA SYNTHETASES

AMINO ACID DECARBOXYLASES, AROMATIC see **AROMATIC AMINO ACID DECARBOXYLASES**

AMINO ACID ISOMERASES

CHEMISTRY

Receptor (immunophilin-binding) assay for immunosuppressive drugs. Soldin SJ. **Ther Drug Monit** 1995 Dec;17(6):574-6 (18 ref.)

METABOLISM

Structure-function relationships in the FK506-binding protein (FKBP) family of peptidylprolyl cis-trans isomerases. Kay JE. **Biochem J** 1996 Mar 1;314 (Pt 2):361-85 (308 ref.)
Protein folding. Prolyl isomerases join the fold. Schmid FX. **Curr Biol** 1995 Sep 1;5(9):993-4 (12 ref.)
The Escherichia coli trigger factor. Hesterkamp T, et al. **FEBS Lett** 1996 Jun 24;389(1):32-4 (21 ref.)

PHYSIOLOGY

Immunophilins and the nervous system. Snyder SH, et al. **Nat Med** 1995 Jan;1(1):32-7 (82 ref.)

AMINO ACID METABOLISM, INBORN ERRORS

DIAGNOSIS

Urea cycle disorders: diagnosis, pathophysiology, and therapy. Brusilow SW, et al. **Adv Pediatr** 1996;43:127-70 (59 ref.)
Critical points for determining moderate hyperhomocyst(e)inaemia. Kang SS. **Eur J Clin Invest** 1995 Nov;25(11):806-8 (15 ref.)
Hyperhomocysteinaemia; with reference to its neuroradiological aspects. van den Berg M, et al. **Neuroradiology** 1995 Jul;37(5):403-11 (78 ref.)

METABOLISM

[Inborn errors of amino acid metabolism] Owada M. **Ryoikibetsu Shokogun Shirizu** 1995;(8):352-7 (23 ref.) **(Jpn)**
[Urea cycle disorders] Tazawa Y. **Ryoikibetsu Shokogun Shirizu** 1995;(8):367-9 (9 ref.) **(Jpn)**

THERAPY

Gene therapy for ornithine transcarbamylase deficiency. Kiwaki K, et al. **Acta Paediatr Jpn** 1996 Apr;38(2):189-92 (31 ref.)
Urea cycle disorders: diagnosis, pathophysiology, and therapy. Brusilow SW, et al. **Adv Pediatr** 1996;43:127-70 (59 ref.)
Tyrosinaemia--treatment and outcome. Kvittingen EA. **J Inherit Metab Dis** 1995;18(4):375-9 (16 ref.)

AMINO ACID NAPHTHYLAMIDASES

BLOOD

[Arylamidase] Seki T. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:409-11 (10 ref.) **(Jpn)**

AMINO ACID NEUROTRANSMITTERS

PHYSIOLOGY

Neurotransmitters and vulnerability of the developing brain. Johnston MV. **Brain Dev** 1995 Sep-Oct;17(5):301-6 (42 ref.)
Amino acids in neurotransmission and disease. Kalloniatis M. **J Am Optom Assoc** 1995 Dec;66(12):750-7 (57 ref.)

AMINO ACID OXIDOREDUCTASES

CHEMISTRY

Glycine decarboxylase: protein chemistry and molecular biology of the major protein in leaf mitochondria. Oliver DJ, et al. **J Bioenerg Biomembr** 1995 Aug;27(4):407-14 (57 ref.)

METABOLISM

Glycine decarboxylase: protein chemistry and molecular biology of the major protein in leaf mitochondria. Oliver DJ, et al. **J Bioenerg Biomembr** 1995 Aug;27(4):407-14 (57 ref.)
[Oxidases of l-amino acids and outlook for their practical application] Iaroshik LV, et al. **Ukr Biokhim Zh** 1995 Mar-Apr;67(2):17-24 (24 ref.) (Eng. Abstr.) **(Rus)**

AMINO ACID SEQUENCE

Protein structure prediction: recognition of primary, secondary, and tertiary structural features from amino acid sequence. Eisenhaber F, et al. **Crit Rev Biochem Mol Biol** 1995;30(1):1-94 (487 ref.)
Wilson's disease: a new gene and an animal model for an old disease. Cuthbert JA. **J Investig Med** 1995 Aug; 43(4):323-36 (121 ref.)
The unveiling of calreticulin--a clinically relevant tour of modern cell biology. Sontheimer RD, et al. **J Investig Med** 1995 Aug;43(4):362-70 (92 ref.)
Partition of aminoacyl-tRNA synthetases in two different structural classes dating back to early metabolism: implications for the origin of the genetic code and the nature of protein sequences. Delarue M. **J Mol Evol** 1995 Dec;41(6):703-11 (52 ref.)

AMINO ACIDS

ADMINISTRATION & DOSAGE

Value of specialty intravenous amino acid solutions. Melnik G. **Am J Health Syst Pharm** 1996 Mar 15;53(6):671-4 (29 ref.)
Protein and amino acids in nutritional support. McNurlan MA, et al. **Crit Care Clin** 1995 Jul;11(3):635-50 (114 ref.)
Intraperitoneal amino acids: a therapy whose time has come? Jones MR. **Perit Dial Int** 1995;15(5 Suppl):S67-74 (68 ref.)
Renal hemodynamic response to intravenous and oral amino acids in animals. Lang F, et al. **Semin Nephrol** 1995 Sep; 15(5):415-8 (65 ref.)
Renal effects of intravenous amino acid administration in humans with and without renal disease: hormonal correlates. ter Wee PM. **Semin Nephrol** 1995 Sep; 15(5):426-32 (76 ref.)

ANALYSIS

Separation and detection of amino acids and their enantiomers by capillary electrophoresis: a review. Issaq HJ, et al. **Electrophoresis** 1995 Apr;16(4):467-80 (81 ref.)
Molecular biological studies on teeth, and inquests. Yamamoto K. **Forensic Sci Int** 1996 Jun 28;80(1-2):79-87 (21 ref.)

BIOSYNTHESIS

Biocatalytic syntheses of aromatics from D-glucose: renewable microbial sources of aromatic compounds. Frost JW, et al. **Annu Rev Microbiol** 1995;49:557-79 (81 ref.)

BLOOD

The plasma level of some amino acids and physical and mental fatigue. Newsholme EA, et al. **Experientia** 1996 May 15;52(5):413-5 (14 ref.)
[Free amino acids] Kohno M, et al. **Nippon Rinsho** 1995 Feb; 53 Su Pt 1:481-5 (16 ref.) **(Jpn)**
[Homocysteine--an independent risk factor of premature vascular disease] Mansoor MA, et al. **Tidsskr Nor Laegeforen** 1996 May 30;116(14):1663-7 (41 ref.) **(Nor)**

CHEMISTRY

Urethane-protected alpha-amino acid N-carboxyanhydrides and peptide synthesis. Fuller WD, et al. **Biopolymers** 1996; 40(2):183-205 (56 ref.)
Conformational characteristics of peptides containing alpha, beta-dehydroamino acid residues. Jain R, et al. **Biopolymers** 1996;40(1):105-19 (80 ref.)
Role of oxidized amino acids in protein breakdown and stability. Stadtman ER. **Methods Enzymol** 1995;258:379-93 (56 ref.)
[Surface potential energy of peptides and conformation of amino acid residues in proteins. Preliminary results of processing using databank protein structures] Basharov MA. **Biofizika** 1995 Mar-Apr;40(2):260-73 (50 ref.) (Eng. Abstr.) **(Rus)**

METABOLISM

The role of the Opaque2 transcriptional factor in the regulation of protein accumulation and amino acid metabolism in maize seeds. Yunes JA, et al. **An Acad Bras Cienc** 1994;66 Su 1 (Pt 2):227-37; quiz 237-8 (60 ref.)
Transport mutants and transport genes of Corynebacterium glutamicum. Eggeling L, et al. **Ann N Y Acad Sci** 1996 May 15;782:191-201 (32 ref.)
Amino acid transporters. Kinne RK. **Curr Opin Nephrol Hypertens** 1995 Sep;4(5):412-5 (36 ref.)
The stimulation of Na,K,Cl cotransport and of system A for neutral amino acid transport is a mechanism for cell volume increase during the cell cycle. Bussolati O, et al. **FASEB J** 1996 Jun;10(8):920-6 (49 ref.)
Carbohydrate and amino acid metabolism in Giardia: a review. Jarroll EL, et al. **Folia Parasitol (Praha)** 1995; 42(2):81-9 (49 ref.)
Regulation of organic nutrient metabolism during transition from late pregnancy to early lactation. Bell AW. **J Anim Sci** 1995 Sep;73(9):2804-19 (117 ref.)
Ruminal microbial metabolism of peptides and amino acids. Wallace RJ. **J Nutr** 1996 Apr;126(4 Suppl):1326S-34S (79 ref.)
Recent advances in methods of assessing dietary amino acid requirements for adult humans. Zello GA, et al. **J Nutr** 1995 Dec;125(12):2907-15 (64 ref.)
Role of oxidized amino acids in protein breakdown and stability. Stadtman ER. **Methods Enzymol** 1995;258:379-93 (56 ref.)
Renal handling of drugs and amino acids after impairment of kidney or liver function--influences of maturity and protective treatment. Fleck C, et al. **Pharmacol Ther** 1995; 67(1):53-77 (341 ref.)
Amino acid transport in the small intestine [corrected and republished with original paging, article originally printed in Physiol Res 1994;43(6):335-45] Munck LK, et al. **Physiol Res** 1995;44(2):335-46 (116 ref.)
Quantitative aspects of blood and amino acid flows in cattle. Lescoat P, et al. **Reprod Nutr Dev** 1996;36(2):137-74 (158 ref.)
Amino acid metabolism and the vascular endothelium: regulation and disease implications [editorial] Pan M, et al. **Shock** 1995 Aug;4(2):79-88 (96 ref.)
Unique organ specific characteristics of amino acid metabolism in early development. Battaglia FC, et al. **Trans Am Clin Climatol Assoc** 1994;106:141-9; discussion 149-50 (22 ref.)

PHYSIOLOGY

Role of hydrophobic amino acids at position 74 of DRB1 chain in rheumatoid arthritis. Cerná M, et al. **Arch Immunol Ther Exp (Warsz)** 1995;43(2):139-44 (40 ref.)
New views on the pathogenesis of kwashiorkor: methionine and other amino acids. Roediger WE. **J Pediatr Gastroenterol Nutr** 1995 Aug;21(2):130-6 (75 ref.)
Eukaryotic gene expression: metabolite control by amino acids. Laine RO, et al. **Prog Nucleic Acid Res Mol Biol** 1996;53:219-48 (110 ref.)

STANDARDS

Do athletes need more dietary protein and amino acids? Lemon PW. **Int J Sport Nutr** 1995 Jun;5 Suppl:S39-61 (91 ref.)

URINE

[Biochemical markers of bone turnover in urine--pyridinoline, deoxypyridinoline and aminoterminal cross-links of type I collagen] Hayashi Y. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:523-6 (7 ref.) **(Jpn)**

AMINO ACIDS, BRANCHED-CHAIN

ADMINISTRATION & DOSAGE

Severe recurrent hepatic encephalopathy that responded to oral branched chain amino acids. Chalasani N, et al. **Am J Gastroenterol** 1996 Jun;91(6):1266-8 (12 ref.)

METABOLISM

Acidosis and glucocorticoids induce branched-chain amino acid catabolism. England BK, et al. **Miner Electrolyte Metab** 1996;22(1-3):69-71 (26 ref.)

PHYSIOLOGY

Carbohydrates, branched-chain amino acids, and endurance: the central fatigue hypothesis. Davis JM. **Int J Sport Nutr** 1995 Jun;5 Suppl:S29-38 (42 ref.)

THERAPEUTIC USE

Overview of randomized clinical trials of oral branched-chain amino acid treatment in chronic hepatic encephalopathy. Fabbri A, et al. **JPEN J Parenter Enteral Nutr** 1996 Mar-Apr;20(2):159-64 (44 ref.)

AMINO ACIDS, ESSENTIAL

ADMINISTRATION & DOSAGE

Glutamine--a conditionally essential amino acid in cirrhosis? Teran JC, et al. **Am J Clin Nutr** 1995 Nov;62(5):897-900 (40 ref.)
The requirements of adult man for indispensable amino acids. Waterlow JC. **Eur J Clin Nutr** 1996 Feb;50 Suppl 1:S151-76; discussion S176-9 (160 ref.)
Pattern of amino acid requirements in humans: an interspecies comparison using published amino acid requirement recommendations. McLarney MJ, et al. **J Nutr** 1996 Jul; 126(7):1871-82 (55 ref.)

METABOLISM

The requirements of adult man for indispensable amino acids. Waterlow JC. **Eur J Clin Nutr** 1996 Feb;50 Suppl 1:S151-76; discussion S176-9 (160 ref.)

PHYSIOLOGY

Pattern of amino acid requirements in humans: an interspecies comparison using published amino acid requirement recommendations. McLarney MJ, et al. **J Nutr** 1996 Jul; 126(7):1871-82 (55 ref.)

AMINO ACIDS, EXCITATORY see **EXCITATORY AMINO ACIDS**

AMINO ACIDS, EXCITATORY, AGONISTS see **EXCITATORY AMINO ACID AGONISTS**

AMINO ACIDS, EXCITATORY, ANTAGONISTS see **EXCITATORY AMINO ACID ANTAGONISTS**

AMINO ACIDS, SULFUR

METABOLISM

Nutritional and hormonal regulation of glutathione homeostasis. Taylor CG, et al. **Curr Top Cell Regul** 1996; 34:189-208 (129 ref.)

AMINO ACYL T RNA SYNTHETASES

Mammalian aminoacyl-tRNA synthetases. Yang DC. **Curr Top Cell Regul** 1996;34:101-36 (192 ref.)

[Mechanism of tRNA-recognition by aminoacyl-tRNA synthetases] Nureki S, et al. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1609-19 (37 ref.) **(Jpn)**

CHEMISTRY

Eleven down and nine to go. Cusack S. **Nat Struct Biol** 1995 Oct;2(10):824-31 (38 ref.)

METABOLISM

Partition of aminoacyl-tRNA synthetases in two different structural classes dating back to early metabolism: implications for the origin of the genetic code and the nature of protein sequences. Delarue M. **J Mol Evol** 1995 Dec;41(6):703-11 (52 ref.)

Substrate selection by aminoacyl-tRNA synthetases. Ibba M, et al. **Nucleic Acids Symp Ser** 1995;(33):40-2 (12 ref.)

AMINO SUGARS

METABOLISM

Control and function of complex-type oligosaccharide synthesis. Novel variants of the lacNAc pathway. Van den Eijnden DH, et al. **Adv Exp Med Biol** 1995;376:47-52 (26 ref.)

AMINOACETIC ACID see GLYCINE

4-AMINOBENZOIC ACID

ANALOGS & DERIVATIVES

[BT-PABA test] Koizumi M, et al. **Nippon Rinsho** 1995 Feb; 53 Su Pt 1:1088-91 (12 ref.) **(Jpn)**

P-AMINOBENZOIC ACID see 4-AMINOBENZOIC ACID

O-AMINOBENZOIC ACIDS see ANTHRANILIC ACIDS

AMINOBUTYRATE AMINOTRANSFERASE

ANTAGONISTS & INHIBITORS

Vigabatrin-associated reversible acute psychosis in a child. Cánovas Martínez A, et al. **Ann Pharmacother** 1995 Nov; 29(11):1115-7 (10 ref.)

4-AMINOBUTYRIC ACID see GABA

AMINOBUTYRIC ACIDS

see related
RECEPTORS, GABA-A

ANALYSIS

[Aminobutyric acid] Endo M, et al. **Nippon Rinsho** 1995 Feb; 53 Su Pt 1:486-8 (12 ref.) **(Jpn)**

AMINOETHANOLS see ETHANOLAMINES

AMINOGLYCOSIDE ANTIBIOTICS see ANTIBIOTICS, AMINOGLYCOSIDE

AMINOGLYCOSIDES

PHARMACOKINETICS

Pharmacokinetic issues in the treatment of continuous ambulatory peritoneal dialysis-associated peritonitis. Bailie GR, et al. **J Antimicrob Chemother** 1995 May;35(5):563-7 (33 ref.)

PHARMACOLOGY

Pharmacodynamics of antimicrobial therapy in surgery. DiPiro JT, et al. **Am J Surg** 1996 Jun;171(6):615-22 (46 ref.)

THERAPEUTIC USE

Pharmacodynamics of antimicrobial therapy in surgery. DiPiro JT, et al. **Am J Surg** 1996 Jun;171(6):615-22 (46 ref.)

4-AMINOHIPPURIC ACID see P-AMINOHIPPURIC ACID

P-AMINOHIPPURIC ACID

DIAGNOSTIC USE

Conventional measurement of renal function utilizing serum creatinine, creatinine clearance, inulin and para-aminohippuric acid clearance. Toto RD. **Curr Opin Nephrol Hypertens** 1995 Nov;4(6):505-9; discussion 503-4 (21 ref.)

[Paraaminohippuric acid clearance] Nagase S, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:1082-4 (7 ref.) **(Jpn)**

AMINOLEVULINATE HYDRO-LYASE see AMINOLEVULINIC ACID DEHYDRATASE

AMINOLEVULINIC ACID

ANALYSIS

[delta-Aminolevulinic acid (ALA)] Tajima Y. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:877-80 (22 ref.) **(Jpn)**

PHARMACOLOGY

How do Ca2+ and 5-aminolevulinic acid-derived oxyradicals promote injury to isolated mitochondria? Hermes-Lima M. **Free Radic Biol Med** 1995 Sep; 19(3):381-90 (87 ref.)

AMINOLEVULINIC ACID DEHYDRATASE

ANALYSIS

[delta-Aminolevulinic acid dehydratase] Tajima Y. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:886-90 (25 ref.) **(Jpn)**

METABOLISM

Porphobilinogen synthase, the first source of heme's asymmetry. Jaffe EK. **J Bioenerg Biomembr** 1995 Apr; 27(2):169-79 (76 ref.)

AMINOLEVULINIC ACID SYNTHETASE

ANALYSIS

[delta-Aminolevulinic acid synthase(ALAS)] Kondo M. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:881-5 (27 ref.) **(Jpn)**

GENETICS

Molecular defects of erythroid 5-aminolevulinate synthase in X-linked sideroblastic anemia. Bottomley SS, et al. **J Bioenerg Biomembr** 1995 Apr;27(2):161-8 (50 ref.)

METABOLISM

5-Aminolevulinate synthase and the first step of heme biosynthesis. Ferreira GC, et al. **J Bioenerg Biomembr** 1995 Apr;27(2):151-9 (84 ref.)

1-AMINONAPHTHALENE see 1-NAPHTHYLAMINE

AMINOPEPTIDASE N see ANTIGENS, CD13

AMINOPEPTIDASES

ANALYSIS

[Glycylproline dipeptidyl aminopeptidase (GPDAP)] Matsuda Y, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:365-8 (20 ref.) **(Jpn)**

CHEMISTRY

Bacterial aminopeptidases: properties and functions. Gonzales T, et al. **FEMS Microbiol Rev** 1996 Jul;18(4):319-44 (252 ref.)

METABOLISM

Two novel metallopeptidases with a specificity for basic residues: functional properties, structure and cellular distribution. Foulon T, et al. **Ann N Y Acad Sci** 1996 Mar 22;780:106-20 (49 ref.)

HPr: heteromorphous protein. Vadeboncoeur C. **Res Microbiol** 1995 Sep;146(7):525-30 (41 ref.)

PHYSIOLOGY

Bacterial aminopeptidases: properties and functions. Gonzales T, et al. **FEMS Microbiol Rev** 1996 Jul;18(4):319-44 (252 ref.)

AMINOPHENAZONE see AMINOPYRINE

AMINOPROPANOLS see PROPANOLAMINES

3-AMINOPROPIONIC ACID see BETA-ALANINE

AMINOPTERIN

ANALOGS & DERIVATIVES

Edatrexate studies in non-small cell lung cancer. Gralla RJ. **Lung Cancer** 1995 Apr;12 Suppl 1:S187-91 (21 ref.)

2-AMINOPURINE

ANALOGS & DERIVATIVES

Famciclovir: efficacy in zoster and issues in the assessment of pain. Boon RJ, et al. **Adv Exp Med Biol** 1996;394:17-31 (37 ref.)

Use of penciclovir and famciclovir in the management of genital herpes. Sacks SL. **Curr Probl Dermatol** 1996; 24:219-26 (34 ref.)

Famciclovir. A review of its pharmacological properties and therapeutic efficacy in herpesvirus infections. Perry CM, et al. **Drugs** 1995 Aug;50(2):396-415 (64 ref.)

Efficacy of famciclovir in the treatment of herpes zoster: reduction of pain associated with zoster. Boon RJ, et al. **Neurology** 1995 Dec;45(12 Suppl 8):S76-7 (9 ref.)

AMINOPYRINE

ADVERSE EFFECTS

[Amidazophen. Yes or no?] Jákó J, et al. **Orv Hetil** 1995 Sep 24;136(39):2121-4 (50 ref.) (Eng. Abstr.) **(Hun)**

AMINOQUINOLINES

THERAPEUTIC USE

New drugs for hyperprolactinaemia. **Drug Ther Bull** 1995 Sep;33(9):65-7 (24 ref.)

4-AMINOSALICYLIC ACID see P-AMINOSALICYLIC ACID

P-AMINOSALICYLIC ACID

THERAPEUTIC USE

Current problems with tuberculosis treatment. Grosset J. **Res Microbiol** 1996 Jan-Feb;147(1-2):10-6 (32 ref.)

AMINOSALICYLIC ACIDS

ADMINISTRATION & DOSAGE

[Crohn disease: prevention and drug therapy] Gross V, et al. **Chirurg** 1995 Aug;66(8):757-63 (42 ref.) (Eng. Abstr.) **(Ger)**

[5-aminosalicylic acid and chronic inflammatory bowel diseases in children] Klotz U. **Klin Padiatr** 1995 Sep-Oct; 207(5):285-7 (18 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Mesalamine-induced lung toxicity. Bitton A, et al. **Am J Gastroenterol** 1996 May;91(5):1039-40 (10 ref.)

Pleuropericarditis related to the use of mesalamine. Gujral N, et al. **Dig Dis Sci** 1996 Mar;41(3):624-6 (12 ref.)

PHARMACOLOGY

Effects of mesalazine on the formation of lipoxygenase and cyclooxygenase products. Lauritsen K, et al. **Adv Exp Med Biol** 1995;371B:1301-6 (66 ref.)

Antioxidant properties of 5-aminosalicylic acid: potential mechanism for its protective effect in ulcerative colitis. Miles AM, et al. **Adv Exp Med Biol** 1995;371B:1317-21 (20 ref.)

Effects of mesalazine on lamina propria white cell functions. Verspaget HW. **Adv Exp Med Biol** 1995;371A:317-20 (20 ref.)

Leukocyte-endothelial cell interactions: potential targets for mesalazine in Crohn's disease. Wakefield AJ, et al. **Adv Exp Med Biol** 1995;371B:1307-11 (72 ref.)

Sulphasalazine, sulphapyridine or 5-aminosalicylic acid--which is the active moiety in rheumatoid arthritis? Bird HA. **Br J Rheumatol** 1995 Nov;34 Suppl 2:16-9 (11 ref.)

THERAPEUTIC USE

Use of old and new oral 5-aminosalicylic acid formulations in inflammatory bowel disease. Brzezinski A, et al. **Cleve Clin J Med** 1995 Sep-Oct;62(5):317-23 (37 ref.)

Aminosalicylates for the treatment of inflammatory bowel disease. Leichtner AM. **J Pediatr Gastroenterol Nutr** 1995 Oct;21(3):245-52 (66 ref.)

AMINOTRANSFERASES

GENETICS

Evolutionary recruitment of biochemically specialized subdivisions of Family I within the protein superfamily of aminotransferases. Jensen RA, et al. **J Bacteriol** 1996 Apr; 178(8):2161-71 (68 ref.)

AMIODARONE

ADVERSE EFFECTS

Canalicular cholestasis due to amiodarone toxicity. A definite diagnosis obtained by electron microscopy. Macarri G, et al. **Ital J Gastroenterol** 1995 Oct-Nov;27(8):436-8 (18 ref.)

An evaluation of possible mechanisms underlying

amiodarone-induced pulmonary toxicity. Reasor MJ, et al. **Proc Soc Exp Biol Med** 1996 Sep;212(4):297-304 (89 ref.)
[Early diagnosis of amiodarone-induced pulmonary toxicity: are repeated lung function tests of any value?] Ulrik CS, et al. **Ugeskr Laeger** 1996 Jun 10;158(24):3445-7 (17 ref.) (Eng. Abstr.) **(Dan)**
[Effects of amiodarone on thyroid function] Caron P. **Presse Med** 1995 Dec 2;24(37):1747-51 (25 ref.) (Eng. Abstr.) **(Fre)**
[Adverse reactions to amiodarone] Edoute Y, et al. **Harefuah** 1995 Jul;129(1-2):57-61 (28 ref.) **(Heb)**
[Acute hepatotoxicity from amiodarone] Tosetti C, et al. **Minerva Med** 1995 Sep;86(9):387-90 (21 ref.) (Eng. Abstr.) **(Ita)**
[Recurrent amiodarone lung toxicity after withdrawal of the drug and treatment with corticoids] Donado Uña JR, et al. **Arch Bronconeumol** 1995 Oct;31(8):426-8 (13 ref.) (Eng. Abstr.) **(Spa)**

ANALOGS & DERIVATIVES

A systematic review and critical comparison of internal standards for the routine liquid chromatographic assay of amiodarone and desethylamiodarone. Pollak PT. **Ther Drug Monit** 1996 Apr;18(2):168-78 (53 ref.)

ANALYSIS

A systematic review and critical comparison of internal standards for the routine liquid chromatographic assay of amiodarone and desethylamiodarone. Pollak PT. **Ther Drug Monit** 1996 Apr;18(2):168-78 (53 ref.)

PHARMACOKINETICS

[Amiodarone absorption and elimination after oral and intravenous administration in healthy individuals] Gaete LE, et al. **Rev Med Chil** 1995 Jun;123(6):713-9 (18 ref.) (Eng. Abstr.) **(Spa)**

THERAPEUTIC USE

Antiarrhythmic actions of amiodarone: a profile of a paradoxical agent. Singh BN. **Am J Cardiol** 1996 Aug 29; 78(4A):41-53 (64 ref.)
Successful treatment of supraventricular tachycardia-induced cardiomyopathy with amiodarone: case report and review of literature. Chen RP, et al. **Can J Cardiol** 1995 Nov;11(10):918-22 (20 ref.)
Should post-infarction asymptomatic ventricular arrhythmias be treated? The need for caution. Sleight P. **Eur Heart J** 1995 Jul;16 Suppl E:49 (29 ref.)
Parenteral antiarrhythmic drug therapy in ventricular tachycardia/ventricular fibrillation: evolving role of class III agents--focus on amiodarone. Scheinman MM. **J Cardiovasc Electrophysiol** 1995 Oct;6(10 Pt 2):914-9 (34 ref.)
[Anti-arrhythmic therapy and cardiac failure] Cosnay P, et al. **Arch Mal Coeur Vaiss** 1995 Dec;88 Spec No 5:35-41 (44 ref.) (Eng. Abstr.) **(Fre)**
[Clinical use of intravenous amiodarone for supraventricular arrhythmias] Assadi S, et al. **Harefuah** 1995 Dec 15; 129(12):583-6 (24 ref.) **(Heb)**

AMITRIPTYLINE

ANALOGS & DERIVATIVES

Five-year multicenter retrospective review of cyclobenzaprine toxicity. Spiller HA, et al. **J Emerg Med** 1995 Nov-Dec;13(6):781-5 (14 ref.)

BLOOD

[Tricyclic antidepressants (imipramine, desipramine, amitriptyline, nortriptyline)] Yasuda K. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:934-7 (20 ref.) **(Jpn)**

THERAPEUTIC USE

Amitriptyline. A review of its pharmacological properties and therapeutic use in chronic pain states. Bryson HM, et al. **Drugs Aging** 1996 Jun;8(6):459-76 (111 ref.)

AMLODIPINE

PHARMACOKINETICS

Amlodipine. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease [published erratum appears in Drugs 1995 Nov;50(5):896] Haria M, et al. **Drugs** 1995 Sep;50(3):560-86 (196 ref.)

PHARMACOLOGY

Amlodipine. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease [published erratum appears in Drugs 1995 Nov;50(5):896] Haria M, et al. **Drugs** 1995 Sep;50(3):560-86 (196 ref.)

THERAPEUTIC USE

Amlodipine. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease [published erratum appears in Drugs 1995 Nov;50(5):896] Haria M, et al. **Drugs** 1995 Sep;50(3):560-86 (196 ref.)

AMMONIA

BLOOD

Urea cycle disorders: diagnosis, pathophysiology, and therapy. Brusilow SW, et al. **Adv Pediatr** 1996;43:127-70 (59 ref.)
[Ammonia nitrogen] Imawari M. **Nippon Rinsho** 1995 Feb; 53 Su Pt 1:478-80 (7 ref.) **(Jpn)**

METABOLISM

Metabolic implications of ammonia production in the ruminant. Parker DS, et al. **Proc Nutr Soc** 1995 Jul; 54(2):549-63 (88 ref.)

AMMONIUM COMPOUNDS

see related
PYRIDINIUM COMPOUNDS

AMMON'S HORN see **HIPPOCAMPUS**

AMNESIA

A minibus driver with amnesia. Gray P, et al. **Practitioner** 1995 Oct;239(1555):567-72 (0 ref.)

DIAGNOSIS

The MILD interview: evaluating complaints of memory loss. Meharg SS, et al. **Am Fam Physician** 1996 Jul;54(1):167-72 (20 ref.)
The detection of exaggerated or simulated memory disorder by neuropsychological methods. Leng NR, et al. **J Psychosom Res** 1995 Aug;39(6):767-76 (37 ref.)
The Autobiographical Memory Interview (AMI) in organic and psychogenic amnesia. Kopelman MD. **Memory** 1994 Jun;2(2):211-35 (66 ref.)

ETIOLOGY

[Amnestic syndrome--research update] Wetterling T. **Fortschr Neurol Psychiatr** 1995 Oct;63(10):402-10 (134 ref.) (Eng. Abstr.) **(Ger)**

NURSING

Cognitive effects of electroconvulsive therapy: a clinical review for nurses. Durr AL, et al. **Convuls Ther** 1995 Sep; 11(3):192-201 (33 ref.)

PHYSIOPATHOLOGY

Memory and consciousness: a selective review of issues and data. Rugg MD. **Neuropsychologia** 1995 Sep;33(9):1131-41 (66 ref.)
Transient global amnesia. Sandson TA, et al. **Semin Neurol** 1995 Jun;15(2):183-7 (51 ref.)

PSYCHOLOGY

Neural Mechanisms in dissociative amnesia for childhood abuse: relevance to the current controversy surrounding the "false memory syndrome". Bremner JD, et al. **Am J Psychiatry** 1996 Jul;153(7 Suppl):71-82 (124 ref.)

AMNESIA, RETROGRADE

ETIOLOGY

[A case of transient amnesia caused by cerebral thrombophlebitis: contribution of neuroimaging to physiopathogenesis of transient amnesia] Attarian S, et al. **Rev Neurol (Paris)** 1995 Oct;151(10):552-8 (32 ref.) (Eng. Abstr.) **(Fre)**

PSYCHOLOGY

Focal retrograde amnesia: a multi-faceted disorder? Parkin AJ. **Acta Neurol Belg** 1996 Mar;96(1):43-50 (37 ref.)

AMNIOCENTESIS

see related
CHORIONIC VILLI SAMPLING

Early amniocentesis: a clinical review. Wilson RD. **Prenat Diagn** 1995 Dec;15(13):1259-73 (97 ref.)
[Amniocentesis and single choroid plexus cyst. Current status] Morales-Roselló J, et al. **Rev Fr Gynecol Obstet** 1995 Oct;90(10):412-6 (30 ref.) (Eng. Abstr.) **(Fre)**
-Amniocentesis or chorionic villi sampling--when and why?- Hebisch G. **Arch Gynecol Obstet** 1995;256 Suppl:S182-92 (17 ref.) **(Ger)**

ECONOMICS

Justifying prenatal screening and genetic amniocentesis programs by cost-effectiveness analyses: a re-evaluation. Ganiats TG. **Med Decis Making** 1996 Jan-Mar;16(1):45-50 (61 ref.)

METHODS

[Prenatal diagnosis of fetal varicella in the second trimester of pregnancy] Pons JC, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(8):829-38 (59 ref.) (Eng. Abstr.) **(Fre)**
[Reliability of invasive prenatal diagnosis in the first trimester in comparison with standard amniocentesis] Crombach G, et al. **Gynakologe** 1995 Oct;28(5):302-14 (93 ref.) **(Ger)**

STANDARDS

Experience with early amniocentesis. Sundberg K, et al. **J Perinat Med** 1995;23(3):149-58 (35 ref.)

AMNION

Intrapartum use of fetal heart rate monitoring, contraction monitoring, and amnioinfusion. Cusick W, et al. **Clin Perinatol** 1995 Dec;22(4):875-906 (130 ref.)
Pitfalls in the diagnosis of nonconjoined monoamniotic twins. Strohbehn K, et al. **J Perinatol** 1995 Nov-Dec;15(6):484-93 (56 ref.)

METABOLISM

Studies on glucocorticoid hormone actions in the regulation of human amnion PGHS. Zakar T, et al. **Reprod Fertil Dev** 1995;7(3):517-20 (12 ref.)

SURGERY

Amniotomy to induce labor. Busowski JD, et al. **Clin Obstet Gynecol** 1995 Jun;38(2):246-58 (41 ref.)

AMNIONITIS see **CHORIOAMNIONITIS**

AMNIOTIC BAND SYNDROME

PATHOLOGY

Congenital constriction band syndrome. Perdue PS, et al. **J South Orthop Assoc** 1996 Spring;5(1):71-5 (12 ref.)

SURGERY

Congenital annular constricting band: a case report with pseudarthrosis and review of the literature. Martinot-Duquennoy V, et al. **Eur J Pediatr Surg** 1995 Dec;5(6):380-4 (23 ref.)

AMNIOTIC BANDS see **AMNIOTIC BAND SYNDROME**

AMNIOTIC FLUID

see related
EMBOLISM, AMNIOTIC FLUID
OLIGOHYDRAMNIOS
POLYHYDRAMNIOS

AMNIOTIC MEMBRANE DRESSINGS see **BIOLOGICAL DRESSINGS**

AMOBARBITAL

DIAGNOSTIC USE

Intracarotid amobarbital procedure. The Wada test. Trenerry MR, et al. **Neuroimaging Clin N Am** 1995 Nov;5(4):721-8 (41 ref.)

AMOEBA

see related
AMEBICIDES

ISOLATION & PURIFICATION

Balamuthia mandrillaris: a newly recognized agent for amebic meningoencephalitis. Rowen JL, et al. **Pediatr Infect Dis J** 1995 Aug;14(8):705-10 (30 ref.)

AMOEBIASIS see **AMEBIASIS**

AMOXICILLIN

ADVERSE EFFECTS

[Acute pancreatitis associated with hepatotoxicity induced by amoxicillin-clavulanic acid] Galindo C, et al. **Rev Esp Enferm Dig** 1995 Aug;87(8):597-600 (23 ref.) (Eng. Abstr.) **(Spa)**

THERAPEUTIC USE

Strategies for Helicobacter pylori eradication in 1995: a review of international and Belgian experience. Deltenre M, et al. **J Physiol Pharmacol** 1996 Mar;47(1):59-69 (66 ref.)
[How to eradicate Helicobacter pylori?] Cayla R. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S119-S130 (83 ref.) **(Fre)**
[How to eradicate Helicobacter pylori in 1995? Critical review of available treatments] Deltenre M, et al. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S44-S52 (122 ref.) **(Fre)**
[Influence of colloidal bismuth subcitrate, metronidazole, and amoxycillin on Helicobacter pylori and gastroduodenal ulcer healing] Quintero M, et al. **G E N** 1995 Apr-Jun; 49(2):116-22 (21 ref.) (Eng. Abstr.) **(Spa)**
[Omeprazole and amoxycillin in the eradicating treatment of Helicobacter pylori] Gisbert JP, et al. **Rev Clin Esp** 1995

Nov;195(11):787–91 (74 ref.) **(Spa)**

AMP see ADENOSINE MONOPHOSPHATE

AMP AMINASE see AMP DEAMINASE

AMP DEAMINASE

DEFICIENCY

[Inherited AMP-deaminase deficiency—molecular basis of the defect] Kaletha K, et al. **Postepy Biochem** 1995; 41(3):183–7 (28 ref.) **(Pol)**

GENETICS

[Inherited AMP-deaminase deficiency—molecular basis of the defect] Kaletha K, et al. **Postepy Biochem** 1995; 41(3):183–7 (28 ref.) **(Pol)**

METABOLISM

[Functional role and properties of AMP-deaminase] Lushchak VI. **Biokhimiia** 1996 Feb;61(2):195–211 (59 ref.) (Eng. Abstr.) **(Rus)**

5'-AMP NUCLEOTIDASE see 5'-NUCLEOTIDASE

AMP PHOSPHATASE see 5'-NUCLEOTIDASE

AMPA RECEPTORS see RECEPTORS, AMPA

D-AMPHETAMINE see DEXTROAMPHETAMINE

AMPHETAMINES

see related
APPETITE DEPRESSANTS
CENTRAL NERVOUS SYSTEM STIMULANTS

ADVERSE EFFECTS

[Main cardiotoxic drugs] Pettirossi G, et al. **Clin Ter** 1996 Jan–Feb;147(1–2):67–77 [illegible]) (Eng. Abstr.) **(Ita)**

PHARMACOLOGY

Addictive drugs as reinforcers: multiple partial actions on memory systems. White NM. **Addiction** 1996 Jul; 91(7):921–49; discussion 951–65 (304 ref.)

AMPHIBIA

ANATOMY & HISTOLOGY

The harderian gland: a tercentennial review. Payne AP. **J Anat** 1994 Aug;185 (Pt 1):1–49 (263 ref.)

[The formation of the karyosphere in the oogenesis of insects and amphibians] Gruzova MN, et al. **Tsitologiia** 1995; 37(8):744–69 (156 ref.) (Eng. Abstr.) **(Rus)**

EMBRYOLOGY

Neural induction and neurogenesis in amphibian embryos. Chitnis A, et al. **Perspect Dev Neurobiol** 1995;3(1):3–15 (63 ref.)

GROWTH & DEVELOPMENT

Tadpole competence and tissue-specific temporal regulation of amphibian metamorphosis: roles of thyroid hormone and its receptors. Shi YB, et al. **Bioessays** 1996 May;18(5):391–9 (63 ref.)

Possible interrelations among environmental toxicants, amphibian development, and decline of amphibian populations. Carey C, et al. **Environ Health Perspect** 1995 May;103 Suppl 4:13–7 (39 ref.)

METABOLISM

[Water homeostasis in amphibia: vasotocin and hydrins] Acher R. **C R Seances Soc Biol Fil** 1995;189(2):199–214 (59 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Veterinary nutritional management of amphibians and reptiles. Donoghue S. **J Am Vet Med Assoc** 1996 Jun 1; 208(11):1816–20 (22 ref.)

Transdifferentiation as a basis for amphibian limb regeneration. Tsonis PA, et al. **Semin Cell Biol** 1995 Jun; 6(3):127–35 (58 ref.)

[Spermatogenesis in amphibians analyzed by culture systems] Abe S. **Tanpakushitsu Kakusan Koso** 1995 Oct; 40(13):1912–26 (40 ref.) **(Jpn)**

AMPHIBOLE ASBESTOS see ASBESTOS, AMPHIBOLE

AMPHIUMA see URODELA

AMPHOTERICIN B

ADMINISTRATION & DOSAGE

Lipid formulations of amphotericin B: recent progress and future directions. Hiemenz JW, et al. **Clin Infect Dis** 1996 May;22 Suppl 2:S133–44 (83 ref.)

The use of lipid formulations of amphotericin B for systemic fungal infections. Leenders AC, et al. **Leukemia** 1996 Oct; 10(10):1570–5 (55 ref.)

ADVERSE EFFECTS

Amphotericin B nephrotoxicity: the adverse consequences of altered membrane properties [editorial] Sawaya BP, et al. **J Am Soc Nephrol** 1995 Aug;6(2):154–64 (133 ref.)

CHEMISTRY

Lipid formulations of amphotericin B. Less toxicity but at what economic cost? Tollemar J, et al. **Drug Saf** 1995 Oct; 13(4):207–18 (86 ref.)

Liposomal and lipid-based formulations of amphotericin B. de Marie S. **Leukemia** 1996 Jun;10 Suppl 2:s93–6 (34 ref.)

PHARMACOLOGY

Use of amphotericin B with azole antifungal drugs: what are we doing? Sugar AM.
Antimicrob Agents Chemother 1995 Sep;39(9):1907–12 (46 ref.)

THERAPEUTIC USE

Use of amphotericin B with azole antifungal drugs: what are we doing? Sugar AM.
Antimicrob Agents Chemother 1995 Sep;39(9):1907–12 (46 ref.)

Rhinocerebral mucormycosis. Therapy with amphotericin B lipid complex. Strasser MD, et al. **Arch Intern Med** 1996 Feb 12;156(3):337–9 (21 ref.)

Amphotericin B: an update. Abu-Salah KM.
Br J Biomed Sci 1996 Jun;53(2):122–33 (148 ref.)

Amphotericin B: a commentary on its role as an antifungal agent and as a comparative agent in clinical trials. Gallis HA. **Clin Infect Dis** 1996 May;22 Suppl 2:S145–7 (18 ref.)

The changing epidemiology of fungal infections: are the lipid-forms of amphotericin B an advance? Herbrecht R. **Eur J Haematol Suppl** 1996;57:12–7 (24 ref.)

Central venous catheter infection with Rhodotorula minuta in a patient with AIDS taking suppressive doses of fluconazole. Goldani LZ, et al. **J Med Vet Mycol** 1995 Jul–Aug;33(4):267–70 (22 ref.)

[Procedures for Candida albicans systemic infections in premature infants] Lauterbach R. **Ginekol Pol** 1995 May; 66(5):289–93 (13 ref.) (Eng. Abstr.) **(Pol)**

[Visceral leishmaniasis refractory to treatment: the efficacy of amphotericin B] Pérez Brea A, et al. **An Esp Pediatr** 1996 Feb;44(2):161–3 (8 ref.) **(Spa)**

AMPICILLIN

THERAPEUTIC USE

[Amoxycillin: 25 years of use in clinical practice] Iakovlev SV. **Antibiot Khimioter** 1995 Jun;40(6):49–55 (13 ref.) **(Rus)**

AMPLIFIERS

ADVERSE EFFECTS

Potential risk of hearing damage associated with exposure to highly amplified music. Hétu R, et al.
J Am Acad Audiol 1995 Sep;6(5):378–86 (43 ref.)

AMPULLA OF VATER see VATER'S AMPULLA

AMPUTATION

Revascularization versus amputation for elderly patients. Bunt TJ. **AORN J** 1995 Sep;62(3):433–5 (7 ref.)

Preventing amputation in the patient with diabetes. Levin ME. **Diabetes Care** 1995 Oct;18(10):1383–94 (117 ref.)

Function after amputation, arthrodesis, or arthroplasty for tumors about the shoulder. Kneisl JS.
J South Orthop Assoc 1995 Fall;4(3):228–36 (36 ref.)

Are type IIIC lower extremity injuries an indication for primary amputation. Quirke TE, et al. **J Trauma** 1996 Jun; 40(6):992–6 (45 ref.)

Amputation surgery and prostheses. Rodriguez RP.
Orthop Clin North Am 1996 Jul;27(3):525–39 (59 ref.)

ECONOMICS

Cost-efficacy issues in the treatment of peripheral vascular disease: primary amputation or revascularization for limb-threatening ischemia. Perler BA.
J Vasc Interv Radiol 1995 Nov–Dec;6(6 Pt 2 Su):111S–115S (28 ref.)

METHODS

[Surgical therapy of soft tissue sarcomas II. Sarcomas of the extremities and their surgical resection] Karakousis CP.
Chirurg 1995 Oct;66(10):1006–15 (9 ref.) (Eng. Abstr.) **(Ger)**

REHABILITATION

Rehabilitation in limb deficiency. 3. The geriatric amputee. Andrews KL. **Arch Phys Med Rehabil** 1996 Mar;77(3 Suppl):S14–7 (41 ref.)

Rehabilitation in limb deficiency. 1. Gait and motion analysis. Czerniecki JM. **Arch Phys Med Rehabil** 1996 Mar;77(3 Suppl):S3–8 (41 ref.)

Rehabilitation in limb deficiency. 4. Limb amputation. Esquenazi A, et al. **Arch Phys Med Rehabil** 1996 Mar;77(3 Suppl):S18–28 (42 ref.)

Rehabilitation in limb deficiency. 2. The pediatric amputee. Jain S. **Arch Phys Med Rehabil** 1996 Mar;77(3 Suppl):S9–13 (42 ref.)

VETERINARY

Amputation and prosthesis. St. Jean G.
Vet Clin North Am Food Anim Pract 1996 Mar;12(1):249–61 (13 ref.)

AMPUTATION, INTRAUTERINE see AMNIOTIC BAND SYNDROME

AMPUTATION, TRAUMATIC

see related
REPLANTATION

The effects of weapons: surgical challenge and medical dilemma. Coupland RM. **J R Coll Surg Edinb** 1996 Apr; 41(2):65–71 (6 ref.)

ETIOLOGY

Male genital self-mutilation. Romilly CS, et al.
Br J Hosp Med 1996 Apr 3–16;55(7):427–31 (24 ref.)

PATHOLOGY

Pulse oximetry for preoperative vascular assessment in a thumb near-amputation [see comments] Schumer E, et al. **J Emerg Med** 1995 Nov–Dec;13(6):753–5 (20 ref.)
Comment in: J Emerg Med 1995 Nov–Dec;13(6):815–6.

SURGERY

Flap reconstruction in the upper limb. Ikuta Y, et al.
Ann Acad Med Singapore 1995 Jul;24(4 Suppl):124–30 (10 ref.)

The role of microsurgery and free tissue transfer in the reconstruction of the paediatric upper extremity. Kay S, et al. **Ann Acad Med Singapore** 1995 Jul;24(4 Suppl):113–23 (50 ref.)

Current concepts of replantation. Raskin KB, et al.
Ann Acad Med Singapore 1995 Jul;24(4 Suppl):131–4 (29 ref.)

Toe-to-hand transfer. Current concepts, techniques, and research. Wei FC, et al. **Clin Plast Surg** 1996 Jan; 23(1):103–16 (64 ref.)

Plea to save the great toe in total thumb reconstruction. Foucher G, et al. **Microsurgery** 1995;16(6):373–6 (23 ref.)

[Traumatic hemipelvectomy. Experiences with 11 cases] Pohlemann T, et al. **Unfallchirurg** 1996 Apr;99(4):304–12 (45 ref.) (Eng. Abstr.) **(Ger)**

AMPUTEES

Exercise performance of lower-extremity amputees. Ward KH, et al. **Sports Med** 1995 Oct;20(4):207–14 (50 ref.)

AMYGDALA see AMYGDALOID BODY

AMYGDALOID BODY

ANATOMY & HISTOLOGY

Two distinct descending inputs to the cricothyroid motoneuron in the medulla originating from the amygdala and the lateral hypothalamic area. Arita H, et al.
Adv Exp Med Biol 1995;393:53–8 (10 ref.)

PHYSIOLOGY

The limbic system of tetrapods: a comparative analysis of cortical and amygdalar populations. Bruce LL, et al.
Brain Behav Evol 1995;46(4–5):224–34 (90 ref.)

Neuroanatomical and neurochemical mechanisms underlying amygdaloid control of defensive rage behavior in the cat. Shaikh MB, et al. **Braz J Med Biol Res** 1994 Dec; 27(12):2759–79 (43 ref.)

Amygdala role in conditioned associative learning. Ono T, et al. **Prog Neurobiol** 1995 Jul;46(4):401–22 (142 ref.)

[The amygdaloid body of the brain: some topics for discussion and little-studied problems] Akmaev IG, et al. **Usp Fiziol Nauk** 1995 Jan–Mar;26(1):3–24 (111 ref.) (Eng. Abstr.) **(Rus)**

AMYL NITRITE

Extreme methaemoglobinaemia secondary to recreational use of amyl nitrite. Edwards RJ, et al. **J Accid Emerg Med** 1995 Jun;12(2):138–42 (41 ref.)

AMYLASES

BLOOD

Pancreatitis with normal serum amylase associated with sodium valproate: a case report. Otusbo S, et al.
Brain Dev 1995 May–Jun;17(3):219–21 (7 ref.)

[Macroamylase] Hayakawa T, et al. **Nippon Rinsho** 1995 Feb; 53 Su Pt 1:442–4 (13 ref.) **(Jpn)**
[Serum amylase] Hayakawa T, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:311–3 (7 ref.) **(Jpn)**

PHYSIOLOGY

Amylolytic enzymes and products derived from starch: a review. Guzmán-Maldonado H, et al. **Crit Rev Food Sci Nutr** 1995 Sep;35(5):373–403 (190 ref.)

AMYLOBARBITONE see **AMOBARBITAL**

AMYLOGLUCOSIDASE see **GLUCAN 1,4-ALPHA-GLUCOSIDASE**

AMYLOID

see related
AMYLOID NEUROPATHIES

[New pancreatic polypeptide amylin] German SV. **Klin Med (Mosk)** 1995;73(5):7–11 (51 ref.) **(Rus)**

ANALYSIS

Leptomeningeal amyloid and variant transthyretins [comment] Benson MD. **Am J Pathol** 1996 Feb; 148(2):351–4 (19 ref.) Comment on: Am J Pathol 1996 Feb;148(2):361–6.
Islet amyloid in type 2 (non-insulin-dependent) diabetes. Clark A, et al. **APMIS** 1996 Jan;104(1):12–8 (47 ref.)

ANTAGONISTS & INHIBITORS

Regulation of APP processing. Potential for the therapeutical reduction of brain amyloid burden. Nitsch RM, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:175–82 (28 ref.)

BIOSYNTHESIS

Anti-amyloid drugs: potential in the treatment of diseases associated with aging. Kisilevsky R. **Drugs Aging** 1996 Feb; 8(2):75–83 (70 ref.)
Pancreatic islet amyloid formation in patients with noninsulin-dependent diabetes mellitus. Implication for therapeutic strategy. Oosterwijk C, et al. **Int J Pancreatol** 1995 Aug;18(1):7–14 (68 ref.)

CHEMISTRY

Alternative conformations of amyloidogenic proteins govern their behavior. Kelly JW. **Curr Opin Struct Biol** 1996 Feb; 6(1):11–7 (44 ref.)
Pathology of the vessels in cerebral amyloid angiopathy. Liberski PP, et al. **Folia Neuropathol** 1995;33(4):207–14 (68 ref.)

CLASSIFICATION

[Classification of amyloidosis] Husby G. **Tidsskr Nor Laegeforen** 1996 Jan 20;116(2):234–7 (40 ref.) (Eng. Abstr.) **(Nor)**

GENETICS

Vitreous amyloidosis in familial amyloidotic polyneuropathy. Report of a case with the Val30Met transthyretin mutation. Ciulla TA, et al. **Surv Ophthalmol** 1995 Nov-Dec; 40(3):197–206 (123 ref.)

ISOLATION & PURIFICATION

Diagnosing amyloidosis [editorial] Westermark P. **Scand J Rheumatol** 1995;24(6):327–9 (12 ref.)

METABOLISM

Regulation of APP processing. Potential for the therapeutical reduction of brain amyloid burden. Nitsch RM, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:175–82 (28 ref.)
The amyloid peptide and its precursor in Alzheimer's disease. Octave JN. **Rev Neurosci** 1995 Oct-Dec;6(4):287–316 (289 ref.)

PHARMACOLOGY

Effects of amylin on appetite regulation and memory. Morley JE, et al. **Can J Physiol Pharmacol** 1995 Jul;73(7):1042–6 (60 ref.)
Pharmacology of receptors for calcitonin gene-related peptide and amylin. Poyner D. **Trends Pharmacol Sci** 1995 Dec;16(12):424–8 (56 ref.)

PHYSIOLOGY

Amyloid fibril toxicity in Alzheimer's disease and diabetes. Lorenzo A, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:89–95 (12 ref.)
The age related amyloids: a growing family of unique biochemical substances. Cornwell GG 3rd, et al. **J Clin Pathol** 1995 Nov;48(11):984–9 (41 ref.)

AMYLOID A4 PROTEIN PRECURSOR see **AMYLOID BETA-PROTEIN PRECURSOR**

AMYLOID ANGIOPATHY, CEREBRAL see **CEREBRAL AMYLOID ANGIOPATHY**

AMYLOID BETA-PROTEIN

see related
CEREBRAL AMYLOID ANGIOPATHY

[Trial to produce animal model of Alzheimer's disease by continuous infusion of beta-amyloid protein into the rat cerebral ventricle] Nabeshima T. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1995 Oct; 15(5):411–8 (27 ref.) (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Amyloid, aluminium and the aetiology of Alzheimer's disease [see comments] Storey E, et al. **Med J Aust** 1995 Sep 4; 163(5):256–9 (49 ref.) Comment in: Med J Aust 1996 Feb 19;164(4):252–3. Comment in: Med J Aust 1996 Mar 18;164(6):382–3.

ANTAGONISTS & INHIBITORS

Therapeutic approaches related to amyloid-beta peptide and Alzheimer's disease. Schenk DB, et al. **J Med Chem** 1995 Oct 13;38(21):4141–54 (181 ref.)

BIOSYNTHESIS

The role of APP processing and trafficking pathways in the formation of amyloid beta-protein. Selkoe DJ, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:57–64 (19 ref.)
A mechanism for beta-amyloid overproduction in Alzheimer's disease: precursor-independent generation of beta-amyloid via antisense RNA-primed mRNA synthesis. Volloch V. **FEBS Lett** 1996 Jul 22;390(2):124–8 (31 ref.)
[Inclusion body myositis] Serratrice G. **Presse Med** 1996 Jun 15;25(21):985–8 (23 ref.) (Eng. Abstr.) **(Fre)**

CHEMISTRY

Amyloid beta-protein and the genetics of Alzheimer's disease. Selkoe DJ. **J Biol Chem** 1996 Aug 2; 271(31):18295–8 (93 ref.)

GENETICS

A beta A4 amyloid precursor protein gene and Alzheimer's disease. Hendriks L, et al. **Eur J Biochem** 1996 Apr 1; 237(1):6–15 (123 ref.)
A mechanism for beta-amyloid overproduction in Alzheimer's disease: precursor-independent generation of beta-amyloid via antisense RNA-primed mRNA synthesis. Volloch V. **FEBS Lett** 1996 Jul 22;390(2):124–8 (31 ref.)
Amyloid beta-protein and the genetics of Alzheimer's disease. Selkoe DJ. **J Biol Chem** 1996 Aug 2; 271(31):18295–8 (93 ref.)

METABOLISM

Amyloid beta-protein, APOE genotype and head injury. Nicoll JA, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:271–5 (9 ref.)
The role of beta-amyloid in the development of Alzheimer's disease. Ii K. **Drugs Aging** 1995 Aug;7(2):97–109 (154 ref.)
Mechanisms of neuronal degeneration in Alzheimer's disease. Yankner BA. **Neuron** 1996 May;16(5):921–32 (172 ref.)

PHARMACOLOGY

Amyloid beta-protein induces the cerebrovascular cellular pathology of Alzheimer's disease and related disorders. Van Nostrand WE, et al. **Ann N Y Acad Sci** 1996 Jan 17; 777:297–302 (19 ref.)

PHYSIOLOGY

Physiological and pathological interrelationships of amyloid beta peptide and the amyloid precursor protein. Larner AJ. **Bioessays** 1995 Sep;17(9):819–24 (45 ref.)
Ion channel hypothesis for Alzheimer amyloid peptide neurotoxicity. Pollard HB, et al. **Cell Mol Neurobiol** 1995 Oct;15(5):513–26 (67 ref.)
Lymphocytes and neutrophils as peripheral models to study the effect of beta-amyloid on cellular calcium signalling in Alzheimer's disease. Eckert A, et al. **Life Sci** 1996; 59(5–6):499–510 (47 ref.)
Soluble beta-amyloid induces Alzheimer's disease features in human fibroblasts and in neuronal tissues. Etcheberrigaray R, et al. **Life Sci** 1996;59(5–6):491–8 (42 ref.)
New clues to Alzheimer's disease: unraveling the roles of amyloid and tau [comment] Yankner BA. **Nat Med** 1996 Aug;2(8):850–2 (22 ref.) Comment on: Nat Med 1996 Aug;2(8):864–70.
Free radicals and disruption of neuronal ion homeostasis in AD: a role for amyloid beta-peptide? [comment] Mattson MP. **Neurobiol Aging** 1995 Jul-Aug;16(4):679–82; discussion 683 (40 ref.) Comment on: Neurobiol Aging 1995 Jul-Aug;16(4):661–74.

TOXICITY

The toxicity in vitro of beta-amyloid protein. Iversen LL, et al. **Biochem J** 1995 Oct 1;311 (Pt 1):1–16 (255 ref.)
Ion channel hypothesis for Alzheimer amyloid peptide neurotoxicity. Pollard HB, et al. **Cell Mol Neurobiol** 1995 Oct;15(5):513–26 (67 ref.)

AMYLOID BETA-PROTEIN PRECURSOR

GENETICS

The amyloid peptide precursor in Alzheimer's disease. Octave JN. **Acta Neurol Belg** 1995 Dec;95(4):197–209 (70 ref.)
Amyloid beta amyloidosis in Alzheimer's disease. Price DL, et al. **Curr Opin Neurol** 1995 Aug;8(4):268–74 (71 ref.)
APP transgenesis: approaches toward the development of animal models for Alzheimer disease neuropathology. Greenberg BD, et al. **Neurobiol Aging** 1996 Mar-Apr; 17(2):153–71 (323 ref.)

METABOLISM

Regulation of APP expression, biogenesis and metabolism by extracellular matrix and cytokines. Beyreuther K, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:74–6 (17 ref.)
Reactive oxygen species as causal agents in the neurotoxicity of the Alzheimer's disease-associated amyloid beta peptide. Hensley K, et al. **Ann N Y Acad Sci** 1996 Jun 15;786:120–34 (49 ref.)
Regulation of APP processing. Potential for the therapeutical reduction of brain amyloid burden. Nitsch RM, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:175–82 (28 ref.)
The role of APP processing and trafficking pathways in the formation of amyloid beta-protein. Selkoe DJ, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:57–64 (19 ref.)
Molecular physiology, biochemistry, and pharmacology of Alzheimer's amyloid precursor protein (APP). Suh YH, et al. **Ann N Y Acad Sci** 1996 Jun 15;786:169–83 (59 ref.)
Processing of the beta-amyloid precursor protein and its regulation in Alzheimer's disease. Checler F. **J Neurochem** 1995 Oct;65(4):1431–44 (101 ref.)
Mechanisms of neuronal degeneration in Alzheimer's disease. Yankner BA. **Neuron** 1996 May;16(5):921–32 (172 ref.)
The amyloid peptide and its precursor in Alzheimer's disease. Octave JN. **Rev Neurosci** 1995 Oct-Dec;6(4):287–316 (289 ref.)

PHYSIOLOGY

Regulation of APP processing by intra- and intercellular signals. Buxbaum JD, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:327–31 (17 ref.)
Cellular signaling pathways and cytoskeletal organization. Kosik KS, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:114–20 (28 ref.)
Physiological and pathological interrelationships of amyloid beta peptide and the amyloid precursor protein. Larner AJ. **Bioessays** 1995 Sep;17(9):819–24 (45 ref.)
The molecular significance of amyloid beta-peptide for Alzheimer's disease. Haass C. **Eur Arch Psychiatry Clin Neurosci** 1996;246(3):118–23 (54 ref.)

AMYLOID FIBRIL PROTEIN (ALZHEIMER'S) see **AMYLOID BETA-PROTEIN**

AMYLOID NEUROPATHIES

GENETICS

Leptomeningeal amyloid and variant transthyretins [comment] Benson MD. **Am J Pathol** 1996 Feb; 148(2):351–4 (19 ref.) Comment on: Am J Pathol 1996 Feb;148(2):361–6.
Ocular amyloidosis, with special reference to the hereditary forms with vitreous involvement. Sandgren O. **Surv Ophthalmol** 1995 Nov-Dec;40(3):173–96 (261 ref.)
[An attempt to generate a closer mouse model of familial amyloidotic polyneuropathy, an autosomal dominantly inherited disease] Maeda S, et al. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2204–13 (30 ref.) **(Jpn)**
[Familial amyloidotic polyneuropathy and liver transplantation (editorial)] Buades Reinés J, et al. **Gastroenterol Hepatol** 1995 Nov;18(9):480–2 (23 ref.) **(Spa)**

PATHOLOGY

Vitreous amyloidosis in familial amyloidotic polyneuropathy. Report of a case with the Val30Met transthyretin mutation. Ciulla TA, et al. **Surv Ophthalmol** 1995 Nov-Dec; 40(3):197–206 (123 ref.)

AMYLOID P COMPONENT

DIAGNOSTIC USE

Imaging amyloidosis with radiolabelled SAP [editorial] Hawkins PN, et al. **Eur J Nucl Med** 1995 Jul;22(7):595–9 (29 ref.)

AMYLOID POLYNEUROPATHIES see **AMYLOID NEUROPATHIES**

AMYLOID PROTEIN A4 see **AMYLOID BETA-PROTEIN**

AMYLOID PROTEIN PRECURSOR see **AMYLOID BETA-PROTEIN PRECURSOR**

AMYLOID PROTEIN SAA

ANALYSIS

[Serum amyloid A (SAA)] Yamada T. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:237–9 (13 ref.) **(Jpn)**

AMYLOID SERUM PROTEIN SAA see **AMYLOID PROTEIN SAA**

AMYLOIDOSIS

Amyloidosis. Hawkins PN. **Blood Rev** 1995 Jun;9(2):135–42 (53 ref.)

Renal amyloidosis in childhood. An overview of the topic with 25 years experience. Tinaztepe K. **Turk J Pediatr** 1995 Oct–Dec;37(4):357–73 (18 ref.)

[Pleural amyloidosis. Apropos of a case and review of the literature] Quinquenel ML, et al. **Rev Pneumol Clin** 1996; 52(1):39–41 (12 ref.) (Eng. Abstr.) **(Fre)**

[Immunoglobulin light-chain type amyloidosis] Isobe T. **Nippon Naika Gakkai Zasshi** 1995 Jul 10;84(7):1112–6 (5 ref.) **(Jpn)**

[Amyloidosis] Gondo T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):284–7 (14 ref.) **(Jpn)**

CLASSIFICATION

Amyloidosis and silicone synovitis: updated classification, updated pathophysiology, and synovial articular abnormalities. Goldman AB, et al. **Radiol Clin North Am** 1996 Mar;34(2):375–94, xi (73 ref.)

[Classification of amyloidosis] Husby G. **Tidsskr Nor Laegeforen** 1996 Jan 20;116(2):234–7 (40 ref.) (Eng. Abstr.) **(Nor)**

COMPLICATIONS

Laryngeal squamous carcinoma associated with longstanding localised amyloidosis. A case report. Navani SS, et al. **Indian J Cancer** 1995 Mar;32(1):43–5 (7 ref.)

When does amyloidosis complicate systemic lupus erythematosus? Orellana C, et al. **Lupus** 1995 Oct; 4(5):415–7 (26 ref.)

Spontaneous liver rupture in amyloidosis. Ooi LL, et al. **Surgery** 1996 Jul;120(1):117–9 (9 ref.)

[Colonic pseudo-obstruction caused by digestive amyloidosis in a chronic hemodialyzed patient. Apropos of a case] Tiffet O, et al. **Ann Chir** 1996;50(3):279–82 (11 ref.) (Eng. Abstr.) **(Fre)**

[Primary AL-type amyloidosis disclosed by Horton disease] Tron AM, et al. **Rev Med Interne** 1995;16(11):850–3 (16 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Twenty-one years survival with systemic AL-amyloidosis. Goldsmith DJ, et al. **Am J Kidney Dis** 1996 Aug; 28(2):278–82 (24 ref.)

Non-Alzheimer's disease amyloidoses of the nervous system. Castaño EM, et al. **Curr Opin Neurol** 1995 Aug;8(4):279–85 (57 ref.)

Clinical and computed tomographic characteristics of amyloid tumor of the lacrimal gland. Massry GG, et al. **Ophthalmology** 1996 Aug;103(8):1233–6 (11 ref.)

Diagnosing amyloidosis [editorial] Westermark P. **Scand J Rheumatol** 1995;24(6):327–9 (12 ref.)

[The gastrointestinal manifestations of amyloidosis] Neef B, et al. **Dtsch Med Wochenschr** 1995 Nov 17; 120(46):1597–602 (50 ref.) **(Ger)**

[Cardiac amyloidosis] Meierhenrich R, et al. **Med Klin** 1995 Oct 15;90(10):599–605 (53 ref.) **(Ger)**

[Primary amyloid tumor of the breast. Case report and review of the literature] Bisceglia M, et al. **Pathologica** 1995 Apr; 87(2):162–7 (20 ref.) (Eng. Abstr.) **(Ita)**

[Thyroid amyloidosis diagnosed by echo-guided needle aspiration with a fine needle] Gimondo P, et al. **Radiol Med (Torino)** 1996 Mar;91(3):316–8 (6 ref.) **(Ita)**

[A case of localized amyloidosis of the ureter] Awakura Y, et al. **Hinyokika Kiyo** 1996 Feb;42(2):135–8 (8 ref.) (Eng. Abstr.) **(Jpn)**

[Primary amyloidosis localized in the bladder] Vicioso Recio L, et al. **Arch Esp Urol** 1995 Nov;48(9):963–6 (8 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Anti-amyloid drugs: potential in the treatment of diseases associated with aging. Kisilevsky R. **Drugs Aging** 1996 Feb; 8(2):75–83 (70 ref.)

ETIOLOGY

Regression of the nephrotic syndrome in rheumatoid arthritis and amyloidosis treated with azathioprine. A case report. Shapiro DL, et al. **Arthritis Rheum** 1995 Dec;38(12):1851–4 (24 ref.)

Beta 2-microglobulin amyloidosis: why and how to look for it. Schaeffer J, et al. **Clin Nephrol** 1995 Nov;44 Suppl 1:S3–9 (93 ref.)

Dialysis-related amyloidosis: from raw clinical facts to unresolved questions. Charra B. **Contrib Nephrol** 1995; 112:119–28 (48 ref.)

Role of macrophages in beta 2-microglobulin-related dialysis amyloidosis. Gejyo F, et al. **Contrib Nephrol** 1995; 112:97–104 (18 ref.)

Beta 2-microglobulin modified with the AGE products of the Maillard reaction in dialysis-related amyloidosis. Miyata T, et al. **Contrib Nephrol** 1995;112:52–64 (52 ref.)

Clinical aspects of dialysis-related amyloidosis. Schäffer J, et al. **Contrib Nephrol** 1995;112:90–6 (36 ref.)

Pathogenesis of dialysis-related amyloidosis. Miyata T, et al. **Curr Opin Nephrol Hypertens** 1995 Nov;4(6):493–7 (51 ref.)

Systemic amyloidosis following ankylosing spondylitis associated with congestive heart failure. A case report. Fujito T, et al. **Jpn Heart J** 1995 Sep;36(5):681–8 (17 ref.)

Pathogenetic and diagnostic aspects of dialysis-related amyloidosis. Schaeffer J, et al. **Nephrol Dial Transplant** 1995;10 Suppl 3:4–8 (66 ref.)

New aspects in the pathogenesis of dialysis-related amyloidosis: pathophysiology of advanced glycation end products in renal failure. Miyata T. **Nippon Jinzo Gakkai Shi** 1996 May;38(5):191–7 (51 ref.)

[Systemic amyloidosis. Its pathogenesis, clinical picture and therapy] Hetzel GR, et al. **Dtsch Med Wochenschr** 1995 Oct 27;120(43):1479–85 (50 ref.) **(Ger)**

[Countermeasure for patients with amyloidosis due to hemodialysis] Gejo F. **Nippon Naika Gakkai Zasshi** 1995 Oct 10;84(10):1673–7 (5 ref.) **(Jpn)**

GENETICS

A new apolipoprotein AI variant, Trp50Arg, causes hereditary amyloidosis. Booth DR, et al. **QJM** 1995 Oct; 88(10):695–702 (43 ref.)

[Finnish hereditary amyloidosis: a mutation in the gelsolin gene] Maury P. **Duodecim** 1994;110(7):675–80 (27 ref.) **(Fin)**

IMMUNOLOGY

Molecular anatomy and the pathological expression of antibody light chains [comment] Schiffer M. **Am J Pathol** 1996 May;148(5):1339–44 (31 ref.) Comment on: Am J Pathol 1996 May;148(5):1397–406.

METABOLISM

The age related amyloids: a growing family of unique biochemical substances. Cornwell GG 3rd, et al. **J Clin Pathol** 1995 Nov;48(11):984–9 (41 ref.)

PATHOLOGY

Intracerebral A lambda amyloidoma diagnosed by stereotactic biopsy. Schröder R, et al. **Clin Neuropathol** 1995 Nov–Dec;14(6):347–50 (34 ref.)

Giant primary amyloidoma of the tonsil. López Amado M, et al. **J Laryngol Otol** 1996 Jun;110(6):613–5 (20 ref.)

Ocular amyloidosis, with special reference to the hereditary forms with vitreous involvement. Sandgren O. **Surv Ophthalmol** 1995 Nov–Dec;40(3):173–96 (261 ref.)

PHYSIOPATHOLOGY

[Amyloidosis, protein conformation dynamics and neurologic diseases] Tranchant C, et al. **Rev Neurol (Paris)** 1996 Mar; 152(3):153–7 (26 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

Prevention of dialysis-related amyloidosis using the polyacrylonitrile AN69 membrane. Chanard J. **Contrib Nephrol** 1995;112:137–44 (23 ref.)

RADIOGRAPHY

[Localized tracheobronchial amyloidosis. The usefulness of computed tomography] Sánchez Antuña A, et al. **Arch Bronconeumol** 1995 Dec;31(10):540–2 (23 ref.) (Eng. Abstr.) **(Spa)**

RADIONUCLIDE IMAGING

Imaging amyloidosis with radiolabelled SAP [editorial] Hawkins PN, et al. **Eur J Nucl Med** 1995 Jul;22(7):595–9 (29 ref.)

THERAPY

[Countermeasure for patients with amyloidosis due to hemodialysis] Gejo F. **Nippon Naika Gakkai Zasshi** 1995 Oct 10;84(10):1673–7 (5 ref.) **(Jpn)**

AMYLOPECTIN

BIOSYNTHESIS

From glycogen to amylopectin: a model for the biogenesis of the plant starch granule. Ball S, et al. **Cell** 1996 Aug 9;86(3):349–52 (18 ref.)

AMYOPLASIA CONGENITA see **ARTHROGRYPOSIS**

AMYOTROPHIC LATERAL SCLEROSIS

Amyotrophic lateral sclerosis. Eisen A. **Intern Med** 1995 Sep; 34(9):824–32 (93 ref.)

Neuroepidemiology of amyotrophic lateral sclerosis: clues to aetiology and pathogenesis. Román GC. **J Neurol Neurosurg Psychiatry** 1996 Aug;61(2):131–7 (87 ref.)

COMPLICATIONS

[Frontal type dementia and amyotrophic lateral sclerosis. 3 cases with (HmPAO Tc99m) single-photon emission tomography study] Vercelletto M, et al. **Rev Neurol (Paris)** 1995 Nov;151(11):640–7 (43 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Atypical amyotrophic lateral sclerosis. Ben Hamida M, et al. **Adv Neurol** 1995;68:153–5 (9 ref.)

Natural history of amyotrophic lateral sclerosis. Quantification of symptoms, signs, strength, and function. Brooks BR, et al. **Adv Neurol** 1995;68:163–84 (27 ref.)

Clues to the diagnosis of amyotrophic lateral sclerosis. Cambier J, et al. **Adv Neurol** 1995;68:161–2 (12 ref.)

Megaslope, natural course, and historical controls in amyotrophic lateral sclerosis trials. Conradi S, et al. **Adv Neurol** 1995;68:219–24 (7 ref.)

Amyotrophic lateral sclerosis. A multifactorial disease. Eisen AA. **Adv Neurol** 1995;68:121–34 (108 ref.)

Natural history of amyotrophic lateral sclerosis. Observations with the Charing Cross Amyotrophic Lateral Sclerosis Rating Scales. Guiloff RJ, et al. **Adv Neurol** 1995;68:185–98 (28 ref.)

Natural history of amyotrophic lateral sclerosis. A discussion. Meininger V, et al. **Adv Neurol** 1995;68:199–207 (18 ref.)

The diagnosis of amyotrophic lateral sclerosis. Pouget J, et al. **Adv Neurol** 1995;68:143–52 (82 ref.)

The diagnosis of amyotrophic lateral sclerosis. A discussion. Swash M. **Adv Neurol** 1995;68:157–60 (21 ref.)

[Chronic progressive spinobulbar spasticity (primary lateral sclerosis)] Heene R, et al. **Fortschr Neurol Psychiatr** 1996 May;64(5):192–203 (42 ref.) (Eng. Abstr.) **(Ger)**

[To disclose to the patients the diagnosis and information about the likely course of amyotrophic lateral sclerosis] Hayashi H. **No To Shinkei** 1996 May;48(5):409–15 (22 ref.) **(Jpn)**

DRUG THERAPY

Neurotrophic factors and amyotrophic lateral sclerosis. Askanas V. **Adv Neurol** 1995;68:241–4 (14 ref.)

Should N-methyl-D-aspartate or non-N-methyl-D-aspartate glutamate receptor antagonist be used in amyotrophic lateral sclerosis? Blin O. **Adv Neurol** 1995;68:259–61 (16 ref.)

Neurotrophic factors as therapeutic agents in amyotrophic lateral sclerosis. Potential and pitfalls. Henderson CE. **Adv Neurol** 1995;68:235–40 (22 ref.)

Excitotoxic blocking strategies in amyotrophic lateral sclerosis. Hugon J. **Adv Neurol** 1995;68:245–52; discussion 253–8 (56 ref.)

Use of growth factors in the treatment of motor neuron diseases. Windebank AJ. **Adv Neurol** 1995;68:229–34 (22 ref.)

Potential use of gabapentin and lamotrigine. Cory PR, et al. **Ann Pharmacother** 1995 Nov;29(11):1160–1 (10 ref.)

The insulin-like growth factor signaling system and ALS neurotrophic factor treatment strategies. Festoff BW, et al. **J Neurol Sci** 1995 May;129 Suppl:114–21 (60 ref.)

EPIDEMIOLOGY

Clinical epidemiology of amyotrophic lateral sclerosis. Brooks BR. **Neurol Clin** 1996 May;14(2):399–420 (298 ref.)

[Amyotrophic lateral sclerosis] Martí-Fàbregas J, et al. **Neurologia** 1996 Mar;11(3):99–108 (157 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

Autoimmunity as an etiological factor in sporadic amyotrophic lateral sclerosis. Appel SH, et al. **Adv Neurol** 1995;68:47–57 (88 ref.)

Amyotrophic lateral sclerosis. A multifactorial disease. Eisen AA. **Adv Neurol** 1995;68:121–34 (108 ref.)

The viral hypothesis. Gastaut JL. **Adv Neurol** 1995;68:135–7 (33 ref.)

The possible role of a secondary pathogenetic factor in amyotrophic lateral sclerosis. Pinelli P, et al. **Adv Neurol** 1995;68:29–40 (25 ref.)

Excitotoxic mechanisms in the pathogenesis of amyotrophic lateral sclerosis. Rothstein JD. **Adv Neurol** 1995;68:7–20; discussion 21–7 (80 ref.)

Amyotrophic lateral sclerosis with paraproteins and autoantibodies. Rowland LP. **Adv Neurol** 1995;68:93–105; discussion 107–11 (136 ref.)

Anti-calcium channel autoantibodies in amyotrophic lateral sclerosis. A review of the evidence. Seagar MJ, et al. **Adv Neurol** 1995;68:67–72 (30 ref.)

[Amyotrophic lateral sclerosis--causative role of trace elements] Yase Y. **Nippon Rinsho** 1996 Jan;54(1):123–8 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Amyotrophic lateral sclerosis] Martí-Fàbregas J, et al. **Neurologia** 1996 Mar;11(3):99–108 (157 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

Motor neuron disease caused by mutations in superoxide dismutase 1. Wong PC, et al. **Curr Opin Neurol** 1995 Aug; 8(4):294–301 (77 ref.)

Familial amyotrophic lateral sclerosis/motor neurone disease (FALS): a review of current developments. de Belleroche J, et al. **J Med Genet** 1995 Nov;32(11):841–7 (65 ref.)

[Hope for amyotrophic lateral sclerosis? (editorial)] Jokelainen M. **Duodecim** 1994;110(16):1499–501 (15 ref.) **(Fin)**

[Two siblings of familial amyotrophic lateral sclerosis with multisystemic degeneration characterized by mild involvement of the middle root zone of the posterior column, Clarke's nuclei and spinocerebellar tract] Yoshida M, et al. **Rinsho Shinkeigaku** 1995 Jun;35(6):589–99 (27 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Amyotrophic lateral sclerosis. An autoimmune disease? Drachman DB, et al. **Adv Neurol** 1995;68:59–65 (54 ref.)

Immunological findings in amyotrophic lateral sclerosis. Antel JP, et al. **Springer Semin Immunopathol** 1995; 17(1):17–28 (103 ref.)

[Hope for amyotrophic lateral sclerosis? (editorial)] Jokelainen M. **Duodecim** 1994;110(16):1499–501 (15 ref.) **(Fin)**

METABOLISM

Amyotrophic lateral sclerosis. A multifactorial disease. Eisen AA. **Adv Neurol** 1995;68:121–34 (108 ref.)

Copper/zinc superoxide dismutase mutations and free radical damage in amyotrophic lateral sclerosis. Hosler BA, et al. **Adv Neurol** 1995;68:41–6 (24 ref.)

Animal models of amyotrophic lateral sclerosis. Mitsumoto H, et al. **Adv Neurol** 1995;68:73–87; discussion 89–91 (80 ref.)

The possible role of a secondary pathogenetic factor in amyotrophic lateral sclerosis. Pinelli P, et al. **Adv Neurol** 1995;68:29–40 (25 ref.)

Excitotoxic mechanisms in the pathogenesis of amyotrophic lateral sclerosis. Rothstein JD. **Adv Neurol** 1995;68:7–20; discussion 21–7 (80 ref.)

Amyotrophic lateral sclerosis with paraproteins and autoantibodies. Rowland LP. **Adv Neurol** 1995;68:93–105; discussion 107–11 (136 ref.)

PATHOLOGY

Neuropathology of the cortex in amyotrophic lateral sclerosis with dementia. Pellissier JF, et al. **Adv Neurol** 1995; 68:139–41 (41 ref.)

Motor neuron disease with involvement of the pallido-luysio-nigral system and mesencephalic tegmentum. Kato S, et al. **Clin Neuropathol** 1995 Jul–Aug; 14(4):241–4 (15 ref.)

PHYSIOPATHOLOGY

Natural history of amyotrophic lateral sclerosis. Quantification of symptoms, signs, strength, and function. Brooks BR, et al. **Adv Neurol** 1995;68:163–84 (27 ref.)

Megaslope, natural course, and historical controls in amyotrophic lateral sclerosis trials. Conradi S, et al. **Adv Neurol** 1995;68:219–24 (7 ref.)

Natural history of amyotrophic lateral sclerosis. Observations with the Charing Cross Amyotrophic Lateral Sclerosis Rating Scales. Guiloff RJ, et al. **Adv Neurol** 1995;68:185–98 (28 ref.)

Natural history of amyotrophic lateral sclerosis. A discussion. Meininger V, et al. **Adv Neurol** 1995;68:199–207 (18 ref.)

Animal models of amyotrophic lateral sclerosis. Mitsumoto H, et al. **Adv Neurol** 1995;68:73–87; discussion 89–91 (80 ref.)

Neuroprotective effects of free radical scavengers and energy repletion in animal models of neurodegenerative disease. Schulz JB, et al. **Ann N Y Acad Sci** 1995 Sep 15;765:100–10; discussion 116–8 (56 ref.)

A role for neurofilaments in the pathogenesis of amyotrophic lateral sclerosis. Julien JP. **Biochem Cell Biol** 1995 Sep–Oct; 73(9–10):593–7 (45 ref.)

Superoxide dismutase in familial amyotrophic lateral sclerosis: models for gain of function. Brown RH Jr. **Curr Opin Neurobiol** 1995 Dec;5(6):841–6 (48 ref.)

Oxidative stress: its role in the pathogenesis of amyotrophic lateral sclerosis. Bergeron C. **J Neurol Sci** 1995 May;129 Suppl:81–4 (57 ref.)

The insulin-like growth factor signaling system and ALS neurotrophic factor treatment strategies. Festoff BW, et al. **J Neurol Sci** 1995 May;129 Suppl:114–21 (60 ref.)

THERAPY

The design of clinical trials in amyotrophic lateral sclerosis. Azulay JP. **Adv Neurol** 1995;68:225–7 (13 ref.)

Megaslope, natural course, and historical controls in amyotrophic lateral sclerosis trials. Conradi S, et al. **Adv Neurol** 1995;68:219–24 (7 ref.)

Issues in amyotrophic lateral sclerosis clinical trial design. Munsat TL. **Adv Neurol** 1995;68:209–18 (33 ref.)

World Federation of Neurology Research Group on Neuromuscular Diseases Subcommittee on Motor Neuron Disease. Airlie House guidelines. Therapeutic trials in amyotrophic lateral sclerosis. Airlie House "Therapeutic Trials in ALS" Workshop Contributors. **J Neurol Sci** 1995 May;129 Suppl:1–10 (0 ref.)

VIROLOGY

The viral hypothesis. Gastaut JL. **Adv Neurol** 1995;68:135–7 (33 ref.)

ANABOLIC STEROIDS

Anabolic steroid use and associated health risk behaviours. Middleman AB, et al. **Sports Med** 1996 Apr;21(4):251–5 (26 ref.)

ADVERSE EFFECTS

CNS effects and abuse liability of anabolic-androgenic steroids. Lukas SE. **Annu Rev Pharmacol Toxicol** 1996; 36:333–57 (125 ref.)

Hepatocellular carcinoma associated with anabolic steroid therapy: report of a case and review of the Japanese literature. Kosaka A, et al. **J Gastroenterol** 1996 Jun; 31(3):450–4 (24 ref.)

Anabolic steroids and the mind. Corrigan B. **Med J Aust** 1996 Aug 19;165(4):222–6 (51 ref.)

[Health risks associated with the use of anabolic steroids] Huhtaniemi I. **Duodecim** 1994;110(10):1020–8 (33 ref.) **(Fin)**

[Anabolic steroid abuse and mental disorder] Nakatani Y, et al. **Arukoru Kenkyuto Yakubutsu Ison** 1995 Oct; 30(5):333–47 (45 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Metabolism of anabolic androgenic steroids [see comments] Schänzer W. **Clin Chem** 1996 Jul;42(7):1001–20 (95 ref.) Comment in: Clin Chem 1996 Jul;42(7):999–1000.

PHARMACOLOGY

Cardiovascular effects of androgenic-anabolic steroids. Melchert RB, et al. **Med Sci Sports Exerc** 1995 Sep; 27(9):1252–62 (114 ref.)

THERAPEUTIC USE

Nandrolone decanoate: pharmacological properties and therapeutic use in osteoporosis. Geusens P. **Clin Rheumatol** 1995 Sep;14 Suppl 3:32–9 (52 ref.)

Clenbuterol: a substitute for anabolic steroids? Prather ID, et al. **Med Sci Sports Exerc** 1995 Aug;27(8):1118–21 (24 ref.)

ANAEROBIC BACTERIA see **BACTERIA, ANAEROBIC**

ANAEROBIC THRESHOLD

Exercise intensity prescription in cardiovascular disease. Theoretical basis for anaerobic threshold determination. Gordon NF, et al. **J Cardpulm Rehabil** 1995 May–Jun; 15(3):193–6 (20 ref.)

The concept of lactate threshold. A short review. Antonutto G, et al. **J Sports Med Phys Fitness** 1995 Mar;35(1):6–12 (39 ref.)

PHYSIOLOGY

[Metabolic and ventilatory thresholds during exercise. Physiological and methodological aspects] Ribeiro JP. **Arq Bras Cardiol** 1995 Feb;64(2):171–81 (178 ref.) **(Por)**

ANAEROBIOSIS

Is the intracellular pH threshold an anaerobic threshold from the view point of intracellular events?: a brief review. Iwanaga K, et al. **Appl Human Sci** 1996 Mar;15(2):59–65 (53 ref.)

ANAL FISSURE see **FISSURE IN ANO**

ANAL FISTULA see **RECTAL FISTULA**

ANAL GLAND see **ANUS**

ANAL SPHINCTER see **ANUS**

ANAL ULCER see **FISSURE IN ANO**

ANALEPTICS see **CENTRAL NERVOUS SYSTEM STIMULANTS**

ANALGESIA

Thoracic paravertebral analgesia [see comments] Richardson J, et al. **Acta Anaesthesiol Scand** 1995 Nov;39(8):1005–15 (94 ref.) Comment in: Acta Anaesthesiol Scand 1995 Nov;39(8):1003–4.

New molecules in analgesia. Rang HP, et al. **Br J Anaesth** 1995 Aug;75(2):145–56 (145 ref.)

Pain management in children. Rice LJ. **Can J Anaesth** 1996 May;43(5 Pt 2):R155–62 (31 ref.) **(Eng, Fre)**

Pain mechanisms and management: an update. Siddall PJ, et al. **Clin Exp Pharmacol Physiol** 1995 Oct;22(10):679–88 (91 ref.)

Recent developments in analgesia during labour. Kan RE, et al. **Drugs** 1995 Sep;50(3):417–22 (41 ref.)

MUJA: manipulation under joint anesthesia/analgesia: a treatment approach for recalcitrant low back pain of synovial joint origin. Dreyfuss P, et al. **J Manipulative Physiol Ther** 1995 Oct;18(8):537–46 (107 ref.)

[Anesthesiologic problems in polytrauma patients] Radke J. **Anaesthesiol Reanim** 1995;20(2):32–6 (6 ref.) (Eng. Abstr.) **(Ger)**

[Principles of analgesia and sedation] Behne M. **Anaesthesist** 1995 Dec;44 Suppl 3:S535–9 (21 ref.) (Eng. Abstr.) **(Ger)**

[Pre-emptive analgesia] Wilder-Smith OH. **Anaesthesist** 1995 Dec;44 Suppl 3:S529–34 (49 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Complications of conscious sedation. Benjamin SB. **Gastrointest Endosc Clin N Am** 1996 Apr;6(2):277–86 (18 ref.)

METHODS

Evaluation of intrapleural analgesia in the management of blunt traumatic chest wall pain: a clinical trial. Short K, et al. **Am Surg** 1996 Jun;62(6):488–93 (50 ref.)

Assessment and control of pain in children [editorial] Lloyd-Thomas A. **Anaesthesia** 1995 Sep;50(9):753–5 (43 ref.)

Pro: intrapleural anesthesia is useful for thoracic analgesia [see comments] McIlvaine WB. **J Cardiothorac Vasc Anesth** 1996 Apr;10(3):425–8 (41 ref.) Comment in: J Cardiothorac Vasc Anesth 1996 Apr;10(3):429–31.

Target-controlled infusion delivery systems: application outside the operating room. Bovill JG, et al. **J Clin Anesth** 1996 May;8(3 Suppl):21S–25S (33 ref.)

Monitored anesthesia care: how much sedation, how much analgesia? Smith I. **J Clin Anesth** 1996 May;8(3 Suppl):76S–80S (19 ref.)

Intravenous anesthesia and analgesia: what is the role of target-controlled infusion? White PF. **J Clin Anesth** 1996 May;8(3 Suppl):26S–28S (22 ref.)

The attentional control of pain: methodological and theoretical concerns. Eccleston C. **Pain** 1995 Oct; 63(1):3–10 (45 ref.)

Progress in the treatment of pain. Mehta M. **Practitioner** 1996 Apr;240(1561):214–24 (11 ref.)

[Postoperative pain relief in children] Hansen TG, et al. **Ugeskr Laeger** 1996 Apr 15;158(16):2241–5 (40 ref.) (Eng. Abstr.) **(Dan)**

[Postoperative analgesia in children: what is new?] Murat I. **Rev Med Suisse Romande** 1996 Apr;116(4):247–50 (18 ref.) **(Fre)**

VETERINARY

Treating moderate and severe pain in small animals. Brock N. **Can Vet J** 1995 Oct;36(10):658–60 (3 ref.)

ANALGESIA, ACUPUNCTURE see **ACUPUNCTURE ANALGESIA**

ANALGESIA, EPIDURAL

Con: unreliable benefit after thoracotomy—epidural is a better choice [comment] Riegler FX. **J Cardiothorac Vasc Anesth** 1996 Apr;10(3):429–31 (20 ref.) Comment on: J Cardiothorac Vasc Anesth 1996 Apr;10(3):425–8.

[Epidural analgesia in delivery] Schneider MC, et al. **Anaesthesist** 1996 Apr;45(4):393–409 (16 ref.) **(Ger)**

[Peridural anesthesia in postoperative pain therapy] Standl T. **Zentralbl Chir** 1995;120(12):916–26 (80 ref.) (Eng. Abstr.) **(Ger)**

[Epidural analgesia for postoperative pain in infants and children] Efrat R, et al. **Harefuah** 1996 Mar 1;130(5):304–7, 358 (28 ref.) (Eng. Abstr.) **(Heb)**

[Epidural analgesia for surgery and postoperative pain] Kosaka Y. **Masui** 1995;44 Suppl:S78–82 (28 ref.) **(Jpn)**

[Epidural anesthesia and postoperative analgesia] Yokoyama K. **Nippon Ika Daigaku Zasshi** 1995 Oct;62(5):413–9 (30 ref.) **(Jpn)**

ADVERSE EFFECTS

Recurrence of herpes simplex virus blepharitis after cesarean section and epidural morphine. James CF. **Anesth Analg** 1996 May;82(5):1094–6 (17 ref.)

Side effects of intrathecal and epidural opioids. Chaney MA. **Can J Anaesth** 1995 Oct;42(10):891–903 (187 ref.)

METHODS

Epidurals redefined in analgesia and anesthesia: a distinction with a difference. Youngstrom PC, et al. **J Obstet Gynecol Neonatal Nurs** 1996 May;25(4):350–4 (14 ref.)

[Treatment of postoperative pain with peridural administration of opioids] Chrubasik S, et al. **Anaesthesiol Reanim** 1995;20(1):16–25 (148 ref.) (Eng. Abstr.) **(Ger)**

STANDARDS

Epidural analgesia during labor: continuous infusion or

patient-controlled administration? Benhamou D. **Eur J Obstet Gynecol Reprod Biol** 1995 May;59 Suppl:S55-6 (9 ref.)
Effects of epidural analgesia on the progress of labor and the mode of delivery. Finster M. **Eur J Obstet Gynecol Reprod Biol** 1995 May;59 Suppl:S31-3 (35 ref.)
Role of patient-controlled epidural analgesia in obstetrics. Gambling DR, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 May;59 Suppl:S39-46 (45 ref.)
Influence of epidural analgesia on fetal and neonatal well-being. Scherer R, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 May;59 Suppl:S17-29 (118 ref.)
Opioids in combination with local anesthetics for epidural analgesia during labor. Vertommen JD. **Eur J Obstet Gynecol Reprod Biol** 1995 May;59 Suppl:S35-8 (23 ref.)

ANALGESIA, OBSTETRICAL

Labour analgesia. A risk-benefit analysis. Eberle RL, et al. **Drug Saf** 1996 Apr;14(4):239-51 (88 ref.)
[Epidural anesthesia for labor] Dailland P, et al. **Cah Anesthesiol** 1996;44(2):127-43 (24 ref.) (Eng. Abstr.) **(Fre)**
[Epidural analgesia in delivery] Schneider MC, et al. **Anaesthesist** 1996 Apr;45(4):393-409 (16 ref.) **(Ger)**
[Spinal opiates in obstetrics. Theoretical aspects and criteria for practical use] Miranda A. **Rev Esp Anestesiol Reanim** 1995 Nov;42(9):369-77 (113 ref.) (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Recurrence of herpes simplex virus blepharitis after cesarean section and epidural morphine. James CF. **Anesth Analg** 1996 May;82(5):1094-6 (17 ref.)
Maternal sequelae of childbirth [editorial] Reynolds F. **Br J Anaesth** 1995 Nov;75(5):515-7 (26 ref.)
[Management of neurologic manifestations after obstetrical epidural anesthesia] Frangié S, et al. **Cah Anesthesiol** 1995; 43(5):455-60 (43 ref.) (Eng. Abstr.) **(Fre)**

METHODS

Intrathecal narcotics: new approach for labor analgesia. Manning J. **J Obstet Gynecol Neonatal Nurs** 1996 Mar-Apr; 25(3):221-4 (9 ref.)
Epidurals redefined in analgesia and anesthesia: a distinction with a difference. Youngstrom PC, et al. **J Obstet Gynecol Neonatal Nurs** 1996 May;25(4):350-4 (14 ref.)
[Drugs for labor pain] Jage J. **Arch Gynecol Obstet** 1995; 257(1-4):135-8 (11 ref.) **(Ger)**

STANDARDS

Epidural analgesia during labor: continuous infusion or patient-controlled administration? Benhamou D. **Eur J Obstet Gynecol Reprod Biol** 1995 May;59 Suppl:S55-6 (9 ref.)
Effects of epidural analgesia on the progress of labor and the mode of delivery. Finster M. **Eur J Obstet Gynecol Reprod Biol** 1995 May;59 Suppl:S31-3 (35 ref.)
Role of patient-controlled epidural analgesia in obstetrics. Gambling DR, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 May;59 Suppl:S39-46 (45 ref.)
Influence of epidural analgesia on fetal and neonatal well-being. Scherer R, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 May;59 Suppl:S17-29 (118 ref.)
Opioids in combination with local anesthetics for epidural analgesia during labor. Vertommen JD. **Eur J Obstet Gynecol Reprod Biol** 1995 May;59 Suppl:S35-8 (23 ref.)

ANALGESIA, PATIENT-CONTROLLED

Patient-controlled intraoperative sedation. Herrick IA. **J Clin Anesth** 1996 May;8(3 Suppl):73S-75S (13 ref.)
[Patient-controlled analgesia as a method for postoperative anesthesia] Lebedeva RN, et al. **Anesteziol Reanimatol** 1996 Jan-Feb;(1):66-71 (145 ref.) **(Rus)**

ADVERSE EFFECTS

The management of opioid and benzodiazepine dependence in infants, children, and adolescents. Yaster M, et al. **Pediatrics** 1996 Jul;98(1):135-40 (41 ref.)

STANDARDS

Epidural analgesia during labor: continuous infusion or patient-controlled administration? Benhamou D. **Eur J Obstet Gynecol Reprod Biol** 1995 May;59 Suppl:S55-6 (9 ref.)
Role of patient-controlled epidural analgesia in obstetrics. Gambling DR, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 May;59 Suppl:S39-46 (45 ref.)

ANALGESIA TESTS see **PAIN MEASUREMENT**

ANALGESIC CUTANEOUS ELECTROSTIMULATION see **TRANSCUTANEOUS ELECTRIC NERVE STIMULATION**

ANALGESICS

Pain mechanisms and management: an update. Siddall PJ, et al. **Clin Exp Pharmacol Physiol** 1995 Oct;22(10):679-88 (91 ref.)

ADMINISTRATION & DOSAGE

Introducing an acute pain service. Hall PA, et al. **Br J Hosp Med** 1996 Jan 17-Feb 6;55(1-2):15-7 (10 ref.)
Clinical management of herpes zoster in the elderly patient. Beutner KR. **Compr Ther** 1996 Mar;22(3):183-6 (6 ref.)
Drugs to treat the tissue complications of diabetes: peripheral neuropathy. Emanuele NV, et al. **Compr Ther** 1995 Oct; 21(10):579-82 (30 ref.)
Management of painful procedures in the newborn. Stevens B. **Curr Opin Pediatr** 1996 Apr;8(2):102-7 (55 ref.)
Pharmacologic treatment of cancer pain. Levy MH. **N Engl J Med** 1996 Oct 10;335(15):1124-32 (101 ref.)
Concerns about analgesics among patients and family caregivers in a hospice setting. Ward SE, et al. **Res Nurs Health** 1996 Jun;19(3):205-11 (31 ref.)
The use of access devices in cancer pain control. Brant JM. **Semin Oncol Nurs** 1995 Aug;11(3):203-12 (44 ref.)
Lumbar zygapophysial (facet) joint injections. Dreyfuss PH, et al. **Spine** 1995 Sep 15;20(18):2040-7 (89 ref.)
[Analgesia after surgery of the spine in adults and adolescents] Bernard JM, et al. **Cah Anesthesiol** 1995; 43(6):557-64 (78 ref.) (Eng. Abstr.) **(Fre)**

ADVERSE EFFECTS

Habitual use of acetaminophen as a risk factor for chronic renal failure: a comparison with phenacetin. Buckalew VM Jr. **Am J Kidney Dis** 1996 Jul;28(1 Suppl 1):S7-13 (31 ref.)
Combination analgesic-induced kidney disease: the Australian experience. Duggin GG. **Am J Kidney Dis** 1996 Jul;28(1 Suppl 1):S39-47 (41 ref.)
Combination analgesic involvement in the pathogenesis of analgesic nephropathy: the European perspective. Elseviers MM, et al. **Am J Kidney Dis** 1996 Jul;28(1 Suppl 1):S48-55 (20 ref.)
Pathophysiologic mechanisms in analgesic-induced papillary necrosis. Sabatini S. **Am J Kidney Dis** 1996 Jul;28(1 Suppl 1):S34-8 (37 ref.)
Concerns with chronic analgesic therapy in elderly patients. Gloth FM 3rd. **Am J Med** 1996 Jul 31;101(1A):19S-24S (39 ref.)
Analgesic rebound headache. How great is the problem and what can be done? Silberstein SD, et al. **Drug Saf** 1995 Sep;13(3):133-44 (62 ref.)

PHARMACOKINETICS

Clinical pharmacokinetics in patients with burns. Jaehde U, et al. **Clin Pharmacokinet** 1995 Jul;29(1):15-28 (75 ref.)
Pharmacokinetic optimisation of drug therapy in elderly patients. Parker BM, et al. **Drugs Aging** 1995 Jul;7(1):10-8 (38 ref.)

PHARMACOLOGY

Molecular biology of pain. Munglani R, et al. **Br J Anaesth** 1995 Aug;75(2):186-92 (84 ref.)
New molecules in analgesia. Rang HP, et al. **Br J Anaesth** 1995 Aug;75(2):145-56 (145 ref.)
Ontogeny of nociception and antinociception. Barr GA. **NIDA Res Monogr** 1995;158:172-201 (56 ref.)
[Effects of analgesia and sedation on cerebrovascular circulation, cerebral blood volume, cerebral metabolism and intracranial pressure] Werner C. **Anaesthesist** 1995 Dec; 44 Suppl 3:S566-72 (83 ref.) (Eng. Abstr.) **(Ger)**
[Drug treatment of migraine attacks. Pharmacological considerations] Salvesen R. **Tidsskr Nor Laegeforen** 1996 Aug 10;116(18):2176-9 (41 ref.) (Eng. Abstr.) **(Nor)**

THERAPEUTIC USE

New pharmacological strategies for pain relief. Dray A, et al. **Annu Rev Pharmacol Toxicol** 1996;36:253-80 (193 ref.)
Analgesics and NSAIDs in the treatment of the acute migraine attack. Pfaffenrath V, et al. **Cephalalgia** 1995 Oct; 15 Suppl 15:14-20 (53 ref.)
Early-phase clinical trials in migraine: efficacy, safety and dose-finding. Pilgrim AJ. **Cephalalgia** 1995 Oct;15 Suppl 15:10-3 (13 ref.)
Acute treatment of migraine attacks. Ferrari MD, et al. **Curr Opin Neurol** 1995 Jun;8(3):237-42 (34 ref.)
The WHO analgesic ladder for cancer pain management. Stepping up the quality of its evaluation [see comments] Jadad AR, et al. **JAMA** 1995 Dec 20;274(23):1870-3 (40 ref.) Comment in: JAMA 1995 Dec 20;274(23):1881-2. Comment in: JAMA 1996 Mar 20;275(11):835; discussion 836. Comment in: JAMA 1996 Mar 20;275(11):835-6.
Cancer pain. O'Neill WM. **Middle East J Anesthesiol** 1996 Feb;13(4):373-8 (7 ref.)
Pharmacologic management of cancer pain. Niles R. **Nurs Clin North Am** 1995 Dec;30(4):745-63 (83 ref.)
Relief of suffering: where the art and science of medicine meet. O'Brien ME. **Postgrad Med** 1996 Jun;99(6):189-92, 197-200, 206-8 (14 ref.)
[Antalgic treatment in pelvic pain] Valade D. **Contracept Fertil Sex** 1996 Mar;24(3):207-12 (0 ref.) (Eng. Abstr.) **(Fre)**
[Strategy of treatment of cancer pain in children] Pichard-Léandri E, et al. **Rev Med Interne** 1995; 16(9):708-16 (28 ref.) (Eng. Abstr.) **(Fre)**
[Analgesia and sedation on patients with sepsis syndrome] Adams HA. **Anaesthesist** 1995 Dec;44 Suppl 3:S573-9 (30 ref.) (Eng. Abstr.) **(Ger)**
[Analgesia and sedation in patients with head-brain trauma] Gremmelt A, et al. **Anaesthesist** 1995 Dec;44 Suppl 3:S559-65 (71 ref.) (Eng. Abstr.) **(Ger)**
[Pain management in cancer patients] Willenbrink HJ, et al. **Dtsch Med Wochenschr** 1995 Oct 6;120(40):1363-6 (13 ref.) **(Ger)**
[Drug treatment of tumor pain] Larsen B, et al. **Internist (Berl)** 1996 Apr;37(4):425-40 (10 ref.) **(Ger)**
[Ambulatory pain treatment in tumor patients] Keseberg A. **Z Gerontol Geriatr** 1995 Sep-Oct;28(5):328-34 (0 ref.) (Eng. Abstr.) **(Ger)**
[Capsaicin for arthritic pain] Niv D, et al. **Harefuah** 1996 Mar 15;130(6):415-20 (43 ref.) **(Heb)**
[Specific problems of analgesic therapy in hospital environment] Baños JE, et al. **Med Clin (Barc)** 1996 Feb 17;106(6):222-6 (59 ref.) **(Spa)**
[Analgesics and non-steroidal anti-inflammatory agents in the treatment of migraine] Iglesias F, et al. **Rev Neurol** 1995;23 Suppl 2:S157-61 (20 ref.) **(Spa)**

ANALGESICS, ADDICTIVE see **ANALGESICS, OPIOID**

ANALGESICS, ANTI-INFLAMMATORY see **ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL**

ANALGESICS, NARCOTIC see **ANALGESICS, OPIOID**

ANALGESICS, NON-NARCOTIC

Drugs and sedation for colonoscopy. Phillips MS. **Prim Care** 1995 Sep;22(3):433-43 (33 ref.)

ADVERSE EFFECTS

Acetaminophen and adverse chronic renal outcomes: an appraisal of the epidemiologic evidence. Barrett BJ. **Am J Kidney Dis** 1996 Jul;28(1 Suppl 1):S14-9 (15 ref.)
Acetaminophen: acute and chronic effects on renal function. Blantz RC. **Am J Kidney Dis** 1996 Jul;28(1 Suppl 1):S3-6 (23 ref.)
Habitual use of acetaminophen as a risk factor for chronic renal failure: a comparison with phenacetin. Buckalew VM Jr. **Am J Kidney Dis** 1996 Jul;28(1 Suppl 1):S7-13 (31 ref.)
Nonrenal toxicities of acetaminophen, aspirin, and nonsteroidal anti-inflammatory agents. Matzke GR. **Am J Kidney Dis** 1996 Jul;28(1 Suppl 1):S63-70 (38 ref.)
Does acetaminophen damage the heart? [see comments] Lip GY, et al. **J Toxicol Clin Toxicol** 1996;34(2):145-7 (23 ref.) Comment in: J Toxicol Clin Toxicol 1996;34(2):149-53. Comment in: J Toxicol Clin Toxicol 1996;34(2):155-6.
[Amidazophen. Yes or no?] Jákó J, et al. **Orv Hetil** 1995 Sep 24;136(39):2121-4 (50 ref.) (Eng. Abstr.) **(Hun)**

BLOOD

[Carbamazepine] Gomita Y, et al. **Nippon Rinsho** 1995 Feb; 53 Su Pt 1:907-10 (8 ref.) **(Jpn)**

PHARMACOLOGY

[Epibatidine--a nicotine-related, analgesic alkaloid from poison-dart frogs] Müller CE. **Pharm Unserer Zeit** 1996 Apr;25(2):85-92 (27 ref.) **(Ger)**

POISONING

Acetaminophen toxicity: report of case and review of the literature. Schueler L, et al. **J Oral Maxillofac Surg** 1995 Oct;53(10):1208-12 (13 ref.)

THERAPEUTIC USE

Amitriptyline. A review of its pharmacological properties and therapeutic use in chronic pain states. Bryson HM, et al. **Drugs Aging** 1996 Jun;8(6):459-76 (111 ref.)
The analgesic efficacy of ketorolac for acute pain. Catapano MS. **J Emerg Med** 1996 Jan-Feb;14(1):67-75 (101 ref.)
[Drugs for labor pain] Jage J. **Arch Gynecol Obstet** 1995; 257(1-4):135-8 (11 ref.) **(Ger)**
[Effectiveness of fixed analgesic combinations exemplified by thomapyrin] Aicher B, et al. **Wien Klin Wochenschr** 1996;108(8):219-33 (104 ref.) (Eng. Abstr.) **(Ger)**

TOXICITY

Acetaminophen/aspirin mixtures: experimental data. Porter GA. **Am J Kidney Dis** 1996 Jul;28(1 Suppl 1):S30-3 (11 ref.)
Series: current issues in mutagenesis and carcinogenesis, No. 65. The genotoxicity and carcinogenicity of paracetamol: a regulatory (re)view. Bergman K, et al. **Mutat Res** 1996 Feb 1;349(2):263-88 (103 ref.)

ANALGESICS, OPIOID

see related
NARCOTICS

Remifentanil: a novel, short-acting, mu-opioid. Bürkle H, et al. **Anesth Analg** 1996 Sep;83(3):646–51 (52 ref.)
Tolerance to opioid analgesics: clinical aspects. Portenoy RK. **Cancer Surv** 1994;21:49–65 (80 ref.)
Perspectives on opioid tolerance from basic research: behavioural studies after spinal administration in rodents. Stevens CW. **Cancer Surv** 1994;21:25–47 (51 ref.)
Pharmacokinetic–pharmacodynamic relationships for opioids in balanced anaesthesia. Lemmens HJ. **Clin Pharmacokinet** 1995 Oct;29(4):231–42 (69 ref.)
Remifentanil: a new opioid. Glass PS. **J Clin Anesth** 1995 Nov;7(7):558–63 (24 ref.)
Drugs and sedation for colonoscopy. Phillips MS. **Prim Care** 1995 Sep;22(3):433–43 (33 ref.)
[Clinical use of sufentanil] Toftegaard M, et al. **Ugeskr Laeger** 1996 Jun 10;158(24):3483–6 (33 ref.) **(Dan)**

ADMINISTRATION & DOSAGE

Biological rhythms in pain and in the effects of opioid analgesics. Labrecque G, et al. **Pharmacol Ther** 1995; 68(1):129–47 (80 ref.)
[Postoperative pain relief in children] Hansen TG, et al. **Ugeskr Laeger** 1996 Apr 15;158(16):2241–5 (40 ref.) (Eng. Abstr.) **(Dan)**
[Treatment of postoperative pain with peridural administration of opioids] Chrubasik S, et al. **Anaesthesiol Reanim** 1995;20(1):16–25 (148 ref.) (Eng. Abstr.) **(Ger)**
[Continuous spinal analgesia in home care of oncologic pain] Ricci V, et al. **Minerva Med** 1995 Oct;86(10):409–14 (30 ref.) (Eng. Abstr.) **(Ita)**
[Spinal opiates in obstetrics. Theoretical aspects and criteria for practical use] Miranda A. **Rev Esp Anestesiol Reanim** 1995 Nov;42(9):369–77 (113 ref.) (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Recurrence of herpes simplex virus blepharitis after cesarean section and epidural morphine. James CF. **Anesth Analg** 1996 May;82(5):1094–6 (17 ref.)
Meperidine associated mental status changes in a patient with chronic renal failure. Stock SL, et al. **J Fla Med Assoc** 1996 May;83(5):315–9 (16 ref.)

ANTAGONISTS & INHIBITORS

Cholecystokinin octapeptide (CCK-8): a negative feedback control mechanism for opioid analgesia. Han JS. **Prog Brain Res** 1995;105:263–71 (20 ref.)

METABOLISM

The pharmacogenetics of codeine hypoalgesia. Sindrup SH, et al. **Pharmacogenetics** 1995 Dec;5(6):335–46 (91 ref.)
Endogenous morphine. Hosztafi S, et al. **Pharmacol Res** 1995 Jul–Aug;32(1–2):15–20 (51 ref.)

PHARMACOKINETICS

Pharmacokinetics, efficacy, and safety of analgesia with a focus on tramadol HCl. Gibson TP. **Am J Med** 1996 Jul 31;101(1A):47S–53S (30 ref.)
Pharmacokinetics of analgesics, sedatives and anaesthetic agents during cardiopulmonary bypass. Gedney JA, et al. **Br J Anaesth** 1995 Sep;75(3):344–51 (74 ref.)
Remifentanil pharmacokinetics and pharmacodynamics. A preliminary appraisal. Egan TD. **Clin Pharmacokinet** 1995 Aug;29(2):80–94 (41 ref.)

PHARMACOLOGY

A novel approach to the pharmacology of analgesics. Raffa RB. **Am J Med** 1996 Jul 31;101(1A):40S–46S (33 ref.)
Remifentanil pharmacokinetics and pharmacodynamics. A preliminary appraisal. Egan TD. **Clin Pharmacokinet** 1995 Aug;29(2):80–94 (41 ref.)
Transnasal butorphanol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute pain management. Gillis JC, et al. **Drugs** 1995 Jul; 50(1):157–75 (47 ref.)
Opioids in combination with local anesthetics for epidural analgesia during labor. Vertommen JD. **Eur J Obstet Gynecol Reprod Biol** 1995 May;59 Suppl:S35–8 (23 ref.)
Modern opioids: uses defined by chrono–pharmacology, not receptor selectivity. Fox AW. **J R Soc Med** 1995 Sep; 88(9):502–4 (12 ref.)
The pharmacogenetics of codeine hypoalgesia. Sindrup SH, et al. **Pharmacogenetics** 1995 Dec;5(6):335–46 (91 ref.)
1994 John J. Bonica Lecture. The clinical effects of morphine pharmacology. Mather LE. **Reg Anesth** 1995 Jul–Aug; 20(4):263–82 (95 ref.)
[Analgesic effect of morphine and its metabolites administered by an intracerebroventricular route] Serrié A. **Bull Acad Natl Med** 1995 Jun;179(6):1237–52; discussion 1252–3 (20 ref.) (Eng. Abstr.) **(Fre)**

THERAPEUTIC USE

Treating moderate and severe pain in small animals. Brock N. **Can Vet J** 1995 Oct;36(10):658–60 (3 ref.)
Neurophysiology of opioid poorly responsive pain. Dickenson AH. **Cancer Surv** 1994;21:5–16 (49 ref.)
Buprenorphine as a pharmacotherapy for cocaine abuse: a review of the evidence. Compton PA, et al. **J Addict Dis** 1995;14(3):97–114 (56 ref.)
Meperidine: therapeutic use and toxicity. Clark RF, et al. **J Emerg Med** 1995 Nov–Dec;13(6):797–802 (62 ref.)
Implementation of a formal treatment agreement for outpatient management of chronic nonmalignant pain with opioid analgesics. Burchman SL, et al. **J Pain Symptom Manage** 1995 Oct;10(7):556–63 (19 ref.)
Principles of opioid pharmacotherapy: practical implications of basic mechanisms. Ferrante FM. **J Pain Symptom Manage** 1996 May;11(5):265–73 (64 ref.)
Government regulatory influences on opioid prescribing and their impact on the treatment of pain of nonmalignant origin. Hill CS Jr. **J Pain Symptom Manage** 1996 May; 11(5):287–98 (38 ref.)
Long-term opioid therapy: assessment of consequences and risks. Savage SR. **J Pain Symptom Manage** 1996 May; 11(5):274–86 (73 ref.)
Sublingual and oral morphine administration. Review and new findings. Robison JM, et al. **Nurs Clin North Am** 1995 Dec;30(4):725–43 (51 ref.)
Effective management of chronic pain. The analgesic dilemma. Stacey BR. **Postgrad Med** 1996 Sep;100(3):281–4, 287–90, 293 passim (27 ref.)
1994 John J. Bonica Lecture. The clinical effects of morphine pharmacology. Mather LE. **Reg Anesth** 1995 Jul–Aug; 20(4):263–82 (95 ref.)
[Post-appendectomy fistulas of the cecum. Apropos of 22 cases] Genier F, et al. **J Chir (Paris)** 1995 Oct;132(10):393–8 (17 ref.) (Eng. Abstr.) **(Fre)**
[Oral opioids for long-term treatment of chronic non-cancer pain] Dertwinkel R, et al. **Anaesthesist** 1996 Jun; 45(6):495–505 (53 ref.) (Eng. Abstr.) **(Ger)**
[Drugs for labor pain] Jage J. **Arch Gynecol Obstet** 1995; 257(1–4):135–8 (11 ref.) **(Ger)**
[Drug treatment of tumor pain] Larsen B, et al. **Internist (Berl)** 1996 Apr;37(4):425–40 (10 ref.) **(Ger)**
[Pain crises in patients with sickle cell diseases. Pathogenesis, clinical aspects, therapy] Dickerhoff R, et al. **Klin Padiatr** 1995 Nov–Dec;207(6):321–5 (29 ref.) (Eng. Abstr.) **(Ger)**
[Ambulatory pain treatment in tumor patients] Keseberg A. **Z Gerontol Geriatr** 1995 Sep–Oct;28(5):328–34 (0 ref.) (Eng. Abstr.) **(Ger)**

ANALGIN see **DIPYRONE**

ANALOGUE PAIN SCALE see **PAIN MEASUREMENT**

ANALYZERS, NEURAL see **NEURAL ANALYZERS**

ANAPHASE

Frontier questions about sister chromatid separation in anaphase. Yanagida M. **Bioessays** 1995 Jun;17(6):519–26 (70 ref.)

ANAPHYLACTOID PURPURA see **PURPURA, SCHOENLEIN-HENOCH**

ANAPHYLAXIS

Anaphylaxis. Friday GA Jr, et al. **Ear Nose Throat J** 1996 Jan;75(1):21–4 (4 ref.)
Anaphylactic shock: mechanisms and treatment [see comments] Brown AF. **J Accid Emerg Med** 1995 Jun; 12(2):89–100 (92 ref.) Comment in: J Accid Emerg Med 1996 Mar;13(2):150.
Anaphylaxis. How to recognize, treat and prevent potentially fatal attacks. Wyatt R. **Postgrad Med** 1996 Aug; 100(2):87–90, 96–9 (10 ref.)

CHEMICALLY INDUCED

Muscle relaxants and histamine release. Moss J. **Acta Anaesthesiol Scand Suppl** 1995;106:7–12 (30 ref.)
Anaphylactoid reactions to methotrexate. Alkins SA, et al. **Cancer** 1996 May 15;77(10):2123–6 (13 ref.)
[Anaphylactoid reactions to radiocontrast media] Confino-Cohen R, et al. **Harefuah** 1995 Jul;129(1–2):55–7 (17 ref.) **(Heb)**

DRUG THERAPY

[Self-administration of adrenaline aerosol in anaphylactic reactions after insect stings] Ackermann RW, et al. **Ugeskr Laeger** 1996 Aug 5;158(32):4497–9 (27 ref.) (Eng. Abstr.) **(Dan)**

ETIOLOGY

Human seminal plasma anaphylaxis (HSPA): case report and literature review. Ebo DG, et al. **Allergy** 1995 Sep; 50(9):747–50 (30 ref.)
Adverse reactions associated with skin testing and immunotherapy. Lockey RF. **Allergy Proc** 1995 Nov–Dec; 16(6):293–6 (11 ref.)
Mast cells and basophils in adverse reactions to drugs used during general anesthesia. Stellato C, et al. **Chem Immunol** 1995;62:108–31 (94 ref.)
IgE-mediated (and food-induced) intestinal disease. Strobel S. **Clin Exp Allergy** 1995 Jul;25 Suppl 1:3–6 (61 ref.)
Idiopathic anaphylaxis: a purely internal reaction. Patterson R, et al. **Hosp Pract (Off Ed)** 1996 Jul 15;31(7):47–51, 55–8, 64 (0 ref.)
[Anesthesiologic pecularities in patients with latex allergy (see comments)] Kisch H, et al. **Anaesthesist** 1996 Jul; 45(7):587–96 (88 ref.) (Eng. Abstr.) Comment in: Anaesthesist 1996 Jul;45(7):585–6. **(Ger)**

PHYSIOPATHOLOGY

Role of nitric oxide in anaphylactic shock. Mitsuhata H, et al. **J Clin Immunol** 1995 Nov;15(6):277–83 (63 ref.)
[Anaphylactic shock] Kaeser P, et al. **Schweiz Rundsch Med Prax** 1995 Nov 7;84(45):1307–13 (30 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

Venom immunotherapy: tolerance to a 3-day protocol of rush-immunotherapy. Diez Gómez ML, et al. **Allergol Immunopathol (Madr)** 1995 Nov–Dec;23(6):277–84 (40 ref.)

THERAPY

ED management of insect stings. Jerrard DA. **Am J Emerg Med** 1996 Jul;14(4):429–33 (44 ref.)
Significance of Africanized bees for public health. A review. Schumacher MJ, et al. **Arch Intern Med** 1995 Oct 23; 155(19):2038–43 (49 ref.)
Treatment of acute anaphylaxis [see comments] Fisher M. **BMJ** 1995 Sep 16;311(7007):731–3 (29 ref.) Comment in: BMJ 1995 Nov 25;311(7017):1434. Comment in: BMJ 1995 Nov 25;311(7017):1434–5. Comment in: BMJ 1995 Nov 25;311(7017):1435. Comment in: BMJ 1995 Nov 25;311(7017):1435–6. Comment in: BMJ 1995 Nov 25;311(7017):1436.
Treatment of adverse reactions to radiographic contrast media in adults. Cohan RH, et al. **Radiol Clin North Am** 1996 Sep;34(5):1055–76 (105 ref.)

ANAPLASMA

GROWTH & DEVELOPMENT

Strategies to interrupt the development of Anaplasma marginale in its tick vector. The effect of bovine-derived antibodies. Kocan KM, et al. **Ann N Y Acad Sci** 1996 Jul 23;791:157–65 (57 ref.)

ANAPLASMOSIS

PREVENTION & CONTROL

Strategies to interrupt the development of Anaplasma marginale in its tick vector. The effect of bovine-derived antibodies. Kocan KM, et al. **Ann N Y Acad Sci** 1996 Jul 23;791:157–65 (57 ref.)

ANASTOMOSIS, ROUX-EN-Y

ADVERSE EFFECTS

Bile duct carcinoma arising from the anastomotic site of hepaticojejunostomy after the excision of congenital biliary dilatation: a case report. Yamamoto J, et al. **Surgery** 1996 Apr;119(4):476–9 (10 ref.)

ANASTOMOSIS, SURGICAL

Cross-face facial nerve anastomosis: historical notes. Scaramella LF. **Ear Nose Throat J** 1996 Jun;75(6):343, 347–52, 354 (11 ref.)

ANATOMIC MODELS see **MODELS, ANATOMIC**

ANATOMY

A new representation of knowledge concerning human anatomy and function. Höhne KH, et al. **Nat Med** 1995 Jun;1(6):506–11 (33 ref.)
[Histochemistry of the organs—application of histochemistry to anatomy] Nagata T. **Kaibogaku Zasshi** 1995 Oct; 70(5):448–71 (175 ref.) (Eng. Abstr.) **(Jpn)**

EDUCATION

Basic surgical training. 4: American and British scenes compared. Ger R. **Clin Anat** 1996;9(3):173–4 (2 ref.)
The future of gross anatomy teaching. Malamed S, et al. **Clin Anat** 1995;8(4):294–6 (13 ref.)
Basic surgical training. 3: A view from Ireland. Monkhouse S. **Clin Anat** 1996;9(3):171–2 (0 ref.)
Basic surgical training. 1: Postgraduate surgical examinations in the UK and Ireland. Raftery AT. **Clin Anat** 1996; 9(3):163–6 (1 ref.)
Basic surgical training. 2: Interactions with the undergraduate medical curriculum. Willan P. **Clin Anat** 1996;9(3):167–70 (1 ref.)

ANATOMY, ARTISTIC

A new representation of knowledge concerning human anatomy and function. Höhne KH, et al. **Nat Med** 1995 Jun;1(6):506–11 (33 ref.)

ANATOXINS

ANATOXINS see TOXOIDS

ANCHORED PCR see POLYMERASE CHAIN REACTION

ANCHORIN CII see ANNEXIN V

ANCILLARY INFORMATION SYSTEMS see INFORMATION SYSTEMS

ANCYLOSTOMA

ISOLATION & PURIFICATION

Ancylostoma genettae, A. protelesis, A. somaliense: three new species from wild Carnivora in the Somali Republic. Macchioni G. **Parassitologia** 1995 Dec;37(2-3):219-28 (26 ref.)

ANCYLOSTOMA CANINUM see ANCYLOSTOMA

ANCYLOSTOMA DUODENALE see ANCYLOSTOMA

ANCYLOSTOMIASIS

VETERINARY

Ancylostoma genettae, A. protelesis, A. somaliense: three new species from wild Carnivora in the Somali Republic. Macchioni G. **Parassitologia** 1995 Dec;37(2-3):219-28 (26 ref.)

ANDERSON-FABRY DISEASE see FABRY'S DISEASE

ANDROGEN ANALOGS see ANDROGENS, SYNTHETIC

ANDROGEN ANTAGONISTS

ADMINISTRATION & DOSAGE

Patient compliance with crucial drug regimens: implications for prostate cancer. Urquhart J. **Eur Urol** 1996;29 Suppl 2:124-31 (62 ref.)

ADVERSE EFFECTS

[Hot flashes and hormonal treatment of prostate cancer] Lanfrey P, et al. **Prog Urol** 1996 Feb;6(1):17-22 (31 ref.) (Eng. Abstr.) **(Fre)**

THERAPEUTIC USE

Neoadjuvant hormonal deprivation in locally advanced prostate cancer: does it make sense? Schulman CC, et al. **Acta Urol Belg** 1996 May;64(2):57-61 (32 ref.)

Compliance with hormonal treatment for prostate cancer. Kaisary AV. **Br J Hosp Med** 1996 Mar 20-Apr 2; 55(6):359-66 (59 ref.)

Anti-androgens in the treatment of prostate cancer. Newling DW. **Br J Urol** 1996 Jun;77(6):776-84 (51 ref.)

Clinical progress with a new antiandrogen, Casodex (bicalutamide). Blackledge GR. **Eur Urol** 1996;29 Suppl 2:96-104 (15 ref.)

Combined androgen blockade. Crawford ED. **Eur Urol** 1996; 29 Suppl 2:54-61 (28 ref.)

Combined androgen blockade is the treatment of choice for patients with advanced prostate cancer: the argument for. Debruyne FM. **Eur Urol** 1996;29 Suppl 2:34-6 (8 ref.)

Advances and trends in hormonal therapy for advanced prostate cancer. Debruyne FM, et al. **Eur Urol** 1995; 28(3):177-88 (98 ref.)

Combined androgen blockade is the treatment of choice for patients with advanced prostate cancer: the argument against. Fitzpatrick JM. **Eur Urol** 1996;29 Suppl 2:37-9 (7 ref.)

The development of Casodex (bicalutamide): preclinical studies. Furr BJ. **Eur Urol** 1996;29 Suppl 2:83-95 (53 ref.)

Androgens, antiandrogens and androgen receptor abnormalities. Kuil CW, et al. **Eur Urol** 1996;29 Suppl 2:78-82 (30 ref.)

The role of induction androgen deprivation prior to radical prostatectomy. Soloway MS, et al. **Eur Urol** 1996;29 Suppl 2:114-8 (27 ref.)

The future of antihormone therapy: innovations based on an established principle. Parczyk K, et al. **J Cancer Res Clin Oncol** 1996;122(7):383-96 (82 ref.)

Policing "perversions": Depo-Provera and John Money's new sexual order. Tsang DC. **J Homosex** 1995;28(3-4):397-426 (110 ref.)

Androgen receptor mediated growth control of breast cancer and endometrial cancer modulated by antiandrogen- and androgen-like steroids. Hackenberg R, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1-6 Spec No):113-7 (56 ref.)

Commentary on maximal androgen blockade in prostate cancer: a theory to put into practice? Denis L. **Prostate** 1995 Nov;27(5):233-40 (43 ref.)

Current status of neoadjuvant therapy in localized prostate cancer. Witjes WP, et al. **Prostate** 1995 Dec;27(6):297-303 (69 ref.)

Optimal duration of neoadjuvant androgen withdrawal therapy before radical prostatectomy in clinically confined prostate cancer. Gleave ME, et al. **Semin Urol Oncol** 1996 May;14(2 Suppl 2):39-45; discussion 46-7 (26 ref.)

Neoadjuvant total androgen suppression and radiotherapy in the management of locally advanced prostate cancer. Roach M 3rd. **Semin Urol Oncol** 1996 May;14(2 Suppl 2):32-7; discussion 38 (33 ref.)

Worldwide activity and safety of bicalutamide: a summary review. Kolvenbag GJ, et al. **Urology** 1996 Jan;47(1A Suppl):70-9; discussion 80-4 (29 ref.)

Defining the role of antiandrogens in the treatment of prostate cancer. McLeod DG, et al. **Urology** 1996 Jan; 47(1A Suppl):85-9; discussion 90-6 (40 ref.)

Combined androgen blockade for the treatment of metastatic cancer of the prostate. Schellhammer PF. **Urology** 1996 May;47(5):622-8 (46 ref.)

[Hormonal treatments for disorders of sexual conduct] Cordier B, et al. **Bull Acad Natl Med** 1996 Mar; 180(3):599-605; discussion 605-10 (15 ref.) (Eng. Abstr.) **(Fre)**

[Treatment of metastatic cancer of the prostate] Fournier G, et al. **Presse Med** 1995 Oct 28;24(32):1465-70 (10 ref.) (Eng. Abstr.) **(Fre)**

[Current drug therapy of benign prostatic hyperplasia] Schmidbauer CP, et al. **Wien Med Wochenschr** 1996; 146(8):161-4 (12 ref.) (Eng. Abstr.) **(Ger)**

ANDROGEN RECEPTORS see RECEPTORS, ANDROGEN

ANDROGENS

see related
ANDROGEN ANTAGONISTS
RECEPTORS, ANDROGEN

Progestogens, progesterone antagonists, progesterone, and androgens: synthesis, classification, and uses. Peterson CM. **Clin Obstet Gynecol** 1995 Dec;38(4):813-20 (13 ref.)

Androgen action. Roy AK, et al. **Crit Rev Eukaryot Gene Expr** 1995;5(2):157-76 (170 ref.)

Androgens in men--uses and abuses. Bagatell CJ, et al. **N Engl J Med** 1996 Mar 14;334(11):707-14 (91 ref.)

ADVERSE EFFECTS

[Steroid-induced liver tumor] Nishizawa Y, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):449-52 (21 ref.) **(Jpn)**

BIOSYNTHESIS

DHEA and peripheral androgen and estrogen formation: intracinology. Labrie F, et al. **Ann N Y Acad Sci** 1995 Dec 29;774:16-28 (70 ref.)

Adrenal androgen production in polycystic ovary syndrome. McKenna TJ, et al. **Eur J Endocrinol** 1995 Oct;133(4):383-9 (35 ref.)

Regulation of ovarian androgen production: a key parameter to success during ovarian stimulation? Andersen CY. **Hum Reprod** 1995 Sep;10(9):2227-33 (58 ref.)

Molecular genetics of androgenic 17 beta-hydroxysteroid dehydrogenases. Andersson S. **J Steroid Biochem Mol Biol** 1995 Dec;55(5-6):533-4 (20 ref.)

BLOOD

[Andropause: myth or reality?] Tomer Y, et al. **Harefuah** 1995 Jun 15;128(12):785-8 (51 ref.) **(Heb)**

DEFICIENCY

[Endocrinology update. II] Burgstaller M, et al. **Med Klin** 1996 Apr 10;91(4):207-17 (171 ref.) **(Ger)**

PHARMACOLOGY

Sterility in neonatally androgenized female rats and the decidual cell reaction. Ohta Y. **Int Rev Cytol** 1995;160:1-52 (250 ref.)

Spatial cognition in humans: possible modulation by androgens and estrogens. Hampson E. **J Psychiatry Neurosci** 1995 Nov;20(5):397-404 (66 ref.)

Androgen and progestagen effects on plasma lipids. Bagatell CJ, et al. **Prog Cardiovasc Dis** 1995 Nov-Dec;38(3):255-71 (125 ref.)

Growth factors as mediators of androgen action during male urogenital development. Cunha GR. **Prostate Suppl** 1996; 6:22-5 (33 ref.)

Genetic regulation of androgen action. Kallio PJ, et al. **Prostate Suppl** 1996;6:45-51 (46 ref.)

Role of androgen in prostate growth and regression: stromal-epithelial interaction. Lee C. **Prostate Suppl** 1996; 6:52-6 (26 ref.)

Androgen regulation of gene expression. Perry JE, et al. **Prostate Suppl** 1996;6:79-81 (22 ref.)

Role of dihydrotestosterone in androgen action. Wilson JD. **Prostate Suppl** 1996;6:88-92 (32 ref.)

PHYSIOLOGY

Androgens, brain, and behavior. Rubinow DR, et al. **Am J Psychiatry** 1996 Aug;153(8):974-84 (179 ref.)

Adrenal androgen action in breast cancer. Boccuzzi G, et al. **Ann N Y Acad Sci** 1996 Apr 30;784:349-61 (55 ref.)

Apoptosis in prostate cancer. Molecular basis to study hormone refractory mechanisms. Colombel M, et al. **Ann N Y Acad Sci** 1996 Apr 30;784:63-9 (20 ref.)

Androgens, antiandrogens and androgen receptor abnormalities. Kuil CW, et al. **Eur Urol** 1996;29 Suppl 2:78-82 (30 ref.)

Role of growth hormone and sex steroids in achieving and maintaining normal bone mass. Holmes SJ, et al. **Horm Res** 1996;45(1-2):86-93 (96 ref.)

Influence of growth hormone and androgens on body composition in adults. Jørgensen JO, et al. **Horm Res** 1996; 45(1-2):94-8 (31 ref.)

Expression and androgenic regulation of human prostate-specific kallikreins. Young CY, et al. **J Androl** 1995 Mar-Apr;16(2):97-9 (16 ref.)

Role of growth factors, steroid and peptide hormones in the regulation of human prostatic tumor growth. Motta M, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1-6 Spec No):107-11 (36 ref.)

Growth factors as mediators of androgen action during the development of the male urogenital tract. Cunha GR, et al. **World J Urol** 1995;13(5):264-76 (124 ref.)

Keratinocyte growth factor: an androgen-regulated mediator of stromal-epithelial interactions in the prostate. Peehl DM, et al. **World J Urol** 1995;13(5):312-7 (43 ref.)

[Androgens and feminine behavior] Kerdelhue B, et al. **Contracept Fertil Sex** 1996 May;24(5):407-12 (28 ref.) (Eng. Abstr.) **(Fre)**

[Cryptorchism--assessment from an andrologic viewpoint] Weidner W, et al. **Urologe A** 1996 Mar;35(2):111-4 (31 ref.) (Eng. Abstr.) **(Ger)**

[The effects of androgens and other sex hormones on serum lipoproteins] Reiner Z. **Lijec Vjesn** 1996 Mar;118 Suppl 1:33-7 (55 ref.) (Eng. Abstr.) **(Scr)**

STANDARDS

The rational use of androgens in hormone replacement therapy. Peterson CM. **Clin Obstet Gynecol** 1995 Dec; 38(4):915-20 (20 ref.)

THERAPEUTIC USE

Androgen receptor mediated growth control of breast cancer and endometrial cancer modulated by antiandrogen- and androgen-like steroids. Hackenberg R, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1-6 Spec No):113-7 (56 ref.)

ANDROGENS, SYNTHETIC

ADMINISTRATION & DOSAGE

[Androgens in the treatment of women] Flöter A, et al. **Lakartidningen** 1996 Jan 3;93(1-2):52-5 (46 ref.) **(Swe)**

ANDROLOGY see UROLOGY

ANDROSTADIENES

ADMINISTRATION & DOSAGE

Once-a-day topical corticosteroids. **Drug Ther Bull** 1995 Mar;33(3):21-2 (15 ref.)

ADVERSE EFFECTS

Fluticasone propionate: safety profile. Johnson M. **Cutis** 1996 Feb;57(2 Suppl):10-2 (15 ref.)

PHARMACOLOGY

Fluticasone propionate--an update on preclinical and clinical experience. Fuller R, et al. **Respir Med** 1995 Sep;89 Suppl A:3-18 (59 ref.)

THERAPEUTIC USE

Topical corticosteroids in clinical practice: focus on fluticasone propionate. Piacquadio DJ. **Cutis** 1996 Feb;57(2 Suppl):4-9 (19 ref.)

5-ANDROSTANE-3,17-DIOL

BLOOD

[Androstanediol] Kinouchi T. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:604-10 (38 ref.) **(Jpn)**

ANDROSTANOLONE see STANOLONE

ANDROSTANOLS

Rocuronium: the newest aminosteroid neuromuscular blocking drug [editorial] Hunter JM. **Br J Anaesth** 1996 Apr;76(4):481-3 (30 ref.)

Onset time and evaluation of intubating conditions: rocuronium in perspective. Agoston S. **Eur J Anaesthesiol Suppl** 1995 Sep;11:31-7 (14 ref.)

PHARMACOKINETICS

The pharmacokinetics of rocuronium bromide in hepatic cirrhosis. Hunter JM. **Eur J Anaesthesiol Suppl** 1995 Sep; 11:39-41 (6 ref.)

ANDROSTENEDIONE

BLOOD

[Androstenedione] Kambegawa A. **Nippon Rinsho** 1995 Mar; 53 Su Pt 2:491–4 (17 ref.) **(Jpn)**

ANDROSTERONE

BLOOD

[Androsterone] Kambegawa A. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:487–90 (13 ref.) **(Jpn)**

ANEMIA

Anemia of pregnancy. Mani S, et al. **Clin Perinatol** 1995 Sep; 22(3):593–607 (41 ref.)

Anemia. Erickson JM. **Semin Oncol Nurs** 1996 Feb;12(1):2–14 (64 ref.)

CHEMICALLY INDUCED

Nonsteroidal antiinflammatory drug–induced enteropathy and severe chronic anemia in a patient with rheumatoid arthritis. Davies NM, et al. **Arthritis Rheum** 1996 Feb; 39(2):321–4 (15 ref.)

DIAGNOSIS

[Perioperative and postoperative normovolemic anemia. Physiological compensation, monitoring and risk evaluation] Ostgaard G. **Tidsskr Nor Laegeforen** 1996 Jan 10;116(1):57–60 (43 ref.) (Eng. Abstr.) **(Nor)**

[Normocytic anemia and hypercholesterolemia as the manifestation of a variant of Hashimoto's thyroiditis] Buitrago Ramírez F, et al. **An Esp Pediatr** 1996 Jul; 45(1):76–8 (10 ref.) **(Spa)**

[Hematologic causes of vascular diseases of the central nervous system] Arboix A, et al. **Rev Neurol** 1995;23 Suppl 1:S41–9 (62 ref.) **(Spa)**

DRUG THERAPY

Erythropoietin and the anemia of cancer. Beguin Y. **Acta Clin Belg** 1996;51(1):36–52 (104 ref.)

Treatment of anemia of nephrotic syndrome with recombinant erythropoietin. Gansevoort RT, et al. **Am J Kidney Dis** 1996 Aug;28(2):274–7 (14 ref.)

Recombinant erythropoietin for zidovudine–induced anemia in AIDS. Kuehl AK, et al. **Ann Pharmacother** 1995 Jul–Aug;29(7–8):778–9 (15 ref.)

Recombinant human erythropoietin in chemotherapy–associated anemia. Cascinu S, et al. **Cancer Treat Rev** 1996 Nov;21(6):553–64 (61 ref.)

Treatment of renal anemia by erythropoietin substitution. The effects on the cardiovascular system. Radermacher J, et al. **Clin Nephrol** 1995 Nov;44 Suppl 1:S56–60 (51 ref.)

Epoetin beta. A review of its pharmacological properties and clinical use in the management of anaemia associated with chronic renal failure. Dunn CJ, et al. **Drugs** 1996 Feb; 51(2):299–318 (91 ref.)

Epoetin alfa. A review of its clinical efficacy in the management of anaemia associated with renal failure and chronic disease and its use in surgical patients. Dunn CJ, et al. **Drugs Aging** 1995 Aug;7(2):131–56 (186 ref.)

rHuEpo before dialysis and in dialysed patients. López–Gómez JM, et al. **Nephrol Dial Transplant** 1995;10 Suppl 6:31–5 (39 ref.)

Poor response to erythropoietin: practical guidelines on investigation and management. Macdougall IC. **Nephrol Dial Transplant** 1995;10(5):607–14 (62 ref.)

Interdependence of vitamin A and iron: an important association for programmes of anaemia control. Bloem MW. **Proc Nutr Soc** 1995 Jul;54(2):501–8 (39 ref.)

ETIOLOGY

Nutritional anemias in infancy. Gallagher PG, et al. **Clin Perinatol** 1995 Sep;22(3):671–92 (127 ref.)

Anemia of cancer. Moliterno AR, et al. **Hematol Oncol Clin North Am** 1996 Apr;10(2):345–63 (78 ref.)

Zonary placenta. Steemers NY, et al. **Int J Gynaecol Obstet** 1995 Dec;51(3):251–3 (3 ref.)

Erythropoiesis and erythropoietin in multiple myeloma. Beguin Y. **Leuk Lymphoma** 1995 Aug;18(5–6):413–21 (135 ref.)

The anemia of inflammation. A common cause of childhood anemia. Abshire TC. **Pediatr Clin North Am** 1996 Jun; 43(3):623–37 (72 ref.)

The aetiology of anaemia . . pregnancy in West Africa. van den Broek N. **Trop Doct** 1996 Jan;26(1):5–7 (16 ref.)

[Treatment of anemia in patients with tumors] Tesařová P, et al. **Cas Lek Cesk** 1995 Oct 18;134(20):647–50 (29 ref.) (Eng. Abstr.) **(Cze)**

[Anemia and hemostasis dysfunction in patients with immunoproliferative disorders] Suehiro A, et al. **Nippon Naika Gakkai Zasshi** 1995 Jul 10;84(7):1091–5 (5 ref.) **(Jpn)**

[Hematologic disturbances in patients with nonhematologic neoplasms. I. Anemias] Kwiatkowski A, et al. **Przegl Lek** 1995;52(8):407–9 (11 ref.) **(Pol)**

PHYSIOPATHOLOGY

Interaction of inflammatory cytokines and erythropoeitin in iron metabolism and erythropoiesis in anaemia of chronic disease. Jongen–Lavrencic M, et al. **Clin Rheumatol** 1995 Sep;14(5):519–25 (93 ref.)

PREVENTION & CONTROL

Management of chemotherapy–induced anemia. Eguchi K. **Curr Opin Oncol** 1995 Jul;7(4):316–9 (33 ref.)

Adult screening for anemia and hemoglobinopathies. **Nurse Pract** 1995 Dec;20(12):48–51 (9 ref.)

THERAPY

Morbidity risk assessment in the surgically anemic patient. Carson JL. **Am J Surg** 1995 Dec;170(6A Suppl):32S–36S (53 ref.)

Endocrinology and PD: optimal treatment of anemia in peritoneal dialysis patients. Bárány P. **Perit Dial Int** 1996; 16 Suppl 1:S260–6 (65 ref.)

[Treatment of anemia in patients with tumors] Tesařová P, et al. **Cas Lek Cesk** 1995 Oct 18;134(20):647–50 (29 ref.) (Eng. Abstr.) **(Cze)**

[Erythropoietin in hematology and oncology. I. Chronic anemia in malignant disease and the pharmacology of erythropoietin] Adam Z, et al. **Vnitr Lek** 1996 Apr; 42(4):285–9 (39 ref.) (Eng. Abstr.) **(Cze)**

[Erythropoietin in oncology. II. Evaluation of the effectiveness of erythropoietin in hematologic and oncologic diseases] Adam Z, et al. **Vnitr Lek** 1996 May; 42(5):351–8 (82 ref.) (Eng. Abstr.) **(Cze)**

[Erythropoiesis and use of hematopoietic growth factors in children] Illum NO. **Ugeskr Laeger** 1996 Jul 15; 158(29):4171–4 (10 ref.) **(Dan)**

[Countermeasure for patients with anemia due to hemodialysis] Suzuki M. **Nippon Naika Gakkai Zasshi** 1995 Oct 10;84(10):1663–7 (5 ref.) **(Jpn)**

ANEMIA, ADDISON'S see **ANEMIA, PERNICIOUS**

ANEMIA, APLASTIC

Bone marrow failure in children. Vlachos A, et al. **Curr Opin Pediatr** 1996 Feb;8(1):33–41 (41 ref.)

CHEMICALLY INDUCED

Severe aplastic anemia induced by ticlopidine: report of a case. Su CC, et al. **J Formos Med Assoc** 1995 Nov; 94(11):689–91 (8 ref.)

COMPLICATIONS

[2 cases of neutropenic enteropathy and bone marrow hypoplasia. An association not reported in Mexico] Gamboa–Domínguez A, et al. **Rev Invest Clin** 1995 Jul–Aug;47(4):303–9 (25 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Hepatocellular carcinoma associated with anabolic steroid therapy: report of a case and review of the Japanese literature. Kosaka A, et al. **J Gastroenterol** 1996 Jun; 31(3):450–4 (24 ref.)

[Recent developments of traditional Chinese medical therapy in treating aplastic anemia] Feng J, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Jun; 15(6):376–8 (21 ref.) **(Chi)**

ETIOLOGY

Interferon or hepatitis C virus induced autoimmune aplastic anemia and severe thrombocytopenia? A case report. Siciliano R, et al. **Ann Ital Med Int** 1995 Jul–Sep; 10(3):193–4 (10 ref.)

NURSING

Hematologic problems in pediatric patients. Cahill M. **Semin Oncol Nurs** 1996 Feb;12(1):38–50 (42 ref.)

THERAPY

Treatment of aplastic anaemia with antilymphocyte globulin and cyclosporin. Marsh JC, et al. **Int J Hematol** 1995 Oct; 62(3):133–44 (79 ref.)

Aplastic anaemia with a trilineage response to erythropoietin therapy. Bernell P. **J Intern Med** 1996 Jan;239(1):79–81 (11 ref.)

Bone marrow transplantation. Storb R. **Transplant Proc** 1995 Oct;27(5):2649–52 (6 ref.)

[Therapeutic approaches of hematopoietic syndrome following accidental total whole body irradiation] Thierry D, et al. **Bull Cancer (Paris)** 1996 May;83(5):361–70 (40 ref.) (Eng. Abstr.) **(Fre)**

[Resolution of psoriasis vulgaris following allogeneic bone marrow transplantation for aplastic anemia] Yokota A, et al. **Rinsho Ketsueki** 1996 Jan;37(1):35–9 (12 ref.) (Eng. Abstr.) **(Jpn)**

ANEMIA, COOLEY'S see **BETA–THALASSEMIA**

ANEMIA, DIAMOND–BLACKFAN see **FANCONI'S ANEMIA**

ANEMIA, DYSERYTHROPOIETIC, CONGENITAL

Congenital dyserythropoietic anemias. Marks PW, et al. **Am J Hematol** 1996 Jan;51(1):55–63 (91 ref.)

ANEMIA, ERYTHROBLASTIC see **BETA–THALASSEMIA**

ANEMIA, FANCONI see **FANCONI'S ANEMIA**

ANEMIA, HEMOLYTIC

Hemolytic anemias in pregnancy. Leduc L. **Clin Obstet Gynecol** 1995 Sep;38(3):463–71 (44 ref.)

Hemolytic anemia in the newborn. Matsunaga AT, et al. **Clin Perinatol** 1995 Sep;22(3):803–28 (76 ref.)

BLOOD

Osmotic scan ektacytometry in clinical diagnosis. Johnson RM, et al. **J Pediatr Hematol Oncol** 1996 May;18(2):122–9 (33 ref.)

DIAGNOSIS

Osmotic scan ektacytometry in clinical diagnosis. Johnson RM, et al. **J Pediatr Hematol Oncol** 1996 May;18(2):122–9 (33 ref.)

[Acute hemolysis—diagnosis and management] Sulek K. **Pol Arch Med Wewn** 1995 May;93(5):395–400 (10 ref.) **(Pol)**

[Hemolytic anemia and kidney failure in a female splenectomy patient] Vargas Pabón M, et al. **Rev Clin Esp** 1996 May;196(5):335–6, 339 (10 ref.) **(Spa)**

ENZYMOLOGY

Molecular basis of erythroenzymopathies associated with hereditary hemolytic anemia: tabulation of mutant enzymes. Miwa S, et al. **Am J Hematol** 1996 Feb;51(2):122–32 (105 ref.)

ETIOLOGY

Hemolytic anemia and cancer. Diehl LF, et al. **Cancer Treat Rev** 1996 Jan;22(1):33–73 (298 ref.)

Hemolytic disorders associated with cancer. Rytting M, et al. **Hematol Oncol Clin North Am** 1996 Apr;10(2):365–76 (87 ref.)

The anemia of inflammation. A common cause of childhood anemia. Abshire TC. **Pediatr Clin North Am** 1996 Jun; 43(3):623–37 (72 ref.)

Fragmentation hemolysis: an unusual indication for valve replacement in native valve infective endocarditis. Gradon JD, et al. **South Med J** 1996 Aug;89(8):818–20 (7 ref.)

GENETICS

Red cell enzymopathies as a model of inborn errors of metabolism. Miwa S, et al. **Southeast Asian J Trop Med Public Health** 1995;26 Suppl 1:112–9 (39 ref.)

PREVENTION & CONTROL

[Quality assurance and prevention of immuno–hemolytic incidents in blood transfusion] Boëlle PY, et al. **Transfus Clin Biol** 1996;3(1):27–34 (26 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

[Acute hemolysis—diagnosis and management] Sulek K. **Pol Arch Med Wewn** 1995 May;93(5):395–400 (10 ref.) **(Pol)**

ANEMIA, HEMOLYTIC, ACQUIRED see **ANEMIA, HEMOLYTIC**

ANEMIA, HEMOLYTIC, AUTOIMMUNE

CHEMICALLY INDUCED

[A case of SLE–like syndrome and severe hemolytic anemia caused by methyldopa] Sakurai Y, et al. **Nippon Naika Gakkai Zasshi** 1995 Dec 10;84(12):2069–71 (9 ref.) **(Jpn)**

DIAGNOSIS

[Chlamydia pneumoniae infection associated with autoimmune hemolytic anemia due to warm antibodies] Belda J, et al. **Arch Bronconeumol** 1996 May;32(5):251–2 (7 ref.) (Eng. Abstr.) **(Spa)**

EPIDEMIOLOGY

Combined autoimmune cytopenias. Martino R, et al. **Haematologica** 1995 Jul–Aug;80(4):305–10 (25 ref.)

ETIOLOGY

Evans' syndrome, myelofibrosis and systemic lupus erythematosus: role of procollagens in myelofibrosis. Ramakrishna R, et al. **Pathology** 1995 Jul;27(3):255–9 (23

ref.)

ANEMIA, HEMOLYTIC, CONGENITAL NONSPHEROCYTIC

BLOOD

Three cases of hereditary nonspherocytic hemolytic anemia associated with red blood cell glutathione deficiency. Hirono A, et al. **Blood** 1996 Mar 1;87(5):2071–4 (28 ref.)

GENETICS

Mutations in pyruvate kinase. Beutler E, et al. **Hum Mutat** 1996;7(1):1–6 (40 ref.)

ANEMIA, HEMOLYTIC, IDIOPATHIC ACQUIRED see **ANEMIA, HEMOLYTIC, AUTOIMMUNE**

ANEMIA, HYPOCHROMIC

ETIOLOGY

[Iron: perspective on the athletic woman] Castillo MC, et al. **Sangre (Barc)** 1995 Jun;40(3):199–205 (82 ref.) **(Spa)**

THERAPY

[Erythropoietin, a milestone in the history of nephrology] Uehlinger DE, et al. **Ther Umsch** 1995 Oct;52(10):672–7 (16 ref.) (Eng. Abstr.) **(Ger)**

ANEMIA, HYPOPLASTIC see **ANEMIA, APLASTIC**

ANEMIA, HYPOPLASTIC, CONGENITAL see **FANCONI'S ANEMIA**

ANEMIA, IRON-DEFICIENCY

Iron deficiency anemia in pregnancy. Schwartz WJ 3rd, et al. **Clin Obstet Gynecol** 1995 Sep;38(3):443–54 (45 ref.)

The young athlete with chronic disease. Small E, et al. **Clin Sports Med** 1995 Jul;14(3):709–26 (144 ref.)

BLOOD

Plasma transferrin receptor helps to predict iron deficiency in the anemia of chronic disease. Fleming D, et al. **Nutr Rev** 1995 Jun;53(6):167–9 (23 ref.)

COMPLICATIONS

One person's view of iron deficiency, development, and cognitive function [see comments] Beard J. **Am J Clin Nutr** 1995 Oct;62(4):709–10 (21 ref.) Comment in: Am J Clin Nutr 1996 Jul;64(1):120–1.

DIAGNOSIS

Plasma transferrin receptor helps to predict iron deficiency in the anemia of chronic disease. Fleming D, et al. **Nutr Rev** 1995 Jun;53(6):167–9 (23 ref.)

DRUG THERAPY

Injectable medications for hemodialysis patients. Stivelman JC. **Am J Nephrol** 1996;16(1):73–8 (55 ref.)

How to diagnose and correct iron deficiency during r-huEPO therapy—a consensus report. Hörl WH, et al. **Nephrol Dial Transplant** 1996 Feb;11(2):246–50 (38 ref.)

[Iron and pregnancy] Beaufrère B, et al. **Arch Pediatr** 1995 Dec;2(12):1209–18 (65 ref.) (Eng. Abstr.) **(Fre)**

NURSING

Hematologic problems in pediatric patients. Cahill M. **Semin Oncol Nurs** 1996 Feb;12(1):38–50 (42 ref.)

ANEMIA, MACROCYTIC

Macrocytic anemia [see comments] Davenport J. **Am Fam Physician** 1996 Jan;53(1):155–62 (30 ref.) Comment in: Am Fam Physician 1996 Aug;54(2):465, 468.

ANEMIA, MEDITERRANEAN see **BETA-THALASSEMIA**

ANEMIA, MEGALOBLASTIC

Megaloblastic anemia in pregnancy. Campbell BA. **Clin Obstet Gynecol** 1995 Sep;38(3):455–62 (44 ref.)

ANEMIA, MICROANGIOPATHIC see **ANEMIA, HEMOLYTIC**

ANEMIA, NEONATAL

Hemolytic anemia in the newborn. Matsunaga AT, et al. **Clin Perinatol** 1995 Sep;22(3):803–28 (76 ref.)

PHYSIOPATHOLOGY

The physiologic impact of anemia in the neonate. Alverson DC. **Clin Perinatol** 1995 Sep;22(3):609–25 (61 ref.)

THERAPY

Recombinant human erythropoietin in neonatal anemia. Shannon K. **Clin Perinatol** 1995 Sep;22(3):627–40 (26 ref.)

Small volume red blood cell transfusions for neonatal patients. Hume H, et al. **Transfus Med Rev** 1995 Jul; 9(3):187–99 (65 ref.)

ANEMIA, PERNICIOUS

DIAGNOSIS

Gastric cancer and pernicious anemia appearing as pseudoachalasia. el-Newihi HM, et al. **South Med J** 1996 Sep;89(9):906–10 (30 ref.)

ANEMIA, REFRACTORY

DIAGNOSIS

Recent-onset myelodysplastic syndrome mimicking acute leukemia during infection. Friedman HD, et al. **Ann Hematol** 1996 Feb;72(2):85–8 (23 ref.)

GENETICS

Molecular analysis of the 5q- chromosome. Nagarajan L. **Leuk Lymphoma** 1995 May;17(5–6):361–6 (37 ref.)

ANEMIA, REFRACTORY, WITH EXCESS OF BLASTS

DIAGNOSIS

[The appearance of Sweet's syndrome during the transition from a myelodysplastic syndrome to erythroleukemia] Grüne S, et al. **Dtsch Med Wochenschr** 1996 Jul 26; 121(30):939–42 (18 ref.) (Eng. Abstr.) **(Ger)**

[Therapy-related leukemia with t(8;21) initially diagnosed as MDS (RAEB in T)] Hanamura A, et al. **Rinsho Ketsueki** 1995 Aug;36(8):755–61 (15 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Therapy-related acute leukemia associated with t(11q23) after primary acute myeloid leukemia with t(8;21): a report of two cases [letter] Roulston D, et al. **Blood** 1995 Nov 1;86(9):3613–4 (7 ref.)

PHYSIOPATHOLOGY

Myelodysplastic syndrome associated with erythrophagocytosis by blasts and myeloid cells. Kuyama J, et al. **Int J Hematol** 1995 Dec;62(4):243–6 (14 ref.)

ANEMIA, SICKLE CELL

Pregnancy complicated by sickle hemoglobinopathy. Rust OA, et al. **Clin Obstet Gynecol** 1995 Sep;38(3):472–84 (42 ref.)

BLOOD

Pharmacologic manipulation of fetal hemoglobin levels in sickle cell diseases and thalassemia: promise and reality. Pearson HA. **Adv Pediatr** 1996;43:309–34 (57 ref.)

COMPLICATIONS

Autoimmune hepatitis in a patient with sickle cell disease. el Younis CM, et al. **Am J Gastroenterol** 1996 May; 91(5):1016–8 (26 ref.)

Sickle cell disease: the clinical manifestations. Childs JW. **J Am Osteopath Assoc** 1995 Oct;95(10):593–8 (46 ref.)

Vertebral bone destruction in sickle cell disease: infection, infarction or both. Kooy A, et al. **Neth J Med** 1996 Jun; 48(6):227–31 (11 ref.)

Systemic lupus erythematosus in a child with sickle cell disease. Eissa MM, et al. **South Med J** 1995 Nov; 88(11):1176–8 (14 ref.)

DIAGNOSIS

Sickle cell disease. Lane PA. **Pediatr Clin North Am** 1996 Jun;43(3):639–64 (108 ref.)

DRUG THERAPY

Pharmacologic manipulation of fetal hemoglobin levels in sickle cell diseases and thalassemia: promise and reality. Pearson HA. **Adv Pediatr** 1996;43:309–34 (57 ref.)

GENETICS

Sickle cell disease and pregnancy. Koshy M. **Blood Rev** 1995 Sep;9(3):157–64 (60 ref.)

Current status of thalassemia and the sickle cell syndromes in Greece. Loukopoulos D. **Semin Hematol** 1996 Jan; 33(1):76–86 (63 ref.)

[Sickle cell anemia: model of variability in expression of monogenic disease (editorial)] Labie D, et al. **Arch Pediatr** 1996 Feb;3(2):101–3 (10 ref.) **(Fre)**

IMMUNOLOGY

New concepts in the immunology of sickle cell disease. Moore CM, et al. **Ann Allergy Asthma Immunol** 1996 May; 76(5):385–400; quiz 400–3 (182 ref.)

METABOLISM

[Stimulation of fetal hemoglobin production in children with sickle cell anemia (editorial)] de Montalembert M. **Arch Pediatr** 1996 Mar;3(3):207–9 (27 ref.) **(Fre)**

NURSING

Nursing management of children with sickle cell disease: an update. Gribbons D, et al. **J Pediatr Nurs** 1995 Aug; 10(4):232–42 (59 ref.)

Hematologic problems in pediatric patients. Cahill M. **Semin Oncol Nurs** 1996 Feb;12(1):38–50 (42 ref.)

PHYSIOPATHOLOGY

The sickle cell painful crisis in adults: phases and objective signs. Ballas SK. **Hemoglobin** 1995;19(6):323–33 (47 ref.)

[Pain crises in patients with sickle cell diseases. Pathogenesis, clinical aspects, therapy] Dickerhoff R, et al. **Klin Padiatr** 1995 Nov-Dec;207(6):321–5 (29 ref.) (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

Neonatal screening for sickle cell disorders: what about the carrier infants? Laird L, et al. **BMJ** 1996 Aug 17; 313(7054):407–11 (51 ref.)

RADIOGRAPHY

[Sickle cell anemia: how to interpret a radiological bone lesion] Tomasini P, et al. **Med Trop (Mars)** 1995; 55(3):216–20 (8 ref.) **(Fre)**

THERAPY

Review: selective filtration—a phlebotomy strategy for sickle cell therapy. Nusbaum NJ. **Am J Med Sci** 1995 Dec; 310(6):264–6 (12 ref.)

[INSERM clinical research network on sickle cell anemia: a tool for therapeutic care and research] Girot R. **Arch Pediatr** 1996;3 Suppl 1:321s–323s (9 ref.) **(Fre)**

ANEMIA, SIDEROBLASTIC

ENZYMOLOGY

Molecular defects of erythroid 5-aminolevulinate synthase in X-linked sideroblastic anemia. Bottomley SS, et al. **J Bioenerg Biomembr** 1995 Apr;27(2):161–8 (50 ref.)

GENETICS

Molecular defects of erythroid 5-aminolevulinate synthase in X-linked sideroblastic anemia. Bottomley SS, et al. **J Bioenerg Biomembr** 1995 Apr;27(2):161–8 (50 ref.)

[The molecular basis and genetics of diseases associated with disorders of heme biosynthesis] Fuchs O. **Cas Lek Cesk** 1996 Jan 17;135(2):54–8 (42 ref.) (Eng. Abstr.) **(Cze)**

METABOLISM

[The molecular basis and genetics of diseases associated with disorders of heme biosynthesis] Fuchs O. **Cas Lek Cesk** 1996 Jan 17;135(2):54–8 (42 ref.) (Eng. Abstr.) **(Cze)**

ANESTHESIA

The laryngeal mask airway—anatomical and physiological implications. Brimacombe J, et al. **Acta Anaesthesiol Scand** 1996 Feb;40(2):201–9 (124 ref.)

Immunomodulation: an important concept in modern anaesthesia. McBride WT, et al. **Anaesthesia** 1996 May; 51(5):465–73 (86 ref.)

Hysteroscopy and anaesthesia. Ananthanarayan C, et al. **Can J Anaesth** 1996 Jan;43(1):56–64 (56 ref.)

The use of fiberoptic endoscopy in anesthesia. Lee AC, et al. **Chest Surg Clin N Am** 1996 May;6(2):329–47 (45 ref.)

Pharmacokinetic-pharmacodynamic relationships for opioids in balanced anaesthesia. Lemmens HJ. **Clin Pharmacokinet** 1995 Oct;29(4):231–42 (69 ref.)

Onset time and evaluation of intubating conditions: rocuronium in perspective. Agoston S. **Eur J Anaesthesiol Suppl** 1995 Sep;11:31–7 (14 ref.)

Neural and endothelial control of the peripheral circulation—implications for anesthesia: Part I. Neural control of the peripheral vasculature. Ebert TJ, et al. **J Cardiothorac Vasc Anesth** 1996 Jan;10(1):147–58 (124 ref.)

Neural and endothelial control of the peripheral circulation—implications for anesthesia: Part II, Endothelium-mediated effects in the normal and diseased circulation. Stowe DF, et al. **J Cardiothorac Vasc Anesth** 1996 Jan;10(1):159–71 (161 ref.)

Antibiotic therapy and the anesthesiologist. Cheng EY, et al. **J Clin Anesth** 1995 Aug;7(5):425–39 (97 ref.)

Nicardipine: applications in anesthesia practice. Tobias JD. **J Clin Anesth** 1995 Sep;7(6):525–33 (56 ref.)

Active cooling during anesthesia and critical care. Illievich UM, et al. **J Neurosurg Anesthesiol** 1996 Jan;8(1):78–82 (56 ref.)

Predicting perioperative stroke. Kim J, et al. **J Neurosurg Anesthesiol** 1995 Jul;7(3):211–5 (24 ref.)

Electrophysiological monitoring and mild hypothermia. Kochs E. **J Neurosurg Anesthesiol** 1995 Jul;7(3):222–8 (56 ref.)

Anaesthesia and craniofacial surgery. Karapurkar SA, et al.

J Postgrad Med 1994 Jan-Mar;40(1):3-6 (6 ref.)
Down's syndrome and anaesthesia. Mitchell V, et al. **Paediatr Anaesth** 1995;5(6):379-84 (49 ref.)
Anaesthesia in children with viral respiratory tract infections. Van der Walt J. **Paediatr Anaesth** 1995;5(4):257-62 (25 ref.)
Molecular mechanisms of neuromuscular blocking agents: is the increased understanding of importance to the practising anaesthetist? Aglan MY, et al. **Pharmacol Ther** 1995; 68(3):365-83 (76 ref.)
[Progresses in anesthesiology in China, 1995] Jin Q, et al. **Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):746-7 (0 ref.) **(Chi)**
[French Society of Anesthesia and Intensive Care. Arterial catheterization and invasive measurement of blood pressure in anesthesia and intensive care in adults] **Ann Fr Anesth Reanim** 1995;14(5):444-53 (6611 ref.) (Eng. Abstr.) **(Fre)**
[Indications for the use of magnesium in anesthesia and intensive care] Desmeau A, et al. **Ann Fr Anesth Reanim** 1995;14(5):406-16 (113 ref.) (Eng. Abstr.) **(Fre)**
[Myocardial ischemia and anesthesia] Lehot JJ, et al. **Ann Fr Anesth Reanim** 1995;14(2):176-97 (210 ref.) (Eng. Abstr.) **(Fre)**
[Effects of anesthesia on postoperative micturition and urinary retention] Pertek JP, et al. **Ann Fr Anesth Reanim** 1995;14(4):340-51 (44 ref.) (Eng. Abstr.) **(Fre)**
[Analysis of heart rate variability. Background, method, and possible use in anesthesia] Baumert JH, et al. **Anaesthesist** 1995 Oct;44(10):677-86 (79 ref.) (Eng. Abstr.) **(Ger)**
[Anesthesiologic pecularities in patients with latex allergy (see comments)] Kisch H, et al. **Anaesthesist** 1996 Jul; 45(7):587-96 (88 ref.) (Eng. Abstr.) Comment in: Anaesthesist 1996 Jul;45(7):585-6. **(Ger)**
[Difficult intubation in adults] Langenstein H, et al. **Anaesthesist** 1996 Apr;45(4):372-83 (39 ref.) (Eng. Abstr.) **(Ger)**
[Anesthesia and the liver] Nöldge-Schomburg GF, et al. **Anaesthesist** 1996 Jun;45(6):567-83 (10 ref.) **(Ger)**
[Intraoperative cardiac risk and preoperative examinations from the anesthetic viewpoint] Rolf N, et al. **Dtsch Med Wochenschr** 1996 Apr 5;121(14):453-8 (47 ref.) **(Ger)**
[Anesthetic management for endoscopic surgery] Kazama T. **Masui** 1995;44 Suppl:S83-92 (11 ref.) **(Jpn)**
[Balanced anesthesia for postoperative management] Namiki A, et al. **Masui** 1995;44 Suppl:S162-6; discussion S173-6 (1 ref.) **(Jpn)**
[Anticancer therapy and anesthetic implications] Nishino T. **Masui** 1995;44 Suppl:S40-4 (16 ref.) **(Jpn)**
[The present state of balanced anesthesia--combination of intravenous and inhaled anesthetics] Sumikawa K, et al. **Masui** 1995;44 Suppl:S149-52; discussion S156-7 (10 ref.) **(Jpn)**

ADVERSE EFFECTS

Minimising cardiac anaesthetic risk: the tortoise or the hare? Juste RN, et al. **Anaesthesia** 1996 Mar;51(3):255-62 (63 ref.)
Severe neurologic deficit after nitrous oxide anesthesia. Hadzic A, et al. **Anesthesiology** 1995 Oct;83(4):863-6 (14 ref.)
The etiology and management of inadvertent perioperative hypothermia. Forstot RM. **J Clin Anesth** 1995 Dec; 7(8):657-74 (188 ref.)
Impact of anesthetic management on the outcome of cardiac patients for non-cardiac surgery. Gabriel FS. **Middle East J Anesthesiol** 1996 Feb;13(4):385-93 (20 ref.)

METHODS

Obesity: an anaesthetic challenge. Oberg B, et al. **Acta Anaesthesiol Scand** 1996 Feb;40(2):191-200 (88 ref.)
Recovery from outpatient anaesthesia. Factors affecting outcome. Korttila K. **Anaesthesia** 1995 Oct;50 Suppl:22-8 (63 ref.)
Measuring the performance of anesthetic depth indicators. Smith WD, et al. **Anesthesiology** 1996 Jan;84(1):38-51 (61 ref.)
Co-induction of anaesthesia: the rationale. Amrein R, et al. **Eur J Anaesthesiol Suppl** 1995 Nov;12:5-11 (41 ref.)
Anesthetic considerations for descending thoracic aortic surgery: Part 1. O'Connor CJ, et al. **J Cardiothorac Vasc Anesth** 1995 Oct;9(5):581-8 (63 ref.)
Monitored anesthesia care: how much sedation, how much analgesia? Smith I. **J Clin Anesth** 1996 May;8(3 Suppl):76S-80S (19 ref.)
Anesthesia for carotid stent procedures. Kharrazi MR. **J Endovasc Surg** 1996 May;3(2):211-6 (8 ref.)
Anesthesia and head trauma. McGrath BJ, et al. **New Horiz** 1995 Aug;3(3):523-33 (103 ref.)
Anesthesia for living related donor liver transplantation. Jawan B, et al. **Transplant Proc** 1996 Aug;28(4):2409-11 (39 ref.)
Anesthetic considerations in the geriatric patient. Burney TL, et al. **Urol Clin North Am** 1996 Feb;23(1):19-26 (20 ref.)
[Diabetes and anesthesia: perioperative management of the diabetic patient] Brogard JM, et al. **Ann Fr Anesth Reanim** 1995;14(6):523-31 (28 ref.) **(Fre)**
[Pediatric anesthesia. Induction, sustaining, awakening] Bissonnette B. **Rev Med Suisse Romande** 1996 Apr; 116(4):239-42 (16 ref.) **(Fre)**
[Transthoracic endoscopic sympathectomy--anesthetic aspects] Rozenberg B, et al. **Harefuah** 1996 Mar 15; 130(6):430-2 (21 ref.) **(Heb)**
[Anesthesia in experimental animals. Basic principles] Cruz JI. **Rev Esp Anestesiol Reanim** 1996 Mar;43(3):99-107 (54 ref.) (Eng. Abstr.) **(Spa)**
[Special anesthesia care in heart transplantation. The management of right ventricular failure] Gómez-Arnau J, et al. **Rev Esp Cardiol** 1995;48 Suppl 7:60-4 (22 ref.) (Eng. Abstr.) **(Spa)**

MORTALITY

[Death under anesthesia. Definition, causes, risk factors and prevention] Maalge R, et al. **Ugeskr Laeger** 1995 Nov 20; 157(47):6561-5 (38 ref.) (Eng. Abstr.) **(Dan)**

NURSING

The perioperative nurse's role in anesthesia management. Stein RH. **AORN J** 1995 Nov;62(5):794-8, 801, 803-4 (21 ref.)

TRENDS

[Prospects of balanced anesthesia--combination with propofol] Shingu K, et al. **Masui** 1995;44 Suppl:S158-61; discussion S173-6 (6 ref.) **(Jpn)**

VETERINARY

Anesthetic management of the trauma patient. Cuvelliez S, et al. **Vet Clin North Am Small Anim Pract** 1995 Sep; 25(5):1073-92 (42 ref.)
[Sedation and anesthesia in dogs and cats with cardiovascular diseases. I. Anesthesia plan considering risk assessment, hemodynamic effects of drugs and monitoring] Skarda RT, et al. **Schweiz Arch Tierheilkd** 1995;137(7):312-21 (13 ref.) (Eng. Abstr.) **(Ger)**

ANESTHESIA ASSISTANTS see **PHYSICIAN ASSISTANTS**

ANESTHESIA, CLOSED-CIRCUIT

Low-flow anaesthesia. Baum JA, et al. **Anaesthesia** 1995 Oct; 50 Suppl:37-44 (43 ref.)

INSTRUMENTATION

[Anesthesia with low fresh gas flow in clinical routine use (see comments)] Hargasser S, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Aug; 30(5):268-75 (79 ref.) (Eng. Abstr.) Comment in: Anasthesiol Intensivmed Notfallmed Schmerzther 1995 Aug;30(5):265-7. **(Ger)**

ANESTHESIA, CONDUCTION

MUJA: manipulation under joint anesthesia/analgesia: a treatment approach for recalcitrant low back pain of synovial joint origin. Dreyfuss P, et al. **J Manipulative Physiol Ther** 1995 Oct;18(8):537-46 (107 ref.)
Clinical aspects of CRNA practice. Regional anesthesia. Spitzer LE. **Nurs Clin North Am** 1996 Sep;31(3):643-65 (20 ref.)
[Reflex sympathetic algodystrophies. Preventive and therapeutic aspects] Viel E, et al. **Cah Anesthesiol** 1995; 43(6):565-71 (69 ref.) (Eng. Abstr.) **(Fre)**
[Analgesia and sedation to supplement incomplete regional anesthesia] Wresch KP. **Anaesthesist** 1995 Dec;44 Suppl 3:S580-7 (102 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

[What are the complications likely to lead to medicolegal problems? How to manage them?] Samii K, et al. **Cah Anesthesiol** 1995;43(6):521-4 (20 ref.) **(Fre)**

ECONOMICS

Practical, cost-effective regional anesthesia for ambulatory surgery. Greenberg CP. **J Clin Anesth** 1995 Nov; 7(7):614-21 (32 ref.)

METHODS

[Which operations can be done without general anesthesia?] Tarkkila P, et al. **Duodecim** 1995;111(4):365-9 (5 ref.) **(Fin)**

TRENDS

[What is new in pediatric loco-regional anesthesia?] Ecoffey C. **Rev Med Suisse Romande** 1996 Apr;116(4):243-6 (28 ref.) **(Fre)**

ANESTHESIA, DENTAL

Four common mandibular nerve anomalies that lead to local anesthesia failures. DeSantis JL, et al. **J Am Dent Assoc** 1996 Jul;127(7):1081-6 (25 ref.)
A review of important elements in sedation study methodology. Wilson S. **Pediatr Dent** 1995 Nov-Dec; 17(7):406-12 (57 ref.)
[General ambulatory anesthesia in oral medicine and maxillofacial surgery] Boufflers E, et al. **Rev Stomatol Chir Maxillofac** 1995;96(4):247-58 (22 ref.) **(Fre)**

METHODS

[Hypnotic desensitization as a supplemental method in dental care of patients with panic disorder. Report of a case] Fábián TK. **Fogorv Sz** 1996 Feb;89(2):57-62 (19 ref.) **(Hun)**
[Highlights in the subject of low frequency-high intensity TENS (review)] Galletti SP, et al. **Minerva Stomatol** 1995 Sep;44(9):421-9 (41 ref.) (Eng. Abstr.) **(Ita)**

ANESTHESIA, EPIDURAL

Hypotensive epidural anesthesia for total hip arthroplasty: a review [see comments] Sharrock NE, et al. **Acta Orthop Scand** 1996 Feb;67(1):91-107 (105 ref.) Comment in: Acta Orthop Scand 1996 Feb;67(1):1.
A review of anatomical and immunological links between epidural morphine and herpes simplex labialis in obstetric patients. Boyle RK. **Anaesth Intensive Care** 1995 Aug; 23(4):425-32 (41 ref.)
[Epidural anesthesia for labor] Dailland P, et al. **Cah Anesthesiol** 1996;44(2):127-43 (24 ref.) (Eng. Abstr.) **(Fre)**
[The high risk cardiac patient in anesthesia] Francke A. **Anaesthesiol Reanim** 1996;21(2):32-42 (89 ref.) (Eng. Abstr.) **(Ger)**
[Cardiovascular interaction and anesthesia] Hoka S. **Masui** 1995;44 Suppl:S52-8 (15 ref.) **(Jpn)**
[Temperature changes and thermoregulatory responses during epidural anesthesia in women undergoing cesarean delivery] Negishi C, et al. **Masui** 1996 May;45(5):558-64 (17 ref.) (Eng. Abstr.) **(Jpn)**
[Balanced anesthesia with epidural anesthesia] Yuge O, et al. **Masui** 1995;44 Suppl:S153-5; discussion S156-7 (13 ref.) **(Jpn)**
[Epidural anesthesia and postoperative analgesia] Yokoyama K. **Nippon Ika Daigaku Zasshi** 1995 Oct;62(5):413-9 (30 ref.) **(Jpn)**
[A case report of vaginal delivery controlled by epidural anesthesia in a woman with high spinal cord injury] Kase H, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Sep; 47(9):957-60 (14 ref.) **(Jpn)**

ADVERSE EFFECTS

Neurological complications of central nerve blocks [editorial; comment] Renck H. **Acta Anaesthesiol Scand** 1995 Oct; 39(7):859-68 (93 ref.) Comment on: Acta Anaesthesiol Scand 1995 Oct;39(7):872-80.
The risk of extradural abscess [editorial] Carson D, et al. **Br J Anaesth** 1995 Nov;75(5):520-1 (13 ref.)
Impaired haemostasis and regional anaesthesia. Stafford-Smith M. **Can J Anaesth** 1996 May;43(5 Pt 2):R129-41 (33 ref.) **(Eng, Fre)**
Epidurals redefined in analgesia and anesthesia: a distinction with a difference. Youngstrom PC, et al. **J Obstet Gynecol Neonatal Nurs** 1996 May;25(4):350-4 (14 ref.)
Auditory, ocular, and facial complications of central neural block. A review of possible mechanisms. Day CJ, et al. **Reg Anesth** 1996 May-Jun;21(3):197-201 (28 ref.)
[Management of neurologic manifestations after obstetrical epidural anesthesia] Frangié S, et al. **Cah Anesthesiol** 1995; 43(5):455-60 (43 ref.) (Eng. Abstr.) **(Fre)**
[Puncture of the dura mater, diagnosis and treatment in obstetrics] Villalpando Bravo J, et al. **Ginecol Obstet Mex** 1996 Feb;64:85-9 (35 ref.) (Eng. Abstr.) **(Spa)**

STANDARDS

Anaesthesia for caesarean section (epidural and general): effects on the neonate. Dick WF. **Eur J Obstet Gynecol Reprod Biol** 1995 May;59 Suppl:S61-7 (42 ref.)

ANESTHESIA, EXTRADURAL see **ANESTHESIA, EPIDURAL**

ANESTHESIA, GENERAL

Anaesthesia for patients with renal impairment. Cranshaw J, et al. **Br J Hosp Med** 1996 Feb 21-Mar 5;55(4):171-5 (23 ref.)
Anaesthesia for day-case surgery. Hitchcock M, et al. **Br J Hosp Med** 1995 Sep 6-19;54(5):202-6 (20 ref.)
Learning during anaesthesia: a review. Andrade J. **Br J Psychol** 1995 Nov;86 (Pt 4):479-506 (110 ref.)
Anaesthesia for major vascular surgery. Beattie C. **Can J Anaesth** 1996 May;43(5 Pt 2):R3-13 (5 ref.) **(Eng, Fre)**
The patient with a pacemaker or related device. Bourke ME. **Can J Anaesth** 1996 May;43(5 Pt 2):R24-41 (28 ref.) **(Eng, Fre)**
Trends in neuroanaesthesia. Cottrell JE. **Can J Anaesth** 1996 May;43(5 Pt 2):R61-74 (73 ref.) **(Eng, Fre)**
The diabetic patient: a challenge or just routine? Ralley FE. **Can J Anaesth** 1996 May;43(5 Pt 2):R14-23 (18 ref.) **(Eng, Fre)**
The patient with heart disease. Ramsay J. **Can J Anaesth**

1996 May;43(5 Pt 2):R99–107 (28 ref.) **(Eng, Fre)**

Anaesthesia and the transplanted patient. Sharpe MD. **Can J Anaesth** 1996 May;43(5 Pt 2):R89–98 (9 ref.) **(Eng, Fre)**

Anesthetic considerations for descending thoracic aortic surgery: part II. O'Connor CJ, et al. **J Cardiothorac Vasc Anesth** 1995 Dec;9(6):734–47 (126 ref.)

Anesthesia for living-related (lobar) lung transplantation. Quinlan JJ, et al. **J Cardiothorac Vasc Anesth** 1996 Apr; 10(3):391–6 (35 ref.)

Recovery advantages of regional anesthesia compared with general anesthesia: adult patients. Mingus ML. **J Clin Anesth** 1995 Nov;7(7):628–33 (69 ref.)

Pediatric ambulatory anesthesia: NPO—before or after surgery? Schreiner MS, et al. **J Clin Anesth** 1995 Nov; 7(7):589–96 (41 ref.)

An information processing theory of anaesthesia. Flohr H. **Neuropsychologia** 1995 Sep;33(9):1169–80 (74 ref.)

Anaesthesia and recently vaccinated children. van der Walt JH, et al. **Paediatr Anaesth** 1996;6(2):135–41 (18 ref.)

Anesthetic actions within the spinal cord: contributions to the state of general anesthesia. Collins JG, et al. **Trends Neurosci** 1995 Dec;18(12):549–53 (42 ref.)

[Awareness during general anesthesia (editorial)] Ranta S, et al. **Duodecim** 1994;110(21):1967–9 (15 ref.) **(Fin)**

[General ambulatory anesthesia in oral medicine and maxillofacial surgery] Boufflers E, et al. **Rev Stomatol Chir Maxillofac** 1995;96(4):247–58 (22 ref.) **(Fre)**

[The high risk cardiac patient in anesthesia] Francke A. **Anaesthesiol Reanim** 1996;21(2):32–42 (89 ref.) (Eng. Abstr.) **(Ger)**

[Anesthesiologic problems in polytrauma patients] Radke J. **Anaesthesiol Reanim** 1995;20(2):32–6 (6 ref.) (Eng. Abstr.) **(Ger)**

[Adrenergic beta receptors in anesthesia and intensive care medicine] Heesen M, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Mar; 31(2):62–71 (154 ref.) (Eng. Abstr.) **(Ger)**

[Medicamentous prevention of acid aspiration syndrome] Kurz-Müller K, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May; 31(4):261–5 (77 ref.) **(Ger)**

[Antagonists in anesthesia] Lauven PM, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Oct; 30(6):331–6 (34 ref.) (Eng. Abstr.) **(Ger)**

[Treatment of aspiration of gastric contents] Müller E. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May; 31(4):265–9 (24 ref.) **(Ger)**

[Clinical potency of nitrous oxide—is MAC the gold standard?] Schwilden H, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Oct; 30(6):337–40 (23 ref.) (Eng. Abstr.) **(Ger)**

[Do general anesthetics act on specific receptors?] Urban BW, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Oct;30(6):375–82 (55 ref.) (Eng. Abstr.) **(Ger)**

[Anesthesiologic procedures in laparoscopic cholecystectomy] Wilhelm W, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Nov; 30(7):450–4 (18 ref.) **(Ger)**

–Complications of hysteroscopy and laparoscopy from the anesthesiologic viewpoint– Zollinger A. **Arch Gynecol Obstet** 1995;256 Suppl:S12–20 (25 ref.) **(Ger)**

[Complications of patient positioning] Staender S. **Swiss Surg** 1995;(3):152–5 (16 ref.) (Eng. Abstr.) **(Ger)**

[Balanced anesthesia—historical aspect] Dohi S. **Masui** 1995; 44 Suppl:S141–3; discussion S147–8 (10 ref.) **(Jpn)**

[Cardiovascular interaction and anesthesia] Hoka S. **Masui** 1995;44 Suppl:S52–8 (15 ref.) **(Jpn)**

[Bronchospasm during anesthesia in a patient with Prader-Willi syndrome] Kawahito S, et al. **Masui** 1995 Dec;44(12):1675–9 (19 ref.) (Eng. Abstr.) **(Jpn)**

[Balanced anesthesia with epidural anesthesia] Yuge O, et al. **Masui** 1995;44 Suppl:S153–5; discussion S156–7 (13 ref.) **(Jpn)**

ADVERSE EFFECTS

Acute lung injury following lung resection: is one lung anaesthesia to blame? [editorial] Williams EA, et al. **Thorax** 1996 Feb;51(2):114–6 (41 ref.)

ECONOMICS

Practical cost-effective choices: ambulatory general anesthesia. Philip BK. **J Clin Anesth** 1995 Nov;7(7):606–13 (31 ref.)

METHODS

Review of uses of the laryngeal mask in ENT anaesthesia [see comments] Nair I, et al. **Anaesthesia** 1995 Oct; 50(10):898–900 (27 ref.) Comment in: Anaesthesia 1996 Apr;51(4):409.

Anaesthesia for cardioversion. Stoneham MD. **Anaesthesia** 1996 Jun;51(6):565–70 (69 ref.)

Anaesthesia for heart transplantation. Hussain A. **Br J Hosp Med** 1995 Nov 1–14;54(9):466–8 (5 ref.)

Anaesthesia for cerebral aneurysm surgery. Nathanson M, et al. **Br J Hosp Med** 1995 Oct 18–31;54(8):405–8 (12 ref.)

Twelve hour anaesthesia in a patient with epidermolysis bullosa. Yonker-Sell AE, et al. **Can J Anaesth** 1995 Aug; 42(8):735–9 (25 ref.)

Clinical aspects of CRNA practice. General anesthesia. Ouellette SM. **Nurs Clin North Am** 1996 Sep;31(3):623–42 (102 ref.)

Acute lung injury following lung resection: is one lung anaesthesia to blame? [editorial] Williams EA, et al. **Thorax** 1996 Feb;51(2):114–6 (41 ref.)

PSYCHOLOGY

Psychological and hypnotic preparation for anesthesia and surgery: an individual differences perspective. Kessler R, et al. **Int J Clin Exp Hypn** 1996 Jul;44(3):189–207 (60 ref.)

[Awareness during general anesthesia. Definition, incidence, clinical relevance, causes, avoidance and medicolegal aspects] Schwender D, et al. **Anaesthesist** 1995 Nov; 44(11):743–54 (84 ref.) (Eng. Abstr.) **(Ger)**

STANDARDS

Anaesthesia for caesarean section (epidural and general): effects on the neonate. Dick WF. **Eur J Obstet Gynecol Reprod Biol** 1995 May;59 Suppl:S61–7 (42 ref.)

ANESTHESIA, INFILTRATION see **ANESTHESIA, LOCAL**

ANESTHESIA, INHALATION

Ventilatory responses to hypoxia and hypercapnia during inhalation anaesthesia and subparalytical muscle relaxation in humans [see comments] Lindahl SG. **Acta Anaesthesiol Sin** 1995 Dec;33(4):223–6 (13 ref.) Comment in: Acta Anaesthesiol Sin 1995 Dec;33(4):i–ii.

Sevoflurane in pediatric anesthesia. Lerman J. **Anesth Analg** 1995 Dec;81(6 Suppl):S4–10 (47 ref.)

The role of sevoflurane in outpatient anesthesia. Smith I, et al. **Anesth Analg** 1995 Dec;81(6 Suppl):S67–72 (24 ref.)

Anaesthetic management of the Kenny-Caffey syndrome using the laryngeal mask. Janke EL, et al. **Paediatr Anaesth** 1996;6(3):235–8 (16 ref.)

[Clinical potency of nitrous oxide—is MAC the gold standard?] Schwilden H, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Oct; 30(6):337–40 (23 ref.) (Eng. Abstr.) **(Ger)**

[An advanced anesthetic management for small children] Kitamura S, et al. **Masui** 1995;44 Suppl:S93–9 (27 ref.) **(Jpn)**

ADVERSE EFFECTS

[Anesthesia for celiosurgery] Schoeffler P, et al. **Ann Chir** 1995;49(10):878–80 (19 ref.) **(Fre)**

METHODS

Inhalation anaesthesia at the extremes of age: geriatric anaesthesia. Conzen P, et al. **Anaesthesia** 1995 Oct;50 Suppl:29–33 (33 ref.)

Inhalational anaesthesia at the extremes of age: paediatric anaesthesia. Olsson GL. **Anaesthesia** 1995 Oct;50 Suppl:34–6 (21 ref.)

ANESTHESIA, INTRATRACHEAL

INSTRUMENTATION

[Intubation trauma of the larynx—a literature review with special reference to arytenoid cartilage dislocation (see comments)] Rieger A, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Jun; 31(5):281–7 (37 ref.) (Eng. Abstr.) Comment in: Anasthesiol Intensivmed Notfallmed Schmerzther 1996 Jun;31(5):279–80. **(Ger)**

ANESTHESIA, INTRAVENOUS

Flumazenil and midazolam in anaesthesia. Whitwam JG. **Acta Anaesthesiol Scand Suppl** 1995;108:15–22 (67 ref.)

Anaesthesia for day-case surgery. Hitchcock M, et al. **Br J Hosp Med** 1995 Sep 6–19;54(5):202–6 (20 ref.)

Intravenous anaesthesia: new drugs, new concepts, and clinical applications. Miller DR. **Can J Anaesth** 1996 May; 43(5 Pt 2):R142–54 (18 ref.) **(Eng, Fre)**

Co-induction of anaesthesia: the cardiac patient. Duthie DJ. **Eur J Anaesthesiol Suppl** 1995 Nov;12:21–4 (26 ref.)

Intravenous anaesthetic drug interactions: practical applications. Vinik HR. **Eur J Anaesthesiol Suppl** 1995 Nov; 12:13–9 (23 ref.)

Co-induction of anaesthesia: day-case surgery. Whitwam JG. **Eur J Anaesthesiol Suppl** 1995 Nov;12:25–34 (50 ref.)

Total intravenous anesthesia—a pharmacokinetic approach. Bovill JG. **Middle East J Anesthesiol** 1995 Feb;13(1):37–60 (36 ref.)

[Gamma-hydroxybutyric acid—significance for anesthesia and intensive care medicine?] Kleinschmidt S, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Nov; 30(7):393–402 (59 ref.) (Eng. Abstr.) **(Ger)**

[Intravenous anesthesia—current aspects] Schraag S, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Dec; 30(8):469–78 (72 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Implications of automation surprises in aviation for the future of total intravenous anesthesia (TIVA). Cook RI, et al. **J Clin Anesth** 1996 May;8(3 Suppl):29S–37S (49 ref.)

Intravenous anesthesia and analgesia: what is the role of target-controlled infusion? White PF. **J Clin Anesth** 1996 May;8(3 Suppl):26S–28S (22 ref.)

Clinical aspects of CRNA practice. General anesthesia. Ouellette SM. **Nurs Clin North Am** 1996 Sep;31(3):623–42 (102 ref.)

ANESTHESIA, LOCAL

see related **ANESTHETICS, LOCAL**

What is the role of diphenhydramine in local anesthesia? [editorial; comment] Green SM. **Acad Emerg Med** 1996 Mar;3(3):198–200 (11 ref.) Comment on: Acad Emerg Med 1996 Mar;3(3):228–33.

Local anesthetics. Skidmore RA, et al. **Dermatol Surg** 1996 Jun;22(6):511–22; quiz 523–4 (83 ref.)

Four common mandibular nerve anomalies that lead to local anesthesia failures. DeSantis JL, et al. **J Am Dent Assoc** 1996 Jul;127(7):1081–6 (25 ref.)

Con: unreliable benefit after thoracotomy—epidural is a better choice [comment] Riegler FX. **J Cardiothorac Vasc Anesth** 1996 Apr;10(3):429–31 (20 ref.) Comment on: J Cardiothorac Vasc Anesth 1996 Apr;10(3):425–8.

Techniques to reduce the discomfort of paediatric laceration repair. Roberts PA, et al. **Med J Aust** 1996 Jan 1; 164(1):32–5 (37 ref.)

Local anaesthetic agents in infancy. Eyres RL. **Paediatr Anaesth** 1995;5(4):213–8 (47 ref.)

[Use of topical anesthesia—EMLA cream] Raveh T, et al. **Harefuah** 1996 Apr 1;130(7):490–1 (26 ref.) **(Heb)**

METHODS

Pro: intrapleural anesthesia is useful for thoracic analgesia [see comments] McIlvaine WB. **J Cardiothorac Vasc Anesth** 1996 Apr;10(3):425–8 (41 ref.) Comment in: J Cardiothorac Vasc Anesth 1996 Apr;10(3):429–31.

TRENDS

[What is new in pediatric loco-regional anesthesia?] Ecoffey C. **Rev Med Suisse Romande** 1996 Apr;116(4):243–6 (28 ref.) **(Fre)**

ANESTHESIA, OBSTETRICAL

A review of anatomical and immunological links between epidural morphine and herpes simplex labialis in obstetric patients. Boyle RK. **Anaesth Intensive Care** 1995 Aug; 23(4):425–32 (41 ref.)

Spinal anaesthesia in obstetrics. Morgan P. **Can J Anaesth** 1995 Dec;42(12):1145–63 (134 ref.)

[Temperature changes and thermoregulatory responses during epidural anesthesia in women undergoing cesarean delivery] Negishi C, et al. **Masui** 1996 May;45(5):558–64 (17 ref.) (Eng. Abstr.) **(Jpn)**

[A case report of vaginal delivery controlled by epidural anesthesia in a woman with high spinal cord injury] Kase H, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Sep; 47(9):957–60 (14 ref.) **(Jpn)**

ADVERSE EFFECTS

Maternal sequelae of childbirth [editorial] Reynolds F. **Br J Anaesth** 1995 Nov;75(5):515–7 (26 ref.)

Epidurals redefined in analgesia and anesthesia: a distinction with a difference. Youngstrom PC, et al. **J Obstet Gynecol Neonatal Nurs** 1996 May;25(4):350–4 (14 ref.)

METHODS

[Advantages and disadvantages of induced labor without medical indications: the viewpoint of the anesthesiologist] Hamza J. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24 Suppl 1:97–107 (49 ref.) **(Fre)**

[Puncture of the dura mater, diagnosis and treatment in obstetrics] Villalpando Bravo J, et al. **Ginecol Obstet Mex** 1996 Feb;64:85–9 (35 ref.) (Eng. Abstr.) **(Spa)**

ANESTHESIA, PERIDURAL see **ANESTHESIA, EPIDURAL**

ANESTHESIA, REBREATHING see **ANESTHESIA, CLOSED-CIRCUIT**

ANESTHESIA RECOVERY PERIOD

Spontaneous recovery or evoked reversal of neuromuscular block. Mirakhur RK. **Acta Anaesthesiol Scand Suppl** 1995; 106:62–5 (25 ref.)

Recovery from outpatient anaesthesia. Factors affecting outcome. Korttila K. **Anaesthesia** 1995 Oct;50 Suppl:22–8 (63 ref.)

Recovery room problems or problems in the PACU. Rose DK. **Can J Anaesth** 1996 May;43(5 Pt 2):R116–28 (50 ref.) **(Eng, Fre)**

Pediatric postanesthesia recovery care. Hall SC. **J Clin Anesth** 1995 Nov;7(7):600–5 (27 ref.)

Recovery advantages of regional anesthesia compared with general anesthesia: adult patients. Mingus ML. **J Clin Anesth** 1995 Nov;7(7):628–33 (69 ref.)

ANESTHESIA, RECTAL

[Rectal administration of anesthetic agents] Ceriana P, et al. **Minerva Anestesiol** 1995 May;61(5):219–28 (33 ref.) (Eng. Abstr.) **(Ita)**

ANESTHESIA, REFRIGERATION see **HYPOTHERMIA, INDUCED**

ANESTHESIA, REGIONAL see **ANESTHESIA, CONDUCTION**

ANESTHESIA, SPINAL

Spinal anaesthesia in obstetrics. Morgan P. **Can J Anaesth** 1995 Dec;42(12):1145–63 (134 ref.)

Spinal anesthesia for outpatients: appropriate agents and techniques. Mulroy MF, et al. **J Clin Anesth** 1995 Nov; 7(7):622–7 (39 ref.)

ADVERSE EFFECTS

Neurological complications of central nerve blocks [editorial; comment] Renck H. **Acta Anaesthesiol Scand** 1995 Oct; 39(7):859–68 (93 ref.) Comment on: Acta Anaesthesiol Scand 1995 Oct;39(7):872–80.

Impaired haemostasis and regional anaesthesia. Stafford-Smith M. **Can J Anaesth** 1996 May;43(5 Pt 2):R129–41 (33 ref.) **(Eng, Fre)**

Auditory, ocular, and facial complications of central neural block. A review of possible mechanisms. Day CJ, et al. **Reg Anesth** 1996 May–Jun;21(3):197–201 (28 ref.)

ANESTHESIOLOGY

The practice of anaesthesia--a stressor for the middle-aged? Seeley HF. **Anaesthesia** 1996 Jun;51(6):571–4 (16 ref.)

Technology assessment: a Canadian perspective. Byrick RJ. **Can J Anaesth** 1996 May;43(5 Pt 2):R108–15 (20 ref.) **(Eng, Fre)**

Quality in anaesthesia: an integrated and constructive model. Hardy JF, et al. **Can J Anaesth** 1996 May;43(5 Pt 2):R75–88 (23 ref.) **(Eng, Fre)**

Patient data management systems in anaesthesia: an emerging technology. Weiss YG, et al. **Can J Anaesth** 1995 Oct; 42(10):914–21 (32 ref.)

Receptor regulation: why should an anesthesiologist care? Smiley RM. **J Clin Anesth** 1996 May;8(3 Suppl):42S–47S (40 ref.)

Injury prevention in anesthesiology. Berry AJ. **Surg Clin North Am** 1995 Dec;75(6):1123–32 (21 ref.)

EDUCATION

Virtual reality in anaesthesia. Burt DE. **Br J Anaesth** 1995 Oct;75(4):472–80 (20 ref.)

INSTRUMENTATION

Anesthesia systems. **Health Devices** 1996 May–Jun; 25(5–6):158–211 (25 ref.)

Laryngeal mask airway: uses in anesthesiology. Pinosky M. **South Med J** 1996 Jun;89(6):551–5 (21 ref.)

[Problems and limits in noninvasive oxygen monitoring] Bardenheuer HJ, et al. **Anaesthesist** 1996 Jul;45(7):614–25 (86 ref.) (Eng. Abstr.) **(Ger)**

LEGISLATION & JURISPRUDENCE

[Closed claims analysis of anesthesia in Japan] Ito Y. **Masui** 1995;44 Suppl:S179–82 (7 ref.) **(Jpn)**

METHODS

Measuring the performance of anesthetic depth indicators. Smith WD, et al. **Anesthesiology** 1996 Jan;84(1):38–51 (61 ref.)

TRENDS

Research in anaesthesia--the key to the future [editorial] Smith G. **Br J Anaesth** 1995 Oct;75(4):383–6 (5 ref.)

ANESTHETICS

[Balanced anesthesia for postoperative management] Namiki A, et al. **Masui** 1995;44 Suppl:S162–6; discussion S173–6 (1 ref.) **(Jpn)**

[Balanced anesthesia with epidural anesthesia] Yuge O, et al. **Masui** 1995;44 Suppl:S153–5; discussion S156–7 (13 ref.) **(Jpn)**

ADVERSE EFFECTS

Neurological and psychiatric adverse effects of anaesthetics: epidemiology and treatment. Klafta JM, et al. **Drug Saf** 1995 Nov;13(5):281–95 (137 ref.)

[Effects of anesthesia on postoperative micturition and urinary retention] Pertek JP, et al. **Ann Fr Anesth Reanim** 1995;14(4):340–51 (44 ref.) (Eng. Abstr.) **(Fre)**

[Masseter muscle spasm--approach to patient] Ben-Abraham R, et al. **Harefuah** 1995 Aug;129(3–4):135–8 (20 ref.) **(Heb)**

ANTAGONISTS & INHIBITORS

[Antagonists in anesthesia] Lauven PM, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Oct; 30(6):331–6 (34 ref.) (Eng. Abstr.) **(Ger)**

CHEMISTRY

Isomerism and anaesthetic drugs. Calvey TN. **Acta Anaesthesiol Scand Suppl** 1995;106:83–90 (50 ref.)

METABOLISM

[Cytochrome P450-dependent monooxygenase system and anesthetics] Chen TL, et al. **Acta Anaesthesiol Sin** 1995 Sep;33(3):185–94 (64 ref.) (Eng. Abstr.) **(Chi)**

PHARMACOKINETICS

Pharmacokinetics of analgesics, sedatives and anaesthetic agents during cardiopulmonary bypass. Gedney JA, et al. **Br J Anaesth** 1995 Sep;75(3):344–51 (74 ref.)

[The fundamentals of pharmacokinetics] Lauven PM, et al. **Anaesthesist** 1995 Sep;44(9):663–76 (14 ref.) **(Ger)**

[Rectal administration of anesthetic agents] Ceriana P, et al. **Minerva Anestesiol** 1995 May;61(5):219–28 (33 ref.) (Eng. Abstr.) **(Ita)**

PHARMACOLOGY

Immunomodulation: an important concept in modern anaesthesia. McBride WT, et al. **Anaesthesia** 1996 May; 51(5):465–73 (86 ref.)

Muscarinic signaling in the central nervous system. Recent developments and anesthetic implications. Durieux ME. **Anesthesiology** 1996 Jan;84(1):173–89 (171 ref.)

Propofol. An update of its use in anaesthesia and conscious sedation. Bryson HM, et al. **Drugs** 1995 Sep;50(3):513–59 (622 ref.)

Actions of anesthetics on ligand-gated ion channels: role of receptor subunit composition. Harris RA, et al. **FASEB J** 1995 Nov;9(14):1454–62 (59 ref.)

An anesthetic-sensitive superfamily of neurotransmitter-gated ion channels. Franks NP, et al. **J Clin Anesth** 1996 May;8(3 Suppl):3S–7S (32 ref.)

Anesthetic actions within the spinal cord: contributions to the state of general anesthesia. Collins JG, et al. **Trends Neurosci** 1995 Dec;18(12):549–53 (42 ref.)

[Effects of anesthesia on the lower sphincter of the esophagus] Chassard D, et al. **Ann Fr Anesth Reanim** 1996; 15(3):277–83 (61 ref.) (Eng. Abstr.) **(Fre)**

[Do general anesthetics act on specific receptors?] Urban BW, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Oct;30(6):375–82 (55 ref.) (Eng. Abstr.) **(Ger)**

[Signal transduction systems of nerve growth cone: effects of anesthetics on the machinery] Saito S, et al. **Masui** 1995; 44 Suppl:S113–8 (15 ref.) **(Jpn)**

[Anesthetics and the glutamate receptor channels expressed in Xenopus oocytes] Yamakura T, et al. **Masui** 1995;44 Suppl:S121–4 (14 ref.) **(Jpn)**

STANDARDS

Anesthetic management of the trauma patient. Cuvelliez S, et al. **Vet Clin North Am Small Anim Pract** 1995 Sep; 25(5):1073–92 (42 ref.)

THERAPEUTIC USE

Propofol. An update of its use in anaesthesia and conscious sedation. Bryson HM, et al. **Drugs** 1995 Sep;50(3):513–59 (622 ref.)

TOXICITY

An overview of the toxicology of HFA-134a (1,1,1,2-tetrafluoroethane). Alexander DJ, et al. **Hum Exp Toxicol** 1995 Sep;14(9):715–20 (8 ref.)

ANESTHETICS, CONDUCTION-BLOCKING see **ANESTHETICS, LOCAL**

ANESTHETICS, GENERAL

Clinical aspects of CRNA practice. General anesthesia. Ouellette SM. **Nurs Clin North Am** 1996 Sep;31(3):623–42 (102 ref.)

ADVERSE EFFECTS

Mast cells and basophils in adverse reactions to drugs used during general anesthesia. Stellato C, et al. **Chem Immunol** 1995;62:108–31 (94 ref.)

Role of mast cells, basophils and their mediators in adverse reactions to general anesthetics and radiocontrast media. Genovese A, et al. **Int Arch Allergy Immunol** 1996 May; 110(1):13–22 (102 ref.)

PHARMACOLOGY

[Regulatory actions of general anesthetics on inhibitory receptor channels] Akagi H. **Masui** 1995;44 Suppl:S125–6 (4 ref.) **(Jpn)**

ANESTHETICS, INHALATION

Which inhalation anaesthetic agent is best for pediatric use? Lindahl SG. **Acta Anaesthesiol Belg** 1996;47(1):23–7 (14 ref.)

Adult clinical experience with sevoflurane and pharmaco-economic aspects. Young CJ, et al. **Acta Anaesthesiol Belg** 1996;47(1):29–42 (180 ref.)

Sevoflurane in pediatric anesthesia. Lerman J. **Anesth Analg** 1995 Dec;81(6 Suppl):S4–10 (47 ref.)

Sevoflurane--a long-awaited volatile anaesthetic. Smith I, et al. **Br J Anaesth** 1996 Mar;76(3):435–45 (92 ref.)

Inhalational anesthetics in the intensive care unit. Kong KL. **Crit Care Clin** 1995 Oct;11(4):887–902 (74 ref.)

Sevoflurane. A review of its pharmacodynamic and pharmacokinetic properties and its clinical use in general anaesthesia. Patel SS, et al. **Drugs** 1996 Apr;51(4):658–700 (471 ref.)

Inhalational anesthetics: desflurane and sevoflurane. Young CJ, et al. **J Clin Anesth** 1995 Nov;7(7):564–77 (198 ref.)

[Sevoflurane] Murat I, et al. **Ann Fr Anesth Reanim** 1995; 14(6):489–501 (149 ref.) (Eng. Abstr.) **(Fre)**

[Intraoperative awareness and auditory evoked potentials] Schwender D, et al. **Anaesthesist** 1996 Feb;45 Suppl 1:S46–51 (30 ref.) (Eng. Abstr.) **(Ger)**

[Clinical potency of nitrous oxide--is MAC the gold standard?] Schwilden H, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Oct; 30(6):337–40 (23 ref.) (Eng. Abstr.) **(Ger)**

[The present state of balanced anesthesia--combination of intravenous and inhaled anesthetics] Sumikawa K, et al. **Masui** 1995;44 Suppl:S149–52; discussion S156–7 (10 ref.) **(Jpn)**

[The narcotic properties of xenon and the prospects for its use in anesthesiology] Damir EA, et al. **Anesteziol Reanimatol** 1996 Jan–Feb;(1):71–5 (88 ref.) **(Rus)**

ADMINISTRATION & DOSAGE

Implications of chemical and physical properties of desflurane for longer surgery. Weiskopf RB. **Anaesthesia** 1995 Oct;50 Suppl:9–13 (57 ref.)

The role of sevoflurane in outpatient anesthesia. Smith I, et al. **Anesth Analg** 1995 Dec;81(6 Suppl):S67–72 (24 ref.)

Intravenous drug delivery systems: toward an intravenous "vaporizer". Egan TD. **J Clin Anesth** 1996 May;8(3 Suppl):8S–14S (38 ref.)

ADVERSE EFFECTS

The organ toxicity of inhaled anesthetics. Kenna JG, et al. **Anesth Analg** 1995 Dec;81(6 Suppl):S51–66 (143 ref.)

Severe neurologic deficit after nitrous oxide anesthesia. Hadzic A, et al. **Anesthesiology** 1995 Oct;83(4):863–6 (14 ref.)

Target-controlled infusions: stress free anesthesia? Kenny GN, et al. **J Clin Anesth** 1996 May;8(3 Suppl):15S–20S (46 ref.)

CHEMISTRY

Physicochemical properties and pharmacodynamics of desflurane. Eger EI 2nd. **Anaesthesia** 1995 Oct;50 Suppl:3–8 (41 ref.)

ECONOMICS

Economic analysis and pharmaceutical policy: a consideration of the economics of the use of desflurane. Eger EI 2nd. **Anaesthesia** 1995 Oct;50 Suppl:45–8 (22 ref.)

METABOLISM

Metabolism and toxicity of the new anesthetic agents. Kharasch ED. **Acta Anaesthesiol Belg** 1996;47(1):7–14 (46 ref.)

PHARMACOKINETICS

What is the role of absorption atelectasis in the genesis of perioperative pulmonary collapse? Joyce CJ, et al. **Anaesth Intensive Care** 1995 Dec;23(6):691–6 (57 ref.)

Biotransformation of sevoflurane. Kharasch ED. **Anesth Analg** 1995 Dec;81(6 Suppl):S27–38 (68 ref.)

[Uptake of anaesthetic gases and vapours (see comments)] Lin CY. **Acta Anaesthesiol Sin** 1995 Sep;33(3):173–83 (16 ref.) Comment in: Acta Anaesthesiol Sin 1995 Sep;33(3):i. **(Chi)**

[Sevoflurane in pediatric anesthesia] Hobbhahn J, et al. **Anaesthesist** 1996 Feb;45 Suppl 1:S22–7 (35 ref.) (Eng. Abstr.) **(Ger)**

PHARMACOLOGY

Cardiovascular and autonomic effects of sevoflurane. Ebert TJ. **Acta Anaesthesiol Belg** 1996;47(1):15–21 (22 ref.)

Circulatory effects of desflurane. Coriat P. **Anaesthesia** 1995 Oct;50 Suppl:18–21 (19 ref.)

Cardiovascular effects of desflurane in experimental animals and volunteers. Weiskopf RB. **Anaesthesia** 1995 Oct;50 Suppl:14–7 (29 ref.)

Cardiovascular responses to sevoflurane: a review. Ebert TJ, et al. **Anesth Analg** 1995 Dec;81(6 Suppl):S11–22 (43 ref.)

The hepatic effects of sevoflurane. Frink EJ Jr. **Anesth Analg** 1995 Dec;81(6 Suppl):S46–50 (29 ref.)

The ventilatory effects of sevoflurane. Green WB Jr. **Anesth Analg** 1995 Dec;81(6 Suppl):S23–6 (19 ref.)

Sevoflurane and renal function. Malan TP Jr. **Anesth Analg** 1995 Dec;81(6 Suppl):S39–45 (34 ref.)

ANESTHETICS, INHALATION

Desflurane. A review of its pharmacodynamic and pharmacokinetic properties and its efficacy in general anaesthesia. Patel SS, et al. **Drugs** 1995 Oct;50(4):742–67 (201 ref.)

Pharmacologic drugs for controlled hypotension. Testa LD, et al. **J Clin Anesth** 1995 Jun;7(4):326–37 (64 ref.)

[Effects of sevoflurane on the area of the liver and spleen] Schindler E, et al. **Anaesthesist** 1996 Feb;45 Suppl 1:S29–31 (30 ref.) (Eng. Abstr.) **(Ger)**

TOXICITY

Metabolism and toxicity of the new anesthetic agents. Kharasch ED. **Acta Anaesthesiol Belg** 1996;47(1):7–14 (46 ref.)

[Nephrotoxicity and fluoride from the viewpoint of the nephrologist] Bosch T. **Anaesthesist** 1996 Feb;45 Suppl 1:S41–5 (28 ref.) (Eng. Abstr.) **(Ger)**

[Fluoride-induced nephrotoxicity: factor fiction?] Nuscheler M, et al. **Anaesthesist** 1996 Feb;45 Suppl 1:S32–40 (54 ref.) (Eng. Abstr.) **(Ger)**

ANESTHETICS, INTRAVENOUS

Intravenous anaesthesia: new drugs, new concepts, and clinical applications. Miller DR. **Can J Anaesth** 1996 May; 43(5 Pt 2):R142–54 (18 ref.) **(Eng, Fre)**

Co-induction of anaesthesia: the rationale. Amrein R, et al. **Eur J Anaesthesiol Suppl** 1995 Nov;12:5–11 (41 ref.)

Intravenous anaesthetic drug interactions: practical applications. Vinik HR. **Eur J Anaesthesiol Suppl** 1995 Nov; 12:13–9 (23 ref.)

Clinical aspects of CRNA practice. General anesthesia. Ouellette SM. **Nurs Clin North Am** 1996 Sep;31(3):623–42 (102 ref.)

[Intravenous anesthesia—current aspects] Schraag S, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Dec; 30(8):469–78 (72 ref.) (Eng. Abstr.) **(Ger)**

[Prospects of balanced anesthesia—combination with propofol] Shingu K, et al. **Masui** 1995;44 Suppl:S158–61; discussion S173–6 (6 ref.) **(Jpn)**

[The present state of balanced anesthesia—combination of intravenous and inhaled anesthetics] Sumikawa K, et al. **Masui** 1995;44 Suppl:S149–52; discussion S156–7 (10 ref.) **(Jpn)**

ADMINISTRATION & DOSAGE

Co-induction of anaesthesia: the cardiac patient. Duthie DJ. **Eur J Anaesthesiol Suppl** 1995 Nov;12:21–4 (26 ref.)

Co-induction of anaesthesia: day-case surgery. Whitwam JG. **Eur J Anaesthesiol Suppl** 1995 Nov;12:25–34 (50 ref.)

ADVERSE EFFECTS

Target-controlled infusions: stress free anesthesia? Kenny GN, et al. **J Clin Anesth** 1996 May;8(3 Suppl):15S–20S (46 ref.)

PHARMACOKINETICS

Pharmacokinetic and pharmacodynamic principles in providing "fast-track" recovery. Glass PS. **J Cardiothorac Vasc Anesth** 1995 Oct;9(5 Suppl 1):16–20 (29 ref.)

Total intravenous anesthesia—a pharmacokinetic approach. Bovill JG. **Middle East J Anesthesiol** 1995 Feb;13(1):37–60 (36 ref.)

[Gamma-hydroxybutyric acid—significance for anesthesia and intensive care medicine?] Kleinschmidt S, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Nov; 30(7):393–402 (59 ref.) (Eng. Abstr.) **(Ger)**

PHARMACOLOGY

Pharmacokinetic and pharmacodynamic principles in providing "fast-track" recovery. Glass PS. **J Cardiothorac Vasc Anesth** 1995 Oct;9(5 Suppl 1):16–20 (29 ref.)

Pharmacodynamics as a research tool. Bailey JM. **J Clin Anesth** 1996 May;8(3 Suppl):48S–52S (12 ref.)

THERAPEUTIC USE

Perioperative use of propofol for cardiac surgery. Jain U. **J Clin Anesth** 1996 May;8(3 Suppl):61S–66S (81 ref.)

ANESTHETICS, LOCAL

What is the role of diphenhydramine in local anesthesia? [editorial; comment] Green SM. **Acad Emerg Med** 1996 Mar;3(3):198–200 (11 ref.) Comment on: Acad Emerg Med 1996 Mar;3(3):228–33.

Ropivacaine. McClure JH. **Br J Anaesth** 1996 Feb; 76(2):300–7 (88 ref.)

Local anesthetics. Skidmore RA, et al. **Dermatol Surg** 1996 Jun;22(6):511–22; quiz 523–4 (83 ref.)

Spinal anesthesia for outpatients: appropriate agents and techniques. Mulroy MF, et al. **J Clin Anesth** 1995 Nov; 7(7):622–7 (39 ref.)

Local anaesthetic agents in infancy. Eyres RL. **Paediatr Anaesth** 1995;5(4):213–8 (47 ref.)

[Peridural anesthesia in postoperative pain therapy] Standl T. **Zentralbl Chir** 1995;120(12):916–26 (80 ref.) (Eng. Abstr.) **(Ger)**

[Use of topical anesthesia—EMLA cream] Raveh T, et al. **Harefuah** 1996 Apr 1;130(7):490–1 (26 ref.) **(Heb)**

ADMINISTRATION & DOSAGE

Evaluation of intrapleural analgesia in the management of blunt traumatic chest wall pain: a clinical trial. Short K, et al. **Am Surg** 1996 Jun;62(6):488–93 (50 ref.)

ADVERSE EFFECTS

Ambulatory phlebectomy. A rare complication of local anesthetic: case report and literature review. Olivencia JA. **Dermatol Surg** 1996 Jan;22(1):53–5 (15 ref.)

Adverse reactions to local anesthetics: analysis of 197 cases. Gall H, et al. **J Allergy Clin Immunol** 1996 Apr;97(4):933–7 (20 ref.)

Localized reactions to injected therapeutic materials. Part 2. Surgical agents. Morgan AM. **J Cutan Pathol** 1995 Aug; 22(4):289–303 (65 ref.)

1995 Gaston Labat Lecture. Ropivacaine. White knight or dark horse? de Jong RH. **Reg Anesth** 1995 Nov–Dec; 20(6):474–81 (37 ref.)

IMMUNOLOGY

Adverse reactions to local anesthetics: analysis of 197 cases. Gall H, et al. **J Allergy Clin Immunol** 1996 Apr;97(4):933–7 (20 ref.)

PHARMACOKINETICS

Application of saliva for drug monitoring. An in vivo model for transmembrane transport. Haeckel R, et al. **Eur J Clin Chem Clin Biochem** 1996 Mar;34(3):171–91 (179 ref.)

PHARMACOLOGY

Opioids in combination with local anesthetics for epidural analgesia during labor. Vertommen JD. **Eur J Obstet Gynecol Reprod Biol** 1995 May;59 Suppl:S35–8 (23 ref.)

A review of the pharmacology, pharmacokinetics, and regulatory control in the US of local anaesthetics in the horse. Harkins JD, et al. **J Vet Pharmacol Ther** 1995 Dec; 18(6):397–406 (56 ref.)

[Alkalinization of local anesthetics: theoretically justified but clinically useless] Chassard D, et al. **Can J Anaesth** 1996 Apr;43(4):384–93 (68 ref.) (Eng. Abstr.) **(Fre)**

THERAPEUTIC USE

Local anesthetics. Sklar DP. **Ann Emerg Med** 1996 Apr; 27(4):464–5 (10 ref.)

Control of pain after photorefractive keratectomy. Verma S, et al. **J Refract Surg** 1996 Mar–Apr;12(3):358–64 (37 ref.)

1995 Gaston Labat Lecture. Ropivacaine. White knight or dark horse? de Jong RH. **Reg Anesth** 1995 Nov–Dec; 20(6):474–81 (37 ref.)

ANESTRUS

Endocrine bases of lactational anoestrus in the sow. Quesnel H, et al. **Reprod Nutr Dev** 1995;35(4):395–414 (107 ref.)

ANETHOLE TRITHIONE

PHARMACOLOGY

Anethole dithiolethione: biochemical considerations. Christen MO. **Methods Enzymol** 1995;252:316–23 (40 ref.)

ANETHOLTRITHION see **ANETHOLE TRITHIONE**

ANEUPLOIDY

Multiple polysomies in nasal polyps in children. Speleman F, et al. **Cancer Genet Cytogenet** 1996 Aug;90(1):86–7 (13 ref.)

Mosaic "tetrasomy" 8p: case report and review of the literature. Winters J, et al. **Clin Genet** 1995 Oct;48(4):195–8 (9 ref.)

Flow cytometric and clinicopathologic study of 197 hydatidiform moles with special reference to the significance of cytometric aneuploidy and literature review. Fukunaga M, et al. **Cytometry** 1995 Jun 15;22(2):135–8 (21 ref.)

Aetiology of age-associated aneuploidy: a mechanism based on the 'free radical theory of ageing'. Tarin JJ. **Hum Reprod** 1995 Jun;10(6):1563–5 (25 ref.)

The incidence, origin, and etiology of aneuploidy. Griffin DK. **Int Rev Cytol** 1996;167:263–96 (89 ref.)

The influence of intrinsic and extrinsic factors on the developmental potential and chromosomal normality of the human oocyte. Van Blerkom J. **J Soc Gynecol Investig** 1996 Jan–Feb;3(1):3–11 (38 ref.)

Advantages and limitations of using fluorescence in situ hybridization for the detection of aneuploidy in interphase human cells. Eastmond DA, et al. **Mutat Res** 1995 Dec; 348(4):153–62 (46 ref.)

Important biological variables that can influence the degree of chemical-induced aneuploidy in mammalian oocyte and zygotes. Mailhes JB. **Mutat Res** 1995 Oct;339(3):155–76 (144 ref.)

The detection and evaluation of aneugenic chemicals. Parry JM, et al. **Mutat Res** 1996 Jun 12;353(1–2):11–46 (90 ref.)

Sex chromosome aneuploidy and aging. Stone JF, et al. **Mutat Res** 1995 Oct;338(1–6):107–13 (51 ref.)

Intrauterine diagnosis of sex chromosome aneuploidy. Linden MG, et al. **Obstet Gynecol** 1996 Mar;87(3):468–75 (51 ref.)

ANEURIN see **THIAMINE**

ANEURYSM

Giant aneurysm of main pulmonary artery. Chen YF, et al. **Ann Thorac Surg** 1996 Jul;62(1):272–4 (8 ref.)

Popliteal vein aneurysm. al Zahrani HA. **Cardiovasc Surg** 1995 Oct;3(5):505–7 (11 ref.)

True aneurysm of the inferior thyroid artery. Case report and review of the literature. Raso AM, et al. **J Cardiovasc Surg (Torino)** 1995 Oct;36(5):493–5 (8 ref.)

Aneurysms of the infrapopliteal arteries. Marmorale A, et al. **J R Coll Surg Edinb** 1995 Oct;40(5):324–6 (4 ref.)

[Aneurysms of the popliteal artery. A clinical case and revision of the literature] Giani L, et al. **Minerva Chir** 1995 Nov;50(11):1019–23 (21 ref.) (Eng. Abstr.) **(Ita)**

[Extrahepatic portal vein aneurysm] Iwasaki M, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):180–3 (24 ref.) **(Jpn)**

[Hepatic artery aneurysm] Kojima K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):199–201 (10 ref.) **(Jpn)**

[Intrahepatic portal vein aneurysm] Toshima K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):218–20 (19 ref.) **(Jpn)**

COMPLICATIONS

Aneurysms of the pancreaticoduodenal artery associated with occlusion of the celiac artery. Uher P, et al. **Abdom Imaging** 1995 Sep–Oct;20(5):470–3 (22 ref.)

Right aortic arch with aberrant left subclavian artery: aneurysmal dilatation causing symptomatic compression of the right main bronchus in an adult. Patiniotis TC, et al. **Aust N Z J Surg** 1995 Sep;65(9):690–2 (9 ref.)

Deep venous thrombosis with pulmonary embolus after selective embolization of an internal iliac artery aneurysm. Su WT, et al. **J Vasc Surg** 1996 Jan;23(1):152–5 (13 ref.)

Systemic multiple aneurysms of the intracranial arteries and visceral arteries: case report. Fuse T, et al. **Surg Neurol** 1996 Sep;46(3):258–61; discussion 261–2 (13 ref.)

[Renovascular hypertension and hydronephrosis due to a renal artery aneurysm] Hering M, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Feb;164(2):176–8 (12 ref.) **(Ger)**

[A case of cholangiocarcinoma with temporary subsegmental fatty liver and intrahepatic portal aneurysm] Miyanaga O, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Sep; 92(9):1297–303 (9 ref.) **(Jpn)**

DIAGNOSIS

Pulmonary artery aneurysm: review and case report. Lopez-Candales A, et al. **Clin Cardiol** 1995 Dec; 18(12):738–40 (15 ref.)

An aneurysm of the internal jugular vein. Refson JS, et al. **Eur J Vasc Endovasc Surg** 1996 Apr;11(3):371–2 (5 ref.)

True infrapopliteal artery aneurysms: report of two cases and literature review. Mönig SP, et al. **J Vasc Surg** 1996 Aug; 24(2):276–8 (20 ref.)

Aneurysms of the pancreaticoduodenal artery. Paty PS, et al. **J Vasc Surg** 1996 Apr;23(4):710–3 (12 ref.)

EPIDEMIOLOGY

Aneurysms of the digital artery: a review and report of three cases. Yajima H, et al. **Microsurgery** 1995;16(8):566–70 (19 ref.)

ETIOLOGY

Wegener's granulomatosis complicated by arterial aneurysm. Aoki N, et al. **Intern Med** 1995 Aug;34(8):790–3 (14 ref.)

SURGERY

Endovascular stents and stented grafts for the treatment of aneurysms and other arterial lesions. Marin ML, et al. **Adv Surg** 1996;29:93–109 (50 ref.)

Perioperative management of aneurysmal subarachnoid hemorrhage: Part 1. Operative management. Guy J, et al. **Anesth Analg** 1995 Nov;81(5):1060–72 (154 ref.)

Aneurysm of the left pulmonary artery: surgical allograft repair. Casselman F, et al. **Ann Thorac Surg** 1995 Nov; 60(5):1423–5 (6 ref.)

Repair of an aneurysm of the left main coronary artery. Lepojärvi M, et al. **Ann Thorac Surg** 1996 Apr;61(4):1247–9 (11 ref.)

The present status of endoluminal stented grafts for the treatment of aneurysms, traumatic injuries and arterial occlusions. Veith FJ, et al. **Cardiovasc Surg** 1996 Feb; 4(1):3–7 (30 ref.)

Aneurysm of a congenitally persistent sciatic artery presenting as a soft-tissue mass of the buttock. A case report. Benevenia J, et al. **J Bone Joint Surg Am** 1995 Nov; 77(11):1724–8 (33 ref.)

Isolated true atherosclerotic aneurysms of the deep femoral artery. Case report and literature review. Yahel J, et al. **J Cardiovasc Surg (Torino)** 1996 Feb;37(1):17–20 (23 ref.)

Surgical treatment of an enormous aneurysmal portahepatic venous fistula: report of a case. Miyauchi A, et al. **Surg Today** 1995;25(9):855–8 (11 ref.)
Combined membranous obstruction and saccular aneurysm of the inferior vena cava. Augustin N, et al. **Thorac Cardiovasc Surg** 1995 Aug;43(4):223–6 (30 ref.)

THERAPY

[Experiences with the endovascular embolization therapy of aneurysms of the splanchnic arteries—a report on 13 cases] Kramann B, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1995 Nov;163(5):417–23 (35 ref.) (Eng. Abstr.) **(Ger)**

ULTRASONOGRAPHY

Azygos vein aneurysm: contribution of transesophageal echography. Léna H, et al. **Ann Thorac Surg** 1996 Apr; 61(4):1253–5 (7 ref.)
A pulsatile gluteal mass due to sciatic artery aneurysm. Chleboun JO, et al. **Aust N Z J Surg** 1995 Dec; 65(12):907–10 (18 ref.)
[Aneurysm of the right hepatic artery. Diagnosis by color Doppler echography] Cozza S, et al. **Radiol Med (Torino)** 1995 Dec;90(6):834–7 (17 ref.) **(Ita)**

ANEURYSM, ARTERIOVENOUS see **ARTERIOVENOUS FISTULA**

ANEURYSM, BACTERIAL see **ANEURYSM, INFECTED**

ANEURYSM, CORONARY see **CORONARY ANEURYSM**

ANEURYSM, DISSECTING

Spontaneous dissection of the hepatic artery. Müller MF, et al. **Abdom Imaging** 1995 Sep–Oct;20(5):462–5 (13 ref.)
Management of descending aortic dissection. Orend KH, et al. **Ann Ital Chir** 1995 Nov–Dec;66(6):821–4 (8 ref.)
[Pathophysiology and clinical aspects of dissecting aortic aneurysms] Szabóová–Tomoriová E, et al. **Vnitr Lek** 1995 Jul;41(7):480–4 (36 ref.) (Eng. Abstr.) **(Slo)**

COMPLICATIONS

Survival after aortic dissection in giant cell arteritis [letter] Richardson MP, et al. **Ann Rheum Dis** 1996 May; 55(5):332–3 (20 ref.)
Lymphoplasmacytic aortitis and acute aortic dissection. An uncommon association. Faye–Petersen OM, et al. **Arch Pathol Lab Med** 1996 Apr;120(4):402–4 (20 ref.)
Subarachnoid haemorrhage and myths about saccular aneurysms. Weller RO. **J Clin Pathol** 1995 Dec; 48(12):1078–81 (29 ref.)
[Raeder's syndrome (the paratrigeminal syndrome): its etiology related to carotid artery dissection. A case report] Monti L, et al. **Radiol Med (Torino)** 1996 Apr;91(4):473–5 (16 ref.) **(Ita)**

DIAGNOSIS

Dissection of the internal carotid and vertebral arteries: imaging features. Provenzale JM. **AJR Am J Roentgenol** 1995 Nov;165(5):1099–104 (53 ref.)
Acute dissection of the aorta: options for diagnostic imaging. Razavi M. **Cleve Clin J Med** 1995 Nov–Dec;62(6):360–5 (16 ref.)
Management of aortic dissection. Westaby S. **Curr Opin Cardiol** 1995 Sep;10(5):505–10 (17 ref.)
Spontaneous extracranial carotid artery dissection in children. Patel H, et al. **Pediatr Neurol** 1995 Jul;13(1):55–60 (26 ref.)
Spontaneous dissecting aneurysm of the anterior cerebral artery: report of two cases. Koyama S, et al. **Surg Neurol** 1996 Jul;46(1):55–61 (15 ref.)
[Exploration of the thoracic aorta, excluding the aortic valve] Douek P, et al. **Ann Cardiol Angeiol (Paris)** 1995 Dec; 44(10):552–60 (12 ref.) (Eng. Abstr.) **(Fre)**
[Aortic dissection. Symptoms with indications for surgery] Defraigne JO, et al. **Rev Med Liege** 1996 Jun;51(6):411–25 (49 ref.) **(Fre)**
[Clinical evaluation and neurological ultrasonography in 60 cases of carotid dissection] Despland PA, et al. **Rev Med Suisse Romande** 1996 Aug;116(8):591–6 (29 ref.) **(Fre)**
[Dissection of the carotid artery and vertebral artery—diagnosis and therapy] Sperling W, et al. **Fortschr Neurol Psychiatr** 1996 Apr;64(4):153–60 (37 ref.) (Eng. Abstr.) **(Ger)**
[Cerebral artery dissection] Sturzenegger M, et al. **Ther Umsch** 1996 Jul;53(7):544–51 (32 ref.) (Eng. Abstr.) **(Ger)**
[Total atrioventricular block as the primary clinical manifestation of undiagnosed aortic dissection] Lorenzoni R, et al. **G Ital Cardiol** 1995 Aug;25(8):1031–5 (12 ref.) (Eng. Abstr.) **(Ita)**
[Spontaneous dissection of the left vertebral artery in a young woman. A report and the diagnostic considerations of a case] La Brocca A, et al. **Minerva Med** 1996 Jan–Feb; 87(1–2):41–4 (23 ref.) (Eng. Abstr.) **(Ita)**

ETIOLOGY

Aortic dissection in a 5-year old girl with Marfan's syndrome [letter] Ruiz ME, et al. **Arch Pediatr Adolesc Med** 1996 Apr;150(4):440–2 (14 ref.)

GENETICS

[Another case of dissecting aortic aneurysm with familial incidence] Conte MR, et al. **Cardiologia** 1992 Jul; 37(7):513–7 (19 ref.) (Eng. Abstr.) **(Ita)**

PHYSIOPATHOLOGY

Spontaneous dissecting aneurysm of the anterior cerebral artery: report of two cases. Koyama S, et al. **Surg Neurol** 1996 Jul;46(1):55–61 (15 ref.)

SURGERY

Critical-illness polyneuropathy complicating cardiac operation. Alhan HC, et al. **Ann Thorac Surg** 1996 Apr; 61(4):1237–9 (8 ref.)
Acute aortic dissection in a patient with osteogenesis imperfecta [see comments] Moriyama Y, et al. **Ann Thorac Surg** 1995 Nov;60(5):1397–9 (8 ref.) Comment in: Ann Thorac Surg 1996 Apr;61(4):1294.
Dissecting descending thoracic and thoracoabdominal aortic aneurysms: Part II. Panneton JM, et al. **Ann Vasc Surg** 1995 Nov;9(6):596–605 (56 ref.)
Rupture of a dissecting thoracic aortic aneurysm into the pulmonary artery: successful surgical repair. Coselli JS, et al. **Cardiovasc Surg** 1995 Dec;3(6):697–701 (34 ref.)
Management of aortic dissection. Westaby S. **Curr Opin Cardiol** 1995 Sep;10(5):505–10 (17 ref.)
Ruptured dissecting aneurysm of the peripheral anterior cerebral artery—case report. Yano H, et al. **Neurol Med Chir (Tokyo)** 1995 Jul;35(7):450–3 (17 ref.)
[A case report of bentall type operation for annuloaortic ectasia with anomalous origin of the right coronary artery complicated by aortic dissection] Hirai M, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Jul;43(7):1044–9 (20 ref.) (Eng. Abstr.) **(Jpn)**
[Rupture of dissecting aortic aneurysm associated with the right-sided aortic arch and anomalous course of the left brachiocephalic vein—a case report] Kanoh M, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Jul;43(7):1086–91 (14 ref.) (Eng. Abstr.) **(Jpn)**
[A case of anterior cerebral artery dissecting aneurysm] Araki T, et al. **No Shinkei Geka** 1996 Jan;24(1):87–91 (19 ref.) (Eng. Abstr.) **(Jpn)**

THERAPY

Cardiovascular shock. Rodgers KG. **Emerg Med Clin North Am** 1995 Nov;13(4):793–810 (61 ref.)
Intravascular stenting of traumatic abdominal aortic dissection. Marty–Ané CH, et al. **J Vasc Surg** 1996 Jan; 23(1):156–61 (13 ref.)
The autoperfusion balloon catheter with special attention to its use as a bail-out device. Bonnier JJ. **Z Kardiol** 1995; 84 Suppl 2:79–82 (17 ref.)

ULTRASONOGRAPHY

[The main indications for transesophageal echocardiography] Lesbre JP. **Ann Cardiol Angeiol (Paris)** 1995 Dec; 44(10):547–51 (21 ref.) (Eng. Abstr.) **(Fre)**

ANEURYSM, FALSE

COMPLICATIONS

Carotid artery pseudoaneurysm and pellet embolism to the middle cerebral artery following a shotgun wound of the neck. Cogbill TH, et al. **J Trauma** 1995 Oct;39(4):763–7 (16 ref.)

DIAGNOSIS

Presentation of Ehlers–Danlos syndrome: iliac artery pseudoaneurysm rupture. Meldon S, et al. **Ann Emerg Med** 1996 Aug;28(2):231–4 (14 ref.)
Late rupture of femoropopliteal Dacron grafts: a rare complication. Vrancken Peeters MT, et al. **Eur J Vasc Endovasc Surg** 1996 Feb;11(2):243–6 (5 ref.)
False traumatic aneurysm of the dorsal wall of the supraclinoid internal carotid artery—case report. Saito K, et al. **Neurol Med Chir (Tokyo)** 1995 Dec;35(12):886–91 (26 ref.)

EPIDEMIOLOGY

Aneurysms of the digital artery: a review and report of three cases. Yajima H, et al. **Microsurgery** 1995;16(8):566–70 (19 ref.)

ETIOLOGY

Coronary pseudoaneurysm after angioplasty. Flum DR, et al. **Am Surg** 1995 Dec;61(12):1035–8 (40 ref.)
Traumatic fistula between the left anterior descending coronary artery and a left ventricular pseudoaneurysm. Haapanen YT, et al. **Cardiovasc Intervent Radiol** 1996 Jul–Aug;19(4):272–4 (11 ref.)
Native hepatic artery pseudoaneurysm after liver transplantation: an unusual presentation with biliary leak. Soin AS, et al. **Eur J Vasc Endovasc Surg** 1995 Oct; 10(3):376–9 (9 ref.)
Traumatic pseudoaneurysm of the superficial temporal artery associated with facial nerve palsy. Lalak NJ, et al. **J Cardiovasc Surg (Torino)** 1996 Apr;37(2):119–23 (54 ref.)
Renal artery pseudoaneurysm after blunt abdominal trauma: case report and literature review. Swana HS, et al. **J Trauma** 1996 Mar;40(3):459–61 (15 ref.)
Infected iliac pseudoaneurysm after uncomplicated percutaneous balloon angioplasty and (Palmaz) stent insertion: a case report and literature review. Weinberg DJ, et al. **J Vasc Surg** 1996 Jan;23(1):162–6 (17 ref.)

PHYSIOPATHOLOGY

False traumatic aneurysm of the dorsal wall of the supraclinoid internal carotid artery—case report. Saito K, et al. **Neurol Med Chir (Tokyo)** 1995 Dec;35(12):886–91 (26 ref.)

SURGERY

False aneurysm of the thyrocervical trunk: an unconventional surgical approach. Abrokwah J, et al. **Eur J Vasc Endovasc Surg** 1996 Apr;11(3):373–4 (4 ref.)
Ligation of the common carotid artery for the management of a mycotic pseudoaneurysm of an extracranial internal carotid artery. A case report and review of the literature. Lueg EA, et al. **Int J Pediatr Otorhinolaryngol** 1995 Aug; 33(1):67–74 (21 ref.)

THERAPY

[Experiences with the endovascular embolization therapy of aneurysms of the splanchnic arteries—a report on 13 cases] Kramann B, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1995 Nov;163(5):417–23 (35 ref.) (Eng. Abstr.) **(Ger)**
[Selective embolization with an adhesive fluid of complicated aneurysms of the hepatic artery: 3 cases] Cotroneo AR, et al. **Radiol Med (Torino)** 1996 Apr;91(4):492–6 (21 ref.) **(Ita)**

ANEURYSM, INFECTED

COMPLICATIONS

Surgical treatment of an aortopulmonary artery fistula complicating a syphilitic aortic aneurysm. Pessotto R, et al. **Cardiovasc Surg** 1995 Dec;3(6):707–10 (17 ref.)

DIAGNOSIS

Pulmonary artery aneurysm presenting as a lung mass. Chung CW, et al. **Chest** 1995 Oct;108(4):1164–6 (10 ref.)

ETIOLOGY

Salmonella mycotic aneurysm of the aortic arch: case report and review. Meerkin D, et al. **Clin Infect Dis** 1995 Sep; 21(3):523–8 (32 ref.)
Escherichia coli infection of an abdominal aortic aneurysm. Khaira HS, et al. **J Infect** 1996 Mar;32(2):161–3 (14 ref.)
Infected iliac pseudoaneurysm after uncomplicated percutaneous balloon angioplasty and (Palmaz) stent insertion: a case report and literature review. Weinberg DJ, et al. **J Vasc Surg** 1996 Jan;23(1):162–6 (17 ref.)

MICROBIOLOGY

Contained rupture of infected abdominal aortic aneurysm due to systemic candidiasis. Ikeda M, et al. **Cardiovasc Surg** 1995 Dec;3(6):711–4 (30 ref.)
Double clostridial mycotic aneurysms of the aorta. Messa CA 3rd, et al. **Cardiovasc Surg** 1995 Dec;3(6):687–92 (28 ref.)

SURGERY

Mycotic aneurysm of the aorta: evolving surgical concept [editorial; comment] Pasic M. **Ann Thorac Surg** 1996 Apr; 61(4):1053–4 (16 ref.) Comment on: Ann Thorac Surg 1996 Apr;61(4):1146–52.
Surgical treatment of an aortopulmonary artery fistula complicating a syphilitic aortic aneurysm. Pessotto R, et al. **Cardiovasc Surg** 1995 Dec;3(6):707–10 (17 ref.)
Ligation of the common carotid artery for the management of a mycotic pseudoaneurysm of an extracranial internal carotid artery. A case report and review of the literature. Lueg EA, et al. **Int J Pediatr Otorhinolaryngol** 1995 Aug; 33(1):67–74 (21 ref.)

ANEURYSM, MYCOTIC see **ANEURYSM, INFECTED**

ANEURYSM, RUPTURED

Spontaneous dissection of the hepatic artery. Müller MF, et al. **Abdom Imaging** 1995 Sep–Oct;20(5):462–5 (13 ref.)
[Fissured aneurysm of the superior mesenteric vein. Report of a case] Catalano O. **Radiol Med (Torino)** 1995 Jul–Aug; 90(1–2):148–9 (19 ref.) **(Ita)**

COMPLICATIONS

Rapidly progressive destruction of the hip. Case report and review of the literature. Puylaert D, et al. **Acta Orthop Belg** 1995;61(4):312–4 (5 ref.)
Subarachnoid haemorrhage and myths about saccular aneurysms. Weller RO. **J Clin Pathol** 1995 Dec;

48(12):1078–81 (29 ref.)
Innovations in aneurysmal subarachnoid hemorrhage: intracisternal t-PA for the prevention of vasospasm. Bell TE, et al. **J Neurosci Nurs** 1996 Apr;28(2):107–13 (37 ref.)
Anomalous internal carotid artery–anterior cerebral artery anastomosis associated with fenestration and cerebral aneurysm. Fujimura M, et al. **Neurol Med Chir (Tokyo)** 1996 Apr;36(4):229–33 (26 ref.)
Treatment of ruptured cerebral aneurysm in moyamoya disease. Kodama N, et al. **Surg Neurol** 1996 Jul;46(1):62–6 (12 ref.)
[Neurofibromatosis associated with multiple intracranial vascular lesions: stenosis of the internal carotid artery and peripheral aneurysm of the Heubner's artery; report of a case] Sasaki J, et al. **No Shinkei Geka** 1995 Sep;23(9):813–7 (22 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Presentation of Ehlers–Danlos syndrome: iliac artery pseudoaneurysm rupture. Meldon S, et al. **Ann Emerg Med** 1996 Aug;28(2):231–4 (14 ref.)

EPIDEMIOLOGY

Rupture of true profunda femoris artery aneurysms. Two new cases. Levi N, et al. **J Cardiovasc Surg (Torino)** 1996 Apr;37(2):117–8 (9 ref.)

PATHOLOGY

Carotid–cavernous sinus fistula and aneurysmal rupture associated with fibromuscular dysplasia. A case report. Hirai T, et al. **Acta Radiol** 1996 Jan;37(1):49–51 (8 ref.)

PHYSIOPATHOLOGY

Protection of the brain after aneurysmal rupture. Weir B. **Can J Neurol Sci** 1995 Aug;22(3):177–86 (73 ref.)
Ruptured aneurysm of the distal posterior inferior cerebellar artery in a neonate—case report. Hosotani K, et al. **Neurol Med Chir (Tokyo)** 1995 Dec;35(12):892–5 (11 ref.)
Complications of Swan–Ganz catheterization for hemodynamic monitoring in patients with subarachnoid hemorrhage. Rosenwasser RH, et al. **Neurosurgery** 1995 Nov;37(5):872–5; discussion 875–6 (21 ref.)

RADIOGRAPHY

Ruptured aneurysm at the origin of duplication of the middle cerebral artery—case report. Koyama S, et al. **Neurol Med Chir (Tokyo)** 1995 Sep;35(9):671–3 (24 ref.)

SURGERY

Ruptured dissecting aneurysm of the peripheral anterior cerebral artery—case report. Yano H, et al. **Neurol Med Chir (Tokyo)** 1995 Jul;35(7):450–3 (17 ref.)
Treatment of ruptured cerebral aneurysm in moyamoya disease. Kodama N, et al. **Surg Neurol** 1996 Jul;46(1):62–6 (12 ref.)

THERAPY

[Selective embolization with an adhesive fluid of complicated aneurysms of the hepatic artery: 3 cases] Cotroneo AR, et al. **Radiol Med (Torino)** 1996 Apr;91(4):492–6 (21 ref.) **(Ita)**

ANF see **ATRIAL NATRIURETIC FACTOR**

ANF RECEPTORS see **RECEPTORS, ATRIAL NATRIURETIC FACTOR**

ANGELMAN SYNDROME

GENETICS

Angelman syndrome. Williams CA, et al. **Curr Probl Pediatr** 1995 Aug;25(7):216–31 (89 ref.)

ANGER

Anger in nurses: don't lose it, use it. Droppleman PG, et al. **Am J Nurs** 1996 Apr;96(4):26–31; quiz 32 (11 ref.)

PHYSIOLOGY

Reversible cardiogenic shock in an angry woman—case report and review of the literature. Kovacs KA, et al. **Can J Cardiol** 1996 Jul;12(7):689–93 (52 ref.)
Life-threatening cardiovascular consequences of anger in patients with coronary heart disease. Verrier RL, et al. **Cardiol Clin** 1996 May;14(2):289–307 (112 ref.)

ANGIITIS see **VASCULITIS**

ANGIITIS, ALLERGIC CUTANEOUS see **VASCULITIS, ALLERGIC CUTANEOUS**

ANGIITIS, ALLERGIC GRANULOMATOUS see **CHURG-STRAUSS SYNDROME**

ANGIITIS, HYPERSENSITIVITY see **VASCULITIS, HYPERSENSITIVITY**

ANGIITIS, LEUKOCYTOCLASTIC see **VASCULITIS, HYPERSENSITIVITY**

ANGINA AT REST see **ANGINA, UNSTABLE**

ANGINA, MICROVASCULAR see **SYNDROME X**

ANGINA PECTORIS

Characterization and identification of women with angina pectoris. Holdright DR, et al. **Eur Heart J** 1996 Apr; 17(4):510–7 (70 ref.)
Angina: an update for dentistry. Herman WW, et al. **J Am Dent Assoc** 1996 Jan;127(1):98–104 (62 ref.)

DIAGNOSIS

[Sinoatrial block caused by gastroesophageal reflux. The role of simultaneous 24 hr. esophageal pH-metry and Holter-ECG in the differential diagnosis of angina pectoris] Patai A, et al. **Orv Hetil** 1996 Mar 31;137(13):687–90 (38 ref.) (Eng. Abstr.) **(Hun)**

DRUG THERAPY

Heart rate reduction in the treatment of chronic stable angina pectoris: experiences with a sinus node inhibitor [editorial] Frishman WH, et al. **Am Heart J** 1996 Jan;131(1):204–10 (63 ref.)
Prognosis of patients with stable angina pectoris on antianginal drug therapy. Hjemdahl P, et al. **Am J Cardiol** 1996 Jun 20;77(16):6D–15D (67 ref.)
Intermittent or continuous transdermal nitroglycerin: still an issue, or is the case closed? Klemsdal TO, et al. **Cardiovasc Drugs Ther** 1996 Mar;10(1):5–10 (61 ref.)
Medical management of stable angina and unstable angina in the elderly with coronary artery disease. Olson HG, et al. **Clin Geriatr Med** 1996 Feb;12(1):121–40 (72 ref.)
Nicorandil for angina. **Drug Ther Bull** 1995 Dec;33(12):89–92 (26 ref.)
Nifedipine gastrointestinal therapeutic system (GITS). A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in hypertension and angina pectoris. Brogden RN, et al. **Drugs** 1995 Sep; 50(3):495–512 (82 ref.)
Amlodipine. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease [published erratum appears in Drugs 1995 Nov;50(5):896] Haria M, et al. **Drugs** 1995 Sep;50(3):560–86 (196 ref.)
Celiprolol. An evaluation of its pharmacological properties and clinical efficacy in the management of hypertension and angina pectoris. Dunn CJ, et al. **Drugs Aging** 1995 Nov; 7(5):394–411 (111 ref.)
Are antianginal drugs effective in secondary prevention after myocardial infarction? Julian DG. **Eur Heart J** 1995 Jul; 16 Suppl E:38–40 (13 ref.)
Are antianginal drugs effective in post-myocardial infarction secondary prevention? Sleight P. **Eur Heart J** 1995 Jul;16 Suppl E:36–7 (11 ref.)
Relevance of the pharmacokinetic profile in the treatment of angina pectoris: the need for 24 h control. Tamargo J, et al. **Eur Heart J** 1995 Jul;16 Suppl E:57–61 (33 ref.)
Chronic stable angina pectoris. Strategies for effective drug therapy. Thadani U, et al. **Postgrad Med** 1995 Dec; 98(6):175–6, 179–83, 187–8 (28 ref.)
Calcium channel antagonists in the management of anginal syndromes: changing concepts in relation to the role of coronary vasospasm. Opie LH. **Prog Cardiovasc Dis** 1996 Jan–Feb;38(4):291–314 (154 ref.)
[Treatment of Angina pectoris using nitrates] van Wijngaarden J, et al. **Ned Tijdschr Geneeskd** 1996 Apr 13; 140(15):819–22 (25 ref.) **(Dut)**
[Controlled clinical studies of tolerance development and dosing problems in nitrate therapy] Abshagen U. **Herz** 1996 Jun;21 Suppl 1:23–30 (18 ref.) (Eng. Abstr.) **(Ger)**
[Characteristics of angina pectoris therapy with nitrates] Silber S. **Herz** 1996 Jun;21 Suppl 1:4–22 (331 ref.) (Eng. Abstr.) **(Ger)**
[Drug therapy in angina pectoris] Follath F. **Schweiz Rundsch Med Prax** 1995 Oct 17;84(42):1186–9 (22 ref.) (Eng. Abstr.) **(Ger)**
[Local drug administration systems, preclinical and clinical use: perspectives and limitations] Gonschior P, et al. **Z Kardiol** 1996 Mar;85(3):155–65 (59 ref.) (Eng. Abstr.) **(Ger)**

ECONOMICS

Can improved quality of care reduce the costs of managing angina pectoris? Cleland JG. **Eur Heart J** 1996 Mar;17 Suppl A:29–40 (74 ref.)

ETIOLOGY

Microvascular angina in systemic hypertension: diagnosis and treatment with enalapril. Iriarte MM, et al. **Am J Cardiol** 1995 Nov 2;76(13):31D–34D (18 ref.)
Microvascular angina in patients with normal coronary arteries and with other ischaemic syndromes. Cianflone D, et al. **Eur Heart J** 1995 Aug;16 Suppl.I:96–103 (77 ref.)
Migraine and angina pectoris by coronary artery spasm. Lafitte C, et al. **Headache** 1996 May;36(5):332–4 (14 ref.)
The evaluation of chest pain in women. Douglas PS, et al. **N Engl J Med** 1996 May 16;334(20):1311–5 (55 ref.)
[Atresia of the left coronary artery: a case in a marathon runner. Review of the literature] Bouchiat C, et al. **Arch Mal Coeur Vaiss** 1996 Apr;89(4):485–7 (10 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Angina reassessed: pain or protector? [see comments] Yellon DM, et al. **Lancet** 1996 Apr 27;347(9009):1159–62 (45 ref.) Comment in: Lancet 1996 Jul 20;348(9021):204.
[Pharmacology of nitrates and other NO donors] Dendorfer A. **Herz** 1996 Jun;21 Suppl 1:38–49 (54 ref.) (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

[Risk predictors and secondary prevention in angina pectoris and after myocardial infarct] Huber K, et al. **Internist (Berl)** 1995 Sep;36(9):883–90 (74 ref.) **(Ger)**

REHABILITATION

Cardiac rehabilitation: how can it be improved? [editorial] Thompson DR. **J Psychosom Res** 1995 Jul;39(5):519–23 (20 ref.)

SURGERY

The management of patients with stable angina and multivessel disease. PTCA or coronary bypass surgery? Gersh BJ. **Eur Heart J** 1995 Jul;16 Suppl E:32–5 (20 ref.)

THERAPY

North of England evidence based guidelines development project: summary version of evidence based guideline for the primary care management angina. North of England Stable Angina Guideline Development Group. **BMJ** 1996 Mar 30;312(7034):827–32 (123 ref.)
Right coronary artery pseudo-transection due to mechanical straightening during coronary angioplasty. Blankenship JC. **Cathet Cardiovasc Diagn** 1995 Sep;36(1):43–5 (7 ref.)
Coronary angioplasty versus coronary surgery in the management of angina. Rickards AF, et al. **Curr Opin Cardiol** 1995 Jul;10(4):399–403 (15 ref.)
Can improved quality of care reduce the costs of managing angina pectoris? Cleland JG. **Eur Heart J** 1996 Mar;17 Suppl A:29–40 (74 ref.)
Education from RITA. Randomized Intervention Treatment of Angina. Hampton JR. **Eur Heart J** 1995 Jul;16(7):878–81 (20 ref.)
Comparison of medical treatment, coronary angioplasty and coronary artery bypass surgery in patients with chronic stable angina. Gogna A, et al. **J Assoc Physicians India** 1995 Aug;43(8):548–52 (33 ref.)
Does counselling for angina and hypertension work? Browne D. **Practitioner** 1995 Nov;239(1556):679–81 (13 ref.)
[Epidural electrostimulation in the treatment of refractory angina pectoris in elderly patients: preliminary results] Romanò M, et al. **Cardiologia** 1995 Jun;40(6):399–405 (32 ref.) (Eng. Abstr.) **(Ita)**

ANGINA PECTORIS, VARIANT

DRUG THERAPY

Effect of calcium antagonists in variant or Prinzmetal angina. Pepine CJ. **Can J Cardiol** 1995 Nov;11(10):952–6 (44 ref.)

ANGINA PECTORIS WITH NORMAL CORONARY ARTERIOGRAM see **SYNDROME X**

ANGINA, PREINFARCTION see **ANGINA, UNSTABLE**

ANGINA, UNSTABLE

[Unstable angina pectoris. Pathogenesis, treatment and prognosis] Kirkebøen KA. **Tidsskr Nor Laegeforen** 1995 Nov 10;115(27):3376–81 (67 ref.) (Eng. Abstr.) **(Nor)**

COMPLICATIONS

Spontaneous iliopsoas hematoma in patients with unstable coronary syndromes receiving intravenous heparin in therapeutic doses. Sasson Z, et al. **Can J Cardiol** 1996 May; 12(5):490–4 (35 ref.)

DIAGNOSIS

Risk stratification in patients with unstable angina: 'déjà vu all over again'? [editorial; comment] Pitt B. **Circulation** 1996 May 1;93(9):1618–20 (21 ref.) Comment on: Circulation 1996 May 1;93(9):1651–7.
Unstable angina pectoris. What is the likelihood of further cardiac events? Bankwala Z, et al. **Postgrad Med** 1995 Dec; 98(6):155–8, 161–2, 164–5 (18 ref.)
[Unstable angina. Physiopathology, clinical course and therapeutic principles] Aubry P, et al. **Presse Med** 1995 Dec 9;24(38):1788–94 (30 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

Relation between systemic anticoagulation as determined by activated partial thromboplastin time and heparin measurements and in-hospital clinical events in unstable angina and non-Q wave myocardiaL infarction. Thrombolysis in Myocardial Ischemia III B Investigators. Becker RC, et al. **Am Heart J** 1996 Mar;131(3):421–33 (66

ref.)
Prognosis of patients with unstable angina or acute myocardial infarction treated with calcium channel antagonists. Ferrari R. **Am J Cardiol** 1996 Jun 20; 77(16):22D–25D (44 ref.)
Clinical applications of new antithrombotic agents. Beijering RJ, et al. **Ann Hematol** 1996 Apr;72(4):177–83 (52 ref.)
Prehospital administration of aspirin in patients with unstable angina and acute myocardial infarction. Eisenberg MJ, et al. **Arch Intern Med** 1996 Jul 22;156(14):1506–10 (34 ref.)
Medical management of stable angina and unstable angina in the elderly with coronary artery disease. Olson HG, et al. **Clin Geriatr Med** 1996 Feb;12(1):121–40 (72 ref.)
Antiplatelet, antithrombotic, and lytic therapy for unstable angina, and the appropriate role of revascularization. de Feyter PJ, et al. **Curr Opin Cardiol** 1995 Jul;10(4):389–98 (36 ref.)
Pharmacological properties of hirudin and its derivatives. Potential clinical advantages over heparin. Monreal M, et al. **Drugs Aging** 1996 Mar;8(3):171–82 (52 ref.)
r-hirudin in unstable angina pectoris. Rationale and preliminary data from the APT pilot study. Fox KA. **Eur Heart J** 1995 Jul;16 Suppl D:28–32 (15 ref.)
[Treatment of unstable angina pectoris] Luomanmäki K. **Duodecim** 1995;111(8):715–22 (37 ref.) **(Fin)**
-New perspectives in therapy of unstable angina- Hamm CW. **Herz** 1996 Feb;21(1):37–43 (69 ref.) (Eng. Abstr.) **(Ger)**
[Contemporary opinions on the use of aspirin, heparin and thrombolytic therapy in unstable angina pectoris--pathogenetic findings versus results of many clinical tests] Popiel M, et al. **Przegl Lek** 1996;53(1):33–40 (40 ref.) (Eng. Abstr.) **(Pol)**

ETIOLOGY

Morphological and functional significance of findings in unstable atherothrombotic plaque underlying acute coronary syndromes: a review. Baroldi G. **Int J Cardiol** 1995 Aug;49 Suppl:S3–9 (18 ref.)

PHYSIOPATHOLOGY

[Unstable angina pectoris. Pathogenesis, risk assessment and therapy] Schoebel FC, et al. **Dtsch Med Wochenschr** 1996 Mar 8;121(10):310–7 (63 ref.) **(Ger)**

THERAPY

Unstable angina. Strategies to minimize myocardial injury. Blake-Inada LM, et al. **Postgrad Med** 1996 Aug; 100(2):139–42, 147–9, 153–4 (20 ref.)
[Treatment of refractory unstable angina by transluminal coronary angioplasty] Baladier V, et al. **Arch Mal Coeur Vaiss** 1996 Feb;89(2):181–6 (28 ref.) (Eng. Abstr.) **(Fre)**
[Unstable angina. Physiopathology, clinical course and therapeutic principles] Aubry P, et al. **Presse Med** 1995 Dec 9;24(38):1788–94 (30 ref.) (Eng. Abstr.) **(Fre)**
[Clinical aspects and therapy of unstable angina pectoris] Rupprecht HJ, et al. **Med Klin** 1996 Jun 15;91(6):366–71 (54 ref.) **(Ger)**

ANGIODYSPLASIA

COMPLICATIONS

Angiodysplasia as the cause of massive lower gastrointestinal hemorrhage in a young adult. Report of a case. Greason KL, et al. **Dis Colon Rectum** 1996 Jun;39(6):702–4 (12 ref.)
[Digestive hemorrhage due to duodenal angiodysplasia in the periampullary area] Pamplona J, et al. **Gastroenterol Hepatol** 1996 May;19(5):250–2 (22 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

[Angiodysplasia of the right colon and aortic stenosis. A case report] Arcidiacono G, et al. **Minerva Cardioangiol** 1996 Apr;44(4):173–7 (25 ref.) (Eng. Abstr.) **(Ita)**

DRUG THERAPY

Watermelon stomach. An unusual cause of recurrent upper GI tract bleeding in the uraemic patient: efficient treatment with oestrogen-progesterone therapy. Hermans C, et al. **Nephrol Dial Transplant** 1996 May;11(5):871–4 (29 ref.)

ETIOLOGY

Watermelon stomach. An unusual cause of recurrent upper GI tract bleeding in the uraemic patient: efficient treatment with oestrogen-progesterone therapy. Hermans C, et al. **Nephrol Dial Transplant** 1996 May;11(5):871–4 (29 ref.)

ANGIOEDEMA see **ANGIONEUROTIC EDEMA**

ANGIOFIBROMA

PATHOLOGY

Angiomyofibroblastoma of the vulva and vagina. Nielsen GP, et al. **Mod Pathol** 1996 Mar;9(3):284–91 (25 ref.)

ANGIOFOLLICULAR LYMPHOID HYPERPLASIA see **GIANT LYMPH NODE HYPERPLASIA**

ANGIOGENESIS FACTOR

[Regulators of angiogenesis] Sato Y. **Nippon Yakurigaku Zasshi** 1996 Mar;107(3):109–17 (51 ref.) (Eng. Abstr.) **(Jpn)**

ANGIOGENESIS, PATHOLOGIC see **NEOVASCULARIZATION, PATHOLOGIC**

ANGIOGENESIS, PHYSIOLOGIC see **NEOVASCULARIZATION, PHYSIOLOGIC**

ANGIOGRANULOMA see **GRANULOMA, PYOGENIC**

ANGIOGRAPHY

CT angiography [see comments] Zeman RK, et al. **AJR Am J Roentgenol** 1995 Nov;165(5):1079–88 (65 ref.) Comment in: AJR Am J Roentgenol 1996 May;166(5):1227–9.
Interventional radiology in the treatment of blunt liver trauma: case report with review of literature. Harms J, et al. **Bildgebung** 1996 Mar;63(1):51–4 (22 ref.)
Arteriography and interventional therapy for diseases of the hand. Loring LA, et al. **Radiographics** 1995 Nov; 15(6):1299–310 (25 ref.)
The arterial blood supply of the pancreas: a review. III. The inferior pancreaticoduodenal artery. An anatomical review and a radiological study. Bertelli E, et al. **Surg Radiol Anat** 1996;18(2):67–74 (42 ref.)

ADVERSE EFFECTS

Vasodilatative and vasoconstrictive effects of angiography contrast media. Karstoft J, et al. **Acta Radiol Suppl** 1995; 399:164–9 (41 ref.)

METHODS

Reevaluation of duplex criteria for diagnosis of high-grade carotid artery stenosis: when do we need angiography and when can we operate without angiography? Karacagil S, et al. **Int Angiol** 1995 Dec;14(4):410–4 (14 ref.)
Spiral CT angiography--can we forget about arteriography to diagnose renal artery stenosis? [editorial] Olbricht CJ, et al. **Nephrol Dial Transplant** 1996 Jul;11(7):1227–31 (28 ref.)
[Ultrasonic angiography: principles and clinical use] Skjoldbye B, et al. **Ugeskr Laeger** 1995 Oct 2; 157(40):5530–3 (8 ref.) (Eng. Abstr.) **(Dan)**

STANDARDS

Angiographic and duplex grading of internal carotid stenosis: can we overcome the confusion? Nicolaides AN, et al. **J Endovasc Surg** 1996 May;3(2):158–65 (32 ref.)

ANGIOGRAPHY, CEREBRAL see **CEREBRAL ANGIOGRAPHY**

ANGIOGRAPHY, CORONARY see **CORONARY ANGIOGRAPHY**

ANGIOGRAPHY, DIGITAL SUBTRACTION

[The evaluation of 3DFT time-of-flight MR-angiography versus angiography in the study of carotid atheromatous lesions with a review of the literature] Auffray-Calvier E, et al. **J Neuroradiol** 1995 Dec;22(4):272–87 (30 ref.) (Eng. Abstr.) **(Fre)**
[Spiral scanning angiography of pulmonary embolism] Rémy J, et al. **J Radiol** 1996 May;77(5):325–38 (60 ref.) **(Fre)**

INSTRUMENTATION

Intravenous coronary angiography with dichromography using synchrotron radiation. Hamm CW, et al. **Herz** 1996 Apr;21(2):127–31 (13 ref.)

ANGIOGRAPHY, MAGNETIC RESONANCE see **MAGNETIC RESONANCE ANGIOGRAPHY**

ANGIOHEMOPHILIA see **VON WILLEBRAND'S DISEASE**

ANGIOIMMUNOBLASTIC LYMPHADENOPATHY see **IMMUNOBLASTIC LYMPHADENOPATHY**

ANGIOKERATOMA CORPORIS DIFFUSUM see **FABRY'S DISEASE**

ANGIOLEIOMYOMA see **ANGIOMYOMA**

ANGIOLIPOMA

Angiolipoma of suprasellar region. Shuangshoti S, et al. **J Med Assoc Thai** 1995 Nov;78(11):631–4 (7 ref.)

COMPLICATIONS

[An adult case of intussusception due to inverted Meckel's diverticulum accompanied by angiolipoma] Kaneko T, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Apr;93(4):260–5 (14 ref.) **(Jpn)**

DIAGNOSIS

[Angiolipoma of the cecum] Saroglia G, et al. **Minerva Chir** 1996 Jan-Feb;51(1-2):59–62 (5 ref.) (Eng. Abstr.) **(Ita)**

PATHOLOGY

Cavernous angioma associated with oligo-astrocytoma-like proliferation. Report of two cases and review of the literature with a reappraisal of the term "angioglioma". Palma L, et al. **Acta Neurochir (Wien)** 1995;133(3-4):169–73 (36 ref.)
Spinal extradural angiolipoma. Krishnan VB, et al. **Aust N Z J Surg** 1996 Mar;66(3):194–6 (13 ref.)
Angiolipoma of the cheek: report of a case. Ali MH, et al. **J Oral Maxillofac Surg** 1996 Feb;54(2):213–5 (17 ref.)

ANGIOLYMPHOID HYPERPLASIA WITH EOSINOPHILIA

COMPLICATIONS

Kimura's disease and minimal-change nephrotic syndrome. Sud K, et al. **Nephrol Dial Transplant** 1996 Jul; 11(7):1349–51 (13 ref.)

PATHOLOGY

Angiolymphoid hyperplasia with eosinophilia affecting the oral mucosa: report of a case and a review of the literature. Bartralot R, et al. **Br J Dermatol** 1996 Apr;134(4):744–8 (28 ref.)

ANGIOMA see **HEMANGIOMA**

ANGIOMA, SCLEROSING see **DERMATOFIBROMA**

ANGIOMATOSIS

see related
TELANGIECTASIA, HEREDITARY HEMORRHAGIC

[Diffuse gastric angiomatosis. A clinical case. Review of the literature] Germain MA, et al. **Chirurgie** 1996;121(1):11–4 (20 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

[A case of angiosarcoma of the pelvis associated with angiomatosis of the spine] Uribe Uribe NO, et al. **Rev Invest Clin** 1996 Jan-Feb;48(1):49–53 (9 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Cystic angiomatosis: case report and review of the literature. Levey DS, et al. **Skeletal Radiol** 1996 Apr;25(3):287–93 (45 ref.)

ANGIOMATOSIS, BACILLARY

Bacillary angiomatosis: microbiology, histopathology, clinical presentation, diagnosis and management. Ramirez Ramirez CR, et al. **Bol Asoc Med P R** 1995 Jul-Sep; 87(7-9):140–6 (22 ref.)
Bacillary angiomatosis. Manders SM. **Clin Dermatol** 1996 May-Jun;14(3):295–9 (51 ref.)
[Bartonella (Rochalimaea) infections: cat-scratch disease and bacillary angiomatosis] Sander A, et al. **Dtsch Med Wochenschr** 1996 Jan 19;121(3):65–9 (47 ref.) **(Ger)**

COMPLICATIONS

Bacillary angiomatosis and parenchymal peliosis: frequent absence of mucocutaneous lesions [editorial] Schwartzman WA. **Clin Infect Dis** 1996 May;22(5):801–2 (14 ref.)

DIAGNOSIS

Bacillary angiomatosis and parenchymal peliosis: frequent absence of mucocutaneous lesions [editorial] Schwartzman WA. **Clin Infect Dis** 1996 May;22(5):801–2 (14 ref.)
Neurologic complications of Bartonella henselae infection. Marra CM. **Curr Opin Neurol** 1995 Jun;8(3):164–9 (65 ref.)

ANGIOMATOSIS, EPITHELIOID see **ANGIOMATOSIS, BACILLARY**

ANGIOMYOLIPOMA

[Lipomatous tumors (lipoma, angiomyolipoma, myelolipoma, focal fatty change) in the liver] Imaoka S, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):288–91 (24 ref.) **(Jpn)**

DIAGNOSIS

[Renal angiomyolipoma located intrasinusally. An anomalous location which poses diagnostic problems] Franco A, et al. **Actas Urol Esp** 1995 Mar;19(3):239–41; discussion 241–2 (7 ref.) (Eng. Abstr.) **(Spa)**

PATHOLOGY

Angiomyolipoma of the kidney with extension into the

ANGIOMYOLIPOMA

inferior vena cava. Hibi H, et al. **Int J Urol** 1995 Nov; 2(5):332–5 (14 ref.)

[Angiomyolipoma: the role of puncture–aspiration cytodiagnosis] Farina LA, et al. **Prog Urol** 1995 Sep; 5(4):575–7 (36 ref.) (Eng. Abstr.) **(Fre)**

ANGIOMYOMA

[Smooth muscle tumors of the extra–hepatic bile duct] Saito K. **Ryoikibetsu Shokogun Shirizu** 1996;(9):64–7 (22 ref.) **(Jpn)**

GENETICS

An angiomyoma with t(X;10)(q22;q23.2). Sonobe H, et al. **Cancer Genet Cytogenet** 1996 Aug;90(1):54–6 (17 ref.)

PATHOLOGY

Angiomyofibroblastoma of the vulva and vagina. Nielsen GP, et al. **Mod Pathol** 1996 Mar;9(3):284–91 (25 ref.)

SURGERY

[A case of vascular leiomyoma in the larynx] Kamata T, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1995 Jul;98(7):1119–24 (29 ref.) (Eng. Abstr.) **(Jpn)**

ANGIOMYXOMA see **MYXOMA**

ANGIONEUROTIC EDEMA

Urticaria and angioedema: a clinical spectrum. Charlesworth EN. **Ann Allergy Asthma Immunol** 1996 Jun;76(6):484–95; quiz 495–9 (90 ref.)

CHEMICALLY INDUCED

Perioperative angioedema in a patient on long–term angiotensin–converting enzyme (ACE)–inhibitor therapy. Ogbureke KU, et al. **J Oral Maxillofac Surg** 1996 Jul; 54(7):917–20 (18 ref.)

[Clinicopharmacological case report (3). Drug–induced angioedema] Kind B, et al. **Schweiz Rundsch Med Prax** 1996 Apr 23;85(17):567–9 (27 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Update on urticaria and angioedema (hives). Fox RW. **Allergy Proc** 1995 Nov–Dec;16(6):289–92 (20 ref.)

ANGIOPLASTY

see related

ENDARTERECTOMY

[Radiation–induced coronary ostial stenosis, a case of redo coronary bypass for the restenosis following patch angioplasty] Takewa Y, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Feb;44(2):220–5 (16 ref.) (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Peripheral vascular complications following coronary interventional procedures. Nasser TK, et al. **Clin Cardiol** 1995 Nov;18(11):609–14 (54 ref.)

METHODS

Endovascular surgical approach to intracranial vascular diseases. Higashida RT, et al. **J Endovasc Surg** 1996 May; 3(2):146–57 (57 ref.)

ANGIOPLASTY, BALLOON

Interventional neuroradiology. Pelz DM. **Baillieres Clin Neurol** 1995 Aug;4(2):297–315 (60 ref.)

Intravascular ultrasound imaging of peripheral arteries as an adjunct to balloon angioplasty and atherectomy. Korogi Y, et al. **Cardiovasc Intervent Radiol** 1996 Jan–Feb;19(1):1–9 (39 ref.)

Percutaneous revascularization in peripheral arterial disease. Rosenfield K, et al. **Curr Probl Cardiol** 1996 Jan;21(1):7–93 (228 ref.)

New concepts of the renin–angiotensin system—implications for vascular and endovascular surgery. O'Donohoe MK, et al. **Eur J Vasc Endovasc Surg** 1996 May;11(4):393–401 (117 ref.)

Intravascular ultrasound assessment in carotid interventions. Reid DB, et al. **J Endovasc Surg** 1996 May;3(2):203–10 (9 ref.)

Angioplasty for the treatment of visceral ischemia. Hallisey MJ, et al. **J Vasc Interv Radiol** 1995 Sep–Oct;6(5):785–91 (26 ref.)

Infrapopliteal percutaneous transluminal angioplasty: what we know [comment] Bakal CW, et al. **Radiology** 1996 Jul; 200(1):36–43 (58 ref.) Comment on: Radiology 1996 Jul;200(1):33–6.

Percutaneous transluminal angioplasty of the infrapopliteal vessels: the evidence [see comments] Fraser SC, et al. **Radiology** 1996 Jul;200(1):33–6 (44 ref.) Comment in: Radiology 1996 Jul;200(1):36–43.

Options for therapy of ischemic nephropathy: role of angioplasty and surgery. Novick AC. **Semin Nephrol** 1996 Jan;16(1):53–60 (61 ref.)

[Renal revascularization for kidney salvage or preservation] Van Damme H, et al. **Rev Med Liege** 1996 Feb;51(2):175–86 (47 ref.) **(Fre)**

[Percutaneous local thrombolytic therapy and thrombectomy in occlusion of extremity arteries] Schneider E, et al. **Internist (Berl)** 1996 Jun;37(6):607–12 (23 ref.) **(Ger)**

[Quality of life after an episode of myocardial infarct] Borrello G, et al. **Minerva Cardioangiol** 1995 Jul–Aug; 43(7–8):315–27 (39 ref.) (Eng. Abstr.) **(Ita)**

[Percutaneous transluminal angioplasty of the vena cava inferior] Ledesma Velasco M, et al. **Arch Inst Cardiol Mex** 1995 May–Jun;65(3):255–9 (7 ref.) (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Complications associated with extracranial carotid artery interventions. Dorros G. **J Endovasc Surg** 1996 May; 3(2):166–70 (15 ref.)

Infected iliac pseudoaneurysm after uncomplicated percutaneous balloon angioplasty and (Palmaz) stent insertion: a case report and literature review. Weinberg DJ, et al. **J Vasc Surg** 1996 Jan;23(1):162–6 (17 ref.)

Prevention of late lumen loss after coronary angioplasty by photodynamic therapy: role of activated neutrophils. Sluiter W, et al. **Mol Cell Biochem** 1996 Apr 12–26; 157(1–2):233–8 (44 ref.)

INSTRUMENTATION

Traumatic bilateral carotid–cavernous fistulas treated with detachable balloon. A case report. Kim JK, et al. **Acta Radiol** 1996 Jan;37(1):46–8 (6 ref.)

Endovascular repair of abdominal aortic aneurysms using the EGS tube and bifurcated graft systems. Colburn MD, et al. **World J Surg** 1996 Jul–Aug;20(6):664–72 (44 ref.)

Endovascular technology and its impact on the relationships among vascular surgeons, interventional radiologists, and other specialists. Veith FJ, et al. **World J Surg** 1996 Jul–Aug;20(6):687–91 (36 ref.)

[Endovascular reconstruction of infrarenal abdominal aortic aneurysm] Allenberg JR, et al. **Chirurg** 1995 Sep; 66(9):870–7 (24 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Carotid angioplasty and stenting: is endovascular treatment for cerebrovascular disease justified [editorial] Bergeron P. **J Endovasc Surg** 1996 May;3(2):129–31 (12 ref.)

Indications for carotid artery stenting: a preview of the potential derived from early clinical experience [editorial] Diethrich EB. **J Endovasc Surg** 1996 May;3(2):132–9 (15 ref.)

Percutaneous techniques for endoluminal carotid interventions. Diethrich EB, et al. **J Endovasc Surg** 1996 May;3(2):182–202 (8 ref.)

Anesthesia for carotid stent procedures. Kharrazi MR. **J Endovasc Surg** 1996 May;3(2):211–6 (8 ref.)

[Value of interventional angiology in carotid stenosis] Zanella FE. **Schweiz Med Wochenschr** 1995 Oct 28;125(43):2046–52 (33 ref.) (Eng. Abstr.) **(Ger)**

NURSING

Patient preparation and monitoring for carotid stenting: the operating room nurse's perspective. Plat S, et al. **J Endovasc Surg** 1996 May;3(2):224–7 (6 ref.)

ANGIOPLASTY, BALLOON, CORONARY see **ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY**

ANGIOPLASTY, BALLOON, LASER–ASSISTED

[Progresses in laser medicine in China, 1995] Xu S. **Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):774–6 (0 ref.) **(Chi)**

[Excimer laser assisted angioplasty. Immediate results in the treatment of complex coronary lesions] Escojido H, et al. **Arch Mal Coeur Vaiss** 1996 Apr;89(4):407–15 (29 ref.) (Eng. Abstr.) **(Fre)**

[The popliteal artery entrapment syndrome in an older patient. Its diagnosis after unsuccessful laser–assisted percutaneous transluminal angioplasty] Bail DH, et al. **Dtsch Med Wochenschr** 1996 Mar 15;121(11):336–40 (18 ref.) (Eng. Abstr.) **(Ger)**

INSTRUMENTATION

[PTCA or alternative techniques? Balloon angioplasty remains dominant] Reifart N. **Z Kardiol** 1995;84 Suppl 2:43–52 (30 ref.) (Eng. Abstr.) **(Ger)**

METHODS

New devices in interventional cardiology: present and future. Beyar R. **Isr J Med Sci** 1996 Jul;32(7):515–25 (42 ref.)

ANGIOPLASTY, CORONARY BALLOON see **ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY**

ANGIOPLASTY, EXCIMER LASER see **ANGIOPLASTY, BALLOON, LASER–ASSISTED**

ANGIOPLASTY, LASER–ASSISTED, BALLOON see **ANGIOPLASTY, BALLOON, LASER–ASSISTED**

ANGIOPLASTY, TRANSLUMINAL see **ANGIOPLASTY, BALLOON**

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY

Roles of percutaneous transluminal coronary angioplasty and bypass graft surgery for the treatment of coronary artery disease. Cishek MB, et al. **Am Heart J** 1996 May; 131(5):1012–7 (58 ref.)

Management of restenosis after coronary intervention. Dangas G, et al. **Am Heart J** 1996 Aug;132(2 (Pt 1)):428–36 (58 ref.)

Acute stent thrombosis associated with exercise testing after successful percutaneous transluminal coronary angioplasty. Samuels B, et al. **Am Heart J** 1995 Nov;130(5):1120–2 (15 ref.)

Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective. Tcheng JE. **Am J Cardiol** 1996 Aug 14; 78(3A):35–40 (27 ref.)

Thrombolysis of primary angioplasty? An ongoing controversy in the management of acute myocardial infarction. Futterman LG, et al. **Am J Crit Care** 1996 Mar; 5(2):160–66 (20 ref.)

Fluvastatin for the prevention of restenosis after coronary balloon angioplasty: angiographic and methodological background of the fluvastatin angioplasty restenosis trial. Foley DP, et al. **Br J Clin Pract Symp Suppl** 1996 Jan; 77A:40–53 (53 ref.)

Direct angioplasty in acute myocardial infarction. State of the art and current controversies. Horrigan MC, et al. **Cardiol Clin** 1995 Aug;13(3):321–38 (108 ref.)

Aggressive interventional treatment of acute myocardial infarction. Lessons from the animal laboratory applied to the catheterization suite. Feld S, et al. **Cardiology** 1995; 86(5):365–73 (65 ref.)

Coronary angioplasty and surgical revascularization: emerging concepts. Philippides GJ, et al. **Cardiology** 1995; 86(4):324–38 (53 ref.)

The role of thrombin and thrombin inhibitors in coronary angioplasty. Ali MN, et al. **Chest** 1995 Nov;108(5):1409–19 (78 ref.)

Antithrombotic therapy in patients undergoing coronary angioplasty [published erratum appears in Chest 1996 Jan;109(1):295–6] Popma JJ, et al. **Chest** 1995 Oct;108(4 Suppl):486S–501S (133 ref.)

Restenosis—an open file. Gottsauner–Wolf M, et al. **Clin Cardiol** 1996 May;19(5):347–56 (118 ref.)

Percutaneous transluminal coronary angioplasty in the elderly. Thompson RC, et al. **Clin Geriatr Med** 1996 Feb; 12(1):181–94 (106 ref.)

The importance of early patency after acute myocardial infarction. Grover A, et al. **Curr Opin Cardiol** 1995 Jul; 10(4):361–6 (29 ref.)

Coronary angioplasty versus coronary surgery in the management of angina. Rickards AF, et al. **Curr Opin Cardiol** 1995 Jul;10(4):399–403 (15 ref.)

Direct angioplasty for acute myocardial infarction. Stewart RE, et al. **Curr Opin Cardiol** 1995 Jul;10(4):367–71 (32 ref.)

Pharmacological properties of hirudin and its derivatives. Potential clinical advantages over heparin. Monreal M, et al. **Drugs Aging** 1996 Mar;8(3):171–82 (52 ref.)

The management of patients with stable angina and multivessel disease. PTCA or coronary bypass surgery? Gersh BJ. **Eur Heart J** 1995 Jul;16 Suppl E:32–5 (20 ref.)

Multivessel angioplasty versus bypass surgery. A case for PTCA. Grines CL, et al. **Eur Heart J** 1995 Jul;16 Suppl E:29–31 (13 ref.)

Restenosis after coronary angioplasty. Hamon M, et al. **Eur Heart J** 1995 Aug;16 Suppl I:33–48 (163 ref.)

The effects of calcium antagonists after PTCA. Hoberg E. **Eur Heart J** 1995 Aug;16 Suppl H:9–12 (12 ref.)

Comparison of medical treatment, coronary angioplasty and coronary artery bypass surgery in patients with chronic stable angina. Gogna A, et al. **J Assoc Physicians India** 1995 Aug;43(8):548–52 (33 ref.)

Clinical aspects of preconditioning and implications for the cardiac surgeon. Kloner RA, et al. **J Card Surg** 1995 Jul; 10(4 Suppl):369–75 (38 ref.)

Thallium imaging in management of post–revascularization patients. Alazraki P, et al. **Q J Nucl Med** 1996 Mar; 40(1):85–90 (26 ref.)

Treatment of acute myocardial infarction by invasive cardiology techniques. Morris DC. **Semin Thorac Cardiovasc Surg** 1995 Oct;7(4):184–90 (42 ref.)

Cell biology of restenosis post–angioplasty. Badimon L, et al. **Z Kardiol** 1995;84 Suppl 4:145–9 (25 ref.)

Interrelation between atherosclerosis and restenosis. Kranzhöfer R, et al. **Z Kardiol** 1995;84 Suppl 4:125–8 (28 ref.)

Angioplasty or thrombolysis for acute infarction? Reeder GS. **Z Kardiol** 1995;84 Suppl 2:1–4 (14 ref.)

[Progress in the interventional therapy of coronary disease] Wang L, et al. **Chung Hua Nei Ko Tsa Chih** 1995 May; 34(5):347–9 (17 ref.) **(Chi)**

[15 years of coronary angioplasty: focus on the different techniques] Dupouy P, et al.

Ann Cardiol Angeiol (Paris) 1995 Oct;44(8):433–7 (31 ref.) (Eng. Abstr.) **(Fre)**

[Treatment of refractory unstable angina by transluminal coronary angioplasty] Baladier V, et al. **Arch Mal Coeur Vaiss** 1996 Feb;89(2):181–6 (28 ref.) (Eng. Abstr.) **(Fre)**

[Is plasma lipoprotein (a) level a reliable indicator predicting restenosis after angioplasty?] Bussière JL, et al. **Arch Mal Coeur Vaiss** 1996 Apr;89(4):425–9 (24 ref.) (Eng. Abstr.) **(Fre)**

[Excimer laser assisted angioplasty. Immediate results in the treatment of complex coronary lesions] Escojido H, et al. **Arch Mal Coeur Vaiss** 1996 Apr;89(4):407–15 (29 ref.) (Eng. Abstr.) **(Fre)**

[Mechanisms of restenosis after coronary angioplasty] Leclercq F, et al. **Arch Mal Coeur Vaiss** 1996 Mar; 89(3):359–65 (42 ref.) (Eng. Abstr.) **(Fre)**

[Indications of coronary angioplasty after thrombolysis] Vahanian A, et al. **Arch Mal Coeur Vaiss** 1995 Aug;88 Spec No 3:19–24 (30 ref.) (Eng. Abstr.) **(Fre)**

[Angioplasty or bypass for multitruncal coronary disease. Viewpoint of the cardiologist] Urban P. **Schweiz Med Wochenschr** 1995 Oct 28;125(43):2062–6 (30 ref.) (Eng. Abstr.) **(Fre)**

[Coronary angioplasty in elderly patients] Eeckhout E, et al. **Schweiz Rundsch Med Prax** 1996 Feb 6;85(6):168–71 (18 ref.) (Eng. Abstr.) **(Fre)**

[Immediate PTCA in acute myocardial infarct—results and indications] Deutsch HJ, et al. **Herz** 1996 Jun;21(3):201–6 (30 ref.) **(Ger)**

–Differential antithrombotic therapy in patients with low and high PTCA risk– Silber S, et al. **Herz** 1996 Feb;21(1):44–59 (213 ref.) (Eng. Abstr.) **(Ger)**

[Risk predictors and secondary prevention after PTCA and bypass operations] Gulba DC, et al. **Internist (Berl)** 1995 Sep;36(9):891–901 (82 ref.) **(Ger)**

[Symptomatic therapy refractory myocardial ischemia in coronary heart disease. Chronic intermittent urokinase therapy and invasive therapeutic measures] Leschke M, et al. **Internist (Berl)** 1996 Jun;37(6):597–606 (50 ref.) **(Ger)**

[Therapeutic measures following acute myocardial infarct: differential use of PTCA, surgery and drugs] Noll G, et al. **Schweiz Med Wochenschr** 1996 Feb 3;126(5):164–76 (81 ref.) (Eng. Abstr.) **(Ger)**

[Myocardial stunning during coronary angioplasty: significance and clinical relevance] Trevi G, et al. **Cardiologia** 1996 May;41(5):427–33 (70 ref.) **(Ita)**

[Rescue angioplasty: when?] Klugmann S, et al. **G Ital Cardiol** 1995 Nov;25(11):1439–46 (11 ref.) **(Ita)**

[Surgical or percutaneous revascularization in multi-vessel coronary disease] Zingone B. **G Ital Cardiol** 1995 Dec; 25(12):1607–19 (123 ref.) (Eng. Abstr.) **(Ita)**

[Angioplasty, surgical, or clinical treatment. Therapeutic options for obstructive coronary artery disease (editorial)] Hueb WA, et al. **Arq Bras Cardiol** 1995 Jul;65(1):7–10 (28 ref.) **(Por)**

[The effect of angioplasty on cerebral vasomotor reactivity in patients with important stenosis of the internal carotid artery] Arenas C, et al. **Rev Neurol** 1996 Feb;24(126):224–6 (12 ref.) (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Coronary pseudoaneurysm after angioplasty. Flum DR, et al. **Am Surg** 1995 Dec;61(12):1035–8 (40 ref.)

Restenosis following coronary angioplasty: clinical presentations and therapeutic options. Levine GN, et al. **Clin Cardiol** 1995 Dec;18(12):693–703 (80 ref.)

Invasive staphylococcal infections complicating percutaneous transluminal coronary angioplasty: three cases and review. Cleveland KO, et al. **Clin Infect Dis** 1995 Jul;21(1):93–6 (17 ref.)

Myocardial protection with calcium-channel blockers during ischaemia and reperfusion by PTCA. Chouairi S, et al. **Eur Heart J** 1995 Aug;16 Suppl H:3–8 (42 ref.)

Coronary ventricular fistula as a complication of PTCA: a case report and literature review. el-Omar MM, et al. **Int J Cardiol** 1995 Sep;51(2):113–6 (10 ref.)

Recent insights into the mechanisms of iatrogenic arteriosclerosis [editorial] Ferns GA, et al. **J Pathol** 1995 Aug;176(4):331–2 (15 ref.)

The three processes leading to post PTCA restenosis: dependence on the lesion substrate. Fuster V, et al. **Thromb Haemost** 1995 Jul;74(1):552–9 (55 ref.)

[Restenosis: physiopathology, treatments and prevention] Lafont A, et al. **Ann Cardiol Angeiol (Paris)** 1995 Sep; 44(7):349–53 (31 ref.) (Eng. Abstr.) **(Fre)**

[Risks in diagnostic and therapeutic invasive cardiological procedures] Seiler C, et al. **Schweiz Med Wochenschr** 1996 Apr 6;126(14):559–65 (25 ref.) (Eng. Abstr.) **(Ger)**

[Reperfusion in myocardial infarction: a two-edged sword] Emanuelsson H, et al. **Lakartidningen** 1996 Mar 20; 93(12):1112–5 (20 ref.) **(Swe)**

[Antithrombotic treatment in connection with PTCA. New substances and regimes are coming] Scherstén F, et al. **Lakartidningen** 1996 Jun 26;93(26–27):2499–502 (29 ref.) **(Swe)**

INSTRUMENTATION

Reuse of coronary angioplasty equipment: technical and clinical issues [editorial] Mak K-H, et al. **Am Heart J** 1996 Mar;131(3):624–30 (49 ref.)

Right coronary artery pseudo-transection due to mechanical straightening during coronary angioplasty. Blankenship JC. **Cathet Cardiovasc Diagn** 1995 Sep;36(1):43–5 (7 ref.)

Intracoronary stents. Wong SC, et al. **Curr Opin Cardiol** 1995 Jul;10(4):404–11 (37 ref.)

Intravascular stents: current applications. Bailey SR, et al. **Curr Probl Cardiol** 1995 Sep;20(9):614–78 (191 ref.)

The autoperfusion balloon catheter with special attention to its use as a bail-out device. Bonnier JJ. **Z Kardiol** 1995; 84 Suppl 2:79–82 (17 ref.)

Coronary stents. Sigwart U. **Z Kardiol** 1995;84 Suppl 2:65–77 (75 ref.)

–Anticoagulation after intracoronary stent implantation– Bode C, et al. **Herz** 1996 Feb;21(1):60–3 (21 ref.) (Eng. Abstr.) **(Ger)**

[Local drug administration systems, preclinical and clinical use: perspectives and limitations] Gonschior P, et al. **Z Kardiol** 1996 Mar;85(3):155–65 (59 ref.) (Eng. Abstr.) **(Ger)**

[Drug and instrumental therapeutic approaches for prevention of restenosis] Höfling B, et al. **Z Kardiol** 1995; 84 Suppl 4:151–8 (36 ref.) (Eng. Abstr.) **(Ger)**

[PTCA or alternative techniques? Balloon angioplasty remains dominant] Reifart N. **Z Kardiol** 1995;84 Suppl 2:43–52 (30 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Percutaneous coronary revascularization versus coronary bypass surgery in multivessel disease. Banka VS, et al. **Indian Heart J** 1996 Jan–Feb;48(1):73–7 (24 ref.)

New devices in interventional cardiology: present and future. Beyar R. **Isr J Med Sci** 1996 Jul;32(7):515–25 (42 ref.)

[Treatment policy in coronary sclerosis in The Netherlands: suitable and less suitable indications for invasive interventions] Rigter H, et al. **Ned Tijdschr Geneeskd** 1996 Aug 3;140(31):1584–7 (14 ref.) **(Dut)**

[New tools in coronary artery angioplasty (editorial)] Peuhkurinen K, et al. **Duodecim** 1994;110(6):541–5 (21 ref.) **(Fin)**

[Myocardial adaptation to ischemia. A study during repeated prolonged coronary occlusions in angioplasty] Tron C, et al. **Arch Mal Coeur Vaiss** 1996 Apr;89(4):399–406 (27 ref.) (Eng. Abstr.) **(Fre)**

[Is coronary angioplasty the best treatment of acute myocardial infarction?] Himbert D, et al. **Presse Med** 1995 Dec 9;24(38):1831–5 (32 ref.) (Eng. Abstr.) **(Fre)**

[New aspects of blood coagulation inhibitory therapy within the scope of percutaneous transluminal coronary angioplasty (PTCA)] Schächinger V, et al. **Z Kardiol** 1995 Sep;84(9):651–67 (152 ref.) (Eng. Abstr.) **(Ger)**

MORTALITY

Potentiation of vasculopathy by insulin: implications from an NHLBI clinical alert [editorial] Sobel BE. **Circulation** 1996 May 1;93(9):1613–5 (20 ref.)

REHABILITATION

Diagnostic and functional exercise testing: test selection and interpretation. Franklin BA. **J Cardiovasc Nurs** 1995 Oct; 10(1):8–29 (57 ref.)

STANDARDS

Primary angioplasty and thrombolysis for acute myocardial infarction: an evidence summary [see comments] Lieu TA, et al. **J Am Coll Cardiol** 1996 Mar 1;27(3):737–50 (76 ref.) Comment in: J Am Coll Cardiol 1996 Mar 1;27(3):736.

ANGIOSARCOMA see **HEMANGIOSARCOMA**

ANGIOSCOPY

Angioscopy in vascular surgery: the state of the art. Pevec WC. **Ann Vasc Surg** 1996 Jan;10(1):66–75 (71 ref.)

Coronary angioscopy: exploring new frontiers. Shaw D, et al. **Indian Heart J** 1995 May–Jun;47(3):269–73 (51 ref.)

ANGIOTENSIN see **ANGIOTENSIN II**

ANGIOTENSIN I

BIOSYNTHESIS

[Alternative pathways of angiotensin I. The glimpse of new possibilities in the treatment of hypertension and heart failure (editorial)] Francischetti EA. **Arq Bras Cardiol** 1995 Mar;64(3):191–4 (49 ref.) **(Por)**

BLOOD

[Angiotensin I] Arita M, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:695–8 (12 ref.) **(Jpn)**

METABOLISM

Molecular biology of angiotensin receptors and their role in human cardiovascular disease. Regitz-Zagrosek V, et al. **J Mol Med** 1996 May;74(5):233–51 (229 ref.)

ANGIOTENSIN II

see related
RENIN-ANGIOTENSIN SYSTEM

ANALOGS & DERIVATIVES

Design and pharmacology of peptide mimetics. Moore GJ, et al. **Adv Pharmacol** 1995;33:91–41 (112 ref.)

ANALYSIS

Ontogeny of angiotensin II receptors. Shanmugam S, et al. **Cell Biol Int** 1996 Mar;20(3):169–76 (42 ref.)

ANTAGONISTS & INHIBITORS

Direct selective blockade of the vascular angiotensin II receptors in therapy for hypertension and severe congestive heart failure. Awan NA, et al. **Am Heart J** 1996 Jan; 131(1):177–85 (81 ref.)

Angiotensin II receptor blockers. A new class of antihypertensive drugs. Velasquez MT. **Arch Fam Med** 1996 Jun;5(6):351–6 (60 ref.)

Angiotensin II receptor antagonism: losartan – sites and mechanisms of action. Triggle DJ. **Clin Ther** 1995 Nov–Dec;17(6):1005–30 (132 ref.)

Effect of angiotensin II blockade on cardiac hypertrophy and remodelling: a review. Dahlöf B. **J Hum Hypertens** 1995 Nov;9 Suppl 5:S37–44 (84 ref.)

The future role of losartan. Hansson L. **J Hum Hypertens** 1995 Nov;9 Suppl 5:S55–8 (24 ref.)

Evolution of blockade of the renin-angiotensin system. Johnston CI, et al. **J Hum Hypertens** 1995 Jun;9(6):375–80 (46 ref.)

Discovery of losartan, the first angiotensin II receptor antagonist. Timmermans PB, et al. **J Hum Hypertens** 1995 Nov;9 Suppl 5:S3–18 (199 ref.)

BIOSYNTHESIS

Mechanisms of angiotensin II formation in humans. Urata H, et al. **Eur Heart J** 1995 Dec;16 Suppl N:79–85 (63 ref.)

[Alternative pathways of angiotensin I. The glimpse of new possibilities in the treatment of hypertension and heart failure (editorial)] Francischetti EA. **Arq Bras Cardiol** 1995 Mar;64(3):191–4 (49 ref.) **(Por)**

BLOOD

[Angiotensin II] Wanaka Y, et al. **Nippon Rinsho** 1995 Mar; 53 Su Pt 2:699–701 (9 ref.) **(Jpn)**

CHEMISTRY

[Comparative study of the structure and molecular functions of angiotensin II and vasopressin receptors] Clauser E. **C R Seances Soc Biol Fil** 1995;189(2):179–90 (37 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Molecular basis of human hypertension: the role of angiotensin. Peters J. **Baillieres Clin Endocrinol Metab** 1995 Jul;9(3):657–78 (80 ref.)

METABOLISM

Angiotensin peptides in the brain. Campbell DJ. **Adv Exp Med Biol** 1995;377:349–55 (30 ref.)

The angiotensin type 1 and type 2 receptor families. Siblings or cousins? Fluharty SJ, et al. **Adv Exp Med Biol** 1995; 377:193–215 (99 ref.)

Cloning, expression and regulation of angiotensin II receptors. Inagami T, et al. **Adv Exp Med Biol** 1995; 377:311–7 (36 ref.)

Regulation of angiotensin II receptor expression in ovarian follicles. A review. Nielsen AH, et al. **Adv Exp Med Biol** 1995;377:407–10 (19 ref.)

Brain angiotensin and the female reproductive cycle. Phillips MI, et al. **Adv Exp Med Biol** 1995;377:357–70 (19 ref.)

AT1 receptors and angiotensin actions in the brain and neuronal cultures of normotensive and hypertensive rats. Raizada MK, et al. **Adv Exp Med Biol** 1995;377:331–48 (124 ref.)

Angiotensin II receptors. Structural and functional considerations. Speth RC, et al. **Adv Exp Med Biol** 1995; 377:169–92 (170 ref.)

Chymase-dependent angiotensin II forming systems in humans. Urata H, et al. **Am J Hypertens** 1996 Mar; 9(3):277–84 (63 ref.)

Enhancement of intrarenal angiotensin II levels in 2 kidney 1 clip and angiotensin II induced hypertension. Navar LG, et al. **Blood Press Suppl** 1995;2:88–92 (23 ref.)

The role of angiotensin II and its receptors in regulation of adipose tissue metabolism and cellularity. Zorad S, et al. **Gen Physiol Biophys** 1995 Oct;14(5):383–91 (43 ref.)

Importance of tyrosine phosphorylation in angiotensin II type 1 receptor signaling. Schieffer B, et al. **Hypertension** 1996 Mar;27(3 Pt 2):476–80 (51 ref.)

Molecular biology of angiotensin receptors and their role in human cardiovascular disease. Regitz-Zagrosek V, et al. **J Mol Med** 1996 May;74(5):233–51 (229 ref.)

[Comparative study of the structure and molecular functions of angiotensin II and vasopressin receptors] Clauser E. **C R Seances Soc Biol Fil** 1995;189(2):179–90 (37 ref.) (Eng. Abstr.) **(Fre)**

PHARMACOLOGY

Design and pharmacology of peptide mimetics. Moore GJ, et al. **Adv Pharmacol** 1995;33:91–41 (112 ref.)

ANGIOTENSIN II

Role of peripheral angiotensin in salt appetite of the sodium-deplete rat. Thunhorst RL.
Neurosci Biobehav Rev 1996;20(1):101-6 (33 ref.)

PHYSIOLOGY

Angiotensin and the brain. Andersson B, et al.
Acta Physiol Scand 1995 Oct;155(2):117-25 (52 ref.)
Angiotensin II in cell growth and matrix production. Hsueh WA, et al. **Adv Exp Med Biol** 1995;377:217-23 (49 ref.)
The pathophysiology of ovarian hyperstimulation syndrome (OHSS). A proposal role of the ovarian derived prorenin to angiotensin cascade (ODPAC). Morris RS, et al.
Adv Exp Med Biol 1995;377:391-8 (37 ref.)
AT1 receptors and angiotensin actions in the brain and neuronal cultures of normotensive and hypertensive rats. Raizada MK, et al. **Adv Exp Med Biol** 1995;377:331-48 (124 ref.)
Angiotensin as a renal growth promoting factor. Wolf G. **Adv Exp Med Biol** 1995;377:225-36 (99 ref.)
Role of angiotensin II and prostaglandin E2 in regulating cardiac fibroblast collagen turnover. Brilla CG, et al.
Am J Cardiol 1995 Nov 2;76(13):8D-13D (42 ref.)
Angiotensin receptors and their therapeutic implications. Griendling KK, et al. **Annu Rev Pharmacol Toxicol** 1996; 36:281-306 (135 ref.)
Relationship of rostral ventrolateral medullary neurons and angiotensin in the central control of blood pressure. Chan YS, et al. **Biol Signals** 1995 May-Jun;4(3):133-41 (42 ref.)
Angiotensin II--an important stress hormone. Yang G, et al. **Biol Signals** 1996 Jan-Feb;5(1):1-8 (41 ref.)
Angiotensin II-mediated signal transduction events in vascular smooth muscle cells: kinases and phosphatases. Duff JL, et al. **Blood Press Suppl** 1995;2:55-60 (68 ref.)
Angiotensin II as a modulator of cardiovascular autonomic control. Townend JN. **Cardiologia** 1996 Mar;41(3):217-25 (83 ref.)
Angiotensin II signal transduction and the mitogen-activated protein kinase pathway. Duff JL, et al. **Cardiovasc Res** 1995 Oct;30(4):511-7 (102 ref.)
The role of tyrosine phosphorylation in angiotensin II-mediated intracellular signalling. Marrero MB, et al.
Cardiovasc Res 1995 Oct;30(4):530-6 (54 ref.)
Angiotensin II: biosynthesis, molecular recognition, and signal transduction. Riordan JF. **Cell Mol Neurobiol** 1995 Dec;15(6):637-51 (62 ref.)
Angiotensin II signalling events mediated by tyrosine phosphorylation. Marrero MB, et al. **Cell Signal** 1996 Jan; 8(1):21-6 (30 ref.)
Structural remodelling of the heart by fibrous tissue: role of circulating hormones and locally produced peptides. Weber KT, et al. **Eur Heart J** 1995 Dec;16 Suppl N:12-8 (83 ref.)
Cardiovascular hypertrophy: role of angiotensin II and bradykinin. Waeber B, et al. **J Cardiovasc Pharmacol** 1996; 27 Suppl 2:S36-40 (37 ref.)
Clinical review 79: Angiotensin II: an insulin-sensitizing vasoactive hormone? Morris AD, et al.
J Clin Endocrinol Metab 1996 Apr;81(4):1303-6 (40 ref.)
Vascular smooth muscle polyploidy in genetic hypertension: the role of angiotensin II. Devlin AM, et al.
J Hum Hypertens 1995 Jun;9(6):497-500 (16 ref.)
Role of angiotensin II in blood pressure regulation and in the pathophysiology of cardiovascular disorders. Fyhrquist F, et al. **J Hum Hypertens** 1995 Nov;9 Suppl 5:S19-24 (50 ref.)
Angiotensin II and glomerulonephritis. Jardine AG.
J Hypertens 1995 May;13(5):487-93 (73 ref.)
Angiotensin II-mediated renal injury. Harris RC, et al.
Miner Electrolyte Metab 1995;21(4-5):328-35 (83 ref.)
Angiotensin II signalling pathways in cardiac fibroblasts: conventional versus novel mechanisms in mediating cardiac growth and function. Dostal DE, et al.
Mol Cell Biochem 1996 Apr 12-26;157(1-2):15-21 (66 ref.)
Protein tyrosine phosphorylation in cardiovascular system. Srivastava AK. **Mol Cell Biochem** 1995 Aug-Sep; 149-150:87-94 (90 ref.)
Renal scarring: the role of angiotensin II. el Nahas AM.
Nephrol Dial Transplant 1995 Oct;10 Suppl 9:28-32 (53 ref.)
Angiotensin II and its different receptor subtypes in placenta and fetal membranes. Kalenga MK, et al. **Placenta** 1996 Mar-Apr;17(2-3):103-110 (50 ref.)
Role of angiotensin in the regulation of renal response to proteins. Gabbai FB, et al. **Semin Nephrol** 1995 Sep; 15(5):396-404 (56 ref.)

ANGIOTENSIN III

PHYSIOLOGY

Neurobiology of central angiotensin III and dipsogenesis. Yang CC, et al. **Biol Signals** 1995 Mar-Apr;4(2):59-71 (70 ref.)

ANGIOTENSIN BINDING SITES see **RECEPTORS, ANGIOTENSIN**

ANGIOTENSIN CONVERTING ENZYME see **PEPTIDYL-DIPEPTIDASE A**

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS

ADMINISTRATION & DOSAGE

Angiotensin converting enzyme inhibition in asymptomatic left ventricular systolic dysfunction and early heart failure. Konstam MA. **Eur Heart J** 1995 Dec;16 Suppl N:59-64 (44 ref.)
Effects of ACE inhibitors on mortality when started in the early phase of myocardial infarction: evidence from the larger randomized controlled trials. Flather MD, et al.
J Cardiovasc Risk 1995 Oct;2(5):423-8 (27 ref.)
Clinical background to the use of ACE inhibitor therapy after myocardial infarction. Hall AS, et al.
J Cardiovasc Risk 1995 Oct;2(5):396-405 (66 ref.)
Angiotensin converting enzyme inhibitors and calcium antagonists alone or combined: does the progression of diabetic renal disease differ? Bakris GL, et al.
J Hypertens Suppl 1995 Aug;13(2):S95-101 (52 ref.)
The pharmacological basis for the combination of calcium channel antagonists and angiotensin converting enzyme inhibitors in the treatment of hypertension. Osswald H, et al. **J Hypertens Suppl** 1995 Aug;13(2):S21-8 (58 ref.)
[Renal function during treatment with angiotensin converting enzyme inhibitors] Rasmussen K, et al. **Ugeskr Laeger** 1995 Sep 25;157(39):5377-81 (17 ref.) (Eng. Abstr.) **(Dan)**
[ACE inhibitors and early diabetic nephropathy] Bangstad HJ, et al. **Tidsskr Nor Laegeforen** 1995 Oct 10; 115(24):3039-41 (25 ref.) (Eng. Abstr.) **(Nor)**

ADVERSE EFFECTS

Adverse effects of the angiotensin-converting enzyme inhibitors. Alderman CP. **Ann Pharmacother** 1996 Jan; 30(1):55-61 (61 ref.)
ACE inhibitors in elderly patients with hypertension. Special considerations. Ravid M, et al. **Drugs Aging** 1996 Jan; 8(1):29-37 (89 ref.)
Delayed renal revascularisation after enalapril induced renal failure in renal artery stenosis. Khaira HS, et al.
Eur J Vasc Endovasc Surg 1996 Apr;11(3):375-7 (17 ref.)
Putative mechanisms of cough after treatment with angiotensin converting enzyme inhibitors. Semple PF.
J Hypertens Suppl 1995 Sep;13 Suppl 3:S17-21 (38 ref.)
Perioperative angioedema in a patient on long-term angiotensin-converting enzyme (ACE)-inhibitor therapy. Ogbureke KU, et al. **J Oral Maxillofac Surg** 1996 Jul; 54(7):917-20 (18 ref.)
Acute renal failure induced by angiotensin converting enzyme inhibitor in a patient with polyarteritis nodosa. Wang AY, et al. **Ren Fail** 1996 Mar;18(2):293-8 (17 ref.)
[Psychotropic effects of angiotensin-converting enzyme inhibitors: what are the arguments?] Mesure G, et al.
Encephale 1995 Sep-Oct;21(5):609-14 (59 ref.) (Eng. Abstr.) **(Fre)**
[ACE inhibitor-associated interstitial lung infiltrates (see comments)] Obergassel L, et al. **Dtsch Med Wochenschr** 1995 Sep 22;120(38):1273-7 (22 ref.) (Eng. Abstr.)
Comment in: Dtsch Med Wochenschr 1996 Jan 19;121(3):81. **(Ger)**
[Clinicopharmacological case report (3). Drug-induced angioedema] Kind B, et al. **Schweiz Rundsch Med Prax** 1996 Apr 23;85(17):567-9 (27 ref.) (Eng. Abstr.) **(Ger)**
[Cough as an adverse effect during angiotensin-converting enzyme inhibitor therapy] Adamek L, et al.
Pol Arch Med Wewn 1996 Mar;95(3):254-60 (33 ref.) **(Pol)**

BLOOD

[Inhibitors of renin-angiotensin system] Kawabe H, et al.
Nippon Rinsho 1995 Feb;53 Su Pt 1:994-7 (18 ref.) **(Jpn)**

CONTRAINDICATIONS

Current controversies with ACE inhibitor treatment in heart failure. Visser FC, et al. **Cardiology** 1996;87 Suppl 1:23-8 (21 ref.)

PHARMACOLOGY

Biochemistry and cell biology of angiotensin-converting enzyme and converting enzyme inhibitors. Berecek KH, et al. **Adv Exp Med Biol** 1995;377:141-68 (256 ref.)
Renin inhibition: a novel therapy for cardiovascular disease. Lin C, et al. **Am Heart J** 1996 May;131(5):1024-34 (115 ref.)
Endothelium-derived relaxing factors and converting enzyme inhibition. Vanhoutte PM, et al. **Am J Cardiol** 1995 Nov 24;76(15):3E-12E (83 ref.)
The role of the renin-angiotensin and natriuretic peptide systems in the pulmonary vasculature. Cargill RI, et al.
Br J Clin Pharmacol 1995 Jul;40(1):11-8 (68 ref.)
Role of bradykinin in the antihypertensive and cardioprotective actions of converting enzyme inhibitors. Zhu YC, et al. **Can J Physiol Pharmacol** 1995 Jul; 73(7):827-31 (39 ref.)
Angiotensin converting enzyme (ACE) inhibitors and kinin metabolism: evidence that ACE inhibitors may inhibit a kininase other than ACE. Campbell DJ.
Clin Exp Pharmacol Physiol 1995 Dec;22(12):903-11 (99 ref.)
Captopril. A review of its pharmacology and therapeutic efficacy after myocardial infarction and in ischaemic heart disease. Plosker GL, et al. **Drugs Aging** 1995 Sep; 7(3):226-53 (171 ref.)
Does ACE inhibition limit structural changes in the heart following myocardial infarction? Smits JF, et al.
Eur Heart J 1995 Dec;16 Suppl N:46-51 (48 ref.)
Renal circulation and blockade of the renin-angiotensin system. Is angiotensin-converting enzyme inhibition the last word? Hollenberg NK, et al. **Hypertension** 1995 Oct; 26(4):602-9 (108 ref.)
Effects of ACE inhibition on the heart. Gavras I, et al.
J Hum Hypertens 1995 Jun;9(6):455-8 (61 ref.)
Angiotensin converting enzyme inhibitors, left ventricular hypertrophy and fibrosis. Linz W, et al.
Mol Cell Biochem 1995 Jun 7-21;147(1-2):89-97 (73 ref.)
Effects of ACE inhibitors and calcium channel blockers on insulin sensitivity and other components of the syndrome. Sowers JR. **Nephrol Dial Transplant** 1995 Oct;10 Suppl 9:52-5 (41 ref.)
Angiotensin converting enzyme inhibitors--do they have an anti-ischemic action? Rutherford JD.
Trans Am Clin Climatol Assoc 1995;107:57-66; discussion 66-7 (47 ref.)
[Anti-atherosclerotic action of ACE inhibitors. I. Inactivation of the renin-angiotensin system] Stajszczyk M, et al. **Postepy Hig Med Dosw** 1996;50(2):157-71 (80 ref.) (Eng. Abstr.) **(Pol)**
[Alternative pathways of angiotensin I. The glimpse of new possibilities in the treatment of hypertension and heart failure (editorial)] Francischetti EA. **Arq Bras Cardiol** 1995 Mar;64(3):191-4 (49 ref.) **(Por)**

POISONING

Poisoning with anti-hypertensive drugs: angiotensin converting enzyme inhibitors. Lip GY, et al.
J Hum Hypertens 1995 Sep;9(9):711-5 (27 ref.)

THERAPEUTIC USE

ACE inhibitors: myocardial infarction and congestive heart failure. Cody RJ. **Am Fam Physician** 1995 Nov 1; 52(6):1801-6 (18 ref.)
Direct selective blockade of the vascular angiotensin II receptors in therapy for hypertension and severe congestive heart failure. Awan NA, et al. **Am Heart J** 1996 Jan; 131(1):177-85 (81 ref.)
Who should be treated with angiotensin-converting enzyme inhibitors after myocardial infarction? Ball SG, et al.
Am Heart J 1996 Jul;132(1 Pt 2 Su):244-50 (22 ref.)
Successful heart failure therapy is effective antiarrhythmia therapy [editorial] Khosla S, et al. **Am Heart J** 1996 May; 131(5):1048-50 (23 ref.)
The renin-angiotensin system in left ventricular remodeling. Blaufarb IS, et al. **Am J Cardiol** 1996 May 30; 77(13):8C-16C (121 ref.)
Effect of chronic angiotensin-converting enzyme inhibition on endothelial function in patients with chronic heart failure. Drexler H, et al. **Am J Cardiol** 1995 Nov 24; 76(15):13E-18E (35 ref.)
Microvascular angina in systemic hypertension: diagnosis and treatment with enalapril. Iriarte MM, et al.
Am J Cardiol 1995 Nov 2;76(13):31D-34D (18 ref.)
Treatment of viral myocarditis with focus on captopril [editorial] Rezkalla SH, et al. **Am J Cardiol** 1996 Mar 15; 77(8):634-7 (41 ref.)
Duration of action of angiotensin converting enzyme inhibitors. Zannad F. **Am J Hypertens** 1995 Oct;8(10 Pt 2):75S-81S (43 ref.)
Effects of ACE inhibitors and calcium antagonists on progression of chronic renal disease. Epstein M.
Blood Press Suppl 1995;2:108-12 (41 ref.)
Is aspirin safe for patients with heart failure? Cleland JG, et al. **Br Heart J** 1995 Sep;74(3):215-9 (53 ref.)
Improving outcome after acute myocardial infarction: what is the role of ACE inhibitors? [see comments] Purcell H, et al. **Br J Clin Pract** 1995 Jul-Aug;49(4):195-9 (59 ref.)
Comment in: Br J Clin Pract 1995 Jul-Aug;49(4):171.
Angiotensin-converting enzyme inhibitors post-myocardial infarction. Young JB. **Cardiol Clin** 1995 Aug;13(3):379-90 (56 ref.)
Anti-ischemic properties of ACE-inhibitors. Deedwania PC.
Cardiologia 1996 Mar;41(3):209-15 (30 ref.)
Interruption of the progression of heart failure: are ACE inhibitors the solution? Coats A. **Cardiology** 1996;87 Suppl 1:11-5 (7 ref.)
The cost-effective way forward for the management of the patient with heart failure. Giles T. **Cardiology** 1996;87 Suppl 1:33-9 (15 ref.)
Myocardial infarction: when and how should we initiate treatment with ACE inhibitors? GISSI-3 Investigators. Latini R, et al. **Cardiology** 1996;87 Suppl 1:16-22 (22 ref.)
Identification, diagnosis and treatment of heart failure: could we do better? Struthers AD. **Cardiology** 1996;87 Suppl 1:29-32 (11 ref.)
Current controversies with ACE inhibitor treatment in heart failure. Visser FC, et al. **Cardiology** 1996;87 Suppl 1:23-8 (21 ref.)
Coadministration of calcium antagonists and ACE inhibitors--is a skeptic convinced?: a personal view. Campbell RW. **Cardiovasc Drugs Ther** 1995 Aug;9 Suppl 3:525-8 (33 ref.)

ACE inhibitors and calcium antagonists in the treatment of congestive heart failure. Hansen JF. **Cardiovasc Drugs Ther** 1995 Aug;9 Suppl 3:503–7 (30 ref.)
Vascular protective effects of ACE inhibitors and calcium antagonists: theoretical basis for a combination therapy in hypertension and other cardiovascular diseases. Lüscher TF, et al. **Cardiovasc Drugs Ther** 1995 Aug;9 Suppl 3:509–23 (89 ref.)
Angiotensin II receptor antagonists in heart failure: rationale and design of the evaluation of losartan in the elderly (ELITE) trial. Pitt B, et al. **Cardiovasc Drugs Ther** 1995 Oct;9(5):693–700 (80 ref.)
ACE inhibitor use in patients with myocardial infarction. Summary of evidence from clinical trials. Latini R, et al. **Circulation** 1995 Nov 15;92(10):3132–7 (35 ref.)
The use of angiotensin converting enzyme inhibitors in asymptomatic patients with left ventricular dysfunction after myocardial infarction. Bazunga M. **Conn Med** 1995 Nov;59(11):663–6 (39 ref.)
Angiotensin-converting enzyme inhibition in type I diabetic nephropathy. Lewis EJ. **Contrib Nephrol** 1996;118:206–13 (4 ref.)
Are angiotensin-converting enzyme inhibitors the renal protective antihypertensive drugs of choice? [editorial] Bauer JH. **Curr Opin Nephrol Hypertens** 1995 Sep; 4(5):427–31 (23 ref.)
The management of hypertension in diabetes: with special reference to diabetic kidney disease. Leese GP, et al. **Diabet Med** 1996 May;13(5):401–10 (145 ref.)
Who needs nine ACE inhibitors? **Drug Ther Bull** 1995 Jan 19;33(1):1–3 (26 ref.)
Diabetic vascular injury and ACE. Potential for pharmacological prevention of complications of later life. Cooper ME, et al. **Drugs Aging** 1996 Jan;8(1):38–46 (90 ref.)
Quality of life in older patients with congestive heart failure. Effects of ACE inhibitors. Fergus I, et al. **Drugs Aging** 1996 Jan;8(1):23–8 (45 ref.)
ACE inhibitors. Differential use in elderly patients with hypertension. Israili ZH, et al. **Drugs Aging** 1995 Nov; 7(5):355–71 (225 ref.)
Captopril. A review of its pharmacology and therapeutic efficacy after myocardial infarction and in ischaemic heart disease. Plosker GL, et al. **Drugs Aging** 1995 Sep; 7(3):226–53 (171 ref.)
ACE inhibitors in elderly patients with hypertension. Special considerations. Ravid M, et al. **Drugs Aging** 1996 Jan; 8(1):29–37 (89 ref.)
ACE inhibitors in non-ischaemic heart failure: results from the MEGA trials. Cohn JN. **Eur Heart J** 1995 Dec;16 Suppl O:133–6 (31 ref.)
Should ACE inhibitors be administered to all patients after acute myocardial infarction? A (cautious) negative response. Julian DG. **Eur Heart J** 1995 Jul;16 Suppl E:44–5 (7 ref.)
What is the ideal study design for evaluation of treatment for heart failure? Insights from trials assessing the effect of ACE inhibitors on exercise capacity. Narang R, et al. **Eur Heart J** 1996 Jan;17(1):120–34 (45 ref.)
Should ACE inhibitors be administered to all patients with acute myocardial infarction? Prashad R, et al. **Eur Heart J** 1995 Jul;16 Suppl E:41–3 (26 ref.)
Effects of angiotensin receptor antagonists in heart failure: clinical and experimental aspects. Regitz-Zagrosek V, et al. **Eur Heart J** 1995 Dec;16 Suppl N:86–91 (19 ref.)
Neurohormonal modulation in heart failure: ACE inhibition and beyond. Remme WJ. **Eur Heart J** 1995 Dec;16 Suppl N:73–8 (36 ref.)
Anti-ischaemic effects of converting enzyme inhibitors: underlying mechanisms and future prospects. Remme WJ, et al. **Eur Heart J** 1995 Aug;16 Suppl I:87–95 (51 ref.)
Neurohormonal activation and congestive heart failure: today's experience with ACE inhibitors and rationale for their use. Sigurdsson A, et al. **Eur Heart J** 1995 Dec;16 Suppl N:65–72 (53 ref.)
Aldosterone escape during ACE inhibitor therapy in chronic heart failure. Struthers AD. **Eur Heart J** 1995 Dec;16 Suppl N:103–6 (26 ref.)
Should angiotensin converting enzyme inhibitors be routinely used in patients with acute myocardial infarction? Chatterjee K. **Indian Heart J** 1995 May-Jun;47(3):275–8 (17 ref.)
Ongoing clinical trials of angiotensin-converting enzyme inhibitors for treatment of coronary artery disease in patients with preserved left ventricular function. Pepine CJ. **J Am Coll Cardiol** 1996 Apr;27(5):1048–52 (14 ref.)
Impact of advances in therapy for heart failure on secular trends in mortality [editorial] Rector TS. **J Card Fail** 1996 Mar;2(1):31–2 (7 ref.)
Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure. Struthers AD. **J Card Fail** 1996 Mar;2(1):47–54 (56 ref.)
Quality of life with ACE inhibitors in chronic heart failure. Bulpitt CJ. **J Cardiovasc Pharmacol** 1996;27 Suppl 2:S31–5 (35 ref.)
Cardiovascular hypertrophy: role of angiotensin II and bradykinin. Waeber B, et al. **J Cardiovasc Pharmacol** 1996; 27 Suppl 2:S36–40 (37 ref.)
Pathophysiological aspects of the renin-angiotensin-aldosterone system in acute myocardial infarction. Dargie HJ, et al. **J Cardiovasc Risk** 1995 Oct; 2(5):389–95 (48 ref.)
Prevention of congestive heart failure by ACE inhibition in patients with acute myocardial infarction. Sigurdsson A, et al. **J Cardiovasc Risk** 1995 Oct;2(5):406–12 (44 ref.)
Practical issues for the use of ACE inhibitors in acute myocardial infarction. Testa M, et al. **J Cardiovasc Risk** 1995 Oct;2(5):429–33 (27 ref.)
Drug differences between ACE inhibitors in experimental settings and clinical practice. Voors AA, et al. **J Cardiovasc Risk** 1995 Oct;2(5):413–22 (105 ref.)
Natural history of early diabetic nephropathy: what are the effects of therapeutic intervention? Melbourne Diabetic Nephropathy Study Group. Jerums G, et al. **J Diabetes Complications** 1995 Oct-Dec;9(4):308–14 (47 ref.)
Impact of converting enzyme inhibitors and calcium entry blockers on cardiac allograft vasculopathy: from bench to bedside. Mehra MR, et al. **J Heart Lung Transplant** 1995 Nov-Dec;14(6 Pt 2):S246–9 (16 ref.)
Medical treatment of chronic valvular regurgitation. Schön HR. **J Heart Valve Dis** 1995 Oct;4 Suppl 2:S170–4 (26 ref.)
ACE inhibitors for the prevention and treatment of heart failure: why are they under-used? Cleland JG. **J Hum Hypertens** 1995 Jun;9(6):435–42 (47 ref.)
Angiotensin converting enzyme inhibitors in hypertension: potential problems. Antonios TF, et al. **J Hypertens Suppl** 1995 Sep;13 Suppl 3:S11–6 (87 ref.)
Update on the use of angiotensin converting enzyme inhibitors and calcium antagonists in postinfarction patients. Persson S. **J Hypertens Suppl** 1995 Aug;13(2):S57–63 (33 ref.)
Effects of angiotensin converting enzyme inhibitors on the progression of diabetic nephropathy. Ruilope LM. **J Hypertens Suppl** 1995 Aug;13(2):S91–3 (26 ref.)
Adrenergic and muscarinic receptor regulation and therapeutic implications in heart failure. Schmitz W, et al. **Mol Cell Biochem** 1996 Apr 12–26;157(1–2):251–8 (91 ref.)
Effects of ACE inhibitors and calcium antagonists alone or combined on progression of diabetic nephropathy. Lash JP, et al. **Nephrol Dial Transplant** 1995 Oct;10 Suppl 9:56–62 (52 ref.)
Effects of ACE inhibitors and calcium channel blockers on the development of glomerular sclerosis in models of renal damage. Raij L. **Nephrol Dial Transplant** 1995 Oct;10 Suppl 9:23–7 (55 ref.)
Is there any reason to lower proteinuria in a child with nephrotic-range proteinuria who is not clinically edematous? Kees-Folts D. **Pediatr Nephrol** 1996 Apr; 10(2):180 (17 ref.)
Angiotensin-converting enzyme inhibitors in left ventricular dysfunction. Linn WD. **Pharmacotherapy** 1996 Mar-Apr; 16(2 Pt 2):50S–58S (48 ref.)
Pharmacological inhibition of restenosis: learning from experience. Shaw LA, et al. **Trends Pharmacol Sci** 1995 Dec;16(12):401–4 (36 ref.)
[Angiotensin converting enzyme inhibitors in the treatment of arterial hypertension] Widimský J Jr. **Vnitr Lek** 1995 Aug;41(8):560–4 (16 ref.) (Eng. Abstr.) **(Cze)**
[Enzyme converting inhibitors. Current knowledge and perspectives] Pathé M. **Presse Med** 1995 Dec 9; 24(38):1852–6 (56 ref.) (Eng. Abstr.) **(Fre)**
[ACE inhibitor after myocardial infarct: are there differences?] Jahrmärker H. **Herz** 1995 Aug;20(4):293–6 (15 ref.) **(Ger)**
[Therapy of heart failure. Digitalis, diuretic plus ACE inhibitor or more?] Becker H, et al. **Internist (Berl)** 1995 Dec;36(12):1117–23 (43 ref.) **(Ger)**
[ACE-inhibitors in acute heart infarct] Genoni M, et al. **Schweiz Rundsch Med Prax** 1996 Apr 23;85(17):548–53 (20 ref.) (Eng. Abstr.) **(Ger)**
[Recent molecular and pharmacologic aspects of ACE inhibitors] Köppel H, et al. **Wien Med Wochenschr** 1995; 145(23):633–7 (20 ref.) (Eng. Abstr.) **(Ger)**
[ACE inhibitors in the treatment of patients with acute myocardial infarct] Borghi C, et al. **Ann Ital Med Int** 1995 Jul-Sep;10(3):175–87 (75 ref.) (Eng. Abstr.) **(Ita)**
[The coronary circulation, renin-angiotensin system and ACE inhibition] Campa PP. **Cardiologia** 1995 Sep; 40(9):635–41 (97 ref.) **(Ita)**
[Clinical evaluation of ACE inhibitors for therapy of chronic congestive heart failure] Matsuo H. **Nippon Naika Gakkai Zasshi** 1995 Sep 10;84(9):1470–4 (17 ref.) **(Jpn)**
[Physiopathology of heart failure and new approach to the therapy] Yazaki Y. **Nippon Naika Gakkai Zasshi** 1995 Sep 10;84(9):1449–53 (10 ref.) **(Jpn)**
[Pathophysiologic and clinical aspects of usefulness regarding angiotensin converting enzyme inhibitors in diabetes] Jasik M. **Pol Arch Med Wewn** 1996 Mar;95(3):261–9 (29 ref.) **(Pol)**
[The effect of angiotensin-converting enzyme inhibitors on left ventricular hypertrophy in patients with arterial hypertension] Diadyk AI, et al. **Ter Arkh** 1995;67(8):65–8 (88 ref.) **(Rus)**
[The use of perindopril (prestarium) in arterial hypertension] Filatova NP. **Ter Arkh** 1995;67(9):81–3 (35 ref.) **(Rus)**
[Angiotensin converting enzyme inhibitors in ischemic heart disease] Takáč M, et al. **Vnitr Lek** 1996 Apr;42(4):290–6 (62 ref.) (Eng. Abstr.) **(Slo)**
[Controversies in the treatment of arterial hypertension: other drugs as the first step (calcium antagonists, ACE inhibitors and alpha-blockers)] Castro Beiras A, et al. **Rev Esp Cardiol** 1995;48 Suppl 4:72–80 (31 ref.) (Eng. Abstr.) **(Spa)**

ANGIOTENSIN-FORMING ENZYME see RENIN

ANGIOTENSIN RECEPTORS see RECEPTORS, ANGIOTENSIN

ANGIOTENSINOGEN

BLOOD

[Angiotensinogen (renin substrate)] Tamura K, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:692–4 (19 ref.) **(Jpn)**

GENETICS

Recent advances in the study of renin and angiotensinogen genes: from molecules to the whole body. Tamura K, et al. **Hypertens Res** 1995 Mar;18(1):7–18 (134 ref.)
Mechanisms for inducible control of angiotensinogen gene transcription. Brasier AR, et al. **Hypertension** 1996 Mar; 27(3 Pt 2):465–75 (108 ref.)

PHYSIOLOGY

Role of angiotensinogen in the genetics of essential hypertension. Hata A. **Life Sci** 1995 Nov 17;57(26):2385–95 (73 ref.)

ANGIOTENSINOGENASE see RENIN

ANGIOTENSINS

see related
RECEPTORS, ANGIOTENSIN
RENIN-ANGIOTENSIN SYSTEM

[Histocytochemical and functional aspects on the "brain-vascular peptides"] Yamada H, et al. **Kaibogaku Zasshi** 1995 Oct;70(5):422–35 (108 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

The renin angiotensin system and the stress response. Aguilera G, et al. **Ann N Y Acad Sci** 1995 Dec 29; 771:173–86 (41 ref.)
Evidence for the role of angiotensin in the establishment and maintenance of renal morphology. Niimura F, et al. **Contrib Nephrol** 1996;118:234–7 (4 ref.)
Angiotensin receptors and their antagonists. Goodfriend TL, et al. **N Engl J Med** 1996 Jun 20;334(25):1649–54 (81 ref.)

ANGLE CLASS I see MALOCCLUSION, ANGLE CLASS I

ANGLE CLASS II see MALOCCLUSION, ANGLE CLASS II

ANGLE CLASS III see MALOCCLUSION, ANGLE CLASS III

ANGOR PECTORIS see ANGINA PECTORIS

ANGUILLULIASIS see STRONGYLOIDIASIS

ANHIDROTIC ECTODERMAL DYSPLASIA see ECTODERMAL DYSPLASIA

ANHYDRIDES

CHEMISTRY

Urethane-protected alpha-amino acid N-carboxyanhydrides and peptide synthesis. Fuller WD, et al. **Biopolymers** 1996; 40(2):183–205 (56 ref.)

ANILIDES

THERAPEUTIC USE

Clinical progress with a new antiandrogen, Casodex (bicalutamide). Blackledge GR. **Eur Urol** 1996;29 Suppl 2:96–104 (15 ref.)
The development of Casodex (bicalutamide): preclinical studies. Furr BJ. **Eur Urol** 1996;29 Suppl 2:83–95 (53 ref.)
Worldwide activity and safety of bicalutamide: a summary review. Kolvenbag GJ, et al. **Urology** 1996 Jan;47(1A Suppl):70–9; discussion 80–4 (29 ref.)

ANILINE COMPOUNDS

Interactions of aniline with soil and groundwater at an industrial spill site. Kosson DS, et al. **Environ Health Perspect** 1995 Jun;103 Suppl 5:71–3 (13 ref.)

ANIMAL CARE COMMITTEES see ANIMAL WELFARE

ANIMAL COMMUNICATION

see related
PHEROMONES
VOCALIZATION, ANIMAL

An evolutionary perspective on signaling in behavior and

immunology. McKean KA, et al. **Naturwissenschaften** 1995 Nov;82(11):509–16 (74 ref.)

[The neurobiological bases of acoustical communication. A comparative physiological review of structures and mechanisms] Vartanian IA, et al. **Zh Evol Biokhim Fiziol** 1995 Sep–Dec;31(5–6):677–84 (33 ref.) **(Rus)**

ANIMAL DISEASES

DIAGNOSIS

[Diagnostic and pathophysiological aspects of the determination of kidney function in animals (corrected and republished with original paging, article originally printed in Zentralbl Veterinarmed A 1994 May;41(4):253–67)] Reder S, et al. **Zentralbl Veterinarmed A** 1995 May; 42(3):253–67 (56 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Veterinary use of new quinolones in Japan. Nakamura S. **Drugs** 1995;49 Suppl 2:152–8 (41 ref.)

ECONOMICS

Impact and risk of foreign animal diseases. Brown CC, et al. **J Am Vet Med Assoc** 1996 Apr 1;208(7):1038–40 (16 ref.)

EPIDEMIOLOGY

Animal health monitoring and surveillance in Switzerland. Stärk KD. **Aust Vet J** 1996 Mar;73(3):96–7 (14 ref.)

GENETICS

Animal selection and breeding techniques that create diseased populations and compromise welfare. Ott RS. **J Am Vet Med Assoc** 1996 Jun 15;208(12):1969–74 (48 ref.)

PHYSIOPATHOLOGY

[Diagnostic and pathophysiological aspects of the determination of kidney function in animals (corrected and republished with original paging, article originally printed in Zentralbl Veterinarmed A 1994 May;41(4):253–67)] Reder S, et al. **Zentralbl Veterinarmed A** 1995 May; 42(3):253–67 (56 ref.) (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

Environmental considerations of disinfectants used in agriculture. Bruins G, et al. **Rev Sci Tech** 1995 Mar; 14(1):81–94 (15 ref.)

Disinfection of trucks and trailers. Mateost Poumian A. **Rev Sci Tech** 1995 Mar;14(1):165–76 (4 ref.) **(Eng, Spa)**

Risk of introducing exotic disease through importation of animals and animal products. Metcalf HE, et al. **Rev Sci Tech** 1995 Dec;14(4):951–6 (12 ref.)

[The importance of tropical animal hygiene for indigenous animal production] Böhnel H. **Berl Munch Tierarztl Wochenschr** 1995 Dec;108(12):443–6 (6 ref.) (Eng. Abstr.) **(Ger)**

TRANSMISSION

The role of dipterous insects in the mechanical transmission of animal viruses. Carn VM. **Br Vet J** 1996 Jul; 152(4):377–93 (55 ref.)

ANIMAL FEED

[The ipriflavone story] György L, et al. **Acta Pharm Hung** 1995 Nov;65(6):191–4 (20 ref.) (Eng. Abstr.) **(Hun)**

STANDARDS

Characteristics of plant cell walls affecting intake and digestibility of forages by ruminants. Jung HG, et al. **J Anim Sci** 1995 Sep;73(9):2774–90 (147 ref.)

Whole-body fuel selection in ruminants: nutrient supply and utilization by major tissues. Ortigues I, et al. **Proc Nutr Soc** 1995 Mar;54(1):235–51 (55 ref.)

[Determination of the protein quality of food and animal feed] Bergner H. **Arch Tierernahr** 1994;45(4):293–332 (104 ref.) (Eng. Abstr.) **(Ger)**

ANIMAL HOSPITALS see **HOSPITALS, ANIMAL**

ANIMAL-HUMAN BONDING see **BONDING, HUMAN-PET**

ANIMAL HUSBANDRY

see related
VETERINARY MEDICINE

Veterinary nutritional management of amphibians and reptiles. Donoghue S. **J Am Vet Med Assoc** 1996 Jun 1; 208(11):1816–20 (22 ref.)

Environmental considerations of livestock producers. Morse D. **J Anim Sci** 1995 Sep;73(9):2733–40 (35 ref.)

The commercial and agricultural applications of animal transgenesis. Ward KA, et al. **Mol Biotechnol** 1995 Oct; 4(2):167–78 (63 ref.)

Sarcoptic mange and production performance of swine: a review of the literature and studies of associations between mite infestation, growth rate and measures of mange severity in growing pigs. Davies PR. **Vet Parasitol** 1995 Dec;60(3–4):249–64 (51 ref.)

[The importance of tropical animal hygiene for indigenous animal production] Böhnel H. **Berl Munch Tierarztl Wochenschr** 1995 Dec;108(12):443–6 (6 ref.) (Eng. Abstr.) **(Ger)**

[Increased resistance after administration of antibiotics to animals] Franklin A. **Lakartidningen** 1996 Apr 24; 93(17):1627–30 (21 ref.) **(Swe)**

ECONOMICS

Costs of major parasites to the Australian livestock industries. McLeod RS. **Int J Parasitol** 1995 Nov;25(11):1363–7 (25 ref.)

Measuring financial performance: an overview of financial statements. Dalsted NL. **Vet Clin North Am Food Anim Pract** 1995 Jul;11(2):293–311 (2 ref.)

SPA: marketing and financial performance measures for the cow–calf enterprise. Gutierrez PH. **Vet Clin North Am Food Anim Pract** 1995 Jul;11(2):313–60 (3 ref.)

Stocker/feeder cattle standardized performance analysis. McGrann JM, et al. **Vet Clin North Am Food Anim Pract** 1995 Jul;11(2):361–73 (3 ref.)

Farm Financial Standards. McGrann JM. **Vet Clin North Am Food Anim Pract** 1995 Jul;11(2):279–91 (3 ref.)

HISTORY

The history of IRM and SPA. Corah LR. **Vet Clin North Am Food Anim Pract** 1995 Jul;11(2):191–8 (8 ref.)

STANDARDS

Animal care and use: an issue now and in the future. Kertz AF. **J Anim Sci** 1996 Jan;74(1):257–61 (16 ref.)

Bad ethics, good ethics and the genetic engineering of animals in agriculture. Rollin BE. **J Anim Sci** 1996 Mar; 74(3):535–41 (10 ref.)

Farm animal well-being and intensive production systems. Swanson JC. **J Anim Sci** 1995 Sep;73(9):2744–51 (60 ref.)

Disinfecting equine facilities. Dwyer RM. **Rev Sci Tech** 1995 Jun;14(2):403–18 (4 ref.)

Disinfection procedures for personnel and vehicles entering and leaving contaminated premises. Ford WB. **Rev Sci Tech** 1995 Jun;14(2):393–401 (10 ref.)

Disinfection of livestock production premises. Fotheringham VJ. **Rev Sci Tech** 1995 Mar;14(1):191–205 (21 ref.)

Use of disinfectants in zoos and game parks. Heuschele WP. **Rev Sci Tech** 1995 Jun;14(2):447–54 (14 ref.)

Disinfecting poultry production premises. Meroz M, et al. **Rev Sci Tech** 1995 Jun;14(2):273–91 (27 ref.)

Application of disinfectants in poultry hatcheries. Samberg Y, et al. **Rev Sci Tech** 1995 Jun;14(2):365–80 (31 ref.)

SPA: marketing and financial performance measures for the cow–calf enterprise. Gutierrez PH. **Vet Clin North Am Food Anim Pract** 1995 Jul;11(2):313–60 (3 ref.)

Standardized performance analysis. Hamilton ED. **Vet Clin North Am Food Anim Pract** 1995 Jul;11(2):199–213 (2 ref.)

NCA–IRM desk record. Kniffen D. **Vet Clin North Am Food Anim Pract** 1995 Jul;11(2):215–78 (0 ref.)

Farm Financial Standards. McGrann JM. **Vet Clin North Am Food Anim Pract** 1995 Jul;11(2):279–91 (3 ref.)

Stocker/feeder cattle standardized performance analysis. McGrann JM, et al. **Vet Clin North Am Food Anim Pract** 1995 Jul;11(2):361–73 (3 ref.)

Seedstock beef cattle: SPA. McGrann JM, et al. **Vet Clin North Am Food Anim Pract** 1995 Jul;11(2):375–88 (2 ref.)

STATISTICS & NUMERICAL DATA

NCA–IRM desk record. Kniffen D. **Vet Clin North Am Food Anim Pract** 1995 Jul;11(2):215–78 (0 ref.)

TRENDS

Prospects for expanded mohair and cashmere production and processing in the United States of America. Lupton CJ. **J Anim Sci** 1996 May;74(5):1164–72 (18 ref.)

[The organization of veterinary services in African animal husbandry systems: chances for the exchange of interdisciplinary learning processes] Kirk M. **Berl Munch Tierarztl Wochenschr** 1995 Dec;108(12):447–50 (16 ref.) (Eng. Abstr.) **(Ger)**

[Developmental trends in farm animal husbandry from an ethological point of view] Graf B. **Schweiz Arch Tierheilkd** 1995;137(9):423–31 (12 ref.) (Eng. Abstr.) **(Ger)**

ANIMAL NUTRITION

Energy partitioning and modeling in animal nutrition. Baldwin RL, et al. **Annu Rev Nutr** 1995;15:191–211 (56 ref.)

Nutritional and hormonal regulation of thyroid hormone deiodinases. Larsen PR, et al. **Annu Rev Nutr** 1995; 15:323–52 (149 ref.)

The nutritional significance of endogenous N-losses along the gastro-intestinal tract of farm animals. Tamminga S, et al. **Arch Tierernahr** 1995;48(1–2):9–22 (44 ref.)

Nutritional and physiological characteristics in germ-free chickens. Furuse M, et al. **Comp Biochem Physiol A Physiol** 1994 Nov;109(3):547–56 (68 ref.)

Veterinary nutritional management of amphibians and reptiles. Donoghue S. **J Am Vet Med Assoc** 1996 Jun 1; 208(11):1816–20 (22 ref.)

Impact of changes in organic nutrient metabolism on feeding the transition dairy cow. Grummer RR. **J Anim Sci** 1995 Sep;73(9):2820–33 (81 ref.)

Reassessing the manipulation of protein synthesis by rumen microbes. Broudiscou L, et al. **Reprod Nutr Dev** 1995; 35(5):517–35 (144 ref.)

Commentary. The uncontrolled variable in risk assessment: ad libitum overfed rodents—fat, facts and fiction. Keenan KP. **Toxicol Pathol** 1996 May–Jun;24(3):376–83 (57 ref.)

[A shift in types of nutrition and digestion in ontogeny] Arshavskiĭ IA, et al. **Usp Fiziol Nauk** 1996 Jan–Mar; 27(1):109–29 (95 ref.) (Eng. Abstr.) **(Rus)**

ANIMAL RIGHTS

TRENDS

Animal care and use: an issue now and in the future. Kertz AF. **J Anim Sci** 1996 Jan;74(1):257–61 (16 ref.)

ANIMAL TESTING ALTERNATIVES

The three Rs of Russell & Burch and the testing of biological products. Balls M, et al. **Dev Biol Stand** 1996;86:11–8 (13 ref.)

Evaluation of new approaches to poliovirus vaccine neurovirulence tests. Wood DJ. **Dev Biol Stand** 1996; 86:79–83 (16 ref.)

[Alternative methods to animal experimentation. Scientific and ethical problems] Adolphe M. **Bull Acad Natl Med** 1995 Jun;179(6):1009–16; discussion 1116–9 (16 ref.) (Eng. Abstr.) **(Fre)**

METHODS

Alternative method of assessing toxicity. Atterwill CK. **Methods Mol Biol** 1995;43:1–9 (8 ref.)

ANIMAL VIRUSES see **VIRUSES**

ANIMAL VOCALIZATION see **VOCALIZATION, ANIMAL**

ANIMAL WELFARE

see related
ANIMAL TESTING ALTERNATIVES

Eastern barred bandicoot recovery: the role of the veterinarian in the management of endangered species. Seebeck J, et al. **Aust Vet J** 1996 Mar;73(3):81–3 (21 ref.)

Feline behavior and welfare. Landsberg G. **J Am Vet Med Assoc** 1996 Feb 15;208(4):502–5 (9 ref.)

Animal shelter issues. Luke C. **J Am Vet Med Assoc** 1996 Feb 15;208(4):524–7 (1 ref.)

Animal selection and breeding techniques that create diseased populations and compromise welfare. Ott RS. **J Am Vet Med Assoc** 1996 Jun 15;208(12):1969–74 (48 ref.)

Advances in feline health research: impact of recent developments in vaccinology on feline welfare. Richards JR. **J Am Vet Med Assoc** 1996 Feb 15;208(4):505–10 (30 ref.)

Care of fish in biological research. Klontz GW. **J Anim Sci** 1995 Nov;73(11):3485–92 (24 ref.)

Bad ethics, good ethics and the genetic engineering of animals in agriculture. Rollin BE. **J Anim Sci** 1996 Mar; 74(3):535–41 (10 ref.)

[Well–being—intrinsic value—integrity. Developments in the reevaluation of the domesticated animal] Grommers FJ, et al. **Tijdschr Diergeneeskd** 1995 Sep 1;120(17):490–4 (27 ref.) (Eng. Abstr.) **(Dut)**

["Breeding for distress" in fowl] Bartels T. **DTW Dtsch Tierarztl Wochenschr** 1995 Mar;102(3):117–9 (34 ref.) (Eng. Abstr.) **(Ger)**

STANDARDS

Animal health monitoring and surveillance in Switzerland. Stärk KD. **Aust Vet J** 1996 Mar;73(3):96–7 (14 ref.)

Farm animal well-being and intensive production systems. Swanson JC. **J Anim Sci** 1995 Sep;73(9):2744–51 (60 ref.)

TRENDS

Animal care and use: an issue now and in the future. Kertz AF. **J Anim Sci** 1996 Jan;74(1):257–61 (16 ref.)

ANIMALS

GROWTH & DEVELOPMENT

Size control: the regulation of cell numbers in animal development. Raff MC. **Cell** 1996 Jul 26;86(2):173–5 (20 ref.)

PHYSIOLOGY

The lessons of middle-ear function in non-mammals: improving columellar prostheses [editorial] Manley GA. **J R Soc Med** 1995 Jul;88(7):367–8 (8 ref.)

ANIMALS, DOMESTIC

Health hazards to humans associated with domestic pets. Plaut M, et al. **Annu Rev Public Health** 1996;17:221–45 (87 ref.)

The nutritional significance of endogenous N-losses along the gastro-intestinal tract of farm animals. Tamminga S, et al. **Arch Tierernahr** 1995;48(1-2):9–22 (44 ref.)

The interference by maternally-derived antibody with active immunization of farm animals against foot-and-mouth disease. Kitching RP, et al. **Br Vet J** 1995 Jul-Aug; 151(4):379–89 (40 ref.)

Current perspectives in salmonellosis [see comments] Lax AJ, et al. **Br Vet J** 1995 Jul-Aug;151(4):351–77 (230 ref.) Comment in: Br Vet J 1995 Jul-Aug;151(4):339–41.

Extrinsic regulation of domestic animal-derived satellite cells. Dodson MV, et al. **Domest Anim Endocrinol** 1996 Mar;13(2):107–26 (130 ref.)

Impact and risk of foreign animal diseases. Brown CC, et al. **J Am Vet Med Assoc** 1996 Apr 1;208(7):1038–40 (16 ref.)

Clinical application of interferons in large animal medicine. Moore BR. **J Am Vet Med Assoc** 1996 May 15; 208(10):1711–5 (50 ref.)

Animal selection and breeding techniques that create diseased populations and compromise welfare. Ott RS. **J Am Vet Med Assoc** 1996 Jun 15;208(12):1969–74 (48 ref.)

Animal care and use: an issue now and in the future. Kertz AF. **J Anim Sci** 1996 Jan;74(1):257–61 (16 ref.)

Plant poisonings and mycotoxicoses as constraints in livestock production in east Africa: the southern African experience. Naudé TW, et al. **J S Afr Vet Assoc** 1996 Mar; 67(1):8–11 (18 ref.)

Food preferences in farm animals: why don't they always choose wisely? Forbes JM, et al. **Proc Nutr Soc** 1995 Jul; 54(2):429–40 (45 ref.)

Reproductive research on farm animals for Australia--some long-distance goals. Martin GB. **Reprod Fertil Dev** 1995; 7(5):967–82 (85 ref.)

Transgenic sheep and wool growth: possibilities and current status. Powell BC, et al. **Reprod Fertil Dev** 1994;6(5):615–23 (28 ref.)

Strategies for production of pharmaceutical proteins in milk. Wilmut I, et al. **Reprod Fertil Dev** 1994;6(5):625–30 (51 ref.)

Aircraft and ship disinfection. Cancellotti FM. **Rev Sci Tech** 1995 Mar;14(1):177–89 (20 ref.)

Epidemiology of Mycobacterium bovis infection in animals and humans, with particular reference to Africa. Cosivi O, et al. **Rev Sci Tech** 1995 Sep;14(3):733–46 (63 ref.)

Disinfection procedures for personnel and vehicles entering and leaving contaminated premises. Ford WB. **Rev Sci Tech** 1995 Jun;14(2):393–401 (10 ref.)

Disinfection of stockyards. Fotheringham VJ. **Rev Sci Tech** 1995 Jun;14(2):293–307 (21 ref.)

Disinfection of livestock production premises. Fotheringham VJ. **Rev Sci Tech** 1995 Mar;14(1):191–205 (21 ref.)

Disinfection of trucks and trailers. Mateost Poumian A. **Rev Sci Tech** 1995 Mar;14(1):165–76 (4 ref.) **(Eng, Spa)**

Risk of introducing exotic disease through importation of animals and animal products. Metcalf HE, et al. **Rev Sci Tech** 1995 Dec;14(4):951–6 (12 ref.)

Client counseling in orthopedic emergencies. Brackenridge SS, et al. **Vet Clin North Am Small Anim Pract** 1995 Sep; 25(5):1047–58 (7 ref.)

Embryonic stem cells in farm animals. Galli C, et al. **Zygote** 1994 Nov;2(4):385–9 (47 ref.)

[Well-being--intrinsic value--integrity. Developments in the reevaluation of the domesticated animal] Grommers FJ, et al. **Tijdschr Diergeneeskd** 1995 Sep 1;120(17):490–4 (27 ref.) (Eng. Abstr.) **(Dut)**

[Veterinary dentistry (12). Discoloration of teeth in companion animals] van Foreest AW. **Tijdschr Diergeneeskd** 1996 Jun 1;121(11):316–22 (18 ref.) (Eng. Abstr.) **(Dut)**

[Domestic animals and pets as sources of infection] Vuento R. **Duodecim** 1994;110(6):555–66 (34 ref.) **(Fin)**

[The importance of tropical animal hygiene for indigenous animal production] Böhnel H. **Berl Munch Tierarztl Wochenschr** 1995 Dec;108(12):443–6 (6 ref.) (Eng. Abstr.) **(Ger)**

EMBRYOLOGY

The development of the genital peritoneum in domestic mammals. An analysis of the literature and nomenclature. Martin E. **Anat Histol Embryol** 1995 Dec;24(4):285–7 (18 ref.)

GENETICS

Progress and emerging problems in livestock transgenesis: a summary perspective. Seamark RF. **Reprod Fertil Dev** 1994;6(5):653–7 (36 ref.)

Livestock QTLs--bringing home the bacon? Haley CS. **Trends Genet** 1995 Dec;11(12):488–92 (27 ref.)

GROWTH & DEVELOPMENT

Farm animal well-being and intensive production systems. Swanson JC. **J Anim Sci** 1995 Sep;73(9):2744–51 (60 ref.)

IMMUNOLOGY

Effects of selenium and vitamin E on the immune responses of domestic animals. Finch JM, et al. **Res Vet Sci** 1996 Mar;60(2):97–106 (108 ref.)

INJURIES

Gunshot injuries: pathophysiology and treatments. Bebchuk TN, et al. **Vet Clin North Am Small Anim Pract** 1995 Sep; 25(5):1111–26 (33 ref.)

Management of fracture-associated thoracic trauma. Cockshutt JR. **Vet Clin North Am Small Anim Pract** 1995 Sep;25(5):1031–46 (53 ref.)

Anesthetic management of the trauma patient. Cuvelliez S, et al. **Vet Clin North Am Small Anim Pract** 1995 Sep; 25(5):1073–92 (42 ref.)

Spinal fracture/luxation. Kirby BM. **Vet Clin North Am Small Anim Pract** 1995 Sep; 25(5):1149–74 (49 ref.)

Management of penetrating joint injuries. Lewis DD. **Vet Clin North Am Small Anim Pract** 1995 Sep; 25(5):1197–223 (107 ref.)

Traumatic joint luxations in small animals. McLaughlin RM Jr. **Vet Clin North Am Small Anim Pract** 1995 Sep; 25(5):1175–96 (28 ref.)

General management considerations for the trauma patient. Payne JT. **Vet Clin North Am Small Anim Pract** 1995 Sep; 25(5):1015–29 (6 ref.)

Fracture management decisions. Roush JK. **Vet Clin North Am Small Anim Pract** 1995 Sep; 25(5):1059–72 (19 ref.)

Skull trauma and mandibular fractures. Smith MM, et al. **Vet Clin North Am Small Anim Pract** 1995 Sep; 25(5):1127–48 (47 ref.)

Open fracture management. Tillson DM. **Vet Clin North Am Small Anim Pract** 1995 Sep; 25(5):1093–110 (55 ref.)

METABOLISM

Control of growth hormone synthesis. Tuggle CK, et al. **Domest Anim Endocrinol** 1996 Jan;13(1):1–33 (256 ref.)

PARASITOLOGY

Costs of major parasites to the Australian livestock industries. McLeod RS. **Int J Parasitol** 1995 Nov;25(11):1363–7 (25 ref.)

Current research on Sarcocystis species of domestic animals. Tenter AM. **Int J Parasitol** 1995 Nov;25(11):1311–30 (132 ref.)

[Anthelmintics resistance in gastrointestinal nematodes in domestic animals] Geerts S. **Verh K Acad Geneeskd Belg** 1995;57(5):351–69; discussion 369–70 (45 ref.) (Eng. Abstr.) **(Dut)**

PHYSIOLOGY

The ovarian insulin and insulin-like growth factor system with an emphasis on domestic animals. Spicer LJ, et al. **Domest Anim Endocrinol** 1995 Jul;12(3):223–45 (182 ref.)

Environmental considerations of livestock producers. Morse D. **J Anim Sci** 1995 Sep;73(9):2733–40 (35 ref.)

Farm animal well-being and intensive production systems. Swanson JC. **J Anim Sci** 1995 Sep;73(9):2744–51 (60 ref.)

[Reproductive medicine in transition: new developments in embryo transfer] Binder H, et al. **Schweiz Arch Tierheilkd** 1996;138(5):245–50 (18 ref.) (Eng. Abstr.) **(Ger)**

[Developmental trends in farm animal husbandry from an ethological point of view] Graf B. **Schweiz Arch Tierheilkd** 1995;137(9):423–31 (12 ref.) (Eng. Abstr.) **(Ger)**

PSYCHOLOGY

[Some theoretical aspects of behavior research in domestic animals] Puppe B. **Berl Munch Tierarztl Wochenschr** 1995 Apr;108(4):133–7 (60 ref.) (Eng. Abstr.) **(Ger)**

ANIMALS, LABORATORY

see related
ANIMAL TESTING ALTERNATIVES

Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals. Kararli TT. **Biopharm Drug Dispos** 1995 Jul; 16(5):351–80 (79 ref.)

Harmonization of animal clinical pathology testing in toxicity and safety studies. The Joint Scientific Committee for International Harmonization of Clinical Pathology Testing. Weingand K, et al. **Fundam Appl Toxicol** 1996 Feb; 29(2):198–201 (26 ref.)

Animal models of antisense oligonucleotides: lessons for use in humans. Plenat F. **Mol Med Today** 1996 Jun;2(6):250–7 (37 ref.)

[Procedures for health monitoring in a breeding facility for specific pathogen free mice and rats] Wyss-Spillmann SK, et al. **Schweiz Arch Tierheilkd** 1995;137(11):505–14 (39 ref.) (Eng. Abstr.) **(Ger)**

[Application of the common marmoset to pharmacological studies] Nomoto M. **Nippon Yakurigaku Zasshi** 1995 Jul; 106(1):11–8 (23 ref.) (Eng. Abstr.) **(Jpn)**

[Anesthesia in experimental animals. Basic principles] Cruz JI. **Rev Esp Anestesiol Reanim** 1996 Mar;43(3):99–107 (54 ref.) (Eng. Abstr.) **(Spa)**

PSYCHOLOGY

Exploration and predation models of anxiety: evidence from laboratory and wild species. Hendrie CA, et al. **Pharmacol Biochem Behav** 1996 May;54(1):13–20 (56 ref.)

ANIMALS, NEWBORN

GROWTH & DEVELOPMENT

Quantitative cancer assessment for vinyl chloride: indications of early-life sensitivity. Cogliano VJ, et al. **Toxicology** 1996 Jul 17;111(1-3):21–8 (11 ref.)

Efficient tissue repair underlies the resiliency of postnatally developing rats to chlordecone + CCl4 hepatotoxicity. Dalu A, et al. **Toxicology** 1996 Jul 17;111(1-3):29–42 (41 ref.)

PHYSIOLOGY

Physiological studies of gastro-oesophageal reflux and airway protective responses in the young animal and human infant. Jeffery HE, et al. **Clin Exp Pharmacol Physiol** 1995 Aug;22(8):544–9 (51 ref.)

Perinatal thermogenesis. Gunn TR, et al. **Early Hum Dev** 1995 Aug 18;42(3):169–83 (60 ref.)

ANIMALS, NONDOMESTIC see **ANIMALS, WILD**

ANIMALS, TRANSGENIC

see related
CHIMERA

Transgenic animal models of renal development and pathogenesis. Kopp JB, et al. **Am J Physiol** 1995 Nov;269(5 Pt 2):F601–20 (216 ref.)

Transgenic animals in the study of blood pressure regulation and hypertension. Thompson MW, et al. **Am J Physiol** 1995 Nov;269(5 Pt 1):E793–803 (101 ref.)

Gene-targeting and transgenic approaches to IGF and IGF binding protein function. Wood TL. **Am J Physiol** 1995 Oct;269(4 Pt 1):E613–22 (101 ref.)

Transgenic models and cancer treatment. Coletta PL, et al. **Cancer Treat Rev** 1996 Nov;21(6):565–76 (79 ref.)

Transgenic models to assess the neuropathogenic potential of HIV-1 proteins and cytokines. Mucke L, et al. **Curr Top Microbiol Immunol** 1995;202:187–205 (98 ref.)

Targeted mutagenesis: analysis of phenotype without germ line transmission. Nagy A, et al. **J Clin Invest** 1996 Mar 15;97(6):1360–5 (38 ref.)

The commercial and agricultural applications of animal transgenesis. Ward KA, et al. **Mol Biotechnol** 1995 Oct; 4(2):167–78 (63 ref.)

Transgenic animals. Shuldiner AR. **N Engl J Med** 1996 Mar 7;334(10):653–5 (0 ref.)

The generation of transgenic pigs as potential organ donors for humans. Cozzi E, et al. **Nat Med** 1995 Sep;1(9):964–6 (30 ref.)

Challenges and progress in the production of transgenic cattle. Eyestone WH. **Reprod Fertil Dev** 1994;6(5):647–52 (37 ref.)

Transgenic strategies to increase disease resistance in livestock. Müller M, et al. **Reprod Fertil Dev** 1994; 6(5):605–13 (83 ref.)

Transgenic sheep and wool growth: possibilities and current status. Powell BC, et al. **Reprod Fertil Dev** 1994;6(5):615–23 (28 ref.)

Progress and emerging problems in livestock transgenesis: a summary perspective. Seamark RF. **Reprod Fertil Dev** 1994;6(5):653–7 (36 ref.)

Site-specific transgene insertion: an approach. Wigley P, et al. **Reprod Fertil Dev** 1994;6(5):585–8 (21 ref.)

Strategies for production of pharmaceutical proteins in milk. Wilmut I, et al. **Reprod Fertil Dev** 1994;6(5):625–30 (51 ref.)

The production of pharmaceutical proteins from the milk of transgenic animals. Houdebine LM. **Reprod Nutr Dev** 1995;35(6):609–17 (64 ref.)

Transgenesis in rats: technical aspects and models. Charreau B, et al. **Transgenic Res** 1996 Jul;5(4):223–34 (75 ref.)

[Transgenic animals in medicine] Goetz P. **Cas Lek Cesk** 1996 Feb 14;135(4):102–5 (11 ref.) (Eng. Abstr.) **(Cze)**

[A transgenic animal model: new possibilities for cardiovascular research] Franz WM, et al. **Z Kardiol** 1995; 84 Suppl 4:17–32 (105 ref.) (Eng. Abstr.) **(Ger)**

[Transgene expression and integration in the zebrafish, Danio rerio] Amanuma K, et al. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2257–64 (19 ref.) **(Jpn)**

[Transgenic rabbit] Imai H, et al.

Tanpakushitsu Kakusan Koso 1995 Oct;40(14):2234–40 (16 ref.) **(Jpn)**
[Transgenic rat] Matsumoto K. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2223–33 (49 ref.) **(Jpn)**
[Transgenic bird] Mochii M. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2265–73 (22 ref.) **(Jpn)**
[Current status and challenges in the production of transgenic pigs] Nagashima H. **Tanpakushitsu Kakusan Koso** 1995 Oct; 40(14):2241–8 (16 ref.) **(Jpn)**
[Transgenesis and ES cell lines in Medaka] Ozato K, et al. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2249–56 (19 ref.) **(Jpn)**

GENETICS

Transgenic animals: how they are made and their role in animal production and research. Dziadek M. **Aust Vet J** 1996 May;73(5):182–7 (67 ref.)
Transgenic manipulation of myocardial G protein–coupled receptors and receptor kinases. Koch WJ, et al. **Circ Res** 1996 Apr;78(4):511–6 (29 ref.)
Transgenic fish in aquaculture and developmental biology. Gong Z, et al. **Curr Top Dev Biol** 1995;30:177–214 (174 ref.)
Recent advances in gene mutagenesis by site-directed recombination. Marth JD. **J Clin Invest** 1996 May 1; 97(9):1999–2002 (29 ref.)
Transgenesis in the rat and larger mammals. Mullins LJ, et al. **J Clin Invest** 1996 Apr 1;97(7):1557–60 (33 ref.)
Treatment protocols for transgenic mutation assays in vivo. Heddle JA, et al. **Mutagenesis** 1995 Nov;10(6):467–70 (17 ref.)
APP transgenesis: approaches toward the development of animal models for Alzheimer disease neuropathology. Greenberg BD, et al. **Neurobiol Aging** 1996 Mar–Apr; 17(2):153–71 (323 ref.)
Transgenic livestock as genetic models of human disease. Petters RM. **Reprod Fertil Dev** 1994;6(5):643–5 (24 ref.)
Regulation and expression of transgenes in fish — a review. Iyengar A, et al. **Transgenic Res** 1996 May;5(3):147–66 (101 ref.)
[Transgenic rats as a model for investigation of the pathogenesis of hypertension] Paul M. **Z Kardiol** 1995;84 Suppl 4:55–60 (32 ref.) (Eng. Abstr.) **(Ger)**

METABOLISM

Production of proteins in the milk of transgenic livestock: problems, solutions, and successes. Colman A. **Am J Clin Nutr** 1996 Apr;63(4):639S–45S (30 ref.)

PHYSIOLOGY

The hypertensive Ren-2 transgenic rat TGR (mREN2)27 in hypertension research. Characteristics and functional aspects. Langheinrich M, et al. **Am J Hypertens** 1996 May; 9(5):506–12 (36 ref.)
Physiological characterization of the hypertensive transgenic rat TGR(mREN2)27. Lee MA, et al. **Am J Physiol** 1996 Jun;270(6 Pt 1):E919–29 (92 ref.)
Transgenic approaches to salivary gland research. Samuelson LC. **Annu Rev Physiol** 1996;58:209–29 (106 ref.)
Transgenic animals: how they are made and their role in animal production and research. Dziadek M. **Aust Vet J** 1996 May;73(5):182–7 (67 ref.)
The renin-angiotensin system in transgenic rats. Wagner J, et al. **Pediatr Nephrol** 1996 Feb;10(1):108–12 (20 ref.)

ANIMALS, WILD

Organization versus activation: the role of endocrine-disrupting contaminants (EDCs) during embryonic development in wildlife. Guillette LJ Jr, et al. **Environ Health Perspect** 1995 Oct;103 Suppl 7:157–64 (81 ref.)
Impact and risk of foreign animal diseases. Brown CC, et al. **J Am Vet Med Assoc** 1996 Apr 1;208(7):1038–40 (16 ref.)
Feral cats in the United Kingdom. Remfry J. **J Am Vet Med Assoc** 1996 Feb 15;208(4):520–3 (10 ref.)
Disinfection and wildlife. Corn JL, et al. **Rev Sci Tech** 1995 Jun;14(2):455–68 (17 ref.)
Epidemiology of Mycobacterium bovis infection in animals and humans, with particular reference to Africa. Cosivi O, et al. **Rev Sci Tech** 1995 Sep;14(3):733–46 (63 ref.)
Wildlife, people and development: veterinary contributions to wildlife health and resource management in Africa. Kock MD. **Trop Anim Health Prod** 1996 Feb;28(1):68–80 (28 ref.)

EMBRYOLOGY

Environmentally Induced Alterations in Development: a Focus on Wildlife. Proceedings of a meeting. Racine, Wisconsin, December 10–12, 1993. **Environ Health Perspect** 1995 May;103 Suppl 4:1–100 (0 ref.)

GENETICS

[DNA fingerprinting in wild equid and Poitou ass breeding] Werner P, et al. **Schweiz Arch Tierheilkd** 1995;137(8):395–7 (10 ref.) **(Ger)**

GROWTH & DEVELOPMENT

Environmentally Induced Alterations in Development: a Focus on Wildlife. Proceedings of a meeting. Racine, Wisconsin, December 10–12, 1993. **Environ Health Perspect** 1995 May;103 Suppl 4:1–100 (0 ref.)

PARASITOLOGY

Introduction: ecological impact of parasitism on wildlife host populations. Grenfell BT, et al. **Parasitology** 1995;111 Suppl:S3–14 (185 ref.)

PHYSIOLOGY

Defining the role of pollutants in the disruption of reproduction in wildlife. Hose JE, et al. **Environ Health Perspect** 1995 May;103 Suppl 4:87–91 (44 ref.)

PSYCHOLOGY

Exploration and predation models of anxiety: evidence from laboratory and wild species. Hendrie CA, et al. **Pharmacol Biochem Behav** 1996 May;54(1):13–20 (56 ref.)

ANIMALS, ZOO

Use of disinfectants in zoos and game parks. Heuschele WP. **Rev Sci Tech** 1995 Jun;14(2):447–54 (14 ref.)

ANION EXCHANGERS see **ANTIPORTERS**

ANION GAP see **ACID–BASE EQUILIBRIUM**

ANION PUMPS see **ION PUMPS**

ANION TRANSPORT PROTEIN, ERYTHROCYTE see **BAND 3 PROTEIN**

ANIONS

METABOLISM

Unusual dehydrations in anaerobic bacteria: considering ketyls (radical anions) as reactive intermediates in enzymatic reactions. Buckel W. **FEBS Lett** 1996 Jun 24; 389(1):20–4 (43 ref.)

ANIRIDIA

DIAGNOSIS

Six signs in children with life-threatening implications. Tien DR. **R I Med** 1995 Dec;78(12):342–5 (6 ref.)

GENETICS

Genetics of aniridia and anterior segment dysgenesis. Churchill A, et al. **Br J Ophthalmol** 1996 Jul;80(7):669–73 (53 ref.)
Aniridia: recent achievements in paediatric practice. Ivanov I, et al. **Eur J Pediatr** 1995 Oct;154(10):795–800 (41 ref.)
Pax6: more than meets the eye. Hanson I, et al. **Trends Genet** 1995 Jul;11(7):268–72 (41 ref.)

ANKLE

Myxoid liposarcoma of the ankle. Werd MB, et al. **J Foot Ankle Surg** 1995 Sep–Oct;34(5):465–74 (39 ref.)

PATHOLOGY

Accessory soleus presenting as a posterior ankle mass: a case report and literature review. Travis MT, et al. **Foot Ankle Int** 1995 Oct;16(10):651–4 (14 ref.)
Tumors of the ankle and foot. Shankman S, et al. **Magn Reson Imaging Clin N Am** 1994 Feb;2(1):139–53 (57 ref.)

PHYSIOLOGY

Mechanical and electromyographic stretch responses in spastic and healthy subjects. Toft E. **Acta Neurol Scand Suppl** 1995;163:1–24 (103 ref.)

PHYSIOPATHOLOGY

Mechanical and electromyographic stretch responses in spastic and healthy subjects. Toft E. **Acta Neurol Scand Suppl** 1995;163:1–24 (103 ref.)

SURGERY

Surgery to the ankle. Rowley DI. **Br J Rheumatol** 1995 Sep; 34(9):854–7 (31 ref.)
Musculoskeletal applications of hyaluronan and hylan. Potential uses in the foot and ankle. Weiss C, et al. **Clin Podiatr Med Surg** 1995 Jul;12(3):497–517 (44 ref.)
Appropriate methods for bone fixation [editorial] Reinherz RP. **J Foot Ankle Surg** 1996 Mar–Apr;35(2):93 (29 ref.)

ANKLE INJURIES

Evaluation of pediatric foot problems: Part II. The hindfoot and the ankle. Manusov EG, et al. **Am Fam Physician** 1996 Sep 1;54(3):1012–26, 1031 (21 ref.)
Gunshot wounds to the foot and ankle. Sergi AR, et al. **Clin Podiatr Med Surg** 1995 Oct;12(4):689–702 (41 ref.)

DIAGNOSIS

Current concepts in the diagnosis and treatment of ankle sprains. Kuwada GT. **Clin Podiatr Med Surg** 1995 Oct; 12(4):653–65 (39 ref.)
Evaluation and treatment of ankle sprains. Anderson SJ. **Compr Ther** 1996 Jan;22(1):30–8 (52 ref.)
Magnetic resonance imaging of ankle ligaments. Emphasis on anatomy and injuries to lateral collateral ligaments. Mesgarzadeh M, et al. **Magn Reson Imaging Clin N Am** 1994 Feb;2(1):39–58 (48 ref.)
[Ankle sprain—a harmless injury? (editorial)] Hintermann B. **Schweiz Rundsch Med Prax** 1996 Mar 26;85(13):396–8 (17 ref.) **(Ger)**

ETIOLOGY

Accessory calcaneus: a case report and literature review. Krause JO, et al. **Foot Ankle Int** 1995 Oct;16(10):646–50 (11 ref.)

PHYSIOPATHOLOGY

Practical methods of preventing ankle injuries. Rifat SF, et al. **Am Fam Physician** 1996 Jun;53(8):2491–8, 2501–3 (27 ref.)

PREVENTION & CONTROL

Practical methods of preventing ankle injuries. Rifat SF, et al. **Am Fam Physician** 1996 Jun;53(8):2491–8, 2501–3 (27 ref.)
Effectiveness of prophylactic ankle stabilisers for prevention of ankle injuries. Sitler MR, et al. **Sports Med** 1995 Jul; 20(1):53–7 (24 ref.)

SURGERY

The internal fixation of ankle fracture repair. Savage TJ, et al. **Clin Podiatr Med Surg** 1995 Oct;12(4):603–31 (82 ref.)
Transfibular osteotomy in the correction of ankle joint incongruity. Davis JL, et al. **J Foot Ankle Surg** 1995 Jul–Aug;34(4):389–99 (23 ref.)
Tibiofibular arthrodesis for malunion of the talocrural joint. Loder BG, et al. **J Foot Ankle Surg** 1995 May–Jun; 34(3):283–8 (8 ref.)
Talar fracture/dislocation in the adolescent patient. Valentine BC 2nd, et al. **J Foot Ankle Surg** 1995 Jul–Aug;34(4):379–83 (11 ref.)

ANKLE JOINT

Hemophilic ankle arthropathy. Ribbans WJ, et al. **Clin Orthop** 1996 Jul;(328):39–45 (10 ref.)
Volkmann's ischemic contracture of the foot and ankle: evaluation and treatment of established deformity. Santi MD, et al. **Foot Ankle Int** 1995 Jun;16(6):368–77 (72 ref.)
Periarticular ankle sarcoidosis: a variant of Löfgren's syndrome. Mañá J, et al. **J Rheumatol** 1996 May;23(5):874–7 (21 ref.)

ABNORMALITIES

Evaluation of pediatric foot problems: Part II. The hindfoot and the ankle. Manusov EG, et al. **Am Fam Physician** 1996 Sep 1;54(3):1012–26, 1031 (21 ref.)

ANATOMY & HISTOLOGY

Normal magnetic resonance imaging anatomy of the ankle and foot. Kirsch MD, et al. **Magn Reson Imaging Clin N Am** 1994 Feb;2(1):1–21 (24 ref.)
Technical considerations for magnetic resonance imaging of the ankle and foot. Kneeland JB. **Magn Reson Imaging Clin N Am** 1994 Feb;2(1):23–8 (7 ref.)
Magnetic resonance imaging of ankle ligaments. Emphasis on anatomy and injuries to lateral collateral ligaments. Mesgarzadeh M, et al. **Magn Reson Imaging Clin N Am** 1994 Feb;2(1):39–58 (48 ref.)

PATHOLOGY

Magnetic resonance imaging manifestations of synovial lesions of the ankle and foot. Bergman AG. **Magn Reson Imaging Clin N Am** 1994 Feb;2(1):131–8 (33 ref.)
Achilles tendon and miscellaneous tendon lesions. Chandnani VP, et al. **Magn Reson Imaging Clin N Am** 1994 Feb; 2(1):89–96 (21 ref.)
Clinical significance of magnetic resonance imaging of the ankle and foot. Jahss MH. **Magn Reson Imaging Clin N Am** 1994 Feb;2(1):29–38 (10 ref.)
Magnetic resonance imaging of pediatric disorders of the ankle and foot. Schoenberg NY, et al. **Magn Reson Imaging Clin N Am** 1994 Feb;2(1):109–22 (51 ref.)

PHYSIOLOGY

Is prophylactic bracing of the ankle cost effective? Jerosch J, et al. **Orthopedics** 1996 May;19(5):405–14 (47 ref.)

SURGERY

New method for reconstruction in lateral ankle instability. Bauer GR. **J Am Podiatr Med Assoc** 1995 Sep;85(9):459–63 (32 ref.)

[Arthrodesis of the ankle joint] Bauer G, et al. **Orthopade** 1996 Apr;25(2):158–65 (74 ref.) (Eng. Abstr.) **(Ger)**

[Screw arthrodesis of the ankle joint. Technique and outcome] Thermann H, et al. **Orthopade** 1996 Apr; 25(2):166–76 (55 ref.) (Eng. Abstr.) **(Ger)**

[Hindfoot arthrodesis] Wülker N, et al. **Orthopade** 1996 Apr; 25(2):177–86 (57 ref.) (Eng. Abstr.) **(Ger)**

ANKYLOSIS

ETIOLOGY

Concurrent osteochondroma of the mandibular condyle and ipsilateral cranial base resulting in temperomandibular joint ankylosis: report of a case and review of the literature. Karras SC, et al. **J Oral Maxillofac Surg** 1996 May; 54(5):640–6 (27 ref.)

VETERINARY

Surgical management of digit disorders in cattle. Desrochers A, et al. **Vet Clin North Am Food Anim Pract** 1996 Mar; 12(1):277–98 (45 ref.)

ANLL see LEUKEMIA, NONLYMPHOCYTIC, ACUTE

ANNELIDA

PHYSIOLOGY

Bioluminescence in scale-worm photosomes: the photoprotein polynoidin is specific for the detection of superoxide radicals. Bassot JM, et al. **Histochem Cell Biol** 1995 Sep;104(3):199–210 (79 ref.)

ANNEXIN I

PHYSIOLOGY

Fifteenth Gaddum Memorial Lecture December 1994. Stress and the neuroendocrine–immune axis: the pivotal role of glucocorticoids and lipocortin 1. Buckingham JC. **Br J Pharmacol** 1996 May;118(1):1–19 (138 ref.)

ANNEXIN II

CHEMISTRY

Annexin II tetramer: structure and function. Waisman DM. **Mol Cell Biochem** 1995 Aug–Sep;149–150:301–22 (215 ref.)

ANNEXIN V

CHEMISTRY

Structure and function of the ion channel model system annexin V. Voges D, et al. **Adv Enzymol Relat Areas Mol Biol** 1995;71:209–39 (144 ref.)

PHYSIOLOGY

Structure and function of the ion channel model system annexin V. Voges D, et al. **Adv Enzymol Relat Areas Mol Biol** 1995;71:209–39 (144 ref.)

ANNEXIN VI

PHYSIOLOGY

Functional and genetic analysis of annexin VI. Edwards HC, et al. **Mol Cell Biochem** 1995 Aug–Sep;149–150:293–9 (75 ref.)

ANNEXIN VIII see ANNEXINS

ANNEXIN IX see ANNEXINS

ANNEXIN X see ANNEXINS

ANNEXIN XI see ANNEXINS

ANNEXINS

PHYSIOLOGY

Annexins of plant cells. Clark GB, et al. **Plant Physiol** 1995 Dec;109(4):1133–9 (53 ref.)

ANNUAL IMPLEMENTATION PLANS see REGIONAL HEALTH PLANNING

ANNULAR GROOVES see AMNIOTIC BAND SYNDROME

ANODE see ELECTRODES

ANODONTIA

GENETICS

GAPO syndrome: a new case. Sandgren G. **Am J Med Genet** 1995 Jul 31;58(1):87–90 (16 ref.)

PATHOLOGY

Odontotrichodysplasia: a case report with a review of conditions combining ectodermal dysplasia (subgroup 1–2) with skin manifestations. Yadav TP, et al. **J Dermatol** 1995 Aug;22(8):606–10 (14 ref.)

THERAPY

Lateral thinking: the management of missing upper lateral incisors. Millar BJ, et al. **Br Dent J** 1995 Aug 5; 179(3):99–106 (16 ref.)

ANODYNES see ANALGESICS

ANOMIE

see related
PERSONALITY DISORDERS
SOCIAL BEHAVIOR DISORDERS

ANOPHELES

Some emerging issues on the malaria problem in Kenya. Oloo AJ, et al. **East Afr Med J** 1996 Jan;73(1):50–3 (48 ref.)

CLASSIFICATION

A review of the use of ribosomal DNA (rDNA) to differentiate among cryptic Anopheles species. Collins FH, et al. **Insect Mol Biol** 1996 Feb;5(1):1–9 (55 ref.)

PARASITOLOGY

Regulation of infectivity of Plasmodium to the mosquito vector. Sinden RE, et al. **Adv Parasitol** 1996;38:53–117 (314 ref.)

Interactions between parasites and insects vectors. Hurd H. **Mem Inst Oswaldo Cruz** 1994;89 Suppl 2:27–30 (20 ref.)

Early sporogonic development in local vectors of Plasmodium falciparum in rural Cameroon. Robert V, et al. **Mem Inst Oswaldo Cruz** 1994;89 Suppl 2:23–6 (10 ref.)

[Vector control, perspectives and realities] Carnevale P. **Med Trop (Mars)** 1995;55(4 Suppl):56–65 (89 ref.) (Eng. Abstr.) **(Fre)**

[The utilization of molecular biological tools in the study of malaria transmission: example of programs conducted in Senegal] Fontenille D, et al. **Med Trop (Mars)** 1995;55(4 Suppl):52–5 (15 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Studies on clasper movement of Anopheles species. Kang W, et al. **Indian J Malariol** 1995 Mar;32(1):37–41 (12 ref.)

ANOPHTHALMOS

DIAGNOSIS

Complicated anophthalmos. Bajwa GS, et al. **Indian Pediatr** 1995 Apr;32(4):480–2 (5 ref.)

PATHOLOGY

[Cerebro-oculofacial dysplasia associated with vertebral changes] Munteanu G, et al. **Oftalmologia** 1995 Oct–Dec; 39(4):316–21 (10 ref.) (Eng. Abstr.) **(Rum)**

ANORECTICS see APPETITE DEPRESSANTS

ANOREXIA

Strategies for potential manipulation of anorexia during acute and chronic disease. Plata-Salamán CR. **Nutrition** 1995 Sep–Oct;11(5 Suppl):702–4 (39 ref.)

Anorexia during acute and chronic disease. Plata-Salamán CR. **Nutrition** 1996 Feb;12(2):69–78 (147 ref.)

Anorexia, cachexia, and dysphagia: the symptom experience. Grant MM, et al. **Semin Oncol Nurs** 1995 Nov;11(4):266–71 (32 ref.)

ECONOMICS

Towards a political economy of anorexia? Fine B. **Appetite** 1995 Jun;24(3):231–42 (28 ref.)

EPIDEMIOLOGY

Anorexia in older persons: epidemiology and optimal treatment. Morley JE. **Drugs Aging** 1996 Feb;8(2):134–55 (205 ref.)

ETIOLOGY

Anorexia and cachexia in advanced cancer patients. Vigano A, et al. **Cancer Surv** 1994;21:99–115 (76 ref.)

Anorexia in dialysis patients. Bergström J. **Semin Nephrol** 1996 May;16(3):222–9 (88 ref.)

PHYSIOPATHOLOGY

Neutral mediation of food aversions and anorexia induced by tumor necrosis factor and tumors. Bernstein IL. **Neurosci Biobehav Rev** 1996;20(1):177–81 (27 ref.)

PSYCHOLOGY

Towards a political economy of anorexia? Fine B. **Appetite** 1995 Jun;24(3):231–42 (28 ref.)

THERAPY

Anorexia in older persons: epidemiology and optimal treatment. Morley JE. **Drugs Aging** 1996 Feb;8(2):134–55 (205 ref.)

ANOREXIA NERVOSA

Anorexia nervosa: an overview. Hobbs WL, et al. **Am Fam Physician** 1996 Sep 15;54(4):1273–9, 1284–6 (16 ref.)

Anorexia nervosa: issues for the obstetrician and gynecologist. Hertweck SP. **Curr Opin Obstet Gynecol** 1995 Oct;7(5):371–4 (26 ref.)

Anorexia nervosa and bulimia nervosa. When the pursuit of bodily 'perfection' becomes a killer. Zerbe KJ. **Postgrad Med** 1996 Jan;99(1):161–4, 167–9 (21 ref.)

[Bulimia and anorexia nervosa] Sakuramoto M, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):345–7 (18 ref.) **(Jpn)**

[Anorexia nervosa] Mrass D, et al. **Lijec Vjesn** 1996 Jan–Feb; 118(1–2):34–8 (271 ref.) (Eng. Abstr.) **(Scr)**

COMPLICATIONS

Anorexia nervosa and the heart. Cooke RA, et al. **Br J Hosp Med** 1995 Oct 4–17;54(7):313–7 (41 ref.)

Anorexia and bulimia nervosa (the eating disorders): conditions of interest to the dental practitioner. Robb ND, et al. **J Dent** 1996 Jan–Mar;24(1–2):7–16 (77 ref.)

Eating disorder and obsessive-compulsive disorder: neurochemical and phenomenological commonalities. Jarry JL, et al. **J Psychiatry Neurosci** 1996 Jan;21(1):36–48 (125 ref.)

DIAGNOSIS

[Anorexia nervosa. A frequent antecedent of obsessive compulsive disorder] Zribi S, et al. **Encephale** 1989 May–Jun;15(3):355–8 (19 ref.) (Eng. Abstr.) **(Fre)**

[Considerations on the diagnosis of infantile anorexia] Robin D, et al. **Psychiatr Enfant** 1995;38(1):365–401 (54 ref.) (Eng. Abstr.) **(Fre)**

ECONOMICS

The cost of the illness that defies [editorial] Howlett M, et al. **Postgrad Med J** 1995 Dec;71(842):705–6 (15 ref.)

EPIDEMIOLOGY

Eating disturbances among American minority groups: a review. Crago M, et al. **Int J Eat Disord** 1996 Apr; 19(3):239–48 (59 ref.)

[Comorbidity of bipolar and eating disorders. Epidemiologic and therapeutic aspects] Mury M, et al. **Encephale** 1995 Sep–Oct;21(5):545–53 (44 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Anorexia nervosa—diagnosis, aetiology, and treatment. Hartman D. **Postgrad Med J** 1995 Dec;71(842):712–6 (30 ref.)

METABOLISM

Bone metabolism and osteopenia in eating disorders. Carmichael KA, et al. **Medicine (Baltimore)** 1995 Sep; 74(5):254–67 (132 ref.)

PSYCHOLOGY

Eating disorder research in the past decade. Halmi KA. **Ann N Y Acad Sci** 1996 Jun 18;789:67–77 (56 ref.)

Bone metabolism and osteopenia in eating disorders. Carmichael KA, et al. **Medicine (Baltimore)** 1995 Sep; 74(5):254–67 (132 ref.)

Anorexia nervosa, self-starvation and the reward of stress. Bergh C, et al. **Nat Med** 1996 Jan;2(1):21–2 (13 ref.)

THERAPY

Conceptual models and integrative therapy: anorexia nervosa as a prototype. Greben DH, et al. **Can J Psychiatry** 1995 Dec;40(10):584–92 (65 ref.)

Anorexia nervosa—diagnosis, aetiology, and treatment. Hartman D. **Postgrad Med J** 1995 Dec;71(842):712–6 (30 ref.)

[Problems involving "target weight" in treatment of anorexia nervosa] Hebebrand J, et al. **Z Kinder Jugendpsychiatr** 1996 Jun;24(2):92–104 (60 ref.) **(Ger)**

ANOSMIA

DIAGNOSIS

[Diagnostic methods in the assessment of anosmia in neurologic diseases] Kobal G, et al. **Nervenarzt** 1995 Dec;

ANOSMIA

66(12):869–84 (54 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

[Zinc-deficient disorders of sense organs—dark adaptation, taste and smell disorders] Tomita H. **Nippon Rinsho** 1996 Jan;54(1):141–7 (40 ref.) (Eng. Abstr.) **(Jpn)**

PSYCHOLOGY

Recent advances in the neuropsychology of human olfaction and anosmia. Sullivan TE, et al. **Brain Inj** 1995 Aug–Sep; 9(6):641–6 (22 ref.)

ANOXEMIA

COMPLICATIONS

[Hepatopulmonary syndrome] Akahane T, et al. **Ryofukibetsu Shokogun Shiriza** 1995;(8):505–8 (18 ref.) **(Jpn)**

ETIOLOGY

A 37-year-old woman with end-stage cirrhosis, progressive dyspnea, platypnea, and hypoxemia. Lange PA, et al. **Cleve Clin J Med** 1996 Jan–Feb;63(1):8–11 (6 ref.)

Mechanisms of gas exchange impairment in patients with liver cirrhosis. Agusti AG, et al. **Clin Chest Med** 1996 Mar; 17(1):49–66 (159 ref.)

Hepatopulmonary syndrome. A pulmonary vascular complication of liver disease. Castro M, et al. **Clin Chest Med** 1996 Mar;17(1):35–48 (81 ref.)

Structural and pathologic changes in the lung vasculature in chronic liver disease. Schraufnagel DE, et al. **Clin Chest Med** 1996 Mar;17(1):1–15 (94 ref.)

Nocturnal hypoxaemia in patients with chronic obstructive pulmonary disease: who should be treated and how? Heijdra YF, et al. **Neth J Med** 1995 Dec;47(6):296–301 (30 ref.)

METABOLISM

Studies of hypoxemic/reoxygenation injury: I. Linkage between cardiac function and oxidant damage. Buckberg GD. **J Thorac Cardiovasc Surg** 1995 Oct;110(4 Pt 2):1164–70 (47 ref.)

PHYSIOPATHOLOGY

Effect of hypoxaemia on water and sodium homeostatic hormones and renal function. Olsen NV. **Acta Anaesthesiol Scand Suppl** 1995;107:165–70 (55 ref.)

The effects of hypoxaemia and recommendations for postoperative oxygen therapy. Powell JF, et al. **Anaesthesia** 1996 Aug;51(8):769–72 (41 ref.)

[Is infection and septic shock caused by a global oxygen deficiency? An overview in 2 parts. I: Infection and correlation between DO2 and VO2] Ensinger H, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Apr; 31(3):132–42 (0 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Home oxygen therapy. O'Donohue WJ Jr. **Med Clin North Am** 1996 May;80(3):611–22 (38 ref.)

Nocturnal hypoxaemia in patients with chronic obstructive pulmonary disease: who should be treated and how? Heijdra YF, et al. **Neth J Med** 1995 Dec;47(6):296–301 (30 ref.)

Orthodeoxia and platypnoea after acute organophosphorus poisoning reversed by CPAP: a newly described cause and review of the literature. Bouros D, et al. **Respir Med** 1995 Oct;89(9):625–8 (33 ref.)

ANOXIA

COMPLICATIONS

Non-ischemic hypoxia of the arterial wall is a primary cause of atherosclerosis. Simanonok JP. **Med Hypotheses** 1996 Feb;46(2):155–61 (80 ref.)

[The role of hypoxia in the development of bronchial asthma] Ialkut SI. **Ter Arkh** 1995;67(8):71–4 (40 ref.) **(Rus)**

[Cerebral ischemia and respiratory diseases] Castillo J, et al. **Rev Neurol** 1995;23 Suppl 1:S61–9 (81 ref.) **(Spa)**

DRUG THERAPY

Calcium blockage in pulmonary hypertension and hypoxic vasoconstriction. Neely CF, et al. **New Horiz** 1996 Feb; 4(1):99–106 (74 ref.)

ENZYMOLOGY

Role of xanthine oxidase and its inhibitor in hypoxia: reoxygenation injury. Saugstad OD. **Pediatrics** 1996 Jul; 98(1):103–7 (83 ref.)

GENETICS

Possible genomic mechanism involved in control systems responses to hypoxia. Cherniack NS, et al. **Adv Exp Med Biol** 1995;393:89–94 (26 ref.)

METABOLISM

Na(+)-Ca2+ exchange in anoxic/ischemic injury of CNS myelinated axons. Stys PK, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:366–78 (41 ref.)

Hypoxia, oxidative stress and rheumatoid arthritis. Mapp PI, et al. **Br Med Bull** 1995 Apr;51(2):419–36 (43 ref.)

Ion channels, oxygen sensation and signal transduction in pulmonary arterial smooth muscle. Kozlowski RZ. **Cardiovasc Res** 1995 Sep;30(3):318–25 (73 ref.)

Hypoxic and metabolic regulation of voltage-gated K+ channels in rat pulmonary artery smooth muscle cells. Yuan XJ, et al. **Exp Physiol** 1995 Sep;80(5):803–13 (24 ref.)

PHYSIOPATHOLOGY

Ventilatory responses to hypoxia and hypercapnia during inhalation anaesthesia and subparalytical muscle relaxation in humans [see comments] Lindahl SG. **Acta Anaesthesiol Sin** 1995 Dec;33(4):223–6 (13 ref.) Comment in: Acta Anaesthesiol Sin 1995 Dec;33(4):i–ii.

Increase in carotid body sensitivity during sustained hypoxia. Bisgard GE. **Biol Signals** 1995 Sep–Oct;4(5):292–7 (43 ref.)

Influence of body temperature on responses to hypoxia and hypercapnia: implications for SIDS. Maskrey M. **Clin Exp Pharmacol Physiol** 1995 Aug;22(8):527–32 (60 ref.)

Hypoxic inhibition of breathing and motor activity in the foetus and newborn. Walker DW. **Clin Exp Pharmacol Physiol** 1995 Aug;22(8):533–6 (30 ref.)

Clinical aspects of hypoxic pulmonary vasoconstriction. Leach RM, et al. **Exp Physiol** 1995 Sep;80(5):865–75 (29 ref.)

The role of the endothelium in hypoxic pulmonary vasoconstriction. Ward JP, et al. **Exp Physiol** 1995 Sep; 80(5):793–801 (24 ref.)

Ventilatory depression during mild hypoxia in adult humans. Honda Y. **Jpn J Physiol** 1995;45(6):947–59 (41 ref.)

Hypoxia-associated proteins. Graven KK, et al. **New Horiz** 1995 May;3(2):208–18 (58 ref.)

Calcium blockage in pulmonary hypertension and hypoxic vasoconstriction. Neely CF, et al. **New Horiz** 1996 Feb; 4(1):99–106 (74 ref.)

The effects of chronic hypoxia on the pharmacological responsiveness of the pulmonary artery. Karamsetty VS, et al. **Pharmacol Ther** 1995;68(2):233–46 (110 ref.)

Oxygen sensing and molecular adaptation to hypoxia. Bunn HF, et al. **Physiol Rev** 1996 Jul;76(3):839–85 (388 ref.)

[Hypoxic pulmonary vasoconstriction] Theissen IL, et al. **Anaesthesist** 1996 Jul;45(7):643–52 (137 ref.) (Eng. Abstr.) **(Ger)**

[Lung problems in acute to subacute exposure to medium altitudes] Marugg D. **Schweiz Rundsch Med Prax** 1995 Oct 3;84(40):1101–7 (41 ref.) (Eng. Abstr.) **(Ger)**

[Immunophysiologic mechanisms of adaptation to extreme conditions] Novikov VS. **Fiziol Cheloveka** 1996 Mar–Apr; 22(2):25–34 (44 ref.) **(Rus)**

[Molecular factors of cerebral hypoxia-ischemia] Macaya A, et al. **Rev Neurol** 1996 Jul;24(131):855–64 (84 ref.) (Eng. Abstr.) **(Spa)**

PREVENTION & CONTROL

Airway management and mechanical ventilation. Abrams KJ. **New Horiz** 1995 Aug;3(3):479–87 (65 ref.)

[Problems and limits in noninvasive oxygen monitoring] Bardenheuer HJ, et al. **Anaesthesist** 1996 Jul;45(7):614–25 (86 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Noninvasive nasal mask positive pressure ventilation in a pediatric patient with acute hypoxic respiratory failure. Padman R, et al. **Pediatr Emerg Care** 1996 Feb;12(1):44–7 (63 ref.)

ANOXIA, CELLULAR see **CELL HYPOXIA**

ANOXIA, FETAL see **FETAL ANOXIA**

ANP see **ATRIAL NATRIURETIC FACTOR**

ANP RECEPTORS see **RECEPTORS, ATRIAL NATRIURETIC FACTOR**

ANT VENOMS

IMMUNOLOGY

Fire ant venom allergy. Hoffman DR. **Allergy** 1995 Jul; 50(7):535–44 (89 ref.)

Hypersensitivity to fire ant venom [see comments] Stafford CT. **Ann Allergy Asthma Immunol** 1996 Aug;77(2):87–95; quiz 96–9 (50 ref.) Comment in: Ann Allergy Asthma Immunol 1996 Aug;77(2):85.

ANTACIDS

PHARMACOLOGY

The history of acid inhibition. Baron JH. **Yale J Biol Med** 1994 May–Aug;67(3–4):97–106 (32 ref.)

THERAPEUTIC USE

Bismuth therapy for Helicobacter pylori infection. A review of five years experience at a university hospital in Norway. Berstad A, et al. **J Physiol Pharmacol** 1996 Mar;47(1):31–49 (45 ref.)

[Reinstatement of calcium-containing antacids] Tytgat GN. **Ned Tijdschr Geneeskd** 1995 Nov 25;139(47):2405–7 (14 ref.) **(Dut)**

ANTERIOR CHAMBER

IMMUNOLOGY

Influence of the anterior chamber of the eye on T-cell production of extracellular antigen-specific proteins. Cone RE, et al. **Adv Exp Med Biol** 1995;383:237–48 (31 ref.)

SURGERY

Flexible open-loop anterior chamber intraocular lens implantation after posterior capsule complications in extracapsular cataract extraction. Rattigan SM, et al. **J Cataract Refract Surg** 1996 Mar;22(2):243–6 (10 ref.)

ANTERIOR CHAMBER EPITHELIUM see **ENDOTHELIUM, CORNEAL**

ANTERIOR CRUCIATE LIGAMENT

see related

POSTERIOR CRUCIATE LIGAMENT

Computed tomography—guided aspiration of a ganglion cyst of the anterior cruciate ligament: a case report. Campagnolo DI, et al. **Arch Phys Med Rehabil** 1996 Jul; 77(7):732–3 (22 ref.)

Review on tension in the natural and reconstructed anterior cruciate ligament. Andersen HN, et al. **Knee Surg Sports Traumatol Arthrosc** 1994;2(4):192–202 (90 ref.)

ABNORMALITIES

[Agenesis of the anterior cruciate ligament. Report of a case and review of the literature] Barbuti D, et al. **Radiol Med (Torino)** 1995 Jul–Aug;90(1–2):134–6 (20 ref.) **(Ita)**

INJURIES

Revision ACL surgery. Etiology, indications, techniques, and results. Johnson DL, et al. **Am J Knee Surg** 1995 Fall; 8(4):155–67 (106 ref.)

Hamstring spasm in anterior cruciate ligament injuries. Frank CB, et al. **Arthroscopy** 1995 Aug;11(4):444–8 (19 ref.)

Biologic incorporation of allograft anterior cruciate ligament replacements. Jackson DW, et al. **Clin Orthop** 1996 Mar; (324):126–33 (26 ref.)

Anterior cruciate ligament: injuries and treatment. Larson RV, et al. **Instr Course Lect** 1996;45:235–43 (47 ref.)

Popliteal cysts and associated disorders of the knee. Critical review with MR imaging. Sansone V, et al. **Int Orthop** 1995;19(5):275–9 (20 ref.)

MR imaging of anterior cruciate ligament injuries. Vahey TN, et al. **Magn Reson Imaging Clin N Am** 1994 Aug; 2(3):365–80 (58 ref.)

Electromyography and biomechanics of a dynamic knee brace for anterior cruciate ligament deficiency. Acierno SP, et al. **Orthopedics** 1995 Nov;18(11):1101–7 (33 ref.)

Anterior cruciate ligament injuries in young athletes. Recommendations for treatment and rehabilitation. McCarroll JR, et al. **Sports Med** 1995 Aug;20(2):117–27 (32 ref.)

[The "gold standard" in cruciate ligament replacement] Benedetto KP. **Chirurg** 1995 Nov;66(11):1061–70 (57 ref.) (Eng. Abstr.) **(Ger)**

[Cruciate ligament allograft transplant: a reliable alternative?] Lobenhoffer P, et al. **Chirurg** 1995 Nov;66(11):1071–8 (69 ref.) (Eng. Abstr.) **(Ger)**

[Sense and nonsense of cruciate ligament prostheses] Neumann K, et al. **Chirurg** 1995 Nov;66(11):1079–84 (32 ref.) (Eng. Abstr.) **(Ger)**

[Possibilities and limits of conservative management of cruciate ligament injuries] Paar O, et al. **Chirurg** 1995 Nov; 66(11):1050–60 (48 ref.) (Eng. Abstr.) **(Ger)**

[Arthroscopic approaches to reconstruction of the cruciate ligament: refresher course] Kohn D. **Sportverletz Sportschaden** 1995 Dec;9(4):A31–42 (0 ref.) **(Ger)**

[Progression of arthrosis after alloplasty—what factors play a role?] Küllmer K, et al. **Unfallchirurgie** 1996 Jun; 22(3):130–8 (36 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Revision ACL surgery. Etiology, indications, techniques, and results. Johnson DL, et al. **Am J Knee Surg** 1995 Fall; 8(4):155–67 (106 ref.)

Subcutaneous pretibial cyst formation associated with anterior cruciate ligament allografts: a report of four cases and literature review. Victoroff BN, et al. **Arthroscopy** 1995 Aug;11(4):486–94 (25 ref.)

Review of outcome instruments for evaluation of anterior cruciate ligament reconstruction. Vangsness CT Jr, et al. **Bull Hosp Jt Dis** 1995;54(1):25–9 (29 ref.)

Meniscus repair: cases and review of the literature. Pellacci F, et al. **Chir Organi Mov** 1995 Jul–Aug;80(3):309–21 (80 ref.)

Biologic incorporation of allograft anterior cruciate ligament replacements. Jackson DW, et al. **Clin Orthop** 1996 Mar;

(324):126–33 (26 ref.)
Biology of ACL reconstructions: what happens to the graft? Arnoczky SP. **Instr Course Lect** 1996;45:229–33 (52 ref.)
Anterior cruciate ligament: injuries and treatment. Larson RV, et al. **Instr Course Lect** 1996;45:235–43 (47 ref.)
Prevention of complications after autogenous bone-patellar tendon-bone ACL reconstruction. Shelbourne KD, et al. **Instr Course Lect** 1996;45:253–62 (30 ref.)

ANTERIOR EYE SEGMENT

ABNORMALITIES

Genetics of aniridia and anterior segment dysgenesis. Churchill A, et al. **Br J Ophthalmol** 1996 Jul;80(7):669–73 (53 ref.)

BLOOD SUPPLY

Microvasculature of the ocular anterior segment. Morrison JC, et al. **Microsc Res Tech** 1996 Apr 15;33(6):480–9 (18 ref.)

METABOLISM

Free radicals and aging of anterior segment tissues of the eye: a hypothesis. Green K. **Ophthalmic Res** 1995;27 Suppl 1:143–9 (41 ref.)

SURGERY

Complications of anterior segment laser procedures. Carr LW 3rd, et al. **Optom Clin** 1995;4(4):33–49 (50 ref.)
Lasers and liability. Classé JG. **Optom Clin** 1995;4(4):113–23 (19 ref.)

ULTRASONOGRAPHY

Practical application of ultrasound biomicroscopy. Pavlin CJ. **Can J Ophthalmol** 1995 Jun;30(4):225–9 (44 ref.)

ANTERIOR LONGITUDINAL LIGAMENT see **LONGITUDINAL LIGAMENTS**

ANTERIOR PERFORATED SUBSTANCE see **OLFACTORY PATHWAYS**

ANTERIOR TIBIAL MUSCLE see **MUSCLE, SKELETAL**

ANTHELMINTICS

ADVERSE EFFECTS

Albendazole-induced pseudomembranous colitis. Shah V, et al. **Am J Gastroenterol** 1996 Jul;91(7):1453–4 (11 ref.)

CHEMICAL SYNTHESIS

The pharmacology of FMRFamide-related neuropeptides in nematodes: new opportunities for rational anthelmintic discovery? Geary TG, et al. **Int J Parasitol** 1995 Nov; 25(11):1273–80 (42 ref.)

CHEMISTRY

Structure and activity of avermectins and milbemycins in animal health. Shoop WL, et al. **Vet Parasitol** 1995 Sep; 59(2):139–56 (54 ref.)

PHARMACOLOGY

[Structural disorders in the tissues of nematodes of the suborder Ascaridata after exposure to anthelmintics] Bogoiavlenskiĭ IuK, et al. **Med Parazitol (Mosk)** 1995 Apr–Jun;(2):19–27 (30 ref.) (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Antiparasitic drugs. Liu LX, et al. **N Engl J Med** 1996 May 2;334(18):1178–84 (100 ref.)
Effect of chemoprophylaxis on immunity to gastrointestinal nematodes in cattle. Vercruysse J, et al. **Verh K Acad Geneeskd Belg** 1996;58(1):51–60 (18 ref.)
The prevalence of anthelmintic resistance in nematode parasites of sheep in southern Latin America: general overview. Waller PJ, et al. **Vet Parasitol** 1996 Apr; 62(3–4):181–7 (20 ref.)
[Anthelmintics resistance in gastrointestinal nematodes in domestic animals] Geerts S. **Verh K Acad Geneeskd Belg** 1995;57(5):351–69; discussion 369–70 (45 ref.) (Eng. Abstr.) **(Dut)**
[Antiparasitic therapeutics: the present] Magnaval JF. **Med Trop (Mars)** 1995;55(3 Suppl):10–2 (15 ref.) **(Fre)**
[Kidney reactivity in helminthiases and after anthelmintic treatment] Grishina EA, et al. **Med Parazitol (Mosk)** 1995 Apr–Jun;(2):27–30 (15 ref.) (Eng. Abstr.) **(Rus)**

ANTHOCYANINS

ANALYSIS

Anthocyanins in grapes and grape products. Mazza G. **Crit Rev Food Sci Nutr** 1995 Jul;35(4):341–71 (167 ref.)

ANTHRACENEDIONES see **ANTHRAQUINONES**

ANTHRACYCLINE ANTIBIOTICS see **ANTIBIOTICS, ANTHRACYCLINE**

ANTHRACYCLINES

ADVERSE EFFECTS

Anthracycline-induced cardiotoxicity. Shan K, et al. **Ann Intern Med** 1996 Jul 1;125(1):47–58 (146 ref.)
Cytoprotective agents for anthracyclines. Dorr RT. **Semin Oncol** 1996 Aug;23(4 Suppl 8):23–34 (122 ref.)

PHARMACOLOGY

Taxoids: effective agents in anthracycline-resistant breast cancer. Ravdin PM. **Semin Oncol** 1995 Dec;22(6 Suppl 13):29–34 (34 ref.)

THERAPEUTIC USE

The role of anthracyclines in adjuvant chemotherapy of breast cancer: a critical appraisal. Mouridsen HT. **Recent Results Cancer Res** 1996;140:191–9 (33 ref.)

ANTHRALIN

THERAPEUTIC USE

Tars and anthralins. Silverman A, et al. **Dermatol Clin** 1995 Oct;13(4):817–33 (137 ref.)

ANTHRANILIC ACIDS

ADVERSE EFFECTS

Nephrogenic diabetes insipidus induced by lobenzarit disodium treatment in patients with rheumatoid arthritis. Sakane N, et al. **Intern Med** 1996 Feb;35(2):119–22 (17 ref.)

ANTHRAQUINONES

PHARMACOLOGY

[The mechanism of action of sennosides] Lemli J. **Ann Gastroenterol Hepatol (Paris)** 1996 Mar–Apr; 32(2):109–12 (29 ref.) (Eng. Abstr.) **(Fre)**
[Mechanism of action of sennosides] Lemli J. **Bull Acad Natl Med** 1995 Nov;179(8):1605–11 (29 ref.) (Eng. Abstr.) **(Fre)**

ANTHRAX

DIAGNOSIS

A case of cutaneous anthrax. Natori N. **Tohoku J Exp Med** 1995 Jul;176(3):187–90 (7 ref.)

ANTHROPOIDEA see **HAPLORHINI**

ANTHROPOLOGY

see related
HOMINIDAE

[Anthropology and cardiology in Niamey (Niger)] Jaffré Y, et al. **Bull Soc Pathol Exot** 1996;89(1):68–75 (24 ref.) (Eng. Abstr.) **(Fre)**

TRENDS

Toward a more comprehensive medical anthropology: the case of adolescent psychopathology. Fabrega H Jr, et al. **Med Anthropol Q** 1995 Dec;9(4):431–61 (185 ref.)

ANTHROPOLOGY, CULTURAL

see related
ETHNOPSYCHOLOGY

Antiscience trends in the rise of the "alternative medicine" movement. Sampson W. **Ann N Y Acad Sci** 1996 Jun 24; 775:188–97 (34 ref.)
Ethnography: a stepwise approach for primary care researchers. Ventres WB, et al. **Fam Med** 1996 Jan; 28(1):52–6 (25 ref.)

ANTHROPOLOGY, FORENSIC see **FORENSIC ANTHROPOLOGY**

ANTHROPOLOGY, PHYSICAL

see related
ANTHROPOMETRY
GENETICS, MEDICAL

[Cranial morphology of modern kyongsangnam-do Koreans] Takenaka M. **Kaibogaku Zasshi** 1995 Oct;70(5):419–21 (12 ref.) **(Jpn)**

ANTHROPOMETRY

Superimposition and reconstruction in forensic facial identification: a survey. Aulsebrook WA, et al. **Forensic Sci Int** 1995 Oct 30;75(2–3):101–20 (230 ref.)

METHODS

Prediction of body composition in elderly men over 75 years of age. Fuller NJ, et al. **Ann Hum Biol** 1996 Mar–Apr; 23(2):127–47 (64 ref.)

ANTI-D-IMMUNOGLOBULIN see **RHO(D) IMMUNE GLOBULIN**

ANTIAGGREGANTS, PLATELET see **PLATELET AGGREGATION INHIBITORS**

ANTI-ALLERGIC AGENTS

see related
HISTAMINE H1 ANTAGONISTS

PHARMACOLOGY

Clinical implications of the pharmacological profile of Tilarin. Davies RJ. **Allergy** 1996;51(28 Suppl):8–13 (26 ref.)
Glucocorticosteroid inhibition of cytokine production: relevance to antiallergic actions. Schwiebert LA, et al. **J Allergy Clin Immunol** 1996 Jan;97(1 Pt 2):143–52 (105 ref.)

THERAPEUTIC USE

Therapeutic options in ocular allergic disease. Hingorani M, et al. **Drugs** 1995 Aug;50(2):208–21 (167 ref.)
[Anti-allergic agent therapy of asthma] Fujimura M. **Nippon Naika Gakkai Zasshi** 1996 Feb 10;85(2):216–21 (5 ref.) **(Jpn)**

ANTIANDROGENS see **ANDROGEN ANTAGONISTS**

ANTI-ANTIBODIES see **ANTIBODIES, ANTI-IDIOTYPIC**

ANTI-ANXIETY AGENTS

see related
ADRENERGIC BETA-ANTAGONISTS

[Assessment of anxiolytics (3)—biochemical approach] Ito Y. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1995 Jun; 15(3):223–9 (11 ref.) (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Photosensitivity associated with antipsychotics, antidepressants and anxiolytics. Harth Y, et al. **Drug Saf** 1996 Apr;14(4):252–9 (47 ref.)

PHARMACOKINETICS

Clinical pharmacokinetics in patients with burns. Jaehde U, et al. **Clin Pharmacokinet** 1995 Jul;29(1):15–28 (75 ref.)

PHARMACOLOGY

Neurosteroids: molecular mechanisms of action and psychopharmacological significance. Rupprecht R, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1–6 Spec No):163–8 (50 ref.)
A review of the validity and variability of the elevated plus-maze as an animal model of anxiety. Hogg S. **Pharmacol Biochem Behav** 1996 May;54(1):21–30 (56 ref.)
Central noradrenergic neurones and stress. Stanford SC. **Pharmacol Ther** 1995;68(2):297–42 (360 ref.)
Aggression, anxiety and vocalizations in animals: GABAA and 5-HT anxiolytics. Miczek KA, et al. **Psychopharmacology (Berl)** 1995 Sep;121(1):38–56 (161 ref.)
The road to tranquility: the search for selective anti-anxiety agents. Estes JW. **Synapse** 1995 Sep;21(1):10–20 (69 ref.)

THERAPEUTIC USE

Azapirones: an alternative to benzodiazepines for anxiety. Cadieux RJ. **Am Fam Physician** 1996 May 15;53(7):2349–53 (23 ref.)
Management of delirium tremens on the head and neck service. Alvi A, et al. **Am J Otolaryngol** 1995 Jul–Aug; 16(4):224–31 (25 ref.)
Augmentation with buspirone: a review. Harvey KV, et al. **Ann Clin Psychiatry** 1995 Sep;7(3):143–7 (32 ref.)
Augmentation strategies: focus on anxiolytics. Joffe RT, et al. **J Clin Psychiatry** 1996;57 Suppl 7:25–31; discussion 32–3 (56 ref.)
Future directions in anxiolytic pharmacotherapy. Kunovac JL, et al. **Psychiatr Clin North Am** 1995 Dec;18(4):895–909 (90 ref.)
Generalized anxiety disorder. Longitudinal course and pharmacologic treatment. Schweizer E. **Psychiatr Clin North Am** 1995 Dec;18(4):843–57 (76 ref.)
The road to tranquility: the search for selective anti-anxiety agents. Estes JW. **Synapse** 1995 Sep;21(1):10–20 (69 ref.)
[Treatment of generalized anxiety: new pharmacologic approaches] Boulenger JP. **Encephale** 1995 Nov–Dec; 21(6):459–66 (51 ref.) (Eng. Abstr.) **(Fre)**
[Epidemiology of the use of anxiolytic and hypnotic drugs in France and in the world] Pélissolo A, et al. **Encephale** 1996 May–Jun;22(3):187–96 (68 ref.) (Eng. Abstr.) **(Fre)**
[Panic disorder and agoraphobia: what is effective?] Bandelow B, et al. **Fortschr Neurol Psychiatr** 1995 Nov; 63(11):451–64 (120 ref.) (Eng. Abstr.) **(Ger)**

ANTI-ANXIETY AGENTS, BENZODIAZEPINE

The management of opioid and benzodiazepine dependence in infants, children, and adolescents. Yaster M, et al. **Pediatrics** 1996 Jul;98(1):135–40 (41 ref.)

[Progresses in psychiatry in China, 1995] Zhang M, et al. **Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):725–6 (0 ref.) **(Chi)**

ADMINISTRATION & DOSAGE

Sedation with benzodiazepines. Gempeler F, et al. **Middle East J Anesthesiol** 1995 Jun;13(2):117–45 (73 ref.)

ADVERSE EFFECTS

Benzodiazepines on trial: a research strategy for their rehabilitation. Costa E, et al. **Trends Pharmacol Sci** 1996 May;17(5):192–200 (60 ref.)

POISONING

Benzodiazepine poisoning in companion animals. Bertini S, et al. **Vet Hum Toxicol** 1995 Dec;37(6):559–62 (24 ref.)

THERAPEUTIC USE

Detoxification: the use of benzodiazepines. Shaw GK. **Alcohol Alcohol** 1995 Nov;30(6):765–70 (20 ref.)

Azapirones: an alternative to benzodiazepines for anxiety. Cadieux RJ. **Am Fam Physician** 1996 May 15;53(7):2349–53 (23 ref.)

Benzodiazepines for alcohol withdrawal in the elderly and in patients with liver disease. Peppers MP. **Pharmacotherapy** 1996 Jan–Feb;16(1):49–57 (49 ref.)

Benzodiazepines on trial: a research strategy for their rehabilitation. Costa E, et al. **Trends Pharmacol Sci** 1996 May;17(5):192–200 (60 ref.)

[New non-benzodiazepine hypnotics. Progress in therapy of sleep disorders?] Hajak G, et al. **Internist (Berl)** 1995 Nov; 36(11):1085–90; discussion 1090–1 (51 ref.) **(Ger)**

ANTI-ARRHYTHMIA AGENTS

see related
ADRENERGIC BETA-ANTAGONISTS
CALCIUM CHANNEL BLOCKERS

ADMINISTRATION & DOSAGE

Novel delivery of antiarrhythmic agents. Labhasetwar V, et al. **Clin Pharmacokinet** 1995 Jul;29(1):1–5 (24 ref.)

ADVERSE EFFECTS

What have clinical trials taught us about proarrhythmia? Skanes AC, et al. **Can J Cardiol** 1996 Apr;12 Suppl B:20B–26B (39 ref.)

Dilantin hypersensitivity reaction. Conger LA Jr, et al. **Cutis** 1996 Apr;57(4):223–6 (32 ref.)

Canalicular cholestasis due to amiodarone toxicity. A definite diagnosis obtained by electron microscopy. Macarri G, et al. **Ital J Gastroenterol** 1995 Oct–Nov;27(8):436–8 (18 ref.)

Proarrhythmia with class III antiarrhythmic drugs: definition, electrophysiologic mechanisms, incidence, predisposing factors, and clinical implications. Hohnloser SH, et al. **J Cardiovasc Electrophysiol** 1995 Oct;6(10 Pt 2):920–36 (102 ref.)

An evaluation of possible mechanisms underlying amiodarone-induced pulmonary toxicity. Reasor MJ, et al. **Proc Soc Exp Biol Med** 1996 Sep;212(4):297–304 (89 ref.)

[Early diagnosis of amiodarone-induced pulmonary toxicity: are repeated lung function tests of any value?] Ulrik CS, et al. **Ugeskr Laeger** 1996 Jun 10;158(24):3445–7 (17 ref.) (Eng. Abstr.) **(Dan)**

[Supraventricular tachycardia with wide QRS complexes during Vaughan-Williams class I anti-arrhythmic treatment. Diagnostic and therapeutic implications] Aouate P, et al. **Arch Mal Coeur Vaiss** 1995 Dec;88(12):1869–74 (27 ref.) (Eng. Abstr.) **(Fre)**

[Effects of amiodarone on thyroid function] Caron P. **Presse Med** 1995 Dec 2;24(37):1747–51 (25 ref.) (Eng. Abstr.) **(Fre)**

[Proarrhythmic effects of anti-arrhythmia agents] Scanu P, et al. **Rev Med Interne** 1995;16(8):602–7 (24 ref.) (Eng. Abstr.) **(Fre)**

["Arrhythmica" or: history, extent and practical consequences of pro-arrhythmia effects] Gertsch M. **Schweiz Med Wochenschr** 1996 Apr 6;126(14):566–75 (13 ref.) (Eng. Abstr.) **(Ger)**

[Adverse reactions to amiodarone] Edoute Y, et al. **Harefuah** 1995 Jul;129(1–2):57–61 (28 ref.) **(Heb)**

[Main cardiotoxic drugs] Pettirossi G, et al. **Clin Ter** 1996 Jan–Feb;147(1–2):67–77 (34 ref.) (Eng. Abstr.) **(Ita)**

ANALYSIS

A systematic review and critical comparison of internal standards for the routine liquid chromatographic assay of amiodarone and desethylamiodarone. Pollak PT. **Ther Drug Monit** 1996 Apr;18(2):168–78 (53 ref.)

BLOOD

[Procainamide] Nishihara K. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:954–6 (8 ref.) **(Jpn)**

[Lidocaine hydrochloride] Saito Y, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:983–5 (9 ref.) **(Jpn)**

[Beta-blocking agents] Suzuki M. **Nippon Rinsho** 1995 Feb; 53 Su Pt 1:978–82 (16 ref.) **(Jpn)**

[Disopyramide, mexiletine, aprindine] Suzuki M. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:989–93 (25 ref.) **(Jpn)**

[Quinidine] Yamada K. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:957–9 (8 ref.) **(Jpn)**

CLASSIFICATION

Clinical pharmacology and classification of antiarrhythmic drugs. MacFadyen RJ, et al. **Br J Hosp Med** 1995 Nov 15–Dec 12;54(10):515–9 (16 ref.)

PHARMACOKINETICS

Novel delivery of antiarrhythmic agents. Labhasetwar V, et al. **Clin Pharmacokinet** 1995 Jul;29(1):1–5 (24 ref.)

[Amiodarone absorption and elimination after oral and intravenous administration in healthy individuals] Gaete LE, et al. **Rev Med Chil** 1995 Jun;123(6):713–9 (18 ref.) (Eng. Abstr.) **(Spa)**

PHARMACOLOGY

Mechanisms and management of congenital and acquired long QT syndromes. Lazzara R. **Arch Mal Coeur Vaiss** 1996 Feb;89 Spec No 1:51–5 (34 ref.)

Is there a need for new antiarrhythmic drugs? Roden DM. **Arch Mal Coeur Vaiss** 1996 Feb;89 Spec No 1:13–8 (36 ref.)

Topical beta-adrenergic antagonists and quinidine. A risky interaction [editorial] Higginbotham EJ. **Arch Ophthalmol** 1996 Jun;114(6):745–6 (7 ref.)

Clinical pharmacology and classification of antiarrhythmic drugs. MacFadyen RJ, et al. **Br J Hosp Med** 1995 Nov 15–Dec 12;54(10):515–9 (16 ref.)

Interactions between antiarrhythmic drugs and implantable cardioverter-defibrillators. Dougherty AH. **Curr Opin Cardiol** 1996 Jan;11(1):2–8 (25 ref.)

Basic concepts in cellular cardiac electrophysiology: Part II: Block of ion channels by antiarrhythmic drugs. Whalley DW, et al. **Pacing Clin Electrophysiol** 1995 Sep;18(9 Pt 1):1686–704 (119 ref.)

[Flecainide acetate] Bordier P, et al. **Ann Cardiol Angeiol (Paris)** 1996 May;45(5):263–79 (135 ref.) (Eng. Abstr.) **(Fre)**

[Variability of antiarrhythmic drug action in prolonging action potential duration during various rates of heart action] Zakrzewski D, et al. **Pol Arch Med Wewn** 1996 Apr;95(4):383–7 (20 ref.) **(Pol)**

THERAPEUTIC USE

Evolution of the management of malignant ventricular tachyarrhythmias: the roles of drug therapy and implantable defibrillators [editorial] Kim SG. **Am Heart J** 1995 Nov;130(5):1144–50 (59 ref.)

Drug therapy versus implantation of a cardiac defibrillator for the treatment of malignant arrhythmias in left ventricular dysfunction [editorial] Mannino MM, et al. **Am Heart J** 1996 Jun;131(6):1251–9 (44 ref.)

Maintaining sinus rhythm with antifibrillatory drugs in atrial fibrillation. Antman EM. **Am J Cardiol** 1996 Aug 29; 78(4A):67–72 (23 ref.)

Interactions between pharmacologic and nonpharmacologic antiarrhythmic therapy. Greene HL. **Am J Cardiol** 1996 Aug 29;78(4A):61–6 (49 ref.)

Prospective trials of implantable cardioverter defibrillators versus drugs: are they addressing the right question? [editorial] Josephson M, et al. **Am J Cardiol** 1996 Apr 15; 77(10):859–63 (29 ref.)

Evolving role of sotalol in the management of ventricular tachyarrhythmias. O'Callaghan PA, et al. **Am J Cardiol** 1996 Aug 29;78(4A):54–60 (40 ref.)

Antiarrhythmic actions of amiodarone: a profile of a paradoxical agent. Singh BN. **Am J Cardiol** 1996 Aug 29; 78(4A):41–53 (64 ref.)

The cardiac ion channels: relevance to management of arrhythmias. Roden DM, et al. **Annu Rev Med** 1996; 47:135–48 (66 ref.)

ABC of atrial fibrillation. Drugs for atrial fibrillation [see comments] Lip GY, et al. **BMJ** 1995 Dec 16; 311(7020):1631–4 (4 ref.) Comment in: BMJ 1996 Apr 6;312(7035):911–2. Comment in: BMJ 1996 Apr 6;312(7035):912.

Assessment of arrhythmias after myocardial infarction in the post-CAST era. Camm AJ, et al. **Can J Cardiol** 1996 Apr; 12 Suppl B:9B–19B; discussion 27B–28B (106 ref.)

Heart rate control in patients with atrial fibrillation. Gardner MJ, et al. **Can J Cardiol** 1996 Jan;12 Suppl A:21A–23A (26 ref.)

An overview of antiarrhythmic drug management of electrical storm. Kowey PR. **Can J Cardiol** 1996 Apr;12 Suppl B:3B–8B; discussion 27B–28B (15 ref.)

Chronic drug therapy to prevent recurrence of atrial fibrillation. Newman D, et al. **Can J Cardiol** 1996 Jan;12 Suppl A:24A–28A (43 ref.)

Restoration of sinus rhythm in patients with atrial fibrillation. Talajic M, et al. **Can J Cardiol** 1996 Jan;12 Suppl A:29A–35A (83 ref.)

The antiarrhythmic treatment of atrial fibrillation. **Drug Ther Bull** 1996 Jun;34(6):41–5 (34 ref.)

Guidelines for the use of propafenone in treating supraventricular arrhythmias. Kishore AG, et al. **Drugs** 1995 Aug;50(2):250–62 (73 ref.)

Narrow complex tachycardias. Collier WW, et al. **Emerg Med Clin North Am** 1995 Nov;13(4):925–54 (99 ref.)

Should post-infarction asymptomatic ventricular arrhythmias be treated? Campbell RW. **Eur Heart J** 1995 Jul;16 Suppl E:46–8 (37 ref.)

Atrial fibrillation: steering a management course between thromboembolism and proarrhythmic risk. Campbell RW. **Eur Heart J** 1995 Aug;16 Suppl G:28–31 (56 ref.)

Digitalis—friend or foe? Erdmann E. **Eur Heart J** 1995 Jul; 16 Suppl F:16–9 (18 ref.)

Future prospects of antiarrhythmic treatment based on experimental studies. Janse MJ. **Eur Heart J** 1995 Aug;16 Suppl G:2–6 (44 ref.)

Should post-infarction asymptomatic ventricular arrhythmias be treated? The need for caution. Sleight P. **Eur Heart J** 1995 Jul;16 Suppl E:49 (29 ref.)

Management of cardiac arrest survivors: drugs or devices. Madan N, et al. **Indian Heart J** 1995 Jul–Aug;47(4):387–93 (38 ref.)

Drugs versus devices: contemporary practice in light of contemporary trials. Epstein AE. **J Cardiovasc Electrophysiol** 1995 Oct;6(10 Pt 2):937–41 (32 ref.)

Parenteral antiarrhythmics for life-threatening ventricular arrhythmias. Filart RA, et al. **J Cardiovasc Electrophysiol** 1995 Oct;6(10 Pt 2):901–13 (70 ref.)

Propafenone: an effective agent for the management of supraventricular arrhythmias. Grant AO. **J Cardiovasc Electrophysiol** 1996 Apr;7(4):353–64 (74 ref.)

Cardiac arrhythmias and antiarrhythmic drugs: recent advances in our understanding of mechanism. Rosen MR. **J Cardiovasc Electrophysiol** 1995 Oct;6(10 Pt 2):868–79 (40 ref.)

Parenteral antiarrhythmic drug therapy in ventricular tachycardia/ventricular fibrillation: evolving role of class III agents—focus on amiodarone. Scheinman MM. **J Cardiovasc Electrophysiol** 1995 Oct;6(10 Pt 2):914–9 (34 ref.)

Expanding indications for the use of Class III agents in patients at high risk for sudden death. Singh BN. **J Cardiovasc Electrophysiol** 1995 Oct;6(10 Pt 2):887–900 (47 ref.)

Antiarrhythmic and anti-ischemic properties of calcium-channel antagonists. Apostolakos MJ, et al. **New Horiz** 1996 Feb;4(1):45–57 (94 ref.)

Cardioversion of atrial fibrillation. Lip GY. **Postgrad Med J** 1995 Aug;71(838):457–65 (68 ref.)

Implantable defibrillators are preferable to pharmacologic therapy for patients with ventricular tachyarrhythmias: an antagonist's viewpoint. Anderson J. **Prog Cardiovasc Dis** 1996 Mar–Apr;38(5):393–400 (32 ref.)

Implanted cardioverter-defibrillators are preferable to drugs as primary therapy in sustained ventricular tachyarrhythmias. Saksena S, et al. **Prog Cardiovasc Dis** 1996 May–Jun;38(6):445–54 (51 ref.)

Medical treatment of cardiac arrhythmias in Chagas' heart disease. de Paola AA, et al. **Rev Paul Med** 1995 Mar–Apr; 113(2):858–61 (29 ref.)

Atrial fibrillation pearls and perils of management. Kudenchuk PJ. **West J Med** 1996 May;164(5):425–34 (109 ref.)

[The treatment of chronic atrial fibrillation] Gosselink AT. **Tijdschr Gerontol Geriatr** 1995 Dec;26(6):259–63 (20 ref.) (Eng. Abstr.) **(Dut)**

[The treatment of atrial fibrillation] Halinen MO. **Duodecim** 1995;111(8):705–13 (29 ref.) **(Fin)**

[Adenosine in the treatment of supraventricular arrhythmias] Lommi J, et al. **Duodecim** 1994;110(5):473–7 (27 ref.) **(Fin)**

[Anti-arrhythmic therapy and cardiac failure] Cosnay P, et al. **Arch Mal Coeur Vaiss** 1995 Dec;88 Spec No 5:35–41 (44 ref.) (Eng. Abstr.) **(Fre)**

[Long term drug therapy for the prevention of recurrence in atrial fibrillation] Newman D, et al. **Can J Cardiol** 1996 Feb;12 Suppl A:21A–26A (43 ref.) **(Fre)**

[Restoration of the sinus rhythm in atrial fibrillation] Talajic M, et al. **Can J Cardiol** 1996 Feb;12 Suppl A:27A–34A (83 ref.) **(Fre)**

[Pharma-clinics. How I treat... supraventricular tachycardia in children] Massin M. **Rev Med Liege** 1996 Mar; 51(3):210–3 (32 ref.) **(Fre)**

[Pharma-clinics. How I treat.... Ventricular tachycardia in children] Massin M. **Rev Med Liege** 1996 Feb;51(2):147–9 (28 ref.) **(Fre)**

[Use of current anti-arrhythmia agents in pediatric cardiology] Massin M. **Rev Med Liege** 1995 Dec; 50(12):505–9 (40 ref.) **(Fre)**

[Ventricular arrhythmias: diagnosis and drug therapy] Schüpfer C, et al. **Schweiz Rundsch Med Prax** 1996 May 14;85(20):647–54 (40 ref.) (Eng. Abstr.) **(Ger)**

[Effects of adenosine on the heart—therapeutic and diagnostic possibilities] Stark U, et al. **Wien Klin Wochenschr** 1996;108(12):343–51 (61 ref.) (Eng. Abstr.) **(Ger)**

[Calcium antagonists in treatment of ventricular tachycardia] Melichercik J, et al. **Z Kardiol** 1996 May;85(5):319–25 (31

ref.) (Eng. Abstr.) **(Ger)**
[How do you want to die? The therapeutic options in ventricular tachyarrhythmia at the end of the anti-arrhythmia drug era] Seipel L. **Z Kardiol** 1995 Oct; 84(10):787–90 (38 ref.) **(Ger)**
[Clinical use of intravenous amiodarone for supraventricular arrhythmias] Assadi S, et al. **Harefuah** 1995 Dec 15; 129(12):583–6 (24 ref.) **(Heb)**
[Management of patients with sustained ventricular arrhythmia: anti-arrhythmia agents or defibrillator?] Cappato R, et al. **Cardiologia** 1996 Feb;41(2):95–105 (75 ref.) **(Ita)**
[Magnesium sulfate in acute myocardial infarction] Balli E, et al. **G Ital Cardiol** 1995 Nov;25(11):1425–32 (33 ref.) (Eng. Abstr.) **(Ita)**
[Treatment of supraventricular tachyarrhythmias: drugs or ablation?] Chimienti M, et al. **G Ital Cardiol** 1996 Feb; 26(2):213–26 (80 ref.) **(Ita)**
[Emergency drug therapy of arrhythmia] Mitamura H. **Nippon Naika Gakkai Zasshi** 1995 Nov 10;84(11):1804–9 (5 ref.) **(Jpn)**
[Auricular fibrillation. Antiarrhythmic treatment revisited] Elvas L, et al. **Acta Med Port** 1995 Mar;8(3):173–9 (55 ref.) (Eng. Abstr.) **(Por)**
[Prophylactic use of lidocaine in the acute period of myocardial infarction] Fomichev VI, et al. **Klin Med (Mosk)** 1995;73(4):17–20 (26 ref.) **(Rus)**
[Tactics of treatment of patients with arrhythmia] Glezer MG, et al. **Klin Med (Mosk)** 1995;73(4):13–7 (0 ref.) **(Rus)**
[Treatment of cardiac arrhythmias during pregnancy] Rodriguez Blanco VM, et al. **Med Clin (Barc)** 1996 Jun 1;107(1):29–36 (125 ref.) **(Spa)**

ANTI-ASTHMATIC AGENTS

Regulation of airway wall remodeling: prospects for the development of novel antiasthma drugs. Stewart AG, et al. **Adv Pharmacol** 1995;33:209–53 (204 ref.)
Leukotriene receptor antagonists and biosynthesis inhibitors: potential breakthrough in asthma therapy. Chung KF. **Eur Respir J** 1995 Jul;8(7):1203–13 (117 ref.)
[Corticoid resistance in asthma] Perrin-Fayolle M, et al. **Rev Pneumol Clin** 1996;52(2):150–8 (43 ref.) (Eng. Abstr.) **(Fre)**

ADMINISTRATION & DOSAGE

Issues in the use of inhaled glucocorticoids. The Asthma Clinical Research Network. Kamada AK, et al. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 1):1739–48 (86 ref.)
Optimizing inhaled drug delivery in patients with asthma. Jackson C, et al. **Br J Gen Pract** 1995 Dec;45(401):683–7 (35 ref.)
Aerosol delivery systems for bronchial asthma. Ariyananda PL, et al. **Postgrad Med J** 1996 Mar;72(845):151–6 (60 ref.)
Inhaled sodium cromoglycate. Holgate ST. **Respir Med** 1996 Aug;90(7):387–90 (45 ref.)
Patient education and guided self-management plans. Neville R. **Respir Med** 1996 Aug;90(7):385–6 (15 ref.)
[Nebulization for basic treatment of asthma in adults] Demoly P, et al. **Presse Med** 1996 May 25;25(18):857–62 (39 ref.) (Eng. Abstr.) **(Fre)**
[Inhaled corticotherapy in asthma: when should it be started and how to stop?] Aubier M. **Rev Pneumol Clin** 1996; 52(2):145–9 (19 ref.) (Eng. Abstr.) **(Fre)**
[Chronopharmacology of reversible airway obstruction] Haen E. **Wien Med Wochenschr** 1995;145(17–18):439–45 (38 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Issues in the use of inhaled glucocorticoids. The Asthma Clinical Research Network. Kamada AK, et al. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 1):1739–48 (86 ref.)
Controversies involving inhaled beta-agonists and inhaled corticosteroids in the treatment of asthma. Fahy JV, et al. **Clin Chest Med** 1995 Dec;16(4):715–33 (145 ref.)
[Hypersensitivity syndrome caused by dapsone. Transient circulating clone T] Bocquet H, et al. **Ann Dermatol Venereol** 1995;122(8):514–6 (14 ref.) (Eng. Abstr.) **(Fre)**
[Primum non nocere: inhaled corticoids] Lacronique J. **Rev Pneumol Clin** 1996;52(2):137–43 (81 ref.) (Eng. Abstr.) **(Fre)**

PHARMACOKINETICS

Pharmacokinetic-pharmacodynamic modelling as applied to bronchial asthma. Koopmans RP, et al. **Clin Pharmacokinet** 1995 Oct;29(4):213–20 (47 ref.)

PHARMACOLOGY

PDE isoenzymes as targets for anti-asthma drugs. Schudt C, et al. **Eur Respir J** 1995 Jul;8(7):1179–83 (18 ref.)
Leukotriene antagonists and synthesis inhibitors: new directions in asthma therapy. Holgate ST, et al. **J Allergy Clin Immunol** 1996 Jul;98(1):1–13 (89 ref.)
Cysteinyl leukotrienes in asthma: old mediators up to new tricks. Hay DW, et al. **Trends Pharmacol Sci** 1995 Sep; 16(9):304–9 (54 ref.)

THERAPEUTIC USE

Modern treatment of asthma in children. Zeffren BS, et al. **Adv Pediatr** 1996;43:423–68 (214 ref.)
Guidelines for the emergency management of asthma in adults. CAEP/CTS Asthma Advisory Committee. Canadian Association of Emergency Physicians and the Canadian Thoracic Society. Beveridge RC, et al. **Can Med Assoc J** 1996 Jul 1;155(1):25–37 (167 ref.)
Asthma: current controversies and emerging therapies. Kavuru MS, et al. **Cleve Clin J Med** 1995 Sep–Oct; 62(5):293–304 (122 ref.)
Asthma mechanisms, determinants of severity and treatment: the role of nedocromil sodium. Report of a workshop held in Whistler, British Columbia, Canada, 18–19 May 1995. Barnes PJ, et al. **Clin Exp Allergy** 1995 Aug;25(8):771–87 (146 ref.)
Anti-inflammatory effects of long-acting beta-agonists in asthma [editorial] Bradding P. **Clin Exp Allergy** 1995 Oct; 25(10):912–4 (36 ref.)
Oral sodium cromoglycate: its use in the management of food allergy. Edwards AM. **Clin Exp Allergy** 1995 Jul;25 Suppl 1:31–3 (30 ref.)
Effectiveness and safety of beclomethasone dipropionate, an intranasal corticosteroid, in the treatment of patients with allergic rhinitis. Edwards TB. **Clin Ther** 1995 Nov–Dec; 17(6):1032–41 (31 ref.)
Anti-inflammatory treatment of asthma in children. What strategy is appropriate? Frazier CA. **N C Med J** 1995 Dec; 56(12):616–8 (15 ref.)
Asthma. Specific preventive strategies. Morris RJ. **Postgrad Med** 1996 Aug;100(2):105–6, 109–12, 118 passim (21 ref.)
Asthma. Calverley PM. **Postgrad Med J** 1996 Jan; 72(843):12–8 (34 ref.)
The efficacy and therapeutic position of nedocromil sodium. Holgate ST. **Respir Med** 1996 Aug;90(7):391–4 (32 ref.)
[Beta-2 adrenergic receptor agonists in asthma treatment] Haahtela T, et al. **Duodecim** 1995;111(8):744–8 (28 ref.) **(Fin)**
[Limitations of current treatment of asthma: possibilities for new treatment forms] Wilkens H, et al. **Med Klin** 1996 May 15;91(5):302–7 (55 ref.) **(Ger)**

ANTI-AUSTRALIA ANTIGENS see **HEPATITIS B ANTIBODIES**

ANTIBIOSIS

Anticarcinogenic, hypocholesterolemic, and antagonistic activities of Lactobacillus acidophilus. Mital BK, et al. **Crit Rev Microbiol** 1995;21(3):175–214 (371 ref.)
Biotherapeutic agents. A neglected modality for the treatment and prevention of selected intestinal and vaginal infections [see comments] Elmer GW, et al. **JAMA** 1996 Mar 20;275(11):870–6 (81 ref.) Comment in: JAMA 1996 Jul 3;276(1):29–30.

ANTIBIOTIC-ASSOCIATED COLITIS see **ENTEROCOLITIS, PSEUDOMEMBRANOUS**

ANTIBIOTIC PROPHYLAXIS

Surgical infections: prevention and treatment--1965 to 1995. Nichols RL. **Am J Surg** 1996 Jul;172(1):68–74 (54 ref.)
Prevention of infective endocarditis: enthusiasm tempered by realism. Prasad A, et al. **Br J Hosp Med** 1995 Oct 4–17; 54(7):341–7 (40 ref.)
Antimicrobial prophylaxis in patients undergoing solid organ transplantation. Basgoz N, et al. **Curr Clin Top Infect Dis** 1995;15:344–64 (79 ref.)
Prophylaxis in bowel surgery. Nichols RL, et al. **Curr Clin Top Infect Dis** 1995;15:76–96 (89 ref.)
Antimicrobial prophylaxis of infection. Dickinson GM, et al. **Infect Dis Clin North Am** 1995 Sep;9(3):783–804 (83 ref.)
Preventing pelvic infection after abortion [editorial] Stevenson MM, et al. **Int J STD AIDS** 1995 Sep–Oct; 6(5):305–12 (61 ref.)
Antibiotic prophylaxis and infection control measures in minimally invasive surgery. Wilson AP. **J Antimicrob Chemother** 1995 Jul;36(1):1–5 (36 ref.)
The use of antibiotics for wound prophylaxis in spinal surgery. Rimoldi RL, et al. **Orthop Clin North Am** 1996 Jan;27(1):47–52 (33 ref.)
Epidemiology and prevention of meningococcal disease. Riedo FX, et al. **Pediatr Infect Dis J** 1995 Aug;14(8):643–57 (163 ref.)
Antibiotic prophylaxis for lower gastrointestinal endoscopy. Varma JR. **Prim Care** 1995 Sep;22(3):445–50 (6 ref.)
[Prophylactic and therapeutic use of antibiotics in trauma surgery (see comments) Hansis M, et al. **Unfallchirurg** 1996 May;99(5):316–22 (35 ref.) (Eng. Abstr.) Comment in: Unfallchirurg 1996 May;99(5):315. **(Ger)**
[Use of mini-septopal in trauma surgery of the hand. Experimental and clinical studies] Zimmer K. **Polim Med** 1996;26(1–2):3–57 (136 ref.) (Eng. Abstr.) **(Pol)**

METHODS

[Antibiotic prophylaxis and endoscopic retrograde cholangiopancreatography] Le Dreau G, et al. **Gastroenterol Clin Biol** 1996 Feb;20(1):55–63 (100 ref.) **(Fre)**

STANDARDS

Improving the quality of antimicrobial drug use can result in cost containment. Gyssens IC, et al. **Pharm World Sci** 1995 Sep 22;17(5):163–7 (19 ref.)

ANTIBIOTIC RESISTANCE see **DRUG RESISTANCE, MICROBIAL**

ANTIBIOTICS

The role of antibiotics in the evolution of microorganisms. Cavallo G. **G Batteriol Virol Immunol** 1992 Jan–1993 Dec; 85(1–12):3–11 (9 ref.)

ADMINISTRATION & DOSAGE

Inhalation of antibiotics in cystic fibrosis. Touw DJ, et al. **Eur Respir J** 1995 Sep;8(9):1594–604 (65 ref.)
The outpatient management of febrile neutropenia in cancer patients. Freifeld AG, et al. **Oncology (Huntingt)** 1996 Apr; 10(4):599–606, 611–2; discussion 615–6 (31 ref.)
Community-acquired pneumonia. Cost-effective antimicrobial therapy [see comments] Cunha BA. **Postgrad Med** 1996 Jan;99(1):109–10, 113–4, 117–9, passim (13 ref.) Comment in: Postgrad Med 1996 Apr;99(4):62–4.
[Antibiotic bonding on arterial prostheses: a necessity] Goeau-Brissonniere O. **J Mal Vasc** 1996;21 Suppl A:146–51 (42 ref.) (Eng. Abstr.) **(Fre)**
[Antibiotics in aerosols] Héritier F. **Rev Med Suisse Romande** 1996 May;116(5):341–4 (30 ref.) **(Fre)**
[Treatment of periprosthetic infection of the hip using one-stage exchange surgery] Steinbrink K, et al. **Orthopade** 1995 Aug;24(4):335–43 (30 ref.) (Eng. Abstr.) **(Ger)**
[Proper use of antibiotics--what is that?] Jensenius M, et al. **Tidsskr Nor Laegeforen** 1995 Nov 20;115(28):3504–7 (23 ref.) (Eng. Abstr.) **(Nor)**
[Increased resistance after administration of antibiotics to animals] Franklin A. **Lakartidningen** 1996 Apr 24; 93(17):1627–30 (21 ref.) **(Swe)**
[Can lymphoma be cured by antibiotics?] Gunvén P, et al. **Lakartidningen** 1996 Feb 28;93(9):767–8 (7 ref.) **(Swe)**
[Reconsider management of Helicobacter pylori infections. Time to go over to the triple therapy] Jaup BH. **Lakartidningen** 1996 Feb 28;93(9):800–1 (12 ref.) **(Swe)**

ADVERSE EFFECTS

Renal and electrolyte complications associated with antibiotic therapy. Kasama R, et al. **Am Fam Physician** 1996 Jan; 53(1):227–32 (23 ref.)
Ototoxicity of ear drops: a clinical perspective. Linder TE, et al. **Am J Otol** 1995 Sep;16(5):653–7 (23 ref.)
Rifabutin-associated uveitis. Tseng AL, et al. **Ann Pharmacother** 1995 Nov;29(11):1149–55 (45 ref.)
Mycobacterium avium complex infection, rifabutin, and uveitis--is there a connection? Nichols CW. **Clin Infect Dis** 1996 Apr;22 Suppl 1:S43–7; discussion S47–9 (21 ref.)
Adverse reactions to antibiotics: is the patient really allergic? Boguniewicz M. **Drug Saf** 1995 Nov;13(5):273–80 (51 ref.)
Antibiotic-induced diarrhoea. **Drug Ther Bull** 1995 Mar; 33(3):23–4 (22 ref.)
The Garrod Lecture. Selective toxicity and concordant pharmacodynamics of antibiotics and other drugs. Williams JD. **J Antimicrob Chemother** 1995 Jun;35(6):721–37 (63 ref.)
Peracute disseminated fatal Aspergillus fumigatus sepsis as a complication of corticoid-treated systemic lupus erythematosus. Nenoff P, et al. **Mycoses** 1995 Nov–Dec; 38(11–12):467–71 (21 ref.)
[Side effects and consequences of frequently used antibiotics in clinical practice] Cerny A. **Schweiz Med Wochenschr** 1996 Mar 30;126(13):528–34 (38 ref.) (Eng. Abstr.) **(Ger)**
[Acute pancreatitis associated with hepatotoxicity induced by amoxicillin-clavulanic acid] Galindo C, et al. **Rev Esp Enferm Dig** 1995 Aug;87(8):597–600 (23 ref.) (Eng. Abstr.) **(Spa)**
[Clostridium difficile-associated diarrhea--an increasing problem. Reduce the administration of antibiotics and improve hygiene!] Svenungsson B. **Lakartidningen** 1996 Aug 28;93(35):2931–4 (67 ref.) **(Swe)**

BIOSYNTHESIS

Polyketide synthase gene manipulation: a structure-function approach in engineering novel antibiotics. Hutchinson CR, et al. **Annu Rev Microbiol** 1995;49:201–38 (144 ref.)
Isoprenoid antibiotics. Cane DE. **Biotechnology** 1995; 28:633–55 (99 ref.)
Rifamycin SV and related ansamycins. Chiao JS, et al. **Biotechnology** 1995;28:477–98 (110 ref.)
Agrocins. Clare BG. **Biotechnology** 1995;28:619–32 (53 ref.)
Global physiological controls. Doull JL, et al. **Biotechnology** 1995;28:9–63 (257 ref.)
Genetics of antibiotic production in Streptomyces coelicolor A3(2), a model streptomycete. Hopwood DA, et al. **Biotechnology** 1995;28:65–102 (132 ref.)
Aminoglycosides and aminocyclitols (other than streptomycin). Hotta K, et al. **Biotechnology** 1995;28:571–95

(82 ref.)
Microcins. Moreno F, et al. **Biotechnology** 1995;28:307–21 (58 ref.)
Bialaphos. Thompson CJ, et al. **Biotechnology** 1995; 28:197–222 (68 ref.)
Genetic and environmental control of antibiotic production. Vining LC. **Biotechnology** 1995;28:1–7 (26 ref.)
Chloramphenicol. Vining LC, et al. **Biotechnology** 1995; 28:505–30 (80 ref.)
1995 Colworth Prize Lecture. The regulation of antibiotic production in Streptomyces coelicolor A3(2). Bibb M. **Microbiology** 1996 Jun;142 (Pt 6):1335–44 (117 ref.)

CHEMICAL SYNTHESIS

Synthesis and chemistry of the ionophore antibiotic tetronasin. Ley SV, et al. **Farmaco** 1996 Mar;51(3):147–57 (27 ref.)
[Synthesis of lactone ring-containing bioactive natural products. Cardiotonic steroids, naphthoquinone antibiotics, and tetronic acid ionophore antibiotics] Yoshii E. **Yakugaku Zasshi** 1996 Jan;116(1):1–20 (45 ref.) (Eng. Abstr.) **(Jpn)**

CHEMISTRY

Isoprenoid antibiotics. Cane DE. **Biotechnology** 1995; 28:633–55 (99 ref.)
Agrocins. Clare BG. **Biotechnology** 1995;28:619–32 (53 ref.)
Microcins. Moreno F, et al. **Biotechnology** 1995;28:307–21 (58 ref.)

ECONOMICS

Community-acquired pneumonia. Cost-effective antimicrobial therapy [see comments] Cunha BA. **Postgrad Med** 1996 Jan;99(1):109–10, 113–4, 117–9, passim (13 ref.) Comment in: Postgrad Med 1996 Apr;99(4):62–4.

ISOLATION & PURIFICATION

Developments and newer approaches in downstream processing of biopharmaceuticals. Chatterjee NR, et al. **Hindustan Antibiot Bull** 1994 Aug-Nov;36(3–4):78–97 (66 ref.)

PHARMACOKINETICS

The clinical pharmacokinetics of rifabutin. Blaschke TF, et al. **Clin Infect Dis** 1996 Apr;22 Suppl 1:S15–21; discussion S21–2 (28 ref.)
Application of saliva for drug monitoring. An in vivo model for transmembrane transport. Haeckel R, et al. **Eur J Clin Chem Clin Biochem** 1996 Mar;34(3):171–91 (179 ref.)
[Tissue pharmacokinetics of antibiotics. Theoretical bases and new pharmacological approaches] Bergogne-Bérézin E. **Presse Med** 1996 Mar 2–9;25(8):399–406 (55 ref.) (Eng. Abstr.) **(Fre)**
[Pharmacokinetics of antibiotics in burn patients] Lesne-Hulin A, et al. **Therapie** 1995 Nov-Dec;50(6):575–86 (74 ref.) (Eng. Abstr.) **(Fre)**

PHARMACOLOGY

Newer antibiotics: a dermatologist's guide. Webster GF. **Adv Dermatol** 1996;11:105–15; discussion 116 (60 ref.)
Emerging antibiotic resistance: real and relative [editorial] Jones DB. **Arch Ophthalmol** 1996 Jan;114(1):91–2 (12 ref.)
Molecular mechanisms of drug inhibition of DNA gyrase. Lewis RJ, et al. **Bioessays** 1996 Aug;18(8):661–71 (73 ref.)
Rifabutin in the treatment of Mycobacterium avium complex infection: experience in Europe. Dautzenberg B. **Clin Infect Dis** 1996 Apr;22 Suppl 1:S33–6 (22 ref.)
Antimicrobial activity of rifabutin. Kunin CM. **Clin Infect Dis** 1996 Apr;22 Suppl 1:S3–13; discussion S13–4 (124 ref.)
Rifabutin prophylaxis for Mycobacterium avium complex infection in patients with AIDS. Siegal FP. **Clin Infect Dis** 1996 Apr;22 Suppl 1:S23–30; discussion S30–2 (38 ref.)
Speculations on the influence of infecting phenotype on virulence and antibiotic susceptibility of Legionella pneumophila. Barker J, et al. **J Antimicrob Chemother** 1995 Jul;36(1):7–21 (131 ref.)
The Garrod Lecture. Selective toxicity and concordant pharmacodynamics of antibiotics and other drugs. Williams JD. **J Antimicrob Chemother** 1995 Jun;35(6):721–37 (63 ref.)
Update on mupirocin resistance. Poupard JA. **J Chemother** 1995 Jul;7 Suppl 3:71–4 (14 ref.)
Pharmacologic treatment of neonatal sepsis: antimicrobial agents and immunotherapy. Cavaliere TA. **J Obstet Gynecol Neonatal Nurs** 1995 Sep;24(7):647–58 (77 ref.)
[Overcoming tumor multiple drug resistance. MDR modulators] Dudnik IuV, et al. **Antibiot Khimioter** 1995 Oct;40(10):48–54 (81 ref.) **(Rus)**
[Antimicrobial peptides and resistance in animals] Kharchenko EP. **Antibiot Khimioter** 1995 Jul;40(7):45–53 (33 ref.) **(Rus)**
[Modern methods and means for the rapid determination of the sensitivity of the causative agents of dangerous infectious diseases to antibiotics and chemical preparations] D'iakov SI, et al. **Voen Med Zh** 1996 Mar;317(3):44–7 (17 ref.) **(Rus)**

THERAPEUTIC USE

No Helicobacter pylori, no Helicobacter pylori-associated peptic ulcer disease. Tytgat GN. **Aliment Pharmacol Ther** 1995;9 Suppl 1:39–42 (15 ref.)
Resistant respiratory pathogens and extended-spectrum antibiotics. Pichichero ME. **Am Fam Physician** 1995 Nov 1;52(6):1739–46 (30 ref.)
Pylephlebitis: a case report and review of outcome in the antibiotic era. Saxena R, et al. **Am J Gastroenterol** 1996 Jun;91(6):1251–3 (17 ref.)
Impact of changing pathogens and antimicrobial susceptibility patterns in the treatment of serious infections in hospitalized patients. Jones RN. **Am J Med** 1996 Jun 24;100(6A):3S–12S (53 ref.)
Sequential therapy in the hospital management of lower respiratory infections. Vogel F. **Am J Med** 1995 Dec 29; 99(6B):14S–19S (27 ref.)
Reasons for the emergence of antibiotic resistance. Tenover FC, et al. **Am J Med Sci** 1996 Jan;311(1):9–16 (82 ref.)
Antimicrobial-resistant pathogens in the 1990s. Jacoby GA. **Annu Rev Med** 1996;47:169–79 (62 ref.)
Management of meningitis caused by penicillin-resistant Streptococcus pneumoniae. Paris MM, et al. **Antimicrob Agents Chemother** 1995 Oct;39(10):2171–5 (64 ref.)
The endophthalmitis vitrectomy study [editorial; comment] [see comments] Forster RK. **Arch Ophthalmol** 1995 Dec; 113(12):1555–7 (6 ref.) Comment on: Arch Ophthalmol 1995 Dec;113(12):1479–96. Comment in: Arch Ophthalmol 1996 Aug;114(8):1025; discussion 1026–7. Comment in: Arch Ophthalmol 1996 Aug;114(8):1029–30; discussion 1028–9.
Treatment of urinary tract infections. Korman TM, et al. **Aust Fam Physician** 1995 Dec;24(12):2205–11 (5 ref.)
Prevention of preterm birth. Owen P, et al. **Baillieres Clin Obstet Gynaecol** 1995 Sep;9(3):465–79 (96 ref.)
Antimicrobial therapy for rheumatoid arthritis. Kloppenburg M, et al. **Baillieres Clin Rheumatol** 1995 Nov;9(4):759–69 (89 ref.)
Current aspects in the management of pneumonia. Woodhead M. **Br J Clin Pract** 1995 Jul-Aug;49(4):205–10 (83 ref.)
Empiric therapy for bacterial infections in neutropenic patients. Klastersky J. **Cancer Treat Res** 1995;79:101–12 (34 ref.)
Rifabutin therapy for disseminated Mycobacterium avium complex infection. Sullam PM. **Clin Infect Dis** 1996 Apr; 22 Suppl 1:S37–41; discussion S41–2 (41 ref.)
Adjunctive care of preterm labor—the use of antibiotics. Lewis R, et al. **Clin Obstet Gynecol** 1995 Dec;38(4):755–70 (69 ref.)
Management of otitis media. A review. Liston TE. **Clin Pediatr (Phila)** 1995 Oct;34(10):542–8 (53 ref.)
Antibiotic therapy in diabetic foot infection. van der Meer JW, et al. **Diabet Med** 1996;13 Suppl 1:S48–51 (19 ref.)
Diagnosis and treatment of streptococcal sore throat. **Drug Ther Bull** 1995 Feb;33(2):9–12 (28 ref.)
The thrombocytopenic purpuras. Recognition and management. Gillis S. **Drugs** 1996 Jun;51(6):942–53 (104 ref.)
An approach to the design and implementation of clinical trials of empirical antibiotic therapy in febrile and neutropenic cancer patients. Viscoli C, et al. **Eur J Cancer** 1995 Nov;31A(12):2013–22 (60 ref.)
Antibiotic selection factors and description of a hospital-based outpatient antibiotic therapy program in the USA. Craig WA. **Eur J Clin Microbiol Infect Dis** 1995 Jul;14(7):636–42 (27 ref.)
Experience with a physician-directed, clinic-based program for outpatient parenteral antibiotic therapy in the USA. Tice AD. **Eur J Clin Microbiol Infect Dis** 1995 Jul; 14(7):655–61 (8 ref.)
Infection, the gut and the development of the multiple organ dysfunction syndrome. Nieuwenhuijzen GA, et al. **Eur J Surg** 1996 Apr;162(4):259–73 (185 ref.)
Evolving therapies for peptic ulcer disease: Helicobacter pylori treatment. Cohen JC. **Gastroenterologist** 1995 Dec; 3(4):289–300 (129 ref.)
Antibiotic concerns in the elderly. A clinician's perspective. Gleckman RA. **Infect Dis Clin North Am** 1995 Sep; 9(3):575–90 (60 ref.)
Antibacterial agents in pediatrics. LiPuma JJ, et al. **Infect Dis Clin North Am** 1995 Sep;9(3):561–74 (55 ref.)
Bacteria and antimicrobial agents in the treatment of acne. Parry EJ, et al. **Int J Dermatol** 1996 Apr;35(4):249–51 (15 ref.)
Partially treated meningitis in children—room for clinical judgement [editorial; comment] Ashkenazi S, et al. **Isr J Med Sci** 1995 Oct;31(10):638–9 (20 ref.) Comment on: Isr J Med Sci 1995 Oct;31(10):611–5.
Anti-infective strategies in neutropenia. Boogaerts MA. **J Antimicrob Chemother** 1995 Jul;36 Suppl A:167–78 (54 ref.)
Antibiotics and the expression of staphylococcal virulence. Gemmell CG. **J Antimicrob Chemother** 1995 Aug; 36(2):283–91 (54 ref.)
Neutropenic infections: strategies for empirical therapy. Kibbler CC. **J Antimicrob Chemother** 1995 Oct;36 Suppl B:107–17 (65 ref.)
Empiric antibiotic therapy for acute infective diarrhoea in the developed world. Moss PJ, et al. **J Antimicrob Chemother** 1995 Jun;35(6):903–13 (74 ref.)
Antibiotic therapy and the anesthesiologist. Cheng EY, et al. **J Clin Anesth** 1995 Aug;7(5):425–39 (97 ref.)
Adjunctive dexamethasone therapy for pediatric bacterial meningitis. Bonadio WA. **J Emerg Med** 1996 Mar-Apr; 14(2):165–72 (40 ref.)
Infections in liver transplantation: risk factors and strategies for prevention. Kibbler CC. **J Hosp Infect** 1995 Jun;30 Suppl:209–17 (40 ref.)
Pharmacologic treatment of neonatal sepsis: antimicrobial agents and immunotherapy. Cavaliere TA. **J Obstet Gynecol Neonatal Nurs** 1995 Sep;24(7):647–58 (77 ref.)
Consensus conference. Medical treatment of peptic ulcer disease. Practice guidelines. Practice Parameters Committee of the American College of Gastroenterology [published erratum appears in JAMA 1996 May 1;275(17):1314] Soll AH. **JAMA** 1996 Feb 28;275(8):622–9 (99 ref.)
Antimicrobial therapy in expectant management of preterm premature rupture of the membranes [see comments] [published erratum appears in Lancet 1996 Feb 10;347(8998):410] Mercer BM, et al. **Lancet** 1995 Nov 11; 346(8985):1271–9 (46 ref.) Comment in: Lancet 1996 Jan 20;347(8995):203. Comment in: Lancet 1996 Jan 20;347(8995):203–4. Comment in: Lancet 1996 Jan 20;347(8995):204. Comment in: Lancet 1996 Mar 23;347(9004):837–8.
Managing HIV. Part 5: Treating secondary outcomes. 5.16 HIV and bacterial infections. Allworth AM, et al. **Med J Aust** 1996 May 6;164(9):546–8 (5 ref.)
Pediatric bone and joint infections. Diagnosis and antimicrobial management. Sonnen GM, et al. **Pediatr Clin North Am** 1996 Aug;43(4):933–47 (30 ref.)
Rational selection of antimicrobials for pediatric upper respiratory infections. Harrison CJ. **Pediatr Infect Dis J** 1995 Jul;14(7 Suppl):S121–9 (28 ref.)
Practical strategies for the appropriate use of antimicrobials. Guglielmo BJ. **Pharm World Sci** 1995 Jul 28;17(4):96–102 (29 ref.)
Improving the quality of antimicrobial drug use can result in cost containment. Gyssens IC, et al. **Pharm World Sci** 1995 Sep 22;17(5):163–7 (19 ref.)
The best of times, the worst of times. The global challenge of antimicrobial resistance. Tenover FC. **Pharm World Sci** 1995 Sep 22;17(5):149–51 (40 ref.)
Common bacterial pyodermas. Taking aim against the most likely pathogens. Carroll JA. **Postgrad Med** 1996 Sep; 100(3):311–3, 317–22 (22 ref.)
Recurrent streptococcal pharyngitis. Using practical treatment options to interrupt the cycle. Ruoff GE. **Postgrad Med** 1996 Feb;99(2):211–4, 219–22 (19 ref.)
Overview of the newer antibiotics. Lea AS. **Proc Annu Meet Med Sect Am Counc Life Insur** 1995; :109–17 (0 ref.)
Antibiotic therapy for rheumatoid arthritis. Scientific and anecdotal appraisals. Trentham DE, et al. **Rheum Dis Clin North Am** 1995 Aug;21(3):817–34 (58 ref.)
Helicobacter pylori eradication: unravelling the facts. Dixon JS. **Scand J Gastroenterol Suppl** 1995;212:48–62 (244 ref.)
Helicobacter pylori eradication: a critical appraisal and current concerns. Hunt RH. **Scand J Gastroenterol Suppl** 1995;210:73–6 (18 ref.)
Helicobacter pylori and peptic ulcer. Korman MG, et al. **Scand J Gastroenterol Suppl** 1995;210:92–6 (61 ref.)
Sucralfate in Helicobacter pylori eradication strategies. Lam SK, et al. **Scand J Gastroenterol Suppl** 1995;210:89–91 (19 ref.)
Peptic ulcer and Helicobacter pylori: eradication and relapse. Tytgat GN. **Scand J Gastroenterol Suppl** 1995;210:70–2 (13 ref.)
General management considerations for the trauma patient. Payne JT. **Vet Clin North Am Small Anim Pract** 1995 Sep; 25(5):1015–29 (6 ref.)
[Rational use of antibiotics in the neutropenic patient with fever] de Pauw BE, et al. **Ned Tijdschr Geneeskd** 1995 Aug 26;139(34):1725–9 (26 ref.) **(Dut)**
[Are antibiotics necessary for a child with the flu? (editorial)] Mäkelä M, et al. **Duodecim** 1995;111(7):583–4 (12 ref.) **(Fin)**
[Antibiotics in gynecology. Treatment of acute infections] Judlin P. **Contracept Fertil Sex** 1996 May;24(5):353–8 (0 ref.) **(Fre)**
[Therapeutic management of duodenal ulcer except in emergency: eradication of Helicobacter pylori] Lamouliatte H. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S58–S63 (63 ref.) **(Fre)**
[Therapeutic applications of tissue pharmacokinetics of antibiotics] Bergogne-Bérézin E. **Presse Med** 1996 Mar 2–9; 25(8):408–10, 412–4, 416–8 (41 ref.) (Eng. Abstr.) **(Fre)**
[Treatment of non-tuberculous mycobacterial infections] Dautzenberg B. **Rev Mal Respir** 1996;13(1):81–3 (17 ref.) **(Fre)**
[Antibiotic resistance in pneumococci] Moreillon P, et al. **Schweiz Med Wochenschr** 1996 Feb 17;126(7):255–63 (30 ref.) (Eng. Abstr.) **(Fre)**
[Antibiotic therapy for pneumonias acquired outside the hospital] Achermann E, et al. **Dtsch Med Wochenschr** 1996 Aug 23;121(34–35):1057–9 (14 ref.) **(Ger)**
[Emergency drug therapy of meningoencephalitis] Kuzuhara S. **Nippon Naika Gakkai Zasshi** 1995 Nov 10;84(11):1837–42 (5 ref.) **(Jpn)**
[Current approaches to the treatment and prevention of

subacute infectious endocarditis] Belokrinitskaia OA, et al. **Klin Med (Mosk)** 1995;73(5):23–8 (50 ref.) **(Rus)**

[Critical approach to antibiotic therapy in Lyme disease] Bojić I. **Vojnosanit Pregl** 1994 May–Jun;51(3):233–6 (30 ref.) **(Scr)**

[Current clinical problems in evaluating microbiological and pharmacological data] Aguado JM. **Enferm Infecc Microbiol Clin** 1995 Oct;13(8):477–81 (11 ref.) **(Spa)**

[Pneumococcus resistance. Reconsiderations on its empirical treatment] Pallarés M. **Rev Med Univ Navarra** 1995 Apr–Jun;40(2):90–2 (13 ref.) **(Spa)**

TOXICITY

Hepatotoxicity of antibiotics. Hautekeete ML. **Acta Gastroenterol Belg** 1995 May–Aug;58(3–4):290–6 (64 ref.)

Experimental evidence of ototoxicity of ear drops. A review of the literature. Kuhweide R. **Acta Otorhinolaryngol Belg** 1995;49(3):293–8 (28 ref.)

ANTIBIOTICS, AMINOGLYCOSIDE

ADMINISTRATION & DOSAGE

The evolution of aminoglycoside therapy: a single daily dose [see comments] Deamer RL, et al. **Am Fam Physician** 1996 Apr;53(5):1782–6 (24 ref.) Comment in: Am Fam Physician 1996 Apr;53(5):1512–4.

Once-daily versus multiple-daily dosing of aminoglycosides. Craig WA. **J Chemother** 1995 Jun;7 Suppl 2:47–52 (22 ref.)

Once-daily dosing regimen for aminoglycoside plus betalactam combination therapy of serious lower respiratory tract infections. Paradisi F, et al. **J Chemother** 1995 Aug;7(4):338–43 (54 ref.)

Preclinical and clinical evaluation of once-daily aminoglycoside chemotherapy. Periti P. **J Chemother** 1995 Aug;7(4):311–37 (184 ref.)

Hematogenous osteomyelitis of the calcaneus in children: surgical treatment and use of implanted antibiotic beads. Kelsey R, et al. **J Foot Ankle Surg** 1995 Nov–Dec; 34(6):547–55; discussion 594 (26 ref.)

Aminoglycoside dosing: one, two or three times a day? [see comments] McLean AJ, et al. **Med J Aust** 1996 Jan 1; 164(1):39–42 (54 ref.) Comment in: Med J Aust 1996 May 20;164(10):636–7.

Effects of streptozotocin-induced diabetes on postpneumonectomy lung growth and connective tissue levels. Ofulue AF, et al. **Pediatr Pulmonol** 1995 Jun; 19(6):365–70 (29 ref.)

[Dosing aminoglycosides once a day] Blaser J. **Schweiz Med Wochenschr Suppl** 1996;76:39S–48S (61 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Chronic finger dermatitis after trauma. Diagnosis: posttraumatic eczema with allergic contact dermatitis to neomycin, bacitracin, and topical corticosteroids. Sherertz EF. **Arch Dermatol** 1996 Apr;132(4):461, 464 (11 ref.)

Toxic effects and drug interactions of antimycobacterial therapy. Chan-Tompkins NH. **Clin Dermatol** 1995 May–Jun;13(3):223–33 (99 ref.)

Gentamicin nephrotoxicity in humans and animals: some recent research. Ali BH. **Gen Pharmacol** 1995 Nov; 26(7):1477–87 (119 ref.)

[Aminoglycoside nephrotoxicity and obstructive jaundice (editorial)] Lucena MI, et al. **Med Clin (Barc)** 1995 Oct 14;105(12):457–60 (55 ref.) **(Spa)**

BIOSYNTHESIS

Aminoglycosides and aminocyclitols (other than streptomycin). Hotta K, et al. **Biotechnology** 1995;28:571–95 (82 ref.)

Streptomycin and related aminoglycosides. Piepersberg W. **Biotechnology** 1995;28:531–70 (179 ref.)

BLOOD

[Aminoglycosides] Kubo H. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:998–1001 (11 ref.) **(Jpn)**

CHEMISTRY

Streptomycin and related aminoglycosides. Piepersberg W. **Biotechnology** 1995;28:531–70 (179 ref.)

The enediyne antibiotics. Smith AL, et al. **J Med Chem** 1996 May 24;39(11):2103–17 (130 ref.)

ECONOMICS

Pharmacoeconomic evaluation of once-daily aminoglycoside treatment. Periti P. **J Chemother** 1995 Aug;7(4):380–94 (137 ref.)

PHARMACOKINETICS

Pharmacokinetics of isepamicin. Barr WH, et al. **J Chemother** 1995 Jun;7 Suppl 2:53–61 (46 ref.)

Preclinical and clinical evaluation of once-daily aminoglycoside chemotherapy. Periti P. **J Chemother** 1995 Aug;7(4):311–37 (184 ref.)

PHARMACOLOGY

Isepamicin (SCH 21420, 1-N-HAPA gentamicin B): microbiological characteristics including antimicrobial potency of spectrum of activity. Jones RN. **J Chemother** 1995 Jun;7 Suppl 2:7–16 (39 ref.)

Aminoglycosides and polyamines: targets and effects in the mammalian organism of two important groups of natural aliphatic polycations. Seiler N, et al. **Prog Drug Res** 1996; 46:183–241 (610 ref.)

THERAPEUTIC USE

Diagnosis and treatment of nosocomial pneumonia. Bonten MJ, et al. **Br J Hosp Med** 1995 Oct 4–17;54(7):335–40 (25 ref.)

The role of aminoglycosides in modern therapy. Beaucaire G. **J Chemother** 1995 Jun;7 Suppl 2:111–23 (58 ref.)

The place of tobramycin in lower respiratory tract infections (LRTI). Gialdroni Grassi G. **J Chemother** 1995 Aug; 7(4):344–54 (80 ref.)

Treatment of disseminated Mycobacterium avium complex disease: a clinician's perspective. Benson CA. **Res Microbiol** 1996 Jan–Feb;147(1–2):16–24 (43 ref.)

Treatment of infections caused by rapidly growing mycobacteria in the era of the newer macrolides. Wallace RJ Jr. **Res Microbiol** 1996 Jan–Feb;147(1–2):30–5 (34 ref.)

Use of aminoglycosides: the Swiss consensus. Swiss Society of Infectious Diseases. **Schweiz Med Wochenschr Suppl** 1996;76:5S–52S (0 ref.)

The use of aminoglycosides in neutropenic patients. Cometta A, et al. **Schweiz Med Wochenschr Suppl** 1996;76:21S–27S (10 ref.)

[Treatment of severe infections: should one always administer an aminoglycoside?] Cometta A, et al. **Schweiz Med Wochenschr Suppl** 1996;76:28S–33S (30 ref.) (Eng. Abstr.) **(Fre)**

[Aminoglycosides in the treatment of infectious endocarditis] Malinverni R. **Schweiz Med Wochenschr Suppl** 1996; 76:14S–20S (41 ref.) (Eng. Abstr.) **(Ger)**

[The role of aminoglycosides in HIV-infected patients] Opravil M. **Schweiz Med Wochenschr Suppl** 1996; 76:49S–53S (27 ref.) (Eng. Abstr.) **(Ger)**

[Aminoglycosides in pediatrics] Schaad UB. **Schweiz Med Wochenschr Suppl** 1996;76:34S–38S (23 ref.) (Eng. Abstr.) **(Ger)**

ANTIBIOTICS, ANTHRACYCLINE

ADMINISTRATION & DOSAGE

Pharmacokinetics, targeting and delivery systems in anthracycline-resistant cancers. Cassidy J. **Eur J Cancer** 1995;31A Suppl 7:S18–20 (23 ref.)

Liposomal doxorubicin (Doxil). Porche DJ. **J Assoc Nurses AIDS Care** 1996 Mar–Apr;7(2):55–9 (6 ref.)

Treatment of metastatic breast cancer with paclitaxel and doxorubicin. Dombernowsky P, et al. **Semin Oncol** 1995 Dec;22(6 Suppl 15):13–7 (14 ref.)

ADVERSE EFFECTS

Prevention of anthracycline cardiotoxicity by iron chelation. Hershko C, et al. **Acta Haematol** 1996;95(1):87–92 (68 ref.)

[Pediatric aspects of anthracycline cardiotoxicity and practical implications for prevention] Pein F, et al. **Arch Pediatr** 1995 Oct;2(10):988–99 (75 ref.) (Eng. Abstr.) **(Fre)**

BIOSYNTHESIS

Anthracyclines. Hutchinson CR. **Biotechnology** 1995; 28:331–57 (118 ref.)

HISTORY

Antitumor antibiotics discovered and studied at the Institute of Microbial Chemistry. Takeuchi T. **J Cancer Res Clin Oncol** 1995;121(9–10):505–10 (52 ref.)

METABOLISM

[New anti-HIV drug which binds the oligosaccharides of HIV envelope glycoprotein] Mizuochi T, et al. **Nippon Rinsho** 1995 Sep;53(9):2340–9 (20 ref.) (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

Multidrug resistance proteins and other drug transport-related resistance to natural product agents. Broxterman HJ, et al. **Curr Opin Oncol** 1995 Nov; 7(6):532–40 (78 ref.)

MDR1 reversal: criteria for clinical trials designed to overcome the multidrug resistance phenotype. Hegewisch-Becker S. **Leukemia** 1996 Jul;10 Suppl 3:S32–S38 (53 ref.)

THERAPEUTIC USE

Cytotoxic agents with activity in breast cancer patients previously exposed to anthracyclines: current status and future prospects. Piccart MJ, et al. **Eur J Cancer** 1995;31A Suppl 7:S1–10 (117 ref.)

Anthracycline resistance in breast cancer: clinical applications of current knowledge. Ravdin PM. **Eur J Cancer** 1995;31A Suppl 7:S11–4 (47 ref.)

The role of anthracyclines in adult acute lymphoblastic leukaemia. Bassan R, et al. **Leukemia** 1996 Jun;10 Suppl 2:s58–61 (11 ref.)

ANTIBIOTICS, ANTIFUNGAL

ADMINISTRATION & DOSAGE

Lipid formulations of amphotericin B: recent progress and future directions. Hiemenz JW, et al. **Clin Infect Dis** 1996 May;22 Suppl 2:S133–44 (83 ref.)

The use of lipid formulations of amphotericin B for systemic fungal infections. Leenders AC, et al. **Leukemia** 1996 Oct; 10(10):1570–5 (55 ref.)

CHEMISTRY

Lipid formulations of amphotericin B. Less toxicity but at what economic cost? Tollemar J, et al. **Drug Saf** 1995 Oct; 13(4):207–18 (86 ref.)

Liposomal and lipid-based formulations of amphotericin B. de Marie S. **Leukemia** 1996 Jun;10 Suppl 2:s93–6 (34 ref.)

METABOLISM

[New anti-HIV drug which binds the oligosaccharides of HIV envelope glycoprotein] Mizuochi T, et al. **Nippon Rinsho** 1995 Sep;53(9):2340–9 (20 ref.) (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

Use of amphotericin B with azole antifungal drugs: what are we doing? Sugar AM. **Antimicrob Agents Chemother** 1995 Sep;39(9):1907–12 (46 ref.)

[A complex antibiotic preparation obtained from a medicinal plant from the family Asteraceae] Smirnov VV, et al. **Mikrobiol Z** 1995 Jul–Aug;57(4):73–82 (29 ref.) (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Use of amphotericin B with azole antifungal drugs: what are we doing? Sugar AM. **Antimicrob Agents Chemother** 1995 Sep;39(9):1907–12 (46 ref.)

Rhinocerebral mucormycosis. Therapy with amphotericin B lipid complex. Strasser MD, et al. **Arch Intern Med** 1996 Feb 12;156(3):337–9 (21 ref.)

Amphotericin B: an update. Abu-Salah KM. **Br J Biomed Sci** 1996 Jun;53(2):122–33 (148 ref.)

Old and new therapies for sporotrichosis. Kauffman CA. **Clin Infect Dis** 1995 Oct;21(4):981–5 (63 ref.)

Management of scalp ringworm. **Drug Ther Bull** 1996 Jan; 34(1):5–6 (15 ref.)

[Rational use of antimycotics against yeast infections] Hof H, et al. **Immun Infekt** 1995 Dec;23(6):209–15 (29 ref.) (Eng. Abstr.) **(Ger)**

[Procedures for Candida albicans systemic infections in premature infants] Lauterbach R. **Ginekol Pol** 1995 May; 66(5):289–93 (13 ref.) (Eng. Abstr.) **(Pol)**

ANTIBIOTICS, ANTINEOPLASTIC

ADMINISTRATION & DOSAGE

Bolus mitomycin C and 5-FU with sequential radiation for poor-prognosis locally advanced cervical cancer. Denehy TR, et al. **Gynecol Oncol** 1996 Jan;60(1):64–71 (21 ref.)

ADVERSE EFFECTS

[Complications of intravesical mitomycin chemotherapy, apropos of 2 clinical case reports] Pouya M, et al. **Acta Urol Belg** 1996 Mar;64(1):47–53 (24 ref.) (Eng. Abstr.) **(Fre)**

BLOOD

Mycophenolic acid: measurement and relationship to pharmacologic effects. Shaw LM, et al. **Ther Drug Monit** 1995 Dec;17(6):685–9 (22 ref.)

CHEMISTRY

The enediyne antibiotics. Smith AL, et al. **J Med Chem** 1996 May 24;39(11):2103–17 (130 ref.)

HISTORY

Antitumor antibiotics discovered and studied at the Institute of Microbial Chemistry. Takeuchi T. **J Cancer Res Clin Oncol** 1995;121(9–10):505–10 (52 ref.)

PHARMACOLOGY

Status of new anthrapyrazole and pyrazoloacridine derivatives. Berg SL. **Crit Rev Oncol Hematol** 1996 Mar; 22(2):79–87 (57 ref.)

Re-evaluation of the molecular pharmacology of mitomycin C. Cummings J, et al. **Eur J Cancer** 1995 Nov; 31A(12):1928–33 (61 ref.)

Mycophenolic acid: measurement and relationship to pharmacologic effects. Shaw LM, et al. **Ther Drug Monit** 1995 Dec;17(6):685–9 (22 ref.)

Mechanism of action of rapamycin (Sirolimus, Rapamune).

ANTIBIOTICS, ANTINEOPLASTIC

Molnar-Kimber KL. **Transplant Proc** 1996 Apr;28(2):964-9 (127 ref.)

THERAPEUTIC USE

Role of anthracyclines in the treatment of adult acute lymphoblastic leukemia. Bassan R, et al. **Acta Haematol** 1996;95(3-4):188-92 (22 ref.)

Mitomycins. Verweij J. **Cancer Chemother Biol Response Modif** 1996;16:48-56 (43 ref.)

TOXICITY

DNA damage and mutagenesis by radiomimetic DNA-cleaving agents: bleomycin, neocarzinostatin and other enediynes. Povirk LF. **Mutat Res** 1996 Aug 17; 355(1-2):71-89 (125 ref.)

ANTIBIOTICS, ANTITUBERCULAR

ADVERSE EFFECTS

Tuberculosis in the elderly. Epidemiology and optimal management. Davies PD. **Drugs Aging** 1996 Jun;8(6):436-44 (31 ref.)

[Two cases of therapy-related myelodysplastic syndrome] Takahashi A, et al. **Rinsho Ketsueki** 1996 Jan;37(1):53-9 (16 ref.) (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

Antimicrobial agent resistance in mycobacteria: molecular genetic insights. Musser JM. **Clin Microbiol Rev** 1995 Oct; 8(4):496-514 (181 ref.)

Rapid measurement of antimycobacterial drug activity. Gordon S, et al. **Res Microbiol** 1996 Jan-Feb; 147(1-2):79-86 (31 ref.)

The genetics of multiple drug resistance in Mycobacterium tuberculosis and the Mycobacterium avium complex. Morris SL, et al. **Res Microbiol** 1996 Jan-Feb; 147(1-2):68-73 (40 ref.)

Ribosomal drug resistance in mycobacteria. Sander P, et al. **Res Microbiol** 1996 Jan-Feb;147(1-2):59-67 (73 ref.)

Novel strategies for the detection of drug resistance in Mycobacterium tuberculosis. Telenti A, et al. **Res Microbiol** 1996 Jan-Feb;147(1-2):73-9 (34 ref.)

[A complex antibiotic preparation obtained from a medicinal plant from the family Asteraceae] Smirnov VV, et al. **Mikrobiol Z** 1995 Jul-Aug;57(4):73-82 (29 ref.) (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Potential role of rifabutin in prophylaxis for tuberculosis and infections due to multiple opportunistic pathogens. Chaisson RE. **Clin Infect Dis** 1996 Apr;22 Suppl 1:S61-6; discussion S66-9 (51 ref.)

Use of rifabutin in the treatment of pulmonary tuberculosis. Grassi C, et al. **Clin Infect Dis** 1996 Apr;22 Suppl 1:S50-4 (21 ref.)

Vancomycin, trimethoprim-sulfamethoxazole, and rifampin. Lundstrom TS, et al. **Infect Dis Clin North Am** 1995 Sep; 9(3):747-67 (91 ref.)

Clinical and epidemiologic implications of polyclonal infection due to Mycobacterium avium complex. von Reyn CF, et al. **Res Microbiol** 1996 Jan-Feb;147(1-2):24-30 (46 ref.)

ANTIBIOTICS, BETA-LACTAM see **ANTIBIOTICS, LACTAM**

ANTIBIOTICS, CARBAPENEM see **CARBAPENEMS**

ANTIBIOTICS, CEPHALOSPORIN see **CEPHALOSPORINS**

ANTIBIOTICS, COMBINATION see **ANTIBIOTICS, COMBINED**

ANTIBIOTICS, COMBINED

ADMINISTRATION & DOSAGE

Comparison of intravenous and oral antibiotic therapy in the treatment of fractures caused by low-velocity gunshots. A prospective, randomized study of infection rates. Knapp TP, et al. **J Bone Joint Surg Am** 1996 Aug;78(8):1167-71 (35 ref.)

Once-daily dosing regimen for aminoglycoside plus betalactam combination therapy of serious lower respiratory tract infections. Paradisi F, et al. **J Chemother** 1995 Aug;7(4):338-43 (54 ref.)

ADVERSE EFFECTS

[Cholestatic hepatitis and amoxicillin-clavulanic acid combination. Personnel case report and literature review] Watteeuw G, et al. **Rev Med Brux** 1995 Dec;16(6):391-3 (11 ref.) (Eng. Abstr.) **(Fre)**

PHARMACOLOGY

Cefotaxime and desacetylcefotaxime antimicrobial interactions. The clinical relevance of enhanced activity: a review. Jones RN. **Diagn Microbiol Infect Dis** 1995 May-Jun;22(1-2):19-33 (79 ref.)

Newer penicillins and beta-lactamase inhibitors. Bush LM, et al. **Infect Dis Clin North Am** 1995 Sep;9(3):653-86 (154 ref.)

THERAPEUTIC USE

Cephalosporin-metronidazole combinations in the management of intra-abdominal infections. Nicolau DP, et al. **Diagn Microbiol Infect Dis** 1995 May-Jun; 22(1-2):189-94 (28 ref.)

Rationale for the choice of antibiotics for the eradication of Helicobacter pylori. Mégraud F. **Eur J Gastroenterol Hepatol** 1995 Aug;7 Suppl 1:S49-54 (46 ref.)

Pelvic inflammatory disease: an ongoing epidemic. Augenbraun MH, et al. **Hosp Pract (Off Ed)** 1995 Sep 15; 30(9):61-6 (6 ref.)

Selective decontamination of the digestive tract: indications and problems [editorial] Lode H, et al. **Infection** 1995 May-Jun;23(3):129-32 (31 ref.)

Cure of a solitary brainstem abscess with antibiotic therapy: case report. Fulgham JR, et al. **Neurology** 1996 May; 46(5):1451-4 (10 ref.)

Meningitis caused by Streptococcus pneumoniae showing high level resistance to penicillin. Wise KA, et al. **Pathology** 1995 Apr;27(2):165-7 (35 ref.)

Lateral sinus thrombosis associated with otitis media and mastoiditis in children. Garcia RD, et al. **Pediatr Infect Dis J** 1995 Jul;14(7):617-23 (35 ref.)

The use of aminoglycosides in neutropenic patients. Cometta A, et al. **Schweiz Med Wochenschr Suppl** 1996;76:21S-27S (10 ref.)

[Prevention and therapy of airway infections in patients with cystic fibrosis] Möller AV, et al. **Ned Tijdschr Geneeskd** 1995 Nov 18;139(46):2350-3 (26 ref.) **(Dut)**

[Antibiotic prophylaxis in biliary surgery] Gondret R, et al. **Ann Chir** 1995;49(6):493-9 (52 ref.) (Eng. Abstr.) **(Fre)**

[What antibiotic combinations for pneumococcal meningitis in children in 1996? (editorial)] Bégué P. **Arch Pediatr** 1996 May;3(5):411-3 (16 ref.) **(Fre)**

[Role of antibiotics in the treatment of infected joint prosthesis] Zimmerli W. **Orthopade** 1995 Aug;24(4):308-13 (22 ref.) (Eng. Abstr.) **(Ger)**

[The problem of resistance in the treatment of Mycobacterium infections: new experimental results and combinations for the treatment of tuberculosis and leprosy] Seydel JK, et al. **Pharm Unserer Zeit** 1995 Nov; 24(6):313-23 (14 ref.) **(Ger)**

ANTIBIOTICS, GLYCOPEPTIDE

Current perspectives on glycopeptide resistance. Woodford N, et al. **Clin Microbiol Rev** 1995 Oct;8(4):585-615 (429 ref.)

BLOOD

[Vancomycin] Furuta I, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:1028-30 (6 ref.) **(Jpn)**

PHARMACOLOGY

Pharmacodynamics of antimicrobial therapy in surgery. DiPiro JT, et al. **Am J Surg** 1996 Jun;171(6):615-22 (46 ref.)

Antibiotic resistance in Enterococcus species: an update. Eliopoulos GM. **Curr Clin Top Infect Dis** 1996;16:21-51 (231 ref.)

Emerging resistance in Enterococcus spp. Heath CH, et al. **Med J Aust** 1996 Jan 15;164(2):116-20 (44 ref.)

THERAPEUTIC USE

Pharmacodynamics of antimicrobial therapy in surgery. DiPiro JT, et al. **Am J Surg** 1996 Jun;171(6):615-22 (46 ref.)

Controversies in endophthalmitis prevention. The risk for emerging resistance to vancomycin [editorial; comment] Alfonso EC, et al. **Arch Ophthalmol** 1995 Nov; 113(11):1369-70 (15 ref.) Comment on: Arch Ophthalmol 1995 Nov;113(11):1353-4.

Antimicrobial resistance patterns in long term geriatric care. Implications for drug therapy. Mao CA, et al. **Drugs Aging** 1996 Mar;8(3):162-70 (66 ref.)

Vancomycin, trimethoprim-sulfamethoxazole, and rifampin. Lundstrom TS, et al. **Infect Dis Clin North Am** 1995 Sep; 9(3):747-67 (91 ref.)

Vancomycin administration and monitoring reappraisal. Saunders NJ. **J Antimicrob Chemother** 1995 Aug; 36(2):279-82 (32 ref.)

The comparative efficacy and safety of teicoplanin and vancomycin. Wood MJ. **J Antimicrob Chemother** 1996 Feb; 37(2):209-22 (27 ref.)

ANTIBIOTICS, GLYCOSIDE see **ANTIBIOTICS, AMINOGLYCOSIDE**

ANTIBIOTICS, LACTAM

ADMINISTRATION & DOSAGE

Continuous infusion of beta-lactam antibiotics: a rational dosing approach. Patel KB, et al. **Conn Med** 1995 Aug; 59(8):471-4 (26 ref.)

Once-daily dosing regimen for aminoglycoside plus betalactam combination therapy of serious lower respiratory tract infections. Paradisi F, et al. **J Chemother** 1995 Aug;7(4):338-43 (54 ref.)

Are the currently recommended doses of benzathine penicillin G adequate for secondary prophylaxis of rheumatic fever? Currie BJ. **Pediatrics** 1996 Jun;97(6 Pt 2):989-91 (21 ref.)

BIOSYNTHESIS

Beta-lactams. Jensen SE, et al. **Biotechnology** 1995;28:239-68 (208 ref.)

METABOLISM

[Beta-lactamase and its molecular evolution] Sawai T, et al. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(13):1887-99 (34 ref.) **(Jpn)**

PHARMACOLOGY

Pharmacodynamics of antimicrobial therapy in surgery. DiPiro JT, et al. **Am J Surg** 1996 Jun;171(6):615-22 (46 ref.)

Antibiotic resistance in Enterococcus species: an update. Eliopoulos GM. **Curr Clin Top Infect Dis** 1996;16:21-51 (231 ref.)

Beta-lactam/beta-lactamase inhibitor combinations: development, antibacterial activity and clinical applications. Sutherland R. **Infection** 1995 Jul-Aug; 23(4):191-200 (49 ref.)

The beta-lactamase problem: new therapeutic options. Schito GC, et al. **J Chemother** 1995 May;7 Suppl 1:5-8 (29 ref.)

Beta-lactamases and bacterial resistance to antibiotics. Frère JM. **Mol Microbiol** 1995 May;16(3):385-95 (51 ref.)

[beta-Lactamases of Branhamella catarrhalis and their phenotypic implications] Chaïbi EB, et al. **Res Microbiol** 1995 Nov-Dec;146(9):761-71 (40 ref.) (Eng. Abstr.) **(Fre)**

[Clinical and laboratory significance of inducible beta-lactamases] Bedenić B, et al. **Lijec Vjesn** 1995 Sep-Oct;117(9-10):249-53 (41 ref.) (Eng. Abstr.) **(Scr)**

THERAPEUTIC USE

Pharmacodynamics of antimicrobial therapy in surgery. DiPiro JT, et al. **Am J Surg** 1996 Jun;171(6):615-22 (46 ref.)

Diagnosis and treatment of nosocomial pneumonia. Bonten MJ, et al. **Br J Hosp Med** 1995 Oct 4-17;54(7):335-40 (25 ref.)

Novel plasmid-mediated beta-lactamases in enterobacteriaceae: emerging problems for new beta-lactam antibiotics. Thomson KS, et al. **Curr Clin Top Infect Dis** 1996;16:151-63 (46 ref.)

Meropenem--an advantageous antibiotic? **Drug Ther Bull** 1996 Jul;34(7):53-5 (23 ref.)

Are the currently recommended doses of benzathine penicillin G adequate for secondary prophylaxis of rheumatic fever? Currie BJ. **Pediatrics** 1996 Jun;97(6 Pt 2):989-91 (21 ref.)

Antibiotic resistance: relationship to persistence of group A streptococci in the upper respiratory tract. Gerber MA. **Pediatrics** 1996 Jun;97(6 Pt 2):971-5 (59 ref.)

Evaluation of penicillins, cephalosporins, and macrolides for therapy of streptococcal pharyngitis. Shulman ST. **Pediatrics** 1996 Jun;97(6 Pt 2):955-9 (34 ref.)

ANTIBIOTICS, MACROLIDE

[Clarithromycin] Schouenborg P. **Ugeskr Laeger** 1996 May 13;158(20):2870-3 (31 ref.) **(Dan)**

[New macrolides in pediatrics or new perspectives for an old classification of antibiotics] Bourrillon A. **Arch Pediatr** 1996;3 Suppl 1:302s-305s (16 ref.) **(Fre)**

ADMINISTRATION & DOSAGE

Treatment of chancroid with azithromycin. Ballard RC, et al. **Int J STD AIDS** 1996;7 Suppl 1:9-12 (16 ref.)

Azithromycin in gonorrhoea. Waugh MA. **Int J STD AIDS** 1996;7 Suppl 1:2-4 (11 ref.)

[Clarithromycin combined with pyrimethamine in cerebral toxoplasmosis--a a report of 2 cases] Dalston MO, et al. **Rev Soc Bras Med Trop** 1995 Oct-Dec;28(4):409-13 (11 ref.) (Eng. Abstr.) **(Por)**

ADVERSE EFFECTS

Erythromycin-induced polymorphous ventricular tachycardia with normal QT interval. Chennareddy SB, et al. **Am Heart J** 1996 Sep;132(3):691-4 (11 ref.)

Macrolides versus azalides: a drug interaction update. Amsden GW. **Ann Pharmacother** 1995 Sep;29(9):906-17 (109 ref.)

Toxic effects and drug interactions of antimycobacterial therapy. Chan-Tompkins NH. **Clin Dermatol** 1995 May-Jun;13(3):223-33 (99 ref.)

Macrolide antibacterials. Drug interactions of clinical significance. von Rosenstein NA, et al. **Drug Saf** 1995 Aug; 13(2):105-22 (237 ref.)

Erythromycin-induced acute pancreatitis. Fang CC, et al. **J Toxicol Clin Toxicol** 1996;34(1):93-5 (13 ref.)

BIOSYNTHESIS

Macrolides. Katz L, et al. **Biotechnology** 1995;28:385–420 (136 ref.)

BLOOD

[Macrolide] Watanabe H, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:1024–7 (9 ref.) **(Jpn)**

CHEMISTRY

[Macrolides, the attractive antibiotics--from a structural and functional aspect] Nakajima Y.
Nippon Saikingaku Zasshi 1995 Jul;50(3):717–36 (120 ref.) **(Jpn)**

ECONOMICS

Cost-effectiveness of H. pylori eradication. Roesch W.
J Physiol Pharmacol 1996 Mar;47(1):71–7 (20 ref.)

PHARMACOLOGY

Erythromycin-resistant Staphylococcus aureus in Denmark. Westh H. **APMIS Suppl** 1996;57:1–37 (126 ref.)

[In vitro susceptibility of Pasteurella and related bacteria to five orally administered antibiotics] Lion C, et al.
Pathol Biol (Paris) 1996 May;44(5):341–6 (13 ref.) (Eng. Abstr.) **(Fre)**

[Effect of the molecular structure of azithromycin on pharmacokinetics and the antimicrobial activity] Pechère JC. **Pathol Biol (Paris)** 1995 Jun;43(6):483–7 (8 ref.) (Eng. Abstr.) **(Fre)**

THERAPEUTIC USE

Azithromycin. Johnson RB. **Curr Probl Dermatol** 1996; 24:184–93 (30 ref.)

Gonorrhoea: single-dose oral treatment. Kohl PK, et al. **Curr Probl Dermatol** 1996;24:82–9 (29 ref.)

Benzamycin gel for acne. **Drug Ther Bull** 1995 Aug; 33(8):62–4 (13 ref.)

Macrolide antibiotics in paediatric infectious diseases. Guay DR. **Drugs** 1996 Apr;51(4):515–36 (205 ref.)

A guide to the treatment of lower respiratory tract infections. Vogel F. **Drugs** 1995 Jul;50(1):62–72 (56 ref.)

Clarithromycin for treatment of Helicobacter pylori infections. Graham DY. **Eur J Gastroenterol Hepatol** 1995 Aug;7 Suppl 1:S55–8 (46 ref.)

The newer macrolides. Azithromycin and clarithromycin. Zuckerman JM, et al. **Infect Dis Clin North Am** 1995 Sep; 9(3):731–45 (66 ref.)

The potential role of azithromycin in the treatment of prophylaxis of toxoplasmosis. Chang HR.
Int J STD AIDS 1996;7 Suppl 1:18–22 (34 ref.)

Treatment and prophylaxis of Mycobacterium avium complex. Young LS. **Int J STD AIDS** 1996;7 Suppl 1:23–7 (15 ref.)

Strategies for Helicobacter pylori eradication in 1995: a review of international and Belgian experience. Deltenre M, et al. **J Physiol Pharmacol** 1996 Mar;47(1):59–69 (66 ref.)

Treatment of disseminated Mycobacterium avium complex disease: a clinician's perspective. Benson CA.
Res Microbiol 1996 Jan–Feb;147(1–2):16–24 (43 ref.)

Clinical and epidemiologic implications of polyclonal infection due to Mycobacterium avium complex. von Reyn CF, et al. **Res Microbiol** 1996 Jan–Feb;147(1–2):24–30 (46 ref.)

Treatment of infections caused by rapidly growing mycobacteria in the era of the newer macrolides. Wallace RJ Jr. **Res Microbiol** 1996 Jan–Feb;147(1–2):30–5 (34 ref.)

Cholesterol gallstone formation in man and potential treatments of the gallbladder motility defect. Portincasa P, et al. **Scand J Gastroenterol Suppl** 1995;212:63–78 (294 ref.)

Clarithromycin against Mycobacterium avium complex infections. Heifets LB. **Tuber Lung Dis** 1996 Feb; 77(1):19–26 (105 ref.)

[Role of macrolides in the treatment of respiratory tract infections in children] Floret D. **Arch Pediatr** 1995 Dec; 2(12):1184–91 (41 ref.) (Eng. Abstr.) **(Fre)**

[Contemporary macrolides--characterization of the action, importance in the treatment of bacterial infections] Fomina IP. **Antibiot Khimioter** 1995 Sep;40(9):47–56 (35 ref.) **(Rus)**

[Visceral leishmaniasis refractory to treatment: the efficacy of amphotericin B] Pérez Brea A, et al. **An Esp Pediatr** 1996 Feb;44(2):161–3 (8 ref.) **(Spa)**

ANTIBIOTICS, MONOBACTAM see **MONOBACTAMS**

ANTIBIOTICS, PENICILLIN see **PENICILLINS**

ANTIBIOTICS, PEPTIDE

Quinupristin/dalfopristin (RP 59500): a new streptogramin antibiotic. Chant C, et al. **Ann Pharmacother** 1995 Oct; 29(10):1022–7 (30 ref.)

Peptide antibiotics: holy or heretic grails of innate immunity? Boman HG. **Scand J Immunol** 1996 May;43(5):475–82 (51 ref.)

ADVERSE EFFECTS

Chronic finger dermatitis after trauma. Diagnosis: posttraumatic eczema with allergic contact dermatitis to neomycin, bacitracin, and topical corticosteroids. Sherertz EF. **Arch Dermatol** 1996 Apr;132(4):461, 464 (11 ref.)

BIOSYNTHESIS

Engineered biosynthesis of peptide antibiotics. Stachelhaus T, et al. **Biochem Pharmacol** 1996 Jul 26;52(2):177–86 (64 ref.)

The genetics of lantibiotic biosynthesis. Jack R, et al.
Bioessays 1995 Sep;17(9):793–802 (69 ref.)

Lantibiotics. Gasson MJ. **Biotechnology** 1995;28:283–306 (78 ref.)

Peptidolactones. Keller U. **Biotechnology** 1995;28:173–96 (74 ref.)

Thiopeptides. Strohl WR, et al. **Biotechnology** 1995;28:223–38 (50 ref.)

Peptide and peptide-derived antibiotics. Vining LC, et al. **Biotechnology** 1995;28:121–7 (12 ref.)

Peptides. von Döhren H. **Biotechnology** 1995;28:129–71 (256 ref.)

Glycopeptides. Zmijewski MJ Jr, et al. **Biotechnology** 1995; 28:269–81 (49 ref.)

CHEMISTRY

Molecular structure and mechanisms of action of cyclic and linear ion transport antibiotics. Duax WL, et al.
Biopolymers 1996;40(1):141–55 (44 ref.)

Lantibiotics. Gasson MJ. **Biotechnology** 1995;28:283–306 (78 ref.)

Glycopeptides. Zmijewski MJ Jr, et al. **Biotechnology** 1995; 28:269–81 (49 ref.)

METABOLISM

Maturation pathway of nisin and other lantibiotics: post-translationally modified antimicrobial peptides exported by gram-positive bacteria. de Vos WM, et al.
Mol Microbiol 1995 Aug;17(3):427–37 (73 ref.)

PHARMACOLOGY

Peptides as weapons against microorganisms in the chemical defense system of vertebrates. Nicolas P, et al.
Annu Rev Microbiol 1995;49:277–304 (116 ref.)

Bacterial responses to host-defense peptides. Groisman EA. **Trends Microbiol** 1996 Apr;4(4):127–8; discussion 128–9 (17 ref.)

[In vitro susceptibility of Pasteurella and related bacteria to five orally administered antibiotics] Lion C, et al.
Pathol Biol (Paris) 1996 May;44(5):341–6 (13 ref.) (Eng. Abstr.) **(Fre)**

ANTIBIOTICS, TETRACYCLINE

ADVERSE EFFECTS

Serious adverse reactions induced by minocycline. Report of 13 patients and review of the literature. Knowles SR, et al. **Arch Dermatol** 1996 Aug;132(8):934–9 (38 ref.)

PHARMACOLOGY

Tetracyclines and calcified tissues. van der Bijl P, et al.
Ann Dent 1995 Summer-Fall;54(1–2):69–72 (46 ref.)

THERAPEUTIC USE

Minocycline in rheumatoid arthritis. Langevitz P, et al.
Isr J Med Sci 1996 May;32(5):327–30 (33 ref.)

Clinical significance of bacterial resistance to tetracyclines in the treatment of periodontal diseases. Greenstein G.
J Periodontol 1995 Nov;66(11):925–32 (72 ref.)

Treatment of infections caused by rapidly growing mycobacteria in the era of the newer macrolides. Wallace RJ Jr. **Res Microbiol** 1996 Jan–Feb;147(1–2):30–5 (34 ref.)

Antibiotic therapy for rheumatoid arthritis. Scientific and anecdotal appraisals. Trentham DE, et al.
Rheum Dis Clin North Am 1995 Aug;21(3):817–34 (58 ref.)

ANTIBIOTICS, THIENAMYCIN see **THIENAMYCINS**

ANTIBODIES

see related
ANTIGEN-ANTIBODY REACTIONS

Oriented immobilization of antibodies and its applications in immunoassays and immunosensors. Lu B, et al. **Analyst** 1996 Mar;121(3):29R–32R (47 ref.)

Brain GABAA receptors studied with subunit-specific antibodies. De Blas AL. **Mol Neurobiol** 1996 Feb; 12(1):55–71 (139 ref.)

Synthetic human antibodies. Barbas CF 3rd. **Nat Med** 1995 Aug;1(8):837–9 (32 ref.)

[Anti-gangliosides antibodies in neuromuscular's pathology] Illa I. **Rev Neurol** 1995 Jul–Aug;23(122):885–8 (48 ref.) **(Spa)**

ANALYSIS

Capillary isoelectric focusing as a tool in the examination of antibodies, peptides and proteins of pharmaceutical interest. Liu X, et al. **J Chromatogr A** 1996 May 31; 735(1–2):165–90 (72 ref.)

Anti-Thomsen-Friedenreich (T) antibody and its application to human breast carcinoma: where are we after 20 years? [editorial; comment] McCarty KS Jr.
J Immunol Methods 1995 Dec 27;188(2):171–3 (7 ref.)
Comment on: J Immunol Methods 1995 Dec 27;188(2):175–85.

[Joint and systemic manifestations related to type 2 anti-mitochondrial antibodies] Dhôte R, et al.
Ann Med Interne (Paris) 1995;146(8):536–40 (31 ref.) (Eng. Abstr.) **(Fre)**

[Factor IX inhibitor] Higasa S, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:98–9 (6 ref.) **(Jpn)**

[Factor VIII inhibitors] Takamatsu J. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:94–7 (11 ref.) **(Jpn)**

[Neurologic paraneoplastic syndromes and anti-neuronal antibodies] Mygland A. **Tidsskr Nor Laegeforen** 1996 Jan 30;116(3):361–5 (44 ref.) (Eng. Abstr.) **(Nor)**

CHEMISTRY

Selection of ligands for polyclonal antibodies from random peptide libraries: potential identification of (auto)antigens that may trigger B and T cell responses in autoimmune diseases. Sioud M, et al. **Clin Immunol Immunopathol** 1996 May;79(2):105–14 (65 ref.)

Antibody engineering. Nilsson B. **Curr Opin Struct Biol** 1995 Aug;5(4):450–6 (77 ref.)

Model building of antibody combining sites. Bajorath J, et al. **Ther Immunol** 1995 Apr;2(2):95–103 (104 ref.)

GENETICS

Molecular studies on thyrotropin (TSH) receptor and anti-TSH receptor antibodies. Akamizu T, et al.
Endocr J 1995 Oct;42(5):617–27 (46 ref.)

Molecular basis for a geographic variation of varicella-zoster virus recognized by a peptide antibody. Kinchington PR, et al. **Neurology** 1995 Dec;45(12 Suppl 8):S13–4 (7 ref.)

IMMUNOLOGY

Clinical significance of antibodies against calcitonin. Grauer A, et al. **Exp Clin Endocrinol Diabetes** 1995;103(6):345–51 (37 ref.)

Nitric oxide synthase isozymes antibodies. Pollock JS, et al. **Histochem J** 1995 Oct;27(10):738–44 (61 ref.)

Novel genetic immunotoxins and intracellular antibodies for cancer therapy. Chen SY, et al. **Semin Oncol** 1996 Feb; 23(1):148–53 (55 ref.)

[Crohn disease, hemorrhagic rectocolitis: antibodies and humans (editorial)] Duclos B. **Gastroenterol Clin Biol** 1995 Nov;19(11):865–6 (21 ref.) **(Fre)**

METABOLISM

Catalytic antibodies. Structure and possible applications. Amital H, et al. **Methods Mol Biol** 1995;51:203–10 (29 ref.)

PHYSIOLOGY

Structure and function of natural antibodies. Casali P, et al. **Curr Top Microbiol Immunol** 1996;210:167–79 (74 ref.)

THERAPEUTIC USE

Immunoconjugates and immunotoxins for therapy of carcinomas. Hellström I, et al. **Adv Pharmacol** 1995; 33:349–88 (159 ref.)

Antibodies proposed as therapeutic agents. Bismuth C, et al. **Arch Toxicol Suppl** 1996;18:321–32 (39 ref.)

Engineering recombinant antibodies for immunotherapy. Neri D, et al. **Cell Biophys** 1995 Aug;27(1):47–61 (62 ref.)

Return to the past: the case for antibody-based therapies in infectious diseases. Casadevall A, et al. **Clin Infect Dis** 1995 Jul;21(1):150–61 (181 ref.)

[Antibodies as medication] Kurki P, et al. **Duodecim** 1995; 111(8):788–96 (29 ref.) **(Fin)**

ANTIBODIES, ALLOTYPIC see **IMMUNOGLOBULIN ALLOTYPES**

ANTIBODIES, ANTICARDIOLIPIN

BLOOD

Anticardiolipin antibodies and cardiovascular disease [see comments] Muir KW. **J R Soc Med** 1995 Aug;88(8):433–6 (53 ref.) Comment in: J R Soc Med 1996 Feb;89(2):119.

Anticardiolipin antibodies and beta 2-glycoprotein I. Koike T, et al. **Lupus** 1996 Apr;5(2):156–7 (13 ref.)

ANTIBODIES, ANTI-DNA see **ANTIBODIES, ANTINUCLEAR**

ANTIBODIES, ANTI-IDIOTYPIC

see related
IMMUNOGLOBULIN IDIOTYPES
MOLECULAR MIMICRY

BIOSYNTHESIS

A genetic approach to idiotypic vaccination for B cell lymphoma. Stevenson FK, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:212–26 (23 ref.)

ANTIBODIES, ANTI-IDIOTYPIC

Antiantiidiotypic response and clinical course of the disease in patients with malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2-23. Mittelman A, et al. **Hybridoma** 1995 Apr;14(2):175-81 (31 ref.)

DIAGNOSTIC USE

[Anti-idiotypic antibodies as vaccinal and diagnostic preparations in viral infections] Tarasishin LA. **Mikrobiol Z** 1996 Jan-Feb;58(1):97-105 (30 ref.) (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

Will immunogenicity limit the use, efficacy, and future development of therapeutic monoclonal antibodies? Kuus-Reichel K, et al. **Clin Diagn Lab Immunol** 1994 Jul; 1(4):365-72 (82 ref.)

Auto-anti-idiotypy, autoimmunity and some thoughts on the structure of internal images. Erlanger BF. **Int Rev Immunol** 1989;5(2):131-7 (29 ref.)

Review and preview of anti-T-cell antibodies. Helderman JH. **Transplant Proc** 1995 Oct;27(5 Suppl 1):8-9 (7 ref.)

[A case of Guillain-Barré syndrome associated with anti-GM2 antibody due to cytomegalovirus infection--special reference to the effect of ganciclovir] Niwa K, et al. **Rinsho Shinkeigaku** 1995 Jun;35(6):652-6 (18 ref.) (Eng. Abstr.) **(Jpn)**

[Anti-idiotypic antibodies as vaccinal and diagnostic preparations in viral infections] Tarasishin LA. **Mikrobiol Z** 1996 Jan-Feb;58(1):97-105 (30 ref.) (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Controlling allergy with anti-idiotypic antibodies [editorial] Shakib F. **Clin Exp Allergy** 1995 Oct;25(10):908-9 (18 ref.)

Anti-IgE therapy. Jardieu P. **Curr Opin Immunol** 1995 Dec; 7(6):779-82 (36 ref.)

ANTIBODIES, ANTINUCLEAR

see related
COLLAGEN DISEASES

ANALYSIS

Significance of the anti-Ro (SS-A) antibody in evaluation of patients with cutaneous manifestations of a connective tissue disease. Provost TT, et al. **J Am Acad Dermatol** 1996 Aug;35(2 Pt 1):147-69; quiz 170-2 (213 ref.)

BLOOD

[Antinuclear antibodies and juvenile chronic rheumatoid arthritis (editorial)] Modesto Caballero C. **An Esp Pediatr** 1996 Apr;44(4):305-9 (33 ref.) **(Spa)**

CLASSIFICATION

[Isotypes and subtypes of anti-SS-A and/or SS-B antibodies in different subgroups of Sjögren's syndrome] Takaya M, et al. **Nippon Rinsho** 1995 Oct;53(10):2429-33 (17 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

B-1 cellular origin and VH segment structure of IgG, IgA, and IgM anti-DNA autoantibodies in patients with systemic lupus erythematosus. Kasaian MT, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:410-23 (52 ref.)

Origins of anti-DNA antibodies and their implications for B-cell tolerance. Radic MZ, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:384-96 (13 ref.)

IMMUNOLOGY

Immunological properties of bacterial DNA. Pisetsky DS, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:152-63 (33 ref.)

Chronic ulcerative stomatitis with stratified epithelium-specific antinuclear antibodies. Lewis JE, et al. **Int J Dermatol** 1996 Apr;35(4):272-5 (7 ref.)

Properties of a system of public idiotypes of lupus autoantibodies. Schwartz RS. **Int Rev Immunol** 1989; 5(2):153-5 (13 ref.)

Pathogenic aspects of systemic lupus erythematosus. Kalden JR. **Isr J Med Sci** 1996 Jan;32(1):3-6 (28 ref.)

The immunologic properties of DNA. Pisetsky DS. **J Immunol** 1996 Jan 15;156(2):421-3 (37 ref.)

[Epitopes of the target proteins of anti-SS-A/Ro and anti-SS-B/La autoantibodies] Kato T. **Nippon Rinsho** 1995 Oct;53(10):2434-9 (26 ref.) (Eng. Abstr.) **(Jpn)**

ANTIBODIES, ANTIPHOSPHOLIPID

see related
ANTIPHOSPHOLIPID SYNDROME

ANALYSIS

[Progressive lupus dementia. 2 cases with or without antiphospholipid antibodies] Robin C, et al. **Rev Neurol (Paris)** 1995 Dec;151(12):699-707 (48 ref.) (Eng. Abstr.) **(Fre)**

BLOOD

Clinical manifestations and management of the antiphospholipid syndrome. Derksen RH. **Lupus** 1996 Apr; 5(2):167-9 (18 ref.)

Laboratory detection of antiphospholipid antibodies. Kandiah DA, et al. **Lupus** 1996 Apr;5(2):160-2 (10 ref.)

Immunology of antiphospholipid antibodies and their interaction with plasma proteins. Kandiah DA, et al. **Lupus** 1996 Apr;5(2):153-5 (31 ref.)

Antiphospholipid antibodies and thrombosis: assessment of the potential risk for thrombosis. Salem HH. **Lupus** 1996 Apr;5(2):163-6 (24 ref.)

Cutaneous polyarteritis nodosa in a child with positive antiphospholipid and P-ANCA. Pereira BA, et al. **Scand J Rheumatol** 1995;24(6):386-8 (14 ref.)

[The Budd-Chiari syndrome and the antiphospholipid antibody in childhood] Pérez Payarols J, et al. **An Esp Pediatr** 1996 Jul;45(1):79-81 (12 ref.) **(Spa)**

IMMUNOLOGY

The Michael Mason Prize Essay (1994). Antiphospholipid antibodies and disease. Mackworth-Young CG. **Br J Rheumatol** 1995 Nov;34(11):1009-30 (160 ref.)

Antiphospholipid antibodies and antiphospholipid syndrome. Khamashta MA, et al. **Curr Opin Rheumatol** 1995 Sep; 7(5):389-94 (69 ref.)

The antiphospholipid-protein syndrome. Cines DB, et al. **J Clin Immunol** 1995 Nov;15(6 Suppl):86S-100S (186 ref.)

[Recent findings on antigens reactive to antiphospholipid antibodies] Matsuda S. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Feb;19(1):27-38 (66 ref.) **(Jpn)**

PHYSIOLOGY

[The heart and antiphospholipid antibodies. Personal experience and review of the literature] Laraki R, et al. **Rev Med Interne** 1996;17(1):46-57 (78 ref.) (Eng. Abstr.) **(Fre)**

ANTIBODIES, BACTERIAL

Strategies to interrupt the development of Anaplasma marginale in its tick vector. The effect of bovine-derived antibodies. Kocan KM, et al. **Ann N Y Acad Sci** 1996 Jul 23;791:157-65 (57 ref.)

BIOSYNTHESIS

Are polysaccharide antibody responses independent: the T cell enigma? Lane P. **Clin Exp Immunol** 1996 Jul; 105(1):10-1 (16 ref.)

Branhamella catarrhalis: epidemiology, surface antigenic structure, and immune response. Murphy TF. **Microbiol Rev** 1996 Jun;60(2):267-79 (186 ref.)

BLOOD

Serological diagnosis of tuberculosis. Bothamley GH. **Eur Respir J Suppl** 1995 Sep;20:676s-688s (114 ref.)

Endogenous endotoxin-core antibody (EndoCAb) as a marker of endotoxin exposure and a prognostic indicator: a review. Barclay GR. **Prog Clin Biol Res** 1995;392:263-72 (20 ref.)

Uses of serology for the diagnosis of contagious bovine pleuropneumonia. Rurangirwa FR. **Rev Sci Tech** 1995 Sep; 14(3):603-9 (30 ref.)

[Cat scratch disease. Bartonella henselae antibodies and DNA detection in regional lymphadenopathy] Heizmann WR, et al. **Dtsch Med Wochenschr** 1996 May 10;121(19):622-6 (33 ref.) (Eng. Abstr.) **(Ger)**

[Current status and diagnostic value of nucleic acid amplification and conventional methods in laboratory diagnosis of tuberculosis] Küchler R. **Pneumologie** 1996 Apr;50(4):323-6 (19 ref.) **(Ger)**

[Chlamydia pneumoniae infection associated with autoimmune hemolytic anemia due to warm antibodies] Belda J, et al. **Arch Bronconeumol** 1996 May;32(5):251-2 (7 ref.) (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

Host response assessment in recurring periodontitis. Ebersole JL, et al. **J Clin Periodontol** 1996 Mar;23(3 Pt 2):258-62 (22 ref.)

Antibodies to lipopolysaccharide. Poxton IR. **J Immunol Methods** 1995 Oct 12;186(1):1-15 (85 ref.)

PHYSIOLOGY

Contradictory roles for antibody and complement in the interaction of Brucella abortus with its host. Hoffmann EM, et al. **Crit Rev Microbiol** 1995;21(3):153-63 (50 ref.)

ANTIBODIES, BISPECIFIC

see related
IMMUNOTOXINS
RADIOIMMUNOTHERAPY

IMMUNOLOGY

Redirection of cellular cytotoxicity. A two-step approach using recombinant single-chain Fv molecules. George AJ, et al. **Cell Biophys** 1995 Jun;26(3):153-65 (39 ref.)

Targeting lipoproteins to Fc gamma receptors with bispecific antibodies. Morganelli PM. **J Hematother** 1995 Oct; 4(5):457-61 (19 ref.)

Alternative triggering molecules and single chain bispecific antibodies. Segal DM, et al. **J Hematother** 1995 Oct; 4(5):377-82 (31 ref.)

ISOLATION & PURIFICATION

Toward the production of bispecific antibody fragments for clinical applications. Carter P, et al. **J Hematother** 1995 Oct;4(5):463-70 (63 ref.)

THERAPEUTIC USE

Bifunctional antibodies for radioimmunotherapy. Chatal JF, et al. **Hybridoma** 1995 Apr;14(2):125-8 (9 ref.)

Tumor therapy by immune recruitment with bispecific antibodies. Renner C, et al. **Immunol Rev** 1995 Jun; 145:179-209 (153 ref.)

G-CSF-stimulated PMN in immunotherapy of breast cancer with a bispecific antibody to Fc gamma RI and to HER-2/neu (MDX-210). Repp R, et al. **J Hematother** 1995 Oct;4(5):415-21 (26 ref.)

Performance of CD3xCD19 bispecific monoclonal antibodies in B cell malignancy. Haagen IA. **Leuk Lymphoma** 1995 Nov;19(5-6):381-93 (160 ref.)

ANTIBODIES, BLOCKING

IMMUNOLOGY

[Hypothyroidism and blocking antibodies] Ducornet B, et al. **Ann Med Interne (Paris)** 1995;146(8):559-74 (129 ref.) **(Fre)**

THERAPEUTIC USE

Therapeutic potential for blockade of the CD40 ligand, gp39. Buhlmann JE, et al. **J Clin Immunol** 1996 Mar;16(2):83-9 (56 ref.)

ANTIBODIES, CATALYTIC

CHEMISTRY

Antibody catalysis via strategic use of haptenic charge. Kikuchi K, et al. **Acta Chem Scand** 1996 Apr;50(4):333-6 (34 ref.)

From molecular diversity to catalysis: lessons from the immune system. Schultz PG, et al. **Science** 1995 Sep 29; 269(5232):1835-42 (74 ref.)

METABOLISM

Antibody catalysis via strategic use of haptenic charge. Kikuchi K, et al. **Acta Chem Scand** 1996 Apr;50(4):333-6 (34 ref.)

Enzymes: chemistry and biochemistry. Jeffery J. **EXS** 1995; 73:79-104 (181 ref.)

Catalytic antibodies: evolution of protein function in real time. Lerner RA, et al. **EXS** 1995;73:121-38 (36 ref.)

From molecular diversity to catalysis: lessons from the immune system. Schultz PG, et al. **Science** 1995 Sep 29; 269(5232):1835-42 (74 ref.)

ANTIBODIES, ENHANCING see **ANTIBODIES, BLOCKING**

ANTIBODIES, FUNGAL

IMMUNOLOGY

Antibody immunity and invasive fungal infections. Casadevall A. **Infect Immun** 1995 Nov;63(11):4211-8 (133 ref.)

ANTIBODIES, HEPATITIS see **HEPATITIS ANTIBODIES**

ANTIBODIES, INTERNAL IMAGE see **ANTIBODIES, ANTI-IDIOTYPIC**

ANTIBODIES, MONOCLONAL

Criteria for investigation of the product equivalence of monoclonal antibodies for therapeutic and in vivo-diagnostic use in case of introduction of changes in the manufacturing process. Schäffner G, et al. **Biologicals** 1995 Sep;23(3):253-9 (32 ref.)

Monoclonal, human autoantibodies to the TSH receptor--the Holy Grail and why are we looking for it? [editorial] McLachlan SM, et al. **J Clin Endocrinol Metab** 1996 Sep; 81(9):3152-4 (29 ref.)

Complement-specific antibodies: designing novel anti-inflammatories. Matis LA, et al. **Nat Med** 1995 Aug; 1(8):839-42 (18 ref.)

Monoclonal antibodies: the promise and the reality. Coons T. **Radiol Technol** 1995 Sep-Oct;67(1):39-60; quiz 61-4 (75 ref.)

[Monoclonal antibodies: George Kohler] Danon YL. **Harefuah** 1996 Jan 15;130(2):108-9 (14 ref.) **(Heb)**

[Construction and clinical application of chimeric antibodies] Kuroki M, et al. **Nippon Rinsho** 1995 Dec;53(12):3122-31 (23 ref.) (Eng. Abstr.) **(Jpn)**

[General properties and kinds of antibodies for enzyme immunoassay--characteristics and advantages of polyclonal and monoclonal antibodies] Miyanishi S. **Nippon Rinsho** 1995 Sep;53(9):2149–53 (16 ref.) (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Interference by human antibodies with tumor marker assays. Reinsberg J. **Hybridoma** 1995 Apr;14(2):205–8 (30 ref.)

BIOSYNTHESIS

Generation of human monoclonal antibodies against ganglioside antigens and their applications in the diagnosis and therapy of cancer. Alfonso M, et al. **Acta Oncol** 1996; 35(3):287–95 (67 ref.)

Production of humanized monoclonal antibodies for in vivo imaging and therapy. Harris WJ. **Biochem Soc Trans** 1995 Nov;23(4):1035–8 (21 ref.)

Production of fully human antibodies by transgenic mice. Jakobovits A. **Curr Opin Biotechnol** 1995 Oct;6(5):561–6 (24 ref.)

Production of monoclonal antibodies in COS and CHO cells. Trill JJ, et al. **Curr Opin Biotechnol** 1995 Oct;6(5):553–60 (53 ref.)

Liposomes as carriers of peptide antigens: induction of antibodies and cytotoxic T lymphocytes to conjugated and unconjugated peptides. Alving CR, et al. **Immunol Rev** 1995 Jun;145:5–31 (104 ref.)

Recombinant antibodies: alternative strategies for developing and manipulating murine-derived monoclonal antibodies. Peterson NC. **Lab Anim Sci** 1996 Feb;46(1):8–14 (69 ref.)

Characteristics of human antibody repertoires following active immune responses in vivo. Ohlin M, et al. **Mol Immunol** 1996 May-Jun;33(7–8):583–92 (79 ref.)

CHEMISTRY

Developmental regulation of the human beta-globin cluster. Jane SM, et al. **Aust N Z J Med** 1995 Dec;25(6):865–9 (30 ref.)

Molecular inactivation. Spatially and temporally defined molecular knockouts. Müller BK, et al. **Curr Biol** 1995 Nov 1;5(11):1255–6 (9 ref.)

Characteristics of human antibody repertoires following active immune responses in vivo. Ohlin M, et al. **Mol Immunol** 1996 May-Jun;33(7–8):583–92 (79 ref.)

Interactions of protein antigens with antibodies. Davies DR, et al. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):7–12 (69 ref.)

Considerations in the design and production of small anti-receptor antibody forms: optimizing gains while reducing size. Peterson NC, et al. **Ther Immunol** 1994 Oct; 1(5):289–95 (58 ref.)

DIAGNOSTIC USE

Monoclonal antibodies in the management of acute leukemia. Wang JC, et al. **Am J Hematol** 1995 Nov;50(3):188–99 (159 ref.)

Production of monoclonal and polyclonal antibodies against various haemoglobins for the detection of thalassaemias. Gan YY, et al. **Ann Acad Med Singapore** 1996 Jan; 25(1):75–8 (20 ref.)

Immunocytochemistry of cytological specimens as a diagnostic and prognostic tool. Giovagnoli MR, et al. **Anticancer Res** 1996 Jul-Aug;16(4B):2225–32 (56 ref.)

Novel approaches to tumor detection and therapy using a combination of monoclonal antibody and cytokine. Greiner JW, et al. **Anticancer Res** 1996 Jul-Aug;16(4B):2129–33 (23 ref.)

Tumor markers as targets for selective diagnostic and therapeutic procedures. Roselli M, et al. **Anticancer Res** 1996 Jul-Aug;16(4B):2187–92 (59 ref.)

Radiolabeled monoclonal antibodies. Brumley CL, et al. **AORN J** 1995 Sep;62(3):343–50, 353–5; quiz 356–8, 361–2 (12 ref.)

Monoclonal antibodies used in the detection and treatment of epithelial ovarian cancer. Muto MG, et al. **Cancer** 1995 Nov 15;76(10 Suppl):2016–27 (100 ref.)

Recent progress in the use of monoclonal antibodies for imaging and therapy. Monson JR. **Curr Opin Gen Surg** 1993;:334–9 (24 ref.)

Micrometastasis detection and treatment with monoclonal antibodies. Pantel K, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 3):1–18 (88 ref.)

Neuropeptide receptors in health and disease: the molecular basis for in vivo imaging. Reubi JC. **J Nucl Med** 1995 Oct; 36(10):1825–35 (61 ref.)

Monoclonal antibodies: innovations in diagnosis and therapy. Baquiran DC, et al. **Semin Oncol Nurs** 1996 May; 12(2):130–41 (71 ref.)

Radioimmunoguided Surgery system improves survival for patients with recurrent colorectal cancer. Bertsch DJ, et al. **Surgery** 1995 Oct;118(4):634–8; discussion 638–9 (9 ref.)

[Monoclonal antibodies for diagnosis and therapy in oncological patients] Boven E, et al. **Ned Tijdschr Geneeskd** 1995 Dec 9;139(49):2552–8 (31 ref.) **(Dut)**

[Indium III monoclonal antimyosin antibody scintigraphy for the detection of chronic myocardial infarction apart from the acute phase] Adrie C, et al. **Arch Mal Coeur Vaiss** 1995 Dec;88(12):1863–8 (33 ref.) (Eng. Abstr.) **(Fre)**

[Diagnosis and targeting therapy of colorectal cancer using antibody] Yamaguchi T, et al. **Gan To Kagaku Ryoho** 1996 Apr;23(5):549–53 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Image diagnosis of heart diseases using new radioisotope compounds] Nishimura T. **Nippon Naika Gakkai Zasshi** 1995 Sep 10;84(9):1564–8 (8 ref.) **(Jpn)**

[Monoclonal antibodies in diagnosis of acute leukemias] Krawczyńska A, et al. **Przegl Lek** 1996;53(1):20–5 (41 ref.) (Eng. Abstr.) **(Pol)**

GENETICS

Human antibodies from transgenic mice. Lonberg N, et al. **Int Rev Immunol** 1995;13(1):65–93 (102 ref.)

IMMUNOLOGY

The use of neutralizing antibodies to demonstrate the role of transforming growth factor-beta and Amadori-glycated albumin as mediators of experimental diabetic kidney disease. Ziyadeh FN, et al. **Contrib Nephrol** 1996; 118:188–94 (39 ref.)

Molecular recognition of lysozyme by monoclonal antibodies. Smith-Gill SJ. **EXS** 1996;75:277–300 (59 ref.)

Antiantiidiotypic response and clinical course of the disease in patients with malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2-23. Mittelman A, et al. **Hybridoma** 1995 Apr;14(2):175–81 (31 ref.)

Antibody-interleukin 2 fusion proteins: a new approach to cancer therapy. Reisfeld RA, et al. **J Clin Lab Anal** 1996; 10(3):160–6 (34 ref.)

Monoclonal antibodies to cell-specific cell surface carbohydrates in plant cell biology and development. Pennell RI, et al. **Methods Cell Biol** 1995;49:123–41 (61 ref.)

Monoclonal antibodies as tools for studying the osteoblast lineage. Aubin JE, et al. **Microsc Res Tech** 1996 Feb 1; 33(2):128–40 (119 ref.)

Replacement therapy with a monoclonal antibody purified protein C concentrate in newborns with severe congenital protein C deficiency. Dreyfus M, et al. **Semin Thromb Hemost** 1995;21(4):371–81 (26 ref.)

Monoclonal anti-D specificity and Rh D structure: criteria for selection of monoclonal anti-D reagents for routine typing of patients and donors [see comments] Jones J, et al. **Transfus Med** 1995 Sep;5(3):171–84 (59 ref.) Comment in: Transfus Med 1995 Dec;5(4):304–5.

[Antiplatelet glycoprotein monoclonal antibodies: properties and practical value] Saffroy R, et al. **Ann Biol Clin (Paris)** 1995;53(3):97–105 (119 ref.) (Eng. Abstr.) **(Fre)**

PHARMACOLOGY

Anti-platelet monoclonal antibodies for the prevention of arterial thrombosis: experience with ReoPro, a monoclonal antibody directed against the platelet GPIIb/IIIa receptor. Weisman HF, et al. **Biochem Soc Trans** 1995 Nov; 23(4):1051–7 (25 ref.)

Mechanisms of action and overview of OKT3. Norman DJ. **Ther Drug Monit** 1995 Dec;17(6):615–20 (72 ref.)

An anti-CD2 monoclonal antibody that elicits alloantigen-specific hyporesponsiveness. Schad V, et al. **Transplant Proc** 1996 Aug;28(4):2051–3 (17 ref.)

Transmembrane signaling requirements of T cells: implications for regulation of alloimmunity. Suthanthiran M. **Transplant Proc** 1995 Oct;27(5 Suppl 1):5–7 (25 ref.)

THERAPEUTIC USE

Monoclonal antibody therapy of leukemia and lymphoma. Jurcic JG, et al. **Adv Pharmacol** 1995;33:287–314 (104 ref.)

Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective. Tcheng JE. **Am J Cardiol** 1996 Aug 14; 78(3A):35–40 (27 ref.)

Monoclonal antibodies in the management of acute leukemia. Wang JC, et al. **Am J Hematol** 1995 Nov;50(3):188–99 (159 ref.)

Do monoclonal antibodies and anticytokines still have a future in infectious diseases? Cohen J, et al. **Am J Med** 1995 Dec 29;99(6A):45S–52S; discussion 52S–53S (36 ref.)

Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies. Bodey B, et al. **Anticancer Res** 1996 Mar-Apr;16(2):661–74 (172 ref.)

Antibodies proposed as therapeutic agents. Bismuth C, et al. **Arch Toxicol Suppl** 1996;18:321–32 (39 ref.)

Therapeutic monoclonals. Boleti E, et al. **Biochem Soc Trans** 1995 Nov;23(4):1044–7 (49 ref.)

Clinical trials with CAMPATH-1 and other monoclonal antibodies. Hale G, et al. **Biochem Soc Trans** 1995 Nov; 23(4):1057–63 (49 ref.)

Anti-respiratory syncytial virus monoclonal antibodies show promise in the treatment and prophylaxis of viral disease. Taylor G, et al. **Biochem Soc Trans** 1995 Nov;23(4):1063–7 (24 ref.)

Therapeutic monoclonal antibodies. Choy EH, et al. **Br J Rheumatol** 1995 Aug;34(8):707–15 (64 ref.)

Monoclonal antibody therapy of inflammatory rheumatic diseases. Breedveld FC, et al. **Br Med Bull** 1995 Apr; 51(2):493–502 (47 ref.)

Monoclonal antibodies used in the detection and treatment of epithelial ovarian cancer. Muto MG, et al. **Cancer** 1995 Nov 15;76(10 Suppl):2016–27 (100 ref.)

Monoclonal antibody therapy of cancer. Jurcic JG, et al. **Cancer Chemother Biol Response Modif** 1996;16:168–88 (124 ref.)

Immunoconjugates and immunotoxins for therapy of solid tumors. Hellström I, et al. **Cancer Chemother Pharmacol** 1996;38 Suppl:S35–6 (13 ref.)

The integrin alpha 4 beta 1 (VLA-4) as a therapeutic target. Elices MJ. **Ciba Found Symp** 1995;189:79–85; discussion 85–90, 174–6 (56 ref.)

Treatment of inflammatory diseases with a monoclonal antibody to intercellular adhesion molecule 1. Rothlein R, et al. **Ciba Found Symp** 1995;189:200–8; discussion 208–11 (41 ref.)

The clinical role of platelet glycoprotein IIb/IIIa receptor inhibitors in ischemic heart disease. Lefkovits J, et al. **Cleve Clin J Med** 1996 May-Jun;63(3):181–9 (32 ref.)

Will immunogenicity limit the use, efficacy, and future development of therapeutic monoclonal antibodies? Kuus-Reichel K, et al. **Clin Diagn Lab Immunol** 1994 Jul; 1(4):365–72 (82 ref.)

Adhesion molecules as therapeutic targets in the treatment of allergic and immunologically mediated diseases. Kavanaugh A. **Clin Immunol Immunopathol** 1996 Sep;80(3 Pt 2):S15–22 (37 ref.)

Micrometastasis detection and treatment with monoclonal antibodies. Pantel K, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 3):1–18 (88 ref.)

Endotoxin-based molecular strategies for the prevention and treatment of gram-negative sepsis and septic shock. Pollack M, et al. **Curr Top Microbiol Immunol** 1996;216:275–97 (185 ref.)

Prevention of manifest metastasis with monoclonal antibodies: a novel approach to immunotherapy of solid tumours. Schneider-Gädicke E, et al. **Eur J Cancer** 1995 Jul-Aug;31A(7–8):1326–30 (51 ref.)

Monoclonal anti-TNF alpha antibody as a probe of pathogenesis and therapy of rheumatoid disease. Maini RN, et al. **Immunol Rev** 1995 Apr;144:195–223 (112 ref.)

New therapeutic approaches in sepsis: a critical review. Eidelman LA, et al. **Intensive Care Med** 1995 Nov;21 Suppl 2:S269–72 (18 ref.)

G-CSF-stimulated PMN in immunotherapy of breast cancer with a bispecific antibody to Fc gamma RI and to HER-2/neu (MDX-210). Repp R, et al. **J Hematother** 1995 Oct;4(5):415–21 (26 ref.)

Adhesion molecules and liver transplantation: new strategies for therapeutic intervention. Adams DH. **J Hepatol** 1995 Aug;23(2):225–31 (58 ref.)

Performance of CD3xCD19 bispecific monoclonal antibodies in B cell malignancy. Haagen IA. **Leuk Lymphoma** 1995 Nov;19(5–6):381–93 (160 ref.)

New immunotherapies for sepsis. Young LS, et al. **Proc Assoc Am Physicians** 1995 Oct;107(3):361–4 (19 ref.)

Monoclonal antibodies in tumor therapy. Matzku S. **Recent Results Cancer Res** 1996;141:1–8 (31 ref.)

Biologic interventions in rheumatoid arthritis. Cush JJ, et al. **Rheum Dis Clin North Am** 1995 Aug;21(3):797–816 (74 ref.)

Monoclonal antibodies: innovations in diagnosis and therapy. Baquiran DC, et al. **Semin Oncol Nurs** 1996 May; 12(2):130–41 (71 ref.)

Anti-integrin immunotherapy in rheumatoid arthritis: protective effect of anti-alpha 4 antibody in adjuvant arthritis. Barbadillo C, et al. **Springer Semin Immunopathol** 1995;16(4):427–36 (59 ref.)

The introduction of human monoclonal anti-D for therapeutic use. Fletcher A, et al. **Transfus Med Rev** 1995 Oct;9(4):314–26 (87 ref.)

[Monoclonal antibodies for diagnosis and therapy in oncological patients] Boven E, et al. **Ned Tijdschr Geneeskd** 1995 Dec 9;139(49):2552–8 (31 ref.) **(Dut)**

[Immunotherapy of colorectal cancers] Bécouarn Y, et al. **Gastroenterol Clin Biol** 1996 Feb;20(1):20–32 (106 ref.) **(Fre)**

ANTIBODIES, NEOPLASM

ADMINISTRATION & DOSAGE

Secondary antibodies as tools to improve tumor to non tumor ratio at radioimmunolocalisation and radioimmunotherapy. Ullén A, et al. **Acta Oncol** 1996;35(3):281–5 (37 ref.)

BLOOD

Immunologic status of the cancer patient and the effects of blood transfusion on antitumor responses. Browell DA, et al. **Curr Opin Gen Surg** 1993;:325–33 (110 ref.)

IMMUNOLOGY

A genetic approach to idiotypic vaccination for B cell lymphoma. Stevenson FK, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:212–26 (23 ref.)

THERAPEUTIC USE

Clinical trials with CAMPATH-1 and other monoclonal antibodies. Hale G, et al. **Biochem Soc Trans** 1995 Nov; 23(4):1057–63 (49 ref.)

Recombinant antibody fusion proteins for cancer

ANTIBODIES, NEOPLASM

immunotherapy. Reisfeld RA, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 3):27-53 (67 ref.)

Intervention in receptor tyrosine kinase-mediated pathways: recombinant antibody fusion proteins targeted to ErbB2. Weis W, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 3):113-28 (47 ref.)

ANTIBODIES, PROTOZOAN

IMMUNOLOGY

Immune mechanisms underlying the premunition against Plasmodium falciparum malaria. Pérignon JL, et al. **Mem Inst Oswaldo Cruz** 1994;89 Suppl 2:51-3 (13 ref.)

ANTIBODIES, VIRAL

ANALYSIS

Searching for antibodies specific for human cytomegalovirus: is it diagnostically useful? When and how. Landini MP, et al. **Scand J Infect Dis Suppl** 1995;99:18-23 (43 ref.)

[Viral tumor markers] Ohtsuru A, et al. **Nippon Rinsho** 1996 Jun;54(6):1529-35 (18 ref.) (Eng. Abstr.) **(Jpn)**

BIOSYNTHESIS

Protective efficacy of intramuscular immunization with naked DNA. Donnelly JJ, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:40-6 (26 ref.)

Influence of breast-feeding and oral poliovirus vaccine on the immunogenicity and efficacy of rotavirus vaccines. Rennels MB. **J Infect Dis** 1996 Sep;174 Suppl 1:S107-11 (35 ref.)

[Immune reactions and mechanisms in classical swine fever] Kolontsov AA, et al. **Mol Gen Mikrobiol Virusol** 1995 Apr-Jun;(2):18-21 (46 ref.) (Eng. Abstr.) **(Rus)**

[Mechanisms involved in the prolonged humoral immune response: behavior of aphthous fever virus] Wigdorovitz A, et al. **Rev Argent Microbiol** 1996 Jan-Mar;28(1):45-54 (45 ref.) (Eng. Abstr.) **(Spa)**

BLOOD

[Value of anti-Epstein-Barr antibody detection in the diagnosis and management of undifferentiated carcinoma of the nasopharynx] Mazeron MC. **Bull Cancer Radiother** 1996;83(1):3-7 (29 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSTIC USE

[Anti-idiotypic antibodies as vaccinal and diagnostic preparations in viral infections] Tarasishin LA. **Mikrobiol Z** 1996 Jan-Feb;58(1):97-105 (30 ref.) (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

Rubella immunity. Defining the level of protective antibody. Skendzel LP. **Am J Clin Pathol** 1996 Aug;106(2):170-4 (39 ref.)

The interference by maternally-derived antibody with active immunization of farm animals against foot-and-mouth disease. Kitching RP, et al. **Br Vet J** 1995 Jul-Aug; 151(4):379-89 (40 ref.)

Antibody recognition of picornaviruses and escape from neutralization: a structural view. Mateu MG. **Virus Res** 1995 Sep;38(1):1-24 (161 ref.)

[Anti-idiotypic antibodies as vaccinal and diagnostic preparations in viral infections] Tarasishin LA. **Mikrobiol Z** 1996 Jan-Feb;58(1):97-105 (30 ref.) (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Anti-respiratory syncytial virus monoclonal antibodies show promise in the treatment and prophylaxis of viral disease. Taylor G, et al. **Biochem Soc Trans** 1995 Nov;23(4):1063-7 (24 ref.)

Antiviral antibodies in transplantation. Snydman DR. **Transplant Proc** 1995 Oct;27(5 Suppl 1):10-2 (22 ref.)

ANTIBODY AFFINITY

Selection of ligands for polyclonal antibodies from random peptide libraries: potential identification of (auto)antigens that may trigger B and T cell responses in autoimmune diseases. Sioud M, et al. **Clin Immunol Immunopathol** 1996 May;79(2):105-14 (65 ref.)

Quantitative determination of antibody binding capacity (ABC) by flow cytometry. Schwartz A, et al. **Eur J Histochem** 1994;38 Suppl 1:13-20 (14 ref.)

[Antibody avidity in immune response and in the diagnosis of infectious diseases] Seppälä I, et al. **Duodecim** 1994; 110(2):178-84 (34 ref.) **(Fin)**

ANTIBODY AVIDITY see **ANTIBODY AFFINITY**

ANTIBODY BINDING SITES see **BINDING SITES, ANTIBODY**

ANTIBODY DEFICIENCY SYNDROME see **IMMUNOLOGIC DEFICIENCY SYNDROMES**

ANTIBODY-DEPENDENT CELL CYTOTOXICITY

Antibody-dependent cellular cytotoxicity in HIV infections. Ahmad A, et al. **FASEB J** 1996 Feb;10(2):258-66 (57 ref.)

ANTIBODY DIVERSITY

Development of the antibody repertoire in rabbits. Knight KL, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:198-206 (23 ref.)

Development of the mouse B-cell repertoire. Martin F, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:207-21 (56 ref.)

Unconventional B-cell antigens and human immune repertoires. Silverman GJ. **Ann N Y Acad Sci** 1995 Sep 29;764:342-55 (42 ref.)

Development of the immunoglobulin repertoire. Fanning LJ, et al. **Clin Immunol Immunopathol** 1996 Apr;79(1):1-14 (129 ref.)

B-cell superantigens: implications for selection of the human antibody repertoire. Zouali M. **Immunol Today** 1995 Aug; 16(8):399-405 (73 ref.)

GENETICS

Developmental regulation of the human antibody repertoire. Schroeder HW Jr, et al. **Ann N Y Acad Sci** 1995 Sep 29; 764:242-60 (60 ref.)

PHYSIOLOGY

Somatic hypermutation: how many mechanisms diversify V region sequences? Maizels N. **Cell** 1995 Oct 6;83(1):9-12 (26 ref.)

ANTIBODY ENZYME TECHNIQUE, UNLABELED see **IMMUNOENZYME TECHNIQUES**

ANTIBODY FORMATION

The human intestinal immune system: basic cellular and humoral mechanisms. Brandtzaeg P. **Baillieres Clin Rheumatol** 1996 Feb;10(1):1-24 (91 ref.)

Humoral immune response and natural killer activity in patients with mixed cryoglobulinemia. Gabrielli A, et al. **Clin Exp Rheumatol** 1995 Nov-Dec;13 Suppl 13:S95-9 (21 ref.)

Role of vascular endothelial cells in the allograft response. Brindle NP. **Eye** 1995;9 (Pt 2):167-72 (63 ref.)

From the forehead of Zeus: the ontogeny of the immune response. Silverstein AM. **Eye** 1995;9 (Pt 2):147-51 (36 ref.)

T-cell mediated immunosuppression and its implications for the development of protective immunity. Baker PJ, et al. **Folia Biol (Praha)** 1994;40(6):349-58 (50 ref.)

Pulmonary immunity to Pseudomonas aeruginosa. Cripps AW, et al. **Immunol Cell Biol** 1995 Oct;73(5):418-24 (84 ref.)

Role of antibody and indirect antigen presentation in transplant-associated coronary artery vasculopathy. Rose ML. **J Heart Lung Transplant** 1996 Apr;15(4):342-9 (75 ref.)

[Analysis of regulatory mechanism for humoral immunity using transgenic mice of rearranged immunoglobulin genes] Shimizu A. **Tanpakushitsu Kakusan Koso** 1995 Oct; 40(14):2107-17 (21 ref.) **(Jpn)**

IMMUNOLOGY

The humoral immune system in coeliac disease. Mäki M. **Baillieres Clin Gastroenterol** 1995 Jun;9(2):231-49 (115 ref.)

Immunoglobulin gene usage in the human anti-pathogen response. Newkirk MM, et al. **Infect Agents Dis** 1995 Sep; 4(3):153-60 (59 ref.)

[The function of antigen presentation of dendritic cells] Péguet-Navarro J. **Pathol Biol (Paris)** 1995 Dec; 43(10):863-70 (54 ref.) (Eng. Abstr.) **(Fre)**

[Effect of menstrual cycle on the immune response to surgical stress] Lazzaretti MG, et al. **Minerva Ginecol** 1995 May; 47(5):197-205 (48 ref.) (Eng. Abstr.) **(Ita)**

[Biologic effects of immunotherapy] Dávila González I, et al. **Allergol Immunopathol (Madr)** 1996;24 Suppl 1:60-8 (85 ref.) **(Spa)**

PHYSIOLOGY

Clonal selection and learning in the antibody system. Rajewsky K. **Nature** 1996 Jun 27;381(6585):751-8 (182 ref.)

ANTIBODY FRAGMENTS see **IMMUNOGLOBULIN FRAGMENTS**

ANTIBODY SPECIFICITY

see related
ANTIBODIES, BISPECIFIC

From the forehead of Zeus: the ontogeny of the immune response. Silverstein AM. **Eye** 1995;9 (Pt 2):147-51 (36 ref.)

Monoclonal anti-D specificity and Rh D structure: criteria for selection of monoclonal anti-D reagents for routine typing of patients and donors [see comments] Jones J, et al. **Transfus Med** 1995 Sep;5(3):171-84 (59 ref.) Comment in: Transfus Med 1995 Dec;5(4):304-5.

Xenoreactive natural antibodies in the world of natural antibodies: typical or unique? Parker W, et al. **Transpl Immunol** 1995 Sep;3(3):181-91 (88 ref.)

ANTIBODY-TOXIN CONJUGATES see **IMMUNOTOXINS**

ANTIBODY-TOXIN HYBRIDS see **IMMUNOTOXINS**

ANTICANCER DRUG COMBINATIONS see **ANTINEOPLASTIC AGENTS, COMBINED**

ANTICANCER DRUG SENSITIVITY TESTS see **DRUG SCREENING ASSAYS, ANTITUMOR**

ANTICARCINOGENIC AGENTS

see related
ANTIMUTAGENIC AGENTS
ANTINEOPLASTIC AGENTS

Capsaicin in hot chili pepper: carcinogen, co-carcinogen or anticarcinogen? Surh YJ, et al. **Food Chem Toxicol** 1996 Mar;34(3):313-6 (48 ref.)

Ascorbic acid and gastrointestinal cancer. Cohen M, et al. **J Am Coll Nutr** 1995 Dec;14(6):565-78 (136 ref.)

Dietary antioxidants in disease prevention. Gordon M. **Nat Prod Rep** 1996 Aug;13(4):265-73 (130 ref.)

[Calcium and colon cancer] Liberman-Insel V, et al. **Harefuah** 1996 Jan 15;130(2):129-31 (20 ref.) **(Heb)**

ADMINISTRATION & DOSAGE

Chemoprevention of colon cancer by minor dietary constituents and their synthetic analogues. Reddy BS. **Prev Med** 1996 Jan-Feb;25(1):48-50 (13 ref.)

ADVERSE EFFECTS

-Tamoxifen and the endometrium: monitoring and evaluation of endometrial changes- Rageth JC, et al. **Arch Gynecol Obstet** 1995;256 Suppl:S122-7 (24 ref.) **(Ger)**

PHARMACOLOGY

How can carcinogenesis be inhibited? Smith TJ, et al. **Ann N Y Acad Sci** 1995 Sep 30;768:82-90 (67 ref.)

Saffron chemoprevention in biology and medicine: a review. Nair SC, et al. **Cancer Biother** 1995 Winter;10(4):257-64 (41 ref.)

Phytoestrogens: epidemiology and a possible role in cancer protection. Adlercreutz H. **Environ Health Perspect** 1995 Oct;103 Suppl 7:103-12 (133 ref.)

Dietary modifiers of carcinogenesis. Kohlmeier L, et al. **Environ Health Perspect** 1995 Nov;103 Suppl 8:177-84 (78 ref.)

Nutrient antioxidants in the pathogenesis and prevention of cervical dysplasias and cancer. Romney SL, et al. **J Cell Biochem Suppl** 1995;23:96-103 (45 ref.)

Antioxidant defences against reactive oxygen species causing genetic and other damage. Anderson D. **Mutat Res** 1996 Feb 19;350(1):103-8 (46 ref.)

Natural toxins and protective factors in brassica species, including rapeseed. Heaney RK, et al. **Nat Toxins** 1995; 3(4):233-7; discussion 242 (16 ref.)

Transforming growth factor-beta s in mammary tumorigenesis: promoters or antipromoters? Wakefield LM, et al. **Prog Clin Biol Res** 1995;391:133-48 (56 ref.)

The role of lactic acid bacteria in colon cancer prevention. Rafter JJ. **Scand J Gastroenterol** 1995 Jun;30(6):497-502 (56 ref.)

Chemoprevention of breast cancer by tamoxifen: risks and opportunities. Smith LL, et al. **Toxicol Lett** 1995 Dec; 82-83:181-6 (18 ref.)

Chemoprotection against cancer by phase 2 enzyme induction. Talalay P, et al. **Toxicol Lett** 1995 Dec; 82-83:173-9 (36 ref.)

Antioxidant agents and colorectal carcinogenesis: role of beta-carotene, vitamin E and vitamin C. Pappalardo G, et al. **Tumori** 1996 Jan-Feb;82(1):6-11 (88 ref.)

THERAPEUTIC USE

Indole-3-carbinol. A novel approach to breast cancer prevention. Bradlow HL, et al. **Ann N Y Acad Sci** 1995 Sep 30;768:180-200 (22 ref.)

Retinoids in cancer chemoprevention. Clinical trials with the synthetic analogue fenretinide. Costa A, et al. **Ann N Y Acad Sci** 1995 Sep 30;768:148-62 (49 ref.)

The potential application of finasteride for chemoprevention of prostate cancer. Gormley GJ, et al. **Ann N Y Acad Sci** 1995 Sep 30;768:163-9 (22 ref.)

Preventive clinical trials. An overview. Greenwald P. **Ann N Y Acad Sci** 1995 Sep 30;768:129-40 (41 ref.)

An overview of considerations for the testing of tamoxifen as a preventive for breast cancer. Jordan VC. **Ann N Y Acad Sci** 1995 Sep 30;768:141-7 (47 ref.)

Strategies for colon cancer prevention. Lipkin M. **Ann N Y Acad Sci** 1995 Sep 30;768:170-9 (10 ref.)

What are the critical attributes for cancer chemopreventive agents? Wattenberg LW. **Ann N Y Acad Sci** 1995 Sep 30; 768:73-81 (35 ref.)

Evaluating the role of niacin in human carcinogenesis. Jacobson EL, et al. **Biochimie** 1995;77(5):394-8 (22 ref.)

Chemoprevention trials and surrogate end point biomarkers in the cervix. Mitchell MF, et al. **Cancer** 1995 Nov 15;76(10 Suppl):1956–77 (227 ref.)
Healthcare resources should be targeted to chemoprevention in prostate cancer: the argument for. Denis LJ. **Eur Urol** 1996;29 Suppl 2:13–6 (13 ref.)
Healthcare resources should be targeted to chemoprevention: the argument against. Trachtenberg J. **Eur Urol** 1996;29 Suppl 2:17–8 (1 ref.)
Retinoids in cancer chemoprevention. Lotan R. **FASEB J** 1996 Jul;10(9):1031–9 (47 ref.)
Strategies for intervention with chemopreventive agents. Lipkin M. **Int J Cancer** 1996 Feb 20;69(1):64–7 (10 ref.)
Effects of oltipraz and related chemoprevention compounds on gene expression in rat liver. Anderson L, et al. **J Cell Biochem Suppl** 1995;22:108–16 (20 ref.)
Potential criteria for cohort selection in chemoprevention trials of uterine adenocarcinoma. Baker VV. **J Cell Biochem Suppl** 1995;23:184–8 (32 ref.)
Chemoprevention of cancer by organoselenium compounds. el-Bayoumy K, et al. **J Cell Biochem Suppl** 1995;22:92–100 (34 ref.)
beta-carotene and cancer chemoprevention. Buring JE, et al. **J Cell Biochem Suppl** 1995;22:226–30 (37 ref.)
Chemopreventive properties and mechanisms of N-Acetylcysteine. The experimental background. De Flora S, et al. **J Cell Biochem Suppl** 1995;22:33–41 (37 ref.)
Controlled clinical trials with fenretinide in breast cancer, basal cell carcinoma and oral leukoplakia. De Palo G, et al. **J Cell Biochem Suppl** 1995;22:11–7 (16 ref.)
A phase II chemoprevention trial design to identify surrogate endpoint biomarkers in breast cancer. Dhingra K. **J Cell Biochem Suppl** 1995;23:19–24 (27 ref.)
Probing the molecular program of apoptosis by cancer chemopreventive agents. Fésüs L, et al. **J Cell Biochem Suppl** 1995;22:151–61 (49 ref.)
Chemoprevention by isothiocyanates. Hecht SS. **J Cell Biochem Suppl** 1995;22:195–209 (33 ref.)
Strategies for phase II cancer chemoprevention trials: cervix, endometrium, and ovary. Kelloff GJ, et al. **J Cell Biochem Suppl** 1995;23:1–9 (51 ref.)
Effects of protease inhibitors on levels of proteolytic activity in normal and premalignant cells and tissues. Kennedy AR, et al. **J Cell Biochem Suppl** 1995;22:188–94 (22 ref.)
Oltipraz: clinical opportunities for cancer chemoprevention. p Kensler TW, et al. **J Cell Biochem Suppl** 1995;22:101–7 (38 ref.)
Calcium and the prevention of colon cancer. Lipkin M, et al. **J Cell Biochem Suppl** 1995;22:65–73 (54 ref.)
Retinoids and chemoprevention: clinical and basic studies. Lippman SM, et al. **J Cell Biochem Suppl** 1995;22:1–10 (66 ref.)
Chemoprevention trials in the cervix: design, feasibility, and recruitment. Mitchell MF, et al. **J Cell Biochem Suppl** 1995; 23:104–12 (43 ref.)
Fostering chemopreventive agent development: how to proceed? Mulshine JL. **J Cell Biochem Suppl** 1995;22:254–9 (16 ref.)
Tamoxifen's role in chemoprevention of breast cancer: an update. Nayfield SG. **J Cell Biochem Suppl** 1995;22:42–50 (63 ref.)
The vitamin D Endocrine system: manipulation of structure-function relationships to provide opportunities for development of new cancer chemopreventive and immunosuppressive agents. Norman AW. **J Cell Biochem Suppl** 1995;22:218–25 (39 ref.)
Ornithine decarboxylase as a target for chemoprevention. Pegg AE, et al. **J Cell Biochem Suppl** 1995;22:132–8 (41 ref.)
Surrogate endpoint biomarkers for cervical cancer chemopreventive trials. Ruffin MT 4th, et al. **J Cell Biochem Suppl** 1995;23:113–24 (98 ref.)
Cancer prevention with dehydroepiandrosterone and non-androgenic structural analogs. Schwartz AG, et al. **J Cell Biochem Suppl** 1995;22:210–7 (58 ref.)
Endometrial cancer chemoprevention: implications of diverse pathways of carcinogenesis. Sherman ME, et al. **J Cell Biochem Suppl** 1995;23:160–4 (27 ref.)
Polyphenols as cancer chemopreventive agents. Stoner GD, et al. **J Cell Biochem Suppl** 1995;22:169–80 (87 ref.)
N-acetylcysteine (NAC) and glutathione (GSH): antioxidant and chemopreventive properties, with special reference to lung cancer. van Zandwijk N. **J Cell Biochem Suppl** 1995; 22:24–32 (48 ref.)
Chalcones, myo-inositol and other novel inhibitors of pulmonary carcinogenesis. Wattenberg L. **J Cell Biochem Suppl** 1995;22:162–8 (40 ref.)
Calcium-cell cycle regulator, differentiator, killer, chemopreventor, and maybe, tumor promoter. Whitfield JF, et al. **J Cell Biochem Suppl** 1995;22:74–91 (38 ref.)
Chemoprevention of head and neck cancer. Voravud N. **J Med Assoc Thai** 1996 Mar;79(3):185–93 (65 ref.)
Folic acid as a cancer-preventing agent. Jennings E. **Med Hypotheses** 1995 Sep;45(3):297–303 (60 ref.)
Breast cancer chemoprevention: clinical trials and research. Noguchi M, et al. **Oncology** 1996 May-Jun;53(3):175–81 (111 ref.)
Chemoprevention of cancer. Wattenberg LW. **Prev Med** 1996 Jan-Feb;25(1):44–5 (11 ref.)
The tumor promoter receptor protein kinase C: a novel target for chemoprevention and therapy of human colon cancer. O'Brian CA, et al. **Prog Clin Biol Res** 1995;391:117–20 (20 ref.)
Skin carcinogenesis: characteristics, mechanisms, and prevention. Slaga TJ, et al. **Prog Clin Biol Res** 1995; 391:1–20 (43 ref.)
-Results of ongoing breast cancer prevention studies- Jungi WF. **Arch Gynecol Obstet** 1995;256 Suppl:S116–21 (18 ref.) **(Ger)**

ANTICARDIOLIPIN ANTIBODIES see ANTIBODIES, ANTICARDIOLIPIN

ANTICHOLESTEREMIC AGENTS

Squalene synthase inhibitors: their potential as hypocholesterolaemic agents. Watson NS, et al. **Prog Med Chem** 1996;33:331–78 (83 ref.)

ADVERSE EFFECTS

The cholesterol controversy [see comments] Geurian KL. **Ann Pharmacother** 1996 May;30(5):495–500 (60 ref.) Comment in: Ann Pharmacother 1996 May;30(5):539–42.
Cholesterol-lowering therapy: is there really a controversy? [comment] Jungnickel PW. **Ann Pharmacother** 1996 May; 30(5):539–42 (33 ref.) Comment on: Ann Pharmacother 1996 May;30(5):495–500.
Safety profile of fluvastatin. Peters TK. **Br J Clin Pract Symp Suppl** 1996 Jan;77A:20–3 (4 ref.)

ECONOMICS

Cost effectiveness of cholesterol-lowering drugs: a review of the evidence. Thorvik E, et al. **Wien Klin Wochenschr** 1996;108(8):234–43 (23 ref.)

PHARMACOKINETICS

Development and pharmacology of fluvastatin. Jokubaitis LA. **Br J Clin Pract Symp Suppl** 1996 Jan;77A:11–5 (4 ref.)
Simvastatin. A reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolaemia. Plosker GL, et al. **Drugs** 1995 Aug;50(2):334–63 (239 ref.)

PHARMACOLOGY

Discovery, biosynthesis, and mechanism of action of the zaragozic acids: potent inhibitors of squalene synthase. Bergstrom JD, et al. **Annu Rev Microbiol** 1995;49:607–39 (80 ref.)
Fats for the food industry: implications for cholesterol-lowering. Nestel P, et al. **Lipids** 1996 Mar;31 Suppl:S65–9 (10 ref.)
[Cholesterol turnover in triglyceride transport and effect of probucol] Titov VN. **Vopr Med Khim** 1995 Sep-Oct; 41(5):2–8 (80 ref.) **(Rus)**

THERAPEUTIC USE

Treatment of hyperlipidemia after heart transplantation and rationale for the Heart Transplant Lipid Registry. Ballantyne CM, et al. **Am J Cardiol** 1996 Sep 1;78(5):532–5 (34 ref.)
What benefit can be derived from treating normocholesterolemic patients with coronary artery disease? Brown G, et al. **Am J Cardiol** 1995 Sep 28; 76(9):93C–97C (20 ref.)
Unresolved issues in early trials of cholesterol lowering. LaRosa JC. **Am J Cardiol** 1995 Sep 28;76(9):5C–9C (28 ref.)
The influence of pretreatment low density lipoprotein cholesterol concentrations on the effect of hypocholesterolemic therapy on coronary atherosclerosis in angiographic trials. Harvard Atherosclerosis Reversibility Project Research Group. Sacks FM, et al. **Am J Cardiol** 1995 Sep 28;76(9):78C–85C (30 ref.)
Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors. Garnett WR. **Am J Health Syst Pharm** 1995 Aug 1;52(15):1639–45 (44 ref.)
Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia [see comments] Hsu I, et al. **Ann Pharmacother** 1995 Jul-Aug; 29(7-8):743–59 (114 ref.) Comment in: Ann Pharmacother 1995 Dec;29(12):1304.
Fluvastatin in combination with other lipid-lowering agents. Jokubaitis LA. **Br J Clin Pract Symp Suppl** 1996 Jan; 77A:28–32 (4 ref.)
Treatment of dyslipidaemias with fluvastatin. Peters TK. **Br J Clin Pract Symp Suppl** 1996 Jan;77A:16–9 (7 ref.)
Statin therapy in clinical practice: new developments. Shepherd J. **Curr Opin Lipidol** 1995 Oct;6(5):254–5 (13 ref.)
Simvastatin. A reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolaemia. Plosker GL, et al. **Drugs** 1995 Aug;50(2):334–63 (239 ref.)
The 4S study. Implications for prescribing. van Boven AJ, et al. **Drugs** 1996 Apr;51(4):507–14 (55 ref.)
Treating elevated cholesterol levels: the great Satan in perspective. Gibaldi M, et al. **J Clin Pharmacol** 1996 Mar; 36(3):189–97 (45 ref.)
Effects of lipids on the pathogenesis of progressive renal failure: role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in the prevention of glomerulosclerosis. Guijarro C, et al. **Miner Electrolyte Metab** 1996; 22(1-3):147–52 (45 ref.)
New targets for lipid lowering and atherosclerosis prevention. Sirtori CR. **Pharmacol Ther** 1995;67(3):433–47 (108 ref.)
[Cholesterol synthesis inhibitors: lowering of cholesterol for everybody?] Westendorp RG, et al. **Ned Tijdschr Geneeskd** 1996 Feb 24;140(8):411–4 (14 ref.) **(Dut)**
[The drug therapy of hypercholesterolemia] Berthold HK, et al. **Dtsch Med Wochenschr** 1996 May 31;121(22):729–34 (30 ref.) **(Ger)**
[Drug therapy of hypercholesterolemia] Schwandt P, et al. **Wien Klin Wochenschr** 1995;107(18):544–8 (64 ref.) (Eng. Abstr.) **(Ger)**
[An update on the use of fluvastatin in primary hypercholesterolemia] Baggio G. **Ann Ital Med Int** 1995 Oct;10 Suppl:43S (5 ref.) **(Ita)**
[The pharmacological treatment of hypercholesterolemia] Pérez Jiménez F. **Rev Esp Cardiol** 1995;48 Suppl 5:31–8 (53 ref.) (Eng. Abstr.) **(Spa)**

ANTICHOLINERGIC AGENTS see CHOLINERGIC ANTAGONISTS

ANTICHOLINESTERASE AGENTS see CHOLINESTERASE INHIBITORS

ANTICIPATORY VOMITING see VOMITING, ANTICIPATORY

ANTICOAGULANTS

4th American College of Chest Physicians Consensus Conference on Antithrombotic Therapy. Tucson, Arizona, April 1995. Proceedings. **Chest** 1995 Oct;108(4 Suppl):225S–522S (0 ref.)

ADMINISTRATION & DOSAGE

Are you up to date on weight-based heparin dosing? Sparks KS. **Am J Nurs** 1996 Apr;96(4):33–6; quiz 37 (6 ref.)
Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range. Hirsh J, et al. **Chest** 1995 Oct;108(4 Suppl):231S–246S (160 ref.)
Guidelines for prevention of thromboembolic events in valvular heart disease. Study Group of the Working Group on Valvular Heart Disease of the European Society of Cardiology. Gohlke-Bärwolf C, et al. **Eur Heart J** 1995 Oct;16(10):1320–30 (165 ref.)
Surgical management of patients on warfarin sodium. Beirne OR, et al. **J Oral Maxillofac Surg** 1996 Sep;54(9):1115–8 (18 ref.)
International Normalized Ratio (INR): an improved way to monitor oral anticoagulant therapy. Oertel LB. **Nurse Pract** 1995 Sep;20(9):15–6, 21–2 (12 ref.)
Heparin dosing. Farnsworth TL. **S D J Med** 1995 Nov; 48(11):386–7 (13 ref.)
Treatment of a patient with an undefined hypercoagulable state with long-term low-molecular-weight heparin. Dobie SA, et al. **West J Med** 1996 Apr;164(4):350–3 (6 ref.)
[Duration of antivitamin K therapy in venous thromboembolic disease] Ferrari E, et al. **Arch Mal Coeur Vaiss** 1995 Dec;88(12):1891–4 (24 ref.) (Eng. Abstr.) **(Fre)**
[Prevention and treatment of thrombosis in pregnancy] Winkler UH, et al. **Geburtshilfe Frauenheilkd** 1996 Jun; 56(6):301–12 (83 ref.) (Eng. Abstr.) **(Ger)**
-Anticoagulation after intracoronary stent implantation- Bode C, et al. **Herz** 1996 Feb;21(1):60–3 (21 ref.) (Eng. Abstr.) **(Ger)**
[Recommendations for prevention of thromboembolism in heart valve diseases. Working Group on Valvular Heart Disease, European Society of Cardiology] Gohlke-Bärwolf C, et al. **Z Kardiol** 1995 Dec;84(12):1018–32 (168 ref.) (Eng. Abstr.) **(Ger)**
[Local drug administration systems, preclinical and clinical use: perspectives and limitations] Gonschior P, et al. **Z Kardiol** 1996 Mar;85(3):155–65 (59 ref.) (Eng. Abstr.) **(Ger)**
[Oral anticoagulants treatment of thrombosis] Matsuda T. **Nippon Naika Gakkai Zasshi** 1995 Sep 10;84(9):1523–7 (2 ref.) **(Jpn)**
[Anticoagulants in hemodialysis therapy] Malyszko J, et al. **Przegl Lek** 1996;53(5):454–8 (49 ref.) **(Pol)**

ADVERSE EFFECTS

Spermatic cord hematoma: case report and literature review. McKenney MG, et al. **Am Surg** 1996 Sep;62(9):768–9 (13 ref.)
Adverse interactions between warfarin and nonsteroidal antiinflammatory drugs: mechanisms, clinical significance, and avoidance [see comments] Chan TY. **Ann Pharmacother** 1995 Dec;29(12):1274–83 (89 ref.) Comment in: Ann Pharmacother 1995 Dec;29(12):1289–91.
Warfarin-induced changes in procoagulant and anticoagulant proteins. Stirling Y. **Blood Coagul Fibrinolysis** 1995 Jul; 6(5):361–73 (115 ref.)
Hemorrhagic complications of anticoagulant treatment. Levine MN, et al. **Chest** 1995 Oct;108(4 Suppl):276S–290S (118 ref.)
Anticoagulation and pregnancy. Oakley CM. **Eur Heart J**

1995 Oct;16(10):1317–9 (22 ref.)
Spinal epidural hematoma during anticoagulant therapy. A case report and review of the literature. Rodriguez y Baena R, et al. **J Neurosurg Sci** 1995 Mar;39(1):87–94 (90 ref.)
Antenatal drugs affecting vitamin K status of the fetus and the newborn. Astedt B. **Semin Thromb Hemost** 1995; 21(4):364–70 (84 ref.)
Washington's experience and recommendations Re: Anticoagulant rodenticides. Morrissey B, et al. **Vet Hum Toxicol** 1995 Aug;37(4):362–3 (4 ref.)

ANALYSIS

[Tissue factor pathway inhibitor (TFPI)] Matsuo T, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:157–61 (10 ref.) **(Jpn)**

ANTAGONISTS & INHIBITORS

Oral vitamin K1: an option to reduce warfarin's activity. Harrell CC, et al. **Ann Pharmacother** 1995 Dec; 29(12):1228–32 (26 ref.)
[Thrombophilia characterized by resistance to anticoagulants with indirect action] Barkagan ZS, et al. **Ter Arkh** 1995; 67(7):50–2 (8 ref.) (Eng. Abstr.) **(Rus)**

BLOOD

International Normalized Ratio (INR): an improved way to monitor oral anticoagulant therapy. Oertel LB. **Nurse Pract** 1995 Sep;20(9):15–6, 21–2 (12 ref.)

CHEMISTRY

Thrombin active site inhibitors. Das J, et al. **Bioorg Med Chem** 1995 Aug;3(8):999–1007 (57 ref.)

PHARMACOLOGY

Resistance to activated protein C, the FV:Q506 allele, and venous thrombosis. Dahlbäck B, et al. **Ann Hematol** 1996 Apr;72(4):166–76 (152 ref.)
Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Hirsh J, et al. **Chest** 1995 Oct;108(4 Suppl):258S–275S (268 ref.)
Thrombin inhibitors as antithrombotic agents: the importance of rapid inhibition. Stone SR, et al. **J Enzym Inhib** 1995; 9(1):3–15 (56 ref.)
Anticoagulant effects of Pseudechis australis (Australian king brown snake) venom on human blood: a computerized thromboelastography study. Dambisya YM, et al. **Toxicon** 1995 Oct;33(10):1378–82 (16 ref.)

STANDARDS

Selection of anticoagulant–preservatives for canine and feline blood storage. Wardrop KJ. **Vet Clin North Am Small Anim Pract** 1995 Nov; 25(6):1263–76 (50 ref.)
[Analysis of the individual quality of an oral anticoagulant using the ratio F1+2/INR] Bruhn HD, et al. **Dtsch Med Wochenschr** 1995 Oct 20;120(42):1441–4 (10 ref.) **(Ger)**

THERAPEUTIC USE

Prevention of thromboembolic events in valvular heart disease. Gohlke-Bärwolf C, et al. **Acta Cardiol** 1996; 51(2):129–42 (37 ref.)
Relation between systemic anticoagulation as determined by activated partial thromboplastin time and heparin measurements and in-hospital clinical events in unstable angina and non-Q wave myocardiaL infarction. Thrombolysis in Myocardial Ischemia III B Investigators. Becker RC, et al. **Am Heart J** 1996 Mar;131(3):421–33 (66 ref.)
Atrial fibrillation, anticoagulation, and stroke. Morley J, et al. **Am J Cardiol** 1996 Jan 25;77(3):38A–44A (29 ref.)
Atrial fibrillation: restoration and maintenance of sinus rhythm and indications for anticoagulation therapy. Golzari H, et al. **Ann Intern Med** 1996 Aug 15;125(4):311–23 (205 ref.)
Activated clotting time versus activated partial thromboplastin time for therapeutic monitoring of heparin [see comments] Simko RJ, et al. **Ann Pharmacother** 1995 Oct;29(10):1015–21; quiz 1061 (36 ref.) Comment in: Ann Pharmacother 1995 Oct;29(10):1045–6.
Anticoagulation. Chong BH. **Aust Fam Physician** 1996 Jan; 25(1):74–8 (8 ref.)
ABC of atrial fibrillation. Antithrombotic treatment for atrial fibrillation. Lip GY, et al. **BMJ** 1996 Jan 6;312(7022):45–9 (0 ref.)
Anticoagulants in pregnancy. Oakley CM. **Br Heart J** 1995 Aug;74(2):107–11 (54 ref.)
Warfarin and aspirin as thromboprophylaxis in atrial fibrillation. Lip GY, et al. **Br J Clin Pharmacol** 1996 May; 41(5):369–79 (83 ref.)
Anticoagulant therapy in ischaemic heart disease in seafarers. Częstochowska E. **Bull Inst Marit Trop Med Gdynia** 1993–94;44–45(1–4):13–5 (10 ref.)
Antithrombotic therapy in atrial fibrillation. Turpie AG, et al. **Can Fam Physician** 1996 Jul;42:1341–5 (16 ref.)
Thrombin inhibitors in acute myocardial infarction. Cannon CP. **Cardiol Clin** 1995 Aug;13(3):421–33 (73 ref.)
Antiplatelet and anticoagulant use after myocardial infarction. Almony GT, et al. **Clin Cardiol** 1996 May; 19(5):357–65 (109 ref.)
Anticoagulation: risks and benefits in atrial fibrillation. Fiore LD. **Geriatrics** 1996 Jun;51(6):22–4, 27–8, 31 (37 ref.)
Low molecular weight heparins in the initial treatment of deep vein thrombosis. Volteas SK, et al. **Int Angiol** 1996 Mar;15(1):67–74 (46 ref.)
Maintaining blood flow in the extracorporeal circuit: haemostasis and anticoagulation. Webb AR, et al. **Intensive Care Med** 1995 Jan;21(1):84–93 (77 ref.)
Contemporary use of and future roles for heparin in antithrombotic therapy. Gibaldi M, et al. **J Clin Pharmacol** 1995 Nov;35(11):1031–45 (67 ref.)
Optimization of oral anticoagulation for patients with mechanical heart valve prostheses. Piper C, et al. **J Heart Valve Dis** 1995 Mar;4(2):127–37 (83 ref.)
Guidelines for anticoagulation therapy in pregnancy. Ryan K, et al. **JPMA J Pak Med Assoc** 1995 May;45(5):133–6 (4 ref.)
Outpatient anticoagulation issues for the primary care physician. Spandorfer JM, et al. **Med Clin North Am** 1996 Mar;80(2):475–91 (79 ref.)
Heparin therapy: current regimens and principles of monitoring. Berry BR, et al. **Postgrad Med** 1996 Jun; 99(6):64–6, 69–76 (19 ref.)
Oral anticoagulant therapy: practical aspects of management. Brigden ML. **Postgrad Med** 1996 Jun;99(6):81–4, 87–9, 93–4 passim (22 ref.)
New developments in acute anticoagulation therapy: what improvements over traditional heparin are on the horizon? Carter CJ. **Postgrad Med** 1996 Jun;99(6):129–36 (22 ref.)
Cardioversion of atrial fibrillation. Lip GY. **Postgrad Med J** 1995 Aug;71(838):457–65 (68 ref.)
Current recommendations for the anticoagulation of patients with atrial fibrillation. Orsinelli DA. **Prog Cardiovasc Dis** 1996 Jul–Aug;39(1):1–20 (52 ref.)
Anticoagulant therapy for deep vein thrombosis: its proper application. Rohrer MJ, et al. **Semin Vasc Surg** 1996 Mar; 9(1):13–20 (38 ref.)
Anticoagulation for prevention of cerebral infarcts following subarachnoid hemorrhage. Wang DZ, et al. **Surg Neurol** 1995 Sep;44(3):270–4 (22 ref.)
Current status of anticoagulation and thrombosis-related issues in mechanical valves. Gray RJ. **Tex Heart Inst J** 1996;23(1):36–41 (34 ref.)
Oral anticoagulant treatment with and without aspirin. Altman R, et al. **Thromb Haemost** 1995 Jul;74(1):506–10 (37 ref.)
Atrial fibrillation pearls and perils of management. Kudenchuk PJ. **West J Med** 1996 May;164(5):425–34 (109 ref.)
[Anticoagulation in cardiology] Meier B. **Ann Cardiol Angeiol (Paris)** 1995 Dec;44(10):567–77 (53 ref.) (Eng. Abstr.) **(Fre)**
[Antithrombotic treatment of atrial fibrillation] Connelly SJ, et al. **Can J Cardiol** 1996 Feb;12 Suppl A:14A–18A (13 ref.) **(Fre)**
[Therapeutic role of coagulation in small cell lung cancers] LeBeau B. **Rev Mal Respir** 1996;13(1):21–6 (41 ref.) (Eng. Abstr.) **(Fre)**
[The treatment of deep venous thrombosis with low-molecular-weight heparin] Samama MM, et al. **Rev Med Brux** 1995 Jul–Aug;16(4):304–9 (30 ref.) (Eng. Abstr.) **(Fre)**
-Anticoagulant drugs- Gulba DC. **Herz** 1996 Feb; 21(1):12–27 (164 ref.) (Eng. Abstr.) **(Ger)**
-New perspectives in therapy of unstable angina- Hamm CW. **Herz** 1996 Feb;21(1):37–43 (69 ref.) (Eng. Abstr.) **(Ger)**
[Anticoagulation in patients with atrial fibrillation] Mügge A. **Herz** 1996 Feb;21(1):28–36 (60 ref.) (Eng. Abstr.) **(Ger)**
[Drug therapy of deep venous thrombosis] Bounameaux H. **Ther Umsch** 1996 Apr;53(4):272–6 (16 ref.) (Eng. Abstr.) **(Ger)**
[Blood thinning in heart patients] Meier B. **Ther Umsch** 1995 Oct;52(10):661–71 (55 ref.) (Eng. Abstr.) **(Ger)**
[New aspects of blood coagulation inhibitory therapy within the scope of percutaneous transluminal coronary angioplasty (PTCA)] Schächinger V, et al. **Z Kardiol** 1995 Sep;84(9):651–67 (152 ref.) (Eng. Abstr.) **(Ger)**
[Emergency therapy of disseminated intravascular coagulation] Yawata Y. **Nippon Naika Gakkai Zasshi** 1995 Nov 10;84(11):1858–64 (5 ref.) **(Jpn)**
[Atrial fibrillation due to non-valvular causes: indications for antithrombotic therapy] Codinach Huix P. **Med Clin (Barc)** 1996 Apr 20;106(15):586–9 (25 ref.) **(Spa)**
[Guidelines for the management of acute cerebrovascular disease in patients] Alonso de Leciñana M, et al. **Rev Neurol** 1995 Mar–Apr;23(120):363–9 (54 ref.) (Eng. Abstr.) **(Spa)**

ANTICONVULSANTS

New antiepileptic drugs. Dichter MA, et al. **N Engl J Med** 1996 Jun 13;334(24):1583–90 (101 ref.)
[Drug-resistant epilepsy in adults] Loiseau P, et al. **Rev Neurol (Paris)** 1995 May;151(5):295–306 (96 ref.) (Eng. Abstr.) **(Fre)**

ADMINISTRATION & DOSAGE

Vigabatrin: effect on brain GABA levels measured by nuclear magnetic resonance spectroscopy. Mattson RH, et al. **Acta Neurol Scand Suppl** 1995;162:27–30 (16 ref.)
Established role of magnesium sulfate as prophylactic anticonvulsive agent in preeclampsia/eclampsia. Skajaa K. **Acta Obstet Gynecol Scand** 1996 Apr;75(4):313–5 (18 ref.)
[Discontinuation of epilepsy drug therapy] Keränen T. **Duodecim** 1994;110(18):1725–9 (26 ref.) **(Fin)**
[Epilepsy is difficult to treat during an attack of porphyria] Bylesjö EI, et al. **Lakartidningen** 1996 Jun 26; 93(26–27):2506–8 (15 ref.) **(Swe)**

ADVERSE EFFECTS

Behavioural abnormalities and retention rates of anti-epilepsy drugs during long-term treatment of epilepsy: a clinical perspective. Schmidt D. **Acta Neurol Scand Suppl** 1995; 162:7–10 (28 ref.)
Prenatal exposure to phenytoin, facial development, and a possible role for vitamin K. Howe AM, et al. **Am J Med Genet** 1995 Sep 11;58(3):238–44 (52 ref.)
Hand anomalies in fetal-hydantoin syndrome: from nail/phalangeal hypoplasia to unilateral acheiria [letter] Sabry MA, et al. **Am J Med Genet** 1996 Apr 24;62(4):410–2 (34 ref.)
Vigabatrin-associated reversible acute psychosis in a child. Cánovas Martínez A, et al. **Ann Pharmacother** 1995 Nov; 29(11):1115–7 (10 ref.)
Systemic corticosteroids in the phenytoin hypersensitivity syndrome. Chopra S, et al. **Br J Dermatol** 1996 Jun; 134(6):1109–12 (19 ref.)
Gabapentin: pharmacokinetics, efficacy, and safety. Beydoun A, et al. **Clin Neuropharmacol** 1995 Dec;18(6):469–81 (61 ref.)
Anticonvulsant hypersensitivity syndrome. Licata AL, et al. **Compr Ther** 1996 Mar;22(3):152–5 (22 ref.)
Update in the treatment of epilepsy. Schachter SC. **Compr Ther** 1995 Sep;21(9):473–9 (7 ref.)
Dilantin hypersensitivity reaction. Conger LA Jr, et al. **Cutis** 1996 Apr;57(4):223–6 (32 ref.)
Oropharyngeal dysphagia due to iatrogenic neurological dysfunction. Buchholz DW. **Dysphagia** 1995 Fall; 10(4):248–54 (51 ref.)
Cognitive and behavioral effects of antiepileptic drugs. Devinsky O. **Epilepsia** 1995;36 Suppl 2:S46–65 (106 ref.)
Efficacy and adverse effects of established and new antiepileptic drugs. Mattson RH. **Epilepsia** 1995;36 Suppl 2:S13–26 (108 ref.)
Cognitive side-effects of chronic antiepileptic drug treatment: a review of 25 years of research. Vermeulen J, et al. **Epilepsy Res** 1995 Oct;22(2):65–95 (130 ref.)
Lymphoblastic lymphoma following prenatal exposure to phenytoin. Murray JC, et al. **J Pediatr Hematol Oncol** 1996 May;18(2):241–3 (23 ref.)
Adverse effects of established and new antiepileptic drugs: an attempted comparison. Rogvi-Hansen B, et al. **Pharmacol Ther** 1995;68(3):425–34 (98 ref.)
Antenatal drugs affecting vitamin K status of the fetus and the newborn. Astedt B. **Semin Thromb Hemost** 1995; 21(4):364–70 (84 ref.)
[Side effects of phenytoin and carbamazepine on cognitive functioning] Pulliainen V, et al. **Duodecim** 1994; 110(14):1320–8 (44 ref.) **(Fin)**
[Multiple myeloma associated with phenytoin (diphenylhydantoin) therapy] Kanoh T, et al. **Rinsho Ketsueki** 1996 Mar;37(3):239–43 (15 ref.) (Eng. Abstr.) **(Jpn)**
[Acute pancreatitis caused by valproic acid: apropos a case] Bahamonde Carrasco A, et al. **Gastroenterol Hepatol** 1996 May;19(5):253–4 (21 ref.) (Eng. Abstr.) **(Spa)**

BLOOD

[Phenytoin] Furuno K, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:924–7 (21 ref.) **(Jpn)**
[Primidone] Furuno K, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:928–30 (21 ref.) **(Jpn)**
[Carbamazepine] Gomita Y, et al. **Nippon Rinsho** 1995 Feb; 53 Su Pt 1:907–10 (8 ref.) **(Jpn)**
[Ethosuximide] Ichiba M, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:915–7 (8 ref.) **(Jpn)**
[Phenobarbital] Kawasaki H, et al. **Nippon Rinsho** 1995 Feb; 53 Su Pt 1:921–3 (12 ref.) **(Jpn)**
[Valproic acid] Kohda Y. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:918–20 (10 ref.) **(Jpn)**
[Zonisamide] Shuto H, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:931–3 (6 ref.) **(Jpn)**
[Clonazepam, nitrazepam, diazepam] Yasuda K. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:911–4 (19 ref.) **(Jpn)**

PHARMACOKINETICS

Pharmacokinetic and pharmacodynamic drug interactions during treatment with vigabatrin. Richens A. **Acta Neurol Scand Suppl** 1995;162:43–6 (16 ref.)
Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part II. Phenytoin, carbamazepine, sulthiame, lamotrigine, vigabatrin, oxcarbazepine and felbamate. Battino D, et al. **Clin Pharmacokinet** 1995 Nov;29(5):341–69 (126 ref.)
Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part I: Phenobarbital, primidone, valproic acid, ethosuximide and mesuximide. Battino D, et al. **Clin Pharmacokinet** 1995 Oct;29(4):257–86 (136 ref.)

Phenytoin disposition and toxicity: role of pharmacogenetic and interethnic factors. Edeki TI, et al. **Drug Metab Rev** 1995;27(3):449–69 (89 ref.)
Pharmacokinetic optimisation of drug therapy in elderly patients. Parker BM, et al. **Drugs Aging** 1995 Jul;7(1):10–8 (38 ref.)
Drug interaction profile of topiramate. Bourgeois BF. **Epilepsia** 1996;37 Suppl 2:S14–S17 (23 ref.)
Important pharmacokinetic properties of antiepileptic drugs. Bourgeois BF. **Epilepsia** 1995;36 Suppl 5:S1–7 (17 ref.)
Neuropharmacology and drug interactions in clinical practice. Graves NM. **Epilepsia** 1995;36 Suppl 2:S27–33 (20 ref.)
Pharmacokinetic profile of topiramate in comparison with other new antiepileptic drugs. Perucca E. **Epilepsia** 1996; 37 Suppl 2:S8–S13 (55 ref.)
The effect of age on pharmacokinetics of antiepileptic drugs. Willmore LJ. **Epilepsia** 1995;36 Suppl 5:S14–21 (72 ref.)
Pharmacology and pharmacokinetics of fosphenytoin. Browne TR, et al. **Neurology** 1996 Jun;46(6 Suppl 1):S3–7 (48 ref.)
Clinical pharmacokinetics of new antiepileptic drugs. Walker MC, et al. **Pharmacol Ther** 1995;67(3):351–84 (164 ref.)

PHARMACOLOGY

Mechanism of action of antiepileptic and antimyoclonic drugs. Pranzatelli MR, et al. **Adv Neurol** 1995;67:329–60 (251 ref.)
Neuroprotective properties of the uncompetitive NMDA receptor antagonist remacemide hydrochloride. Palmer GC, et al. **Ann N Y Acad Sci** 1995 Sep 15;765:236–47; discussion 248 (38 ref.)
Phenytoin–folic acid interaction [see comments] Lewis DP, et al. **Ann Pharmacother** 1995 Jul–Aug;29(7–8):726–35 (65 ref.) Comment in: Ann Pharmacother 1995 Dec;29(12):1303–4.
Gabapentin: pharmacokinetics, efficacy, and safety. Beydoun A, et al. **Clin Neuropharmacol** 1995 Dec;18(6):469–81 (61 ref.)
Tiagabine pharmacology in profile. Brodie MJ. **Epilepsia** 1995;36 Suppl 6:S7–S9 (18 ref.)
Antiepileptic drug mechanisms of action. Macdonald RL, et al. **Epilepsia** 1995;36 Suppl 2:S2–12 (112 ref.)
Antiepileptic drugs and mechanisms of epileptogenesis. A review. Mutani R, et al. **Ital J Neurol Sci** 1995 May; 16(4):217–22 (51 ref.)
Neurochemical correlates of antiepileptic drugs in the genetically epilepsy-prone rat (GEPR). Dailey JW, et al. **Life Sci** 1995;58(4):259–66 (49 ref.)
Pharmacology and pharmacokinetics of fosphenytoin. Browne TR, et al. **Neurology** 1996 Jun;46(6 Suppl 1):S3–7 (48 ref.)
Cognitive effects of vigabatrin: a review. Monaco F. **Neurology** 1996 Jul;47(1 Suppl 1):S6–11 (71 ref.)
NMDA antagonists: antiepileptic–neuroprotective drugs with diversified neuropharmacological profiles. Sagratella S. **Pharmacol Res** 1995 Jul–Aug;32(1–2):1–13 (124 ref.)
Excitatory amino acid antagonists and the anticonvulsive activity of conventional antiepileptic drugs. Kleinrok Z, et al. **Pol J Pharmacol** 1995 May–Jun;47(3):247–52 (47 ref.)
[Interaction of sleep, epilepsy and antiepileptic drugs in an adult] Salas Puig J. **Rev Neurol** 1995 Nov–Dec; 23(124):1287–9 (10 ref.) **(Spa)**

THERAPEUTIC USE

Rationalized polytherapy for epilepsy. Goldsmith P, et al. **Acta Neurol Scand Suppl** 1995;162:35–9 (27 ref.)
Pharmacological principles as a basis for polytherapy. Perucca E. **Acta Neurol Scand Suppl** 1995;162:31–4 (16 ref.)
Clinical use of drugs useful in the treatment of atonic seizures. Bourgeois B. **Adv Neurol** 1995;67:361–7 (42 ref.)
Second-line and 'alternative' treatments for alcohol withdrawal: alpha-agonists, beta-blockers, anticonvulsants, acupuncture and neuro-electric therapy. Brewer C. **Alcohol Alcohol** 1995 Nov;30(6):799–803 (25 ref.)
The management of alcohol withdrawal using chlormethiazole. Morgan MY. **Alcohol Alcohol** 1995 Nov; 30(6):771–4 (21 ref.)
Potential use of gabapentin and lamotrigine. Cory PR, et al. **Ann Pharmacother** 1995 Nov;29(11):1160–1 (10 ref.)
Possible interaction involving phenytoin, dexamethasone, and antineoplastic agents: a case report and review. Gattis WA, et al. **Ann Pharmacother** 1996 May;30(5):520–6 (20 ref.)
Acetazolamide in the treatment of seizures. Reiss WG, et al. **Ann Pharmacother** 1996 May;30(5):514–9 (68 ref.)
Anticonvulsant drugs for management of pain: a systematic review. McQuay H, et al. **BMJ** 1995 Oct 21; 311(7012):1047–52 (53 ref.)
Magnesium sulphate: the time of reckoning [see comments] Robson SC. **Br J Obstet Gynaecol** 1996 Feb;103(2):99–102 (30 ref.) Comment in: Br J Obstet Gynaecol 1996 Feb;103(2):vii–viii.
New drugs for the treatment of epilepsy. Fraser AD. **Clin Biochem** 1996 Apr;29(2):97–110 (114 ref.)
The role of therapeutic drug monitoring in improving the cost effectiveness of anticonvulsant therapy. Eadie MJ. **Clin Pharmacokinet** 1995 Jul;29(1):29–35 (26 ref.)
Update in the treatment of epilepsy. Schachter SC. **Compr Ther** 1995 Sep;21(9):473–9 (7 ref.)
Lamotrigine. An update of its pharmacology and therapeutic use in epilepsy. Fitton A, et al. **Drugs** 1995 Oct; 50(4):691–713 (175 ref.)
Vigabatrin. Ben-Menachem E. **Epilepsia** 1995;36 Suppl 2:S95–104 (70 ref.)
Antiepileptic drugs in pediatric practice. Bourgeois BF. **Epilepsia** 1995;36 Suppl 2:S34–45 (100 ref.)
Antiepileptic drug therapy: when is epilepsy truly intractable? Camfield PR, et al. **Epilepsia** 1996;37 Suppl 1:S60–5 (18 ref.)
Rational polypharmacy. Ferrendelli JA. **Epilepsia** 1995;36 Suppl 2:S115–8 (11 ref.)
Clobazam, oxcarbazepine, tiagabine, topiramate, and other new antiepileptic drugs. Fisher R, et al. **Epilepsia** 1995;36 Suppl 2:S105–14 (113 ref.)
Neuropharmacology and drug interactions in clinical practice. Graves NM. **Epilepsia** 1995;36 Suppl 2:S27–33 (20 ref.)
Felbamate. Leppik IE. **Epilepsia** 1995;36 Suppl 2:S66–72 (55 ref.)
Gabapentin. McLean MJ. **Epilepsia** 1995;36 Suppl 2:S73–86 (70 ref.)
Efficacy and adverse effects of established and new antiepileptic drugs. Mattson RH. **Epilepsia** 1995;36 Suppl 2:S13–26 (108 ref.)
Lamotrigine. Messenheimer JA. **Epilepsia** 1995;36 Suppl 2:S87–94 (64 ref.)
Status epilepticus and acute repetitive seizures in children, adolescents, and young adults: etiology, outcome, and treatment. Mitchell WG. **Epilepsia** 1996;37 Suppl 1:S74–80 (53 ref.)
Utilization of new antiepileptic drugs in children. Pellock JM. **Epilepsia** 1996;37 Suppl 1:S66–73 (-0 ref.)
Does antiepileptic drug therapy prevent the development of "chronic" epilepsy? Shinnar S, et al. **Epilepsia** 1996 Aug; 37(8):701–8 (92 ref.)
The epidemiology and treatment of chronic and refractory epilepsy. Shorvon SD. **Epilepsia** 1996;37 Suppl 2:S1–S3 (6 ref.)
Psychopharmacology in child and adolescent psychiatry: a review of the past seven years. Part II. Campbell M, et al. **J Am Acad Child Adolesc Psychiatry** 1995 Oct; 34(10):1262–72 (138 ref.)
Managing patients who have seizure disorders: dental and medical issues. Sanders BJ, et al. **J Am Dent Assoc** 1995 Dec;126(12):1641–7 (18 ref.)
Anticonvulsant and other non-neuroleptic treatment of agitation in dementia. Tariot PN, et al. **J Geriatr Psychiatry Neurol** 1995 Oct;8 Suppl 1:S28–39 (103 ref.)
Does early anti-epileptic drug treatment alter the prognosis for remission of the epilepsies? O'Donoghue M, et al. **J R Soc Med** 1996 May;89(5):245–8 (38 ref.)
Selection of antiepileptic drugs: a practical approach. Britton JW, et al. **Mayo Clin Proc** 1996 Aug;71(8):778–86 (76 ref.)
Antiepileptic drugs [published erratum appears in N Engl J Med 1996 Feb 15;334(7):479] Brodie MJ, et al. **N Engl J Med** 1996 Jan 18;334(3):168–75 (83 ref.)
Parenteral antiepileptic/anticonvulsant drugs. Mattson RH. **Neurology** 1996 Jun;46(6 Suppl 1):S8–13 (42 ref.)
Cognitive effects of vigabatrin: a review. Monaco F. **Neurology** 1996 Jul;47(1 Suppl 1):S6–11 (71 ref.)
Fosphenytoin use in children. Pellock JM. **Neurology** 1996 Jun;46(6 Suppl 1):S14–6 (8 ref.)
Intravenous administration of fosphenytoin: options for the management of seizures. Ramsay RE, et al. **Neurology** 1996 Jun;46(6 Suppl 1):S17–9 (12 ref.)
Emergency treatment of status epilepticus. Runge JW, et al. **Neurology** 1996 Jun;46(6 Suppl 1):S20–3 (25 ref.)
Intramuscular use of fosphenytoin: an overview. Uthman BM, et al. **Neurology** 1996 Jun;46(6 Suppl 1):S24–8 (28 ref.)
Treatment of childhood epilepsy. Appleton RE. **Pharmacol Ther** 1995;67(3):419–31 (72 ref.)
Interactions involving new antiepileptic drugs. Mawer GE, et al. **Pharmacol Ther** 1995;68(2):209–31 (110 ref.)
Carbamazepine clinical pharmacology: a review. Albani F, et al. **Pharmacopsychiatry** 1995 Nov;28(6):235–44 (189 ref.)
Design of clinical antiepileptic drug trials. Binnie CD. **Seizure** 1995 Sep;4(3):187–92 (14 ref.)
Management issues in severe childhood epilepsies. Wallace SJ. **Seizure** 1995 Sep;4(3):215–20 (46 ref.)
Clonazepam-sensitive intermittent dystonic tremor. Davis TL, et al. **South Med J** 1995 Oct;88(10):1069–71 (16 ref.)
Treatment of acute isoniazid overdose in dogs. Villar D, et al. **Vet Hum Toxicol** 1995 Oct;37(5):473–7 (50 ref.)
[Withdrawal of antiepileptic treatment] Balslev T. **Ugeskr Laeger** 1996 Apr 1;158(14):1961–4 (24 ref.) (Eng. Abstr.) **(Dan)**
[Current anti-epilepsy drugs] Iivanainen M, et al. **Duodecim** 1995;111(8):751–8 (30 ref.) **(Fin)**
[XIV Consensus Conference on Intensive care and emergency medicine. Management of status epilepticus (children–adults). 23 June 1995, Le Kremlin–Bicêtre] **Ann Fr Anesth Reanim** 1996;15(1):106–9 (0 ref.) **(Fre)**
[Current viewpoints in the treatment of epilepsies: role of new antiepileptics?] Despland PA. **Schweiz Rundsch Med Prax** 1995 Sep 19;84(38):1036–41 (51 ref.) (Eng. Abstr.) **(Fre)**
[Value of old and new anticonvulsants in treatment of psychiatric diseases] Walden J, et al. **Fortschr Neurol Psychiatr** 1995 Aug;63(8):320–35 (185 ref.) (Eng. Abstr.) **(Ger)**
[Therapy of epilepsy: trends and effectiveness of new anticonvulsants] Scollo-Lavizzari G, et al. **Schweiz Arch Neurol Psychiatr** 1995;146(4):168–73 (27 ref.) (Eng. Abstr.) **(Ger)**
[Gabapentin (Neurontin): a new possibility in the add-on therapy of partial epilepsies] Krämer G. **Schweiz Rundsch Med Prax** 1996 Jan 23;85(4):84–93 (106 ref.) (Eng. Abstr.) **(Ger)**
[Treatment of epilepsy: where are we today?] Wieser HG. **Schweiz Rundsch Med Prax** 1996 Jan 23;85(4):74–9 (29 ref.) (Eng. Abstr.) **(Ger)**
[Drug treatment after a first unprovoked epileptic seizure] Gilad R, et al. **Harefuah** 1995 Jun 15;128(12):806–8 (19 ref.) **(Heb)**
[Diagnosis and treatment of drug-resistant epilepsy] Arroyo S. **Neurologia** 1996 Feb;11(2):56–68 (137 ref.) (Eng. Abstr.) **(Spa)**
[Refractory epilepsy in adults and the new antiepileptic drugs: the role of gabapentin] Galdames D, et al. **Rev Med Chil** 1995 Apr;123(4):500–8 (34 ref.) (Eng. Abstr.) **(Spa)**
[Pharmacological treatment of migraine: other treatments] Gómez Aranda F, et al. **Rev Neurol** 1995;23 Suppl 2:S198–200 (43 ref.) **(Spa)**
[The concept and treatment of drug-resistant intractable epilepsy] Iváñez V. **Rev Neurol** 1995 Nov–Dec; 23(124):1214–9 (85 ref.) (Eng. Abstr.) **(Spa)**
[Advances in the diagnostic and treatment of infantile epilepsy] Legido A. **Rev Neurol** 1996 Jun;24(130):688–93 (25 ref.) **(Spa)**
[Neonatal seizures: diagnostic and therapeutic controversies] Legido A. **Rev Neurol** 1996 Jun;24(130):694–700 (40 ref.) **(Spa)**
[Felbamate: perspectives for new antiepileptic treatment] Pérez-Miranda J, et al. **Rev Neurol** 1995 Nov–Dec; 23(124):1220–5 (46 ref.) (Eng. Abstr.) **(Spa)**
[Interaction of sleep, epilepsy and antiepileptic drugs in an adult] Salas Puig J. **Rev Neurol** 1995 Nov–Dec; 23(124):1287–9 (10 ref.) **(Spa)**

TOXICITY

Phenytoin disposition and toxicity: role of pharmacogenetic and interethnic factors. Edeki TI, et al. **Drug Metab Rev** 1995;27(3):449–69 (89 ref.)
Pathogenesis of drug-induced gingival overgrowth. A review of studies in the rat model. Nishikawa S, et al. **J Periodontol** 1996 May;67(5):463–71 (94 ref.)

ANTIDEPRESSANTS see **ANTIDEPRESSIVE AGENTS**

ANTIDEPRESSANTS, ATYPICAL see **ANTIDEPRESSIVE AGENTS, SECOND-GENERATION**

ANTIDEPRESSANTS, TRICYCLIC see **ANTIDEPRESSIVE AGENTS, TRICYCLIC**

ANTIDEPRESSIVE AGENTS

see related

MONOAMINE OXIDASE INHIBITORS

Prospects for improved antidepressants. Broekkamp CL, et al. **J Med Chem** 1995 Nov 10;38(23):4615–33 (196 ref.)
Phosphodiesterase type IV inhibitors. Palfreyman MN, et al. **Prog Med Chem** 1996;33:1–52 (306 ref.)
[Peripeteia in the development of new antidepressive agents in the early 1990s] Svestka J. **Ceska Slov Psychiatr** 1995 Nov;91(5):282–90 (88 ref.) **(Cze)**
[New antidepressive agents] LaBranche S. **Union Med Can** 1995 Nov;124(3):8–13 (23 ref.) **(Fre)**

ADMINISTRATION & DOSAGE

Maintenance therapies for late-life recurrent major depression: research and review circa 1995. Reynolds CF 3rd, et al. **Int Psychogeriatr** 1995;7 Suppl:27–39 (27 ref.)
[Delay in the effect of antidepressive agents: pharmacologic approach] Allain H, et al. **Encephale** 1995 Mar;21 Spec No 2:9–15 (39 ref.) (Eng. Abstr.) **(Fre)**
[Practical considerations in initial treatment] Allilaire JF. **Encephale** 1995 Mar;21 Spec No 2:23–9 (0 ref.) (Eng. Abstr.) **(Fre)**
[The long-term course of depression (epidemiology and clinical aspects)] Cardot H, et al. **Encephale** 1995 Mar;21 Spec No 2:51–9 (77 ref.) (Eng. Abstr.) **(Fre)**
[Delay of the antidepressant effect: clinical studies] Escande M, et al. **Encephale** 1995 Mar;21 Spec No 2:3–8 (30 ref.) (Eng. Abstr.) **(Fre)**
[Consolidation treatment. The status in dysthymia] Hardy P. **Encephale** 1995 Mar;21 Spec No 2:39–42 (15 ref.) (Eng. Abstr.) **(Fre)**
[Initiating thymoregulator treatment] Olié JP, et al. **Encephale** 1995 Mar;21 Spec No 2:71–8 (86 ref.) (Eng. Abstr.) **(Fre)**
[Efficacy of antidepressants and thymoregulators in the long-term evolution of depression] Pringuey D, et al. **Encephale** 1995 Mar;21 Spec No 2:61–70 (18 ref.) (Eng. Abstr.) **(Fre)**
[Long-term clinical effects of antidepressive agents] Sechter D. **Encephale** 1995 Mar;21 Spec No 2:35–8 (14 ref.) (Eng. Abstr.) **(Fre)**

ADVERSE EFFECTS

Clinical implications of antidepressant drug effects on sexual function. Harvey KV, et al. **Ann Clin Psychiatry** 1995 Dec;

7(4):189–201 (107 ref.)
Discontinuation reactions following sertraline. Leiter FL, et al. **Biol Psychiatry** 1995 Nov 15;38(10):694–5 (7 ref.)
Photosensitivity associated with antipsychotics, antidepressants and anxiolytics. Harth Y, et al. **Drug Saf** 1996 Apr;14(4):252–9 (47 ref.)
Antidepressant-induced hyponatraemia in the aged. Avoidance and management strategies. Sharma H, et al. **Drugs Aging** 1996 Jun;8(6):430–5 (26 ref.)
The safety and tolerability of citalopram. Muldoon C. **Int Clin Psychopharmacol** 1996 Mar;11 Suppl 1:35–40 (17 ref.)
Do antidepressants cause, promote, or inhibit cancers? Steingart AB, et al. **J Clin Epidemiol** 1995 Nov; 48(11):1407–12 (43 ref.)
Tolerability and safety: essentials in antidepressant pharmacotherapy. Lader MH. **J Clin Psychiatry** 1996;57 Suppl 2:39–44 (26 ref.)
Moclobemide safety: monitoring a newly developed product in the 1990s. Hilton S, et al. **J Clin Psychopharmacol** 1995 Aug;15(4 Suppl 2):76S–83S (28 ref.)
Antidepressant-induced orgasm disorder. Segraves RT. **J Sex Marital Ther** 1995 Fall;21(3):192–201 (81 ref.)
[Inhibition of saliva secretion caused by antidepressive drugs; a risk for oral health] Peeters FP, et al. **Ned Tijdschr Geneeskd** 1996 Mar 9;140(10):533–6 (25 ref.) **(Dut)**
[Sleep, depression and antidepressive treatments (2)] Arriaga F. **Acta Med Port** 1995 Mar;8(3):181–6 (73 ref.) (Eng. Abstr.) **(Por)**

BLOOD

[Lithium carbonate] Higuchi S, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:942–4 (9 ref.) **(Jpn)**

CLASSIFICATION

The future of antidepressants. Bourin M, et al. **Biomed Pharmacother** 1996;50(1):7–12 (53 ref.)

DIAGNOSTIC USE

Novel therapeutic and diagnostic applications of hypocrellins and hypericins. Diwu Z. **Photochem Photobiol** 1995 Jun; 61(6):529–39 (118 ref.)

ECONOMICS

Pharmacoeconomic issues in the treatment of depression. Saklad SR. **Pharmacotherapy** 1995 Nov–Dec;15(6 Pt 2):76S–83S (24 ref.)

PHARMACOKINETICS

Antidepressants and drug-metabolizing enzymes—expert group report. Meyer UA, et al. **Acta Psychiatr Scand** 1996 Feb;93(2):71–9 (45 ref.)
Principles to optimize drug treatment in the depressed elderly: practical pharmacokinetics and drug interactions. Cohen LJ. **Geriatrics** 1995 Oct;50 Suppl 1:S32–40 (33 ref.)

PHARMACOLOGY

Newer antidepressants and the cytochrome P450 system. Nemeroff CB, et al. **Am J Psychiatry** 1996 Mar; 153(3):311–20 (101 ref.)
The P-450 system. Definition and relevance to the use of antidepressants in medical practice. Goldberg RJ. **Arch Fam Med** 1996 Jul–Aug;5(7):406–12 (104 ref.)
Managing selective serotonin reuptake inhibitor-drug interactions in clinical practice. Rosenbaum JR. **Clin Pharmacokinet** 1995;29 Suppl 1:53–9 (17 ref.)
Metabolism of drugs by cytochrome P450 3A isoforms. Implications for drug interactions in psychopharmacology. von Moltke LL, et al. **Clin Pharmacokinet** 1995;29 Suppl 1:33–43; discussion 43–4 (66 ref.)
Antidepressants and hypothalamic–pituitary–adrenocortical regulation. Holsboer F, et al. **Endocr Rev** 1996 Apr; 17(2):187–205 (237 ref.)
Are pharmacokinetic drug interactions with the SSRIs an issue? Brøsen K. **Int Clin Psychopharmacol** 1996 Mar;11 Suppl 1:23–7 (9 ref.)
Does selectivity matter? Deakin JFW. **Int Clin Psychopharmacol** 1996 Mar;11 Suppl 1:13–7 (12 ref.)
Serotonin: current understanding and the way forward. Dinan TG. **Int Clin Psychopharmacol** 1996 Mar;11 Suppl 1:19–21 (10 ref.)
Do antidepressants cause, promote, or inhibit cancers? Steingart AB, et al. **J Clin Epidemiol** 1995 Nov; 48(11):1407–12 (43 ref.)
Adrenoceptors and serotonin receptor function: relevance to antidepressant mechanisms of action. Potter WZ. **J Clin Psychiatry** 1996;57 Suppl 4:4–8 (45 ref.)
Effects of antidepressants on cognitive functions: a review. Amado-Boccara I, et al. **Neurosci Biobehav Rev** 1995 Fall; 19(3):479–93 (68 ref.)
Central noradrenergic neurones and stress. Stanford SC. **Pharmacol Ther** 1995;68(2):297–42 (360 ref.)
Recent advances in the GABA-A-benzodiazepine receptor pharmacology. Kostowski W. **Pol J Pharmacol** 1995 May–Jun;47(3):237–46 (57 ref.)
Administration of antidepressants, diazepam and psychomotor stimulants further confirms the utility of Flinders Sensitive Line rats as an animal model of depression. Overstreet DH, et al. **Psychopharmacology (Berl)** 1995 Sep;121(1):27–37 (62 ref.)
[Antidepressants and migraine] Legarda I. **Rev Neurol** 1995; 23 Suppl 2:S193–7 (47 ref.) **(Spa)**

THERAPEUTIC USE

Interactions with drugs used in the treatment of depressive illness. D'Arcy PF, et al. **Adverse Drug React Toxicol Rev** 1995 Winter;14(4):211–31 (160 ref.)
Panic disorder [see comments] Weinstein RS. **Am Fam Physician** 1995 Nov 15;52(7):2055–63, 2067–8 (35 ref.) Comment in: Am Fam Physician 1995 Nov 15;52(7):1999–2000.
Antidepressant treatment during breast-feeding. Wisner KL, et al. **Am J Psychiatry** 1996 Sep;153(9):1132–7 (52 ref.)
Clinical implications of antidepressant drug effects on sexual function. Harvey KV, et al. **Ann Clin Psychiatry** 1995 Dec; 7(4):189–201 (107 ref.)
Corticotropin releasing hormone in the pathophysiology of melancholic and atypical depression and in the mechanism of action of antidepressant drugs. Gold PW, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:716–29 (53 ref.)
Practical management of treatment-resistant affective disorders. Bridges PK, et al. **Br J Hosp Med** 1995 Nov 15–Dec 12;54(10):501–6 (58 ref.)
Recent advances in the treatment of depression. Hale AS. **Br J Hosp Med** 1996 Feb 21–Mar 5;55(4):183–6 (23 ref.)
Treatment of acute bipolar depression: a review of the literature. Srisurapanont M, et al. **Can J Psychiatry** 1995 Nov;40(9):533–44 (89 ref.)
Pharmacology of neuropathic pain. Ollat H, et al. **Clin Neuropharmacol** 1995 Oct;18(5):391–404 (62 ref.)
Adjunctive therapy in patients with Alzheimer's disease. A practical approach. Corey-Bloom J, et al. **Drugs Aging** 1995 Aug;7(2):79–87 (46 ref.)
Rational antidepressant selection in the elderly. Christensen DD. **Geriatrics** 1995 Oct;50 Suppl 1:S41–50 (41 ref.)
Scandinavian experience with citalopram in the elderly. Gottfries CG. **Int Clin Psychopharmacol** 1996 Mar;11 Suppl 1:41–4 (14 ref.)
The antidepressant efficacy of citalopram. Montgomery SA, et al. **Int Clin Psychopharmacol** 1996 Mar;11 Suppl 1:29–33 (9 ref.)
Antidepressants in geriatric depression: what difference have they made? Baldwin RC. **Int Psychogeriatr** 1995;7 Suppl:55–68 (65 ref.)
Treatment-resistant depression in the elderly. Bonner D, et al. **Int Psychogeriatr** 1995;7 Suppl:83–94 (70 ref.)
Late-life delusional depression: acute and long-term treatment. Meyers BS. **Int Psychogeriatr** 1995;7 Suppl:113–24 (73 ref.)
Efficacy of acute treatment for geriatric depression. Schneider LS, et al. **Int Psychogeriatr** 1995;7 Suppl:7–25 (75 ref.)
Efficacy and tolerability of antidepressant therapy in the old-old. Finkel SI. **J Clin Psychiatry** 1996;57 Suppl 5:23–8 (47 ref.)
Antidepressant treatment of binge-eating disorder: research findings and clinical guidelines. Hudson JI, et al. **J Clin Psychiatry** 1996;57 Suppl 8:73–9 (37 ref.)
Augmentation strategies: focus on anxiolytics. Joffe RT, et al. **J Clin Psychiatry** 1996;57 Suppl 7:25–31; discussion 32–3 (56 ref.)
New developments in the pharmacologic treatment of schizoaffective disorder. Keck PE Jr, et al. **J Clin Psychiatry** 1996;57 Suppl 9:41–8 (78 ref.)
Tolerability and safety: essentials in antidepressant pharmacotherapy. Lader MH. **J Clin Psychiatry** 1996;57 Suppl 2:39–44 (26 ref.)
Efficacy in long-term treatment of depression. Montgomery SA. **J Clin Psychiatry** 1996;57 Suppl 2:24–30 (28 ref.)
Antidepressants and cognitive impairment in the elderly. Oxman TE. **J Clin Psychiatry** 1996;57 Suppl 5:38–44 (59 ref.)
The diagnosis and treatment of late-life depression. Rothschild AJ. **J Clin Psychiatry** 1996;57 Suppl 5:5–11 (80 ref.)
Recent clinical development with reversible and selective amine oxidase inhibitors: a valuable addition to the armamentarium. Chairman's introduction. Priest RG. **J Clin Psychopharmacol** 1995 Aug;15(4 Suppl 2):1S–3S (18 ref.)
Nefazodone and venlafaxine: two new agents for the treatment of depression. Goldberg RJ. **J Fam Pract** 1995 Dec;41(6):591–4 (19 ref.)
The depressions of Alzheimer's disease: sorting, pharmacotherapy, and clinical advice. Knesper DJ. **J Geriatr Psychiatry Neurol** 1995 Oct;8 Suppl 1:S40–51 (147 ref.)
Antidepressants for children. Is scientific support necessary? Fisher RL, et al. **J Nerv Ment Dis** 1996 Feb;184(2):99–102 (31 ref.)
New antidepressants. Kupecz D. **Nurse Pract** 1995 Sep; 20(9):64–7 (18 ref.)
Novel therapeutic and diagnostic applications of hypocrellins and hypericins. Diwu Z. **Photochem Photobiol** 1995 Jun; 61(6):529–39 (118 ref.)
Treatment algorithms in treatment-resistant depression. Amsterdam JD, et al. **Psychiatr Clin North Am** 1996 Jun; 19(2):371–86 (72 ref.)
Definition and epidemiology of treatment-resistant depression. Fava M, et al. **Psychiatr Clin North Am** 1996 Jun;19(2):179–200 (104 ref.)
The management of treatment-resistant depression in the medically ill. Franco-Bronson K. **Psychiatr Clin North Am** 1996 Jun;19(2):329–50 (154 ref.)
Pharmacotherapy for chronic depression. Friedman RA, et al. **Psychiatr Clin North Am** 1996 Mar;19(1):121–32 (31 ref.)
Treatment-resistant depression in children and adolescents. Geller B, et al. **Psychiatr Clin North Am** 1996 Jun; 19(2):253–67 (89 ref.)
The management of treatment-resistant depression in disorders on the interface of psychiatry and medicine. Fibromyalgia, chronic fatigue syndrome, migraine, irritable bowel syndrome, atypical facial pain, and premenstrual dysphoric disorder. Gruber AJ, et al. **Psychiatr Clin North Am** 1996 Jun;19(2):351–69 (79 ref.)
Novel strategies for treatment-resistant depression. Hornig-Rohan M, et al. **Psychiatr Clin North Am** 1996 Jun;19(2):387–405 (133 ref.)
Management of treatment resistance in the depressed geriatric patient. Kamholz BA, et al. **Psychiatr Clin North Am** 1996 Jun;19(2):269–86 (147 ref.)
Combined medication and psychotherapy in the treatment of chronic mood disorders. Miller IW, et al. **Psychiatr Clin North Am** 1996 Mar;19(1):151–71 (70 ref.)
The management of treatment resistance in depressed patients with substance use disorders. Nunes EV, et al. **Psychiatr Clin North Am** 1996 Jun;19(2):311–27 (92 ref.)
Management of treatment-resistant unipolar and chronically depressed patients. Reus VI. **Psychiatr Clin North Am** 1996 Jun;19(2):201–13 (134 ref.)
Treatment-resistant bipolar depression. Sachs GS. **Psychiatr Clin North Am** 1996 Jun;19(2):215–36 (78 ref.)
The role of Axis II comorbidity in the management of patients with treatment-resistant depression. Thase ME. **Psychiatr Clin North Am** 1996 Jun;19(2):287–309 (97 ref.)
[Effect of adjuvant drug therapy following successful electroconvulsive therapy for therapy-resistant depression is still disappointing] Leentjens AF, et al. **Ned Tijdschr Geneeskd** 1996 Feb 3;140(5):241–3 (31 ref.) **(Dut)**
[Pharmacologic treatment of bulimia] Corcos M, et al. **Encephale** 1996 Mar–Apr;22(2):133–42 (37 ref.) (Eng. Abstr.) **(Fre)**
[Biological factors and resistance to antidepressive agents] Puech AJ, et al. **Encephale** 1995 Mar;21 Spec No 2:17–21 (25 ref.) (Eng. Abstr.) **(Fre)**
[Status of thymoleptics in the treatment of bipolar disorders] Sechter D. **Encephale** 1996 Jan–Feb;22(1):65–8 (24 ref.) (Eng. Abstr.) **(Fre)**
[Evolution of benefit-risk ratio of antidepressants] Corruble E, et al. **Therapie** 1995 Nov–Dec;50(6):515–21 (46 ref.) (Eng. Abstr.) **(Fre)**
[St. John's wort as antidepressive therapy] Ernst E. **Fortschr Med** 1995 Sep 10;113(25):354–5 (13 ref.) (Eng. Abstr.) **(Ger)**
[Panic disorder and agoraphobia: what is effective?] Bandelow B, et al. **Fortschr Neurol Psychiatr** 1995 Nov; 63(11):451–64 (120 ref.) (Eng. Abstr.) **(Ger)**
[Drug therapy and affective disorders: state of the art] Cugurra F. **Clin Ter** 1995 Oct;146(10):577–85 (32 ref.) (Eng. Abstr.) **(Ita)**
[Depression, antidepressants and the biological clock] Arushanian EB, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995;95(3):85–9 (71 ref.) **(Rus)**
[Antidepressants and migraine] Legarda I. **Rev Neurol** 1995; 23 Suppl 2:S193–7 (47 ref.) **(Spa)**

TOXICITY

Antidepressant toxicity and the need for identification and concentration monitoring in overdose. Power BM, et al. **Clin Pharmacokinet** 1995 Sep;29(3):154–71 (137 ref.)
Enhancement of tumor growth by drugs with some common molecular actions. LaBella FS, et al. **Mol Carcinog** 1996 Jun;16(2):68–76 (91 ref.)

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION

ADVERSE EFFECTS

Akathisia: a review and case report following paroxetine treatment. Baldassano CF, et al. **Compr Psychiatry** 1996 Mar–Apr;37(2):122–4 (40 ref.)
The safety profile of nefazodone. Robinson DS, et al. **J Clin Psychiatry** 1996;57 Suppl 2:31–8 (20 ref.)

PHARMACOKINETICS

Overview of the pharmacokinetics of fluvoxamine. van Harten J. **Clin Pharmacokinet** 1995;29 Suppl 1:1–9 (49 ref.)

PHARMACOLOGY

Drug interactions and the cytochrome P450 system. The role of cytochrome P450 1A2. Brøsen K. **Clin Pharmacokinet** 1995;29 Suppl 1:20–5 (20 ref.)
Fluvoxamine. A review of global drug–drug interaction data. Wagner W, et al. **Clin Pharmacokinet** 1995;29 Suppl 1:26–31; discussion 31–2 (23 ref.)

New approaches to the treatment of depression. Leonard BE. **J Clin Psychiatry** 1996;57 Suppl 4:26–33 (67 ref.)
Antidepressant drug interactions and the cytochrome P450 system: a critical appraisal. Riesenman C. **Pharmacotherapy** 1995 Nov–Dec;15(6 Pt 2):84S–99S (78 ref.)

THERAPEUTIC USE

Nefazodone: a new antidepressant. Ellingrod VL, et al. **Am J Health Syst Pharm** 1995 Dec 15;52(24):2799–812 (54 ref.)
New antidepressants. Kupecz D. **Nurse Pract** 1995 Sep; 20(9):64–7 (18 ref.)
Therapeutic options for treating major depression, and the role of venlafaxine. Scott MA, et al. **Pharmacotherapy** 1996 May–Jun;16(3):352–65 (91 ref.)
Recent developments in antidepressant agents. Claghorn J, et al. **Prog Drug Res** 1996;46:243–62 (72 ref.)

ANTIDEPRESSIVE AGENTS, TRICYCLIC

ADMINISTRATION & DOSAGE

Drugs to treat the tissue complications of diabetes: peripheral neuropathy. Emanuele NV, et al. **Compr Ther** 1995 Oct; 21(10):579–82 (30 ref.)

ADVERSE EFFECTS

Clinical implications of antidepressant drug effects on sexual function. Harvey KV, et al. **Ann Clin Psychiatry** 1995 Dec; 7(4):189–201 (107 ref.)
Selective serotonin reuptake inhibitors and tricyclic antidepressants in combination. Interactions and therapeutic uses. Taylor D. **Br J Psychiatry** 1995 Nov; 167(5):575–80 (38 ref.)
Tricyclic medication in children and the QT interval: case report and discussion. Alderton HR. **Can J Psychiatry** 1995 Aug;40(6):325–9 (30 ref.)
Five-year multicenter retrospective review of cyclobenzaprine toxicity. Spiller HA, et al. **J Emerg Med** 1995 Nov–Dec;13(6):781–5 (14 ref.)
Drugs that cause weight gain. Fernstrom MH. **Obes Res** 1995 Nov;3 Suppl 4:435S–439S (18 ref.)

BLOOD

[Tricyclic antidepressants (imipramine, desipramine, amitriptyline, nortriptyline)] Yasuda K. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:934–7 (20 ref.) **(Jpn)**

PHARMACOKINETICS

Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6. Ereshefsky L, et al. **Clin Pharmacokinet** 1995;29 Suppl 1:10–8; discussion 18–9 (38 ref.)

PHARMACOLOGY

The pharmacologic profile of mirtazapine. de Boer T. **J Clin Psychiatry** 1996;57 Suppl 4:19–25 (48 ref.)

POISONING

Drug-specific antibodies as antidotes for tricyclic antidepressant overdose. Pentel PR, et al. **Toxicol Lett** 1995 Dec;82–83:801–6 (20 ref.)

THERAPEUTIC USE

Clinical implications of antidepressant drug effects on sexual function. Harvey KV, et al. **Ann Clin Psychiatry** 1995 Dec; 7(4):189–201 (107 ref.)
A guide to the understanding and use of tricyclic antidepressants in the overall management of fibromyalgia and other chronic pain syndromes. Godfrey RG. **Arch Intern Med** 1996 May 27;156(10):1047–52 (44 ref.)
Amitriptyline. A review of its pharmacological properties and therapeutic use in chronic pain states. Bryson HM, et al. **Drugs Aging** 1996 Jun;8(6):459–76 (111 ref.)
Obsessive-compulsive disorder in elderly patients. Jackson CW. **Drugs Aging** 1995 Dec;7(6):438–48 (108 ref.)
One foot on the bandwagon? [editorial] Pies R. **J Clin Psychopharmacol** 1995 Oct;15(5):303–5 (16 ref.)
Emergency pharmacotherapy: the evolving role of medications in the emergency department. Ellison JM, et al. **New Dir Ment Health Serv** 1995 Fall;(67):87–98 (64 ref.)
Ethnicity and psychopharmacology. Bridging the gap. Lin KM, et al. **Psychiatr Clin North Am** 1995 Sep;18(3):635–47 (56 ref.)
[Drug therapy and other biological therapies in mood disorders] Syvälahti E, et al. **Duodecim** 1994;110(3):295–304 (26 ref.) **(Fin)**
[Prediction of therapeutic response in depressive states] Radat F, et al. **Ann Med Psychol (Paris)** 1996 May;154(2):89–102 (53 ref.) (Eng. Abstr.) **(Fre)**
[Therapeutic strategies in mixed or combined headache] Morales F. **Rev Neurol** 1995;23 Suppl 2:S238–9 (7 ref.) **(Spa)**

TOXICITY

Antidepressant toxicity and the need for identification and concentration monitoring in overdose. Power BM, et al. **Clin Pharmacokinet** 1995 Sep;29(3):154–71 (137 ref.)

ANTIDIABETICS see **HYPOGLYCEMIC AGENTS**

ANTIDIURETIC HORMONE, INAPPROPRIATE SECRETION see **INAPPROPRIATE ADH SYNDROME**

ANTIDIURETIC HORMONES see **VASOPRESSINS**

ANTI-DNA ANTIBODIES see **ANTIBODIES, ANTINUCLEAR**

ANTIDOTES

see related
CHELATING AGENTS

ADMINISTRATION & DOSAGE

[Clinical-toxicological case (1). Dosage of N-acetylcysteine in acute paracetamol poisoning] Kind B, et al. **Schweiz Rundsch Med Prax** 1996 Aug 2;85(31–32):935–8 (33 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Antidotes: benefits and risks. Proudfoot AT. **Toxicol Lett** 1995 Dec;82–83:779–83 (20 ref.)

PHARMACOLOGY

The effects of flumazenil in neuropsychiatric disorders. Malizia AL, et al. **Clin Neuropharmacol** 1995 Jun; 18(3):215–32 (134 ref.)
The role of interferon-alpha as a modulator of fluorouracil and leucovorin. Grem JL, et al. **Eur J Cancer** 1995 Jul–Aug;31A(7–8):1316–20 (29 ref.)
Role of leucovorin dosing and administration schedule. Jolivet J. **Eur J Cancer** 1995 Jul–Aug;31A(7–8):1311–5 (52 ref.)
Modifying toxicokinetics with antidotes. Baud FJ, et al. **Toxicol Lett** 1995 Dec;82–83:785–93 (20 ref.)
Modification of cyanide toxicodynamics: mechanistic based antidote development. Isom GE, et al. **Toxicol Lett** 1995 Dec;82–83:795–9 (14 ref.)

THERAPEUTIC USE

Conservative management options for cervical pregnancy; case reports and literature review. Creinin MD, et al. **Int J Fertil Menopausal Stud** 1995 Jul–Aug;40(4):175–86 (67 ref.)
Risks of parenteral deferoxamine for acute iron poisoning. Howland MA. **J Toxicol Clin Toxicol** 1996;34(5):491–7 (50 ref.)
Benefits of parenteral deferoxamine for acute iron poisoning. Tenenbein M. **J Toxicol Clin Toxicol** 1996;34(5):485–9 (36 ref.)
Prevention and treatment of aluminum toxicity including chelation therapy: status and research needs. Yokel RA, et al. **J Toxicol Environ Health** 1996 Aug 30;48(6):667–83 (90 ref.)
Drug-specific antibodies as antidotes for tricyclic antidepressant overdose. Pentel PR, et al. **Toxicol Lett** 1995 Dec;82–83:801–6 (20 ref.)

ANTIDROMIC POTENTIALS see **EVOKED POTENTIALS**

ANTI-DYSKINESIA AGENTS

THERAPEUTIC USE

[Botulinum toxin--from threat to cure] Odergren T, et al. **Lakartidningen** 1996 Apr 24;93(17):1619–24 (40 ref.) **(Swe)**

ANTIEMETICS

Granisetron: the second serotonin-receptor antagonist. Adams VR, et al. **Ann Pharmacother** 1995 Dec; 29(12):1240–51 (72 ref.)
Ondansetron. Thavaraj V, et al. **Indian Pediatr** 1995 Aug; 32(8):898–901 (12 ref.)

ADMINISTRATION & DOSAGE

[Prevention and treatment of postoperative nausea and vomiting with 5-HT3-receptor blockers] Alon E, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May; 31(4):200–4 (47 ref.) (Eng. Abstr.) **(Ger)**

ECONOMICS

Economic impact of antiemesis. Grunberg SM. **Oncology (Huntingt)** 1995 Nov;9(11 Suppl):155–60 (16 ref.)

PHARMACOLOGY

A pharmacologic profile of oral granisetron (Kytril tablets). Blower P. **Semin Oncol** 1995 Aug;22(4 Suppl 10):3–5 (13 ref.)

THERAPEUTIC USE

Development of antiemetic therapy in cancer patients. Herrstedt J. **Acta Oncol** 1995;34(5):637–40 (42 ref.)
Assessing the comparative clinical value of tropisetron. Olver IN. **Aust N Z J Med** 1995 Oct;25(5):523–7 (31 ref.)
Prevention of vomiting after paediatric strabismus surgery: a systematic review using the numbers-needed-to-treat method. Tramèr M, et al. **Br J Anaesth** 1995 Nov; 75(5):556–61 (48 ref.)
Progress in reducing nausea and emesis. Comparisons of ondansetron (Zofran), granisetron (Kytril), and tropisetron (Navoban). Morrow GR, et al. **Cancer** 1995 Aug 1; 76(3):343–57 (121 ref.)
Emesis and anti-emesis. Naylor RJ, et al. **Cancer Surv** 1994; 21:117–35 (138 ref.)
The pharmacological treatment of Menière's disease. Brookes GB. **Clin Otolaryngol** 1996 Feb;21(1):3–11 (78 ref.)
Management of acute emesis. Singhal S, et al. **J Assoc Physicians India** 1995 Aug;43(8):560–2 (6 ref.)
Towards understanding the aetiology and pathophysiology of the emetic reflex: novel approaches to antiemetic drugs. Bountra C, et al. **Oncology** 1996 Jun;53 Suppl 1:102–9 (17 ref.)
Mechanisms and management of nausea and emesis [editorial] Dicato M. **Oncology** 1996 Jun;53 Suppl 1:1–3 (16 ref.)
Management of cisplatin-induced delayed emesis. Hesketh P. **Oncology** 1996 Jun;53 Suppl 1:73–7 (14 ref.)
Antiemetic study methodology: recommendations for future studies. Olver IN. **Oncology** 1996 Jun;53 Suppl 1:96–101 (32 ref.)
Management of other non-cisplatin-induced emesis. Schmoll HJ, et al. **Oncology** 1996 Jun;53 Suppl 1:51–5 (24 ref.)
Optimal control of cyclophosphamide-induced emesis. Stewart A. **Oncology** 1996 Jun;53 Suppl 1:32–8 (38 ref.)
Optimal control of acute cisplatin-induced emesis. Verweij J, et al. **Oncology** 1996 Jun;53 Suppl 1:56–64 (80 ref.)
Economic impact of antiemesis. Grunberg SM. **Oncology (Huntingt)** 1995 Nov;9(11 Suppl):155–60 (16 ref.)
Preventing chemotherapy-induced nausea and vomiting: an update and a review of emesis. Ettinger DS. **Semin Oncol** 1995 Aug;22(4 Suppl 10):6–18 (109 ref.)
Prophylaxis with oral granisetron for acute emesis induced by moderately emetogenic chemotherapy. Hesketh P. **Semin Oncol** 1995 Aug;22(4 Suppl 10):19–23 (23 ref.)
[Methodology of the evaluation of antiemetics] Bergmann JF. **Bull Cancer (Paris)** 1995 Dec;82(12):1062–6 (18 ref.) (Eng. Abstr.) **(Fre)**
[Optimal control by ondansetron of acute and prolonged emesis induced by chemotherapy without cisplatin] Harousseau JL. **Bull Cancer (Paris)** 1996 Jan;83(1):71–76 (27 ref.) (Eng. Abstr.) **(Fre)**
[Anti-5-HT-3: a new group of antiemetics] Galindo JR. **Rev Clin Esp** 1996 Feb;196(2):119–24 (73 ref.) **(Spa)**

TOXICITY

Bendectin: review of the medical literature of a comprehensively studied human nonteratogen and the most prevalent tortogen-litigen. Brent RL. **Reprod Toxicol** 1995 Jul–Aug;9(4):337–49 (178 ref.)

ANTIEPILEPTIC AGENTS see **ANTICONVULSANTS**

ANTIESTROGENS see **ESTROGEN ANTAGONISTS**

ANTIFIBRILLATORY AGENTS see **ANTI-ARRHYTHMIA AGENTS**

ANTIFIBRINOLYSINS see **ANTIFIBRINOLYTIC AGENTS**

ANTIFIBRINOLYTIC AGENTS

ADMINISTRATION & DOSAGE

Oral vitamin K1: an option to reduce warfarin's activity. Harrell CC, et al. **Ann Pharmacother** 1995 Dec; 29(12):1228–32 (26 ref.)
Antifibrinolytic therapy in cardiac surgery. Chen RH, et al. **Tex Heart Inst J** 1995;22(3):211–5 (73 ref.)

ADVERSE EFFECTS

[Cutaneous hypersensitivity at the site of injection of vitamin K1] Moreau-Cabarrot A, et al. **Ann Dermatol Venereol** 1996;123(3):177–9 (22 ref.) (Eng. Abstr.) **(Fre)**

ANALYSIS

[alpha 2-Plasmin inhibitor-plasmin complex (PIC)] Yoshikawa Y, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:55–8 (13 ref.) **(Jpn)**

ANTIFOLATES see **FOLIC ACID ANTAGONISTS**

ANTIFUNGAL AGENTS

see related
FUNGICIDES, INDUSTRIAL

ADMINISTRATION & DOSAGE

Oral fluconazole for vaginal candidiasis. Desai PC, et al. **Am Fam Physician** 1996 Sep 15;54(4):1337–40, 1345–6 (11 ref.)

ANTIFUNGAL AGENTS

ADVERSE EFFECTS

Subacute mitochondrial liver disease in a patien: with AIDS: possible relationship to prolonged fluconazole administration. Guillaume MP, et al. **Am J Gastroenterol** 1996 Jan;91(1):165–8 (14 ref.)

Contact allergy to imidazoles used as antimycotic agents. Dooms-Goossens A, et al. **Contact Dermatitis** 1995 Aug; 33(2):73–7 (54 ref.)

Ethylenebisdithiocarbamates and ethylenethiourea: possible human health hazards. Houeto P, et al. **Environ Health Perspect** 1995 Jun;103(6):568–73 (102 ref.)

HIV medicine: drug side effects and interactions. Bates CM. **Postgrad Med J** 1996 Jan;72(843):30–6 (27 ref.)

BLOOD

[Antifungal drugs] Murase S, et al. **Nippon Rinsho** 1995 Feb; 53 Su Pt 1:1006–9 (15 ref.) **(Jpn)**

PHARMACOKINETICS

Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients. Goa KL, et al. **Drugs** 1995 Oct;50(4):658–90 (204 ref.)

PHARMACOLOGY

Discovery, biosynthesis, and mechanism of action of the zaragozic acids: potent inhibitors of squalene synthase. Bergstrom JD, et al. **Annu Rev Microbiol** 1995;49:607–39 (80 ref.)

Use of amphotericin B with azole antifungal drugs: what are we doing? Sugar AM. **Antimicrob Agents Chemother** 1995 Sep;39(9):1907–12 (46 ref.)

Is antifungal susceptibility testing useful in guiding fluconazole therapy? Ghannoum MA. **Clin Infect Dis** 1996 May;22 Suppl 2:S161–5 (25 ref.)

Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients. Goa KL, et al. **Drugs** 1995 Oct;50(4):658–90 (204 ref.)

Atovaquone. A review of its pharmacological properties and therapeutic efficacy in opportunistic infections. Spencer CM, et al. **Drugs** 1995 Jul;50(1):176–96 (64 ref.)

Antifungal drug targets: Candida secreted aspartyl protease and fungal wall beta-glucan synthesis. Goldman RC, et al. **Infect Agents Dis** 1995 Dec;4(4):228–47 (120 ref.)

P450 inhibitors of use in medical treatment: focus on mechanisms of action. Vanden Bossche H, et al. **Pharmacol Ther** 1995;67(1):79–100 (155 ref.)

Biocides: mechanisms of antifungal action and fungal resistance. Russell AD, et al. **Sci Prog** 1996;79 (Pt 1):27–48 (102 ref.)

THERAPEUTIC USE

Peritoneal dialysis complicated by Bipolaris hawaiiensis peritonitis: successful therapy with catheter removal and oral itraconazol without the use of amphotericin-B. Gadallah MF, et al. **Am J Nephrol** 1995;15(4):348–52 (19 ref.)

Antifungal prophylaxis in bone marrow transplant. Lam HH, et al. **Ann Pharmacother** 1995 Sep;29(9):921–4 (12 ref.)

Nystatin prophylaxis in immunocompromised children. Taylor TL. **Ann Pharmacother** 1996 May;30(5):534–5 (8 ref.)

Use of amphotericin B with azole antifungal drugs: what are we doing? Sugar AM. **Antimicrob Agents Chemother** 1995 Sep;39(9):1907–12 (46 ref.)

Antifungal agents in neonatal systemic candidiasis. van den Anker JN, et al. **Antimicrob Agents Chemother** 1995 Jul; 39(7):1391–7 (66 ref.)

Pseudallescheria boydii in an immunocompromised host. Successful treatment with debridement and itraconazole. Ruxin TA, et al. **Arch Dermatol** 1996 Apr;132(4):382–4 (23 ref.)

Cutaneous mycoses in children. Elewski BE. **Br J Dermatol** 1996 Jun;134 Suppl 46:7–11: discussion 37–8 (34 ref.)

New antifungal compounds and strategies for treatment of invasive fungal infections in patients with neoplastic diseases. Walsh TJ, et al. **Cancer Treat Res** 1995;79:113–48 (268 ref.)

New antifungal drugs for pulmonary mycoses. Klein NC, et al. **Chest** 1996 Aug;110(2):525–32 (100 ref.)

Amphotericin B: a commentary on its role as an antifungal agent and as a comparative agent in clinical trials. Gallis HA. **Clin Infect Dis** 1996 May;22 Suppl 2:S145–7 (18 ref.)

The future of antifungal therapy. Graybill JR. **Clin Infect Dis** 1996 May;22 Suppl 2:S166–78 (147 ref.)

Role of azoles in antifungal therapy. Kauffman CA. **Clin Infect Dis** 1996 May;22 Suppl 2:S148–53 (72 ref.)

Old and new therapies for sporotrichosis. Kauffman CA. **Clin Infect Dis** 1995 Oct;21(4):981–5 (63 ref.)

Recent advances in the management of cryptococcal meningitis in patients with AIDS. Powderly WG. **Clin Infect Dis** 1996 May;22 Suppl 2:S119–23 (32 ref.)

Problems and controversies in the management of hematogenous candidiasis. Uzun O, et al. **Clin Infect Dis** 1996 May;22 Suppl 2:S95–101 (62 ref.)

Therapy of fungal meningitis. Slavoski LA, et al. **Clin Neuropharmacol** 1995 Apr;18(2):95–112 (81 ref.)

When and how to treat serious candidal infections: concepts and controversies. Filler SG, et al. **Curr Clin Top Infect Dis** 1995;15:1–18 (122 ref.)

Fluconazole: its properties and efficacy in vaginal candidiasis. Troke PF. **Curr Probl Dermatol** 1996;24:203–8 (19 ref.)

Itraconazole and therapy of fungal infections. Van Cutsem J. **Curr Probl Dermatol** 1996;24:194–202 (29 ref.)

Oral candidiasis in HIV-infected patients. Brawner DL, et al. **Curr Top Med Mycol** 1995;6:113–25 (68 ref.)

Dematiaceous fungal infections in China. Li R, et al. **Curr Top Med Mycol** 1995;6:283–305 (48 ref.)

Treatment of eumycetoma and actinomycetoma. Welsh O, et al. **Curr Top Med Mycol** 1995;6:47–71 (105 ref.)

Itraconazole. A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections. Haria M, et al. **Drugs** 1996 Apr;51(4):585–620 (245 ref.)

Fungal urinary tract infections in the elderly: treatment guidelines. Jacobs LG. **Drugs Aging** 1996 Feb;8(2):89–96 (32 ref.)

Current drug therapy of systemic mycoses: a review. Yonga G. **East Afr Med J** 1995 Jun;72(6):394–8 (59 ref.)

Therapy for opportunistic fungal infections: past, present and future. Stevens DA. **Indian J Cancer** 1995 Mar;32(1):1–9 (15 ref.)

Diagnosis and treatment of tinea versicolor. Savin R. **J Fam Pract** 1996 Aug;43(2):127–32 (25 ref.)

Diagnosing and treating onychomycosis. Zaias N, et al. **J Fam Pract** 1996 May;42(5):513–8 (20 ref.)

Central venous catheter infection with Rhodotorula minuta in a patient with AIDS taking suppressive doses of fluconazole. Goldani LZ, et al. **J Med Vet Mycol** 1995 Jul-Aug;33(4):267–70 (22 ref.)

Tinea of the skin, hair and nails. Wargon O. **Med J Aust** 1996 May 6;164(9):552–6 (23 ref.)

Opportunistic fungal infections in patients with HIV disease: combating cryptococcosis and histoplasmosis. Kirchner JT. **Postgrad Med** 1996 Jun;99(6):209–16 (34 ref.)

Options in the management of pneumonia caused by Pneumocystis carinii in patients with acquired immune deficiency syndrome and intolerance to trimethoprim/sulfamethoxazole. Korraa H, et al. **South Med J** 1996 Mar;89(3):272–7 (38 ref.)

Prevention and therapy of fungal infections in cancer patients. A review of recently published information [see comments] Klastersky J. **Support Care Cancer** 1995 Nov; 3(6):393–401 (42 ref.) Comment in: Support Care Cancer 1995 Nov;3(6):385–6.

New challenges to the therapy of systemic fungal infections. Medoff G. **Trans Am Clin Climatol Assoc** 1995;107:146–57; discussion 157–8 (24 ref.)

Successfully treated invasive pulmonary aspergillosis associated with smoking marijuana in a renal transplant recipient. Marks WH, et al. **Transplantation** 1996 Jun 27; 61(12):1771–4 (8 ref.)

[Oral antifungal drugs] Ruutu P, et al. **Duodecim** 1995; 111(8):687–94 (27 ref.) **(Fin)**

[Recurrent vulvovaginal mycoses] Salvat J, et al. **Rev Fr Gynecol Obstet** 1995 Nov;90(11):494–501 (17 ref.) (Eng. Abstr.) **(Fre)**

[Multiple digestive involvement in visceral leishmaniasis in a patient with HIV infection: favourable course with itraconazole] Béchade D, et al. **Rev Med Interne** 1996; 17(3):234–7 (20 ref.) (Eng. Abstr.) **(Fre)**

[Curative antifungal treatment of invasive pulmonary aspergillosis] Andrès E, et al. **Rev Pneumol Clin** 1995; 51(4):228–31 (31 ref.) (Eng. Abstr.) **(Fre)**

[Rational use of antimycotics against yeast infections] Hof H, et al. **Immun Infekt** 1995 Dec;23(6):209–15 (29 ref.) (Eng. Abstr.) **(Ger)**

[Therapy and prevention of pneumocystis carinii pneumonia] Goebel FD, et al. **Internist (Berl)** 1995 Dec;36(12):1150–5 (31 ref.) **(Ger)**

[Emergency drug therapy of meningoencephalitis] Kuzuhara S. **Nippon Naika Gakkai Zasshi** 1995 Nov 10;84(11):1837–42 (5 ref.) **(Jpn)**

[Current status of antifungal prophylaxis in opportunistic mycoses] Torres-Rodríguez JM. **Enferm Infecc Microbiol Clin** 1996 Jan;14(1):44–53 (73 ref.) **(Spa)**

ANTIGAMMA GLOBULIN ANTIBODIES see **ANTIBODIES, ANTI-IDIOTYPIC**

ANTIGEN-ANTIBODY COMPLEX

[Dynamics of antigen-antibody interaction--an introduction] Sakurabayashi I. **Nippon Rinsho** 1995 Sep;53(9):2126–33 (4 ref.) (Eng. Abstr.) **(Jpn)**

ANALYSIS

[HCV-RNA in the circulating immune complexes] Hada H, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:143–9 (24 ref.) **(Jpn)**

CHEMISTRY

The crystal structures of complexes formed between lysozyme and antibody fragments. Bentley GA. **EXS** 1996; 75:301–19 (42 ref.)

The use of antibody fragments for crystallization and structure determinations. Kovari LC, et al. **Structure** 1995 Dec 15;3(12):1291–3 (34 ref.)

IMMUNOLOGY

Mitochondrial antigen/antibody systems in primary biliary cirrhosis: revisited. Berg PA, et al. **Liver** 1995 Dec; 15(6):281–92 (73 ref.)

[Hypervariable region specific formation of immune complexes in a plasma with quasispecies of hepatitis C virus] Hijikata M, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:150–5 (19 ref.) **(Jpn)**

METABOLISM

The effects of altered glycosylation of IgG on rheumatoid factor-binding and immune complex formation. Soltys AJ, et al. **Adv Exp Med Biol** 1995;376:155–60 (12 ref.)

Michael Mason Prize Essay 1995. Complement, immune complexes and systemic lupus erythematosus. Davies KA. **Br J Rheumatol** 1996 Jan;35(1):5–23 (69 ref.)

Mechanism of immune complex trapping by follicular dendritic cells. Van den Berg TK, et al. **Curr Top Microbiol Immunol** 1995;201:49–67 (110 ref.)

Targeting lipoproteins to Fc gamma receptors with bispecific antibodies. Morganelli PM. **J Hematother** 1995 Oct; 4(5):457–61 (19 ref.)

ANTIGEN-ANTIBODY REACTIONS

see related
BINDING SITES, ANTIBODY
HYPERSENSITIVITY, IMMEDIATE

Analysis of the structural correlates for self-antigen binding by natural and disease-related autoantibodies. In vitro expression of recombinant and/or mutagenized human IgG. Ichiyoshi Y, et al. **Ann N Y Acad Sci** 1995 Sep 29; 764:328–41 (35 ref.)

Force field development and conformational search strategy in the simulation of biomolecular recognition processes. Tenette C, et al. **Biochem Soc Trans** 1996 Feb;24(1):268–74 (43 ref.)

Interactions of protein antigens with antibodies. Davies DR, et al. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):7–12 (69 ref.)

ANTIGEN, B7 see **ANTIGENS, CD80**

ANTIGEN BRONCHIAL PROVOCATION TESTS see **BRONCHIAL PROVOCATION TESTS**

ANTIGEN CA-15-3 see **CA-15-3 ANTIGEN**

ANTIGEN CA-19-9 see **CA-19-9 ANTIGEN**

ANTIGEN CA-125 see **CA-125 ANTIGEN**

ANTIGEN, LYT-1 see **ANTIGENS, LY**

ANTIGEN PRESENTATION

Dendritic cells "in vivo": their role in the initiation of intestinal immune responses. Liu L, et al. **Adv Exp Med Biol** 1995;371A:271–4 (5 ref.)

The dendritic cell lineage: a ubiquitous antigen-presenting organization. Massard G, et al. **Ann Thorac Surg** 1996 Jan; 61(1):252–8 (67 ref.)

Follicular dendritic cells: antigen retention, B cell activation, and cytokine production. Kosco-Vilbois MH, et al. **Curr Top Microbiol Immunol** 1995;201:69–82 (30 ref.)

Murine follicular dendritic cells: accessory activities in vitro. Tew JG, et al. **Curr Top Microbiol Immunol** 1995; 201:93–104 (50 ref.)

How selective is the transporter associated with antigen processing? Androlewicz MJ, et al. **Immunity** 1996 Jul; 5(1):1–5 (41 ref.)

HLA-DM: an in vivo facilitator of MHC class II peptide loading. Roche PA. **Immunity** 1995 Sep;3(3):259–62 (31 ref.)

Selective mechanisms utilized by persistent and oncogenic viruses to interfere with antigen processing and presentation. Ehrlich R. **Immunol Res** 1995;14(2):77–97 (165 ref.)

Antigen-presenting function of the TL antigen and mouse CD1 molecules. Cheroutre H, et al. **Immunol Rev** 1995 Oct;147:31–52 (73 ref.)

Synthesis and assembly of MHC-peptide complexes. Benham A, et al. **Immunol Today** 1995 Jul;16(7):359–62 (20 ref.)

Issues concerning the nature of antigen recognition by alpha beta and gamma delta T-cell receptors. Davis MM, et al. **Immunol Today** 1995 Jul;16(7):316–8 (21 ref.)

Consequences of IgE/CD23-mediated antigen presentation in allergy. Mudde GC, et al. **Immunol Today** 1995 Aug; 16(8):380–3 (41 ref.)

Molecular recognition of antigen involves lattice formation between CD4, MHC class II and TCR molecules. Sakihama T, et al. **Immunol Today** 1995 Dec;16(12):581–7 (43 ref.)

Antigen presentation--recent developments. Rammensee HG. **Int Arch Allergy Immunol** 1996 Aug;110(4):299–307 (63 ref.)

On the issue of inappropriate HLA class II expression on

endocrine cells: an answer to a sceptic. Todd I, et al. **J Autoimmun** 1995 Jun;8(3):313–22 (48 ref.)
Antigen presentation in the pathogenesis of autoimmune endocrine disease. Weetman AP. **J Autoimmun** 1995 Jun; 8(3):305–12 (38 ref.)
Role of antibody and indirect antigen presentation in transplant–associated coronary artery vasculopathy. Rose ML. **J Heart Lung Transplant** 1996 Apr;15(4):342–9 (75 ref.)
Population biology of antigen presentation by MHC class I molecules [see comments] Parham P, et al. **Science** 1996 Apr 5;272(5258):67–74 (71 ref.) Comment in: Science 1996 Aug 9;273(5276):723–5.
CNS antigen presentation. Hart MN, et al. **Trends Neurosci** 1995 Nov;18(11):475–81 (56 ref.)

DRUG EFFECTS

Calcitonin gene–related peptide modulates Langerhans cell antigen–presenting function. Asahina A, et al. **Proc Assoc Am Physicians** 1995 Jul;107(2):242–4 (18 ref.)

GENETICS

The CD1 family: a third lineage of antigen–presenting molecules. Porcelli SA. **Adv Immunol** 1995;59:1–98 (179 ref.)
Antigen presentation by class I major histocompatibility complex molecules: a context for thinking about HLA–G. Parham P. **Am J Reprod Immunol** 1995 Jul;34(1):10–9 (48 ref.)

IMMUNOLOGY

Antigen–presenting cells. Professionals and amateurs. Sprent J. **Curr Biol** 1995 Oct 1;5(10):1095–7 (18 ref.)
Absorption and presentation of antigens by epithelial cells of the small intestine: hypotheses and predictions relating to the pathogenesis of coeliac disease. Mayrhofer G. **Immunol Cell Biol** 1995 Oct;73(5):433–9 (63 ref.)
Class I MHC presentation of exogenous antigens. Harding CV. **J Clin Immunol** 1996 Mar;16(2):90–6 (50 ref.)
Alloantigen processing and presentation. Tambur AR, et al. **J Heart Lung Transplant** 1995 Nov–Dec;14(6 Pt 1):1031–7 (49 ref.)
Trauma–induced suppression of antigen presentation and expression of major histocompatibility class II antigen complex in leukocytes [editorial] Ayala A, et al. **Shock** 1996 Feb;5(2):79–90 (140 ref.)
[Expression of HLA molecules on the surface of hepatocytes and antigen presentation] Manabe K, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:166–72 (20 ref.) **(Jpn)**

PHYSIOLOGY

Functional and ultrastructural aspects of antigen processing by dendritic cells. Ossevoort MA, et al. **Adv Exp Med Biol** 1995;378:227–31 (24 ref.)
Endogenous pathway of class II presentation. Aichinger G, et al. **Biochem Soc Trans** 1995 Aug;23(3):657–60 (48 ref.)
Antigen processing by the class I pathway. Benham AM, et al. **Biochem Soc Trans** 1995 Aug;23(3):664–9 (45 ref.)
Presentation of N–formylated peptides by H2–M3. Lindahl KF, et al. **Biochem Soc Trans** 1995 Aug;23(3):669–74 (34 ref.)
Proteasome and class I antigen processing and presentation. Belich MP, et al. **Mol Biol Rep** 1995;21(1):53–6 (39 ref.)

ANTIGEN–PRESENTING CELLS

see related
ANTIGEN PRESENTATION
HISTOCOMPATIBILITY ANTIGENS CLASS II
LYMPHOCYTE TRANSFORMATION

Antigen–presenting cell engineering. The molecular toolbox. Tykocinski ML, et al. **Am J Pathol** 1996 Jan;148(1):1–16 (180 ref.)

IMMUNOLOGY

Presentation of self peptides by dendritic cells: possible implications for the pathogenesis of rheumatoid arthritis. Thomas R, et al. **Arthritis Rheum** 1996 Feb;39(2):183–90 (85 ref.)
Role of antigen presenting cells in rheumatoid arthritis. Viner NJ. **Br Med Bull** 1995 Apr;51(2):359–67 (40 ref.)
The two faces of interleukin 12: a pro–inflammatory cytokine and a key immunoregulatory molecule produced by antigen–presenting cells. Trinchieri G. **Ciba Found Symp** 1995;195:203–14; discussion 214–20 (59 ref.)
Antigen–presenting cells. Professionals and amateurs. Sprent J. **Curr Biol** 1995 Oct 1;5(10):1095–7 (18 ref.)
The mechanisms of corneal graft failure in the rat. Katami M. **Eye** 1995;9 (Pt 2):197–207 (38 ref.)
Presentation of antigen and MHC–restricted unresponsiveness. Říhová B. **Folia Biol (Praha)** 1995; 41(3–4):140–62 (28 ref.)
Class I MHC presentation of exogenous antigens. Harding CV. **J Clin Immunol** 1996 Mar;16(2):90–6 (50 ref.)
Comparative study of the role of professional versus semiprofessional or nonprofessional antigen presenting cells in the rejection of vascularized organ allografts. Sundstrom JB, et al. **Transpl Immunol** 1995 Dec;3(4):273–89 (147 ref.)

PHYSIOLOGY

The antigen–presenting cell function of Reed–Sternberg cells. Delabie J, et al. **Leuk Lymphoma** 1995 Jun;18(1–2):35–40 (55 ref.)

VIROLOGY

Selective mechanisms utilized by persistent and oncogenic viruses to interfere with antigen processing and presentation. Ehrlich R. **Immunol Res** 1995;14(2):77–97 (165 ref.)

ANTIGEN PROCESSING see **ANTIGEN PRESENTATION**

ANTIGEN, PROLIFERATING CELL NUCLEAR see **PROLIFERATING CELL NUCLEAR ANTIGEN**

ANTIGEN RECEPTORS see **RECEPTORS, ANTIGEN**

ANTIGEN RECEPTORS, B–CELL see **RECEPTORS, ANTIGEN, B–CELL**

ANTIGEN RECEPTORS, T–CELL see **RECEPTORS, ANTIGEN, T–CELL**

ANTIGEN RECEPTORS, T–CELL, ALPHA–BETA see **RECEPTORS, ANTIGEN, T–CELL, ALPHA–BETA**

ANTIGEN RECEPTORS, T–CELL, GAMMA–DELTA see **RECEPTORS, ANTIGEN, T–CELL, GAMMA–DELTA**

ANTIGEN S 100 see **NERVE TISSUE PROTEIN S 100**

ANTIGEN SWITCHING see **ANTIGENIC VARIATION**

ANTIGENIC DETERMINANTS see **EPITOPES**

ANTIGENIC MIMICRY see **MOLECULAR MIMICRY**

ANTIGENIC MODULATION

Peptide modulation of allergen–specific immune responses. Hoyne GF, et al. **Curr Opin Immunol** 1995 Dec;7(6):757–61 (41 ref.)

ANTIGENIC SPECIFICITY see **EPITOPES**

ANTIGENIC VARIATION

IMMUNOLOGY

Antigenic variants in a plaque–isolate of foot–and–mouth disease virus: implications for vaccine production. Piatti P, et al. **Vaccine** 1995;13(8):781–4 (23 ref.)

ANTIGENS

see related
ANTIGEN–ANTIBODY REACTIONS
RECEPTORS, ANTIGEN

ADMINISTRATION & DOSAGE

Dose–dependent activation and deletion of antigen–specific T cells following oral tolerance. Chen YH, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:111–21 (60 ref.)
Cholera toxin B subunit as transmucosal carrier–delivery and immunomodulating system for induction of antiinfectious and antipathological immunity. Czerkinsky C, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:185–93 (32 ref.)
Induction of anergy in Th1 lymphocytes by oral tolerance. Importance of antigen dosage and frequency of feeding. Friedman A. **Ann N Y Acad Sci** 1996 Feb 13;778:103–10 (47 ref.)
Effects of oral antigen in T–cell receptor transgenic mice. Hurst SD, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:163–73 (20 ref.)
Intraocular inflammatory disease (uveitis) and the use of oral tolerance: a status report. Nussenblatt RB, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:325–37 (23 ref.)
Oral tolerance: mechanisms and possible role in inflammatory joint diseases. Kagnoff MF. **Baillieres Clin Rheumatol** 1996 Feb;10(1):41–54 (71 ref.)
Delivery of protein antigen to the major histocompatibility complex class I–restricted antigen presentation pathway. Zhou F, et al. **J Drug Target** 1995;3(2):91–109 (177 ref.)
Liposomal presentation of antigens for human vaccines. Glück R. **Pharm Biotechnol** 1995;6:325–45 (142 ref.)

ANALYSIS

[Ultrastructural localisation of pemphigus vulgaris and pemphigus foliaceus antigens by indirect immunoelectron microscopy. Apropos of 7 cases] Boulinguez S, et al. **Ann Dermatol Venereol** 1995;122(6–7):417–21 (25 ref.) (Eng. Abstr.) **(Fre)**
[Retinal antigens in eye diseases—clinical value of diagnostic tests] Misiuk–Hojło M, et al. **Klin Oczna** 1995 Mar–Apr; 97(3–4):86–9 (26 ref.) (Eng. Abstr.) **(Pol)**

CHEMISTRY

Molecular inactivation. Spatially and temporally defined molecular knockouts. Müller BK, et al. **Curr Biol** 1995 Nov 1;5(11):1255–6 (9 ref.)
The use of antibody fragments for crystallization and structure determinations. Kovari LC, et al. **Structure** 1995 Dec 15;3(12):1291–3 (34 ref.)

GENETICS

Virus–vectored immunocontraception for control of wild rabbits: identification of target antigens and construction of recombinant viruses. Holland MK, et al. **Reprod Fertil Dev** 1994;6(5):631–42 (61 ref.)

IMMUNOLOGY

Generation of human monoclonal antibodies against ganglioside antigens and their applications in the diagnosis and therapy of cancer. Alfonso M, et al. **Acta Oncol** 1996; 35(3):287–95 (67 ref.)
Immunology of chondroitin/dermatan sulfate. Hascall VC, et al. **Adv Exp Med Biol** 1995;376:205–16 (34 ref.)
The regulation of pulmonary immunity. Lipscomb MF, et al. **Adv Immunol** 1995;59:369–455 (534 ref.)
The use of multiple antigen peptides in the analysis and induction of protective immune responses against infectious diseases. Nardin EH, et al. **Adv Immunol** 1995;60:105–49 (135 ref.)
Oriented immobilization of antibodies and its applications in immunoassays and immunosensors. Lu B, et al. **Analyst** 1996 Mar;121(3):29R–32R (47 ref.)
T–cell recognition of antigen. A process controlled by transient intermolecular interactions. Boniface JJ, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:62–9 (34 ref.)
Active immunity or tolerance to foods in patients with celiac disease or inflammatory bowel disease. Ferguson A, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:202–16 (25 ref.)
Role of gamma delta T cells in the regulation of mucosal IgA response and oral tolerance. Fujihashi K, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:55–63 (42 ref.)
Studying immunological tolerance by physically monitoring antigen–specific T cells in vivo. Khoruts A, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:72–9 (43 ref.)
Antigen trafficking in the intestine. Mayer L, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:28–35 (16 ref.)
Neonatal oral tolerance. Strobel S. **Ann N Y Acad Sci** 1996 Feb 13;778:88–102 (92 ref.)
Oral tolerance: mechanisms and possible role in inflammatory joint diseases. Kagnoff MF. **Baillieres Clin Rheumatol** 1996 Feb;10(1):41–54 (71 ref.)
Lymphatics and the processing of antigen. Ryan TJ, et al. **Clin Dermatol** 1995 Sep–Oct;13(5):485–92 (34 ref.)
IgG and IgA antibodies to dietary antigens in food allergy and intolerance. Barnes RM. **Clin Exp Allergy** 1995 Jul;25 Suppl 1:7–9 (39 ref.)
Autocrine feedback death and the regulation of mature T lymphocyte antigen responses. Lenardo MJ, et al. **Int Rev Immunol** 1995;13(2):115–34 (76 ref.)
Antigen and Fc receptor signaling. The awesome power of the immunoreceptor tyrosine–based activation motif (ITAM). Cambier JC. **J Immunol** 1995 Oct 1;155(7):3281–5 (65 ref.)
Soluble extracellular antigen–specific T cell immunoproteins. Cone RE. **J Leukoc Biol** 1996 May;59(5):605–12 (65 ref.)
Essential flexibility in the T–cell recognition of antigen. Kersh GJ, et al. **Nature** 1996 Apr 11;380(6574):495–8 (69 ref.)
Giant cell arteritis as an antigen–driven disease. Weyand CM, et al. **Rheum Dis Clin North Am** 1995 Nov;21(4):1027–39 (43 ref.)
[Structure and function of major tissue histocompatibility complex (MHC) class I antigens] Falkiewicz B, et al. **Postepy Biochem** 1996;42(1):41–8 (64 ref.) **(Pol)**
[Studies on diversification and restriction of immune response against glycopeptide antigens] Czerwiński M. **Postepy Hig Med Dosw** 1995;49(1):23–31 (47 ref.) (Eng. Abstr.) **(Pol)**

METABOLISM

Predicting major histocompatibility complex–binding sequences within protein antigens. Sinigaglia F, et al. **Biochem Soc Trans** 1995 Aug;23(3):675–7 (18 ref.)
Another twist to MHC–peptide recognition [comment] Wilson IA. **Science** 1996 May 17;272(5264):973–4 (20 ref.) Comment on: Nature 1996 May 17;272(5264):1001–4.

PHYSIOLOGY

Regulation of G protein–coupled receptors by receptor kinases and arrestins. Sterne–Marr R, et al. **Vitam Horm** 1995;51:193–234 (121 ref.)

THERAPEUTIC USE

Antigen–specific immunotherapy of autoimmune disease: a commentary [editorial] Wraith DC. **Clin Exp Immunol** 1996 Mar;103(3):349–52 (38 ref.)
From epitopes to peptides to immunotherapy. Hoyne G, et al. **Clin Immunol Immunopathol** 1996 Sep;80(3 Pt 2):S23–30 (90 ref.)
Antigen–specific therapy for autoimmune disease: prospects for the prevention of insulin–dependent diabetes. Harrison LC. **Mol Med** 1995 Nov;1(7):722–7 (34 ref.)

ANTIGENS, BACTERIAL

[The role of some cellular components of bacterial parasites in determining the incidence of tuberculosis: studies on mycobacterial antigens, with special reference to mycobacterial immunoreactive ribosomal and secreted proteins] Yamada T, et al. **Kekkaku** 1995 Nov; 70(11):639–44 (40 ref.) (Eng. Abstr.) **(Jpn)**

[K-antigen as a marker of Klebsiella pneumoniae and its use in clinical and epidemiological analysis (literature review)] Priamukhina NS, et al. **Klin Lab Diagn** 1996 Mar–Apr; (2):47–9 (29 ref.) **(Rus)**

ADMINISTRATION & DOSAGE

Live attenuated Shigella flexneri mutants as vaccine candidates against shigellosis and vectors for antigen delivery. Phalipon A, et al. **Biologicals** 1995 Jun; 23(2):125–34 (54 ref.)

ANALYSIS

Branhamella catarrhalis: epidemiology, surface antigenic structure, and immune response. Murphy TF. **Microbiol Rev** 1996 Jun;60(2):267–79 (186 ref.)

BLOOD

Serological diagnosis of tuberculosis. Bothamley GH. **Eur Respir J Suppl** 1995 Sep;20:676s–688s (114 ref.)

Uses of serology for the diagnosis of contagious bovine pleuropneumonia. Rurangirwa FR. **Rev Sci Tech** 1995 Sep; 14(3):603–9 (30 ref.)

CHEMISTRY

The variable surface glycolipids of mycobacteria: structures, synthesis of epitopes, and biological properties. Aspinall GO, et al. **Adv Carbohydr Chem Biochem** 1995;51:169–242 (226 ref.)

GENETICS

Antigenic and genetic heterogeneity among Haemophilus influenzae and Neisseria IgA1 proteases. Lomholt H, et al. **Adv Exp Med Biol** 1995;371A:599–603 (18 ref.)

IMMUNOLOGY

Bacterial antigen priming of marine fish larvae. Olafsen JA. **Adv Exp Med Biol** 1995;371A:349–52 (36 ref.)

Unconventional B-cell antigens and human immune repertoires. Silverman GJ. **Ann N Y Acad Sci** 1995 Sep 29;764:342–55 (42 ref.)

A new typhoid vaccine composed of the Vi capsular polysaccharide. Plotkin SA, et al. **Arch Intern Med** 1995 Nov 27;155(21):2293–9 (70 ref.)

T-cell recognition of mycobacterial antigens. Vordermeier HM. **Eur Respir J Suppl** 1995 Sep;20:657s–667s (121 ref.)

New approaches to identification of antigens of Mycobacterium tuberculosis. Wallis RS. **Infect Agents Dis** 1996 Mar;5(2):119–25 (70 ref.)

Bacterial stimulators of macrophages. Hauschildt S, et al. **Int Rev Cytol** 1995;161:263–331 (341 ref.)

Immune system stimulation by probiotics. Perdigon G, et al. **J Dairy Sci** 1995 Jul;78(7):1597–606 (18 ref.)

Antibodies to lipopolysaccharide. Poxton IR. **J Immunol Methods** 1995 Oct 12;186(1):1–15 (85 ref.)

Lymphomas of mucosa-associated lymphoid tissue and antigen drive [editorial; comment] Wright DH. **J Pathol** 1996 Feb;178(2):111–2 (14 ref.) Comment on: J Pathol 1996 Feb;178(2):122–7.

Lyme vaccine enhancement. N-terminal acylation of a protein antigen and inclusion of a saponin adjuvant. Coughlin RT, et al. **Pharm Biotechnol** 1995;6:719–35 (126 ref.)

Phenotypic variation of carbohydrate surface antigens and the pathogenesis of Haemophilus influenzae infections. Roche RJ, et al. **Trends Microbiol** 1995 Aug;3(8):304–9 (60 ref.)

Bacterial superantigens in human disease: structure, function and diversity. Ulrich RG, et al. **Trends Microbiol** 1995 Dec; 3(12):463–8 (51 ref.)

URINE

Legionella urinary antigen testing: potential impact on diagnosis and antibiotic therapy. Kashuba AD, et al. **Diagn Microbiol Infect Dis** 1996 Mar;24(3):129–39 (31 ref.)

ANTIGENS, CARBOHYDRATE, TUMOR-ASSOCIATED
see **ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE**

ANTIGENS, CD

CD34+ progenitor cell selection: clinical transplantation, tumor cell purging, gene therapy, ex vivo expansion, and cord blood processing. Colter M, et al. **J Hematother** 1996 Apr;5(2):179–84 (22 ref.)

[CD22: a cell adhesion molecule that displays alpha 2–6–linked sialic acid–binding lectin activity] Hanasaki K. **Seikagaku** 1995 Aug;67(8):1040–7 (15 ref.) **(Jpn)**

ANALYSIS

The immunodiagnosis of Hodgkin's disease [editorial] Carbone A, et al. **Int J Biol Markers** 1996 Jan–Mar; 11(1):1–5 (36 ref.)

[Expression of primitive stem cell antigens on the blast cells of patients with chronic myeloid leukemia] Baryshnikov Alu. **Vestn Ross Akad Med Nauk** 1996;(3):9–13 (53 ref.) (Eng. Abstr.) **(Rus)**

BIOSYNTHESIS

Control of the production of soluble interleukin–4 receptors: implications in immunoregulation. Fernandez–Botran R, et al. **J Leukoc Biol** 1996 Apr;59(4):499–504 (35 ref.)

TCR delta gene rearrangements in acute myeloid leukemia with T-lymphoid antigen expression. Schmidt CA, et al. **Leuk Lymphoma** 1995 Dec;20(1–2):45–9 (57 ref.)

CHEMISTRY

Biology of natural and recombinant soluble interleukin–4 receptor. Enssle K, et al. **Behring Inst Mitt** 1995 Jun; (96):103–17 (78 ref.)

Invariant chain structure and MHC class II function. Cresswell P. **Cell** 1996 Feb 23;84(4):505–7 (17 ref.)

IMMUNOLOGY

Therapeutic interference with interferon–gamma (IFN–gamma) and soluble IL–4 receptor (sIL–4R) in allergic diseases. Nasert S, et al. **Behring Inst Mitt** 1995 Jun;(96):118–30 (55 ref.)

Cell surface antigens in leukemias and lymphomas. Freedman AS. **Cancer Invest** 1996;14(3):252–76 (354 ref.)

Role of B7 signaling in the differentiation of naive CD4+ T cells to effector interleukin–4–producing T helper cells. Gause WC, et al. **Immunol Res** 1995;14(3):176–88 (84 ref.)

B7–mediated costimulation can either provoke or prevent clinical manifestations of experimental allergic encephalomyelitis. Perrin PJ, et al. **Immunol Res** 1995; 14(3):189–99 (47 ref.)

Control of the production of soluble interleukin–4 receptors: implications in immunoregulation. Fernandez–Botran R, et al. **J Leukoc Biol** 1996 Apr;59(4):499–504 (35 ref.)

Anti–integrin immunotherapy in rheumatoid arthritis: protective effect of anti–alpha 4 antibody in adjuvant arthritis. Barbadillo C, et al. **Springer Semin Immunopathol** 1995;16(4):427–36 (59 ref.)

Transmembrane signaling requirements of T cells: implications for regulation of alloimmunity. Suthanthiran M. **Transplant Proc** 1995 Oct;27(5 Suppl 1):5–7 (25 ref.)

[CD23/sCD23—receptor/cytokine in IgE–dependent reactions] Rogala B, et al. **Postepy Hig Med Dosw** 1995; 49(3):425–32 (35 ref.) (Eng. Abstr.) **(Pol)**

METABOLISM

Cytokine signal transduction through a homo– or heterodimer of gp130. Kishimoto T, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:224–34 (22 ref.)

Antagonistic mutant proteins of interleukin–4. Duschl A, et al. **Behring Inst Mitt** 1995 Jun;(96):87–94 (27 ref.)

Biology of natural and recombinant soluble interleukin–4 receptor. Enssle K, et al. **Behring Inst Mitt** 1995 Jun; (96):103–17 (78 ref.)

Association of TM4SF proteins with integrins: relevance to cancer. Hemler ME, et al. **Biochim Biophys Acta** 1996 Jun 7;1287(2–3):67–71 (58 ref.)

Intracellular trafficking of lysosomal membrane proteins. Hunziker W, et al. **Bioessays** 1996 May;18(5):379–89 (88 ref.)

Immunosuppression through blockade of CD28:B7–mediated costimulatory signals. Judge TA, et al. **Immunol Res** 1996; 15(1):38–49 (34 ref.)

Regulation of interleukin–4 activity by soluble interleukin–4 receptors. Enssle K, et al. **J Clin Lab Anal** 1995;9(6):450–5 (38 ref.)

Blocking CD28/B7 with soluble competitors: immunological phenotype of mCTLA4–H gamma 1 transgenic mice. Lane P. **Res Immunol** 1995 Mar–Apr;146(3):176–9 (30 ref.)

CD80 (B7–1) and CD86 (B7–2): potential targets for immunotherapy? van Gool SW, et al. **Res Immunol** 1995 Mar–Apr;146(3):183–96 (106 ref.)

Signal transduction through the IL–4 and insulin receptor families. Wang LM, et al. **Stem Cells (Dayt)** 1995 Jul; 13(4):360–8 (47 ref.)

CD46–mediated measles virus entry: a first key to host–range specificity. Gerlier D, et al. **Trends Microbiol** 1995 Sep; 3(9):338–45 (65 ref.)

PHYSIOLOGY

Cytokine signal transduction through a homo– or heterodimer of gp130. Kishimoto T, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:224–34 (22 ref.)

Molecular mechanisms of APO–1/Fas(CD95)–mediated apoptosis in tolerance and AIDS. Dhein J, et al. **Behring Inst Mitt** 1995 Jun;(96):13–20 (37 ref.)

C–type lectins of natural killer cells: carbohydrate ligands and role in tumour cell lysis. Bezouška K. **Biochem Soc Trans** 1996 Feb;24(1):156–61 (24 ref.)

The role of ICAM expression in immunity and disease. Simmons DL. **Cancer Surv** 1995;24:141–55 (58 ref.)

Involvement of alpha 6 and alpha v integrins in metastasis. Imhof BA, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 1):195–203 (36 ref.)

Functional significance of IL–4 receptor on B cells in IL–4–induced human IgE production. Yanagihara Y, et al. **J Allergy Clin Immunol** 1995 Dec;96(6 Pt 2):1145–51 (39 ref.)

Molecular analysis of the physiological and pathophysiological role of alpha 4–integrins. Kilger G, et al. **J Mol Med** 1995 Jul;73(7):347–54 (124 ref.)

Gp130, a shared signal transducing receptor component for hematopoietic and neuropoietic cytokines. Taga T. **J Neurochem** 1996 Jul;67(1):1–10 (90 ref.)

Human regulator of complement activation (RCA) gene family proteins and their relationship to microbial infection. Seya T. **Microbiol Immunol** 1995;39(5):295–305 (82 ref.)

Receptor tails unlock developmental checkpoints for B lymphocytes [comment] Roth PE, et al. **Science** 1996 Jun 21;272(5269):1752–4 (7 ref.) Comment on: Science 1996 Jun 21;272(5269):1804–8.

The role of alpha v–integrins in tumour progression and metastasis. Marshall JF, et al. **Semin Cancer Biol** 1996 Jun; 7(3):129–38 (85 ref.)

Alpha 4 integrin–induced cytokine production and eosinophil function. Broide DH. **Springer Semin Immunopathol** 1995; 16(4):405–15 (85 ref.)

Alpha 4–integrin–dependent emigration of monocytes. Chuluyan HE, et al. **Springer Semin Immunopathol** 1995; 16(4):391–404 (82 ref.)

Function and regulation of the beta 3 integrins in hemostasis and vascular biology. Shattil SJ. **Thromb Haemost** 1995 Jul;74(1):149–55 (98 ref.)

[VLA and alpha6, beta4 integrins. Expression in normal and neoplastic human tissues] Hofman P, et al. **Arch Anat Cytol Pathol** 1995;43(5–6):309–24 (112 ref.) (Eng. Abstr.) **(Fre)**

[Cytokine binding proteins: a model of interleukin 6] Brailly H, et al. **Arch Inst Pasteur Tunis** 1994 Jul–Oct; 71(3–4):535–48 (35 ref.) **(Fre)**

ANTIGENS, CD1

The CD1 family: a third lineage of antigen–presenting molecules. Porcelli SA. **Adv Immunol** 1995;59:1–98 (179 ref.)

CHEMISTRY

Structure and function of the CD1 family of MHC–like cell surface proteins. Blumberg RS, et al. **Immunol Rev** 1995 Oct;147:5–29 (86 ref.)

IMMUNOLOGY

Antigen–presenting function of the mouse CD1 molecule. Tangri S, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:288–96 (21 ref.)

MHC class I–like, class II–like and CD1 molecules: distinct roles in immunity. Beckman EM, et al. **Immunol Today** 1995 Jul;16(7):349–52 (38 ref.)

CD1 and the expanding universe of T cell antigens. Porcelli SA, et al. **J Immunol** 1995 Oct 15;155(8):3709–10 (18 ref.)

PHYSIOLOGY

Structure and function of the CD1 family of MHC–like cell surface proteins. Blumberg RS, et al. **Immunol Rev** 1995 Oct;147:5–29 (86 ref.)

Antigen–presenting function of the TL antigen and mouse CD1 molecules. Cheroutre H, et al. **Immunol Rev** 1995 Oct;147:31–52 (73 ref.)

ANTIGENS, CD2

IMMUNOLOGY

An anti–CD2 monoclonal antibody that elicits alloantigen–specific hyporesponsiveness. Schad V, et al. **Transplant Proc** 1996 Aug;28(4):2051–3 (17 ref.)

Transmembrane signaling requirements of T cells: implications for regulation of alloimmunity. Suthanthiran M. **Transplant Proc** 1995 Oct;27(5 Suppl 1):5–7 (25 ref.)

ANTIGENS, CD3

see related
RECEPTORS, ANTIGEN, T-CELL

ANALYSIS

Discordant CD3 expression in lymphomas when studied on frozen and paraffin sections. Chan JK, et al. **Hum Pathol** 1995 Oct;26(10):1139–43 (48 ref.)

IMMUNOLOGY

Performance of CD3xCD19 bispecific monoclonal antibodies in B cell malignancy. Haagen IA. **Leuk Lymphoma** 1995 Nov;19(5–6):381–93 (160 ref.)

ANTIGENS, CD4

see related
HIV ENVELOPE PROTEIN GP120

Molecular recognition of antigen involves lattice formation between CD4, MHC class II and TCR molecules. Sakihama T, et al. **Immunol Today** 1995 Dec;16(12):581–7 (43 ref.)

The ontogeny of class–regulation of CD4+ T lymphocyte populations. Carneiro J, et al. **Int Immunol** 1995 Aug;

7(8):1265–77 (37 ref.)

CHEMISTRY

The structure of CD4. Brady RL, et al.
Curr Top Microbiol Immunol 1996;205:1–18 (49 ref.)
The receptor for HIV: dissection of CD4 and studies on putative accessory factors. James W, et al.
Curr Top Microbiol Immunol 1996;205:137–58 (152 ref.)

GENETICS

Selenium and cellular immunity. Evidence that selenoproteins may be encoded in the +1 reading frame overlapping the human CD4, CD8, and HLA-DR genes. Taylor EW.
Biol Trace Elem Res 1995 Aug–Sep;49(2–3):85–95 (37 ref.)

METABOLISM

The regulation and function of the CD4 coreceptor during T lymphocyte development. Killeen N, et al.
Curr Top Microbiol Immunol 1996;205:89–106 (82 ref.)
The structural basis of CD4-MHC class II interactions: coreceptor contributions to T cell receptor antigen recognition and oligomerization-dependent signal transduction. König R, et al.
Curr Top Microbiol Immunol 1996;205:19–46 (93 ref.)
Endocytic and exocytic regulation of CD4 expression and function. Marsh M, et al. **Curr Top Microbiol Immunol** 1996;205:107–35 (143 ref.)
CD4 and signal transduction. Ravichandran KS, et al.
Curr Top Microbiol Immunol 1996;205:47–62 (97 ref.)

PHYSIOLOGY

The CD4 molecule. Roles in T lymphocytes and in HIV disease. Introduction. Littman DR.
Curr Top Microbiol Immunol 1996;205:v–x (13 ref.)
The role of CD4 in HIV envelope-mediated pathogenesis. Siliciano RF. **Curr Top Microbiol Immunol** 1996;205:159–79 (121 ref.)
The role of human immunodeficiency virus type 1 envelope glycoproteins in virus infection. Freed EO, et al.
J Biol Chem 1995 Oct 13;270(41):23883–6 (153 ref.)

ANTIGENS, CD7

ANALYSIS

Biological characteristics of CD7(+) acute leukemia. Miwa H, et al. **Leuk Lymphoma** 1996 Apr;21(3–4):239–44 (21 ref.)

PHYSIOLOGY

Biological characteristics of CD7(+) acute leukemia. Miwa H, et al. **Leuk Lymphoma** 1996 Apr;21(3–4):239–44 (21 ref.)

ANTIGENS, CD8

BLOOD

The role of CD8+, CD57+ cells in human cytomegalovirus and other viral infections. Wang EC, et al.
Scand J Infect Dis Suppl 1995;99:69–77 (78 ref.)

GENETICS

Selenium and cellular immunity. Evidence that selenoproteins may be encoded in the +1 reading frame overlapping the human CD4, CD8, and HLA-DR genes. Taylor EW.
Biol Trace Elem Res 1995 Aug–Sep;49(2–3):85–95 (37 ref.)

METABOLISM

Glycosylation and maturation rate of membrane and secretory forms of human CD8 alpha glycoprotein. Implications in the activation of T-lymphocytes. Serafini-Cessi F, et al. **Adv Exp Med Biol** 1995;376:135–45 (33 ref.)

PHYSIOLOGY

Coreceptors and adapter proteins in T-cell signaling. Ravichandran KS, et al. **Ann N Y Acad Sci** 1995 Sep 7; 766:117–33 (91 ref.)

ANTIGENS, CD10 see **MEMBRANE METALLO-ENDOPEPTIDASE**

ANTIGENS, CD11

ANALYSIS

Expression of CD11a and CD45R isoforms defines distinct subsets of CD8+ TCR alpha beta and TCR gamma delta CTL in vivo. Hedlund G, et al. **Immunol Rev** 1995 Aug; 146:82–94 (33 ref.)

PHYSIOLOGY

Leukocyte and endothelial adhesion molecules in ischaemia/reperfusion injuries. Winn RK, et al.
Ciba Found Symp 1995;189:63–71; discussion 72–6, 77–8 (52 ref.)

ANTIGENS, CD11A see **LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1**

ANTIGENS, CD13

DRUG EFFECTS

Dual inhibitors of enkephalin-degrading enzymes (neutral endopeptidase 24.11 and aminopeptidase N) as potential new medications in the management of pain and opioid addiction. Roques BP, et al. **NIDA Res Monogr** 1995; 147:104–45 (149 ref.)

PHARMACOLOGY

Dual inhibitors of enkephalin-degrading enzymes (neutral endopeptidase 24.11 and aminopeptidase N) as potential new medications in the management of pain and opioid addiction. Roques BP, et al. **NIDA Res Monogr** 1995; 147:104–45 (149 ref.)

URINE

[Alanine aminopeptidase in urine] Seki T. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:445–6 (7 ref.) **(Jpn)**

ANTIGENS, CD14

METABOLISM

Knowledge of cellular receptors for bacterial endotoxin--1995. Viriyakosol S, et al. **Clin Infect Dis** 1995 Oct;21 Suppl 2:S190–5 (41 ref.)

PHYSIOLOGY

Novel insight into molecular mechanism of endotoxin shock: biochemical analysis of LPS receptor signaling in a cell-free system targeting NF-kappaB and regulation of cytokine production/action through beta2 integrin in vivo. Mukaida N, et al. **J Leukoc Biol** 1996 Feb;59(2):145–51 (42 ref.)

ANTIGENS, CD15

ANALYSIS

[Clinical value of carbohydrate antigens, sialyl Lewis-x and sialyl Lewis-a in gastrointestinal cancer] Nakamori S, et al. **Nippon Geka Gakkai Zasshi** 1996 Feb;97(2):165–71 (27 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

[Molecular biology of Lewis antigens--histo-blood type antigens and sialyl Lewis antigens as tumor associated antigens] Narimatsu H. **Nippon Geka Gakkai Zasshi** 1996 Feb;97(2):115–22 (39 ref.) (Eng. Abstr.) **(Jpn)**

ANTIGENS, CD16 see **RECEPTORS, IGG**

ANTIGENS, CD18

see related
LEUKOCYTE ADHESION DEFICIENCY SYNDROME
LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1

PHYSIOLOGY

Novel insight into molecular mechanism of endotoxin shock: biochemical analysis of LPS receptor signaling in a cell-free system targeting NF-kappaB and regulation of cytokine production/action through beta2 integrin in vivo. Mukaida N, et al. **J Leukoc Biol** 1996 Feb;59(2):145–51 (42 ref.)

ANTIGENS, CD19

IMMUNOLOGY

Performance of CD3xCD19 bispecific monoclonal antibodies in B cell malignancy. Haagen IA. **Leuk Lymphoma** 1995 Nov;19(5–6):381–93 (160 ref.)

METABOLISM

CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy. Scheuermann RH, et al.
Leuk Lymphoma 1995 Aug;18(5–6):385–97 (94 ref.)

ANTIGENS, CD23 see **RECEPTORS, IGE**

ANTIGENS, CD25 see **RECEPTORS, INTERLEUKIN-2**

ANTIGENS, CD26

METABOLISM

HIV and CD26 [comment] Dalgleish A. **Nat Med** 1995 Sep; 1(9):881–2 (20 ref.) Comment on: Nat Med 1995 Sep;1(9):919–26.

PHYSIOLOGY

Lu-ECAM-1 and DPP IV in lung metastasis. Elble RC, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 1):107–22 (77 ref.)

ANTIGENS, CD27

PHYSIOLOGY

CD27–CD70 interaction: unravelling its implication in normal and neoplastic B-cell growth. Lens SM, et al.
Leuk Lymphoma 1995 Jun;18(1–2):51–9 (78 ref.)

ANTIGENS, CD28

see related
ANTIGENS, CD80

CD28 and apoptosis. Boise LH, et al.
Curr Opin Immunol 1995 Oct;7(5):620–5 (49 ref.)

IMMUNOLOGY

Costimulation and its role in organ transplantation. Bluestone JA. **Clin Transplant** 1996 Feb;10(1 Pt 2):104–9 (23 ref.)
The critical role of CD28 signalling in the prevention of human T-cell anergy. Boussiotis VA, et al.
Res Immunol 1995 Mar–Apr;146(3):140–9 (72 ref.)
Mechanisms of CD28 signalling. Schneider H, et al.
Res Immunol 1995 Mar–Apr;146(3):149–54 (59 ref.)
The Yin and Yang of T cell costimulation [see comments] Allison JP, et al. **Science** 1995 Nov 10;270(5238):932–3 (17 ref.) Comment in: Science 1995 Nov 10;270(5238):985–8.

METABOLISM

Immunosuppression through blockade of CD28:B7-mediated costimulatory signals. Judge TA, et al. **Immunol Res** 1996; 15(1):38–49 (34 ref.)
Signaling through CD28/CTLA-4 family receptors: puzzling participation of phosphatidylinositol-3 kinase. Hutchcroft JE, et al. **J Immunol** 1996 Jun 1;156(11):4071–4 (69 ref.)
Signalling intermediates of CD28. Ben-Neriah Y, et al.
Res Immunol 1995 Mar–Apr;146(3):154–8 (28 ref.)
CD28 costimulation regulates long-term expression of the three genes (alpha, beta, gamma) encoding the high-affinity IL2 receptor. Cerdan C, et al. **Res Immunol** 1995 Mar–Apr; 146(3):164–8 (43 ref.)
The role of CD28 in the activation of T lymphocytes to proliferate in response to IL4. Chiodetti L, et al.
Res Immunol 1995 Mar–Apr;146(3):169–71 (23 ref.)
Regulation of IL2 gene transcription via the T-cell accessory molecule CD28. Civil A, et al. **Res Immunol** 1995 Mar–Apr; 146(3):158–64 (19 ref.)
Blocking CD28/B7 with soluble competitors: immunological phenotype of mCTLA4-H gamma 1 transgenic mice. Lane P. **Res Immunol** 1995 Mar–Apr;146(3):176–9 (30 ref.)
CD28/CTLA-4 receptor structure, binding stoichiometry and aggregation during T-cell activation. Linsley PS, et al. **Res Immunol** 1995 Mar–Apr;146(3):130–40 (78 ref.)
T-cell costimulation via CD28–CD80/CD86 and CD40–CD40 ligand interactions. Somoza C, et al.
Res Immunol 1995 Mar–Apr;146(3):171–6 (50 ref.)

PHARMACOLOGY

Can co-stimulated tumor immunity be therapeutically efficacious? Hellström KE, et al. **Immunol Rev** 1995 Jun; 145:123–45 (110 ref.)

PHYSIOLOGY

Phosphoinositide 3-kinase and CD28-mediated T-cell co-stimulation. Ward SG. **Biochem Soc Trans** 1996 Feb; 24(1):240–5 (50 ref.)
Upstream-downstream: CD28 cosignaling pathways and T cell function. Rudd CE. **Immunity** 1996 Jun;4(6):527–34 (71 ref.)
The CD28 costimulatory pathway. Leung HT, et al.
Ther Immunol 1994 Aug;1(4):217–28 (104 ref.)

ANTIGENS, CD29

see related
RECEPTORS, FIBRONECTIN

ANTIGENS, CD30

IMMUNOLOGY

Role for CD30 antigen in human T helper 2-type responses. Romagnani S. **Ciba Found Symp** 1995;195:55–62; discussion 62–7 (43 ref.)

PHYSIOLOGY

CD30 expression in normal and neoplastic lymphoid tissue: biological aspects and clinical implications. de Bruin PC, et al. **Leukemia** 1995 Oct;9(10):1620–7 (166 ref.)

ANTIGENS, CD32 see **RECEPTORS, IGG**

ANTIGENS, CD34

CD34: structure, biology, and clinical utility. Krause DS, et al. **Blood** 1996 Jan 1;87(1):1–13 (141 ref.)
CD34-positive cells: biology and clinical relevance. Stella CC, et al. **Haematologica** 1995 Jul–Aug;80(4):367–87 (156 ref.)
CD34+ progenitor cell selection: clinical transplantation, tumor cell purging, gene therapy, ex vivo expansion, and

ANTIGENS, CD34

cord blood processing. Colter M, et al. **J Hematother** 1996 Apr;5(2):179–84 (22 ref.)

ANALYSIS

CD34 cell separation: from basic research to clinical applications. Nadali G, et al. **Int J Clin Lab Res** 1995; 25(3):121–7 (39 ref.)

[Molecular and biological features of human CD34+ Hematopoietic stem/progenitor cells] Xi YZ. **Sheng Li Ko Hsueh Chin Chan** 1995 Oct;26(4):317–23 (20 ref.) (Eng. Abstr.) **(Chi)**

IMMUNOLOGY

A standardized flow cytometry protocol for mobilized peripheral CD34+ cells estimation and collection for autotransplantation in cancer patients. Brando B, et al. **Eur J Histochem** 1994;38 Suppl 1:21–6 (12 ref.)

PHYSIOLOGY

[Recent data and current studies of epidermal Langerhans cells] Dezutter-Dambuyant C. **Pathol Biol (Paris)** 1995 Dec;43(10):841–7 (78 ref.) (Eng. Abstr.) **(Fre)**

[In vitro differenciation and functions of dendritic cells obtained from CD34+ hematopoietic progenitors] Dubois B, et al. **Pathol Biol (Paris)** 1995 Dec;43(10):829–40 (88 ref.) (Eng. Abstr.) **(Fre)**

[The function of the CD34 molecule: still an unknown] Inglés Esteve J, et al. **Sangre (Barc)** 1996 Feb;41(1):47–54 (75 ref.) **(Spa)**

ANTIGENS, CD36

METABOLISM

A docking receptor for HDL cholesterol esters [comment] Steinberg D. **Science** 1996 Jan 26;271(5248):460–1 (15 ref.) Comment on: Science 1996 Jan 26;271(5248):518–20.

PHYSIOLOGY

[Platelet collagen receptors] Kralisz U. **Postepy Biochem** 1995;41(3):188–94 (78 ref.) **(Pol)**

ANTIGENS, CD40

IMMUNOLOGY

CD40 and its ligand in host defense. Noelle RJ. **Immunity** 1996 May;4(5):415–9 (43 ref.)

Therapeutic potential for blockade of the CD40 ligand, gp39. Buhlmann JE, et al. **J Clin Immunol** 1996 Mar;16(2):83–9 (56 ref.)

METABOLISM

CD40–CD40 ligand (CD40L) interactions and X-linked hyperIgM syndrome (HIGMX-1). Ramesh N, et al. **Clin Immunol Immunopathol** 1995 Sep;76(3 Pt 2):S208–13 (37 ref.)

CD40-mediated signaling in B cells. Balancing cell survival, growth, and death. Kehry MR. **J Immunol** 1996 Apr 1; 156(7):2345–8 (77 ref.)

ANTIGENS, CD41 see **PLATELET GLYCOPROTEIN GPIIB–IIIA COMPLEX**

ANTIGENS, CD42A see **PLATELET GLYCOPROTEIN GPIB–IX COMPLEX**

ANTIGENS, CD42B see **PLATELET GLYCOPROTEIN GPIB–IX COMPLEX**

ANTIGENS, CD42C see **PLATELET GLYCOPROTEIN GPIB–IX COMPLEX**

ANTIGENS, CD42D see **PLATELET GLYCOPROTEIN GPIB–IX COMPLEX**

ANTIGENS, CD44

ANALYSIS

Are CD44 variant isoforms involved in human tumour progression? Günthert U, et al. **Cancer Surv** 1995;24:19–42 (116 ref.)

Differentiation and prognosis of neuroblastoma in correlation to the expression of CD44s. Terpe HJ, et al. **Eur J Cancer** 1995;31A(4):549–52 (60 ref.)

BIOSYNTHESIS

The role of CD44 splice variants in human metastatic cancer. Sleeman J, et al. **Ciba Found Symp** 1995;189:142–51; discussion 151–6, 174–6 (43 ref.)

CD44: physiological expression of distinct isoforms as evidence for organ-specific metastasis formation. Zöller M. **J Mol Med** 1995 Sep;73(9):425–38 (265 ref.)

Expression of the CD44 adhesion molecule in tumours of the central and peripheral nervous system. Baltuch GH, et al. **J Neurooncol** 1995 Dec;26(3):191–8 (62 ref.)

Schwann cell tumors express characteristic patterns of CD44 splice variants. Sherman L, et al. **J Neurooncol** 1995 Dec; 26(3):171–84 (57 ref.)

The clinical significance of malfunction of the CD44 locus in malignancy. Tarin D, et al. **J Neurooncol** 1995 Dec; 26(3):209–19 (59 ref.)

CHEMISTRY

Modulation of the hyaluronan receptor, CD44, by its transmembrane and cytoplasmic domains. Sheikh H, et al. **Biochem Soc Trans** 1995 Nov;23(4):831–5 (33 ref.)

DRUG EFFECTS

Hyaluronan receptor antagonists alter skin inflammation and fibrosis following injury. Savani RC, et al. **Proc West Pharmacol Soc** 1995;38:131–6 (68 ref.)

GENETICS

The clinical significance of malfunction of the CD44 locus in malignancy. Tarin D, et al. **J Neurooncol** 1995 Dec; 26(3):209–19 (59 ref.)

Retention of CD44 introns in bladder cancer: understanding the alternative splicing of pre-mRNA opens new insights into the pathogenesis of human cancers [editorial] Cooper DL. **J Pathol** 1995 Sep;177(1):1–3 (28 ref.)

IMMUNOLOGY

Alternative triggering molecules and single chain bispecific antibodies. Segal DM, et al. **J Hematother** 1995 Oct; 4(5):377–82 (31 ref.)

Lutheran antigens, CD44-related antigens, and Lutheran regulatory genes. Telen MJ. **Transfus Clin Biol** 1995; 2(4):291–301 (70 ref.)

METABOLISM

Modulation of the hyaluronan receptor, CD44, by its transmembrane and cytoplasmic domains. Sheikh H, et al. **Biochem Soc Trans** 1995 Nov;23(4):831–5 (33 ref.)

Interactions between CD44 and hyaluronic acid: their role in tumor growth and metastasis. Sy MS, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 3):129–53 (150 ref.)

PHYSIOLOGY

CD44 in malignant disorders. Günthert U. **Curr Top Microbiol Immunol** 1996;213 (Pt 1):271–85 (93 ref.)

Does soluble CD44 reflect the clinical behavior of human cancer? Ristamäki R, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 3):155–66 (53 ref.)

The CD44 proteins in embryonic development and in cancer. Sherman L, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 1):249–69 (123 ref.)

Joint features of metastasis formation and lymphocyte maturation and activation. Zöller M. **Curr Top Microbiol Immunol** 1996;213 (Pt 1):215–47 (330 ref.)

CD44 in colon cancer. Herrlich P, et al. **Eur J Cancer** 1995 Jul-Aug;31A(7–8):1110–2 (32 ref.)

Involvement of CD44 and its variant isoforms in membrane–cytoskeleton interaction, cell adhesion and tumor metastasis. Bourrguignon LY, et al. **J Neurooncol** 1995 Dec;26(3):201–8 (44 ref.)

Hyaluronan: RHAMM mediated cell locomotion and signaling in tumorigenesis. Hall CL, et al. **J Neurooncol** 1995 Dec;26(3):221–9 (84 ref.)

ANTIGENS, CD45

ANALYSIS

Expression of CD11a and CD45R isoforms defines distinct subsets of CD8+ TCR alpha beta and TCR gamma delta CTL in vivo. Hedlund G, et al. **Immunol Rev** 1995 Aug; 146:82–94 (33 ref.)

IMMUNOLOGY

Regulation of immune function by protein tyrosine phosphatases. Okumura M, et al. **Curr Opin Immunol** 1995 Jun;7(3):312–9 (101 ref.)

METABOLISM

CD45 (leucocyte common antigen) expression in T and B lymphocyte subsets. Poppema S, et al. **Leuk Lymphoma** 1996 Jan;20(3–4):217–22 (63 ref.)

PHYSIOLOGY

Positive and negative regulation of leukocyte activation by protein tyrosine phosphatases. Thomas ML. **Semin Immunol** 1995 Aug;7(4):279–88 (85 ref.)

ANTIGENS, CD54 see **INTERCELLULAR ADHESION MOLECULE-1**

ANTIGENS, CD55

PHYSIOLOGY

Human regulator of complement activation (RCA) gene family proteins and their relationship to microbial infection. Seya T. **Microbiol Immunol** 1995;39(5):295–305 (82 ref.)

Glycosyl phosphatidylinositol-linked blood group antigens and paroxysmal nocturnal hemoglobinuria. Telen MJ. **Transfus Clin Biol** 1995;2(4):277–90 (73 ref.)

ANTIGENS, CD57

BLOOD

The role of CD8+, CD57+ cells in human cytomegalovirus and other viral infections. Wang EC, et al. **Scand J Infect Dis Suppl** 1995;99:69–77 (78 ref.)

PHYSIOLOGY

Functions of the L2/HNK-1 carbohydrate in the nervous system. Schachner M, et al. **Prog Brain Res** 1995;105:183–8 (39 ref.)

ANTIGENS, CD59

PHYSIOLOGY

Glycosyl phosphatidylinositol-linked blood group antigens and paroxysmal nocturnal hemoglobinuria. Telen MJ. **Transfus Clin Biol** 1995;2(4):277–90 (73 ref.)

ANTIGENS, CD62E see **E-SELECTIN**

ANTIGENS, CD62L see **L-SELECTIN**

ANTIGENS, CD62P see **P-SELECTIN**

ANTIGENS, CD64 see **RECEPTORS, IGG**

ANTIGENS, CD73 see **5'-NUCLEOTIDASE**

ANTIGENS, CD80

IMMUNOLOGY

Role of B7 signaling in the differentiation of naive CD4+ T cells to effector interleukin-4–producing T helper cells. Gause WC, et al. **Immunol Res** 1995;14(3):176–88 (84 ref.)

B7-mediated costimulation can either provoke or prevent clinical manifestations of experimental allergic encephalomyelitis. Perrin PJ, et al. **Immunol Res** 1995; 14(3):189–99 (47 ref.)

METABOLISM

Immunosuppression through blockade of CD28:B7-mediated costimulatory signals. Judge TA, et al. **Immunol Res** 1996; 15(1):38–49 (34 ref.)

CD80 (B7-1) and CD86 (B7-2): potential targets for immunotherapy? van Gool SW, et al. **Res Immunol** 1995 Mar-Apr;146(3):183–96 (106 ref.)

PHARMACOLOGY

Can co-stimulated tumor immunity be therapeutically efficacious? Hellström KE, et al. **Immunol Rev** 1995 Jun; 145:123–45 (110 ref.)

PHYSIOLOGY

The CD28 costimulatory pathway. Leung HT, et al. **Ther Immunol** 1994 Aug;1(4):217–28 (104 ref.)

ANTIGENS, CD95

ANALYSIS

[Fas antigen expression and apoptosis in liver tissues of patients with chronic hepatitis B] Mochizuki K, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:228–33 (17 ref.) **(Jpn)**

[Immunohistochemical observation of Fas in the liver of chronic hepatitis B and its ultrastructural localization] Takatani M, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:234–40 (23 ref.) **(Jpn)**

[Immunohistochemical observation of Fas in the liver with chronic hepatitis C] Takatani M, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:667–74 (23 ref.) **(Jpn)**

GENETICS

Life and death during lymphocyte development and function: evidence for two distinct killing mechanisms. Strasser A. **Curr Opin Immunol** 1995 Apr;7(2):228–34 (97 ref.)

IMMUNOLOGY

Cytotoxic T lymphocytes: the newly identified Fas (CD95)-mediated killing mechanism and a novel aspect of their biological functions. Takayama H, et al. **Adv Immunol** 1995;60:289–321 (180 ref.)

Die and let live: eliminating dangerous lymphocytes. Abbas AK. **Cell** 1996 Mar 8;84(5):655–7 (15 ref.)

Autoimmunity. The Fas track. Rathmell JC, et al. **Curr Biol** 1995 Nov 1;5(11):1218–21 (31 ref.)

Fas bridging cell death and cytotoxicity: the reaper connection. Golstein P, et al. **Immunol Rev** 1995 Aug; 146:45–56 (58 ref.)

Fas and the art of lymphocyte maintenance [comment] Lenardo MJ. **J Exp Med** 1996 Mar 1;183(3):721–4 (31 ref.) Comment on: J Exp Med 1996 Mar 1;183(3):1071–82.

[Role of Fas system in apoptosis induced by hepatitis C virus infection] Mita E, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:198–202 (14 ref.) **(Jpn)**

METABOLISM

[Expression of ductal Fas antigen in sialoadenitis of Sjögren's syndrome] Matsumura R, et al. **Nippon Rinsho** 1995 Oct; 53(10):2446–50 (13 ref.) (Eng. Abstr.) **(Jpn)**

[Analysis of Fas and bcl-2 expression on peripheral blood lymphocytes from primary Sjögren's syndrome] Ohashi H, et al. **Nippon Rinsho** 1995 Oct;53(10):2451–5 (24 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Molecular mechanisms of APO-1/Fas(CD95)-mediated apoptosis in tolerance and AIDS. Dhein J, et al. **Behring Inst Mitt** 1995 Jun;(96):13–20 (37 ref.)

Fas-mediated cytotoxicity—a new immunoregulatory and pathogenic function of Th1 CD4+ T cells. Yagita H, et al. **Immunol Rev** 1995 Aug;146:223–39 (71 ref.)

Fas and FasL in the homeostatic regulation of immune responses. Lynch DH, et al. **Immunol Today** 1995 Dec; 16(12):569–74 (61 ref.)

Regulation of apoptosis in neutrophils—Fas track to death? Liles WC, et al. **J Immunol** 1995 Oct 1;155(7):3289–91 (71 ref.)

Lupus in the Fas lane? Singh AK. **J R Coll Physicians Lond** 1995 Nov-Dec;29(6):475–8 (40 ref.)

[The Fas/APO-1 antigen—a molecule mediating apoptosis] Baryshnikov AIu, et al. **Gematol Transfuziol** 1995 Nov-Dec;40(6):35–8 (28 ref.) **(Rus)**

ANTIGENS, CD106 see **VASCULAR CELL ADHESION MOLECULE-1**

ANTIGENS, CD117 see **PROTO-ONCOGENE PROTEINS C-KIT**

ANTIGENS, CDW121A see **RECEPTORS, INTERLEUKIN-1**

ANTIGENS, CDW121B see **RECEPTORS, INTERLEUKIN-1**

ANTIGENS, CD122 see **RECEPTORS, INTERLEUKIN-2**

ANTIGENS, DIFFERENTIATION

GENETICS

Blocking CD28/B7 with soluble competitors: immunological phenotype of mCTLA4-H gamma 1 transgenic mice. Lane P. **Res Immunol** 1995 Mar-Apr;146(3):176–9 (30 ref.)

IMMUNOLOGY

Murine CD38: an immunoregulatory ectoenzyme. Lund F, et al. **Immunol Today** 1995 Oct;16(10):469–73 (46 ref.)

The Yin and Yang of T cell costimulation [see comments] Allison JP, et al. **Science** 1995 Nov 10;270(5238):932–3 (17 ref.) Comment in: Science 1995 Nov 10;270(5238):985–8.

METABOLISM

New aspects of the physiological significance of NAD, poly ADP-ribose and cyclic ADP-ribose. Okamoto H, et al. **Biochimie** 1995;77(5):356–63 (41 ref.)

1995 Mack-Forster Award Lecture. Review. Mast cell differentiation antigens: expression in normal and malignant cells and use for diagnostic purposes. Valent P. **Eur J Clin Invest** 1995 Oct;25(10):715–20 (51 ref.)

Signaling through CD28/CTLA-4 family receptors: puzzling participation of phosphatidylinositol-3 kinase. Hutchcroft JE, et al. **J Immunol** 1996 Jun 1;156(11):4071–4 (69 ref.)

CD28/CTLA-4 receptor structure, binding stoichiometry and aggregation during T-cell activation. Linsley PS, et al. **Res Immunol** 1995 Mar-Apr;146(3):130–40 (76 ref.)

PHYSIOLOGY

The leucocyte protein L1 (calprotectin): a putative nonspecific defence factor at epithelial surfaces. Brandtzaeg P, et al. **Adv Exp Med Biol** 1995;371A:201–6 (30 ref.)

The CD28 costimulatory pathway. Leung HT, et al. **Ther Immunol** 1994 Aug;1(4):217–28 (104 ref.)

ANTIGENS, DIFFERENTIATION, B-CELL see **ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE**

ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE

[CD22: a cell adhesion molecule that displays alpha 2-6-linked sialic acid-binding lectin activity] Hanasaki K. **Seikagaku** 1995 Aug;67(8):1040–7 (15 ref.) **(Jpn)**

CHEMISTRY

Invariant chain structure and MHC class II function. Cresswell P. **Cell** 1996 Feb 23;84(4):505–7 (17 ref.)

METABOLISM

Another twist to MHC-peptide recognition [comment] Wilson IA. **Science** 1996 May 17;272(5264):973–4 (20 ref.) Comment on: Nature 1996 May 17;272(5264):1001–4.

ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE

IMMUNOLOGY

T-cell recognition of antigen. A process controlled by transient intermolecular interactions. Boniface JJ, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:62–9 (34 ref.)

CD1 and the expanding universe of T cell antigens. Porcelli SA, et al. **J Immunol** 1995 Oct 15;155(8):3709–10 (18 ref.)

PHYSIOLOGY

C-type lectins of natural killer cells: carbohydrate ligands and role in tumour cell lysis. Bezouška K. **Biochem Soc Trans** 1996 Feb;24(1):156–61 (24 ref.)

ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC

ANALYSIS

CD31 immunoreactivity in mesenchymal neoplasms of the skin and subcutis: report of 145 cases and review of putative immunohistologic markers of endothelial differentiation. DeYoung BR, et al. **J Cutan Pathol** 1995 Jun;22(3):215–22 (45 ref.)

PHYSIOLOGY

PECAM-1: its expression and function as a cell adhesion molecule on hemopoietic and endothelial cells. Watt SM, et al. **Leuk Lymphoma** 1995 Apr;17(3–4):229–44 (85 ref.)

ANTIGENS, DIFFERENTIATION, T-CELL see **ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE**

ANTIGENS, FUNGAL

ANALYSIS

Tools and trends in the detection of Aspergillus fumigatus. Latgé JP. **Curr Top Med Mycol** 1995;6:245–81 (137 ref.)

BLOOD

Comparative assessment of the detection of candidal antigens as a diagnostic tool. Matthews RC. **J Med Vet Mycol** 1996 Jan-Feb;34(1):1–10 (83 ref.)

DIAGNOSTIC USE

Biochemistry and molecular biology of the main diagnostic antigen of Paracoccidioides brasiliensis. Travassos LR, et al. **Arch Med Res** 1995 Autumn;26(3):297–304 (30 ref.)

IMMUNOLOGY

T-cell activation, anergy and immunomodulation by molecules of viral, fungal and vegetal origin. Bemer V, et al. **Res Immunol** 1995 May-Jun;146(4–5):249–62 (81 ref.)

ANTIGENS, HELMINTH

ANALYSIS

[Phosphocholine antigens in muscle larvae of Trichinella spiralis] Bitkowska E. **Wiad Parazytol** 1996;42(1):57–63 (37 ref.) (Eng. Abstr.) **(Pol)**

IMMUNOLOGY

Progress on vaccination against Haemonchus contortus. Newton SE. **Int J Parasitol** 1995 Nov;25(11):1281–9 (35 ref.)

Comparison of purified 12 kDa and recombinant 15 kDa Fasciola hepatica antigens related to a Schistosoma mansoni fatty acid binding protein. Hillyer GV. **Mem Inst Oswaldo Cruz** 1995 Mar-Apr;90(2):249–53 (17 ref.)

THERAPEUTIC USE

Synthetic peptide vaccines for schistosomiasis. Harn DA, et al. **Pharm Biotechnol** 1995;6:891–905 (41 ref.)

ANTIGENS, HETEROGENETIC see **ANTIGENS, HETEROPHILE**

ANTIGENS, HETEROPHILE

IMMUNOLOGY

Comparison of purified 12 kDa and recombinant 15 kDa Fasciola hepatica antigens related to a Schistosoma mansoni fatty acid binding protein. Hillyer GV. **Mem Inst Oswaldo Cruz** 1995 Mar-Apr;90(2):249–53 (17 ref.)

ANTIGENS, HLA-C see **HLA-C ANTIGENS**

ANTIGENS, HLA-D see **HLA-D ANTIGENS**

ANTIGENS, HUMAN PLATELET

IMMUNOLOGY

Human platelet alloantigens: recent findings, new perspectives. Newman PJ, et al. **Thromb Haemost** 1995 Jul; 74(1):234–9 (26 ref.)

[Platelet antigens: immunology and immuno-allergology] de Sousa JC, et al. **Allerg Immunol (Paris)** 1996 Feb; 28(2):48–51 (22 ref.) (Eng. Abstr.) **(Fre)**

[Diagnosis and therapy of fetal alloimmune thrombocytopenia] Marzusch K, et al. **Geburtshilfe Frauenheilkd** 1995 Oct;55(10):587–91 (29 ref.) (Eng. Abstr.) **(Ger)**

ANTIGENS, IMMUNE RESPONSE see **HISTOCOMPATIBILITY ANTIGENS CLASS II**

ANTIGENS, KI-1 see **ANTIGENS, CD30**

ANTIGENS, LEUKEMIA, COMMON ACUTE LYMPHOBLASTIC see **MEMBRANE METALLO-ENDOPEPTIDASE**

ANTIGENS, LY

Tissue expression, structure and function of the murine Ly-6 family of molecules. Gumley TP, et al. **Immunol Cell Biol** 1995 Aug;73(4):277–96 (111 ref.)

ANTIGENS, NEOPLASM

Tumor antigens in astrocytic gliomas. Kurpad SN, et al. **Glia** 1995 Nov;15(3):244–56 (105 ref.)

Analysis of TCR usage in human tumors: a new tool for assessing tumor-specific immune responses. Sensi M, et al. **Immunol Today** 1995 Dec;16(12):588–95 (64 ref.)

Onconeural antigens and the paraneoplastic neurologic disorders: at the intersection of cancer, immunity, and the brain. Darnell RB. **Proc Natl Acad Sci U S A** 1996 May 14;93(10):4529–36 (107 ref.)

Studies on the expression of T-(Gal beta (1-3) GalNAc alpha 1-O-R) and T-like antigens in normal and pathologic human and rat urothelium. Langkilde NC. **Scand J Urol Nephrol Suppl** 1995;176:7–46 (188 ref.)

Antigens recognized on human tumors by cytolytic T lymphocytes: towards vaccination? Coulie PG. **Stem Cells (Dayt)** 1995 Jul;13(4):393–403 (65 ref.)

ANALYSIS

TAG-72 expression and its role in the biological evaluation of human colorectal cancer. Guadagni F, et al. **Anticancer Res** 1996 Jul-Aug;16(4B):2141–8 (71 ref.)

Tumor markers as targets for selective diagnostic and therapeutic procedures. Roselli M, et al. **Anticancer Res** 1996 Jul-Aug;16(4B):2187–92 (59 ref.)

Squamous cell carcinoma-associated antigens used in novel strategies for the detection and treatment of minimal residual head and neck cancer. van Dongen GA, et al. **Anticancer Res** 1996 Jul-Aug;16(4C):2409–13 (41 ref.)

T and Tn pancarcinoma markers: autoantigenic adhesion molecules in pathogenesis, prebiopsy carcinoma-detection, and long-term breast carcinoma immunotherapy. Springer GF. **Crit Rev Oncog** 1995;6(1):57–85 (220 ref.)

Differentiation and prognosis of neuroblastoma in correlation to the expression of CD44s. Terpe HJ, et al. **Eur J Cancer** 1995;31A(4):549–52 (60 ref.)

Radioimmunoguided Surgery system improves survival for patients with recurrent colorectal cancer. Bertsch DJ, et al. **Surgery** 1995 Oct;118(4):634–8; discussion 638–9 (9 ref.)

[Future of malignant stage I melanoma. Immunology and immunotherapy] Nicolas JF, et al. **Ann Dermatol Venereol** 1995;122(5):324–35 (105 ref.) **(Fre)**

BLOOD

Serum (circulating) tumor markers for breast cancer. Hayes DF. **Recent Results Cancer Res** 1996;140:101–13 (52 ref.)

CLASSIFICATION

[Kinds of cancer-associated antigens and their properties] Sawabu N. **Nippon Rinsho** 1996 Jun;54(6):1489–93 (4 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

The immunotherapy of solid cancers based on cloning the genes encoding tumor-rejection antigens. Rosenberg SA. **Annu Rev Med** 1996;47:481–91 (38 ref.)

Tumors antigens encoded by oncogenes and the impact of oncogenes upon the immune responses. Appleman LJ, et al. **Cell Immunol** 1996 May 25;170(1):1–10 (129 ref.)

Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Van Pel A, et al. **Immunol Rev** 1995 Jun; 145:229–50 (92 ref.)

Human tumor rejection antigens MAGE. Itoh K, et al. **J Biochem (Tokyo)** 1996 Mar;119(3):385–90 (33 ref.)

ANTIGENS, NEOPLASM

IMMUNOLOGY

A genetic approach to idiotypic vaccination for B cell lymphoma. Stevenson FK, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:212–26 (23 ref.)

Costimulation of T-cell–mediated tumor immunity. Hellström KE, et al. **Cancer Chemother Pharmacol** 1996; 38 Suppl:S40–1 (30 ref.)

The polymorphic epithelial mucin: potential as an immunogen for a cancer vaccine. Graham RA, et al. **Cancer Immunol Immunother** 1996 Feb;42(2):71–80 (61 ref.)

New tumor antigens recognized by T cells. Van den Eynde B, et al. **Curr Opin Immunol** 1995 Oct;7(5):674–81 (71 ref.)

Curing metastases? Gene and peptide therapy. Eisenbach L. **Curr Top Microbiol Immunol** 1996;213 (Pt 3):85–100 (150 ref.)

Immunity to oncogenic proteins. Cheever MA, et al. **Immunol Rev** 1995 Jun;145:33–59 (81 ref.)

Tumor therapy by immune recruitment with bispecific antibodies. Renner C, et al. **Immunol Rev** 1995 Jun; 145:179–209 (153 ref.)

Human tumor antigens recognized by T lymphocytes. Boon T, et al. **J Exp Med** 1996 Mar 1;183(3):725–9 (60 ref.)

Human melanoma antigens recognized by T lymphocytes. Kawakami Y, et al. **Keio J Med** 1996 Jun;45(2):100–8 (78 ref.)

Performance of CD3xCD19 bispecific monoclonal antibodies in B cell malignancy. Haagen IA. **Leuk Lymphoma** 1995 Nov;19(5–6):381–93 (160 ref.)

Regulation by tumour antigens defines a role for PP2A in signal transduction. Mumby M. **Semin Cancer Biol** 1995 Aug;6(4):229–37 (59 ref.)

[Dendritic cells and immune function in cancer] Chaux P. **Pathol Biol (Paris)** 1995 Dec;43(10):897–903 (53 ref.) (Eng. Abstr.) **(Fre)**

[Dendritic cells and tumor cell therapy] Pioche C, et al. **Pathol Biol (Paris)** 1995 Dec;43(10):904–9 (43 ref.) (Eng. Abstr.) **(Fre)**

[How do melanoma cells circumvent the immune response? Consequences for future therapy attempts and current biopsy processing] Dummer R, et al. **Schweiz Med Wochenschr** 1995 Sep 2;125(35):1638–41 (24 ref.) (Eng. Abstr.) **(Ger)**

[Tumor rejection antigen and cancer immunotherapy] Matsutake T, et al. **Gan To Kagaku Ryoho** 1995 Nov; 22(13):1871–7 (37 ref.) (Eng. Abstr.) **(Jpn)**

[Tumor–rejection antigens expressed on human squamous cell carcinoma] Itoh K, et al. **Hum Cell** 1995 Dec;8(4):149–54 (7 ref.) (Eng. Abstr.) **(Jpn)**

[Analysis of tumor rejection antigen peptides recognized by specific CTL] Uenaka A, et al. **Nippon Rinsho** 1996 Jan; 54(1):242–9 (20 ref.) (Eng. Abstr.) **(Jpn)**

ISOLATION & PURIFICATION

Human tumour antigens recognized by T-cells: perspectives for new cancer vaccines. Van den Eynde B, et al. **Biochem Soc Trans** 1995 Aug;23(3):681–6 (38 ref.)

PHYSIOLOGY

Expression and function of squamous cell carcinoma antigen. Kato H. **Anticancer Res** 1996 Jul–Aug;16(4B):2149–53 (19 ref.)

CD44 in colon cancer. Herrlich P, et al. **Eur J Cancer** 1995 Jul–Aug;31A(7–8):1110–2 (32 ref.)

Antigen–presenting function of the TL antigen and mouse CD1 molecules. Cheroutre H, et al. **Immunol Rev** 1995 Oct;147:31–52 (73 ref.)

THERAPEUTIC USE

The immunotherapy of solid cancers based on cloning the genes encoding tumor–rejection antigens. Rosenberg SA. **Annu Rev Med** 1996;47:481–91 (38 ref.)

T-cell immunotherapy of tumors by adoptive transfer of cytotoxic T lymphocytes and by vaccination with minimal essential epitopes. Melief CJ, et al. **Immunol Rev** 1995 Jun; 145:167–77 (42 ref.)

From defined human tumor antigens to effective immunization? Boon T, et al. **Immunol Today** 1995 Jul; 16(7):334–6 (18 ref.)

ANTIGENS, PLATELET-SPECIFIC see **ANTIGENS, HUMAN PLATELET**

ANTIGENS, POLYOMAVIRUS TRANSFORMING

GENETICS

[Establishment of immortalized cell lines with differentiation phenotypes from the transgenic mice harboring temperature–sensitive SV40 T–antigen gene] Obinata M. **Seikagaku** 1995 Dec;67(12):1391–6 (11 ref.) **(Jpn)**

ANTIGENS, PROTOZOAN

ANALYSIS

Specialized surface adaptations of Giardia lamblia. Aley SB, et al. **Infect Agents Dis** 1995 Sep;4(3):161–6 (32 ref.)

IMMUNOLOGY

Nucleic acid malaria vaccines. Current status and potential. Hoffman SL, et al. **Ann N Y Acad Sci** 1995 Nov 27; 772:88–94 (11 ref.)

Advances toward the development of an asexual blood stage MSP–1 vaccine of Plasmodium vivax. Levitus G, et al. **Mem Inst Oswaldo Cruz** 1994;89 Suppl 2:81–4 (13 ref.)

The role of MHC– and non–MHC–associated genes in determining the human immune response to malaria antigens. Riley EM. **Parasitology** 1996;112 Suppl:S39–51 (78 ref.)

[Towards a vaccination against malaria] Ambroise–Thomas P. **Rev Med Interne** 1995;16(9):717–23 (48 ref.) (Eng. Abstr.) **(Fre)**

ANTIGENS, SURFACE

Tissue expression, structure and function of the murine Ly–6 family of molecules. Gumley TP, et al. **Immunol Cell Biol** 1995 Aug;73(4):277–96 (111 ref.)

Studies on the expression of T–(Gal beta (1–3) GalNAc alpha 1–O–R) and T–like antigens in normal and pathologic human and rat urothelium. Langkilde NC. **Scand J Urol Nephrol Suppl** 1995;176:7–46 (188 ref.)

[K–antigen as a marker of Klebsiella pneumoniae and its use in clinical and epidemiological analysis (literature review)] Priamukhina NS, et al. **Klin Lab Diagn** 1996 Mar–Apr; (2):47–9 (29 ref.) **(Rus)**

ANALYSIS

Specialized surface adaptations of Giardia lamblia. Aley SB, et al. **Infect Agents Dis** 1995 Sep;4(3):161–6 (32 ref.)

[Leukocyte surface antigen] Nakahara K. **Nippon Rinsho** 1996 Jun;54(6):1536–41 (8 ref.) (Eng. Abstr.) **(Jpn)**

CHEMISTRY

The variable surface glycolipids of mycobacteria: structures, synthesis of epitopes, and biological properties. Aspinall GO, et al. **Adv Carbohydr Chem Biochem** 1995;51:169–242 (226 ref.)

IMMUNOLOGY

The gut associated addressins: lymphocyte homing in the gut. De Keyser F, et al. **Baillieres Clin Rheumatol** 1996 Feb;10(1):25–39 (65 ref.)

Human melanoma antigens recognized by T lymphocytes. Kawakami Y, et al. **Keio J Med** 1996 Jun;45(2):100–8 (78 ref.)

Monoclonal antibodies to cell–specific cell surface carbohydrates in plant cell biology and development. Pennell RI, et al. **Methods Cell Biol** 1995;49:123–41 (61 ref.)

Cholinergic–specific glycoconjugates. Whittaker VP, et al. **Neurochem Res** 1995 Nov;20(11):1377–87 (47 ref.)

Phenotypic variation of carbohydrate surface antigens and the pathogenesis of Haemophilus influenzae infections. Roche RJ, et al. **Trends Microbiol** 1995 Aug;3(8):304–9 (60 ref.)

[Follicular dendritic cells: phenotype, origin and functions] Heinen E. **Pathol Biol (Paris)** 1995 Dec;43(10):848–57 (43 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

The alpha 6 beta 1 and alpha 6 beta 4 integrins in human prostate cancer progression. Cress AE, et al. **Cancer Metastasis Rev** 1995 Sep;14(3):219–28 (67 ref.)

A family of murine NK cell receptors specific for target cell MHC class I molecules. Yokoyama WM, et al. **Semin Immunol** 1995 Apr;7(2):89–101 (93 ref.)

PHYSIOLOGY

C–type lectins of natural killer cells: carbohydrate ligands and role in tumour cell lysis. Bezouska K. **Biochem Soc Trans** 1996 Feb;24(1):156–61 (24 ref.)

ADAM, a novel family of membrane proteins containing A Disintegrin And Metalloprotease domain: multipotential functions in cell–cell and cell–matrix interactions. Wolfsberg TG, et al. **J Cell Biol** 1995 Oct;131(2):275–8 (22 ref.)

Plasma–membrane–bound macromolecules are dynamically aggregated to form non–random codistribution patterns of selected functional elements. Do pattern recognition processes govern antigen presentation and intercellular interactions? Vereb G, et al. **J Mol Recognit** 1995 Jul–Aug; 8(4):237–46 (78 ref.)

ANTIGENS, SYNTHETIC see **VACCINES, SYNTHETIC**

ANTIGENS, T-INDEPENDENT

IMMUNOLOGY

Are polysaccharide antibody responses independent: the T cell enigma? Lane P. **Clin Exp Immunol** 1996 Jul; 105(1):10–1 (16 ref.)

T cell independent antigens. Mond JJ, et al. **Curr Opin Immunol** 1995 Jun;7(3):349–54 (55 ref.)

The one signal theory of B cell activation revisited: a role for surface immunoglobulin in regulating T–independent antibody responses? Mamchak AA, et al. **Immunol Cell Biol** 1995 Jun;73(3):266–71 (29 ref.)

ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE

Studies on the expression of T–(Gal beta (1–3) GalNAc alpha 1–O–R) and T–like antigens in normal and pathologic human and rat urothelium. Langkilde NC. **Scand J Urol Nephrol Suppl** 1995;176:7–46 (188 ref.)

ANALYSIS

A simple mucus test for cancer screening. Shamsuddin AM. **Anticancer Res** 1996 Jul–Aug;16(4B):2193–9 (57 ref.)

T and Tn pancarcinoma markers: autoantigenic adhesion molecules in pathogenesis, prebiopsy carcinoma–detection, and long–term breast carcinoma immunotherapy. Springer GF. **Crit Rev Oncog** 1995;6(1):57–85 (220 ref.)

CA 50: a tumor marker for gastrointestinal malignancies. Bunworasate U, et al. **J Med Assoc Thai** 1995 May; 78(5):255–70 (155 ref.)

T–antigens in primary non–invasive and superficially invasive human urinary bladder tumors: the correlation to tumor recurrence and tumor progression. A mini–review. Langkilde NC. **Scand J Urol Nephrol Suppl** 1995;172:45–9 (55 ref.)

[Clinical value of carbohydrate antigens, sialyl Lewis–x and sialyl Lewis–a in gastrointestinal cancer] Nakamori S, et al. **Nippon Geka Gakkai Zasshi** 1996 Feb;97(2):165–71 (27 ref.) (Eng. Abstr.) **(Jpn)**

[Carbohydrate antigens as tumor marker] Ohkura H. **Nippon Geka Gakkai Zasshi** 1996 Feb;97(2):145–51 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Biological function of cancer–associated carbohydrate antigens] Kannagi R. **Nippon Rinsho** 1996 Jun;54(6):1551–9 (33 ref.) (Eng. Abstr.) **(Jpn)**

BLOOD

Circulating blood group related carbohydrate antigens as tumour markers. Orntoft TF, et al. **Glycoconj J** 1995 Jun; 12(3):200–5 (41 ref.)

IMMUNOLOGY

MUC–1 epithelial tumor mucin–based immunity and cancer vaccines. Finn OJ, et al. **Immunol Rev** 1995 Jun;145:61–89 (112 ref.)

METABOLISM

[Carbohydrate antigens in carcinoma invasion and metastasis] Izumi Y, et al. **Nippon Geka Gakkai Zasshi** 1996 Feb; 97(2):140–4 (13 ref.) (Eng. Abstr.) **(Jpn)**

[Expression of carbohydrate antigen in lung cancers] Miyake M. **Nippon Geka Gakkai Zasshi** 1996 Feb;97(2):160–4 (19 ref.) **(Jpn)**

[Biological malignant potential and carbohydrate antigens in breast cancer] Narita T, et al. **Nippon Geka Gakkai Zasshi** 1996 Feb;97(2):172–6 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Prognosis of colorectal cancer and sialyl–lea antigen] Watanabe M, et al. **Nippon Geka Gakkai Zasshi** 1996 Feb; 97(2):177–81 (13 ref.) **(Jpn)**

PHYSIOLOGY

Possible roles of tumor–associated carbohydrate antigens. Fukuda M. **Cancer Res** 1996 May 15;56(10):2237–44 (92 ref.)

[Functions of mucin molecules in gastrointestinal cancer] Imai K, et al. **Nippon Geka Gakkai Zasshi** 1996 Feb; 97(2):152–9 (34 ref.) (Eng. Abstr.) **(Jpn)**

[Carbohydrate antigens as cell adhesion molecules] Kannagi R. **Nippon Geka Gakkai Zasshi** 1996 Feb;97(2):131–9 (43 ref.) (Eng. Abstr.) **(Jpn)**

[Antisense strategies in studies on the role of sugar chains in phenotype expression of neoplasms] Ugorski M. **Postepy Hig Med Dosw** 1995;49(1):77–84 (22 ref.) (Eng. Abstr.) **(Pol)**

ANTIGENS, VIRAL

Superantigenic characteristics of mouse mammary tumor viruses play a critical role in susceptibility to infection in mice. Pucillo CE, et al. **Immunol Res** 1995;14(1):58–68 (62 ref.)

ADMINISTRATION & DOSAGE

Retrovirus and retrotransposon particles as antigen presentation and delivery systems. Adams SE, et al. **Pharm Biotechnol** 1995;6:769–86 (63 ref.)

ANALYSIS

Molecular diagnosis of nasopharyngeal carcinoma: a review. Gan YY, et al. **Ann Acad Med Singapore** 1996 Jan; 25(1):71–4 (32 ref.)

[Viral tumor markers] Ohtsuru A, et al. **Nippon Rinsho** 1996 Jun;54(6):1529–35 (18 ref.) (Eng. Abstr.) **(Jpn)**

BLOOD

The cytomegalovirus antigenemia assay: a plea for standardization. The TH, et al.

Scand J Infect Dis Suppl 1995;99:25-9 (31 ref.)

CHEMISTRY

Interactions of protein antigens with antibodies. Davies DR, et al. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):7-12 (69 ref.)

DIAGNOSTIC USE

Production of recombinant hantavirus nucleocapsid protein expressed in silkworm larvae and its use as a diagnostic antigen in detecting antibodies in serum from infected rats. Yoshimatsu K, et al. **Lab Anim Sci** 1995 Dec;45(6):641-6 (8 ref.)

GENETICS

Antigenic variants in a plaque-isolate of foot-and-mouth disease virus: implications for vaccine production. Piatti P, et al. **Vaccine** 1995;13(8):781-4 (23 ref.)

IMMUNOLOGY

DNA immunization with bovine herpesvirus-1 genes. Babiuk LA, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:47-63 (56 ref.)

Molecular mimicry between Fc receptors and viral antigens. Oleszak EL. **Arch Immunol Ther Exp (Warsz)** 1994; 42(2):83-8 (53 ref.)

T-cell activation, anergy and immunomodulation by molecules of viral, fungal and vegetal origin. Bemer V, et al. **Res Immunol** 1995 May-Jun;146(4-5):249-62 (81 ref.)

Antigenic differences among pestiviruses. Edwards S, et al. **Vet Clin North Am Food Anim Pract** 1995 Nov;11(3):563-77 (107 ref.)

[Antibodies generated against hepatitis C virus (HCV) core antigen: IgM and IgA antibody against HCV core] Sato S, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:253-9 (16 ref.) **(Jpn)**

ANTIGENS, XENOGENEIC see **ANTIGENS, HETEROPHILE**

ANTIGLOBULINS see **ANTIBODIES, ANTI-IDIOTYPIC**

ANTIGOUT AGENTS see **GOUT SUPPRESSANTS**

ANTI-HBAG see **HEPATITIS B ANTIBODIES**

ANTI-HCV ANTIBODIES see **HEPATITIS C ANTIBODIES**

ANTIHEMOPHILIC FACTOR see **FACTOR VIII**

ANTIHEPARIN FACTOR see **PLATELET FACTOR 4**

ANTI-HEPATITIS B ANTIGENS see **HEPATITIS B ANTIBODIES**

ANTI-HEPATITIS C VIRUS ANTIBODIES see **HEPATITIS C ANTIBODIES**

ANTIHISTAMINES see **HISTAMINE H1 ANTAGONISTS**

ANTIHISTAMINES, CLASSICAL see **HISTAMINE H1 ANTAGONISTS**

ANTIHISTAMINICS, CLASSICAL see **HISTAMINE H1 ANTAGONISTS**

ANTIHISTAMINICS, H1 see **HISTAMINE H1 ANTAGONISTS**

ANTIHISTAMINICS, H2 see **HISTAMINE H2 ANTAGONISTS**

ANTI-HIV POSITIVITY see **HIV SEROPOSITIVITY**

ANTI-HUMAN GLOBULIN COMPLEMENT-DEPENDENT CYTOTOXICITY TESTS see **CYTOTOXICITY TESTS, IMMUNOLOGIC**

ANTIHYPERTENSIVE AGENTS

see related
ADRENERGIC ALPHA-ANTAGONISTS
ADRENERGIC BETA-ANTAGONISTS
ANGIOTENSIN-CONVERTING ENZYME INHIBITORS
DIURETICS
VASODILATOR AGENTS

Low-dose thiazides in the treatment of hypertension: benefits and risks in perspective. Silverberg DS, et al. **J Hum Hypertens** 1995 Nov;9(11):869-73 (80 ref.)

Discovery of losartan, the first angiotensin II receptor antagonist. Timmermans PB, et al. **J Hum Hypertens** 1995 Nov;9 Suppl 5:S3-18 (199 ref.)

Angiotensin receptor antagonists: focus on losartan. Johnston CI. **Lancet** 1995 Nov 25;346(8987):1403-7 (36 ref.)

ADMINISTRATION & DOSAGE

Risk factors and differential antihypertensive therapies. Os I. **Acta Med Austriaca** 1995;22(3):45-7 (31 ref.)

Angiotensin converting enzyme inhibitors and calcium antagonists alone or combined: does the progression of diabetic renal disease differ? Bakris GL, et al. **J Hypertens Suppl** 1995 Aug;13(2):S95-101 (52 ref.)

Guidelines for the treatment of hypertension: an American view. Fifth Joint National Committee. Kaplan NM. **J Hypertens Suppl** 1995 Aug;13(2):S113-7 (16 ref.)

The pharmacological basis for the combination of calcium channel antagonists and angiotensin converting enzyme inhibitors in the treatment of hypertension. Osswald H, et al. **J Hypertens Suppl** 1995 Aug;13(2):S21-8 (58 ref.)

Main objectives and new aspects of combination treatment of hypertension. Waeber B, et al. **J Hypertens Suppl** 1995 Aug;13(2):S15-9 (17 ref.)

Practical relevance of the 24-hour trough: peak ratio of antihypertensive drugs. Zannad F. **J Hypertens Suppl** 1995 Aug;13(2):S109-12 (41 ref.)

Non-responders. Os I. **Wien Med Wochenschr** 1995; 145(15-16):357-60 (32 ref.)

[Antihypertensive therapy in stroke: acute therapy, primary and secondary prevention] Brainin M. **Acta Med Austriaca** 1995;22(3):54-7 (36 ref.) (Eng. Abstr.) **(Ger)**

[Refractory hypertension--principles of combination therapy] Hitzenberger G. **Acta Med Austriaca** 1995; 22(3):43-5 (14 ref.) (Eng. Abstr.) **(Ger)**

[Antihypertensive therapy in renal failure] Mayer G. **Acta Med Austriaca** 1995;22(3):51-3 (19 ref.) (Eng. Abstr.) **(Ger)**

[Interactions between antihypertensive agents of different mechanisms of action] Hitzenberger G. **Wien Med Wochenschr** 1995;145(15-16):352-4 (22 ref.) (Eng. Abstr.) **(Ger)**

[What are the therapeutic consequences of evaluating hypertensive patients with 24-hour blood pressure monitors and blood pressure self-measurement?] Zweiker R, et al. **Wien Med Wochenschr** 1995;145(15-16):365-72 (74 ref.) (Eng. Abstr.) **(Ger)**

[Anti-hypertensive therapy in chronic hemodialysis] Takabatake T. **Nippon Naika Gakkai Zasshi** 1995 Oct 10; 84(10):1643-7 (5 ref.) **(Jpn)**

[Combination drugs in the treatment of hypertension. Simpler for patients, physicians and pharmacies] Himmelmann A, et al. **Lakartidningen** 1995 Sep 27;92(39):3557-8, 3563 (20 ref.) **(Swe)**

ADVERSE EFFECTS

Factors influencing the success of withdrawal of antihypertensive drug therapy. Jennings GL, et al. **Blood Press Suppl** 1995;2:99-107 (28 ref.)

The changing face of hypertension and antihypertensive agents. Kitler ME. **Drugs Aging** 1996 Jan;8(1):5-11 (43 ref.)

Improving the therapeutic balance between efficacy and tolerability in antihypertensive drugs--the rationale and benefits of combining felodipine and metoprolol. Trenkwalder P, et al. **J Hum Hypertens** 1995 Jul;9 Suppl 2:S37-42 (17 ref.)

Perioperative angioedema in a patient on long-term angiotensin-converting enzyme (ACE)-inhibitor therapy. Ogbureke KU, et al. **J Oral Maxillofac Surg** 1996 Jul; 54(7):917-20 (18 ref.)

Hydralazine-induced constrictive pericarditis. Franssen CF, et al. **Neth J Med** 1996 May;48(5):193-7 (21 ref.)

At risk nephrons and the decline in renal function in response to treatment of hypertension. Walker WG, et al. **Trans Am Clin Climatol Assoc** 1995;107:134-43; discussion 143-5 (26 ref.)

[Psychotropic effects of angiotensin-converting enzyme inhibitors: what are the arguments?] Mesure G, et al. **Encephale** 1995 Sep-Oct;21(5):609-14 (59 ref.) (Eng. Abstr.) **(Fre)**

[Side effects of antihypertensive drugs] Córdoba García R. **Aten Primaria** 1996 Apr 15;17(6):420-4 (54 ref.) **(Spa)**

[Concomitant therapies in the clinical trial in Alzheimer's disease] Bermejo F, et al. **Rev Neurol** 1995 Jan-Feb; 23(119):118-24 (81 ref.) (Eng. Abstr.) **(Spa)**

BLOOD

[Beta-blocking agents] Suzuki M. **Nippon Rinsho** 1995 Feb; 53 Su Pt 1:978-82 (16 ref.) **(Jpn)**

CHEMISTRY

Renin inhibitors. Rosenberg SH. **Prog Med Chem** 1995; 32:37-114 (296 ref.)

ECONOMICS

Cost-effectiveness of hypertension treatment. Ménard J. **Clin Exp Hypertens** 1996 Apr-May;18(3-4):399-413 (77 ref.)

[The cost/benefit of antihypertensive therapy] Pessina AC. **Ann Ital Med Int** 1995 Oct;10 Suppl:96S-98S (16 ref.) (Eng. Abstr.) **(Ita)**

PHARMACOKINETICS

Clinical pharmacokinetics and efficacy of renin inhibitors. Rongen GA, et al. **Clin Pharmacokinet** 1995 Jul;29(1):6-14 (71 ref.)

PHARMACOLOGY

Angiotensin-II receptor antagonists: a new class of antihypertensive agents. Weir MR. **Am Fam Physician** 1996 Feb 1;53(2):589-94 (26 ref.)

Disparate effects of antihypertensive drugs on large artery distensibility and compliance in hypertension. Van Bortel LM, et al. **Am J Cardiol** 1995 Nov 24;76(15):46E-49E (24 ref.)

Torsemide: a new loop diuretic. Fowler SF, et al. **Am J Health Syst Pharm** 1995 Aug 15;52(16):1771-80; quiz 1814-5 (60 ref.)

Review: the effects of antihypertensive agents on serum lipids. Madu EC, et al. **Am J Med Sci** 1996 Aug; 312(2):76-84 (143 ref.)

Angiotensin II antagonists: a new class of antihypertensive agent. Waeber B, et al. **Br J Clin Pract** 1996 Jul-Aug; 50(5):265-8 (35 ref.)

Role of bradykinin in the antihypertensive and cardioprotective actions of converting enzyme inhibitors. Zhu YC, et al. **Can J Physiol Pharmacol** 1995 Jul; 73(7):827-31 (39 ref.)

Renin inhibition. Kleinert HD. **Cardiovasc Drugs Ther** 1995 Oct;9(5):645-55 (80 ref.)

New central mediators as targets of centrally acting antihypertensive drugs. van Zwieten PA. **Clin Exp Hypertens** 1996 Apr-May;18(3-4):291-303 (38 ref.)

Antiatherosclerotic effects of antihypertensive drugs: recent evidence and ongoing trials. Zanchetti A. **Clin Exp Hypertens** 1996 Apr-May;18(3-4):489-99 (12 ref.)

Vascular effects of selected antihypertensive drugs derived from traditional medicinal herbs. Kwan CY. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S297-9 (12 ref.)

Angiotensin II receptor antagonism: losartan - sites and mechanisms of action. Triggle DJ. **Clin Ther** 1995 Nov-Dec;17(6):1005-30 (132 ref.)

Effects of chronic MPTP and 3-nitropropionic acid in nonhuman primates. Brouillet E, et al. **Curr Opin Neurol** 1995 Dec;8(6):469-73 (44 ref.)

Carvedilol, a novel vasodilating beta-blocker with the potential for cardiovascular organ protection. Feuerstein GZ, et al. **Eur Heart J** 1996 Apr;17 Suppl B:24-9 (24 ref.)

Effect of angiotensin II blockade on cardiac hypertrophy and remodelling: a review. Dahlöf B. **J Hum Hypertens** 1995 Nov;9 Suppl 5:S37-44 (84 ref.)

Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy. Wexler RR, et al. **J Med Chem** 1996 Feb 2;39(3):625-56 (326 ref.)

Hypertension and associated metabolic abnormalities--the role of insulin resistance and the sympathoadrenal system. Reaven GM, et al. **N Engl J Med** 1996 Feb 8;334(6):374-81 (85 ref.)

Influence of anti-hypertensive drugs on glomerular hemodynamics. Ito S, et al. **Nippon Jinzo Gakkai Shi** 1996 Mar;38(3):115-8 (20 ref.)

Central imidazoline receptors as a target for centrally acting antihypertensive drugs. van Zwieten PA. **Pharm World Sci** 1995 Nov 24;17(6):186-90 (28 ref.)

Interactions between endothelial mediators. Gryglewski RJ. **Pharmacol Toxicol** 1995 Jul;77(1):1-9 (120 ref.)

[Adrenomedullin] Zeng Z. **Chung Hua Nei Ko Tsa Chih** 1995 Sep;34(9):635-7 (14 ref.) **(Chi)**

[Angiotensin receptor antagonists. A new class of antihypertensive agents] Mann J. **Dtsch Med Wochenschr** 1996 Apr 26;121(17):568-71 (22 ref.) **(Ger)**

[Role of ambulatory blood pressure monitoring in the evaluation of the therapeutic efficacy of antihypertensive drugs. Trough/peak relation] Nobre F. **Arq Bras Cardiol** 1995 Mar;64(3):247-9 (27 ref.) **(Por)**

POISONING

Poisoning with anti-hypertensive drugs: alpha-adrenoceptor antagonists. Lip GY, et al. **J Hum Hypertens** 1995 Jul; 9(7):523-6 (21 ref.)

Poisoning with anti-hypertensive drugs: methyldopa and clonidine. Zarifis J, et al. **J Hum Hypertens** 1995 Oct; 9(10):787-90 (31 ref.)

[Acute voluntary poisoning with acebutolol (letter)] Darmanaden R, et al. **Therapie** 1995 Nov-Dec;50(6):591-3 (18 ref.) **(Fre)**

THERAPEUTIC USE

Management of hypertension, Part II [see comments] Moser M. **Am Fam Physician** 1996 Jun;53(8):2553-60 (21 ref.) Comment in: Am Fam Physician 1996 Jun;53(8):2427-8.

Direct selective blockade of the vascular angiotensin II receptors in therapy for hypertension and severe congestive heart failure. Awan NA, et al. **Am Heart J** 1996 Jan; 131(1):177-85 (81 ref.)

Implications of the links between hypertension and myocardial infarction for choice of drug therapy in patients with hypertension. Meredith PA. **Am Heart J** 1996 Jul; 132(1 Pt 2 Su):222-8 (29 ref.)

Comparative effects of indapamide and captopril on blood pressure and albumin excretion rate in diabetic microalbuminuria. Donnelly R, et al. **Am J Cardiol** 1996 Feb 22;77(6):26B-30B (33 ref.)

Microvascular angina in systemic hypertension: diagnosis and treatment with enalapril. Iriarte MM, et al.

Am J Cardiol 1995 Nov 2;76(13):31D–34D (18 ref.)

Cardioprotection and antihypertensive therapy: the key importance of addressing the associated coronary risk factors (the Framingham experience). Kannel WB. **Am J Cardiol** 1996 Feb 22;77(6):6B–11B (19 ref.)

Diuretics: cornerstone of antihypertensive therapy. Kaplan NM. **Am J Cardiol** 1996 Feb 22;77(6):3B–5B (22 ref.)

Response of hypertensive left ventricular hypertrophy and coronary microvascular disease to calcium antagonists. Vogt M, et al. **Am J Cardiol** 1995 Nov 2;76(13):24D–30D (52 ref.)

Prevention and treatment of diabetic nephropathy. Foote EF. **Am J Health Syst Pharm** 1995 Aug 15;52(16):1781–92 (94 ref.)

Torsemide: a new loop diuretic. Fowler SF, et al. **Am J Health Syst Pharm** 1995 Aug 15;52(16):1771–80; quiz 1814–5 (60 ref.)

The coronary artery disease paradox. Black HR. **Am J Hypertens** 1996 Apr;9(4 Pt 3):2S–10S (66 ref.)

Cardioprotective potential of antihypertensives. Hansson L. **Am J Hypertens** 1995 Oct;8(10 Pt 2):49S–52S (20 ref.)

Lessons on the interaction of race and antihypertensive drugs from the VA cooperative study group on antihypertensive agents. Materson BJ. **Am J Hypertens** 1995 Dec;8(12 Pt 2):91s–93s (13 ref.)

Are antihypertensive drugs similar in protecting the kidney? Ritz E. **Am J Hypertens** 1995 Oct;8(10 Pt 2):53S–58S (45 ref.)

A chronotherapeutic approach to the management of hypertension. White WB. **Am J Hypertens** 1996 Apr;9(4 Pt 3):29S–33S (27 ref.)

Absolute cardiovascular risk: the basis for deciding to treat. Alderman MH. **Am J Nephrol** 1996;16(3):182–9 (40 ref.)

Differing effects of antihypertensive agents on urinary albumin excretion. Weir MR. **Am J Nephrol** 1996; 16(3):237–45 (69 ref.)

Angiotensin II receptor blockers. A new class of antihypertensive drugs. Velasquez MT. **Arch Fam Med** 1996 Jun;5(6):351–6 (60 ref.)

Calcium antagonists should continue to be used for first-line treatment of hypertension [see comments] Epstein M. **Arch Intern Med** 1995 Nov 13;155(20):2150–6 (52 ref.) Comment in: Arch Intern Med 1995 Nov 13;155(20):2145. Comment in: Arch Intern Med 1996 May 27;156(10):1115–6.

Should dihydropyridines be used as first-line drugs in the treatment of hypertension? The con side [see comments] Furberg CD, et al. **Arch Intern Med** 1995 Nov 13; 155(20):2157–61 (32 ref.) Comment in: Arch Intern Med 1995 Nov 13;155(20):2145. Comment in: Arch Intern Med 1996 May 27;156(10):1115–6.

Review of studies with urapidil in elderly hypertensives. Hansson L, et al. **Blood Press** 1995;Suppl 3:21–5 (21 ref.)

Potential beneficial effects of urapidil in primary and secondary prevention of stroke. Späh F, et al. **Blood Press** 1995;Suppl 3:62–7 (49 ref.)

Pharmacological backgrounds of the drug treatment of hypertension in the elderly. van Zwieten PA. **Blood Press** 1995;Suppl 3:15–20 (33 ref.)

Review of studies with urapidil in elderly hypertensives. Hansson L, et al. **Blood Press Suppl** 1995;3:21–5 (21 ref.)

Pharmacological backgrounds of the drug treatment of hypertension in the elderly. Van Zwieten PA. **Blood Press Suppl** 1995;3:15–20 (33 ref.)

Doxazosin: a new approach to hypertension and benign prostatic hyperplasia. Pool JL. **Br J Clin Pract** 1996 Apr–May;50(3):154–63 (70 ref.)

Drug treatment of hypertension in the elderly. Lund-Johansen P. **Cardiologia** 1995 Jul;40(7):465–75 (88 ref.)

Angiotensin II receptor antagonists in heart failure: rationale and design of the evaluation of losartan in the elderly (ELITE) trial. Pitt B, et al. **Cardiovasc Drugs Ther** 1995 Oct;9(5):693–700 (80 ref.)

Cardiovascular structural alterations in hypertension: effect of treatment. Agabiti-Rosei E, et al. **Clin Exp Hypertens** 1996 Apr–May;18(3–4):513–22 (42 ref.)

Impact of guidelines for antihypertensive treatment on clinical practice. Chalmers J. **Clin Exp Hypertens** 1996 Apr–May;18(3–4):415–23 (15 ref.)

Compliance with antihypertensive treatment. Costa FV. **Clin Exp Hypertens** 1996 Apr–May;18(3–4):463–72 (20 ref.)

The case for a greater blood pressure fall. Hansson L. **Clin Exp Hypertens** 1996 Apr–May;18(3–4):425–34 (19 ref.)

Antihypertensive treatment in the elderly. Lindholm LH. **Clin Exp Hypertens** 1996 Apr–May;18(3–4):435–47 (33 ref.)

Ambulatory blood pressure, blood pressure variability and antihypertensive treatment. Mancia G, et al. **Clin Exp Hypertens** 1996 Apr–May;18(3–4):449–62 (22 ref.)

Cost-effectiveness of hypertension treatment. Ménard J. **Clin Exp Hypertens** 1996 Apr–May;18(3–4):399–413 (77 ref.)

Experimental approaches to determining the choice of first-step therapy for patients with hypertension. The ALLHAT Research Group Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Whelton PK, et al. **Clin Exp Hypertens** 1996 Apr–May; 18(3–4):569–79 (17 ref.)

Diabetes and hypertension. Smolar EN. **Compr Ther** 1995 Oct;21(10):597–601 (25 ref.)

Treatment modalities for hypertensive patients with intracranial pathology: options and risks. Tietjen CS, et al. **Crit Care Med** 1996 Feb;24(2):311–22 (86 ref.)

Newer antihypertensive drugs. Gregoire JR, et al. **Curr Opin Cardiol** 1995 Sep;10(5):445–9 (38 ref.)

Are angiotensin-converting enzyme inhibitors the renal protective antihypertensive drugs of choice? [editorial] Bauer JH. **Curr Opin Nephrol Hypertens** 1995 Sep; 4(5):427–31 (23 ref.)

Measuring the effects of antihypertensive therapy upon the quality of life. Fletcher A. **Curr Opin Nephrol Hypertens** 1995 Nov;4(6):538–42 (33 ref.)

The management of hypertension in diabetes: with special reference to diabetic kidney disease. Leese GP, et al. **Diabet Med** 1996 May;13(5):401–10 (145 ref.)

Simvastatin. A reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolaemia. Plosker GL, et al. **Drugs** 1995 Aug;50(2):334–63 (239 ref.)

Risk and management of hypertension-related left ventricular hypertrophy. Teo KK. **Drugs** 1995 Dec;50(6):959–70 (80 ref.)

Celiprolol. An evaluation of its pharmacological properties and clinical efficacy in the management of hypertension and angina pectoris. Dunn CJ, et al. **Drugs Aging** 1995 Nov; 7(5):394–411 (111 ref.)

The changing face of hypertension and antihypertensive agents. Kitler ME. **Drugs Aging** 1996 Jan;8(1):5–11 (43 ref.)

Hypertensive emergencies. Murphy C. **Emerg Med Clin North Am** 1995 Nov;13(4):973–1007 (141 ref.)

Nonemergent hypertension. New perspectives for the emergency medicine physician. Thach AM, et al. **Emerg Med Clin North Am** 1995 Nov;13(4):1009–35 (107 ref.)

Carvedilol, a novel multiple action antihypertensive agent with antioxidant activity and the potential for myocardial and vascular protection. Feuerstein GZ, et al. **Eur Heart J** 1995 Jul;16 Suppl F:38–42 (21 ref.)

Directions in antihypertensive treatment—our future from the past. Maisch B, et al. **Eur Heart J** 1995 May;16 Suppl C:74–83 (75 ref.)

Neuropsychological consequences of antihypertensive medication use. Muldoon MF, et al. **Exp Aging Res** 1995 Oct-Dec;21(4):353–68 (68 ref.)

Should calcium antagonists be first line drugs in hypertension? Furberg CD, et al. **Herz** 1995 Dec; 20(6):365–9 (10 ref.)

Hypertension and CHD risk: whither alpha-1 blockers? Pandit RB. **Indian Heart J** 1996 May-Jun;48(3):265–71 (41 ref.)

Controversy in the pharmacologic treatment of hypertension in African Americans [see comments] Lockette W. **J Assoc Acad Minor Phys** 1995;6(4):125–9 (32 ref.) Comment in: J Assoc Acad Minor Phys 1995;6(4):124.

Management of hypertensive urgencies and emergencies. Abdelwahab W, et al. **J Clin Pharmacol** 1995 Aug; 35(8):747–62 (100 ref.)

The future role of losartan. Hansson L. **J Hum Hypertens** 1995 Nov;9 Suppl 5:S55–8 (24 ref.)

Managing hypertension in general practice: can we do better? Hosie J, et al. **J Hum Hypertens** 1995 Jul;9 Suppl 2:S15–8 (7 ref.)

What are the implications for the community of the discrepancy between the theory and practice of BP control? Jackson R. **J Hum Hypertens** 1995 Jul;9 Suppl 2:S25–8 (8 ref.)

Current issues in the control of hypertension. Lund-Johansen P. **J Hum Hypertens** 1995 Nov;9 Suppl 5:S25–8 (31 ref.)

Improving the management of hypertension in clinical practice. Mancia G. **J Hum Hypertens** 1995 Jul;9 Suppl 2:S29–31 (13 ref.)

Limiting factors in the control of BP: why is there a gap between theory and practice? Ménard J, et al. **J Hum Hypertens** 1995 Jul;9 Suppl 2:S19–23 (17 ref.)

The hidden truth: what do the clinical trials really tell us about BP control? Ruilope LM. **J Hum Hypertens** 1995 Jul;9 Suppl 2:S3–7 (13 ref.)

New ideas for treating hypertension. Schachter M. **J Hum Hypertens** 1995 Aug;9(8):663–7 (40 ref.)

The heterogeneity of hypertension: why doesn't every patient respond to every antihypertensive drug? Sever P. **J Hum Hypertens** 1995 Jul;9 Suppl 2:S33–6 (8 ref.)

Management guidelines for hypertension: is anyone taking notice? Swales JD. **J Hum Hypertens** 1995 Jul;9 Suppl 2:S9–13 (13 ref.)

Improving the therapeutic balance between efficacy and tolerability in antihypertensive drugs—the rationale and benefits of combining felodipine and metoprolol. Trenkwalder P, et al. **J Hum Hypertens** 1995 Jul;9 Suppl 2:S37–42 (17 ref.)

Managing the elderly hypertensive patient beyond blood pressure reduction. Holzgreve H. **J Hypertens Suppl** 1995 Aug;13(2):S103–7 (15 ref.)

Metabolic aspects of the treatment of hypertension. Lithell H. **J Hypertens Suppl** 1995 Aug;13(2):S77–80 (29 ref.)

Update on the use of angiotensin converting enzyme inhibitors and calcium antagonists in postinfarction patients. Persson S. **J Hypertens Suppl** 1995 Aug;13(2):S57–63 (33 ref.)

Hypertension in the non-insulin-dependent diabetes mellitus syndrome: a critical review of therapeutic intervention. Rett K, et al. **J Hypertens Suppl** 1995 Aug;13(2):S81–5 (26 ref.)

Effects of angiotensin converting enzyme inhibitors on the progression of diabetic nephropathy. Ruilope LM. **J Hypertens Suppl** 1995 Aug;13(2):S91–3 (26 ref.)

Guidelines for the management of hypertension: the World Health Organization/International Society of Hypertension view. World Health Organization. International Society of Hypertension. Zanchetti A. **J Hypertens Suppl** 1995 Aug; 13(2):S119–22 (19 ref.)

Long-term therapy of hypertension. Yoo WS. **Korean J Intern Med** 1995 Jul;10(2):79–86 (25 ref.)

A practical guideline for management of hypertension in patients with diabetes. Fatourechi V, et al. **Mayo Clin Proc** 1996 Jan;71(1):53–8 (37 ref.)

Treatment of hypertension in pregnant women. Sibai BM. **N Engl J Med** 1996 Jul 25;335(4):257–65 (93 ref.)

Renal involvement in essential hypertension and treatment effects. de Leeuw PW, et al. **Neth J Med** 1995 Oct; 47(4):199–204 (43 ref.)

Reversibility of left ventricular hypertrophy by antihypertensive drugs. Fagard RH. **Neth J Med** 1995 Oct; 47(4):173–9 (47 ref.)

Effects of antihypertensive drugs on large artery compliance. Slama M, et al. **Neth J Med** 1995 Oct;47(4):162–8 (48 ref.)

The use of calcium-channel blockers in pregnancy. Lewis R, et al. **New Horiz** 1996 Feb;4(1):115–22 (45 ref.)

Current considerations in patients with coexistent diabetes and hypertension. Wood MH. **Nurse Pract** 1996 Apr; 21(4):19–20, 27–31 (24 ref.)

Antihypertensive drug use in the long-term care facility: a pilot study and review of the literature. Fish JT, et al. **Pharmacotherapy** 1995 Nov–Dec;15(6):785–8 (11 ref.)

Hypertensive crises. The need for urgent management [see comments] Varon J, et al. **Postgrad Med** 1996 Jan; 99(1):189–91, 195–6, 199–200, passim (21 ref.) Comment in: Postgrad Med 1996 Mar;99(3):70–1.

Blood pressure lowering for the primary and secondary prevention of coronary and cerebrovascular disease. MacMahon S, et al. **Schweiz Med Wochenschr** 1995 Dec 26;125(51–52):2479–86 (28 ref.)

[Diagnosis and treatment of hypertensive emergencies] Burnier M, et al. **Schweiz Med Wochenschr** 1995 Nov 25; 125(47):2261–6 (8 ref.) (Eng. Abstr.) **(Fre)**

[Diagnosis and treatment of arterial hypertension in the elderly] Waeber B, et al. **Schweiz Rundsch Med Prax** 1996 Feb 6;85(6):150–4 (19 ref.) (Eng. Abstr.) **(Fre)**

[Antihypertensive therapy and coronary heart disease: significance of the effect of concomitant cardiovascular risk factors] Huber K, et al. **Acta Med Austriaca** 1995; 22(3):48–51 (47 ref.) (Eng. Abstr.) **(Ger)**

[Angiotensin receptor antagonists. A new class of antihypertensive agents] Mann J. **Dtsch Med Wochenschr** 1996 Apr 26;121(17):568–71 (22 ref.) **(Ger)**

[Retrospective studies and prospects of therapy for hypertension] Maisch B, et al. **Herz** 1995 Dec;20(6):370–89 (96 ref.) (Eng. Abstr.) **(Ger)**

[Angiotensin II receptor antagonists. Clinical relevance] Scholze J. **Internist (Berl)** 1996 Jun;37(6):636–42 (47 ref.) **(Ger)**

[Therapy of hypertension 1996. Effectiveness, tolerance, cost-benefit aspects] Rahn KH. **Med Klin** 1996 Jun 15; 91(6):380–3 (8 ref.) **(Ger)**

[Hypertension in the elderly] Reinhart WH. **Schweiz Med Wochenschr** 1996 Aug 24;126(34):1442–5 (19 ref.) (Eng. Abstr.) **(Ger)**

[Treatment of hypertension in elderly patients] Vetter W, et al. **Schweiz Rundsch Med Prax** 1995 Oct 31; 84(44):1277–81 (25 ref.) (Eng. Abstr.) **(Ger)**

[Beta blockers and diuretics: therapeutic drugs of first choice in diabetes mellitus and hypertension] Sawicki PT. **Wien Klin Wochenschr** 1995;107(21):629–39 (98 ref.) (Eng. Abstr.) **(Ger)**

[Results of the 3rd Consensus Conference on "Individualized Therapy of Hypertension" and brief explanation of individual evaluation] **Wien Med Wochenschr** 1995; 145(15–16):339–49 (0 ref.) **(Ger)**

[Evaluation of the antihypertensive drugs carvedilol, doxazosin and moxonidine] Dominiak P. **Wien Med Wochenschr** 1995;145(15–16):373–82 (92 ref.) (Eng. Abstr.) **(Ger)**

[Selected passages from the clinical trials of Cordaflex] Somogyi M, et al. **Acta Pharm Hung** 1996 Jan;66(1):47–51 (16 ref.) (Eng. Abstr.) **(Hun)**

[Basic principles of current trends in the management of hypertension and kidney disease in pregnancy] Vajó Z, et al. **Orv Hetil** 1995 Nov 19;136(47):2561–6 (45 ref.) (Eng. Abstr.) **(Hun)**

[New therapeutic outlooks in the treatment of the hypertensive patient] Ambrosioni E, et al. **Ann Ital Med Int** 1995 Oct;10 Suppl:78S–81S (20 ref.) (Eng. Abstr.) **(Ita)**

[The intervention trial in the evaluation of antihypertensive therapy] Mancia G, et al. **Ann Ital Med Int** 1995 Oct;10 Suppl:108S–111S (20 ref.) (Eng. Abstr.) **(Ita)**

[The treatment of intraoperative arterial hypertension with Urapidil] Filosso PL. **Minerva Cardioangiol** 1996 Apr; 44(4):197–207 (45 ref.) **(Ita)**

[Losartan and the LIFE-study. Antihypertensive treatment with AT1-receptor antagonist] Kjeldsen SE, et al. **Tidsskr Nor Laegeforen** 1996 Feb 10;116(4):504–7 (25 ref.) (Eng. Abstr.) **(Nor)**

[Imidazol receptor agonists—new possibilities for treating

hypertension] Nowicki M, et al. **Postepy Hig Med Dosw** 1995;49(5):631–43 (56 ref.) (Eng. Abstr.) **(Pol)**

[Our point of view. Trough to peak ratio of antihypertensive drugs: methodologic issues and clinical implications] Polónia J. **Rev Port Cardiol** 1996 Apr;15(4):281–92 (30 ref.) **(Por)**

[The use of perindopril (prestarium) in arterial hypertension] Filatova NP. **Ter Arkh** 1995;67(9):81–3 (35 ref.) **(Rus)**

ANTI-IDIOTYPE ANTIBODIES see **ANTIBODIES, ANTI-IDIOTYPIC**

ANTI-INFECTIVE AGENTS

see related
ANTHELMINTICS
ANTIPROTOZOAL AGENTS

NO inhibitions: antimicrobial properties of nitric oxide. De Groote MA, et al. **Clin Infect Dis** 1995 Oct;21 Suppl 2:S162–5 (55 ref.)

The panorama of cyclosporin research. Balakrishnan K, et al. **J Basic Microbiol** 1996;36(2):121–47 (292 ref.)

Oligosaccharide anti-infective agents. Zopf D, et al. **Lancet** 1996 Apr 13;347(9007):1017–21 (28 ref.)

ADMINISTRATION & DOSAGE

Practical guidelines for the treatment of cholera. Seas C, et al. **Drugs** 1996 Jun;51(6):966–73 (24 ref.)

Use of antimicrobial-impregnated polymethyl methacrylate. Tobias KM, et al. **J Am Vet Med Assoc** 1996 Mar 15; 208(6):841–5 (50 ref.)

ADVERSE EFFECTS

The risks and benefits of antimicrobial therapy in pregnancy. Garland SM, et al. **Drug Saf** 1995 Sep;13(3):188–205 (46 ref.)

Dapsone toxicity: some current perspectives. Coleman MD. **Gen Pharmacol** 1995 Nov;26(7):1461–7 (51 ref.)

Trimethoprim–sulfamethoxazole–associated acute febrile neutrophilic dermatosis: case report and review of drug-induced Sweet's syndrome. Walker DC, et al. **J Am Acad Dermatol** 1996 May;34(5 Pt 2):918–23 (21 ref.)

Sulfadiazine-associated nephrotoxicity in patients with the acquired immunodeficiency syndrome. Becker K, et al. **Medicine (Baltimore)** 1996 Jul;75(4):185–94 (56 ref.)

[Kidney insufficiency: toxicity factor of methyl-bromo-hydroxyquinoline (letter)] Zeraidi N, et al. **Ann Med Interne (Paris)** 1995;146(8):593–5 (16 ref.) **(Fre)**

[Cotrimoxazole induced dermatitis and curative treatment of AIDS pneumocystosis] Caumes E. **Rev Mal Respir** 1996; 13(2):101–6 (45 ref.) (Eng. Abstr.) **(Fre)**

ANALYSIS

Cathelicidins: a novel protein family with a common proregion and a variable C-terminal antimicrobial domain. Zanetti M, et al. **FEBS Lett** 1995 Oct 23;374(1):1–5 (55 ref.)

BLOOD

[Sulfa drugs] Fukaya K. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:1017–9 (6 ref.) **(Jpn)**

CHEMISTRY

Antibacterial and immunostimulating casein-derived substances from milk: casecidin, isracidin peptides. Lahov E, et al. **Food Chem Toxicol** 1996 Jan;34(1):131–45 (49 ref.)

Drug chirality: a consideration of the significance of the stereochemistry of antimicrobial agents. Hutt AJ, et al. **J Antimicrob Chemother** 1996 Jan;37(1):7–32 (83 ref.)

METABOLISM

Polyethers. Birch AW, et al. **Biotechnology** 1995;28:443–76 (100 ref.)

PHARMACOKINETICS

Local antibacterial therapy for the management of orthopaedic infections. Pharmacokinetic considerations. Henry SL, et al. **Clin Pharmacokinet** 1995 Jul;29(1):36–45 (88 ref.)

Clinical pharmacokinetics in patients with burns. Jaehde U, et al. **Clin Pharmacokinet** 1995 Jul;29(1):15–28 (75 ref.)

Antibacterial agents in renal failure. Livornese LL Jr, et al. **Infect Dis Clin North Am** 1995 Sep;9(3):591–614 (41 ref.)

PHARMACOLOGY

Cationic bactericidal peptides. Hancock RE, et al. **Adv Microb Physiol** 1995;37:135–75 (215 ref.)

Recent advances: antiinfectives. Briceland LL, et al. **Ann Pharmacother** 1995 Oct;29(10):1035–40 (49 ref.)

Antimicrobial properties of tea (Camellia sinensis L.). Hamilton-Miller JM. **Antimicrob Agents Chemother** 1995 Nov;39(11):2375–7 (48 ref.)

Drug interaction and pharmacological considerations during anti-infective therapy in cancer patients. Petitjean O, et al. **Cancer Treat Res** 1995;79:255–80 (223 ref.)

In-vitro activity of antibacterial drugs and clinical practice. **Drug Ther Bull** 1995 Sep;33(9):71–2 (12 ref.)

Meropenem. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Wiseman LR, et al. **Drugs** 1995 Jul;50(1):73–101 (195 ref.)

Pharmacological aspects and therapeutic applications of lysozymes. Sava G. **EXS** 1996;75:433–49 (79 ref.)

Pharmacodynamics of antimicrobial agents. Bactericidal and postantibiotic effects. Levison ME. **Infect Dis Clin North Am** 1995 Sep;9(3):483–95 (26 ref.)

In vitro testing of antimicrobial agents. Woods GL. **Infect Dis Clin North Am** 1995 Sep;9(3):463–81 (60 ref.)

Development of vaginal microbicides for the prevention of heterosexual transmission of HIV. Pauwels R, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Mar 1;11(3):211–21 (70 ref.)

Susceptibility of oral bacterial biofilms to antimicrobial agents. Wilson M. **J Med Microbiol** 1996 Feb;44(2):79–87 (54 ref.)

Bacterial responses to host-defense peptides. Groisman EA. **Trends Microbiol** 1996 Apr;4(4):127–8; discussion 128–9 (17 ref.)

[Propolis: its use in technology and research] Gallo FR, et al. **Boll Chim Farm** 1995 Oct;134(9):483–91 (15 ref.) (Eng. Abstr.) **(Ita)**

[Modern methods and means for the rapid determination of the sensitivity of the causative agents of dangerous infectious diseases to antibiotics and chemical preparations] D'iakov SI, et al. **Voen Med Zh** 1996 Mar;317(3):44–7 (17 ref.) **(Rus)**

THERAPEUTIC USE

Past, present, and future of antimicrobial agents. Moellering RC Jr. **Am J Med** 1995 Dec 29;99(6A):11S–18S (37 ref.)

Local antibacterial therapy for the management of orthopaedic infections. Pharmacokinetic considerations. Henry SL, et al. **Clin Pharmacokinet** 1995 Jul;29(1):36–45 (88 ref.)

Gonorrhoea: single-dose oral treatment. Kohl PK, et al. **Curr Probl Dermatol** 1996;24:82–9 (29 ref.)

Antimicrobial treatment of psoriasis. Skinner RB Jr, et al. **Dermatol Clin** 1995 Oct;13(4):909–13 (18 ref.)

In-vitro activity of antibacterial drugs and clinical practice. **Drug Ther Bull** 1995 Sep;33(9):71–2 (12 ref.)

Bacterial meningitis. Practical guidelines for management. Rockowitz J, et al. **Drugs** 1995 Nov;50(5):838–53 (98 ref.)

Adjuncts to antibacterial therapy. Frank MO, et al. **Infect Dis Clin North Am** 1995 Sep;9(3):769–81 (63 ref.)

Principles of selection and use of antibacterial agents. Hessen MT, et al. **Infect Dis Clin North Am** 1995 Sep;9(3):531–45 (61 ref.)

Antibacterial agents in pregnancy. Korzeniowski OM. **Infect Dis Clin North Am** 1995 Sep;9(3):639–51 (65 ref.)

Antibacterial agents in infections of the central nervous system and eye. Papastamelos AG, et al. **Infect Dis Clin North Am** 1995 Sep;9(3):615–37 (81 ref.)

Antimicrobial agents for treatment of infectious keratitis in horses. Moore CP, et al. **J Am Vet Med Assoc** 1995 Oct 1;207(7):855–62 (29 ref.)

Tarnished gold: sixty years of antimicrobial drug use and misuse [editorial] Greenwood D. **J Med Microbiol** 1995 Dec;43(6):395–6 (12 ref.)

Management of HIV infection. A 1995–96 overview for the clinician. Henry K. **Minn Med** 1995 Nov;78(11):17–24 (25 ref.)

Cure of a solitary brainstem abscess with antibiotic therapy: case report. Fulgham JR, et al. **Neurology** 1996 May; 46(5):1451–4 (10 ref.)

Microbiology and antimicrobial therapy of spinal infections. Sapico FL. **Orthop Clin North Am** 1996 Jan;27(1):9–13 (22 ref.)

Options in the management of pneumonia caused by Pneumocystis carinii in patients with acquired immune deficiency syndrome and intolerance to trimethoprim/sulfamethoxazole. Korraa H, et al. **South Med J** 1996 Mar;89(3):272–7 (38 ref.)

[Endophthalmitis. 2: treatment] Bron A. **J Fr Ophtalmol** 1996; 19(4):294–314 (164 ref.) **(Fre)**

[Influence of colloidal bismuth subcitrate, metronidazole, and amoxycillin on Helicobacter pylori and gastroduodenal ulcer healing] Quintero M, et al. **G E N** 1995 Apr–Jun; 49(2):116–22 (21 ref.) (Eng. Abstr.) **(Spa)**

ANTI-INFECTIVE AGENTS, FLUOROQUINOLONE

ADMINISTRATION & DOSAGE

Oral fleroxacin prophylaxis in transurethral surgery. Gasser TC, et al. **J Urol** 1996 Jul;156(1):146–8 (27 ref.)

ADVERSE EFFECTS

Tolerability of fluoroquinolone antibiotics. Past, present and future. Ball P, et al. **Drug Saf** 1995 Dec;13(6):343–58 (130 ref.)

Fluoroquinolone toxicities. An update. Lietman PS. **Drugs** 1995;49 Suppl 2:159–63 (20 ref.)

Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group. Jaillon P, et al. **J Antimicrob Chemother** 1996 May;37 Suppl A:161–7 (4 ref.)

ANALYSIS

[Fluoroquinolone] Matsumoto F, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:1010–6 (12 ref.) **(Jpn)**

CHEMISTRY

Pharmacokinetic interactions related to the chemical structures of fluoroquinolones. Mizuki Y, et al. **J Antimicrob Chemother** 1996 May;37 Suppl A:41–55 (46 ref.)

Quinolones: structure-activity relationships and future predictions. Tillotson GS. **J Med Microbiol** 1996 May; 44(5):320–4 (19 ref.)

CLASSIFICATION

Classification and structure-activity relationships of fluoroquinolones. Bryskier A, et al. **Drugs** 1995;49 Suppl 2:16–28 (27 ref.)

PHARMACOKINETICS

Pharmacokinetic interactions related to the chemical structures of fluoroquinolones. Mizuki Y, et al. **J Antimicrob Chemother** 1996 May;37 Suppl A:41–55 (46 ref.)

Pharmacokinetics of sparfloxacin in healthy volunteers and patients: a review. Montay G. **J Antimicrob Chemother** 1996 May;37 Suppl A:27–39 (20 ref.)

A review of the penetration of sparfloxacin into the lower respiratory tract and sinuses. Wise R, et al. **J Antimicrob Chemother** 1996 May;37 Suppl A:57–63 (18 ref.)

[Pharmacokinetics of fluoroquinolones in patients with renal insufficiency] Iakovlev SV, et al. **Antibiot Khimioter** 1995 Oct;40(10):39–47 (57 ref.) **(Rus)**

PHARMACOLOGY

Antimicrobial agent resistance in mycobacteria: molecular genetic insights. Musser JM. **Clin Microbiol Rev** 1995 Oct; 8(4):496–514 (181 ref.)

Classification and structure-activity relationships of fluoroquinolones. Bryskier A, et al. **Drugs** 1995;49 Suppl 2:16–28 (27 ref.)

Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability. Davis R, et al. **Drugs** 1996 Jun;51(6):1019–74 (517 ref.)

In vitro activity of fluoroquinolones against gram-positive bacteria. Eliopoulos GM. **Drugs** 1995;49 Suppl 2:48–57 (37 ref.)

Mechanisms of resistance to fluoroquinolones: state-of-the-art 1992–1994. Piddock LJ. **Drugs** 1995;49 Suppl 2:29–35 (27 ref.)

In-vitro activity of sparfloxacin in comparison with currently available antimicrobials against respiratory tract pathogens. Baquero F, et al. **J Antimicrob Chemother** 1996 May;37 Suppl A:1–18 (76 ref.)

Quinolones: structure-activity relationships and future predictions. Tillotson GS. **J Med Microbiol** 1996 May; 44(5):320–4 (19 ref.)

Resistance to quinolones in mycobacteria. Cambau E, et al. **Res Microbiol** 1996 Jan–Feb;147(1–2):52–9 (41 ref.)

Antimycobacterial quinolones: a comparative analysis of structure-activity and structure-cytotoxicity relationships. Klopman G, et al. **Res Microbiol** 1996 Jan–Feb; 147(1–2):86–96 (32 ref.)

[Mechanism of action and resistance to fluoroquinolones] Alarcón T, et al. **Enferm Infecc Microbiol Clin** 1996 Feb; 14(2):111–7 (83 ref.) **(Spa)**

THERAPEUTIC USE

Fluoroquinolones in paediatrics—1995. Dagan R. **Drugs** 1995; 49 Suppl 2:92–9 (54 ref.)

Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability. Davis R, et al. **Drugs** 1996 Jun;51(6):1019–74 (517 ref.)

The use of fluoroquinolones in sexually transmitted diseases in Southeast Asia. Sivayathorn A. **Drugs** 1995;49 Suppl 2:123–7 (23 ref.)

Fluoroquinolones. Hendershot EF. **Infect Dis Clin North Am** 1995 Sep;9(3):715–30 (44 ref.)

Fluoroquinolones and bacterial enteritis, when and for whom? Wiström J, et al. **J Antimicrob Chemother** 1995 Jul; 36(1):23–39 (84 ref.)

Quinolones: a practical review of clinical uses, dosing considerations, and drug interactions. Borcherding SM, et al. **J Fam Pract** 1996 Jan;42(1):69–78 (70 ref.)

Lower respiratory tract infection therapy—the role of ciprofloxacin. Ball AP, et al. **J Int Med Res** 1995 Sep–Oct; 23(5):315–27 (55 ref.)

Treatment of infections caused by rapidly growing mycobacteria in the era of the newer macrolides. Wallace RJ Jr. **Res Microbiol** 1996 Jan–Feb;147(1–2):30–5 (34 ref.)

[Treatment of cystitis in women] Lobel B. **Presse Med** 1995 Oct 28;24(32):1527–9 (9 ref.) (Eng. Abstr.) **(Fre)**

[Fluoroquinolones in clinical practice. Pefloxacin (abaktal, peflacine)] Fomina IP, et al. **Antibiot Khimioter** 1995 Nov–Dec;40(11–12):70–7 (28 ref.) **(Rus)**

ANTI-INFECTIVE AGENTS, LOCAL

see related
DISINFECTANTS

Antiseptics and disinfectants. Current issues. Terleckyj B, et al. **J Am Podiatr Med Assoc** 1995 Aug;85(8):439–45 (32 ref.)

Antimicrobial skin preparations for the maxillofacial region. Morgan JP 3rd, et al. **J Oral Maxillofac Surg** 1996 Jan; 54(1):89–94 (56 ref.)

ADMINISTRATION & DOSAGE

An analysis of bacteremias during dental extractions. A double-blind, placebo-controlled study of chlorhexidine. Lockhart PB. **Arch Intern Med** 1996 Mar 11;156(5):513–20 (67 ref.)

Choice of wound dressings and ointments. Brown CD, et al. **Otolaryngol Clin North Am** 1995 Oct;28(5):1081–91 (52 ref.)

ADVERSE EFFECTS

[Daily administration of nose drops can cause chronic nasal congestion] Graf P, et al. **Lakartidningen** 1996 Jan 24; 93(4):259–62 (17 ref.) **(Swe)**

PHARMACOLOGY

Antimicrobial actions of fluoride for oral bacteria. Marquis RE. **Can J Microbiol** 1995 Nov;41(11):955–64 (92 ref.)

THERAPEUTIC USE

Topical antibacterial agents. Kaye ET, et al. **Infect Dis Clin North Am** 1995 Sep;9(3):547–59 (58 ref.)

Principles of pharmacologic intervention. Goodson JM. **J Clin Periodontol** 1996 Mar;23(3 Pt 2):268–72 (17 ref.)

[Antiseptics in skin diseases] Wolkenstein P, et al. **Ann Dermatol Venereol** 1996;123(5):343–8 (50 ref.) **(Fre)**

TOXICITY

Toxicological aspects of topical silver pharmaceuticals. Hollinger MA. **Crit Rev Toxicol** 1996 May;26(3):255–60 (57 ref.)

ANTI-INFECTIVE AGENTS, QUINOLONE

PHARMACOLOGY

Molecular mechanisms of drug inhibition of DNA gyrase. Lewis RJ, et al. **Bioessays** 1996 Aug;18(8):661–71 (73 ref.)

Quinolone activity against anaerobes: microbiological aspects. Appelbaum PC. **Drugs** 1995;49 Suppl 2:76–80 (42 ref.)

Activity of quinolones against gram-positive cocci: clinical features. Giamarellou H. **Drugs** 1995;49 Suppl 2:58–66 (60 ref.)

Epidemiology of quinolone resistance: Europe and North and South America. Goldstein FW, et al. **Drugs** 1995;49 Suppl 2:36–42 (49 ref.)

Quinolone mode of action. Hooper DC. **Drugs** 1995;49 Suppl 2:10–5 (32 ref.)

Activity of quinolones against mycobacteria. Jacobs MR. **Drugs** 1995;49 Suppl 2:67–75 (29 ref.)

Effect of quinolones on the human intestinal microflora. Nord CE. **Drugs** 1995;49 Suppl 2:81–5 (22 ref.)

THERAPEUTIC USE

Role of quinolones in the treatment of diarrhoeal diseases. Akalin HE. **Drugs** 1995;49 Suppl 2:128–31 (31 ref.)

Quinolones in the elderly. Bergan T. **Drugs** 1995;49 Suppl 2:112–4 (25 ref.)

The role of new quinolones in the treatment of respiratory tract infections. Finch RG. **Drugs** 1995;49 Suppl 2:144–51 (20 ref.)

The use of quinolones as therapy in granulocytopenic cancer patients. Comparison with other antimicrobials. Krcméry V Jr. **Drugs** 1995;49 Suppl 2:139–43 (30 ref.)

Quinolones and osteomyelitis: state-of-the-art. Lew DP, et al. **Drugs** 1995;49 Suppl 2:100–11 (48 ref.)

Short course quinolone therapy of typhoid fever in developing countries. Limson BM. **Drugs** 1995;49 Suppl 2:136–8 (21 ref.)

Veterinary use of new quinolones in Japan. Nakamura S. **Drugs** 1995;49 Suppl 2:152–8 (41 ref.)

Prophylactic use of the new quinolones for prevention of nosocomial infection in the intensive care unit. Potgieter PD, et al. **Drugs** 1995;49 Suppl 2:86–91 (34 ref.)

Quinolones in sexually transmitted diseases. Global experience. Ridgway GL. **Drugs** 1995;49 Suppl 2:115–22 (46 ref.)

A guide to the treatment of lower respiratory tract infections. Vogel F. **Drugs** 1995 Jul;50(1):62–72 (56 ref.)

The new quinolones in the treatment of diarrhoea and typhoid fever. Waiz A. **Drugs** 1995;49 Suppl 2:132–5 (54 ref.)

[Prevention using quinolones in transurethral surgery] Gasser TC. **Ann Urol (Paris)** 1996;30(3):124–8 (30 ref.) **(Eng. Abstr.)** **(Fre)**

[Urinary infections and the role of quinolones] Rutschmann O. **Rev Med Suisse Romande** 1996 May;116(5):405–8 (34 ref.) **(Fre)**

ANTI-INFECTIVE AGENTS, TOPICAL see **ANTI-INFECTIVE AGENTS, LOCAL**

ANTI-INFECTIVE AGENTS, URINARY

ADVERSE EFFECTS

[Trimethoprim-sulfamethoxazole-induced cholestatic hepatitis. Clinico-immunological demonstration of its allergic origin] Cario E, et al. **Dtsch Med Wochenschr** 1996 Feb 2;121(5):129–32 (10 ref.) (Eng. Abstr.) **(Ger)**

THERAPEUTIC USE

Urinary tract infections in elderly women. Nygaard IE, et al. **Am Fam Physician** 1996 Jan;53(1):175–82 (29 ref.)

Treatment of urinary tract infections. Korman TM, et al. **Aust Fam Physician** 1995 Dec;24(12):2205–11 (5 ref.)

Cotrimoxazole. Rationale for re-examining its indications for use. Howe RA, et al. **Drug Saf** 1996 Apr;14(4):213–8 (35 ref.)

Vancomycin, trimethoprim-sulfamethoxazole, and rifampin. Lundstrom TS, et al. **Infect Dis Clin North Am** 1995 Sep; 9(3):747–67 (91 ref.)

ANTI-INFLAMMATORY AGENTS

Immunosuppressive and anti-inflammatory properties of interleukin 10. de Vries JE. **Ann Med** 1995 Oct;27(5):537–41 (48 ref.)

Molecular mechanisms of anti-inflammatory action of glucocorticoids. Cato AC, et al. **Bioessays** 1996 May; 18(5):371–8 (67 ref.)

Complement-specific antibodies: designing novel anti-inflammatories. Matis LA, et al. **Nat Med** 1995 Aug; 1(8):839–42 (18 ref.)

Phosphodiesterase type IV inhibitors. Palfreyman MN, et al. **Prog Med Chem** 1996;33:1–52 (306 ref.)

ADMINISTRATION & DOSAGE

The adjuvant therapy of pemphigus. An update. Bystryn JC, et al. **Arch Dermatol** 1996 Feb;132(2):203–12 (89 ref.)

PHARMACOLOGY

Anti-inflammatory mechanisms of glucocorticoids. Barnes PJ. **Biochem Soc Trans** 1995 Nov;23(4):940–5 (50 ref.)

Sulphasalazine, sulphapyridine or 5-aminosalicylic acid—which is the active moiety in rheumatoid arthritis? Bird HA. **Br J Rheumatol** 1995 Nov;34 Suppl 2:16–9 (11 ref.)

The antirheumatic agents sulphasalazine and methotrexate share an anti-inflammatory mechanism. Cronstein BN. **Br J Rheumatol** 1995 Nov;34 Suppl 2:30–2 (20 ref.)

Sulphasalazine: mechanism of action in rheumatoid arthritis. Smedegård G, et al. **Br J Rheumatol** 1995 Nov;34 Suppl 2:7–15 (133 ref.)

Theophylline and selective phosphodiesterase inhibitors as anti-inflammatory drugs in the treatment of bronchial asthma. Banner KH, et al. **Eur Respir J** 1995 Jun; 8(6):996–1000 (50 ref.)

Methotrexate for inflammatory bowel disease: pharmacology and preliminary results [see comments] Egan LJ, et al. **Mayo Clin Proc** 1996 Jan;71(1):69–80 (98 ref.) Comment in: Mayo Clin Proc 1996 Jan;71(1):104–5.

Immunomodulatory actions of xanthines and isoenzyme selective phosphodiesterase inhibitors. Banner KH, et al. **Monaldi Arch Chest Dis** 1995 Aug;50(4):286–92 (96 ref.)

Mechanism of action of anti-inflammatory drugs. Vane JR, et al. **Scand J Rheumatol Suppl** 1996;102:9–21 (75 ref.)

[Heparin—new perspectives on its antiinflammatory action] Krasnowska M, et al. **Postepy Hig Med Dosw** 1995; 49(5):661–9 (56 ref.) (Eng. Abstr.) **(Pol)**

THERAPEUTIC USE

Modern treatment of asthma in children. Zeffren BS, et al. **Adv Pediatr** 1996;43:423–68 (214 ref.)

Anti-inflammatory drugs in the fight against Alzheimer's disease. McGeer PL, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:213–20 (16 ref.)

Anti-inflammatory agents in allergic diseases [editorial] Bonham CA, et al. **Clin Exp Immunol** 1995 Oct;102(1):1–5 (45 ref.)

Treatment of early rheumatoid arthritis: a review of current and future concepts and therapy [see comments] Dawes PT, et al. **Clin Exp Rheumatol** 1995 May–Jun;13(3):381–94 (87 ref.) Comment in: Clin Exp Rheumatol 1996 Jan–Feb;14(1):106.

Anti-inflammatory treatment of asthma in children. What strategy is appropriate? Frazier CA. **N C Med J** 1995 Dec; 56(12):616–8 (15 ref.)

Investigational agents for rheumatoid arthritis. Merkel PA, et al. **Rheum Dis Clin North Am** 1995 Aug;21(3):779–96 (85 ref.)

[Treatment of asthma; are there still questions? (see comments)] van Schayck CP. **Ned Tijdschr Geneeskd** 1996 Jan 13;140(2):72–7 (47 ref.) Comment in: Ned Tijdschr Geneeskd 1996 Mar 2;140(9):508–9. **(Dut)**

[Use of anti-inflammatory drugs in children] Hoppu K, et al. **Duodecim** 1994;110(6):607–14 (29 ref.) **(Fin)**

[Changing treatment of inflammatory bowel diseases] Karvonen AL, et al. **Duodecim** 1994;110(20):1945–54 (58 ref.) **(Fin)**

[Treatment of inflammation with anti-inflammatory cytokines: example in models of auto-immune diseases] Bessis N, et al. **C R Seances Soc Biol Fil** 1995;189(4):579–90 (33 ref.) (Eng. Abstr.) **(Fre)**

[The leukotriene signal pathway--a very promising point of entry for inhibitors in therapy of inflammatory diseases] Müller MJ. **Pharm Unserer Zeit** 1995 Sep;24(5):264–72 (53 ref.) **(Ger)**

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL

Use of nonsteroidal anti-inflammatory drugs in cancer. Pace V. **Palliat Med** 1995 Oct;9(4):273–86 (105 ref.)

[Nabumetone] Simón M, et al. **Rev Med Univ Navarra** 1995 Jul–Sep;39(3):164–72 (51 ref.) **(Spa)**

ADMINISTRATION & DOSAGE

Chemoprevention of colon cancer by minor dietary constituents and their synthetic analogues. Reddy BS. **Prev Med** 1996 Jan–Feb;25(1):48–50 (13 ref.)

Schizophrenia, Alzheimer's disease, and anti-inflammatory agents. Oken RJ, et al. **Schizophr Bull** 1996;22(1):1–4 (24 ref.)

[Crohn disease: prevention and drug therapy] Gross V, et al. **Chirurg** 1995 Aug;66(8):757–63 (42 ref.) (Eng. Abstr.) **(Ger)**

[5-aminosalicylic acid and chronic inflammatory bowel diseases in children] Klotz U. **Klin Padiatr** 1995 Sep–Oct; 207(5):285–7 (18 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Phenomenology, pathogenesis, diagnosis and treatment of aspirin-sensitive rhinosinusitis. Schapowal AG, et al. **Acta Otorhinolaryngol Belg** 1995;49(3):235–50 (0 ref.)

Mesalamine-induced lung toxicity. Bitton A, et al. **Am J Gastroenterol** 1996 May;91(5):1039–40 (10 ref.)

Nonsteroidal anti-inflammatory drug-induced colonic strictures: two cases and literature review. Gargot D, et al. **Am J Gastroenterol** 1995 Nov;90(11):2035–8 (18 ref.)

The renal effects of nonsteroidal anti-inflammatory drugs: summary and recommendations. Bennett WM, et al. **Am J Kidney Dis** 1996 Jul;28(1 Suppl 1):S56–62 (28 ref.)

Does aspirin cause acute or chronic renal failure in experimental animals and in humans? D'Agati V. **Am J Kidney Dis** 1996 Jul;28(1 Suppl 1):S24–9 (34 ref.)

Nonrenal toxicities of acetaminophen, aspirin, and nonsteroidal anti-inflammatory agents. Matzke GR. **Am J Kidney Dis** 1996 Jul;28(1 Suppl 1):S63–70 (38 ref.)

Nonsteroidal anti-inflammatory drug-induced gastrointestinal injury. Bjorkman DJ. **Am J Med** 1996 Jul 31;101(1A):25S–32S (88 ref.)

Adverse interactions between warfarin and nonsteroidal antiinflammatory drugs: mechanisms, clinical significance, and avoidance [see comments] Chan TY. **Ann Pharmacother** 1995 Dec;29(12):1274–83 (89 ref.) Comment in: Ann Pharmacother 1995 Dec;29(12):1289–91.

A unifying hypothesis for the mechanism of NSAID related gastrointestinal toxicity. Mahmud T, et al. **Ann Rheum Dis** 1996 Apr;55(4):211–3 (31 ref.)

NSAID gastropathy. A new understanding. Roth SH. **Arch Intern Med** 1996 Aug 12–26;156(15):1623–8 (82 ref.)

Nonsteroidal antiinflammatory drug-induced enteropathy and severe chronic anemia in a patient with rheumatoid arthritis. Davies NM, et al. **Arthritis Rheum** 1996 Feb; 39(2):321–4 (15 ref.)

Side-effects of drugs used in the treatment of rheumatoid arthritis. Evans PJ, et al. **Biochem Soc Symp** 1995; 61:195–207 (49 ref.)

An evidence-based approach to prescribing NSAIDs in musculoskeletal disease: a Canadian consensus. Canadian NSAID Consensus Participants. Tannenbaum H, et al. **Can Med Assoc J** 1996 Jul 1;155(1):77–88 (99 ref.)

Allergy and intolerance to nonsteroidal anti-inflammatory agents. Arnaud A. **Clin Rev Allergy Immunol** 1995 Fall; 13(3):245–51 (26 ref.)

Idiosyncratic liver toxicity of nonsteroidal antiinflammatory drugs: molecular mechanisms and pathology. Boelsterli UA, et al. **Crit Rev Toxicol** 1995;25(3):207–35 (245 ref.)

Nonsteroidal anti-inflammatory drugs: gastroduodenal injury and beyond. Bernsdorff KR, et al. **Dig Dis** 1995 Jul–Aug; 13(4):251–66 (134 ref.)

Nonsteroidal anti-inflammatory drugs and gastrointestinal disease: pathophysiology, treatment and prevention. Bjorkman DJ, et al. **Dig Dis** 1995 Mar–Apr;13(2):119–29 (81 ref.)

Pleuropericarditis related to the use of mesalamine. Gujral N, et al. **Dig Dis Sci** 1996 Mar;41(3):624–6 (12 ref.)

Toxicity of nonsteroidal anti-inflammatory drugs in the large intestine. Davies NM. **Dis Colon Rectum** 1995 Dec; 38(12):1311–21 (105 ref.)

Colonic ulceration associated with nonsteroidal anti-inflammatory drugs. Report of three cases. Kaufman HL, et al. **Dis Colon Rectum** 1996 Jun;39(6):705–10 (36 ref.)

Nonsteroidal anti-inflammatory drugs and hypertension. The risks in perspective. de Leeuw PW. **Drugs** 1996 Feb; 51(2):179–87 (49 ref.)

Diclofenac/misoprostol. A review of its pharmacology and therapeutic efficacy in painful inflammatory conditions.

Davis R, et al. **Drugs Aging** 1995 Nov;7(5):372–93 (76 ref.)
Use of misoprostol in the elderly: is the expense justified? Stucki G, et al. **Drugs Aging** 1996 Feb;8(2):84–8 (24 ref.)
Review of Arthrotec clinical data. McKenna F. **Eur J Rheumatol Inflamm** 1994;14(3 Suppl):25–9 (9 ref.)
NSAIDs and the gut—where are we now? Shield M. **Eur J Rheumatol Inflamm** 1994;14(3 Suppl):13–23 (62 ref.)
Non-steroidal anti-inflammatory drug-induced gastric damage in experimental animals: underlying pathological mechanisms. Trevethick MA, et al. **Gen Pharmacol** 1995 Nov;26(7):1455–9 (63 ref.)
Nephrogenic diabetes insipidus induced by lobenzarit disodium treatment in patients with rheumatoid arthritis. Sakane N, et al. **Intern Med** 1996 Feb;35(2):119–22 (17 ref.)
Renal complications associated with use of nonsteroidal anti-inflammatory agents. Palmer BF. **J Investig Med** 1995 Dec;43(6):516–33 (174 ref.)
A risk assessment of cervical manipulation vs. NSAIDs for the treatment of neck pain. Dabbs V, et al. **J Manipulative Physiol Ther** 1995 Oct;18(8):530–6 (43 ref.)
Indomethacin hastens large joint osteoarthritis in humans—how strong is the evidence? [editorial] Doherty M, et al. **J Rheumatol** 1995 Nov;22(11):2013–6 (32 ref.)
A reader's guide to the evaluation of causation. Podrebarac T, et al. **Postgrad Med J** 1996 Mar;72(845):131–6 (19 ref.)
Risk factors for gastrointestinal complications of nonsteroidal antiinflammatory drugs. Florent C, et al. **Rev Rhum Engl Ed** 1996 Feb;63(2):125–30 (44 ref.)
Prevention of gastrointestinal damage induced by nonsalicylate nonsteroidal antiinflammatory drugs. Florent C, et al. **Rev Rhum Engl Ed** 1996 Feb;63(2):131–4 (15 ref.)
NSAID-associated upper gastrointestinal damage in patients with rheumatoid arthritis. Dijkmans BA, et al. **Scand J Gastroenterol Suppl** 1995;212:105–8 (26 ref.)
Review of clinical trials and benefit/risk ratio of meloxicam. Barner A. **Scand J Rheumatol Suppl** 1996;102:29–37 (15 ref.)
Aspirin, a silent risk factor in urology. Zhu JP, et al. **Scand J Urol Nephrol** 1995 Dec;29(4):369–74 (64 ref.)
Nonsteroidal anti-inflammatory drugs and the gut. Hirschowitz BI. **South Med J** 1996 Mar;89(3):259–63 (20 ref.)
['Stomach-friendly' NSAIDs: careful optimism? (see comments)] Lems WF, et al. **Ned Tijdschr Geneeskd** 1995 Nov 4;139(44):2232–5 (23 ref.) Comment in: Ned Tijdschr Geneeskd 1995 Dec 30;139(52):2757–8. **(Dut)**
[Nonsteroidal antirheumatic drugs and acetylsalicylic acid: adverse effects distal to the duodenum] Gut A, et al. **Schweiz Med Wochenschr** 1996 Apr 13;126(15):616–25 (95 ref.) (Eng. Abstr.) **(Ger)**
[Cutaneous side-effects of nonsteroidal anti-inflammatory drugs (NSAID)] Gebhardt M, et al. **Z Rheumatol** 1995 Nov-Dec;54(6):405–12 (49 ref.) (Eng. Abstr.) **(Ger)**
[Prevention and treatment of upper gastrointestinal bleeding by nonsteroidal anti-inflammatory drugs] Bar-Dayan Y, et al. **Harefuah** 1996 Apr 15;130(8):535–7 (34 ref.) **(Heb)**
[Amidazophen. Yes or no?] Jákó J, et al. **Orv Hetil** 1995 Sep 24;136(39):2121–4 (50 ref.) (Eng. Abstr.) **(Hun)**
[Aspirin-induced asthma] Sakakibara H. **Nippon Naika Gakkai Zasshi** 1996 Feb 10;85(2):227–33 (5 ref.) **(Jpn)**
[Clinical aspects of drug-induced tubulo-interstitial nephropathy] Shibasaki T. **Nippon Rinsho** 1995 Aug; 53(8):2047–51 (7 ref.) (Eng. Abstr.) **(Jpn)**
[Helicobacter pylori, nonsteroidal anti-inflammatory agents and gastroduodenal changes] Teixeira AV. **Acta Med Port** 1995 Sep;8(9):517–21 (70 ref.) (Eng. Abstr.) **(Por)**
[A possible association between the maternal administration of metamizole and persistent pulmonary hypertension in a newborn infant] Martí Solé JJ, et al. **An Esp Pediatr** 1996 Apr;44(4):387–8 (10 ref.) **(Spa)**
[Morphology of gastric mucosa lesions induced by nonsteroidal anti-inflammatory agents] Valenzuela M, et al. **Rev Esp Enferm Dig** 1996 May;88(5):351–8 (55 ref.) **(Spa)**

BLOOD

[Salicylic acid] Onouchi T, et al. **Nippon Rinsho** 1995 Feb; 53 Su Pt 1:1040–2 (13 ref.) **(Jpn)**

CLASSIFICATION

Practical classification for the use of nonsteroidal anti-inflammatory drugs. Friedman SL. **J Am Podiatr Med Assoc** 1996 Jun;86(6):263–5 (0 ref.)

ECONOMICS

Assessing the cost effectiveness of NSAID: an international perspective. Drummond M, et al. **J Rheumatol** 1995 Jul; 22(7):1408–11 (5 ref.)

HISTORY

[Aspirin, an always current drug] Van Cauwenberge H. **Rev Med Liege** 1996 Jan;51(1):7–18 (29 ref.) **(Fre)**

IMMUNOLOGY

Allergy and intolerance to nonsteroidal anti-inflammatory agents. Arnaud A. **Clin Rev Allergy Immunol** 1995 Fall; 13(3):245–51 (26 ref.)

PHARMACOKINETICS

The pharmacokinetics of tenidap sodium: introduction. Pullar T. **Br J Clin Pharmacol** 1995;39 Suppl 1:1S–2S (0 ref.)
A review of the clinical pharmacokinetics of meloxicam. Türck D, et al. **Br J Rheumatol** 1996 Apr;35 Suppl 1:13–6 (28 ref.)
Pharmacokinetic optimisation of drug therapy in elderly patients. Parker BM, et al. **Drugs Aging** 1995 Jul;7(1):10–8 (38 ref.)

PHARMACOLOGY

Effects of mesalazine on the formation of lipoxygenase and cyclooxygenase products. Lauritsen K, et al. **Adv Exp Med Biol** 1995;371B:1301–6 (66 ref.)
Effects of mesalazine on lamina propria white cell functions. Verspaget HW. **Adv Exp Med Biol** 1995;371A:317–20 (20 ref.)
Leukocyte-endothelial cell interactions: potential targets for mesalazine in Crohn's disease. Wakefield AJ, et al. **Adv Exp Med Biol** 1995;371B:1307–11 (72 ref.)
Possible modes of action of nimesulide in controlling neutrophilic inflammation. Dallegri F, et al. **Arzneimitteiforschung** 1995 Oct;45(10):1114–7 (36 ref.)
Influence of anti-rheumatic drugs on gut permeability and on the gut associated lymphoid tissue. Bjarnason I, et al. **Baillieres Clin Rheumatol** 1996 Feb;10(1):165–76 (75 ref.)
Sulphasalazine, sulphapyridine or 5-aminosalicylic acid—which is the active moiety in rheumatoid arthritis? Bird HA. **Br J Rheumatol** 1995 Nov;34 Suppl 2:16–9 (11 ref.)
Pharmacology of meloxicam, a new non-steroidal anti-inflammatory drug with an improved safety profile through preferential inhibition of COX-2. Engelhardt G. **Br J Rheumatol** 1996 Apr;35 Suppl 1:4–12 (69 ref.)
Cytokine-processing enzymes. Stopping the cuts. Dinarello CA, et al. **Curr Biol** 1995 Jun 1;5(6):587–90 (34 ref.)
Tiaprofenic acid. A reappraisal of its pharmacological properties and use in the management of rheumatic diseases. Plosker GL, et al. **Drugs** 1995 Dec;50(6):1050–75 (146 ref.)
Development of novel anti-inflammatory agents: a pharmacologic perspective on leukotrienes and their receptors. Jackson WT, et al. **Prog Drug Res** 1996; 46:115–68 (322 ref.)
Phospholipase A2 inhibitors: a challenge for the future. Berenbaum F. **Rev Rhum Engl Ed** 1995 Jun;62(6):409–14 (45 ref.)
[Non-steroidal anti-inflammatory drugs (NSAIDs)] Miura Y. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:1031–5 (20 ref.) **(Jpn)**
[The central component in the mechanism of the analgesic action of nonsteroidal anti-inflammatory agents] Lemina Elu, et al. **Eksp Klin Farmakol** 1995 Jul-Aug;58(4):59–62 (52 ref.) **(Rus)**

THERAPEUTIC USE

Unanswered questions about Helicobacter pylori. Walsh JH. **Aliment Pharmacol Ther** 1995;9 Suppl 1:31–7 (72 ref.)
Therapeutic uses of aspirin in renal diseases. Winchester JF. **Am J Kidney Dis** 1996 Jul;28(1 Suppl 1):S20–3 (44 ref.)
Nonsteroidal anti-inflammatory drugs: practical and theoretical considerations in their selection. Polisson R. **Am J Med** 1996 Feb 26;100(2A):31S–36S (29 ref.)
Topical nonsteroidal antiinflammatory drugs for acute soft tissue injuries. Heyneman CA. **Ann Pharmacother** 1995 Jul-Aug;29(7–8):780–2 (14 ref.)
Colorectal cancer: surgical prophylaxis and chemoprevention [see comments] Nugent KP. **Ann R Coll Surg Engl** 1995 Sep;77(5):372–6 (55 ref.) Comment in: Ann R Coll Surg Engl 1996 Mar;78(2):154–5.
Tenidap: not just another NSAID? Canvin JM, et al. **Ann Rheum Dis** 1996 Feb;55(2):79–82 (29 ref.)
The role of anti-inflammatory drugs in the prevention and treatment of Alzheimer's disease. Breitner JC. **Annu Rev Med** 1996;47:401–11 (81 ref.)
New pharmacological strategies for pain relief. Dray A, et al. **Annu Rev Pharmacol Toxicol** 1996;36:253–80 (193 ref.)
Prophylactic indomethacin: systematic review and meta-analysis. Fowlie PW. **Arch Dis Child Fetal Neonatal Ed** 1996 Mar;74(2):F81–7 (35 ref.)
Practical management of osteoarthritis. Integration of pharmacologic and nonpharmacologic measures. Griffin MR, et al. **Arch Fam Med** 1995 Dec;4(12):1049–55 (102 ref.)
Innovative treatment approaches for rheumatoid arthritis. Cyclosporin, leflunomide and nitrogen mustard. Furst DE. **Baillieres Clin Rheumatol** 1995 Nov;9(4):711–29 (41 ref.)
The emerging roles of topical non-steroidal anti-inflammatory agents in ophthalmology. Koay P. **Br J Ophthalmol** 1996 May;80(5):480–5 (98 ref.)
Treating musculoskeletal disease with NSAIDs. Practitioner's guide. Bellamy N. **Can Fam Physician** 1996 Mar;42:482–6, 489–92 (38 ref.)
Analgesics and NSAIDs in the treatment of the acute migraine attack. Pfaffenrath V, et al. **Cephalalgia** 1995 Oct; 15 Suppl 15:14–20 (53 ref.)
Prophylactic treatment of migraine: evaluation of clinical trials and choice among drugs. Tfelt-Hansen P. **Cephalalgia** 1995 Oct;15 Suppl 15:29–32 (15 ref.)
Use of old and new oral 5-aminosalicylic acid formulations in inflammatory bowel disease. Brzezinski A, et al. **Cleve Clin J Med** 1995 Sep-Oct;62(5):317–23 (37 ref.)
Anti-inflammatory effects of long-acting beta-agonists in asthma [editorial] Bradding P. **Clin Exp Allergy** 1995 Oct; 25(10):912–4 (36 ref.)
Effective pain management in terminal care. Dahl JL. **Clin Geriatr Med** 1996 May;12(2):279–300 (92 ref.)
Indomethacin. Gordon MC, et al. **Clin Obstet Gynecol** 1995 Dec;38(4):697–705 (23 ref.)
Lornoxicam. A review of its pharmacology and therapeutic potential in the management of painful and inflammatory conditions. Balfour JA, et al. **Drugs** 1996 Apr;51(4):639–57 (76 ref.)
Tiaprofenic acid. A reappraisal of its pharmacological properties and use in the management of rheumatic diseases. Plosker GL, et al. **Drugs** 1995 Dec;50(6):1050–75 (146 ref.)
Pharmacological intervention in older patients with rheumatoid arthritis. Quality of life aspects. Bendtsen P, et al. **Drugs Aging** 1995 Nov;7(5):338–46 (55 ref.)
The role of nonsteroidal anti-inflammatory drugs in colorectal cancer prevention. Giardiello FM, et al. **Eur J Cancer** 1995 Jul-Aug;31A(7–8):1071–6 (55 ref.)
Review of Arthrotec clinical data. McKenna F. **Eur J Rheumatol Inflamm** 1994;14(3 Suppl):25–9 (9 ref.)
The role of nonsteroidal antiinflammatory drugs in ocular inflammation. Samiy N, et al. **Int Ophthalmol Clin** 1996 Winter;36(1):195–206 (38 ref.)
Pentoxifylline in severe inflammatory response syndrome. Graninger W, et al. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S134–8 (37 ref.)
Drug treatment in children with juvenile rheumatoid arthritis. Past, present, and future. Giannini EH, et al. **Pediatr Clin North Am** 1995 Oct;42(5):1099–125 (89 ref.)
[Recent advances in experimental and clinical study on ligustrazine in treating respiratory disease] Zhang KJ, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Oct; 15(10):638–40 (22 ref.) **(Chi)**
[Indications for antineoplastic effects of nonsteroidal anti-inflammatory drugs] Kooy A, et al. **Ned Tijdschr Geneeskd** 1995 Nov 4;139(44):2235–9 (49 ref.) **(Dut)**
[Clinical application of extracts of Echinacea purpurea or Echinacea pallida. Critical evaluation of controlled clinical studies] Dorsch W. **Z Arztl Fortbild (Jena)** 1996 Apr; 90(2):117–22 (20 ref.) (Eng. Abstr.) **(Ger)**
[Non steroidal anti-inflammatory drugs and rheumatic diseases] Cossermelli W, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1995 Mar-Apr; 50(2):115–24 (58 ref.) (Eng. Abstr.) **(Por)**
[Acetyl-salicylic acid and trifusal in the prevention of atherothrombotic stroke] Alvarez Sabín J. **Rev Neurol** 1995 Sep-Oct;23(123):1091–5 (36 ref.) **(Spa)**
[Analgesics and non-steroidal anti-inflammatory agents in the treatment of migraine] Iglesias F, et al. **Rev Neurol** 1995;23 Suppl 2:S157–61 (20 ref.) **(Spa)**

TOXICITY

Acetaminophen/aspirin mixtures: experimental data. Porter GA. **Am J Kidney Dis** 1996 Jul;28(1 Suppl 1):S30–3 (11 ref.)
The developmental toxicity of indomethacin and sulindac. Lione A, et al. **Reprod Toxicol** 1995 Jan-Feb;9(1):7–20 (111 ref.)

ANTI-INFLAMMATORY AGENTS, STEROIDAL

ADMINISTRATION & DOSAGE

Issues in the use of inhaled glucocorticoids. The Asthma Clinical Research Network. Kamada AK, et al. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 1):1739–48 (86 ref.)
The delivery of aerosolized steroids from MDIs with nozzle extensions: quantitative laboratory evaluation of a method to improve aerosol delivery to intubated patients. Hess D, et al. **Intensive Care Med** 1995 Nov;21(11):945–51 (36 ref.)
Counseling patients about allergic rhinitis. Swanson KA. **J Am Pharm Assoc (Wash)** 1996 May;NS36(5):300–7 (40 ref.)
[Crohn disease: prevention and drug therapy] Gross V, et al. **Chirurg** 1995 Aug;66(8):757–63 (42 ref.) (Eng. Abstr.) **(Ger)**
[Asthma therapy with topically active steroids] Matthys H. **Internist (Berl)** 1995 Oct;36(10):1005–9 (21 ref.) **(Ger)**
[Chronopharmacology of reversible airway obstruction] Haen E. **Wien Med Wochenschr** 1995;145(17–18):439–45 (38 ref.) (Eng. Abstr.) **(Ger)**
[A case of acute eosinophilic pneumonia: bronchoalveolar lavage findings before and after steroid treatment] Kawaguchi H, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Jul;33(7):738–44 (21 ref.) (Eng. Abstr.) **(Jpn)**
[Steroid inhalation therapy of asthma] Hozawa S. **Nippon Naika Gakkai Zasshi** 1996 Feb 10;85(2):205–9 (5 ref.) **(Jpn)**
[Steroid inhalation therapy of bronchial asthma] Makino S. **Nippon Naika Gakkai Zasshi** 1995 Dec 10;84(12):2085–90 (9 ref.) **(Jpn)**

ADVERSE EFFECTS

Issues in the use of inhaled glucocorticoids. The Asthma

Clinical Research Network. Kamada AK, et al. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 1):1739–48 (86 ref.)

Fluticasone propionate: safety profile. Johnson M. **Cutis** 1996 Feb;57(2 Suppl):10–2 (15 ref.)

Sensitisation to corticosteroids. Consequences for anti-inflammatory therapy. Dooms-Goossens A. **Drug Saf** 1995 Aug;13(2):123–9 (47 ref.)

PHARMACOLOGY

Budesonide. A review of its pharmacological properties and therapeutic efficacy in inflammatory bowel disease. Spencer CM, et al. **Drugs** 1995 Nov;50(5):854–72 (51 ref.)

Fluticasone propionate—an update on preclinical and clinical experience. Fuller R, et al. **Respir Med** 1995 Sep;89 Suppl A:3–18 (59 ref.)

THERAPEUTIC USE

The role of anti-inflammatory drugs in the prevention and treatment of Alzheimer's disease. Breitner JC. **Annu Rev Med** 1996;47:401–11 (81 ref.)

Corticosteroid therapy of eye disease. Fifty years later [editorial; comment] Raizman M. **Arch Ophthalmol** 1996 Aug;114(8):1000–1 (25 ref.) Comment on: Arch Ophthalmol 1996 Aug;114(8):933–7.

Drug trials in neuropathy. Hughes RA, et al. **Baillieres Clin Neurol** 1995 Nov;4(3):607–27 (87 ref.)

Systemic corticosteroids in the phenytoin hypersensitivity syndrome. Chopra S, et al. **Br J Dermatol** 1996 Jun; 134(6):1109–12 (19 ref.)

Topical corticosteroids in clinical practice: focus on fluticasone propionate. Piacquadio DJ. **Cutis** 1996 Feb;57(2 Suppl):4–9 (19 ref.)

Deflazacort. A review of its pharmacological properties and therapeutic efficacy. Markham A, et al. **Drugs** 1995 Aug; 50(2):317–33 (68 ref.)

Bilateral inguinal scrofuloderma during steroid therapy in a patient with bullous pemphigoid. Kawabata E, et al. **J Dermatol** 1995 Aug;22(8):582–6 (22 ref.)

[For the present Duchenne' disease should not be treated with prednisone] Jennekens FG, et al. **Ned Tijdschr Geneeskd** 1996 May 25;140(21):1109–11 (21 ref.) **(Dut)**

[Recent view on drug therapy of bronchial asthma] Mano K. **Nippon Naika Gakkai Zasshi** 1996 Mar 10;85(3):417–22 (9 ref.) **(Jpn)**

[A case of lupus cystitis successfully treated with corticosteroid accompanied by gastrointestinal symptoms] Sato M, et al. **Ryumachi** 1995 Oct;35(5):814–20 (38 ref.) (Eng. Abstr.) **(Jpn)**

[Advances in the topical steroid treatment of inflammatory bowel diseases] Diaz Blasco J, et al. **Rev Esp Enferm Dig** 1995 Nov;87(11):802–7 (62 ref.) **(Spa)**

[New treatments for multiple sclerosis] Masdeu JC. **Rev Neurol** 1996 Jun;24(130):708–11 (38 ref.) **(Spa)**

TOXICITY

Review of the toxicology of beclomethasone dipropionate. Libretto SE. **Arch Toxicol** 1995;69(8):509–25 (68 ref.)

ANTI-INFLAMMATORY AGENTS, TOPICAL

THERAPEUTIC USE

[Advances in the topical steroid treatment of inflammatory bowel diseases] Diaz Blasco J, et al. **Rev Esp Enferm Dig** 1995 Nov;87(11):802–7 (62 ref.) **(Spa)**

ANTILEPROTIC AGENTS see **LEPROSTATIC AGENTS**

ANTILIPEMIC AGENTS

[Dyslipidemia, lipid lowering drugs and thrombosis] Ambrosi P, et al. **Arch Mal Coeur Vaiss** 1995 Nov;88(11):1641–5 (31 ref.) (Eng. Abstr.) **(Fre)**

ADMINISTRATION & DOSAGE

[Modifying increased plasma cholesterol levels in secondary prevention of coronary heart disease] Jost S, et al. **Z Kardiol** 1995 Aug;84(8):577–95 (159 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

[Toxic myopathies related to the administration of hypolipidemic agents: are the drugs the only things responsible?] Galiana J, et al. **Rev Clin Esp** 1995 Sep; 195(9):620–2 (28 ref.) (Eng. Abstr.) **(Spa)**

PHARMACOLOGY

Gemfibrozil. A reappraisal of its pharmacological properties and place in the management of dyslipidaemia. Spencer CM, et al. **Drugs** 1996 Jun;51(6):982–1018 (234 ref.)

Effect of royal jelly on serum lipids in experimental animals and humans with atherosclerosis. Vittek J. **Experientia** 1995 Sep 29;51(9–10):927–35 (68 ref.)

THERAPEUTIC USE

Approaches to the treatment of hyperlipidemia in the solid organ transplant recipient. Kirk JK, et al. **Ann Pharmacother** 1995 Sep;29(9):879–91 (98 ref.)

Treatment of lipids. Implications for the general practitioner. Simons LA. **Aust Fam Physician** 1996 Jul;25(7):1053–9 (6 ref.)

Currently available hypolipidaemic drugs and future therapeutic developments. Farmer JA, et al. **Baillieres Clin Endocrinol Metab** 1995 Oct;9(4):825–47 (59 ref.)

Angiographic trials of lipid-lowering therapy: end of an era? Thompson GR. **Br Heart J** 1995 Oct;74(4):343–7 (27 ref.)

Fluvastatin in combination with other lipid-lowering agents. Jokubaitis LA. **Br J Clin Pract Symp Suppl** 1996 Jan; 77A:28–32 (4 ref.)

Cardiovascular effects of estrogen and lipid-lowering therapies in postmenopausal women. Guetta V, et al. **Circulation** 1996 May 15;93(10):1928–37 (153 ref.)

Management of hyperlipidemia in diabetes. Vinik AI, et al. **Compr Ther** 1995 Oct;21(10):602–9 (50 ref.)

Hyperlipidemia and its management in renal disease. Massy ZA, et al. **Curr Opin Nephrol Hypertens** 1996 Mar; 5(2):141–6 (63 ref.)

Gemfibrozil. A reappraisal of its pharmacological properties and place in the management of dyslipidaemia. Spencer CM, et al. **Drugs** 1996 Jun;51(6):982–1018 (234 ref.)

Lipid lowering and coronary risk. Gotto AM Jr. **Isr J Med Sci** 1996 Jun;32(6):355–9 (27 ref.)

Dual roles of HMG-CoA reductase inhibitors in solid organ transplantation: lipid lowering and immunosuppression. Katznelson S, et al. **Kidney Int Suppl** 1995 Dec;52:S112–5 (30 ref.)

Clinical utility of antilipidemic therapies in chronic renal allograft failure. Wanner C, et al. **Kidney Int Suppl** 1995 Dec;52:S60–2 (38 ref.)

Pharmacologic prevention of coronary artery disease. What do clinical trials show? Milani RV, et al. **Postgrad Med** 1996 Feb;99(2):109–12, 115–20 (38 ref.)

Hyperlipidemia. When does treatment make a difference? Wise GR, et al. **Postgrad Med** 1996 Jul;100(1):138–49 (17 ref.)

[Secondary prevention of coronary heart disease with lipid lowering drugs. Evaluating outcome eliminates the controversy] Pedersen TR. **Internist (Berl)** 1995 Dec; 36(12):1174–8 (32 ref.) **(Ger)**

[Mixed dyslipoproteinemias: new therapeutic opportunities] Capurso A. **Ann Ital Med Int** 1995 Oct;10 Suppl:44S–47S (20 ref.) (Eng. Abstr.) **(Ita)**

[Fenofibrate and arteriosclerosis. The new developments of the last 5 years (editorial)] Millán Núñez Cortés J, et al. **Rev Clin Esp** 1995 Dec;195(12):817–9 (46 ref.) **(Spa)**

[The relationship between clinical events and the angiographic lesions in coronary atherosclerosis. Hypolipemic treatment and plaque stabilization] Castro Beiras A, et al. **Rev Esp Cardiol** 1995;48 Suppl 5:23–30 (47 ref.) (Eng. Abstr.) **(Spa)**

[The practical aspects of lipid management in secondary prevention] de Teresa Galván E, et al. **Rev Esp Cardiol** 1995;48 Suppl 5:52–6 (16 ref.) (Eng. Abstr.) **(Spa)**

[Why the cardiologists should be interested in lipids?] López-Sendón JL, et al. **Rev Esp Cardiol** 1995;48 Suppl 2:23–32 (61 ref.) (Eng. Abstr.) **(Spa)**

TOXICITY

Carcinogenicity of lipid-lowering drugs [see comments] Newman TB, et al. **JAMA** 1996 Jan 3;275(1):55–60 (54 ref.) Comment in: JAMA 1996 Jan 3;275(1):67–9. Comment in: JAMA 1996 May 15;275(19):1479; discussion 1481–2. Comment in: JAMA 1996 May 15;275(19):1479–80; discussion 1481–2. Comment in: JAMA 1996 May 15;275(19):1480; discussion 1481–2. Comment in: JAMA 1996 May 15;275(19):1480–1; discussion 1481–2. Comment in: JAMA 1996 May 15;275(19):1481–2.

ANTILYMPHOBLAST GLOBULINS see **ANTILYMPHOCYTE SERUM**

ANTILYMPHOCYTE ANTIBODIES see **ANTILYMPHOCYTE SERUM**

ANTILYMPHOCYTE GLOBULIN see **ANTILYMPHOCYTE SERUM**

ANTILYMPHOCYTE SERUM

ADVERSE EFFECTS

Minimizing the toxicity of antilymphocyte antibody therapy. Pascual M, et al. **Transplant Proc** 1996 Aug;28(4):2113–4 (15 ref.)

PHARMACOLOGY

Mechanisms of immunosuppression induced by antithymocyte globulins and OKT3. Bonnefoy-Berard N, et al. **J Heart Lung Transplant** 1996 May;15(5):435–42 (52 ref.)

THERAPEUTIC USE

Treatment of aplastic anaemia with antilymphocyte globulin and cyclosporin. Marsh JC, et al. **Int J Hematol** 1995 Oct; 62(3):133–44 (79 ref.)

Developments in immunosuppressive therapy. Daar AS. **Transplant Proc** 1995 Oct;27(5):2671–5 (5 ref.)

ANTIMALARIALS

Malaria, the submerged disease. Olliaro P, et al. **JAMA** 1996 Jan 17;275(3):230–3 (54 ref.)

ADMINISTRATION & DOSAGE

[Clarithromycin combined with pyrimethamine in cerebral toxoplasmosis—a report of 2 cases] Dalston MO, et al. **Rev Soc Bras Med Trop** 1995 Oct-Dec;28(4):409–13 (11 ref.) (Eng. Abstr.) **(Por)**

ADVERSE EFFECTS

Side-effects of drugs used in the treatment of rheumatoid arthritis. Evans PJ, et al. **Biochem Soc Symp** 1995; 61:195–207 (49 ref.)

CNS adverse events associated with antimalarial agents. Fact or fiction? Phillips-Howard PA, et al. **Drug Saf** 1995 Jun; 12(6):370–83 (77 ref.)

ANTAGONISTS & INHIBITORS

[Malaria resistant to chemotherapy] Năsçuţiu AM. **Bacteriol Virusol Parazitol Epidemiol** 1995 Jul-Dec; 40(3–4):271–6 (16 ref.) **(Rum)**

HISTORY

Localized permanent epidemics: the genesis of chloroquine resistance in Plasmodium falciparum. Verdrager J. **Southeast Asian J Trop Med Public Health** 1995 Mar; 26(1):23–8 (18 ref.)

PHARMACOLOGY

Iron chelators: mode of action as antimalarials. Cabantchik ZI, et al. **Acta Haematol** 1996;95(1):70–7 (40 ref.)

Effects of mefloquine on Ca2+ uptake by crude microsomes of rabbit skeletal muscle. Go ML, et al. **Arch Int Pharmacodyn Ther** 1995 Mar-Apr;329(2):255–71 (29 ref.)

Pharmacology and pharmacokinetics of new antimalarials. Watkins WM. **Med Trop (Mars)** 1995;55(4 Suppl):33–6 (31 ref.)

Recent developments and rationale towards new strategies for malarial chemotherapy. Vial H. **Parasite** 1996 Mar; 3(1):3–23 (148 ref.)

[Malaria and drug resistance] Kager PA, et al. **Ned Tijdschr Geneeskd** 1996 Jan 20;140(3):151–5 (20 ref.) (Eng. Abstr.) **(Dut)**

THERAPEUTIC USE

Clinical studies of iron chelators in malaria. Mabeza GF, et al. **Acta Haematol** 1996;95(1):78–86 (69 ref.)

Mechanisms of drug resistance in malaria. Cowman AF. **Aust N Z J Med** 1995 Dec;25(6):837–44 (89 ref.)

Status of antimalarial drugs under development. Olliaro PL, et al. **Bull World Health Organ** 1995;73(5):565–71 (35 ref.)

Artesunate. A review of its pharmacology and therapeutic efficacy in the treatment of malaria. Barradell LB, et al. **Drugs** 1995 Oct;50(4):714–41 (101 ref.)

Disease-modifying antirheumatic drugs. Potential effects in older patients. Gardner G, et al. **Drugs Aging** 1995 Dec; 7(6):420–37 (43 ref.)

Artemisinin and the antimalarial endoperoxides: from herbal remedy to targeted chemotherapy. Meshnick SR, et al. **Microbiol Rev** 1996 Jun;60(2):301–15 (189 ref.)

The treatment of malaria. White NJ. **N Engl J Med** 1996 Sep 12;335(11):800–6 (49 ref.)

[The role of qinghaosu derivatives in the treatment of malaria in 1995] Ambroise-Thomas P. **Med Trop (Mars)** 1995;55(3 Suppl):18–20 (7 ref.) **(Fre)**

[For new antimalarial drugs: the methods of fundamental research] Ambroise-Thomas P. **Med Trop (Mars)** 1995;55(4 Suppl):23–6 (11 ref.) (Eng. Abstr.) **(Fre)**

[Decision making policies on the utilization of antimalarials in response to a modification of chloroquine efficacy. Applications to Africa] Baudon D. **Med Trop (Mars)** 1995; 55(4 Suppl):37–40 (5 ref.) (Eng. Abstr.) **(Fre)**

[Qinghao derivatives in the treatment of severe malaria (letter)] Danis M. **Med Trop (Mars)** 1995;55(4 Suppl):115 (8 ref.) **(Fre)**

[The status of malaria chemoresistance in Africa] Le Bras J. **Med Trop (Mars)** 1995;55(4 Suppl):9–13 (24 ref.) (Eng. Abstr.) **(Fre)**

[Current perspectives in antimalarial therapy] Le Bras J. **Med Trop (Mars)** 1995;55(3 Suppl):13–7 (8 ref.) **(Fre)**

[Correct usage of amino alcohols] Touze JE. **Med Trop (Mars)** 1995;55(3 Suppl):24–5 (8 ref.) **(Fre)**

[Role of modulators in Plasmodium falciparum resistance to antimalarials] Verdier F, et al. **Med Trop (Mars)** 1995;55(4 Suppl):27–32 (20 ref.) (Eng. Abstr.) **(Fre)**

[Antimalarial preparations in rheumatology: new prospects] Nasonov EL. **Ter Arkh** 1996;68(1):67–71 (50 ref.) **(Rus)**

ANTIMANIC AGENTS

ADMINISTRATION & DOSAGE

Bipolar mood disorder: practical strategies for acute and maintenance phase treatment. Sachs GS. **J Clin Psychopharmacol** 1996 Apr;16(2 Suppl 1):32S–47S (87 ref.)

[Calcium antagonists and lithium in preventive treatment of manic-depressive disorder] Sarfati Y, et al. **Encephale** 1996 Mar–Apr;22(2):149–53 (43 ref.) (Eng. Abstr.) **(Fre)**

ADVERSE EFFECTS

Lithium-induced diabetes insipidus in a surgical patient: report of a case and review of the literature. Gray EJ, et al. **J Oral Maxillofac Surg** 1996 Jul;54(7):909–12 (20 ref.)

BLOOD

[Lithium carbonate] Higuchi S, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:942–4 (9 ref.) **(Jpn)**

PHARMACOLOGY

Inositol monophosphatase--a putative target for Li+ in the treatment of bipolar disorder. Atack JR, et al. **Trends Neurosci** 1995 Aug;18(8):343–9 (97 ref.)

THERAPEUTIC USE

How does lithium work on manic depression? Clinical and psychological correlates of the inositol theory. Belmaker RH, et al. **Annu Rev Med** 1996;47:47–56 (23 ref.)

Role of newer medications for bipolar disorder. Bowden CL. **J Clin Psychopharmacol** 1996 Apr;16(2 Suppl 1):48S–55S (65 ref.)

Predictors of response to mood stabilizers. Calabrese JR, et al. **J Clin Psychopharmacol** 1996 Apr;16(2 Suppl 1):24S–31S (88 ref.)

Outcome in the pharmacologic treatment of bipolar disorder. Keck PE Jr, et al. **J Clin Psychopharmacol** 1996 Apr;16(2 Suppl 1):15S–23S (86 ref.)

Psychotherapy in combination with drug treatment for bipolar disorder. Miklowitz DJ. **J Clin Psychopharmacol** 1996 Apr;16(2 Suppl 1):56S–66S (68 ref.)

The emerging role of valproate in bipolar disorder and other psychiatric disorders. Guay DR. **Pharmacotherapy** 1995 Sep–Oct;15(5):631–47 (146 ref.)

Inositol monophosphatase--a putative target for Li+ in the treatment of bipolar disorder. Atack JR, et al. **Trends Neurosci** 1995 Aug;18(8):343–9 (97 ref.)

ANTIMETABOLITES

ADMINISTRATION & DOSAGE

Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): response to methotrexate and mercaptopurine. Horneff G, et al. **Med Pediatr Oncol** 1996 Sep;27(3):187–92 (24 ref.)

THERAPEUTIC USE

Use of clodronate in multiple myeloma. Jantunen E, et al. **Leuk Lymphoma** 1995 Oct;19(3–4):207–11 (29 ref.)

Trabeculectomy with intraoperative sponge 5-fluorouracil. Mora JS, et al. **Ophthalmology** 1996 Jun;103(6):963–70 (28 ref.)

[Use of methotrexate in spondylarthropathies. Review of the literature] Toussirot E, et al. **Rev Med Interne** 1996; 17(4):333–9 (40 ref.) (Eng. Abstr.) **(Fre)**

TOXICITY

Biological modeling of 5-fluorouracil developmental toxicity. Shuey DL, et al. **Toxicology** 1995 Sep 1;102(1–2):207–13 (23 ref.)

ANTIMETABOLITES, ANTINEOPLASTIC

ADMINISTRATION & DOSAGE

High-dose methotrexate in the treatment of adult acute lymphoblastic leukemia. Gökbuget N, et al. **Ann Hematol** 1996 Apr;72(4):194–201 (58 ref.)

Preclinical studies of chemotherapy and radiation therapy for pancreatic carcinoma. Robertson JM, et al. **Cancer** 1996 Aug 1;78(3 Suppl):674–9 (48 ref.)

Concepts in use of high-dose methotrexate therapy. Treon SP, et al. **Clin Chem** 1996 Aug;42(8 Pt 2):1322–9 (66 ref.)

Locoregional chemotherapy for adjuvant treatment of colorectal adenocarcinoma. Penna C, et al. **Eur J Cancer** 1996 Jun;32A(7):1117–22 (47 ref.)

Bolus mitomycin C and 5-FU with sequential radiation for poor-prognosis locally advanced cervical cancer. Denehy TR, et al. **Gynecol Oncol** 1996 Jan;60(1):64–71 (21 ref.)

ADVERSE EFFECTS

Safety profile of gemcitabine. Tonato M, et al. **Anticancer Drugs** 1995 Dec;6 Suppl 6:27–32 (11 ref.)

Clinical, toxicological and pharmacological aspects of gemcitabine. Guchelaar HJ, et al. **Cancer Treat Rev** 1996 Jan;22(1):15–31 (54 ref.)

Punctal and canalicular stenosis associated with systemic fluorouracil therapy. Report of five cases and review of the literature. Brink HM, et al. **Doc Ophthalmol** 1995; 90(1):1–6 (23 ref.)

Tumor lysis syndrome induced by fludarabine monophosphate: a case report [letter] Nakhoul F, et al. **Eur J Haematol** 1996 Apr;56(4):254–5 (12 ref.)

[Severe 5-fluorouracil toxicity in a woman treated for breast cancer with concurrent osteogenesis imperfecta and dehydrogenase deficiency] Beuzeboc P, et al. **Bull Cancer (Paris)** 1996 Apr;83(4):324–7 (24 ref.) (Eng. Abstr.) **(Fre)**

BLOOD

[Methotrexate (MTX)] Yamada M. **Nippon Rinsho** 1995 Feb; 53 Su Pt 1:1053–5 (8 ref.) **(Jpn)**

CHEMICAL SYNTHESIS

Synthesis and antitumor activity of 5-fluorouracil derivatives. Ozaki S. **Med Res Rev** 1996 Jan;16(1):51–86 (55 ref.)

DIAGNOSTIC USE

Bromodeoxyuridine: a diagnostic tool in biology and medicine, Part II: Oncology, chemotherapy and carcinogenesis. Dolbeare F. **Histochem J** 1995 Dec; 27(12):923–64 (468 ref.)

[Use of rhodamine 123 for the detection of multidrug resistance] Canitrot Y, et al. **Bull Cancer (Paris)** 1995 Sep; 82(9):687–97 (86 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Preclinical characteristics of gemcitabine. Plunkett W, et al. **Anticancer Drugs** 1995 Dec;6 Suppl 6:7–13 (33 ref.)

Fluoropyrimidine catabolism. Diasio RB, et al. **Cancer Treat Res** 1995;78:71–93 (103 ref.)

Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Plunkett W, et al. **Semin Oncol** 1995 Aug; 22(4 Suppl 11):3–10 (26 ref.)

PHARMACOKINETICS

2-Chloro-2'-deoxyadenosine--clinical, biochemical and pharmacokinetic considerations. Liliemark J, et al. **Arch Immunol Ther Exp (Warsz)** 1994;42(1):7–10 (19 ref.)

PHARMACOLOGY

Discovery, mechanism and expected clinical significance of selective cytotoxicity of 2-chloro-2'-deoxyadenosine (2-CdA). Grieb P. **Arch Immunol Ther Exp (Warsz)** 1994; 42(1):1–5 (34 ref.)

Antimetabolites. Johnston PG, et al. **Cancer Chemother Biol Response Modif** 1996;16:1–27 (77 ref.)

Cancer chemotherapy and biological response modifiers annual 16. Introduction. Pinedo HM, et al. **Cancer Chemother Biol Response Modif** 1996;16:xvii–xviii (77 ref.)

Aspects of one-carbon folate cycling related to fluoropyrimidine and antifolate therapy. Spears CP, et al. **Cancer Treat Res** 1995;78:115–34 (128 ref.)

The role of interferon-alpha as a modulator of fluorouracil and leucovorin. Grem JL, et al. **Eur J Cancer** 1995 Jul–Aug;31A(7–8):1316–20 (29 ref.)

Role of leucovorin dosing and administration schedule. Jolivet J. **Eur J Cancer** 1995 Jul–Aug;31A(7–8):1311–5 (52 ref.)

Thymidylate synthase and drug resistance. Peters GJ, et al. **Eur J Cancer** 1995 Jul–Aug;31A(7–8):1299–305 (41 ref.)

Synthesis and antitumor activity of 5-fluorouracil derivatives. Ozaki S. **Med Res Rev** 1996 Jan;16(1):51–86 (55 ref.)

[The ribonucleotide reductase enzyme as a target for enzyme-directed chemotherapy effects of trimidox (3,4,5-trihydroxybenzohydroxamidoxim), a new inhibitor of ribonucleotide reductases] Findenig G, et al. **Wien Klin Wochenschr** 1995;107(22):694–7 (28 ref.) (Eng. Abstr.) **(Ger)**

THERAPEUTIC USE

Current chemotherapy of advanced non-small cell lung cancer. Abratt RP. **Anticancer Drugs** 1995 Dec;6 Suppl 6:15–8 (29 ref.)

Phase II trials of single-agent activity of gemcitabine in patients with advanced non-small cell lung cancer: an overview. Shepherd FA. **Anticancer Drugs** 1995 Dec;6 Suppl 6:19–25 (13 ref.)

Symptomatic benefit from gemcitabine and other chemotherapy in advanced non-small cell lung cancer: changes in performance status and tumour-related symptoms. Thatcher N, et al. **Anticancer Drugs** 1995 Dec; 6 Suppl 6:39–48 (68 ref.)

2-Chloro-2'-deoxyadenosine--clinical, biochemical and pharmacokinetic considerations. Liliemark J, et al. **Arch Immunol Ther Exp (Warsz)** 1994;42(1):7–10 (19 ref.)

Activity of gemcitabine in patients with advanced pancreatic carcinoma. A review. Moore M. **Cancer** 1996 Aug 1;78(3 Suppl):633–8 (21 ref.)

Bleomycin. Lazo JS, et al. **Cancer Chemother Biol Response Modif** 1996;16:39–47 (55 ref.)

Cancers of the large bowel and hepatobiliary tract. Vaughn DJ, et al. **Cancer Chemother Biol Response Modif** 1996; 16:495–510 (63 ref.)

Clinical, toxicological and pharmacological aspects of gemcitabine. Guchelaar HJ, et al. **Cancer Treat Rev** 1996 Jan;22(1):15–31 (54 ref.)

Adjuvant radiation therapy for colon cancer. Minsky BD. **Cancer Treat Rev** 1995 Sep;21(5):407–14 (18 ref.)

Thymidylate synthase inhibition, a dead end? [editorial] Herrmann R. **Eur J Cancer** 1995 Nov;31A(12):1919–20 (7 ref.)

ZD1694 (Tomudex): a new thymidylate synthase inhibitor with activity in colorectal cancer. Jackman AL, et al. **Eur J Cancer** 1995 Jul–Aug;31A(7–8):1277–82 (30 ref.)

Butyrate and phenylacetate as differentiating agents: practical problems and opportunities. Newmark HL, et al. **J Cell Biochem Suppl** 1995;22:247–53 (45 ref.)

Biochemical modulation of fluoropyrimidines: is there an optimal (6R,S) leucovorin dose and schedule? [editorial; comment] Doroshow JH. **J Natl Cancer Inst** 1996 Apr 3; 88(7):393–5 (24 ref.) Comment on: J Natl Cancer Inst 1996 Apr 3;88(7):430–6.

Postremission therapy of acute myeloid leukemia in older adults. Schiller GJ. **Leukemia** 1996 Apr;10 Suppl 1:S18–20 (19 ref.)

Gemcitabine in non-small cell lung cancer. Sørensen JB. **Lung Cancer** 1995 Apr;12 Suppl 1:S173–5 (8 ref.)

Prognostic variable in patients with advanced colorectal cancer treated with fluorouracil and leucovorin-based chemotherapy. Fountzilas G, et al. **Med Pediatr Oncol** 1996 May;26(5):305–17 (45 ref.)

Clinical development of new fluoropyrimidines: a major improvement in colorectal cancer treatment? Colleoni M, et al. **Tumori** 1995 Sep–Oct;81(5):303–7 (44 ref.)

[Use of 5-fluorouracil in digestive cancer] Setiz JF, et al. **Gastroenterol Clin Biol** 1996;20(5 Pt 2):B80–88 (68 ref.) **(Fre)**

[Factors of the therapeutic effectiveness of 5-fluorouracil] Manziuk LV, et al. **Vopr Onkol** 1996;42(2):31–6 (33 ref.) **(Rus)**

TOXICITY

Preclinical characteristics of gemcitabine. Plunkett W, et al. **Anticancer Drugs** 1995 Dec;6 Suppl 6:7–13 (33 ref.)

Inhibitors of thymine nucleotide biosynthesis: antimetabolites that provoke genetic change via primary non-DNA targets. Kunz BA. **Mutat Res** 1996 Aug 17;355(1–2):129–40 (135 ref.)

ANTIMITOTIC AGENTS see **ANTINEOPLASTIC AGENTS**

ANTIMUSCARINIC AGENTS see **MUSCARINIC ANTAGONISTS**

ANTIMUTAGENIC AGENTS

see related
ANTICARCINOGENIC AGENTS

PHARMACOLOGY

Recent progress in the study of anticancer drugs originating from plants and traditional medicine in China. Han R. **Chin Med J (Engl)** 1995 Oct;108(10):729–31 (9 ref.)

Natural antimutagenic agents. Mitscher LA, et al. **Mutat Res** 1996 Feb 19;350(1):143–52 (38 ref.)

Activity profiles of antimutagens: in vitro and in vivo data. Waters MD, et al. **Mutat Res** 1996 Feb 19;350(1):109–29 (117 ref.)

THERAPEUTIC USE

[Vitamin A derivatives and prevention of bronchial cancers] Thiberville L, et al. **Rev Mal Respir** 1996;13(2):193–5 (19 ref.) **(Fre)**

ANTINEMATODAL AGENTS

THERAPEUTIC USE

Chemotherapy of human nematodes: learning from the problems in sheep. Coles GC. **J R Soc Med** 1995 Nov; 88(11):649P–651P (10 ref.)

ANTINEOPLASTIC AGENTS

see related
ANTICARCINOGENIC AGENTS
CHEMOEMBOLIZATION, THERAPEUTIC
INFUSIONS, INTRA-ARTERIAL
PERFUSION, REGIONAL
TUMOR LYSIS SYNDROME

Molecular targets in the National Cancer Institute drug screen. Bates SE, et al. **J Cancer Res Clin Oncol** 1995; 121(9–10):495–500 (20 ref.)

Current concepts of treatment in medical oncology: new anticancer drugs. Unger C. **J Cancer Res Clin Oncol** 1996; 122(4):189–98 (29 ref.)

SH2 and SH3 domains: potential targets for anti-cancer drug design. Smithgall TE. **J Pharmacol Toxicol Methods** 1995 Nov;34(3):125–32 (52 ref.)

Monitoring of occupational exposure to cytostatic anticancer agents. Sorsa M, et al. **Mutat Res** 1996 Aug 17;

355(1-2):253-61 (58 ref.)
[Dose optimization in clinical oncology: pharmacokinetic-pharmacodynamic relationship] Canal P, et al. **Bull Cancer (Paris)** 1996 Apr;83(4):256-65 (65 ref.) (Eng. Abstr.) **(Fre)**
[Cisplatin and carboplatin--update] Geffen DB, et al. **Harefuah** 1995 Aug;129(3-4):131-5 (40 ref.) **(Heb)**
[Anticancer agents and apoptosis] Fukuoka K, et al. **Nippon Rinsho** 1996 Jan;54(1):250-8 (33 ref.) (Eng. Abstr.) **(Jpn)**
[Design of antitumor 2'-deoxy-(2'-C-substituted) cytidines] Matsuda A. **Tanpakushitsu Kakusan Koso** 1994 Jul; 40(10):1232-41 (18 ref.) **(Jpn)**

ADMINISTRATION & DOSAGE

Exfoliated tumour cells and locally recurrent colorectal cancer. Basha G, et al. **Acta Chir Belg** 1996 Apr;96(2):66-70 (41 ref.)
High-dose chemotherapy with stem-cell rescue for the treatment of breast cancer. McCauley DL. **Am J Health Syst Pharm** 1996 Mar 1;53(5):521-34; quiz 561-2 (87 ref.)
Will increases in dose intensity improve outcome: con [comment] Souhami RL. **Am J Med** 1995 Dec 29; 99(6A):71S-76S (39 ref.) Comment on: Am J Med 1995 Dec 29;99(6A):69S-70S.
What accounts for the association of vegetables and fruits with lower incidence of cancers and coronary heart disease? [editorial; comment] Omenn GS. **Ann Epidemiol** 1995 Jul;5(4):333-5 (12 ref.) Comment on: Ann Epidemiol 1995 Jul;5(4):255-60. Comment on: Ann Epidemiol 1995 Jul;5(4):261-9.
High-dose chemotherapy for breast cancer. Gradishar WJ, et al. **Ann Intern Med** 1996 Oct 1;125(7):599-604 (55 ref.)
Dose-intensive chemotherapy in breast cancer--the need for appropriate measures of outcome [editorial] Basser RL. **Ann Oncol** 1995 Sep;6(7):633-5 (23 ref.)
High-dose chemotherapy of solid tumours. Crown J. **Ann Oncol** 1995;6 Suppl 1:11-4; discussion 14-5 (57 ref.)
Experience with dose and schedule variations in germ cell tumors. De Mulder PH, et al. **Anticancer Drugs** 1995 Oct; 6 Suppl 5:43-52 (57 ref.)
The importance of dose and schedule in cancer chemotherapy: breast cancer. Leonard RC. **Anticancer Drugs** 1995 Oct;6 Suppl 5:17-27 (75 ref.)
The importance of dose and schedule in cancer chemotherapy: epithelial ovarian cancer. Mainwaring PN, et al. **Anticancer Drugs** 1995 Oct;6 Suppl 5:29-41 (116 ref.)
The problem of thrombocytopenia and its management. Newland AC. **Anticancer Drugs** 1995 Oct;6 Suppl 5:65-73 (76 ref.)
The importance of dose and schedule in chemotherapy for small cell lung cancer. Ranson M, et al. **Anticancer Drugs** 1995 Oct;6 Suppl 5:53-63 (112 ref.)
The importance of dose and schedule in cancer chemotherapy: haematological cancer. Sweetenham JW. **Anticancer Drugs** 1995 Oct;6 Suppl 5:7-15 (50 ref.)
Chemotherapy of metastatic bowel cancer. Ross PJ, et al. **Br J Hosp Med** 1996 Mar 6-19;55(5):263-6 (20 ref.)
Arterial therapy of hepatic colorectal metastases. Vauthey JN, et al. **Br J Surg** 1996 Apr;83(4):447-55 (104 ref.)
European School of Oncology European consensus on the use of granulocyte colony-stimulating factor: the example of breast cancer. Antoine EC, et al. **Cancer Chemother Pharmacol** 1996;38 Suppl:S103-9 (71 ref.)
Is there a role for intraperitoneal therapy in the management of gastrointestinal malignancies? Markman M. **Cancer Invest** 1995;13(6):625-8 (27 ref.)
High-dose chemotherapy for malignancies: a review. Roman-Unfer S, et al. **Compr Ther** 1996 Feb;22(2):107-20 (128 ref.)
Regional chemotherapy of colorectal cancer. Kemeny NE. **Eur J Cancer** 1995 Jul-Aug;31A(7-8):1271-6 (45 ref.)
High-dose chemotherapy for breast cancer. Leonard RC. **Eur J Cancer** 1996 Feb;32A(2):205-8 (30 ref.)
Chronomodulation of chemotherapy against metastatic colorectal cancer. International Organization for Cancer Chronotherapy. Lévi F, et al. **Eur J Cancer** 1995 Jul-Aug; 31A(7-8):1264-70 (43 ref.)
Haemopoietic stem cell inhibition: potential for dose intensification. Marshall E. **Eur J Cancer** 1995 Sep; 31A(10):1586-91 (92 ref.)
High dose chemotherapy with haemopoietic support for breast cancer. Steward WP. **Eur J Cancer** 1995;31A Suppl 7:S21-4 (18 ref.)
Patient compliance with crucial drug regimens: implications for prostate cancer. Urquhart J. **Eur Urol** 1996;29 Suppl 2:124-31 (62 ref.)
Chemotherapeutic tumour targeting using clostridial spores. Minton NP, et al. **FEMS Microbiol Rev** 1995 Oct; 17(3):357-64 (40 ref.)
Antibody-targeted polymer-bound drugs. Říhová B. **Folia Microbiol (Praha)** 1995;40(4):367-84 (121 ref.)
Preoperative chemoradiation for adenocarcinoma of the pancreas: excessive toxicity of prophylactic hepatic irradiation [see comments] Evans DB, et al. **Int J Radiat Oncol Biol Phys** 1995 Nov 1;33(4):913-8 (35 ref.) Comment in: Int J Radiat Oncol Biol Phys 1995 Nov 1;33(4):969-70.
Regional chemotherapy: revisited [editorial] Markman M. **J Cancer Res Clin Oncol** 1996;122(1):1-2 (11 ref.)
Current concepts for chronochemotherapy of cancer. Laerum OD, et al. **J Infus Chemother** 1995;5(3 Suppl 1):159-70 (189 ref.)
Adjuvant therapy for resectable gastric adenocarcinoma: preoperative and postoperative chemotherapy trials. Leach SD, et al. **J Infus Chemother** 1995 Summer;5(3):104-11 (46 ref.)
Implantable pumps for drug delivery to the brain. Bakhshi S, et al. **J Neurooncol** 1995 Nov;26(2):133-9 (68 ref.)
Distribution of drugs following controlled delivery to the brain interstitium. Mak M, et al. **J Neurooncol** 1995 Nov; 26(2):91-102 (61 ref.)
High dose chemotherapy for breast cancer: the case for trials in adjuvant therapy. Leonard RC. **J R Soc Med** 1996 Jun; 89(6):337P-9P (22 ref.)
Oral therapy for small cell lung cancer. Postmus PE, et al. **Lung Cancer** 1995 Jun;12 Suppl 3:S63-70 (29 ref.)
Errors involving pediatric patients receiving chemotherapy: a literature review. Trinkle R, et al. **Med Pediatr Oncol** 1996 May;26(5):344-51 (47 ref.)
Advances in chemotherapy for brain tumors. Conrad CA, et al. **Neurol Clin** 1995 Nov;13(4):795-812 (106 ref.)
New delivery systems for brain tumor therapy. Sipos EP, et al. **Neurol Clin** 1995 Nov;13(4):813-25 (81 ref.)
Intratumoral chemotherapy. Walter KA, et al. **Neurosurgery** 1995 Dec;37(6):1128-45 (131 ref.)
Combination regimens of paclitaxel and the platinum drugs as first-line regimens for ovarian cancer. Ozols RF. **Semin Oncol** 1995 Dec;22(6 Suppl 15):1-6 (17 ref.)
High-dose chemotherapy for breast cancer: twenty years later. Whom should we treat? And when? Wright-Browne V, et al. **Tumori** 1996 May-Jun;82(3):187-92 (45 ref.)
[High-dose chemotherapy and autologous bone marrow transplantation in solid tumors. A review] Handberg J, et al. **Ugeskr Laeger** 1996 Jul 15;158(29):4175-80 (40 ref.) (Eng. Abstr.) **(Dan)**
[Transfusion-refractory thrombocytopenia during chemotherapy: pathogenesis, frequency and treatment] Helleberg C, et al. **Ugeskr Laeger** 1995 Sep 11; 157(37):5082-6 (40 ref.) (Eng. Abstr.) **(Dan)**
[Immediate intraperitoneal chemotherapy after surgery for the reduction of peritoneal malignancies: for what purpose and for whom? (editorial)] Elias D. **Ann Chir** 1995; 49(7):567-72 (34 ref.) (Eng. Abstr.) **(Fre)**
[Clinical phase I studies in oncology and hematology. Concepts, implementation and ethical considerations] Hanauske AR. **Med Klin** 1996 Apr 12;91 Suppl 3:68-70 (28 ref.) **(Ger)**
[Methods for optimizing cytostatic drug therapy] Lipp HP. **Med Monatsschr Pharm** 1995 Oct;18(10):282-91 (63 ref.) **(Ger)**
[Results of resection and adjuvant therapy of liver metastases of primary colorectal tumors--a review of the literature] Lorenz M, et al. **Zentralbl Chir** 1995;120(10):769-79 (74 ref.) (Eng. Abstr.) **(Ger)**
[Regional adjuvant therapy in colorectal liver metastases: requirements for clinical therapy studies from the statistical viewpoint (see comments)] Müller HH, et al. **Zentralbl Chir** 1995;120(10):755-9 (10 ref.) (Eng. Abstr.) Comment in: Zentralbl Chir 1995;120(10):753-4. **(Ger)**
[The study of the biological activation induced by the lymphocyte transfusion--the induction of the bio-reproducing protein (BRP)] Sato I. **Hum Cell** 1995 Sep; 8(3):77-84 (18 ref.) (Eng. Abstr.) **(Jpn)**
[Chemotherapy of hepatocellular carcinoma] Okada S. **Nippon Naika Gakkai Zasshi** 1995 Dec 10;84(12):2028-31 (5 ref.) **(Jpn)**
[Neoadjuvant chemotherapy in advanced gynecologic cancer] Hirabayashi K. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Aug; 47(8):797-802 (7 ref.) **(Jpn)**
[High-dose therapy with cytostatic agents as primary treatment of advanced breast cancer] Matheson I. **Tidsskr Nor Laegeforen** 1996 Jun 20;116(16):1904-6 (18 ref.) (Eng. Abstr.) **(Nor)**

ADVERSE EFFECTS

Effect of chemotherapy on growth. Ogilvy-Stuart AL, et al. **Acta Paediatr Suppl** 1995 Sep;411:52-6 (46 ref.)
Anthracycline-induced cardiotoxicity. Shan K, et al. **Ann Intern Med** 1996 Jul 1;125(1):47-58 (146 ref.)
The problem of thrombocytopenia and its management. Newland AC. **Anticancer Drugs** 1995 Oct;6 Suppl 5:65-73 (76 ref.)
Cutaneous eruptions from suramin. A clinical and histopathologic study of 60 patients. Lowitt MH, et al. **Arch Dermatol** 1995 Oct;131(10):1147-53 (30 ref.)
The role of haematopoietic stem cell-supported myeloablative therapy for the management of multiple myeloma. Cavo M, et al. **Baillieres Clin Haematol** 1995 Dec;8(4):795-813 (58 ref.)
Role of 5-hydroxytryptamine3 (5-HT3) antagonists in the prevention of emesis caused by anticancer therapy. Karim F, et al. **Biochem Pharmacol** 1996 Sep 13;52(5):685-92 (64 ref.)
Mechanism and management of treatment-related gonadal failure in recipients of high dose chemoradiotherapy. Apperley JF, et al. **Blood Rev** 1995 Jun;9(2):93-116 (158 ref.)
Hydroxyurea-induced dermatomyositis-like eruption. Senet P, et al. **Br J Dermatol** 1995 Sep;133(3):455-9 (32 ref.)
Progress in reducing nausea and emesis. Comparisons of ondansetron (Zofran), granisetron (Kytril), and tropisetron (Navoban). Morrow GR, et al. **Cancer** 1995 Aug 1; 76(3):343-57 (121 ref.)
Is interleukin 3 active in anticancer drug-induced thrombocytopenia? Newland AC. **Cancer Chemother Pharmacol** 1996;38 Suppl:S83-8 (46 ref.)
Emesis and anti-emesis. Naylor RJ, et al. **Cancer Surv** 1994; 21:117-35 (138 ref.)
Oral complications of local and systemic cancer treatment. Carl W. **Curr Opin Oncol** 1995 Jul;7(4):320-4 (28 ref.)
Management of diarrhea induced by tumors or cancer therapy. Cascinu S. **Curr Opin Oncol** 1995 Jul;7(4):325-9 (63 ref.)
Cardiotoxicity and cardioprotection during chemotherapy. Hochster H, et al. **Curr Opin Oncol** 1995 Jul;7(4):304-9 (37 ref.)
Cardiovascular toxicity with cancer chemotherapy. Frishman WH, et al. **Curr Probl Cardiol** 1996 Apr;21(4):225-86 (227 ref.)
Cutaneous side effects associated with interferon-alpha therapy: a review. Chang LW, et al. **Cutis** 1995 Sep; 56(3):144 (14 ref.)
Comparative adverse effect profiles of platinum drugs. McKeage MJ. **Drug Saf** 1995 Oct;13(4):228-44 (154 ref.)
The use of quinolones as therapy in granulocytopenic cancer patients. Comparison with other antimicrobials. Krcméry V Jr. **Drugs** 1995;49 Suppl 2:139-43 (30 ref.)
Monitoring chemotherapy-induced hearing loss in children. Bellman SC. **Eur J Cancer** 1996 Jun;32A(7):1185-8 (25 ref.)
Protection of normal tissue from the cytotoxic effects of chemotherapy and radiation by amifostine: clinical experiences. Capizzi RL, et al. **Eur J Cancer** 1995;31A Suppl 1:S8-13 (11 ref.)
Protection of normal tissues from the cytotoxic effects of chemotherapy and radiation by amifostine (WR-2721): preclinical aspects. Peters GJ, et al. **Eur J Cancer** 1995;31A Suppl 1:S1-7 (45 ref.)
Late effects of treatment for Wilms tumor. Green DM, et al. **Hematol Oncol Clin North Am** 1995 Dec;9(6):1317-27 (83 ref.)
Chemotherapy and neutropenia. Kim SK, et al. **Hematol Oncol Clin North Am** 1996 Apr;10(2):377-95 (123 ref.)
Thrombotic microangiopathies associated with drugs and bone marrow transplantation. Moake JL, et al. **Hematol Oncol Clin North Am** 1996 Apr;10(2):485-97 (66 ref.)
Hemolytic disorders associated with cancer. Rytting M, et al. **Hematol Oncol Clin North Am** 1996 Apr;10(2):365-76 (87 ref.)
Philadelphia chromosome-negative cells with trisomy 8 after busulfan and interferon treatment of Ph1-positive chronic myelogenous leukemia. Izumi T, et al. **Int J Hematol** 1996 Jul;64(1):73-7 (17 ref.)
An overview of the oral complications of adult patients with malignant haematological conditions who have undergone radiotherapy or chemotherapy. Coleman S. **J Adv Nurs** 1995 Dec;22(6):1085-91 (47 ref.)
Cancer chemotherapy in the elderly. Conti JA, et al. **J Clin Gastroenterol** 1995 Jul;21(1):65-71 (63 ref.)
The secondary leukemias: challenges and research directions. Smith MA, et al. **J Natl Cancer Inst** 1996 Apr 3; 88(7):407-18 (199 ref.)
Pediatric phase I drug tolerance: a review and comparison of recent adult and pediatric phase I trials. Carlson L, et al. **J Pediatr Hematol Oncol** 1996 Aug;18(3):250-6 (83 ref.)
Central nervous system toxicity of cancer therapy in children. Moore IM. **J Pediatr Oncol Nurs** 1995 Oct;12(4):203-10; discussion 211 (50 ref.)
Interferon-induced acute renal failure: a case report and literature review. Horowitz R, et al. **Med Oncol** 1995 Mar; 12(1):55-7 (10 ref.)
Mutagenic and carcinogenic properties of platinum-based anticancer drugs. Sanderson BJ, et al. **Mutat Res** 1996 Aug 17;355(1-2):59-70 (59 ref.)
Serotonin mechanisms in chemotherapy-induced emesis in cancer patients. Cubeddu LX. **Oncology** 1996 Jun;53 Suppl 1:18-25 (34 ref.)
Pathophysiology, severity, pattern, and risk factors for carboplatin-induced emesis. du Bois A, et al. **Oncology** 1996 Jun;53 Suppl 1:46-50 (29 ref.)
Management of cisplatin-induced delayed emesis. Hesketh P. **Oncology** 1996 Jun;53 Suppl 1:73-7 (14 ref.)
The severity and pattern of emesis following different cytotoxic agents. Martin M. **Oncology** 1996 Jun;53 Suppl 1:26-31 (16 ref.)
Mechanisms of chemotherapy/radiotherapy-induced emesis in animal models. Naylor RJ, et al. **Oncology** 1996 Jun;53 Suppl 1:8-17 (77 ref.)
Management of other non-cisplatin-induced emesis. Schmoll HJ, et al. **Oncology** 1996 Jun;53 Suppl 1:51-5 (24 ref.)
Optimal control of acute cisplatin-induced emesis. Verweij J, et al. **Oncology** 1996 Jun;53 Suppl 1:56-64 (80 ref.)
Late effects of cancer treatment in children. Ried H, et al. **Pediatr Dent** 1995 Jul-Aug;17(4):273-84 (117 ref.)
Sucralfate: prophylaxis of mucosal damage during cancer therapy. Henriksson R, et al. **Scand J Gastroenterol Suppl** 1995;210:45-7 (29 ref.)
Future development of amifostine in cancer treatment. Alberts DS, et al. **Semin Oncol** 1996 Aug;23(4 Suppl 8):90-9 (61 ref.)
Amifostine and chemotherapy-related thrombocytopenia.

Budd GT. **Semin Oncol** 1996 Aug;23(4 Suppl 8):49–52 (31 ref.)

Amifostine: the preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies. Capizzi R. **Semin Oncol** 1996 Aug;23(4 Suppl 8):2–17 (99 ref.)

Preventing chemotherapy-induced nausea and vomiting: an update and a review of emesis. Ettinger DS. **Semin Oncol** 1995 Aug;22(4 Suppl 10):6–18 (109 ref.)

Prophylaxis with oral granisetron for acute emesis induced by moderately emetogenic chemotherapy. Hesketh P. **Semin Oncol** 1995 Aug;22(4 Suppl 10):19–23 (23 ref.)

[Vascular disorders following chemotherapy] van der Lelie J, et al. **Ned Tijdschr Geneeskd** 1995 Nov 11;139(45):2296–9 (24 ref.) **(Dut)**

[Cytotoxic chemotherapy in elderly patients: present and future] Freyer G, et al. **Bull Cancer (Paris)** 1995 Jul; 82(7):531–40 (66 ref.) (Eng. Abstr.) **(Fre)**

[Mental confusion syndromes in oncology] Reich MG, et al. **Bull Cancer (Paris)** 1996 Feb;83(2):115–28 (73 ref.) (Eng. Abstr.) **(Fre)**

[Late complications of chemoradiotherapeutic combinations: fundamental aspects and clinical experience] Balosso J, et al. **Bull Cancer Radiother** 1995;82(2):101–12 (37 ref.) **(Fre)**

[Oro-dental manifestations of leukemia in children] Nikoui M, et al. **J Can Dent Assoc** 1996 May;62(5):443–6, 449–50 (41 ref.) (Eng. Abstr.) **(Fre)**

[Thymus hyperplasia following chemotherapy] Cumin I, et al. **Presse Med** 1996 Feb 24;25(7):291–2 (13 ref.) (Eng. Abstr.) **(Fre)**

[Nephrotic syndrome complicating treatment with interferon alpha] Dhib M, et al. **Presse Med** 1996 Jun 29;25(23):1066–8 (18 ref.) (Eng. Abstr.) **(Fre)**

[Cardiotoxicity and cardioprotection in chemo- and radiotherapy for malignant diseases (editorial)] Wagdi P, et al. **Schweiz Rundsch Med Prax** 1995 Oct 24;84(43):1216–9 (46 ref.) **(Ger)**

[Main cardiotoxic drugs] Pettirossi G, et al. **Clin Ter** 1996 Jan-Feb;147(1-2):67–77 (34 ref.) (Eng. Abstr.) **(Ita)**

[The prevention of work risks deriving from the use of chemotherapeutic antineoplastics in the health environment: the consensus document (November 1995)] **Med Lav** 1996 Jan-Feb;87(1):78–86 (0 ref.) **(Ita)**

[Side effects of cancer chemotherapy and steps to deal with them] Taguchi T. **Gan To Kagaku Ryoho** 1995 Dec; 22(14):2017–28 (9 ref.) (Eng. Abstr.) **(Jpn)**

[Pathogenic mechanism of fulminant hepatic failure in HBs Ag carrier after withdrawal of cytotoxic chemotherapy] Inoue K, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:467–72 (22 ref.) **(Jpn)**

[Tubulointerstitial changes in some hematological disorders] Morita H, et al. **Nippon Rinsho** 1995 Aug;53(8):2007–12 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Drug-induced nephrotoxicity] Takeda M, et al. **Nippon Yakurigaku Zasshi** 1996 Jan;107(1):1–8 (50 ref.) (Eng. Abstr.) **(Jpn)**

[Lung toxicity of cancer treatment] de Castro Carpeño J, et al. **Med Clin (Barc)** 1995 Nov 18;105(17):661–8 (76 ref.) **(Spa)**

ANTAGONISTS & INHIBITORS

[The molecular mechanisms of the multiple drug resistance of tumors] Leont'eva OV. **Antibiot Khimioter** 1995 May; 40(5):48–60 (84 ref.) **(Rus)**

BLOOD

[Anticancer drugs] Fujita H. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:1043–52 (15 ref.) **(Jpn)**

CHEMICAL SYNTHESIS

Mechanistic insight from kinetic studies on the interaction of model palladium (II) complexes with nucleic acid components. Rau T, et al. **Met Ions Biol Syst** 1996; 32:339–78 (95 ref.)

CHEMISTRY

Cisplatin and derived anticancer drugs: mechanism and current status of DNA binding. Bloemink MJ, et al. **Met Ions Biol Syst** 1996;32:641–85 (191 ref.)

Interactions of metallopharmaceuticals with DNA. Clarke MJ, et al. **Met Ions Biol Syst** 1996;32:727–80 (235 ref.)

Current status of structure-activity relationships of platinum anticancer drugs: activation of the trans geometry. Farrell N. **Met Ions Biol Syst** 1996;32:603–39 (104 ref.)

Trans-diammineplatinum(II): what makes it different from cis-DDP? Coordination chemistry of a neglected relative of cisplatin and its interaction with nucleic acids. Lippert B. **Met Ions Biol Syst** 1996;33:105–41 (153 ref.)

Chemical and biological properties of cytotoxic alpha-(N)-heterocyclic carboxaldehyde thiosemicarbazones. Liu MC, et al. **Prog Med Chem** 1995; 32:1–35 (157 ref.)

METABOLISM

The role of the MDR protein in altered drug translocation across tumor cell membranes. Roepe PD. **Biochim Biophys Acta** 1995 Dec 20;1241(3):385–405 (135 ref.)

The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. Kivistö KT, et al. **Br J Clin Pharmacol** 1995 Dec;40(6):523–30 (73 ref.)

On the phosphorylation of 2-chlorodeoxyadenosine (CdA) and its correlation with clinical response in leukemia treatment. Arnér ES. **Leuk Lymphoma** 1996 Apr; 21(3-4):225–31 (64 ref.)

Interaction of alpha-interferon with chemotherapeutic agents: effects on cytotoxic drug metabolism and multiple drug resistance. Sewell GJ. **Med Oncol** 1995 Mar;12(1):9–14 (43 ref.)

Proteins that bind to and mediate the biological activity of platinum anticancer drug-DNA adducts. Whitehead JP, et al. **Met Ions Biol Syst** 1996;32:687–726 (111 ref.)

PHARMACOKINETICS

Pharmacokinetic modelling--a prelude to therapeutic drug monitoring for all cancer patients? [editorial; comment] Judson IR. **Eur J Cancer** 1995 Oct;31A(11):1733–5 (24 ref.) Comment on: Eur J Cancer 1995 Oct;31A(11):1794–8. Comment on: Eur J Cancer 1995 Oct;31A(11):1804–10.

Pharmacological blood-brain barrier modification for selective drug delivery. Cloughesy TF, et al. **J Neurooncol** 1995 Nov;26(2):125–32 (39 ref.)

Distribution of drugs following controlled delivery to the brain interstitium. Mak M, et al. **J Neurooncol** 1995 Nov; 26(2):91–102 (61 ref.)

Insights into mechanisms of cisplatin resistance and potential for its clinical reversal. Gosland M, et al. **Pharmacotherapy** 1996 Jan-Feb;16(1):16–39 (200 ref.)

[Pharmacology of regional chemotherapy of colorectal liver metastases] Schalhorn A, et al. **Zentralbl Chir** 1995; 120(10):764–8 (15 ref.) (Eng. Abstr.) **(Ger)**

[Mechanism of resistance to antitumor agents--its involvement in blood-brain barrier] Tsuruo T. **Yakugaku Zasshi** 1995 Jul;115(7):513–22 (36 ref.) (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

Review article: drug development in gastroenterology--the changing view of industry. Parsons ME, et al. **Aliment Pharmacol Ther** 1995 Oct;9(5):457–63 (14 ref.)

Folate-based thymidylate synthase inhibitors as anticancer drugs. Jackman AL, et al. **Ann Oncol** 1995 Nov;6(9):871–81 (84 ref.)

Anticancer drug development at Lilly Research Laboratories. Pearce HL. **Ann Oncol** 1995;6 Suppl 1:55–62 (39 ref.)

SRC as a target for anti-cancer drugs. Levitzki A. **Anticancer Drug Des** 1996 Apr;11(3):175–82 (45 ref.)

Human DNA topoisomerase II: biochemistry and role in chemotherapy resistance (review). Withoff S, et al. **Anticancer Res** 1996 Jul-Aug;16(4A):1867–80 (184 ref.)

Do telomerase antagonists represent a novel anti-cancer strategy? [editorial] Parkinson EK. **Br J Cancer** 1996 Jan; 73(1):1–4 (47 ref.)

Antisense oligodeoxynucleotides as clinical therapeutic agents. Tonkinson JL, et al. **Cancer Invest** 1996;14(1):54–65 (103 ref.)

Use of hydroxyurea to alter drug resistance of human tumor cells. Van den Berg C, et al. **Cancer Treat Res** 1995; 78:95–114 (123 ref.)

New drugs. The anthrapyrazoles. Gogas H, et al. **Cancer Treat Rev** 1996 Nov;21(6):541–52 (53 ref.)

Anticarcinogenic, hypocholesterolemic, and antagonistic activities of Lactobacillus acidophilus. Mital BK, et al. **Crit Rev Microbiol** 1995;21(3):175–214 (371 ref.)

Ribonucleotide reductase inhibitors: new strategies for cancer cnemotherapy. Nocentini G. **Crit Rev Oncol Hematol** 1996 Mar;22(2):89–126 (335 ref.)

Advances in glyoxalase research. Glyoxalase expression in malignancy, anti-proliferative effects of methylglyoxal, glyoxalase I inhibitor diesters and S-D-lactoylglutathione, and methylglyoxal-modified protein binding and endocytosis by the advanced glycation endproduct receptor. Thornalley PJ. **Crit Rev Oncol Hematol** 1995 Aug;20(1-2):99–128 (225 ref.)

Anticancer drugs acting against signaling pathways. Powis G. **Curr Opin Oncol** 1995 Nov;7(6):554–9 (95 ref.)

Tretinoin. A review of its pharmacodynamic and pharmacokinetic properties and use in the management of acute promyelocytic leukaemia. Gillis JC, et al. **Drugs** 1995 Nov;50(5):897–923 (160 ref.)

Apoptosis and chemotherapy resistance. Hickman JA. **Eur J Cancer** 1996 Jun;32A(6):921–6 (67 ref.)

Gene expression and neuroblastoma cell differentiation in response to retinoic acid: differential effects of 9-cis and all-trans retinoic acid. Redfern CP, et al. **Eur J Cancer** 1995;31A(4):486–94 (73 ref.)

Heterocyclic betaines containing pi-deficient and pi-excessive moieties. Synthetic and biological aspects. Alcalde E, et al. **Farmaco** 1996 Jun;51(6):381–93 (51 ref.)

Mechanisms of resistance to topoisomerases poisons. Prost S. **Gen Pharmacol** 1995 Dec;26(8):1673–84 (88 ref.)

Signal transduction by Ras-like GTPases: a potential target for anticancer drugs. Spaargaren M, et al. **Gene Expr** 1995; 4(6):345–56 (122 ref.)

The nuclear matrix as a site of anticancer drug action. Fernandes DJ, et al. **Int Rev Cytol** 1995;162A:539–76 (260 ref.)

Ayurvedic herbal drugs with possible cytostatic activity. Smit HF, et al. **J Ethnopharmacol** 1995 Jul 7;47(2):75–84 (53 ref.)

DNA repair: enzymatic mechanisms and relevance to drug response. Chaney SG, et al. **J Natl Cancer Inst** 1996 Oct 2;88(19):1346–60 (253 ref.)

Antitumor effects of antisense phosphorothioate c-myc oligodeoxynucleotides: a question of mechanism [editorial; comment] Stein C.A.. **J Natl Cancer Inst** 1996 Apr 3; 88(7):391–3 (9 ref.) Comment on: J Natl Cancer Inst 1996 Apr 3;88(7):419–29.

Mechanisms of resistance of human tumours to anticancer drugs of the platinum family: a review. Ferguson PJ. **J Otolaryngol** 1995 Aug;24(4):242–52 (100 ref.)

On the phosphorylation of 2-chlorodeoxyadenosine (CdA) and its correlation with clinical response in leukemia treatment. Arnér ES. **Leuk Lymphoma** 1996 Apr; 21(3-4):225–31 (64 ref.)

Modulation of 5-fluorouracil by interferon: a review of potential cellular targets. Horowitz R, et al. **Med Oncol** 1995 Mar;12(1):3–8 (48 ref.)

Interaction of alpha-interferon with chemotherapeutic agents: effects on cytotoxic drug metabolism and multiple drug resistance. Sewell GJ. **Med Oncol** 1995 Mar;12(1):9–14 (43 ref.)

Antimitotic natural products and their interactions with tubulin. Hamel E. **Med Res Rev** 1996 Mar;16(2):207–31 (143 ref.)

DNA damage, p53 and anticancer therapies. Milner J. **Nat Med** 1995 Sep;1(9):879–80 (8 ref.)

Circadian rhythms and cancer chemotherapy. Focan C. **Pharmacol Ther** 1995;67(1):1–52 (289 ref.)

Single-chain fusion toxins for the treatment of breast cancer: antitumor activity of BR96 sFv-PE40 and heregulin-PE40. Siegall CB. **Recent Results Cancer Res** 1996;140:51–60 (21 ref.)

Modulators of signal transduction as cancer chemotherapeutic agents--novel mechanisms and toxicities. Gescher A. **Toxicol Lett** 1995 Dec;82-83:159–65 (19 ref.)

Structure-activity-relationship studies on modulators of the multidrug transporter P-glycoprotein--an overview. Ecker G, et al. **Wien Klin Wochenschr** 1995;107(22):681–6 (51 ref.)

[Modulation of integrin alpha-v-beta-1 expression on human tumor cells by leukemia inhibitory factor (LIF) and oncostatin M (OSM)] Heymann D, et al. **Bull Cancer (Paris)** 1996 Jan;83(1):13–21 (41 ref.) (Eng. Abstr.) **(Fre)**

[Expression of the MDR1 gene in five human cell lines of medullary thyroid cancer and reversion of the resistance to doxorubicine by ciclosporin A and verapamil] Massart C, et al. **Bull Cancer (Paris)** 1996 Jan;83(1):39–45 (32 ref.) (Eng. Abstr.) **(Fre)**

[Update on the use of interferons in clinical practice] Lauta VM. **Clin Ter** 1995 Jun-Jul;146(6-7):393–448 (160 ref.) (Eng. Abstr.) **(Ita)**

[Current problems in development of new anticancer agents for new molecular targets] Nishii K. **Gan To Kagaku Ryoho** 1996 Jan;23(2):211–8 (12 ref.) (Eng. Abstr.) **(Jpn)**

[Cell cycle regulation by anticancer agent] Nomoto T, et al. **Gan To Kagaku Ryoho** 1995 Oct;22(12):1719–23 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Cancer chemosensitivity test--from laboratory to clinic] Kubota T. **Hum Cell** 1995 Dec;8(4):189–94 (11 ref.) (Eng. Abstr.) **(Jpn)**

[On the novel differentiation-apoptosis inducers in tumor cells] Nakaya K. **Tanpakushitsu Kakusan Koso** 1996 Feb; 41(2):119–26 (38 ref.) **(Jpn)**

[Strategies for studies on mechanism of action of antineoplastic agents] Kuśnierczyk H. **Postepy Hig Med Dosw** 1995;49(1):85–96 (20 ref.) (Eng. Abstr.) **(Pol)**

THERAPEUTIC USE

2-Chloro-2'-deoxyadenosine [editorial] Delannoy A, et al. **Acta Clin Belg** 1995;50(4):193–6 (10 ref.)

Role of deferoxamine in tumor therapy. Donfrancesco A, et al. **Acta Haematol** 1996;95(1):66–9 (16 ref.)

Present research trends in cancer chemotherapy. Eckhardt S. **Acta Med Hung** 1994;50(3-4):133–40 (14 ref.)

High-dose therapy with autologous bone marrow stem cell support in primary and metastatic human breast cancer. A review. Bergh J. **Acta Oncol** 1995;34(5):669–74 (48 ref.)

Chronobiology. Implications for cancer chemotherapy. Bjarnason GA. **Acta Oncol** 1995;34(5):615–24 (120 ref.)

Chemotherapy for advanced bladder carcinoma: new molecules and regimens. Abi-Aad AS. **Acta Urol Belg** 1996 May;64(2):43–5 (19 ref.)

Single institution experience with recombinant gamma-interferon in the treatment of patients with metastatic renal cell carcinoma. Mani S, et al. **Am J Clin Oncol** 1996 Apr;19(2):149–53 (26 ref.)

Recombinant beta-interferon in the treatment of patients with metastatic renal cell carcinoma. Mani S, et al. **Am J Clin Oncol** 1996 Apr;19(2):187–9 (19 ref.)

High-dose chemotherapy with stem-cell rescue for the treatment of breast cancer. McCauley DL. **Am J Health Syst Pharm** 1996 Mar 1;53(5):521–34; quiz 561–2 (87 ref.)

Combination of BRMs with chemotherapy. Tursz T. **Am J Med** 1995 Dec 29;99(6A):56S–58S (7 ref.)

Interferon-alpha therapy for chronic myelogenous leukemia.

Wetzler M, et al. **Am J Med** 1995 Oct;99(4):402–11 (67 ref.)

Allogenic bone marrow transplantation or chemotherapy for patients with acute myeloid leukemia in first complete remission: a decision analysis approach. Hertenstein B, et al. **Ann Hematol** 1996 Apr;72(4):223–30 (47 ref.)

Therapy of childhood acute myelogenous leukemias. Vormoor J, et al. **Ann Hematol** 1996 Jul;73(1):11–24 (24 ref.)

Preparative regimens: chemotherapy versus chemoradiotherapy. A historical perspective. Santos GW. **Ann N Y Acad Sci** 1995 Dec 29;770:1–7 (38 ref.)

Matrix metalloproteinase inhibition: a review of anti–tumour activity. Brown PD, et al. **Ann Oncol** 1995 Dec; 6(10):967–74 (48 ref.)

Dealing with initial chemotherapy doses: a new basis for treatment optimisation in limited small–cell lung cancer. Le Cesne A, et al. **Ann Oncol** 1995;6 Suppl 3:S53–6 (26 ref.)

New drugs in the treatment of non–small cell lung cancer. Steward WP, et al. **Ann Oncol** 1995;6 Suppl 1:49–54 (38 ref.)

Induction or concomitant chemotherapy and radiotherapy for non–small–cell lung cancer: myth or reality. Van Houtte P. **Ann Oncol** 1995;6 Suppl 3:S37–40 (21 ref.)

Possible interaction involving phenytoin, dexamethasone, and antineoplastic agents: a case report and review. Gattis WA, et al. **Ann Pharmacother** 1996 May;30(5):520–6 (20 ref.)

Potential uses of interferon alpha 2 as adjuvant therapy in cancer. Agarwala SS, et al. **Ann Surg Oncol** 1995 Jul; 2(4):365–71 (44 ref.)

P–glycoproteins and multidrug resistance. Bellamy WT. **Annu Rev Pharmacol Toxicol** 1996;36:161–83 (127 ref.)

Current chemotherapy of advanced non–small cell lung cancer. Abratt RP. **Anticancer Drugs** 1995 Dec;6 Suppl 6:15–8 (29 ref.)

Experience with dose and schedule variations in germ cell tumors. De Mulder PH, et al. **Anticancer Drugs** 1995 Oct; 6 Suppl 5:43–52 (57 ref.)

Treatment of metastatic malignant melanoma. Falkson CI. **Anticancer Drugs** 1995 Dec;6(6):709–16 (120 ref.)

The importance of dose and schedule in cancer chemotherapy: breast cancer. Leonard RC. **Anticancer Drugs** 1995 Oct;6 Suppl 5:17–27 (75 ref.)

The importance of dose and schedule in cancer chemotherapy: epithelial ovarian cancer. Mainwaring PN, et al. **Anticancer Drugs** 1995 Oct;6 Suppl 5:29–41 (116 ref.)

The importance of dose and schedule in chemotherapy for small cell lung cancer. Ranson M, et al. **Anticancer Drugs** 1995 Oct;6 Suppl 5:53–63 (112 ref.)

The importance of dose and schedule in cancer chemotherapy: haematological cancer. Sweetenham JW. **Anticancer Drugs** 1995 Oct;6 Suppl 5:7–15 (50 ref.)

Symptomatic benefit from gemcitabine and other chemotherapy in advanced non–small cell lung cancer: changes in performance status and tumour–related symptoms. Thatcher N, et al. **Anticancer Drugs** 1995 Dec; 6 Suppl 6:39–48 (68 ref.)

Human DNA topoisomerase II: biochemistry and role in chemotherapy resistance (review). Withoff S, et al. **Anticancer Res** 1996 Jul–Aug;16(4A):1867–80 (184 ref.)

The role of chemotherapy in the treatment of multiple myeloma. Bergsagel DE. **Baillieres Clin Haematol** 1995 Dec;8(4):783–94 (38 ref.)

Modulation of multidrug resistance in multiple myeloma. Sonneveld P. **Baillieres Clin Haematol** 1995 Dec; 8(4):831–44 (107 ref.)

Drug trials in neuropathy. Hughes RA, et al. **Baillieres Clin Neurol** 1995 Nov;4(3):607–27 (87 ref.)

High–dose therapy for breast cancer. Vahdat L, et al. **Blood Rev** 1995 Sep;9(3):191–200 (118 ref.)

Adjuvant chemotherapy for colorectal cancer. Kerr DJ, et al. **Br J Hosp Med** 1996 Mar 6–19;55(5):259–62 (17 ref.)

Melanoma: chemotherapy. Lee SM, et al. **Br Med Bull** 1995 Jul;51(3):609–30 (151 ref.)

Promising new therapies in the treatment of advanced ovarian cancer. Runowicz CD, et al. **Cancer** 1995 Nov 15; 76(10 Suppl):2028–33 (37 ref.)

Chemotherapy of head and neck cancer. LaFollette S, et al. **Cancer Chemother Biol Response Modif** 1996;16:462–73 (50 ref.)

Brain tumors. Obbens EA, et al. **Cancer Chemother Biol Response Modif** 1996;16:625–43 (39 ref.)

New anticancer agents. Weiss GR, et al. **Cancer Chemother Biol Response Modif** 1996;16:132–67 (205 ref.)

Promising new agents in the treatment of non–small cell lung cancer. Edelman, MJ, et al. **Cancer Chemother Pharmacol** 1996;37(5):385–93 (96 ref.)

Angiogenesis as a new target for cancer treatment. Ono M, et al. **Cancer Chemother Pharmacol** 1996;38 Suppl:S78–82 (38 ref.)

New promising anticancer agents in development: what comes next? Verweij J. **Cancer Chemother Pharmacol** 1996; 38 Suppl:S3–10 (69 ref.)

Genetic and cellular changes in colorectal cancer: proposed targets of chemopreventive agents. Greenwald P, et al. **Cancer Epidemiol Biomarkers Prev** 1995 Oct–Nov; 4(7):691–702 (175 ref.)

Assessing new anti–tumour agents and strategies in oncogene transgenic mice. Thomas H, et al. **Cancer Metastasis Rev** 1995 Jun;14(2):91–5 (18 ref.)

High–dose chemotherapy with peripheral blood progenitor autografting. Crown JP, et al. **Cancer Treat Res** 1995; 78:209–26 (115 ref.)

The reversal of multidrug resistance. Fisher GA, et al. **Cancer Treat Res** 1995;78:45–70 (138 ref.)

Potential for protein kinase C inhibitors in cancer therapy. Philip PA, et al. **Cancer Treat Res** 1995;78:3–27 (156 ref.)

High–dose chemotherapy and autologous stem cell transplantation for breast cancer. Weaver CH, et al. **Cancer Treat Res** 1995;76:59–85 (104 ref.)

Somatostatin receptors: clinical implications for endocrinology and oncology. Lamberts SW, et al. **Ciba Found Symp** 1995;190:222–36; discussion 236–9 (48 ref.)

The search for optimal chemotherapy for advanced epithelial ovarian cancer. Harrington KJ, et al. **Clin Oncol (R Coll Radiol)** 1995;7(6):359–65 (63 ref.)

Management of cancer in the aged. Balducci L, et al. **Compr Ther** 1996 Feb;22(2):88–93 (28 ref.)

The treatment of hormone refractory prostate cancer. Panvichian R, et al. **Compr Ther** 1996 Feb;22(2):81–7 (27 ref.)

The present state of the art in chemotherapy for soft tissue sarcomas in adults: the EORTC point of view. Verweij J, et al. **Crit Rev Oncol Hematol** 1995 Oct;20(3):193–201 (58 ref.)

Treatment of malignant glioma in adults. Forsyth PA, et al. **Curr Opin Neurol** 1995 Dec;8(6):414–8 (56 ref.)

Chemotherapy for gynecologic malignancies. Vermorken JB, et al. **Curr Opin Oncol** 1995 Sep;7(5):457–65 (79 ref.)

Immunological and biochemical modulation in the treatment of advanced colorectal cancer: update and future directions. Hilgenfeld RU, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 3):217–40 (93 ref.)

Risks and benefits of retinoids in the chemoprevention of cancer. de Palo G, et al. **Drug Saf** 1995 Oct;13(4):245–56 (80 ref.)

Tretinoin. A review of its pharmacodynamic and pharmacokinetic properties and use in the management of acute promyelocytic leukaemia. Gillis JC, et al. **Drugs** 1995 Nov;50(5):897–923 (160 ref.)

Current drug treatment guidelines for epithelial ovarian cancer. Lorigan PC, et al. **Drugs** 1996 Apr;51(4):571–84 (65 ref.)

Potential of antineoplastons in diseases of old age. Burzynski SR. **Drugs Aging** 1995 Sep;7(3):157–67 (175 ref.)

The role of the immune system in anti–tumour responses. Potential for drug therapy. Dermime S, et al. **Drugs Aging** 1995 Oct;7(4):266–77 (152 ref.)

Estramustine phosphate sodium. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer. Perry CM, et al. **Drugs Aging** 1995 Jul;7(1):49–74 (124 ref.)

The impact of cytokines on high dose chemotherapy followed by transplantation of purified and ex vivo expanded peripheral blood stem cells: achieving a state of minimal residual disease for tumor immunotherapy with cytokine gene transfected cells [editorial] Mertelsmann R. **Eur Cytokine Netw** 1995 Mar–Apr;6(2):79–82 (12 ref.)

Radiolabelled mIBG in the treatment of neuroblastoma. Gaze MN, et al. **Eur J Cancer** 1996 Jan;32A(1):93–6 (33 ref.)

Cytotoxic agents with activity in breast cancer patients previously exposed to anthracyclines: current status and future prospects. Piccart MJ, et al. **Eur J Cancer** 1995;31A Suppl 7:S1–10 (117 ref.)

Colony–stimulating factors as an adjunct to chemotherapy in small cell lung cancer. Urban T, et al. **Eur Respir J** 1996 Mar;9(3):596–602 (66 ref.)

Clinical progress with a new antiandrogen, Casodex (bicalutamide). Blackledge GR. **Eur Urol** 1996;29 Suppl 2:96–104 (15 ref.)

The development of Casodex (bicalutamide): preclinical studies. Furr BJ. **Eur Urol** 1996;29 Suppl 2:83–95 (53 ref.)

Retinoid differentiation therapy in promyelocytic leukemia. Chomienne C, et al. **FASEB J** 1996 Jul;10(9):1025–30 (67 ref.)

A phase I study of intraperitoneal interferon–alpha 2b and intravenous cis–platinum plus cyclophosphamide chemotherapy in patients with untreated stage III epithelial ovarian cancer: a Gynecologic Oncology Group pilot study. Moore DH, et al. **Gynecol Oncol** 1995 Nov; 59(2):267–72 (25 ref.)

Results of single–agent and combination chemotherapy for advanced soft tissue sarcomas. Implications for decision making in the clinic. Demetri GD, et al. **Hematol Oncol Clin North Am** 1995 Aug;9(4):765–85 (123 ref.)

Adjuvant chemotherapy for soft tissue sarcomas. Mertens WC, et al. **Hematol Oncol Clin North Am** 1995 Aug; 9(4):801–15 (41 ref.)

Chemotherapy for mycosis fungoides and the Sézary syndrome. Rosen ST, et al. **Hematol Oncol Clin North Am** 1995 Oct;9(5):1109–16 (18 ref.)

New drugs for the treatment of sarcomas. van Oosterom AT, et al. **Hematol Oncol Clin North Am** 1995 Aug;9(4):909–25 (74 ref.)

Systemic adjuvant chemotherapy for soft tissue sarcomas. Zalupski MM, et al. **Hematol Oncol Clin North Am** 1995 Aug;9(4):787–800 (49 ref.)

The role of chemotherapy in the treatment of adenocarcinoma of the pancreas. Fennelly D, et al. **Hepatogastroenterology** 1996 Mar–Apr;43(8):356–62 (30 ref.)

Drug resistance, illustration of the complexity of translational research. Steiner Award lecture 1995. Pinedo HM. **Int J Cancer** 1996 Mar 1;65(5):561–6 (62 ref.)

Intravesical chemotherapy and immunotherapy: how do we assess their effectiveness and what are their limitations and uses? Lamm DL, et al. **Int J Urol** 1995 Jun;2 Suppl 2:23–35 (38 ref.)

Development of inhibitors of protein farnesylation as potential chemotherapeutic agents. Kohl NE, et al. **J Cell Biochem Suppl** 1995;22:145–50 (29 ref.)

Use of cytokines in the treatment of acute myelocytic leukemia: a critical review. Geller RB. **J Clin Oncol** 1996 Apr;14(4):1371–82 (65 ref.)

Chemotherapy in malignant pleural mesothelioma. A review. Ong ST, et al. **J Clin Oncol** 1996 Mar;14(3):1007–17 (79 ref.)

The role of chemotherapy for metastatic gastric cancer. O'Brien ME, et al. **J Infus Chemother** 1995 Summer; 5(3):112–6 (45 ref.)

Cancer chemoprevention. Hong WK, et al. **J Natl Cancer Inst Monogr** 1995;(17):49–53 (29 ref.)

Mechanisms of resistance of human tumours to anticancer drugs of the platinum family: a review. Ferguson PJ. **J Otolaryngol** 1995 Aug;24(4):242–52 (100 ref.)

Alpha–interferon in chronic myelogenous leukaemia [see comments] Kumar L, et al. **Lancet** 1995 Oct 14; 346(8981):984–6 (12 ref.) Comment in: Lancet 1996 Jan 6;347(8993):57–8.

High–dose chemotherapy in adult acute myeloid leukemia: rationale and results. Stasi R, et al. **Leuk Res** 1996 Jul; 20(7):535–49 (70 ref.)

Does it matter how remission is achieved in acute leukemia? Bishop JF. **Leukemia** 1996 Apr;10 Suppl 1:S7–9 (6 ref.)

New chemotherapeutic agents in acute myeloid leukemia. Kantarjian HM, et al. **Leukemia** 1996 Apr;10 Suppl 1:S4–6 (0 ref.)

Treatment of acute myeloid leukemia with antecedent myelodysplastic syndrome. Larson RA. **Leukemia** 1996 Apr;10 Suppl 1:S23–5 (7 ref.)

The role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia. List AF. **Leukemia** 1996 Apr;10 Suppl 1:S36–8 (0 ref.)

Differentiating therapy with all–trans retinoic acid in acute myeloid leukemia. Tallman MS. **Leukemia** 1996 Apr;10 Suppl 1:S12–5 (28 ref.)

Differentiating therapy in acute myeloid leukemia. Tallman MS. **Leukemia** 1996 Aug;10(8):1262–8 (62 ref.)

Pharmacokinetic and pharmacodynamic optimization of intraperitoneal chemotherapy. Balthasar JP, et al. **Life Sci** 1996;58(7):535–43 (71 ref.)

Camptothecin analogues in the treatment of non–small cell lung cancer. Ardizzoni A. **Lung Cancer** 1995 Apr;12 Suppl 1:S177–85 (19 ref.)

Scheduling of chemotherapy and radiotherapy in locally advanced non–small cell lung cancer. Bishop JF. **Lung Cancer** 1995 Jun;12 Suppl 2:S53–61 (52 ref.)

Biological response modifiers. Calabresi F, et al. **Lung Cancer** 1995 Apr;12 Suppl 1:S193–8 (28 ref.)

New chemotherapy agents in the treatment of advanced non–small cell lung cancer: an update including data from the Seventh World Conference on Lung Cancer. Comis RL, et al. **Lung Cancer** 1995 Jun;12 Suppl 2:S63–99 (163 ref.)

New drugs for treating small cell lung cancer. Ettinger DS. **Lung Cancer** 1995 Jun;12 Suppl 3:S53–61 (20 ref.)

New drugs in non–small cell lung cancer. An overview. Giaccone G. **Lung Cancer** 1995 Apr;12 Suppl 1:S155–62 (35 ref.)

Edatrexate studies in non–small cell lung cancer. Gralla RJ. **Lung Cancer** 1995 Apr;12 Suppl 1:S187–91 (21 ref.)

MR mammography with pharmacokinetic mapping for monitoring of breast cancer treatment during neoadjuvant therapy. Knopp MV, et al. **Magn Reson Imaging Clin N Am** 1994 Nov;2(4):633–58 (42 ref.)

Successful cancer therapy with promethazine: the rationale. Jones GR. **Med Hypotheses** 1996 Jan;46(1):25–9 (28 ref.)

Alpha interferon as an immunomodulator in the treatment of patients with tumors. Alvarez–Mon M, et al. **Med Oncol** 1995 Mar;12(1):15–21 (45 ref.)

Interferons and other cytokines in head and neck cancer. Hamasaki VK, et al. **Med Oncol** 1995 Mar;12(1):23–33 (64 ref.)

Interferon and chronic myelogenous leukaemia. Lauta VM. **Med Oncol** 1995 Mar;12(1):41–6 (27 ref.)

Interferon and multiple myeloma. Lauta VM. **Med Oncol** 1995 Mar;12(1):63–9 (31 ref.)

Alpha interferon: new associations in haematology/oncology. The Montpellier experience. Rossi JF. **Med Oncol** 1995 Mar;12(1):59–61 (23 ref.)

Antitumor activity of vanadium compounds. Djordjevic C. **Met Ions Biol Syst** 1995;31:595–616 (89 ref.)

The role of cladribine in the treatment of lymphoid malignancies. Nelson MC, et al. **Oncol Nurs Forum** 1995 Oct;22(9):1395–400 (22 ref.)

Update on the diagnosis of and therapy for acute promyelocytic leukemia and chronic myelogenous leukemia. Wujcik D. **Oncol Nurs Forum** 1996 Apr;

23(3):478–87 (70 ref.)
New anticancer agents in clinical development. Eckardt J, et al. **Oncology (Huntingt)** 1995 Dec;9(12):1321–8; 1331; discussion 1332–4 (147 ref.)
New anticancer agents in clinical development. Eckardt J, et al. **Oncology (Huntingt)** 1995 Nov;9(11):1191–9 (0 ref.)
Paclitaxel: a unique tubulin interacting anticancer agent. Vyas DM, et al. **Prog Med Chem** 1995;32:289–337 (301 ref.)
Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Denmeade SR, et al. **Prostate** 1996 Apr;28(4):251–65 (94 ref.)
The use of radioimmunotherapy in combination with bioreductive agents. Langmuir VK.
Recent Results Cancer Res 1996;141:137–43 (40 ref.)
The role of anthracyclines in adjuvant chemotherapy of breast cancer: a critical appraisal. Mouridsen HT.
Recent Results Cancer Res 1996;140:191–9 (33 ref.)
Fighting cancer by attacking its blood supply. Folkman J. **Sci Am** 1996 Sep;275(3):150–4 (0 ref.)
Therapy of neuroendocrine tumors with radiolabeled MIBG and somatostatin analogues. Wiseman GA, et al.
Semin Nucl Med 1995 Jul;25(3):272–8 (39 ref.)
High-dose chemotherapy with autologous hematopoietic progenitor cell support for metastatic and high-risk primary breast cancer. Bearman SI, et al. **Semin Oncol** 1996 Feb;23(1 Suppl 2):60–7 (62 ref.)
Colorectal cancer: hepatic-directed therapy—the role of surgery, regional chemotherapy, and novel modalities. Busch E, et al. **Semin Oncol** 1995 Oct;22(5):494–508 (110 ref.)
Adjuvant therapy of gastric cancer: the Japanese experience. Fukushima M. **Semin Oncol** 1996 Jun;23(3):369–78 (52 ref.)
The role of primary chemotherapy in early breast cancer. Harris L, et al. **Semin Oncol** 1996 Feb;23(1 Suppl 2):31–42 (46 ref.)
Adjuvant and neoadjuvant therapy for gastric cancer. Kelsen DP. **Semin Oncol** 1996 Jun;23(3):379–89 (48 ref.)
Adjuvant therapy for cutaneous melanoma. Nathan FE, et al. **Semin Oncol** 1995 Dec;22(6):647–61 (85 ref.)
Adjuvant systemic therapy of prostate cancer. Raghavan D. **Semin Oncol** 1995 Dec;22(6):633–40 (72 ref.)
Chemotherapy for advanced breast cancer: a current perspective. Seidman AD. **Semin Oncol** 1996 Feb;23(1 Suppl 2):55–9 (44 ref.)
Neoadjuvant and adjuvant chemotherapy for invasive bladder cancer. Smith MR, et al. **Semin Oncol** 1995 Dec; 22(6):625–32 (28 ref.)
The potential role of amifostine in conjunction with cisplatin in the treatment of locally advanced carcinoma of the cervix. Wadler S, et al. **Semin Oncol** 1996 Aug;23(4 Suppl 8):64–8 (33 ref.)
Prodrugs in cancer chemotherapy. Connors TA, et al.
Stem Cells (Dayt) 1995 Sep;13(5):501–11 (76 ref.)
Adjuvant chemotherapy in the node-negative breast cancer patient. Styblo TM, et al. **Surg Clin North Am** 1996 Apr; 76(2):327–41 (26 ref.)
Clinical development of new fluoropyrimidines: a major improvement in colorectal cancer treatment? Colleoni M, et al. **Tumori** 1995 Sep–Oct;81(5):303–7 (44 ref.)
Radiation and concurrent carboplatin administration in locally advanced head and neck cancer. A Hellenic Cooperative Oncology Group Study. Fountzilas G, et al. **Tumori** 1995 Sep–Oct;81(5):354–8 (19 ref.)
Long-lasting complete remission of pulmonary metastases consequent to renal cell carcinoma obtained with interferon-beta therapy: review of the literature and a case report. Scoponi C, et al. **Tumori** 1995 May–Jun;81(3):201–3 (24 ref.)
Chemotherapy for invasive bladder cancer. Malkowicz SB, et al. **Urology** 1996 Apr;47(4):602–14 (105 ref.)
Cytostatic treatment in veterinary medicine. Rutteman GR, et al. **Vet Q** 1995 Apr;17 Suppl 1:S25–7 (4 ref.)
[Indications for antineoplastic effects of nonsteroidal anti-inflammatory drugs] Kooy A, et al.
Ned Tijdschr Geneeskd 1995 Nov 4;139(44):2235–9 (49 ref.) **(Dut)**
[Chemotherapy in brain tumors] van den Bent MJ, et al.
Ned Tijdschr Geneeskd 1996 Mar 30;140(13):702–6 (42 ref.) **(Dut)**
[Current therapeutic methods in onco-hematology] Madelaine-Chambrin I, et al. **Ann Pharm Fr** 1996; 54(2):73–6 (15 ref.) (Eng. Abstr.) **(Fre)**
[A new concept: treatment using differentiation of the malignant cell in man] Degos L. **Bull Acad Natl Med** 1995 Nov;179(8):1689–700 (39 ref.) (Eng. Abstr.) **(Fre)**
[Topoisomerase I inhibitors. Review of phase II trials with irinotecan (CPT-11) and topotecan] Bonneterre J.
Bull Cancer (Paris) 1995 Aug;82(8):623–8 (52 ref.) (Eng. Abstr.) **(Fre)**
[Chemotherapy of metastatic endometrial carcinoma. Review of the literature] Pierga JY, et al. **Bull Cancer (Paris)** 1995 Dec;82(12):1005–18 (110 ref.) (Eng. Abstr.) **(Fre)**
[Prevention of second primary cancer with vitamin supplementation in patients treated for head and neck cancers] Bairati I, et al. **Bull Cancer Radiother** 1996; 83(1):12–6 (37 ref.) (Eng. Abstr.) **(Fre)**
[Resistance to chemotherapy: current therapeutic approach] Ries F, et al. **Bull Soc Sci Med Grand Duche Luxemb** 1995; 132(3):19–26 (60 ref.) **(Fre)**
[Resistance to chemotherapy in cancers of the kidney and therapeutic perspectives] Oudard S, et al. **J Urol (Paris)** 1995;101(3):122–4 (25 ref.) (Eng. Abstr.) **(Fre)**
[Chemotherapy of metastatic soft tissue sarcoma] Le Cesne A. **Presse Med** 1995 Sep 16;24(26):1214–20 (53 ref.) (Eng. Abstr.) **(Fre)**
[[Therapeutic perspectives in multiple sclerosis (editorial)] Lubetzki C, et al. **Presse Med** 1996 Jun 15;25(21):964–6 (10 ref.) (Eng. Abstr.) **(Fre)**
[Treatment of metastatic carcinoid tumors with interferon-alpha. Five cases] Votte A, et al.
Presse Med 1996 Jan 20;25(2):63–7 (30 ref.) (Eng. Abstr.) **(Fre)**
[Use of interferon alpha in multiple myeloma] Harousseau JL, et al. **Rev Med Interne** 1996;17(6):488–95 (53 ref.) (Eng. Abstr.) **(Fre)**
[Evaluation of tumor response during chemotherapy of bronchial cancer] Pujol JL, et al. **Rev Med Interne** 1995; 16(10):759–66 (36 ref.) (Eng. Abstr.) **(Fre)**
[New drugs in therapy of breast carcinoma] Grunewald R. **Geburtshilfe Frauenheilkd** 1996 Jun;56(6):M75–81 (65 ref.) **(Ger)**
[Anti-angiogenesis: a new concept in therapy of solid malignancies?] Schweigerer L. **Med Klin** 1995 Dec 15; 90(12):709–12 (52 ref.) **(Ger)**
[Tumor diagnosis, therapy and drug targeting with magnetic fluids] Günther D. **Pharm Unserer Zeit** 1996 May; 25(3):130–4 (10 ref.) **(Ger)**
[Chemotherapy of gastrointestinal carcinomas and non-small-cell pulmonary carcinoma: a controversy] Fey MF, et al. **Schweiz Med Wochenschr** 1996 May 18; 126(20):872–8 (26 ref.) (Eng. Abstr.) **(Ger)**
[Use of taxol in the management of malignant tumors] Eckhardt S. **Orv Hetil** 1995 Sep 10;136(37):1987–93 (85 ref.) (Eng. Abstr.) **(Hun)**
[Platinum-based antineoplastic agents: biomedical applications and therapeutic aspects] Dominici C, et al.
Ann Ist Super Sanita 1995;31(2):289–94 (52 ref.) (Eng. Abstr.) **(Ita)**
[Interferons in the therapy of solid tumors] Tomao S, et al.
Clin Ter 1995 Aug–Sep;146(8–9):491–502 (96 ref.) (Eng. Abstr.) **(Ita)**
[What is the role of neoadjuvant therapy in prostate cancer?] Witjes WP, et al. **Minerva Urol Nefrol** 1995 Dec; 47(4):209–14 (53 ref.) **(Ita)**
[Recent advance in chemotherapy for advanced colorectal cancer] Aiba K. **Gan To Kagaku Ryoho** 1996 Apr; 23(5):535–48 (83 ref.) (Eng. Abstr.) **(Jpn)**
[Current status and problems in clinical trial for new anticancer drug in Japan] Fukuoka M.
Gan To Kagaku Ryoho 1996 Jan;23(2):141–5 (5 ref.) (Eng. Abstr.) **(Jpn)**
[Photodynamic therapy of centrally located early-stage lung cancer] Furuse K. **Gan To Kagaku Ryoho** 1996 Jan; 23(1):27–30 (17 ref.) (Eng. Abstr.) **(Jpn)**
[The potential of interleukin-12 for use in cancer therapy] Gately MK, et al. **Gan To Kagaku Ryoho** 1996 Jul; 23(8):961–71 (74 ref.) (Eng. Abstr.) **(Jpn)**
[Novel targets for cancer chemotherapy] Inoue S.
Gan To Kagaku Ryoho 1996 Jan;23(2):191–201 (31 ref.) (Eng. Abstr.) **(Jpn)**
[Photodynamic therapy for multiple primary lung cancer] Konaka C, et al. **Gan To Kagaku Ryoho** 1996 Jan;23(1):31–5 (8 ref.) (Eng. Abstr.) **(Jpn)**
[Impact of rapid advancement of international standardization on technical requirements for new drug registration] Kurokawa T. **Gan To Kagaku Ryoho** 1996 Apr; 23(5):509–16 (3 ref.) (Eng. Abstr.) **(Jpn)**
[Photodynamic therapy for gastric cancer] Mimura S, et al.
Gan To Kagaku Ryoho 1996 Jan;23(1):41–6 (5 ref.) (Eng. Abstr.) **(Jpn)**
[Nedaplatin] Ota K. **Gan To Kagaku Ryoho** 1996 Feb; 23(3):379–87 (13 ref.) (Eng. Abstr.) **(Jpn)**
[Contribution of Japan to develop new anticancer agents] Sajjo N. **Gan To Kagaku Ryoho** 1996 Jan;23(2):242–6 (0 ref.) (Eng. Abstr.) **(Jpn)**
[Photodynamic therapy for esophageal cancer] Shimao H, et al. **Gan To Kagaku Ryoho** 1996 Jan;23(1):36–40 (13 ref.) (Eng. Abstr.) **(Jpn)**
[Survival and changes of clinical laboratory data in phase II study with 5'-DFUR] Taguchi T.
Gan To Kagaku Ryoho 1996 Jul;23(8):1019–29 (31 ref.) (Eng. Abstr.) **(Jpn)**
[Mechanism of photodynamic therapy] Takemura T, et al.
Gan To Kagaku Ryoho 1996 Jan;23(1):16–21 (6 ref.) (Eng. Abstr.) **(Jpn)**
[Development of new anti-cancer agents in Europe] Terada K. **Gan To Kagaku Ryoho** 1996 Jan;23(2):231–7 (9 ref.) (Eng. Abstr.) **(Jpn)**
[Immunotherapy of patients with head and neck carcinomas] Tsukuda M. **Gan To Kagaku Ryoho** 1996 Feb;23(3):283–90 (32 ref.) (Eng. Abstr.) **(Jpn)**
[Preventive use of retinoids for occurrence of liver neoplasm] Muto Y. **Nippon Naika Gakkai Zasshi** 1995 Dec 10; 84(12):2032–7 (5 ref.) **(Jpn)**
[Drug therapy of hematologic malignancy] Shimoyama M. **Nippon Naika Gakkai Zasshi** 1996 Mar 10;85(3):337–41 (15 ref.) **(Jpn)**
[Mechanism of action of antileukemic agents in leukemia chemotherapy] Nakamura T. **Rinsho Ketsueki** 1996 May; 37(5):380–91 (29 ref.) **(Jpn)**
[Colon cancer and vitamin D—in vivo growth inhibition of colon cancer by a fluorinated analogue of 1,25-(OH)2D3, DD-003] Tanaka N, et al. **Seikagaku** 1996 Mar;68(3):214–9 (19 ref.) **(Jpn)**
[Fludarabine in the treatment of chronic lymphocytic leukemia and other lymphoproliferative disorders] Pawelski S. **Acta Haematol Pol** 1995;26(3):263–8 (32 ref.) (Eng. Abstr.) **(Pol)**
[Clinical pharmacology of all-trans retinoic acid (ATRA)] Robak T. **Acta Haematol Pol** 1995;26(3):269–77 (34 ref.) (Eng. Abstr.) **(Pol)**
[Role of chemotherapy in treatment of osteosarcoma] Perek D, et al. **Pediatr Pol** 1995 Nov;70(11):939–47 (39 ref.) (Eng. Abstr.) **(Pol)**
[Principles of procedure for patients treated with cytostatics] Kuliczkowski K. **Pol Arch Med Wewn** 1995 May; 93(5):377–83 (29 ref.) **(Pol)**
[New approaches to antitumor therapy: the use of preparations acting on processes regulated by epidermal and/or alpha-transforming growth factors] Kushlinskii NE, et al. **Eksp Klin Farmakol** 1996 Jan–Feb;59(1):74–80 (64 ref.) **(Rus)**
[The experimental chemotherapy of malignant tumors today] Syrkin AB, et al. **Vopr Onkol** 1995;41(2):41–5 (23 ref.) **(Rus)**

TOXICITY

Strategies to prevent nephrotoxicity of anticancer drugs. Skinner R. **Curr Opin Oncol** 1995 Jul;7(4):310–5 (38 ref.)
New chemotherapy agents in the treatment of advanced non-small cell lung cancer: an update including data from the Seventh World Conference on Lung Cancer. Comis RL, et al. **Lung Cancer** 1995 Jun;12 Suppl 2:S63–99 (163 ref.)
Current status of structure-activity relationships of platinum anticancer drugs: activation of the trans geometry. Farrell N. **Met Ions Biol Syst** 1996;32:603–39 (104 ref.)
Mutagenicity of anticancer drugs that inhibit topoisomerase enzymes. Ferguson LR, et al. **Mutat Res** 1996 Aug 17; 355(1–2):91–101 (81 ref.)
Cytogenetic damage measured in human sperm following cancer chemotherapy. Robbins WA. **Mutat Res** 1996 Aug 17;355(1–2):235–52 (109 ref.)
The mutagenic properties of DNA minor-groove binding ligands. Turner PR, et al. **Mutat Res** 1996 Aug 17; 355(1–2):141–69 (116 ref.)
Mutagenicity of anticancer drugs in mammalian germ cells. Witt KL, et al. **Mutat Res** 1996 Aug 17;355(1–2):209–34 (207 ref.)

ANTINEOPLASTIC AGENTS, ALKYLATING

ADMINISTRATION & DOSAGE

The role of ifosfamide and systemic therapy in the management of carcinoma of the cervix. Thigpen T, et al. **Semin Oncol** 1996 Jun;23(3 Suppl 6):56–64 (52 ref.)

ADVERSE EFFECTS

Variability in DNA repair and individual susceptibility to genotoxins. Kyrtopoulos SA. **Clin Chem** 1995 Dec;41(12 Pt 2):1848–53 (51 ref.)
Philadelphia chromosome-negative cells with trisomy 8 after busulfan and interferon treatment of Ph1-positive chronic myelogenous leukemia. Izumi T, et al. **Int J Hematol** 1996 Jul;64(1):73–7 (17 ref.)
Ifosfamide nephrotoxicity in children: histopathological features in two cases. Morland BJ, et al.
Med Pediatr Oncol 1996 Jul;27(1):57–61 (17 ref.)
Oral administration of mesna with ifosfamide. Goren MP. **Semin Oncol** 1996 Jun;23(3 Suppl 6):91–6 (51 ref.)
Intravesical thiotepa-induced eosinophilic cystitis. Choe JM, et al. **Urology** 1995 Nov;46(5):729–31 (15 ref.)
[Transitional cell carcinoma of the ureter and cyclophosphamide: apropos of a case] Ponsot Y, et al.
Prog Urol 1995 Sep;5(4):578–9 (8 ref.) (Eng. Abstr.) **(Fre)**

CHEMISTRY

Trenimon: structure and reactivity of a versatile chemical agent. Rademacher P, et al. **Mutat Res** 1995 Nov; 340(1):37–49 (76 ref.)

PHARMACOLOGY

DNA adducts from chemotherapeutic agents. Lawley PD, et al. **Mutat Res** 1996 Aug 17;355(1–2):13–40 (174 ref.)

THERAPEUTIC USE

Alkylating agents. Berger NA.
Cancer Chemother Biol Response Modif 1996;16:28–38 (68 ref.)
Estramustine revisited. Kreis W. **Cancer Treat Res** 1995; 78:163–84 (90 ref.)
Topical treatment of early cutaneous T-cell lymphoma. Ramsay DL, et al. **Hematol Oncol Clin North Am** 1995 Oct;9(5):1031–56 (84 ref.)
Ifosfamide in the treatment of lymphoma. Coiffier B.
Semin Oncol 1996 Jun;23(3 Suppl 7):2–7 (46 ref.)
Ifosfamide in the treatment of soft tissue sarcomas. Connelly EF, et al. **Semin Oncol** 1996 Jun;23(3 Suppl 6):16–21 (21 ref.)
High-dose ifosfamide in the treatment of sarcomas of soft tissues and bone. Demetri GD. **Semin Oncol** 1996 Jun;23(3

Suppl 6):22–6 (19 ref.)
Ifosfamide in the treatment of small cell lung cancer. Ettinger DS. **Semin Oncol** 1996 Jun;23(3 Suppl 6):2–6 (20 ref.)
Ifosfamide in non-small cell lung cancer. Johnson DH. **Semin Oncol** 1996 Jun;23(3 Suppl 6):7–10 (27 ref.)
Ifosfamide in the treatment of ovarian cancer. Markman M. **Semin Oncol** 1996 Jun;23(3 Suppl 6):47–9 (22 ref.)
Ifosfamide in the treatment of germ cell tumors. Nichols CR. **Semin Oncol** 1996 Jun;23(3 Suppl 6):65–73 (55 ref.)
Ifosfamide in the treatment of breast cancer. Overmoyer BA. **Semin Oncol** 1996 Jun;23(3 Suppl 6):38–41 (24 ref.)
Ifosfamide in the treatment of non-Hodgkin's lymphoma. Pohlman B. **Semin Oncol** 1996 Jun;23(3 Suppl 6):27–32 (24 ref.)
Ongoing clinical studies of ifosfamide for pediatric cancer in the United States. Pratt CB. **Semin Oncol** 1996 Jun;23(3 Suppl 6):84–90 (51 ref.)
Ifosfamide in the treatment of bladder cancer. Roth BJ. **Semin Oncol** 1996 Jun;23(3 Suppl 6):50–5 (48 ref.)
Dose-intensive ifosfamide for the treatment of non-Hodgkin's lymphoma. Vose JM. **Semin Oncol** 1996 Jun;23(3 Suppl 6):33–7 (20 ref.)
[Treatment of multiple myeloma—melphalan monotherapy after bone marrow transplantation] Hájek R, et al. **Vnitr Lek** 1996 Apr;42(4):278–84 (0 ref.) (Eng. Abstr.) **(Cze)**

TOXICITY

Alkylation of DNA and its aftermath. Lawley PD. **Bioessays** 1995 Jun;17(6):561–8 (54 ref.)

ANTINEOPLASTIC AGENTS, COMBINED

ADMINISTRATION & DOSAGE

High dose versus standard dose chemotherapy for the treatment of breast cancer. A review of current concepts. Fields KK, et al. **Ann N Y Acad Sci** 1995 Dec 29; 770:288–304 (27 ref.)
Haematological support of high-dose sequential chemotherapy: clinical evidence for reduction of toxicity and high response rates in poor risk lymphomas. Tarella C, et al. **Ann Oncol** 1995;6 Suppl 4:3–8 (30 ref.)
Sequential treatment of recurrent mesenteric desmoid tumor. Bauernhofer T, et al. **Cancer** 1996 Mar 15;77(6):1061–5 (44 ref.)
Prolonged continuous infusion cisplatin and 5-fluorouracil with radiation for locally advanced carcinoma of the vulva. Eifel PJ, et al. **Gynecol Oncol** 1995 Oct;59(1):51–6 (22 ref.)
Effectiveness and toxicity of preoperative therapy in stage IIIA non-small cell lung cancer including the Memorial Sloan-Kettering experience with induction MVP in patients with bulky mediastinal lymph node metastases (Clinical N2). Kris MG, et al. **Lung Cancer** 1995 Apr;12 Suppl 1:S47–57 (38 ref.)
Neoadjuvant chemotherapy of locally advanced non-small cell lung cancer. Pujol JL, et al. **Lung Cancer** 1995 Apr; 12 Suppl 1:S107–18 (46 ref.)
Role of chemotherapy dose intensification in the treatment of advanced ovarian cancer. Fennelly D, et al. **Oncology (Huntingt)** 1995 Oct;9(10):911–21; discussion 922, 924, 926 (59 ref.)
Chemotherapy of intermediate-grade non-Hodgkin's lymphoma: is "more" or "less" better? Gaynor ER, et al. **Oncology (Huntingt)** 1995 Dec;9(12):1273–9; discussion 1283–4 (18 ref.)
New approaches to adjuvant chemotherapy for breast cancer. Hudis C. **Pharmacotherapy** 1996 May–Jun;16(3 Pt 2):88S–93S (16 ref.)
Non-invasive loco-regional therapy for hepatocellular carcinoma. Tanikawa K. **Semin Surg Oncol** 1996 May–Jun; 12(3):189–92 (15 ref.)
[High dose chemotherapy in treatment of breast carcinoma: current status and limits of this method of therapy] Derigs HG, et al. **Geburtshilfe Frauenheilkd** 1996 Apr;56(4):190–7 (40 ref.) (Eng. Abstr.) **(Ger)**
[The use of high-dose chemotherapy in the treatment of breast cancer (comment)] Espinosa E, et al. **Med Clin (Barc)** 1996 Jun 8;107(2):56–8 (21 ref.) Comment on: Med Clin (Barc) 1995 May 13;104(18):702–8. **(Spa)**
[Leukemia and pregnancy. Review apropos of a clinical case] Perucca E, et al. **Rev Chil Obstet Ginecol** 1995; 60(2):118–23; discussion 123–4 (13 ref.) (Eng. Abstr.) **(Spa)**
[The intraperitoneal chemotherapy of patients with ovarian cancer] Shparyk IaV, et al. **Vrach Delo** 1995 Jan–Feb; (1–2):29–35 (48 ref.) **(Ukr)**

ADVERSE EFFECTS

Therapy-related acute promyelocytic leukemia with t(15;17)(q22;q12) following chemotherapy with drugs targeting DNA topoisomerase II. A report of two cases and a review of the literature [see comments] Hoffmann L, et al. **Ann Oncol** 1995 Oct;6(8):781–8 (32 ref.) Comment in: Ann Oncol 1995 Oct;6(8):751–3.
Source of stem cells impacts on hematopoietic recovery after high-dose chemotherapy. Zimmerman TM, et al. **Bone Marrow Transplant** 1995 Jun;15(6):923–7 (29 ref.)
Hemolytic uremic syndrome after high dose chemotherapy with autologous stem cell support. van der Lelie H, et al. **Cancer** 1995 Dec 1;76(11):2338–42 (21 ref.)
Should hematopoietic growth factors routinely be given concurrently with cytotoxic chemotherapy? Croockewit AJ, et al. **Clin Pharmacol Ther** 1996 Jan;59(1):1–6 (31 ref.)
Hepar lobatum carcinomatosum due to chemotherapy of a metastatic breast carcinoma. Uhlmann F, et al. **Gen Diagn Pathol** 1996 Mar;141(3–4):279–84 (21 ref.)
Atypical MRI findings in treatment-related leukoencephalopathy: case report. Ohmoto Y, et al. **Neuroradiology** 1996 Feb;38(2):128–33 (30 ref.)
Optimal control of cyclophosphamide-induced emesis. Stewart A. **Oncology** 1996 Jun;53 Suppl 1:32–8 (38 ref.)
[Efficacy of ondansetron in acute and delayed cisplatin-induced nausea and vomiting] Depierre A. **Bull Cancer (Paris)** 1996 Feb;83(2):147–53 (29 ref.) (Eng. Abstr.) **(Fre)**
[Optimal control by ondansetron of acute and prolonged emesis induced by chemotherapy without cisplatin] Harousseau JL. **Bull Cancer (Paris)** 1996 Jan;83(1):71–76 (27 ref.) (Eng. Abstr.) **(Fre)**
[Sclerosing peritonitis. A series of 10 cases and review of the literature] Carbonnel F, et al. **Gastroenterol Clin Biol** 1995 Nov;19(11):876–82 (33 ref.) (Eng. Abstr.) **(Fre)**
[A case of secondary leukemia in anaplastic seminoma patient treated with long-term chemotherapy] Kamai T, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 May;87(5):875–9 (12 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Metastatic colorectal cancer: advances in biochemical modulation and new drug development. Meropol NJ, et al. **Semin Oncol** 1995 Oct;22(5):509–24 (153 ref.)

PHARMACOLOGY

The role of interferon-alpha as a modulator of fluorouracil and leucovorin. Grem JL, et al. **Eur J Cancer** 1995 Jul–Aug;31A(7–8):1316–20 (29 ref.)

THERAPEUTIC USE

Chemotherapy of advanced breast cancer. Szántó J. **Acta Med Hung** 1994;50(3–4):185–93 (28 ref.)
New aspects in the treatment of bone sarcomas. Szendröi M. **Acta Med Hung** 1994;50(3–4):237–44 (14 ref.)
Hematopoietic growth factors and treatment of testicular cancer: biological interactions, routine use and dose-intensive chemotherapy. Bokemeyer C, et al. **Ann Hematol** 1996 Jan;72(1):1–9 (62 ref.)
Potential strategies for improving the results of high-dose chemotherapy in patients with metastatic breast cancer. Crown J, et al. **Ann Oncol** 1995;6 Suppl 4:21–6 (61 ref.)
The role of induction therapy and surgery for stage IIIA lung cancer. Ginsberg RJ. **Ann Oncol** 1995;6 Suppl 3:S29–32 (32 ref.)
Rationale for high-dose chemotherapy and application of haematopoietic growth factors in acute myeloid leukaemia. Hiddemann W, et al. **Ann Oncol** 1995;6 Suppl 4:27–31 (33 ref.)
High-dose chemotherapy for breast cancer: clinical advantages of autologous peripheral blood progenitor cells (PBPC) compared with autologous bone marrow transplantation (ABMT). Martin M. **Ann Oncol** 1995;6 Suppl 4:33–7 (18 ref.)
First-line systemic therapy for metastatic breast cancer and management of pleural effusion. Perrone F, et al. **Ann Oncol** 1995 Dec;6(10):1033–43 (93 ref.)
Combination chemotherapy for disseminated malignant melanoma. Abbott KL, et al. **Anticancer Drugs** 1995 Aug; 6(4):489–97 (74 ref.)
Current chemotherapy of advanced non-small cell lung cancer. Abratt RP. **Anticancer Drugs** 1995 Dec;6 Suppl 6:15–8 (29 ref.)
Symptomatic benefit from gemcitabine and other chemotherapy in advanced non-small cell lung cancer: changes in performance status and tumour-related symptoms. Thatcher N, et al. **Anticancer Drugs** 1995 Dec; 6 Suppl 6:39–48 (68 ref.)
New drugs for the management of lung cancer. Giaccone G. **Br J Hosp Med** 1996 May 15–Jun 4;55(10):634–8 (45 ref.)
High-dose chemotherapy with stem cell rescue for solid tumours. Protheroe AS, et al. **Br J Hosp Med** 1996 Apr 3–16;55(7):437–41 (29 ref.)
Chemotherapy for desmoid tumours in association with familial adenomatous polyposis: a report of three cases. Hamilton L, et al. **Can J Surg** 1996 Jun;39(3):247–52 (21 ref.)
Gestational trophoblastic disease. Berkowitz RS, et al. **Cancer** 1995 Nov 15;76(10 Suppl):2079–85 (81 ref.)
Promising new agents in the treatment of non-small cell lung cancer. Edelman, MJ, et al. **Cancer Chemother Pharmacol** 1996;37(5):385–93 (96 ref.)
The case for adjuvant radiation therapy in advanced Hodgkin's disease. Prosnitz LR, et al. **Cancer Invest** 1996; 14(4):361–70 (77 ref.)
Systemic therapy of skin carcinoma. Kempf RA. **Cancer Treat Res** 1995;78:137–62 (122 ref.)
Recent clinical advances with camptothecin analogues. Slichenmyer WJ, et al. **Cancer Treat Res** 1995;78:29–43 (103 ref.)
Chemotherapy in locally advanced head and neck cancer: a critical reappraisal. Jassem J, et al. **Cancer Treat Rev** 1995 Sep;21(5):447–62 (106 ref.)
The search for optimal chemotherapy for advanced epithelial ovarian cancer. Harrington KJ, et al. **Clin Oncol (R Coll Radiol)** 1995;7(6):359–65 (63 ref.)
The treatment of hormone refractory prostate cancer. Panvichian R, et al. **Compr Ther** 1996 Feb;22(2):81–7 (27 ref.)
The present state of the art in chemotherapy for soft tissue sarcomas in adults: the EORTC point of view. Verweij J, et al. **Crit Rev Oncol Hematol** 1995 Oct;20(3):193–201 (58 ref.)
Chemotherapy for gynecologic malignancies. Vermorken JB, et al. **Curr Opin Oncol** 1995 Sep;7(5):457–65 (79 ref.)
Current drug treatment guidelines for epithelial ovarian cancer. Lorigan PC, et al. **Drugs** 1996 Apr;51(4):571–84 (65 ref.)
The impact of cytokines on high dose chemotherapy followed by transplantation of purified and ex vivo expanded peripheral blood stem cells: achieving a state of minimal residual disease for tumor immunotherapy with cytokine gene transfected cells [editorial] Mertelsmann R. **Eur Cytokine Netw** 1995 Mar–Apr;6(2):79–82 (12 ref.)
Current and future trends in the multidisciplinary approach for high-risk breast cancer. The experience of the Milan Cancer Institute. Bonadonna G. **Eur J Cancer** 1996 Feb; 32A(2):209–14 (31 ref.)
Neoadjuvant treatment in oesophageal cancer: the needs for future trials. The Rotterdam Esophageal Tumor Study Group. Kok TC, et al. **Eur J Surg Oncol** 1996 Aug; 22(4):323–5 (30 ref.)
Supportive care is not the only option in prostate cancer patients resistant to hormone therapy: the argument against. Jewett MA, et al. **Eur Urol** 1996;29 Suppl 2:45–8 (11 ref.)
Supportive care is not the only option in prostate cancer patients resistant to hormone therapy: the argument for. Scher HI. **Eur Urol** 1996;29 Suppl 2:40–4 (36 ref.)
Chemotherapy treatment of chyloperitoneum and peritoneal carcinomatosis due to cervical cancer—review of literature. Keung YK, et al. **Gynecol Oncol** 1996 Jun;61(3):448–50 (11 ref.)
Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas. Implications for decision making in the clinic. Demetri GD, et al. **Hematol Oncol Clin North Am** 1995 Aug;9(4):765–85 (123 ref.)
Chemotherapy in osteosarcoma. Basis for application and antagonism to implementation; early controversies surrounding its implementation. Jaffe N, et al. **Hematol Oncol Clin North Am** 1995 Aug;9(4):825–40 (79 ref.)
Tumor size and prognosis in aggressively treated osteosarcoma. Bieling P, et al. **J Clin Oncol** 1996 Mar; 14(3):848–58 (38 ref.)
Perspectives on investigational chemotherapy and biologic therapy for childhood brain tumors. Kadota RP. **J Pediatr Hematol Oncol** 1996 Feb;18(1):13–22 (110 ref.)
Desmoplastic small cell tumor: a report of three cases and a review of the literature. Kretschmar CS, et al. **J Pediatr Hematol Oncol** 1996 Aug;18(3):293–8 (29 ref.)
Chemotherapeutic treatment of malignant chordoma in children. Scimeca PG, et al. **J Pediatr Hematol Oncol** 1996 May;18(2):237–40 (10 ref.)
Intensive therapy and autologous stem cell transplantation for Hodgkin's disease in first relapse after combination chemotherapy. Reece DE, et al. **Leuk Lymphoma** 1996 Apr; 21(3–4):245–53 (55 ref.)
High-dose chemotherapy in adult acute myeloid leukemia: rationale and results. Stasi R, et al. **Leuk Res** 1996 Jul; 20(7):535–49 (70 ref.)
New chemotherapeutic agents in acute myeloid leukemia. Kantarjian HM, et al. **Leukemia** 1996 Apr;10 Suppl 1:S4–6 (0 ref.)
The role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia. List AF. **Leukemia** 1996 Apr;10 Suppl 1:S36–8 (0 ref.)
Hodgkin's disease: from basic science to clinical application. Tesch H, et al. **Leukemia** 1996 Jun;10 Suppl 2:s74–7 (21 ref.)
Carboplatin/etoposide combination chemotherapy in the treatment of poor prognosis patients with small cell lung cancer. Carney DN. **Lung Cancer** 1995 Jun;12 Suppl 3:S77–83 (10 ref.)
Trials with mitomycin, ifosfamide and cisplatin in non-small cell lung cancer. Cullen MH. **Lung Cancer** 1995 Apr;12 Suppl 1:S95–106 (12 ref.)
New drugs for treating small cell lung cancer. Ettinger DS. **Lung Cancer** 1995 Jun;12 Suppl 3:S53–61 (20 ref.)
Adjuvant chemotherapy: results and perspectives. Evans WK. **Lung Cancer** 1995 Apr;12 Suppl 1:S35–45 (27 ref.)
Impact of chemotherapy on survival in locally advanced non-small cell lung cancer: the Gustave-Roussy experience. Le Cesne A, et al. **Lung Cancer** 1995 Apr;12 Suppl 1:S79–85 (25 ref.)
Oral therapy for small cell lung cancer. Postmus PE, et al. **Lung Cancer** 1995 Jun;12 Suppl 3:S63–70 (29 ref.)
Combined platinum etoposide with radiation therapy in limited stage small cell lung cancer: an effective treatment strategy. Turrisi AT 3rd. **Lung Cancer** 1995 Jun;12 Suppl 3:S41–51 (26 ref.)
Pancreatic blastomatous tumor in a child responding to therapy used for hepatoblastoma: case report and review

of the literature. Morgan ER, et al. **Med Pediatr Oncol** 1996 Apr;26(4):284–92 (29 ref.)
Sarcomas: the role of adjuvant chemotherapy and a proposed new staging system. Baker LH, et al. **Monogr Pathol** 1996; 38:240–51 (49 ref.)
Adjuvant therapy of colon cancer: towards a new consensus [editorial] Blijham GH. **Neth J Med** 1996 Jul;49(1):1–3 (19 ref.)
Neoadjuvant chemotherapy for locally advanced cervical cancer—where does it stand?: a review. Edelmann DZ, et al. **Obstet Gynecol Surv** 1996 May;51(5):305–13 (63 ref.)
Adjuvant systemic therapy for breast cancer. Issues for primary care physicians. Berkowitz LD, et al. **Postgrad Med** 1995 Oct;98(4):85–8, 91, 94 (2 ref.)
Adjuvant treatment of breast cancer. Akerley WL 3rd. **R I Med** 1995 Sep;78(9):250–3 (12 ref.)
Future developments in adjuvant systemic therapy for high-risk breast cancer. Bonadonna G. **Recent Results Cancer Res** 1996;140:227–34 (16 ref.)
Adjuvant systemic therapy: the issues of timing and sequence. Castiglione-Gertsch M, et al. **Recent Results Cancer Res** 1996;140:201–13 (22 ref.)
The primary use of chemotherapy for operable breast cancer: does systemic therapy make surgery superfluous? Rudenstam CM. **Recent Results Cancer Res** 1996; 140:177–88 (21 ref.)
Carboplatin versus cisplatin in ovarian cancer. Alberts DS. **Semin Oncol** 1995 Oct;22(5 Suppl 12):88–90 (6 ref.)
Role of chemotherapy for advanced colorectal cancer: new opportunities. Bleiberg H. **Semin Oncol** 1996 Feb;23(1 Suppl 3):42–50 (71 ref.)
Ifosfamide in the treatment of lymphoma. Coiffier B. **Semin Oncol** 1996 Jun;23(3 Suppl 7):2–7 (46 ref.)
Paclitaxel and doxorubicin, a highly active combination in the treatment of metastatic breast cancer. Dombernowsky P, et al. **Semin Oncol** 1996 Feb;23(1 Suppl 1):13–8 (17 ref.)
Treatment of metastatic breast cancer with paclitaxel and doxorubicin. Dombernowsky P, et al. **Semin Oncol** 1995 Dec;22(6 Suppl 15):13–7 (14 ref.)
Perioperative therapy of non-small cell lung cancer: a review of adjuvant and neoadjuvant approaches. Friedland DM, et al. **Semin Oncol** 1995 Dec;22(6):571–81 (41 ref.)
Adjuvant and neoadjuvant treatment for primary brain tumors in adults. Grossman SA, et al. **Semin Oncol** 1995 Dec;22(6):530–9 (75 ref.)
Adjuvant systemic therapy for breast cancer. Harris DT. **Semin Oncol** 1995 Dec;22(6):553–70 (123 ref.)
Adjuvant and neoadjuvant treatment of head and neck cancers: the next chapter. Jacobs C, et al. **Semin Oncol** 1995 Dec;22(6):540–52 (66 ref.)
The role of ifosfamide in small cell lung cancer. Loehrer PJ Sr. **Semin Oncol** 1996 Jun;23(3 Suppl 7):40–4 (29 ref.)
Metastatic colorectal cancer: advances in biochemical modulation and new drug development. Meropol NJ, et al. **Semin Oncol** 1995 Oct;22(5):509–24 (153 ref.)
Adjuvant chemotherapy for patients with stage II nonseminomatous testis cancer. Motzer RJ. **Semin Oncol** 1995 Dec;22(6):641–6 (33 ref.)
Combination regimens of paclitaxel and the platinum drugs as first-line regimens for ovarian cancer. Ozols RF. **Semin Oncol** 1995 Dec;22(6 Suppl 15):1–6 (17 ref.)
The role of paclitaxel in the therapy of bladder cancer. Roth BJ. **Semin Oncol** 1995 Oct;22(5 Suppl 12):33–40 (73 ref.)
The role of ifosfamide in the treatment of testicular and urothelial malignancies. Roth BJ. **Semin Oncol** 1996 Jun; 23(3 Suppl 7):19–27 (83 ref.)
Memorial Sloan-Kettering Cancer Center experience with paclitaxel in the treatment of breast cancer. Seidman AD, et al. **Semin Oncol** 1995 Oct;22(5 Suppl 12):108–16 (53 ref.)
Adjuvant therapy of colon cancer. Shulman K, et al. **Semin Oncol** 1995 Dec;22(6):600–10 (108 ref.)
The platinum compounds and paclitaxel in the management of carcinomas of the endometrium and uterine cervix. Thigpen T, et al. **Semin Oncol** 1995 Oct;22(5 Suppl 12):67–75 (25 ref.)
The role of ifosfamide and systemic therapy in the management of carcinoma of the cervix. Thigpen T, et al. **Semin Oncol** 1996 Jun;23(3 Suppl 6):56–64 (52 ref.)
Paclitaxel couplets with cyclophosphamide or cisplatin in metastatic breast cancer. Tolcher AW. **Semin Oncol** 1996 Feb;23(1 Suppl 1):37–43 (22 ref.)
The treatment of advanced gastric cancer. Wils J. **Semin Oncol** 1996 Jun;23(3):397–406 (73 ref.)
The role of chemotherapy in the management of the patient with T3b bladder cancer. Millikan R, et al. **Semin Urol Oncol** 1996 May;14(2):81–5 (23 ref.)
Neoadjuvant chemotherapy in stage IIIa non-small cell lung cancer. Milroy R, et al. **Thorax** 1995 Sep;50 Suppl 1:S25–30 (54 ref.)
Resection of stage III non-small cell lung cancer following induction therapy. Rusch VW. **World J Surg** 1995 Nov-Dec;19(6):817–22 (35 ref.)
[Role of chemotherapy in non-small cell lung carcinoma] Giaccone G, et al. **Ned Tijdschr Geneeskd** 1996 May 25; 140(21):1111–4 (21 ref.) **(Dut)**
[Therapeutic choices in cancer of the rectum] **Ann Chir** 1995; 49(5):373–81 (0 ref.) **(Fre)**
[Concomitant preoperative radiochemotherapy for rectal cancers] Bosset JF, et al. **Ann Chir** 1996;50(4):302–10; discussion 311 (53 ref.) (Eng. Abstr.) **(Fre)**
[Current treatment of cancers of the anal canal] Gérard JP, et al. **Ann Chir** 1995;49(5):363–8; discussion 368–72 (39 ref.) (Eng. Abstr.) **(Fre)**
[Concomitant radiochemotherapy with cisplatin (CDDP), 5-fluorouracil (5-FU) and mitomycin C (MMC) in locally advanced carcinoma of the oropharynx. Results of a phase II trial] Berger C, et al. **Bull Cancer (Paris)** 1995 Dec; 82(12):1044–51 (38 ref.) (Eng. Abstr.) **(Fre)**
[Hodgkin disease: should high-risk patients be selected and chemotherapy be intensified?] Carde P. **Bull Cancer (Paris)** 1995 Aug;82(8):637–49 (58 ref.) (Eng. Abstr.) **(Fre)**
[Carboplatin and etoposide combination for the treatment of recurrent epithelial ovarian cancer] Chauvergne J, et al. **Bull Cancer (Paris)** 1996 Apr;83(4):315–23 (52 ref.) (Eng. Abstr.) **(Fre)**
[Maintenance of the dose-intensity of chemotherapy combining carboplatin, cyclophosphamide, etoposide in women with ovarian cancer aged 70 and over] Delva R, et al. **Bull Cancer (Paris)** 1996 Jan;83(1):63–69 (36 ref.) (Eng. Abstr.) **(Fre)**
[Standards, options and recommendations for a successful practice in chemotherapy. National Federation of Centers for the Fight against Cancer] Heron JF, et al. **Bull Cancer (Paris)** 1995 Oct;82(10):823–34 (44 ref.) **(Fre)**
[Is there a place for chemotherapy in the initial treatment of cervical cancer? Review of the literature] Lhommé C, et al. **Bull Cancer (Paris)** 1996 Apr;83(4):276–92 (67 ref.) (Eng. Abstr.) **(Fre)**
[Cancers of the esophagus. Combined modality therapy by radiotherapy, chemotherapy with or without surgery] Calais G, et al. **Bull Cancer Radiother** 1995;82(2):137–46 (67 ref.) **(Fre)**
[Comparison of concomitant radiotherapy and chemotherapy with radiotherapy alone in advanced cancers of the head and neck: results of a randomized trial] Haddad E, et al. **Bull Cancer Radiother** 1996;83(2):97–103 (35 ref.) (Eng. Abstr.) **(Fre)**
[Cancers of the breast. First line chemotherapy for cancers of the breast] Mauriac L. **Bull Cancer Radiother** 1995; 82(2):158–67 (82 ref.) **(Fre)**
[Chemotherapy of osteogenic sarcomas] Brain E, et al. **Chirurgie** 1994–95;120(13):193–8 (70 ref.) **(Fre)**
[High-dose therapy and hematopoietic cell autotransplantation in the treatment of adult gynecologic tumors] Lotz JP, et al. **Contracept Fertil Sex** 1996 Apr; 24(4):307–18 (71 ref.) (Eng. Abstr.) **(Fre)**
[Chemotherapy for gynecologic tumors] Machover D. **Contracept Fertil Sex** 1996 Apr;24(4):264–7 (0 ref.) **(Fre)**
[Treatment of stage I non-seminomatous germ cell tumors of the testis] Droz JP. **Presse Med** 1995 Oct 28; 24(32):1501–3 (10 ref.) (Eng. Abstr.) **(Fre)**
[Chemotherapy of metastatic soft tissue sarcoma] Le Cesne A. **Presse Med** 1995 Sep 16;24(26):1214–20 (53 ref.) (Eng. Abstr.) **(Fre)**
[Therapeutic role of coagulation in small cell lung cancers] LeBeau B. **Rev Mal Respir** 1996;13(1):21–6 (41 ref.) (Eng. Abstr.) **(Fre)**
[Primary therapy of advanced ovarian carcinoma: current status and perspectives] Köchli OR, et al. **Gynakol Geburtshilfliche Rundsch** 1996;36(1):3–8 (25 ref.) (Eng. Abstr.) **(Ger)**
[Modern strategies in therapy of acute myeloid leukemia (AML) in adulthood. I. Primary treatment of de novo AML] Jehn U, et al. **Internist (Berl)** 1996 Jun;37(6):661–8 (17 ref.) **(Ger)**
[II. Leukemia in the elderly, secondary, recurrent and refractory leukemia, chloroma] Jehn U, et al. **Internist (Berl)** 1996 Jun;37(6):669–77 (18 ref.) **(Ger)**
[Clinical studies on combination of ifosfamide, carboplatin and etoposide (ICE) with whole body hyperthermia] Wiedemann GJ, et al. **Med Klin** 1996 May 15;91(5):279–83 (59 ref.) **(Ger)**
[Germ cell tumors in children and adolescents] Göbel U, et al. **Schweiz Rundsch Med Prax** 1995 Sep 26;84(39):1063–7 (9 ref.) (Eng. Abstr.) **(Ger)**
[Integrative concept on the treatment of highly malignant non-Hodgkin lymphomas] Havemann K, et al. **Schweiz Rundsch Med Prax** 1996 Mar 19;85(12):353–6 (26 ref.) (Eng. Abstr.) **(Ger)**
[Multiple myeloma] Peest D. **Ther Umsch** 1996 Feb; 53(2):147–51 (17 ref.) (Eng. Abstr.) **(Ger)**
[Paclitaxel (Taxol)—drug of choice in ovarian cancer] Fishman A. **Harefuah** 1996 Apr 15;130(8):557–60 (47 ref.) **(Heb)**
[Angiocentric T-cell lymphoma of the lung] Csanaky G, et al. **Orv Hetil** 1996 Mar 3;137(9):473–6 (28 ref.) (Eng. Abstr.) **(Hun)**
[Mega-dose chemotherapy with peripheral blood stem cell transplantation (PBS-CT) for small cell lung cancer (SCLC)] Chou T, et al. **Gan To Kagaku Ryoho** 1995 Oct; 22(12):1741–8 (14 ref.) (Eng. Abstr.) **(Jpn)**
[Myeloablative chemotherapy with autologous bone marrow and/or peripheral blood stem cell transplantation in children with high-risk solid tumor] Endo M, et al. **Gan To Kagaku Ryoho** 1995 Oct;22(12):1762–70 (32 ref.) (Eng. Abstr.) **(Jpn)**
[High-dose chemotherapy (HDCT) with peripheral blood stem cell transplantation (PBSCT) in ovarian cancer patients with poor prognosis] Hayakawa S, et al. **Gan To Kagaku Ryoho** 1995 Oct;22(12):1756–61 (13 ref.) (Eng. Abstr.) **(Jpn)**
[Treatment for hormone-refractory or relapsing prostatic cancer] Hirao Y, et al. **Gan To Kagaku Ryoho** 1996 Mar; 23(4):418–26 (17 ref.) (Eng. Abstr.) **(Jpn)**
[Head and neck cancer] Inuyama Y, et al. **Gan To Kagaku Ryoho** 1996 Aug;23(9):1136–42 (19 ref.) (Eng. Abstr.) **(Jpn)**
[Germ cell tumor] Kasai M, et al. **Gan To Kagaku Ryoho** 1995 Oct;22(12):1749–55 (19 ref.) (Eng. Abstr.) **(Jpn)**
[Salvage therapy for refractory testicular cancer] Kawai K, et al. **Gan To Kagaku Ryoho** 1996 Aug;23(9):1129–35 (35 ref.) (Eng. Abstr.) **(Jpn)**
[Chemotherapy of head and neck cancer] Kohno N, et al. **Gan To Kagaku Ryoho** 1996 Feb;23(3):277–82 (33 ref.) (Eng. Abstr.) **(Jpn)**
[Chemotherapy of small cell lung cancer] Komiya T, et al. **Gan To Kagaku Ryoho** 1996 Aug;23(9):1116–23 (36 ref.) (Eng. Abstr.) **(Jpn)**
[Combination phase I trials] Masuda N. **Gan To Kagaku Ryoho** 1996 Jan;23(2):219–25 (13 ref.) (Eng. Abstr.) **(Jpn)**
[High-dose chemotherapy with autologous bone marrow transplantation or peripheral blood stem cell transplantation—testicular cancer] Miyanaga N, et al. **Gan To Kagaku Ryoho** 1995 Oct;22(12):1771–6 (16 ref.) (Eng. Abstr.) **(Jpn)**
[Autologous hematopoietic stem cell transplantation for the treatment of breast cancer] Mukaiyama T, et al. **Gan To Kagaku Ryoho** 1995 Oct;22(12):1731–40 (16 ref.) (Eng. Abstr.) **(Jpn)**
[Chemotherapy for recurrent ovarian cancer] Nishimura H, et al. **Gan To Kagaku Ryoho** 1996 Aug;23(9):1124–8 (22 ref.) (Eng. Abstr.) **(Jpn)**
[Chemo-endocrine therapy including mitomycin C and medroxyprogesterone acetate in doxorubicin-refractory advanced breast cancer] Nomura Y, et al. **Gan To Kagaku Ryoho** 1996 Mar;23(4):439–45 (11 ref.) (Eng. Abstr.) **(Jpn)**
[Non-Hodgkin lymphoma] Ogawa M. **Gan To Kagaku Ryoho** 1996 Aug;23(9):1143–8 (25 ref.) (Eng. Abstr.) **(Jpn)**
[High dose chemotherapy followed by hematopoietic stem cell transplantation for malignant lymphoma] Tobinai K. **Gan To Kagaku Ryoho** 1995 Oct;22(12):1724–30 (23 ref.) (Eng. Abstr.) **(Jpn)**
[Adjuvant chemotherapy for advanced gastric cancer] Furukawa H, et al. **Nippon Geka Gakkai Zasshi** 1996 Apr; 97(4):312–6 (24 ref.) (Eng. Abstr.) **(Jpn)**
[Primary retroperitoneal pure choriocarcinoma] Okubo Y, et al. **Nippon Hinyokika Gakkai Zasshi** 1995 Dec; 86(12):1784–8 (14 ref.) (Eng. Abstr.) **(Jpn)**
[Chemotherapy of solid tumor] Ogawa M. **Nippon Naika Gakkai Zasshi** 1996 Mar 10;85(3):342–6 (28 ref.) **(Jpn)**
[Chemotherapy with combined treatment of malignant germ cell tumors in children] Zaleska-Czepko E. **Pediatr Pol** 1995 Nov;70(11):955–8 (33 ref.) (Eng. Abstr.) **(Pol)**
[Adjuvant chemotherapy of gastric cancer] Shparik IaV. **Klin Khir** 1995;(5):38–41 (36 ref.) **(Ukr)**
[Adjuvant therapy of breast cancer without regional metastases] Shparik IaV, et al. **Klin Khir** 1995;(5):42–6 (47 ref.) **(Ukr)**
[Adjuvant chemotherapy of colonic cancer] Shparyk IaV, et al. **Klin Khir** 1995;(6):38–41 (32 ref.) **(Ukr)**
[Regional adjuvant chemotherapy in colorectal cancer] Shparyk IaV, et al. **Klin Khir** 1995;(9–10):41–5 (38 ref.) **(Ukr)**

ANTINEOPLASTIC AGENTS, HORMONAL

The effect of tamoxifen on the endometrium. Barakat RR. **Oncology (Huntingt)** 1995 Feb;9(2):129–34; discussion 139–40, 142 (27 ref.)

ADMINISTRATION & DOSAGE

[Recent multicenter study protocols in the USA for patients with metastatic prostatic carcinoma] DeAntoni E, et al. **Urologe A** 1995 Sep;34(5):382–8 (14 ref.) (Eng. Abstr.) **(Ger)**
[Renaissance of estrogen therapy in advanced prostate carcinoma?] Smith PH, et al. **Urologe A** 1995 Sep; 34(5):393–7 (17 ref.) (Eng. Abstr.) **(Ger)**
[Intramuscular depot estrogens (Estradurin) in treatment of patients with prostate carcinoma. Historical aspects, mechanism of action, results and current clinical status] Stege R, et al. **Urologe A** 1995 Sep;34(5):398–403 (52 ref.) (Eng. Abstr.) **(Ger)**
[Advanced prostatic carcinoma—which hormone therapy when?] Studer UE. **Urologe A** 1995 Sep;34(5):361–6 (34 ref.) **(Ger)**

ADVERSE EFFECTS

The effects of tamoxifen treatment on the endometrium. Daniel Y, et al. **Fertil Steril** 1996 Jun;65(6):1083–9 (94 ref.)
Uterine neoplasms in patients treated with tamoxifen. Silva EG, et al. **J Cell Biochem Suppl** 1995;23:179–83 (22 ref.)
Tamoxifen-associated eye disease. A review. Nayfield SG, et al. **J Clin Oncol** 1996 Mar;14(3):1018–26 (58 ref.)
Tamoxifen and endometrial cancer: from experiment to patient. Assikis VJ, et al. **Recent Results Cancer Res** 1996; 140:61–71 (41 ref.)
[Expansive uterine myoma during tamoxifen therapy. 11

cases] Le Bouëdec G, et al. **Presse Med** 1995 Nov 25; 24(36):1694–6 (18 ref.) (Eng. Abstr.) **(Fre)**

[Gynecologic monitoring of tamoxifen treatment of breast cancer] Le Bouedec G, et al. **Rev Fr Gynecol Obstet** 1995 Jul–Sep;90(7–9):379–82 (30 ref.) **(Fre)**

[Theoretical considerations and initial clinical results of intermittent hormone treatment of patients with advanced prostatic carcinoma] Bruchovsky N, et al. **Urologe A** 1995 Sep;34(5):389–92 (8 ref.) (Eng. Abstr.) **(Ger)**

PHARMACOLOGY

Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in benign gynaecological disorders. Perry CM, et al. **Drugs** 1996 Feb; 51(2):319–46 (113 ref.)

Role of growth factors, steroid and peptide hormones in the regulation of human prostatic tumor growth. Motta M, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1–6 Spec No):107–11 (36 ref.)

Gynaecologic effects of tamoxifen. Kuo DY, et al. **Med Oncol** 1995 Jun;12(2):87–94 (79 ref.)

THERAPEUTIC USE

Neoadjuvant hormonal deprivation in locally advanced prostate cancer: does it make sense? Schulman CC, et al. **Acta Urol Belg** 1996 May;64(2):57–61 (32 ref.)

Tamoxifen therapy—long-term results and complications. Moore MP, et al. **Adv Surg** 1996;29:263–9 (29 ref.)

Aromatase inhibitors: current status. Ibrahim NK, et al. **Am J Clin Oncol** 1995 Oct;18(5):407–17 (142 ref.)

Pure antiestrogens. The most important advance in the endocrine therapy of breast cancer since 1896. Nicholson RI, et al. **Ann N Y Acad Sci** 1996 Apr 30;784:325–35 (60 ref.)

Progress toward hormonal therapy of gastrointestinal cancer [see comments] Bold RJ, et al. **Ann Surg** 1996 Jan; 223(1):4–11 (36 ref.) Comment in: Ann Surg 1996 Jan;223(1):12–3.

Possible mechanisms in the emergence of tamoxifen-resistant breast cancer. Tonetti DA, et al. **Anticancer Drugs** 1995 Aug;6(4):498–507 (87 ref.)

Third annual William L. McGuire Memorial Lecture. "Studies on the estrogen receptor in breast cancer"—20 years as a target for the treatment and prevention of cancer. Jordan VC. **Breast Cancer Res Treat** 1995;36(3):267–85 (123 ref.)

Treatment approaches for metastatic cancer of the prostate based on recent molecular evidence. Middleman MN, et al. **Cancer Treat Rev** 1996 Mar;22(2):105–18 (61 ref.)

Mifepristone: antineoplastic studies. Sartor O, et al. **Clin Obstet Gynecol** 1996 Jun;39(2):498–505 (28 ref.)

Hormone resistance in cancer: the role of abnormal steroid receptors. Sluyser M. **Crit Rev Oncog** 1994;5(6):539–54 (122 ref.)

Recent advances in hormonal therapy for cancer. Traynor A. **Curr Opin Oncol** 1995 Nov;7(6):572–81 (75 ref.)

Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in benign gynaecological disorders. Perry CM, et al. **Drugs** 1996 Feb; 51(2):319–46 (113 ref.)

New endocrine therapies for breast cancer. Howell A, et al. **Eur J Cancer** 1996 Apr;32A(4):576–88 (106 ref.)

Prebiopsy neo-adjuvant endocrine therapy for breast cancer to prevent post-surgery trauma-induced growth factor and immune-suppression mediated tumour progression. Oliver RT, et al. **Eur J Cancer** 1996 Mar;32A(3):396–7 (20 ref.)

Combined androgen blockade. Crawford ED. **Eur Urol** 1996; 29 Suppl 2:54–61 (28 ref.)

Supportive care is not the only option in prostate cancer patients resistant to hormone therapy: the argument against. Jewett MA, et al. **Eur Urol** 1996;29 Suppl 2:45–8 (11 ref.)

The management of hormone refractory prostate cancer. Newling DW. **Eur Urol** 1996;29 Suppl 2:69–74 (24 ref.)

Supportive care is not the only option in prostate cancer patients resistant to hormone therapy: the argument for. Scher HI. **Eur Urol** 1996;29 Suppl 2:40–4 (36 ref.)

The role of induction androgen deprivation prior to radical prostatectomy. Soloway MS, et al. **Eur Urol** 1996;29 Suppl 2:114–8 (27 ref.)

The future of antihormone therapy: innovations based on an established principle. Parczyk K, et al. **J Cancer Res Clin Oncol** 1996;122(7):383–96 (82 ref.)

Endocrine treatment of cancer. Gulliford T, et al. **J R Soc Med** 1996 Aug;89(8):448–53 (37 ref.)

The control and biological importance of intratumoural aromatase in breast cancer. Dowsett M, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1–6 Spec No):145–50 (22 ref.)

Androgen receptor mediated growth control of breast cancer and endometrial cancer modulated by antiandrogen- and androgen-like steroids. Hackenberg R, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1–6 Spec No):113–7 (56 ref.)

Octreotide. Lamberts SW, et al. **N Engl J Med** 1996 Jan 25;334(4):246–54 (76 ref.)

Current status of endocrine therapy for metastatic breast cancer. Kimmick G, et al. **Oncology (Huntingt)** 1995 Sep; 9(9):877–86, 889–90; discussion 892–4 (129 ref.)

Advanced prostate cancer. Endocrine therapies and palliative measures. Taub M, et al. **Postgrad Med** 1996 Sep; 100(3):139–40, 143–6, 152 passim (16 ref.)

Commentary on maximal androgen blockade in prostate cancer: a theory to put into practice? Denis L. **Prostate** 1995 Nov;27(5):233–40 (43 ref.)

Adjuvant treatment of breast cancer. Akerley WL 3rd. **R I Med** 1995 Sep;78(9):250–3 (12 ref.)

Current and future roles of adjuvant endocrine therapy in the management of early carcinoma of the breast. Baum M, et al. **Recent Results Cancer Res** 1996;140:215–26 (30 ref.)

Optimal duration of neoadjuvant androgen withdrawal therapy before radical prostatectomy in clinically confined prostate cancer. Gleave ME, et al. **Semin Urol Oncol** 1996 May;14(2 Suppl 2):39–45; discussion 46–7 (26 ref.)

Risk factors for progression in patients with prostate cancer treated with radical prostatectomy. Lerner SE, et al. **Semin Urol Oncol** 1996 May;14(2 Suppl 2):12–20; discussion 21 (36 ref.)

Neoadjuvant total androgen suppression and radiotherapy in the management of locally advanced prostate cancer. Roach M 3rd. **Semin Urol Oncol** 1996 May;14(2 Suppl 2):32–7; discussion 38 (33 ref.)

Neoadjuvant hormonal treatment before radical prostatectomy. Watson RB, et al. **Semin Urol Oncol** 1996 May;14(2 Suppl 2):48–55; discussion 55–6 (59 ref.)

Hormonal treatment of advanced breast cancer. Tellez C, et al. **Surg Oncol Clin N Am** 1995 Oct;4(4):751–77 (199 ref.)

[Treatment of metastatic cancer of the prostate] Fournier G, et al. **Presse Med** 1995 Oct 28;24(32):1465–70 (10 ref.) (Eng. Abstr.) **(Fre)**

[Hormone replacement therapy in menopausal women previously treated for breast cancer (editorial)] This P. **Presse Med** 1996 Feb 3;25(4):141–4 (25 ref.) (Eng. Abstr.) **(Fre)**

[Hot flushes in men after surgical or pharmacologic castration] Aubert J, et al. **Prog Urol** 1995 Sep;5(4):507–9 (13 ref.) (Eng. Abstr.) **(Fre)**

[Metastasizing pancreatic vipoma. Its diagnosis and therapy with the somatostatin analog octreotide] Scheffold N, et al. **Dtsch Med Wochenschr** 1995 Oct 27;120(43):1463–7 (21 ref.) (Eng. Abstr.) **(Ger)**

[New strategies of drugs for treatment of hormone-related tumors] von Angerer E. **Pharm Unserer Zeit** 1996 Apr; 25(2):74–84 (42 ref.) **(Ger)**

[An overview of clinical trials in endocrine therapy for cancer] Hinotsu S, et al. **Gan To Kagaku Ryoho** 1996 May; 23(6):689–94 (9 ref.) (Eng. Abstr.) **(Jpn)**

[Progress of endocrine therapy for prostate cancer and results] Kanetake H. **Gan To Kagaku Ryoho** 1996 Mar; 23(4):413–7 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Strategy of drug development for hormone-dependent tumor] Kudoh M. **Gan To Kagaku Ryoho** 1996 May; 23(6):668–72 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Hormone therapy of endometrial carcinoma] Kuramoto H, et al. **Gan To Kagaku Ryoho** 1996 May;23(6):673–7 (19 ref.) (Eng. Abstr.) **(Jpn)**

[New development of endocrine therapy in prostate cancer] Naito S. **Gan To Kagaku Ryoho** 1996 May;23(6):684–8 (18 ref.) (Eng. Abstr.) **(Jpn)**

[New developments in hormonal therapy for breast cancer] Tominaga T. **Gan To Kagaku Ryoho** 1996 May;23(6):678–83 (1 ref.) (Eng. Abstr.) **(Jpn)**

[Recent problems on the endocrine and chemotherapy] Nishiya I, et al. **Hum Cell** 1995 Sep;8(3):107–14 (39 ref.) (Eng. Abstr.) **(Jpn)**

[Leukoregulin—a new possibility in the treatment of virus infections and malignant tumors] Bojić I. **Vojnosanit Pregl** 1994 Nov–Dec;51(6):540–2 (20 ref.) **(Scr)**

ANTINEOPLASTIC AGENTS, PHYTOGENIC

[Paclitaxel (Taxol)] Hájek R. **Cas Lek Cesk** 1996 Jun 12; 135(12):393–6 (20 ref.) (Eng. Abstr.) **(Cze)**

ADMINISTRATION & DOSAGE

Theoretical and practical aspects of paclitaxel scheduling [editorial; comment] Gianni L. **Ann Oncol** 1995 Nov; 6(9):861–3 (26 ref.) Comment on: Ann Oncol 1995 Nov;6(9):883–5.

Review of current clinical experience with prolonged (oral) etoposide in cancer treatment. de Jong RS, et al. **Anticancer Res** 1995 Sep–Oct;15(5B):2319–30 (120 ref.)

Treatment of metastatic breast cancer with paclitaxel and doxorubicin. Dombernowsky P, et al. **Semin Oncol** 1995 Dec;22(6 Suppl 15):13–7 (14 ref.)

Single-agent paclitaxel for the treatment of breast cancer: an overview. Hortobagyi GN, et al. **Semin Oncol** 1996 Feb; 23(1 Suppl 1):4–9 (17 ref.)

Combination regimens of paclitaxel and the platinum drugs as first-line regimens for ovarian cancer. Ozols RF. **Semin Oncol** 1995 Dec;22(6 Suppl 15):1–6 (17 ref.)

Role of paclitaxel in the treatment of breast cancer: the American Cooperative Group Experience. Sledge GW Jr. **Semin Oncol** 1996 Feb;23(1 Suppl 1):10–2 (9 ref.)

[Etoposide: specificity of prolonged oral administration] Munck JN. **Bull Cancer (Paris)** 1996 May;83(5):352–60 (66 ref.) (Eng. Abstr.) **(Fre)**

ADVERSE EFFECTS

Hypersensitivity reactions to etoposide. Hoetelmans RM, et al. **Ann Pharmacother** 1996 Apr;30(4):367–71 (25 ref.)

Therapy-related acute leukemia associated with t(11q23) after primary acute myeloid leukemia with t(8;21): a report of two cases [letter] Roulston D, et al. **Blood** 1995 Nov 1;86(9):3613–4 (7 ref.)

Case report: paclitaxel-induced myocardial ischemia. Soe MS, et al. **Md Med J** 1996 Jan;45(1):41–3 (4 ref.)

Transient encephalopathy after paclitaxel (Taxol) infusion. Perry JR, et al. **Neurology** 1996 Jun;46(6):1596–9 (15 ref.)

CHEMICAL SYNTHESIS

Strategies for the synthesis of some complex antitumor alkaloids. Pandit UK. **Farmaco** 1995 Nov;50(11):749–54 (32 ref.)

CHEMISTRY

Recent advances in Annonaceous acetogenins. Zeng L, et al. **Nat Prod Rep** 1996 Aug;13(4):275–306 (177 ref.)

METABOLISM

Targeting plant toxins to the urokinase and alpha 2-macroglobulin receptors. Cavallaro U, et al. **Semin Cancer Biol** 1995 Oct;6(5):269–78 (60 ref.)

PHARMACOLOGY

Effects of taxol on the polymerization and posttranslational modification of class III beta-tubulin in P19 embryonal carcinoma cells. Laferrière NB, et al. **Biochem Cell Biol** 1995 Sep–Oct;73(9–10):687–94 (36 ref.)

Homoharringtonine: an effective new natural product in cancer chemotherapy. Zhou DC, et al. **Bull Cancer (Paris)** 1995 Dec;82(12):987–95 (83 ref.)

Taxanes. Fojo A. **Cancer Chemother Biol Response Modif** 1996;16:57–67 (42 ref.)

Recent clinical advances with camptothecin analogues. Slichenmyer WJ, et al. **Cancer Treat Res** 1995;78:29–43 (103 ref.)

The comparative clinical pharmacology of vincristine and vindesine: does vindesine offer any advantage in clinical use? Joel S. **Cancer Treat Rev** 1996 Nov;21(6):513–25 (75 ref.)

Recent progress in the study of anticancer drugs originating from plants and traditional medicine in China. Han R. **Chin Med J (Engl)** 1995 Oct;108(10):729–31 (9 ref.)

Multidrug resistance proteins and other drug transport-related resistance to natural product agents. Broxterman HJ, et al. **Curr Opin Oncol** 1995 Nov; 7(6):532–40 (78 ref.)

Docetaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer. Fulton B, et al. **Drugs** 1996 Jun;51(6):1075–92 (86 ref.)

Early clinical studies with docetaxel. Docetaxel Investigators Group. Aapro M, et al. **Eur J Cancer** 1995;31A Suppl 4:S7–10 (13 ref.)

Preclinical pharmacology of docetaxel. Bissery MC. **Eur J Cancer** 1995;31A Suppl 4:S1–6 (42 ref.)

Pharmacology of oleanolic acid and ursolic acid. Liu J. **J Ethnopharmacol** 1995 Dec 1;49(2):57–68 (91 ref.)

The water-insoluble camptothecin analogues: promising drugs for the effective treatment of haematological malignancies. Pantazis P. **Leuk Res** 1995 Nov;19(11):775–88 (151 ref.)

Genetic toxicology of mitotic spindle inhibitors used as anticancer drugs. Kirsch-Volders M, et al. **Mutat Res** 1996 Aug 17;355(1–2):103–28 (220 ref.)

Molecular, cellular, and clinical aspects of the pharmacology of 20(S)camptothecin and its derivatives. Rivory LP, et al. **Pharmacol Ther** 1995;68(2):269–96 (170 ref.)

Preclinical evaluation of CPT-11 and its active metabolite SN-38. Lavelle F, et al. **Semin Oncol** 1996 Feb;23(1 Suppl 3):11–20 (44 ref.)

Eukaryotic DNA topoisomerase I: genome gatekeeper and its intruders, camptothecins. Pommier Y. **Semin Oncol** 1996 Feb;23(1 Suppl 3):3–10 (87 ref.)

[Pharmacology of Catharanthus alkaloids] Levêque D, et al. **Bull Cancer (Paris)** 1996 Mar;83(3):176–86 (90 ref.) (Eng. Abstr.) **(Fre)**

[Combined effect of Paclitaxel and ionizing radiation. Experimental data of in-vitro and in-vivo models] Rübe C, et al. **Strahlenther Onkol** 1996 May;172 Suppl 1:2–5 (30 ref.) **(Ger)**

THERAPEUTIC USE

Vinorelbine: a new antineoplastic drug for the treatment of non-small-cell lung cancer. Jones SF, et al. **Ann Pharmacother** 1996 May;30(5):501–6 (29 ref.)

The role of vindesine in oncology—recommendations after 10 years' experience. Dancey J, et al. **Anticancer Drugs** 1995 Oct;6(5):625–36 (122 ref.)

Docetaxel: meeting the challenge of non-small cell lung cancer management. Le Chevalier T. **Anticancer Drugs** 1995 Jul;6 Suppl 4:13–7 (23 ref.)

Docetaxel: a new defence in the management of breast cancer. Piccart M. **Anticancer Drugs** 1995 Jul;6 Suppl 4:7–11 (12 ref.)

Docetaxel delivers new management opportunities for

gastrointestinal carcinomas. Rougier P. **Anticancer Drugs** 1995 Jul;6 Suppl 4:25–9 (16 ref.)
Current perspectives on camptothecins in cancer treatment [editorial] Dancey J, et al. **Br J Cancer** 1996 Aug; 74(3):327–38 (146 ref.)
Phase II study of oral etoposide for patients with advanced breast cancer. Atienza DM, et al. **Cancer** 1995 Dec 15; 76(12):2485–90 (39 ref.)
Progress in preclinical and clinical studies for the development of new anticancer drugs in Japan, with emphasis on taxanes. Saijo N, et al. **Cancer Chemother Pharmacol** 1996;38 Suppl:S11–5 (21 ref.)
Taxoid compounds in breast cancer: current status and future prospects. Piccart MJ. **Cancer Treat Res** 1995;78:185–207 (56 ref.)
Vinorelbine: an overview. Johnson SA, et al. **Cancer Treat Rev** 1996 Mar;22(2):127–42 (88 ref.)
Docetaxel (Taxotere): single agent activity, development of combination treatment and reducing side-effects. Pronk LC, et al. **Cancer Treat Rev** 1995 Sep;21(5):463–78 (93 ref.)
Taking the path of combining traditional Chinese medicine with Western medicine in cancer research and control. Yu R. **Chin Med J (Engl)** 1995 Oct;108(10):732–3 (0 ref.)
Docetaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer. Fulton B, et al. **Drugs** 1996 Jun;51(6):1075–92 (86 ref.)
CPT–11 (irinotecan) in the treatment of colorectal cancer. Armand JP, et al. **Eur J Cancer** 1995 Jul–Aug; 31A(7–8):1283–7 (41 ref.)
Docetaxel. Cortes JE, et al. **J Clin Oncol** 1995 Oct; 13(10):2643–55 (104 ref.)
Paclitaxel in patients with platinum–resistant ovarian cancer: a selected review of literature and clinical experience. Kudelka AP, et al. **J Med Assoc Thai** 1996 Apr;79(4):240–5 (26 ref.)
New drugs for treating small cell lung cancer. Ettinger DS. **Lung Cancer** 1995 Jun;12 Suppl 3:S53–61 (20 ref.)
Paclitaxel (Taxol) and docetaxel (Taxotere): active chemotherapeutic agents in lung cancer. Francis PA, et al. **Lung Cancer** 1995 Apr;12 Suppl 1:S163–72 (40 ref.)
Current status of vinorelbine for breast cancer. Smith GA. **Oncology (Huntingt)** 1995 Aug;9(8):767–73; discussion 774, 776, 779 (41 ref.)
CPT–11: clinical experience in phase I studies. Armand JP. **Semin Oncol** 1996 Feb;23(1 Suppl 3):27–33 (22 ref.)
The role of taxanes in the treatment of breast cancer. Capri G, et al. **Semin Oncol** 1996 Feb;23(1 Suppl 2):68–75 (62 ref.)
Combined–modality therapy for advanced non–small cell lung cancer: paclitaxel and thoracic irradiation. Choy H, et al. **Semin Oncol** 1995 Dec;22(6 Suppl 15):38–44 (41 ref.)
Update: vinorelbine (navelbine) in non–small cell lung cancer. Crawford J. **Semin Oncol** 1996 Apr;23(2 Suppl 5):2–7 (24 ref.)
Taxoids: effective agents in anthracycline–resistant breast cancer. Ravdin PM. **Semin Oncol** 1995 Dec;22(6 Suppl 13):29–34 (34 ref.)
The role of paclitaxel in the therapy of bladder cancer. Roth BJ. **Semin Oncol** 1995 Oct;22(5 Suppl 12):33–40 (73 ref.)
CPT–11: an original spectrum of clinical activity. Rothenberg ML. **Semin Oncol** 1996 Feb;23(1 Suppl 3):21–6 (38 ref.)
CPT–11 in the treatment of colorectal cancer: clinical efficacy and safety profile. Rougier P, et al. **Semin Oncol** 1996 Feb;23(1 Suppl 3):34–41 (35 ref.)
Memorial Sloan–Kettering Cancer Center experience with paclitaxel in the treatment of breast cancer. Seidman AD, et al. **Semin Oncol** 1995 Oct;22(5 Suppl 12):108–16 (53 ref.)
The role of paclitaxel in the management of coelomic epithelial carcinoma of the ovary: a review with emphasis on the Gynecologic Oncology Group experience. Thigpen T, et al. **Semin Oncol** 1995 Dec;22(6 Suppl 14):23–31 (30 ref.)
The role of paclitaxel in the treatment of head and neck cancer. Vokes EE, et al. **Semin Oncol** 1995 Oct;22(5 Suppl 12):8–12 (27 ref.)
[Paclitaxel, a new anticancer drug] Jekunen A, et al. **Duodecim** 1994;110(13):1235–40 (39 ref.) **(Fin)**
[Paclitaxel (Taxol) and docetaxel (Taxotere): results of phase II trials in monochemotherapy] Fumoleau P, et al. **Bull Cancer (Paris)** 1995 Aug;82(8):629–36 (58 ref.) (Eng. Abstr.) **(Fre)**
[Paclitaxel (Taxol)—drug of choice in ovarian cancer] Fishman A. **Harefuah** 1996 Apr 15;130(8):557–60 (47 ref.) **(Heb)**
[Current status of phase I and phase II trials—experience in Habikino from 1988 to 1994] Masuda N, et al. **Gan To Kagaku Ryoho** 1996 Jan;23(2):166–71 (14 ref.) (Eng. Abstr.) **(Jpn)**

TOXICITY

Genetic toxicology of mitotic spindle inhibitors used as anticancer drugs. Kirsch–Volders M, et al. **Mutat Res** 1996 Aug 17;355(1–2):103–28 (220 ref.)

ANTINEOPLASTIC ANTIBIOTICS see ANTIBIOTICS, ANTINEOPLASTIC

ANTINEOPLASTIC ANTIMETABOLITES see ANTIMETABOLITES, ANTINEOPLASTIC

ANTINEOPLASTIC DRUG COMBINATIONS see ANTINEOPLASTIC AGENTS, COMBINED

ANTINEOPLASTIC DRUG RESISTANCE see DRUG RESISTANCE, NEOPLASM

ANTINEOPLASTICS, BOTANICAL see ANTINEOPLASTIC AGENTS, PHYTOGENIC

ANTINOCICEPTIVE AGENTS see ANALGESICS

ANTINUCLEAR ANTIBODIES see ANTIBODIES, ANTINUCLEAR

ANTINUCLEAR FACTORS see ANTIBODIES, ANTINUCLEAR

ANTIONCOGENES see GENES, SUPPRESSOR, TUMOR

ANTIOXIDANTS

see related
OXIDATIVE STRESS

The antioxidant vitamins and cardiovascular disease. A critical review of epidemiologic and clinical trial data [see comments] Jha P, et al. **Ann Intern Med** 1995 Dec 1; 123(11):860–72 (55 ref.) Comment in: Ann Intern Med 1995 Dec 1;123(11):887.
Micronutrients, antioxidants and risk of cancer. Schorah CJ. **Bibl Nutr Dieta** 1995;(52):92–107 (101 ref.)
Anti–oxidants and apoptosis. McGowan AJ, et al. **Biochem Soc Trans** 1996 Feb;24(1):229–33 (35 ref.)
Effect of vitamin E, vitamin C and beta–carotene on LDL oxidation and atherosclerosis. Jialal I, et al. **Can J Cardiol** 1995 Oct;11 Suppl G:97G–103G (97 ref.)
Antioxidants in the Mediterranean diet. Mancini M, et al. **Can J Cardiol** 1995 Oct;11 Suppl G:105G–109G (20 ref.)
Low–density lipoprotein oxidation, antioxidants, and atherosclerosis: a clinical biochemistry perspective. Jialal I, et al. **Clin Chem** 1996 Apr;42(4):498–506 (92 ref.)
Functional diversity of the pineal hormone melatonin: its role as an antioxidant. Reiter RJ. **Exp Clin Endocrinol Diabetes** 1996;104(1):10–6 (52 ref.)
Dietary antioxidants in disease prevention. Gordon M. **Nat Prod Rep** 1996 Aug;13(4):265–73 (130 ref.)
[Antioxidants in nutrition and their importance in the anti–/oxidative balance in the immune system] Biesalski HK, et al. **Immun Infekt** 1995 Oct;23(5):166–73 (72 ref.) (Eng. Abstr.) **(Ger)**
[New findings on reactive oxidative materials and their role in biological systems] Jovičić A, et al. **Vojnosanit Pregl** 1995 Nov–Dec;52(6):579–84 (24 ref.) **(Scr)**

ADMINISTRATION & DOSAGE

Considerations of the scientific substantiation for antioxidant vitamins and beta–carotene in disease prevention. Blumberg JB. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1521S–1526S (59 ref.)
Evidence from cancer intervention and biomarker studies and the development of biochemical markers. Bowen PE, et al. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1403S–1409S (54 ref.)
Antioxidants in oral cancer prevention. Garewal H. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1410S–1416S (54 ref.)
Antioxidant vitamin–cardiovascular disease hypothesis is still promising, but still unproven: the need for randomized trials. Hennekens CH, et al. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1377S–1380S (26 ref.)
Epidemiologic evidence of a role of carotenoids in cardiovascular disease prevention. Kohlmeier L, et al. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1370S–1376S (38 ref.)
Prevention of cervical intraepithelial neoplasia and cervical cancer. Meyskens FL Jr, et al. **Am J Clin Nutr** 1995 Dec; 62(6 Suppl):1417S–1419S (24 ref.)
Evidence for protection against age–related macular degeneration by carotenoids and antioxidant vitamins. Snodderly DM. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1448S–1461S (153 ref.)
Relations among aging, antioxidant status, and cataract. Taylor A, et al. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1439S–1447S (80 ref.)
Epidemiologic evidence for beta–carotene and cancer prevention. van Poppel G, et al. **Am J Clin Nutr** 1995 Dec; 62(6 Suppl):1393S–1402S (127 ref.)
Antioxidants and age–related eye disease. Current and future perspectives. Christen WG, et al. **Ann Epidemiol** 1996 Jan; 6(1):60–6 (79 ref.)
Fish oil and antioxidants after heart transplantation: future strategies or eye of newt and wing of bat revisited? Young JB. **J Heart Lung Transplant** 1995 Nov–Dec;14(6 Pt 2):S250–4 (29 ref.)
[Free oxygen radicals during transplantation surgery] Bolbjerg ML, et al. **Ugeskr Laeger** 1995 Oct 16; 157(42):5841–5 (40 ref.) (Eng. Abstr.) **(Dan)**
[Antioxidative vitamins and cataracts in the elderly] Heseker H. **Z Ernahrungswiss** 1995 Sep;34(3):167–76 (68 ref.) (Eng. Abstr.) **(Ger)**
[Can vitamin E prevent development of coronary heart disease?] Nguyen KN, et al. **Tidsskr Nor Laegeforen** 1996 Mar 30;116(9):1109–13 (61 ref.) (Eng. Abstr.) **(Nor)**

ADVERSE EFFECTS

Safety of antioxidant vitamins and beta–carotene. Diplock AT. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1510S–1516S (56 ref.)
Safety of antioxidant vitamins. Meyers DG, et al. **Arch Intern Med** 1996 May 13;156(9):925–35 (208 ref.)
[Safety of antioxidants] Mäntylä E, et al. **Duodecim** 1994; 110(17):1629–39 (59 ref.) **(Fin)**

ANALYSIS

Plasma concentrations of cytokines, their soluble receptors, and antioxidant vitamins can predict the development of multiple organ failure in patients at risk. Borrelli E, et al. **Crit Care Med** 1996 Mar;24(3):392–7 (38 ref.)

CHEMISTRY

How to characterize an antioxidant: an update. Halliwell B. **Biochem Soc Symp** 1995;61:73–101 (229 ref.)
Plant polyphenols: free radical scavengers or chain–breaking antioxidants? Rice–Evans C. **Biochem Soc Symp** 1995; 61:103–16 (53 ref.)
Antioxidants in food packaging: a risk factor? Scott G. **Biochem Soc Symp** 1995;61:225–46 (28 ref.)
Characterization of drugs as antioxidant prophylactics. Aruoma OI. **Free Radic Biol Med** 1996;20(5):675–705 (473 ref.)

ISOLATION & PURIFICATION

Antioxidant agents in raw materials and processed foods. Eriksson CE, et al. **Biochem Soc Symp** 1995;61:221–34 (106 ref.)

METABOLISM

Why tetrahydrobiopterin? Mayer B, et al. **Adv Pharmacol** 1995;34:251–61 (50 ref.)
Exercise and oxidative stress: role of the cellular antioxidant systems. Ji LL. **Exerc Sport Sci Rev** 1995;23:135–66 (140 ref.)
Antioxidant and redox regulation of gene transcription. Sen CK, et al. **FASEB J** 1996 May;10(7):709–20 (94 ref.)
Functional pleiotropy of the neurohormone melatonin: antioxidant protection and neuroendocrine regulation. Reiter RJ. **Front Neuroendocrinol** 1995 Oct;16(4):383–415 (133 ref.)
Update on the biological characteristics of the antioxidant micronutrients: vitamin C, vitamin E, and the carotenoids. Rock CL, et al. **J Am Diet Assoc** 1996 Jul;96(7):693–702; quiz 703–4 (128 ref.)
Oxidative stress and aging: still a hypothesis [editorial; comment] Kritchevsky SB, et al. **J Am Geriatr Soc** 1996 Jul;44(7):873–5 (25 ref.) Comment on: J Am Geriatr Soc 1996 Jul;44(7):823–7.
Oxidants and antioxidants in exercise. Sen CK. **J Appl Physiol** 1995 Sep;79(3):675–86 (100 ref.)
Reduced, oxidized and protein–bound forms of homocysteine and other aminothiols in plasma comprise the redox thiol status—a possible element of the extracellular antioxidant defense system. Ueland PM, et al. **J Nutr** 1996 Apr;126(4 Suppl):1281S–4S (28 ref.)
Determinants of antioxidant status in humans. Papas AM. **Lipids** 1996 Mar;31 Suppl:S77–82 (66 ref.)
Hypothesis: spermine may be an important epidermal antioxidant. Løvaas E. **Med Hypotheses** 1995 Jul; 45(1):59–67 (125 ref.)
Ebselen. Sies H. **Methods Enzymol** 1995;252:341–2 (18 ref.)
The role of the neurohormone melatonin as a buffer against macromolecular oxidative damage. Reiter RJ. **Neurochem Int** 1995 Dec;27(6):453–60 (54 ref.)
[Role of vitamin E and C, carotenoids, ubiquinone and selenium in the antioxidative defense system] Alho H, et al. **Duodecim** 1994;110(17):1621–8 (49 ref.) **(Fin)**
[Role of free radicals and antioxidants in the cell defense system] Antila E. **Duodecim** 1994;110(17):1611–9 (27 ref.) **(Fin)**
[Oxidants and antioxidants. Biological effects and therapeutic perspectives] Urban T, et al. **Ann Chir** 1995;49(5):427–34 (55 ref.) (Eng. Abstr.) **(Fre)**
[Lipoproteins, antioxidants, and coronary cardiopathy] Guimarães AC. **Arq Bras Cardiol** 1995 Sep;65(3):289–95 (31 ref.) **(Por)**
[Vitamins with antioxidant action and rheumatic diseases (a review)] Lobareva LS, et al. **Vopr Pitan** 1995;(4):24–9 (71 ref.) (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

Antioxidant properties of 5–aminosalicylic acid: potential mechanism for its protective effect in ulcerative colitis. Miles AM, et al. **Adv Exp Med Biol** 1995;371B:1317–21 (20 ref.)
Antioxidants and immune response in aged persons: overview of present evidence. Meydani SN, et al. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1462S–1476S (146 ref.)
Vitamins E and C, beta–carotene, and other carotenoids as antioxidants. Sies H, et al. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1315S–1321S (87 ref.)
Coantioxidants make alpha–tocopherol an efficient antioxidant for low–density lipoprotein. Thomas SR, et al. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1357S–1364S (66

ref.)
Vitamin E: beyond antioxidant function. Traber MG, et al. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1501S–1509S (91 ref.)
Aging and disease: extending functional life span. Harman D. **Ann N Y Acad Sci** 1996 Jun 15;786:321–36 (87 ref.)
Atherogenic and anti-atherogenic factors in the human diet. Addis PB, et al. **Biochem Soc Symp** 1995;61:259–71 (64 ref.)
Plant carotenoids and related molecules: important dietary antioxidants. Krinsky NI. **Biochem Soc Symp** 1995; 61:117–26 (47 ref.)
Tamoxifen as an antioxidant and cardioprotectant. Wiseman H. **Biochem Soc Symp** 1995;61:209–19 (65 ref.)
Lipid peroxidation and antioxidants as biomarkers of tissue damage. Gutteridge JM. **Clin Chem** 1995 Dec;41(12 Pt 2):1819–28 (56 ref.)
Free radicals, oxidative stress, oxidized low density lipoprotein (LDL), and the heart: antioxidants and other strategies to limit cardiovascular damage. Sinatra ST, et al. **Conn Med** 1995 Oct;59(10):579–88 (94 ref.)
The use of antioxidants in healing. Martin A. **Dermatol Surg** 1996 Feb;22(2):156–60 (30 ref.)
How 'safe' are antioxidant vitamins? Garewal HS, et al. **Drug Saf** 1995 Jul;13(1):8–14 (57 ref.)
Free radicals and exercise: effects of nutritional antioxidant supplementation. Kanter M. **Exerc Sport Sci Rev** 1995; 23:375–97 (142 ref.)
Molecular actions of ebselen--an antiinflammatory antioxidant. Schewe T. **Gen Pharmacol** 1995 Oct; 26(6):1153–69 (91 ref.)
Radioprotective and antioxidant action of caffeine: mechanistic considerations. Devasagayam TP, et al. **Indian J Exp Biol** 1996 Apr;34(4):291–7 (69 ref.)
Oxygen toxicity and antioxidants: state of the art. Sen CK. **Indian J Physiol Pharmacol** 1995 Jul;39(3):177–96 (91 ref.)
Antioxidants, carnitine, and choline as putative ergogenic aids. Kanter MM, et al. **Int J Sport Nutr** 1995 Jun;5 Suppl:S120–31 (73 ref.)
Antioxidants, oxidants and free radical stress in cardiovascular disease. Singh RB, et al. **J Assoc Physicians India** 1996 Jan;44(1):43–8 (55 ref.)
Nutrient antioxidants in the pathogenesis and prevention of cervical dysplasias and cancer. Romney SL, et al. **J Cell Biochem Suppl** 1995;23:96–103 (45 ref.)
Prevention of atherosclerosis with dietary antioxidants: fact or fiction? Duell PB. **J Nutr** 1996 Apr;126(4 Suppl):1067S–71S (38 ref.)
Benefits and liabilities of vitamin A and carotenoids. Olson JA. **J Nutr** 1996 Apr;126(4 Suppl):1208S–12S (30 ref.)
The dual roles of nutrients as antioxidants and prooxidants: their effects on tumor cell growth. Schwartz JL. **J Nutr** 1996 Apr;126(4 Suppl):1221S–7S (42 ref.)
Beyond oxidized LDL: the initiation and progression of atherosclerosis. Hirose N, et al. **Keio J Med** 1996 Jun; 45(2):90–4 (26 ref.)
Antioxidants, lipoprotein oxidation, and arterial function. Bruckdorfer KR. **Lipids** 1996 Mar;31 Suppl:S83–5 (17 ref.)
Anethole dithiolethione: biochemical considerations. Christen MO. **Methods Enzymol** 1995;252:316–23 (40 ref.)
Antioxidant defences against reactive oxygen species causing genetic and other damage. Anderson D. **Mutat Res** 1996 Feb 19;350(1):103–8 (46 ref.)
New pharmacologic approaches to acute spinal cord injury. Rhoney DH, et al. **Pharmacotherapy** 1996 May–Jun; 16(3):382–92 (82 ref.)
Atherosclerosis, oxidative stress, and antioxidant protection in endothelium-derived relaxing factor action. Keaney JF Jr, et al. **Prog Cardiovasc Dis** 1995 Sep–Oct;38(2):129–54 (202 ref.)
Antioxidant defenses in metal-induced liver damage. Sokol RJ. **Semin Liver Dis** 1996 Feb;16(1):39–46 (40 ref.)
Adenosine, antioxidant enzymes and cytoprotection. Ramkumar V, et al. **Trends Pharmacol Sci** 1995 Sep; 16(9):283–5 (31 ref.)
Antioxidant agents and colorectal carcinogenesis: role of beta-carotene, vitamin E and vitamin C. Pappalardo G, et al. **Tumori** 1996 Jan–Feb;82(1):6–11 (88 ref.)
[Free radicals and antioxidants. Advantages of antioxidants in clinical medicine, truth or fiction? (editorial)] Huttunen J. **Duodecim** 1994;110(17):1606–8 (25 ref.) **(Fin)**

POISONING

[Chronic obstructive bronchopneumopathy after acute inhalation of sulfur anhydride. Apropos of a case] Ramakers M, et al. **Rev Pneumol Clin** 1995;51(6):343–7 (31 ref.) (Eng. Abstr.) **(Fre)**

STANDARDS

Oxidative damage and defense. Jacob RA, et al. **Am J Clin Nutr** 1996 Jun;63(6):985S–990S (43 ref.)

THERAPEUTIC USE

Antioxidants in neonatal lung disease. Pardy CH, et al. **Arch Dis Child Fetal Neonatal Ed** 1995 Sep;73(2):F112–7 (66 ref.)
Carvedilol, a novel multiple action antihypertensive agent with antioxidant activity and the potential for myocardial and vascular protection. Feuerstein GZ, et al. **Eur Heart J** 1995 Jul;16 Suppl F:38–42 (21 ref.)
Characterization of drugs as antioxidant prophylactics. Aruoma OI. **Free Radic Biol Med** 1996;20(5):675–705 (473 ref.)
Epidemiologic studies of antioxidants and cancer in humans. Flagg EW, et al. **J Am Coll Nutr** 1995 Oct;14(5):419–27 (88 ref.)
beta-carotene and cancer chemoprevention. Buring JE, et al. **J Cell Biochem Suppl** 1995;22:226–30 (37 ref.)
N-acetylcysteine (NAC) and glutathione (GSH): antioxidant and chemopreventive properties, with special reference to lung cancer. van Zandwijk N. **J Cell Biochem Suppl** 1995; 22:24–32 (48 ref.)
The role of N-acetylcysteine in the treatment of chronic obstructive pulmonary disease [editorial] van Herwaarden CL, et al. **Neth J Med** 1995 Aug;47(2):45–8 (21 ref.)
Antioxidant therapy in critical care medicine. Tanswell AK, et al. **New Horiz** 1995 May;3(2):330–41 (140 ref.)
Antioxidants in pediatric gastrointestinal disease. Sokol RJ, et al. **Pediatr Clin North Am** 1996 Apr;43(2):471–88 (102 ref.)
Natural antioxidants for the prevention of atherosclerosis. Odeh RM, et al. **Pharmacotherapy** 1995 Sep–Oct; 15(5):648–59 (105 ref.)
Oxidative stress and antioxidant therapy in Parkinson's disease. Ebadi M, et al. **Prog Neurobiol** 1996 Jan;48(1):1–19 (340 ref.)
Possibilities of brain protection with tirilazad after cardiac arrest. Sterz F, et al. **Semin Thromb Hemost** 1996; 22(1):105–12 (37 ref.)
Oxidants/antioxidants in idiopathic pulmonary fibrosis. MacNee W, et al. **Thorax** 1995 Sep;50 Suppl 1:S53–8 (64 ref.)
[Is ubiquinone worth noticing? (editorial)] Alho H. **Duodecim** 1994;110(4):369–71 (18 ref.) **(Fin)**
[Safety of antioxidants] Mäntylä E, et al. **Duodecim** 1994; 110(17):1629–39 (59 ref.) **(Fin)**
[The role of antioxidants in the prevention of tumors] Ginter E. **Bratisl Lek Listy** 1995 Apr;96(4):195–209 (32 ref.) (Eng. Abstr.) **(Slo)**

ANTIPARASITIC AGENTS

METABOLISM

Avermectins. MacNeil DJ. **Biotechnology** 1995;28:421–42 (59 ref.)

THERAPEUTIC USE

Dreamtime, devastation and deviation: Australia's contribution to the chemotherapy of human parasitic infections. Boreham PF. **Int J Parasitol** 1995 Sep; 25(9):1009–22 (73 ref.)
Endectocidal drugs: ecological risks and counter-measures. Herd R. **Int J Parasitol** 1995 Aug;25(8):875–85 (82 ref.)
[Treatment of intestinal parasitic diseases] Siikamäki H. **Duodecim** 1994;110(14):1349–55 (13 ref.) **(Fin)**

ANTIPARKINSON AGENTS

ADVERSE EFFECTS

Involvement of serotonin in clinical features of Parkinson's disease and complications of L-DOPA therapy. Melamed E, et al. **Adv Neurol** 1996;69:545–50 (47 ref.)
[Value of clozapine in treatment of psychotic disorder in Parkinson disease] Abbar M, et al. **Encephale** 1996 Jan–Feb; 22(1):53–63 (46 ref.) (Eng. Abstr.) **(Fre)**
[Levodopa and malignant melanoma--case report and review of the literature. A contribution to causal relationship between levodopa and the development of malignant melanoma] Kleinhans M, et al. **Hautarzt** 1996 Jun; 47(6):432–7 (29 ref.) (Eng. Abstr.) **(Ger)**
[Parkinson syndrome: iatrogenic causes, iatrogenic treatment results] Burgunder JM. **Schweiz Med Wochenschr** 1996 Mar 30;126(13):522–7 (22 ref.) (Eng. Abstr.) **(Ger)**

PHARMACOKINETICS

Effects of catechol-O-methyltransferase (COMT) inhibition on the pharmacokinetics of L-DOPA. Nutt JG. **Adv Neurol** 1996;69:493–6 (15 ref.)
Concentration-effect relationship of levodopa in patients with Parkinson's disease. Harder S, et al. **Clin Pharmacokinet** 1995 Oct;29(4):243–56 (51 ref.)
Pharmacokinetics of apomorphine in Parkinson's disease. Gancher S. **J Neural Transm Suppl** 1995;45:137–41 (21 ref.)

PHARMACOLOGY

Apomorphine continuous stimulation in Parkinson's disease: receptor desensitization as a possible mechanism of reduced motor response. Maggio R, et al. **J Neural Transm Suppl** 1995;45:133–6 (22 ref.)

THERAPEUTIC USE

Possible neuroprotective therapy for Parkinson's disease. Ogawa N. **Acta Med Okayama** 1995 Aug;49(4):179–85 (70 ref.)
New drugs in the treatment of Parkinson's disease. An introduction. Bracco F. **Adv Neurol** 1996;69:513–7 (66 ref.)
Controversies in the therapy of Parkinson's disease. Fahn S. **Adv Neurol** 1996;69:477–86 (72 ref.)
Preclamol. A "designer drug" in the treatment of advanced Parkinson's disease. Pirtošek Z, et al. **Adv Neurol** 1996; 69:535–40 (26 ref.)
Treatment options for early Parkinson's disease. Stacy M, et al. **Am Fam Physician** 1996 Mar;53(4):1281–7 (29 ref.)
Drug management of Parkinson's disease. Kishore A, et al. **Can Fam Physician** 1996 May;42:946–52 (13 ref.)
Concentration-effect relationship of levodopa in patients with Parkinson's disease. Harder S, et al. **Clin Pharmacokinet** 1995 Oct;29(4):243–56 (51 ref.)
Management of parkinsonism and treatment of associated complications. Nutt JG. **Curr Opin Neurol** 1995 Aug; 8(4):327–30 (31 ref.)
Drugs for Parkinson's disease reviewed. **Drug Ther Bull** 1995 Jul;33(7):49–52 (25 ref.)
Dihydroergocryptine in the treatment of Parkinson's disease. Bonuccelli U, et al. **J Neural Transm Suppl** 1995;45:239–45 (33 ref.)
Ropinirole in the symptomatic treatment of Parkinson's disease. Brooks DJ, et al. **J Neural Transm Suppl** 1995; 45:231–8 (15 ref.)
Pergolide mesylate in Parkinson's disease treatment. Pezzoli G, et al. **J Neural Transm Suppl** 1995;45:203–12 (48 ref.)
Dopaminergic agonists in the treatment of Parkinson's disease: a review. Piccoli F, et al. **J Neural Transm Suppl** 1995;45:187–95 (46 ref.)
Second generation of dopamine agonists: pros and cons. Rabey JM. **J Neural Transm Suppl** 1995;45:213–24 (63 ref.)
Treatment of early Parkinson's disease: are complicated strategies justified? Ahlskog JE. **Mayo Clin Proc** 1996 Jul; 71(7):659–70 (90 ref.)
Dopamine receptors--the present state of research and perspectives. Wolfarth S, et al. **Pol J Pharmacol** 1995 May–Jun;47(3):207–18 (95 ref.)
Moderate Parkinson's disease. Strategies for maximizing treatment. Silverstein PM. **Postgrad Med** 1996 Jan; 99(1):52–4, 61–3, 67–8, passim (21 ref.)
Drug therapy for Parkinson's disease. Charles PD, et al. **South Med J** 1996 Sep;89(9):851–6 (22 ref.)
[New therapeutic possibilities with low-affinity NMDA receptor antagonists] Kornhuber J, et al. **Nervenarzt** 1996 Jan;67(1):77–82 (22 ref.) (Eng. Abstr.) **(Ger)**
[Stage-adjusted treatment of idiopathic Parkinson syndrome] Ludin HP. **Wien Med Wochenschr** 1995;145(13):294–8 (15 ref.) (Eng. Abstr.) **(Ger)**
[Clinical aspects and conservative therapy of Parkinson disease] Dengler R. **Zentralbl Neurochir** 1995;56(4):148–52 (5 ref.) (Eng. Abstr.) **(Ger)**
[Present strategy and future perspective of therapy in Parkinson's disease] Kuno S. **No To Shinkei** 1996 Jan; 48(1):18–25 (35 ref.) **(Jpn)**
[Therapeutic problems in the application of antiparkinsonian drugs in psychiatry] Piasecki T. **Psychiatr Pol** 1996 Jan–Feb;30(1):137–50 (26 ref.) (Eng. Abstr.) **(Pol)**
[Treatment of Parkinson disease] Cardoso F. **Arq Neuropsiquiatr** 1995 Mar;53(1):1–10 (34 ref.) (Eng. Abstr.) **(Por)**
[The neuroleptic malignant syndrome in an adolescent. Its treatment with dantrolene, bromocryptin and diazepam] Real Rodríguez B, et al. **An Esp Pediatr** 1996 Jan;44(1):60–2 (20 ref.) **(Spa)**

ANTIPHOSPHOLIPID ANTIBODIES see **ANTIBODIES, ANTIPHOSPHOLIPID**

ANTIPHOSPHOLIPID SYNDROME

The antiphospholipid syndrome: when does the presence of antiphospholipid antibodies require therapy? Devine DV, et al. **Postgrad Med** 1996 Jun;99(6):105–8, 113–25 (26 ref.)
Protean clinical presentation of antiphospholipid-protein antibodies (APA). Triplett DA. **Thromb Haemost** 1995 Jul; 74(1):329–37 (138 ref.)
[Antiphospholipid syndrome] Koike T. **Nippon Naika Gakkai Zasshi** 1995 Sep 10;84(9):1569–73 (5 ref.) **(Jpn)**
[Pregnancy and antiphospholipid syndrome] Aoki K, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Aug; 47(8):852–62 (27 ref.) **(Jpn)**

BLOOD

The role of beta 2-glycoprotein I in the antiphospholipid syndrome. Krilis SA, et al. **Lupus** 1996 Apr;5(2):150–2 (16 ref.)
The antiphospholipid syndrome and SLE: is there a clue in the link between complement and coagulation? Merrill JT, et al. **Lupus** 1996 Feb;5(1):6–10 (63 ref.)

COMPLICATIONS

Giant gastric ulceration associated with antiphospholipid antibody syndrome. Kalman DR, et al. **Am J Gastroenterol** 1996 Jun;91(6):1244–7 (19 ref.)
Renal infarction and thrombosis of the infrarenal aorta in a 35-year-old man with primary antiphospholipid syndrome. Poux JM, et al. **Am J Kidney Dis** 1996 May; 27(5):721–5 (20 ref.)
Heart valve involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome. Hojnik M, et al. **Circulation** 1996 Apr 15;93(8):1579–87 (110 ref.)
Superior mesenteric artery thrombosis in a patient with the antiphospholipid syndrome. England RJ, et al. **Eur J Vasc Endovasc Surg** 1995 Oct;10(3):372–3 (4 ref.)
Adrenal insufficiency in the antiphospholipid antibody syndrome. Arnason JA, et al. **Semin Arthritis Rheum** 1995

Oct;25(2):109–16 (27 ref.)
[A case of SLE associated with antiphospholipid syndrome and mitral stenosis] Takahashi M, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Feb;18(1):90–7 (28 ref.) (Eng. Abstr.) **(Jpn)**
[The characteristics of kidney involvement in a female patient with systemic lupus erythematosus and the antiphospholipid syndrome] Kozlovskaia NL, et al. **Klin Med (Mosk)** 1995;73(3):93–6 (27 ref.) (Eng. Abstr.) **(Rus)**

DIAGNOSIS

The lupus anticoagulant/antiphospholipid syndrome. Shapiro SS. **Annu Rev Med** 1996;47:533–53 (182 ref.)
Thrombocytopenia in the antiphospholipid syndrome. Galli M, et al. **Br J Haematol** 1996 Apr;93(1):1–5 (50 ref.)
[Primary antiphospholipid syndrome with a familial element and myocardial infarct in an adolescent] Gaeta G, et al. **G Ital Cardiol** 1995 Aug;25(8):1025–30 (35 ref.) (Eng. Abstr.) **(Ita)**
[Antiphospholipid syndrome as an interdisciplinary medical problem] Turkowska M, et al. **Pol Arch Med Wewn** 1996 May;95(5):486–92 (40 ref.) **(Pol)**
[Idiopathic white atrophy and the primary antiphospholipid syndrome: a promise still unfulfilled (letter)] LLamas P, et al. **Rev Clin Esp** 1996 May;196(5):342–3 (10 ref.) **(Spa)**

IMMUNOLOGY

The Michael Mason Prize Essay (1994). Antiphospholipid antibodies and disease. Mackworth-Young CG. **Br J Rheumatol** 1995 Nov;34(11):1009–30 (160 ref.)
Antiphospholipid antibodies and antiphospholipid syndrome. Khamashta MA, et al. **Curr Opin Rheumatol** 1995 Sep; 7(5):389–94 (69 ref.)
The antiphospholipid–protein syndrome. Cines DB, et al. **J Clin Immunol** 1995 Nov;15(6 Suppl):86S–100S (186 ref.)
Anticardiolipin antibodies and beta 2-glycoprotein I. Koike T, et al. **Lupus** 1996 Apr;5(2):156–7 (13 ref.)

PATHOLOGY

Placental changes in a first trimester missed abortion in maternal systemic lupus erythematosus with antiphospholipid syndrome; a case report and review of the literature. Nayar R, et al. **Hum Pathol** 1996 Feb; 27(2):201–6 (36 ref.)

PHYSIOPATHOLOGY

Clinical manifestations and management of the antiphospholipid syndrome. Derksen RH. **Lupus** 1996 Apr; 5(2):167–9 (18 ref.)
Neurological and obstetric manifestations of the antiphospholipid syndrome. Gatenby PA. **Lupus** 1996 Apr; 5(2):170–2 (13 ref.)

PREVENTION & CONTROL

[Aspirin during pregnancy. Indications and modalities of prescription after the publication of the later trials] Uzan S, et al. **Presse Med** 1996 Jan 6–13;25(1):31–6 (30 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Clinical manifestations and management of the antiphospholipid syndrome. Derksen RH. **Lupus** 1996 Apr; 5(2):167–9 (18 ref.)
[Antiphospholipid syndrome as an interdisciplinary medical problem] Turkowska M, et al. **Pol Arch Med Wewn** 1996 May;95(5):486–92 (40 ref.) **(Pol)**

ANTIPLASMIN

ANALYSIS

[alpha 2-Plasmin inhibitor-plasmin complex (PIC)] Yoshikawa Y, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:55–8 (13 ref.) **(Jpn)**

ANTIPLASMINS see **ANTIFIBRINOLYTIC AGENTS**

ANTIPLATELET AGENTS see **PLATELET AGGREGATION INHIBITORS**

ANTIPORT see **ION TRANSPORT**

ANTIPORTERS

METABOLISM

Alterations in sodium metabolism as an etiological model for hypertension. Lijnen P. **Cardiovasc Drugs Ther** 1995 Jun; 9(3):377–99 (238 ref.)
Renal chloride–bicarbonate exchangers. Godinich MJ, et al. **Curr Opin Nephrol Hypertens** 1995 Sep;4(5):398–401 (34 ref.)

ANTIPROTOZOAL AGENTS

ADVERSE EFFECTS

Diabetes mellitus associated with pentamidine isethionate in diffuse cutaneous leishmaniasis. Costa JM, et al. **Rev Soc Bras Med Trop** 1995 Oct–Dec;28(4):405–7 (13 ref.)

CHEMISTRY

Structure and activity of avermectins and milbemycins in animal health. Shoop WL, et al. **Vet Parasitol** 1995 Sep; 59(2):139–56 (54 ref.)

ISOLATION & PURIFICATION

Plant metabolites active against Trypanosoma cruzi. Sepúlveda-Boza S, et al. **Planta Med** 1996 Apr;62(2):98–105 (63 ref.)

PHARMACOLOGY

New mechanisms of drug resistance in parasitic protozoa. Borst P, et al. **Annu Rev Microbiol** 1995;49:427–60 (196 ref.)
Atovaquone. A review of its pharmacological properties and therapeutic efficacy in opportunistic infections. Spencer CM, et al. **Drugs** 1995 Jul;50(1):176–96 (64 ref.)

THERAPEUTIC USE

Therapeutic approaches for AIDS-related toxoplasmosis [see comments] Behbahani R, et al. **Ann Pharmacother** 1995 Jul–Aug;29(7–8):760–8 (52 ref.) Comment in: Ann Pharmacother 1995 Dec;29(12):1303–4.
The surface glycoconjugates of parasitic protozoa: potential targets for new drugs. McConville MJ. **Aust N Z J Med** 1995 Dec;25(6):768–76 (40 ref.)
Reactivation toxoplasmic retinochoroiditis in patients undergoing bone marrow transplantation: is there a role for chemoprophylaxis? Peacock JE Jr, et al. **Bone Marrow Transplant** 1995 Jun;15(6):983–7 (23 ref.)
Human antiprotozoal therapy: past, present, and future. Khaw M, et al. **Clin Microbiol Rev** 1995 Jul;8(3):427–39 (182 ref.)
Antiparasitic drugs. Liu LX, et al. **N Engl J Med** 1996 May 2;334(18):1178–84 (100 ref.)
Chemotherapy of human and animal coccidioses: state and perspectives. Haberkorn A. **Parasitol Res** 1996;82(3):193–9 (97 ref.)
[Antiparasitic therapeutics: the present] Magnaval JF. **Med Trop (Mars)** 1995;55(3 Suppl):10–2 (15 ref.) **(Fre)**

ANTIPRURITICS

THERAPEUTIC USE

Treating pruritus. What's new in safe relief of symptoms? Millikan LE. **Postgrad Med** 1996 Jan;99(1):173–6, 179–84 (17 ref.)

ANTIPSYCHOTIC AGENTS

see related
DOPAMINE ANTAGONISTS

Barbiturates, neuroleptics, and propofol for sedation. Lund N, et al. **Crit Care Clin** 1995 Oct;11(4):875–86 (38 ref.)
[Recent progress in development of psychotropic drugs (2)—antipsychotics] Murasaki M. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1995 Jun; 15(3):191–210 (55 ref.) (Eng. Abstr.) **(Jpn)**

ADMINISTRATION & DOSAGE

Denouement of an execution competency case: is Perry pyrrhic? Mossman D. **Bull Am Acad Psychiatry Law** 1995; 23(2):269–84 (113 ref.)
Neuroleptic dosing and neuroleptic plasma levels in schizophrenia: determining the optimal regimen. Shriqui CL. **Can J Psychiatry** 1995 Sep;40(7 Suppl 2):S38–48 (77 ref.)
Maintenance treatment of schizophrenia: a review of dose reduction and family treatment strategies. Schooler NR, et al. **Psychiatr Q** 1995 Winter;66(4):279–92 (41 ref.)
Conventional antipsychotic medications for schizophrenia. Dixon LB, et al. **Schizophr Bull** 1995;21(4):567–77 (40 ref.)
Adjunctive treatments in schizophrenia: pharmacotherapies and electroconvulsive therapy. Johns CA, et al. **Schizophr Bull** 1995;21(4):607–19 (85 ref.)
[Treatment of negative symptoms in schizophrenia by amisulpride. Review of the literature] Pélissolo A, et al. **Encephale** 1996 May–Jun;22(3):215–9 (25 ref.) (Eng. Abstr.) **(Fre)**
[The "neuroleptic threshold"—a review of the literature] Abraham D, et al. **Psychiatr Prax** 1996 May;23(3):109–16 (42 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Neuroleptic malignant syndrome and catatonia: one entity or two? [editorial] Fink M. **Biol Psychiatry** 1996 Jan 1; 39(1):1–4 (30 ref.)
Priapism associated with psychotropic drugs. Patel AG, et al. **Br J Hosp Med** 1996 Mar 20–Apr 2;55(6):315–9 (63 ref.)
Tardive dyskinesia: a review. Latimer PR. **Can J Psychiatry** 1995 Sep;40(7 Suppl 2):S49–54 (44 ref.)
Management of suspected neuroleptic malignant syndrome. Velamoor VR, et al. **Can J Psychiatry** 1995 Nov; 40(9):545–50 (33 ref.)
Tardive syndromes and other drug-induced movement disorders. Jankovic J. **Clin Neuropharmacol** 1995 Jun; 18(3):197–214 (124 ref.)
Photosensitivity associated with antipsychotics, antidepressants and anxiolytics. Harth Y, et al. **Drug Saf** 1996 Apr;14(4):252–9 (47 ref.)
Adverse effects of antipsychotic agents. Do newer agents offer advantages? Owens DG. **Drugs** 1996 Jun; 51(6):895–930 (195 ref.)
Oropharyngeal dysphagia due to iatrogenic neurological dysfunction. Buchholz DW. **Dysphagia** 1995 Fall; 10(4):248–54 (51 ref.)
Clozapine-induced neuroleptic malignant syndrome: review and report of new cases. Sachdev P, et al. **J Clin Psychopharmacol** 1995 Oct;15(5):365–71 (29 ref.)
Current topics in neuroleptic-induced extrapyramidal symptoms in Japan. Inada T, et al. **Keio J Med** 1996 Jun; 45(2):95–9 (36 ref.)
Tardive tourettism after exposure to neuroleptic therapy. Bharucha KJ, et al. **Mov Disord** 1995 Nov;10(6):791–3 (17 ref.)
Novel versus conventional antipsychotic drugs. Love RC. **Pharmacotherapy** 1996 Jan–Feb;16(1 Pt 2):6–10 (24 ref.)
Schizophrenia, Alzheimer's disease, and anti-inflammatory agents. Oken RJ, et al. **Schizophr Bull** 1996;22(1):1–4 (24 ref.)
The epidemiology of drug-induced akathisia: Part II. Chronic, tardive, and withdrawal akathisias. Sachdev P. **Schizophr Bull** 1995;21(3):451–61 (70 ref.)
The epidemiology of drug-induced akathisia: Part I. Acute akathisia. Sachdev P. **Schizophr Bull** 1995;21(3):431–49 (130 ref.)
Weight gain associated with neuroleptic medication: a review. Stanton JM. **Schizophr Bull** 1995;21(3):463–72 (100 ref.)
The treatment of tardive dyskinesia. Raja M. **Schweiz Arch Neurol Psychiatr** 1996;147(1):13–8 (99 ref.)
[Agranulocytosis caused by clozapine: the importance of leukocyte monitoring and efficacy of hematopoietic growth factors] van Melick EJ, et al. **Ned Tijdschr Geneeskd** 1995 Nov 25;139(47):2437–40 (18 ref.) (Eng. Abstr.) **(Dut)**
[Current aspects of the use of clozapine in the Châlons-sur-Marne Psychiatric Hospital: intestinal occlusion with clozapine] Théret L, et al. **Ann Med Psychol (Paris)** 1995 Aug–Sep;153(7):474–7 (24 ref.) (Eng. Abstr.) **(Fre)**
[Tolerance of neuroleptics, deficit syndrome and cognitive functions] Kahn JP. **Encephale** 1996 Jun;22 Spec No 2:49–54 (35 ref.) (Eng. Abstr.) **(Fre)**
[Deficit: the value and difficulty of defining the primary or secondary character of observed symptoms] Petit M, et al. **Encephale** 1996 Jun;22 Spec No 2:13–8 (20 ref.) (Eng. Abstr.) **(Fre)**
[Schizophrenic deficit syndrome and neurologic tolerance] Verdoux H, et al. **Encephale** 1996 Jun;22 Spec No 2:45–7 (27 ref.) (Eng. Abstr.) **(Fre)**
[Neuroleptics and nicotine] Erdmann R. **Psychiatr Prax** 1995 Nov;22(6):223–7 (34 ref.) (Eng. Abstr.) **(Ger)**
[Neuroleptic malignant syndrome: a review of literature] Crespo Facorro B, et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1995 Sep–Oct;23(5):273–8 (57 ref.) (Eng. Abstr.) **(Spa)**

CHEMISTRY

Does the dopamine receptor subtype selectivity of antipsychotic agents provide useful leads for the development of novel therapeutic agents? Hacksell U, et al. **Pharmacol Toxicol** 1995 May;76(5):320–4 (21 ref.)

ECONOMICS

Pharmacoeconomics of antipsychotic drug therapy. Hargreaves WA, et al. **J Clin Psychiatry** 1996;57 Suppl 9:66–76 (47 ref.)

PHARMACOKINETICS

Pharmacokinetics of clozapine and risperidone: a review of recent literature. Byerly MJ, et al. **J Clin Psychopharmacol** 1996 Apr;16(2):177–87 (78 ref.)

PHARMACOLOGY

Pre-clinical pharmacology of atypical antipsychotic drugs: a selective review. Meltzer HY. **Br J Psychiatry Suppl** 1996 May;(29):23–31 (130 ref.)
Role of serotonin in the action of atypical antipsychotic drugs. Meltzer HY. **Clin Neurosci** 1995;3(2):64–75 (162 ref.)
Effects of neuroleptic medications on the cognition of patients with schizophrenia: a review of recent studies. Goldberg TE, et al. **J Clin Psychiatry** 1996;57 Suppl 9:62–5 (23 ref.)
New insights into the biology of schizophrenia through the mechanism of action of clozapine. Brunello N, et al. **Neuropsychopharmacology** 1995 Nov;13(3):177–213 (400 ref.)
Antipsychotics and neuropeptides: the atypical profile of CI-943 and its relationship to neurotensin. Liégeois JF, et al. **Neurosci Biobehav Rev** 1995 Winter;19(4):519–31 (101 ref.)

THERAPEUTIC USE

Insight and adherence to treatment in psychotic disorders. Kemp RA, et al. **Br J Hosp Med** 1995 Sep 6–19;54(5):222–7

(46 ref.)
Schizophrenia: recent advances in psychopharmacology. Sharma T. **Br J Hosp Med** 1996 Feb 21–Mar 5;55(4):194–8 (21 ref.)
Effectiveness of clozapine in hospitalised people with chronic neuroleptic-resistant schizophrenia. Avnon M, et al. **Br J Psychiatry** 1995 Dec;167(6):760–4 (15 ref.)
Consent to neuroleptic medication for schizophrenia: clinical, ethical and legal issues. Brabbins C, et al. **Br J Psychiatry** 1996 May;168(5):540–4 (23 ref.)
The treatment of negative symptoms: pharmacological and methodological issues. Carpenter WT Jr. **Br J Psychiatry Suppl** 1996 May;(29):17–22 (45 ref.)
Perspectives on treatment needs in schizophrenia. Meise U, et al. **Br J Psychiatry Suppl** 1996 May;(29):9–16 (110 ref.)
Understanding schizophrenia: the impact of novel antipsychotics. Remington G. **Can J Psychiatry** 1995 Sep; 40(7 Suppl 2):S29–32 (39 ref.)
The drug treatment of patients with schizophrenia. **Drug Ther Bull** 1995 Nov;33(11):81–6 (43 ref.)
Adjunctive therapy in patients with Alzheimer's disease. A practical approach. Corey-Bloom J, et al. **Drugs Aging** 1995 Aug;7(2):79–87 (46 ref.)
Late-life delusional depression: acute and long-term treatment. Meyers BS. **Int Psychogeriatr** 1995;7 Suppl:113–24 (73 ref.)
Psychopharmacology in child and adolescent psychiatry: a review of the past seven years. Part I. Campbell M, et al. **J Am Acad Child Adolesc Psychiatry** 1995 Sep; 34(9):1124–32 (132 ref.)
Maintenance therapy of persons with schizophrenia. Carpenter WT Jr. **J Clin Psychiatry** 1996;57 Suppl 9:10–8 (118 ref.)
Antipsychotic medications in children and adolescents. Findling RL, et al. **J Clin Psychiatry** 1996;57 Suppl 9:19–23 (33 ref.)
Antipsychotics in bipolar disorder. Gelenberg AJ, et al. **J Clin Psychiatry** 1996;57 Suppl 9:49–52 (38 ref.)
Pharmacoeconomics of antipsychotic drug therapy. Hargreaves WA, et al. **J Clin Psychiatry** 1996;57 Suppl 9:66–76 (47 ref.)
New developments in the pharmacologic treatment of schizoaffective disorder. Keck PE Jr, et al. **J Clin Psychiatry** 1996;57 Suppl 9:41–8 (78 ref.)
Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia. Lieberman JA, et al. **J Clin Psychiatry** 1996;57 Suppl 9:5–9 (43 ref.)
Mania, psychosis, and antipsychotics. McElroy SL, et al. **J Clin Psychiatry** 1996;57 Suppl 3:14–26; discussion 47–9 (168 ref.)
Considerations of natural history and pathophysiology in the psychopharmacology of Tourette's syndrome. Peterson BS. **J Clin Psychiatry** 1996;57 Suppl 9:24–34 (82 ref.)
Treatment of the elderly suffering from psychosis and dementia. Sunderland T. **J Clin Psychiatry** 1996;57 Suppl 9:53–6 (30 ref.)
Neuroleptic treatment of agitation and psychosis in dementia. Devanand DP, et al. **J Geriatr Psychiatry Neurol** 1995 Oct; 8 Suppl 1:S18–27 (141 ref.)
Clozapine as a treatment for psychosis in Parkinson's disease: a review. Musser WS, et al. **J Neuropsychiatry Clin Neurosci** 1996 Winter;8(1):1–9 (52 ref.)
Schizophrenia. Kane JM. **N Engl J Med** 1996 Jan 4; 334(1):34–41 (97 ref.)
Emergency pharmacotherapy: the evolving role of medications in the emergency department. Ellison JM, et al. **New Dir Ment Health Serv** 1995 Fall;(67):87–98 (64 ref.)
Does the dopamine receptor subtype selectivity of antipsychotic agents provide useful leads for the development of novel therapeutic agents? Hacksell U, et al. **Pharmacol Toxicol** 1995 May;76(5):320–4 (21 ref.)
Chronic schizophrenia. Options for pharmacologic management. Pary R, et al. **Postgrad Med** 1995 Nov; 98(5):163–4, 167–70, 173 (25 ref.)
Ethnicity and psychopharmacology. Bridging the gap. Lin KM, et al. **Psychiatr Clin North Am** 1995 Sep;18(3):635–47 (56 ref.)
Clozapine: efficacy and safety. Buchanan RW. **Schizophr Bull** 1995;21(4):579–91 (80 ref.)
Risperidone: efficacy and safety. Umbricht D, et al. **Schizophr Bull** 1995;21(4):593–606 (22 ref.)
Cognitive impairment as a target for pharmacological treatment in schizophrenia. Davidson M, et al. **Schizophr Res** 1995 Sep;17(1):123–9 (55 ref.)
Cortical maldevelopment, anti-psychotic drugs, and schizophrenia: a search for common ground. Weinberger DR, et al. **Schizophr Res** 1995 Aug 1;16(2):87–110 (215 ref.)
[Dopamine D4-receptor variants, schizophrenia and clozapine therapy] Ewald HL, et al. **Ugeskr Laeger** 1996 Jun 17;158(25):3601–3 (17 ref.) (Eng. Abstr.) **(Dan)**
[What is used as a drug for problem drinking?] Heinälä P, et al. **Duodecim** 1995;111(8):761–8 (30 ref.) **(Fin)**
[Value of clozapine in treatment of psychotic disorder in Parkinson disease] Abbar M, et al. **Encephale** 1996 Jan–Feb; 22(1):53–63 (46 ref.) (Eng. Abstr.) **(Fre)**
[Associated psychotropic drugs in deficit schizophrenia] Beaufils B. **Encephale** 1996 Jun;22 Spec No 2:41–3 (18 ref.) (Eng. Abstr.) **(Fre)**
[Methodological constraints in evaluating anti-deficit effects] Boyer P, et al. **Encephale** 1996 Jun;22 Spec No 2:25–7 (16 ref.) (Eng. Abstr.) **(Fre)**
[Incidence of the deficit form in refractory schizophrenia] Samuelian JC. **Encephale** 1996 Jun;22 Spec No 2:19–23 (30 ref.) (Eng. Abstr.) **(Fre)**
[Deficit schizophrenia: from pharmacology to clinical practice] Tassin JP. **Encephale** 1996 Jun;22 Spec No 2:9–12 (20 ref.) (Eng. Abstr.) **(Fre)**
[Profile of the action of neuroleptics in deficit schizophrenia] Vanelle JM. **Encephale** 1996 Jun;22 Spec No 2:33–9 (35 ref.) (Eng. Abstr.) **(Fre)**
[Recent developments in antipsychotic medication] Möller HJ. **Schweiz Arch Neurol Psychiatr** 1995;146(5):230–9 (50 ref.) (Eng. Abstr.) **(Ger)**
[Schizophrenia combination therapy with neuroleptics and benzodiazepines] Ruzikowska A. **Psychiatr Pol** 1996 Jan–Feb;30(1):55–64 (23 ref.) (Eng. Abstr.) **(Pol)**
[Pharmacological treatment of migraine: other treatments] Gómez Aranda F, et al. **Rev Neurol** 1995;23 Suppl 2:S198–200 (43 ref.) **(Spa)**

TOXICITY

Enhancement of tumor growth by drugs with some common molecular actions. LaBella FS, et al. **Mol Carcinog** 1996 Jun;16(2):68–76 (91 ref.)

ANTIPSYCHOTIC AGENTS, BUTYROPHENONE

ADVERSE EFFECTS

Neuroleptic malignant syndrome in a trauma patient [see comments] Burke C, et al. **J Trauma** 1995 Oct;39(4):796–8 (11 ref.) Comment in: J Trauma 1996 Apr;40(4):673.
[The neuroleptic malignant syndrome (NMS). A report of a clinical case with a protracted and recurrent course. A review of the literature] Marelli A, et al. **Minerva Med** 1996 Jan–Feb;87(1–2):45–51 (30 ref.) (Eng. Abstr.) **(Ita)**

BLOOD

[Haloperidol] Sakamoto N, et al. **Nippon Rinsho** 1995 Feb; 53 Su Pt 1:938–41 (14 ref.) **(Jpn)**

ANTIPSYCHOTIC AGENTS, PHENOTHIAZINE

ADVERSE EFFECTS

Drug-induced vanishing bile duct syndrome: response to ursodiol. O'Brien CB, et al. **Am J Gastroenterol** 1996 Jul; 91(7):1456–7 (10 ref.)

ANTIPYRETICS see **ANALGESICS, NON-NARCOTIC**

ANTIREJECTION THERAPY see **IMMUNOSUPPRESSION**

ANTIRHEUMATIC AGENTS

see related
ANTIMALARIALS
IMMUNOSUPPRESSIVE AGENTS
Clinical use of cyclosporin in rheumatoid arthritis. Richardson C, et al. **Drugs** 1995;50 Suppl 1:26–36 (53 ref.)

ADMINISTRATION & DOSAGE

Combination therapy with cyclosporin in rheumatoid arthritis. Yocum DE. **Drugs** 1995;50 Suppl 1:37–40 (20 ref.)
[Disease-modifying drugs in rheumatoid arthritis. Duration of treatment and reasons for withdrawal] Grefslie H, et al. **Tidsskr Nor Laegeforen** 1996 Mar 20;116(8):958–62 (32 ref.) (Eng. Abstr.) **(Nor)**

ADVERSE EFFECTS

Acute febrile toxic reaction in patients with refractory rheumatoid arthritis who are receiving combined therapy with methotrexate and azathioprine. Blanco R, et al. **Arthritis Rheum** 1996 Jun;39(6):1016–20 (19 ref.)
Hazards of low dose methotrexate [editorial] Conaghan PG, et al. **Aust N Z J Med** 1995 Dec;25(6):670–3 (30 ref.)
Folate supplementation and methotrexate. Dijkmans BA. **Br J Rheumatol** 1995 Dec;34(12):1172–4 (22 ref.)
Adverse events in methotrexate-treated rheumatoid arthritis patients. Sandoval DM, et al. **Br J Rheumatol** 1995 Nov; 34 Suppl 2:49–56 (76 ref.)
Methotrexate in rheumatoid arthritis: toxicity issues [editorial] Weinblatt ME. **Br J Rheumatol** 1996 May; 35(5):403–5 (27 ref.)
Management of adverse effects of disease-modifying antirheumatic drugs. Wijnands MJ, et al. **Drug Saf** 1995 Oct;13(4):219–27 (31 ref.)
Safety aspects of cyclosporin in rheumatoid arthritis. Dijkmans BA. **Drugs** 1995;50 Suppl 1:41–7 (37 ref.)
Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. Salloum E, et al. **J Clin Oncol** 1996 Jun;14(6):1943–9 (56 ref.)
Adverse drug reactions and their measurement in the rheumatic diseases. Day RO, et al. **J Rheumatol** 1995 May; 22(5):983–8 (48 ref.)
Fatal pulmonary fibrosis complicating low dose methotrexate therapy for rheumatoid arthritis. van der Veen MJ, et al. **J Rheumatol** 1995 Sep;22(9):1766–8 (20 ref.)
Coexistent membranous nephropathy and ANCA-positive crescentic glomerulonephritis in association with penicillamine. Mathieson PW, et al. **Nephrol Dial Transplant** 1996 May;11(5):863–6 (26 ref.)
Pancytopenia and severe cytopenia induced by low-dose methotrexate. Eight case-reports and a review of one hundred cases from the literature (with twenty-four deaths) [see comments] Berthelot JM, et al. **Rev Rhum Engl Ed** 1995 Jul-Sep;62(7–8):477–86 (108 ref.) Comment in: Rev Rhum Engl Ed 1995 Jul-Sep;62(7–8):471–3.
[A case of rheumatoid arthritis with malignant lymphoma taking methotrexate] Hayakawa M, et al. **Ryumachi** 1995 Aug;35(4):678–82 (23 ref.) (Eng. Abstr.) **(Jpn)**
[Pneumocystis carinii pneumonia associated with low dose methotrexate treatment for malignant rheumatoid arthritis] Okuda Y, et al. **Ryumachi** 1995 Aug;35(4):699–704 (18 ref.) (Eng. Abstr.) **(Jpn)**

PHARMACOKINETICS

Practical clinical pharmacology and drug interactions of low-dose methotrexate therapy in rheumatoid arthritis. Furst DE. **Br J Rheumatol** 1995 Nov;34 Suppl 2:20–5 (50 ref.)

PHARMACOLOGY

Sulphasalazine, sulphapyridine or 5-aminosalicylic acid—which is the active moiety in rheumatoid arthritis? Bird HA. **Br J Rheumatol** 1995 Nov;34 Suppl 2:16–9 (11 ref.)
The antirheumatic agents sulphasalazine and methotrexate share an anti-inflammatory mechanism. Cronstein BN. **Br J Rheumatol** 1995 Nov;34 Suppl 2:30–2 (20 ref.)
Possible mechanisms of action of methotrexate in patients with rheumatoid arthritis. Kremer JM. **Br J Rheumatol** 1995 Nov;34 Suppl 2:26–9 (37 ref.)
Sulphasalazine: mechanism of action in rheumatoid arthritis. Smedegård G, et al. **Br J Rheumatol** 1995 Nov;34 Suppl 2:7–15 (133 ref.)
Slow-acting antirheumatic drugs. Drug interactions of clinical significance. Munro RA, et al. **Drug Saf** 1995 Jul; 13(1):25–30 (34 ref.)

THERAPEUTIC USE

Rheumatoid arthritis—changing theories and treatment modalities. van de Putte LB, et al. **Acta Orthop Scand Suppl** 1995 Oct;266:10–3 (13 ref.)
Management of osteoarthritis and rheumatoid arthritis: prospects and possibilities. Blackburn WD. **Am J Med** 1996 Feb 26;100(2A):24S–30S (47 ref.)
Regression of the nephrotic syndrome in rheumatoid arthritis and amyloidosis treated with azathioprine. A case report. Shapiro DL, et al. **Arthritis Rheum** 1995 Dec;38(12):1851–4 (24 ref.)
The epidemiology of drug treatment failure in rheumatoid arthritis. Wolfe F. **Baillieres Clin Rheumatol** 1995 Nov; 9(4):619–32 (40 ref.)
The history of the use of sulphasalazine in rheumatology. Amos RS. **Br J Rheumatol** 1995 Nov;34 Suppl 2:2–6 (51 ref.)
Clinical efficacy of sulphasalazine—a review. Capell HA. **Br J Rheumatol** 1995 Nov;34 Suppl 2:35–9 (30 ref.)
Therapeutic approaches for early rheumatoid arthritis. How early? How aggressive? Emery P. **Br J Rheumatol** 1995 Nov;34 Suppl 2:87–90 (16 ref.)
How and when should combination therapy be used? The role of an anchor drug. Farr M, et al. **Br J Rheumatol** 1995 Nov;34 Suppl 2:100–3 (38 ref.)
Combining sulphasalazine and methotrexate in rheumatoid arthritis: early clinical impressions. Haagsma CJ, et al. **Br J Rheumatol** 1995 Nov;34 Suppl 2:104–8 (30 ref.)
Clinical trial design for evaluating combination therapies. Paulus HE. **Br J Rheumatol** 1995 Nov;34 Suppl 2:92–5 (26 ref.)
Efficacy of methotrexate in rheumatoid arthritis. Weinblatt ME. **Br J Rheumatol** 1995 Nov;34 Suppl 2:43–8 (49 ref.)
Overview of combination second-line or disease-modifying antirheumatic drug therapy in rheumatoid arthritis. Williams HJ. **Br J Rheumatol** 1995 Nov;34 Suppl 2:96–9 (34 ref.)
How do second-line agents work? Choy E, et al. **Br Med Bull** 1995 Apr;51(2):472–92 (124 ref.)
Methotrexate in rheumatoid arthritis: when NSAIDs fail. Flynn JA, et al. **Cleve Clin J Med** 1995 Nov-Dec; 62(6):351–9 (92 ref.)
Treatment of scleroderma. Gelber AC, et al. **Curr Opin Rheumatol** 1995 Nov;7(6):551–9 (66 ref.)
Sulfasalazine. A review of its pharmacological properties and therapeutic efficacy in the treatment of rheumatoid arthritis [published erratum appears in Drugs 1995 Oct;50(4):625] Rains CP, et al. **Drugs** 1995 Jul;50(1):137–56 (134 ref.)
Clinical use of cyclosporin in rheumatoid arthritis. Richardson C, et al. **Drugs** 1995;50 Suppl 1:26–36 (53 ref.)
International consensus recommendations on cyclosporin use in rheumatoid arthritis. Tugwell P. **Drugs** 1995;50 Suppl 1:48–56 (32 ref.)
Disease-modifying antirheumatic drugs. Potential effects in older patients. Gardner G, et al. **Drugs Aging** 1995 Dec; 7(6):420–37 (43 ref.)
A review on the strategies for the development and

application of new anti-arthritic agents. Lewis AJ, et al. **Immunopharmacol Immunotoxicol** 1995 Nov;17(4):607–63 (272 ref.)
Drug treatment in children with juvenile rheumatoid arthritis. Past, present, and future. Giannini EH, et al. **Pediatr Clin North Am** 1995 Oct;42(5):1099–125 (89 ref.)
The changing face of therapy for rheumatoid arthritis. Kremer JM. **Rheum Dis Clin North Am** 1995 Aug; 21(3):845–52 (34 ref.)
Investigational agents for rheumatoid arthritis. Merkel PA, et al. **Rheum Dis Clin North Am** 1995 Aug;21(3):779–96 (85 ref.)
Rheumatoid arthritis. Outcome measures. Paulus HE, et al. **Rheum Dis Clin North Am** 1995 Aug;21(3):605–18 (52 ref.)
[Methotrexate in rheumatology: a therapeutic revolution] Kaye O, et al. **Rev Med Liege** 1995 Nov;50(11):453–7 (10 ref.) **(Fre)**
[Therapy of rheumatoid arthritis] Sieper J, et al. **Dtsch Med Wochenschr** 1996 Apr 26;121(17):563–7 (12 ref.) **(Ger)**
[Methotrexate treatment of rheumatoid arthritis] Beyeler C. **Schweiz Med Wochenschr** 1996 Apr 27;126(17):703–12 (61 ref.) (Eng. Abstr.) **(Ger)**
[Felty syndrome: a therapy-resistant variant of chronic rheumatoid arthritis? 2 case reports and literature review] Brücker R, et al. **Schweiz Rundsch Med Prax** 1996 Apr 16;85(16):534–40 (38 ref.) (Eng. Abstr.) **(Ger)**
[Prognosis and outcome of rheumatoid arthritis. Influence of anti-rheumatic therapy on natural course of disease and objectives in daily treatment] Fujimori J, et al. **Nippon Ika Daigaku Zasshi** 1995 Aug;62(4):396–400 (8 ref.) **(Jpn)**
[Antimalarial preparations in rheumatology: new prospects] Nasonov EL. **Ter Arkh** 1996;68(1):67–71 (50 ref.) **(Rus)**

ANTI-RHEUMATIC AGENTS, NON-STEROIDAL see **ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL**

ANTI-RHEUMATIC AGENTS, STEROIDAL see **ANTI-INFLAMMATORY AGENTS, STEROIDAL**

ANTISCHISTOSOMAL AGENTS see **SCHISTOSOMICIDES**

ANTISENSE DNA see **DNA, ANTISENSE**

ANTISENSE ELEMENTS (GENETICS)

see related
TRANSCRIPTION, GENETIC

[Regulation of gene expression by antisense molecule] Matsukura M. **Tanpakushitsu Kakusan Koso** 1994 Jul; 40(10):1378–82 (20 ref.) **(Jpn)**

THERAPEUTIC USE

Antisense strategies and therapeutic applications. Putnam DA. **Am J Health Syst Pharm** 1996 Jan 15;53(2):151–60; quiz 182–3 (76 ref.)
Antisense oncogene and tumor suppressor gene therapy of cancer. Zhang WW. **J Mol Med** 1996 Apr;74(4):191–204 (137 ref.)

ANTISENSE OLIGODEOXYRIBONUCLEOTIDES see **OLIGONUCLEOTIDES, ANTISENSE**

ANTISENSE OLIGONUCLEOTIDES see **OLIGONUCLEOTIDES, ANTISENSE**

ANTISENSE OLIGORIBONUCLEOTIDES see **OLIGONUCLEOTIDES, ANTISENSE**

ANTISENSE PROBES see **ANTISENSE ELEMENTS (GENETICS)**

ANTISENSE RNA see **RNA, ANTISENSE**

ANTISEPSIS

METHODS

APIC guideline for handwashing and hand antisepsis in health care settings. Larson EL. **Am J Infect Control** 1995 Aug;23(4):251–69 (239 ref.)

ANTISEPTICS see **ANTI-INFECTIVE AGENTS, LOCAL**

ANTISEPTICS, URINARY see **ANTI-INFECTIVE AGENTS, URINARY**

ANTISERA see **IMMUNE SERA**

ANTISEROTONERGIC AGENTS see **SEROTONIN ANTAGONISTS**

ANTISOCIAL PERSONALITY DISORDER

What price the concept of psychopathic disorder? Prins H. **Med Sci Law** 1995 Oct;35(4):307–15 (56 ref.)
The philosophy of psychopathy. Stein DJ. **Perspect Biol Med** 1996 Summer;39(4):569–80 (26 ref.)

DIAGNOSIS

Psychopathy--a clinical and legal dilemma [editorial] Reed J. **Br J Psychiatry** 1996 Jan;168(1):4–9 (20 ref.)
Sociopathy: forever forensic? Robertson MD, et al. **Med J Aust** 1996 Mar 4;164(5):304–7 (24 ref.)
[Psychopathy and neuropsychology of the prefrontal cortex] Jurado MA, et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1996 May-Jun;24(3):148–55 (49 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

Antisocial personality disorder: a biopsychosocial model. Paris J. **Can J Psychiatry** 1996 Mar;41(2):75–80 (70 ref.)

PHYSIOPATHOLOGY

[Psychopathy and neuropsychology of the prefrontal cortex] Jurado MA, et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1996 May-Jun;24(3):148–55 (49 ref.) (Eng. Abstr.) **(Spa)**

PSYCHOLOGY

Sociopathy: forever forensic? Robertson MD, et al. **Med J Aust** 1996 Mar 4;164(5):304–7 (24 ref.)

THERAPY

[Can "psychopathy" be cured?] Huttunen MO. **Duodecim** 1994;110(1):69–74 (17 ref.) **(Fin)**
[Psychotherapy with dyssocial patients] Rauchfleisch U. **Schweiz Arch Neurol Psychiatr** 1995;146(3):115–20 (13 ref.) (Eng. Abstr.) **(Ger)**

ANTITHROMBIN II see **ANTITHROMBIN III**

ANTITHROMBIN III

see related
ANTICOAGULANTS

ANALYSIS

[Antithrombin III (AT III)] Okajima K. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:43–7 (24 ref.) **(Jpn)**
[Thrombin antithrombin III complex (TAT)] Sakuragawa N. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:48–50 (14 ref.) **(Jpn)**

BIOSYNTHESIS

[Alpha-fetoprotein producing hepatocellular carcinoma, AT-III producing hepatocellular carcinoma] Nakamura K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):265–8 (11 ref.) **(Jpn)**

DEFICIENCY

Disseminated intravascular coagulation and antithrombin III depression in acute fatty liver of pregnancy. Castro MA, et al. **Am J Obstet Gynecol** 1996 Jan;174(1 Pt 1):211–6 (13 ref.)
[Hereditary antithrombin III deficiency. Report of an obstetric case and review of the literature] Leal-Tijerina G, et al. **Ginecol Obstet Mex** 1996 Apr;64:177–83 (18 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

A review of mutations causing deficiencies of antithrombin, protein C and protein S. Aiach M, et al. **Thromb Haemost** 1995 Jul;74(1):81–9 (120 ref.)

METABOLISM

Insight into the mechanism of action of heparin cofactor II. Tollefsen DM. **Thromb Haemost** 1995 Nov;74(5):1209–14 (64 ref.)

PHYSIOLOGY

The role of thrombin and thrombin inhibitors in coronary angioplasty. Ali MN, et al. **Chest** 1995 Nov;108(5):1409–19 (78 ref.)

ANTITHROMBIN VI see **FIBRIN FIBRINOGEN DEGRADATION PRODUCTS**

ANTITHROMBINS

see related
ANTICOAGULANTS

CHEMISTRY

Thrombin active site inhibitors. Das J, et al. **Bioorg Med Chem** 1995 Aug;3(8):999–1007 (57 ref.)

DEFICIENCY

Molecular genetics of human antithrombin deficiency. Perry DJ, et al. **Hum Mutat** 1996;7(1):7–22 (119 ref.)

GENETICS

Annotation. The unhinged antithrombins [comment] Carrell RW, et al. **Br J Haematol** 1996 May;93(2):253–7 (39 ref.) Comment on: Br J Haematol 1995 Mar;89(3):589–601.

PHARMACOLOGY

Thrombin inhibitors as antithrombotic agents: the importance of rapid inhibition. Stone SR, et al. **J Enzym Inhib** 1995; 9(1):3–15 (56 ref.)
Comparative pharmacology of site directed antithrombin agents. Implication in drug development. Callas D, et al. **Thromb Haemost** 1995 Jul;74(1):473–81 (54 ref.)

THERAPEUTIC USE

Thrombin inhibitors in acute myocardial infarction. Cannon CP. **Cardiol Clin** 1995 Aug;13(3):421–33 (73 ref.)
Pharmacological properties of hirudin and its derivatives. Potential clinical advantages over heparin. Monreal M, et al. **Drugs Aging** 1996 Mar;8(3):171–82 (52 ref.)
r-hirudin in unstable angina pectoris. Rationale and preliminary data from the APT pilot study. Fox KA. **Eur Heart J** 1995 Jul;16 Suppl D:28–32 (15 ref.)
Thrombolytic and antithrombotic treatment in myocardial infarction: main achievements and future perspectives. Agnelli G. **Int J Cardiol** 1995 Aug;49 Suppl:S77–87 (60 ref.)
New developments in acute anticoagulation therapy: what improvements over traditional heparin are on the horizon? Carter CJ. **Postgrad Med** 1996 Jun;99(6):129–36 (22 ref.)
Thrombin functions and antithrombotic intervention. Fenton JW 2nd. **Thromb Haemost** 1995 Jul;74(1):493–8 (63 ref.)
Antithrombotic benefits and hemorrhagic risks of direct thrombin antagonists. Harker LA, et al. **Thromb Haemost** 1995 Jul;74(1):464–72 (80 ref.)

ANTITHROMBOTIC AGENTS see **FIBRINOLYTIC AGENTS**

ANTITHYROID AGENTS

ADVERSE EFFECTS

Aplasia cutis congenita after exposure to methimazole: a causal relationship? Vogt T, et al. **Br J Dermatol** 1995 Dec; 133(6):994–6 (23 ref.)

PHARMACOLOGY

Role of goitrogens in iodine deficiency disorders & brain development. Rao PS, et al. **Indian J Med Res** 1995 Nov; 102:223–6 (16 ref.)

THERAPEUTIC USE

[Treatment of hyperthyroidism with antithyroid drugs] Eber O. **Acta Med Austriaca** 1995;22(5):83–90 (21 ref.) (Eng. Abstr.) **(Ger)**

ANTITOXINS

THERAPEUTIC USE

Kawasaki syndrome: immunomodulatory benefit and potential toxin neutralization by intravenous immune globulin. Leung DY. **Clin Exp Immunol** 1996 May;104 Suppl 1:49–54 (41 ref.)

ANTITRICHOMONAL AGENTS

THERAPEUTIC USE

Cephalosporin–metronidazole combinations in the management of intra-abdominal infections. Nicolau DP, et al. **Diagn Microbiol Infect Dis** 1995 May-Jun; 22(1–2):189–94 (28 ref.)
Metronidazole: utilization in the obstetric and gynecologic patient. Schwebke JR. **Sex Transm Dis** 1995 Nov-Dec; 22(6):370–6 (84 ref.)

ANTITRUST LAWS

Physician-run health plans and antitrust. American College of Physicians. **Ann Intern Med** 1996 Jul 1;125(1):59–65 (20 ref.)

ANTITRUST LIABILITY see **ANTITRUST LAWS**

ANTITUBERCULAR AGENTS

see related
TUBERCULOSIS, MULTIDRUG-RESISTANT

[Status quo of pyrazinamide as an antituberculosis drug] Kameda K. **Kekkaku** 1995 Jul;70(7):445–55 (80 ref.) (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Toxic effects and drug interactions of antimycobacterial therapy. Chan-Tompkins NH. **Clin Dermatol** 1995 May-Jun;13(3):223–33 (99 ref.)
Anti-tuberculosis medication and the liver: dangers and recommendations in management [see comments] Thompson NP, et al. **Eur Respir J** 1995 Aug;8(8):1384–8 (39 ref.) Comment in: Eur Respir J 1995 Aug;8(8):1247–9.
HIV medicine: drug side effects and interactions. Bates CM. **Postgrad Med J** 1996 Jan;72(843):30–6 (27 ref.)

ANTITUBERCULAR AGENTS

BLOOD

[Antituberculosis drug] Goromaru T. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:1002–5 (19 ref.) **(Jpn)**

PHARMACOLOGY

Short course chemotherapy in childhood tuberculosis [editorial] Chopra K. **Indian Pediatr** 1995 Jun;32(6):625–8 (10 ref.)

Glycosyltransferases as targets for inhibition of cell wall synthesis in M. tuberculosis and M. avium. Maddry JA, et al. **Res Microbiol** 1996 Jan–Feb;147(1–2):106–12 (25 ref.)

The structure and function of the isoniazid target in M. tuberculosis. Sacchettini JC, et al. **Res Microbiol** 1996 Jan–Feb;147(1–2):36–43 (29 ref.)

POISONING

Isoniazid overdose: four case reports and review of the literature. Alvarez FG, et al. **Intensive Care Med** 1995 Aug; 21(8):641–4 (28 ref.)

Treatment of acute isoniazid overdose in dogs. Villar D, et al. **Vet Hum Toxicol** 1995 Oct;37(5):473–7 (50 ref.)

THERAPEUTIC USE

Preventive therapy for tuberculosis in HIV infection: the promise and the reality [editorial] O'Brien RJ, et al. **AIDS** 1995 Jul;9(7):665–73 (83 ref.)

Outpatient management of tuberculosis [see comments] McColloster P, et al. **Am Fam Physician** 1996 Apr; 53(5):1579–94 (12 ref.) Comment in: Am Fam Physician 1996 Apr;53(5):1511–2.

Prophylaxis for tuberculosis in Europe—ongoing research. Carosi G, et al. **Clin Infect Dis** 1996 Apr;22 Suppl 1:S55–60 (31 ref.)

Drug-resistant tuberculosis in the 1990s [see comments] Yew WW, et al. **Eur Respir J** 1995 Jul;8(7):1184–92 (103 ref.) Comment in: Eur Respir J 1995 Jul;8(7):1073–5.

Drug resistance in Mycobacterium tuberculosis. Cole ST, et al. **Eur Respir J Suppl** 1995 Sep;20:701s–713s (116 ref.)

New drugs for tuberculosis. Grassi C, et al. **Eur Respir J Suppl** 1995 Sep;20:714s–718s (73 ref.)

Present-day management of pulmonary tuberculosis. Kundu AK, et al. **J Indian Med Assoc** 1995 Apr;93(4):144–8 (2 ref.)

Tuberculosis: diagnosis and treatment of resurgent disease. Strull GE, et al. **J Oral Maxillofac Surg** 1995 Nov; 53(11):1334–40 (23 ref.)

Tuberculous inguinal lymphadenitis. Challapalli M, et al. **Pediatr Infect Dis J** 1995 Aug;14(8):723–4 (5 ref.)

Solving the dilemma of antimycobacterial chemotherapy. Rastogi N, et al. **Res Microbiol** 1996 Jan–Feb;147(1–2):7–10 (30 ref.)

The chemotherapy of tuberculosis—from the past to the future. Collazos J, et al. **Respir Med** 1995 Aug;89(7):463–9 (68 ref.)

Multi drug resistant tuberculosis. Dey AB, et al. **Trop Gastroenterol** 1995 Apr–Jun;16(2):92–100 (39 ref.)

[Tuberculosis in aged persons residing in Quebec facilities: are screening and chemoprophylaxis indicated? (see comments)] Marchand RS, et al. **Can J Public Health** 1995 Jul–Aug;86(4):238–42 (55 ref.) (Eng. Abstr.) Comment in: Can J Public Health 1995 Jul–Aug;86(4):221–3. **(Fre)**

[Multidrug-resistant tuberculosis] Bouvet E. **Presse Med** 1996 Mar 2–9;25(8):393–8 (25 ref.) (Eng. Abstr.) **(Fre)**

[Renaissance of tuberculosis?] Meyer FJ, et al. **Internist (Berl)** 1995 Dec;36(12):1162–73 (80 ref.) **(Ger)**

[The problem of resistance in the treatment of Mycobacterium infections: new experimental results and combinations for the treatment of tuberculosis and leprosy] Seydel JK, et al. **Pharm Unserer Zeit** 1995 Nov; 24(6):313–23 (14 ref.) **(Ger)**

[Therapeutic approaches in diseases caused by mycobacteria] Urbanczik R. **Pneumologie** 1995 Dec;49 Suppl 3:649–52 (32 ref.) (Eng. Abstr.) **(Ger)**

[Therapy and prognosis of tuberculosis] Fischer B, et al. **Versicherungsmedizin** 1995 Dec 1;47(6):212–6 (12 ref.) (Eng. Abstr.) **(Ger)**

[Emergency drug therapy of meningoencephalitis] Kuzuhara S. **Nippon Naika Gakkai Zasshi** 1995 Nov 10;84(11):1837–42 (5 ref.) **(Jpn)**

ANTITUMOR DRUG SCREENING ASSAYS see **DRUG SCREENING ASSAYS, ANTITUMOR**

ANTITUSSIVE AGENTS

see related
EXPECTORANTS

PHARMACOLOGY

Discriminative stimulus properties of dextromethorphan in rats. Gavend M, et al. **Biomed Pharmacother** 1995; 49(10):456–64 (59 ref.)

Recent advances in neuropharmacology of the centrally acting antitussive drugs. Kamei J. **Methods Find Exp Clin Pharmacol** 1995 Apr;17(3):193–205 (103 ref.)

ANTI-ULCER AGENTS

see related
HISTAMINE H2 ANTAGONISTS

ADMINISTRATION & DOSAGE

Stress ulcer prophylaxis. Do critically ill patients need it? DePriest JL. **Postgrad Med** 1995 Oct;98(4):159–61, 165–6, 168 (23 ref.)

ADVERSE EFFECTS

Hyponatremia with consciousness disturbance caused by omeprazole administration. A case report and literature review. Shiba S, et al. **Dig Dis Sci** 1996 Aug;41(8):1615–7 (5 ref.)

ECONOMICS

Cost-effectiveness of H. pylori eradication. Roesch W. **J Physiol Pharmacol** 1996 Mar;47(1):71–7 (20 ref.)

PHARMACOKINETICS

Clinical pharmacokinetics in patients with burns. Jaehde U, et al. **Clin Pharmacokinet** 1995 Jul;29(1):15–28 (75 ref.)

PHARMACOLOGY

Review article: drug development in gastroenterology—the changing view of industry. Parsons ME, et al. **Aliment Pharmacol Ther** 1995 Oct;9(5):457–63 (14 ref.)

Similarities and differences in the properties of substituted benzimidazoles: a comparison between pantoprazole and related compounds. Kromer W. **Digestion** 1995; 56(6):443–54 (90 ref.)

Ebrotidine. Patel SS, et al. **Drugs** 1996 Jun;51(6):974–80; discussion 981 (41 ref.)

The history of acid inhibition. Baron JH. **Yale J Biol Med** 1994 May–Aug;67(3–4):97–106 (32 ref.)

[Gastrin/CCK-B receptor antagonists for a novel antiulcer agent] Miyata K, et al. **Nippon Yakurigaku Zasshi** 1995 Sep;106(3):171–80 (38 ref.) (Eng. Abstr.) **(Jpn)**

POISONING

Cisapride toxicosis in dogs. Volmer PA. **Vet Hum Toxicol** 1996 Apr;38(2):118–20 (20 ref.)

THERAPEUTIC USE

The role of proton pump inhibitors in the treatment of gastro-oesophageal reflux disease. Bardhan KD. **Aliment Pharmacol Ther** 1995;9 Suppl 1:15–25 (73 ref.)

Review article: the development of atrophic gastritis—Helicobacter pylori and the effects of acid suppressive therapy. Kuipers EJ, et al. **Aliment Pharmacol Ther** 1995 Aug;9(4):331–40 (97 ref.)

Drug therapy of peptic ulcer disease. Ching CK, et al. **Br J Hosp Med** 1995 Jul 12–Aug 15;54(2–3):101–6 (39 ref.)

Prophylaxis for stress-related gastrointestinal hemorrhage: a cost effectiveness analysis. Ben-Menachem T, et al. **Crit Care Med** 1996 Feb;24(2):338–45 (59 ref.)

A risk-benefit assessment of cisapride in the treatment of gastrointestinal disorders. Tack J, et al. **Drug Saf** 1995 Jun; 12(6):384–92 (103 ref.)

Ebrotidine. Patel SS, et al. **Drugs** 1996 Jun;51(6):974–80; discussion 981 (41 ref.)

Diclofenac/misoprostol. A review of its pharmacology and therapeutic efficacy in painful inflammatory conditions. Davis R, et al. **Drugs Aging** 1995 Nov;7(5):372–93 (76 ref.)

Use of misoprostol in the elderly: is the expense justified? Stucki G, et al. **Drugs Aging** 1996 Feb;8(2):84–8 (24 ref.)

Critical issues in the pathophysiology and management of peptic ulcer disease. Hunt RH, et al. **Eur J Gastroenterol Hepatol** 1995 Jul;7(7):685–99 (156 ref.)

Bismuth therapy for Helicobacter pylori infection. A review of five years experience at a university hospital in Norway. Berstad A, et al. **J Physiol Pharmacol** 1996 Mar;47(1):31–49 (45 ref.)

Strategies for Helicobacter pylori eradication in 1995: a review of international and Belgian experience. Deltenre M, et al. **J Physiol Pharmacol** 1996 Mar;47(1):59–69 (66 ref.)

Critical evaluation of the treatment of peptic ulcer diseases associated with Helicobacter pylori infection. Gabryelewicz A. **J Physiol Pharmacol** 1996 Mar;47(1):51–8 (44 ref.)

Consensus conference. Medical treatment of peptic ulcer disease. Practice guidelines. Practice Parameters Committee of the American College of Gastroenterology [published erratum appears in JAMA 1996 May 1;275(17):1314] Soll AH. **JAMA** 1996 Feb 28;275(8):622–9 (99 ref.)

Stress bleeding prophylaxis in the ICU: obligate or obsolete? [editorial] Bonten MJ, et al. **Neth J Med** 1996 Jan;48(1):4–7 (24 ref.)

Helicobacter pylori eradication: unravelling the facts. Dixon JS. **Scand J Gastroenterol Suppl** 1995;212:48–62 (244 ref.)

Quality of life and cost of therapy in reflux disease. Glise H. **Scand J Gastroenterol Suppl** 1995;210:38–42 (33 ref.)

Sucralfate: prophylaxis of mucosal damage during cancer therapy. Henriksson R, et al. **Scand J Gastroenterol Suppl** 1995;210:45–7 (29 ref.)

Long-term strategies for peptic ulcer. Korman MG. **Scand J Gastroenterol Suppl** 1995;210:60–3 (39 ref.)

Helicobacter pylori and peptic ulcer. Korman MG, et al. **Scand J Gastroenterol Suppl** 1995;210:92–6 (61 ref.)

Sucralfate in Helicobacter pylori eradication strategies. Lam SK, et al. **Scand J Gastroenterol Suppl** 1995;210:89–91 (19 ref.)

Growth factors: new 'endogenous drugs' for ulcer healing. Szabo S, et al. **Scand J Gastroenterol Suppl** 1995;210:15–8 (33 ref.)

Medical management of esophageal reflux. Hirschowitz BI. **Yale J Biol Med** 1994 May–Aug;67(3–4):223–31 (35 ref.)

[Proton pump blockers and their significance in gastroenterology] Dítě P, et al. **Vnitr Lek** 1995 Aug; 41(8):549–54 (23 ref.) (Eng. Abstr.) **(Cze)**

[What is the right therapeutic management of duodenal ulcer except in emergency?] Bouhnik Y. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S131–S134 (40 ref.) **(Fre)**

[Medical treatment of stomach ulcer except in emergency] Bretagne JF. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S73–S80 (68 ref.) **(Fre)**

[How to eradicate Helicobacter pylori?] Cayla R. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S119–S130 (83 ref.) **(Fre)**

[Treatment of stomach ulcer] Hudziak H. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S136–S142 (51 ref.) **(Fre)**

[Therapeutic management of duodenal ulcer except in emergency: eradication of Helicobacter pylori] Lamouliatte H. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S58–S63 (63 ref.) **(Fre)**

[Management of duodenal ulcer except in emergency: surgical treatment] Michot F, et al. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S64–S72 (87 ref.) **(Fre)**

[Therapeutic management of duodenal ulcer except in emergency cases: antisecretory treatment] Ruszniewski P. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S53–S57 (48 ref.) **(Fre)**

[Gastroesophageal reflux: current status of therapy] Seifert E. **Leber Magen Darm** 1995 Jul;25(4):156–60, 163 (55 ref.) (Eng. Abstr.) **(Ger)**

[Prevention and treatment of upper gastrointestinal bleeding by nonsteroidal anti-inflammatory drugs] Bar-Dayan Y, et al. **Harefuah** 1996 Apr 15;130(8):535–7 (34 ref.) **(Heb)**

[Losek (omeprazole), a new therapeutic agent in the treatment of peptic ulcer and hyperacidity states] Bulgakov SA. **Klin Med (Mosk)** 1995;73(5):11–6 (77 ref.) **(Rus)**

[Clinical aspects of Kvamatel (famotidine) administration] Golochevskaia VS. **Klin Med (Mosk)** 1996;74(1):45–7 (10 ref.) **(Rus)**

[Omeprazole and amoxycillin in the eradicating treatment of Helicobacter pylori] Gisbert JP, et al. **Rev Clin Esp** 1995 Nov;195(11):787–91 (74 ref.) **(Spa)**

ANTIVENINS

Heterologous antisera and antivenins are essential biologicals: perspectives on a worldwide crisis. Wilde H, et al. **Ann Intern Med** 1996 Aug 1;125(3):233–6 (22 ref.)

ANTIVIRAL AGENTS

see related
REVERSE TRANSCRIPTASE INHIBITORS

Recent development in the design of antiviral agents. Saunders J, et al. **Med Res Rev** 1995 Nov;15(6):497–531 (86 ref.)

[Biological study of fullerene C60] Huang WD, et al. **Sheng Li Ko Hsueh Chin Chan** 1995 Oct;26(4):367–9 (10 ref.) **(Chi)**

[Non-nucleoside antiretroviral agents] Sereni D, et al. **Presse Med** 1996 Mar 2–9;25(8):361–4, 366–9 (29 ref.) (Eng. Abstr.) **(Fre)**

[Progress on antiviral agents] Shigeta S. **Nippon Naika Gakkai Zasshi** 1995 Sep 10;84(9):1555–8 (2 ref.) **(Jpn)**

[Design of S-adenosylhomocystein hydrolase (SHAase) inhibitors as potent anti-RNA viral agents] Shuto S. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1261–7 (27 ref.) **(Jpn)**

[Didanosine] **Enferm Infecc Microbiol Clin** 1995 Oct; 13(8):487–90 (0 ref.) **(Spa)**

ADMINISTRATION & DOSAGE

Combination therapy for HIV-1 infection-overview: preclinical and clinical analysis of antiretroviral combinations. Johnson VA. **Antiviral Res** 1996 Jan; 29(1):35–9 (21 ref.)

Clinical management of herpes zoster in the elderly patient. Beutner KR. **Compr Ther** 1996 Mar;22(3):183–6 (6 ref.)

Targeting HIV with liposome-encapsulated antivirals [editorial] Désormeaux A, et al. **Int J Med Microbiol Virol Parasitol Infect Dis** 1995 Apr; 282(3):225–31 (15 ref.)

[Therapeutic effects of interferon on chronic hepatitis C from the aspect of dosage and method of administration] Shoji S, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:997–1000 (10 ref.) **(Jpn)**

[A case of Guillain-Barré syndrome associated with anti-GM2 antibody due to cytomegalovirus infection—special reference to the effect of ganciclovir]

Niwa K, et al. **Rinsho Shinkeigaku** 1995 Jun;35(6):652–6 (18 ref.) (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Nephrogenic diabetes insipidus and renal tubular acidosis secondary to foscarnet therapy. Navarro JF, et al. **Am J Kidney Dis** 1996 Mar;27(3):431–4 (16 ref.)

Cutaneous side effects associated with interferon-alpha therapy: a review. Chang LW, et al. **Cutis** 1995 Sep; 56(3):144 (14 ref.)

Primary biliary cirrhosis induced by interferon-alpha therapy for hepatitis C virus infection. D'Amico E, et al. **Dig Dis Sci** 1995 Oct;40(10):2113–6 (20 ref.)

Does interferon precipitate rejection of liver allografts? [editorial] Min AD, et al. **Hepatology** 1995 Oct;22(4 Pt 1):1333–5 (22 ref.)

Sarcoidosis after interferon therapy for chronic active hepatitis C. Teragawa H, et al. **Intern Med** 1996 Jan; 35(1):19–23 (20 ref.)

HIV medicine: drug side effects and interactions. Bates CM. **Postgrad Med J** 1996 Jan;72(843):30–6 (27 ref.)

[Depressive disorders and interferon alpha (editorial)] Hardy P. **Gastroenterol Clin Biol** 1996;20(3):255–7 (13 ref.) **(Fre)**

[Side effects of interferon-alpha] Vial T, et al. **Gastroenterol Clin Biol** 1996;20(5):462–89 (305 ref.) **(Fre)**

[Adverse effect of interferon therapy and its prevention] Sainokami S, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:1026–33 (9 ref.) **(Jpn)**

CHEMICAL SYNTHESIS

Design and synthesis of substrate-based peptidomimetic human immunodeficiency virus protease inhibitors containing the hydroxymethylcarbonyl isostere. Kiso Y. **Biopolymers** 1996;40(2):235–44 (27 ref.)

Non-nucleoside anti-HIV-1 reverse transcriptase inhibitors (NNRTIs): a chemical survey from lead compounds to selected drugs for clinical trials. Artico M. **Farmaco** 1996 May;51(5):305–31 (92 ref.)

CHEMISTRY

[Human interferon: molecular mechanisms of antiviral activities] Yoshida I. **Nippon Rinsho** 1995 Sep;53 Suppl:909–22 (40 ref.) **(Jpn)**

DIAGNOSTIC USE

Novel therapeutic and diagnostic applications of hypocrellins and hypericins. Diwu Z. **Photochem Photobiol** 1995 Jun; 61(6):529–39 (118 ref.)

METABOLISM

Metabolism of Zidovudine. Veal GJ, et al. **Gen Pharmacol** 1995 Nov;26(7):1469–75 (54 ref.)

Hepatic purine and pyrimidine metabolism: implications for antiviral chemotherapy of viral hepatitis. Shaw T, et al. **Liver** 1995 Aug;15(4):169–84 (117 ref.)

PHARMACOKINETICS

Valacyclovir HCl (Valtrex): an acyclovir prodrug with improved pharmacokinetics and better efficacy for treatment of zoster. Smiley ML, et al. **Adv Exp Med Biol** 1996;394:33–9 (23 ref.)

Pharmacokinetics of new antiherpetic agents. Rolan P. **Clin Pharmacokinet** 1995 Nov;29(5):333–40 (32 ref.)

Pharmacokinetic optimisation of antiretroviral therapy in patients with HIV infection. Stretcher BN. **Clin Pharmacokinet** 1995 Jul;29(1):46–65 (135 ref.)

Drug interactions with antiviral drugs. Taburet AM, et al. **Clin Pharmacokinet** 1996 May;30(5):385–401 (101 ref.)

Iontophoresis for enhancing penetration of dermatologic and antiviral drugs. Gangarosa LP Sr, et al. **J Dermatol** 1995 Nov;22(11):865–75 (39 ref.)

Passive and facilitative transport of nucleobases, nucleosides, and oligonucleotides--application to antiviral and other therapies. Brewster ME, et al. **NIDA Res Monogr** 1995; 154:61–85 (62 ref.)

PHARMACOLOGY

Cytomegalovirus: genetics of drug resistance. Biron KK. **Adv Exp Med Biol** 1996;394:135–43 (43 ref.)

Saquinavir: an HIV proteinase inhibitor. Bragman K. **Adv Exp Med Biol** 1996;394:305–17 (25 ref.)

Antiviral drug resistance in herpes simplex virus. Coen DM. **Adv Exp Med Biol** 1996;394:49–57 (15 ref.)

In vivo selection of HIV-1 variants with reduced susceptibility to the protease inhibitor L-735,524 and related compounds. Emini EA, et al. **Adv Exp Med Biol** 1996;394:327–31 (8 ref.)

Delavirdine mesylate, a potent non-nucleoside HIV-1 reverse transcriptase inhibitor. Freimuth WW. **Adv Exp Med Biol** 1996;394:279–89 (42 ref.)

A preclinical and clinical overview of the nucleotide-based antiviral agent cidofovir (HPMPC). Lalezari JP, et al. **Adv Exp Med Biol** 1996;394:105–15 (26 ref.)

Promising anti-HIV compounds in preclinical or early clinical development. Litterst C. **Adv Exp Med Biol** 1996; 394:397–404 (16 ref.)

Antiretroviral drug resistance: mechanisms, pathogenesis, clinical significance. Richman DD. **Adv Exp Med Biol** 1996; 394:383–95 (94 ref.)

Treatment of acyclovir-resistant herpes simplex and varicella zoster virus infections. Safrin S. **Adv Exp Med Biol** 1996; 394:59–66 (44 ref.)

Sorivudine: a potent inhibitor of varicella zoster virus replication. Whitley RJ. **Adv Exp Med Biol** 1996;394:41–4 (11 ref.)

Discovery and in vitro development of AIDS antiviral drugs as biopharmaceuticals. Rice WG, et al. **Adv Pharmacol** 1995;33:389–438 (204 ref.)

Structural mechanisms of HIV drug resistance. Erickson JW, et al. **Annu Rev Pharmacol Toxicol** 1996;36:545–71 (74 ref.)

Valacyclovir: a review of its antiviral activity, pharmacokinetic properties, and clinical efficacy. Beutner KR. **Antiviral Res** 1995 Dec;28(4):281–90 (29 ref.)

Models of antiviral resistance. Kimberlin DW, et al. **Antiviral Res** 1995 Apr;26(4):415–22 (23 ref.)

Antiviral resistance in clinical practice. Kimberlin DW, et al. **Antiviral Res** 1995 Apr;26(4):423–38 (64 ref.)

Molecular mechanisms of antiviral resistance. Kimberlin DW, et al. **Antiviral Res** 1995 Apr;26(4):369–401 (79 ref.)

Assays for antiviral drug resistance. Kimberlin DW, et al. **Antiviral Res** 1995 Apr;26(4):403–13 (23 ref.)

Antiretroviral activity of stavudine (2',3'-didehydro-3'-deoxythymidine, D4T). Riddler SA, et al. **Antiviral Res** 1995 Jun;27(3):189–203 (48 ref.)

Clinical significance of drug resistance in human immunodeficiency virus. Richman DD. **Clin Infect Dis** 1995 Oct;21 Suppl 2:S166–9 (26 ref.)

Molecular detection of human cytomegalovirus and determination of genotypic ganciclovir resistance in clinical specimens. Spector SA, et al. **Clin Infect Dis** 1995 Oct;21 Suppl 2:S170–3 (22 ref.)

Interferon-alpha-2a. A review of its pharmacological properties and therapeutic use in the management of viral hepatitis. Haria M, et al. **Drugs** 1995 Nov;50(5):873–96 (149 ref.)

Drug resistance in cytomegalovirus: current knowledge and implications for patient management. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996;12 Suppl 1:S1–22 (81 ref.)

Viral resistance and the selection of antiretroviral combinations. Larder BA. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995;10 Suppl 1:S28–33 (28 ref.)

Development of vaginal microbicides for the prevention of heterosexual transmission of HIV. Pauwels R, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Mar 1;11(3):211–21 (70 ref.)

Rapid screening of antiretroviral combinations. St Clair M, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995; 10 Suppl 1:S24–7 (15 ref.)

Closing in on human immunodeficiency virus-1 [see comments] Mellors JW. **Nat Med** 1996 Mar;2(3):274–5 (23 ref.) Comment in: Nat Med 1996 May;2(5):490.

[Active antiviral agents against human cytomegalovirus and their use in pediatrics] Mazeron MC, et al. **Arch Pediatr** 1996;3 Suppl 1:309s–311s (12 ref.) **(Fre)**

[Update on the use of interferons in clinical practice] Lauta VM. **Clin Ter** 1995 Jun-Jul;146(6-7):393–448 (160 ref.) (Eng. Abstr.) **(Ita)**

[Anti-hemophilia drugs: from cryoprecipitate to factor VIII concentrates of high purity] Gutsalo AE, et al. **Ukr Biokhim Zh** 1995 Jan-Feb;67(1):3–13 (62 ref.) (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Update on therapy of influenza and rhinovirus infections. Arruda E, et al. **Adv Exp Med Biol** 1996;394:175–87 (93 ref.)

Famciclovir: efficacy in zoster and issues in the assessment of pain. Boon RJ, et al. **Adv Exp Med Biol** 1996;394:17–31 (37 ref.)

Current clinical experience with nevirapine for HIV infection. Carr A, et al. **Adv Exp Med Biol** 1996; 394:299–304 (17 ref.)

Efficacy of combination antiretroviral therapy. Collier AC. **Adv Exp Med Biol** 1996;394:355–72 (100 ref.)

Subclinical shedding of HSV: its potential for reduction by antiviral therapy. Corey L, et al. **Adv Exp Med Biol** 1996; 394:11–6 (7 ref.)

Zidovudine: anno 1995. Danner SA. **Adv Exp Med Biol** 1996; 394:225–43 (114 ref.)

Oral ganciclovir for cytomegalovirus infections. Follansbee SE, et al. **Adv Exp Med Biol** 1996;394:93–103 (10 ref.)

Stavudine (d4T, Zerit). Friedland G, et al. **Adv Exp Med Biol** 1996;394:271–7 (21 ref.)

Current management of cytomegalovirus retinitis in AIDS update on ganciclovir and foscarnet for CMV infections. Jacobson MA. **Adv Exp Med Biol** 1996;394:85–92 (28 ref.)

The clinical use of didanosine. Kahn J. **Adv Exp Med Biol** 1996;394:245–56 (47 ref.)

Use of antiretroviral therapy in children and pregnant women. McKinney RE Jr. **Adv Exp Med Biol** 1996; 394:345–54 (22 ref.)

Management of genital herpes. Mertz GJ. **Adv Exp Med Biol** 1996;394:1–10 (30 ref.)

Management of respiratory syncytial virus infections. Mills J. **Adv Exp Med Biol** 1996;394:163–74 (59 ref.)

Antiretroviral drug resistance: mechanisms, pathogenesis, clinical significance. Richman DD. **Adv Exp Med Biol** 1996; 394:383–95 (94 ref.)

New initiatives in combination antiretroviral chemotherapy. Rooney JF, et al. **Adv Exp Med Biol** 1996;394:373–82 (29 ref.)

Treatment of acyclovir-resistant herpes simplex and varicella zoster virus infections. Safrin S. **Adv Exp Med Biol** 1996; 394:59–66 (44 ref.)

ddC (zalcitabine). Skowron G. **Adv Exp Med Biol** 1996; 394:257–69 (49 ref.)

Valacyclovir HCl (Valtrex): an acyclovir prodrug with improved pharmacokinetics and better efficacy for treatment of zoster. Smiley ML, et al. **Adv Exp Med Biol** 1996;394:33–9 (23 ref.)

Therapy for chronic hepatitis B infection. Terrault NA, et al. **Adv Exp Med Biol** 1996;394:189–205 (129 ref.)

Controversies in initiating anti-retroviral therapy and in the use of combination therapies. Volberding PA. **Adv Exp Med Biol** 1996;394:333–43 (14 ref.)

Prophylaxis and treatment of CMV infections in transplantation. Zaia JA. **Adv Exp Med Biol** 1996; 394:117–34 (72 ref.)

Management of cytomegalovirus disease. Danner SA. **AIDS** 1995 Dec;9 Suppl 2:S3–S8 (16 ref.)

Drug-resistance patterns of saquinavir and other HIV proteinase inhibitors. Roberts NA. **AIDS** 1995 Dec;9 Suppl 2:27–S32 (34 ref.)

Correlation between viral load measurements and outcome in clinical trials of antiviral drugs. Schooley RT. **AIDS** 1995 Dec;9 Suppl 2:S15–S19 (21 ref.)

Clinical experience with saquinavir. Vella S. **AIDS** 1995 Dec; 9 Suppl 2:S21–S25 (22 ref.)

New developments in antiretroviral drug therapy for HIV-1 infections. Johnson VA. **AIDS Clin Rev** 1995–96;:305–46 (106 ref.)

HIV viral load quantification, HIV resistance, and antiretroviral therapy. Katzenstein DA, et al. **AIDS Clin Rev** 1995–96;:277–303 (107 ref.)

Prophylaxis for occupational exposure to HIV. Gerberding JL. **Ann Intern Med** 1996 Sep 15;125(6):497–501 (31 ref.)

Viral dynamics of HIV: implications for drug development and therapeutic strategies. Havlir DV, et al. **Ann Intern Med** 1996 Jun 1;124(11):984–94 (112 ref.)

Consensus symposium on combined antiviral therapy. Lisbon, Portugal, July 25-27. **Antiviral Res** 1996 Jan;29(1):3–122 (0 ref.)

Consensus symposium on combined antiviral therapy. International Society for Antiviral Research and the National Institutes of Allergy and Infectious Diseases. de Jong MD, et al. **Antiviral Res** 1996 Jan;29(1):5–29 (70 ref.)

Summary: antiviral treatment of hepatitis C virus. Dusheiko GM. **Antiviral Res** 1996 Jan;29(1):77–82 (30 ref.)

Herpetic eye disease study. You can help [editorial] Dawson CR, et al. **Arch Ophthalmol** 1996 Jan;114(1):89–90 (8 ref.)

Antiretroviral therapy of human immunodeficiency virus type-1 (HIV-1) infection. Emery S, et al. **Aust N Z J Med** 1995 Aug;25(4):344–9 (41 ref.)

New strategies for treating AIDS. Sandstrom PA, et al. **Bioessays** 1996 May;18(5):343–6 (20 ref.)

Zidovudine therapy in HIV infection: which patients should be treated and when. Barry MG, et al. **Br J Clin Pharmacol** 1995 Aug;40(2):107–10 (39 ref.)

The role of antiretroviral therapy in the management of HIV infection in women. Mofenson LM. **Clin Obstet Gynecol** 1996 Jun;39(2):361–85 (113 ref.)

The diagnosis and management of perinatal HIV infection. Nesheim SR. **Clin Obstet Gynecol** 1996 Jun;39(2):396–410 (84 ref.)

Therapeutic applications of alpha interferon for chronic viral hepatitis in pediatric patients. Kay MH, et al. **Clin Pediatr (Phila)** 1995 Jul;34(7):372–9 (50 ref.)

The treatment of multiple sclerosis: current and future. Polman CH, et al. **Curr Opin Neurol** 1995 Jun;8(3):200–9 (87 ref.)

Use of penciclovir and famciclovir in the management of genital herpes. Sacks SL. **Curr Probl Dermatol** 1996; 24:219–26 (34 ref.)

Aciclovir and its l-valyl ester, valaciclovir. Smiley ML, et al. **Curr Probl Dermatol** 1996;24:209–18 (56 ref.)

Therapeutic approaches to HIV infection based on virus structure and the host pathogen interaction. Pauza CD, et al. **Curr Top Microbiol Immunol** 1995;202:117–32 (94 ref.)

Interferon-alpha-2a. A review of its pharmacological properties and therapeutic use in the management of viral hepatitis. Haria M, et al. **Drugs** 1995 Nov;50(5):873–96 (149 ref.)

Famciclovir. A review of its pharmacological properties and therapeutic efficacy in herpesvirus infections. Perry CM, et al. **Drugs** 1995 Aug;50(2):396–415 (64 ref.)

Antiviral therapy of acute herpes zoster in older patients. Herne K, et al. **Drugs Aging** 1996 Feb;8(2):97–112 (89 ref.)

Ups and downs--and ups in the antiviral therapy of HIV infection. Weller IV, et al. **Genitourin Med** 1996 Feb; 72(1):2–5 (24 ref.)

Long-term effect of interferon alpha alone or after prednisone withdrawal in chronic hepatitis B. Interim report and review of the literature. Gonzalez-Mateos F, et al. **Hepatogastroenterology** 1995 Nov-Dec;42(6):893–9 (25 ref.)

Early treatment of herpes zoster. Tyring SK. **Hosp Pract (Off Ed)** 1996 Jul 15;31(7):137–44 (0 ref.)

Controversies in the treatment of cytomegalovirus retinitis: foscarnet versus ganciclovir. Jabs DA. **Infect Agents Dis** 1995 Sep;4(3):131–42 (63 ref.)

Herpes simplex virus resistance to acyclovir: clinical relevance. Pottage JC Jr, et al. **Infect Agents Dis** 1995 Sep; 4(3):115–24 (111 ref.)
Antiviral agents in dermatology: current status and future prospects. Memar OM, et al. **Int J Dermatol** 1995 Sep; 34(9):597–606 (98 ref.)
Management of cytomegalovirus infection. The Jefferiss Wing Therapeutics and Protocols Group. Fisher M, et al. **Int J STD AIDS** 1995 Sep–Oct;6(5):313–9 (28 ref.)
Oral ganciclovir: a new option for patients with CMV retinitis [editorial] Fisher M, et al. **Int J STD AIDS** 1996 Jan–Feb;7(1):1–3 (19 ref.)
Antiviral chemotherapy in genital herpes simplex virus infections. Patel R, et al. **Int J STD AIDS** 1995 Sep–Oct; 6(5):320–8 (78 ref.)
Failure of antiretroviral therapy: role of viral and cellular factors. Cinatl J Jr, et al. **Intervirology** 1994;37(6):307–14 (76 ref.)
Combination therapy from a clinician's perspective. Goebel FD. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995; 10 Suppl 1:S62–8 (38 ref.)
Measuring viral load in the clinical setting. Harrigan R. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995;10 Suppl 1:S34–40 (26 ref.)
Studies of zidovudine in combination with didanosine and zalcitabine. Jablonowski H. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995;10 Suppl 1:S52–6 (17 ref.)
Therapeutic interventions in primary HIV infection. Kinloch-de Loës S, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995;10 Suppl 1:S69–76 (44 ref.)
Triple combinations: present and future. Lange JM. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995;10 Suppl 1:S77–82 (24 ref.)
Current HIV clinical trial design issues. Lange JM. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995;10 Suppl 1:S47–51 (24 ref.)
Individualization of therapy using viral markers. Merigan T. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995;10 Suppl 1:S41–6 (28 ref.)
HIV pathogenesis and treatment strategies. Vella S. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995;10 Suppl 1:S20–3 (22 ref.)
Treatment options for chronic hepatitis C infection. James DG. **J Antimicrob Chemother** 1995 Oct;36(4):591–3 (19 ref.)
Oltipraz, a novel inhibitor of human immunodeficiency virus type 1 (HIV-1) replication. Prochaska HJ, et al. **J Cell Biochem Suppl** 1995;22:117–25 (40 ref.)
Future studies of combination therapy for chronic hepatitis C: optimizing response rates for each hepatitis C population. Main J. **J Hepatol** 1995;23 Suppl 2:32–5; discussion 35–6 (18 ref.)
Antiviral therapy for chronic hepatitis C viral infection. Sherlock S. **J Hepatol** 1995;23 Suppl 2:3–7 (31 ref.)
Approaches to the development of novel inhibitors of hepatitis C virus replication. Clarke BE. **J Viral Hepat** 1995;2(1):1–8 (40 ref.)
Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society–USA. Carpenter CC, et al. **JAMA** 1996 Jul 10;276(2):146–54 (109 ref.)
HIV-associated respiratory diseases. Miller R. **Lancet** 1996 Aug 3;348(9023):307–12 (50 ref.)
Managing HIV. Part 4: Primary therapy. 4.1 Antiretroviral therapies for HIV. Crowe S, et al. **Med J Aust** 1996 Mar 4;164(5):290–5 (20 ref.)
Managing HIV. Antiretroviral therapy. Fulcher D, et al. **Med J Aust** 1996 May 20;164(10):607 (0 ref.)
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of human immunodeficiency virus type 1 (HIV-1) infections: strategies to overcome drug resistance development. de Clercq E. **Med Res Rev** 1996 Mar;16(2):125–57 (180 ref.)
Management of HIV infection. A 1995–96 overview for the clinician. Henry K. **Minn Med** 1995 Nov;78(11):17–24 (25 ref.)
Ganciclovir. Crumpacker CS. **N Engl J Med** 1996 Sep 5; 335(10):721–9 (86 ref.)
Efficacy of famciclovir in the treatment of herpes zoster: reduction of pain associated with zoster. Boon RJ, et al. **Neurology** 1995 Dec;45(12 Suppl 8):S76–7 (9 ref.)
Sorivudine: a promising drug for the treatment of varicella-zoster virus infection. Whitley RJ. **Neurology** 1995 Dec;45(12 Suppl 8):S73–5 (10 ref.)
State of the art. Antiviral treatment of HIV infection. Bechtel-Boenning C. **Nurs Clin North Am** 1996 Mar; 31(1):1–13 (48 ref.)
Perinatal herpes: current status and obstetric management strategies. Scott LL. **Pediatr Infect Dis J** 1995 Oct; 14(10):827–32; discussion 832–5 (73 ref.)
Reassessment of the indications for ribavirin therapy in respiratory syncytial virus infections. American Academy of Pediatrics Committee on Infectious Diseases. **Pediatrics** 1996 Jan;97(1):137–40 (28 ref.)
Management of herpesvirus infections in the healthy host. Dudley MN. **Pharmacotherapy** 1995 Sep–Oct;15(5 Pt 2):43S–48S (31 ref.)
Novel therapeutic and diagnostic applications of hypocrellins and hypericins. Diwu Z. **Photochem Photobiol** 1995 Jun; 61(6):529–39 (118 ref.)
Why we should treat chronic viral hepatitis. King PD. **Postgrad Med** 1996 Sep;100(3):68–70, 73; discussion 73, 78 (13 ref.)
Chronic viral hepatitis and use of interferon. Whom are we treating? Koretz RL. **Postgrad Med** 1996 Sep;100(3):55–7, 61–2, 68 (11 ref.)
Combination antiretroviral therapy for the treatment of human immunodeficiency virus type-1 infection. Wilson CC, et al. **Proc Assoc Am Physicians** 1995 Apr;107(1):19–27 (85 ref.)
New developments in antiviral therapy for chronic hepatitis B infection. De Man RA, et al. **Scand J Gastroenterol Suppl** 1995;212:100–4 (26 ref.)
Update (1995) on clinical trials of antiviral therapy and prophylaxis for AIDS-related cytomegalovirus disease. Jacobson MA. **Scand J Infect Dis Suppl** 1995;99:96–9 (25 ref.)
Anti-infective therapy for viral pneumonia. Mahmood W, et al. **Semin Respir Infect** 1995 Dec;10(4):270–81 (39 ref.)
Prophylactic cytomegalovirus management strategies. Martin M. **Transplant Proc** 1995 Oct;27(5 Suppl 1):23–7 (30 ref.)
Role of immunoglobulins and new antivirals in treatment of cytomegalovirus infection. Paya CV. **Transplant Proc** 1995 Oct;27(5 Suppl 1):28–30 (21 ref.)
[New medication for herpesvirus infections (editorial)] Vesikari T. **Duodecim** 1995;111(8):680, 683–4 (12 ref.) **(Fin)**
[Active antiviral agents against human cytomegalovirus and their use in pediatrics] Mazeron MC, et al. **Arch Pediatr** 1996;3 Suppl 1:309s–311s (12 ref.) **(Fre)**
[Compared efficiency of three strategies of management of chronic hepatitis C. Effect on the risk of cirrhosis 8 years after diagnosis] Michel P, et al. **Gastroenterol Clin Biol** 1996 Feb;20(1):47–54 (61 ref.) (Eng. Abstr.) **(Fre)**
[Current knowledge in the treatment of chronic hepatitis C] Pirotte J. **Rev Med Liege** 1995 Dec;50(12):501–4 (29 ref.) **(Fre)**
[Antiretroviral therapy in HIV infection] Jablonowski H. **Med Monatsschr Pharm** 1996 Jul;19(7):196–205 (38 ref.) **(Ger)**
[New strategies in anti-HIV therapy—consequences for the neurologist?] Enzensberger W, et al. **Nervenarzt** 1996 Jun; 67(6):506–8 (2 ref.) **(Ger)**
[New treatments in HIV] Turner D, et al. **Harefuah** 1996 Apr 1;130(7):467–70 (32 ref.) **(Heb)**
[Emergency drug therapy of meningoencephalitis] Kuzuhara S. **Nippon Naika Gakkai Zasshi** 1995 Nov 10;84(11):1837–42 (5 ref.) **(Jpn)**
[HCV-serotype and IFN response] Abe K, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:959–64 (10 ref.) **(Jpn)**
[Changes of serum 2',5'-oligoadenylate synthetase activity and neopterin during interferon treatment for chronic hepatitis C] Daito K, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:981–5 (16 ref.) **(Jpn)**
[Does interferon therapy on type C liver cirrhosis prevent the occurrence of hepatocellular carcinoma?] Harada H, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:754–8 (17 ref.) **(Jpn)**
[Fluctuation of hepatitis C virus quasispecies with interferon treatment and interferon-resistant variants in hepatitis C virus 1b] Sakuma I, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:930–5 (9 ref.) **(Jpn)**
[Leukoregulin—a new possibility in the treatment of virus infections and malignant tumors] Bojić I. **Vojnosanit Pregl** 1994 Nov–Dec;51(6):540–2 (20 ref.) **(Scr)**

TOXICITY

Mitochondrial toxicity of antiviral drugs. Lewis W, et al. **Nat Med** 1995 May;1(5):417–22 (66 ref.)

ANTRUM, PYLORIC see **PYLORIC ANTRUM**

ANTS

IMMUNOLOGY

Hypersensitivity to fire ant venom [see comments] Stafford CT. **Ann Allergy Asthma Immunol** 1996 Aug;77(2):87–95; quiz 96–9 (50 ref.) Comment in: Ann Allergy Asthma Immunol 1996 Aug;77(2):85.

METABOLISM

Storage proteins in ants (Hymenoptera:Formicidae). Wheeler DE, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1995 Sep;112(1):15–9 (41 ref.)

ANURA

ANATOMY & HISTOLOGY

Amphibian parathyroids: morphological and functional aspects. Srivastav AK, et al. **Microsc Res Tech** 1995 Oct 1;32(2):79–90 (113 ref.)

METABOLISM

[Epibatidine—a nicotine-related, analgesic alkaloid from poison-dart frogs] Müller CE. **Pharm Unserer Zeit** 1996 Apr;25(2):85–92 (27 ref.) **(Ger)**

PARASITOLOGY

Parasitic disease in amphibians: control by the regulation of worm burdens. Tinsley RC. **Parasitology** 1995;111 Suppl:S153–78 (62 ref.)

PHYSIOLOGY

Nineteenth century research on naturally occurring cell death and related phenomena. Clarke PG, et al. **Anat Embryol (Berl)** 1996 Feb;193(2):81–99 (143 ref.)
Alkaloids from frog skins: selective probes for ion channels and nicotinic receptors. Daly JW. **Braz J Med Biol Res** 1995 Oct;28(10):1033–42 (28 ref.)
Molecular mechanisms of gustatory transduction in frog taste cells. Sato T, et al. **Prog Neurobiol** 1995 Jun;46(2-3):239–87 (100 ref.)
Modular organization of motor behavior in the frog's spinal cord. Bizzi E, et al. **Trends Neurosci** 1995 Oct;18(10):442–6 (30 ref.)

ANUS

see related
PROCTOSCOPY

Squamous cell carcinoma complicating perianal hidradenitis suppurativa. Pérez-Díaz D, et al. **Int J Colorectal Dis** 1995; 10(4):225–8 (23 ref.)
[Anal migration of ventriculo-peritoneal shunt catheter. Apropos of 3 cases] Sami A, et al. **Neurochirurgie** 1995; 41(4):315–8 (25 ref.) (Eng. Abstr.) **(Fre)**

ABNORMALITIES

Familial arhinia, choanal atresia, and microphthalmia. Thiele H, et al. **Am J Med Genet** 1996 May 3;63(1):310–3 (7 ref.)
The Currarino syndrome—hereditary transmitted syndrome of anorectal, sacral and presacral anomalies. Case report and review of the literature. Köchling J, et al. **Eur J Pediatr Surg** 1996 Apr;6(2):114–9 (35 ref.)

PATHOLOGY

Risk of dysplasia in anal condyloma. Metcalf AM, et al. **Surgery** 1995 Oct;118(4):724–6 (14 ref.)
[Complications of the surgical treatment of hemorrhoids and its therapy] Corno F, et al. **Ann Ital Chir** 1995 Nov–Dec; 66(6):813–6 (15 ref.) (Eng. Abstr.) **(Ita)**

PHYSIOLOGY

Anorectal and pelvic floor function. Relevance of continence, incontinence, and constipation. Sagar PM, et al. **Gastroenterol Clin North Am** 1996 Mar;25(1):163–82 (102 ref.)

PHYSIOPATHOLOGY

[Anorectal manometry in hemorrhoidal disease] Girardi S, et al. **Ann Ital Chir** 1995 Nov–Dec;66(6):757–60 (17 ref.) (Eng. Abstr.) **(Ita)**

SURGERY

Effect of some abdominal surgical operations on small bowel motility in humans: our experience. Bassotti G, et al. **J Clin Gastroenterol** 1995 Oct;21(3):211–6 (86 ref.)

ULTRASONOGRAPHY

Anal endosonography in faecal incontinence [editorial] Bartram C. **Endoscopy** 1996 Feb;28(2):259–60 (26 ref.)

ANUS, ARTIFICIAL see **COLOSTOMY**

ANUS DISEASES

Anorectal disorders. Five common causes of pain, itching, and bleeding. Metcalf A. **Postgrad Med** 1995 Nov; 98(5):81–4, 87–9, 92–4 (19 ref.)
[Hemorrhoidal thrombosis and perianal hematoma: diagnosis and treatment] Delaini GG, et al. **Ann Ital Chir** 1995 Nov–Dec;66(6):783–5 (8 ref.) (Eng. Abstr.) **(Ita)**

DIAGNOSIS

Clinical aspects of genito-anal papillomavirus infection with a focus on when and how to investigate. von Krogh G. **Curr Probl Dermatol** 1996;24:140–50 (42 ref.)
[Condylomata acuminata in children: a case report, update and management protocol] Niguez Carbonell JC, et al. **An Esp Pediatr** 1996 Mar;44(3):292–4 (20 ref.) **(Spa)**

PATHOLOGY

Perianal Crohn's disease in children and adolescents. Tolia V. **Am J Gastroenterol** 1996 May;91(5):922–6 (32 ref.)
Perianal lymphangioma circumscriptum mistaken for genital warts. Darmstadt GL. **Pediatrics** 1996 Sep;98(3 Pt 1):461–3 (18 ref.)

SURGERY

The management of perianal diseases. Fazio VW, et al. **Adv Surg** 1996;29:59–78 (70 ref.)
Surgery for anal lesions in HIV-infected patients. Weiss EG, et al. **Ann Med** 1995 Aug;27(4):467–75 (44 ref.)

THERAPY

Current therapy for recurrent and extensive anal warts.

Congilosi SM, et al. **Dis Colon Rectum** 1995 Oct; 38(10):1101–7 (51 ref.)

ULTRASONOGRAPHY

Anal endosonography in faecal incontinence [editorial] Bartram C. **Endoscopy** 1996 Feb;28(2):259–60 (26 ref.)

ANUS, IMPERFORATE

DIAGNOSIS

MRI and radiographic findings in Currarino's triad. Pfluger T, et al. **Pediatr Radiol** 1996;26(8):524–7 (21 ref.)

[The Townes–Brocks syndrome] Arroyo Carrera I, et al. **An Esp Pediatr** 1996 Apr;44(4):364–6 (18 ref.) **(Spa)**

RADIOGRAPHY

The various types of anorectal fistula in male imperforate anus. Currarino G. **Pediatr Radiol** 1996;26(8):512–22; discussion 523 (35 ref.)

SURGERY

Management of congenital anorectal malformations. Wakhlu AK. **Indian Pediatr** 1995 Nov;32(11):1239–42 (0 ref.)

[Surgery of atresia of the gastrointestinal tract] Joppich I, et al. **Chirurg** 1996 Jun;67(6):576–83 (10 ref.) (Eng. Abstr.) **(Ger)**

ANUS NEOPLASMS

[Anus cancer] Keldsen N, et al. **Ugeskr Laeger** 1996 Jul 8; 158(28):4073–6 (40 ref.) (Eng. Abstr.) **(Dan)**

[Cancer of the anal canal] Gérard JP, et al. **Bull Cancer Radiother** 1990;77(1):23–31 (41 ref.) **(Fre)**

[Anal cancer. A review] Tanum G. **Tidsskr Nor Laegeforen** 1996 May 20;116(13):1567–70 (31 ref.) (Eng. Abstr.) **(Nor)**

EPIDEMIOLOGY

Risk of dysplasia in anal condyloma. Metcalf AM, et al. **Surgery** 1995 Oct;118(4):724–6 (14 ref.)

PATHOLOGY

Patterns of recurrence in squamous cell carcinoma of the anal canal. Luna-Pérez P, et al. **Arch Med Res** 1995 Autumn;26(3):213–9 (20 ref.)

Perianal lymphangioma circumscriptum mistaken for genital warts. Darmstadt GL. **Pediatrics** 1996 Sep;98(3 Pt 1):461–3 (18 ref.)

Intradural metastasis to the cauda equina from carcinoma of the anus. Cho DY, et al. **Spine** 1995 Nov 1;20(21):2341–4 (15 ref.)

RADIOTHERAPY

[Interdisciplinary therapy of anal carcinoma] Döker R, et al. **Schweiz Rundsch Med Prax** 1995 Nov 21;84(47):1389–97 (43 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

[Current treatment of cancers of the anal canal] Gérard JP, et al. **Ann Chir** 1995;49(5):363–8; discussion 368–72 (39 ref.) (Eng. Abstr.) **(Fre)**

ANUS PROLAPSE see **RECTAL PROLAPSE**

ANXIETY

Aggression, anxiety and vocalizations in animals: GABAA and 5-HT anxiolytics. Miczek KA, et al. **Psychopharmacology (Berl)** 1995 Sep;121(1):38–56 (161 ref.)

COMPLICATIONS

Treatment strategies for anxiety, stress, and developmental conflict during reproduction [see comments] Lederman RP. **Behav Med** 1995 Fall;21(3):113–22 (69 ref.) Comment in: Behav Med 1996 Fall;21(3):123–9.

Relationship of anxiety, stress, and psychosocial development to reproductive health [see comments] Lederman RP. **Behav Med** 1995 Fall;21(3):101–12 (110 ref.) Comment in: Behav Med 1995 Fall;21(3):123–9.

DIAGNOSIS

Evaluation and treatment of anxiety symptoms and disorders in alcoholics. Kranzler HR. **J Clin Psychiatry** 1996;57 Suppl 7:15–21; discussion 22–4 (60 ref.)

Recognition and management of anxiety and depression in elderly patients [see comments] Martin LM, et al. **Mayo Clin Proc** 1995 Oct;70(10):999–1006 (09 ref.) Comment in: Mayo Clin Proc 1996 Apr;71(4):424.

[New concepts relating to histochemistry of the serotonergic neural systems of the raphe nucleus] Villar MJ. **Acta Psiquiatr Psicol Am Lat** 1994 Dec;40(4):293–300 (36 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Evaluation and treatment of anxiety symptoms and disorders in alcoholics. Kranzler HR. **J Clin Psychiatry** 1996;57 Suppl 7:15–21; discussion 22–4 (60 ref.)

ETIOLOGY

Sundown syndrome: etiology and management. Burney-Puckett M. **J Psychosoc Nurs Ment Health Serv** 1996 May;34(5):40–3 (15 ref.)

Anxiety and panic in recreational scuba divers. Morgan WP. **Sports Med** 1995 Dec;20(6):398–421 (117 ref.)

IMMUNOLOGY

Stress and the immune system in the etiology of anxiety and depression. Leonard BE, et al. **Pharmacol Biochem Behav** 1996 May;54(1):299–303 (74 ref.)

NURSING

Theoretical and practical considerations on the use of reassurance in the nursing management of anxious patients. Teasdale K. **J Adv Nurs** 1995 Jul;22(1):79–86 (61 ref.)

PHYSIOPATHOLOGY

Cholecystokinin and anxiety: promises and pitfalls. Rodgers RJ, et al. **Crit Rev Neurobiol** 1995;9(4):345–69 (202 ref.)

Stress and the immune system in the etiology of anxiety and depression. Leonard BE, et al. **Pharmacol Biochem Behav** 1996 May;54(1):299–303 (74 ref.)

PSYCHOLOGY

More than just a game: research developments and issues in competitive anxiety in sport. Jones G. **Br J Psychol** 1995 Nov;86 (Pt 4):449–78 (190 ref.)

Recent developments in anxiety, stress, and depression. File SE. **Pharmacol Biochem Behav** 1996 May;54(1):3–12 (156 ref.)

Role of 5-HT in stress, anxiety, and depression. Graeff FG, et al. **Pharmacol Biochem Behav** 1996 May;54(1):129–41 (112 ref.)

Exploration and predation models of anxiety: evidence from laboratory and wild species. Hendrie CA, et al. **Pharmacol Biochem Behav** 1996 May;54(1):13–20 (56 ref.)

A review of the validity and variability of the elevated plus-maze as an animal model of anxiety. Hogg S. **Pharmacol Biochem Behav** 1996 May;54(1):21–30 (56 ref.)

Of creatures large and small: size anxiety, psychic size, shame, and the analytic situation. Kilborne B. **Psychoanal Q** 1995 Oct;64(4):672–90 (24 ref.)

THERAPY

Anxiety and its control. Morse DR. **Int J Psychosom** 1995; 42(1–4):54–64 (40 ref.)

Sundown syndrome: etiology and management. Burney-Puckett M. **J Psychosoc Nurs Ment Health Serv** 1996 May;34(5):40–3 (15 ref.)

Recognition and management of anxiety and depression in elderly patients [see comments] Martin LM, et al. **Mayo Clin Proc** 1995 Oct;70(10):999–1006 (09 ref.) Comment in: Mayo Clin Proc 1996 Apr;71(4):424.

ANXIETY, DENTAL see **DENTAL ANXIETY**

ANXIETY DISORDERS

Anxiety disorders in children and adolescents. Black B. **Curr Opin Pediatr** 1995 Aug;7(4):387–91 (32 ref.)

Common anxiety disorders in children and adolescents. Martini DR. **Curr Probl Pediatr** 1995 Oct;25(9):271–80 (54 ref.)

Serotonin receptors and their function in sleep, anxiety disorders and depression. Leonard BE. **Psychother Psychosom** 1996 Mar–Apr;65(2):66–75 (75 ref.)

COMPLICATIONS

Psychiatric aspects of chronic pain. Eisendrath SJ. **Neurology** 1995 Dec;45(12 Suppl 9):S26–34; discussion S35–6 (36 ref.)

Feeling hopeless and helpless. When anxiety symptoms coexist with depressive disorder. Nesse RE. **Postgrad Med** 1996 Aug;100(2):163–6, 171–2, 175–7 (21 ref.)

DIAGNOSIS

Anxiety in medically ill older patients: a review and update. Hocking LB, et al. **Int J Psychiatry Med** 1995;25(3):221–38 (74 ref.)

Evaluation and treatment of anxiety symptoms and disorders in alcoholics. Kranzler HR. **J Clin Psychiatry** 1996;57 Suppl 7:15–21; discussion 22–4 (60 ref.)

Agitation as a possible expression of generalized anxiety disorder in demented elderly patients: toward a treatment approach. Mintzer JE, et al. **J Clin Psychiatry** 1996;57 Suppl 7:55–63; discussion 73–5 (79 ref.)

Overview of generalized anxiety disorder in the elderly. Schneider LS. **J Clin Psychiatry** 1996;57 Suppl 7:34–45; discussion 52–4 (56 ref.)

[Anxious-excited depression: a mixed affective syndrome] Koukopoulos A, et al. **Encephale** 1995 Dec;21 Spec No 6:33–6 (21 ref.) (Eng. Abstr.) **(Fre)**

[Anxiety disorders in the elderly—diagnostic problems and therapeutic prospects] Boerner RJ. **Z Gerontol Geriatr** 1995 Nov-Dec;28(6):435–43 (48 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Azapirones: an alternative to benzodiazepines for anxiety. Cadieux RJ. **Am Fam Physician** 1996 May 15;53(7):2349–53 (23 ref.)

The psychopharmacology of anxiety. Nutt DJ. **Br J Hosp Med** 1996 Feb 21–Mar 5;55(4):187–91 (19 ref.)

A review of the effects of moderate alcohol intake on the treatment of anxiety and mood disorders. Castaneda R, et al. **J Clin Psychiatry** 1996 May;57(5):207–12 (82 ref.)

Evaluation and treatment of anxiety symptoms and disorders in alcoholics. Kranzler HR. **J Clin Psychiatry** 1996;57 Suppl 7:15–21; discussion 22–4 (60 ref.)

The long-term management of generalized anxiety disorder: issues and dilemmas. Schweizer E, et al. **J Clin Psychiatry** 1996;57 Suppl 7:9–12; discussion 13–4 (45 ref.)

Epidemiology and psychopharmacology of anxiety in medical patients. Stoudemire A. **J Clin Psychiatry** 1996;57 Suppl 7:64–72; 73–5 (107 ref.)

Future directions in anxiolytic pharmacotherapy. Kunovac JL, et al. **Psychiatr Clin North Am** 1995 Dec;18(4):895–909 (90 ref.)

Generalized anxiety disorder. Longitudinal course and pharmacologic treatment. Schweizer E. **Psychiatr Clin North Am** 1995 Dec;18(4):843–57 (76 ref.)

[Treatment of generalized anxiety: new pharmacologic approaches] Boulenger JP. **Encephale** 1995 Nov-Dec; 21(6):459–66 (51 ref.) (Eng. Abstr.) **(Fre)**

[Pharmacotherapy of anxiety disorders] Bitter I. **Orv Hetil** 1995 Nov 5;136(45):2435–9 (19 ref.) (Eng. Abstr.) **(Hun)**

EPIDEMIOLOGY

Progress in the epidemiology of anxiety disorders. Eaton WW. **Epidemiol Rev** 1995;17(1):32–8 (55 ref.)

Psychiatric and physical morbidity effects of dementia caregiving: prevalence, correlates, and causes. Schulz R, et al. **Gerontologist** 1995 Dec;35(6):771–91 (90 ref.)

Generalized anxiety disorder: issues in epidemiology. Brawman-Mintzer O, et al. **J Clin Psychiatry** 1996;57 Suppl 7:3–8 (29 ref.)

Generalized anxiety and mixed anxiety-depression: association with disability and health care utilization. Roy-Byrne PP. **J Clin Psychiatry** 1996;57 Suppl 7:86–91 (33 ref.)

Epidemiology and psychopharmacology of anxiety in medical patients. Stoudemire A. **J Clin Psychiatry** 1996;57 Suppl 7:64–72; 73–5 (107 ref.)

ETIOLOGY

Research on the treatment of sexually abused children: a review and recommendations. Finkelhor D, et al. **J Am Acad Child Adolesc Psychiatry** 1995 Nov; 34(11):1408–23 (76 ref.)

[Stress and anxiety] González de Rivera y Revuelta JL. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1995 Nov-Dec;23(6):310–3 (33 ref.) (Eng. Abstr.) **(Spa)**

[Psychooncology: anxiety] Matías J, et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1995 Nov-Dec;23(6):305–9 (26 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

Serotonin receptor specificity in anxiety disorders. Lucki I. **J Clin Psychiatry** 1996;57 Suppl 6:5–10 (48 ref.)

Serotonin dysfunction disorders: a behavioral neurochemistry perspective. Petty F, et al. **J Clin Psychiatry** 1996;57 Suppl 8:11–6 (24 ref.)

Cholecystokinin in psychiatric research: a time for cautious excitement. Abelson JL. **J Psychiatr Res** 1995 Sep–Oct; 29(5):389–96 (60 ref.)

The neurobiology of anxiety disorders. Johnson MR, et al. **Psychiatr Clin North Am** 1995 Dec;18(4):681–725 (152 ref.)

PSYCHOLOGY

Primate models of anxiety. Longitudinal perspectives. Coplan JD, et al. **Psychiatr Clin North Am** 1995 Dec;18(4):727–43 (59 ref.)

The cultural context of anxiety disorders. Kirmayer LJ, et al. **Psychiatr Clin North Am** 1995 Sep;18(3):503–21 (88 ref.)

Anxiety disorders of childhood, Implications for adult psychopathology. Pollock RA, et al. **Psychiatr Clin North Am** 1995 Dec;18(4):745–66 (102 ref.)

The emotional Stroop task and psychopathology. Williams JM, et al. **Psychol Bull** 1996 Jul;120(1):3–24 (95 ref.)

THERAPY

Theoretical foundations of cognitive-behavior therapy for anxiety and depression. Brewin CR. **Annu Rev Psychol** 1996;47:33–57 (90 ref.)

Advances in the psychosocial treatment of anxiety disorders. Implications for national health care. Barlow DH, et al. **Arch Gen Psychiatry** 1996 Aug;53(8):727–35 (117 ref.)

The efficacy of psychosocial treatments in primary care. A review of randomized clinical trials. Brown C, et al. **Gen Hosp Psychiatry** 1995 Nov;17(6):414–24 (43 ref.)

Anxiety and its control. Morse DR. **Int J Psychosom** 1995; 42(1–4):54–64 (40 ref.)

Research on the treatment of sexually abused children: a review and recommendations. Finkelhor D, et al.

ANXIETY DISORDERS

J Am Acad Child Adolesc Psychiatry 1995 Nov; 34(11):1408–23 (76 ref.)
Issues in the transportability of treatment: the case of anxiety disorders in youths. Kendall PC, et al. **J Consult Clin Psychol** 1995 Oct;63(5):702–8 (60 ref.)
Treatment of anxiety disorders of childhood. Albano AM, et al. **Psychiatr Clin North Am** 1995 Dec;18(4):767–84 (90 ref.)
Cognitive–behavior therapy for generalized anxiety disorder. Harvey AG, et al. **Psychiatr Clin North Am** 1995 Dec; 18(4):859–70 (55 ref.)
Psychotherapeutic issues in long–term treatment of anxiety disorder patients. Shear MK. **Psychiatr Clin North Am** 1995 Dec;18(4):885–94 (90 ref.)
Anxiety in the elderly. Course and treatment. Sheikh JI, et al. **Psychiatr Clin North Am** 1995 Dec;18(4):871–83 (90 ref.)
[Cognitive experimental approach to anxiety disorders] Azaïs F. **Encephale** 1995 Sep–Oct;21(5):597–607 (35 ref.) (Eng. Abstr.) **(Fre)**

ANXIETY NEUROSES see **ANXIETY DISORDERS**

ANXIETY, SEPARATION

COMPLICATIONS

Factors in the etiology and pathogenesis of panic disorder: revisiting the attachment–separation paradigm. Shear MK. **Am J Psychiatry** 1996 Jul;153(7 Suppl):125–36 (64 ref.)

PSYCHOLOGY

Attachment and separation in young children. Field T. **Annu Rev Psychol** 1996;47:541–61 (45 ref.)
[Reflections on international adoption] Laurent A, et al. **Ann Med Psychol (Paris)** 1995 Oct;153(8):528–30; discussion 531 (2 ref.) (Eng. Abstr.) **(Fre)**

ANXIETY STATES, NEUROTIC see **ANXIETY DISORDERS**

ANXIOLYTIC AGENTS see **ANTI-ANXIETY AGENTS**

ANXIOLYTICS, BENZODIAZEPINE see **ANTI-ANXIETY AGENTS, BENZODIAZEPINE**

AORTA

see related
CORONARY ARTERY BYPASS

Iatrogenic aorto–coronary venous fistula as a complication of coronary artery bypass surgery: patient report and review of the literature. Calkins JB Jr, et al. **Cathet Cardiovasc Diagn** 1996 Jan;37(1):55–9 (19 ref.)
[Atherosclerotic disease of the aorta: a source of thromboembolism] Gur H, et al. **Harefuah** 1996 Mar 1; 130(5):339–43 (34 ref.) **(Heb)**
[Clinico–pathological studies and problems on para–aortic lymph node dissection—D4 dissection] Kitamura M, et al. **Nippon Geka Gakkai Zasshi** 1996 Apr;97(4):302–7 (15 ref.) (Eng. Abstr.) **(Jpn)**

ABNORMALITIES

Anomalous origin of coronary artery in association with aorticopulmonary window. D'Souza VJ, et al. **Pediatr Cardiol** 1996 Sep–Oct;17(5):316–8 (12 ref.)

INJURIES

Acute repair of aorta–innominate vein fistulas. Roye GD, et al. **J Trauma** 1995 Oct;39(4):753–6 (12 ref.)

PATHOLOGY

Magnetic resonance angiography of the aorta and renal arteries. Grist TM. **Magn Reson Imaging Clin N Am** 1993 Dec;1(2):253–69 (42 ref.)
Magnetic resonance of the heart and great vessels. de Roos A, et al. **Nat Med** 1995 Jul;1(7):711–3 (6 ref.)

PHYSIOPATHOLOGY

Aortic–based therapy for cardiac arrest. Paradis NA. **Ann Emerg Med** 1996 May;27(5):563–8 (42 ref.)
Increased protection of the ischemic myocardium by decreased aortic pressure. Nakamura Y, et al. **Jpn Heart J** 1995 Nov;36(6):689–97 (34 ref.)

SURGERY

Coarctation of the aorta. Repair with polytetrafluoroethylene patch aortoplasty. Backer CL, et al. **Circulation** 1995 Nov 1;92(9 Suppl):II132–6 (37 ref.)

AORTA, ABDOMINAL

Primary leiomyosarcoma of the abdominal aorta. Malone MD, et al. **J Vasc Surg** 1996 Sep;24(3):487–93 (36 ref.)
Ureteroarterial fistula: case report and review of the literature. Batter SJ, et al. **Urology** 1996 Sep;48(3):481–9 (35 ref.)

PATHOLOGY

Time–of–flight magnetic resonance angiography of aorta and renal arteries: state–of–the–art. Laissy JP, et al. **Eur J Radiol** 1996 Feb;21(3):201–11 (71 ref.)
[Isolated stenosing calcified lesions of the aorta] Sapoval M, et al. **J Radiol** 1995 Nov;76(11):1021–4 (10 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Preservation of the pelvic circulation during infrarenal aortic surgery. Connolly JE, et al. **Cardiovasc Surg** 1996 Feb; 4(1):65–70 (46 ref.)
Aortic graft infection with mycoplasma (Ureaplasma urealyticum). Levi N, et al. **Eur J Vasc Endovasc Surg** 1995 Oct;10(3):374–5 (14 ref.)
Aortocaval fistula treated by aortic exclusion. Woolley DS, et al. **J Vasc Surg** 1995 Nov;22(5):639–42 (27 ref.)
Horseshoe kidney and aortic surgery. Wymenga LF, et al. **Scand J Urol Nephrol** 1995 Sep;29(3):331–4 (10 ref.)

AORTA, ASCENDING see **AORTA**

AORTA, DESCENDING see **AORTA, THORACIC**

AORTA, THORACIC

ABNORMALITIES

Right aortic arch with aberrant left subclavian artery: aneurysmal dilatation causing symptomatic compression of the right main bronchus in an adult. Patiniotis TC, et al. **Aust N Z J Surg** 1995 Sep;65(9):690–2 (9 ref.)
Interruption of aortic arch and hypoplastic left heart syndrome. Devloo–Blancquaert A, et al. **Pediatr Cardiol** 1995 Nov–Dec;16(6):304–8 (10 ref.)
A case of the incomplete double aortic arch diagnosed in adulthood by MR imaging. Ito K, et al. **Radiat Med** 1995 Sep–Oct;13(5):263–7 (23 ref.)
[The surgical correction of the right aortic arch with aberrant left subclavian artery and left ligamentum arteriosum—a rare case from clinical practice] Baev B, et al. **Khirurgiia (Sofiia)** 1995;48(1):48–50 (14 ref.) (Eng. Abstr.) **(Bul)**
[Atresia of the aortic arch. A rare cause of asymmetrical arterial hypertension in adulthood] Heinrich U, et al. **Dtsch Med Wochenschr** 1996 May 31;121(22):719–22 (34 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

MR imaging of the thoracic aorta. Flamm SD, et al. **Magn Reson Imaging Clin N Am** 1996 May;4(2):217–35 (54 ref.)
Magnetic resonance angiography of the thoracic aorta. Hartnell GG. **Magn Reson Imaging Clin N Am** 1993 Dec; 1(2):315–26 (47 ref.)
[Calcified proliferation of the descending thoracic aorta] Fadel E, et al. **Arch Mal Coeur Vaiss** 1995 Jul;88(7):1039–42 (10 ref.) (Eng. Abstr.) **(Fre)**

RADIOGRAPHY

[Exploration of the thoracic aorta, excluding the aortic valve] Douek P, et al. **Ann Cardiol Angeiol (Paris)** 1995 Dec; 44(10):552–60 (12 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Late aneurysm after subclavian flap aortoplasty for coarctation of the aorta. Kino K, et al. **Ann Thorac Surg** 1996 Apr;61(4):1262–4 (8 ref.)
[Prevention and therapy of prosthesis infections in the thoracic area] Haverich A, et al. **Zentralbl Chir** 1995; 120(8):630–4 (21 ref.) (Eng. Abstr.) **(Ger)**
[A case report of mediastinitis due to methicillin resistant Staphylococcus aureus after total aortic arch replacement] Asano S, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Jun;44(6):814–9 (18 ref.) (Eng. Abstr.) **(Jpn)**

AORTIC ANEURYSM

[Pathophysiology and clinical aspects of dissecting aortic aneurysms] Szabóová–Tomoriová E, et al. **Vnitr Lek** 1995 Jul;41(7):480–4 (36 ref.) (Eng. Abstr.) **(Slo)**

COMPLICATIONS

Lymphoplasmacytic aortitis and acute aortic dissection. An uncommon association. Faye–Petersen OM, et al. **Arch Pathol Lab Med** 1996 Apr;120(4):402–4 (20 ref.)
Primary aortoesophageal fistula caused by an atherosclerotic thoracoabdominal aortic aneurysm: a case report and review of the literature. Hageman JH, et al. **Cardiovasc Surg** 1995 Oct;3(5):495–9 (17 ref.)

DIAGNOSIS

Acute dissection of the aorta: options for diagnostic imaging. Razavi M. **Cleve Clin J Med** 1995 Nov–Dec;62(6):360–5 (16 ref.)
Management of aortic dissection. Westaby S. **Curr Opin Cardiol** 1995 Sep;10(5):505–10 (17 ref.)

SURGERY

Acute aortic dissection in a patient with osteogenesis imperfecta [see comments] Moriyama Y, et al. **Ann Thorac Surg** 1995 Nov;60(5):1397–9 (8 ref.) Comment in: Ann Thorac Surg 1996 Apr;61(4):1294.
Management of aortic dissection. Westaby S. **Curr Opin Cardiol** 1995 Sep;10(5):505–10 (17 ref.)
[Giant isolated extracadiac unruptured aneurysm of the right coronary sinus of valsalva—a case report] Mizushima T, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Feb; 44(2):202–7 (17 ref.) (Eng. Abstr.) **(Jpn)**

THERAPY

Cardiovascular shock. Rodgers KG. **Emerg Med Clin North Am** 1995 Nov;13(4):793–810 (61 ref.)

ULTRASONOGRAPHY

[The main indications for transesophageal echocardiography] Lesbre JP. **Ann Cardiol Angeiol (Paris)** 1995 Dec; 44(10):547–51 (21 ref.) (Eng. Abstr.) **(Fre)**

AORTIC ANEURYSM, ABDOMINAL

Management of descending aortic dissection. Orend KH, et al. **Ann Ital Chir** 1995 Nov–Dec;66(6):821–4 (8 ref.)
[Asymptomatic aneurysms of the abdominal aorta: in whom are they detected? When should a beta–blocker be prescribed? Who should have surgery and by which technique? (editorial)] Mellière D. **J Mal Vasc** 1995; 20(4):274–8 (12 ref.) **(Fre)**

COMPLICATIONS

Survival after aortic dissection in giant cell arteritis [letter] Richardson MP, et al. **Ann Rheum Dis** 1996 May; 55(5):332–3 (20 ref.)
Escherichia coli infection of an abdominal aortic aneurysm. Khaira HS, et al. **J Infect** 1996 Mar;32(2):161–3 (14 ref.)
[Coronary artery disease in patients with aortic abdominal aneurysm. Apropos of a consecutive series of 172 cases] Langanay T, et al. **Arch Mal Coeur Vaiss** 1996 Feb; 89(2):211–8 (30 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Abdominal aortic aneurysm. Rose WM 3rd, et al. **Compr Ther** 1995 Jul;21(7):339–43 (19 ref.)
Primary aortoenteric fistula: two new case reports and a review of 44 previously reported cases. Tareen AH, et al. **Eur J Vasc Endovasc Surg** 1996 Jul;12(1):5–10 (34 ref.)

ETIOLOGY

Aortic dissection in a 5–year old girl with Marfan's syndrome [letter] Ruiz ME, et al. **Arch Pediatr Adolesc Med** 1996 Apr;150(4):440–2 (14 ref.)
Aortic aneurysms in patients with autoimmune disorders treated with corticosteroids. Sato O, et al. **Eur J Vasc Endovasc Surg** 1995 Oct;10(3):366–9 (17 ref.)
Current views on the pathogenesis of abdominal aortic aneurysms. Patel MI, et al. **J Am Coll Surg** 1995 Oct; 181(4):371–82 (152 ref.)
[Etiology and pathogenesis of abdominal aortic aneurysms] Sukharev II, et al. **Klin Khir** 1995;(7–8):25–8 (32 ref.) **(Rus)**

GENETICS

[Mode of genetic inheritance of abdominal aortic aneurysm: still no clear answers] Powell JT, et al. **Chirurg** 1995 Sep; 66(9):841–4 (21 ref.) (Eng. Abstr.) **(Ger)**

MICROBIOLOGY

Microbiological monitoring of aortic aneurysm sac contents during abdominal aneurysmectomy: results in 176 patients and review of the literature. Fourneau I, et al. **Acta Chir Belg** 1996 Jun;96(3):119–22 (14 ref.)
Contained rupture of infected abdominal aortic aneurysm due to systemic candidiasis. Ikeda M, et al. **Cardiovasc Surg** 1995 Dec;3(6):711–4 (30 ref.)
[Abdominal aortic aneurysm infected with Campylobacter fetus spp fetus. Report of a case and review of the literature] Kuzniec S, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1995 Sep–Oct;50(5):284–8 (39 ref.) (Eng. Abstr.) **(Por)**

PREVENTION & CONTROL

Abdominal aortic aneurysm screening: an epidemiological point of view. Hak E, et al. **Eur J Vasc Endovasc Surg** 1996 Apr;11(3):270–8 (115 ref.)

SURGERY

Nondissecting thoracoabdominal aortic aneurysms: Part I. Panneton JM, et al. **Ann Vasc Surg** 1995 Sep;9(5):503–14 (86 ref.)
Dissecting descending thoracic and thoracoabdominal aortic aneurysms: Part II. Panneton JM, et al. **Ann Vasc Surg** 1995 Nov;9(6):596–605 (56 ref.)
Aortocaval fistula treated by aortic exclusion. Woolley DS, et al. **J Vasc Surg** 1995 Nov;22(5):639–42 (27 ref.)
[Treatment of abdominal aortic aneurysms: importance of the bifurcated prosthesis] Batt M, et al. **J Mal Vasc** 1996; 21 Suppl A:53–7 (26 ref.) (Eng. Abstr.) **(Fre)**
[Infrarenal aneurysm: traditional surgery] Limet R. **J Mal Vasc** 1996;21 Suppl A:58–62 (19 ref.) (Eng. Abstr.)

(Fre)

[Surgical treatment of infrarenal abdominal aortic aneurysm] Hagmüller GW, et al. **Chirurg** 1995 Sep;66(9):857–69 (38 ref.) (Eng. Abstr.) **(Ger)**

[Ischemic colitis after vascular surgery reconstruction of an abdominal aortic aneurysm] Kaiser MM, et al. **Chirurg** 1996 Apr;67(4):380–6 (30 ref.) (Eng. Abstr.) **(Ger)**

[A case report of bentall type operation for annuloaortic ectasia with anomalous origin of the right coronary artery complicated by aortic dissection] Hirai M, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Jul;43(7):1044–9 (20 ref.) (Eng. Abstr.) **(Jpn)**

THERAPY

Intravascular stenting of traumatic abdominal aortic dissection. Marty-Ané CH, et al. **J Vasc Surg** 1996 Jan; 23(1):156–61 (13 ref.)

Endovascular repair of abdominal aortic aneurysms using the EGS tube and bifurcated graft systems. Colburn MD, et al. **World J Surg** 1996 Jul–Aug;20(6):664–72 (44 ref.)

[Medical treatment of aortic abdominal aneurysms. Outstanding questions] Cacoub P, et al. **Presse Med** 1996 Apr 20;25(14):683–5 (15 ref.) (Eng. Abstr.) **(Fre)**

[Endovascular reconstruction of infrarenal abdominal aortic aneurysm] Allenberg JR, et al. **Chirurg** 1995 Sep; 66(9):870–7 (24 ref.) (Eng. Abstr.) **(Ger)**

AORTIC ANEURYSM, RUPTURED see **AORTIC RUPTURE**

AORTIC ANEURYSM, THORACIC

COMPLICATIONS

Right aortic arch with aberrant left subclavian artery: aneurysmal dilatation causing symptomatic compression of the right main bronchus in an adult. Patiniotis TC, et al. **Aust N Z J Surg** 1995 Sep;65(9):690–2 (9 ref.)

Surgical treatment of an aortopulmonary artery fistula complicating a syphilitic aortic aneurysm. Pessotto R, et al. **Cardiovasc Surg** 1995 Dec;3(6):707–10 (17 ref.)

DIAGNOSIS

[Exploration of the thoracic aorta, excluding the aortic valve] Douek P, et al. **Ann Cardiol Angeiol (Paris)** 1995 Dec; 44(10):552–60 (12 ref.) (Eng. Abstr.) **(Fre)**

[Aortic dissection. Symptoms with indications for surgery] Defraigne JO, et al. **Rev Med Liege** 1996 Jun;51(6):411–25 (49 ref.) **(Fre)**

[Total atrioventricular block as the primary clinical manifestation of undiagnosed aortic dissection] Lorenzoni R, et al. **G Ital Cardiol** 1995 Aug;25(8):1031–5 (12 ref.) (Eng. Abstr.) **(Ita)**

ETIOLOGY

Late aneurysm after subclavian flap aortoplasty for coarctation of the aorta. Kino K, et al. **Ann Thorac Surg** 1996 Apr;61(4):1262–4 (8 ref.)

Aortic dissection in a 5-year old girl with Marfan's syndrome [letter] Ruiz ME, et al. **Arch Pediatr Adolesc Med** 1996 Apr;150(4):440–2 (14 ref.)

Salmonella mycotic aneurysm of the aortic arch: case report and review. Meerkin D, et al. **Clin Infect Dis** 1995 Sep; 21(3):523–8 (32 ref.)

GENETICS

[Another case of dissecting aortic aneurysm with familial incidence] Conte MR, et al. **Cardiologia** 1992 Jul; 37(7):513–7 (19 ref.) (Eng. Abstr.) **(Ita)**

MICROBIOLOGY

Double clostridial mycotic aneurysms of the aorta. Messa CA 3rd, et al. **Cardiovasc Surg** 1995 Dec;3(6):687–92 (28 ref.)

SURGERY

Critical-illness polyneuropathy complicating cardiac operation. Alhan HC, et al. **Ann Thorac Surg** 1996 Apr; 61(4):1237–9 (8 ref.)

Mycotic aneurysm of the aorta: evolving surgical concept [editorial; comment] Pasic M. **Ann Thorac Surg** 1996 Apr; 61(4):1053–4 (16 ref.) Comment on: Ann Thorac Surg 1996 Apr;61(4):1146–52.

Dissecting descending thoracic and thoracoabdominal aortic aneurysms: Part II. Panneton JM, et al. **Ann Vasc Surg** 1995 Nov;9(6):596–605 (56 ref.)

Nondissecting thoracoabdominal aortic aneurysms: Part I. Panneton JM, et al. **Ann Vasc Surg** 1995 Sep;9(5):503–14 (86 ref.)

Surgical treatment of an aortopulmonary artery fistula complicating a syphilitic aortic aneurysm. Pessotto R, et al. **Cardiovasc Surg** 1995 Dec;3(6):707–10 (17 ref.)

Anesthetic considerations for descending thoracic aortic surgery: part II. O'Connor CJ, et al. **J Cardiothorac Vasc Anesth** 1995 Dec;9(6):734–47 (126 ref.)

Anesthetic considerations for descending thoracic aortic surgery: Part 1. O'Connor CJ, et al. **J Cardiothorac Vasc Anesth** 1995 Oct;9(5):581–8 (63 ref.)

AORTIC ARCH see **AORTA, THORACIC**

AORTIC BODIES

Functioning glomus vagale tumor: report of case. Guiral H, et al. **J Oral Maxillofac Surg** 1996 Feb;54(2):227–30 (12 ref.)

AORTIC COARCTATION

COMPLICATIONS

Ebstein's anomaly with coarctation of the aorta--an unusual association. Salkar HR, et al. **Indian Heart J** 1996 May–Jun; 48(3):283–4 (7 ref.)

[Cholestasis in congenital heart diseases (hypoplastic left heart syndrome, aortic coarctation)] Konno T. **Ryoikibetsu Shokogun Shirizu** 1995;(7):571–3 (9 ref.) **(Jpn)**

DIAGNOSIS

Recent advances in the diagnosis and treatment of coarctation of the aorta. Hougen TJ, et al. **Curr Opin Cardiol** 1995 Sep;10(5):524–9 (19 ref.)

[Coarctation of the abdominal aorta] Karasch T, et al. **Dtsch Med Wochenschr** 1996 Feb 9;121(6):159–64 (35 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Late aneurysm after subclavian flap aortoplasty for coarctation of the aorta. Kino K, et al. **Ann Thorac Surg** 1996 Apr;61(4):1262–4 (8 ref.)

Coarctation of the aorta. Repair with polytetrafluoroethylene patch aortoplasty. Backer CL, et al. **Circulation** 1995 Nov 1;92(9 Suppl):II132–6 (37 ref.)

THERAPY

Recent advances in the diagnosis and treatment of coarctation of the aorta. Hougen TJ, et al. **Curr Opin Cardiol** 1995 Sep;10(5):524–9 (19 ref.)

Coarctation of the aorta: aortoplasty with Inoue balloon. Ramachandran P, et al. **Indian Heart J** 1996 May–Jun; 48(3):287–9 (11 ref.)

AORTIC DISEASES

Primary leiomyosarcoma of the abdominal aorta. Malone MD, et al. **J Vasc Surg** 1996 Sep;24(3):487–93 (36 ref.)

COMPLICATIONS

The proximal aorta: a source of stroke. Jones EF, et al. **Baillieres Clin Neurol** 1995 Aug;4(2):207–20 (45 ref.)

Aortic atheromatosis and risks of cerebral embolization. Barbut D, et al. **J Cardiothorac Vasc Anesth** 1996 Jan; 10(1):24–9; quiz 29–30 (72 ref.)

DIAGNOSIS

Time-of-flight magnetic resonance angiography of aorta and renal arteries: state-of-the-art. Laissy JP, et al. **Eur J Radiol** 1996 Feb;21(3):201–11 (71 ref.)

Primary aortoenteric fistula: two new case reports and a review of 44 previously reported cases. Tareen AH, et al. **Eur J Vasc Endovasc Surg** 1996 Jul;12(1):5–10 (34 ref.)

Imaging the thoracic aorta [editorial] Reid JH. **Heart** 1996 Jul;76(1):3–5 (11 ref.)

MR imaging of the thoracic aorta. Flamm SD, et al. **Magn Reson Imaging Clin N Am** 1996 May;4(2):217–35 (54 ref.)

[Angiosarcoma of the aorta--a case report] Düx M, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1995 Oct;163(4):361–3 (8 ref.) **(Ger)**

[An intramural hematoma of the ascending aorta. The radiological trap] Bagnolesi P, et al. **Radiol Med (Torino)** 1995 Sep;90(3):317–20 (8 ref.) **(Ita)**

ETIOLOGY

Renal infarction and thrombosis of the infrarenal aorta in a 35-year-old man with primary antiphospholipid syndrome. Poux JM, et al. **Am J Kidney Dis** 1996 May; 27(5):721–5 (20 ref.)

Primary aortoesophageal fistula caused by an atherosclerotic thoracoabdominal aortic aneurysm: a case report and review of the literature. Hageman JH, et al. **Cardiovasc Surg** 1995 Oct;3(5):495–9 (17 ref.)

Oesophago-vascular fistulae secondary to benign peptic ulcer disease: a rare cause of fatal haemorrhage. Kenny PJ, et al. **Eur J Vasc Endovasc Surg** 1995 Oct;10(3):370–1 (6 ref.)

PATHOLOGY

[Calcified proliferation of the descending thoracic aorta] Fadel E, et al. **Arch Mal Coeur Vaiss** 1995 Jul;88(7):1039–42 (10 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Aortic reconstruction in kidney transplant recipients. Panneton JM, et al. **Ann Vasc Surg** 1996 Mar;10(2):97–108 (44 ref.)

Blue toe syndrome from a "coral reef" aorta. Rosenberg GD, et al. **Ann Vasc Surg** 1995 Nov;9(6):561–4 (19 ref.)

Primary aortoenteric fistula: report of eight new cases and review of the literature. Voorhoeve R, et al. **Ann Vasc Surg** 1996 Jan;10(1):40–8 (76 ref.)

Spinal cord protection during surgical procedures on the descending thoracic and thoracoabdominal aorta: review of current techniques. Gharagozloo F, et al. **Chest** 1996 Mar;109(3):799–809 (98 ref.)

[Emboligenic aortopathies. Cholesterol embolisms: surgical treatment] Fichelle JM, et al. **J Mal Vasc** 1996;21 Suppl A:100–12 (73 ref.) (Eng. Abstr.) **(Fre)**

[Is preventive perioperative dopamine administration of value?] Bund M, et al. **Anaesthesiol Reanim** 1995; 20(3):76–81 (45 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Management of aortic intramural hematoma [editorial] Braverman AC, et al. **Curr Opin Cardiol** 1995 Sep; 10(5):501–4 (14 ref.)

AORTIC GLOMUS see **AORTIC BODIES**

AORTIC INCOMPETENCE see **AORTIC VALVE INSUFFICIENCY**

AORTIC REGURGITATION see **AORTIC VALVE INSUFFICIENCY**

AORTIC RUPTURE

COMPLICATIONS

Surgical treatment of an aortopulmonary artery fistula complicating a syphilitic aortic aneurysm. Pessotto R, et al. **Cardiovasc Surg** 1995 Dec;3(6):707–10 (17 ref.)

DIAGNOSIS

[The perforation of a right-coronary sinus of Valsalva aneurysm into the right atrium] Elsner M, et al. **Dtsch Med Wochenschr** 1995 Dec 15;120(50):1728–33 (38 ref.) (Eng. Abstr.) **(Ger)**

MICROBIOLOGY

Contained rupture of infected abdominal aortic aneurysm due to systemic candidiasis. Ikeda M, et al. **Cardiovasc Surg** 1995 Dec;3(6):711–4 (30 ref.)

NURSING

Traumatic rupture of the descending thoracic aorta. Butler KL, et al. **AORN J** 1996 May;63(5):917–25 (32 ref.)

SURGERY

Rupture of a dissecting thoracic aortic aneurysm into the pulmonary artery: successful surgical repair. Coselli JS, et al. **Cardiovasc Surg** 1995 Dec;3(6):697–701 (34 ref.)

Surgical treatment of an aortopulmonary artery fistula complicating a syphilitic aortic aneurysm. Pessotto R, et al. **Cardiovasc Surg** 1995 Dec;3(6):707–10 (17 ref.)

Aortocaval fistula treated by aortic exclusion. Woolley DS, et al. **J Vasc Surg** 1995 Nov;22(5):639–42 (27 ref.)

[Ischemic colitis after vascular surgery reconstruction of an abdominal aortic aneurysm] Kaiser MM, et al. **Chirurg** 1996 Apr;67(4):380–6 (30 ref.) (Eng. Abstr.) **(Ger)**

[Rupture of dissecting aortic aneurysm associated with the right-sided aortic arch and anomalous course of the left brachiocephalic vein--a case report] Kanoh M, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Jul;43(7):1086–91 (14 ref.) (Eng. Abstr.) **(Jpn)**

ULTRASONOGRAPHY

[Post-traumatic dissection of the aortic isthmus with favorable outcome without surgical treatment. Value of transesophageal echocardiography] Bourgeois M, et al. **Ann Fr Anesth Reanim** 1995;14(2):218–21 (16 ref.) (Eng. Abstr.) **(Fre)**

AORTIC SINUS see **SINUS OF VALSALVA**

AORTIC STENOSIS see **AORTIC VALVE STENOSIS**

AORTIC STENOSIS, SUPRAVALVULAR see **AORTIC VALVE STENOSIS**

AORTIC VALVE

Coronary artery obstruction caused by perivalvular abscess in aortic valve endocarditis. Schlaifer JD, et al. **Am Heart J** 1996 Feb;131(2):413–6 (8 ref.)

A rare complication of aortic valve endocarditis: diagnosis with transesophageal echocardiography. Winslow TM, et al. **J Am Soc Echocardiogr** 1995 Jul–Aug;8(4):546–50 (25 ref.)

Porcine bioprosthetic valves prepared with permanent pre-dilation of the aortic root: a review. Fisher J. **J Heart Valve Dis** 1995 Jul;4 Suppl 1:S81–3; discussion S83–4 (14 ref.)

Salmonella prosthetic valve endocarditis. Fukushima N, et al. **J Thorac Cardiovasc Surg** 1996 Sep;112(3):840–2 (5 ref.)

INJURIES

[Traumatic aortic valve insufficiency] Nascimento J, et al. **Rev Port Cardiol** 1996 Feb;15(2):147–52, 101 (17 ref.) (Eng.

Abstr.) **(Por)**

SURGERY

Surgical treatment of aortic valve disease in the nineties with special emphasis on the use of the pulmonary autograft (Ross-operation). Pettersson G. **Ann Chir Gynaecol** 1995; 84(3):251-9 (10 ref.)

TRANSPLANTATION

Osteogenesis imperfecta and cardiovascular diseases [see comments] Wong RS, et al. **Ann Thorac Surg** 1995 Nov; 60(5):1439-43 (36 ref.) Comment in: Ann Thorac Surg 1996 Apr;61(4):1294.

AORTIC VALVE INCOMPETENCE see **AORTIC VALVE INSUFFICIENCY**

AORTIC VALVE INSUFFICIENCY

DIAGNOSIS

Aortic valve insufficiency: changing concepts in diagnosis and management. Otto CM. **Cardiologia** 1996 Jun; 41(6):505-13 (41 ref.)

[Chronic aortic valve insufficiency. The current status of its diagnosis and therapy] Hoppe UC, et al. **Dtsch Med Wochenschr** 1995 Dec 8;120(49):1709-13 (34 ref.) **(Ger)**

DRUG THERAPY

Medical treatment of chronic valvular regurgitation. Schön HR. **J Heart Valve Dis** 1995 Oct;4 Suppl 2:S170-4 (26 ref.)

ETIOLOGY

Osteogenesis imperfecta and cardiovascular diseases [see comments] Wong RS, et al. **Ann Thorac Surg** 1995 Nov; 60(5):1439-43 (36 ref.) Comment in: Ann Thorac Surg 1996 Apr;61(4):1294.

[Traumatic aortic valve insufficiency] Nascimento J, et al. **Rev Port Cardiol** 1996 Feb;15(2):147-52, 101 (17 ref.) (Eng. Abstr.) **(Por)**

SURGERY

Combined valve replacement and coronary bypass grafting in osteogenesis imperfecta [see comments] Almassi GH, et al. **Ann Thorac Surg** 1995 Nov;60(5):1395-7 (15 ref.) Comment in: Ann Thorac Surg 1996 Apr;61(4):1294.

Osteogenesis imperfecta and cardiovascular diseases [see comments] Wong RS, et al. **Ann Thorac Surg** 1995 Nov; 60(5):1439-43 (36 ref.) Comment in: Ann Thorac Surg 1996 Apr;61(4):1294.

[Left ventricular rupture following aortic and mitral valve replacement in a patient with osteogenesis imperfecta: a case report] Ichikawa H, et al. **Kyobu Geka** 1996 Apr; 49(4):294-6 (13 ref.) (Eng. Abstr.) **(Jpn)**

[A case report of bentall type operation for annuloaortic ectasia with anomalous origin of the right coronary artery complicated by aortic dissection] Hirai M, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Jul;43(7):1044-9 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Echocardiographic indicators of the surgical moment in chronic severe aortic insufficiency] Rosas Munive E. **Arch Inst Cardiol Mex** 1995 Jul-Aug;65(4):359-64 (22 ref.) **(Spa)**

ULTRASONOGRAPHY

[The quantification of valvular regurgitation. What new does echocardiography offer?] Mele D. **G Ital Cardiol** 1995 Sep; 25(9):1195-203 (54 ref.) **(Ita)**

AORTIC VALVE STENOSIS

see related
CARDIOMYOPATHY, HYPERTROPHIC

CONGENITAL

[Surgical treatment of congenital aortic stenosis by aortoseptal approach] Mizuhara H, et al. **Kyobu Geka** 1995 Aug;48(9):768-72 (14 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

[Angiodysplasia of the right colon and aortic stenosis. A case report] Arcidiacono G, et al. **Minerva Cardioangiol** 1996 Apr;44(4):173-7 (25 ref.) (Eng. Abstr.) **(Ita)**

PATHOLOGY

[Isolated stenosing calcified lesions of the aorta] Sapoval M, et al. **J Radiol** 1995 Nov;76(11):1021-4 (10 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Progression of valvular aortic stenosis in adults: literature review and clinical implications. Faggiano P, et al. **Am Heart J** 1996 Aug;132(2 (Pt 1)):408-17 (77 ref.)

Left ventricular function in aortic stenosis: a clinical review. Roger VL. **J Heart Valve Dis** 1995 Oct;4 Suppl 2:S230-5 (49 ref.)

PREVENTION & CONTROL

Pharmacological inhibition of restenosis: learning from experience. Shaw LA, et al. **Trends Pharmacol Sci** 1995 Dec;16(12):401-4 (36 ref.)

SURGERY

Indications for valve surgery in asymptomatic patients with aortic and mitral stenosis. Carabello BA. **Chest** 1995 Dec; 108(6):1678-82 (30 ref.)

[Valvular replacement for aortic stenosis in octogenarians. Apropos of a consecutive series of 200 cases] Logeais Y, et al. **Arch Mal Coeur Vaiss** 1995 Feb;88(2):189-95 (30 ref.) (Eng. Abstr.) **(Fre)**

[Surgical treatment of congenital aortic stenosis by aortoseptal approach] Mizuhara H, et al. **Kyobu Geka** 1995 Aug;48(9):768-72 (14 ref.) (Eng. Abstr.) **(Jpn)**

THERAPY

How should we manage symptomatic aortic stenosis in the patient who is 80 or older? Sprigings DC, et al. **Br Heart J** 1995 Nov;74(5):481-4 (42 ref.)

[Cardiology update--II] Trappe HJ. **Med Klin** 1995 Oct 15; 90(10):567-78 (139 ref.) **(Ger)**

ULTRASONOGRAPHY

Stenotic lesions. Wranne B, et al. **Heart** 1996 Jun;75(6 Suppl 2):36-42 (42 ref.)

AORTICOPULMONARY SEPTAL DEFECT see **AORTOPULMONARY SEPTAL DEFECT**

AORTITIS

COMPLICATIONS

Lymphoplasmacytic aortitis and acute aortic dissection. An uncommon association. Faye-Petersen OM, et al. **Arch Pathol Lab Med** 1996 Apr;120(4):402-4 (20 ref.)

DIAGNOSIS

[Exploration of the thoracic aorta, excluding the aortic valve] Douek P, et al. **Ann Cardiol Angeiol (Paris)** 1995 Dec; 44(10):552-60 (12 ref.) (Eng. Abstr.) **(Fre)**

MICROBIOLOGY

Primary Clostridium septicum aortitis: a rare cause of necrotizing suprarenal aortic infection. A case report and review of the literature. Sailors DM, et al. **J Vasc Surg** 1996 Apr;23(4):714-8 (24 ref.)

AORTITIS, SYPHILITIC see **SYPHILIS, CARDIOVASCULAR**

AORTOCORONARY BYPASS see **CORONARY ARTERY BYPASS**

AORTOPULMONARY SEPTAL DEFECT

SURGERY

Surgical repair of d-transposition with aortopulmonary window: a case report. Marangi D, et al. **J Thorac Cardiovasc Surg** 1996 Mar;111(3):671-2 (9 ref.)

AP-1 ENHANCER-BINDING PROTEIN see **TRANSCRIPTION FACTOR AP-1**

APC VIRUSES see **ADENOVIRUSES, HUMAN**

APE, BARBARY see **MACACA**

APE, BLACK see **MACACA**

APE, CELEBES see **MACACA**

APEU VIRUS see **BUNYAVIRUS**

APHAKIA, POSTCATARACT

SURGERY

Differentiated treatment of secondary cataract following extracapsular cataract operation. Adank AM, et al. **Bull Soc Belge Ophtalmol** 1994;254:37-40 (18 ref.)

APHANIPTERA see **FLEAS**

APHASIA

see related
LANDAU-KLEFFNER SYNDROME

COMPLICATIONS

Issues arising in contemporary studies of disorders of syntactic processing in sentence comprehension in agrammatic patients. Caplan D. **Brain Lang** 1995 Sep; 50(3):325-38 (37 ref.)

On the relation between representational and processing models of asyntactic comprehension. Cornell TL. **Brain Lang** 1995 Sep;50(3):304-24 (19 ref.)

A time-based approach to agrammatic production. Kolk H. **Brain Lang** 1995 Sep;50(3):282-303 (53 ref.)

DIAGNOSIS

Syndromes of language dissolution in aging and dementia. Kirshner HS, et al. **Compr Ther** 1995 Sep;21(9):519-23 (30 ref.)

Acquired epileptiform opercular syndrome: a second case report, review of the literature, and comparison to the Landau-Kleffner syndrome. Shafrir Y, et al. **Epilepsia** 1995 Oct;36(10):1050-7 (32 ref.)

PSYCHOLOGY

A reverse length effect in dysphasic naming: when elephant is easier than ant. Best W. **Cortex** 1995 Dec;31(4):637-52 (50 ref.)

REHABILITATION

Recovery from aphasia. Farmer LJ. **J Miss State Med Assoc** 1996 Aug;37(8):690-3 (52 ref.)

APHASIA, ACQUIRED see **APHASIA**

APHASIA, ACQUIRED EPILEPTIC see **LANDAU-KLEFFNER SYNDROME**

APHASIA, BROCA

COMPLICATIONS

The time course of syntactic activation during language processing: a model based on neuropsychological and neurophysiological data. Friederici AD. **Brain Lang** 1995 Sep;50(3):259-81 (61 ref.)

The breakdown of functional categories and the economy of derivation. Hagiwara H. **Brain Lang** 1995 Jul; 50(1):92-116 (50 ref.)

The elusive character of agrammatism. Kean ML. **Brain Lang** 1995 Sep;50(3):369-84 (50 ref.)

Examining the empirical and linguistic bases of current theories of agrammatism. Mauner G. **Brain Lang** 1995 Sep; 50(3):339-68 (48 ref.)

PHYSIOPATHOLOGY

Acquired aphasia in children [editorial] Rapin I. **J Child Neurol** 1995 Jul;10(4):267-70 (24 ref.)

Neuroanatomical correlates of category-specific semantic disorders: a critical survey. Gainotti G, et al. **Memory** 1995 Sep-Dec;3(3-4):247-64 (50 ref.)

APHASIA, EPILEPTIC, ACQUIRED see **LANDAU-KLEFFNER SYNDROME**

APHASIA, EXPRESSIVE see **APHASIA, BROCA**

APHASIA, FLUENT see **APHASIA, WERNICKE**

APHASIA, MOTOR see **APHASIA, BROCA**

APHASIA, NONFLUENT see **APHASIA, BROCA**

APHASIA, PRIMARY PROGRESSIVE

see related
ALZHEIMER'S DISEASE

DIAGNOSIS

[Progressive aphasia without dementia--the onset of an atrophic process of the brain] Kadykov AS, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1996;96(1):42-4 (11 ref.) (Eng. Abstr.) **(Rus)**

APHASIA, RECEPTIVE see **APHASIA, WERNICKE**

APHASIA, SENSORY see **APHASIA, WERNICKE**

APHASIA TESTS see **NEUROPSYCHOLOGICAL TESTS**

APHASIA, WERNICKE

PHYSIOPATHOLOGY

Acquired aphasia in children [editorial] Rapin I. **J Child Neurol** 1995 Jul;10(4):267-70 (24 ref.)

Neuroanatomical correlates of category-specific semantic disorders: a critical survey. Gainotti G, et al. **Memory** 1995 Sep-Dec;3(3-4):247-64 (50 ref.)

APHERESIS see **BLOOD COMPONENT REMOVAL**

APHIDS

MICROBIOLOGY

Genetics, physiology, and evolutionary relationships of the genus Buchnera: intracellular symbionts of aphids. Baumann P, et al. **Annu Rev Microbiol** 1995;49:55-94 (179 ref.)

PHYSIOLOGY

The evolution of soldiers in aphids. Stern DL, et al. **Biol Rev Camb Philos Soc** 1996 Feb;71(1):27–79 (166 ref.)

APHONIA

PSYCHOLOGY

Psychological processes in psychogenic voice disorder. Butcher P. **Eur J Disord Commun** 1995;30(4):467–74 (15 ref.)

APHTHAE see **STOMATITIS, APHTHOUS**

APHTHOVIRUS

IMMUNOLOGY

The interference by maternally-derived antibody with active immunization of farm animals against foot-and-mouth disease. Kitching RP, et al. **Br Vet J** 1995 Jul-Aug; 151(4):379–89 (40 ref.)

Quantitative risk analysis applied to innocuity and potency tests on the oil-adjuvanted vaccine against foot and mouth disease in Argentina. Cané BG, et al. **Rev Sci Tech** 1995 Dec;14(4):1097–119 (5 ref.) **(Eng, Spa)**

[Mechanisms involved in the prolonged humoral immune response: behavior of aphthous fever virus] Wigdorovitz A, et al. **Rev Argent Microbiol** 1996 Jan-Mar;28(1):45–54 (45 ref.) (Eng. Abstr.) **(Spa)**

ISOLATION & PURIFICATION

Antigenic variants in a plaque-isolate of foot-and-mouth disease virus: implications for vaccine production. Piatti P, et al. **Vaccine** 1995;13(8):781–4 (23 ref.)

APICOMPLEXA

CLASSIFICATION

The genus Hepatozoon (Apicomplexa: Adeleina). Smith TG. **J Parasitol** 1996 Aug;82(4):565–85 (118 ref.)

APIS VENOMS see **BEE VENOMS**

APLASIA CUTIS CONGENITA see **ECTODERMAL DYSPLASIA**

APLYSIA

PHYSIOLOGY

The biochemistry of learning and memory. Fagnou DD, et al. **Mol Cell Biochem** 1995 Aug-Sep;149–150:279–86 (84 ref.)

Molecular enhancement of memory formation. Carew TJ. **Neuron** 1996 Jan;16(1):5–8 (24 ref.)

APNEA

PHYSIOPATHOLOGY

Breath-holding spells. Breningstall GN. **Pediatr Neurol** 1996 Feb;14(2):91–7 (35 ref.)

APNEA, CENTRAL see **SLEEP APNEA SYNDROMES**

APNEA, OBSTRUCTIVE see **SLEEP APNEA SYNDROMES**

APNEA, SLEEP see **SLEEP APNEA SYNDROMES**

APO A-I see **APOLIPOPROTEIN A-I**

APO-B see **APOLIPOPROTEINS B**

APO-C see **APOLIPOPROTEINS C**

APO-E see **APOLIPOPROTEINS E**

APO-1 ANTIGEN see **ANTIGENS, CD95**

APOLIPOPROTEIN A-I

CHEMISTRY

Pre-beta HDL: structure and metabolism. Barrans A, et al. **Biochim Biophys Acta** 1996 Apr 19;1300(2):73–85 (150 ref.)

GENETICS

A new apolipoprotein AI variant, Trp50Arg, causes hereditary amyloidosis. Booth DR, et al. **QJM** 1995 Oct; 88(10):695–702 (43 ref.)

METABOLISM

Pre-beta HDL: structure and metabolism. Barrans A, et al. **Biochim Biophys Acta** 1996 Apr 19;1300(2):73–85 (150 ref.)

Apolipoprotein A-I-containing lipoproteins and atherosclerosis. Leroy A, et al. **Curr Opin Lipidol** 1995 Oct; 6(5):281–5 (36 ref.)

APOLIPOPROTEINS

BLOOD

[Apolipoproteins and their fractions] Koga S. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:654–7 (14 ref.) **(Jpn)**

GENETICS

Transcriptional regulation of the genes involved in lipoprotein transport. The role of proximal promoters and long-range regulatory elements and factors in apolipoprotein gene regulation. Kardassis D, et al. **Hypertension** 1996 Apr;27(4):980–1008 (116 ref.)

METABOLISM

Chylomicron assembly and catabolism: role of apolipoproteins and receptors. Hussain MM, et al. **Biochim Biophys Acta** 1996 May 20;1300(3):151–70 (313 ref.)

Synovial fluid lipids and apolipoproteins: a contemporary perspective. Prete PE, et al. **Biorheology** 1995 Jan-Feb; 32(1):1–16 (103 ref.)

[Transport of cholesterol by high density lipoproteins from the standpoint of protein biochemistry] Titov VN. **Vopr Med Khim** 1995 May-Jun;41(3):2–8 (85 ref.) **(Rus)**

APOLIPOPROTEINS B

BLOOD

Metabolic disruptions in the adipocyte-hepatocyte fatty acid axis as causes of HyperapoB. Sniderman AD, et al. **Int J Obes Relat Metab Disord** 1995 May;19 Suppl 1:S27–33 (68 ref.)

Why are lipids not predictive of cardiovascular death in the dialysis patient? Ritz E. **Miner Electrolyte Metab** 1996; 22(1–3):9–12 (25 ref.)

CHEMISTRY

[Conformation of apolipoprotein B-100--structure and functional classification of low density lipoproteins] Titov VN. **Biokhimiia** 1996 Jan;61(1):3–23 (93 ref.) (Eng. Abstr.) **(Rus)**

DEFICIENCY

Surfactant apoprotein B deficiency. Chetcuti PA, et al. **Arch Dis Child Fetal Neonatal Ed** 1995 Nov;73(3):F125–7 (30 ref.)

GENETICS

Genetic variation of apolipoprotein B can produce both low and high levels of apoB-containing lipoproteins in plasma. Schonfeld G. **Can J Cardiol** 1995 Oct;11 Suppl G:86G–92G (79 ref.)

Apolipoprotein B mRNA editing protein: a tool for dissecting lipoprotein metabolism and a potential therapeutic gene for hypercholesterolemia. Chan L, et al. **Z Gastroenterol** 1996 Jun;34 Suppl 3:31–2 (16 ref.)

Reconstitution of apoB mRNA editing in liver by gene-transfer as a potential approach for the treatment of severe forms of polygenic hypercholesterolemia--an outline of the rationale. Greeve J, et al. **Z Gastroenterol** 1996 Jun;34 Suppl 3:27–30 (70 ref.)

[Genetic variation in the apolipoprotein B gene] Vedie B, et al. **Ann Genet** 1995;38(4):187–201 (107 ref.) (Eng. Abstr.) **(Fre)**

[The relationship of apoB gene polymorphism to dyslipoproteinemia as the cause of atherosclerosis] Kravchenko NA. **Tsitol Genet** 1995 Jul-Aug;29(4):84–7 (33 ref.) (Eng. Abstr.) **(Rus)**

METABOLISM

Biosynthesis of apolipoprotein B48-containing lipoproteins. Regulation by novel post-transcriptional mechanisms. Innerarity TL, et al. **J Biol Chem** 1996 Feb 2;271(5):2353–6 (78 ref.)

[Conformation of apolipoprotein B-100--structure and functional classification of low density lipoproteins] Titov VN. **Biokhimiia** 1996 Jan;61(1):3–23 (93 ref.) (Eng. Abstr.) **(Rus)**

SECRETION

Factors affecting the regulation of apo B secretion by liver cells. Hahn SE, et al. **J Clin Lab Anal** 1995;9(6):431–49 (149 ref.)

APOLIPOPROTEINS C

METABOLISM

[The important role of apolipoprotein C-III in lipoprotein metabolism] Fruchart JC, et al. **C R Seances Soc Biol Fil** 1995;189(5):889–97 (30 ref.) (Eng. Abstr.) **(Fre)**

APOLIPOPROTEINS E

CHEMISTRY

Apolipoprotein E. Structure, function, and possible roles in Alzheimer's disease. Mahley RW, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:139–45 (24 ref.)

DEFICIENCY

Apolipoprotein E and the apolipoprotein E-deficient mouse. Plump AS, et al. **Annu Rev Nutr** 1995;15:495–518 (109 ref.)

DRUG EFFECTS

The rat, a useful animal model for pharmacological studies on apolipoprotein E. Leininger-Muller B, et al. **Life Sci** 1996;58(6):455–67 (102 ref.)

GENETICS

Impact of apolipoprotein E genotype variation on means, variances, and correlations of plasma lipid, lipoprotein, and apolipoprotein traits in octogenarians. Haviland MB, et al. **Am J Med Genet** 1995 Sep 25;58(4):315–31 (64 ref.)

Clinical and neuropathological correlates of apolipoprotein E genotype in Alzheimer's disease. Window on molecular epidemiology. Hyman BT, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:158–65 (27 ref.)

Amyloid beta-protein, APOE genotype and head injury. Nicoll JA, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:271–5 (9 ref.)

Morphological, biochemical, and genetic support for an apolipoprotein E effect on microtubular metabolism. Roses AD, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:146–57 (35 ref.)

Apolipoprotein E alleles as risk factors in Alzheimer's disease. Roses AD. **Annu Rev Med** 1996;47:387–400 (66 ref.)

Apolipoprotein E polymorphism and dietary plasma cholesterol response. Tikkanen M, et al. **Can J Cardiol** 1995 Oct;11 Suppl G:93G–96G (25 ref.)

Underexpression of the apolipoprotein E2 and E4 alleles in the Greek Cypriot population of Cyprus. Cariolou MA, et al. **Genet Epidemiol** 1995;12(5):489–97 (29 ref.)

Apolipoprotein E and Alzheimer's disease. Stephens D. **J R Soc Health** 1996 Feb;116(1):41–3 (7 ref.)

Statement on use of apolipoprotein E testing for Alzheimer disease. American College of Medical Genetics/American Society of Human Genetics Working Group on ApoE and Alzheimer disease. **JAMA** 1995 Nov 22–29;274(20):1627–9 (55 ref.)

Apolipoprotein E genotyping in Alzheimer's disease. National Institute on Aging/Alzheimer's Association Working Group [see comments] **Lancet** 1996 Apr 20; 347(9008):1091–5 (77 ref.) Comment in: Lancet 1996 Apr 27;347(9009):1184–5. Comment in: Lancet 1996 Aug 3;348(9023):334.

METABOLISM

[Alzheimer disease: hypotheses implicating apolipoproteins E] Blain H, et al. **Presse Med** 1996 May 4–11;25(16):763–8 (35 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Apolipoprotein E, synaptic plasticity and Alzheimer's disease. Poirier J, et al. **Ann Med** 1995 Dec;27(6):663–70 (89 ref.)

Apolipoprotein E. Structure, function, and possible roles in Alzheimer's disease. Mahley RW, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:139–45 (24 ref.)

Morphological, biochemical, and genetic support for an apolipoprotein E effect on microtubular metabolism. Roses AD, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:146–57 (35 ref.)

Apolipoprotein E and the apolipoprotein E-deficient mouse. Plump AS, et al. **Annu Rev Nutr** 1995;15:495–518 (109 ref.)

The rat, a useful animal model for pharmacological studies on apolipoprotein E. Leininger-Muller B, et al. **Life Sci** 1996;58(6):455–67 (102 ref.)

[Isoform 4 of apolipoprotein E and Alzheimer disease. Specificity and clinical study] Mahieux F, et al. **Rev Neurol (Paris)** 1995 Apr;151(4):231–9 (71 ref.) (Eng. Abstr.) **(Fre)**

APOMORPHINE

PHARMACOKINETICS

Pharmacokinetics of apomorphine in Parkinson's disease. Gancher S. **J Neural Transm Suppl** 1995;45:137–41 (21 ref.)

PHARMACOLOGY

Apomorphine continuous stimulation in Parkinson's disease: receptor desensitization as a possible mechanism of reduced motor response. Maggio R, et al. **J Neural Transm Suppl** 1995;45:133–6 (22 ref.)

[Apomorphine] Esteban Muñoz J. **Neurologia** 1995 Oct; 10(8):330–7 (55 ref.) **(Spa)**

APOPLEXY see **CEREBROVASCULAR DISORDERS**

APOPLEXY, PITUITARY see **PITUITARY APOPLEXY**

APOPTOSIS

see related
GERMINAL CENTER
NECROSIS

T cell apoptosis as a consequence of chronic activation of the immune system in HIV infection. Gougeon ML. **Adv Exp Med Biol** 1995;374:121–7 (46 ref.)

Cell cycle–related protein kinases and T cell death. Lahti JM, et al. **Adv Exp Med Biol** 1995;376:247–58 (84 ref.)

Apoptosis during HIV infection. A cytopathic effect of HIV or an important host–defense mechanism against viruses in general? Martin SJ, et al. **Adv Exp Med Biol** 1995; 374:129–38 (46 ref.)

Programmed death of T cells in the course of HIV infection. Meyaard L, et al. **Adv Exp Med Biol** 1995;374:115–20 (27 ref.)

Nineteenth century research on naturally occurring cell death and related phenomena. Clarke PG, et al. **Anat Embryol (Berl)** 1996 Feb;193(2):81–99 (143 ref.)

Receptors that regulate T–cell susceptibility to apoptotic cell death. Boise LH, et al. **Ann N Y Acad Sci** 1995 Sep 7; 766:70–80 (32 ref.)

Lymphopoiesis, apoptosis, and immune amnesia. Donnenberg AD, et al. **Ann N Y Acad Sci** 1995 Dec 29;770:213–26 (33 ref.)

Apoptosis and angiogenesis: two promising tumor markers in breast cancer (review). Wu J. **Anticancer Res** 1996 Jul–Aug;16(4B):2233–9 (80 ref.)

Apoptosis: The history and trends of its studies. Uchiyama Y. **Arch Histol Cytol** 1995 Jun;58(2):127–37 (73 ref.)

The Gerhard Zbinden Memorial Lecture. Alteration of cell signalling in chemical toxicity. Nicotera P. **Arch Toxicol Suppl** 1996;18:3–11 (46 ref.)

Molecular mechanisms of APO–1/Fas(CD95)–mediated apoptosis in tolerance and AIDS. Dhein J, et al. **Behring Inst Mitt** 1995 Jun;(96):13–20 (37 ref.)

Anti–oxidants and apoptosis. McGowan AJ, et al. **Biochem Soc Trans** 1996 Feb;24(1):229–33 (35 ref.)

Out–of body experiences: cell–free cell death. Hengartner MO. **Bioessays** 1995 Jun;17(6):549–52 (16 ref.)

Apoptosis and oncosis in ocular disease. Heathcote JG. **Can J Ophthalmol** 1995 Oct;30(6):298–300 (14 ref.)

Apoptosis: inhibitor or instigator of carcinogenesis? Manning FC, et al. **Cancer Invest** 1996;14(5):455–65 (130 ref.)

Apoptosis and its association with autoimmunity [editorial] George J, et al. **Clin Rheumatol** 1995 Sep;14(5):505–9 (29 ref.)

Role of apoptosis in the progression of glomerulosclerosis. Makino H, et al. **Contrib Nephrol** 1996;118:41–7 (30 ref.)

Programmed cell death and cell transformation in craniofacial development. Shuler CF. **Crit Rev Oral Biol Med** 1995;6(3):202–17 (124 ref.)

Apoptosis in brain–specific autoimmune disease. Bauer J, et al. **Curr Opin Immunol** 1995 Dec;7(6):839–43 (48 ref.)

The killer and the executioner: how apoptosis controls malignancy. Green DR, et al. **Curr Opin Immunol** 1995 Oct;7(5):694–703 (102 ref.)

Activation–induced death of mature T cells in the regulation of immune responses. Russell JH. **Curr Opin Immunol** 1995 Jun;7(3):382–8 (43 ref.)

Regulation of p53–dependent apoptosis by E1A and E1B. White E. **Curr Top Microbiol Immunol** 1995;199 (Pt 3):34–58 (103 ref.)

Measurement of apoptotic cells in peripheral blood. Carbonari M, et al. **Cytometry** 1995 Sep 15;22(3):161–7 (52 ref.)

Apoptosis: molecular regulation of cell death. Hale AJ, et al. **Eur J Biochem** 1996 Feb 15;236(1):1–26 (380 ref.)

Programmed cell death and its clearance in the developing mammalian kidney. Camp V, et al. **Exp Nephrol** 1996 Mar–Apr;4(2):105–11 (29 ref.)

Expression of apoptosis–related molecules in acute renal injury. Yoshimura A, et al. **Exp Nephrol** 1996 Jan–Feb; 4(1):15–8 (18 ref.)

The biochemistry of programmed cell death. Kroemer G, et al. **FASEB J** 1995 Oct;9(13):1277–87 (84 ref.)

Apoptosis, programmed cell death in the central nervous system. Mašlińska D, et al. **Folia Neuropathol** 1995; 33(2):69–76 (76 ref.)

Novel insights into the biology of myelodysplastic syndromes: excessive apoptosis and the role of cytokines. Raza A, et al. **Int J Hematol** 1996 Jun;63(4):265–78 (52 ref.)

Radiation–induced apoptosis: relevance to radiotherapy. Dewey WC, et al. **Int J Radiat Oncol Biol Phys** 1995 Nov 1;33(4):781–96 (78 ref.)

Programmed cell death in development. Sanders EJ, et al. **Int Rev Cytol** 1995;163:105–73 (410 ref.)

Proteolysis and the biochemistry of life–or–death decisions [comment] Ashkenas J, et al. **J Exp Med** 1996 May 1; 183(5):1947–51 (34 ref.) Comment on: J Exp Med 1996 May 1;183(5):1957–64.

The role of calcium in the regulation of apoptosis. McConkey DJ, et al. **J Leukoc Biol** 1996 Jun;59(6):775–83 (125 ref.)

Neuronal apoptosis: current understanding of molecular mechanisms and potential role in ischemic brain injury. Johnson EM JR, et al. **J Neurotrauma** 1995 Oct; 12(5):843–52 (102 ref.)

Significance of programmed cell death (apoptosis) in mammalian limb and palate development. Mori C. **Kaibogaku Zasshi** 1995 Dec;70(6):503–8 (12 ref.)

Apoptosis, nucleosomes, and nephritis in systemic lupus erythematosus [editorial] Tax WJ, et al. **Kidney Int** 1995 Sep;48(3):666–73 (88 ref.)

Apoptosis overview emphasizing the role of oxidative stress, DNA damage and signal–transduction pathways. Payne CM, et al. **Leuk Lymphoma** 1995 Sep;19(1–2):43–93 (720 ref.)

Apoptosis in myelodysplasia: a paradox or paradigm. Yoshida Y, et al. **Leuk Res** 1995 Dec;19(12):887–91 (31 ref.)

Apoptosis—the cell's silent exit. Bär PR. **Life Sci** 1996; 59(5–6):369–78 (45 ref.)

Can virus therapy of human cancer be improved by apoptosis induction? [published erratum appears in Med Hypotheses 1995 Sep;45(3):316] Sinkovics JG, et al. **Med Hypotheses** 1995 May;44(5):359–68 (72 ref.)

Reversal of malignancy by the adenovirus E1a gene. Frisch SM. **Mutat Res** 1996 Feb 19;350(1):261–6 (31 ref.)

Apoptosis and multistage carcinogenesis in rat liver. Schulte–Hermann R, et al. **Mutat Res** 1995 Dec; 333(1–2):81–7 (43 ref.)

The beneficial effects of dietary restriction: reduced oxidative damage and enhanced apoptosis. Wachsman JT. **Mutat Res** 1996 Feb 19;350(1):25–34 (75 ref.)

The molecular biology of apoptosis. Vaux DL, et al. **Proc Natl Acad Sci U S A** 1996 Mar 19;93(6):2239–44 (125 ref.)

Control of tumor progression by maintenance of apoptosis. Bruchovsky N, et al. **Prostate Suppl** 1996;6:13–21 (27 ref.)

Gonadal cell apoptosis. Hsueh AJ, et al. **Recent Prog Horm Res** 1996;51:433–55; discussion 455–6 (66 ref.)

Programmed cell death in human breast cancer cells. McCloskey DE, et al. **Recent Prog Horm Res** 1996; 51:493–508 (60 ref.)

Cross–linking of cell surface receptors as a trigger or cell apoptosis and proliferation. Korystov YN. **Scanning Microsc** 1995 Sep;9(3):757–62 (55 ref.)

The origin of programmed cell death. Ameisen JC. **Science** 1996 May 31;272(5266):1278–9 (11 ref.)

Hierarchical control of lymphocyte survival. Boise LH, et al. **Science** 1996 Oct 4;274(5284):67–8 (17 ref.)

Sequential triggering of apoptosis, somatic mutation and isotype switch during germinal center development. Liu YJ, et al. **Semin Immunol** 1996 Jun;8(3):169–77 (51 ref.)

Relationships between B cell cytokine production in secondary lymphoid follicles and apoptosis of germinal center B lymphocytes. Pistoia V, et al. **Stem Cells (Dayt)** 1995 Sep;13(5):487–500 (105 ref.)

Better dead than red. Evan IG. **Ther Immunol** 1994 Dec; 1(6):343–8 (80 ref.)

The role of nitric oxide in cell injury. Brüne B, et al. **Toxicol Lett** 1995 Dec;82–83:233–7 (20 ref.)

Role of active cell death (apoptosis) in multi–stage carcinogenesis. Schulte–Hermann R, et al. **Toxicol Lett** 1995 Dec;82–83:143–8 (20 ref.)

Signalling mechanisms and oxidative stress in apoptosis. Slater AF, et al. **Toxicol Lett** 1995 Dec;82–83:149–53 (24 ref.)

A toxicologic pathologist's view of apoptosis or I used to call it necrobiosis, but now I'm singing the apoptosis blues [see comments] Levin S. **Toxicol Pathol** 1995 Jul–Aug; 23(4):533–9 (34 ref.) Comment in: Toxicol Pathol 1995 Sep–Oct;23(5):617–21.

Role of three cancer "master genes" p53, bcl2 and c–myc on the apoptotic process. Chiarugi V, et al. **Tumori** 1996 May–Jun;82(3):205–9 (57 ref.)

Role of apoptosis in biology and pathology: resistance to apoptosis in colon carcinogenesis. Payne CM, et al. **Ultrastruct Pathol** 1995 Jul–Aug;19(4):221–48 (246 ref.)

[Programmed neural cell death?] Langmeier M. **Cesk Fysiol** 1995 Dec;44(4):188–90 (26 ref.) (Eng. Abstr.) **(Cze)**

[Significance of PUVA therapy for adult T–cell leukemia/lymphoma—PUVA therapy can induce apoptosis in leukemic cells] Takemori N, et al. **Hum Cell** 1995 Sep; 8(3):121–6 (30 ref.) (Eng. Abstr.) **(Jpn)**

[Anticancer agents and apoptosis] Fukuoka K, et al. **Nippon Rinsho** 1996 Jan;54(1):250–8 (33 ref.) (Eng. Abstr.) **(Jpn)**

[Role of Fas system in apoptosis induced by hepatitis C virus infection] Mita E, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:198–202 (14 ref.) **(Jpn)**

[Immunohistochemical observation of Fas in the liver with chronic hepatitis C] Takatani M, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:667–74 (23 ref.) **(Jpn)**

[Immunohistochemical observation of Fas in the liver of chronic hepatitis B and its ultrastructural localization] Takatani M, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:234–40 (23 ref.) **(Jpn)**

[TUNEL method rarely revealed DNA fragmentation in chronic hepatitis C] Tanaka Y. **Nippon Rinsho** 1995 Sep; 53 Suppl:192–7 (17 ref.) **(Jpn)**

[Apoptosis: its molecular mechanisms and biological roles] Tanuma S. **Nippon Rinsho** 1995 Dec;53(12):3113–21 (12 ref.) (Eng. Abstr.) **(Jpn)**

[Significance of apoptosis in hepatitis C and possible involvement of soluble factor in hepatocyte apoptosis] Torimoto Y, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:186–91 (16 ref.) **(Jpn)**

[Therapy of malignant brain tumors by using apoptosis] Kuchino Y. **No To Shinkei** 1995 Sep;47(9):829–34 (34 ref.) **(Jpn)**

[Apoptosis in autoimmune diseases] Kobayashi S, et al. **Ryumachi** 1995 Aug;35(4):712–25 (64 ref.) **(Jpn)**

[Evaluation of tumor response through of morphometric measurements. Quantification of apoptosis] Vargas F, et al. **G E N** 1995 Apr–Jun;49(2):161–4 (42 ref.) (Eng. Abstr.) **(Spa)**

[Apoptosis and autoimmune diseases (editorial)] Font J, et al. **Med Clin (Barc)** 1996 Apr 27;106(16):619–21 (37 ref.) **(Spa)**

DRUG EFFECTS

Inhibition of T lymphocyte activation and apoptotic cell death by cyclosporin A and tacrolimus (FK506). Its relevance to therapy of HIV infection. Thomson AW, et al. **Adv Exp Med Biol** 1995;374:211–6 (46 ref.)

Dopamine–induced, genotoxic activation of programmed cell death. A role in nigrostriatal neuronal degeneration in Parkinson's disease? Ziv I, et al. **Adv Neurol** 1996;69:229–33 (26 ref.)

Apoptosis and chemotherapy resistance. Hickman JA. **Eur J Cancer** 1996 Jun;32A(6):921–6 (67 ref.)

The short–chain fatty acid butyrate induces apoptosis in colorectal tumour cell lines. Hague A, et al. **Eur J Cancer Prev** 1995 Oct;4(5):359–64 (36 ref.)

Autocrine feedback death and the regulation of mature T lymphocyte antigen responses. Lenardo MJ, et al. **Int Rev Immunol** 1995;13(2):115–34 (76 ref.)

Probing the molecular program of apoptosis by cancer chemopreventive agents. Fésüs L, et al. **J Cell Biochem Suppl** 1995;22:151–61 (49 ref.)

Calcium–cell cycle regulator, differentiator, killer, chemopreventor, and maybe, tumor promoter. Whitfield JF, et al. **J Cell Biochem Suppl** 1995;22:74–91 (38 ref.)

Apoptosis. Kim IK. **J Korean Med Sci** 1995 Oct;10(5):307–13 (10 ref.)

P53 and induction of apoptosis as a target for anticancer therapy. Neubauer A, et al. **Leukemia** 1996 Jul;10 Suppl 3:S2–S4 (46 ref.)

Calcium, cell death, and tumor promotion. Trump BF, et al. **Prog Clin Biol Res** 1995;391:121–31 (49 ref.)

Role of Fenton chemistry in thiol–induced toxicity and apoptosis. Held KD, et al. **Radiat Res** 1996 May; 145(5):542–53 (81 ref.)

The biochemistry and molecular biology of glucocorticoid–induced apoptosis in the immune system. Cidlowski JA, et al. **Recent Prog Horm Res** 1996;51:457–90; discussion 490–1 (161 ref.)

[Hormone–dependent cell death (editorial)] Tapanainen J. **Duodecim** 1994;110(10):933–5 (13 ref.) **(Fin)**

[Cisplatin resistance in a murine leukemia cell line associated with defect of apoptosis] Segal–Bendirdjian E, et al. **Bull Cancer (Paris)** 1996 May;83(5):371–8 (37 ref.) (Eng. Abstr.) **(Fre)**

[On the novel differentiation–apoptosis inducers in tumor cells] Nakaya K. **Tanpakushitsu Kakusan Koso** 1996 Feb; 41(2):119–26 (38 ref.) **(Jpn)**

GENETICS

Cell death suffers a TKO. Osborne BA, et al. **Bioessays** 1995 Jun;17(6):557–9 (13 ref.)

Apoptosis, cancer and the p53 tumour suppressor gene. Lee JM, et al. **Cancer Metastasis Rev** 1995 Jun;14(2):149–61 (113 ref.)

The genetics of programmed (apoptotic) cell death. Lin X, et al. **Cancer Surv** 1995;25:173–94 (101 ref.)

The olfactory system as a model for the analysis of the contribution of gene expression to programmed cell death. Hayward MD, et al. **Chem Senses** 1995 Apr;20(2):261–9 (100 ref.)

The genetics of programmed cell death in the nematode Caenorhabditis elegans. Horvitz HR, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:377–85 (56 ref.)

Bcl–2 gene family and the regulation of programmed cell death. Yin XM, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:387–93 (46 ref.)

Life, death, and the pursuit of apoptosis. White E. **Genes Dev** 1996 Jan 1;10(1):1–15 (191 ref.)

BCR–ABL: an anti–apoptosis gene in chronic myelogenous leukemia. Cotter TG. **Leuk Lymphoma** 1995 Jul; 18(3–4):231–6 (32 ref.)

The repression of apoptosis by activated abl oncogenes in chronic myelogenous leukaemia. Fernandes RS, et al. **Leukemia** 1996 Jun;10 Suppl 2:s17–21 (39 ref.)

Mammalian DNA damage–inducible genes associated with growth arrest and apoptosis. Smith ML, et al. **Mutat Res** 1996 Jun;340(2–3):109–24 (143 ref.)

DNA damage, p53 and anticancer therapies. Milner J. **Nat Med** 1995 Sep;1(9):879–80 (8 ref.)

Cellular responses to DNA damage: cell–cycle checkpoints, apoptosis and the roles of p53 and ATM. Enoch T, et al. **Trends Biochem Sci** 1995 Oct;20(10):426–30 (45 ref.)

[Bcl–2 with anti–apoptotic activity] Katsumata M, et al. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2062–73 (64 ref.) **(Jpn)**

[Regulation of apoptosis by products of the bcl–2 gene family] Miyawaki T, et al. **Tanpakushitsu Kakusan Koso** 1996 Feb;41(2):127–35 (44 ref.) **(Jpn)**

[Apoptosis: molecular and cellular mechanisms] Umanskiĭ SP. **Mol Biol (Mosk)** 1996 May–Jun;30(3):487–502 (153 ref.) **(Rus)**

[Oncogenes and suppressor genes: apoptosis mechanisms]

Mezquita C. **Med Clin (Barc)** 1995 Sep 30;105(10):389–95 (53 ref.) **(Spa)**

IMMUNOLOGY

From cell activation to cell depletion. The programmed cell death hypothesis of AIDS pathogenesis. Ameisen JC. **Adv Exp Med Biol** 1995;374:139–63 (159 ref.)

The role of surface CD4 in HIV-induced apoptosis. Corbeil J, et al. **Adv Exp Med Biol** 1995;374:91–9 (59 ref.)

Autoimmunity, apoptosis defects and retroviruses. Mountz JD, et al. **Adv Exp Med Biol** 1995;374:183–201 (84 ref.)

Target cell apoptosis induced by cytotoxic T cells and natural killer cells involves synergy between the pore-forming protein, perforin, and the serine protease, granzyme B. Trapani JA. **Aust N Z J Med** 1995 Dec;25(6):793–9 (63 ref.)

Apoptosis as a cause of T-cell unresponsiveness in experimental Chagas' disease. Lopes MF, et al. **Braz J Med Biol Res** 1995 Aug;28(8):913–8 (35 ref.)

CD28 and apoptosis. Boise LH, et al. **Curr Opin Immunol** 1995 Oct;7(5):620–5 (49 ref.)

Life and death during lymphocyte development and function: evidence for two distinct killing mechanisms. Strasser A. **Curr Opin Immunol** 1995 Apr;7(2):228–34 (97 ref.)

ICE family proteases: mediators of all apoptotic cell death? Henkart PA. **Immunity** 1996 Mar;4(3):195–201 (52 ref.)

Fas bridging cell death and cytotoxicity: the reaper connection. Golstein P, et al. **Immunol Rev** 1995 Aug; 146:45–56 (58 ref.)

Nuclear changes in the cytotoxic T lymphocyte-induced model of apoptosis. Sellins KS, et al. **Immunol Rev** 1995 Aug;146:241–66 (104 ref.)

Granzyme B plays a critical role in cytotoxic lymphocyte-induced apoptosis. Shresta S, et al. **Immunol Rev** 1995 Aug;146:211–21 (32 ref.)

Autocrine feedback death and the regulation of mature T lymphocyte antigen responses. Lenardo MJ, et al. **Int Rev Immunol** 1995;13(2):115–34 (76 ref.)

T cells commit suicide, but B cells are murdered! Scott DW, et al. **J Immunol** 1996 Apr 1;156(7):2352–6 (42 ref.)

Cyclosporine-induced apoptosis in CD4+ T lymphocytes and computer-simulated analysis: modeling a treatment scenario for HIV infection. Huss R, et al. **Res Immunol** 1995 Feb;146(2):101–8 (32 ref.)

[Apoptosis (programmed cell death) in autoimmunity—autoimmunological aspect] George J, et al. **Harefuah** 1995 Nov 1;129(9):339–41 (27 ref.) **(Heb)**

PHYSIOLOGY

Parkinson's disease. The apoptosis hypothesis. Stern G. **Adv Neurol** 1996;69:101–7 (29 ref.)

Potential roles of apoptosis in viral pathogenesis. Collins M. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 2):S20–4 (63 ref.)

Apoptosis in prostate cancer. Molecular basis to study hormone refractory mechanisms. Colombel M, et al. **Ann N Y Acad Sci** 1996 Apr 30;784:63–9 (20 ref.)

Neural apoptosis. Bredesen DE. **Ann Neurol** 1995 Dec; 38(6):839–51 (143 ref.)

The involvement of macrophages and lymphocytes in the apoptosis of enterocytes. Iwanaga T. **Arch Histol Cytol** 1995 Jun;58(2):151–9 (38 ref.)

Apoptosis in the nervous system: morphological features, methods, pathology, and prevention. Lo AC, et al. **Arch Histol Cytol** 1995 Jun;58(2):139–49 (107 ref.)

Mechanisms of photoreceptor death in retinal degenerations. From the cell biology of the 1990s to the ophthalmology of the 21st century? Adler R. **Arch Ophthalmol** 1996 Jan; 114(1):79–83 (43 ref.)

Photoreceptor apoptosis in animal models. Implications for retinitis pigmentosa research [editorial] Wong F. **Arch Ophthalmol** 1995 Oct;113(10):1245–7 (24 ref.)

Protein phosphorylation in apoptosis. Gjertsen BT, et al. **Biochim Biophys Acta** 1995 Nov 9;1269(2):187–99 (309 ref.)

In vitro models for studying colorectal carcinogenesis: cellular and molecular events including APC and Rb cleavage in the control of proliferation, differentiation and apoptosis. Williams AC, et al. **Biochim Biophys Acta** 1996 Aug 8;1288(1):F9–19 (91 ref.)

The role of inducible transcription factors in apoptotic nerve cell death. Dragunow M, et al. **Brain Res Brain Res Rev** 1995 Jul;21(1):1–28 (374 ref.)

Involvement of integrins in cell survival. Bates RC, et al. **Cancer Metastasis Rev** 1995 Sep;14(3):191–203 (85 ref.)

A license to kill. Fraser A, et al. **Cell** 1996 Jun 14;85(6):781–4 (21 ref.)

Sex hormones, proto-oncogene expression and apoptosis: their effects on rheumatoid synovial tissue. Cutolo M, et al. **Clin Exp Rheumatol** 1996 Jan-Feb;14(1):87–94 (58 ref.)

The role of programmed cell death as an emerging new concept for the pathogenesis of autoimmune diseases. Mountz JD, et al. **Clin Immunol Immunopathol** 1996 Sep; 80(3 Pt 2):S2–14 (103 ref.)

Apoptosis. A sticky business. Häcker G, et al. **Curr Biol** 1995 Jun 1;5(6):622–4 (26 ref.)

Apoptosis and the cell cycle. Evan GI, et al. **Curr Opin Cell Biol** 1995 Dec;7(6):825–34 (84 ref.)

Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance. Reed JC. **Curr Opin Oncol** 1995 Nov;7(6):541–6 (57 ref.)

Role of c-myc in myeloid differentiation, growth arrest and apoptosis. Hoffman B, et al. **Curr Top Microbiol Immunol** 1996;211:17–27 (51 ref.)

Introduction to apoptosis. Salomon RN, et al. **Diagn Mol Pathol** 1995 Dec;4(4):235–8 (27 ref.)

Apoptosis: programmed cell death in fetal development. Haanen C, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Jan;64(1):129–33 (58 ref.)

Mast cell ontogeny and apoptosis. Metcalfe DD, et al. **Exp Dermatol** 1995 Aug;4(4 Pt 2):227–30 (34 ref.)

The role of proteases during apoptosis. Patel T, et al. **FASEB J** 1996 Apr;10(5):587–97 (97 ref.)

Role of multiple cellular proteases in the execution of programmed cell death. Kumar S, et al. **FEBS Lett** 1995 Nov 20;375(3):169–73 (53 ref.)

Control of apoptosis by the cellular ATP level. Richter C, et al. **FEBS Lett** 1996 Jan 8;378(2):107–10 (62 ref.)

Cell death by apoptosis: basic concepts and disease relevance for the gastroenterologist [see comments] Que FG, et al. **Gastroenterology** 1996 Apr;110(4):1238–43 (21 ref.) Comment in: Gastroenterology 1996 Aug;111(2):567–8.

Protein kinase C involvement in apoptosis. Lucas M, et al. **Gen Pharmacol** 1995 Sep;26(5):881–7 (70 ref.)

Role of apoptosis in HIV disease pathogenesis. Oyaizu N, et al. **J Clin Immunol** 1995 Sep;15(5):217–31 (165 ref.)

Regulation of apoptosis in neutrophils—Fas track to death? Liles WC, et al. **J Immunol** 1995 Oct 1;155(7):3289–91 (71 ref.)

Lupus in the Fas lane? Singh AK. **J R Coll Physicians Lond** 1995 Nov-Dec;29(6):475–8 (40 ref.)

Insulin-like growth factor-I receptor. Its role in cell proliferation, apoptosis, and tumorigenicity. Rubin R, et al. **Lab Invest** 1995 Sep;73(3):311–31 (274 ref.)

The role of intracellular signalling pathways regulating thymocyte and leukemic T cell apoptosis. Conroy LA, et al. **Leukemia** 1996 Sep;10(9):1422–35 (205 ref.)

Control of apoptosis in hematopoiesis and leukemia by cytokines, tumor suppressor and oncogenes. Lotem J, et al. **Leukemia** 1996 Jun;10(6):925–31 (131 ref.)

Morphology and significance of programmed cell death in the developing limb bud of the vertebrate embryo. Hurle JM, et al. **Microsc Res Tech** 1996 Jun 15;34(3):236–46 (86 ref.)

Apoptosis of larval cells during amphibian metamorphosis. Ishizuya-Oka A. **Microsc Res Tech** 1996 Jun 15; 34(3):228–35 (73 ref.)

Apoptosis in the human female reproductive tract. Spencer SJ, et al. **Obstet Gynecol Surv** 1996 May;51(5):314–23 (103 ref.)

Redox signalling and the control of cell growth and death. Powis G, et al. **Pharmacol Ther** 1995;68(1):149–73 (240 ref.)

Ceramide: an intracellular mediator of apoptosis and growth suppression. Saba JD, et al. **Philos Trans R Soc Lond B Biol Sci** 1996 Feb 29; 351(1336):233–40; discussion 240–1 (40 ref.)

Apoptosis in the developing CNS. Naruse I, et al. **Prog Neurobiol** 1995 Oct;47(2):135–55 (152 ref.)

Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Denmeade SR, et al. **Prostate** 1996 Apr;28(4):251–65 (94 ref.)

Protein thiol modification and apoptotic cell death as cGMP-independent nitric oxide (NO) signaling pathways. Brüne B, et al. **Rev Physiol Biochem Pharmacol** 1996; 127:1–30 (105 ref.)

p53: DNA damage, DNA repair, and apoptosis. Götz C, et al. **Rev Physiol Biochem Pharmacol** 1996;127:65–95 (230 ref.)

Apoptosis: relevance to rheumatology. Tebib JG. **Rev Rhum Engl Ed** 1995 Nov;62(10):618–26 (52 ref.)

Apoptosis, I: General considerations. Oros A, et al. **Rom J Morphol Embryol** 1995 Jul-Dec;41(3–4):89–99 (56 ref.)

Cell death in the embryonic developing limb. Hurle JM, et al. **Scanning Microsc** 1995 Jun;9(2):519–33; discussion 533–4 (118 ref.)

Cell death in health and disease: the biology and regulation of apoptosis. Bellamy CO, et al. **Semin Cancer Biol** 1995 Feb;6(1):3–16 (126 ref.)

Induction of apoptosis by tumor suppressor genes and oncogenes. Canman CE, et al. **Semin Cancer Biol** 1995 Feb; 6(1):17–25 (90 ref.)

Survival factors, intracellular signal transduction, and the activation of endonucleases in apoptosis. Eastman A. **Semin Cancer Biol** 1995 Feb;6(1):45–52 (69 ref.)

Implications of apoptotic cell death regulation in cancer therapy. McDonnell TJ, et al. **Semin Cancer Biol** 1995 Feb; 6(1):53–60 (80 ref.)

Induction of genes during apoptosis: examples from the immune system. Osborne BA. **Semin Cancer Biol** 1995 Feb; 6(1):27–33 (61 ref.)

[Signals for cellular selection for life and death by a new family of cytokines] Hintzen RQ, et al. **Ned Tijdschr Geneeskd** 1996 Jan 27;140(4):182–6 (29 ref.) **(Dut)**

[Apoptosis—programmed cell death] Baumgartner-Parzer SM. **Wien Klin Wochenschr** 1996;108(11):311–20 (122 ref.) (Eng. Abstr.) **(Ger)**

[Apoptosis—programmed cell death—molecular aspect] Kaplinsky C, et al. **Harefuah** 1995 Nov 1;129(9):346–50 (53 ref.) **(Heb)**

[Apoptosis: cell do not die at random—biochemical aspect] Sela BA. **Harefuah** 1995 Nov 1;129(9):342–5 (27 ref.) **(Heb)**

[Fas antigen expression and apoptosis in liver tissues of patients with chronic hepatitis B] Mochizuki K, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:228–33 (17 ref.) **(Jpn)**

[Apoptosis and fulminant hepatitis] Sata M, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:488–91 (18 ref.) **(Jpn)**

[The Fas/APO-1 antigen—a molecule mediating apoptosis] Baryshnikov AIu, et al. **Gematol Transfuziol** 1995 Nov-Dec;40(6):35–8 (28 ref.) **(Rus)**

[Morphology of apoptosis in normal and pathologic hematopoiesis] Pogorelov VM, et al. **Gematol Transfuziol** 1995 Sep-Oct;40(5):17–25 (61 ref.) **(Rus)**

RADIATION EFFECTS

P53 and induction of apoptosis as a target for anticancer therapy. Neubauer A, et al. **Leukemia** 1996 Jul;10 Suppl 3:S2–S4 (46 ref.)

Apoptosis and the assessment of radiation injury. Vincent PC. **Stem Cells (Dayt)** 1995 May;13 Suppl 1:153–64 (129 ref.)

[Gene transfer and radiotherapy] Bourhis J, et al. **Bull Cancer (Paris)** 1996 Feb;83(2):107–13 (43 ref.) (Eng. Abstr.) **(Fre)**

[The biological significance and clinical prospects of apoptosis within the parameters of radiotherapy response (editorial)] Tordiglione M, et al. **Radiol Med (Torino)** 1996 Mar;91(3):286–91 (44 ref.) **(Ita)**

APPARATUS AND INSTRUMENTS see **EQUIPMENT AND SUPPLIES**

APPENDECTOMY

Laparoscopic appendectomy and the management of gynecologic pathologic conditions found at laparoscopy for presumed appendicitis. Apelgren KN, et al. **Surg Clin North Am** 1996 Jun;76(3):469–82 (47 ref.)

[Postappendectomy vascular complications in childhood] Díez García R, et al. **An Esp Pediatr** 1996 Mar;44(3):270–2 (19 ref.) **(Spa)**

ADVERSE EFFECTS

[Post-appendectomy fistulas of the cecum. Apropos of 22 cases] Genier F, et al. **J Chir (Paris)** 1995 Oct;132(10):393–8 (17 ref.) (Eng. Abstr.) **(Fre)**

ECONOMICS

Cost-effective evaluation and management of the acute abdomen. Gill BD, et al. **Surg Clin North Am** 1996 Feb; 76(1):71–82 (13 ref.)

APPENDICEAL NEOPLASMS

see related **PSEUDOMYXOMA PERITONEI**

COMPLICATIONS

[Adenocarcinoma of the appendix. A propos of a case complicated by double local and parietal recurrence] de Souza N, et al. **J Chir (Paris)** 1996 Jun;133(4):159–61 (10 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Venous hemangioma of the mesoappendix: report of a case and a brief review of the Japanese literature. Hanatate F, et al. **Surg Today** 1995;25(11):962–4 (8 ref.)

PATHOLOGY

[A case of goblet cell carcinoid of the appendix] Kamada T, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 May; 93(5):367–72 (16 ref.) **(Jpn)**

APPENDICITIS

Perforated appendicitis: past and future controversies. Blewett CJ, et al. **Semin Pediatr Surg** 1995 Nov;4(4):234–8 (34 ref.)

COMPLICATIONS

Appendicovesical fistula. Athanassopoulos A, et al. **Int Urol Nephrol** 1995;27(6):705–8 (9 ref.)

DIAGNOSIS

Recent advances in the diagnosis and treatment of acute appendicitis. Calder JD, et al. **Br J Hosp Med** 1995 Aug 16-Sep 5;54(4):129–33 (24 ref.)

Epiploic appendicitis: ultrasound and CT characteristics. Rutten MJ, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Mar;164(3):264–5 (6 ref.)

Laparoscopic appendectomy and the management of gynecologic pathologic conditions found at laparoscopy for presumed appendicitis. Apelgren KN, et al. **Surg Clin North Am** 1996 Jun;76(3):469–82 (47 ref.)

[Appendicitis and pregnancy. Seven case reports] Dufour P, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(4):411–5 (14 ref.) (Eng. Abstr.) **(Fre)**

APPENDICITIS

EPIDEMIOLOGY

Appendicitis: an African perspective. Walker AR, et al. **J R Soc Med** 1995 Nov;88(11):616–9 (53 ref.)

GENETICS

Simultaneous acute appendicitis in monozygotic twins: coincidence or genetic? Gurbuz AT, et al. **Am Surg** 1996 May;62(5):407–8 (6 ref.)

SURGERY

[Appendicitis and pregnancy. Seven case reports] Dufour P, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(4):411–5 (14 ref.) (Eng. Abstr.) **(Fre)**

[Indications for celioscopic surgery in children (editorial)] Heloury Y. **Presse Med** 1995 Oct 14;24(30):1374–5 (9 ref.) **(Fre)**

THERAPY

Recent advances in the diagnosis and treatment of acute appendicitis. Calder JD, et al. **Br J Hosp Med** 1995 Aug 16–Sep 5;54(4):129–33 (24 ref.)

ULTRASONOGRAPHY

[Value of ultrasound in diagnosis of acute appendicitis] Zoller WG, et al. **Bildgebung** 1996 Jun;63(2):78–82 (38 ref.) (Eng. Abstr.) **(Ger)**

APPENDIX

see related
APPENDECTOMY

Appendicovesical fistula. Athanassopoulos A, et al. **Int Urol Nephrol** 1995;27(6):705–8 (9 ref.)

Foreign bodies of dental origin in the appendix. Mellor TK, et al. **J R Army Med Corps** 1995 Oct;141(3):174–6 (25 ref.)

External abdominal hernia of mucocele of the appendix in drain–tube removal site. Bacchin P, et al. **Radiol Med (Torino)** 1995 Dec;90(6):827–9 (13 ref.)

[Appendiceal mucocele: diagnosis by echography, spiral computed tomography and magnetic resonance] Bertolotto M, et al. **Radiol Med (Torino)** 1995 Dec;90(6):829–32 (6 ref.) **(Ita)**

[Current possibilities in the diagnosis and treatment of appendiceal mucocele] Fedorov VD, et al. **Khirurgiia (Mosk)** 1996;(1):27–8 (10 ref.) (Eng. Abstr.) **(Rus)**

BLOOD SUPPLY

Venous hemangioma of the mesoappendix: report of a case and a brief review of the Japanese literature. Hanatate F, et al. **Surg Today** 1995;25(11):962–4 (8 ref.)

RADIOGRAPHY

Epiploic appendicitis: ultrasound and CT characteristics. Rutten MJ, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Mar;164(3):264–5 (6 ref.)

ULTRASONOGRAPHY

Epiploic appendicitis: ultrasound and CT characteristics. Rutten MJ, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Mar;164(3):264–5 (6 ref.)

APPETITE

see related
APPETITE DEPRESSANTS

[Regulation of food intake and appetite: overview] Aou S, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:13–8 (23 ref.) **(Jpn)**

DRUG EFFECTS

Effects of amylin on appetite regulation and memory. Morley JE, et al. **Can J Physiol Pharmacol** 1995 Jul;73(7):1042–6 (60 ref.)

Effect of sucrose and sweeteners on appetite and energy intake. Blundell JE, et al. **Int J Obes Relat Metab Disord** 1996 Mar;20 Suppl 2:S12–7 (46 ref.)

Role of peripheral angiotensin in salt appetite of the sodium–deplete rat. Thunhorst RL. **Neurosci Biobehav Rev** 1996;20(1):101–6 (33 ref.)

PHYSIOLOGY

Techniques for the experimental measurement of human eating behaviour and food intake: a practical guide. Hill AJ, et al. **Int J Obes Relat Metab Disord** 1995 Jun; 19(6):361–75 (91 ref.)

Macronutrient effects on appetite. Stubbs RJ. **Int J Obes Relat Metab Disord** 1995 Nov;19 Suppl 5:S11–9 (54 ref.)

Food intake and the menstrual cycle: a retrospective analysis, with implications for appetite research. Buffenstein R, et al. **Physiol Behav** 1995 Dec;58(6):1067–77 (142 ref.)

[Progress in research on the central mechanism of feeding behavior—neuronal network] Oomura Y, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:585–96 (20 ref.) **(Jpn)**

[Role of cytokines in regulation of food intake and appetite] Shimizu H. **Nippon Rinsho** 1995 Jun;53 Suppl:58–63 (39 ref.) **(Jpn)**

APPETITE DEPRESSANTS

Cytokines and feeding suppression: an integrative view from neurologic to molecular levels. Plata–Salamán CR. **Nutrition** 1995 Sep–Oct;11(5 Suppl):674–7 (26 ref.)

ADVERSE EFFECTS

[Iatrogenic pulmonary artery hypertension] Weitzenblum E, et al. **Rev Mal Respir** 1996;13(2):133–9 (32 ref.) (Eng. Abstr.) **(Fre)**

PHARMACOLOGY

Biological actions of drugs affecting serotonin and eating. Garattini S. **Obes Res** 1995 Nov;3 Suppl 4:463S–470S (65 ref.)

THERAPEUTIC USE

Appetite suppressants as adjuncts in the treatment of obesity. Elks ML. **J Fam Pract** 1996 Mar;42(3):287–92 (57 ref.)

Clinical studies with dexfenfluramine: from past to future. Guy–Grand B. **Obes Res** 1995 Nov;3 Suppl 4:491S–496S (34 ref.)

Clinical studies with mazindol. Inoue S. **Obes Res** 1995 Nov; 3 Suppl 4:549S–552S (11 ref.)

Sibutramine: a novel new agent for obesity treatment. Ryan DH, et al. **Obes Res** 1995 Nov;3 Suppl 4:553S–559S (29 ref.)

[Anorexics in the treatment of eating disorders] Faltus F, et al. **Ceska Slov Psychiatr** 1995 Nov;91(5):291–8 (47 ref.) **(Cze)**

[Drug treatment of obesity] Meinders AE, et al. **Ned Tijdschr Geneeskd** 1996 Aug 10;140(32):1632–4 (22 ref.) **(Dut)**

[Therapy of obesity using appetite depressants] Ikeda Y. **Nippon Naika Gakkai Zasshi** 1995 Aug 10;84(8):1290–4 (4 ref.) **(Jpn)**

APPETITE DISORDERS see EATING DISORDERS

APPETITE REGULATION

Cytokines and feeding suppression: an integrative view from neurologic to molecular levels. Plata–Salamán CR. **Nutrition** 1995 Sep–Oct;11(5 Suppl):674–7 (26 ref.)

[Etiology and physiopathology of obesity: mechanism of appetite control] Inokuchi T. **Nippon Naika Gakkai Zasshi** 1995 Aug 10;84(8):1221–5 (5 ref.) **(Jpn)**

PHYSIOLOGY

[Cyclic enteral nutrition] Hébuterne X, et al. **Presse Med** 1996 Feb 10;25(5):202–6 (30 ref.) (Eng. Abstr.) **(Fre)**

APPETITE SUPPRESSANTS see APPETITE DEPRESSANTS

APPLE see FRUIT

APPROPRIATENESS REVIEW see REGIONAL HEALTH PLANNING

APRAXIA

COMPLICATIONS

[Characterization of gestural disorders in primary progressive apraxia: diagnostic and nosographic contribution] Habib M, et al. **Rev Neurol (Paris)** 1995 Oct;151(10):541–51 (29 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

The basal ganglia and apraxia. Pramstaller PP, et al. **Brain** 1996 Feb;119 (Pt 1):319–40 (105 ref.)

Diagonistic dyspraxia. Clinical characteristics, responsible lesion and possible underlying mechanism. Tanaka Y, et al. **Brain** 1996 Jun;119 (Pt 3):859–73 (75 ref.)

Acquired epileptiform opercular syndrome: a second case report, review of the literature, and comparison to the Landau–Kleffner syndrome. Shafrir Y, et al. **Epilepsia** 1995 Oct;36(10):1050–7 (32 ref.)

ETIOLOGY

The basal ganglia and apraxia. Pramstaller PP, et al. **Brain** 1996 Feb;119 (Pt 1):319–40 (105 ref.)

[Progressive severity of left unilateral apraxia in 2 cases of Alzheimer disease] Ceccaldi M, et al. **Rev Neurol (Paris)** 1995 Apr;151(4):240–6 (36 ref.) (Eng. Abstr.) **(Fre)**

[Anarthria, progressive apraxia and extrapyramidal syndrome: an uncommon clinical form of corticobasal degeneration? A case studied by HMPAO Tc99m single–photon emission tomography] Fayet G, et al. **Rev Neurol (Paris)** 1995 Apr;151(4):247–50 (14 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Diagonistic dyspraxia. Clinical characteristics, responsible lesion and possible underlying mechanism. Tanaka Y, et al. **Brain** 1996 Jun;119 (Pt 3):859–73 (75 ref.)

APRICOT see FRUIT

APRINDINE

BLOOD

[Disopyramide, mexiletine, aprindine] Suzuki M. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:989–93 (25 ref.) **(Jpn)**

APROTININ

CHEMISTRY

The roles of partly folded intermediates in protein folding. Creighton TE, et al. **FASEB J** 1996 Jan;10(1):110–8 (55 ref.)

PHARMACOLOGY

Aprotinin [see comments] Robert S, et al. **Ann Pharmacother** 1996 Apr;30(4):372–80 (68 ref.) Comment in: Ann Pharmacother 1996 Apr;30(4):407–8.

THERAPEUTIC USE

Aprotinin in patients having coronary artery bypass graft surgery. Royston D. **Curr Opin Cardiol** 1995 Nov; 10(6):591–6 (50 ref.)

Is aprotinin safe when used in the context of profound hypothermia and circulatory arrest? A literary review [comment] Hornick P, et al. **J Heart Valve Dis** 1995 Nov; 4(6):669–73 (60 ref.) Comment on: J Heart Valve Dis 1995 Nov;4(6):674–7.

[Aprotinin in the control of surgical hemorrhage] Rocha E, et al. **Med Clin (Barc)** 1996 Mar 2;106(8):307–16 (161 ref.) **(Spa)**

[Use of aprotinin in cardiovascular surgery] Colorio C, et al. **Sangre (Barc)** 1995 Jun;40(3):207–11 (34 ref.) **(Spa)**

APTITUDE TESTS

Measurement of intelligence: misplaced trust and the lure of prophecy [see comments] Slack WV. **MD Comput** 1995 Sep–Oct;12(5):363–72 (127 ref.) Comment in: MD Comput 1995 Sep–Oct;12(5):325–6, 329.

APUD CELLS

ULTRASTRUCTURE

[Current methods for studying the functional morphology of apud cells] Iuzhakov VV, et al. **Arkh Patol** 1996 Mar–Apr;58(2):21–8 (37 ref.) (Eng. Abstr.) **(Rus)**

APUDOMA

see related
MULTIPLE ENDOCRINE NEOPLASIA

DIAGNOSIS

Cartinoid tumor of the middle ear and mastoid. Himi T, et al. **Auris Nasus Larynx** 1995;22(2):128–33 (21 ref.)

PATHOLOGY

Cartinoid tumor of the middle ear and mastoid. Himi T, et al. **Auris Nasus Larynx** 1995;22(2):128–33 (21 ref.)

APYRASE

PHYSIOLOGY

Apyrases (ATP diphosphohydrolases, EC 3.6.1.5): function and relationship to ATPases. Komoszyński M, et al. **Biochim Biophys Acta** 1996 Feb 2;1310(2):233–41 (91 ref.)

AQUACULTURE

Transgenic fish in aquaculture and developmental biology. Gong Z, et al. **Curr Top Dev Biol** 1995;30:177–214 (174 ref.)

STANDARDS

Care of fish in biological research. Klontz GW. **J Anim Sci** 1995 Nov;73(11):3485–92 (24 ref.)

Disinfection in aquaculture. Torgersen Y, et al. **Rev Sci Tech** 1995 Jun;14(2):419–34 (39 ref.)

AQUAREOVIRUS see REOVIRIDAE

AQUEOUS HUMOR

PHYSIOLOGY

Morphology of the aqueous outflow pathway. Gong H, et al. **Microsc Res Tech** 1996 Mar 1;33(4):336–67 (76 ref.)

ARA-A see VIDARABINE

ARA-AMP see VIDARABINE PHOSPHATE

ARA-C see CYTARABINE

ARA-U see ARABINOFURANOSYLURACIL

ARABIDOPSIS

DRUG EFFECTS

The ethylene signal transduction pathway in Arabidopsis: an emerging paradigm? Chang C. **Trends Biochem Sci** 1996 Apr;21(4):129–33 (35 ref.)

EMBRYOLOGY

Pattern formation in the Arabidopsis embryo: a genetic perspective. Jürgens G, et al. **Philos Trans R Soc Lond B Biol Sci** 1995 Oct 30; 350(1331):19–25 (38 ref.)

GENETICS

Transgene inactivation in Arabidopsis thaliana. Scheid OM. **Curr Top Microbiol Immunol** 1995;197:29–42 (57 ref.)

Gene expression in plant cell cultures under continuous blue light irradiation of high intensity. Kaldenhoff R. **J Photochem Photobiol B** 1995 Dec;31(3):97–100 (35 ref.)

Molecular methods for isolation of signal transduction pathway mutants. Chory J, et al. **Methods Cell Biol** 1995; 49:441–54 (16 ref.)

Agrobacterium-mediated transformation of Arabidopsis thaliana. Application in T-DNA tagging. Topping JF, et al. **Methods Mol Biol** 1995;49:63–76 (26 ref.)

Regulation of flowering time: Arabidopsis as a model system to study genes that promote or delay flowering. Coupland G. **Philos Trans R Soc Lond B Biol Sci** 1995 Oct 30; 350(1331):27–34 (54 ref.)

Genetic analysis of a seedling stress response to ethylene in Arabidopsis. Roman G, et al. **Philos Trans R Soc Lond B Biol Sci** 1995 Oct 30; 350(1331):75–81 (48 ref.)

Arabidopsis in Madison: genes and phenotypes spread like weeds. Chasan R. **Plant Cell** 1995 Nov;7(11):1737–48 (34 ref.)

The genome of Arabidopsis thaliana. Goodman HM, et al. **Proc Natl Acad Sci U S A** 1995 Nov 21;92(24):10831–5 (64 ref.)

GROWTH & DEVELOPMENT

Signal-transduction pathways controlling light-regulated development in Arabidopsis. Chory J, et al. **Philos Trans R Soc Lond B Biol Sci** 1995 Oct 30; 350(1331):59–65 (62 ref.)

Green light for steroid hormones [comment] Russell DW. **Science** 1996 Apr 19;272(5260):370–1 (7 ref.) Comment on: Science 1996 Apr 19;272(5260):398–401.

PHYSIOLOGY

Plant morphogenesis. Life on a different plane. Lloyd C. **Curr Biol** 1995 Oct 1;5(10):1085–7 (9 ref.)

Genetic and environmental control of flowering time in Arabidopsis. Coupland G. **Trends Genet** 1995 Oct; 11(10):393–7 (38 ref.)

ARABIDOPSIS THALIANA see ARABIDOPSIS

ARABINOFURANOSYLADENINE see VIDARABINE

ARABINOFURANOSYLADENINE MONOPHOSPHATE see VIDARABINE PHOSPHATE

ARABINOFURANOSYLCYTOSINE see CYTARABINE

ARABINOFURANOSYLURACIL

ANALOGS & DERIVATIVES

Sorivudine: a potent inhibitor of varicella zoster virus replication. Whitley RJ. **Adv Exp Med Biol** 1996;394:41–4 (11 ref.)

Sorivudine: a promising drug for the treatment of varicella-zoster virus infection. Whitley RJ. **Neurology** 1995 Dec;45(12 Suppl 8):S73–5 (10 ref.)

ARABINOSYLADENINE see VIDARABINE

ARABINOSYLCYTOSINE see CYTARABINE

ARABINOSYLURACIL see ARABINOFURANOSYLURACIL

ARACHIDONATE 5-LIPOXYGENASE

ANTAGONISTS & INHIBITORS

Leukotriene receptor antagonists and biosynthesis inhibitors: potential breakthrough in asthma therapy. Chung KF. **Eur Respir J** 1995 Jul;8(7):1203–13 (117 ref.)

METABOLISM

Arachidonate 5-lipoxygenase. Rådmark O. **J Lipid Mediat Cell Signal** 1995 Oct;12(2–3):171–84 (58 ref.)

The orphan receptor family RZR/ROR, melatonin and 5-lipoxygenase: an unexpected relationship. Carlberg C, et al. **J Pineal Res** 1995 May;18(4):171–8 (51 ref.)

ARACHIDONATE 12-LIPOXYGENASE

CHEMISTRY

Arachidonate 12-lipoxygenase. Yoshimoto T, et al. **J Lipid Mediat Cell Signal** 1995 Oct;12(2–3):195–212 (128 ref.)

METABOLISM

Lipoxin biosynthesis and actions: role of the human platelet LX-synthase. Serhan CN, et al. **J Lipid Mediat Cell Signal** 1995 Oct;12(2–3):293–306 (41 ref.)

Arachidonate 12-lipoxygenase. Yoshimoto T, et al. **J Lipid Mediat Cell Signal** 1995 Oct;12(2–3):195–212 (128 ref.)

ARACHIDONATE 15-LIPOXYGENASE

GENETICS

Arachidonate 15-lipoxygenase. Kühn H, et al. **J Lipid Mediat Cell Signal** 1995 Oct;12(2–3):157–70 (72 ref.)

METABOLISM

Leukotrienes and 15-lipoxygenase products in glomerulonephritis. Badr KF. **Adv Nephrol Necker Hosp** 1995;24:19–31 (58 ref.)

Arachidonate 15-lipoxygenase. Kühn H, et al. **J Lipid Mediat Cell Signal** 1995 Oct;12(2–3):157–70 (72 ref.)

ARACHIDONIC ACID

CHEMISTRY

The isoprostanes. Current knowledge and directions for future research. Morrow JD, et al. **Biochem Pharmacol** 1996 Jan 12;51(1):1–9 (54 ref.)

METABOLISM

Control of arachidonate levels within inflammatory cells. Chilton FH, et al. **Biochim Biophys Acta** 1996 Jan 5; 1299(1):1–15 (139 ref.)

Signal transduction of the gonadotropin releasing hormone (GnRH) receptor: cross-talk of calcium, protein kinase C (PKC), and arachidonic acid. Naor Z, et al. **Cell Mol Neurobiol** 1995 Oct;15(5):527–44 (142 ref.)

Arachidonic acid maldistribution in obesity. Phinney SD. **Lipids** 1996 Mar;31 Suppl:S271–4 (14 ref.)

[Role of metabolic arachidonic acid cascade and prostaglandin E2 in the pathogenesis of immunodeficiency in traumatic shock and acute hemorrhage] Pavlovskiĭ MP, et al. **Klin Khir** 1995;(4):35–8 (62 ref.) **(Ukr)**

PHARMACOLOGY

Antagonistic effects of dietary arachidonic acid and n-3 polyunsaturated fatty acids. Whelan J. **J Nutr** 1996 Apr; 126(4 Suppl):1086S–91S (35 ref.)

[The modulation of cellular ion channel activity by arachidonic acid, its metabolic products and other fatty acids] Krutetskaia ZI, et al. **Tsitologiia** 1995;37(1–2):5–65 (241 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Arachidonic acid as a neurotoxic and neurotrophic substance. Katsuki H, et al. **Prog Neurobiol** 1995 Aug;46(6):607–36 (345 ref.)

Arachidonic acid and eicosanoids as targets and effectors in second messenger interactions. Di Marzo V. **Prostaglandins Leukot Essent Fatty Acids** 1995 Oct; 53(4):239–54 (183 ref.)

[Reactive oxygen species and arachidonic acid metabolites of polymorphonuclear leukocytes] Döring G, et al. **Immun Infekt** 1995 Oct;23(5):148–57 (163 ref.) (Eng. Abstr.) **(Ger)**

TOXICITY

Arachidonic acid as a neurotoxic and neurotrophic substance. Katsuki H, et al. **Prog Neurobiol** 1995 Aug;46(6):607–36 (345 ref.)

ARACHIDONIC ACIDS

[Anandamide: an endogenous cannabinoid receptor agonist] Ueda N. **Seikagaku** 1995 Aug;67(8):1036–40 (19 ref.) **(Jpn)**

[Anandamide: a marijuana-like compound produced in animal tissues] Ueda N, et al. **Tanpakushitsu Kakusan Koso** 1995 Nov;40(15):2329–39 (59 ref.) **(Jpn)**

PHARMACOLOGY

Evidence that iodolactones are the mediators of growth inhibition by iodine on the thyroid. Gärtner R, et al. **Acta Med Austriaca** 1996;23(1–2):47–51 (34 ref.)

ARACHNID VECTORS

Recent acquisitions on tick and tick-borne disease resistance in N'dama (Bos taurus) and Gobra zebu (Bos indicus) cattle. Mattioli RC, et al. **Parassitologia** 1995 Apr;37(1):63–7 (40 ref.)

[The role of ticks in the epidemiology of Lyme borreliosis] Wegner Z, et al. **Przegl Epidemiol** 1995;49(3):245–50 (33 ref.) (Eng. Abstr.) **(Pol)**

[The interrelationships of ixodid ticks (Ixodidae) with the causative agents of transmissible vertebrate infections] Balashov IuS. **Parazitologiia** 1995 Sep–Oct;29(5):337–52 (90 ref.) (Eng. Abstr.) **(Rus)**

VIROLOGY

Persistence and transmission of tick-borne viruses: Ixodes ricinus and louping-ill virus in red grouse populations. Hudson PJ, et al. **Parasitology** 1995;111 Suppl:S49–58 (27 ref.)

ARACHNIDISM

Scorpion envenomation [editorial] Sofer S. **Intensive Care Med** 1995 Aug;21(8):626–8 (20 ref.)

Spider bites [see comments] Blackman JR. **J Am Board Fam Pract** 1995 Jul–Aug;8(4):288–94 (35 ref.) Comment in: J Am Board Fam Pract 1995 Nov–Dec;8(6):503.

[Scorpion stings in children. Saudi Arabian experience] el Aminn EO, et al. **Arch Pediatr** 1995 Aug;2(8):766–73 (64 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

Black widow spider bite in a child. Reeves JA, et al. **Am J Emerg Med** 1996 Sep;14(5):469–71 (17 ref.)

Chronic relapsing pancreatitis from a scorpion sting in Trinidad. George Angus LD, et al. **Ann Trop Paediatr** 1995 Dec;15(4):285–9 (18 ref.)

DIAGNOSIS

Chronic relapsing pancreatitis from a scorpion sting in Trinidad. George Angus LD, et al. **Ann Trop Paediatr** 1995 Dec;15(4):285–9 (18 ref.)

Spider bite reactions. Carbonaro PA, et al. **Cutis** 1995 Nov; 56(5):256–9 (36 ref.)

ARACHNODACTYLY see MARFAN SYNDROME

ARACHNOID

PATHOLOGY

The natural history of arachnoid cysts: endoscopic and cine-mode MRI evidence of a slit-valve mechanism. Santamarta D, et al. **Minim Invasive Neurosurg** 1995 Dec; 38(4):133–7 (28 ref.)

ARACHNOID CYSTS

Craniospinal arachnoid cyst: case report] Fukushima Y, et al. **No Shinkei Geka** 1996 Jan;24(1):75–9 (14 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Large arachnoid cyst. Mondal T, et al. **Indian Pediatr** 1995 Aug;32(8):927–9 (12 ref.)

The natural history of arachnoid cysts: endoscopic and cine-mode MRI evidence of a slit-valve mechanism. Santamarta D, et al. **Minim Invasive Neurosurg** 1995 Dec; 38(4):133–7 (28 ref.)

GENETICS

Absence/hypoplasia of tibia, polydactyly, retrocerebellar arachnoid cyst, and other anomalies: an autosomal recessive disorder. Holmes LB, et al. **J Med Genet** 1995 Nov; 32(11):896–900 (29 ref.)

PHYSIOPATHOLOGY

The natural history of arachnoid cysts: endoscopic and cine-mode MRI evidence of a slit-valve mechanism. Santamarta D, et al. **Minim Invasive Neurosurg** 1995 Dec; 38(4):133–7 (28 ref.)

SURGERY

Arachnoid cyst within the fourth ventricle--a case report. Nadkarni T, et al. **Br J Neurosurg** 1995;9(5):675–8 (10 ref.)

Cystplastic cyst-subarachnoid shunt procedure for arachnoid cyst of the middle cranial fossa--technical note. Takeuchi T, et al. **Neurol Med Chir (Tokyo)** 1996 Jun;36(6):396–9 (7 ref.)

Arachnoid cysts: does surgery improve epileptic seizures and headaches? Koch CA, et al. **Neurosurg Rev** 1995; 18(3):173–81 (37 ref.)

Burr hole neuroendoscopic fenestration of quadrigeminal

ARACHNOID CYSTS

cistern arachnoid cyst: technical case report. Ruge JR, et al. **Neurosurgery** 1996 Apr;38(4):830–7 (32 ref.)

ARACHNOIDITIS

THERAPY

Neurosurgical care of spinal epidural, subdural, and intramedullary abscesses and arachnoiditis. Martin RJ, et al. **Orthop Clin North Am** 1996 Jan;27(1):125–36 (72 ref.)

ARAURIDINE see **ARABINOFURANOSYLURACIL**

ARBITRATING see **NEGOTIATING**

ARBOVIRUS INFECTIONS

EPIDEMIOLOGY

Arboviruses causing neurological disorders in the central nervous system. Dobler G. **Arch Virol Suppl** 1996;11:33–40 (18 ref.)

Arboviruses as imported disease agents: the need for increased awareness. Gubler DJ. **Arch Virol Suppl** 1996; 11:21–32 (29 ref.)

ETIOLOGY

Arboviruses and the central nervous system. Griffin DE. **Springer Semin Immunopathol** 1995;17(2–3):121–32 (79 ref.)

IMMUNOLOGY

Arboviruses and the central nervous system. Griffin DE. **Springer Semin Immunopathol** 1995;17(2–3):121–32 (79 ref.)

TRANSMISSION

Arboviruses causing neurological disorders in the central nervous system. Dobler G. **Arch Virol Suppl** 1996;11:33–40 (18 ref.)

Australian arboviruses: at what risk New Zealand? [editorial] Weinstein P, et al. **Aust N Z J Med** 1995 Dec;25(6):666–9 (19 ref.)

VETERINARY

Australian–Indonesian collaboration in veterinary arbovirology—a review. Daniels PW, et al. **Vet Microbiol** 1995 Sep;46(1–3):151–74 (108 ref.)

Veterinary arbovirus vectors in Australia—a retrospective. Muller MJ. **Vet Microbiol** 1995 Sep;46(1–3):101–16 (67 ref.)

ARBOVIRUSES

see related
BUNYAVIRIDAE
REOVIRIDAE

The role of Aedes albopictus as an arbovirus vector. Mitchell CJ. **Parassitologia** 1995 Dec;37(2–3):109–13 (17 ref.)

Arbovirus surveillance in Italy. Verani P, et al. **Parassitologia** 1995 Dec;37(2–3):105–8 (19 ref.)

Australian–Indonesian collaboration in veterinary arbovirology—a review. Daniels PW, et al. **Vet Microbiol** 1995 Sep;46(1–3):151–74 (108 ref.)

CLASSIFICATION

Arboviruses as imported disease agents: the need for increased awareness. Gubler DJ. **Arch Virol Suppl** 1996; 11:21–32 (29 ref.)

ISOLATION & PURIFICATION

Veterinary arbovirus vectors in Australia—a retrospective. Muller MJ. **Vet Microbiol** 1995 Sep;46(1–3):101–16 (67 ref.)

PATHOGENICITY

Arboviruses causing neurological disorders in the central nervous system. Dobler G. **Arch Virol Suppl** 1996;11:33–40 (18 ref.)

ARBOVIRUSES, GROUP A see **ALPHAVIRUS**

ARCHAEA see **ARCHAEOBACTERIA**

ARCHAEBACTERIA see **ARCHAEOBACTERIA**

ARCHAEOBACTERIA

A hot topic: the origin of hyperthermophiles. Forterre P. **Cell** 1996 Jun 14;85(6):789–92 (20 ref.)

ENZYMOLOGY

Glyceraldehyde-3-phosphate dehydrogenase from Thermotoga maritima: strategies of protein stabilization. Jaenicke R. **FEMS Microbiol Rev** 1996 May;18(2–3):215–24 (33 ref.)

Insights into the molecular basis of thermal stability from the structure determination of Pyrococcus furiosus glutamate dehydrogenase. Rice DW, et al. **FEMS Microbiol Rev** 1996 May;18(2–3):105–17 (43 ref.)

GENETICS

General vectors for archaeal hyperthermophiles: strategies based on a mobile intron and a plasmid. Aagaard C, et al. **FEMS Microbiol Rev** 1996 May;18(2–3):93–104 (38 ref.)

The unique DNA topology and DNA topoisomerases of hyperthermophilic archaea. Forterre P, et al. **FEMS Microbiol Rev** 1996 May;18(2–3):237–48 (47 ref.)

Archaeal transcription factors and their role in transcription initiation. Thomm M. **FEMS Microbiol Rev** 1996 May; 18(2–3):159–71 (64 ref.)

Viruses, plasmids and other genetic elements of thermophilic and hyperthermophilic Archaea. Zillig W, et al. **FEMS Microbiol Rev** 1996 May;18(2–3):225–36 (28 ref.)

Archaeal ubiquity. Stein JL, et al. **Proc Natl Acad Sci U S A** 1996 Jun 25;93(13):6228–30 (13 ref.)

Transcription: new insights from studies on Archaea. Baumann P, et al. **Trends Genet** 1995 Jul;11(7):279–83 (43 ref.)

METABOLISM

Respiratory chains of archaea and extremophiles. Schäfer G, et al. **Biochim Biophys Acta** 1996 Jul 18;1275(1–2):16–20 (39 ref.)

Histones and chromatin structure in hyperthermophilic Archaea. Grayling RA, et al. **FEMS Microbiol Rev** 1996 May;18(2–3):203–13 (29 ref.)

On the origin of respiration: electron transport proteins from archaea to man. Schäfer G, et al. **FEMS Microbiol Rev** 1996 May;18(2–3):173–88 (55 ref.)

VIROLOGY

Viruses, plasmids and other genetic elements of thermophilic and hyperthermophilic Archaea. Zillig W, et al. **FEMS Microbiol Rev** 1996 May;18(2–3):225–36 (28 ref.)

ARCHAEOLOGY

[Ancient DNA] Ueda S. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):733–7 (19 ref.) **(Jpn)**

ARCHENTERON see **GASTRULA**

ARCUATE NUCLEUS

METABOLISM

Neuropeptide Y, the hypothalamus, and diabetes: insights into the central control of metabolism. Frankish HM, et al. **Peptides** 1995;16(4):757–71 (154 ref.)

ARDS, HUMAN see **RESPIRATORY DISTRESS SYNDROME, ADULT**

AREAWIDE PLANNING see **REGIONAL HEALTH PLANNING**

ARECA

Oral cancer and precancer related to betel and miang chewing in Thailand: a review. Reichart PA. **J Oral Pathol Med** 1995 Jul;24(6):241–3 (17 ref.)

ARGENTAFFIN CELLS see **ENTEROCHROMAFFIN CELLS**

ARGENTAFFIN SYSTEM see **CHROMAFFIN SYSTEM**

ARGENTAFFINOMA see **CARCINOID TUMOR**

ARGINASE

BLOOD

[Arginase] Ikemoto M. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:198–201 (9 ref.) **(Jpn)**

CHEMISTRY

Comparative properties of arginases. Jenkinson CP, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1996 May; 114(1):107–32 (270 ref.)

PHYSIOLOGY

Comparative properties of arginases. Jenkinson CP, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1996 May; 114(1):107–32 (270 ref.)

ARGININE

ADMINISTRATION & DOSAGE

Nutritional pharmacology and malignant disease: a therapeutic modality in patients with cancer. Heys SD, et al. **Br J Surg** 1996 May;83(5):608–19 (135 ref.)

ANALOGS & DERIVATIVES

Regulation of blood pressure by nitroxidergic nerve. Toda N. **J Diabetes Complications** 1995 Oct–Dec;9(4):200–2 (21 ref.)

Vascular structure in NG-nitro-L-arginine methyl ester-induced hypertension: methodological considerations for studies of small arteries in hypertension [editorial] [see comments] Schiffrin EL. **J Hypertens** 1995 Aug; 13(8):817–21 (40 ref.) Comment in: J Hypertens 1995 Oct;13(10):1217–21.

Perspectives on the N-methyl-D-aspartate/nitric oxide cascade and opioid tolerance. Pasternak GW, et al. **Neuropsychopharmacology** 1995 Dec;13(4):309–13 (24 ref.)

Inhibitors of nitric oxide synthase and the opioid withdrawal syndrome. London ED, et al. **NIDA Res Monogr** 1995; 147:170–81 (26 ref.)

DRUG EFFECTS

Protein kinases and phosphatases that act on histidine, lysine, or arginine residues in eukaryotic proteins: a possible regulator of the mitogen-activated protein kinase cascade. Matthews HR. **Pharmacol Ther** 1995;67(3):323–50 (154 ref.)

METABOLISM

Neuronal nitric oxide synthase, a modular enzyme formed by convergent evolution: structure studies of a cysteine thiolate-liganded heme protein that hydroxylates L-arginine to produce NO. as a cellular signal. Masters BS, et al. **FASEB J** 1996 Apr;10(5):552–8 (70 ref.)

Nitric oxide, sepsis, and arginine metabolism. Kelly E, et al. **JPEN J Parenter Enteral Nutr** 1995 May–Jun; 19(3):234–8 (52 ref.)

The L-arginine/nitric oxide pathway—biological properties and therapeutic applications. Neilly PJ, et al. **Ulster Med J** 1994 Oct;63(2):193–200 (67 ref.)

[The L-arginine/nitric oxide metabolic pathway. Its physiopathology and clinical implications] Mengozzi G, et al. **Ann Ital Med Int** 1996 Jan–Mar;11(1):46–51 (48 ref.) (Eng. Abstr.) **(Ita)**

PHARMACOLOGY

Impact of the L-arginine/nitric oxide system in pregnancy. Neri I, et al. **Obstet Gynecol Surv** 1995 Dec;50(12):851–8 (64 ref.)

PHYSIOLOGY

[Leishmania–macrophage interactions: role of cytokines and molecules co-involved in killing] Faliero SM, et al. **Parassitologia** 1995 Apr;37(1):5–15 (126 ref.) (Eng. Abstr.) **(Ita)**

[The bioregulatory system L-arginine—nitric oxide] Markov KhM. **Patol Fiziol Eksp Ter** 1996 Jan–Mar;(1):34–9 (76 ref.) **(Rus)**

THERAPEUTIC USE

The L-arginine/nitric oxide pathway—biological properties and therapeutic applications. Neilly PJ, et al. **Ulster Med J** 1994 Oct;63(2):193–200 (67 ref.)

ARGININE OXYTOCIN see **VASOTOCIN**

ARGININE VASOPRESSIN see **ARGIPRESSIN**

ARGININE VASOTOCIN see **VASOTOCIN**

ARGININOSUCCINATE SYNTHETASE

BLOOD

[Argininosuccinate synthetase (ASS)] Miura T, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:415–8 (7 ref.) **(Jpn)**

ARGIPRESSIN

ANTAGONISTS & INHIBITORS

Potential use of oxytocin and vasopressin V1a antagonists in the treatment of preterm labour and primary dysmenorrhoea. Akerlund M, et al. **Adv Exp Med Biol** 1995; 395:595–600 (32 ref.)

METABOLISM

Strategies for cell biological studies in oxytocinergic neurons. Gainer H, et al. **Adv Exp Med Biol** 1995;395:1–8 (58 ref.)

PHYSIOLOGY

Protein tyrosine phosphorylation in cardiovascular system. Srivastava AK. **Mol Cell Biochem** 1995 Aug–Sep; 149–150:87–94 (90 ref.)

[Neurohormonal factors in heart failure. II] Cosín Aguilar J, et al. **Rev Esp Cardiol** 1996 May;49(5):317–27 (47 ref.) (Eng. Abstr.) **(Spa)**

ARGIPRESTOCIN see **VASOTOCIN**

ARHINENCEPHALY see **HOLOPROSENCEPHALY**

ARM

see related
FORELIMB

Focused review: postmastectomy lymphedema. Brennan MJ, et al. **Arch Phys Med Rehabil** 1996 Mar;77(3 Suppl):S74–80 (55 ref.)

Classification systems of soft tissue disorders of the neck and upper limb: do they satisfy methodological guidelines? Buchbinder R, et al. **J Clin Epidemiol** 1996 Feb;49(2):141–9

(76 ref.)
Opportunistic mycotic infections of the upper limb. A review. al-Qattan MM. **J Hand Surg [Br]** 1996 Apr;21(2):148–50 (21 ref.)
Computer simulation of the upper extremities. Buford WL Jr, et al. **J Hand Ther** 1995 Apr–Jun;8(2):167–74 (33 ref.)
[Treatment of primary hyperhidrosis of the upper limbs by transthoracic endoscopic sympathectomy] Lesèche G, et al. **Presse Med** 1995 Nov 4;24(33):1569–73 (36 ref.) (Eng. Abstr.) **(Fre)**

INNERVATION

Clinical diagnosis of peripheral nerve compression in the upper extremity. Anto C, et al. **Orthop Clin North Am** 1996 Apr;27(2):227–36 (31 ref.)
Electrodiagnosis in compression neuropathies of the upper extremities. de Araujo MP. **Orthop Clin North Am** 1996 Apr;27(2):237–44 (50 ref.)
Dynamics and pathophysiology of nerve compression in the upper extremity. Delfiner JS. **Orthop Clin North Am** 1996 Apr;27(2):219–26 (25 ref.)
Persistence of symptoms after surgical release of compressive neuropathies and subsequent management. Idler RS. **Orthop Clin North Am** 1996 Apr;27(2):409–16 (21 ref.)
Differential diagnosis and pitfalls in electrodiagnostic studies and special tests for diagnosing compressive neuropathies. Kaufman MA. **Orthop Clin North Am** 1996 Apr; 27(2):245–52 (32 ref.)
Unusual compressive neuropathies of the upper limb. Osterman AL, et al. **Orthop Clin North Am** 1996 Apr; 27(2):389–408 (116 ref.)
Multiple compression neuropathies and the double-crush syndrome. Simpson RL, et al. **Orthop Clin North Am** 1996 Apr;27(2):381–8 (59 ref.)

PHYSIOLOGY

Current issues in directional motor control [see comments] Georgopoulos AP. **Trends Neurosci** 1995 Nov; 18(11):506–10 (63 ref.) Comment in: Trends Neurosci 1996 Apr;19(4):137–8.

PHYSIOPATHOLOGY

The performance of rapid arm movements in Parkinson's disease. A review. Agostino R, et al. **Adv Neurol** 1996; 69:135–46 (61 ref.)
Single-joint rapid arm movements in normal subjects and in patients with motor disorders. Berardelli A, et al. **Brain** 1996 Apr;119 (Pt 2):661–74 (78 ref.)

SURGERY

[Surgery of soft tissue sarcoma (with the exception of the retroperitoneum)] Stöckle E, et al. **Ann Chir** 1996; 50(3):263–75 (85 ref.) (Eng. Abstr.) **(Fre)**
[1984–1994: Ten years of skin flaps. Development of transfer techniques. New methods of autoplasty described during this period] Martin D. **Ann Chir Plast Esthet** 1995 Oct; 40(5):527–82 (126 ref.) (Eng. Abstr.) **(Fre)**

ARM ERGOMETRY TEST see **EXERCISE TEST**

ARM INJURIES

Upper extremity injuries in young athletes. Ireland ML, et al. **Clin Sports Med** 1995 Jul;14(3):533–69 (101 ref.)
Upper extremity disorders: a literature review to determine work-relatedness. Vender MI, et al. **J Hand Surg [Am]** 1995 Jul;20(4):534–41 (79 ref.)

DIAGNOSIS

Common upper-extremity injuries. Lillegard WA, et al. **Arch Fam Med** 1996 Mar;5(3):159–68 (40 ref.)

ETIOLOGY

Sports-specific injuries. Plancher KD, et al. **Clin Sports Med** 1996 Apr;15(2):207–18 (16 ref.)

SURGERY

The role of microsurgery and free tissue transfer in the reconstruction of the paediatric upper extremity. Kay S, et al. **Ann Acad Med Singapore** 1995 Jul;24(4 Suppl):113–23 (50 ref.)
Traumatic plastic deformity of an adult forearm: case report and literature review. Simonian PT, et al. **J Orthop Trauma** 1996;10(3):213–5 (12 ref.)
[Rupture of the distal tendon of the biceps brachialis: apropos of 43 cases] Catonné Y, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1995;81(2):163–72 (17 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Common upper-extremity injuries. Lillegard WA, et al. **Arch Fam Med** 1996 Mar;5(3):159–68 (40 ref.)

ARMED FORCES PERSONNEL see **MILITARY PERSONNEL**

ARNOLD-CHIARI DEFORMITY

DIAGNOSIS

Esophageal dysphagia as the sole symptom in type I Chiari malformation. Elta GH, et al. **Dig Dis Sci** 1996 Mar; 41(3):512–5 (11 ref.)
Scoliosis as the first sign of a cystic spinal cord lesion. Samuelsson L, et al. **Eur Spine J** 1995;4(5):284–90 (41 ref.)
Syringomyelia and chiari malformation presenting as scoliosis in cystic fibrosis. Rusakow LS, et al. **Pediatr Pulmonol** 1995 May;19(5):317–8 (10 ref.)

ETIOLOGY

[Syringomyelia, scoliosis and idiopathic Arnold-Chiari malformations: a common etiology] Royo-Salvador MB. **Rev Neurol** 1996 Aug;24(132):937–59 (119 ref.) (Eng. Abstr.) **(Spa)**

SURGERY

Surgical indication and results of foramen magnum decompression versus syringosubarachnoid shunting for syringomyelia associated with Chiari I malformation. Hida K, et al. **Neurosurgery** 1995 Oct;37(4):673–8; discussion 678–9 (33 ref.)

AROMATASE

ANALYSIS

Sperm, a source of estrogen. Hess RA, et al. **Environ Health Perspect** 1995 Oct;103 Suppl 7:59–62 (41 ref.)

ANTAGONISTS & INHIBITORS

Aromatase inhibitors: current status. Ibrahim NK, et al. **Am J Clin Oncol** 1995 Oct;18(5):407–17 (142 ref.)
Inhibition of aromatase. Banting L. **Prog Med Chem** 1996; 33:147–84 (151 ref.)

GENETICS

Identification and characterization of transcriptional regulatory elements of the human aromatase cytochrome P450 gene (CYP19). Toda K, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1–6 Spec No):151–9 (22 ref.)

METABOLISM

Effects of testosterone and its metabolites on aromatase-immunoreactive cells in the quail brain: relationship with the activation of male reproductive behavior. Balthazart J, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1–6 Spec No):185–200 (125 ref.)

PHYSIOLOGY

The control and biological importance of intratumoural aromatase in breast cancer. Dowsett M, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1–6 Spec No):145–50 (22 ref.)
Regulation of sex-specific formation of oestrogen in brain development: endogenous inhibitors of aromatase. Hutchison JB, et al. **J Steroid Biochem Mol Biol** 1996 Jan; 56(1–6 Spec No):201–7 (37 ref.)

AROMATIC AMINO ACID DECARBOXYLASES

METABOLISM

Aromatic L-amino acid decarboxylase modulation and Parkinson's disease. Neff NH, et al. **Prog Brain Res** 1995; 106:91–7 (39 ref.)

AROUSAL

Attachment and separation in young children. Field T. **Annu Rev Psychol** 1996;47:541–61 (45 ref.)
Smoking cessation leads to reduced stress, but why? Parrott AC. **Int J Addict** 1995 Sep;30(11):1509–16 (17 ref.)
Stress, smoking, and the cardiovascular system. Pomerleau OF, et al. **J Subst Abuse** 1989;1(3):331–43 (50 ref.)

DRUG EFFECTS

Chronic psychiatric patients' use of caffeine: pharmacological effects and mechanisms. Kruger A. **Psychol Rep** 1996 Jun; 78(3 Pt 1):915–23 (50 ref.)
[Intraoperative awareness and auditory evoked potentials] Schwender D, et al. **Anaesthesist** 1996 Feb;45 Suppl 1:S46–51 (30 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

The role of neuroimaging in the discovery of processing stages. A review. Mulder G, et al. **Acta Psychol (Amst)** 1995 Nov;90(1–3):63–79 (66 ref.)
Corticotropin-releasing hormone involvement in stressor-induced alterations in sleep and in the regulation of waking. Opp MR. **Adv Neuroimmunol** 1995;5(2):127–43 (100 ref.)
Brain imaging and cognitive neuroscience. Toward strong inference in attributing function to structure. Sarter M, et al. **Am Psychol** 1996 Jan;51(1):13–21 (75 ref.)
Relationship of anxiety, stress, and psychosocial development to reproductive health [see comments] Lederman RP. **Behav Med** 1995 Fall;21(3):101–12 (110 ref.) Comment in: Behav Med 1995 Fall;21(3):123–9.
Hemoconcentration and stress: a review of physiological mechanisms and relevance for cardiovascular disease risk. Allen MT, et al. **Biol Psychol** 1995 Aug;41(1):1–27 (125 ref.)
Psychophysiology and adaptive automation. Byrne EA, et al. **Biol Psychol** 1996 Feb 5;42(3):249–68 (75 ref.)
Primary (idiopathic) generalized epilepsy and underlying mechanisms. Niedermeyer E. **Clin Electroencephalogr** 1996 Jan;27(1):1–21 (147 ref.)
Discrete, patterned and purposeful adaptive physiological adjustments integrated by forebrain influences. Wolf S. **Integr Physiol Behav Sci** 1995 Jul–Sep;30(3):190–9 (21 ref.)
Assessment of the cardiovascular effects of stress. Engler MB, et al. **J Cardiovasc Nurs** 1995 Oct;10(1):51–63 (85 ref.)
Dynamic neuroimaging of brain function. Simpson GV, et al. **J Clin Neurophysiol** 1995 Sep;12(5):432–49 (65 ref.)
Psychophysiological aspects of autistic disorders: overview. Murray JB. **J Psychol** 1996 Mar;130(2):145–58 (95 ref.)
The pedunculopontine nucleus--auditory input, arousal and pathophysiology. Reese NB, et al. **Prog Neurobiol** 1995 Oct;47(2):105–33 (365 ref.)
Neurofunctional mechanisms in autism. Waterhouse L, et al. **Psychol Rev** 1996 Jul;103(3):457–89 (280 ref.)
Arousal: revisiting the reticular activating system [comment] Steriade M. **Science** 1996 Apr 12;272(5259):225–6 (14 ref.) Comment on: Science 1996 Apr 12;272(5259):271–4. Comment on: Science 1996 Apr 12;272(5259):274–7.
Magnocellular nuclei of the basal forebrain: substrates of sleep and arousal regulation. Szymusiak R. **Sleep** 1995 Jul; 18(6):478–500 (181 ref.)
[Psychological stress and neuronal plasticity. An expanded model of the stress reaction process as the basis for understand central nervous system adaptation processes] Huether G, et al. **Z Psychosom Med Psychoanal** 1996; 42(2):107–27 (70 ref.) (Eng. Abstr.) **(Ger)**

ARRHYTHMIA

see related
ANTI-ARRHYTHMIA AGENTS
ELECTRIC COUNTERSHOCK

CHEMICALLY INDUCED

Cardiac electrophysiology, arrhythmogenic mechanisms and roentgen contrast media. Jacobsen EA, et al. **Acta Radiol Suppl** 1995;399:105–14 (60 ref.)
What have clinical trials taught us about proarrhythmia? Skanes AC, et al. **Can J Cardiol** 1996 Apr;12 Suppl B:20B–26B (39 ref.)
Proarrhythmia with class III antiarrhythmic drugs: definition, electrophysiologic mechanisms, incidence, predisposing factors, and clinical implications. Hohnloser SH, et al. **J Cardiovasc Electrophysiol** 1995 Oct;6(10 Pt 2):920–36 (102 ref.)
Cardiovascular safety in depressed patients: focus on venlafaxine. Feighner JP. **J Clin Psychiatry** 1995 Dec; 56(12):574–9 (44 ref.)
Electrophysiologic and proarrhythmic effects of intravenous inotropic agents. Tisdale JE, et al. **Prog Cardiovasc Dis** 1995 Sep–Oct;38(2):167–80 (104 ref.)
[Proarrhythmic effects of anti-arrhythmia agents] Scanu P, et al. **Rev Med Interne** 1995;16(8):602–7 (24 ref.) (Eng. Abstr.) **(Fre)**
["Arrhythmica" or: history, extent and practical consequences of pro-arrhythmia effects] Gertsch M. **Schweiz Med Wochenschr** 1996 Apr 6;126(14):566–75 (13 ref.) (Eng. Abstr.) **(Ger)**

COMPLICATIONS

Risk assessment and prevention of sudden cardiac death in hypertrophic cardiomyopathy. Slade AK, et al. **Arch Mal Coeur Vaiss** 1996 Feb;89 Spec No 1:37–49 (74 ref.)

DIAGNOSIS

Electrophysiologic study in chronic Chagas' heart disease. Scanavacca M, et al. **Rev Paul Med** 1995 Mar–Apr; 113(2):841–50 (45 ref.)
[Ventricular arrhythmias: diagnosis and drug therapy] Schüpfer C, et al. **Schweiz Rundsch Med Prax** 1996 May 14;85(20):647–54 (40 ref.) (Eng. Abstr.) **(Ger)**
[Electrocardiogram in pre-excitation] Oreto G, et al. **G Ital Cardiol** 1996 Mar;26(3):303–22 (55 ref.) **(Ita)**

DRUG THERAPY

Successful heart failure therapy is effective antiarrhythmia therapy [editorial] Khosla S, et al. **Am Heart J** 1996 May; 131(5):1048–50 (23 ref.)
The cardiac ion channels: relevance to management of arrhythmias. Roden DM, et al. **Annu Rev Med** 1996; 47:135–48 (66 ref.)
Is there a need for new antiarrhythmic drugs? Roden DM. **Arch Mal Coeur Vaiss** 1996 Feb;89 Spec No 1:13–8 (36

ref.)
Assessment of arrhythmias after myocardial infarction in the post-CAST era. Camm AJ, et al. **Can J Cardiol** 1996 Apr; 12 Suppl B:9B-19B; discussion 27B-28B (106 ref.)
Guidelines for the use of propafenone in treating supraventricular arrhythmias. Kishore AG, et al. **Drugs** 1995 Aug;50(2):250-62 (73 ref.)
Should post-infarction asymptomatic ventricular arrhythmias be treated? Campbell RW. **Eur Heart J** 1995 Jul;16 Suppl E:46-8 (37 ref.)
Should post-infarction asymptomatic ventricular arrhythmias be treated? The need for caution. Sleight P. **Eur Heart J** 1995 Jul;16 Suppl E:49 (29 ref.)
Propafenone: an effective agent for the management of supraventricular arrhythmias. Grant AO. **J Cardiovasc Electrophysiol** 1996 Apr;7(4):353-64 (74 ref.)
Cardiac arrhythmias and antiarrhythmic drugs: recent advances in our understanding of mechanism. Rosen MR. **J Cardiovasc Electrophysiol** 1995 Oct;6(10 Pt 2):868-79 (40 ref.)
Phosphodiesterase inhibition and Ca2+ sensitization. Ravens U, et al. **Mol Cell Biochem** 1996 Apr 12-26;157(1-2):245-9 (21 ref.)
Antiarrhythmic and anti-ischemic properties of calcium-channel antagonists. Apostolakos MJ, et al. **New Horiz** 1996 Feb;4(1):45-57 (94 ref.)
Medical treatment of cardiac arrhythmias in Chagas' heart disease. de Paola AA, et al. **Rev Paul Med** 1995 Mar-Apr; 113(2):858-61 (29 ref.)
[Anti-arrhythmic therapy and cardiac failure] Cosnay P, et al. **Arch Mal Coeur Vaiss** 1995 Dec;88 Spec No 5:35-41 (44 ref.) (Eng. Abstr.) **(Fre)**
[Use of current anti-arrhythmia agents in pediatric cardiology] Massin M. **Rev Med Liege** 1995 Dec; 50(12):505-9 (40 ref.) **(Fre)**
[Ventricular arrhythmias: diagnosis and drug therapy] Schüpfer C, et al. **Schweiz Rundsch Med Prax** 1996 May 14;85(20):647-54 (40 ref.) (Eng. Abstr.) **(Ger)**
[Clinical use of intravenous amiodarone for supraventricular arrhythmias] Assadi S, et al. **Harefuah** 1995 Dec 15; 129(12):583-6 (24 ref.) **(Heb)**
[Emergency drug therapy of arrhythmia] Mitamura H. **Nippon Naika Gakkai Zasshi** 1995 Nov 10;84(11):1804-9 (5 ref.) **(Jpn)**
[Tactics of treatment of patients with arrhythmia] Glezer MG, et al. **Klin Med (Mosk)** 1995;73(4):13-7 (0 ref.) **(Rus)**

ETIOLOGY

Cardiac arrhythmias and left ventricular hypertrophy in systemic hypertension and their influences on prognosis. Bayés-Genís A, et al. **Am J Cardiol** 1995 Nov 2; 76(13):54D-59D (53 ref.)
Assessment of arrhythmias after myocardial infarction in the post-CAST era. Camm AJ, et al. **Can J Cardiol** 1996 Apr; 12 Suppl B:9B-19B; discussion 27B-28B (106 ref.)
Mechanosensitive connective tissue: potential influence on heart rhythm. Kohl P, et al. **Cardiovasc Res** 1996 Jul; 32(1):62-8 (63 ref.)
Effects of mechano-electrical feedback: potential arrhythmogenic influence in patients with congestive heart failure. Reiter MJ. **Cardiovasc Res** 1996 Jul;32(1):44-51 (44 ref.)
New insights into myocardial arrhythmogenesis: distribution of gap-junctional coupling in normal, ischaemic and hypertrophied human hearts. Peters NS. **Clin Sci (Colch)** 1996 Jun;90(6):447-52 (56 ref.)
Structural and non-structural disease underlying high-risk cardiac arrhythmias relevant to sports medicine. Rossi L. **J Sports Med Phys Fitness** 1995 Jun;35(2):79-86 (29 ref.)
Identifying the causes of syncope and palpitations. Burn S, et al. **Practitioner** 1995 Nov;239(1556):666-9 (3 ref.)
Arrhythmias induced by exercise in athletes and others. McGovern BA, et al. **S Afr Med J** 1996 Apr;86 Suppl 2:C78-82 (22 ref.)
[Ventricular arrhythmias and arterial hypertension] Dorobantu M, et al. **Ann Cardiol Angeiol (Paris)** 1996 May; 45(5):291-5 (23 ref.) (Eng. Abstr.) **(Fre)**
[Outcome of arrhythmogenic right ventricular dysplasia. Apropos of 4 cases] Fontaine G, et al. **Arch Mal Coeur Vaiss** 1995 Jul;88(7):973-9 (12 ref.) (Eng. Abstr.) **(Fre)**
[Influence of post-infarction myocardial revascularization on the prevalence of delayed potentials] Lomama E, et al. **Arch Mal Coeur Vaiss** 1995 Sep;88(9):1267-72 (29 ref.) (Eng. Abstr.) **(Fre)**
[Excess of histamine as a possible cause of cardiac arrhythmias] Marra L, et al. **Clin Ter** 1996 Mar;147(3):145-7 (10 ref.) (Eng. Abstr.) **(Ita)**
[Chronic Chagas cardiopathy as a model for an insight on the pathogenesis of arrhythmogenic right ventricular cardiomyopathy (editorial)] Rossi MA. **Arq Bras Cardiol** 1995 Jul;65(1):3-5 (39 ref.) **(Por)**
[Cardiovascular impact of alcoholism] Faintuch JJ. **Rev Hosp Clin Fac Med Sao Paulo** 1995 Jan-Feb;50(1):76-9 (47 ref.) (Eng. Abstr.) **(Por)**

GENETICS

Molecular genetic insights into cardiovascular disease. Keating MT, et al. **Science** 1996 May 3;272(5262):681-5 (33 ref.)

PATHOLOGY

Endomyocardial biopsy in arrhythmogenic right ventricular cardiomyopathy [editorial] Angelini A, et al. **Am Heart J** 1996 Jul;132(1 Pt 1):203-6 (35 ref.)

PHYSIOPATHOLOGY

Evidence favoring the hypothesis that ventricular arrhythmias have prognostic significance in left ventricular hypertrophy secondary to systemic hypertension. Almendral J, et al. **Am J Cardiol** 1995 Nov 2; 76(13):60D-63D (27 ref.)
Functional roles of sodium-calcium exchange in normal and abnormal cardiac rhythm. Noble D, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:480-8 (17 ref.)
Mechano-electrical feedback in ventricular myocardium. Franz MR. **Cardiovasc Res** 1996 Jul;32(1):15-24 (40 ref.)
Athletes and arrhythmias: clinical considerations and perspectives. Josephson ME, et al. **Eur Heart J** 1996 Apr; 17(4):498-505 (47 ref.)
Cardiac arrhythmias and antiarrhythmic drugs: recent advances in our understanding of mechanism. Rosen MR. **J Cardiovasc Electrophysiol** 1995 Oct;6(10 Pt 2):868-79 (40 ref.)
Age, altitude, and arrhythmia. Alexander JK. **Tex Heart Inst J** 1995;22(4):308-16 (69 ref.)
[Sudden cardiac death: definition, mechanisms and risk factors] Evéquoz D, et al. **Schweiz Rundsch Med Prax** 1996 Feb 13;85(7):188-96 (56 ref.) (Eng. Abstr.) **(Fre)**
[Assessment of ventricular arrhythmias] Osswald S, et al. **Schweiz Rundsch Med Prax** 1996 Feb 13;85(7):179-87 (48 ref.) (Eng. Abstr.) **(Ger)**
[Indications for electrophysiological studies and catheter ablation of cardiac arrhythmias. Recommendations of the Department of Arrhythmias and Clinical Electrophysiology of the Brazilian Society of Cardiology] Sosa EA, et al. **Arq Bras Cardiol** 1995 Feb;64(2):149-51 (1 ref.) **(Por)**
[The prostanoid system in patients with disordered heart rhythm] Bobrov VA, et al. **Ter Arkh** 1995;67(8):68-71 (69 ref.) **(Rus)**

PREVENTION & CONTROL

Management and prophylaxis of life-threatening arrhythmias--recent achievements. Andresen D, et al. **Eur Heart J** 1995 Aug;16 Suppl G:20-3 (24 ref.)
The use of ungating with the Medstone lithotriptor. Cass AS. **J Urol** 1996 Sep;156(3):896-8 (15 ref.)
[The high risk cardiac patient in anesthesia] Francke A. **Anaesthesiol Reanim** 1996;21(2):32-42 (89 ref.) (Eng. Abstr.) **(Ger)**
[Stratification of arrhythmia risk and therapeutic options in survivors of acute myocardial infarction] Arós Borau F, et al. **Rev Esp Cardiol** 1996 Mar;49(3):157-65 (85 ref.) (Eng. Abstr.) **(Spa)**

SURGERY

Treatment of arrhythmias by radiofrequency ablation. De Giovanni JV. **Arch Dis Child** 1995 Nov;73(5):385-7 (18 ref.)
Radiofrequency ablation of arrhythmias in the pediatric patient. Moak JP. **Curr Opin Cardiol** 1996 Jan;11(1):81-92 (47 ref.)
Future ablation concepts of tachyarrhythmias. Chen SA, et al. **J Cardiovasc Electrophysiol** 1995 Oct;6(10 Pt 1):852-62 (99 ref.)
Delayed effects of radiofrequency energy: mechanisms and clinical implications. Fenelon G, et al. **Pacing Clin Electrophysiol** 1996 Apr;19(4 Pt 1):484-9 (31 ref.)
[Radiofrequency ablation of the atrioventricular accessory pathways. Value of unipolar and bipolar recordings] Aliot E, et al. **Arch Mal Coeur Vaiss** 1996 Feb;89 Spec No 1:89-97 (35 ref.) (Eng. Abstr.) **(Fre)**
[Radiofrequency ablation: physical bases and principles] Lavergne T, et al. **Arch Mal Coeur Vaiss** 1996 Feb;89 Spec No 1:57-63 (35 ref.) (Eng. Abstr.) **(Fre)**
[Biophysical basis and cardiac lesions caused by different techniques of cardiac arrhythmia ablation] Lévy S. **Arch Mal Coeur Vaiss** 1995 Oct;88(10):1465-9 (28 ref.) (Eng. Abstr.) **(Fre)**
[Ablation of arrhythmia disorders: endocavitary catheter surgery. 2 decades of cardia electrophysiology] Fontaine G. **Bull Mem Acad R Med Belg** 1995;150(10-11):380-414 (33 ref.) **(Fre)**
[Indications for electrophysiological studies and catheter ablation of cardiac arrhythmias. Recommendations of the Department of Arrhythmias and Clinical Electrophysiology of the Brazilian Society of Cardiology] Sosa EA, et al. **Arq Bras Cardiol** 1995 Feb;64(2):149-51 (1 ref.) **(Por)**

THERAPY

Drug therapy versus implantation of a cardiac defibrillator for the treatment of malignant arrhythmias in left ventricular dysfunction [editorial] Mannino MM, et al. **Am Heart J** 1996 Jun;131(6):1251-9 (44 ref.)
Treatment of arrhythmias during pregnancy. Page RL. **Am Heart J** 1995 Oct;130(4):871-6 (50 ref.)
Prospective trials of implantable cardioverter defibrillators versus drugs: are they addressing the right question? [editorial] Josephson M, et al. **Am J Cardiol** 1996 Apr 15; 77(10):859-63 (29 ref.)
Interactions between antiarrhythmic drugs and implantable cardioverter-defibrillators. Dougherty AH. **Curr Opin Cardiol** 1996 Jan;11(1):2-8 (25 ref.)
Radiofrequency ablation--what is left? Zipes DP. **Eur Heart J** 1995 Aug;16 Suppl G:24-7 (13 ref.)
Issues in cardiac pacing: optimising pacemaker therapy [editorial] Gambhir DS. **Indian Heart J** 1996 Mar-Apr; 48(2):115-7 (32 ref.)
Drugs versus devices: contemporary practice in light of contemporary trials. Epstein AE. **J Cardiovasc Electrophysiol** 1995 Oct;6(10 Pt 2):937-41 (32 ref.)
Mechanisms and therapy of complex arrhythmias in pediatric patients. Saul JP, et al. **J Cardiovasc Electrophysiol** 1995 Dec;6(12):1129-48 (146 ref.)
Nonpharmacological therapy for malignant ventricular arrhythmias: implantable defibrillator trials. Saksena S, et al. **Prog Cardiovasc Dis** 1996 May-Jun;38(6):429-44 (90 ref.)
[To treat a cardiac arrest or to count ventricular arrhythmias? (editorial)] Toivonen L, et al. **Duodecim** 1994;110(9):857-9 (15 ref.) **(Fin)**
[Long term drug therapy for the prevention of recurrence in atrial fibrillation] Newman D, et al. **Can J Cardiol** 1996 Feb;12 Suppl A:21A-26A (43 ref.) **(Fre)**
[Current pacemaker treatment and technology] Candinas R, et al. **Schweiz Rundsch Med Prax** 1996 May 14; 85(20):663-70 (24 ref.) (Eng. Abstr.) **(Ger)**
[Management of patients with sustained ventricular arrhythmia: anti-arrhythmia agents or defibrillator?] Cappato R, et al. **Cardiologia** 1996 Feb;41(2):95-105 (75 ref.) **(Ita)**
[Treatment of supraventricular tachyarrhythmias: drugs or ablation?] Chimienti M, et al. **G Ital Cardiol** 1996 Feb; 26(2):213-26 (80 ref.) **(Ita)**
[Treatment of arrhythmia] Hayakawa K. **Nippon Naika Gakkai Zasshi** 1995 Sep 10;84(9):1512-6 (5 ref.) **(Jpn)**
[Biophysical basis and clinical use of catheter guided electric high frequency ablation in treatment of cardiac arrhythmias] Stanke A. **Pol Tyg Lek** 1995 Sep; 50(36-39):90-4 (35 ref.) **(Pol)**
[Treatment of cardiac arrhythmias during pregnancy] Rodriguez Blanco VM, et al. **Med Clin (Barc)** 1996 Jun 1;107(1):29-36 (125 ref.) **(Spa)**

ULTRASONOGRAPHY

In vivo and in vitro studies on the mechanism and clinical significance of spontaneous echocardiographic contrast in patients with atrial dysrhythmias. Castello R, et al. **Prog Cardiovasc Dis** 1996 Jul-Aug;39(1):47-56 (65 ref.)

ARRHYTHMIA, SINUS

DRUG THERAPY

[Restoration of the sinus rhythm in atrial fibrillation] Talajic M, et al. **Can J Cardiol** 1996 Feb;12 Suppl A:27A-34A (83 ref.) **(Fre)**

ETIOLOGY

Persistent atrial mechanical dysfunction after spontaneous conversion of chronic atrial fibrillation to sinus rhythm. Kahn ZU, et al. **Am Heart J** 1996 Mar;131(3):606-8 (14 ref.)

ARSENIC

ADVERSE EFFECTS

Arsenic in Dermatology. Maloney ME. **Dermatol Surg** 1996 Mar;22(3):301-4 (31 ref.)

ANALYSIS

[Arsenic (As)] Sakai T, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:846-9 (9 ref.) **(Jpn)**

TOXICITY

Role of arsenic as a reproductive toxin with particular attention to neural tube defects. Shalat SL, et al. **J Toxicol Environ Health** 1996 Jun 28;48(3):253-72 (130 ref.)
Implications of arsenic genotoxicity for dose response of carcinogenic effects. Rudel R, et al. **Regul Toxicol Pharmacol** 1996 Apr;23(2):87-105 (55 ref.)

ARSENIC COMPOUNDS see **ARSENICALS**

ARSENICALS

POISONING

Arsine toxicity: chemical and mechanistic implications. Klimecki WT, et al. **J Toxicol Environ Health** 1995 Dec; 46(4):399-409 (49 ref.)

TOXICITY

Is ingested inorganic arsenic a "threshold" carcinogen? Abernathy CO, et al. **Fundam Appl Toxicol** 1996 Feb;

29(2):168–75 (59 ref.)

ART

see related
ANATOMY, ARTISTIC
MEDICAL ILLUSTRATION

[White walls for black holes: essay on graffiti psychopathology] Catheline–Antipoff N, et al. **Psychiatr Enfant** 1995;38(2):625–53 (16 ref.) (Eng. Abstr.) **(Fre)**

ART–TRS GENE PROTEIN, HIV see **GENE PRODUCTS, REV**

ART–TRS GENES see **GENES, REV**

ARTERIAL CATHETERIZATION, PERIPHERAL see **CATHETERIZATION, PERIPHERAL**

ARTERIAL LINES see **CATHETERS, INDWELLING**

ARTERIAL OBSTRUCTIVE DISEASES see **ARTERIAL OCCLUSIVE DISEASES**

ARTERIAL OCCLUSIVE DISEASES

Popliteal artery entrapment syndrome. Anatomic and embryologic bases, diagnostic and therapeutic considerations following a series of 15 cases with a review of the literature. Rosset E, et al. **Surg Radiol Anat** 1995; 17(2):161–9, 23–7 (89 ref.) **(Eng, Fre)**

COMPLICATIONS

Aneurysms of the pancreaticoduodenal artery associated with occlusion of the celiac artery. Uher P, et al. **Abdom Imaging** 1995 Sep–Oct;20(5):470–3 (22 ref.)

[Preventive treatment of cerebrovascular accidents of arterial origin] Castillo V, et al. **Schweiz Rundsch Med Prax** 1996 Feb 6;85(6):159–63 (33 ref.) (Eng. Abstr.) **(Fre)**

CONGENITAL

Endovascular stents in children under 1 year of age: acute impact and late results. Hatai Y, et al. **Br Heart J** 1995 Dec;74(6):689–95 (16 ref.)

DIAGNOSIS

Diagnosis of arterial disease of the lower extremities with duplex ultrasonography. Koelemay MJ, et al. **Br J Surg** 1996 Mar;83(3):404–9 (48 ref.)

Bio–acoustic signals from stenotic tube flow: state of the art and perspectives for future methodological development. Ask P, et al. **Med Biol Eng Comput** 1995 Sep;33(5):669–75 (29 ref.)

Cystic adventitial disease of the popliteal artery—a case of young boy. Ishibashi S, et al. **Tohoku J Exp Med** 1995 Jul;176(3):173–80 (20 ref.)

[Angiology update] Ranke C, et al. **Med Klin** 1995 Aug 15; 90(8):467–79 (129 ref.) **(Ger)**

DRUG THERAPY

Thrombolysis in extremital arteries—indications and methods. Wellander E, et al. **Ann Chir Gynaecol** 1995; 84(4):341–8 (74 ref.)

Antithrombotic therapy in peripheral arterial occlusive disease. Clagett GP, et al. **Chest** 1995 Oct;108(4 Suppl):431S–443S (193 ref.)

Thrombolytic therapy for acute arterial occlusion. Ouriel K. **Curr Opin Gen Surg** 1994;:257–64 (39 ref.)

Pharmacologic approaches to the treatment of atherosclerotic arterial obstruction. Capron L. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S40–3 (15 ref.)

Prevention studies with pentoxifylline: new clinical projects. Eugène–Jolchine I, et al. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S143–6 (29 ref.)

The promise of new genetically engineered plasminogen activators. Cutler D, et al. **J Vasc Interv Radiol** 1995 Nov–Dec;6(6 Pt 2 Su):3S–7S (16 ref.)

Technical determinants of success in catheter–directed thrombolysis for peripheral arterial occlusions. Kandarpa K. **J Vasc Interv Radiol** 1995 Nov–Dec;6(6 Pt 2 Su):55S–61S (54 ref.)

Drug variables in thrombolytic therapy. Meyerovitz MF. **J Vasc Interv Radiol** 1995 Nov–Dec;6(6 Pt 2 Su):62S–65S (34 ref.)

Surgery versus thrombolytic therapy in the management of peripheral arterial occlusions. Ouriel K. **J Vasc Interv Radiol** 1995 Nov–Dec;6(6 Pt 2 Su):48S–54S (42 ref.)

The role of thrombolysis in the management of acute arterial occlusions of the lower limb. Browning NG, et al. **S Afr J Surg** 1995 Dec;33(4):170–4 (52 ref.)

Thrombolytic therapy: overview of results in major vascular occlusions. Marder VJ. **Thromb Haemost** 1995 Jul; 74(1):101–5 (60 ref.)

[Thrombolytic therapy in arterial disorders other than myocardial infarction] Verstraete M. **Arch Mal Coeur Vaiss** 1996 Jan;89(1):77–82 (47 ref.) (Eng. Abstr.) **(Fre)**

[Acute carotid occlusion: thrombolytic treatment] Maiza D, et al. **J Mal Vasc** 1996;21 Suppl A:83–9 (10 ref.) (Eng. Abstr.) **(Fre)**

[Platelet antiaggregants and atheromatous arteriopathy of the lower limbs] Lévesque H, et al. **Rev Med Interne** 1996; 17(2):163–8 (47 ref.) (Eng. Abstr.) **(Fre)**

[Early reperfusion as a rationale from of therapy in ischemic stroke] Garcia JH. **Rev Neurol** 1995 Sep–Oct; 23(123):1067–73 (40 ref.) (Eng. Abstr.) **(Spa)**

ECONOMICS

Cost–efficacy issues in the treatment of peripheral vascular disease: primary amputation or revascularization for limb–threatening ischemia. Perler BA. **J Vasc Interv Radiol** 1995 Nov–Dec;6(6 Pt 2 Su):111S–115S (28 ref.)

Clinical economics and noncoronary vascular disease. Schwartz JS. **J Vasc Interv Radiol** 1995 Nov–Dec;6(6 Pt 2 Su):116S–124S (16 ref.)

ETIOLOGY

Plasma homocyst(e)ine: a risk factor for arterial occlusive diseases. Malinow MR. **J Nutr** 1996 Apr;126(4 Suppl):1238S–43S (38 ref.)

Homocysteine, vitamins and arterial occlusive disease: an overview. Rosenberg IH. **J Nutr** 1996 Apr;126(4 Suppl):1235S–7S (26 ref.)

Traumatic occlusion of the anterior cerebral artery—case report. Ishibashi A, et al. **Neurol Med Chir (Tokyo)** 1995 Dec;35(12):882–5 (7 ref.)

[Arterial stenosis after radiotherapy] Piedbois P, et al. **Bull Cancer Radiother** 1990;77(1):3–13 (89 ref.) (Eng. Abstr.) **(Fre)**

[Smoking and peripheral vascular disorders] Stammler F, et al. **Z Arztl Fortbild (Jena)** 1995 Oct;89(5):459–66 (12 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

Mesenteric ischaemia: a multidisciplinary approach. Bradbury AW, et al. **Br J Surg** 1995 Nov;82(11):1446–59 (224 ref.)

PHYSIOPATHOLOGY

Neurocritical care for acute ischemic stroke. Hund E, et al. **Neurol Clin** 1995 Aug;13(3):511–27 (87 ref.)

PREVENTION & CONTROL

Gastrointestinal bleeding during low–dose aspirin administration for prevention of arterial occlusive events. A critical analysis. Stalnikowicz–Darvasi R. **J Clin Gastroenterol** 1995 Jul;21(1):13–6 (20 ref.)

[Risk predictors and risk–adjusted prevention in peripheral arterial occlusive diseases] Rieger H. **Internist (Berl)** 1995 Sep;36(9):902–8 (30 ref.) **(Ger)**

RADIOGRAPHY

Intraarterial pressure measurements during angiographic evaluation of peripheral vascular disease: techniques, interpretation, applications, and limitations. Kinney TB, et al. **AJR Am J Roentgenol** 1996 Feb;166(2):277–84 (44 ref.)

SURGERY

Endovascular stents and stented grafts for the treatment of aneurysms and other arterial lesions. Marin ML, et al. **Adv Surg** 1996;29:93–109 (50 ref.)

Circulatory arrest in a reoperation for brachiocephalic arterial occlusive disease. Bastounis EA, et al. **Ann Thorac Surg** 1996 Apr;61(4):1259–61 (7 ref.)

The present status of endoluminal stented grafts for the treatment of aneurysms, traumatic injuries and arterial occlusions. Veith FJ, et al. **Cardiovasc Surg** 1996 Feb; 4(1):3–7 (30 ref.)

Current status of atherectomy for peripheral arterial occlusive disease. Ahn SS, et al. **World J Surg** 1996 Jul–Aug;20(6):635–43 (45 ref.)

[Current status of reconstructive surgery of the sub–inguinal artery] Testart J, et al. **Chirurgie** 1994–95;120(10):582–8 (55 ref.) (Eng. Abstr.) **(Fre)**

[Early reperfusion as a rationale from of therapy in ischemic stroke] Garcia JH. **Rev Neurol** 1995 Sep–Oct; 23(123):1067–73 (40 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

The results of arterial thrombolysis. Kroese AJ, et al. **Ann Chir Gynaecol** 1995;84(4):350–3 (17 ref.)

Percutaneous revascularization in peripheral arterial disease. Rosenfield K, et al. **Curr Probl Cardiol** 1996 Jan;21(1):7–93 (228 ref.)

Interventionalists' guide to the patient's experience of lower extremity arterial occlusive disease. McDaniel MD, et al. **J Vasc Interv Radiol** 1995 Nov–Dec;6(6 Pt 2 Su):30S–35S (27 ref.)

Indications and results of arterial stents for occlusive disease. Ahn SS, et al. **World J Surg** 1996 Jul–Aug;20(6):644–8 (29 ref.)

[Angiology update] Ranke C, et al. **Med Klin** 1996 Apr 1; 91 Suppl 1:140–52 (129 ref.) **(Ger)**

[Angioplasty, surgical, or clinical treatment. Therapeutic options for obstructive coronary artery disease (editorial)] Hueb WA, et al. **Arq Bras Cardiol** 1995 Jul;65(1):7–10 (28 ref.) **(Por)**

ARTERIES

see related
ANGIOGRAPHY
ENDARTERECTOMY

ABNORMALITIES

Aneurysm of a congenitally persistent sciatic artery presenting as a soft–tissue mass of the buttock. A case report. Benevenia J, et al. **J Bone Joint Surg Am** 1995 Nov; 77(11):1724–8 (33 ref.)

ANATOMY & HISTOLOGY

Morphology of isolated small arteries from patients with essential hypertension. Aalkjaer C, et al. **Blood Press Suppl** 1995;2:113–6 (33 ref.)

The influence of optimization target selection on the structure of arterial tree models generated by constrained constructive optimization. Schreiner W, et al. **J Gen Physiol** 1995 Oct;106(4):583–99 (34 ref.)

The arterial blood supply of the pancreas: a review. III. The inferior pancreaticoduodenal artery. An anatomical review and a radiological study. Bertelli E, et al. **Surg Radiol Anat** 1996;18(2):67–74 (42 ref.)

[The structure of the arteries and the hemodynamic characteristics in the area of the ostia of efferent vessels] Gansburgskiĭ AN. **Morfologiia** 1995;108(1):82–91 (112 ref.) **(Rus)**

DRUG EFFECTS

Morphology of isolated small arteries from patients with essential hypertension. Aalkjaer C, et al. **Blood Press Suppl** 1995;2:113–6 (33 ref.)

Elastase in the prevention of arterial aging and the treatment of atherosclerosis. Ooyama T, et al. **Ciba Found Symp** 1995; 192:307–17; discussion 318–20 (36 ref.)

Comparison of the effect of dopamine in primate arteries and veins. Okamura T, et al. **Hypertens Res** 1995 Jun;18 Suppl 1:S35–7 (19 ref.)

[Arterial wall: a new pharmacological and therapeutic target?] Laurent S, et al. **Therapie** 1995 Jul–Aug; 50(4):387–98 (73 ref.) (Eng. Abstr.) **(Fre)**

EMBRYOLOGY

Formation of the arterial media during vascular development. Thayer JM, et al. **Cell Mol Biol Res** 1995;41(4):251–62 (100 ref.)

INJURIES

Peripheral vascular injury. Flynn TC. **Curr Opin Gen Surg** 1994;:30–4 (41 ref.)

INNERVATION

The autonomic nervous system and the regulation of arterial tone in migraine. Thomsen LL, et al. **Clin Auton Res** 1995 Oct;5(5):243–50 (111 ref.)

Regulation of blood pressure by nitroxidergic nerve. Toda N. **J Diabetes Complications** 1995 Oct–Dec;9(4):200–2 (21 ref.)

METABOLISM

Structure of cholesterol–containing particles accumulating in atherosclerotic lesions and the mechanisms of their derivation. Hoff HF, et al. **Curr Opin Lipidol** 1995 Oct; 6(5):317–25 (91 ref.)

PATHOLOGY

MR angiography of abdominal and peripheral arteries. Techniques and clinical applications. Ekelund L, et al. **Acta Radiol** 1996 Jan;37(1):3–13 (109 ref.)

Uremic small–artery disease with medial calcification and intimal hyperplasia (so–called calciphylaxis): a complication of chronic renal failure and benefit from parathyroidectomy. Hafner J, et al. **J Am Acad Dermatol** 1995 Dec;33(6):954–62 (61 ref.)

Structural changes of large conduit arteries in hypertension. Safar ME, et al. **J Hypertens** 1996 May;14(5):545–55 (67 ref.)

Vascular structure in NG–nitro–L–arginine methyl ester–induced hypertension: methodological considerations for studies of small arteries in hypertension [editorial] [see comments] Schiffrin EL. **J Hypertens** 1995 Aug; 13(8):817–21 (40 ref.) Comment in: J Hypertens 1995 Oct;13(10):1217–21.

[Arterial wall: a new pharmacological and therapeutic target?] Laurent S, et al. **Therapie** 1995 Jul–Aug; 50(4):387–98 (73 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Effects of endothelin–1 and the ETA receptor antagonist BQ–123 on resistance arteries from normal pregnant and preeclamptic women. Wolff K, et al. **Acta Obstet Gynecol Scand** 1996 May;75(5):432–8 (34 ref.)

Vascular reactivity of arterial coronary artery bypass grafts—implications for their performance. Dzimiri N, et al. **Clin Cardiol** 1996 Mar;19(3):165–71 (63 ref.)

Evaluation of arterial compliance in humans. Giannattasio C, et al. **Clin Exp Hypertens** 1996 Apr-May;18(3-4):347-62 (23 ref.)
Mechanics of the arterial wall: review and directions. Humphrey JD. **Crit Rev Biomed Eng** 1995;23(1-2):1-162 (512 ref.)
Superoxide anion and endothelial regulation of arterial tone. Katusic ZS. **Free Radic Biol Med** 1996;20(3):443-8 (52 ref.)
Paracrine functions of the coronary vascular endothelium. Fleming I, et al. **Mol Cell Biochem** 1996 Apr 12-26; 157(1-2):137-45 (49 ref.)

PHYSIOPATHOLOGY

Arterial and cardiac changes in hypertension in the elderly. Asmar R, et al. **Blood Press** 1995;Suppl 3:31-7 (48 ref.)
Pathophysiology of smooth muscle in hypertension. Lee RM, et al. **Can J Physiol Pharmacol** 1995 May;73(5):574-84 (103 ref.)
The autonomic nervous system and the regulation of arterial tone in migraine. Thomsen LL, et al. **Clin Auton Res** 1995 Oct;5(5):243-50 (111 ref.)
[The vascular changes in arterial hypertension] Ponte E, et al. **Minerva Med** 1995 Sep;86(9):357-65 (60 ref.) (Eng. Abstr.) **(Ita)**

RADIATION EFFECTS

[Arterial stenosis after radiotherapy] Piedbois P, et al. **Bull Cancer Radiother** 1996;77(1):3-13 (89 ref.) (Eng. Abstr.) **(Fre)**

TRANSPLANTATION

Vascular reactivity of arterial coronary artery bypass grafts--implications for their performance. Dzimiri N, et al. **Clin Cardiol** 1996 Mar;19(3):165-71 (63 ref.)
Arterial and venous conduits for coronary artery bypass. A current review. Cooper GJ, et al. **Eur J Cardiothorac Surg** 1996;10(2):129-40 (197 ref.)
Current status of the inferior epigastric artery. Buche M, et al. **Semin Thorac Cardiovasc Surg** 1996 Jan;8(1):10-4 (19 ref.)
Complete revascularization with internal thoracic artery grafts. Tector AJ, et al. **Semin Thorac Cardiovasc Surg** 1996 Jan;8(1):29-41 (67 ref.)

ARTERIO-ARTERIAL FISTULA

ETIOLOGY

Coronary-pulmonary steal syndrome. Najm HK, et al. **Ann Thorac Surg** 1996 Jul;62(1):264-5 (7 ref.)
Rupture of a dissecting thoracic aortic aneurysm into the pulmonary artery: successful surgical repair. Coselli JS, et al. **Cardiovasc Surg** 1995 Dec;3(6):697-701 (34 ref.)
Surgical treatment of an aortopulmonary artery fistula complicating a syphilitic aortic aneurysm. Pessotto R, et al. **Cardiovasc Surg** 1995 Dec;3(6):707-10 (17 ref.)

PATHOLOGY

Multiple fistulas between coronary and pulmonary arteries. Van Dam DW, et al. **Eur J Cardiothorac Surg** 1995; 9(12):707-8 (10 ref.)

SURGERY

Rupture of a dissecting thoracic aortic aneurysm into the pulmonary artery: successful surgical repair. Coselli JS, et al. **Cardiovasc Surg** 1995 Dec;3(6):697-701 (34 ref.)
Surgical treatment of an aortopulmonary artery fistula complicating a syphilitic aortic aneurysm. Pessotto R, et al. **Cardiovasc Surg** 1995 Dec;3(6):707-10 (17 ref.)

ARTERIOGRAPHY see **ANGIOGRAPHY**

ARTERIOHEPATIC DYSPLASIA see **ALAGILLE SYNDROME**

ARTERIOSCLEROSIS

[Progress on diagnosis and therapy of diabetic angiopathies] Haranou Y, et al. **Nippon Naika Gakkai Zasshi** 1996 Apr 10;85(4):562-7 (12 ref.) **(Jpn)**

DRUG THERAPY

[A free radical mechanism for inhibition of arteriosclerosis development with calcium antagonists] Andrzejak R, et al. **Postepy Hig Med Dosw** 1995;49(5):645-59 (87 ref.) (Eng. Abstr.) **(Pol)**
[Fenofibrate and arteriosclerosis. The new developments of the last 5 years (editorial)] Millán Núñez Cortés J, et al. **Rev Clin Esp** 1995 Dec;195(12):817-9 (46 ref.) **(Spa)**

ETIOLOGY

Nutritional ecogenetics: homocysteine-related arteriosclerotic vascular disease, neural tube defects, and folic acid [editorial; comment] Motulsky AG. **Am J Hum Genet** 1996 Jan;58(1):17-20 (28 ref.) Comment on: Am J Hum Genet 1996 Jan;58(1):35-41.
Adhesion molecules and cell surface receptors in the heart transplant-associated arteriosclerosis. Hinek A. **Folia Histochem Cytobiol** 1996;34(1):3-19 (140 ref.)
Homocysteine as a risk factor for arteriosclerosis. Kuritzky L. **Hosp Pract (Off Ed)** 1996 Mar 15;31(3):37, 41 (5 ref.)
[Insulin resistance and arteriosclerosis] Matsuzawa Y. **Nippon Naika Gakkai Zasshi** 1995 Sep 10;84(9):1579-82 (8 ref.) **(Jpn)**
[Homocysteine--an independent risk factor of premature vascular disease] Mansoor MA, et al. **Tidsskr Nor Laegeforen** 1996 May 30;116(14):1663-7 (41 ref.) **(Nor)**
[Free radicals and their importance in medicine] Andrzejak R, et al. **Postepy Hig Med Dosw** 1995;49(4):531-49 (89 ref.) (Eng. Abstr.) **(Pol)**

METABOLISM

Adhesion molecules and cell surface receptors in the heart transplant-associated arteriosclerosis. Hinek A. **Folia Histochem Cytobiol** 1996;34(1):3-19 (140 ref.)

PATHOLOGY

[An autopsy case of "diffuse neurofibrillary tangles with calcification", multiple infarctions and hyaline arteriosclerosis] Arai T, et al. **No To Shinkei** 1996 Jan; 48(1):69-76 (26 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

Endothelins as cardiovascular peptides. Levin ER. **Am J Nephrol** 1996;16(3):246-51 (64 ref.)
[Molecular medicine and gene therapy as exemplified with arteriosclerosis and restenosis] Lüscher TF, et al. **Schweiz Med Wochenschr** 1995 Nov 4;125(44):2107-21 (112 ref.) (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

Oestradiol inhibition of vascular myointimal proliferation following immune, chemical and mechanical injury. Foegh ML, et al. **Ciba Found Symp** 1995;191:139-45; discussion 145-9 (19 ref.)
[Overview--suppression effect of essential trace elements on arteriosclerotic development and it's mechanism] Saito N. **Nippon Rinsho** 1996 Jan;54(1):59-66 (21 ref.) (Eng. Abstr.) **(Jpn)**

SURGERY

Horseshoe kidney and aortic surgery. Wymenga LF, et al. **Scand J Urol Nephrol** 1995 Sep;29(3):331-4 (10 ref.)
Current status of atherectomy for peripheral arterial occlusive disease. Ahn SS, et al. **World J Surg** 1996 Jul-Aug;20(6):635-43 (45 ref.)
[Arterial wall texture after uncomplicated endarterectomy] Bürrig KF, et al. **Pathologe** 1995 Sep;16(5):336-41 (49 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

[Molecular medicine and gene therapy as exemplified with arteriosclerosis and restenosis] Lüscher TF, et al. **Schweiz Med Wochenschr** 1995 Nov 4;125(44):2107-21 (112 ref.) (Eng. Abstr.) **(Ger)**
[Treatment of atherosclerotic occlusion of blood vessels] Genik SM. **Klin Khir** 1995;(7-8):28-30 (36 ref.) **(Ukr)**

ARTERIOSCLEROSIS, CORONARY see **CORONARY ARTERIOSCLEROSIS**

ARTERIOSCLEROSIS OBLITERANS

DIAGNOSIS

Arteriosclerosis obliterans. Diagnostic and nonoperative treatment options. Ku A, et al. **Postgrad Med** 1995 Nov; 98(5):203-4, 207-10, 212 (29 ref.)

ETIOLOGY

Acute arterial obliteration: a new feature of the POEMS syndrome? Lesprit P, et al. **Medicine (Baltimore)** 1996 Jul; 75(4):226-32 (45 ref.)

THERAPY

Arteriosclerosis obliterans. Diagnostic and nonoperative treatment options. Ku A, et al. **Postgrad Med** 1995 Nov; 98(5):203-4, 207-10, 212 (29 ref.)

ARTERIOSCLEROTIC DEMENTIA see **DEMENTIA, VASCULAR**

ARTERIOVENOUS ANASTOMOSIS

PHYSIOPATHOLOGY

Anomalous internal carotid artery-anterior cerebral artery anastomosis associated with fenestration and cerebral aneurysm. Fujimura M, et al. **Neurol Med Chir (Tokyo)** 1996 Apr;36(4):229-33 (26 ref.)

ARTERIOVENOUS ANEURYSM see **ARTERIOVENOUS FISTULA**

ARTERIOVENOUS FISTULA

see related
ARTERIOVENOUS MALFORMATIONS

Ureteroarterial fistula: case report and review of the literature. Batter SJ, et al. **Urology** 1996 Sep;48(3):481-9 (35 ref.)
[Intrahepatic arterioportal shunt and arteriovenous shunt] Nagayama K, et al. **Ryoikibetsu Shokogun Shirizu** 1995; (8):210-3 (21 ref.) **(Jpn)**
[Intrahepatic arteriovenous fistula] Toshima K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):207-9 (23 ref.) **(Jpn)**

COMPLICATIONS

Rapidly progressive portal hypertension 23 years after post-traumatic arterioportal fistula of the liver. Kayser S, et al. **Am J Gastroenterol** 1996 Jul;91(7):1442-6 (30 ref.)
Posttraumatic high-flow priapism treated by N-butyl-cyanoacrylate embolization. Numan F, et al. **Cardiovasc Intervent Radiol** 1996 Jul-Aug;19(4):278-80 (22 ref.)
A cervical dural arteriovenous fistula in a patient presenting with radiculopathy. Case report. Kohno M, et al. **J Neurosurg** 1996 Jan;84(1):119-23 (26 ref.)
Innominate artery enlargement in congenital arteriovenous fistula with subsequent tracheal compression and stridor. Döhlemann C, et al. **Pediatr Cardiol** 1995 Nov-Dec; 16(6):287-90 (17 ref.)
[A rare cause of neurologic bladder: arteriovenous dural fistula with venous epidural drainage] Punga-Maole ML, et al. **Prog Urol** 1995 Dec;5(6):1001-8 (32 ref.) (Eng. Abstr.) **(Fre)**

CONGENITAL

Innominate artery enlargement in congenital arteriovenous fistula with subsequent tracheal compression and stridor. Döhlemann C, et al. **Pediatr Cardiol** 1995 Nov-Dec; 16(6):287-90 (17 ref.)
[Pulmonary arteriovenous fistulae and brain abscesses: a report of 2 cases treated by embolization and a review of the literature] Ricci P, et al. **Radiol Med (Torino)** 1996 Apr; 91(4):497-501 (24 ref.) **(Ita)**

DIAGNOSIS

MR imaging and MR angiography in the diagnosis of dural arteriovenous fistulas. Panasci DJ, et al. **Magn Reson Imaging Clin N Am** 1995 Aug;3(3):493-508 (32 ref.)
Dural arteriovenous fistulas of superior sagittal sinus: case report and review of literature. Kurl S, et al. **Surg Neurol** 1996 Mar;45(3):250-5 (23 ref.)
Spinal giant intradural perimedullary arteriovenous fistula: clinical and neuroradiological study in one case with review of literature. Nagashima C, et al. **Surg Neurol** 1996 Jun;45(6):524-31; discussion 531-2 (18 ref.)

ETIOLOGY

Carotid-jugular arteriovenous fistula: a complication of temporary hemodialysis catheter. el-Shahawy MA, et al. **Am J Nephrol** 1995;15(4):332-6 (51 ref.)
Arteriovenous fistulae complicating orthopaedic procedures. Ward AS, et al. **Aust N Z J Surg** 1995 Dec;65(12):905-7 (20 ref.)
Iatrogenic aorto-coronary venous fistula as a complication of coronary artery bypass surgery: patient report and review of the literature. Calkins JB Jr, et al. **Cathet Cardiovasc Diagn** 1996 Jan;37(1):55-9 (19 ref.)
[Vascular complications of lumbar disk surgery. Report of two cases and review of the literature on 122 cases] Pillet JC, et al. **J Mal Vasc** 1995;20(3):219-23 (85 ref.) (Eng. Abstr.) **(Fre)**
[Arteriovenous fistula with cardiac insufficiency disclosing kidney cancer] Jan N, et al. **Rev Med Interne** 1996; 17(4):329-32 (30 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Carotid-cavernous sinus fistula and aneurysmal rupture associated with fibromuscular dysplasia. A case report. Hirai T, et al. **Acta Radiol** 1996 Jan;37(1):49-51 (8 ref.)

PHYSIOPATHOLOGY

[Paradoxical aggravation of carotid cavernous fistula] Muraine M, et al. **J Fr Ophtalmol** 1996;19(1):51-4 (12 ref.) (Eng. Abstr.) **(Fre)**

RADIOGRAPHY

Angiographic workup of a carotid cavernous sinus fistula (CCF) or what information does the interventionalist need for treatment? [see comments] Debrun GM. **Surg Neurol** 1995 Jul;44(1):75-9 (18 ref.) Comment in: Surg Neurol 1996 Aug;46(2):193.

SURGERY

Splenic arteriovenous fistula. Brothers TE, et al. **Int Surg** 1995 Apr-Jun;80(2):189-94 (90 ref.)
Endovascular surgical approach to intracranial vascular diseases. Higashida RT, et al. **J Endovasc Surg** 1996 May; 3(2):146-57 (57 ref.)

Acute repair of aorta-innominate vein fistulas. Roye GD, et al. **J Trauma** 1995 Oct;39(4):753-6 (12 ref.)
Aortocaval fistula treated by aortic exclusion. Woolley DS, et al. **J Vasc Surg** 1995 Nov;22(5):639-42 (27 ref.)
Postsurgical development of dural arteriovenous malformations after transpetrosal and transtentorial operations: case report. Sasaki T, et al. **Neurosurgery** 1995 Oct;37(4):820-4; discussion 824-5 (14 ref.)
Surgical treatment of an enormous aneurysmal portahepatic venous fistula: report of a case. Miyauchi A, et al. **Surg Today** 1995;25(9):855-8 (11 ref.)

THERAPY

Traumatic bilateral carotid-cavernous fistulas treated with detachable balloon. A case report. Kim JK, et al. **Acta Radiol** 1996 Jan;37(1):46-8 (6 ref.)
Posttraumatic high-flow priapism treated by N-butyl-cyanoacrylate embolization. Numan F, et al. **Cardiovasc Intervent Radiol** 1996 Jul-Aug;19(4):278-80 (22 ref.)
Interventional neuroradiology of the head and neck. Hurst RW. **Neuroimaging Clin N Am** 1996 May;6(2):473-95 (38 ref.)
[Pulmonary arteriovenous fistulae and brain abscesses: a report of 2 cases treated by embolization and a review of the literature] Ricci P, et al. **Radiol Med (Torino)** 1996 Apr; 91(4):497-501 (24 ref.) **(Ita)**

ARTERIOVENOUS HEMOFILTRATION see **HEMOFILTRATION**

ARTERIOVENOUS MALFORMATIONS

see related
ANGIOMATOSIS
ARTERIOVENOUS FISTULA
HEMANGIOMA

Hepatic vascular anomalies in infancy: a twenty-seven-year experience. Boon LM, et al. **J Pediatr** 1996 Sep; 129(3):346-54 (52 ref.)

COMPLICATIONS

Bleeding from polypoid colonic arteriovenous malformations. Koziara FJ, et al. **Am J Gastroenterol** 1996 Mar;91(3):584-6 (6 ref.)
Combined malformation of the Vein of Galen and of spinal vessels: endovascular embolization. Hammen A, et al. **Clin Neuropathol** 1995 Jul-Aug;14(4):233-6 (15 ref.)
Massive lower gastrointestinal bleeding due to 'Dieulafoy's vascular malformation' of the jejunum: case report. Goins WA, et al. **J Natl Med Assoc** 1995 Oct;87(10):766-70 (27 ref.)
[A case of arteriovenous malformation of the ileum complicated with decompensated liver cirrhosis: effective case of home parenteral nutrition for intestinal bleeding] Fukushima M, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Nov;92(11):1871-5 (15 ref.) **(Jpn)**

DIAGNOSIS

Left innominate vein compression by a brachiocephalic artery anomaly. Moes CA, et al. **Pediatr Cardiol** 1995 Nov-Dec; 16(6):291-3 (7 ref.)

PATHOLOGY

Congenital absence of portal venous system associated with a large inferior mesenteric-caval shunt: a case report. Komatsu S, et al. **Hepatogastroenterology** 1995 Jul; 42(3):286-90 (17 ref.)

RADIOGRAPHY

Normal and abnormal vascular structures that simulate neoplasms on chest radiographs: clues to the diagnosis. Cole TJ, et al. **Radiographics** 1995 Jul;15(4):867-91 (23 ref.)

SURGERY

Hepatic artery ligation for hepatic vascular tumors with arteriovenous and arterioportal venous shunts in the newborn: successful management of two cases and review of the literature. Hazebroek FW, et al. **J Pediatr Surg** 1995 Aug;30(8):1127-30 (15 ref.)

THERAPY

[A patient with Rendu-Osler-Weber disease and pulmonary arteriovenous malformations treated satisfactorily by embolization] Martin Diaz E, et al. **Arch Bronconeumol** 1996 Jun-Jul;32(6):307-9 (12 ref.) (Eng. Abstr.) **(Spa)**

ULTRASONOGRAPHY

Prenatal diagnosis of cerebral arteriovenous malformation using color Doppler ultrasonography: case report and review of the literature. Sepulveda W, et al. **Ultrasound Obstet Gynecol** 1995 Oct;6(4):282-6 (30 ref.)

ARTERIOVENOUS MALFORMATIONS, CEREBRAL see **CEREBRAL ARTERIOVENOUS MALFORMATIONS**

ARTERIOVENOUS SHUNT, SURGICAL

Candida infection of the arteriovenous fistula used for hemodialysis. Nguyen MH, et al. **Am J Kidney Dis** 1996 Apr;27(4):596-8 (8 ref.)
Surgery versus thrombolytic therapy in the management of peripheral arterial occlusions. Ouriel K. **J Vasc Interv Radiol** 1995 Nov-Dec;6(6 Pt 2 Su):48S-54S (42 ref.)
Lessons from vascular access procedures for hemodialysis. Shaffer D. **Surg Oncol Clin N Am** 1995 Jul;4(3):537-48 (70 ref.)

ECONOMICS

Cost-efficacy issues in the treatment of peripheral vascular disease: primary amputation or revascularization for limb-threatening ischemia. Perler BA. **J Vasc Interv Radiol** 1995 Nov-Dec;6(6 Pt 2 Su):111S-115S (28 ref.)

METHODS

Interposition vein cuffs [editorial] Harris P, et al. **Eur J Vasc Endovasc Surg** 1996 Apr;11(3):257-9 (11 ref.)
Contemporary vascular access surgery for chronic haemodialysis. Koo Seen Lin LC, et al. **J R Coll Surg Edinb** 1996 Jun;41(3):164-9 (75 ref.)
Upper arm arteriovenous fistula for chronic hemodialysis: 20 years later. Dagher FJ. **Transplant Proc** 1996 Aug; 28(4):2325-7 (12 ref.)

ARTERITIS

COMPLICATIONS

[An autopsy case of segmental mediolytic arteritis (SMA) accompanied with microscopic polyarteritis nodosa] Ito MR, et al. **Ryumachi** 1995 Aug;35(4):693-8 (16 ref.) (Eng. Abstr.) **(Jpn)**
[Cerebrovascular diseases and non-infectious inflammatory arteriopathies] Vivancos F, et al. **Rev Neurol** 1995;23 Suppl 1:S22-32 (84 ref.) **(Spa)**

DIAGNOSIS

Pan-nephritis (glomerulonephritis, arteriolitis, and tubulointerstitial nephritis) associated with predominant mesangial C1q deposition and hypocomplementemia: a variant type of C1q nephropathy? Imai H, et al. **Am J Kidney Dis** 1996 Apr;27(4):583-7 (15 ref.)

PHYSIOPATHOLOGY

[Cerebrovascular diseases and non-infectious inflammatory arteriopathies] Vivancos F, et al. **Rev Neurol** 1995;23 Suppl 1:S22-32 (84 ref.) **(Spa)**

ULTRASONOGRAPHY

[Ultrasound diagnosis, follow-up and therapy of cystic degeneration of the adventitia. 2 case reports and review of the literature] Schäberle W, et al. **Ultraschall Med** 1996 Jun;17(3):131-7 (39 ref.) (Eng. Abstr.) **(Ger)**

ARTERITIS, TAKAYASU'S see **TAKAYASU'S ARTERITIS**

ARTERITIS, TEMPORAL see **TEMPORAL ARTERITIS**

ARTERIVIRUS

PHYSIOLOGY

[Significance of PRRS virus infections for respiratory tract infections in swine--a literature review] Beilage EG. **DTW Dtsch Tierarztl Wochenschr** 1995 Dec;102(12):457-69 (127 ref.) (Eng. Abstr.) **(Ger)**

ARTERIVIRUS INFECTIONS

IMMUNOLOGY

Lactate dehydrogenase-elevating virus: an ideal persistent virus? Plagemann PG, et al. **Springer Semin Immunopathol** 1995;17(2-3):167-86 (78 ref.)

VETERINARY

[Significance of PRRS virus infections for respiratory tract infections in swine--a literature review] Beilage EG. **DTW Dtsch Tierarztl Wochenschr** 1995 Dec;102(12):457-69 (127 ref.) (Eng. Abstr.) **(Ger)**

VIROLOGY

Lactate dehydrogenase-elevating virus: an ideal persistent virus? Plagemann PG, et al. **Springer Semin Immunopathol** 1995;17(2-3):167-86 (78 ref.)

ARTHRALGIA

COMPLICATIONS

[The Schnitzler syndrome as a cause of recurrent fever of unknown origin] Winckelmann G, et al. **Dtsch Med Wochenschr** 1996 Jul 5;121(27):860-4 (14 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

[Topical capsaicin and joint pain: a therapeutic break-through?] Gratton N, et al. **Union Med Can** 1995 Mar;124(1):2-4 (17 ref.) **(Fre)**

ETIOLOGY

Cryoglobulinemia: recent findings in cutaneous and extracutaneous manifestations. Davis MD, et al. **Int J Dermatol** 1996 Apr;35(4):240-8 (50 ref.)

THERAPY

[Conservative therapy of shoulder pain] Tilscher H. **Wien Med Wochenschr** 1996;146(6-7):138-42 (4 ref.) (Eng. Abstr.) **(Ger)**

ARTHRITIS

Spondyloarthropathies of childhood. Cabral DA, et al. **Pediatr Clin North Am** 1995 Oct;42(5):1051-70 (73 ref.)
Rapid destructive arthritis of the shoulder. Nguyen VD. **Skeletal Radiol** 1996 Feb;25(2):107-12 (44 ref.)
[Monoarthritis] Scutellari PN, et al. **Radiol Med (Torino)** 1995 Dec;90(6):689-98 (48 ref.) (Eng. Abstr.) **(Ita)**

CHEMICALLY INDUCED

Calcium pyrophosphate crystal deposition disease and other crystal deposition diseases. Fam AG. **Curr Opin Rheumatol** 1995 Jul;7(4):364-8 (32 ref.)

CLASSIFICATION

Clinical and genetic evidence that juvenile arthritis is not a single disease. Fink CW, et al. **Pediatr Clin North Am** 1995 Oct;42(5):1155-69 (68 ref.)

COMPLICATIONS

Arthritis associated with monoclonal gammapathy: clinical characteristics. Jorgensen C, et al. **Br J Rheumatol** 1996 Mar;35(3):241-3 (14 ref.)
An unusual case of mixed sclerosing bone dystrophy presenting with morning stiffness and joint swelling in childhood: a case report. Foeldvari I, et al. **Clin Exp Rheumatol** 1995 Jul-Aug;13(4):525-8 (19 ref.)
Sacroiliitis in sarcoidosis: case reports and review of the literature. Kötter I, et al. **Clin Rheumatol** 1995 Nov; 14(6):695-700 (29 ref.)

DIAGNOSIS

Biologic markers of arthritis. Scher DM, et al. **Am J Orthop** 1996 Apr;25(4):263-72 (69 ref.)
Magnetic resonance imaging of arthritides affecting the shoulder. Ferraro FA, et al. **Magn Reson Imaging Clin N Am** 1993 Sep;1(1):157-70 (76 ref.)
[The shoulder joint--diagnostic imaging] Imhof H, et al. **Wien Med Wochenschr** 1996;146(6-7):116-20 (24 ref.) (Eng. Abstr.) **(Ger)**
[Jaccoud's arthropathy] Shostak NA. **Ter Arkh** 1995; 67(11):80-3 (26 ref.) (Eng. Abstr.) **(Rus)**

DIET THERAPY

Diet and arthritis. Cleland LG, et al. **Baillieres Clin Rheumatol** 1995 Nov;9(4):771-85 (43 ref.)

DRUG THERAPY

A review on the strategies for the development and application of new anti-arthritic agents. Lewis AJ, et al. **Immunopharmacol Immunotoxicol** 1995 Nov;17(4):607-63 (272 ref.)

ENZYMOLOGY

Proteinases and inhibitors. Cawston TE. **Br Med Bull** 1995 Apr;51(2):385-401 (65 ref.)
Phospholipase A2 inhibitors: a challenge for the future. Berenbaum F. **Rev Rhum Engl Ed** 1995 Jun;62(6):409-14 (45 ref.)

ETIOLOGY

Crystal-induced arthritis: an overview. Schumacher HR. **Am J Med** 1996 Feb 26;100(2A):46S-52S (22 ref.)
Human models: Whipple's disease, coeliac disease and jejunoileal bypass. Utsinger PD, et al. **Baillieres Clin Rheumatol** 1996 Feb;10(1):77-103 (129 ref.)
Role of mast cells in arthritis. Arnason JA, et al. **Chem Immunol** 1995;62:204-38 (279 ref.)
The adolescent with arthritis. Lindsley CB. **Compr Ther** 1996 Jan;22(1):48-51 (7 ref.)
Metabolic and endocrine disease and arthritis. Matteucci BM. **Curr Opin Rheumatol** 1995 Jul;7(4):356-8 (8 ref.)
Acute sarcoid arthritis: a favourable outcome? A retrospective survey of 49 patients with review of the literature. Gran JT, et al. **Scand J Rheumatol** 1996; 25(2):70-3 (23 ref.)
[Parvovirus B19 infection. New physiopathological approaches] Labau E, et al. **Presse Med** 1996 Feb 3;

25(4):162–6 (26 ref.) (Eng. Abstr.) **(Fre)**
[Rheumatic involvement in Hansen's disease]
Cossermelli–Messina W, et al.
Rev Hosp Clin Fac Med Sao Paulo 1995 Mar–Apr; 50(2):107–10 (50 ref.) (Eng. Abstr.) **(Por)**

GENETICS

Genes and arthritis. Wordsworth P. **Br Med Bull** 1995 Apr; 51(2):249–66 (63 ref.)

IMMUNOLOGY

Nitric oxide in inflammation and immune response. Moilanen E, et al. **Ann Med** 1995 Jun;27(3):359–67 (119 ref.)
Animal models of intestinal and joint inflammation. Sartor RB, et al. **Baillieres Clin Rheumatol** 1996 Feb;10(1):55–76 (54 ref.)
Role of HLA–B27 in spondyloarthropathies. Khare SD, et al. **Curr Top Microbiol Immunol** 1996;206:85–100 (77 ref.)
"The good, the bad, and the ugly." The role of chemokines in models of human disease. Strieter RM, et al.
J Immunol 1996 May 15;156(10):3583–6 (33 ref.)
Antineutrophil cytoplasmic antibodies: major autoantigens, pathophysiology, and disease associations. Schultz DR, et al. **Semin Arthritis Rheum** 1995 Dec;25(3):143–59 (120 ref.)
[Joint and systemic manifestations related to type 2 anti–mitochondrial antibodies] Dhôte R, et al.
Ann Med Interne (Paris) 1995;146(8):536–40 (31 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Hyaluronan in inflammatory joint disease. Laurent TC, et al. **Acta Orthop Scand Suppl** 1995 Oct;266:116–20 (39 ref.)

PATHOLOGY

Animal models of intestinal and joint inflammation. Sartor RB, et al. **Baillieres Clin Rheumatol** 1996 Feb;10(1):55–76 (54 ref.)

PHYSIOPATHOLOGY

Cerebral mechanisms operating in the presence and absence of inflammatory pain. Jones AK, et al. **Ann Rheum Dis** 1996 Jul;55(7):411–20 (83 ref.)
[Capsaicin for arthritic pain] Niv D, et al. **Harefuah** 1996 Mar 15;130(6):415–20 (43 ref.) **(Heb)**

RADIOGRAPHY

[Computed tomography of the sacroiliac joints] Miquel A, et al. **Ann Radiol (Paris)** 1995;38(4):177–85 (28 ref.) **(Fre)**

THERAPY

Psycho–educational interventions in the treatment of arthritis. Hawley DJ. **Baillieres Clin Rheumatol** 1995 Nov; 9(4):803–23 (46 ref.)
[Conservative therapy of shoulder pain] Tilscher H.
Wien Med Wochenschr 1996;146(6–7):138–42 (4 ref.) (Eng. Abstr.) **(Ger)**
[The measurement of outcomes in chronic pathology. Its application to arthritis] Zeni L. **Minerva Med** 1995 May; 86(5):215–22 (35 ref.) **(Ita)**

ULTRASONOGRAPHY

[Ultrasound examination of the shoulder joint] Lick–Schiffer W. **Wien Med Wochenschr** 1996;146(6–7):121–3 (11 ref.) (Eng. Abstr.) **(Ger)**

VIROLOGY

Mosquito–borne viruses and epidemic polyarthritis. Mackenzie JS, et al. **Med J Aust** 1996 Jan 15;164(2):90–3 (21 ref.)

ARTHRITIS, ADJUVANT

IMMUNOLOGY

Arthritis: animal models of oral tolerance. Staines NA, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:297–305 (14 ref.)

METABOLISM

Local expression of corticotropin–releasing hormone in inflammatory arthritis. Crofford LJ, et al.
Ann N Y Acad Sci 1995 Dec 29;771:459–71 (63 ref.)
Effects of ankle joint inflammation on the proportion of calcitonin gene–related peptide (CGRP)–immunopositive perikarya in dorsal root ganglia. Hanesch U, et al.
Prog Brain Res 1995;104:339–47 (72 ref.)

THERAPY

Anti–integrin immunotherapy in rheumatoid arthritis: protective effect of anti–alpha 4 antibody in adjuvant arthritis. Barbadillo C, et al.
Springer Semin Immunopathol 1995;16(4):427–36 (59 ref.)

ARTHRITIS, BACTERIAL see **ARTHRITIS, INFECTIOUS**

ARTHRITIS, DEGENERATIVE see **OSTEOARTHRITIS**

ARTHRITIS–ENCEPHALITIS VIRUS, CAPRINE

Selected models of HIV–induced neurological disease. Narayan O, et al. **Curr Top Microbiol Immunol** 1995; 202:151–66 (61 ref.)

ARTHRITIS, GOUTY

ETIOLOGY

[Hyperuricemia] Gröbner W, et al. **Urologe A** 1996 May; 35(3):263–77 (13 ref.) **(Ger)**

PSYCHOLOGY

[Pain and pain perception in the elderly from the viewpoint of rheumatology] Nehen HG. **Z Gerontol Geriatr** 1995 Sep–Oct;28(5):335–8 (10 ref.) (Eng. Abstr.) **(Ger)**

ARTHRITIS, INFECTIOUS

Fungal arthritis. A review. Hansen BL, et al.
Scand J Rheumatol 1995;24(4):248–50 (34 ref.)

COMPLICATIONS

Emphysematous septic arthritis: case report and review of the literature. Roy R, et al. **J Rheumatol** 1995 Sep; 22(9):1776–8 (29 ref.)

DIAGNOSIS

Needle arthroscopy: a new frontier in rheumatology. Panchal P, et al. **Compr Ther** 1996 Jan;22(1):44–7 (14 ref.)
Viral arthritis: the lessons of parvovirus B19. Mangi RJ.
Hosp Pract (Off Ed) 1995 Nov 15;30(11):65–72 (7 ref.)
Pediatric bone and joint infections. Diagnosis and antimicrobial management. Sonnen GM, et al.
Pediatr Clin North Am 1996 Aug;43(4):933–47 (30 ref.)
Septic arthritis. Brower AC. **Radiol Clin North Am** 1996 Mar; 34(2):293–309, x (19 ref.)
[Juvenile chronic arthritis (JCA) or chronic arthropathy due to parvovirus B19?] Andreu Alapont E, et al.
An Esp Pediatr 1996 Feb;44(2):157–8 (14 ref.) **(Spa)**

DRUG THERAPY

Pediatric bone and joint infections. Diagnosis and antimicrobial management. Sonnen GM, et al.
Pediatr Clin North Am 1996 Aug;43(4):933–47 (30 ref.)

EPIDEMIOLOGY

[Osteoarticular infections by Salmonella non–typhi] Ramos JM, et al. **Enferm Infecc Microbiol Clin** 1995 Aug–Sep; 13(7):406–10 (30 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

Enterococcal arthritis: case report and review. Raymond NJ, et al. **Clin Infect Dis** 1995 Sep;21(3):516–22 (54 ref.)
Early postsplenectomy arthritis caused by penicillin–resistant Streptococcus pneumoniae. Merle–Melet M, et al.
Eur J Clin Microbiol Infect Dis 1996 Feb;15(2):159–60 (7 ref.)
[Pneumococcal septic arthritis in HIV infection] Trivalle C, et al. **Presse Med** 1995 Nov 4;24(33):1566–8 (13 ref.) (Eng. Abstr.) **(Fre)**

MICROBIOLOGY

Enterococcal arthritis with avascular necrosis in a lupus patient. Markov G, et al. **Br J Rheumatol** 1996 Jun; 35(6):595–7 (11 ref.)
Invasive staphylococcal infections complicating percutaneous transluminal coronary angioplasty: three cases and review. Cleveland KO, et al. **Clin Infect Dis** 1995 Jul;21(1):93–6 (17 ref.)
Joint infections due to Listeria monocytogenes: case report and review. Ellis LC, et al. **Clin Infect Dis** 1995 Jun; 20(6):1548–50 (15 ref.)
Bacterial arthritis. Goldenberg DL. **Curr Opin Rheumatol** 1995 Jul;7(4):310–4 (44 ref.)
[Meningococcal arthritis] Mader R. **Harefuah** 1995 Sep; 129(5–6):214–6 (26 ref.) **(Heb)**

RADIOGRAPHY

HIV arthritis. Eustace SJ, et al. **Radiol Clin North Am** 1996 Mar;34(2):450–3 (46 ref.)
Lyme arthropathy. Eustace SJ, et al.
Radiol Clin North Am 1996 Mar;34(2):454–5 (22 ref.)
[Computed tomography of the sacroiliac joints] Miquel A, et al. **Ann Radiol (Paris)** 1995;38(4):177–85 (28 ref.) **(Fre)**

VETERINARY

Surgical management of digit disorders in cattle. Desrochers A, et al. **Vet Clin North Am Food Anim Pract** 1996 Mar; 12(1):277–98 (45 ref.)
Arthroscopy in food animal practice. Gaughan EM.
Vet Clin North Am Food Anim Pract 1996 Mar;12(1):233–47 (11 ref.)
Orthopedic conditions of small ruminants. Llama, sheep, goat, and deer. Kaneps AJ.
Vet Clin North Am Food Anim Pract 1996 Mar;12(1):211–31 (51 ref.)

VIROLOGY

Viral arthritis including HIV. Naides SJ.
Curr Opin Rheumatol 1995 Jul;7(4):337–42 (36 ref.)
Viral arthritis: the lessons of parvovirus B19. Mangi RJ.
Hosp Pract (Off Ed) 1995 Nov 15;30(11):65–72 (7 ref.)
[Virus–associated arthritis (see comments)] Saal JG.
Z Rheumatol 1995 Nov–Dec;54(6):391–404 (148 ref.) (Eng. Abstr.) Comment in: Z Rheumatol 1995 Nov–Dec;54(6):389–90. **(Ger)**

ARTHRITIS, JUVENILE CHRONIC see **ARTHRITIS, JUVENILE RHEUMATOID**

ARTHRITIS, JUVENILE RHEUMATOID

Juvenile rheumatoid arthritis: current concepts and practice. Arnason JA, et al. **J Pediatr Ophthalmol Strabismus** 1995 Nov–Dec;32(6):383–5 (25 ref.)
The school experience of children with arthritis. Coping in the 1990s and transition into adulthood. Spencer CH, et al. **Pediatr Clin North Am** 1995 Oct;42(5):1285–98 (25 ref.)
[Juvenile chronic arthritis in children] Zgradić I.
Med Pregl 1995;48(1–2):19–23 (13 ref.) (Eng. Abstr.) **(Scr)**

COMPLICATIONS

Intraocular lens implantation in patients with juvenile rheumatoid arthritis–associated uveitis: an unresolved management issue [editorial; comment] Holland GN.
Am J Ophthalmol 1996 Aug;122(2):255–7 (10 ref.) Comment on: Am J Ophthalmol 1996 Aug;122(2):161–70.
Intraocular lens implantation in patients with juvenile rheumatoid arthritis [see comments] Probst LE, et al.
Am J Ophthalmol 1996 Aug;122(2):161–70 (24 ref.) Comment in: Am J Ophthalmol 1996 Aug;122(2):255–7.
Bone mineral metabolism in children with juvenile rheumatoid arthritis. Cassidy JT, et al.
Pediatr Clin North Am 1995 Oct;42(5):1017–33 (117 ref.)

DIAGNOSIS

Juvenile spondyloarthropathies: clinical manifestations and medical imaging. Azouz EM, et al. **Skeletal Radiol** 1995 Aug;24(6):399–408 (64 ref.)
[Juvenile chronic arthritis (JCA) or chronic arthropathy due to parvovirus B19?] Andreu Alapont E, et al.
An Esp Pediatr 1996 Feb;44(2):157–8 (14 ref.) **(Spa)**
[Antinuclear antibodies and juvenile chronic rheumatoid arthritis (editorial)] Modesto Caballero C.
An Esp Pediatr 1996 Apr;44(4):305–9 (33 ref.) **(Spa)**

DRUG THERAPY

Drug treatment in children with juvenile rheumatoid arthritis. Past, present, and future. Giannini EH, et al.
Pediatr Clin North Am 1995 Oct;42(5):1099–125 (89 ref.)

GENETICS

Juvenile rheumatoid arthritis and spondyloarthropathies. Lindsley CB. **Curr Opin Rheumatol** 1995 Sep;7(5):425–9 (46 ref.)

IMMUNOLOGY

Juvenile rheumatoid arthritis and spondyloarthropathies. Lindsley CB. **Curr Opin Rheumatol** 1995 Sep;7(5):425–9 (46 ref.)
Immunopathogenesis of juvenile rheumatoid arthritis: role of T cells and MHC. Sakkas LI, et al. **Immunol Res** 1995; 14(3):218–36 (179 ref.)

THERAPY

Use of intravenous immune globulin in the therapy of children with rheumatological diseases. Roifman CM.
J Clin Immunol 1995 Nov;15(6 Suppl):42S–51S (10 ref.)

ARTHRITIS, POSTINFECTIOUS see **ARTHRITIS, REACTIVE**

ARTHRITIS, PSORIATIC

[Management of psoriatic arthritis] Abu–Shakra M, et al.
Harefuah 1996 Feb 15;130(4):283–7 (53 ref.) **(Heb)**

CLASSIFICATION

Psoriatic arthritis. New types, new treatments [editorial] Ruzicka T. **Arch Dermatol** 1996 Feb;132(2):215–9 (47 ref.)

COMPLICATIONS

Psoriatic onycho–pachydermo–periostitis. A variant of psoriatic distal interphalangeal arthritis? Boisseau–Garsaud AM, et al. **Arch Dermatol** 1996 Feb;132(2):176–80 (22 ref.)
Odontoid fracture and C1–C2 subluxation in psoriatic cervical spondyloarthropathy. A case report. Sosner J, et al. **Spine** 1996 Feb 15;21(4):519–21 (6 ref.)
[Reflexions on the Tietze syndrome. Clinical contribution] Pappalardo A, et al. **Clin Ter** 1995 Nov;146(11):675–82 (32

ref.) (Eng. Abstr.) **(Ita)**

DIAGNOSIS

The myriad faces of psoriatic arthritis. Rothschild BM. **Compr Ther** 1996 Mar;22(3):165–8 (15 ref.)
Seronegative spondyloarthropathies. El-Khoury GY, et al. **Radiol Clin North Am** 1996 Mar;34(2):343–57, xi (56 ref.)
Juvenile spondyloarthropathies: clinical manifestations and medical imaging. Azouz EM, et al. **Skeletal Radiol** 1995 Aug;24(6):399–408 (64 ref.)

DRUG THERAPY

Psoriatic arthritis. New types, new treatments [editorial] Ruzicka T. **Arch Dermatol** 1996 Feb;132(2):215–9 (47 ref.)
Hazards of low dose methotrexate [editorial] Conaghan PG, et al. **Aust N Z J Med** 1995 Dec;25(6):670–3 (30 ref.)

ETIOLOGY

[Post-traumatic psoriatic arthritis. 2 cases] Thomachot B, et al. **Presse Med** 1996 Jan 6–13;25(1):21–4 (13 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Psoriatic arthritis. Winchester R. **Dermatol Clin** 1995 Oct; 13(4):779–92 (11 ref.)

RADIOGRAPHY

HIV arthritis. Eustace SJ, et al. **Radiol Clin North Am** 1996 Mar;34(2):450–3 (46 ref.)

RADIONUCLIDE IMAGING

[Psoriatic osteoarthropathy and bone scintigraphy] Holzmann H, et al. **Hautarzt** 1996 Jun;47(6):427–31 (19 ref.) (Eng. Abstr.) **(Ger)**

REHABILITATION

[The therapeutic use of physical factors in the combined therapy of patients with psoriatic arthritis] Grigor'eva VD, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1995 Nov–Dec; (6):48–52 (51 ref.) **(Rus)**

ARTHRITIS, REACTIVE

see related

REITER'S DISEASE

[Tropical reactive arthritis] Jeandel P. **Med Trop (Mars)** 1995; 55(4):325–8 (0 ref.) **(Fre)**
[Reactive arthritis] del Pino J. **An Med Interna** 1995 Oct; 12(10):469–71 (44 ref.) **(Spa)**

DIAGNOSIS

Reactive arthritis, diagnosis and treatment: a review. Nordstrom DC. **Acta Orthop Scand** 1996 Apr;67(2):196–201 (42 ref.)

DRUG THERAPY

Reactive arthritis, diagnosis and treatment: a review. Nordstrom DC. **Acta Orthop Scand** 1996 Apr;67(2):196–201 (42 ref.)
Epidemiologic, clinical, and therapeutic aspects of reactive arthritis and ankylosing spondylitis. Toivanen A, et al. **Curr Opin Rheumatol** 1995 Jul;7(4):279–83 (53 ref.)

ETIOLOGY

The pathogenetic role of HLA-B27. Feltkamp TE, et al. **Immunol Today** 1996 Jan;17(1):5–7 (4 ref.)
[Relationship between intestinal inflammation and arthritis] Helenius P, et al. **Duodecim** 1994;110(1):19–26 (36 ref.) **(Fin)**
[Reactive arthritis] Hitzelhammer J, et al. **Hautarzt** 1996 Jun; 47(6):479–87; quiz 485–6 (37 ref.) **(Ger)**

IMMUNOLOGY

Aetiological agents and immune mechanisms in enterogenic reactive arthritis. Sieper J, et al. **Baillieres Clin Rheumatol** 1996 Feb;10(1):105–21 (83 ref.)
Etiopathogenesis of reactive arthritis and ankylosing spondylitis. Careless DJ, et al. **Curr Opin Rheumatol** 1995 Jul;7(4):290–8 (70 ref.)
Epidemiologic, clinical, and therapeutic aspects of reactive arthritis and ankylosing spondylitis. Toivanen A, et al. **Curr Opin Rheumatol** 1995 Jul;7(4):279–83 (53 ref.)

MICROBIOLOGY

Aetiological agents and immune mechanisms in enterogenic reactive arthritis. Sieper J, et al. **Baillieres Clin Rheumatol** 1996 Feb;10(1):105–21 (83 ref.)
Etiopathogenesis of reactive arthritis and ankylosing spondylitis. Careless DJ, et al. **Curr Opin Rheumatol** 1995 Jul;7(4):290–8 (70 ref.)

ARTHRITIS, RHEUMATIC, ACUTE see **RHEUMATIC FEVER**

ARTHRITIS, RHEUMATOID

Prognostic markers in rheumatoid arthritis and classification of antirheumatic therapies. Choy EH, et al. **Drugs** 1995;50 Suppl 1:15–25 (73 ref.)
Rheumatoid arthritis in the elderly. Prevalence and optimal management. van Schaardenburg D. **Drugs Aging** 1995 Jul; 7(1):30–7 (57 ref.)
Perioperative management of the rheumatoid patient. Haynie RL, et al. **J Foot Ankle Surg** 1996 Mar–Apr;35(2):94–100 (74 ref.)
Perioperative management of rheumatoid arthritis. Areas of concern for primary care physicians. Lyssy KJ, et al. **Postgrad Med** 1996 Feb;99(2):191–4, 199–201, 205–6 (27 ref.)
Eicosanoids in rheumatoid arthritis. Sperling RI. **Rheum Dis Clin North Am** 1995 Aug;21(3):741–58 (84 ref.)
[Human leukocyte antigen (HLA) and the related diseases] Mizuki N, et al. **Nippon Naika Gakkai Zasshi** 1995 Dec 10;84(12):2091–103 (12 ref.) **(Jpn)**
[Chronic rheumatoid arthritis model mice transgenic for the HTLV-I tax gene] Iwakura Y. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2074–82 (33 ref.) **(Jpn)**

CLASSIFICATION

What is rheumatoid arthritis? Symmons DP. **Br Med Bull** 1995 Apr;51(2):243–8 (13 ref.)

COMPLICATIONS

Rheumatoid arthritis preceding the onset of polyarticular tophaceous gout [letter] Zonana-Nacach A, et al. **Ann Rheum Dis** 1996 Jul;55(7):489–90 (25 ref.)
The coexistence of systemic sclerosis and rheumatoid arthritis in five patients. Clinical and immunogenetic features suggest a distinct entity. Horiki T, et al. **Arthritis Rheum** 1996 Jan;39(1):152–6 (15 ref.)
Osteoporosis in rheumatoid arthritis. Dequeker J, et al. **Clin Exp Rheumatol** 1995 Sep–Oct;13 Suppl 12:S21–6 (60 ref.)
Coexisting rheumatoid arthritis and ankylosing spondylitis discussion of 3 cases with review of the literature. Toussirot E, et al. **Clin Rheumatol** 1995 Sep;14(5):554–60 (27 ref.)
Pyoderma gangrenosum with hepatopancreatic manifestations in a patient with rheumatoid arthritis. Hastier P, et al. **Dig Dis Sci** 1996 Mar;41(3):594–7 (9 ref.)
The underestimated long term medical and economic consequences of rheumatoid arthritis. Pincus T. **Drugs** 1995; 50 Suppl 1:1–14 (80 ref.)
Extensor tendon ruptures in rheumatoid arthritis. Williamson SC, et al. **Hand Clin** 1995 Aug;11(3):449–59 (21 ref.)
Rheumatoid neutrophilic dermatitis. Hassab-el-Naby HM, et al. **Int J Dermatol** 1996 Mar;35(3):207–8 (6 ref.)
Rheumatoid arthritis associated with membranous nephropathy and IgA nephritis with necrotizing lesions. Irie F, et al. **Nephrol Dial Transplant** 1996 Jul;11(7):1338–41 (28 ref.)
[Pleuropulmonary manifestations of rheumatoid arthritis] Crestani B, et al. **Presse Med** 1996 May 18;25(17):807–12 (25 ref.) (Eng. Abstr.) **(Fre)**
[Association of polymyositis and rheumatoid arthritis. Apropos of a new case not related to drug ingestion] Jardin H, et al. **Rev Med Interne** 1996;17(4):321–4 (27 ref.) (Eng. Abstr.) **(Fre)**
[Generalized osteoporosis in chronic polyarthritis--pathomechanisms and treatment approaches] Ringe JD. **Z Rheumatol** 1996 May-Jun;55(3):149–57 (49 ref.) (Eng. Abstr.) **(Ger)**
[Loculated pericardial effusion leading to functional tricuspid stenosis in a case of rheumatoid arthritis] Galli CA, et al. **Cardiologia** 1995 Sep;40(9):685–8 (11 ref.) (Eng. Abstr.) **(Ita)**
[Recurrent rheumatism and idiopathic osteoporosis in young adults. Coincidence or association?] Giordano N, et al. **Clin Ter** 1995 Dec;146(12):811–7 (16 ref.) (Eng. Abstr.) **(Ita)**
[A case of rheumatoid arthritis associated with multiple myeloma] Inoue F, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Feb;19(1):94–9 (10 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Crowned dens syndrome: a manifestation of hydroxy-apatite rheumatism. Malca SA, et al. **Acta Neurochir (Wien)** 1995; 135(3–4):126–30 (21 ref.)
Long-term outcomes in rheumatoid arthritis. Pincus T. **Br J Rheumatol** 1995 Nov;34 Suppl 2:59–73 (77 ref.)
Needle arthroscopy [editorial] Reece R, et al. **Br J Rheumatol** 1995 Dec;34(12):1102–4 (18 ref.)
Short-term outcomes in recent-onset rheumatoid arthritis. Young A. **Br J Rheumatol** 1995 Nov;34 Suppl 2:79–86 (34 ref.)
Managing early presentation of rheumatoid arthritis. Systematic overview. Glazier R. **Can Fam Physician** 1996 May;42:913–22 (85 ref.)
Paleopathology, its character and contribution to understanding and distinguishing among rheumatologic diseases: perspectives on rheumatoid arthritis and spondyloarthropathy. Rothschild BM. **Clin Exp Rheumatol** 1995 Sep–Oct;13(5):657–62 (31 ref.)
Needle arthroscopy: a new frontier in rheumatology. Panchal P, et al. **Compr Ther** 1996 Jan;22(1):44–7 (14 ref.)
Evaluation and treatment of the rheumatoid wrist. Terrono AL, et al. **Instr Course Lect** 1996;45:15–26 (64 ref.)
Magnetic resonance imaging of rheumatoid arthritis. Winalski CS, et al. **Radiol Clin North Am** 1996 Mar;34(2):243–58, x (59 ref.)
[Diagnosis of rheumatoid arthritis] Sieper J, et al. **Dtsch Med Wochenschr** 1996 Apr 19;121(16):523–6 (9 ref.) **(Ger)**
[Assessment of disease course in chronic rheumatoid arthritis: new quantitative dimensions for clinical practice] Stucki G, et al. **Schweiz Med Wochenschr** 1995 Oct 21; 125(42):2003–14 (39 ref.) (Eng. Abstr.) **(Ger)**
[RS3PE syndrome. A new rheumatic inflammatory syndrome in advanced age] Pittau E, et al. **Clin Ter** 1995 Nov; 146(11):663–73 (35 ref.) (Eng. Abstr.) **(Ita)**
[Usefulness of the determination of C reactive protein and other acute phase proteins in rheumatoid arthritis] Galeazzi M, et al. **Recenti Prog Med** 1995 Nov;86(11):456–62 (40 ref.) (Eng. Abstr.) **(Ita)**

DRUG THERAPY

Rheumatoid arthritis--changing theories and treatment modalities. van de Putte LB, et al. **Acta Orthop Scand Suppl** 1995 Oct;266:10–3 (13 ref.)
Management of osteoarthritis and rheumatoid arthritis: prospects and possibilities. Blackburn WD. **Am J Med** 1996 Feb 26;100(2A):24S–30S (47 ref.)
Tenidap: not just another NSAID? Canvin JM, et al. **Ann Rheum Dis** 1996 Feb;55(2):79–82 (29 ref.)
Acute febrile toxic reaction in patients with refractory rheumatoid arthritis who are receiving combined therapy with methotrexate and azathioprine. Blanco R, et al. **Arthritis Rheum** 1996 Jun;39(6):1016–20 (19 ref.)
Nonsteroidal antiinflammatory drug-induced enteropathy and severe chronic anemia in a patient with rheumatoid arthritis. Davies NM, et al. **Arthritis Rheum** 1996 Feb; 39(2):321–4 (15 ref.)
Regression of the nephrotic syndrome in rheumatoid arthritis and amyloidosis treated with azathioprine. A case report. Shapiro DL, et al. **Arthritis Rheum** 1995 Dec;38(12):1851–4 (24 ref.)
Innovative treatment approaches for rheumatoid arthritis. Combination therapy. Borigini MJ, et al. **Baillieres Clin Rheumatol** 1995 Nov;9(4):689–710 (61 ref.)
Innovative treatment approaches for rheumatoid arthritis. Cyclosporin, leflunomide and nitrogen mustard. Furst DE. **Baillieres Clin Rheumatol** 1995 Nov;9(4):711–29 (41 ref.)
Antimicrobial therapy for rheumatoid arthritis. Kloppenburg M, et al. **Baillieres Clin Rheumatol** 1995 Nov;9(4):759–69 (89 ref.)
Innovative treatment approaches for rheumatoid arthritis. New cyclo-oxygenase and cytokine inhibitors. Richardson CE, et al. **Baillieres Clin Rheumatol** 1995 Nov;9(4):731–58 (73 ref.)
The epidemiology of drug treatment failure in rheumatoid arthritis. Wolfe F. **Baillieres Clin Rheumatol** 1995 Nov; 9(4):619–32 (40 ref.)
Side-effects of drugs used in the treatment of rheumatoid arthritis. Evans PJ, et al. **Biochem Soc Symp** 1995; 61:195–207 (49 ref.)
Clinical efficacy of sulphasalazine--a review. Capell HA. **Br J Rheumatol** 1995 Nov;34 Suppl 2:35–9 (30 ref.)
Folate supplementation and methotrexate. Dijkmans BA. **Br J Rheumatol** 1995 Dec;34(12):1172–4 (22 ref.)
Therapeutic approaches for early rheumatoid arthritis. How early? How aggressive? Emery P. **Br J Rheumatol** 1995 Nov;34 Suppl 2:87–90 (16 ref.)
How and when should combination therapy be used? The role of an anchor drug. Farr M, et al. **Br J Rheumatol** 1995 Nov;34 Suppl 2:100–3 (38 ref.)
Combining sulphasalazine and methotrexate in rheumatoid arthritis: early clinical impressions. Haagsma CJ, et al. **Br J Rheumatol** 1995 Nov;34 Suppl 2:104–8 (30 ref.)
Possible mechanisms of action of methotrexate in patients with rheumatoid arthritis. Kremer JM. **Br J Rheumatol** 1995 Nov;34 Suppl 2:26–9 (37 ref.)
Clinical trial design for evaluating combination therapies. Paulus HE. **Br J Rheumatol** 1995 Nov;34 Suppl 2:92–5 (26 ref.)
Adverse events in methotrexate-treated rheumatoid arthritis patients. Sandoval DM, et al. **Br J Rheumatol** 1995 Nov; 34 Suppl 2:49–56 (76 ref.)
Sulphasalazine: mechanism of action in rheumatoid arthritis. Smedegård G, et al. **Br J Rheumatol** 1995 Nov;34 Suppl 2:7–15 (133 ref.)
Efficacy of methotrexate in rheumatoid arthritis. Weinblatt ME. **Br J Rheumatol** 1995 Nov;34 Suppl 2:43–8 (49 ref.)
Methotrexate in rheumatoid arthritis: toxicity issues [editorial] Weinblatt ME. **Br J Rheumatol** 1996 May; 35(5):403–5 (27 ref.)
Overview of combination second-line or disease-modifying antirheumatic drug therapy in rheumatoid arthritis. Williams HJ. **Br J Rheumatol** 1995 Nov;34 Suppl 2:96–9 (34 ref.)
How do second-line agents work? Choy E, et al. **Br Med Bull** 1995 Apr;51(2):472–92 (124 ref.)
Cyclosporine in the treatment of rheumatoid arthritis. Stein CM. **Bull Rheum Dis** 1995 Nov;44(7):1–4 (11 ref.)
Methotrexate in rheumatoid arthritis: when NSAIDs fail. Flynn JA, et al. **Cleve Clin J Med** 1995 Nov–Dec; 62(6):351–9 (92 ref.)
Treatment of early rheumatoid arthritis: a review of current and future concepts and therapy [see comments] Dawes PT, et al. **Clin Exp Rheumatol** 1995 May–Jun;13(3):381–94

(87 ref.) Comment in: Clin Exp Rheumatol 1996 Jan-Feb;14(1):106.

Aggressive therapy for rheumatoid arthritis. Kahn MF. **Clin Exp Rheumatol** 1995 Sep-Oct;13 Suppl 12:S31-4 (26 ref.)

A perspective on anti-cytokine and anti-T cell-directed therapies in rheumatoid arthritis. Maini RN. **Clin Exp Rheumatol** 1995 Sep-Oct;13 Suppl 12:S35-40 (40 ref.)

Rheumatoid arthritis: new trends in therapy. van de Putte LB, et al. **Clin Exp Rheumatol** 1995 Sep-Oct;13 Suppl 12:S27-30 (11 ref.)

Mechanism of action of cyclosporin in rheumatoid arthritis. Bentin J. **Clin Rheumatol** 1995 Sep;14 Suppl 2:22-5 (50 ref.)

Cyclosporine in rheumatoid arthritis: an overview. Førre O. **Clin Rheumatol** 1995 Sep;14 Suppl 2:33-6 (20 ref.)

Management of adverse effects of disease-modifying antirheumatic drugs. Wijnands MJ, et al. **Drug Saf** 1995 Oct;13(4):219-27 (31 ref.)

Methotrexate for rheumatoid arthritis. **Drug Ther Bull** 1995 Mar;33(3):17-9 (31 ref.)

Safety aspects of cyclosporin in rheumatoid arthritis. Dijkmans BA. **Drugs** 1995;50 Suppl 1:41-7 (37 ref.)

Sulfasalazine. A review of its pharmacological properties and therapeutic efficacy in the treatment of rheumatoid arthritis [published erratum appears in Drugs 1995 Oct;50(4):625] Rains CP, et al. **Drugs** 1995 Jul;50(1):137-56 (134 ref.)

Clinical use of cyclosporin in rheumatoid arthritis. Richardson C, et al. **Drugs** 1995;50 Suppl 1:26-36 (53 ref.)

International consensus recommendations on cyclosporin use in rheumatoid arthritis. Tugwell P. **Drugs** 1995;50 Suppl 1:48-56 (32 ref.)

Combination therapy with cyclosporin in rheumatoid arthritis. Yocum DE. **Drugs** 1995;50 Suppl 1:37-40 (20 ref.)

Pharmacological intervention in older patients with rheumatoid arthritis. Quality of life aspects. Bendtsen P, et al. **Drugs Aging** 1995 Nov;7(5):338-46 (55 ref.)

Disease-modifying antirheumatic drugs. Potential effects in older patients. Gardner G, et al. **Drugs Aging** 1995 Dec; 7(6):420-37 (43 ref.)

Low dose corticosteroids in early rheumatoid arthritis. Can these drugs slow disease progression? Kirwan JR, et al. **Drugs Aging** 1996 Mar;8(3):157-61 (16 ref.)

Nephrogenic diabetes insipidus induced by lobenzarit disodium treatment in patients with rheumatoid arthritis. Sakane N, et al. **Intern Med** 1996 Feb;35(2):119-22 (17 ref.)

Minocycline in rheumatoid arthritis. Langevitz P, et al. **Isr J Med Sci** 1996 May;32(5):327-30 (33 ref.)

Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. Salloum E, et al. **J Clin Oncol** 1996 Jun;14(6):1943-9 (56 ref.)

Advances and issues in the pharmacotherapy of rheumatoid arthritis. Dahl SL. **J Clin Pharm Ther** 1995 Jun; 20(3):131-47 (77 ref.)

Neurogenic influences in arthritis: potential modification by capsaicin [editorial] Matucci Cerinic M, et al. **J Rheumatol** 1995 Aug;22(8):1447-9 (27 ref.)

Assessment of radiographic abnormalities in rheumatoid arthritis: what have we accomplished and where should we go from here? Sharp JT. **J Rheumatol** 1995 Sep; 22(9):1787-91 (48 ref.)

Fatal pulmonary fibrosis complicating low dose methotrexate therapy for rheumatoid arthritis. van der Veen MJ, et al. **J Rheumatol** 1995 Sep;22(9):1766-8 (20 ref.)

Pancytopenia and severe cytopenia induced by low-dose methotrexate. Eight case-reports and a review of one hundred cases from the literature (with twenty-four deaths) [see comments] Berthelot JM, et al. **Rev Rhum Engl Ed** 1995 Jul-Sep;62(7-8):477-86 (108 ref.) Comment in: Rev Rhum Engl Ed 1995 Jul-Sep;62(7-8):471-3.

Low-dose glucocorticoid therapy in rheumatoid arthritis. Trèves R. **Rev Rhum Engl Ed** 1995 Nov;62(10):611-7 (40 ref.)

The changing face of therapy for rheumatoid arthritis. Kremer JM. **Rheum Dis Clin North Am** 1995 Aug; 21(3):845-52 (34 ref.)

Investigational agents for rheumatoid arthritis. Merkel PA, et al. **Rheum Dis Clin North Am** 1995 Aug;21(3):779-96 (85 ref.)

Rheumatoid arthritis. Outcome measures. Paulus HE, et al. **Rheum Dis Clin North Am** 1995 Aug;21(3):605-18 (52 ref.)

Antibiotic therapy for rheumatoid arthritis. Scientific and anecdotal appraisals. Trentham DE, et al. **Rheum Dis Clin North Am** 1995 Aug;21(3):817-34 (58 ref.)

Cyclosporine in rheumatoid arthritis. Yocum DE, et al. **Rheum Dis Clin North Am** 1995 Aug;21(3):835-44 (57 ref.)

Review of clinical trials and benefit/risk ratio of meloxicam. Barner A. **Scand J Rheumatol Suppl** 1996;102:29-37 (15 ref.)

Botanical lipids: effects on inflammation, immune responses, and rheumatoid arthritis. Rothman D, et al. **Semin Arthritis Rheum** 1995 Oct;25(2):87-96 (75 ref.)

[Towards more individualized parenteral gold therapy (editorial)] Kaarela K, et al. **Duodecim** 1994;110(11):1046-7 (14 ref.) **(Fin)**

[Cutaneous pseudolymphoma during treatment of rheumatoid polyarthritis with low-dose methotrexate] Delaporte E, et al. **Ann Dermatol Venereol** 1995;122(8):521-5 (33 ref.) (Eng. Abstr.) **(Fre)**

[Methotrexate in rheumatology: a therapeutic revolution] Kaye O, et al. **Rev Med Liege** 1995 Nov;50(11):453-7 (10 ref.) **(Fre)**

[Methotrexate treatment of rheumatoid arthritis] Beyeler C. **Schweiz Med Wochenschr** 1996 Apr 27;126(17):703-12 (61 ref.) (Eng. Abstr.) **(Ger)**

[Felty syndrome: a therapy-resistant variant of chronic rheumatoid arthritis? 2 case reports and literature review] Brücker R, et al. **Schweiz Rundsch Med Prax** 1996 Apr 16;85(16):534-40 (38 ref.) (Eng. Abstr.) **(Ger)**

[Cutaneous side-effects of nonsteroidal anti-inflammatory drugs (NSAID)] Gebhardt M, et al. **Z Rheumatol** 1995 Nov-Dec;54(6):405-12 (49 ref.) (Eng. Abstr.) **(Ger)**

[Prognosis and outcome of rheumatoid arthritis. Influence of anti-rheumatic therapy on natural course of disease and objectives in daily treatment] Fujimori J, et al. **Nippon Ika Daigaku Zasshi** 1995 Aug;62(4):396-400 (8 ref.) **(Jpn)**

[A case of rheumatoid arthritis with malignant lymphoma taking methotrexate] Hayakawa M, et al. **Ryumachi** 1995 Aug;35(4):678-82 (23 ref.) (Eng. Abstr.) **(Jpn)**

[Pneumocystis carinii pneumonia associated with low dose methotrexate treatment for malignant rheumatoid arthritis] Okuda Y, et al. **Ryumachi** 1995 Aug;35(4):699-704 (18 ref.) (Eng. Abstr.) **(Jpn)**

[Disease-modifying drugs in rheumatoid arthritis. Duration of treatment and reasons for withdrawal] Grefslie H, et al. **Tidsskr Nor Laegeforen** 1996 Mar 20;116(8):958-62 (32 ref.) (Eng. Abstr.) **(Nor)**

ECONOMICS

The underestimated long term medical and economic consequences of rheumatoid arthritis. Pincus T. **Drugs** 1995; 50 Suppl 1:1-14 (80 ref.)

ENZYMOLOGY

Beta 1,4-galactosyltransferase variations in rheumatoid arthritis. Alavi A, et al. **Adv Exp Med Biol** 1995;376:185-92 (35 ref.)

Evaluation of beta 1,4-galactosyltransferase in rheumatoid arthritis and its role in the glycosylation network associated with this disease. Alavi A, et al. **Glycoconj J** 1995 Jun; 12(3):206-10 (35 ref.)

EPIDEMIOLOGY

The epidemiology of hip osteoarthritis and rheumatoid arthritis in the Orient. Lau EM, et al. **Clin Orthop** 1996 Feb;(323):81-90 (67 ref.)

Epidemiology of rheumatoid arthritis. Alarcón GS. **Rheum Dis Clin North Am** 1995 Aug;21(3):589-604 (144 ref.)

ETIOLOGY

Rheumatoid arthritis: pathogenesis and early recognition. Pope RM. **Am J Med** 1996 Feb 26;100(2A):3S-9S (53 ref.)

Innovative treatment approaches for rheumatoid arthritis. T-cell regulation. Choy EH, et al. **Baillieres Clin Rheumatol** 1995 Nov;9(4):653-71 (76 ref.)

Hormonal control of rheumatoid inflammation. Panayi GS. **Br Med Bull** 1995 Apr;51(2):462-71 (34 ref.)

Monoclonal anti-TNF alpha antibody as a probe of pathogenesis and therapy of rheumatoid disease. Maini RN, et al. **Immunol Rev** 1995 Apr;144:195-223 (112 ref.)

The estrogen connection: the etiological relationship between diabetes, cancer, rheumatoid arthritis and psychiatric disorders. Holden RJ. **Med Hypotheses** 1995 Aug; 45(2):169-89 (162 ref.)

GENETICS

Collagen arthritis in T cell receptor congenic mice. A unique approach to study the role of T cell receptor genotypes in autoimmune arthritis. Nabozny GH, et al. **Adv Exp Med Biol** 1995;383:99-104 (20 ref.)

Should patients with recent onset rheumatoid arthritis be offered genetic screening? Symmons DP, et al. **Ann Rheum Dis** 1996 Jul;55(7):407-10 (25 ref.)

Role of hydrophobic amino acids at position 74 of DRB1 chain in rheumatoid arthritis. Cerná M, et al. **Arch Immunol Ther Exp (Warsz)** 1995;43(2):139-44 (40 ref.)

Genetic epidemiology of rheumatoid disease. Ollier WE, et al. **Br Med Bull** 1995 Apr;51(2):267-85 (102 ref.)

Rheumatoid arthritis in Greece: clinical, serological and genetic considerations. Drosos AA, et al. **Clin Exp Rheumatol** 1995 Sep-Oct;13 Suppl 12:S7-12 (48 ref.)

Are both genetic and reproductive associations with rheumatoid arthritis linked to prolactin? Brennan P, et al. **Lancet** 1996 Jul 13;348(9020):106-9 (40 ref.)

Oncogenes in rheumatoid arthritis. Müller-Ladner U, et al. **Rheum Dis Clin North Am** 1995 Aug;21(3):675-90 (97 ref.)

IMMUNOLOGY

Significance and molecular basis for IgG glycosylation changes in rheumatoid arthritis. Rademacher TW, et al. **Adv Exp Med Biol** 1995;376:193-204 (52 ref.)

Immunomodulatory mechanisms mediated by sex hormones in rheumatoid arthritis. Cutolo M, et al. **Ann N Y Acad Sci** 1996 Apr 30;784:237-51 (75 ref.)

TNF alpha is an effective therapeutic target for rheumatoid arthritis. Feldmann M, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:272-8 (20 ref.)

Evidence that type II collagen feeding can induce a durable therapeutic response in some patients with rheumatoid arthritis. Trentham DE. **Ann N Y Acad Sci** 1996 Feb 13; 778:306-14 (15 ref.)

Presentation of self peptides by dendritic cells: possible implications for the pathogenesis of rheumatoid arthritis. Thomas R, et al. **Arthritis Rheum** 1996 Feb;39(2):183-90 (85 ref.)

Oral tolerance: mechanisms and possible role in inflammatory joint diseases. Kagnoff MF. **Baillieres Clin Rheumatol** 1996 Feb;10(1):41-54 (71 ref.)

T cell receptor usage in rheumatoid arthritis. Lanchbury JS, et al. **Br Med Bull** 1995 Apr;51(2):346-58 (62 ref.)

The role of T-lymphocytes in rheumatoid arthritis. Salmon M, et al. **Br Med Bull** 1995 Apr;51(2):332-45 (51 ref.)

Immunology of systemic rheumatoid disease. Snowden N, et al. **Br Med Bull** 1995 Apr;51(2):437-48 (50 ref.)

Role of antigen presenting cells in rheumatoid arthritis. Viner NJ. **Br Med Bull** 1995 Apr;51(2):359-67 (40 ref.)

Rheumatoid arthritis. Feldmann M, et al. **Cell** 1996 May 3; 85(3):307-10 (35 ref.)

Autoimmune connective tissue disease, chronic polyarthritides and B cell expansion: risks and perspectives with immunosuppressive drugs. Ferraccioli GF, et al. **Clin Exp Rheumatol** 1996 Jan-Feb;14 Suppl 14:S71-80 (100 ref.)

Humoral immunity and glycosylation abnormalities in rheumatoid arthritis. Isenberg DA. **Clin Exp Rheumatol** 1995 Sep-Oct;13 Suppl 12:S17-20 (18 ref.)

Immunologic mechanisms in common rheumatologic diseases. Miller-Blair DJ, et al. **Clin Orthop** 1996 May; (326):43-54 (28 ref.)

B lymphocytes and humoral immune responses in rheumatoid arthritis. De Clerck LS. **Clin Rheumatol** 1995 Sep;14 Suppl 2:14-8 (56 ref.)

Therapeutic regulation of T cells in rheumatoid arthritis. Breedveld FC, et al. **Immunol Rev** 1995 Apr;144:5-16 (48 ref.)

Effects of modulation of inflammatory and immune parameters in patients with rheumatic and inflammatory disease receiving dietary supplementation of n-3 and n-6 fatty acids. Kremer JM. **Lipids** 1996 Mar;31 Suppl:S243-7 (50 ref.)

Prospects of immunotherapy for rheumatoid arthritis. 't Hart BA, et al. **Pharm World Sci** 1995 Nov 24;17(6):178-85 (112 ref.)

Autoimmunity. Insights provided by the SCID mouse model. Jorgensen C, et al. **Rev Rhum Engl Ed** 1995 Jul-Sep; 62(7-8):519-24 (38 ref.)

T cells in rheumatoid arthritis. Paradigms and facts. Goronzy JJ, et al. **Rheum Dis Clin North Am** 1995 Aug;21(3):655-74 (102 ref.)

METABOLISM

Aggrecan degradation in osteoarthritis and rheumatoid arthritis. Lark MW, et al. **Acta Orthop Scand Suppl** 1995 Oct;266:92-7 (31 ref.)

Local expression of corticotropin-releasing hormone in inflammatory arthritis. Crofford LJ, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:459-71 (63 ref.)

Synovial fluid lipids and apolipoproteins: a contemporary perspective. Prete PE, et al. **Biorheology** 1995 Jan-Feb; 32(1):1-16 (103 ref.)

Practical clinical pharmacology and drug interactions of low-dose methotrexate therapy in rheumatoid arthritis. Furst DE. **Br J Rheumatol** 1995 Nov;34 Suppl 2:20-5 (50 ref.)

Cytokine expression in chronic inflammatory disease. Brennan FM, et al. **Br Med Bull** 1995 Apr;51(2):368-84 (60 ref.)

Hypoxia, oxidative stress and rheumatoid arthritis. Mapp PI, et al. **Br Med Bull** 1995 Apr;51(2):419-36 (43 ref.)

Alterations in neurokinin 1 receptor gene expression in models of pain and inflammation. Krause JE, et al. **Can J Physiol Pharmacol** 1995 Jul;73(7):854-9 (49 ref.)

Sex hormones, proto-oncogene expression and apoptosis: their effects on rheumatoid synovial tissue. Cutolo M, et al. **Clin Exp Rheumatol** 1996 Jan-Feb;14(1):87-94 (58 ref.)

Humoral immunity and glycosylation abnormalities in rheumatoid arthritis. Isenberg DA. **Clin Exp Rheumatol** 1995 Sep-Oct;13 Suppl 12:S17-20 (18 ref.)

Biochemical markers of joint damage: is there any hope? Wollheim FA. **Clin Exp Rheumatol** 1995 Sep-Oct;13 Suppl 12:S3-5 (21 ref.)

Cytokines in rheumatoid arthritis. Houssiau FA. **Clin Rheumatol** 1995 Sep;14 Suppl 2:10-3 (21 ref.)

MORTALITY

Mortality in rheumatoid arthritis: do age and gender make a difference? Anderson ST. **Semin Arthritis Rheum** 1996 Apr;25(5):291-6 (18 ref.)

Mortality in rheumatoid arthritis. Myllykangas-Luosujärvi RA, et al. **Semin Arthritis Rheum** 1995 Dec;25(3):193-202 (65 ref.)

PATHOLOGY

Is rheumatoid arthritis a failure of B cell death in synovium? Edwards JC, et al. **Ann Rheum Dis** 1995 Sep;54(9):696-700 (37 ref.)

Course of gut inflammation in spondylarthropathies and therapeutic consequences. Mielants H, et al.

Baillieres Clin Rheumatol 1996 Feb;10(1):147–64 (75 ref.)
The anatomy of the rheumatoid lesion. Palmer DG. **Br Med Bull** 1995 Apr;51(2):286–95 (45 ref.)
Role of adhesion molecules in the pathogenesis of rheumatoid arthritis. Liao HX, et al. **Rheum Dis Clin North Am** 1995 Aug;21(3):715–40 (150 ref.)
The neutrophil in rheumatoid arthritis. Pillinger MH, et al. **Rheum Dis Clin North Am** 1995 Aug;21(3):691–714 (135 ref.)

PHYSIOPATHOLOGY

Differential release of molecular markers in joint disease. Saxne T. **Acta Orthop Scand Suppl** 1995 Oct;266:80–3 (29 ref.)
Predictors of joint damage in rheumatoid arthritis. Wollheim FA. **APMIS** 1996 Feb;104(2):81–93 (103 ref.)
Methodological problems in comparing the severity of rheumatoid arthritis between populations. Ali-Gombe A, et al. **Br J Rheumatol** 1995 Aug;34(8):781–4 (27 ref.)
Bone mass measurement and bone metabolism in rheumatoid arthritis: a review. Deodhar AA, et al. **Br J Rheumatol** 1996 Apr;35(4):309–22 (88 ref.)
Why does an inflammation in the joint hurt? [editorial] Schaible HG. **Br J Rheumatol** 1996 May;35(5):405–6 (11 ref.)
Rheumatoid arthritis in Greece: clinical, serological and genetic considerations. Drosos AA, et al. **Clin Exp Rheumatol** 1995 Sep–Oct;13 Suppl 12:S7–12 (48 ref.)
Pro- and antiinflammatory cytokine balance in rheumatoid arthritis. Miossec P. **Clin Exp Rheumatol** 1995 Sep–Oct;13 Suppl 12:S13–6 (16 ref.)
The role of T cells in rheumatoid arthritis. De Keyser F, et al. **Clin Rheumatol** 1995 Sep;14 Suppl 2:5–9 (21 ref.)
Prognostic factors of severe rheumatoid arthritis. Westhovens R. **Clin Rheumatol** 1995 Sep;14 Suppl 2:19–21 (24 ref.)
Cellular adhesion molecules in rheumatoid arthritis: regulation by cytokines and possible clinical importance. Szekanecz Z, et al. **J Investig Med** 1996 Apr;44(4):124–35 (164 ref.)
The role of chemokines in inflammatory joint disease. Kunkel SL, et al. **J Leukoc Biol** 1996 Jan;59(1):6–12 (26 ref.)
Hypothalamic–pituitary–adrenal–glucocorticoid axis function in rheumatoid arthritis [editorial; comment] Masi AT, et al. **J Rheumatol** 1996 Apr;23(4):577–81 (19 ref.) Comment on: J Rheumatol 1996 Apr;23(4):596–602.
Physical fitness in children with juvenile rheumatoid arthritis and other chronic pediatric illnesses. Singsen BH. **Pediatr Clin North Am** 1995 Oct;42(5):1035–50 (61 ref.)
Hormonal and pregnancy relationships to rheumatoid arthritis: convergent effects with immunologic and microvascular systems. Masi AT, et al. **Semin Arthritis Rheum** 1995 Aug;25(1):1–27 (166 ref.)
[Kidney function problems in rheumatoid arthritis] Nordin H, et al. **Ugeskr Laeger** 1996 May 27;158(22):3137–40 (40 ref.) (Eng. Abstr.) **(Dan)**
[Prognostic factors in early inflammatory arthritis] Combe B. **Rev Med Interne** 1996;17(3):224–30 (67 ref.) (Eng. Abstr.) **(Fre)**

PSYCHOLOGY

[Pain and pain perception in the elderly from the viewpoint of rheumatology] Nehen HG. **Z Gerontol Geriatr** 1995 Sep–Oct;28(5):335–8 (10 ref.) (Eng. Abstr.) **(Ger)**

RADIOGRAPHY

The radiology of rheumatoid arthritis. Brown JH, et al. **Am Fam Physician** 1995 Oct;52(5):1372–80 (04 ref.)
Joint erosions and patients with early rheumatoid arthritis. van der Heijde DM. **Br J Rheumatol** 1995 Nov;34 Suppl 2:74–8 (31 ref.)
Radiographic evaluation of the upper cervical spine in rheumatoid arthritis: a retrospective analysis. Kuhr M, et al. **Eur Spine J** 1996;5(2):107–11 (30 ref.)
The validity of radiography as outcome measure in rheumatoid arthritis. Boers M. **J Rheumatol** 1995 Sep; 22(9):1783–6 (18 ref.)
Assessment of radiographic abnormalities in rheumatoid arthritis: what have we accomplished and where should we go from here? Sharp JT. **J Rheumatol** 1995 Sep; 22(9):1787–91 (48 ref.)
Scoring radiographic abnormalities in rheumatoid arthritis. Sharp JT. **Radiol Clin North Am** 1996 Mar;34(2):233–41, x (66 ref.)

RADIONUCLIDE IMAGING

New agents for scintigraphy in rheumatoid arthritis. de Bois MH, et al. **Eur J Nucl Med** 1995 Nov;22(11):1339–46 (73 ref.)

REHABILITATION

Therapeutic monoclonal antibodies. Choy EH, et al. **Br J Rheumatol** 1995 Aug;34(8):707–15 (64 ref.)
[Rheumatoid arthritis and quality of life] Kawai S. **Ryumachi** 1995 Jun;35(3):609–20 (43 ref.) **(Jpn)**

SURGERY

In the rheumatoid patient: surgery to the cervical spine. Casey AT, et al. **Br J Rheumatol** 1995 Nov;34(11):1079–86 (48 ref.)
Evaluation and treatment of the rheumatoid wrist. Terrono AL, et al. **Instr Course Lect** 1996;45:15–26 (64 ref.)
Periprosthetic infections due to Mycobacterium tuberculosis in patients with no prior history of tuberculosis. Spinner RJ, et al. **J Arthroplasty** 1996 Feb;11(2):217–22 (46 ref.)
Long-term results of forefoot arthroplasty in patients with rheumatoid arthritis. Patsalis T, et al. **Orthopedics** 1996 May;19(5):439–47 (48 ref.)
Surgical management of cervical rheumatoid problems. Crockard HA. **Spine** 1995 Dec 1;20(23):2584–90 (40 ref.)
[Rheumatoid orthopedics and endoprosthetics of the shoulder joint] Schwägerl W, et al. **Wien Med Wochenschr** 1996; 146(6–7):124–9 (31 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

TNF alpha is an effective therapeutic target for rheumatoid arthritis. Feldmann M, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:272–8 (20 ref.)
Evidence that type II collagen feeding can induce a durable therapeutic response in some patients with rheumatoid arthritis. Trentham DE. **Ann N Y Acad Sci** 1996 Feb 13; 778:306–14 (15 ref.)
Workshop on chronic pain, pain control, and patient outcomes in rheumatoid arthritis and osteoarthritis. Bellamy N, et al. **Arthritis Rheum** 1996 Mar;39(3):357–62 (26 ref.)
Innovative treatment approaches for rheumatoid arthritis. T-cell regulation. Choy EH, et al. **Baillieres Clin Rheumatol** 1995 Nov;9(4):653–71 (76 ref.)
Anti-cytokine therapy in rheumatoid arthritis. Elliott MJ, et al. **Baillieres Clin Rheumatol** 1995 Nov;9(4):633–52 (81 ref.)
Course of gut inflammation in spondylarthropathies and therapeutic consequences. Mielants H, et al. **Baillieres Clin Rheumatol** 1996 Feb;10(1):147–64 (75 ref.)
Innovative treatment approaches for rheumatoid arthritis. Issues in clinical trials of biological agents. Strand V. **Baillieres Clin Rheumatol** 1995 Nov;9(4):825–35 (38 ref.)
Health economics as an aspect of health outcome: basic principles and application in rheumatoid arthritis [see comments] Lambert CM, et al. **Br J Rheumatol** 1995 Aug; 34(8):774–80 (49 ref.) Comment in: Br J Rheumatol 1996 May;35(5):494.
Gene therapy of rheumatoid arthritis via cytokine regulation: future perspectives. Chernajovsky Y, et al. **Br Med Bull** 1995 Apr;51(2):503–16 (41 ref.)
Managing early presentation of rheumatoid arthritis. Systematic overview. Glazier R. **Can Fam Physician** 1996 May;42:913–22 (85 ref.)
Therapeutic regulation of T cells in rheumatoid arthritis. Breedveld FC, et al. **Immunol Rev** 1995 Apr;144:5–16 (48 ref.)
Monoclonal anti-TNF alpha antibody as a probe of pathogenesis and therapy of rheumatoid disease. Maini RN, et al. **Immunol Rev** 1995 Apr;144:195–223 (112 ref.)
Prospects of immunotherapy for rheumatoid arthritis. ʏ Hart BA, et al. **Pharm World Sci** 1995 Nov 24;17(6):178–85 (112 ref.)
Biologic interventions in rheumatoid arthritis. Cush JJ, et al. **Rheum Dis Clin North Am** 1995 Aug;21(3):797–816 (74 ref.)
Marine and botanical lipids as immunomodulatory and therapeutic agents in the treatment of rheumatoid arthritis. DeLuca P, et al. **Rheum Dis Clin North Am** 1995 Aug; 21(3):759–77 (91 ref.)
Assessment of long-term outcomes of rheumatoid arthritis. How choices of measures and study designs may lead to apparently different conclusions. Pincus T. **Rheum Dis Clin North Am** 1995 Aug;21(3):619–54 (112 ref.)
Anti-integrin immunotherapy in rheumatoid arthritis: protective effect of anti-alpha 4 antibody in adjuvant arthritis. Barbadillo C, et al. **Springer Semin Immunopathol** 1995;16(4):427–36 (59 ref.)
[Immunotherapy in rheumatoid arthritis; current status] Breedveld FC, et al. **Ned Tijdschr Geneeskd** 1996 Jun 15; 140(24):1255–9 (30 ref.) **(Dut)**
[Therapy of rheumatoid arthritis] Sieper J, et al. **Dtsch Med Wochenschr** 1996 Apr 26;121(17):563–7 (12 ref.) **(Ger)**

ARTHRITIS, SEPTIC see **ARTHRITIS, INFECTIOUS**

ARTHRITIS, VIRAL see **ARTHRITIS, INFECTIOUS**

ARTHRODERMA see **ASCOMYCETES**

ARTHRODESIS

Function after amputation, arthrodesis, or arthroplasty for tumors about the shoulder. Kneisl JS. **J South Orthop Assoc** 1995 Fall;4(3):228–36 (36 ref.)

METHODS

Medial compartment arthrosis of the knee. Dearborn JT, et al. **Am J Orthop** 1996 Jan;25(1):18–26 (64 ref.)
Tibiofibular arthrodesis for malunion of the talocrural joint. Loder BG, et al. **J Foot Ankle Surg** 1995 May–Jun; 34(3):283–8 (8 ref.)
[Arthrodesis of the ankle joint] Bauer G, et al. **Orthopade** 1996 Apr;25(2):158–65 (74 ref.) (Eng. Abstr.) **(Ger)**
[Primary arthrodesis of the knee joint] Gossé F, et al. **Orthopade** 1996 Apr;25(2):146–52 (27 ref.) (Eng. Abstr.) **(Ger)**
[Elbow arthrodesis and its alternative] Hahn MP, et al. **Orthopade** 1996 Apr;25(2):112–20 (70 ref.) (Eng. Abstr.) **(Ger)**
[Arthrodesis of the wrist in arthritis] Knopp W, et al. **Orthopade** 1996 Apr;25(2):121–5 (23 ref.) (Eng. Abstr.) **(Ger)**
[Arthrodesis following revision of a knee endoprosthesis. Literature review 1984–1994] Kohn D, et al. **Orthopade** 1996 Apr;25(2):153–7 (27 ref.) (Eng. Abstr.) **(Ger)**
[Arthrodesis of the shoulder joint] Reichelt A. **Orthopade** 1996 Apr;25(2):104–11 (61 ref.) (Eng. Abstr.) **(Ger)**
[Screw arthrodesis of the ankle joint. Technique and outcome] Thermann H, et al. **Orthopade** 1996 Apr; 25(2):166–76 (55 ref.) (Eng. Abstr.) **(Ger)**
[Hip joint arthrodesis using the cobra plate. Indication, technique, outcome] Wagner M, et al. **Orthopade** 1996 Apr; 25(2):129–39 (69 ref.) (Eng. Abstr.) **(Ger)**
[Hindfoot arthrodesis] Wülker N, et al. **Orthopade** 1996 Apr; 25(2):177–86 (57 ref.) (Eng. Abstr.) **(Ger)**
[Arthrodesis of the metatarsophalangeal joint of the large toe] Wülker N. **Orthopade** 1996 Apr;25(2):187–93 (28 ref.) (Eng. Abstr.) **(Ger)**

ARTHROGRAPHY

Optimizing joint-imaging: (CT)-arthrography. Obermann WR. **Eur Radiol** 1996;6(3):275–83 (8 ref.)

CLASSIFICATION

Scoring radiographic abnormalities in rheumatoid arthritis. Sharp JT. **Radiol Clin North Am** 1996 Mar;34(2):233–41, x (66 ref.)

ARTHROGRYPOSIS

Lethal arthrogryposis multiplex congenital (fetal akinesia deformation sequence, FADS). Porter HJ. **Pediatr Pathol Lab Med** 1995 Jul–Aug;15(4):617–37 (96 ref.)

ETIOLOGY

Arthrogryposis associated with unsuccessful attempts at termination of pregnancy. Hall JG. **Am J Med Genet** 1996 May 3;63(1):293–300 (40 ref.)

GENETICS

Arthrogryposis, renal dysfunction and cholestasis syndrome: report of five patients from three Italian families. Di Rocco M, et al. **Eur J Pediatr** 1995 Oct;154(10):835–9 (8 ref.)

ARTHROMYODYSPLASIA, CONGENITAL see **ARTHROGRYPOSIS**

ARTHROPATHY, NEUROGENIC

PHYSIOPATHOLOGY

The Charcot joint in diabetes. Klenerman L. **Diabet Med** 1996;13 Suppl 1:S52–4 (11 ref.)

THERAPY

The Charcot joint in diabetes. Klenerman L. **Diabet Med** 1996;13 Suppl 1:S52–4 (11 ref.)

ARTHROPLASTY

Function after amputation, arthrodesis, or arthroplasty for tumors about the shoulder. Kneisl JS. **J South Orthop Assoc** 1995 Fall;4(3):228–36 (36 ref.)

METHODS

Subcapital fracture of a congenitally dislocated hip: revival of Girdlestone resection arthroplasty. Taha AM. **Bull Hosp Jt Dis** 1995;54(1):35–42 (100 ref.)
Long-term results of forefoot arthroplasty in patients with rheumatoid arthritis. Patsalis T, et al. **Orthopedics** 1996 May;19(5):439–47 (48 ref.)

ARTHROPLASTY, REPLACEMENT see **JOINT PROSTHESIS**

ARTHROPLASTY, REPLACEMENT, HIP see **HIP PROSTHESIS**

ARTHROPLASTY, REPLACEMENT, KNEE see **KNEE PROSTHESIS**

ARTHROPOD-BORNE VIRUSES see **ARBOVIRUSES**

ARTHROPOD VECTORS

MICROBIOLOGY

[Lyme borreliosis: epidemiologic and etiopathogenic aspects] Oteo-Revuelta JA, et al. **Enferm Infecc Microbiol Clin** 1995 Nov;13(9):550–5 (53 ref.) **(Spa)**

ARTHROPOD VECTORS

PHYSIOLOGY

Blood-feeding arthropods: live syringes or invertebrate pharmacologists? Ribeiro JM. **Infect Agents Dis** 1995 Sep; 4(3):143–52 (100 ref.)

ARTHROPODS

[Porocephalosis, a little known parasitosis, literature review and a Congolese case report] Faisy C, et al. **Med Trop (Mars)** 1995;55(3):258–62 (26 ref.) (Eng. Abstr.) **(Fre)**

ANATOMY & HISTOLOGY

Inductive signals. Revolving vertebrates. Jones CM, et al. **Curr Biol** 1995 Jun 1;5(6):574–6 (16 ref.)

EMBRYOLOGY

The evolution of arthropod segmentation: insights from comparisons of gene expression patterns. Patel NH. **Dev Suppl** 1994;:201–7 (34 ref.)

GENETICS

The evolving role of Hox genes in arthropods. Akam M, et al. **Dev Suppl** 1994;:209–15 (62 ref.)

PHYSIOLOGY

Blood-feeding arthropods: live syringes or invertebrate pharmacologists? Ribeiro JM. **Infect Agents Dis** 1995 Sep; 4(3):143–52 (100 ref.)

ARTHROSCOPY

An intermeniscal fibrous band in a recreational runner. Butler JP, et al. **Arthroscopy** 1995 Dec;11(6):735–7 (16 ref.)

Suprascapular nerve entrapment by ganglion cysts: a report of six cases with arthroscopic findings and review of the literature. Fehrman DA, et al. **Arthroscopy** 1995 Dec; 11(6):727–34 (47 ref.)

Needle arthroscopy [editorial] Reece R, et al. **Br J Rheumatol** 1995 Dec;34(12):1102–4 (18 ref.)

Arthroscopy of the elbow. Baker CL, et al. **Clin Sports Med** 1996 Apr;15(2):261–81 (32 ref.)

The role of arthroscopy in athletic injuries of the wrist. Savoie FH 3rd, et al. **Clin Sports Med** 1996 Apr; 15(2):219–33 (12 ref.)

Arthroscopic Bankart procedures for anterior shoulder instability. A review of the literature. el Akad AM, et al. **Knee Surg Sports Traumatol Arthrosc** 1993;1(2):113–22 (61 ref.)

Arthroscopic surgery of the hip: current status. Norman-Taylor FH, et al. **Knee Surg Sports Traumatol Arthrosc** 1994;2(4):255–8 (23 ref.)

Rehabilitation following arthroscopic meniscectomy. St-Pierre DM. **Sports Med** 1995 Nov;20(5):338–47 (147 ref.)

[Arthroscopic holmium-YAG laser compared to conventional procedures on the knee joint. 2-year results of a randomized prospective study] Lübbers C, et al. **Orthopade** 1996 Feb;25(1):64–72 (35 ref.) (Eng. Abstr.) **(Ger)**

[Arthroscopic shoulder surgery] Okamura K. **Hokkaido Igaku Zasshi** 1995 May;70(3):375–81 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Current advances and future direction of arthroscopic surgery for disorders in the knee joint] Yasuda K. **Hokkaido Igaku Zasshi** 1995 May;70(3):383–9 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Lateral release of the patella. II. Arthroscopic technique of subcutaneous lateral release, complications] Latosiewicz R. **Chir Narzadow Ruchu Ortop Pol** 1994;59(3):235–8 (19 ref.) (Eng. Abstr.) **(Pol)**

INSTRUMENTATION

Needle arthroscopy: a new frontier in rheumatology. Panchal P, et al. **Compr Ther** 1996 Jan;22(1):44–7 (14 ref.)

[Critical considerations in arthroscopic stabilization of the unstable shoulder joint] Jerosch J. **Sportverletz Sportschaden** 1996 Mar;10(1):1–12 (93 ref.) (Eng. Abstr.) **(Ger)**

[Arthroscopic approaches to reconstruction of the cruciate ligament: refresher course] Kohn D. **Sportverletz Sportschaden** 1995 Dec;9(4):A31–42 (0 ref.) **(Ger)**

[Arthroscopy and arthroscopic surgery of the shoulder joint] Landsiedl F. **Wien Med Wochenschr** 1996;146(6–7):146–8 (18 ref.) (Eng. Abstr.) **(Ger)**

METHODS

The case for a simple method of grading osteoarthritis severity at arthroscopy [editorial; comment] Marshall KW. **J Rheumatol** 1996 Apr;23(4):582–5 (24 ref.) Comment on: J Rheumatol 1996 Apr;23(4):698–706.

Tibial plateau fractures: the arthroscopic option. Bobic V, et al. **Knee Surg Sports Traumatol Arthrosc** 1993; 1(3–4):239–42 (23 ref.)

[Arthroscopy of the knee joint. Conclusions and recommendations] **Rev Chir Orthop Reparatrice Appar Mot** 1996;82(2):175–86 (0 ref.) **(Fre)**

[Arthroscopic treatment possibilities of the rotator cuff] Landsiedl F. **Orthopade** 1995 Nov;24(6):529–40 (80 ref.) (Eng. Abstr.) **(Ger)**

[Lateral release of the patella. I—Diagnostics, indications] Latosiewicz R. **Chir Narzadow Ruchu Ortop Pol** 1994; 59(3):231–4 (19 ref.) (Eng. Abstr.) **(Pol)**

VETERINARY

Arthroscopy in food animal practice. Gaughan EM. **Vet Clin North Am Food Anim Pract** 1996 Mar;12(1):233–47 (11 ref.)

Arthroscopy in the diagnosis and treatment of front leg lameness. van Bree H, et al. **Vet Q** 1995 Apr;17 Suppl 1:S32–4 (0 ref.)

ARTICULATION DISORDERS

ETIOLOGY

[Anarthria, progressive apraxia and extrapyramidal syndrome: an uncommon clinical form of corticobasal degeneration? A case studied by HMPAO Tc99m single-photon emission tomography] Fayet G, et al. **Rev Neurol (Paris)** 1995 Apr;151(4):247–50 (14 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

[Basic principles for indications in phonosurgery] Friedrich G. **Laryngorhinootologie** 1995 Nov;74(11):663–5 (24 ref.) (Eng. Abstr.) **(Ger)**

ARTIFACTS

Common methodological problems and artifacts associated with studies of myocardial stunning in vivo. Bolli R. **Basic Res Cardiol** 1995 Jul-Aug;90(4):257–62 (13 ref.)

Review of artifacts associated with transrectal ultrasound: understanding, recognition, and prevention of misinterpretation. Hulsmans FJ, et al. **J Clin Ultrasound** 1995 Oct;23(8):483–94 (21 ref.)

Radiographic artifacts. Kirberger RM, et al. **J S Afr Vet Assoc** 1995 Jun;66(2):85–94 (8 ref.)

Functional MRI: are we all moving towards artifactual conclusions? Or fMRI fact or fancy? Weisskoff RM. **NMR Biomed** 1995 May;8(3):101–3 (10 ref.)

ARTIFICIAL INSEMINATION see **INSEMINATION, ARTIFICIAL**

ARTIFICIAL INTELLIGENCE

see related
NEURAL NETWORKS (COMPUTER)

Types of planning: can artificial intelligence yield insights into prefrontal function? Hendler JA. **Ann N Y Acad Sci** 1995 Dec 15;769:265–76 (45 ref.)

Use of artificial intelligence in analytical systems for the clinical laboratory. Place JF, et al. **Clin Biochem** 1995 Aug; 28(4):373–89 (84 ref.)

Effective domain-dependent reuse in medical knowledge bases. Dojat M, et al. **Comput Biomed Res** 1995 Dec; 28(6):403–32 (53 ref.)

The use of artificial intelligence in the analysis of sports performance: a review of applications in human gait analysis and future directions for sports biomechanics. Lapham AC, et al. **J Sports Sci** 1995 Jun;13(3):229–37 (38 ref.)

Problems of knowledge acquisition automation in medical expert systems. Stempczyńska J, et al. **Medinfo** 1995;8 Pt 1:857–60 (9 ref.)

Hints. Abu-Mostafa YS. **Neural Comput** 1995 Jul;7(4):639–71 (34 ref.)

Consciousness: perspectives from symbolic and connectionist AI. Bechtel W. **Neuropsychologia** 1995 Sep;33(9):1075–86 (37 ref.)

Reviewing the behavioral science knowledge base on technology transfer. Introduction. Backer TE, et al. **NIDA Res Monogr** 1995;155:1–20 (23 ref.)

Assessing and enhancing readiness for change: implications for technology transfer. Backer TE. **NIDA Res Monogr** 1995;155:21–41 (40 ref.)

Image representations for visual learning. Beymer D, et al. **Science** 1996 Jun 28;272(5270):1905–9 (61 ref.)

Toxicity estimation by chemical substructure analysis: the TOX II program. Klopman G, et al. **Toxicol Lett** 1995 Sep;79(1–3):145–55 (14 ref.)

[Artificial intelligence and its medical applications] Armoni A, et al. **Harefuah** 1996 Feb 1;130(3):185–90 (34 ref.) **(Heb)**

ARTIFICIAL LIMBS

Interface mechanics in external prosthetics: review of interface stress measurement techniques. Sanders JE. **Med Biol Eng Comput** 1995 Jul;33(4):509–16 (41 ref.)

Perspectives on the role of afferent signals in control of motor neuroprostheses. Johnson KO, et al. **Med Eng Phys** 1995 Oct;17(7):481–96 (99 ref.)

Amputation surgery and prostheses. Rodriguez RP. **Orthop Clin North Am** 1996 Jul;27(3):525–39 (59 ref.)

REHABILITATION

Rehabilitation in limb deficiency. 3. The geriatric amputee. Andrews KL. **Arch Phys Med Rehabil** 1996 Mar;77(3 Suppl):S14–7 (41 ref.)

Rehabilitation in limb deficiency. 1. Gait and motion analysis. Czerniecki JM. **Arch Phys Med Rehabil** 1996 Mar;77(3 Suppl):S3–8 (41 ref.)

Rehabilitation in limb deficiency. 4. Limb amputation. Esquenazi A, et al. **Arch Phys Med Rehabil** 1996 Mar;77(3 Suppl):S18–28 (42 ref.)

Rehabilitation in limb deficiency. 2. The pediatric amputee. Jain S. **Arch Phys Med Rehabil** 1996 Mar;77(3 Suppl):S9–13 (42 ref.)

ARTIFICIAL ORGANS

Implantable biohybrid artificial organs. Colton CK. **Cell Transplant** 1995 Jul-Aug;4(4):415–36 (72 ref.)

Use of mammalian liver cells for artificial liver support. Jauregui HO, et al. **Cell Transplant** 1996 May-Jun; 5(3):353–67 (130 ref.)

Mass transfer limitations to the performance of membrane bioartificial liver support devices. Catapano G. **Int J Artif Organs** 1996 Jan;19(1):18–35 (70 ref.)

Hybrid liver support [editorial] Gerlach J. **Int J Artif Organs** 1996 Jan;19(1):1–2 (8 ref.)

Assessment of bioartificial liver support in acute liver failure. Hughes RD, et al. **Int J Artif Organs** 1996 Jan;19(1):3–6 (18 ref.)

Role of transport proteins in bioartificial liver assist systems. Mitzner S, et al. **Int J Artif Organs** 1996 Jan;19(1):49–52 (6 ref.)

Hepatocyte encapsulation—initial intentions and new aspects for its use in bioartificial liver support. Stange J, et al. **Int J Artif Organs** 1996 Jan;19(1):45–8 (26 ref.)

Cell sources for bioartificial liver support. Stange J, et al. **Int J Artif Organs** 1996 Jan;19(1):14–7 (25 ref.)

Tissue engineering of a bioartificial kidney: a universal donor organ. Humes HD. **Transplant Proc** 1996 Aug;28(4):2032–5 (24 ref.)

[Pulmonary (side)effects of extracorporeal therapy procedures] Kolb G. **Wien Klin Wochenschr Suppl** 1996; 1:15–20 (42 ref.) **(Ger)**

[Activation of blood coagulation in extracorporeal circulation] Nowak G. **Wien Klin Wochenschr Suppl** 1996; 1:9–14 (28 ref.) **(Ger)**

[Clinical aspects of biocompatibility] Schiffl H, et al. **Wien Klin Wochenschr Suppl** 1996;1:4–8 (27 ref.) **(Ger)**

[An artificial liver on its way to clinical reality?] Thasler WE, et al. **Zentralbl Chir** 1995;120(8):614–23 (82 ref.) (Eng. Abstr.) **(Ger)**

TRENDS

Artificial liver. Evolution and future perspectives. Rozga J, et al. **ASAIO J** 1995 Oct-Dec;41(4):831–7 (58 ref.)

The future of artificial organs [editorial] Gurland HJ, et al. **Int J Artif Organs** 1995 Feb;18(2):64–8 (10 ref.)

ARTIFICIAL SWEETENERS see **SWEETENING AGENTS**

ARTIFICIAL TEARS see **OPHTHALMIC SOLUTIONS**

ARTIFICIAL VENTRICLE see **HEART-ASSIST DEVICES**

ARVICOLINAE see **MICROTINAE**

ARVICOLINES see **MICROTINAE**

ARYL HYDROCARBON RECEPTORS see **RECEPTORS, ARYL HYDROCARBON**

ARYLAMIDASES see **AMINO ACID NAPHTHYLAMIDASES**

ARYLAMINE ACETYLASES see **ARYLAMINE ACETYLTRANSFERASES**

ARYLAMINE ACETYLTRANSFERASES

GENETICS

Metabolic polymorphisms and cancer susceptibility. Smith G, et al. **Cancer Surv** 1995;25:27–65 (249 ref.)

Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer. Nebert DW, et al. **DNA Cell Biol** 1996 Apr;15(4):273–80 (96 ref.)

ARYLSULFATASES

ANALYSIS

[Arylsulfatase] Tajima Y. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:392–5 (21 ref.) **(Jpn)**

ANTAGONISTS & INHIBITORS

Regulation and inhibition of steroid sulfatase activity in breast cancer. Purohit A, et al. **Ann N Y Acad Sci** 1996 Apr 30; 784:40–9 (28 ref.)

METABOLISM

Regulation and inhibition of steroid sulfatase activity in breast cancer. Purohit A, et al. **Ann N Y Acad Sci** 1996 Apr 30; 784:40–9 (28 ref.)

ARYLSULFATE SULFOHYDROLASES see ARYLSULFATASES

ARYTENOID CARTILAGE

INJURIES

Arytenoid dislocation. Faries PL, et al. **Otolaryngol Head Neck Surg** 1996 Jul;115(1):160–2 (9 ref.)

[Intubation trauma of the larynx—a literature review with special reference to arytenoid cartilage dislocation (see comments)] Rieger A, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Jun; 31(5):281–7 (37 ref.) (Eng. Abstr.) Comment in: Anasthesiol Intensivmed Notfallmed Schmerzther 1996 Jun;31(5):279–80. **(Ger)**

AS IF PERSONALITY see PERSONALITY DISORDERS

ASBESTOS

Deposition of inhaled asbestos and man-made mineral fibres in the respiratory tract. Morgan A. **Ann Occup Hyg** 1995 Oct;39(5):747–58 (40 ref.)

Airborne fibre concentrations and lung burden compared to the tumour response in rats and humans exposed to asbestos. Rödelsperger K, et al. **Ann Occup Hyg** 1995 Oct; 39(5):715–25 (27 ref.)

Occupational exposure to dusts containing asbestos and chronic airways disease. Zejda JE. **Int J Occup Med Environ Health** 1996;9(2):117–25 (50 ref.)

ADVERSE EFFECTS

Malignant peritoneal mesothelioma. Case report and review of the literature. Watteeuw G, et al. **Acta Clin Belg** 1995; 50(4):222–6 (18 ref.)

Mechanisms of carcinogenesis and clinical features of asbestos-associated cancers. Mossman BT, et al. **Cancer Invest** 1996;14(5):466–80 (126 ref.)

Expression of genes coding for growth factors in experimental pneumoconiosis. Morris GF, et al. **Chest** 1996 Mar;109(3 Suppl):45S–49S (55 ref.)

Asbestos: facts and fiction [letter] Mossman BT. **Environ Health Perspect** 1994 May;102(5):424–6 (20 ref.)

The mesothelial cell and its role in asbestos-induced pleural injury. Kuwahara M, et al. **Int J Exp Pathol** 1995 Jun; 76(3):163–70 (58 ref.)

The origin and development of the asbestos Threshold Limit Value: scientific indifference and corporate influence. Egilman DS, et al. **Int J Health Serv** 1995;25(4):667–96 (98 ref.)

Vermiculite: a review of the mineralogy and health effects of vermiculite exploitation. Addison J. **Regul Toxicol Pharmacol** 1995 Jun;21(3):397–405 (74 ref.)

A case study in avoiding a deadly legacy in developing countries. Lemen RA, et al. **Toxicol Ind Health** 1994 Jan–Apr;10(1–2):59–87 (210 ref.)

[Malignant peritoneal mesothelioma: its relation to asbestos] Pentimone F, et al. **Minerva Med** 1995 Oct;86(10):439–43 (38 ref.) (Eng. Abstr.) **(Ita)**

CHEMISTRY

Vermiculite: a review of the mineralogy and health effects of vermiculite exploitation. Addison J. **Regul Toxicol Pharmacol** 1995 Jun;21(3):397–405 (74 ref.)

[Relationship between the physiochemical properties of asbestos and pulmonary fibrosis] Wrzaszczyk B, et al. **Med Pr** 1996;47(4):401–9 (39 ref.) (Eng. Abstr.) **(Pol)**

ASBESTOS, AMPHIBOLE

ADVERSE EFFECTS

Occupational exposure to chrysotile asbestos and cancer risk: a review of the amphibole hypothesis. Stayner LT, et al. **Am J Public Health** 1996 Feb;86(2):179–86 (72 ref.)

ASBESTOS, CROCIDOLITE

ADVERSE EFFECTS

Malignant mesothelioma in Pilbara Aborigines. Musk AW, et al. **Aust J Public Health** 1995 Oct;19(5):520–2 (10 ref.)

ASBESTOS, SERPENTINE

ADVERSE EFFECTS

Occupational exposure to chrysotile asbestos and cancer risk: a review of the amphibole hypothesis. Stayner LT, et al. **Am J Public Health** 1996 Feb;86(2):179–86 (72 ref.)

PHARMACOLOGY

[Lipid peroxidation in the presence of inorganic compounds. Relation to oxidative stress mechanisms] Fournier J, et al. **C R Seances Soc Biol Fil** 1995;189(3):429–42 (36 ref.) (Eng. Abstr.) **(Fre)**

ASBESTOSIS

Asbestos exposure and asbestosis: clarifying terminology and avoiding confusion [see comments] Woodard PK, et al. **J R Soc Med** 1995 Dec;88(12):669–71 (19 ref.) Comment in: J R Soc Med 1996 Apr;89(4):240.

New developments in asbestos-related pleural disease. Rudd RM. **Thorax** 1996 Feb;51(2):210–6 (59 ref.)

COMPLICATIONS

The association of occupational asbestos dust exposure and laryngeal carcinoma [see comments] Kraus T, et al. **Isr J Med Sci** 1995 Sep;31(9):540–8 (76 ref.) Comment in: Isr J Med Sci 1995 Sep;31(9):563–4.

GENETICS

Asbestos and mesothelioma: genetic lessons from a tragedy [comment] Knudson A. **Proc Natl Acad Sci U S A** 1995 Nov 21;92(24):10819–20 (21 ref.) Comment on: Proc Natl Acad Sci U S A 1995 Nov 21;92(24):10854–8.

ASCARIASIS

[Hepatic ascariasis] Nakasaki H, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):58–60 (16 ref.) **(Jpn)**

[Intragallbladder ascariasis] Nakazawa O, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):464–7 (11 ref.) **(Jpn)**

COMPLICATIONS

[Cholecystolithiasis with ascariasis] Shibayama K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):391–3 (19 ref.) **(Jpn)**

DIAGNOSIS

Acute pancreatitis caused by biliary ascaris in pregnancy. Asrat T, et al. **J Perinatol** 1995 Jul–Aug;15(4):330–2 (15 ref.)

PATHOLOGY

[Interstitial nephritis with acute renal failure in Ascaris lumbricoides infection] Meister P, et al. **Pathologe** 1995 Nov;16(6):434–8 (16 ref.) (Eng. Abstr.) **(Ger)**

ASCARIDIDA

DRUG EFFECTS

[Structural disorders in the tissues of nematodes of the suborder Ascaridata after exposure to anthelmintics] Bogoiavlenskii IuK, et al. **Med Parazitol (Mosk)** 1995 Apr–Jun;(2):19–27 (30 ref.) (Eng. Abstr.) **(Rus)**

ASCARIDIDA INFECTIONS

PARASITOLOGY

[Parasitologic significance of the alteration of the causative Anisakidae worm and of the Pseudoterranova decipiens female immature adult worm, casting off the cuticles, and excreted from human in Kanazawa City] Ishikura H, et al. **Hokkaido Igaku Zasshi** 1995 Sep;70(5):667–85 (48 ref.) (Eng. Abstr.) **(Jpn)**

ASCARIDOIDEA

Visceral larva migrans induced eosinophilic cardiac pseudotumor: a cause of sudden death in a child. Boschetti A, et al. **J Forensic Sci** 1995 Nov;40(6):1097–9 (12 ref.)

[Parasitologic significance of the alteration of the causative Anisakidae worm and of the Pseudoterranova decipiens female immature adult worm, casting off the cuticles, and excreted from human in Kanazawa City] Ishikura H, et al. **Hokkaido Igaku Zasshi** 1995 Sep;70(5):667–85 (48 ref.) (Eng. Abstr.) **(Jpn)**

ASCARIS LUMBRICOIDES

[Interstitial nephritis with acute renal failure in Ascaris lumbricoides infection] Meister P, et al. **Pathologe** 1995 Nov;16(6):434–8 (16 ref.) (Eng. Abstr.) **(Ger)**

CYTOLOGY

Worm sperm and advances in cell locomotion. Theriot JA. **Cell** 1996 Jan 12;84(1):1–4 (18 ref.)

ISOLATION & PURIFICATION

Acute pancreatitis caused by biliary ascaris in pregnancy. Asrat T, et al. **J Perinatol** 1995 Jul–Aug;15(4):330–2 (15 ref.)

ASCARIS SUUM

METABOLISM

Actions of neurotoxins (bungarotoxins, neosurugatoxin and lophotoxins) on insect and nematode nicotinic acetylcholine receptors. Tornøe C, et al. **Toxicon** 1995 Apr;33(4):411–24 (61 ref.)

PHYSIOLOGY

Cell biology of nematode sperm. L'Hernault SW, et al. **Methods Cell Biol** 1995;48:273–301 (38 ref.)

ASCAROIDEA see ASCARIDOIDEA

ASCHELMINTHES see HELMINTHS

ASCITES

Malignant ascites. Parsons SL, et al. **Br J Surg** 1996 Jan; 83(1):6–14 (92 ref.)

COMPLICATIONS

Ovarian hemangioma associated with concomitant stromal luteinization and ascites. Yamawaki T, et al. **Gynecol Oncol** 1996 Jun;61(3):438–41 (13 ref.)

DIAGNOSIS

Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Arroyo V, et al. **Hepatology** 1996 Jan;23(1):164–76 (119 ref.)

Bile ascites. Chaturvedi A, et al. **Indian Pediatr** 1995 Feb; 32(2):251–3 (6 ref.)

ETIOLOGY

Evaluation and initial management of patients with ascites. Lipsky MS, et al. **Am Fam Physician** 1996 Sep 15; 54(4):1327–33 (18 ref.)

Unexplained effusions: association with allogeneic bone marrow transplantation and acute or chronic graft-versus-host disease. Seber A, et al. **Bone Marrow Transplant** 1996 Feb;17(2):207–11 (28 ref.)

Acute ascites with blunt cardiac rupture. Dagenais F, et al. **Can J Cardiol** 1996 Jan;12(1):86–8 (12 ref.)

Hepatic venoocclusive disease as a complication of whole abdominopelvic irradiation and treatment with the transjuglar intrahepatic portosystemic shunt: case report and literature review. Shen-Gunther J, et al. **Gynecol Oncol** 1996 May;61(2):282–6 (25 ref.)

Cirrhosis: ascites and hepatorenal syndrome. Recent advances in pathogenesis. Henriksen JH. **J Hepatol** 1995; 23 Suppl 1:25–30 (74 ref.)

Ascites due to endometriosis. Spitzer M, et al. **Obstet Gynecol Surv** 1995 Aug;50(8):628–31 (17 ref.)

[Lymphocytic ascites revealing systemic mastocytosis] Essner C, et al. **Gastroenterol Clin Biol** 1995 Nov; 19(11):948–51 (23 ref.) (Eng. Abstr.) **(Fre)**

[Diagnosis and therapy of ascites] Frick E, et al. **Internist (Berl)** 1995 Aug;36(8):853–65 (0 ref.) **(Ger)**

PHYSIOPATHOLOGY

Ascites and its effects upon respiratory muscle loading and work of breathing. Rosado M, et al. **Crit Care Med** 1996 Mar;24(3):538–40 (22 ref.)

Ascites and hepatorenal syndrome: pathophysiology and management. Roberts LR, et al. **Mayo Clin Proc** 1996 Sep; 71(9):874–81 (37 ref.)

SURGERY

Peritoneovenous shunting in cirrhosis: its role in the management of refractory ascites in the 1990s [editorial; comment] Wong F, et al. **Am J Gastroenterol** 1995 Dec; 90(12):2086–9 (39 ref.) Comment on: Am J Gastroenterol 1995 Dec;90(12):2097–102.

Pancreatic pseudocysts, ascites, and fistulas. Yeo CJ. **Curr Opin Gen Surg** 1994;:173–8 (36 ref.)

Large-volume paracentesis in the treatment of cirrhotic patients with refractory ascites. The role of postparacentesis plasma volume expansion. Forouzandeh B, et al. **J Clin Gastroenterol** 1996 Apr;22(3):207–10 (51 ref.)

[Surgical treatment of refractory ascites with peritoneovenous shunt] Massari R, et al. **Chir Ital** 1995; 47(1):57–0 (14 ref.) (Eng. Abstr.) **(Ita)**

THERAPY

Evaluation and initial management of patients with ascites. Lipsky MS, et al. **Am Fam Physician** 1996 Sep 15; 54(4):1327–33 (18 ref.)

Ascites and hepatorenal syndrome: pathophysiology and management. Roberts LR, et al. **Mayo Clin Proc** 1996 Sep; 71(9):874–81 (37 ref.)

ASCITES, CHYLOUS see CHYLOPERITONEUM

ASCITES, GELATINOUS see PSEUDOMYXOMA PERITONEI

ASCITES SHUNT, PERITONEOVENOUS see PERITONEOVENOUS SHUNT

ASCITIC FLUID

CHEMISTRY

[Ascitic fluid: benignancy and malignancy parameters] Fluixá Carrascosa F, et al. **Rev Esp Enferm Dig** 1996 Jan; 88(1):35–8 (28 ref.) **(Spa)**

IMMUNOLOGY

PELs and the perforin and granzyme independent mechanism of CTL–mediated lysis. Berke G. **Immunol Rev** 1995 Aug; 146:21–31 (52 ref.)

ASCOMYCETES

GENETICS

MIP: an epigenetic gene silencing process in Ascobolus immersus. Rossignol JL, et al.
Curr Top Microbiol Immunol 1995;197:179–91 (32 ref.)
Natural plasmids of filamentous fungi. Griffiths AJ.
Microbiol Rev 1995 Dec;59(4):673–85 (102 ref.)

GROWTH & DEVELOPMENT

[Advances in the study on artificial cultivation of Cordyceps sinensis] Yin D, et al. **Chung Kuo Chung Yao Tsa Chih** 1995 Dec;20(12):707–9, inside back cover (29 ref.) **(Chi)**

PHYSIOLOGY

Steroid hormone signalling system and fungi. Zakelj–Mavrič M, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1995 Dec;112(4):637–42 (69 ref.)

ASCORBIC ACID

Vitamin C and human health—a review of recent data relevant to human requirements. Weber P, et al.
Int J Vitam Nutr Res 1996;66(1):19–30 (107 ref.)
Catalytic metals, ascorbate and free radicals: combinations to avoid. Buettner GR, et al. **Radiat Res** 1996 May; 145(5):532–41 (79 ref.)

ADMINISTRATION & DOSAGE

Considerations of the scientific substantiation for antioxidant vitamins and beta–carotene in disease prevention. Blumberg JB. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1521S–1526S (59 ref.)
Evidence from cancer intervention and biomarker studies and the development of biochemical markers. Bowen PE, et al. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1403S–1409S (54 ref.)
Antioxidant vitamin–cardiovascular disease hypothesis is still promising, but still unproven: the need for randomized trials. Hennekens CH, et al. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1377S–1380S (26 ref.)
Determination of optimal vitamin C requirements in humans. Levine M, et al. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1347S–1356S (137 ref.)
Relations among aging, antioxidant status, and cataract. Taylor A, et al. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1439S–1447S (80 ref.)
[Antioxidative vitamins and cataracts in the elderly] Heseker H. **Z Ernahrungswiss** 1995 Sep;34(3):167–76 (68 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Safety of antioxidant vitamins and beta–carotene. Diplock AT. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1510S–1516S (56 ref.)

BLOOD

[Vitamin C (ascorbic acid)] Hashizume N. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:709–11 (2 ref.) **(Jpn)**

METABOLISM

Proposed role for a combination of citric acid and ascorbic acid in the production of dietary iron overload: a fundamental cause of disease. Crawford RD.
Biochem Mol Med 1995 Feb;54(1):1–11 (77 ref.)
The nitric oxide/ascorbate cycle: how neurones may control their own oxygen supply. Millar J. **Med Hypotheses** 1995 Jul;45(1):21–6 (65 ref.)

PHARMACOKINETICS

The mechanism of uptake of ascorbic acid into osteoblasts and leukocytes. Wolf G. **Nutr Rev** 1996 May;54(5):150–2 (12 ref.)

PHARMACOLOGY

Vitamins E and C, beta–carotene, and other carotenoids as antioxidants. Sies H, et al. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1315S–1321S (87 ref.)
Effect of vitamin C on plasma lipids. Howard PA, et al. **Ann Pharmacother** 1995 Nov;29(11):1129–36 (58 ref.)
Vitamin C–driven free radical generation from iron. Herbert V, et al. **J Nutr** 1996 Apr;126(4 Suppl):1213S–20S (61 ref.)
The dual roles of nutrients as antioxidants and prooxidants: their effects on tumor cell growth. Schwartz JL.
J Nutr 1996 Apr;126(4 Suppl):1221S–7S (42 ref.)
Antioxidant agents and colorectal carcinogenesis: role of beta–carotene, vitamin E and vitamin C. Pappalardo G, et al. **Tumori** 1996 Jan–Feb;82(1):6–11 (88 ref.)

PHYSIOLOGY

The antioxidant vitamins and cardiovascular disease. A critical review of epidemiologic and clinical trial data [see comments] Jha P, et al. **Ann Intern Med** 1995 Dec 1; 123(11):860–72 (55 ref.) Comment in: Ann Intern Med 1995 Dec 1;123(11):887.
Effect of vitamin E, vitamin C and beta–carotene on LDL oxidation and atherosclerosis. Jialal I, et al.
Can J Cardiol 1995 Oct;11 Suppl G:97G–103G (97 ref.)
Update on the biological characteristics of the antioxidant micronutrients: vitamin C, vitamin E, and the carotenoids. Rock CL, et al. **J Am Diet Assoc** 1996 Jul;96(7):693–702; quiz 703–4 (128 ref.)

THERAPEUTIC USE

Vitamin C and the genesis of autoimmune disease and allergy (review). Kodama M, et al. **In Vivo** 1995 May–Jun; 9(3):231–8 (38 ref.)
Ascorbic acid and gastrointestinal cancer. Cohen M, et al. **J Am Coll Nutr** 1995 Dec;14(6):565–78 (136 ref.)
Epidemiologic studies of antioxidants and cancer in humans. Flagg EW, et al. **J Am Coll Nutr** 1995 Oct;14(5):419–27 (88 ref.)

ASCORBIC ACID DEFICIENCY

see related
SCURVY

ASIALIA see **XEROSTOMIA**

ASIALOGANGLIOSIDES see **GLYCOSPHINGOLIPIDS**

ASIALOGLYCOPROTEINS

METABOLISM

[Establishment of in vitro model for HBV infection via asialoglycoprotein receptor] Neda H, et al.
Nippon Rinsho 1995 Oct;53 Suppl:121–4 (15 ref.) **(Jpn)**

ASIAN AMERICANS

Drug abuse prevention research concerns in Asian and Pacific Islander populations. Kuramoto FH.
NIDA Res Monogr 1994;139:249–72 (13 ref.)
Prevention in practice. Ethnic groups. Millar J, et al.
Prim Care 1995 Dec;22(4):713–30 (27 ref.)

STATISTICS & NUMERICAL DATA

Picture imperfect: hidden problems among Asian Pacific islander elderly. Tanjasiri SP, et al. **Gerontologist** 1995 Dec; 35(6):753–60 (65 ref.)

ASIATIC RACE see **MONGOLOID RACE**

ASP see **VIPERIDAE**

ASPA CEMENT see **GLASS IONOMER CEMENTS**

ASPARAGINE

METABOLISM

Asparagine–linked glycosylation: specificity and function of oligosaccharyl transferase. Imperiali B, et al.
Bioorg Med Chem 1995 Dec;3(12):1565–78 (86 ref.)

ASPARTAME

PHARMACOLOGY

Prevention of nephrotoxicity of ochratoxin A, a food contaminant. Creppy EE, et al. **Toxicol Lett** 1995 Dec; 82–83:869–77 (54 ref.)

ASPARTATE AMINOTRANSFERASE

BLOOD

[Aspartate aminotransferase (AST) and alanine aminotransferase (ALT)] Miura Y. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:266–71 (12 ref.) **(Jpn)**

ASPARTATE AMINOTRANSFERASE ISOENZYMES see **ASPARTATE AMINOTRANSFERASE**

ASPARTATE AMINOTRANSFERASE ISOZYMES see **ASPARTATE AMINOTRANSFERASE**

ASPARTIC ACID

ANALOGS & DERIVATIVES

[N–acetyl–aspartate abnormalities in internal–temporal epileptic foci using proton magnetic resonance spectroscopy] Giroud M, et al. **Rev Neurol (Paris)** 1995 Jun–Jul;151(6–7):404–9 (28 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

N–acetylaspartate in neuropsychiatric disorders. Tsai G, et al. **Prog Neurobiol** 1995 Aug;46(5):531–40 (178 ref.)

PHARMACOLOGY

N–acetylaspartate in neuropsychiatric disorders. Tsai G, et al. **Prog Neurobiol** 1995 Aug;46(5):531–40 (178 ref.)

PHYSIOLOGY

N–acetylaspartate in neuropsychiatric disorders. Tsai G, et al. **Prog Neurobiol** 1995 Aug;46(5):531–40 (178 ref.)

ASPARTIC PROTEINASES

[Biosynthetic mechanism of endothelins with various physiological and physiopathological significance—structure and function of endothelin converting enzyme] Takayanagi R.
Fukuoka Igaku Zasshi 1995 Sep;86(9):362–6 (3 ref.) **(Jpn)**

ANTAGONISTS & INHIBITORS

Antifungal drug targets: Candida secreted aspartyl protease and fungal wall beta–glucan synthesis. Goldman RC, et al. **Infect Agents Dis** 1995 Dec;4(4):228–47 (120 ref.)
[Synthetic inhibitors targeting serine and aspartic acid proteases] Reboud–Ravaux MC, et al. **J Pharm Belg** 1996 May–Jun;51(3):161–4 (44 ref.) (Eng. Abstr.) **(Fre)**

CHEMISTRY

Structure and possible function of aspartic proteinases in barley and other plants. Kervinen J, et al.
Adv Exp Med Biol 1995;362:241–54 (72 ref.)

METABOLISM

Structure and possible function of aspartic proteinases in barley and other plants. Kervinen J, et al.
Adv Exp Med Biol 1995;362:241–54 (72 ref.)
Proenkephalin–processing enzymes in chromaffin granules: model for neuropeptide biosynthesis. Hook VY, et al.
Ann N Y Acad Sci 1996 Mar 22;780:121–33 (22 ref.)
Molecular pharmacology of endothelin converting enzymes. Turner AJ, et al. **Biochem Pharmacol** 1996 Jan 26; 51(2):91–102 (127 ref.)
The role of prohormone convertases in insulin biosynthesis: evidence for inherited defects in their action in man and experimental animals. Steiner DF, et al. **Diabetes Metab** 1996 Apr;22(2):94–104 (72 ref.)

PHYSIOLOGY

The role of Candida albicans secreted aspartic proteinase in the development of candidoses. Hoegl L, et al.
J Mol Med 1996 Mar;74(3):135–42 (71 ref.)

ASPARTYL PROTEINASES see **ASPARTIC PROTEINASES**

ASPARTYLGLUCOSAMINIDASE see **ASPARTYLGLUCOSYLAMINASE**

ASPARTYLGLUCOSYLAMINASE

GENETICS

[Aspartylglucosaminuria: a point mutation as a cause of mental defect] Ikonen E, et al. **Duodecim** 1994; 110(7):667–73 (21 ref.) **(Fin)**

ASPARTYLGLUCOSYLAMINE DEASPARTYLASE see **ASPARTYLGLUCOSYLAMINASE**

ASPARTYLGLYCOSAMINE AMIDOHYDROLASE see **ASPARTYLGLUCOSYLAMINASE**

ASPARTYLPHENYLALANINE METHYL ESTER see **ASPARTAME**

ASPERGILLOSIS

[Hepatic aspergillosis] Ito A.
Ryoikibetsu Shokogun Shirizu 1995;(7):43–4 (5 ref.) **(Jpn)**

COMPLICATIONS

Aspergillus sinusitis in patients with AIDS: report of three cases and review. Teh W, et al. **Clin Infect Dis** 1995 Sep; 21(3):529–35 (46 ref.)
Clusterlike headache. A case of sphenoidal aspergilloma. Zanchin G, et al. **Headache** 1995 Sep;35(8):494–7 (20 ref.)
Invasive aspergilloma of the frontal base causing internal carotid artery occlusion. Satoh H, et al. **Surg Neurol** 1995 Nov;44(5):483–8 (30 ref.)
Commentary: unusual manifestations of aspergillosis [comment] Denning DW. **Thorax** 1995 Jul;50(7):812–3 (23 ref.) Comment on: Thorax 1995 Jul;50(7):805–6. Comment on: Thorax 1995 Jul;50(7):807–8. Comment on: Thorax 1995 Jul;50(7):809–10. Comment on: Thorax 1995 Jul;50(7):810–1.

DIAGNOSIS

Diagnosis and management of invasive aspergillosis. Denning DW. **Curr Clin Top Infect Dis** 1996;16:277–99 (41 ref.)
Tools and trends in the detection of Aspergillus fumigatus. Latgé JP. **Curr Top Med Mycol** 1995;6:245–81 (137 ref.)
Aspergillus infections: problems in diagnosis and treatment. Andriole VT. **Infect Agents Dis** 1996 Jan;5(1):47–54 (74 ref.)

DRUG THERAPY

Aspergillus infections: problems in diagnosis and treatment. Andriole VT. **Infect Agents Dis** 1996 Jan;5(1):47–54 (74 ref.)
Successfully treated invasive pulmonary aspergillosis associated with smoking marijuana in a renal transplant recipient. Marks WH, et al. **Transplantation** 1996 Jun 27; 61(12):1771–4 (8 ref.)
[Curative antifungal treatment of invasive pulmonary aspergillosis] Andrès E, et al. **Rev Pneumol Clin** 1995; 51(4):228–31 (31 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Peracute disseminated fatal Aspergillus fumigatus sepsis as a complication of corticoid-treated systemic lupus erythematosus. Nenoff P, et al. **Mycoses** 1995 Nov–Dec; 38(11–12):467–71 (21 ref.)
Aspergillus endophthalmitis. An unrecognized endemic disease in orthotopic liver transplantation. Hunt KE, et al. **Ophthalmology** 1996 May;103(5):757–67 (65 ref.)
Successfully treated invasive pulmonary aspergillosis associated with smoking marijuana in a renal transplant recipient. Marks WH, et al. **Transplantation** 1996 Jun 27; 61(12):1771–4 (8 ref.)
[A case of bronchial asthma complicated by mycosis] Andronova NV, et al. **Ter Arkh** 1995;67(11):33–5 (7 ref.) **(Rus)**

RADIOGRAPHY

CT manifestations of pulmonary aspergillosis. Logan PM, et al. **Crit Rev Diagn Imaging** 1996 Feb;37(1):1–37 (43 ref.)
Varied radiologic appearances of pulmonary aspergillosis. Thompson BH, et al. **Radiographics** 1995 Nov; 15(6):1273–84 (36 ref.)

THERAPY

Diagnosis and management of invasive aspergillosis. Denning DW. **Curr Clin Top Infect Dis** 1996;16:277–99 (41 ref.)

ASPERGILLOSIS, ALLERGIC BRONCHOPULMONARY

DIAGNOSIS

[Invasive aspergillosis in intensive care (see comments)] Le Conte P, et al. **Ann Fr Anesth Reanim** 1995;14(2):198–208 (78 ref.) (Eng. Abstr.) Comment in: Ann Fr Anesth Reanim 1995;14(5):454–6. **(Fre)**

ETIOLOGY

[Invasive aspergillosis during resuscitation (comment)] Coronel B, et al. **Ann Fr Anesth Reanim** 1995;14(5):454–5 (13 ref.) Comment on: Ann Fr Anesth Reanim 1995;14(2):198–208. **(Fre)**
[Bronchopulmonary aspergillosis and mucoviscidosis] Baculard A, et al. **Rev Pneumol Clin** 1995;51(3):160–3 (29 ref.) (Eng. Abstr.) **(Fre)**

ASPERGILLUS

CLASSIFICATION

Epidemiology of fungal infections: the promise of molecular typing. Pfaller MA. **Clin Infect Dis** 1995 Jun;20(6):1535–9 (61 ref.)
Molecular typing of Aspergillus species. Birch M, et al. **J Hosp Infect** 1995 Jun;30 Suppl:339–51 (43 ref.)

ASPERGILLUS FLAVUS

see related
AFLATOXINS

ASPERGILLUS FUMIGATUS

Tools and trends in the detection of Aspergillus fumigatus. Latgé JP. **Curr Top Med Mycol** 1995;6:245–81 (137 ref.)
Peracute disseminated fatal Aspergillus fumigatus sepsis as a complication of corticoid-treated systemic lupus erythematosus. Nenoff P, et al. **Mycoses** 1995 Nov–Dec; 38(11–12):467–71 (21 ref.)

GENETICS

[Aspergillus fumigatus: from saprophytism to virulence. Phenotypic and genotypic biodiversity] Grillot R, et al. **Ann Pharm Fr** 1996;54(2):68–72 (21 ref.) (Eng. Abstr.) **(Fre)**

PATHOGENICITY

The search for virulence determinants in Aspergillus fumigatus. Bouchara JP, et al. **Trends Microbiol** 1995 Aug; 3(8):327–30 (25 ref.)
[Aspergillus fumigatus: from saprophytism to virulence. Phenotypic and genotypic biodiversity] Grillot R, et al. **Ann Pharm Fr** 1996;54(2):68–72 (21 ref.) (Eng. Abstr.) **(Fre)**

ASPERGILLUS NIDULANS

CYTOLOGY

Cell cycle regulation in Aspergillus by two protein kinases. Osmani SA, et al. **Biochem J** 1996 Aug 1;317 (Pt 3):633–41 (127 ref.)

PHYSIOLOGY

Cell cycle. The NIMA kinase joins forces with Cdc2. Fry AM, et al. **Curr Biol** 1995 Oct 1;5(10):1122–5 (16 ref.)

ASPERGILLUS NIGER

[A case of bronchial asthma complicated by mycosis] Andronova NV, et al. **Ter Arkh** 1995;67(11):33–5 (7 ref.) **(Rus)**

ASPHYXIA

EPIDEMIOLOGY

Review: autoerotic asphyxiation in the United States [retracted in J Forensic Sci 1995 Nov;40(6):932] Uva JL. **J Forensic Sci** 1995 Jul;40(4):574–81 (76 ref.)

PHYSIOPATHOLOGY

Suffocation and related problems. Suzuki T. **Forensic Sci Int** 1996 Jun 28;80(1–2):71–8 (12 ref.)

ASPHYXIA NEONATORUM

COMPLICATIONS

[Cerebral palsy and perinatal asphyxia in full term newborn infants] Bréart G, et al. **Arch Pediatr** 1996 Jan;3(1):70–4 (15 ref.) (Eng. Abstr.) **(Fre)**
[Perinatal risk factors and motor deficiency due to cerebral palsy] Rumeau-Rouquette C, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(2):119–23 (24 ref.) (Eng. Abstr.) **(Fre)**
–Brain damage in infancy: mostly not intrapartum. On the etiology of mental and neurologic handicaps– Largo RH, et al. **Arch Gynecol Obstet** 1995;256 Suppl:S71–80 (18 ref.) **(Ger)**
–Neonatal asphyxia as the cause of brain damage in children?– Schneider H. **Arch Gynecol Obstet** 1995;256 Suppl:S32–42 (75 ref.) (Eng. Abstr.) **(Ger)**
[Prognostic indicators of neurological sequelae in perinatal asphyxia: state of the art] González de Dios J. **Rev Neurol** 1995 Mar–Apr;23(120):351–62 (194 ref.) **(Spa)**

DIAGNOSIS

[Nuclear magnetic resonance spectroscopy: methodology and applications to the study of asphyxia neonatorum] Barantin L, et al. **Neurophysiol Clin** 1995;25(3):115–29 (56 ref.) (Eng. Abstr.) **(Fre)**
[Intensive monitoring of the fetus sub partu—value and false interpretation] Saling E. **Geburtshilfe Frauenheilkd** 1995 Nov;55(11):628–33 (18 ref.) (Eng. Abstr.) **(Ger)**
[Significance of intrapartum hypoxia for cerebral long-term morbidity] Schneider H. **Z Geburtshilfe Neonatol** 1996 Mar–Apr;200(2):43–9 (47 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

–Perinatal asphyxia of the neonate at term– Fawer CL. **Arch Gynecol Obstet** 1995;256 Suppl:S61–70 (13 ref.) **(Fre)**

METABOLISM

[Exploration of brain metabolism and hemodynamics in perinatal asphyxia in full-term neonates] Saliba E, et al. **Arch Pediatr** 1996;3 Suppl 1:248s–250s (9 ref.) **(Fre)**

PATHOLOGY

Neuronal death after perinatal asphyxia. de Haan HH, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Aug;61(2):123–7 (46 ref.)

PHYSIOPATHOLOGY

[Exploration of brain metabolism and hemodynamics in perinatal asphyxia in full-term neonates] Saliba E, et al. **Arch Pediatr** 1996;3 Suppl 1:248s–250s (9 ref.) **(Fre)**

PREVENTION & CONTROL

[Progresses in pediatrics in China, 1995] Hu Y. **Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):751–2 (0 ref.) **(Chi)**

ASPIDIUM see **PLANTS, MEDICINAL**

ASPIRATION BIOPSY see **BIOPSY, NEEDLE**

ASPIRATION LIPECTOMY see **LIPECTOMY**

ASPIRATION, MECHANICAL see **SUCTION**

ASPIRATION, MECONIUM see **MECONIUM ASPIRATION**

ASPIRATION OF GASTRIC CONTENTS see **PNEUMONIA, ASPIRATION**

ASPIRATION PNEUMONIA see **PNEUMONIA, ASPIRATION**

ASPIRIN

ADMINISTRATION & DOSAGE

Patterns of aspirin use in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study. Shahar E, et al. **Am Heart J** 1996 May;131(5):915–22 (37 ref.)
Prehospital administration of aspirin in patients with unstable angina and acute myocardial infarction. Eisenberg MJ, et al. **Arch Intern Med** 1996 Jul 22;156(14):1506–10 (34 ref.)
Aspirin and other platelet-active drugs. The relationship among dose, effectiveness, and side effects. Hirsh J, et al. **Chest** 1995 Oct;108(4 Suppl):247S–257S (148 ref.)
–Is prevention of pre-eclampsia with low dosage aspirin possible? Critical assessment of available studies– Lippert TH, et al. **Geburtshilfe Frauenheilkd** 1996 Feb;56(2):88–92 (23 ref.) (Eng. Abstr.) **(Ger)**
[High dosage acetylsalicylic acid administration for prevention of acute cerebral ischemia] Hartmann A. **Nervenarzt** 1995 Dec;66(12):886–9; discussion 885 (18 ref.) (Eng. Abstr.) **(Ger)**
[Aspirin dosage for prevention of cerebral infarct: arguments for low dosage] Hennerici MG, et al. **Nervenarzt** 1995 Dec; 66(12):890–4; discussion 885 (38 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Phenomenology, pathogenesis, diagnosis and treatment of aspirin-sensitive rhinosinusitis. Schapowal AG, et al. **Acta Otorhinolaryngol Belg** 1995;49(3):235–50 (0 ref.)
Does aspirin cause acute or chronic renal failure in experimental animals and in humans? D'Agati V. **Am J Kidney Dis** 1996 Jul;28(1 Suppl 1):S24–9 (34 ref.)
Nonrenal toxicities of acetaminophen, aspirin, and nonsteroidal anti-inflammatory agents. Matzke GR. **Am J Kidney Dis** 1996 Jul;28(1 Suppl 1):S63–70 (38 ref.)
Is aspirin safe for patients with heart failure? Cleland JG, et al. **Br Heart J** 1995 Sep;74(3):215–9 (53 ref.)
Gastrointestinal bleeding during low-dose aspirin administration for prevention of arterial occlusive events. A critical analysis. Stalnikowicz-Darvasi R. **J Clin Gastroenterol** 1995 Jul;21(1):13–6 (20 ref.)
Aspirin, a silent risk factor in urology. Zhu JP, et al. **Scand J Urol Nephrol** 1995 Dec;29(4):369–74 (64 ref.)
Aspirin dose in stroke prevention: beautiful hypotheses slain by ugly facts [editorial; comment] Barnett HJ, et al. **Stroke** 1996 Apr;27(4):588–92 (60 ref.) Comment on: Stroke 1996 Apr;27(4):756–60.
[Nonsteroidal antirheumatic drugs and acetylsalicylic acid: adverse effects distal to the duodenum] Gut A, et al. **Schweiz Med Wochenschr** 1996 Apr 13;126(15):616–25 (95 ref.) (Eng. Abstr.) **(Ger)**
[Aspirin-induced asthma] Sakakibara H. **Nippon Naika Gakkai Zasshi** 1996 Feb 10;85(2):227–33 (5 ref.) **(Jpn)**
[Sensitivity to acetylsalicylic acid] Elverland HH. **Tidsskr Nor Laegeforen** 1996 Feb 28;116(6):754–6 (22 ref.) (Eng. Abstr.) **(Nor)**

HISTORY

[Aspirin, an always current drug] Van Cauwenberge H. **Rev Med Liege** 1996 Jan;51(1):7–18 (29 ref.) **(Fre)**

PHARMACOLOGY

Antiplatelet drugs. A comparative review. Schrör K. **Drugs** 1995 Jul;50(1):7–28 (189 ref.)
Aspirin—now we can see it. Allen KN. **Nat Med** 1995 Sep; 1(9):882–3 (13 ref.)

THERAPEUTIC USE

Therapeutic uses of aspirin in renal diseases. Winchester JF. **Am J Kidney Dis** 1996 Jul;28(1 Suppl 1):S20–3 (44 ref.)
Antiplatelet therapy and the prevention of thrombosis. Rodgers A, et al. **Aust N Z J Med** 1996 Apr;26(2):210–5 (19 ref.)
The pharmacological prevention of pre-eclampsia. Dekker GA. **Baillieres Clin Obstet Gynaecol** 1995 Sep;9(3):509–28 (109 ref.)
ABC of atrial fibrillation. Antithrombotic treatment for atrial fibrillation. Lip GY, et al. **BMJ** 1996 Jan 6;312(7022):45–9 (0 ref.)
Warfarin and aspirin as thromboprophylaxis in atrial fibrillation. Lip GY, et al. **Br J Clin Pharmacol** 1996 May; 41(5):369–79 (83 ref.)
Antithrombotic therapy in atrial fibrillation. Turpie AG, et

al. **Can Fam Physician** 1996 Jul;42:1341–5 (16 ref.)
Platelets and platelet inhibitors in acute myocardial infarction. Kamat SG, et al. **Cardiol Clin** 1995 Aug; 13(3):435–47 (139 ref.)
Aspirin augmentation of the efficacy of thrombolysis. O'Donnell CJ, et al. **Coron Artery Dis** 1995 Dec;6(12):936–9 (23 ref.)
Long–term aspirin in the prevention of cardiovascular disorders. Recent developments and variations on a theme. Catella–Lawson F, et al. **Drug Saf** 1995 Aug;13(2):69–75 (53 ref.)
Aspirin for primary prevention of coronary disease. Fuster V, et al. **Eur Heart J** 1995 Jul;16 Suppl E:16–20 (23 ref.)
Anticoagulation: risks and benefits in atrial fibrillation. Fiore LD. **Geriatrics** 1996 Jun;51(6):22–4, 27–8, 31 (37 ref.)
Aspirin dose in stroke prevention: beautiful hypotheses slain by ugly facts [editorial; comment] Barnett HJ, et al. **Stroke** 1996 Apr;27(4):588–92 (60 ref.) Comment on: Stroke 1996 Apr;27(4):756–60.
Aspirin wars: the optimal dose of aspirin prevent stroke [editorial; comment] Hart RG, et al. **Stroke** 1996 Apr; 27(4):585–7 (45 ref.) Comment on: Stroke 1996 Apr;27(4):756–60.
Aspirin in ischemic cerebrovascular disease. How strong is the case for a different dosing regimen? [see comments] Patrono C, et al. **Stroke** 1996 Apr;27(4):756–60 (36 ref.) Comment in: Stroke 1996 Apr;27(4):585–7. Comment in: Stroke 1996 Apr;27(4):588–92.
Oral anticoagulant treatment with and without aspirin. Altman R, et al. **Thromb Haemost** 1995 Jul;74(1):506–10 (37 ref.)
Antiplatelet therapy with aspirin: from clinical trials to practice. Goodnight SH. **Thromb Haemost** 1995 Jul; 74(1):401–5 (64 ref.)
Thrombin generation in myocardial infarction and hypercholesterolemia: effects of aspirin. Szczeklik A. **Thromb Haemost** 1995 Jul;74(1):77–80 (34 ref.)
The role of coumadin and aspirin in atrial fibrillation. Hutter AM Jr. **Trans Am Clin Climatol Assoc** 1995;107:79–85; discussion 85–6 (17 ref.)
[Anticoagulation in cardiology] Meier B. **Ann Cardiol Angeiol (Paris)** 1995 Dec;44(10):567–77 (53 ref.) (Eng. Abstr.) **(Fre)**
[Antithrombotic treatment of atrial fibrillation] Connelly SJ, et al. **Can J Cardiol** 1996 Feb;12 Suppl A:14A–18A (13 ref.) **(Fre)**
[Can nitrogen monoxide replace aspirin in the prevention of preeclampsia?] Ohl J, et al. **Contracept Fertil Sex** 1996 Apr;24(4):259–61 (16 ref.) **(Fre)**
[Uterine velocimetry and vascular pregnancy pathologies prevented with low–dose aspirin] Haddad B, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(4):396–404 (51 ref.) (Eng. Abstr.) **(Fre)**
[Aspirin during pregnancy. Indications and modalities of prescription after the publication of the later trials] Uzan S, et al. **Presse Med** 1996 Jan 6–13;25(1):31–6 (30 ref.) (Eng. Abstr.) **(Fre)**
[Effectiveness of fixed analgesic combinations exemplified by thomapyrin] Aicher B, et al. **Wien Klin Wochenschr** 1996;108(8):219–33 (104 ref.) (Eng. Abstr.) **(Ger)**
[The new frontier of antithrombotic therapy: ASA + warfarin, the ideal solution?] Cimminiello C, et al. **G Ital Cardiol** 1995 Sep;25(9):1187–93 (36 ref.) (Eng. Abstr.) **(Ita)**
[Contemporary opinions on the use of aspirin, heparin and thrombolytic therapy in unstable angina pectoris—pathogenetic findings versus results of many clinical tests] Popiel M, et al. **Przegl Lek** 1996;53(1):33–40 (40 ref.) (Eng. Abstr.) **(Pol)**
[Atrial fibrillation due to non–valvular causes: indications for antithrombotic therapy] Codinach Huix P. **Med Clin (Barc)** 1996 Apr 20;106(15):586–9 (25 ref.) **(Spa)**
[Acetyl–salicylic acid and trifusal in the prevention of atherothrombotic stroke] Alvarez Sabín J. **Rev Neurol** 1995 Sep–Oct;23(123):1091–5 (36 ref.) **(Spa)**

TOXICITY

Acetaminophen/aspirin mixtures: experimental data. Porter GA. **Am J Kidney Dis** 1996 Jul;28(1 Suppl 1):S30–3 (11 ref.)

ASPIRIN–LIKE AGENTS see **ANTI–INFLAMMATORY AGENTS, NON–STEROIDAL**

ASSAULTIVE BEHAVIOR see **VIOLENCE**

ASSERTIVENESS

[Cognitive distortion in the affirmation of self. Various observations] Masson A, et al. **Rev Med Liege** 1995 Sep; 50(9):390–5 (21 ref.) **(Fre)**

ASSESSMENT, EDUCATIONAL see **EDUCATIONAL MEASUREMENT**

ASSESSMENT OF HEALTH CARE NEEDS see **HEALTH SERVICES NEEDS AND DEMAND**

ASSESSMENT, RISK see **RISK ASSESSMENT**

ASSISTED CIRCULATION

see related
HEART–ASSIST DEVICES

METHODS

[Circulatory support. I. Indications and description of systems] Defraigne JO, et al. **Rev Med Liege** 1996 Apr; 51(4):295–306 (0 ref.) **(Fre)**

ASSISTED SUICIDE see **SUICIDE, ASSISTED**

ASSOCIATION

Naming faces and naming names: exploring an interactive activation model of person recognition. Burton AM, et al. **Memory** 1993 Dec;1(4):457–80 (26 ref.)

ASSOCIATION LEARNING

Higher–order behavior classes: contingencies, beliefs, and verbal behavior [comment] Catania AC. **J Behav Ther Exp Psychiatry** 1995 Sep;26(3):191–200 (60 ref.) Comment on: J Behav Ther Exp Psychiatry 1995 Sep;26(3):179–90.

PHYSIOLOGY

Configural association theory and the hippocampal formation: an appraisal and reconfiguration. Rudy JW, et al. **Hippocampus** 1995;5(5):375–89 (80 ref.)

ASTASIA–ABASIA see **CONVERSION DISORDER**

ASTEMIZOLE

ADVERSE EFFECTS

Cardiac actions of antihistamines. Woosley RL. **Annu Rev Pharmacol Toxicol** 1996;36:233–52 (73 ref.)

ASTHMA

see related
ANTI–ASTHMATIC AGENTS

Risk factors for asthmatic patients requiring intubation: A comprehensive review. LeSon S, et al. **Allergol Immunopathol (Madr)** 1995 Sep–Oct;23(5):235–47 (133 ref.)
Asthma in infants and small children. Brugman SM, et al. **Clin Chest Med** 1995 Dec;16(4):637–56 (242 ref.)
Problems in the phenotypic assessment of asthma. Weiss ST. **Clin Exp Allergy** 1995 Nov;25 Suppl 2:12–4; discussion 17–8 (4 ref.)
The young athlete with chronic disease. Small E, et al. **Clin Sports Med** 1995 Jul;14(3):709–26 (144 ref.)
Current concepts of fatal asthma. Igwebe T, et al. **Compr Ther** 1995 Aug;21(8):407–12 (44 ref.)
Asthma in the pregnant adolescent: a review. Shulman V, et al. **J Adolesc Health** 1996 Mar;18(3):168–76 (89 ref.)
Internet for the allergist. Bell T. **J Asthma** 1996;33(3):143–8 (6 ref.)
What is asthma? An update on the mechanisms. O'Byrne PM. **J Investig Allergol Clin Immunol** 1995 Jan–Feb; 5(1):6–11 (39 ref.)
Chronic asthma: an update. Kemper KJ. **Pediatr Rev** 1996 Apr;17(4):111–8 (18 ref.)
Childhood asthma: what is it and where is it going? [editorial] Christie G, et al. **Thorax** 1995 Oct;50(10):1027–30 (81 ref.)
Prognostic factors for the outcome of childhood asthma in adolescence. Roorda RJ. **Thorax** 1996 Jan;51 Suppl 1:S7–12 (98 ref.)
Overview of diisocyanate occupational asthma. Bernstein JA. **Toxicology** 1996 Jul 17;111(1–3):181–9 (24 ref.)
[Concept and definition of asthma] Adachi M, et al. **Nippon Naika Gakkai Zasshi** 1996 Feb 10;85(2):163–7 (9 ref.) **(Jpn)**
[Recent trends in the treatment and physiopathology of bronchial asthma] Inoue H. **Nippon Naika Gakkai Zasshi** 1996 Mar 10;85(3):449–53 (6 ref.) **(Jpn)**
[Inflammatory mediators in asthma] Ota K. **Nippon Naika Gakkai Zasshi** 1996 Feb 10;85(2):178–83 (5 ref.) **(Jpn)**
[Child asthma in 1996] Ojeda Casas JA. **Allergol Immunopathol (Madr)** 1996;24 Suppl 1:104–17 (30 ref.) **(Spa)**

CHEMICALLY INDUCED

Impact of environmental pollution on respiratory sensitization and asthma. Kimber I. **Arch Toxicol Suppl** 1996;18:34–48 (85 ref.)
Reactive airways dysfunction syndrome. Alberts WM, et al. **Chest** 1996 Jun;109(6):1618–26 (72 ref.)
Asthma and the beta 2–agonist controversy: much ado about something. Lieberman JS, et al. **Del Med J** 1995 Dec; 67(12):624–8 (28 ref.)
Occupational asthma caused by natural rubber latex. Vandenplas O. **Eur Respir J** 1995 Nov;8(11):1957–65 (80 ref.)
Occupational asthma due to isocyanates. Baur X. **Lung** 1996; 174(1):23–30 (50 ref.)
[Occupational asthma: definition—epidemiology—etiologic substances—prognosis—prevention—diagnosis—expert assessment aspects] Merget R, et al. **Pneumologie** 1996 May; 50(5):356–63 (83 ref.) **(Ger)**
[Drug–induced asthma] Gani F, et al. **Recenti Prog Med** 1996 Jan;87(1):31–40 (30 ref.) **(Ita)**
[Persistent reactive airway dysfunction syndrome after exposure to chromate] Nagasaka Y, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Jul;33(7):759–64 (16 ref.) (Eng. Abstr.) **(Jpn)**
[Aspirin–induced asthma] Sakakibara H. **Nippon Naika Gakkai Zasshi** 1996 Feb 10;85(2):227–33 (5 ref.) **(Jpn)**

COMPLICATIONS

Sinusitis and asthma: associations, influences and principles of management. Halpern GM. **Allergol Immunopathol (Madr)** 1995 Jul–Aug;23(4):171–81 (60 ref.)
Management of sinusitis in the asthmatic patient. Senior BA, et al. **Ann Allergy Asthma Immunol** 1996 Jul;77(1):6–15; quiz 15–9 (47 ref.)
Mechanisms of increased airway microvascular permeability: role in airway inflammation and obstruction. Goldie RG, et al. **Clin Exp Pharmacol Physiol** 1995 Jun–Jul; 22(6–7):387–96 (88 ref.)
Cough and asthma in children. Newson T, et al. **Pediatr Ann** 1996 Mar;25(3):156–8, 161 (29 ref.)
Use of fiberoptic bronchoscopy in asthmatic children with lung collapse. Barbato A, et al. **Pediatr Med Chir** 1995 May–Jun;17(3):253–5 (9 ref.)
Hopkins syndrome: T2–weighted high intensity of anterior horn on spinal MR imaging. Arita J, et al. **Pediatr Neurol** 1995 Oct;13(3):263–5 (15 ref.)
[A case of bronchial asthma complicated by mycosis] Andronova NV, et al. **Ter Arkh** 1995;67(11):33–5 (7 ref.) **(Rus)**

DIAGNOSIS

Clinical evaluation of asthma. Li JT, et al. **Ann Allergy Asthma Immunol** 1996 Jan;76(1):1–13; quiz 13–5 (86 ref.)
Emergency management of acute adult asthma. Grunfeld AF, et al. **Can Fam Physician** 1995 Nov;41:1909–16 (42 ref.)
Assessment of asthma in the workplace. ACCP consensus statement. American College of Chest Physicians. Chan–Yeung M. **Chest** 1995 Oct;108(4):1084–117 (159 ref.)
Physiologic diagnosis and function in asthma. Cherniack RM. **Clin Chest Med** 1995 Dec;16(4):567–81 (17 ref.)
Occupational asthma. Diagnosis, management, and prevention. Newman LS. **Clin Chest Med** 1995 Dec; 16(4):621–36 (187 ref.)
Late–onset asthma: making the diagnosis, choosing drug therapy. Sherman CB. **Geriatrics** 1995 Dec;50(12):24–6, 29–30, 33 (22 ref.)
Cough and asthma in children. Newson T, et al. **Pediatr Ann** 1996 Mar;25(3):156–8, 161 (29 ref.)
Occupational lung disease. 8. The diagnosis of occupational asthma from serial measurements of lung function at and away from work. Bright P, et al. **Thorax** 1996 Aug; 51(8):857–63 (49 ref.)
[Diagnosis of bronchial asthma and chronic obstructive lung disease by the family physician. Ad hoc consensus group 'Diagnosis of asthma/chronic obstructive lung disease by the family physician' (see comments)] van Schayck CP. **Ned Tijdschr Geneeskd** 1995 Sep 30;139(39):1966–71 (22 ref.) Comment in: Ned Tijdschr Geneeskd 1995 Dec 2;139(48):2512–3. **(Dut)**
[Asthma in children] Dutau G. **Rev Pneumol Clin** 1996; 52(2):111–6 (5 ref.) (Eng. Abstr.) **(Fre)**
[Atopy, asthma and the judgement of preemployment fitness] Innocenti A. **Med Lav** 1995 Jul–Aug;86(4):303–8 (36 ref.) (Eng. Abstr.) **(Ita)**
[Diagnosis of bronchial asthma] Nakagawa T. **Nippon Naika Gakkai Zasshi** 1996 Feb 10;85(2):194–8 (5 ref.) **(Jpn)**
[Asthma and chronic obstructive pulmonary disease. Similarities and differences] Pierzchala W. **Pneumonol Alergol Pol** 1995;63(5–6):332–5 (24 ref.) **(Pol)**

DIET THERAPY

Dietary fish oil and airways obstruction. Britton J. **Thorax** 1995 Sep;50 Suppl 1:S11–5 (28 ref.)
[Is a fish oil enriched diet therapeutically beneficial?] Machura E, et al. **Pediatr Pol** 1995 Jul;70(7):597–602 (23 ref.) (Eng. Abstr.) **(Pol)**

DRUG THERAPY

Modern treatment of asthma in children. Zeffren BS, et al. **Adv Pediatr** 1996;43:423–68 (214 ref.)
Anticholinergic antimuscarinic agents in the treatment of airways bronchoconstriction in children. Martinati LC, et al. **Allergy** 1996 Jan;51(1):2–7 (33 ref.)
B2 agonists and their safety in the treatment of asthma. Fireman P. **Allergy Proc** 1995 Sep–Oct;16(5):235–9 (22 ref.)
Glucocorticoid resistance in asthma. Barnes PJ, et al. **Am J Respir Crit Care Med** 1995 Dec;152(6 Pt 2):S125–40 (231 ref.)
Can steroids cause asthma to remit? Pedersen S. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 2):S31–2

(16 ref.)
How do steroids work? Schleimer RP. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 2):S28–30 (34 ref.)
The role of theophylline in the treatment of asthma [editorial] Kamada AK, et al. **Ann Allergy Asthma Immunol** 1996 Jul; 77(1):1–3 (47 ref.)
Leukotriene inhibitors and antagonists in asthma. Spector SL. **Ann Allergy Asthma Immunol** 1995 Dec;75(6 Pt 1):463–70, 473; quiz 473–4 (78 ref.)
Salmeterol for the treatment of asthma [editorial; comment] Weinberger M. **Ann Allergy Asthma Immunol** 1995 Sep; 75(3):209–11 (26 ref.) Comment on: Ann Allergy Asthma Immunol 1995 Sep;75(3):243–8.
Molecular mechanisms of antiasthma therapy. Barnes PJ. **Ann Med** 1995 Oct;27(5):531–5 (35 ref.)
Long-and short-acting beta 2-adrenergic agonists. Effects on airway function in patients with asthma. Busse WW. **Arch Intern Med** 1996 Jul 22;156(14):1514–20 (63 ref.)
Beta-2 agonists in asthma—the Thoracic Society of Australia and New Zealand. Wilson J, et al. **Aust N Z J Med** 1995 Aug;25(4):358–61 (39 ref.)
Drugs affecting the leukotriene pathway in asthma. Barnes NC, et al. **Br J Clin Pract** 1995 Sep–Oct;49(5):262–6 (55 ref.)
Optimizing inhaled drug delivery in patients with asthma. Jackson C, et al. **Br J Gen Pract** 1995 Dec;45(401):683–7 (35 ref.)
Glucocorticosteroid treatment of asthma. Bai TR. **Can Fam Physician** 1995 Nov;41:1921–7 (25 ref.)
Goals of asthma management. A step–care approach. Bone RC. **Chest** 1996 Apr;109(4):1056–65 (60 ref.)
Controversies involving inhaled beta–agonists and inhaled corticosteroids in the treatment of asthma. Fahy JV, et al. **Clin Chest Med** 1995 Dec;16(4):715–33 (145 ref.)
Childhood asthma. Older children and adolescents. Gern JE, et al. **Clin Chest Med** 1995 Dec;16(4):657–70 (99 ref.)
Chronobiology and chronotherapy of asthma. Pincus DJ, et al. **Clin Chest Med** 1995 Dec;16(4):699–713 (62 ref.)
Nonstandard and potential future therapies for asthma. Rennard SI, et al. **Clin Chest Med** 1995 Dec;16(4):735–44 (79 ref.)
Asthma mechanisms, determinants of severity and treatment: the role of nedocromil sodium. Report of a workshop held in Whistler, British Columbia, Canada, 18–19 May 1995. Barnes PJ, et al. **Clin Exp Allergy** 1995 Aug;25(8):771–87 (146 ref.)
Anti–inflammatory effects of long–acting beta–agonists in asthma [editorial] Bradding P. **Clin Exp Allergy** 1995 Oct; 25(10):912–4 (36 ref.)
Bronchodilator therapy in the management of acute asthma. Moan MJ, et al. **Compr Ther** 1995 Aug;21(8):421–7 (39 ref.)
Theophylline and selective phosphodiesterase inhibitors as anti–inflammatory drugs in the treatment of bronchial asthma. Banner KH, et al. **Eur Respir J** 1995 Jun; 8(6):996–1000 (50 ref.)
Leukotriene receptor antagonists and biosynthesis inhibitors: potential breakthrough in asthma therapy. Chung KF. **Eur Respir J** 1995 Jul;8(7):1203–13 (117 ref.)
PDE isoenzymes as targets for anti–asthma drugs. Schudt C, et al. **Eur Respir J** 1995 Jul;8(7):1179–83 (18 ref.)
Late–onset asthma: making the diagnosis, choosing drug therapy. Sherman CB. **Geriatrics** 1995 Dec;50(12):24–6, 29–30, 33 (22 ref.)
Helping patients live with asthma. Rachelefsky GS. **Hosp Pract (Off Ed)** 1995 Nov 15;30(11):51–6, 59–64 (14 ref.)
Molecular mechanisms of steroid action in asthma. Barnes PJ. **J Allergy Clin Immunol** 1996 Jan;97(1 Pt 2):159–68 (74 ref.)
Leukotriene antagonists and synthesis inhibitors: new directions in asthma therapy. Holgate ST, et al. **J Allergy Clin Immunol** 1996 Jul;98(1):1–13 (89 ref.)
Pharmacodynamics and pharmacokinetics of inhaled glucocorticoids. Johnson M. **J Allergy Clin Immunol** 1996 Jan;97(1 Pt 2):169–76 (26 ref.)
Remodeling of asthmatic airways by glucocorticosteroids. Laitinen LA, et al. **J Allergy Clin Immunol** 1996 Jan;97(1 Pt 2):153–8 (22 ref.)
Clinical use of inhaled corticosteroids in asthma. Wasserfallen JB, et al. **J Allergy Clin Immunol** 1996 Jan;97(1 Pt 2):177–82 (41 ref.)
Medication compliance and asthma: overlooking the trees because of the forest [see comments] Creer TL, et al. **J Asthma** 1996;33(4):203–11 (45 ref.) Comment in: J Asthma 1996;33(4):199–202.
Two new roles for theophylline in the asthmatic? [see comments] Jenne JW. **J Asthma** 1995;32(2):89–95 (56 ref.) Comment in: J Asthma 1995;32(2):85–7.
Inhaled corticosteroids: benefits and risks [see comments] Robinson DS, et al. **J Asthma** 1996;33(1):5–16 (103 ref.) Comment in: J Asthma 1996;33(1):1–3.
Long–acting inhaled beta agonists [see comments] Tilles SA, et al. **J Asthma** 1995;32(6):397–404 (51 ref.) Comment in: J Asthma 1995;32(6):395–6.
Zileuton. McGill KA, et al. **Lancet** 1996 Aug 24; 348(9026):519–24 (38 ref.)
Outpatient asthma management. Cockcroft DW, et al. **Med Clin North Am** 1996 Jul;80(4):701–18 (60 ref.)
Methotrexate in the treatment of systemic glucocorticoid–dependent severe persistent asthma: a word of caution. Fabbri L, et al. **Monaldi Arch Chest Dis** 1996 Apr;51(2):130–7 (118 ref.)
Anti–inflammatory treatment of asthma in children. What strategy is appropriate? Frazier CA. **N C Med J** 1995 Dec; 56(12):616–8 (15 ref.)
Theophylline in asthma. Weinberger M, et al. **N Engl J Med** 1996 May 23;334(21):1380–8 (100 ref.)
Use of magnesium sulfate in asthma in childhood. Monem GF, et al. **Pediatr Ann** 1996 Mar;25(3):136, 139–44 (52 ref.)
Behavioral side effects of medications used to treat asthma and allergic rhinitis. Milgrom H, et al. **Pediatr Rev** 1995 Sep;16(9):333–5; quiz 336 (21 ref.)
The use of beta 2–adrenoceptor agonists in the treatment of bronchial asthma. Svedmyr N, et al. **Pharmacol Toxicol** 1996 Jan;78(1):3–11 (94 ref.)
Asthma. Specific preventive strategies. Morris RJ. **Postgrad Med** 1996 Aug;100(2):105–6, 109–12, 118 passim (21 ref.)
Aerosol delivery systems for bronchial asthma. Ariyananda PL, et al. **Postgrad Med J** 1996 Mar;72(845):151–6 (60 ref.)
Inhaled glucocorticoids: new developments relevant to updating of the asthma management guidelines. Barnes PJ. **Respir Med** 1996 Aug;90(7):379–84 (44 ref.)
Fluticasone propionate—an update on preclinical and clinical experience. Fuller R, et al. **Respir Med** 1995 Sep;89 Suppl A:3–18 (59 ref.)
Phosphodiesterase inhibitors: Lily the Pink's medicinal compound for asthma? Dent G, et al. **Thorax** 1996 Jun; 51(6):647–9 (12 ref.)
[Inhalation therapy in young children with asthma] Roorda RJ. **Ned Tijdschr Geneeskd** 1995 Dec 9;139(49):2548–51 (43 ref.) **(Dut)**
[Treatment of asthma; are there still questions? (see comments)] van Schayck CP. **Ned Tijdschr Geneeskd** 1996 Jan 13;140(2):72–7 (47 ref.) Comment in: Ned Tijdschr Geneeskd 1996 Mar 2;140(9):508–9. **(Dut)**
[Beta–2 adrenergic receptor agonists in asthma treatment] Haahtela T, et al. **Duodecim** 1995;111(8):744–8 (28 ref.) **(Fin)**
[Hypersensitivity syndrome caused by dapsone. Transient circulating clone T] Bocquet H, et al. **Ann Dermatol Venereol** 1995;122(8):514–6 (14 ref.) (Eng. Abstr.) **(Fre)**
[Nebulization for basic treatment of asthma in adults] Demoly P, et al. **Presse Med** 1996 May 25;25(18):857–62 (39 ref.) (Eng. Abstr.) **(Fre)**
[Inhalation treatment: glucocorticoids] Aubert JD. **Rev Med Suisse Romande** 1996 May;116(5):329–33 (20 ref.) **(Fre)**
[Inhaled corticotherapy in asthma: when should it be started and how to stop?] Aubier M. **Rev Pneumol Clin** 1996; 52(2):145–9 (19 ref.) (Eng. Abstr.) **(Fre)**
[Primum non nocere: inhaled corticoids] Lacronique J. **Rev Pneumol Clin** 1996;52(2):137–43 (81 ref.) (Eng. Abstr.) **(Fre)**
[Corticoid resistance in asthma] Perrin–Fayolle M, et al. **Rev Pneumol Clin** 1996;52(2):150–8 (43 ref.) (Eng. Abstr.) **(Fre)**
[Modes of administration of beta agonists in asthma] Salmeron S, et al. **Rev Pneumol Clin** 1996;52(2):119–27 (76 ref.) (Eng. Abstr.) **(Fre)**
[Leukotriene blockade in asthma—a new anti–inflammatory therapeutic principle] Griese M, et al. **Dtsch Med Wochenschr** 1996 Jun 21;121(25–26):845–51 (61 ref.) **(Ger)**
[Gastroesophageal reflux and bronchial asthma (letter)] Müller–Lissner S. **Dtsch Med Wochenschr** 1996 Aug 2; 121(31–32):1000–1 (11 ref.) **(Ger)**
[Beta 2–sympathomimetic drugs] Criée CP, et al. **Internist (Berl)** 1995 Sep;36(9):918–23 (28 ref.) **(Ger)**
[Asthma therapy with topically active steroids] Matthys H. **Internist (Berl)** 1995 Oct;36(10):1005–9 (21 ref.) **(Ger)**
[Limitations of current treatment of asthma: possibilities for new treatment forms] Wilkens H, et al. **Med Klin** 1996 May 15;91(5):302–7 (55 ref.) **(Ger)**
[Safety and side effects of inhalant steroid therapy in children with bronchial asthma] Schöni MH. **Schweiz Rundsch Med Prax** 1995 Oct 3;84(40):1108–13 (37 ref.) (Eng. Abstr.) **(Ger)**
[Chronopharmacology of reversible airway obstruction] Haen E. **Wien Med Wochenschr** 1995;145(17–18):439–45 (38 ref.) (Eng. Abstr.) **(Ger)**
[On the studies and treatments of asthma, and their future] Ito K. **Arerugi** 1996 Jun;45(6):533–41 (10 ref.) **(Jpn)**
[Anti–allergic agent therapy of asthma] Fujimura M. **Nippon Naika Gakkai Zasshi** 1996 Feb 10;85(2):216–21 (5 ref.) **(Jpn)**
[Steroid inhalation therapy of asthma] Hozawa S. **Nippon Naika Gakkai Zasshi** 1996 Feb 10;85(2):205–9 (5 ref.) **(Jpn)**
[Emergency drug therapy of bronchial asthma] Inoue H. **Nippon Naika Gakkai Zasshi** 1995 Nov 10;84(11):1791–7 (8 ref.) **(Jpn)**
[Therapy of asthma using bronchodilator agents—special reference to adrenergic beta 2–receptor agonists] Kurosawa M, et al. **Nippon Naika Gakkai Zasshi** 1996 Feb 10; 85(2):210–5 (5 ref.) **(Jpn)**
[Steroid inhalation therapy of bronchial asthma] Makino S. **Nippon Naika Gakkai Zasshi** 1995 Dec 10;84(12):2085–90 (9 ref.) **(Jpn)**
[Recent view on drug therapy of bronchial asthma] Mano K. **Nippon Naika Gakkai Zasshi** 1996 Mar 10;85(3):417–22 (9 ref.) **(Jpn)**
[The role of long–acting beta–mimetics in patients with chronic bronchial spasm and bronchial asthma] Chazan R, et al. **Pol Arch Med Wewn** 1995 Jul;94(1):59–63 (47 ref.) **(Pol)**
[Broncholytic agents in the treatment of bronchial asthma] Tkachenko Iulia, et al. **Vrach Delo** 1995 Jan–Feb;(1–2):13–6 (38 ref.) **(Rus)**
[The use of steroids in asthmatic children] Meza Morales A, et al. **Rev Alerg Mex** 1995 Jul–Aug;42(4):74–7 (19 ref.) (Eng. Abstr.) **(Spa)**

EPIDEMIOLOGY

Epidemiologic methods for the study of occupational asthma. Current problems and solutions. Cullen MR. **Chest** 1996 Mar;109(3 Suppl):51S–54S (28 ref.)
Asthma epidemiology in the Far East. Lai CK, et al. **Clin Exp Allergy** 1996 Jan;26(1):5–12 (47 ref.)
Asthma genetics studies in Western Australia. Le Souëf PN. **Clin Exp Allergy** 1995 Nov;25 Suppl 2:26–8 (10 ref.)
Time trends in asthma and allergy: ten questions, fewer answers [editorial; comment] Strachan DP. **Clin Exp Allergy** 1995 Sep;25(9):791–4 (30 ref.) Comment on: Clin Exp Allergy 1995 Sep;25(9):815–9.
Towards a better understanding of childhood asthma. Van Asperen PP. **J Paediatr Child Health** 1995 Aug;31(4):272–5 (36 ref.)
[Morbidity and mortality induced by asthma in 1996] Taytard A. **Rev Pneumol Clin** 1996;52(2):65–9 (31 ref.) (Eng. Abstr.) **(Fre)**
[Epidemiology of asthma (occurrence and death)] Sano Y. **Nippon Naika Gakkai Zasshi** 1996 Feb 10;85(2):168–73 (5 ref.) **(Jpn)**

ETIOLOGY

The role of the bone marrow in allergy and asthma. Denburg JA, et al. **Allergy** 1996 Mar;51(3):141–8 (109 ref.)
Why does asthma become persistent? Barnes PJ, et al. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 2):S23–5 (49 ref.)
Is occupational asthma a relevant model? Fabbri LM. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 2):S26 (21 ref.)
How does inflammation cause symptoms? Woolcock AJ. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 2):S21–2 (28 ref.)
ABC of work related disorders. Occupational asthma and other respiratory diseases. Madan I. **BMJ** 1996 Aug 3; 313(7052):291–4 (0 ref.)
Tachykinins, sensory nerves, and asthma—an overview. Lundberg JM. **Can J Physiol Pharmacol** 1995 Jul; 73(7):908–14 (99 ref.)
Role of mast cells and basophils in asthma. Redington AE, et al. **Chem Immunol** 1995;62:22–59 (293 ref.)
Childhood asthma. Older children and adolescents. Gern JE, et al. **Clin Chest Med** 1995 Dec;16(4):657–70 (99 ref.)
Gastroesophageal reflux and sinusitis in asthma. Hamilos DL. **Clin Chest Med** 1995 Dec;16(4):683–97 (61 ref.)
Food intolerance and asthma. Warner JO. **Clin Exp Allergy** 1995 Jul;25 Suppl 1:29–30 (10 ref.)
Observations on asthma. Bates DV. **Environ Health Perspect** 1995 Sep;103 Suppl 6:243–7 (49 ref.)
Basic mechanisms of asthma. Boushey HA, et al. **Environ Health Perspect** 1995 Sep;103 Suppl 6:229–33 (47 ref.)
Occupational asthma. Chan–Yeung M. **Environ Health Perspect** 1995 Sep;103 Suppl 6:249–52 (40 ref.)
Indoor air pollution and childhood asthma: effective environmental interventions. Etzel RA. **Environ Health Perspect** 1995 Sep;103 Suppl 6:55–8 (43 ref.)
Associations between criteria air pollutants and asthma. Koren HS. **Environ Health Perspect** 1995 Sep;103 Suppl 6:235–42 (106 ref.)
Evaluation of a possible association of urban air toxics and asthma. Leikauf GD, et al. **Environ Health Perspect** 1995 Sep;103 Suppl 6:253–71 (179 ref.)
Environmental risk factors of childhood asthma in urban centers. Malveaux FJ, et al. **Environ Health Perspect** 1995 Sep;103 Suppl 6:59–62 (30 ref.)
Rubber latex in the air: an occupational and environmental cause of asthma? Hopkins J. **Food Chem Toxicol** 1995 Oct; 33(10):895–9 (23 ref.)
The role of nitric oxide in the development of asthma. Curran AD. **Int Arch Allergy Immunol** 1996 Sep;111(1):1–4 (34 ref.)
Asthma and oxidant stress: nutritional, environmental, and genetic risk factors. Greene LS. **J Am Coll Nutr** 1995 Aug; 14(4):317–24 (80 ref.)
Gastroesophageal reflux disease. Kahrilas PJ. **JAMA** 1996 Sep 25;276(12):983–8 (66 ref.)
Nonsensitizing causes of occupational asthma. Lemière C, et al. **Med Clin North Am** 1996 Jul;80(4):749–74 (67 ref.)
Are non–allergenic environmental factors important in asthma? Abramson MJ, et al. **Med J Aust** 1995 Nov 20; 163(10):542–5 (47 ref.)
Are cytokines responsible for the asthmatic state of the airways? Kips JC, et al. **Monaldi Arch Chest Dis** 1996 Jun; 51(3):223–7 (52 ref.)
Progression of allergy and asthma through childhood to

adolescence. von Mutius E. **Thorax** 1996 Jan;51 Suppl 1:S3–6 (58 ref.)
Occupational asthma. Brooks SM. **Toxicol Lett** 1995 Dec; 82–83:39–45 (32 ref.)
Asthma and the environment: do environmental factors affect the incidence and prognosis of asthma? Samet JM. **Toxicol Lett** 1995 Dec;82–83:33–8 (15 ref.)
Environmentally induced asthma. Utell MJ, et al. **Toxicol Lett** 1995 Dec;82–83:47–53 (21 ref.)
[Ski racing and asthma (editorial)] Laitinen L. **Duodecim** 1994;110(19):1754–6 (21 ref.) **(Fin)**
[Occupational asthma in an agricultural setting] Bessot JC, et al. **Rev Mal Respir** 1996 Jul;13(3):205–15 (103 ref.) (Eng. Abstr.) **(Fre)**
[Role of atmospheric pollutants in asthma] Charpin D, et al. **Rev Pneumol Clin** 1996;52(2):70–8 (54 ref.) (Eng. Abstr.) **(Fre)**
[New hypotheses in asthma: the mastocytes] Kassel O, et al. **Rev Pneumol Clin** 1996;52(2):59–63 (34 ref.) (Eng. Abstr.) **(Fre)**
[Progress of allergology and cell reaction—recognition of adult onset intractable asthma] Kimura I. **Arerugi** 1995 Oct; 44(10):1193–8 (21 ref.) **(Jpn)**
[Occupational asthma] Shiro T. **Arerugi** 1995 Sep; 44(9):1105–10 (37 ref.) **(Jpn)**
[Occupational asthma] Fujimura N. **Nippon Naika Gakkai Zasshi** 1996 Feb 10;85(2):234–9 (8 ref.) **(Jpn)**
[The role of viral respiratory tract infections on pathogenesis of bronchial asthma. I. Clinical and experimental investigations] Kroczyńska–Bednarek J, et al. **Pneumonol Alergol Pol** 1995;63(9–10):566–9 (35 ref.) **(Pol)**
[Progress in pathophysiology and therapy of bronchial asthma] Rutkowski R, et al. **Pneumonol Alergol Pol** 1995; 63 Suppl 2:93–9 (39 ref.) **(Pol)**
[Bronchial asthma—a chronic inflammatory disorder] Adamek–Guzik T, et al. **Przegl Lek** 1996;53(1):12–9 (25 ref.) (Eng. Abstr.) **(Pol)**
[Allergic bronchitis in bronchial asthma] Fal AM, et al. **Wiad Lek** 1994 Sep;47(17–18):688–93 (26 ref.) (Eng. Abstr.) **(Pol)**
[Arachnids as risk factors in occupational exposure] Dutkiewicz J. **Wiad Parazytol** 1995;41(3):253–66 (48 ref.) (Eng. Abstr.) **(Pol)**
[The etiopathogenesis of bronchial asthma] Petrui ID. **Pneumoftiziologia** 1995 Jan–Jun;44(1–2):53–61 (43 ref.) **(Rum)**
[The role of hypoxia in the development of bronchial asthma] Ialkut SI. **Ter Arkh** 1995;67(8):71–4 (40 ref.) **(Rus)**
[Early identification of respiratory viruses in asthmatic children] Morfin Maciel BM, et al. **Rev Alerg Mex** 1996 Mar–Apr;43(2):45–8 (22 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

The genetics of asthma and atopy. Panhuysen CI, et al. **Allergy** 1995 Nov;50(11):863–9 (62 ref.)
The genetics of asthma. Sandford A, et al. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 1):1749–65 (188 ref.)
Transcription factors. Barnes PJ, et al. **Clin Exp Allergy** 1995 Nov;25 Suppl 2:46–9 (27 ref.)
11q and high–affinity IgE receptor in asthma and allergy. Cookson WO. **Clin Exp Allergy** 1995 Nov;25 Suppl 2:71–3; discussion 95–6 (23 ref.)
Asthma genetics studies in Western Australia. Le Souëf PN. **Clin Exp Allergy** 1995 Nov;25 Suppl 2:26–8 (10 ref.)
Genetic abnormalities of the human beta 2 adrenergic receptor. Potter PC. **Clin Exp Allergy** 1995 Jul;25(7):596–8 (18 ref.)
Genetics of asthma and atopy. Rosenwasser LJ. **Toxicol Lett** 1996 Aug;86(2–3):73–7 (19 ref.)

IMMUNOLOGY

The immunological defects in allergic asthmatic children and the working mechanisms of immunotherapy (hyposensitization) [editorial] Hsieh KH. **Acta Paediatr Sin** 1995 Nov–Dec;36(6):399–400 (25 ref.)
Mast–cell–leukocyte cytokine cascades in allergic inflammation. Galli SJ, et al. **Allergy** 1995 Nov; 50(11):851–62 (129 ref.)
The one–two of T helper cells: does interferon–gamma knock out the Th2 hypothesis for asthma? [comment] Holtzman MJ, et al. **Am J Respir Cell Mol Biol** 1996 Apr;14(4):316–8 (24 ref.) Comment on: Am J Respir Cell Mol Biol 1996 Apr;14(4):319–26.
Immunotherapy for childhood asthma: is there a rationale for its use? Sigman K, et al. **Ann Allergy Asthma Immunol** 1996 Apr;76(4):299–305; quiz 305–9 (39 ref.)
What the pulmonologist needs to know about allergy. Hoover GE, et al. **Clin Chest Med** 1995 Dec;16(4):603–20 (129 ref.)
Tumour necrosis factor alpha: a potential mediator of asthma. Shah A, et al. **Clin Exp Allergy** 1995 Nov;25(11):1038–44 (59 ref.)
Is there a dose–response relationship between exposure to indoor allergens and symptoms of asthma? [editorial] Platts–Mills TA, et al. **J Allergy Clin Immunol** 1995 Oct; 96(4):435–40 (44 ref.)
Allergen levels causing sensitisation, bronchial hyperreactivity and asthma. Dreborg S. **Pediatr Allergy Immunol** 1995;6 Suppl 7:22–6 (44 ref.)
[The immunopathological basis of asthma] Zaks T, et al. **Harefuah** 1996 Jan 15;130(2):104–7 (42 ref.) **(Heb)**
[Atopy score in infancy and the severity of asthma at 7 years of age] Uhereczky G, et al. **Orv Hetil** 1996 Jan 28; 137(4):175–8 (46 ref.) (Eng. Abstr.) **(Hun)**
[Mechanism of airway inflammation in patients with asthma] Morita Y. **Nippon Naika Gakkai Zasshi** 1996 Feb 10; 85(2):174–7 (7 ref.) **(Jpn)**
[Adhesion molecules in bronchial asthma] Fal AM, et al. **Pneumonol Alergol Pol** 1995;63(9–10):577–80 (23 ref.) **(Pol)**
[Role of viral respiratory tract infections on the pathogenesis of bronchial asthma. II. Effect on the immune system] Kroczyńska–Bednarek J, et al. **Pneumonol Alergol Pol** 1995; 63(9–10):570–6 (40 ref.) **(Pol)**
[Histamine releasing factors and chemotactic factors in evaluation of mucosal inflammation in bronchial asthma] Kuna P, et al. **Pneumonol Alergol Pol** 1995;63(5–6):322–7 (29 ref.) **(Pol)**

METABOLISM

Pharmacokinetic–pharmacodynamic modelling as applied to bronchial asthma. Koopmans RP, et al. **Clin Pharmacokinet** 1995 Oct;29(4):213–20 (47 ref.)
Activation and regulation of chemokines in allergic airway inflammation. Lukacs NW, et al. **J Leukoc Biol** 1996 Jan; 59(1):13–7 (34 ref.)
[Glucocorticoid receptor anomalies in asthma] Demoly P, et al. **Presse Med** 1996 May 4–11;25(16):769–74 (26 ref.) (Eng. Abstr.) **(Fre)**

MORTALITY

Fatal asthma. FitzGerald JM, et al. **Annu Rev Med** 1996; 47:161–8 (32 ref.)
Death from asthma: rare but real. Wobig EK, et al. **J Emerg Med** 1996 Mar–Apr;14(2):233–40 (90 ref.)
Asthma and the beta agonist debate. Crane J, et al. **Thorax** 1995 Sep;50 Suppl 1:S5–10 (37 ref.)

PATHOLOGY

Extracellular matrix. Rennard SI. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 2):S14–5 (24 ref.)
Acute and chronic inflammatory mechanisms in asthma. Holgate ST. **Br J Clin Pract Symp Suppl** 1995 Sep;81:11–3 (0 ref.)
Cellular inflammation in asthma. Bousquet J, et al. **Clin Exp Allergy** 1995 Nov;25 Suppl 2:39–42 (23 ref.)
Eosinophils and asthma. What do measurements tell us? [editorial; comment] Robinson DS. **Clin Exp Allergy** 1995 Sep;25(9):795–8 (55 ref.) Comment on: Clin Exp Allergy 1995 Sep;25(9):820–7.
Activation and regulation of chemokines in allergic airway inflammation. Lukacs NW, et al. **J Leukoc Biol** 1996 Jan; 59(1):13–7 (34 ref.)

PHYSIOPATHOLOGY

Leukotrienes as therapeutic target in asthma. Pauwels RA, et al. **Allergy** 1995 Aug;50(8):615–22 (73 ref.)
Neural receptors and asthma. Baraniuk JN. **Allergy Proc** 1995 Sep–Oct;16(5):227–33 (76 ref.)
Drugs to be used with caution in patients with asthma. Craig TJ. **Am Fam Physician** 1996 Sep 1;54(3):947–53, 957–8 (24 ref.)
What is the role of nerves in chronic asthma and symptoms? Barnes PJ. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 2):S5–8 (58 ref.)
Role of airway smooth muscle. Black JL. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 2):S2–4 (39 ref.)
The inflammatory response. Denburg JA. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 2):S11–3 (53 ref.)
Airway behavior and its regulation: how do structural changes affect airway behavior? Hogg JC. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 2):S16–8 (31 ref.)
Can airway function be predicted? Macklem PT. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 2):S19–20 (9 ref.)
Epithelial cells: barrier functions and shedding–restitution mechanisms. Persson CG. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 2):S9–10 (16 ref.)
Nitric oxide and airway disease. Barnes PJ. **Ann Med** 1995 Jun;27(3):389–93 (56 ref.)
Neural mechanisms and axon reflexes in asthma. Where are we? Verleden GM. **Biochem Pharmacol** 1996 May 17; 51(10):1247–57 (176 ref.)
Physiologic diagnosis and function in asthma. Cherniack RM. **Clin Chest Med** 1995 Dec;16(4):567–81 (17 ref.)
Inflammation and asthma. Horwitz RJ, et al. **Clin Chest Med** 1995 Dec;16(4):583–602 (161 ref.)
Leukotrienes as mediators of airway obstruction and inflammation in asthma. Dahlén B, et al. **Clin Exp Allergy** 1995 Nov;25 Suppl 2:50–4 (42 ref.)
Linkage homology for bronchial hyperresponsiveness between DNA markers on human chromosome 5q31–q33 and mouse chromosome 13. Levitt RC, et al. **Clin Exp Allergy** 1995 Nov;25 Suppl 2:61–3 (21 ref.)
The role of airway inflammation in the pathophysiology of nocturnal asthma. Oosterhoff Y, et al. **Clin Exp Allergy** 1995 Oct;25(10):915–21 (39 ref.)
Lung surfactants and asthma [editorial] Postle AD. **Clin Exp Allergy** 1995 Nov;25(11):1030–3 (31 ref.)
The place of airway hyperresponsiveness in the asthma phenotype. Sterk PJ. **Clin Exp Allergy** 1995 Nov;25 Suppl 2:8–11; discussion 17–8 (30 ref.)
Effect of air pollution in asthma and respiratory allergy. Peden DB. **Otolaryngol Head Neck Surg** 1996 Feb; 114(2):242–7 (33 ref.)
NO or no NO in asthma? Barnes PJ. **Thorax** 1996 Feb; 51(2):218–20 (12 ref.)
Cysteinyl leukotrienes in asthma: old mediators up to new tricks. Hay DW, et al. **Trends Pharmacol Sci** 1995 Sep; 16(9):304–9 (54 ref.)
[Oxygen radicals and asthma] Kinnula V. **Duodecim** 1994; 110(9):863–9 (29 ref.) **(Fin)**
[Indications for respiratory function tests (RFT). The role of RFT and blood gases in the monitoring of asthma and chronic obstructive bronchopnumopathies] **Rev Mal Respir** 1995;12 Suppl 3:R115–31 (57 ref.) **(Fre)**
[Clinical significance of bronchial hyperreactivity] Weber T. **Rev Med Liege** 1995 Sep;50(9):384–7 (32 ref.) **(Fre)**
[Occupational asthma: medical and social prognosis] Pauli G, et al. **Rev Pneumol Clin** 1996;52(2):104–9 (25 ref.) (Eng. Abstr.) **(Fre)**
[Patients with lung diseases and sports] Villiger B. **Schweiz Rundsch Med Prax** 1995 Sep 5;84(36):953–62 (38 ref.) (Eng. Abstr.) **(Ger)**
[Limits in the evaluation of bronchial reactivity in children with asthma] Mingoni S, et al. **Pediatr Med Chir** 1995 Sep–Oct;17(5):417–22 (49 ref.) (Eng. Abstr.) **(Ita)**
[Airway inflammation in asthma] Fukuda T. **Nippon Naika Gakkai Zasshi** 1996 Feb 10;85(2):189–93 (7 ref.) **(Jpn)**
[Cough variant asthma] Hirata K, et al. **Nippon Naika Gakkai Zasshi** 1996 Feb 10;85(2):240–4 (5 ref.) **(Jpn)**
[Role of cytokines in pathophysiology of asthma] Ishioka S. **Nippon Naika Gakkai Zasshi** 1996 Feb 10;85(2):184–8 (5 ref.) **(Jpn)**
[Management of asthma based on their peak expiratory flow rate monitoring] Tamura G. **Nippon Naika Gakkai Zasshi** 1996 Feb 10;85(2):222–6 (11 ref.) **(Jpn)**
[Role of prostaglandins F and E in regulation of bronchial activity] Mastalerz L. **Pol Arch Med Wewn** 1995 Feb; 93(2):179–83 (35 ref.) (Eng. Abstr.) **(Pol)**
[Role of the autonomic nervous system (adrenergic, cholinergic and nonadrenergic, noncholinergic) in regulation of respiratory system function] Liebhart J, et al. **Postepy Hig Med Dosw** 1995;49(3):395–407 (45 ref.) (Eng. Abstr.) **(Pol)**

PREVENTION & CONTROL

The non–drug treatment of asthma. Liang AY. **Acta Paediatr Sin** 1995 Nov–Dec;36(6):401–4 (12 ref.)
What are the prospects for immunization? Holt PG. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 2):S27 (16 ref.)
Asthma in pregnancy. Mabie WC. **Clin Obstet Gynecol** 1996 Mar;39(1):56–69 (44 ref.)
Asthma. Specific preventive strategies. Morris RJ. **Postgrad Med** 1996 Aug;100(2):105–6, 109–12, 118 passim (21 ref.)
Issues in adolescent asthma: what are the needs? Price JF. **Thorax** 1996 Jan;51 Suppl 1:S13–7 (33 ref.)
[Role of breast milk feeding in avoidance of asthma and other allergic disorders] Barr J, et al. **Harefuah** 1995 Oct; 129(7–8):274–8 (43 ref.) **(Heb)**

PSYCHOLOGY

Perception, personality, and respiratory control in life–threatening asthma. Gibson GJ. **Thorax** 1995 Sep;50 Suppl 1:S2–4 (15 ref.)

RADIOGRAPHY

[Value of imaging in asthma] Paganin F, et al. **Rev Pneumol Clin** 1996;52(2):88–96 (36 ref.) (Eng. Abstr.) **(Fre)**
[Is the bronchial provocation test justified in occupational respiratory disease?] Pauli G, et al. **Rev Pneumol Clin** 1996; 52(2):97–102 (20 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

The immunological defects in allergic asthmatic children and the working mechanisms of immunotherapy (hyposensitization) [editorial] Hsieh KH. **Acta Paediatr Sin** 1995 Nov–Dec;36(6):399–400 (25 ref.)
Leukotrienes as therapeutic target in asthma. Pauwels RA, et al. **Allergy** 1995 Aug;50(8):615–22 (73 ref.)
The role of immunotherapy in allergic rhinitis/allergic asthma. Creticos PS. **Allergy Proc** 1995 Nov–Dec; 16(6):297–302 (78 ref.)
Management of sinusitis in the asthmatic patient. Senior BA, et al. **Ann Allergy Asthma Immunol** 1996 Jul;77(1):6–15; quiz 15–9 (47 ref.)
Immunotherapy for childhood asthma: is there a rationale for its use? Sigman K, et al.

Ann Allergy Asthma Immunol 1996 Apr;76(4):299–305; quiz 305–9 (39 ref.)
Management of asthma in the hospital emergency department. Beasley R, et al. **Br J Hosp Med** 1996 Mar 6–19;55(5):253–7 (18 ref.)
Guidelines for the emergency management of asthma in adults. CAEP/CTS Asthma Advisory Committee. Canadian Association of Emergency Physicians and the Canadian Thoracic Society. Beveridge RC, et al. **Can Med Assoc J** 1996 Jul 1;155(1):25–37 (167 ref.)
Asthma: current controversies and emerging therapies. Kavuru MS, et al. **Cleve Clin J Med** 1995 Sep–Oct; 62(5):293–304 (122 ref.)
How to implement an asthma education program. Kohler CL, et al. **Clin Chest Med** 1995 Dec;16(4):557–65 (18 ref.)
Intravenous immune globulin: an alternative therapy in steroid-dependent allergic diseases. Gelfand EW, et al. **Clin Exp Immunol** 1996 May;104 Suppl 1:61–6 (56 ref.)
Acute asthma. Kardon EM. **Emerg Med Clin North Am** 1996 Feb;14(1):93–114 (63 ref.)
Managed care and the treatment of asthma. O'Brien KP. **J Asthma** 1995;32(5):325–34 (46 ref.)
Emergent management of acute asthma. Abou-Shala N, et al. **Med Clin North Am** 1996 Jul;80(4):677–99 (74 ref.)
Near-fatal asthma and mechanical ventilation [editorial] Rossi A, et al. **Monaldi Arch Chest Dis** 1996 Apr; 51(2):99–101 (36 ref.)
Asthma. Calverley PM. **Postgrad Med J** 1996 Jan; 72(843):12–8 (34 ref.)
Therapeutic approaches to asthma based on VLA-4 integrin and its counter receptors. Metzger WJ. **Springer Semin Immunopathol** 1995;16(4):467–78 (65 ref.)
Cysteinyl leukotrienes in asthma: current state of therapeutic evaluation. Taylor IK. **Thorax** 1995 Sep;50(9):1005–10 (93 ref.)
[Management of severe acute asthma in adults] Teboul JL, et al. **Presse Med** 1995 Nov 11;24(34):1590–3 (27 ref.) **(Fre)**
[Treatment of severe acute asthma] Roué C, et al. **Rev Pneumol Clin** 1996;52(2):129–34 (28 ref.) (Eng. Abstr.) **(Fre)**
[Severe life threatening asthma attack] Magnussen H, et al. **Internist (Berl)** 1995 Aug;36(8):779–84 (31 ref.) **(Ger)**
[Guidelines for the treatment of asthma] Akiyama K. **Nippon Naika Gakkai Zasshi** 1996 Feb 10;85(2):199–204 (3 ref.) **(Jpn)**
[Progress in pathophysiology and therapy of bronchial asthma] Rutkowski R, et al. **Pneumonol Alergol Pol** 1995; 63 Suppl 2:93–9 (39 ref.) **(Pol)**

VETERINARY

Feline asthma syndrome. Corcoran BM, et al. **Vet Q** 1995 Apr;17 Suppl 1:S15–6 (3 ref.)

VIROLOGY

The effects of rhinovirus infections on allergic airway responses. Gern JE, et al. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 2):S40–5 (40 ref.)
Natural and experimental rhinovirus infections of the lower respiratory tract. Johnston SL. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 2):S46–52 (71 ref.)

ASTHMA, BRONCHIAL see **ASTHMA**

ASTHMA, CARDIAC see **DYSPNEA, PAROXYSMAL**

ASTHMA, EXERCISE-INDUCED

Exercise-induced bronchospasm in children: effects and therapies. Guill M. **Pediatr Ann** 1996 Mar;25(3):146–9, 153 (29 ref.)

DIAGNOSIS

Exercise-induced asthma. What family physicians should do. D'Urzo A. **Can Fam Physician** 1995 Nov;41:1900–6 (50 ref.)

PHYSIOPATHOLOGY

Exercise- and cold-induced asthma. Giesbrecht GG, et al. **Can J Appl Physiol** 1995 Sep;20(3):300–14 (100 ref.)
Exercise-induced airway obstruction. McFadden ER Jr. **Clin Chest Med** 1995 Dec;16(4):671–82 (103 ref.)
Models and mechanisms of exercise-induced asthma. Freed AN. **Eur Respir J** 1995 Oct;8(10):1770–85 (183 ref.)

ASTHMATIC CRISIS see **STATUS ASTHMATICUS**

ASTHMATIC SHOCK see **STATUS ASTHMATICUS**

ASTIGMATISM

EPIDEMIOLOGY

Distribution of astigmatism in the adult population. McKendrick AM, et al. **J Opt Soc Am A** 1996 Feb; 13(2):206–14 (42 ref.)

ETIOLOGY

[Principal factors affecting postoperative astigmatism after cataract extraction] Naim Dzheries Dzhadalla Kaĭkikh. **Vestn Oftalmol** 1995 Jul–Sep;111(3):34–6 (49 ref.) **(Rus)**

ASTRAGALUS see **TALUS**

ASTROCYTES

see related
BLOOD-BRAIN BARRIER

CHEMISTRY

Localization of the Na(+)-Ca2+ exchanger in vascular smooth muscle, and in neurons and astrocytes. Juhaszova M, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:318–35 (31 ref.)

CYTOLOGY

Regulation of astrocyte cell biology by the cAMP/protein kinase A signaling pathway. Huneycutt BS, et al. **Adv Neuroimmunol** 1995;5(3):261–9 (45 ref.)
From rodent glial precursor cell to human glial neoplasia in the oligodendrocyte-type-2 astrocyte lineage. Noble M, et al. **Glia** 1995 Nov;15(3):222–30 (63 ref.)

DRUG EFFECTS

Astrocytes and microglia as potential targets for calcitonin gene related peptide in the central nervous system. Reddington M, et al. **Can J Physiol Pharmacol** 1995 Jul; 73(7):1047–9 (18 ref.)
Stimulation of phospholipase A2 expression in rat cultured astrocytes by LPS, TNF alpha and IL-1 beta. Sun GY, et al. **Prog Brain Res** 1995;105:231–8 (27 ref.)

IMMUNOLOGY

Neuro-glial-immune interactions. An experimental, neural transplant and lesion study. Finsen B. **Dan Med Bull** 1995 Sep;42(4):323–41 (192 ref.)
Grumose or foamy spheroid bodies involving astrocytes in the human brain. Arai N. **Neuropathol Appl Neurobiol** 1995 Jun;21(3):238–45 (27 ref.)

METABOLISM

Metabolic trafficking between neurons and astrocytes: the glutamate/glutamine cycle revisited. Westergaard N, et al. **Dev Neurosci** 1995;17(4):203–11 (97 ref.)
A RT-PCR study of gene expression in a mechanical injury model. Eng LF, et al. **Prog Brain Res** 1995;105:219–29 (29 ref.)
Gene expression in astrocytes during and after ischemia. Yu AC, et al. **Prog Brain Res** 1995;105:245–53 (50 ref.)

PATHOLOGY

Role for astrocytosis in HIV-1-associated dementia. Vitkovic L, et al. **Curr Top Microbiol Immunol** 1995;202:105–16 (49 ref.)

VIROLOGY

Spread of MHV-JHM from nasal cavity to white matter of spinal cord. Transneuronal movement and involvement of astrocytes. Perlman S, et al. **Adv Exp Med Biol** 1995; 380:73–8 (21 ref.)

ASTROCYTOMA

Management of primary malignant brain tumours [editorial] Whittle IR. **J Neurol Neurosurg Psychiatry** 1996 Jan; 60(1):2–5 (50 ref.)

COMPLICATIONS

Tuberous sclerosis with a brain tumor. Chaudhary D, et al. **Indian Pediatr** 1995 Feb;32(2):235–8 (13 ref.)

DIAGNOSIS

Low-grade astrocytomas: prognosis factors and elements of management. Loiseau H, et al. **Surg Neurol** 1995 Sep; 44(3):224–7 (44 ref.)
Prognostic factors in low-grade supratentorial astrocytomas: a uni-multivariate statistical analysis in 76 surgically treated adult patients. Nicolato A, et al. **Surg Neurol** 1995 Sep; 44(3):208–21; discussion 221–3 (60 ref.)
[A case of uncomplicated retinal astrocytoma] Ikeda T, et al. **Nippon Ganka Gakkai Zasshi** 1995 Sep;99(9):1052–5 (21 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Genetic alterations associated with the evolution and progression of astrocytic brain tumours. Ohgaki H, et al. **Virchows Arch** 1995;427(2):113–8 (44 ref.)

IMMUNOLOGY

Tumor antigens in astrocytic gliomas. Kurpad SN, et al. **Glia** 1995 Nov;15(3):244–56 (105 ref.)

PATHOLOGY

Granular cell change in astrocytic tumors. Geddes JF, et al. **Am J Surg Pathol** 1996 Jan;20(1):55–63 (50 ref.)
Brain astrocytomas: biopsy, then irradiation. Lunsford LD, et al. **Clin Neurosurg** 1995;42:464–79 (43 ref.)
Clinical, radiological, and therapeutic features of pleomorphic xanthoastrocytoma: report of three patients and review of the literature. van Roost D, et al. **J Neurol Neurosurg Psychiatry** 1996 Jun;60(6):690–2 (12 ref.)
Multiple neuroepithelial tumors of different cell types--case report. Akai T, et al. **Neurol Med Chir (Tokyo)** 1995 Dec; 35(12):901–4 (9 ref.)

RADIOTHERAPY

Brain astrocytomas: biopsy, then irradiation. Lunsford LD, et al. **Clin Neurosurg** 1995;42:464–79 (43 ref.)
The low-grade glioma debate: evidence defending the position of early radiation therapy. Shaw EG. **Clin Neurosurg** 1995;42:488–94 (10 ref.)
External beam radiotherapy: hard facts and painful realities. Vick NA, et al. **J Neurooncol** 1995;24(1):93–5 (15 ref.)

SURGERY

Management of low-grade gliomas: results of resections without electrocorticography. Fried I. **Clin Neurosurg** 1995;42:453–63 (41 ref.)
Surgical issues in the management of supratentorial low-grade gliomas. Kelly PJ. **Clin Neurosurg** 1995; 42:399–436 (39 ref.)
Intracranial meningioma and astrocytoma in the same patient. Case report and review of the literature. Dario A, et al. **J Neurosurg Sci** 1995 Mar;39(1):27–35 (44 ref.)
Pleomorphic xanthoastrocytoma: case report and analysis of the literature concerning the efficacy of resection and the significance of necrosis. Pahapill PA, et al. **Neurosurgery** 1996 Apr;38(4):822–8; discussion 828–9 (32 ref.)
Prognostic factors in low-grade supratentorial astrocytomas: a uni-multivariate statistical analysis in 76 surgically treated adult patients. Nicolato A, et al. **Surg Neurol** 1995 Sep; 44(3):208–21; discussion 221–3 (60 ref.)

THERAPY

High-grade astrocytomas. Wen PY, et al. **Neurol Clin** 1995 Nov;13(4):875–900 (164 ref.)
The management of brainstem gliomas in patients with neurofibromatosis 1. Pollack IF, et al. **Neurology** 1996 Jun; 46(6):1652–60 (48 ref.)
Low-grade astrocytomas: prognosis factors and elements of management. Loiseau H, et al. **Surg Neurol** 1995 Sep; 44(3):224–7 (44 ref.)
[Treatment of hypothalamic-pituitary tumors--experiences at Hiroshima University School of Medicine] Uozumi T. **Nippon Naibunpi Gakkai Zasshi** 1995 Nov 20;71(7):1019–36 (43 ref.) (Eng. Abstr.) **(Jpn)**

ASTROCYTOMA, SUBEPENDYMAL GIANT CELL see **GLIOMA**

ASTROGLIA see **ASTROCYTES**

ASTRONOMY

The history of the galaxies. Fukugita M, et al. **Nature** 1996 Jun 6;381(6582):489–95 (94 ref.)

ASTROVIRUSES

PATHOGENICITY

Astrovirus gastroenteritis. Blacklow NR, et al. **Trans Am Clin Climatol Assoc** 1994;106:58–66; discussion 66–8 (31 ref.)

ASYMMETRIC SEPTAL HYPERTROPHY see **CARDIOMYOPATHY, HYPERTROPHIC**

ASYSTOLE see **HEART ARREST**

ATARACTICS see **TRANQUILIZING AGENTS**

ATAXIA

CHEMICALLY INDUCED

Carbohydrate tolerance in patients with tropical ataxic neuropathy--A human model of chronic cyanide intoxication. Famuyiwa OO, et al. **Afr J Med Med Sci** 1995 Jun;24(2):151–7 (28 ref.)

CLASSIFICATION

Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. The Consensus Committee of the American Autonomic Society and the American Academy of Neurology. **Neurology** 1996 May;46(5):1470 (1 ref.)

COMPLICATIONS

Progressive myoclonic ataxia associated with coeliac disease. The myoclonus is of cortical origin, but the pathology is in the cerebellum. Bhatia KP, et al. **Brain** 1995 Oct;118 (Pt 5):1087–93 (14 ref.)

ATAXIA

ETIOLOGY

[Sensory ataxic neuropathy associated with Sjögren's syndrome] Yasuda T, et al. **Nippon Rinsho** 1995 Oct; 53(10):2568–73 (23 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

[Tremor and ataxia] Dueñas DA. **Rev Neurol** 1995;23 Suppl 3:S349–54 (41 ref.) **(Spa)**

ATAXIA, CEREBELLAR see **CEREBELLAR ATAXIA**

ATAXIA TELANGIECTASIA

[Chromosome breakage syndrome and fragile X syndrome] Shiraishi Y. **Nippon Rinsho** 1995 Nov;53(11):2807–14 (16 ref.) (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

Leukemia and lymphoma in ataxia telangiectasia. Taylor AM, et al. **Blood** 1996 Jan 15;87(2):423–38 (110 ref.)

GENETICS

Ataxia–telangiectasia and cellular responses to DNA damage. Meyn MS. **Cancer Res** 1995 Dec 15;55(24):5991–6001 (148 ref.)

Cancer predisposition. Ataxia–telangiectasia at the crossroads. Jackson SP. **Curr Biol** 1995 Nov 1;5(11):1210–2 (13 ref.)

Ataxia–telangiectasia: closer to unraveling the mystery. Shiloh Y. **Eur J Hum Genet** 1995;3(2):116–38 (259 ref.)

Regulation of the cell cycle following DNA damage in normal and Ataxia telangiectasia cells. Lohrer HD. **Experientia** 1996 Apr 15;52(4):316–28 (186 ref.)

The ATM gene and the radiobiology of ataxia–telangiectasia. Jorgensen TJ, et al. **Int J Radiat Biol** 1996 May; 69(5):527–37 (104 ref.)

Relationship of the ataxia–telangiectasia protein ATM to phosphoinositide 3–kinase. Lavin MF, et al. **Trends Biochem Sci** 1995 Oct;20(10):382–3 (22 ref.)

The ataxia–telangiectasia gene: a link between checkpoint controls, neurodegeneration and cancer. Lehmann AR, et al. **Trends Genet** 1995 Oct;11(10):375–7 (23 ref.)

[Ataxia telangiectasia and genetic predisposition to cancer] Bay JO, et al. **Bull Cancer (Paris)** 1996 Mar;83(3):171–5 (31 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Regulation of the cell cycle following DNA damage in normal and Ataxia telangiectasia cells. Lohrer HD. **Experientia** 1996 Apr 15;52(4):316–28 (186 ref.)

ATAXIAS, HEREDITARY see **SPINOCEREBELLAR DEGENERATION**

ATELECTASIS

CONGENITAL

Lobar emphysema and atelectasis syndrome, a nosological unity. Ring–Mrozik E, et al. **Eur J Pediatr Surg** 1995 Jun; 5(3):131–5 (27 ref.)

ETIOLOGY

Use of fiberoptic bronchoscopy in asthmatic children with lung collapse. Barbato A, et al. **Pediatr Med Chir** 1995 May–Jun;17(3):253–5 (9 ref.)

METABOLISM

What is the role of absorption atelectasis in the genesis of perioperative pulmonary collapse? Joyce CJ, et al. **Anaesth Intensive Care** 1995 Dec;23(6):691–6 (57 ref.)

PREVENTION & CONTROL

Postoperative atelectasis and pneumonia: risk factors. Brooks–Brunn JA. **Am J Crit Care** 1995 Sep;4(5):340–9; quiz 350–1 (90 ref.)

THERAPY

Chest physical therapy for patients in the intensive care unit. Ciesla ND. **Phys Ther** 1996 Jun;76(6):609–25 (133 ref.)

ATELECTASIS, CONGESTIVE see **RESPIRATORY DISTRESS SYNDROME, ADULT**

ATELES see **CEBIDAE**

ATELINAE see **CEBIDAE**

ATHERECTOMY

see related
ENDARTERECTOMY

Intravascular ultrasound imaging of peripheral arteries as an adjunct to balloon angioplasty and atherectomy. Korogi Y, et al. **Cardiovasc Intervent Radiol** 1996 Jan–Feb;19(1):1–9 (39 ref.)

INSTRUMENTATION

Current status of atherectomy for peripheral arterial occlusive disease. Ahn SS, et al. **World J Surg** 1996 Jul–Aug;20(6):635–43 (45 ref.)

ATHERECTOMY, CORONARY

Matching to guide the design and predict the outcome of randomized atherectomy trials [editorial] Umans VA, et al. **Am Heart J** 1995 Nov;130(5):1135–43 (48 ref.)

INSTRUMENTATION

Atherectomy (directional, rotational, extractional) and its role in percutaneous revascularization. Kaufmann UP, et al. **Curr Opin Cardiol** 1995 Jul;10(4):412–9 (53 ref.)

[Alternative methods in interventional therapy of coronary heart disease] Erbel R, et al. **Z Kardiol** 1995;84 Suppl 2:53–64 (72 ref.) (Eng. Abstr.) **(Ger)**

[Drug and instrumental therapeutic approaches for prevention of restenosis] Höfling B, et al. **Z Kardiol** 1995; 84 Suppl 4:151–8 (36 ref.) (Eng. Abstr.) **(Ger)**

[PTCA or alternative techniques? Balloon angioplasty remains dominant] Reifart N. **Z Kardiol** 1995;84 Suppl 2:43–52 (30 ref.) (Eng. Abstr.) **(Ger)**

METHODS

New devices in interventional cardiology: present and future. Beyar R. **Isr J Med Sci** 1996 Jul;32(7):515–25 (42 ref.)

ATHEROEMBOLISM see **EMBOLISM, CHOLESTEROL**

ATHEROMA see **ATHEROSCLEROSIS**

ATHEROSCLEROSIS

see related
ATHERECTOMY
EMBOLISM, CHOLESTEROL

Atherosclerosis: an update. Basha BJ, et al. **Am Heart J** 1996 Jun;131(6):1192–202 (107 ref.)

Fibrinolysis and atherosclerosis. Hamsten A, et al. **Baillieres Clin Haematol** 1995 Jun;8(2):345–63 (119 ref.)

Peripheral arterial–vascular disease in women: prevalence, prognosis, and treatment. Gerhard M, et al. **Cardiology** 1995;86(4):349–55 (56 ref.)

Aneurysms of the infrapopliteal arteries. Marmorale A, et al. **J R Coll Surg Edinb** 1995 Oct;40(5):324–6 (4 ref.)

Beyond oxidized LDL: the initiation and progression of atherosclerosis. Hirose N, et al. **Keio J Med** 1996 Jun; 45(2):90–4 (26 ref.)

Mouse models of atherosclerosis. Breslow JL. **Science** 1996 May 3;272(5262):685–8 (26 ref.)

BLOOD

The role of lipoprotein(a) in atherogenesis and thrombosis. Hajjar KA, et al. **Annu Rev Med** 1996;47:423–42 (137 ref.)

Lipoproteins and the progression/regression of atherosclerosis. Barth JD. **Baillieres Clin Endocrinol Metab** 1995 Oct;9(4):849–66 (74 ref.)

Low–density lipoprotein oxidation, antioxidants, and atherosclerosis: a clinical biochemistry perspective. Jialal I, et al. **Clin Chem** 1996 Apr;42(4):498–506 (92 ref.)

The role of lipids in cardiovascular disease: lessons from rare mutations and special populations. Hegele RA. **Clin Invest Med** 1996 Jun;19(3):161–70 (42 ref.)

Platelet activation mechanisms and markers in arterial thrombosis. Wu KK. **J Intern Med** 1996 Jan;239(1):17–34 (110 ref.)

Lipoprotein(a), plasmin modulation, and atherogenesis. Harpel PC, et al. **Thromb Haemost** 1995 Jul;74(1):382–6 (83 ref.)

[Decrease in plasma cholesterol and regression of atherosclerosis] Wang Y, et al. **Chung Hua Nei Ko Tsa Chih** 1995 Aug;34(8):561–4 (21 ref.) **(Chi)**

[Regulation of HDL lipoprotein plasma levels in relation to atherogenesis] Ružek V. **Vnitr Lek** 1995 Aug;41(8):555–9 (56 ref.) (Eng. Abstr.) **(Cze)**

[The significance of ixidized low density lipoprotein in atherosclerosis] Hansen PR. **Ugeskr Laeger** 1996 May 6; 158(19):2706–10 (40 ref.) (Eng. Abstr.) **(Dan)**

[Atherogenicity of low–density lipoproteins (LDL). A problem of quantity or quality?] Dejager S, et al. **Presse Med** 1995 Dec 9;24(38):1772–6 (16 ref.) (Eng. Abstr.) **(Fre)**

[Serum elastin peptide concentration and human leukocyte elastase/antiproteinase balance in peripheral obstructive atherosclerosis] Mohácsi A, et al. **Orv Hetil** 1996 Jan 7; 137(1):15–21 (49 ref.) (Eng. Abstr.) **(Hun)**

[Multiple modifications of low density lipoproteins in blood of patients with atherosclerosis] Orekhov AN, et al. **Biull Eksp Biol Med** 1995 Aug;120(8):118–21 (38 ref.) **(Rus)**

COMPLICATIONS

The proximal aorta: a source of stroke. Jones EF, et al. **Baillieres Clin Neurol** 1995 Aug;4(2):207–20 (45 ref.)

Do glomerular atherosclerosis and lipid–mediated tubulo–interstitial disease cause progressive renal failure in man? Moorhead JF, et al. **Blood Purif** 1996;14(1):58–66 (69 ref.)

Primary aortoesophageal fistula caused by an atherosclerotic thoracoabdominal aortic aneurysm: a case report and review of the literature. Hageman JH, et al. **Cardiovasc Surg** 1995 Oct;3(5):495–9 (17 ref.)

Aortic atheromatosis and risks of cerebral embolization. Barbut D, et al. **J Cardiothorac Vasc Anesth** 1996 Jan; 10(1):24–9; quiz 29–30 (72 ref.)

[Atheromatous embolisms and cholesterol embolisms: medical treatment] Vayssairat M, et al. **J Mal Vasc** 1996; 21 Suppl A:97–9 (17 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

New diagnostic inroads in hypertension and atherosclerosis. Ayers CR. **Curr Opin Cardiol** 1995 Sep;10(5):480–4 (14 ref.)

[The evaluation of 3DFT time–of–flight MR–angiography versus angiography in the study of carotid atheromatous lesions with a review of the literature] Auffray–Calvier E, et al. **J Neuroradiol** 1995 Dec;22(4):272–87 (30 ref.) (Eng. Abstr.) **(Fre)**

DIET THERAPY

[Dietary treatment of hypercholesterolemia] Richter WO. **Wien Klin Wochenschr** 1995;107(18):549–54 (83 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Elastase in the prevention of arterial aging and the treatment of atherosclerosis. Ooyama T, et al. **Ciba Found Symp** 1995; 192:307–17; discussion 318–20 (36 ref.)

New approaches to the prevention of atherosclerosis. Naito M, et al. **Drugs** 1995 Sep;50(3):440–53 (154 ref.)

Carvedilol, a novel multiple action antihypertensive agent with antioxidant activity and the potential for myocardial and vascular protection. Feuerstein GZ, et al. **Eur Heart J** 1995 Jul;16 Suppl F:38–42 (21 ref.)

Pharmacologic approaches to the treatment of atherosclerotic arterial obstruction. Capron L. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S40–3 (15 ref.)

Oxylanosterols as modifiers of cholesterol biosynthesis. Trzaskos JM. **Prog Lipid Res** 1995;34(2):99–116 (28 ref.)

[Platelet antiaggregants and atheromatous arteriopathy of the lower limbs] Lévesque H, et al. **Rev Med Interne** 1996; 17(2):163–8 (47 ref.) (Eng. Abstr.) **(Fre)**

[The pharmacology of the statins: the evidence of a direct antiatherosclerotic action] Raiteri M, et al. **Ann Ital Med Int** 1995 Oct;10 Suppl:35S–42S (74 ref.) (Eng. Abstr.) **(Ita)**

[Anti–atherosclerotic action of ACE inhibitors. I. Inactivation of the renin–angiotensin system] Stajszczyk M, et al. **Postepy Hig Med Dosw** 1996;50(2):157–71 (80 ref.) (Eng. Abstr.) **(Pol)**

ENZYMOLOGY

Triglyceride lipases and atherosclerosis. Olivecrona G, et al. **Curr Opin Lipidol** 1995 Oct;6(5):291–305 (122 ref.)

EPIDEMIOLOGY

Atherosclerosis: risk factors and the vascular endothelium. Glasser SP, et al. **Am Heart J** 1996 Feb;131(2):379–84 (56 ref.)

Plasma lipid profiles and epidemiology of atherosclerotic diseases in Taiwan—a unique experience. Pan WH, et al. **Atherosclerosis** 1995 Dec;118(2):285–95 (47 ref.)

Hyperlipidemia, hypertension and atherosclerosis in women. Reality and perspectives. Bugliosi R, et al. **Clin Ter** 1995 Aug–Sep;146(8–9):503–18 (66 ref.)

The hypothetical epidemic of coronary heart disease and atherosclerosis. Stehbens WE. **Med Hypotheses** 1995 Nov; 45(5):449–54 (55 ref.)

Lipoprotein(a) in chronic renal disease. Stenvinkel P, et al. **Miner Electrolyte Metab** 1996;22(1–3):16–21 (67 ref.)

[Arterial hypertension and atherosclerosis: their epidemiology and physiopathology] Lembo G, et al. **Ann Ital Med Int** 1995 Oct;10 Suppl:69S–72S (13 ref.) (Eng. Abstr.) **(Ita)**

ETIOLOGY

Pathogenesis of atherosclerosis. Navab M, et al. **Am J Cardiol** 1995 Sep 28;76(9):18C–23C (34 ref.)

The early natural history of atherosclerosis and hypertension in the young: National Institutes of Health perspectives. Lenfant C, et al. **Am J Med Sci** 1995 Dec;310 Suppl 1:S3–7 (16 ref.)

The Yin and Yang of oxidation in the development of the fatty streak. A review based on the 1994 George Lyman Duff Memorial Lecture. Navab M, et al. **Arterioscler Thromb Vasc Biol** 1996 Jul;16(7):831–42 (108 ref.)

Advances in atherosclerosis. Spence JD. **Baillieres Clin Neurol** 1995 Aug;4(2):191–205 (105 ref.)

Atherogenic and anti–atherogenic factors in the human diet. Addis PB, et al. **Biochem Soc Symp** 1995;61:259–71 (64 ref.)

A pivotal role for TGF–beta in atherogenesis? Grainger DJ, et al. **Biol Rev Camb Philos Soc** 1995 Nov;70(4):571–96 (108 ref.)

Mechanisms of cardiovascular injury in renal disease. Rabelink TJ, et al. **Blood Purif** 1996;14(1):67–74 (64 ref.)

Role of mast cells in atherosclerosis. Kovanen PT. **Chem Immunol** 1995;62:132–70 (120 ref.)
Hyperinsulinemia and atherosclerosis. Standl E. **Clin Invest Med** 1995 Aug;18(4):261–6 (40 ref.)
Oxidatively modified LDL and atherosclerosis: an evolving plausible scenario. Jialal I, et al. **Crit Rev Food Sci Nutr** 1996 Apr;36(4):341–55 (115 ref.)
Postprandial state and atherosclerosis. Ebenbichler CF, et al. **Curr Opin Lipidol** 1995 Oct;6(5):286–90 (37 ref.)
Smooth muscle cells and atherosclerosis. Stein O, et al. **Curr Opin Lipidol** 1995 Oct;6(5):269–74 (54 ref.)
Cytokines, modified lipoproteins, and arteriosclerosis in diabetes. Lopes-Virella MF, et al. **Diabetes** 1996 Jul;45 Suppl 3:S40–4 (49 ref.)
Hyperinsulinemia and atherosclerosis. Stout RW. **Diabetes** 1996 Jul;45 Suppl 3:S45–6 (26 ref.)
The role of oxidized lipoproteins in atherogenesis. Berliner JA, et al. **Free Radic Biol Med** 1996;20(5):707–27 (265 ref.)
The role of oxidized low density lipoprotein in atherogenesis. Jialal I, et al. **J Nutr** 1996 Apr;126(4 Suppl):1053S–7S (39 ref.)
Cigarette smoking and health of the heart. Leone A. **J R Soc Health** 1995 Dec;115(6):354–5 (13 ref.)
Hyperglycemia-induced latent scurvy and atherosclerosis: the scorbutic-metaplasia hypothesis. Price KD, et al. **Med Hypotheses** 1996 Feb;46(2):119–29 (136 ref.)
Non-ischemic hypoxia of the arterial wall is a primary cause of atherosclerosis. Simanonok JP. **Med Hypotheses** 1996 Feb;46(2):155–61 (80 ref.)
Many roads lead to atheroma [comment] Hayden MR, et al. **Nat Med** 1995 Jan;1(1):22–3 (18 ref.) Comment on: Nat Med 1995 Jan;1(1):74–9.
Homocysteine—an atherogenic and a thrombogenic factor? Ubbink JB. **Nutr Rev** 1995 Nov;53(11):323–5 (18 ref.)
Pathogenesis of atherosclerosis. Massy ZA, et al. **Semin Nephrol** 1996 Jan;16(1):12–20 (65 ref.)
[Smoking and peripheral vascular disorders] Stammler F, et al. **Z Arztl Fortbild (Jena)** 1995 Oct;89(5):459–66 (12 ref.) (Eng. Abstr.) **(Ger)**
[Hyperhomocysteinemia as a risk factor in atherosclerotic and thrombotic vascular processes] Sela B. **Harefuah** 1995 Nov 15;129(10):407–12 (35 ref.) **(Heb)**
[Oxidized lipoproteins and atherogenesis] Bellomo G, et al. **Cardiologia** 1996 May;41(5):417–25 (61 ref.) **(Ita)**
[Neutrophilic leukocytes, thrombotic risk factors in vascular diseases] Berti F. **Cardiologia** 1996 Feb;41(2):107–16 (95 ref.) **(Ita)**
[Fibrinogen as a cardiovascular risk factor] Giannasi G, et al. **Minerva Cardioangiol** 1995 May;43(5):169–75 (100 ref.) (Eng. Abstr.) **(Ita)**
[Obesity and vascular diseases] Oikawa S, et al. **Nippon Naika Gakkai Zasshi** 1995 Aug 10;84(8):1246–50 (5 ref.) **(Jpn)**
[Phenotypic change of the smooth muscle cell and atherosclerosis] Mori S, et al. **Nippon Yakurigaku Zasshi** 1996 Mar;107(3):161–70 (50 ref.) (Eng. Abstr.) **(Jpn)**
[Serum lipoprotein and atherogenicity—relationship with particle size and composition of low density lipoproteins, and their modifications by oxidation and glycation] Takeuchi N, et al. **Rinsho Byori** 1995 Aug;43(8):753–62 (47 ref.) (Eng. Abstr.) **(Jpn)**
[The pathogenesis of the evolution of the atheroma plaque] Ferreira Montero IJ, et al. **Rev Esp Cardiol** 1995;48 Suppl 5:13–22 (56 ref.) (Eng. Abstr.) **(Spa)**
[New discoveries on atherosclerosis. LDL oxidation plays a central role] Nilsson J. **Lakartidningen** 1995 Oct 4; 92(40):3684–6, 3691 (19 ref.) **(Swe)**

GENETICS

Insight into atherosclerosis: a review of c-myc and the vascular smooth muscle cell. Golja AM, et al. **Cell Mol Biol Res** 1995;41(6):487–99 (74 ref.)
The role of lipids in cardiovascular disease: lessons from rare mutations and special populations. Hegele RA. **Clin Invest Med** 1996 Jun;19(3):161–70 (42 ref.)
Environmental and genetic risk factors in early human atherogenesis: lessons from the PDAY study. Pathobiological Determinants of Atherosclerosis in Youth. Strong JP, et al. **Pathol Int** 1995 Jun;45(6):403–8 (30 ref.)
[Genetic variation in the apolipoprotein B gene] Vedie B, et al. **Ann Genet** 1995;38(4):187–201 (107 ref.) (Eng. Abstr.) **(Fre)**
[The metabolic syndrome and chronic vascular disease. Cellular mechanisms and potential candidate genes] Haller H, et al. **Internist (Berl)** 1996 Jul;37(7):687–97 (100 ref.) **(Ger)**
[Application of genetic principles to the causal assessment of atherosclerosis] Miserez AR, et al. **Ther Umsch** 1995 Dec;52(12):835–43 (48 ref.) (Eng. Abstr.) **(Ger)**
[Lipoprotein(a)—atherogenic waste product of evolution?] Kronenberg F, et al. **Wien Med Wochenschr** 1994; 144(12–13):324–30 (68 ref.) (Eng. Abstr.) **(Ger)**
[The relationship of apoB gene polymorphism to dyslipoproteinemia as the cause of atherosclerosis] Kravchenko NA. **Tsitol Genet** 1995 Jul–Aug;29(4):84–7 (33 ref.) (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

Immunology of atherosclerosis: the promise of mouse models [comment] Lichtman AH, et al. **Am J Pathol** 1996 Aug; 149(2):351–7 (81 ref.) Comment on: Am J Pathol 1996 Aug;149(2):359–66.
Atherosclerosis as an autoimmune condition. Kleindienst R, et al. **Isr J Med Sci** 1995 Oct;31(10):596–9 (26 ref.)

METABOLISM

Development of the lipid-rich core in human atherosclerosis. Guyton JR, et al. **Arterioscler Thromb Vasc Biol** 1996 Jan; 16(1):4–11 (104 ref.)
Cholesteryl ester transfer proteins, reverse cholesterol transport, and atherosclerosis. Bruce C, et al. **Curr Opin Lipidol** 1995 Oct;6(5):306–11 (47 ref.)
Structure of cholesterol-containing particles accumulating in atherosclerotic lesions and the mechanisms of their derivation. Hoff HF, et al. **Curr Opin Lipidol** 1995 Oct; 6(5):317–25 (91 ref.)
Apolipoprotein A-I-containing lipoproteins and atherosclerosis. Leroy A, et al. **Curr Opin Lipidol** 1995 Oct; 6(5):281–5 (36 ref.)
The stimulation of the cholesterol esterification pathway by atherogenic lipoproteins in macrophages. Tabas I. **Curr Opin Lipidol** 1995 Oct;6(5):260–8 (112 ref.)
Anti-atherogenicity of high density lipoprotein. Stein Y, et al. **Isr J Med Sci** 1996 Jun;32(6):503–8 (61 ref.)
Lipids and atherosclerosis. Halpern MJ. **Mol Aspects Med** 1995;16(6):509–710 (1120 ref.)
Atherosclerosis, oxidative stress, and antioxidant protection in endothelium-derived relaxing factor action. Keaney JF Jr, et al. **Prog Cardiovasc Dis** 1995 Sep–Oct;38(2):129–54 (202 ref.)
[Role of lipid oxidation in the development of atherosclerosis] Ylä-Herttuala S, et al. **Duodecim** 1994;110(17):1643–52 (55 ref.) **(Fin)**
[Biology of the endothelial cell and atherogenesis] Demuth K, et al. **Ann Biol Clin (Paris)** 1995;53(4):171–91 (211 ref.) (Eng. Abstr.) **(Fre)**

MICROBIOLOGY

Chlamydia in coronary plaques—hidden culprit or harmless hobo? Capron L. **Nat Med** 1996 Aug;2(8):856–7 (9 ref.)

MORTALITY

Patterns of aspirin use in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study. Shahar E, et al. **Am Heart J** 1996 May;131(5):915–22 (37 ref.)

PATHOLOGY

An overview of the quantitative influence of several risk factors on progression of atherosclerosis in young people in the United States. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Wissler RW. **Am J Med Sci** 1995 Dec;310 Suppl 1:S29–36 (22 ref.)
Development of the lipid-rich core in human atherosclerosis. Guyton JR, et al. **Arterioscler Thromb Vasc Biol** 1996 Jan; 16(1):4–11 (104 ref.)
Induction of tissue inhibitor of metalloproteinase and its mitogenic response to endothelial cells in human atherosclerotic and restenotic lesions. Tyagi SC, et al. **Can J Cardiol** 1996 Apr;12(4):353–62 (42 ref.)
Pathophysiology and inflammatory aspects of plaque rupture. Schroeder AP, et al. **Cardiol Clin** 1996 May;14(2):211–20 (94 ref.)
The pathogenesis of atherosclerosis. Hegele RA. **Clin Chim Acta** 1996 Mar 15;246(1–2):21–38 (19 ref.)
Diabetic macroangiopathy and atherosclerosis. Andresen JL, et al. **Diabetes** 1996 Jul;45 Suppl 3:S91–4 (39 ref.)
Sick vessel syndrome: vascular changes in hypertension and atherosclerosis. Heistad DD, et al. **J Hum Hypertens** 1995 Jun;9(6):449–53 (38 ref.)
Environmental and genetic risk factors in early human atherogenesis: lessons from the PDAY study. Pathobiological Determinants of Atherosclerosis in Youth. Strong JP, et al. **Pathol Int** 1995 Jun;45(6):403–8 (30 ref.)
LDL-platelet interaction under oxidative stress induces macrophage foam cell formation. Aviram M. **Thromb Haemost** 1995 Jul;74(1):560–4 (41 ref.)
Assessment of factors important in atherosclerotic occlusion and restenosis. Schwartz SM, et al. **Thromb Haemost** 1995 Jul;74(1):541–51 (114 ref.)
Atherosclerotic lesions in humans—plaque stabilization and regression. Kritz H, et al. **Wien Klin Wochenschr** 1995; 107(18):555–66 (60 ref.)
[Retrospect and prospect of cardiovascular pathology] Wang T, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1995 Aug; 24(4):210–3 (25 ref.) **(Chi)**
[Biology of the endothelial cell and atherogenesis] Demuth K, et al. **Ann Biol Clin (Paris)** 1995;53(4):171–91 (211 ref.) (Eng. Abstr.) **(Fre)**
[Calcified proliferation of the descending thoracic aorta] Fadel E, et al. **Arch Mal Coeur Vaiss** 1995 Jul;88(7):1039–42 (10 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Insulin resistance syndrome and atherosclerotic cardiovascular disease. Scheen AJ. **Acta Clin Belg** 1996; 51(2):65–9 (44 ref.)
The vascular biology of nitric oxide and its role in atherogenesis. Lloyd-Jones DM, et al. **Annu Rev Med** 1996; 47:365–75 (52 ref.)
Lipoproteins and the progression/regression of atherosclerosis. Barth JD. **Baillieres Clin Endocrinol Metab** 1995 Oct;9(4):849–66 (74 ref.)
Pathophysiology and inflammatory aspects of plaque rupture. Schroeder AP, et al. **Cardiol Clin** 1996 May;14(2):211–20 (94 ref.)
The atherogenic potential of endothelin. Hasdai D, et al. **Coron Artery Dis** 1995 Nov;6(11):901–4 (60 ref.)
Early atherogenesis in diabetes mellitus. Schaper NC. **Diabet Med** 1996;13 Suppl 1:S23–5 (30 ref.)
Effect of royal jelly on serum lipids in experimental animals and humans with atherosclerosis. Vittek J. **Experientia** 1995 Sep 29;51(9–10):927–35 (68 ref.)
Cytokines regulate vascular functions related to stability of the atherosclerotic plaque. Libby P, et al. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S9–12 (23 ref.)
Sick vessel syndrome: vascular changes in hypertension and atherosclerosis. Heistad DD, et al. **J Hum Hypertens** 1995 Jun;9(6):449–53 (38 ref.)
Endothelium, fibrinolysis, cardiac risk factors, and prostaglandins: a unified model of atherogenesis. Kadish J. **Med Hypotheses** 1995 Aug;45(2):205–13 (106 ref.)
Up-regulation of intracellular signalling pathways may play a central pathogenic role in hypertension, atherogenesis, insulin resistance, and cancer promotion—the 'PKC syndrome'. McCarty MF. **Med Hypotheses** 1996 Mar; 46(3):191–221 (402 ref.)
Carbamylation of proteins and atherogenesis in renal failure. Roxborough HE, et al. **Med Hypotheses** 1995 Aug; 45(2):125–8 (28 ref.)
Role of atherogenic lipoproteins in cytokine-mediated renovascular injury. Kirschenbaum MA, et al. **Miner Electrolyte Metab** 1996;22(1–3):47–50 (20 ref.)
Homocysteine and vascular disease. McCully KS. **Nat Med** 1996 Apr;2(4):386–9 (20 ref.)
Effects of oxidized low-density lipoprotein on vascular contraction and relaxation: clinical and pharmacological implications in atherosclerosis. Cox DA, et al. **Pharmacol Rev** 1996 Mar;48(1):3–19 (182 ref.)
Role of nitric oxide in progression and regression of atherosclerosis. Cooke JP. **West J Med** 1996 May; 164(5):419–24 (52 ref.)
[New findings on the pathogenesis of atherosclerosis] Fialová L. **Cesk Fysiol** 1995 Jun;44(2):92–101 (17 ref.) (Eng. Abstr.) **(Cze)**
[Atherosclerotic disease of the aorta: a source of thromboembolism] Gur H, et al. **Harefuah** 1996 Mar 1; 130(5):339–43 (34 ref.) **(Heb)**
[Non-inflammatory arteriopathies] Alvarez-Sabín J. **Rev Neurol** 1995;23 Suppl 1:S33–40 (52 ref.) **(Spa)**

PREVENTION & CONTROL

Atherosclerosis and cholesterol. The end of the controversy? [editorial] Heller FR. **Acta Clin Belg** 1996;51(1):1–7 (50 ref.)
Is reverse cholesterol transport a misnomer for suggesting its role in the prevention of atheroma formation? Quintão EC. **Atherosclerosis** 1995 Jul;116(1):1–14 (162 ref.)
Antiatherosclerotic effects of antihypertensive drugs: recent evidence and ongoing trials. Zanchetti A. **Clin Exp Hypertens** 1996 Apr–May;18(3–4):489–99 (12 ref.)
Diet in the prevention and treatment of atherosclerosis. A perspective for the elderly. Srinath U, et al. **Clin Geriatr Med** 1995 Nov;11(4):591–611 (46 ref.)
New approaches to the prevention of atherosclerosis. Naito M, et al. **Drugs** 1995 Sep;50(3):440–53 (154 ref.)
Cardiovascular disease in women: implications of hormone replacement therapy. Sarrel PM. **Int J Fertil Menopausal Stud** 1996 Mar–Apr;41(2):90–3 (20 ref.)
Prevention of atherosclerosis with dietary antioxidants: fact or fiction? Duell PB. **J Nutr** 1996 Apr;126(4 Suppl):1067S–71S (38 ref.)
Anticholesterol antibodies and plaque formation. Ordovas JM. **Nutr Rev** 1996 Apr;54(4 Pt 1):124–7 (28 ref.)
New targets for lipid lowering and atherosclerosis prevention. Sirtori CR. **Pharmacol Ther** 1995;67(3):433–47 (108 ref.)
Natural antioxidants for the prevention of atherosclerosis. Odeh RM, et al. **Pharmacotherapy** 1995 Sep–Oct; 15(5):648–59 (105 ref.)
[1995 consensus guidelines for cholesterol. Society of Physicians in Vienna] Sinzinger H, et al. **Wien Klin Wochenschr** 1995;107(18):537–9 (5 ref.) **(Ger)**
[Nutrition-related prevention studies in children and adolescents on a population level—concepts, methods, outcome] Kersting M, et al. **Z Arztl Fortbild (Jena)** 1996 Feb;90(1):25–31 (34 ref.) (Eng. Abstr.) **(Ger)**
[Prevention of coronary disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension] Pyörälä K, et al. **Cardiologia** 1996 Feb;41(2):149–82 (192 ref.) **(Ita)**
[Sex hormones, glycolipid metabolism, and atherogenesis] Sarubbi B, et al. **Minerva Med** 1995 Jun;86(6):265–73 (67 ref.) (Eng. Abstr.) **(Ita)**

REHABILITATION

Exercise rehabilitation for patients with peripheral arterial disease. Regensteiner JG, et al. **Exerc Sport Sci Rev** 1995;

ATHEROSCLEROSIS

23:1-24 (95 ref.)

SURGERY

[Preservation of renal function by revascularization in renovascular disease] Halimi JM, et al. **J Mal Vasc** 1995; 20(4):241-6 (55 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

The next generation extracorporeal method for the management of atherosclerosis [editorial] Matsuda Y, et al. **Artif Organs** 1995 Sep;19(9):877-9 (22 ref.)

Prevention of late lumen loss after coronary angioplasty by photodynamic therapy: role of activated neutrophils. Sluiter W, et al. **Mol Cell Biochem** 1996 Apr 12-26; 157(1-2):233-8 (44 ref.)

Molecular therapies for vascular diseases. Gibbons GH, et al. **Science** 1996 May 3;272(5262):689-93 (32 ref.)

Options for therapy of ischemic nephropathy: role of angioplasty and surgery. Novick AC. **Semin Nephrol** 1996 Jan;16(1):53-60 (61 ref.)

Gene therapy: prospects for treatment of liver disease. Sandig V, et al. **Z Gastroenterol** 1996 Jun;34 Suppl 3:25-6 (32 ref.)

[Angiology update] Ranke C, et al. **Med Klin** 1996 Apr 1; 91 Suppl 1:140-52 (129 ref.) **(Ger)**

ULTRASONOGRAPHY

Intravascular ultrasound imaging of peripheral arteries as an adjunct to balloon angioplasty and atherectomy. Korogi Y, et al. **Cardiovasc Intervent Radiol** 1996 Jan-Feb;19(1):1-9 (39 ref.)

[Intravascular echography: a new approach to the pathophysiologic assessment of atherosclerotic lesions] Marsico F. **G Ital Cardiol** 1995 Dec;25(12):1649-51 (16 ref.) **(Ita)**

[Importance of ischemic heart disease in patients with carotid arteriosclerosis and lower extremity arteriopathy. Results of a prospective study] Racco F, et al. **Minerva Cardioangiol** 1995 Sep;43(9):345-54 (32 ref.) (Eng. Abstr.) **(Ita)**

VIROLOGY

Cytomegalovirus and atherosclerosis. Melnick JL, et al. **Bioessays** 1995 Oct;17(10):899-903 (28 ref.)

ATHEROSCLEROSIS, CORONARY see **CORONARY ARTERIOSCLEROSIS**

ATHETOSIS

DIAGNOSIS

[Chorea and athetosis in childhood] Fernández-Alvarez E. **Rev Neurol** 1995;23 Suppl 3:S330-3 (59 ref.) **(Spa)**

GENETICS

[Choreoacanthocytosis. A neurologic-hematologic syndrome] Hiersemenzel LP, et al. **Nervenarzt** 1996 Jun; 67(6):490-5 (39 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Paroxysmal choreoathetosis. Marsden CD. **Adv Neurol** 1996; 70:467-70 (19 ref.)

ATHIORHODACEAE see **RHODOSPIRILLACEAE**

ATHLETIC INJURIES

Sports injuries in young athletes. Bernhardt DT, et al. **Adv Pediatr** 1995;42:465-500 (77 ref.)

Gamekeeper's thumb: ulnar collateral ligament injury. Richard JR. **Am Fam Physician** 1996 Apr;53(5):1775-81 (12 ref.)

Periostitis of the upper extremity: a report of 2 cases and literature review. Meese MA, et al. **Clin Orthop** 1996 Mar; (324):222-6 (17 ref.)

Muscle-tendon injuries in young athletes. Best TM. **Clin Sports Med** 1995 Jul;14(3):669-86 (75 ref.)

Head and spine injuries in youth sports. Cantu RC. **Clin Sports Med** 1995 Jul;14(3):517-32 (31 ref.)

Back injuries in the young athlete. Gerbino PG 2nd, et al. **Clin Sports Med** 1995 Jul;14(3):571-90 (120 ref.)

Soft-tissue injuries of the wrist. Halikis MN, et al. **Clin Sports Med** 1996 Apr;15(2):235-59 (64 ref.)

Upper extremity injuries in young athletes. Ireland ML, et al. **Clin Sports Med** 1995 Jul;14(3):533-69 (101 ref.)

Shoulder instability in the overhand or throwing athlete. Kvitne RS, et al. **Clin Sports Med** 1995 Oct;14(4):917-35 (25 ref.)

Sports injuries in children and adolescents. Questions and controversies. Micheli LJ. **Clin Sports Med** 1995 Jul; 14(3):727-45 (43 ref.)

Injuries about the hip and pelvis in the young athlete. Paletta GA Jr, et al. **Clin Sports Med** 1995 Jul;14(3):591-628 (224 ref.)

Knee injuries in young athletes. Smith AD, et al. **Clin Sports Med** 1995 Jul;14(3):629-50 (76 ref.)

Lower leg, foot, and ankle injuries in young athletes. Stanish WD. **Clin Sports Med** 1995 Jul;14(3):651-68 (71 ref.)

Is sport good for us? A personal view on sporting injuries and how to manage them. McGregor JC. **J R Coll Surg Edinb** 1995 Dec;40(6):359-62 (20 ref.)

Lower leg overuse injuries in athletes. Järvinen M. **Knee Surg Sports Traumatol Arthrosc** 1993;1(2):126-30 (33 ref.)

Common injuries in runners. Diagnosis, rehabilitation and prevention. Fredericson M. **Sports Med** 1996 Jan; 21(1):49-72 (137 ref.)

Aging, physical activity and sports injuries. An overview of common sports injuries in the elderly. Kallinen M, et al. **Sports Med** 1995 Jul;20(1):41-52 (76 ref.)

Diagnosis and treatment of common knee injuries in athletes. Honari DB, et al. **Wis Med J** 1996 Jun;95(6):361-6 (20 ref.)

[Athletic injuries] König H. **Schweiz Rundsch Med Prax** 1995 Aug 29;84(35):928-32 (49 ref.) (Eng. Abstr.) **(Ger)**

COMPLICATIONS

Axillary neuropathy in volleyball players: report of two cases and literature review. Paladini D, et al. **J Neurol Neurosurg Psychiatry** 1996 Mar;60(3):345-7 (14 ref.)

[Lesions of the growth plate caused by sports stress] Segesser B, et al. **Orthopade** 1995 Sep;24(5):446-56 (60 ref.) (Eng. Abstr.) **(Ger)**

DIAGNOSIS

Arthroscopy of the elbow. Baker CL, et al. **Clin Sports Med** 1996 Apr;15(2):261-81 (32 ref.)

The immature athlete. Common injuries and overuse syndromes of the elbow and wrist. Gill TJ 4th, et al. **Clin Sports Med** 1996 Apr;15(2):401-23 (49 ref.)

Bony injuries of the wrist, forearm, and elbow. Griggs SM, et al. **Clin Sports Med** 1996 Apr;15(2):373-400 (114 ref.)

Compressive neuropathies and tendinopathies in the athletic elbow and wrist. Plancher KD, et al. **Clin Sports Med** 1996 Apr;15(2):331-71 (142 ref.)

Medial and lateral epicondylitis in the athlete. Plancher KD, et al. **Clin Sports Med** 1996 Apr;15(2):283-305 (52 ref.)

The role of arthroscopy in athletic injuries of the wrist. Savoie FH 3rd, et al. **Clin Sports Med** 1996 Apr; 15(2):219-33 (12 ref.)

Unusual problems of the athlete's elbow, forearm, and wrist. Shaffer B, et al. **Clin Sports Med** 1996 Apr;15(2):425-38 (11 ref.)

The neuropsychiatric aspects of boxing. Mendez MF. **Int J Psychiatry Med** 1995;25(3):249-62 (74 ref.)

[Shoulder problems in leisure athletes: physical examination, diagnosis and therapy. Sensible procedures in daily practice] Vaeckenstedt J, et al. **Schweiz Med Wochenschr** 1996 Mar 16;126(11):447-56 (21 ref.) (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

Athletic knee injuries. Similarities and differences between Asian and Western experience. Maffulli N, et al. **Clin Orthop** 1996 Feb;(323):98-105 (90 ref.)

ETIOLOGY

Elbow injuries to the throwing athlete. Johnston J, et al. **Clin Sports Med** 1996 Apr;15(2):307-29 (33 ref.)

Sports-specific injuries. Plancher KD, et al. **Clin Sports Med** 1996 Apr;15(2):207-18 (16 ref.)

NURSING

The diagnosis and management of plantar fasciitis. Quaschnick MS. **Nurse Pract** 1996 Apr;21(4):50-4, 60-3, quiz 64-5 (33 ref.)

PHYSIOPATHOLOGY

Overuse injuries in the young athlete. Outerbridge AR, et al. **Clin Sports Med** 1995 Jul;14(3):503-16 (38 ref.)

[Stress fractures in athletes and military recruits. An overview] Orava S, et al. **Orthopade** 1995 Sep;24(5):457-66 (51 ref.) (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

The primary care physician as a sports medicine and exercise advocate and activist. Rouzier PA. **Prim Care** 1995 Dec; 22(4):785-804 (43 ref.)

Use of knee braces in sport. Current recommendations [editorial] Albright JP, et al. **Sports Med** 1995 Nov; 20(5):281-301 (49 ref.)

REHABILITATION

Silicone rubber splinting for athletic hand and wrist injuries. Canelón MF. **J Hand Ther** 1995 Oct-Dec;8(4):252-7 (43 ref.)

Anterior cruciate ligament injuries in young athletes. Recommendations for treatment and rehabilitation. McCarroll JR, et al. **Sports Med** 1995 Aug;20(2):117-27 (32 ref.)

Rehabilitation following arthroscopic meniscectomy. St-Pierre DM. **Sports Med** 1995 Nov;20(5):338-47 (147 ref.)

SURGERY

[Critical considerations in arthroscopic stabilization of the unstable shoulder joint] Jerosch J. **Sportverletz Sportschaden** 1996 Mar;10(1):1-12 (93 ref.) (Eng. Abstr.) **(Ger)**

[Tendon injuries/diseases of the shoulder joint] Resch H. **Sportverletz Sportschaden** 1996 Mar;10(1):A1-10 (0 ref.) **(Ger)**

[Acute isolated ventral dislocation of the head of the fibula] Kohler G, et al. **Unfallchirurg** 1996 Mar;99(3):221-2 (10 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Management of back pain in athletes. Dreisinger TE, et al. **Sports Med** 1996 Apr;21(4):313-20 (32 ref.)

Anterior cruciate ligament injuries in young athletes. Recommendations for treatment and rehabilitation. McCarroll JR, et al. **Sports Med** 1995 Aug;20(2):117-27 (32 ref.)

ATHLETICS see **SPORTS**

ATLANTO-AXIAL JOINT

Atlanto-axial subluxation and cervical osteomyelitis: two unusual complications of adenoidectomy. Baker LL, et al. **Ann Otol Rhinol Laryngol** 1996 Apr;105(4):295-9 (12 ref.)

Upper cervical instability: fact or fiction? Swinkels RA, et al. **J Manipulative Physiol Ther** 1996 Mar-Apr;19(3):185-94 (93 ref.)

[Progress in the study on occipitocervical biomechanics] Lu Y, et al. **Chung Hua Wai Ko Tsa Chih** 1995 Mar; 33(3):158-60 (23 ref.) **(Chi)**

ABNORMALITIES

Craniovertebral junction anomalies in inherited disorders: part of the syndrome or caused by the disorder? Crockard HA, et al. **Eur J Pediatr** 1995 Jul;154(7):504-12 (48 ref.)

INJURIES

Traumatic atlantoaxial rotatory subluxation and dislocation. Moore KR, et al. **Spine** 1995 Sep 1;20(17):1928-30 (10 ref.)

PHYSIOLOGY

Craniocervical junction as a focus for craniofacial growth studies. Huggare J. **Acta Odontol Scand** 1995 Jun; 53(3):186-91 (36 ref.)

SURGERY

Occipitocervical fusion by Luque loop rod instrumentation in Down syndrome. Higo M, et al. **J Pediatr Orthop** 1995 Jul-Aug;15(4):539-42 (17 ref.)

Instrumentational posterior fusion for atlanto-axial subluxation in a young child with Down's syndrome--case report. Kohno M, et al. **Neurol Med Chir (Tokyo)** 1995 Oct;35(10):753-8 (22 ref.)

ATLANTO-OCCIPITAL JOINT

[Progress in the study on occipitocervical biomechanics] Lu Y, et al. **Chung Hua Wai Ko Tsa Chih** 1995 Mar; 33(3):158-60 (23 ref.) **(Chi)**

INJURIES

Traumatic atlantooccipital dislocation with survival: case report and review of the literature. Guigui P, et al. **Eur Spine J** 1995;4(4):242-7 (36 ref.)

PHYSIOLOGY

Craniocervical junction as a focus for craniofacial growth studies. Huggare J. **Acta Odontol Scand** 1995 Jun; 53(3):186-91 (36 ref.)

ATLAS

INJURIES

[Pseudarthrosis of the atlas after Jefferson's fracture] Wichmann HU, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1995 Nov;163(5):452-3 (11 ref.) **(Ger)**

PHYSIOLOGY

Craniocervical junction as a focus for craniofacial growth studies. Huggare J. **Acta Odontol Scand** 1995 Jun; 53(3):186-91 (36 ref.)

RADIOGRAPHY

[Pseudarthrosis of the atlas after Jefferson's fracture] Wichmann HU, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1995 Nov;163(5):452-3 (11 ref.) **(Ger)**

ATLOIDO-OCCIPITAL JOINT see **ATLANTO-OCCIPITAL JOINT**

ATLV see **HTLV-I**

ATLV-ASSOCIATED LEUKEMIA-LYMPHOMA see **LEUKEMIA-LYMPHOMA, T-CELL, ACUTE, HTLV-I-ASSOCIATED**

ATMOSPHERE

Ozone depletion update. Coldiron BM. **Dermatol Surg** 1996 Mar;22(3):296–9 (11 ref.)

ATMOSPHERIC PRESSURE

see related
ALTITUDE
ANOXIA
BAROTRAUMA
DECOMPRESSION SICKNESS
HYPERBARIC OXYGENATION

Effects of diving and hyperbaria on responses to exercise. Shiraki K, et al. **Exerc Sport Sci Rev** 1995;23:459–85 (76 ref.)

ATOMIC FORCE MICROSCOPY see **MICROSCOPY, ATOMIC FORCE**

ATOMIC MEDICINE see **NUCLEAR MEDICINE**

ATOMIC WARFARE see **NUCLEAR WARFARE**

ATOMIZERS see **NEBULIZERS AND VAPORIZERS**

ATOPIC HYPERSENSITIVITY see **HYPERSENSITIVITY, IMMEDIATE**

ATP see **ADENOSINE TRIPHOSPHATE**

ATP-BINDING CASSETTE TRANSPORTERS see **ABC TRANSPORTERS**

ATP CHOLINE TRANSPHOSPHATASE see **CHOLINE KINASE**

ATP-DIPHOSPHATASE see **APYRASE**

ATP RECEPTORS see **RECEPTORS, PURINERGIC P2**

ATPASE see **ADENOSINETRIPHOSPHATASE**

ATPASE, ACTOMYOSIN see **MYOSIN ATPASE**

ATPASE, CALCIUM see **CA(2+)-TRANSPORTING ATPASE**

ATPASE, DYNEIN see **DYNEIN ATPASE**

ATPASE, F0 see **H(+)-TRANSPORTING ATP SYNTHASE**

ATPASE, F1 see **H(+)-TRANSPORTING ATP SYNTHASE**

ATPASE, HYDROGEN, POTASSIUM see **H(+)-K(+)-EXCHANGING ATPASE**

ATPASE, MYOSIN see **MYOSIN ATPASE**

ATPASE, SODIUM, POTASSIUM see **NA(+)-K(+)-EXCHANGING ATPASE**

ATRAZINE

METABOLISM

Atrazine retention and transport in soils. Ma L, et al. **Rev Environ Contam Toxicol** 1996;145:129–73 (209 ref.)

POISONING

Epidemiology of atrazine. Loosli R. **Rev Environ Contam Toxicol** 1995;143:47–57 (31 ref.)

ATRESIA, BILIARY see **BILIARY ATRESIA**

ATRESIA, CHOANAL see **CHOANAL ATRESIA**

ATRESIA, ESOPHAGEAL see **ESOPHAGEAL ATRESIA**

ATRESIA, FOLLICULAR see **FOLLICULAR ATRESIA**

ATRESIA, INTESTINAL see **INTESTINAL ATRESIA**

ATRESIA, PULMONARY see **PULMONARY ATRESIA**

ATRIAL ECTOPIC BEATS see **ATRIAL PREMATURE COMPLEXES**

ATRIAL ECTOPIC TACHYCARDIA see **TACHYCARDIA, ECTOPIC ATRIAL**

ATRIAL FIBRILLATION

Paroxysmal atrial fibrillation. A common but neglected entity. Aboaf AP, et al. **Arch Intern Med** 1996 Feb 26; 156(4):362–7 (55 ref.)

ABC of atrial fibrillation. Aetiology, pathophysiology, and clinical features. Lip GY, et al. **BMJ** 1995 Nov 25; 311(7017):1425–8 (0 ref.)

ABC of atrial fibrillation. Investigation and non-drug management of atrial fibrillation. Lip GY, et al. **BMJ** 1995 Dec 9;311(7019):1562–5 (0 ref.)

ABC of atrial fibrillation. History, epidemiology, and importance of atrial fibrillation [see comments] [published erratum appears in BMJ 1996 Jan 6;312(7022):49] Lip GY, et al. **BMJ** 1995 Nov 18;311(7016):1361–3 (0 ref.) Comment in: BMJ 1996 Mar 9;312(7031):641–2.

ABC of atrial fibrillation. Atrial fibrillation in general and hospital practice [see comments] Lip GY, et al. **BMJ** 1996 Jan 20;312(7024):175–8 (5 ref.) Comment in: BMJ 1996 Apr 27;312(7028):1101.

Atrial fibrillation and atrial flutter. Cuddy TE, et al. **Can J Cardiol** 1996 Jan;12 Suppl A:9A–11A (20 ref.)

[Canadian Society of Cardiology Consensus Conference on Atrial Fibrillation. 1994, 1995] **Can J Cardiol** 1996 Feb;12 Suppl A:1A–62A (0 ref.) **(Fre)**

CLASSIFICATION

[Auricular fibrillation: future orientation] Kerr CR, et al. **Can J Cardiol** 1996 Feb;12 Suppl A:59A–62A (32 ref.) **(Fre)**

COMPLICATIONS

Atrial fibrillation, anticoagulation, and stroke. Morley J, et al. **Am J Cardiol** 1996 Jan 25;77(3):38A–44A (29 ref.)

Warfarin and aspirin as thromboprophylaxis in atrial fibrillation. Lip GY, et al. **Br J Clin Pharmacol** 1996 May; 41(5):369–79 (83 ref.)

Prognosis of individuals with atrial fibrillation. Laupacis A, et al. **Can J Cardiol** 1996 Jan;12 Suppl A:14A–16A (22 ref.)

Does atrial fibrillation confer a hypercoagulable state? Lip GY. **Lancet** 1995 Nov 18;346(8986):1313–4 (16 ref.)

Control of rapid heart rate in patients with atrial fibrillation: drugs or ablation? Brignole M, et al. **Pacing Clin Electrophysiol** 1996 Mar;19(3):348–56 (63 ref.)

Risk of thromboembolism in new onset or transient atrial fibrillation. Stoddard MF. **Prog Cardiovasc Dis** 1996 Jul-Aug;39(1):69–80 (67 ref.)

[Diagnosis and treatment of cerebrovascular accidents of cardioembolic origin] Ricou FJ, et al. **Schweiz Rundsch Med Prax** 1996 Feb 6;85(6):155–8 (25 ref.) (Eng. Abstr.) **(Fre)**

[Anticoagulation in patients with atrial fibrillation] Mügge A. **Herz** 1996 Feb;21(1):28–36 (60 ref.) (Eng. Abstr.) **(Ger)**

DIAGNOSIS

ABC of atrial fibrillation. Differential diagnosis of atrial fibrillation. Lip GY, et al. **BMJ** 1995 Dec 2; 311(7018):1495–8 (0 ref.)

Investigation of the patient with atrial fibrillation. Gillis AM, et al. **Can J Cardiol** 1996 Jan;12 Suppl A:12A–13A (27 ref.)

[Study of auricular fibrillation] Gillis AM, et al. **Can J Cardiol** 1996 Feb;12 Suppl A:9A–11A (27 ref.) **(Fre)**

DRUG THERAPY

Maintaining sinus rhythm with antifibrillatory drugs in atrial fibrillation. Antman EM. **Am J Cardiol** 1996 Aug 29; 78(4A):67–72 (23 ref.)

Drug therapy for prevention of atrial fibrillation. Coumel P, et al. **Am J Cardiol** 1996 Jan 25;77(3):3A–9A (27 ref.)

ABC of atrial fibrillation. Antithrombotic treatment for atrial fibrillation. Lip GY, et al. **BMJ** 1996 Jan 6;312(7022):45–9 (0 ref.)

ABC of atrial fibrillation. Drugs for atrial fibrillation [see comments] Lip GY, et al. **BMJ** 1995 Dec 16; 311(7020):1631–4 (4 ref.) Comment in: BMJ 1996 Apr 6;312(7035):911–2. Comment in: BMJ 1996 Apr 6;312(7035):912.

Antithrombotic therapy in atrial fibrillation. Turpie AG, et al. **Can Fam Physician** 1996 Jul;42:1341–5 (16 ref.)

Antithrombotic therapy in atrial fibrillation. Connolly SJ, et al. **Can J Cardiol** 1996 Jan;12 Suppl A:17A–20A (13 ref.)

Heart rate control in patients with atrial fibrillation. Gardner MJ, et al. **Can J Cardiol** 1996 Jan;12 Suppl A:21A–23A (26 ref.)

Chronic drug therapy to prevent recurrence of atrial fibrillation. Newman D, et al. **Can J Cardiol** 1996 Jan;12 Suppl A:24A–28A (43 ref.)

Antithrombotic therapy in atrial fibrillation. Laupacis A, et al. **Chest** 1995 Oct;108(4 Suppl):352S–359S (52 ref.)

The antiarrhythmic treatment of atrial fibrillation. **Drug Ther Bull** 1996 Jun;34(6):41–5 (34 ref.)

Atrial fibrillation: steering a management course between thromboembolism and proarrhythmic risk. Campbell RW. **Eur Heart J** 1995 Aug;16 Suppl G:28–31 (56 ref.)

Anticoagulation: risks and benefits in atrial fibrillation. Fiore LD. **Geriatrics** 1996 Jun;51(6):22–4, 27–8, 31 (37 ref.)

The risks and benefits of antithrombotic therapy in chronic atrial fibrillation. Hankey GJ, et al. **Med J Aust** 1996 May 20;164(10):624–6 (16 ref.)

Current recommendations for the anticoagulation of patients with atrial fibrillation. Orsinelli DA. **Prog Cardiovasc Dis** 1996 Jul-Aug;39(1):1–20 (52 ref.)

Antithrombotic therapy in atrial fibrillation: a review of randomized trials with special reference to the Stroke Prevention in Atrial Fibrillation II (SPAF II) Trial. Shivkumar K, et al. **Prog Cardiovasc Dis** 1996 Jan-Feb; 38(4):337–42 (25 ref.)

The role of coumadin and aspirin in atrial fibrillation. Hutter AM Jr. **Trans Am Clin Climatol Assoc** 1995;107:79–85; discussion 85–6 (17 ref.)

Atrial fibrillation pearls and perils of management. Kudenchuk PJ. **West J Med** 1996 May;164(5):425–34 (109 ref.)

[The treatment of atrial fibrillation] Halinen MO. **Duodecim** 1995;111(8):705–13 (29 ref.) **(Fin)**

[Antithrombotic treatment of atrial fibrillation] Connelly SJ, et al. **Can J Cardiol** 1996 Feb;12 Suppl A:14A–18A (13 ref.) **(Fre)**

[Long term drug therapy for the prevention of recurrence in atrial fibrillation] Newman D, et al. **Can J Cardiol** 1996 Feb;12 Suppl A:21A–26A (43 ref.) **(Fre)**

[Restoration of the sinus rhythm in atrial fibrillation] Talajic M, et al. **Can J Cardiol** 1996 Feb;12 Suppl A:27A–34A (83 ref.) **(Fre)**

[Digitalis in atrial fibrillation. Still relevant treatment or an old-fashioned therapy?] Gjesdal K. **Tidsskr Nor Laegeforen** 1996 Mar 20;116(8):973–5 (39 ref.) (Eng. Abstr.) **(Nor)**

[Auricular fibrillation. Antiarrhythmic treatment revisited] Elvas L, et al. **Acta Med Port** 1995 Mar;8(3):173–9 (55 ref.) (Eng. Abstr.) **(Por)**

[Atrial fibrillation due to non-valvular causes: indications for antithrombotic therapy] Codinach Huix P. **Med Clin (Barc)** 1996 Apr 20;106(15):586–9 (25 ref.) **(Spa)**

[Non-rheumatic atrial fibrillation and antithrombotic treatment: current status] Gayán Laviña R, et al. **Rev Clin Esp** 1995 Aug;195(8):559–64 (28 ref.) **(Spa)**

ETIOLOGY

Persistent atrial mechanical dysfunction after spontaneous conversion of chronic atrial fibrillation to sinus rhythm. Kahn ZU, et al. **Am Heart J** 1996 Mar;131(3):606–8 (14 ref.)

Atrial fibrillation and flutter in children and in young adults with congenital heart disease. Gow RM. **Can J Cardiol** 1996 Jan;12 Suppl A:45A–48A (40 ref.)

Atrial fibrillation following cardiac surgery. Pagé PL, et al. **Can J Cardiol** 1996 Jan;12 Suppl A:40A–44A (45 ref.)

Mechanoelectric feedback and atrial arrhythmias. Nazir SA, et al. **Cardiovasc Res** 1996 Jul;32(1):52–61 (92 ref.)

[Atrial fibrillation and flutter in children and young adults with congenital cardiopathies] Gow RM. **Can J Cardiol** 1996 Feb;12 Suppl A:43A–48A (40 ref.) **(Fre)**

[Post-heart surgery auricular fibrillation] Pagé PL, et al. **Can J Cardiol** 1996 Feb;12 Suppl A:38A–43A (45 ref.) **(Fre)**

[Atrial fibrillation due to non-valvular causes: indications for antithrombotic therapy] Codinach Huix P. **Med Clin (Barc)** 1996 Apr 20;106(15):586–9 (25 ref.) **(Spa)**

MORTALITY

[Prognosis of auricular fibrillation] Laupacis A, et al. **Can J Cardiol** 1996 Feb;12 Suppl A:11A–13A (22 ref.) **(Fre)**

PHYSIOPATHOLOGY

Electrophysiologic characteristics of human atrial muscle in paroxysmal atrial fibrillation. Hashiba K, et al. **Am Heart J** 1996 Apr;131(4):778–89 (77 ref.)

Electrophysiologic mechanisms of perpetuation of atrial fibrillation. Allessie MA, et al. **Am J Cardiol** 1996 Jan 25; 77(3):10A–23A (56 ref.)

Atrial fibrillation: restoration and maintenance of sinus rhythm and indications for anticoagulation therapy. Golzari H, et al. **Ann Intern Med** 1996 Aug 15;125(4):311–23 (205 ref.)

Atrial fibrillation--new aspects on mechanism and treatment. Olsson SB. **J Intern Med** 1996 Jan;239(1):3–15 (43 ref.)

[Control of heart rate and atrial fibrillation] Gardner MJ, et al. **Can J Cardiol** 1996 Feb;12 Suppl A:18A–21A (26 ref.) **(Fre)**

[Mechanisms of atrial fibrillation. Recent progress and therapeutic implications] Le Heuzey JY, et al. **Presse Med** 1996 Apr 6;25(12):590–4 (25 ref.) (Eng. Abstr.) **(Fre)**

[Non-valvular atrial fibrillation and cerebral infarction] Martín R. **Rev Neurol** 1995 Mar-Apr;23(120):370–6 (81 ref.) (Eng. Abstr.) **(Spa)**

PREVENTION & CONTROL

Drug therapy for prevention of atrial fibrillation. Coumel P, et al. **Am J Cardiol** 1996 Jan 25;77(3):3A–9A (27 ref.)

SURGERY

Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation [see comments] Blackshear JL, et al. **Ann Thorac Surg** 1996 Feb;61(2):755–9 (59 ref.) Comment in: Ann Thorac Surg 1996 Feb;61(2):515.

THERAPY

Newer developments in the management of atrial fibrillation.

ATRIAL FIBRILLATION

Nattel S. **Am Heart J** 1995 Nov;130(5):1094–106 (169 ref.)
Nonpharmacologic strategies for treating atrial fibrillation. Lüderitz B, et al. **Am J Cardiol** 1996 Jan 25;77(3):45A–52A (53 ref.)
Atrial fibrillation: maintenance of sinus rhythm versus rate control. Sopher SM, et al. **Am J Cardiol** 1996 Jan 25; 77(3):24A–37A (128 ref.)
Atrial fibrillation: restoration and maintenance of sinus rhythm and indications for anticoagulation therapy. Golzari H, et al. **Ann Intern Med** 1996 Aug 15;125(4):311–23 (205 ref.)
ABC of atrial fibrillation. Cardioversion of atrial fibrillation [see comments] Lip GY, et al. **BMJ** 1996 Jan 13; 312(7023):112–5 (0 ref.) Comment in: BMJ 1996 May 18;312(7041):1300.
The implantable cardiac defibrillator. Kamalvand K, et al. **Br J Hosp Med** 1996 Jan 17–Feb 6;55(1–2):37–41 (16 ref.)
Atrial fibrillation and flutter in children and in young adults with congenital heart disease. Gow RM. **Can J Cardiol** 1996 Jan;12 Suppl A:45A–48A (40 ref.)
Pacing and atrial fibrillation. Kerr CR, et al. **Can J Cardiol** 1996 Jan;12 Suppl A:36A–39A (31 ref.)
Atrial fibrillation—future directions. Kerr CR, et al. **Can J Cardiol** 1996 Jan;12 Suppl A:58A–61A (30 ref.)
Nonpharmacological therapy of atrial fibrillation. Klein GJ, et al. **Can J Cardiol** 1996 Jan;12 Suppl A:49A–50A (18 ref.)
Restoration of sinus rhythm in patients with atrial fibrillation. Talajic M, et al. **Can J Cardiol** 1996 Jan;12 Suppl A:29A–35A (83 ref.)
Management of patients with atrial fibrillation. A Statement for Healthcare Professionals. From the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association. Prystowsky EN, et al. **Circulation** 1996 Mar 15;93(6):1262–77 (155 ref.)
Future prospects of antiarrhythmic treatment based on experimental studies. Janse MJ. **Eur Heart J** 1995 Aug;16 Suppl G:2–6 (44 ref.)
Atrial fibrillation and flutter: maintaining stability of sinus rhythm versus ventricular rate control. Antman EM. **J Cardiovasc Electrophysiol** 1995 Oct;6(10 Pt 2):962–71 (75 ref.)
Nonpharmacologic approaches to the treatment of atrial fibrillation and atrial flutter. Baker BM, et al. **J Cardiovasc Electrophysiol** 1995 Oct;6(10 Pt 2):972–8 (66 ref.)
Implantable atrial defibrillators [see comments] Hillsley RE, et al. **J Cardiovasc Electrophysiol** 1995 Aug;6(8):634–48 (107 ref.) Comment in: J Cardiovasc Electrophysiol 1995 Aug;6(8):649–51.
The causes and management of atrial fibrillation. Rudd JH, et al. **J Clin Pharm Ther** 1996 Feb;21(1):37–43 (34 ref.)
Atrial fibrillation—new aspects on mechanism and treatment. Olsson SB. **J Intern Med** 1996 Jan;239(1):3–15 (43 ref.)
Management of atrial fibrillation in adults: prevention of thromboembolism and symptomatic treatment. Blackshear JL, et al. **Mayo Clin Proc** 1996 Feb;71(2):150–60 (65 ref.)
Cardioversion of atrial fibrillation. Lip GY. **Postgrad Med J** 1995 Aug;71(838):457–65 (68 ref.)
Transesophageal echocardiography-guided approach to cardioversion of atrial fibrillation. Leung DY, et al. **Prog Cardiovasc Dis** 1996 Jul–Aug;39(1):21–32 (67 ref.)
Atrial anatomy and function postcardioversion: insights from transthoracic and transesophageal echocardiography. Manning WJ, et al. **Prog Cardiovasc Dis** 1996 Jul–Aug; 39(1):33–46 (60 ref.)
[The treatment of chronic atrial fibrillation] Gosselink AT. **Tijdschr Gerontol Geriatr** 1995 Dec;26(6):259–63 (20 ref.) (Eng. Abstr.) **(Dut)**
[Non-pharmacological treatment of atrial fibrillation] Kirkorian G. **Arch Mal Coeur Vaiss** 1995 Dec;88 Spec No 5:49–54 (22 ref.) (Eng. Abstr.) **(Fre)**
[Cardiac stimulation and atrial fibrillation] Kerr CR, et al. **Can J Cardiol** 1996 Feb;12 Suppl A:34A–37A (31 ref.) **(Fre)**
[Reduction of atrial fibrillation. New concepts, new strategies] Lardoux H, et al. **Presse Med** 1995 Dec 9; 24(38):1820–3 (33 ref.) (Eng. Abstr.) **(Fre)**
[When, why, and how to treat atrial fibrillation] Thumala A. **Rev Med Chil** 1995 Jan;123(1):90–7 (44 ref.) (Eng. Abstr.) **(Spa)**

ATRIAL FLUTTER

Atrial fibrillation and atrial flutter. Cuddy TE, et al. **Can J Cardiol** 1996 Jan;12 Suppl A:9A–11A (20 ref.)

ETIOLOGY

Atrial fibrillation and flutter in children and in young adults with congenital heart disease. Gow RM. **Can J Cardiol** 1996 Jan;12 Suppl A:45A–48A (40 ref.)
[Atrial fibrillation and flutter in children and young adults with congenital cardiopathies] Gow RM. **Can J Cardiol** 1996 Feb;12 Suppl A:43A–48A (40 ref.) **(Fre)**

PHYSIOPATHOLOGY

Atrial flutter mapping and ablation. I. Studying atrial flutter mechanisms by mapping and entrainment. Cosio FG, et al. **Pacing Clin Electrophysiol** 1996 May;19(5):841–53 (39 ref.)

SURGERY

Results of radiofrequency catheter ablation for atrial flutter. Saxon LA, et al. **Am J Cardiol** 1996 May 1;77(11):1014–6 (18 ref.)
[Auricular flutter associated with an interatrial septal aneurysm submitted to radiofrequency ablation] Araya Gómez V, et al. **Arch Inst Cardiol Mex** 1995 May–Jun; 65(3):245–54 (17 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

Atrial fibrillation and flutter in children and in young adults with congenital heart disease. Gow RM. **Can J Cardiol** 1996 Jan;12 Suppl A:45A–48A (40 ref.)
Atrial fibrillation and flutter: maintaining stability of sinus rhythm versus ventricular rate control. Antman EM. **J Cardiovasc Electrophysiol** 1995 Oct;6(10 Pt 2):962–71 (75 ref.)
Nonpharmacologic approaches to the treatment of atrial fibrillation and atrial flutter. Baker BM, et al. **J Cardiovasc Electrophysiol** 1995 Oct;6(10 Pt 2):972–8 (66 ref.)
New approaches to treatment of atrial flutter and tachycardia. Lesh MD, et al. **J Cardiovasc Electrophysiol** 1996 Apr;7(4):368–81 (72 ref.)

ATRIAL FUNCTION, LEFT

[Recent morphofunctional findings on the left atrium: their relations to thromboembolic risk] Zeppellini R, et al. **G Ital Cardiol** 1995 Aug;25(8):1055–65 (57 ref.) (Eng. Abstr.) **(Ita)**

ATRIAL NATRIURETIC FACTOR

see related
RECEPTORS, ATRIAL NATRIURETIC FACTOR

[Histocytochemical and functional aspects on the "brain–vascular peptides"] Yamada H, et al. **Kaibogaku Zasshi** 1995 Oct;70(5):422–35 (108 ref.) (Eng. Abstr.) **(Jpn)**
[Atrial natriuretic factor] Tarverdieva GA. **Klin Med (Mosk)** 1996;74(1):12–4 (32 ref.) **(Rus)**

BLOOD

[Atrial natriuretic factor and brain natriuretic peptide. Variations in elderly subjects with heart failure] Tissandier O, et al. **Presse Med** 1995 Dec 9;24(38):1837–41 (27 ref.) (Eng. Abstr.) **(Fre)**
[Human atrial natriuretic peptide (hANP), human brain natriuretic peptide (hBNP)] Tsujino M, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:737–40 (8 ref.) **(Jpn)**

METABOLISM

'Til death do us part: a case of failed affection. Weber KT, et al. **Cardiovasc Res** 1995 Jul;30(1):26–30 (32 ref.)
Anterior hypothalamic norepinephrine, atrial natriuretic peptide, and hypertension. Oparil S, et al. **Front Neuroendocrinol** 1996 Apr;17(2):212–46 (122 ref.)
The nocturnal polyuria syndrome (NPS). Asplund R. **Gen Pharmacol** 1995 Oct;26(6):1203–9 (29 ref.)

PHYSIOLOGY

Cerebral salt wasting in children: the role of atrial natriuretic hormone. Kappy MS, et al. **Adv Pediatr** 1996;43:271–308 (104 ref.)
Phosphodiesterase activity as a mediator of renal resistance to ANP in pathological salt retention. Lee EY, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):F3–6 (27 ref.)
Atrial natriuretic peptide and body fluid homeostasis: leading actor or bit-part player? Richards AM, et al. **Cardiologia** 1995 Sep;40(9):643–50 (71 ref.)
The natriuretic peptides in hypertension. Januszewicz A. **Curr Opin Cardiol** 1995 Sep;10(5):495–500 (32 ref.)
Natriuretic peptides and hypertension. Prins BA, et al. **Curr Opin Nephrol Hypertens** 1996 Mar;5(2):170–3 (29 ref.)
Vasoactive peptides and uterine vessels. Stjernquist M, et al. **Gynecol Endocrinol** 1995 Jun;9(2):165–76 (77 ref.)
Brain natriuretic peptide in hypertension. Takeda T, et al. **Hypertens Res** 1995 Dec;18(4):259–66 (52 ref.)
Evaluation of the endocrine function of the heart in humans: proposal for an integrated approach for the assessment of production, secretion, distribution and degradation of atrial natriuretic factor and related peptides. Clerico A, et al. **Int J Clin Pharmacol Res** 1995;15(2):65–86 (73 ref.)
Defective ANF-R2/ANP-C receptor-mediated signalling in hypertension. Marcil J, et al. **Mol Cell Biochem** 1995 Aug–Sep;149–150:223–31 (92 ref.)
Natriuretic peptides and acute renal failure. Weinmann M. **New Horiz** 1995 Nov;3(4):624–33 (110 ref.)
[Etiological significance of humoral nerve factors in congestive heart failure] Kinoshita M, et al. **Nippon Naika Gakkai Zasshi** 1995 Sep 10;84(9):1454–8 (14 ref.) **(Jpn)**
[Natriuretic peptides and the homeostasis of renal circulation in cirrhosis (editorial)] Jiménez W. **Gastroenterol Hepatol** 1995 Nov;18(9):477–9 (20 ref.) **(Spa)**

THERAPEUTIC USE

Natriuretic peptides and acute renal failure. Weinmann M. **New Horiz** 1995 Nov;3(4):624–33 (110 ref.)

ATRIAL NATRIURETIC FACTOR RECEPTORS see **RECEPTORS, ATRIAL NATRIURETIC FACTOR**

ATRIAL NATRIURETIC PEPTIDES see **ATRIAL NATRIURETIC FACTOR**

ATRIAL NATRIURETIC PEPTIDES RECEPTORS see **RECEPTORS, ATRIAL NATRIURETIC FACTOR**

ATRIAL PREMATURE COMPLEXES

DIAGNOSIS

[Problems in the diagnosis and clinical assessment of atrial dissociation (a report on 2 cases and review of the literature)] Snezhitskii VA, et al. **Ter Arkh** 1995;67(9):73–5 (11 ref.) (Eng. Abstr.) **(Rus)**

ATRIAL SEPTAL DEFECTS see **HEART SEPTAL DEFECTS, ATRIAL**

ATRIOPEPTIN RECEPTORS see **RECEPTORS, ATRIAL NATRIURETIC FACTOR**

ATRIOPEPTINS see **ATRIAL NATRIURETIC FACTOR**

ATRIOVENTRICULAR BLOCK see **HEART BLOCK**

ATRIOVENTRICULAR BUNDLE see **BUNDLE OF HIS**

ATRIOVENTRICULAR NODAL REENTRY TACHYCARDIA see **TACHYCARDIA, ATRIOVENTRICULAR NODAL REENTRY**

ATRIOVENTRICULAR NODE

PATHOLOGY

Mahaim, Kent and abnormal atrioventricular conduction. Anderson RH, et al. **Cardiovasc Res** 1996 Apr;31(4):480–91 (44 ref.)

SURGERY

[Catheter ablation and modulation of the atrioventricular junction; current aspects] Robert F, et al. **Arch Mal Coeur Vaiss** 1996 Feb;89 Spec No 1:65–73 (50 ref.) (Eng. Abstr.) **(Fre)**

ATROCITIES see **VIOLENCE**

ATROPHY

GENETICS

[Striato-pallido-dentate calcifications and acquired facial atrophy] Derex L, et al. **Rev Neurol (Paris)** 1995 Oct; 151(10):559–62 (13 ref.) (Eng. Abstr.) **(Fre)**

ATTENDING PHYSICIANS, HOSPITAL see **MEDICAL STAFF, HOSPITAL**

ATTENTION

Auditory psychophysics and perception. Hirsh IJ, et al. **Annu Rev Psychol** 1996;47:461–84 (110 ref.)
The assessment of unwanted intrusive thoughts: a review and critique of the literature. Clark DA, et al. **Behav Res Ther** 1995 Nov;33(8):967–76 (60 ref.)
Perils and pitfalls on the path to normal potential: the role of impaired attention. Homage to Herbert G. Birch. Mirsky AF. **J Clin Exp Neuropsychol** 1995 Aug;17(4):481–98 (36 ref.)
Flashbulb memories: conceptual and methodological issues. Wright DB, et al. **Memory** 1995 Mar;3(1):67–80 (55 ref.)
The attentional control of pain: methodological and theoretical concerns. Eccleston C. **Pain** 1995 Oct; 63(1):3–10 (45 ref.)
Feature, phoneme, syllable or word: how is speech mentally represented? Sendlmeier WF. **Phonetica** 1995;52(3):131–43 (30 ref.)
Inverse-intensity effect in duration of visible persistence. Di Lollo V, et al. **Psychol Bull** 1995 Sep;118(2):223–37 (100 ref.)
Cognitive components of picture naming. Johnson CJ, et al. **Psychol Bull** 1996 Jul;120(1):113–39 (310 ref.)
The emotional Stroop task and psychopathology. Williams JM, et al. **Psychol Bull** 1996 Jul;120(1):3–24 (95 ref.)
Reconciling simplicity and likelihood principles in perceptual organization. Chater N. **Psychol Rev** 1996 Jul;103(3):566–81 (80 ref.)
Monitoring and control processes in the strategic regulation of memory accuracy. Koriat A, et al. **Psychol Rev** 1996 Jul;103(3):490–517 (140 ref.)
Goodness of visual regularities: a nontransformational approach. van der Helm PA, et al. **Psychol Rev** 1996 Jul; 103(3):429–56 (95 ref.)
Symptom management: loss of concentration. Cimprich B. **Semin Oncol Nurs** 1995 Nov;11(4):279–88 (80 ref.)

[Neuropsychological analysis of schizophrenia-induced attention deficits--attempt at an overview] Gebauer W, et al. **Rehabilitation (Stuttg)** 1995 Aug;34(3):128–38 (85 ref.) (Eng. Abstr.) **(Ger)**

[A case of hemichorea presenting with inattention and denial of involuntary movement] Ichikawa H, et al. **Rinsho Shinkeigaku** 1995 Nov;35(11):1230–4 (15 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

The role of neuroimaging in the discovery of processing stages. A review. Mulder G, et al. **Acta Psychol (Amst)** 1995 Nov;90(1–3):63–79 (66 ref.)

A multidisciplinary approach to anterior attentional functions. Stuss DT, et al. **Ann N Y Acad Sci** 1995 Dec 15;769:191–211 (87 ref.)

Object segmentation and visual neglect. Driver J. **Behav Brain Res** 1995 Nov;71(1–2):135–46 (74 ref.)

Multiple mechanisms of visual-spatial attention: recent evidence from human electrophysiology. Luck SJ. **Behav Brain Res** 1995 Nov;71(1–2):113–23 (52 ref.)

Cognitive functions of the basal forebrain cholinergic system in monkeys: memory or attention? Voytko ML. **Behav Brain Res** 1996 Feb;75(1–2):13–25 (123 ref.)

The role of attention in learning about odorants. Smith BH. **Biol Bull** 1996 Aug;191(1):76–83 (54 ref.)

How good are patients with panic disorder at perceiving their heartbeats? Ehlers A, et al. **Biol Psychol** 1996 Jan 5;42(1–2):165–82 (55 ref.)

Generators of electrical and magnetic mismatch responses in humans. Näätänen R, et al. **Brain Topogr** 1995 Summer; 7(4):315–20 (63 ref.)

Dynamic neuroimaging of brain function. Simpson GV, et al. **J Clin Neurophysiol** 1995 Sep;12(5):432–49 (65 ref.)

Corpus callosum and simple visuomotor integration. Berlucchi G, et al. **Neuropsychologia** 1995 Aug; 33(8):923–36 (74 ref.)

Visual integration in the split brain. Corballis MC. **Neuropsychologia** 1995 Aug;33(8):937–59 (78 ref.)

Neurofunctional mechanisms in autism. Waterhouse L, et al. **Psychol Rev** 1996 Jul;103(3):457–89 (280 ref.)

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY

Attention-deficit hyperactivity disorder: the pharmacist's role. Levin GM. **Am Pharm** 1995 Nov;NS35(11):10–20 (34 ref.)

Attention-deficit hyperactivity disorder in children. Baxter PS. **Curr Opin Pediatr** 1995 Aug;7(4):381–6 (50 ref.)

Childhood mania revisited. Biederman J, et al. **Isr J Med Sci** 1995 Nov;31(11):647–51 (71 ref.)

Attention deficit disorder: a review of the past 10 years. Cantwell DP. **J Am Acad Child Adolesc Psychiatry** 1996 Aug;35(8):978–87 (60 ref.)

Attention-deficit hyperactivity disorder in adults. Feifel D. **Postgrad Med** 1996 Sep;100(3):207–11, 215–8 (15 ref.)

COMPLICATIONS

ADHD and co-morbidities in infants, toddlers, and preschoolers at risk. Billeaud FP. **Semin Speech Lang** 1995 Nov;16(4):289–302 (50 ref.)

DIAGNOSIS

Attention-deficit hyperactivity disorders in adolescence. Wender EH. **J Dev Behav Pediatr** 1995 Jun;16(3):192–5 (10 ref.)

Attention deficit hyperactivity disorder: the scope of the problem. Augustine LE, et al. **Semin Speech Lang** 1995 Nov;16(4):243–57; quiz 257–8 (72 ref.)

The metaphysics of ADHD a unifying case scenario. Smith MD, et al. **Semin Speech Lang** 1995 Nov;16(4):303–12; quiz 312–3 (29 ref.)

DRUG THERAPY

Tricyclic medication in children and the QT interval: case report and discussion. Alderton HR. **Can J Psychiatry** 1995 Aug;40(6):325–9 (30 ref.)

The run on Ritalin. Attention deficit disorder and stimulant treatment in the 1990s. Diller LH. **Hastings Cent Rep** 1996 Mar-Apr;26(2):12–8 (45 ref.)

Psychopharmacology in child and adolescent psychiatry: a review of the past seven years. Part I. Campbell M, et al. **J Am Acad Child Adolesc Psychiatry** 1995 Sep; 34(9):1124–32 (132 ref.)

Pharmacotherapy of adult attention deficit/hyperactivity disorder: a review. Wilens TE, et al. **J Clin Psychopharmacol** 1995 Aug;15(4):270–9 (81 ref.)

Neuroendocrine responses to methylphenidate and d-amphetamine: applications to attention-deficit disorder. Lurie S, et al. **J Neuropsychiatry Clin Neurosci** 1991 Winter; 3(1):41–50 (70 ref.)

ETIOLOGY

Attention deficit disorder: a review of the past 10 years. Cantwell DP. **J Am Acad Child Adolesc Psychiatry** 1996 Aug;35(8):978–87 (60 ref.)

GENETICS

Fragile X syndrome--a review. Keenan E, et al. **Ir Med J** 1993 May;86(3):92, 95–6 (28 ref.)

PHYSIOPATHOLOGY

The contribution of alpha 2-noradrenergic mechanisms of prefrontal cortical cognitive function. Potential significance for attention-deficit hyperactivity disorder. Arnsten AF, et al. **Arch Gen Psychiatry** 1996 May;53(5):448–55 (130 ref.)

Biological correlates of learning and attention: what is relevant to learning disability and attention-deficit hyperactivity disorder? Denckla MB. **J Dev Behav Pediatr** 1996 Apr;17(2):114–9 (37 ref.)

Neurometrics, dynamic brain imaging and attention deficit hyperactivity disorder. Levy F, et al. **J Paediatr Child Health** 1995 Aug;31(4):279–83 (49 ref.)

PSYCHOLOGY

Executive functions and developmental psychopathology. Pennington BF, et al. **J Child Psychol Psychiatry** 1996 Jan; 37(1):51–87 (225 ref.)

THERAPY

The management of hyperactive children. **Drug Ther Bull** 1995 Aug;33(8):57–60 (22 ref.)

ATTENTION DEFICIT HYPERACTIVITY DISORDER
see **ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY**

ATTITUDE

see related
PUBLIC OPINION
SET (PSYCHOLOGY)

Correcting faulty appraisals of obsessional thoughts. Freeston MH, et al. **Behav Res Ther** 1996 May-Jun;34(5–6):433–46 (52 ref.)

Parents' attributions for their children's behavior. Miller SA. **Child Dev** 1995 Dec;66(6):1557–84 (110 ref.)

The climacteric in The Netherlands: a review of Dutch studies on epidemiology, attitudes and use of hormone replacement therapy. Barentsen R. **Eur J Obstet Gynecol Reprod Biol** 1996 Apr;64 Suppl:S7–11 (22 ref.)

Science and belief: psychobiological research on sexual orientation. Byne W. **J Homosex** 1995;28(3–4):303–44 (140 ref.)

Insight and psychosis: a social perspective. Johnson S, et al. **Psychol Med** 1995 May;25(3):515–20 (24 ref.)

Gender differences in risk perception: effects differ in stressed vs. non-stressed environments. Greenberg MR, et al. **Risk Anal** 1995 Aug;15(4):503–11 (29 ref.)

ATTITUDE OF HEALTH PERSONNEL

Point-of-care testing in the intensive care unit. The intensive care physician's perspective. Castro HJ, et al. **Am J Clin Pathol** 1995 Oct;104(4 Suppl 1):S95–9 (22 ref.)

Freudian suspicion versus suspicion of Freud. Crews F. **Ann N Y Acad Sci** 1996 Jun 24;775:470–82 (58 ref.)

Genetic testing of children. Fryer A. **Arch Dis Child** 1995 Aug;73(2):97–9 (9 ref.)

Why do psychiatrists neglect religion? Neeleman J, et al. **Br J Med Psychol** 1995 Jun;68 (Pt 2):169–78 (83 ref.)

The euthanasia debate: attitudes, practices and psychiatric considerations. Chochinov HM, et al. **Can J Psychiatry** 1995 Dec;40(10):593–602 (69 ref.)

Clinical trials and quality of life assessment: the nurses' viewpoint. Molin C, et al. **Eur J Cancer** 1995;31A Suppl 6:S8–10 (25 ref.)

The value of curiosity and naiveté for the cross-cultural psychotherapist. Dyche L, et al. **Fam Process** 1995 Dec; 34(4):389–99 (33 ref.)

Training to think culturally: a multidimensional comparative framework. Falicov CJ. **Fam Process** 1995 Dec; 34(4):373–88 (56 ref.)

Effects of ageism on individual and health care providers' responses to healthy aging. Grant LD. **Health Soc Work** 1996 Feb;21(1):9–15 (46 ref.)

Gender bias in the diagnosis and treatment of coronary artery disease. Beery TA. **Heart Lung** 1995 Nov-Dec;24(6):427–35 (64 ref.)

Neglected conflicts in the discipline of nursing: perceptions of the importance and value of practical skill. Bjørk IT. **J Adv Nurs** 1995 Jul;22(1):6–12 (44 ref.)

Challenging old notions of professionalism: how can nurses work with paraprofessional ethnic health workers? Fuller J. **J Adv Nurs** 1995 Sep;22(3):465–72 (44 ref.)

Bilateral prophylactic mastectomy: issues and concerns. Stefanek ME. **J Natl Cancer Inst Monogr** 1995;(17):37–42 (31 ref.)

Inquiry based learning, nursing student attitudes and the HIV patient. Cerny JE, et al. **J Nurs Educ** 1996 May; 35(5):219–22 (24 ref.)

Nurses' attitudes about acquired immunodeficiency syndrome care: what research tells us. Bennett JA. **J Prof Nurs** 1995 Nov-Dec;11(6):339–50 (67 ref.)

Self-efficacy in pediatric resuscitation: implications for education and performance. Maibach EW, et al. **Pediatrics** 1996 Jan;97(1):94–9 (33 ref.)

[Pregnancy after breast cancer] Mignot L, et al. **Contracept Fertil Sex** 1996 Apr;24(4):319–21 (16 ref.) (Eng. Abstr.) **(Fre)**

[Benefits and risks of intramuscular injection. Are expectations of physicians and patients irrational?] Sohn W. **Fortschr Med** 1996 Jun 20;114(17):217–20 (28 ref.) (Eng. Abstr.) **(Ger)**

[Evolution in consumption of and attitude towards tobacco towards physicians at the regional hospital "Reina Sofía," Córdoba] Mengual Luque P, et al. **Gac Sanit** 1996 Jan-Feb; 10(52):18–24 (32 ref.) (Eng. Abstr.) **(Spa)**

ATTITUDE TO COMPUTERS

[Computer systems in medical practice. I. The aims, difficulties and implementation of computerization in health care organizations] Michalak J. **Med Pr** 1995;46(5):509–16 (12 ref.) (Eng. Abstr.) **(Pol)**

ATTITUDE TO DEATH

Redefining death in America, 1968. Stevens ML. **Caduceus** 1995 Winter;11(3):207–19 (41 ref.)

Death and dying and recognizing approaching death. Long MC. **Clin Geriatr Med** 1996 May;12(2):359–68 (25 ref.)

Good care of the dying patient. Council on Scientific Affairs, American Medical Association. **JAMA** 1996 Feb 14; 275(6):474–8 (96 ref.)

ATTITUDE TO HEALTH

see related
PATIENT DROPOUTS
SICK ROLE

AIDS phobia, public health warnings, and lawsuits: deterring harm or rewarding ignorance? Mariner WK. **Am J Public Health** 1995 Nov;85(11):1562–8 (42 ref.)

Psychosocial and ethical implications of defining genetic risk for cancers. Kash KM. **Ann N Y Acad Sci** 1995 Sep 30; 768:41–52 (26 ref.)

Harnessing the power of the placebo effect and renaming it "remembered wellness". Benson H, et al. **Annu Rev Med** 1996;47:193–9 (18 ref.)

Ethnicity and health beliefs with respect to cancer: a critical review of methodology. Pfeffer N, et al. **Br J Cancer** 1996 Sep;74 Suppl 29:S66–72 (112 ref.)

Ethnicity and health beliefs with respect to cancer: a critical review of methodology. Pfeffer N, et al. **Br J Cancer Suppl** 1996 Sep;29:S66–72 (112 ref.)

Hope and quality of life, two central issues for cancer patients: a theoretical analysis. Rustøen T. **Cancer Nurs** 1995 Oct;18(5):355–61 (60 ref.)

Neglected conflicts in the discipline of nursing: perceptions of the importance and value of practical skill. Bjørk IT. **J Adv Nurs** 1995 Jul;22(1):6–12 (44 ref.)

Exploring the attitudes of adults who stutter. Watson JB. **J Commun Disord** 1995 Jun;28(2):143–64 (55 ref.)

Bilateral prophylactic mastectomy: issues and concerns. Stefanek ME. **J Natl Cancer Inst Monogr** 1995;(17):37–42 (31 ref.)

Psychosocial/cultural issues in medicine and psychiatry: treating African Americans. Carter JH. **J Natl Med Assoc** 1995 Dec;87(12):857–60 (18 ref.)

Insight in clinical psychiatry. A new model. Marková IS, et al. **J Nerv Ment Dis** 1995 Dec;183(12):743–51 (44 ref.)

Entitlements and the federal budget: facts, folklore, and future. Gist JR. **Milbank Q** 1996;74(3):327–59 (42 ref.)

Multiple meanings of pain and complexities of pain management. Benoliel JQ. **Nurs Clin North Am** 1995 Dec; 30(4):583–96 (91 ref.)

HIV infection. What nurses need to know. The consumer perspective. Schietinger H, et al. **Nurs Clin North Am** 1996 Mar;31(1):137–52 (21 ref.)

Women's psychological reactions to breast cancer. Payne DK, et al. **Semin Oncol** 1996 Feb;23(1 Suppl 2):89–97 (27 ref.)

The menstrual cycle and the well being of women. Bancroft J. **Soc Sci Med** 1995 Sep;41(6):785–91 (29 ref.)

Fear of AIDS and homophobia: implications for direct practice and advocacy. O'Hare T, et al. **Soc Work** 1996 Jan;41(1):51–8 (22 ref.)

[Transcultural symptomatology. Its expression in family practice] Ferron M. **Can Fam Physician** 1995 Oct; 41:1718–25 (20 ref.) (Eng. Abstr.) **(Fre)**

[Benefits and risks of intramuscular injection. Are expectations of physicians and patients irrational?] Sohn W. **Fortschr Med** 1996 Jun 20;114(17):217–20 (28 ref.) (Eng. Abstr.) **(Ger)**

ETHNOLOGY

Rationing health care and the need for credible scarcity: why Americans can't say no. Mariner WK. **Am J Public Health** 1995 Oct;85(10):1439–45 (50 ref.)

[Study of a custom in Somalia: the circumcision of girls] Bayoudh F, et al. **Med Trop (Mars)** 1995;55(3):238–42 (15 ref.) (Eng. Abstr.) **(Fre)**

[Myth reconstruction and health representations in a Southern Congolese therapeutic sect] Hagenbucher-Sacripanti F. **Sante** 1996 Jan-Feb;6(1):43–52 (6 ref.) **(Fre)**

ATYPICAL ANTIDEPRESSANTS

ATYPICAL ANTIDEPRESSANTS see ANTIDEPRESSIVE AGENTS, SECOND-GENERATION

AUDIOMETRY

[Audiometric results of 81 ossiculoplasties after tympanoplasty with closed technique in chronic cholesteatomatous otitis] Caprio D, et al. **Ann Otolaryngol Chir Cervicofac** 1995;112(3):107–17 (16 ref.) (Eng. Abstr.) **(Fre)**

AUDIOMETRY, SPEECH

METHODS

Speech pattern audiometry for clinical use. Hazan V, et al. **Eur J Disord Commun** 1995;30(2):116–23 (15 ref.)

AUDIOVISUAL AIDS

Graphic format for teaching long-term control of systemic arterial pressure. Faber JJ. **Am J Physiol** 1996 Jun;270(6 Pt 3):S40–9 (22 ref.)

Poster presentation: an effective means of scientific communication. Harikrishnan KM, et al. **J Assoc Physicians India** 1995 Aug;43(8):546–7 (4 ref.)

AUDITORY BRAIN STEM EVOKED RESPONSES see EVOKED POTENTIALS, AUDITORY, BRAIN STEM

AUDITORY CANAL, EXTERNAL see EAR CANAL

AUDITORY CORTEX

Central auditory processing: a view from auditory neuroscience. Phillips DP. **Am J Otol** 1995 May; 16(3):338–52 (88 ref.)

ANATOMY & HISTOLOGY

Anatomy of the auditory cortex. Pandya DN. **Rev Neurol (Paris)** 1995 Aug–Sep;151(8–9):486–94 (60 ref.)

PHYSIOLOGY

Generators of electrical and magnetic mismatch responses in humans. Näätänen R, et al. **Brain Topogr** 1995 Summer; 7(4):315–20 (63 ref.)

Hearing. Asking the auditory cortex the right question. King AJ. **Curr Biol** 1995 Oct 1;5(10):1110–3 (23 ref.)

Order and disorder in auditory cortical maps. Schreiner CE. **Curr Opin Neurobiol** 1995 Aug;5(4):489–96 (60 ref.)

AUDITORY EVOKED POTENTIALS see EVOKED POTENTIALS, AUDITORY

AUDITORY EVOKED RESPONSE see EVOKED POTENTIALS, AUDITORY

AUDITORY NERVE see ACOUSTIC NERVE

AUDITORY PATHWAYS

Biologic bases of noise-induced hearing loss. Henderson D, et al. **Occup Med** 1995 Jul–Aug;10(3):513–34 (27 ref.)

EMBRYOLOGY

Development of second-order vestibular projections in the chicken embryo. Glover JC. **Ann N Y Acad Sci** 1996 Jun 19;781:13–20 (12 ref.)

AUDITORY PERCEPTION

The management of drug-resistant, persistent and unpleasant auditory hallucinations. Lecompte D. **Acta Psychiatr Belg** 1996 Jan–Feb;96(1):21–9 (21 ref.)

Auditory psychophysics and perception. Hirsh IJ, et al. **Annu Rev Psychol** 1996;47:461–84 (110 ref.)

PHYSIOLOGY

Central auditory processing: a view from auditory neuroscience. Phillips DP. **Am J Otol** 1995 May; 16(3):338–52 (88 ref.)

Hearing. Asking the auditory cortex the right question. King AJ. **Curr Biol** 1995 Oct 1;5(10):1110–3 (23 ref.)

Synaesthesia: reconciling the subjective with the objective. Harrison J, et al. **Endeavour** 1995;19(4):157–60 (20 ref.)

Functional development of auditory sensitivity in the fetus and neonate. Sohmer H, et al. **J Basic Clin Physiol Pharmacol** 1995;6(2):95–108 (74 ref.)

[Prenatal auditory perception—on the relevance of new concepts of perception] Schmidt HU, et al. **Geburtshilfe Frauenheilkd** 1995 Oct;55(10):M125–8 (13 ref.) **(Ger)**

AUDITORY PERCEPTUAL DISORDERS

ETIOLOGY

Is central hyperacusis a symptom of 5-hydroxytryptamine (5-HT) dysfunction? Marriage J, et al. **J Laryngol Otol** 1995 Oct;109(10):915–21 (73 ref.)

PSYCHOLOGY

[Acoustic and optical perceptual disorders in depressive diseases—an overview of results from experimental studies] Kallert TW. **Schweiz Arch Neurol Psychiatr** 1996; 147(1):4–11 (61 ref.) (Eng. Abstr.) **(Ger)**

AUDITORY PROSTHESIS see COCHLEAR IMPLANT

AUDITORY STIMULATION see ACOUSTIC STIMULATION

AUDITORY THRESHOLD

see related
AUDIOMETRY

DRUG EFFECTS

Combined effects of noise and chemicals. Fechter LD. **Occup Med** 1995 Jul–Aug;10(3):609–21 (51 ref.)

AUDITORY TUBE see EUSTACHIAN TUBE

AUJESZKY'S DISEASE see PSEUDORABIES

AUJESZKY'S DISEASE VIRUS see HERPESVIRUS 1, SUID

AURICULAR FIBRILLATION see ATRIAL FIBRILLATION

AURICULAR FLUTTER see ATRIAL FLUTTER

AURICULIN see ATRIAL NATRIURETIC FACTOR

AURICULO-VENTRICULAR DISSOCIATION see HEART BLOCK

AURICULOTEMPORAL SYNDROME see SWEATING, GUSTATORY

AUROTHIOMALATE see GOLD SODIUM THIOMALATE

AUSCULTATION

see related
HEART AUSCULTATION

Acoustic properties of the normal chest. Dalmay F, et al. **Eur Respir J** 1995 Oct;8(10):1761–9 (68 ref.)

Chest percussion. Yernault JC, et al. **Eur Respir J** 1995 Oct; 8(10):1756–60 (33 ref.)

Is listening for abdominal bruits useful in the evaluation of hypertension? Turnbull JM. **JAMA** 1995 Oct 25; 274(16):1299–301 (26 ref.)

METHODS

Bio-acoustic signals from stenotic tube flow: state of the art and perspectives for future methodological development. Ask P, et al. **Med Biol Eng Comput** 1995 Sep;33(5):669–75 (29 ref.)

AUSTRALIA ANTIGEN see HEPATITIS B SURFACE ANTIGENS

AUSTRALOID RACE

New World syndrome in Western Australian aborigines. Gracey M. **Clin Exp Pharmacol Physiol** 1995 Mar; 22(3):220–5 (38 ref.)

AUTACOIDS

see related
NEUROTRANSMITTERS

Three autacoids—endogenous digitalis-like factor, clonidine-displacing substance, and quinidine-like immunoreactivity. Kölbel F, et al. **Sb Lek** 1995; 96(4):405–15 (65 ref.)

AUTISM

Diagnosis, treatment, and neurobiology of autism in children. Lainhart JE, et al. **Curr Opin Pediatr** 1995 Aug; 7(4):392–400 (89 ref.)

ETIOLOGY

An enzyme/brain-barrier theory of psychiatric pathogenesis: unifying observations on phenylketonuria, autism, schizophrenia and postpartum psychosis. Seim AR, et al. **Med Hypotheses** 1995 Nov;45(5):498–502 (36 ref.)

AUTISM, INFANTILE

The State of the Science in Autism. Conference proceedings. Bethesda, Maryland, April 1995. **J Autism Dev Disord** 1996 Apr;26(2):115–280 (0 ref.)

State of the science in autism: report to the National Institutes Health. Bristol MM, et al. **J Autism Dev Disord** 1996 Apr; 26(2):121–54 (0 ref.)

[Infantile autism in France in 1994] Golse B. **Psychiatr Enfant** 1995;38(2):463–76 (23 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Current research findings on childhood autism. Sigman M, et al. **Can J Psychiatry** 1995 Aug;40(6):289–94 (48 ref.)

Brief report: neuropsychology of autism: a report on the state of the science. Dawson G. **J Autism Dev Disord** 1996 Apr; 26(2):179–84 (38 ref.)

Brief report: neuroimaging in autism: the state of the science 1995. Filipek PA. **J Autism Dev Disord** 1996 Apr; 26(2):211–5 (21 ref.)

Autism: towards an integration of clinical, genetic, neuropsychological, and neurobiological perspectives. Bailey A, et al. **J Child Psychol Psychiatry** 1996 Jan; 37(1):89–126 (280 ref.)

[Prevalence of autistic states in a cohort of very young children followed up in home care] Drossart F, et al. **Acta Psychiatr Belg** 1995 May–Jun;95(3):122–38 (64 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

Psychopharmacology in child and adolescent psychiatry: a review of the past seven years. Part I. Campbell M, et al. **J Am Acad Child Adolesc Psychiatry** 1995 Sep; 34(9):1124–32 (132 ref.)

Brief report: psychopharmacology of autism spectrum disorders. Lewis MH. **J Autism Dev Disord** 1996 Apr; 26(2):231–5 (11 ref.)

Efficacy of vitamin B6 and magnesium in the treatment of autism: a methodology review and summary of outcomes. Pfeiffer SI, et al. **J Autism Dev Disord** 1995 Oct; 25(5):481–93 (36 ref.)

[Psychopharmacology of autism] Chabrol H, et al. **Encephale** 1996 May–Jun;22(3):197–203 (40 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Autism and medical disorders: a review of the literature. Gillberg C, et al. **Dev Med Child Neurol** 1996 Mar; 38(3):191–202 (75 ref.)

Autism research: prospects and priorities. Rutter M. **J Autism Dev Disord** 1996 Apr;26(2):257–75 (50 ref.)

Brief report: genetic, prenatal, and immunologic factors. Smalley SL, et al. **J Autism Dev Disord** 1996 Apr; 26(2):195–8 (16 ref.)

[Theoretical perspectives on autism] Klin A, et al. **Psychiatr Enfant** 1995;38(2):477–94 (14 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Brief report: neuroanatomic observations of the brain in pervasive developmental disorders. Bauman ML. **J Autism Dev Disord** 1996 Apr;26(2):199–203 (18 ref.)

PHYSIOPATHOLOGY

Brief report: medial temporal lobe and autism: a putative animal model in primates. Bachevalier J. **J Autism Dev Disord** 1996 Apr;26(2):217–20 (5 ref.)

Brief report: pathophysiology of autism: neurochemistry. Cook EH Jr. **J Autism Dev Disord** 1996 Apr;26(2):221–5 (11 ref.)

Brief report: brain mechanisms in autism: functional and structural abnormalities. Minshew NJ. **J Autism Dev Disord** 1996 Apr;26(2):205–9 (6 ref.)

Brief report: developmental neurobiological aspects of autism. Voeller KK. **J Autism Dev Disord** 1996 Apr; 26(2):189–93 (9 ref.)

Psychophysiological aspects of autistic disorders: overview. Murray JB. **J Psychol** 1996 Mar;130(2):145–58 (95 ref.)

Neurofunctional mechanisms in autism. Waterhouse L, et al. **Psychol Rev** 1996 Jul;103(3):457–89 (280 ref.)

PSYCHOLOGY

Executive functions and developmental psychopathology. Pennington BF, et al. **J Child Psychol Psychiatry** 1996 Jan; 37(1):51–87 (225 ref.)

[Theoretical perspectives on autism] Klin A, et al. **Psychiatr Enfant** 1995;38(2):477–94 (14 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Brief report: alternative approaches to the development of effective treatments for autism. Rimland B, et al. **J Autism Dev Disord** 1996 Apr;26(2):237–41 (7 ref.)

Brief report: early intervention in autism. Rogers SJ. **J Autism Dev Disord** 1996 Apr;26(2):243–6 (10 ref.)

Brief report: the case for social and behavioral intervention research. Schreibman L. **J Autism Dev Disord** 1996 Apr; 26(2):247–50 (8 ref.)

AUTO-PEEP see POSITIVE-PRESSURE RESPIRATION, INTRINSIC

AUTOANTIBODIES

see related
AUTOIMMUNE DISEASES
AUTOIMMUNITY

Amyotrophic lateral sclerosis with paraproteins and

autoantibodies. Rowland LP. **Adv Neurol** 1995;68:93–105; discussion 107–11 (136 ref.)
Anti-calcium channel autoantibodies in amyotrophic lateral sclerosis. A review of the evidence. Seagar MJ, et al. **Adv Neurol** 1995;68:67–72 (30 ref.)
Human cytokine autoantibodies. Characteristics, test procedures and possible physiological and clinical significance. Hansen MB. **APMIS Suppl** 1996;59:1–33 (258 ref.)
Anti-endothelial cell antibodies: only for scientists or for clinicians too? Meroni PL, et al. **Clin Exp Immunol** 1996 May;104(2):199–202 (29 ref.)
DNA methylation: a potential pathway to abnormal autoreactive lupus B cells. Huck S, et al. **Clin Immunol Immunopathol** 1996 Jul;80(1):1–8 (85 ref.)
Autoimmune hepatitis versus viral hepatitis C. Strassburg CP, et al. **Liver** 1995 Oct;15(5):225–32 (72 ref.)
Natural autoantibodies: the other side of the immune system. Avrameas S, et al. **Res Immunol** 1995 May–Jun; 146(4–5):235–48 (116 ref.)
[Anti-endothelial cell antibodies] Mayet WJ, et al. **Dtsch Med Wochenschr** 1996 May 24;121(21):702–9 (68 ref.) **(Ger)**
[Primary biliary cirrhosis--antimitochondrial antibody and the reactive antigens] Ishibashi H. **Fukuoka Igaku Zasshi** 1995 Oct;86(10):385–8 (4 ref.) **(Jpn)**
[Neuropathy and anti-ganglioside antibodies] Kusunoki S. **Nippon Naika Gakkai Zasshi** 1996 Apr 10;85(4):629–34 (13 ref.) **(Jpn)**
[Autoantibodies to coagulation factors] Suehisa E, et al. **Rinsho Byori** 1995 Dec;43(12):1189–94 (13 ref.) **(Jpn)**

ANALYSIS

The clinical utility of ANCA positivity [editorial] Edgar JD. **Ann Rheum Dis** 1996 Aug;55(8):494–6 (37 ref.)
Antineutrophil cytoplasmic antibodies in the classification of vasculitis. Niles JL. **Annu Rev Med** 1996;47:303–13 (32 ref.)
Dermatological presentation of disease associated with antineutrophil cytoplasmic antibodies: a report of two contrasting cases and a review of the literature. Irvine AD, et al. **Br J Dermatol** 1996 May;134(5):924–8 (30 ref.)
Antineutrophil cytoplasmic autoantibodies (ANCA) associated vasculitides--immunologic and clinical aspects. Schulz JI. **Bratisl Lek Listy** 1995 Oct;96(10):520–2 (20 ref.)
Analytical and clinical performance goals for testing autoantibodies to thyroperoxidase, thyroglobulin, and thyrotropin receptor. Feldt-Rasmussen U. **Clin Chem** 1996 Jan;42(1):160–3 (20 ref.)
Paraneoplastic pemphigus: report of a case. Izaki S, et al. **J Dermatol** 1996 Jun;23(6):397–404 (24 ref.)
Stiff-person syndrome with anti-glutamic acid decarboxylase autoantibodies: complete remission of symptoms after intrathecal baclofen administration. Seitz RJ, et al. **J Neurol** 1995 Oct;242(10):618–22 (32 ref.)
Autoantibodies, neurotoxins and the nervous system. Vincent A, et al. **J Physiol Paris** 1995;89(3):129–36 (75 ref.)
Hydralazine-induced constrictive pericarditis. Franssen CF, et al. **Neth J Med** 1996 May;48(5):193–7 (21 ref.)
Antineutrophil cytoplasmic autoantibody testing in vasculitides. Gross WL. **Rheum Dis Clin North Am** 1995 Nov;21(4):987–1011 (182 ref.)
[Autoimmunity and glutamate decarboxylase antibodies in the pathogenesis of type I diabetes mellitus in experimental and clinical practice] Kučera P, et al. **Vnitr Lek** 1996 May; 42(5):359–67 (65 ref.) (Eng. Abstr.) **(Cze)**
[Acquired factor VIII inhibitor and chronic lymphoid leukemia: apropos of a case] Ceballos P, et al. **Rev Med Interne** 1996;17(2):150–3 (15 ref.) (Eng. Abstr.) **(Fre)**
[Pure cerebellar syndrome associated with anti-Hu antibodies] Pradat PF, et al. **Rev Neurol (Paris)** 1995 May; 151(5):341–3 (12 ref.) (Eng. Abstr.) **(Fre)**
[Cytoplasmic islet cell antibodies and GAD antibodies in diagnosis of diabetes] Bieg S, et al. **Med Klin** 1995 Oct 15;90(10):594–8 (48 ref.) **(Ger)**
[Significance of antineutrophil cytoplasmic antibodies (ANCA) in diagnosis and immunopathogenesis of chronic inflammatory liver diseases] Mayet WJ, et al. **Med Klin** 1996 Jun 15;91(6):384–8 (33 ref.) **(Ger)**
[Anti-GOR antibodies] Kato M, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:241–6 (23 ref.) **(Jpn)**
[Autoantibodies in patients with Sjögren's syndrome and their clinical significance] Miyawaki S. **Nippon Rinsho** 1995 Oct;53(10):2422–8 (11 ref.) (Eng. Abstr.) **(Jpn)**
[Enzyme-immunoassay for autoantibodies using recombinant antigens] Yamanaka K, et al. **Nippon Rinsho** 1995 Sep; 53(9):2283–9 (10 ref.) (Eng. Abstr.) **(Jpn)**
[Marked clinical improvement by plasmapheresis in a patient with stiff-man syndrome: a case with a negative anti-GAD antibody] Nakamagoe K, et al. **Rinsho Shinkeigaku** 1995 Aug;35(8):897–900 (12 ref.) (Eng. Abstr.) **(Jpn)**
[Autoantibodies against neutrophil cytoplasm and their significance in the classification of systemic vasculitis] Fijalkowska-Morawska J, et al. **Przegl Lek** 1995; 52(6):318–22 (20 ref.) (Eng. Abstr.) **(Pol)**

BIOSYNTHESIS

Autoimmune mechanisms of depletion of CD4 cells in HIV infection. Dalgleish AG. **Br J Haematol** 1995 Nov; 91(3):525–34 (106 ref.)
Mechanisms of the pathogenic autoimmune response in lupus: prospects for specific immunotherapy. Datta SK, et al. **Immunol Res** 1995;14(2):132–47 (156 ref.)
Involvement of B-1 cells in mucosal immunity and autoimmunity. Murakami M, et al. **Immunol Today** 1995 Nov;16(11):534–9 (38 ref.)
Immune-mediated side-effects of cytokines in humans. Vial T, et al. **Toxicology** 1995 Dec 20;105(1):31–57 (239 ref.)

BLOOD

Chronic motor neuropathies. Kornberg AJ, et al. **Adv Neurol** 1995;68:113–9 (52 ref.)
The humoral immune system in coeliac disease. Mäki M. **Baillieres Clin Gastroenterol** 1995 Jun;9(2):231–49 (115 ref.)
Markers of neurotoxicity: from behavior to autoantibodies against brain proteins. Evans HL. **Clin Chem** 1995 Dec; 41(12 Pt 2):1874–81 (116 ref.)
HLA and glutamic acid decarboxylase in human insulin-dependent diabetes mellitus. Sanjeevi CB, et al. **Diabet Med** 1996 Mar;13(3):209–17 (68 ref.)
The pathogenesis and prevention of diabetes in adults. Genes, autoimmunity, and demography. Zimmet PZ. **Diabetes Care** 1995 Jul;18(7):1050–64 (142 ref.)
Anti-topoisomerase-I and clinical findings in systemic sclerosis (scleroderma). Shoenfeld Y, et al. **Isr J Med Sci** 1996 Jul;32(7):537–42 (32 ref.)
Monoclonal, human autoantibodies to the TSH receptor--the Holy Grail and why are we looking for it? [editorial] McLachlan SM, et al. **J Clin Endocrinol Metab** 1996 Sep; 81(9):3152–4 (29 ref.)
Use and interpretation of rheumatologic tests: a guide for clinicians. Moder KG. **Mayo Clin Proc** 1996 Apr; 71(4):391–6 (17 ref.)
Autoantibodies to cytokines in inflammatory joint disorders [editorial] Jouvenne P, et al. **Rev Rhum Engl Ed** 1995 Oct; 62(9):541–5 (20 ref.)
Cutaneous polyarteritis nodosa in a child with positive antiphospholipid and P-ANCA. Pereira BA, et al. **Scand J Rheumatol** 1995;24(6):386–8 (14 ref.)
Anti-neutrophil cytoplasmic antibodies in primary small vessel vasculitides. Wiik AS. **Scand J Rheumatol** 1996; 25(2):65–9 (35 ref.)
Diagnostic methodologies for circulating anticoagulants. Exner T. **Thromb Haemost** 1995 Jul;74(1):338–44 (59 ref.)
[Primary sclerosing cholangitis (PSC)--humoral immune phenomena, pathogenetic aspects and therapeutic possibilities] Hopf U, et al. **Z Gastroenterol** 1993 Feb;31 Suppl 2:106–10 (31 ref.) (Eng. Abstr.) **(Ger)**
[ANCA-associated vasculitis (Wegener's granulomatosis, Churg-Strauss syndrome, microscopic polyangiitis). 2. Diagnostic procedure (see comments) de Groot K, et al. **Z Rheumatol** 1995 Sep–Oct;54(5):291–302 (59 ref.) (Eng. Abstr.) Comment in: Z Rheumatol 1995 Sep–Oct;54(5):277–8. **(Ger)**
[ANCA-associated vasculitis (Wegener's granulomatosis, Churg-Strauss syndrome, microscopic polyangiitis). 1. Systemic aspects, pathogenesis and clinical aspects (see comments)] Gross WL, et al. **Z Rheumatol** 1995 Sep–Oct; 54(5):279–90 (22 ref.) (Eng. Abstr.) Comment in: Z Rheumatol 1995 Sep–Oct;54(5):277–8. **(Ger)**
[ANCA-associated vasculitis (Wegener's granulomatosis, Churg-Strauss syndrome, microscopic polyangiitis). 3. Therapeutic procedure (see comments)] Reinhold-Keller E, et al. **Z Rheumatol** 1995 Sep–Oct;54(5):303–9 (30 ref.) (Eng. Abstr.) Comment in: Z Rheumatol 1995 Sep–Oct;54(5):277–8. **(Ger)**
[Thyroglobulin antibodies] Kobayashi I. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:410–3 (10 ref.) **(Jpn)**
[Microsomal antibodies] Kobayashi I. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:414–7 (10 ref.) **(Jpn)**
[TSH receptor antibody] Shishiba Y. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:407–9 (11 ref.) **(Jpn)**

DIAGNOSTIC USE

Non-invasive detection of myocyte necrosis in myocarditis and dilated cardiomyopathy with radiolabelled antimyosin. Khaw BA, et al. **Eur Heart J** 1995 Dec;16 Suppl O:119–23 (16 ref.)

IMMUNOLOGY

Autoimmune recognition of acetylcholine receptor and manipulation of the autoimmune responses by synthetic peptides. Atassi MZ, et al. **Adv Exp Med Biol** 1995; 383:141–56 (71 ref.)
Autoantibodies to specific enzymes: a review. Kiechle FL, et al. **Ann Clin Lab Sci** 1996 May–Jun;26(3):195–207 (70 ref.)
Analysis of the structural correlates for self-antigen binding by natural and disease-related autoantibodies. In vitro expression of recombinant and/or mutagenized human IgG. Ichiyoshi Y, et al. **Ann N Y Acad Sci** 1995 Sep 29; 764:328–41 (35 ref.)
B-1 cells and autoimmunity. Murakami M, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:402–9 (34 ref.)
Cell injury mediated by autoantibodies to intracellular antigens. Reichlin M. **Clin Immunol Immunopathol** 1995 Sep;76(3 Pt 1):215–9 (31 ref.)
Natural autoantibodies. Coutinho A, et al. **Curr Opin Immunol** 1995 Dec;7(6):812–8 (90 ref.)
Bullous skin diseases. Nousari HC, et al. **Curr Opin Immunol** 1995 Dec;7(6):844–52 (76 ref.)
Autoantibodies in systemic lupus erythematosus. Elkon K. **Curr Opin Rheumatol** 1995 Sep;7(5):384–8 (40 ref.)
Anti-neutrophil cytoplasmic antibodies in generalized autoimmune diseases. Schnabel A, et al. **Int Arch Allergy Immunol** 1996 Mar;109(3):201–6 (32 ref.)
Auto-anti-idiotypy, autoimmunity and some thoughts on the structure of internal images. Erlanger BF. **Int Rev Immunol** 1989;5(2):131–7 (29 ref.)
Properties of a system of public idiotypes of lupus autoantibodies. Schwartz RS. **Int Rev Immunol** 1989; 5(2):153–5 (13 ref.)
Treatment of systemic and renal-limited vasculitic disorders with pooled human intravenous immune globulin. Jordan SC. **J Clin Immunol** 1995 Nov;15(6 Suppl):76S–85S (40 ref.)
Autoepitopes in lupus. Harley JB, et al. **J Lab Clin Med** 1995 Dec;126(6):509–16 (75 ref.)
Antineutrophil cytoplasmic antibodies: major autoantigens, pathophysiology, and disease associations. Schultz DR, et al. **Semin Arthritis Rheum** 1995 Dec;25(3):143–59 (120 ref.)
Infertility due to antisperm antibodies. Ohl DA, et al. **Urology** 1995 Oct;46(4):591–602 (170 ref.)
[The role of Fc gamma R specific autoantibodies in autoimmune diseases. Review of the literature and authors' own research] Szegedi A, et al. **Orv Hetil** 1996 Mar 17; 137(11):581–4 (34 ref.) (Eng. Abstr.) **(Hun)**
[Recent findings on antigens reactive to antiphospholipid antibodies] Matsuda S. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Feb;19(1):27–38 (66 ref.) **(Jpn)**
[Epitopes of the target proteins of anti-SS-A/Ro and anti-SS-B/La autoantibodies] Kato T. **Nippon Rinsho** 1995 Oct;53(10):2434–9 (26 ref.) (Eng. Abstr.) **(Jpn)**
[Molecular mimicry between LKM 1-autoantigen and HCV-polyproteins] Miyakawa H, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:885–91 (20 ref.) **(Jpn)**
[Antimitochondrial antibody negative primary biliary cirrhosis] Aizawa Y, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):527–30 (12 ref.) **(Jpn)**
[Immunologic reactions in the male and female reproductive system] Kasprzak M, et al. **Postepy Hig Med Dosw** 1995; 49(6):693–717 (47 ref.) (Eng. Abstr.) **(Pol)**
[Autoantibodies in liver diseases: interpretation and pathogenic importance] Pons Romero F, et al. **Gastroenterol Hepatol** 1996 Jun–Jul;19(6):326–33 (70 ref.) **(Spa)**

ISOLATION & PURIFICATION

[Does a clinician need autoimmune assays of the thyroid gland?] Välimäki MJ. **Duodecim** 1994;110(10):969–73 (14 ref.) **(Fin)**

METABOLISM

Studies of patients with anti-epiligrin cicatricial pemphigoid. Yancey KB, et al. **J Dermatol** 1995 Nov;22(11):829–35 (25 ref.)
[Anti-platelet antibody and severe thrombocytopenia during interferon-alpha therapy for chronic active hepatitis C] Tanaka Y, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Apr;19(2):150–6 (17 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Cardiac surgery and cold-reactive proteins. Agarwal SK, et al. **Ann Thorac Surg** 1995 Oct;60(4):1143–50 (47 ref.)
Nephritogenic autoantibodies in lupus: current concepts and continuing controversies. Lefkowith JB, et al. **Arthritis Rheum** 1996 Jun;39(6):894–903 (100 ref.)
Emerging concepts regarding B cells and autoantibodies in murine lupus nephritis. B cells have multiple roles; all autoantibodies are not equal [editorial] Madaio MP, et al. **J Am Soc Nephrol** 1996 Mar;7(3):387–96 (104 ref.)

AUTOANTIGENS

Recent progress in studies on autoantigens for various autoimmune blistering skin diseases. Hashimoto T. **Keio J Med** 1995 Dec;44(4):115–23 (84 ref.)
Antigen-specific therapies for the treatment of autoimmune diseases. Hafler DA, et al. **Springer Semin Immunopathol** 1995;17(1):61–76 (78 ref.)
[Primary biliary cirrhosis--antimitochondrial antibody and the reactive antigens] Ishibashi H. **Fukuoka Igaku Zasshi** 1995 Oct;86(10):385–8 (4 ref.) **(Jpn)**
[Recent findings on antigens reactive to antiphospholipid antibodies] Matsuda S. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Feb;19(1):27–38 (66 ref.) **(Jpn)**

ADMINISTRATION & DOSAGE

Treatment of autoimmune diseases by oral tolerance to autoantigens. Weiner HL, et al. **Adv Exp Med Biol** 1995; 371B:1217–23 (30 ref.)
Evidence that type II collagen feeding can induce a durable therapeutic response in some patients with rheumatoid arthritis. Trentham DE. **Ann N Y Acad Sci** 1996 Feb 13; 778:306–14 (15 ref.)

ANALYSIS

Molecular analysis of the pathological autoimmune antigens

of Heymann nephritis [comment] Farquhar MG. **Am J Pathol** 1996 May;148(5):1331–7 (46 ref.) Comment on: Am J Pathol 1996 May;148(5):1613–24.

CHEMISTRY

Selection of ligands for polyclonal antibodies from random peptide libraries: potential identification of (auto)antigens that may trigger B and T cell responses in autoimmune diseases. Sioud M, et al. **Clin Immunol Immunopathol** 1996 May;79(2):105–14 (65 ref.)

IMMUNOLOGY

Oral tolerance in myasthenia gravis. Drachman DB, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:258–72 (58 ref.)

Analysis of the structural correlates for self–antigen binding by natural and disease–related autoantibodies. In vitro expression of recombinant and/or mutagenized human IgG. Ichiyoshi Y, et al. **Ann N Y Acad Sci** 1995 Sep 29; 764:328–41 (35 ref.)

Origins of anti–DNA antibodies and their implications for B–cell tolerance. Radic MZ, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:384–96 (13 ref.)

Unconventional B–cell antigens and human immune repertoires. Silverman GJ. **Ann N Y Acad Sci** 1995 Sep 29;764:342–55 (42 ref.)

T–cell recognition of beta–cell autoantigens in insulin–dependent diabetes mellitus. Kallan AA, et al. **APMIS** 1996 Jan;104(1):3–11 (84 ref.)

Immune surveillance and autoantigen recognition in the central nervous system. Sedgwick JD. **Aust N Z J Med** 1995 Dec;25(6):784–92 (46 ref.)

Monoclonal gammopathies antigen driven in autoimmune diseases. Osterland CK. **Clin Exp Rheumatol** 1996 Jan–Feb; 14 Suppl 14:S37–44 (34 ref.)

Cell injury mediated by autoantibodies to intracellular antigens. Reichlin M. **Clin Immunol Immunopathol** 1995 Sep;76(3 Pt 1):215–9 (31 ref.)

Glutamic acid decarboxylase and other autoantigens in IDDM. Nepom GT. **Curr Opin Immunol** 1995 Dec; 7(6):825–30 (63 ref.)

Ribonucleoprotein complexes as autoantigens. van Venrooij WJ, et al. **Curr Opin Immunol** 1995 Dec;7(6):819–24 (48 ref.)

T–cell responses to autoantigens in IDDM. The search for the Holy Grail. Roep BO. **Diabetes** 1996 Sep;45(9):1147–56 (123 ref.)

Lupus autoimmunity: from peptides to particles. Mamula MJ. **Immunol Rev** 1995 Apr;144:301–14 (58 ref.)

Induction of antigen–specific unresponsiveness with synthetic peptides: specific immunotherapy for treatment of allergic and autoimmune conditions. Wraith DC. **Int Arch Allergy Immunol** 1995 Dec;108(4):355–9 (29 ref.)

Regulation of CD4 T cell reactivity to self and non–self. Lo D, et al. **Int Rev Immunol** 1995;13(2):147–60 (38 ref.)

Identification of the alpha 3 chain of type IV collagen as the common autoantigen in antibasement membrane disease and Goodpasture syndrome. Kalluri R, et al. **J Am Soc Nephrol** 1995 Oct;6(4):1178–85 (64 ref.)

Insulin–dependent diabetes mellitus as a beta–cell targeted disease of immunoregulation. Bach JF. **J Autoimmun** 1995 Aug;8(4):439–63 (172 ref.)

Cryptocrine signaling in the thymus network and T cell education to neuroendocrine self–antigens. Geenen V, et al. **J Mol Med** 1995 Sep;73(9):449–55 (49 ref.)

An animal model of bullous pemphigoid: what can it teach us? Giudice GJ, et al. **Proc Assoc Am Physicians** 1995 Jul; 107(2):237–41 (33 ref.)

Viruses, cytokines, antigens, and autoimmunity. Gianani R, et al. **Proc Natl Acad Sci U S A** 1996 Mar 19;93(6):2257–9 (43 ref.)

A few autoreactive cells in an autoimmune infiltrate control a vast population of nonspecific cells: a tale of smart bombs and the infantry. Steinman L. **Proc Natl Acad Sci U S A** 1996 Mar 19;93(6):2253–6 (26 ref.)

Antineutrophil cytoplasmic antibodies: major autoantigens, pathophysiology, and disease associations. Schultz DR, et al. **Semin Arthritis Rheum** 1995 Dec;25(3):143–59 (120 ref.)

Role of viruses in the loss of tolerance to self–antigens and in autoimmune diseases. von Herrath MG, et al. **Trends Microbiol** 1995 Nov;3(11):424–30 (61 ref.)

[Autoimmune diseases and autoantigens] Miettinen A. **Duodecim** 1994;110(2):207–14 (38 ref.) **(Fin)**

[Molecular mimicry between LKM 1–autoantigen and HCV–polyproteins] Miyakawa H, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:885–91 (20 ref.) **(Jpn)**

ISOLATION & PURIFICATION

The Heymann nephritis antigenic complex: megalin (gp330) and RAP [editorial] Farquhar MG, et al. **J Am Soc Nephrol** 1995 Jul;6(1):35–47 (70 ref.)

PHARMACOLOGY

Treatment of autoimmune disease by oral tolerance to autoantigens. Whitacre CC, et al. **Clin Immunol Immunopathol** 1996 Sep;80(3 Pt 2):S31–9 (75 ref.)

Autoantigen–induced deletion of peripheral self–reactive T cells. Miller JF. **Int Rev Immunol** 1995;13(2):107–14 (47 ref.)

PHYSIOLOGY

Ro/SS–A and La/SS–B: autoantigens in Sjögren's syndrome? Smeenk RJ. **Clin Rheumatol** 1995 Jul;14 Suppl 1:11–6 (53 ref.)

The role of the La autoantigen in internal initiation. Belsham GJ, et al. **Curr Top Microbiol Immunol** 1995;203:85–98 (57 ref.)

AUTOCRINE MOTILITY FACTOR

PHYSIOLOGY

Stimulation and regulation of tumor cell motility in invasion and metastasis. Levine MD, et al. **EXS** 1995;74:157–79 (135 ref.)

AUTOGRAFT see TRANSPLANTATION, AUTOLOGOUS

AUTOIMMUNE DISEASES

The variant forms of autoimmune hepatitis. Czaja AJ. **Ann Intern Med** 1996 Oct 1;125(7):588–98 (85 ref.)

Viral myocarditis: are we dealing with an autoimmune phenomenon? Finkelstein Y, et al. **Ann Med Interne (Paris)** 1995;146(5):322–4 (28 ref.)

The effects of pregnancy on autoimmune diseases. Buyon JP, et al. **Clin Immunol Immunopathol** 1996 Feb; 78(2):99–104 (57 ref.)

Selection of ligands for polyclonal antibodies from random peptide libraries: potential identification of (auto)antigens that may trigger B and T cell responses in autoimmune diseases. Sioud M, et al. **Clin Immunol Immunopathol** 1996 May;79(2):105–14 (65 ref.)

Cicatricial pemphigoid: diagnosis and treatment. Nguyen QD, et al. **Int Ophthalmol Clin** 1996 Winter;36(1):41–60 (52 ref.)

Inclusion body myositis [editorial] Garlepp MJ, et al. **J Neurol Neurosurg Psychiatry** 1996 Mar;60(3):251–5 (73 ref.)

Autoimmune hepatitis. Krawitt EL. **N Engl J Med** 1996 Apr 4;334(14):897–903 (79 ref.)

Protean clinical presentation of antiphospholipid–protein antibodies (APA). Triplett DA. **Thromb Haemost** 1995 Jul; 74(1):329–37 (138 ref.)

[Autoimmune enteropathy] Lachaux A. **Arch Pediatr** 1996 Mar;3(3):261–6 (32 ref.) (Eng. Abstr.) **(Fre)**

[Autoimmune hepatitis and hepatitis C] Cacoub P, et al. **Rev Med Interne** 1996;17(2):131–4 (23 ref.) (Eng. Abstr.) **(Fre)**

[Human leukocyte antigen (HLA) and the related diseases] Mizuki N, et al. **Nippon Naika Gakkai Zasshi** 1995 Dec 10;84(12):2091–103 (12 ref.) **(Jpn)**

[Autoimmune liver cirrhosis] Yamada G, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):175–80 (13 ref.) **(Jpn)**

[Retrovirus and autoimmune diseases] Shibata M, et al. **Ryumachi** 1995 Aug;35(4):705–11 (33 ref.) **(Jpn)**

[Autoimmune diseases of the liver, III. Primary sclerosing cholangitis] Garassini Serra MA, et al. **G E N** 1995 Apr–Jun;49(2):170–8 (59 ref.) (Eng. Abstr.) **(Spa)**

[Liver autoimmune diseases. II. Primary biliary cirrhosis] Garassini Serra MA, et al. **G E N** 1995 Jan–Mar;49(1):82–9 (55 ref.) **(Spa)**

CHEMICALLY INDUCED

Mercury: god of Th2 cells? [editorial; comment] Mathieson PW. **Clin Exp Immunol** 1995 Nov;102(2):229–30 (26 ref.) Comment on: Clin Exp Immunol 1995 Nov;102(2):297–307.

Metal ion induced autoimmunity. Griem P, et al. **Curr Opin Immunol** 1995 Dec;7(6):831–8 (57 ref.)

Hydralazine–induced constrictive pericarditis. Franssen CF, et al. **Neth J Med** 1996 May;48(5):193–7 (21 ref.)

Cytokine knockout mice: possible application in toxicological research. Ryffel B. **Toxicology** 1995 Dec 20;105(1):69–80 (55 ref.)

COMPLICATIONS

Autoimmune hepatitis in a patient with sickle cell disease. el Younis CM, et al. **Am J Gastroenterol** 1996 May; 91(5):1016–8 (26 ref.)

Concurrent thrombotic thrombocytopenic purpura and immune thrombocytopenic purpura in an HIV–positive patient: case report and review of the literature. Yospur LS, et al. **Am J Hematol** 1996 Jan;51(1):73–8 (29 ref.)

Rheumatological manifestations of haematological diseases. Menon S, et al. **Ann Rheum Dis** 1995 Oct;54(10):787–95 (126 ref.)

Aortic aneurysms in patients with autoimmune disorders treated with corticosteroids. Sato O, et al. **Eur J Vasc Endovasc Surg** 1995 Oct;10(3):366–9 (17 ref.)

Fever in rheumatic and autoimmune disease. Carsons SE. **Infect Dis Clin North Am** 1996 Mar;10(1):67–84 (49 ref.)

Autoimmune premature ovarian failure. Kim JG, et al. **J Obstet Gynaecol** 1995 Feb;21(1):59–66 (53 ref.)

Recurrent hypoglycaemia caused by the insulin autoimmune syndrome: the first Dutch case [see comments] Schlemper RJ, et al. **Neth J Med** 1996 May;48(5):188–92 (27 ref.) Comment in: Neth J Med 1996 May;48(5):167–8.

[Inclusion body myositis] Serratrice G. **Presse Med** 1996 Jun 15;25(21):985–8 (23 ref.) (Eng. Abstr.) **(Fre)**

[Malignancy in autoimmune diseases] Sugai S. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Feb;19(1):1–14 (38 ref.) (Eng. Abstr.) **(Jpn)**

[HCV infection in autoimmune hepatitis] Komeda T, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:871–6 (23 ref.) **(Jpn)**

DIAGNOSIS

Anti–neutrophil cytoplasmic antibodies in generalized autoimmune diseases. Schnabel A, et al. **Int Arch Allergy Immunol** 1996 Mar;109(3):201–6 (32 ref.)

Diagnosis and therapy of autoimmune liver disease. Czaja AJ. **Med Clin North Am** 1996 Sep;80(5):973–94 (100 ref.)

[The diagnosis and therapy of acquired factor–VIII inhibitors in combination with lupus anticoagulants] Grossmann R, et al. **Dtsch Med Wochenschr** 1996 Jul 12;121(28–29):906–10 (14 ref.) (Eng. Abstr.) **(Ger)**

[Diagnosis and therapy of autoimmune hepatitis] Heintges T, et al. **Z Gastroenterol** 1995 Aug;33(8):462–7 (52 ref.) (Eng. Abstr.) **(Ger)**

[Postgravid health care and laboratory tests] Hidaka Y, et al. **Rinsho Byori** 1995 Nov;43(11):1101–7 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Autoimmune hepatitis] Zeniya M, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):526–33 (25 ref.) **(Jpn)**

[Endocrine exophthalmos] Apostol S, et al. **Oftalmologia** 1996 Jan–Mar;40(1):4–10 (5 ref.) (Eng. Abstr.) **(Rum)**

DRUG THERAPY

Immunosuppressive treatment for myocarditis and dilated cardiomyopathy. Maisch B, et al. **Eur Heart J** 1995 Dec; 16 Suppl O:153–61 (81 ref.)

Pharmacological intervention in antibody mediated disease. Coutts SM, et al. **Lupus** 1996 Apr;5(2):158–9 (13 ref.)

Diagnosis and therapy of autoimmune liver disease. Czaja AJ. **Med Clin North Am** 1996 Sep;80(5):973–94 (100 ref.)

Management of acquired bullous skin diseases [see comments] Fine JD. **N Engl J Med** 1995 Nov 30;333(22):1475–84 (112 ref.) Comment in: N Engl J Med 1996 Mar 28;334(13):864–5. Comment in: N Engl J Med 1996 Mar 28;334(13):865.

Deoxyspergualin: a new immunosuppressive drug for the treatment of auto–immune disease [editorial] Nikolic–Paterson DJ, et al. **Nephron** 1995;70(4):391–6 (63 ref.)

[Treatment of inflammation with anti–inflammatory cytokines: example in models of auto–immune diseases] Bessis N, et al. **C R Seances Soc Biol Fil** 1995;189(4):579–90 (33 ref.) (Eng. Abstr.) **(Fre)**

[Pemphigus vulgaris. Clinical aspects, pathophysiology and therapy of a bullous autoimmune dermatosis] Sunderkötter CH, et al. **Med Monatsschr Pharm** 1995 Sep;18(9):255–63 (39 ref.) **(Ger)**

[Pulse–dose cyclophosphamide therapy for steroid–refractory autoimmune neurological diseases] Watanabe T, et al. **Rinsho Shinkeigaku** 1995 Jun;35(6):611–6 (30 ref.) (Eng. Abstr.) **(Jpn)**

EPIDEMIOLOGY

Combined autoimmune cytopenias. Martino R, et al. **Haematologica** 1995 Jul–Aug;80(4):305–10 (25 ref.)

Exposure to superantigens as an immunogenetic explanation of type I diabetes mini–epidemics. Trucco M, et al. **J Pediatr Endocrinol Metab** 1995 Jan–Mar;8(1):3–10 (41 ref.)

ETIOLOGY

Silica exposure and autoimmune diseases. Steenland K, et al. **Am J Ind Med** 1995 Nov;28(5):603–8 (24 ref.)

Interferon or hepatitis C virus induced autoimmune aplastic anemia and severe thrombocytopenia? A case report. Siciliano R, et al. **Ann Ital Med Int** 1995 Jul–Sep; 10(3):193–4 (10 ref.)

Autoimmune hepatitis. Mieli–Vergani G, et al. **Arch Dis Child** 1996 Jan;74(1):2–5 (35 ref.)

TSH receptor and disease. Tonacchera M, et al. **Clin Endocrinol (Oxf)** 1996 Jun;44(6):621–33 (106 ref.)

The role of programmed cell death as an emerging new concept for the pathogenesis of autoimmune diseases. Mountz JD, et al. **Clin Immunol Immunopathol** 1996 Sep; 80(3 Pt 2):S2–14 (103 ref.)

The pathogenesis of postinfectious myocarditis. Rose NR, et al. **Clin Immunol Immunopathol** 1996 Sep;80(3 Pt 2):S92–9 (51 ref.)

T cell receptor usage in autoimmune disease. Olive C. **Immunol Cell Biol** 1995 Aug;73(4):297–307 (174 ref.)

Cryoglobulinemia: recent findings in cutaneous and extracutaneous manifestations. Davis MD, et al. **Int J Dermatol** 1996 Apr;35(4):240–8 (50 ref.)

Antigen presentation in the pathogenesis of autoimmune endocrine disease. Weetman AP. **J Autoimmun** 1995 Jun; 8(3):305–12 (38 ref.)

Autoimmune disease of the kidney: an update. Biancone L, et al. **Proc Soc Exp Biol Med** 1996 Jul;212(3):225–38 (175 ref.)

Immune–mediated side–effects of cytokines in humans. Vial T, et al. **Toxicology** 1995 Dec 20;105(1):31–57 (239 ref.)

[Autoimmune liver disease complicating Sjögren's syndrome] Masaki N, et al. **Nippon Rinsho** 1995 Oct;53(10):2530–5 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Campylobacter jejuni and autoimmune–mediated neurologic

diseases: pathogenesis of Guillain-Barré syndrome and Fisher's syndrome] Yuki N. **Nippon Saikingaku Zasshi** 1995 Oct;50(4):991-1003 (41 ref.) **(Jpn)**

[A case of primary biliary cirrhosis complicated with autoimmune hepatitis] Nakao M, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Jan;93(1):49-53 (23 ref.) **(Jpn)**

[Autoimmune hypoglycemia] Wiszniewski P, et al. **Pol Arch Med Wewn** 1995 Mar;93(3):250-2 (18 ref.) **(Pol)**

[The current concepts of the etiology and pathogenesis of autoimmune endocrinopathies (editorial)] Lukianchikov VS, et al. **Ter Arkh** 1995;67(10):3-6 (22 ref.) **(Rus)**

GENETICS

Gene hypothesis of autoimmunity, and autoimmune disease. Storch WB. **Adv Exp Med Biol** 1995;371B:1213-5 (22 ref.)

Genetic analysis of autoimmune disease. Vyse TJ, et al. **Cell** 1996 May 3;85(3):311-8 (73 ref.)

Genetics of autoimmune disease. Merriman TR, et al. **Curr Opin Immunol** 1995 Dec;7(6):786-92 (69 ref.)

Transgenic/knockout mice--tools to study autoimmunity. Mueller R, et al. **Curr Opin Immunol** 1995 Dec;7(6):799-803 (53 ref.)

Twin studies in insulin dependent diabetes and other autoimmune diseases. Rowe RE, et al. **Diabetes Metab Rev** 1995 Jul;11(2):121-35 (85 ref.)

Immunoprinting reveals different genetic bases for (auto)immuno diseases. Epplen C, et al. **Electrophoresis** 1995 Sep;16(9):1693-7 (32 ref.)

TCR gene polymorphisms and autoimmune disease. Kay RA. **Eur J Immunogenet** 1996 Apr;23(2):161-77 (129 ref.)

Genetics of autoimmune diseases. Miller FW. **Exp Clin Immunogenet** 1995;12(3):182-90 (52 ref.)

Genetics of tumour necrosis factor-alpha in autoimmune, infectious, and neoplastic diseases. Wilson AG, et al. **J Inflamm** 1995;45(1):1-12 (114 ref.)

Genetic background and environment contribute synergistically to the onset of autoimmune diseases. Luppi P, et al. **J Mol Med** 1995 Aug;73(8):381-93 (190 ref.)

IMMUNOLOGY

Immune-mediated cell death in neurodegenerative disease. Appel SH, et al. **Adv Neurol** 1996;69:153-9 (55 ref.)

Transient hemorrhagic diathesis associated with an inhibitor of prothrombin with lupus anticoagulant in a 1 1/2-year-old girl: report of a case and review of the literature. Lee MT, et al. **Am J Hematol** 1996 Apr; 51(4):307-14 (46 ref.)

B-1 cellular origin and VH segment structure of IgG, IgA, and IgM anti-DNA autoantibodies in patients with systemic lupus erythematosus. Kasaian MT, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:410-23 (52 ref.)

Human cytokine autoantibodies. Characteristics, test procedures and possible physiological and clinical significance. Hansen MB. **APMIS Suppl** 1996;59:1-33 (258 ref.)

Dermatological presentation of disease associated with antineutrophil cytoplasmic antibodies: a report of two contrasting cases and a review of the literature. Irvine AD, et al. **Br J Dermatol** 1996 May;134(5):924-8 (30 ref.)

The contribution of animal models to the understanding of the pathogenesis of type 1 diabetes. Carnaud C. **Braz J Med Biol Res** 1995 Aug;28(8):925-9 (35 ref.)

Nitric oxide in infectious and autoimmune diseases. Liew FY. **Ciba Found Symp** 1995;195:234-9; discussion 239-44 (26 ref.)

T cell subsets in infectious and autoimmune diseases. Introduction. Mitchison NA. **Ciba Found Symp** 1995; 195:1-5; discussion 5-6 (9 ref.)

Anti-endothelial cell antibodies: only for scientists or for clinicians too? Meroni PL, et al. **Clin Exp Immunol** 1996 May;104(2):199-202 (29 ref.)

Autoimmune diseases and monoclonal gammopathies. Youinou P, et al. **Clin Exp Rheumatol** 1996 Jan-Feb;14 Suppl 14:S55-8 (27 ref.)

Animal models of human disease. Transgenic and knockout models of autoimmunity: Building a better disease? [see comments] Lo D. **Clin Immunol Immunopathol** 1996 May; 79(2):96-104 (60 ref.) Comment in: Clin Immunol Immunopathol 1996 May;79(2):93-4.

Treatment of autoimmune disease by oral tolerance to autoantigens. Whitacre CC, et al. **Clin Immunol Immunopathol** 1996 Sep;80(3 Pt 2):S31-9 (75 ref.)

Bacterial pyrogenic exotoxins as superantigens. Kotb M. **Clin Microbiol Rev** 1995 Jul;8(3):411-26 (292 ref.)

Apoptosis in brain-specific autoimmune disease. Bauer J, et al. **Curr Opin Immunol** 1995 Dec;7(6):839-43 (48 ref.)

Transgenic/knockout mice--tools to study autoimmunity. Mueller R, et al. **Curr Opin Immunol** 1995 Dec;7(6):799-803 (53 ref.)

Leucocyte migration into autoimmune diseased endocrine tissues [comment] Delemarre FG, et al. **Eur J Endocrinol** 1996 Jan;134(1):9-11 (35 ref.) Comment on: Eur J Endocrinol 1996 Jan;134(1):51-60.

TCR gene polymorphisms and autoimmune disease. Kay RA. **Eur J Immunogenet** 1996 Apr;23(2):161-77 (129 ref.)

Oral tolerance: mobilizing the gut. Weiner HL. **Hosp Pract (Off Ed)** 1995 Sep 15;30(9):53-8 (6 ref.)

Primary biliary cirrhosis: the molecule and the mimic. Coppel RL, et al. **Immunol Rev** 1995 Apr;144:17-49 (140 ref.)

Chronicity of tissue-specific experimental autoimmune disease: a role for B cells? Holmdahl R, et al. **Immunol Rev** 1995 Apr;144:109-35 (164 ref.)

Organ-specific autoimmunity. Bach JF. **Immunol Today** 1995 Jul;16(7):353-5 (15 ref.)

Involvement of B-1 cells in mucosal immunity and autoimmunity. Murakami M, et al. **Immunol Today** 1995 Nov;16(11):534-9 (38 ref.)

The role of IL-12 in the induction of organ-specific autoimmune diseases. Trembleau S, et al. **Immunol Today** 1995 Aug;16(8):383-6 (51 ref.)

Leprous neuropathy as an autoimmune phenomenon. Desikan P. **Indian J Lepr** 1996 Jan-Mar;68(1):15-21 (34 ref.)

Immune network and autoimmunity. George J, et al. **Intern Med** 1996 Jan;35(1):3-9 (49 ref.)

Identification of the alpha 3 chain of type IV collagen as the common autoantigen in antibasement membrane disease and Goodpasture syndrome. Kalluri R, et al. **J Am Soc Nephrol** 1995 Oct;6(4):1178-85 (64 ref.)

On the issue of inappropriate HLA class II expression on endocrine cells: an answer to a sceptic. Todd I, et al. **J Autoimmun** 1995 Jun;8(3):313-22 (48 ref.)

Lupus in the Fas lane? Singh AK. **J R Coll Physicians Lond** 1995 Nov-Dec;29(6):475-8 (40 ref.)

Psoriasis, T cells and autoimmunity. Griffiths CE, et al. **J R Soc Med** 1996 Jun;89(6):315-9 (60 ref.)

The Hughlings Jackson Lecture: autoimmunity and the nervous system. Newsom-Davis J. **J R Soc Med** 1995 Nov; 88(11):639P-643P (20 ref.)

Recent progress in studies on autoantigens for various autoimmune blistering skin diseases. Hashimoto T. **Keio J Med** 1995 Dec;44(4):115-23 (84 ref.)

Autoimmune hepatitis versus viral hepatitis C. Strassburg CP, et al. **Liver** 1995 Oct;15(5):225-32 (72 ref.)

Managing HIV. Part 3. Mechanisms of disease. 3.4 How HIV leads to autoimmune disorders. Gala S, et al. **Med J Aust** 1996 Feb 19;164(4):224-6 (15 ref.)

Structure and function of the natural-resistance-associated macrophage protein (Nramp1), a candidate protein for infectious and autoimmune disease susceptibility. Blackwell JM. **Mol Med Today** 1996 May;2(5):205-11 (38 ref.)

Checkpoints in the progression of autoimmune disease: lessons from diabetes models. André I, et al. **Proc Natl Acad Sci U S A** 1996 Mar 19;93(6):2260-3 (67 ref.)

Superantigens: structure and relevance to human disease. Johnson HM, et al. **Proc Soc Exp Biol Med** 1996 Jun; 212(2):99-109 (88 ref.)

Superantigens in autoimmune disease. Youinou P, et al. **Rev Rhum Engl Ed** 1995 Oct;62(9):591-7 (35 ref.)

Abnormal cellular immune mechanisms associated with autoimmune thrombocytopenia. Semple JW, et al. **Transfus Med Rev** 1995 Oct;9(4):327-38 (102 ref.)

[Autoimmune diseases and autoantigens] Miettinen A. **Duodecim** 1994;110(2):207-14 (38 ref.) **(Fin)**

[Superantigens and their implication in autoimmune diseases] Meyer O. **Presse Med** 1995 Sep 2-9;24(25):1171-7 (28 ref.) (Eng. Abstr.) **(Fre)**

[Autoimmune diseases of the peripheral cornea. Immunopathology, clinical aspects and therapy] Pleyer U, et al. **Klin Monatsbl Augenheilkd** 1996 Feb;208(2):73-81 (45 ref.) (Eng. Abstr.) **(Ger)**

[The role of Fc gamma R specific autoantibodies in autoimmune diseases. Review of the literature and authors' own research] Szegedi A, et al. **Orv Hetil** 1996 Mar 17; 137(11):581-4 (34 ref.) (Eng. Abstr.) **(Hun)**

[Autoimmune Addison's disease. Current knowledge and prospects] De Bellis A, et al. **Minerva Endocrinol** 1996 Mar; 21(1):1-6 (35 ref.) (Eng. Abstr.) **(Ita)**

[Recent findings on antigens reactive to antiphospholipid antibodies] Matsuda S. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Feb;19(1):27-38 (66 ref.) **(Jpn)**

[Heat shock protein and immunity] Nomaguchi H. **Nippon Rai Gakkai Zasshi** 1995 Nov;64(3):188-99 (66 ref.) **(Jpn)**

[Clinical manifestation and immunogenetic background of HCV-marker-positive autoimmune hepatitis] Zeniya M. **Nippon Rinsho** 1995 Sep;53 Suppl:877-84 (11 ref.) **(Jpn)**

[Immune cytopenias and some associated problems of immunohematology] Zotikov EA. **Biull Eksp Biol Med** 1996 Apr;121(4):364-9 (41 ref.) **(Rus)**

[Autoimmune diseases of the liver. Autoimmune hepatitis] Garassini Serra MA, et al. **G E N** 1994 Oct-Dec; 48(4):256-63 (51 ref.) **(Spa)**

[Structure and function of the T-lymphocyte antigen receptor and its role in infectious diseases] Peralta Zaragoza O, et al. **Rev Invest Clin** 1996 Jan-Feb;48(1):69-79 (84 ref.) (Eng. Abstr.) **(Spa)**

PATHOLOGY

Immune-mediated cell death in neurodegenerative disease. Appel SH, et al. **Adv Neurol** 1996;69:153-9 (55 ref.)

The pathology of the endocrine pancreas in type 1 (insulin-dependent) diabetes mellitus. Foulis AK. **APMIS** 1996 Mar;104(3):161-7 (32 ref.)

The role of programmed cell death as an emerging new concept for the pathogenesis of autoimmune diseases. Mountz JD, et al. **Clin Immunol Immunopathol** 1996 Sep; 80(3 Pt 2):S2-14 (103 ref.)

Dermatitis herpetiformis associated with lichen planopilaris. Isaac M, et al. **J Am Acad Dermatol** 1995 Dec;33(6):1050-1 (3 ref.)

[Autoimmune hepatitis] Dienes HP. **Verh Dtsch Ges Pathol** 1995;79:177-85 (18 ref.) (Eng. Abstr.) **(Ger)**

[Apoptosis in autoimmune diseases] Kobayashi S, et al. **Ryumachi** 1995 Aug;35(4):712-25 (64 ref.) **(Jpn)**

[Apoptosis and autoimmune diseases (editorial)] Font J, et al. **Med Clin (Barc)** 1996 Apr 27;106(16):619-21 (37 ref.) **(Spa)**

PHYSIOPATHOLOGY

Sex steroids and the immune system. Fox HS. **Ciba Found Symp** 1995;191:203-11; discussion 211-7 (31 ref.)

Cytokines and the endocrine system. II. Roles in substrate metabolism, modulation of thyroidal and pancreatic endocrine cell functions and autoimmune endocrine diseases. Mandrup-Poulsen T, et al. **Eur J Endocrinol** 1996 Jan;134(1):21-30 (174 ref.)

Pre-eclampsia, autoimmune diseases and breast cancer etiology. Polednak AP. **Med Hypotheses** 1995 May; 44(5):414-8 (46 ref.)

[Fungi and autoimmune conditions] George J, et al. **Harefuah** 1996 Mar 15;130(6):388-90 (24 ref.) **(Heb)**

PREVENTION & CONTROL

The development and use of T cell receptor peptide vaccines. Brostoff S. **Adv Exp Med Biol** 1995;383:249-54 (18 ref.)

Immunotolerance and prevention of ocular autoimmune disease. Rizzo LV, et al. **Curr Eye Res** 1995 Sep; 14(9):857-64 (99 ref.)

Vitamin C and the genesis of autoimmune disease and allergy (review). Kodama M, et al. **In Vivo** 1995 May-Jun; 9(3):231-8 (38 ref.)

Vaccines to prevent and treat autoimmune diseases. Mor F, et al. **Int Arch Allergy Immunol** 1995 Dec;108(4):345-9 (42 ref.)

RADIOGRAPHY

Inflammatory myopathies: radiologic evaluation. Fleckenstein JL, et al. **Radiol Clin North Am** 1996 Mar; 34(2):427-39, xii (92 ref.)

THERAPY

Treatment of autoimmune diseases by oral tolerance to autoantigens. Weiner HL, et al. **Adv Exp Med Biol** 1995; 371B:1217-23 (30 ref.)

Bone marrow transplantation in auto-immune disease. Hamilton JA, et al. **Baillieres Clin Rheumatol** 1995 Nov; 9(4):673-87 (58 ref.)

Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology [see comments] George JN, et al. **Blood** 1996 Jul 1;88(1):3-40 (295 ref.) Comment in: Blood 1996 Jul 1;88(1):1-2.

The use of oral tolerance as a therapy for ocular autoimmunity. Rizzo LV. **Braz J Med Biol Res** 1995 Aug; 28(8):931-6 (23 ref.)

Mechanisms of action of intravenous immune globulin in immune-mediated diseases. Mouthon L, et al. **Clin Exp Immunol** 1996 May;104 Suppl 1:3-9 (63 ref.)

Antigen-specific immunotherapy of autoimmune disease: a commentary [editorial] Wraith DC. **Clin Exp Immunol** 1996 Mar;103(3):349-52 (38 ref.)

Adhesion molecules as targets for the treatment of autoimmune diseases. Oppenheimer-Marks N, et al. **Clin Immunol Immunopathol** 1996 Jun;79(3):203-10 (58 ref.)

Treatment of autoimmune disease by oral tolerance to autoantigens. Whitacre CC, et al. **Clin Immunol Immunopathol** 1996 Sep;80(3 Pt 2):S31-9 (75 ref.)

Vaccines to prevent and treat autoimmune diseases. Mor F, et al. **Int Arch Allergy Immunol** 1995 Dec;108(4):345-9 (42 ref.)

Induction of antigen-specific unresponsiveness with synthetic peptides: specific immunotherapy for treatment of allergic and autoimmune conditions. Wraith DC. **Int Arch Allergy Immunol** 1995 Dec;108(4):355-9 (29 ref.)

Idiopathic thrombocytopenic purpura (ITP): immunomodulation by intravenous immunoglobulin (IVIg). Imbach P, et al. **Int Rev Immunol** 1989;5(2):181-8 (34 ref.)

Treatment of systemic and renal-limited vasculitic disorders with pooled human intravenous immune globulin. Jordan SC. **J Clin Immunol** 1995 Nov;15(6 Suppl):76S-85S (40 ref.)

T cell receptor peptides in treatment of autoimmune disease: rationale and potential. Vandenbark AA, et al. **J Neurosci Res** 1996 Feb 15;43(4):391-402 (80 ref.)

Antigen-specific therapies for the treatment of autoimmune diseases. Hafler DA, et al. **Springer Semin Immunopathol** 1995;17(1):61-76 (78 ref.)

Immunospecific drug design--prospects for treatment of autoimmune diseases. Arnon R, et al. **Ther Immunol** 1994 Jan;1(1):65-70 (59 ref.)

Mucosal tolerance and the immunotherapy of autoimmune disease: a commentary. Wraith DC, et al. **Ther Immunol** 1995 Feb;2(1):53-8 (49 ref.)

[Plasma- and lymphapheresis in autoimmune diseases] Schneider M. **Z Rheumatol** 1996 Mar-Apr;55(2):90-104

(165 ref.) (Eng. Abstr.) **(Ger)**
[Indication for use and mechanisms of action of intravenous immune globulin in autoimmune diseases] Cohen AD, et al. **Harefuah** 1995 Aug;129(3–4):123–7 (50 ref.) **(Heb)**
[Selection of therapy for chronic hepatitis C with feature of autoimmune hepatitis] Kakumu S. **Nippon Rinsho** 1995 Sep;53 Suppl:892–6 (16 ref.) **(Jpn)**

VIROLOGY

Human T lymphotropic virus type I in arthropathy and autoimmune disorders. Nishioka K, et al. **Arthritis Rheum** 1996 Aug;39(8):1410–8 (55 ref.)
The pathogenesis of postinfectious myocarditis. Rose NR, et al. **Clin Immunol Immunopathol** 1996 Sep;80(3 Pt 2):S92–9 (51 ref.)
Managing HIV. Part 3. Mechanisms of disease. 3.4 How HIV leads to autoimmune disorders. Gala S, et al. **Med J Aust** 1996 Feb 19;164(4):224–6 (15 ref.)
Glomerulonephritis, thrombocytopenia, and autoimmune neutropenia probably induced by a virus-like illness: case report and review of the literature. Mackey JR, et al. **Nephron** 1995;71(4):454–8 (33 ref.)
The Epstein-Barr virus in autoimmunity. Vaughan JH. **Springer Semin Immunopathol** 1995;17(2–3):203–30 (162 ref.)
Role of viruses in the loss of tolerance to self-antigens and in autoimmune diseases. von Herrath MG, et al. **Trends Microbiol** 1995 Nov;3(11):424–30 (61 ref.)
The viral-autoimmunity relationship. Cohen AD, et al. **Viral Immunol** 1995;8(1):1–9 (83 ref.)

AUTOIMMUNE POLYENDOCRINOPATHY-CANDIDIASIS-ECTODERMAL-DYSTROPHY see **POLYENDOCRINOPATHIES, AUTOIMMUNE**

AUTOIMMUNE RESPONSE see **AUTOIMMUNITY**

AUTOIMMUNE SYNDROME TYPE I, POLYGLANDULAR see **POLYENDOCRINOPATHIES, AUTOIMMUNE**

AUTOIMMUNE SYNDROME TYPE II, POLYGLANDULAR see **POLYENDOCRINOPATHIES, AUTOIMMUNE**

AUTOIMMUNE THROMBOCYTOPENIC PURPURA see **PURPURA, THROMBOCYTOPENIC, IDIOPATHIC**

AUTOIMMUNE THYROIDITIS see **THYROIDITIS, AUTOIMMUNE**

AUTOIMMUNITY

see related
AUTOANTIBODIES
AUTOIMMUNE DISEASES

Autoimmunity, apoptosis defects and retroviruses. Mountz JD, et al. **Adv Exp Med Biol** 1995;374:183–201 (84 ref.)
Autoimmunity as an etiological factor in sporadic amyotrophic lateral sclerosis. Appel SH, et al. **Adv Neurol** 1995;68:47–57 (88 ref.)
Amyotrophic lateral sclerosis. An autoimmune disease? Drachman DB, et al. **Adv Neurol** 1995;68:59–65 (54 ref.)
The possible role of a secondary pathogenetic factor in amyotrophic lateral sclerosis. Pinelli P, et al. **Adv Neurol** 1995;68:29–40 (25 ref.)
B-1 cells and autoimmunity. Murakami M, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:402–9 (34 ref.)
Apoptosis and its association with autoimmunity [editorial] George J, et al. **Clin Rheumatol** 1995 Sep;14(5):505–9 (29 ref.)
The Th1/Th2 balance in autoimmunity. Charlton B, et al. **Curr Opin Immunol** 1995 Dec;7(6):793–8 (51 ref.)
The regulation of self-reactive B cells. Cornall RJ, et al. **Curr Opin Immunol** 1995 Dec;7(6):804–11 (52 ref.)
Metal ion induced autoimmunity. Griem P, et al. **Curr Opin Immunol** 1995 Dec;7(6):831–8 (57 ref.)
Immunthrombocytopenic purpura as a model for pathogenesis and treatment of autoimmunity. Imbach P, et al. **Eur J Pediatr** 1995;154(9 Suppl 4):S60–4 (37 ref.)
Costimulation in tolerance and autoimmunity. Guerder S, et al. **Int Rev Immunol** 1995;13(2):135–46 (49 ref.)
Atherosclerosis as an autoimmune condition. Kleindienst R, et al. **Isr J Med Sci** 1995 Oct;31(10):596–9 (26 ref.)
The Hughlings Jackson Lecture: autoimmunity and the nervous system. Newsom-Davis J. **J R Soc Med** 1995 Nov; 88(11):639P–643P (20 ref.)
The clinical significance of an autoimmune response against glutamic acid decarboxylase. Ellis TM, et al. **Nat Med** 1996 Feb;2(2):148–53 (30 ref.)
Viruses, cytokines, antigens, and autoimmunity. Gianani R, et al. **Proc Natl Acad Sci U S A** 1996 Mar 19;93(6):2257–9 (43 ref.)
Balancing immunity and tolerance: deleting and tuning lymphocyte repertoires. Goodnow CC. **Proc Natl Acad Sci U S A** 1996 Mar 19;93(6):2264–71 (256 ref.)
A few autoreactive cells in an autoimmune infiltrate control a vast population of nonspecific cells: a tale of smart bombs and the infantry. Steinman L. **Proc Natl Acad Sci U S A** 1996 Mar 19;93(6):2253–6 (26 ref.)
Autoimmunity in Chagas' heart disease. Cunha-Neto E, et al. **Rev Paul Med** 1995 Mar-Apr;113(2):757–66 (39 ref.)
[Autoimmunity and glutamate decarboxylase antibodies in the pathogenesis of type I diabetes mellitus in experimental and clinical practice] Kučera P, et al. **Vnitr Lek** 1996 May; 42(5):359–67 (65 ref.) (Eng. Abstr.) **(Cze)**

GENETICS

Gene hypothesis of autoimmunity, and autoimmune disease. Storch WB. **Adv Exp Med Biol** 1995;371B:1213–5 (22 ref.)

IMMUNOLOGY

The role of subsets of CD4+ T cells in autoimmunity. Fowell D, et al. **Ciba Found Symp** 1995;195:173–82; discussion 182–8 (42 ref.)
Autoimmunity. The Fas track. Rathmell JC, et al. **Curr Biol** 1995 Nov 1;5(11):1218–21 (31 ref.)
Immune network and autoimmunity. George J, et al. **Intern Med** 1996 Jan;35(1):3–9 (49 ref.)
Infection, evolution and autoimmunity: a hypothesis. Jones DE, et al. **QJM** 1995 Dec;88(12):919–25 (56 ref.)
Autoimmunity. Insights provided by the SCID mouse model. Jorgensen C, et al. **Rev Rhum Engl Ed** 1995 Jul-Sep; 62(7–8):519–24 (38 ref.)
The two-signal model and 'self'-reactivity: are they really compatible? A reply to Faro & Carneiro. Cohn M. **Scand J Immunol** 1996 Jan;43(1):1–5; discussion 6–8 (8 ref.)
T cell immune responses to haptens. Structural models for allergic and autoimmune reactions. Weltzien HU, et al. **Toxicology** 1996 Feb 22;107(2):141–51 (54 ref.)
[B-cell function and autoimmunity in humans] Zouali M. **Arch Inst Pasteur Tunis** 1994 Jul-Oct;71(3–4):511–6 (27 ref.) **(Fre)**
[Apoptosis (programmed cell death) in autoimmunity--autoimmunological aspect] George J, et al. **Harefuah** 1995 Nov 1;129(9):339–41 (27 ref.) **(Heb)**

PHYSIOLOGY

Autoimmunity in the peripheral nervous system. Hartung HP, et al. **Baillieres Clin Neurol** 1996 Mar;5(1):1–45 (310 ref.)

AUTOLOGOUS FIBRIN TISSUE ADHESIVE see **FIBRIN TISSUE ADHESIVE**

AUTOMATED MEDICAL RECORDS SYSTEMS see **MEDICAL RECORDS SYSTEMS, COMPUTERIZED**

AUTOMATIC DATA PROCESSING

Data processing techniques for serial EIT spectroscopy images: a review of some preliminary results. Smallwood RH, et al. **Physiol Meas** 1995 Aug;16(3 Suppl A):A129–42 (37 ref.)

AUTOMATION

INSTRUMENTATION

Psychophysiology and adaptive automation. Byrne EA, et al. **Biol Psychol** 1996 Feb 5;42(3):249–68 (75 ref.)

AUTOMATION, OFFICE see **OFFICE AUTOMATION**

AUTOMATISM

[Uncommon reflex automatisms after brain death] Awada A. **Rev Neurol (Paris)** 1995 Oct;151(10):586–8 (11 ref.) (Eng. Abstr.) **(Fre)**

HISTORY

The evolution and definition of the concept of 'automatism' in Canadian case law. Jang D, et al. **Med Law** 1995; 14(3–4):221–38 (22 ref.)

AUTOMOBILE DRIVING

see related
ACCIDENTS, TRAFFIC
MOTOR VEHICLES

Methamphetamine and driving impairment. Logan BK. **J Forensic Sci** 1996 May;41(3):457–64 (37 ref.)
[Iatrogenic driving incapacity] Beer JH, et al. **Schweiz Med Wochenschr** 1996 Apr 6;126(14):584–93 (46 ref.) (Eng. Abstr.) **(Ger)**
[Neurological diseases and driving] Mola S. **Rev Neurol** 1995 Mar-Apr;23(120):334–50 (139 ref.) (Eng. Abstr.) **(Spa)**

LEGISLATION & JURISPRUDENCE

Drink driving legislation: medicine and the law. Marks P. **Med Leg J** 1995;63 (Pt 3):119–27 (17 ref.)
The older driver—a review. Morgan R, et al. **Postgrad Med J** 1995 Sep;71(839):525–8 (30 ref.)
[Revoking the right to drive—a blunt weapon against alcohol intoxicated drivers, hit-and-run drivers and speed limit and red light offenders? (see comments)] Zabel GE. **Blutalkohol** 1995 Sep;32(5):254–67 (56 ref.) (Eng. Abstr.) Comment in: Blutalkohol 1995 Nov;32(6):314–6. **(Ger)**

AUTOMOBILE EXHAUST see **VEHICLE EMISSIONS**

AUTOMOBILES

see related
AIR BAGS
SEAT BELTS

Thermal aspects of vehicle comfort. Holmér I, et al. **Appl Human Sci** 1995 Jul;14(4):159–65 (19 ref.)

AUTONOMIC FIBERS, POSTGANGLIONIC

PHYSIOLOGY

The ratio of pre- to postganglionic neurons and related issues in the autonomic nervous system. Wang FB, et al. **Brain Res Brain Res Rev** 1995 Jul;21(1):93–115 (260 ref.)

AUTONOMIC FIBERS, PREGANGLIONIC

PHYSIOLOGY

Pre-sympathetic neurones in the rostral ventrolateral medulla of the rat: electrophysiology, morphology and relationship to adjacent neuronal groups. Lipski J, et al. **Acta Neurobiol Exp (Warsz)** 1996;56(1):373–84 (44 ref.)

AUTONOMIC GANGLIA see **GANGLIA, AUTONOMIC**

AUTONOMIC NERVE BLOCK

Does sympathetic ganglionic block prevent postherpetic neuralgia? Literature review. Ali NM. **Reg Anesth** 1995 May-Jun;20(3):227–33 (44 ref.)

AUTONOMIC NERVES see **AUTONOMIC PATHWAYS**

AUTONOMIC NERVOUS SYSTEM

see related
VISCERAL AFFERENTS

CHEMISTRY

Peptides as neurotransmitters in vascular autonomic neurons. Morris JL. **Clin Exp Pharmacol Physiol** 1995 Nov; 22(11):792–802 (119 ref.)

DRUG EFFECTS

Cardiovascular and autonomic effects of sevoflurane. Ebert TJ. **Acta Anaesthesiol Belg** 1996;47(1):15–21 (22 ref.)
Pharmacology of cotransmission in the autonomic nervous system: integrative aspects on amines, neuropeptides, adenosine triphosphate, amino acids and nitric oxide. Lundberg JM. **Pharmacol Rev** 1996 Mar;48(1):113–78 (975 ref.)

EMBRYOLOGY

Autonomic and sensory neuron cultures. Nishi R. **Methods Cell Biol** 1996;51:249–63 (11 ref.)

IMMUNOLOGY

Local regulation of the immune response by the autonomic nervous system. Esquifino AI, et al. **Neuroimmunomodulation** 1994 Sep-Oct;1(5):265–73 (61 ref.)

METABOLISM

Biological adaptation of the myocardium to chronic mechanical overload. Molecular determinants of the autonomic nervous system. Mondry A, et al. **Eur Heart J** 1995 Aug;16 Suppl I:64–73 (96 ref.)

PATHOLOGY

[Acute Chagas cardiopathy. A systematic study of the intracardiac excitatory-conduction and autonomic nervous systems in an autochthonous case in Acre] Rocha A, et al. **Rev Soc Bras Med Trop** 1996 Jul-Aug;29(4):367–71 (12 ref.) (Eng. Abstr.) **(Por)**

PHYSIOLOGY

Interactions and coexistence of neuropeptides and serotonin in spinal autonomic systems. Helke CJ, et al. **Ann N Y Acad Sci** 1996 Mar 22;780:185–92 (49 ref.)
The role of the autonomic nerves in the control of nasal circulation. Lung MA. **Biol Signals** 1995 May-Jun; 4(3):179–85 (33 ref.)
The ratio of pre- to postganglionic neurons and related issues in the autonomic nervous system. Wang FB, et al. **Brain Res Brain Res Rev** 1995 Jul;21(1):93–115 (260 ref.)
Angiotensin II as a modulator of cardiovascular autonomic control. Townend JN. **Cardiologia** 1996 Mar;41(3):217–25 (83 ref.)
Power spectral analysis of heart rate variability during upright tilt test: a comparison of patients with syncope and normal subjects. Boulos M, et al. **Cardiology** 1996 Jan-Feb; 87(1):28–32 (20 ref.)
Cardiovascular protection by oestrogen is partly mediated through modulation of autonomic nervous function. Du

XJ, et al. **Cardiovasc Res** 1995 Aug;30(2):161–5 (57 ref.)
Autonomic receptor—effector coupling during post-natal development. Robinson RB. **Cardiovasc Res** 1996 Feb;31 Spec No:E68–76 (68 ref.)
Capsaicin-sensitive sensory-motor neurotransmission in the peripheral control of cardiovascular function. Rubino A, et al. **Cardiovasc Res** 1996 Apr;31(4):467–79 (160 ref.)
Neurogenic control of the cerebral circulation. Branston NM. **Cerebrovasc Brain Metab Rev** 1995 Winter;7(4):338–49 (61 ref.)
Chronotropic incompetence—Part I: Normal regulation of the heart rate. Camm AJ, et al. **Clin Cardiol** 1996 May; 19(5):424–8 (45 ref.)
Changes in autonomic nervous system activity and consecutive hyperinsulinaemia: respective roles in the development of obesity in rodents. Pénicaud L, et al. **Diabetes Metab** 1996 Feb;22(1):15–24 (67 ref.)
Insulin, corticosterone and the autonomic nervous system in animal obesities: a viewpoint. Jeanrenaud B. **Diabetologia** 1995 Aug;38(8):998–1002 (61 ref.)
How do we study autonomic function in humans? Macdonald IA. **Fundam Clin Pharmacol** 1995;9(5):443–9 (25 ref.)
[Correlation between the nervous system and immune system] Katafuchi T. **Fukuoka Igaku Zasshi** 1996 Jun;87(6):127–32 (3 ref.) **(Jpn)**
[The control of smooth muscle tissues by nonadrenergic noncholinergic (NANC) nerve fibres in the autonomic nervous system] Itoh H, et al. **J Smooth Muscle Res** 1995 Jun;31(3):67–78 (41 ref.) (Eng. Abstr.) **(Jpn)**
[A research tool for autonomic nervous function: methodology and application of microneurography] Mano T. **Masui** 1995;44 Suppl:S17–25 (41 ref.) **(Jpn)**
[Nervous regulation of metabolism] Niijima A. **Nippon Rinsho** 1995 Jun;53 Suppl:3–10 (10 ref.) **(Jpn)**
[Role of the autonomic nervous system (adrenergic, cholinergic and nonadrenergic, noncholinergic) in regulation of respiratory system function] Liebhart J, et al. **Postepy Hig Med Dosw** 1995;49(3):395–407 (45 ref.) (Eng. Abstr.) **(Pol)**
[The current status of the study of the physiology of the autonomic nervous system in Russia] Nozdrachev AD. **Fiziol Zh Im I M Sechenova** 1995 Jan;81(1):3–18 (55 ref.) **(Rus)**
[The neural mechanisms of the autonomic responses evoked by somatic sensory stimulation] Sato A. **Fiziol Zh Im I M Sechenova** 1995 Nov;81(11):56–69 (27 ref.) **(Rus)**
[The chemical structure of the peripheral autonomic (visceral) reflex] Nozdrachev AD. **Usp Fiziol Nauk** 1996 Apr-Jun;27(2):28–60 (74 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Participation of autonomic nervous system in the pathogenesis of Chagas disease. Sterin-Borda LJ, et al. **Acta Physiol Pharmacol Ther Latinoam** 1994;44(4):109–23 (89 ref.)
Biochemical and pharmacologic assessment of autonomic function. Polinsky RJ. **Adv Neurol** 1996;69:373–6 (17 ref.)
Can serial tilt testing be used to evaluate therapy in neurally mediated syncope? Morillo CA, et al. **Am J Cardiol** 1996 Mar 1;77(7):521–3 (34 ref.)
The hibernator heart—nature's model of resistance to ventricular fibrillation. Johansson BW. **Cardiovasc Res** 1996 May;31(5):826–32 (39 ref.)
The autonomic nervous system and the regulation of arterial tone in migraine. Thomsen LL, et al. **Clin Auton Res** 1995 Oct;5(5):243–50 (111 ref.)
Effect of different interventions on heart rate variability after heart transplantation: non-autonomic vs autonomic factors. Bernardi L, et al. **Clin Sci (Colch)** 1996;91 Suppl:22–4 (24 ref.)
Autonomic markers of prognosis after myocardial infarction. La Rovere MT. **Clin Sci (Colch)** 1996;91 Suppl:133–5 (30 ref.)
Analysis of heart rate and blood pressure variability in the assessment of autonomic regulation in arterial hypertension. Parati G, et al. **Clin Sci (Colch)** 1996;91 Suppl:129–32 (39 ref.)
Insulin, corticosterone and the autonomic nervous system in animal obesities: a viewpoint. Jeanrenaud B. **Diabetologia** 1995 Aug;38(8):998–1002 (61 ref.)
The role of the autonomic nervous system in hypertension. Amerena J, et al. **Hypertens Res** 1995 Jun;18(2):99–110 (119 ref.)
Autonomic nervous system and sudden cardiac death. Barron HV, et al. **J Am Coll Cardiol** 1996 Apr;27(5):1053–60 (42 ref.)
Assessment: Clinical autonomic testing report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. **Neurology** 1996 Mar;46(3):873–80 (101 ref.)
Energy homeostasis, autonomic activity and obesity. Scheurink AJ, et al. **Obes Res** 1995 Dec;3 Suppl 5:721S–727S (54 ref.)
Functional alterations of the autonomic nervous system in Chagas' heart disease. Amorim DD, et al. **Rev Paul Med** 1995 Mar-Apr;113(2):772–84 (75 ref.)
[Autonomic nervous systems and cardiovascular diseases] Inoue H. **Nippon Naika Gakkai Zasshi** 1996 Mar 10; 85(3):428–31 (8 ref.) **(Jpn)**
[Laboratory evaluation of autonomic function] Koike Y. **Rinsho Byori** 1995 Sep;43(9):871–6 (9 ref.) (Eng. Abstr.) **(Jpn)**
[Function of the autonomic nervous system in uremia] Rozentryt P, et al. **Postepy Hig Med Dosw** 1995; 49(4):551–61 (100 ref.) (Eng. Abstr.) **(Pol)**
[Neurohormonal factors in heart failure. I] Cosin Aguilar J, et al. **Rev Esp Cardiol** 1996 Apr;49(4):239–52 (112 ref.) (Eng. Abstr.) **(Spa)**

AUTONOMIC NERVOUS SYSTEM DISEASES

The definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. **J Auton Nerv Syst** 1996 Apr 20;58(1–2):123–4 (1 ref.)
[Dysautonomia. An introduction] Soares JL. **Acta Med Port** 1995 Jul-Aug;8(7–8):425–32 (40 ref.) (Eng. Abstr.) **(Por)**

CLASSIFICATION

Failure of the autonomic nervous system. Mitsky V, et al. **Compr Ther** 1995 Sep;21(9):529–34 (8 ref.)
Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. The Consensus Committee of the American Autonomic Society and the American Academy of Neurology. **Neurology** 1996 May;46(5):1470 (1 ref.)

COMPLICATIONS

Disorders affecting autonomic function in parkinsonian patients. Mathias CJ. **Adv Neurol** 1996;69:383–91 (20 ref.)
Disorders of the central and autonomic nervous systems as a cause for emesis in infants. Johns DW. **Semin Pediatr Surg** 1995 Aug;4(3):152–6 (37 ref.)
[Autonomic nervous system disease—sweat disorders] Kihara M, et al. **Nippon Naika Gakkai Zasshi** 1995 Sep 10; 84(9):1435–7 (12 ref.) **(Jpn)**

DIAGNOSIS

Failure of the autonomic nervous system. Mitsky V, et al. **Compr Ther** 1995 Sep;21(9):529–34 (8 ref.)
[Diabetic cardiovascular neuropathy] Luft D. **Z Arztl Fortbild (Jena)** 1996 Apr;90(2):139–43 (38 ref.) (Eng. Abstr.) **(Ger)**
[Uremic autonomic neuropathy—pathogenesis, diagnostic methods] Rozentryt P, et al. **Postepy Hig Med Dosw** 1995; 49(5):671–89 (101 ref.) (Eng. Abstr.) **(Pol)**
[Diagnosis and treatment of the neurovegetative disorders: autonomic neuropathies] Suárez GA. **Rev Neurol** 1996 Jun; 24(130):671–5 (3 ref.) **(Spa)**

DRUG THERAPY

New potential uses for transdermal scopolamine (hyoscine). La Rovere MT, et al. **Drugs** 1995 Nov;50(5):769–76 (49 ref.)

ETIOLOGY

Autonomic disorders in Parkinson's disease. Martignoni E, et al. **J Neural Transm Suppl** 1995;45:11–9 (51 ref.)
Autonomic nervous system disorders and reflex sympathetic dystrophy in lightning and electrical injuries. Cohen JA. **Semin Neurol** 1995 Dec;15(4):387–90 (23 ref.)
[Acute hepatic porphyria and its neurological syndrome] Bont A, et al. **Schweiz Med Wochenschr** 1996 Jan 9; 126(1–2):6–14 (45 ref.) (Eng. Abstr.) **(Ger)**
[Obesity associated with distorted function of autonomic nervous system] Ookuma K, et al. **Nippon Rinsho** 1995 Jun; 53 Suppl:371–6 (13 ref.) **(Jpn)**
[Sensory ataxic neuropathy associated with Sjögren's syndrome] Yasuda T, et al. **Nippon Rinsho** 1995 Oct; 53(10):2568–73 (23 ref.) (Eng. Abstr.) **(Jpn)**
[Uremic autonomic neuropathy—pathogenesis, diagnostic methods] Rozentryt P, et al. **Postepy Hig Med Dosw** 1995; 49(5):671–89 (101 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOPATHOLOGY

Autonomic nervous system dysfunction and adrenoceptor regulation in Parkinson's disease. Clinical and pharmacological consequences. Montastruc JL, et al. **Adv Neurol** 1996;69:377–81 (36 ref.)
Diabetic autonomic neuropathy. Spallone V, et al. **Diabetes Metab Rev** 1995 Oct;11(3):227–57 (322 ref.)
Autonomic epilepsy. Freeman R, et al. **Semin Neurol** 1995 Jun;15(2):158–66 (134 ref.)

SURGERY

[Tumor of the gastrointestinal autonomic nervous system (GAN-tumor or plexus sarcoma)] Flückiger R, et al. **Chirurg** 1996 Apr;67(4):371–9 (20 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Cardiac coherence: a new, noninvasive measure of autonomic nervous system order. Tiller WA, et al. **Altern Ther Health Med** 1996 Jan;2(1):52–65 (65 ref.)
Failure of the autonomic nervous system. Mitsky V, et al. **Compr Ther** 1995 Sep;21(9):529–34 (8 ref.)
[Prevention and treatment of uremic autonomic neuropathy] Rozentryt P, et al. **Postepy Hig Med Dosw** 1995; 49(6):767–82 (97 ref.) (Eng. Abstr.) **(Pol)**

AUTONOMIC PATHWAYS

PHYSIOLOGY

Role of peripheral autonomic neurones in maintaining adequate cardiac function. Horackova M, et al. **Cardiovasc Res** 1995 Sep;30(3):326–35 (88 ref.)
Can the neurotrophic hypothesis explain degeneration and loss of plasticity in mature and ageing autonomic nerves? Gavazzi I, et al. **J Auton Nerv Syst** 1996 Apr 20; 58(1–2):1–10 (79 ref.)

PHYSIOPATHOLOGY

Autonomic nerve affection in leprosy. Katoch K. **Indian J Lepr** 1996 Jan-Mar;68(1):49–54 (33 ref.)

AUTONOMOUS REPLICATION see **DNA REPLICATION**

AUTOPROTHROMBIN II see **FACTOR IX**

AUTOPSY

Autopsy. A crucial component of human clinical investigation. Kaufman SR. **Arch Pathol Lab Med** 1996 Aug;120(8):767–70 (43 ref.)
The autopsy. Some ethical reflections on the obligations of pathologists, hospitals, families, and society. Pellegrino ED. **Arch Pathol Lab Med** 1996 Aug;120(8):739–42 (0 ref.)
Study on electrocution death by low-voltage. Zhang P, et al. **Forensic Sci Int** 1995 Dec 18;76(2):115–9 (4 ref.)
Necropsy as a research method in the age of molecular pathology. Kleiner DE, et al. **Lancet** 1995 Oct 7; 346(8980):945–8 (31 ref.)

ECONOMICS

The role of managed health care organizations in autopsy reimbursement. Chernof D. **Arch Pathol Lab Med** 1996 Aug;120(8):771–2 (0 ref.)
College of American Pathologists Conference XXIX on restructuring autopsy practice for health care reform. Let's make this autopsy conference matter. Lundberg GD. **Arch Pathol Lab Med** 1996 Aug;120(8):736–8 (11 ref.)
The role for regional autopsy centers in the evaluation of covered deaths. Survey of opinions of US and Canadian chairs of pathology and major health insurers in the United States. Trelstad RL, et al. **Arch Pathol Lab Med** 1996 Aug; 120(8):753–8 (48 ref.)
Funding the clinical autopsy [editorial] Start RD, et al. **J Pathol** 1995 Sep;177(1):5–9 (17 ref.)

LEGISLATION & JURISPRUDENCE

A potpourri of legal issues relating to the autopsy. Bierig JR. **Arch Pathol Lab Med** 1996 Aug;120(8):759–62 (26 ref.)

METHODS

Epidemiologic and clinical challenges in reviving the necropsy. Feinstein AR. **Arch Pathol Lab Med** 1996 Aug; 120(8):749–52 (11 ref.)

STANDARDS

On the need for more expertise in death investigation (and a National Office of Death Investigation Affairs?) [editorial] Hanzlick R. **Arch Pathol Lab Med** 1996 Apr; 120(4):329–32 (26 ref.)
Relating autopsy requirements to the contemporary accreditation process. O'Leary DS. **Arch Pathol Lab Med** 1996 Aug;120(8):763–6 (5 ref.)
The need for a national autopsy policy. Setlow VP. **Arch Pathol Lab Med** 1996 Aug;120(8):773–7 (6 ref.)

STATISTICS & NUMERICAL DATA

High autopsy rates at a university medical center. What has gone right? Haque AK, et al. **Arch Pathol Lab Med** 1996 Aug;120(8):727–32 (19 ref.)
Maximizing the benefits of autopsy for clinicians and families. What needs to be done. McPhee SJ. **Arch Pathol Lab Med** 1996 Aug;120(8):743–8 (53 ref.)

AUTORADIOGRAPHY

UTILIZATION

Progressive application of autoradiography in pharmacokinetic and metabolic studies for the development of new drugs. Shigematsu A, et al. **Regul Toxicol Pharmacol** 1995 Oct;22(2):122–42 (20 ref.)

AUTORECEPTORS

PHYSIOLOGY

Somatodendritic autoreceptors on oxytocin neurones. Freund-Mercier MJ, et al. **Adv Exp Med Biol** 1995; 395:185–94 (31 ref.)
Aminotetralin drugs and D3 receptor functions. What may partially selective D3 receptor ligands tell us about dopamine D3 receptor functions? Lévesque D.

AUTORECEPTORS

Biochem Pharmacol 1996 Aug 23;52(4):511–8 (102 ref.)

AUTOREGULATION see **HOMEOSTASIS**

AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY see **KIDNEY, POLYCYSTIC, AUTOSOMAL DOMINANT**

AUTOSOMAL RECESSIVE POLYCYSTIC KIDNEY see **KIDNEY, POLYCYSTIC, AUTOSOMAL RECESSIVE**

AUTOSOME ABNORMALITIES see **CHROMOSOME ABNORMALITIES**

AUTOTRANSFUSION see **BLOOD TRANSFUSION, AUTOLOGOUS**

AUTOTRANSPLANT see **TRANSPLANTATION, AUTOLOGOUS**

AUXINS

PHARMACOLOGY

DNA elements responsive to auxin. Abel S, et al. **Bioessays** 1996 Aug;18(8):647–54 (62 ref.)

AV NODE see **ATRIOVENTRICULAR NODE**

AVAILABILITY EQUIVALENCY see **BIOLOGICAL AVAILABILITY**

AVAILABILITY OF HEALTH SERVICES see **HEALTH SERVICES ACCESSIBILITY**

AVIAN HYPERSENSITIVITY PNEUMONITIS see **BIRD FANCIER'S LUNG**

AVIAN LEUKOSIS

GENETICS

Gene regulation by NF-M and Myb during differentiation and leukemic transformation. Kowenz-Leutz E, et al. **Immunobiology** 1995 Jul;193(2–4):356–62 (15 ref.)

PATHOLOGY

Lymphoid leukosis viruses, their recognition as 'persistent' viruses and comparisons with certain other retroviruses of veterinary importance. Darcel C. **Vet Res Commun** 1996; 20(1):83–108 (112 ref.)

AVIAN LEUKOSIS-SARCOMA VIRUSES see **RETROVIRUSES, ALV-RELATED**

AVIAN MYELOBLASTOSIS VIRUS see **MYELOBLASTOSIS VIRUS, AVIAN**

AVIAN ORTHOMYXOVIRUS TYPE A see **ORTHOMYXOVIRUS TYPE A, AVIAN**

AVIAN PARAMYXOVIRUS TYPE 1 see **NEWCASTLE DISEASE VIRUS**

AVIAN RETICULOENDOTHELIOSIS VIRUS see **RETICULOENDOTHELIOSIS VIRUS, AVIAN**

AVIATION

see related
AIRCRAFT

Convulsive syncope in the aviation environment. Voge VM, et al. **Aviat Space Environ Med** 1995 Dec;66(12):1198–204 (45 ref.)

AVIATION MEDICINE see **AEROSPACE MEDICINE**

AVIDITY, ANTIBODY see **ANTIBODY AFFINITY**

AVITAMINOSIS

[Malnutrition] Hosoda S, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):297–300 (9 ref.) **(Jpn)**

EPIDEMIOLOGY

[Vitamin and mineral deficiency in Mexico. A critical review of the state of the art. II. Vitamin deficiency] Rosado JL, et al. **Salud Publica Mex** 1995 Sep–Oct;37(5):452–61 (59 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

[Vitamin disturbances in chronic renal insufficiency. II. Fat soluble vitamins] Pietrzak I. **Przegl Lek** 1996;53(1):29–32 (22 ref.) (Eng. Abstr.) **(Pol)**

AVOIDANCE LEARNING

PHYSIOLOGY

[Food-acquisition and avoidance behaviors: the role of immunomodulators in their systemic organization] Zhuravlev BV, et al. **Usp Fiziol Nauk** 1996 Apr–Jun; 27(2):90–106 (107 ref.) (Eng. Abstr.) **(Rus)**

AWARENESS

Insight and adherence to treatment in psychotic disorders. Kemp RA, et al. **Br J Hosp Med** 1995 Sep 6–19;54(5):222–7 (46 ref.)

Malignant melanoma: perspectives on incidence and its effects on awareness, diagnosis, and treatment [editorial] Rigel DS. **CA Cancer J Clin** 1996 Jul–Aug;46(4):195–8 (21 ref.)

Insight in clinical psychiatry revisited. Marková IS, et al. **Compr Psychiatry** 1995 Sep–Oct;36(5):367–76 (37 ref.)

Insight in clinical psychiatry. A new model. Marková IS, et al. **J Nerv Ment Dis** 1995 Dec;183(12):743–51 (44 ref.)

Consciousness and the natural method. Flanagan O. **Neuropsychologia** 1995 Sep;33(9):1103–15 (26 ref.)

Insight and psychosis: a social perspective. Johnson S, et al. **Psychol Med** 1995 May;25(3):515–20 (24 ref.)

[Awareness during general anesthesia (editorial)] Ranta S, et al. **Duodecim** 1994;110(21):1967–9 (15 ref.) **(Fin)**

[The phenomenon of hypoglycemia unawareness—definition, frequency, pathogenesis and clinical forms] Mokáň M. **Bratisl Lek Listy** 1995 Aug;96(8):413–9 (39 ref.) (Eng. Abstr.) **(Slo)**

DRUG EFFECTS

Learning during anaesthesia: a review. Andrade J. **Br J Psychol** 1995 Nov;86 (Pt 4):479–506 (110 ref.)

An information processing theory of anaesthesia. Flohr H. **Neuropsychologia** 1995 Sep;33(9):1169–80 (74 ref.)

[Intraoperative awareness and auditory evoked potentials] Schwender D, et al. **Anaesthesist** 1996 Feb;45 Suppl 1:S46–51 (30 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

How good are patients with panic disorder at perceiving their heartbeats? Ehlers A, et al. **Biol Psychol** 1996 Jan 5;42(1–2):165–82 (55 ref.)

Neurobiology of visceral afferent neurons: neuroanatomy, functions, organ regulations and sensations. Jänig W. **Biol Psychol** 1996 Jan 5;42(1–2):29–51 (105 ref.)

Interoception. Vaitl D. **Biol Psychol** 1996 Jan 5;42(1–2):1–27 (100 ref.)

On the neurophysiology of consciousness: Part II. Constraining the semantic problem [see comments] Bogen JE. **Conscious Cogn** 1995 Jun;4(2):137–58 (100 ref.) Comment in: Conscious Cogn 1995 Jun;4(2):159–62. Comment in: Conscious Cogn 1995 Jun;4(2):163–6. Comment in: Conscious Cogn 1995 Jun;4(2):167–71. Comment in: Conscious Cogn 1995 Jun;4(2):172–93.

On the neurophysiology of consciousness: I. An overview. Bogen JE. **Conscious Cogn** 1995 Mar;4(1):52–62 (70 ref.)

Thalamic contributions to attention and consciousness [comment] Newman J. **Conscious Cogn** 1995 Jun; 4(2):172–93 (65 ref.) Comment on: Conscious Cogn 1995 Jun;4(2):137–58.

Physical motion in dreams: one measure of three theories. Porte HS, et al. **J Abnorm Psychol** 1996 Aug;105(3):329–35 (45 ref.)

Consciousness: perspectives from symbolic and connectionist AI. Bechtel W. **Neuropsychologia** 1995 Sep;33(9):1075–86 (37 ref.)

An introduction to the biology of consciousness. Delacour J. **Neuropsychologia** 1995 Sep;33(9):1061–74 (55 ref.)

Cerebral correlates of visual awareness. Milner AD. **Neuropsychologia** 1995 Sep;33(9):1117–30 (84 ref.)

Conscious and pre-conscious processes as seen from the standpoint of sleep-waking cycle neurophysiology. Paré D, et al. **Neuropsychologia** 1995 Sep;33(9):1155–68 (98 ref.)

AXENIC ANIMALS see **GERM-FREE LIFE**

AXEROPHTHAL see **RETINALDEHYDE**

AXILLA

INNERVATION

Axillary neuropathy in volleyball players: report of two cases and literature review. Paladini D, et al. **J Neurol Neurosurg Psychiatry** 1996 Mar;60(3):345–7 (14 ref.)

AXILLARY ARTERY

INJURIES

Axillary artery injuries secondary to anterior dislocation of the shoulder. Gates JD, et al. **J Trauma** 1995 Sep; 39(3):581–3 (17 ref.)

AXIOGRAPHY see **JAW RELATION RECORD**

AXOLOTL see **AMBYSTOMA**

AXON-ASSOCIATED ADHESION MOLECULES see **CELL ADHESION MOLECULES, NEURONAL**

AXON TERMINALS see **PRESYNAPTIC TERMINALS**

AXONAL TRANSPORT

Neurospecific binding, internalization, and retrograde axonal transport. Halpern JL, et al. **Curr Top Microbiol Immunol** 1995;195:221–41 (147 ref.)

PHYSIOLOGY

Tubulin expression and axonal transport in injured and regenerating neurons in the adult mammalian central nervous system. Fournier AE, et al. **Biochem Cell Biol** 1995 Sep–Oct;73(9–10):659–64 (39 ref.)

Functional consequences of retrograde axonal transport of receptor-bound neurotensin. Laduron PM. **Trends Pharmacol Sci** 1995 Oct;16(10):338–43 (55 ref.)

AXONS

CHEMISTRY

Kinesin-II, a membrane traffic motor in axons, axonemes, and spindles. Scholey JM. **J Cell Biol** 1996 Apr;133(1):1–4 (29 ref.)

METABOLISM

Na(+)-Ca2+ exchange in anoxic/ischemic injury of CNS myelinated axons. Stys PK, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:366–78 (41 ref.)

PATHOLOGY

Axonal CIDP: a premature concept? Feasby TE. **Muscle Nerve** 1996 Mar;19(3):372–4 (16 ref.)

PHYSIOLOGY

Human motor units studied by spike-triggered averaging and intraneural motor axon stimulation. Thomas CK. **Adv Exp Med Biol** 1995;384:147–60 (75 ref.)

Neural mechanisms and axon reflexes in asthma. Where are we? Verleden GM. **Biochem Pharmacol** 1996 May 17; 51(10):1247–57 (176 ref.)

Axonal growth mediated by cell adhesion molecules requires activation of fibroblast growth factor receptors. Saffell JL, et al. **Biochem Soc Trans** 1995 Aug;23(3):469–70 (12 ref.)

Axonal regeneration. Brecknell JE, et al. **Biol Rev Camb Philos Soc** 1996 May;71(2):227–55 (260 ref.)

Backpropagation of action potentials generated at ectopic axonal loci: hypothesis that axon terminals integrate local environmental signals. Pinault D. **Brain Res Brain Res Rev** 1995 Jul;21(1):42–92 (484 ref.)

Neuronal growth and death: order and disorder in the axoplasm. Cleveland DW. **Cell** 1996 Mar 8;84(5):663–6 (17 ref.)

Axon guidance molecules. Keynes R, et al. **Cell** 1995 Oct 20;83(2):161–9 (60 ref.)

Schwann cells and the regrowth of axons in the mammalian CNS: a review of transplantation studies in the rat visual system. Harvey AR, et al. **Clin Exp Pharmacol Physiol** 1995 Aug;22(8):569–79 (77 ref.)

Axon guidance: following the Eph plan. Orike N, et al. **Curr Biol** 1996 Feb 1;6(2):108–10 (15 ref.)

Regeneration in the adult mammalian CNS: guided by development. Aubert I, et al. **Curr Opin Neurobiol** 1995 Oct;5(5):625–35 (118 ref.)

The GAL4 system as a tool for unravelling the mysteries of the Drosophila nervous system. Brand AH, et al. **Curr Opin Neurobiol** 1995 Oct;5(5):572–8 (60 ref.)

Myelin-associated glycoprotein: a role in myelination and in the inhibition of axonal regeneration? Filbin MT. **Curr Opin Neurobiol** 1995 Oct;5(5):588–95 (58 ref.)

Olfactory bulb ensheathing glia: a unique cell type with axonal growth-promoting properties. Ramón-Cueto A, et al. **Glia** 1995 Jul;14(3):163–73 (145 ref.)

The pathobiology of traumatically induced axonal injury in animals and humans: a review of current thoughts. Povlishock JT, et al. **J Neurotrauma** 1995 Aug;12(4):555–64 (76 ref.)

PY in the fly receptor-like tyrosine phosphatases in axonal pathfinding. Chien CB. **Neuron** 1996 Jun;16(6):1065–8 (17 ref.)

Degeneration and regeneration of axons in the lesioned spinal cord. Schwab ME, et al. **Physiol Rev** 1996 Apr;76(2):319–70 (774 ref.)

The economics of neurite outgrowth—the addition of new membrane to growing axons. Futerman AH, et al. **Trends Neurosci** 1996 Apr;19(4):144–9 (55 ref.)

[Nerve transplantation in the central nervous system: a strategy for inducing nerve fiber regeneration in lesions of the brain and spinal cord] Gauthier P, et al. **Rev Neurol (Paris)** 1996 Feb;152(2):106–15 (62 ref.) (Eng. Abstr.) **(Fre)**

[The axon reflex: new views in an old area] Nozdrachev AD. **Fiziol Zh Im I M Sechenova** 1995 Nov;81(11):135–42 (24 ref.) **(Rus)**

ULTRASTRUCTURE

Axonal growth mediated by cell adhesion molecules requires activation of fibroblast growth factor receptors. Saffell JL, et al. **Biochem Soc Trans** 1995 Aug;23(3):469–70 (12 ref.)

Neuronal growth and death: order and disorder in the axoplasm. Cleveland DW. **Cell** 1996 Mar 8;84(5):663–6 (17 ref.)

The pathobiology of traumatically induced axonal injury in animals and humans: a review of current thoughts. Povlishock JT, et al. **J Neurotrauma** 1995 Aug;12(4):555–64 (76 ref.)

AXOPLASMIC FLOW see **AXONAL TRANSPORT**

AXOPLASMIC TRANSPORT see **AXONAL TRANSPORT**

AYERZA'S SYNDROME see **HYPERTENSION, PULMONARY**

AYURVEDIC MEDICINE see **MEDICINE, AYURVEDIC**

AZACYCLOPROPANES see **AZIRIDINES**

AZATHIOPRINE

ADMINISTRATION & DOSAGE

[Crohn disease: prevention and drug therapy] Gross V, et al. **Chirurg** 1995 Aug;66(8):757–63 (42 ref.) (Eng. Abstr.) **(Ger)**

[Chronic recurrent subileus due to Strongyloides stercoralis infection under immunosuppressive therapy] Birck R, et al. **Dtsch Med Wochenschr** 1996 May 31;121(22):723–6 (17 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Acute febrile toxic reaction in patients with refractory rheumatoid arthritis who are receiving combined therapy with methotrexate and azathioprine. Blanco R, et al. **Arthritis Rheum** 1996 Jun;39(6):1016–20 (19 ref.)

Azathioprine hypersensitivity-like reactions—a case report and a review of the literature. Knowles SR, et al. **Clin Exp Dermatol** 1995 Jul;20(4):353–6 (35 ref.)

Cutaneous alternariosis in an immunocompromised patient. Chaidemenos GC, et al. **Cutis** 1995 Sep;56(3):145–50 (40 ref.)

Azathioprine-induced pure red-cell aplasia. Pruijt JF, et al. **Nephrol Dial Transplant** 1996 Jul;11(7):1371–3 (20 ref.)

THERAPEUTIC USE

A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Sandborn WJ. **Am J Gastroenterol** 1996 Mar;91(3):423–33 (65 ref.)

Regression of the nephrotic syndrome in rheumatoid arthritis and amyloidosis treated with azathioprine. A case report. Shapiro DL, et al. **Arthritis Rheum** 1995 Dec;38(12):1851–4 (24 ref.)

AZEPINES

PHARMACOLOGY

Activation of the phospholipase/cyclooxygenase cascade in the rabbit cornea by platelet-activating factor is challenged by PAF receptor antagonists. Hurst JS, et al. **J Ocul Pharmacol Ther** 1995 Fall;11(3):329–37 (39 ref.)

AZIDES

[Analysis of GTP-binding protein function with a photoaffinity GTP analog] Hatta S, et al. **Nippon Yakurigaku Zasshi** 1995 Jun;105(6):431–6 (18 ref.) (Eng. Abstr.) **(Jpn)**

AZIDOTHYMIDINE see **ZIDOVUDINE**

AZIRIDINES

TOXICITY

The AF64A model of cholinergic hypofunction: an update. Hanin I. **Life Sci** 1996;58(22):1955–64 (66 ref.)

AZITHROMYCIN

ADMINISTRATION & DOSAGE

Treatment of chancroid with azithromycin. Ballard RC, et al. **Int J STD AIDS** 1996;7 Suppl 1:9–12 (16 ref.)

Azithromycin in gonorrhoea. Waugh MA. **Int J STD AIDS** 1996;7 Suppl 1:2–4 (11 ref.)

ADVERSE EFFECTS

Macrolides versus azalides: a drug interaction update. Amsden GW. **Ann Pharmacother** 1995 Sep;29(9):906–17 (109 ref.)

PHARMACOKINETICS

[Clinical pharmacokinetics of azithromycin] Singlas E. **Pathol Biol (Paris)** 1995 Jun;43(6):505–11 (16 ref.) (Eng. Abstr.) **(Fre)**

PHARMACOLOGY

Review of azithromycin activity against Legionella spp. Edelstein PH. **Pathol Biol (Paris)** 1995 Jun;43(6):569–72 (18 ref.)

[Azithromycin: tissue pharmacology] Bergogne-Bérézin E. **Pathol Biol (Paris)** 1995 Jun;43(6):498–504 (29 ref.) (Eng. Abstr.) **(Fre)**

[New pathogens and mode of action of azithromycin: Toxoplasma gondii] Derouin F. **Pathol Biol (Paris)** 1995 Jun;43(6):561–4 (25 ref.) (Eng. Abstr.) **(Fre)**

[Helicobacter pylori and azithromycin] Mégraud F, et al. **Pathol Biol (Paris)** 1995 Jun;43(6):555–60 (15 ref.) (Eng. Abstr.) **(Fre)**

[Effect of the molecular structure of azithromycin on pharmacokinetics and the antimicrobial activity] Pechère JC. **Pathol Biol (Paris)** 1995 Jun;43(6):483–7 (8 ref.) (Eng. Abstr.) **(Fre)**

[Azithromycin and Mycobacterium avium infection] Perronne C. **Pathol Biol (Paris)** 1995 Jun;43(6):565–7 (12 ref.) (Eng. Abstr.) **(Fre)**

[Azithromycin: critical points] Philippon A, et al. **Pathol Biol (Paris)** 1995 Jun;43(6):488–97 (55 ref.) (Eng. Abstr.) **(Fre)**

THERAPEUTIC USE

Azithromycin. Johnson RB. **Curr Probl Dermatol** 1996; 24:184–93 (30 ref.)

Gonorrhoea: single-dose oral treatment. Kohl PK, et al. **Curr Probl Dermatol** 1996;24:82–9 (29 ref.)

The newer macrolides. Azithromycin and clarithromycin. Zuckerman JM, et al. **Infect Dis Clin North Am** 1995 Sep; 9(3):731–45 (66 ref.)

The potential role of azithromycin in the treatment of prophylaxis of toxoplasmosis. Chang HR. **Int J STD AIDS** 1996;7 Suppl 1:18–22 (34 ref.)

Treatment and prophylaxis of Mycobacterium avium complex. Young LS. **Int J STD AIDS** 1996;7 Suppl 1:23–7 (15 ref.)

[Azithromycin, pharmacodynamic evaluation in animal models] Lagrange PH. **Pathol Biol (Paris)** 1995 Jun; 43(6):515–23 (37 ref.) (Eng. Abstr.) **(Fre)**

[Azithromycin and bronchopulmonary infections] Leophonte P. **Pathol Biol (Paris)** 1995 Jun;43(6):534–41 (38 ref.) (Eng. Abstr.) **(Fre)**

[Azithromycin and genital infections] Micoud M, et al. **Pathol Biol (Paris)** 1995 Jun;43(6):542–6 (19 ref.) (Eng. Abstr.) **(Fre)**

AZOLES

METABOLISM

Ebselen. Sies H. **Methods Enzymol** 1995;252:341–2 (18 ref.)

PHARMACOLOGY

Use of amphotericin B with azole antifungal drugs: what are we doing? Sugar AM. **Antimicrob Agents Chemother** 1995 Sep;39(9):1907–12 (46 ref.)

Molecular actions of ebselen—an antiinflammatory antioxidant. Schewe T. **Gen Pharmacol** 1995 Oct; 26(6):1153–69 (91 ref.)

THERAPEUTIC USE

Use of amphotericin B with azole antifungal drugs: what are we doing? Sugar AM. **Antimicrob Agents Chemother** 1995 Sep;39(9):1907–12 (46 ref.)

AZOOSPERMIA see **OLIGOSPERMIA**

AZOREAN DISEASE see **MACHADO-JOSEPH DISEASE**

AZOSPIRILLUM

METABOLISM

Synthesis of phytohormones by plant-associated bacteria. Costacurta A, et al. **Crit Rev Microbiol** 1995;21(1):1–18 (169 ref.)

AZOTEMIA see **UREMIA**

AZOTOBACTER

ENZYMOLOGY

Vanadium nitrogenases of Azotobacter. Eady RR. **Met Ions Biol Syst** 1995;31:363–405 (106 ref.)

AZT (ANTIVIRAL) see **ZIDOVUDINE**

AZTREONAM

THERAPEUTIC USE

The newer cephalosporins. Aztreonam and imipenem. Ennis DM, et al. **Infect Dis Clin North Am** 1995 Sep;9(3):687–713 (123 ref.)

AZURE STAINS

Comparison of acridine orange and giemsa stains for malaria diagnosis. Kong HH, et al. **Korean J Parasitol** 1995 Dec; 33(4):391–4 (18 ref.)

AZURIN

CHEMISTRY

Electron transfer in ruthenium-modified proteins. Bjerrum MJ, et al. **J Bioenerg Biomembr** 1995 Jun;27(3):295–302 (39 ref.)

METABOLISM

Electron transfer in ruthenium-modified proteins. Bjerrum MJ, et al. **J Bioenerg Biomembr** 1995 Jun;27(3):295–302 (39 ref.)

AZYGOS VEIN

Migration of jugular or subclavian venous catheters into inferior tributaries of the brachiocephalic veins or into the azygos vein, with possible complications. Currarino G. **Pediatr Radiol** 1996 Jul;26(7):439–49 (52 ref.)

ABNORMALITIES

Large spleno-caval shunt not accompanied by cirrhosis or encephalopathy. Mitsui H, et al. **J Gastroenterol** 1996 Apr; 31(2):278–83 (33 ref.)

INJURIES

Traumatic injury to the azygous vein: case report. Butler DA, et al. **J Trauma** 1995 Oct;39(4):761–2 (10 ref.)

ULTRASONOGRAPHY

Azygos vein aneurysm: contribution of transesophageal echography. Léna H, et al. **Ann Thorac Surg** 1996 Apr; 61(4):1253–5 (7 ref.)

B7 ANTIGEN see **ANTIGENS, CD80**

B7-1 COSTIMULATORY MOLECULE see **ANTIGENS, CD80**

B16 MELANOMA see **MELANOMA, EXPERIMENTAL**

B220 ANTIGENS see **ANTIGENS, CD45**

B-CELL ACTIVATION ANTIGEN see **ANTIGENS, CD80**

B-CELL DIFFERENTIATION ANTIGENS see **ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE**

B-CELL DIFFERENTIATION FACTOR-2 see **INTERLEUKIN-6**

B-CELL GENE REARRANGEMENT see **GENE REARRANGEMENT, B-LYMPHOCYTE**

B-CELL GROWTH FACTOR see **INTERLEUKIN-4**

B-CELL GROWTH FACTOR-II see **INTERLEUKIN-5**

B-CELL HEAVY CHAIN GENE REARRANGEMENT see **GENE REARRANGEMENT, B-LYMPHOCYTE, HEAVY CHAIN**

B-CELL LEUKEMIA see **LEUKEMIA, B-CELL**

B-CELL LEUKEMIA, CHRONIC see **LEUKEMIA, B-CELL, CHRONIC**

B-CELL LIGHT CHAIN GENE REARRANGEMENT see **GENE REARRANGEMENT, B-LYMPHOCYTE, LIGHT CHAIN**

B-CELL LYMPHOMA see **LYMPHOMA, B-CELL**

B-CELL STIMULATORY FACTOR-1 see **INTERLEUKIN-4**

B-CELL STIMULATORY FACTOR-2 see **INTERLEUKIN-6**

B-CELL SUBSETS see **B-LYMPHOCYTE SUBSETS**

B-CELLS see **B-LYMPHOCYTES**

B FIBERS see **AUTONOMIC FIBERS, PREGANGLIONIC**

B-K MOLE SYNDROME see **DYSPLASTIC NEVUS SYNDROME**

BABESIA

CLASSIFICATION

[Ticks (Ixodidae) in zoonotic propagation of piroplasma Babesia micorti and Babesia divergens] Siński E, et al. **Wiad Parazytol** 1995;41(3):321–7 (13 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOLOGY

Babesiosis. Boustani MR, et al. **Clin Infect Dis** 1996 Apr; 22(4):611–5 (8 ref.)

BABESIASIS

BABESIASIS see BABESIOSIS

BABESIOSIS

Babesiosis. Boustani MR, et al. **Clin Infect Dis** 1996 Apr; 22(4):611–5 (8 ref.)

Babesiosis: new insights from phylogenetic analysis. Persing DH, et al. **Infect Agents Dis** 1995 Dec;4(4):182–95 (117 ref.)

DIAGNOSIS

Equine piroplasmosis an update on diagnosis, treatment and prevention. Brüning A. **Br Vet J** 1996 Mar;152(2):139–51 (58 ref.)

PARASITOLOGY

[Ticks (Ixodidae) in zoonotic propagation of piroplasma Babesia micorti and Babesia divergens] Siński E, et al. **Wiad Parazytol** 1995;41(3):321–7 (13 ref.) (Eng. Abstr.) **(Pol)**

THERAPY

Supportive treatment of canine babesiosis. Jacobson LS, et al. **J S Afr Vet Assoc** 1995 Jun;66(2):95–105 (128 ref.)

BACILLACEAE INFECTIONS

COMPLICATIONS

Bacillus subtilis as a cause of cholangitis in polycystic kidney and liver disease [letter] Wallet F, et al. **Am J Gastroenterol** 1996 Jul;91(7):1477–8 (11 ref.)

DIAGNOSIS

Bacillus licheniformis prosthetic aortic valve endocarditis. Santini F, et al. **J Clin Microbiol** 1995 Nov;33(11):3070–3 (12 ref.)

MICROBIOLOGY

The safety of Bacillus species as insect vector control agents. Drobniewski FA. **J Appl Bacteriol** 1994 Feb;76(2):101–9 (80 ref.)

BACILLUS

The safety of Bacillus species as insect vector control agents. Drobniewski FA. **J Appl Bacteriol** 1994 Feb;76(2):101–9 (80 ref.)

GENETICS

Peptides. von Döhren H. **Biotechnology** 1995;28:129–71 (256 ref.)

METABOLISM

Energetic problems of extremely alkaliphilic aerobes. Krulwich TA, et al. **Biochim Biophys Acta** 1996 Jul 18; 1275(1–2):21–6 (49 ref.)

Peptides. von Döhren H. **Biotechnology** 1995;28:129–71 (256 ref.)

PHYSIOLOGY

Mechanisms for the prevention of damage to DNA in spores of Bacillus species. Setlow P. **Annu Rev Microbiol** 1995; 49:29–54 (91 ref.)

BACILLUS CALMETTE GUERIN VACCINE see BCG VACCINE

BACILLUS PHAGES

ENZYMOLOGY

Relating structure to function in phi29 DNA polymerase. Blanco L, et al. **J Biol Chem** 1996 Apr 12;271(15):8509–12 (46 ref.)

BACILLUS STEAROTHERMOPHILUS

ULTRASTRUCTURE

The suitability of a monofunctional reagent of an undecagold cluster for phasing data collected from the large ribosomal subunits from Bacillus stearothermophilus. Bartels H, et al. **Biopolymers** 1995;37(6):411–9 (19 ref.)

BACILLUS SUBTILIS

Bacillus subtilis as a cause of cholangitis in polycystic kidney and liver disease [letter] Wallet F, et al. **Am J Gastroenterol** 1996 Jul;91(7):1477–8 (11 ref.)

ENZYMOLOGY

Biosynthesis of riboflavin: structure and mechanism of lumazine synthase. Bacher A, et al. **Biochem Soc Trans** 1996 Feb;24(1):89–94 (28 ref.)

GENETICS

Advances in the use of Bacillus subtilis for the expression and secretion of heterologous proteins. Wong SL. **Curr Opin Biotechnol** 1995 Oct;6(5):517–22 (46 ref.)

Sequencing and functional analysis of the genome of Bacillus subtilis strain 168. Harwood CR, et al. **FEBS Lett** 1996 Jun 24;389(1):84–7 (39 ref.)

Heat-shock and general stress response in Bacillus subtilis. Hecker M, et al. **Mol Microbiol** 1996 Feb;19(3):417–28 (49 ref.)

The signal-transduction network for Pho regulation in Bacillus subtilis. Hulett FM. **Mol Microbiol** 1996 Mar; 19(5):933–9 (27 ref.)

METABOLISM

The role of CcpA transcriptional regulator in carbon metabolism in Bacillus subtilis. Henkin TM. **FEMS Microbiol Lett** 1996 Jan 1;135(1):9–15 (35 ref.)

Aspartyl-phosphate phosphatases deactivate the response regulator components of the sporulation signal transduction system in Bacillus subtilis. Perego M, et al. **Mol Microbiol** 1996 Mar;19(6):1151–7 (25 ref.)

PHYSIOLOGY

Bacterial differentiation: sizing up sporulation. Jenal U, et al. **Curr Biol** 1996 Feb 1;6(2):111–4 (17 ref.)

Chemotaxis in Bacillus subtilis: how bacteria monitor environmental signals. Garrity LF, et al. **Pharmacol Ther** 1995;68(1):87–104 (85 ref.)

BACILLUS THURINGIENSIS

GENETICS

Regulation of insecticidal crystal protein production in Bacillus thuringiensis. Baum JA, et al. **Mol Microbiol** 1995 Oct;18(1):1–12 (50 ref.)

GROWTH & DEVELOPMENT

Bacillus thuringiensis growth and toxicity. Basic and applied considerations. Avignone-Rossa C, et al. **Mol Biotechnol** 1995 Aug;4(1):55–71 (148 ref.)

METABOLISM

How does Bacillus thuringiensis produce so much insecticidal crystal protein? Agaisse H, et al. **J Bacteriol** 1995 Nov; 177(21):6027–32 (59 ref.)

Bacillus thuringiensis growth and toxicity. Basic and applied considerations. Avignone-Rossa C, et al. **Mol Biotechnol** 1995 Aug;4(1):55–71 (148 ref.)

PHYSIOLOGY

Bacillus thuringiensis: fermentation process and risk assessment. A short review. Capalbo DM. **Mem Inst Oswaldo Cruz** 1995 Jan–Feb;90(1):135–8 (27 ref.)

Some environmental and biological factors influencing the activity of entomopathogenic Bacillus on mosquito larvae in Brazil. Consoli RA, et al. **Mem Inst Oswaldo Cruz** 1995 Jan–Feb;90(1):121–4 (55 ref.)

Transfer of toxin genes to alternate bacterial hosts for mosquito control. Orduz S, et al. **Mem Inst Oswaldo Cruz** 1995 Jan–Feb;90(1):97–107 (88 ref.)

BACITRACIN

ADVERSE EFFECTS

Chronic finger dermatitis after trauma. Diagnosis: posttraumatic eczema with allergic contact dermatitis to neomycin, bacitracin, and topical corticosteroids. Sherertz EF. **Arch Dermatol** 1996 Apr;132(4):461, 464 (11 ref.)

BACK

INJURIES

Back injuries in the young athlete. Gerbino PG 2nd, et al. **Clin Sports Med** 1995 Jul;14(3):571–90 (120 ref.)

SURGERY

Wound management in spinal infection. Rubayi S. **Orthop Clin North Am** 1996 Jan;27(1):137–53 (47 ref.)

BACK PAIN

see related
LOW BACK PAIN

A practical approach to the patient with back pain [see comments] Gillette RD. **Am Fam Physician** 1996 Feb 1; 53(2):670–6, 683–4 (30 ref.) Comment in: Am Fam Physician 1996 Aug;54(2):456.

Back pain. Croft P, et al. **Baillieres Clin Rheumatol** 1995 Aug; 9(3):565–83 (66 ref.)

ABC of work related disorders. Back pain. Jayson MI. **BMJ** 1996 Aug 10;313(7053):355–8 (0 ref.)

DIAGNOSIS

Back pain in children and adolescents. Payne WK 3rd, et al. **Pediatr Clin North Am** 1996 Aug;43(4):899–917 (44 ref.)

ETIOLOGY

Diagnostic tests for the evaluation of back and neck pain. Haldeman S. **Neurol Clin** 1996 Feb;14(1):103–17 (52 ref.)

[Acute lumbago: infectious traps] Bonny O, et al. **Rev Med Suisse Romande** 1996 May;116(5):399–403 (8 ref.) **(Fre)**

PSYCHOLOGY

Behavioral factors in the management of back pain. Gillette RD. **Am Fam Physician** 1996 Mar;53(4):1313–8 (29 ref.)

SURGERY

Should backache be treated with spinal fusion? The case for spinal fusion is unproved [comment] Wilson-MacDonald J. **BMJ** 1996 Jan 6;312(7022):39–40 (10 ref.) Comment on: BMJ 1996 Jan 6;312(7022):38–9.

THERAPY

Behavioral factors in the management of back pain. Gillette RD. **Am Fam Physician** 1996 Mar;53(4):1313–8 (29 ref.)

Complications of spinal manipulation: a comprehensive review of the literature. Assendelft WJ, et al. **J Fam Pract** 1996 May;42(5):475–80 (41 ref.)

Management of back pain in athletes. Dreisinger TE, et al. **Sports Med** 1996 Apr;21(4):313–20 (32 ref.)

BACKACHE see BACK PAIN

BACLOFEN

PHARMACOLOGY

A physiological role for GABAB receptors and the effects of baclofen in the mammalian central nervous system. Misgeld U, et al. **Prog Neurobiol** 1995 Jul;46(4):423–62 (412 ref.)

THERAPEUTIC USE

Stiff-person syndrome with anti-glutamic acid decarboxylase autoantibodies: complete remission of symptoms after intrathecal baclofen administration. Seitz RJ, et al. **J Neurol** 1995 Oct;242(10):618–22 (32 ref.)

BACLOFEN RECEPTORS see RECEPTORS, GABA-B

BACLOPHEN see BACLOFEN

BACTERIAL FIMBRIAE see FIMBRIAE, BACTERIAL

BACTEREMIA

[Bacteremia: clinico-bacteriological aspects (literature review)] Fedorov VV, et al. **Klin Lab Diagn** 1995 May–Jun; (3):3–7 (76 ref.) **(Rus)**

COMPLICATIONS

Involvement of bacteria/endotoxin translocation in the development of multiple organ failure. Bahrami S, et al. **Curr Top Microbiol Immunol** 1996;216:239–58 (111 ref.)

Rahnella aquatilis bacteremia in an HIV-infected intravenous drug abuser. Funke G, et al. **Diagn Microbiol Infect Dis** 1995 Jul;22(3):293–6 (8 ref.)

[Hematogenic bacterial endophthalmitis. A rare infection with very poor functional prognosis] Magadur-Joly G, et al. **Ann Med Interne (Paris)** 1996;147(3):212–7 (54 ref.) (Eng. Abstr.) **(Fre)**

[Cerebrovascular manifestations of infectious diseases] Martínez Vázquez F, et al. **Rev Neurol** 1995;23 Suppl 1:S11–21 (88 ref.) **(Spa)**

DIAGNOSIS

Capnocytophaga canimorsus septicemia: fifth report of a cat-associated infection and five other cases. Valtonen M, et al. **Eur J Clin Microbiol Infect Dis** 1995 Jun;14(6):520–3 (25 ref.)

Factitious disorder presenting as bacteremia. Case report and literature review. Catalano G, et al. **J Fla Med Assoc** 1995 Aug;82(8):535–9 (29 ref.)

Plesiomonas shigelloides septicemia: case report and literature review. Lee AC, et al. **Pediatr Hematol Oncol** 1996 May–Jun;13(3):265–9 (23 ref.)

DRUG THERAPY

Pharmacodynamic (kinetic) considerations in the treatment of moderately severe infections with cefotaxime. Turnidge JD. **Diagn Microbiol Infect Dis** 1995 May–Jun; 22(1–2):57–69 (94 ref.)

The position of recently developed broad-spectrum cephem antibiotics in bacterial septicemia. Shah PM. **J Chemother** 1996 Feb;8 Suppl 2:105–11 (17 ref.)

ETIOLOGY

Pathogenesis and prevention of catheter-related septicemia. Sitges-Serra A, et al. **Am J Infect Control** 1995 Oct; 23(5):310–6 (45 ref.)

Bacteriology, safety and prevention of infection associated with continuous intravenous infusions. Mermel LA. **Blood Coagul Fibrinolysis** 1996 Mar;7 Suppl 1:S45–51 (81

ref.)
Trauma and bacterial translocation [see comments] Saadia R. **Br J Surg** 1995 Sep;82(9):1243–4 (18 ref.) Comment in: Br J Surg 1996 Feb;83(2):282–3. Comment in: Br J Surg 1996 Feb;83(2):283.
Infections complicating tunneled intraspinal catheter systems used to treat chronic pain. Byers K, et al. **Clin Infect Dis** 1995 Aug;21(2):403–8 (30 ref.)
Spectrum and significance of bacteremia due to Moraxella catarrhalis. Ioannidis JP, et al. **Clin Infect Dis** 1995 Aug; 21(2):390–7 (45 ref.)
Report of four cases of Yersinia pseudotuberculosis septicemia and a literature review. Ljungberg P, et al. **Eur J Clin Microbiol Infect Dis** 1995 Sep;14(9):804–10 (31 ref.)
Early postsplenectomy arthritis caused by penicillin-resistant Streptococcus pneumoniae. Merle-Melet M, et al. **Eur J Clin Microbiol Infect Dis** 1996 Feb;15(2):159–60 (7 ref.)
Staphylococcus aureus colonisation and bacteraemia in persons infected with human immunodeficiency virus: a dynamic interaction with the host. Craven DE. **J Chemother** 1995 Jul;7 Suppl 3:19–28 (46 ref.)
Identifying the patient risk for Staphylococcus aureus bloodstream infections. Espersen F. **J Chemother** 1995 Jul; 7 Suppl 3:11–7 (41 ref.)
Corynebacterium CDC group JK (Corynebacterium jeikeium) sepsis in haematological patients: a report of three cases and a systematic literature review. van der Lelie H, et al. **Scand J Infect Dis** 1995;27(6):581–4 (36 ref.)
[Partial properdin deficiency revealed by a septicemia caused by Neisseria meningitidis] Frémeaux-Bacchi V, et al. **Presse Med** 1995 Sep 30;24(28):1305–7 (14 ref.) (Eng. Abstr.) **(Fre)**

MICROBIOLOGY

Bartonella infections. Evolution from the esoteric [editorial; comment] Cockerell CJ, et al. **Am J Clin Pathol** 1995 Nov; 104(5):487–90 (31 ref.) Comment on: Am J Clin Pathol 1995 Nov;104(5):530–6.
An analysis of bacteremias during dental extractions. A double-blind, placebo-controlled study of chlorhexidine. Lockhart PB. **Arch Intern Med** 1996 Mar 11;156(5):513–20 (67 ref.)
Bacteremia due to Clostridium difficile: case report and review of extraintestinal C. difficile infections. Feldman RJ, et al. **Clin Infect Dis** 1995 Jun;20(6):1560–2 (39 ref.)
Recovery of uncommon bacteria from blood: association with neoplastic disease. Beebe JL, et al. **Clin Microbiol Rev** 1995 Jul;8(3):336–56 (332 ref.)
Lemierre syndrome: postanginal sepsis. Leugers CM, et al. **J Am Board Fam Pract** 1995 Sep–Oct;8(5):384–91 (40 ref.)
Nosocomial bacteremia due to Acinetobacter baumannii. Clinical features, epidemiology, and predictors of mortality. Seifert H, et al. **Medicine (Baltimore)** 1995 Nov;74(6):340–9 (46 ref.)
[A case of Pasteurella multocida subsp. multocida septicemia due to cat bites in liver cirrhosis patient] Shimizu T, et al. **Kansenshogaku Zasshi** 1995 Nov;69(11):1302–6 (11 ref.) (Eng. Abstr.) **(Jpn)**

PREVENTION & CONTROL

Pathogenesis and prevention of catheter-related septicemia. Sitges-Serra A, et al. **Am J Infect Control** 1995 Oct; 23(5):310–6 (45 ref.)
Prevention of neonatal septicaemia due to group B streptococci. Adriaanse AH. **Baillieres Clin Obstet Gynaecol** 1995 Sep;9(3):545–52 (33 ref.)
Bacteriology, safety and prevention of infection associated with continuous intravenous infusions. Mermel LA. **Blood Coagul Fibrinolysis** 1996 Mar;7 Suppl 1:S45–51 (81 ref.)
Antibiotic prophylaxis for lower gastrointestinal endoscopy. Varma JR. **Prim Care** 1995 Sep;22(3):445–50 (6 ref.)
[Antibiotic prophylaxis and endoscopic retrograde cholangiopancreatography] Le Dreau G, et al. **Gastroenterol Clin Biol** 1996 Feb;20(1):55–63 (100 ref.) **(Fre)**

SURGERY

[Removal of infected pacemaker leads in the elderly under extracorporeal circulation: two case reports and review of Japanese literature] Sato M, et al. **Kyobu Geka** 1995 Nov; 48(12):1009–12 (11 ref.) (Eng. Abstr.) **(Jpn)**

THERAPY

Bacteremia and sepsis. Ferguson KL, et al. **Emerg Med Clin North Am** 1996 Feb;14(1):185–95 (36 ref.)

TRANSMISSION

Transfusion reaction due to Yersinia enterocolitica and review of other reported cases. Beresford AM. **Pathology** 1995 Apr;27(2):133–5 (19 ref.)

VETERINARY

Mediators and vascular effects in response to endotoxin [see comments] Olson NC, et al. **Br Vet J** 1995 Sep–Oct; 151(5):489–522 (152 ref.) Comment in: Br Vet J 1995 Sep–Oct;151(5):469–71.

BACTERIA

Molecular evolution in bacteria. Trevors JT. **Antonie Van Leeuwenhoek** 1995;67(4):315–24 (76 ref.)
Marine natural products research: current directions and future potential. König GM, et al. **Planta Med** 1996 Jun; 62(3):193–211 (160 ref.)

CLASSIFICATION

Molecular biology as a tool for taxonomy. Wilson KH. **Clin Infect Dis** 1995 Jun;20 Suppl 2:S117–21 (20 ref.)
Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. Tenover FC, et al. **J Clin Microbiol** 1995 Sep;33(9):2233–9 (48 ref.)
Polyphasic taxonomy, a consensus approach to bacterial systematics. Vandamme P, et al. **Microbiol Rev** 1996 Jun; 60(2):407–38 (374 ref.)
New approaches to typing and identification of bacteria using the 16S–23S rDNA spacer region. Gürtler V, et al. **Microbiology** 1996 Jan;142 (Pt 1):3–16 (100 ref.)

CYTOLOGY

How do bacteria decide where to divide? Rothfield LI, et al. **Cell** 1996 Jan 26;84(2):183–6 (20 ref.)

DRUG EFFECTS

Cationic bactericidal peptides. Hancock RE, et al. **Adv Microb Physiol** 1995;37:135–75 (215 ref.)
Trends in antimicrobial susceptibility of bacterial pathogens of the respiratory tract. Doern GV. **Am J Med** 1995 Dec 29;99(6B):3S–7S (22 ref.)
Reasons for the emergence of antibiotic resistance. Tenover FC, et al. **Am J Med Sci** 1996 Jan;311(1):9–16 (82 ref.)
Microbiology of oral cephalosporins. Cullmann W. **Antibiot Chemother** 1995;47:72–109 (143 ref.)
Pharmacology and toxicology of oral cephalosporins. Gialdroni Grassi G. **Antibiot Chemother** 1995;47:8–33 (135 ref.)
Antimicrobial properties of tea (Camellia sinensis L.). Hamilton-Miller JM. **Antimicrob Agents Chemother** 1995 Nov;39(11):2375–7 (48 ref.)
Emerging antibiotic resistance: real and relative [editorial] Jones DB. **Arch Ophthalmol** 1996 Jan;114(1):91–2 (12 ref.)
Microbial interactions with aluminium. Piña RG, et al. **Biometals** 1996 Jul;9(3):311–6 (63 ref.)
In-vitro activity of antibacterial drugs and clinical practice. **Drug Ther Bull** 1995 Sep;33(9):71–2 (12 ref.)
Classification and structure-activity relationships of fluoroquinolones. Bryskier A, et al. **Drugs** 1995;49 Suppl 2:16–28 (27 ref.)
Quinolone mode of action. Hooper DC. **Drugs** 1995;49 Suppl 2:10–5 (32 ref.)
Mechanisms of resistance to fluoroquinolones: state-of-the-art 1992–1994. Piddock LJ. **Drugs** 1995;49 Suppl 2:29–35 (27 ref.)
Quo vadis with bacterial resistance? Williams JD. **Drugs** 1995; 49 Suppl 2:1–9 (8 ref.)
Meropenem. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Wiseman LR, et al. **Drugs** 1995 Jul;50(1):73–101 (195 ref.)
Pathogens resistant to antimicrobial agents. Epidemiology, molecular mechanisms, and clinical management. Fraimow HS, et al. **Infect Dis Clin North Am** 1995 Sep;9(3):497–530 (113 ref.)
Pharmacodynamics of antimicrobial agents. Bactericidal and postantibiotic effects. Levison ME. **Infect Dis Clin North Am** 1995 Sep;9(3):483–95 (26 ref.)
In vitro testing of antimicrobial agents. Woods GL. **Infect Dis Clin North Am** 1995 Sep;9(3):463–81 (60 ref.)
Iron and infection: new developments and their implications. Ward CG, et al. **J Trauma** 1996 Aug;41(2):356–64 (83 ref.)
Rational selection of antimicrobials for pediatric upper respiratory infections. Harrison CJ. **Pediatr Infect Dis J** 1995 Jul;14(7 Suppl):S121–9 (28 ref.)
Ceftibuten: a review of antimicrobial activity, spectrum and other microbiologic features. Jones RN. **Pediatr Infect Dis J** 1995 Jul;14(7 Suppl):S77–83 (36 ref.)
Ceftibuten: minimal inhibitory concentrations, postantibiotic effect and beta-lactamase stability—a rationale for dosing programs. Neu HC. **Pediatr Infect Dis J** 1995 Jul;14(7 Suppl):S88–92 (29 ref.)
Modes of action of disinfectants. Maris P. **Rev Sci Tech** 1995 Mar;14(1):47–55 (24 ref.)
Testing disinfectants for efficacy. Tamási G. **Rev Sci Tech** 1995 Mar;14(1):75–9 (9 ref.)
[Mechanism of antibiotic resistance in bacteria responsible for respiratory infections] Dye D, et al. **Rev Mal Respir** 1995;12(5):415–27 (67 ref.) (Eng. Abstr.) **(Fre)**
[Antimicrobial oligopeptides—an important factor in non-specific defense against infection] Haegele B, et al. **Immun Infekt** 1995 Dec;23(6):205–8 (27 ref.) (Eng. Abstr.) **(Ger)**

ENZYMOLOGY

CO dehydrogenase. Ferry JG. **Annu Rev Microbiol** 1995; 49:305–33 (132 ref.)
Extended-spectrum and inhibitor-resistant TEM-type beta-lactamases: mutations, specificity, and three-dimensional structure. Knox JR. **Antimicrob Agents Chemother** 1995 Dec;39(12):2593–601 (93 ref.)
Biological significance of IgA1 proteases in bacterial colonization and pathogenesis: critical evaluation of experimental evidence. Kilian M, et al. **APMIS** 1996 May; 104(5):321–38 (155 ref.)
A compilation of mutations located in the cytochrome b subunit of the bacterial and mitochondrial bc1 complex. Brasseur G, et al. **Biochim Biophys Acta** 1996 Jul 18; 1275(1–2):61–9 (45 ref.)
Bacterial lysozymes. Höltje JV. **EXS** 1996;75:65–74 (48 ref.)
Bacterial aminopeptidases: properties and functions. Gonzales T, et al. **FEMS Microbiol Rev** 1996 Jul;18(4):319–44 (252 ref.)
Bacterial collagenases and collagen-degrading enzymes and their potential role in human disease. Harrington DJ. **Infect Immun** 1996 Jun;64(6):1885–91 (82 ref.)
Molecular biology of microbial ureases. Mobley HL, et al. **Microbiol Rev** 1995 Sep;59(3):451–80 (307 ref.)
Beta-lactamases and bacterial resistance to antibiotics. Frère JM. **Mol Microbiol** 1995 May;16(3):385–95 (51 ref.)
Are there biological functions for bacterial endo-N-acetyl-beta-D-glucosaminidases? Karamanos Y, et al. **Res Microbiol** 1995 Jul–Aug;146(6):437–43 (42 ref.)
A mechanistic approach to deriving quantitative structure-activity relationship models for microbial degradation of organic compounds. Damborský J. **SAR QSAR Environ Res** 1996;5(1):27–36 (57 ref.)
Are bacterial proteinases pathogenic factors? Travis J, et al. **Trends Microbiol** 1995 Oct;3(10):405–7 (28 ref.)
[Studies on the pathogenicity of microbial proteases] Maeda H. **Nippon Saikingaku Zasshi** 1995 Oct;50(4):921–36 (45 ref.) **(Jpn)**
[Bacterial metalloproteases] Okabe A, et al. **Nippon Saikingaku Zasshi** 1995 Oct;50(4):971–89 (126 ref.) **(Jpn)**
[Clinical and laboratory significance of inducible beta-lactamases] Bedenić B, et al. **Lijec Vjesn** 1995 Sep–Oct;117(9–10):249–53 (41 ref.) (Eng. Abstr.) **(Scr)**

GENETICS

Chromosomal duplications in bacteria, fruit flies, and humans. Lupski JR, et al. **Am J Hum Genet** 1996 Jan;58(1):21–7 (79 ref.)
Conjugative transposition. Scott JR, et al. **Annu Rev Microbiol** 1995;49:367–97 (108 ref.)
Extended-spectrum and inhibitor-resistant TEM-type beta-lactamases: mutations, specificity, and three-dimensional structure. Knox JR. **Antimicrob Agents Chemother** 1995 Dec;39(12):2593–601 (93 ref.)
The interface between research and the diagnosis of an emerging tick-borne disease, human ehrlichiosis due to Ehrlichia chaffeensis [see comments] Dawson JE, et al. **Arch Intern Med** 1996 Jan 22;156(2):137–42 (25 ref.) Comment in: Arch Intern Med 1996 Jan 22;156(2):124.
The molecular regulation of the reductive pentose phosphate pathway in Proteobacteria and Cyanobacteria. Gibson JL, et al. **Arch Microbiol** 1996 Sep;166(3):141–50 (69 ref.)
Recombination, mutation and the origin of species. Cox EC. **Bioessays** 1995 Sep;17(9):747–9 (23 ref.)
Transduction in microbial biosensors using multiplexed bioluminescence. Wood KV, et al. **Biosens Bioelectron** 1996;11(3):207–14 (12 ref.)
A powerful bacterial world. Mathieu LG, et al. **Endeavour** 1995;19(3):112–7 (17 ref.)
Natural selection of PAH-degrading bacterial guilds at coal-tar disposal sites. Ghiorse WC, et al. **Environ Health Perspect** 1995 Jun;103 Suppl 5:107–11 (15 ref.)
Genetic adaptation of bacteria to halogenated aliphatic compounds. Janssen DB, et al. **Environ Health Perspect** 1995 Jun;103 Suppl 5:29–32 (27 ref.)
Regulation and organization of the groE and dnaK operons in Eubacteria. Segal R, et al. **FEMS Microbiol Lett** 1996 Apr 15;138(1):1–10 (32 ref.)
Pathogenicity islands and the evolution of bacterial pathogens. Lee CA. **Infect Agents Dis** 1996 Jan;5(1):1–7 (46 ref.)
Analysis of bacterial genomes by pulsed field gel electrophoresis. Méndez-Alvarez S, et al. **Microbiologia** 1995 Sep;11(3):323–36 (93 ref.)
The planctomycetes: emerging models for microbial ecology, evolution and cell biology. Fuerst JA. **Microbiology** 1995 Jul;141 (Pt 7):1493–506 (94 ref.)
New approaches to typing and identification of bacteria using the 16S–23S rDNA spacer region. Gürtler V, et al. **Microbiology** 1996 Jan;142 (Pt 1):3–16 (100 ref.)
Programmed cell death in bacteria: proteic plasmid stabilization systems. Jensen RB, et al. **Mol Microbiol** 1995 Jul;17(2):205–10 (48 ref.)
Relaxing and unwinding on Holliday: DNA helicase-mediated branch migration. Adams DE, et al. **Mutat Res** 1995 Nov;337(3):149–59 (70 ref.)
A brief history of hemoglobins: plant, animal, protist, and bacteria. Hardison RC. **Proc Natl Acad Sci U S A** 1996 Jun 11;93(12):5675–9 (33 ref.)
Eukaryotic gene expression: metabolite control by amino acids. Laine RO, et al.

Prog Nucleic Acid Res Mol Biol 1996;53:219–48 (110 ref.)

GROWTH & DEVELOPMENT

Is thermophily a transferrable property in bacteria? Lindsay JA. **Crit Rev Microbiol** 1995;21(3):165–74 (55 ref.)

Bacterial growth with chlorinated methanes. Leisinger T, et al. **Environ Health Perspect** 1995 Jun;103 Suppl 5:33–6 (13 ref.)

Understanding physical inactivation processes: combined preservation opportunities using heat, ultrasound and pressure. Earnshaw RG, et al. **Int J Food Microbiol** 1995 Dec;28(2):197–219 (122 ref.)

The significance of bacteria in stationary phase to food microbiology. Rees CE, et al. **Int J Food Microbiol** 1995 Dec;28(2):263–75 (74 ref.)

IMMUNOLOGY

Nonopsonic phagocytosis of microorganisms. Ofek I, et al. **Annu Rev Microbiol** 1995;49:239–76 (187 ref.)

Direct antimicrobial activity of T cells. Levitz SM, et al. **Immunol Today** 1995 Aug;16(8):387–91 (36 ref.)

Bacterial stimulators of macrophages. Hauschildt S, et al. **Int Rev Cytol** 1995;161:263–331 (341 ref.)

Antibodies to lipopolysaccharide. Poxton IR. **J Immunol Methods** 1995 Oct 12;186(1):1–15 (85 ref.)

Human blood groups: incidental receptors for viruses and bacteria. Moulds JM, et al. **Transfusion** 1996 Apr; 36(4):362–74 (126 ref.)

[Resistance development of major pathogenic bacteria] Kristiansen BE, et al. **Tidsskr Nor Laegeforen** 1995 Sep 10;115(21):2663–8 (62 ref.) (Eng. Abstr.) **(Nor)**

ISOLATION & PURIFICATION

Molecular site assessment and process monitoring in bioremediation and natural attenuation. off Sayler GS, et al. **Appl Biochem Biotechnol** 1995 Jul–Sep;54(1–3):277–90 (25 ref.)

Luminescence-based systems for detection of bacteria in the environment. Prosser JI, et al. **Crit Rev Biotechnol** 1996; 16(2):157–83 (90 ref.)

Strategies to accelerate the applicability of gene amplification protocols for pathogen detection in meat and meat products. Pillai SD, et al. **Crit Rev Microbiol** 1995; 21(4):239–61 (121 ref.)

Probes and polymerase chain reaction for detection of food-borne bacterial pathogens. Olsen JE, et al. **Int J Food Microbiol** 1995 Nov;28(1):1–78 (331 ref.)

Generation of DNA probes for detection of microorganisms by polymerase chain reaction fingerprinting [editorial] Giesendorf BA, et al. **Zentralbl Bakteriol** 1996 Apr; 283(4):417–30 (47 ref.)

[Is polymerase chain reaction practical in the diagnosis of microbes?] Ranki-Pesonen M. **Duodecim** 1994; 110(6):615–21 (15 ref.) **(Fin)**

METABOLISM

Manipulations of catabolic genes for the degradation and detoxification of xenobiotics. Lal R, et al. **Adv Appl Microbiol** 1995;41:55–95 (181 ref.)

Breakdown of plastics and polymers by microorganisms. Kawai F. **Adv Biochem Eng Biotechnol** 1995;52:151–94 (190 ref.)

Production of poly(hydroxyalkanoic acid). Lee SY, et al. **Adv Biochem Eng Biotechnol** 1995;52:27–58 (131 ref.)

Osmoadaptation in bacteria. Galinski EA. **Adv Microb Physiol** 1995;37:272–328 (265 ref.)

Methylglyoxal and regulation of its metabolism in microorganisms. Inoue Y, et al. **Adv Microb Physiol** 1995; 37:177–227 (310 ref.)

Calcium and bacteria. Smith RJ. **Adv Microb Physiol** 1995; 37:83–133 (221 ref.)

Cellulose hydrolysis by bacteria and fungi. Tomme P, et al. **Adv Microb Physiol** 1995;37:1–81 (367 ref.)

The regulation of methane oxidation in soil. Mancinelli RL. **Annu Rev Microbiol** 1995;49:581–605 (216 ref.)

Biodegradation of nitroaromatic compounds. Spain JC. **Annu Rev Microbiol** 1995;49:523–55 (136 ref.)

Environmental aspects of PAH biodegradation. Shuttleworth KL, et al. **Appl Biochem Biotechnol** 1995 Jul–Sep; 54(1–3):291–302 (41 ref.)

Sec-dependent preprotein translocation in bacteria. den Blaauwen T, et al. **Arch Microbiol** 1996 Jan;165(1):1–8 (73 ref.)

Peptidolactones. Keller U. **Biotechnology** 1995;28:173–96 (74 ref.)

Peptide and peptide-derived antibiotics. Vining LC, et al. **Biotechnology** 1995;28:121–7 (12 ref.)

Environmental processes mediated by iron-reducing bacteria. Fredrickson JK, et al. **Curr Opin Biotechnol** 1996 Jun; 7(3):287–94 (48 ref.)

Microbial recognition of target-cell glycoconjugates. Karlsson KA. **Curr Opin Struct Biol** 1995 Oct;5(5):622–35 (74 ref.)

Natural selection of PAH-degrading bacterial guilds at coal-tar disposal sites. Ghiorse WC, et al. **Environ Health Perspect** 1995 Jun;103 Suppl 5:107–11 (15 ref.)

Genetic adaptation of bacteria to halogenated aliphatic compounds. Janssen DB, et al. **Environ Health Perspect** 1995 Jun;103 Suppl 5:29–32 (27 ref.)

Bacterial growth with chlorinated methanes. Leisinger T, et al. **Environ Health Perspect** 1995 Jun;103 Suppl 5:33–6 (13 ref.)

Physiological attributes of microbial BTEX degradation in oxygen-limited environments. Olsen RH, et al. **Environ Health Perspect** 1995 Jun;103 Suppl 5:49–51 (7 ref.)

Recruitment of co-metabolic enzymes for environmental detoxification of organohalides. Wackett LP. **Environ Health Perspect** 1995 Jun;103 Suppl 5:45–8 (20 ref.)

Bacterial fermentation of complex carbohydrate in the human colon. Hill MJ. **Eur J Cancer Prev** 1995 Oct;4(5):353–8 (23 ref.)

Tungsten in biological systems. Kletzin A, et al. **FEMS Microbiol Rev** 1996 Mar;18(1):5–63 (346 ref.)

Biogenic amines: their importance in foods. Silla Santos MH. **Int J Food Microbiol** 1996 Apr;29(2–3):213–31 (140 ref.)

Fancy meeting you here! A fresh look at "prokaryotic" protein phosphorylation. Kennelly PJ, et al. **J Bacteriol** 1996 Aug;178(16):4759–64 (54 ref.)

Calcium signalling in bacteria. Norris V, et al. **J Bacteriol** 1996 Jul;178(13):3677–82 (88 ref.)

Maximizing microbial protein synthesis in the rumen. Firkins JL. **J Nutr** 1996 Apr;126(4 Suppl):1347S–54S (71 ref.)

Ruminal microbial metabolism of peptides and amino acids. Wallace RJ. **J Nutr** 1996 Apr;126(4 Suppl):1326S–34S (79 ref.)

Field evaluations of marine oil spill bioremediation. Swannell RP, et al. **Microbiol Rev** 1996 Jun;60(2):342–65 (121 ref.)

beta-oxidation of fatty acids in mitochondria, peroxisomes, and bacteria: a century of continued progress. Kunau WH, et al. **Prog Lipid Res** 1995;34(4):267–342 (951 ref.)

Biochemical mechanisms of resistance to non-cell wall antibacterial agents. Allen NE. **Prog Med Chem** 1995; 32:157–238 (539 ref.)

[Formation of so-called byproducts (propanols, butanols et al.) from ethanol by microorganisms] Stöhlmacher P. **Blutalkohol** 1996 May;33(3):113–41 (200 ref.) (Eng. Abstr.) **(Ger)**

[Bacterial nutrition and respiration] Dumitrescu V. **Bacteriol Virusol Parazitol Epidemiol** 1995 Jan–Mar; 40(1):9–16 (8 ref.) **(Rum)**

[Mechanism of action and resistance to fluoroquinolones] Alarcón T, et al. **Enferm Infecc Microbiol Clin** 1996 Feb; 14(2):111–7 (83 ref.) **(Spa)**

PATHOGENICITY

Impact of changing pathogens and antimicrobial susceptibility patterns in the treatment of serious infections in hospitalized patients. Jones RN. **Am J Med** 1996 Jun 24;100(6A):3S–12S (53 ref.)

Reasons for the emergence of antibiotic resistance. Tenover FC, et al. **Am J Med Sci** 1996 Jan;311(1):9–16 (82 ref.)

Biological significance of IgA1 proteases in bacterial colonization and pathogenesis: critical evaluation of experimental evidence. Kilian M, et al. **APMIS** 1996 May; 104(5):321–38 (155 ref.)

Entry of pathogens into the central nervous system. Tuomanen E. **FEMS Microbiol Rev** 1996 Jul;18(4):289–99 (42 ref.)

Pathogenicity islands and the evolution of bacterial pathogens. Lee CA. **Infect Agents Dis** 1996 Jan;5(1):1–7 (46 ref.)

Role of adhesion in microbial colonization of host tissues: a contribution of oral microbiology. Gibbons RJ. **J Dent Res** 1996 Mar;75(3):866–70 (34 ref.)

Bacterial modulins: a novel class of virulence factors which cause host tissue pathology by inducing cytokine synthesis. Henderson B, et al. **Microbiol Rev** 1996 Jun;60(2):316–41 (260 ref.)

Molecular genetic approaches for the study of virulence in both pathogenic bacteria and fungi. Hensel M, et al. **Microbiology** 1996 May;142 (Pt 5):1049–58 (52 ref.)

The role of bacterial translocation on Kupffer cell immune function following hemorrhage. Chaudry IH, et al. **Prog Clin Biol Res** 1995;392:209–18 (54 ref.)

Cellular microbiology emerging. Cossart P, et al. **Science** 1996 Jan 19;271(5247):315–6 (22 ref.)

[Validly published pathogenic bacterial names and new biosafety level of National Institute of Health] Ezaki T, et al. **Nippon Saikingaku Zasshi** 1995 Jul;50(3):803–38 (11 ref.) **(Jpn)**

[Pathogenic opportunistic microorganisms] Buiuc D. **Bacteriol Virusol Parazitol Epidemiol** 1995 Jan–Mar; 40(1):3–7 (4 ref.) **(Rum)**

[Pathogenic bacteria common to man and plants: the problem and the facts] Litvin VIu, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Mar–Apr; (2):101–4 (45 ref.) **(Rus)**

PHYSIOLOGY

Genetics, physiology, and evolutionary relationships of the genus Buchnera: intracellular symbionts of aphids. Baumann P, et al. **Annu Rev Microbiol** 1995;49:55–94 (179 ref.)

Microbiology to 10,500 meters in the deep sea. Yayanos AA. **Annu Rev Microbiol** 1995;49:777–805 (170 ref.)

A yeast transcription factor activating G1 cyclin expression has similarity to bacterial signal transduction proteins. Johnston LH, et al. **Biochem Soc Trans** 1996 Feb; 24(1):49–54 (26 ref.)

Global physiological controls. Doull JL, et al. **Biotechnology** 1995;28:9–63 (257 ref.)

Does variability in salivary protein concentrations influence oral microbial ecology and oral health? Rudney JD. **Crit Rev Oral Biol Med** 1995;6(4):343–67 (249 ref.)

Bacterial pathogenesis. When a turn off is a turn on. Strauss EJ. **Curr Biol** 1995 Jul 1;5(7):706–9 (19 ref.)

The role of antibiotics in the evolution of microorganisms. Cavallo G. **G Batteriol Virol Immunol** 1992 Jan–1993 Dec; 85(1–12):3–11 (9 ref.)

Flow cytometry applications in physiological study and detection of foodborne microorganisms. Ueckert J, et al. **Int J Food Microbiol** 1995 Dec;28(2):317–26 (30 ref.)

Dental unit water contamination. Peters E, et al. **J Can Dent Assoc** 1996 Jun;62(6):492–5 (41 ref.)

Periodontal and microbiological changes associated with the placement of orthodontic appliances. A review. Atack NE, et al. **J Periodontol** 1996 Feb;67(2):78–85 (61 ref.)

Nitrogen control in bacteria. Merrick MJ, et al. **Microbiol Rev** 1995 Dec;59(4):604–22 (275 ref.)

The bacterial 'enigma': cracking the code of cell-cell communication. Salmond GP, et al. **Mol Microbiol** 1995 May;16(4):615–24 (62 ref.)

Repair, refold, recycle: how bacteria can deal with spontaneous and environmental damage to proteins. Visick JE, et al. **Mol Microbiol** 1995 Jun;16(5):835–45 (124 ref.)

The Leeuwenhoek Lecture, 1995. Adaptation to life without oxygen. Guest JR. **Philos Trans R Soc Lond B Biol Sci** 1995 Nov 29;350(1332):189–202 (61 ref.)

Sexual potency and adaptive mutation in bacteria. Bridges BA. **Trends Microbiol** 1995 Aug;3(8):291–2; discussion 292–4 (16 ref.)

The varied lifestyles of intracellular pathogens within eukaryotic vacuolar compartments. Garcia-del Portillo F, et al. **Trends Microbiol** 1995 Oct;3(10):373–80 (69 ref.)

[Bacterial chemotactic transducer-type protein family] Kuroda A, et al. **Tanpakushitsu Kakusan Koso** 1996 Feb; 41(2):146–53 (33 ref.) **(Jpn)**

[Anti-infective defence strategies and methods of escape from entomologic pathogens under immunologic control of insects] Jarosz J. **Wiad Parazytol** 1996;42(1):3–27 (63 ref.) (Eng. Abstr.) **(Pol)**

[Protozoa as reservoirs for human bacterial pathogens] Kołodyński J. **Wiad Parazytol** 1996;42(1):37–43 (34 ref.) (Eng. Abstr.) **(Pol)**

VIROLOGY

Frequency of morphological phage descriptions in 1995. Ackermann HW. **Arch Virol** 1996;141(2):209–18 (21 ref.)

BACTERIA, AEROBIC

METABOLISM

Aerobic and anaerobic PCB biodegradation in the environment. Abramowicz DA. **Environ Health Perspect** 1995 Jun;103 Suppl 5:97–9 (27 ref.)

BACTERIA, ANAEROBIC

Overview of clinically important anaerobes. Finegold SM. **Clin Infect Dis** 1995 Jun;20 Suppl 2:205–7 (16 ref.)

Foot infections in diabetic patients: the role of anaerobes. Gerding DN. **Clin Infect Dis** 1995 Jun;20 Suppl 2:S283–8 (17 ref.)

The role of anaerobic bacteria in recurrent episodes of sinusitis and tonsillitis. Nord CE. **Clin Infect Dis** 1995 Jun; 20(6):1512–24 (107 ref.)

[Current methods for the laboratory diagnosis of infections caused by asporogenous anaerobic bacteria] Vorob'ev AA, et al. **Klin Lab Diagn** 1996 Jan–Feb;(1):14–6 (16 ref.) (Eng. Abstr.) **(Rus)**

[Latent anaerobic infection in the development of pathological processes in the oral cavity] Ivashkevich LG. **Vrach Delo** 1995 Jan–Feb;(1–2):16–9 (32 ref.) **(Rus)**

[Nosocomial infections caused by anaerobes] Garcia-Rodriguez JA, et al. **Enferm Infecc Microbiol Clin** 1995 Aug–Sep;13(7):429–34 (21 ref.) **(Spa)**

DRUG EFFECTS

Antimicrobial activity of cefotaxime tested against infrequently isolated pathogenic species (unusual pathogens). Cormican MG, et al. **Diagn Microbiol Infect Dis** 1995 May–Jun;22(1–2):43–8 (46 ref.)

Quinolone activity against anaerobes: microbiological aspects. Appelbaum PC. **Drugs** 1995;49 Suppl 2:76–80 (42 ref.)

ENZYMOLOGY

Coenzyme A ligases involved in anaerobic biodegradation of aromatic compounds. Villemur R. **Can J Microbiol** 1995 Oct;41(10):855–61 (49 ref.)

ISOLATION & PURIFICATION

The biochemical milieu of the host in the selection of anaerobic species in the oral cavity. Shah HN, et al. **Clin Infect Dis** 1995 Jun;20 Suppl 2:S291–300 (59 ref.)

METABOLISM

Aerobic and anaerobic PCB biodegradation in the environment. Abramowicz DA. **Environ Health Perspect** 1995 Jun;103 Suppl 5:97–9 (27 ref.)
Reductive dechlorination of tetrachloroethene by a high rate anaerobic microbial consortium. Zinder SH, et al. **Environ Health Perspect** 1995 Jun;103 Suppl 5:5–7 (12 ref.)
Unusual dehydrations in anaerobic bacteria: considering ketyls (radical anions) as reactive intermediates in enzymatic reactions. Buckel W. **FEBS Lett** 1996 Jun 24; 389(1):20–4 (43 ref.)

PATHOGENICITY

Anaerobic septic bursitis: case report and review. Fischer PA, et al. **Clin Infect Dis** 1996 May;22(5):879 (3 ref.)

BACTERIAL ADHESINS see ADHESINS, BACTERIAL

BACTERIAL ADHESION

see related
ADHESINS, BACTERIAL

Adherence & colonization properties of Vibrio cholerae & diarrhoeagenic Escherichia coli. Ghose AC. **Indian J Med Res** 1996 Jul;104:38–51 (160 ref.)
Role of adhesion in microbial colonization of host tissues: a contribution of oral microbiology. Gibbons RJ. **J Dent Res** 1996 Mar;75(3):866–70 (34 ref.)
Use of flow chamber devices and image analysis methods to study microbial adhesion. Busscher HJ, et al. **Methods Enzymol** 1995;253:455–77 (43 ref.)
Erythrocytes as target cells for testing bacterial adhesins. Goldhar J. **Methods Enzymol** 1995;253:43–50 (32 ref.)
Analysis of ocular microbial adhesion. Hazlett LD. **Methods Enzymol** 1995;253:53–66 (29 ref.)
Strategies for studying bacterial adhesion in vivo. Leffler H, et al. **Methods Enzymol** 1995;253:206–20 (69 ref.)
Binding of extracellular matrix proteins by microbes. Ljungh A, et al. **Methods Enzymol** 1995;253:501–14 (50 ref.)
Interaction of bacteria with mast cells. Malaviya R, et al. **Methods Enzymol** 1995;253:27–43 (47 ref.)
Adhesion of oral bacteria to soft tissue. Meyer DH, et al. **Methods Enzymol** 1995;253:373–85 (44 ref.)
Association of bacteria with human phagocytes. Rest RF. **Methods Enzymol** 1995;253:12–26 (22 ref.)
Adhesion of microbial pathogens to leukocyte integrins: methods to study ligand mimicry. Rozdzinski E, et al. **Methods Enzymol** 1995;253:3–12 (36 ref.)
Triggering bacterial virulence [comment] Cotter PA, et al. **Science** 1996 Aug 30;273(5279):1183–4 (15 ref.) Comment on: Science 1996 Aug 30;273(5279):1231–3. Comment on: Science 1996 Aug 30;273(5279):1234–6.
[The adhesive activity of clinical strains of Klebsiella] Bondarenko VM, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Mar–Apr; (2):104–9 (50 ref.) **(Rus)**

GENETICS

Molecular analysis of Streptococcus pyogenes adhesion. Hanski E, et al. **Methods Enzymol** 1995;253:269–305 (49 ref.)

PHYSIOLOGY

Interaction of pathogenic neisseriae with nonphagocytic cells. Nassif X, et al. **Clin Microbiol Rev** 1995 Jul; 8(3):376–88 (148 ref.)
Aspects of adherence of oral spirochetes. Thomas DD. **Crit Rev Oral Biol Med** 1996;7(1):4–11 (48 ref.)
Molecular aspects of bacterial colonization. Bisno AL. **Infect Control Hosp Epidemiol** 1995 Nov;16(11):648–57 (83 ref.)
Adhesion properties of Helicobacter pylori. Evans DG, et al. **Methods Enzymol** 1995;253:336–60 (62 ref.)
Anchorage and release of Gram-positive bacterial cell-surface polypeptides. Jenkinson HF. **Trends Microbiol** 1995 Sep;3(9):333–5 (15 ref.)

BACTERIAL ANTIBODIES see ANTIBODIES, BACTERIAL

BACTERIAL ANTIGENS see ANTIGENS, BACTERIAL

BACTERIAL CAPSULES

BIOSYNTHESIS

Pseudomonas aeruginosa, mucoidy and the chronic infection phenotype in cystic fibrosis. Deretic V, et al. **Trends Microbiol** 1995 Sep;3(9):351–6 (59 ref.)

CHEMISTRY

Structure and function of Bacteroides fragilis capsular polysaccharides: relationship to induction and prevention of abscesses. Tzianabos AO, et al. **Clin Infect Dis** 1995 Jun; 20 Suppl 2:S132–40 (35 ref.)

GENETICS

Haemophilus influenzae: capsule vaccine and capsulation genetics. Kroll JS, et al. **Mol Med Today** 1996 Apr; 2(4):160–5 (37 ref.)

IMMUNOLOGY

Qualitative and quantitative immune response to bacterial capsular polysaccharides and their conjugates in mouse and man. Fattom A. **Adv Exp Med Biol** 1995;383:131–9 (34 ref.)
Pneumococcal virulence factors and host immune responses to them. Watson DA, et al. **Eur J Clin Microbiol Infect Dis** 1995 Jun;14(6):479–90 (87 ref.)

PHYSIOLOGY

Relationship between virulence and immunity as revealed in recent studies of the F1 capsule of Yersinia pestis. Friedlander AM, et al. **Clin Infect Dis** 1995 Oct;21 Suppl 2:S178–81 (28 ref.)

BACTERIAL CONJUGATION see CONJUGATION, GENETIC

BACTERIAL CONJUNCTIVITIS see CONJUNCTIVITIS, BACTERIAL

BACTERIAL DNA see DNA, BACTERIAL

BACTERIAL ELONGATION FACTOR TU see PEPTIDE ELONGATION FACTOR TU

BACTERIAL EYE INFECTIONS see EYE INFECTIONS, BACTERIAL

BACTERIAL GENE EXPRESSION REGULATION see GENE EXPRESSION REGULATION, BACTERIAL

BACTERIAL GENE PRODUCTS see BACTERIAL PROTEINS

BACTERIAL GENE PROTEINS see BACTERIAL PROTEINS

BACTERIAL GENOME see GENOME, BACTERIAL

BACTERIAL INFECTIONS

The clinical impact of human respiratory virus infections. Denny FW Jr. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 2):S4–12 (40 ref.)
Flavimonas oryzihabitans sepsis in children. Reed RP. **Clin Infect Dis** 1996 Apr;22(4):733–4 (10 ref.)
Infectious etiologies of rhabdomyolysis: three case reports and review. Singh U, et al. **Clin Infect Dis** 1996 Apr; 22(4):642–9 (125 ref.)
Septic thrombophlebitis of major dural venous sinuses. Southwick FS. **Curr Clin Top Infect Dis** 1995;15:179–203 (161 ref.)
Bacterial infection as a cause of cancer. Parsonnet J. **Environ Health Perspect** 1995 Nov;103 Suppl 8:263–8 (93 ref.)
Spontaneous bacterial peritonitis: pathogenesis, diagnosis, and management. Guarner C, et al. **Gastroenterologist** 1995 Dec;3(4):311–28 (153 ref.)
Bacterial and fungal infections in the neonate. Askin DF. **J Obstet Gynecol Neonatal Nurs** 1995 Sep;24(7):635–43 (40 ref.)
Nurses: at special risk. Jackson MM, et al. **J Obstet Gynecol Neonatal Nurs** 1995 Jul–Aug;24(6):533–40 (37 ref.)
The challenges of emerging infectious diseases. Development and spread of multiply-resistant bacterial pathogens. Tenover FC, et al. **JAMA** 1996 Jan 24–31;275(4):300–4 (63 ref.)
Emerging bacterial zoonotic and vector-borne diseases. Ecological and epidemiological factors. Walker DH, et al. **JAMA** 1996 Feb 14;275(6):463–9 (92 ref.)
[Acute tubulointerstitial nephritis in acute infection] Kobayashi Y. **Nippon Rinsho** 1995 Aug;53(8):1954–61 (41 ref.) (Eng. Abstr.) **(Jpn)**
[Infections in intensive care units. A challenge for the specialist of infectious diseases?] von der Lippe E, et al. **Tidsskr Nor Laegeforen** 1995 Nov 20;115(28):3508–10 (12 ref.) (Eng. Abstr.) **(Nor)**
[Clinical aspects, diagnosis and treatment of intrauterine infections] Simakova MG, et al. **Akush Ginekol (Mosk)** 1995;(4):7–10 (54 ref.) **(Rus)**
[Reactive arthritis] del Pino J. **An Med Interna** 1995 Oct; 12(10):469–71 (44 ref.) **(Spa)**
[Nosocomial infections caused by anaerobes] García-Rodríguez JA, et al. **Enferm Infecc Microbiol Clin** 1995 Aug–Sep;13(7):429–34 (21 ref.) **(Spa)**

BLOOD

Infectious hazards associated with blood transfusion. Hurley DR. **Adverse Drug React Toxicol Rev** 1995 Autumn; 14(3):157–74 (69 ref.)
Disorders of neutrophil function. Bogomolski-Yahalom V, et al. **Blood Rev** 1995 Sep;9(3):183–90 (71 ref.)
[The clinical use of CRP measurements] Rintala E, et al. **Duodecim** 1995;111(2):173–8 (38 ref.) **(Fin)**

CLASSIFICATION

Overview and classification of spinal infections. Calderone RR, et al. **Orthop Clin North Am** 1996 Jan;27(1):1–8 (38 ref.)

COMPLICATIONS

The role of urogenital tract infections in the etiology of preterm birth: a review. Martius J, et al. **Arch Gynecol Obstet** 1996;258(1):1–19 (166 ref.)
Bacterially induced bone destruction: mechanisms and misconceptions. Nair SP, et al. **Infect Immun** 1996 Jul; 64(7):2371–80 (137 ref.)
Infections, idiotypes and SLE [editorial; comment] George J, et al. **Lupus** 1995 Oct;4(5):333–5 (40 ref.) Comment on: Lupus 1995 Oct;4(5):339–47.
Infectious gastroenterocolitides in children: an update on emerging pathogens. Sherman PM, et al. **Pediatr Clin North Am** 1996 Apr;43(2):391–407 (114 ref.)
Secretory diarrhea in children: newly recognized toxins and hormone-secreting tumors. Udall JN Jr. **Pediatr Clin North Am** 1996 Apr;43(2):333–53 (78 ref.)
[Diabetes and infection] Tajeddin M, et al. **Rev Med Suisse Romande** 1995 Sep;115(9):659–65 (53 ref.) **(Fre)**
[Infected liver cysts] Kiryu Y, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):94–8 (19 ref.) **(Jpn)**
[Latent anaerobic infection in the development of pathological processes in the oral cavity] Ivashkevich LG. **Vrach Delo** 1995 Jan–Feb;(1-2):16–9 (32 ref.) **(Rus)**

DIAGNOSIS

Septic thrombophlebitis of the portal vein (pylephlebitis): diagnosis and management in the modern era. Plemmons RM, et al. **Clin Infect Dis** 1995 Nov;21(5):1114–20 (32 ref.)
Antibodies to lipopolysaccharide. Poxton IR. **J Immunol Methods** 1995 Oct 12;186(1):1–15 (85 ref.)
The diagnosis of infections of the spine by modern imaging techniques. Rothman SL. **Orthop Clin North Am** 1996 Jan; 27(1):15–31 (15 ref.)
Acute renal infections. Papanicolaou N, et al. **Radiol Clin North Am** 1996 Sep;34(5):965–95 (46 ref.)
Diagnosis of pulmonary infections in mechanically ventilated patients. Chastre J, et al. **Semin Respir Infect** 1996 Jun; 11(2):65–76 (58 ref.)
[Radiologic diagnosis of infectious spondylitis] Wikström M, et al. **Rontgenpraxis** 1996 Apr;49(4):79–84 (30 ref.) **(Ger)**
[Current methods for the laboratory diagnosis of infections caused by asporogenous anaerobic bacteria] Vorob'ev AA, et al. **Klin Lab Diagn** 1996 Jan–Feb;(1):14–6 (16 ref.) (Eng. Abstr.) **(Rus)**

DRUG THERAPY

Resistant respiratory pathogens and extended-spectrum antibiotics. Pichichero ME. **Am Fam Physician** 1995 Nov 1;52(6):1739–46 (30 ref.)
Antimicrobial-resistant pathogens in the 1990s. Jacoby GA. **Annu Rev Med** 1996;47:169–79 (62 ref.)
Microbiology of oral cephalosporins. Cullmann W. **Antibiot Chemother** 1995;47:72–109 (143 ref.)
Empiric therapy for bacterial infections in neutropenic patients. Klastersky J. **Cancer Treat Res** 1995;79:101–12 (34 ref.)
Septic thrombophlebitis of the portal vein (pylephlebitis): diagnosis and management in the modern era. Plemmons RM, et al. **Clin Infect Dis** 1995 Nov;21(5):1114–20 (32 ref.)
Antibiotic therapy in diabetic foot infection. van der Meer JW, et al. **Diabet Med** 1996;13 Suppl 1:S48–51 (19 ref.)
Cefotaxime use in pediatric infections. Dajani AS. **Diagn Microbiol Infect Dis** 1995 May-Jun;22(1-2):105–10 (19 ref.)
Cefotaxime and desacetylcefotaxime antimicrobial interactions. The clinical relevance of enhanced activity: a review. Jones RN. **Diagn Microbiol Infect Dis** 1995 May-Jun;22(1-2):19–33 (79 ref.)
Cephalosporin-metronidazole combinations in the management of intra-abdominal infections. Nicolau DP, et al. **Diagn Microbiol Infect Dis** 1995 May-Jun; 22(1-2):189–94 (28 ref.)
Experience with cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis. Rimola A, et al. **Diagn Microbiol Infect Dis** 1995 May-Jun;22(1-2):141–5 (30 ref.)
The role of cefotaxime in the treatment of surgical infections. Wittmann DH. **Diagn Microbiol Infect Dis** 1995 May-Jun; 22(1-2):173–82 (67 ref.)
Review and reassessment of dosing schedules for cefotaxime in selected medical indications. Young LS. **Diagn Microbiol Infect Dis** 1995 May-Jun;22(1-2):147–54 (11 ref.)
A risk-benefit assessment of teicoplanin in the treatment of infections. de Lalla F, et al. **Drug Saf** 1995 Nov; 13(5):317–28 (74 ref.)
Cotrimoxazole. Rationale for re-examining its indications for use. Howe RA, et al. **Drug Saf** 1996 Apr;14(4):213–8 (35 ref.)
In-vitro activity of antibacterial drugs and clinical practice. **Drug Ther Bull** 1995 Sep;33(9):71–2 (12 ref.)
Quinolones in the elderly. Bergan T. **Drugs** 1995;49 Suppl 2:112–4 (25 ref.)
Fluoroquinolones in paediatrics—1995. Dagan R. **Drugs** 1995; 49 Suppl 2:92–9 (54 ref.)
The use of quinolones as therapy in granulocytopenic cancer

patients. Comparison with other antimicrobials. Krcméry V Jr. **Drugs** 1995;49 Suppl 2:139–43 (30 ref.)
Veterinary use of new quinolones in Japan. Nakamura S. **Drugs** 1995;49 Suppl 2:152–8 (41 ref.)
Meropenem. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Wiseman LR, et al. **Drugs** 1995 Jul;50(1):73–101 (195 ref.)
Antibacterial agents in pregnancy. Korzeniowski OM. **Infect Dis Clin North Am** 1995 Sep;9(3):639–51 (65 ref.)
Antibacterial agents in pediatrics. LiPuma JJ, et al. **Infect Dis Clin North Am** 1995 Sep;9(3):561–74 (55 ref.)
Anti-infective strategies in neutropenia. Boogaerts MA. **J Antimicrob Chemother** 1995 Jul;36 Suppl A:167–78 (54 ref.)
Vancomycin administration and monitoring reappraisal. Saunders NJ. **J Antimicrob Chemother** 1995 Aug; 36(2):279–82 (32 ref.)
Fluoroquinolones and bacterial enteritis, when and for whom? Wiström J, et al. **J Antimicrob Chemother** 1995 Jul; 36(1):23–39 (84 ref.)
Clinical experience with the fourth generation cephalosporins. Giamarellou H. **J Chemother** 1996 Feb;8 Suppl 2:91–104 (30 ref.)
Quinolones: a practical review of clinical uses, dosing considerations, and drug interactions. Borcherding SM, et al. **J Fam Pract** 1996 Jan;42(1):69–78 (70 ref.)
Tarnished gold: sixty years of antimicrobial drug use and misuse [editorial] Greenwood D. **J Med Microbiol** 1995 Dec;43(6):395–6 (12 ref.)
Managing HIV. Part 5: Treating secondary outcomes. 5.16 HIV and bacterial infections. Allworth AM, et al. **Med J Aust** 1996 May 6;164(9):546–8 (5 ref.)
The outpatient management of febrile neutropenia in cancer patients. Freifeld AG, et al. **Oncology (Huntingt)** 1996 Apr; 10(4):599–606, 611–2; discussion 615–6 (31 ref.)
Pharmacokinetics of ceftibuten in children. Barr WH, et al. **Pediatr Infect Dis J** 1995 Jul;14(7 Suppl):S93–101 (30 ref.)
Ceftibuten: minimal inhibitory concentrations, postantibiotic effect and beta-lactamase stability—a rationale for dosing programs. Neu HC. **Pediatr Infect Dis J** 1995 Jul;14(7 Suppl):S88–92 (29 ref.)
Worldwide safety experience with ceftibuten pediatric suspension. Reidenberg BE. **Pediatr Infect Dis J** 1995 Jul; 14(7 Suppl):S130–3 (22 ref.)
Use of aminoglycosides: the Swiss consensus. Swiss Society of Infectious Diseases. **Schweiz Med Wochenschr Suppl** 1996;76:5S–52S (0 ref.)
[Clinical infectiology—1. Diagnosis, pathogen spectrum and resistance] Schrappe M. **Med Klin** 1996 Apr 1;91 Suppl 1:166–75 (157 ref.) **(Ger)**
[Contemporary macrolides—characterization of the action, importance in the treatment of bacterial infections] Fomina IP. **Antibiot Khimioter** 1995 Sep;40(9):47–56 (35 ref.) **(Rus)**
[Amoxycillin: 25 years of use in clinical practice] Iakovlev SV. **Antibiot Khimioter** 1995 Jun;40(6):49–55 (13 ref.) **(Rus)**
[Cefpodoxime] **Enferm Infecc Microbiol Clin** 1995 Aug-Sep; 13(7):437–8 (0 ref.) **(Spa)**
[Current clinical problems in evaluating microbiological and pharmacological data] Aguado JM. **Enferm Infecc Microbiol Clin** 1995 Oct;13(8):477–81 (11 ref.) **(Spa)**

ENZYMOLOGY

Biological significance of IgA1 proteases in bacterial colonization and pathogenesis: critical evaluation of experimental evidence. Kilian M, et al. **APMIS** 1996 May; 104(5):321–38 (155 ref.)
Molecular biology of microbial ureases. Mobley HL, et al. **Microbiol Rev** 1995 Sep;59(3):451–80 (307 ref.)

EPIDEMIOLOGY

The changing epidemiology of foodborne diseases. Altekruse SF, et al. **Am J Med Sci** 1996 Jan;311(1):23–9 (50 ref.)
Bacterial enteric infections in persons infected with human immunodeficiency virus. Angulo FJ, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S84–93 (96 ref.)
Epidemiology of quinolone resistance: Europe and North and South America. Goldstein FW, et al. **Drugs** 1995;49 Suppl 2:36–42 (49 ref.)
Quo vadis with bacterial resistance? Williams JD. **Drugs** 1995; 49 Suppl 2:1–9 (8 ref.)
Epidemiologic review of pediatric and adult maxillofacial infections in hospitalized patients. Scutari P Jr, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Mar;81(3):270–4 (11 ref.)
[Retrospective study of postoperative infectious morbidity following cesarean section] Di Lieto A, et al. **Minerva Ginecol** 1996 Mar;48(3):85–92 (45 ref.) (Eng. Abstr.) **(Ita)**
[The epidemiological characteristics of acute intestinal infections in wartime] Kartsev AD. **Voen Med Zh** 1996 May;317(5):40–3 (24 ref.) **(Rus)**

ETIOLOGY

Cerebrospinal fluid shunt infections. Hanekom WA, et al. **Adv Pediatr Infect Dis** 1996;11:29–54 (90 ref.)
Foodborne and waterborne illness in children. Rivera-Matos IR, et al. **Adv Pediatr Infect Dis** 1996;11:101–34 (112 ref.)
Bacterial infections in HIV disease. Currier JS, et al. **AIDS Clin Rev** 1995–96;:131–52 (102 ref.)
Management of sinusitis in the asthmatic patient. Senior BA, et al. **Ann Allergy Asthma Immunol** 1996 Jul;77(1):6–15; quiz 15–9 (47 ref.)
Guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen. Working Party of the British Committee for Standards in Haematology Clinical Haematology Task Force [see comments] **BMJ** 1996 Feb 17;312(7028):430–4 (53 ref.) Comment in: BMJ 1996 May 25;312(7042):1359–60; discussion 1361. Comment in: BMJ 1996 May 25;312(7042):1360. Comment in: BMJ 1996 May 25;312(7042):1360; discussion 1361. Comment in: BMJ 1996 May 25;312(7042):1360–1. Comment in: BMJ 1996 May 25;312(7042):1361.
Infections complicating tunneled intraspinal catheter systems used to treat chronic pain. Byers K, et al. **Clin Infect Dis** 1995 Aug;21(2):403–8 (30 ref.)
Anaerobic septic bursitis: case report and review. Fischer PA, et al. **Clin Infect Dis** 1996 May;22(5):879 (3 ref.)
Simian bites and bacterial infection. Goldstein EJ, et al. **Clin Infect Dis** 1995 Jun;20(6):1551–2 (14 ref.)
Infection in the bone marrow transplant recipient. Walter EA, et al. **Infect Dis Clin North Am** 1995 Dec;9(4):823–47 (133 ref.)
Bacterial collagenases and collagen-degrading enzymes and their potential role in human disease. Harrington DJ. **Infect Immun** 1996 Jun;64(6):1885–91 (82 ref.)
Bacterial complications of transplantation: diagnosis and treatment. Donnelly JP. **J Antimicrob Chemother** 1995 Oct; 36 Suppl B:59–72 (65 ref.)
Intravascular device-related infections in critically ill patients. Pittet D, et al. **J Chemother** 1995 Jul;7 Suppl 3:55–66 (91 ref.)
Peritoneal access. Bhatla B, et al. **J Postgrad Med** 1994 Jul-Sep;40(3):170–8 (50 ref.)
Bacterial infections during immunosuppression – immunosuppressive agents interfere not only with immune response, but also with polymorphonuclear cell function. [editorial] Schmaldienst S, et al. **Nephrol Dial Transplant** 1996 Jul;11(7):1243–5 (26 ref.)
Peritoneal dialysis catheter complications. Bernardini J. **Perit Dial Int** 1996;16 Suppl 1:S486–71 (42 ref.)
Significance, epidemiology, and prevention of peritoneal dialysis catheter infections. Burkart JM. **Perit Dial Int** 1996; 16 Suppl 1:S340–6 (38 ref.)
Peritoneoscopic placement of Swan neck peritoneal dialysis catheters. Copley JB, et al. **Perit Dial Int** 1996;16 Suppl 1:S330–2 (18 ref.)
The role of bacterial translocation on Kupffer cell immune function following hemorrhage. Chaudry IH, et al. **Prog Clin Biol Res** 1995;392:209–18 (54 ref.)
[Infections related to central venous catheters] Nielsen J, et al. **Ugeskr Laeger** 1996 Feb 5;158(6):764–8 (40 ref.) (Eng. Abstr.) **(Dan)**
[Bacterial complications of blood transfusions] Avril JL, et al. **Transfus Clin Biol** 1996;3(1):43–9 (34 ref.) **(Fre)**
[Susceptibility to infections in diabetes—effects on metabolism] Perschel WT, et al. **Immun Infekt** 1995 Dec; 23(6):196–200 (34 ref.) (Eng. Abstr.) **(Ger)**
[Infections in diabetes mellitus] Schubert S, et al. **Immun Infekt** 1995 Dec;23(6):200–4 (57 ref.) (Eng. Abstr.) **(Ger)**
[Pathogenesis of infections—a complex interplay between microbes and the immune defence] Haug CJ, et al. **Tidsskr Nor Laegeforen** 1995 Oct 30;115(26):3254–8 (25 ref.) (Eng. Abstr.) **(Nor)**
[The etiology and pathogenesis of intrauterine infection] Durova AA, et al. **Akush Ginekol (Mosk)** 1995;(6):9–12 (59 ref.) **(Rus)**
[The pathogenetic characteristics of the development of a bacterial carrier state] Bukharin OV, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Mar-Apr; (2):98–101 (42 ref.) **(Rus)**

IMMUNOLOGY

Aetiological agents and immune mechanisms in enterogenic reactive arthritis. Sieper J, et al. **Baillieres Clin Rheumatol** 1996 Feb;10(1):105–21 (83 ref.)
Bacterial pyrogenic exotoxins as superantigens. Kotb M. **Clin Microbiol Rev** 1995 Jul;8(3):411–26 (292 ref.)
Effects of IL-12 on immune responses to microbial infections: a key mediator in regulating disease outcome. Biron CA, et al. **Curr Opin Immunol** 1995 Aug;7(4):485–96 (93 ref.)
Growth hormone and the immune response to bacterial infection. Saito H, et al. **Horm Res** 1996;45(1-2):50–4 (39 ref.)
Immunity to intracellular microbial pathogens. Kaufmann SH. **Immunol Today** 1995 Jul;16(7):338–42 (32 ref.)
Immunoglobulin gene usage in the human anti-pathogen response. Newkirk MM, et al. **Infect Agents Dis** 1995 Sep; 4(3):153–60 (59 ref.)
Human regulator of complement activation (RCA) gene family proteins and their relationship to microbial infection. Seya T. **Microbiol Immunol** 1995;39(5):295–305 (82 ref.)
Bacterial superantigens in human disease: structure, function and diversity. Ulrich RG, et al. **Trends Microbiol** 1995 Dec; 3(12):463–8 (51 ref.)
[New immunopathogenetic aspects of infectious diseases] Müller F, et al. **Tidsskr Nor Laegeforen** 1995 Oct 30; 115(26):3259–62 (33 ref.) (Eng. Abstr.) **(Nor)**
[Cytokines and nonviral infections] Grabchenko NI, et al. **Mikrobiol Z** 1995 Nov-Dec;57(6):63–78 (99 ref.) (Eng. Abstr.) **(Rus)**

METABOLISM

Nitric oxide and infection: another view. Schoedon G, et al. **Clin Infect Dis** 1995 Oct;21 Suppl 2:S152–7 (30 ref.)
Iron and infection: new developments and their implications. Ward CG, et al. **J Trauma** 1996 Aug;41(2):356–64 (83 ref.)
Hypothesis: compartmentalization of cytokines in intraabdominal infection. Schein M, et al. **Surgery** 1996 Jun; 119(6):694–700 (80 ref.)

MICROBIOLOGY

Spontaneous bacterial peritonitis. Planas R, et al. **Acta Gastroenterol Belg** 1995 May-Aug;58(3-4):297–310 (100 ref.)
Impact of changing pathogens and antimicrobial susceptibility patterns in the treatment of serious infections in hospitalized patients. Jones RN. **Am J Med** 1996 Jun 24;100(6A):3S–12S (53 ref.)
Biological significance of IgA1 proteases in bacterial colonization and pathogenesis: critical evaluation of experimental evidence. Kilian M, et al. **APMIS** 1996 May; 104(5):321–38 (155 ref.)
Overview of clinically important anaerobes. Finegold SM. **Clin Infect Dis** 1995 Jun;20 Suppl 2:205–7 (16 ref.)
Foot infections in diabetic patients: the role of anaerobes. Gerding DN. **Clin Infect Dis** 1995 Jun;20 Suppl 2:S283–8 (17 ref.)
The role of anaerobic bacteria in recurrent episodes of sinusitis and tonsillitis. Nord CE. **Clin Infect Dis** 1995 Jun; 20(6):1512–24 (107 ref.)
Epidemiology of quinolone resistance: Europe and North and South America. Goldstein FW, et al. **Drugs** 1995;49 Suppl 2:36–42 (49 ref.)
Brain abscess in children: microbiology and management. Brook I. **J Child Neurol** 1995 Jul;10(4):283–8 (47 ref.)
Microbiology and antimicrobial therapy of spinal infections. Sapico FL. **Orthop Clin North Am** 1996 Jan;27(1):9–13 (22 ref.)
[Pathogenesis and diagnosis of bacterial airway infections in patients with cystic fibrosis] Möller AV, et al. **Ned Tijdschr Geneeskd** 1995 Nov 18;139(46):2346–9 (28 ref.) **(Dut)**
[Emerging pathogens] van der Meer JW, et al. **Ned Tijdschr Geneeskd** 1996 Jan 20;140(3):116–8 (36 ref.) **(Dut)**
[New opportunistic pathogens in AIDS] Morillon M. **Med Trop (Mars)** 1996;56(1):17–20 (20 ref.) **(Fre)**
[Cyanobacteria, their toxins and health risks] Thébault l, et al. **Med Trop (Mars)** 1995;55(4):375–80 (43 ref.) (Eng. Abstr.) **(Fre)**
[Diagnostic value of Stamey's test in chronic prostatitis] Sibert L, et al. **Prog Urol** 1996 Feb;6(1):107–11 (20 ref.) (Eng. Abstr.) **(Fre)**
[Bacterial resistance—state and development in human and animal isolates] Schlatterer B. **DTW Dtsch Tierarztl Wochenschr** 1995 Jun;102(6):251–6 (6 ref.) **(Ger)**
[Protozoa as reservoirs for human bacterial pathogens] Kołodyński J. **Wiad Parazytol** 1996;42(1):37–43 (34 ref.) (Eng. Abstr.) **(Pol)**
[Neurosurgical infections] Martínez E, et al. **Enferm Infecc Microbiol Clin** 1996 Jan;14(1):34–43 (161 ref.) **(Spa)**

MORTALITY

Long-term consequences of peritonitis. Boeschoten EW. **Perit Dial Int** 1996;16 Suppl 1:S349–54 (43 ref.)

PATHOLOGY

Infections of the eyelid, lacrimal system, conjunctiva, and cornea. Durand M, et al. **Curr Clin Top Infect Dis** 1996; 16:125–50 (150 ref.)

PHYSIOPATHOLOGY

[Role of gram-negative bacterial endotoxins in infectious and non-infectious diseases] Likhoded VG, et al. **Arkh Patol** 1996 Mar-Apr;58(2):8–13 (43 ref.) (Eng. Abstr.) **(Rus)**

PREVENTION & CONTROL

Intravenous immunoglobins (IVIGs) to prevent and treat infectious diseases. Cross AS. **Adv Exp Med Biol** 1995; 383:123–30 (19 ref.)
Surgical infections: prevention and treatment—1965 to 1995. Nichols RL. **Am J Surg** 1996 Jul;172(1):68–74 (54 ref.)
Chemoprophylaxis for the prevention of bacterial and fungal infections. Donnelly JP. **Cancer Treat Res** 1995;79:45–81 (276 ref.)
Infections and antibiotic resistance in nursing homes. Nicolle LE, et al. **Clin Microbiol Rev** 1996 Jan;9(1):1–17 (188 ref.)
The epidemiology of colonization. Jarvis WR. **Infect Control Hosp Epidemiol** 1996 Jan;17(1):47–52 (43 ref.)
Prevention of bacterial infection in the transplant recipient. The role of selective bowel decontamination. Arnow PM. **Infect Dis Clin North Am** 1995 Dec;9(4):849–62 (63 ref.)
Selective decontamination of the digestive tract: indications

and problems [editorial] Lode H, et al. **Infection** 1995 May-Jun;23(3):129-32 (31 ref.)
Genetic detoxification of bacterial toxins: a new approach to vaccine development. Rappuoli R, et al. **Int Arch Allergy Immunol** 1995 Dec;108(4):327-33 (39 ref.)
Microbiological monitoring. Mombelli A. **J Clin Periodontol** 1996 Mar;23(3 Pt 2):251-7 (95 ref.)
Infections in liver transplantation: risk factors and strategies for prevention. Kibbler CC. **J Hosp Infect** 1995 Jun;30 Suppl:209-17 (40 ref.)
Prevention of infection dropout in PD. Viglino G, et al. **Perit Dial Int** 1996;16 Suppl 1:S355-61 (56 ref.)
Postsplenectomy care. Strategies to decrease the risk of infection. Williams DN, et al. **Postgrad Med** 1996 Jul; 100(1):195-8, 201, 205 (15 ref.)
[Antimicrobial oligopeptides--an important factor in non-specific defense against infection] Haegele B, et al. **Immun Infekt** 1995 Dec;23(6):205-8 (27 ref.) (Eng. Abstr.) **(Ger)**
[Prophylactic and therapeutic use of antibiotics in trauma surgery (see comments)] Hansis M, et al. **Unfallchirurg** 1996 May;99(5):316-22 (35 ref.) (Eng. Abstr.) Comment in: Unfallchirurg 1996 May;99(5):315. **(Ger)**
[Communicable diseases in Norway. Epidemiological status and future challenge for prevention of the most important diseases] Lystad A, et al. **Tidsskr Nor Laegeforen** 1995 Sep 30;115(23):2899-903 (29 ref.) (Eng. Abstr.) **(Nor)**
[Protective properties of antibodies raised against conjugates of endotoxin core oligosaccharides with proteins] Jachymek W. **Postepy Hig Med Dosw** 1995;49(1):171-8 (6 ref.) (Eng. Abstr.) **(Pol)**

THERAPY

Management of catheter-related infections. Piraino B. **Am J Kidney Dis** 1996 May;27(5):754-8 (33 ref.)
Management of sinusitis in the asthmatic patient. Senior BA, et al. **Ann Allergy Asthma Immunol** 1996 Jul;77(1):6-15; quiz 15-9 (47 ref.)
Return to the past: the case for antibody-based therapies in infectious diseases. Casadevall A, et al. **Clin Infect Dis** 1995 Jul;21(1):150-61 (181 ref.)
Adjuncts to antibacterial therapy. Frank MO, et al. **Infect Dis Clin North Am** 1995 Sep;9(3):769-81 (63 ref.)
Clinical perspectives of granulocyte transfusions: efficacy to date. Strauss RG. **J Clin Apheresis** 1995;10(3):114-8 (23 ref.)
Considerations in the management of maxillofacial infections in the pregnant patient. Lawrenz DR, et al. **J Oral Maxillofac Surg** 1996 Apr;54(4):474-85 (47 ref.)
Smaller fleas ... ad infinitum: therapeutic bacteriophage redux. Lederberg J. **Proc Natl Acad Sci U S A** 1996 Apr 16;93(8):3167-8 (21 ref.)

TRANSMISSION

Current concepts on the transmission of bacteria and parasites by blood components. Wendel Neto S. **Rev Paul Med** 1995 Nov-Dec;113(6):1036-52 (107 ref.)
[The interrelationships of ixodid ticks (Ixodidae) with the causative agents of transmissible vertebrate infections] Balashov IuS. **Parazitologiia** 1995 Sep-Oct;29(5):337-52 (90 ref.) (Eng. Abstr.) **(Rus)**

URINE

[Diagnostic value of Stamey's test in chronic prostatitis] Sibert L, et al. **Prog Urol** 1996 Feb;6(1):107-11 (20 ref.) (Eng. Abstr.) **(Fre)**

VETERINARY

Veterinary use of new quinolones in Japan. Nakamura S. **Drugs** 1995;49 Suppl 2:152-8 (41 ref.)
Clinical application of interferons in large animal medicine. Moore BR. **J Am Vet Med Assoc** 1996 May 15; 208(10):1711-5 (50 ref.)
Use of antimicrobial-impregnated polymethyl methacrylate. Tobias KM, et al. **J Am Vet Med Assoc** 1996 Mar 15; 208(6):841-5 (50 ref.)
Bacterial urinary tract infections. Lees GE. **Vet Clin North Am Small Anim Pract** 1996 Mar; 26(2):297-304 (12 ref.)
[Bacterial resistance--state and development in human and animal isolates] Schlatterer B. **DTW Dtsch Tierarztl Wochenschr** 1995 Jun;102(6):251-6 (6 ref.) **(Ger)**

BACTERIAL INFECTIONS, GRAM-NEGATIVE see **GRAM-NEGATIVE BACTERIAL INFECTIONS**

BACTERIAL INFECTIONS, GRAM-POSITIVE see **GRAM-POSITIVE BACTERIAL INFECTIONS**

BACTERIAL LUMINESCENCE see **LUMINESCENCE, BACTERIAL**

BACTERIAL OUTER MEMBRANE PROTEINS

[Bacterial chemotactic transducer-type protein family] Kuroda A, et al. **Tanpakushitsu Kakusan Koso** 1996 Feb; 41(2):146-53 (33 ref.) **(Jpn)**

CHEMISTRY

Disulfide cross-linked envelope proteins: the functional equivalent of peptidoglycan in chlamydiae? Hatch TP. **J Bacteriol** 1996 Jan;178(1):1-5 (49 ref.)
Treponema pallidum and the quest for outer membrane proteins. Radolf JD. **Mol Microbiol** 1995 Jun;16(6):1067-73 (60 ref.)

GENETICS

Triggering bacterial virulence [comment] Cotter PA, et al. **Science** 1996 Aug 30;273(5279):1183-4 (15 ref.) Comment on: Science 1996 Aug 30;273(5279):1231-3. Comment on: Science 1996 Aug 30;273(5279):1234-6.

IMMUNOLOGY

Treponema pallidum and the quest for outer membrane proteins. Radolf JD. **Mol Microbiol** 1995 Jun;16(6):1067-73 (60 ref.)

METABOLISM

Anchorage and release of Gram-positive bacterial cell-surface polypeptides. Jenkinson HF. **Trends Microbiol** 1995 Sep;3(9):333-5 (15 ref.)
Prepilin-like molecules in type 4 pilus biogenesis: minor subunits, chaperones or mediators of organelle translocation? Koomey M. **Trends Microbiol** 1995 Nov; 3(11):409-10; discussion 411-3 (49 ref.)

BACTERIAL PHOTOSYNTHETIC REACTION CENTER see **PHOTOSYNTHETIC REACTION CENTER, BACTERIAL**

BACTERIAL PILI see **FIMBRIAE, BACTERIAL**

BACTERIAL POLYSACCHARIDES see **POLYSACCHARIDES, BACTERIAL**

BACTERIAL PROTEINS

Phylogenetic, structural and functional analyses of the LacI-GalR family of bacterial transcription factors. Nguyen CC, et al. **FEBS Lett** 1995 Dec 18;377(2):98-102 (23 ref.)
Vanadium nitrogenases of Azotobacter. Eady RR. **Met Ions Biol Syst** 1995;31:363-405 (106 ref.)
Nucleoid proteins. Hayat MA, et al. **Micron** 1995; 26(5):461-80 (220 ref.)
High pressure influences on gene and protein expression. Bartlett DH, et al. **Res Microbiol** 1995 Oct;146(8):697-706 (63 ref.)

BIOSYNTHESIS

Ribosome recycling by ribosome recycling factor (RRF)--an important but overlooked step of protein biosynthesis. Janosi L, et al. **Adv Biophys** 1996;32:121-201 (188 ref.)
Does replication-induced transcription regulate synthesis of the myriad low copy number proteins of Escherichia coli? Guptasarma P. **Bioessays** 1995 Nov;17(11):987-97 (57 ref.)
Elongation in bacterial protein biosynthesis. Nyborg J, et al. **Curr Opin Biotechnol** 1996 Aug;7(4):369-75 (48 ref.)
How does Bacillus thuringiensis produce so much insecticidal crystal protein? Agaisse H, et al. **J Bacteriol** 1995 Nov; 177(21):6027-32 (59 ref.)
Maximizing microbial protein synthesis in the rumen. Firkins JL. **J Nutr** 1996 Apr;126(4 Suppl):1347S-54S (71 ref.)
Regulation of insecticidal crystal protein production in Bacillus thuringiensis. Baum JA, et al. **Mol Microbiol** 1995 Oct;18(1):1-12 (50 ref.)
Transcriptional regulation of bioluminesence genes from Vibrio fischeri. Sitnikov DM, et al. **Mol Microbiol** 1995 Sep;17(5):801-12 (84 ref.)

CHEMISTRY

Purple bacterial antenna complexes. Fyfe PK, et al. **Curr Opin Struct Biol** 1996 Aug;6(4):467-72 (41 ref.)
Structures of bacterial immunoglobulin-binding domains and their complexes with immunoglobulins. Tashiro M, et al. **Curr Opin Struct Biol** 1995 Aug;5(4):471-81 (61 ref.)
Theory of the mobility-shift assay of nonspecific protein-DNA complexes governed by conditional probabilities: the HU:DNA complex. Cann JR, et al. **Electrophoresis** 1995 Jun;16(6):881-7 (29 ref.)
Stability and folding of ultrastable proteins: eye lens crystallins and enzymes from thermophiles. Jaenicke R. **FASEB J** 1996 Jan;10(1):84-92 (50 ref.)
Repair, refold, recycle: how bacteria can deal with spontaneous and environmental damage to proteins. Visick JE, et al. **Mol Microbiol** 1995 Jun;16(5):835-45 (124 ref.)
The whole lactose repressor [comment] Matthews KS. **Science** 1996 Mar 1;271(5253):1245-6 (16 ref.) Comment on: Science 1996 Mar 1;271(5253):1247-54.
Copper amine oxidase: a novel use for a tyrosine [comment] Fontecave M, et al. **Structure** 1995 Nov 15;3(11):1127-9 (22 ref.) Comment on: Structure 1995 Nov 15;3(11):1171-84.
[Structure and function of the Ada protein] Ohkubo T, et al. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1620-6 (31 ref.) **(Jpn)**

GENETICS

Antigenic and genetic heterogeneity among Haemophilus influenzae and Neisseria IgA1 proteases. Lomholt H, et al. **Adv Exp Med Biol** 1995;371A:599-603 (18 ref.)
Does replication-induced transcription regulate synthesis of the myriad low copy number proteins of Escherichia coli? Guptasarma P. **Bioessays** 1995 Nov;17(11):987-97 (57 ref.)
The genetics of lantibiotic biosynthesis. Jack R, et al. **Bioessays** 1995 Sep;17(9):793-802 (69 ref.)
Expression of correctly folded proteins in Escherichia coli. Georgiou G, et al. **Curr Opin Biotechnol** 1996 Apr; 7(2):190-7 (40 ref.)
Evolution of ATP-binding cassette transporter genes. Dean M, et al. **Curr Opin Genet Dev** 1995 Dec;5(6):779-85 (42 ref.)
The catabolite repressor/activator (Cra) protein of enteric bacteria. Saier MH Jr, et al. **J Bacteriol** 1996 Jun; 178(12):3411-7 (46 ref.)
Heat-shock and general stress response in Bacillus subtilis. Hecker M, et al. **Mol Microbiol** 1996 Feb;19(3):417-28 (49 ref.)
The signal-transduction network for Pho regulation in Bacillus subtilis. Hulett FM. **Mol Microbiol** 1996 Mar; 19(5):933-9 (27 ref.)
Programmed cell death in bacteria: proteic plasmid stabilization systems. Jensen RB, et al. **Mol Microbiol** 1995 Jul;17(2):205-10 (48 ref.)
Novel PTS proteins revealed by bacterial genome sequencing: a unique fructose-specific phosphoryl transfer protein with two HPr-like domains in Haemophilus influenzae. Reizer J, et al. **Res Microbiol** 1996 May; 147(4):209-15 (29 ref.)
[Initiation of DNA replication in Streptomyces; organizational comparison of the oriC region in prokaryotic organisms] Zakrzewska-Czerwińska J. **Postepy Hig Med Dosw** 1995;49(1):149-60 (43 ref.) (Eng. Abstr.) **(Pol)**

IMMUNOLOGY

[The role of some cellular components of bacterial parasites in determining the incidence of tuberculosis: studies on mycobacterial antigens, with special reference to mycobacterial immunoreactive ribosomal and secreted proteins] Yamada T, et al. **Kekkaku** 1995 Nov; 70(11):639-44 (40 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Ribosome recycling by ribosome recycling factor (RRF)--an important but overlooked step of protein biosynthesis. Janosi L, et al. **Adv Biophys** 1996;32:121-201 (188 ref.)
Leucine-responsive regulatory protein: a global regulator of gene expression in E. coli. Newman EB, et al. **Annu Rev Microbiol** 1995;49:747-75 (122 ref.)
Staphylococcal alpha-toxin, streptolysin-O, and Escherichia coli hemolysin: prototypes of pore-forming bacterial cytolysins. Bhakdi S, et al. **Arch Microbiol** 1996 Feb; 165(2):73-9 (45 ref.)
Sec-dependent preprotein translocation in bacteria. den Blaauwen T, et al. **Arch Microbiol** 1996 Jan;165(1):1-8 (73 ref.)
HPr: a model protein. Anderson JW. **Biochem Cell Biol** 1995 May-Jun;73(5-6):219-22 (15 ref.)
SecA, a novel ATPase that converts chemical energy into a mechanical force to drive precursor protein translocation. Driessen AJ, et al. **Biochem Soc Trans** 1995 Nov; 23(4):981-5 (32 ref.)
Translocation of folded proteins across bacterial outer membranes: a novel secretory phenomenon. Hirst TR, et al. **Biochem Soc Trans** 1995 Nov;23(4):985-91 (46 ref.)
Lytic transglycosylases. Höltje JV. **EXS** 1996;75:425-9 (20 ref.)
Fancy meeting you here! A fresh look at "prokaryotic" protein phosphorylation. Kennelly PJ, et al. **J Bacteriol** 1996 Aug;178(16):4759-64 (54 ref.)
The RuvABC proteins and Holliday junction processing in Escherichia coli. West SC. **J Bacteriol** 1996 Mar; 178(5):1237-41 (59 ref.)
Why does Escherichia coli recycle its cell wall peptides? Park JT. **Mol Microbiol** 1995 Aug;17(3):421-6 (41 ref.)
The SMR family: a novel family of multidrug efflux proteins involved with the efflux of lipophilic drugs. Paulsen IT, et al. **Mol Microbiol** 1996 Mar;19(6):1167-75 (64 ref.)
Cation and sugar selectivity determinants in a novel family of transport proteins. Poolman B, et al. **Mol Microbiol** 1996 Mar;19(5):911-22 (63 ref.)
Repair, refold, recycle: how bacteria can deal with spontaneous and environmental damage to proteins. Visick JE, et al. **Mol Microbiol** 1995 Jun;16(5):835-45 (124 ref.)
HPr: heteromorphous protein. Vadeboncoeur C. **Res Microbiol** 1995 Sep;146(7):525-30 (41 ref.)
The beta-prism: a new folding motif. Shimizu T, et al. **Trends Biochem Sci** 1996 Jan;21(1):3-6 (28 ref.)
Prepilin-like molecules in type 4 pilus biogenesis: minor subunits, chaperones or mediators of organelle translocation? Koomey M. **Trends Microbiol** 1995 Nov; 3(11):409-10; discussion 411-3 (49 ref.)

PHARMACOLOGY

Single cell protein: a promising dietary substitute. Puniya AK, et al. **Indian J Exp Biol** 1995 Aug;33(8):545-51 (101

ref.)

PHYSIOLOGY

Negative regulation of transcription by anti-sigma factors. Wolska KI. **Acta Microbiol Pol** 1996;45(1):7-17 (71 ref.)
Mechaniams for the prevention of damage to DNA in spores of Bacillus species. Setlow P. **Annu Rev Microbiol** 1995; 49:29-54 (91 ref.)
Sec-dependent preprotein translocation in bacteria. den Blaauwen T, et al. **Arch Microbiol** 1996 Jan;165(1):1-8 (73 ref.)
Global physiological controls. Doull JL, et al. **Biotechnology** 1995;28:9-63 (257 ref.)
Relationship between virulence and immunity as revealed in recent studies of the F1 capsule of Yersinia pestis. Friedlander AM, et al. **Clin Infect Dis** 1995 Oct;21 Suppl 2:S178-81 (28 ref.)
On the origin of respiration: electron transport proteins from archaea to man. Schäfer G, et al. **FEMS Microbiol Rev** 1996 May;18(2-3):173-88 (55 ref.)
Bacteriocin release proteins: mode of action, structure, and biotechnological application. van der Wal FJ, et al. **FEMS Microbiol Rev** 1995 Dec;17(4):381-99 (174 ref.)
The catabolite repressor/activator (Cra) protein of enteric bacteria. Saier MH Jr, et al. **J Bacteriol** 1996 Jun; 178(12):3411-7 (46 ref.)
Bacterial modulins: a novel class of virulence factors which cause host tissue pathology by inducing cytokine synthesis. Henderson B, et al. **Microbiol Rev** 1996 Jun;60(2):316-41 (260 ref.)
The role of anti-sigma factors in gene regulation. Brown KL, et al. **Mol Microbiol** 1995 May;16(3):397-404 (49 ref.)
Beta-lactamases and bacterial resistance to antibiotics. Frère JM. **Mol Microbiol** 1995 May;16(3):385-95 (51 ref.)
Virulence in Actinobacillus pleuropneumoniae and RTX toxins. Frey J. **Trends Microbiol** 1995 Jul;3(7):257-61 (50 ref.)
Heat-shock proteins in host-pathogen interactions: implications for cystic fibrosis. Polla BS, et al. **Trends Microbiol** 1995 Oct;3(10):392-6 (51 ref.)
What makes nodulation signals host-plant specific? Schultze M, et al. **Trends Microbiol** 1995 Oct;3(10):370-2 (24 ref.)
Are bacterial proteinases pathogenic factors? Travis J, et al. **Trends Microbiol** 1995 Oct;3(10):405-7 (28 ref.)
[Discovery of epidermal cell differentiation inhibitor (EDIN) produced by Staphylococcus aureus and studies on the mode of action of EDIN] Sugai M. **Nippon Saikingaku Zasshi** 1995 Oct;50(4):937-46 (43 ref.) **(Jpn)**
[Structure and function of the Ada protein] Ohkubo T, et al. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1620-6 (31 ref.) **(Jpn)**

TOXICITY

Pathogenesis of sepsis syndrome: possible relevance of pore-forming bacterial toxins. Bhakdi S, et al. **Curr Top Microbiol Immunol** 1996;216:101-18 (64 ref.)

BACTERIAL RNA see **RNA, BACTERIAL**

BACTERIAL SENSITIVITY TESTS see **MICROBIAL SENSITIVITY TESTS**

BACTERIAL SPORES see **SPORES, BACTERIAL**

BACTERIAL STRUCTURAL GENES see **GENES, STRUCTURAL, BACTERIAL**

BACTERIAL TOXINS

ADVERSE EFFECTS

Secretory diarrhea in children: newly recognized toxins and hormone-secreting tumors. Udall JN Jr. **Pediatr Clin North Am** 1996 Apr;43(2):333-53 (78 ref.)
[Cyanobacteria, their toxins and health risks] Thébault l, et al. **Med Trop (Mars)** 1995;55(4):375-80 (43 ref.) (Eng. Abstr.) **(Fre)**

ANALYSIS

Update on diagnosis of Clostridium difficile-associated diarrhea. DeMaio J, et al. **Curr Clin Top Infect Dis** 1995; 15:97-114 (139 ref.)
[Detection of bacterial protein toxins by a bead-ELISA] Kurazono H, et al. **Nippon Rinsho** 1995 Sep;53(9):2296-300 (11 ref.) (Eng. Abstr.) **(Jpn)**

BIOSYNTHESIS

How does Bacillus thuringiensis produce so much insecticidal crystal protein? Agaisse H, et al. **J Bacteriol** 1995 Nov; 177(21):6027-32 (59 ref.)
[Infections with verocytotoxin-producing Escherichia coli and hemolytic-uremic syndrome] van de Kar NC, et al. **Ned Tijdschr Geneeskd** 1996 Jan 20;140(3):134-7 (22 ref.) (Eng. Abstr.) **(Dut)**
[Regulation of the toxin production in Clostridium perfringens] Shimizu T. **Nippon Saikingaku Zasshi** 1995 Jul; 50(3):737-44 (27 ref.) **(Jpn)**
[Cytolysins and homologous proteins produced by gram-negative bacteria. I. Hemolysis and leukotoxins of Escherichia coli, Bordetella pertussis, Pasteurella haemolytica and Actinobacillus sp] Różalski A. **Postepy Hig Med Dosw** 1996;50(2):173-90 (103 ref.) (Eng. Abstr.) **(Pol)**

GENETICS

Genetic detoxification of bacterial toxins: a new approach to vaccine development. Rappuoli R, et al. **Int Arch Allergy Immunol** 1995 Dec;108(4):327-33 (39 ref.)
Transfer of toxin genes to alternate bacterial hosts for mosquito control. Orduz S, et al. **Mem Inst Oswaldo Cruz** 1995 Jan-Feb;90(1):97-107 (88 ref.)

METABOLISM

Staphylococcal alpha-toxin, streptolysin-O, and Escherichia coli hemolysin: prototypes of pore-forming bacterial cytolysins. Bhakdi S, et al. **Arch Microbiol** 1996 Feb; 165(2):73-9 (45 ref.)
Studies on the active-site structure of C3-like exoenzymes: involvement of glutamic acid in catalysis of ADP-ribosylation. Aktories K, et al. **Biochimie** 1995; 77(5):326-32 (62 ref.)
Battling against host phagocytes: the wherefore of the RTX family of toxins? Welch RA, et al. **Infect Agents Dis** 1995 Dec;4(4):254-72 (191 ref.)
Bacillus thuringiensis growth and toxicity. Basic and applied considerations. Avignone-Rossa C, et al. **Mol Biotechnol** 1995 Aug;4(1):55-71 (148 ref.)
Role of verotoxin receptors in pathogenesis. Lingwood CA. **Trends Microbiol** 1996 Apr;4(4):147-53 (89 ref.)

PHARMACOLOGY

Bacterial toxins deliver the goods. Pugsley AP. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8155-6 (18 ref.)

THERAPEUTIC USE

Bacterial toxins deliver the goods. Pugsley AP. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8155-6 (18 ref.)

TOXICITY

Pathogenesis of sepsis syndrome: possible relevance of pore-forming bacterial toxins. Bhakdi S, et al. **Curr Top Microbiol Immunol** 1996;216:101-18 (64 ref.)
Bacterial endotoxin: Chemical constitution, biological recognition, host response, and immunological detoxification. Rietschel ET, et al. **Curr Top Microbiol Immunol** 1996;216:39-81 (265 ref.)
Biological effects of RTX toxins: the possible role of lipopolysaccharide. Czuprynski CJ, et al. **Trends Microbiol** 1995 Dec;3(12):480-3 (48 ref.)

BACTERIAL TRANSLOCATION

Trauma and bacterial translocation [see comments] Saadia R. **Br J Surg** 1995 Sep;82(9):1243-4 (18 ref.) Comment in: Br J Surg 1996 Feb;83(2):282-3. Comment in: Br J Surg 1996 Feb;83(2):283.
Infection, the gut and the development of the multiple organ dysfunction syndrome. Nieuwenhuijzen GA, et al. **Eur J Surg** 1996 Apr;162(4):259-73 (185 ref.)

PHYSIOLOGY

Role of the gut in multiple organ failure: bacterial translocation and permeability changes. Swank GM, et al. **World J Surg** 1996 May;20(4):411-7 (65 ref.)

BACTERIAL TYPING TECHNIQUES

Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. Tenover FC, et al. **J Clin Microbiol** 1995 Sep;33(9):2233-9 (48 ref.)
New approaches to typing and identification of bacteria using the 16S-23S rDNA spacer region. Gürtler V, et al. **Microbiology** 1996 Jan;142 (Pt 1):3-16 (100 ref.)
Restriction fragment length polymorphism typing of Mycobacterium tuberculosis. Hayward AC. **Thorax** 1995 Nov;50(11):1211-8 (66 ref.)

BACTERIAL VACCINES

Qualitative and quantitative immune response to bacterial capsular polysaccharides and their conjugates in mouse and man. Fattom A. **Adv Exp Med Biol** 1995;383:131-9 (34 ref.)
Strategies to interrupt the development of Anaplasma marginale in its tick vector. The effect of bovine-derived antibodies. Kocan KM, et al. **Ann N Y Acad Sci** 1996 Jul 23;791:157-65 (57 ref.)
Animal models and vaccine development. Lee A. **Baillieres Clin Gastroenterol** 1995 Sep;9(3):615-32 (74 ref.)
Immunization in adults in the 1990s. Gardner P, et al. **Curr Clin Top Infect Dis** 1995;15:271-300 (115 ref.)
Pneumococcal virulence factors and host immune responses to them. Watson DA, et al. **Eur J Clin Microbiol Infect Dis** 1995 Jun;14(6):479-90 (87 ref.)
Streptococcus pneumoniae: virulence factors, pathogenesis, and vaccines. AlonsoDeVelasco E, et al. **Microbiol Rev** 1995 Dec;59(4):591-603 (163 ref.)
Epidemiology and prevention of meningococcal disease. Riedo FX, et al. **Pediatr Infect Dis J** 1995 Aug;14(8):643-57 (163 ref.)
Vaccines for gonorrhea: where are we on the curve? Blake MS, et al. **Trends Microbiol** 1995 Dec;3(12):469-74 (63 ref.)
[Leprosy and vaccine] Matsumoto S, et al. **Nippon Rai Gakkai Zasshi** 1995 Nov;64(3):163-73 (63 ref.) **(Jpn)**

ADMINISTRATION & DOSAGE

Oral vaccines against cholera and enterotoxigenic Escherichia coli diarrhea. Svennerholm AM, et al. **Adv Exp Med Biol** 1995;371B:1623-8 (19 ref.)
Live Salmonella vaccines as a route towards oral immunisation. Everest P, et al. **Biologicals** 1995 Jun; 23(2):119-24 (48 ref.)
Features of oral immunization. Ruedl C, et al. **Int Arch Allergy Immunol** 1995 Dec;108(4):334-9 (38 ref.)
The contribution of the case-control approach to vaccine evaluation: Pneumococcal and Haemophilus influenzae type B PRP vaccines. Mills OF, et al. **J Clin Epidemiol** 1996 Jun;49(6):631-6 (34 ref.)

CLASSIFICATION

[Immunity--technical aspects of vaccines. I. Immunoprophylaxis in dogs and cats] Overgaauw PA. **Tijdschr Diergeneeskd** 1996 Feb 15;121(4):90-5 (0 ref.) (Eng. Abstr.) **(Dut)**

IMMUNOLOGY

Listeria monocytogenes: a live vector able to deliver heterologous protein within the cytosol and to drive a CD8 dependent T cell response. Goossens PL, et al. **Biologicals** 1995 Jun;23(2):135-43 (92 ref.)
Genetic detoxification of bacterial toxins: a new approach to vaccine development. Rappuoli R, et al. **Int Arch Allergy Immunol** 1995 Dec;108(4):327-33 (39 ref.)
The long-term antimicrobial prophylaxis of chronic bronchitis exacerbations. Crimi N, et al. **J Chemother** 1995 Aug;7(4):307-10 (14 ref.)
Transferrin receptors of Neisseria meningitidis: promising candidates for a broadly cross-protective vaccine. Ala'Aldeen DA. **J Med Microbiol** 1996 Apr;44(4):237-43 (40 ref.)
Lyme vaccine enhancement. N-terminal acylation of a protein antigen and inclusion of a saponin adjuvant. Coughlin RT, et al. **Pharm Biotechnol** 1995;6:719-35 (126 ref.)
Pneumococcal conjugate vaccines. Eby R. **Pharm Biotechnol** 1995;6:695-718 (140 ref.)
Haemophilus influenzae type b conjugate vaccines. Kniskern PJ, et al. **Pharm Biotechnol** 1995;6:673-94 (63 ref.)
Prospects for new vaccines against tuberculosis. Orme IM. **Trends Microbiol** 1995 Oct;3(10):401-4 (27 ref.)

ISOLATION & PURIFICATION

Prospects for a vaccine to prevent Lyme disease in humans. Wormser GP. **Clin Infect Dis** 1995 Nov;21(5):1267-74 (113 ref.)

STANDARDS

Contagious bovine pleuropneumonia vaccines: the need for improvements. Rweyemamu MM, et al. **Rev Sci Tech** 1995 Sep;14(3):593-601 (14 ref.)

SUPPLY & DISTRIBUTION

[New vaccines. What can we expect in the coming years?] Bjune G, et al. **Tidsskr Nor Laegeforen** 1995 Oct 10; 115(24):3032-4 (20 ref.) (Eng. Abstr.) **(Nor)**

THERAPEUTIC USE

Live attenuated Shigella flexneri mutants as vaccine candidates against shigellosis and vectors for antigen delivery. Phalipon A, et al. **Biologicals** 1995 Jun; 23(2):125-34 (54 ref.)
The value of influenza and pneumococcal vaccines in the elderly. Monto AS, et al. **Drugs Aging** 1996 Jun;8(6):445-51 (35 ref.)
Designer vaccines to prevent infections due to group B Streptococcus. Kasper DL. **Proc Assoc Am Physicians** 1995 Oct;107(3):369-73 (22 ref.)

BACTERIAL VAGINOSIS see **VAGINOSIS, BACTERIAL**

BACTERIOCHLOROPHYLLS

CHEMISTRY

Relationship between the oxidation potential of the bacteriochlorophyll dimer and electron transfer in photosynthetic reaction centers. Allen JP, et al. **J Bioenerg Biomembr** 1995 Jun;27(3):275-83 (50 ref.)

METABOLISM

Relationship between the oxidation potential of the bacteriochlorophyll dimer and electron transfer in photosynthetic reaction centers. Allen JP, et al.

J Bioenerg Biomembr 1995 Jun;27(3):275–83 (50 ref.)

BACTERIOCIN TYPING see BACTERIAL TYPING TECHNIQUES

BACTERIOCINS

BIOSYNTHESIS

Microcins. Moreno F, et al. **Biotechnology** 1995;28:307–21 (58 ref.)

CHEMISTRY

Microcins. Moreno F, et al. **Biotechnology** 1995;28:307–21 (58 ref.)

METABOLISM

Bacteriocin release proteins: mode of action, structure, and biotechnological application. van der Wal FJ, et al. **FEMS Microbiol Rev** 1995 Dec;17(4):381–99 (174 ref.)

PHARMACOLOGY

Bacteriocins: modes of action and potentials in food preservation and control of food poisoning. Abee T, et al. **Int J Food Microbiol** 1995 Dec;28(2):169–85 (56 ref.)

Lactococcal bacteriocins: mode of action and immunity. Venema K, et al. **Trends Microbiol** 1995 Aug;3(8):299–304 (48 ref.)

BACTERIOLOGICAL TECHNIQUES

see related

CULTURE MEDIA

Detection and identification of Campylobacter spp. using the polymerase chain reaction. Giesendorf BA, et al. **Cell Mol Biol (Noisy-le-grand)** 1995 Jul;41(5):625–38 (123 ref.)

Diagnostic mycobacteriology laboratory practices. Shinnick TM, et al. **Clin Infect Dis** 1995 Aug;21(2):291–9 (56 ref.)

Strategies for studying bacterial adhesion in vivo. Leffler H, et al. **Methods Enzymol** 1995;253:206–20 (69 ref.)

[Current status and diagnostic value of nucleic acid amplification and conventional methods in laboratory diagnosis of tuberculosis] Küchler R. **Pneumologie** 1996 Apr;50(4):323–6 (19 ref.) **(Ger)**

CLASSIFICATION

[Bacteriological diagnosis of tuberculosis: current hieratic classification of methods] Carbonnelle B, et al. **Rev Med Interne** 1995;16(7):518–23 (45 ref.) (Eng. Abstr.) **(Fre)**

INSTRUMENTATION

Microbial detection. Hobson NS, et al. **Biosens Bioelectron** 1996;11(5):455–77 (133 ref.)

BACTERIOLOGY

HISTORY

[Shibasaburo Kitasato's discovery of plague bacillus and its historical background—on the occasion of the centennial anniversary] Nakase Y. **Nippon Saikingaku Zasshi** 1995 Jul; 50(3):637–50 (53 ref.) **(Jpn)**

[Influenza-bacillus: who discovered the organism?] Taguchi F, et al. **Nippon Saikingaku Zasshi** 1995 Jul;50(3):787–91 (8 ref.) **(Jpn)**

BACTERIOPHAGE HK022 see BACTERIOPHAGE LAMBDA

BACTERIOPHAGE LAMBDA

GENETICS

Transcription antitermination: the lambda paradigm updated. Friedman DI, et al. **Mol Microbiol** 1995 Oct;18(2):191–200 (70 ref.)

PHYSIOLOGY

Virus DNA packaging: the strategy used by phage lambda. Catalano CE, et al. **Mol Microbiol** 1995 Jun;16(6):1075–86 (87 ref.)

BACTERIOPHAGE M13

GROWTH & DEVELOPMENT

Single-stranded DNA binding protein encoded by the filamentous bacteriophage M13: structural and functional characteristics. Stassen AP, et al. **Mol Biol Rep** 1994–95; 20(3):109–27 (101 ref.)

BACTERIOPHAGE MU

GENETICS

Quality control in Mu DNA transposition [comment] Craigie R. **Cell** 1996 Apr 19;85(2):137–40 (11 ref.) Comment on: Cell 1996 Apr 19;85(2):257–69. Comment on: Cell 1996 Apr 19;85(2):271–80.

Transposition of phage Mu DNA. Lavoie BD, et al. **Curr Top Microbiol Immunol** 1996;204:83–102 (89 ref.)

Unity in transposition reactions. Craig NL. **Science** 1995 Oct 13;270(5234):253–4 (22 ref.)

BACTERIOPHAGE PHI 29 see BACILLUS PHAGES

BACTERIOPHAGE PHI 105 see BACILLUS PHAGES

BACTERIOPHAGE T4

ENZYMOLOGY

Structural and genetic analysis of the folding and function of T4 lysozyme. Matthews BW. **FASEB J** 1996 Jan; 10(1):35–41 (29 ref.)

GENETICS

The amber mutants of phage T4. Stahl FW. **Genetics** 1995 Oct;141(2):439–42 (24 ref.)

PHYSIOLOGY

DNA packaging and cutting by phage terminases: control in phage T4 by a synaptic mechanism. Black LW. **Bioessays** 1995 Dec;17(12):1025–30 (55 ref.)

BACTERIOPHAGES

Designing DNA-binding proteins on the surface of filamentous phage. Choo Y, et al. **Curr Opin Biotechnol** 1995 Aug;6(4):431–6 (23 ref.)

The use of phage display in neurobiology. Bradbury A, et al. **Trends Neurosci** 1995 Jun;18(6):243–9 (63 ref.)

CLASSIFICATION

Frequency of morphological phage descriptions in 1995. Ackermann HW. **Arch Virol** 1996;141(2):209–18 (21 ref.)

ENZYMOLOGY

Phage lysozymes. Fastrez J. **EXS** 1996;75:35–64 (146 ref.)

GENETICS

Filamentous phage display of oligopeptide libraries. Burritt JB, et al. **Anal Biochem** 1996 Jun 15;238(1):1–13 (102 ref.)

Phage display: protein engineering by directed evolution. O'Neil KT, et al. **Curr Opin Struct Biol** 1995 Aug; 5(4):443–9 (54 ref.)

Bacteriophage resistance in Lactococcus. Dinsmore PK, et al. **Mol Biotechnol** 1995 Dec;4(3):297–314 (115 ref.)

An ace up the sleeve of the cholera bacterium. Richardson SH, et al. **Nat Med** 1996 Aug;2(8):853–5 (8 ref.)

IMMUNOLOGY

Phage libraries--a new route to clinically useful antibodies. Marks C, et al. **N Engl J Med** 1996 Sep 5;335(10):730–3 (0 ref.)

PATHOGENICITY

Bacteriophage resistance in Lactococcus. Dinsmore PK, et al. **Mol Biotechnol** 1995 Dec;4(3):297–314 (115 ref.)

A role for bacteriophages in the evolution and transfer of bacterial virulence determinants. Cheetham BF, et al. **Mol Microbiol** 1995 Oct;18(2):201–8 (85 ref.)

PHYSIOLOGY

Smaller fleas ... ad infinitum: therapeutic bacteriophage redux. Lederberg J. **Proc Natl Acad Sci U S A** 1996 Apr 16;93(8):3167–8 (21 ref.)

ULTRASTRUCTURE

Frequency of morphological phage descriptions in 1995. Ackermann HW. **Arch Virol** 1996;141(2):209–18 (21 ref.)

BACTERIORHODOPSIN

Langmuir-Blodgett films of photosensitive proteins. Pepe IM, et al. **J Photochem Photobiol B** 1996 May;33(3):191–200 (82 ref.)

BACTERIURIA

Bacteriuria and urinary infections in the elderly. Childs SJ, et al. **Urol Clin North Am** 1996 Feb;23(1):43–54 (121 ref.)

DIAGNOSIS

Review: urinary tract infection in elderly people--time to review management? Gray RP, et al. **Age Ageing** 1995 Jul; 24(4):341–5 (45 ref.)

Urinary tract infection [editorial] Mehta KP. **Indian Pediatr** 1996 Mar;33(3):173–6 (14 ref.)

ETIOLOGY

Urinary tract infection. Gulati S, et al. **Indian Pediatr** 1996 Mar;33(3):211–7 (20 ref.)

[Bacteriuria caused by bladder catheters; value of various preventive measures] Geenen RW, et al. **Ned Tijdschr Geneeskd** 1996 Apr 27;140(17):918–22 (27 ref.) **(Dut)**

BACTEROIDES

GENETICS

In the driver's seat: the Bacteroides conjugative transposons and the elements they mobilize. Salyers AA, et al. **J Bacteriol** 1995 Oct;177(20):5727–31 (22 ref.)

BACTEROIDES CORRODENS see EIKENELLA CORRODENS

BACTEROIDES FRAGILIS

CHEMISTRY

Structure and function of Bacteroides fragilis capsular polysaccharides: relationship to induction and prevention of abscesses. Tzianabos AO, et al. **Clin Infect Dis** 1995 Jun; 20 Suppl 2:S132–40 (35 ref.)

PHYSIOLOGY

Enterotoxigenic Bacteroides fragilis. Sears CL, et al. **Clin Infect Dis** 1995 Jun;20 Suppl 2:S142–8 (33 ref.)

BACTEROIDES GINGIVALIS see PORPHYROMONAS GINGIVALIS

BACULOVIRIDAE

Development of recombinant baculoviruses for insect control. Bonning BC, et al. **Annu Rev Entomol** 1996; 41:191–210 (113 ref.)

GENETICS

Assembly of macromolecular complexes in bacterial and baculovirus expression systems. Roy P, et al. **Curr Opin Struct Biol** 1996 Apr;6(2):157–61 (53 ref.)

Replication of baculovirus DNA. Kool M, et al. **J Gen Virol** 1995 Sep;76 (Pt 9):2103–18 (150 ref.)

[Expression of HCV proteins by using recombinant baculoviruses] Aizaki H, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:80–4 (16 ref.) **(Jpn)**

BAGASSOSIS see PNEUMOCONIOSIS

BAKER'S CYST see POPLITEAL CYST

BAKER'S YEAST see SACCHAROMYCES CEREVISIAE

BAKING SODA see SODIUM BICARBONATE

BALANCE see EQUILIBRIUM

BALANITIS

Pseudoepitheliomatous, keratotic and micaceous balanitis. Case report and review of the literature. Krunic AL, et al. **Urol Int** 1996;56(2):125–8 (15 ref.)

ETIOLOGY

Balanitis and balanoposthitis: a review. Edwards S. **Genitourin Med** 1996 Jun;72(3):155–9 (98 ref.)

BALDNESS see ALOPECIA

BALINT PSYCHOANALYTIC THERAPY see PSYCHOANALYTIC THERAPY

BALLISTICS, WOUND see WOUNDS, GUNSHOT

BALLOON ANGIOPLASTY see ANGIOPLASTY, BALLOON

BALLOON CATHETERIZATION see BALLOON DILATATION

BALLOON DILATATION

Serial changes of left atrial thrombus in mitral stenosis: transesophageal echocardiographic studies in candidates for balloon mitral commissurotomy. Hase M, et al. **Can J Cardiol** 1996 Mar;12(3):278–84 (28 ref.)

Endovascular therapy for surgical diseases of the cranial base. Chaloupka JC, et al. **Clin Plast Surg** 1995 Jul;22(3):417–50 (193 ref.)

Interventional cardiology in pregnancy. Presbitero P, et al. **Eur Heart J** 1996 Feb;17(2):182–8 (104 ref.)

Technology assessment status evaluation: balloon dilation of gastrointestinal tract strictures. American Society for Gastrointestinal Endoscopy. Kimmey MB, et al. **Gastrointest Endosc** 1995 Dec;42(6):608–11 (18 ref.)

Coarctation of the aorta: aortoplasty with Inoue balloon. Ramachandran P, et al. **Indian Heart J** 1996 May-Jun; 48(3):287–9 (11 ref.)

[Percutaneous pulmonary valvuloplasty in neonates and infants with tetralogy of Fallot] Godart F, et al. **Arch Mal Coeur Vaiss** 1996 May;89(5):533–9 (30 ref.) (Eng. Abstr.) **(Fre)**

[Percutaneous balloon mitral valvoplasty. Immediate results,

complications and hospital outcome] Peixoto EC, et al. **Arq Bras Cardiol** 1995 Feb;64(2):109–16 (86 ref.) (Eng. Abstr.) **(Por)**

[Percutaneous mitral commissurotomy with an Inoue catheter in congenital mitral stenosis] Ledesma Velasco M, et al. **Arch Inst Cardiol Mex** 1995 May–Jun;65(3):261–3 (13 ref.) (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Oestradiol inhibition of vascular myointimal proliferation following immune, chemical and mechanical injury. Foegh ML, et al. **Ciba Found Symp** 1995;191:139–45; discussion 145–9 (19 ref.)

[Complications of percutaneous mitral commissurotomy. Personal experience and review of the literature] Ben Farhat M, et al. **Arch Mal Coeur Vaiss** 1996 Apr; 89(4):417–23 (30 ref.) (Eng. Abstr.) **(Fre)**

METHODS

Endovascular stents in children under 1 year of age: acute impact and late results. Hatai Y, et al. **Br Heart J** 1995 Dec;74(6):689–95 (16 ref.)

[Current attitude to severe acute digestive hemorrhage caused by rupture of esophageal varices in cirrhotic patients] Castaing D, et al. **Ann Chir** 1995;49(6):463–8; discussion 468–70 (37 ref.) **(Fre)**

[Mitral valvuloplasty using the Inoue balloon] Hellmüller B, et al. **Schweiz Med Wochenschr** 1995 Nov 4;125(44):2122–30 (36 ref.) (Eng. Abstr.) **(Ger)**

BALLOON DILATATION, CORONARY ARTERY see **ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY**

BALLOON TAMPONADE see **BALLOON DILATATION**

BALLOON VALVOTOMY see **BALLOON DILATATION**

BALLOON VALVULOPLASTY see **BALLOON DILATATION**

BALNEOLOGY

see related
HEALTH RESORTS
MINERAL WATERS

Dermatology at the Dead Sea spas. Even-Paz Z. **Isr J Med Sci** 1996 Jul;32 Suppl:S11–5 (23 ref.)

Balneotherapy for rheumatic diseases at the Dead Sea area. Sukenik S. **Isr J Med Sci** 1996 Jul;32 Suppl:S16–9 (11 ref.)

METHODS

The Dead Sea is alive. Sukenik S, et al. **Isr J Med Sci** 1996 Jul;32 Suppl:S1–3 (9 ref.)

The medical and scientific aspects of spa therapy. Tishler M, et al. **Isr J Med Sci** 1996 Jul;32 Suppl:S8–10 (10 ref.)

BALNEOTHERAPY see **BALNEOLOGY**

BANANA see **FRUIT**

BANCROFTIAN ELEPHANTIASIS see **ELEPHANTIASIS, FILARIAL**

BAND 3 PROTEIN

METABOLISM

Plasticity in epithelial polarity of renal intercalated cells: targeting of the H(+)-ATPase and band 3. Al-Awqati Q. **Am J Physiol** 1996 Jun;270(6 Pt 1):C1571–80 (67 ref.)

BANDAGES

The use of gauze versus transparent dressings for peripheral intravenous catheter sites. Pettit DM, et al. **Nurs Clin North Am** 1995 Sep;30(3):495–506 (15 ref.)

[Treatment of ulcus cruris. What is the role of wound dressings?] Sedlarik KM. **Med Monatsschr Pharm** 1995 Dec;18(12):358–62 (21 ref.) **(Ger)**

BANDAGES, OCCLUSIVE see **OCCLUSIVE DRESSINGS**

BAR CODES see **AUTOMATIC DATA PROCESSING**

BARANY'S TEST see **CALORIC TESTS**

BARBAMYL see **AMOBARBITAL**

BARBARY APE see **MACACA**

BARBITURATE SEDATIVES see **SEDATIVES, BARBITURATE**

BARBITURATES

see related
ANESTHETICS, INTRAVENOUS
ANTICONVULSANTS
SEDATIVES, BARBITURATE

Barbiturates, neuroleptics, and propofol for sedation. Lund N, et al. **Crit Care Clin** 1995 Oct;11(4):875–86 (38 ref.)

ADMINISTRATION & DOSAGE

High-dose barbiturates for intracranial pressure control. Wilberger JE, et al. **New Horiz** 1995 Aug;3(3):469–73 (27 ref.)

PHARMACOLOGY

Pharmacology of barbiturate tolerance/dependence: GABAA receptors and molecular aspects. Ito T, et al. **Life Sci** 1996;59(3):169–95 (176 ref.)

BARE LYMPHOCYTE SYNDROME see **SEVERE COMBINED IMMUNODEFICIENCY**

BAREFOOT DOCTORS see **COMMUNITY HEALTH AIDES**

BARIUM SULFATE

DIAGNOSTIC USE

Barium enema: colorectal polyps and carcinoma. Ott DJ. **Semin Roentgenol** 1996 Apr;31(2):125–41 (64 ref.)

BARLEY

ENZYMOLOGY

Structure and possible function of aspartic proteinases in barley and other plants. Kervinen J, et al. **Adv Exp Med Biol** 1995;362:241–54 (72 ref.)

GENETICS

Stable transformation of barley via direct DNA uptake. Electroporation- and PEG-mediated protoplast transformation. Lazzeri PA. **Methods Mol Biol** 1995; 49:95–106 (20 ref.)

BARMAH FOREST VIRUS see **ALPHAVIRUS**

BARNACLES

Voltage dependence of Na-Ca exchange in barnacle muscle cells. I. Na-Na exchange activated by alpha-chymotrypsin. Rasgado-Flores H, et al. **Ann N Y Acad Sci** 1996 Apr 15; 779:236–48 (28 ref.)

BARORECEPTORS see **PRESSORECEPTORS**

BAROREFLEX

PHYSIOLOGY

How sympathetic tone maintains or alters arterial pressure. Julien C, et al. **Fundam Clin Pharmacol** 1995;9(4):343–9 (39 ref.)

Baroreflex sensitivity. La Rovere MT, et al. **J Cardiovasc Electrophysiol** 1995 Sep;6(9):761–74 (86 ref.)

Baroreflexes and cardiovascular regulation in hypertension. Head GA. **J Cardiovasc Pharmacol** 1995;26 Suppl 2:S7–16 (86 ref.)

BAROSMIN see **DIOSMIN**

BAROTRAUMA

see related
DECOMPRESSION SICKNESS

Barotrauma. Tocino I, et al. **Radiol Clin North Am** 1996 Jan; 34(1):59–81 (126 ref.)

COMPLICATIONS

Self-induced pneumoparotitis. Goguen LA, et al. **Arch Otolaryngol Head Neck Surg** 1995 Dec;121(12):1426–9 (28 ref.)

[Gastric rupture secondary to barotrauma in the framework of a diving accident. Apropos of a case report and literature review] Vuilleumier H, et al. **Swiss Surg** 1995;(5):226–9 (8 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Recreational scuba diving injuries. Clenney TL, et al. **Am Fam Physician** 1996 Apr;53(5):1761–74 (17 ref.)

ETIOLOGY

Recreational scuba diving injuries. Clenney TL, et al. **Am Fam Physician** 1996 Apr;53(5):1761–74 (17 ref.)

BARRETT ESOPHAGUS

COMPLICATIONS

A systematic review of the association between Barrett's esophagus and colon neoplasms [see comments] Howden CW, et al. **Am J Gastroenterol** 1995 Oct;90(10):1814–9 (29 ref.) Comment in: Am J Gastroenterol 1996 May;91(5):1056–7.

Barrett's esophagus: a model of human neoplastic progression. Neshat K, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:577–83 (58 ref.)

Risk factors for neoplastic progression in Barrett's mucosa. Menke-Pluymers MB. **Eur J Surg Oncol** 1996 Aug; 22(4):311–6 (65 ref.)

Barrett's esophagus: a review. Sawyer DR, et al. **Mo Med** 1995 Oct;92(10):645–7 (13 ref.)

[From Barrett esophagus to adenocarcinoma: can the dangers of natural history be overcome?] Robaszkiewicz M. **Gastroenterol Clin Biol** 1996;20(5 Pt 2):B89–97 (111 ref.) **(Fre)**

DIAGNOSIS

The columnar-lined esophagus, intestinal metaplasia, and Norman Barrett [see comments] Spechler SJ, et al. **Gastroenterology** 1996 Feb;110(2):614–21 (63 ref.) Comment in: Gastroenterology 1996 Aug;111(2):565–6.

Barrett's esophagus. Spechler SJ. **Semin Gastrointest Dis** 1996 Apr;7(2):51–60 (66 ref.)

PATHOLOGY

Barrett's esophagus and esophageal adenocarcinoma: the scope of the problem. Levine MS, et al. **Abdom Imaging** 1995 Jul–Aug;20(4):291–8 (69 ref.)

The biopsy diagnosis of gastroesophageal reflux disease, "carditis," and Barrett's esophagus, and sequelae of therapy. Riddell RH. **Am J Surg Pathol** 1996;20 Suppl 1:S31–50 (82 ref.)

SURGERY

Surgical management of Barrett's esophagus. Clark GW, et al. **Ann Chir Gynaecol** 1995;84(2):139–44 (30 ref.)

Barrett's esophagus. Attwood SE. **Curr Opin Gen Surg** 1993; :180–8 (45 ref.)

ULTRASONOGRAPHY

Gastroesophageal reflux and Barrett's esophagus. Van Dam J. **Gastrointest Endosc Clin N Am** 1995 Jul;5(3):649–54 (9 ref.)

BARTHOLIN'S GLANDS

Adenoid cystic carcinoma of Bartholin's gland: a review of the literature and report of a patient. DePasquale SE, et al. **Gynecol Oncol** 1996 Apr;61(1):122–5 (32 ref.)

BARTONELLA

CLASSIFICATION

Bartonella (Rochalimaea) infections: beyond cat scratch. Schwartzman W. **Annu Rev Med** 1996;47:355–64 (26 ref.)

BARTONELLA HENSELAE

Cat-scratch disease. Midani S, et al. **Adv Pediatr** 1996; 43:397–422 (97 ref.)

Neurologic complications of Bartonella henselae infection. Marra CM. **Curr Opin Neurol** 1995 Jun;8(3):164–9 (65 ref.)

New pathogens, and diseases old and new. I) Afipia felis and Rochalimaea. II) Parvovirus B 19. III) herpesvirus 6. Zannolli R, et al. **Panminerva Med** 1995 Dec;37(4):238–47 (111 ref.)

[Bartonella (Rochalimaea) infections: cat-scratch disease and bacillary angiomatosis] Sander A, et al. **Dtsch Med Wochenschr** 1996 Jan 19;121(3):65–9 (47 ref.) **(Ger)**

CLASSIFICATION

Bartonella (Rochalimaea) infections: beyond cat scratch. Schwartzman W. **Annu Rev Med** 1996;47:355–64 (26 ref.)

IMMUNOLOGY

[Cat scratch disease. Bartonella henselae antibodies and DNA detection in regional lymphadenopathy] Heizmann WR, et al. **Dtsch Med Wochenschr** 1996 May 10;121(19):622–6 (33 ref.) (Eng. Abstr.) **(Ger)**

ISOLATION & PURIFICATION

Bartonella infections. Evolution from the esoteric [editorial; comment] Cockerell CJ, et al. **Am J Clin Pathol** 1995 Nov; 104(5):487–90 (31 ref.) Comment on: Am J Clin Pathol 1995 Nov;104(5):530–6.

Fever, abdominal pain and an intracranial mass. Wong M, et al. **Pediatr Infect Dis J** 1995 Aug;14(8):725–8 (18 ref.)

[Cat-scratch disease and other infections caused by Bartonella species] Schellekens JF. **Ned Tijdschr Geneeskd** 1996 Jan 20;140(3):144–7 (25 ref.) (Eng. Abstr.) **(Dut)**

[Cat scratch disease caused by Bartonella henselae] Sölder B, et al. **Immun Infekt** 1995 Dec;23(6):228–31 (25 ref.) (Eng. Abstr.) **(Ger)**

BARTONELLA INFECTIONS

Bartonella infections. Evolution from the esoteric [editorial; comment] Cockerell CJ, et al. **Am J Clin Pathol** 1995 Nov; 104(5):487–90 (31 ref.) Comment on: Am J Clin Pathol 1995 Nov;104(5):530–6.

The role of molecular techniques in the understanding of emerging infections. Sable CA, et al. **Mol Med Today** 1996

Mar;2(3):120–8 (43 ref.)

COMPLICATIONS

Bartonella infections. Koehler JE. **Adv Pediatr Infect Dis** 1996;11:1–27 (67 ref.)

DIAGNOSIS

Bartonella (Rochalimaea) infections: beyond cat scratch. Schwartzman W. **Annu Rev Med** 1996;47:355–64 (26 ref.)

EPIDEMIOLOGY

Infections associated with Bartonella species in persons infected with human immunodeficiency virus. Regnery RL, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S94–8 (36 ref.)

Verruga peruana: an infectious endemic angiomatosis. Cáceres-Ríos H, et al. **Crit Rev Oncog** 1995;6(1):47–56 (96 ref.)

MICROBIOLOGY

[Cat-scratch disease and other infections caused by Bartonella species] Schellekens JF. **Ned Tijdschr Geneeskd** 1996 Jan 20;140(3):144–7 (25 ref.) (Eng. Abstr.) **(Dut)**

[Cat scratch disease caused by Bartonella henselae] Sölder B, et al. **Immun Infekt** 1995 Dec;23(6):228–31 (25 ref.) (Eng. Abstr.) **(Ger)**

BARTONELLOSIS see **BARTONELLA INFECTIONS**

BASAL CELL NEVUS SYNDROME

DIAGNOSIS

[The Gorlin syndrome. A review of 11 cases] Alegre M, et al. **Rev Clin Esp** 1995 Oct;195(10):684–7 (16 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

The Gorlin syndrome gene: a tumor suppressor active in basal cell carcinogenesis and embryonic development. Bale AE, et al. **Proc Assoc Am Physicians** 1995 Jul;107(2):253–7 (35 ref.)

BASAL GANGLIA

ANATOMY & HISTOLOGY

Chemical anatomy of primate basal ganglia. Parent A, et al. **Prog Neurobiol** 1995 Jun;46(2–3):131–97 (500 ref.)

The anatomy of the basal ganglia and Parkinson's disease: a review. Lee TK, et al. **Singapore Med J** 1995 Feb; 36(1):74–6 (14 ref.)

[Descending pathways of the basal ganglia] Takada M. **Kaibogaku Zasshi** 1995 Aug;70(4):289–93 (10 ref.) **(Jpn)**

METABOLISM

Anatomical localization and regulation of somatostatin gene expression in the basal ganglia and its clinical implications. Chesselet MF, et al. **Ciba Found Symp** 1995;190:51–9; discussion 59–64 (47 ref.)

Electrophysiology of dopamine D-1 receptors in the basal ganglia: old facts and new perspectives. Stefani A, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1995 Sep; 19(5):779–93 (45 ref.)

PATHOLOGY

Extrapyramidal symptoms in a BMT recipient with hyperintense basal ganglia and elevated manganese. Fredstrom S, et al. **Bone Marrow Transplant** 1995 Jun; 15(6):989–92 (19 ref.)

The basal ganglia and apraxia. Pramstaller PP, et al. **Brain** 1996 Feb;119 (Pt 1):319–40 (105 ref.)

A rare case of idiopathic hypoparathyroidism with varied neurological manifestations. Abe S, et al. **Intern Med** 1996 Feb;35(2):129–34 (37 ref.)

Grumose or foamy spheroid bodies involving astrocytes in the human brain. Arai N. **Neuropathol Appl Neurobiol** 1995 Jun;21(3):238–45 (27 ref.)

[Anarthria, progressive apraxia and extrapyramidal syndrome: an uncommon clinical form of corticobasal degeneration? A case studied by HMPAO Tc99m single-photon emission tomography] Fayet G, et al. **Rev Neurol (Paris)** 1995 Apr;151(4):247–50 (14 ref.) (Eng. Abstr.) **(Fre)**

[Corticobasal degeneration: clinical features] Ueno E. **No To Shinkei** 1996 Jun;48(6):505–12 (42 ref.) **(Jpn)**

[Neuropathology of corticobasal degeneration] Wakabayashi K, et al. **No To Shinkei** 1996 Jun;48(6):521–32 (88 ref.) **(Jpn)**

[Bilateral necrosis of the basal ganglia in methylmalonic acidemia] Vázquez López M, et al. **An Esp Pediatr** 1996 Mar;44(3):273–6 (29 ref.) **(Spa)**

PHYSIOLOGY

Basal ganglia function during normal and parkinsonian movement. PET activation studies. Brooks DJ. **Adv Neurol** 1996;69:433–41 (38 ref.)

Physiology of startle phenomena. Brown P. **Adv Neurol** 1995; 67:273–87 (79 ref.)

A model of the dynamics of prefrontal cortico-thalamo-basal ganglionic loops in verbal response selection tasks. Gullapalli V, et al. **Ann N Y Acad Sci** 1995 Dec 15; 769:375–80 (22 ref.)

Neuroprotection and selective vulnerability of neurons within the nucleus basalis magnocellularis. Wenk GL. **Behav Brain Res** 1995 Dec 14;72(1–2):17–24 (87 ref.)

Neurotransmitter organization and connectivity of the basal ganglia in vertebrates: implications for the evolution of basal ganglia. Medina L, et al. **Brain Behav Evol** 1995; 46(4–5):235–58 (214 ref.)

Building action repertoires: memory and learning functions of the basal ganglia. Graybiel AM. **Curr Opin Neurobiol** 1995 Dec;5(6):733–41 (89 ref.)

Genetics and the organization of the basal ganglia. Hitzemann R, et al. **Int Rev Neurobiol** 1995;38:43–94 (356 ref.)

Role of basal ganglia in behavioral learning. Kimura M. **Neurosci Res** 1995 Jul;22(4):353–8 (33 ref.)

The corticostriatal projection: from synaptic plasticity to dysfunctions of the basal ganglia. Calabresi P, et al. **Trends Neurosci** 1996 Jan;19(1):19–24 (58 ref.)

PHYSIOPATHOLOGY

From basal ganglia to motoneurons. Probable involvement of pathways relaying in the medulla. Delwaide PJ, et al. **Adv Neurol** 1996;69:111–6 (26 ref.)

Basal ganglia disorders. An electrophysiologic approach. Mercuri NB, et al. **Adv Neurol** 1996;69:117–21 (33 ref.)

Review article: the functions of the basal ganglia and the paradox of stereotaxic surgery in Parkinson's disease [letter; comment] Iansek R, et al. **Brain** 1995 Dec;118 (Pt 6):1613–7 (21 ref.) Comment on: Brain 1994 Aug;117 (Pt 4):877–97.

The anatomy of melancholia: does frontal-subcortical pathophysiology underpin its psychomotor and cognitive manifestations? [editorial] Austin MP, et al. **Psychol Med** 1995 Jul;25(4):665–72 (90 ref.)

[Neurobiology of parkinsonism. I. Neural substrates an neurochemistry of the basal ganglia] Ponzoni S, et al. **Arq Neuropsiquiatr** 1995 Sep;53(3–B):706–10 (13 ref.) (Eng. Abstr.) **(Por)**

RADIOGRAPHY

CT of a peripatetic intracranial foreign body. Bearcroft PW, et al. **Neuroradiology** 1995 Oct;37(7):542–4 (16 ref.)

BASAL GANGLIA DISEASES

Neoplasms of the basal ganglia. Simonetti L, et al. **Rays** 1996 Jan–Mar;21(1):70–86 (46 ref.) **(Eng, Ita)**

[Subcortical dementia: is a revision of the concept necessary?] Godefroy O, et al. **Rev Neurol (Paris)** 1995 Dec; 151(12):675–81 (91 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Symptomatic or secondary basal ganglia diseases and tardive dyskinesias. Berardelli A. **Curr Opin Neurol** 1995 Aug; 8(4):320–2 (16 ref.)

[Clinical synthesis and investigation protocol: "extrapyramidal" signs, clinical orientation] Evrard P, et al. **Arch Pediatr** 1996;3 Suppl 1:176s–178s (16 ref.) **(Fre)**

[Bilateral necrosis of the basal ganglia in methylmalonic acidemia] Vázquez López M, et al. **An Esp Pediatr** 1996 Mar;44(3):273–6 (29 ref.) **(Spa)**

EPIDEMIOLOGY

Current topics in neuroleptic-induced extrapyramidal symptoms in Japan. Inada T, et al. **Keio J Med** 1996 Jun; 45(2):95–9 (36 ref.)

ETIOLOGY

[Anarthria, progressive apraxia and extrapyramidal syndrome: an uncommon clinical form of corticobasal degeneration? A case studied by HMPAO Tc99m single-photon emission tomography] Fayet G, et al. **Rev Neurol (Paris)** 1995 Apr;151(4):247–50 (14 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Use of genetically engineered mice as models for understanding human neurodegenerative disease. Andersen JK, et al. **J Am Geriatr Soc** 1996 Jun;44(6):717–22 (34 ref.)

METABOLISM

Mitochondrial defects in basal ganglia diseases. Shoffner JM. **Curr Opin Neurol** 1995 Dec;8(6):474–9 (81 ref.)

PHYSIOPATHOLOGY

Basal ganglia disorders. An electrophysiologic approach. Mercuri NB, et al. **Adv Neurol** 1996;69:117–21 (33 ref.)

Neuroprotective effects of free radical scavengers and energy repletion in animal models of neurodegenerative disease. Schulz JB, et al. **Ann N Y Acad Sci** 1995 Sep 15;765:100–10; discussion 116–8 (56 ref.)

BASAL LAMINA see **BASEMENT MEMBRANE**

BASAL METABOLISM

see related

CALORIMETRY

PHYSIOLOGY

Biochemical principles of metabolic depression. Guppy M, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1994 Oct-Nov;109(2–3):175–89 (108 ref.)

BASAL NUCLEI see **BASAL GANGLIA**

BASAL VEIN see **CEREBRAL VEINS**

BASE COMPOSITION

Detection of mismatched bases in double stranded DNA by gel electrophoresis. Ganguly A, et al. **Electrophoresis** 1995 Oct;16(10):1830–5 (49 ref.)

BASE PAIRS see **BASE COMPOSITION**

BASE RATIO see **BASE COMPOSITION**

BASE SEQUENCE

Fluorescence photobleaching in DNA sequencing. Chu B. **Adv Biophys** 1996;32:17–29 (81 ref.)

Simple sequences and the expanding genome. Hancock JM. **Bioessays** 1996 May;18(5):421–5 (50 ref.)

CpG islands and genes. Cross SH, et al. **Curr Opin Genet Dev** 1995 Jun;5(3):309–14 (55 ref.)

Prediction of function in DNA sequence analysis. Gelfand MS. **J Comput Biol** 1995 Spring;2(1):87–115 (449 ref.)

Variation in synonymous substitution rates among mammalian genes and the correlation between synonymous and nonsynonymous divergences. Ohta T, et al. **J Mol Evol** 1995 Dec;41(6):717–20 (20 ref.)

Interpreting cDNA sequences: some insights from studies on translation. Kozak M. **Mamm Genome** 1996 Aug; 7(8):563–74 (258 ref.)

Pressing ahead with human genome sequencing. Gibbs RA. **Nat Genet** 1995 Oct;11(2):121–5 (35 ref.)

[Nucleotide sequence substitutions of hepatitis C virus] Chayama K. **Nippon Rinsho** 1995 Sep;53 Suppl:657–61 (14 ref.) **(Jpn)**

[Genotyping of hepatitis C virus by polymerase chain reaction with a mixed primer set derived from nucleotide sequences of NS5 region] Chayama K. **Nippon Rinsho** 1995 Sep;53 Suppl:321–5 (14 ref.) **(Jpn)**

[Direct sequencing for PCR products] Daikoku M, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:305–9 (8 ref.) **(Jpn)**

[PCR-SSCP.direct sequencing] Kagimoto S. **Nippon Rinsho** 1995 Oct;53 Suppl:310–5 (5 ref.) **(Jpn)**

BASE SEQUENCE HOMOLOGY see **SEQUENCE HOMOLOGY, NUCLEIC ACID**

BASEDOW'S DISEASE see **GRAVES' DISEASE**

BASEMENT LAMINA see **BASEMENT MEMBRANE**

BASEMENT MEMBRANE

CHEMISTRY

Molecular complexity of the cutaneous basement membrane zone. Revelations from the paradigms of epidermolysis bullosa. Christiano AM, et al. **Exp Dermatol** 1996 Feb; 5(1):1–11 (97 ref.)

Laminins: a family of diverse multifunctional molecules of basement membranes. Aumailley M, et al. **J Invest Dermatol** 1996 Feb;106(2):209–214 (67 ref.)

CYTOLOGY

[Morphology of basement membrane and associated matrix proteins in normal and pathological tissues] Nerlich A. **Veroff Pathol** 1995;145:1–139 (336 ref.) (Eng. Abstr.) **(Ger)**

EMBRYOLOGY

Role of laminin-nidogen complexes in basement membrane formation during embryonic development. Dziadek M. **Experientia** 1995 Sep 29;51(9–10):901–13 (136 ref.)

IMMUNOLOGY

Identification of the alpha 3 chain of type IV collagen as the common autoantigen in antibasement membrane disease and Goodpasture syndrome. Kalluri R, et al. **J Am Soc Nephrol** 1995 Oct;6(4):1178–85 (64 ref.)

PATHOLOGY

[Morphology of basement membrane and associated matrix proteins in normal and pathological tissues] Nerlich A. **Veroff Pathol** 1995;145:1–139 (336 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

The basement membrane at the neuromuscular junction: a synaptic mediatrix. Carbonetto S, et al.

BASEMENT MEMBRANE

Curr Opin Neurobiol 1995 Oct;5(5):596–605 (64 ref.)
Structure and function of basement membranes. Engvall E. **Int J Dev Biol** 1995 Oct;39(5):781–7 (71 ref.)

BASIC FIBROBLAST GROWTH FACTOR see **FIBROBLAST GROWTH FACTOR, BASIC**

BASIC LIFE SUPPORT see **CARDIOPULMONARY RESUSCITATION**

BASIC PANCREATIC TRYPSIN INHIBITOR see **APROTININ**

BASIDIOMYCETES

ENZYMOLOGY

Lignocellulose degradation by Phanerochaete chrysosporium: gene families and gene expression for a complex process. Broda P, et al. **Mol Microbiol** 1996 Mar; 19(5):923–32 (78 ref.)

METABOLISM

Mechanisms of degradation by white rot fungi. Aust SD. **Environ Health Perspect** 1995 Jun;103 Suppl 5:59–61 (19 ref.)

BASILAR ARTERY

[Surgical treatment of aneurysms at basilar artery and posterior cerebral artery associated with moyamoya disease: a case report] Kawaguti T, et al. **No Shinkei Geka** 1995 Sep;23(9):807–11 (15 ref.) (Eng. Abstr.) **(Jpn)**

ABNORMALITIES

Anatomy of segmental duplication in the human basilar artery. Possible site of aneurysm formation. De Caro R, et al. **Clin Neuropathol** 1995 Nov–Dec;14(6):303–9 (35 ref.)

SURGERY

[BA top aneurysm] Nagata I, et al. **No Shinkei Geka** 1996 Jun;24(6):517–22 (12 ref.) **(Jpn)**

BASILAR ARTERY INSUFFICIENCY see **VERTEBROBASILAR INSUFFICIENCY**

BASILAR BONE see **OCCIPITAL BONE**

BASILAR IMPRESSION see **PLATYBASIA**

BASKETBALL

INJURIES

Knee injury patterns among men and women in collegiate basketball and soccer. NCAA data and review of literature. Arendt E, et al. **Am J Sports Med** 1995 Nov–Dec; 23(6):694–701 (34 ref.)
Acute intracranial epidural haematoma in a basketball player: a case report. Datti R, et al. **Br J Sports Med** 1995 Jun; 29(2):95–6 (9 ref.)
Noncontact knee dislocation in a female basketball player: a case report. Putukian M, et al. **Clin J Sport Med** 1995 Oct;5(4):258–61 (15 ref.)

BASOPHILS

CYTOLOGY

Cytokines involved in growth and differentiation of human basophils and mast cells. Valent P. **Exp Dermatol** 1995 Aug; 4(4 Pt 2):255–9 (40 ref.)

DRUG EFFECTS

Cytokines in the regulation of basophil effector functions. Cieslewicz G, et al. **Allergy Asthma Proc** 1996 Jan–Feb; 17(1):13–6 (31 ref.)
Relationship of histamine-releasing factors and histamine-releasing inhibitory factors to chemokine group of cytokine. Kuna P, et al. **Allergy Asthma Proc** 1996 Jan–Feb;17(1):5–11 (38 ref.)
Mast cells and basophils in adverse reactions to drugs used during general anesthesia. Stellato C, et al. **Chem Immunol** 1995;62:108–31 (94 ref.)

IMMUNOLOGY

The role of mast cells and basophils in immunoregulation. Nolte H. **Allergy Asthma Proc** 1996 Jan–Feb;17(1):17–21 (13 ref.)
Chemokines and the allergic response. Kaplan AP, et al. **Exp Dermatol** 1995 Aug;4(4 Pt 2):260–5 (36 ref.)

METABOLISM

Basophil histamine release in allergic and non-allergic patient populations. Applications of a novel washed blood histamine release assay. Nielsen BW. **Dan Med Bull** 1995 Nov;42(5):455–72 (305 ref.)

PHYSIOLOGY

The role of the basophil in allergic inflammation. Schroeder JT, et al. **Allergy** 1995 Jun;50(6):463–72 (113 ref.)
Protein tyrosine phosphorylation as a mechanism of signalling in mast cells and basophils. Hamawy MM, et al. **Cell Signal** 1995 Aug;7(6):535–44 (90 ref.)
Role of basophils and mast cells in acute and late reactions in the skin. Charlesworth EN. **Chem Immunol** 1995; 62:84–107 (73 ref.)
Role of mast cells and basophils in rhinitis. Peebles RS Jr, et al. **Chem Immunol** 1995;62:60–83 (113 ref.)
Role of mast cells and basophils in asthma. Redington AE, et al. **Chem Immunol** 1995;62:22–59 (293 ref.)
Role of mast cells and basophils in gastrointestinal inflammation. Wershil BK. **Chem Immunol** 1995;62:187–203 (83 ref.)
Role of mast cells, basophils and their mediators in adverse reactions to general anesthetics and radiocontrast media. Genovese A, et al. **Int Arch Allergy Immunol** 1996 May; 110(1):13–22 (102 ref.)

BASOPHILS, TISSUE see **MAST CELLS**

BATHS

Modulatory effects of selenium and strontium salts on keratinocyte-derived inflammatory cytokines. Celerier P, et al. **Arch Dermatol Res** 1995;287(7):680–2 (11 ref.)
[Treatment of chronic congestive heart failure to improve their quality of life—clinical study of thermal vasodilation therapy] Tei C, et al. **Nippon Naika Gakkai Zasshi** 1995 Sep 10;84(9):1475–82 (35 ref.) **(Jpn)**

BATRACHOTOXINS

PHYSIOLOGY

Alkaloids from frog skins: selective probes for ion channels and nicotinic receptors. Daly JW. **Braz J Med Biol Res** 1995 Oct;28(10):1033–42 (28 ref.)

BATS see **CHIROPTERA**

BATTEN-SPIELMEYER-VOGT DISEASE see **NEURONAL CEROID-LIPOFUSCINOSIS**

BATTERED WOMEN

see related
SPOUSE ABUSE

Violence in intimate relationships and the practicing internist: new "disease" or new agenda? [comment] [see comments] Alpert EJ. **Ann Intern Med** 1995 Nov 15;123(10):774–81 (33 ref.) Comment on: Ann Intern Med 1995 Nov 15;123(10):737–46. Comment on: Ann Intern Med 1995 Nov 15;123(10):782–94. Comment on: Ann Intern Med 1995 Nov 15;123(10):800–2. Comment on: Ann Intern Med 1995 Nov 15;123(10):804–5. Comment in: Ann Intern Med 1996 Sep 1;125(5):426; discussion 426–7.
Addressing battering during pregnancy: reducing low birth weight and ongoing abuse. Campbell JC. **Semin Perinatol** 1995 Aug;19(4):301–6 (37 ref.)
[Violence towards pregnant women] Rasmussen KL, et al. **Ugeskr Laeger** 1996 Apr 22;158(17):2373–6 (35 ref.) (Eng. Abstr.) **(Dan)**

LEGISLATION & JURISPRUDENCE

The risk of domestic violence and women with HIV infection: implications for partner notification, public policy, and the law. Rothenberg KH, et al. **Am J Public Health** 1995 Nov;85(11):1569–76 (98 ref.)
Domestic violence: legal issues for health care practitioners and institutions. Hyman A. **J Am Med Womens Assoc** 1996 May–Jul;51(3):101–5 (27 ref.)
Battered woman syndrome: a conceptual analysis of its status vis-à-vis DSM IV mental disorders. Roth DL, et al. **Med Law** 1995;14(7–8):641–58 (39 ref.)

PSYCHOLOGY

Depression in battered women. Campbell J, et al. **J Am Med Womens Assoc** 1996 May–Jul;51(3):106–10 (56 ref.)
Battered woman syndrome: a conceptual analysis of its status vis-à-vis DSM IV mental disorders. Roth DL, et al. **Med Law** 1995;14(7–8):641–58 (39 ref.)
Asymmetrical role-taking: comparing battered and nonbattered women. Forte JA, et al. **Soc Work** 1996 Jan; 41(1):59–73 (56 ref.)

STATISTICS & NUMERICAL DATA

Prevalence of violence against pregnant women. Gazmararian JA, et al. **JAMA** 1996 Jun 26;275(24):1915–20 (38 ref.)

BATTEY BACILLUS see **MYCOBACTERIUM AVIUM COMPLEX**

BAYES THEOREM

The backpropagation neural network—a Bayesian classifier. Introduction and applicability to pharmacokinetics. Erb RJ. **Clin Pharmacokinet** 1995 Aug;29(2):69–79 (50 ref.)
Adaptive control of drug dosage regimens using maximum a posteriori probability Bayesian fitting. Proost JH. **Int J Clin Pharmacol Ther** 1995 Oct;33(10):531–6 (43 ref.)
Methods for combining experts' probability assessments. Jacobs RA. **Neural Comput** 1995 Sep;7(5):867–88 (51 ref.)
Clinical applications of Bayesian belief networks in pathology. Hamilton PW, et al. **Pathologica** 1995 Jun; 87(3):237–45 (11 ref.)
Estimating the probability of occurrence of tumor for a rare cancer with zero occurrence in a sample. Basu AP, et al. **Regul Toxicol Pharmacol** 1996 Apr;23(2):139–44 (13 ref.)
[Clinical application of statistics] Morita S. **Masui** 1995;44 Suppl:S71–7 (0 ref.) **(Jpn)**

BAYESIAN ANALYSIS see **BAYES THEOREM**

BAYESIAN FORECAST see **BAYES THEOREM**

BAYESIAN METHOD see **BAYES THEOREM**

BAYESIAN PREDICTION see **BAYES THEOREM**

BCG see **MYCOBACTERIUM BOVIS**

BCG VACCINE

New vaccines against tuberculosis. Silva CL. **Braz J Med Biol Res** 1995 Aug;28(8):843–51 (33 ref.)
Vaccination against tuberculosis. Lowrie DB, et al. **Int Arch Allergy Immunol** 1995 Dec;108(4):309–12 (25 ref.)
Variation in protection by BCG: implications of and for heterologous immunity [see comments] Fine PE. **Lancet** 1995 Nov 18;346(8986):1339–45 (73 ref.) Comment in: Lancet 1996 Feb 3;347(8997):333–4. Comment in: Lancet 1996 Feb 3;347(8997):334.
Use of BCG in high prevalence areas for HIV. Felten MK, et al. **Trop Med Parasitol** 1995 Jun;46(2):69–71 (30 ref.)

ADMINISTRATION & DOSAGE

BCG against tuberculosis: 1996. Lenner R. **Conn Med** 1996 Jun;60(6):329–34 (67 ref.)
BCG immunization: review of past experience, current use, and future prospects. Brewer TF, et al. **Curr Clin Top Infect Dis** 1995;15:253–70 (94 ref.)
BCG vaccination against tuberculosis: past disappointments and future hopes. Roche PW, et al. **Trends Microbiol** 1995 Oct;3(10):397–401 (34 ref.)

GENETICS

BCG as a vector for the construction of multivalent recombinant vaccines. Gicquel B. **Biologicals** 1995 Jun; 23(2):113–8 (34 ref.)

IMMUNOLOGY

BCG vaccination in the control of tuberculosis. Huebner RE. **Curr Top Microbiol Immunol** 1996;215:263–82 (103 ref.)
Animal models of protective immunity in tuberculosis to evaluate candidate vaccines. Griffin JF, et al. **Trends Microbiol** 1995 Nov;3(11):418–24 (50 ref.)
[Variations in the degree of protection conferred by BCG: role and implications for heterologous immunity] Moren A. **Rev Epidemiol Sante Publique** 1996 Jun;44(3):290–2 (4 ref.) **(Fre)**

THERAPEUTIC USE

Intravesical chemotherapy and immunotherapy: how do we assess their effectiveness and what are their limitations and uses? Lamm DL, et al. **Int J Urol** 1995 Jun;2 Suppl 2:23–35 (38 ref.)
BCG immunotherapy for transitional-cell carcinoma in situ of the bladder. Lamm DL. **Oncology (Huntingt)** 1995 Oct; 9(10):947–52, 955, discussion 955–65 (51 ref.)
[Immunotherapy of colorectal cancers] Bécouarn Y, et al. **Gastroenterol Clin Biol** 1996 Feb;20(1):20–32 (106 ref.) **(Fre)**
[Place of endovesical "BCG Therapy" in superficial tumors of the bladder] Zerbib M. **J Urol (Paris)** 1995;101(2):59–63 (30 ref.) (Eng. Abstr.) **(Fre)**
[Immunization against tuberculosis: new vaccination strategies or is there an alternative to BCG?] Kaufman SH. **Immun Infekt** 1995 Aug;23(4):119–24 (24 ref.) (Eng. Abstr.) **(Ger)**

BCNU see **CARMUSTINE**

BCR-ABL FUSION PROTEINS see **FUSION PROTEINS, BCR-ABL**

BEANS see **LEGUMES**

BEARS

METABOLISM

Environmental pollutants in marine mammals from the Norwegian coast and Arctic. Skaare JU. **Sci Total Environ** 1996 Jul 16;186(1–2):25–7 (12 ref.)

BEAUTY

Beauty and the beast—a medical essay. Lawrence G. **Indian J Cancer** 1995 Dec;32(4):189–99 (27 ref.)

BEAVERS see **RODENTIA**

BECHTEREW'S DISEASE see **SPONDYLITIS, ANKYLOSING**

BECKER MUSCULAR DYSTROPHY see **MUSCULAR DYSTROPHY**

BECKWITH-WIEDEMANN SYNDROME

GENETICS

Genomic imprinting and cancer. Brenton JD, et al. **Cancer Surv** 1995;25:161–71 (68 ref.)

BECLOMETHASONE

ADMINISTRATION & DOSAGE

The delivery of aerosolized steroids from MDIs with nozzle extensions: quantitative laboratory evaluation of a method to improve aerosol delivery to intubated patients. Hess D, et al. **Intensive Care Med** 1995 Nov;21(11):945–51 (36 ref.)

[Steroid inhalation therapy of asthma] Hozawa S. **Nippon Naika Gakkai Zasshi** 1996 Feb 10;85(2):205–9 (5 ref.) **(Jpn)**

[Steroid inhalation therapy of bronchial asthma] Makino S. **Nippon Naika Gakkai Zasshi** 1995 Dec 10;84(12):2085–90 (9 ref.) **(Jpn)**

THERAPEUTIC USE

Effectiveness and safety of beclomethasone dipropionate, an intranasal corticosteroid, in the treatment of patients with allergic rhinitis. Edwards TB. **Clin Ther** 1995 Nov–Dec; 17(6):1032–41 (31 ref.)

TOXICITY

Review of the toxicology of beclomethasone dipropionate. Libretto SE. **Arch Toxicol** 1995;69(8):509–25 (68 ref.)

BECLOMETHASONE DIPROPIONATE see **BECLOMETHASONE**

BED REST

ADVERSE EFFECTS

Bed rest and high-risk pregnancy. Differentiating the effects of diagnosis, setting, and treatment. Maloni JA. **Nurs Clin North Am** 1996 Jun;31(2):313–25 (35 ref.)

BEDDING AND LINENS

From efficacy to effectiveness: insecticide-treated bednets in Africa. Lengeler C, et al. **Bull World Health Organ** 1996; 74(3):325–32 (40 ref.)

What can we infer from findings in subgroups? [editorial; comment] Hatch M. **Epidemiology** 1995 Sep;6(5):473–5 (4 ref.) Comment on: Epidemiology 1995 Sep;6(5):485–9.

ECONOMICS

Economic aspects of the use of impregnated mosquito nets for malaria control. Brinkmann U, et al. **Bull World Health Organ** 1995;73(5):651–8 (23 ref.)

BEDS

ADVERSE EFFECTS

[Fatal burns from an electric mattress] Sánchez-Hanke M, et al. **An Esp Pediatr** 1996 Jun;44(6):591–2 (10 ref.) **(Spa)**

BEDSIDE COMPUTING see **POINT-OF-CARE SYSTEMS**

BEDSIDE TESTING see **POINT-OF-CARE SYSTEMS**

BEDSORE see **DECUBITUS ULCER**

BEE VENOMS

ADVERSE EFFECTS

Allergy to bee and wasp venom. Gelder C, et al. **Br J Hosp Med** 1996 Mar 20–Apr 2;55(6):349–52 (30 ref.)

THERAPEUTIC USE

Venom immunotherapy: tolerance to a 3-day protocol of rush-immunotherapy. Díez Gómez ML, et al. **Allergol Immunopathol (Madr)** 1995 Nov–Dec;23(6):277–84 (40 ref.)

BEER

Beer potomania: two cases and review of the literature. Fenves AZ, et al. **Clin Nephrol** 1996 Jan;45(1):61–4 (14 ref.)

BEES

see related
HONEY
PROPOLIS

Venom immunotherapy: tolerance to a 3-day protocol of rush-immunotherapy. Díez Gómez ML, et al. **Allergol Immunopathol (Madr)** 1995 Nov–Dec;23(6):277–84 (40 ref.)

What physicians should know about Africanized honeybees. Sherman RA. **West J Med** 1995 Dec;163(6):541–6 (75 ref.)

CLASSIFICATION

Significance of Africanized bees for public health. A review. Schumacher MJ, et al. **Arch Intern Med** 1995 Oct 23; 155(19):2038–43 (49 ref.)

PHYSIOLOGY

Biochemistry of insect learning: lessons from bees and flies. Meller VH, et al. **Insect Biochem Mol Biol** 1996 Apr; 26(4):327–35 (81 ref.)

BEET YELLOWS VIRUSES see **CLOSTEROVIRUS**

BEETLES

Site-specific integrated pest management for high value crops: sample units for map generation using the Colorado potato beetle (Coleoptera: Chrysomelidae) as a model system. Weisz R, et al. **J Econ Entomol** 1995 Oct; 88(5):1069–80 (36 ref.)

Ingestion of a blister beetle (Mecoidae family). Mallari RQ, et al. **Pediatrics** 1996 Sep;98(3 Pt 1):458–9 (11 ref.)

GENETICS

Cosmic influences on the expression of a specific gene in the Colorado potato beetle: the diapause protein 1 gene. de Kort CA. **Arch Insect Biochem Physiol** 1996; 32(3–4):567–73 (15 ref.)

BEHAVIOR

see related
GENETICS, BEHAVIORAL

Behavioral factors in the management of back pain. Gillette RD. **Am Fam Physician** 1996 Mar;53(4):1313–8 (29 ref.)

The circadian clock: from molecules to behaviour. Florez JC, et al. **Ann Med** 1995 Aug;27(4):481–90 (84 ref.)

Mapping genes for psychiatric disorders and behavioral traits. McInnes LA, et al. **Curr Opin Genet Dev** 1995 Jun; 5(3):376–81 (41 ref.)

Higher-order behavior classes: contingencies, beliefs, and verbal behavior [comment] Catania AC. **J Behav Ther Exp Psychiatry** 1995 Sep;26(3):191–200 (60 ref.) Comment on: J Behav Ther Exp Psychiatry 1995 Sep;26(3):179–90.

On the battle between behavior and cognition: lessons from physicists and pragmatists. Corrigan PW. **J Behav Ther Exp Psychiatry** 1995 Sep;26(3):209–14 (44 ref.)

Neurobehavioral outcome of closed head injury: implications for clinical trials. Levin HS. **J Neurotrauma** 1995 Aug; 12(4):601–10 (60 ref.)

Risk communication: a tool for behavior change. McCallum DB. **NIDA Res Monogr** 1995;155:65–89 (27 ref.)

DRUG EFFECTS

Risk assessment strategies for neuroprotective agents. Slikker W Jr, et al. **Ann N Y Acad Sci** 1995 Sep 15;765:198–208; discussion 209 (18 ref.)

Markers of neurotoxicity: from behavior to autoantibodies against brain proteins. Evans HL. **Clin Chem** 1995 Dec; 41(12 Pt 2):1874–81 (116 ref.)

The behavioral toxicity of reversible inhibitors of monoamine oxidase A: laboratory and clinical investigations. Fairweather DB, et al. **J Clin Psychopharmacol** 1995 Aug; 15(4 Suppl 2):68S–75S (43 ref.)

Neurobehavioral assessment in toxic injury evaluations. Lees-Haley PR. **Toxicol Lett** 1995 Dec;82–83:197–202 (58 ref.)

Neurobehavioural test batteries: current status, critical evaluation and new directions. Williamson AM. **Toxicol Lett** 1995 Dec;82–83:203–9 (34 ref.)

PHYSIOLOGY

Estrogen modulation of oxytocin and its relation to behavior. McCarthy MM. **Adv Exp Med Biol** 1995;395:235–45 (67 ref.)

Androgens, brain, and behavior. Rubinow DR, et al. **Am J Psychiatry** 1996 Aug;153(8):974–84 (179 ref.)

Anatomic and behavioral aspects of frontal-subcortical circuits. Cummings JL. **Ann N Y Acad Sci** 1995 Dec 15; 769:1–13 (69 ref.)

Physiological release of excitatory amino acids. Fillenz M. **Behav Brain Res** 1995 Nov;71(1-2):51–67 (159 ref.)

Behavioral regulation of gonadotropin-releasing hormone. Rissman EF. **Biol Reprod** 1996 Feb;54(2):413–9 (89 ref.)

Interactions among neural networks for behavior. Dickinson PS. **Curr Opin Neurobiol** 1995 Dec;5(6):792–8 (48 ref.)

Building action repertoires: memory and learning functions of the basal ganglia. Graybiel AM. **Curr Opin Neurobiol** 1995 Dec;5(6):733–41 (89 ref.)

Intrinsic and extrinsic neuromodulation of motor circuits. Katz PS. **Curr Opin Neurobiol** 1995 Dec;5(6):799–808 (83 ref.)

Human EEG, behavioral stillness and biofeedback. Mulholland T. **Int J Psychophysiol** 1995 Apr;19(3):263–79 (107 ref.)

Internal regulation and the evolution of normal growth as the basis for prevention of obesity in children. Satter EM. **J Am Diet Assoc** 1996 Sep;96(9):860–4 (35 ref.)

Electrical stimulation of neural tissue to evoke behavioral responses. Tehovnik EJ. **J Neurosci Methods** 1996 Mar; 65(1):1–17 (144 ref.)

Set as a physiological determinant of behavior. Kostandov EA. **Neurosci Behav Physiol** 1996 Jan–Feb;26(1):80–7 (20 ref.)

Food reward: brain substrates of wanting and liking. Berridge KC. **Neurosci Biobehav Rev** 1996;20(1):1–25 (162 ref.)

Role of basal ganglia in behavioral learning. Kimura M. **Neurosci Res** 1995 Jul;22(4):353–8 (33 ref.)

Brain cooling across wake-sleep behavioral states in homeothermic species: an analysis of the underlying physiological mechanisms. Parmeggiani PL. **Rev Neurosci** 1995 Oct–Dec;6(4):353–63 (36 ref.)

Behavioral consequences of lightning and electrical injury. Primeau M, et al. **Semin Neurol** 1995 Sep;15(3):279–85 (31 ref.)

[Control mechanisms of locomotor movements from a viewpoint of behavioral control] Mori S. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1995 Jun; 15(3):281–7 (22 ref.) (Eng. Abstr.) **(Jpn)**

[Behavioral activity in an uncertain environment (the methodological characteristics of an experimental study)] Saltykov AB, et al. **Usp Fiziol Nauk** 1996 Jan–Mar; 27(1):100–8 (51 ref.) (Eng. Abstr.) **(Rus)**

BEHAVIOR, ADAPTIVE see **ADAPTATION, PSYCHOLOGICAL**

BEHAVIOR, ADDICTIVE

see related
SUBSTANCE USE DISORDERS

[Pathologic gambling] Nešpor K. **Cas Lek Cesk** 1996 Jan 31;135(3):67–70 (20 ref.) (Eng. Abstr.) **(Cze)**

PHYSIOPATHOLOGY

Reversing a history of unmet needs: approaches to care for persons with co-occurring addictive and mental disorders. Osher FC, et al. **Am J Orthopsychiatry** 1996 Jan;66(1):4–11 (40 ref.)

PSYCHOLOGY

Heterogeneity of person and place: assessing co-occurring addictive and mental disorders. Lehman AF. **Am J Orthopsychiatry** 1996 Jan;66(1):32–41 (41 ref.)

Addictive sexual behavior. Myers WA. **Am J Psychother** 1995 Fall;49(4):473–83 (27 ref.)

[The addictive behavior of servicemen under combat conditions] Litvintsev SV, et al. **Voen Med Zh** 1995 Nov; (11):39–43, 80 (29 ref.) (Eng. Abstr.) **(Rus)**

BEHAVIOR, ADOLESCENT see **ADOLESCENT BEHAVIOR**

BEHAVIOR, ANIMAL

Observations on task-related behaviour of Macaca arctoides. Linnankoski I, et al. **Folia Primatol (Basel)** 1995;65(1):34–7 (7 ref.)

Feline behavior and welfare. Landsberg G. **J Am Vet Med Assoc** 1996 Feb 15;208(4):502–5 (9 ref.)

The domestic cat: perspective on the nature and diversity of cats. Miller J. **J Am Vet Med Assoc** 1996 Feb 15; 208(4):498–502 (4 ref.)

Synthesizing animal and human behavior research via neural network learning theory. Tryon WW. **J Behav Ther Exp Psychiatry** 1995 Dec;26(4):303–12 (98 ref.)

Dimensions of stimulus complexity. Fetterman JG. **J Exp Psychol Anim Behav Process** 1996 Jan;22(1):3–18 (176 ref.)

Methods of studying behavioral plasticity in Caenorhabditis elegans. Gannon TN, et al. **Methods Cell Biol** 1995; 48:205–23 (30 ref.)

[Some theoretical aspects of behavior research in domestic animals] Puppe B. **Berl Munch Tierarztl Wochenschr** 1995 Apr;108(4):133–7 (60 ref.) (Eng. Abstr.) **(Ger)**

[Developmental trends in farm animal husbandry from an ethological point of view] Graf B. **Schweiz Arch Tierheilkd** 1995;137(9):423–31 (12 ref.) (Eng. Abstr.) **(Ger)**

BEHAVIOR, ANIMAL

DRUG EFFECTS

Risk assessment strategies for neuroprotective agents. Slikker W Jr, et al. **Ann N Y Acad Sci** 1995 Sep 15;765:198–208; discussion 209 (18 ref.)

Modulation of drug-induced sensitization processes by endogenous opioid systems. Spanagel R. **Behav Brain Res** 1995 Sep;70(1):37–49 (148 ref.)

Steroid hormone effects on neurons subserving behavior. Weeks JC, et al. **Curr Opin Neurobiol** 1995 Dec;5(6):809–15 (57 ref.)

Enhanced N-methyl-D-aspartate (NMDA)-induced activity following morphine: sensitivity to sigma and PCP ligands. Larson AA, et al. **NIDA Res Monogr** 1995;147:146–60 (20 ref.)

Effects of prenatal morphine and cocaine on postnatal behaviors and brain neurotransmitters. Vathy I. **NIDA Res Monogr** 1995;158:88–114 (118 ref.)

A review of the validity and variability of the elevated plus-maze as an animal model of anxiety. Hogg S. **Pharmacol Biochem Behav** 1996 May;54(1):21–30 (56 ref.)

Behavioural pharmacology of 'D-1-like'dopamine receptors: further subtyping, new pharmacological probes and interactions with 'D-2-like' receptors. Waddington JL, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1995 Sep; 19(5):811–31 (65 ref.)

Behavioural consequences of maternal exposure to natural cannabinoids in rats. Navarro M, et al. **Psychopharmacology (Berl)** 1995 Nov;122(1):1–14 (110 ref.)

[Anti-sense in medicine and central nervous system disorders] Cohen H, et al. **Harefuah** 1996 Apr 1;130(7):500–2 (14 ref.) **(Heb)**

PHYSIOLOGY

The role of CRF in behavioral aspects of stress. Heinrichs SC, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:92–104 (63 ref.)

Regulation of pigeon crop milk secretion and parental behaviors by prolactin. Horseman ND, et al. **Annu Rev Nutr** 1995;15:213–38 (130 ref.)

Physiological release of excitatory amino acids. Fillenz M. **Behav Brain Res** 1995 Nov;71(1–2):51–67 (159 ref.)

The problem of animal consciousness in relation to neuropsychology. Weiskrantz L. **Behav Brain Res** 1995 Nov;71(1–2):171–5 (17 ref.)

Brain microdialysis and its application for the study of animal behaviour. Westerink BH. **Behav Brain Res** 1995 Oct; 70(2):103–24 (153 ref.)

Steroid control of higher brain function and behavior. Mortaud S, et al. **Behav Genet** 1996 Jul;26(4):367–72 (22 ref.)

Application of antisense DNA method for the study of molecular bases of brain function and behavior. Ogawa S, et al. **Behav Genet** 1996 May;26(3):279–92 (85 ref.)

The economy of winter: phenotypic plasticity in behavior and brain structure. Jacobs LF. **Biol Bull** 1996 Aug; 191(1):92–100 (61 ref.)

Neuroanatomical and neurochemical mechanisms underlying amygdaloid control of defensive rage behavior in the cat. Shaikh MB, et al. **Braz J Med Biol Res** 1994 Dec; 27(12):2759–79 (43 ref.)

Actions of sex steroids on behaviours beyond reproductive reflexes. Priest CA, et al. **Ciba Found Symp** 1995;191:74–84; discussion 84–9 (69 ref.)

Interactions among neural networks for behavior. Dickinson PS. **Curr Opin Neurobiol** 1995 Dec;5(6):792–8 (48 ref.)

Steroid hormone effects on neurons subserving behavior. Weeks JC, et al. **Curr Opin Neurobiol** 1995 Dec;5(6):809–15 (57 ref.)

"Adaptive" changes in the behaviour of parasitized animals: a critical review. Poulin R. **Int J Parasitol** 1995 Dec; 25(12):1371–83 (102 ref.)

Electrical stimulation of neural tissue to evoke behavioral responses. Tehovnik EJ. **J Neurosci Methods** 1996 Mar; 65(1):1–17 (144 ref.)

Repeated acquisition of response sequences: the analysis of behavior in transition. Cohn J, et al. **Neurosci Biobehav Rev** 1995 Fall;19(3):397–406 (46 ref.)

Effects of oral experience on rewarding properties of oral stimulation. Swithers SE. **Neurosci Biobehav Rev** 1996; 20(1):27–32 (22 ref.)

Gustatory function in the parabrachial nuclei: implications from lesion studies in rats. Spector AC. **Rev Neurosci** 1995 Apr-Jun;6(2):143–75 (163 ref.)

Ensemble activity and behavior: what's the code? Deadwyler SA, et al. **Science** 1995 Nov 24;270(5240):1316–8 (24 ref.)

[Neuroendocrine mechanisms in the shaping of adaptive behavior] Shaliapina VG, et al. **Fiziol Zh Im I M Sechenova** 1995 Aug;81(8):94–100 (25 ref.) (Eng. Abstr.) **(Rus)**

[Neurophysiological mechanisms of the cortical-subcortical interrelationships in the organization of behavior] Shuvaev VT, et al. **Fiziol Zh Im I M Sechenova** 1995 Aug; 81(8):110–20 (29 ref.) (Eng. Abstr.) **(Rus)**

[The temporal factors in behavioral response conditioning] Zieliński K. **Fiziol Zh Im I M Sechenova** 1995 Nov; 81(11):30–42 (53 ref.) **(Rus)**

[Behavioral activity in an uncertain environment (the methodological characteristics of an experimental study)] Saltykov AB, et al. **Usp Fiziol Nauk** 1996 Jan-Mar; 27(1):100–8 (51 ref.) (Eng. Abstr.) **(Rus)**

[The complex interaction of the hypothalamic suprachiasmatic nuclei with the epiphysis and corpus striatum--a functionally unified system for regulating circadian behavioral fluctuations] Arushanian EB. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1996 Jan-Feb; 46(1):15–22 (44 ref.) (Eng. Abstr.) **(Rus)**

[Motivation and reinforcement in the systemic mechanisms of behavior: the dynamic engrams of reinforcement] Sudakov KV. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1995 Jul-Aug;45(4):627–37 (40 ref.) (Eng. Abstr.) **(Rus)**

BEHAVIOR, ASSAULTIVE see **VIOLENCE**

BEHAVIOR, CHILD see **CHILD BEHAVIOR**

BEHAVIOR, COMPULSIVE see **COMPULSIVE BEHAVIOR**

BEHAVIOR, DANGEROUS see **DANGEROUS BEHAVIOR**

BEHAVIOR MODIFICATION see **BEHAVIOR THERAPY**

BEHAVIOR THERAPY

Research update on the psychosocial treatment of schizophrenia. Penn DL, et al. **Am J Psychiatry** 1996 May; 153(5):607–17 (89 ref.)

An integrated behavioral medicine approach to improving care of patients with diabetes mellitus. Jenkins CD. **Behav Med** 1995 Summer;21(2):53–65; discussion 66–8 (19 ref.)

Treatment methodology. Guiding of behaviour through redirection in brain injury rehabilitation. Yuen HK, et al. **Brain Inj** 1996 Mar;10(3):229–38 (15 ref.)

Efficacy of behavioral treatment for oropharyngeal dysphagia. Langmore SE. **Dysphagia** 1995 Fall; 10(4):259–62 (43 ref.)

New perspectives on dietary and behavioural treatments for obesity. Fairburn CG, et al. **Int J Obes Relat Metab Disord** 1996 Feb;20 Suppl 1:S9–13 (63 ref.)

Brief report: the case for social and behavioral intervention research. Schreibman L. **J Autism Dev Disord** 1996 Apr; 26(2):247–50 (8 ref.)

Matching verbal repertoires: understanding the contingencies of practice in order to functionally communicate with clinicians. Montgomery RW, et al. **J Behav Ther Exp Psychiatry** 1995 Jun;26(2):99–105 (29 ref.)

Behavior therapy: endogenous serotonin therapy? Baer L. **J Clin Psychiatry** 1996;57 Suppl 6:33–5 (12 ref.)

Integration of behavioral and relaxation approaches into the treatment of chronic pain and insomnia. NIH Technology Assessment Panel on Integration of Behavioral and Relaxation Approaches into the Treatment of Chronic Pain and Insomnia. **JAMA** 1996 Jul 24–31;276(4):313–8 (0 ref.)

Developing effective behavior change interventions: some lessons learned from behavioral research. Fishbein M. **NIDA Res Monogr** 1995;155:246–61 (27 ref.)

Behavioral treatment of pediatric headache. McGrath PJ, et al. **Pediatr Ann** 1995 Sep;24(9):486–91 (22 ref.)

Preventing relapse in weight control: a discussion of cognitive and behavioral strategies. Turner LW, et al. **Psychol Rep** 1995 Oct;77(2):651–6 (25 ref.)

Physical restraint procedures for managing challenging behaviours presented by mentally retarded adults and children. Harris J. **Res Dev Disabil** 1996 Mar-Apr; 17(2):99–134 (52 ref.)

Behavioural treatment for enuresis. Houts AC. **Scand J Urol Nephrol Suppl** 1995;173:83–6; discussion 87 (14 ref.)

[Behavior therapy of obesity] Sakata T. **Nippon Naika Gakkai Zasshi** 1995 Aug 10;84(8):1284–9 (5 ref.) **(Jpn)**

[Cognitive-behavioral therapy for obesity--with special reference to binge eating disorder] Komaki G. **Nippon Rinsho** 1995 Jun;53 Suppl:468–74 (14 ref.) **(Jpn)**

[Behavioural modification for therapy of obesity] Ohno M, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:460–7 (15 ref.) **(Jpn)**

METHODS

Habits affecting dental and maxillofacial growth and development. Josell SD. **Dent Clin North Am** 1995 Oct; 39(4):851–60 (32 ref.)

Managing behavior of precooperative children. Nathan JE. **Dent Clin North Am** 1995 Oct;39(4):789–816 (39 ref.)

Personality development. Managing behavior of the cooperative preschool child. Pinkham JR. **Dent Clin North Am** 1995 Oct;39(4):771–87 (32 ref.)

Habit reversal: a review of applications and variations. Woods DW, et al. **J Behav Ther Exp Psychiatry** 1995 Jun; 26(2):123–31 (55 ref.)

Psychoneuroimmunology and innovative behavioral interventions in patients with leukemia. Caudell KA. **Oncol Nurs Forum** 1996 Apr;23(3):493–502 (60 ref.)

Behavioral treatment of depression in the context of marital discord. Beach SR, et al. **Prog Behav Modif** 1996;30:99–122 (110 ref.)

Posttraumatic stress disorder: conceptualization and treatment. Boudewyns PA. **Prog Behav Modif** 1996; 30:165–89 (150 ref.)

Psychosocial interventions for adolescent depression: issues, evidence, and future directions. Hoberman HM, et al. **Prog Behav Modif** 1996;30:25–73 (250 ref.)

Functional analysis in behavior therapy. Kohlenberg RJ, et al. **Prog Behav Modif** 1996;30:1–24 (120 ref.)

Analog baselines: a critical review of the methodology. Sturmey P. **Res Dev Disabil** 1995 Jul-Aug;16(4):269–84 (54 ref.)

Predicting treatment outcome with conditioning alarms. Moffatt ME, et al. **Scand J Urol Nephrol Suppl** 1995; 173:119–22 (12 ref.)

[Behavior therapy of obsessive compulsive disorders] Légeron P, et al. **Encephale** 1989 May-Jun;15(3):343–50 (75 ref.) (Eng. Abstr.) **(Fre)**

[Panic disorder and agoraphobia: what is effective?] Bandelow B, et al. **Fortschr Neurol Psychiatr** 1995 Nov; 63(11):451–64 (120 ref.) (Eng. Abstr.) **(Ger)**

BEHAVIOR THERAPY, COGNITIVE see **COGNITIVE THERAPY**

BEHAVIORAL MEDICINE

Behavioral medicine, clinical health psychology, and cost offset. Friedman R, et al. **Health Psychol** 1995 Nov; 14(6):509–18 (52 ref.)

BEHAVIORAL SCIENCES

Synthesis of behavioral science learnings about technology transfer. Backer TE, et al. **NIDA Res Monogr** 1995; 155:262–79 (2 ref.)

Assessing and enhancing readiness for change: implications for technology transfer. Backer TE. **NIDA Res Monogr** 1995;155:21–41 (40 ref.)

Developing effective behavior change interventions: some lessons learned from behavioral research. Fishbein M. **NIDA Res Monogr** 1995;155:246–61 (27 ref.)

Collaboration and diversity in technology transfer. Kavanagh KH. **NIDA Res Monogr** 1995;155:42–64 (81 ref.)

BEHCET'S SYNDROME

Behcet's disease: a case report. Thomas RV, et al. **J Indian Med Assoc** 1995 Apr;93(4):151–3 (25 ref.)

Behçet's disease in Lebanon: report of 100 cases. Ghayad E, et al. **J Med Liban** 1995;43(1):2–7 (23 ref.)

[Behçet's disease] Kötter I, et al. **Dtsch Med Wochenschr** 1996 Mar 22;121(12):382–8 (50 ref.) **(Ger)**

COMPLICATIONS

Sweet's syndrome associated with Behçet's disease. Lee MS, et al. **Australas J Dermatol** 1996 May;37(2):99–101 (15 ref.)

Asymptomatic pericarditis in Adamantiadis-Behçet's disease. Vaiopoulos G, et al. **Clin Exp Rheumatol** 1995 Sep-Oct; 13(5):649–51 (18 ref.)

Behçet's disease and Takayasu's disease in children. Martini A. **Curr Opin Rheumatol** 1995 Sep;7(5):449–54 (71 ref.)

[Cardiac manifestations of Behçet disease. A propos of 3 cases (letter)] Bennis A, et al. **Ann Med Interne (Paris)** 1996; 147(2):126–9 (23 ref.) **(Fre)**

[Thrombosis of the superior mesenteric artery and Behçet's syndrome] Mercié P, et al. **Rev Med Interne** 1996; 17(6):470–3 (16 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Diagnosis and ophthalmological features of Behçet's disease. Bhisitkul RB, et al. **Int Ophthalmol Clin** 1996 Winter; 36(1):127–34 (19 ref.)

[Behçet disease with primary involvement of the cerebral vessels] Proebstle TM, et al. **Dtsch Med Wochenschr** 1996 Jan 5;121(1–2):16–20 (19 ref.) (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

Behçet's disease. Chavis PS, et al. **Int Ophthalmol Clin** 1995 Spring;35(2):43–67 (117 ref.)

THERAPY

Behçet's disease and Takayasu's disease in children. Martini A. **Curr Opin Rheumatol** 1995 Sep;7(5):449–54 (71 ref.)

BELGIAN HARE see **RABBITS**

BELL'S PALSY see **FACIAL PARALYSIS**

BENCE JONES PROTEIN

URINE

Bence Jones proteinuria and myeloma kidney [editorial] Chauveau D, et al. **Nephrol Dial Transplant** 1996 Mar; 11(3):413–5 (7 ref.)

[Bence Jones protein--detection and clinical aspects] Mafune N, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:147–9 (2 ref.) **(Jpn)**

BENDS see **DECOMPRESSION SICKNESS**

BENECKEA see **VIBRIO**

BENHYDRAMIN see **DIPHENHYDRAMINE**

BENIGN INTRACRANIAL HYPERTENSION see **PSEUDOTUMOR CEREBRI**

BENIGN MONOCLONAL GAMMOPATHIES see **MONOCLONAL GAMMOPATHIES, BENIGN**

BENZALACETOPHENONE see **CHALCONE**

BENZAMIDES

ADVERSE EFFECTS

Moclobemide safety: monitoring a newly developed product in the 1990s. Hilton S, et al. **J Clin Psychopharmacol** 1995 Aug;15(4 Suppl 2):76S–83S (28 ref.)

DIAGNOSTIC USE

D2-receptor imaging with [123I]IBZM and single photon emission tomography in psychiatry: a survey of current status. Schlösser R, et al. **J Neural Transm Gen Sect** 1995; 99(1–3):173–85 (52 ref.)

PHARMACOKINETICS

Clinical pharmacokinetics of the monoamine oxidase-A inhibitor moclobemide. Mayersohn M, et al. **Clin Pharmacokinet** 1995 Nov;29(5):292–332 (132 ref.)

PHARMACOLOGY

Tachykinin NK2 receptors further characterized in the lung with nonpeptide receptor antagonists. Advenier C. **Can J Physiol Pharmacol** 1995 Jul;73(7):878–84 (73 ref.)

Stimulation of insulin release by non-sulfonylurea hypoglycemic agents: the meglitinide family. Malaisse WJ. **Horm Metab Res** 1995 Jun;27(6):263–6 (18 ref.)

Gastrointestinal prokinetic benzamides: the pharmacology underlying stimulation of motility. Briejer MR, et al. **Pharmacol Rev** 1995 Dec;47(4):631–51 (203 ref.)

THERAPEUTIC USE

Nicotinamide and other benzamide analogs as agents for overcoming hypoxic cell radiation resistance in tumours. A review. Horsman MR. **Acta Oncol** 1995;34(5):571–87 (158 ref.)

BENZAMIDINES

PHARMACOLOGY

[The ribonucleotide reductase enzyme as a target for enzyme-directed chemotherapy effects of trimidox (3,4,5-trihydroxybenzohydroxamidoxim), a new inhibitor of ribonucleotide reductases] Findenig G, et al. **Wien Klin Wochenschr** 1995;107(22):694–7 (28 ref.) (Eng. Abstr.) **(Ger)**

BENZATHINE PENICILLIN see **PENICILLIN G, BENZATHINE**

BENZENE

ANALYSIS

A population-based exposure model for benzene. MacIntosh DL, et al. **J Expo Anal Environ Epidemiol** 1995 Jul–Sep; 5(3):375–403 (73 ref.)

METABOLISM

Physiological attributes of microbial BTEX degradation in oxygen-limited environments. Olsen RH, et al. **Environ Health Perspect** 1995 Jun;103 Suppl 5:49–51 (7 ref.)

Cation-pi interactions in chemistry and biology: a new view of benzene, Phe, Tyr, and Trp. Dougherty DA. **Science** 1996 Jan 12;271(5246):163–8 (66 ref.)

BENZENE DERIVATIVES

METABOLISM

Physiological attributes of microbial BTEX degradation in oxygen-limited environments. Olsen RH, et al. **Environ Health Perspect** 1995 Jun;103 Suppl 5:49–51 (7 ref.)

BENZENE HEXACHLORIDE see **LINDANE**

BENZENESULFONATES

PHARMACOLOGY

Ebrotidine. Patel SS, et al. **Drugs** 1996 Jun;51(6):974–80; discussion 981 (41 ref.)

THERAPEUTIC USE

Ebrotidine. Patel SS, et al. **Drugs** 1996 Jun;51(6):974–80; discussion 981 (41 ref.)

BENZIDINES

see related
CARCINOGENS

ADVERSE EFFECTS

Human health perspectives on environmental exposure to benzidine: a review. Choudhary G. **Chemosphere** 1996 Jan; 32(2):267–91 (80 ref.)

BENZIMIDAZOLES

PHARMACOLOGY

Review article: the continuing development of proton pump inhibitors with particular reference to pantoprazole. Huber R, et al. **Aliment Pharmacol Ther** 1995 Aug;9(4):363–78 (59 ref.)

Similarities and differences in the properties of substituted benzimidazoles: a comparison between pantoprazole and related compounds. Kromer W. **Digestion** 1995; 56(6):443–54 (90 ref.)

THERAPEUTIC USE

Review article: the continuing development of proton pump inhibitors with particular reference to pantoprazole. Huber R, et al. **Aliment Pharmacol Ther** 1995 Aug;9(4):363–78 (59 ref.)

BENZODIAZEPINE-GABA RECEPTORS see **RECEPTORS, GABA-A**

BENZODIAZEPINE TRANQUILIZERS see **ANTI-ANXIETY AGENTS, BENZODIAZEPINE**

BENZODIAZEPINES

see related
ANTI-ANXIETY AGENTS, BENZODIAZEPINE
RECEPTORS, GABA-A

Addiction to benzodiazepines--how common? [see comments] Piper A Jr. **Arch Fam Med** 1995 Nov; 4(11):964–70 (111 ref.) Comment in: Arch Fam Med 1996 Jul–Aug;5(7):383–4. Comment in: Arch Fam Med 1996 Jul–Aug;5(7):384.

Optimal intravenous dosing strategies for sedatives and analgesics in the intensive care unit. Barr J, et al. **Crit Care Clin** 1995 Oct;11(4):827–47 (64 ref.)

Opioids and benzodiazepines. Murray MJ, et al. **Crit Care Clin** 1995 Oct;11(4):849–73 (91 ref.)

ADVERSE EFFECTS

Benzodiazepine side effects: role of pharmacokinetics and pharmacodynamics. Vgontzas AN, et al. **Pharmacology** 1995 Oct;51(4):205–23 (196 ref.)

ANTAGONISTS & INHIBITORS

The role of flumazenil in the critically ill. Park GR, et al. **Acta Anaesthesiol Scand Suppl** 1995;108:23–34 (120 ref.)

Pharmacology of flumazenil. Whitwam JG, et al. **Acta Anaesthesiol Scand Suppl** 1995;108:3–14 (97 ref.)

Involvement of endogenous benzodiazepine receptor ligands in brain disorders: therapeutic potential for benzodiazepine antagonists? Polc P. **Med Hypotheses** 1995 Jun;44(6):439–46 (51 ref.)

PHARMACOKINETICS

Pharmacokinetic-pharmacodynamic relationships for benzodiazepines. Laurijssens BE, et al. **Clin Pharmacokinet** 1996 Jan;30(1):52–76 (111 ref.)

Benzodiazepine side effects: role of pharmacokinetics and pharmacodynamics. Vgontzas AN, et al. **Pharmacology** 1995 Oct;51(4):205–23 (196 ref.)

PHARMACOLOGY

Pharmacokinetic-pharmacodynamic relationships for benzodiazepines. Laurijssens BE, et al. **Clin Pharmacokinet** 1996 Jan;30(1):52–76 (111 ref.)

Perinatal benzodiazepine modulation of GABAA receptor function: influence on adaptive responses. Kellogg CK. **NIDA Res Monogr** 1995;158:202–26 (78 ref.)

THERAPEUTIC USE

Management of delirium tremens on the head and neck service. Alvi A, et al. **Am J Otolaryngol** 1995 Jul–Aug; 16(4):224–31 (25 ref.)

Benzodiazepines for depression? A review of the literature. Birkenhäger TK, et al. **Int Clin Psychopharmacol** 1995 Sep; 10(3):181–95 (73 ref.)

Benzodiazepines for insomnia in community-dwelling elderly: a review of benefit and risk. Grad RM. **J Fam Pract** 1995 Nov;41(5):473–81 (41 ref.)

Pharmacotherapy of insomnia: practice and prospects. Dingemanse J. **Pharm World Sci** 1995 May 26;17(3):67–75 (114 ref.)

[Pharmacotherapy of anxiety disorders] Bitter I. **Orv Hetil** 1995 Nov 5;136(45):2435–9 (19 ref.) (Eng. Abstr.) **(Hun)**

[Schizophrenia combination therapy with neuroleptics and benzodiazepines] Ruzikowska A. **Psychiatr Pol** 1996 Jan–Feb;30(1):55–64 (23 ref.) (Eng. Abstr.) **(Pol)**

TOXICITY

Genetic toxicology of four commonly used benzodiazepines: a review. Giri AK, et al. **Mutat Res** 1996 Jun; 340(2–3):93–108 (100 ref.)

BENZODIONES see **BENZOQUINONES**

BENZOFURANS

ANALYSIS

Sources of PCDD/PCDF and impact on the environment. Fiedler H. **Chemosphere** 1996 Jan;32(1):55–64 (17 ref.)

Biomarkers for Great Lakes priority contaminants: halogenated aromatic hydrocarbons. Feeley MM. **Environ Health Perspect** 1995 Dec;103 Suppl 9:7–16 (106 ref.)

Reliability of the determinations of polychlorinated contaminants (biphenyls, dioxins, furans). Horwitz W, et al. **J AOAC Int** 1996 May–Jun;79(3):589–621 (55 ref.)

Validation of a methodology for modelling PCDD and PCDF intake via the foodchain. Eduljee GH, et al. **Sci Total Environ** 1996 Sep 9;187(3):211–29 (36 ref.)

POISONING

Growth abnormalities in the population exposed in utero and early postnatally to polychlorinated biphenyls and dibenzofurans. Guo YL, et al. **Environ Health Perspect** 1995 Sep;103 Suppl 6:117–22 (53 ref.)

BENZOL see **BENZENE**

BENZO(A)PYRENE

METABOLISM

Induction and repair of benzo[a]pyrene-DNA adducts in C57BL/6 and BALB/c mice: association with aging and longevity. Boerrigter ME, et al. **Mech Ageing Dev** 1995 Jul 28;82(1):31–50 (50 ref.)

3,4-BENZOPYRENE see **BENZO(A)PYRENE**

1,2-BENZOPYRONES see **COUMARINS**

BENZOQUINONES

THERAPEUTIC USE

The therapy of respiratory chain encephalomyopathy: a critical review of the past and current perspective. Walker UA, et al. **Acta Neurol Scand** 1995 Oct;92(4):273–80 (77 ref.)

1,2-BENZOQUINONES see **BENZOQUINONES**

1,4-BENZOQUINONES see **BENZOQUINONES**

BENZOTHIADIAZINE DIURETICS see **DIURETICS, THIAZIDE**

BENZOXAZOLES

THERAPEUTIC USE

Clinical experience with non-nucleoside reverse transcriptase inhibitors: L-697,661 and nevirapine. Kilby JM, et al. **Adv Exp Med Biol** 1996;394:291–8 (23 ref.)

BENZOYL PEROXIDE

THERAPEUTIC USE

Benzamycin gel for acne. **Drug Ther Bull** 1995 Aug; 33(8):62–4 (13 ref.)

TOXICITY

Benzoyl peroxide: review of experimental carcinogenesis and human safety data. Binder RL, et al. **Prog Clin Biol Res** 1995;391:245–94 (168 ref.)

BENZOYL SUPEROXIDE see **BENZOYL PEROXIDE**

BENZYLIDENEACETOPHENONE see **CHALCONE**

BENZYLPENICILLIN see **PENICILLIN G**

BER-H2 ANTIGENS see **ANTIGENS, CD30**

BEREAVEMENT

see related
GRIEF

Bereavement: a protocol for primary care. Charlton R, et al. **Br J Gen Pract** 1995 Aug;45(397):427–30 (49 ref.)

The Pinwheel Model of Bereavement. Solari-Twadell PA, et al. **Image J Nurs Sch** 1995 Winter;27(4):323–6 (21 ref.)

BEREAVEMENT CARE see **HOSPICE CARE**

BERGER'S DISEASE see **GLOMERULONEPHRITIS, IGA**

BERNARD-SOULIER SYNDROME

[Giant platelet syndrome] Jantunen E, et al. **Duodecim** 1994; 110(8):793–801 (33 ref.) **(Fin)**

BERNARD'S SYNDROME see **HORNER'S SYNDROME**

BERRIES see **FRUIT**

BERRY ANEURYSM see **CEREBRAL ANEURYSM**

BERTIELLIASIS see **CESTODE INFECTIONS**

BERYLLIOSIS

EPIDEMIOLOGY

Immunology, genetics, and epidemiology of beryllium disease. Newman LS. **Chest** 1996 Mar;109(3 Suppl):40S–43S (48 ref.)

GENETICS

Immunology, genetics, and epidemiology of beryllium disease. Newman LS. **Chest** 1996 Mar;109(3 Suppl):40S–43S (48 ref.)

IMMUNOLOGY

Immunology, genetics, and epidemiology of beryllium disease. Newman LS. **Chest** 1996 Mar;109(3 Suppl):40S–43S (48 ref.)

BERYLLIUM DISEASE see **BERYLLIOSIS**

BESNIER-BOECK DISEASE see **SARCOIDOSIS**

BESNOITIASIS see **COCCIDIOSIS**

BETA-N-ACETYLHEXOSAMINIDASE

ANALYSIS

[Hexosaminidase isoenzyme pattern in leukemia] Sasaki R. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:190–4 (13 ref.) **(Jpn)**

BLOOD

[beta-Hexosaminidase] Ishii S, et al. **Nippon Rinsho** 1995 Feb; 53 Su Pt 1:398–401 (19 ref.) **(Jpn)**

GENETICS

[Biochemical, molecular and social aspects of carrier screening for Tay-Sachs disease] Peleg L, et al. **Harefuah** 1995 Dec 1;129(11):475–80 (43 ref.) **(Heb)**

BETA-ADRENERGIC BLOCKING AGENTS see **ADRENERGIC BETA-ANTAGONISTS**

BETA-ADRENERGIC RECEPTOR AGONISTS see **ADRENERGIC BETA-AGONISTS**

BETA-ADRENERGIC RECEPTOR BLOCKADERS see **ADRENERGIC BETA-ANTAGONISTS**

BETA-ADRENERGIC RECEPTORS see **RECEPTORS, ADRENERGIC, BETA**

BETA-1 ADRENERGIC RECEPTORS see **RECEPTORS, ADRENERGIC, BETA-1**

BETA-2 ADRENERGIC RECEPTORS see **RECEPTORS, ADRENERGIC, BETA-2**

BETA-ALANINE

BIOSYNTHESIS

Uracil metabolism—UMP synthesis from orotic acid or uridine and conversion of uracil to beta-alanine: enzymes and cDNAs. Traut TW, et al. **Prog Nucleic Acid Res Mol Biol** 1996;53:1–78 (273 ref.)

BETA-ALANINE KETOGLUTARATE AMINOTRANSFERASE see **AMINOBUTYRATE AMINOTRANSFERASE**

BETA-AMYLOID PROTEIN see **AMYLOID BETA-PROTEIN**

BETA-AMYLOID PROTEIN PRECURSOR see **AMYLOID BETA-PROTEIN PRECURSOR**

BETA,BETA-DIMETHYLCYSTEINE see **PENICILLAMINE**

BETA-BLOCKERS, ADRENERGIC see **ADRENERGIC BETA-ANTAGONISTS**

BETA CELL, ARTIFICIAL see **INSULIN INFUSION SYSTEMS**

BETA-CELL TUMOR see **INSULINOMA**

BETA-ENDORPHIN

BLOOD

[beta-Endorphin] Kato Y. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:324–8 (31 ref.) **(Jpn)**

PHYSIOLOGY

[Beta-endorphin—physiologic role and menstrual cycle disorders] Męczekalski B, et al. **Ginekol Pol** 1995 Oct; 66(10):586–95 (44 ref.) (Eng. Abstr.) **(Pol)**

BETA-ENDOTHELIAL GROWTH FACTOR see **ENDOTHELIAL GROWTH FACTORS**

17 BETA-ESTRADIOL see **ESTRADIOL**

BETA-GALACTOSIDASE

DEFICIENCY

[Galactosialidosis—protective protein and related enzymes] Hirasawa M. **Nippon Rinsho** 1995 Dec;53(12):2967–72 (22 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

The 67 kDa spliced variant of beta-galactosidase serves as a reusable protective chaperone for tropoelastin. Hinek A. **Ciba Found Symp** 1995;192:185–91; discussion 191–6 (30 ref.)

BETA-GLOBIN see **GLOBIN**

BETA-GLUCOSIDASE

GENETICS

Co-suppression of beta-1,3-glucanase genes in Nicotiana tabacum. de Carvalho Niebel F, et al. **Curr Top Microbiol Immunol** 1995;197:91–103 (39 ref.)

TOXICITY

Safety evaluation of beta-glucanase derived from Trichoderma reesei: summary of toxicological data. Coenen TM, et al. **Food Chem Toxicol** 1995 Oct;33(10):859–66 (24 ref.)

BETA-HCG see **CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN**

BETA-HEPARIN see **DERMATAN SULFATE**

BETA-HEXOSAMINIDASE see **BETA-N-ACETYLHEXOSAMINIDASE**

3 BETA-HYDROXY-DELTA-5-STEROID DEHYDROGENASE see **PROGESTERONE REDUCTASE**

17 BETA-HYDROXYSTEROID DEHYDROGENASES see **17-HYDROXYSTEROID DEHYDROGENASES**

BETA-HYPOPHAMINE see **VASOPRESSINS**

BETA 2 INTEGRIN SUBUNIT see **ANTIGENS, CD18**

BETA-INTERFERON see **INTERFERON-BETA**

BETA-KETOTHIOLASE see **ACETYL COA ACYLTRANSFERASE**

BETA-LACTAM ANTIBIOTICS see **ANTIBIOTICS, LACTAM**

BETA-LACTAM RESISTANCE

Trends in antimicrobial susceptibility of bacterial pathogens of the respiratory tract. Doern GV. **Am J Med** 1995 Dec 29;99(6B):3S–7S (22 ref.)

beta-Lactamases in laboratory and clinical resistance. Livermore DM. **Clin Microbiol Rev** 1995 Oct;8(4):557–84 (283 ref.)

Novel plasmid-mediated beta-lactamases in enterobacteriaceae: emerging problems for new beta-lactam antibiotics. Thomson KS, et al. **Curr Clin Top Infect Dis** 1996;16:151–63 (46 ref.)

The beta-lactamase problem: new therapeutic options. Schito GC, et al. **J Chemother** 1995 May;7 Suppl 1:5–8 (29 ref.)

Beta-lactamases and bacterial resistance to antibiotics. Frère JM. **Mol Microbiol** 1995 May;16(3):385–95 (51 ref.)

GENETICS

Extended-spectrum and inhibitor-resistant TEM-type beta-lactamases: mutations, specificity, and three-dimensional structure. Knox JR. **Antimicrob Agents Chemother** 1995 Dec;39(12):2593–601 (93 ref.)

BETA-LACTAMASES

[Beta-lactamase and its molecular evolution] Sawai T, et al. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(13):1887–99 (34 ref.) **(Jpn)**

ANTAGONISTS & INHIBITORS

Beta-lactam/beta-lactamase inhibitor combinations: development, antibacterial activity and clinical applications. Sutherland R. **Infection** 1995 Jul-Aug; 23(4):191–200 (49 ref.)

BIOSYNTHESIS

Beta-lactamase-producing enterococci. Rice LB, et al. **Dev Biol Stand** 1995;85:107–14 (33 ref.)

[Clinical and laboratory significance of inducible beta-lactamases] Bedenić B, et al. **Lijec Vjesn** 1995 Sep-Oct;117(9–10):249–53 (41 ref.) (Eng. Abstr.) **(Scr)**

CHEMISTRY

Extended-spectrum and inhibitor-resistant TEM-type beta-lactamases: mutations, specificity, and three-dimensional structure. Knox JR. **Antimicrob Agents Chemother** 1995 Dec;39(12):2593–601 (93 ref.)

[beta-Lactamases of Branhamella catarrhalis and their phenotypic implications] Chaïbi EB, et al. **Res Microbiol** 1995 Nov-Dec;146(9):761–71 (40 ref.) (Eng. Abstr.) **(Fre)**

CLASSIFICATION

A functional classification scheme for beta-lactamases and its correlation with molecular structure. Bush K, et al. **Antimicrob Agents Chemother** 1995 Jun;39(6):1211–33 (338 ref.)

DRUG EFFECTS

Extended-spectrum plasmid-mediated beta-lactamases. Sirot D. **J Antimicrob Chemother** 1995 Jul;36 Suppl A:19–34 (129 ref.)

GENETICS

Extended-spectrum plasmid-mediated beta-lactamases. Sirot D. **J Antimicrob Chemother** 1995 Jul;36 Suppl A:19–34 (129 ref.)

METABOLISM

Novel plasmid-mediated beta-lactamases in enterobacteriaceae: emerging problems for new beta-lactam antibiotics. Thomson KS, et al. **Curr Clin Top Infect Dis** 1996;16:151–63 (46 ref.)

The beta-lactamase problem: new therapeutic options. Schito GC, et al. **J Chemother** 1995 May;7 Suppl 1:5–8 (29 ref.)

PHYSIOLOGY

beta-Lactamases in laboratory and clinical resistance. Livermore DM. **Clin Microbiol Rev** 1995 Oct;8(4):557–84 (283 ref.)

Beta-lactamases and bacterial resistance to antibiotics. Frère JM. **Mol Microbiol** 1995 May;16(3):385–95 (51 ref.)

BETA-LACTAMS, MONOCYCLIC see **MONOBACTAMS**

BETA-LIPOPROTEINS see **LIPOPROTEINS, LDL**

BETA-LIPOTROPIN see **LIPOTROPIN**

BETA-LIPOTROPIN C FRAGMENT see **BETA-ENDORPHIN**

BETA 2-MICROGLOBULIN

ANALYSIS

[beta 2-Microglobulin] Itoh Y. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:230–2 (7 ref.) **(Jpn)**

IMMUNOLOGY

Conformational changes induced in the MHC class I molecule by peptide and beta 2-microglobulin. Solheim JC, et al. **Immunol Res** 1995;14(3):200–17 (57 ref.)

ISOLATION & PURIFICATION

Development of a PMMA membrane which can remove beta 2-microglobulin and its clinical significance. Kunitomo T, et al. **Contrib Nephrol** 1995;112:145–55 (22 ref.)

METABOLISM

Beta 2-microglobulin amyloidosis: why and how to look for it. Schaeffer J, et al. **Clin Nephrol** 1995 Nov;44 Suppl 1:S3–9 (93 ref.)

Role of macrophages in beta 2-microglobulin-related dialysis amyloidosis. Gejyo F, et al. **Contrib Nephrol** 1995; 112:97–104 (18 ref.)

Beta 2-microglobulin modified with the AGE products of the Maillard reaction in dialysis-related amyloidosis. Miyata T, et al. **Contrib Nephrol** 1995;112:52–64 (52 ref.)

Clinical aspects of dialysis-related amyloidosis. Schäffer J, et al. **Contrib Nephrol** 1995;112:90–6 (36 ref.)

Pathogenesis of dialysis-related amyloidosis. Miyata T, et

al. **Curr Opin Nephrol Hypertens** 1995 Nov;4(6):493–7 (51 ref.)
Effects of alpha-interferon on serum beta-2-microglobulin. Remes K, et al. **Leuk Lymphoma** 1996 Apr;21(3–4):233–8 (57 ref.)
Pathogenetic and diagnostic aspects of dialysis-related amyloidosis. Schaeffer J, et al. **Nephrol Dial Transplant** 1995;10 Suppl 3:4–8 (66 ref.)

BETA-SHEET CONFORMATION, PROTEIN see **PROTEIN STRUCTURE, SECONDARY**

BETA-THALASSEMIA

BLOOD

Pharmacologic manipulation of fetal hemoglobin levels in sickle cell diseases and thalassemia: promise and reality. Pearson HA. **Adv Pediatr** 1996;43:309–34 (57 ref.)

COMPLICATIONS

Management of cardiac complications in patients with thalassemia major. Vecchio C, et al. **Semin Hematol** 1995 Oct;32(4):288–96 (41 ref.)

DIAGNOSIS

[Thalassemia] Hattori Y. **Rinsho Byori** 1995 Aug;43(8):776–80 (8 ref.) (Eng. Abstr.) **(Jpn)**

DRUG THERAPY

Pharmacologic manipulation of fetal hemoglobin levels in sickle cell diseases and thalassemia: promise and reality. Pearson HA. **Adv Pediatr** 1996;43:309–34 (57 ref.)
Therapeutic iron chelators and their potential side-effects. Singh S, et al. **Biochem Soc Symp** 1995;61:127–37 (21 ref.)
Reactivation of fetal hemoglobin in patients with beta-thalassemia. Olivieri NF. **Semin Hematol** 1996 Jan; 33(1):24–42 (121 ref.)

EMBRYOLOGY

In utero transplantation of fetal liver stem cells into human fetuses. Touraine JL. **J Hematother** 1996 Apr;5(2):195–9 (15 ref.)

EPIDEMIOLOGY

Hematologic disorders in children from southeast Asia. Glader BE, et al. **Pediatr Clin North Am** 1996 Jun; 43(3):665–81 (48 ref.)

GENETICS

Clinical experience of management of thalassemia: the Sardinian experience. Cao A, et al. **Semin Hematol** 1996 Jan;33(1):66–75 (40 ref.)
The thalassemia syndromes lessons from molecular medicines index case. Benz EJ Jr. **Trans Am Clin Climatol Assoc** 1995; 107:20–36; discussion 35–6 (15 ref.)

PREVENTION & CONTROL

Prevention of beta-thalassemia major and Hb Bart's hydrops fetalis syndrome. Beris P, et al. **Semin Hematol** 1995 Oct; 32(4):244–61 (86 ref.)

THERAPY

Clinical experience of management of thalassemia: the Sardinian experience. Cao A, et al. **Semin Hematol** 1996 Jan;33(1):66–75 (40 ref.)
The management of patients with Cooley's anemia: transfusions and splenectomy. Piomelli S. **Semin Hematol** 1995 Oct;32(4):262–8 (43 ref.)
Blood transfusion in beta thalassaemia major. Rebulla P. **Transfus Med** 1995 Dec;5(4):247–58 (131 ref.)
[Bone marrow transplantation in beta-thalassemia major] Gaziev DG, et al. **Klin Med (Mosk)** 1995;73(4):35–9 (71 ref.) **(Rus)**

BETA-THROMBOGLOBULIN

ANALYSIS

[beta-Thromboglobulin (beta-TG)] Narahara N. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:105–8 (15 ref.) **(Jpn)**

BETAINE

ANALOGS & DERIVATIVES

Heterocyclic betaines containing pi-deficient and pi-excessive moieties. Synthetic and biological aspects. Alcalde E, et al. **Farmaco** 1996 Jun;51(6):381–93 (51 ref.)

PHARMACOLOGY

Heterocyclic betaines containing pi-deficient and pi-excessive moieties. Synthetic and biological aspects. Alcalde E, et al. **Farmaco** 1996 Jun;51(6):381–93 (51 ref.)

BETATRONS see **PARTICLE ACCELERATORS**

BETEL see **ARECA**

BEVERAGES

Blood pressure-lowering effect of adding grapefruit juice to nifedipine and terazosin in a patient with severe renovascular hypertension. Pisarik P. **Arch Fam Med** 1996 Jul-Aug;5(7):413–6 (17 ref.)
[Should one consider monitoring various products containing caffeine?] Lafontaine A, et al. **Rev Med Liege** 1996 Mar; 51(3):244–8 (42 ref.) **(Fre)**

BEZOARS

COMPLICATIONS

Obturation of the small bowel. Gaddie D, et al. **Aust N Z J Surg** 1995 Dec;65(12):902–5 (25 ref.)

DIAGNOSIS

[Trichobezoar: unusual diagnosis. Report of 3 cases] Parilli JC, et al. **G E N** 1995 Apr-Jun;49(2):157–60 (11 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

Pharmacobezoar: an evolving new entity. Stack PE, et al. **Dig Dis** 1995 Nov-Dec;13(6):356–64 (38 ref.)
Gastric bezoar following penetrating abdominal injury. Diagnosis and endoscopic therapy. Kaplan LJ, et al. **Surg Endosc** 1996 Jan;10(1):62–4 (16 ref.)

RADIOGRAPHY

Duodenal phytobezoar: a case report and review of the literature. Arda K, et al. **Acta Gastroenterol Belg** 1995 Sep-Dec;58(5–6):470–4 (11 ref.)

BHANG see **CANNABIS**

BIACETYL see **DIACETYL**

BIANILINES see **BENZIDINES**

BIAS (EPIDEMIOLOGY)

Bias in the analysis and reporting of randomized controlled trials. Stewart LA, et al. **Int J Technol Assess Health Care** 1996 Spring;12(2):264–75 (35 ref.)
The rough and ready jackknife. Resnick B. **Nurs Res** 1996 May-Jun;45(3):185–8 (19 ref.)

BIAS, AGGREGATION see **BIAS (EPIDEMIOLOGY)**

BIAS, ECOLOGICAL see **BIAS (EPIDEMIOLOGY)**

BIAS, STATISTICAL see **BIAS (EPIDEMIOLOGY)**

BIAS, SYSTEMATIC see **BIAS (EPIDEMIOLOGY)**

BIBLE

[Leprosy--current aspects of a disease from biblical times] Sticht-Groh V, et al. **Immun Infekt** 1995 Dec;23(6):216–21 (71 ref.) (Eng. Abstr.) **(Ger)**

BIBLIOGRAPHY

see related
DOCUMENTATION

Bibliography database managers. A comparative review. Nicoll LH, et al. **Comput Nurs** 1996 Jan-Feb;14(1):45–56 (3 ref.)
[Scientific literature: bibliometric and bibliographic indicators as integrative criteria for an objective evaluation of research activity] Dracos A, et al. **Ann Ist Super Sanita** 1995;31(3):381–90 (24 ref.) (Eng. Abstr.) **(Ita)**

BIBLIOGRAPHY, STATISTICAL see **BIBLIOMETRICS**

BIBLIOMETRICS

The nature of nursing administration research. Knowledge building or fire stomping? Lynn MR, et al. **J Nurs Adm** 1996 May;26(5):9–14 (11 ref.)
[Role of bibliometrics in the evaluation of medical research] Nieminen P, et al. **Duodecim** 1995;111(2):134–43 (20 ref.) **(Fin)**
[Bibliometry of biomedical periodicals] Similowski T, et al. **Rev Mal Respir** 1995;12(6):543–50 (32 ref.) (Eng. Abstr.) **(Fre)**

BICARBONATE IONS see **BICARBONATES**

BICARBONATES

ADMINISTRATION & DOSAGE

Bicarbonate: the alternative buffer for peritoneal dialysis. Passlick-Deetjen J, et al. **Perit Dial Int** 1996;16 Suppl 1:S109–13 (44 ref.)

BLOOD

Acid-base balance: origin of plasma [H+] during exercise. Kowalchuk JM, et al. **Can J Appl Physiol** 1995 Sep; 20(3):341–56 (33 ref.)
[Plasma bicarbonate] Matsuzaki K. **Nippon Rinsho** 1995 Feb; 53 Su Pt 1:787–91 (10 ref.) **(Jpn)**

METABOLISM

Renal chloride-bicarbonate exchangers. Godinich MJ, et al. **Curr Opin Nephrol Hypertens** 1995 Sep;4(5):398–401 (34 ref.)

PHARMACOLOGY

Effects of bicarbonate, citrate, and phosphate loading on performance. Horswill CA. **Int J Sport Nutr** 1995 Jun;5 Suppl:S111–9 (49 ref.)
Lactate-versus bicarbonate-based peritoneal dialysis solutions. Pedersen FB. **Perit Dial Int** 1995;15(7 Suppl):S47–50; discussion S51 (33 ref.)

BICUSPID

GROWTH & DEVELOPMENT

Cementogenesis reviewed: a comparison between human premolars and rodent molars. Bosshardt DD, et al. **Anat Rec** 1996 Jun;245(2):267–92 (141 ref.)

BICUSPID VALVE see **MITRAL VALVE**

BICYCLE ERGOMETRY TEST see **EXERCISE TEST**

BICYCLING

INJURIES

Ipsilateral peroneus brevis tendon grafting in a complicated case of traumatic rupture of tibialis anterior tendon. Forst R, et al. **Foot Ankle Int** 1995 Jul;16(7):440–4 (33 ref.)
Fatal cycling injuries. Noakes TD. **Sports Med** 1995 Nov; 20(5):348–62 (104 ref.)

PHYSIOLOGY

Physiological monitoring of elite cyclists. Practical methods. Boulay MR. **Sports Med** 1995 Jul;20(1):1–11 (22 ref.)
[Factors limiting performance in the triathlon] Margaritis I. **Can J Appl Physiol** 1996 Feb;21(1):1–15 (69 ref.) (Eng. Abstr.) **(Fre)**

BICYCLO COMPOUNDS, HETEROCYCLIC

PHARMACOLOGY

Discovery, biosynthesis, and mechanism of action of the zaragozic acids: potent inhibitors of squalene synthase. Bergstrom JD, et al. **Annu Rev Microbiol** 1995;49:607–39 (80 ref.)
[Epibatidine--a nicotine-related, analgesic alkaloid from poison-dart frogs] Müller CE. **Pharm Unserer Zeit** 1996 Apr;25(2):85–92 (27 ref.) **(Ger)**

BIFIDOBACTERIUM

The role of lactic acid bacteria in colon cancer prevention. Rafter JJ. **Scand J Gastroenterol** 1995 Jun;30(6):497–502 (56 ref.)

CLASSIFICATION

[Approaches to classifying bifidobacteria based on DNA structural data] Blokhina IN, et al. **Mol Gen Mikrobiol Virusol** 1995 Oct-Dec;(4):27–9 (14 ref.) (Eng. Abstr.) **(Rus)**

BIFUNCTIONAL ANTIBODIES see **ANTIBODIES, BISPECIFIC**

BIFUNCTIONAL REAGENTS see **CROSS-LINKING REAGENTS**

BIGUANIDES

ADVERSE EFFECTS

[Lactic acidosis associated with biguanides] Safadi R, et al. **Harefuah** 1996 Feb 15;130(4):280–3 (40 ref.) **(Heb)**

BILAYERS, LIPID see **LIPID BILAYERS**

BILE

[Biloma] Uchino J, et al. **Ryoikibetsu Shokogun Shirizu** 1996; (9):492–5 (17 ref.) **(Jpn)**
[Hepatic biloma] Watanabe H, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):106–8 (22 ref.) **(Jpn)**

CHEMISTRY

Update on physical state of bile. Carey MC, et al. **Ital J Gastroenterol** 1995 Mar;27(2):92–100 (77 ref.)
Cholesterol nucleation in bile. Holzbach RT. **Ital J Gastroenterol** 1995 Mar;27(2):101–5 (38 ref.)

BILE

METABOLISM

Molecular mechanisms of hepatic bile salt transport from sinusoidal blood into bile. Meier PJ. **Am J Physiol** 1995 Dec;269(6 Pt 1):G801–12 (190 ref.)

Phospholipid vesicles and other cholesterol carriers in bile. Gilat T, et al. **Biochim Biophys Acta** 1996 Jun 10; 1286(2):95–115 (108 ref.)

Phase III elimination: another two-edge sword [editorial] Vore M. **Environ Health Perspect** 1994 May;102(5):422–3 (9 ref.)

Cholestasis: pathophysiology and pathobiochemistry. Krell H, et al. **Z Gastroenterol** 1993 Feb;31 Suppl 2:11–5 (58 ref.)

[Calcareous bile syndrome] Vorob'ev LP, et al. **Klin Med (Mosk)** 1995;73(5):16–20 (58 ref.) **(Rus)**

PHYSIOLOGY

The role of mdr2 P-glycoprotein in biliary lipid secretion. Cross-talk between cancer research and biliary physiology. Oude Elferink RP, et al. **J Hepatol** 1995 Nov;23(5):617–25 (62 ref.)

SECRETION

Bile secretion--models, mechanisms, and malfunctions. A perspective on the development of modern cellular and molecular concepts of bile secretion and cholestasis. Boyer JL. **J Gastroenterol** 1996 Jun;31(3):475–81 (78 ref.)

BILE ACIDS AND SALTS

BLOOD

Molecular mechanisms of hepatic bile salt transport from sinusoidal blood into bile. Meier PJ. **Am J Physiol** 1995 Dec;269(6 Pt 1):G801–12 (190 ref.)

Serum bile acids: physiology and clinical relevance [see comments] Reichel C, et al. **Eur J Gastroenterol Hepatol** 1995 Oct;7(10):951–3 (13 ref.) Comment in: Eur J Gastroenterol Hepatol 1995 Oct;7(10):1011.

[Serum bile acids and their profile] Matsuzaki Y, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:662–4 (11 ref.) **(Jpn)**

CHEMISTRY

Bile acids: physico-chemical properties, function and activity. Roda A, et al. **Ital J Gastroenterol** 1995 Jul–Aug; 27(6):327–31 (31 ref.)

ISOLATION & PURIFICATION

Bile acid separation. Scalia S. **J Chromatogr B Biomed Appl** 1995 Sep 15;671(1–2):299–317 (92 ref.)

METABOLISM

Rat and human bile acid binders are members of the monomeric reductase gene family. Stolz A, et al. **Adv Exp Med Biol** 1995;372:269–80 (56 ref.)

Molecular mechanisms of hepatic bile salt transport from sinusoidal blood into bile. Meier PJ. **Am J Physiol** 1995 Dec;269(6 Pt 1):G801–12 (190 ref.)

Bile acid malabsorption: mechanisms and treatment. Eusufzai S. **Dig Dis** 1995 Sep–Oct;13(5):312–21 (85 ref.)

Suggested sterol-binding mechanisms of dietary fibre based on ileostomy studies. Andersson H. **Eur J Clin Nutr** 1995 Oct;49 Suppl 3:S173–7 (39 ref.)

In vitro binding properties of dietary fibre. Kritchevsky D. **Eur J Clin Nutr** 1995 Oct;49 Suppl 3:S113–5 (18 ref.)

Bile acid structure and intestinal absorption in the animal model. Aldini R, et al. **Ital J Gastroenterol** 1995 Apr; 27(3):141–4 (33 ref.)

Intestinal absorption of bile acids: effect of ursodeoxycholic acid treatment. Stiehl A. **Ital J Gastroenterol** 1995 May; 27(4):193–5 (31 ref.)

[Congenital disorders of the bile acid metabolism (3 beta-hydroxy-delta 5-steroid dehydrogenase/isomerase deficiency, delta 4-3-oxosteroid 5 beta-reductase deficiency, cerebrotendinous xanthomatosis, and peroxisomal disorders] Kondo KH, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):362–6 (23 ref.) **(Jpn)**

PHARMACOKINETICS

Clinical pharmacokinetics of therapeutic bile acids. Crosignani A, et al. **Clin Pharmacokinet** 1996 May; 30(5):333–58 (156 ref.)

PHARMACOLOGY

Bile acids as drugs: principles, mechanisms of action and formulations. Hofmann AF. **Ital J Gastroenterol** 1995 Mar; 27(2):106–13 (77 ref.)

PHYSIOLOGY

Role of bile acids in colorectal carcinogenesis. Nagengast FM, et al. **Eur J Cancer** 1995 Jul–Aug;31A(7–8):1067–70 (44 ref.)

Bile acids: physico-chemical properties, function and activity. Roda A, et al. **Ital J Gastroenterol** 1995 Jul–Aug; 27(6):327–31 (31 ref.)

THERAPEUTIC USE

[Bile acids and their therapeutic use in children] Lacaille F. **Arch Pediatr** 1995 Dec;2(12):1200–8 (57 ref.) (Eng. Abstr.) **(Fre)**

BILE ALCOHOLS see **CHOLESTANOLS**

BILE CANALICULI

PATHOLOGY

Canalicular cholestasis due to amiodarone toxicity. A definite diagnosis obtained by electron microscopy. Macarri G, et al. **Ital J Gastroenterol** 1995 Oct–Nov;27(8):436–8 (18 ref.)

BILE DUCT DISEASES

[Idiopathic adulthood ductopenia] Haratake J, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):577–9 (11 ref.) **(Jpn)**

[Pneumobilia] Watanabe F, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):512–3 (2 ref.) **(Jpn)**

CHEMICALLY INDUCED

Drug-induced vanishing bile duct syndrome: response to ursodiol. O'Brien CB, et al. **Am J Gastroenterol** 1996 Jul; 91(7):1456–7 (10 ref.)

COMPLICATIONS

Choledochocele-containing stones. Tajiri H. **Am J Gastroenterol** 1996 May;91(5):1046–8 (10 ref.)

DIAGNOSIS

[HIV infection: findings in liver and bile ducts] Jablonowski H. **Bildgebung** 1995 Dec;62(4):260–70 (89 ref.) (Eng. Abstr.) **(Ger)**

[1995 literature review: ultrasound and roentgen diagnosis of gallbladder, bile ducts and pancreas] Brambs HJ, et al. **Rontgenpraxis** 1996 Apr;49(4):94–9 (31 ref.) **(Ger)**

ETIOLOGY

Native hepatic artery pseudoaneurysm after liver transplantation: an unusual presentation with biliary leak. Soin AS, et al. **Eur J Vasc Endovasc Surg** 1995 Oct; 10(3):376–9 (9 ref.)

[Vanishing bile duct syndrome] Hashimoto E, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):574–6 (18 ref.) **(Jpn)**

[Cholangiopathy after orthotopic liver transplantation: Rejection cholangiopathy] Hashimoto E, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):550–2 (20 ref.) **(Jpn)**

SURGERY

Benign biliary strictures: repair and outcome with a contemporary approach. McDonald ML, et al. **Surgery** 1995 Oct;118(4):582–90; discussion 590–1 (21 ref.)

BILE DUCT NEOPLASMS

Extrahepatic biliary cystadenomas and cystadenocarcinoma. Report of seven cases and review of the literature. Davies W, et al. **Ann Surg** 1995 Nov;222(5):619–25 (20 ref.)

[Inflammatory polyp of the extra-hepatic bile duct] Adachi K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):149–51 (7 ref.) **(Jpn)**

[Lipoma and liposarcoma of the extrahepatic bile ducts] Fukusato T, et al. **Ryoikibetsu Shokogun Shirizu** 1996; (9):34–6 (21 ref.) **(Jpn)**

[Squamous cell carcinoma of the extrahepatic bile duct] Funakawa T, et al. **Ryoikibetsu Shokogun Shirizu** 1996; (9):61–3 (21 ref.) **(Jpn)**

[Adenomyoma of the extrahepatic bile duct] Hoso M, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):50–2 (19 ref.) **(Jpn)**

[Klatskin tumor] Kakita A, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):24–6 (15 ref.) **(Jpn)**

[Intramucosal carcinoma of extrahepatic choledochus] Katagiri K, et al. **Ryoikibetsu Shokogun Shirizu** 1996; (9):95–8 (10 ref.) **(Jpn)**

[Adenoacanthoma, adenosquamous carcinoma of the extrahepatic bile duct] Kimoto E, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):47–9 (36 ref.) **(Jpn)**

[Cholangiocarcinoma] Komatsu M, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):398–401 (12 ref.) **(Jpn)**

[Tumor of the extrahepatic bile ducts--benign, malignant] Kuno N, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):27–33 (18 ref.) **(Jpn)**

[Neoplasms of the cystic duct] Nakamura S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):265–9 (26 ref.) **(Jpn)**

[Diffuse bile duct carcinoma] Nakao A. **Ryoikibetsu Shokogun Shirizu** 1996;(9):74–6 (14 ref.) **(Jpn)**

[Adenocarcinoma of the extra bile duct] Noguchi T. **Ryoikibetsu Shokogun Shirizu** 1996;(9):43–6 (8 ref.) **(Jpn)**

[Papillary extrahepatic bile duct carcinoma, invasive papillary extrahepatic bile duct carcinoma] Nomoto S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):88–91 (12 ref.) **(Jpn)**

[Smooth muscle tumors of the extra-hepatic bile duct] Saito K. **Ryoikibetsu Shokogun Shirizu** 1996;(9):64–7 (22 ref.) **(Jpn)**

[Signet ring cell carcinoma of the intrahepatic bile duct] Saito K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):395–7 (14 ref.) **(Jpn)**

[Squamous cell carcinoma of the intrahepatic bile duct] Saito K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):417–9 (15 ref.) **(Jpn)**

[Mucinous cholangiocarcinoma, mucus producing carcinoma] Sakamoto H, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):414–6 (17 ref.) **(Jpn)**

[Intrahepatic sarcomatoid cholangiocarcinoma] Sasaki M, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):408–10 (14 ref.) **(Jpn)**

[Mucoepidermoid carcinoma of the liver or the intrahepatic bile duct] Sasaki Y, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):426–8 (13 ref.) **(Jpn)**

[Adenoma, cyst adenoma of the extrahepatic bile duct] Shiga J. **Ryoikibetsu Shokogun Shirizu** 1996;(9):53–6 (21 ref.) **(Jpn)**

[Fibroma and fibrosarcoma of the extra hepatic bile ducts] Shiga J. **Ryoikibetsu Shokogun Shirizu** 1996;(9):40–2 (20 ref.) **(Jpn)**

[Peripheral type of cholangiocarcinoma without intrahepatic bile duct dilatation] Sugiura N, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):498–500 (9 ref.) **(Jpn)**

[Liver adenoma and hepatobiliary cystadenoma] Takahama T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):387–91 (7 ref.) **(Jpn)**

[Cholangiocellular carcinoma (intrahepatic bile duct carcinoma)] Tarao K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):476–9 (10 ref.) **(Jpn)**

[Intrahepatic biliary papillomatosis] Terada T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):411–3 (7 ref.) **(Jpn)**

[Intrahepatic bile duct adenocarcinoma] Terada T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):402–4 (7 ref.) **(Jpn)**

[Special types of extrahepatic bile duct cancers] Terada T. **Ryoikibetsu Shokogun Shirizu** 1996;(9):85–7 (6 ref.) **(Jpn)**

[Biliary papillomatosis] Tsuneyama K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):81–4 (16 ref.) **(Jpn)**

[Carcinoma of the hilar bile ducts] Tsuyuguchi T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):435–7 (14 ref.) **(Jpn)**

[Cancer of the main hepatic duct junction] Tsuzuki T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):68–70 (4 ref.) **(Jpn)**

[Mucin producing extrahepatic bile duct carcinoma] Yamanaka T. **Ryoikibetsu Shokogun Shirizu** 1996;(9):92–4 (9 ref.) **(Jpn)**

[Neuroma of the extrahepatic bile duct, amputation neuroma of the bile duct] Yamauchi H, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):37–9 (13 ref.) **(Jpn)**

COMPLICATIONS

[A case of cholangiocarcinoma with temporary subsegmental fatty liver and intrahepatic portal aneurysm] Miyanaga O, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Sep; 92(9):1297–303 (9 ref.) **(Jpn)**

[A case of the hypoplasia of the hepatic left lobe complicated with cholangiocarcinoma] Suzuki T, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Apr;93(4):276–81 (20 ref.) **(Jpn)**

[Cholangiocellular carcinoma associated with liver cirrhosis] Suzuki Y, et al. **Ryoikibetsu Shokogun Shirizu** 1995; (7):357–9 (20 ref.) **(Jpn)**

DIAGNOSIS

[A giant unifocal biliary cystadenoma: a chance finding in a young asymptomatic athlete] Busoni F, et al. **Radiol Med (Torino)** 1996 Apr;91(4):480–2 (12 ref.) **(Ita)**

[Nodular-type carcinoma of extrahepatic bile ducts] Horiguchi Y, et al. **Ryoikibetsu Shokogun Shirizu** 1996; (9):71–3 (4 ref.) **(Jpn)**

ETIOLOGY

Bile duct carcinoma arising from the anastomotic site of hepaticojejunostomy after the excision of congenital biliary dilatation: a case report. Yamamoto J, et al. **Surgery** 1996 Apr;119(4):476–9 (10 ref.)

METABOLISM

[Ectopic hormone producing cholangiocarcinoma] Kawanami C, et al. **Ryoikibetsu Shokogun Shirizu** 1996; (9):99–102 (14 ref.) **(Jpn)**

PATHOLOGY

Clinico-pathological findings of asymptomatic intrahepatic cholangiocellular carcinoma: report of two cases and

review of the literature. Chijiiwa K, et al. **Eur J Surg Oncol** 1996 Apr;22(2):186–8 (15 ref.)
Biliary tumors of the liver. Colombari R, et al. **Semin Liver Dis** 1995 Nov;15(4):402–13 (108 ref.)
[Invasive extrahepatic bile duct cancer] Kaneko T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):77–80 (20 ref.) **(Jpn)**

SURGERY

Surgical therapy for hilar bile duct cancer. Miyagawa S, et al. **Chir Ital** 1995;47(1):7–11 (30 ref.)
Current status of surgery for Klatskin tumors. Lillemoe KD. **Curr Opin Gen Surg** 1994;:161–7 (25 ref.)
Biliary neoplasms. Puntis MC. **Curr Opin Gen Surg** 1993; :277–81 (24 ref.)
[Stenting or operation in malignant or benign stenoses: where are the limits?—from the viewpoint of the surgeon] Schoenberg MH, et al. **Bildgebung** 1995 Oct;62 Suppl 2:73–6 (13 ref.) **(Ger)**
[A simultaneous operation for esophageal and cholangiocellular carcinomas—a case of report] Kudo T, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Oct; 92(10):1789–93 (12 ref.) **(Jpn)**

THERAPY

[Plastic prostheses or self-expanding stents—is there an ideal drainage? Pro metal] Hochberger J, et al. **Bildgebung** 1995 Oct;62 Suppl 2:59–63 (22 ref.) **(Ger)**
[Plastic prostheses or self-expanding stents—is there an ideal drainage? Pro synthetics] Soehendra N, et al. **Bildgebung** 1995 Oct;62 Suppl 2:55–8 (23 ref.) **(Ger)**

ULTRASONOGRAPHY

[Indications for endosonography in tumors of the pancreas and bile ducts] Nattermann C. **Bildgebung** 1995 Oct;62 Suppl 2:35–9 (37 ref.) **(Ger)**

VETERINARY

Biliary cystadenoma of cats. Adler R, et al. **Vet Pathol** 1995 Jul;32(4):415–8 (23 ref.)

BILE DUCT OBSTRUCTION see **CHOLESTASIS**

BILE DUCT OBSTRUCTION, EXTRAHEPATIC

[Extraductal bile duct obstruction, extraductal bile duct stenosis] Imai H, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):176–8 (7 ref.) **(Jpn)**
[Congenital bile duct stenosis and biliary atresia] Matsushiro T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):127–30 (13 ref.) **(Jpn)**
[Extrahepatic cholestatic syndrome in childhood] Tazawa Y. **Ryoikibetsu Shokogun Shirizu** 1996;(9):159–62 (19 ref.) **(Jpn)**
[Syndrome of extrahepatic cholestasis, extrahepatic obstructive jaundice] Tsunoda T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):152–4 (10 ref.) **(Jpn)**

DIAGNOSIS

[Rational laboratory diagnosis of cholestasis syndrome] Nilius R, et al. **Z Gastroenterol** 1993 Feb;31 Suppl 2:33–8 (24 ref.) (Eng. Abstr.) **(Ger)**
[The role of ERCP in the diagnosis and therapy of Mirizzi's syndrome. Apropos a clinical case] De Monti M, et al. **Minerva Gastroenterol Dietol** 1996 Mar;42(1):39–43 (18 ref.) (Eng. Abstr.) **(Ita)**

ETIOLOGY

Long term survival after obstruction of the common bile duct by ductal hepatocellular carcinoma. Jan YY, et al. **Eur J Surg** 1995 Oct;161(10):771–4 (17 ref.)

PHYSIOPATHOLOGY

Cholestasis: pathophysiology and pathobiochemistry. Krell H, et al. **Z Gastroenterol** 1993 Feb;31 Suppl 2:11–5 (58 ref.)

THERAPY

[Hepatobiliary stenting in malignant and benign stenosis—which approach is the best? Endoscopic approach] Jung M, et al. **Bildgebung** 1995 Oct;62 Suppl 2:47–52 (24 ref.) **(Ger)**

ULTRASONOGRAPHY

[Status of ultrasound diagnosis in differential cholestasis diagnosis] Busse HJ, et al. **Z Gastroenterol** 1993 Feb;31 Suppl 2:39–41 (25 ref.) (Eng. Abstr.) **(Ger)**

BILE DUCT OBSTRUCTION, INTRAHEPATIC see **CHOLESTASIS, INTRAHEPATIC**

BILE DUCTS

see related
CHOLANGIOGRAPHY
CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE

PORTOENTEROSTOMY, HEPATIC

Prevention of biliary stent clogging: a clinical review. Libby ED, et al. **Am J Gastroenterol** 1996 Jul;91(7):1301–8 (59 ref.)

ABNORMALITIES

Bile duct carcinoma arising from the anastomotic site of hepaticojejunostomy after the excision of congenital biliary dilatation: a case report. Yamamoto J, et al. **Surgery** 1996 Apr;119(4):476–9 (10 ref.)
[Anomalous arrangement of the pancreaticobiliary ductal system] Matsumoto Y, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):163–6 (10 ref.) **(Jpn)**

BLOOD SUPPLY

Cholangitis associated with paroxysmal nocturnal hemoglobinuria: another instance of ischemic cholangiopathy? Le Thi Huong D, et al. **Gastroenterology** 1995 Oct;109(4):1338–43 (52 ref.)

INJURIES

[Bile duct injury] Furukawa M, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):179–82 (17 ref.) **(Jpn)**

PATHOLOGY

Pathology and immunopathology of primary biliary cirrhosis with emphasis on bile duct lesions: recent progress. Nakanuma Y, et al. **Semin Liver Dis** 1995 Nov;15(4):313–28 (132 ref.)
[Hepatic neoductules] Fischer HP, et al. **Verh Dtsch Ges Pathol** 1995;79:36–46 (42 ref.) (Eng. Abstr.) **(Ger)**
[Vanishing bile duct syndrome] Hashimoto E, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):574–6 (18 ref.) **(Jpn)**
[Histiocytosis syndrome] Tsunematsu Y, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):379–87 (17 ref.) **(Jpn)**

SECRETION

Bile secretion—models, mechanisms, and malfunctions. A perspective on the development of modern cellular and molecular concepts of bile secretion and cholestasis. Boyer JL. **J Gastroenterol** 1996 Jun;31(3):475–81 (78 ref.)

SURGERY

Benign biliary strictures: repair and outcome with a contemporary approach. McDonald ML, et al. **Surgery** 1995 Oct;118(4):582–90; discussion 590–1 (21 ref.)

BILE DUCTS, EXTRAHEPATIC

Extrahepatic biliary cystadenomas and cystadenocarcinoma. Report of seven cases and review of the literature. Davies W, et al. **Ann Surg** 1995 Nov;222(5):619–25 (20 ref.)
[Inflammatory polyp of the extra-hepatic bile duct] Adachi K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):149–51 (7 ref.) **(Jpn)**
[Lipoma and liposarcoma of the extrahepatic bile ducts] Fukusato T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):34–6 (21 ref.) **(Jpn)**
[Squamous cell carcinoma of the extrahepatic bile duct] Funakawa T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):61–3 (21 ref.) **(Jpn)**
[Nodular-type carcinoma of extrahepatic bile ducts] Horiguchi Y, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):71–3 (4 ref.) **(Jpn)**
[Adenomyoma of the extrahepatic bile duct] Hoso M, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):50–2 (19 ref.) **(Jpn)**
[Invasive extrahepatic bile duct cancer] Kaneko T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):77–80 (20 ref.) **(Jpn)**
[Extra-hepatic cholangiolithiasis-choledocholithiasis] Kashima K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):142–5 (15 ref.) **(Jpn)**
[Intramucosal carcinoma of extrahepatic choledochus] Katagiri K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):95–8 (10 ref.) **(Jpn)**
[Ectopic hormone producing cholangiocarcinoma] Kawanami C, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):99–102 (14 ref.) **(Jpn)**
[Adenoacanthoma, adenosquamous carcinoma of the extrahepatic bile duct] Kimoto E, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):47–9 (36 ref.) **(Jpn)**
[Tumor of the extrahepatic bile ducts—benign, malignant] Kuno N, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):27–33 (18 ref.) **(Jpn)**
[Congenital bile duct dilatation, congenital biliary dilatation] Miyazaki I, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):118–26 (52 ref.) **(Jpn)**
[Extrahepatic cholangitis] Murakami K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):5–7 (19 ref.) **(Jpn)**
[Diffuse bile duct carcinoma] Nakao A. **Ryoikibetsu Shokogun Shirizu** 1996;(9):74–6 (14 ref.) **(Jpn)**
[Parasitic infections in the extrahepatic biliary tree] Nakazawa O. **Ryoikibetsu Shokogun Shirizu** 1996;(9):485–8 (6 ref.) **(Jpn)**
[Adenocarcinoma of the extra bile duct] Noguchi T. **Ryoikibetsu Shokogun Shirizu** 1996;(9):43–6 (8 ref.) **(Jpn)**
[Papillary extrahepatic bile duct carcinoma, invasive papillary extrahepatic bile duct carcinoma] Nomoto S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):88–91 (12 ref.) **(Jpn)**
[Smooth muscle tumors of the extra-hepatic bile duct] Saito K. **Ryoikibetsu Shokogun Shirizu** 1996;(9):64–7 (22 ref.) **(Jpn)**
[Adenoma, cyst adenoma of the extrahepatic bile duct] Shiga J. **Ryoikibetsu Shokogun Shirizu** 1996;(9):53–6 (21 ref.) **(Jpn)**
[Fibroma and fibrosarcoma of the extra hepatic bile ducts] Shiga J. **Ryoikibetsu Shokogun Shirizu** 1996;(9):40–2 (20 ref.) **(Jpn)**
[Special types of extrahepatic bile duct cancers] Terada T. **Ryoikibetsu Shokogun Shirizu** 1996;(9):85–7 (6 ref.) **(Jpn)**
[Biliary papillomatosis] Tsuneyama K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):81–4 (16 ref.) **(Jpn)**
[Carcinoma of the hilar bile ducts] Tsuyuguchi T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):435–7 (14 ref.) **(Jpn)**
[Mucin producing extrahepatic bile duct carcinoma] Yamanaka T. **Ryoikibetsu Shokogun Shirizu** 1996;(9):92–4 (9 ref.) **(Jpn)**
[Neuroma of the extrahepatic bile duct, amputation neuroma of the bile duct] Yamauchi H, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):37–9 (13 ref.) **(Jpn)**

ABNORMALITIES

[A rare case of gallbladder interposition in the extrahepatic bile ducts] Nikolov K, et al. **Khirurgiia (Sofiia)** 1994; 47(6):52–3 (2 ref.) (Eng. Abstr.) **(Bul)**
[Accessory bile ducts] Nakagawara G, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):139–41 (15 ref.) **(Jpn)**
[Aberrant biliary duct (vasa aberantia)] Nakagawara G, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):103–6 (18 ref.) **(Jpn)**
[Aberrant drainage of bile duct] Nakagawara G, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):107–10 (18 ref.) **(Jpn)**
[Duplication of extra-hepatic biliary duct (duplication of common hepatic duct, duplication of cystic duct, duplication of common bile duct)] Nakagawara G, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):111–3 (15 ref.) **(Jpn)**
[Anomalies and variations of extrahepatic biliary tract] Nakagawara G, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):114–7 (13 ref.) **(Jpn)**

INJURIES

Non-surgical trauma to the extrahepatic biliary tract. Parks RW, et al. **Br J Surg** 1995 Oct;82(10):1303–10 (127 ref.)

PATHOLOGY

[Extraductal bile duct obstruction, extraductal bile duct stenosis] Imai H, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):176–8 (7 ref.) **(Jpn)**
[Extrahepatic intrabile duct tumor growth of hepatocellular carcinoma] Kashihara T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):57–60 (20 ref.) **(Jpn)**

BILE DUCTS, INTRAHEPATIC

The management of intrahepatic stones. Cheung KL, et al. **Adv Surg** 1996;29:111–29 (108 ref.)
[Intrahepatic cholangitis with presumably immunologic bases] Klinge O. **Verh Dtsch Ges Pathol** 1995;79:198–232 (128 ref.) (Eng. Abstr.) **(Ger)**
[A giant unifocal biliary cystadenoma: a chance finding in a young asymptomatic athlete] Busoni F, et al. **Radiol Med (Torino)** 1996 Apr;91(4):480–2 (12 ref.) **(Ita)**
[A simultaneous operation for esophageal and cholangiocellular carcinomas—a case of report] Kudo T, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Oct; 92(10):1789–93 (12 ref.) **(Jpn)**
[A case of cholangiocarcinoma with temporary subsegmental fatty liver and intrahepatic portal aneurysm] Miyanaga O, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Sep; 92(9):1297–303 (9 ref.) **(Jpn)**
[A case of the hypoplasia of the hepatic left lobe complicated with cholangiocarcinoma] Suzuki T, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Apr;93(4):276–81 (20 ref.) **(Jpn)**
[Hepatobiliary disease in malignant lymphoma, leukemia, and MDS] Ishikawa T. **Ryoikibetsu Shokogun Shirizu** 1995;(8):375–8 (21 ref.) **(Jpn)**
[Cholangiocarcinoma] Komatsu M, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):398–401 (12 ref.) **(Jpn)**
[Intra-hepatic biliary cyst] Motoo Y, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):80–2 (12 ref.) **(Jpn)**
[Combined hepatocellular and cholangiocarcinoma] Omagari K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):473–5 (14

ref.) (Jpn)
[Squamous cell carcinoma of the intrahepatic bile duct] Saito K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):417–9 (15 ref.) (Jpn)
[Signet ring cell carcinoma of the intrahepatic bile duct] Saito K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):395–7 (14 ref.) (Jpn)
[Mucinous cholangiocarcinoma, mucus producing carcinoma] Sakamoto H, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):414–6 (17 ref.) (Jpn)
[Mucinous cholangiocarcinoma] Sasaki M, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):423–5 (15 ref.) (Jpn)
[Intrahepatic sarcomatoid cholangiocarcinoma] Sasaki M, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):408–10 (14 ref.) (Jpn)
[Mucoepidermoid carcinoma of the liver or the intrahepatic bile duct] Sasaki Y, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):426–8 (13 ref.) (Jpn)
[Peripheral type of cholangiocarcinoma without intrahepatic bile duct dilatation] Sugiura N, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):498–500 (9 ref.) (Jpn)
[Cholangiocellular carcinoma associated with liver cirrhosis] Suzuki Y, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):357–9 (20 ref.) (Jpn)
[Sarcoidosis of the liver and intrahepatic biliary system] Tachibana T. **Ryoikibetsu Shokogun Shirizu** 1995;(8):333–6 (22 ref.) (Jpn)
[Liver adenoma and hepatobiliary cystadenoma] Takahama T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):387–91 (7 ref.) (Jpn)
[Cholangiocellular carcinoma (intrahepatic bile duct carcinoma)] Tarao K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):476–9 (10 ref.) (Jpn)
[Intrahepatic biliary papillomatosis] Terada T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):411–3 (7 ref.) (Jpn)
[Intrahepatic bile duct adenocarcinoma] Terada T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):402–4 (7 ref.) (Jpn)
[Cancer of the main hepatic duct junction] Tsuzuki T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):68–70 (4 ref.) (Jpn)
[Biloma] Uchino J, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):492–5 (17 ref.) (Jpn)
[Hepatic biloma] Watanabe H, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):106–8 (22 ref.) (Jpn)

ABNORMALITIES

[Dysmorphogenesis of intrahepatic bile duct] Okanoue T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):553–4 (12 ref.) (Jpn)

PATHOLOGY

Clinico-pathological findings of asymptomatic intrahepatic cholangiocellular carcinoma: report of two cases and review of the literature. Chijiiwa K, et al. **Eur J Surg Oncol** 1996 Apr;22(2):186–8 (15 ref.)
Biliary tumors of the liver. Colombari R, et al. **Semin Liver Dis** 1995 Nov;15(4):402–13 (108 ref.)
[Idiopathic adulthood ductopenia] Haratake J, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):577–9 (11 ref.) (Jpn)
[Cholangiopathy after orthotopic liver transplantation: Rejection cholangiopathy] Hashimoto E, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):550–2 (20 ref.) (Jpn)
[Idiopathic adulthood ductopenia] Satoh K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):569–70 (9 ref.) (Jpn)
[Drug-induced vanishing-bile-duct syndrome] Suto T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):59–62 (20 ref.) (Jpn)

SURGERY

[Role of extracorporeal shock wave lithotripsy in the treatment of common bile duct and intrahepatic calculi] Dagenais M, et al. **Ann Chir** 1995;49(8):659–63 (15 ref.) (Eng. Abstr.) (Fre)
[Percutaneous treatment of malignant stenoses of the hilum] Bonnel D, et al. **Gastroenterol Clin Biol** 1995 Jun–Jul;19(6–7):564–71 (24 ref.) (Eng. Abstr.) (Fre)
[Treatment of tumoral stenoses of the hepatic hilum (editorial)] Valette PJ. **Gastroenterol Clin Biol** 1995 Jun–Jul;19(6–7):561–3 (17 ref.) (Fre)

BILE PIGMENTS

ANALYSIS

[Dipyrrole bile pigments] Yamaguchi T, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:895–8 (9 ref.) (Jpn)

METABOLISM

[Pigment stone (black stones, calcium bilirubinate stones)] Ise H, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):404–7 (18 ref.) (Jpn)

BILE REFLUX

ETIOLOGY

[Endoscopic management of bile leakage following laparoscopic cholecystectomy] Lakatos L, et al. **Orv Hetil** 1996 Mar 17;137(11):569–75 (47 ref.) (Eng. Abstr.) (Hun)

BILE SALTS see **BILE ACIDS AND SALTS**

BILHARZIASIS see **SCHISTOSOMIASIS**

BILIARY ATRESIA

Biliary atresia: an overview. Lugo Vicente HL. **Bol Asoc Med P R** 1995 Jul–Sep;87(7–9):147–53 (53 ref.)
Biliary atresia: current concepts and research directions. Summary of a symposium. Balistreri WF, et al. **Hepatology** 1996 Jun;23(6):1682–92 (93 ref.)
[Congenital bile duct stenosis and biliary atresia] Matsushiro T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):127–30 (13 ref.) (Jpn)

PHYSIOPATHOLOGY

[Non syndromatic intrahepatic biliary atresia in children] Okaniwa M. **Ryoikibetsu Shokogun Shirizu** 1995;(8):541–3 (17 ref.) (Jpn)

RADIONUCLIDE IMAGING

[Hepatobiliary radionuclide imaging. Clinical applications] Zerbib E. **Ann Chir** 1995;49(7):637–43 (35 ref.) (Eng. Abstr.) (Fre)

SURGERY

Is there a place for the Kasai procedure in biliary atresia? Grosfeld J. **Curr Opin Gen Surg** 1994;:168–72 (22 ref.)
[Liver transplantation in children] Valayer J. **Presse Med** 1995 Oct 21;24(31):1438–43 (21 ref.) (Eng. Abstr.) (Fre)

BILIARY CALCULI see **CHOLELITHIASIS**

BILIARY CALCULI, COMMON BILE DUCT see **COMMON BILE DUCT CALCULI**

BILIARY CIRRHOSIS see **LIVER CIRRHOSIS, BILIARY**

BILIARY DYSKINESIA

Sphincter of Oddi. Toouli J. **Gastroenterologist** 1996 Mar;4(1):44–53 (44 ref.)
[Biliary dyskinesia, sphincter of Oddi dysfunction] Makino I, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):183–6 (10 ref.) (Jpn)

BILIARY FISTULA

[Biliary ileus. Case report and therapeutic considerations] Ferranti F, et al. **Minerva Chir** 1995 Jul–Aug;50(7–8):707–11 (28 ref.) (Eng. Abstr.) (Ita)
[Biliary fistula (postoperative, spontaneous)] Ohta T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):500–2 (6 ref.) (Jpn)
[Cholecystogastric fistula, cholecystoenteric fistula] Souda S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):436–8 (8 ref.) (Jpn)
[Parapapillary choledochoduodenal fistula] Uetsuji S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):528–9 (14 ref.) (Jpn)

COMPLICATIONS

[Hemobilia due to a portobiliary fistula as a complication of a fine-needle liver biopsy] De Santis M, et al. **Radiol Med (Torino)** 1996 Apr;91(4):482–5 (18 ref.) (Ita)
[Hepatic biloma] Watanabe H, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):106–8 (22 ref.) (Jpn)

ETIOLOGY

[Internal biliary fistula: study of 13 cases and review of the literature] Machado MA, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1995 Jan–Feb;50(1):45–8 (17 ref.) (Eng. Abstr.) (Por)

SURGERY

[Bronchobiliary fistula] Nishimura S, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Jun;34(6):689–93 (11 ref.) (Eng. Abstr.) (Jpn)

BILIARY SLUDGE see **BILE**

BILIARY STASIS see **CHOLESTASIS**

BILIARY STASIS, EXTRAHEPATIC see **BILE DUCT OBSTRUCTION, EXTRAHEPATIC**

BILIARY STASIS, INTRAHEPATIC see **CHOLESTASIS, INTRAHEPATIC**

BILIARY SURGERY see **BILIARY TRACT SURGERY**

BILIARY TRACT

see related
CHOLAGOGUES AND CHOLERETICS
CHOLANGIOGRAPHY

ABNORMALITIES

Choledocholithiasis in anomalous biliary system. Leung LC, et al. **Aust N Z J Surg** 1996 Jun;66(6):416–7 (5 ref.)

INJURIES

[Laparoscopic cholecystectomy causing injury to biliary tracts. Analysis of the results of 26,440 operations in Hungary] Ihász M, et al. **Orv Hetil** 1996 May 5;137(18):955–63 (29 ref.) (Eng. Abstr.) (Hun)

METABOLISM

Recent advances in carrier-mediated hepatic uptake and biliary excretion of xenobiotics. Yamazaki M, et al. **Pharm Res** 1996 Apr;13(4):497–513 (77 ref.)
[Kinetic analysis of hepatobiliary transport of drugs: importance of carrier-mediated transport] Yamazaki M, et al. **Yakugaku Zasshi** 1995 Dec;115(12):953–77 (101 ref.) (Eng. Abstr.) (Jpn)

PHYSIOPATHOLOGY

Liver and biliary tract changes and injury associated with total parenteral nutrition: pathogenesis and prevention. Briones ER, et al. **J Am Coll Nutr** 1995 Jun;14(3):219–28 (119 ref.)

BILIARY TRACT DISEASES

see related
CHOLANGIOGRAPHY
Biliary tract disease in children. McEvoy CF, et al. **Pediatr Clin North Am** 1996 Feb;43(1):75–98 (115 ref.)

COMPLICATIONS

Hepatobiliary pruritus: what are effective treatments? Connolly CS, et al. **J Am Acad Dermatol** 1995 Nov;33(5 Pt 1):801–5 (32 ref.)
[Liver, biliary tracts and human immunodeficiency virus infection. 2: hepatobiliary complications of AIDS] Vuitton DA, et al. **Gastroenterol Clin Biol** 1996;20(3):281–93 (146 ref.) (Fre)
[Diseases of the gallbladder and biliary tract in patients with AIDS] Regev A, et al. **Harefuah** 1996 Mar 1;130(5):330–2 (15 ref.) (Heb)
[Biliary peritonitis] Toyama K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):496–9 (15 ref.) (Jpn)

CONGENITAL

Neonatal hepatobiliary disorders. Andres JM. **Clin Perinatol** 1996 Jun;23(2):321–52 (172 ref.)

DIAGNOSIS

Motility of Oddi's sphincter: recent developments and clinical applications. Coelho JC, et al. **Am J Surg** 1996 Jul;172(1):48–51 (34 ref.)
[Endoscopic manometry in suspected dysfunction of the sphincter of Oddi] Wehrmann T, et al. **Dtsch Med Wochenschr** 1996 Apr 19;121(16):509–16 (30 ref.) (Eng. Abstr.) (Ger)

ETIOLOGY

Hepatobiliary complications of inflammatory bowel disease. Bhutani MS, et al. **Am Fam Physician** 1995 Oct;52(5):1440–4 (19 ref.)
Endoscopic diagnosis and management of biliary complications following orthotopic liver transplantation. Gholson CF, et al. **Dig Dis Sci** 1996 Jun;41(6):1045–53 (49 ref.)
Managing HIV. Part 5: Treating secondary outcomes. 5.3 HIV, gastrointestinal and hepatobiliary disease. Sievert W, et al. **Med J Aust** 1996 Mar 18;164(6):360–5 (25 ref.)
Peritonitis biliaris: some aspects of its origin. Vomela J, et al. **Rocz Akad Med Bialymst** 1995;40(1):58–64 (24 ref.)

PATHOLOGY

[Non-neoplastic diseases of the intrahepatic biliary tracts in adults] Zafrani ES, et al. **Ann Pathol** 1995;15(5):348–56 (56 ref.) (Fre)

PREVENTION & CONTROL

[Antibiotic prophylaxis and endoscopic retrograde cholangiopancreatography] Le Dreau G, et al. **Gastroenterol Clin Biol** 1996 Feb;20(1):55–63 (100 ref.) (Fre)

SURGERY

Liver, biliary tract, and pancreas [editorial] Rikkers LF, et al. **Curr Opin Gen Surg** 1993;:233–8 (16 ref.)
[The role of emergency therapeutic endoscopic retrograde

cholangiopancreatography in acute biliary pancreatitis] Moreira Vicente V, et al. **Rev Clin Esp** 1995 Sep; 195(9):645–8 (56 ref.) **(Spa)**

THERAPY

[1995 gastroenterology update—II] Layer P, et al. **Med Klin** 1996 Apr 1;91 Suppl 1:81–8 (88 ref.) **(Ger)**

BILIARY TRACT HEMORRHAGE see HEMOBILIA

BILIARY TRACT NEOPLASMS

[Carcinoma of the biliary tract] Yoshikawa T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):519–23 (22 ref.) **(Jpn)**

DRUG THERAPY

Cancers of the large bowel and hepatobiliary tract. Vaughn DJ, et al. **Cancer Chemother Biol Response Modif** 1996; 16:495–510 (63 ref.)

SURGERY

Liver transplantation for primary liver cancer. Ringe B, et al. **Transplant Proc** 1996 Jun;28(3):1174–5 (10 ref.)

[Biliary and esophageal self–expandable stents] Dumas R, et al. **Gastroenterol Clin Biol** 1996;20(5 Pt 2):B145–51 (84 ref.) **(Fre)**

[Surgical treatment of biliary tract neoplasm] Chijiiwa K. **Fukuoka Igaku Zasshi** 1996 Mar;87(3):61–5 (4 ref.) **(Jpn)**

THERAPY

Update on regional treatments for hepatobiliary malignancies. Curley SA. **Gan To Kagaku Ryoho** 1995 Sep;22(11):1437–52 (23 ref.)

[1995 gastroenterology update—II] Layer P, et al. **Med Klin** 1996 Apr 1;91 Suppl 1:81–8 (88 ref.) **(Ger)**

ULTRASONOGRAPHY

[Ultrasonic laparoscopy in digestive diseases] Catheline JM, et al. **Ann Chir** 1996;50(1):51–7 (30 ref.) (Eng. Abstr.) **(Fre)**

BILIARY TRACT SURGERY

METHODS

Is local excision of pT1–ampullary carcinomas justified? Klein P, et al. **Eur J Surg Oncol** 1996 Aug;22(4):366–71 (24 ref.)

Benign biliary strictures: repair and outcome with a contemporary approach. McDonald ML, et al. **Surgery** 1995 Oct;118(4):582–90; discussion 590–1 (21 ref.)

[Is there still a place for biliointestinal bypass in the treatment of super obesity? (editorial)] Benhamou G, et al. **G Chir** 1996 Apr;17(4):149–53 (16 ref.) **(Ita)**

TRENDS

What's new in gastrointestinal and hepatobiliary surgery. Meyers WC. **J Am Coll Surg** 1996 Feb;182(2):100–6 (52 ref.)

BILIRUBIN

see related
HYPERBILIRUBINEMIA

ANALYSIS

[Bilirubin] Kawasaki H. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:865–8 (12 ref.) **(Jpn)**

[Rare gallstone (calcium carbonate calculus)] Goto K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):418–20 (11 ref.) **(Jpn)**

METABOLISM

Protein–mediated facilitated uptake processes for fatty acids, bilirubin, and other amphipathic compounds [see comments] Fitscher BA, et al. **Proc Soc Exp Biol Med** 1996 May;212(1):15–23 (99 ref.) Comment in: Proc Soc Exp Biol Med 1996 May;212(1):1–4.

[Dipyrrole bile pigments] Yamaguchi T, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:895–8 (9 ref.) **(Jpn)**

[Pigment stone (black stones, calcium bilirubinate stones)] Ise H, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):404–7 (18 ref.) **(Jpn)**

URINE

[Urinary bilirubin] Adachi Y, et al. **Nippon Rinsho** 1995 Feb; 53 Su Pt 1:144–6 (9 ref.) **(Jpn)**

BILIRUBINEMIA see HYPERBILIRUBINEMIA

BILIVERDINE

BLOOD

[Biliverdin] Yamaguchi T, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:869–70 (7 ref.) **(Jpn)**

BINDING PROTEINS see CARRIER PROTEINS

BINDING SITES

see related
PROTEIN BINDING
RECEPTORS, CELL SURFACE

[Second messenger–mediated transcriptional regulation of neural genes and possible drug action sites] Higuchi H, et al. **Nippon Yakurigaku Zasshi** 1995 Dec;106(6):365–78 (50 ref.) (Eng. Abstr.) **(Jpn)**

BINDING SITES, ANTIBODY

see related
ANTIBODY AFFINITY

Interactions of protein antigens with antibodies. Davies DR, et al. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):7–12 (69 ref.)

The structure of the antigen–binding site of immunoglobulins and T–cell receptors. Bentley GA, et al. **Res Immunol** 1995 May–Jun;146(4–5):277–90 (27 ref.)

Model building of antibody combining sites. Bajorath J, et al. **Ther Immunol** 1995 Apr;2(2):95–103 (104 ref.)

BINOCULAR VISION see VISION, BINOCULAR

BIOASSAY see BIOLOGICAL ASSAY

BIOAVAILABILITY see BIOLOGICAL AVAILABILITY

BIOCHEMICAL MARKERS see BIOLOGICAL MARKERS

BIOCHEMISTRY

Synthetic peptides in biochemical research. Hancock DC, et al. **Mol Biotechnol** 1995 Aug;4(1):73–86 (104 ref.)

[From the Smart alpha 2–macroglobulin to single molecule biochemistry] Ikai A. **Seikagaku** 1996 Mar;68(3):179–95 (47 ref.) **(Jpn)**

[Affinity electrophoresis—its application for studies on heterogeneity and functions of biomolecules] Nakamura K. **Seikagaku** 1996 Apr;68(4):265–81 (57 ref.) **(Jpn)**

EDUCATION

The use of computers in the teaching of biochemistry: support for learning the qualitative differences. McAleese R. **Biochem Soc Trans** 1996 Feb;24(1):293–7 (19 ref.)

BIOCOMPATIBLE MATERIALS

Toxic epidermal necrolysis: a review and report of the successful use of Biobrane for early wound coverage. Bradley T, et al. **Ann Plast Surg** 1995 Aug;35(2):124–32 (45 ref.)

The use of expanded polytetrafluoroethylene (Gore–Tex) in rhinoplasty. A 6–year experience. Godin MS, et al. **Arch Otolaryngol Head Neck Surg** 1995 Oct;121(10):1131–6 (20 ref.)

Blood–contacting biomaterials: bioengineering viewpoints. Courtney JM, et al. **Artif Organs** 1995 Aug;19(8):852–6 (31 ref.)

Biodegradable polymers for protein and peptide drug delivery. Gombotz WR, et al. **Bioconjug Chem** 1995 Jul–Aug;6(4):332–51 (234 ref.)

Sterilization, toxicity, biocompatibility and clinical applications of polylactic acid/polyglycolic acid copolymers. Athanasiou KA, et al. **Biomaterials** 1996 Jan; 17(2):93–102 (100 ref.)

Role of material surfaces in regulating bone and cartilage cell response. Boyan BD, et al. **Biomaterials** 1996 Jan; 17(2):137–46 (94 ref.)

Surface modification of polymers: chemical, biological and surface analytical challenges. Ratner BD. **Biosens Bioelectron** 1995;10(9–10):797–804 (41 ref.)

Biocompatibility aspects of chronic hemodialysis and their clinical relevance. Wauters JP. **Clin Nephrol** 1995 Nov;44 Suppl 1:S19–23 (43 ref.)

Plastic surgery's plastics. Ousterhout DK, et al. **Clin Plast Surg** 1996 Jan;23(1):183–90 (46 ref.)

Applications of biodegradable lactides and glycolides in podiatry. Athanasiou KA, et al. **Clin Podiatr Med Surg** 1995 Jul;12(3):475–95 (90 ref.)

Future materials for foot surgery. Latour RA Jr. **Clin Podiatr Med Surg** 1995 Jul;12(3):519–44 (76 ref.)

Bioabsorbable polymers update: degradation mechanisms, safety, and application. Shalaby SW, et al. **J Appl Biomater** 1995 Fall;6(3):219–21 (28 ref.)

Objective and subjective observations of low–temperature thermoplastic materials. Lee DB. **J Hand Ther** 1995 Apr–Jun;8(2):138–43 (7 ref.)

Haemocompatibility of invasive sensors. Benmakroha Y, et al. **Med Biol Eng Comput** 1995 Nov;33(6):811–21 (155 ref.)

What is the ideal technique for testing the biocompatibility of peritoneal dialysis solutions? [editorial] Topley N. **Perit Dial Int** 1995 Jul–Sep;15(6):205–9 (29 ref.)

Is prosthetic valve thrombogenicity related to design or material? Edmunds LH Jr. **Tex Heart Inst J** 1996;23(1):24–7 (20 ref.)

Induction of soft connective tissue formation by various prosthetic implants. Oryan A. **Transplant Proc** 1995 Oct; 27(5):2754–5 (23 ref.)

[Materials for hip endoprostheses—alternatives to standard materials] Bosdorf K, et al. **Biomed Tech (Berl)** 1995 Dec; 40(12):356–62 (35 ref.) (Eng. Abstr.) **(Ger)**

[Pulmonary (side)effects of extracorporeal therapy procedures] Kolb G. **Wien Klin Wochenschr Suppl** 1996; 1:15–20 (42 ref.) **(Ger)**

[Activation of blood coagulation in extracorporeal circulation] Nowak G. **Wien Klin Wochenschr Suppl** 1996; 1:9–14 (28 ref.) **(Ger)**

[Clinical aspects of biocompatibility] Schiffl H, et al. **Wien Klin Wochenschr Suppl** 1996;1:4–8 (27 ref.) **(Ger)**

[Biocompatibility and extracorporeal circulation] Camici M. **Clin Ter** 1995 Nov;146(11):713–9 (30 ref.) (Eng. Abstr.) **(Ita)**

[Hybrid biomaterial] Emi N. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2514–8 (14 ref.) **(Jpn)**

[Use of irradiation technique for obtaining and modifying biopolymers. Review.] Lewandowska–Szumieł M, et al. **Polim Med** 1995;25(1–2):57–67 (35 ref.) (Eng. Abstr.) **(Pol)**

[Biomaterials and hernia surgery. Rationale for using them] Amid PK, et al. **Rev Esp Enferm Dig** 1995 Aug;87(8):582–6 (30 ref.) (Eng. Abstr.) **(Spa)**

ADMINISTRATION & DOSAGE

Rationale and treatment results with bioinjectables. Burney TL, et al. **J Endourol** 1996 Jun;10(3):273–7 (29 ref.)

ADVERSE EFFECTS

[Complications from silicone implants and other so–called inert materials] Faure M. **Ann Dermatol Venereol** 1995; 122(6–7):455–9 (54 ref.) **(Fre)**

CHEMISTRY

Characterization of hydrogels using nuclear magnetic resonance spectroscopy. Mathur AM, et al. **Biomaterials** 1996 Mar;17(6):547–57 (80 ref.)

METABOLISM

Breakdown of plastics and polymers by microorganisms. Kawai F. **Adv Biochem Eng Biotechnol** 1995;52:151–94 (190 ref.)

New methods for the investigation of blood–biomaterial interaction. Schütt W, et al. **Artif Organs** 1995 Aug; 19(8):847–51 (32 ref.)

Membranes for dialysis. Klinkmann H, et al. **Nephrol Dial Transplant** 1995;10 Suppl 3:39–45 (43 ref.)

STANDARDS

Small particles in medicine [editorial] Falkenhagen D. **Artif Organs** 1995 Aug;19(8):792–4 (32 ref.)

Biomaterials for rotary blood pumps. van Oeveren W. **Artif Organs** 1995 Jul;19(7):603–7 (25 ref.)

Hastings lecture. Breaking the blood–biomaterial barrier. Edmunds LH Jr. **ASAIO J** 1995 Oct–Dec;41(4):824–30 (52 ref.)

Corrosion and other electrochemical aspects of biomaterials. Bundy KJ. **Crit Rev Biomed Eng** 1994;22(3–4):139–251 (1712 ref.)

Biocompatibility: is it a relevant consideration for today's haemodialysis? [editorial] Shaldon S, et al. **Int J Artif Organs** 1996 Apr;19(4):201–14 (105 ref.)

Biocompatibility and immunology in the encapsulation of islets of Langerhans (bioartificial pancreas). Zekorn TD, et al. **Int J Artif Organs** 1996 Apr;19(4):251–7 (34 ref.)

THERAPEUTIC USE

Role of polymers in improving the results of stenting in coronary arteries. Peng T, et al. **Biomaterials** 1996 Apr; 17(7):685–94 (90 ref.)

[The use of hydroxyapatite for the surgical preparation of the oral cavity for prosthesis] Zuev VP, et al. **Stomatologiia (Mosk)** 1996;75(1):71–4 (69 ref.) **(Rus)**

BIOCOMPATIBLE MATERIALS TESTING see MATERIALS TESTING

BIOCONTROL see PEST CONTROL, BIOLOGICAL

BIODEGRADATION

Cytochrome P450 proteins and potential utilization in biodegradation. Guengerich FP. **Environ Health Perspect** 1995 Jun;103 Suppl 5:25–8 (27 ref.)

Field evaluations of marine oil spill bioremediation. Swannell RP, et al. **Microbiol Rev** 1996 Jun;60(2):342–65 (121 ref.)

Impact of biodegradation test methods on the development and applicability of biodegradation QSARs. Cowan CE, et al. **SAR QSAR Environ Res** 1996;5(1):37–49 (20 ref.)

A mechanistic approach to deriving quantitative structure–activity relationship models for microbial degradation of organic compounds. Damborský J. **SAR QSAR Environ Res** 1996;5(1):27–36 (57 ref.)

Descriptors and techniques for quantitative structure–biodegradability studies. Dearden JC. **SAR QSAR Environ Res** 1996;5(1):17–26 (40 ref.)

BIODIVERSITY see ECOSYSTEM

BIOELECTRICAL IMPEDANCE see ELECTRIC IMPEDANCE

BIOENERGETICS

BIOENERGETICS see **ENERGY METABOLISM**

BIOETHICS

Ethical, social and counselling issues in hereditary cancer susceptibility. Garber JE, et al. **Cancer Surv** 1995;25:381–97 (54 ref.)

Legal trends in bioethics. Davis D. **J Clin Ethics** 1995 Fall; 6(3):285–8 (12 ref.)

The Human Genome Project: an overview of ethical issues and public policy concerns. Ott BB. **Nurs Outlook** 1995 Sep–Oct;43(5):228–31 (13 ref.)

Ethical and legal aspects, and the history of organ transplantation in Turkey. Haberal M, et al. **Transplant Proc** 1996 Feb;28(1):382–3 (12 ref.)

Ethical issues in living related donor liver transplantation. Strong RW, et al. **Transplant Proc** 1996 Aug;28(4):2366–9 (21 ref.)

Ethical concerns in the research and treatment of complex disease. Parker LS. **Trends Genet** 1995 Dec;11(12):520–3 (40 ref.)

[Why bioethics today?] Figueroa G. **Rev Med Chil** 1995 Jun; 123(6):777–84 (26 ref.) (Eng. Abstr.) **(Spa)**

BIOFEEDBACK (PSYCHOLOGY)

Biofeedback training in children with functional constipation. A critical review. Loening-Baucke V. **Dig Dis Sci** 1996 Jan;41(1):65–71 (31 ref.)

Human EEG, behavioral stillness and biofeedback. Mulholland T. **Int J Psychophysiol** 1995 Apr;19(3):263–79 (107 ref.)

BIOFILMS

see related
BACTERIAL ADHESION
PROSTHESIS–RELATED INFECTIONS

Microbial biofilms. Costerton JW, et al. **Annu Rev Microbiol** 1995;49:711–45 (127 ref.)

Biofilm infections: implications for diagnosis and treatment. Reid G, et al. **N Z Med J** 1996 Feb 23;109(1016):41–2 (17 ref.)

DRUG EFFECTS

Susceptibility of oral bacterial biofilms to antimicrobial agents. Wilson M. **J Med Microbiol** 1996 Feb;44(2):79–87 (54 ref.)

GROWTH & DEVELOPMENT

Biofilm and the dental office. Shearer BG. **J Am Dent Assoc** 1996 Feb;127(2):181–9 (49 ref.)

BIOFILTRATION, ACETATE–FREE see **HEMODIAFILTRATION**

BIOFLAVONOIDS

PHARMACOLOGY

Review of the biology of Quercetin and related bioflavonoids. Formica JV, et al. **Food Chem Toxicol** 1995 Dec;33(12):1061–80 (210 ref.)

THERAPEUTIC USE

Cellular basis of inflammation, edema and the activity of Daflon 500 mg. Friesenecker B, et al. **Int J Microcirc Clin Exp** 1995;15 Suppl 1:17–21 (44 ref.)

[Role of glycosoaminoglycans in venous disease. Mode of action of some flavonoid drugs] Drubaix I, et al. **Pathol Biol (Paris)** 1995 May;43(5):461–70 (37 ref.) (Eng. Abstr.) **(Fre)**

BIOGENESIS

The origin and early evolution of life: prebiotic chemistry, the pre–RNA world, and time. Lazcano A, et al. **Cell** 1996 Jun 14;85(6):793–8 (53 ref.)

Origin of genetic code: A needle in the haystack of tRNA sequences. Schimmel P. **Proc Natl Acad Sci U S A** 1996 May 14;93(10):4521–2 (17 ref.)

BIOGENIC AMINE NEUROTRANSMITTERS

see related
RECEPTORS, BIOGENIC AMINE

METABOLISM

Voltammetric and microdialysis monitoring of brain monoamine neurotransmitter release during sociosexual interactions. Mas M, et al. **Behav Brain Res** 1995 Nov; 71(1–2):69–79 (62 ref.)

BIOGENIC AMINE RECEPTORS see **RECEPTORS, BIOGENIC AMINE**

BIOGENIC AMINES

see related
BIOGENIC AMINE NEUROTRANSMITTERS
RECEPTORS, BIOGENIC AMINE

Biogenic amines: their importance in foods. Silla Santos MH. **Int J Food Microbiol** 1996 Apr;29(2–3):213–31 (140 ref.)

ANALYSIS

Biogenic amines in fish and shellfish. Rawles DD, et al. **Adv Food Nutr Res** 1996;39:329–65 (147 ref.)

ISOLATION & PURIFICATION

[Biogenic amines in food] Crahay F, et al. **Rev Med Liege** 1996 Jul;51(7):479–84 (23 ref.) **(Fre)**

METABOLISM

Monoamine neurotransmitters in invertebrates and vertebrates: an examination of the diverse enzymatic pathways utilized to synthesize and inactivate biogenic amines. Sloley BD, et al. **Int Rev Neurobiol** 1995;38:253–303 (490 ref.)

Role of aldehyde oxidase in biogenic amine metabolism. Beedham C, et al. **Prog Brain Res** 1995;106:345–53 (52 ref.)

Monoamines, cytoskeletal elements and psychiatric disorders: a neurochemical fugue. Harris J, et al. **Prog Brain Res** 1995; 106:241–8 (54 ref.)

PHYSIOLOGY

Adrenergic receptors and fat cells: differential recruitment by physiological amines and homologous regulation. Lafontan M, et al. **Obes Res** 1995 Nov;3 Suppl 4:507S–514S (56 ref.)

[Role of biogenic amines (catecholamines, histamine, serotonin, etc.) in food intake] Tsujii S. **Nippon Rinsho** 1995 Jun;53 Suppl:33–9 (20 ref.) **(Jpn)**

BIOGENIC MONOAMINES

BIOSYNTHESIS

Exercise and brain neurotransmission. Meeusen R, et al. **Sports Med** 1995 Sep;20(3):160–88 (117 ref.)

PHYSIOLOGY

Monoamine modulation of the synaptic inhibition in the hippocampus. Bijak M. **Acta Neurobiol Exp (Warsz)** 1996; 56(1):385–95 (45 ref.)

BIOGENIC POLYAMINES

METABOLISM

Polyamines in brain tumor therapy. Redgate ES, et al. **J Neurooncol** 1995;25(2):167–79 (76 ref.)

[Polyamine transport in Escherichia coli and Eukaryotic cells] Kashiwagi K. **Yakugaku Zasshi** 1996 Mar; 116(3):175–91 (40 ref.) (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

Aminoglycosides and polyamines: targets and effects in the mammalian organism of two important groups of natural aliphatic polycations. Seiler N, et al. **Prog Drug Res** 1996; 46:183–241 (610 ref.)

Modulation of channel function by polyamines. Johnson TD. **Trends Pharmacol Sci** 1996 Jan;17(1):22–7 (52 ref.)

PHYSIOLOGY

Modulation of channel function by polyamines. Johnson TD. **Trends Pharmacol Sci** 1996 Jan;17(1):22–7 (52 ref.)

BIOHAZARDS CONTAINMENT see **CONTAINMENT OF BIOHAZARDS**

BIOINORGANIC CHEMISTRY see **CHEMISTRY, BIOINORGANIC**

BIOLOGICAL ASSAY

Radiation therapy tolerance limits. For one or for all?—Janeway Lecture. Peters LJ. **Cancer** 1996 Jun 1; 77(11):2379–85 (39 ref.)

Cytokines and cytokine measurements in a clinical laboratory. Whiteside TL. **Clin Diagn Lab Immunol** 1994 May; 1(3):257–60 (24 ref.)

Risk estimation—an overview: disease risk estimation based upon animal bioassays. Gaylor DW. **Drug Metab Rev** 1996 Feb–May;28(1–2):9–27 (39 ref.)

METHODS

Medium–term liver and multi–organ carcinogenesis bioassays for carcinogens and chemopreventive agents. Ito N, et al. **Exp Toxicol Pathol** 1996 Feb;48(2–3):113–9 (40 ref.)

STANDARDS

Bioassay designs for validating biologically based mathematical models of carcinogenesis for risk assessment. Kodell RL. **Drug Metab Rev** 1996 Feb–May;28(1–2):219–23 (6 ref.)

Reducing uncertainty in risk assessment by using specific knowledge to replace default options. McClellan RO. **Drug Metab Rev** 1996 Feb–May;28(1–2):149–79 (64 ref.)

BIOLOGICAL AVAILABILITY

[Studies on development of pharmaceutical preparation with the purpose of improving controlled–release and bioavailability] Goto S. **Yakugaku Zasshi** 1995 Nov; 115(11):871–91 (26 ref.) (Eng. Abstr.) **(Jpn)**

BIOLOGICAL AVAILABILITY, NUTRITIONAL see **NUTRITIVE VALUE**

BIOLOGICAL CLOCKS

see related
CIRCADIAN RHYTHM

New computational models of the respiratory oscillator in mammals. Smith JC. **Adv Exp Med Biol** 1995;393:7–13 (10 ref.)

[Shift work systems from the chronobiological viewpoint] Knauth P. **Wien Med Wochenschr** 1995;145(17–18):406–10 (31 ref.) (Eng. Abstr.) **(Ger)**

[Disorders of the circadian sleep–wake rhythm—diagnostic and therapeutic principles] Mayer G, et al. **Wien Med Wochenschr** 1995;145(17–18):423–30 (38 ref.) (Eng. Abstr.) **(Ger)**

[Molecular analysis of biological clocks] Fukada Y, et al. **Seikagaku** 1995 Sep;67(9):1137–42 (15 ref.) **(Jpn)**

DRUG EFFECTS

[Depression, antidepressants and the biological clock] Arushanian EB, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995;95(3):85–9 (71 ref.) **(Rus)**

GENETICS

Molecular biological approach to the circadian clock mechanism. Ishida N. **Neurosci Res** 1995 Oct;23(3):231–40 (96 ref.)

PHYSIOLOGY

New models in vogue for circadian clocks. Kay SA, et al. **Cell** 1995 Nov 3;83(3):361–4 (20 ref.)

A case for interstitial cells of Cajal as pacemakers and mediators of neurotransmission in the gastrointestinal tract. Sanders KM. **Gastroenterology** 1996 Aug;111(2):492–515 (154 ref.)

[Concepts and models of sleep regulation] Achermann P, et al. **Wien Med Wochenschr** 1995;145(17–18):402–6 (40 ref.) (Eng. Abstr.) **(Ger)**

[Interaction of epileptic seizures and biological rhythms] Büilau P, et al. **Wien Med Wochenschr** 1995; 145(17–18):448–51 (37 ref.) (Eng. Abstr.) **(Ger)**

[Chronobiology of depression] Giedke H. **Wien Med Wochenschr** 1995;145(17–18):411–8 (108 ref.) (Eng. Abstr.) **(Ger)**

[Chronobiology and chronopharmacology of cardiovascular diseases] Lemmer B. **Wien Med Wochenschr** 1995; 145(17–18):445–7 (29 ref.) (Eng. Abstr.) **(Ger)**

[Chronobiological health of the circadian system: examples for disorders of the sleep–waking rhythm] Moog R. **Wien Med Wochenschr** 1995;145(17–18):452–3 (18 ref.) (Eng. Abstr.) **(Ger)**

[Chronobiological viewpoints of respiratory regulation] Raschke F. **Wien Med Wochenschr** 1995;145(17–18):435–9 (16 ref.) (Eng. Abstr.) **(Ger)**

[Cellular mechanisms of circadian clocks] Roenneberg T, et al. **Wien Med Wochenschr** 1995;145(17–18):385–9 (74 ref.) (Eng. Abstr.) **(Ger)**

[Pulsatile hormone secretion for control of target organs] Schöfl C, et al. **Wien Med Wochenschr** 1995; 145(17–18):431–5 (23 ref.) (Eng. Abstr.) **(Ger)**

[Role of signal transduction mechanisms in light–induced entrainment of biological clocks] Shibata S. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(16):2408–17 (46 ref.) **(Jpn)**

BIOLOGICAL DRESSINGS

[Dura–plasty in intracranial operations] Ernestus RI, et al. **Zentralbl Neurochir** 1995;56(3):106–10 (20 ref.) (Eng. Abstr.) **(Ger)**

BIOLOGICAL FACTORS

ADVERSE EFFECTS

Viral iatrogenic contamination and safety of biologicals. Horaud F. **Blood Coagul Fibrinolysis** 1995 Jul;6 Suppl 2:S5–9 (21 ref.)

CHEMISTRY

Marine natural products. Faulkner DJ. **Nat Prod Rep** 1996 Apr;13(2):75–125 (549 ref.)

GENETICS

The azoospermia factor (AZF) of the human Y chromosome in Yq11: function and analysis in spermatogenesis. Vogt

PH, et al. **Reprod Fertil Dev** 1995;7(4):685–93 (56 ref.)

PHARMACOLOGY

Antimitotic natural products and their interactions with tubulin. Hamel E. **Med Res Rev** 1996 Mar;16(2):207–31 (143 ref.)

PHYSIOLOGY

Endothelium-dependent hyperpolarization. Beyond nitric oxide and cyclic GMP. Cohen RA, et al. **Circulation** 1995 Dec 1;92(11):3337–49 (211 ref.)

Paracrine functions of the coronary vascular endothelium. Fleming I, et al. **Mol Cell Biochem** 1996 Apr 12–26; 157(1–2):137–45 (49 ref.)

The role of nitric oxide and other endothelium-derived vasoactive substances in vascular disease. Cohen RA. **Prog Cardiovasc Dis** 1995 Sep–Oct;38(2):105–28 (294 ref.)

[Relation between the parathyroid glands and arterial pressure: is there a parathyroid hypertensive factor?] Barlet JP, et al. **Presse Med** 1995 Nov 25;24(36):1703–6 (25 ref.) (Eng. Abstr.) **(Fre)**

[Bioactive substances in the regulation of vitreoretinal proliferation] Balashova LM. **Vestn Oftalmol** 1995 Jul–Sep; 111(3):31–3 (57 ref.) **(Rus)**

BIOLOGICAL MARKERS

see related

MOLECULAR PROBES

The case for cardiac troponin T: marker for effective risk stratification of patients with acute cardiac ischemia. Alonsozana GL, et al. **Clin Chem** 1996 May;42(5):803–8 (51 ref.)

Significance of individual sensitivity to chemicals: elucidation of host susceptibility by use of biomarkers in environmental health research. Cullen MR, et al. **Clin Chem** 1995 Dec; 41(12 Pt 2):1809–13 (21 ref.)

Assessment of immunotoxic effects in humans. Descotes J, et al. **Clin Chem** 1995 Dec;41(12 Pt 2):1870–3 (36 ref.)

Biomarkers in epidemiology. Grandjean P. **Clin Chem** 1995 Dec;41(12 Pt 2):1800–3 (13 ref.)

Biomarkers as tools in human health risk assessment. Greim H, et al. **Clin Chem** 1995 Dec;41(12 Pt 2):1804–8 (13 ref.)

Lipid peroxidation and antioxidants as biomarkers of tissue damage. Gutteridge JM. **Clin Chem** 1995 Dec;41(12 Pt 2):1819–28 (56 ref.)

Induced gene transcription: implications for biomarkers. Sewall CH, et al. **Clin Chem** 1995 Dec;41(12 Pt 2):1829–34 (59 ref.)

Markers of activated coagulation and their usefulness in the clinical laboratory. Tripodi A, et al. **Clin Chem** 1996 May; 42(5):664–9 (55 ref.)

Biochemical markers of joint damage: is there any hope? Wollheim FA. **Clin Exp Rheumatol** 1995 Sep–Oct;13 Suppl 12:S3–5 (21 ref.)

Biomarker research in neurotoxicology: the role of mechanistic studies to bridge the gap between the laboratory and epidemiological investigations. Costa LG. **Environ Health Perspect** 1996 Mar;104 Suppl 1:55–67 (187 ref.)

Consensus statement. Scientific Advisory Committee on Surrogate Markers of HIV. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995;10 Suppl 2:S114–6 (0 ref.)

Evaluating surrogate markers. Hughes MD, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995;10 Suppl 2:S1–8 (22 ref.)

Individualization of therapy using viral markers. Merigan T. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995;10 Suppl 1:S41–6 (28 ref.)

Causal thinking, biomarkers, and mechanisms of carcinogenesis. Vineis P, et al. **J Clin Epidemiol** 1996 Sep; 49(9):951–6 (44 ref.)

Cancer risks and biomarker studies in the atomic bomb survivors. Preston D. **Stem Cells (Dayt)** 1995 May;13 Suppl 1:40–8 (24 ref.)

Biomarkers for low-level exposure causing epigenetic responses in stem cells. Trosko JE. **Stem Cells (Dayt)** 1995 May;13 Suppl 1:231–9 (90 ref.)

Biologic indicators of exposure: are markers associated with oncogenesis useful as biologic markers of effect? Ziegler BL, et al. **Stem Cells (Dayt)** 1995 May;13 Suppl 1:326–38 (151 ref.)

[Usefulness of biological markers in pleural effusion] Díez J de M, et al. **Rev Clin Esp** 1996 Feb;196(2):107–12 (73 ref.) **(Spa)**

ANALYSIS

Biochemical markers of bone turnover. Delmas PD. **Acta Orthop Scand Suppl** 1995 Oct;266:176–82 (70 ref.)

Validating markers in osteoarthritis. Felson DT. **Acta Orthop Scand Suppl** 1995 Oct;266:205–7 (1 ref.)

The role of molecular markers to monitor disease, intervention and cartilage breakdown in osteoarthritis. Lohmander LS, et al. **Acta Orthop Scand Suppl** 1995 Oct; 266:84–7 (32 ref.)

Role of biochemical markers in assessment of osteoporosis. Riggs BL, et al. **Acta Orthop Scand Suppl** 1995 Oct; 266:14–8 (24 ref.)

Molecular epidemiology: issues in study design and statistical analysis. Chia KS, et al. **Ann Acad Med Singapore** 1996 Jan;25(1):55–63 (46 ref.)

Positive and negative selection events during B lymphopoiesis. Melchers F, et al. **Curr Opin Immunol** 1995 Apr;7(2):214–27 (119 ref.)

Biomarkers and pediatric environmental health. Lubin B, et al. **Environ Health Perspect** 1995 Sep;103 Suppl 6:99–104 (25 ref.)

Application of biologic markers to studies of environmental risks in children and the developing fetus. Whyatt RM, et al. **Environ Health Perspect** 1995 Sep;103 Suppl 6:105–10 (66 ref.)

Detection of hepatic fibrogenesis: a review of available techniques. Wu J, et al. **Scand J Gastroenterol** 1995 Sep; 30(9):817–25 (78 ref.)

The study of interactive effects of pollutants: a biomarker approach. Johnston G. **Sci Total Environ** 1995 Oct 27; 171(1–3):205–12 (18 ref.)

Immunologic and biologic markers for silicone. Vojdani A, et al. **Toxicol Ind Health** 1994 Jan–Apr;10(1–2):25–42 (92 ref.)

Development and application of non-invasive biomarkers for carcinogen-DNA adduct analysis in occupationally exposed populations. Talaska G, et al. **Toxicology** 1996 Jul 17;111(1–3):207–12 (17 ref.)

[P-methylmalonate and P-homocysteine: metabolic markers of vitamin deficiencies. Background, validity and applications] Rasmussen K. **Ugeskr Laeger** 1996 Jul 1; 158(27):3913–8 (40 ref.) (Eng. Abstr.) **(Dan)**

[Sero-epidemiologic study of Epstein-Barr virus markers in patients without mononucleosis at a department for infectious diseases] Ternák G, et al. **Orv Hetil** 1995 Dec 10;136(50):2727–30 (38 ref.) (Eng. Abstr.) **(Hun)**

[Reference values in biological monitoring of occupational exposure to mutagens and carcinogens] Clonfero E, et al. **G Ital Med Lav** 1994 Jan–Nov;16(1–6):25–9 (43 ref.) (Eng. Abstr.) **(Ita)**

[Hepatitis B virus-specific DNA polymerase activity as a sensitive marker of viral replication] Matsuura K, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:275–83 (19 ref.) **(Jpn)**

[Immunological markers for early diagnosis and foresight of HBV- related fulminant hepatitis] Onji M. **Nippon Rinsho** 1995 Oct;53 Suppl:498–501 (13 ref.) **(Jpn)**

[Hepatitis A virus marker] Yotsuyanagi H, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:828–31 (7 ref.) **(Jpn)**

BLOOD

Use of biomarkers to investigate occupational and environmental lung disorders. Schulte PA. **Chest** 1996 Mar; 109(3 Suppl):9S–12S (26 ref.)

Biological markers and risk assessment. Goldstein BD. **Drug Metab Rev** 1996 Feb–May;28(1–2):225–33 (12 ref.)

Maternal serum markers for fetal trisomy 21 screening. Muller F, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Mar;65(1):3–6 (30 ref.)

Non-invasive circulating indicators of bone metabolism in uraemic patients: can they replace bone biopsy? [editorial] Schmidt-Gayk H, et al. **Nephrol Dial Transplant** 1996 Mar; 11(3):415–8 (8 ref.)

First trimester serum screening for Down's syndrome [see comments] Wald NJ, et al. **Prenat Diagn** 1995 Dec; 15(13):1227–40 (44 ref.) Comment in: Prenat Diagn 1995 Dec;15(3):1209–13.

[Contribution of the hemostasis laboratory in the diagnosis of deep venous thrombosis] Demarmels Biasiutti F, et al. **Ther Umsch** 1996 Apr;53(4):265–71 (24 ref.) (Eng. Abstr.) **(Ger)**

[Troponin T] Nishimura H, et al. **Nippon Rinsho** 1995 Feb; 53 Su Pt 1:246–7 (4 ref.) **(Jpn)**

[Blood markers in the prenatal diagnosis of Down's syndrome: the triple test] Ortega-Benito JM. **Med Clin (Barc)** 1995 Sep 9;105(7):264–8 (32 ref.) **(Spa)**

CHEMISTRY

[Biological markers of precancer of the large intestine] Zagrebin VM. **Arkh Patol** 1995 Jul–Aug;57(4):89–92 (50 ref.) (Eng. Abstr.) **(Rus)**

URINE

[Biochemical markers of bone turnover in urine--pyridinoline, deoxypyridinoline and aminoterminal cross-links of type I collagen] Hayashi Y. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:523–6 (7 ref.) **(Jpn)**

BIOLOGICAL MONITORING see **ENVIRONMENTAL MONITORING**

BIOLOGICAL OSCILLATORS see **BIOLOGICAL CLOCKS**

BIOLOGICAL PEST CONTROL see **PEST CONTROL, BIOLOGICAL**

BIOLOGICAL PRODUCTS

Risk analysis in the manufacture of veterinary biologicals. Moreau Y. **Rev Sci Tech** 1995 Dec;14(4):937–50 (10 ref.)

Risk analysis systems for veterinary biologicals: a regulator's tool box. Osborne CG, et al. **Rev Sci Tech** 1995 Dec; 14(4):925–35 (8 ref.)

[Radiation-protective action of microbial substances] Andrushchenko VN, et al. **Radiats Biol Radioecol** 1996 Mar–Apr;36(2):195–208 (95 ref.) (Eng. Abstr.) **(Rus)**

[Immunobiological preparations: their present and future] Vorob'ev AA, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1995 Nov–Dec; (6):105–11 (22 ref.) **(Rus)**

ADVERSE EFFECTS

DNA, dragons and sanity. Petricciani JC, et al. **Biologicals** 1995 Sep;23(3):233–8 (26 ref.)

Risk assessment related to veterinary biologicals: side-effects in target animals. Martinod S. **Rev Sci Tech** 1995 Dec; 14(4):979–89 (48 ref.)

Risk assessment related to veterinary biologicals: specific issues in developing nations. Ward DE. **Rev Sci Tech** 1995 Dec;14(4):991–1007 (35 ref.)

ECONOMICS

OMERACT II: the biologics perspective. Strand V. **J Rheumatol** 1995 Jul;22(7):1415–7 (24 ref.)

PHARMACOLOGY

Anticarcinogenic, hypocholesterolemic, and antagonistic activities of Lactobacillus acidophilus. Mital BK, et al. **Crit Rev Microbiol** 1995;21(3):175–214 (371 ref.)

The three Rs of Russell & Burch and the testing of biological products. Balls M, et al. **Dev Biol Stand** 1996;86:11–8 (13 ref.)

STANDARDS

The safety and hazards of blood-derived drugs. Grabenstein JD. **Am J Health Syst Pharm** 1995 Nov 1;52(21):2448–52 (27 ref.)

Criteria for investigation of the product equivalence of monoclonal antibodies for therapeutic and in vivo-diagnostic use in case of introduction of changes in the manufacturing process. Schäffner G, et al. **Biologicals** 1995 Sep;23(3):253–9 (32 ref.)

The role of international and regional organisations in the regulation of veterinary biologicals. Blancou J, et al. **Rev Sci Tech** 1995 Dec;14(4):1193–206 (11 ref.)

Registration of veterinary products in Argentina. Butler E, et al. **Rev Sci Tech** 1995 Dec;14(4):1121–31 (4 ref.) **(Eng, Spa)**

Present systems and future needs for risk assessment of veterinary biologicals in Australia: the perspective of the regulator. Doyle KA. **Rev Sci Tech** 1995 Dec;14(4):1157–70 (16 ref.)

Models used in Australia in risk assessments for veterinary biologicals. Doyle KA. **Rev Sci Tech** 1995 Dec; 14(4):1021–42 (27 ref.)

Present systems and future needs for risk assessment of biologicals in the United States of America: the perspective of the regulator. Espeseth DA. **Rev Sci Tech** 1995 Dec; 14(4):1143–55 (3 ref.)

Application of risk assessment to veterinary biologicals: the perspective of the animal health industry. Folkers C, et al. **Rev Sci Tech** 1995 Dec;14(4):1207–16 (5 ref.)

Biologicals: test procedures available to assess components and products, with limitations. Lee AM. **Rev Sci Tech** 1995 Dec;14(4):1073–82 (11 ref.)

Models of risk assessments for biologicals or related products in the European Union. Moos M. **Rev Sci Tech** 1995 Dec; 14(4):1009–20 (6 ref.)

Risk analysis methods and techniques for veterinary biologicals used in Australia. Owusu J. **Rev Sci Tech** 1995 Dec;14(4):1083–96 (9 ref.)

Risk analysis for the importation of veterinary biologicals into the United States of America. Roth HJ, et al. **Rev Sci Tech** 1995 Dec;14(4):1061–72 (6 ref.)

Risk analysis for veterinary biologicals released into the environment. Silva SV, et al. **Rev Sci Tech** 1995 Dec; 14(4):1043–59 (16 ref.)

Regulatory framework and requirements for managing risks associated with veterinary biological products in Africa: present systems and future needs. Sylla D, et al. **Rev Sci Tech** 1995 Dec;14(4):1171–84 (18 ref.)

Present systems and future needs for risk assessments of biologicals: the perspective of the regulator in the People's Republic of China. Xia Y, et al. **Rev Sci Tech** 1995 Dec; 14(4):1185–91 (4 ref.)

Current good manufacturing practices. Zuck TF. **Transfusion** 1995 Nov–Dec;35(11):955–66 (23 ref.)

THERAPEUTIC USE

Innovative treatment approaches for rheumatoid arthritis. Issues in clinical trials of biological agents. Strand V. **Baillieres Clin Rheumatol** 1995 Nov;9(4):825–35 (38 ref.)

TOXICITY

Reproductive toxicity testing of therapeutic biotechnology agents. Henck JW, et al. **Teratology** 1996 Mar;53(3):185–95 (34 ref.)

BIOLOGICAL PSYCHIATRY

TRENDS

Neuropsychiatry and society. Cummings JL. **J Neuropsychiatry Clin Neurosci** 1996 Winter;8(1):104–9

(40 ref.)

BIOLOGICAL PUMP see BIOLOGICAL TRANSPORT, ACTIVE

BIOLOGICAL RESPONSE MODIFIERS

see related
ANTINEOPLASTIC AGENTS
IMMUNOSUPPRESSIVE AGENTS

ADMINISTRATION & DOSAGE

Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide. Kleinerman ES. **Hematol Oncol Clin North Am** 1995 Aug;9(4):927–38 (37 ref.)

ADVERSE EFFECTS

Nursing management of patients receiving biological therapy. Sandstrom SK. **Semin Oncol Nurs** 1996 May;12(2):152–62 (34 ref.)

PHARMACOLOGY

MDR1 reversal: criteria for clinical trials designed to overcome the multidrug resistance phenotype. Hegewisch-Becker S. **Leukemia** 1996 Jul;10 Suppl 3:S32–S38 (53 ref.)

THERAPEUTIC USE

Do monoclonal antibodies and anticytokines still have a future in infectious diseases? Cohen J, et al. **Am J Med** 1995 Dec 29;99(6A):45S–52S; discussion 52S–53S (36 ref.)

Present status of biological response modifiers in cancer. Parkinson DR. **Am J Med** 1995 Dec 29;99(6A):54S–56S (9 ref.)

Combination of BRMs with chemotherapy. Tursz T. **Am J Med** 1995 Dec 29;99(6A):56S–58S (7 ref.)

Recombinant alpha-interferon as treatment for chronic myelogenous leukemia in relapse after allogeneic bone marrow transplantation: a report from the Société Française de Greffe de Moelle. Pigneux A, et al. **Bone Marrow Transplant** 1995 Jun;15(6):819–24 (31 ref.)

Biological response modifiers in melanoma. Bridgewater JA, et al. **Br Med Bull** 1995 Jul;51(3):656–77 (88 ref.)

Alkylating agents. Berger NA. **Cancer Chemother Biol Response Modif** 1996;16:28–38 (68 ref.)

Biological response modifiers. Clark JW. **Cancer Chemother Biol Response Modif** 1996;16:239–73 (296 ref.)

Biologic therapies for gynecologic cancer. Bookman MA. **Curr Opin Oncol** 1995 Sep;7(5):478–84 (73 ref.)

Antitumor and antimetastatic activity of interleukin-12. Hendrzak JA, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 3):65–83 (131 ref.)

Therapeutic approaches to HIV infection based on virus structure and the host pathogen interaction. Pauza CD, et al. **Curr Top Microbiol Immunol** 1995;202:117–32 (94 ref.)

The role of biological response modifiers in the management of patients with colorectal cancer. Wagstaff J. **Eur J Cancer** 1995 Jul-Aug;31A(7–8):1323–5 (29 ref.)

Biological response modifiers. Calabresi F, et al. **Lung Cancer** 1995 Apr;12 Suppl 1:S193–8 (28 ref.)

Biotherapy and the oncology nurse. Farrell MM. **Semin Oncol Nurs** 1996 May;12(2):82–8 (31 ref.)

Future projections in biotherapy. Rieger PT. **Semin Oncol Nurs** 1996 May;12(2):163–71 (49 ref.)

BIOLOGICAL SCIENCES

TRENDS

A cell biological perspective on genome research. McIntosh JR, et al. **J Cell Biol** 1995 Dec;131(6 Pt 1):1361–4 (12 ref.)

BIOLOGICAL TRANSPORT

see related
CELL MEMBRANE PERMEABILITY
MATERNAL-FETAL EXCHANGE
MUCOCILIARY CLEARANCE
PERMEASES

The secretory pathway: mechanisms of protein sorting and transport. Harter C, et al. **Biochim Biophys Acta** 1996 Jun 10;1286(2):75–93 (276 ref.)

PHYSIOLOGY

Neurotransmitter transporters: molecular biology, function, and regulation. Borowsky B, et al. **Int Rev Neurobiol** 1995; 38:139–99 (250 ref.)

Optical methods to measure membrane transport processes. Verkman AS. **J Membr Biol** 1995 Nov;148(2):99–110 (87 ref.)

The protein machinery of vesicle budding and fusion. Rothman JE. **Protein Sci** 1996 Feb;5(2):185–94 (92 ref.)

[Magnesium and the transport system] Langmeier M. **Cesk Fysiol** 1995 Dec;44(4):191–4 (17 ref.) (Eng. Abstr.) **(Cze)**

BIOLOGICAL TRANSPORT, ACTIVE

see related
ION PUMPS

Normal and pathological aspects of mass transport across the vascular wall. Kennedy JH, et al. **Cardiovasc Surg** 1995 Dec;3(6):611–5 (45 ref.)

PHYSIOLOGY

Ion gradients and contractility in skeletal muscle: the role of active Na+, K+ transport. Nielsen OB, et al. **Acta Physiol Scand** 1996 Mar;156(3):247–56 (70 ref.)

Cell swelling and ion transport pathways in cardiac myocytes. Vandenberg JI, et al. **Cardiovasc Res** 1996 Jul; 32(1):85–97 (94 ref.)

BIOLOGICAL WASTE DISPOSAL see MEDICAL WASTE DISPOSAL

BIOLOGICS see BIOLOGICAL PRODUCTS

BIOLOGY

Thoughts over cell biology: a commentary. Henics T. **Physiol Chem Phys Med NMR** 1995;27(2):139–44 (49 ref.)

[Toward virtual life from bioinformatics] Sugawara H. **Tanpakushitsu Kakusan Koso** 1995 Sep;40(12):1809–21 (15 ref.) **(Jpn)**

[Development of information biology] Tateno Y. **Tanpakushitsu Kakusan Koso** 1995 Sep;40(12):1803–8 (16 ref.) **(Jpn)**

[The contribution of space biology and medicine to the solution of ecological problems] Grigor'ev AI, et al. **Aviakosm Ekolog Med** 1995;29(3):21–4 (14 ref.) (Eng. Abstr.) **(Rus)**

METHODS

[Microsensory systems in cell biology basic research and medical diagnostics] Brischwein M, et al. **Naturwissenschaften** 1996 May;83(5):193–200 (28 ref.) (Eng. Abstr.) **(Ger)**

BIOLUMINESCENCE see LUMINESCENCE

BIOLUMINESCENT PROTEINS see LUMINESCENT PROTEINS

BIOMATERIALS see BIOCOMPATIBLE MATERIALS

BIOMECHANICS

Mechanoreception at the cellular level: the detection, interpretation, and diversity of responses to mechanical signals. Banes AJ, et al. **Biochem Cell Biol** 1995 Jul-Aug; 73(7–8):349–65 (130 ref.)

Basic biomechanics. Giurintano DJ. **J Hand Ther** 1995 Apr-Jun;8(2):79–84 (4 ref.)

Biomechanical epidemiology: a new approach to injury control research. Winston FK, et al. **J Trauma** 1996 May; 40(5):820–4 (32 ref.)

Biomechanics of fusion and stabilization. Goel VK, et al. **Spine** 1995 Dec 15;20(24 Suppl):85S–99S (141 ref.)

BIOMEDICAL ENGINEERING

see related
ELECTRONICS, MEDICAL
MEDICAL INFORMATICS APPLICATIONS

Clinical laboratories are laboratories for re-engineering. Lincoln TL. **Am J Clin Pathol** 1996 Apr;105(4 Suppl 1):S33–9 (12 ref.)

Wavelets in biomedical engineering. Akay M. **Ann Biomed Eng** 1995 Sep-Oct;23(5):531–42 (34 ref.)

Service documentation and the biomedical engineer: results of a survey. Goffin K, et al. **Biomed Instrum Technol** 1996 May-Jun;30(3):223–35 (24 ref.)

Bioengineering in dermatology: general aspects and perspectives. Andreassi L. **Clin Dermatol** 1995 Jul-Aug; 13(4):289–92 (48 ref.)

The application of engineering and technology in the management of diabetes. Claremont DJ. **J Med Eng Technol** 1995 Nov-Dec;19(6):205–10 (64 ref.)

Cellular engineering--prospects for sensing and processing. Rolfe P. **Technol Health Care** 1996 Apr;4(1):9–13 (7 ref.)

[Clinical engineering. Rationale for implementing the technology in hospitals] Prieto Hernández F, et al. **Gac Med Mex** 1995 Jan-Feb;131(1):83–90 (13 ref.) (Eng. Abstr.) **(Spa)**

BIOMEDICAL RESEARCH see RESEARCH

BIOMEDICAL TECHNOLOGY see TECHNOLOGY, MEDICAL

BIOMODULATORS see BIOLOGICAL RESPONSE MODIFIERS

BIONICS

see related
CYBERNETICS

BIONOMICS see ECOLOGY

BIOPERIODICITY see PERIODICITY

BIOPHARMACEUTICS

see related
DRUG COMPOUNDING

Lipid microemulsions for improving drug dissolution and oral absorption: physical and biopharmaceutical aspects. Constantinides PP. **Pharm Res** 1995 Nov;12(11):1561–72 (50 ref.)

BIOPHYSICS

Biophysics: fifty years after Schrödinger. Oosawa F. **Adv Biophys** 1996;32:1–15 (41 ref.)

Biophysical mechanisms of cell membrane damage in electrical shock. Lee RC, et al. **Semin Neurol** 1995 Dec; 15(4):367–74 (28 ref.)

[Thermodynamics of biophysical system: basics of network thermodynamics] Imai Y. **Nippon Seirigaku Zasshi** 1996; 58(3):133–41 (16 ref.) **(Jpn)**

HISTORY

The early history of x-ray diagnosis with emphasis on the contributions of physics 1895–1915. Mould RF. **Phys Med Biol** 1995 Nov;40(11):1741–87 (87 ref.)

BIOPOLYMERS

Bioabsorbable polymers update: degradation mechanisms, safety, and application. Shalaby SW, et al. **J Appl Biomater** 1995 Fall;6(3):219–21 (28 ref.)

[Preparation of stable isotope labeled DNA oligomers: applications to the structural analysis of nucleic acids by heteronuclear multidimensional NMR spectroscopy] Ono A, et al. **Tanpakushitsu Kakusan Koso** 1994 Jul; 40(10):1509–17 (21 ref.) **(Jpn)**

ISOLATION & PURIFICATION

[Classical and pulsed gel electrophoresis of biopolymers. Theory and applications] Chebotarev VIu, et al. **Biofizika** 1992 Mar-Apr;37(2):243–89 (85 ref.) (Eng. Abstr.) **(Rus)**

METABOLISM

Osmotic effects of water compartments in protein polymers. Lew VL, et al. **Cell Biochem Funct** 1995 Sep;13(3):173–6 (15 ref.)

RADIATION EFFECTS

[Use of irradiation technique for obtaining and modifying biopolymers. Review.] Lewandowska-Szumiel M, et al. **Polim Med** 1995;25(1-2):57–67 (35 ref.) (Eng. Abstr.) **(Pol)**

BIOPROBES see BIOSENSORS

BIOPROSTHESIS

Regenerative bladder augmentation: a review of the initial preclinical studies with porcine small intestinal submucosa. Kropp BP, et al. **Adv Exp Med Biol** 1995;385:229–35 (26 ref.)

Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Stein PD, et al. **Chest** 1995 Oct;108(4 Suppl):371S–379S (59 ref.)

Introl bladder neck support prosthesis: a nonsurgical urethropexy. Davila GW. **J Endourol** 1996 Jun;10(3):293–6 (7 ref.)

Porcine bioprosthetic valves prepared with permanent pre-dilation of the aortic root: a review. Fisher J. **J Heart Valve Dis** 1995 Jul;4 Suppl 1:S81–3; discussion S83–4 (14 ref.)

Tissue engineering of a bioartificial kidney: a universal donor organ. Humes HD. **Transplant Proc** 1996 Aug;28(4):2032–5 (24 ref.)

The prosthetic bladder. Gürpinar T, et al. **World J Urol** 1996; 14(1):47–52 (22 ref.)

ADVERSE EFFECTS

[A case of secondary valve replacement caused by pulmonary bioprosthetic valve endocarditis] Fujii H, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Jul;43(7):1081–5 (18 ref.) (Eng. Abstr.) **(Jpn)**

METHODS

Evolution of the surgical approach for replacement of degenerated mitral bioprostheses. Geha AS, et al. **Surgery** 1995 Oct;118(4):662–6; discussion 666–8 (14 ref.)

STANDARDS

The effect of prosthesis-patient mismatch on aortic bioprosthetic valve hemodynamic performance and patient clinical status. Pibarot P, et al. **Can J Cardiol** 1996 Apr; 12(4):379–87 (43 ref.)

BIOPSY

Endomyocardial biopsy in arrhythmogenic right ventricular cardiomyopathy [editorial] Angelini A, et al. **Am Heart J** 1996 Jul;132(1 Pt 1):203–6 (35 ref.)
Orofacial biopsies: a survey of 1,723 cases seen over a 10 year period. Chidzonga MM, et al. **Cent Afr J Med** 1996 Apr;42(4):102–8 (17 ref.)
Reflux esophagitis: biopsy or not? Vandenplas Y. **J Pediatr Gastroenterol Nutr** 1996 Apr;22(3):326–7 (10 ref.)
Liver biopsy in the mid–1990s: questions and answers. van Leeuwen DJ, et al. **Semin Liver Dis** 1995 Nov;15(4):340–59 (98 ref.)
Arguments against routine contralateral mastectomy or undirected biopsy for invasive lobular breast cancer. Lee JS, et al. **Surgery** 1995 Oct;118(4):640–7; discussion 647–8 (22 ref.)
[Lymphatic mapping and biopsy of sentinel nodes—a new approach in lymphadenectomy. Review] Fait V, et al. **Rozhl Chir** 1995 Dec;74(8):425–8 (25 ref.) (Eng. Abstr.) **(Cze)**
[A critical review of the role of endomyocardial biopsy in heart transplantation] Vázquez de Prada JA. **Rev Esp Cardiol** 1995;48 Suppl 7:86–91 (25 ref.) (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Endoscopic transmission of Helicobacter pylori. Tytgat GN. **Aliment Pharmacol Ther** 1995;9 Suppl 2:105–10 (31 ref.)
Acute cholecystitis resulting from hemobilia after tru–cut biopsy: a case report and brief review of the literature. Counihan TC, et al. **Am Surg** 1996 Sep;62(9):757–8 (5 ref.)
[Digestive endoscopy and risk of transmission of hepatitis C virus: hygiene and discussion] René E, et al. **Gastroenterol Clin Biol** 1996 Feb;20(1):109–11 (8 ref.) **(Fre)**

INSTRUMENTATION

Outpatient endometrial biopsy: the pipelle. Youssif SN, et al. **Br J Hosp Med** 1995 Sep 6–19;54(5):198–201 (23 ref.)
Muscle biopsy. O'Rourke KS, et al. **Curr Opin Rheumatol** 1995 Nov;7(6):462–8 (31 ref.)
Esophageal tissue band transected with hot biopsy forceps. Su AY, et al. **Dig Dis Sci** 1995 Oct;40(10):2197–9 (7 ref.)
High–resolution light microscopy for interpretation of renal biopsies. Hoffmann EO. **Pediatr Nephrol** 1995 Dec; 9(6):763–9 (81 ref.)

METHODS

Outpatient endometrial assessment. Read MD. **Br J Hosp Med** 1995 Aug 16–Sep 5;54(4):150–3 (45 ref.)
When can stereotactic core biopsy replace excisional biopsy?—A clinical perspective. Morrow M. **Breast Cancer Res Treat** 1995;36(1):1–9 (54 ref.)
Bronchoscopic biopsies and bronchoalveolar lavage. Kvale PA. **Chest Surg Clin N Am** 1996 May;6(2):205–22 (73 ref.)
A comparison of small–intestinal mucosal biopsies in children obtained by blind suction capsule with those obtained by endoscopy. Branski D, et al. **J Pediatr Gastroenterol Nutr** 1996 Feb;22(2):194–6 (17 ref.)
Colonoscopic biopsy and polypectomy. Pierzchajlo RP. **Prim Care** 1995 Sep;22(3):451–70 (78 ref.)
Diagnosing the indeterminate pulmonary nodule: percutaneous biopsy versus thoracoscopy. Mitruka S, et al. **Surgery** 1995 Oct;118(4):676–84 (25 ref.)
[How to look for Helicobacter pylori?] Mégraud F. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S38–S43 (35 ref.) **(Fre)**

BIOPSY, CHORIONIC VILLI see **CHORIONIC VILLI SAMPLING**

BIOPSY, NEEDLE

Fine–needle aspiration biopsy of the breast. Kline TS. **Am Fam Physician** 1995 Nov 15;52(7):2021–5 (25 ref.)
The diagnosis and reporting of adenocarcinoma of the prostate in core needle biopsy specimens. Epstein JI. **Cancer** 1996 Jul 15;78(2):350–6 (39 ref.)
Fine–needle aspiration cytology of the ovary. Ganjei P. **Clin Lab Med** 1995 Sep;15(3):705–26 (19 ref.)
Muscle biopsy as a tool in the study of aging. Coggan AR. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:30–4 (38 ref.)
Renal transplant fine needle aspiration and cytokine gene expression. Nast CC. **Pediatr Nephrol** 1995;9 Suppl:S56–60 (31 ref.)
Diagnosing the indeterminate pulmonary nodule: percutaneous biopsy versus thoracoscopy. Mitruka S, et al. **Surgery** 1995 Oct;118(4):676–84 (25 ref.)
[Angiomyolipoma: the role of puncture–aspiration cytodiagnosis] Farina LA, et al. **Prog Urol** 1995 Sep; 5(4):575–7 (36 ref.) (Eng. Abstr.) **(Fre)**
[Puncture cytologic diagnosis of thyroid diseases: potentialities and limitations of the method] Malor NN, et al. **Arkh Patol** 1996 Mar–Apr;58(2):74–8 (52 ref.) (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

Liver biopsy complications and routine ultrasound [editorial; comment] Stotland BR, et al. **Am J Gastroenterol** 1996 Jul; 91(7):1295–6 (10 ref.) Comment on: Am J Gastroenterol 1996 Jul;91(7):1318–21.
Pancreatitis secondary to percutaneous liver biopsy–associated hemobilia. Van Os EC, et al. **Am J Gastroenterol** 1996 Mar;91(3):577–80 (18 ref.)
Outcomes of percutaneous kidney biopsy, including those of solitary native kidneys. Mendelssohn DC, et al. **Am J Kidney Dis** 1995 Oct;26(4):580–5 (15 ref.)
Histological changes mimicking papillary carcinoma following fine needle aspiration of the thyroid gland. Lopez JI, et al. **Arch Anat Cytol Pathol** 1996;44(2–3):98–100 (11 ref.)
Fine needle aspiration (FNA)–induced necrosis of tumours of the thyroid. Ramp U, et al. **Cytopathology** 1995 Aug; 6(4):248–54 (13 ref.)
Liver biopsy: review of methodology and complications. Tobkes AI, et al. **Dig Dis** 1995 Sep–Oct;13(5):267–74 (36 ref.)
[Complications of ultrasound–guided transperineal puncture biopsy of the prostate] Castiñeiras J, et al. **Actas Urol Esp** 1995 Jul–Aug;19(7):544–8 (12 ref.) (Eng. Abstr.) **(Spa)**

INSTRUMENTATION

[The risk of liver biopsy] Glaser J, et al. **Z Gastroenterol** 1995 Nov;33(11):673–6 (31 ref.) (Eng. Abstr.) **(Ger)**

METHODS

The staging of lung cancer by bronchoscopic transbronchial needle aspiration. Harrow EM, et al. **Chest Surg Clin N Am** 1996 May;6(2):223–35 (35 ref.)
Transbronchial needle aspiration and percutaneous needle aspiration for staging and diagnosis of lung cancer. Wang KP. **Clin Chest Med** 1995 Sep;16(3):535–52 (26 ref.)
Fine needle aspiration (FNA) in the diagnosis of soft tissue tumours; a review of 22 years experience. Willén H, et al. **Cytopathology** 1995 Aug;6(4):236–47 (41 ref.)
Liver biopsy: review of methodology and complications. Tobkes AI, et al. **Dig Dis** 1995 Sep–Oct;13(5):267–74 (36 ref.)
Endoscopic ultrasonography–guided puncture of the lymph nodes: first experience and clinical consequences. Hoffman BJ, et al. **Gastrointest Endosc Clin N Am** 1995 Jul; 5(3):587–93 (17 ref.)
Puncture of submucosal and extrinsic tumors: is there a clinical need? Puncture techniques and their accuracy. Wegener M, et al. **Gastrointest Endosc Clin N Am** 1995 Jul;5(3):615–23 (24 ref.)
Needle biopsy techniques. Parker SH, et al. **Radiol Clin North Am** 1995 Nov;33(6):1171–86 (19 ref.)
A practical approach to minimally invasive breast biopsy. Parker SH, et al. **Radiology** 1996 Jul;200(1):11–20 (50 ref.)
The current role of percutaneous biopsy in the evaluation of renal masses. Herts BR, et al. **Semin Urol Oncol** 1995 Nov;13(4):254–61 (40 ref.)
[Role of fine needle puncture in the diagnosis of a hepatic mass] Fabre M, et al. **Ann Pathol** 1995;15(5):380–7 (31 ref.) **(Fre)**
[Imaging guided biopsy: principles, technique and indication] Vollrath T. **Schweiz Med Wochenschr** 1996 Jul 20; 126(29):1264–9 (17 ref.) (Eng. Abstr.) **(Ger)**
[Evaluation of tumor response through of morphometric measurements. Quantification of apoptosis] Vargas F, et al. **G E N** 1995 Apr–Jun;49(2):161–4 (42 ref.) (Eng. Abstr.) **(Spa)**

VETERINARY

[Diagnosis of tumors by needle aspiration cytology] Kessler M. **Tierarztl Prax** 1995 Dec;23(6):534–41 (27 ref.) (Eng. Abstr.) **(Ger)**

BIOPTERIN

ANALOGS & DERIVATIVES

Why tetrahydrobiopterin? Mayer B, et al. **Adv Pharmacol** 1995;34:251–61 (50 ref.)
[Changes of serum 2',5'–oligoadenylate synthetase activity and neopterin during interferon treatment for chronic hepatitis C] Daito K, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:981–5 (16 ref.) **(Jpn)**
[Amines and pteridines] Shimpo K, et al. **Nippon Rinsho** 1996 Jun;54(6):1515–20 (22 ref.) (Eng. Abstr.) **(Jpn)**

BIORHYTHMS see **PERIODICITY**

BIOSATELLITES see **SPACECRAFT**

BIOSENSORS

Conducting polymers and the bioanalytical sciences: new tools for biomolecular communication. A review. Adeloju SB, et al. **Analyst** 1996 Jun;121(6):699–703 (46 ref.)
Oriented immobilization of antibodies and its applications in immunoassays and immunosensors. Lu B, et al. **Analyst** 1996 Mar;121(3):29R–32R (47 ref.)
Optical probes and transducers. Brecht A, et al. **Biosens Bioelectron** 1995;10(9–10):923–36 (19 ref.)
Interface analysis in biosensor design. Göpel W, et al. **Biosens Bioelectron** 1995;10(9–10):853–83 (201 ref.)
Microbial detection. Hobson NS, et al. **Biosens Bioelectron** 1996;11(5):455–77 (133 ref.)
Surface modification of polymers: chemical, biological and surface analytical challenges. Ratner BD. **Biosens Bioelectron** 1995;10(9–10):797–804 (41 ref.)
Applications of electrochemical immunosensors to environmental monitoring. Sadik OA, et al. **Biosens Bioelectron** 1996;11(8):i–xi (32 ref.)
Transduction in microbial biosensors using multiplexed bioluminescence. Wood KV, et al. **Biosens Bioelectron** 1996;11(3):207–14 (12 ref.)
Immunosensors: technology and opportunities in laboratory medicine. Morgan CL, et al. **Clin Chem** 1996 Feb; 42(2):193–209 (186 ref.)
Optical immunosensors. Rabbany SY, et al. **Crit Rev Biomed Eng** 1994;22(5–6):307–46 (117 ref.)
Non–invasive glucose monitoring. Arnold MA. **Curr Opin Biotechnol** 1996 Feb;7(1):46–9 (22 ref.)
Immunosensors. Gizeli E, et al. **Curr Opin Biotechnol** 1996 Feb;7(1):66–71 (34 ref.)
Amperometric biosensors. Heller A. **Curr Opin Biotechnol** 1996 Feb;7(1):50–4 (39 ref.)
Biomagnetic neurosensors. Rechnitz GA, et al. **Curr Opin Biotechnol** 1996 Feb;7(1):55–9 (56 ref.)
Surface plasmon resonance and its use in biomolecular interaction analysis (BIA). Szabo A, et al. **Curr Opin Struct Biol** 1995 Oct;5(5):699–705 (38 ref.)
Haemocompatibility of invasive sensors. Benmakroha Y, et al. **Med Biol Eng Comput** 1995 Nov;33(6):811–21 (155 ref.)
[Fiber optic chemical gas sensors based on environmental chromism] Sadaoka Y. **Tanpakushitsu Kakusan Koso** 1995 Nov;40(15):2355–60 (14 ref.) **(Jpn)**
[Optical sensing of molecular recognition in surface monolayers] Shimomura M, et al. **Tanpakushitsu Kakusan Koso** 1996 Jan;41(1):83–8 (6 ref.) **(Jpn)**
[Taste sensor] Toko K. **Tanpakushitsu Kakusan Koso** 1995 Sep;40(12):1859–65 (10 ref.) **(Jpn)**
[Microbial sensors: achievements, problems, prospects] Korpan IaI, et al. **Biokhimiia** 1995 Dec;60(12):1988–98 (57 ref.) (Eng. Abstr.) **(Rus)**
[Tissue and cell biosensors (possibilities of clinical use)] Safronova OG, et al. **Med Tekh** 1995 Jul–Aug;(4):39–46 (95 ref.) (Eng. Abstr.) **(Rus)**
[Biosensor models based on potentiometric and amperometric transducers for use in medicine, biotechnology, and environmental monitoring (review)] Reshetilov AN. **Prikl Biokhim Mikrobiol** 1996 Jan–Feb;32(1):78–93 (61 ref.) (Eng. Abstr.) **(Rus)**

BIOSYNTHETIC PROTEINS see **RECOMBINANT PROTEINS**

BIOTECHNOLOGY

see related
GENETIC ENGINEERING
RECOMBINANT PROTEINS

Chromatography in the downstream processing of biotechnological products. Freitag R, et al. **Adv Biochem Eng Biotechnol** 1996;53:17–59 (383 ref.)
Review: methods of monitoring for process micro–organisms in biotechnology. Crook B. **Ann Occup Hyg** 1996 Jun; 40(3):245–60 (23 ref.)
Intent and coincidence in pharmaceutical discovery. The impact of biotechnology. Drews J. **Arzneimittelforschung** 1995 Aug;45(8):934–9 (24 ref.)
Safety and regulation at the leading edge of biomedical biotechnology. Cohen–Haguenauer O. **Curr Opin Biotechnol** 1996 Jun;7(3):265–72 (54 ref.)
Knowledge–based systems, artificial neural networks and pattern recognition: applications to biotechnological processes. Kamimura R, et al. **Curr Opin Biotechnol** 1996 Apr;7(2):231–4 (18 ref.)
Combinatorial chemistry and biology: an opportunity for engineers. Khosla C. **Curr Opin Biotechnol** 1996 Apr; 7(2):219–22 (25 ref.)
Position of the American Dietetic Association: biotechnology and the future of food. **J Am Diet Assoc** 1995 Dec; 95(12):1429–32 (29 ref.)
Designing trials for gene therapy. Geddes D. **J Inherit Metab Dis** 1995;18(4):517–24 (7 ref.)
Environmental safety assessment of vaccines derived from biotechnology. Pastoret PP, et al. **Rev Sci Tech** 1995 Dec; 14(4):963–77 (40 ref.)
Diagnostic test studies: biotechnology assessment. Lossing AG, et al. **Surgery** 1996 Jul;120(1):1–6 (32 ref.)
[Biosensor models based on potentiometric and amperometric transducers for use in medicine, biotechnology, and environmental monitoring (review)] Reshetilov AN. **Prikl Biokhim Mikrobiol** 1996 Jan–Feb;32(1):78–93 (61 ref.) (Eng. Abstr.) **(Rus)**

METHODS

Antisense approach to restenosis. Simons M. **Jpn Circ J** 1996 Jan;60(1):1–9 (50 ref.)

STANDARDS

Immunotoxicity assessment of biotechnology products: a regulatory point of view [editorial] Cavagnaro JA. **Toxicology** 1995 Dec 20;105(1):1–6 (12 ref.)
Safety evaluation of biological and biotechnology–derived

medicines. Dayan AD. **Toxicology** 1995 Dec 20; 105(1):59–68 (18 ref.)

TRENDS

Reaction engineering methods to study intracellular metabolite concentrations. Weuster-Botz D, et al. **Adv Biochem Eng Biotechnol** 1996;54:75–108 (62 ref.)

In vivo stationary flux analysis by 13C labeling experiments. Wiechert W, et al. **Adv Biochem Eng Biotechnol** 1996; 54:109–54 (144 ref.)

Protein purification in the nineties. Scopes RK. **Biotechnol Appl Biochem** 1996 Jun;23 (Pt 3):197–204 (10 ref.)

An overview of health-related industrial biotechnology in Latin America and the Caribbean. Marques MB. **Bull Pan Am Health Organ** 1996 Jun;30(2):95–105 (36 ref.)

Biotechnological developments in New Zealand. Maddox IS, et al. **Crit Rev Biotechnol** 1996;16(2):119–43 (86 ref.)

Luminescence-based systems for detection of bacteria in the environment. Prosser JI, et al. **Crit Rev Biotechnol** 1996; 16(2):157–83 (90 ref.)

Application of innovative downstream processing techniques in isolation and purification of biomolecules. Kumar ML, et al. **Hindustan Antibiot Bull** 1994 Aug-Nov; 36(3–4):98–134 (204 ref.)

Membrane separations in biotechnology. Musale DA, et al. **Hindustan Antibiot Bull** 1994 Aug-Nov;36(3–4):157–63 (24 ref.)

New trends in downstream processing of biotechnological products. Patkar AY, et al. **Hindustan Antibiot Bull** 1994 Aug-Nov;36(3–4):141–56 (64 ref.)

Application of gene and cell therapies in the tissue engineering of a bioartificial kidney [editorial] Humes HD. **Int J Artif Organs** 1996 Apr;19(4):215–7 (22 ref.)

Recent developments and perspectives of biotechnology-derived products. Thomas JA. **Toxicology** 1995 Dec 20;105(1):7–22 (31 ref.)

[Immunobiological preparations: their present and future] Vorob'ev AA, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1995 Nov-Dec; (6):105–11 (22 ref.) **(Rus)**

BIOTIN

BLOOD

[Biotin (vitamin H)] Oishi N, et al. **Nippon Rinsho** 1995 Feb; 53 Su Pt 1:734–7 (14 ref.) **(Jpn)**

BIOTRANSFORMATION

Biocatalytic syntheses of aromatics from D-glucose: renewable microbial sources of aromatic compounds. Frost JW, et al. **Annu Rev Microbiol** 1995;49:557–79 (81 ref.)

[Abiotic and biotic transformation of persistent organochlorine compounds in the environment] Struciński P, et al. **Rocz Panstw Zakl Hig** 1995;46(3):279–92 (51 ref.) (Eng. Abstr.) **(Pol)**

BIOTYPING, BACTERIAL see **BACTERIAL TYPING TECHNIQUES**

BIOTYPING, MYCOLOGICAL see **MYCOLOGICAL TYPING TECHNIQUES**

BIPHENYL COMPOUNDS

Discovery of losartan, the first angiotensin II receptor antagonist. Timmermans PB, et al. **J Hum Hypertens** 1995 Nov;9 Suppl 5:S3–18 (199 ref.)

Angiotensin receptor antagonists: focus on losartan. Johnston CI. **Lancet** 1995 Nov 25;346(8987):1403–7 (36 ref.)

METABOLISM

Aerobic and anaerobic PCB biodegradation in the environment. Abramowicz DA. **Environ Health Perspect** 1995 Jun;103 Suppl 5:97–9 (27 ref.)

PHARMACOLOGY

Angiotensin II antagonists: a new class of antihypertensive agent. Waeber B, et al. **Br J Clin Pract** 1996 Jul-Aug; 50(5):265–8 (35 ref.)

Angiotensin II receptor antagonism: losartan - sites and mechanisms of action. Triggle DJ. **Clin Ther** 1995 Nov-Dec;17(6):1005–30 (132 ref.)

Effect of angiotensin II blockade on cardiac hypertrophy and remodelling: a review. Dahlöf B. **J Hum Hypertens** 1995 Nov;9 Suppl 5:S37–44 (84 ref.)

Brequinar sodium. Cramer DV. **Transplant Proc** 1996 Apr; 28(2):960–3 (20 ref.)

[Antagonists of angiotensin II receptor] Karasek D, et al. **Postepy Hig Med Dosw** 1996;50(1):21–32 (64 ref.) (Eng. Abstr.) **(Pol)**

THERAPEUTIC USE

Angiotensin II receptor antagonists in heart failure: rationale and design of the evaluation of losartan in the elderly (ELITE) trial. Pitt B, et al. **Cardiovasc Drugs Ther** 1995 Oct;9(5):693–700 (80 ref.)

The future role of losartan. Hansson L. **J Hum Hypertens** 1995 Nov;9 Suppl 5:S55–8 (24 ref.)

Brequinar sodium. Cramer DV. **Pediatr Nephrol** 1995;9 Suppl:S52–5 (29 ref.)

Brequinar sodium. Cramer DV. **Transplant Proc** 1996 Apr; 28(2):960–3 (20 ref.)

[Losartan and the LIFE-study. Antihypertensive treatment with AT1-receptor antagonist] Kjeldsen SE, et al. **Tidsskr Nor Laegeforen** 1996 Feb 10;116(4):504–7 (25 ref.) (Eng. Abstr.) **(Nor)**

BIPHENYLDIAMINES see **BENZIDINES**

BIPOLAR DISORDER

Childhood mania revisited. Biederman J, et al. **Isr J Med Sci** 1995 Nov;31(11):647–51 (71 ref.)

CLASSIFICATION

Nosology of chronic mood disorders. First MB, et al. **Psychiatr Clin North Am** 1996 Mar;19(1):29–39 (10 ref.)

DIAGNOSIS

Women with bipolar illness: clinical and research issues. Leibenluft E. **Am J Psychiatry** 1996 Feb;153(2):163–73 (132 ref.)

The prevalent clinical spectrum of bipolar disorders: beyond DSM-IV. Akiskal HS. **J Clin Psychopharmacol** 1996 Apr; 16(2 Suppl 1):4S–14S (91 ref.)

[The bipolar spectrum: research and clinical perspectives] Akiskal HS. **Encephale** 1995 Dec;21 Spec No 6:3–11 (51 ref.) (Eng. Abstr.) **(Fre)**

[Rapidly cycling bipolar disorders] Azorin JM. **Encephale** 1995 Dec;21 Spec No 6:43–8 (42 ref.) (Eng. Abstr.) **(Fre)**

[Importance of DSM IV (APA) and ICD-10 (WHO) in diagnosis and treatment of mood disorders] Bourgeois M. **Encephale** 1995 Dec;21 Spec No 5:47–52 (22 ref.) (Eng. Abstr.) **(Fre)**

[Dysphoric mania and mixed states] Bourgeois M, et al. **Encephale** 1995 Dec;21 Spec No 6:21–32 (39 ref.) (Eng. Abstr.) **(Fre)**

[Anxious-excited depression: a mixed affective syndrome] Koukopoulos A, et al. **Encephale** 1995 Dec;21 Spec No 6:33–6 (21 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

Lithium therapy: limitations and alternatives in the treatment of bipolar disorders. Calabrese JR, et al. **Ann Clin Psychiatry** 1995 Jun;7(2):103–12 (80 ref.)

How does lithium work on manic depression? Clinical and psychological correlates of the inositol theory. Belmaker RH, et al. **Annu Rev Med** 1996;47:47–56 (23 ref.)

Lithium revisited. A re-examination of the placebo-controlled trials of lithium prophylaxis in manic-depressive disorder [editorial] Moncrieff J. **Br J Psychiatry** 1995 Nov;167(5):569–73; discussion 573–4 (26 ref.)

Treatment of acute bipolar depression: a review of the literature. Srisurapanont M, et al. **Can J Psychiatry** 1995 Nov;40(9):533–44 (89 ref.)

Antipsychotics in bipolar disorder. Gelenberg AJ, et al. **J Clin Psychiatry** 1996;57 Suppl 9:49–52 (38 ref.)

Role of newer medications for bipolar disorder. Bowden CL. **J Clin Psychopharmacol** 1996 Apr;16(2 Suppl 1):48S–55S (65 ref.)

Predictors of response to mood stabilizers. Calabrese JR, et al. **J Clin Psychopharmacol** 1996 Apr;16(2 Suppl 1):24S–31S (88 ref.)

Outcome in the pharmacologic treatment of bipolar disorder. Keck PE Jr, et al. **J Clin Psychopharmacol** 1996 Apr;16(2 Suppl 1):15S–23S (86 ref.)

Psychotherapy in combination with drug treatment for bipolar disorder. Miklowitz DJ. **J Clin Psychopharmacol** 1996 Apr;16(2 Suppl 1):56S–66S (68 ref.)

Bipolar mood disorder: practical strategies for acute and maintenance phase treatment. Sachs GS. **J Clin Psychopharmacol** 1996 Apr;16(2 Suppl 1):32S–47S (87 ref.)

The emerging role of valproate in bipolar disorder and other psychiatric disorders. Guay DR. **Pharmacotherapy** 1995 Sep-Oct;15(5):631–47 (146 ref.)

Treatment algorithms in treatment-resistant depression. Amsterdam JD, et al. **Psychiatr Clin North Am** 1996 Jun; 19(2):371–86 (72 ref.)

Treatment-resistant bipolar depression. Sachs GS. **Psychiatr Clin North Am** 1996 Jun;19(2):215–36 (78 ref.)

Inositol monophosphatase--a putative target for Li+ in the treatment of bipolar disorder. Atack JR, et al. **Trends Neurosci** 1995 Aug;18(8):343–9 (97 ref.)

[Practical considerations in initial treatment] Allilaire JF. **Encephale** 1995 Mar;21 Spec No 2:23–9 (0 ref.) (Eng. Abstr.) **(Fre)**

[The long-term course of depression (epidemiology and clinical aspects)] Cardot H, et al. **Encephale** 1995 Mar;21 Spec No 2:51–9 (77 ref.) (Eng. Abstr.) **(Fre)**

[Initiating thymoregulator treatment] Olié JP, et al. **Encephale** 1995 Mar;21 Spec No 2:71–8 (86 ref.) (Eng. Abstr.) **(Fre)**

[Efficacy of antidepressants and thymoregulators in the long-term evolution of depression] Pringuey D, et al. **Encephale** 1995 Mar;21 Spec No 2:61–70 (18 ref.) (Eng. Abstr.) **(Fre)**

[Calcium antagonists and lithium in preventive treatment of manic-depressive disorder] Sarfati Y, et al. **Encephale** 1996 Mar-Apr;22(2):149–53 (43 ref.) (Eng. Abstr.) **(Fre)**

[Status of thymoleptics in the treatment of bipolar disorders] Sechter D. **Encephale** 1996 Jan-Feb;22(1):65–8 (24 ref.) (Eng. Abstr.) **(Fre)**

[Long-term clinical effects of antidepressive agents] Sechter D. **Encephale** 1995 Mar;21 Spec No 2:35–8 (14 ref.) (Eng. Abstr.) **(Fre)**

[Evolution of benefit-risk ratio of antidepressants] Corruble E, et al. **Therapie** 1995 Nov-Dec;50(6):515–21 (46 ref.) (Eng. Abstr.) **(Fre)**

[Value of old and new anticonvulsants in treatment of psychiatric diseases] Walden J, et al. **Fortschr Neurol Psychiatr** 1995 Aug;63(8):320–35 (185 ref.) (Eng. Abstr.) **(Ger)**

ENZYMOLOGY

Inositol monophosphatase--a putative target for Li+ in the treatment of bipolar disorder. Atack JR, et al. **Trends Neurosci** 1995 Aug;18(8):343–9 (97 ref.)

EPIDEMIOLOGY

The epidemiology of bipolar affective disorder. Bebbington P, et al. **Soc Psychiatry Psychiatr Epidemiol** 1995 Nov; 30(6):279–92 (110 ref.)

[Epidemiology of the bipolar spectrum] Angst J. **Encephale** 1995 Dec;21 Spec No 6:37–42 (18 ref.) (Eng. Abstr.) **(Fre)**

[Comorbidity of bipolar and eating disorders. Epidemiologic and therapeutic aspects] Mury M, et al. **Encephale** 1995 Sep-Oct;21(5):545–53 (44 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Diagnostic and genetic issues of depression and bipolar illness. Berrettini W. **Pharmacotherapy** 1995 Nov-Dec;15(6 Pt 2):69S–75S (78 ref.)

A continuum of psychosis, one human gene, and not much else--the case for homogeneity. Crow TJ. **Schizophr Res** 1995 Oct;17(2):135–45 (85 ref.)

[Genetics and manic-depressive psychosis: review and current findings] Souery D, et al. **Acta Psychiatr Belg** 1994 May-Jun;94(3):134–50 (65 ref.) (Eng. Abstr.) **(Fre)**

PSYCHOLOGY

Chaos and complexity. Can it help us to understand mood and behavior? Ehlers CL. **Arch Gen Psychiatry** 1995 Nov; 52(11):960–4 (57 ref.)

Social influences on bipolar affective disorders. Ramana R, et al. **Soc Psychiatry Psychiatr Epidemiol** 1995 Jul; 30(4):152–60 (55 ref.)

[A psychopathological study of hypochondriacal symptoms in manic-depressive psychosis] Okajima Y. **Seishin Shinkeigaku Zasshi** 1995;97(8):623–52 (63 ref.) (Eng. Abstr.) **(Jpn)**

THERAPY

Psychotherapy for bipolar disorder. Scott J. **Br J Psychiatry** 1995 Nov;167(5):581–8 (29 ref.)

Current concepts in treating bipolar disorder. Bowden CL, et al. **J Clin Psychiatry** 1996 Apr;57(4):suppl 1–12 (18 ref.)

BIRD DISEASES

Studies on the helminth parasites of birds from Egypt: 1-trematoda and cestoda. Ashour AA, et al. **J Egypt Soc Parasitol** 1996 Apr;26(1):207–16 (24 ref.)

Diseases of the respiratory tract in psittacine birds. Zwart P. **Vet Q** 1995 Apr;17 Suppl 1:S52–3 (3 ref.)

DIAGNOSIS

[Clinical use of rigid endoscopes in avian patients] Hochleithner M, et al. **Tierarztl Prax** 1995 Oct;23(5):469–74 (23 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

The influence of petrochemicals and stress on the immune system of seabirds. Briggs KT, et al. **Regul Toxicol Pharmacol** 1996 Apr;23(2):145–55 (77 ref.)

TRANSMISSION

Persistence and transmission of tick-borne viruses: Ixodes ricinus and louping-ill virus in red grouse populations. Hudson PJ, et al. **Parasitology** 1995;111 Suppl:S49–58 (27 ref.)

BIRD FANCIER'S LUNG

EPIDEMIOLOGY

[Extrinsic allergic alveolitis of occupational origin] Toubas D, et al. **Presse Med** 1995 Oct 14;24(30):1391–6 (42 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Pigeon breeder's disease [editorial; comment] Allen JT, et al. **J Lab Clin Med** 1996 Jan;127(1):10–2 (26 ref.) Comment on: J Lab Clin Med 1996 Jan;127(1):23–8.

BIRDS

Ocular injury from a rooster attack. Kronwith SD, et al. **Clin Pediatr (Phila)** 1996 Apr;35(4):219–20 (10 ref.)
A nuclear matrix acceptor site for the progesterone receptor in the avian c-myc gene promoter. Spelsberg TC, et al. **Recent Prog Horm Res** 1996;51:63–96 (121 ref.)
[Transgenic bird] Mochii M. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2265–73 (22 ref.) **(Jpn)**

ANATOMY & HISTOLOGY

Comparative anatomy of the external and middle ear of palaeognathous birds. Starck JM. **Adv Anat Embryol Cell Biol** 1995;131:1–137 (225 ref.)
The harderian gland: a tercentennial review. Payne AP. **J Anat** 1994 Aug;185 (Pt 1):1–49 (263 ref.)

EMBRYOLOGY

Time-lapse cinephotomicrography, videography, and videomicrography of the avian blastoderm. Bortier H, et al. **Methods Cell Biol** 1996;51:331–54 (18 ref.)
Migration and adhesion assays. Lallier T. **Methods Cell Biol** 1996;51:285–99 (3 ref.)
Operations on limb buds of avian embryos. Saunders JW Jr. **Methods Cell Biol** 1996;51:125–45 (30 ref.)
Cell division and differentiation in avian embryos: techniques for study of early neurogenesis and myogenesis. Sechrist J, et al. **Methods Cell Biol** 1996;51:301–29 (57 ref.)
Somite strips: an embryo fillet preparation. Tosney KW, et al. **Methods Cell Biol** 1996;51:93–108 (10 ref.)
Origin of the avian neural crest. Bronner-Fraser M. **Stem Cells (Dayt)** 1995 Nov;13(6):640–6 (22 ref.)

GROWTH & DEVELOPMENT

A review of factors affecting productivity of bald eagles in the Great Lakes region: implications for recovery. Bowerman WW, et al. **Environ Health Perspect** 1995 May; 103 Suppl 4:51–9 (58 ref.)

IMMUNOLOGY

The influence of petrochemicals and stress on the immune system of seabirds. Briggs KT, et al. **Regul Toxicol Pharmacol** 1996 Apr;23(2):145–55 (77 ref.)

METABOLISM

Structural basis for oxygen delivery: muscle capillaries and manifolds in tuna red muscle. Mathieu-Costello O, et al. **Comp Biochem Physiol A Physiol** 1996 Jan;113(1):25–31 (37 ref.)

PARASITOLOGY

Lice and cospeciation: a response to Barker. Page RD, et al. **Int J Parasitol** 1996 Feb;26(2):213–8 (41 ref.)
Studies on the helminth parasites of birds from Egypt: 1-trematoda and cestoda. Ashour AA, et al. **J Egypt Soc Parasitol** 1996 Apr;26(1):207–16 (24 ref.)

PHYSIOLOGY

The hypothalamo-neurohypophyseal system in birds. Grossmann R, et al. **Adv Exp Med Biol** 1995;395:657–66 (34 ref.)
The neuroethological development of food-storing memory: a case of use it, or lose it! Clayton NS. **Behav Brain Res** 1995 Sep;70(1):95–102 (54 ref.)
Behavioral learning. The illuminated songbird. Mooney R. **Curr Biol** 1995 Jun 1;5(6):609–11 (611 ref.)
A review of factors affecting productivity of bald eagles in the Great Lakes region: implications for recovery. Bowerman WW, et al. **Environ Health Perspect** 1995 May; 103 Suppl 4:51–9 (58 ref.)
Reproductive effects in birds exposed to pesticides and industrial chemicals. Fry DM. **Environ Health Perspect** 1995 Oct;103 Suppl 7:165–71 (85 ref.)
The King Solomon Lectures in Neuroethology. A white canary on Mount Acropolis. Nottebohm F. **J Comp Physiol [A]** 1996 Aug;179(2):149–56 (57 ref.)
Timing of seasonal breeding in birds, with particular reference to New Zealand birds. Cockrem JF. **Reprod Fertil Dev** 1995;7(1):1–19 (72 ref.)
[Neurogenesis of brain space of song learning in adult songbirds] Li DF. **Sheng Li Ko Hsueh Chin Chan** 1995 Jul;26(3):273–5 (10 ref.) **(Chi)**

BIRNAVIRIDAE

ISOLATION & PURIFICATION

Viruses associated with the epizootic ulcerative syndrome (EUS) of fish in South-East Asia. Frerichs GN. **Vet Res** 1995;26(5–6):449–54 (26 ref.)

BIRNAVIRIDAE INFECTIONS

VETERINARY

Viruses associated with the epizootic ulcerative syndrome (EUS) of fish in South-East Asia. Frerichs GN. **Vet Res** 1995;26(5–6):449–54 (26 ref.)

BIRNAVIRUS INFECTIONS see **BIRNAVIRIDAE INFECTIONS**

BIRTH see **LABOR**

BIRTH CONTROL see **FAMILY PLANNING**

BIRTH DEFECTS see **ABNORMALITIES**

BIRTH INJURIES

ETIOLOGY

Medico-legal aspects of brachial plexus injury: the obstetrician's point of view. Jakobovits A. **Med Law** 1996; 15(1):175–82 (30 ref.)
Spontaneous intrauterine linear skull fracture: a rare complication of spontaneous vaginal delivery. Heise RH, et al. **Obstet Gynecol** 1996 May;87(5 Pt 2):851–4 (15 ref.)

PREVENTION & CONTROL

Benefits and risks of episiotomy: a review of the English-language literature since 1980. Part II. Woolley RJ. **Obstet Gynecol Surv** 1995 Nov;50(11):821–35 (189 ref.)

BIRTH INTERVALS

Family planning: an essential component of prenatal care. Klerman LV, et al. **J Am Med Wom Assoc** 1995 Sep–Oct; 50(5):147–51 (31 ref.)

BIRTH RATE

Women's education and fertility: results from 26 Demographic and Health Surveys. Castro Martin T. **Stud Fam Plann** 1995 Jul–Aug;26(4):187–202 (50 ref.)

BIRTH SPACING see **BIRTH INTERVALS**

BIRTH WEIGHT

see related
FETAL MACROSOMIA
INFANT, LOW BIRTH WEIGHT
INFANT, VERY LOW BIRTH WEIGHT

Guessing the weight of the baby [comment] Hall MH. **Br J Obstet Gynaecol** 1996 Aug;103(8):734–6 (24 ref.) Comment on: Br J Obstet Gynaecol 1996 Aug;103(8):747–54.
Trend of birthweights of African newborns: an overview. Airede AK. **East Afr Med J** 1996 Apr;73(4):271–5 (48 ref.)
Birth weights of Nigerian newborn infants—a review. Airede AI. **West Afr J Med** 1995 Apr–Jun;14(2):116–20 (36 ref.)

PHYSIOLOGY

The influence of fetal and maternal factors on the distribution of birthweight. Cogswell ME, et al. **Semin Perinatol** 1995 Jun;19(3):222–40 (58 ref.)

BIRTHING CENTERS, HOSPITAL see **DELIVERY ROOMS**

BISEXUALITY

Identity formation for lesbian, bisexual, and gay persons: beyond a "minoritizing" view. Eliason MJ. **J Homosex** 1996; 30(3):31–58 (40 ref.)
Drug use and HIV risk among gay and bisexual men: an overview. Battjes RJ. **NIDA Res Monogr** 1994;143:82–7 (4 ref.)
Substance use and HIV-transmitting behaviors among gay and bisexual men. Ostrow DG. **NIDA Res Monogr** 1994; 143:88–113 (35 ref.)

PHYSIOLOGY

Biology of bisexuality: critique and observations. Van Wyk PH, et al. **J Homosex** 1995;28(3–4):357–73 (65 ref.)

STATISTICS & NUMERICAL DATA

Sampling homosexuals, bisexuals, gays, and lesbians for public health research: a review of the literature from 1990 to 1992. Sell RL, et al. **J Homosex** 1996;30(4):31–47 (19 ref.)

BISMUTH

ANALYSIS

[Bismuth] Sakai T, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:862–4 (8 ref.) **(Jpn)**

THERAPEUTIC USE

Bismuth therapy for Helicobacter pylori infection. A review of five years experience at a university hospital in Norway. Berstad A, et al. **J Physiol Pharmacol** 1996 Mar;47(1):31–49 (45 ref.)
[How to eradicate Helicobacter pylori in 1995? Critical review of available treatments] Deltenre M, et al. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S44–S52 (122 ref.) **(Fre)**

BIS(5'-NUCLEOSIDYL)OLIGOPHOSPHATES see **DINUCLEOSIDE PHOSPHATES**

BIS(5'-NUCLEOSIDYL)PHOSPHATES see **DINUCLEOSIDE PHOSPHATES**

BISON

Brucellosis in free-ranging bison (Bison bison) in Yellowstone, Grand Teton, and Wood Buffalo National Parks: a review [letter] Meyer ME, et al. **J Wildl Dis** 1995 Oct;31(4):579–98 (110 ref.)

BISPECIFIC ANTIBODIES see **ANTIBODIES, BISPECIFIC**

BISPHOSPHOGLYCERATES see **DIPHOSPHOGLYCERIC ACIDS**

BISPHOSPHONATES see **DIPHOSPHONATES**

BITE FORCE

A review of residual ridge resorption and bone density. Klemetti E. **J Prosthet Dent** 1996 May;75(5):512–4 (32 ref.)
Stress-induced cervical lesions: review of advances in the past 10 years. Lee WC, et al. **J Prosthet Dent** 1996 May; 75(5):487–94 (65 ref.)

BITE REGISTRATION see **JAW RELATION RECORD**

BITES AND STINGS

Immunizations, animal-induced injuries and disease, neonatal jaundice, and viral infections. Gerson WT. **Curr Opin Pediatr** 1995 Aug;7(4):477–86 (73 ref.)

COMPLICATIONS

Simian bites and bacterial infection. Goldstein EJ, et al. **Clin Infect Dis** 1995 Jun;20(6):1551–2 (14 ref.)
Septic shock due to Pasteurella multocida subspecies multocida in a previously healthy woman [letter] Ruiz-Irastorza G, et al. **Clin Infect Dis** 1995 Jul;21(1):232–4 (13 ref.)
[Arachnids as risk factors in occupational exposure] Dutkiewicz J. **Wiad Parazytol** 1995;41(3):253–66 (48 ref.) (Eng. Abstr.) **(Pol)**

EPIDEMIOLOGY

Dog, cat, and human bites: a review. Griego RD, et al. **J Am Acad Dermatol** 1995 Dec;33(6):1019–29 (115 ref.)
Severe dog bites in children. Brogan TV, et al. **Pediatrics** 1995 Nov;96(5 Pt 1):947–50 (19 ref.)

MICROBIOLOGY

[A case of Pasteurella multocida subsp. multocida septicemia due to cat bites in liver cirrhosis patient] Shimizu T, et al. **Kansenshogaku Zasshi** 1995 Nov;69(11):1302–6 (11 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

A case of tick bite by a spontaneously retreated Ixodes nipponensis. Cho BK, et al. **Korean J Parasitol** 1995 Sep; 33(3):239–42 (15 ref.)

PHYSIOPATHOLOGY

The scorpion envenoming syndrome. Ismail M. **Toxicon** 1995 Jul;33(7):825–58 (201 ref.)

PREVENTION & CONTROL

Health hazards to humans associated with domestic pets. Plaut M, et al. **Annu Rev Public Health** 1996;17:221–45 (87 ref.)

THERAPY

[Dog bites: publications on risk factors, infections, antibiotics and primary wound closure (see comments)] de Melker HE, et al. **Ned Tijdschr Geneeskd** 1996 Mar 30; 140(13):709–13 (41 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1996 Jun 1;140(22):1202–3. **(Dut)**

BITES, HUMAN

Human bites to the hand. Carr MM. **J Can Dent Assoc** 1995 Sep;61(9):782–4 (32 ref.)

EPIDEMIOLOGY

Dog, cat, and human bites: a review. Griego RD, et al. **J Am Acad Dermatol** 1995 Dec;33(6):1019–29 (115 ref.)

BITEWING RADIOGRAPHY see **RADIOGRAPHY, BITEWING**

BITIS see **VIPERIDAE**

BITTNER VIRUS see **MAMMARY TUMOR VIRUSES, MOUSE**

BK VIRUS see **POLYOMAVIRUS HOMINIS 1**

BLACK APE

BLACK APE see **MACACA**

BLACK PEPPER see **SPICES**

BLACK WIDOW SPIDER

Black widow spider bite in a child. Reeves JA, et al. **Am J Emerg Med** 1996 Sep;14(5):469–71 (17 ref.)

BLACKS

see related
NEGROID RACE

Occupational conditions and workers' sense of community: variations by gender and race. Lambert SJ, et al. **Am J Community Psychol** 1995 Apr;23(2):151–79 (78 ref.)

Creating a culturally responsive psychotherapeutic environment for African American youths: a critical analysis. Kendall J. **ANS Adv Nurs Sci** 1996 Jun;18(4):11–28 (43 ref.)

Smoking cessation programmes targeted at black and minority ethnic communities. Farren C, et al. **Br J Cancer Suppl** 1996 Sep;29:S78–80 (17 ref.)

Coronary heart disease in African Americans: primary and secondary prevention. Clark LT, et al. **Cleve Clin J Med** 1995 Sep–Oct;62(5):285–92 (52 ref.)

Ethnic differences in stroke: black–white differences in the United States population. SECORDS Investigators. Southeastern Consortium on Racial Differences in Stroke. Gaines K, et al. **Neuroepidemiology** 1995;14(5):209–39 (194 ref.)

Issues in drug abuse prevention intervention research with African Americans. Beatty LA. **NIDA Res Monogr** 1994; 139:171–201 (68 ref.)

Reaching out to the African American community through innovative strategies. Robinson KD, et al. **Oncol Nurs Forum** 1995 Oct;22(9):1383–91 (28 ref.)

Prevention in practice. Ethnic groups. Millar J, et al. **Prim Care** 1995 Dec;22(4):713–30 (27 ref.)

Role of dietary factors in the hypertension of African Americans. Adrogué HJ, et al. **Semin Nephrol** 1996 Mar; 16(2):94–101 (45 ref.)

Hypertension in the African American community: social, cultural, and psychological factors. Dressler WW. **Semin Nephrol** 1996 Mar;16(2):71–82 (52 ref.)

Preterm birth in the African–American community. Hogue CJ, et al. **Semin Perinatol** 1995 Aug;19(4):255–62 (70 ref.)

Afro–American women living with HIV infection: special therapeutic interventions for a growing population. Williams JK. **Soc Work Health Care** 1995;21(2):41–53 (30 ref.)

EDUCATION

Educating African–Americans about cancer prevention and detection: a review of the literature. Lowe JI, et al. **Soc Work Health Care** 1995;21(4):17–36 (36 ref.)

PSYCHOLOGY

African–American women: considering diverse identities and societal barriers in psychotherapy. Greene B. **Ann N Y Acad Sci** 1996 Jun 18;789:191–209 (30 ref.)

Eating disturbances among American minority groups: a review. Crago M, et al. **Int J Eat Disord** 1996 Apr; 19(3):239–48 (59 ref.)

Group therapy as an effective treatment modality for people of color. Fenster A. **Int J Group Psychother** 1996 Jul; 46(3):399–416 (42 ref.)

Inconsistencies in the literature on collegiate adult children of alcoholics: factors to consider for African Americans. Rodney HE. **J Am Coll Health** 1996 Jul;45(1):19–25 (58 ref.)

Psychosocial/cultural issues in medicine and psychiatry: treating African Americans. Carter JH. **J Natl Med Assoc** 1995 Dec;87(12):857–60 (18 ref.)

Child rearing beliefs in the African–American community: implications for culturally competent pediatric care. Yoos HL, et al. **J Pediatr Nurs** 1995 Dec;10(6):343–53 (73 ref.)

African American families, religion, and disability: a conceptual framework. Rogers–Dulan J, et al. **Ment Retard** 1995 Aug;33(4):226–38 (65 ref.)

Familial and ecological correlates of self–esteem in African American children. Walker K, et al. **New Dir Child Dev** 1995 Summer;(68):23–34 (70 ref.)

Cancer fatalism among African–Americans: a review of the literature. Powe BD. **Nurs Outlook** 1996 Jan–Feb; 44(1):18–21 (25 ref.)

Ethnicity and psychotherapy. A component in the treatment of cocaine addiction in African Americans. Foulks EF, et al. **Psychiatr Clin North Am** 1995 Sep;18(3):607–20 (59 ref.)

STATISTICS & NUMERICAL DATA

Breast cancer in black women. Moormeier J. **Ann Intern Med** 1996 May 15;124(10):897–905 (98 ref.)

Racial differences in health: not just black and white, but shades of gray. Lillie–Blanton M, et al. **Annu Rev Public Health** 1996;17:411–48 (52 ref.)

Differences in cancer incidence, mortality, and survival between African Americans and whites. Walker B, et al. **Environ Health Perspect** 1995 Nov;103 Suppl 8:275–81 (64 ref.)

Framing the debate: can prenatal care help to reduce the black–white disparity in infant mortality? Rowley DL. **J Am Med Wom Assoc** 1995 Sep–Oct;50(5):187–93 (119 ref.)

Separate black and white infant mortality models: differences in the importance of structural variables. Bird ST. **Soc Sci Med** 1995 Dec;41(11):1507–12 (37 ref.)

BLADDER

see related
CYSTECTOMY
CYSTOSTOMY
URINARY CATHETERIZATION

Bladder instillations and bladder washouts in the management of catheterized patients. Getliffe KA. **J Adv Nurs** 1996 Mar; 23(3):548–54 (49 ref.)

Introl bladder neck support prosthesis: a nonsurgical urethropexy. Davila GW. **J Endourol** 1996 Jun;10(3):293–6 (7 ref.)

Factors that modulate the initiation of micturition. Levin RM, et al. **Scand J Urol Nephrol Suppl** 1995;175:3–10 (56 ref.)

[Effects of anesthesia on postoperative micturition and urinary retention] Pertek JP, et al. **Ann Fr Anesth Reanim** 1995;14(4):340–51 (44 ref.) (Eng. Abstr.) **(Fre)**

[Intravesical foreign body caused arising from ureterostomy protective resin–gum] Oliver Llinares FJ, et al. **Arch Esp Urol** 1995 Oct;48(8):847–8 (6 ref.) (Eng. Abstr.) **(Spa)**

ABNORMALITIES

Agenesis of bladder associated with multiple organ anomalies. Sarica K, et al. **Int Urol Nephrol** 1995; 27(6):697–703 (10 ref.)

Complete duplication of the bladder and urethra: a case report and review of the literature. Ciftci AO, et al. **J Pediatr Surg** 1995 Nov;30(11):1605–6 (10 ref.)

ANATOMY & HISTOLOGY

The role of proteoglycans in bladder structure and function. Levy BJ, et al. **Adv Exp Med Biol** 1995;385:191–205; discussion 223–8 (66 ref.)

Anatomical relationships of urinary bladders compared: their potential role in the development of bladder tumours in humans and rats. DeSesso JM. **Food Chem Toxicol** 1995 Sep;33(9):705–14 (31 ref.)

Functional anatomy of the organs of micturition. Elbadawi A. **Urol Clin North Am** 1996 May;23(2):177–210 (255 ref.)

CYTOLOGY

Cell proliferation in the bladder and implications for cancer risk assessment. Cohen SM. **Toxicology** 1995 Sep 1; 102(1–2):149–59 (24 ref.)

DRUG EFFECTS

[Bladder retraction, a complication of chemoprophylaxis of superficial bladder cancer using intravesical mitomycin C. Apropos of a case and review of the literature] Punga–Maole ML, et al. **Prog Urol** 1995 Sep;5(4):580–5 (39 ref.) (Eng. Abstr.) **(Fre)**

EMBRYOLOGY

Fetal bovine bladder: physiology and pharmacology. Koo HP, et al. **Adv Exp Med Biol** 1995;385:251–3 (16 ref.)

ENZYMOLOGY

Nitric oxide synthase and the lower urinary tract: possible implications for physiology and pathophysiology. Andersson KE, et al. **Scand J Urol Nephrol Suppl** 1995; 175:43–53 (102 ref.)

GROWTH & DEVELOPMENT

Developmental aspects of excitation contraction coupling in urinary bladder smooth muscle. Zderic SA, et al. **Adv Exp Med Biol** 1995;385:105–15; discussion 131–9 (39 ref.)

IMMUNOLOGY

Studies on the expression of T–(Gal beta (1–3) GalNAc alpha 1–O–R) and T–like antigens in normal and pathologic human and rat urothelium. Langkilde NC. **Scand J Urol Nephrol Suppl** 1995;176:7–46 (188 ref.)

INJURIES

ABC of urology. Urological trauma and bladder reconstruction. Dawson C, et al. **BMJ** 1996 May 25; 312(7042):1352–4 (5 ref.)

INNERVATION

The neuronal response to bladder outlet obstruction, a role for NGF. Dupont MC, et al. **Adv Exp Med Biol** 1995; 385:41–54; discussion 75–9 (85 ref.)

Neuronal circuitry of the lower urinary tract; central and peripheral neuronal control of the micturition cycle. Kinder MV, et al. **Anat Embryol (Berl)** 1995 Sep;192(3):195–209 (55 ref.)

Suprapontine influences on the micturition reflex. Torrens M. **Scand J Urol Nephrol Suppl** 1995;175:11–3 (24 ref.)

Neurophysiology of micturition and continence. Chai TC, et al. **Urol Clin North Am** 1996 May;23(2):221–36 (142 ref.)

METABOLISM

Metabolism of detrusor smooth muscle in normal and obstructed urinary bladder. Uvelius B, et al. **Adv Exp Med Biol** 1995;385:29–39; discussion 75–9 (42 ref.)

PATHOLOGY

Contrast–enhanced MR imaging of the bladder and prostate. Siegelman ES, et al. **Magn Reson Imaging Clin N Am** 1996 Feb;4(1):153–69 (61 ref.)

Staging and prognosis of T3b bladder cancer. Levy DA, et al. **Semin Urol Oncol** 1996 May;14(2):56–61 (54 ref.)

PHYSIOLOGY

The role of proteoglycans in bladder structure and function. Levy BJ, et al. **Adv Exp Med Biol** 1995;385:191–205; discussion 223–8 (66 ref.)

The collagens and their urologic implications. Macarak EJ, et al. **Adv Exp Med Biol** 1995;385:173–7; discussion 179–84 (25 ref.)

Elastic fibers and their role in bladder extracellular matrix. Rosenbloom J, et al. **Adv Exp Med Biol** 1995;385:161–72; discussion 179–84 (52 ref.)

Developmental aspects of excitation contraction coupling in urinary bladder smooth muscle. Zderic SA, et al. **Adv Exp Med Biol** 1995;385:105–15; discussion 131–9 (39 ref.)

Cystometry. Dmochowski R. **Urol Clin North Am** 1996 May; 23(2):243–52 (51 ref.)

Videourodynamic studies. McGuire EJ, et al. **Urol Clin North Am** 1996 May;23(2):309–21 (13 ref.)

Smooth–muscle physiology. Zimmern PE, et al. **Urol Clin North Am** 1996 May;23(2):211–9 (45 ref.)

PHYSIOPATHOLOGY

Bladder function in experimental outlet obstruction: pharmacologic responses to alterations in innervation, energetics, calcium mobilization, and genetics. Levin RM, et al. **Adv Exp Med Biol** 1995;385:7–19; discussion 75–9 (61 ref.)

Electrical properties of obstructed guinea pig bladder. Mostwin JL, et al. **Adv Exp Med Biol** 1995;385:21–8; discussion 75–9 (16 ref.)

Matrix changes in the bladder associated with normal aging. Shapiro E, et al. **Adv Exp Med Biol** 1995;385:187–90; discussion 223–8 (23 ref.)

Visceral pain. McMahon SB, et al. **Br J Anaesth** 1995 Aug; 75(2):132–44 (114 ref.)

Leak–point pressures. McGuire EJ, et al. **Urol Clin North Am** 1996 May;23(2):253–62 (12 ref.)

Detrusor–sphincter dyssynergia. Barsanti JA, et al. **Vet Clin North Am Small Anim Pract** 1996 Mar; 26(2):327–38 (32 ref.)

SURGERY

Regenerative bladder augmentation: a review of the initial preclinical studies with porcine small intestinal submucosa. Kropp BP, et al. **Adv Exp Med Biol** 1995;385:229–35 (26 ref.)

Experience with augmentation cystoplasty. A review. Mast P, et al. **Paraplegia** 1995 Oct;33(10):560–4 (25 ref.)

[Simplified vesico–urethral anastomosis after radical retropubic prostatectomy for cancer. A preliminary comparative study] Doré B, et al. **J Urol (Paris)** 1995; 101(3):113–21 (31 ref.) (Eng. Abstr.) **(Fre)**

ULTRASONOGRAPHY

Imaging of the lower urinary tract. Koelbl H, et al. **Curr Opin Obstet Gynecol** 1995 Oct;7(5):382–5 (18 ref.)

BLADDER CALCULI

ETIOLOGY

[Uterine perforation and localization of an IUD in the bladder associated with bladder calculosis. Report of a case and review of the literature] Reyes–Acevedo J, et al. **Ginecol Obstet Mex** 1995 Oct;63:407–9 (13 ref.) (Eng. Abstr.) **(Spa)**

BLADDER DISEASES

[Bladder hernia] Basile G, et al. **Ann Ital Chir** 1995 May–Jun; 66(3):363–9 (28 ref.) (Eng. Abstr.) **(Ita)**

COMPLICATIONS

[Female urology: new advances in 1995] Chassagne S, et al. **J Urol (Paris)** 1996;102(1):33–9 (32 ref.) **(Fre)**

[Urinary incontinence of bladder origin — bladder instability] **Prog Urol** 1995 Nov;5(5):773–87 (124 ref.) **(Fre)**

DIAGNOSIS

Condyloma acuminatum of the bladder: radiologic findings. Levine CD, et al. **AJR Am J Roentgenol** 1995 Dec; 165(6):1467–8 (3 ref.)

Urinary bladder rupture in an elderly patient: case report.

Marcus EL, et al. **Can Fam Physician** 1995 Nov;41:1945-7 (9 ref.)

Contrast-enhanced MR imaging of the bladder and prostate. Siegelman ES, et al. **Magn Reson Imaging Clin N Am** 1996 Feb;4(1):153-69 (61 ref.)

[Bladder dysfunction in children] Bensman A, et al. **Ann Urol (Paris)** 1995;29(5):302-5 (15 ref.) **(Fre)**

[Nonmalignant proliferative lesions of the urinary bladder] Halachmi S, et al. **Harefuah** 1995 Dec 1;129(11):516-9 (46 ref.) **(Heb)**

[Primary amyloidosis localized in the bladder] Vicioso Recio L, et al. **Arch Esp Urol** 1995 Nov;48(9):963-6 (8 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

Spontaneous rupture of the urinary bladder: a late complication of radiotherapy--case report and review of the literature. Addar MH, et al. **Gynecol Oncol** 1996 Aug; 62(2):314-6 (16 ref.)

[Bladder and sphincter disorders in multiple sclerosis. Clinical, urodynamic and neurophysiological study of 225 cases] Amarenco G, et al. **Rev Neurol (Paris)** 1995 Dec; 151(12):722-30 (34 ref.) (Eng. Abstr.) **(Fre)**

PARASITOLOGY

[Bladder schistosomiasis: report of 2 new cases with different anatomoclinical features and review of the literature] Peinado Ibarra F, et al. **Actas Urol Esp** 1995 Oct; 19(9):724-8 (17 ref.) (Eng. Abstr.) **(Spa)**

PATHOLOGY

Malignant transformation in endometriosis of the urinary bladder: case report of clear cell adenocarcinoma. Balat O, et al. **Eur J Gynaecol Oncol** 1996;17(1):13-6 (14 ref.)

[Bladder schistosomiasis: report of 2 new cases with different anatomoclinical features and review of the literature] Peinado Ibarra F, et al. **Actas Urol Esp** 1995 Oct; 19(9):724-8 (17 ref.) (Eng. Abstr.) **(Spa)**

SURGERY

The prosthetic bladder. Gürpinar T, et al. **World J Urol** 1996; 14(1):47-52 (22 ref.)

BLADDER EXSTROPHY

DIAGNOSIS

[A rare case of bladder exstrophy in a newborn infant] Lazarov L, et al. **Akush Ginekol (Sofiia)** 1995;34(3):68 (8 ref.) **(Bul)**

SURGERY

Bladder exstrophy from childhood into adult life. Ben-Chaim J, et al. **J R Soc Med** 1996 Jan;89(1):39P-46P (62 ref.)

BLADDER FISTULA

DIAGNOSIS

Appendicovesical fistula. Athanassopoulos A, et al. **Int Urol Nephrol** 1995;27(6):705-8 (9 ref.)

ETIOLOGY

Colonic duplication: an unusual cause of enterovesical fistula. Payne CE, et al. **Urology** 1995 Nov;46(5):726-8 (10 ref.)

BLADDER NECK OBSTRUCTION

Bladder outlet obstruction--an overview. Wein AJ. **Adv Exp Med Biol** 1995;385:3-5; discussion 75-9 (1 ref.)

Obstructive uropathy in the male. Blaivas JG. **Urol Clin North Am** 1996 Aug;23(3):373-84 (40 ref.)

Bladder outlet obstruction in women. Carr LK, et al. **Urol Clin North Am** 1996 Aug;23(3):385-91 (29 ref.)

COMPLICATIONS

Inverted Y duplication of the ureter with associated ureterocele and bladder outlet obstruction. Regan TC, et al. **J Urol** 1996 Feb;155(2):642 (3 ref.)

CONGENITAL

Congenital bladder obstruction: research strategies and directions. Peters CA. **Adv Exp Med Biol** 1995;385:117-30; discussion 131-9 (38 ref.)

DIAGNOSIS

Symptom indices in bladder outlet obstruction. Hines JE. **Br J Urol** 1996 Apr;77(4):494-501 (57 ref.)

Venous obstruction due to a distended urinary bladder. Evans JM, et al. **Mayo Clin Proc** 1995 Nov;70(11):1077-9 (17 ref.)

ETIOLOGY

Is collagen remodeling associated with bladder obstruction? Ehrlich HP. **Adv Exp Med Biol** 1995;385:143-9; discussion 179-84 (30 ref.)

GENETICS

Bladder function in experimental outlet obstruction: pharmacologic responses to alterations in innervation, energetics, calcium mobilization, and genetics. Levin RM, et al. **Adv Exp Med Biol** 1995;385:7-19; discussion 75-9 (61 ref.)

Molecular aspects of bladder outlet obstruction. Lin VK, et al. **Adv Exp Med Biol** 1995;385:65-74; discussion 75-9 (83 ref.)

METABOLISM

Metabolism of detrusor smooth muscle in normal and obstructed urinary bladder. Uvelius B, et al. **Adv Exp Med Biol** 1995;385:29-39; discussion 75-9 (42 ref.)

PHYSIOPATHOLOGY

Contractile proteins and their response to bladder outlet obstruction. Chacko S, et al. **Adv Exp Med Biol** 1995; 385:55-63; discussion 75-9 (111 ref.)

The neuronal response to bladder outlet obstruction, a role for NGF. Dupont MC, et al. **Adv Exp Med Biol** 1995; 385:41-54; discussion 75-9 (85 ref.)

Bladder function in experimental outlet obstruction: pharmacologic responses to alterations in innervation, energetics, calcium mobilization, and genetics. Levin RM, et al. **Adv Exp Med Biol** 1995;385:7-19; discussion 75-9 (61 ref.)

Electrical properties of obstructed guinea pig bladder. Mostwin JL, et al. **Adv Exp Med Biol** 1995;385:21-8; discussion 75-9 (16 ref.)

Leak-point pressures. McGuire EJ, et al. **Urol Clin North Am** 1996 May;23(2):253-62 (12 ref.)

BLADDER NEOPLASMS

Verrucous carcinoma of the bladder. Blackmore CC, et al. **Abdom Imaging** 1995 Sep-Oct;20(5):480-2 (8 ref.)

ABC of Urology. Urological malignancy--II: Urothelial tumours. Dawson C, et al. **BMJ** 1996 Apr 27; 312(7038):1090-4 (0 ref.)

Bladder cancer, 1996. Lamm DL, et al. **CA Cancer J Clin** 1996 Mar-Apr;46(2):93-112 (101 ref.)

Proceedings of the 4th International Bladder Consensus Meeting. Antwerp, Belgium, March 24-26, 1993. **Int J Urol** 1995 Jun;2 Suppl 2:1-131 (0 ref.)

Transitional cell carcinoma of the bladder in the pediatric patient. Hoenig DM, et al. **J Urol** 1996 Jul;156(1):203-5 (23 ref.)

Bladder cancer. Current diagnostic methods and treatment options. Badalament RA, et al. **Postgrad Med** 1996 Aug; 100(2):217-9, 223-4, 230 (22 ref.)

Characteristics of invasive bladder cancers: histological and molecular markers. Liebert M, et al. **Semin Urol Oncol** 1996 May;14(2):62-72 (136 ref.)

Primary signet ring cell carcinoma of the urinary bladder. Review of the literature and report of two cases. Erdoğru T, et al. **Urol Int** 1995;55(1):34-7 (23 ref.)

Small cell carcinoma of the bladder and prostate. Abbas F, et al. **Urology** 1995 Nov;46(5):617-30 (114 ref.)

[Urachal adenocarcinoma associated with urothelial tumor of the bladder. Report of a case] Payen E, et al. **Prog Urol** 1996 Apr;6(2):288-91 (13 ref.) (Eng. Abstr.) **(Fre)**

[Adenoacanthoma] Honda K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):303-4 (17 ref.) **(Jpn)**

[Fibrous polyp of the gallbladder] Takashimizu I, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):295-8 (16 ref.) **(Jpn)**

[Carcinosarcoma and so-called carcinosarcoma of the gallbladder] Taniguchi H, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):270-2 (13 ref.) **(Jpn)**

[Bladder leiomyoma. Review and report of a case] Alapont Pérez FM, et al. **Arch Esp Urol** 1995 Dec;48(10):1035-7 (10 ref.) (Eng. Abstr.) **(Spa)**

[Characteristics of bladder leiomyoma in our setting] Blasco Casares FJ, et al. **Arch Esp Urol** 1995 Dec;48(10):987-90 (13 ref.) (Eng. Abstr.) **(Spa)**

CHEMICALLY INDUCED

Genotoxicity in the rodent urinary bladder. King C, et al. **Food Chem Toxicol** 1995 Sep;33(9):757-69 (73 ref.)

Saccharin-induced bladder cancer in rats. Garland EM, et al. **Prog Clin Biol Res** 1995;391:237-43 (21 ref.)

Role of cell proliferation in regenerative and neoplastic disease. Cohen SM. **Toxicol Lett** 1995 Dec;82-83:15-21 (20 ref.)

Relationship of DNA adducts derived from 2-acetylaminofluorene to cell proliferation and the induction of rodent liver and bladder tumors. Cohen SM, et al. **Toxicol Pathol** 1995 Mar-Apr;23(2):136-42 (21 ref.)

Cell proliferation in the bladder and implications for cancer risk assessment. Cohen SM. **Toxicology** 1995 Sep 1; 102(1-2):149-59 (24 ref.)

CLASSIFICATION

The current TNM-classification of bladder carcinoma--is it as good as we need it to be? Kotake T, et al. **Int J Urol** 1995 Jun;2 Suppl 2:36-40 (16 ref.)

DIAGNOSIS

Current methods of assessing and treating carcinoma in situ of the bladder with or without involvement of the prostatic urethra. Kurth KH, et al. **Int J Urol** 1995 Jun;2 Suppl 2:8-22 (124 ref.)

Computer tomography and magnetic resonance imaging in the evaluation of bladder cancer. Husband JE. **J Belge Radiol** 1995 Dec;78(6):350-5 (33 ref.)

Contrast-enhanced MR imaging of the bladder and prostate. Siegelman ES, et al. **Magn Reson Imaging Clin N Am** 1996 Feb;4(1):153-69 (61 ref.)

[Nonmalignant proliferative lesions of the urinary bladder] Halachmi S, et al. **Harefuah** 1995 Dec 1;129(11):516-9 (46 ref.) **(Heb)**

[Bladder carcinosarcoma. A clinical case] Pena Outeiriño JM, et al. **Actas Urol Esp** 1995 Mar;19(3):234-7 (11 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Chemotherapy for advanced bladder carcinoma: new molecules and regimens. Abi-Aad AS. **Acta Urol Belg** 1996 May;64(2):43-5 (19 ref.)

Cisplatin-based chemotherapy in renal transplant recipients. A case report and a review of the literature. Benisovich VI, et al. **Cancer** 1996 Jan 1;77(1):160-3 (22 ref.)

Neoadjuvant and adjuvant chemotherapy in advanced disease--what are the effects on survival and prognosis? Sternberg CN, et al. **Int J Urol** 1995 Jun;2 Suppl 2:76-88 (101 ref.)

Ifosfamide in the treatment of bladder cancer. Roth BJ. **Semin Oncol** 1996 Jun;23(3 Suppl 6):50-5 (48 ref.)

The role of ifosfamide in the treatment of testicular and urothelial malignancies. Roth BJ. **Semin Oncol** 1996 Jun; 23(3 Suppl 7):19-27 (83 ref.)

The role of paclitaxel in the therapy of bladder cancer. Roth BJ. **Semin Oncol** 1995 Oct;22(5 Suppl 12):33-40 (73 ref.)

Neoadjuvant and adjuvant chemotherapy for invasive bladder cancer. Smith MR, et al. **Semin Oncol** 1995 Dec; 22(6):625-32 (28 ref.)

The role of chemotherapy in the management of the patient with T3b bladder cancer. Millikan R, et al. **Semin Urol Oncol** 1996 May;14(2):81-5 (23 ref.)

Chemotherapy for invasive bladder cancer. Malkowicz SB, et al. **Urology** 1996 Apr;47(4):602-14 (105 ref.)

[Complications of intravesical mitomycin chemotherapy, apropos of 2 clinical case reports] Pouya M, et al. **Acta Urol Belg** 1996 Mar;64(1):47-53 (24 ref.) (Eng. Abstr.) **(Fre)**

[Place of endovesical "BCG Therapy" in superficial tumors of the bladder] Zerbib M. **J Urol (Paris)** 1995;101(2):59-63 (30 ref.) (Eng. Abstr.) **(Fre)**

[Infiltrating carcinoma of the bladder. Neo-adjuvant chemotherapy (2nd. part). Historic review and new treatment guidelines] Escudero Barrilero A, et al. **Actas Urol Esp** 1995 May;19(5):363-75 (28 ref.) (Eng. Abstr.) **(Spa)**

EPIDEMIOLOGY

Human bladder cancer: evidence for a potential irritation-induced mechanism. Burin GJ, et al. **Food Chem Toxicol** 1995 Sep;33(9):785-95 (86 ref.)

The procarcinogen hypothesis for bladder cancer: activities of individual drug metabolizing enzymes as risk factors. Branch RA, et al. **Pharmacogenetics** 1995;5 Spec No:S97-102 (26 ref.)

ETIOLOGY

Urinary bladder carcinogenesis: implications for risk assessment. Rodent Bladder Carcinogenesis Working Group. **Food Chem Toxicol** 1995 Sep;33(9):797-802 (32 ref.)

Human bladder cancer: evidence for a potential irritation-induced mechanism. Burin GJ, et al. **Food Chem Toxicol** 1995 Sep;33(9):785-95 (86 ref.)

Effects of stones and other physical factors on the induction of rodent bladder cancer. Clayson DB, et al. **Food Chem Toxicol** 1995 Sep;33(9):771-84 (142 ref.)

Role of urinary physiology and chemistry in bladder carcinogenesis. Cohen SM. **Food Chem Toxicol** 1995 Sep; 33(9):715-30 (110 ref.)

Anatomical relationships of urinary bladders compared: their potential role in the development of bladder tumours in humans and rats. DeSesso JM. **Food Chem Toxicol** 1995 Sep;33(9):705-14 (31 ref.)

The etiology of bladder cancer--are there any new clues or predictors of behavior? Shirai T, et al. **Int J Urol** 1995 Jun;2 Suppl 2:64-75 (147 ref.)

GENETICS

Molecular and genetic events in schistosomiasis-associated human bladder cancer: role of oncogenes and tumor suppressor genes. Badawi AF. **Cancer Lett** 1996 Aug 2; 105(2):123-38 (111 ref.)

Recent advances in the study of molecular biology of bladder cancer in China. Gu F. **Chin Med J (Engl)** 1996 Feb; 109(2):126-9 (26 ref.)

Basic research. Debruyne F, et al. **Int J Urol** 1995 Jun;2 Suppl 2:117-21 (22 ref.)

Retention of CD44 introns in bladder cancer: understanding the alternative splicing of pre-mRNA opens new insights into the pathogenesis of human cancers [editorial] Cooper

DL. **J Pathol** 1995 Sep;177(1):1–3 (28 ref.)

Nephrogenic adenoma of the bladder in renal transplant recipients: a report of 9 cases with assessment of deoxyribonucleic acid ploidy and long-term followup. Fournier G, et al. **J Urol** 1996 Jul;156(1):41–4 (21 ref.)

Familial transitional cell carcinoma [see comments] Kiemeney LA, et al. **J Urol** 1996 Sep;156(3):867–72 (73 ref.) Comment in: J Urol 1996 Sep;156(3):961.

Clinical application of flow cytometry to urological malignancies. Tachibana M. **Keio J Med** 1996 Jun; 45(2):73–80 (54 ref.)

Genetic susceptibility and carcinogen-DNA adduct formation in human urinary bladder carcinogenesis. Kadlubar FF, et al. **Toxicol Lett** 1995 Dec;82–83:627–32 (19 ref.)

[Familial bladder cancer] Terai A. **Nippon Rinsho** 1995 Nov; 53(11):2749–53 (27 ref.) (Eng. Abstr.) **(Jpn)**

[P53 protein gene. Review of the literature and assessment of the prognostic impact of its mutations in bladder tumors] Marchal Escalona C, et al. **Actas Urol Esp** 1996 Feb; 20(2):93–102 (42 ref.) (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

Studies on the expression of T-(Gal beta (1–3) GalNAc alpha 1-O-R) and T-like antigens in normal and pathologic human and rat urothelium. Langkilde NC. **Scand J Urol Nephrol Suppl** 1995;176:7–46 (188 ref.)

T-antigens in primary non-invasive and superficially invasive human urinary bladder tumors: the correlation to tumor recurrence and tumor progression. A mini-review. Langkilde NC. **Scand J Urol Nephrol Suppl** 1995;172:45–9 (55 ref.)

METABOLISM

Genotoxicity in the rodent urinary bladder. King C, et al. **Food Chem Toxicol** 1995 Sep;33(9):757–69 (73 ref.)

MORTALITY

Staging and prognosis of T3b bladder cancer. Levy DA, et al. **Semin Urol Oncol** 1996 May;14(2):56–61 (54 ref.)

[Prognostic factors in bladder cancer] Kuroda M, et al. **Gan To Kagaku Ryoho** 1995 Dec;22(14):2123–8 (26 ref.) (Eng. Abstr.) **(Jpn)**

NURSING

An overview of bladder cancer: treatment and nursing implications. Kelly LP, et al. **Oncol Nurs Forum** 1996 Apr; 23(3):459–68 (66 ref.)

PATHOLOGY

Pseudosarcomatous myofibroblastic tumor of the urinary bladder in children: a study of 11 cases with review of the literature. An Intergroup Rhabdomyosarcoma Study. Hojo H, et al. **Am J Surg Pathol** 1995 Nov;19(11):1224–36 (43 ref.)

Carcinosarcoma of the urinary bladder—case report and literature review. Swaminathan I, et al. **Ann Acad Med Singapore** 1995 Jul;24(4):640–3 (15 ref.)

Malignant transformation in endometriosis of the urinary bladder: case report of clear cell adenocarcinoma. Balat O, et al. **Eur J Gynaecol Oncol** 1996;17(1):13–6 (14 ref.)

Primary staging of urinary bladder carcinoma: the role of MRI and a comparison with CT. Barentsz JO, et al. **Eur Radiol** 1996;6(2):129–33 (49 ref.)

The histogenesis of clear cell adenocarcinoma of the lower urinary tract. Case series and review of the literature. Drew PA, et al. **Hum Pathol** 1996 Mar;27(3):248–52 (32 ref.)

What is the biology of invasion and metastasis in bladder cancer? Kakizoe T, et al. **Int J Urol** 1995 Jun;2 Suppl 2:58–63 (57 ref.)

Optimal staging procedures, including imaging, to define prognosis of bladder cancer. Paulson D, et al. **Int J Urol** 1995 Jun;2 Suppl 2:1–7 (8 ref.)

Nephrogenic adenoma of the urinary tract: a review of the microscopic appearance of 80 cases with emphasis on unusual features. Oliva E, et al. **Mod Pathol** 1995 Sep; 8(7):722–30 (27 ref.)

What to do if the lymph nodes are positive. Evans CP, et al. **Semin Urol Oncol** 1996 May;14(2):96–102 (22 ref.)

Staging and prognosis of T3b bladder cancer. Levy DA, et al. **Semin Urol Oncol** 1996 May;14(2):56–61 (54 ref.)

Prognostic factors for bladder cancer [editorial] Otto T, et al. **Urol Res** 1995;23(3):137–41 (35 ref.)

Annular constriction of the rectum secondary to transitional cell carcinoma of the bladder. Langenstroer P, et al. **Urology** 1996 Mar;47(3):442–4 (6 ref.)

Recommendations for the reporting of urinary bladder specimens containing bladder neoplasms. Association of Directors of Anatomic and Surgical Pathology. **Virchows Arch** 1996 Apr;428(1):1–3 (6 ref.)

[Proliferative cystitis forming tumorous lesion: a case report] Inaba Y, et al. **Hinyokika Kiyo** 1995 Aug;41(8):617–20 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Asynchronous metastases solely to the bilateral adrenal glands from bladder cancer: a case report] Watanabe J, et al. **Hinyokika Kiyo** 1996 Jan;42(1):63–6 (7 ref.) (Eng. Abstr.) **(Jpn)**

[Cellular biological approach for determining of malignant potential and invasiveness of bladder cancers] Tachibana M. **Nippon Hinyokika Gakkai Zasshi** 1996 Mar;87(3):629–42 (122 ref.) **(Jpn)**

[Skin metastasis from transitional cell carcinoma of the bladder] Alvarez Castelo LM, et al. **Arch Esp Urol** 1995 Sep;48(7):749–50 (9 ref.) (Eng. Abstr.) **(Spa)**

PREVENTION & CONTROL

Retinoids in cancer chemoprevention. Clinical trials with the synthetic analogue fenretinide. Costa A, et al. **Ann N Y Acad Sci** 1995 Sep 30;768:148–62 (49 ref.)

[Bladder retraction, a complication of chemoprophylaxis of superficial bladder cancer using intravesical mitomycin C. Apropos of a case and review of the literature] Punga-Maole ML, et al. **Prog Urol** 1995 Sep;5(4):580–5 (39 ref.) (Eng. Abstr.) **(Fre)**

RADIOTHERAPY

The place of radiation therapy as definitive treatment of bladder cancer. Gospodarowicz MK, et al. **Int J Urol** 1995 Jun;2 Suppl 2:41–8 (50 ref.)

Gold, electron microscopy, and cancer therapy. Hainfeld JF. **Scanning Microsc** 1995 Mar;9(1):239–54; discussion 254–6 (28 ref.)

Radiotherapy for stage T3b transitional cell carcinoma of the bladder. Pollack A, et al. **Semin Urol Oncol** 1996 May; 14(2):86–95 (63 ref.)

SECONDARY

Metastatic breast cancer to the bladder: a case report. Schneidau T, et al. **Int Urol Nephrol** 1995;27(3):297–300 (11 ref.)

Metastatic merkel cell tumour to the bladder. Woo HH, et al. **Int Urol Nephrol** 1995;27(3):301–5 (13 ref.)

SURGERY

Bladder preservation—a prospect for patients with urinary bladder cancer. Sternberg CN. **Acta Oncol** 1995; 34(5):589–97; discusion 588 (72 ref.)

What are the risks of cystectomy and the advances in perioperative care? Montie JE, et al. **Int J Urol** 1995 Jun; 2 Suppl 2:89–104 (78 ref.)

Which patients are suitable for continent diversion or bladder substitution following cystectomy or other definitive local treatment? Skinner DG, et al. **Int J Urol** 1995 Jun;2 Suppl 2:105–12 (105 ref.)

Laparoscopic surgery for bladder carcinoma. Parra RO, et al. **Semin Surg Oncol** 1996 Mar–Apr;12(2):145–52 (38 ref.)

Bladder preservation and continent urinary diversion in T3b transitional cell carcinoma of the bladder. Cespedes RD, et al. **Semin Urol Oncol** 1996 May;14(2):103–11 (56 ref.)

Radical cystectomy for stage T3b bladder cancer. Hall CM, et al. **Semin Urol Oncol** 1996 May;14(2):73–80 (33 ref.)

The use of neobladders in women undergoing cystectomy for transitional-cell cancer. Stenzl A, et al. **World J Urol** 1996;14(1):15–21 (37 ref.)

[The treatment of bladder tumors with the Nd:YAG laser] Khinev A. **Khirurgiia (Sofiia)** 1995;48(5):58–62 (29 ref.) (Eng. Abstr.) **(Bul)**

[Prognostic factors of survival in infiltrating urothelial bladder carcinoma. A retrospective study of 158 patients treated by radical cystectomy] Thieblemont C, et al. **Bull Cancer (Paris)** 1996 Feb;83(2):139–46 (35 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Superficial bladder cancer—treatment approach. Abi-Aad A, et al. **Acta Urol Belg** 1996 May;64(2):19–24 (37 ref.)

Phase II trials in Ta, T1 bladder cancer. The marker tumour concept. van der Meijden AP, et al. **Br J Urol** 1996 May; 77(5):634–7 (14 ref.)

The design of clinical trials for new therapies in bladder cancer. Is it time for new strategies? De Mulder PH, et al. **Int J Urol** 1995 Jun;2 Suppl 2:113–6 (18 ref.)

The status of bladder-preserving therapeutic strategies in the management of patients with muscle-invasive bladder cancer. Koiso K, et al. **Int J Urol** 1995 Jun;2 Suppl 2:49–57 (54 ref.)

Current methods of assessing and treating carcinoma in situ of the bladder with or without involvement of the prostatic urethra. Kurth KH, et al. **Int J Urol** 1995 Jun;2 Suppl 2:8–22 (124 ref.)

Intravesical chemotherapy and immunotherapy: how do we assess their effectiveness and what are their limitations and uses? Lamm DL, et al. **Int J Urol** 1995 Jun;2 Suppl 2:23–35 (38 ref.)

Carcinoma in situ and treatment options. Erton M, et al. **Int Urol Nephrol** 1996;28(1):33–42 (25 ref.)

BCG immunotherapy for transitional-cell carcinoma in situ of the bladder. Lamm DL. **Oncology (Huntingt)** 1995 Oct; 9(10):947–52, 955, discussion 955–65 (51 ref.)

The management of locally recurrent invasive bladder cancer following radical cystectomy. Pisters LL, et al. **Semin Urol Oncol** 1996 May;14(2):112–9 (25 ref.)

Management of prostate and bladder cancer in the elderly. Dreicer R, et al. **Urol Clin North Am** 1996 Feb;23(1):87–97 (85 ref.)

VIROLOGY

Do human papillomaviruses have a role in the pathogenesis of bladder carcinoma? Mvula M, et al. **J Urol** 1996 Feb; 155(2):471–4 (24 ref.)

Unsuccessful effort to detect human papillomavirus DNA in urinary bladder cancers by the polymerase chain reaction and in situ hybridization. Sano T, et al. **Pathol Int** 1995 Jul;45(7):506–12 (32 ref.)

BLADDER, NEUROGENIC

Pediatric neurourology. Ewalt DH, et al. **Urol Clin North Am** 1996 Aug;23(3):501–9 (42 ref.)

DIAGNOSIS

Investigation of the neurogenic bladder. Fowler CJ. **J Neurol Neurosurg Psychiatry** 1996 Jan;60(1):6–13 (52 ref.)

[Cystometry in neurogenic bladder disorders. Methodologic problems and assessment of risk of renal complications] Thyberg M, et al. **Tidsskr Nor Laegeforen** 1995 Sep 30; 115(23):2904–8 (23 ref.) (Eng. Abstr.) **(Nor)**

ETIOLOGY

Peripheral neuropathy and peripheral nerve injury. Nickell K, et al. **Urol Clin North Am** 1996 Aug;23(3):491–500 (93 ref.)

[A rare cause of neurologic bladder: arteriovenous dural fistula with venous epidural drainage] Punga-Maole ML, et al. **Prog Urol** 1995 Dec;5(6):1001–8 (32 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Leak-point pressures. McGuire EJ, et al. **Urol Clin North Am** 1996 May;23(2):253–62 (12 ref.)

REHABILITATION

[Electric stimulation—hope for patients with urinary incontinence] Franek A, et al. **Pol Tyg Lek** 1996 Feb; 51(6–9):109–12 (40 ref.) **(Pol)**

BLADDER STONES see **BLADDER CALCULI**

BLAST-2 ANTIGEN, B-CELL see **ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE**

BLAST CRISIS

IMMUNOLOGY

[Expression of primitive stem cell antigens on the blast cells of patients with chronic myeloid leukemia] Baryshnikov AIu. **Vestn Ross Akad Med Nauk** 1996;(3):9–13 (53 ref.) (Eng. Abstr.) **(Rus)**

PATHOLOGY

Acute myelofibrosis terminating in acute lymphoblastic leukemia: case report and review of the literature. Dunphy CH, et al. **Am J Hematol** 1996 Jan;51(1):85–9 (21 ref.)

BLAST INJURIES

Blast injury of the ear: an overview and guide to management. Garth RJ. **Injury** 1995 Jul;26(6):363–6 (14 ref.)

COMPLICATIONS

[Arterial air embolism in explosive trauma to the lungs] Fomin NF, et al. **Vestn Khir Im I I Grek** 1995;154(2):120–3 (26 ref.) **(Rus)**

ETIOLOGY

Antipersonnel mines: the global epidemic. Chaloner EJ, et al. **Ann R Coll Surg Engl** 1996 Jan;78(1):1–4 (37 ref.)

Injuries due to antipersonnel land mines in Sri Lanka. Goonetilleke G. **Ceylon Med J** 1995 Dec;40(4):141–5 (8 ref.)

PATHOLOGY

[Bilateral ocular blast injury after refractive surgery by 2 current techniques. Comparative anatomo-clinical analysis of a case] Schmitt-Bernard CF, et al. **J Fr Ophtalmol** 1996; 19(4):287–91 (19 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Management of penetrating war wounds. Teh J. **Aust Fam Physician** 1995 Dec;24(12):2186–90 (0 ref.)

BLAST PHASE see **BLAST CRISIS**

BLAST TRANSFORMATION see **LYMPHOCYTE TRANSFORMATION**

BLASTOCRITHIDIA see **TRYPANOSOMATINA**

BLASTOCYST

see related
PREIMPLANTATION PHASE

CYTOLOGY

In vitro differentiation of murine embryonic stem cells. New

approaches to old problems. Weiss MJ, et al. **J Clin Invest** 1996 Feb 1;97(3):591–5 (59 ref.)
Co-culture of the early human embryo: factors affecting human blastocyst formation in vitro. Ménézo YJ, et al. **Microsc Res Tech** 1995 Sep 1;32(1):50–6 (52 ref.)

PHYSIOLOGY

The role of prostaglandins in blastocyst implantation. Psychoyos A, et al. **Hum Reprod** 1995 Dec;10 Suppl 2:30–42 (105 ref.)
The signals and molecular pathways involved in implantation, a symbiotic interaction between blastocyst and endometrium involving adhesion and tissue invasion. Tabibzadeh S, et al. **Hum Reprod** 1995 Jun;10(6):1579–602 (200 ref.)
Role of gap junctions in the development of the preimplantation mouse embryo. Becker DL, et al. **Microsc Res Tech** 1995 Aug 1;31(5):364–74 (31 ref.)

BLASTOCYST TRANSFER see **EMBRYO TRANSFER**

BLASTOCYSTIS HOMINIS

DRUG EFFECTS

Is there any reason to continue treating Blastocystis infections? [editorial; comment] Markell EK. **Clin Infect Dis** 1995 Jul;21(1):104–5 (11 ref.) Comment on: Clin Infect Dis 1995 Jul;21(1):97–101.

PATHOGENICITY

Blastocystis hominis and traveler's diarrhea [editorial; comment] Keystone JS. **Clin Infect Dis** 1995 Jul;21(1):102–3 (31 ref.) Comment on: Clin Infect Dis 1995 Jul;21(1):97–101.

BLASTOCYSTIS INFECTIONS

DRUG THERAPY

Is there any reason to continue treating Blastocystis infections? [editorial; comment] Markell EK. **Clin Infect Dis** 1995 Jul;21(1):104–5 (11 ref.) Comment on: Clin Infect Dis 1995 Jul;21(1):97–101.

PARASITOLOGY

Blastocystis hominis and traveler's diarrhea [editorial; comment] Keystone JS. **Clin Infect Dis** 1995 Jul;21(1):102–3 (31 ref.) Comment on: Clin Infect Dis 1995 Jul;21(1):97–101.

BLASTOCYTES see **BLASTOMERES**

BLASTODERM

PHYSIOLOGY

Role of the actin cytoskeleton in early Drosophila development. Miller KG. **Curr Top Dev Biol** 1995; 31:167–96 (59 ref.)
Time-lapse cinephotomicrography, videography, and videomicrography of the avian blastoderm. Bortier H, et al. **Methods Cell Biol** 1996;51:331–54 (18 ref.)

BLASTOGENESIS see **LYMPHOCYTE TRANSFORMATION**

BLASTOMA, PULMONARY see **PULMONARY BLASTOMA**

BLASTOMERES

Ethical and policy issues in human embryo twinning. Bonnicksen AL. **Camb Q Healthc Ethics** 1995 Summer; 4(3):268–84 (94 ref.)

CHEMISTRY

Fluorescent PCR: a new technique for PGD of sex and single-gene defects. Findlay I, et al. **J Assist Reprod Genet** 1996 Feb;13(2):96–103 (28 ref.)

CYTOLOGY

Blastomere culture and analysis. Edgar LG. **Methods Cell Biol** 1995;48:303–21 (15 ref.)

BLASTOMYCOSIS

ETIOLOGY

Histoplasmosis and blastomycosis. Bradsher RW. **Clin Infect Dis** 1996 May;22 Suppl 2:S102–11 (97 ref.)
Pneumonia due to blastomyces dermatitidis in a European renal transplant recipient. Winkler S, et al. **Nephrol Dial Transplant** 1996 Jul;11(7):1376–9 (13 ref.)

BLASTOMYCOSIS, NORTH AMERICAN see **BLASTOMYCOSIS**

BLASTOMYCOSIS, SOUTH AMERICAN see **PARACOCCIDIOIDOMYCOSIS**

BLASTOPORE see **GASTRULA**

BLASTULA see **BLASTOCYST**

BLEEDING see **HEMORRHAGE**

BLEEDING TIME

The preoperative bleeding time test: assessing its clinical usefulness. Gewirtz AS, et al. **Cleve Clin J Med** 1995 Nov-Dec;62(6):379–82 (41 ref.)
Bleeding time: an unreliable predictor of clinical hemostasis. De Rossi SS, et al. **J Oral Maxillofac Surg** 1996 Sep; 54(9):1119–20 (21 ref.)
[Bleeding time] Samori T. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:3–5 (3 ref.) **(Jpn)**

BLEOMYCIN

Metallobleomycin-DNA interactions: structures and reactions related to bleomycin-induced DNA damage. Petering DH, et al. **Met Ions Biol Syst** 1996;33:619–48 (92 ref.)

ANALOGS & DERIVATIVES

RNA recognition and cleavage by iron(II)–bleomycin. Battigello JM, et al. **Met Ions Biol Syst** 1996;33:593–617 (98 ref.)

THERAPEUTIC USE

Bleomycin. Lazo JS, et al. **Cancer Chemother Biol Response Modif** 1996;16:39–47 (55 ref.)

TOXICITY

DNA damage and mutagenesis by radiomimetic DNA-cleaving agents: bleomycin, neocarzinostatin and other enediynes. Povirk LF. **Mutat Res** 1996 Aug 17; 355(1–2):71–89 (125 ref.)

BLEPHARITIS

Eyelid dermatitis. A common, often confounding rash. Parkinson RW. **Postgrad Med** 1996 Aug;100(2):231–6, 239–40 (12 ref.)

ETIOLOGY

Chronic blepharitis: a review. Smith RE, et al. **CLAO J** 1995 Jul;21(3):200–7 (81 ref.)

VIROLOGY

Recurrence of herpes simplex virus blepharitis after cesarean section and epidural morphine. James CF. **Anesth Analg** 1996 May;82(5):1094–6 (17 ref.)

BLEPHAROPHIMOSIS

GENETICS

Blepharophimosis–ptosis–epicanthus inversus syndrome (BPES). Strømme P, et al. **Acta Ophthalmol Scand** 1996 Feb;74(1):45–7 (24 ref.)

BLEPHAROPTOSIS

ETIOLOGY

Traumatic superior orbital fissure syndrome: report of two cases. Bun RJ, et al. **J Oral Maxillofac Surg** 1996 Jun; 54(6):758–61 (16 ref.)

GENETICS

Blepharophimosis–ptosis–epicanthus inversus syndrome (BPES). Strømme P, et al. **Acta Ophthalmol Scand** 1996 Feb;74(1):45–7 (24 ref.)

SURGERY

Surgical treatment of myogenic blepharoptosis. De Wilde F, et al. **Bull Soc Belge Ophtalmol** 1995;255:139–46 (9 ref.)
Ptosis repair and blepharoplasty in the adult. Older JJ. **Ophthalmic Surg** 1995 Jul-Aug;26(4):304–8 (1 ref.)

BLEPHAROSPASM

PHYSIOPATHOLOGY

Blepharospasm: report of a workshop. Hallett M, et al. **Neurology** 1996 May;46(5):1213–8 (43 ref.)

BLIND SPOT see **OPTIC DISK**

BLINDNESS

see related
VISION, SUBNORMAL

EPIDEMIOLOGY

Blindness due to cataract: epidemiology and prevention. Javitt JC, et al. **Annu Rev Public Health** 1996;17:159–77 (109 ref.)
Public health aspects of ophthalmic disease: introduction. Sommer A. **Annu Rev Public Health** 1996;17:115–9 (26 ref.)
Epidemiology of blindness and eye disease. Krumpaszky HG, et al. **Ophthalmologica** 1996;210(1):1–84 (293 ref.)

ETIOLOGY

Transient cortical blindness following bypass graft angiography. A case report. Kamata J, et al. **Angiology** 1995 Oct;46(10):937–46 (33 ref.)
Basal encephaloceles with morning glory syndrome, and progressive hormonal and visual disturbances: case report and review of the literature. Morioka M, et al. **Brain Dev** 1995 May-Jun;17(3):196–201 (27 ref.)
Ocular injury from a rooster attack. Kronwith SD, et al. **Clin Pediatr (Phila)** 1996 Apr;35(4):219–20 (10 ref.)
Blindness due to electrocoagulation following functional endoscopic sinus surgery. Vanden Abeele D, et al. **J Laryngol Otol** 1996 Mar;110(3):261–4 (26 ref.)

GENETICS

Norrie disease and MAO genes: nearest neighbors. Chen ZY, et al. **Hum Mol Genet** 1995;4 Spec No:1729–37 (100 ref.)
[Hyperornithinemia and gyrate atrophy: ornithine aminotransferase gene error causing a Finnish disease] Sipilä I, et al. **Duodecim** 1994;110(7):681–6 (18 ref.) **(Fin)**

PREVENTION & CONTROL

Blindness due to cataract: epidemiology and prevention. Javitt JC, et al. **Annu Rev Public Health** 1996;17:159–77 (109 ref.)
Public health aspects of ophthalmic disease: introduction. Sommer A. **Annu Rev Public Health** 1996;17:115–9 (26 ref.)
Strategic issues in preventing cataract blindness in developing countries. Ellwein LB, et al. **Bull World Health Organ** 1995; 73(5):681–90 (21 ref.)
Preventing blindness in Americans: the need for eye health education. Javitt JC. **Surv Ophthalmol** 1995 Jul-Aug; 40(1):41–4 (25 ref.)

BLINKING

PHYSIOLOGY

A line imaging system for measurement of eyelid movements. Gittins J, et al. **Physiol Meas** 1995 Nov;16(4):303–11 (6 ref.)

BLISTER

Friction blisters. Pathophysiology, prevention and treatment. Knapik JJ, et al. **Sports Med** 1995 Sep;20(3):136–47 (79 ref.)

ETIOLOGY

Fracture blisters. Wallace GF, et al. **Clin Podiatr Med Surg** 1995 Oct;12(4):801–12 (19 ref.)

BLOCH-SULZBERGER SYNDROME see **INCONTINENTIA PIGMENTI**

BLOCKING ANTIBODIES see **ANTIBODIES, BLOCKING**

BLOOD

see related
HEMATOPOIESIS
OCCULT BLOOD

The safety and hazards of blood-derived drugs. Grabenstein JD. **Am J Health Syst Pharm** 1995 Nov 1;52(21):2448–52 (27 ref.)
Blood-contacting biomaterials: bioengineering viewpoints. Courtney JM, et al. **Artif Organs** 1995 Aug;19(8):852–6 (31 ref.)
Oxidative damage by ozone and nitrogen dioxide: synergistic toxicity in vivo but no evidence of synergistic oxidative damage in an extracellular fluid. O'Neill CA, et al. **Biochem Soc Symp** 1995;61:139–52 (49 ref.)
The place of blood stem cells in allogeneic transplantation. Russel N, et al. **Br J Haematol** 1996 Jun 2;93(4):747–53 (55 ref.)
Haemocompatibility of invasive sensors. Benmakroha Y, et al. **Med Biol Eng Comput** 1995 Nov;33(6):811–21 (155 ref.)
Blood and air pollution: state of knowledge and research needs. Badman DG, et al. **Otolaryngol Head Neck Surg** 1996 Feb;114(2):205–8 (16 ref.)
The photodecontamination of cellular blood components: mechanisms and use of photosensitization in transfusion medicine. Ben-Hur E, et al. **Transfus Med Rev** 1996 Jan; 10(1):15–22 (71 ref.)
Hemospermia: diagnosis and management. Mulhall JP, et al. **Urology** 1995 Oct;46(4):463–7 (51 ref.)
[Hemospermia associated with a urogenital sinus cyst: diagnostic contribution of MRI. Report a case] Cinque T, et al. **Radiol Med (Torino)** 1995 Dec;90(6):840–2 (8 ref.) **(Ita)**

MICROBIOLOGY

Impact of the resin blood culture medium on the treatment

of critically ill patients. Levin PD, et al. **Crit Care Med** 1996 May;24(5):797–801 (24 ref.)
Advances in photochemical approaches for blood sterilization. Ben-Hur E, et al. **Photochem Photobiol** 1995 Sep;62(3):383–8 (81 ref.)

PHYSIOLOGY

Hastings lecture. Breaking the blood-biomaterial barrier. Edmunds LH Jr. **ASAIO J** 1995 Oct–Dec;41(4):824–30 (52 ref.)

RADIATION EFFECTS

Advances in photochemical approaches for blood sterilization. Ben-Hur E, et al. **Photochem Photobiol** 1995 Sep;62(3):383–8 (81 ref.)

BLOOD-AIR BARRIER

99mTc DTPA transfer/permeability in patients with HIV disease. O'Doherty MJ. **Q J Nucl Med** 1995 Sep; 39(3):231–42 (60 ref.)

PHYSIOLOGY

Epithelial cells: barrier functions and shedding-restitution mechanisms. Persson CG. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 2):S9–10 (16 ref.)
Simulation of intraluminal gas transport processes in the microcirculation. Hellums JD, et al. **Ann Biomed Eng** 1996 Jan–Feb;24(1):1–24 (97 ref.)
[VO2 and DO2 during cardiogenic shock and infection] Beale R. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May;31(1 Suppl):S22–5 (19 ref.) **(Ger)**

BLOOD, ARTIFICIAL see **BLOOD SUBSTITUTES**

BLOOD BACTERICIDAL ACTIVITY

Antibiotic proteins of polymorphonuclear leukocytes. Levy O. **Eur J Haematol** 1996 May;56(5):263–77 (177 ref.)
Cathelicidins: a novel protein family with a common proregion and a variable C-terminal antimicrobial domain. Zanetti M, et al. **FEBS Lett** 1995 Oct 23;374(1):1–5 (55 ref.)

BLOOD BANKS

Blood center perspective of granulocyte transfusions: future applications. Price TH. **J Clin Apheresis** 1995;10(3):119–23 (34 ref.)
Clinical perspectives of granulocyte transfusions: efficacy to date. Strauss RG. **J Clin Apheresis** 1995;10(3):114–8 (23 ref.)

ECONOMICS

Blood transfusion economics in Greece. Kyriopoulos JE, et al. **Transfus Clin Biol** 1995;2(5):387–94 (17 ref.)

MANPOWER

The role of the transfusion medicine consultant. Popovsky MA, et al. **Am J Clin Pathol** 1996 Jun;105(6):798–801 (12 ref.)

METHODS

Modern veterinary blood banking practices and their applications in companion animal practice. Feldman BF, et al. **Vet Clin North Am Small Anim Pract** 1995 Nov; 25(6):1231–43 (14 ref.)
General principles of small animal blood component administration. Kristensen AT, et al. **Vet Clin North Am Small Anim Pract** 1995 Nov; 25(6):1277–90 (19 ref.)
Selection of anticoagulant-preservatives for canine and feline blood storage. Wardrop KJ. **Vet Clin North Am Small Anim Pract** 1995 Nov; 25(6):1263–76 (50 ref.)

ORGANIZATION & ADMINISTRATION

[How to do blood transfusions in the tropical environment?] Aubert M, et al. **Med Trop (Mars)** 1996;56(1):28–32 (9 ref.) **(Fre)**

STANDARDS

Autologous peripheral blood progenitor cell transplantation. Anderson KC. **J Clin Apheresis** 1995;10(3):131–8 (60 ref.)
Infectious disease testing for blood transfusions. NIH Consensus Development Panel on Infectious Disease Testing for Blood Transfusions. **JAMA** 1995 Nov 1; 274(17):1374–9 (0 ref.)
Reducing risks in blood transfusion: process and outcome. McClelland DB, et al. **Transfus Med** 1996 Mar;6(1):1–10 (35 ref.)

TRENDS

The continuing evolution of the nation's blood supply system. McCullough J. **Am J Clin Pathol** 1996 Jun;105(6):689–95 (50 ref.)

BLOOD-BORNE PATHOGENS

see related
UNIVERSAL PRECAUTIONS

The safety and hazards of blood-derived drugs. Grabenstein JD. **Am J Health Syst Pharm** 1995 Nov 1;52(21):2448–52 (27 ref.)
Postexposure protocol. Younai FS. **Dent Clin North Am** 1996 Apr;40(2):457–86 (118 ref.)
A work-systems analysis of compliance with universal precautions among health care workers. DeJoy DM, et al. **Health Educ Q** 1996 May;23(2):159–74 (80 ref.)
Transfusion reaction due to Yersinia enterocolitica and review of other reported cases. Beresford AM. **Pathology** 1995 Apr;27(2):133–5 (19 ref.)
Syringe-mediated drug sharing among injecting drug users: patterns, social context and implications for transmission of blood-borne pathogens. Grund JP, et al. **Soc Sci Med** 1996 Mar;42(5):691–703 (89 ref.)
Preventing bloodborne pathogen transmission from health-care workers to patients. The CDC perspective. Bell DM, et al. **Surg Clin North Am** 1995 Dec;75(6):1189–203 (80 ref.)
Microbiologic considerations. Disinfection and sterilization strategies and the potential for airborne transmission of bloodborne pathogens. Favero MS, et al. **Surg Clin North Am** 1995 Dec;75(6):1071–89 (40 ref.)
Prevention of blood exposure. Body and facial protection. Fry DE, et al. **Surg Clin North Am** 1995 Dec;75(6):1141–57 (27 ref.)
Bloodborne pathogen transmission from healthcare worker to patients. Legal issues and provider perspectives. Rhodes RS, et al. **Surg Clin North Am** 1995 Dec;75(6):1205–17 (29 ref.)
[Microbial safety of blood products] Höher PG. **Infusionsther Transfusionsmed** 1996 Feb;23(1):42–58 (183 ref.) (Eng. Abstr.) **(Ger)**
[Blood transmission and infections] Eggen BM. **Tidsskr Nor Laegeforen** 1995 Oct 10;115(24):3035–8 (73 ref.) (Eng. Abstr.) **(Nor)**

ISOLATION & PURIFICATION

Infectious disease testing for blood transfusions [news] **Oncology (Huntingt)** 1995 Nov;9(11):1141–2 (0 ref.)

BLOOD-BRAIN BARRIER

Penetration of solutes, viruses, and cells across the blood-brain barrier. Brightman MW, et al. **Curr Top Microbiol Immunol** 1995;202:63–78 (56 ref.)
Transporting therapeutics across the blood-brain barrier. Abbott NJ, et al. **Mol Med Today** 1996 Mar;2(3):106–13 (41 ref.)
Conformationally constrained peptide drugs targeted at the blood-brain barrier. Davis TP, et al. **NIDA Res Monogr** 1995;154:47–60 (24 ref.)
Cerebrovascular permeability to peptides: manipulations of transport systems at the blood-brain barrier. Zlokovic BV. **Pharm Res** 1995 Oct;12(10):1395–406 (72 ref.)
Blood-brain interfaces: relevance to cerebral drug metabolism. Ghersi-Egea JF, et al. **Toxicol Lett** 1995 Dec; 82–83:645–53 (37 ref.)
In vitro models of the blood-brain barrier to study bacterial meningitis. Townsend GC, et al. **Trends Microbiol** 1995 Nov;3(11):441–5 (24 ref.)
[The blood-brain barrier: a specialty of cerebral microcirculation systems] Wolf S, et al. **Naturwissenschaften** 1996 Jul;83(7):302–11 (41 ref.) **(Ger)**
[Mechanism of resistance to antitumor agents—its involvement in blood-brain barrier] Tsuruo T. **Yakugaku Zasshi** 1995 Jul;115(7):513–22 (36 ref.) (Eng. Abstr.) **(Jpn)**

DRUG EFFECTS

Pharmacological blood-brain barrier modification for selective drug delivery. Cloughesy TF, et al. **J Neurooncol** 1995 Nov;26(2):125–32 (39 ref.)

IMMUNOLOGY

Physiology and immunology of lymphatic drainage of interstitial and cerebrospinal fluid from the brain. Knopf PM, et al. **Neuropathol Appl Neurobiol** 1995 Jun; 21(3):175–80 (16 ref.)

PHYSIOLOGY

On the principles underlying the diagnosis of brain tumours—a survey article. Go KG, et al. **Acta Neurochir (Wien)** 1995;135(1–2):1–11 (31 ref.)
Signal transduction at the blood-brain barrier. Staddon JM, et al. **Biochem Soc Trans** 1995 Aug;23(3):475–9 (47 ref.)
Entry of pathogens into the central nervous system. Tuomanen E. **FEMS Microbiol Rev** 1996 Jul;18(4):289–99 (42 ref.)
Cerebrospinal fluid. Thompson EJ. **J Neurol Neurosurg Psychiatry** 1995 Oct;59(4):349–57 (58 ref.)
Diffusion-weighted imaging in epilepsy. Helpern JA, et al. **Magn Reson Imaging** 1995;13(8):1227–31 (32 ref.)
The blood-brain barrier and selective vulnerability in experimental thiamine-deficiency encephalopathy in the mouse. Harata N, et al. **Metab Brain Dis** 1996 Mar; 11(1):55–69 (78 ref.)
Permeability of the blood-brain barrier to melanocortins. Banks WA, et al. **Peptides** 1995;16(6):1157–61 (70 ref.)

BLOOD CELL COUNT

Interpretation of the complete blood count. Walters MC, et al. **Pediatr Clin North Am** 1996 Jun;43(3):599–622 (58 ref.)

BLOOD CELL COUNT, WHITE see **LEUKOCYTE COUNT**

BLOOD CELL NUMBER see **BLOOD CELL COUNT**

BLOOD CELLS

CYTOLOGY

Stem cells from bone marrow, umbilical cord blood and peripheral blood for clinical application: current status and future application. Lu L, et al. **Crit Rev Oncol Hematol** 1996 Mar;22(2):61–78 (243 ref.)
[Rheologic and biophysical aspects of cellular adhesion and aggregation: importance in hemorheology] Stoltz JF, et al. **J Mal Vasc** 1995;20(4):247–51 (25 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Na-Ca exchange in circulating blood cells. Gardner JP, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:502–14 (27 ref.)
Defects in Wiskott-Aldrich syndrome blood cells. Remold-O'Donnell E, et al. **Blood** 1996 Apr 1; 87(7):2621–31 (118 ref.)
Circulating neutrophils from patients with ulcerative colitis have a normal respiratory burst. Haydek JM, et al. **Inflammation** 1995 Dec;19(6):701–15 (42 ref.)
[Characteristics and diagnostics of blood cell defects in paroxysmal nocturnal haemoglobinuria (NNH)] Bogdanik I. **Acta Haematol Pol** 1995;26(4):353–60 (36 ref.) (Eng. Abstr.) **(Pol)**

PATHOLOGY

[Value of the blood picture and flow cytometry immunotyping in the early diagnosis of low-grade lymphoma] Schleiffenbaum B, et al. **Ther Umsch** 1996 Feb; 53(2):117–22 (15 ref.) (Eng. Abstr.) **(Ger)**
[Morphologic analysis of blood cells] Kikuchi T, et al. **Rinsho Byori** 1995 Sep;43(9):917–24 (15 ref.) (Eng. Abstr.) **(Jpn)**
[Morphology of apoptosis in normal and pathologic hematopoiesis] Pogorelov VM, et al. **Gematol Transfuziol** 1995 Sep–Oct;40(5):17–25 (61 ref.) **(Rus)**

PHYSIOLOGY

Adhesion molecules—Part II: Blood vessels and blood cells. Frenette PS, et al. **N Engl J Med** 1996 Jul 4;335(1):43–5 (0 ref.)

RADIATION EFFECTS

Use of irradiated blood components: practice parameter. Przepiorka D, et al. **Am J Clin Pathol** 1996 Jul;106(1):6–11 (55 ref.)

TRANSPLANTATION

Is blood a better source of allogeneic hematopoietic stem cells for use after radiation accidents? Frickhofen N, et al. **Bone Marrow Transplant** 1996 Feb;17(2):131–5 (48 ref.)

VIROLOGY

[Dendritic cells of spleen and blood and HIV-1 infection] Hosmalin A. **Pathol Biol (Paris)** 1995 Dec;43(10):889–96 (54 ref.) (Eng. Abstr.) **(Fre)**

BLOOD CELLS, RED see **ERYTHROCYTES**

BLOOD CELLS, WHITE see **LEUKOCYTES**

BLOOD CHEMICAL ANALYSIS

Forensic applications of genetic polymorphisms detected in human body fluids (urine, semen and blood). Kishi K, et al. **Forensic Sci Int** 1996 Jun 28;80(1–2):89–97 (55 ref.)

METHODS

Pseudohyperphosphatemia. Larner AJ. **Clin Biochem** 1995 Aug;28(4):391–3 (40 ref.)

BLOOD CIRCULATION

see related
HYPEREMIA
ISCHEMIA
PLETHYSMOGRAPHY

Neural and endothelial control of the peripheral circulation—implications for anesthesia: Part I. Neural control of the peripheral vasculature. Ebert TJ, et al. **J Cardiothorac Vasc Anesth** 1996 Jan;10(1):147–58 (124 ref.)

Neural and endothelial control of the peripheral circulation--implications for anesthesia: Part II, Endothelium-mediated effects in the normal and diseased circulation. Stowe DF, et al. **J Cardiothorac Vasc Anesth** 1996 Jan;10(1):159-71 (161 ref.)

Gravity, blood circulation, and the adaptation of form and function in lower vertebrates. Lillywhite HB. **J Exp Zool** 1996 Jun 1-15;275(2-3):217-25 (37 ref.)

[Blood circulation in retarded and normal offspring of hypertonic pregnant women] Jakobovits A, et al. **Orv Hetil** 1996 Apr 14;137(15):793-7 (46 ref.) (Eng. Abstr.) **(Hun)**

[Organization of mobile structures in the blood stream--basis for the function of perfluorocarbon "artificial blood"] Ivanitskiĭ GR, et al. **Biofizika** 1996 Jan-Feb;41(1):178-90 (47 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Sympathetic reflex regulation of the peripheral circulation in humans. Jacobsen TN. **Dan Med Bull** 1996 Apr; 43(2):126-40 (148 ref.)

Endothelium-dependent regulation of the cardiovascular system. Shimokawa H, et al. **Intern Med** 1995 Oct; 34(10):939-46 (105 ref.)

Essentials of blood flow. Caro CG, et al. **Perfusion** 1995 May; 10(3):131-4 (9 ref.)

BLOOD CLOTTING see **BLOOD COAGULATION**

BLOOD COAGULATION

see related
ANTICOAGULANTS
HEMOSTATICS

Risk factors for cerebrovascular disease and the role of coagulation and fibrinolysis. Catto AJ, et al. **Blood Coagul Fibrinolysis** 1995 Sep;6(6):497-510 (173 ref.)

Markers of activated coagulation and their usefulness in the clinical laboratory. Tripodi A, et al. **Clin Chem** 1996 May; 42(5):664-9 (55 ref.)

Why do hemophiliacs bleed? Agarwal BR, et al. **Indian Pediatr** 1995 Apr;32(4):505-9 (18 ref.)

Organization of the provisional fibronectin matrix: control by products of blood coagulation. Mosher DF. **Thromb Haemost** 1995 Jul;74(1):529-33 (62 ref.)

[Blood coagulation and fibrinolysis in patients with acute coronary syndrome] Ogawa H, et al. **Nippon Naika Gakkai Zasshi** 1995 Oct 10;84(10):1755-9 (12 ref.) **(Jpn)**

[Abnormality of coagulation and fibrinolysis in obesity] Terada H. **Nippon Rinsho** 1995 Jun;53 Suppl:365-70 (21 ref.) **(Jpn)**

[Circulating anticoagulant] Watanabe K. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:147-9 (5 ref.) **(Jpn)**

DRUG EFFECTS

Coagulation inhibitor substitution during sepsis. Fourrier F, et al. **Intensive Care Med** 1995 Nov;21 Suppl 2:S264-8 (34 ref.)

[Effects of thrombolysis on platelets and coagulation] Helft G, et al. **Ann Cardiol Angeiol (Paris)** 1995 Sep;44(7):354-60 (34 ref.) (Eng. Abstr.) **(Fre)**

[Therapeutic role of coagulation in small cell lung cancers] LeBeau B. **Rev Mal Respir** 1996;13(1):21-6 (41 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Stimulation of bone resorption by the kallikrein-kinin system and the coagulation cascade. Lerner UH. **Acta Orthop Scand Suppl** 1995 Oct;266:45-50 (30 ref.)

Rheology of blood coagulation. Kaibara M. **Biorheology** 1996 Mar-Apr;33(2):101-17 (54 ref.)

Inflammation. They're not just for clots anymore. Esmon CT. **Curr Biol** 1995 Jul 1;5(7):743-6 (15 ref.)

Initiation of blood coagulation: the tissue factor/factor VIIa complex. Kirchhofer D, et al. **Curr Opin Biotechnol** 1996 Aug;7(4):386-91 (46 ref.)

Maintaining blood flow in the extracorporeal circuit: haemostasis and anticoagulation. Webb AR, et al. **Intensive Care Med** 1995 Jan;21(1):84-93 (77 ref.)

The antiphospholipid syndrome and SLE: is there a clue in the link between complement and coagulation? Merrill JT, et al. **Lupus** 1996 Feb;5(1):6-10 (63 ref.)

Hypercoagulability, intraglomerular coagulation, and thromboembolism in nephrotic syndrome [editorial] Sagripanti A, et al. **Nephron** 1995;70(3):271-81 (118 ref.)

Inflammatory cell participation in coagulation. Altieri DC. **Semin Cell Biol** 1995 Oct;6(5):269-74 (47 ref.)

Cellular regulation of the protein C pathway. Esmon CT, et al. **Semin Cell Biol** 1995 Oct;6(5):259-68 (73 ref.)

Induction of cellular procoagulant activity by the membrane attack complex of complement. Sims PJ, et al. **Semin Cell Biol** 1995 Oct;6(5):275-82 (63 ref.)

Platelet-vessel wall interaction: from the bedside to molecules. Caen JP, et al. **Thromb Haemost** 1995 Jul; 74(1):18-24 (42 ref.)

Biochemical and molecular aspects of the coagulation cascade. Davie EW. **Thromb Haemost** 1995 Jul;74(1):1-6 (78 ref.)

The tissue factor pathway: how it has become a "prima ballerina". Rapaport SI, et al. **Thromb Haemost** 1995 Jul; 74(1):7-17 (147 ref.)

Cell biology of tissue factor, the principal initiator of blood coagulation. Camerer E, et al. **Thromb Res** 1996 Jan 1; 81(1):1-41 (294 ref.)

Regulation of the extrinsic pathway system in health and disease: the role of factor VIIa and tissue factor pathway inhibitor. Petersen LC, et al. **Thromb Res** 1995 Jul 1; 79(1):1-47 (256 ref.)

[Dyslipidemia and blood coagulation] Serrano Júnior CV, et al. **Arq Bras Cardiol** 1995 Sep;65(3):273-7 (46 ref.) **(Por)**

[Structural-functional features of factor VIII (FVIII) and its role in the cascade system of blood coagulation] Gutsalo AE. **Ukr Biokhim Zh** 1995 Jul-Aug;67(4):12-23 (62 ref.) (Eng. Abstr.) **(Rus)**

BLOOD COAGULATION DISORDERS

Pathophysiology of fibrinolysis. Juhan-Vague I, et al. **Baillieres Clin Haematol** 1995 Jun;8(2):329-43 (109 ref.)

Role of fibrin sealants in surgical procedures on patients with hemostatic disorders. Martinowitz U, et al. **Clin Orthop** 1996 Jul;(328):65-75 (76 ref.)

BLOOD

Markers of activated coagulation and their usefulness in the clinical laboratory. Tripodi A, et al. **Clin Chem** 1996 May; 42(5):664-9 (55 ref.)

COMPLICATIONS

Thrombophilia and the surgeon. Rhodes EG. **Ann R Coll Surg Engl** 1996 Jul;78(4):331-5 (33 ref.)

Extensive necrotizing livedo reticularis in a patient with chronic renal failure, hyperparathyroidism and coagulation disorder: regression after subtotal parathyroidectomy. Dereure O, et al. **Dermatology** 1996;192(2):167-70 (33 ref.)

The investigation of a patient with unexpected venous thrombosis. Wilde JT. **Postgrad Med J** 1995 Dec; 71(842):720-4 (35 ref.)

[Cerebrovascular complications in patients with cancer] Casado JL, et al. **Rev Neurol** 1995;23 Suppl 1:S70-8 (75 ref.) **(Spa)**

CONGENITAL

Inherited disorders of coagulation in pregnancy. Rigby FB, et al. **Clin Obstet Gynecol** 1995 Sep;38(3):497-513 (81 ref.)

DIAGNOSIS

[Recommendations for initial diagnosis and therapy in acute blood coagulation disorders] Sütterlin R, et al. **Anaesthesiol Reanim** 1996;21(3):76-80 (24 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Coagulation disorders in cancer. Goad KE, et al. **Hematol Oncol Clin North Am** 1996 Apr;10(2):457-84 (308 ref.)

Hypercoagulability in cancer. Green KB, et al. **Hematol Oncol Clin North Am** 1996 Apr;10(2):499-530 (144 ref.)

[Dyslipidemia, lipid lowering drugs and thrombosis] Ambrosi P, et al. **Arch Mal Coeur Vaiss** 1995 Nov;88(11):1641-5 (31 ref.) (Eng. Abstr.) **(Fre)**

[Snake bites] Vincent JL, et al. **Rev Med Brux** 1995 Nov; 16(5):349-52 (12 ref.) (Eng. Abstr.) **(Fre)**

[Anemia and hemostasis dysfunction in patients with immunoproliferative disorders] Suehiro A, et al. **Nippon Naika Gakkai Zasshi** 1995 Jul 10;84(7):1091-5 (5 ref.) **(Jpn)**

[The pathogenesis and treatment of the hemostatic disorder in acute promyelocytic leukemia] Velasco F, et al. **Med Clin (Barc)** 1996 Jun 8;107(2):59-61 (27 ref.) **(Spa)**

GENETICS

The rarer inherited coagulation disorders: a review. Bolton-Maggs PH, et al. **Blood Rev** 1995 Jun;9(2):65-76 (64 ref.)

Annotation. The unhinged antithrombins [comment] Carrell RW, et al. **Br J Haematol** 1996 May;93(2):253-7 (39 ref.) Comment on: Br J Haematol 1995 Mar;89(3):589-601.

[Hereditary antithrombin III deficiency. Report of an obstetric case and review of the literature] Leal-Tijerina G, et al. **Ginecol Obstet Mex** 1996 Apr;64:177-83 (18 ref.) (Eng. Abstr.) **(Spa)**

[Resistance to activated protein C. A common genetic risk factor in venous thrombosis] Berntorp E, et al. **Lakartidningen** 1995 Sep 27;92(39):3587-90 (27 ref.) **(Swe)**

PHYSIOPATHOLOGY

Developmental hemostasis: relevance to hemostatic problems during childhood. Andrew M. **Semin Thromb Hemost** 1995; 21(4):341-56 (166 ref.)

[Traumatic emergencies and hemostasis] Samama CM. **Cah Anesthesiol** 1995;43(5):479-82 (23 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Treatment of inherited coagulation disorders. Cohen AJ, et al. **Am J Med** 1995 Dec;99(6):675-82 (17 ref.)

Management of patients with thrombophilia. **Drug Ther Bull** 1995 Jan 19;33(1):6-8 (28 ref.)

Management of acquired coagulation disorders in emergency and intensive-care medicine. Staudinger T, et al. **Semin Thromb Hemost** 1996;22(1):93-104 (192 ref.)

VETERINARY

Hemostatic disorders in cats: a retrospective study and review of the literature. Peterson JL, et al. **J Vet Intern Med** 1995 Sep-Oct;9(5):298-303 (56 ref.)

Use of blood and blood components in canine and feline patients with hemostatic disorders. de Gopegui RR, et al. **Vet Clin North Am Small Anim Pract** 1995 Nov; 25(6):1387-402 (69 ref.)

BLOOD COAGULATION FACTORS

see related
CALCIUM

ADVERSE EFFECTS

High-purity factor IX concentrates for treatment of hemophilia B: relative purity and thrombogenic potential. Limentani SA, et al. **Acta Haematol** 1995;94 Suppl 1:12-7 (24 ref.)

In vivo models of thrombogenic potential: usefulness and limitations. MacGregor I, et al. **Acta Haematol** 1995;94 Suppl 1:18-23; discussion 24 (25 ref.)

The need for highly purified products to treat hemophilia B. Scharrer I. **Acta Haematol** 1995;94 Suppl 1:2-7 (44 ref.)

ANALYSIS

[Enzyme immunoassay of blood coagulation and fibrinolysis factors] Koike K, et al. **Nippon Rinsho** 1995 Sep; 53(9):2269-76 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Activated coagulation factors in various thrombotic diseases] Komiyama Y, et al. **Rinsho Byori** 1995 Dec;43(12):1195-200 (19 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

[Autoantibodies to coagulation factors] Suehisa E, et al. **Rinsho Byori** 1995 Dec;43(12):1189-94 (13 ref.) **(Jpn)**

METABOLISM

Warfarin-induced changes in procoagulant and anticoagulant proteins. Stirling Y. **Blood Coagul Fibrinolysis** 1995 Jul; 6(5):361-73 (115 ref.)

Vitamin K and energy transduction: a base strength amplification mechanism [see comments] Dowd P, et al. **Science** 1995 Sep 22;269(5231):1684-91 (39 ref.) Comment in: Science 1995 Nov 24;270(5240):1285.

[Activation of blood coagulation in extracorporeal circulation] Nowak G. **Wien Klin Wochenschr Suppl** 1996; 1:9-14 (28 ref.) **(Ger)**

PHYSIOLOGY

Diet, blood coagulation and fibrinolysis. Marckmann P. **Dan Med Bull** 1995 Nov;42(5):410-25 (275 ref.)

THERAPEUTIC USE

Continuous infusion of factor concentrates: review of use in hemophilia A and demonstration of safety and efficacy in hemophilia B. Martinowitz UP, et al. **Acta Haematol** 1995;94 Suppl 1:35-42 (30 ref.)

Hemostasis: a practical review of conservative and operative care. Shopnick RI, et al. **Clin Orthop** 1996 Jul;(328):34-8 (39 ref.)

Hemophilia: yesterday, today, and tomorrow. Aledort LM. **Mt Sinai J Med** 1996 May-Sep;63(3-4):225-35 (21 ref.)

BLOOD COAGULATION TESTS

Designing a point-of-care program for coagulation testing. Macik BG. **Arch Pathol Lab Med** 1995 Oct;119(10):929-38 (34 ref.)

Diagnostic methodologies for circulating anticoagulants. Exner T. **Thromb Haemost** 1995 Jul;74(1):338-44 (59 ref.)

[Recommendations for initial diagnosis and therapy in acute blood coagulation disorders] Sütterlin R, et al. **Anaesthesiol Reanim** 1996;21(3):76-80 (24 ref.) (Eng. Abstr.) **(Ger)**

[Thrombotest (TBT), hepaplastin test (HPT)] Ueda M. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:14-7 (5 ref.) **(Jpn)**

INSTRUMENTATION

[Blood specimen collection from central venous catheters--reliable also for blood coagulation analysis?] Werner W, et al. **Z Arztl Fortbild (Jena)** 1995 Dec; 89(7):739-41 (6 ref.) (Eng. Abstr.) **(Ger)**

[Some aspects of newly developed instruments for blood coagulation tests] Matsuo T, et al. **Rinsho Byori** 1995 Dec; 43(12):1209-13 (13 ref.) (Eng. Abstr.) **(Jpn)**

METHODS

Sonoclot analysis. Hett DA, et al. **Br J Anaesth** 1995 Dec; 75(6):771-6 (41 ref.)

BLOOD COAGULATION TIME, WHOLE

BLOOD COAGULATION TIME, WHOLE see WHOLE BLOOD COAGULATION TIME

BLOOD COMPONENT REMOVAL

Review: selective filtration--a phlebotomy strategy for sickle cell therapy. Nusbaum NJ. **Am J Med Sci** 1995 Dec; 310(6):264–6 (12 ref.)

[Extracorporeal elimination of LDL-cholesterol in the treatment of hypercholesterolemia: indications and methods] Bláha V, et al. **Vnitr Lek** 1995 Oct;41(10):724–9 (40 ref.) (Eng. Abstr.) **(Cze)**

[Why remove leukocytes from labile blood products in 1995?] Andreu G, et al. **Transfus Clin Biol** 1996;3(1):57–74 (119 ref.) (Eng. Abstr.) **(Fre)**

METHODS

CD34+ progenitor cell selection: clinical transplantation, tumor cell purging, gene therapy, ex vivo expansion, and cord blood processing. Colter M, et al. **J Hematother** 1996 Apr;5(2):179–84 (22 ref.)

Stem cell purging ex vivo. Seiden MV, et al. **J Infus Chemother** 1996 Winter;6(1):17–22 (56 ref.)

STANDARDS

[Current data on the counting of weak leukocyte concentrations in labile blood products] Masse M. **Transfus Clin Biol** 1995;2(5):365–72 (19 ref.) (Eng. Abstr.) **(Fre)**

BLOOD COMPONENT TRANSFUSION

Fetal transfusion therapy. Skupski DW, et al. **Obstet Gynecol Surv** 1996 Mar;51(3):181–92 (73 ref.)

Blood component therapy in neonatal hemostatic disorders. Andrew M, et al. **Transfus Med Rev** 1995 Jul;9(3):231–50 (145 ref.)

The photodecontamination of cellular blood components: mechanisms and use of photosensitization in transfusion medicine. Ben-Hur E, et al. **Transfus Med Rev** 1996 Jan; 10(1):15–22 (71 ref.)

The fetus as a recipient and donor of blood components. Roberts GT, et al. **Transfus Med Rev** 1995 Jul;9(3):260–70 (59 ref.)

Blood component and immunotherapy in neonatal sepsis. Sweetman RW, et al. **Transfus Med Rev** 1995 Jul;9(3):251–9 (47 ref.)

[Therapy with blood and blood products] Kreienbühl G. **Anaesthesist** 1995 Oct;44(10):725–41 (46 ref.) **(Ger)**

[Disorders of acid–base balance caused by blood products] Schmitt HJ. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Oct; 30 Suppl 1:S62–4 (20 ref.) **(Ger)**

[Conservative hemotherapy. Blood component therapy instead of whole blood transfusion and homologous blood saving methods (editorial)] Reiff K, et al. **Gynakologe** 1995 Dec;28(6):393–400 (55 ref.) **(Ger)**

[Microbial safety of blood products] Höher PG. **Infusionsther Transfusionsmed** 1996 Feb;23(1):42–58 (183 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Current concepts on the transmission of bacteria and parasites by blood components. Wendel Neto S. **Rev Paul Med** 1995 Nov-Dec;113(6):1036–52 (107 ref.)

[Why remove leukocytes from labile blood products in 1995?] Andreu G, et al. **Transfus Clin Biol** 1996;3(1):57–74 (119 ref.) (Eng. Abstr.) **(Fre)**

METHODS

Use of irradiated blood components: practice parameter. Przepiorka D, et al. **Am J Clin Pathol** 1996 Jul;106(1):6–11 (55 ref.)

STANDARDS

Use of irradiated blood components: practice parameter. Przepiorka D, et al. **Am J Clin Pathol** 1996 Jul;106(1):6–11 (55 ref.)

VETERINARY

Use of blood and blood components in canine and feline patients with hemostatic disorders. de Gopegui RR, et al. **Vet Clin North Am Small Anim Pract** 1995 Nov; 25(6):1387–402 (69 ref.)

Modern veterinary blood banking practices and their applications in companion animal practice. Feldman BF, et al. **Vet Clin North Am Small Anim Pract** 1995 Nov; 25(6):1231–43 (14 ref.)

Transfusion therapy in emergency and critical care medicine. Kirby R. **Vet Clin North Am Small Anim Pract** 1995 Nov; 25(6):1365–86 (25 ref.)

General principles of small animal blood component administration. Kristensen AT, et al. **Vet Clin North Am Small Anim Pract** 1995 Nov; 25(6):1277–90 (19 ref.)

The role of blood component therapy in the management of canine and feline patients with cancer. Rudloff E. **Vet Clin North Am Small Anim Pract** 1995 Nov; 25(6):1403–16 (72 ref.)

Blood components. Collection, processing, and storage. Schneider A. **Vet Clin North Am Small Anim Pract** 1995 Nov;25(6):1245–61 (24 ref.)

BLOOD COUNT, COMPLETE see BLOOD CELL COUNT

BLOOD DISEASES see HEMATOLOGIC DISEASES

BLOOD DONORS

Use of Oxygent, a perfluorochemical-based oxygen carrier, as an alternative to intraoperative blood transfusion. Keipert PE. **Artif Cells Blood Substit Immobil Biotechnol** 1995; 23(3):381–94 (29 ref.)

Infectious risk of plasma donations: relationship to safety of intravenous immune globulins. Dodd RY. **Clin Exp Immunol** 1996 May;104 Suppl 1:31–4 (25 ref.)

Infectious disease testing for blood transfusions. NIH Consensus Development Panel on Infectious Disease Testing for Blood Transfusions. **JAMA** 1995 Nov 1; 274(17):1374–9 (0 ref.)

Infectious disease testing for blood transfusions. **NIH Consens Statement** 1995 Jan 9–11;13(1):1–27 (0 ref.)

Reducing risks in blood transfusion: process and outcome. McClelland DB, et al. **Transfus Med** 1996 Mar;6(1):1–10 (35 ref.)

[Quality assurance of bacterial incidents associated with blood transfusion] Noël L. **Transfus Clin Biol** 1996; 3(1):35–42 (28 ref.) (Eng. Abstr.) **(Fre)**

[Hepatitis C virus antibody in the serum of blood donors] Barna TK, et al. **Orv Hetil** 1996 Mar 10;137(10):507–11 (48 ref.) (Eng. Abstr.) **(Hun)**

[Tests for donors of blood and bone marrow] Taniwaki K, et al. **Rinsho Byori** 1995 Jul;Suppl 99:102–10 (10 ref.) **(Jpn)**

[Current status of the plasmapheresis problem] Kalinin NN. **Gematol Transfuziol** 1995 Mar-Apr;40(2):46–8 (12 ref.) **(Rus)**

[The actual risk of retrovirus transmission from transfusions] Soriano V, et al. **Sangre (Barc)** 1995 Oct;40(5):407–16 (118 ref.) **(Spa)**

STATISTICS & NUMERICAL DATA

Hepatitis C virus : prevalence in Lebanese blood donors and brief overview of the disease. Araj GF, et al. **J Med Liban** 1995;43(1):11–6 (44 ref.)

BLOOD DOPING see DOPING IN SPORTS

BLOOD EXPANDERS see PLASMA SUBSTITUTES

BLOOD FLOW VELOCITY

[The importance of measuring pulmonary venous flow using doppler echocardiography] Veselka J. **Vnitr Lek** 1995 Nov; 41(11):787–91 (32 ref.) (Eng. Abstr.) **(Cze)**

DRUG EFFECTS

Thrombolysis, flow, and vessel wall interactions. Grabowski EF. **J Vasc Interv Radiol** 1995 Nov-Dec;6(6 Pt 2 Su):25S–29S (37 ref.)

PHYSIOLOGY

Regulation of vascular tone. Rossitti S, et al. **Can J Physiol Pharmacol** 1995 May;73(5):544–50 (43 ref.)

[The concept of the structuring of the blood flow in microvessels] Mchedlishvili GI. **Fiziol Zh Im I M Sechenova** 1995 Jun;81(6):48–53 (8 ref.) **(Rus)**

BLOOD GAS ANALYSIS

Review: perinatal monitoring. Huch R. **Acta Anaesthesiol Scand Suppl** 1995;107:91–4 (11 ref.)

[Indications for respiratory function tests (RFT). The role of RFT and blood gases in the monitoring of asthma and chronic obstructive bronchopnumopathies] **Rev Mal Respir** 1995;12 Suppl 3:R115–31 (57 ref.) **(Fre)**

INSTRUMENTATION

Clinical and economic performance criteria for intraarterial and extraarterial blood gas monitors, with comparison with in vitro testing. Shapiro BA. **Am J Clin Pathol** 1995 Oct; 104(4 Suppl 1):S100–6 (39 ref.)

Emerging technology in critical care: continuous intra-arterial blood gas monitoring. Szaflarski NL. **Am J Crit Care** 1996 Jan;5(1):55–65 (45 ref.)

BLOOD GLUCOSE

see related
GLUCOSE CLAMP TECHNIQUE
GLUCOSE TOLERANCE TEST
HEMOGLOBIN A, GLYCOSYLATED
HYPERGLYCEMIA
HYPOGLYCEMIA

ANALYSIS

Glucose monitoring as a guide to diabetes management. Critical subject review. Koch B. **Can Fam Physician** 1996 Jun;42:1142–6, 1149–52 (65 ref.)

Non-invasive glucose monitoring. Arnold MA. **Curr Opin Biotechnol** 1996 Feb;7(1):46–9 (22 ref.)

Amperometric biosensors. Heller A. **Curr Opin Biotechnol** 1996 Feb;7(1):50–4 (39 ref.)

Hypoglycaemia--real and unreal, lawful and unlawful: the 1994 Banting Lecture. Marks V. **Diabet Med** 1995 Oct; 12(10):850–64 (107 ref.)

An alternative approach to the diagnosis of diabetes with a review of the literature. Davidson MB, et al. **Diabetes Care** 1995 Jul;18(7):1065–71 (49 ref.)

Tests of glycemia in diabetes. Goldstein DE, et al. **Diabetes Care** 1995 Jun;18(6):896–909 (144 ref.)

Why use the oral glucose tolerance test? Stolk RP, et al. **Diabetes Care** 1995 Jul;18(7):1045–9 (40 ref.)

Can hypoglycaemia be predicted before its onset? (Comment). Maggs D. **Diabetologia** 1996 May;39(5):615–7 (16 ref.)

Glucose monitoring and insulin therapy during pregnancy. Homko CJ, et al. **Obstet Gynecol Clin North Am** 1996 Mar; 23(1):47–74 (95 ref.)

[Gestational diabetes and adult type of diabetes with relative insulin resistance] Forsén T, et al. **Duodecim** 1994; 110(8):808–14 (30 ref.) **(Fin)**

[Glucose] Maegawa H, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:527–31 (5 ref.) **(Jpn)**

DRUG EFFECTS

Effect of konjac fibre (glucomannan) on glucose and lipids. Doi K. **Eur J Clin Nutr** 1995 Oct;49 Suppl 3:S190–7 (18 ref.)

METABOLISM

Glucose and insulin metabolism in hypertension. Corry DB, et al. **Am J Nephrol** 1996;16(3):223–36 (188 ref.)

The pathophysiology of diabetic complications: how much does the glucose hypothesis explain? Nathan DM. **Ann Intern Med** 1996 Jan 1;124(1 Pt 2):86–9 (51 ref.)

Understanding the pathogenesis of type 2 diabetes: can we get off the metabolic merry-go-rounds? Proietto J, et al. **Aust N Z J Med** 1995 Dec;25(6):870–5 (33 ref.)

Unexplained improvement in diabetes control: a wolf in sheep's clothing. Snow KJ. **Compr Ther** 1995 Oct; 21(10):590–3 (16 ref.)

Impaired glucose tolerance--fact or fiction. Alberti KG. **Diabet Med** 1996;13(3 Suppl 2):S6–8 (14 ref.)

Prevention of macrovascular disease: absolute proof or absolute risk? [editorial] [see comments] Durrington PN. **Diabet Med** 1995 Jul;12(7):561–2 (12 ref.) Comment in: Diabet Med 1996 Mar;13(3):284–5.

Insulin resistance: a multifaceted metabolic syndrome. Insights gained using a low-dose insulin infusion technique. Krentz AJ, et al. **Diabet Med** 1996 Jan;13(1):30–9 (54 ref.)

Dietary carbohydrates and glucose metabolism in diabetic patients. Parillo M, et al. **Diabete Metab** 1995 Dec; 21(6):391–401 (67 ref.)

Alcohol and the NIDDM patient. Bell DS. **Diabetes Care** 1996 May;19(5):509–13 (60 ref.)

Screening for NIDDM in nonpregnant adults. A review of principles, screening tests, and recommendations. Engelgau MM, et al. **Diabetes Care** 1995 Dec;18(12):1606–18 (118 ref.)

Beyond glycemia. Vinik AI, et al. **Diabetes Care** 1995 Jul; 18(7):1037–41 (34 ref.)

Insulin therapy and GH-IGF-I axis disorders in diabetes: impact of glycaemic control and hepatic insulinization. Hanaire-Broutin H, et al. **Diabetes Metab** 1996 Jul; 22(4):245–50 (42 ref.)

Pancreas and islet transplantation in humans. Kendall DM, et al. **Diabetes Metab** 1996 Jun;22(3):157–63 (40 ref.)

Extrapancreatic effects of sulfonylureas--a comparison between glimepiride and conventional sulfonylureas. Müller G, et al. **Diabetes Res Clin Pract** 1995 Aug;28 Suppl:S115–37 (109 ref.)

Can hypoglycaemia be predicted before its onset? Lönnroth P. **Diabetologia** 1996 May;39(5):613–4 (17 ref.)

Does fall in tissue glucose precede fall in blood glucose? Sternberg F, et al. **Diabetologia** 1996 May;39(5):609–12 (22 ref.)

Some thoughts on the importance of insulin in the regulation of the blood glucose level. Newsholme EA, et al. **Experientia** 1996 May 15;52(5):421–5 (21 ref.)

Risk factors for non-insulin-dependent diabetes mellitus. Haffner SM. **J Hypertens Suppl** 1995 Aug;13(2):S73–6 (50 ref.)

NMR studies of brain 13C-glucose uptake and metabolism: present status. van Zijl PC, et al. **Magn Reson Imaging** 1995;13(8):1213–21 (44 ref.)

Insulin-like growth factor binding proteins as glucoregulators. Baxter RC. **Metabolism** 1995 Oct;44(10 Suppl 4):12–7 (48 ref.)

Hemiatrophy, juvenile-onset exertional alternating leg paresis, hypotonia, and hemidystonia and adult-onset hemiparkinsonism: the spectrum of hemiparkinsonism-hemiatrophy syndrome. Lang AE. **Mov Disord** 1995 Jul;10(4):489–95 (32 ref.)

Treatment of the pre-azotaemic phases of kidney disease in diabetes. Viberti GC. **Nephrol Dial Transplant** 1995;10 Suppl 7:38–42 (58 ref.)

The impact of intraperitoneal glucose and insulin on the liver. Bargman JM. **Perit Dial Int** 1996;16 Suppl 1:S211–4 (27

ref.)
The importance of tight blood glucose control in diabetes [editorial] Andersson DK. **Scand J Prim Health Care** 1995 Jun;13(2):81–2 (12 ref.)
[Endotoxemia and carbonhydrate metabolism] Zhai Z, et al. **Chung Hua Cheng Hsing Shao Shang Wai Ko Tsa Chih** 1996 Jan;12(1):62–5 (21 ref.) **(Chi)**
[Raised blood glucose level increases risk of atherosclerosis in non-insulin-dependent diabetes (editorial)] Uusitupa M, et al. **Duodecim** 1994;110(12):1119–20 (16 ref.) **(Fin)**
[Quality of blood sugar control and late complications of diabetes] Sélam JL. **Rev Med Suisse Romande** 1995 Sep; 115(9):653–7 (25 ref.) **(Fre)**
[Hypoglycemia—occurrence, causes and hormonal counterregulatory mechanisms in healthy persons and in patients with IDDM] Mokáň M. **Bratisl Lek Listy** 1995 Jun;96(6):311–6 (34 ref.) (Eng. Abstr.) **(Slo)**

PHYSIOLOGY

Control of motor and secretory functions of the stomach by a portal glucose signal. Sakaguchi T. **Neurosci Biobehav Rev** 1995 Fall;19(3):469–78 (134 ref.)

BLOOD GLUCOSE SELF-MONITORING

Glucose monitoring as a guide to diabetes management. Critical subject review. Koch B. **Can Fam Physician** 1996 Jun;42:1142–6, 1149–52 (65 ref.)

INSTRUMENTATION

Application of computers in diabetes care—a review. I. Computers for data collection and interpretation. Lehmann ED, et al. **Med Inf (Lond)** 1995 Oct–Dec;20(4):281–302 (142 ref.)

METHODS

Advances and strategies for glucose monitoring. Chmielewski SA. **Am J Clin Pathol** 1995 Oct;104(4 Suppl 1):S59–71 (113 ref.)

TRENDS

Advances and strategies for glucose monitoring. Chmielewski SA. **Am J Clin Pathol** 1995 Oct;104(4 Suppl 1):S59–71 (113 ref.)

BLOOD GROUP INCOMPATIBILITY

DIAGNOSIS

[Diagnosis and therapy of fetal alloimmune thrombocytopenia] Marzusch K, et al. **Geburtshilfe Frauenheilkd** 1995 Oct;55(10):587–91 (29 ref.) (Eng. Abstr.) **(Ger)**

VETERINARY

Canine transfusion reactions and their management. Harrell KA, et al. **Vet Clin North Am Small Anim Pract** 1995 Nov; 25(6):1333–64 (63 ref.)

BLOOD GROUPING AND CROSSMATCHING

Monoclonal anti-D specificity and Rh D structure: criteria for selection of monoclonal anti-D reagents for routine typing of patients and donors [see comments] Jones J, et al. **Transfus Med** 1995 Sep;5(3):171–84 (59 ref.) Comment in: Transfus Med 1995 Dec;5(4):304–5.

METHODS

Detection of red cell antibodies: current and future techniques. Knight RC, et al. **Br J Biomed Sci** 1995 Dec; 52(4):297–305 (67 ref.)
Biochemical approaches to the detection and characterization of membrane proteins carrying blood group determinants. Blanchard D. **Transfus Clin Biol** 1995;2(4):217–22 (19 ref.)
Rh haemolytic disease of the newborn and Rh genotyping by RFLP—and allele-specific—PCR. Le Van Kim C, et al. **Transfus Clin Biol** 1995;2(4):317–24 (16 ref.)

STANDARDS

The future of blood groups and other markers in reference laboratories. Rouger P, et al. **Transfus Clin Biol** 1995; 2(4):329–34 (8 ref.)

VETERINARY

Feline transfusion medicine. Blood types and their clinical importance. Griot-Wenk ME, et al. **Vet Clin North Am Small Anim Pract** 1995 Nov; 25(6):1305–22 (35 ref.)

BLOOD GROUPS

see related
ISOANTIBODIES
ISOANTIGENS

ANALYSIS

Biochemical approaches to the detection and characterization of membrane proteins carrying blood group determinants. Blanchard D. **Transfus Clin Biol** 1995;2(4):217–22 (19 ref.)
The future of blood groups and other markers in reference laboratories. Rouger P, et al. **Transfus Clin Biol** 1995; 2(4):329–34 (8 ref.)

CHEMISTRY

ABH and Colton blood group antigens on aquaporin-1, the human red cell water channel protein. Agre P, et al. **Transfus Clin Biol** 1995;2(4):303–8 (21 ref.)
Biochemical characterization of blood group-active glycosphingolipids. Bouhours JF, et al. **Transfus Clin Biol** 1995;2(4):223–33 (50 ref.)

GENETICS

Review of studies of polymorphic blood systems in the Aymara indigenous population from Bolivia, Peru, and Chile. Dittmar M. **Anthropol Anz** 1995 Dec;53(4):289–315 (55 ref.)
Red cell polymorphisms in nonhuman primates: a review. Socha WW, et al. **J Med Primatol** 1995 Dec;24(4):282–305 (115 ref.)
Gerbich blood groups and minor glycophorins of human erythrocytes. Colin Y. **Transfus Clin Biol** 1995;2(4):259–68 (47 ref.)
Molecular genetics of H, Se, Lewis and other fucosyltransferase genes. Mollicone R, et al. **Transfus Clin Biol** 1995;2(4):235–42 (60 ref.)

IMMUNOLOGY

Human blood groups: incidental receptors for viruses and bacteria. Moulds JM, et al. **Transfusion** 1996 Apr; 36(4):362–74 (126 ref.)
Canine blood groups and their importance in veterinary transfusion medicine. Hale AS. **Vet Clin North Am Small Anim Pract** 1995 Nov; 25(6):1323–32 (22 ref.)

PHYSIOLOGY

Glycosyl phosphatidylinositol-linked blood group antigens and paroxysmal nocturnal hemoglobinuria. Telen MJ. **Transfus Clin Biol** 1995;2(4):277–90 (73 ref.)

BLOOD LOSS, POSTOPERATIVE see **POSTOPERATIVE HEMORRHAGE**

BLOOD LOSS, SURGICAL

see related
HEMOSTASIS, SURGICAL
Sonoclot analysis. Hett DA, et al. **Br J Anaesth** 1995 Dec; 75(6):771–6 (41 ref.)
[Which technique should be chosen to reuse blood lost intraoperatively? Does the type of surgery constitute any contraindication for reutilization (cancer, infection)?] Lefevre P. **Ann Fr Anesth Reanim** 1995;14 Suppl 1:53–62 (104 ref.) **(Fre)**
[Hemorrhagic complications of ORL surgery] Boisson-Bertrand D, et al. **Cah Anesthesiol** 1995; 43(5):489–95 (48 ref.) **(Fre)**

PHYSIOPATHOLOGY

[Conservative hemotherapy. Blood component therapy instead of whole blood transfusion and homologous blood saving methods (editorial)] Reiff K, et al. **Gynakologe** 1995 Dec;28(6):393–400 (55 ref.) **(Ger)**

PREVENTION & CONTROL

Consensus conference: Blood Management Surgical Practice Guidelines. Dallas, Texas, January 12–14, 1995. **Am J Surg** 1995 Dec;170(6A Suppl):1S–73S (0 ref.)
Current methods to reduce the adverse haematological consequences of cardiopulmonary bypass. John LC, et al. **Br J Clin Pract** 1996 Jun;50(4):203–6 (66 ref.)
Blood transfusion in orthopaedic operations. Lemos MJ, et al. **J Bone Joint Surg Am** 1996 Aug;78(8):1260–70 (128 ref.)
Is aprotinin safe when used in the context of profound hypothermia and circulatory arrest? A literary review [comment] Hornick P, et al. **J Heart Valve Dis** 1995 Nov; 4(6):669–73 (60 ref.) Comment on: J Heart Valve Dis 1995 Nov;4(6):674–7.
Limiting excessive postoperative blood transfusion after cardiac procedures. A review. Ferraris VA, et al. **Tex Heart Inst J** 1995;22(3):216–30 (167 ref.)
Fibrin sealant in surgery of patients with a hemorrhagic diathesis. Martinowitz U, et al. **Thromb Haemost** 1995 Jul; 74(1):486–92 (81 ref.)
[Use of red blood cells to compensate for surgical blood loss in adults. Consensus development conference. Paris, 17 December 1993] **Ann Fr Anesth Reanim** 1995;14 Suppl 1:1–117 (0 ref.) **(Fre)**
[Aprotinin in the control of surgical hemorrhage] Rocha E, et al. **Med Clin (Barc)** 1996 Mar 2;106(8):307–16 (161 ref.) **(Spa)**
[Use of aprotinin in cardiovascular surgery] Colorio C, et al. **Sangre (Barc)** 1995 Jun;40(3):207–11 (34 ref.) **(Spa)**

BLOOD PLASMA see **PLASMA**

BLOOD PLATELET COUNT see **PLATELET COUNT**

BLOOD PLATELET DISORDERS

Disorders of platelet function. Fuse I. **Crit Rev Oncol Hematol** 1996 Jan;22(1):1–25 (375 ref.)
Platelet-associated bleeding disorders. Shuey KM. **Semin Oncol Nurs** 1996 Feb;12(1):15–27 (66 ref.)

BLOOD

Platelet-vessel wall interaction: from the bedside to molecules. Caen JP, et al. **Thromb Haemost** 1995 Jul; 74(1):18–24 (42 ref.)

COMPLICATIONS

Thrombogenic and lipid risk factors in hypertension and coronary artery disease. Ding YA. **Jpn Circ J** 1996 Feb; 60(2):75–84 (41 ref.)

VETERINARY

Use of blood and blood components in canine and feline patients with hemostatic disorders. de Gopegui RR, et al. **Vet Clin North Am Small Anim Pract** 1995 Nov; 25(6):1387–402 (69 ref.)

BLOOD PLATELET NUMBER see **PLATELET COUNT**

BLOOD PLATELET TRANSFUSION see **PLATELET TRANSFUSION**

BLOOD PLATELETS

see related
PLATELET ACTIVATION
PLATELET ADHESIVENESS
PLATELET AGGREGATION
PLATELET AGGREGATION INHIBITORS
PLATELET COUNT
PLATELET FUNCTION TESTS
PLATELET TRANSFUSION
THROMBOCYTOPENIA
THROMBOCYTOSIS
Platelets and platelet inhibitors in acute myocardial infarction. Kamat SG, et al. **Cardiol Clin** 1995 Aug; 13(3):435–47 (139 ref.)
Platelet production in the Old World—and the New. Murphy S, et al. **Transfusion** 1996 Aug;36(8):751–4 (30 ref.)
[Current data on the counting of weak leukocyte concentrations in labile blood products] Masse M. **Transfus Clin Biol** 1995;2(5):365–72 (19 ref.) (Eng. Abstr.) **(Fre)**

CYTOLOGY

Mechanisms involved in platelet vessel wall interaction. Hawiger J. **Thromb Haemost** 1995 Jul;74(1):369–72 (37 ref.)
Thrombopoietin: the primary regulator of megakaryocyte and platelet production. Kaushansky K. **Thromb Haemost** 1995 Jul;74(1):521–5 (43 ref.)
c-mpl, the thrombopoietin receptor. Vainchenker W, et al. **Thromb Haemost** 1995 Jul;74(1):526–8 (15 ref.)
[Cloning of thrombopoietin and its physiologic role in megakaryocytopoiesis and thrombopoiesis] Miyazaki H. **Rinsho Ketsueki** 1996 Jan;37(1):1–6 (19 ref.) **(Jpn)**

DRUG EFFECTS

Thrombopoietin induces tyrosine phosphorylation of Stat3 and Stat5 in human blood platelets. Miyakawa Y, et al. **Blood** 1996 Jan 15;87(2):439–46 (36 ref.)
Effects of alcohol on platelet functions. Renaud SC, et al. **Clin Chim Acta** 1996 Mar 15;246(1–2):77–89 (50 ref.)
Antiplatelet effects of fibrinolytic agents: a potential contributor to the hemostatic defect after thrombolysis. Kamat SG, et al. **Coron Artery Dis** 1995 Dec;6(12):930–5 (55 ref.)
Antiplatelet drugs. A comparative review. Schrör K. **Drugs** 1995 Jul;50(1):7–28 (189 ref.)
Platelet glycoprotein IIb/IIIa receptor antagonists in coronary artery disease. Lefkovits J, et al. **Eur Heart J** 1996 Jan;17(1):9–18 (81 ref.)
ADP receptors on platelets and ADP-selective antiaggregating agents. Savi P, et al. **Med Res Rev** 1996 Mar;16(2):159–79 (206 ref.)
[Effects of thrombolysis on platelets and coagulation] Helft G, et al. **Ann Cardiol Angeiol (Paris)** 1995 Sep;44(7):354–60 (34 ref.) (Eng. Abstr.) **(Fre)**

ENZYMOLOGY

Phospholipase D in platelets and megakaryocytic cells. Halenda SP, et al. **Chem Phys Lipids** 1996 May 24; 80(1–2):21–6 (18 ref.)
Lipoxin biosynthesis and actions: role of the human platelet LX-synthase. Serhan CN, et al. **J Lipid Mediat Cell Signal** 1995 Oct;12(2–3):293–306 (41 ref.)
The correlation between platelet MAO activity and personality: short review of findings and a discussion on possible mechanisms. Oreland L, et al. **Prog Brain Res** 1995; 106:77–84 (52 ref.)

BLOOD PLATELETS

IMMUNOLOGY

Anti-platelet monoclonal antibodies for the prevention of arterial thrombosis: experience with ReoPro, a monoclonal antibody directed against the platelet GPIIb/IIIa receptor. Weisman HF, et al. **Biochem Soc Trans** 1995 Nov; 23(4):1051-7 (25 ref.)

Platelets and hypersensitivity. de Sousa JR, et al. **J Investig Allergol Clin Immunol** 1995 Jan-Feb;5(1):12-7 (50 ref.)

[Anti-platelet antibody and severe thrombocytopenia during interferon-alpha therapy for chronic active hepatitis C] Tanaka Y, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Apr;19(2):150-6 (17 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

With platelets, as with T lymphocytes, the blood cell system behaves as a neuron [editorial] Mathé G. **Biomed Pharmacother** 1995;49(10):433-4 (25 ref.)

Blockade of platelet GPIIb/IIIa receptors as an antithrombotic strategy. Coller BS. **Circulation** 1995 Nov 1;92(9):2373-80 (76 ref.)

Platelet adhesion receptors. Williams MJ, et al. **Semin Cell Biol** 1995 Oct;6(5):305-14 (75 ref.)

LDL-platelet interaction under oxidative stress induces macrophage foam cell formation. Aviram M. **Thromb Haemost** 1995 Jul;74(1):560-4 (41 ref.)

Platelet integrins. Ginsberg MH, et al. **Thromb Haemost** 1995 Jul;74(1):352-9 (176 ref.)

PATHOLOGY

Von Willebrand's disease and the mechanisms of platelet function. Ruggeri ZM. **Ciba Found Symp** 1995;189:35-45; discussion 45-50, 77-8 (37 ref.)

PHYSIOLOGY

Thrombophilia: the discovery of activated protein C resistance. Dahlbäck B. **Adv Genet** 1995;33:135-75 (114 ref.)

Platelets and shear stress. Kroll MH, et al. **Blood** 1996 Sep 1;88(5):1525-41 (186 ref.)

The role of platelets in essential hypertension. Islim IF, et al. **Blood Press** 1995 Jul;4(4):199-214 (214 ref.)

Platelet activation. Blockmans D, et al. **Blood Rev** 1995 Sep; 9(3):143-56 (124 ref.)

Profibrinolytic and antifibrinolytic effects of platelets. Devine DV, et al. **Coron Artery Dis** 1995 Dec;6(12):915-22 (62 ref.)

Platelets in fibrinolytic system. Korbut R, et al. **J Physiol Pharmacol** 1995 Dec;46(4):409-18 (42 ref.)

Role of platelets in progressive glomerular diseases. Zoja C, et al. **Pediatr Nephrol** 1995 Aug;9(4):495-502 (86 ref.)

Developmental hemostasis: relevance to hemostatic problems during childhood. Andrew M. **Semin Thromb Hemost** 1995; 21(4):341-56 (166 ref.)

The physiologic role and therapeutic potential of the Mpl-ligand in thrombopoiesis. Hunt P. **Stem Cells** 1995 Nov;13(6):579-87 (66 ref.)

Platelet-vessel wall interaction: from the bedside to molecules. Caen JP, et al. **Thromb Haemost** 1995 Jul; 74(1):18-24 (42 ref.)

The molecular basis of platelet and endothelial cell interaction with neutrophils and monocytes: role of P-selectin and the P-selectin ligand, PSGL-1. Furie B, et al. **Thromb Haemost** 1995 Jul;74(1):224-7 (56 ref.)

Role of platelets, thrombin, integrin IIb-IIIa, fibronectin and von Willebrand factor on tumor adhesion in vitro and metastasis in vivo. Nierodzik ML, et al. **Thromb Haemost** 1995 Jul;74(1):282-90 (67 ref.)

ULTRASTRUCTURE

Adhesive receptors expressed by tumor cells and platelets: novel targets for therapeutic anti-metastatic strategies. Oleksowicz L, et al. **Med Oncol** 1995 Jun;12(2):95-102 (161 ref.)

ADP receptors on platelets and ADP-selective antiaggregating agents. Savi P, et al. **Med Res Rev** 1996 Mar;16(2):159-79 (206 ref.)

BLOOD POISONING see **SEPTICEMIA**

BLOOD PRESERVATION

Stem cell cryopreservation. Gorlin J. **J Infus Chemother** 1996 Winter;6(1):23-7 (24 ref.)

[Microbial safety of blood products] Höher PG. **Infusionsther Transfusionsmed** 1996 Feb;23(1):42-58 (183 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Methods of isolation and cryopreservation of stem cells from cord blood. Quillen K, et al. **J Hematother** 1996 Apr; 5(2):153-5 (12 ref.)

TRENDS

The continuing evolution of the nation's blood supply system. McCullough J. **Am J Clin Pathol** 1996 Jun;105(6):689-95 (50 ref.)

VETERINARY

Blood components. Collection, processing, and storage. Schneider A. **Vet Clin North Am Small Anim Pract** 1995 Nov;25(6):1245-61 (24 ref.)

Selection of anticoagulant-preservatives for canine and feline blood storage. Wardrop KJ. **Vet Clin North Am Small Anim Pract** 1995 Nov; 25(6):1263-76 (50 ref.)

BLOOD PRESSURE

see related
HYPERTENSION
HYPOTENSION

Body weight and blood pressure regulation. McCarron DA, et al. **Am J Clin Nutr** 1996 Mar;63(3 Suppl):423S-425S (31 ref.)

Blood pressure. Thomas SA, et al. **Annu Rev Nurs Res** 1996; 14:3-22 (87 ref.)

Relationship of rostral ventrolateral medullary neurons and angiotensin in the central control of blood pressure. Chan YS, et al. **Biol Signals** 1995 May-Jun;4(3):133-41 (42 ref.)

Gene targeting and its application to basic hypertension research [editorial] Clark AF, et al. **Clin Sci (Colch)** 1996 Jun;90(6):435-46 (71 ref.)

A review of heart rate and blood pressure responses in the cold in healthy subjects and coronary artery disease patients. Emmett JD. **J Cardpulm Rehabil** 1995 Jan-Feb; 15(1):19-24 (47 ref.)

Fetal influences on adult hypertension. Law C. **J Hum Hypertens** 1995 Aug;9(8):649-51 (30 ref.)

Dietary calcium and blood pressure: a review of the observational studies. Pryer J, et al. **J Hum Hypertens** 1995 Aug;9(8):597-604 (53 ref.)

Endogenous ouabain, sodium balance and blood pressure: a review and a hypothesis [see comments] Hamlyn JM, et al. **J Hypertens** 1996 Feb;14(2):151-67 (136 ref.) Comment in: J Hypertens 1996 Feb;14(2):169-71.

Endogenous ouabain, sodium balance and blood pressure [comment] Pidgeon GB, et al. **J Hypertens** 1996 Feb; 14(2):169-71 (28 ref.) Comment on: J Hypertens 1996 Feb;14(2):151-67.

Dietary protein and blood pressure [see comments] Obarzanek E, et al. **JAMA** 1996 May 22-29; 275(20):1598-603 (52 ref.) Comment in: JAMA 1996 May 22-29;275(20):1604-6.

Vascular alpha-1 adrenergic receptor subtypes in the regulation of arterial pressure. Vargas HM, et al. **Life Sci** 1995;57(25):2291-308 (139 ref.)

[Treatment when blood pressure rises or falls in hypertension--new considerations for optimal prevention of cardiovascular damage] Zimlichman R. **Harefuah** 1996 Mar 15;130(6):404-6 (11 ref.) **(Heb)**

[Physical exercise and increase in arterial pressure and temperature in a female heterozygote for anhidrotic ectodermal dysplasia] Bandinelli G, et al. **Ann Ital Med Int** 1996 Jan-Mar;11(1):59-61 (12 ref.) (Eng. Abstr.) **(Ita)**

[Role of ambulatory blood pressure monitoring in the evaluation of the therapeutic efficacy of antihypertensive drugs. Trough/peak relation] Nobre F. **Arq Bras Cardiol** 1995 Mar;64(3):247-9 (27 ref.) **(Por)**

DRUG EFFECTS

Blood pressure-lowering effect of adding grapefruit juice to nifedipine and terazosin in a patient with severe renovascular hypertension. Pisarik P. **Arch Fam Med** 1996 Jul-Aug;5(7):413-6 (17 ref.)

The case for a greater blood pressure fall. Hansson L. **Clin Exp Hypertens** 1996 Apr-May;18(3-4):425-34 (19 ref.)

Ambulatory blood pressure, blood pressure variability and antihypertensive treatment. Mancia G, et al. **Clin Exp Hypertens** 1996 Apr-May;18(3-4):449-62 (22 ref.)

Cardiovascular actions of insulin: are they important in long-term blood pressure regulation? Hall JE, et al. **Clin Exp Pharmacol Physiol** 1995 Oct;22(10):689-700 (89 ref.)

Salt sensitivity of blood pressure in humans. Weinberger MH. **Hypertension** 1996 Mar;27(3 Pt 2):481-90 (104 ref.)

Salt and blood pressure revisited. Swales JD. **J Hum Hypertens** 1995 Jun;9(6):517-21 (41 ref.)

Managing the elderly hypertensive patient beyond blood pressure reduction. Holzgreve H. **J Hypertens Suppl** 1995 Aug;13(2):S103-7 (15 ref.)

Practical relevance of the 24-hour trough: peak ratio of antihypertensive drugs. Zannad F. **J Hypertens Suppl** 1995 Aug;13(2):S109-12 (41 ref.)

Dietary salt and blood pressure [comment] Dyer AR, et al. **Nat Med** 1995 Oct;1(10):994-6 (18 ref.) Comment on: Nat Med 1995 Oct;1(10):1009-16.

L-DOPA systems for blood pressure regulation in the lower brainstem. Misu Y, et al. **Neurosci Res** 1995 Sep; 23(2):147-58 (58 ref.)

[Licorice, aldosterone and blood pressure] Sane T. **Duodecim** 1994;110(10):974-80 (27 ref.) **(Fin)**

[The trough/peak ratio] Salvetti A, et al. **Ann Ital Med Int** 1995 Oct;10 Suppl:91S-95S (21 ref.) (Eng. Abstr.) **(Ita)**

[How does smoking affect blood pressure?] Omvik P. **Tidsskr Nor Laegeforen** 1996 Feb 20;116(5):621-4 (44 ref.) (Eng. Abstr.) **(Nor)**

[Alternative pathways of angiotensin I. The glimpse of new possibilities in the treatment of hypertension and heart failure (editorial)] Francischetti EA. **Arq Bras Cardiol** 1995 Mar;64(3):191-4 (49 ref.) **(Por)**

GENETICS

Molecular genetics of human blood pressure variation. Lifton RP. **Science** 1996 May 3;272(5262):676-80 (33 ref.)

Blood pressure variation in blacks: genetic factors. Grim CE, et al. **Semin Nephrol** 1996 Mar;16(2):83-93 (49 ref.)

PHYSIOLOGY

Intraarterial pressure measurements during angiographic evaluation of peripheral vascular disease: techniques, interpretation, applications, and limitations. Kinney TB, et al. **AJR Am J Roentgenol** 1996 Feb;166(2):277-84 (44 ref.)

Transgenic animals in the study of blood pressure regulation and hypertension. Thompson MW, et al. **Am J Physiol** 1995 Nov;269(5 Pt 1):E793-803 (101 ref.)

Aldosterone and its mechanism of action: more questions than answers. Fuller PJ. **Aust N Z J Med** 1995 Dec;25(6):800-7 (57 ref.)

Blood pressure measurement in pregnancy [see comments] de Swiet M, et al. **Br J Obstet Gynaecol** 1996 Sep; 103(9):862-3 (12 ref.) Comment in: Br J Obstet Gynaecol 1996 Sep;103(9):vii.

Chaos in blood pressure control. Wagner CD, et al. **Cardiovasc Res** 1996 Mar;31(3):380-7 (68 ref.)

Ambulatory blood pressure, blood pressure variability and antihypertensive treatment. Mancia G, et al. **Clin Exp Hypertens** 1996 Apr-May;18(3-4):449-62 (22 ref.)

Vegetarian diet components, protein and blood pressure: which nutrients are important? Beilin LJ, et al. **Clin Exp Pharmacol Physiol** 1995 Mar;22(3):195-8 (48 ref.)

Good vibrations? Respiratory rhythms in the central control of blood pressure. Pilowsky P. **Clin Exp Pharmacol Physiol** 1995 Sep;22(9):594-604 (90 ref.)

Analysis of heart rate and blood pressure variability in the assessment of autonomic regulation in arterial hypertension. Parati G, et al. **Clin Sci (Colch)** 1996;91 Suppl:129-32 (39 ref.)

Dietary factors and blood pressure regulation. Moore TJ, et al. **Endocrinol Metab Clin North Am** 1995 Sep; 24(3):643-55 (54 ref.)

How sympathetic tone maintains or alters arterial pressure. Julien C, et al. **Fundam Clin Pharmacol** 1995;9(4):343-9 (39 ref.)

Blood pressure regulation by the kallikrein-kinin system. Sharma JN, et al. **Gen Pharmacol** 1996 Jan;27(1):55-63 (149 ref.)

Genetic determinants of dopaminergic activity: potential role in blood pressure regulation. Kuchel O. **Hypertens Res** 1995 Jun;18 Suppl 1:S1-10 (72 ref.)

Thermal balance and dialysis hypotension. Maggiore Q, et al. **Int J Artif Organs** 1995 Sep;18(9):518-25 (11 ref.)

The effects of endurance and resistance training on blood pressure. Schwartz RS, et al. **Int J Obes Relat Metab Disord** 1995 Oct;19 Suppl 4:S52-7 (38 ref.)

Pressure natriuresis and long-term blood pressure control. Anderson WP, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 2:S17-23 (44 ref.)

Regulation of blood pressure by nitroxidergic nerve. Toda N. **J Diabetes Complications** 1995 Oct-Dec;9(4):200-2 (21 ref.)

Role of angiotensin II in blood pressure regulation and in the pathophysiology of cardiovascular disorders. Fyhrquist F, et al. **J Hum Hypertens** 1995 Nov;9 Suppl 5:S19-24 (50 ref.)

Renin-angiotensin-aldosterone system for blood pressure and electrolyte homeostasis and its involvement in hypertension, in congestive heart failure and in associated cardiovascular damage (myocardial infarction and stroke). Laragh JH. **J Hum Hypertens** 1995 Jun;9(6):385-90 (47 ref.)

Structural cardiovascular alterations and blood pressure variability in human hypertension. Mancia G, et al. **J Hypertens Suppl** 1995 Aug;13(2):S7-14 (39 ref.)

Nitric oxide: its identity and role in blood pressure control. Das S, et al. **Life Sci** 1995;57(17):1547-56 (66 ref.)

Volaemia and blood pressure in renal failure: have old truths been forgotten? Mees EJ. **Nephrol Dial Transplant** 1995; 10(8):1297-8 (8 ref.)

Heart rate and blood pressure variability: implications for psychiatric research. Yeragani VK. **Neuropsychobiology** 1995;32(4):182-91 (80 ref.)

L-DOPA systems for blood pressure regulation in the lower brainstem. Misu Y, et al. **Neurosci Res** 1995 Sep; 23(2):147-58 (58 ref.)

The relationship between social support and physiological processes: a review with emphasis on underlying mechanisms and implications for health. Uchino BN, et al. **Psychol Bull** 1996 May;119(3):488-531 (276 ref.)

[Relation between the parathyroid glands and arterial pressure: is there a parathyroid hypertensive factor?] Barlet JP, et al. **Presse Med** 1995 Nov 25;24(36):1703-6 (25 ref.) (Eng. Abstr.) **(Fre)**

[Diurnal blood pressure rhythm in patients with hypertension] Dąbrowska E, et al. **Pol Arch Med Wewn** 1996 Feb;95(2):147-52 (48 ref.) **(Pol)**

[Effects of aerobic physical conditioning on blood pressure control] Waib PH, et al. **Arq Bras Cardiol** 1995 Mar; 64(3):243-6 (80 ref.) **(Por)**

BLOOD PRESSURE DETERMINATION

[New aspects in evaluating the hypertensive patient: measuring blood pressure in the physician's office—ambulatory blood pressure monitoring—blood pressure self-measurement] Magometschnigg D. **Acta Med Austriaca** 1995;22(3):38–43 (9 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

[White-coat hypertension] Verdecchia P, et al. **G Ital Cardiol** 1995 Jul;25(7):899–909 (37 ref.) (Eng. Abstr.) **(Ita)**

METHODS

Intraarterial pressure measurements during angiographic evaluation of peripheral vascular disease: techniques, interpretation, applications, and limitations. Kinney TB, et al. **AJR Am J Roentgenol** 1996 Feb;166(2):277–84 (44 ref.)

Blood pressure measurement in pregnancy [see comments] de Swiet M, et al. **Br J Obstet Gynaecol** 1996 Sep; 103(9):862–3 (12 ref.) Comment in: Br J Obstet Gynaecol 1996 Sep;103(9):vii.

Non-invasive blood pressure monitoring in man. Portaluppi F. **Pathol Biol (Paris)** 1996 Mar;44(3):196–200 (80 ref.)

A system for non-invasively measuring blood pressure on a treadmill. Chong-pong Au T, et al. **Physiol Meas** 1995 Nov;16(4):273–85 (7 ref.)

[French Society of Anesthesia and Intensive Care. Arterial catheterization and invasive measurement of blood pressure in anesthesia and intensive care in adults] **Ann Fr Anesth Reanim** 1995;14(5):444–53 (6611 ref.) (Eng. Abstr.) **(Fre)**

[Principles and practice in invasive arterial blood pressure measurement] Gilly H, et al. **Anaesthesist** 1995 Dec; 44(12):931–52 (67 ref.) **(Ger)**

BLOOD PRESSURE, HIGH see **HYPERTENSION**

BLOOD PRESSURE, LOW see **HYPOTENSION**

BLOOD PRESSURE MONITORING, AMBULATORY

Role of whole-day ambulatory blood pressure monitoring in the management of hypertension. Neutel JM. **Am J Nephrol** 1996;16(3):202–9 (32 ref.)

Ambulatory blood pressure monitoring: methodologic issues. Prisant LM, et al. **Am J Nephrol** 1996;16(3):190–201 (119 ref.)

Normotension and hypertension defined by 24-hour ambulatory blood pressure monitoring. O'Brien E, et al. **Blood Press** 1995 Sep;4(5):266–82 (133 ref.)

Ambulatory blood pressure monitoring in the diagnosis of hypertension. Prisant LM. **Cardiol Clin** 1995 Nov; 13(4):479–90 (119 ref.)

Ambulatory blood pressure monitoring in the evaluation of hypertension therapy. White WB. **Cardiol Clin** 1995 Nov; 13(4):569–77 (40 ref.)

Ambulatory blood pressure, blood pressure variability and antihypertensive treatment. Mancia G, et al. **Clin Exp Hypertens** 1996 Apr–May;18(3–4):449–62 (22 ref.)

Ambulatory blood pressure monitoring for evaluating the relationships between lifestyle, hypertension and cardiovascular risk. Pickering TG, et al. **Clin Exp Pharmacol Physiol** 1995 Mar;22(3):226–31 (58 ref.)

Ambulatory blood pressure monitoring in current clinical practice and research. Mansoor GA, et al. **Curr Opin Nephrol Hypertens** 1995 Nov;4(6):531–7 (46 ref.)

A consensus view on the technique of ambulatory blood pressure monitoring. The Fourth International Consensus Conference on 24-Hour Ambulatory Blood Pressure Monitoring. Staessen JA, et al. **Hypertension** 1995 Dec;26(6 Pt 1):913–8 (85 ref.)

Ambulatory blood pressure monitoring: from research to clinical practice. Padfield PL, et al. **J Hum Hypertens** 1995 Jun;9(6):413–6 (14 ref.)

Ambulatory blood pressure measurement and the occurrence of hypertensive organ involvement. O'Brien E, et al. **Neth J Med** 1995 Oct;47(4):145–51 (60 ref.)

[New aspects in evaluating the hypertensive patient: measuring blood pressure in the physician's office—ambulatory blood pressure monitoring—blood pressure self-measurement] Magometschnigg D. **Acta Med Austriaca** 1995;22(3):38–43 (9 ref.) (Eng. Abstr.) **(Ger)**

[Long-term ambulatory blood pressure determination—I: Current status in the diagnosis and management of hypertension] Wellhausen CE, et al. **Med Klin** 1996 Mar 15;91(3):155–62 (0 ref.) **(Ger)**

[What are the therapeutic consequences of evaluating hypertensive patients with 24-hour blood pressure monitors and blood pressure self-measurement?] Zweiker R, et al. **Wien Med Wochenschr** 1995;145(15–16):365–72 (74 ref.) (Eng. Abstr.) **(Ger)**

[The clinical utility of the automatic ambulatory recording of the arterial pressure in the diagnosis, prognosis and treatment of arterial hypertension] Palma Gámiz JL, et al. **Rev Esp Cardiol** 1995;48 Suppl 4:57–65 (34 ref.) (Eng. Abstr.) **(Spa)**

ECONOMICS

Clinical significance and cost-effectiveness of 24-hour ambulatory blood pressure monitoring. Imai Y. **Tohoku J Exp Med** 1995 May;176(1):1–15 (48 ref.)

INSTRUMENTATION

State of the market. A review of ambulatory blood pressure monitoring devices. O'Brien E, et al. **Hypertension** 1995 Nov;26(5):835–42 (97 ref.)

METHODS

[Ambulatory measurement of blood pressure] Mallion JM, et al. **Presse Med** 1995 Dec 9;24(38):1842–8 (25 ref.) (Eng. Abstr.) **(Fre)**

[Role of ambulatory blood pressure monitoring in the evaluation of the therapeutic efficacy of antihypertensive drugs. Trough/peak relation] Nobre F. **Arq Bras Cardiol** 1995 Mar;64(3):247–9 (27 ref.) **(Por)**

STANDARDS

Special feature: what is a normal blood pressure in ambulatory monitoring? Staessen JA, et al. **Nephrol Dial Transplant** 1996 Feb;11(2):241–5 (49 ref.)

Clinical significance and cost-effectiveness of 24-hour ambulatory blood pressure monitoring. Imai Y. **Tohoku J Exp Med** 1995 May;176(1):1–15 (48 ref.)

BLOOD PRESSURE MONITORS

Ambulatory blood pressure monitoring: methodologic issues. Prisant LM, et al. **Am J Nephrol** 1996;16(3):190–201 (119 ref.)

[New aspects in evaluating the hypertensive patient: measuring blood pressure in the physician's office—ambulatory blood pressure monitoring—blood pressure self-measurement] Magometschnigg D. **Acta Med Austriaca** 1995;22(3):38–43 (9 ref.) (Eng. Abstr.) **(Ger)**

[What are the therapeutic consequences of evaluating hypertensive patients with 24-hour blood pressure monitors and blood pressure self-measurement?] Zweiker R, et al. **Wien Med Wochenschr** 1995;145(15–16):365–72 (74 ref.) (Eng. Abstr.) **(Ger)**

BLOOD PROTEINS

see related
PROTEIN BINDING
SERPINS

ANALYSIS

[Plasma proteins] Horikawa K, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:159–62 (7 ref.) **(Jpn)**

[Protein Z] Takamatsu J. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:130–1 (8 ref.) **(Jpn)**

[Methodological aspects of the determination of total blood proteins] Titov VN, et al. **Klin Lab Diagn** 1995 May–Jun; (3):15–8 (23 ref.) **(Rus)**

CHEMISTRY

Pleckstrin homology domains. Frech M, et al. **Biochem Soc Trans** 1995 Aug;23(3):616–8 (29 ref.)

The pleckstrin homology domain: an intriguing multifunctional protein module. Shaw G. **Bioessays** 1996 Jan;18(1):35–46 (69 ref.)

PH domains: diverse sequences with a common fold recruit signaling molecules to the cell surface. Lemmon MA, et al. **Cell** 1996 May 31;85(5):621–4 (20 ref.)

Pleckstrin homology domains: a fact file. Saraste M, et al. **Curr Opin Struct Biol** 1995 Jun;5(3):403–8 (39 ref.)

Structure, function, and membrane integration of defensins. White SH, et al. **Curr Opin Struct Biol** 1995 Aug;5(4):521–7 (43 ref.)

DEFICIENCY

Management of patients with hereditary defects predisposing to thrombosis including pregnant women. Bauer KA. **Thromb Haemost** 1995 Jul;74(1):94–100 (93 ref.)

GENETICS

Red cell membrane polypeptides under normal conditions and in genetic disorders. Delaunay J. **Transfus Clin Biol** 1995;2(4):207–16 (29 ref.)

IMMUNOLOGY

Influence of the anterior chamber of the eye on T-cell production of extracellular antigen-specific proteins. Cone RE, et al. **Adv Exp Med Biol** 1995;383:237–48 (31 ref.)

Immunology of antiphospholipid antibodies and their interaction with plasma proteins. Kandiah DA, et al. **Lupus** 1996 Apr;5(2):153–5 (31 ref.)

METABOLISM

New methods for the investigation of blood-biomaterial interaction. Schütt W, et al. **Artif Organs** 1995 Aug; 19(8):847–51 (32 ref.)

Hastings lecture. Breaking the blood-biomaterial barrier. Edmunds LH Jr. **ASAIO J** 1995 Oct–Dec;41(4):824–30 (52 ref.)

Deposits of eosinophil granule proteins in eosinophilic cholecystitis and eosinophilic colitis associated with hypereosinophilic syndrome. Tajima K, et al. **Dig Dis Sci** 1996 Feb;41(2):282–8 (25 ref.)

Role of transport proteins in bioartificial liver assist systems. Mitzner S, et al. **Int J Artif Organs** 1996 Jan;19(1):49–52 (6 ref.)

Role of Amadori-modified nonenzymatically glycated serum proteins in the pathogenesis of diabetic nephropathy [editorial] Cohen MP, et al. **J Am Soc Nephrol** 1996 Feb; 7(2):183–90 (127 ref.)

Protein adsorption on low temperature isotropic carbon: V. How is it related to its blood compatibility? Feng L, et al. **J Biomater Sci Polym Ed** 1995;7(5):439–52 (104 ref.)

[Metalloproteins, cellular targets of nitric oxide: a concise review] Henry Y, et al. **C R Seances Soc Biol Fil** 1995; 189(6):1039–57 (110 ref.) (Eng. Abstr.) **(Fre)**

PHARMACOLOGY

Bacterial responses to host-defense peptides. Groisman EA. **Trends Microbiol** 1996 Apr;4(4):127–8; discussion 128–9 (17 ref.)

PHYSIOLOGY

Structure, function, and membrane integration of defensins. White SH, et al. **Curr Opin Struct Biol** 1995 Aug;5(4):521–7 (43 ref.)

Antibiotic proteins of polymorphonuclear leukocytes. Levy O. **Eur J Haematol** 1996 May;56(5):263–77 (177 ref.)

Cathelicidins: a novel protein family with a common proregion and a variable C-terminal antimicrobial domain. Zanetti M, et al. **FEBS Lett** 1995 Oct 23;374(1):1–5 (55 ref.)

Koch's postulates and the digitalis-like factor. Hollenberg NK, et al. **Hypertens Res** 1995 Mar;18(1):1–6 (32 ref.)

The acylation stimulating protein-adipsin system. Cianflone K, et al. **Int J Obes Relat Metab Disord** 1995 May;19 Suppl 1:S34–8 (57 ref.)

Developmental hemostasis: relevance to hemostatic problems during childhood. Andrew M. **Semin Thromb Hemost** 1995; 21(4):341–56 (166 ref.)

[Endogenous digitalis-like substance. I. Basic characteristics] Martinka E. **Vnitr Lek** 1995 Sep;41(9):637–43 (31 ref.) (Eng. Abstr.) **(Slo)**

[Endogenous digitalis-like substance. II. Relation to pathologic states and diseases] Martinka E. **Vnitr Lek** 1995 Oct;41(10):719–23 (37 ref.) (Eng. Abstr.) **(Slo)**

THERAPEUTIC USE

Endotoxin-based molecular strategies for the prevention and treatment of gram-negative sepsis and septic shock. Pollack M, et al. **Curr Top Microbiol Immunol** 1996;216:275–97 (185 ref.)

BLOOD SPECIMEN COLLECTION

INSTRUMENTATION

[Pulmonary artery catheter. Theory and practice] Versprille A. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May;31(1 Suppl):S9–16 (22 ref.) **(Ger)**

[Blood specimen collection from central venous catheters—reliable also for blood coagulation analysis?] Werner W, et al. **Z Arztl Fortbild (Jena)** 1995 Dec; 89(7):739–41 (6 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Dynamics of the regulation of the hypothalamo-pituitary-adrenal (HPA) axis determined using a nonsurgical method for collecting pituitary venous blood from horses. Alexander SL, et al. **Front Neuroendocrinol** 1996 Jan;17(1):1–50 (220 ref.)

[Erythropoietin and delayed taking of autologous blood: from physiologic secretion to the rationale for exogenous supplementation] Casadevall N. **Nouv Rev Fr Hematol** 1995;37 Suppl 1:S11–5 (35 ref.) **(Fre)**

VETERINARY

Blood components. Collection, processing, and storage. Schneider A. **Vet Clin North Am Small Anim Pract** 1995 Nov;25(6):1245–61 (24 ref.)

BLOOD SUBSTITUTES

see related
PLASMA SUBSTITUTES

Blood substitutes: fluids, drugs, or miracle solutions? Dietz NM, et al. **Anesth Analg** 1996 Feb;82(2):390–405 (201 ref.)

Engineering and design of blood substitutes. Sanders KE, et al. **Curr Opin Struct Biol** 1996 Aug;6(4):534–40 (60 ref.)

Blood substitutes—a moving target. Winslow RM. **Nat Med** 1995 Nov;1(11):1212–5 (30 ref.)

[Organization of mobile structures in the blood stream—basis for the function of perfluorocarbon "artificial blood"] Ivanitskil GR, et al. **Biofizika** 1996 Jan–Feb;41(1):178–90 (47 ref.) (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

Perfluorocarbon emulsions and cardiopulmonary bypass: a

BLOOD SUBSTITUTES

technique for the future. Spiess BD, et al. **J Cardiothorac Vasc Anesth** 1996 Jan;10(1):83–89; quiz 89–90 (65 ref.)

STANDARDS

Blood substitutes: oxygen–carrying acellular fluids. Wohl JS, et al. **Vet Clin North Am Small Anim Pract** 1995 Nov; 25(6):1417–40 (120 ref.)

THERAPEUTIC USE

Perfluorocarbons in the twenty–first century: clinical applications as transfusion alternatives. Spence RK. **Artif Cells Blood Substit Immobil Biotechnol** 1995; 23(3):367–80 (35 ref.)

Modified haemoglobins as oxygen–transporting blood substitutes. Mallick A, et al. **Br J Hosp Med** 1996 Apr 3–16;55(7):443–8 (20 ref.)

BLOOD SUGAR see **BLOOD GLUCOSE**

BLOOD SUGAR SELF–MONITORING see **BLOOD GLUCOSE SELF–MONITORING**

BLOOD–TESTIS BARRIER

PHYSIOLOGY

The epididymis as protector of maturing spermatozoa. Hinton BT, et al. **Reprod Fertil Dev** 1995;7(4):731–45 (149 ref.)

BLOOD TESTS see **HEMATOLOGIC TESTS**

BLOOD TRANSFUSION

see related
BLOOD GROUP INCOMPATIBILITY
BLOOD GROUPING AND CROSSMATCHING

The role of the transfusion medicine consultant. Popovsky MA, et al. **Am J Clin Pathol** 1996 Jun;105(6):798–801 (12 ref.)

Morbidity risk assessment in the surgically anemic patient. Carson JL. **Am J Surg** 1995 Dec;170(6A Suppl):32S–36S (53 ref.)

Blood transfusion–induced immunomodulation. Landers DF, et al. **Anesth Analg** 1996 Jan;82(1):187–204 (219 ref.)

Use of Oxygent, a perfluorochemical–based oxygen carrier, as an alternative to intraoperative blood transfusion. Keipert PE. **Artif Cells Blood Substit Immobil Biotechnol** 1995; 23(3):381–94 (29 ref.)

The role of cytokines in blood transfusion reactions. Muylle L. **Blood Rev** 1995 Jun;9(2):77–83 (74 ref.)

Organisation of blood transfusion services. Hewitt PE, et al. **Br J Hosp Med** 1995 Oct 18–31;54(8):383–6 (12 ref.)

Minimizing donor blood exposure in the neonatal intensive care unit. Current trends and future prospects. Bifano EM, et al. **Clin Perinatol** 1995 Sep;22(3):657–69 (64 ref.)

Blood use in cardiac surgery and the limitations of hemodilution. Mossad E, et al. **Curr Opin Cardiol** 1995 Nov; 10(6):584–90 (44 ref.)

Immunologic status of the cancer patient and the effects of blood transfusion on antitumor responses. Browell DA, et al. **Curr Opin Gen Surg** 1993;:325–33 (110 ref.)

Transfusion and stem cell support in cancer treatment. Wuest DL. **Hematol Oncol Clin North Am** 1996 Apr;10(2):397–429 (223 ref.)

Blood transfusion in orthopaedic operations. Lemos MJ, et al. **J Bone Joint Surg Am** 1996 Aug;78(8):1260–70 (128 ref.)

Clinical challenges and cord blood transplantation: are we asking the right questions? Lowry PA. **J Hematother** 1996 Apr;5(2):99–104 (37 ref.)

Osteogenic sarcoma in a child with transfusion–dependent Diamond–Blackfan anemia. Aquino VM, et al. **J Pediatr Hematol Oncol** 1996 May;18(2):230–2 (17 ref.)

Infectious disease testing for blood transfusions. **NIH Consens Statement** 1995 Jan 9–11;13(1):1–27 (0 ref.)

Infectious disease testing for blood transfusions [news] **Oncology (Huntingt)** 1995 Nov;9(11):1141–2 (0 ref.)

What's new in transfusion medicine? Manno CS. **Pediatr Clin North Am** 1996 Jun;43(3):793–808 (51 ref.)

Answering patients' questions about transfusions. Kay L. **Practitioner** 1995 Oct;239(1555):576–8, 583, 585–6 (7 ref.)

The management of patients with Cooley's anemia: transfusions and splenectomy. Piomelli S. **Semin Hematol** 1995 Oct;32(4):262–8 (43 ref.)

Platelet transfusion and alternatives to transfusion in patients with malignancy. Vaickus L, et al. **Stem Cells (Dayt)** 1995 Nov;13(6):588–96 (86 ref.)

Massive transfusion in the neonate. Luban NL. **Transfus Med Rev** 1995 Jul;9(3):200–14 (59 ref.)

Medical ethics in relation to transfusion medicine. Young IF. **Transfus Med Rev** 1996 Jan;10(1):23–30 (43 ref.)

Transfusion and the immune system: a paradigm shift in progress? Blumberg N, et al. **Transfusion** 1995 Oct; 35(10):879–83 (55 ref.)

Developments in immunosuppressive therapy. Daar AS. **Transplant Proc** 1995 Oct;27(5):2671–5 (5 ref.)

[Therapy with blood and blood products] Kreienbühl G. **Anaesthesist** 1995 Oct;44(10):725–41 (46 ref.) **(Ger)**

[Hepatitis C virus antibody in the serum of blood donors] Barna TK, et al. **Orv Hetil** 1996 Mar 10;137(10):507–11 (48 ref.) (Eng. Abstr.) **(Hun)**

[Tests for donors of blood and bone marrow] Taniwaki K, et al. **Rinsho Byori** 1995 Jul;Suppl 99:102–10 (10 ref.) **(Jpn)**

[Immunohematologic study in 112 patients with myelodysplastic syndromes: 10–year analysis] Arriaga F, et al. **Sangre (Barc)** 1995 Jun;40(3):177–80 (17 ref.) (Eng. Abstr.) **(Spa)**

[The actual risk of retrovirus transmission from transfusions] Soriano V, et al. **Sangre (Barc)** 1995 Oct;40(5):407–16 (118 ref.) **(Spa)**

ADVERSE EFFECTS

Infectious hazards associated with blood transfusion. Hurley DR. **Adverse Drug React Toxicol Rev** 1995 Autumn; 14(3):157–74 (69 ref.)

Irradiation in the prevention of transfusion associated graft–versus–host disease. Webb DK. **Arch Dis Child** 1995 Nov;73(5):388–9 (38 ref.)

Clinical evaluation of virus safety and inhibitor incidence: statistical considerations. Buyse M, et al. **Blood Coagul Fibrinolysis** 1995 Jul;6 Suppl 2:S86–92 (23 ref.)

Leukocyte–reduced blood components: patient benefits and practical applications. Higgins VL. **Oncol Nurs Forum** 1996 May;23(4):659–67 (57 ref.)

Transfusion reaction due to Yersinia enterocolitica and review of other reported cases. Beresford AM. **Pathology** 1995 Apr;27(2):133–5 (19 ref.)

Transfusion–transmitted cytomegalovirus: the part–time pathogen. Gunter KC. **Pediatr Pathol Lab Med** 1995 May–Jun;15(3):515–34 (100 ref.)

Transfusion–dependent thalassemia: viral complications (epidemiology and follow–up). de Montalembert M, et al. **Semin Hematol** 1995 Oct;32(4):280–7 (46 ref.)

Chelation therapy in beta–thalassemia: the benefits and limitations of desferrioxamine. Giardina PJ, et al. **Semin Hematol** 1995 Oct;32(4):304–12 (93 ref.)

Reducing risks in blood transfusion: process and outcome. McClelland DB, et al. **Transfus Med** 1996 Mar;6(1):1–10 (35 ref.)

Blood transfusion in beta thalassaemia major. Rebulla P. **Transfus Med** 1995 Dec;5(4):247–58 (131 ref.)

Transfusion–transmitted infections in the newborn. Delage G. **Transfus Med Rev** 1995 Jul;9(3):271–6 (62 ref.)

Noninfectious adverse effects of blood transfusion in the neonate. Holman P, et al. **Transfus Med Rev** 1995 Jul; 9(3):277–87 (81 ref.)

Survey of transfusion–associated graft–versus–host disease in immunocompetent recipients. Ohto H, et al. **Transfus Med Rev** 1996 Jan;10(1):31–43 (132 ref.)

Posttransfusion graft–versus–host disease in Japanese newborns [see comments] Ohto H, et al. **Transfusion** 1996 Feb;36(2):117–23 (60 ref.) Comment in: Transfusion 1996 Feb;36(2):101–3.

Virally inactivated fresh frozen plasma. Williamson LM, et al. **Vox Sang** 1995;69(3):159–65 (45 ref.)

[Blood salvage: a conditional safety] Andreassian B, et al. **J Mal Vasc** 1996;21 Suppl A:22–35 (48 ref.) (Eng. Abstr.) **(Fre)**

[Hepatitis C virus infection. Epidemiology] Bastie A, et al. **Pathol Biol (Paris)** 1995 Oct;43(8):674–80 (78 ref.) (Eng. Abstr.) **(Fre)**

[Transfusion and hepatitis C] Jullien AM. **Pathol Biol (Paris)** 1995 Oct;43(8):725–34 (74 ref.) (Eng. Abstr.) **(Fre)**

[Bacterial complications of blood transfusions] Avril JL, et al. **Transfus Clin Biol** 1996;3(1):43–9 (34 ref.) **(Fre)**

[Quality assurance and prevention of immuno–hemolytic incidents in blood transfusion] Boëlle PY, et al. **Transfus Clin Biol** 1996;3(1):27–34 (26 ref.) (Eng. Abstr.) **(Fre)**

[Quality assurance of bacterial incidents associated with blood transfusion] Noël L. **Transfus Clin Biol** 1996; 3(1):35–42 (28 ref.) (Eng. Abstr.) **(Fre)**

[Adverse effects due to unstable blood products] Hauser SP, et al. **Schweiz Med Wochenschr** 1996 Apr 13;126(15):637–45 (45 ref.) (Eng. Abstr.) **(Ger)**

[Incidence of post–transfusion hepatitis in Hungary 1987–1993] Sere G, et al. **Orv Hetil** 1996 Feb 25; 137(8):405–9 (42 ref.) (Eng. Abstr.) **(Hun)**

[Epidemiology and prevention of HCV infection in dialysis centers] Cialdea L, et al. **Ann Ist Super Sanita** 1995; 31(3):313–5 (23 ref.) (Eng. Abstr.) **(Ita)**

[Posttransfusion fulminant hepatitis associated with HBV mutants] Shimizu M, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:516–21 (20 ref.) **(Jpn)**

[Blood transmission and infections] Eggen BM. **Tidsskr Nor Laegeforen** 1995 Oct 10;115(24):3035–8 (73 ref.) (Eng. Abstr.) **(Nor)**

[Acute, post–transfusion lung injury (TRALI) and related states] Kotlarek–Haus S. **Pol Arch Med Wewn** 1995 May; 93(5):372–6 (27 ref.) **(Pol)**

[Complications in hemotherapy] Sharygin SL. **Ter Arkh** 1995; 67(7):85–7 (59 ref.) **(Rus)**

[The problem of cytomegalovirus infection in military blood transfusions] Shevchenko IuL, et al. **Voen Med Zh** 1995 Nov;(11):27–31, 80 (18 ref.) (Eng. Abstr.) **(Rus)**

ECONOMICS

Blood transfusion economics in Greece. Kyriopoulos JE, et al. **Transfus Clin Biol** 1995;2(5):387–94 (17 ref.)

METHODS

Transfusion therapy in pregnancy. Naef RW 3rd, et al. **Clin Obstet Gynecol** 1995 Sep;38(3):547–57 (29 ref.)

[How to do blood transfusions in the tropical environment?] Aubert M, et al. **Med Trop (Mars)** 1996;56(1):28–32 (9 ref.) **(Fre)**

STANDARDS

Consensus conference: Blood Management Surgical Practice Guidelines. Dallas, Texas, January 12–14, 1995. **Am J Surg** 1995 Dec;170(6A Suppl):1S–73S (0 ref.)

Infectious disease testing for blood transfusions. NIH Consensus Development Panel on Infectious Disease Testing for Blood Transfusions. **JAMA** 1995 Nov 1; 274(17):1374–9 (0 ref.)

Current good manufacturing practices. Zuck TF. **Transfusion** 1995 Nov–Dec;35(11):955–66 (23 ref.)

TRENDS

The continuing evolution of the nation's blood supply system. McCullough J. **Am J Clin Pathol** 1996 Jun;105(6):689–95 (50 ref.)

Perfluorocarbons in the twenty–first century: clinical applications as transfusion alternatives. Spence RK. **Artif Cells Blood Substit Immobil Biotechnol** 1995; 23(3):367–80 (35 ref.)

UTILIZATION

Limiting excessive postoperative blood transfusion after cardiac procedures. A review. Ferraris VA, et al. **Tex Heart Inst J** 1995;22(3):216–30 (167 ref.)

VETERINARY

Use of blood and blood components in canine and feline patients with hemostatic disorders. de Gopegui RR, et al. **Vet Clin North Am Small Anim Pract** 1995 Nov; 25(6):1387–402 (69 ref.)

Modern veterinary blood banking practices and their applications in companion animal practice. Feldman BF, et al. **Vet Clin North Am Small Anim Pract** 1995 Nov; 25(6):1231–43 (14 ref.)

Feline transfusion medicine. Blood types and their clinical importance. Griot–Wenk ME, et al. **Vet Clin North Am Small Anim Pract** 1995 Nov; 25(6):1305–22 (35 ref.)

Canine blood groups and their importance in veterinary transfusion medicine. Hale AS. **Vet Clin North Am Small Anim Pract** 1995 Nov; 25(6):1323–32 (22 ref.)

Canine transfusion reactions and their management. Harrell KA, et al. **Vet Clin North Am Small Anim Pract** 1995 Nov; 25(6):1333–64 (63 ref.)

BLOOD TRANSFUSION, AUTOLOGOUS

Consensus statement on autologous transfusion. Proceedings of a consensus conference held by the Royal College of Physicians of Edinburgh, October 4–6, 1995. **Br J Anaesth** 1996 Mar;76(3):470 (0 ref.)

Intraoperative blood salvage (IOBS) in cardiac and vascular surgery. Valbonesi M, et al. **Int J Artif Organs** 1995 Mar; 18(3):130–5 (19 ref.)

T–cell responses in photoimmune therapy. Heald PW, et al. **J Clin Apheresis** 1995;10(3):144–9 (26 ref.)

Autologous blood transfusion in the pediatric patient. Thompson HW, et al. **J Pediatr Surg** 1995 Oct; 30(10):1406–11 (21 ref.)

What's new in transfusion medicine? Manno CS. **Pediatr Clin North Am** 1996 Jun;43(3):793–808 (51 ref.)

Consensus statement on autologous transfusion. Royal College of Physicians of Edinburgh. **Transfus Med** 1996 Mar;6(1):69–70 (0 ref.)

Royal College of Physicians of Edinburgh Consensus Conference on Autologous Transfusion. Edinburgh, 4–6 October 1995. **Transfusion** 1996 Jul;36(7):625–67 (0 ref.)

Consensus conference on autologous transfusion. General background paper. Thomas MJ, et al. **Transfusion** 1996 Jul; 36(7):628–32 (61 ref.)

Consensus conference on autologous transfusion. Preoperative autologous donation. Thomas MJ, et al. **Transfusion** 1996 Jul;36(7):633–9 (94 ref.)

[Which technique should be chosen to reuse blood lost intraoperatively? Does the type of surgery constitute any contraindication for reutilization (cancer, infection)?] Lefevre P. **Ann Fr Anesth Reanim** 1995;14 Suppl 1:53–62 (104 ref.) **(Fre)**

[Blood salvage: a conditional safety] Andreassian B, et al. **J Mal Vasc** 1996;21 Suppl A:22–35 (48 ref.) (Eng. Abstr.) **(Fre)**

[Blood salvage: decisive progress in vascular surgery] Patra P, et al. **J Mal Vasc** 1996;21 Suppl A:13–21 (86 ref.) (Eng. Abstr.) **(Fre)**

[Erythropoietin and delayed taking of autologous blood: from physiologic secretion to the rationale for exogenous supplementation] Casadevall N. **Nouv Rev Fr Hematol** 1995;37 Suppl 1:S11–5 (35 ref.) **(Fre)**

[Eprex and daily autologous transfusion] Chassaigne M, et

al. **Nouv Rev Fr Hematol** 1995;37 Suppl 1:S37–40 (21 ref.) **(Fre)**

[Conservative hemotherapy. Blood component therapy instead of whole blood transfusion and homologous blood saving methods (editorial)] Reiff K, et al. **Gynakologe** 1995 Dec;28(6):393–400 (55 ref.) **(Ger)**

METHODS

Consensus conference on autologous transfusion. Perioperative red cell salvage. Desmond MJ, et al. **Transfusion** 1996 Jul;36(7):644–51 (49 ref.)

[Delayed autologous transfusion and erythropoietin] Baron JF. **Nouv Rev Fr Hematol** 1995;37 Suppl 1:S17–25 (41 ref.) **(Fre)**

[Blood transfusions in cancer patients] Elias D, et al. **Presse Med** 1996 Feb 17;25(6):255–8 (30 ref.) (Eng. Abstr.) **(Fre)**

VETERINARY

Autotransfusion in the emergency patient. Purvis D. **Vet Clin North Am Small Anim Pract** 1995 Nov; 25(6):1291–304 (59 ref.)

BLOOD TRANSFUSION, INTRAUTERINE

Fetal transfusion for red blood cell alloimmunization in pregnancy. Schumacher B, et al. **Obstet Gynecol** 1996 Jul; 88(1):137–50 (161 ref.)

Fetal transfusion therapy. Skupski DW, et al. **Obstet Gynecol Surv** 1996 Mar;51(3):181–92 (73 ref.)

The fetus as a recipient and donor of blood components. Roberts GT, et al. **Transfus Med Rev** 1995 Jul;9(3):260–70 (59 ref.)

BLOOD TYPING see **BLOOD GROUPING AND CROSSMATCHING**

BLOOD UREA NITROGEN

Dialysate-based kinetic modeling. Garred LJ. **Adv Ren Replace Ther** 1995 Oct;2(4):305–18 (35 ref.)

[Blood urea nitrogen, non-protein nitrogen] Orita Y, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:473–7 (10 ref.) **(Jpn)**

BLOOD VESSEL PROSTHESIS

Endovascular stents and stented grafts for the treatment of aneurysms and other arterial lesions. Marin ML, et al. **Adv Surg** 1996;29:93–109 (50 ref.)

Rupture of a dissecting thoracic aortic aneurysm into the pulmonary artery: successful surgical repair. Coselli JS, et al. **Cardiovasc Surg** 1995 Dec;3(6):697–701 (34 ref.)

Contained rupture of infected abdominal aortic aneurysm due to systemic candidiasis. Ikeda M, et al. **Cardiovasc Surg** 1995 Dec;3(6):711–4 (30 ref.)

Carotid Dacron patch angioplasty: immediate and long-term results of a prospective series. Perler BA, et al. **Cardiovasc Surg** 1995 Dec;3(6):631–6 (43 ref.)

The present status of endoluminal stented grafts for the treatment of aneurysms, traumatic injuries and arterial occlusions. Veith FJ, et al. **Cardiovasc Surg** 1996 Feb; 4(1):3–7 (30 ref.)

Coarctation of the aorta. Repair with polytetrafluoroethylene patch aortoplasty. Backer CL, et al. **Circulation** 1995 Nov 1;92(9 Suppl):II132–6 (37 ref.)

New concepts of the renin-angiotensin system—implications for vascular and endovascular surgery. O'Donohoe MK, et al. **Eur J Vasc Endovasc Surg** 1996 May;11(4):393–401 (117 ref.)

Late rupture of femoropopliteal Dacron grafts: a rare complication. Vrancken Peeters MT, et al. **Eur J Vasc Endovasc Surg** 1996 Feb;11(2):243–6 (5 ref.)

Three-dimensional intracoronary ultrasound imaging. Methodology and clinical relevance for the assessment of coronary arteries and bypass grafts. Von Birgelen C, et al. **J Cardiovasc Surg (Torino)** 1996 Apr;37(2):129–39 (100 ref.)

Surgery versus thrombolytic therapy in the management of peripheral arterial occlusions. Ouriel K. **J Vasc Interv Radiol** 1995 Nov–Dec;6(6 Pt 2 Su):48S–54S (42 ref.)

Neo-endothelialisation of PTFE microvascular grafts: a five-year experience. Lanzetta M, et al. **Microsurgery** 1995; 16(6):404–11 (35 ref.)

Horseshoe kidney and aortic surgery. Wymenga LF, et al. **Scand J Urol Nephrol** 1995 Sep;29(3):331–4 (10 ref.)

Prosthetic grafts: when are they a reasonable alternative? Abbott WM, et al. **Semin Vasc Surg** 1995 Sep;8(3):236–45 (51 ref.)

Endovascular repair of abdominal aortic aneurysms using the EGS tube and bifurcated graft systems. Colburn MD, et al. **World J Surg** 1996 Jul–Aug;20(6):664–72 (44 ref.)

Endovascular technology and its impact on the relationships among vascular surgeons, interventional radiologists, and other specialists. Veith FJ, et al. **World J Surg** 1996 Jul–Aug;20(6):687–91 (36 ref.)

[Surgical vein reconstruction in patients with tumor invasiveness of the superior caval system. Retrospective study of 7 cases] Jeanfaivre T, et al. **J Chir (Paris)** 1996 Apr;133(2):61–4 (19 ref.) (Eng. Abstr.) **(Fre)**

[Infrarenal aneurysm: traditional surgery] Limet R. **J Mal Vasc** 1996;21 Suppl A:58–62 (19 ref.) (Eng. Abstr.) **(Fre)**

[Renal revascularization for kidney salvage or preservation] Van Damme H, et al. **Rev Med Liege** 1996 Feb;51(2):175–86 (47 ref.) **(Fre)**

[Prevention and therapy of prosthesis infections in the thoracic area] Haverich A, et al. **Zentralbl Chir** 1995; 120(8):630–4 (21 ref.) (Eng. Abstr.) **(Ger)**

[A case report of bentall type operation for annuloaortic ectasia with anomalous origin of the right coronary artery complicated by aortic dissection] Hirai M, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Jul;43(7):1044–9 (20 ref.) (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

An overview of the treatment of infected prosthetic vascular grafts. Calligaro KD, et al. **Adv Surg** 1996;29:3–16 (52 ref.)

The case for conservative management of infected prosthetic grafts. Perler BA. **Adv Surg** 1996;29:17–32 (85 ref.)

The case against the conservative nonresectional management of infected prosthetic grafts. Yeager RA, et al. **Adv Surg** 1996;29:33–9 (35 ref.)

Aortic graft infection with mycoplasma (Ureaplasma urealyticum). Levi N, et al. **Eur J Vasc Endovasc Surg** 1995 Oct;10(3):374–5 (14 ref.)

[Antibiotic bonding on arterial prostheses: a necessity] Goeau-Brissonniere O. **J Mal Vasc** 1996;21 Suppl A:146–51 (42 ref.) (Eng. Abstr.) **(Fre)**

[A case report of mediastinitis due to methicillin resistant Staphylococcus aureus after total aortic arch replacement] Asano S, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Jun;44(6):814–9 (18 ref.) (Eng. Abstr.) **(Jpn)**

ECONOMICS

Cost-efficacy issues in the treatment of peripheral vascular disease: primary amputation or revascularization for limb-threatening ischemia. Perler BA. **J Vasc Interv Radiol** 1995 Nov–Dec;6(6 Pt 2 Su):111S–115S (28 ref.)

INSTRUMENTATION

[Treatment of abdominal aortic aneurysms: importance of the bifurcated prosthesis] Batt M, et al. **J Mal Vasc** 1996; 21 Suppl A:53–7 (26 ref.) (Eng. Abstr.) **(Fre)**

METHODS

Interposition vein cuffs. Harris P, et al. **J Mal Vasc** 1996; 21 Suppl A:178–80 (11 ref.)

Arterial reconstruction for limb salvage: is the terminal peroneal artery a disadvantaged outflow tract? Darling RC 3rd, et al. **Surgery** 1995 Oct;118(4):763–7 (24 ref.)

[Pros and cons of use of collagenated arterial prostheses] Barral X, et al. **J Mal Vasc** 1996;21 Suppl A:36–40 (11 ref.) (Eng. Abstr.) **(Fre)**

[Impregnated polyester prostheses: a theoretical advantage] Becquemin JP, et al. **J Mal Vasc** 1996;21 Suppl A:41–7 (25 ref.) (Eng. Abstr.) **(Fre)**

BLOOD VESSEL TUMORS see **NEOPLASMS, VASCULAR TISSUE**

BLOOD VESSELS

see related
ANGIOGENESIS FACTOR
ANGIOGRAPHY
VASCULAR RESISTANCE
VASCULAR SURGERY
VASOMOTOR SYSTEM

CYTOLOGY

Development of the embryonic vascular system. Wilting J, et al. **Cell Mol Biol Res** 1995;41(4):219–32 (152 ref.)

DRUG EFFECTS

Vascular affinity of trandolapril. Miyazaki M, et al. **Am J Hypertens** 1995 Oct;8(10 Pt 2):63S–67S (21 ref.)

Roles of peptides and other substances in cotransmission from vascular autonomic and sensory neurons. Morris JL, et al. **Can J Physiol Pharmacol** 1995 May;73(5):521–32 (123 ref.)

Complementary vascular-protective actions of magnesium and taurine: a rationale for magnesium taurate. McCarty MF. **Med Hypotheses** 1996 Feb;46(2):89–100 (136 ref.)

EMBRYOLOGY

Vasculogenesis. Risau W, et al. **Ann Rev Cell Dev Biol** 1995; 11:73–91 (122 ref.)

Formation of the arterial media during vascular development. Thayer JM, et al. **Cell Mol Biol Res** 1995;41(4):251–62 (100 ref.)

Development of the embryonic vascular system. Wilting J, et al. **Cell Mol Biol Res** 1995;41(4):219–32 (152 ref.)

Embryonic angiogenesis: a review. Wilting J, et al. **Naturwissenschaften** 1996 Apr;83(4):153–64 (168 ref.)

GROWTH & DEVELOPMENT

Resistance vessel growth and remodelling: cause or consequence in cardiovascular disease. Mulvany MJ. **J Hum Hypertens** 1995 Jun;9(6):479–85 (43 ref.)

INJURIES

Diagnosis of vascular trauma. Modrall JG, et al. **Ann Vasc Surg** 1995 Jul;9(4):415–21 (61 ref.)

The present status of endoluminal stented grafts for the treatment of aneurysms, traumatic injuries and arterial occlusions. Veith FJ, et al. **Cardiovasc Surg** 1996 Feb; 4(1):3–7 (30 ref.)

Abdominal vascular injuries. Mullins RJ, et al. **Surg Clin North Am** 1996 Aug;76(4):813–32 (45 ref.)

Difficult peripheral vascular injuries. Weaver FA, et al. **Surg Clin North Am** 1996 Aug;76(4):843–59 (54 ref.)

INNERVATION

The role of the autonomic nerves in the control of nasal circulation. Lung MA. **Biol Signals** 1995 May–Jun; 4(3):179–85 (33 ref.)

Peptides as neurotransmitters in vascular autonomic neurons. Morris JL. **Clin Exp Pharmacol Physiol** 1995 Nov; 22(11):792–802 (119 ref.)

Vascular alpha-1 adrenergic receptor subtypes in the regulation of arterial pressure. Vargas HM, et al. **Life Sci** 1995;57(25):2291–308 (139 ref.)

METABOLISM

Increased substance P receptor expression by blood vessels and lymphoid aggregates in Clostridium difficile-induced pseudomembranous colitis. Mantyh CR, et al. **Dig Dis Sci** 1996 Mar;41(3):614–20 (22 ref.)

PATHOLOGY

Evidence in vivo for induction of cardiovascular growth processes by vasoconstrictor systems. Adams MA, et al. **Blood Press Suppl** 1995;2:61–7 (64 ref.)

Transforming growth factor-beta 1 and the development of vascular hypertrophy in hypertension. Agrotis A, et al. **Blood Press Suppl** 1995;2:43–8 (43 ref.)

Quantitative microvessel density. A staging and prognostic marker for human prostatic carcinoma. Brawer MK. **Cancer** 1996 Jul 15;78(2):345–9 (25 ref.)

Molecular mechanisms of vascular hypertrophy in the spontaneously hypertensive rat. Marche P, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S114–6 (23 ref.)

Sick vessel syndrome: vascular changes in hypertension and atherosclerosis. Heistad DD, et al. **J Hum Hypertens** 1995 Jun;9(6):449–53 (38 ref.)

Vascular structure, smooth muscle cell phenotype and growth in hypertension. Lindop GB, et al. **J Hum Hypertens** 1995 Jun;9(6):475–8 (44 ref.)

Pathogenic mechanisms of vessel damage in vasculitis syndromes. Sundy JS, et al. **Rheum Dis Clin North Am** 1995 Nov;21(4):861–81 (101 ref.)

PHYSIOLOGY

Endothelins as cardiovascular peptides. Levin ER. **Am J Nephrol** 1996;16(3):246–51 (64 ref.)

Carbohydrate-protein interactions in vascular biology. Nelson RM, et al. **Ann Rev Cell Dev Biol** 1995;11:601–31 (185 ref.)

Vascular remodeling in hypertension: role of autocrine-paracrine factors. Gibbons GH. **Blood Press Suppl** 1995;2:49–54 (56 ref.)

Regulation of vascular tone: cross-talk between sarcoplasmic reticulum and plasmalemma. Daniel EE, et al. **Can J Physiol Pharmacol** 1995 May;73(5):551–7 (46 ref.)

Regulation of vascular tone. Rossitti S, et al. **Can J Physiol Pharmacol** 1995 May;73(5):544–50 (43 ref.)

Intracellular mechanisms involved in the regulation of vascular smooth muscle tone. Walsh MP, et al. **Can J Physiol Pharmacol** 1995 May;73(5):565–73 (53 ref.)

Elastin in blood vessels. Robert L, et al. **Ciba Found Symp** 1995;192:286–99; discussion 299–303 (53 ref.)

Adhesion molecules—Part II: Blood vessels and blood cells. Frenette PS, et al. **N Engl J Med** 1996 Jul 4;335(1):43–5 (0 ref.)

[Vascular aging. Role of elastin receptor] Robert L. **C R Seances Soc Biol Fil** 1995;189(6):959–66 (21 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Role of nitric oxide in the vascular dysfunction of septic shock. Rees DD. **Biochem Soc Trans** 1995 Nov; 23(4):1025–9 (38 ref.)

Cytokines regulate vascular functions related to stability of the atherosclerotic plaque. Libby P, et al. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S9–12 (23 ref.)

Sick vessel syndrome: vascular changes in hypertension and atherosclerosis. Heistad DD, et al. **J Hum Hypertens** 1995 Jun;9(6):449–53 (38 ref.)

Resistance vessel growth and remodelling: cause or consequence in cardiovascular disease. Mulvany MJ. **J Hum Hypertens** 1995 Jun;9(6):479–85 (43 ref.)

Abnormal vascular function following ischemia-reperfusion injury. Conger JD, et al. **J Investig Med** 1995 Oct; 43(5):431–42 (62 ref.)

BLOOD VESSELS

ULTRASONOGRAPHY

What have we learned from in vitro intravascular ultrasound? [editorial] Gussenhoven EJ, et al. **Am Heart J** 1996 Sep; 132(3):702–10 (48 ref.)

BLOOD VISCOSITY

see related
HEMORHEOLOGY

Neonatal polycythemia and hyperviscosity. Werner EJ. **Clin Perinatol** 1995 Sep;22(3):693–710 (97 ref.)

[Hyperviscosity syndrome in patients with immunoproliferative disorder] Hashimoto T. **Nippon Naika Gakkai Zasshi** 1995 Jul 10;84(7):1096–9 (5 ref.) **(Jpn)**

DRUG EFFECTS

Haemorheological consequences of chronic cigarette smoking. Ernst E. **J Cardiovasc Risk** 1995 Oct;2(5):435–9 (70 ref.)

PHYSIOLOGY

Hemoconcentration and stress: a review of physiological mechanisms and relevance for cardiovascular disease risk. Allen MT, et al. **Biol Psychol** 1995 Aug;41(1):1–27 (125 ref.)

[Hypertension and hemorheology] Klein W, et al. **Wien Med Wochenschr** 1995;145(15–16):355–7 (22 ref.) (Eng. Abstr.) **(Ger)**

[The rheological properties of the erythrocytes. Current study methods] Katiukhin LN. **Fiziol Zh Im I M Sechenova** 1995 Jun;81(6):122–9 (24 ref.) (Eng. Abstr.) **(Rus)**

BLOOD VOLUME

Personal factors and blood volume movement in causation of median neuropathy at the carpal tunnel. A commentary. Radecki P. **Am J Phys Med Rehabil** 1996 May–Jun; 75(3):235–8 (27 ref.)

DRUG EFFECTS

[Effects of analgesia and sedation on cerebrovascular circulation, cerebral blood volume, cerebral metabolism and intracranial pressure] Werner C. **Anaesthesist** 1995 Dec; 44 Suppl 3:S566–72 (83 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Hemoconcentration and stress: a review of physiological mechanisms and relevance for cardiovascular disease risk. Allen MT, et al. **Biol Psychol** 1995 Aug;41(1):1–27 (125 ref.)

Effective blood volume: an effective concept or a modern myth. Michell AR. **Perspect Biol Med** 1996 Summer; 39(4):471–90 (72 ref.)

BLOODLETTING

see related
PHLEBOTOMY

BLOOM SYNDROME

[Chromosome breakage syndrome and fragile X syndrome] Shiraishi Y. **Nippon Rinsho** 1995 Nov;53(11):2807–14 (16 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Bloom syndrome: is the gene mapped to the point? Bamezai R. **Indian J Exp Biol** 1996 Apr;34(4):298–301 (38 ref.)

BLOOM-TORRE-MACHACEK SYNDROME see **BLOOM SYNDROME**

BLOTTING, NORTHERN

METHODS

Northern analysis and nucleic acid probes. Sabelli PA, et al. **Methods Mol Biol** 1995;49:213–28 (32 ref.)

BLOTTING, SOUTHERN

METHODS

Gene characterization by southern analysis. Sabelli PA, et al. **Methods Mol Biol** 1995;49:161–80 (39 ref.)

Nonradioactive probes. Isaac PG, et al. **Mol Biotechnol** 1995 Jun;3(3):259–65 (24 ref.)

BLOTTING, WESTERN

METHODS

Western blotting analysis. Fido RJ, et al. **Methods Mol Biol** 1995;49:423–37 (24 ref.)

[Western blotting in the diagnosis of dystrophinopathies] Navarro C. **Rev Neurol** 1995;23 Suppl 3:S401–3 (26 ref.) **(Spa)**

BLOW-OUT FRACTURES see **ORBITAL FRACTURES**

BLUE-GREEN BACTERIA see **CYANOBACTERIA**

BLUE TOE SYNDROME

SURGERY

Blue toe syndrome from a "coral reef" aorta. Rosenberg GD, et al. **Ann Vasc Surg** 1995 Nov;9(6):561–4 (19 ref.)

BLUETONGUE

EPIDEMIOLOGY

Culicoides variipennis and bluetongue-virus epidemiology in the United States. Tabachnick WJ. **Annu Rev Entomol** 1996; 41:23–43 (135 ref.)

PREVENTION & CONTROL

Culicoides variipennis and bluetongue disease. Research on arthropod-borne animal diseases for control and prevention in the year 2000. Tabachnick WJ, et al. **Ann N Y Acad Sci** 1996 Jul 23;791:219–26 (30 ref.)

BLUETONGUE VIRUS

Culicoides variipennis and bluetongue-virus epidemiology in the United States. Tabachnick WJ. **Annu Rev Entomol** 1996; 41:23–43 (135 ref.)

Handling small arbovirus vectors safely during biosafety level 3 containment: Culicoides variipennis sonorensis (Diptera:Ceratopogonidae) and exotic bluetongue viruses. Hunt GJ, et al. **J Med Entomol** 1996 May;33(3):271–7 (17 ref.)

BLUNT INJURIES see **WOUNDS, NONPENETRATING**

BLV see **LEUKEMIA VIRUS, BOVINE**

BLV INFECTIONS see **HTLV-BLV INFECTIONS**

BOARD, GOVERNING see **GOVERNING BOARD**

BOATS see **SHIPS**

BODY BUILD see **SOMATOTYPES**

BODY BURDEN

see related
DRUG RESIDUES
PESTICIDE RESIDUES

Comparisons of estimated human body burdens of dioxinlike chemicals and TCDD body burdens in experimentally exposed animals. DeVito MJ, et al. **Environ Health Perspect** 1995 Sep;103(9):820–31 (113 ref.)

Conceptual framework for designing a national survey of human exposure. Lioy PJ, et al. **J Expo Anal Environ Epidemiol** 1995 Jul–Sep;5(3):425–44 (31 ref.)

BODY COMPOSITION

Increasing physical activity: alterations in body mass and composition. Wilmore JH. **Am J Clin Nutr** 1996 Mar;63(3 Suppl):456S–460S (27 ref.)

Prediction of body composition in elderly men over 75 years of age. Fuller NJ, et al. **Ann Hum Biol** 1996 Mar–Apr; 23(2):127–47 (64 ref.)

Body composition: overview of methods and future directions of research. Deurenberg P, et al. **Ann Nutr Metab** 1995;39(6):325–33 (31 ref.)

Phytoestrogens, body composition, and breast cancer. Horn-Ross PL. **Cancer Causes Control** 1995 Nov; 6(6):567–73 (59 ref.)

Aging and body composition: biological changes and methodological issues. Going S, et al. **Exerc Sport Sci Rev** 1995;23:411–58 (173 ref.)

Influence of growth hormone and androgens on body composition in adults. Jørgensen JO, et al. **Horm Res** 1996; 45(1–2):94–8 (31 ref.)

The regulation of adipose tissue distribution in humans. Björntorp P. **Int J Obes Relat Metab Disord** 1996 Apr; 20(4):291–302 (117 ref.)

The role of progressive resistance training and nutrition in the preservation of lean body mass in the elderly. Fielding RA. **J Am Coll Nutr** 1995 Dec;14(6):587–94 (51 ref.)

Techniques of assessing muscle mass and function (sarcopenia) for epidemiological studies of the elderly. Chumlea WC, et al. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:45–51 (48 ref.)

Loss of skeletal muscle mass with aging: effect on glucose tolerance. Kohrt WM, et al. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:68–72 (43 ref.)

Relationship of age-related decreases in muscle mass and strength to skeletal status. Marcus R. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:86–7 (12 ref.)

Body composition by DXA: tried and true? Kohrt WM. **Med Sci Sports Exerc** 1995 Oct;27(10):1349–53 (34 ref.)

Visceral fat accumulation and cardiovascular disease. Matsuzawa Y, et al. **Obes Res** 1995 Dec;3 Suppl 5:645S–647S (11 ref.)

Bioelectrical impedance analysis and dual energy x-ray absorptiometry to monitor nutritional status. Stall S, et al. **Perit Dial Int** 1995;15(5 Suppl):S59–62 (31 ref.)

[Bio-electrical impedance analysis method for body fat mass] Sato T. **Nippon Rinsho** 1995 Jun;53 Suppl:179–82 (10 ref.) **(Jpn)**

[The current status of methods for evaluating body composition: their description, reproducibility, accuracy, scope of application, safety, cost and future prospects] Valtueña Martínez S, et al. **Med Clin (Barc)** 1996 Apr 27; 106(16):624–35 (145 ref.) **(Spa)**

DRUG EFFECTS

Trophic factor supplementation: effect on the age-associated changes in body composition. Schwartz RS. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:151–6 (53 ref.)

PHYSIOLOGY

Integration of the overall response to exercise. Flatt JP. **Int J Obes Relat Metab Disord** 1995 Oct;19 Suppl 4:S31–40 (23 ref.)

Variations in physical activity habits and body composition. Wilmore JH. **Int J Obes Relat Metab Disord** 1995 Oct;19 Suppl 4:S107–12 (30 ref.)

Impact of composition manipulation on lean lamb production in the United States. Beermann DH, et al. **J Anim Sci** 1995 Aug;73(8):2493–502 (37 ref.)

What is sarcopenia? Evans WJ. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:5–8 (36 ref.)

Effects of exercise on body composition and functional capacity of the elderly. Evans WJ. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:147–50 (23 ref.)

Functional consequences of sarcopenia: effects on thermoregulation. Kenney WL, et al. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:78–85 (73 ref.)

Sarcopenia in aging humans: the impact of menopause and disease. Poehlman ET, et al. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:73–7 (25 ref.)

Trophic factor supplementation: effect on the age-associated changes in body composition. Schwartz RS. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:151–6 (53 ref.)

Strength and aerobic training attenuate muscle wasting and improve resistance to the development of disability with aging. Tseng BS, et al. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:113–9 (49 ref.)

Susceptibility to development of central adiposity among populations. Fujimoto WY, et al. **Obes Res** 1995 Sep;3 Suppl 2:179S–186S (28 ref.)

Pathophysiology and pathogenesis of visceral fat obesity. Matsuzawa Y, et al. **Obes Res** 1995 Sep;3 Suppl 2:187S–194S (14 ref.)

BODY CONSTITUTION

Prediction of body composition in elderly men over 75 years of age. Fuller NJ, et al. **Ann Hum Biol** 1996 Mar–Apr; 23(2):127–47 (64 ref.)

Maximal and submaximal oxygen uptake during running: how should body mass be accounted for? Svedenhag J. **Scand J Med Sci Sports** 1995 Aug;5(4):175–80 (33 ref.)

[On the diagnosis of so-called "constitutional" bone diseases] Nigro N, et al. **Minerva Pediatr** 1995 Jun;47(6):229–31 (15 ref.) (Eng. Abstr.) **(Ita)**

GENETICS

Long-term programming of body size. Bouchard C. **Nutr Rev** 1996 Feb;54(2 Pt 2):S8–16 (58 ref.)

PHYSIOLOGY

Size control: the regulation of cell numbers in animal development. Raff MC. **Cell** 1996 Jul 26;86(2):173–5 (20 ref.)

BODY FLUID COMPARTMENTS

PHYSIOLOGY

Solute disequilibrium and multicompartment modeling. Kaufman AM, et al. **Adv Ren Replace Ther** 1995 Oct; 2(4):319–29 (39 ref.)

BODY FLUIDS

see related
DEHYDRATION

Disorders of body fluid balance: a new look into the mechanisms of disease. Plante GE, et al. **Can J Cardiol** 1995 Oct;11(9):788–802 (89 ref.)

CHEMISTRY

Factors affecting the measurement of cytokines in biological

fluids: implications for their clinical measurement. Heney D, et al. **Ann Clin Biochem** 1995 Jul;32 (Pt 4):358–68 (62 ref.)
Capillary electrophoretic analyses of drugs in body fluids: sample pretreatment and methods for direct injection of biofluids. Lloyd DK. **J Chromatogr A** 1996 May 31; 735(1–2):29–42 (69 ref.)
[Reference values for trace elements in biological fluids] Apostoli P. **Ann Ist Super Sanita** 1995;31(2):261–74 (30 ref.) (Eng. Abstr.) **(Ita)**
[Cytologic and biochemical characteristics of breast fluid obtained through the nipple of non-lactating women] Vizoso F. **Med Clin (Barc)** 1995 Sep 23;105(9):349–56 (137 ref.) **(Spa)**

CYTOLOGY

[Cytologic and biochemical characteristics of breast fluid obtained through the nipple of non-lactating women] Vizoso F. **Med Clin (Barc)** 1995 Sep 23;105(9):349–56 (137 ref.) **(Spa)**

METABOLISM

Keratan sulfate in body fluids in joint disease. Thonar EJ, et al. **Acta Orthop Scand Suppl** 1995 Oct;266:103–6 (19 ref.)
The inscrutable renal cyst in ADPKD [editorial] Grantham JJ. **Nephrol Dial Transplant** 1995;10(7):1106–9 (15 ref.)
[Exploration of cytokines in inflammation in biological fluids] Bienvenu J. **C R Seances Soc Biol Fil** 1995;189(4):545–55 (19 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Atrial natriuretic peptide and body fluid homeostasis: leading actor or bit-part player? Richards AM, et al. **Cardiologia** 1995 Sep;40(9):643–50 (71 ref.)
Anteroventral wall of the third ventricle and dorsal lamina terminalis: headquarters for control of body fluid homeostasis? McKinley MJ, et al. **Clin Exp Pharmacol Physiol** 1996 Apr;23(4):271–81 (96 ref.)
Neuroendocrine regulation of sodium and volume following subarachnoid hemorrhage. Diringer MN. **Clin Neuropharmacol** 1995 Apr;18(2):114–26 (64 ref.)
Role of hepatic receptors in controlling body fluid homeostasis. Morita H, et al. **Jpn J Physiol** 1995; 45(3):355–68 (47 ref.)
Volaemia and blood pressure in renal failure: have old truths been forgotten? Mees EJ. **Nephrol Dial Transplant** 1995; 10(8):1297–8 (8 ref.)

BODY HEIGHT

Identification and assessment of the slowly growing child. Duck SC. **Am Fam Physician** 1996 May 15;53(7):2305–12 (18 ref.)
Short stature and growth hormone deficiency. Hindmarsh PC, et al. **Clin Endocrinol (Oxf)** 1995 Aug;43(2):133–42 (35 ref.)
Common causes of short stature detectable by a height surveillance programme. Hyer W, et al. **J Med Screen** 1995; 2(3):150–3 (47 ref.)
Short stature: does it matter? A review of the evidence. Voss LD. **J Med Screen** 1995;2(3):130–2 (35 ref.)
[Indices of obesity derived from body weight and height] Kataoka K. **Nippon Rinsho** 1995 Jun;53 Suppl:147–53 (30 ref.) **(Jpn)**
[Significance of somatometric analysis in medical research] Gubina-Vakulik GI. **Arkh Patol** 1995 Nov-Dec;57(6):77–9 (68 ref.) (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

[Growth hormone therapy in childhood. Growth hormone therapy in small children without growth hormone deficiency] Butenandt O. **Fortschr Med** 1996 Jun 10; 114(16):201–4 (42 ref.) (Eng. Abstr.) **(Ger)**

BODY IMAGE

The social body and the biomechanical body: can they coexist in nurse education? Brown C, et al. **J Adv Nurs** 1996 Apr; 23(4):651–6 (36 ref.)

BODY LANGUAGE see **KINESICS**

BODY MASS INDEX

see related
SKINFOLD THICKNESS

Physical fitness, mortality and obesity. Barlow CE, et al. **Int J Obes Relat Metab Disord** 1995 Oct;19 Suppl 4:S41–4 (14 ref.)
Variations in physical activity habits and body composition. Wilmore JH. **Int J Obes Relat Metab Disord** 1995 Oct;19 Suppl 4:S107–12 (30 ref.)
High-density lipoprotein-cholesterol: determining hygienic factors for intervention [published erratum appears in J Occup Environ Med 1995 Sep;37(9):1121] Anzalone DA, et al. **J Occup Environ Med** 1995 Jul;37(7):856–61 (32 ref.)
[Waist to hip circumference ratio] Abe T, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:221–6 (16 ref.) **(Jpn)**
[Dual photon absorptiometry, dual energy X-ray absorptiometry for analysis of body fat mass] Itabashi A. **Nippon Rinsho** 1995 Jun;53 Suppl:174–8 (11 ref.) **(Jpn)**
[Techniques of measurement of human body fat mass: overview] Kataoka K. **Nippon Rinsho** 1995 Jun;53 Suppl:157–64 (42 ref.) **(Jpn)**
[Indices of obesity derived from body weight and height] Kataoka K. **Nippon Rinsho** 1995 Jun;53 Suppl:147–53 (30 ref.) **(Jpn)**
[Densitometry (hydrostatic weighing) for measurement of human body fat mass] Koda M, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:165–9 (11 ref.) **(Jpn)**
[Skinfold thickness for analysis of body fat mass] Koda M, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:189–93 (21 ref.) **(Jpn)**
[Near infrared interactance for measurement of body fat mass] Sawai S, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:183–8 (11 ref.) **(Jpn)**

BODY ROCKING see **STEREOTYPED BEHAVIOR**

BODY SIZE see **BODY CONSTITUTION**

BODY SURFACE MAPPING see **BODY SURFACE POTENTIAL MAPPING**

BODY SURFACE POTENTIAL MAPPING

Ventricular tachycardia in ischaemic heart disease: insights into the mechanisms from cardiac mapping and implications for patient management. Doig JC, et al. **Eur Heart J** 1995 Aug;16(8):1027–35 (71 ref.)
Atrial flutter mapping and ablation. I. Studying atrial flutter mechanisms by mapping and entrainment. Cosio FG, et al. **Pacing Clin Electrophysiol** 1996 May;19(5):841–53 (39 ref.)
[Value of mapping in surgical treatment of ventricular tachycardia] Lacroix D, et al. **Arch Mal Coeur Vaiss** 1996 Feb;89 Spec No 1:109–13 (20 ref.) (Eng. Abstr.) **(Fre)**

METHODS

Topographic concepts in computerized electrocardiology. Kneppo P, et al. **Crit Rev Biomed Eng** 1992;19(5):343–418 (240 ref.)

BODY TEMPERATURE

see related
FEVER
THERMOGRAPHY

[Temperature and male fertility] Bujan L, et al. **Contracept Fertil Sex** 1996 Jun;24(6):429–38 (40 ref.) **(Fre)**
[Physical exercise and increase in arterial pressure and temperature in a female heterozygote for anhidrotic ectodermal dysplasia] Bandinelli G, et al. **Ann Ital Med Int** 1996 Jan-Mar;11(1):59–61 (12 ref.) (Eng. Abstr.) **(Ita)**
[Temperature changes and thermoregulatory responses during epidural anesthesia in women undergoing cesarean delivery] Negishi C, et al. **Masui** 1996 May;45(5):558–64 (17 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Thermal aspects of vehicle comfort. Holmér I, et al. **Appl Human Sci** 1995 Jul;14(4):159–65 (19 ref.)
Influence of body temperature on responses to hypoxia and hypercapnia: implications for SIDS. Maskrey M. **Clin Exp Pharmacol Physiol** 1995 Aug;22(8):527–32 (60 ref.)
Does thermoregulatory feeding occur in newborn infants? A novel view of the role of brown adipose tissue thermogenesis in control of food intake. Himms-Hagen J. **Obes Res** 1995 Jul;3(4):361–9 (54 ref.)
Brain cooling across wake-sleep behavioral states in homeothermic species: an analysis of the underlying physiological mechanisms. Parmeggiani PL. **Rev Neurosci** 1995 Oct-Dec;6(4):353–63 (36 ref.)

BODY TEMPERATURE REGULATION

DRUG EFFECTS

Pharmacological and clinical studies of ephedrine and other thermogenic agonists. Astrup A, et al. **Obes Res** 1995 Nov; 3 Suppl 4:537S–540S (12 ref.)
Hypothalamic neuronal histamine modulates adaptive behavior and thermogenesis in response to endogenous pyrogen. Sakata T, et al. **Obes Res** 1995 Dec;3 Suppl 5:707S–712S (26 ref.)

PHYSIOLOGY

Thermogenesis and thyroid function. Freake HC, et al. **Annu Rev Nutr** 1995;15:263–91 (161 ref.)
Role of membrane lipids in temperature acclimatization of carp. Buda C, et al. **Arch Tierernahr** 1996;49(1):61–2 (7 ref.)
Energy conservation and sleep. Berger RJ, et al. **Behav Brain Res** 1995 Jul-Aug;69(1–2):65–73 (77 ref.)
Thermosensation. Some like it hot. Thomas JH. **Curr Biol** 1995 Nov 1;5(11):1222–4 (12 ref.)
Perinatal thermogenesis. Gunn TR, et al. **Early Hum Dev** 1995 Aug 18;42(3):169–83 (60 ref.)
Effects of diving and hyperbaria on responses to exercise. Shiraki K, et al. **Exerc Sport Sci Rev** 1995;23:459–85 (76 ref.)
Brain temperature and hippocampal function. Andersen P, et al. **Hippocampus** 1995;5(6):491–8 (35 ref.)
Thermal balance and dialysis hypotension. Maggiore Q, et al. **Int J Artif Organs** 1995 Sep;18(9):518–25 (11 ref.)
Exercise and thermogenesis in obesity. Segal KR. **Int J Obes Relat Metab Disord** 1995 Oct;19 Suppl 4:S80–7 (25 ref.)
Functional consequences of sarcopenia: effects on thermoregulation. Kenney WL, et al. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:78–85 (73 ref.)
Adaptation to heat. Hori S. **Jpn J Physiol** 1995;45(6):921–46 (82 ref.)
A regulatory pathway of thermogenesis in brown fat through retinoic acid. Wolf G. **Nutr Rev** 1995 Aug;53(8):230–1 (4 ref.)
Does thermoregulatory feeding occur in newborn infants? A novel view of the role of brown adipose tissue thermogenesis in control of food intake. Himms-Hagen J. **Obes Res** 1995 Jul;3(4):361–9 (54 ref.)
Thermoregulation. Perlstein PH. **Pediatr Ann** 1995 Oct; 24(10):531–7 (28 ref.)
Thyroid hormone control of thermogenesis and energy balance. Silva JE. **Thyroid** 1995 Dec;5(6):481–92 (99 ref.)
[Temperature changes and thermoregulatory responses during epidural anesthesia in women undergoing cesarean delivery] Negishi C, et al. **Masui** 1996 May;45(5):558–64 (17 ref.) (Eng. Abstr.) **(Jpn)**
[Skin circulation--measurements with laser-doppler] Marszalek A. **Med Pr** 1996;47(4):411–8 (16 ref.) (Eng. Abstr.) **(Pol)**
[Role of peptidergic mechanisms in thermoregulation] Marianovich AT. **Fiziol Cheloveka** 1996 Mar-Apr; 22(2):35–42 (83 ref.) **(Rus)**
[Immunophysiologic mechanisms of adaptation to extreme conditions] Novikov VS. **Fiziol Cheloveka** 1996 Mar-Apr; 22(2):25–34 (44 ref.) **(Rus)**
[Theoretical and clinical aspects of the problem of low-grade fever] Semenenia IN, et al. **Fiziol Cheloveka** 1995 Nov-Dec;21(6):127–36 (30 ref.) **(Rus)**

BODY TYPES see **SOMATOTYPES**

BODY WATER

[Water and chloride channels and urine concentrating system] Marumo F. **Nippon Naika Gakkai Zasshi** 1995 Dec 10; 84(12):2080–4 (12 ref.) **(Jpn)**
[Total body water by D2O dilution] Koda M, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:170–3 (10 ref.) **(Jpn)**

CHEMISTRY

Instrumental evaluation of cutaneous hydration. Berardesca E, et al. **Clin Dermatol** 1995 Jul-Aug;13(4):323–7 (43 ref.)

DRUG EFFECTS

Hydropharmacology. Dikstein S. **Cell Biochem Funct** 1995 Sep;13(3):195–200 (53 ref.)

METABOLISM

Cellular water content and volume regulation in animal cells. Katz U. **Cell Biochem Funct** 1995 Sep;13(3):189–93 (23 ref.)
Mitochondrial water loss and aging of cells. von Zglinicki T, et al. **Cell Biochem Funct** 1995 Sep;13(3):181–7 (48 ref.)
Aquaporin water channels: unanswered questions and unresolved controversies. Agre P, et al. **Curr Opin Cell Biol** 1995 Aug;7(4):472–83 (84 ref.)
Mathematical description of transport of water and macromolecules through the glomerular capillary wall. Remuzzi A. **Curr Opin Nephrol Hypertens** 1995 Jul; 4(4):343–8 (23 ref.)
Cellular distribution of the aquaporins: a family of water channel proteins. Brown D, et al. **Histochem Cell Biol** 1995 Jul;104(1):1–9 (61 ref.)
Water channels in the peritoneum [editorial] Ho-dac-Pannekeet MM, et al. **Perit Dial Int** 1996 May-Jun;16(3):255–9 (62 ref.)
[Water homeostasis in amphibia: vasotocin and hydrins] Acher R. **C R Seances Soc Biol Fil** 1995;189(2):199–214 (59 ref.) (Eng. Abstr.) **(Fre)**
[Aggrephores and aquaporins] Verbavatz JM. **C R Seances Soc Biol Fil** 1995;189(2):191–7 (34 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Effect of hypoxaemia on water and sodium homeostatic hormones and renal function. Olsen NV. **Acta Anaesthesiol Scand Suppl** 1995;107:165–70 (55 ref.)
Lipid films in water conservation of biological systems. Tiffany JM. **Cell Biochem Funct** 1995 Sep;13(3):177–80 (29 ref.)
Salt, starch, and water on the brain. Schell RM, et al. **J Neurosurg Anesthesiol** 1996 Apr;8(2):178–82 (56 ref.)

BODY WEIGHT

see related
OBESITY
THINNESS

BODY WEIGHT

American Health Foundation Roundtable on Healthy Weight. Proceedings of an expert panel discussion. New York, New York, September 20, 1994. **Am J Clin Nutr** 1996 Mar;63(3 Suppl):409S–477S (0 ref.)

Healthy body weights: an alternative perspective. Abernathy RP, et al. **Am J Clin Nutr** 1996 Mar;63(3 Suppl):448S–451S (50 ref.)

Policy and healthy weight. Dwyer J. **Am J Clin Nutr** 1996 Mar;63(3 Suppl):415S–418S (27 ref.)

Weight and osteoarthritis. Felson DT. **Am J Clin Nutr** 1996 Mar;63(3 Suppl):430S–432S (10 ref.)

Fractionating healthy weight. Garn SM. **Am J Clin Nutr** 1996 Mar;63(3 Suppl):412S–414S (13 ref.)

Does weight cycling present a health risk? Jeffery RW. **Am J Clin Nutr** 1996 Mar;63(3 Suppl):452S–455S (16 ref.)

Effect of weight on cardiovascular disease. Kannel WB, et al. **Am J Clin Nutr** 1996 Mar;63(3 Suppl):419S–422S (20 ref.)

Body weight and blood pressure regulation. McCarron DA, et al. **Am J Clin Nutr** 1996 Mar;63(3 Suppl):423S–425S (31 ref.)

Summary and recommendations from the American Health Foundation's Expert Panel on Healthy Weight. Meisler JG, et al. **Am J Clin Nutr** 1996 Mar;63(3 Suppl):474S–477S (13 ref.)

Weight and non-insulin-dependent diabetes mellitus. Pi-Sunyer FX. **Am J Clin Nutr** 1996 Mar;63(3 Suppl):426S–429S (53 ref.)

Overweight and health: communications challenges and opportunities. Rippe JM. **Am J Clin Nutr** 1996 Mar;63(3 Suppl):470S–473S (32 ref.)

Body weight and colon cancer. Shike M. **Am J Clin Nutr** 1996 Mar;63(3 Suppl):442S–444S (30 ref.)

Putting body weight and osteoporosis into perspective. Wardlaw GM. **Am J Clin Nutr** 1996 Mar;63(3 Suppl):433S–436S (43 ref.)

Increasing physical activity: alterations in body mass and composition. Wilmore JH. **Am J Clin Nutr** 1996 Mar;63(3 Suppl):456S–460S (27 ref.)

Are you up to date on weight-based heparin dosing? Sparks KS. **Am J Nurs** 1996 Apr;96(4):33–6; quiz 37 (6 ref.)

The nature of the ponderostat: Hervey's hypothesis revived. Cabanac M, et al. **Appetite** 1996 Feb;26(1):45–54 (77 ref.)

Manaing HIV. Part 5: Treating secondary outcomes. 5.17 HIV, weight loss and wasting syndrome. Kelly MD, et al. **Med J Aust** 1996 May 6;164(9):549–50 (9 ref.)

Trends in body weight and overweight in the U.S. population. Flegal KM. **Nutr Rev** 1996 Apr;54(4 Pt 2):S97–100 (13 ref.)

[Problems involving "target weight" in treatment of anorexia nervosa] Hebebrand J, et al. **Z Kinder Jugenpsychiatr** 1996 Jun;24(2):92–104 (60 ref.) **(Ger)**

[Indices of obesity derived from body weight and height] Kataoka K. **Nippon Rinsho** 1995 Jun;53 Suppl:147–53 (30 ref.) **(Jpn)**

[Guidelines for body weight in adults] Kataoka K. **Nippon Rinsho** 1995 Jun;53 Suppl:141–6 (19 ref.) **(Jpn)**

[Densitometry (hydrostatic weighing) for measurement of human body fat mass] Koda M, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:165–9 (11 ref.) **(Jpn)**

[Significance of somatometric analysis in medical research] Gubina-Vakulik GI. **Arkh Patol** 1995 Nov-Dec;57(6):77–9 (68 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

McCollum Award Lecture, 1995: diet, lifestyle, and weight maintenance. Flatt JP. **Am J Clin Nutr** 1995 Oct; 62(4):820–36 (91 ref.)

Body composition, respiratory quotient, and weight maintenance. Flatt JP. **Am J Clin Nutr** 1995 Nov;62(5 Suppl):1107S–1117S (72 ref.)

Upper limits to mass-specific metabolic rates. Suarez RK. **Annu Rev Physiol** 1996;58:583–605 (146 ref.)

Physical activity, body weight, and adiposity: an epidemiologic perspective. DiPietro L. **Exerc Sport Sci Rev** 1995;23:275–303 (146 ref.)

Endocrine regulation of food intake and body weight. Figlewicz DP, et al. **J Lab Clin Med** 1996 Apr; 127(4):328–32 (43 ref.)

Prevention of obesity in middle-aged monkeys: food intake during body weight clamp. Hansen BC, et al. **Obes Res** 1995 Sep;3 Suppl 2:199s–204s (26 ref.)

Pregnancy as a risk factor for obesity: lessons from the Stockholm Pregnancy and Weight Development Study. Rössner S, et al. **Obes Res** 1995 Sep;3 Suppl 2:267s–275s (22 ref.)

[Effect of gut peptides on feeding and body weight regulation] Inui A, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:40–8 (15 ref.) **(Jpn)**

[Effect of brain peptides on feeding and body weight regulation] Inui A, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:49–57 (20 ref.) **(Jpn)**

BOECK'S SARCOID see **SARCOIDOSIS**

BOMBESIN

see related
RECEPTORS, BOMBESIN

PHYSIOLOGY

Roles of bombesin-like peptides in lung development and lung injury [comment] Spindel ER. **Am J Respir Cell Mol Biol** 1996 May;14(5):407–8 (18 ref.)
Comment on: Am J Respir Cell Mol Biol 1996 May;14(5):409–16.

Bombesin receptors in the brain. Woodruff GN, et al. **Ann N Y Acad Sci** 1996 Mar 22;780:223–43 (74 ref.)

BOMBESIN RECEPTORS see **RECEPTORS, BOMBESIN**

BOMBINA see **ANURA**

BOMBYX see **SILKWORMS**

BONDING (PSYCHOLOGY) see **OBJECT ATTACHMENT**

BONDING, DENTAL see **DENTAL BONDING**

BONDING, HUMAN-PET

Health enhancement and companion animal ownership. Beck AM, et al. **Annu Rev Public Health** 1996;17:247–57 (60 ref.)

Cats and their people: a (nearly) perfect relationship. Zasloff RL. **J Am Vet Med Assoc** 1996 Feb 15;208(4):512–6 (29 ref.)

BONDS, EMOTIONAL see **OBJECT ATTACHMENT**

BONE AND BONES

see related
ARTHRODESIS
CALCIFICATION, PHYSIOLOGIC
OSTEOGENESIS
OSTEOTOMY

ABNORMALITIES

Distinct skeletal abnormalities in four girls with Shprintzen-Goldberg syndrome. Adès LC, et al. **Am J Med Genet** 1995 Jul 17;57(4):565–72 (13 ref.)

Hunter-McAlpine craniosynostosis phenotype associated with skeletal anomalies and interstitial deletion of chromosome 17q. Thomas JA, et al. **Am J Med Genet** 1996 Apr 24;62(4):372–5 (8 ref.)

The role of BMPs and GDFs in development of region-specific skeletal structures. King JA, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:70–9 (56 ref.)

Campomelic dysplasia with XY sex reversal: diverse phenotypes resulting from mutations in a single gene. Schafer AJ, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:137–49 (46 ref.)

Filippi syndrome: a new case with skeletal abnormalities. Héron D, et al. **J Med Genet** 1995 Aug;32(8):659–61 (6 ref.)

ANATOMY & HISTOLOGY

Basic anatomical and physiological data for use in radiological protection: the skeleton. A report of a Task Group of Committee 2 of the International Commission on Radiological Protection. **Ann ICRP** 1995;25(2):1–80 (223 ref.)

Biomechanical stability of the skeleton--it is not only bone mass, but also bone structure that counts. Delling G, et al. **Nephrol Dial Transplant** 1995;10(5):601–6 (48 ref.)

CYTOLOGY

Characteristics and regulation of Pi transport in osteogenic cells for bone metabolism. Caverzasio J, et al. **Kidney Int** 1996 Apr;49(4):975–80 (24 ref.)

[Histological and morphometric studies of femurs with stable hip joint replacement. An autopsy study with special reference to factors leading to late loosening] Bos J, et al. **Z Orthop Ihre Grenzgeb** 1995 Sep-Oct;133(5):460–6 (46 ref.) (Eng. Abstr.) **(Ger)**

DRUG EFFECTS

Tetracyclines and calcified tissues. van der Bijl P, et al. **Ann Dent** 1995 Summer-Fall;54(1-2):69–72 (46 ref.)

Tissue-selective actions of estrogen analogs. Evans GL, et al. **Bone** 1995 Oct;17(4 Suppl):181S–190S (61 ref.)

Fluoride and the skeleton. Kleerekoper M. **Crit Rev Clin Lab Sci** 1996 Apr;33(2):139–61 (81 ref.)

Systemic aluminum toxicity: effects on bone, hematopoietic tissue, and kidney. Jeffery EH, et al. **J Toxicol Environ Health** 1996 Aug 30;48(6):649–65 (80 ref.)

Bone: target and source of environmental pollutant exposure. McGowan JA. **Otolaryngol Head Neck Surg** 1996 Feb; 114(2):220–3 (14 ref.)

[Anti-estrogens and bone tissue] Ribot C, et al. **Ann Endocrinol (Paris)** 1995;56(6):603–8 (40 ref.) (Eng. Abstr.) **(Fre)**

EMBRYOLOGY

Pax genes and skeletal development. Balling R, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:27–33 (29 ref.)

Function of homeobox genes in skeletal development. Capecchi MR. **Ann N Y Acad Sci** 1996 Jun 8;785:34–7 (11 ref.)

The role of BMPs and GDFs in development of region-specific skeletal structures. King JA, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:70–9 (56 ref.)

A new subclass of helix-loop-helix transcription factors expressed in paraxial mesoderm and chondrogenic cell lineages. Olson EN, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:108–18 (30 ref.)

Signaling pathways in skeletal formation: a role for BMP receptors. Rosen V, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:59–69 (45 ref.)

[Function of Hox genes in formation of skeletons] Suemori H. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2144–51 (31 ref.) **(Jpn)**

ENZYMOLOGY

The tartrate-resistant purple acid phosphatase of bone osteoclasts--a protein phosphatase with multivalent substrate specificity and regulation. Andersson G, et al. **Acta Orthop Scand Suppl** 1995 Oct;266:189–94 (28 ref.)

INJURIES

Genetic influences on bone turnover, bone density and fracture. Kelly PJ, et al. **Eur J Endocrinol** 1995 Sep; 133(3):265–71 (42 ref.)

Recombinant bone morphogenetic proteins: novel substances for enhancing bone healing. Kirker-Head CA. **Vet Surg** 1995 Sep-Oct;24(5):408–19 (80 ref.)

[The characteristics of bone injuries in childhood] Kuznetsov LE, et al. **Sud Med Ekspert** 1996 Apr-Jun;39(2):7–9 (36 ref.) (Eng. Abstr.) **(Rus)**

METABOLISM

Genetic regulation of peak bone mass. Kelly PJ, et al. **Acta Paediatr Suppl** 1995 Sep;411:24–9; discussion 30 (38 ref.)

Role of vitamin K in bone metabolism. Vermeer C, et al. **Annu Rev Nutr** 1995;15:1–22 (102 ref.)

The role of bone turnover in the pathophysiology of osteoporosis. Riis BJ. **Br J Obstet Gynaecol** 1996 May;103 Suppl 13:9–14; discussion 14–5 (18 ref.)

Oestrogens and calcium regulatory hormones: potential implications for bone. Naveh-Many T, et al. **Curr Opin Nephrol Hypertens** 1995 Jul;4(4):319–23 (50 ref.)

Noninvasive parameters of bone metabolism. Schmidt-Gayk H, et al. **Curr Opin Nephrol Hypertens** 1995 Jul;4(4):334–8 (19 ref.)

Growth, physical activity, and bone mineral acquisition. Bailey DA, et al. **Exerc Sport Sci Rev** 1996;24:233–66 (146 ref.)

beta-Alanyl-L-histidinato zinc and bone resorption. Yamaguchi M. **Gen Pharmacol** 1995 Oct;26(6):1179–83 (27 ref.)

Effects of growth hormone on phosphocalcium homeostasis and bone metabolism. Saggese G, et al. **Horm Res** 1995; 44 Suppl 3:55–63 (86 ref.)

The skeleton as an ion exchange system: implications for the role of acid-base imbalance in the genesis of osteoporosis. Barzel US. **J Bone Miner Res** 1995 Oct;10(10):1431–6 (31 ref.)

Changing phosphorus content of the U.S. diet: potential for adverse effects on bone. Calvo MS, et al. **J Nutr** 1996 Apr; 126(4 Suppl):1168S–80S (72 ref.)

Transport of vitamin K to bone in humans. Kohlmeier M, et al. **J Nutr** 1996 Apr;126(4 Suppl):1192S–6S (28 ref.)

Effects of vitamin K on bone mass and bone metabolism. Vermeer C, et al. **J Nutr** 1996 Apr;126(4 Suppl):1187S–91S (42 ref.)

Characteristics and regulation of Pi transport in osteogenic cells for bone metabolism. Caverzasio J, et al. **Kidney Int** 1996 Apr;49(4):975–80 (24 ref.)

New insights into the pathogenesis of idiopathic hypercalciuria: the role of bone. Weisinger JR. **Kidney Int** 1996 May;49(5):1507–18 (100 ref.)

Bone metabolism and osteopenia in eating disorders. Carmichael KA, et al. **Medicine (Baltimore)** 1995 Sep; 74(5):254–67 (132 ref.)

Osteopontin at mineralized tissue interfaces in bone, teeth, and osseointegrated implants: ultrastructural distribution and implications for mineralized tissue formation, turnover, and repair. McKee MD, et al. **Microsc Res Tech** 1996 Feb 1;33(2):141–64 (112 ref.)

Bone mineral metabolism in children with juvenile rheumatoid arthritis. Cassidy JT, et al. **Pediatr Clin North Am** 1995 Oct;42(5):1017–33 (117 ref.)

[Growth hormone and bone metabolism] Manten JW, et al. **Ned Tijdschr Geneeskd** 1996 May 18;140(20):1064–8 (37 ref.) **(Dut)**

[Fundamental aspects of osteoinductive activity of bone tissue and potential clinical application] Aldinger G, et al. **Z Orthop Ihre Grenzgeb** 1996 May-Jun;134(3):205–9 (22 ref.) (Eng. Abstr.) **(Ger)**

[Pyridinium cross-links: sensitive markers of bone catabolism] Sela BA. **Harefuah** 1995 Oct;129(7-8):264–8 (30 ref.) **(Heb)**

[Effects of essential trace elements on bone turnover--in relation to the osteoporosis] Okano T. **Nippon Rinsho** 1996 Jan;54(1):148–54 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Regulation of cancellous bone structure by bone remodeling] Nakamura T. **Nippon Seikeigeka Gakkai Zasshi** 1995 Jul; 69(7):528–34 (25 ref.) **(Jpn)**

[Calcium metabolism in bone] Lorenc RS. **Pol Tyg Lek** 1995

Nov;50(44–47):48–52 (28 ref.) **(Pol)**

PATHOLOGY

Relationship of age-related decreases in muscle mass and strength to skeletal status. Marcus R. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:86–7 (12 ref.)

Malignant bone tumors of childhood. Himelstein BP, et al. **Pediatr Clin North Am** 1996 Aug;43(4):967–84 (38 ref.)

Spinal cord and bone metastasizing renal tumor of childhood. Arrotegui JI, et al. **Rev Neurol** 1995 Nov–Dec; 23(124):1231–2 (15 ref.)

The mechanisms of bone lesions in human plasmacytomas. Bataille R. **Stem Cells (Dayt)** 1995 Aug;13 Suppl 2:40–7 (67 ref.)

[MR tomography (MRT) of the skeleton, peripheral soft tissues and joints—current overview] Bohndorf K, et al. **Aktuelle Radiol** 1996 May;6(3):136–43 (47 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

In vitro modeling of the bone/implant interface. Davies JE. **Anat Rec** 1996 Jun;245(2):426–45 (94 ref.)

Basic anatomical and physiological data for use in radiological protection: the skeleton. A report of a Task Group of Committee 2 of the International Commission on Radiological Protection. **Ann ICRP** 1995;25(2):1–80 (223 ref.)

Endogenous and nutritional factors affecting bone. Marcus R. **Bone** 1996 Jan;18(1 Suppl):11S–13S (21 ref.)

Dose-response relationship between physical loading and mechanical competence of bone. Smith EL, et al. **Bone** 1996 Jan;18(1 Suppl):455–505 (66 ref.)

The oestrogen receptor in bone–evolution of our knowledge. Lindsay R. **Br J Obstet Gynaecol** 1996 May;103 Suppl 13:16–8; discussion 18–9 (27 ref.)

Mechanotransduction and the functional response of bone to mechanical strain. Duncan RL, et al. **Calcif Tissue Int** 1995 Nov;57(5):344–58 (225 ref.)

Bone biology. I: Structure, blood supply, cells, matrix, and mineralization. Buckwalter JA, et al. **Instr Course Lect** 1996;45:371–86 (125 ref.)

Bone biology. II: Formation, form, modeling, remodeling, and regulation of cell function. Buckwalter JA, et al. **Instr Course Lect** 1996;45:387–99 (222 ref.)

Chemistry, nutritional sources, tissue distribution and metabolism of vitamin K with special reference to bone health. Shearer MJ, et al. **J Nutr** 1996 Apr;126(4 Suppl):1181S–6S (25 ref.)

New trends in bone research. Hewison M. **J R Coll Physicians Lond** 1995 Sep–Oct;29(5):383–7 (47 ref.)

Fos and bone cell development: lessons from a nuclear oncogene. Grigoriadis AE, et al. **Trends Genet** 1995 Nov; 11(11):436–41 (57 ref.)

Fracture biology, biomechanics, and internal fixation. Trostle SS, et al. **Vet Clin North Am Food Anim Pract** 1996 Mar; 12(1):19–46 (52 ref.)

[Physical exercise and the skeleton] Barlet JP, et al. **Arch Physiol Biochem** 1995 Dec;103(6):681–98 (214 ref.) (Eng. Abstr.) **(Fre)**

[Parathyroid hormone related peptide (PTHrP) and bone metabolism] Rouffet J, et al. **Arch Physiol Biochem** 1995 Apr;103(1):3–13 (76 ref.) (Eng. Abstr.) **(Fre)**

[Bone structure and mechanical resistance of the bone tissue] Benhamou CL, et al. **Presse Med** 1996 Feb 17;25(6):249–54 (43 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Bone changes in metabolic bone disease. Eriksen EF, et al. **Acta Orthop Scand Suppl** 1995 Oct;266:195–201 (36 ref.)

RADIATION EFFECTS

Radiotherapy for bone pain [editorial] Hoskin PJ. **Pain** 1995 Nov;63(2):137–9 (12 ref.)

RADIOGRAPHY

Multicentric reticulohistiocytosis. A report of 3 cases and review of literature. Uhl M, et al. **Bildgebung** 1996 Jun; 63(2):126–9 (13 ref.)

Perspectives of pQCT technology associated to biomechanical studies in skeletal research employing rat models. Ferretti JL. **Bone** 1995 Oct;17(4 Suppl):353S–364S (48 ref.)

Quantitative computed tomography (QCT) of the lumbar spine and appendicular skeleton. Glüer CC, et al. **Eur J Radiol** 1995 Sep;20(3):173–8 (55 ref.)

Skeletal lesions in early congenital syphilis (a review of 86 cases). Ghadouane M, et al. **Rev Rhum Engl Ed** 1995 Jun; 62(6):433–7 (10 ref.)

Skeletal 3-D CT: advantages of volume rendering over surface rendering. Kuszyk BS, et al. **Skeletal Radiol** 1996 Apr;25(3):207–14 (16 ref.)

RADIONUCLIDE IMAGING

[Psoriatic osteoarthropathy and bone scintigraphy] Holzmann H, et al. **Hautarzt** 1996 Jun;47(6):427–31 (19 ref.) (Eng. Abstr.) **(Ger)**

ULTRASONOGRAPHY

Ultrasound measurement of bone. van Daele PL, et al. **Clin Endocrinol (Oxf)** 1996 Apr;44(4):363–9 (52 ref.)

On measuring bone to predict osteoporotic fracture: moving beyond statistical inference [editorial; comment] Beck TJ. **Radiology** 1996 Jun;199(3):612–4 (25 ref.) Comment on: Radiology 1996 Jun;199(3):725–32.

ULTRASTRUCTURE

Using functional loading to influence bone mass and architecture: objectives, mechanisms, and relationship with estrogen of the mechanically adaptive process in bone. Lanyon LE. **Bone** 1996 Jan;18(1 Suppl):37S–43S (74 ref.)

Ultrastructural organic–inorganic relationships in calcified tissues: cartilage and bone vs. enamel. Bonucci E. **Connect Tissue Res** 1995;33(1–3):157–62 (67 ref.)

Structural relationship between the primary crystal formations and the matrix macromolecules in different hard tissues. Discussion of a general principle. Höhling HJ, et al. **Connect Tissue Res** 1995;33(1–3):171–8 (59 ref.)

Scanning electron microscopy of bone: instrument, specimen, and issues. Boyde A, et al. **Microsc Res Tech** 1996 Feb 1;33(2):92–120 (131 ref.)

Bone surface morphology reflects local skeletal metabolism. Marks SC Jr, et al. **Microsc Res Tech** 1996 Feb 1; 33(2):121–7 (23 ref.)

VIROLOGY

Primary adult T cell leukemia of bone: two patients with primary bone lesion showing monoclonal integration of HTLV-I proviral DNA. Takemoto S, et al. **Leukemia** 1996 Feb;10(2):333–7 (24 ref.)

BONE CEMENTS

THERAPEUTIC USE

Bone cement as a seal protecting the femur from the ingress of particulate debris and femoral osteolysis. Harris WH, et al. **Instr Course Lect** 1996;45:183–5 (23 ref.)

BONE CYSTS

Unicameral bone cyst of the patella. A case report. Saglik Y, et al. **Int Orthop** 1995;19(5):280–1 (15 ref.)

Unicameral and aneurysmal bone cysts. Capanna R, et al. **Orthop Clin North Am** 1996 Jul;27(3):605–14 (49 ref.)

RADIOGRAPHY

Traumatic bone cysts in the jaws of a Hong Kong Chinese population. MacDonald-Jankowski DS. **Clin Radiol** 1995 Nov;50(11):787–91 (29 ref.)

[The labrum acetabulare] Bellaïche L, et al. **Ann Radiol (Paris)** 1995;38(5):280–3 (16 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

[Cystic bone changes. Etiology, diagnosis, therapeutic principles and personal results of treatment] Maurer F, et al. **Langenbecks Arch Chir** 1996;381(3):165–74 (33 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

[Essential bone cysts in children. Value of systematic cystography. Apropos of a series of 42 cysts] Journeau P, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1995; 81(3):248–56 (26 ref.) (Eng. Abstr.) **(Fre)**

BONE CYSTS, ANEURYSMAL

PATHOLOGY

[Aneurysmal bone cyst of the mandible. Apropos of a case and review of the literature] Kadiri F, et al. **Rev Stomatol Chir Maxillofac** 1995;96(6):356–9 (40 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

[Metacarpal aneurysmal cysts. Report of two cases and review of the literature] Duteille F, et al. **Ann Chir Main Memb Super** 1995;14(4–5):229–34 (35 ref.) (Eng. Abstr.) **(Fre)**

[Cystic bone changes. Etiology, diagnosis, therapeutic principles and personal results of treatment] Maurer F, et al. **Langenbecks Arch Chir** 1996;381(3):165–74 (33 ref.) (Eng. Abstr.) **(Ger)**

BONE DEMINERALIZATION, PATHOLOGIC

see related
OSTEOPOROSIS

BONE DENSITY

see related
ABSORPTIOMETRY, PHOTON

Bone absorptiometry: a critical appraisal of various methods. Slosman DO, et al. **Acta Paediatr Suppl** 1995 Sep;411:9–11 (7 ref.)

The state of the art of non-invasive diagnostics for bone densitometry. Methods of photonic absorption. Baruffaldi F, et al. **Chir Organi Mov** 1995 Oct–Dec;80(4):427–48 (71 ref.) **(Eng, Ita)**

The role of vitamin D and calcium supplementation in the prevention of osteoporotic fractures in the elderly. Compston JE. **Clin Endocrinol (Oxf)** 1995 Oct; 43(4):393–405 (146 ref.)

Water fluoridation, bone density and hip fractures: a review of recent literature. Raheb J. **Community Dent Oral Epidemiol** 1995 Oct;23(5):309–16 (49 ref.)

Quantitative ultrasound. Fuerst T, et al. **Eur J Radiol** 1995 Sep;20(3):188–92 (46 ref.)

Quantitative computed tomography (QCT) of the lumbar spine and appendicular skeleton. Glüer CC, et al. **Eur J Radiol** 1995 Sep;20(3):173–8 (55 ref.)

Factors associated with menstrual irregularities and decreased bone mineral density in female athletes. Fruth SJ, et al. **J Orthop Sports Phys Ther** 1995 Jul;22(1):26–38 (54 ref.)

A review of residual ridge resorption and bone density. Klemetti E. **J Prosthet Dent** 1996 May;75(5):512–4 (32 ref.)

Bone mass, nutrition, and other lifestyle factors. Heaney RP. **Nutr Rev** 1996 Apr;54(4 Pt 2):S3–10 (56 ref.)

Peak bone mass and physical activity: a short review. Vuori I. **Nutr Rev** 1996 Apr;54(4 Pt 2):S11–4 (54 ref.)

[Comparative histomorphometry of subchondral bone density and articular cartilage thickness in the tibial head in early human arthritis] Böhringer ME, et al. **Z Orthop Ihre Grenzgeb** 1995 Jul–Aug;133(4):291–302 (61 ref.) (Eng. Abstr.) **(Ger)**

[Bone densitometry] Yamamoto I, et al. **Rinsho Byori** 1996 May;44(5):423–7 (12 ref.) (Eng. Abstr.) **(Jpn)**

DRUG EFFECTS

Tiludronate: bone pharmacology and safety. Bonjour JP, et al. **Bone** 1995 Nov;17(5 Suppl):473S–477S (39 ref.)

Osteoporosis: diagnosis and management today and tomorrow. Christiansen C. **Bone** 1995 Nov;17(5 Suppl):513S–516S (17 ref.)

Maintenance therapy for added bone mass or how to keep the profit after withdrawal of therapy of osteopenia. Jee WS, et al. **Bone** 1995 Oct;17(4 Suppl):309S–319S (49 ref.)

Prevention of hip fractures: drug therapy. Lips P. **Bone** 1996 Mar;18(3 Suppl):159S–163S (46 ref.)

Efficacy and safety of drugs for Paget's disease of bone. Reginster JY, et al. **Bone** 1995 Nov;17(5 Suppl):485S–488S (49 ref.)

Present and future of osteoporosis therapy. Seeman E, et al. **Bone** 1995 Aug;17(2 Suppl):23S–29S (47 ref.)

Comparative clinical pharmacology and therapeutic use of bisphosphonates in metabolic bone diseases. Rosen CJ, et al. **Drugs** 1996 Apr;51(4):537–51 (80 ref.)

The impact of bone loss in women with endometriosis. Stevenson JC. **Int J Gynaecol Obstet** 1995 Sep;50 Suppl 1:S11–5 (26 ref.)

Anabolic effects of insulin on bone suggest a role for chromium picolinate in preservation of bone density. McCarty MF. **Med Hypotheses** 1995 Sep;45(3):241–6 (69 ref.)

Do dairy products improve bone density in adolescent girls? Kerstetter JE. **Nutr Rev** 1995 Nov;53(11):328–32 (26 ref.)

GENETICS

Genetic regulation of peak bone mass. Kelly PJ, et al. **Acta Paediatr Suppl** 1995 Sep;411:24–9; discussion 30 (38 ref.)

Genetic influences on bone turnover, bone density and fracture. Kelly PJ, et al. **Eur J Endocrinol** 1995 Sep; 133(3):265–71 (42 ref.)

Vitamin D receptor gene alleles and osteoporosis: an affirmative view [editorial] Eisman JA. **J Bone Miner Res** 1995 Sep;10(9):1289–93 (43 ref.)

PHYSIOLOGY

Late consequences of a low peak bone mass. Ribot C, et al. **Acta Paediatr Suppl** 1995 Sep;411:31–5; discussion 36 (39 ref.)

Nutritional aspects of hip fractures. Bonjour JP, et al. **Bone** 1996 Mar;18(3 Suppl):139S–144S (87 ref.)

Osteoporosis: diagnosis and management today and tomorrow. Christiansen C. **Bone** 1995 Nov;17(5 Suppl):513S–516S (17 ref.)

Treatable and untreatable risk factors for hip fracture. Cummings SR. **Bone** 1996 Mar;18(3 Suppl):165S–167S (20 ref.)

The clinical impact of vertebral fractures: quality of life in women with osteoporosis. Gold DT. **Bone** 1996 Mar;18(3 Suppl):185S–189S (29 ref.)

Pathogenesis of osteoporosis. Johnston CC Jr, et al. **Bone** 1995 Aug;17(2 Suppl):19S–22S (30 ref.)

Evaluation of the risk of hip fracture. Kanis JA, et al. **Bone** 1996 Mar;18(3 Suppl):127S–132S (36 ref.)

Using functional loading to influence bone mass and architecture: objectives, mechanisms, and relationship with estrogen of the mechanically adaptive process in bone. Lanyon LE. **Bone** 1996 Jan;18(1 Suppl):37S–43S (74 ref.)

Are the etiologies of cervical and trochanteric hip fractures different? Mautalen CA, et al. **Bone** 1996 Mar;18(3

BONE DENSITY

Suppl):133S–137S (39 ref.)
Drug therapy for vertebral fractures in osteoporosis: evidence that decreases in bone turnover and increases in bone mass both determine antifracture efficacy. Riggs BL, et al. **Bone** 1996 Mar;18(3 Suppl):197S–201S (26 ref.)
The worldwide problem of osteoporosis: insights afforded by epidemiology. Riggs BL, et al. **Bone** 1995 Nov;17(5 Suppl):505S–511S (47 ref.)
Exercise and bone mass in young and premenopausal women. Snow CM. **Bone** 1996 Jan;18(1 Suppl):51S–55S (30 ref.)
Vertebral fracture epidemiology. Wasnich RD. **Bone** 1996 Mar;18(3 Suppl):179S–183S (24 ref.)
Bone mass measurement and bone metabolism in rheumatoid arthritis: a review. Deodhar AA, et al. **Br J Rheumatol** 1996 Apr;35(4):309–22 (88 ref.)
Mechanotransduction and the functional response of bone to mechanical strain. Duncan RL, et al. **Calcif Tissue Int** 1995 Nov;57(5):344–58 (225 ref.)
Bone densitometry: patients with end-stage renal disease. Erlichman M, et al. **Health Technol Assess** 1996 Mar; (8):1–27 (174 ref.)
Role of growth hormone and sex steroids in achieving and maintaining normal bone mass. Holmes SJ, et al. **Horm Res** 1996;45(1–2):86–93 (96 ref.)
Diagnostic value of ultrasound analysis and bone densitometry as predictors of vertebral deformity in postmenopausal women. Gonnelli S, et al. **Osteoporos Int** 1995;5(6):413–8 (40 ref.)
[Bone disorders in intestinal cryptogenetic inflammatory diseases] Abitbol V, et al. **Gastroenterol Clin Biol** 1995 Oct; 19(10):826–32 (54 ref.) **(Fre)**
[Bone structure and mechanical resistance of the bone tissue] Benhamou CL, et al. **Presse Med** 1996 Feb 17;25(6):249–54 (43 ref.) (Eng. Abstr.) **(Fre)**

BONE-DERIVED TRANSFORMING GROWTH FACTOR
see **TRANSFORMING GROWTH FACTOR BETA**

BONE DEVELOPMENT

Some aspects of bone formation and remodeling pertinent to craniofacial development and reconstructive treatment. Vargervik K. **Acta Odontol Scand** 1995 Jun;53(3):167–73 (16 ref.)
Role of cartilage collagens in formation of the skeleton. Olsen BR. **Ann N Y Acad Sci** 1996 Jun 8;785:124–30 (30 ref.)
Calcium, phosphorus and human bone development. Anderson JJ. **J Nutr** 1996 Apr;126(4 Suppl):1153S–8S (32 ref.)
Vitamin D and bone health. Holick MF. **J Nutr** 1996 Apr; 126(4 Suppl):1159S–64S (33 ref.)
Non-invasive circulating indicators of bone metabolism in uraemic patients: can they replace bone biopsy? [editorial] Schmidt-Gayk H, et al. **Nephrol Dial Transplant** 1996 Mar; 11(3):415–8 (8 ref.)

DRUG EFFECTS

Basic fibroblast growth factor for stimulation of bone formation in osteoinductive or conductive implants. Wang JS. **Acta Orthop Scand Suppl** 1996 Apr;269:1–33 (204 ref.)
Tiludronate: bone pharmacology and safety. Bonjour JP, et al. **Bone** 1995 Nov;17(5 Suppl):473S–477S (39 ref.)
Animal models of cortical porosity. Sietsema WK. **Bone** 1995 Oct;17(4 Suppl):297S–305S (19 ref.)
Growth hormone and calcitriol as modifiers of bone formation in renal osteodystrophy. Salusky IB, et al. **Kidney Int** 1995 Sep;48(3):657–65 (107 ref.)

PHYSIOLOGY

Cartilage-derived morphogenetic proteins. Key regulators in chondrocyte differentiation? Luyten FP. **Acta Orthop Scand Suppl** 1995 Oct;266:51–4 (22 ref.)
Postablation bone marrow regeneration: an in vivo model to study differential regulation of bone formation and resorption. Bab IA. **Bone** 1995 Oct;17(4 Suppl):437S–441S (20 ref.)
Mechanical factors in bone growth and development. Carter DR, et al. **Bone** 1996 Jan;18(1 Suppl):5S–10S (46 ref.)
The effects of cytokines and growth factors on osteoblastic cells. Mundy GR, et al. **Bone** 1995 Aug;17(2 Suppl):71S–75S (41 ref.)
The heterogeneity of the osteopetroses reflects the diversity of cellular influences during skeletal development. Popoff SN, et al. **Bone** 1995 Nov;17(5):437–45 (131 ref.)
Discovery and clinical applications of bone morphogenetic proteins. Vukičević S, et al. **Eur J Clin Chem Clin Biochem** 1995 Oct;33(10):661–71 (81 ref.)
Some aspects of the anabolic action of parathyroid hormone. Martin TJ, et al. **Miner Electrolyte Metab** 1995; 21(1–3):87–90 (25 ref.)
Biomechanical stability of the skeleton—it is not only bone mass, but also bone structure that counts. Delling G, et al. **Nephrol Dial Transplant** 1995;10(5):601–6 (48 ref.)
Recent developments in the chemotherapy of osteoporosis. Dwivedy I, et al. **Prog Drug Res** 1995;45:289–338 (326 ref.)
[Bone disorders in intestinal cryptogenetic inflammatory diseases] Abitbol V, et al. **Gastroenterol Clin Biol** 1995 Oct; 19(10):826–32 (54 ref.) **(Fre)**
[Bone structure and mechanical resistance of the bone tissue] Benhamou CL, et al. **Presse Med** 1996 Feb 17;25(6):249–54 (43 ref.) (Eng. Abstr.) **(Fre)**
[Sports, bones and hormones. Multiple interactions (editorial)] Maugars Y, et al. **Presse Med** 1995 Sep 30; 24(28):1284–6 (15 ref.) (Eng. Abstr.) **(Fre)**

BONE DISEASES

CHEMICALLY INDUCED

[Osteo-articular complications of heart transplantation] Rozenberg S, et al. **Presse Med** 1995 Dec 9;24(38):1809–12 (26 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

1-alpha-Hydroxyvitamin D3 derivatives in the treatment of renal bone diseases: justification and optimal modalities of administration. Fournier A, et al. **Nephron** 1995; 71(3):254–83 (194 ref.)

DIAGNOSIS

Fibrogenesis imperfecta ossium. Carr AJ, et al. **J Bone Joint Surg Br** 1995 Sep;77(5):820–9 (22 ref.)
[Systemic mastocytosis: a case with diffuse bone involvement] Biarese V, et al. **Minerva Med** 1996 Jan-Feb;87(1–2):33–9 (16 ref.) (Eng. Abstr.) **(Ita)**
[On the diagnosis of so-called "constitutional" bone diseases] Nigro N, et al. **Minerva Pediatr** 1995 Jun;47(6):229–31 (15 ref.) (Eng. Abstr.) **(Ita)**

DRUG THERAPY

Local antibacterial therapy for the management of orthopaedic infections. Pharmacokinetic considerations. Henry SL, et al. **Clin Pharmacokinet** 1995 Jul;29(1):36–45 (88 ref.)
Bisphosphonates and the treatment of bone disease in the elderly. Johansen A, et al. **Drugs Aging** 1996 Feb; 8(2):113–26 (133 ref.)
Use of clodronate in multiple myeloma. Jantunen E, et al. **Leuk Lymphoma** 1995 Oct;19(3–4):207–11 (29 ref.)
1-alpha-Hydroxyvitamin D3 derivatives in the treatment of renal bone diseases: justification and optimal modalities of administration. Fournier A, et al. **Nephron** 1995; 71(3):254–83 (194 ref.)

EPIDEMIOLOGY

Osteochondrodysplasias in South Africa. Beighton P. **Am J Med Genet** 1996 May 3;63(1):7–11 (45 ref.)

ETIOLOGY

Endocrine disorders and orthopedic problems in children. Mann DC. **Curr Opin Pediatr** 1996 Feb;8(1):68–70 (12 ref.)
Bacterially induced bone destruction: mechanisms and misconceptions. Nair SP, et al. **Infect Immun** 1996 Jul; 64(7):2371–80 (137 ref.)
The haemophilic pseudotumour. Rodriguez Merchan EC. **Int Orthop** 1995;19(4):255–60 (11 ref.)
Clinical and molecular aspects of the pathogenesis of Staphylococcus aureus bone and joint infections. Cunningham R, et al. **J Med Microbiol** 1996 Mar; 44(3):157–64 (55 ref.)
Will bone disease still remain one of the most serious complications in dialysis patients? Drüeke TB. **Nephrol Dial Transplant** 1995;10 Suppl 7:16–9 (24 ref.)
Is there a link between erythropoietin therapy and adynamic bone disease? Smans KA, et al. **Nephrol Dial Transplant** 1996 Jul;11(7):1248–9 (13 ref.)
Orthopedic manifestations of acute pediatric leukemia. Gallagher DJ, et al. **Orthop Clin North Am** 1996 Jul; 27(3):635–44 (28 ref.)
Bone: target and source of environmental pollutant exposure. McGowan JA. **Otolaryngol Head Neck Surg** 1996 Feb; 114(2):220–3 (14 ref.)
[Extracutaneous manifestations of neutrophilic dermatosis] Rodot S, et al. **Ann Dermatol Venereol** 1996;123(2):129–34 (45 ref.) **(Fre)**
[Bone involvement in idiopathic calcium lithiasis] Ghazali A, et al. **Nephrologie** 1995;16(5):351–69 (129 ref.) (Eng. Abstr.) **(Fre)**
[Collagen genes and skeletal disorders] Kimura T, et al. **Ryumachi** 1995 Jun;35(3):600–8 (39 ref.) **(Jpn)**
[Bone involvement in chronic disseminated paracoccidioidomycosis. A report on the first cases in Rio Grande do Sul] Severo LC, et al. **Rev Soc Bras Med Trop** 1996 May-Jun;29(3):241–4 (12 ref.) (Eng. Abstr.) **(Por)**

GENETICS

Osteochondrodysplasias in South Africa. Beighton P. **Am J Med Genet** 1996 May 3;63(1):7–11 (45 ref.)
Fibroblast-growth-factor receptor mutations in human skeletal disorders. Muenke M, et al. **Trends Genet** 1995 Aug; 11(8):308–13 (50 ref.)

METABOLISM

Bone and mineral metabolism in childhood end-stage renal disease. Salusky IB. **Pediatr Clin North Am** 1995 Dec; 42(6):1531–50 (103 ref.)

PATHOLOGY

Langerhans' cell histiocytosis: case reports and literature review. Henry RJ, et al. **Pediatr Dent** 1996 Jan-Feb; 18(1):11–6 (45 ref.)

PHYSIOPATHOLOGY

Healing of experimentally created defects: a review. Aaboe M, et al. **Br J Oral Maxillofac Surg** 1995 Oct;33(5):312–8 (130 ref.)

RADIOGRAPHY

Skeletal 3-D CT: advantages of volume rendering over surface rendering. Kuszyk BS, et al. **Skeletal Radiol** 1996 Apr;25(3):207–14 (16 ref.)
[Sickle cell anemia: how to interpret a radiological bone lesion] Tomasini P, et al. **Med Trop (Mars)** 1995; 55(3):216–20 (8 ref.) **(Fre)**
[The reliability of apical x-ray pictures in the diagnosis of mandibular bone lesions. A review of the literature and in-vitro study] Briseño Marroquin B, et al. **Schweiz Monatsschr Zahnmed** 1995;105(9):1142–8 (38 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

[Percutaneous autologus bone marrow grafting in the treatment of ununited fractures and bone defects] Zhu J, et al. **Chung Hua Wai Ko Tsa Chih** 1995 Sep;33(9):574–6 (18 ref.) **(Chi)**

VETERINARY

Recombinant bone morphogenetic proteins: novel substances for enhancing bone healing. Kirker-Head CA. **Vet Surg** 1995 Sep-Oct;24(5):408–19 (80 ref.)

VIROLOGY

Retroviruses and bone diseases. Labat ML. **Clin Orthop** 1996 May;(326):287–309 (109 ref.)

BONE DISEASES, DEVELOPMENTAL

COMPLICATIONS

An unusual case of mixed sclerosing bone dystrophy presenting with morning stiffness and joint swelling in childhood: a case report. Foeldvari I, et al. **Clin Exp Rheumatol** 1995 Jul-Aug;13(4):525–8 (19 ref.)

DIAGNOSIS

[Juvenile nephronophthisis with tapetoretinal degeneration, skeletal changes and special phenotypic traits] Castro-Gago M, et al. **An Esp Pediatr** 1996 Jul;45(1):90–2 (16 ref.) **(Spa)**

ETIOLOGY

Caso quiz. Tibia vara caused by focal fibrocartilaginous dysplasia. Marchiodi L, et al. **Chir Organi Mov** 1995 Oct-Dec;80(4):453–6 (9 ref.) **(Eng, Ita)**
Genu varum and genu valgum in children: differential diagnosis and guidelines for evaluation. Greene WB. **Compr Ther** 1996 Jan;22(1):22–9 (15 ref.)

GENETICS

Finding genes involved in human developmental disorders. Muenke M. **Curr Opin Genet Dev** 1995 Jun;5(3):354–61 (80 ref.)
[Schimmelpenning-Feuerstein-Mims syndrome and its neurologic manifestations. 6 personal cases and review of the literature] Fritzsch C, et al. **Klin Padiatr** 1995 Sep-Oct; 207(5):288–97 (40 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

An unusual case of mixed sclerosing bone dystrophy presenting with morning stiffness and joint swelling in childhood: a case report. Foeldvari I, et al. **Clin Exp Rheumatol** 1995 Jul-Aug;13(4):525–8 (19 ref.)

THERAPY

[Skeletal dysplasia. Medical interdisciplinary care is necessary for optimal treatment] Gustavson KH, et al. **Lakartidningen** 1995 Sep 20;92(38):3425–30 (12 ref.) **(Swe)**

BONE DISEASES, METABOLIC

DRUG THERAPY

[Osteopenia and treatment with L-thyroxine] Medeiros-Neto GA. **Rev Assoc Med Bras** 1995 Jan-Feb;41(1):34–6 (16 ref.) (Eng. Abstr.) **(Por)**

ETIOLOGY

Bone changes in metabolic bone disease. Eriksen EF, et al. **Acta Orthop Scand Suppl** 1995 Oct;266:195–201 (36 ref.)
Renal bone disease—an ongoing challenge to the nephrologist. Malluche HH. **Clin Nephrol** 1995 Nov;44 Suppl 1:S38–41 (17 ref.)
Bone metabolism and osteopenia in eating disorders.

Carmichael KA, et al. **Medicine (Baltimore)** 1995 Sep; 74(5):254–67 (132 ref.)
Bone metabolism in spinal cord injured individuals and in others who have prolonged immobilisation. A review. Uebelhart D, et al. **Paraplegia** 1995 Nov;33(11):669–73 (42 ref.)
Bone mineral metabolism in children with juvenile rheumatoid arthritis. Cassidy JT, et al. **Pediatr Clin North Am** 1995 Oct;42(5):1017–33 (117 ref.)
[Countermeasure for patients with bone disease due to hemodialysis] Fukagawa M, et al. **Nippon Naika Gakkai Zasshi** 1995 Oct 10;84(10):1668–72 (5 ref.) **(Jpn)**
[Hepatic osteodystrophy] Murawaki Y, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):478–81 (19 ref.) **(Jpn)**

PATHOLOGY

Distinct skeletal abnormalities in four girls with Shprintzen–Goldberg syndrome. Adès LC, et al. **Am J Med Genet** 1995 Jul 17;57(4):565–72 (13 ref.)
Bone and cancer: pathophysiology and treatment of metastases. Kanis JA. **Bone** 1995 Aug;17(2 Suppl):101S–105S (29 ref.)

PHYSIOPATHOLOGY

Bone changes in metabolic bone disease. Eriksen EF, et al. **Acta Orthop Scand Suppl** 1995 Oct;266:195–201 (36 ref.)
Collagen crosslinks in metabolic bone disease. Robins SP. **Acta Orthop Scand Suppl** 1995 Oct;266:171–5 (28 ref.)
Available animal models of osteopenia—small and large. Miller SC, et al. **Bone** 1995 Oct;17(4 Suppl):117S–123S (64 ref.)

BONE DYSPLASIAS see **BONE DISEASES, DEVELOPMENTAL**

BONE GLA PROTEIN see **OSTEOCALCIN**

BONE HYPERTROPHY see **HYPEROSTOSIS**

BONE LENGTHENING

METHODS

Management of pediatric limb length inequality. Guidera KJ, et al. **Adv Pediatr** 1995;42:501–43 (66 ref.)
Distraction osteogenesis in congenital limb length discrepancy: a review. Maffuli N, et al. **J R Coll Surg Edinb** 1996 Aug;41(4):258–64 (77 ref.)
[Bone lengthening: application to the mandible. Review of the literature] Aldegheri A, et al. **Rev Stomatol Chir Maxillofac** 1995;96(5):335–41 (45 ref.) (Eng. Abstr.) **(Fre)**

BONE LOSS, AGE-RELATED see **OSTEOPOROSIS**

BONE LOSS, OSTEOCLASTIC see **BONE RESORPTION**

BONE LOSS, PERIMENOPAUSAL see **OSTEOPOROSIS, POSTMENOPAUSAL**

BONE LOSS, PERIODONTAL see **ALVEOLAR BONE LOSS**

BONE LOSS, POSTMENOPAUSAL see **OSTEOPOROSIS, POSTMENOPAUSAL**

BONE MALALIGNMENT

DIAGNOSIS

Torsional and angular deformities. Bruce RW Jr. **Pediatr Clin North Am** 1996 Aug;43(4):867–81 (18 ref.)

BONE MARROW

Use of cryopreserved bone marrow in unrelated allogeneic transplantation. Stockschläder M, et al. **Bone Marrow Transplant** 1996 Feb;17(2):197–9 (18 ref.)
Bone marrow and clinical gene therapy. Schmidt-Wolf GD, et al. **J Hematother** 1995 Dec;4(6):551–61 (90 ref.)

BLOOD SUPPLY

Angiogenesis in B cell lymphoproliferative diseases. Biological and clinical studies. Vacca A, et al. **Leuk Lymphoma** 1995 Dec;20(1–2):27–38 (61 ref.)

CHEMISTRY

Detection of minimal residual disease in hematopoietic tissues. Sharp JG, et al. **Ann N Y Acad Sci** 1995 Dec 29; 770:242–61 (89 ref.)

CYTOLOGY

The interdependence of lymphocyte, stromal cell, and follicular dendritic cell maturation. Clark EA. **Adv Exp Med Biol** 1995;378:285–8 (26 ref.)
Multiple lines of evidence favoring a bone marrow derivation of follicular dendritic cells (FDCs). Szakal AK, et al. **Adv Exp Med Biol** 1995;378:267–72 (29 ref.)
Biology of bone marrow stroma. Clark BR, et al. **Ann N Y Acad Sci** 1995 Dec 29;770:70–8 (57 ref.)
In vitro studies of human B lymphopoiesis. Pribyl JR, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:9–18 (40 ref.)
Molecular signals for the production of lymphocytes in bone marrow. Kincade PW. **Braz J Med Biol Res** 1994 Nov; 27(11):2533–8 (23 ref.)
B cell differentiation in bone marrow. Melchers F. **Clin Immunol Immunopathol** 1995 Sep;76(3 Pt 2):S188–91 (23 ref.)
Stem cells from bone marrow, umbilical cord blood and peripheral blood for clinical application: current status and future application. Lu L, et al. **Crit Rev Oncol Hematol** 1996 Mar;22(2):61–78 (243 ref.)
Ex vivo culture systems for hematopoietic cells. Collins PC, et al. **Curr Opin Biotechnol** 1996 Apr;7(2):223–30 (50 ref.)
Mast cell ontogeny and apoptosis. Metcalfe DD, et al. **Exp Dermatol** 1995 Aug;4(4 Pt 2):227–30 (34 ref.)
The extracellular matrix of the hematopoietic microenvironment. Klein G. **Experientia** 1995 Sep 29; 51(9–10):914–26 (123 ref.)
Specificity of hematopoietic stem cell homing. Hardy CL, et al. **Hematol Oncol** 1996 Mar;14(1):17–27 (69 ref.)
Topobiology in hematopoiesis. Naeim F. **Hematol Pathol** 1995;9(2):107–19 (76 ref.)
Retrovirus-mediated transfer of MHC class II cDNA into swine bone marrow cells. LeGuern C, et al. **J Mol Med** 1995 Jun;73(6):269–78 (86 ref.)
Interaction of acute leukemia cells with the bone marrow microenvironment: implications for control of minimal residual disease. Bradstock KF, et al. **Leuk Lymphoma** 1995 Jun;18(1–2):1–16 (152 ref.)
Making the in-vitro model closer to actual B lymphopoiesis in the bone marrow. Yasunaga M, et al. **Semin Immunol** 1995 Jun;7(3):185–96 (59 ref.)
[Histological and morphometric studies of femurs with stable hip joint replacement. An autopsy study with special reference to factors leading to late loosening] Bos J, et al. **Z Orthop Ihre Grenzgeb** 1995 Sep–Oct;133(5):460–6 (46 ref.) (Eng. Abstr.) **(Ger)**
[Hand-mirror cells acute lymphoblastic leukemia (L3)] Uemura K, et al. **Rinsho Byori** 1995 Nov;43(11):1173–7 (24 ref.) (Eng. Abstr.) **(Jpn)**

ENZYMOLOGY

The function of src family tyrosine kinases in hematopoietic cells. Xu Y, et al. **Leuk Res** 1996 Mar;20(3):229–34 (60 ref.)

GROWTH & DEVELOPMENT

A theory of follicular dendritic cell origin. Szakal AK, et al. **Curr Top Microbiol Immunol** 1995;201:1–13 (39 ref.)

IMMUNOLOGY

Multiple lines of evidence favoring a bone marrow derivation of follicular dendritic cells (FDCs). Szakal AK, et al. **Adv Exp Med Biol** 1995;378:267–72 (29 ref.)
Positive and negative selection events during B lymphopoiesis. Melchers F, et al. **Curr Opin Immunol** 1995 Apr;7(2):214–27 (119 ref.)

INJURIES

Magnetic resonance imaging of bone marrow and osteochondral injury. Vellet D. **Magn Reson Imaging Clin N Am** 1994 Aug;2(3):413–23 (22 ref.)

PATHOLOGY

Haemophagocytosis in bone marrow aspirate—a review of the clinical course of 10 cases. Linn YC, et al. **Acta Haematol** 1995;94(4):182–91 (25 ref.)
Stromal abnormalities in neoplastic bone marrow diseases. Dührsen U, et al. **Ann Hematol** 1996 Aug;73(2):53–70 (222 ref.)
Recent-onset myelodysplastic syndrome mimicking acute leukemia during infection. Friedman HD, et al. **Ann Hematol** 1996 Feb;72(2):85–8 (23 ref.)
Morphology, biology and biochemistry of cobalamin- and folate-deficient bone marrow cells. Wickramasinghe SN. **Baillieres Clin Haematol** 1995 Sep;8(3):441–59 (70 ref.)
Emergence of novel transient clonal chromosomal bone marrow changes in remission of acute lymphoblastic leukemia. Andreasson P, et al. **Leukemia** 1996 Feb; 10(2):378–83 (14 ref.)
Composition and function of the hemopoietic microenvironment in human myeloid leukemia. Mayani H. **Leukemia** 1996 Jun;10(6):1041–7 (76 ref.)
[The diagnosis of severe disseminated paracoccidioidomycosis in a bone marrow aspirate: a case report] Ozaki KS, et al. **Rev Soc Bras Med Trop** 1996 Jul–Aug;29(4):363–6 (15 ref.) (Eng. Abstr.) **(Por)**

PHYSIOLOGY

The role of the bone marrow in allergy and asthma. Denburg JA, et al. **Allergy** 1996 Mar;51(3):141–8 (109 ref.)
Relative contributions of marrow microenvironment, growth factors, and stem cells to hematopoiesis in vivo in man. Review of results from autologous stem cell transplant trials and laboratory studies at the Moffitt Cancer Center. Elfenbein GJ, et al. **Ann N Y Acad Sci** 1995 Dec 29; 770:315–38 (21 ref.)
Postablation bone marrow regeneration: an in vivo model to study differential regulation of bone formation and resorption. Bab IA. **Bone** 1995 Oct;17(4 Suppl):437S–441S (20 ref.)
Sex steroids, cytokines and the bone marrow: new concepts on the pathogenesis of osteoporosis. Manolagas SC, et al. **Ciba Found Symp** 1995;191:187–96; discussion 197–202 (45 ref.)
[Megakaryocytes as a component of bone marrow-blood barrier] Dzięcioł J. **Pol Arch Med Wewn** 1995 May; 93(5):433–8 (40 ref.) **(Pol)**

PHYSIOPATHOLOGY

Parvovirus B19 infection and hematopoiesis. Brown KE, et al. **Blood Rev** 1995 Sep;9(3):176–82 (30 ref.)

ULTRASTRUCTURE

Gap junctions in blood forming tissues. Rosendaal M. **Microsc Res Tech** 1995 Aug 1;31(5):396–407 (70 ref.)

BONE MARROW DISEASES

DIAGNOSIS

Magnetic resonance imaging of bone marrow disorders of the knee. Beltran J, et al. **Magn Reson Imaging Clin N Am** 1994 Aug;2(3):463–73 (41 ref.)
Osteonecrosis, transient osteoporosis, and transient bone marrow edema: current concepts. Froberg PK, et al. **Radiol Clin North Am** 1996 Mar;34(2):273–91, x (63 ref.)
Differential diagnoses of bone marrow granuloma. Eid A, et al. **West J Med** 1996 Jun;164(6):510–5 (49 ref.)

ETIOLOGY

Haemophagocytosis in bone marrow aspirate—a review of the clinical course of 10 cases. Linn YC, et al. **Acta Haematol** 1995;94(4):182–91 (25 ref.)

GENETICS

Dyskeratosis congenita: an inherited bone marrow failure syndrome. Dokal I. **Br J Haematol** 1996 Mar;92(4):775–9 (52 ref.)

METABOLISM

Colony-stimulating factors: current applications and perspectives. Bron D, et al. **Cancer Treat Res** 1995; 79:245–54 (63 ref.)

THERAPY

Is blood a better source of allogeneic hematopoietic stem cells for use after radiation accidents? Frickhofen N, et al. **Bone Marrow Transplant** 1996 Feb;17(2):131–5 (48 ref.)
Peripheral blood progenitor cells for marrow reconstitution: mobilization and collection strategies [see comments] Gillespie TW, et al. **Transfusion** 1996 Jul;36(7):611–24 (123 ref.) Comment in: Transfusion 1996 Jul;36(7):585–9.
[Patient information and conditioning for allogeneic stem cell transplantation] Brinch L. **Nord Med** 1995;110(12):318–9, 322 (16 ref.) (Eng. Abstr.) **(Nor)**

BONE MARROW FIBROSIS see **MYELOFIBROSIS**

BONE MARROW NEOPLASMS

DIAGNOSIS

Immunodiagnosis and immunotherapy of isolated tumor cells disseminated to bone marrow of patients with colorectal cancer. Braun S, et al. **Tumori** 1995 May–Jun;81(3 Suppl):78–83 (51 ref.)

PATHOLOGY

Stromal abnormalities in neoplastic bone marrow diseases. Dührsen U, et al. **Ann Hematol** 1996 Aug;73(2):53–70 (222 ref.)

SECONDARY

Biological characteristics of micrometastatic carcinoma cells in bone marrow. Braun S, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 1):163–77 (55 ref.)
Bone marrow metastases. Shpall EJ, et al. **Hematol Oncol Clin North Am** 1996 Apr;10(2):321–43 (79 ref.)
Diffuse bone marrow metastases from glioblastoma multiforme: the role of dural invasion. Kleinschmidt-Demasters BK. **Hum Pathol** 1996 Feb; 27(2):197–201 (22 ref.)

THERAPY

Immunodiagnosis and immunotherapy of isolated tumor cells disseminated to bone marrow of patients with colorectal cancer. Braun S, et al. **Tumori** 1995 May–Jun;81(3 Suppl):78–83 (51 ref.)

BONE MARROW PURGING

[Preservation of hematopoietic stem cells] Nakamura H, et al. **Rinsho Byori** 1995 Jul;Suppl 99:44–53 (14 ref.) **(Jpn)**

METHODS

Culture methods for the detection of minimal tumor contamination of hematopoietic harvests: a review. Sharp JG, et al. **J Hematother** 1995 Jun;4(3):141–8 (53 ref.)

Purging of peripheral blood stem cell grafts. Gee A. **Stem Cells** 1995 Dec;13 Suppl 3:52–62 (77 ref.)

Selective elimination of malignant stem cells using photosensitizers followed by light treatment. Levy JG, et al. **Stem Cells (Dayt)** 1995 Jul;13(4):336–43 (28 ref.)

[Ex vivo purging for autologous hemopoietic progenitor cell transplantation] Moriyama Y. **Rinsho Byori** 1995 Jul;Suppl 99:54–65 (26 ref.) **(Jpn)**

BONE MARROW TRANSPLANTATION

see related
BONE MARROW PURGING
HEMATOPOIETIC STEM CELL TRANSPLANTATION

T cells, graft–versus–host disease and graft–versus–leukemia: innovative approaches for blood and marrow transplantation. Champlin R, et al. **Acta Haematol** 1996; 95(3–4):157–63 (67 ref.)

Neurophysiologic evaluation of cyclosporine toxicity associated with bone marrow transplantation. Edwards LL, et al. **Acta Neurol Scand** 1995 Nov;92(5):423–9 (11 ref.)

High–dose therapy with autologous bone marrow stem cell support in primary and metastatic human breast cancer. A review. Bergh J. **Acta Oncol** 1995;34(5):669–74 (48 ref.)

Successful autologous bone marrow transplant for relapsed Ki–1 lymphoma. Takamura M, et al. **Acta Paediatr Jpn** 1995 Aug;37(4):541–4 (9 ref.)

The dichotomous functions of passenger leukocytes in solid–organ transplantation. Demetris AJ, et al. **Adv Nephrol Necker Hosp** 1995;24:341–54 (66 ref.)

Autologous bone marrow transplantation versus chemotherapy in relapsed/refractory non–Hodgkin's lymphoma: estimates of long–term survival from the recent literature. Meehan KR, et al. **Am J Hematol** 1995 Oct; 50(2):116–23 (52 ref.)

Allogenic bone marrow transplantation or chemotherapy for patients with acute myeloid leukemia in first complete remission: a decision analysis approach. Hertenstein B, et al. **Ann Hematol** 1996 Apr;72(4):223–30 (47 ref.)

Graft–versus–leukemia and graft–versus–lymphoma effects of allogeneic bone marrow transplantation and of allogeneic donor leukocyte transfusions. Vandenberghe P, et al. **Ann Hematol** 1995 Nov;71(5):209–17 (65 ref.)

High–dose chemotherapy for breast cancer. Gradishar WJ, et al. **Ann Intern Med** 1996 Oct 1;125(7):599–604 (55 ref.)

Strategies to enhance the graft–versus–malignancy effect in allogeneic transplants. Barrett JA. **Ann N Y Acad Sci** 1995 Dec 29;770:203–12 (45 ref.)

Lymphopoiesis, apoptosis, and immune amnesia. Donnenberg AD, et al. **Ann N Y Acad Sci** 1995 Dec 29;770:213–26 (33 ref.)

Cytokine inhibitors and graft–versus–host disease. Ferrara JL. **Ann N Y Acad Sci** 1995 Dec 29;770:227–36 (38 ref.)

Organization and development of the immune system. Relation to its reconstruction. Good RA. **Ann N Y Acad Sci** 1995 Dec 29;770:8–33 (169 ref.)

Antitumor activity of syngeneic/autologous graft–versus–host disease. Hess AD, et al. **Ann N Y Acad Sci** 1995 Dec 29;770:189–202 (59 ref.)

Lymphocyte migration following bone marrow transplantation. Sackstein R. **Ann N Y Acad Sci** 1995 Dec 29;770:177–88 (65 ref.)

Bone marrow transplantation from bench to bedside. Thomas ED. **Ann N Y Acad Sci** 1995 Dec 29;770:34–41 (11 ref.)

High–dose chemotherapy for breast cancer: clinical advantages of autologous peripheral blood progenitor cells (PBPC) compared with autologous bone marrow transplantation (ABMT). Martin M. **Ann Oncol** 1995;6 Suppl 4:33–7 (18 ref.)

Efficacy of mesna for prevention of hemorrhagic cystitis after high–dose cyclophosphamide therapy. Haselberger MB, et al. **Ann Pharmacother** 1995 Sep;29(9):918–21 (21 ref.)

Antifungal prophylaxis in bone marrow transplant. Lam HH, et al. **Ann Pharmacother** 1995 Sep;29(9):921–4 (12 ref.)

Bone marrow transplantation in auto–immune disease. Hamilton JA, et al. **Baillieres Clin Rheumatol** 1995 Nov; 9(4):673–87 (58 ref.)

Late infections after allogeneic bone marrow transplantations: comparison of incidence in related and unrelated donor transplant recipients. Ochs L, et al. **Blood** 1995 Nov 15; 86(10):3979–86 (35 ref.)

Fulminant adenovirus hepatitis after allogeneic bone marrow transplantation. Bertheau P, et al. **Bone Marrow Transplant** 1996 Feb;17(2):295–8 (14 ref.)

Bone marrow transplantation for multiple sclerosis [editorial] Burt RK, et al. **Bone Marrow Transplant** 1995 Jul;16(1):1–6 (74 ref.)

Extrapyramidal symptoms in a BMT recipient with hyperintense basal ganglia and elevated manganese. Fredstrom S, et al. **Bone Marrow Transplant** 1995 Jun; 15(6):989–92 (19 ref.)

Comparison of autologous bone marrow transplantation and peripheral blood stem cell transplantation after first remission induction treatment in multiple myeloma. Harousseau JL, et al. **Bone Marrow Transplant** 1995 Jun; 15(6):963–9 (35 ref.)

Successful allogeneic bone marrow transplantation in a case with myelodysplastic syndrome which developed following Fanconi anemia. Ikushima S, et al. **Bone Marrow Transplant** 1995 Oct;16(4):621–4 (21 ref.)

Autotransplants for neuroblastoma [editorial] Kamani NR. **Bone Marrow Transplant** 1996 Mar;17(3):301–4 (27 ref.)

Herpes simplex virus (HSV) colitis in a bone marrow transplant recipient. Naik HR, et al. **Bone Marrow Transplant** 1996 Feb;17(2):285–6 (11 ref.)

Recombinant alpha–interferon as treatment for chronic myelogenous leukemia in relapse after allogeneic bone marrow transplantation: a report from the Société Française de Greffe de Moelle. Pigneux A, et al. **Bone Marrow Transplant** 1995 Jun;15(6):819–24 (31 ref.)

Use of cryopreserved bone marrow in unrelated allogeneic transplantation. Stockschläder M, et al. **Bone Marrow Transplant** 1996 Feb;17(2):197–9 (18 ref.)

Source of stem cells impacts on hematopoietic recovery after high–dose chemotherapy. Zimmerman TM, et al. **Bone Marrow Transplant** 1995 Jun;15(6):923–7 (29 ref.)

Graft–versus–leukaemia: understanding and using the alloimmune response to treat haematological malignancies. Barrett AJ, et al. **Br J Haematol** 1996 Jun 2;93(4):754–61 (89 ref.)

The use of bone marrow and peripheral blood stem cell transplantation in the treatment of cancer [see comments] Appelbaum FR. **CA Cancer J Clin** 1996 May–Jun; 46(3):142–64 (181 ref.) Comment in: CA Cancer J Clin 1996 May–Jun;46(3):131–6.

Marrow transplantation from unrelated volunteer donors. Anasetti C, et al. **Cancer Treat Res** 1995;76:137–68 (45 ref.)

Cytomegalovirus infection in marrow transplantation. Boeckh M, et al. **Cancer Treat Res** 1995;76:97–136 (203 ref.)

Marrow transplantation for chronic myeloid leukemia. Clift RA. **Cancer Treat Res** 1995;76:1–42 (125 ref.)

Genetic therapy using bone marrow transplantation. Giles RE, et al. **Cancer Treat Res** 1995;76:271–80 (20 ref.)

Detection of minimal residual disease. Gribben J, et al. **Cancer Treat Res** 1995;76:249–70 (94 ref.)

Recombinant hematopoietic growth factors in bone marrow transplantation. Nemunaitis J. **Cancer Treat Res** 1995; 76:225–48 (151 ref.)

Bone marrow transplantation for metabolic diseases. Parkman R, et al. **Cancer Treat Res** 1995;76:87–96 (33 ref.)

Myeloablative radiolabeled antibody therapy with autologous bone marrow transplantation for relapsed B cell lymphomas. Press OW, et al. **Cancer Treat Res** 1995; 76:281–97 (68 ref.)

Cellular adoptive immunotherapy after bone marrow transplantation. Riddell SR, et al. **Cancer Treat Res** 1995; 76:337–69 (192 ref.)

Bone marrow transplantation from volunteer unrelated donors. Goulden NJ, et al. **Cancer Treat Rev** 1995 Jul; 21(4):325–53 (143 ref.)

Bone marrow transplantation in children with hereditary disorders. Gluckman E. **Curr Opin Pediatr** 1996 Feb; 8(1):42–4 (17 ref.)

Haemopoietic growth factors and childhood cancer. Hann IM. **Eur J Cancer** 1995;31A(9):1476–8 (27 ref.)

Oral verruca vulgaris in a bone marrow transplant patient: a case report and review of literature. Barasch A, et al. **Eur J Cancer B Oral Oncol** 1996 Mar;32B(2):137–9 (13 ref.)

Separation of graft–vs.–host disease and graft–vs.–leukemia effect against chronic myelogenous leukemia [editorial; comment] Champlin R. **Exp Hematol** 1995 Oct; 23(11):1148–51 (48 ref.) Comment on: Exp Hematol 1995 Oct;23(11):1167–72.

HIV–1–associated pathology in hemato–lymphoid organs and the experimental evaluation in the SCID–hu mouse. Kaneshima H. **Int J Hematol** 1996 Jun;63(4):253–64 (89 ref.)

Immunization against hepatitis B through adoptive transfer of immunity. Shouval D, et al. **Intervirology** 1995; 38(1–2):41–6 (37 ref.)

Bone marrow transplantation: current situation, complications and prevention. Hunter AE, et al. **J Antimicrob Chemother** 1995 Oct;36 Suppl B:119–33 (65 ref.)

Cytokines and bone marrow transplantation. Takaku F. **J Cancer Res Clin Oncol** 1995;121(12):701–9 (88 ref.)

Immunomodulatory effects of donor lymphocyte infusions following allogeneic bone marrow transplantation. Soiffer RJ, et al. **J Clin Apheresis** 1995;10(3):139–43 (36 ref.)

The role of bone marrow transplantation in the treatment of myelodysplastic syndromes. Schultz AB, et al. **J Hematother** 1995 Aug;4(4):323–34 (92 ref.)

The role of natural killer cells in the treatment of chronic myeloid leukemia. Silla LM, et al. **J Hematother** 1995 Aug; 4(4):269–79 (103 ref.)

Immunotherapy and immunoprophylaxis in bone marrow transplantation. Barnes RA. **J Hosp Infect** 1995 Jun;30 Suppl:223–31 (53 ref.)

The future for treatment by bone marrow transplantation for adrenoleukodystrophy, metachromatic leukodystrophy, globoid cell leukodystrophy and Hurler syndrome. Krivit W, et al. **J Inherit Metab Dis** 1995;18(4):398–412 (23 ref.)

Neuropsychological outcomes of several storage diseases with and without bone marrow transplantation. Shapiro EG, et al. **J Inherit Metab Dis** 1995;18(4):413–29 (29 ref.)

Bone marrow transplantation in low–grade non–Hodgkin's lymphoma. Lazarus HM. **Leuk Lymphoma** 1995 Apr; 17(3–4):199–210 (172 ref.)

Adoptive immunotherapy for relapsed leukemia following allogeneic bone marrow transplantation. Porter DL, et al. **Leuk Lymphoma** 1995 Apr;17(3–4):191–7 (46 ref.)

Storage of haemopoietic stem cells for autologous bone marrow transplantation. Raju GM, et al. **Natl Med J India** 1995 Sep–Oct;8(5):216–21 (82 ref.)

Pediatric bone marrow transplantation. Chan KW. **Pediatr Dent** 1995 Jul–Aug;17(4):291–3 (8 ref.)

Plesiomonas shigelloides septicemia: case report and literature review. Lee AC, et al. **Pediatr Hematol Oncol** 1996 May–Jun;13(3):265–9 (23 ref.)

Bone marrow transplantation in Hunter syndrome (mucopolysaccharidosis type II): two–year follow–up of the first Italian patient and review of the literature. Coppa GV, et al. **Pediatr Med Chir** 1995 May–Jun;17(3):227–35 (56 ref.)

When are bone marrow transplants considered? Antman K. **Sci Am** 1996 Sep;275(3):124–5 (0 ref.)

Bone marrow transplantation in thalassemia. Lucarelli G, et al. **Semin Hematol** 1995 Oct;32(4):297–303 (26 ref.)

Chimerism and thoracic organ transplantation. Gammie JS, et al. **Semin Thorac Cardiovasc Surg** 1996 Apr;8(2):149–55 (45 ref.)

The contribution of marker gene studies to hemopoietic stem cell therapies. Brenner MK. **Stem Cells (Dayt)** 1995 Sep; 13(5):453–61 (44 ref.)

Allogeneic bone marrow transplantation for the treatment of multiple myeloma. An overview of published reports. Cavo M, et al. **Stem Cells (Dayt)** 1995 Aug;13 Suppl 2:126–31 (25 ref.)

The role of bone marrow transplantation in the management of advanced local disease. Safah H, et al. **Surg Oncol Clin N Am** 1995 Oct;4(4):735–49 (83 ref.)

Immunotherapy and gene transfer in the treatment of the oncology patient: role of transfusion medicine. Hillyer CD, et al. **Transfus Med Rev** 1996 Jan;10(1):1–14 (111 ref.)

Transfusion of donor buffy coat cells in the treatment of persistent or recurrent malignancy after allogeneic bone marrow transplantation. Collins RH Jr, et al. **Transfusion** 1995 Nov–Dec;35(11):891–8 (41 ref.)

Bone marrow transplantation. Storb R. **Transplant Proc** 1995 Oct;27(5):2649–52 (6 ref.)

Prevention of graft–versus–host disease after bone marrow transplantation. Storb R. **Transplant Proc** 1995 Oct; 27(5):2653–6 (20 ref.)

[Treatment of multiple myeloma—melphalan monotherapy after bone marrow transplantation] Hájek R, et al. **Vnitr Lek** 1996 Apr;42(4):278–84 (0 ref.) (Eng. Abstr.) **(Cze)**

[High–dose chemotherapy and autologous bone marrow transplantation in solid tumors. A review] Handberg J, et al. **Ugeskr Laeger** 1996 Jul 15;158(29):4175–80 (40 ref.) (Eng. Abstr.) **(Dan)**

[High–dose therapy and hematopoietic cell autotransplantation in the treatment of adult gynecologic tumors] Lotz JP, et al. **Contracept Fertil Sex** 1996 Apr; 24(4):307–18 (71 ref.) (Eng. Abstr.) **(Fre)**

[Indications, technique and risks in bone marrow transplantation in adulthood] Heyll A, et al. **Schweiz Rundsch Med Prax** 1996 Mar 19;85(12):378–86 (26 ref.) (Eng. Abstr.) **(Ger)**

[Bone marrow transplantation] Slavin S, et al. **Harefuah** 1995 Nov 15;129(10):398–407 (0 ref.) **(Heb)**

[Myeloablative chemotherapy with autologous bone marrow and/or peripheral blood stem cell transplantation in children with high–risk solid tumor] Endo M, et al. **Gan To Kagaku Ryoho** 1995 Oct;22(12):1762–70 (32 ref.) (Eng. Abstr.) **(Jpn)**

[Bone marrow transplantation and GVH reaction] Imamura M. **Nippon Naika Gakkai Zasshi** 1995 Sep 10;84(9):1489–93 (22 ref.) **(Jpn)**

[Hematopoietic stem cell transplantation in multiple myeloma] Okamoto S. **Nippon Naika Gakkai Zasshi** 1995 Jul 10;84(7):1127–31 (4 ref.) **(Jpn)**

[Autologous bone marrow transplantation] Sakai M. **Nippon Naika Gakkai Zasshi** 1995 Sep 10;84(9):1485–8 (10 ref.) **(Jpn)**

[Bone marrow transplantation for lysosomal storage diseases] Imaizumi M. **Nippon Rinsho** 1995 Dec;53(12):3083–8 (21 ref.) (Eng. Abstr.) **(Jpn)**

[Autologous bone marrow transplantation] Fujimori Y, et al. **Rinsho Byori** 1995 Jul;Suppl 99:9–14 (9 ref.) **(Jpn)**

[DNA typing of HLA] Kashiwase K, et al. **Rinsho Byori** 1995 Jul;Suppl 99:92–101 (17 ref.) **(Jpn)**

[Laboratory examinations and therapy for infections after bone marrow transplantation] Kimura Y, et al. **Rinsho Byori** 1995 Jul;Suppl 99:146–53 (16 ref.) **(Jpn)**

[Utilization of bone marrow donor bank] Kodera Y. **Rinsho Byori** 1995 Jul;Suppl 99:66–73 (2 ref.) **(Jpn)**

[Indication of bone marrow transplantation] Masaoka T. **Rinsho Byori** 1995 Jul;Suppl 99:1–7 (0 ref.) **(Jpn)**

[Clinical and histologic diagnosis of graft–versus–host disease] Takahashi S, et al. **Rinsho Byori** 1995 Jul;Suppl 99:111–6 (12 ref.) **(Jpn)**

[Serological typing of HLA] Tanaka H, et al. **Rinsho Byori** 1995 Jul;Suppl 99:85–91 (4 ref.) **(Jpn)**

[Tests for donors of blood and bone marrow] Taniwaki K, et al. **Rinsho Byori** 1995 Jul;Suppl 99:102–10 (10 ref.) **(Jpn)**

[Allogenic bone marrow transplantation] Yamane T, et al. **Rinsho Byori** 1995 Jul;Suppl 99:15–23 (26 ref.) **(Jpn)**

[Function of the bio-clean room for bone marrow transplantation] Yamayoshi T. **Rinsho Byori** 1995 Jul;Suppl 99:74–83 (22 ref.) **(Jpn)**

[Resolution of psoriasis vulgaris following allogeneic bone marrow transplantation for aplastic anemia] Yokota A, et al. **Rinsho Ketsueki** 1996 Jan;37(1):35–9 (12 ref.) (Eng. Abstr.) **(Jpn)**

[Bone marrow transplantation in beta-thalassemia major] Gaziev DG, et al. **Klin Med (Mosk)** 1995;73(4):35–9 (71 ref.) **(Rus)**

[Extramedullary toxicity in bone marrow transplantation using busulfan and cyclophosphamide conditioning] Pascual MJ, et al. **Sangre (Barc)** 1995 Jun;40(3):191–7 (31 ref.) (Eng. Abstr.) **(Spa)**

[Allogeneic bone marrow transplantation in malignant blood diseases] Ruutu T. **Nord Med** 1995;110(12):310–3 (15 ref.) (Eng. Abstr.) **(Swe)**

ADVERSE EFFECTS

Growth and endocrine disturbances after bone marrow transplantation in childhood. Sklar C. **Acta Paediatr Suppl** 1995 Sep;411:57–61; discussion 62 (30 ref.)

Allogeneic bone marrow transplantation: acute and late complications. Tabbara IA. **Anticancer Res** 1996 Mar-Apr; 16(2):1019–26 (68 ref.)

Mucormycosis after bone marrow transplantation: report of four cases in thalassemia and review of the literature. Gaziev D, et al. **Bone Marrow Transplant** 1996 Mar; 17(3):409–14 (34 ref.)

Reactivation toxoplasmic retinochoroiditis in patients undergoing bone marrow transplantation: is there a role for chemoprophylaxis? Peacock JE Jr, et al. **Bone Marrow Transplant** 1995 Jun;15(6):983–7 (23 ref.)

Unexplained effusions: association with allogeneic bone marrow transplantation and acute or chronic graft-versus-host disease. Seber A, et al. **Bone Marrow Transplant** 1996 Feb;17(2):207–11 (28 ref.)

Thrombotic microangiopathic syndromes after bone marrow transplantation [see comments] Byrnes JJ, et al. **Cancer Invest** 1996;14(2):151–7 (45 ref.) Comment in: Cancer Invest 1996;14(2):180–1.

Liver dysfunction in the early post-bone marrow transplant period. Storek J. **Cas Lek Cesk** 1996 May 15;135(10):295–8 (64 ref.)

Pulmonary complications of bone marrow transplantation. Soubani AO, et al. **Chest** 1996 Apr;109(4):1066–77 (91 ref.)

Pulmonary veno-occlusive disease in an adult following bone marrow transplantation. Case report and review of the literature. Williams LM, et al. **Chest** 1996 May; 109(5):1388–91 (26 ref.)

Immunomodulation in allogeneic marrow transplantation: use of intravenous immune globulin to suppress acute graft-versus-host disease. Sullivan KM. **Clin Exp Immunol** 1996 May;104 Suppl 1:43–8 (68 ref.)

Predicting graft-versus-host disease. Theobald M. **Curr Opin Immunol** 1995 Oct;7(5):649–55 (57 ref.)

Thrombotic microangiopathies associated with drugs and bone marrow transplantation. Moake JL, et al. **Hematol Oncol Clin North Am** 1996 Apr;10(2):485–97 (66 ref.)

Infection in the bone marrow transplant recipient. Walter EA, et al. **Infect Dis Clin North Am** 1995 Dec;9(4):823–47 (133 ref.)

Cytomegalovirus infection in the bone marrow transplant recipient. Zaia JA, et al. **Infect Dis Clin North Am** 1995 Dec;9(4):879–900 (95 ref.)

Prevention studies with pentoxifylline: new clinical projects. Eugène-Jolchine I, et al. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S143–6 (29 ref.)

Haemolytic uraemic syndrome following bone marrow transplantation. Case report and review of the literature. Verburgh CA, et al. **Nephrol Dial Transplant** 1996 Jul; 11(7):1332–7 (146 ref.)

Bone marrow transplant nephropathy: radiation nephritis revisited. Cohen EP, et al. **Nephron** 1995;70(2):217–22 (54 ref.)

Pulmonary complications after bone marrow transplantation. Winer-Muram HT, et al. **Radiol Clin North Am** 1996 Jan; 34(1):97–117 (36 ref.)

IMMUNOLOGY

Donor-specific transfusion and donor bone marrow infusion in renal transplantation tolerance: a review of efficacy and mechanisms. Brennan DC, et al. **Am J Kidney Dis** 1995 Nov;26(5):701–15 (130 ref.)

Multiple bone marrow infusions to enhance acceptance of allografts from the same donor. Ricordi C, et al. **Ann N Y Acad Sci** 1995 Dec 29;770:345–50 (23 ref.)

HLA and bone marrow transplantation. Eiermann TH. **Arch Immunol Ther Exp (Warsz)** 1995;43(2):83–7 (21 ref.)

Bone marrow transplantation for chronic myeloid leukemia with volunteer unrelated donors using ex vivo or in vivo T-cell depletion: major prognostic impact of HLA class I identity between donor and recipient. Spencer A, et al. **Blood** 1995 Nov 1;86(9):3590–7 (40 ref.)

Graft versus leukemia in humans. Butturini A, et al. **Cancer Treat Res** 1995;76:299–314 (102 ref.)

Interleukin-2 in bone marrow transplantation. Verma UN, et al. **Cancer Treat Res** 1995;76:315–36 (99 ref.)

The role of natural killer cells in transplantation. Lanier LL. **Curr Opin Immunol** 1995 Oct;7(5):626–31 (65 ref.)

Bone marrow transplantation across HLA barriers by increasing the number of transplanted cells. Reisner Y, et al. **Immunol Today** 1995 Sep;16(9):437–40 (31 ref.)

Immunotherapy and immunoprophylaxis in bone marrow transplantation. Barnes RA. **J Hosp Infect** 1995 Jun;30 Suppl:223–31 (53 ref.)

Busulfan. O'Marcaigh AS, et al. **J Pediatr Oncol Nurs** 1996 Jul;13(3):150–2 (12 ref.)

The biology of the cytokine sequence cascade. Fraser JK, et al. **Semin Oncol** 1996 Apr;23(2 Suppl 4):2–8 (28 ref.)

Induction of donor-specific tolerance by transplantation of bone marrow. Kaufman CL, et al. **Ther Immunol** 1994 Apr; 1(2):101–11 (123 ref.)

Current progress in chimerism and donor-specific tolerance. Jankowski RA, et al. **Transplant Proc** 1996 Aug; 28(4):2071–4 (39 ref.)

[Skin manifestations of graft-versus-host reaction following bone marrow transplantation] Itin PH, et al. **Schweiz Med Wochenschr** 1996 Mar 2;126(9):339–47 (41 ref.) (Eng. Abstr.) **(Ger)**

[Immunologic aspects of bone marrow transplantation] Klimczak A. **Postepy Hig Med Dosw** 1995;49(1):99–106 (13 ref.) (Eng. Abstr.) **(Pol)**

[Problems with donor-recipient matching in kidney and bone marrow transplantation] Nowakowska B. **Postepy Hig Med Dosw** 1995;49(1):107–15 (11 ref.) (Eng. Abstr.) **(Pol)**

METHODS

Pharmacology of bone marrow transplantation conditioning regimens. Jones RJ, et al. **Ann N Y Acad Sci** 1995 Dec 29;770:237–41 (15 ref.)

Preparative regimens: chemotherapy versus chemoradiotherapy. A historical perspective. Santos GW. **Ann N Y Acad Sci** 1995 Dec 29;770:1–7 (38 ref.)

Allogeneic bone marrow transplantation. Tabbara IA. **South Med J** 1996 Sep;89(9):857–68 (113 ref.)

Allogeneic marrow transplantation and the use of hematopoietic growth factors. Appelbaum FR. **Stem Cells (Dayt)** 1995 Jul;13(4):344–50 (30 ref.)

[Percutaneous autologus bone marrow grafting in the treatment of ununited fractures and bone defects] Zhu J, et al. **Chung Hua Wai Ko Tsa Chih** 1995 Sep;33(9):574–6 (18 ref.) **(Chi)**

[Indications for bone marrow and peripheral stem cell transplantation in malignant hematological diseases] Gratwohl A. **Ther Umsch** 1996 Feb;53(2):152–7 (15 ref.) (Eng. Abstr.) **(Ger)**

[Collection of bone marrow fluid] Tsubaki K. **Rinsho Byori** 1995 Jul;Suppl 99:24–30 (17 ref.) **(Jpn)**

[Bone marrow transplantation in primary immunodeficiency syndrome and in osteopetrosis] Fasth A. **Nord Med** 1995; 110(12):316–7 (15 ref.) (Eng. Abstr.) **(Swe)**

NURSING

Chronic myelogenous leukemia and acute promyelocytic leukemia: new bone marrow transplantation options. Viele CS. **Oncol Nurs Forum** 1996 Apr;23(3):488–93 (22 ref.)

PATHOLOGY

Microglia: the effector cell for reconstitution of the central nervous system following bone marrow transplantation for lysosomal and peroxisomal storage diseases. Krivit W, et al. **Cell Transplant** 1995 Jul-Aug;4(4):385–92 (71 ref.)

PHYSIOLOGY

[Dynamic bone marrow take and lymphohematopoietic chimerism following allogeneic bone marrow transplantation] Demidova IA, et al. **Ter Arkh** 1995; 67(8):74–80 (90 ref.) **(Rus)**

TRENDS

Current progress in chimerism and donor-specific tolerance. Jankowski RA, et al. **Transplant Proc** 1996 Aug; 28(4):2071–4 (39 ref.)

[Progress on the treatment of tumors--present status and future of bonemarrow and peripheral hematopoietic stem cell transplantation] Takaue Y. **Nippon Naika Gakkai Zasshi** 1996 Mar 10;85(3):347–50 (5 ref.) **(Jpn)**

BONE MATRIX

[Physical activity and bone mineral content in postmenopausal women] Eiken PA. **Ugeskr Laeger** 1995 Sep 11;157(37):5086–91 (47 ref.) (Eng. Abstr.) **(Dan)**

ENZYMOLOGY

Matrix metalloproteinases and their inhibitors. Murphy G. **Acta Orthop Scand Suppl** 1995 Oct;266:55–60 (53 ref.)

METABOLISM

Collagen propeptides as indicators of collagen assembly. Risteli J, et al. **Acta Orthop Scand Suppl** 1995 Oct;266:183–8 (18 ref.)

TRANSPLANTATION

Does xenogeneic demineralized bone matrix have clinical utility as a bone graft substitute? Block JE, et al. **Med Hypotheses** 1995 Jul;45(1):27–32 (60 ref.)

Use of demineralized bone implants in orbital and craniofacial reconstruction and a review of the literature. Neigel JM, et al. **Ophthal Plast Reconstr Surg** 1996 Jun;12(2):108–20 (63 ref.)

BONE MINERAL CONTENT see **BONE DENSITY**

BONE MINERAL DENSITY see **BONE DENSITY**

BONE MINERALIZATION see **CALCIFICATION, PHYSIOLOGIC**

BONE NAILS

The rationales of interlocking nailing of the femur, tibia, and humerus. Brumback RJ. **Clin Orthop** 1996 Mar; (324):292–320 (142 ref.)

BONE NEOPLASMS

Mesenchymal chondrosarcoma of the foot, an unusual location: case report and review of the literature. Sans M, et al. **Med Pediatr Oncol** 1996 Feb;26(2):139–42 (12 ref.)

Osteosarcoma and its variants. Vander Griend RA. **Orthop Clin North Am** 1996 Jul;27(3):575–81 (30 ref.)

Ewing's sarcoma. Vlasak R, et al. **Orthop Clin North Am** 1996 Jul;27(3):591–603 (51 ref.)

Cancer of bone in children. Jaffe N. **Pediatr Dent** 1995 Jul-Aug;17(4):263–7 (56 ref.)

COMPLICATIONS

Osteogenic sarcoma in a child with transfusion-dependent Diamond-Blackfan anemia. Aquino VM, et al. **J Pediatr Hematol Oncol** 1996 May;18(2):230–2 (17 ref.)

Osteochondroma: an unusual cause of vascular disease in young adults. Eschelman DJ, et al. **J Vasc Interv Radiol** 1995 Jul-Aug;6(4):605–13 (54 ref.)

Osteogenic sarcoma in the Rothmund-Thomson syndrome. Leonard A, et al. **Med Pediatr Oncol** 1996 Apr;26(4):249–53 (22 ref.)

[A case of angiosarcoma of the pelvis associated with angiomatosis of the spine] Uribe Uribe NO, et al. **Rev Invest Clin** 1996 Jan-Feb;48(1):49–53 (9 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Anaplastic large cell Ki-1 lymphoma: primary bone presentation in an elderly man. Wang JC, et al. **Acta Haematol** 1996;96(1):45–9 (20 ref.)

Hodgkin's disease presenting as a solitary bone tumor. A report of four cases and review of the literature. Ozdemirli M, et al. **Cancer** 1996 Jan 1;77(1):79–88 (35 ref.)

Extraosseous osteogenic sarcoma of the mediastinum occurring in a Chinese patient. Lin J, et al. **Clin Oncol (R Coll Radiol)** 1995;7(3):200–1 (10 ref.)

Unusual problems of the athlete's elbow, forearm, and wrist. Shaffer B, et al. **Clin Sports Med** 1996 Apr;15(2):425–38 (11 ref.)

Benign bone tumors. Gitelis S, et al. **Instr Course Lect** 1996; 45:425–46 (58 ref.)

MR imaging of musculoskeletal tumors of the hand and wrist. Kransdorf MJ, et al. **Magn Reson Imaging Clin N Am** 1995 May;3(2):327–44 (105 ref.)

Surgical considerations in a diagnostic imaging evaluation of musculoskeletal masses. Moreau G, et al. **Magn Reson Imaging Clin N Am** 1995 Nov;3(4):577–90 (30 ref.)

MR spectroscopy of musculoskeletal soft-tissue tumors. Negendank WG. **Magn Reson Imaging Clin N Am** 1995 Nov;3(4):713–25 (53 ref.)

Benign and malignant masses. MR imaging differentiation. Weatherall PT. **Magn Reson Imaging Clin N Am** 1995 Nov; 3(4):669–94 (84 ref.)

Clinicopathologic features and treatment of osteoid osteoma and osteoblastoma in children and adolescents. Frassica FJ, et al. **Orthop Clin North Am** 1996 Jul;27(3):559–74 (66 ref.)

Benign pediatric bone tumors. Evaluation and treatment. Copley L, et al. **Pediatr Clin North Am** 1996 Aug; 43(4):949–66 (28 ref.)

From the archives of the AFIP. Musculoskeletal angiomatous lesions: radiologic-pathologic correlation. Murphey MD, et al. **Radiographics** 1995 Jul;15(4):893–917 (84 ref.)

Giant bone island of femur. Case report, literature review, and its distinction from low grade osteosarcoma. Brien EW, et al. **Skeletal Radiol** 1995 Oct;24(7):546–50 (15 ref.)

Multifocal vascular lesions of bone: imaging characteristics. Lomasney LM, et al. **Skeletal Radiol** 1996 Apr;25(3):255–61 (31 ref.)

High-grade surface osteosarcoma of the humerus. Okada K, et al. **Skeletal Radiol** 1995 Oct;24(7):531–4 (15 ref.)

[Musculoskeletal tumors: epidemiology, clinical aspects and diagnostic requirements] Rechl H, et al. **Rontgenpraxis** 1995

Aug;48(8):217–22 (32 ref.) **(Ger)**

[The shoulder joint—diagnostic imaging] Imhof H, et al. **Wien Med Wochenschr** 1996;146(6–7):116–20 (24 ref.) (Eng. Abstr.) **(Ger)**

[Sellar metastases simulating the Tolosa–Hunt syndrome] Aprile I, et al. **Radiol Med (Torino)** 1996 Mar;91(3):311–3 (9 ref.) **(Ita)**

[Tarsal metastases from breast carcinoma: a case report and review of the literature] Sandomenico F, et al. **Radiol Med (Torino)** 1996 Mar;91(3):306–8 (16 ref.) **(Ita)**

DRUG THERAPY

Bisphosphonates in multiple myeloma: current status; future perspectives. Jantunen E, et al. **Br J Haematol** 1996 Jun 1;93(3):501–6 (58 ref.)

The role of chemotherapy in osteogenic sarcoma. Bramwell VH. **Crit Rev Oncol Hematol** 1995 Aug;20(1–2):61–85 (187 ref.)

Chemotherapy in osteosarcoma. Basis for application and antagonism to implementation; early controversies surrounding its implementation. Jaffe N, et al. **Hematol Oncol Clin North Am** 1995 Aug;9(4):825–40 (79 ref.)

Tumor size and prognosis in aggressively treated osteosarcoma. Bieling P, et al. **J Clin Oncol** 1996 Mar; 14(3):848–58 (38 ref.)

The evolution of chemotherapeutic agents for the treatment of pediatric musculoskeletal malignancies. Velez-Yanguas MC, et al. **Orthop Clin North Am** 1996 Jul;27(3):545–9 (48 ref.)

High-dose ifosfamide in the treatment of sarcomas of soft tissues and bone. Demetri GD. **Semin Oncol** 1996 Jun;23(3 Suppl 6):22–6 (19 ref.)

[Chemotherapy of osteogenic sarcomas] Brain E, et al. **Chirurgie** 1994–95;120(13):193–8 (70 ref.) **(Fre)**

[Role of chemotherapy in treatment of osteosarcoma] Perek D, et al. **Pediatr Pol** 1995 Nov;70(11):939–47 (39 ref.) (Eng. Abstr.) **(Pol)**

[Metastatic bone lesions in solid tumors and possible use of clodronate (Bonephos) in clinical oncology] Moiseenko VM, et al. **Vopr Onkol** 1996;42(2):17–30 (93 ref.) **(Rus)**

GENETICS

Cytogenetics and molecular genetics of bone and soft tissue tumors. Mandahl N. **Adv Cancer Res** 1996;69:63–99 (143 ref.)

Osteosarcoma and other tumors of bone. Mertens WC, et al. **Curr Opin Oncol** 1995 Jul;7(4):349–54 (40 ref.)

Bone and brain involvement in a case of diffuse large B cell lymphoma associated with t(2;3)(p12;q27). Utsumi S, et al. **Int J Hematol** 1995 Dec;62(4):247–52 (16 ref.)

Chromosomal aberrations in musculoskeletal tumours: clinical importance. Rydholm A. **J Bone Joint Surg Br** 1996 May;78(3):501–6 (7 ref.)

The molecular pathology of small round-cell tumours—relevance to diagnosis, prognosis, and classification. McManus AP, et al. **J Pathol** 1996 Feb; 178(2):116–21 (80 ref.)

[Osteosarcoma in 2 siblings. A case report] Danckwerth F, et al. **Klin Padiatr** 1995 Sep–Oct;207(5):298–301 (41 ref.) (Eng. Abstr.) **(Ger)**

METABOLISM

MDR1 gene expression: evaluation of its use as a molecular marker for prognosis and chemotherapy of bone and soft tissue sarcomas. Stein U, et al. **Eur J Cancer** 1996 Jan; 32A(1):86–92 (82 ref.)

[Study of the reactivity of giant cell tumors of bones to different lectins] Illés T, et al. **Arch Anat Cytol Pathol** 1995; 43(5–6):331–7 (23 ref.) (Eng. Abstr.) **(Fre)**

MORTALITY

[Prognostic factors of bone and soft tissue sarcoma] Kawaguchi N, et al. **Gan To Kagaku Ryoho** 1996 Jul; 23(8):1093–8 (5 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Primary embryonal rhabdomyosarcoma of long bone. Case report and review of the literature. Lucas DR, et al. **Am J Surg Pathol** 1996 Feb;20(2):239–44 (32 ref.)

Painless osteoid osteoma of the rib in an adult. A case report and a review of the literature. McDermott MB, et al. **Cancer** 1996 Apr 15;77(8):1442–9 (62 ref.)

Regulation of insulin-like growth factors and IGF-binding proteins in bone tumours. Zumkeller W, et al. **Growth Regul** 1996 Mar;6(1):10–5 (51 ref.)

Osteosarcoma. Specimen management following primary chemotherapy. Raymond AK, et al. **Hematol Oncol Clin North Am** 1995 Aug;9(4):841–67 (70 ref.)

Chondrosarcoma: a review. Springfield DS, et al. **Instr Course Lect** 1996;45:417–24 (38 ref.)

Tumor size and prognosis in aggressively treated osteosarcoma. Bieling P, et al. **J Clin Oncol** 1996 Mar; 14(3):848–58 (38 ref.)

Low-grade papillary adenomatous tumors of the temporal bone: report of two cases and review of the literature. Lavoie M, et al. **Mod Pathol** 1995 Aug;8(6):603–8 (17 ref.)

Malignant bone tumors of childhood. Himelstein BP, et al. **Pediatr Clin North Am** 1996 Aug;43(4):967–84 (38 ref.)

[Retrospect and prospect of research in osteogenic tumors] Qiu J, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1995 Aug; 24(4):242–4 (20 ref.) **(Chi)**

[Pathology of Ewing sarcoma] Roessner A, et al. **Pathologe** 1996 Jan;17(1):6–17 (112 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Bone and cancer: pathophysiology and treatment of metastases. Kanis JA. **Bone** 1995 Aug;17(2 Suppl):101S–105S (29 ref.)

Regulation of insulin-like growth factors and IGF-binding proteins in bone tumours. Zumkeller W, et al. **Growth Regul** 1996 Mar;6(1):10–5 (51 ref.)

Function after amputation, arthrodesis, or arthroplasty for tumors about the shoulder. Kneisl JS. **J South Orthop Assoc** 1995 Fall;4(3):228–36 (36 ref.)

[The effect of hormones on the development of bone tumors] Stoliarov VI, et al. **Vopr Onkol** 1996;42(3):7–14 (43 ref.) **(Rus)**

RADIOGRAPHY

Intraosseous neurilemmoma of the lower third of the fibula [letter] Chevalier X, et al. **AJR Am J Roentgenol** 1995 Dec; 165(6):1555–6 (4 ref.)

[Imaging of osteosclerotic metastases] Feydy A, et al. **J Radiol** 1995 Sep;76(9):561–72 (61 ref.) (Eng. Abstr.) **(Fre)**

RADIONUCLIDE IMAGING

Bone scintigraphy screening in stage I–II breast cancer: is it cost-effective? Wikenheiser KA, et al. **Cleve Clin J Med** 1996 Jan–Feb;63(1):43–7 (26 ref.)

[Primary malignant tumor of the breast. Monitoring after treatment (editorial)] Guastalla JP, et al. **Presse Med** 1995 Oct 21;24(31):1415–7 (22 ref.) (Eng. Abstr.) **(Fre)**

RADIOTHERAPY

Strontium chloride Sr 89 for treating pain from metastatic bone disease. Nightengale B, et al. **Am J Health Syst Pharm** 1995 Oct 15;52(20):2189–95 (87 ref.)

Current controversies in pediatric radiation oncology. Marcus RB Jr. **Orthop Clin North Am** 1996 Jul;27(3):551–7 (20 ref.)

Radiotherapy for bone pain [editorial] Hoskin PJ. **Pain** 1995 Nov;63(2):137–9 (12 ref.)

[Radiotherapy and Ewing tumor in children] Carrie C, et al. **Bull Cancer (Paris)** 1995 Jul;82(7):527–30 (28 ref.) (Eng. Abstr.) **(Fre)**

[Radiotherapy in advanced osseous destruction in chronic myeloid leukemia. A case report] Sadick M, et al. **Strahlenther Onkol** 1996 Jun;172(6):330–1 (9 ref.) (Eng. Abstr.) **(Ger)**

SECONDARY

Carcinoma of the prostate: treatment of bone metastasis. Scalliet P. **Acta Urol Belg** 1996 May;64(2):87–90 (13 ref.)

Strontium chloride Sr 89 for treating pain from metastatic bone disease. Nightengale B, et al. **Am J Health Syst Pharm** 1995 Oct 15;52(20):2189–95 (87 ref.)

Bone and cancer: pathophysiology and treatment of metastases. Kanis JA. **Bone** 1995 Aug;17(2 Suppl):101S–105S (29 ref.)

Bone scintigraphy screening in stage I–II breast cancer: is it cost-effective? Wikenheiser KA, et al. **Cleve Clin J Med** 1996 Jan–Feb;63(1):43–7 (26 ref.)

Recurrent endometrial adenocarcinoma presenting as a solitary humeral metastasis. Schöls WA, et al. **Gynecol Oncol** 1995 Oct;59(1):148–50 (14 ref.)

Hepatocellular carcinoma metastatic to bones (Case report with review of literature). Doval DC, et al. **Indian J Cancer** 1995 Mar;32(1):31–5 (25 ref.)

Metastatic endometrial carcinoma of the foot. A case report. Clarke SJ, et al. **J Am Podiatr Med Assoc** 1996 Jul; 86(7):331–3 (6 ref.)

Giant cell tumour of metacarpal with pulmonary and skeletal metastases. Sanjay BK, et al. **J Hand Surg [Br]** 1996 Feb; 21(1):126–32 (22 ref.)

Malignant joint effusions secondary to solid tumor metastasis. Munn RK, et al. **J Rheumatol** 1995 May;22(5):973–5 (15 ref.)

Bilateral patellar metastases as the clinical presentation of bronchogenic adenocarcinoma. Pauzner R, et al. **J Rheumatol** 1996 May;23(5):939–41 (22 ref.)

Strontium-89 for treatment of painful bone metastasis from prostate cancer. Altman GB, et al. **Oncol Nurs Forum** 1996 Apr;23(3):523–7 (30 ref.)

Radiotherapy for bone pain [editorial] Hoskin PJ. **Pain** 1995 Nov;63(2):137–9 (12 ref.)

Spinal cord and bone metastasizing renal tumor of childhood. Arrotegui JI, et al. **Rev Neurol** 1995 Nov–Dec; 23(124):1231–2 (15 ref.)

Strategy for identifying primary malignancies with inaugural bone metastases. Alcalay M, et al. **Rev Rhum Engl Ed** 1995 Nov;62(10):632–42 (70 ref.)

[Chemotherapy of metastatic soft tissue sarcoma] Le Cesne A. **Presse Med** 1995 Sep 16;24(26):1214–20 (53 ref.) (Eng. Abstr.) **(Fre)**

[Sellar metastases simulating the Tolosa–Hunt syndrome] Aprile I, et al. **Radiol Med (Torino)** 1996 Mar;91(3):311–3 (9 ref.) **(Ita)**

[Tarsal metastases from breast carcinoma: a case report and review of the literature] Sandomenico F, et al. **Radiol Med (Torino)** 1996 Mar;91(3):306–8 (16 ref.) **(Ita)**

[Bone metastasis: pathomechanism and treatment procedures] Senkus-Konefka E. **Przegl Lek** 1995;52(7):368–71 (20 ref.) **(Pol)**

[Metastatic bone lesions in solid tumors and possible use of clodronate (Bonephos) in clinical oncology] Moiseenko VM, et al. **Vopr Onkol** 1996;42(2):17–30 (93 ref.) **(Rus)**

SURGERY

Desmoplastic fibroma of the bone. A report of two patients, review of the literature, and therapeutic implications. Böhm P, et al. **Cancer** 1996 Sep 1;78(5):1011–23 (97 ref.)

Desmoplastic fibroma. Aggressive curettage as a surgical alternative for treatment. Nishida J, et al. **Clin Orthop** 1995 Nov;(320):142–8 (27 ref.)

Surgical management of primary bone sarcomas. Yasko AW, et al. **Hematol Oncol Clin North Am** 1995 Aug;9(4):719–31 (31 ref.)

Consolidation of massive bone allografts in limb-preserving operations for bone tumours. San Julian Aranguren M, et al. **Int Orthop** 1995;19(6):377–82 (53 ref.)

Chondromyxoid fibroma of a metacarpal: a case report and review of the literature. Strauch RJ, et al. **J Hand Surg [Am]** 1996 Mar;21(2):293–5 (6 ref.)

Function after amputation, arthrodesis, or arthroplasty for tumors about the shoulder. Kneisl JS. **J South Orthop Assoc** 1995 Fall;4(3):228–36 (36 ref.)

Venous gas embolism during cryosurgery for bone tumors. Schreuder HW, et al. **J Surg Oncol** 1995 Nov;60(3):196–200 (11 ref.)

Surgical considerations in a diagnostic imaging evaluation of musculoskeletal masses. Moreau G, et al. **Magn Reson Imaging Clin N Am** 1995 Nov;3(4):577–90 (30 ref.)

Endoprosthetic bone reconstruction following malignant tumor resection in skeletally immature patients. Ward WG, et al. **Orthop Clin North Am** 1996 Jul;27(3):493–502 (43 ref.)

The staging and surgery of musculoskeletal neoplasms. Wolf RE, et al. **Orthop Clin North Am** 1996 Jul;27(3):473–81 (21 ref.)

Limb salvage procedures in osteosarcomas around the knee joint. Rodriguez Merchán EC, et al. **Rev Paul Med** 1994 Oct–Dec;112(4):661–7 (42 ref.)

THERAPY

New aspects in the treatment of bone sarcomas. Szendröi M. **Acta Med Hung** 1994;50(3–4):237–44 (14 ref.)

Carcinoma of the prostate: treatment of bone metastasis. Scalliet P. **Acta Urol Belg** 1996 May;64(2):87–90 (13 ref.)

Soft tissue and bone sarcomas. Santoro A, et al. **Cancer Chemother Biol Response Modif** 1996;16:617–24 (36 ref.)

Osteosarcoma and other tumors of bone. Mertens WC, et al. **Curr Opin Oncol** 1995 Jul;7(4):349–54 (40 ref.)

Primary bone malignancies in children. Hahn M, et al. **Curr Opin Pediatr** 1996 Feb;8(1):71–4 (26 ref.)

Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide. Kleinerman ES. **Hematol Oncol Clin North Am** 1995 Aug;9(4):927–38 (37 ref.)

Osteoma of the long bones and the spine. A study of eleven patients and a review of the literature. Peyser AB, et al. **J Bone Joint Surg Am** 1996 Aug;78(8):1172–80 (20 ref.)

Current combined treatment of high-grade osteosarcomas. Damron TA, et al. **Oncology (Huntingt)** 1995 Apr; 9(4):327–43; discussion 343–4, 347–50 (54 ref.)

[Bone metastasis: pathomechanism and treatment procedures] Senkus-Konefka E. **Przegl Lek** 1995;52(7):368–71 (20 ref.) **(Pol)**

VIROLOGY

Primary adult T cell leukemia of bone: two patients with primary bone lesion showing monoclonal integration of HTLV-I proviral DNA. Takemoto S, et al. **Leukemia** 1996 Feb;10(2):333–7 (24 ref.)

BONE PINS see BONE NAILS

BONE PLATES

Removal of asymptomatic bone plates used for orthognathic surgery and facial fractures. Alpert B, et al. **J Oral Maxillofac Surg** 1996 May;54(5):618–21 (41 ref.)

Retention of asymptomatic bone plates used for orthognathic surgery and facial fractures. Haug RH. **J Oral Maxillofac Surg** 1996 May;54(5):611–7 (90 ref.)

[Plate osteosynthesis in humerus shaft fracture] Kuner EH, et al. **Chirurg** 1995 Nov;66(11):1085–91 (14 ref.) (Eng. Abstr.) **(Ger)**

[Long-term results of the surgical treatment of spondylolisthesis using Schöllner's sacral plate] Halm H, et al. **Z Orthop Ihre Grenzgeb** 1996 May–Jun;134(3):219–25 (35 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Complications of posterior cervical plating. Heller JG, et al. **Spine** 1995 Nov 15;20(22):2442–8 (21 ref.)

BONE REGENERATION

see related
FRACTURE HEALING

Poly(alpha-hydroxy acids): carriers for bone morphogenetic proteins. Hollinger JO, et al. **Biomaterials** 1996 Jan; 17(2):187–94 (101 ref.)

Evolution of bone transplantation: molecular, cellular and tissue strategies to engineer human bone. Yaszemski MJ, et al. **Biomaterials** 1996 Jan;17(2):175–85 (74 ref.)

PHYSIOLOGY

Postablation bone marrow regeneration: an in vivo model to study differential regulation of bone formation and resorption. Bab IA. **Bone** 1995 Oct;17(4 Suppl):437S–441S (20 ref.)

Biologic factors affecting spinal fusion and bone regeneration. Boden SD, et al. **Spine** 1995 Dec 15;20(24 Suppl):102S–112S (127 ref.)

BONE REMODELING

Some aspects of bone formation and remodeling pertinent to craniofacial development and reconstructive treatment. Vargervik K. **Acta Odontol Scand** 1995 Jun;53(3):167–73 (16 ref.)

Osteoporosis: using bone markers' for diagnosis and monitoring. Arnaud CD. **Geriatrics** 1996 Apr;51(4):24–30 (25 ref.)

[Regulation of cancellous bone structure by bone remodeling] Nakamura T. **Nippon Seikeigeka Gakkai Zasshi** 1995 Jul; 69(7):528–34 (25 ref.) **(Jpn)**

DRUG EFFECTS

Assessing bone quality--animal models in preclinical osteoporosis research. Mosekilde L. **Bone** 1995 Oct;17(4 Suppl):343S–352S (35 ref.)

GENETICS

Genetic influences on bone turnover, bone density and fracture. Kelly PJ, et al. **Eur J Endocrinol** 1995 Sep; 133(3):265–71 (42 ref.)

Vitamin D receptor gene alleles and osteoporosis: an affirmative view [editorial] Eisman JA.
J Bone Miner Res 1995 Sep;10(9):1289–93 (43 ref.)

PHYSIOLOGY

Biochemical markers of bone turnover. Delmas PD.
Acta Orthop Scand Suppl 1995 Oct;266:176–82 (70 ref.)

Bone changes in metabolic bone disease. Eriksen EF, et al.
Acta Orthop Scand Suppl 1995 Oct;266:195–201 (36 ref.)

In vitro modeling of the bone/implant interface. Davies JE.
Anat Rec 1996 Jun;245(2):426–45 (94 ref.)

Endogenous and nutritional factors affecting bone. Marcus R. **Bone** 1996 Jan;18(1 Suppl):11S–13S (21 ref.)

The effects of cytokines and growth factors on osteoblastic cells. Mundy GR, et al. **Bone** 1995 Aug;17(2 Suppl):71S–75S (41 ref.)

Bone mass measurement and bone metabolism in rheumatoid arthritis: a review. Deodhar AA, et al. **Br J Rheumatol** 1996 Apr;35(4):309–22 (88 ref.)

Mechanotransduction and the functional response of bone to mechanical strain. Duncan RL, et al.
Calcif Tissue Int 1995 Nov;57(5):344–58 (225 ref.)

Regulation of bone formation by bone morphogenetic proteins and other growth factors. Mundy GR.
Clin Orthop 1996 Mar;(324):24–8 (25 ref.)

BONE REPLACEMENT MATERIALS see **BONE SUBSTITUTES**

BONE RESORPTION

Interactions of connective tissue cells with the extracellular matrix. Horton MA. **Bone** 1995 Aug;17(2 Suppl):51S–53S (20 ref.)

Osteoporosis into the year 2010. Mundy GR.
Br J Obstet Gynaecol 1996 May;103 Suppl 13:32–7; discussion 37–8 (46 ref.)

Cellular biology of bone–resorbing cells. Athanasou NA.
J Bone Joint Surg Am 1996 Jul;78(7):1096–112 (170 ref.)

Cytoskeletal changes in osteoclasts during the resorption cycle. Lakkakorpi PT, et al. **Microsc Res Tech** 1996 Feb 1;33(2):171–81 (90 ref.)

CHEMICALLY INDUCED

PTH-mediated osteoblast retraction: possible participation of the calpain pathway. Murray EJ, et al.
Miner Electrolyte Metab 1995;21(1–3):184–8 (20 ref.)

COMPLICATIONS

Progressive mandibular retrusion--idiopathic condylar resorption. Part I. Arnett GW, et al.
Am J Orthod Dentofacial Orthop 1996 Jul;110(1):8–15 (0 ref.)

Progressive mandibular retrusion–idiopathic condylar resorption. Part II. Arnett GW, et al.
Am J Orthod Dentofacial Orthop 1996 Aug;110(2):117–27 (109 ref.)

DIAGNOSIS

[Bone resorption markers] Takahashi M, et al.
Rinsho Byori 1996 May;44(5):415–22 (38 ref.) (Eng. Abstr.) **(Jpn)**

DRUG THERAPY

Tiludronate: bone pharmacology and safety. Bonjour JP, et al. **Bone** 1995 Nov;17(5 Suppl):473S–477S (39 ref.)

Skeletal safety of tiludronate. Neer RM. **Bone** 1995 Nov;17(5 Suppl):501S–503S (27 ref.)

Drug therapy for vertebral fractures in osteoporosis: evidence that decreases in bone turnover and increases in bone mass both determine antifracture efficacy. Riggs BL, et al.
Bone 1996 Mar;18(3 Suppl):197S–201S (26 ref.)

Animal models of cortical porosity. Sietsema WK. **Bone** 1995 Oct;17(4 Suppl):297S–305S (19 ref.)

ETIOLOGY

Role of cytokines in bone resorption. Manolagas SC.
Bone 1995 Aug;17(2 Suppl):63S–67S (45 ref.)

Mandibular resorption due to systemic sclerosis. Case report of surgical correction of a secondary open bite deformity. Haers PE, et al. **Int J Oral Maxillofac Surg** 1995 Aug; 24(4):261–7 (44 ref.)

Bone metabolism in spinal cord injured individuals and in others who have prolonged immobilisation. A review. Uebelhart D, et al. **Paraplegia** 1995 Nov;33(11):669–73 (42 ref.)

GENETICS

Molecular mechanisms of bone resorption. Teitelbaum SL, et al. **J Cell Biochem** 1995 Sep;59(1):1–10 (113 ref.)

METABOLISM

Molecular mechanisms of bone resorption. An update. Baron R. **Acta Orthop Scand Suppl** 1995 Oct;266:66–70 (35 ref.)

beta-Alanyl-L-histidinato zinc and bone resorption. Yamaguchi M. **Gen Pharmacol** 1995 Oct;26(6):1179–83 (27 ref.)

Role of microscopy in elucidating the mechanism and regulation of the osteoclast resorptive apparatus. Gay CV.
Microsc Res Tech 1996 Feb 1;33(2):165–70 (74 ref.)

Some aspects of the anabolic action of parathyroid hormone. Martin TJ, et al. **Miner Electrolyte Metab** 1995; 21(1–3):87–90 (25 ref.)

Cellular and molecular mechanisms of bone resorption. Teitelbaum SL, et al. **Miner Electrolyte Metab** 1995; 21(1–3):193–6 (18 ref.)

[Osteoclast activating factor (OAF)] Kamihagi K, et al.
Nippon Rinsho 1995 Mar;53 Su Pt 2:756–8 (14 ref.) **(Jpn)**

PATHOLOGY

Cellular and molecular mechanisms of bone resorption. Teitelbaum SL, et al. **Miner Electrolyte Metab** 1995; 21(1–3):193–6 (18 ref.)

PHYSIOPATHOLOGY

The specificity of collagen cross-links as markers of bone and connective tissue degradation. Eyre DR.
Acta Orthop Scand Suppl 1995 Oct;266:166–70 (23 ref.)

Stimulation of bone resorption by the kallikrein-kinin system and the coagulation cascade. Lerner UH.
Acta Orthop Scand Suppl 1995 Oct;266:45–50 (30 ref.)

Collagen crosslinks in metabolic bone disease. Robins SP.
Acta Orthop Scand Suppl 1995 Oct;266:171–5 (28 ref.)

Postablation bone marrow regeneration: an in vivo model to study differential regulation of bone formation and resorption. Bab IA. **Bone** 1995 Oct;17(4 Suppl):437S–441S (20 ref.)

The insulin-like growth factor system and the coupling of formation to resorption. Hayden JM, et al. **Bone** 1995 Aug; 17(2 Suppl):93S–98S (32 ref.)

Small bone-building fragments of parathyroid hormone: new therapeutic agents for osteoporosis. Whitfield JF, et al.
Trends Pharmacol Sci 1995 Nov;16(11):382–6 (47 ref.)

PREVENTION & CONTROL

Maintenance therapy for added bone mass or how to keep the profit after withdrawal of therapy of osteopenia. Jee WS, et al. **Bone** 1995 Oct;17(4 Suppl):309S–319S (49 ref.)

Bisphosphonates: mechanisms of action. Rodan GA, et al.
J Clin Invest 1996 Jun 15;97(12):2692–6 (54 ref.)

Anabolic effects of insulin on bone suggest a role for chromium picolinate in preservation of bone density. McCarty MF. **Med Hypotheses** 1995 Sep;45(3):241–6 (69 ref.)

[Calcitonin] Reginster JY. **Rev Med Liege** 1996 Jan; 51(1):116–9 (23 ref.) **(Fre)**

SURGERY

Mandibular resorption due to systemic sclerosis. Case report of surgical correction of a secondary open bite deformity. Haers PE, et al. **Int J Oral Maxillofac Surg** 1995 Aug; 24(4):261–7 (44 ref.)

BONE SCREWS

Internal fixation (pedicle screw fixation) for fusions of the lumbar spine. Vaccaro AR, et al. **Spine** 1995 Dec 15;20(24 Suppl):157S–165S (54 ref.)

STANDARDS

Orientruded polylactide based body-absorbable osteosynthesis devices: a short review. Tunc DC.
J Biomater Sci Polym Ed 1995;7(4):375–80 (9 ref.)

BONE SUBSTITUTES

Osteoinductive agents. Basic science and clinical applications. Kale AA, et al. **Am J Orthop** 1995 Oct;24(10):752–61 (92 ref.)

Role of bone substitutes. Hollinger JO, et al. **Clin Orthop** 1996 Mar;(324):55–65 (89 ref.)

Mechanical testing of materials and the material–tissue interface. Ashry HR, et al. **Clin Podiatr Med Surg** 1995 Jul;12(3):385–401 (33 ref.)

Implantable bone substitute materials. Hanft JR, et al.
Clin Podiatr Med Surg 1995 Jul;12(3):437–55 (108 ref.)

Mechanical properties of implantable biomaterials. Meaney DF. **Clin Podiatr Med Surg** 1995 Jul;12(3):363–84 (6 ref.)

Does xenogeneic demineralized bone matrix have clinical utility as a bone graft substitute? Block JE, et al.
Med Hypotheses 1995 Jul;45(1):27–32 (60 ref.)

[Bone substitutes. State of the art and: what lies ahead?] Rueger JM. **Unfallchirurg** 1996 Mar;99(3):228–36 (15 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

The microscopic interaction between silicone and the surrounding tissues. Needelman L.
Clin Podiatr Med Surg 1995 Jul;12(3):415–23 (31 ref.)

BONE TRANSPLANTATION

Basic fibroblast growth factor for stimulation of bone formation in osteoinductive or conductive implants. Wang JS. **Acta Orthop Scand Suppl** 1996 Apr;269:1–33 (204 ref.)

Bone allograft banking in South Australia. Campbell DG, et al. **Aust N Z J Surg** 1995 Dec;65(12):865–9 (43 ref.)

The use of bone allografts in the spine. Buttermann GR, et al. **Clin Orthop** 1996 Mar;(324):75–85 (53 ref.)

Bone allografts in periodontal therapy. Mellonig JT.
Clin Orthop 1996 Mar;(324):116–25 (84 ref.)

Implantable bone substitute materials. Hanft JR, et al.
Clin Podiatr Med Surg 1995 Jul;12(3):437–55 (108 ref.)

Does xenogeneic demineralized bone matrix have clinical utility as a bone graft substitute? Block JE, et al.
Med Hypotheses 1995 Jul;45(1):27–32 (60 ref.)

Use of demineralized bone implants in orbital and craniofacial reconstruction and a review of the literature. Neigel JM, et al. **Ophthal Plast Reconstr Surg** 1996 Jun;12(2):108–20 (63 ref.)

[Bone substitutes. State of the art and: what lies ahead?] Rueger JM. **Unfallchirurg** 1996 Mar;99(3):228–36 (15 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Arteriovenous fistulae complicating orthopaedic procedures. Ward AS, et al. **Aust N Z J Surg** 1995 Dec;65(12):905–7 (20 ref.)

Fracture of the iliac crest following bone grafting: a case report and literature review. Friend KD, et al.
Bull Hosp Jt Dis 1995;54(1):49–51 (8 ref.)

Transmission of disease through transplantation of musculoskeletal allografts. Tomford WW.
J Bone Joint Surg Am 1995 Nov;77(11):1742–54 (164 ref.)

METHODS

Alternative donor site for alveolar bone grafting in adults with cleft lip and palate. So LL, et al. **Angle Orthod** 1996; 66(1):9–16 (64 ref.)

Evolution of bone transplantation: molecular, cellular and tissue strategies to engineer human bone. Yaszemski MJ, et al. **Biomaterials** 1996 Jan;17(2):175–85 (74 ref.)

Acetabular allografts for restoration of bone stock in revision arthroplasty of the hip. Gross AE, et al.
Instr Course Lect 1996;45:135–42 (41 ref.)

Consolidation of massive bone allografts in limb–preserving operations for bone tumours. San Julian Aranguren M, et al. **Int Orthop** 1995;19(6):377–82 (53 ref.)

Alveolar cleft bone grafting (Part I): Primary bone grafting. Eppley BL. **J Oral Maxillofac Surg** 1996 Jan;54(1):74–82 (23 ref.)

Alveolar cleft bone grafting (Part II): Secondary bone grafting. Ochs MW. **J Oral Maxillofac Surg** 1996 Jan; 54(1):83–8 (37 ref.)

Recurrent melanoma of the hard palate treated by en bloc excision and reconstruction with an autologous palatal bone graft subjected to cryotherapy and a buccal mucosal flap. Rosales J, et al. **J Oral Maxillofac Surg** 1995 Oct; 53(10):1218–20 (16 ref.)

[The musculus pectoralis major rib flap. Personal experiences with 7 cases] Koch A, et al. **Chirurg** 1996 Mar;67(3):273–7

BONE TRANSPLANTATION

(26 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Factors affecting bone graft incorporation. Stevenson S, et al. **Clin Orthop** 1996 Mar;(324):66–74 (46 ref.)

BONE TUBERCULOSIS see **TUBERCULOSIS, OSTEOARTICULAR**

BOOK INDUSTRY

see related
PUBLISHING

BOOP see **BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA**

BORDER DISEASE

Border disease in sheep. Løken T.
Vet Clin North Am Food Anim Pract 1995 Nov;11(3):579–95 (110 ref.)

BORDER DISEASE VIRUS

PHYSIOLOGY

Border disease in sheep. Løken T.
Vet Clin North Am Food Anim Pract 1995 Nov;11(3):579–95 (110 ref.)

BORDERLINE PERSONALITY DISORDER

The 'stably unstable' borderline personality disorder: history, theory, and nursing intervention. Greene H, et al.
J Psychosoc Nurs Ment Health Serv 1995 Dec;33(12):26–30 (38 ref.)

DIAGNOSIS

Demography of DSM–III borderline personality disorder (PD): a comparison with Axis II PDs, affective illness and schizophrenia convergent and discriminant validation. Taub JM. **Int J Neurosci** 1995 Jun;82(3–4):191–214 (96 ref.)

PSYCHOLOGY

Family relationships of adults with borderline personality disorder. Allen DM, et al. **Compr Psychiatry** 1996 Jan–Feb; 37(1):43–51 (43 ref.)

THERAPY

The borderline patient: update on the diagnosis, theory, and treatment from a psychodynamic perspective. Goldstein WN. **Am J Psychother** 1995 Summer;49(3):317–37 (59 ref.)
Supportive psychotherapy. The search for positive meanings. Holmes J. **Br J Psychiatry** 1995 Oct;167(4):439–45; discussion 446–7 (48 ref.)

BORDETELLA

ISOLATION & PURIFICATION

Characteristics of Bordetella hinzii strains isolated from a cystic fibrosis patient over a 3–year period. Funke G, et al. **J Clin Microbiol** 1996 Apr;34(4):966–9 (17 ref.)

PATHOGENICITY

New perspectives on Bordetella pathogenicity [editorial] Parton R. **J Med Microbiol** 1996 Apr;44(4):233–5 (19 ref.)

BORDETELLA INFECTIONS

MICROBIOLOGY

New perspectives on Bordetella pathogenicity [editorial] Parton R. **J Med Microbiol** 1996 Apr;44(4):233–5 (19 ref.)
Understanding signal transduction during bacterial infection. Akerley BJ, et al. **Trends Microbiol** 1996 Apr;4(4):141–6 (39 ref.)

BORDETELLA PERTUSSIS

see related
PERTUSSIS TOXINS
PERTUSSIS VACCINE

IMMUNOLOGY

[Efficacy of acellular pertussis vaccines] Wirsing von König CH, et al. **Immun Infekt** 1995 Aug;23(4):125–9 (15 ref.) (Eng. Abstr.) **(Ger)**

BORDETELLA PERTUSSIS TOXINS see **PERTUSSIS TOXINS**

BORNA DISEASE VIRUS

ISOLATION & PURIFICATION

[Detection of Borna disease virus RNA by RT–PCR in PBMC] Nakaya T, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):700–4 (20 ref.) **(Jpn)**

BORNHOLM DISEASE VIRUS see **COXSACKIEVIRUSES B**

BORON COMPOUNDS

ADMINISTRATION & DOSAGE

Targeted drug delivery for boron neutron capture therapy. Mehta SC, et al. **Pharm Res** 1996 Mar;13(3):344–51 (50 ref.)

BORON NEUTRON CAPTURE THERAPY

[Neutron capturing irradiation: principle, current results and perspectives] Pignol JP, et al. **Bull Cancer Radiother** 1995; 82(3):283–97 (145 ref.) (Eng. Abstr.) **(Fre)**

METHODS

Targeted drug delivery for boron neutron capture therapy. Mehta SC, et al. **Pharm Res** 1996 Mar;13(3):344–51 (50 ref.)

BORRELIA BURGDORFERI

see related
LYME DISEASE

[Lyme borreliosis: epidemiologic and etiopathogenic aspects] Oteo–Revuelta JA, et al. **Enferm Infecc Microbiol Clin** 1995 Nov;13(9):550–5 (53 ref.) **(Spa)**

GENETICS

Polymerase chain reaction of Borrelia burgdorferi flagellin gene in Shulman syndrome. Hashimoto Y, et al.
Dermatology 1996;192(2):136–9 (26 ref.)

IMMUNOLOGY

Prospects for a vaccine to prevent Lyme disease in humans. Wormser GP. **Clin Infect Dis** 1995 Nov;21(5):1267–74 (113 ref.)
Lyme vaccine enhancement. N–terminal acylation of a protein antigen and inclusion of a saponin adjuvant. Coughlin RT, et al. **Pharm Biotechnol** 1995;6:719–35 (126 ref.)

BOTANICAL INSECTICIDES see **INSECTICIDES, BOTANICAL**

BOTANY

see related
PLANTS

BOTRYTIS see **HYPHOMYCETES**

BOTTLE FEEDING

Transition to breast/bottle feedings: the premature infant. Lemons PK, et al. **J Am Coll Nutr** 1996 Apr;15(2):126–35 (34 ref.)

ADVERSE EFFECTS

Etiology of nursing caries: a microbiologic perspective. Berkowitz R. **J Public Health Dent** 1996 Winter;56(1):51–4 (48 ref.)
Description and epidemiology of nursing caries. Milnes AR. **J Public Health Dent** 1996 Winter;56(1):38–50 (59 ref.)

BOTULIN see **BOTULINUM TOXINS**

BOTULINUM TOXINS

Molecular aspects of tetanus and botulinum neurotoxin poisoning. Ahnert–Hilger G, et al. **Prog Neurobiol** 1995 May;46(1):83–96 (180 ref.)

ANALYSIS

The metallo–proteinase activity of tetanus and botulism neurotoxins. Rossetto O, et al. **J Physiol Paris** 1995; 89(1):43–50 (60 ref.)

BIOSYNTHESIS

Expression of a large, nontoxic fragment of botulinum neurotoxin serotype A and its use as an immunogen. LaPenotiere HF, et al. **Toxicon** 1995 Oct;33(10):1383–6 (8 ref.)

CLASSIFICATION

The typing of botulinal neurotoxins. Giménez DF, et al. **Int J Food Microbiol** 1995 Sep;27(1):1–9 (16 ref.)

GENETICS

Molecular genetics of clostridial neurotoxins. Minton NP. **Curr Top Microbiol Immunol** 1995;195:161–94 (83 ref.)

IMMUNOLOGY

Botulinum toxin therapy, immunologic resistance, and problems with available materials. Borodic G, et al. **Neurology** 1996 Jan;46(1):26–9 (20 ref.)

METABOLISM

Neurospecific binding, internalization, and retrograde axonal transport. Halpern JL, et al.
Curr Top Microbiol Immunol 1995;195:221–41 (147 ref.)
Quantal neurotransmitter release and the clostridial neurotoxins' targets. Poulain B, et al.
Curr Top Microbiol Immunol 1995;195:243–55 (77 ref.)
Intracellular targets and metalloprotease activity of tetanus and botulism neurotoxins. Schiavo G, et al.
Curr Top Microbiol Immunol 1995;195:257–74 (90 ref.)
Bacterial neurotoxins—a thousand years later. Linial M.
Isr J Med Sci 1995 Oct;31(10):591–5 (15 ref.)

THERAPEUTIC USE

Therapeutic uses of botulinum toxin (Botox). Epperson LW.
Ala Med 1995 Nov–1996 Jan;65(5–7):49–50 (4 ref.)
Clinical use of botulinum neurotoxins. Cardoso F, et al.
Curr Top Microbiol Immunol 1995;195:123–41 (195 ref.)
Botulinum A exotoxin use in clinical dermatology. Carruthers A, et al. **J Am Acad Dermatol** 1996 May;34(5 Pt 1):788–97 (118 ref.)
Botulinum toxin therapy, immunologic resistance, and problems with available materials. Borodic G, et al.
Neurology 1996 Jan;46(1):26–9 (20 ref.)
Botulinum neurotoxin A in ophthalmology. Bentley C.
Ophthalmic Physiol Opt 1996 Mar;16 Suppl 1:S9–14 (43 ref.)
[Clinical application of botulinum toxin] Grandas F.
Neurologia 1995 Jun–Jul;10(6):224–33 (141 ref.) **(Spa)**
[Botulinum toxin—from threat to cure] Odergren T, et al.
Lakartidningen 1996 Apr 24;93(17):1619–24 (40 ref.) **(Swe)**

TOXICITY

The mechanism of action of tetanus and botulinum neurotoxins. Montecucco C, et al. **Arch Toxicol Suppl** 1996; 18:342–54 (66 ref.)

BOTULISM

see related
BOTULINUM TOXINS

Botulism: the present status of the disease. Hatheway CL.
Curr Top Microbiol Immunol 1995;195:55–75 (80 ref.)

DIAGNOSIS

Immunodiagnosis and immunotherapy of tetanus and botulinum neurotoxins. Middlebrook JL, et al.
Curr Top Microbiol Immunol 1995;195:89–122 (179 ref.)
[Infantile botulism: apropos a case] Lizarraga Azparren MA, et al. **An Esp Pediatr** 1996 Apr;44(4):399–401 (20 ref.) **(Spa)**

EPIDEMIOLOGY

[Epidemic of type B botulism: Sion, December 1993–January 1994] Troillet N, et al. **Schweiz Med Wochenschr** 1995 Sep 30;125(39):1805–12 (18 ref.) (Eng. Abstr.) **(Fre)**

MICROBIOLOGY

A second case of infant botulism type F caused by Clostridium baratii. Paisley JW, et al.
Pediatr Infect Dis J 1995 Oct;14(10):912–4 (17 ref.)

THERAPY

Immunodiagnosis and immunotherapy of tetanus and botulinum neurotoxins. Middlebrook JL, et al.
Curr Top Microbiol Immunol 1995;195:89–122 (179 ref.)

BOUILLAUD'S DISEASE see **RHEUMATIC HEART DISEASE**

BOURNEVILLE'S DISEASE see **TUBEROUS SCLEROSIS**

BOVINE DIARRHEA VIRUS see **DIARRHEA VIRUS, BOVINE VIRAL**

BOVINE HERPESVIRUS 1 see **HERPESVIRUS 1, BOVINE**

BOVINE KUNITZ PANCREATIC TRYPSIN INHIBITOR see **APROTININ**

BOVINE LEUKEMIA see **ENZOOTIC BOVINE LEUKOSIS**

BOVINE LEUKEMIA VIRUS see **LEUKEMIA VIRUS, BOVINE**

BOVINE LEUKOSIS see **ENZOOTIC BOVINE LEUKOSIS**

BOVINE LYMPHOMA see **ENZOOTIC BOVINE LEUKOSIS**

BOVINE LYMPHOSARCOMA see **ENZOOTIC BOVINE**

LEUKOSIS

BOVINE PAPILLOMATOSIS VIRUS see PAPILLOMAVIRUS, BOVINE

BOVINE PAPULAR DERMATITIS VIRUS see PAPILLOMAVIRUS, BOVINE

BOVINE PESTIVIRUS see DIARRHEA VIRUS, BOVINE VIRAL

BOVINE SPONGIFORM ENCEPHALOPATHY see ENCEPHALOPATHY, BOVINE SPONGIFORM

BOVINE SYNCYTIAL VIRUS see SPUMAVIRUS

BOVINE VIRUS DIARRHEA-MUCOSAL DISEASE

COMPLICATIONS

Pathogenesis of intrauterine infections with bovine viral diarrhea virus. Moennig V, et al. **Vet Clin North Am Food Anim Pract** 1995 Nov;11(3):477–87 (51 ref.)

DIAGNOSIS

Diagnosis of bovine viral diarrhea virus infections. Brock KV. **Vet Clin North Am Food Anim Pract** 1995 Nov; 11(3):549–61 (52 ref.)

EPIDEMIOLOGY

Epidemiology of bovine viral diarrhea virus. Houe H. **Vet Clin North Am Food Anim Pract** 1995 Nov;11(3):521–47 (93 ref.)

ETIOLOGY

The pathologies of bovine viral diarrhea virus infection. A window on the pathogenesis. Bielefeldt-Ohmann H. **Vet Clin North Am Food Anim Pract** 1995 Nov;11(3):447–76 (147 ref.)

IMMUNOLOGY

Immunology of bovine viral diarrhea virus. Potgieter LN. **Vet Clin North Am Food Anim Pract** 1995 Nov;11(3):501–20 (116 ref.)

PATHOLOGY

The pathologies of bovine viral diarrhea virus infection. A window on the pathogenesis. Bielefeldt-Ohmann H. **Vet Clin North Am Food Anim Pract** 1995 Nov;11(3):447–76 (147 ref.)

PHYSIOPATHOLOGY

The clinical manifestations of bovine viral diarrhea infection. Baker JC. **Vet Clin North Am Food Anim Pract** 1995 Nov; 11(3):425–45 (129 ref.)

PREVENTION & CONTROL

Control of bovine viral diarrhea virus infection without vaccines. Bitsch V, et al. **Vet Clin North Am Food Anim Pract** 1995 Nov;11(3):627–40 (16 ref.)

Control of bovine viral diarrhea infection by use of vaccination. Bolin SR. **Vet Clin North Am Food Anim Pract** 1995 Nov;11(3):615–25 (74 ref.)

VIROLOGY

The pathogenesis of mucosal disease. Bolin SR. **Vet Clin North Am Food Anim Pract** 1995 Nov; 11(3):489–500 (65 ref.)

Molecular biology of bovine viral diarrhea virus and its interactions with the host. Donis RO. **Vet Clin North Am Food Anim Pract** 1995 Nov; 11(3):393–423 (133 ref.)

BOVINE WART VIRUS see PAPILLOMAVIRUS, BOVINE

BOXING

A neurologist's reflections on boxing. III. Vascular injuries. Unterharnscheidt F. **Rev Neurol** 1995 Jul–Aug; 23(122):847–55 (27 ref.)

A neurologist's reflections on boxing. II. Acute and chronic clinical findings secondary to central nervous system damage. Unterharnscheidt F. **Rev Neurol** 1995 Jul–Aug; 23(122):833–46 (92 ref.)

A neurologist's reflections on boxing. V. Conclude remarks. Unterharnscheidt F. **Rev Neurol** 1995 Sep–Oct; 23(123):1027–32 (19 ref.)

INJURIES

The neuropsychiatric aspects of boxing. Mendez MF. **Int J Psychiatry Med** 1995;25(3):249–62 (74 ref.)

A critique of published studies into the effects of amateur boxing: why is there a lack of consensus? Kemp PL. **J R Nav Med Serv** 1995 Winter;81(3):182–9 (19 ref.)

A neurologist's reflections on boxing. I: Impact mechanics in boxing and injuries other than central nervous system damage. Unterharnscheidt F. **Rev Neurol** 1995 May–Jun; 23(121):661–74 (63 ref.)

BRACES

Electromyography and biomechanics of a dynamic knee brace for anterior cruciate ligament deficiency. Acierno SP, et al. **Orthopedics** 1995 Nov;18(11):1101–7 (33 ref.)

Is prophylactic bracing of the ankle cost effective? Jerosch J, et al. **Orthopedics** 1996 May;19(5):405–14 (47 ref.)

Use of back belts in occupational settings. Minor SD. **Phys Ther** 1996 Apr;76(4):403–8 (21 ref.)

Use of knee braces in sport. Current recommendations [editorial] Albright JP, et al. **Sports Med** 1995 Nov; 20(5):281–301 (49 ref.)

[Stabilization of the spine in accident victims] Meertens JH, et al. **Ned Tijdschr Geneeskd** 1996 Aug 10;140(32):1635–9 (30 ref.) **(Dut)**

BRACHIAL PLEXUS

see related
THORACIC OUTLET SYNDROME

Diagnosis and management of brachial plexus lesions in cancer patients. Kori SH. **Oncology (Huntingt)** 1995 Aug; 9(8):756–60; discussion 765 (31 ref.)

ANATOMY & HISTOLOGY

Advanced imaging techniques of the brachial plexus. Panasci DJ, et al. **Hand Clin** 1995 Nov;11(4):545–53 (17 ref.)

Magnetic resonance imaging of the brachial plexus. Reede DL. **Magn Reson Imaging Clin N Am** 1993 Sep;1(1):185–95 (16 ref.)

INJURIES

An approach to obstetrical brachial plexus injuries. Clarke HM, et al. **Hand Clin** 1995 Nov;11(4):563–80; discussion 580–1 (52 ref.)

The role of neurophysiological investigation in traumatic brachial plexus lesions in adults and children. Smith SJ. **J Hand Surg [Br]** 1996 Apr;21(2):145–7 (20 ref.)

Medico-legal aspects of brachial plexus injury: the obstetrician's point of view. Jakobovits A. **Med Law** 1996; 15(1):175–82 (30 ref.)

SURGERY

Electrodiagnosis in the management of brachial plexus surgery. Deletis V, et al. **Hand Clin** 1995 Nov;11(4):555–61 (11 ref.)

BRACHIOCEPHALIC TRUNK

ABNORMALITIES

Left innominate vein compression by a brachiocephalic artery anomaly. Moes CA, et al. **Pediatr Cardiol** 1995 Nov–Dec; 16(6):291–3 (7 ref.)

PATHOLOGY

Innominate artery enlargement in congenital arteriovenous fistula with subsequent tracheal compression and stridor. Döhlemann C, et al. **Pediatr Cardiol** 1995 Nov–Dec; 16(6):287–90 (17 ref.)

SURGERY

Circulatory arrest in a reoperation for brachiocephalic arterial occlusive disease. Bastounis EA, et al. **Ann Thorac Surg** 1996 Apr;61(4):1259–61 (7 ref.)

BRACHIOCEPHALIC VEINS

Migration of jugular or subclavian venous catheters into inferior tributaries of the brachiocephalic veins or into the azygos vein, with possible complications. Currarino G. **Pediatr Radiol** 1996 Jul;26(7):439–49 (52 ref.)

ABNORMALITIES

[Rupture of dissecting aortic aneurysm associated with the right-sided aortic arch and anomalous course of the left brachiocephalic vein—a case report] Kanoh M, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Jul;43(7):1086–91 (14 ref.) (Eng. Abstr.) **(Jpn)**

INJURIES

Acute repair of aorta-innominate vein fistulas. Roye GD, et al. **J Trauma** 1995 Oct;39(4):753–6 (12 ref.)

PHYSIOPATHOLOGY

Left innominate vein compression by a brachiocephalic artery anomaly. Moes CA, et al. **Pediatr Cardiol** 1995 Nov–Dec; 16(6):291–3 (7 ref.)

BRACHIOPODA see INVERTEBRATES

BRACHYDANIO RERIO see ZEBRAFISH

BRACHYTHERAPY

Indications for brachytherapy for brain tumours. Bernstein M, et al. **Acta Neurochir Suppl (Wien)** 1995;63:25–8 (25 ref.)

Brachytherapy in the management of breast cancer: a review. Pieters BR, et al. **Cancer Treat Rev** 1996 Nov;21(6):527–39 (62 ref.)

Endobronchial brachytherapy. Villanueva AG, et al. **Clin Chest Med** 1995 Sep;16(3):445–54 (45 ref.)

Brachytherapy in sarcomas. Harrison LB, et al. **Hematol Oncol Clin North Am** 1995 Aug;9(4):747–63 (32 ref.)

Brachytherapy for pancreatic cancer: a review. Dobelbower RR, et al. **Hepatogastroenterology** 1996 Mar–Apr; 43(8):333–7 (33 ref.)

Operation and permanent low activity 125I brachytheraphy for recurrent high-grade astrocytomas. Halligan JB, et al. **Int J Radiat Oncol Biol Phys** 1996 Jun 1;35(3):541–7 (24 ref.)

125I seeds implantation plus pelvic lymphadenectomy in the management of localized prostate cancer. D'Addessi A, et al. **Minerva Urol Nefrol** 1995 Sep;47(3):105–11 (33 ref.)

Carcinoma of the pancreatic head area. Therapy: intraluminal brachytherapy. Montemaggi P, et al. **Rays** 1995 Jul–Sep; 20(3):338–49 (51 ref.) **(Eng, Ita)**

Treatment of unresectable lung cancer with brachytherapy. Aygun C, et al. **World J Surg** 1995 Nov–Dec;19(6):823–7 (27 ref.)

[Standards, options and recommendations for the practice of external radiotherapy and brachytherapy in oncology. National Federation of Centers for the fight against Cancer] Bey P, et al. **Bull Cancer (Paris)** 1995 Oct;82(10):811–22 (81 ref.) **(Fre)**

[ORL brachytherapy. Salvage brachytherapy in ORL cancers (oral cavity, oropharynx, nasopharynx)] Ardiet JM, et al. **Bull Cancer Radiother** 1995;82(2):199–202 (27 ref.) **(Fre)**

[Time factor and curietherapy: the example of epidermoid carcinoma of the mobile tongue] Mazeron JJ, et al. **Bull Cancer Radiother** 1990;77(1):15–22 (34 ref.) (Eng. Abstr.) **(Fre)**

[Brachytherapy in the treatment of prostatic carcinoma] Casas F, et al. **Actas Urol Esp** 1995 Sep;19(8):662–9 (34 ref.) (Eng. Abstr.) **(Spa)**

INSTRUMENTATION

[Ultrasound studies in afterloading therapy of uterine malignancy] Günter HH, et al. **Ultraschall Med** 1995 Aug; 16(4):162–6 (20 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Endoscopic brachytherapy. Spratling L, et al. **Chest Surg Clin N Am** 1996 May;6(2):293–304 (17 ref.)

Remote controlled high dose rate brachytherapy. Nag S, et al. **Crit Rev Oncol Hematol** 1996 Mar;22(2):127–50 (115 ref.)

Role of interstitial radiotherapy in the management of clinically organ-confined prostate cancer: the jury is still out [see comments] D'Amico AV, et al. **J Clin Oncol** 1996 Jan;14(1):304–15 (35 ref.) Comment in: J Clin Oncol 1996 Jun;14(6):1965. Comment in: J Clin Oncol 1996 Jun;14(6):1965–7.

Endoluminal high-dose-rate brachytherapy with a palliative aim in esophageal cancer: preliminary results at the Institut Gustave Roussy. Rovirosa A, et al. **Tumori** 1995 Sep–Oct; 81(5):359–63 (37 ref.)

[ORL brachytherapy. Brachytherapy of epidermoid carcinoma of the oral cavity] Haie-Meder C, et al. **Bull Cancer Radiother** 1995;82(2):186–90 (42 ref.) **(Fre)**

[ORL brachytherapy. Brachytherapy of squamous cell carcinoma of the oropharynx] Hoffstetter S. **Bull Cancer Radiother** 1995;82(2):191–8 (53 ref.) **(Fre)**

[ORL brachytherapy. Focus on brachytherapy for squamous cell carcinoma of the oral cavity and pharynx] Mazeron JJ. **Bull Cancer Radiother** 1995;82(2):179–85 (68 ref.) **(Fre)**

[Place of iridium 192 implantation in irradiation of T1–T2 squamous cell carcinoma of the velopharyngeal arch] Mazeron JJ, et al. **Bull Cancer Radiother** 1996;83(1):47–53 (43 ref.) (Eng. Abstr.) **(Fre)**

[Value of the combination of external radiotherapy and curietherapy in carcinoma of the velo-tonsillar region. Statistical study of a series of 361 patients] Pernot M, et al. **Bull Cancer Radiother** 1996;83(1):40–6 (32 ref.) (Eng. Abstr.) **(Fre)**

[Contribution of curietherapy in the treatment of ENT tumors] Beauvois S. **Rev Med Brux** 1996 Apr;17(2):86–90 (23 ref.) (Eng. Abstr.) **(Fre)**

TRENDS

Innovations in brachytherapy in gynecologic oncology. Brady LW, et al. **Cancer** 1995 Nov 15;76(10 Suppl):2143–51 (62 ref.)

BRACYTELES see CEBIDAE

BRADYARRHYTHMIA see BRADYCARDIA

BRADYCARDIA

BRADYCARDIA

DIAGNOSIS

Normal sinus heart rate: appropriate rate thresholds for sinus tachycardia and bradycardia. Spodick DH. **South Med J** 1996 Jul;89(7):666–7 (9 ref.)

ETIOLOGY

The mystery of bradyasystole during cardiac arrest. Ornato JP, et al. **Ann Emerg Med** 1996 May;27(5):576–87 (233 ref.)

[Bradycardia in sleep–related respiratory disorders. Clinical relevance, pathogenesis and therapy] Koehler U, et al. **Dtsch Med Wochenschr** 1995 Oct 6;120(40):1369–73 (26 ref.) **(Ger)**

[Acute life–threatening bradycardia: food poisoning by Turkish wild honey] von Malottki K, et al. **Dtsch Med Wochenschr** 1996 Jul 26;121(30):936–8 (8 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

The current status of the implantable cardioverter defibrillator. Gillis AM. **Annu Rev Med** 1996;47:85–93 (20 ref.)

Basic principles of permanent cardiac pacing. Rozkovec A. **Br J Hosp Med** 1996 Jan 17–Feb 6;55(1–2):31–7 (16 ref.)

Advances in pacing. Skehan JD. **Br J Hosp Med** 1996 Jan 17–Feb 6;55(1–2):41–3 (6 ref.)

BRADYKININ

see related
RECEPTORS, BRADYKININ

METABOLISM

Adenosine and bradykinin: are they independent triggers of preconditioning? Miura T. **Basic Res Cardiol** 1996 Jan–Feb; 91(1):20–2 (14 ref.)

PHYSIOLOGY

Bradykinin as an endogenous myocardial protective substance with particular reference to ischemic preconditioning––a brief review of the evidence. Parratt JR, et al. **Can J Physiol Pharmacol** 1995 Jul;73(7):837–42 (36 ref.)

Role of bradykinin in the antihypertensive and cardioprotective actions of converting enzyme inhibitors. Zhu YC, et al. **Can J Physiol Pharmacol** 1995 Jul; 73(7):827–31 (39 ref.)

Molecular responses of endothelial tissue to kinins. Busse R, et al. **Diabetes** 1996 Jan;45 Suppl 1:S8–13 (70 ref.)

Potential role of bradykinin in forearm muscle metabolism in humans. Dietze GJ, et al. **Diabetes** 1996 Jan;45 Suppl 1:S110–4 (43 ref.)

Modulation of insulin receptor signaling. Potential mechanisms of a cross talk between bradykinin and the insulin receptor. Häring HU, et al. **Diabetes** 1996 Jan;45 Suppl 1:S115–9 (35 ref.)

Role of kinins in the pathophysiology of myocardial ischemia. In vitro and in vivo studies. Linz W, et al. **Diabetes** 1996 Jan;45 Suppl 1:S51–8 (62 ref.)

Cardiovascular hypertrophy: role of angiotensin II and bradykinin. Waeber B, et al. **J Cardiovasc Pharmacol** 1996; 27 Suppl 2:S36–40 (37 ref.)

BRADYKININ RECEPTORS see **RECEPTORS, BRADYKININ**

BRAIN

[The effect of angioplasty on cerebral vasomotor reactivity in patients with important stenosis of the internal carotid artery] Arenas C, et al. **Rev Neurol** 1996 Feb;24(126):224–6 (12 ref.) (Eng. Abstr.) **(Spa)**

ABNORMALITIES

Imaging of the cobblestone lissencephalies [comment] Barkovich AJ. **AJNR Am J Neuroradiol** 1996 Apr; 17(4):615–8 (56 ref.) Comment on: AJNR Am J Neuroradiol 1996 Apr;17(4):605–13.

Distinct skeletal abnormalities in four girls with Shprintzen–Goldberg syndrome. Adès LC, et al. **Am J Med Genet** 1995 Jul 17;57(4):565–72 (13 ref.)

Detection of a subtle rearrangement of chromosome 22 using molecular techniques. Biesecker LG, et al. **Am J Med Genet** 1995 Sep 25;58(4):389–94 (15 ref.)

Patient with craniosynostosis and marfanoid phenotype (Shprintzen–Goldberg syndrome) and cloverleaf skull. Saal HM, et al. **Am J Med Genet** 1995 Jul 17;57(4):573–8 (16 ref.)

Fryns syndrome survivors and neurologic outcome. Van Hove JL, et al. **Am J Med Genet** 1995 Nov 20;59(3):334–40 (39 ref.)

Happenstance, circumstance or enemy action: cyclin D1 in breast, eye and brain. Schmidt EV. **Bioessays** 1996 Jan; 18(1):6–8 (29 ref.)

Joint dislocation and cerebral anomalies are consistently associated with oral–facial–digital syndrome type IV. Digilio MC, et al. **Clin Genet** 1995 Sep;48(3):156–9 (11 ref.)

Pictorial review: MR imaging of neuronal migration anomalies. Boardman P, et al. **Clin Radiol** 1996 Jan; 51(1):11–7 (17 ref.)

Brief report: neuroimaging in autism: the state of the science 1995. Filipek PA. **J Autism Dev Disord** 1996 Apr; 26(2):211–5 (21 ref.)

Syndromes with lissencephaly. Pilz DT, et al. **J Med Genet** 1996 Apr;33(4):319–23 (20 ref.)

The Aicardi–Goutières syndrome (familial, early onset encephalopathy with calcifications of the basal ganglia and chronic cerebrospinal fluid lymphocytosis). Tolmie JL, et al. **J Med Genet** 1995 Nov;32(11):881–4 (26 ref.)

Central neuronal tumors in childhood: relationship to dysplasia. Becker LE. **J Neurooncol** 1995;24(1):13–9 (32 ref.)

Malformations of the brain. Norman MG. **J Neuropathol Exp Neurol** 1996 Feb;55(2):133–43 (47 ref.)

MRI in cerebral developmental malformations and epilepsy. Kuzniecky RI. **Magn Reson Imaging** 1995;13(8):1137–45 (31 ref.)

Lissencephaly and other malformations of cortical development: 1995 update. Dobyns WB, et al. **Neuropediatrics** 1995 Jun;26(3):132–47 (70 ref.)

Orofaciodigital syndrome type I in a patient with severe CNS defects. Leão MJ, et al. **Pediatr Neurol** 1995 Oct; 13(3):247–51 (34 ref.)

[Isotretinoin (RoAccutane) embryopathy. A case report] Pilorget H, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(5):511–5 (14 ref.) (Eng. Abstr.) **(Fre)**

[Schimmelpenning–Feuerstein–Mims syndrome and its neurologic manifestations. 6 personal cases and review of the literature] Fritzsch C, et al. **Klin Padiatr** 1995 Sep–Oct; 207(5):288–97 (40 ref.) (Eng. Abstr.) **(Ger)**

ANATOMY & HISTOLOGY

The Mackenzie Davidson Memorial Lecture: detection of small changes to the brain with serial magnetic resonance imaging. Bydder GM. **Br J Radiol** 1995 Dec; 68(816):1271–95 (17 ref.)

Advanced application of magnetic resonance imaging in human brain science. Caviness VS Jr, et al. **Brain Dev** 1995 Nov–Dec;17(6):399–408 (61 ref.)

Structural brain imaging in schizophrenia. Pfefferbaum A, et al. **Clin Neurosci** 1995;3(2):105–11 (82 ref.)

Homology in the evolution of the cerebral hemispheres. The case of reptilian dorsal ventricular ridge and its possible correspondence with mammalian neocortex. Aboitiz F. **J Hirnforsch** 1995;36(4):461–72 (84 ref.)

Magnetic resonance imaging of brain iron in health and disease. Vymazal J, et al. **J Neurol Sci** 1995 Dec;134 Suppl:19–26 (55 ref.)

The brain and the lymphatic system (I). Földi M. **Lymphology** 1996 Mar;29(1):1–9 (46 ref.)

[Pathogenesis of schizophrenia. Illustrated by anatomical, physiological and neuropsychological aspects of the brain] Nielsen JR. **Ugeskr Laeger** 1996 Jul 22;158(30):4278–82 (40 ref.) (Eng. Abstr.) **(Dan)**

[Human brain function makes magnetic resonance imaging live] Hakumäki J, et al. **Duodecim** 1994;110(11):1068–75 (23 ref.) **(Fin)**

[Cognitive neuroanatomy of language: contribution of functional cerebral imaging] Habib M, et al. **Rev Neurol (Paris)** 1996 Apr;152(4):249–60 (63 ref.) (Eng. Abstr.) **(Fre)**

[The brain of the Agnatha] Kusunoki T, et al. **Kaibogaku Zasshi** 1995 Oct;70(5):436–47 (57 ref.) (Eng. Abstr.) **(Jpn)**

BLOOD SUPPLY

Amyloid beta–protein induces the cerebrovascular cellular pathology of Alzheimer's disease and related disorders. Van Nostrand WE, et al. **Ann N Y Acad Sci** 1996 Jan 17; 777:297–302 (19 ref.)

Intracranial pressure and cerebral arterial flow velocity indices in childhood hydrocephalus: current review. Goh D, et al. **Childs Nerv Syst** 1995 Jul;11(7):392–6 (25 ref.)

Venous disease and tumors. Knopp EA. **Magn Reson Imaging Clin N Am** 1995 Aug;3(3):509–28 (22 ref.)

Regional cerebral blood flow in schizophrenia and the local circuit neurons hypothesis. Bachneff SA. **Schizophr Bull** 1996;22(1):163–82 (160 ref.)

Magnetic resonance imaging of human brain function. Moseley ME, et al. **Surg Neurol** 1996 Apr;45(4):385–91 (12 ref.)

Near infrared spectroscopy: methodological principles and clinical application in preterm infants. Bernert G, et al. **Wien Klin Wochenschr** 1995;107(19):569–73 (36 ref.)

[The significance of so–called "high–intensity transient signals" (HITS) during transcranial Doppler sonography] Sliwka U, et al. **Dtsch Med Wochenschr** 1995 Dec 1; 120(48):1667–70 (28 ref.) **(Ger)**

[Investigation of cerebrovascular reactivity using transcranial doppler ultrasonography] Sapieja W. **Neurol Neurochir Pol** 1995 Jul–Aug;29(4):591–5 (24 ref.) (Eng. Abstr.) **(Pol)**

CYTOLOGY

Microglia: intrinsic immuneffector cell of the brain. Gehrmann J, et al. **Brain Res Brain Res Rev** 1995 Mar; 20(3):269–87 (122 ref.)

Cell protective role of melatonin in the brain. Acuña–Castroviejo D, et al. **J Pineal Res** 1995 Sep; 19(2):57–63 (66 ref.)

Intercellular communication in the brain: wiring versus volume transmission. Agnati LF, et al. **Neuroscience** 1995 Dec;69(3):711–26 (159 ref.)

DRUG EFFECTS

How does trimethyltin affect the brain: facts and hypotheses. Koczyk D. **Acta Neurobiol Exp (Warsz)** 1996;56(2):587–96 (85 ref.)

Vigabatrin: effect on brain GABA levels measured by nuclear magnetic resonance spectroscopy. Mattson RH, et al. **Acta Neurol Scand Suppl** 1995;162:27–30 (16 ref.)

Role of acetaldehyde in the actions of ethanol on the brain––a review. Hunt WA. **Alcohol** 1996 Mar–Apr;13(2):147–51 (66 ref.)

Conference summary: Consensus Conference on Alcohol Dependence and the Role of Pharmacotherapy in its Treatment. Chick J, et al. **Alcohol Clin Exp Res** 1996 Apr; 20(2):391–402 (82 ref.)

Cocaine–associated agitated delirium and the neuroleptic malignant syndrome. Wetli CV, et al. **Am J Emerg Med** 1996 Jul;14(4):425–8 (18 ref.)

Initiation and adaptation: a paradigm for understanding psychotropic drug action. Hyman SE, et al. **Am J Psychiatry** 1996 Feb;153(2):151–62 (49 ref.)

Neuroprotective properties of the uncompetitive NMDA receptor antagonist remacemide hydrochloride. Palmer GC, et al. **Ann N Y Acad Sci** 1995 Sep 15;765:236–47; discussion 248 (38 ref.)

Quantitative histological evaluation of neuroprotective compounds. Scallet AC. **Ann N Y Acad Sci** 1995 Sep 15; 765:47–58; discussion 59–61 (39 ref.)

Dexamethasone and the prevention of neonatal hypoxic–ischemic brain damage. Tuor UI. **Ann N Y Acad Sci** 1995 Sep 15;765:179–95; discussion 196–7 (97 ref.)

Developmental neurotoxicology in the neonate––effects of pesticides and polychlorinated organic substances. Eriksson P. **Arch Toxicol Suppl** 1996;18:81–8 (26 ref.)

The neurobehavioural toxicology and teratology of lead. Winneke G, et al. **Arch Toxicol Suppl** 1996;18:57–70 (60 ref.)

Psychopharmacology of Alzheimer's disease. Procter AW. **Br J Hosp Med** 1996 Feb 21–Mar 5;55(4):191–4 (20 ref.)

Pre–clinical pharmacology of atypical antipsychotic drugs: a selective review. Meltzer HY. **Br J Psychiatry Suppl** 1996 May;(29):23–31 (130 ref.)

Behavioral toxicology. Needleman HL. **Environ Health Perspect** 1995 Sep;103 Suppl 6:77–9 (15 ref.)

Developing brain as a target of toxicity. Rodier PM. **Environ Health Perspect** 1995 Sep;103 Suppl 6:73–6 (32 ref.)

Pharmacology and pharmacokinetics of citalopram and other SSRIs. Baumann P. **Int Clin Psychopharmacol** 1996 Mar; 11 Suppl 1:5–11 (62 ref.)

Central nervous system toxicity of cancer therapy in children. Moore IM. **J Pediatr Oncol Nurs** 1995 Oct;12(4):203–10; discussion 211 (50 ref.)

Sites, mechanisms, and structural characteristics of the brain's nicotine receptor. Abood LG, et al. **J Subst Abuse** 1989; 1(3):259–71 (50 ref.)

Differential effect of chronic nicotine treatment on nicotinic receptor numbers in various brain regions of mice. Collins AC, et al. **J Subst Abuse** 1989;1(3):273–86 (43 ref.)

Neurochemical correlates of antiepileptic drugs in the genetically epilepsy–prone rat (GEPR). Dailey JW, et al. **Life Sci** 1995;58(4):259–66 (49 ref.)

Cerebral metabolic effects of serotonin drugs and neurotoxins. Freo U. **Life Sci** 1996;59(11):877–91 (109 ref.)

The AF64A model of cholinergic hypofunction: an update. Hanin I. **Life Sci** 1996;58(22):1955–64 (66 ref.)

The use of toxicokinetics for the safety assessment of drugs acting in the brain. Campbell DB. **Mol Neurobiol** 1995 Aug–Dec;11(1–3):193–216 (125 ref.)

Under siege: The brain on opiates. Nestler EJ. **Neuron** 1996 May;16(5):897–900 (26 ref.)

Atypical MRI findings in treatment–related leukoencephalopathy: case report. Ohmoto Y, et al. **Neuroradiology** 1996 Feb;38(2):128–33 (30 ref.)

Prenatal cocaine produces biochemical and functional changes in brain serotonin systems in rat progeny. Battaglia G, et al. **NIDA Res Monogr** 1995;158:115–48 (56 ref.)

Targeting drugs to the brain by sequential metabolism. Bodor N. **NIDA Res Monogr** 1995;147:1–32 (83 ref.)

Effects of cocaine on fetal brain metabolism and behavioral state in the sheep model. Burchfield DJ. **NIDA Res Monogr** 1995;158:58–66 (30 ref.)

Perinatal benzodiazepine modulation of GABAA receptor function: influence on adaptive responses. Kellogg CK. **NIDA Res Monogr** 1995;158:202–26 (78 ref.)

Dopamine, a common substrate for the rewarding effects of brain stimulation reward, cocaine, and morphine. Kornetsky C, et al. **NIDA Res Monogr** 1994;145:19–39 (66 ref.)

Effects of prenatal morphine and cocaine on postnatal behaviors and brain neurotransmitters. Vathy I. **NIDA Res Monogr** 1995;158:88–114 (118 ref.)

NMDA antagonists: antiepileptic–neuroprotective drugs with diversified neuropharmacological profiles. Sagratella S. **Pharmacol Res** 1995 Jul–Aug;32(1–2):1–13 (124 ref.)

Serotonin uptake inhibitors: uses in clinical therapy and in laboratory research. Fuller RW. **Prog Drug Res** 1995; 45:167–204 (280 ref.)

In vivo antisense approaches to the role of immediate early gene expression in the brain. Cirelli C, et al. **Regul Pept** 1995 Oct 20;59(2):151–62 (48 ref.)

GABAergic deafferentation hypothesis of brain aging and Alzheimer's disease; pharmacologic profile of the benzodiazepine antagonist, flumazenil. Marczynski TJ. **Rev Neurosci** 1995 Jul–Sep;6(3):221–58 (164 ref.)

The study of interactive effects of pollutants: a biomarker approach. Johnston G. **Sci Total Environ** 1995 Oct 27; 171(1–3):205–12 (18 ref.)

Neurobehavioral assessment in toxic injury evaluations. Lees–Haley PR. **Toxicol Lett** 1995 Dec;82–83:197–202 (58 ref.)

Neurobehavioural test batteries: current status, critical evaluation and new directions. Williamson AM. **Toxicol Lett** 1995 Dec;82–83:203–9 (34 ref.)

[Glutamate antagonists—a new stage in the development of cerebral protection?] Vasilev D, et al. **Khirurgiia (Sofiia)** 1995;48(5):63–5 (10 ref.) (Eng. Abstr.) **(Bul)**

[Effects of IL-2 on the central nervous system] Jiang CL, et al. **Sheng Li Ko Hsueh Chin Chan** 1995 Oct;26(4):352–4 (10 ref.) **(Chi)**

[Delay in the effect of antidepressive agents: pharmacologic approach] Allain H, et al. **Encephale** 1995 Mar;21 Spec No 2:9–15 (39 ref.) (Eng. Abstr.) **(Fre)**

[Effects of analgesia and sedation on cerebrovascular circulation, cerebral blood volume, cerebral metabolism and intracranial pressure] Werner C. **Anaesthesist** 1995 Dec; 44 Suppl 3:S566–72 (83 ref.) (Eng. Abstr.) **(Ger)**

[Do general anesthetics act on specific receptors?] Urban BW, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Oct;30(6):375–82 (55 ref.) (Eng. Abstr.) **(Ger)**

[Recent developments in antipsychotic medication] Möller HJ. **Schweiz Arch Neurol Psychiatr** 1995;146(5):230–9 (50 ref.) (Eng. Abstr.) **(Ger)**

EMBRYOLOGY

Human prenatal craniofacial development related to brain development under normal and pathologic conditions. Kjaer I. **Acta Odontol Scand** 1995 Jun;53(3):135–43 (69 ref.)

Transient expression of somatostatin receptors in the brain during development. Leroux P, et al. **Ciba Found Symp** 1995;190:127–37; discussion 137–41 (45 ref.)

The brain of the asphyxiated fetus—basic research. Jensen A. **Eur J Obstet Gynecol Reprod Biol** 1996 Mar;65(1):19–24 (57 ref.)

Cadherin expression in the developing vertebrate CNS: from neuromeres to brain nuclei and neural circuits. Redies C. **Exp Cell Res** 1995 Oct;220(2):243–56 (187 ref.)

The vascularization of the developing human brain. Dąmbska M. **Folia Neuropathol** 1995;33(4):189–93 (29 ref.)

Regulation of sex-specific formation of oestrogen in brain development: endogenous inhibitors of aromatase. Hutchison JB, et al. **J Steroid Biochem Mol Biol** 1996 Jan; 56(1–6 Spec No):201–7 (37 ref.)

[Molecular mechanisms for the formation of crossed and uncrossed projections in the brain] Murakami F, et al. **Tanpakushitsu Kakusan Koso** 1996 May;41(6):775–84 (27 ref.) **(Jpn)**

ENZYMOLOGY

Multifunctional calcium and calmodulin-dependent kinase II in neuronal function and disease. Churn SB. **Adv Neuroimmunol** 1995;5(3):241–59 (141 ref.)

Two novel metallopeptidases with a specificity for basic residues: functional properties, structure and cellular distribution. Foulon T, et al. **Ann N Y Acad Sci** 1996 Mar 22;780:106–20 (49 ref.)

Cytochrome P450 in the brain: neuroendocrine functions. Warner M, et al. **Front Neuroendocrinol** 1995 Jul; 16(3):224–36 (50 ref.)

Matrix metalloproteinases in brain injury. Rosenberg GA. **J Neurotrauma** 1995 Oct;12(5):833–42 (69 ref.)

An enzyme/brain-barrier theory of psychiatric pathogenesis: unifying observations on phenylketonuria, autism, schizophrenia and postpartum psychosis. Seim AR, et al. **Med Hypotheses** 1995 Nov;45(5):498–502 (36 ref.)

Monoamine oxidase: distribution in the cat brain studied by enzyme- and immunohistochemistry: recent progress. Kitahama K, et al. **Prog Neurobiol** 1994 Jan;42(1):53–78 (189 ref.)

Localization and characterization of cytochrome P450 in the brain. In vivo and in vitro investigations on phenytoin- and phenobarbital-inducible isoforms. Volk B, et al. **Toxicol Lett** 1995 Dec;82–83:655–62 (11 ref.)

[Heterogenity of diacylglycerol Kinase—Structure, biochemical characteristics and gene expression in the brain] Goto K. **Kaibogaku Zasshi** 1995 Dec;70(6):509–11 (4 ref.) **(Jpn)**

[The role of enzymatic systems in pathophysiology and pharmacotherapy of Parkinson's disease] Kuran W. **Neurol Neurochir Pol** 1995 Jul–Aug;29(4):561–8 (30 ref.) (Eng. Abstr.) **(Pol)**

GROWTH & DEVELOPMENT

In vitro models for the effects of sex hormones on neurons. Lustig RH. **Ann N Y Acad Sci** 1996 Apr 30;784:370–80 (72 ref.)

Neuronal actions of dehydroepiandrosterone. Possible roles in brain development, aging, memory, and affect. Majewska MD. **Ann N Y Acad Sci** 1995 Dec 29;774:111–20 (86 ref.)

A functional role for REM sleep in brain maturation. Marks GA, et al. **Behav Brain Res** 1995 Jul–Aug;69(1–2):1–11 (71 ref.)

Neurotransmitters and vulnerability of the developing brain. Johnston MV. **Brain Dev** 1995 Sep–Oct;17(5):301–6 (42 ref.)

Development and plasticity of the neural circuitry underlying visual recognition memory. Webster MJ, et al. **Can J Physiol Pharmacol** 1995 Sep;73(9):1364–71 (37 ref.)

Developing brain as a target of toxicity. Rodier PM. **Environ Health Perspect** 1995 Sep;103 Suppl 6:73–6 (32 ref.)

Developmental aspects of epileptogenesis. Johnston MV. **Epilepsia** 1996;37 Suppl 1:S2–9 (64 ref.)

Thyroid hormones and brain development. Bernal J, et al. **Eur J Endocrinol** 1995 Oct;133(4):390–8 (68 ref.)

Effects of growth hormone on cerebral development: morphological studies. Noguchi T. **Horm Res** 1996; 45(1–2):5–17 (41 ref.)

Role of goitrogens in iodine deficiency disorders & brain development. Rao PS, et al. **Indian J Med Res** 1995 Nov; 102:223–6 (16 ref.)

Role of proteoglycans in neural development, regeneration, and the aging brain. Small DH, et al. **J Neurochem** 1996 Sep;67(3):889–99 (140 ref.)

The genetics of brain development: conserved programs in flies and mice. Thor S. **Neuron** 1995 Nov;15(5):975–7 (18 ref.)

The gene knockout technology for the analysis of learning and memory, and neural development. Tonegawa S, et al. **Prog Brain Res** 1995;105:3–14 (43 ref.)

Breastfeeding for optimal mental development. The alpha and the omega in human milk. de Andraca I, et al. **World Rev Nutr Diet** 1995;78:1–27 (74 ref.)

[Neurogenesis of brain space of song learning in adult songbirds] Li DF. **Sheng Li Ko Hsueh Chin Chan** 1995 Jul;26(3):273–5 (10 ref.) **(Chi)**

[Polyunsaturated fatty acids and cerebral-sensory development in infants (editorial)] Ghisolfi J. **Arch Pediatr** 1995 Sep;2(9):825–30 (15 ref.) **(Fre)**

IMMUNOLOGY

Microglia: intrinsic immuneffector cell of the brain. Gehrmann J, et al. **Brain Res Brain Res Rev** 1995 Mar; 20(3):269–87 (122 ref.)

Markers of neurotoxicity: from behavior to autoantibodies against brain proteins. Evans HL. **Clin Chem** 1995 Dec; 41(12 Pt 2):1874–81 (116 ref.)

The neurological basis of fever. Samii A. **Surg Neurol** 1996 Apr;45(4):392–3 (11 ref.)

METABOLISM

Is lead toxicosis a reflection of altered energy metabolism in brain synaptosomes? Rafałowska U, et al. **Acta Neurobiol Exp (Warsz)** 1996;56(2):611–7 (30 ref.)

Brain swelling after dialysis: old urea or new osmoles? Silver SM, et al. **Am J Kidney Dis** 1996 Jul;28(1):1–13 (49 ref.)

Modulatory actions of corticotropin-releasing factor-binding protein. Behan DP, et al. **Ann N Y Acad Sci** 1996 Mar 22;780:81–95 (55 ref.)

High affinity choline transporter status in Alzheimer's disease tissue from rapid autopsy. Bissette G, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:197–204 (12 ref.)

Postmortem and cerebrospinal fluid studies of corticotropin-releasing factor in humans. Hartline KM, et al. **Ann N Y Acad Sci** 1996 Mar 22;780:96–105 (44 ref.)

Free intracellular calcium in aging and Alzheimer's disease. Müller WE, et al. **Ann N Y Acad Sci** 1996 Jun 15;786:305–20 (55 ref.)

Regulation of APP processing. Potential for the therapeutical reduction of brain amyloid burden. Nitsch RM, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:175–82 (28 ref.)

Adenosine: a prototherapeutic concept in neurodegeneration. von Lubitz DK, et al. **Ann N Y Acad Sci** 1995 Sep 15; 765:163–78; discussion 196–7 (123 ref.)

Function and metabolism of brain synaptosomes in chronic renal failure. Smogorzewski M, et al. **Artif Organs** 1995 Aug;19(8):795–800 (55 ref.)

Role of cyclic AMP in the actions of cannabinoid receptors. Childers SR, et al. **Biochem Pharmacol** 1996 Sep 27; 52(6):819–27 (68 ref.)

Expression of newly cloned brain dopamine receptors in peripheral organs. O'Connell DP. **Biochem Soc Trans** 1996 Feb;24(1):169–72 (16 ref.)

A putative receptor for neurosteroids on the GABAA receptor complex: the pharmacological properties and therapeutic potential of epalons. Gee KW, et al. **Crit Rev Neurobiol** 1995;9(2–3):207–27 (102 ref.)

Xenobiotic metabolism in brain. Ravindranath V, et al. **Drug Metab Rev** 1995;27(3):419–48 (117 ref.)

Involvement of brain catecholamines and acetylcholine in growth hormone hypersecretory states. Pathophysiological, diagnostic and therapeutic implications. Müller EE, et al. **Drugs** 1995 Nov; 50(5):805–37 (285 ref.)

Magnetic resonance studies of the effects of cardiovascular surgery on brain metabolism and function. Deslauriers R, et al. **J Cardiothorac Vasc Anesth** 1996 Jan;10(1):127–37; quiz 137–8 (49 ref.)

Near-infrared spectroscopy: theory and applications. Wahr JA, et al. **J Cardiothorac Vasc Anesth** 1996 Apr; 10(3):406–18 (96 ref.)

Implantable pumps for drug delivery to the brain. Bakhshi S, et al. **J Neurooncol** 1995 Nov;26(2):133–9 (68 ref.)

Distribution of drugs following controlled delivery to the brain interstitium. Mak M, et al. **J Neurooncol** 1995 Nov; 26(2):91–102 (61 ref.)

Cerebral metabolic rate and hypothermia: their relationship with ischemic neurologic injury. Lanier WL. **J Neurosurg Anesthesiol** 1995 Jul;7(3):216–21 (31 ref.)

Transgenic mice and knockout mutants in the study of oxidative stress in brain injury. Chan PH, et al. **J Neurotrauma** 1995 Oct;12(5):815–24 (63 ref.)

Changes in gene expression following traumatic brain injury in the rat. Hayes RL, et al. **J Neurotrauma** 1995 Oct; 12(5):779–90 (59 ref.)

The neurochemical and metabolic cascade following brain injury: moving from animal models to man. Hovda DA, et al. **J Neurotrauma** 1995 Oct;12(5):903–6 (27 ref.)

Neurotrophic factors in central nervous system trauma. Mocchetti I, et al. **J Neurotrauma** 1995 Oct;12(5):853–70 (186 ref.)

The calcium hypothesis of brain aging and neurodegenerative disorders: significance in diabetic neuropathy. Biessels G, et al. **Life Sci** 1996;59(5–6):379–87 (67 ref.)

Decreased plasma membrane calcium transport activity in aging brain. Michaelis ML, et al. **Life Sci** 1996; 59(5–6):405–12 (16 ref.)

Effect of dietary docosahexaenoic acid on brain composition and neural function in term infants. Gibson RA, et al. **Lipids** 1996 Mar;31 Suppl:S177–81 (28 ref.)

Schizophrenia, suicide and the serotonin story. Holden RJ. **Med Hypotheses** 1995 May;44(5):379–91 (85 ref.)

Regulation of neuropeptide expression in the brain by neurotrophins. Potential role in vivo. Carnahan J, et al. **Mol Neurobiol** 1995 Apr–Jun;10(2–3):135–49 (107 ref.)

Somatic mutations in the brain: relationship to aging? Evans DA, et al. **Mutat Res** 1995 Oct;338(1–6):173–82 (47 ref.)

APP transgenesis: approaches toward the development of animal models for Alzheimer disease neuropathology. Greenberg BD, et al. **Neurobiol Aging** 1996 Mar–Apr; 17(2):153–71 (323 ref.)

Free radicals and disruption of neuronal ion homeostasis in AD: a role for amyloid beta-peptide? [comment] Mattson MP. **Neurobiol Aging** 1995 Jul–Aug;16(4):679–82; discussion 683 (40 ref.) Comment on: Neurobiol Aging 1995 Jul–Aug;16(4):661–74.

Platelet-activating factor is a synapse messenger and a modulator of gene expression in the nervous system. Bazan NG, et al. **Neurochem Int** 1995 May;26(5):435–41 (72 ref.)

Enzymes of platelet activating factor synthesis in brain. Baker RR. **Neurochem Res** 1995 Nov;20(11):1345–51 (70 ref.)

Alpha-methyl-L-tryptophan as a tracer to study brain serotonergic system. Diksic M, et al. **Neurochem Res** 1995 Nov;20(11):1353–60 (51 ref.)

The stress response. Brown IR. **Neuropathol Appl Neurobiol** 1995 Dec;21(6):473–5 (5 ref.)

Anatomical pathways for lymphatic drainage of the brain and their pathological significance. Kida S, et al. **Neuropathol Appl Neurobiol** 1995 Jun;21(3):181–4 (17 ref.)

Cerebral blood flow in severe clinical head injury. Bouma GJ, et al. **New Horiz** 1995 Aug;3(3):384–94 (52 ref.)

Cerebral metabolic management. Robertson CS, et al. **New Horiz** 1995 Aug;3(3):410–22 (97 ref.)

Vector-mediated delivery of opioid peptides to the brain. Bickel U, et al. **NIDA Res Monogr** 1995;154:28–46 (39 ref.)

Targeting drugs to the brain by sequential metabolism. Bodor N. **NIDA Res Monogr** 1995;147:1–32 (83 ref.)

In vivo quantitation of metabolite concentrations in the brain by means of proton MRS. Henriksen O. **NMR Biomed** 1995 Jun;8(4):139–48 (76 ref.)

Structure and pharmacology of gamma-aminobutyric acidA receptor subtypes. Sieghart W. **Pharmacol Rev** 1995 Jun; 47(2):181–234 (504 ref.)

Alpha 2-adrenoceptors and I2 sites in the mammalian central nervous system. French N. **Pharmacol Ther** 1995; 68(2):175–208 (300 ref.)

Structure and function of voltage-dependent sodium channels: comparison of brain II and cardiac isoforms. Fozzard HA, et al. **Physiol Rev** 1996 Jul;76(3):887–926 (258 ref.)

Organ fuel selection: brain. Amiel SA. **Proc Nutr Soc** 1995 Mar;54(1):151–5 (20 ref.)

N-acetylaspartate in neuropsychiatric disorders. Tsai G, et al. **Prog Neurobiol** 1995 Aug;46(5):531–40 (178 ref.)

Brain angiotensin receptor subtypes AT1, AT2, and AT4 and their functions. Wright JW, et al. **Regul Pept** 1995 Nov 10;59(3):269–95 (294 ref.)

Lipofuscin and ceroid pigments in aging and brain pathology. A review. I. Biochemical and morphological properties. Riga D, et al. **Rom J Neurol Psychiatry** 1995 Apr–Jun; 33(2):121–36 (107 ref.)

Exercise and brain neurotransmission. Meeusen R, et al. **Sports Med** 1995 Sep;20(3):160–88 (117 ref.)

Blood–brain interfaces: relevance to cerebral drug metabolism. Ghersi-Egea JF, et al. **Toxicol Lett** 1995 Dec; 82–83:645–53 (37 ref.)

Xenobiotic metabolism in brain. Ravindranath V, et al. **Toxicol Lett** 1995 Dec;82–83:633–8 (19 ref.)

[Brain neurochemical systems which control appetite] Pesonen U, et al. **Duodecim** 1994;110(13):1241–50 (26 ref.) **(Fin)**

[Biological factors in severe depression] Syvälahti E. **Duodecim** 1994;110(3):261–6 (18 ref.) **(Fin)**

[Magnetic resonance spectroscopy: a new technique for the exploration of brain metabolism in pediatrics] Chabrol B, et al. **Arch Pediatr** 1995 Aug;2(8):783–92 (39 ref.) (Eng. Abstr.) **(Fre)**

[Exploration of brain metabolism and hemodynamics in perinatal asphyxia in full–term neonates] Saliba E, et al. **Arch Pediatr** 1996;3 Suppl 1:248s–250s (9 ref.) **(Fre)**

[Expression of neurotrophin proteins in the brain, and its physiological significance] Furukawa S. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1995 Oct; 15(5):405–10 (17 ref.) **(Jpn)**

[Steroid hormone receptors in the CNS from animal models with fatty syndrome] Takeda R. **Nippon Rinsho** 1995 Jun; 53 Suppl:70–4 (13 ref.) **(Jpn)**

[Functional significance of diazepam binding inhibitor (DBI) in establishment of alcohol dependence] Katsura M, et al. **Nippon Yakurigaku Zasshi** 1995 Sep;106(3):217–27 (50 ref.) (Eng. Abstr.) **(Jpn)**

[Ryanodine receptors in the central nervous system] Ogawa Y, et al. **Nippon Yakurigaku Zasshi** 1995 Jun;105(6):423–30 (50 ref.) (Eng. Abstr.) **(Jpn)**

[Biochemical studies on AIDS dementia complex—possible contribution of quinolinic acid during brain damage] Saito K. **Rinsho Byori** 1995 Sep;43(9):891–901 (36 ref.) (Eng. Abstr.) **(Jpn)**

[Nerve growth factor strategy and preparation of animal model for Alzheimer–type senile dementia] Nabeshima T. **Yakugaku Zasshi** 1995 Jul;115(7):499–512 (59 ref.) (Eng. Abstr.) **(Jpn)**

[The role of enzymatic systems in pathophysiology and pharmacotherapy of Parkinson's disease] Kuran W. **Neurol Neurochir Pol** 1995 Jul–Aug;29(4):561–8 (30 ref.) (Eng. Abstr.) **(Pol)**

[Cerebral glucose metabolism in craniocerebral trauma: an evaluation] Schelp AO, et al. **Arq Neuropsiquiatr** 1995 Sep; 53(3–B):698–705 (44 ref.) (Eng. Abstr.) **(Por)**

[Cerebral oximetry] Lubnin AIu, et al. **Anesteziol Reanimatol** 1996 Mar–Apr;(2):85–90 (50 ref.) **(Rus)**

[The role of mediator–metabolic factors in the development of brain edema–swelling] Novikov VE, et al. **Usp Fiziol Nauk** 1996 Apr–Jun;27(2):78–89 (118 ref.) (Eng. Abstr.) **(Rus)**

PATHOLOGY

The neurobiology of Alzheimer's disease. Brion JP. **Acta Clin Belg** 1996;51(2):80–90 (76 ref.)

Protein serine/threonine kinases (PKA, PKC and CaMKII) involved in ischemic brain pathology. Domańska–Janik K. **Acta Neurobiol Exp (Warsz)** 1996;56(2):579–85 (44 ref.)

Making the diagnosis of mixed and non–Alzheimer's dementias. Hansen LA, et al. **Arch Pathol Lab Med** 1995 Nov;119(11):1023–31 (34 ref.)

Neurochemical and morphological changes associated with human epilepsy. Glass M, et al. **Brain Res Brain Res Rev** 1995 Jul;21(1):29–41 (158 ref.)

Motor neuron disease with involvement of the pallido–luysio–nigral system and mesencephalic tegmentum. Kato S, et al. **Clin Neuropathol** 1995 Jul–Aug; 14(4):241–4 (15 ref.)

New morphological and neuropathological findings in schizophrenia: a neurodevelopmental perspective. Bunney BG, et al. **Clin Neurosci** 1995;3(2):81–8 (120 ref.)

Magnetic resonance imaging and spectroscopy in multiple sclerosis. Miller DH. **Curr Opin Neurol** 1995 Jun;8(3):210–5 (44 ref.)

Quantitative neuropathologic assessment of HIV–1 encephalitis. Wiley CA. **Curr Top Microbiol Immunol** 1995; 202:55–61 (32 ref.)

Neuroimaging in pediatric epilepsy. Kuzniecky RI. **Epilepsia** 1996;37 Suppl 1:S10–21 (77 ref.)

Inflammatory mechanisms in Alzheimer's disease. Hüll M, et al. **Eur Arch Psychiatry Clin Neurosci** 1996;246(3):124–8 (36 ref.)

Neuroimaging in child and adolescent neuropsychiatric disorders. Peterson BS. **J Am Acad Child Adolesc Psychiatry** 1995 Dec; 34(12):1560–76 (115 ref.)

Brief report: neuroanatomic observations of the brain in pervasive developmental disorders. Bauman ML. **J Autism Dev Disord** 1996 Apr;26(2):199–203 (18 ref.)

Quantitative computed tomography and magnetic resonance imaging in aging and Alzheimer's disease. A review. Smith CD. **J Neuroimaging** 1996 Jan;6(1):44–53 (122 ref.)

Clinical, radiological, and therapeutic features of pleomorphic xanthoastrocytoma: report of three patients and review of the literature. van Roost D, et al. **J Neurol Neurosurg Psychiatry** 1996 Jun;60(6):690–2 (12 ref.)

Malformations of the brain. Norman MG. **J Neuropathol Exp Neurol** 1996 Feb;55(2):133–43 (47 ref.)

Can schizophrenia be localized? Trimble MR. **J Neuropsychiatry Clin Neurosci** 1991 Winter;3(1):89–94 (12 ref.)

Cerebral metabolic rate and hypothermia: their relationship with ischemic neurologic injury. Lanier WL. **J Neurosurg Anesthesiol** 1995 Jul;7(3):216–21 (31 ref.)

Neuronal apoptosis: current understanding of molecular mechanisms and potential role in ischemic brain injury. Johnson EM JR, et al. **J Neurotrauma** 1995 Oct; 12(5):843–52 (102 ref.)

Mechanisms of secondary brain damage in global and focal ischemia: a speculative synthesis. Siesjö BK, et al. **J Neurotrauma** 1995 Oct;12(5):943–56 (113 ref.)

Canavan disease: from spongy degeneration to molecular analysis. Matalon R, et al. **J Pediatr** 1995 Oct;127(4):511–7 (75 ref.)

Magnetic resonance imaging in epilepsy. Jack CR Jr. **Mayo Clin Proc** 1996 Jul;71(7):695–711 (70 ref.)

Progressive multifocal leukoencephalopathy: a review of the pathology and pathogenesis. Aksamit AJ Jr. **Microsc Res Tech** 1995 Nov 1;32(4):302–11 (39 ref.)

The canine as an animal model of human aging and dementia. Cummings BJ, et al. **Neurobiol Aging** 1996 Mar–Apr; 17(2):259–68 (106 ref.)

Magnetic resonance imaging. Neuroimaging and anatomy. Jack CR Jr. **Neuroimaging Clin N Am** 1995 Nov; 5(4):597–622 (94 ref.)

Grumose or foamy spheroid bodies involving astrocytes in the human brain. Arai N. **Neuropathol Appl Neurobiol** 1995 Jun;21(3):238–45 (27 ref.)

Diffusion–weighted NMR imaging: application to experimental focal cerebral ischemia. Hoehn–Berlage M. **NMR Biomed** 1995 Nov–Dec;8(7–8):345–58 (103 ref.)

Magnetic resonance imaging of the aging brain in Down syndrome. Emerson JF, et al. **Prog Clin Biol Res** 1995; 393:123–38 (28 ref.)

Ischemic stroke and incomplete infarction. Garcia JH, et al. **Stroke** 1996 Apr;27(4):761–5 (48 ref.)

The neurobiology of canine distemper virus infection. Vandevelde M, et al. **Vet Microbiol** 1995 May; 44(2–4):271–80 (57 ref.)

Magnetic resonance imaging of multiple sclerosis lesions. Measuring outcome in treatment trials [see comments] Simon JH. **West J Med** 1996 Jun;164(6):502–9 (71 ref.) Comment in: West J Med 1996 Jun;164(6):531–2.

[Multiple intracerebral granulocytic sarcomas in a patient with chronic myeloid leukemia] Grondin L, et al. **Can Assoc Radiol J** 1996 Apr;47(2):132–5 (12 ref.) (Eng. Abstr.) **(Fre)**

[Cadasil—a new model for subcortical dementia] Davous P, et al. **Rev Neurol (Paris)** 1995 Nov;151(11):634–9 (31 ref.) (Eng. Abstr.) **(Fre)**

[Patchy changes in white matter in cranial computerized and magnetic resonance tomography—significance for (differential) diagnosis of dementia of the Alzheimer type and vascular dementia] Stoppe G, et al. **Fortschr Neurol Psychiatr** 1995 Nov;63(11):425–40 (150 ref.) (Eng. Abstr.) **(Ger)**

[Echo–planar imaging of the brain] Brüning R, et al. **Radiologe** 1995 Dec;35(12):902–10 (61 ref.) (Eng. Abstr.) **(Ger)**

[Fast and ultra–fast MRI of the brain] Schuierer G, et al. **Radiologe** 1995 Dec;35(12):894–901 (25 ref.) (Eng. Abstr.) **(Ger)**

[Clinical application of functional mapping; the present state of the art and its future prospects: (series 1) functional MRI: signal mechanism of fMRI and quantification of brain function by echo planar imaging] Naruse S, et al. **No Shinkei Geka** 1996 Jan;24(1):7–17 (55 ref.) **(Jpn)**

[An autopsy case of "diffuse neurofibrillary tangles with calcification", multiple infarctions and hyaline arteriosclerosis] Arai T, et al. **No To Shinkei** 1996 Jan; 48(1):69–76 (26 ref.) (Eng. Abstr.) **(Jpn)**

[Serial changes of MRI and SPECT findings in a case of adult–onset SSPE] Kunika N, et al. **Rinsho Shinkeigaku** 1995 Nov;35(11):1214–20 (26 ref.) (Eng. Abstr.) **(Jpn)**

[Morphological analysis of NCAM–180 deficient mouse brain—polysialic acid moiety and neuronal migration] Ono K. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2188–96 (44 ref.) **(Jpn)**

[Magnetic resonance of brain involvement in progressive facial hemiatrophy (Romberg's disease). Reconsideration of a syndrome] Terstegge K, et al. **Arq Neuropsiquiatr** 1995 Mar;53(1):98–113 (54 ref.) (Eng. Abstr.) **(Por)**

[Progressive aphasia without dementia—the onset of an atrophic process of the brain] Kadykov AS, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1996;96(1):42–4 (11 ref.) (Eng. Abstr.) **(Rus)**

[Behr's syndrome. A report of 2 siblings studied by MR] Pascual–Castroviejo I, et al. **An Esp Pediatr** 1996 Jun; 44(6):593–5 (11 ref.) **(Spa)**

[Cranial NMR in the late diagnosis of congenital rubella] Ruiz Pérez JJ, et al. **An Esp Pediatr** 1996 Jun;44(6):585–7 (20 ref.) **(Spa)**

[Mid–line cerebral tumors in children] Weil RJ, et al. **Rev Neurol** 1995;23 Suppl 3:S368–72 (31 ref.) **(Spa)**

[Signal changes in the cerebral white matter. Common findings by MRI examinations of the elderly] Bronge LH, et al. **Lakartidningen** 1996 Apr 17;93(16):1529–33 (67 ref.) **(Swe)**

PHYSIOLOGY

c–Fos expression as a tool to search for the neurobiological base of the sexual behaviour of males. Bialy M, et al. **Acta Neurobiol Exp (Warsz)** 1996;56(2):567–77 (52 ref.)

Hemispheric asymmetry for visual information processing. Hellige JB. **Acta Neurobiol Exp (Warsz)** 1996;56(1):485–97 (66 ref.)

Carnitine—a known compound, a novel function in neural cells. Nałęcz KA, et al. **Acta Neurobiol Exp (Warsz)** 1996; 56(2):597–609 (86 ref.)

Is the central nervous system a target for growth hormone and insulin–like growth factors? Han VK. **Acta Paediatr Suppl** 1995 Sep;411:3–8 (63 ref.)

Angiotensin and the brain. Andersson B, et al. **Acta Physiol Scand** 1995 Oct;155(2):117–25 (52 ref.)

The role of neuroimaging in the discovery of processing stages. A review. Mulder G, et al. **Acta Psychol (Amst)** 1995 Nov;90(1–3):63–79 (66 ref.)

Neurobiology of breathing control. Where to look and what to look for. Feldman JL. **Adv Exp Med Biol** 1995;393:3–5 (2 ref.)

Some positive effects of transcranial magnetic stimulation. Amassian VE, et al. **Adv Neurol** 1995;67:79–106 (62 ref.)

Transcranial magnetic stimulation. Negative effects. Hallett M. **Adv Neurol** 1995;67:107–13 (40 ref.)

Cortical electrical stimulation in humans. The negative motor areas. Lüders HO, et al. **Adv Neurol** 1995;67:115–29 (66 ref.)

Biologic differences between early– and late–onset Alzheimer disease. Terry RD. **Alzheimer Dis Assoc Disord** 1995;9 Suppl 1:S26–7 (7 ref.)

The social construction of the human brain. Eisenberg L. **Am J Psychiatry** 1995 Nov;152(11):1563–75 (163 ref.)

Androgens, brain, and behavior. Rubinow DR, et al. **Am J Psychiatry** 1996 Aug;153(8):974–84 (179 ref.)

Brain imaging and cognitive neuroscience. Toward strong inference in attributing function to structure. Sarter M, et al. **Am Psychol** 1996 Jan;51(1):13–21 (75 ref.)

Neuroprotective use–dependent blockers of Na+ and Ca2+ channels controlling presynaptic release of glutamate. Goldin SM, et al. **Ann N Y Acad Sci** 1995 Sep 15;765:210–29 (59 ref.)

Galanin and 5–HT1A receptor interactions as an integrative mechanism in 5–HT neurotransmission in the brain. Hedlund PB, et al. **Ann N Y Acad Sci** 1996 Mar 22; 780:193–212 (82 ref.)

The role of CRF in behavioral aspects of stress. Heinrichs SC, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:92–104 (63 ref.)

Dehydroepiandrosterone (DHEA) is a neuroactive neurosteroid. Robel P, et al. **Ann N Y Acad Sci** 1995 Dec 29;774:82–110 (75 ref.)

Bombesin receptors in the brain. Woodruff GN, et al. **Ann N Y Acad Sci** 1996 Mar 22;780:223–43 (74 ref.)

Aspects of the search for neural mechanisms of memory. Rosenzweig MR. **Annu Rev Psychol** 1996;47:1–32 (150 ref.)

Mind and consciousness during sleep. Bosinelli M. **Behav Brain Res** 1995 Jul–Aug;69(1–2):195–201 (53 ref.)

An integrative analysis to sleep functions. Cai ZJ. **Behav Brain Res** 1995 Jul–Aug;69(1–2):187–94 (95 ref.)

EEG slow waves and sleep spindles: windows on the sleeping brain. Dijk DJ. **Behav Brain Res** 1995 Jul–Aug; 69(1–2):109–16 (61 ref.)

The function of sleep is to regulate brain excitability in order to satisfy the requirements imposed by waking. Drucker–Colín R. **Behav Brain Res** 1995 Jul–Aug; 69(1–2):117–24 (18 ref.)

Sensations and brain processes. Flohr H. **Behav Brain Res** 1995 Nov;71(1–2):157–61 (13 ref.)

Brain organization and sleep function. Krueger JM, et al. **Behav Brain Res** 1995 Jul–Aug;69(1–2):177–85 (44 ref.)

The function of sleep. Comments on the symposium and an attempt at synthesis. Moorcroft WH. **Behav Brain Res** 1995 Jul–Aug;69(1–2):207–10 (27 ref.)

Brain microdialysis and its application for the study of animal behaviour. Westerink BH. **Behav Brain Res** 1995 Oct; 70(2):103–24 (153 ref.)

Steroid control of higher brain function and behavior. Mortaud S, et al. **Behav Genet** 1996 Jul;26(4):367–72 (22 ref.)

Application of antisense DNA method for the study of molecular bases of brain function and behavior. Ogawa S, et al. **Behav Genet** 1996 May;26(3):279–92 (85 ref.)

The use of null mutant mice to study complex learning and memory processes. Wehner JM, et al. **Behav Genet** 1996 May;26(3):301–12 (75 ref.)

The dopamine D1 receptor family: structural and functional aspects. Jensen AA, et al. **Biochem Soc Trans** 1996 Feb; 24(1):163–9 (35 ref.)

D2 receptor agonists and partial agonists: relationship between receptor binding measures and functional activity. O'Boyle KM, et al. **Biochem Soc Trans** 1996 Feb; 24(1):183–8 (43 ref.)

Dopamine receptor multiplicity: "D1–like'–"D2–like' interactions and " D1–like" receptors not linked to adenylate cyclase. Waddington JL, et al. **Biochem Soc Trans** 1996 Feb;24(1):177–82 (77 ref.)

Brain POU–er. Sharp ZD, et al. **Bioessays** 1996 May; 18(5):347–50 (23 ref.)

Neurobiology of visceral afferent neurons: neuroanatomy, functions, organ regulations and sensations. Jänig W. **Biol Psychol** 1996 Jan 5;42(1–2):29–51 (105 ref.)

Cognitive and biological determinants of P300: an integrative review. Polich J, et al. **Biol Psychol** 1995 Oct;41(2):103–46 (257 ref.)

Neurobiology of central angiotensin III and dipsogenesis. Yang CC, et al. **Biol Signals** 1995 Mar–Apr;4(2):59–71 (70 ref.)

3M Mayneord Memorial Lecture: functional brain

imaging—an overview. Orrison WW Jr. **Br J Radiol** 1996 Jun;69(822):493–501 (17 ref.)

Noun and verb retrieval by normal subjects. Studies with PET. Warburton E, et al. **Brain** 1996 Feb;119 (Pt 1):159–79 (85 ref.)

Neurotransmitters and vulnerability of the developing brain. Johnston MV. **Brain Dev** 1995 Sep–Oct;17(5):301–6 (42 ref.)

Exploring memory functions by means of brain electrical topography: a review. Rösler F, et al. **Brain Topogr** 1995 Summer;7(4):301–13 (45 ref.)

Central tachykinins: mediators of defence reaction and stress reactions. Culman J, et al. **Can J Physiol Pharmacol** 1995 Jul;73(7):885–91 (54 ref.)

Emotion: systems, cells, synaptic plasticity. Rogan MT, et al. **Cell** 1996 May 17;85(4):469–75 (40 ref.)

A VIP hybrid antagonist: from developmental neurobiology to clinical applications. Gozes I, et al.
Cell Mol Neurobiol 1995 Dec;15(6):675–87 (74 ref.)

Galanin—a neuropeptide with inhibitory actions. Kask K, et al. **Cell Mol Neurobiol** 1995 Dec;15(6):653–73 (146 ref.)

Recent advances in molecular recognition and signal transduction of active peptides: receptors for opioid peptides. Kieffer BL. **Cell Mol Neurobiol** 1995 Dec; 15(6):615–35 (101 ref.)

The parietal system and some higher brain functions. Mountcastle VB. **Cereb Cortex** 1995 Sep–Oct;5(5):377–90 (41 ref.)

Coupling of brain activity and cerebral blood flow: basis of functional neuroimaging. Villringer A, et al.
Cerebrovasc Brain Metab Rev 1995 Fall;7(3):240–76 (268 ref.)

Actions of sex steroids on behaviours beyond reproductive reflexes. Priest CA, et al. **Ciba Found Symp** 1995;191:74–84; discussion 84–9 (69 ref.)

Mechanisms for electrical stimulation of excitable tissue. Roth BJ. **Crit Rev Biomed Eng** 1994;22(3–4):253–305 (194 ref.)

A conceptual overview and critique of functional neuroimaging techniques in humans: I. MRI/FMRI and PET. Aine CJ. **Crit Rev Neurobiol** 1995;9(2–3):229–309 (312 ref.)

Neurobiology and clinical aspects of neuropeptide Y. Heilig M, et al. **Crit Rev Neurobiol** 1995;9(2–3):115–36 (252 ref.)

Face recognition. What are faces for? Tovée MJ.
Curr Biol 1995 May 1;5(5):480–2 (23 ref.)

Binding in models of perception and brain function. von der Malsburg C. **Curr Opin Neurobiol** 1995 Aug;5(4):520–6 (70 ref.)

Future of functional brain imaging. Kuikka JT, et al.
Eur J Nucl Med 1996 Jul;23(7):737–40 (26 ref.)

Hormone delivery systems to the brain–transthyretin. Schreiber G, et al. **Exp Clin Endocrinol Diabetes** 1995; 103(2):75–80 (51 ref.)

The plasma level of some amino acids and physical and mental fatigue. Newsholme EA, et al. **Experientia** 1996 May 15;52(5):413–5 (14 ref.)

The functional significance of brain metallothioneins. Aschner M. **FASEB J** 1996 Aug;10(10):1129–36 (70 ref.)

Endocrine glia: roles of glial cells in the brain actions of steroid and thyroid hormones and in the regulation of hormone secretion. Garcia-Segura LM, et al.
Front Neuroendocrinol 1996 Apr;17(2):180–211 (253 ref.)

Role of calcium in brain aging. Gareri P, et al.
Gen Pharmacol 1995 Dec;26(8):1651–7 (64 ref.)

The anatomy of intelligence. Shobris JG.
Genet Soc Gen Psychol Monogr 1996 May;122(2):133–58 (70 ref.)

Growth hormone and its receptors in the central nervous system—location and functional significance. Nyberg F, et al. **Horm Res** 1996;45(1–2):18–22 (28 ref.)

Jungian metapsychology and neurobiological theory. Tresan DI. **J Anal Psychol** 1996 Jul;41(3):399–436 (140 ref.)

Dynamic neuroimaging of brain function. Simpson GV, et al. **J Clin Neurophysiol** 1995 Sep;12(5):432–49 (65 ref.)

Science and belief: psychobiological research on sexual orientation. Byne W. **J Homosex** 1995;28(3–4):303–44 (140 ref.)

Sexuality in the brain. Doell RG. **J Homosex** 1995; 28(3–4):345–54 (27 ref.)

Biomedical concepts of homosexuality: folk belief in a white coat. Gooren LJ. **J Homosex** 1995;28(3–4):237–46 (16 ref.)

Biology of bisexuality: critique and observations. Van Wyk PH, et al. **J Homosex** 1995;28(3–4):357–73 (65 ref.)

Some considerations on estimating event-related brain signals. Krieger S, et al. **J Neural Transm Gen Sect** 1995; 99(1–3):103–29 (72 ref.)

The study of the brain using PET and SPECT: implications for space and underwater neurology. Newberg AB, et al. **J Neurol Sci** 1996 Mar;136(1–2):1–9 (84 ref.)

Functional MRI of the brain principles, applications and limitations. Le Bihan D. **J Neuroradiol** 1996 Jun;23(1):1–5 (15 ref.)

Cell protective role of melatonin in the brain. Acuña-Castroviejo D, et al. **J Pineal Res** 1995 Sep; 19(2):57–63 (66 ref.)

The brain and the lymphatic system (II). Földi M.
Lymphology 1996 Mar;29(1):10–4 (29 ref.)

Neuropoiesis: proposal for a connectionistic neurobiology. Jobe TH, et al. **Med Hypotheses** 1995 Aug;45(2):147–63 (145 ref.)

Brain GABAA receptors studied with subunit-specific antibodies. De Blas AL. **Mol Neurobiol** 1996 Feb; 12(1):55–71 (139 ref.)

Roles of cytokines in the neural–immune interactions: modulation of NMDA responses by IFN-alpha. Katafuchi T, et al. **Neurobiology (Bp)** 1995;3(3–4):319–27 (39 ref.)

Drug addiction: the yin and yang of hedonic homeostasis. Koob GF. **Neuron** 1996 May;16(5):893–6 (25 ref.)

The neurobiology of human consciousness: an evolutionary approach. Donald M. **Neuropsychologia** 1995 Sep; 33(9):1087–102 (74 ref.)

Current issues in the neuropsychology of image generation. Farah MJ. **Neuropsychologia** 1995 Nov;33(11):1455–71 (79 ref.)

Synchronization and cooperative interaction in brain activity. Kozhedub RG. **Neurosci Behav Physiol** 1995 Nov–Dec; 25(6):517–30 (129 ref.)

Food reward: brain substrates of wanting and liking. Berridge KC. **Neurosci Biobehav Rev** 1996;20(1):1–25 (162 ref.)

The evaluation of insulin as a metabolic signal influencing behavior via the brain. Woods SC, et al.
Neurosci Biobehav Rev 1996;20(1):139–44 (42 ref.)

Serotonergic modulation of cholinergic function in the central nervous system: cognitive implications. Cassel JC, et al. **Neuroscience** 1995 Nov;69(1):1–41 (261 ref.)

Action of opioid drugs on the brain–reward system. Kornetsky C. **NIDA Res Monogr** 1995;147:33–52 (47 ref.)

Functional MRI: are we all moving towards artifactual conclusions? Or fMRI fact or fancy? Weisskoff RM.
NMR Biomed 1995 May;8(3):101–3 (10 ref.)

Exercise, physical activity, nutrition, and the brain. Hollmann W, et al. **Nutr Rev** 1996 Apr;54(4 Pt 2):S37–43 (42 ref.)

Brain peptides and obesity: pharmacologic treatment. Leibowitz SF. **Obes Res** 1995 Nov;3 Suppl 4:573S–589S (196 ref.)

Brain serotonin, carbohydrate-craving, obesity and depression. Wurtman RJ, et al. **Obes Res** 1995 Nov;3 Suppl 4:477S–480S (34 ref.)

Angiotensin receptors in the brain. Höhle S, et al.
Pharmacol Toxicol 1995 Nov;77(5):306–15 (84 ref.)

Nonsynaptic modulation of neuronal activity in the brain: electric currents and extracellular ions. Jefferys JG.
Physiol Rev 1995 Oct;75(4):689–723 (404 ref.)

Central neural organization and control of sympathetic nervous system in mammals. Sun MK. **Prog Neurobiol** 1995 Oct;47(3):157–233 (1200 ref.)

D–1 receptors in neurology and psychiatry an overview. Bédard PJ. **Prog Neuropsychopharmacol Biol Psychiatry** 1995 Sep;19(5):713–26 (73 ref.)

Hebb's concept of cell assemblies and the psychophysiology of word processing. Pulvermüller F. **Psychophysiology** 1996 Jul;33(4):317–33 (145 ref.)

The state of hypnosis: evidence and applications. Gruzelier J. **QJM** 1996 Apr;89(4):313–7 (52 ref.)

Brain cooling across wake–sleep behavioral states in homeothermic species: an analysis of the underlying physiological mechanisms. Parmeggiani PL.
Rev Neurosci 1995 Oct–Dec;6(4):353–63 (36 ref.)

Long-term depression: a learning-related type of synaptic plasticity in the mammalian central nervous system. Zhuo M, et al. **Rev Neurosci** 1995 Jul–Sep;6(3):259–77 (142 ref.)

Ensemble activity and behavior: what's the code? Deadwyler SA, et al. **Science** 1995 Nov 24;270(5240):1316–8 (24 ref.)

Cracking the neuronal code. Ferster D, et al. **Science** 1995 Nov 3;270(5237):756–7 (20 ref.)

Magnetic resonance imaging of human brain function. Moseley ME, et al. **Surg Neurol** 1996 Apr;45(4):385–91 (12 ref.)

Mapping cognitive brain function with modern high-resolution electroencephalography. Gevins A, et al.
Trends Neurosci 1995 Oct;18(10):429–36 (48 ref.)

Theory of mind: evolutionary history of a cognitive specialization. Povinelli DJ, et al. **Trends Neurosci** 1995 Sep;18(9):418–24 (58 ref.)

Mast cells in the brain: evidence and functional significance. Silver R, et al. **Trends Neurosci** 1996 Jan;19(1):25–31 (64 ref.)

Breastfeeding for optimal mental development. The alpha and the omega in human milk. de Andraca I, et al.
World Rev Nutr Diet 1995;78:1–27 (74 ref.)

Limits of natural science: brain research and computers. Stieve H. **Z Naturforsch [C]** 1995 May–Jun;50(5–6):317–36 (86 ref.)

[Hypothalamic–pituitary stress hormones and serotonergic system in the brain] Yan J, et al.
Sheng Li Ko Hsueh Chin Chan 1995 Oct;26(4):337–40 (8 ref.) **(Chi)**

[Is the mind located in the brain?] Louhiala P. **Duodecim** 1994;110(1):35–41 (22 ref.) **(Fin)**

[Study of functional neuro-anatomy of perception using positron emission tomography] Baron JC.
Rev Neurol (Paris) 1995 Aug–Sep;151(8–9):511–7 (58 ref.) (Eng. Abstr.) **(Fre)**

[The blood–brain barrier: a specialty of cerebral microcirculation systems] Wolf S, et al.
Naturwissenschaften 1996 Jul;83(7):302–11 (41 ref.) **(Ger)**

[Nuclear medicine for evaluation of brain function] Yonekura Y. **Kaku Igaku** 1995 Dec;32(12):1375–9 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Control mechanisms of locomotor movements from a viewpoint of behavioral control] Mori S.
Nihon Shinkei Seishin Yakurigaku Zasshi 1995 Jun; 15(3):281–7 (22 ref.) (Eng. Abstr.) **(Jpn)**

[Molecular and pharmacological studies on signal transduction in the brain] Yamamoto H.
Nippon Yakurigaku Zasshi 1996 Jan;107(1):9–19 (49 ref.) (Eng. Abstr.) **(Jpn)**

[The development of I. P. Pavlov's concepts of the food center] Kassil' VG. **Fiziol Zh Im I M Sechenova** 1995 Nov; 81(11):18–29 (49 ref.) **(Rus)**

[The basic molecular cellular mechanisms of adaptive reactions in the brain] Samoilov MO.
Fiziol Zh Im I M Sechenova 1995 Aug;81(8):3–11 (32 ref.) **(Rus)**

[The organized brain (an essay on the principles of the design and functional organization of the brain). I] Adrianov OS. **Usp Fiziol Nauk** 1995 Jan–Mar;26(1):25–45 (153 ref.) (Eng. Abstr.) **(Rus)**

[The self-organization of the brain as the integration of the processes of different spatial and time scales] Kozhedub RG. **Usp Fiziol Nauk** 1995 Oct–Dec;26(4):28–47 (75 ref.) (Eng. Abstr.) **(Rus)**

[The plasticity of systemic brain mechanisms] Sudakov KV. **Usp Fiziol Nauk** 1996 Apr–Jun;27(2):3–27 (91 ref.) (Eng. Abstr.) **(Rus)**

[The development of electrocardiogram] Alfonso I, et al. **Rev Neurol** 1995;23 Suppl 3:S278–9 (12 ref.) **(Spa)**

[Neuropsychology of left-handedness: current knowledge] Estévez-González A, et al. **Rev Neurol** 1996 May; 24(129):515–22 (183 ref.) (Eng. Abstr.) **(Spa)**

[Degeneration and regeneration of the peripheral nervous system with aging] Verdú E, et al. **Rev Neurol** 1995 May–Jun;23(121):648–55 (98 ref.) (Eng. Abstr.) **(Spa)**

[Pictures of the psyche. Imaging the highest functions of the brain: consciousness, language, emotions, is now possible] Ingvar DH. **Lakartidningen** 1995 Dec 20;92(51–52):4885–9 (20 ref.) **(Swe)**

PHYSIOPATHOLOGY

Neural Mechanisms in dissociative amnesia for childhood abuse: relevance to the current controversy surrounding the "false memory syndrome". Bremner JD, et al.
Am J Psychiatry 1996 Jul;153(7 Suppl):71–82 (124 ref.)

Receptor–effector coupling dysfunctions in Alzheimer's disease. Fowler CJ, et al. **Ann N Y Acad Sci** 1996 Jun 15;786:294–304 (72 ref.)

A role for CRH and the sympathetic nervous system in stress-induced immunosuppression. Friedman EM, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:396–418 (125 ref.)

Cerebral mechanisms operating in the presence and absence of inflammatory pain. Jones AK, et al. **Ann Rheum Dis** 1996 Jul;55(7):411–20 (83 ref.)

Nitric oxide synthase: role as a transmitter/mediator in the brain and endocrine system. Dawson TM, et al.
Annu Rev Med 1996;47:219–27 (40 ref.)

Dopamine receptors and schizophrenia. Reynolds GP.
Biochem Soc Trans 1996 Feb;24(1):202–5 (35 ref.)

The neuropathology of parkinsonism: an overview. Cornford ME, et al. **Brain Cogn** 1995 Aug;28(3):321–41 (72 ref.)

Developmental aspects of epileptogenesis. Johnston MV.
Epilepsia 1996;37 Suppl 1:S2–9 (64 ref.)

Are mental diseases brain diseases? The contribution of neuropathology to understanding of schizophrenic psychoses. Knable MB, et al.
Eur Arch Psychiatry Clin Neurosci 1995;245(4–5):224–30 (78 ref.)

Quantitative electroencephalography in aging brain and cerebrovascular disease: the effects of almitrine–raubasine. Sebban C. **Eur Neurol** 1995;35 Suppl 1:37–42 (16 ref.)

Cerebral blood flow and brain function in hypertension. Fujishima M, et al. **Hypertens Res** 1995 Jun;18(2):111–7 (23 ref.)

Diagnosis, physiology, pathology and rehabilitation of traumatic brain injuries. Berker E. **Int J Neurosci** 1996 Apr; 85(3–4):195–220 (135 ref.)

Chronic relapsing multiple sclerosis: a case of rapid recovery by application of weak electromagnetic fields. Sandyk R. **Int J Neurosci** 1995 Jun;82(3–4):223–42 (160 ref.)

Brain electrical activity (quantitative EEG and bit–mapping neurocognitive CNV components), psychometrics and clinical findings in presenile subjects with initial mild cognitive decline or probable Alzheimer–type dementia. Zappoli R, et al. **Ital J Neurol Sci** 1995 Sep;16(6):341–76 (177 ref.)

Brief report: pathophysiology of autism: neurochemistry. Cook EH Jr. **J Autism Dev Disord** 1996 Apr;26(2):221–5 (11 ref.)

Brief report: developmental neurobiological aspects of autism. Voeller KK. **J Autism Dev Disord** 1996 Apr; 26(2):189–93 (9 ref.)

Pathophysiology of status epilepticus. Fountain NB, et al.
J Clin Neurophysiol 1995 Jul;12(4):326–42 (114 ref.)

Mapping function in the human brain with magnetoencephalography, anatomical magnetic resonance imaging, and functional magnetic resonance imaging. George JS, et al. **J Clin Neurophysiol** 1995 Sep;12(5):406–31 (90 ref.)

Functional neuroanatomy of obsessive–compulsive disorder. Trivedi MH. **J Clin Psychiatry** 1996;57 Suppl 8:26–35; discussion 36 (69 ref.)

Corticotropin–releasing factor (CRF) and stress-related reproductive failure: the brain as a state of the art or the ovary as a novel clue? Nappi RE, et al.
J Endocrinol Invest 1995 Dec;18(11):872–80 (89 ref.)

Neuroepidemiology of amyotrophic lateral sclerosis: clues to aetiology and pathogenesis. Román GC.

J Neurol Neurosurg Psychiatry 1996 Aug;61(2):131–7 (87 ref.)

Mitochondria, magnesium and migraine. Welch KM, et al. **J Neurol Sci** 1995 Dec;134(1–2):9–14 (62 ref.)

The central control of vomiting. Meadows N. **J Pediatr Gastroenterol Nutr** 1995;21 Suppl 1:S20–1 (8 ref.)

Psychophysiological aspects of autistic disorders: overview. Murray JB. **J Psychol** 1996 Mar;130(2):145–58 (95 ref.)

Addiction: brain mechanisms and their treatment implications [see comments] Nutt DJ. **Lancet** 1996 Jan 6;347(8993):31–6 (47 ref.) Comment in: Lancet 1995 Jan 6;347(8993):6.

Clinical correlations: MRI and EEG. Fish DR, et al. **Magn Reson Imaging** 1995;13(8):1113–7 (18 ref.)

Application of spectroscopic imaging in epilepsy. Garcia PA, et al. **Magn Reson Imaging** 1995;13(8):1181–5 (28 ref.)

Overview—the role of NMR spectroscopy in epilepsy. Novotny EJ Jr. **Magn Reson Imaging** 1995;13(8):1171–3 (17 ref.)

Brain electrical activity in neurogerontology and psychogeriatric disorders. Franco-Maside A, et al. **Methods Find Exp Clin Pharmacol** 1995 Apr;17(3):207–24 (93 ref.)

Glutamate and Parkinson's disease. Blandini F, et al. **Mol Neurobiol** 1996 Feb;12(1):73–94 (165 ref.)

Anorexia nervosa, self-starvation and the reward of stress. Bergh C, et al. **Nat Med** 1996 Jan;2(1):21–2 (13 ref.)

Alzheimer's disease: maladaptive synaptoplasticity hypothesis. Neill D. **Neurodegeneration** 1995 Jun; 4(2):217–32 (250 ref.)

Functional MR imaging in the evaluation of the patient with epilepsy. Functional localization. Latchaw RE, et al. **Neuroimaging Clin N Am** 1995 Nov;5(4):683–93 (20 ref.)

Malignant cerebral edema and intracranial hypertension. Bingaman WE, et al. **Neurol Clin** 1995 Aug;13(3):479–509 (175 ref.)

Neurocritical care for acute ischemic stroke. Hund E, et al. **Neurol Clin** 1995 Aug;13(3):511–27 (87 ref.)

Epidural hematoma associated with cephalohematoma in a neonate—case report. Yamamoto T, et al. **Neurol Med Chir (Tokyo)** 1995 Oct;35(10):749–52 (24 ref.)

The neuropathology of Rett syndrome—overview 1994. Armstrong DD. **Neuropediatrics** 1995 Apr;26(2):100–4 (47 ref.)

Cerebral correlates of visual awareness. Milner AD. **Neuropsychologia** 1995 Sep;33(9):1117–30 (84 ref.)

Pathophysiology of recurrent headaches in children and adolescents. Rothner AD. **Pediatr Ann** 1995 Sep;24(9):458, 461–6 (34 ref.)

Central noradrenergic neurones and stress. Stanford SC. **Pharmacol Ther** 1995;68(2):297–42 (360 ref.)

The neurobiology of anxiety disorders. Johnson MR, et al. **Psychiatr Clin North Am** 1995 Dec;18(4):681–725 (152 ref.)

Analyses of the molecular basis of kindling development. McNamara JO. **Psychiatry Clin Neurosci** 1995 Jun; 49(3):S175–8 (33 ref.)

Neurofunctional mechanisms in autism. Waterhouse L, et al. **Psychol Rev** 1996 Jul;103(3):457–89 (280 ref.)

Post-traumatic epilepsy and recovery of function from experimental brain damage: a review. Droogan J. **Seizure** 1995 Sep;4(3):163–7 (31 ref.)

The neurological basis of fever. Samii A. **Surg Neurol** 1996 Apr;45(4):392–3 (11 ref.)

Stress and the brain: a paradoxical role for adrenal steroids. McEwen BS, et al. **Vitam Horm** 1995;51:371–402 (113 ref.)

[Exploration of brain metabolism and hemodynamics in perinatal asphyxia in full-term neonates] Saliba E, et al. **Arch Pediatr** 1996;3 Suppl 1:248s–250s (9 ref.) **(Fre)**

[Neuroimaging and neurobiology of obsessive compulsive disorder: review of recent developments in research] Huguelet P, et al. **Encephale** 1996 Jan–Feb;22(1):41–5 (29 ref.) (Eng. Abstr.) **(Fre)**

[The calcium hypothesis of brain aging] Müller WE, et al. **Nervenarzt** 1996 Jan;67(1):15–24 (59 ref.) (Eng. Abstr.) **(Ger)**

[Plasticity of brain structure and function as the neurobiological principle of psychotherapy] Bogerts B. **Z Klin Psychol Psychopathol Psychother** 1996;44(3):243–52 (22 ref.) (Eng. Abstr.) **(Ger)**

[Synaptic reorganization in early childhood experience and learning processes: relevance for the development of psychological diseases] Braun K. **Z Klin Psychol Psychopathol Psychother** 1996;44(3):253–66 (60 ref.) (Eng. Abstr.) **(Ger)**

[Neurobiological and psychodynamic correlations in obsessive-compulsive disorders and bulimia nervosa] Csef H. **Z Klin Psychol Psychopathol Psychother** 1996; 44(3):267–79 (70 ref.) (Eng. Abstr.) **(Ger)**

[How are psychological processes, the neuroendocrine system and immune system integrated?] Kaschka WP. **Z Klin Psychol Psychopathol Psychother** 1996;44(3):280–9 (50 ref.) (Eng. Abstr.) **(Ger)**

[Psychological stress and neuronal plasticity. An expanded model of the stress reaction process as the basis for understand central nervous system adaptation processes] Huether G, et al. **Z Psychosom Med Psychoanal** 1996; 42(2):107–27 (70 ref.) (Eng. Abstr.) **(Ger)**

[The role of enzymatic systems in pathophysiology and pharmacotherapy of Parkinson's disease] Kuran W. **Neurol Neurochir Pol** 1995 Jul–Aug;29(4):561–8 (30 ref.) (Eng. Abstr.) **(Pol)**

[Current views on pathophysiology of migraine. Part IV: autonomic disturbances. Central neural hypothesis. Conclusions] Prusiński A. **Neurol Neurochir Pol** 1995 Nov–Dec;29(6):877–88 (20 ref.) (Eng. Abstr.) **(Pol)**

[Current views on pathophysiology of migraine. Part II: Further development and current status of the vascular theory. Migraine and allergy] Prusiński A, et al. **Neurol Neurochir Pol** 1995 Nov–Dec;29(6):857–66 (28 ref.) (Eng. Abstr.) **(Pol)**

[Current views on pathophysiology of migraine. Part III: Biochemical hypothesis. The role of blood platelets] Prusiński A, et al. **Neurol Neurochir Pol** 1995 Nov–Dec; 29(6):867–76 (26 ref.) (Eng. Abstr.) **(Pol)**

[The nociceptive flexor reflex: a method for studying the brain mechanisms of pain control] Danilov AB, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1996; 96(1):107–11 (63 ref.) **(Rus)**

[Positive and negative symptoms of schizophrenia] Lagomarsino AJ. **Acta Psiquiatr Psicol Am Lat** 1995 May; 41(2):141–7 (19 ref.) (Eng. Abstr.) **(Spa)**

[Status migrainosus] Alberca R, et al. **Rev Neurol** 1995;23 Suppl 2:S208–11 (13 ref.) **(Spa)**

[Non-inflammatory arteriopathies] Alvarez-Sabín J. **Rev Neurol** 1995;23 Suppl 1:S33–40 (52 ref.) **(Spa)**

[Stereotypies] Campos-Castelló J. **Rev Neurol** 1995;23 Suppl 3:S363–7 (33 ref.) **(Spa)**

[A cerebral accident: ictus is a medical emergency] Castillo J. **Rev Neurol** 1995 Mar–Apr;23(120):322–3 (22 ref.) **(Spa)**

[Stroke units: modality, structure, organization and utilization] Díez-Tejedor E, et al. **Rev Neurol** 1995 Mar–Apr;23(120):377–80 (21 ref.) **(Spa)**

[Prion-type pathologies: from scrapie to prion-related dementias. On the borderline between veterinary and human pathology] Domich L. **Rev Neurol** 1996 Jul; 24(131):785–802 (250 ref.) **(Spa)**

[Tremor and ataxia] Dueñas DA. **Rev Neurol** 1995;23 Suppl 3:S349–54 (41 ref.) **(Spa)**

[Dementias: present situation and future perspectives (II). Biological markers] Espert R, et al. **Rev Neurol** 1995 Jan–Feb;23(119):77–85 (107 ref.) (Eng. Abstr.) **(Spa)**

[Chorea and athetosis in childhood] Fernández-Alvarez E. **Rev Neurol** 1995;23 Suppl 3:S330–3 (59 ref.) **(Spa)**

[Clinical features of cluster headache attack] Gómez-Aranda F, et al. **Rev Neurol** 1995;23 Suppl 4:S500–5 (37 ref.) **(Spa)**

[Neonatal seizures] Holmes GL. **Rev Neurol** 1995;23 Suppl 3:S280–4 (37 ref.) **(Spa)**

[Molecular factors of cerebral hypoxia-ischemia] Macaya A, et al. **Rev Neurol** 1996 Jul;24(131):855–64 (84 ref.) (Eng. Abstr.) **(Spa)**

[Non-valvular atrial fibrillation and cerebral infarction] Martín R. **Rev Neurol** 1995 Mar–Apr;23(120):370–6 (81 ref.) (Eng. Abstr.) **(Spa)**

[Basic mechanisms of the migraine physiopathology] Martínez F, et al. **Rev Neurol** 1995 Jul–Aug;23(122):800–18 (205 ref.) **(Spa)**

[Stroke units] Matías-Guiu J. **Rev Neurol** 1995 Mar–Apr; 23(120):324–5 (26 ref.) **(Spa)**

[Migraine in childhood] Mederer S. **Rev Neurol** 1995;23 Suppl 2:S232–7 (55 ref.) **(Spa)**

[Chronic paroxysmal hemicrania] Morales-Asín F. **Rev Neurol** 1995;23 Suppl 4:S535–9 (27 ref.) **(Spa)**

[Cerebral congenital hypotonia] Papazian O, et al. **Rev Neurol** 1995;23 Suppl 3:S289–99 (50 ref.) **(Spa)**

[Cluster headache: anatomical and physiopathological basis of pain] Pascual-Gómez J. **Rev Neurol** 1995;23 Suppl 4:S487–91 (40 ref.) **(Spa)**

[Neurocutaneous syndromes with predominant vascular anomalies] Rodríguez-Barrionuevo AC. **Rev Neurol** 1996 Sep;24(133):1072–84 (121 ref.) **(Spa)**

[Therapeutic strategies in menstrual migraine] Targa C, et al. **Rev Neurol** 1995;23 Suppl 2:S226–31 (63 ref.) **(Spa)**

[Cerebral magnetic resonance angiography] Viaño J, et al. **Rev Neurol** 1995;23 Suppl 3:S300–6 (20 ref.) **(Spa)**

[Cerebrovascular diseases and non-infectious inflammatory arteriopathies] Vivancos F, et al. **Rev Neurol** 1995;23 Suppl 1:S22–32 (84 ref.) **(Spa)**

[Organic hyperactivity] Yelin B. **Rev Neurol** 1995;23 Suppl 3:S314–7 (36 ref.) **(Spa)**

[Anatomy and genetics of mental disorders. New findings in schizophrenia research] Wetterberg L. **Lakartidningen** 1996 May 22;93(21):2049–55 (20 ref.) **(Swe)**

RADIATION EFFECTS

Radiation injury of the brain. Valk PE, et al. **AJNR Am J Neuroradiol** 1991 Jan;12(1):45–62 (90 ref.)

Handling of large brain specimens: the use of microwaves. A review. Marani E, et al. **Eur J Morphol** 1995 Apr; 33(2):158–64 (33 ref.)

Central nervous system toxicity of cancer therapy in children. Moore IM. **J Pediatr Oncol Nurs** 1995 Oct;12(4):203–10; discussion 211 (50 ref.)

RADIOGRAPHY

Brain segmentation and white matter lesion detection in MR images. Zijdenbos AP, et al. **Crit Rev Biomed Eng** 1994; 22(5–6):401–65 (192 ref.)

Some methodological issues in neuroradiological research in psychiatry. Becker T, et al. **J Neural Transm Gen Sect** 1995; 99(1–3):7–54 (292 ref.)

RADIONUCLIDE IMAGING

Noun and verb retrieval by normal subjects. Studies with PET. Warburton E, et al. **Brain** 1996 Feb;119 (Pt 1):159–79 (85 ref.)

The use of PET in Parkinson's disease. Shinotoh H, et al. **Brain Cogn** 1995 Aug;28(3):297–310 (67 ref.)

Positron emission tomography studies of abnormal glucose metabolism in schizophrenic illness. Buchsbaum MS. **Clin Neurosci** 1995;3(2):122–30 (77 ref.)

Utilization of radioligands in schizophrenia research. Sedvall G, et al. **Clin Neurosci** 1995;3(2):112–21 (47 ref.)

Radioligands for brain 5-HT2 receptor imaging in vivo: why do we need them? [editorial] Busatto GF. **Eur J Nucl Med** 1996 Aug;23(8):867–70 (36 ref.)

D2-receptor imaging with [123I]IBZM and single photon emission tomography in psychiatry: a survey of current status. Schlösser R, et al. **J Neural Transm Gen Sect** 1995; 99(1–3):173–85 (52 ref.)

Fluorine-18-fluorodeoxyglucose PET to determine regional cerebral glucose utilization: a re-examination. Schmidt KC, et al. **J Nucl Med** 1996 Feb;37(2):394–9 (42 ref.)

Development of imaging agents for the dopamine transporter. Carroll FI, et al. **Med Res Rev** 1995 Sep;15(5):419–44 (144 ref.)

Assessment of brain SPECT. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. **Neurology** 1996 Jan;46(1):278–85 (27 ref.)

Localized and lateralized cerebral glucose metabolism associated with eye movements during REM sleep and wakefulness: a positron emission tomography (PET) study. Hong CC, et al. **Sleep** 1995 Sep;18(7):570–80 (71 ref.)

[Positron-emission tomographic studies of the brain in parkinsonism patients] Berezhkova LV. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995;95(6):93–7 (43 ref.) **(Rus)**

[SPECT. An important clinical method for brain function studies] Wikkelsø C, et al. **Lakartidningen** 1996 Jul 10; 93(28–29):2585–91 (78 ref.) **(Swe)**

SURGERY

Microelectrode monitoring of cortical and subcortical structures during stereotactic surgery. Lozano AM, et al. **Acta Neurochir Suppl (Wien)** 1995;64:30–4 (19 ref.)

Systematic approach to intradural tumors ventral to the brain stem. Jackler RK, et al. **Am J Otol** 1995 Jan;16(1):39–51 (38 ref.)

Trends in neuroanaesthesia. Cottrell JE. **Can J Anaesth** 1996 May;43(5 Pt 2):R61–74 (73 ref.) **(Eng, Fre)**

Surgical management of giant intracranial aneurysms: experience with 171 patients. Lawton MT, et al. **Clin Neurosurg** 1995;42:245–66 (74 ref.)

Intractable epilepsy in children. Holmes GL. **Epilepsia** 1996; 37 Suppl 3:14–27 (129 ref.)

Surgery for catastrophic localization-related epilepsy in infants. Wyllie E. **Epilepsia** 1996;37 Suppl 1:S22–5 (36 ref.)

Hemispherectomy: a hemidecortication approach and review of 52 cases. Carson BS, et al. **J Neurosurg** 1996 Jun; 84(6):903–11 (59 ref.)

Cystplastic cyst-subarachnoid shunt procedure for arachnoid cyst of the middle cranial fossa—technical note. Takeuchi T, et al. **Neurol Med Chir (Tokyo)** 1996 Jun;36(6):396–9 (7 ref.)

[Neurosurgical infections] Martínez E, et al. **Enferm Infecc Microbiol Clin** 1996 Jan;14(1):34–43 (161 ref.) **(Spa)**

[Early reperfusion as a rationale from of therapy in ischemic stroke] Garcia JH. **Rev Neurol** 1995 Sep–Oct; 23(123):1067–73 (40 ref.) (Eng. Abstr.) **(Spa)**

ULTRASTRUCTURE

The Golgi apparatus and the pathogenesis of Alzheimer's disease [comment] Dal Canto MC. **Am J Pathol** 1996 Feb; 148(2):355–60 (40 ref.) Comment on: Am J Pathol 1996 Feb;148(2):415–26.

Neurodegenerative disorders with extensive tau pathology: a comparative study and review. Feany MB, et al. **Ann Neurol** 1996 Aug;40(2):139–48 (93 ref.)

The Duffy antigen receptor for chemokines: structural analysis and expression in the brain. Horuk R, et al. **J Leukoc Biol** 1996 Jan;59(1):29–38 (28 ref.)

Grumose or foamy spheroid bodies involving astrocytes in the human brain. Arai N. **Neuropathol Appl Neurobiol** 1995 Jun;21(3):238–45 (27 ref.)

[Molecular factors of cerebral hypoxia-ischemia] Macaya A, et al. **Rev Neurol** 1996 Jul;24(131):855–64 (84 ref.) (Eng. Abstr.) **(Spa)**

VIROLOGY

Measles virus infection of cerebral endothelial cells and effect on their adhesive properties. Cosby SL, et al. **Vet Microbiol** 1995 May;44(2–4):135–9 (21 ref.)

[Penetration of neurotropic viruses into the central nervous system after airborne mode of transmission] Ryzhikov AB, et al. **Vopr Virusol** 1995 Jul–Aug;40(4):146–50 (51 ref.) **(Rus)**

[Nervous system infections by retroviruses] Román GC. **Rev Neurol** 1996 Jun;24(130):703–7 (9 ref.) **(Spa)**

BRAIN ABSCESS

DIAGNOSIS

Intrasellar abscess following transsphenoidal surgery. Henegar MM, et al. **Surg Neurol** 1996 Feb;45(2):183–8 (24 ref.)

[Bacterial brain abscess] Schielke E. **Nervenarzt** 1995 Oct; 66(10):745–53 (47 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Cure of a solitary brainstem abscess with antibiotic therapy: case report. Fulgham JR, et al. **Neurology** 1996 May; 46(5):1451–4 (10 ref.)

ETIOLOGY

Tuberculous brain abscess should be considered in HIV/AIDS patients [letter] Velasco-Martínez JJ, et al. **AIDS** 1995 Oct;9(10):1197–9 (16 ref.)

Cerebral abscess complicating dental treatment. Case report and review of the literature. Renton TF, et al. **Aust Dent J** 1996 Feb;41(1):12–5 (32 ref.)

Intrasellar abscess following transsphenoidal surgery. Henegar MM, et al. **Surg Neurol** 1996 Feb;45(2):183–8 (24 ref.)

[Frontal cerebral abscess, a rare complication of nasosinusal polyposis. Apropos of a case] Abgrall S, et al. **Neurochirurgie** 1995;41(5):367–71 (13 ref.) (Eng. Abstr.) **(Fre)**

[Pulmonary arteriovenous fistulae and brain abscesses: a report of 2 cases treated by embolization and a review of the literature] Ricci P, et al. **Radiol Med (Torino)** 1996 Apr; 91(4):497–501 (24 ref.) **(Ita)**

MICROBIOLOGY

Brain abscess in children: microbiology and management. Brook I. **J Child Neurol** 1995 Jul;10(4):283–8 (47 ref.)

BRAIN CHEMISTRY

Probing brain chemistry. Stamford JA, et al. **Anal Chem** 1996 Jun 1;68(11):359A–363A (40 ref.)

Mass spectrometry, high performance liquid chromatography, and brain peptides. Desiderio DM. **Biopolymers** 1996;40(3):257–64 (45 ref.)

Mineralocorticoid receptors in the central nervous system. Funder JW. **J Steroid Biochem Mol Biol** 1996 Jan;56(1–6 Spec No):179–83 (44 ref.)

5-Hydroxytryptamine in the central nervous system. Chojnacka-Wójcik E. **Pol J Pharmacol** 1995 May–Jun; 47(3):219–35 (173 ref.)

The basic pharmacology of gangliosides. Toffano G. **Rev Neurol** 1995 Jul–Aug;23(122):880–4 (51 ref.)

The nuclear hormone-receptor family in the brain: classics and orphans. Lopes da Silva S, et al. **Trends Neurosci** 1995 Dec;18(12):542–8 (47 ref.)

Which GABAA-receptor subtypes really occur in the brain? McKernan RM, et al. **Trends Neurosci** 1996 Apr; 19(4):139–43 (48 ref.)

Central 5-HT4 receptors. Eglen RM, et al. **Trends Pharmacol Sci** 1995 Nov;16(11):391–8 (84 ref.)

[Progress in the study of the central ACTH receptors] Fang Y, et al. **Sheng Li Ko Hsueh Chin Chan** 1995 Jul; 26(3):199–203 (19 ref.) (Eng. Abstr.) **(Chi)**

[Brain neurochemical systems which control appetite] Pesonen U, et al. **Duodecim** 1994;110(13):1241–50 (26 ref.) **(Fin)**

[Comparative biochemistry of the triune brain] Bureau M, et al. **Acta Psychiatr Belg** 1994;94(4–6):225–47 (63 ref.) (Eng. Abstr.) **(Fre)**

[Polyunsaturated fatty acids and cerebral-sensory development in infants (editorial)] Ghisolfi J. **Arch Pediatr** 1995 Sep;2(9):825–30 (15 ref.) **(Fre)**

DRUG EFFECTS

Antipsychotics and neuropeptides: the atypical profile of CI-943 and its relationship to neurotensin. Liégeois JF, et al. **Neurosci Biobehav Rev** 1995 Winter;19(4):519–31 (101 ref.)

Targeting drugs to the brain by sequential metabolism. Bodor N. **NIDA Res Monogr** 1995;147:1–32 (83 ref.)

Psychopharmacology of central serotonergic systems. Baumgarten HG, et al. **Pharmacopsychiatry** 1995 Oct;28 Suppl 2:73–9 (42 ref.)

GENETICS

Identification of a new exon of the brain microtubule-associated protein 2. Guilleminot J, et al. **C R Acad Sci III** 1995 Sep;318(9):959–64 (21 ref.)

PHYSIOLOGY

Molecular biology of brain aging and neurodegenerative disorders. Wisniewski T, et al. **Acta Neurobiol Exp (Warsz)** 1996;56(1):267–79 (93 ref.)

Angiotensin peptides in the brain. Campbell DJ. **Adv Exp Med Biol** 1995;377:349–55 (30 ref.)

Brain angiotensin and the female reproductive cycle. Phillips MI, et al. **Adv Exp Med Biol** 1995;377:357–70 (19 ref.)

AT1 receptors and angiotensin actions in the brain and neuronal cultures of normotensive and hypertensive rats. Raizada MK, et al. **Adv Exp Med Biol** 1995;377:331–48 (124 ref.)

Sleep function(s) and cerebral metabolism. Maquet P. **Behav Brain Res** 1995 Jul-Aug;69(1–2):75–83 (79 ref.)

Voltammetric and microdialysis monitoring of brain monoamine neurotransmitter release during sociosexual interactions. Mas M, et al. **Behav Brain Res** 1995 Nov; 71(1–2):69–79 (62 ref.)

On the significance of brain extracellular uric acid detected with in-vivo monitoring techniques: a review. O'Neill RD, et al. **Behav Brain Res** 1995 Nov;71(1–2):33–49 (254 ref.)

Neurochemical and morphological changes associated with human epilepsy. Glass M, et al. **Brain Res Brain Res Rev** 1995 Jul;21(1):29–41 (158 ref.)

Neuropeptides in the human brain. Takahashi K, et al. **Funct Neurol** 1996 Mar-Jun;11(2–3):65–98 (266 ref.)

Brain natriuretic peptide in hypertension. Takeda T, et al. **Hypertens Res** 1995 Dec;18(4):259–66 (52 ref.)

Glucocorticoid receptors in depression. Pariante CM, et al. **Isr J Med Sci** 1995 Dec;31(12):705–12 (25 ref.)

The history of iron in the brain. Koeppen AH. **J Neurol Sci** 1995 Dec;134 Suppl:1–9 (47 ref.)

Magnetic resonance imaging of brain iron in health and disease. Vymazal J, et al. **J Neurol Sci** 1995 Dec;134 Suppl:19–26 (55 ref.)

Plasma membrane Ca(2+)-pump functional specialization in the brain. Complex of isoform expression and regulation by effectors. Lehotský J. **Mol Chem Neuropathol** 1995 Jun-Aug;25(2–3):175–87 (45 ref.)

Therapeutic effects of endothelin receptor antagonists in stroke. Barone FC, et al. **Neurol Res** 1995 Aug;17(4):259–64 (70 ref.)

Biochemical background for an analysis of cost-benefit interrelations in aggression. Haller J. **Neurosci Biobehav Rev** 1995 Winter;19(4):599–604 (52 ref.)

Psychopharmacology of central serotonergic systems. Baumgarten HG, et al. **Pharmacopsychiatry** 1995 Oct;28 Suppl 2:73–9 (42 ref.)

Neuropeptide changes in cortical and deep gray structures in Alzheimer's disease. Roeske LC, et al. **Rev Neurosci** 1995 Oct-Dec;6(4):317–28 (156 ref.)

BRAIN CONCUSSION

DIAGNOSIS

Minor head injury: attempts at clarifying the confusion. Kibby MY, et al. **Brain Inj** 1996 Mar;10(3):159–86 (71 ref.)

The post-concussional syndrome: physiogenesis, psychogenesis and malingering. An integrative model. Jacobson RR. **J Psychosom Res** 1995 Aug;39(6):675–93 (119 ref.)

ETIOLOGY

Unilateral spatial neglect due to a haemorrhagic contusion in the right frontal lobe. Maeshima S, et al. **J Neurol** 1995 Oct;242(10):613–7 (15 ref.)

REHABILITATION

[Neuropedagogic aspects of children with acquired craniocerebral trauma--an overview] Vandermeulen JA, et al. **Rehabilitation (Stuttg)** 1995 Aug;34(3):139–47 (140 ref.) (Eng. Abstr.) **(Ger)**

BRAIN DAMAGE, CHRONIC

CHEMICALLY INDUCED

Neurobehavioral effects of developmental methylmercury exposure. Gilbert SG, et al. **Environ Health Perspect** 1995 Sep;103 Suppl 6:135–42 (107 ref.)

CONGENITAL

-Prenatal diagnosis of brain damage in the fetus- Dürig P. **Arch Gynecol Obstet** 1995;256 Suppl:S43–9 (46 ref.) **(Ger)**

DIAGNOSIS

Vascular cognitive impairment: a new approach to vascular dementia. Bowler JV, et al. **Baillieres Clin Neurol** 1995 Aug;4(2):357–76 (75 ref.)

Minor head injury: attempts at clarifying the confusion. Kibby MY, et al. **Brain Inj** 1996 Mar;10(3):159–86 (71 ref.)

The neuropsychiatric aspects of boxing. Mendez MF. **Int J Psychiatry Med** 1995;25(3):249–62 (74 ref.)

Neuroimaging in child and adolescent neuropsychiatric disorders. Peterson BS. **J Am Acad Child Adolesc Psychiatry** 1995 Dec; 34(12):1560–76 (115 ref.)

Brief report: neuropsychology of autism: a report on the state of the science. Dawson G. **J Autism Dev Disord** 1996 Apr; 26(2):179–84 (38 ref.)

The post-concussional syndrome: physiogenesis, psychogenesis and malingering. An integrative model. Jacobson RR. **J Psychosom Res** 1995 Aug;39(6):675–93 (119 ref.)

Clinical correlations: MRI and EEG. Fish DR, et al. **Magn Reson Imaging** 1995;13(8):1113–7 (18 ref.)

The accuracy of automated and clinical detection of brain damage and lateralization in neuropsychology. Russell EW. **Neuropsychol Rev** 1995 Mar;5(1):1–68 (105 ref.)

Degenerative central nervous system disease. Vadasz AG, et al. **Pediatr Rev** 1995 Nov;16(11):426–31 (0 ref.)

Neuropsychological principia brevita: an application to traumatic (acquired) brain injury. Persinger MA. **Psychol Rep** 1995 Dec;77(3 Pt 1):707–24 (41 ref.)

[Activity and motivational disorders in neurology: proposal for an evaluation scale] Habib M. **Encephale** 1995 Sep-Oct; 21(5):563–70 (21 ref.) (Eng. Abstr.) **(Fre)**

[Intensive monitoring of the fetus sub partu--value and false interpretation] Saling E. **Geburtshilfe Frauenheilkd** 1995 Nov;55(11):628–33 (18 ref.) (Eng. Abstr.) **(Ger)**

[Significance of intrapartum hypoxia for cerebral long-term morbidity] Schneider H. **Z Geburtshilfe Neonatol** 1996 Mar-Apr;200(2):43–9 (47 ref.) (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

Psychiatric sequelae of low birth weight. Breslau N. **Epidemiol Rev** 1995;17(1):96–106 (70 ref.)

ETIOLOGY

The Zavanelli maneuver for fetal shoulder dystocia. Three cases with poor outcomes. Spellacy WN. **J Reprod Med** 1995 Jul;40(7):543–4 (7 ref.)

Brain damage and postoperative hyponatremia: the role of gender. Ayus JC, et al. **Neurology** 1996 Feb;46(2):323–8 (72 ref.)

Role of oxidants in ischemic brain damage. Chan PH. **Stroke** 1996 Jun;27(6):1124–9 (56 ref.)

-Perinatal asphyxia of the neonate at term- Fawer CL. **Arch Gynecol Obstet** 1995;256 Suppl:S61–70 (13 ref.) **(Fre)**

[Bird headed dwarfism in Seckel syndrome. Nosologic difficulties] Parent P, et al. **Arch Pediatr** 1996 Jan;3(1):55–62 (47 ref.) (Eng. Abstr.) **(Fre)**

-Brain damage in infancy: mostly not intrapartum. On the etiology of mental and neurologic handicaps- Largo RH, et al. **Arch Gynecol Obstet** 1995;256 Suppl:S71–80 (18 ref.) **(Ger)**

-Neonatal asphyxia as the cause of brain damage in children?- Schneider H. **Arch Gynecol Obstet** 1995;256 Suppl:S32–42 (75 ref.) (Eng. Abstr.) **(Ger)**

[Amnestic syndrome--research update] Wetterling T. **Fortschr Neurol Psychiatr** 1995 Oct;63(10):402–10 (134 ref.) (Eng. Abstr.) **(Ger)**

GENETICS

MRI in cerebral developmental malformations and epilepsy. Kuzniecky RI. **Magn Reson Imaging** 1995;13(8):1137–45 (31 ref.)

PHYSIOPATHOLOGY

Brief report: brain mechanisms in autism: functional and structural abnormalities. Minshew NJ. **J Autism Dev Disord** 1996 Apr;26(2):205–9 (6 ref.)

Models of delayed recovery. Leviton A, et al. **J Child Neurol** 1995 Sep;10(5):385–91 (55 ref.)

Neuroanatomical correlates of category-specific semantic disorders: a critical survey. Gainotti G, et al. **Memory** 1995 Sep-Dec;3(3–4):247–64 (50 ref.)

The role of the neurohormone melatonin as a buffer against macromolecular oxidative damage. Reiter RJ. **Neurochem Int** 1995 Dec;27(6):453–60 (54 ref.)

Normal and abnormal calcium homeostasis in neurons: a basis for the pathophysiology of traumatic and ischemic central nervous system injury. Tymianski M, et al. **Neurosurgery** 1996 Jun;38(6):1176–95 (300 ref.)

Near infrared spectroscopy: methodological principles and clinical application in preterm infants. Bernert G, et al. **Wien Klin Wochenschr** 1995;107(19):569–73 (36 ref.)

PREVENTION & CONTROL

Dexamethasone and the prevention of neonatal hypoxic-ischemic brain damage. Tuor UI. **Ann N Y Acad Sci** 1995 Sep 15;765:179–95; discussion 196–7 (97 ref.)

[Function-controlled neurosurgery. Neurophysiologic and neuropsychological monitoring during surgery of the nervous system] Schmid UD, et al. **Nervenarzt** 1995 Aug; 66(8):582–95 (84 ref.) (Eng. Abstr.) **(Ger)**

PSYCHOLOGY

Recent advances in the neuropsychology of human olfaction and anosmia. Sullivan TE, et al. **Brain Inj** 1995 Aug-Sep; 9(6):641–6 (22 ref.)

RADIONUCLIDE IMAGING

Brain SPECT imaging of neuropsychiatric disorders. Krausz Y, et al. **Eur J Radiol** 1996 Feb;21(3):183–7 (39 ref.)

REHABILITATION

Recovery from stroke: rehabilitation. Speach DP, et al. **Baillieres Clin Neurol** 1995 Aug;4(2):317–38 (115 ref.)

Models of brain injury rehabilitation. Burke DC. **Brain Inj** 1995 Oct;9(7):735–43 (34 ref.)

The effectiveness of traumatic brain injury rehabilitation: a review. Cope DN. **Brain Inj** 1995 Oct;9(7):649–70 (56 ref.)

A multi-factor account of disability after brain injury: implications for neuropsychological counselling. Montgomery GK. **Brain Inj** 1995 Jul;9(5):453–69 (45 ref.)

BRAIN DAMAGE, CHRONIC

The evolution of the clinician-scientist model of neurological rehabilitation. Peters MD, et al. **Brain Inj** 1995 Aug-Sep; 9(6):543-52 (28 ref.)

Level of care options for the low-functioning brain injury survivor. Walker WC, et al. **Brain Inj** 1996 Jan;10(1):65-75 (30 ref.)

Treatment methodology. Guiding of behaviour through redirection in brain injury rehabilitation. Yuen HK, et al. **Brain Inj** 1996 Mar;10(3):229-38 (15 ref.)

[Pedagogic responsibilities in rehabilitation of brain damaged patients] Stadler H. **Rehabilitation (Stuttg)** 1996 May; 35(2):109-18 (25 ref.) (Eng. Abstr.) **(Ger)**

[Neuropedagogic aspects of children with acquired craniocerebral trauma--an overview] Vandermeulen JA, et al. **Rehabilitation (Stuttg)** 1995 Aug;34(3):139-47 (140 ref.) (Eng. Abstr.) **(Ger)**

BRAIN DEATH

Redefining death in America, 1968. Stevens ML. **Caduceus** 1995 Winter;11(3):207-19 (41 ref.)

Death on neurological grounds. Machado C. **J Neurosurg Sci** 1994 Dec;38(4):209-22 (100 ref.)

Your child is brain dead. Blair AW, et al. **Postgrad Med J** 1996 Mar;72(845):137-40 (33 ref.)

[Uncommon reflex automatisms after brain death] Awada A. **Rev Neurol (Paris)** 1995 Oct;151(10):586-8 (11 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Criteria for the diagnosis of brain stem death. Review by a working group convened by the Royal College of Physicians and endorsed by the Conference of Medical Royal Colleges and their Faculties in the United Kingdom. **J R Coll Physicians Lond** 1995 Sep-Oct;29(5):381-2 (7 ref.)

LEGISLATION & JURISPRUDENCE

[General aspects of organ donation] Gubernatis G, et al. **Chirurg** 1996 Apr;67(4):300-9 (30 ref.) (Eng. Abstr.) **(Ger)**

BRAIN DISEASES

see related
ORGANIC MENTAL DISORDERS, PSYCHOTIC

[Primary angiitis of the central nervous system] Abu-Shakra M, et al. **Harefuah** 1996 Jan 1;130(1):26-9 (24 ref.) **(Heb)**

CHEMICALLY INDUCED

Neurophysiologic evaluation of cyclosporine toxicity associated with bone marrow transplantation. Edwards LL, et al. **Acta Neurol Scand** 1995 Nov;92(5):423-9 (11 ref.)

Transient encephalopathy after paclitaxel (Taxol) infusion. Perry JR, et al. **Neurology** 1996 Jun;46(6):1596-9 (15 ref.)

NMDA antagonists as neurotherapeutic drugs, psychotogens, neurotoxins, and research tools for studying schizophrenia. Olney JW, et al. **Neuropsychopharmacology** 1995 Dec; 13(4):335-45 (75 ref.)

[Encephalopathy, convulsions and hypopotassemia in theophylline poisoning: a case analysis] Suárez Ortega S, et al. **Arch Bronconeumol** 1995 Aug-Sep;31(7):368-70 (23 ref.) (Eng. Abstr.) **(Spa)**

CLASSIFICATION

[Classification and pathogenesis of cerebral cortical malformations] Takashima S, et al. **No To Hattatsu** 1996 Jan;28(1):14-22 (22 ref.) (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

Treatment modalities for hypertensive patients with intracranial pathology: options and risks. Tietjen CS, et al. **Crit Care Med** 1996 Feb;24(2):311-22 (86 ref.)

Ophthalmologic abnormalities in encephalocraniocutaneous lipomatosis. MacLaren MJ, et al. **Doc Ophthalmol** 1995; 90(1):87-98 (31 ref.)

Are mental diseases brain diseases? The contribution of neuropathology to understanding of schizophrenic psychoses. Knable MB, et al. **Eur Arch Psychiatry Clin Neurosci** 1995;245(4-5):224-30 (78 ref.)

Fever in neurologic diseases. Powers JH, et al. **Infect Dis Clin North Am** 1996 Mar;10(1):45-66 (57 ref.)

Diagnostic testing for the evaluation of headaches. Evans RW. **Neurol Clin** 1996 Feb;14(1):1-26 (159 ref.)

Central pain: diagnosis and treatment strategies. Gonzales GR. **Neurology** 1995 Dec;45(12 Suppl 9):S11-6; discussion S35-6 (24 ref.)

Fever, abdominal pain and an intracranial mass. Wong M, et al. **Pediatr Infect Dis J** 1995 Aug;14(8):725-8 (18 ref.)

Invasive aspergilloma of the frontal base causing internal carotid artery occlusion. Satoh H, et al. **Surg Neurol** 1995 Nov;44(5):483-8 (30 ref.)

[Liver transplantation and neurological complications of hepatopathy] Gisbert C, et al. **Rev Neurol** 1995 Sep-Oct; 23(123):1033-6 (7 ref.) **(Spa)**

[Organic hyperactivity] Yelin B. **Rev Neurol** 1995;23 Suppl 3:S314-7 (36 ref.) **(Spa)**

CONGENITAL

A nine-month-old boy with microcephaly, cataracts, intracerebral calcifications and dysmorphic signs: an additional observation of an autosomal recessive congenital infection-like syndrome? Wieczorek D, et al. **Genet Couns** 1995;6(4):297-302 (18 ref.)

[Corpus callosum agenesis and parasagittal interhemispheric cyst] Doffe L, et al. **J Radiol** 1996 Jun;77(6):427-30 (15 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Clinical applications of proton MR spectroscopy. Castillo M, et al. **AJNR Am J Neuroradiol** 1996 Jan;17(1):1-15 (64 ref.)

Advances in neuroimaging of the visual pathways. Davis PC, et al. **Am J Ophthalmol** 1996 Jun;121(6):690-705 (37 ref.)

Familial bilateral periventricular nodular heterotopia mimics tuberous sclerosis. Jardine PE, et al. **Arch Dis Child** 1996 Mar;74(3):244-6 (13 ref.)

Imaging methods as a diagnostic tool in neuro-AIDS. A review. Arendt G. **Bildgebung** 1995 Dec;62(4):310-9 (51 ref.)

3M Mayneord Memorial Lecture: functional brain imaging--an overview. Orrison WW Jr. **Br J Radiol** 1996 Jun;69(822):493-501 (17 ref.)

Non-Alzheimer's disease amyloidoses of the nervous system. Castaño EM, et al. **Curr Opin Neurol** 1995 Aug;8(4):279-85 (57 ref.)

A rare case of idiopathic hypoparathyroidism with varied neurological manifestations. Abe S, et al. **Intern Med** 1996 Feb;35(2):129-34 (37 ref.)

Neurologic assessment and cardiac surgery. Heyer EJ, et al. **J Cardiothorac Vasc Anesth** 1996 Jan;10(1):99-103; quiz 103-4 (42 ref.)

MR angiography flow analysis. Neurovascular applications. Turski PA, et al. **Magn Reson Imaging Clin N Am** 1995 Aug;3(3):541-55 (38 ref.)

Base of skull, nasopharynx, and parapharyngeal space. Vogl TJ, et al. **Neuroimaging Clin N Am** 1996 May;6(2):357-78 (25 ref.)

Central pain: diagnosis and treatment strategies. Gonzales GR. **Neurology** 1995 Dec;45(12 Suppl 9):S11-6; discussion S35-6 (24 ref.)

Positron emission tomography: present and future. Heiss WD. **Technol Health Care** 1996 Apr;4(1):15-29 (60 ref.)

[Magnetic resonance or computerized tomography for imaging of the brain?] Suoranta H, et al. **Duodecim** 1994; 110(16):1540-7 (9 ref.) **(Fin)**

[MRI aspect and course of supra-tentorial sarcoidosic lesions] Caparros-lefebvre D, et al. **Rev Neurol (Paris)** 1996 Mar; 152(3):196-201 (45 ref.) (Eng. Abstr.) **(Fre)**

[Anarthria, progressive apraxia and extrapyramidal syndrome: an uncommon clinical form of corticobasal degeneration? A case studied by HMPAO Tc99m single-photon emission tomography] Fayet G, et al. **Rev Neurol (Paris)** 1995 Apr;151(4):247-50 (14 ref.) (Eng. Abstr.) **(Fre)**

[Neuroradiology in ophthalmology. 2] Müller-Forell W, et al. **Ophthalmologe** 1995 Oct;92(5):757-84 (26 ref.) **(Ger)**

[Neuroradiology in ophthalmology. 1] Müller-Forell W, et al. **Ophthalmologe** 1995 Aug;92(4):595-614 (0 ref.) **(Ger)**

[Echo-planar imaging of the brain] Brüning R, et al. **Radiologe** 1995 Dec;35(12):902-10 (61 ref.) (Eng. Abstr.) **(Ger)**

[Fast and ultra-fast MRI of the brain] Schuierer G, et al. **Radiologe** 1995 Dec;35(12):894-901 (25 ref.) (Eng. Abstr.) **(Ger)**

[Magnetic resonance in AIDS-related encephalopathy] Gualdi GF, et al. **Clin Ter** 1995 Dec;146(12):843-56 (42 ref.) (Eng. Abstr.) **(Ita)**

[A case of cysticercosis of the third ventricle] El'iashevich GP. **Lik Sprava** 1995 Jul-Aug;(7-8):131-2 (9 ref.) **(Rus)**

[Intracranial mass as single manifestation of sarcoidosis] Rodríguez-Carballeira M, et al. **Rev Clin Esp** 1995 Nov; 195(11):765-8 (22 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Clinical potential for the use of neuroprotective agents. A brief overview. Trembly B. **Ann N Y Acad Sci** 1995 Sep 15;765:1-20; discussion 26-7 (87 ref.)

Rhinocerebral mucormycosis. Therapy with amphotericin B lipid complex. Strasser MD, et al. **Arch Intern Med** 1996 Feb 12;156(3):337-9 (21 ref.)

Oropharyngeal dysphagia due to iatrogenic neurological dysfunction. Buchholz DW. **Dysphagia** 1995 Fall; 10(4):248-54 (51 ref.)

Involvement of endogenous benzodiazepine receptor ligands in brain disorders: therapeutic potential for benzodiazepine antagonists? Polc P. **Med Hypotheses** 1995 Jun;44(6):439-46 (51 ref.)

Transporting therapeutics across the blood-brain barrier. Abbott NJ, et al. **Mol Med Today** 1996 Mar;2(3):106-13 (41 ref.)

EMBRYOLOGY

Fetal porencephaly: a review of etiology, diagnosis, and prognosis. Eller KM, et al. **Obstet Gynecol Surv** 1995 Sep; 50(9):684-7 (14 ref.)

ENZYMOLOGY

Multifunctional calcium and calmodulin-dependent kinase II in neuronal function and disease. Churn SB. **Adv Neuroimmunol** 1995;5(3):241-59 (141 ref.)

EPIDEMIOLOGY

[Neuroepidemiology: study of epidemic forms of neuropathies] Román GC. **Rev Neurol** 1996 Jun; 24(130):701-2 (8 ref.) **(Spa)**

ETIOLOGY

The management of temperature during cardiopulmonary bypass: effect on neuropsychological outcome. Nathan HJ, et al. **J Card Surg** 1995 Jul;10(4 Suppl):481-7 (50 ref.)

Neuropsychologic change after cardiac surgery: a critical review. Borowicz LM, et al. **J Cardiothorac Vasc Anesth** 1996 Jan;10(1):105-11; quiz 111-2 (61 ref.)

Neuropsychologic dysfunction after cardiac surgery: what is the problem? Gill R, et al. **J Cardiothorac Vasc Anesth** 1996 Jan;10(1):91-8 (62 ref.)

Hypothermia, circulatory arrest, and the pediatric brain. Jonas RA. **J Cardiothorac Vasc Anesth** 1996 Jan;10(1):66-74 (34 ref.)

Normothermic versus hypothermic cardiopulmonary bypass: central nervous system outcomes. McLean RF, et al. **J Cardiothorac Vasc Anesth** 1996 Jan;10(1):45-52; quiz 52-3 (114 ref.)

Adverse neurologic events: risks of intracardiac versus extracardiac surgery. Nussmeier NA. **J Cardiothorac Vasc Anesth** 1996 Jan;10(1):31-7 (86 ref.)

Neurologic evaluation of the patient with acute bacterial meningitis. Ashwal S. **Neurol Clin** 1995 Aug;13(3):549-77 (105 ref.)

Critical neurologic illness in the immunocompromised patient. Cohen JA, et al. **Neurol Clin** 1995 Aug;13(3):659-77 (93 ref.)

Secondary brain insults after head injury: clinical perspectives. Chesnut RM. **New Horiz** 1995 Aug; 3(3):366-75 (44 ref.)

Neuronal damage in the developing brain following intrauterine asphyxia. Mallard EC, et al. **Reprod Fertil Dev** 1995;7(3):647-53 (100 ref.)

Central nervous system complications of lightning and electrical injuries. Cherington M. **Semin Neurol** 1995 Sep; 15(3):233-40 (107 ref.)

[Classification and pathogenesis of cerebral cortical malformations] Takashima S, et al. **No To Hattatsu** 1996 Jan;28(1):14-22 (22 ref.) (Eng. Abstr.) **(Jpn)**

[Free radicals and neurological disorders] Yokoi I, et al. **No To Shinkei** 1995 Nov;47(11):1039-49 (66 ref.) **(Jpn)**

[Cerebrovascular complications in patients with cancer] Casado JL, et al. **Rev Neurol** 1995;23 Suppl 1:S70-8 (75 ref.) **(Spa)**

[Neurological complications after liver transplantation] Casanova B, et al. **Rev Neurol** 1995 Sep-Oct; 23(123):1037-40 (28 ref.) **(Spa)**

[Prognostic indicators of neurological sequelae in perinatal asphyxia: state of the art] González de Dios J. **Rev Neurol** 1995 Mar-Apr;23(120):351-62 (194 ref.) **(Spa)**

[Cerebrovascular manifestations of infectious diseases] Martínez Vázquez F, et al. **Rev Neurol** 1995;23 Suppl 1:S11-21 (88 ref.) **(Spa)**

[Neurological complications after transplants: cerebrovascular complications] Martinez-Vila E, et al. **Rev Neurol** 1995;23 Suppl 1:S79-86 (49 ref.) **(Spa)**

GENETICS

Absence makes the search grow longer [editorial; comment] Dobyns WB. **Am J Hum Genet** 1996 Jan;58(1):7-16 (121 ref.) Comment on: Am J Hum Genet 1996 Jan;58(1):28-34.

The Aicardi-Goutières syndrome (familial, early onset encephalopathy with calcifications of the basal ganglia and chronic cerebrospinal fluid lymphocytosis). Tolmie JL, et al. **J Med Genet** 1995 Nov;32(11):881-4 (26 ref.)

Association of infantile neuroaxonal dystrophy and osteopetrosis: a rare autosomal recessive disorder. Rees H, et al. **Pediatr Neurosurg** 1995;22(6):321-7 (36 ref.)

[Striato-pallido-dentate calcifications and acquired facial atrophy] Derex L, et al. **Rev Neurol (Paris)** 1995 Oct; 151(10):559-62 (13 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Neuro-glial-immune interactions. An experimental, neural transplant and lesion study. Finsen B. **Dan Med Bull** 1995 Sep;42(4):323-41 (192 ref.)

[Role of gamma-delta T-cells and heat shock proteins in immunological response and in pathogenesis of neurological diseases] Fiszer U. **Neurol Neurochir Pol** 1995 Sep-Oct;29(5):737-45 (30 ref.) (Eng. Abstr.) **(Pol)**

METABOLISM

Disturbances of acetyl-CoA, energy and acetylcholine metabolism in some encephalopathies. Szutowicz A, et al. **Acta Neurobiol Exp (Warsz)** 1996;56(1):323-39 (110 ref.)

[Congenital disorders of the bile acid metabolism (3 beta-hydroxy-delta 5-steroid dehydrogenase/isomerase deficiency, delta 4-3-oxosteroid 5 beta-reductase

deficiency, cerebrotendinous xanthomatosis, and peroxisomal disorders] Kondo KH, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):362–6 (23 ref.) **(Jpn)**

MICROBIOLOGY

Managing HIV. Part 5: Treating secondary outcomes. 5.5 HIV and opportunistic neurological infections. Jones PD, et al. **Med J Aust** 1996 Apr 1;164(7):418–21 (22 ref.)

Invasive aspergilloma of the frontal base causing internal carotid artery occlusion. Satoh H, et al. **Surg Neurol** 1995 Nov;44(5):483–8 (30 ref.)

PARASITOLOGY

Cysticercosis. Sotelo J, et al. **Curr Clin Top Infect Dis** 1996; 16:240–59 (109 ref.)

Distinctive serial magnetic resonance changes in a young woman with rapidly evolved neurocysticercosis, with positron emission tomography results. Nagayama M, et al. **J Neuroimaging** 1996 Jul;6(3):198–201 (15 ref.)

Magnetoencephalographic features in neurocysticercosis. Morioka T, et al. **Surg Neurol** 1996 Feb;45(2):176–81; discussion 181–2 (46 ref.)

[Occurrence of cysticercosis in autopsies performed in Uberlandia, Minas Gerais, Brazil] Costa-Cruz JM, et al. **Arq Neuropsiquiatr** 1995 Jun;53(2):227–32 (25 ref.) (Eng. Abstr.) **(Por)**

PATHOLOGY

Xanthoma disseminatum with massive intracranial involvement. Hammond RR, et al. **Clin Neuropathol** 1995 Nov–Dec;14(6):314–21 (32 ref.)

Intracerebral A lambda amyloidoma diagnosed by stereotactic biopsy. Schröder R, et al. **Clin Neuropathol** 1995 Nov–Dec;14(6):347–50 (34 ref.)

The history of iron in the brain. Koeppen AH. **J Neurol Sci** 1995 Dec;134 Suppl:1–9 (47 ref.)

[Occurrence of cysticercosis in autopsies performed in Uberlandia, Minas Gerais, Brazil] Costa-Cruz JM, et al. **Arq Neuropsiquistr** 1995 Jun;53(2):227–32 (25 ref.) (Eng. Abstr.) **(Por)**

PHYSIOPATHOLOGY

Cognitive functioning in "diffuse" pathology. Role of prefrontal and limbic structures. Boller F, et al. **Ann N Y Acad Sci** 1995 Dec 15;769:23–39 (51 ref.)

Experimental approach to prefrontal functions in humans. Dubois B, et al. **Ann N Y Acad Sci** 1995 Dec 15;769:41–60 (65 ref.)

Toward a cognitive account of frontal lobe function: simulating frontal lobe deficits in normal subjects. Dunbar K, et al. **Ann N Y Acad Sci** 1995 Dec 15;769:289–304 (34 ref.)

Planning and script analysis following prefrontal lobe lesions. Sirigu A, et al. **Ann N Y Acad Sci** 1995 Dec 15;769:277–88 (18 ref.)

Adenosine: a prototherapeutic concept in neurodegeneration. von Lubitz DK, et al. **Ann N Y Acad Sci** 1995 Sep 15; 765:163–78; discussion 196–7 (123 ref.)

Hemodynamic mechanisms of neurogenic pulmonary edema. Chen HI. **Biol Signals** 1995 May–Jun;4(3):186–92 (40 ref.)

Are mental diseases brain diseases? The contribution of neuropathology to understanding of schizophrenic psychoses. Knable MB, et al. **Eur Arch Psychiatry Clin Neurosci** 1995;245(4–5):224–30 (78 ref.)

Mapping function in the human brain with magnetoencephalography, anatomical magnetic resonance imaging, and functional magnetic resonance imaging. George JS, et al. **J Clin Neurophysiol** 1995 Sep;12(5):406–31 (90 ref.)

Comparative assessment of sensorimotor function using functional magnetic resonance imaging and electrophysiological methods. Puce A. **J Clin Neurophysiol** 1995 Sep;12(5):450–9 (55 ref.)

Multimodal monitoring in neurointensive care. Kirkpatrick PJ, et al. **J Neurol Neurosurg Psychiatry** 1996 Feb; 60(2):131–9 (96 ref.)

Clinical applications of functional MRI in neuropsychiatry. Levin JM, et al. **J Neuropsychiatry Clin Neurosci** 1995 Fall; 7(4):511–22 (98 ref.)

Involvement of endogenous benzodiazepine receptor ligands in brain disorders: therapeutic potential for benzodiazepine antagonists? Polc P. **Med Hypotheses** 1995 Jun;44(6):439–46 (51 ref.)

The blood–brain barrier and selective vulnerability in experimental thiamine-deficiency encephalopathy in the mouse. Harata N, et al. **Metab Brain Dis** 1996 Mar; 11(1):55–69 (78 ref.)

Cell stress genes and chronic neurodegenerative disorders. Cheetham ME. **Neuropathol Appl Neurobiol** 1995 Dec; 21(6):486–8 (20 ref.)

Cerebral salt wasting syndrome: a review. Harrigan MR. **Neurosurgery** 1996 Jan;38(1):152–60 (80 ref.)

Magnetoencephalographic features in neurocysticercosis. Morioka T, et al. **Surg Neurol** 1996 Feb;45(2):176–81; discussion 181–2 (46 ref.)

PSYCHOLOGY

Neuropsychological aspects of frontotemporal degeneration. Neary D. **Ann N Y Acad Sci** 1995 Dec 15;769:15–22 (31 ref.)

RADIOGRAPHY

Acute neuroradiology: methods, indications and timing. Fagerlund MK. **Ann Med** 1995 Dec;27(6):657–62 (53 ref.)

Early onset bilateral calcifications and epilepsy. Nunes ML, et al. **Pediatr Neurol** 1995 Jul;13(1):80–2 (11 ref.)

RADIONUCLIDE IMAGING

The current status of clinical PET imaging. Cook GJ, et al. **Clin Radiol** 1996 Sep;51(9):603–13 (108 ref.)

Brain SPECT imaging of neuropsychiatric disorders. Krausz Y, et al. **Eur J Radiol** 1996 Feb;21(3):183–7 (39 ref.)

Neurochemical imaging of the brain in health and disease. Biegon A. **Isr J Med Sci** 1996 May;32(5):271–5 (34 ref.)

[SPECT. An important clinical method for brain function studies] Wikkelsø C, et al. **Lakartidningen** 1996 Jul 10; 93(28–29):2585–91 (78 ref.) **(Swe)**

SURGERY

Space-occupying lesions of the sensori-motor region. Ebeling U, et al. **Adv Tech Stand Neurosurg** 1995;22:137–81 (106 ref.)

Neuro-glial-immune interactions. An experimental, neural transplant and lesion study. Finsen B. **Dan Med Bull** 1995 Sep;42(4):323–41 (192 ref.)

Magnetic resonance imaging and epilepsy: neurosurgical decision making. Fried I. **Magn Reson Imaging** 1995; 13(8):1163–70 (47 ref.)

Arteriovenous malformation associated with a large cyst—case report. Hatashita S, et al. **Neurol Med Chir (Tokyo)** 1995 Jun;35(6):377–9 (8 ref.)

Tremor as the result of shunt obstruction: four patients with cysticercosis and secondary parkinsonism: report of four cases. Keane JR. **Neurosurgery** 1995 Sep;37(3):520–2 (3 ref.)

[Function-controlled neurosurgery. Neurophysiologic and neuropsychological monitoring during surgery of the nervous system] Schmid UD, et al. **Nervenarzt** 1995 Aug; 66(8):582–95 (84 ref.) (Eng. Abstr.) **(Ger)**

[Use of hypothermia in neurosurgery] Sogomonian SA, et al. **Anesteziol Reanimatol** 1996 Mar–Apr;(2):90–2 (30 ref.) **(Rus)**

THERAPY

Neurologic emergencies. Piecuch JF, et al. **Dent Clin North Am** 1995 Jul;39(3):567–75 (13 ref.)

Active cooling during anesthesia and critical care. Illievich UM, et al. **J Neurosurg Anesthesiol** 1996 Jan;8(1):78–82 (56 ref.)

VIROLOGY

HSV-1 brain infection by the olfactory nerve route and virus latency and reactivation may cause learning and behavioral deficiencies and violence in children and adults: a point of view. Becker Y. **Virus Genes** 1995;10(3):217–26 (58 ref.)

BRAIN DISEASES, METABOLIC

DIAGNOSIS

Hyperhomocysteinaemia; with reference to its neuroradiological aspects. van den Berg M, et al. **Neuroradiology** 1995 Jul;37(5):403–11 (78 ref.)

Degenerative central nervous system disease. Vadasz AG, et al. **Pediatr Rev** 1995 Nov;16(11):426–31 (0 ref.)

BRAIN DYSFUNCTION, MINIMAL see ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY

BRAIN EDEMA

DRUG THERAPY

Steroids in head injury. Kelly DF. **New Horiz** 1995 Aug; 3(3):453–5 (15 ref.)

[Treatment of ischemic cerebral infarct with glycerine] Winter R, et al. **Nervenarzt** 1995 Aug;66(8):596–602 (63 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Brain swelling after dialysis: old urea or new osmoles? Silver SM, et al. **Am J Kidney Dis** 1996 Jul;28(1):1–13 (49 ref.)

Complications of the gamma knife. Wiet RJ, et al. **Arch Otolaryngol Head Neck Surg** 1996 Apr;122(4):414–6 (13 ref.)

The management of renal failure in patients at risk of cerebral edema/hypoxia. Davenport A. **New Horiz** 1995 Nov; 3(4):717–24 (54 ref.)

[The role of mediator-metabolic factors in the development of brain edema-swelling] Novikov VE, et al. **Usp Fiziol Nauk** 1996 Apr–Jun;27(2):78–89 (118 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Hypothetical roles of angiogenesis, osmotic swelling, and ischemia in high-altitude cerebral edema. Severinghaus JW. **J Appl Physiol** 1995 Aug;79(2):375–9 (68 ref.)

Current concepts of brain edema. Review of laboratory investigations. Kimelberg HK. **J Neurosurg** 1995 Dec; 83(6):1051–9 (92 ref.)

Diffusion-weighted imaging in epilepsy. Helpern JA, et al. **Magn Reson Imaging** 1995;13(8):1227–31 (32 ref.)

Malignant cerebral edema and intracranial hypertension. Bingaman WE, et al. **Neurol Clin** 1995 Aug;13(3):479–509 (175 ref.)

THERAPY

Hyperventilation therapy for severe traumatic brain injury. Marion DW, et al. **New Horiz** 1995 Aug;3(3):439–47 (66 ref.)

BRAIN ELECTRICAL ACTIVITY MAPPING see BRAIN MAPPING

BRAIN INJURIES

Penetrating gunshots to the head and lack of immediate incapacitation. II. Review of case reports. Karger B. **Int J Legal Med** 1995;108(3):117–26 (75 ref.)

Multivariate analysis and prediction of outcome following penetrating head injury. Polin RS, et al. **Neurosurg Clin N Am** 1995 Oct;6(4):689–99 (25 ref.)

Penetrating injuries in the Vietnam war. Traumatic unconsciousness, epilepsy, and psychosocial outcome. Salazar AM, et al. **Neurosurg Clin N Am** 1995 Oct; 6(4):715–26 (34 ref.)

Neurotrauma and trauma systems. Pitts LH. **New Horiz** 1995 Aug;3(3):546–8 (13 ref.)

COMPLICATIONS

Cerebral salt wasting in children: the role of atrial natriuretic hormone. Kappy MS, et al. **Adv Pediatr** 1996;43:271–308 (104 ref.)

Treatment modalities for hypertensive patients with ictracranial pathology: options and risks. Tietjen CS, et al. **Crit Care Med** 1996 Feb;24(2):311–22 (86 ref.)

Posttraumatic cerebral arterial spasm. Martin NA, et al. **J Neurotrauma** 1995 Oct;12(5):897–901 (22 ref.)

The effect of associated injuries, blood loss, and oxygen debt on death and disability in blunt traumatic brain injury: the need for early physiologic predictors of severity. Siegel JH. **J Neurotrauma** 1995 Aug;12(4):579–90 (18 ref.)

Management of traumatic aneurysms caused by high-velocity missile head wounds. Aarabi B. **Neurosurg Clin N Am** 1995 Oct;6(4):775–97 (263 ref.)

Enhanced vulnerability to secondary ischemic insults after experimental traumatic brain injury. DeWitt DS, et al. **New Horiz** 1995 Aug;3(3):376–83 (66 ref.)

Post-traumatic epilepsy: mechanisms and prevention. Willmore LJ. **Psychiatry Clin Neurosci** 1995 Jun; 49(3):S171–3 (11 ref.)

[Neuropsychological description of memory impairment following cortical and subcortical brain injuries] Jodzio K. **Psychiatr Pol** 1995 Jul–Aug;29(4):491–501 (29 ref.) (Eng. Abstr.) **(Pol)**

DIAGNOSIS

Prediction of recovery from traumatic brain injury. Levin HS. **J Neurotrauma** 1995 Oct;12(5):913–22 (44 ref.)

New magnetic resonance imaging techniques for the evaluation of traumatic brain injury. Smith DH, et al. **J Neurotrauma** 1995 Aug;12(4):573–7 (34 ref.)

Neuropsychological principia brevita: an application to traumatic (acquired) brain injury. Persinger MA. **Psychol Rep** 1995 Dec;77(3 Pt 1):707–24 (41 ref.)

[Traumatic brain injuries in children. New imaging methods are better basis for prognosis] Christerson S. **Lakartidningen** 1996 Aug 28;93(35):2951–6 (50 ref.) **(Swe)**

DRUG THERAPY

Clinical potential for the use of neuroprotective agents. A brief overview. Trembly B. **Ann N Y Acad Sci** 1995 Sep 15;765:1–20; discussion 26–7 (87 ref.)

Lazaroids. CNS pharmacology and current research. Clark WM, et al. **Drugs** 1995 Dec;50(6):971–83 (64 ref.)

The role of excitatory amino acids in severe brain trauma: opportunities for therapy: a review. Zauner A, et al. **J Neurotrauma** 1995 Aug;12(4):547–54 (51 ref.)

Options for cerebral protection after penetrating head injury. Rabb CH. **Neurosurg Clin N Am** 1995 Oct;6(4):643–56 (207 ref.)

Mannitol and other diuretics in severe neurotrauma. Bullock R. **New Horiz** 1995 Aug;3(3):448–52 (44 ref.)

Pharmacologic therapy for traumatic brain injury: experimental approaches. Smith DH, et al. **New Horiz** 1995 Aug;3(3):562–72 (111 ref.)

Pharmacological treatment of central nervous system trauma. Faden AI. **Pharmacol Toxicol** 1996 Jan;78(1):12–7 (62 ref.)

How neurotrophic factors protect brain against excitotoxicity. Cuevas Sanchez P. **Surg Neurol** 1996 Aug; 46(2):152–3 (15 ref.)

ENZYMOLOGY

Matrix metalloproteinases in brain injury. Rosenberg GA. **J Neurotrauma** 1995 Oct;12(5):833–42 (69 ref.)

BRAIN INJURIES

EPIDEMIOLOGY

Epidemiologic aspects of brain injury. Kraus JF, et al. **Neurol Clin** 1996 May;14(2):435–50 (54 ref.)

ETIOLOGY

Intracranial reduction of an intact mandibular condyle displaced into the middle cranial fossa. Sandler NA, et al. **J Oral Maxillofac Surg** 1996 Apr;54(4):506–10 (17 ref.)

Hypothermia in shaken infant syndrome. Wahl NG, et al. **Pediatr Emerg Care** 1995 Aug;11(4):233–4 (18 ref.)

A neurologist's reflections on boxing. II. Acute and chronic clinical findings secondary to central nervous system damage. Unterharnscheidt F. **Rev Neurol** 1995 Jul–Aug; 23(122):833–46 (92 ref.)

A neurologist's reflections on boxing. I: Impact mechanics in boxing and injuries other than central nervous system damage. Unterharnscheidt F. **Rev Neurol** 1995 May–Jun; 23(121):661–74 (63 ref.)

GENETICS

Changes in gene expression following traumatic brain injury in the rat. Hayes RL, et al. **J Neurotrauma** 1995 Oct; 12(5):779–90 (59 ref.)

METABOLISM

Inhibition of lipid peroxidation in central nervous system trauma and ischemia. Hall ED. **J Neurol Sci** 1995 Dec;134 Suppl:79–83 (44 ref.)

Mediators of injury in neurotrauma: intracellular signal transduction and gene expression. Bazan NG, et al. **J Neurotrauma** 1995 Oct;12(5):791–814 (249 ref.)

Transgenic mice and knockout mutants in the study of oxidative stress in brain injury. Chan PH, et al. **J Neurotrauma** 1995 Oct;12(5):815–24 (63 ref.)

Cytoskeletal derangements following central nervous system injury: modulation by neurotrophic gene transfection. Hayes RL, et al. **J Neurotrauma** 1995 Oct;12(5):933–41 (58 ref.)

Changes in gene expression following traumatic brain injury in the rat. Hayes RL, et al. **J Neurotrauma** 1995 Oct; 12(5):779–90 (59 ref.)

The neurochemical and metabolic cascade following brain injury: moving from animal models to man. Hovda DA, et al. **J Neurotrauma** 1995 Oct;12(5):903–6 (27 ref.)

Neurotrophic factors in central nervous system trauma. Mocchetti I, et al. **J Neurotrauma** 1995 Oct;12(5):853–70 (186 ref.)

The effect of associated injuries, blood loss, and oxygen debt on death and disability in blunt traumatic brain injury: the need for early physiologic predictors of severity. Siegel JH. **J Neurotrauma** 1995 Aug;12(4):579–90 (18 ref.)

Molecular biology of CNS injury. Yakovlev AG, et al. **J Neurotrauma** 1995 Oct;12(5):767–77 (83 ref.)

A RT-PCR study of gene expression in a mechanical injury model. Eng LF, et al. **Prog Brain Res** 1995;105:219–29 (29 ref.)

[Cerebral glucose metabolism in craniocerebral trauma: an evaluation] Schelp AO, et al. **Arq Neuropsiquiatr** 1995 Sep; 53(3–B):698–705 (44 ref.) (Eng. Abstr.) **(Por)**

PATHOLOGY

The pathobiology of traumatically induced axonal injury in animals and humans: a review of current thoughts. Povlishock JT, et al. **J Neurotrauma** 1995 Aug;12(4):555–64 (76 ref.)

Supertasting, earaches and head injury: genetics and pathology alter our taste worlds. Bartoshuk LM, et al. **Neurosci Biobehav Rev** 1996;20(1):79–87 (64 ref.)

Neuroimaging in head injury. Gean AD, et al. **New Horiz** 1995 Aug;3(3):549–61 (43 ref.)

Does electroconvulsive therapy damage brain cells? Devanand DP. **Semin Neurol** 1995 Dec;15(4):351–7 (100 ref.)

PHYSIOPATHOLOGY

Brain injury and inflammation. A putative role of TNF alpha. Arvin B, et al. **Ann N Y Acad Sci** 1995 Sep 15;765:62–71; discussion 98–9 (67 ref.)

Re-examining the role of executive functions in routine action production. Schwartz MF. **Ann N Y Acad Sci** 1995 Dec 15;769:321–35 (51 ref.)

Brain injury: the need to assess outcome. Olver JH. **Curr Opin Neurol** 1995 Dec;8(6):443–6 (27 ref.)

Traumatic brain injury. Zink BJ. **Emerg Med Clin North Am** 1996 Feb;14(1):115–50 (149 ref.)

Penetrating gunshots to the head and lack of immediate incapacitation. II. Review of case reports. Karger B. **Int J Legal Med** 1995;108(3):117–26 (75 ref.)

Penetrating gunshots to the head and lack of immediate incapacitation. I. Wound ballistics and mechanisms of incapacitation. Karger B. **Int J Legal Med** 1995; 108(2):53–61 (90 ref.)

Diagnosis, physiology, pathology and rehabilitation of traumatic brain injuries. Berker E. **Int J Neurosci** 1996 Apr; 85(3–4):195–220 (135 ref.)

Salt, starch, and water on the brain. Schell RM, et al. **J Neurosurg Anesthesiol** 1996 Apr;8(2):178–82 (56 ref.)

On the mechanics of impact neurotrauma: a review and critical synthesis. Bandak FA. **J Neurotrauma** 1995 Aug; 12(4):635–49 (28 ref.)

Alcohol and head injury: an issue revisited. Kelly DF. **J Neurotrauma** 1995 Oct;12(5):883–90 (62 ref.)

Recent advances in biomechanics of brain injury research: a review. King AI, et al. **J Neurotrauma** 1995 Aug; 12(4):651–8 (39 ref.)

The pathobiology of traumatically induced axonal injury in animals and humans: a review of current thoughts. Povlishock JT, et al. **J Neurotrauma** 1995 Aug;12(4):555–64 (76 ref.)

Mechanical characteristics of vascular tissue and their role in brain injury modeling: a review. Vossoughi J, et al. **J Neurotrauma** 1995 Aug;12(4):755–63 (52 ref.)

Monitoring the impact of traumatic brain injury: a review and update. Waxweiler RJ, et al. **J Neurotrauma** 1995 Aug; 12(4):509–16 (21 ref.)

The role of excitatory amino acids in severe brain trauma: opportunities for therapy: a review. Zauner A, et al. **J Neurotrauma** 1995 Aug;12(4):547–54 (51 ref.)

Maintaining the neuronal phenotype after injury in the adult CNS. Neurotrophic factors, axonal growth substrates, and gene therapy. Tuszynski MH, et al. **Mol Neurobiol** 1995 Apr–Jun;10(2–3):151–67 (107 ref.)

Cell stress genes and acute CNS injury. McIntosh TK, et al. **Neuropathol Appl Neurobiol** 1995 Dec;21(6):477–9 (27 ref.)

Patients with Glasgow Coma Scale scores 3, 4, 5 after gunshot wounds to the brain. Kaufman HH, et al. **Neurosurg Clin N Am** 1995 Oct;6(4):701–14 (63 ref.)

Cerebral hemodynamic disturbances following penetrating craniocerebral injury and their influence on outcome. Kordestani RK, et al. **Neurosurg Clin N Am** 1995 Oct; 6(4):657–67 (68 ref.)

Options for cerebral protection after penetrating head injury. Rabb CH. **Neurosurg Clin N Am** 1995 Oct;6(4):643–56 (207 ref.)

Normal and abnormal calcium homeostasis in neurons: a basis for the pathophysiology of traumatic and ischemic central nervous system injury. Tymianski M, et al. **Neurosurgery** 1996 Jun;38(6):1176–95 (300 ref.)

Hemodynamic management of brain-injured patients. Tonnesen AS. **New Horiz** 1995 Aug;3(3):499–505 (33 ref.)

Ischemia and lesion induced imbalances in cortical function. Luhmann HJ. **Prog Neurobiol** 1996 Feb;48(2):131–66 (415 ref.)

Post-traumatic epilepsy: mechanisms and prevention. Willmore LJ. **Psychiatry Clin Neurosci** 1995 Jun; 49(3):S171–3 (11 ref.)

A neurologist's reflections on boxing. II. Acute and chronic clinical findings secondary to central nervous system damage. Unterharnscheidt F. **Rev Neurol** 1995 Jul–Aug; 23(122):833–46 (92 ref.)

How neurotrophic factors protect brain against excitotoxicity. Cuevas Sanchez P. **Surg Neurol** 1996 Aug; 46(2):152–3 (15 ref.)

[Neurological diseases and driving] Mola S. **Rev Neurol** 1995 Mar–Apr;23(120):334–50 (139 ref.) (Eng. Abstr.) **(Spa)**

PREVENTION & CONTROL

Strategies for neuroprotection with glutamate antagonists. Extrapolating from evidence taken from the first stroke and head injury studies. Bullock R. **Ann N Y Acad Sci** 1995 Sep 15;765:272–8; discussion 298 (11 ref.)

The rationale for glutamate antagonists in the treatment of traumatic brain injury. Myseros JS, et al. **Ann N Y Acad Sci** 1995 Sep 15;765:262–71; discussion 298 (44 ref.)

Development of HU-211 as a neuroprotectant for ischemic brain damage. Biegon A, et al. **Neurol Res** 1995 Aug; 17(4):275–80 (27 ref.)

PSYCHOLOGY

Traumatic brain injury, cognitive and emotional dysfunction. Impact of clinical neuropsychology research. Emilien G, et al. **Acta Neurol Belg** 1996 Jun;96(2):89–101 (73 ref.)

Focal retrograde amnesia: a multi-faceted disorder? Parkin AJ. **Acta Neurol Belg** 1996 Mar;96(1):43–50 (37 ref.)

Recent advances in the neuropsychology of human olfaction and anosmia. Sullivan TE, et al. **Brain Inj** 1995 Aug–Sep; 9(6):641–6 (22 ref.)

RADIOGRAPHY

CT of a peripatetic intracranial foreign body. Bearcroft PW, et al. **Neuroradiology** 1995 Oct;37(7):542–4 (16 ref.)

The radiologic evaluation of craniocerebral missile injuries. Kim PE, et al. **Neurosurg Clin N Am** 1995 Oct;6(4):669–87 (85 ref.)

Delayed post-traumatic epidural hematoma. A review. Domenicucci M, et al. **Neurosurg Rev** 1995;18(2):109–22 (51 ref.)

REHABILITATION

Postacute brain injury rehabilitation. Malec JF, et al. **Arch Phys Med Rehabil** 1996 Feb;77(2):198–207 (140 ref.)

Models of brain injury rehabilitation. Burke DC. **Brain Inj** 1995 Oct;9(7):735–43 (34 ref.)

The effectiveness of traumatic brain injury rehabilitation: a review. Cope DN. **Brain Inj** 1995 Oct;9(7):649–70 (56 ref.)

A multi-factor account of disability after brain injury: implications for neuropsychological counselling. Montgomery GK. **Brain Inj** 1995 Jul;9(5):453–69 (45 ref.)

The evolution of the clinician-scientist model of neurological rehabilitation. Peters MD, et al. **Brain Inj** 1995 Aug–Sep; 9(6):543–52 (28 ref.)

Neurolaw: towards a new medical jurisprudence. Taylor JS. **Brain Inj** 1995 Oct;9(7):745–51 (44 ref.)

Level of care options for the low-functioning brain injury survivor. Walker WC, et al. **Brain Inj** 1996 Jan;10(1):65–75 (30 ref.)

Treatment methodology. Guiding of behaviour through redirection in brain injury rehabilitation. Yuen HK, et al. **Brain Inj** 1996 Mar;10(3):229–38 (15 ref.)

Diagnosis, physiology, pathology and rehabilitation of traumatic brain injuries. Berker E. **Int J Neurosci** 1996 Apr; 85(3–4):195–220 (135 ref.)

[Should a brain-injury patient be rehabilitated? (editorial)] Huittinen VM, et al. **Duodecim** 1994;110(13):1231–3 (17 ref.) **(Fin)**

SURGERY

Acute traumatic posterior fossa subdural haematomas. Borzone M, et al. **Acta Neurochir (Wien)** 1995;135(1–2):32–7 (9 ref.)

Military penetrating craniocerebral injuries. Applications to civilian triage and management. George ED, et al. **Neurosurg Clin N Am** 1995 Oct;6(4):753–9 (101 ref.)

[Nerve transplantation in the central nervous system: a strategy for inducing nerve fiber regeneration in lesions of the brain and spinal cord] Gauthier P, et al. **Rev Neurol (Paris)** 1996 Feb;152(2):106–15 (62 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Critical care of children with acute brain injury. Greenwald BM, et al. **Adv Pediatr** 1995;42:47–89 (135 ref.)

Resuscitation from severe brain trauma. Rosomoff HL, et al. **Crit Care Med** 1996 Feb;24(2 Suppl):S48–56 (69 ref.)

Hypertonic saline as a safe and efficacious treatment of intracranial hypertension. Zornow MH. **J Neurosurg Anesthesiol** 1996 Apr;8(2):175–7 (26 ref.)

Systemic hypothermia in treatment of severe brain injury: a review and update. Clifton GL. **J Neurotrauma** 1995 Oct; 12(5):923–7 (38 ref.)

The efficacy of imagery mnemonics in memory remediation. Richardson JT. **Neuropsychologia** 1995 Nov;33(11):1345–57 (103 ref.)

The management of penetrating vascular injuries. Day JD, et al. **Neurosurg Clin N Am** 1995 Oct;6(4):799–808 (59 ref.)

The prehospital and emergency department management of penetrating head injuries. Eckstein M. **Neurosurg Clin N Am** 1995 Oct;6(4):741–51 (80 ref.)

Care and variations in the care of patients with gunshot wounds to the brain. Kaufman HH. **Neurosurg Clin N Am** 1995 Oct;6(4):727–39 (91 ref.)

Hyperventilation therapy for severe traumatic brain injury. Marion DW, et al. **New Horiz** 1995 Aug;3(3):439–47 (66 ref.)

Fluid management in patients with traumatic brain injury. Zornow MH, et al. **New Horiz** 1995 Aug;3(3):488–98 (55 ref.)

[Primary care and transportation of patients with neural trauma] Glerup OK, et al. **Ugeskr Laeger** 1996 Jun 3; 158(23):3295–301 (33 ref.) (Eng. Abstr.) **(Dan)**

BRAIN MAPPING

Brain microdialysis and its application for the study of animal behaviour. Westerink BH. **Behav Brain Res** 1995 Oct; 70(2):103–24 (153 ref.)

Exploring memory functions by means of brain electrical topography: a review. Rösler F, et al. **Brain Topogr** 1995 Summer;7(4):301–13 (45 ref.)

A conceptual overview and critique of functional neuroimaging techniques in humans: I. MRI/FMRI and PET. Aine CJ. **Crit Rev Neurobiol** 1995;9(2–3):229–309 (312 ref.)

Movement control. Moving the mental maps. Carpenter RH. **Curr Biol** 1995 Oct 1;5(10):1082–4 (11 ref.)

Order and disorder in auditory cortical maps. Schreiner CE. **Curr Opin Neurobiol** 1995 Aug;5(4):489–96 (60 ref.)

Nonparametric analysis of statistic images from functional mapping experiments. Holmes AP, et al. **J Cereb Blood Flow Metab** 1996 Jan;16(1):7–22 (26 ref.)

Neurometrics, dynamic brain imaging and attention deficit hyperactivity disorder. Levy F, et al. **J Paediatr Child Health** 1995 Aug;31(4):279–83 (49 ref.)

Functional MRI: are we all moving towards artifactual conclusions? Or fMRI fact or fancy? Weisskoff RM. **NMR Biomed** 1995 May;8(3):101–3 (10 ref.)

Localized and lateralized cerebral glucose metabolism associated with eye movements during REM sleep and wakefulness: a positron emission tomography (PET) study. Hong CC, et al. **Sleep** 1995 Sep;18(7):570–80 (71 ref.)

Behind the optic nerve: an inside view of the primate visual system. Van Essen DC. **Trans Am Ophthalmol Soc** 1995; 93:123–33 (2 ref.)

Mapping cognitive brain function with modern high-resolution electroencephalography. Gevins A, et al. **Trends Neurosci** 1995 Oct;18(10):429–36 (48 ref.)

The formation of a cortical somatotopic map. Killackey HP, et al. **Trends Neurosci** 1995 Sep;18(9):402–7 (56 ref.)

Mapping the human brain: past, present, and future. Swanson LW. **Trends Neurosci** 1995 Nov;18(11):471–4 (10 ref.)
[The doctrine of brain localization and its development in the 20th century] Wiesendanger M. **Schweiz Rundsch Med Prax** 1995 Dec 5;84(49):1448–58 (39 ref.) (Eng. Abstr.) **(Ger)**
[Clinical application of functional mapping; the present state of the art and its future prospects: (series 1) functional MRI: signal mechanism of fMRI and quantification of brain function by echo planar imaging] Naruse S, et al. **No Shinkei Geka** 1996 Jan;24(1):7–17 (55 ref.) **(Jpn)**
[Clinical application of functional mapping; the present state of the art and its future prospects: (series 5) functional mapping of the human thalamus] Ohye C. **No Shinkei Geka** 1996 Jun;24(6):501–6 (22 ref.) **(Jpn)**
[Pictures of the psyche. Imaging the highest functions of the brain: consciousness, language, emotions, is now possible] Ingvar DH. **Lakartidningen** 1995 Dec 20;92(51–52):4885–9 (20 ref.) **(Swe)**

INSTRUMENTATION

Microelectrode monitoring of cortical and subcortical structures during stereotactic surgery. Lozano AM, et al. **Acta Neurochir Suppl (Wien)** 1995;64:30–4 (19 ref.)
Magnetic resonance imaging and epilepsy: neurosurgical decision making. Fried I. **Magn Reson Imaging** 1995; 13(8):1163–70 (47 ref.)
Application of spectroscopic imaging in epilepsy. Garcia PA, et al. **Magn Reson Imaging** 1995;13(8):1181–5 (28 ref.)
Image-guided surgery of epilepsy. Olivier A, et al. **Neurosurg Clin N Am** 1996 Apr;7(2):229–43 (23 ref.)

METHODS

Pain—old and new methods of study and treatment. Sweet WH. **Acta Neurochir Suppl (Wien)** 1995;64:83–7 (24 ref.)
Advanced application of magnetic resonance imaging in human brain science. Caviness VS Jr, et al. **Brain Dev** 1995 Nov–Dec;17(6):399–408 (61 ref.)
Functional mapping-guided resection of low-grade gliomas. Berger MS. **Clin Neurosurg** 1995;42:437–52 (44 ref.)
Localization of functional regions of human mesial cortex by somatosensory evoked potential recording and by cortical stimulation. Allison T, et al. **Electroencephalogr Clin Neurophysiol** 1996 Mar; 100(2):126–40 (62 ref.)
Mapping function in the human brain with magnetoencephalography, anatomical magnetic resonance imaging, and functional magnetic resonance imaging. George JS, et al. **J Clin Neurophysiol** 1995 Sep;12(5):406–31 (90 ref.)
Comparative assessment of sensorimotor function using functional magnetic resonance imaging and electrophysiological methods. Puce A. **J Clin Neurophysiol** 1995 Sep;12(5):450–9 (55 ref.)
Dynamic neuroimaging of brain function. Simpson GV, et al. **J Clin Neurophysiol** 1995 Sep;12(5):432–49 (65 ref.)
Statistical approaches to human brain mapping by functional magnetic resonance imaging. Lange N. **Stat Med** 1996 Feb 28;15(4):389–428 (93 ref.)

BRAIN NEOPLASMS

Angiolipoma of suprasellar region. Shuangshoti S, et al. **J Med Assoc Thai** 1995 Nov;78(11):631–4 (7 ref.)
Glial neoplasms: classification, treatment, and pathways for the future. Armstrong TS, et al. **Oncol Nurs Forum** 1996 May;23(4):615–25; quiz 626–7 (69 ref.)
Neuroblastoma and brain tumors in childhood. Ater JL. **Pediatr Dent** 1995 Jul–Aug;17(4):268–72 (19 ref.)
Tumors of cerebral hemispheres. Colosimo C, et al. **Rays** 1996 Jan–Mar;21(1):101–33 (44 ref.) **(Eng, Ita)**
Tumors of the pineal region. Piovan E, et al. **Rays** 1996 Jan–Mar;21(1):87–100 (19 ref.) **(Eng, Ita)**
Neoplasms of the basal ganglia. Simonetti L, et al. **Rays** 1996 Jan–Mar;21(1):70–86 (46 ref.) **(Eng, Ita)**

BLOOD SUPPLY

Vascular morphology and angiogenesis in glial tumors. Plate KH, et al. **Exp Toxicol Pathol** 1995 May;47(2–3):89–94 (62 ref.)
Angiogenesis in malignant gliomas. Plate KH, et al. **Glia** 1995 Nov;15(3):339–47 (78 ref.)

CHEMICALLY INDUCED

Brain tumor and exposure to pesticides in humans: a review of the epidemiologic data. Bohnen NI, et al. **J Neurol Sci** 1995 Oct;132(2):110–21 (93 ref.)

CLASSIFICATION

[Classification and grading of glial tumors] Kros JM. **Ned Tijdschr Geneeskd** 1996 Feb 10;140(6):292–7 (33 ref.) **(Dut)**

COMPLICATIONS

Headache as a symptom of organic diseases. Edmeads JG. **Curr Opin Neurol** 1995 Jun;8(3):233–6 (32 ref.)
Intravascular malignant lymphomatosis: a cause of subacute dementia. Treves TA, et al. **Dementia** 1995 Sep–Oct; 6(5):286–93 (107 ref.)
Tuberous sclerosis with a brain tumor. Chaudhary D, et al. **Indian Pediatr** 1995 Feb;32(2):235–8 (13 ref.)
Hydrocephalus and shunts in children with brain tumors. Ryan JA, et al. **J Pediatr Oncol Nurs** 1995 Oct;12(4):223–9 (19 ref.)
Diagnostic testing for the evaluation of headaches. Evans RW. **Neurol Clin** 1996 Feb;14(1):1–26 (159 ref.)
[A case of primary intracranial malignant fibrous histiocytoma associated with peritumoral hemorrhage] Matsuzaki K, et al. **No Shinkei Geka** 1996 Jun;24(6):557–62 (22 ref.) (Eng. Abstr.) **(Jpn)**
[Neurofibromatosis type I (NF1): peculiarities and complications] Pascual-Castroviejo I. **Rev Neurol** 1996 Sep; 24(133):1051–5 (22 ref.) (Eng. Abstr.) **(Spa)**

CONGENITAL

Congenital CNS primitive neuroectodermal tumor: case report and review of the literature. Mitchell D, et al. **Pediatr Pathol Lab Med** 1995 Nov–Dec;15(6):949–56 (30 ref.)

DIAGNOSIS

The neurosurgical aspects in the treatment of cerebral tumours. Czirják S, et al. **Acta Med Hung** 1994; 50(3–4):169–73 (13 ref.)
On the principles underlying the diagnosis of brain tumours—a survey article. Go KG, et al. **Acta Neurochir (Wien)** 1995;135(1–2):1–11 (31 ref.)
Clinical applications of proton MR spectroscopy. Castillo M, et al. **AJNR Am J Neuroradiol** 1996 Jan;17(1):1–15 (64 ref.)
Agenesis and lipoma of corpus callosum. Case report. Silva DF, et al. **Arq Neuropsiquiatr** 1995 Sep;53(3–B):667–70 (34 ref.)
Intraventricular neurocytoma. Ng P, et al. **Australas Radiol** 1996 May;40(2):125–33 (27 ref.)
Radiologic and laboratory evaluation of enhancing brain lesions in patients with AIDS. Johnson MD, et al. **Compr Ther** 1995 Nov;21(11):645–52 (45 ref.)
Oligodendrogliomas: clinicopathological correlations. Kros JM. **J Neurooncol** 1995;24(1):29–31 (26 ref.)
Central nervous system medulloepithelioma: a series of eight cases including two arising in the pons. Molloy PT, et al. **J Neurosurg** 1996 Mar;84(3):430–6 (45 ref.)
Pediatric brain tumors: diagnosis and management. Shiminski-Maher T, et al. **J Pediatr Oncol Nurs** 1995 Oct; 12(4):188–98; quiz 199–202 (25 ref.)
Venous disease and tumors. Knopp EA. **Magn Reson Imaging Clin N Am** 1995 Aug;3(3):509–28 (22 ref.)
Neuroradiology of brain tumors. Schwartz RB. **Neurol Clin** 1995 Nov;13(4):723–56 (59 ref.)
Transcalvarial primary lymphoma of bone. A report of two cases. Paige ML, et al. **Neuroradiology** 1995 Aug; 37(6):456–8 (11 ref.)
Primary brain lymphoma. A brief review of clinical aspects and management. Sharma K, et al. **Neurosurg Rev** 1995; 18(3):193–9 (43 ref.)
Ependymoblastoma: MR presentation. A case report and review of the literature. Dorsay TA, et al. **Pediatr Radiol** 1995;25(6):433–5 (13 ref.)
Pineal germinoma with cranial nerve metastasis. Incesu L, et al. **Radiol Med (Torino)** 1996 Apr;91(4):471–2 (11 ref.)
Proliferation markers as a tool in oncological neuropathology. Tauš V. **Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove** 1995;38(4):145–65 (144 ref.)
Magnetic resonance imaging of massive intracranial invasion by an ethmoidal adenoid cystic carcinoma (cylindroma). Veillon BJ, et al. **South Med J** 1996 Mar;89(3):321–3 (10 ref.)
Intracranial adenoid cystic carcinoma: case report and review of the literature. Alleyne CH, et al. **Surg Neurol** 1996 Mar; 45(3):265–71 (49 ref.)
Primary Ki-1-positive T-cell lymphoma of the brain—an aggressive subtype of lymphoma: case report and review of the literature. Goldbrunner R, et al. **Surg Neurol** 1996 Jul;46(1):37–41 (24 ref.)
Low-grade astrocytomas: prognosis factors and elements of management. Loiseau H, et al. **Surg Neurol** 1995 Sep; 44(3):224–7 (44 ref.)
[The diagnosis of primary cerebral lymphoma in AIDS. The contribution of imaging] Laissy JP, et al. **J Neuroradiol** 1995 Sep;22(3):207–17 (25 ref.) (Eng. Abstr.) **(Fre)**
[Double localization of intracranial germinoma. Apropos of a case] Alifdal M, et al. **Neurochirurgie** 1995;41(6):424–8 (23 ref.) (Eng. Abstr.) **(Fre)**
[Echo-planar imaging of the brain] Brüning R, et al. **Radiologe** 1995 Dec;35(12):902–10 (61 ref.) (Eng. Abstr.) **(Ger)**
[Fast and ultra-fast MRI of the brain] Schuierer G, et al. **Radiologe** 1995 Dec;35(12):894–901 (25 ref.) (Eng. Abstr.) **(Ger)**
[Dysembryoplastic neuroepithelial tumor] Vajtai I, et al. **Orv Hetil** 1995 Nov 26;136(48):2623–7 (38 ref.) (Eng. Abstr.) **(Hun)**
[Cystic ectopic pituitary adenoma: report of a case] Akimoto J, et al. **No To Shinkei** 1995 Nov;47(11):1092–7 (12 ref.) (Eng. Abstr.) **(Jpn)**
[Primary intracranial malignant epidermoid—case report] Fuse T, et al. **No To Shinkei** 1995 Oct;47(10):997–1001 (14 ref.) (Eng. Abstr.) **(Jpn)**
[Malignant brain tumor] Nomura K. **No To Shinkei** 1996 May;48(5):403–8 (5 ref.) **(Jpn)**
[Cerebral metastasis as the form of presentation of a basaloid carcinoma of the esophagus] Carvalho IR, et al. **Acta Med Port** 1995 Sep;8(9):505–9 (9 ref.) (Eng. Abstr.) **(Por)**
[Primary lymphomas of the brain not related to immunodeficiency] Marques H, et al. **Acta Med Port** 1995 Mar;8(3):151–6 (38 ref.) (Eng. Abstr.) **(Por)**
[Oligodendroglioma in childhood: a case report (letter)] del Val Río MR, et al. **An Esp Pediatr** 1996 Jan;44(1):80–2 (10 ref.) **(Spa)**

DRUG THERAPY

Growth hormone/insulin-like growth factor I axis in children treated for brain tumours: relationship to chemotherapy and nutrition. Rappaport R, et al. **Acta Paediatr Suppl** 1995 Sep;411:37–9; discussion 40 (19 ref.)
Implantable pumps for drug delivery to the brain. Bakhshi S, et al. **J Neurooncol** 1995 Nov;26(2):133–9 (68 ref.)
Pharmacological blood-brain barrier modification for selective drug delivery. Cloughesy TF, et al. **J Neurooncol** 1995 Nov;26(2):125–32 (39 ref.)
Central nervous system toxicity of cancer therapy in children. Moore IM. **J Pediatr Oncol Nurs** 1995 Oct;12(4):203–10; discussion 211 (50 ref.)
Advances in chemotherapy for brain tumors. Conrad CA, et al. **Neurol Clin** 1995 Nov;13(4):795–812 (106 ref.)
New delivery systems for brain tumor therapy. Sipos EP, et al. **Neurol Clin** 1995 Nov;13(4):813–25 (81 ref.)
Intratumoral chemotherapy. Walter KA, et al. **Neurosurgery** 1995 Dec;37(6):1128–45 (131 ref.)
Photodynamic therapy of brain tumors. Popovic EA, et al. **Semin Surg Oncol** 1995 Sep–Oct;11(5):335–45 (31 ref.)
Nonresective treatment of pineoblastoma: a case report. Patil AA, et al. **Surg Neurol** 1995 Oct;44(4):386–903; discussion 390–1 (36 ref.)
[Chemotherapy in brain tumors] van den Bent MJ, et al. **Ned Tijdschr Geneeskd** 1996 Mar 30;140(13):702–6 (42 ref.) **(Dut)**
[Endocrinological and auxological sequelae in the treatment of oncological-hematological diseases] Cacciari E, et al. **Minerva Pediatr** 1996 Mar;48(3):63–70 (61 ref.) **(Ita)**

EPIDEMIOLOGY

Extragonadal germ cell tumor: a clinical study. Bassetto MA, et al. **Anticancer Res** 1995 Nov–Dec;15(6B):2751–4 (17 ref.)
Etiology of brain tumors in adults. Inskip PD, et al. **Epidemiol Rev** 1995;17(2):382–414 (452 ref.)
Brain tumor and exposure to pesticides in humans: a review of the epidemiologic data. Bohnen NI, et al. **J Neurol Sci** 1995 Oct;132(2):110–21 (93 ref.)
Triple primary malignant neoplasms including a malignant brain tumor: report of two cases and review of the literature. Nagane M, et al. **Surg Neurol** 1996 Mar; 45(3):219–29 (44 ref.)
Meningioma in children: a report of nine cases and a review of the literature. Sheikh BY, et al. **Surg Neurol** 1996 Apr; 45(4):328–35 (71 ref.)
[The epidemiology of cerebral lymphoma in AIDS] Mikol J, et al. **J Neuroradiol** 1995 Sep;22(3):204–6 (25 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Etiology of brain tumors in adults. Inskip PD, et al. **Epidemiol Rev** 1995;17(2):382–414 (452 ref.)
What occupations have been associated with brain cancer, and, more specifically, what is the connection between brain cancer and electric utility work? **J Occup Environ Med** 1995 Sep;37(9):1067–9 (46 ref.)
Do electromagnetic fields cause brain tumors and other cancers? Deutsch S. **Semin Neurol** 1995 Sep;15(3):304–10 (13 ref.)
Genetic and environmental factors in the etiology of human brain tumors. Kleihues P, et al. **Toxicol Lett** 1995 Dec; 82–83:601–5 (20 ref.)

GENETICS

Genetics and malignant progression of human brain tumours. Furnari FB, et al. **Cancer Surv** 1995;25:233–75 (312 ref.)
The cellular and molecular biology of medulloblastoma. Peringa J, et al. **Curr Opin Neurol** 1995 Dec;8(6):437–40 (20 ref.)
The p53 gene and its role in human brain tumors. Bögler O, et al. **Glia** 1995 Nov;15(3):308–27 (191 ref.)
Gene amplification in human gliomas. Collins VP. **Glia** 1995 Nov;15(3):289–96 (81 ref.)
Neurofibromatosis type 2 and von Hippel-Lindau disease: from gene cloning to function. Kley N, et al. **Glia** 1995 Nov;15(3):297–307 (75 ref.)
Bone and brain involvement in a case of diffuse large B cell lymphoma associated with t(2;3)(p12;q27). Utsumi S, et al. **Int J Hematol** 1995 Dec;62(4):247–52 (16 ref.)
Molecular cytogenetic quantitation of gains and losses of genetic material from human gliomas. Feuerstein BG, et al. **J Neurooncol** 1995;24(1):47–55 (23 ref.)
The molecular biology of brain tumors. Barker FG 2nd, et al. **Neurol Clin** 1995 Nov;13(4):701–21 (170 ref.)
The role of growth factor receptors in central nervous system

development and neoplasia. Weiner HL. **Neurosurgery** 1995 Aug;37(2):179–93; discussion 193–4 (187 ref.)

A tiger behind many doors: multiple genetic pathways to malignant glioma. Louis DN, et al. **Trends Genet** 1995 Oct; 11(10):412–5 (38 ref.)

Genetic alterations associated with the evolution and progression of astrocytic brain tumours. Ohgaki H, et al. **Virchows Arch** 1995;427(2):113–8 (44 ref.)

[Molecular biology in cerebral gliomas: recent advances] Hoang-Xuan K, et al. **Rev Neurol (Paris)** 1995 Nov; 151(11):608–18 (107 ref.) (Eng. Abstr.) **(Fre)**

[Malignant glioma] Okamura K. **Nippon Rinsho** 1995 Nov; 53(11):2678–83 (18 ref.) (Eng. Abstr.) **(Jpn)**

[p53 gene mutations in brain tumors] Koga H, et al. **No To Shinkei** 1995 Sep;47(9):845–55 (108 ref.) **(Jpn)**

[Neurofibromatosis] Bauer MS. **Rev Neurol** 1995;23 Suppl 3:S322–4 (18 ref.) **(Spa)**

IMMUNOLOGY

Tumor antigens in astrocytic gliomas. Kurpad SN, et al. **Glia** 1995 Nov;15(3):244–56 (105 ref.)

METABOLISM

Intratumoral lipids in 1H MRS in vivo in brain tumors: experience of the Siemens cooperative clinical trial. Negendank W, et al. **Anticancer Res** 1996 May-Jun; 16(3B):1533–8 (25 ref.)

Protein kinase C and growth regulation of malignant gliomas. Baltuch GH, et al. **Can J Neurol Sci** 1995 Nov;22(4):264–71 (98 ref.)

Cytokines and tumors of the central nervous system. Van Meir EG. **Glia** 1995 Nov;15(3):264–88 (205 ref.)

Platelet-derived growth factor in human glioma. Westermark B, et al. **Glia** 1995 Nov;15(3):257–63 (60 ref.)

Polyamines in brain tumor therapy. Redgate ES, et al. **J Neurooncol** 1995;25(2):167–79 (76 ref.)

NURSING

The role of stereotactic radiation therapy in the management of children with brain tumors. Lew CM, et al. **J Pediatr Oncol Nurs** 1995 Oct;12(4):212–22 (31 ref.)

PATHOLOGY

Cavernous angioma associated with oligo-astrocytoma-like proliferation. Report of two cases and review of the literature with a reappraisal of the term "angiogliomа". Palma L, et al. **Acta Neurochir (Wien)** 1995;133(3–4):169–73 (36 ref.)

Granular cell change in astrocytic tumors. Geddes JF, et al. **Am J Surg Pathol** 1996 Jan;20(1):55–63 (50 ref.)

Primary epithelioid hemangioendothelioma of the brain. Nora FE, et al. **Am J Surg Pathol** 1996 Jun;20(6):707–14 (37 ref.)

BK virus-induced osteosarcoma (Os515) as a model of human osteosarcoma. Sekiguchi M, et al. **Anticancer Res** 1996 Jul-Aug;16(4A):1835–42 (40 ref.)

Meningioangiomatosis and oligodendroglioma in a 15-year-old boy. López JI, et al. **Arch Pathol Lab Med** 1996 Jun;120(6):587–90 (11 ref.)

So-called intracranial germ cell tumours: are they really of germ cell origin? Sano K. **Br J Neurosurg** 1995;9(3):391–401 (26 ref.)

Mesenchymal chondrosarcoma: a clinicopathologic and flow cytometric study of 13 cases presenting in the central nervous system. Rushing EJ, et al. **Cancer** 1996 May 1; 77(9):1884–91 (36 ref.)

Genetics and malignant progression of human brain tumours. Furnari FB, et al. **Cancer Surv** 1995;25:233–75 (312 ref.)

Central neurocytoma: clinico-pathological study of 5 cases and review of the literature. Maiuri F, et al. **Clin Neurol Neurosurg** 1995 Aug;97(3):219–28 (39 ref.)

Brain astrocytomas: biopsy, then irradiation. Lunsford LD, et al. **Clin Neurosurg** 1995;42:464–79 (43 ref.)

Primary brain tumors in the acquired immunodeficiency syndrome. DeAngelis LM. **Curr Opin Neurol** 1995 Dec; 8(6):419–23 (35 ref.)

Advances in brain tumor diagnostic imaging. DeLaPaz RL. **Curr Opin Neurol** 1995 Dec;8(6):430–6 (42 ref.)

Vascular morphology and angiogenesis in glial tumors. Plate KH, et al. **Exp Toxicol Pathol** 1995 May;47(2–3):89–94 (62 ref.)

Neoplastic vascular tumors of the central nervous system. Papierz W, et al. **Folia Neuropathol** 1995;33(4):215–20 (42 ref.)

Histopathology, classification, and grading of gliomas. Kleihues P, et al. **Glia** 1995 Nov;15(3):211–21 (62 ref.)

From rodent glial precursor cell to human glial neoplasia in the oligodendrocyte-type-2 astrocyte lineage. Noble M, et al. **Glia** 1995 Nov;15(3):222–30 (63 ref.)

Molecular pathways in the formation of gliomas. von Deimling A, et al. **Glia** 1995 Nov;15(3):328–38 (58 ref.)

Diffuse bone marrow metastases from glioblastoma multiforme: the role of dural invasion. Kleinschmidt-Demasters BK. **Hum Pathol** 1996 Feb; 27(2):197–201 (22 ref.)

Clinical, radiological, and therapeutic features of pleomorphic xanthoastrocytoma: report of three patients and review of the literature. van Roost D, et al. **J Neurol Neurosurg Psychiatry** 1996 Jun;60(6):690–2 (12 ref.)

Central neuronal tumors in childhood: relationship to dysplasia. Becker LE. **J Neurooncol** 1995;24(1):13–9 (32 ref.)

The neuroepithelial stem cell concept: implications for neuro-oncology. Brüstle O, et al. **J Neurooncol** 1995; 24(1):57–9 (17 ref.)

Clinicopathologic and cytogenetic analysis of malignant rhabdoid tumor of the central nervous system. Hasserjian RP, et al. **J Neurooncol** 1995;25(3):193–203 (36 ref.)

Interactions of glioma cells and extracellular matrix. Paulus W, et al. **J Neurooncol** 1995;24(1):87–91 (25 ref.)

Multiple neuroepithelial tumors of different cell types—case report. Akai T, et al. **Neurol Med Chir (Tokyo)** 1995 Dec; 35(12):901–4 (9 ref.)

Intracranial meningioma masquerading as a primary pleuropulmonary tumor. Hishima T, et al. **Pathol Int** 1995 Aug;45(8):617–21 (23 ref.)

[Retrospect and prospect of neuropathology in China] Xu Q, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1995 Aug; 24(4):248–51 (16 ref.) **(Chi)**

[Extracerebral metastases of a glioblastoma, in the absence of surgery] Chretien F, et al. **Arch Anat Cytol Pathol** 1995; 43(5–6):342–9 (16 ref.) (Eng. Abstr.) **(Fre)**

[Spontaneous regression of primary cerebral lymphoma] Heinzlef O, et al. **Rev Neurol (Paris)** 1996 Feb;152(2):135–8 (10 ref.) (Eng. Abstr.) **(Fre)**

[Mid-line cerebral tumors in children] Weil RJ, et al. **Rev Neurol** 1995;23 Suppl 3:S368–72 (31 ref.) **(Spa)**

PHYSIOPATHOLOGY

Physiology of transformed glial cells. Brismar T. **Glia** 1995 Nov;15(3):231–43 (136 ref.)

Ganglioside modulation of the PDGF receptor. A model for ganglioside functions. Yates AJ, et al. **J Neurooncol** 1995;24(1):65–73 (66 ref.)

[Cortical function in 107 patients with supratentorial expanding mass. Pre- and postoperative study] Bucciero A, et al. **Minerva Med** 1995 Oct;86(10):403–7 (15 ref.) (Eng. Abstr.) **(Ita)**

RADIOGRAPHY

Primary cranial vault lymphoma mimicking meningioma. Isla A, et al. **Neuroradiology** 1996 Apr;38(3):211–3 (18 ref.)

RADIONUCLIDE IMAGING

Brain SPECT imaging of neuropsychiatric disorders. Krausz Y, et al. **Eur J Radiol** 1996 Feb;21(3):183–7 (39 ref.)

[The use of SPECT with 201Tl in the evaluation of brain tumors] Prat-Acín R, et al. **Rev Neurol** 1996 Aug; 24(132):909–13 (34 ref.) (Eng. Abstr.) **(Spa)**

RADIOTHERAPY

Indications for brachytherapy for brain tumours. Bernstein M, et al. **Acta Neurochir Suppl (Wien)** 1995;63:25–8 (25 ref.)

Radiation therapy of metastatic pheochromocytoma: case report and review of the literature. Yu L, et al. **Am J Clin Oncol** 1996 Aug;19(4):389–93 (29 ref.)

Brain astrocytomas: biopsy, then irradiation. Lunsford LD, et al. **Clin Neurosurg** 1995;42:464–79 (43 ref.)

Management of anterior cranial base and cavernous sinus neoplasms with conservative surgery alone or in combination with fractionated photon or stereotactic proton radiotherapy. Ojemann RG, et al. **Clin Neurosurg** 1995;42:71–98 (76 ref.)

Management of low-grade gliomas: radiation therapy at time of recurrence. Piepmeier JM, et al. **Clin Neurosurg** 1995; 42:495–507 (53 ref.)

The low-grade glioma debate: evidence defending the position of early radiation therapy. Shaw EG. **Clin Neurosurg** 1995;42:488–94 (10 ref.)

Operation and permanent low activity 125I brachytheraphy for recurrent high-grade astrocytomas. Halligan JB, et al. **Int J Radiat Oncol Biol Phys** 1996 Jun 1;35(3):541–7 (24 ref.)

External beam radiotherapy: hard facts and painful realities. Vick NA, et al. **J Neurooncol** 1995;24(1):93–5 (15 ref.)

The role of stereotactic radiation therapy in the management of children with brain tumors. Lew CM, et al. **J Pediatr Oncol Nurs** 1995 Oct;12(4):212–22 (31 ref.)

Central nervous system toxicity of cancer therapy in children. Moore IM. **J Pediatr Oncol Nurs** 1995 Oct;12(4):203–10; discussion 211 (50 ref.)

Advances in radiation therapy for brain tumors. Shrieve DC, et al. **Neurol Clin** 1995 Nov;13(4):773–93 (89 ref.)

The efficacy of cranial irradiation in ovarian cancer metastatic to the brain: analysis of 32 cases. Corn BW, et al. **Obstet Gynecol** 1995 Dec;86(6):955–9 (17 ref.)

An overview of radiotherapy trials for the treatment of brain metastases. Berk L. **Oncology (Huntingt)** 1995 Nov; 9(11):1205–12; discussion 1212–6, 1219 (26 ref.)

Radiation-induced meningioma in children: report of two cases and review of the literature. Starshak RJ. **Pediatr Radiol** 1996;26(8):537–41 (30 ref.)

Nonresective treatment of pineoblastoma: a case report. Patil AA, et al. **Surg Neurol** 1995 Oct;44(4):386–903; discussion 390–1 (36 ref.)

[Endocrinological and auxological sequelae in the treatment of oncological-hematological diseases] Cacciari E, et al. **Minerva Pediatr** 1996 Mar;48(3):63–70 (61 ref.) **(Ita)**

SECONDARY

Radiation therapy of metastatic pheochromocytoma: case report and review of the literature. Yu L, et al. **Am J Clin Oncol** 1996 Aug;19(4):389–93 (29 ref.)

The treatment of brain metastases. Patchell RA. **Cancer Invest** 1996;14(2):169–77 (85 ref.)

Long-term survival following surgical treatment of solitary brain metastasis in non-small cell lung cancer. Shahidi H, et al. **Chest** 1996 Jan;109(1):271–6 (53 ref.)

Pineal and suprasellar metastasis of lung cancer: case report and review of the literature. Izumihara A, et al. **Comput Med Imaging Graph** 1995 Sep-Oct;19(5):435–7 (14 ref.)

Tumor metastasis to brain: role of endothelial cells, neurotrophins, and paracrine growth factors. Nicolson GL, et al. **Crit Rev Oncog** 1994;5(5):451–71 (153 ref.)

Epithelial ovarian carcinoma metastatic to the central nervous system: a report on two cases with review of literature. Sood A, et al. **Gynecol Oncol** 1996 Jul; 62(1):113–8 (36 ref.)

Fibrosarcomatous metastasis the central nervous system with overt hemorrhage: case report and review of the literature. Jeffery DR, et al. **J Neurol Sci** 1995 Dec;134(1–2):207–9 (8 ref.)

Sacrococcygeal chordoma metastatic to the brain with review of the literature. Hall WA, et al. **J Neurooncol** 1995; 25(2):155–9 (16 ref.)

Brain metastases: 1995. A brief review. Posner JB. **J Neurooncol** 1996 Mar;27(3):287–93 (48 ref.)

Surgical treatment of metastatic brain tumors. Sawaya R, et al. **J Neurooncol** 1996 Mar;27(3):269–77 (49 ref.)

Successful treatment for solitary brain metastasis from alveolar soft part sarcoma. Wang CH, et al. **J Neurooncol** 1995;25(2):161–6 (31 ref.)

Prophylactic cranial irradiation in small cell lung cancer—an update. Kristjansen PE, et al. **Lung Cancer** 1995 Jun;12 Suppl 3:S23–40 (82 ref.)

Metastatic brain tumors. Patchell RA. **Neurol Clin** 1995 Nov; 13(4):915–25 (35 ref.)

The efficacy of cranial irradiation in ovarian cancer metastatic to the brain: analysis of 32 cases. Corn BW, et al. **Obstet Gynecol** 1995 Dec;86(6):955–9 (17 ref.)

An overview of radiotherapy trials for the treatment of brain metastases. Berk L. **Oncology (Huntingt)** 1995 Nov; 9(11):1205–12; discussion 1212–6, 1219 (26 ref.)

Central nervous system metastases from esthesioneuroblastoma. Shaari CM, et al. **Otolaryngol Head Neck Surg** 1996 Jun;114(6):808–12 (20 ref.)

Late solitary cerebral metastasis from renal cell carcinoma: a case report and review of the literature. Jubelirer SJ. **W V Med J** 1996 Jan-Feb;92(1):26–7 (28 ref.)

[Cerebral metastasis as the form of presentation of a basaloid carcinoma of the esophagus] Carvalho IR, et al. **Acta Med Port** 1995 Sep;8(9):505–9 (9 ref.) (Eng. Abstr.) **(Por)**

SURGERY

The neurosurgical aspects in the treatment of cerebral tumours. Czirják S, et al. **Acta Med Hung** 1994; 50(3–4):169–73 (13 ref.)

Surgery for gliomas and other mass lesions of the brainstem. Bricolo A, et al. **Adv Tech Stand Neurosurg** 1995;22:261–341 (209 ref.)

Space-occupying lesions of the sensori-motor region. Ebeling U, et al. **Adv Tech Stand Neurosurg** 1995;22:137–81 (106 ref.)

Systematic approach to intradural tumors ventral to the brain stem. Jackler RK, et al. **Am J Otol** 1995 Jan;16(1):39–51 (38 ref.)

Brain stem surgery [editorial] Jackowski A. **Br J Neurosurg** 1995;9(5):581–4 (32 ref.)

Stereotactic radiosurgery for primary and metastatic brain tumors. Petrovich Z, et al. **Cancer Invest** 1996;14(5):445–54 (46 ref.)

Long-term survival following surgical treatment of solitary brain metastasis in non-small cell lung cancer. Shahidi H, et al. **Chest** 1996 Jan;109(1):271–6 (53 ref.)

Functional mapping-guided resection of low-grade gliomas. Berger MS. **Clin Neurosurg** 1995;42:437–52 (44 ref.)

Low-grade glioma: the case for delayed surgery. Cairncross JG. **Clin Neurosurg** 1995;42:391–8 (18 ref.)

Management of low-grade gliomas: results of resections without electrocorticography. Fried I. **Clin Neurosurg** 1995;42:453–63 (41 ref.)

Surgical issues in the management of supratentorial low-grade gliomas. Kelly PJ. **Clin Neurosurg** 1995; 42:399–436 (39 ref.)

Radical resection for the treatment of glioma. Laws ER Jr. **Clin Neurosurg** 1995;42:480–7 (11 ref.)

Radical resection of anterior skull base tumors. Lawton MT, et al. **Clin Neurosurg** 1995;42:43–70 (62 ref.)

Intra-operative monitoring is not essential. Malis LI. **Clin Neurosurg** 1995;42:203–13 (8 ref.)

Management of anterior cranial base and cavernous sinus neoplasms with conservative surgery alone or in combination with fractionated photon or stereotactic proton radiotherapy. Ojemann RG, et al. **Clin Neurosurg** 1995;42:71–98 (76 ref.)

Neurophysiologic monitoring during cranial base surgery: is it necessary? Sekhar LN, et al. **Clin Neurosurg** 1995;

42:180–202 (37 ref.)
Surgery for low-grade glioma: rationale for early intervention. Wilson CB, et al. **Clin Neurosurg** 1995; 42:383–90 (11 ref.)
Vascular lesions of the cranial base. Shin JH, et al. **Clin Plast Surg** 1995 Jul;22(3):531–42 (21 ref.)
Operation and permanent low activity 125I brachytheraphy for recurrent high-grade astrocytomas. Halligan JB, et al. **Int J Radiat Oncol Biol Phys** 1996 Jun 1;35(3):541–7 (24 ref.)
Stereotactic technology in tumor surgery: concepts and principles. Roberts DW. **J Neurooncol** 1995;24(3):281–4 (19 ref.)
Surgical treatment of metastatic brain tumors. Sawaya R, et al. **J Neurooncol** 1996 Mar;27(3):269–77 (49 ref.)
Successful treatment for solitary brain metastasis from alveolar soft part sarcoma. Wang CH, et al. **J Neurooncol** 1995;25(2):161–6 (31 ref.)
Cranial chordomas in children and adolescents. Borba LA, et al. **J Neurosurg** 1996 Apr;84(4):584–91 (57 ref.)
Intracranial meningioma and astrocytoma in the same patient. Case report and review of the literature. Dario A, et al. **J Neurosurg Sci** 1995 Mar;39(1):27–35 (44 ref.)
Magnetic resonance imaging and epilepsy: neurosurgical decision making. Fried I. **Magn Reson Imaging** 1995; 13(8):1163–70 (47 ref.)
Advances in surgery for brain tumors. Sawaya R, et al. **Neurol Clin** 1995 Nov;13(4):757–71 (64 ref.)
Uncommon brain tumors. Schiff D, et al. **Neurol Clin** 1995 Nov;13(4):953–74 (112 ref.)
A technique for interactive image-guided neurosurgical intervention in primary brain tumors. Maciunas RJ, et al. **Neurosurg Clin N Am** 1996 Apr;7(2):245–66 (111 ref.)
Symptomatic cavernous malformations affecting the spine and spinal cord. Harrison MJ, et al. **Neurosurgery** 1995 Aug;37(2):195–204; discussion 204–5 (87 ref.)
Intracranial cavernous malformations: lesion behavior and management strategies. Maraire JN, et al. **Neurosurgery** 1995 Oct;37(4):591–605 (123 ref.)
Primary intracranial squamous cell carcinomas: report of two cases. Nishio S, et al. **Neurosurgery** 1995 Aug;37(2):329–32 (35 ref.)
Pleomorphic xanthoastrocytoma: case report and analysis of the literature concerning the efficacy of resection and the significance of necrosis. Pahapill PA, et al. **Neurosurgery** 1996 Apr;38(4):822–8; discussion 828–9 (32 ref.)
Primary cavernous sinus malignant lymphoma treated by gamma knife radiosurgery: case report and review of the literature. Nakatomi H, et al. **Surg Neurol** 1996 Sep; 46(3):272–8; discussion 278–9 (15 ref.)
[Function-controlled neurosurgery. Neurophysiologic and neuropsychological monitoring during surgery of the nervous system] Schmid UD, et al. **Nervenarzt** 1995 Aug; 66(8):582–95 (84 ref.) (Eng. Abstr.) **(Ger)**
[Gamma knife versus stereotactic linear accelerator. Utilization, clinical results and cost-benefit relations] Becker G, et al. **Radiologe** 1996 Apr;36(4):345–53 (30 ref.) (Eng. Abstr.) **(Ger)**
[A case of thoracic meningioma presenting paraplegia at 4.5 years after removal of a falx meningioma] Suga T, et al. **No Shinkei Geka** 1996 Jun;24(6):567–72 (23 ref.) (Eng. Abstr.) **(Jpn)**

THERAPY

Thermoradiotherapy for brain tumors. Three cases of recurrent malignant astrocytoma and review of clinical experience. Seegenschmiedt MH, et al. **Am J Clin Oncol** 1995 Dec;18(6):510–8 (53 ref.)
Brain tumors. Obbens EA, et al. **Cancer Chemother Biol Response Modif** 1996;16:625–43 (39 ref.)
Oligodendroglioma [see comments] Peterson K, et al. **Cancer Invest** 1996;14(3):243–51 (59 ref.) Comment in: Cancer Invest 1996;14(3):288–9.
Brain tumor gene therapy in mice with a novel "suicide" gene: the cyclophosphamide-activating CYP2B1 gene. Chiocca EA. **Clin Neurosurg** 1995;42:370–82 (49 ref.)
Treatment of malignant glioma in adults. Forsyth PA, et al. **Curr Opin Neurol** 1995 Dec;8(6):414–8 (56 ref.)
Steps toward gene therapy: 2. Cancer and AIDS. Blaese RM. **Hosp Pract (Off Ed)** 1995 Dec 15;30(12):37–45 (6 ref.)
Polyamines in brain tumor therapy. Redgate ES, et al. **J Neurooncol** 1995;25(2):167–79 (76 ref.)
Perspectives on investigational chemotherapy and biologic therapy for childhood brain tumors. Kadota RP. **J Pediatr Hematol Oncol** 1996 Feb;18(1):13–22 (110 ref.)
Pediatric brain tumors: diagnosis and management. Shiminski-Maher T, et al. **J Pediatr Oncol Nurs** 1995 Oct; 12(4):188–98; quiz 199–202 (25 ref.)
Acute promyelocytic leukemia after treatment of malignant glioma in a patient with von Recklinghausen's disease: case report and review of the literature. Wiernik PH, et al. **Leukemia** 1996 Jan;10(1):178–82 (49 ref.)
Novel biologic therapies for malignant gliomas. Antiangiogenesis, immunotherapy, and gene therapy. Fine HA. **Neurol Clin** 1995 Nov;13(4):827–46 (128 ref.)
Primary central nervous system lymphoma. Freilich RJ, et al. **Neurol Clin** 1995 Nov;13(4):901–14 (75 ref.)
Oligodendrogliomas. Peterson K, et al. **Neurol Clin** 1995 Nov;13(4):861–73 (65 ref.)
High-grade astrocytomas. Wen PY, et al. **Neurol Clin** 1995 Nov;13(4):875–900 (164 ref.)
The management of brainstem gliomas in patients with neurofibromatosis 1. Pollack IF, et al. **Neurology** 1996 Jun; 46(6):1652–60 (48 ref.)
Adjuvant and neoadjuvant treatment for primary brain tumors in adults. Grossman SA, et al. **Semin Oncol** 1995 Dec;22(6):530–9 (75 ref.)
Hyperthermia—its actual role in radiation oncology. Part IV: Thermo-radiotherapy for malignant brain tumors. Seegenschmiedt MH, et al. **Strahlenther Onkol** 1995 Oct; 171(10):560–72 (115 ref.)
Low-grade astrocytomas: prognosis factors and elements of management. Loiseau H, et al. **Surg Neurol** 1995 Sep; 44(3):224–7 (44 ref.)
[Prognostic factors in malignant gliomas] Ushio Y, et al. **Gan To Kagaku Ryoho** 1996 Apr;23(5):643–8 (10 ref.) (Eng. Abstr.) **(Jpn)**
[Gene therapy of glioma using cytokine] Ikeda H, et al. **No To Shinkei** 1995 Sep;47(9):835–43 (47 ref.) **(Jpn)**
[Therapy of malignant brain tumors by using apoptosis] Kuchino Y. **No To Shinkei** 1995 Sep;47(9):829–34 (34 ref.) **(Jpn)**
[Approach to human glioma cells using antisense molecules] Yoshida S, et al. **No To Shinkei** 1995 Sep;47(9):823–8 (24 ref.) **(Jpn)**
[Application of myc family genes to therapy of malignant brain tumors] Kuchino Y, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2713–9 (24 ref.) **(Jpn)**
[Usefulness of myelin basic protein gene promoter for the gene therapy of malignant glioma] Miyao Y, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2618–23 (13 ref.) **(Jpn)**
[Cytokine gene therapy for malignant brain tumors] Mizuno M, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec; 40(17):2709–12 (13 ref.) **(Jpn)**

BRAIN REVASCULARIZATION see **CEREBRAL REVASCULARIZATION**

BRAIN STEM

Systematic approach to intradural tumors ventral to the brain stem. Jackler RK, et al. **Am J Otol** 1995 Jan;16(1):39–51 (38 ref.)
Unexpected sudden death in a young pregnant woman: unusual presentation of neurosarcoidosis. Maisel JA, et al. **Ann Emerg Med** 1996 Jul;28(1):94–7 (12 ref.)
Cure of a solitary brainstem abscess with antibiotic therapy: case report. Fulgham JR, et al. **Neurology** 1996 May; 46(5):1451–4 (10 ref.)
The management of brainstem gliomas in patients with neurofibromatosis 1. Pollack IF, et al. **Neurology** 1996 Jun; 46(6):1652–60 (48 ref.)
[Guillain-Barré syndrome associated with external ophthalmoplegia, consciousness disturbance, and extensor plantar responses: an overlap between Guillain-Barré syndrome and Bickerstaff's brainstem encephalitis] Kitazawa K, et al. **Rinsho Shinkeigaku** 1995 Jun; 35(6):626–32 (30 ref.) (Eng. Abstr.) **(Jpn)**

ABNORMALITIES

[Isolated idiopathic syringobulbia: case report and summary of the literature] Kombos T, et al. **Zentralbl Neurochir** 1996; 57(2):103–7 (29 ref.) (Eng. Abstr.) **(Ger)**

BLOOD SUPPLY

Microsurgical anatomy of the posterior choroidal arteries. Vinas FC, et al. **Neurol Res** 1995 Oct;17(5):334–44 (34 ref.)
[See-saw nystagmus. Clinical aspects, diagnosis, pathophysiology: observations in 2 patients] Endres M, et al. **Nervenarzt** 1996 Jun;67(6):484–9 (41 ref.) (Eng. Abstr.) **(Ger)**

CYTOLOGY

Peptides in motoneurons. Raivich G, et al. **Prog Brain Res** 1995;104:3–20 (185 ref.)

DRUG EFFECTS

L-DOPA systems for blood pressure regulation in the lower brainstem. Misu Y, et al. **Neurosci Res** 1995 Sep; 23(2):147–58 (58 ref.)

PATHOLOGY

Mycoplasma pneumoniae infection associated with an acute brainstem syndrome. Pellegrini M, et al. **Acta Neurol Scand** 1996 Feb-Mar;93(2–3):203–6 (10 ref.)
[Vascular stroke of the brain stem. Study of 21 cases] Leal Filho MB, et al. **Arq Neuropsiquiatr** 1995 Mar;53(1):75–81 (17 ref.) (Eng. Abstr.) **(Por)**

PHYSIOLOGY

New computational models of the respiratory oscillator in mammals. Smith JC. **Adv Exp Med Biol** 1995;393:7–13 (10 ref.)
Physiology of atonic seizures. Blume WT. **Adv Neurol** 1995; 67:173–9 (38 ref.)
Anatomy and neurotransmitters of brainstem motor systems. Newman DB. **Adv Neurol** 1995;67:219–44 (138 ref.)
The octavolateralis system and Mauthner cell: interactions and questions. Eaton RC, et al. **Brain Behav Evol** 1995; 46(3):124–30 (60 ref.)
Physiology of primary saccular afferents of goldfish: implications for Mauthner cell response. Fay RR. **Brain Behav Evol** 1995;46(3):141–50 (54 ref.)
Altered L-DOPA systems for blood pressure regulation in the lower brainstem of spontaneously hypertensive rats. Misu Y, et al. **Hypertens Res** 1995 Dec;18(4):267–77 (77 ref.)
Generation of masticatory rhythm in the brainstem. Nakamura Y, et al. **Neurosci Res** 1995 Aug;23(1):1–19 (171 ref.)
The pedunculopontine nucleus--auditory input, arousal and pathophysiology. Reese NB, et al. **Prog Neurobiol** 1995 Oct;47(2):105–33 (365 ref.)
The temporal relationship between the brainstem and primary cortical auditory evoked potentials. Shaw NA. **Prog Neurobiol** 1995 Oct;47(2):95–103 (66 ref.)

SURGERY

Surgery for gliomas and other mass lesions of the brainstem. Bricolo A, et al. **Adv Tech Stand Neurosurg** 1995;22:261–341 (209 ref.)
Brain stem surgery [editorial] Jackowski A. **Br J Neurosurg** 1995;9(5):581–4 (32 ref.)
Light up the "no-man's land" on the brain stem. Kawase T. **Keio J Med** 1995 Dec;44(4):133–9 (61 ref.)

BRAIN STEM AUDITORY EVOKED POTENTIALS see **EVOKED POTENTIALS, AUDITORY, BRAIN STEM**

BRAIN TISSUE TRANSPLANTATION

Neural transplantation. Lindvall O. **Cell Transplant** 1995 Jul-Aug;4(4):393–400 (35 ref.)
Chromaffin cell survival and host dopaminergic fiber recovery in a patient with Parkinson's disease treated by cografts of adrenal medulla and pretransected peripheral nerve. Case report. Date I, et al. **J Neurosurg** 1996 Apr; 84(4):685–9 (33 ref.)
Maintaining the neuronal phenotype after injury in the adult CNS. Neurotrophic factors, axonal growth substrates, and gene therapy. Tuszynski MH, et al. **Mol Neurobiol** 1995 Apr-Jun;10(2–3):151–67 (107 ref.)
Core Assessment Program for Intracerebral Transplantation in Huntington's Disease (CAPIT-HD). Quinn N, et al. **Mov Disord** 1996 Mar;11(2):143–50 (44 ref.)
Tempting fate and commitment in the developing forebrain. Barbe MF. **Neuron** 1996 Jan;16(1):1–4 (16 ref.)
Update on cellular transplantation into the CNS as a novel therapy for chronic pain. Czech KA, et al. **Prog Neurobiol** 1995 Aug;46(5):507–29 (126 ref.)
[Cell and gene transfers for therapeutic use into the central nervous system] Peschanski M. **Ann Endocrinol (Paris)** 1995;56(6):575–7 (17 ref.) (Eng. Abstr.) **(Fre)**
[Neurotransplantation in Parkinson disease: experimental and clinical results of functional reconstruction of the dopaminergic system] Nikkhah G, et al. **Zentralbl Neurochir** 1995;56(4):153–60 (29 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Neuro-glial-immune interactions. An experimental, neural transplant and lesion study. Finsen B. **Dan Med Bull** 1995 Sep;42(4):323–41 (192 ref.)
[Neuronal transplantation in animal models of Parkinson disease: in vivo voltammetry, tissue cryopreservation and immunology] Sautter J, et al. **Zentralbl Neurochir** 1995; 56(4):161–7 (28 ref.) (Eng. Abstr.) **(Ger)**

LEGISLATION & JURISPRUDENCE

[Legal aspects of neurotransplantation] Wolfslast G. **Zentralbl Neurochir** 1995;56(4):210–4 (35 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Schwann cells and the regrowth of axons in the mammalian CNS: a review of transplantation studies in the rat visual system. Harvey AR, et al. **Clin Exp Pharmacol Physiol** 1995 Aug;22(8):569–79 (77 ref.)
Glial cell transplantation and remyelination of the central nervous system. Duncan ID. **Neuropathol Appl Neurobiol** 1996 Apr;22(2):87–100 (100 ref.)

PSYCHOLOGY

[Identity of the personality and personal identity: philosophical questions in relation to transplantation of brain tissue] Birnbacher D. **Zentralbl Neurochir** 1995; 56(4):180–5 (6 ref.) (Eng. Abstr.) **(Ger)**
[Psychological aspects of neurotransplantation] Ellgring H. **Zentralbl Neurochir** 1995;56(4):168–72 (11 ref.) (Eng. Abstr.) **(Ger)**
[Open questions in neurotransplantation. Attempted at an unbiased ethical analysis] Reiter-Theil S. **Zentralbl Neurochir** 1995;56(4):173–9 (8 ref.) (Eng. Abstr.) **(Ger)**

BRAINWASHING see **PERSUASIVE COMMUNICATION**

BRANCH RETINAL ARTERY OCCLUSION see **RETINAL ARTERY OCCLUSION**

BRANCHED-CHAIN KETOACIDURIA see **MAPLE SYRUP URINE DISEASE**

BRANCHIAL CLEFT CYST see **BRANCHIOMA**

BRANCHIAL CYST see **BRANCHIOMA**

BRANCHIOMA

RADIOGRAPHY

Infected third branchial cleft cyst: retropharyngeal extension to the superior mediastinum. Hewel K, et al. **Can Assoc Radiol J** 1996 Apr;47(2):111–3 (8 ref.)

BRANHAMELLA CATARRHALIS see **MORAXELLA (BRANHAMELLA) CATARRHALIS**

BRASSICA

CHEMISTRY

Natural toxins and protective factors in brassica species, including rapeseed. Heaney RK, et al. **Nat Toxins** 1995; 3(4):233–7; discussion 242 (16 ref.)

BRDU see **BROMODEOXYURIDINE**

BREAKBONE FEVER VIRUS see **DENGUE VIRUS**

BREAST

see related
LACTATION
MAMMAE
MAMMAPLASTY
MAMMOGRAPHY
MASTECTOMY

ANATOMY & HISTOLOGY

Breast MR imaging. An analysis of its role with respect to other imaging and interventional modalities. Brenner RJ. **Magn Reson Imaging Clin N Am** 1994 Nov;2(4):705–23 (84 ref.)

Sensitivity of contrast-enhanced MR imaging of the breast. Heywang-Koebrunner SH, et al. **Magn Reson Imaging Clin N Am** 1994 Nov;2(4):527–38 (32 ref.)

Imaging techniques for breast MR imaging. Hylton NM, et al. **Magn Reson Imaging Clin N Am** 1994 Nov;2(4):511–25 (51 ref.)

MR spectroscopy of the breast. Merchant TE. **Magn Reson Imaging Clin N Am** 1994 Nov;2(4):691–703 (38 ref.)

MR imaging of the breast. Imaging and tissue characterization without intravenous contrast. Santyr GE. **Magn Reson Imaging Clin N Am** 1994 Nov;2(4):673–90 (45 ref.)

CYTOLOGY

Mammary tumor fibroblasts are phenotypically distinct from non-tumor fibroblasts. Hornby AE, et al. **EXS** 1995; 74:249–71 (147 ref.)

GROWTH & DEVELOPMENT

The biology of growth regulation in normal and malignant breast epithelium: from bench to clinic. Nguyen B, et al. **Crit Rev Oncol Hematol** 1995 Oct;20(3):223–36 (170 ref.)

METABOLISM

The role of estrogen in mammary carcinogenesis. Fishman J, et al. **Ann N Y Acad Sci** 1995 Sep 30;768:91–100 (31 ref.)

New insights in the molecular mechanism of progestin-induced proliferation of mammary epithelium: induction of the local biosynthesis of growth hormone (GH) in the mammary glands of dogs, cats and humans. Mol JA, et al. **J Steroid Biochem Mol Biol** 1996 Jan; 57(1–2):67–71 (44 ref.)

PATHOLOGY

Gadolinium-enhanced breast MRI. Kelcz F, et al. **Crit Rev Diagn Imaging** 1995;36(4):287–338 (41 ref.)

MR imaging of the breast in the follow-up evaluation of conservative nonoperatively treated breast cancer. Dao TH, et al. **Magn Reson Imaging Clin N Am** 1994 Nov; 2(4):605–22 (46 ref.)

MR imaging of the breast after surgery for breast cancer. Whitehouse GH, et al. **Magn Reson Imaging Clin N Am** 1994 Nov;2(4):591–603 (59 ref.)

Cellular changes involved in conversion of normal to malignant breast: importance of the stromal reaction. Rønnov-Jessen L, et al. **Physiol Rev** 1996 Jan;76(1):69–125 (630 ref.)

Needle biopsy techniques. Parker SH, et al. **Radiol Clin North Am** 1995 Nov;33(6):1171–86 (19 ref.)

MR imaging of the breast for cancer evaluation. Current status and future directions. Stelling CB. **Radiol Clin North Am** 1995 Nov;33(6):1187–204 (60 ref.)

A practical approach to minimally invasive breast biopsy. Parker SH, et al. **Radiology** 1996 Jul;200(1):11–20 (50 ref.)

Tumoral fibrosis and lack of circumscription in granular cell tumor of the breast. Kragel PJ, et al. **South Med J** 1995 Nov;88(11):1146–8 (26 ref.)

Pathology of advanced primary breast carcinoma. Tavassoli FA. **Surg Oncol Clin N Am** 1995 Oct;4(4):591–600 (49 ref.)

[MR-mammography: current status and perspectives] Funke M, et al. **Aktuelle Radiol** 1996 May;6(3):130–5 (47 ref.) (Eng. Abstr.) **(Ger)**

[Progress of ductoscopy of the breast] Okazaki A, et al. **Nippon Geka Gakkai Zasshi** 1996 May;97(5):357–62 (15 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Apoptosis in the human female reproductive tract. Spencer SJ, et al. **Obstet Gynecol Surv** 1996 May;51(5):314–23 (103 ref.)

[Physiological review of the mammary gland development during pregnancy] Merviel P, et al. **Contracept Fertil Sex** 1996 Mar;24(3):218–22 (25 ref.) (Eng. Abstr.) **(Fre)**

RADIATION EFFECTS

Dose to contralateral breast--a comparative study. Brooks PS. **Med Dosim** 1995 Winter;20(4):301–7 (7 ref.)

RADIONUCLIDE IMAGING

[Nuclear medical breast diagnosis--scintigraphy using 99mTc-sestamibi (editorial)] Hahn K. **Nuklearmedizin** 1996 Jun;35(3):4–6 (28 ref.) **(Ger)**

SURGERY

Mammoscopy and endoscopic implant and breast tissue evaluation. Colon GA. **Clin Plast Surg** 1995 Oct; 22(4):697–706 (5 ref.)

Endoscopic techniques in aesthetic breast surgery. Augmentation, mastectomy, biopsy, capsulotomy, capsulorrhaphy, reduction, mastopexy, and reconstructive techniques. Eaves FF 3rd, et al. **Clin Plast Surg** 1995 Oct; 22(4):683–95 (32 ref.)

Endoscopic abdominoplasty, mastopexy, and breast reduction. Faria-Correa MA. **Clin Plast Surg** 1995 Oct; 22(4):723–45 (9 ref.)

Seromas in the breast: imaging findings. Soo MS, et al. **Crit Rev Diagn Imaging** 1995;36(5):385–440 (34 ref.)

Breast-conserving treatment: controversies and consensus. Noguchi M, et al. **J Surg Oncol** 1996 Jul;62(3):228–34 (107 ref.)

BREAST CYSTS see **FIBROCYSTIC DISEASE OF BREAST**

BREAST DISEASES

The diagnosis and management of breast problems during pregnancy and lactation. Scott-Conner CE, et al. **Am J Surg** 1995 Oct;170(4):401–5 (47 ref.)

Mondor's disease. Pugh CM, et al. **J Natl Med Assoc** 1996 Jun;88(6):359–63 (27 ref.)

Breast disease. Bradley AL, et al. **Med Clin North Am** 1995 Nov;79(6):1443–55 (61 ref.)

CHEMICALLY INDUCED

[Destructive paraffinoma of the breast and thoracic wall caused by paraffin injection for mammary increase. Apropos of 3 cases with review of the literature] Zekri A, et al. **Ann Chir Plast Esthet** 1996 Feb;41(1):90–3 (7 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Critical pathways for the future: MR imaging and digital mammography. Newstead GM, et al. **Radiographics** 1995 Jul;15(4):951–62 (40 ref.)

Management of probably benign breast lesions. Sickles EA. **Radiol Clin North Am** 1995 Nov;33(6):1123–30 (42 ref.)

[Magnetic resonance imaging in gynecology] Martin B, et al. **Contracept Fertil Sex** 1996 Feb;24(2):123–6 (0 ref.) **(Fre)**

[Primary amyloid tumor of the breast. Case report and review of the literature] Bisceglia M, et al. **Pathologica** 1995 Apr; 87(2):162–7 (20 ref.) (Eng. Abstr.) **(Ita)**

DRUG THERAPY

[Gestagens and breast diseases] Lober R. **Zentralbl Gynakol** 1995;117 Suppl:19–24 (27 ref.) **(Ger)**

PATHOLOGY

Fine-needle aspiration biopsy of the breast. Kline TS. **Am Fam Physician** 1995 Nov 15;52(7):2021–5 (25 ref.)

Papillomas of the breast. A histologic spectrum including atypical hyperplasia and carcinoma in situ. McKinney CD, et al. **Pathol Annu** 1995;30 Pt 2:137–78 (47 ref.)

Pathology of benign and malignant breast disorders. Sewell CW. **Radiol Clin North Am** 1995 Nov;33(6):1067–80 (16 ref.)

[Diseases of the breast] Bässler R. **Pathologe** 1996 Jan; 17(1):92–106 (23 ref.) **(Ger)**

[Inflammatory pseudotumor of the breast. Report of a case and review of the literature] Bisceglia M, et al. **Pathologica** 1995 Feb;87(1):59–64 (36 ref.) (Eng. Abstr.) **(Ita)**

RADIOGRAPHY

The mammographic spectrum of fat necrosis of the breast. Hogge JP, et al. **Radiographics** 1995 Nov;15(6):1347–56 (25 ref.)

Evaluation of breast microcalcifications. Monsees BS. **Radiol Clin North Am** 1995 Nov;33(6):1109–21 (77 ref.)

[The manifestation of subcutaneous sarcoidosis in the area of the breast] Ludwig K, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1995 Oct;163(4):356–7 (8 ref.) **(Ger)**

RADIONUCLIDE IMAGING

[Nuclear medical breast diagnosis--scintigraphy using 99mTc-sestamibi (editorial)] Hahn K. **Nuklearmedizin** 1996 Jun;35(3):4–6 (28 ref.) **(Ger)**

THERAPY

Conservative management of fibroadenoma of the breast. Alle KM, et al. **Br J Surg** 1996 Jul;83(7):992–3 (10 ref.)

Successful management of breast abscess with ongoing breastfeeding. Banapurmath CR, et al. **Indian Pediatr** 1995 Apr;32(4):488–91 (10 ref.)

ULTRASONOGRAPHY

Sonographic evaluation of benign and malignant breast lesions. Kelly KM. **Crit Rev Diagn Imaging** 1996 Apr; 37(2):79–161 (72 ref.)

BREAST DYSPLASIA see **FIBROCYSTIC DISEASE OF BREAST**

BREAST FEEDING

see related
BOTTLE FEEDING

Antidepressant treatment during breast-feeding. Wisner KL, et al. **Am J Psychiatry** 1996 Sep;153(9):1132–7 (52 ref.)

Should breast-feeding by women with silicone implants be recommended? [letter] Jordan ME, et al. **Arch Pediatr Adolesc Med** 1996 Aug;150(8):880–1 (27 ref.)

Normal puerperium and breast-feeding. Gaál G, et al. **Curr Opin Obstet Gynecol** 1995 Dec;7(6):442–5 (12 ref.)

The effect of hypo-allergenic formulas in infants at risk of allergic disease. Halken S, et al. **Eur J Clin Nutr** 1995 Sep; 49 Suppl 1:S77–83 (35 ref.)

Nutrition and breast-feeding. Koppe JG. **Eur J Obstet Gynecol Reprod Biol** 1995 Jul;61(1):73–8 (11 ref.)

Successful management of breast abscess with ongoing breastfeeding. Banapurmath CR, et al. **Indian Pediatr** 1995 Apr;32(4):488–91 (10 ref.)

Transition to breast/bottle feedings: the premature infant. Lemons PK, et al. **J Am Coll Nutr** 1996 Apr;15(2):126–35 (34 ref.)

Transmission of HIV-1 in the breast-feeding process. Black RF. **J Am Diet Assoc** 1996 Mar;96(3):267–74; quiz 275–6 (61 ref.)

Influence of breast-feeding and oral poliovirus vaccine on the immunogenicity and efficacy of rotavirus vaccines. Rennels MB. **J Infect Dis** 1996 Sep;174 Suppl 1:S107–11 (35 ref.)

State of the science. Breastfeeding for mothers and low birth weight infants. Meier PP, et al. **Nurs Clin North Am** 1996 Jun;31(2):351–65 (69 ref.)

The relationship between breast-feeding and infant health and development. Forsyth JS. **Proc Nutr Soc** 1995 Jul; 54(2):407–18 (45 ref.)

Breastfeeding for optimal mental development. The alpha and the omega in human milk. de Andraca I, et al. **World Rev Nutr Diet** 1995;78:1–27 (74 ref.)

Breastfeeding kinetics. A problem-solving approach to breastfeeding difficulties. Livingstone V. **World Rev Nutr Diet** 1995;78:28–54 (59 ref.)

[Breast feeding: which contraceptive method?] Codaccioni X, et al. **Rev Fr Gynecol Obstet** 1995 May-Jun; 90(5–6):302–5 (7 ref.) (Eng. Abstr.) **(Fre)**

[Role of breast milk feeding in avoidance of asthma and other allergic disorders] Barr J, et al. **Harefuah** 1995 Oct; 129(7–8):274–8 (43 ref.) **(Heb)**

[Breast-milk jaundice] Ishii M, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):591–4 (20 ref.) **(Jpn)**

[Lactational amenorrhea as a method of family planning] Canto-de Cetina T, et al. **Salud Publica Mex** 1996 Jan-Feb; 38(1):58–63 (38 ref.) (Eng. Abstr.) **(Spa)**

ETHNOLOGY

Breastfeeding in Australia. Lund-Adams M, et al. **World Rev Nutr Diet** 1995;78:74–113 (100 ref.)

STATISTICS & NUMERICAL DATA

Breastfeeding trends in Cuba. Amador M, et al.

World Rev Nutr Diet 1995;78:139–63 (61 ref.)
Breastfeeding in Korea. Kim SH, et al.
World Rev Nutr Diet 1995;78:114–27 (12 ref.)
Breastfeeding in China. Liu DS, et al.
World Rev Nutr Diet 1995;78:128–38 (19 ref.)
Breastfeeding patterns in the Arabian Gulf countries. Musaiger AO. **World Rev Nutr Diet** 1995;78:164–90 (72 ref.)

BREAST IMPLANTS

Mammoscopy and endoscopic implant and breast tissue evaluation. Colon GA. **Clin Plast Surg** 1995 Oct; 22(4):697–706 (5 ref.)
Silica, silicon and silicones ... unraveling the mystery. Lane TH, et al. **Curr Top Microbiol Immunol** 1996;210:3–12 (12 ref.)
MR imaging of breast implants. Gorczyca DP. **Magn Reson Imaging Clin N Am** 1994 Nov;2(4):659–72 (29 ref.)
Evaluation of the augmented breast. Reynolds HE. **Radiol Clin North Am** 1995 Nov;33(6):1131–45 (75 ref.)
Primary and secondary breast reconstruction with special emphasis on the use of prostheses. Petit JY, et al. **Recent Results Cancer Res** 1996;140:169–75 (15 ref.)
–Possibilities and limits of imaging for evaluating breast implants– Tristant H. **Arch Gynecol Obstet** 1995;256 Suppl:S135–47 (31 ref.) **(Fre)**

ADVERSE EFFECTS

Reported complications of silicone gel breast implants: an epidemiologic review. Silverman BG, et al. **Ann Intern Med** 1996 Apr 15;124(8):744–56 (104 ref.)
Silicone thorax: a complication of tube thoracostomy in the presence of mammary implants. Rice DC, et al. **Ann Thorac Surg** 1995 Nov;60(5):1417–9 (8 ref.)
Should breast-feeding by women with silicone implants be recommended? [letter] Jordan ME, et al. **Arch Pediatr Adolesc Med** 1996 Aug;150(8):880–1 (27 ref.)
Silicone breast implants and connective-tissue diseases [editorial; comment] Valesini G, et al. **Clin Exp Rheumatol** 1995 Jul–Aug;13(4):421–3 (18 ref.) Comment on: Clin Exp Rheumatol 1995 Jul–aug;13(4):521–3.
Breast cancer risk among women using silicone gel breast implants. Edelman DA, et al. **Int J Fertil Menopausal Stud** 1995 Sep–Oct;40(5):274–80 (41 ref.)
The evolution of FDA policy on silicone breast implants: a case study of politics, bureaucracy, and business in the process of decision-making. Palley HA. **Int J Health Serv** 1995;25(4):573–91 (61 ref.)
Silicone breast implants: immunotoxic and epidemiologic issues [see comments] Yoshida SH, et al. **Life Sci** 1995 Mar 10;56(16):1299–310 (95 ref.) Comment in: Life Sci 1995;57(19):1737–40.
Toxic shock syndrome as a complication of breast prostheses. Poblete JV, et al. **Plast Reconstr Surg** 1995 Dec; 96(7):1702–8 (54 ref.)
A critical assessment of the relationship between silicone breast implants and connective tissue diseases. Wong O. **Regul Toxicol Pharmacol** 1996 Feb;23(1 Pt 1):74–85 (60 ref.)
[Complications from silicone implants and other so-called inert materials] Faure M. **Ann Dermatol Venereol** 1995; 122(6–7):455–9 (54 ref.) **(Fre)**

TRENDS

Breast implants: facts, controversy, and speculations for future research. Jenkins ME, et al. **J Invest Surg** 1996 Jan–Feb;9(1):1–12 (48 ref.)

BREAST NEOPLASMS

Current management of breast cancer. Phillips DM, et al. **Am Fam Physician** 1996 Feb 1;53(2):657–65 (36 ref.)
Transgenic mouse models of breast cancer. Amundadottir LT, et al. **Breast Cancer Res Treat** 1996;39(1):119–35 (133 ref.)
Animal models of breast cancer: their diversity and role in biomedical research. Clarke R. **Breast Cancer Res Treat** 1996;39(1):1–6 (27 ref.)
An update on breast cancer: evolving treatments and persistent questions. Crowe JP Jr. **Cleve Clin J Med** 1996 Jan–Feb;63(1):48–56 (26 ref.)
Growth factors in breast cancer. Dickson RB, et al. **Endocr Rev** 1995 Oct;16(5):559–89 (508 ref.)
Malignant joint effusions secondary to solid tumor metastasis. Munn RK, et al. **J Rheumatol** 1995 May;22(5):973–5 (15 ref.)
Estrogen replacement therapy for the breast cancer survivor. DiSaia PJ. **J Soc Gynecol Investig** 1996 Mar–Apr;3(2):57–9 (10 ref.)
Ductal carcinoma in situ. Margolese RG. **Recent Results Cancer Res** 1996;140:131–8 (25 ref.)
Sex hormones and breast cancer: the issue of hormone replacement. Pritchard KI, et al. **Recent Results Cancer Res** 1996;140:285–93 (33 ref.)
Breast cancer in pregnancy and lactation. DiFronzo LA, et al. **Surg Clin North Am** 1996 Apr;76(2):267–78 (45 ref.)
Paget's disease of the nipple–areola complex. Jamali FR, et al. **Surg Clin North Am** 1996 Apr;76(2):365–81 (82 ref.)
Breast cancer in elderly women: presentation, survival, and treatment options. Law TM, et al. **Surg Clin North Am** 1996 Apr;76(2):289–308 (99 ref.)
Breast sarcoma. Moore MP, et al. **Surg Clin North Am** 1996 Apr;76(2):383–92 (54 ref.)
The woman at high risk for breast cancer. Importance of hyperplasia. Page DL. **Surg Clin North Am** 1996 Apr; 76(2):221–30 (43 ref.)
[Breast cancer during pregnancy] Merviel P, et al. **Bull Cancer (Paris)** 1996 Apr;83(4):266–75 (51 ref.) (Eng. Abstr.) **(Fre)**
[Intraductal cancer of the breast in women under age 35 years] Sananes S, et al. **Bull Cancer (Paris)** 1996 May; 83(5):395–9 (34 ref.) (Eng. Abstr.) **(Fre)**
[Breast angiosarcoma. Five case reports] Gamoudi A, et al. **Rev Fr Gynecol Obstet** 1995 Oct;90(10):435–41 (18 ref.) (Eng. Abstr.) **(Fre)**
[Breast cancer. A historical account, present and future] Lazcano-Ponce EC, et al. **Salud Publica Mex** 1996 Mar–Apr;38(2):139–52 (87 ref.) (Eng. Abstr.) **(Spa)**

BLOOD SUPPLY

Molecular and pharmacologic targeting of angiogenesis factors—the example of pleiotrophin. Czubayko F, et al. **Breast Cancer Res Treat** 1995;36(2):157–68 (68 ref.)
The influence of angiogenesis research on management of patients with breast cancer. Folkman J. **Breast Cancer Res Treat** 1995;36(2):109–18 (78 ref.)
Regulation of the expression of the VEGF/VPS and its receptors: role in tumor angiogenesis. Kolch W, et al. **Breast Cancer Res Treat** 1995;36(2):139–55 (156 ref.)
The modulation of thrombospondin and other naturally occurring inhibitors of angiogenesis during tumor progression. Volpert OV, et al. **Breast Cancer Res Treat** 1995;36(2):119–26 (56 ref.)
Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Weidner N. **Breast Cancer Res Treat** 1995; 36(2):169–80 (66 ref.)
[Breast cancer angiogenesis] Toi M, et al. **Gan To Kagaku Ryoho** 1996 May;23(6):659–66 (50 ref.) (Eng. Abstr.) **(Jpn)**
[The importance of tumor angiogenesis as a prognostic indicator in primary breast cancer] Saji S, et al. **Nippon Geka Gakkai Zasshi** 1996 May;97(5):368–74 (50 ref.) (Eng. Abstr.) **(Jpn)**

CHEMICALLY INDUCED

Organochlorine compounds: Risk of non-Hodgkin's lymphoma and breast cancer? Hoffman W. **Arch Environ Health** 1996 May–Jun;51(3):189–92 (42 ref.)
Hormone replacement therapy and breast cancer risk. Gambrell RD Jr. **Arch Fam Med** 1996 Jun;5(6):341–8 (82 ref.)
Hormone replacement therapy and breast cancer: an overview. Theriault RL. **Br J Obstet Gynaecol** 1996 May; 103 Suppl 13:87–90; discussion 90–1 (17 ref.)
Organochlorine compounds in relation to breast cancer, endometrial cancer, and endometriosis: an assessment of the biological and epidemiological evidence. Ahlborg UG, et al. **Crit Rev Toxicol** 1995;25(6):463–531 (318 ref.)
Does hormone replacement therapy increase the risk of breast cancer? Lécuru F, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Oct;62(2):159–66 (62 ref.)
Hormone replacement therapy in women with breast cancer. Do the risks outweigh the benefits? Roy JA, et al. **J Clin Oncol** 1996 Mar;14(3):997–1006 (85 ref.)
Depot medroxyprogesterone acetate contraception and the risk of breast and gynecologic cancer. Kaunitz AM. **J Reprod Med** 1996 May;41(5 Suppl):419–27 (38 ref.)
Postmenopausal hormone therapy and breast cancer. Speroff L. **Obstet Gynecol** 1996 Feb;87(2 Suppl):44S–54S (81 ref.)
The food-derived heterocyclic amines and breast cancer: a 1995 perspective. Synderwine EG. **Recent Results Cancer Res** 1996;140:17–25 (54 ref.)
Can environmental estrogens cause breast cancer? Davis DL, et al. **Sci Am** 1995 Oct;273(4):167–72 (5 ref.)
[Long-term hormone replacement and risk of breast carcinoma: current status. On behalf of the German Menopause Society and the Professional Society of Gynecologic Endocrinology and Reproductive Medicine of the German Society of Gynecology and Obstetrics] Kuhl H, et al. **Zentralbl Gynakol** 1995;117(10):549–53 (35 ref.) **(Ger)**

CHEMISTRY

Molecular analysis of premalignant and carcinoma in situ lesions of the human breast. Steeg PS, et al. **Am J Pathol** 1996 Sep;149(3):733–8 (49 ref.)
Oncogene products and other diagnostic markers in human breast cancer patients. Treatment effects and their significance. Dowsett M, et al. **Ann N Y Acad Sci** 1996 Apr 30;784:403–11 (11 ref.)
Fibrinolysis components as prognostic markers in breast cancer and colorectal carcinoma. Gandolfo GM, et al. **Anticancer Res** 1996 Jul–Aug;16(4B):2155–9 (37 ref.)
Correlation between pS2 protein positivity, steroid receptor status and other prognostic factors in breast cancer. Racca S, et al. **Int J Biol Markers** 1995 Apr–Jun;10(2):87–93 (35 ref.)
[Should immunohistochemistry be used to evaluate estrogen and progesterone receptors in breast cancers? (editorial)] Balaton AJ, et al. **Ann Pathol** 1996;16(2):78–80 (11 ref.) **(Fre)**
[Biochemical basis for detection of estrogen and progesterone receptors in breast tumors using immunohistochemistry] Goussard J. **Ann Pathol** 1996;16(2):91–7 (41 ref.) **(Fre)**

COMPLICATIONS

Estrogen replacement therapy in survivors of breast cancer: a risk–benefit assessment. Eden JA. **Drugs Aging** 1996 Feb; 8(2):127–33 (34 ref.)
[The assessment of solitary osteolytic bone lesions in breast carcinoma. A special case report] Mose S, et al. **Strahlenther Onkol** 1996 Jan;172(1):43–6 (16 ref.) (Eng. Abstr.) **(Ger)**

DIAGNOSIS

Consensus Conference on 'Follow-up of Breast Cancer Patients'. **Ann Oncol** 1995;6 Suppl 2:69–70 (0 ref.)
Detection of breast cancer local recurrences. Ciatto S. **Ann Oncol** 1995;6 Suppl 2:23–6 (6 ref.)
Tumor markers in breast cancer follow-up: a potentially useful parameter still awaiting definitive assessment. Forza Operativa Nazionale sul Carcinoma Mammario (FONCaM). Gion M, et al. **Ann Oncol** 1995;6 Suppl 2:31–5 (24 ref.)
Evaluating primary care follow-up of breast cancer: methods and preliminary results of three studies. Grunfeld E, et al. **Ann Oncol** 1995;6 Suppl 2:47–52 (30 ref.)
The efficacy of intensive follow-up testing in breast cancer cases. Roselli Del Turco M, et al. **Ann Oncol** 1995;6 Suppl 2:37–9 (5 ref.)
Breast cancer: the search for new prognostic markers. Davis AR. **Br J Biomed Sci** 1996 Jun;53(2):157–61 (20 ref.)
The emerging role of the physician in genetic counselling and testing for heritable breast, ovarian and colon cancer. Taylor KM, et al. **Can Med Assoc J** 1996 Apr 15; 154(8):1155–8 (23 ref.)
The Canadian National Breast Screening Study. Why? What next? And so what? Baines CJ. **Cancer** 1995 Nov 15;76(10 Suppl):2107–12 (42 ref.)
Controversies in breast cancer screening. Leitch AM. **Cancer** 1995 Nov 15;76(10 Suppl):2064–9 (28 ref.)
T and Tn pancarcinoma markers: autoantigenic adhesion molecules in pathogenesis, prebiopsy carcinoma-detection, and long-term breast carcinoma immunotherapy. Springer GF. **Crit Rev Oncog** 1995;6(1):57–85 (220 ref.)
Immunohistochemistry in the diagnosis and treatment of breast cancer. Matsuura N, et al. **Gan To Kagaku Ryoho** 1996 Mar;23 Suppl 1:24–9 (2 ref.)
Tumor markers for breast cancer. Current utilities and future prospects. Hayes DF. **Hematol Oncol Clin North Am** 1994 Jun;8(3):485–506 (114 ref.)
Postexcisional recurrence of carcinoma of the breast. Zavotsky J, et al. **J Am Coll Surg** 1996 Jan;182(1):71–7 (88 ref.)
Anti-Thomsen-Friedenreich (T) antibody and its application to human breast carcinoma: where are we after 20 years? [editorial; comment] McCarty KS Jr. **J Immunol Methods** 1995 Dec 27;188(2):171–3 (7 ref.) Comment on: J Immunol Methods 1995 Dec 27;188(2):175–85.
Breast MR imaging. An analysis of its role with respect to other imaging and interventional modalities. Brenner RJ. **Magn Reson Imaging Clin N Am** 1994 Nov;2(4):705–23 (84 ref.)
MR spectroscopy of the breast. Merchant TE. **Magn Reson Imaging Clin N Am** 1994 Nov;2(4):691–703 (38 ref.)
The specificity of contrast-enhanced breast MR imaging. Piccoli CW. **Magn Reson Imaging Clin N Am** 1994 Nov; 2(4):557–71 (75 ref.)
Recent developments in breast imaging. Säbel M, et al. **Phys Med Biol** 1996 Mar;41(3):315–68 (360 ref.)
Applying cognitive-social theory to health-protective behavior: breast self-examination in cancer screening. Miller SM, et al. **Psychol Bull** 1996 Jan;119(1):70–94 (263 ref.)
Contemporary diagnostic approaches for nonpalpable carcinoma of the breast: the role of the radiologist. Schepps B, et al. **R I Med** 1995 Sep;78(9):239–41 (19 ref.)
Critical pathways for the future: MR imaging and digital mammography. Newstead GM, et al. **Radiographics** 1995 Jul;15(4):951–62 (40 ref.)
Breast masses. Appropriate evaluation. Evans WP. **Radiol Clin North Am** 1995 Nov;33(6):1085–108 (87 ref.)
MR imaging of the breast for cancer evaluation. Current status and future directions. Stelling CB. **Radiol Clin North Am** 1995 Nov;33(6):1187–204 (60 ref.)
MRI's role in assessing and managing breast disease. Coons TA. **Radiol Technol** 1996 Mar–Apr;67(4):311–36; quiz 337–40 (80 ref.)
A critical review of screening for breast cancer. Del Turco MR. **Recent Results Cancer Res** 1996;140:123–30 (24 ref.)
Prognostic variables and future predictors of behaviour and response. Gusterson BA. **Recent Results Cancer Res** 1996; 140:89–100 (60 ref.)
Review of known prognostic variables. Kaufmann M. **Recent Results Cancer Res** 1996;140:77–87 (39 ref.)

A case of breast angiosarcoma: diagnostic imaging and review of the literature. Zincone GE, et al. **Tumori** 1995 Sep–Oct;81(5):387–96 (15 ref.)

Detection of latent prostate cancer from routine screening: comparison with breast cancer screening. Benoit RM, et al. **Urology** 1995 Oct;46(4):533–6; discussion 536–7 (43 ref.)

[Breast cancer during pregnancy. Epidemiology—diagnosis—prognosis] Gorins A, et al. **Contracept Fertil Sex** 1996 Feb;24(2):153–6 (11 ref.) (Eng. Abstr.) **(Fre)**

[Surgical approach to subclinical breast lesions] Coibion M. **Rev Med Brux** 1995 Jul–Aug;16(4):218–24 (24 ref.) (Eng. Abstr.) **(Fre)**

[MR-mammography: current status and perspectives] Funke M, et al. **Aktuelle Radiol** 1996 May;6(3):130–5 (47 ref.) (Eng. Abstr.) **(Ger)**

[Imaging methods in diagnosis and differential diagnosis of breast cancer] Kessler M, et al. **Bildgebung** 1995 Sep; 62(3):160–72 (58 ref.) (Eng. Abstr.) **(Ger)**

[The differential diagnosis of tumors of the nipple and areola] Schulz B, et al. **Dtsch Med Wochenschr** 1996 Jan 5; 121(1–2):23–7 (19 ref.) **(Ger)**

[Giant fibroadenoma of the breast. Its clinical picture and differential diagnosis. A report of a clinical case] Magnoni P, et al. **Minerva Chir** 1996 Jan–Feb;51(1–2):71–5 (16 ref.) (Eng. Abstr.) **(Ita)**

[Primary amyloid tumor of the breast. Case report and review of the literature] Bisceglia M, et al. **Pathologica** 1995 Apr; 87(2):162–7 (20 ref.) (Eng. Abstr.) **(Ita)**

[Magnetic resonance in a case of lobular adenocarcinoma of the breast] Dalpiaz G, et al. **Radiol Med (Torino)** 1996 Apr;91(4):475–7 (12 ref.) **(Ita)**

[Simple lymphangioma of the breast. A case report] Occhiato R, et al. **Radiol Med (Torino)** 1996 Jan–Feb;91(1–2):130–2 (4 ref.) **(Ita)**

[Progress of ductoscopy of the breast] Okazaki A, et al. **Nippon Geka Gakkai Zasshi** 1996 May;97(5):357–62 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Recent progress in the diagnosis of nonpalpable breast lesions] Yoshimoto M, et al. **Nippon Geka Gakkai Zasshi** 1996 May;97(5):343–6 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Invasive lobular carcinoma of the breast with a 10-year evolution] da Fonseca CR, et al. **Acta Med Port** 1995 Mar; 8(3):157–9 (13 ref.) (Eng. Abstr.) **(Por)**

DRUG THERAPY

Chemotherapy of advanced breast cancer. Szántó J. **Acta Med Hung** 1994;50(3–4):185–93 (28 ref.)

Novel mechanisms of antiprogestin action. Horwitz KB, et al. **Acta Oncol** 1996;35(2):129–40 (61 ref.)

Tamoxifen therapy—long-term results and complications. Moore MP, et al. **Adv Surg** 1996;29:263–9 (29 ref.)

Aromatase inhibitors: current status. Ibrahim NK, et al. **Am J Clin Oncol** 1995 Oct;18(5):407–17 (142 ref.)

Oncogene products and other diagnostic markers in human breast cancer patients. Treatment effects and their significance. Dowsett M, et al. **Ann N Y Acad Sci** 1996 Apr 30;784:403–11 (11 ref.)

High dose versus standard dose chemotherapy for the treatment of breast cancer. A review of current concepts. Fields KK, et al. **Ann N Y Acad Sci** 1995 Dec 29; 770:288–304 (27 ref.)

Pure antiestrogens. The most important advance in the endocrine therapy of breast cancer since 1896. Nicholson RI, et al. **Ann N Y Acad Sci** 1996 Apr 30;784:325–35 (60 ref.)

Dose-intensive chemotherapy in breast cancer—the need for appropriate measures of outcome [editorial] Basser RL. **Ann Oncol** 1995 Sep;6(7):633–5 (23 ref.)

Potential strategies for improving the results of high-dose chemotherapy in patients with metastatic breast cancer. Crown J, et al. **Ann Oncol** 1995;6 Suppl 4:21–6 (61 ref.)

Therapy-related acute promyelocytic leukemia with t(15;17)(q22;q12) following chemotherapy with drugs targeting DNA topoisomerase II. A report of two cases and a review of the literature [see comments] Hoffmann L, et al. **Ann Oncol** 1995 Oct;6(8):781–8 (32 ref.) Comment in: Ann Oncol 1995 Oct;6(8):751–3.

High-dose chemotherapy for breast cancer: clinical advantages of autologous peripheral blood progenitor cells (PBPC) compared with autologous bone marrow transplantation (ABMT). Martin M. **Ann Oncol** 1995;6 Suppl 4:33–7 (18 ref.)

First-line systemic therapy for metastatic breast cancer and management of pleural effusion. Perrone F, et al. **Ann Oncol** 1995 Dec;6(10):1033–43 (93 ref.)

The importance of dose and schedule in cancer chemotherapy: breast cancer. Leonard RC. **Anticancer Drugs** 1995 Oct;6 Suppl 5:17–27 (75 ref.)

Docetaxel: a new defence in the management of breast cancer. Piccart M. **Anticancer Drugs** 1995 Jul;6 Suppl 4:7–11 (12 ref.)

Possible mechanisms in the emergence of tamoxifen-resistant breast cancer. Tonetti DA, et al. **Anticancer Drugs** 1995 Aug;6(4):498–507 (87 ref.)

The influence of angiogenesis research on management of patients with breast cancer. Folkman J. **Breast Cancer Res Treat** 1995;36(2):109–18 (78 ref.)

Third annual William L. McGuire Memorial Lecture. "Studies on the estrogen receptor in breast cancer"—20 years as a target for the treatment and prevention of cancer. Jordan VC. **Breast Cancer Res Treat** 1995;36(3):267–85 (123 ref.)

Phase II study of oral etoposide for patients with advanced breast cancer. Atienza DM, et al. **Cancer** 1995 Dec 15; 76(12):2485–90 (39 ref.)

High-dose chemotherapy of metastatic breast cancer: a review. Vahdat L, et al. **Cancer Invest** 1995;13(5):505–10 (44 ref.)

Taxoid compounds in breast cancer: current status and future prospects. Piccart MJ. **Cancer Treat Res** 1995;78:185–207 (56 ref.)

Mifepristone: antineoplastic studies. Sartor O, et al. **Clin Obstet Gynecol** 1996 Jun;39(2):498–505 (28 ref.)

The prognostic implications of chemotherapy in the treatment of breast cancer. O'Brien ME, et al. **Curr Opin Obstet Gynecol** 1996 Feb;8(1):21–6 (28 ref.)

Adjuvant systemic therapy for breast cancer. Roy JA, et al. **Curr Opin Oncol** 1995 Nov;7(6):517–22 (55 ref.)

Metastatic breast cancer. Rubens RD. **Curr Opin Oncol** 1995 Nov;7(6):523–6 (32 ref.)

Docetaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer. Fulton B, et al. **Drugs** 1996 Jun;51(6):1075–92 (86 ref.)

Current and future trends in the multidisciplinary approach for high-risk breast cancer. The experience of the Milan Cancer Institute. Bonadonna G. **Eur J Cancer** 1996 Feb; 32A(2):209–14 (31 ref.)

Pharmacokinetics, targeting and delivery systems in anthracycline-resistant cancers. Cassidy J. **Eur J Cancer** 1995;31A Suppl 7:S18–20 (23 ref.)

Multidrug resistance in breast cancer: mechanisms, strategies. Giaccone G, et al. **Eur J Cancer** 1995;31A Suppl 7:S15–7 (30 ref.)

New endocrine therapies for breast cancer. Howell A, et al. **Eur J Cancer** 1996 Apr;32A(4):576–88 (106 ref.)

High-dose chemotherapy for breast cancer. Leonard RC. **Eur J Cancer** 1996 Feb;32A(2):205–8 (30 ref.)

Prebiopsy neo-adjuvant endocrine therapy for breast cancer to prevent post-surgery trauma-induced growth factor and immune-suppression mediated tumour progression. Oliver RT, et al. **Eur J Cancer** 1996 Mar;32A(3):396–7 (20 ref.)

Cytotoxic agents with activity in breast cancer patients previously exposed to anthracyclines: current status and future prospects. Piccart MJ, et al. **Eur J Cancer** 1995;31A Suppl 7:S1–10 (117 ref.)

Anthracycline resistance in breast cancer: clinical applications of current knowledge. Ravdin PM. **Eur J Cancer** 1995;31A Suppl 7:S11–4 (47 ref.)

High dose chemotherapy with haemopoietic support for breast cancer. Steward WP. **Eur J Cancer** 1995;31A Suppl 7:S21–4 (18 ref.)

Controlled clinical trials with fenretinide in breast cancer, basal cell carcinoma and oral leukoplakia. De Palo G, et al. **J Cell Biochem Suppl** 1995;22:11–7 (16 ref.)

Uterine neoplasms in patients treated with tamoxifen. Silva EG, et al. **J Cell Biochem Suppl** 1995;23:179–83 (22 ref.)

Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. Bines J, et al. **J Clin Oncol** 1996 May;14(5):1718–29 (91 ref.)

High dose chemotherapy for breast cancer: the case for trials in adjuvant therapy. Leonard RC. **J R Soc Med** 1996 Jun; 89(6):337P–9P (22 ref.)

Androgen receptor mediated growth control of breast cancer and endometrial cancer modulated by antiandrogen- and androgen-like steroids. Hackenberg R, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1–6 Spec No):113–7 (56 ref.)

MR mammography with pharmacokinetic mapping for monitoring of breast cancer treatment during neoadjuvant therapy. Knopp MV, et al. **Magn Reson Imaging Clin N Am** 1994 Nov;2(4):633–58 (42 ref.)

Case report: paclitaxel-induced myocardial ischemia. Soe MS, et al. **Md Med J** 1996 Jan;45(1):41–3 (4 ref.)

Targeted anti-estrogens to treat and prevent diseases in women. Tonetti DA, et al. **Mol Med Today** 1996 May; 2(5):218–23 (35 ref.)

Breast cancer chemotherapy after fifty years: more cures and less mutilation. Greenspan EM. **Mt Sinai J Med** 1996 May–Sep;63(3–4):250–5 (37 ref.)

The effect of tamoxifen on the endometrium. Barakat RR. **Oncology (Huntingt)** 1995 Feb;9(2):129–34; discussion 139–40, 142 (27 ref.)

Cost effectiveness and other assessments of adjuvant therapies for early breast cancer. Hillner BE, et al. **Oncology (Huntingt)** 1995 Nov;9(11 Suppl):129–34 (18 ref.)

Current status of vinorelbine for breast cancer. Smith GA. **Oncology (Huntingt)** 1995 Aug;9(8):767–73; discussion 774, 776, 779 (41 ref.)

New approaches to adjuvant chemotherapy for breast cancer. Hudis C. **Pharmacotherapy** 1996 May–Jun;16(3 Pt 2):88S–93S (16 ref.)

Adjuvant systemic therapy for breast cancer. Issues for primary care physicians. Berkowitz LD, et al. **Postgrad Med** 1995 Oct;98(4):85–8, 91, 94 (2 ref.)

Adjuvant treatment of breast cancer. Akerley WL 3rd. **R I Med** 1995 Sep;78(9):250–3 (12 ref.)

Sequencing of chemotherapy and radiation therapy in the treatment of early breast cancer: the devil is in the details [editorial; comment] Ellerbroek NA. **Radiology** 1996 Sep; 200(3):605–7 (24 ref.) Comment on: Radiology 1996 Sep;200(3):615–9.

Tamoxifen and endometrial cancer: from experiment to patient. Assikis VJ, et al. **Recent Results Cancer Res** 1996; 140:61–71 (41 ref.)

Current and future roles of adjuvant endocrine therapy in the management of early carcinoma of the breast. Baum M, et al. **Recent Results Cancer Res** 1996;140:215–26 (30 ref.)

Future developments in adjuvant systemic therapy for high-risk breast cancer. Bonadonna G. **Recent Results Cancer Res** 1996;140:227–34 (16 ref.)

Adjuvant systemic therapy: the issues of timing and sequence. Castiglione-Gertsch M, et al. **Recent Results Cancer Res** 1996;140:201–13 (22 ref.)

The role of anthracyclines in adjuvant chemotherapy of breast cancer: a critical appraisal. Mouridsen HT. **Recent Results Cancer Res** 1996;140:191–9 (33 ref.)

The primary use of chemotherapy for operable breast cancer: does systemic therapy make surgery superfluous? Rudenstam CM. **Recent Results Cancer Res** 1996; 140:177–88 (21 ref.)

Single-chain fusion toxins for the treatment of breast cancer: antitumor activity of BR96 sFv-PE40 and heregulin-PE40. Siegall CB. **Recent Results Cancer Res** 1996;140:51–60 (21 ref.)

High-dose chemotherapy with autologous hematopoietic progenitor cell support for metastatic and high-risk primary breast cancer. Bearman SI, et al. **Semin Oncol** 1996 Feb;23(1 Suppl 2):60–7 (62 ref.)

The role of taxanes in the treatment of breast cancer. Capri G, et al. **Semin Oncol** 1996 Feb;23(1 Suppl 2):68–75 (62 ref.)

Treatment of metastatic breast cancer with paclitaxel and doxorubicin. Dombernowsky P, et al. **Semin Oncol** 1995 Dec;22(6 Suppl 15):13–7 (14 ref.)

Paclitaxel and doxorubicin, a highly active combination in the treatment of metastatic breast cancer. Dombernowsky P, et al. **Semin Oncol** 1996 Feb;23(1 Suppl 1):13–8 (17 ref.)

Adjuvant systemic therapy for breast cancer. Harris DT. **Semin Oncol** 1995 Dec;22(6):553–70 (123 ref.)

The role of primary chemotherapy in early breast cancer. Harris L, et al. **Semin Oncol** 1996 Feb;23(1 Suppl 2):31–42 (46 ref.)

Single-agent paclitaxel for the treatment of breast cancer: an overview. Hortobagyi GN, et al. **Semin Oncol** 1996 Feb; 23(1 Suppl 1):4–9 (17 ref.)

Ifosfamide in the treatment of breast cancer. Overmoyer BA. **Semin Oncol** 1996 Jun;23(3 Suppl 6):38–41 (24 ref.)

Taxoids: effective agents in anthracycline-resistant breast cancer. Ravdin PM. **Semin Oncol** 1995 Dec;22(6 Suppl 13):29–34 (34 ref.)

Chemotherapy for advanced breast cancer: a current perspective. Seidman AD. **Semin Oncol** 1996 Feb;23(1 Suppl 2):55–9 (44 ref.)

Memorial Sloan-Kettering Cancer Center experience with paclitaxel in the treatment of breast cancer. Seidman AD, et al. **Semin Oncol** 1995 Oct;22(5 Suppl 12):108–16 (53 ref.)

Adjuvant therapy for early stage breast cancer. Sledge GW Jr. **Semin Oncol** 1996 Feb;23(1 Suppl 2):51–4 (18 ref.)

Implications of the new biology for therapy in breast cancer. Sledge GW Jr. **Semin Oncol** 1996 Feb;23(1 Suppl 2):76–81 (49 ref.)

Role of paclitaxel in the treatment of breast cancer: the American Cooperative Group Experience. Sledge GW Jr. **Semin Oncol** 1996 Feb;23(1 Suppl 1):10–2 (9 ref.)

Paclitaxel couplets with cyclophosphamide or cisplatin in metastatic breast cancer. Tolcher AW. **Semin Oncol** 1996 Feb;23(1 Suppl 1):37–43 (22 ref.)

Adjuvant chemotherapy in the node-negative breast cancer patient. Styblo TM, et al. **Surg Clin North Am** 1996 Apr; 76(2):327–41 (26 ref.)

Contemporary adjuvant treatment of breast cancer. Akerley WL 3rd. **Surg Oncol Clin N Am** 1995 Oct;4(4):685–99 (31 ref.)

Breast conservation following induction chemotherapy for locally advanced carcinoma of the breast (stages IIB and III). A surgical perspective. Schwartz GF, et al. **Surg Oncol Clin N Am** 1995 Oct;4(4):657–69 (25 ref.)

Hormonal treatment of advanced breast cancer. Tellez C, et al. **Surg Oncol Clin N Am** 1995 Oct;4(4):751–77 (199 ref.)

High-dose chemotherapy for breast cancer: twenty years later. Whom should we treat? And when? Wright-Browne V, et al. **Tumori** 1996 May–Jun;82(3):187–92 (45 ref.)

[Paclitaxel, a new anticancer drug] Jekunen A, et al. **Duodecim** 1994;110(13):1235–40 (39 ref.) **(Fin)**

[Severe 5-fluorouracil toxicity in a woman treated for breast cancer with concurrent osteogenesis imperfecta and dehydrogenase deficiency] Beuzeboc P, et al. **Bull Cancer (Paris)** 1996 Apr;83(4):324–7 (24 ref.) (Eng. Abstr.) **(Fre)**

[Cancers of the breast. First line chemotherapy for cancers of the breast] Mauriac L. **Bull Cancer Radiother** 1995; 82(2):158–67 (82 ref.) **(Fre)**

[Expansive uterine myoma during tamoxifen therapy. 11 cases] Le Bouëdec G, et al. **Presse Med** 1995 Nov 25; 24(36):1694–6 (18 ref.) (Eng. Abstr.) **(Fre)**

[Surveillance of patients treated with tamoxifen] Sananes S, et al. **Presse Med** 1996 Mar 23;25(10):499–502 (25 ref.) (Eng. Abstr.) **(Fre)**

[Gynecologic monitoring of tamoxifen treatment of breast cancer] Le Bouedec G, et al. **Rev Fr Gynecol Obstet** 1995

Jul-Sep;90(7-9):379-82 (30 ref.) **(Fre)**

[High dose chemotherapy in treatment of breast carcinoma: current status and limits of this method of therapy] Derigs HG, et al. **Geburtshilfe Frauenheilkd** 1996 Apr;56(4):190-7 (40 ref.) (Eng. Abstr.) **(Ger)**

[New drugs in therapy of breast carcinoma] Grunewald R. **Geburtshilfe Frauenheilkd** 1996 Jun;56(6):M75-81 (65 ref.) **(Ger)**

[An overview of clinical trials in endocrine therapy for cancer] Hinotsu S, et al. **Gan To Kagaku Ryoho** 1996 May; 23(6):689-94 (9 ref.) (Eng. Abstr.) **(Jpn)**

[Chemo-endocrine therapy including mitomycin C and medroxyprogesterone acetate in doxorubicin-refractory advanced breast cancer] Nomura Y, et al. **Gan To Kagaku Ryoho** 1996 Mar;23(4):439-45 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Survival and changes of clinical laboratory data in phase II study with 5'-DFUR] Taguchi T. **Gan To Kagaku Ryoho** 1996 Jul;23(8):1019-29 (31 ref.) (Eng. Abstr.) **(Jpn)**

[New developments in hormonal therapy for breast cancer] Tominaga T. **Gan To Kagaku Ryoho** 1996 May;23(6):678-83 (1 ref.) (Eng. Abstr.) **(Jpn)**

[High-dose therapy with cytostatic agents as primary treatment of advanced breast cancer] Matheson I. **Tidsskr Nor Laegeforen** 1996 Jun 20;116(16):1904-6 (18 ref.) (Eng. Abstr.) **(Nor)**

[Pituitary gonadotropin releasing hormone (GnRH) and breast cancer] Vargas Hernández VM, et al. **Ginecol Obstet Mex** 1995 Dec;63:493-6 (12 ref.) (Eng. Abstr.) **(Spa)**

[The use of high-dose chemotherapy in the treatment of breast cancer (comment)] Espinosa E, et al. **Med Clin (Barc)** 1996 Jun 8;107(2):56-8 (21 ref.) Comment on: Med Clin (Barc) 1995 May 13;104(18):702-8. **(Spa)**

ECONOMICS

Economic and cost-effectiveness issues in breast cancer treatment. Hillner BE. **Semin Oncol** 1996 Feb;23(1 Suppl 2):98-104 (21 ref.)

ENZYMOLOGY

Regulation and inhibition of steroid sulfatase activity in breast cancer. Purohit A, et al. **Ann N Y Acad Sci** 1996 Apr 30; 784:40-9 (28 ref.)

Cathepsin D and breast cancer [see comments] Westley BR, et al. **Eur J Cancer** 1996 Jan;32A(1):15-24 (78 ref.) Comment in: Eur J Cancer 1996 Jan;32A(1):7-8.

The control and biological importance of intratumoural aromatase in breast cancer. Dowsett M, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1-6 Spec No):145-50 (22 ref.)

EPIDEMIOLOGY

Body weight: estimation of risk for breast and endometrial cancers. Ballard-Barbash R, et al. **Am J Clin Nutr** 1996 Mar;63(3 Suppl):437S-41S (38 ref.)

Who is susceptible to cancers of the breast, colon, and prostate? Willett WC. **Ann N Y Acad Sci** 1995 Sep 30; 768:1-11 (45 ref.)

Breast cancer and environmental risk factors: epidemiological and experimental findings. Wolff MS, et al. **Annu Rev Pharmacol Toxicol** 1996;36:573-96 (116 ref.)

Epidemiology and prevention of breast cancer. Kelsey JL, et al. **Annu Rev Public Health** 1996;17:47-67 (65 ref.)

The practice of causal inference in cancer epidemiology. Weed DL, et al. **Cancer Epidemiol Biomarkers Prev** 1996 Apr;5(4):303-11 (175 ref.)

Epidemiology, prevention, and early detection of breast cancer. Helzlsouer KJ. **Curr Opin Oncol** 1995 Nov; 7(6):489-94 (42 ref.)

Diet, nutrition, and avoidable cancer. Willett WC. **Environ Health Perspect** 1995 Nov;103 Suppl 8:165-70 (58 ref.)

Principal cancers among women: breast, lung and colorectal. Rozenberg S, et al. **Int J Fertil Menopausal Stud** 1996 Mar-Apr;41(2):166-71 (33 ref.)

Postmenopausal estrogens and breast cancer. Colditz GA. **J Soc Gynecol Investig** 1996 Mar-Apr;3(2):50-6 (48 ref.)

Occupational risk factors for female breast cancer: a review. Goldberg MS, et al. **Occup Environ Med** 1996 Mar; 53(3):145-56 (194 ref.)

The "epidemic" of breast cancer in the U.S.--determining the factors. King SE, et al. **Oncology (Huntingt)** 1996 Apr; 10(4):453-62; discussion 462, 464, 470-2 (59 ref.)

Breast cancer in young women. Winchester DP. **Surg Clin North Am** 1996 Apr;76(2):279-87 (72 ref.)

[Breast cancer during pregnancy. Epidemiology--diagnosis--prognosis] Gorins A, et al. **Contracept Fertil Sex** 1996 Feb;24(2):153-6 (11 ref.) (Eng. Abstr.) **(Fre)**

[Obesity as a risk factor of breast cancer (prospective study)] Sakamoto G. **Nippon Rinsho** 1995 Jun;53 Suppl:286-9 (10 ref.) **(Jpn)**

ETHNOLOGY

Breast cancer in black women. Moormeier J. **Ann Intern Med** 1996 May 15;124(10):897-905 (98 ref.)

ETIOLOGY

Estrogen biosynthesis in adipose. Significance in breast cancer development. Simpson ER, et al. **Ann N Y Acad Sci** 1996 Apr 30;784:18-26 (60 ref.)

Who is susceptible to cancers of the breast, colon, and prostate? Willett WC. **Ann N Y Acad Sci** 1995 Sep 30; 768:1-11 (45 ref.)

Apoptosis and angiogenesis: two promising tumor markers in breast cancer (review). Wu J. **Anticancer Res** 1996 Jul-Aug;16(4B):2233-9 (80 ref.)

Breast cancer following treatment for Hodgkin's disease: the need for screening in a young population. Australasian Radiation Oncology Lymphoma Group (AROLG) [see comments] O'Brien PC, et al. **Australas Radiol** 1995 Aug; 39(3):271-6 (30 ref.) Comment in: Australas Radiol 1995 Aug;39(3):207.

Enhanced risks of cancer from protracted exposures to X- or gamma-rays: a radiobiological model of radiation-induced breast cancer [editorial] Elkind MM. **Br J Cancer** 1996 Jan;73(2):133-8 (54 ref.)

Role of cytokines and growth factors in promoting the local recurrence of breast cancer. Reid SE, et al. **Br J Surg** 1996 Mar;83(3):313-20 (97 ref.)

Hormones and breast cancer. Helzlsouer KJ, et al. **Cancer** 1995 Nov 15;76(10 Suppl):2059-63 (34 ref.)

Benefits versus risks from mammography: a critical reassessment [see comments] Mettler FA, et al. **Cancer** 1996 Mar 1;77(5):903-9 (49 ref.) Comment in: Cancer 1996 Mar 1;77(5):818-22.

Organochlorine compounds and estrogen-related cancers in women. Adami HO, et al. **Cancer Causes Control** 1995 Nov; 6(6):551-66 (105 ref.)

Phytoestrogens, body composition, and breast cancer. Horn-Ross PL. **Cancer Causes Control** 1995 Nov; 6(6):567-73 (59 ref.)

Models of breast cancer show that risk is set by events of early life: prevention efforts must shift focus. Colditz GA, et al. **Cancer Epidemiol Biomarkers Prev** 1995 Jul-Aug; 4(5):567-71 (46 ref.)

The melatonin hypothesis: electric power and breast cancer. Stevens RG, et al. **Environ Health Perspect** 1996 Mar;104 Suppl 1:135-40 (66 ref.)

Alcohol as a cause of cancer. Thomas DB. **Environ Health Perspect** 1995 Nov;103 Suppl 8:153-60 (65 ref.)

Selections from current literature: abortion, breast cancer and causal inferences. Rahman MI, et al. **Fam Pract** 1996 Apr; 13(2):194-200 (11 ref.)

Breast cancer risk among women using silicone gel breast implants. Edelman DA, et al. **Int J Fertil Menopausal Stud** 1995 Sep-Oct;40(5):274-80 (41 ref.)

Obesity and breast cancer. Stoll BA. **Int J Obes Relat Metab Disord** 1996 May;20(5):389-92 (43 ref.)

Breast cancer: cause and prevention [see comments] Hulka BS, et al. **Lancet** 1995 Sep 30;346(8979):883-7 (66 ref.) Comment in: Lancet 1995 Dec 23-30;346(8991-8992):1701-2. Comment in: Lancet 1995 Dec 23-30;346(8991-8992):1702-3.

Hormone therapy in the menopause and breast cancer risk--a review. Ewertz M. **Maturitas** 1996 Mar;23(2):241-6 (32 ref.)

Pre-eclampsia, autoimmune diseases and breast cancer etiology. Polednak AP. **Med Hypotheses** 1995 May; 44(5):414-8 (46 ref.)

The role of peroxidase-catalyzed activation of aromatic amines in breast cancer. Josephy PD. **Mutagenesis** 1996 Jan;11(1):3-7 (65 ref.)

The aetiology and pathogenesis of human breast cancer. Adami HO, et al. **Mutat Res** 1995 Dec;333(1-2):29-35 (45 ref.)

Hormones and cancer in humans. Key TJ. **Mutat Res** 1995 Dec;333(1-2):59-67 (85 ref.)

Risk assessment issues in breast cancer. Skegg DC. **Mutat Res** 1995 Dec;333(1-2):51-8 (43 ref.)

Disease heterogeneity: does it impact our ability to detect dietary associations with breast cancer? Slattery ML, et al. **Nutr Cancer** 1995;24(3):213-20 (72 ref.)

The relationship between stress and the development of breast cancer: a literature review. Bryla CM. **Oncol Nurs Forum** 1996 Apr;23(3):441-8 (50 ref.)

Environmental causes and molecular biology of breast cancer: future research directions. Jahnke GD, et al. **Prog Clin Biol Res** 1996;394:455-69 (103 ref.)

Hormonal and environmental factors affecting cell proliferation and neoplasia in the mammary gland. Snedeker SM, et al. **Prog Clin Biol Res** 1996;394:211-53 (315 ref.)

The etiology of breast cancer--from epidemiology to prevention. Kuller LH. **Public Health Rev** 1995; 23(2):157-213 (228 ref.)

Preneoplastic transformation of human mammary epithelial cells. Band V. **Semin Cancer Biol** 1995 Jun;6(3):185-92 (50 ref.)

GENETICS

Genetic predisposition to breast cancer. Olsson H, et al. **Acta Oncol** 1996;35(1):1-8 (22 ref.)

Expression and regulation of cyclin genes in breast cancer. Sutherland RL, et al. **Acta Oncol** 1995;34(5):651-6 (25 ref.)

Pathways of chromosome alteration in human epithelial cancers. Dutrillaux B. **Adv Cancer Res** 1995;67:59-82 (80 ref.)

Breast cancer cytogenetics: a review and proposal for clinical application. Cervantes M, et al. **Ann Clin Lab Sci** 1996 May-Jun;26(3):208-14 (26 ref.)

BRCA1, a gene involved in inherited predisposition to breast and ovarian cancer. Feunteun J, et al. **Biochim Biophys Acta** 1996 Mar 18;1242(3):177-80 (42 ref.)

Estrogen regulated messenger RNAs in human breast cancer cells. May FE, et al. **Biomed Pharmacother** 1995; 49(9):400-14 (85 ref.)

The genetics of breast and ovarian cancer. Ford D, et al. **Br J Cancer** 1995 Oct;72(4):805-12 (69 ref.)

Genetic counselling and testing for susceptibility to breast, ovarian and colon cancer: where are we today? Cole DE, et al. **Can Med Assoc J** 1996 Jan 15;154(2):149-55 (56 ref.)

Trisomy 8 and 20 in desmoid tumors and breast cancer: more than a casual coincidence? [letter; comment] Rohen G, et al. **Cancer Genet Cytogenet** 1996 Jan;86(1):92 (9 ref.) Comment on: Cancer Genet Cytogenet 1995 Feb;79(2):139-43.

Molecular genetics of sporadic and familial breast cancer. Jones KA, et al. **Cancer Surv** 1995;25:315-34 (135 ref.)

Oestrogen- and anti-oestrogen-regulated genes in human breast cancer. Rochefort H. **Ciba Found Symp** 1995; 191:254-65; discussion 265-8 (40 ref.)

Hereditary breast and ovarian cancer: epidemiology, genetics, screening and predictive testing. Foulkes WD, et al. **Clin Invest Med** 1995 Dec;18(6):473-83 (52 ref.)

Molecular cytogenetics of human breast cancer. Gray JW, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:645-52 (54 ref.)

Recent advances in breast cancer biology. Hoskins K, et al. **Curr Opin Oncol** 1995 Nov;7(6):495-500 (48 ref.)

Genetic alterations in familial and sporadic breast cancers. Emi M, et al. **Gan To Kagaku Ryoho** 1996 Mar;23 Suppl 1:80-3 (10 ref.)

Molecular analysis of the estrogen receptor (ER) gene in association with ER negativity in breast cancer. Iwase H, et al. **Gan To Kagaku Ryoho** 1996 Mar;23 Suppl 1:61-5 (13 ref.)

Genetic alterations in breast cancer. Bièche I, et al. **Genes Chromosomes Cancer** 1995 Dec;14(4):227-51 (190 ref.)

Genetic counseling for familial cancer risk. Weitzel JN. **Hosp Pract (Off Ed)** 1996 Feb 15;31(2):57-69 (17 ref.)

Inherited breast and ovarian cancer. Szabo CI, et al. **Hum Mol Genet** 1995;4 Spec No:1811-7 (64 ref.)

Molecular genetics of familial breast-ovarian cancer. van Rensburg EJ, et al. **J Clin Pathol** 1995 Sep;48(9):789-95 (64 ref.)

Translational research on hereditary colon, breast, and ovarian cancers. Li FP. **J Natl Cancer Inst Monogr** 1995; (17):1-4 (26 ref.)

Bilateral prophylactic mastectomy: issues and concerns. Stefanek ME. **J Natl Cancer Inst Monogr** 1995;(17):37-42 (31 ref.)

Alternative splicing of the estrogen receptor primary transcript normally occurs in estrogen receptor positive tissues and cell lines. Pfeffer U, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1-6 Spec No):99-105 (37 ref.)

The impact of genetic developments on breast cancer. Favors AC Jr. **Proc Annu Meet Med Sect Am Counc Life Insur** 1995;:49-59 (43 ref.)

Molecular genetics of human breast cancer. McKenzie K, et al. **Prog Clin Biol Res** 1996;394:183-209 (192 ref.)

Molecular biology of breast cancer: integration of cellular and molecular concepts into therapeutic strategies. Konstadoulakis MM, et al. **R I Med** 1995 Sep;78(9):257-60 (67 ref.)

Familial breast cancer. Weber BL. **Recent Results Cancer Res** 1996;140:5-16 (33 ref.)

Tumor suppressor genes and their alterations in breast cancer. Lee EY. **Semin Cancer Biol** 1995 Jun;6(3):119-25 (46 ref.)

Mutations of the BRCA1 gene in human cancer. Xu CF, et al. **Semin Cancer Biol** 1996 Feb;7(1):33-40 (63 ref.)

THe genetics of familial breast cancer. Cannon-Albright LA, et al. **Semin Oncol** 1996 Feb;23(1 Suppl 2):1-5 (44 ref.)

Inherited breast cancer. Radford DM, et al. **Surg Clin North Am** 1996 Apr;76(2):205-20 (99 ref.)

[Transcription factors of the PEA3 group in mammary cancer] Monté D, et al. **Ann Endocrinol (Paris)** 1995; 56(5):547-51 (8 ref.) (Eng. Abstr.) **(Fre)**

[Biology of solid cancers: breast cancer as an example. First part: genetic systems implicated in carcinogenesis] Bièche I, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996; 25(2):131-41 (37 ref.) (Eng. Abstr.) **(Fre)**

[Biology of solid cancers: breast cancer as an example. Second part: gene disregulation in breast cancer] Bièche I, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996; 25(2):142-52 (65 ref.) (Eng. Abstr.) **(Fre)**

[Hereditary breast cancers] Perey L, et al. **Schweiz Rundsch Med Prax** 1996 Aug 27;85(35):1035-9 (36 ref.) (Eng. Abstr.) **(Fre)**

[Genetic predisposition for breast carcinoma: overview of molecular genetic principles from long familiar epidemiologic observation] Krainer M, et al. **Geburtshilfe Frauenheilkd** 1995 Jul;55(7):M73-6 (10 ref.) **(Ger)**

[Familial colorectal and breast carcinoma--genetic

counseling and presymptomatic diagnosis] Müller H, et al. **Ther Umsch** 1995 Dec;52(12):826–34 (55 ref.) (Eng. Abstr.) **(Ger)**

[Familial cancer and oncogenic factors] Ohmori M, et al. **Gan To Kagaku Ryoho** 1996 Mar;23(4):395–400 (31 ref.) (Eng. Abstr.) **(Jpn)**

[Genetic alterations and DNA-based diagnosis in breast cancer] Matsumoto S, et al. **Nippon Geka Gakkai Zasshi** 1996 May;97(5):375–80 (30 ref.) (Eng. Abstr.) **(Jpn)**

[Molecular mechanisms of breast cancer progression] Tsuda H. **Nippon Geka Gakkai Zasshi** 1996 May;97(5):381–6 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Familial breast cancer] Fukutomi T, et al. **Nippon Rinsho** 1995 Nov;53(11):2764–8 (26 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Human breast cancer cell line xenografts as models of breast cancer. The immunobiologies of recipient mice and the characteristics of several tumorigenic cell lines. Clarke R. **Breast Cancer Res Treat** 1996;39(1):69–86 (147 ref.)

Regarding breast cancer as an immunologically responsive tumor. Mitchell MS. **Proc Assoc Am Physicians** 1995 Oct; 107(3):279–87 (62 ref.)

Serum (circulating) tumor markers for breast cancer. Hayes DF. **Recent Results Cancer Res** 1996;140:101–13 (52 ref.)

[Biological malignant potential and carbohydrate antigens in breast cancer] Narita T, et al. **Nippon Geka Gakkai Zasshi** 1996 Feb;97(2):172–6 (10 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Estrogen content and metabolism in human breast tumor tissues and cells. Castagnetta LA, et al. **Ann N Y Acad Sci** 1996 Apr 30;784:314–24 (47 ref.)

Insulin-like growth factors and breast cancer. Lee AV, et al. **Biomed Pharmacother** 1995;49(9):415–21 (74 ref.)

Can systematic research of hormone and growth factor receptors contribute to the recognition of acute and chronic types of breast cancer, of their specific mammary dysplasias, and of specific treatments? [editorial] Mathé G. **Biomed Pharmacother** 1995;49(9):385–8 (28 ref.)

Growth factors and their receptors in neoplastic mammary glands. Rudland PS, et al. **Biomed Pharmacother** 1995; 49(9):389–99 (95 ref.)

Do heat shock proteins have a role in breast cancer? Conroy SE, et al. **Br J Cancer** 1996 Sep;74(5):717–21 (50 ref.)

Molecular aspects of estrogen receptor variants in breast cancer. Fuqua SA, et al. **Breast Cancer Res Treat** 1995 Sep;35(3):233–41 (19 ref.)

The modulation of thrombospondin and other naturally occurring inhibitors of angiogenesis during tumor progression. Volpert OV, et al. **Breast Cancer Res Treat** 1995;36(2):119–26 (56 ref.)

Biological functions of cell adhesion molecules in breast cancer. Narita T, et al. **Gan To Kagaku Ryoho** 1996 Mar; 23 Suppl 1:56–60 (9 ref.)

Value of cancer-related oncoprotein expression as prognostic factors in breast-cancer with one to three axillary lymph nodes positive. Zhang G, et al. **Gan To Kagaku Ryoho** 1996 Mar;23 Suppl 1:66–74 (22 ref.)

Progesterone receptor A and B protein expression in human breast cancer. Graham JD, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1–6 Spec No):93–8 (33 ref.)

Dual regulation of the epidermal growth factor family of growth factors in breast cancer by sex steroids and protein kinase C. Martinez-Lacaci I, et al. **J Steroid Biochem Mol Biol** 1996 Jan;57(1–2):1–11 (145 ref.)

Retinoid receptors in human lung cancer and breast cancer. Zhang XK, et al. **Mutat Res** 1996 Feb 19;350(1):267–77 (87 ref.)

[Estrogens and breast cancer: from action mechanisms to clinical applications] Garcia M, et al. **Ann Endocrinol (Paris)** 1995;56(5):543–5 (10 ref.) (Eng. Abstr.) **(Fre)**

[Progesterone receptor in breast cancer: fundamental data and clinical applications] Ojasoo T. **Bull Cancer (Paris)** 1996;83 Suppl 1:1–5 (53 ref.) **(Fre)**

MORTALITY

The tumor burden of locally recurrent breast cancer is a neglected prognostic factor. Evans RA. **Am J Surg** 1996 Apr;171(4):445–8 (47 ref.)

The GIVIO trial on the impact of follow-up care on survival and quality of life in breast cancer patients. Interdisciplinary Group for Cancer Care Evaluation. Liberati A. **Ann Oncol** 1995;6 Suppl 2:41–6 (12 ref.)

PATHOLOGY

Adrenal androgen action in breast cancer. Boccuzzi G, et al. **Ann N Y Acad Sci** 1996 Apr 30;784:349–61 (55 ref.)

Sex steroid binding protein is a negative modulator of estrogen-induced breast cancer cell growth. Fraïria R, et al. **Ann N Y Acad Sci** 1996 Apr 30;784:362–9 (18 ref.)

Tubular carcinoma of the breast. Predicting axillary nodal metastases and recurrence. Winchester DJ, et al. **Ann Surg** 1996 Mar;223(3):342–7 (20 ref.)

Carcinosarcoma arising in eccrine spiradenoma of the breast. Report of a case and review of the literature. Saboorian MH, et al. **Arch Pathol Lab Med** 1996 May;120(5):501–4 (19 ref.)

Molecular and pharmacologic targeting of angiogenesis factors—the example of pleiotrophin. Czubayko F, et al. **Breast Cancer Res Treat** 1995;36(2):157–68 (68 ref.)

When can stereotactic core biopsy replace excisional biopsy?—A clinical perspective. Morrow M. **Breast Cancer Res Treat** 1995;36(1):1–9 (54 ref.)

Bilateral primary breast lymphoma in pregnancy: a case report and literature review. Kirkpatrick AW, et al. **Can J Surg** 1996 Aug;39(4):333–5 (26 ref.)

Retroareolar leiomyoma [letter] Way JC. **Can J Surg** 1996 Aug;39(4):339 (7 ref.)

Axillary lymph nodes and breast cancer: a review. Recht A, et al. **Cancer** 1995 Nov 1;76(9):1491–512 (229 ref.)

Bone scintigraphy screening in stage I–II breast cancer: is it cost-effective? Wikenheiser KA, et al. **Cleve Clin J Med** 1996 Jan–Feb;63(1):43–7 (26 ref.)

The pathology of ductal carcinoma in situ of the breast. Bobrow LG, et al. **Clin Oncol (R Coll Radiol)** 1995; 7(4):232–5 (40 ref.)

The biology of growth regulation in normal and malignant breast epithelium: from bench to clinic. Nguyen B, et al. **Crit Rev Oncol Hematol** 1995 Oct;20(3):223–36 (170 ref.)

Recent advances in breast cancer biology. Hoskins K, et al. **Curr Opin Oncol** 1995 Nov;7(6):495–500 (48 ref.)

Metastatic breast cancer. Rubens RD. **Curr Opin Oncol** 1995 Nov;7(6):523–6 (32 ref.)

Pathology of preinvasive and excellent-prognosis breast cancer. Simpson JF, et al. **Curr Opin Oncol** 1995 Nov; 7(6):501–5 (34 ref.)

Ductal carcinoma in situ of the breast: progress and controversy. Swallow CJ, et al. **Curr Probl Surg** 1996 Jul; 33(7):553–600 (171 ref.)

Metaplastic breast carcinoma: a cytohistologic and clinical study of 10 cases. Johnson TL, et al. **Diagn Cytopathol** 1996 May;14(3):226–32 (15 ref.)

Mammary tumor fibroblasts are phenotypically distinct from non-tumor fibroblasts. Hornby AE, et al. **EXS** 1995; 74:249–71 (147 ref.)

The prognostic significance of axillary node metastasis in breast cancer. Miura S. **Gan To Kagaku Ryoho** 1996 Mar; 23 Suppl 1:36–42 (4 ref.)

Detection of breast cancer micrometastases in lymph nodes by amplification of keratin 19 mRNA with reverse-transcriptase polymerase chain reaction. Noguchi S, et al. **Gan To Kagaku Ryoho** 1996 Mar;23 Suppl 1:50–5 (9 ref.)

Hepar lobatum carcinomatosum due to chemotherapy of a metastatic breast carcinoma. Uhlmann F, et al. **Gen Diagn Pathol** 1996 Mar;141(3–4):279–84 (21 ref.)

Mitogenic signal transduction in human breast cancer cells. Strobl JS, et al. **Gen Pharmacol** 1995 Dec;26(8):1643–9 (39 ref.)

Breast carcinoma metastatic to paranasal sinuses. Austin JR, et al. **Head Neck** 1995 Mar–Apr;17(2):161–5 (20 ref.)

Phyllodes tumours of the breast: a clinicopathological review of thirty-two cases. Moffat CJ, et al. **Histopathology** 1995 Sep;27(3):205–18 (38 ref.)

Metastatic breast cancer to the bladder: a case report. Schneidau T, et al. **Int Urol Nephrol** 1995;27(3):297–300 (11 ref.)

Local control following breast-conserving surgery for invasive cancer: results of clinical trials. Morrow M, et al. **J Natl Cancer Inst** 1995 Nov 15;87(22):1669–73 (35 ref.)

The role of the estrogen receptor in tumor progression. Lemieux P, et al. **J Steroid Biochem Mol Biol** 1996 Jan; 56(1–6 Spec No):87–91 (21 ref.)

Technologic considerations for breast tumor size assessment. Davis PL, et al. **Magn Reson Imaging Clin N Am** 1994 Nov;2(4):623–31 (42 ref.)

Staging of breast cancer with MR imaging. Harms SE, et al. **Magn Reson Imaging Clin N Am** 1994 Nov;2(4):573–84 (41 ref.)

Coexistence of nipple duct adenoma and breast carcinoma: a clinicopathologic study of five cases and review of the literature. Jones MW, et al. **Mod Pathol** 1995 Aug; 8(6):633–6 (13 ref.)

Papillomas of the breast. A histologic spectrum including atypical hyperplasia and carcinoma in situ. McKinney CD, et al. **Pathol Annu** 1995;30 Pt 2:137–78 (47 ref.)

Pleomorphic adenoma of the breast: case report and review of the literature. Narita T, et al. **Pathol Int** 1995 Jun; 45(6):441–7 (40 ref.)

Cellular changes involved in conversion of normal to malignant breast: importance of the stromal reaction. Rønnov-Jessen L, et al. **Physiol Rev** 1996 Jan;76(1):69–125 (630 ref.)

Pathology of benign and malignant breast disorders. Sewell CW. **Radiol Clin North Am** 1995 Nov;33(6):1067–80 (16 ref.)

Programmed cell death in human breast cancer cells. McCloskey DE, et al. **Recent Prog Horm Res** 1996; 51:493–508 (60 ref.)

How to predict the risk of local relapse in the preserved breast. Kurtz JM. **Recent Results Cancer Res** 1996; 140:263–72 (26 ref.)

Surgical treatment of breast cancer relapse. Margolese RG. **Recent Results Cancer Res** 1996;140:159–67 (23 ref.)

Preneoplastic transformation of human mammary epithelial cells. Band V. **Semin Cancer Biol** 1995 Jun;6(3):185–92 (50 ref.)

Involvement of extracellular matrix constituents in breast cancer. Lochter A, et al. **Semin Cancer Biol** 1995 Jun; 6(3):165–73 (106 ref.)

The development of a functionally relevant cell culture model of progressive human breast cancer. Weaver VM, et al. **Semin Cancer Biol** 1995 Jun;6(3):175–84 (56 ref.)

Duct carcinoma in situ: biological implications for clinical practice. Lagios MD. **Semin Oncol** 1996 Feb;23(1 Suppl 2):6–11 (31 ref.)

Schwannoma of the breast. Gultekin SH, et al. **South Med J** 1996 Feb;89(2):238–9 (18 ref.)

Tumoral fibrosis and lack of circumscription in granular cell tumor of the breast. Kragel PJ, et al. **South Med J** 1995 Nov;88(11):1146–8 (26 ref.)

Primary squamous cell carcinoma of the breast. Weigel RJ, et al. **South Med J** 1996 May;89(5):511–5 (33 ref.)

Prediction of recurrence for advanced breast cancer. Traditional and contemporary pathologic and molecular markers. Masood S. **Surg Oncol Clin N Am** 1995 Oct; 4(4):601–32 (213 ref.)

Pathology of advanced primary breast carcinoma. Tavassoli FA. **Surg Oncol Clin N Am** 1995 Oct;4(4):591–600 (49 ref.)

Arguments against routine contralateral mastectomy or undirected biopsy for invasive lobular breast cancer. Lee JS, et al. **Surgery** 1995 Oct;118(4):640–7; discussion 647–8 (22 ref.)

Submandibular gland metastasis of breast carcinoma: a case report and review of the literature. Vessecchia G, et al. **Virchows Arch** 1995;427(3):349–51 (25 ref.)

[Lymphocytic mastopathy. A case report and review of the literature] Pellerin P, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(7):683–5 (10 ref.) (Eng. Abstr.) **(Fre)**

[Imaging of osteosclerotic metastases] Feydy A, et al. **J Radiol** 1995 Sep;76(9):561–72 (61 ref.) (Eng. Abstr.) **(Fre)**

[Diseases of the breast] Bässler R. **Pathologe** 1996 Jan; 17(1):92–106 (23 ref.) **(Ger)**

[Diagnosis and biopsy of nonpalpable breast lesions] Hänggi W, et al. **Schweiz Med Wochenschr** 1996 Jan 20;126(3):61–8 (37 ref.) (Eng. Abstr.) **(Ger)**

[Axillary lymph node dissection in breast cancer—is it always necessary?] Merin O, et al. **Harefuah** 1996 Feb 15; 130(4):260–2 (17 ref.) **(Heb)**

[Tumor and tumor-like benign mesenchymal lesions of the breast] Bisceglia M, et al. **Pathologica** 1995 Feb;87(1):20–41 (149 ref.) (Eng. Abstr.) **(Ita)**

[Tarsal metastases from breast carcinoma: a case report and review of the literature] Sandomenico F, et al. **Radiol Med (Torino)** 1996 Mar;91(3):306–8 (16 ref.) **(Ita)**

[Ultrasonographic diagnosis of breast cancer with intraductal spreading of cancer cells] Kamio T, et al. **Nippon Geka Gakkai Zasshi** 1996 May;97(5):338–42 (5 ref.) (Eng. Abstr.) **(Jpn)**

[Molecular mechanisms of breast cancer progression] Tsuda H. **Nippon Geka Gakkai Zasshi** 1996 May;97(5):381–6 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Kinetics of the growth of breast tumors and its role in early detection] Moiceenko VM, et al. **Vopr Onkol** 1996; 42(1):15–22 (64 ref.) **(Rus)**

PHYSIOPATHOLOGY

Novel mechanisms of antiprogestin action. Horwitz KB, et al. **Acta Oncol** 1996;35(2):129–40 (61 ref.)

Adrenal androgen action in breast cancer. Boccuzzi G, et al. **Ann N Y Acad Sci** 1996 Apr 30;784:349–61 (55 ref.)

The role of estrogen in mammary carcinogenesis. Fishman J, et al. **Ann N Y Acad Sci** 1995 Sep 30;768:91–100 (31 ref.)

Postmenopausal estrogen replacement therapy in the patient with breast carcinoma. Cyr MG. **R I Med** 1995 Sep; 78(9):261–3 (23 ref.)

Current and future roles of adjuvant endocrine therapy in the management of early carcinoma of the breast. Baum M, et al. **Recent Results Cancer Res** 1996;140:215–26 (30 ref.)

Prognostic variables and future predictors of behaviour and response. Gusterson BA. **Recent Results Cancer Res** 1996; 140:89–100 (60 ref.)

Menstrual cycle timing of breast cancer resection. Hrushesky WJ. **Recent Results Cancer Res** 1996;140:27–40 (38 ref.)

PREVENTION & CONTROL

Breast cancer screening in premenopausal women: current recommendations and opportunities for research. Mettlin C, et al. **Ann Med** 1995 Aug;27(4):461–5 (15 ref.)

Indole-3-carbinol. A novel approach to breast cancer prevention. Bradlow HL, et al. **Ann N Y Acad Sci** 1995 Sep 30;768:180–200 (22 ref.)

Retinoids in cancer chemoprevention. Clinical trials with the synthetic analogue fenretinide. Costa A, et al. **Ann N Y Acad Sci** 1995 Sep 30;768:148–62 (49 ref.)

An overview of considerations for the testing of tamoxifen as a preventive for breast cancer. Jordan VC. **Ann N Y Acad Sci** 1995 Sep 30;768:141–7 (47 ref.)

Psychosocial and ethical implications of defining genetic risk for cancers. Kash KM. **Ann N Y Acad Sci** 1995 Sep 30; 768:41–52 (26 ref.)

Epidemiology and prevention of breast cancer. Kelsey JL, et al. **Annu Rev Public Health** 1996;17:47–67 (65 ref.)

Genetic counselling and testing for susceptibility to breast,

ovarian and colon cancer: where are we today? Cole DE, et al. **Can Med Assoc J** 1996 Jan 15;154(2):149–55 (56 ref.)

Models of breast cancer show that risk is set by events of early life: prevention efforts must shift focus. Colditz GA, et al. **Cancer Epidemiol Biomarkers Prev** 1995 Jul–Aug; 4(5):567–71 (46 ref.)

The endocrine prevention of breast cancer. Spicer DV, et al. **Cancer Invest** 1995;13(5):495–504 (72 ref.)

Physical activity: breast and reproductive cancer. Francis K. **Compr Ther** 1996 Feb;22(2):94–9 (49 ref.)

Epidemiology, prevention, and early detection of breast cancer. Helzlsouer KJ. **Curr Opin Oncol** 1995 Nov; 7(6):489–94 (42 ref.)

Hormones and breast and endometrial cancers: preventive strategies and future research. Hulka BS, et al. **Environ Health Perspect** 1995 Nov;103 Suppl 8:185–9 (49 ref.)

Is breast cancer avoidable? Could dietary changes help? Walker AR, et al. **Int J Food Sci Nutr** 1995 Nov; 46(4):373–81 (78 ref.)

A phase II chemoprevention trial design to identify surrogate endpoint biomarkers in breast cancer. Dhingra K. **J Cell Biochem Suppl** 1995;23:19–24 (27 ref.)

Alternate antiestrogens and approaches to the prevention of breast cancer. Jordan VC. **J Cell Biochem Suppl** 1995; 22:51–7 (51 ref.)

Tamoxifen's role in chemoprevention of breast cancer: an update. Nayfield SG. **J Cell Biochem Suppl** 1995;22:42–50 (63 ref.)

Hormonally induced differentiation: a novel approach to breast cancer prevention. Russo J, et al. **J Cell Biochem Suppl** 1995;22:58–64 (40 ref.)

Bilateral prophylactic mastectomy: issues and concerns. Stefanek ME. **J Natl Cancer Inst Monogr** 1995;(17):37–42 (31 ref.)

Breast cancer: cause and prevention [see comments] Hulka BS, et al. **Lancet** 1995 Sep 30;346(8979):883–7 (66 ref.) Comment in: Lancet 1995 Dec 23–30;346(8991–8992):1701–2. Comment in: Lancet 1995 Dec 23–30;346(8991–8992):1702–3.

Screening mammography in young women: a different perspective. Margolese R. **Lancet** 1996 Mar 30; 347(9005):881–2 (12 ref.)

Breast cancer screening and compliance and evaluation of lesions. Schapira DV, et al. **Med Clin North Am** 1996 Jan; 80(1):15–26 (42 ref.)

Breast cancer chemoprevention: clinical trials and research. Noguchi M, et al. **Oncology** 1996 May–Jun;53(3):175–81 (111 ref.)

Applying cognitive-social theory to health-protective behavior: breast self-examination in cancer screening. Miller SM, et al. **Psychol Bull** 1996 Jan;119(1):70–94 (263 ref.)

The etiology of breast cancer—from epidemiology to prevention. Kuller LH. **Public Health Rev** 1995; 23(2):157–213 (228 ref.)

Retrospective reviews of breast cancer screening: what do we really learn from them? [editorial; comment] Moskowitz M. **Radiology** 1996 Jun;199(3):615–20 (37 ref.) Comment on: Radiology 1996 Jun;199(3):811–7.

The women's health initiative: will it resolve the issues? Michels KB, et al. **Recent Results Cancer Res** 1996; 140:295–305 (53 ref.)

Design and current status of the NSABP breast cancer prevention trial. Redmond CK, et al. **Recent Results Cancer Res** 1996;140:309–17 (4 ref.)

The current role of prophylactic mastectomy. Lopez MJ, et al. **Surg Clin North Am** 1996 Apr;76(2):231–42 (51 ref.)

Tamoxifen—breast cancer preventive or human carcinogen? Clute E. **Toxicol Ind Health** 1995 Sep–Oct;11(5):503–10 (12 ref.)

Chemoprevention of breast cancer by tamoxifen: risks and opportunities. Smith LL, et al. **Toxicol Lett** 1995 Dec; 82–83:181–6 (18 ref.)

[Is breast cancer prevention by tamoxifen possible?] Namer M, et al. **Bull Cancer (Paris)** 1995 Jul;82 Suppl 3:155s–167s (65 ref.) (Eng. Abstr.) **(Fre)**

[Medical adverse effects of chemoprevention: the example of tamoxifen] Sasco AJ, et al. **Bull Cancer (Paris)** 1995 Jul; 82 Suppl 3:186s–206s (116 ref.) (Eng. Abstr.) **(Fre)**

[Role of the general practitioner in screening for and diagnosis of breast cancer] van der Kaa F, et al. **Rev Med Liege** 1995 Nov;50(11):458–68 (23 ref.) **(Fre)**

-Results of ongoing breast cancer prevention studies- Jungi WF. **Arch Gynecol Obstet** 1995;256 Suppl:S116–21 (18 ref.) **(Ger)**

-Tamoxifen and the endometrium: monitoring and evaluation of endometrial changes- Rageth JC, et al. **Arch Gynecol Obstet** 1995;256 Suppl:S122–7 (24 ref.) **(Ger)**

[Mass screening of breast cancer] Dobashi K, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Aug; 47(8):885–93 (22 ref.) **(Jpn)**

PSYCHOLOGY

Assessment of quality of life in breast cancer. Fallowfield LJ. **Acta Oncol** 1995;34(5):689–94 (41 ref.)

Measurement and practical aspects of quality of life in breast cancer. Hietanen PS. **Acta Oncol** 1996;35(1):39–42 (40 ref.)

Psychosocial issues in breast cancer. Stefanek ME. **Curr Opin Oncol** 1995 Nov;7(6):527–30 (13 ref.)

Beauty and the beast—a medical essay. Lawrence G. **Indian J Cancer** 1995 Dec;32(4):189–99 (27 ref.)

Psychosocial issues in breast cancer. Helping patients get the support they need. Williams TR, et al. **Postgrad Med** 1995 Oct;98(4):97–9, 103–4, 107–8 passim (2 ref.)

Are life events related to the onset of breast cancer [editorial] McGee R, et al. **Psychol Med** 1996 May;26(3):441–7 (35 ref.)

Mechanisms related to psychological well-being in older women with chronic illnesses: age and disease comparisons. Heidrich SM. **Res Nurs Health** 1996 Jun;19(3):225–35 (47 ref.)

Women's psychological reactions to breast cancer. Payne DK, et al. **Semin Oncol** 1996 Feb;23(1 Suppl 2):89–97 (27 ref.)

RADIOGRAPHY

Radiologic procedures for the diagnosis of distant recurrences of breast cancer. Musumeci R. **Ann Oncol** 1995; 6 Suppl 2:27–9 (15 ref.)

Mammographic screening of women aged 40–49 years. Benefit, risk, and cost considerations. Feig SA. **Cancer** 1995 Nov 15;76(10 Suppl):2097–106 (54 ref.)

Mammographic diagnosis of breast cancer. Endo T. **Gan To Kagaku Ryoho** 1996 Mar;23 Suppl 1:8–13 (10 ref.)

Screening and diagnostic breast imaging procedures. A look at lesions through a radiologist's eyes. Schilling K, et al. **Postgrad Med** 1995 Oct;98(4):44–6, 51, 56 passim (7 ref.)

Evaluation of the breast undergoing lumpectomy and radiation therapy. Dershaw DD. **Radiol Clin North Am** 1995 Nov;33(6):1147–60 (50 ref.)

[Primary malignant tumor of the breast. Monitoring after treatment (editorial)] Guastalla JP, et al. **Presse Med** 1995 Oct 21;24(31):1415–7 (22 ref.) (Eng. Abstr.) **(Fre)**

[Morphometric analysis of mammographic images in clinical oncology] Campisi C, et al. **Clin Ter** 1995 Nov; 146(11):683–90 (46 ref.) (Eng. Abstr.) **(Ita)**

[Recent improvement of mammographic diagnosis] Endo T. **Nippon Geka Gakkai Zasshi** 1996 May;97(5):333–7 (15 ref.) (Eng. Abstr.) **(Jpn)**

RADIONUCLIDE IMAGING

[Nuclear medical breast diagnosis--scintigraphy using 99mTc-sestamibi (editorial)] Hahn K. **Nuklearmedizin** 1996 Jun;35(3):4–6 (28 ref.) **(Ger)**

RADIOTHERAPY

Breast-conserving surgery without radiotherapy. Holmberg L. **Acta Oncol** 1995;34(5):681–3 (17 ref.)

The role of radiotherapy in breast conserving treatment. Landberg T. **Acta Oncol** 1995;34(5):675–80 (20 ref.)

Low-grade dermal angiosarcoma of the breast following radiotherapy. Bolin DJ, et al. **Am Surg** 1996 Aug; 62(8):668–72 (19 ref.)

Brachytherapy in the management of breast cancer: a review. Pieters BR, et al. **Cancer Treat Rev** 1996 Nov;21(6):527–39 (62 ref.)

Radiation therapy for breast cancer. McCormick B. **Curr Opin Oncol** 1995 Nov;7(6):511–6 (29 ref.)

Radiation-induced sarcoma of the breast. Mason RW, et al. **J Am Osteopath Assoc** 1996 Jun;96(6):368–70 (15 ref.)

MR imaging of the breast in the follow-up evaluation of conservative nonoperatively treated breast cancer. Dao TH, et al. **Magn Reson Imaging Clin N Am** 1994 Nov; 2(4):605–22 (46 ref.)

Dose to contralateral breast—a comparative study. Brooks PS. **Med Dosim** 1995 Winter;20(4):301–7 (7 ref.)

Evaluation of the breast undergoing lumpectomy and radiation therapy. Dershaw DD. **Radiol Clin North Am** 1995 Nov;33(6):1147–60 (50 ref.)

Sequencing of chemotherapy and radiation therapy in the treatment of early breast cancer: the devil is in the details [editorial; comment] Ellerbroek NA. **Radiology** 1996 Sep; 200(3):605–7 (24 ref.) Comment on: Radiology 1996 Sep;200(3):615–9.

Three cases of breast angiosarcomas after breast-conserving treatment for carcinoma [letter] Weber B, et al. **Radiother Oncol** 1995 Dec;37(3):250–2 (21 ref.)

Radiation therapy in the primary management of early-stage breast cancer. Rutqvist LE. **Recent Results Cancer Res** 1996;140:241–50 (18 ref.)

Quality assurance in early breast cancer treatment: clinical aspects of postoperative, external, whole breast irradiation. Valdagni R, et al. **Recent Results Cancer Res** 1996; 140:251–61 (64 ref.)

Selection of patients with early stage invasive breast cancer for treatment with conservative surgery and radiation therapy. Recht A. **Semin Oncol** 1996 Feb;23(1 Suppl 2):19–30 (129 ref.)

[Cancers of the breast. Conservative treatment of locally advanced cancers of the breast by radiotherapy alone] Le Floch. **Bull Cancer Radiother** 1995;82(2):168–72 (21 ref.) **(Fre)**

[What is the role of radiotherapy in the treatment of breast cancer in 1995?] Van Houtte P, et al. **Rev Med Brux** 1995 Jul–Aug;16(4):237–41 (27 ref.) (Eng. Abstr.) **(Fre)**

[Pericarditis and other cardiac disorders, late consequences of radiotherapy] Chappuis MA, et al. **Rev Med Suisse Romande** 1996 Jun;116(6):429–39 (25 ref.) **(Fre)**

SECONDARY

Choriocarcinoma presenting as a breast lump. Fowler CA, et al. **Eur J Surg Oncol** 1995 Oct;21(5):576–8 (14 ref.)

Comorbidity risk parameters associated with advanced breast cancer and systemic disease. Management of nonbreast disease. Graves TA, et al. **Surg Oncol Clin N Am** 1995 Oct;4(4):633–56 (110 ref.)

The natural history of locally advanced primary breast carcinoma and metastatic disease. Yeatman TJ. **Surg Oncol Clin N Am** 1995 Oct;4(4):569–89 (33 ref.)

[A case of breast metastasis of esophageal squamous cell carcinoma] Meloni GB, et al. **Radiol Med (Torino)** 1996 Jun;91(6):812–4 (7 ref.) **(Ita)**

SURGERY

Breast-conserving surgery without radiotherapy. Holmberg L. **Acta Oncol** 1995;34(5):681–3 (17 ref.)

Role of surgery in invasive breast cancer. Holmberg L. **Acta Oncol** 1995;34(5):625–8 (15 ref.)

Breast reconstruction. van Smitten K. **Acta Oncol** 1995; 34(5):685–8 (21 ref.)

The impact of surgery on breast cancer. Mesiti M. **Ann N Y Acad Sci** 1996 Apr 30;784:412–8 (8 ref.)

The natural history of operable breast cancer after primary treatment. Cocconi G. **Ann Oncol** 1995;6 Suppl 2:11–21 (69 ref.)

Local recurrence after breast-conserving surgery for breast cancer. Macmillan RD, et al. **Br J Surg** 1996 Feb; 83(2):149–55 (52 ref.)

1994 Roussel Lecture: a biologic basis for changes in breast cancer management. Margolese RG. **Can J Surg** 1995 Oct; 38(5):402–8 (24 ref.)

Reconstruction after mastectomy. Osteen RT. **Cancer** 1995 Nov 15;76(10 Suppl):2070–4 (29 ref.)

Early invasive carcinoma of the breast. Frykberg ER, et al. **Curr Opin Gen Surg** 1993;:316–24 (43 ref.)

The diagnosis and treatment of breast cancer. Matory YL. **Curr Opin Gen Surg** 1994;:217–23 (40 ref.)

Surgery for early and minimally invasive breast cancer. Coburn MC, et al. **Curr Opin Oncol** 1995 Nov;7(6):506–10 (39 ref.)

Routine or delayed axillary dissection for primary breast cancer? Epstein RJ. **Eur J Cancer** 1995 Sep;31A(10):1570–3 (29 ref.)

Lumpectomy versus quadrantectomy for breast conservation: a critical appraisal [editorial; comment] Fisher B. **Eur J Cancer** 1995 Sep;31A(10):1567–9 (9 ref.) Comment on: Eur J Cancer 1995 Sep;31A(10):1574–9.

Prebiopsy neo-adjuvant endocrine therapy for breast cancer to prevent post-surgery trauma-induced growth factor and immune-suppression mediated tumour progression. Oliver RT, et al. **Eur J Cancer** 1996 Mar;32A(3):396–7 (20 ref.)

Present and future state of surgical management in breast cancer. van Dongen JA. **Eur J Surg** 1996 Feb;162(2):87–91 (30 ref.)

More detailed documentation of operative procedures in breast conserving treatment: what good will it do us? Christiaens MR, et al. **Eur J Surg Oncol** 1996 Aug; 22(4):326–30 (44 ref.)

Changes in significance of axillary lymph node dissection for patients with breast cancer. Ogawa Y, et al. **Gan To Kagaku Ryoho** 1996 Mar;23 Suppl 1:43–9 (24 ref.)

Indications of breast preserving surgery without radiation. Sano M, et al. **Gan To Kagaku Ryoho** 1996 Mar;23 Suppl 1:100–5 (9 ref.)

Breast cancer surgery: a century after Halsted. Veronesi U, et al. **J Cancer Res Clin Oncol** 1996;122(2):74–7 (20 ref.)

Local control following breast-conserving surgery for invasive cancer: results of clinical trials. Morrow M, et al. **J Natl Cancer Inst** 1995 Nov 15;87(22):1669–73 (35 ref.)

MR imaging of the breast after surgery for breast cancer. Whitehouse GH, et al. **Magn Reson Imaging Clin N Am** 1994 Nov;2(4):591–603 (59 ref.)

Local and regional therapy for primary breast tumors. Answers to major questions. Porterfield LA, et al. **Postgrad Med** 1995 Oct;98(4):65–8, 73, 77 passim (16 ref.)

Breast conservation therapy in the management of invasive and in situ carcinoma. Masko GB, et al. **R I Med** 1995 Sep;78(9):246–9 (18 ref.)

Evaluation of the breast undergoing lumpectomy and radiation therapy. Dershaw DD. **Radiol Clin North Am** 1995 Nov;33(6):1147–60 (50 ref.)

Menstrual cycle timing of breast cancer resection. Hrushesky WJ. **Recent Results Cancer Res** 1996;140:27–40 (38 ref.)

How to predict the risk of local relapse in the preserved breast. Kurtz JM. **Recent Results Cancer Res** 1996; 140:263–72 (26 ref.)

Surgical treatment of breast cancer relapse. Margolese RG. **Recent Results Cancer Res** 1996;140:159–67 (23 ref.)

Primary and secondary breast reconstruction with special emphasis on the use of prostheses. Petit JY, et al. **Recent Results Cancer Res** 1996;140:169–75 (15 ref.)

The primary use of chemotherapy for operable breast cancer: does systemic therapy make surgery superfluous? Rudenstam CM. **Recent Results Cancer Res** 1996; 140:177–88 (21 ref.)

Duct carcinoma in situ: biological implications for clinical practice. Lagios MD. **Semin Oncol** 1996 Feb;23(1 Suppl 2):6–11 (31 ref.)

Selection of patients with early stage invasive breast cancer

for treatment with conservative surgery and radiation therapy. Recht A. **Semin Oncol** 1996 Feb;23(1 Suppl 2):19–30 (129 ref.)

The role and extent of surgery in early invasive breast cancer. Smith T. **Semin Oncol** 1996 Feb;23(1 Suppl 2):12–8 (44 ref.)

Applications of laser technology in breast cancer therapy. Lanzafame RJ. **Semin Surg Oncol** 1995 Jul–Aug; 11(4):328–32 (40 ref.)

Psychological intervention with couples after mastectomy. Baider L. **Support Care Cancer** 1995 Jul;3(4):239–43 (43 ref.)

Controversy in breast reconstruction. Corral CJ, et al. **Surg Clin North Am** 1996 Apr;76(2):309–26 (44 ref.)

Breast conservation following induction chemotherapy for locally advanced carcinoma of the breast (stages IIB and III). A surgical perspective. Schwartz GF, et al. **Surg Oncol Clin N Am** 1995 Oct;4(4):657–69 (25 ref.)

Arguments against routine contralateral mastectomy or undirected biopsy for invasive lobular breast cancer. Lee JS, et al. **Surgery** 1995 Oct;118(4):640–7; discussion 647–8 (22 ref.)

-Axillary lymph node excision: for what reasons and indications- Schäfer P. **Arch Gynecol Obstet** 1995;256 Suppl:S81–4 (14 ref.) **(Fre)**

[Role of plastic surgery in the treatment of breast cancer] Petit JY, et al. **Bull Acad Natl Med** 1996 Feb;180(2):317–28; discussion 328–31 (17 ref.) (Eng. Abstr.) **(Fre)**

[Postoperative lymphoceles and lymphatic fistula in gynecologic and breast neoplasms] Brun JL. **Bull Cancer (Paris)** 1995 Sep;82(9):711–6 (37 ref.) (Eng. Abstr.) **(Fre)**

[Surgical approach to subclinical breast lesions] Coibion M. **Rev Med Brux** 1995 Jul–Aug;16(4):218–24 (24 ref.) (Eng. Abstr.) **(Fre)**

-Breast neoplasms: axillary lymph node excision—at what price- Rageth JC. **Arch Gynecol Obstet** 1995;256 Suppl:S85–92 (45 ref.) **(Ger)**

[Phyllodes breast tumors: apropos 2 cases] Bruzzese A, et al. **G Chir** 1995 Aug–Sep;16(8–9):366–8 (9 ref.) (Eng. Abstr.) **(Ita)**

THERAPY

High-dose therapy with autologous bone marrow stem cell support in primary and metastatic human breast cancer. A review. Bergh J. **Acta Oncol** 1995;34(5):669–74 (48 ref.)

High-dose chemotherapy with stem-cell rescue for the treatment of breast cancer. McCauley DL. **Am J Health Syst Pharm** 1996 Mar 1;53(5):521–34; quiz 561–2 (87 ref.)

High-dose chemotherapy for breast cancer. Gradishar WJ, et al. **Ann Intern Med** 1996 Oct 1;125(7):599–604 (55 ref.)

Can systematic research of hormone and growth factor receptors contribute to the recognition of acute and chronic types of breast cancer, of their specific mammary dysplasias, and of specific treatments? [editorial] Mathé G. **Biomed Pharmacother** 1995;49(9):385–8 (28 ref.)

High-dose therapy for breast cancer. Vahdat L, et al. **Blood Rev** 1995 Sep;9(3):191–200 (118 ref.)

Carcinoma of the breast. Allum WH, et al. **Br J Hosp Med** 1995 Sep 20–Oct 3;54(6):255–8 (11 ref.)

Principles of adjuvant therapy [see comments] Dawson JW, et al. **Br J Hosp Med** 1995 Sep 20–Oct 3;54(6):249–54 (25 ref.) Comment in: Br J Hosp Med 1995 Sep 20–Oct 3;54(6):248.

Breast cancer. Carbone PP, et al. **Cancer Chemother Biol Response Modif** 1996;16:592–616 (86 ref.)

European School of Oncology European consensus on the use of granulocyte colony-stimulating factor: the example of breast cancer. Antoine EC, et al. **Cancer Chemother Pharmacol** 1996;38 Suppl:S103–9 (71 ref.)

High-dose chemotherapy and autologous stem cell transplantation for breast cancer. Weaver CH, et al. **Cancer Treat Res** 1995;76:59–85 (104 ref.)

Hormone replacement therapy for breast cancer survivors: facts versus fears. DiSaia PJ. **Clin Oncol (R Coll Radiol)** 1995;7(4):241–5 (24 ref.)

T and Tn pancarcinoma markers: autoantigenic adhesion molecules in pathogenesis, prebiopsy carcinoma-detection, and long-term breast carcinoma immunotherapy. Springer GF. **Crit Rev Oncog** 1995;6(1):57–85 (220 ref.)

Ductal carcinoma in situ of the breast: progress and controversy. Swallow CJ, et al. **Curr Probl Surg** 1996 Jul; 33(7):553–600 (171 ref.)

Recent progress in breast cancer research at Osaka Medical Center for Cancer and Cardiovascular Diseases. Koyama H. **Gan To Kagaku Ryoho** 1996 Mar;23 Suppl 1:1–7 (16 ref.)

Beauty and the beast—a medical essay. Lawrence G. **Indian J Cancer** 1995 Dec;32(4):189–99 (27 ref.)

Current issues in the management of breast cancer [editorial] Hill AD, et al. **Ir Med J** 1996 Mar–Apr;89(2):46–8 (27 ref.)

G-CSF-stimulated PMN in immunotherapy of breast cancer with a bispecific antibody to Fc gamma RI and to HER-2/neu (MDX-210). Repp R, et al. **J Hematother** 1995 Oct;4(5):415–21 (26 ref.)

Meeting highlights: a reappraisal of research results for the local treatment of early stage breast cancer. Abrams JS, et al. **J Natl Cancer Inst** 1995 Dec 20;87(24):1837–45 (101 ref.)

Psychosocial support, treatment of metastatic disease and palliative care [see comments] Ashby MA, et al. **Med J Aust** 1996 Jan 1;164(1):43–9 (23 ref.) Comment in: Med J Aust 1996 Jun 17;164(12):759–60.

Current status of endocrine therapy for metastatic breast cancer. Kimmick G, et al. **Oncology (Huntingt)** 1995 Sep; 9(9):877–86, 889–90; discussion 892–4 (129 ref.)

Breast cancer in the elderly. Bellet M, et al. **Postgrad Med J** 1995 Nov;71(841):658–64 (81 ref.)

Locally advanced breast cancer: integration of multimodal concepts. Singletary SE. **R I Med** 1995 Sep;78(9):254–6 (19 ref.)

IX. International consensus conference on primary treatment of breast cancer. Goldhirsch A, et al. **Recent Results Cancer Res** 1996;140:325–35 (15 ref.)

Peptide growth factors and breast cancer treatment: recent translational research. Pollak M. **Recent Results Cancer Res** 1996;140:43–9 (17 ref.)

Economic and cost-effectiveness issues in breast cancer treatment. Hillner BE. **Semin Oncol** 1996 Feb;23(1 Suppl 2):98–104 (21 ref.)

Management of breast cancer: status and future trends. Hortobagyi GN. **Semin Oncol** 1995 Oct;22(5 Suppl 12):101–7 (44 ref.)

Breast cancer in older women. Muss HB. **Semin Oncol** 1996 Feb;23(1 Suppl 2):82–8 (47 ref.)

Controversies in the treatment of ductal carcinoma in situ. Hughes KS, et al. **Surg Clin North Am** 1996 Apr; 76(2):243–65 (76 ref.)

Locally advanced noninflammatory breast cancer. Hunt KK, et al. **Surg Clin North Am** 1996 Apr;76(2):393–410 (56 ref.)

Inflammatory breast cancer. Lopez MJ, et al. **Surg Clin North Am** 1996 Apr;76(2):411–29 (88 ref.)

Comorbidity risk parameters associated with advanced breast cancer and systemic disease. Management of nonbreast disease. Graves TA, et al. **Surg Oncol Clin N Am** 1995 Oct;4(4):633–56 (110 ref.)

The role of bone marrow transplantation in the management of advanced local disease. Safah H, et al. **Surg Oncol Clin N Am** 1995 Oct;4(4):735–49 (83 ref.)

Surgical and medical management of local-regional treatment failures in advanced primary breast cancer. Singletary SE, et al. **Surg Oncol Clin N Am** 1995 Oct; 4(4):671–84 (27 ref.)

Current management of ductal carcinoma in situ [see comments] Barth A, et al. **West J Med** 1995 Oct; 163(4):360–6 (78 ref.) Comment in: West J Med 1995 Oct;163(4):390–2.

[Contribution of biology to the therapeutic decision: cancer of the breast in 1995] Chinot O, et al. **Bull Cancer Radiother** 1995;82(2):225–37 (62 ref.) **(Fre)**

[Cancers of the breast. Primary non-surgical treatments of so-called "operable" cancers of the breast] Fourquet A. **Bull Cancer Radiother** 1995;82(2):154–7 (24 ref.) **(Fre)**

[High-dose therapy and hematopoietic cell autotransplantation in the treatment of adult gynecologic tumors] Lotz JP, et al. **Contracept Fertil Sex** 1996 Apr; 24(4):307–18 (71 ref.) (Eng. Abstr.) **(Fre)**

[Pregnancy after breast cancer] Mignot L, et al. **Contracept Fertil Sex** 1996 Apr;24(4):319–21 (16 ref.) (Eng. Abstr.) **(Fre)**

[Hormone replacement therapy in menopausal women previously treated for breast cancer (editorial)] This P. **Presse Med** 1996 Feb 3;25(4):141–4 (25 ref.) (Eng. Abstr.) **(Fre)**

[Pregnancy outcome in long-term survivors with adult acute leukemia, malignant lymphoma and breast cancer] Kawamura S, et al. **Gan To Kagaku Ryoho** 1996 Jun; 23(7):821–6 (30 ref.) (Eng. Abstr.) **(Jpn)**

[Autologous hematopoietic stem cell transplantation for the treatment of breast cancer] Mukaiyama T, et al. **Gan To Kagaku Ryoho** 1995 Oct;22(12):1731–40 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Breast cancer during pregnancy] Jereczek B. **Ginekol Pol** 1995 Aug;66(8):480–3 (24 ref.) (Eng. Abstr.) **(Pol)**

[Breast-preserving (conservative) therapy of breast cancer] Semiglazov VF, et al. **Vopr Onkol** 1996;42(3):26–9 (11 ref.) (Eng. Abstr.) **(Rus)**

[Adjuvant therapy of breast cancer without regional metastases] Shparik IaV, et al. **Klin Khir** 1995;(5):42–6 (47 ref.) **(Ukr)**

ULTRASONOGRAPHY

Breast ultrasound. Ueno E. **Gan To Kagaku Ryoho** 1996 Mar; 23 Suppl 1:14–23 (18 ref.)

[Ultrasonographic diagnosis of breast cancer with intraductal spreading of cancer cells] Kamio T, et al. **Nippon Geka Gakkai Zasshi** 1996 May;97(5):338–42 (5 ref.) (Eng. Abstr.) **(Jpn)**

ULTRASTRUCTURE

Insulin receptors in breast cancer. Belfiore A, et al. **Ann N Y Acad Sci** 1996 Apr 30;784:173–88 (18 ref.)

Insulin-like growth factor-I (IGF-I) receptors in breast cancer. Pezzino V, et al. **Ann N Y Acad Sci** 1996 Apr 30; 784:189–201 (43 ref.)

Oestrogen receptor: a stable phenotype in breast cancer. Robertson JF. **Br J Cancer** 1996 Jan;73(1):5–12 (115 ref.)

Interaction between erbB-receptors and heregulin in breast cancer tumor progression and drug resistance. Lupu R, et al. **Semin Cancer Biol** 1995 Jun;6(3):135–45 (143 ref.)

BREAST NEOPLASMS, MALE

Cancer of the male breast: a review. Williams WL Jr, et al. **J Natl Med Assoc** 1996 Jul;88(7):439–43 (22 ref.)

Breast cancer in men. Donegan WL, et al. **Surg Clin North Am** 1996 Apr;76(2):343–63 (126 ref.)

[Literature lists and male breast cancer (letter)] Clemmesen J. **Ugeskr Laeger** 1996 Mar 11;158(11):1533 (3 ref.) **(Dan)**

[Male breast cancer. A review] Langer SW, et al. **Ugeskr Laeger** 1996 Jan 1;158(1):37–40 (27 ref.) (Eng. Abstr.) **(Dan)**

[Granular cell tumor of the male breast. Case report and review of the literature] Reale D, et al. **Minerva Chir** 1995 Jul–Aug;50(7–8):717–20 (18 ref.) (Eng. Abstr.) **(Ita)**

DIAGNOSIS

[The differential diagnosis of tumors of the nipple and areola] Schulz B, et al. **Dtsch Med Wochenschr** 1996 Jan 5; 121(1–2):23–7 (19 ref.) **(Ger)**

[Diseases of the male breast] Krause W, et al. **Hautarzt** 1996 Jun;47(6):422–6 (16 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Carcinoma of the male breast: a sexually transmitted disease? Amir H, et al. **East Afr Med J** 1996 Mar;73(3):187–90 (32 ref.)

THERAPY

Male breast cancer: results of the treatments and prognostic factors in 397 cases. Cutuli B, et al. **Eur J Cancer** 1995 Nov;31A(12):1960–4 (32 ref.)

BREAST PROSTHESIS, INTERNAL see **BREAST IMPLANTS**

BREAST RECONSTRUCTION see **MAMMAPLASTY**

BREATH TESTS

Measuring and reporting the concentration of acetaldehyde in human breath. Jones AW. **Alcohol Alcohol** 1995 May; 30(3):271–85 (45 ref.)

Medicolegal alcohol determination: variability of the blood-to breath-alcohol ratio and its effect on reported breath-alcohol concentrations. Labianca DA, et al. **Eur J Clin Chem Clin Biochem** 1995 Dec;33(12):919–25 (17 ref.)

Drink driving legislation: medicine and the law. Marks P. **Med Leg J** 1995;63 (Pt 3):119–27 (17 ref.)

Exhaled nitric oxide: a new lung function test [editorial] Barnes PJ, et al. **Thorax** 1996 Mar;51(3):233–7 (73 ref.)

INSTRUMENTATION

The novel selected-ion flow tube approach to trace gas analysis of air and breath. Smith D, et al. **Rapid Commun Mass Spectrom** 1996;10(10):1183–98 (37 ref.)

METHODS

Breathtaking technology for the detection of Helicobacter pylori [editorial] [see comments] Phillips M. **Am J Gastroenterol** 1995 Dec;90(12):2089–90 (9 ref.) Comment in: Am J Gastroenterol 1996 Jul;91(7):1468–9.

The urea breath test: a non-invasive clinical tool for detecting Helicobacter pylori infection. Perri F, et al. **Ital J Gastroenterol** 1995 Mar;27(2):55–63 (77 ref.)

[Cardio-respirography in neonatal medicine: value, interpretation, indications] Favre A, et al. **Arch Pediatr** 1996 May;3(5):480–8 (43 ref.) (Eng. Abstr.) **(Fre)**

[C13 urea breath test in the diagnosis of Helicobacter pylori infection in the gastric mucosa. Validation of the method] Pérez García JI, et al. **Rev Esp Enferm Dig** 1996 Mar; 88(3):202–8 (45 ref.) (Eng. Abstr.) **(Spa)**

BREATHALYZER TESTS see **BREATH TESTS**

BREATHING see **RESPIRATION**

BREATHING EXERCISES

Medical applications of qigong. Sancier KM. **Altern Ther Health Med** 1996 Jan;2(1):40–6 (45 ref.)

Breathing retraining in chronic obstructive pulmonary disease. Breslin EH. **J Cardpulm Rehabil** 1995 Jan–Feb; 15(1):25–33 (51 ref.)

Inspiratory muscle training in the patient with neuromuscular disease. McCool FD, et al. **Phys Ther** 1995 Nov; 75(11):1006–14 (45 ref.)

Considerations when testing and training the respiratory muscles. Reid WD, et al. **Phys Ther** 1995 Nov; 75(11):971–82 (55 ref.)

Respiratory muscle training for patients with chronic obstructive pulmonary disease. Reid WD, et al. **Phys Ther** 1995 Nov;75(11):996–1005 (65 ref.)

[Exercise training: its value in chronic obstructive lung disease] Sergysels R. **Rev Mal Respir** 1996;13(2):95–100 (40 ref.) (Eng. Abstr.) **(Fre)**

BREECH PRESENTATION

The foetal pituitary, postmaturity and breech presentation [comment] de Zegher F, et al. **Acta Paediatr** 1995 Oct; 84(10):1100–2 (32 ref.) Comment on: Acta Paediatr 1995 Oct;84(10):1201–3.

Preterm breech babies and randomised trials of rare conditions [comment] Thornton JG, et al. **Br J Obstet Gynaecol** 1996 Jul;103(7):611–3 (5 ref.) Comment on: Br J Obstet Gynaecol 1996 Jul;103(7):684–9.

Intrapartum management of breech presentation. Scorza WE. **Clin Perinatol** 1996 Mar;23(1):31–49 (83 ref.)

Abnormal fetal presentations. Gimovsky M, et al. **Curr Opin Obstet Gynecol** 1995 Dec;7(6):482–5 (15 ref.)

[Is induced labor justified in cases of scarred uterus, breech presentation and multiple pregnancy?] Schaal JP, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24 Suppl 1:57–61 (39 ref.) **(Fre)**

BREEDING

Animal selection and breeding techniques that create diseased populations and compromise welfare. Ott RS. **J Am Vet Med Assoc** 1996 Jun 15;208(12):1969–74 (48 ref.)

Enrichment of food staples through plant breeding: a new strategy for fighting micronutrient malnutrition. Bouis H. **Nutr Rev** 1996 May;54(5):131–7 (31 ref.)

[The systems organization of the breeding behavior of the moose in its natural habitat] Bogomolova EM, et al. **Usp Fiziol Nauk** 1995 Oct–Dec;26(4):48–74 (47 ref.) (Eng. Abstr.) **(Rus)**

METHODS

[DNA fingerprinting in wild equid and Poitou ass breeding] Werner P, et al. **Schweiz Arch Tierheilkd** 1995;137(8):395–7 (10 ref.) **(Ger)**

STANDARDS

Farm animal well-being and intensive production systems. Swanson JC. **J Anim Sci** 1995 Sep;73(9):2744–51 (60 ref.)

["Breeding for distress" in fowl] Bartels T. **DTW Dtsch Tierarztl Wochenschr** 1995 Mar;102(3):117–9 (34 ref.) (Eng. Abstr.) **(Ger)**

[Procedures for health monitoring in a breeding facility for specific pathogen free mice and rats] Wyss-Spillmann SK, et al. **Schweiz Arch Tierheilkd** 1995;137(11):505–14 (39 ref.) (Eng. Abstr.) **(Ger)**

BREWER'S YEAST see **SACCHAROMYCES CEREVISIAE**

BRIDGED COMPOUNDS

PHARMACOLOGY

Taxanes. Fojo A. **Cancer Chemother Biol Response Modif** 1996;16:57–67 (42 ref.)

THERAPEUTIC USE

The role of taxanes in the treatment of breast cancer. Capri G, et al. **Semin Oncol** 1996 Feb;23(1 Suppl 2):68–75 (62 ref.)

BRIGHT DISEASE see **GLOMERULONEPHRITIS**

BRIQUET SYNDROME see **SOMATOFORM DISORDERS**

BROAD BETA DISEASE see **HYPERLIPOPROTEINEMIA TYPE III**

BROAD LIGAMENT

[Internal hernia of the small intestine through a breach of the broad ligament, apropos of a case. Review of the literature] Fafet P, et al. **J Chir (Paris)** 1995 Jun–Jul; 132(6–7):314–7 (14 ref.) (Eng. Abstr.) **(Fre)**

BROCA AREA see **FRONTAL LOBE**

BROCK'S SYNDROME see **MIDDLE LOBE SYNDROME**

BROMAZEPAM

POISONING

Benzodiazepine poisoning in companion animals. Bertini S, et al. **Vet Hum Toxicol** 1995 Dec;37(6):559–62 (24 ref.)

BROMHEXINE METABOLITE VIII see **AMBROXOL**

BROMOCRIPTINE

ADMINISTRATION & DOSAGE

[The therapy of a macroprolactinoma with the intramuscular application of a long-acting bromocriptine preparation] Kreft B, et al. **Dtsch Med Wochenschr** 1996 Jul 5; 121(27):865–8 (10 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

[Retroperitoneal fibrosis secondary to treatment with L-dopa analogues for Parkinson disease] Sánchez-Chapado M, et al. **Arch Esp Urol** 1995 Dec;48(10):979–83 (28 ref.) (Eng. Abstr.) **(Spa)**

THERAPEUTIC USE

New drugs for hyperprolactinaemia. **Drug Ther Bull** 1995 Sep;33(9):65–7 (24 ref.)

Diagnosis and drug therapy of prolactinoma. Ciccarelli E, et al. **Drugs** 1996 Jun;51(6):954–65 (63 ref.)

[The neuroleptic malignant syndrome in an adolescent. Its treatment with dantrolene, bromocryptin and diazepam] Real Rodríguez B, et al. **An Esp Pediatr** 1996 Jan;44(1):60–2 (20 ref.) **(Spa)**

BROMOCRYPTIN see **BROMOCRIPTINE**

BROMODEOXYURIDINE

DIAGNOSTIC USE

Bromodeoxyuridine: a diagnostic tool in biology and medicine, Part II: Oncology, chemotherapy and carcinogenesis. Dolbeare F. **Histochem J** 1995 Dec; 27(12):923–64 (468 ref.)

2-BROMOERGOCRYPTINE see **BROMOCRIPTINE**

BROMOURACIL DEOXYRIBOSIDE see **BROMODEOXYURIDINE**

BRONCHI

see related
BRONCHODILATOR AGENTS
BRONCHOGRAPHY
BRONCHOSCOPY

Laser-assisted removal of a foreign body in the bronchial system of an infant. Boelcskei PL, et al. **Lasers Surg Med** 1995;17(4):375–7 (20 ref.)

[Hepatic ciliated cyst] Ohmoto K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):99–101 (15 ref.) **(Jpn)**

ABNORMALITIES

Lobar emphysema and atelectasis syndrome, a nosological unity. Ring-Mrozik E, et al. **Eur J Pediatr Surg** 1995 Jun; 5(3):131–5 (27 ref.)

Multiple pulmonary chondrohamartomas in trachea, bronchi and lung parenchyma. Review of the literature. Domínguez H, et al. **Respir Med** 1996 Feb;90(2):111–4 (17 ref.)

ANATOMY & HISTOLOGY

Anatomy of the larynx, trachea, and bronchi. Armstrong WB, et al. **Otolaryngol Clin North Am** 1995 Aug;28(4):685–99 (24 ref.)

BLOOD SUPPLY

[Multiple bronchial varices] Otsuka T, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Mar; 34(3):327–30 (10 ref.) (Eng. Abstr.) **(Jpn)**

DRUG EFFECTS

Remodeling of asthmatic airways by glucocorticosteroids. Laitinen LA, et al. **J Allergy Clin Immunol** 1996 Jan;97(1 Pt 2):153–8 (22 ref.)

Pharmacological basis for duration of effect: formoterol and salmeterol versus short-acting beta 2-adrenoceptor agonists. Lindén A, et al. **Lung** 1996;174(1):1–22 (52 ref.)

ENZYMOLOGY

The role of HMT (histamine N-methyltransferase) in airways: a review. Okinaga S, et al. **Methods Find Exp Clin Pharmacol** 1995 Nov;17 Suppl C:16–20 (52 ref.)

INJURIES

CT in blunt chest trauma: pulmonary, tracheobronchial, and diaphragmatic injuries. Kang EY, et al. **Semin Ultrasound CT MR** 1996 Apr;17(2):114–8 (39 ref.)

METABOLISM

The penetration of novel intravenous cephalosporins into the lung. Baldwin DR. **J Chemother** 1996 Feb;8 Suppl 2:71–82 (89 ref.)

MICROBIOLOGY

Acute on chronic bronchitis: A model of mucosal immunology. Clancy R, et al. **Immunol Cell Biol** 1995 Oct; 73(5):414–7 (26 ref.)

PATHOLOGY

Remodeling of asthmatic airways by glucocorticosteroids. Laitinen LA, et al. **J Allergy Clin Immunol** 1996 Jan;97(1 Pt 2):153–8 (22 ref.)

PHYSIOLOGY

Anatomy of the larynx, trachea, and bronchi. Armstrong WB, et al. **Otolaryngol Clin North Am** 1995 Aug;28(4):685–99 (24 ref.)

[The clearance function of the bronchial epithelium] Kobylianskii VI. **Tsitologiia** 1995;37(3):179–86 (81 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Airway behavior and its regulation: how do structural changes affect airway behavior? Hogg JC. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 2):S16–8 (31 ref.)

Can airway function be predicted? Macklem PT. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 2):S19–20 (9 ref.)

Epithelial cells: barrier functions and shedding-restitution mechanisms. Persson CG. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 2):S9–10 (16 ref.)

SECRETION

Neurokinin receptors subserving airways secretion. Rogers DF. **Can J Physiol Pharmacol** 1995 Jul;73(7):932–9 (80 ref.)

A case of pancreatic carcinoma causing massive bronchial fluid production and electrolyte abnormalities. Lembo T, et al. **Chest** 1995 Oct;108(4):1161–3 (8 ref.)

BRONCHIAL ARTERIES

[Failures and complications of bronchial artery embolization] Mesurolle B, et al. **Rev Mal Respir** 1996 Jul;13(3):217–25 (74 ref.) (Eng. Abstr.) **(Fre)**

RADIOGRAPHY

Radiology of the central airways. Worrell JA. **Otolaryngol Clin North Am** 1995 Aug;28(4):701–20 (23 ref.)

BRONCHIAL ASTHMA see **ASTHMA**

BRONCHIAL CONSTRICTION see **BRONCHOCONSTRICTION**

BRONCHIAL-DILATING AGENTS see **BRONCHODILATOR AGENTS**

BRONCHIAL DISEASES

COMPLICATIONS

Acute bronchial infection in chronic obstructive pulmonary disease. Dorca J. **Monaldi Arch Chest Dis** 1995 Oct; 50(5):366–71 (43 ref.)

[Systemic arterial hypertension in chronic bronchial obstruction: current views and new understandings] Bobrov VA, et al. **Klin Med (Mosk)** 1995;73(3):24–8 (82 ref.) **(Rus)**

DIAGNOSIS

Broncholithiasis: case report and literature review. Ryberg AA, et al. **Nebr Med J** 1996 Jan;81(1):14–7 (17 ref.)

Tracheobronchopathia osteochondroplastica. Report of a young man with severe disease and retrospective review of 18 cases. Vilkman S, et al. **Respiration** 1995;62(3):151–4 (13 ref.)

ETIOLOGY

Massive endobronchial hemorrhage after pulmonary embolectomy. Shimokawa S, et al. **Ann Thorac Surg** 1996 Apr;61(4):1241–2 (11 ref.)

Right aortic arch with aberrant left subclavian artery: aneurysmal dilatation causing symptomatic compression of the right main bronchus in an adult. Patiniotis TC, et al. **Aust N Z J Surg** 1995 Sep;65(9):690–2 (9 ref.)

[Tracheobronchial complications of assisted ventilation in children] Denoyelle F, et al. **Rev Mal Respir** 1996 Jul; 13(3):259–64 (34 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

[Pneumologists and the nose (editorial)] Picado C. **Arch Bronconeumol** 1995 Aug–Sep;31(7):314–6 (11 ref.) **(Spa)**

RADIOGRAPHY

The bronchi: an imaging perspective. Shepard JA. **J Thorac Imaging** 1995 Winter;10(4):236–54 (98 ref.)

[Localized tracheobronchial amyloidosis. The usefulness of computed tomography] Sánchez Antuña A, et al. **Arch Bronconeumol** 1995 Dec;31(10):540–2 (23 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

Expandable stents. Nesbitt JC, et al. **Chest Surg Clin N Am** 1996 May;6(2):305–28 (33 ref.)

Airway stents. Present and future. Colt HG, et al. **Clin Chest Med** 1995 Sep;16(3):465–78 (96 ref.)

Cryotherapy for tracheobronchial disorders. Maiwand MO, et al. **Clin Chest Med** 1995 Sep;16(3):427–43 (57 ref.)

BRONCHIAL FISTULA

Nephrobronchocutaneous fistula. Aly SA, et al.

BRONCHIAL FISTULA

Ulster Med J 1994 Apr;63(1):116–8 (5 ref.)

CHEMICALLY INDUCED

Bronchoesophagopleural fistula after photodynamic therapy for malignant mesothelioma. Luketich JD, et al. **Ann Thorac Surg** 1996 Jul;62(1):283–4 (7 ref.)

ETIOLOGY

Nephrobronchial fistula and lung abscess resulting from nephrolithiasis and pyelonephritis. O'Brien JD, et al. **Chest** 1995 Oct;108(4):1166–8 (6 ref.)

SURGERY

[New techniques in thoracic surgery. II] Andreassian B. **Presse Med** 1995 Jul 1–8;24(24):1127–32 (32 ref.) (Eng. Abstr.) **(Fre)**

[Bronchobiliary fistula] Nishimura S, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Jun; 34(6):689–93 (11 ref.) (Eng. Abstr.) **(Jpn)**

THERAPY

[The treatment of a bronchopleural fistula with fibrin adhesive in a premature infant] Galiana Ferré C, et al. **An Esp Pediatr** 1996 Jun;44(6):596–8 (11 ref.) **(Spa)**

BRONCHIAL HYPERREACTIVITY

see related
ASTHMA

[Clinical significance of bronchial hyperreactivity] Weber T. **Rev Med Liege** 1995 Sep;50(9):384–7 (32 ref.) **(Fre)**

[Limits in the evaluation of bronchial reactivity in children with asthma] Mingoni S, et al. **Pediatr Med Chir** 1995 Sep–Oct;17(5):417–22 (49 ref.) (Eng. Abstr.) **(Ita)**

[Clinical feature and pathology of airway disease in Sjögren's syndrome] Ota T, et al. **Nippon Rinsho** 1995 Oct; 53(10):2521–4 (12 ref.) (Eng. Abstr.) **(Jpn)**

CHEMICALLY INDUCED

[Persistent reactive airway dysfunction syndrome after exposure to chromate] Nagasaka Y, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Jul;33(7):759–64 (16 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

The genetics of asthma and atopy. Panhuysen CI, et al. **Allergy** 1995 Nov;50(11):863–9 (62 ref.)

Linkage homology for bronchial hyperresponsiveness between DNA markers on human chromosome 5q31–q33 and mouse chromosome 13. Levitt RC, et al. **Clin Exp Allergy** 1995 Nov;25 Suppl 2:61–3 (21 ref.)

IMMUNOLOGY

Allergen levels causing sensitisation, bronchial hyperreactivity and asthma. Dreborg S. **Pediatr Allergy Immunol** 1995;6 Suppl 7:22–6 (44 ref.)

PHYSIOPATHOLOGY

The place of airway hyperresponsiveness in the asthma phenotype. Sterk PJ. **Clin Exp Allergy** 1995 Nov;25 Suppl 2:8–11; discussion 17–8 (30 ref.)

[Clinical significance of bronchial hyperreactivity] Weber T. **Rev Med Liege** 1995 Sep;50(9):384–7 (32 ref.) **(Fre)**

BRONCHIAL LAVAGE see **BRONCHOALVEOLAR LAVAGE**

BRONCHIAL LAVAGE FLUID see **BRONCHOALVEOLAR LAVAGE FLUID**

BRONCHIAL NEOPLASMS

[Granular-cell tumor: review of the literature apropos of a case of bronchial site] Hocqueloux L, et al. **Rev Med Interne** 1996;17(5):415–8 (16 ref.) (Eng. Abstr.) **(Fre)**

BLOOD

[CYFRA 21-1 and bronchial cancer] Pujol JL, et al. **Rev Mal Respir** 1995;12(6):533–41 (33 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

Endoscopic management of acute respiratory failure related to tracheobronchial malignancies. Ninane V. **Support Care Cancer** 1995 Nov;3(6):418–21 (40 ref.)

[Fasciitis with eosinophilia and bronchial cancer (letter)] Blanche P, et al. **Ann Med Interne (Paris)** 1996;147(1):62–4 (19 ref.) **(Fre)**

DIAGNOSIS

[Endo-bronchial lipoma. Apropos of a case] Drira I, et al. **Rev Pneumol Clin** 1995;51(4):247–9 (15 ref.) (Eng. Abstr.) **(Fre)**

[Bronchus carcinoid tumor in the Tessin canton, retrospective analysis of 13 years and literature review] John H, et al. **Schweiz Med Wochenschr** 1996 Aug 6; 126(31–32):1339–46 (20 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

[Evaluation of tumor response during chemotherapy of bronchial cancer] Pujol JL, et al. **Rev Med Interne** 1995; 16(10):759–66 (36 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Basaloid-squamous cell carcinoma of the bronchus. Report of a case with review of the literature. Lin O, et al. **Arch Pathol Lab Med** 1995 Dec;119(12):1167–70 (16 ref.)

[Reevaluation of preneoplastic lung lesions in lung carcinoma? In bronchial carcinoma?] Kato H, et al. **Gan To Kagaku Ryoho** 1995 Dec;22(14):2048–54 (32 ref.) (Eng. Abstr.) **(Jpn)**

PREVENTION & CONTROL

[Vitamin A derivatives and prevention of bronchial cancers] Thiberville L, et al. **Rev Mal Respir** 1996;13(2):193–5 (19 ref.) **(Fre)**

RADIOGRAPHY

[Ossified bronchial neuroendocrine tumors: 3 cases] Debourdeau P, et al. **Rev Pneumol Clin** 1995;51(6):325–9 (27 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Endobronchial leiomyoma: report of a case treated by bronchoplasty and a review of the literature. Ayabe H, et al. **Surg Today** 1995;25(12):1057–60 (17 ref.)

[Endobronchial lipoma: endoscopic resection or surgical excision? Report of a case and review of the literature] Destito C, et al. **G Chir** 1995 Oct;16(10):445–7 (19 ref.) (Eng. Abstr.) **(Ita)**

[A case of bronchial neurinoma] Yodonawa S, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Jun;44(6):820–5 (18 ref.) (Eng. Abstr.) **(Jpn)**

BRONCHIAL PROVOCATION TESTS

Bronchial inhalation challenge procedures with allergens and other bronchoconstrictor substances. Spector S. **Allerg Immunol (Paris)** 1996 Apr;28(4):112, 115–8 (38 ref.)

[Is the bronchial provocation test justified in occupational respiratory disease?] Pauli G, et al. **Rev Pneumol Clin** 1996; 52(2):97–102 (20 ref.) (Eng. Abstr.) **(Fre)**

[Limits in the evaluation of bronchial reactivity in children with asthma] Mingoni S, et al. **Pediatr Med Chir** 1995 Sep–Oct;17(5):417–22 (49 ref.) (Eng. Abstr.) **(Ita)**

BRONCHIAL SPASM

CHEMICALLY INDUCED

Delayed pulmonary edema and bronchospasm after accidental lacrimator exposure. Vaca FE, et al. **Am J Emerg Med** 1996 Jul;14(4):402–5 (32 ref.)

DRUG THERAPY

[The role of long-acting beta-mimetics in patients with chronic bronchial spasm and bronchial asthma] Chazan R, et al. **Pol Arch Med Wewn** 1995 Jul;94(1):59–63 (47 ref.) **(Pol)**

ETIOLOGY

[Diagnosing bronchospastic states] Oklek K. **Pneumonol Alergol Pol** 1995;63(5–6):328–31 (9 ref.) **(Pol)**

THERAPY

[Bronchospasm during anesthesia in a patient with Prader–Willi syndrome] Kawahito S, et al. **Masui** 1995 Dec;44(12):1675–9 (19 ref.) (Eng. Abstr.) **(Jpn)**

BRONCHIECTASIS

Bronchiectasis in children. Coleman LT, et al. **J Thorac Imaging** 1995 Winter;10(4):268–79 (38 ref.)

ETIOLOGY

[Bronchiectasis in hemorrhagic rectocolitis. Apropos of a case] Jrad IB, et al. **Rev Pneumol Clin** 1995;51(5):288–90 (11 ref.) (Eng. Abstr.) **(Fre)**

RADIOGRAPHY

Review article: imaging in bronchiectasis. Smith IE, et al. **Br J Radiol** 1996 Jul;69(823):589–93 (45 ref.)

Bronchiectasis: CT/clinical correlations. McGuinness G, et al. **Semin Ultrasound CT MR** 1995 Oct;16(5):395–419 (63 ref.)

BRONCHIOLES see **BRONCHI**

BRONCHIOLITIS

DRUG THERAPY

[Treatment of acute bronchiolitis in infants. Role of bronchodilators and steroids] Labbé A. **Arch Pediatr** 1996 Apr;3(4):383–9 (76 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

[Diffuse panbronchiolilitis associated with bullous pemphigoid] Oshikawa K, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Sep; 33(9):1019–23 (21 ref.) (Eng. Abstr.) **(Jpn)**

BRONCHIOLITIS, EXUDATIVE see **BRONCHIOLITIS OBLITERANS**

BRONCHIOLITIS OBLITERANS

[Bronchiolitis obliterans in the child] Calabria MD. **Allergol Immunopathol (Madr)** 1995 Nov–Dec;23(6):267–70 (22 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

Obliterative bronchiolitis after lung and heart–lung transplantation. Reichenspurner H, et al. **Ann Thorac Surg** 1995 Dec;60(6):1845–53 (86 ref.)

RADIOGRAPHY

Bronchiolitis obliterans in children with Stevens–Johnson syndrome: follow-up with high resolution CT. Kim MJ, et al. **Pediatr Radiol** 1996;26(1):22–5 (9 ref.)

BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA

COMPLICATIONS

Bronchiolitis obliterans organizing pneumonia in an AIDS patient. Sanito NJ, et al. **Eur Respir J** 1995 Jun;8(6):1021–4 (15 ref.)

Polymyositis and Sjögren's syndrome associated with bronchiolitis obliterans organizing pneumonia. Imasaki T, et al. **Intern Med** 1996 Mar;35(3):231–5 (22 ref.)

DIAGNOSIS

Bronchiolitis obliterans organizing pneumonia in an AIDS patient. Sanito NJ, et al. **Eur Respir J** 1995 Jun;8(6):1021–4 (15 ref.)

Bronchiolitis obliterans organizing pneumonia. Epler GR. **Semin Respir Infect** 1995 Jun;10(2):65–77 (49 ref.)

DRUG THERAPY

Bronchiolitis obliterans with organising pneumonia: outcome. Costabel U, et al. **Thorax** 1995 Sep;50 Suppl 1:S59–64 (57 ref.)

PATHOLOGY

[Bronchiolitis obliterans organizing pneumonia: survey based on two cases (see comments)] Barzó P, et al. **Orv Hetil** 1995 Oct 8;136(41):2231–6 (51 ref.) (Eng. Abstr.) Comment in: Orv Hetil 1996 Jan 14;137(2):99. **(Hun)**

BRONCHIOLITIS, PROLIFERATIVE see **BRONCHIOLITIS OBLITERANS**

BRONCHIOLITIS, VIRAL

EPIDEMIOLOGY

Respiratory syncytial virus bronchiolitis: clinical aspects and epidemiology. Boeck KD. **Monaldi Arch Chest Dis** 1996 Jun;51(3):210–3 (28 ref.)

BRONCHITIS

[Evolution in research on chronic bronchitis] Zhiugzhda AI, et al. **Klin Med (Mosk)** 1995;73(6):8–10 (24 ref.) **(Rus)**

COMPLICATIONS

How does inflammation cause symptoms? Woolcock AJ. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 2):S21–2 (28 ref.)

[Allergic bronchitis in bronchial asthma] Fal AM, et al. **Wiad Lek** 1994 Sep;47(17–18):688–93 (26 ref.) (Eng. Abstr.) **(Pol)**

DIAGNOSIS

[Frequent airway infections (clinical conference)] Hohage H, et al. **Schweiz Rundsch Med Prax** 1995 Nov 14; 84(46):1358–63 (56 ref.) (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

Epidemiology of lower respiratory tract infections. Bariffi F, et al. **J Chemother** 1995 Aug;7(4):263–76 (79 ref.)

ETIOLOGY

[Specific respiratory manifestations associated with hemorrhagic rectocolitis. Analysis of a case and review of the literature] Lagier E, et al. **Gastroenterol Clin Biol** 1996;20(4):397–400 (28 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Acute on chronic bronchitis: A model of mucosal immunology. Clancy R, et al. **Immunol Cell Biol** 1995 Oct; 73(5):414–7 (26 ref.)

[Atopy score in infancy and the severity of asthma at 7 years of age] Uhereczky G, et al. **Orv Hetil** 1996 Jan 28; 137(4):175–8 (46 ref.) (Eng. Abstr.) **(Hun)**

PREVENTION & CONTROL

The long-term antimicrobial prophylaxis of chronic bronchitis exacerbations. Crimi N, et al. **J Chemother** 1995 Aug;7(4):307–10 (14 ref.)

SURGERY

Plastic bronchitis. Park JY, et al. **Eur Respir J** 1996 Mar; 9(3):612–4 (11 ref.)

BRONCHOALVEOLAR LAVAGE

Bronchoscopic biopsies and bronchoalveolar lavage. Kvale PA. **Chest Surg Clin N Am** 1996 May;6(2):205–22 (73 ref.)

[Alveolar lipoproteinosis treated by bronchopulmonary lavage] Montero MC, et al. **Arch Bronconeumol** 1995 Dec; 31(10):537–9 (22 ref.) (Eng. Abstr.) **(Spa)**

BRONCHOALVEOLAR LAVAGE FLUID

CHEMISTRY

Age-dependency of surfactant phospholipids and surfactant protein A in bronchoalveolar lavage fluid of children without bronchopulmonary disease. Ratjen F, et al. **Eur Respir J** 1996 Feb;9(2):328–33 (34 ref.)

CYTOLOGY

[Interstitial lung involvement in collagen diseases with special reference to bronchoalveolar lavage and lung biopsy] Witt C, et al. **Pneumologie** 1995 Sep;49(9):487–91 (64 ref.) **(Ger)**

[A case of acute eosinophilic pneumonia: bronchoalveolar lavage findings before and after steroid treatment] Kawaguchi H, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Jul;33(7):738–44 (21 ref.) (Eng. Abstr.) **(Jpn)**

MICROBIOLOGY

The role of bronchoalveolar lavage in the diagnosis of bacterial pneumonia. Sanchez Nieto JM, et al. **Eur J Clin Microbiol Infect Dis** 1995 Oct;14(10):839–50 (93 ref.)

[A case of fulminant psittacosis necessitating mechanical ventilation diagnosed by chlamydial isolation form BALF] Taniguchi H, et al. **Kansenshogaku Zasshi** 1995 Dec; 69(12):1396–401 (9 ref.) (Eng. Abstr.) **(Jpn)**

BRONCHOCONSTRICTION

see related
BRONCHIAL PROVOCATION TESTS

Neurokinin receptors subserving bronchoconstriction. Ellis JL. **Can J Physiol Pharmacol** 1995 Jul;73(7):923–6 (32 ref.)

Models and mechanisms of exercise-induced asthma. Freed AN. **Eur Respir J** 1995 Oct;8(10):1770–85 (183 ref.)

DRUG EFFECTS

Putative mechanisms of cough after treatment with angiotensin converting enzyme inhibitors. Semple PF. **J Hypertens Suppl** 1995 Sep;13 Suppl 3:S17–21 (38 ref.)

PHYSIOLOGY

[Role of prostaglandins F and E in regulation of bronchial activity] Mastalerz L. **Pol Arch Med Wewn** 1995 Feb; 93(2):179–83 (35 ref.) (Eng. Abstr.) **(Pol)**

BRONCHODILATOR AGENTS

Phosphodiesterase type IV inhibitors. Palfreyman MN, et al. **Prog Med Chem** 1996;33:1–52 (306 ref.)

ADMINISTRATION & DOSAGE

Bronchodilator delivery with metered-dose inhalers in mechanically-ventilated patients. Dhand R, et al. **Eur Respir J** 1996 Mar;9(3):585–95 (69 ref.)

[Chronopharmacology of reversible airway obstruction] Haen E. **Wien Med Wochenschr** 1995;145(17–18):439–45 (38 ref.) (Eng. Abstr.) **(Ger)**

[Therapy of asthma using bronchodilator agents—special reference to adrenergic beta 2-receptor agonists] Kurosawa M, et al. **Nippon Naika Gakkai Zasshi** 1996 Feb 10; 85(2):210–5 (5 ref.) **(Jpn)**

[Broncholytic agents in the treatment of bronchial asthma] Tkachenko Iula, et al. **Vrach Delo** 1995 Jan–Feb;(1–2):13–6 (38 ref.) **(Rus)**

ADVERSE EFFECTS

Asthma and the beta 2-agonist controversy: much ado about something. Lieberman JS, et al. **Del Med J** 1995 Dec; 67(12):624–8 (28 ref.)

BLOOD

[Theophylline] Nishihara K. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:966–9 (9 ref.) **(Jpn)**

PHARMACOKINETICS

Pulmonary pharmacology. Hornby PJ, et al. **Clin Obstet Gynecol** 1996 Mar;39(1):17–35 (25 ref.)

PHARMACOLOGY

Pulmonary pharmacology. Hornby PJ, et al. **Clin Obstet Gynecol** 1996 Mar;39(1):17–35 (25 ref.)

Immunomodulatory actions of xanthines and isoenzyme selective phosphodiesterase inhibitors. Banner KH, et al. **Monaldi Arch Chest Dis** 1995 Aug;50(4):286–92 (96 ref.)

Airway smooth muscle relaxation. Knox AJ, et al. **Thorax** 1995 Aug;50(8):894–901 (115 ref.)

Scorpion venoms: taking the sting out of lung disease. Rogers DF. **Thorax** 1996 May;51(5):546–8 (12 ref.)

THERAPEUTIC USE

Modern treatment of asthma in children. Zeffren BS, et al. **Adv Pediatr** 1996;43:423–68 (214 ref.)

Anticholinergic antimuscarinic agents in the treatment of airways bronchoconstriction in children. Martinati LC, et al. **Allergy** 1996 Jan;51(1):2–7 (33 ref.)

An international perspective on anticholinergic therapy. Chapman KR. **Am J Med** 1996 Jan 29;100(1A):2S–4S (19 ref.)

Effectiveness of bronchodilators in cystic fibrosis. Cropp GJ. **Am J Med** 1996 Jan 29;100(1A):19S–29S (38 ref.)

Use of anticholinergic bronchodilation in children. Rubin BK, et al. **Am J Med** 1996 Jan 29;100(1A):49S–53S (40 ref.)

Optimal pharmacologic treatment of the critically ill patient with obstructive airways disease. Siefkin AD. **Am J Med** 1996 Jan 29;100(1A):54S–61S (37 ref.)

Salmeterol for the treatment of asthma [editorial; comment] Weinberger M. **Ann Allergy Asthma Immunol** 1995 Sep; 75(3):209–11 (26 ref.) Comment on: Ann Allergy Asthma Immunol 1995 Sep;75(3):243–8.

Bronchodilator therapy in the management of acute asthma. Moan MJ, et al. **Compr Ther** 1995 Aug;21(8):421–7 (39 ref.)

Use of magnesium sulfate in asthma in childhood. Monem GF, et al. **Pediatr Ann** 1996 Mar;25(3):136, 139–44 (52 ref.)

[Treatment of asthma; are there still questions? (see comments)] van Schayck CP. **Ned Tijdschr Geneeskd** 1996 Jan 13;140(2):72–7 (47 ref.) Comment in: Ned Tijdschr Geneeskd 1996 Mar 2;140(9):508–9. **(Dut)**

[Treatment of acute bronchiolitis in infants. Role of bronchodilators and steroids] Labbé A. **Arch Pediatr** 1996 Apr;3(4):383–9 (76 ref.) (Eng. Abstr.) **(Fre)**

[Bronchodilator drugs] Tschopp JM. **Rev Med Suisse Romande** 1996 May;116(5):325–7 (27 ref.) **(Fre)**

[Beta 2-sympathomimetic drugs] Criée CP, et al. **Internist (Berl)** 1995 Sep;36(9):918–23 (28 ref.) **(Ger)**

[Recent view on drug therapy of bronchial asthma] Mano K. **Nippon Naika Gakkai Zasshi** 1996 Mar 10;85(3):417–22 (9 ref.) **(Jpn)**

BRONCHOGRAPHY

The bronchi: an imaging perspective. Shepard JA. **J Thorac Imaging** 1995 Winter;10(4):236–54 (98 ref.)

BRONCHOPULMONARY ASPERGILLOSIS see **ASPERGILLOSIS, ALLERGIC BRONCHOPULMONARY**

BRONCHOPULMONARY DYSPLASIA

COMPLICATIONS

Infants with bronchopulmonary dysplasia: a developmental perspective. Mitchell SH. **J Pediatr Nurs** 1996 Jun; 11(3):145–51 (18 ref.)

ETIOLOGY

The role of inflammation in the pathogenesis of bronchopulmonary dysplasia. Pierce MR, et al. **Pediatr Pulmonol** 1995 Jun;19(6):371–8 (89 ref.)

[Bronchopulmonary dysplasia] Clément A. **Rev Mal Respir** 1996 Jul;13(3):243–9 (42 ref.) (Eng. Abstr.) **(Fre)**

[Pathogenesis of bronchopulmonary dysplasia] Groneck P, et al. **Z Geburtshilfe Neonatol** 1995 Sep–Oct;199(5):181–9 (68 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Tryptase immunoreactive mast cell hyperplasia in bronchopulmonary dysplasia. Lyle RE, et al. **Pediatr Pulmonol** 1995 Jun;19(6):336–43 (39 ref.)

NURSING

Infants with bronchopulmonary dysplasia: a developmental perspective. Mitchell SH. **J Pediatr Nurs** 1996 Jun; 11(3):145–51 (18 ref.)

PREVENTION & CONTROL

Appropriate fluid regimens to prevent bronchopulmonary dysplasia. Tammela OK. **Eur J Pediatr** 1995;154(8 Suppl 3):S15–8 (18 ref.)

BRONCHOPULMONARY SEQUESTRATION

COMPLICATIONS

[Intralobar pulmonary sequestration as the cause of neonatal respiratory distress] Serrano A, et al. **Arch Bronconeumol** 1996 Jun–Jul;32(6):310–2 (18 ref.) (Eng. Abstr.) **(Spa)**

SURGERY

[A case report of pulmonary sequestration (Pryce I) associated with incomplete lobulation of the left lung] Ichihashi T, et al. **Kyobu Geka** 1995 Nov;48(12):1057–60 (12 ref.) (Eng. Abstr.) **(Jpn)**

[Pryce type I intralobar pulmonary sequestration] Yuasa K, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Jan; 34(1):111–6 (15 ref.) (Eng. Abstr.) **(Jpn)**

ULTRASONOGRAPHY

Extra-lobar pulmonary sequestration with prenatal diagnosis. A report of 5 cases and review of the literature. Plattner V, et al. **Eur J Pediatr Surg** 1995 Aug;5(4):235–7 (16 ref.)

BRONCHOSCOPY

see related
CATHETERIZATION, PERIPHERAL

Use of cardiopulmonary bypass during bronchoscopy following sand aspiration. A case report. Mellema JD, et al. **Chest** 1995 Oct;108(4):1176–7 (6 ref.)

Flexible bronchoscopy. Borchers SD, et al. **Chest Surg Clin N Am** 1996 May;6(2):169–92 (71 ref.)

Laser bronchoscopy. Colt HG. **Chest Surg Clin N Am** 1996 May;6(2):277–91 (60 ref.)

The staging of lung cancer by bronchoscopic transbronchial needle aspiration. Harrow EM, et al. **Chest Surg Clin N Am** 1996 May;6(2):223–35 (35 ref.)

Airway foreign bodies. Kelly SM, et al. **Chest Surg Clin N Am** 1996 May;6(2):253–76 (42 ref.)

Bronchoscopic biopsies and bronchoalveolar lavage. Kvale PA. **Chest Surg Clin N Am** 1996 May;6(2):205–22 (73 ref.)

Future diagnostic procedures. Lam S, et al. **Chest Surg Clin N Am** 1996 May;6(2):363–80 (81 ref.)

The use of fiberoptic endoscopy in anesthesia. Lee AC, et al. **Chest Surg Clin N Am** 1996 May;6(2):329–47 (45 ref.)

Rigid bronchoscopy. Miller JI Jr. **Chest Surg Clin N Am** 1996 May;6(2):161–7 (4 ref.)

The documentation of thoracic endoscopy. Prakash UB, et al. **Chest Surg Clin N Am** 1996 May;6(2):193–203 (27 ref.)

Bronchoscopy in the intensive care unit. Shennib H, et al. **Chest Surg Clin N Am** 1996 May;6(2):349–61 (48 ref.)

Endoscopic brachytherapy. Spratling L, et al. **Chest Surg Clin N Am** 1996 May;6(2):293–304 (17 ref.)

Pediatric bronchoscopy. Wood RE. **Chest Surg Clin N Am** 1996 May;6(2):237–51 (32 ref.)

Rigid bronchoscopy. The forgotten art. Helmers RA, et al. **Clin Chest Med** 1995 Sep;16(3):393–9 (24 ref.)

Pediatric fiberoptic bronchoscopy. Nussbaum E. **Clin Pediatr (Phila)** 1995 Aug;34(8):430–5 (53 ref.)

Use of fiberoptic bronchoscopy in asthmatic children with lung collapse. Barbato A, et al. **Pediatr Med Chir** 1995 May–Jun;17(3):253–5 (9 ref.)

Airways and lung: correlation of CT with fiberoptic bronchoscopy. Naidich DP, et al. **Radiology** 1995 Oct; 197(1):1–12 (98 ref.)

[Endobronchial lipoma: endoscopic resection or surgical excision? Report of a case and review of the literature] Destito C, et al. **G Chir** 1995 Oct;16(10):445–7 (19 ref.) (Eng. Abstr.) **(Ita)**

METHODS

Laser bronchoscopy. Ramser ER, et al. **Clin Chest Med** 1995 Sep;16(3):415–26 (66 ref.)

Endoscopic management of acute respiratory failure related to tracheobronchial malignancies. Ninane V. **Support Care Cancer** 1995 Nov;3(6):418–21 (40 ref.)

BRONCHOSPASM see **BRONCHIAL SPASM**

BRONCHOSPASM, EXERCISE-INDUCED see **ASTHMA, EXERCISE-INDUCED**

BROWN FAT

DRUG EFFECTS

Signal transduction in brown adipose tissue recruitment: noradrenaline and beyond. Cannon B, et al. **Int J Obes Relat Metab Disord** 1996 Mar;20 Suppl 3:S36–42 (37 ref.)

METABOLISM

C/EBP alpha: a critical regulator of genes governing integrative metabolic processes. Darlington GJ, et al.

BROWN FAT

Curr Opin Genet Dev 1995 Oct;5(5):565–70 (37 ref.)
Signal transduction in brown adipose tissue recruitment: noradrenaline and beyond. Cannon B, et al. **Int J Obes Relat Metab Disord** 1996 Mar;20 Suppl 3:S36–42 (37 ref.)
Fuel selection in brown adipose tissue. Trayhurn P. **Proc Nutr Soc** 1995 Mar;54(1):39–47 (46 ref.)

PHYSIOLOGY

Norepinephrine as a morphogen?: its unique interaction with brown adipose tissue. Nedergaard J, et al. **Int J Dev Biol** 1995 Oct;39(5):827–37 (55 ref.)
A regulatory pathway of thermogenesis in brown fat through retinoic acid. Wolf G. **Nutr Rev** 1995 Aug;53(8):230–1 (4 ref.)
Does thermoregulatory feeding occur in newborn infants? A novel view of the role of brown adipose tissue thermogenesis in control of food intake. Himms-Hagen J. **Obes Res** 1995 Jul;3(4):361–9 (54 ref.)

BROXURIDINE see **BROMODEOXYURIDINE**

BRUCELLA ABORTUS

Contradictory roles for antibody and complement in the interaction of Brucella abortus with its host. Hoffmann EM, et al. **Crit Rev Microbiol** 1995;21(3):153–63 (50 ref.)

CHEMISTRY

Heterogeneity of Brucella abortus lipopolysaccharides. Freer E, et al. **Res Microbiol** 1995 Sep;146(7):569–78 (45 ref.)

CLASSIFICATION

Brucellosis in free-ranging bison (Bison bison) in Yellowstone, Grand Teton, and Wood Buffalo National Parks: a review [letter] Meyer ME, et al. **J Wildl Dis** 1995 Oct;31(4):579–98 (110 ref.)

BRUCELLA MELITENSIS

[Brucella pancarditis with fatal outcome] Chevalier P, et al. **Presse Med** 1996 Apr 13;25(13):628–30 (12 ref.) (Eng. Abstr.) **(Fre)**

BRUCELLOSIS

[Brucella pancarditis with fatal outcome] Chevalier P, et al. **Presse Med** 1996 Apr 13;25(13):628–30 (12 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

[Cerebrovascular manifestations of infectious diseases] Martínez Vázquez F, et al. **Rev Neurol** 1995;23 Suppl 1:S11–21 (88 ref.) **(Spa)**

DIAGNOSIS

Spinal epidural abscess caused by Brucella: case report. Paz JF, et al. **J Neurosurg Sci** 1994 Dec;38(4):245–9 (22 ref.)

EPIDEMIOLOGY

Brucellosis: current epidemiology, diagnosis, and management. Young EJ. **Curr Clin Top Infect Dis** 1995; 15:115–28 (92 ref.)

ETIOLOGY

An overview of human brucellosis. Young EJ. **Clin Infect Dis** 1995 Aug;21(2):283–9; quiz 290 (44 ref.)

IMMUNOLOGY

Contradictory roles for antibody and complement in the interaction of Brucella abortus with its host. Hoffmann EM, et al. **Crit Rev Microbiol** 1995;21(3):153–63 (50 ref.)

VETERINARY

Brucellosis in free-ranging bison (Bison bison) in Yellowstone, Grand Teton, and Wood Buffalo National Parks: a review [letter] Meyer ME, et al. **J Wildl Dis** 1995 Oct;31(4):579–98 (110 ref.)

BRUNNER'S GLANDS

[Adenoma of Brunner's gland: a rare cause of duodenal obstruction] Rey P, et al. **J Chir (Paris)** 1996 Jun; 133(4):162–6 (41 ref.) (Eng. Abstr.) **(Fre)**

BRUSH BORDER see **MICROVILLI**

BUBONIC PLAGUE see **PLAGUE**

BUCCA see **CHEEK**

BUCCAL MUCOSA see **MOUTH MUCOSA**

BUCHU RESIN see **DIOSMIN**

BUDD-CHIARI SYNDROME see **HEPATIC VEIN THROMBOSIS**

BUDGERIGAR FANCIER'S LUNG see **BIRD FANCIER'S LUNG**

BUDGETARY CONTROL see **BUDGETS**

BUDGETS

The budget process in schools of nursing: a primer for the novice administrator. Starck PL, et al. **J Prof Nurs** 1996 Mar-Apr;12(2):69–75 (7 ref.)

LEGISLATION & JURISPRUDENCE

National health expenditure limits: the case for a global budget process. Bishop CE, et al. **Milbank Q** 1996; 74(3):361–76 (17 ref.)

STATISTICS & NUMERICAL DATA

Entitlements and the federal budget: facts, folklore, and future. Gist JR. **Milbank Q** 1996;74(3):327–59 (42 ref.)

BUDR see **BROMODEOXYURIDINE**

BUERGER'S DISEASE see **THROMBOANGIITIS OBLITERANS**

BUFFALO, AMERICAN see **BISON**

BUFFALOES

Recent advances in the understanding of Jembrana disease. Wilcox GE, et al. **Vet Microbiol** 1995 Sep;46(1–3):249–55 (23 ref.)

BUFO see **BUFONIDAE**

BUFONIDAE

PARASITOLOGY

Parasitic disease in amphibians: control by the regulation of worm burdens. Tinsley RC. **Parasitology** 1995;111 Suppl:S153–78 (62 ref.)

BUILDING CODES

[Prevention during building construction against electromagnetic fields caused by high voltage electric lines--principles and risk evaluation] Boikat U, et al. **Gesundheitswesen** 1996 Mar;58(3):147–53 (50 ref.) (Eng. Abstr.) **(Ger)**

BULBAR PALSY see **PARALYSIS, BULBAR**

BULIMIA

Anorexia nervosa and bulimia nervosa. When the pursuit of bodily 'perfection' becomes a killer. Zerbe KJ. **Postgrad Med** 1996 Jan;99(1):161–4, 167–9 (21 ref.)
[Bulimia nervosa and obesity] Kuboki T. **Nippon Rinsho** 1995 Jun;53 Suppl:561–6 (17 ref.) **(Jpn)**
[Bulimia and anorexia nervosa] Sakuramoto M, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):345–7 (18 ref.) **(Jpn)**

COMPLICATIONS

Eating disorders: 2. Bulimia nervosa. Mehler PS. **Hosp Pract (Off Ed)** 1996 Feb 15;31(2):107–14, 120, 123, passim (6 ref.)
Anorexia and bulimia nervosa (the eating disorders): conditions of interest to the dental practitioner. Robb ND, et al. **J Dent** 1996 Jan-Mar;24(1–2):7–16 (77 ref.)
Eating disorder and obsessive-compulsive disorder: neurochemical and phenomenological commonalities. Jarry JL, et al. **J Psychiatry Neurosci** 1996 Jan;21(1):36–48 (125 ref.)
Oral manifestations of bulimia nervosa. Zachariasen RD. **Women Health** 1995;22(4):67–76 (39 ref.)

DIAGNOSIS

Bulimia: implications for the practising dentist. Burke FJ, et al. **Br Dent J** 1996 Jun 8;180(11):421–6 (44 ref.)

DRUG THERAPY

[Pharmacologic treatment of bulimia] Corcos M, et al. **Encephale** 1996 Mar-Apr;22(2):133–42 (37 ref.) (Eng. Abstr.) **(Fre)**

EPIDEMIOLOGY

Eating disturbances among American minority groups: a review. Crago M, et al. **Int J Eat Disord** 1996 Apr; 19(3):239–48 (59 ref.)
[Comorbidity of bipolar and eating disorders. Epidemiologic and therapeutic aspects] Mury M, et al. **Encephale** 1995 Sep-Oct;21(5):545–53 (44 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Bone metabolism and osteopenia in eating disorders. Carmichael KA, et al. **Medicine (Baltimore)** 1995 Sep; 74(5):254–67 (132 ref.)

PHYSIOPATHOLOGY

[Neurobiological and psychodynamic correlations in obsessive-compulsive disorders and bulimia nervosa] Csef H. **Z Klin Psychol Psychopathol Psychother** 1996; 44(3):267–79 (70 ref.) (Eng. Abstr.) **(Ger)**

PSYCHOLOGY

Eating disorder research in the past decade. Halmi KA. **Ann N Y Acad Sci** 1996 Jun 18;789:67–77 (56 ref.)
Bone metabolism and osteopenia in eating disorders. Carmichael KA, et al. **Medicine (Baltimore)** 1995 Sep; 74(5):254–67 (132 ref.)

THERAPY

Interrupting the binge-purge cycle in bulimia: the use of planned binges. Steel ZP, et al. **Int J Eat Disord** 1995 Nov; 18(3):199–208 (46 ref.)

BULLA see **BLISTER**

BULLOUS SKIN DISEASES see **SKIN DISEASES, VESICULOBULLOUS**

BUMETANIDE

Loop diuretics: comparison of torsemide, furosemide, and bumetanide. Chen BP. **Conn Med** 1996 Jun;60(6):343–5 (6 ref.)

BUN see **BLOOD UREA NITROGEN**

BUNDLE-BRANCH BLOCK

COMPLICATIONS

Bundle branch reentry ventricular tachycardia. Tchou P, et al. **Pacing Clin Electrophysiol** 1995 Jul;18(7):1427–37 (22 ref.)

DIAGNOSIS

Right bundle branch block, persistent ST-segment elevation in V1-V3 and sudden cardiac death: always a distinct syndrome? D'Onofrio A, et al. **G Ital Cardiol** 1995 Sep; 25(9):1171–5 (12 ref.)

BUNDLE OF HIS

SURGERY

[Survival after His bundle ablation for supraventricular arrhythmia. A 10-years experience in 317 consecutive patients] Poquet F, et al. **Arch Mal Coeur Vaiss** 1995 Nov; 88(11):1593–600 (31 ref.) (Eng. Abstr.) **(Fre)**

BUNDLE OF KENT see **HEART CONDUCTION SYSTEM**

BUNGARUS

GENETICS

Biological significance of minisatellites. Singh L. **Electrophoresis** 1995 Sep;16(9):1586–95 (76 ref.)

BUNION see **HALLUX VALGUS**

BUNOSTOMIASIS see **HOOKWORM INFECTIONS**

BUNYAVIRIDAE

PATHOGENICITY

Lessons learned from the hantaviruses and other hemorrhagic fever viruses. Butler JC, et al. **Am J Med Sci** 1996 Jan; 311(1):55–9 (39 ref.)

BUNYAVIRIDAE INFECTIONS

EPIDEMIOLOGY

Lessons learned from the hantaviruses and other hemorrhagic fever viruses. Butler JC, et al. **Am J Med Sci** 1996 Jan; 311(1):55–9 (39 ref.)

BUNYAVIRUS

ISOLATION & PURIFICATION

Sandfly fever viruses in Italy. Nicoletti L, et al. **Arch Virol Suppl** 1996;11:41–7 (42 ref.)

BUNYAVIRUS INFECTIONS see **BUNYAVIRIDAE INFECTIONS**

BUPHTHALMOS see **HYDROPHTHALMOS**

BUPIVACAINE

ADMINISTRATION & DOSAGE

Evaluation of intrapleural analgesia in the management of blunt traumatic chest wall pain: a clinical trial. Short K,

et al. **Am Surg** 1996 Jun;62(6):488–93 (50 ref.)

BUPRENORPHINE

THERAPEUTIC USE

Buprenorphine as a pharmacotherapy for cocaine abuse: a review of the evidence. Compton PA, et al. **J Addict Dis** 1995;14(3):97–114 (56 ref.)

BURDEN OF ILLNESS see **COST OF ILLNESS**

BURKHOLDERIA CEPACIA

The environmental risk factors associated with medical and dental equipment in the transmission of Burkholderia (Pseudomonas) cepacia in cystic fibrosis patients. Pankhurst CL, et al. **J Hosp Infect** 1996 Apr;32(4):249–55 (32 ref.)

DRUG EFFECTS

The emergence of epidemic, multiple-antibiotic-resistant Stenotrophomonas (Xanthomonas) maltophilia and Burkholderia (Pseudomonas) cepacia. Spencer RC. **J Hosp Infect** 1995 Jun;30 Suppl:453–64 (105 ref.)

ISOLATION & PURIFICATION

Burkholderia cepacia sepsis in neonates. Kahyaoglu O, et al. **Pediatr Infect Dis J** 1995 Sep;14(9):815–6 (9 ref.)

[Cystic fibrosis and Burkholderia (formerly Pseudomonas) cepacia: an increasing clinical and psychosocial problem] Horrevorts AM, et al. **Ned Tijdschr Geneeskd** 1995 Nov 18;139(46):2343–6 (31 ref.) **(Dut)**

BURKHOLDERIA INFECTIONS

IMMUNOLOGY

Burkholderia cepacia sepsis in neonates. Kahyaoglu O, et al. **Pediatr Infect Dis J** 1995 Sep;14(9):815–6 (9 ref.)

MICROBIOLOGY

The emergence of epidemic, multiple-antibiotic-resistant Stenotrophomonas (Xanthomonas) maltophilia and Burkholderia (Pseudomonas) cepacia. Spencer RC. **J Hosp Infect** 1995 Jun;30 Suppl:453–64 (105 ref.)

[Cystic fibrosis and Burkholderia (formerly Pseudomonas) cepacia: an increasing clinical and psychosocial problem] Horrevorts AM, et al. **Ned Tijdschr Geneeskd** 1995 Nov 18;139(46):2343–6 (31 ref.) **(Dut)**

TRANSMISSION

The environmental risk factors associated with medical and dental equipment in the transmission of Burkholderia (Pseudomonas) cepacia in cystic fibrosis patients. Pankhurst CL, et al. **J Hosp Infect** 1996 Apr;32(4):249–55 (32 ref.)

BURKITT HERPESVIRUS see **HERPESVIRUS 4, HUMAN**

BURKITT'S LYMPHOMA

VIROLOGY

Viruses in human tumors--reminiscences and perspectives. zur Hausen H. **Adv Cancer Res** 1996;68:1–22 (119 ref.)

BURKITT'S LYMPHOMA VIRUS see **HERPESVIRUS 4, HUMAN**

BURKITT'S TUMOR see **BURKITT'S LYMPHOMA**

BURN CENTERS see **BURN UNITS**

BURN UNITS

STANDARDS

Quality assurance in burn patient care: the James Laing Memorial Essay, 1994. Wood FM. **Burns** 1995 Dec; 21(8):563–8 (19 ref.)

BURNING MOUTH SYNDROME

Burning mouth syndrome. Lamey PJ. **Dermatol Clin** 1996 Apr;14(2):339–54 (175 ref.)

The burning mouth syndrome remains an enigma [editorial] Zakrzewska JM. **Pain** 1995 Sep;62(3):253–7 (46 ref.)

ETIOLOGY

The burning mouth syndrome. Huang W, et al. **J Am Acad Dermatol** 1996 Jan;34(1):91–8 (48 ref.)

BURNOUT, PROFESSIONAL

[Burnout among rehabilitation professionals] Ohry A, et al. **Harefuah** 1996 Jan 1;130(1):40–1 (5 ref.) **(Heb)**

DIAGNOSIS

[Burn-out syndrome] Klieser E, et al. **Med Monatsschr Pharm** 1996 Jan;19(1):17–20 (6 ref.) **(Ger)**

ETIOLOGY

Burnout. Why do we blame the nurse? Cullen A. **Am J Nurs** 1995 Nov;95(11):22–7; quiz 28 (11 ref.)

PREVENTION & CONTROL

Perinatally transmitted HIV infection. Supporting the helpers. Burr CK. **Nurs Clin North Am** 1996 Mar; 31(1):243–51 (21 ref.)

PSYCHOLOGY

Teacher stress research: problems and progress. Pithers RT. **Br J Educ Psychol** 1995 Dec;65 (Pt 4):387–92 (21 ref.)

BURNS

Factors relating to return to work after burn injury. Wrigley M, et al. **J Burn Care Rehabil** 1995 Jul-Aug;16(4):445–50; discussion 444 (19 ref.)

BLOOD

Alterations in cell signaling and related effector functions in T lymphocytes in burn/trauma/septic injuries [editorial] Sayeed MM. **Shock** 1996 Mar;5(3):157–66 (111 ref.)

COMPLICATIONS

Kaposi's varicelliform eruption in a patient with healing second degree burns. Bartralot R, et al. **Clin Exp Dermatol** 1996 Mar;21(2):127–30 (0 ref.)

Fourth-degree burn induced thrombosis of the femoral artery and vein. De Santis F, et al. **Eur J Vasc Endovasc Surg** 1996 Apr;11(3):378–80 (9 ref.)

Burn-induced bullous pemphigoid [letter; comment] Vassileva S, et al. **Int J Dermatol** 1995 Jul;34(7):516–7 (10 ref.) Comment on: Int J Dermatol 1994 Jan;33(1):55–6.

The complexities of managing severe burns with associated trauma. Dougherty W, et al. **Surg Clin North Am** 1996 Aug;76(4):923–58 (97 ref.)

[Pathogenesis of heat inhalation injury in burn patients] Kurbanov SI, et al. **Klin Med (Mosk)** 1996;74(1):9–11 (90 ref.) **(Rus)**

ETIOLOGY

Ignition potential of the 585-nm pulsed-dye laser. Review of the literature and safety recommendations. Fretzin S, et al. **Dermatol Surg** 1996 Aug;22(8):699–702 (13 ref.)

Acute thermal injury of the esophagus. Javors BR, et al. **Dysphagia** 1996 Winter;11(1):72–4 (6 ref.)

Intraoperative fire with electrocautery. Brechtelsbauer PB, et al. **Otolaryngol Head Neck Surg** 1996 Feb;114(2):328–31 (17 ref.)

IMMUNOLOGY

Burning the largest immune organ. Allgöwer M, et al. **Burns** 1995;21 Suppl 1:S7–47 (222 ref.)

METABOLISM

Clinical pharmacokinetics in patients with burns. Jaehde U, et al. **Clin Pharmacokinet** 1995 Jul;29(1):15–28 (75 ref.)

[Pharmacokinetics of antibiotics in burn patients] Lesne-Hulin A, et al. **Therapie** 1995 Nov-Dec;50(6):575–86 (74 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Multiple malignant melanoma and squamous-cell carcinoma in a burn scar. Ikeda I, et al. **Dermatology** 1995; 191(4):328–32 (20 ref.)

PHYSIOPATHOLOGY

[Hemodynamic profile and serum cytokines in crush syndrome. Analogy with severe burns] Gueugniaud PY, et al. **Presse Med** 1996 Mar 16;25(9):449–51 (16 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

Childhood injury: significance and prevention strategies. Crawley T. **J Pediatr Nurs** 1996 Aug;11(4):225–32 (33 ref.)

PSYCHOLOGY

Psychological and social aspects of burns. Partridge J, et al. **Burns** 1995 Sep;21(6):453–7 (22 ref.)

REHABILITATION

Rehabilitation of the burned hand: questionnaire results. Torres-Gray D, et al. **J Burn Care Rehabil** 1996 Mar-Apr; 17(2):161–8 (38 ref.)

SURGERY

What's new in trauma and burns. Flint L. **J Am Coll Surg** 1996 Feb;182(2):177–84 (68 ref.)

Burns and wound management. Ahrenholz DH, et al. **Otolaryngol Clin North Am** 1995 Oct;28(5):1039–55 (45 ref.)

[Progresses in burn surgery in China, 1995] Xiao G. **Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):742–3 (0 ref.) **(Chi)**

THERAPY

Hypnosis in the treatment of patients with severe burns. Patterson DR, et al. **Am J Clin Hypn** 1996 Jan;38(3):200–12; discussion 213 (50 ref.)

Current treatment of severely burned patients. Nguyen TT, et al. **Ann Surg** 1996 Jan;223(1):14–25 (122 ref.)

Quality assurance in burn patient care: the James Laing Memorial Essay, 1994. Wood FM. **Burns** 1995 Dec; 21(8):563–8 (19 ref.)

Nutritional support of the burn patient. Deitch EA. **Crit Care Clin** 1995 Jul;11(3):735–50 (54 ref.)

Survival and therapy of burn patients at the threshold of the twenty-first century: a review. Periti P, et al. **J Chemother** 1995 Dec;7(6):475–502 (163 ref.)

The complexities of managing severe burns with associated trauma. Dougherty W, et al. **Surg Clin North Am** 1996 Aug;76(4):923–58 (97 ref.)

[Treatment of burns in infants] Foyatier JL, et al. **Arch Pediatr** 1995 Oct;2(10):1000–6 (8 ref.) (Eng. Abstr.) **(Fre)**

[Main principles of the treatment of patients during acute period of burns] Gerasimova LI. **Anesteziol Reanimatol** 1995 Jul-Aug;(4):19–24 (24 ref.) **(Rus)**

[Use of cultured fibroblasts for restoration of skin in severe burns] Sarkisov DS, et al. **Biull Eksp Biol Med** 1995 Jun; 119(6):566–70 (28 ref.) **(Rus)**

BURNS, CHEMICAL

SURGERY

Corrosive injuries of the oesophagus and stomach: experience in management at a regional paediatric centre. Stiff G, et al. **Ann R Coll Surg Engl** 1996 Mar;78(2):119–23 (68 ref.)

THERAPY

Hydrofluoric acid burns: a review. Kirkpatrick JJ, et al. **Burns** 1995 Nov;21(7):483–93 (158 ref.)

BURNS, ELECTRIC

ETIOLOGY

[Fatal burns from an electric mattress] Sánchez-Hanke M, et al. **An Esp Pediatr** 1996 Jun;44(6):591–2 (10 ref.) **(Spa)**

PATHOLOGY

Acute electrical burns. ten Duis HJ. **Semin Neurol** 1995 Dec; 15(4):381–6 (29 ref.)

THERAPY

Electrical burns of the mouth: still searching for an answer. Thomas SS. **Burns** 1996 Mar;22(2):137–40 (15 ref.)

BURNS, INHALATION

PHYSIOPATHOLOGY

[Pathogenesis of heat inhalation injury in burn patients] Kurbanov SI, et al. **Klin Med (Mosk)** 1996;74(1):9–11 (90 ref.) **(Rus)**

BURSA-DEPENDENT LYMPHOCYTES see **B-LYMPHOCYTES**

BURSINE see **CHOLINE**

BURSITIS

Trochanteric bursitis (greater trochanter pain syndrome). Shbeeb MI, et al. **Mayo Clin Proc** 1996 Jun;71(6):565–9 (26 ref.)

COMPLICATIONS

Pterygoid hamulus bursitis: one cause of craniofacial pain. Shankland WE 2nd. **J Prosthet Dent** 1996 Feb;75(2):205–10 (26 ref.)

DIAGNOSIS

Lower extremity bursitis [published erratum appears in Am Fam Physician 1996 Aug;54(2):468] Butcher JD, et al. **Am Fam Physician** 1996 May 15;53(7):2317–24 (13 ref.)

ETIOLOGY

Anaerobic septic bursitis: case report and review. Fischer PA, et al. **Clin Infect Dis** 1996 May;22(5):879 (3 ref.)

THERAPY

Lower extremity bursitis [published erratum appears in Am Fam Physician 1996 Aug;54(2):468] Butcher JD, et al. **Am Fam Physician** 1996 May 15;53(7):2317–24 (13 ref.)

ULTRASONOGRAPHY

[Ultrasound examination of the shoulder joint] Lick-Schiffer W. **Wien Med Wochenschr** 1996;146(6–7):121–3 (11 ref.) (Eng. Abstr.) **(Ger)**

BURST-FORMING UNITS, ERYTHROID see

ERYTHROID PROGENITOR CELLS

BURST-PROMOTING FACTOR, ERYTHROCYTE see **INTERLEUKIN-3**

BUSHMASTER see **VIPERIDAE**

BUSINESS see **COMMERCE**

BUSPIRONE

THERAPEUTIC USE

Azapirones: an alternative to benzodiazepines for anxiety. Cadieux RJ. **Am Fam Physician** 1996 May 15;53(7):2349–53 (23 ref.)

Augmentation with buspirone: a review. Harvey KV, et al. **Ann Clin Psychiatry** 1995 Sep;7(3):143–7 (32 ref.)

BUSULFAN

ADVERSE EFFECTS

Philadelphia chromosome-negative cells with trisomy 8 after busulfan and interferon treatment of Ph1-positive chronic myelogenous leukemia. Izumi T, et al. **Int J Hematol** 1996 Jul;64(1):73–7 (17 ref.)

[Extramedullary toxicity in bone marrow transplantation using busulfan and cyclophosphamide conditioning] Pascual MJ, et al. **Sangre (Barc)** 1995 Jun;40(3):191–7 (31 ref.) (Eng. Abstr.) **(Spa)**

THERAPEUTIC USE

Pharmacology of bone marrow transplantation conditioning regimens. Jones RJ, et al. **Ann N Y Acad Sci** 1995 Dec 29;770:237–41 (15 ref.)

Busulfan. O'Marcaigh AS, et al. **J Pediatr Oncol Nurs** 1996 Jul;13(3):150–2 (12 ref.)

BUSULPHAN see **BUSULFAN**

BUTADIENES

METABOLISM

Isoprene synthesis by plants and animals. Sharkey TD. **Endeavour** 1996;20(2):74–8 (45 ref.)

TOXICITY

Biotransformation and renal processing of nephrotoxic agents. Dekant W. **Arch Toxicol Suppl** 1996;18:163–72 (63 ref.)

2,3-BUTANEDIONE see **DIACETYL**

BUTANOIC ACIDS see **BUTYRIC ACIDS**

1,4-BUTANOLIDE see **4-BUTYROLACTONE**

BUTANOLS see **ALCOHOLS, BUTYL**

BUTANONES

[Nabumetone] Simón M, et al. **Rev Med Univ Navarra** 1995 Jul-Sep;39(3):164–72 (51 ref.) **(Spa)**

BUTORPHANOL

PHARMACOLOGY

Transnasal butorphanol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute pain management. Gillis JC, et al. **Drugs** 1995 Jul; 50(1):157–75 (47 ref.)

BUTTOCKS

BLOOD SUPPLY

A pulsatile gluteal mass due to sciatic artery aneurysm. Chiheoun JO, et al. **Aust N Z J Surg** 1995 Dec; 65(12):907–10 (18 ref.)

BUTYLCYANOACRYLATE see **ENBUCRILATE**

BUTYLHYDROXYBUTYLNITROSAMINE

TOXICITY

[Effect of BBN on the small intestine transplanted to the urinary bladder of rat] Wu B, et al. **Hinyokika Kiyo** 1995 Sep;41(9):665–8 (16 ref.) (Eng. Abstr.) **(Jpn)**

BUTYRATES

METABOLISM

[Butyrate and hemorrhagic rectocolitis] Flourié B, et al. **Gastroenterol Clin Biol** 1995 Jun-Jul;19(6-7):619–24 (51 ref.) **(Fre)**

BUTYRIC ACIDS

Butyrate and the colonocyte. Implications for neoplasia. Velázquez OC, et al. **Dig Dis Sci** 1996 Apr;41(4):727–39 (117 ref.)

ADVERSE EFFECTS

Butyrate and colorectal cancer in animals and in humans (mini-symposium: butyrate and colorectal cancer). Clausen MR. **Eur J Cancer Prev** 1995 Dec;4(6):483–90 (104 ref.)

PHARMACOLOGY

The short-chain fatty acid butyrate induces apoptosis in colorectal tumour cell lines. Hague A, et al. **Eur J Cancer Prev** 1995 Oct;4(5):359–64 (36 ref.)

Butyrate and markers of neoplastic change in the colon. Johnson IT. **Eur J Cancer Prev** 1995 Oct;4(5):365–71 (64 ref.)

Butyrate and colonic cytokinetics: differences between in vitro and in vivo studies. Lupton JR. **Eur J Cancer Prev** 1995 Oct;4(5):373–8 (67 ref.)

THERAPEUTIC USE

Butyrate and phenylacetate as differentiating agents: practical problems and opportunities. Newmark HL, et al. **J Cell Biochem Suppl** 1995;22:247–53 (45 ref.)

4-BUTYROLACTONE

ANALOGS & DERIVATIVES

Autoregulators. Horinouchi S, et al. **Biotechnology** 1995; 28:103–19 (47 ref.)

BUTYROPHENONE ANTIPSYCHOTIC AGENTS see **ANTIPSYCHOTIC AGENTS, BUTYROPHENONE**

BUTYROPHENONE TRANQUILIZERS see **ANTIPSYCHOTIC AGENTS, BUTYROPHENONE**

BUTYROPHENONES

see related
ANTIPSYCHOTIC AGENTS, BUTYROPHENONE

PHARMACOLOGY

Ebastine. a review of its pharmacological properties and clinical efficacy in the treatment of allergic disorders. Wiseman LR, et al. **Drugs** 1996 Feb;51(2):260–77 (90 ref.)

THERAPEUTIC USE

Ebastine. a review of its pharmacological properties and clinical efficacy in the treatment of allergic disorders. Wiseman LR, et al. **Drugs** 1996 Feb;51(2):260–77 (90 ref.)

BYPASS, CORONARY ARTERY see **CORONARY ARTERY BYPASS**

BYSSINOSIS

COMPLICATIONS

Relationship of acute obstructive airway change to chronic (fixed) obstruction. Becklake MR. **Thorax** 1995 Sep;50 Suppl 1:S16–21 (57 ref.)

ETIOLOGY

Byssinosis: a review. McL Niven R, et al. **Thorax** 1996 Jun; 51(6):632–7 (69 ref.)

C1 ESTERASE INHIBITORS see **COMPLEMENT 1 INACTIVATORS**

C1 INACTIVATORS see **COMPLEMENT 1 INACTIVATORS**

C3PA CONVERTASE see **PROPERDIN FACTOR D**

C3PASE see **PROPERDIN FACTOR D**

C4 COMPONENT COMPLEMENT PROTEINS see **COMPLEMENT 4**

C-ABL GENES see **GENES, ABL**

C-ABL PROTEINS see **PROTO-ONCOGENE PROTEINS C-ABL**

C-ERBA ALPHA see **RECEPTORS, THYROID HORMONE**

C-ERBA BETA see **RECEPTORS, THYROID HORMONE**

C-ERBA PROTEINS see **RECEPTORS, THYROID HORMONE**

C-ERBB-2 GENES see **GENES, ERBB-2**

C-ERBB-1 PROTEINS see **RECEPTORS, EPIDERMAL GROWTH FACTOR-UROGASTRONE**

C-ERBB-2 PROTEINS see **PROTO-ONCOGENE PROTEINS C-ERBB-2**

C FIBERS see **NERVE FIBERS**

C-FOS-ASSOCIATED PROTEIN P39 see **PROTO-ONCOGENE PROTEINS C-JUN**

C-FOS GENES see **GENES, FOS**

C-FOS PROTEINS see **PROTO-ONCOGENE PROTEINS C-FOS**

C-HA-RAS GENES see **GENES, RAS**

C-HA-RAS P21 see **PROTO-ONCOGENE PROTEIN P21(RAS)**

C-JUN PROTEINS see **PROTO-ONCOGENE PROTEINS C-JUN**

C-KI-RAS GENES see **GENES, RAS**

C-KI-RAS P21 see **PROTO-ONCOGENE PROTEIN P21(RAS)**

C-KIT LIGAND see **STEM CELL FACTOR**

C-KIT PROTEINS see **PROTO-ONCOGENE PROTEINS C-KIT**

C-KIT RECEPTORS see **PROTO-ONCOGENE PROTEINS C-KIT**

C-MYC GENES see **GENES, MYC**

C-MYC PROTEINS see **PROTO-ONCOGENE PROTEINS C-MYC**

C-N-RAS GENES see **GENES, RAS**

C-ONC PROTEINS see **PROTO-ONCOGENE PROTEINS**

C-PEPTIDE

ANALYSIS

[C-peptide (CPR)] Sato Y, et al. **Nippon Rinsho** 1995 Mar; 53 Su Pt 2:619–21 (10 ref.) **(Jpn)**

BLOOD

[Determination of plasma proinsulins, insulin and C-peptide] Chevenne D, et al. **Ann Biol Clin (Paris)** 1995;53(1-2):3–9 (59 ref.) (Eng. Abstr.) **(Fre)**

C-REACTIVE PROTEIN

ANALYSIS

[The clinical use of CRP measurements] Rintala E, et al. **Duodecim** 1995;111(2):173–8 (38 ref.) **(Fin)**

[Usefulness of the determination of C reactive protein and other acute phase proteins in rheumatoid arthritis] Galeazzi M, et al. **Recenti Prog Med** 1995 Nov;86(11):456–62 (40 ref.) (Eng. Abstr.) **(Ita)**

[C-reactive protein (CRP)] Ohtani H. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:233–6 (8 ref.) **(Jpn)**

CHEMISTRY

[C-reactive protein: structure, properties, and methods of isolation] Zotova EG, et al. **Bioorg Khim** 1995 Oct; 21(10):739–51 (108 ref.) (Eng. Abstr.) **(Rus)**

C-SRC GENES see **GENES, SRC**

C-SRC PROTEIN PP60 see **PROTO-ONCOGENE PROTEIN PP60(C-SRC)**

CA-15-3 ANTIGEN

The epithelial mucin, MUC1, of milk, mammary gland and other tissues. Patton S, et al. **Biochim Biophys Acta** 1995 Dec 20;1241(3):407–23 (127 ref.)

ANALYSIS

[Primary malignant tumor of the breast. Monitoring after treatment (editorial)] Guastalla JP, et al. **Presse Med** 1995 Oct 21;24(31):1415–7 (22 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

The polymorphic epithelial mucin: potential as an immunogen for a cancer vaccine. Graham RA, et al. **Cancer Immunol Immunother** 1996 Feb;42(2):71–80 (61 ref.)

MUC-1 epithelial tumor mucin-based immunity and cancer vaccines. Finn OJ, et al. **Immunol Rev** 1995 Jun;145:61–89 (112 ref.)

METABOLISM

MUC1, endometrium and embryo implantation. Aplin JD, et al. **Biochem Soc Trans** 1995 Nov;23(4):826–31 (49 ref.)

CA-19-9 ANTIGEN

BLOOD

Tumor markers in the diagnosis, monitoring and therapy of pancreatic cancer: state of the art. Plebani M, et al. **Int J Biol Markers** 1995 Oct-Dec;10(4):189-99 (95 ref.)
[A case of bronchiolo-alveolar carcinoma with high production of carbohydrate antigen (CA19-9)] Shioji Y, et al. **Nippon Geka Gakkai Zasshi** 1996 Apr;97(4):325-9 (20 ref.) (Eng. Abstr.) **(Jpn)**

CA-125 ANTIGEN

BLOOD

Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection. Berek JS, et al. **Cancer** 1995 Nov 15;76(10 Suppl):2092-6 (25 ref.)
Ovarian cancer screening. van Nagell JR Jr, et al. **Cancer** 1995 Nov 15;76(10 Suppl):2086-91 (27 ref.)
Meigs' syndrome with elevated serum CA 125 levels: two case reports and review of the literature. Timmerman D, et al. **Gynecol Oncol** 1995 Dec;59(3):405-8 (20 ref.)

CA ANTIGENS see **ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE**

CA(2+) MG(2+)-ATPASE

see related
CA(2+)-TRANSPORTING ATPASE

CA(2+)-TRANSPORTING ATPASE

BIOSYNTHESIS

Regulation of expression of cardiac sarcoplasmic reticulum proteins under pathophysiological conditions. Dillmann WH. **Mol Cell Biochem** 1996 Apr 12-26;157(1-2):125-8 (14 ref.)

CHEMISTRY

Structure-function relationships in the Ca(2+)-ATPase of sarcoplasmic reticulum studied by use of the substrate analogue CrATP and site-directed mutagenesis. Comparison with the Na+,K(+)-ATPase. Vilsen B. **Acta Physiol Scand Suppl** 1995;624:1-146 (255 ref.)
Structure-function relationships in the Ca(2+)-ATPase of sarcoplasmic reticulum: facts, speculations and questions for the future. Martonosi AN. **Biochim Biophys Acta** 1996 Jul 18;1275(1-2):111-7 (116 ref.)

GENETICS

Regulation of expression of sodium-calcium exchanger and plasma membrane calcium ATPase by protein kinases, glucocorticoids, and growth factors. Smith JB, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:258-71 (36 ref.)

METABOLISM

Structure-function relationships in the Ca(2+)-ATPase of sarcoplasmic reticulum studied by use of the substrate analogue CrATP and site-directed mutagenesis. Comparison with the Na+,K(+)-ATPase. Vilsen B. **Acta Physiol Scand Suppl** 1995;624:1-146 (255 ref.)
Hormonal regulation of cytosolic calcium levels in the liver. Kraus-Friedmann N. **Braz J Med Biol Res** 1995 Mar; 28(3):275-84 (61 ref.)
Plasma membrane Ca(2+)-pump functional specialization in the brain. Complex of isoform expression and regulation by effectors. Lehotský J. **Mol Chem Neuropathol** 1995 Jun-Aug;25(2-3):175-87 (45 ref.)

PHYSIOLOGY

The plasma membrane calcium pump--a physiological perspective on its regulation. Monteith GR, et al. **Cell Calcium** 1995 Dec;18(6):459-70 (113 ref.)

CABBAGE see **BRASSICA**

CACAJAO see **CEBIDAE**

CACHECTIN see **TUMOR NECROSIS FACTOR**

CACHECTIN RECEPTORS see **RECEPTORS, TUMOR NECROSIS FACTOR**

CACHEXIA

Anorexia, cachexia, and dysphagia: the symptom experience. Grant MM, et al. **Semin Oncol Nurs** 1995 Nov;11(4):266-71 (32 ref.)

DRUG THERAPY

[Synthetic progestational hormones in the treatment of neoplastic cachexia] Freyer G, et al. **Rev Med Interne** 1996; 17(1):79-84 (21 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Pathophysiology and treatment of the AIDS wasting syndrome. Kotler DP, et al. **AIDS Clin Rev** 1995-96; :229-75 (211 ref.)
Anorexia and cachexia in advanced cancer patients. Vigano A, et al. **Cancer Surv** 1994;21:99-115 (76 ref.)

PHYSIOPATHOLOGY

Mechanisms mediating cancer cachexia. Toomey D, et al. **Cancer** 1995 Dec 15;76(12):2418-26 (75 ref.)
Cancer cachexia: pathophysiological mechanisms. Gough DB, et al. **Eur J Surg Oncol** 1996 Apr;22(2):192-6 (63 ref.)
Calories lost--another mediator of cancer cachexia? Nabel GJ, et al. **Nat Med** 1996 Apr;2(4):397-8 (16 ref.)

PREVENTION & CONTROL

The role of total parenteral nutrition in the patient with cancer. Harrison LE, et al. **Curr Probl Surg** 1995 Oct; 32(10):833-917 (225 ref.)

THERAPY

Manaing HIV. Part 5: Treating secondary outcomes. 5.17 HIV, weight loss and wasting syndrome. Kelly MD, et al. **Med J Aust** 1996 May 6;164(9):549-50 (9 ref.)

CACO-2 CELLS

DRUG EFFECTS

The human intestinal epithelial cell line Caco-2; pharmacological and pharmacokinetic applications. Meunier V, et al. **Cell Biol Toxicol** 1995 Aug; 11(3-4):187-94 (58 ref.)

METABOLISM

The human intestinal epithelial cell line Caco-2; pharmacological and pharmacokinetic applications. Meunier V, et al. **Cell Biol Toxicol** 1995 Aug; 11(3-4):187-94 (58 ref.)

CAD-CAM see **COMPUTER-AIDED DESIGN**

CADHERINS

BIOSYNTHESIS

Cadherin expression in the developing vertebrate CNS: from neuromeres to brain nuclei and neural circuits. Redies C. **Exp Cell Res** 1995 Oct;220(2):243-56 (187 ref.)

PHYSIOLOGY

Adherens junctions in the Drosophila embryo: the role of E-cadherin in their establishment and morphogenetic function. Knust E, et al. **Bioessays** 1996 Aug;18(8):609-12 (21 ref.)
E-cadherin and its associated protein catenins, cancer invasion and metastasis. Jiang WG. **Br J Surg** 1996 Apr; 83(4):437-46 (138 ref.)
E-cadherin mediated adhesion system in cancer cells. Shiozaki H, et al. **Cancer** 1996 Apr 15;77(8 Suppl):1605-13 (88 ref.)
Cancer metastasis: negative regulation by an invasion-suppressor complex. Mareel M, et al. **Cancer Detect Prev** 1995;19(5):451-64 (105 ref.)
Adherens junction proteins in tumour progression. Birchmeier W, et al. **Cancer Surv** 1995;24:129-40 (68 ref.)
The body language of cells: the intimate connection between cell adhesion and behavior. Klymkowsky MW, et al. **Cell** 1995 Oct 6;83(1):5-8 (25 ref.)
E-cadherin as an invasion suppressor. Birchmeier W, et al. **Ciba Found Symp** 1995;189:124-36; discussion 136-41, 174-6 (66 ref.)
Morphogenetic roles of classic cadherins. Takeichi M. **Curr Opin Cell Biol** 1995 Oct;7(5):619-27 (72 ref.)
The E-cadherin/catenin complex in invasion and metastasis. Bracke ME, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 1):123-61 (350 ref.)

CADMIUM

ANALYSIS

[Cadmium] Nomiyama H, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:836-8 (16 ref.) **(Jpn)**

METABOLISM

Mobilizers of stored cadmium. Bláha K, et al. **Arch Toxicol Suppl** 1996;18:195-201 (24 ref.)

TOXICITY

Immunotoxicity of heavy metals in relation to Great Lakes. Bernier J, et al. **Environ Health Perspect** 1995 Dec;103 Suppl 9:23-34 (145 ref.)

CADMIUM POISONING

COMPLICATIONS

Cadmium-associated renal disease. Savolainen H. **Ren Fail** 1995 Sep;17(5):483-7 (30 ref.)
[Tubulointerstitial injuries in heavy metal intoxications] Kaizu K, et al. **Nippon Rinsho** 1995 Aug;53(8):2052-6 (19 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Trace metals (lead and cadmium exposure screening). Daher RT. **Anal Chem** 1995 Jun 15;67(12):405R-410R (66 ref.)

CAENORHABDITIS ELEGANS

ACeDB and macace. Eeckman FH, et al. **Methods Cell Biol** 1995;48:583-605 (5 ref.)
The Worm Community System, release 2.0 (WCSr2). Shoman LM, et al. **Methods Cell Biol** 1995;48:607-25 (17 ref.)

CYTOLOGY

Cleavage plane specification in C. elegans: how to divide the spoils. White J, et al. **Cell** 1996 Jan 26;84(2):195-8 (17 ref.)
The genetics of programmed cell death in the nematode Caenorhabditis elegans. Horvitz HR, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:377-85 (56 ref.)
Laser killing of cells in Caenorhabditis elegans. Bargmann CI, et al. **Methods Cell Biol** 1995;48:225-50 (32 ref.)
Basic culture methods. Lewis JA, et al. **Methods Cell Biol** 1995;48:3-29 (35 ref.)
Immunofluorescence microscopy. Miller DM, et al. **Methods Cell Biol** 1995;48:365-94 (75 ref.)
The differentiation and function of the touch receptor neurons of Caenorhabditis elegans. Chalfie M. **Prog Brain Res** 1995;105:179-82 (24 ref.)

DRUG EFFECTS

Genetic pharmacology: interactions between drugs and gene products in Caenorhabditis elegans. Rand JB, et al. **Methods Cell Biol** 1995;48:187-204 (65 ref.)

EMBRYOLOGY

Hierarchical guidance cues in the developing nervous system of C. elegans. Wadsworth WG, et al. **Bioessays** 1996 May; 18(5):355-62 (47 ref.)
Cell fate decisions in the early embryo of the nematode Caenorhabditis elegans. McGhee JD. **Dev Genet** 1995; 17(2):155-66 (74 ref.)
Cell fate specification and differentiation in the nervous system of Caenorhabditis elegans. Sengupta P, et al. **Dev Genet** 1996;18(1):73-80 (65 ref.)
Blastomere culture and analysis. Edgar LG. **Methods Cell Biol** 1995;48:303-21 (15 ref.)
Genetic dissection of developmental pathways. Huang LS, et al. **Methods Cell Biol** 1995;48:97-122 (34 ref.)
Whole-mount in situ hybridization for the detection of RNA in Caenorhabditis elegans embryos. Seydoux G, et al. **Methods Cell Biol** 1995;48:323-37 (19 ref.)

GENETICS

The genetics of programmed cell death in the nematode Caenorhabditis elegans. Horvitz HR, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:377-85 (56 ref.)
Molecular genetics of proto-oncogenes and candidate tumor suppressors in Caenorhabditis elegans. Sternberg PW, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:155-63 (49 ref.)
Fluorescence in situ hybridization for the detection of DNA and RNA. Albertson DG, et al. **Methods Cell Biol** 1995; 48:339-64 (27 ref.)
Mutagenesis. Anderson P. **Methods Cell Biol** 1995;48:31-58 (102 ref.)
The physical map of the Caenorhabditis elegans genome. Coulson A, et al. **Methods Cell Biol** 1995;48:533-50 (22 ref.)
Genetic balancers. Edgley ML, et al. **Methods Cell Biol** 1995; 48:147-84 (62 ref.)
Genomic DNA sequencing methods. Favello A, et al. **Methods Cell Biol** 1995;48:551-69 (9 ref.)
Large-scale complementary DNA sequencing methods. Fulton LL, et al. **Methods Cell Biol** 1995;48:571-82 (10 ref.)
Mosaic analysis. Herman RK. **Methods Cell Biol** 1995; 48:123-46 (61 ref.)
Techniques for analyzing transcription and translation. Krause M. **Methods Cell Biol** 1995;48:513-29 (52 ref.)
Transcription and translation. Krause M. **Methods Cell Biol** 1995;48:483-512 (149 ref.)
DNA transformation. Mello C, et al. **Methods Cell Biol** 1995; 48:451-82 (45 ref.)
Reverse genetics: from gene sequence to mutant worm. Plasterk RH. **Methods Cell Biol** 1995;48:59-80 (26 ref.)
Genetic mapping with polymorphic sequence-tagged sites. Williams BD. **Methods Cell Biol** 1995;48:81-96 (20 ref.)
The nematode Caenorhabditis elegans and its genome. Hodgkin J, et al. **Science** 1995 Oct 20;270(5235):410-4 (25 ref.)
Equality for X chromosomes [see comments] Kelley RL, et al. **Science** 1995 Dec 8;270(5242):1607-10 (49 ref.) Comment in: Science 1996 May 24;272(5265):1190-1.
Mechanisms and evolution of aging. Lithgow GJ, et al. **Science** 1996 Jul 5;273(5271):80 (14 ref.)

CAENORHABDITIS ELEGANS

[Large scale analysis of C. elegans cDNA] Kohara Y. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(3):715-20 (6 ref.) **(Jpn)**

GROWTH & DEVELOPMENT

Control and integration of cell signaling pathways during C. elegans vulval development. Sundaram M, et al. **Bioessays** 1996 Jun;18(6):473-80 (68 ref.)

LET-23-mediated signal transduction during Caenorhabditis elegans development. Sternberg PW, et al. **Mol Reprod Dev** 1995 Dec;42(4):523-8 (35 ref.)

METABOLISM

Proteins and protein assemblies. Epstein HF, et al. **Methods Cell Biol** 1995;48:437-50 (23 ref.)

PHYSIOLOGY

Thermosensation. Some like it hot. Thomas JH. **Curr Biol** 1995 Nov 1;5(11):1222-4 (12 ref.)

Recent advances in understanding signal transduction pathways in worms and flies. Duffy JB, et al. **Curr Opin Cell Biol** 1996 Apr;8(2):231-8 (44 ref.)

Electrophysiological methods. Avery L, et al. **Methods Cell Biol** 1995;48:251-69 (20 ref.)

Methods of studying behavioral plasticity in Caenorhabditis elegans. Gannon TN, et al. **Methods Cell Biol** 1995; 48:205-23 (30 ref.)

Cell biology of nematode sperm. L'Hernault SW, et al. **Methods Cell Biol** 1995;48:273-301 (38 ref.)

Mechanosensation and the DEG/ENaC ion channels [comment] Corey DP, et al. **Science** 1996 Jul 19; 273(5273):323-4 (21 ref.) Comment on: Science 1996 Jul 19;273(5273):361-4.

Mechanisms and evolution of aging. Lithgow GJ, et al. **Science** 1996 Jul 5;273(5271):80 (14 ref.)

ULTRASTRUCTURE

Electron microscopy and three-dimensional image reconstruction. Hall DH. **Methods Cell Biol** 1995; 48:395-436 (49 ref.)

CAERULEIN RECEPTORS see **RECEPTORS, CHOLECYSTOKININ**

CAERULOPLASMIN see **CERULOPLASMIN**

CAFFEA see **COFFEE**

CAFFEINE

Caffeine dependence: fact or fiction? Strain EC, et al. **J R Soc Med** 1995 Aug;88(8):437-40 (26 ref.)

ADMINISTRATION & DOSAGE

Caffeine consumption. Barone JJ, et al. **Food Chem Toxicol** 1996 Jan;34(1):119-29 (17 ref.)

ADVERSE EFFECTS

Aortic and mitral valve disease induced by ergotamine therapy for migraine: a case report and review of the literature. Hendrikx M, et al. **J Heart Valve Dis** 1996 Mar; 5(2):235-7 (14 ref.)

Chronic psychiatric patients' use of caffeine: pharmacological effects and mechanisms. Kruger A. **Psychol Rep** 1996 Jun; 78(3 Pt 1):915-23 (50 ref.)

[Should one consider monitoring various products containing caffeine?] Lafontaine A, et al. **Rev Med Liege** 1996 Mar; 51(3):244-8 (42 ref.) **(Fre)**

DIAGNOSTIC USE

Update on the use of metabolic probes to quantify liver function: caffeine versus lidocaine. Ziebell J, et al. **Dig Dis** 1995 Jul-Aug;13(4):239-50 (74 ref.)

PHARMACOLOGY

Reproduction and caffeine consumption--a literature review. Golding J. **Early Hum Dev** 1995 Aug 30;43(1):1-14 (56 ref.)

Radioprotective and antioxidant action of caffeine: mechanistic considerations. Devasagayam TP, et al. **Indian J Exp Biol** 1996 Apr;34(4):291-7 (69 ref.)

Caffeine and performance. Spriet LL. **Int J Sport Nutr** 1995 Jun;5 Suppl:S84-99 (56 ref.)

Pharmacokinetic interactions related to the chemical structures of fluoroquinolones. Mizuki Y, et al. **J Antimicrob Chemother** 1996 May;37 Suppl A:41-55 (46 ref.)

THERAPEUTIC USE

[Effectiveness of fixed analgesic combinations exemplified by thomapyrin] Aicher B, et al. **Wien Klin Wochenschr** 1996;108(8):219-33 (104 ref.) (Eng. Abstr.) **(Ger)**

CAISSON DISEASE see **DECOMPRESSION SICKNESS**

CALCANEUS

Metastatic endometrial carcinoma of the foot. A case report. Clarke SJ, et al. **J Am Podiatr Med Assoc** 1996 Jul; 86(7):331-3 (6 ref.)

Hematogenous osteomyelitis of the calcaneus in children: surgical treatment and use of implanted antibiotic beads. Kelsey R, et al. **J Foot Ankle Surg** 1995 Nov-Dec; 34(6):547-55; discussion 594 (26 ref.)

ABNORMALITIES

Accessory calcaneus: a case report and literature review. Krause JO, et al. **Foot Ankle Int** 1995 Oct;16(10):646-50 (11 ref.)

INJURIES

Intra-articular calcaneal fractures. Current concepts. Stone ML. **Clin Podiatr Med Surg** 1995 Oct;12(4):551-64 (19 ref.)

Fractures of the calcaneus. Part I: Anatomy, injury mechanism, and classification. Lowery RB, et al. **Foot Ankle Int** 1996 Apr;17(4):230-5 (67 ref.)

Avulsion fracture of the tuberosity of the calcaneus in children. A report of four cases and review of the literature. Cole RJ, et al. **J Bone Joint Surg Am** 1995 Oct; 77(10):1568-71 (14 ref.)

Irreducible fracture of the calcaneus due to flexor hallucis longus tendon interposition. Anglen JO, et al. **J Orthop Trauma** 1996;10(4):285-8 (4 ref.)

Occult fracture of the calcaneus in toddlers. Schindler A, et al. **J Pediatr Orthop** 1996 Mar-Apr;16(2):201-5 (28 ref.)

[Post-traumatic psoriatic arthritis. 2 cases] Thomachot B, et al. **Presse Med** 1996 Jan 6-13;25(1):21-4 (13 ref.) (Eng. Abstr.) **(Fre)**

CALCIDIOL 1-MONOOXYGENASE see **25-HYDROXYCHOLECALCIFEROL 1-HYDROXYLASE**

CALCIFICATION, PATHOLOGIC see **CALCINOSIS**

CALCIFICATION, PHYSIOLOGIC

see related
BONE DEVELOPMENT
OSTEOGENESIS

Ultrastructural organic-inorganic relationships in calcified tissues: cartilage and bone vs. enamel. Bonucci E. **Connect Tissue Res** 1995;33(1-3):157-62 (67 ref.)

Growth, physical activity, and bone mineral acquisition. Bailey DA, et al. **Exerc Sport Sci Rev** 1996;24:233-66 (146 ref.)

Osteopontin at mineralized tissue interfaces in bone, teeth, and osseointegrated implants: ultrastructural distribution and implications for mineralized tissue formation, turnover, and repair. McKee MD, et al. **Microsc Res Tech** 1996 Feb 1;33(2):141-64 (112 ref.)

PHYSIOLOGY

Bone mass acquisition during infancy, childhood and adolescence. Carrascosa A, et al. **Acta Paediatr Suppl** 1995 Sep;411:18-23 (66 ref.)

Calcium, magnesium and phosphorus in the nutrition of the newborn. Venkataraman PS, et al. **J Am Coll Nutr** 1995 Oct;14(5):439-47 (102 ref.)

CALCIMEDIN 67 KD see **ANNEXIN VI**

CALCIMEDINS see **ANNEXINS**

CALCINOSIS

see related
CHONDROCALCINOSIS

Calcifying disorders of the skin. Walsh JS, et al. **J Am Acad Dermatol** 1995 Nov;33(5 Pt 1):693-706; quiz 707-10 (116 ref.)

[Porcelain gallbladder] Oyama H, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):474-6 (13 ref.) **(Jpn)**

[Calcified gallstone] Saito K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):408-11 (13 ref.) **(Jpn)**

CLASSIFICATION

Proposal for a pathogenesis-based classification of tumoral calcinosis. Smack D, et al. **Int J Dermatol** 1996 Apr; 35(4):265-71 (77 ref.)

COMPLICATIONS

[Sarcoidosis with pulmonary cavitation and calcification] Yokogawa K, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Nov; 33(11):1259-64 (27 ref.) (Eng. Abstr.) **(Jpn)**

CONGENITAL

A nine-month-old boy with microcephaly, cataracts, intracerebral calcifications and dysmorphic signs: an additional observation of an autosomal recessive congenital infection-like syndrome? Wieczorek D, et al. **Genet Couns** 1995;6(4):297-302 (18 ref.)

DIAGNOSIS

A rare case of idiopathic hypoparathyroidism with varied neurological manifestations. Abe S, et al. **Intern Med** 1996 Feb;35(2):129-34 (37 ref.)

Eight cases of gastric tumors with calcification. Ichiishi E, et al. **Intern Med** 1995 Oct;34(10):1038-42 (11 ref.)

Broncholithiasis: case report and literature review. Ryberg AA, et al. **Nebr Med J** 1996 Jan;81(1):14-7 (17 ref.)

Renal calcification in the first year of life. Karlowicz MG, et al. **Pediatr Clin North Am** 1995 Dec;42(6):1397-413 (87 ref.)

[Isolated stenosing calcified lesions of the aorta] Sapoval M, et al. **J Radiol** 1995 Nov;76(11):1021-4 (10 ref.) (Eng. Abstr.) **(Fre)**

[Primary amyloid tumor of the breast. Case report and review of the literature] Bisceglia M, et al. **Pathologica** 1995 Apr; 87(2):162-7 (20 ref.) (Eng. Abstr.) **(Ita)**

EPIDEMIOLOGY

Are there gender differences regarding coronary artery calcification. Kung S, et al. **Am J Card Imaging** 1996 Jan; 10(1):72-7 (60 ref.)

ETIOLOGY

Milia-like idiopathic calcinosis cutis: an unusual dermatosis associated with Down syndrome. Schepis C, et al. **Br J Dermatol** 1996 Jan;134(1):143-6 (17 ref.)

Proposal for a pathogenesis-based classification of tumoral calcinosis. Smack D, et al. **Int J Dermatol** 1996 Apr; 35(4):265-71 (77 ref.)

Calcific myonecrosis following compartment syndrome: report of two cases, review of the literature, and recommendations for treatment. Snyder BJ, et al. **J Trauma** 1995 Oct;39(4):792-5 (6 ref.)

[Tumoral calcinosis--an independent disease?] Mayr E, et al. **Zentralbl Chir** 1996;121(6):496-502 (46 ref.) (Eng. Abstr.) **(Ger)**

[A nephropathic patient with lung problems ...] Cole TJ, et al. **Radiol Med (Torino)** 1995 Dec;90(6):847-50 (9 ref.) **(Ita)**

GENETICS

The Aicardi-Goutières syndrome (familial, early onset encephalopathy with calcifications of the basal ganglia and chronic cerebrospinal fluid lymphocytosis). Tolmie JL, et al. **J Med Genet** 1995 Nov;32(11):881-4 (26 ref.)

[Striato-pallido-dentate calcifications and acquired facial atrophy] Derex L, et al. **Rev Neurol (Paris)** 1995 Oct; 151(10):559-62 (13 ref.) (Eng. Abstr.) **(Fre)**

PARASITOLOGY

[Porocephalosis, a little known parasitosis, literature review and a Congolese case report] Faisy C, et al. **Med Trop (Mars)** 1995;55(3):258-62 (26 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Multiple subepidermal calcified nodules on the eyelids [letter] Butt KI, et al. **Br J Dermatol** 1995 Oct;133(4):664-5 (8 ref.)

Progressive osseous heteroplasia, uncommon cause of soft tissue ossification: a case report and review of the literature. Rodriguez-Jurado R, et al. **Pediatr Pathol Lab Med** 1995 Sep-Oct;15(5):813-27 (15 ref.)

[An autopsy case of "diffuse neurofibrillary tangles with calcification", multiple infarctions and hyaline arteriosclerosis] Arai T, et al. **No To Shinkei** 1996 Jan; 48(1):69-76 (26 ref.) (Eng. Abstr.) **(Jpn)**

RADIOGRAPHY

Calcifications of portal venous system wall: CT findings in three patients. Egiebor O, et al. **Abdom Imaging** 1995 Sep-Oct;20(5):477-9 (7 ref.)

Ultrafast computed tomography for detection of coronary artery calcification. Fusman B, et al. **Am J Card Imaging** 1995 Jul;9(3):206-12 (43 ref.)

Non-invasive visualization of coronary arteries with and without calcification by electron beam computed tomography. Schmermund A, et al. **Herz** 1996 Apr; 21(2):118-26 (49 ref.)

Electron beam computed tomography and coronary artery disease: scanning for coronary artery calcification. Rumberger JA, et al. **Mayo Clin Proc** 1996 Apr; 71(4):369-77 (30 ref.)

Calcification of cervical ganglia: case report. Casolin AL, et al. **Neuroradiology** 1995 Aug;37(6):468-70 (19 ref.)

Early onset bilateral calcifications and epilepsy. Nunes ML, et al. **Pediatr Neurol** 1995 Jul;13(1):80-2 (11 ref.)

Evaluation of breast microcalcifications. Monsees BS. **Radiol Clin North Am** 1995 Nov;33(6):1109-21 (77 ref.)

[Ossified bronchial neuroendocrine tumors: 3 cases] Debourdeau P, et al. **Rev Pneumol Clin** 1995;51(6):325-9 (27 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Blue toe syndrome from a "coral reef" aorta. Rosenberg GD, et al. **Ann Vasc Surg** 1995 Nov;9(6):561-4 (19 ref.)

THERAPY

[Prognosis of shoulder calcifications after irrigation treatment and roentgen findings. A prospective study and literature review] Ludwig R, et al. **Schweiz Rundsch Med Prax** 1996 Apr 16;85(16):526–33 (18 ref.) (Eng. Abstr.) **(Ger)**

VETERINARY

Calcinosis circumscripta in the footpad of a dog. Joffe DJ. **Can Vet J** 1996 Mar;37(3):161–2 (11 ref.)

CALCIPHYLAXIS

ETIOLOGY

Pathogenesis of calciphylaxis: study of three cases with literature review. Fischer AH, et al. **Hum Pathol** 1995 Oct; 26(10):1055–64 (75 ref.)

Uremic small–artery disease with medial calcification and intimal hyperplasia (so–called calciphylaxis): a complication of chronic renal failure and benefit from parathyroidectomy. Hafner J, et al. **J Am Acad Dermatol** 1995 Dec;33(6):954–62 (61 ref.)

CALCITONIN

see related
RECEPTORS, CALCITONIN

ADMINISTRATION & DOSAGE

Calcitonin for prevention and treatment of postmenopausal osteoporosis. Body JJ. **Clin Rheumatol** 1995 Sep;14 Suppl 3:18–21 (22 ref.)

BLOOD

[Detection of residual lesions and metastases of medullary thyroid cancer] Murat A. **Ann Endocrinol (Paris)** 1996; 57(1):27–32 (33 ref.) (Eng. Abstr.) **(Fre)**

[Hypercalcitoninemia in conditions other than medullary cancers of the thyroid] Niccoli P, et al. **Ann Endocrinol (Paris)** 1996;57(1):15–21 (53 ref.) (Eng. Abstr.) **(Fre)**

[Non–neoplastic hypercalcitoninemia. Pathological anatomy] Saint–André JP, et al. **Ann Endocrinol (Paris)** 1996; 57(1):23–6 (14 ref.) (Eng. Abstr.) **(Fre)**

[Calcitonin (CT)] Kosaka H, et al. **Nippon Rinsho** 1995 Mar; 53 Su Pt 2:401–3 (16 ref.) **(Jpn)**

IMMUNOLOGY

Clinical significance of antibodies against calcitonin. Grauer A, et al. **Exp Clin Endocrinol Diabetes** 1995;103(6):345–51 (37 ref.)

THERAPEUTIC USE

Efficacy and safety of drugs for Paget's disease of bone. Reginster JY, et al. **Bone** 1995 Nov;17(5 Suppl):485S–488S (49 ref.)

[Calcitonin] Reginster JY. **Rev Med Liege** 1996 Jan; 51(1):116–9 (25 ref.) **(Fre)**

CALCITONIN GENE–RELATED PEPTIDE

see related
RECEPTORS, CALCITONIN GENE–RELATED PEPTIDE

ANALYSIS

Effects of ankle joint inflammation on the proportion of calcitonin gene–related peptide (CGRP)–immunopositive perikarya in dorsal root ganglia. Hanesch U, et al. **Prog Brain Res** 1995;104:339–47 (72 ref.)

ANTAGONISTS & INHIBITORS

Clinical perspectives of calcitonin gene related peptide pharmacology. Feuerstein G, et al. **Can J Physiol Pharmacol** 1995 Jul;73(7):1070–4 (24 ref.)

BLOOD

[Calcitonin gene–related peptide in diabetes mellitus type 2: a possible etiopathogenetic role] Parlapiano C, et al. **Riv Eur Sci Med Farmacol** 1995 Jan–Feb;17(1):35–9 (46 ref.) (Eng. Abstr.) **(Ita)**

[Calcitonin gene–related peptide (CGRP)] Takami H. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:404–6 (4 ref.) **(Jpn)**

PHARMACOLOGY

Regulation of postsynaptic responses by calcitonin gene related peptide and ATP at developing neuromuscular junctions. Lu B, et al. **Can J Physiol Pharmacol** 1995 Jul; 73(7):1050–6 (42 ref.)

Astrocytes and microglia as potential targets for calcitonin gene related peptide in the central nervous system. Reddington M, et al. **Can J Physiol Pharmacol** 1995 Jul; 73(7):1047–9 (18 ref.)

Calcitonin gene–related peptide modulates Langerhans cell antigen–presenting function. Asahina A, et al. **Proc Assoc Am Physicians** 1995 Jul;107(2):242–4 (18 ref.)

Pharmacology of receptors for calcitonin gene–related peptide and amylin. Poyner D. **Trends Pharmacol Sci** 1995 Dec;16(12):424–8 (56 ref.)

PHYSIOLOGY

Diverse interactions of calcitonin gene related peptide and nitric oxide in the gastric and cutaneous microcirculation. Holzer P, et al. **Can J Physiol Pharmacol** 1995 Jul; 73(7):991–4 (37 ref.)

Calcitonin gene related peptide as inhibitory neurotransmitter in the ureter. Maggi CA, et al. **Can J Physiol Pharmacol** 1995 Jul;73(7):986–90 (21 ref.)

Neuropeptides in morphologically and functionally identified primary afferent neurons in dorsal root ganglia: substance P, CGRP and somatostatin. Lawson SN. **Prog Brain Res** 1995;104:161–73 (56 ref.)

[Calcitonin gene related peptide] Zdrojewicz Z, et al. **Postepy Hig Med Dosw** 1995;49(2):237–52 (104 ref.) (Eng. Abstr.) **(Pol)**

SECRETION

Plasticity of calcitonin gene related peptide neurotransmission in the spinal cord during peripheral inflammation. Seybold VS, et al. **Can J Physiol Pharmacol** 1995 Jul;73(7):1007–14 (51 ref.)

THERAPEUTIC USE

Clinical perspectives of calcitonin gene related peptide pharmacology. Feuerstein G, et al. **Can J Physiol Pharmacol** 1995 Jul;73(7):1070–4 (24 ref.)

CALCITONIN GENE–RELATED PEPTIDE RECEPTORS see **RECEPTORS, CALCITONIN GENE–RELATED PEPTIDE**

CALCITONIN RECEPTORS see **RECEPTORS, CALCITONIN**

CALCITRIOL

see related
RECEPTORS, CALCITRIOL

ADMINISTRATION & DOSAGE

Oral versus intravenous calcitriol: is the route of administration really important? Indridason OS, et al. **Curr Opin Nephrol Hypertens** 1995 Jul;4(4):307–12 (40 ref.)

ANALOGS & DERIVATIVES

Calcipotriol: a new drug for topical psoriasis treatment. Kragballe K. **Pharmacol Toxicol** 1995 Oct;77(4):241–6 (41 ref.)

[Contact eczema caused by calcipotriol] Giordano–Labadie F, et al. **Ann Dermatol Venereol** 1996;123(3):196–7 (7 ref.) **(Fre)**

[Colon cancer and vitamin D—in vivo growth inhibition of colon cancer by a fluorinated analogue of 1,25–(OH)2D3, DD–003] Tanaka N, et al. **Seikagaku** 1996 Mar;68(3):214–9 (19 ref.) **(Jpn)**

BLOOD

1,25–dihydroxyvitamin D–mediated hypercalcemia in a renal transplant recipient. Golconda MS, et al. **Mayo Clin Proc** 1996 Jan;71(1):32–6 (25 ref.)

CHEMISTRY

Differing shapes of 1 alpha,25–dihydroxyvitamin D3 function as ligands for the D–binding protein, nuclear receptor and membrane receptor: a status report. Norman AW, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1–6 Spec No):13–22 (34 ref.)

METABOLISM

The vitamin D Endocrine system: manipulation of structure–function relationships to provide opportunities for development of new cancer chemopreventive and immunosuppressive agents. Norman AW. **J Cell Biochem Suppl** 1995;22:218–25 (39 ref.)

Genesis of disturbed vitamin D metabolism in renal failure. Ritz E, et al. **Nephrol Dial Transplant** 1995;10 Suppl 4:3–10; discussion 37–43 (53 ref.)

PHARMACOKINETICS

Oral versus intravenous calcitriol: is the route of administration really important? Indridason OS, et al. **Curr Opin Nephrol Hypertens** 1995 Jul;4(4):307–12 (40 ref.)

PHARMACOLOGY

Genomic mechanisms involved in the pleiotropic actions of 1,25–dihydroxyvitamin D3. Christakos S, et al. **Biochem J** 1996 Jun 1;316 (Pt 2):361–71 (169 ref.)

New understanding of the molecular mechanism of receptor–mediated genomic actions of the vitamin D hormone. Haussler MR, et al. **Bone** 1995 Aug;17(2 Suppl):33S–38S (30 ref.)

Immunomodulatory effects of 1,25–dihydroxyvitamin D3. Casteels K, et al. **Curr Opin Nephrol Hypertens** 1995 Jul; 4(4):313–8 (75 ref.)

Growth hormone and calcitriol as modifiers of bone formation in renal osteodystrophy. Salusky IB, et al. **Kidney Int** 1995 Sep;48(3):657–65 (107 ref.)

Avian muscle cells as targets for the secosteroid hormone 1,25–dihydroxy–vitamin D3. Boland R, et al. **Mol Cell Endocrinol** 1995 Oct 30;114(1–2):1–8 (91 ref.)

PHYSIOLOGY

Pathogenesis of secondary hyperparathyroidism. Slatopolsky E, et al. **Miner Electrolyte Metab** 1995;21(1–3):91–6 (35 ref.)

Regulation of bone cells by 1,25(OH)2D3. Ljunghall S, et al. **Nephrol Dial Transplant** 1995;10 Suppl 4:11–3; discussion 37–43 (17 ref.)

THERAPEUTIC USE

Noncalcemic actions of 1,25–dihydroxyvitamin D3 and clinical applications. Holick MF. **Bone** 1995 Aug;17(2 Suppl):107S–111S (36 ref.)

Pathogenesis and management of parathyroid hyperplasia in chronic renal failure: role of calcitriol. Fukagawa M, et al. **Miner Electrolyte Metab** 1995;21(1–3):97–100 (22 ref.)

Immunosuppression with the vitamin D analogue MC 1288 in experimental transplantation. Johnsson C, et al. **Transplant Proc** 1996 Apr;28(2):888–91 (35 ref.)

CALCITRIOL RECEPTORS see **RECEPTORS, CALCITRIOL**

CALCIUM

see related
HYPERCALCEMIA
HYPOCALCEMIA

Calcium and phosphorus nutrition in infants. Demarini S, et al. **J Pediatr Gastroenterol Nutr** 1995 Nov;21(4):367–73 (85 ref.)

[Bone involvement in idiopathic calcium lithiasis] Ghazali A, et al. **Nephrologie** 1995;16(5):351–69 (129 ref.) (Eng. Abstr.) **(Fre)**

ADMINISTRATION & DOSAGE

The scientific basis for hypocalcemic cardioplegia and reperfusion in cardiac surgery. Chen RH. **Ann Thorac Surg** 1996 Sep;62(3):910–4 (57 ref.)

The role of vitamin D and calcium supplementation in the prevention of osteoporotic fractures in the elderly. Compston JE. **Clin Endocrinol (Oxf)** 1995 Oct; 43(4):393–405 (146 ref.)

Optimal calcium intake. Sponsored by National Institutes of Health Continuing Medical Education. **Nutrition** 1995 Sep–Oct;11(5):409–17 (0 ref.)

Prescription of calcium concentration and PTH control. Ritz E, et al. **Perit Dial Int** 1996;16 Suppl 1:S300–4 (31 ref.)

ANALYSIS

Recombinant aequorin methods for intracellular calcium measurement in plants. Knight H, et al. **Methods Cell Biol** 1995;49:201–16 (29 ref.)

[Reality in analysis of calcium ion concentration in single cell] Hayashi H, et al. **Nippon Seirigaku Zasshi** 1995; 57(11):441–50 (25 ref.) **(Jpn)**

[Analysis of calcium ion concentration in cells by confocal microscopy] Hisaba K. **Nippon Seirigaku Zasshi** 1996; 58(3):115–24 (10 ref.) **(Jpn)**

[Caged compounds and measurement of calcium ion] Iino M. **Nippon Seirigaku Zasshi** 1996;58(1):7–13 (12 ref.) **(Jpn)**

[Optical measurement of intracellular calcium concentration] Konishi M, et al. **Nippon Seirigaku Zasshi** 1995;57(7):313–24 (23 ref.) **(Jpn)**

[Computer–assisted image analysis of calcium ion concentration] Kudo Y, et al. **Nippon Seirigaku Zasshi** 1996; 58(2):69–82 (17 ref.) **(Jpn)**

[Instruments used for measurement of intracellular calcium ions] Miyakawa A. **Nippon Seirigaku Zasshi** 1995; 57(10):401–17 (18 ref.) **(Jpn)**

[Basic study of calcium ion indicator for measurement of intracellular calcium ion] Ogawa Y, et al. **Nippon Seirigaku Zasshi** 1995;57(8–9):365–74 (54 ref.) **(Jpn)**

[Methodological and diagnostic aspects of the determination of calcium contents] Titova VN. **Klin Lab Diagn** 1996 Mar–Apr;(2):23–6 (31 ref.) **(Rus)**

BLOOD

Why should ionized calcium be determined in acutely ill patients? Vincent JL, et al. **Acta Anaesthesiol Scand Suppl** 1995;107:281–6 (59 ref.)

Physiology and regulation. Ionized calcium, magnesium and lactate measurements in critical care settings. Toffaletti J. **Am J Clin Pathol** 1995 Oct;104(4 Suppl 1):S88–94 (20 ref.)

Na–Ca exchange in circulating blood cells. Gardner JP, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:502–14 (27 ref.)

Homeostatic control of plasma calcium concentration. Hurwitz S. **Crit Rev Biochem Mol Biol** 1996 Feb; 31(1):41–100 (500 ref.)

Normocalcemic hyperparathyroidism. Monchik JM. **Surgery** 1995 Dec;118(6):917–23 (27 ref.)

[Calcium] Akatsu T. **Nippon Rinsho** 1995 Feb;53 Su Pt

1:769–71 (8 ref.) (Jpn)

METABOLISM

Calcium transients in brain ischemia: role in neuronal injury. Lazarewicz JW. **Acta Neurobiol Exp (Warsz)** 1996; 56(1):299–311 (113 ref.)

Calcium uptake and release modulated by counter-ion conductances in the sarcoplasmic reticulum of skeletal muscle. Fink RH, et al. **Acta Physiol Scand** 1996 Mar; 156(3):387–96 (65 ref.)

Membrane abnormalities and Ca homeostasis in muscles of the mdx mouse, an animal model of the Duchenne muscular dystrophy: a review. Gillis JM. **Acta Physiol Scand** 1996 Mar;156(3):397–406 (57 ref.)

Effects of training on potassium, calcium and hydrogen ion regulation in skeletal muscle and blood during exercise. McKenna MJ, et al. **Acta Physiol Scand** 1996 Mar; 156(3):335–46 (68 ref.)

Mechanisms underlying changes of tetanic [Ca2+]i and force in skeletal muscle. Westerblad H, et al. **Acta Physiol Scand** 1996 Mar;156(3):407–16 (68 ref.)

Sodium–calcium relationships and cardiac function during coronary bolus perfusion. Jynge P, et al. **Acta Radiol Suppl** 1995;399:122–34 (74 ref.)

Bladder function in experimental outlet obstruction: pharmacologic responses to alterations in innervation, energetics, calcium mobilization, and genetics. Levin RM, et al. **Adv Exp Med Biol** 1995;385:7–19; discussion 75–9 (61 ref.)

Troponin C – troponin I interactions and molecular signalling in cardiac myofilaments. Solaro RJ. **Adv Exp Med Biol** 1995;382:109–15 (24 ref.)

Calcium and bacteria. Smith RJ. **Adv Microb Physiol** 1995; 37:83–133 (221 ref.)

Calcium dynamics in the central nervous system. DeCoster MA. **Adv Neuroimmunol** 1995;5(3):233–9 (68 ref.)

Molecular mechanisms for neurodegeneration. Synergism between reactive oxygen species, calcium, and excitotoxic amino acids. Gerlach M, et al. **Adv Neurol** 1996;69:177–94 (119 ref.)

The ryanodine receptor family of intracellular calcium release channels. Sorrentino V. **Adv Pharmacol** 1995; 33:67–90 (119 ref.)

The First Annual Bayard D. Catherwood Memorial Lecture. Ca2+-receptor-mediated regulation of parathyroid and renal function. Brown EM, et al. **Am J Med Sci** 1996 Sep; 312(3):99–109 (69 ref.)

Inositol trisphosphate and calcium signaling. Berridge MJ. **Ann N Y Acad Sci** 1995 Sep 7;766:31–43 (43 ref.)

Na–Ca exchange and Ca fluxes during contraction and relaxation in mammalian ventricular muscle. Bers DM, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:430–42 (31 ref.)

The roles of the sodium and calcium current in triggering calcium release from the sarcoplasmic reticulum. Cannell MB, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:443–50 (21 ref.)

Action potential duration modulates calcium influx, Na(+)-Ca2+ exchange, and intracellular calcium release in rat ventricular myocytes. Clark RB, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:417–29 (51 ref.)

Release of catecholamines and enkephalin peptides induced by reversal of the Na(+)-Ca2+ exchanger in chromaffin cells. Duarte EP, et al. **Ann N Y Acad Sci** 1996 Apr 15; 779:391–4 (6 ref.)

Na–Ca exchange studies in sarcolemmal skeletal muscle. Gonzalez-Serratos H, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:556–60 (11 ref.)

Calcium in the cardiac diadic cleft. Implications for sodium–calcium exchange. Langer GA, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:408–16 (24 ref.)

Evidence that reverse Na–Ca exchange can trigger SR calcium release. Litwin S, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:451–63 (20 ref.)

The kidney sodium–calcium exchanger. Lytton J, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:58–72 (30 ref.)

The sodium–calcium exchanger and glutamate–induced calcium loads in aged hippocampal neurons in vitro. Mills LR. **Ann N Y Acad Sci** 1996 Apr 15;779:379–90 (39 ref.)

Free intracellular calcium in aging and Alzheimer's disease. Müller WE, et al. **Ann N Y Acad Sci** 1996 Jun 15;786:305–20 (55 ref.)

Mutagenesis studies of the cardiac Na(+)-Ca2+ exchanger. Nicoll DA, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:86–92 (14 ref.)

Molecular regulation of the Na(+)-Ca2+ exchanger. Philipson KD, et al. **Ann N Y Acad Sci** 1996 Apr 15; 779:20–8 (15 ref.)

The structural basis of Na(+)-Ca2+ exchange activity. Rahamimoff H, et al. **Ann N Y Acad Sci** 1996 Apr 15; 779:29–36 (16 ref.)

Sodium–calcium exchange and calcium homeostasis in transfected Chinese hamster ovary cells. Reeves JP, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:73–85 (27 ref.)

Na–Ca exchange in Ca2+ signaling and neurohormone secretion. Secretory vesicle contributions in adrenal chromaffin cells. Schneider AS, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:356–65 (17 ref.)

Effects of mefloquine on Ca2+ uptake by crude microsomes of rabbit skeletal muscle. Go ML, et al. **Arch Int Pharmacodyn Ther** 1995 Mar–Apr;329(2):255–71 (29 ref.)

Capacitative calcium entry [see comments] Berridge MJ. **Biochem J** 1995 Nov 15;312 (Pt 1):1–11 (126 ref.) Comment in: Biochem J 1996 Mar 15;314 (Pt 3):1054–6.

Using fluorescence to probe calcium signalling mechanisms. Bolsover S. **Biochem Soc Trans** 1995 Aug;23(3):627–9 (12 ref.)

Ca(2+)-dependent sugar recognition by animal lectins. Drickamer K. **Biochem Soc Trans** 1996 Feb;24(1):146–50 (20 ref.)

Regulation of calcium homoeostasis in neurons: the role of calcium–binding proteins. Miller RJ. **Biochem Soc Trans** 1995 Aug;23(3):629–32 (21 ref.)

Why do hormones stimulate Ca2+ mobilization? Taylor CW. **Biochem Soc Trans** 1995 Aug;23(3):637–42 (52 ref.)

Regulation of contraction by calcium binding myosins. Szent-Györgyi AG. **Biophys Chem** 1996 Apr 16; 59(3):357–63 (29 ref.)

Noncalcemic actions of 1,25–dihydroxyvitamin D3 and clinical applications. Holick MF. **Bone** 1995 Aug;17(2 Suppl):107S–111S (36 ref.)

Hormonal regulation of cytosolic calcium levels in the liver. Kraus–Friedmann N. **Braz J Med Biol Res** 1995 Mar; 28(3):275–84 (61 ref.)

The role of Na–Ca exchange current in the cardiac action potential. Janvier NC, et al. **Cardiovasc Res** 1996 Jul; 32(1):69–84 (74 ref.)

Regulation of intracellular calcium concentration in the developing heart. Mahony L. **Cardiovasc Res** 1996 Feb;31 Spec No:E61–7 (83 ref.)

Sarcoplasmic reticulum function during myocardial ischaemia and reperfusion. Mubagwa K. **Cardiovasc Res** 1995 Aug;30(2):166–75 (114 ref.)

TRP: its role in phototransduction and store–operated Ca2+ entry. Friel DD. **Cell** 1996 May 31;85(5):617–9 (20 ref.)

Do nitric oxide and cGMP play a role in calcium cycling? Milbourne EA, et al. **Cell Calcium** 1995 Sep;18(3):207–13 (43 ref.)

Calcium homeostasis in vertebrate retinal rod outer segments. Schnetkamp PP. **Cell Calcium** 1995 Oct;18(4):322–30 (54 ref.)

Calcium–induced calcium release in neurones. Verkhratsky A, et al. **Cell Calcium** 1996 Jan;19(1):1–14 (107 ref.)

Signal transduction of the gonadotropin releasing hormone (GnRH) receptor: cross–talk of calcium, protein kinase C (PKC), and arachidonic acid. Naor Z, et al. **Cell Mol Neurobiol** 1995 Oct;15(5):527–44 (142 ref.)

Spiral calcium waves: implications for signalling. Camacho P, et al. **Ciba Found Symp** 1995;188:66–77; discussion 78–84 (45 ref.)

Calcium oscillations in neurons. Friel DD. **Ciba Found Symp** 1995;188:210–23; discussion 223–34 (36 ref.)

Pancreatic calcium waves and secretion. Kasai H. **Ciba Found Symp** 1995;188:104–16; discussion 116–20 (31 ref.)

Regulation of nuclear calcium concentration. Meyer T, et al. **Ciba Found Symp** 1995;188:252–62; discussion 262–6 (32 ref.)

Calcium signalling during mammalian fertilization. Miyazaki S. **Ciba Found Symp** 1995;188:235–47; discussion 247–51 (42 ref.)

Calcium puffs in Xenopus oocytes. Parker I, et al. **Ciba Found Symp** 1995;188:50–60; discussion 60–5 (30 ref.)

Local calcium spiking in pancreatic acinar cells. Petersen OH. **Ciba Found Symp** 1995;188:85–94; discussion 94–103 (47 ref.)

Intercellular calcium waves mediated by inositol trisphosphate. Sanderson MJ. **Ciba Found Symp** 1995; 188:175–89; discussion 189–94 (43 ref.)

Calcium signalling in cardiac muscle cells. Wier WG, et al. **Ciba Found Symp** 1995;188:146–60; discussion 160–4 (41 ref.)

Calcium homeostasis in pregnancy. Hosking DJ. **Clin Endocrinol (Oxf)** 1996 Jul;45(1):1–6 (45 ref.)

Dentin mineralization and the role of odontoblasts in calcium transport. Linde A. **Connect Tissue Res** 1995;33(1–3):163–70 (46 ref.)

Enamel mineralization and the role of ameloblasts in calcium transport. Takano Y. **Connect Tissue Res** 1995; 33(1–3):127–37 (74 ref.)

Calcium signalling. Cracking ICRAC in the eye. Bennett DL, et al. **Curr Biol** 1995 Nov 1;5(11):1225–8 (22 ref.)

Chloride channels of intracellular organelles. al–Awqati Q. **Curr Opin Cell Biol** 1995 Aug;7(4):504–8 (50 ref.)

Ligand–gated calcium channels inside and out. Striggow F, et al. **Curr Opin Cell Biol** 1996 Aug;8(4):490–5 (57 ref.)

The calcium/parathyroid hormone concept of the parathyroid glands. Lewin E, et al. **Curr Opin Nephrol Hypertens** 1995 Jul;4(4):324–33 (49 ref.)

Oestrogens and calcium regulatory hormones: potential implications for bone. Naveh–Many T, et al. **Curr Opin Nephrol Hypertens** 1995 Jul;4(4):319–23 (50 ref.)

Functional properties of intracellular calcium–release channels. Ehrlich BE. **Curr Opin Neurobiol** 1995 Jun; 5(3):304–9 (48 ref.)

Modulation of inhibitory synapses in the mammalian brain. Marty A, et al. **Curr Opin Neurobiol** 1995 Jun;5(3):335–41 (38 ref.)

Mechanisms of calcium regulation in sea urchin eggs and their activities during fertilization. Shen SS. **Curr Top Dev Biol** 1995;30:63–101 (270 ref.)

Diacylglycerol production, Ca2+ influx, and protein kinase C activation in sustained cellular responses. Rasmussen H, et al. **Endocr Rev** 1995 Oct;16(5):649–81 (268 ref.)

Sodium–calcium balance in coronary angiography and experimental experience with iodixanol. Jynge P. **Eur Radiol** 1996;6 Suppl 2:S8–12 (19 ref.)

Mechanisms of calcium oscillations and waves: a quantitative analysis. Sneyd J, et al. **FASEB J** 1995 Nov;9(14):1463–72 (59 ref.)

Effects of growth hormone on phosphocalcium homeostasis and bone metabolism. Saggese G, et al. **Horm Res** 1995; 44 Suppl 3:55–63 (86 ref.)

Inositolpolyphosphate binding sites and their likely role in calcium regulation in smooth muscle. Zhang L, et al. **Int J Biochem Cell Biol** 1995 Dec;27(12):1231–48 (135 ref.)

Calcium signalling in bacteria. Norris V, et al. **J Bacteriol** 1996 Jul;178(13):3677–82 (88 ref.)

Calcium binding sites of the transmitter release mechanism: clues from short–term facilitation. Liu Y, et al. **J Physiol Paris** 1995;89(3):163–6 (28 ref.)

Intracellular calcium modulators for cardiac muscle in pathological conditions. Ishide N. **Jpn Heart J** 1996 Jan; 37(1):1–17 (80 ref.)

Cross–bridge–dependent changes in the intracellular Ca2+ concentration in mammalian cardiac muscles. Kurihara S, et al. **Jpn Heart J** 1996 Mar;37(2):143–52 (33 ref.)

Crossbridge dynamics under various inotropic states in cardiac muscle: evaluation by perturbation analyses. Saeki Y. **Jpn J Physiol** 1995;45(5):687–705 (101 ref.)

Calcium metabolism in hypertension. McCarron DA. **Keio J Med** 1995 Dec;44(4):105–14 (118 ref.)

Purification and characterization of epithelial Ca(2+)-activated K+ channels. Klaerke DA. **Kidney Int** 1995 Oct;48(4):1047–56 (63 ref.)

Is an elevated concentration of acinar cytosolic free ionised calcium the trigger for acute pancreatitis? Ward JB, et al. **Lancet** 1995 Oct 14;346(8981):1016–9 (42 ref.)

The calcium hypothesis of brain aging and neurodegenerative disorders: significance in diabetic neuropathy. Biessels G, et al. **Life Sci** 1996;59(5–6):379–87 (67 ref.)

Calcium–dependent afterhyperpolarization and learning in young and aging hippocampus. Disterhoft JF, et al. **Life Sci** 1996;59(5–6):413–20 (54 ref.)

Lymphocytes and neutrophils as peripheral models to study the effect of beta–amyloid on cellular calcium signalling in Alzheimer's disease. Eckert A, et al. **Life Sci** 1996; 59(5–6):499–510 (47 ref.)

Calcium–related damage in ischemia. Kristián T, et al. **Life Sci** 1996;59(5–6):357–67 (104 ref.)

Decreased plasma membrane calcium transport activity in aging brain. Michaelis ML, et al. **Life Sci** 1996; 59(5–6):405–12 (16 ref.)

Calcium signals in T lymphocytes from old mice. Miller RA. **Life Sci** 1996;59(5–6):469–75 (22 ref.)

Cytosolic and mitochondrial calcium in synaptosomes during aging. Satrústegui J, et al. **Life Sci** 1996;59(5–6):429–34 (33 ref.)

Calcium, energy metabolism and the development of selective neuronal loss following short–term cerebral ischemia. Sims NR. **Metab Brain Dis** 1995 Sep; 10(3):191–217 (168 ref.)

Pathogenesis of secondary hyperparathyroidism. Slatopolsky E, et al. **Miner Electrolyte Metab** 1995;21(1–3):91–6 (35 ref.)

InsP3–induced Ca2+ excitability of the endoplasmic reticulum. Keizer J, et al. **Mol Biol Cell** 1995 Aug; 6(8):945–51 (71 ref.)

Phosphodiesterase inhibition and Ca2+ sensitization. Ravens U, et al. **Mol Cell Biochem** 1996 Apr 12–26;157(1–2):245–9 (21 ref.)

Signal transduction: regulation of cAMP concentration in cardiac muscle by calmodulin–dependent cyclic nucleotide phosphodiesterase. Sharma RK. **Mol Cell Biochem** 1995 Aug–Sep;149–150:241–7 (23 ref.)

Free radicals and disruption of neuronal ion homeostasis in AD: a role for amyloid beta–peptide? [comment] Mattson MP. **Neurobiol Aging** 1995 Jul–Aug;16(4):679–82; discussion 683 (40 ref.) Comment on: Neurobiol Aging 1995 Jul–Aug;16(4):661–74.

Molecular mechanisms controlling calcium entry through AMPA–type glutamate receptor channels. Jonas P, et al. **Neuron** 1995 Nov;15(5):987–90 (30 ref.)

Pharmacological modulators of the inositol 1,4,5–trisphosphate receptor. Michelangeli F, et al. **Neuropharmacology** 1995 Sep;34(9):1111–22 (108 ref.)

Measurement of calcium transport in heart using modern approaches. Bers DM. **New Horiz** 1996 Feb;4(1):36–44 (29 ref.)

Mechanisms responsible for quantal Ca2+ release from inositol trisphosphate–sensitive calcium stores. Parys JB, et al. **Pflugers Arch** 1996 Jul;432(3):359–67 (89 ref.)

Calcium channels in cerebral arteries. Alborch E, et al. **Pharmacol Ther** 1995;68(1):1–34 (187 ref.)

Aspects of calcium–activated chloride currents: a neuronal perspective. Scott RH, et al. **Pharmacol Ther** 1995 Jun; 66(3):535–65 (178 ref.)

Malignant hyperthermia: excitation–contraction coupling, Ca2+ release channel, and cell Ca2+ regulation defects. Mickelson JR, et al. **Physiol Rev** 1996 Apr;76(2):537–92 (433 ref.)

Iron–zinc and calcium–Fe interactions in relation to Zn and Fe absorption. Fairweather–Tait SJ. **Proc Nutr Soc** 1995 Jul;54(2):465–73 (41 ref.)

Modulator and messenger functions of cyclic ADP–ribose

in calcium signaling. Lee HC. **Recent Prog Horm Res** 1996; 51:355–88; discussion 389 (86 ref.)
Calcium sparks in vascular smooth muscle: relaxation regulators [comment] Fay FS. **Science** 1995 Oct 27; 270(5236):588–9 (15 ref.) Comment on: Science 1995 Oct 27;270(5236):633–7.
Vascular actions of the calcium-regulating hormones. Bukoski RD, et al. **Semin Nephrol** 1995 Nov;15(6):536–49 (154 ref.)
Cell calcium and arterial blood pressure. Gonzalez JM, et al. **Semin Nephrol** 1995 Nov;15(6):564–8 (56 ref.)
Calcium metabolism and familial risk of hypertension. Grobbee DE, et al. **Semin Nephrol** 1995 Nov;15(6):512–8 (39 ref.)
Mechanisms of calcium's effects on blood pressure. Hatton DC, et al. **Semin Nephrol** 1995 Nov;15(6):593–602 (111 ref.)
Calcium metabolism in normal and hypertensive pregnancy. Hojo M, et al. **Semin Nephrol** 1995 Nov;15(6):504–11 (51 ref.)
Genes of intracellular calcium metabolism and blood pressure control in primary hypertension. Orlov SN, et al. **Semin Nephrol** 1995 Nov;15(6):569–92 (240 ref.)
Systemic and cellular calcium metabolism and hypertension. Oshima T, et al. **Semin Nephrol** 1995 Nov;15(6):496–503 (77 ref.)
Blood pressure effects of calcium intake in experimental models of hypertension. Schleiffer R, et al. **Semin Nephrol** 1995 Nov;15(6):526–35 (91 ref.)
Metabolism of myo-inositol phosphates and the alternative pathway in generation of myo-inositol trisphosphate involved in calcium mobilization in plants. Biswas S, et al. **Subcell Biochem** 1996;26:287–316 (203 ref.)
Calcium binding and conformational response in EF-hand proteins. Ikura M. **Trends Biochem Sci** 1996 Jan;21(1):14–7 (29 ref.)
Neuronal Ca2+ stores: activation and function. Simpson PB, et al. **Trends Neurosci** 1995 Jul;18(7):299–306 (63 ref.)
NMDA receptor-dependent excitotoxicity: the role of intracellular Ca2+ release. Mody I, et al. **Trends Pharmacol Sci** 1995 Oct;16(10):356–9 (68 ref.)
Cyclic ADP-ribose, the ryanodine receptor and Ca2+ release. Sitsapesan R, et al. **Trends Pharmacol Sci** 1995 Nov; 16(11):386–91 (50 ref.)
[Ca2+]i in human heart failure: a review and discussion of current areas of controversy. Liao R, et al. **Yale J Biol Med** 1994 Sep-Dec;67(5–6):247–64 (44 ref.)
Calcium and cell cycle control in early embryos. Wilding M. **Zygote** 1996 Feb;4(1):1–6 (69 ref.)
[Mechanisms of mobilization of intracellular stored calcium] Li HW, et al. **Sheng Li Ko Hsueh Chin Chan** 1995 Jul; 26(3):209–12 (17 ref.) (Eng. Abstr.) **(Chi)**
[Calcium sensitizers] Nieminen MS, et al. **Duodecim** 1995; 111(8):779–87 (56 ref.) **(Fin)**
[The calcium hypothesis of brain aging] Müller WE, et al. **Nervenarzt** 1996 Jan;67(1):15–24 (59 ref.) (Eng. Abstr.) **(Ger)**
[Receptor mediated Ca influx and Ca-permeable channels] Inoue R. **Fukuoka Igaku Zasshi** 1996 Apr;87(4):92–6 (15 ref.) **(Jpn)**
[Calcium metabolism in bone] Lorenc RS. **Pol Tyg Lek** 1995 Nov;50(44–47):48–52 (28 ref.) **(Pol)**
[Methodological and diagnostic aspects of the determination of calcium contents] Titova VN. **Klin Lab Diagn** 1996 Mar-Apr;(2):23–6 (31 ref.) **(Rus)**
[Calcareous bile syndrome] Vorob'ev LP, et al. **Klin Med (Mosk)** 1995;73(5):16–20 (58 ref.) **(Rus)**

PHARMACOKINETICS

[Molecular and functional diversity of inositol triphosphate-induced Ca(2+) release] De Smedt H, et al. **Verh K Acad Geneeskd Belg** 1995;57(5):423–58 (76 ref.) (Eng. Abstr.) **(Dut)**

PHARMACOLOGY

Regulation of sodium-calcium exchange in intact myocytes by ATP and calcium. Haworth RA, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:464–79 (42 ref.)
Mammalian calcium-independent phospholipase A2. Ackermann EJ, et al. **Biochim Biophys Acta** 1995 Nov 16; 1259(2):125–36 (102 ref.)
Calcium-induced calcium release in neurones. Verkhratsky A, et al. **Cell Calcium** 1996 Jan;19(1):1–14 (107 ref.)
How do Ca2+ and 5-aminolevulinic acid-derived oxyradicals promote injury to isolated mitochondria? Hermes-Lima M. **Free Radic Biol Med** 1995 Sep; 19(3):381–90 (87 ref.)
Iron-zinc and calcium-Fe interactions in relation to Zn and Fe absorption. Fairweather-Tait SJ. **Proc Nutr Soc** 1995 Jul;54(2):465–73 (41 ref.)
Ca(2+)-activated K+ currents in neurones: types, physiological roles and modulation. Sah P. **Trends Neurosci** 1996 Apr;19(4):150–4 (66 ref.)

PHYSIOLOGY

Multifunctional calcium and calmodulin-dependent kinase II in neuronal function and disease. Churn SB. **Adv Neuroimmunol** 1995;5(3):241–59 (141 ref.)
Calcium uptake by ACTH-stimulated lymphocytes: what is the physiological significance? Clarke BL. **Adv Neuroimmunol** 1995;5(3):271–81 (48 ref.)
Ca2+ excitability of the ER membrane: an explanation for IP3-induced Ca2+ oscillations. Li YX, et al. **Am J Physiol** 1995 Nov;269(5 Pt 1):C1079–92 (103 ref.)
The exchanger and cardiac hypertrophy. Menick DR, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:489–501 (18 ref.)
Routes of calcium entry and extrusion in turtle hair cells. Tucker T, et al. **Ann N Y Acad Sci** 1996 Jun 19;781:123–37 (44 ref.)
Cardiac surgical implications of calcium dyshomeostasis in the heart. Meldrum DR, et al. **Ann Thorac Surg** 1996 Apr; 61(4):1273–80 (61 ref.)
Calcium signalling and cell proliferation. Berridge MJ. **Bioessays** 1995 Jun;17(6):491–500 (71 ref.)
The elemental principles of calcium signaling. Bootman MD, et al. **Cell** 1995 Dec 1;83(5):675–8 (24 ref.)
Calcium ions as extracellular messengers. Brown EM, et al. **Cell** 1995 Dec 1;83(5):679–82 (20 ref.)
Phosphoinositide-mediated phototransduction in Drosophila photoreceptors: the role of Ca2+ and trp. Hardie RC, et al. **Cell Calcium** 1995 Oct;18(4):256–74 (125 ref.)
Control of photoreceptor proteins by Ca2+. Koch KW. **Cell Calcium** 1995 Oct;18(4):314–21 (72 ref.)
Ca2+ flux in retinal rod and cone outer segments: differences in Ca2+ selectivity of the cGMP-gated ion channels and Ca2+ clearance rates. Korenbrot JI. **Cell Calcium** 1995 Oct;18(4):285–300 (75 ref.)
Rods, cones and calcium. McNaughton PA. **Cell Calcium** 1995 Oct;18(4):275–84 (66 ref.)
Distinguishing between roles for calcium in Limulus photoreceptor excitation. Richard EA, et al. **Cell Calcium** 1995 Oct;18(4):331–41 (45 ref.)
Structure and cellular physiology of Ca2+ stores in invertebrate photoreceptors. Walz B, et al. **Cell Calcium** 1995 Oct;18(4):342–51 (52 ref.)
Calcium signalling during chemotaxis. Fay FS, et al. **Ciba Found Symp** 1995;188:121–35; discussion 136–40 (34 ref.)
Calcium waves and development. Jaffe LF. **Ciba Found Symp** 1995;188:4–12; discussion 12–7 (53 ref.)
Subcellular organization of calcium signalling in hepatocytes and the intact liver. Thomas AP, et al. **Ciba Found Symp** 1995;188:18–35; discussion 35–49 (56 ref.)
Calcium regulation of gene expression in neurons: the mode of entry matters. Gallin WJ, et al. **Curr Opin Neurobiol** 1995 Jun;5(3):367–74 (61 ref.)
Extracellular calcium sensitivity and voltage-dependent calcium channels in C cells. Raue F, et al. **Endocr Rev** 1995 Dec;16(6):752–64 (122 ref.)
The role of calcium in aggregation and development of Dictyostelium. Newell PC, et al. **Experientia** 1995 Dec 18; 51(12):1155–65 (104 ref.)
Regulation of cellular calcium through signaling cross-talk involves an intricate interplay between the actions of receptors, G-proteins, and second messengers. Bygrave FL, et al. **FASEB J** 1995 Oct;9(13):1297–303 (62 ref.)
Role of calcium in brain aging. Gareri P, et al. **Gen Pharmacol** 1995 Dec;26(8):1651–7 (64 ref.)
The role of calcium in the regulation of apoptosis. McConkey DJ, et al. **J Leukoc Biol** 1996 Jun;59(6):775–83 (125 ref.)
Calcium and inositol trisphosphate receptors. Taylor CW, et al. **J Membr Biol** 1995 May;145(2):109–18 (108 ref.)
Inositol trisphosphate and cyclic ADP ribose as long range messengers generating local subcellular calcium signals. Petersen OH. **J Physiol Paris** 1995;89(3):125–7 (16 ref.)
The role of intracellular Ca2+ in the regulation of gluconeogenesis. Krauss-Friedmann N, et al. **Metabolism** 1996 Mar;45(3):389–403 (208 ref.)
Regulation of phospholamban and troponin-I phosphorylation in the intact rat cardiomyocytes by adrenergic and cholinergic stimuli: roles of cyclic nucleotides, calcium, protein kinases and phosphatases and depolarization. Sulakhe PV, et al. **Mol Cell Biochem** 1995 Aug-Sep;149–150:103–26 (96 ref.)
Cellular effects of calcium channel blockers on vascular cells. Haller H. **Nephrol Dial Transplant** 1995 Oct;10 Suppl 9:3–8 (60 ref.)
Signal transduction in hair cells and its regulation by calcium. Jaramillo F. **Neuron** 1995 Dec;15(6):1227–30 (19 ref.)
Activation by GABAb, reduction of the intracellular concentration of Ca++, and inhibition of protein kinases are possible mechanisms of the long-term posttetanic modification of the efficiency of inhibitory transmission in the new cortex. Sil'kis IG. **Neurosci Behav Physiol** 1996 Jan-Feb;26(1):88–97 (41 ref.)
The importance of calcium in the control of salt intake. Tordoff MG. **Neurosci Biobehav Rev** 1996;20(1):89–99 (104 ref.)
Normal and abnormal calcium homeostasis in neurons: a basis for the pathophysiology of traumatic and ischemic central nervous system injury. Tymianski M, et al. **Neurosurgery** 1996 Jun;38(6):1176–95 (300 ref.)
Calcium: a regulator of the inflammatory response in endotoxemia and sepsis. Hotchkiss RS, et al. **New Horiz** 1996 Feb;4(1):58–71 (70 ref.)
Acute hypertension and calcium-channel blockers. Kanneganti M, et al. **New Horiz** 1996 Feb;4(1):19–25 (46 ref.)
Calcium blockage in pulmonary hypertension and hypoxic vasoconstriction. Neely CF, et al. **New Horiz** 1996 Feb; 4(1):99–106 (74 ref.)
Alterations in calcium signaling and cellular responses in septic injury. Sayeed MM. **New Horiz** 1996 Feb;4(1):72–86 (114 ref.)
Calcium regulation and nonprotective properties of calcium in surgical ischemia. Shapiro MJ, et al. **New Horiz** 1996 Feb;4(1):134–8 (29 ref.)
Regulation of endothelial permeability by second messengers. Siflinger-Birnboim A, et al. **New Horiz** 1996 Feb;4(1):87–98 (86 ref.)
Calcium homeostasis in smooth muscle cells. Smith JB. **New Horiz** 1996 Feb;4(1):2–18 (137 ref.)
Calcium-mediated cell injury and cell death. Trump BF, et al. **New Horiz** 1996 Feb;4(1):139–50 (38 ref.)
Carnosine: a novel peptide regulator of intracellular calcium and contractility in cardiac muscle. Zaloga GP, et al. **New Horiz** 1996 Feb;4(1):26–35 (92 ref.)
Calcium and the generation of plant form. Knight MR, et al. **Philos Trans R Soc Lond B Biol Sci** 1995 Oct 30; 350(1331):83–6 (23 ref.)
Calcium, cell death, and tumor promotion. Trump BF, et al. **Prog Clin Biol Res** 1995;391:121–31 (49 ref.)
Control of the Ca2+ release induced by myo-inositol trisphosphate and the implication in signal transduction. Missiaen L, et al. **Subcell Biochem** 1996;26:59–95 (216 ref.)
Calcium-independent synaptic transmission: artifact or fact? Piccolino M, et al. **Trends Neurosci** 1996 Apr;19(4):120–5 (37 ref.)
Neuronal Ca2+ stores: activation and function. Simpson PB, et al. **Trends Neurosci** 1995 Jul;18(7):299–306 (63 ref.)
[Endocrinology update—I] Allolio B, et al. **Med Klin** 1996 Apr 1;91 Suppl 1:24–32 (112 ref.) **(Ger)**
[The regulation of calcium homeostasis in nerve cells] Kozlovskii VL. **Usp Fiziol Nauk** 1995 Jul-Sep;26(3):14–24 (105 ref.) (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Pharmacologic prevention of colonic neoplasms. Effects of calcium, vitamins, omega fatty acids, and nonsteroidal anti-inflammatory drugs. Eastwood GL. **Dig Dis** 1996 Mar-Apr;14(2):119–28 (124 ref.)
Calcium and the prevention of colon cancer. Lipkin M, et al. **J Cell Biochem Suppl** 1995;22:65–73 (54 ref.)
Calcium-cell cycle regulator, differentiator, killer, chemopreventor, and maybe, tumor promoter. Whitfield JF, et al. **J Cell Biochem Suppl** 1995;22:74–91 (38 ref.)
Calcium supplementation prevents pregnancy-induced hypertension by increasing the production of vascular nitric oxide. López-Jaramillo P, et al. **Med Hypotheses** 1995 Jul; 45(1):68–72 (73 ref.)
Calcium, why and how much? Palmieri GM. **Miner Electrolyte Metab** 1995;21(1–3):236–41 (44 ref.)

URINE

Vitamin D, calcium, and sarcoidosis. Sharma OP. **Chest** 1996 Feb;109(2):535–9 (78 ref.)
New insights into the pathogenesis of idiopathic hypercalciuria: the role of bone. Weisinger JR. **Kidney Int** 1996 May;49(5):1507–18 (100 ref.)
Salt—more adverse effects. Antonios TF, et al. **Lancet** 1996 Jul 27;348(9022):250–1 (27 ref.)

CALCIUM-ACTIVATED NEUTRAL PROTEASE see **CALPAIN**

CALCIUM-ACTIVATED PHOSPHOLIPID-DEPENDENT KINASE see **PROTEIN KINASE C**

CALCIUM ADENOSINETRIPHOSPHATASE see **CA(2+)-TRANSPORTING ATPASE**

CALCIUM ANTAGONISTS, EXOGENOUS see **CALCIUM CHANNEL BLOCKERS**

CALCIUM ATPASE see **CA(2+)-TRANSPORTING ATPASE**

CALCIUM-BINDING PROTEIN, VITAMIN K-DEPENDENT see **OSTEOCALCIN**

CALCIUM-BINDING PROTEINS

Calponin. Winder SJ, et al. **Curr Top Cell Regul** 1996;34:33–61 (70 ref.)
Calcium-binding proteins. 1: EF-hands. Kawasaki H, et al. **Protein Profile** 1994;1(4):343–517 (6854 ref.)

ANALYSIS

[Calcium-binding proteins] Matsushima S, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:179–81 (14 ref.) **(Jpn)**

CHEMISTRY

Portrait of a myristoyl switch protein. Ames JB, et al. **Curr Opin Struct Biol** 1996 Aug;6(4):432–8 (47 ref.)
Kinesin-II, a membrane traffic motor in axons, axonemes, and spindles. Scholey JM. **J Cell Biol** 1996 Apr;133(1):1–4 (29 ref.)
The unveiling of calreticulin—a clinically relevant tour of modern cell biology. Sontheimer RD, et al. **J Investig Med** 1995 Aug;43(4):362–70 (92 ref.)

CALCIUM-BINDING PROTEINS

GENETICS

Calcium-sensing receptor mutations: insights into a structurally and functionally novel receptor [editorial; comment] Pearce SH, et al. **J Clin Endocrinol Metab** 1996 Apr;81(4):1309–11 (16 ref.) Comment on: J Clin Endocrinol Metab 1996 Apr;81(4):1312–7.

Calcium transport proteins in the nonfailing and failing heart: gene expression and function. Wankerl M, et al. **J Mol Med** 1995 Oct;73(10):487–96 (92 ref.)

METABOLISM

The Merck Frosst Award Lecture 1994/La conference Merck Frosst 1994. Calnexin: a molecular chaperone with a taste for carbohydrate. Williams DB. **Biochem Cell Biol** 1995 Mar–Apr;73(3–4):123–32 (50 ref.)

Regulation of calcium homoeostasis in neurons: the role of calcium-binding proteins. Miller RJ. **Biochem Soc Trans** 1995 Aug;23(3):629–32 (21 ref.)

The extracellular calcium receptor. Hebert SC, et al. **Curr Opin Cell Biol** 1995 Aug;7(4):484–92 (64 ref.)

Calcium-sensing receptor mutations: insights into a structurally and functionally novel receptor [editorial; comment] Pearce SH, et al. **J Clin Endocrinol Metab** 1996 Apr;81(4):1309–11 (16 ref.) Comment on: J Clin Endocrinol Metab 1996 Apr;81(4):1312–7.

Regulation of phospholamban and troponin-I phosphorylation in the intact rat cardiomyocytes by adrenergic and cholinergic stimuli: roles of cyclic nucleotides, calcium, protein kinases and phosphatases and depolarization. Sulakhe PV, et al. **Mol Cell Biochem** 1995 Aug–Sep;149–150:103–26 (96 ref.)

Calcium binding and conformational response in EF-hand proteins. Ikura M. **Trends Biochem Sci** 1996 Jan;21(1):14–7 (29 ref.)

PHYSIOLOGY

The leucocyte protein L1 (calprotectin): a putative nonspecific defence factor at epithelial surfaces. Brandtzaeg P, et al. **Adv Exp Med Biol** 1995;371A:201–6 (30 ref.)

The Ca2+(-)binding proteins parvalbumin and oncomodulin and their genes: new structural and functional findings. Pauls TL, et al. **Biochim Biophys Acta** 1996 Apr 10; 1306(1):39–54 (168 ref.)

Cloning and functional characterization of extracellular Ca(2+)-sensing receptors from parathyroid and kidney. Brown EM, et al. **Bone** 1995 Aug;17(2 Suppl):7S–11S (30 ref.)

Kinesin-related proteins at mitotic spindle poles: function and regulation. Walczak CE, et al. **Cell** 1996 Jun 28; 85(7):943–6 (18 ref.)

Control of photoreceptor proteins by Ca2+. Koch KW. **Cell Calcium** 1995 Oct;18(4):314–21 (72 ref.)

Reg protein: a potential beta-cell-specific growth factor? Baeza N, et al. **Diabetes Metab** 1996 Jul;22(4):229–34 (40 ref.)

Kinesin-II, a membrane traffic motor in axons, axonemes, and spindles. Scholey JM. **J Cell Biol** 1996 Apr;133(1):1–4 (29 ref.)

The unveiling of calreticulin--a clinically relevant tour of modern cell biology. Sontheimer RD, et al. **J Investig Med** 1995 Aug;43(4):362–70 (92 ref.)

Calcium-binding proteins 1: EF-hands. Kawasaki H, et al. **Protein Profile** 1995;2(4):297–490 (7282 ref.)

The S100 family of EF-hand calcium-binding proteins: functions and pathology. Schäfer BW, et al. **Trends Biochem Sci** 1996 Apr;21(4):134–40 (29 ref.)

[Calnexin is involved in the quality-control mechanism of the ER] Wada I. **Seikagaku** 1995 Sep;67(9):1133–7 (26 ref.) **(Jpn)**

CALCIUM BLOCKADERS, EXOGENOUS see **CALCIUM CHANNEL BLOCKERS**

CALCIUM-CALMODULIN DEPENDENT PROTEIN KINASES see **CALMODULIN-DEPENDENT PROTEIN KINASES**

CALCIUM CARBONATE

ANALYSIS

[Rare gallstone (calcium carbonate calculus)] Goto K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):418–20 (11 ref.) **(Jpn)**

METABOLISM

[Limy bile] Ise H, et al. **Ryoikibetsu Shokogun Shirizu** 1996; (9):489–91 (17 ref.) **(Jpn)**

PHARMACOLOGY

[Reinstatement of calcium-containing antacids] Tytgat GN. **Ned Tijdschr Geneeskd** 1995 Nov 25;139(47):2405–7 (14 ref.) **(Dut)**

CALCIUM CHANNEL BLOCKERS

see related
ANTI-ARRHYTHMIA AGENTS
ANTIHYPERTENSIVE AGENTS
VASODILATOR AGENTS

Nicardipine: applications in anesthesia practice. Tobias JD. **J Clin Anesth** 1995 Sep;7(6):525–33 (56 ref.)

ADMINISTRATION & DOSAGE

Angiotensin converting enzyme inhibitors and calcium antagonists alone or combined: does the progression of diabetic renal disease differ? Bakris GL, et al. **J Hypertens Suppl** 1995 Aug;13(2):S95–101 (52 ref.)

The pharmacological basis for the combination of calcium channel antagonists and angiotensin converting enzyme inhibitors in the treatment of hypertension. Osswald H, et al. **J Hypertens Suppl** 1995 Aug;13(2):S21–8 (58 ref.)

[Calcium antagonists and lithium in preventive treatment of manic-depressive disorder] Sarfati Y, et al. **Encephale** 1996 Mar–Apr;22(2):149–53 (43 ref.) (Eng. Abstr.) **(Fre)**

ADVERSE EFFECTS

Calcium antagonists. Drug interactions of clinical significance. Rosenthal T, et al. **Drug Saf** 1995 Sep; 13(3):157–87 (233 ref.)

Calcium channel blockers and hypertension: 1. New trials. Townsend RR, et al. **Hosp Pract (Off Ed)** 1996 Jul 15; 31(7):125–8, 133–6 (10 ref.)

Medications used to prevent migraine headaches and their potential ocular adverse effects. Doughty MJ, et al. **Optom Vis Sci** 1995 Dec;72(12):879–91 (176 ref.)

[Calcium antagonists--much noise about nothing?] Oberpichler-Schwenk H. **Med Monatsschr Pharm** 1995 Dec;18(12):344–9 (14 ref.) **(Ger)**

BLOOD

[Calcium antagonist] Sasaki S, et al. **Nippon Rinsho** 1995 Feb; 53 Su Pt 1:970–3 (9 ref.) **(Jpn)**

PHARMACOKINETICS

The nifedipine gastrointestinal therapeutic system (GITS). Evaluation of pharmaceutical, pharmacokinetic and pharmacological properties. Grundy JS, et al. **Clin Pharmacokinet** 1996 Jan;30(1):28–51 (131 ref.)

PHARMACOLOGY

Neuroprotective use-dependent blockers of Na+ and Ca2+ channels controlling presynaptic release of glutamate. Goldin SM, et al. **Ann N Y Acad Sci** 1995 Sep 15;765:210–29 (59 ref.)

Clentiazem and diltiazem preserve endothelium-dependent relaxation following global rat heart ischemia. Dagenais F, et al. **Can J Cardiol** 1995 Oct;11(9):816–22 (45 ref.)

Intracellular calcium modulators for cardiac muscle in pathological conditions. Ishide N. **Jpn Heart J** 1996 Jan; 37(1):1–17 (80 ref.)

Cellular effects of calcium channel blockers on vascular cells. Haller H. **Nephrol Dial Transplant** 1995 Oct;10 Suppl 9:3–8 (60 ref.)

Renal effects of calcium antagonists. Rodicio JL, et al. **Nephrol Dial Transplant** 1995 Oct;10 Suppl 9:17–22 (57 ref.)

Effects of ACE inhibitors and calcium channel blockers on insulin sensitivity and other components of the syndrome. Sowers JR. **Nephrol Dial Transplant** 1995 Oct;10 Suppl 9:52–5 (41 ref.)

Calcium channel antagonists in the treatment of coronary artery disease: fundamental pharmacological properties relevant to clinical use. Opie LH. **Prog Cardiovasc Dis** 1996 Jan–Feb;38(4):273–90 (93 ref.)

THERAPEUTIC USE

Magnesium in acute myocardial infarction: overview of available evidence. Antman EM. **Am Heart J** 1996 Aug; 132(2 Pt 2 Su):487–95; discussion 496–502 (53 ref.)

Is there a place for magnesium in the treatment of acute myocardial infarction? Seelig MS, et al. **Am Heart J** 1996 Aug;132(2 Pt 2 Su):471–7; discussion 496–502 (73 ref.)

The rationale of magnesium as alternative therapy for patients with acute myocardial infarction without thrombolytic therapy. Shechter M, et al. **Am Heart J** 1996 Aug;132(2 Pt 2 Su):483–6; discussion 496–502 (39 ref.)

Acute myocardial infarction, reperfusion injury, and intravenous magnesium therapy: basic concepts and clinical implications. Steurer G, et al. **Am Heart J** 1996 Aug;132(2 Pt 2 Su):478–82; discussion 496–502 (86 ref.)

Use of calcium channel antagonists in myocardial revascularization procedures. Califf RM, et al. **Am J Cardiol** 1996 Jun 20;77(16):26D–31D (28 ref.)

Prognosis of patients with unstable angina or acute myocardial infarction treated with calcium channel antagonists. Ferrari R. **Am J Cardiol** 1996 Jun 20; 77(16):22D–25D (44 ref.)

Anti-ischemic intervention as prognosis improvement in patients with coronary artery disease, with special focus on verapamil. Jespersen CM. **Am J Cardiol** 1996 Jun 20; 77(16):32D–36D (64 ref.)

Response of hypertensive left ventricular hypertrophy and coronary microvascular disease to calcium antagonists. Vogt M, et al. **Am J Cardiol** 1995 Nov 2;76(13):24D–30D (52 ref.)

Blood pressure-lowering effect of adding grapefruit juice to nifedipine and terazosin in a patient with severe renovascular hypertension. Pisarik P. **Arch Fam Med** 1996 Jul–Aug;5(7):413–6 (17 ref.)

Calcium antagonists should continue to be used for first-line treatment of hypertension [see comments] Epstein M. **Arch Intern Med** 1995 Nov 13;155(20):2150–6 (52 ref.) Comment in: Arch Intern Med 1995 Nov 13;155(20):2145. Comment in: Arch Intern Med 1996 May 27;156(10):1115–6.

Effects of ACE inhibitors and calcium antagonists on progression of chronic renal disease. Epstein M. **Blood Press Suppl** 1995;2:108–12 (41 ref.)

Short acting dihydropyridine (vasodilating) calcium channel blockers for hypertension: is there a risk? Beevers DG, et al. **BMJ** 1996 May 4;312(7039):1143–5 (19 ref.)

Effect of calcium antagonists in variant or Prinzmetal angina. Pepine CJ. **Can J Cardiol** 1995 Nov;11(10):952–6 (44 ref.)

Coadministration of calcium antagonists and ACE inhibitors--is a skeptic convinced?: a personal view. Campbell RW. **Cardiovasc Drugs Ther** 1995 Aug;9 Suppl 3:525–8 (33 ref.)

ACE inhibitors and calcium antagonists in the treatment of congestive heart failure. Hansen JF. **Cardiovasc Drugs Ther** 1995 Aug;9 Suppl 3:503–7 (30 ref.)

Vascular selective calcium entry blockers in the treatment of cardiovascular disorders: focus on felodipine. Little WC, et al. **Cardiovasc Drugs Ther** 1995 Oct;9(5):657–63 (49 ref.)

Vascular protective effects of ACE inhibitors and calcium antagonists: theoretical basis for a combination therapy in hypertension and other cardiovascular diseases. Lüscher TF, et al. **Cardiovasc Drugs Ther** 1995 Aug;9 Suppl 3:509–23 (89 ref.)

Calcium channel blockers. Ray D, et al. **Clin Obstet Gynecol** 1995 Dec;38(4):713–21 (40 ref.)

Calcium antagonists during and after myocardial infarction. Sleight P. **Drugs** 1996 Feb;51(2):216–25 (41 ref.)

Myocardial protection with calcium-channel blockers during ischaemia and reperfusion by PTCA. Chouairi S, et al. **Eur Heart J** 1995 Aug;16 Suppl H:3–8 (42 ref.)

The effects of calcium antagonists after PTCA. Hoberg E. **Eur Heart J** 1995 Aug;16 Suppl H:9–12 (12 ref.)

Anti-ischaemic intervention with verapamil in patients recovering from acute myocardial infarction. Jespersen CM. **Eur Heart J** 1995 Aug;16 Suppl H:13–7 (24 ref.)

The role of calcium antagonists in ischaemic heart disease. Pepine CJ. **Eur Heart J** 1995 Aug;16 Suppl H:19–24 (36 ref.)

Ischemic stroke: treatment on the horizon. Giroux C, et al. **Eur Neurol** 1996;36(2):61–4 (12 ref.)

Should calcium antagonists be first line drugs in hypertension? Furberg CD, et al. **Herz** 1995 Dec; 20(6):365–9 (10 ref.)

Newer calcium antagonists for treatment of systemic hypertension. Singh NK. **J Assoc Physicians India** 1995 Apr;43(4):277–81 (47 ref.)

Impact of converting enzyme inhibitors and calcium entry blockers on cardiac allograft vasculopathy: from bench to bedside. Mehra MR, et al. **J Heart Lung Transplant** 1995 Nov-Dec;14(6 Pt 2):S246–9 (16 ref.)

Update on the use of angiotensin converting enzyme inhibitors and calcium antagonists in postinfarction patients. Persson S. **J Hypertens Suppl** 1995 Aug;13(2):S57–63 (33 ref.)

Calcium channel blockers and renal dysfunction in arterial hypertension. Díez J. **Nephrol Dial Transplant** 1995;10 Suppl 6:22–6 (50 ref.)

Effects of ACE inhibitors and calcium antagonists alone or combined on progression of diabetic nephropathy. Lash JP, et al. **Nephrol Dial Transplant** 1995 Oct;10 Suppl 9:56–62 (52 ref.)

Effects of ACE inhibitors and calcium channel blockers on the development of glomerular sclerosis in models of renal damage. Raij L. **Nephrol Dial Transplant** 1995 Oct;10 Suppl 9:23–7 (55 ref.)

Antiarrhythmic and anti-ischemic properties of calcium-channel antagonists. Apostolakos MJ, et al. **New Horiz** 1996 Feb;4(1):45–57 (94 ref.)

The role of calcium-channel antagonists in solid organ transplantation. Huntress JD, et al. **New Horiz** 1996 Feb; 4(1):129–33 (30 ref.)

Acute hypertension and calcium-channel blockers. Kanneganti M, et al. **New Horiz** 1996 Feb;4(1):19–25 (46 ref.)

The use of calcium-channel blockers in pregnancy. Lewis R, et al. **New Horiz** 1996 Feb;4(1):115–22 (45 ref.)

Calcium blockage in pulmonary hypertension and hypoxic vasoconstriction. Neely CF, et al. **New Horiz** 1996 Feb; 4(1):99–106 (74 ref.)

Calcium antagonists and the kidney. Pearce CJ, et al. **New Horiz** 1996 Feb;4(1):123–8 (47 ref.)

Neuroprotective properties of calcium-channel blockers. Zornow MH, et al. **New Horiz** 1996 Feb;4(1):107–14 (58 ref.)

Evolving role of calcium channel blockers in heart failure. Pieper JA. **Pharmacotherapy** 1996 Mar–Apr;16(2 Pt 2):43S–49S (26 ref.)

Calcium channel antagonists in the treatment of coronary artery disease: fundamental pharmacological properties relevant to clinical use. Opie LH. **Prog Cardiovasc Dis** 1996 Jan–Feb;38(4):273–90 (93 ref.)

Calcium channel antagonists in the management of anginal syndromes: changing concepts in relation to the role of coronary vasospasm. Opie LH. **Prog Cardiovasc Dis** 1996 Jan–Feb;38(4):291–314 (154 ref.)

[Beta blockers, calcium channel blockers and psyche]

Strandberg T, et al. **Duodecim** 1994;110(4):397–402 (29 ref.) **(Fin)**

[Calcium antagonists and treatment of chronic heart failure] Lanfranchi J. **Arch Mal Coeur Vaiss** 1995 Apr;88(4 Suppl):623–31 (49 ref.) (Eng. Abstr.) **(Fre)**

[Calcium antagonists in cardiovascular diseases] Thuillez C. **Arch Mal Coeur Vaiss** 1995 Sep;88 Spec No 4:9–12 (22 ref.) (Eng. Abstr.) **(Fre)**

[Role of modulators in Plasmodium falciparum resistance to antimalarials] Verdier F, et al. **Med Trop (Mars)** 1995;55(4 Suppl):27–32 (20 ref.) (Eng. Abstr.) **(Fre)**

[Controversy over calcium antagonists: is there a rationally differentiating therapy?] Lüscher TF, et al. **Dtsch Med Wochenschr** 1996 Apr 19;121(16):532–8 (64 ref.) **(Ger)**

[Calcium antagonists in treatment of ventricular tachycardia] Melichercik J, et al. **Z Kardiol** 1996 May;85(5):319–25 (31 ref.) (Eng. Abstr.) **(Ger)**

[Selected passages from the clinical trials of Cordaflex] Somogyi M, et al. **Acta Pharm Hung** 1996 Jan;66(1):47–51 (16 ref.) (Eng. Abstr.) **(Hun)**

[Metabolic tolerance of isradipine. Evaluation after three months of therapy] Panuccio D, et al. **Clin Ter** 1995 Nov; 146(11):729–36 (82 ref.) (Eng. Abstr.) **(Ita)**

[A free radical mechanism for inhibition of arteriosclerosis development with calcium antagonists] Andrzejak R, et al. **Postepy Hig Med Dosw** 1995;49(5):645–59 (87 ref.) (Eng. Abstr.) **(Pol)**

[Controversies in the treatment of arterial hypertension: other drugs as the first step (calcium antagonists, ACE inhibitors and alpha-blockers)] Castro Beiras A, et al. **Rev Esp Cardiol** 1995;48 Suppl 4:72–80 (31 ref.) (Eng. Abstr.) **(Spa)**

[Prophylactic treatment of chronic cluster headache] Alberca R. **Rev Neurol** 1995;23 Suppl 4:S530–4 (55 ref.) **(Spa)**

[Calcium antagonists in the prophylaxis of migraine] Lara M, et al. **Rev Neurol** 1995;23 Suppl 2:S179–84 (32 ref.) **(Spa)**

[Prophylactic treatment of episodic forms of cluster headache] Liaño H, et al. **Rev Neurol** 1995;23 Suppl 4:S525–9 (29 ref.) **(Spa)**

TOXICITY

Pathogenesis of drug-induced gingival overgrowth. A review of studies in the rat model. Nishikawa S, et al. **J Periodontol** 1996 May;67(5):463–71 (94 ref.)

CALCIUM CHANNELS

see related
CA(2+)-TRANSPORTING ATPASE
CALCIUM CHANNEL BLOCKERS

The inositol triphosphate receptor family. Joseph SK. **Cell Signal** 1996 Jan;8(1):1–7 (97 ref.)

[Excitation-contraction uncoupling and muscular degeneration lacking functional skeletal muscle ryanodine-receptor gene] Nishi M. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2181–7 (18 ref.) **(Jpn)**

CHEMISTRY

Molecular pore structure of voltage-gated sodium and calcium channels. Heinemann SH, et al. **Braz J Med Biol Res** 1994 Dec;27(12):2781–802 (54 ref.)

Molecular structure and tissue distribution of ryanodine receptors calcium channels. Giannini G, et al. **Med Res Rev** 1995 Jul;15(4):313–23 (73 ref.)

CLASSIFICATION

Functional properties of intracellular calcium-release channels. Ehrlich BE. **Curr Opin Neurobiol** 1995 Jun; 5(3):304–9 (48 ref.)

DRUG EFFECTS

Anti-calcium channel autoantibodies in amyotrophic lateral sclerosis. A review of the evidence. Seagar MJ, et al. **Adv Neurol** 1995;68:67–72 (30 ref.)

Pharmacology of sodium and calcium channel modulation in neurons: implications for neuroprotection. Spedding M, et al. **Biochem Soc Trans** 1995 Aug;23(3):633–6 (50 ref.)

Do KCa channels and carbonic anhydrase play a role in thiazide-induced hyperglycaemia? Pickkers P, et al. **J Hum Hypertens** 1995 Aug;9(8):691–3 (22 ref.)

Pharmacological modulators of the inositol 1,4,5-trisphosphate receptor. Michelangeli F, et al. **Neuropharmacology** 1995 Sep;34(9):1111–22 (108 ref.)

GENETICS

A cloned extracellular Ca(2+)-sensing receptor: molecular mediator of the actions of extracellular Ca2+ on parathyroid and kidney cells? Brown EM, et al. **Kidney Int** 1996 Apr;49(4):1042–6 (37 ref.)

[Excitation-contraction uncoupling and muscular degeneration lacking functional skeletal muscle ryanodine-receptor gene] Nishi M. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2181–7 (18 ref.) **(Jpn)**

IMMUNOLOGY

Anti-calcium channel autoantibodies in amyotrophic lateral sclerosis. A review of the evidence. Seagar MJ, et al. **Adv Neurol** 1995;68:67–72 (30 ref.)

METABOLISM

Calcium uptake and release modulated by counter-ion conductances in the sarcoplasmic reticulum of skeletal muscle. Fink RH, et al. **Acta Physiol Scand** 1996 Mar; 156(3):387–96 (65 ref.)

Low-threshold calcium currents in central nervous system neurons. Huguenard JR. **Annu Rev Physiol** 1996;58:329–48 (111 ref.)

Capacitative calcium entry [see comments] Berridge MJ. **Biochem J** 1995 Nov 15;312 (Pt 1):1–11 (126 ref.) Comment in: Biochem J 1996 Mar 15;314 (Pt 3):1054–6.

Ligand- and voltage-gated calcium release channels at the vacuolar membrane. Sanders D, et al. **Biochem Soc Trans** 1995 Nov;23(4):856–61 (59 ref.)

TRP: its role in phototransduction and store-operated Ca2+ entry. Friel DD. **Cell** 1996 May 31;85(5):617–9 (20 ref.)

The inositol trisphosphate receptor of Xenopus oocytes. Parys JB, et al. **Cell Calcium** 1995 Nov;18(5):353–63 (89 ref.)

Modulation of Ca2+ channels by alpha 1A- and alpha 2A-adrenoceptors in vascular myocytes: involvement of different transduction pathways. Mironneau J, et al. **Cell Signal** 1995 Jul;7(5):471–9 (29 ref.)

Somatostatin modulates voltage-dependent Ca2+ channels in GH3 cells via a specific G(o) splice variant. Kleuss C. **Ciba Found Symp** 1995;190:171–82; discussion 182–6 (38 ref.)

Calcium signalling. Cracking ICRAC in the eye. Bennett DL, et al. **Curr Biol** 1995 Nov 1;5(11):1225–8 (22 ref.)

Ligand-gated calcium channels inside and out. Striggow F, et al. **Curr Opin Cell Biol** 1996 Aug;8(4):490–5 (57 ref.)

The inositol 1,4,5-trisphosphate (InsP3) receptor. Bezprozvanny I, et al. **J Membr Biol** 1995 Jun; 145(3):205–16 (131 ref.)

Molecular biology of calcium channels. Perez-Reyes E, et al. **Kidney Int** 1995 Oct;48(4):1111–24 (156 ref.)

Identification and localization of calcium channel alpha 1 and beta subunit isoforms in the kidney. Yu AS. **Kidney Int** 1995 Oct;48(4):1097–101 (58 ref.)

Aging-related increase in hippocampal calcium channels. Landfield PW. **Life Sci** 1996;59(5–6):399–404 (17 ref.)

Molecular structure and tissue distribution of ryanodine receptors calcium channels. Giannini G, et al. **Med Res Rev** 1995 Jul;15(4):313–23 (73 ref.)

Cell calcium and arterial blood pressure. Gonzalez JM, et al. **Semin Nephrol** 1995 Nov;15(6):564–8 (56 ref.)

Cyclic ADP-ribose, the ryanodine receptor and Ca2+ release. Sitsapesan R, et al. **Trends Pharmacol Sci** 1995 Nov; 16(11):386–91 (50 ref.)

[Mechanisms of mobilization of intracellular stored calcium] Li HW, et al. **Sheng Li Ko Hsueh Chin Chan** 1995 Jul; 26(3):209–12 (17 ref.) (Eng. Abstr.) **(Chi)**

[Receptor mediated Ca influx and Ca-permeable channels] Inoue R. **Fukuoka Igaku Zasshi** 1996 Apr;87(4):92–6 (15 ref.) **(Jpn)**

[Ryanodine receptors in the central nervous system] Ogawa Y, et al. **Nippon Yakurigaku Zasshi** 1995 Jun;105(6):423–30 (50 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

The ryanodine receptor family of intracellular calcium release channels. Sorrentino V. **Adv Pharmacol** 1995; 33:67–90 (119 ref.)

Phosphoinositide-mediated phototransduction in Drosophila photoreceptors: the role of Ca2+ and trp. Hardie RC, et al. **Cell Calcium** 1995 Oct;18(4):256–74 (125 ref.)

Control of photoreceptor proteins by Ca2+. Koch KW. **Cell Calcium** 1995 Oct;18(4):314–21 (72 ref.)

Ca2+ flux in retinal rod and cone outer segments: differences in Ca2+ selectivity of the cGMP-gated ion channels and Ca2+ clearance rates. Korenbrot JI. **Cell Calcium** 1995 Oct;18(4):285–300 (75 ref.)

The inositol triphosphate receptor family. Joseph SK. **Cell Signal** 1996 Jan;8(1):1–7 (97 ref.)

Functional properties of intracellular calcium-release channels. Ehrlich BE. **Curr Opin Neurobiol** 1995 Jun; 5(3):304–9 (48 ref.)

CACN4, the major alpha 1 subunit isoform of voltage-dependent calcium channels in pancreatic beta-cells: a minireview of current progress. Seino S. **Diabetes Res Clin Pract** 1995 Aug;28 Suppl:S99–103 (20 ref.)

Extracellular calcium sensitivity and voltage-dependent calcium channels in C cells. Raue F, et al. **Endocr Rev** 1995 Dec;16(6):752–64 (122 ref.)

Inositolpolyphosphate binding sites and their likely role in calcium regulation in smooth muscle. Zhang L, et al. **Int J Biochem Cell Biol** 1995 Dec;27(12):1231–48 (135 ref.)

Calcium channel diversity in the cardiovascular system. Katz AM. **J Am Coll Cardiol** 1996 Aug;28(2):522–9 (65 ref.)

Calcium and inositol trisphosphate receptors. Taylor CW, et al. **J Membr Biol** 1995 May;145(2):109–18 (108 ref.)

Calcium channels in vascular smooth muscle cells. Hughes AD. **J Vasc Res** 1995 Nov-Dec;32(6):353–70 (294 ref.)

Inositolpolyphosphates and their binding proteins--a short review. Huisamen B, et al. **Mol Cell Biochem** 1996 Apr 12–26;157(1–2):229–32 (29 ref.)

Calcium channels in cerebral arteries. Alborch E, et al. **Pharmacol Ther** 1995;68(1):1–34 (187 ref.)

Malignant hyperthermia: excitation-contraction coupling, Ca2+ release channel, and cell Ca2+ regulation defects. Mickelson JR, et al. **Physiol Rev** 1996 Apr;76(2):537–92 (433 ref.)

Neuronal calcium channels encoded by the alpha 1A subunit and their contribution to excitatory synaptic transmission in the CNS. Wheeler DB, et al. **Prog Brain Res** 1995; 105:65–78 (51 ref.)

Facilitation of Ca2+ current in excitable cells. Dolphin AC. **Trends Neurosci** 1996 Jan;19(1):35–43 (95 ref.)

[The calcium hypothesis of brain aging] Müller WE, et al. **Nervenarzt** 1996 Jan;67(1):15–24 (59 ref.) (Eng. Abstr.) **(Ger)**

[Developmental aspects of electrophysiology in cardiac muscle] Satoh H, et al. **Nippon Yakurigaku Zasshi** 1996 May;107(5):213–23 (38 ref.) (Eng. Abstr.) **(Jpn)**

[The calcium channels of cell membranes] Vislobokov AI, et al. **Usp Fiziol Nauk** 1995 Jan-Mar;26(1):93–110 (78 ref.) (Eng. Abstr.) **(Rus)**

CALCIUM CHLORIDE

ADVERSE EFFECTS

How accurately can bruises be aged in abused children? Literature review and synthesis. Schwartz AJ, et al. **Pediatrics** 1996 Feb;97(2):254–7 (46 ref.)

CALCIUM COMPOUNDS

PHARMACOLOGY

Adjuvant properties of aluminum and calcium compounds. Gupta RK, et al. **Pharm Biotechnol** 1995;6:229–48 (126 ref.)

CALCIUM-DEPENDENT ACTIVATOR PROTEIN see **CALMODULIN**

CALCIUM-DEPENDENT NEUTRAL PROTEINASE see **CALPAIN**

CALCIUM-DEPENDENT REGULATOR see **CALMODULIN**

CALCIUM, DIETARY

Current and future nonhormonal approaches to the treatment of osteoporosis. Bilezikian JP. **Int J Fertil Menopausal Stud** 1996 Mar-Apr;41(2):148–55 (45 ref.)

Dietary calcium and blood pressure: a review of the observational studies. Pryer J, et al. **J Hum Hypertens** 1995 Aug;9(8):597–604 (53 ref.)

Calcium intake and blood pressure: epidemiology revisited. Morris CD, et al. **Semin Nephrol** 1995 Nov;15(6):490–5 (31 ref.)

[Calcium and colon cancer] Liberman-Insel V, et al. **Harefuah** 1996 Jan 15;130(2):129–31 (20 ref.) **(Heb)**

ADMINISTRATION & DOSAGE

Role of calcium and vitamin D in the prevention and the treatment of postmenopausal osteoporosis: an overview. Kaufman JM. **Clin Rheumatol** 1995 Sep;14 Suppl 3:9–13 (46 ref.)

Calcium, phosphorus and human bone development. Anderson JJ. **J Nutr** 1996 Apr;126(4 Suppl):1153S–8S (32 ref.)

Do dairy products improve bone density in adolescent girls? Kerstetter JE. **Nutr Rev** 1995 Nov;53(11):328–32 (26 ref.)

[Optimal calcium intake. Consensus conference of the National Institute of Health] Bornkessel B. **Med Monatsschr Pharm** 1995 Sep;18(9):264–8 (1 ref.) **(Ger)**

METABOLISM

Interactions between large intestine fermentation and dietary calcium. Demigné C, et al. **Eur J Clin Nutr** 1995 Oct;49 Suppl 3:S235–8 (13 ref.)

Mechanisms of calcium's effects on blood pressure. Hatton DC, et al. **Semin Nephrol** 1995 Nov;15(6):593–602 (111 ref.)

Dietary calcium intake: effects on central blood pressure control. Pörsti I, et al. **Semin Nephrol** 1995 Nov; 15(6):550–63 (176 ref.)

PHARMACOLOGY

Calcium, magnesium and phosphorus in the nutrition of the newborn. Venkataraman PS, et al. **J Am Coll Nutr** 1995 Oct;14(5):439–47 (102 ref.)

THERAPEUTIC USE

Calcium and vitamin D: possible protective agents against colorectal cancer? Kleibeuker JH, et al. **Eur J Cancer** 1995 Jul-Aug;31A(7–8):1081–4 (33 ref.)

Blood pressure effects of calcium intake in experimental models of hypertension. Schleiffer R, et al. **Semin Nephrol** 1995 Nov;15(6):526–35 (91 ref.)

CALCIUM HYDROXYAPATITE see **DURAPATITE**

CALCIUM INHIBITORS, EXOGENOUS

CALCIUM INHIBITORS, EXOGENOUS see **CALCIUM CHANNEL BLOCKERS**

CALCIUM LEUCOVORIN see **LEUCOVORIN**

CALCIUM METABOLISM DISORDERS

GENETICS

Recent advances in the genetics of disorders of calcium homeostasis. Root AW. **Adv Pediatr** 1996;43:77–125 (107 ref.)

Molecular genetics of disorders of calcium homeostasis. Bassett JH, et al. **Baillieres Clin Endocrinol Metab** 1995 Jul;9(3):581–608 (128 ref.)

CALCIUM OXALATE

CHEMISTRY

Calcium oxalate monohydrate renal calculi. Formation and development mechanism. Söhnel O, et al. **Adv Colloid Interface Sci** 1995 Aug 31;59:1–17 (36 ref.)

METABOLISM

Histological study of oxalosis in the eye and adnexa of AIDS patients. Pecorella I, et al. **Histopathology** 1995 Nov; 27(5):431–8 (22 ref.)

Calcium oxalate crystal deposition in epithelioid histiocytes of granulomatous lymphadenitis: analysis by light and electronmicroscopy. Symmans PJ, et al. **Histopathology** 1995 Nov;27(5):423–9 (11 ref.)

Hypercalcaemia complicating systemic oxalosis in primary hyperoxaluria type 1. Toussaint C, et al. **Nephrol Dial Transplant** 1995;10 Suppl 8:17–21 (21 ref.)

[Metabolic investigation of calcium oxalate urinary lithiasis. Indicators of lithogenic risk: modalities, applications and perspectives] Robert M. **Prog Urol** 1996 Feb;6(1):44–51 (84 ref.) (Eng. Abstr.) **(Fre)**

[Diagnostic markers in calcium nephrolithiasis—current and traditional ideas with a new look] Hess B. **Schweiz Med Wochenschr** 1995 Dec 26;125(51–52):2460–70 (56 ref.) (Eng. Abstr.) **(Ger)**

URINE

Experimental calcium oxalate nephrolithiasis and the formation of human urinary stones. Khan SR. **Scanning Microsc** 1995 Mar;9(1):89–100; discussion 100–1 (79 ref.)

Heterogeneous nucleation of calcium oxalate crystals in mammalian urine. Khan SR. **Scanning Microsc** 1995 Jun; 9(2):597–614; discussion 614–6 (130 ref.)

CALCIUM PHOSPHATES

METABOLISM

Acute calcific periarthritis of the fingers. Gálvez J, et al. **Rev Rhum Engl Ed** 1995 Oct;62(9):602–4 (11 ref.)

[Diagnostic markers in calcium nephrolithiasis—current and traditional ideas with a new look] Hess B. **Schweiz Med Wochenschr** 1995 Dec 26;125(51–52):2460–70 (56 ref.) (Eng. Abstr.) **(Ger)**

CALCIUM PHOSPHOLIPID-DEPENDENT PROTEIN KINASE see **PROTEIN KINASE C**

CALCIUM PUMP see **CA(2+)-TRANSPORTING ATPASE**

CALCIUM PYROPHOSPHATE

see related
CHONDROCALCINOSIS

CALCIUM PYROPHOSPHATE DIHYDRATE DEPOSITION see **CHONDROCALCINOSIS**

CALCIUM TRANSPORT PROTEINS see **CALCIUM-BINDING PROTEINS**

CALCULATORS, PROGRAMMABLE see **COMPUTERS**

CALCULI

see related
LITHOTRIPSY

[Intrahepatic stones] Tanimura H. **Ryoikibetsu Shokogun Shirizu** 1995;(8):502–4 (14 ref.) **(Jpn)**

COMPLICATIONS

Testicular microlithiasis: a benign condition with a malignant association. Miller RL, et al. **J Clin Ultrasound** 1996 May; 24(4):197–202 (32 ref.)

ULTRASONOGRAPHY

[Testicular microlithiasis. A pediatric case report] Orazi C, et al. **Radiol Med (Torino)** 1996 Jan–Feb;91(1–2):145–7 (27 ref.) **(Ita)**

CALDESMON see **CALMODULIN-BINDING PROTEINS**

CALELECTRIN 67 KD see **ANNEXIN VI**

CALELECTRINS see **ANNEXINS**

CALIBRATION

[Calibration and standardization in enzyme immunoassay] Kuwa K. **Nippon Rinsho** 1995 Sep;53(9):2232–8 (9 ref.) (Eng. Abstr.) **(Jpn)**

CALICIVIRIDAE

ENZYMOLOGY

Proteolytic processing of the arterivirus replicase. Snijder E, et al. **Adv Exp Med Biol** 1995;380:443–51 (28 ref.)

GENETICS

Genome organization in the caliciviridae. Lambden PR, et al. **Trends Microbiol** 1995 Jul;3(7):261–5 (44 ref.)

CALISTHENICS see **GYMNASTICS**

CALLA see **MEMBRANE METALLO-ENDOPEPTIDASE**

CALLA-POSITIVE LYMPHOBLASTIC LEUKEMIA see **LEUKEMIA, CALLA-POSITIVE**

CALLICEBINAE see **CEBIDAE**

CALLITHRIX

[Application of the common marmoset to pharmacological studies] Nomoto M. **Nippon Yakurigaku Zasshi** 1995 Jul; 106(1):11–8 (23 ref.) (Eng. Abstr.) **(Jpn)**

CALLITHRIX JACCHUS see **CALLITHRIX**

CALLOSITIES

Callosities, corns, and calluses. Singh D, et al. **BMJ** 1996 Jun 1;312(7043):1403–6 (12 ref.)

CALMETTE-GUERIN BACILLUS see **MYCOBACTERIUM BOVIS**

CALMETTE GUERIN BACILLUS VACCINE see **BCG VACCINE**

CALMODULIN

CHEMISTRY

PEST sequences in calmodulin-binding proteins. Barnes JA, et al. **Mol Cell Biochem** 1995 Aug–Sep;149–150:17–27 (94 ref.)

Protein engineering and NMR studies of calmodulin. Vogel HJ, et al. **Mol Cell Biochem** 1995 Aug–Sep;149–150:3–15 (67 ref.)

METABOLISM

Signal transduction: regulation of cAMP concentration in cardiac muscle by calmodulin-dependent cyclic nucleotide phosphodiesterase. Sharma RK. **Mol Cell Biochem** 1995 Aug–Sep;149–150:241–7 (23 ref.)

Calmodulin: effects of cell stimuli and drugs on cellular activation. Gnegy ME. **Prog Drug Res** 1995;45:33–65 (248 ref.)

PHYSIOLOGY

Control of electron transfer in neuronal nitric oxide synthase by calmodulin, substrate, substrate analogs, and nitric oxide. Stuehr DJ, et al. **Adv Pharmacol** 1995;34:207–13 (15 ref.)

CALMODULIN-BINDING PROTEINS

Calponin. Winder SJ, et al. **Curr Top Cell Regul** 1996;34:33–61 (70 ref.)

CHEMISTRY

PEST sequences in calmodulin-binding proteins. Barnes JA, et al. **Mol Cell Biochem** 1995 Aug–Sep;149–150:17–27 (94 ref.)

Protein engineering and NMR studies of calmodulin. Vogel HJ, et al. **Mol Cell Biochem** 1995 Aug–Sep;149–150:3–15 (67 ref.)

Insights derived from the structures of the Ser/Thr phosphatases calcineurin and protein phosphatase 1. Lohse DL, et al. **Structure** 1995 Oct 15;3(10):987–90 (24 ref.)

METABOLISM

Calcium signalling. Cracking ICRAC in the eye. Bennett DL, et al. **Curr Biol** 1995 Nov 1;5(11):1225–8 (22 ref.)

Cyclic ADP-ribose, the ryanodine receptor and Ca2+ release. Sitsapesan R, et al. **Trends Pharmacol Sci** 1995 Nov; 16(11):386–91 (50 ref.)

PHYSIOLOGY

The ryanodine receptor family of intracellular calcium release channels. Sorrentino V. **Adv Pharmacol** 1995; 33:67–90 (119 ref.)

The role of calcineurin in immune system responses. Kincaid RL. **J Allergy Clin Immunol** 1995 Dec;96(6 Pt 2):1170–7 (40 ref.)

CALMODULIN-DEPENDENT PROTEIN KINASES

CHEMISTRY

PEST sequences in calmodulin-binding proteins. Barnes JA, et al. **Mol Cell Biochem** 1995 Aug–Sep;149–150:17–27 (94 ref.)

GENETICS

Plant homologues of components of MAPK (mitogen-activated protein kinase) signal pathways in yeast and animal cells. Nishihama R, et al. **Plant Cell Physiol** 1995 Jul;36(5):749–57 (100 ref.)

METABOLISM

Protein serine/threonine kinases (PKA, PKC and CaMKII) involved in ischemic brain pathology. Domańska-Janik K. **Acta Neurobiol Exp (Warsz)** 1996;56(2):579–85 (44 ref.)

Platelet-derived growth factor. Distinct signal transduction pathways associated with migration versus proliferation. Bornfeldt KE, et al. **Ann N Y Acad Sci** 1995 Sep 7; 766:416–30 (67 ref.)

Protein serine/threonine kinases of the MAPK cascade. Graves JD, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:320–43 (151 ref.)

The stress-activated protein kinases. A novel ERK subfamily responsive to cellular stress and inflammatory cytokines. Kyriakis JM, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:303–19 (48 ref.)

Angiotensin II signal transduction and the mitogen-activated protein kinase pathway. Duff JL, et al. **Cardiovasc Res** 1995 Oct;30(4):511–7 (102 ref.)

Regulation of transcription by MAP kinase cascades. Treisman R. **Curr Opin Cell Biol** 1996 Apr;8(2):205–15 (95 ref.)

Mitogen and stress response pathways: MAP kinase cascades and phosphatase regulation in mammals and yeast. Waskiewicz AJ, et al. **Curr Opin Cell Biol** 1995 Dec; 7(6):798–805 (79 ref.)

Furin/PACE/SPC1: a convertase involved in exocytic and endocytic processing of precursor proteins. Denault JB, et al. **FEBS Lett** 1996 Jan 29;379(2):113–6 (46 ref.)

Multiple intracellular MAP kinase signaling cascades [editorial] Bokemeyer D, et al. **Kidney Int** 1996 May; 49(5):1187–98 (191 ref.)

Mitogen-activated protein kinase (MAPK) in cardiac tissues. Page C, et al. **Mol Cell Biochem** 1996 Apr 12–26; 157(1–2):49–57 (39 ref.)

Transcriptional regulation by MAP kinases. Davis RJ. **Mol Reprod Dev** 1995 Dec;42(4):459–67 (31 ref.)

Dynamics and organization of MAP kinase signal pathways. Errede B, et al. **Mol Reprod Dev** 1995 Dec;42(4):477–85 (19 ref.)

Activation mechanism and function of the MAP kinase cascade. Gotoh Y, et al. **Mol Reprod Dev** 1995 Dec; 42(4):486–92 (48 ref.)

Networking with proline-directed protein kinases implicated in tau phosphorylation. Pelech SL. **Neurobiol Aging** 1995 May–Jun;16(3):247–56; discussion 257–61 (135 ref.)

PHYSIOLOGY

Multifunctional calcium and calmodulin-dependent kinase II in neuronal function and disease. Churn SB. **Adv Neuroimmunol** 1995;5(3):241–59 (141 ref.)

Modulation of actin dynamics during stress and physiological stimulation by a signaling pathway involving p38 MAP kinase and heat-shock protein 27. Landry J, et al. **Biochem Cell Biol** 1995 Sep–Oct;73(9–10):703–7 (42 ref.)

Signals for mesoderm induction. Roles of fibroblast growth factor (FGF)/mitogen-activated protein kinase (MAPK) pathway. Gotoh Y, et al. **Biochim Biophys Acta** 1996 Aug 8;1288(1):F1–7 (121 ref.)

Role of CSB/p38/RK stress response kinase in LPS and cytokine signaling mechanisms. Lee JC, et al. **J Leukoc Biol** 1996 Feb;59(2):152–7 (62 ref.)

The regulation of AP-1 activity by mitogen-activated protein kinases. Karin M. **Philos Trans R Soc Lond B Biol Sci** 1996 Feb 29; 351(1336):127–34 (60 ref.)

The involvement of PKC and multifunctional CaM kinase II of the postsynaptic neuron in induction and maintenance of long-term potentiation. Feng TP. **Prog Brain Res** 1995; 105:55–63 (27 ref.)

Examination of the role of MAP kinase in the response of macrophages to lipopolysaccharide. DeFranco AL, et al. **Prog Clin Biol Res** 1995;392:407–20 (30 ref.)

[Second messenger-mediated transcriptional regulation of neural genes and possible drug action sites] Higuchi H, et al. **Nippon Yakurigaku Zasshi** 1995 Dec;106(6):365–78 (50 ref.) (Eng. Abstr.) **(Jpn)**

CALORIC INTAKE

Energy intake and sensory properties of food. Drewnowski A. **Am J Clin Nutr** 1995 Nov;62(5 Suppl):1081S–1085S (38 ref.)

Body composition, respiratory quotient, and weight maintenance. Flatt JP. **Am J Clin Nutr** 1995 Nov;62(5 Suppl):1107S–1117S (72 ref.)

Control of energy intake by energy metabolism. Friedman MI. **Am J Clin Nutr** 1995 Nov;62(5 Suppl):1096S–1100S (45 ref.)

The calorie: myth, measurement, and reality. Heymsfield SB, et al. **Am J Clin Nutr** 1995 Nov;62(5 Suppl):1034S–1041S (78 ref.)

Food sampling strategies for energy intake estimates. Holden JM. **Am J Clin Nutr** 1995 Nov;62(5 Suppl):1151S–1157S (31 ref.)

Alcohol and energy intake. Lands WE. **Am J Clin Nutr** 1995 Nov;62(5 Suppl):1101S–1106S (55 ref.)

Nutrient substitutes and their energy values in fat substitutes and replacers. Miraglio AM. **Am J Clin Nutr** 1995 Nov; 62(5 Suppl):1175S–1179S (22 ref.)

Fat, carbohydrate, and the regulation of energy intake. Rolls BJ, et al. **Am J Clin Nutr** 1995 Nov;62(5 Suppl):1086S–1095S (45 ref.)

Sympathetic nervous system response to intake. Welle S. **Am J Clin Nutr** 1995 Nov;62(5 Suppl):1118S–1122S (46 ref.)

Assessment of food intakes: are we measuring what people eat? Livingstone MB. **Br J Biomed Sci** 1995 Mar; 52(1):58–67 (50 ref.)

Energy requirements of infants. Butte NF. **Eur J Clin Nutr** 1996 Feb;50 Suppl 1:S24–36 (54 ref.)

Dietary fat content and energy density during infancy and childhood; the effect on energy intake and growth. Michaelsen KF, et al. **Eur J Clin Nutr** 1995 Jul;49(7):467–83 (75 ref.)

Energy requirements and dietary energy recommendations for children and adolescents 1 to 18 years old. Torun B, et al. **Eur J Clin Nutr** 1996 Feb;50 Suppl 1:S37–80; discussion S80–1 (164 ref.)

Association of macronutrients and energy intake with hypertension. Preuss HG, et al. **J Am Coll Nutr** 1996 Feb; 15(1):21–35 (207 ref.)

Effects of aging on energy requirements and the control of food intake in men. Roberts SB. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:101–6 (29 ref.)

The beneficial effects of dietary restriction: reduced oxidative damage and enhanced apoptosis. Wachsman JT. **Mutat Res** 1996 Feb 19;350(1):25–34 (75 ref.)

Aging and caloric restriction: human effects and mode of action. Austad SN. **Neurobiol Aging** 1995 Sep–Oct; 16(5):851–2; discussion 855–6 (19 ref.)

Neuroendocrine involvement in aging: evidence from studies of reproductive aging and caloric restriction. Nelson JF, et al. **Neurobiol Aging** 1995 Sep–Oct;16(5):837–43; discussion 855–6 (50 ref.)

Do the salutary effects of food restriction occur because of or despite of the accompanying hyperadrenocorticism? Sapolsky RM. **Neurobiol Aging** 1995 Sep–Oct;16(5):849–50; discussion 855–6 (5 ref.)

Use of caloric restriction to investigate neuroendocrine involvement in aging. Weindruch R, et al. **Neurobiol Aging** 1995 Sep–Oct;16(5):845–7; discussion 855–6 (30 ref.)

The nutritional management of acute renal failure in the intensive care unit. Kierdorf HP. **New Horiz** 1995 Nov; 3(4):699–707 (101 ref.)

Lowered energy intake and dietary macronutrient balance: potential consequences for micronutrient status. Whitehead RG. **Nutr Rev** 1995 Sep;53(9 Pt 2):S2–8 (6 ref.)

Oxidative stress, caloric restriction, and aging. Sohal RS, et al. **Science** 1996 Jul 5;273(5271):59–63 (59 ref.)

[Very low calorie diets for obesity] Tanaka S. **Nippon Rinsho** 1995 Jun;53 Suppl:495–8 (13 ref.) **(Jpn)**

DRUG EFFECTS

Effect of sucrose and sweeteners on appetite and energy intake. Blundell JE, et al. **Int J Obes Relat Metab Disord** 1996 Mar;20 Suppl 2:S12–7 (46 ref.)

PHYSIOLOGY

Energy density and its role in the control of food intake: evidence from metabolic and community studies. Poppitt SD, et al. **Appetite** 1996 Apr;26(2):153–74 (102 ref.)

Role of caloric restriction in the prolongation of life. McCarter RJ. **Clin Geriatr Med** 1995 Nov;11(4):553–65 (53 ref.)

The effects of dietary restriction on drug testing and toxicity. Hart RW, et al. **Exp Toxicol Pathol** 1996 Feb;48(2–3):121–7 (33 ref.)

Energy density of diets and obesity. Poppitt SD. **Int J Obes Relat Metab Disord** 1995 Nov;19 Suppl 5:S20–6 (55 ref.)

Importance of energy density and macronutrients in the regulation of energy intake. Prentice AM, et al. **Int J Obes Relat Metab Disord** 1996 Mar;20 Suppl 2:S18–23 (27 ref.)

Manipulating carbohydrate content and sources in obesity prone subjects: effect on energy expenditure and macronutrient balance. Raben A, et al. **Int J Obes Relat Metab Disord** 1996 Mar;20 Suppl 2:S24–30 (81 ref.)

Antiaging action of caloric restriction: endocrine and metabolic aspects. Masoro EJ. **Obes Res** 1995 Sep;3 Suppl 2:241s–247s (30 ref.)

A very-low-calorie conventional Japanese diet: its implications for prevention of obesity. Sakata T. **Obes Res** 1995 Sep;3 Suppl 2:233s–239s (21 ref.)

CALORIC TESTS

The caloric stimulus: mechanisms of heat transfer [see comments] O'Neill G. **Br J Audiol** 1995 Apr;29(2):87–94 (21 ref.) Comment in: Br J Audiol 1995 Apr;29(2):83–6.

INSTRUMENTATION

Caloric irrigators: air, open-loop water and closed-loop water [see comments] Anderson S. **Br J Audiol** 1995 Apr; 29(2):117–28 (43 ref.) Comment in: Br J Audiol 1995 Apr;29(2):83–6.

METHODS

Adaptation in the oculomotor response to caloric irrigation and the merits of bithermal stimulation [see comments] Barnes G. **Br J Audiol** 1995 Apr;29(2):95–106 (22 ref.) Comment in: Br J Audiol 1995 Apr;29(2):83–6.

Comparison of assessment of caloric nystagmus by observation of duration and by electronystagmographic measurement of slow-phase velocity [see comments] Luxon L. **Br J Audiol** 1995 Apr;29(2):107–15 (29 ref.) Comment in: Br J Audiol 1995 Apr;29(2):83–6.

CALORIMETRY

Calorimetry of proteins and nucleic acids. Plum GE, et al. **Curr Opin Struct Biol** 1995 Oct;5(5):682–90 (71 ref.)

INSTRUMENTATION

Water calorimetry for radiation dosimetry. Ross CK, et al. **Phys Med Biol** 1996 Jan;41(1):1–29 (72 ref.)

METHODS

Theories and assumptions on energy expenditure. Determinations in the clinical setting. Molina P, et al. **Crit Care Clin** 1995 Jul;11(3):587–601 (53 ref.)

The basis of direct and indirect calorimetry and their potentials. Schutz Y. **Diabetes Metab Rev** 1995 Dec; 11(4):383–408 (109 ref.)

Water calorimetry for radiation dosimetry. Ross CK, et al. **Phys Med Biol** 1996 Jan;41(1):1–29 (72 ref.)

Counting the calories to stay in the groove. Ladbury JE. **Structure** 1995 Jul 15;3(7):635–9 (21 ref.)

CALORIMETRY, INDIRECT

Indirect calorimetry in critically ill patients: role of the clinical dietitian in interpreting results. Porter C, et al. **J Am Diet Assoc** 1996 Jan;96(1):49–57 (38 ref.)

CALORIMETRY, RESPIRATION see **CALORIMETRY, INDIRECT**

CALPACTIN I see **ANNEXIN II**

CALPACTIN II see **ANNEXIN I**

CALPACTINS see **ANNEXINS**

CALPAIN

METABOLISM

Calpain: novel family members, activation, and physiologic function. Suzuki K, et al. **Biol Chem Hoppe Seyler** 1995 Sep;376(9):523–9 (61 ref.)

PHYSIOLOGY

PTH-mediated osteoblast retraction: possible participation of the calpain pathway. Murray EJ, et al. **Miner Electrolyte Metab** 1995;21(1–3):184–8 (20 ref.)

PEST sequences in calmodulin-binding proteins. Barnes JA, et al. **Mol Cell Biochem** 1995 Aug–Sep;149–150:17–27 (94 ref.)

Calpain as a novel target for treating acute neurodegenerative disorders. Bartus RT, et al. **Neurol Res** 1995 Aug; 17(4):249–58 (40 ref.)

CALPHOBINDIN I see **ANNEXIN V**

CALPHOBINDIN II see **ANNEXIN VI**

CALSPECTIN see **CALMODULIN-BINDING PROTEINS**

CALVARIA see **SKULL**

CAMELLIA see **TEA**

CAMP-DEPENDENT PROTEIN KINASES see **CYCLIC AMP-DEPENDENT PROTEIN KINASES**

CAMP PHOSPHODIESTERASE see **3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE**

CAMPIMETRY see **PERIMETRY**

CAMPTOTHECIN

ANALOGS & DERIVATIVES

Recent clinical advances with camptothecin analogues. Slichenmyer WJ, et al. **Cancer Treat Res** 1995;78:29–43 (103 ref.)

CPT-11 (irinotecan) in the treatment of colorectal cancer. Armand JP, et al. **Eur J Cancer** 1995 Jul–Aug; 31A(7–8):1283–7 (41 ref.)

The water-insoluble camptothecin analogues: promising drugs for the effective treatment of haematological malignancies. Pantazis P. **Leuk Res** 1995 Nov;19(11):775–88 (151 ref.)

Camptothecin analogues in the treatment of non-small cell lung cancer. Ardizzoni A. **Lung Cancer** 1995 Apr;12 Suppl 1:S177–85 (19 ref.)

Molecular, cellular, and clinical aspects of the pharmacology of 20(S)camptothecin and its derivatives. Rivory LP, et al. **Pharmacol Ther** 1995;68(2):269–96 (170 ref.)

CPT-11: clinical experience in phase I studies. Armand JP. **Semin Oncol** 1996 Feb;23(1 Suppl 3):27–33 (22 ref.)

Preclinical evaluation of CPT-11 and its active metabolite SN-38. Lavelle F, et al. **Semin Oncol** 1996 Feb;23(1 Suppl 3):11–20 (44 ref.)

CPT-11: an original spectrum of clinical activity. Rothenberg ML. **Semin Oncol** 1996 Feb;23(1 Suppl 3):21–6 (38 ref.)

CPT-11 in the treatment of colorectal cancer: clinical efficacy and safety profile. Rougier P, et al. **Semin Oncol** 1996 Feb;23(1 Suppl 3):34–41 (35 ref.)

[Topoisomerase I inhibitors. Review of phase II trials with irinotecan (CPT-11) and topotecan] Bonneterre J. **Bull Cancer (Paris)** 1995 Aug;82(8):623–8 (52 ref.) (Eng. Abstr.) **(Fre)**

[Current status of phase I and phase II trials--experience in Habikino from 1988 to 1994] Masuda N, et al. **Gan To Kagaku Ryoho** 1996 Jan;23(2):166–71 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Development of new anti-cancer agents in Europe] Terada K. **Gan To Kagaku Ryoho** 1996 Jan;23(2):231–7 (9 ref.) (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

Recent clinical advances with camptothecin analogues. Slichenmyer WJ, et al. **Cancer Treat Res** 1995;78:29–43 (103 ref.)

The water-insoluble camptothecin analogues: promising drugs for the effective treatment of haematological malignancies. Pantazis P. **Leuk Res** 1995 Nov;19(11):775–88 (151 ref.)

Molecular, cellular, and clinical aspects of the pharmacology of 20(S)camptothecin and its derivatives. Rivory LP, et al. **Pharmacol Ther** 1995;68(2):269–96 (170 ref.)

Eukaryotic DNA topoisomerase I: genome gatekeeper and its intruders, camptothecins. Pommier Y. **Semin Oncol** 1996 Feb;23(1 Suppl 3):3–10 (87 ref.)

THERAPEUTIC USE

Current perspectives on camptothecins in cancer treatment [editorial] Dancey J, et al. **Br J Cancer** 1996 Aug; 74(3):327–38 (146 ref.)

Camptothecin analogues in the treatment of non-small cell lung cancer. Ardizzoni A. **Lung Cancer** 1995 Apr;12 Suppl 1:S177–85 (19 ref.)

CAMPYLOBACTER

DRUG EFFECTS

Antimicrobial-resistant Campylobacter species--a new threat to travelers to Thailand [editorial] DuPont HL. **Clin Infect Dis** 1995 Sep;21(3):542–3 (18 ref.)

GENETICS

Detection and identification of Campylobacter spp. using the polymerase chain reaction. Giesendorf BA, et al. **Cell Mol Biol (Noisy-le-grand)** 1995 Jul;41(5):625–38 (123 ref.)

ISOLATION & PURIFICATION

Detection and identification of Campylobacter spp. using the polymerase chain reaction. Giesendorf BA, et al. **Cell Mol Biol (Noisy-le-grand)** 1995 Jul;41(5):625–38 (123 ref.)

CAMPYLOBACTER FETUS

[Abdominal aortic aneurysm infected with Campylobacter fetus spp fetus. Report of a case and review of the literature] Kuzniec S, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1995 Sep–Oct;50(5):284–8 (39 ref.) (Eng. Abstr.) **(Por)**

CAMPYLOBACTER INFECTIONS

COMPLICATIONS

[Abdominal aortic aneurysm infected with Campylobacter fetus spp fetus. Report of a case and review of the literature] Kuzniec S, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1995 Sep-Oct;50(5):284-8 (39 ref.) (Eng. Abstr.) **(Por)**

DIAGNOSIS

[Septic abortion in Campylobacter jejuni infection] Abderhalden R, et al. **Geburtshilfe Frauenheilkd** 1995 Oct; 55(10):599-601 (14 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Antimicrobial-resistant Campylobacter species--a new threat to travelers to Thailand [editorial] DuPont HL. **Clin Infect Dis** 1995 Sep;21(3):542-3 (18 ref.)

EPIDEMIOLOGY

[Adenoviruses from stool samples in hospital units. Comparison with main pathogens in gastroenteritis (rotavirus, Campylobacter, Salmonella)] Durepaire N, et al. **Pathol Biol (Paris)** 1995 Sep;43(7):601-10 (22 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

[Campylobacter jejuni and autoimmune-mediated neurologic diseases: pathogenesis of Guillain-Barré syndrome and Fisher's syndrome] Yuki N. **Nippon Saikingaku Zasshi** 1995 Oct;50(4):991-1003 (41 ref.) **(Jpn)**

MICROBIOLOGY

Acute cholecystitis caused by Campylobacter jejuni. Landau Z, et al. **Isr J Med Sci** 1995 Nov;31(11):696-7 (6 ref.)

CAMPYLOBACTER JEJUNI

Acute cholecystitis caused by Campylobacter jejuni. Landau Z, et al. **Isr J Med Sci** 1995 Nov;31(11):696-7 (6 ref.)

[Septic abortion in Campylobacter jejuni infection] Abderhalden R, et al. **Geburtshilfe Frauenheilkd** 1995 Oct; 55(10):599-601 (14 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

[Campylobacter jejuni and autoimmune-mediated neurologic diseases: pathogenesis of Guillain-Barré syndrome and Fisher's syndrome] Yuki N. **Nippon Saikingaku Zasshi** 1995 Oct;50(4):991-1003 (41 ref.) **(Jpn)**

CAMPYLOBACTER PYLORI see **HELICOBACTER PYLORI**

CAMURATI-ENGELMANN SYNDROME see **DIAPHYSEAL DYSPLASIA, PROGRESSIVE**

CANAVAN DISEASE

DIAGNOSIS

Canavan disease: from spongy degeneration to molecular analysis. Matalon R, et al. **J Pediatr** 1995 Oct;127(4):511-7 (75 ref.)

CANAVAN-VAN BOGAERT-BERTRAND DISEASE see **CANAVAN DISEASE**

CANCER see **NEOPLASMS**

CANCER-ASSOCIATED CARBOHYDRATE ANTIGENS see **ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE**

CANCER CARE FACILITIES

ORGANIZATION & ADMINISTRATION

Benefits from specialised cancer care. Selby P, et al. **Lancet** 1996 Aug 3;348(9023):313-8 (52 ref.)

CANCER GENES see **ONCOGENES**

CANCER STAGING see **NEOPLASM STAGING**

CANCER SYNDROMES, HEREDITARY see **NEOPLASTIC SYNDROMES, HEREDITARY**

CANDIDA

Pancreatic fungal infections: a case report and review of the literature. Robbins EG 2nd, et al. **Pancreas** 1996 Apr; 12(3):308-12 (27 ref.)

Torulopsis glabrata spinal osteomyelitis involving two contiguous vertebrae. A case report. Curran MP, et al. **Spine** 1996 Apr 1;21(7):866-70 (8 ref.)

CHEMISTRY

The unique structures of protozoan myoglobin and yeast hemoglobin: an evolutionary diversity. Shikama K, et al. **Int J Biochem Cell Biol** 1995 Nov;27(11):1107-15 (35 ref.)

CLASSIFICATION

Epidemiology of fungal infections: the promise of molecular typing. Pfaller MA. **Clin Infect Dis** 1995 Jun;20(6):1535-9 (61 ref.)

[The changing pattern of Candida infections: different species and increased resistance] Kullberg BJ, et al. **Ned Tijdschr Geneeskd** 1996 Jan 20;140(3):148-51 (25 ref.) (Eng. Abstr.) **(Dut)**

GENETICS

Molecular genetic approaches to identification, epidemiology and taxonomy of non-albicans Candida species. Sullivan DJ, et al. **J Med Microbiol** 1996 Jun;44(6):399-408 (109 ref.)

IMMUNOLOGY

Comparative assessment of the detection of candidal antigens as a diagnostic tool. Matthews RC. **J Med Vet Mycol** 1996 Jan-Feb;34(1):1-10 (83 ref.)

CANDIDA ALBICANS

Candida albicans: a review of its history, taxonomy, epidemiology, virulence attributes, and methods of strain differentiation. McCullough MJ, et al. **Int J Oral Maxillofac Surg** 1996 Apr;25(2):136-44 (100 ref.)

CHEMISTRY

Antifungal drug targets: Candida secreted aspartyl protease and fungal wall beta-glucan synthesis. Goldman RC, et al. **Infect Agents Dis** 1995 Dec;4(4):228-47 (120 ref.)

DRUG EFFECTS

Antifungal drug targets: Candida secreted aspartyl protease and fungal wall beta-glucan synthesis. Goldman RC, et al. **Infect Agents Dis** 1995 Dec;4(4):228-47 (120 ref.)

ENZYMOLOGY

The role of Candida albicans secreted aspartic proteinase in the development of candidoses. Hoegl L, et al. **J Mol Med** 1996 Mar;74(3):135-42 (71 ref.)

GENETICS

[Molecular biology of Candida albicans] Nakagawa Y. **Nippon Saikingaku Zasshi** 1995 Jul;50(3):671-85 (100 ref.) **(Jpn)**

IMMUNOLOGY

T helper cell dichotomy to Candida albicans: implications for pathology, therapy, and vaccine design. Romani L, et al. **Immunol Res** 1995;14(2):148-62 (105 ref.)

ISOLATION & PURIFICATION

Purulent pericarditis caused by Candida species: case report and review. Schrank JH Jr, et al. **Clin Infect Dis** 1995 Jul; 21(1):182-7 (40 ref.)

PATHOGENICITY

Pathogenicity of Candida albicans: quest for a molecular switch. Datta A. **Braz J Med Biol Res** 1994 Dec; 27(12):2721-32 (59 ref.)

PHYSIOLOGY

Adhesion and morphogenesis in Candida albicans. Hostetter MK. **Pediatr Res** 1996 Apr;39(4 Pt 1):569-73 (16 ref.)

CANDIDIASIS

New insights into candidal infections. Hostetter MK. **Adv Pediatr** 1996;43:209-30 (83 ref.)

Isolated candidal epiglottitis: report of a fatal case. Alba D, et al. **Clin Infect Dis** 1996 Apr;22(4):732-3 (10 ref.)

T helper cell dichotomy to Candida albicans: implications for pathology, therapy, and vaccine design. Romani L, et al. **Immunol Res** 1995;14(2):148-62 (105 ref.)

Fungal arthritis. A review. Hansen BL, et al. **Scand J Rheumatol** 1995;24(4):248-50 (34 ref.)

Torulopsis glabrata spinal osteomyelitis involving two contiguous vertebrae. A case report. Curran MP, et al. **Spine** 1996 Apr 1;21(7):866-70 (8 ref.)

[Hepatic candidiasis] Ito A. **Ryoikibetsu Shokogun Shirizu** 1995;(7):63-5 (11 ref.) **(Jpn)**

COMPLICATIONS

Contained rupture of infected abdominal aortic aneurysm due to systemic candidiasis. Ikeda M, et al. **Cardiovasc Surg** 1995 Dec;3(6):711-4 (30 ref.)

DIAGNOSIS

Candida infection of the arteriovenous fistula used for hemodialysis. Nguyen MH, et al. **Am J Kidney Dis** 1996 Apr;27(4):596-8 (8 ref.)

Genital candidosis. Stary A. **Curr Probl Dermatol** 1996; 24:40-9 (23 ref.)

Cell wall polysaccharides of pathogenic yeasts. Fukazawa Y, et al. **Curr Top Med Mycol** 1995;6:189-219 (166 ref.)

Comparative assessment of the detection of candidal antigens as a diagnostic tool. Matthews RC. **J Med Vet Mycol** 1996 Jan-Feb;34(1):1-10 (83 ref.)

[Procedures for Candida albicans systemic infections in premature infants] Lauterbach R. **Ginekol Pol** 1995 May; 66(5):289-93 (13 ref.) (Eng. Abstr.) **(Pol)**

DRUG THERAPY

Antifungal agents in neonatal systemic candidiasis. van den Anker JN, et al. **Antimicrob Agents Chemother** 1995 Jul; 39(7):1391-7 (66 ref.)

Problems and controversies in the management of hematogenous candidiasis. Uzun O, et al. **Clin Infect Dis** 1996 May;22 Suppl 2:S95-101 (62 ref.)

When and how to treat serious candidal infections: concepts and controversies. Filler SG, et al. **Curr Clin Top Infect Dis** 1995;15:1-18 (122 ref.)

Nosocomial candidiasis: epidemiology and drug resistance. Mahayni R, et al. **Infect Agents Dis** 1995 Dec;4(4):248-53 (72 ref.)

[Candida infections in intensive care] Presterl E, et al. **Anaesthesist** 1996 Feb;45(2):195-210 (47 ref.) **(Ger)**

EPIDEMIOLOGY

Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Jarvis WR. **Clin Infect Dis** 1995 Jun; 20(6):1526-30 (21 ref.)

Epidemiology of candidiasis. Cormican MG, et al. **Compr Ther** 1995 Nov;21(11):653-7 (20 ref.)

Epidemiology of candidiasis. Pfaller MA. **J Hosp Infect** 1995 Jun;30 Suppl:329-38 (69 ref.)

ETIOLOGY

Invasive candidiasis complicating spontaneous esophageal perforation (Boerhaave syndrome). Bauer TM, et al. **Am J Gastroenterol** 1996 Jun;91(6):1248-50 (11 ref.)

The role of the gastrointestinal tract in hematogenous candidiasis: from the laboratory to the bedside. Cole GT, et al. **Clin Infect Dis** 1996 May;22 Suppl 2:S73-88 (114 ref.)

Candida albicans septic thrombosis of the right atrium is associated with a central venous catheter. Kentos A, et al. **Clin Infect Dis** 1995 Aug;21(2):440-2 (18 ref.)

Nosocomial candidiasis: emerging species, reservoirs, and modes of transmission. Pfaller MA. **Clin Infect Dis** 1996 May;22 Suppl 2:S89-94 (74 ref.)

Purulent pericarditis caused by Candida species: case report and review. Schrank JH Jr, et al. **Clin Infect Dis** 1995 Jul; 21(1):182-7 (40 ref.)

[A case of bronchial asthma complicated by mycosis] Andronova NV, et al. **Ter Arkh** 1995;67(11):33-5 (7 ref.) **(Rus)**

IMMUNOLOGY

Antibody immunity and invasive fungal infections. Casadevall A. **Infect Immun** 1995 Nov;63(11):4211-8 (133 ref.)

Production and function of cytokines in natural and acquired immunity to Candida albicans infection. Ashman RB, et al. **Microbiol Rev** 1995 Dec;59(4):646-72 (367 ref.)

MICROBIOLOGY

Meningitis caused by Candida species: an emerging problem in neurosurgical patients. Nguyen MH, et al. **Clin Infect Dis** 1995 Aug;21(2):323-7 (26 ref.)

Molecular genetic approaches to identification, epidemiology and taxonomy of non-albicans Candida species. Sullivan DJ, et al. **J Med Microbiol** 1996 Jun;44(6):399-408 (109 ref.)

The role of Candida albicans secreted aspartic proteinase in the development of candidoses. Hoegl L, et al. **J Mol Med** 1996 Mar;74(3):135-42 (71 ref.)

[The changing pattern of Candida infections: different species and increased resistance] Kullberg BJ, et al. **Ned Tijdschr Geneeskd** 1996 Jan 20;140(3):148-51 (25 ref.) (Eng. Abstr.) **(Dut)**

PATHOLOGY

Pancreatic fungal infections: a case report and review of the literature. Robbins EG 2nd, et al. **Pancreas** 1996 Apr; 12(3):308-12 (27 ref.)

PHYSIOPATHOLOGY

Candida-associated diarrhea: a syndrome in search of credibility. Levine J, et al. **Clin Infect Dis** 1995 Oct; 21(4):881-6 (80 ref.)

PREVENTION & CONTROL

Nystatin prophylaxis in immunocompromised children. Taylor TL. **Ann Pharmacother** 1996 May;30(5):534-5 (8 ref.)

Opportunistic candidal infections in patients infected with human immunodeficiency virus: prevention issues and priorities. Reef SE, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S99-102 (24 ref.)

The epidemiology of colonization. Jarvis WR. **Infect Control Hosp Epidemiol** 1996 Jan;17(1):47-52 (43 ref.)

CANDIDIASIS, CUTANEOUS

DRUG THERAPY

Clinical management of oral and perioral candidosis. Fotos PG, et al. **Dermatol Clin** 1996 Apr;14(2):273–80 (70 ref.)

CANDIDIASIS, ORAL

Oral candidiasis, HIV, and saliva glucocorticoids. Enwonwu CO, et al. **Am J Pathol** 1996 Apr;148(4):1313–8 (68 ref.)
Oral candidosis. Mooney MA, et al. **Int J Dermatol** 1995 Nov;34(11):759–65 (48 ref.)

DRUG THERAPY

Clinical management of oral and perioral candidosis. Fotos PG, et al. **Dermatol Clin** 1996 Apr;14(2):273–80 (70 ref.)

ETIOLOGY

Oral candidiasis in HIV-infected patients. Brawner DL, et al. **Curr Top Med Mycol** 1995;6:113–25 (68 ref.)

CANDIDIASIS, VULVOVAGINAL

DIAGNOSIS

Genital candidosis. Stary A. **Curr Probl Dermatol** 1996; 24:40–9 (23 ref.)
Common genitourinary infections. Freeman SB. **J Obstet Gynecol Neonatal Nurs** 1995 Oct;24(8):735–42 (26 ref.)

DRUG THERAPY

Oral fluconazole for vaginal candidiasis. Desai PC, et al. **Am Fam Physician** 1996 Sep 15;54(4):1337–40, 1345–6 (11 ref.)
Genital candidosis. Lauper U. **Curr Probl Dermatol** 1996; 24:123–31 (44 ref.)
Fluconazole: its properties and efficacy in vaginal candidiasis. Troke PF. **Curr Probl Dermatol** 1996;24:203–8 (19 ref.)
[Recurrent vulvovaginal mycoses] Salvat J, et al. **Rev Fr Gynecol Obstet** 1995 Nov;90(11):494–501 (17 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Is vulvovaginal candidiasis an AIDS-related illness? White MH. **Clin Infect Dis** 1996 May;22 Suppl 2:S124–7 (29 ref.)
Candida vulvovaginitis. Sobel JD. **Semin Dermatol** 1996 Mar; 15(1):17–28 (52 ref.)

MICROBIOLOGY

[Recurrent vaginal candidiasis. Reflections of a psychosomatic gynecologist] Bechart E. **Contracept Fertil Sex** 1996 Mar;24(3):233–7 (29 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Biotherapeutic agents. A neglected modality for the treatment and prevention of selected intestinal and vaginal infections [see comments] Elmer GW, et al. **JAMA** 1996 Mar 20;275(11):870–6 (81 ref.) Comment in: JAMA 1996 Jul 3;276(1):29–30.
Effective management of vaginal thrush. White D. **Practitioner** 1995 Oct;239(1555):612–6 (9 ref.)

CANDY

Hyperactivity: is candy causal? Krummel DA, et al. **Crit Rev Food Sci Nutr** 1996 Jan;36(1–2):31–47 (57 ref.)

CANINE DISTEMPER see **DISTEMPER**

CANINE DISTEMPER VIRUS see **DISTEMPER VIRUS, CANINE**

CANINE HIP DYSPLASIA see **HIP DYSPLASIA, CANINE**

CANINE TOOTH see **CUSPID**

CANKER SORE see **STOMATITIS, APHTHOUS**

CANNABINOIDS

see related
HALLUCINOGENS

CHEMISTRY

Relationships between eicosanoids and cannabinoids. Are eicosanoids cannabimimetic agents?. Burstein SH, et al. **Biochem Pharmacol** 1995 Nov 27;50(11):1735–42 (44 ref.)

METABOLISM

Recent advances in the metabolism of cannabinoids [published erratum appears in Int J Biochem Cell Biol 1995 Dec;27(12):1365] Yamamoto I, et al. **Int J Biochem Cell Biol** 1995 Aug;27(8):741–6 (61 ref.)

TOXICITY

Behavioural consequences of maternal exposure to natural cannabinoids in rats. Navarro M, et al. **Psychopharmacology (Berl)** 1995 Nov;122(1):1–14 (110 ref.)

CANNABIS

see related
CANNABINOIDS
MARIJUANA SMOKING

The effects of family structure and family relations on adolescent marijuana use. Hoffmann JP. **Int J Addict** 1995 Aug;30(10):1207–41 (106 ref.)

CANNABIS SMOKING see **MARIJUANA SMOKING**

CANNULATION see **CATHETERIZATION**

CANTHARIDES see **CANTHARIDIN**

CANTHARIDIN

POISONING

Poisoning from "Spanish fly" (cantharidin). Karras DJ, et al. **Am J Emerg Med** 1996 Sep;14(5):478–83 (17 ref.)
Ingestion of a blister beetle (Mecoidae family). Mallari RQ, et al. **Pediatrics** 1996 Sep;98(3 Pt 1):458–9 (11 ref.)

CAOUTCHOUC see **RUBBER**

CAPD see **PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY**

CAPGRAS SYNDROME

DIAGNOSIS

Facial processing in schizophrenia and delusional misidentification: cognitive neuropsychiatric approaches. Phillips ML, et al. **Schizophr Res** 1995 Sep;17(1):109–14 (45 ref.)
[Capgras syndrome in adolescence: a review apropos of one case] Chabrol H, et al. **Encephale** 1995 Nov–Dec; 21(6):477–80 (31 ref.) (Eng. Abstr.) **(Fre)**

CAPILLARIES

CYTOLOGY

Hypotheses regarding the role of pericytes in regulating movement of fluid, nutrients, and hormones across the microcirculatory endothelial barrier. Lonigro AJ, et al. **Diabetes** 1996 Jan;45 Suppl 1:S38–43 (21 ref.)

DRUG EFFECTS

Vascular endothelial cell activation and permeability responses to thrombin. Garcia JG, et al. **Blood Coagul Fibrinolysis** 1995 Oct;6(7):609–26 (129 ref.)

CAPILLARIES, LYMPHATIC see **LYMPHATIC SYSTEM**

CAPILLARY ENDOTHELIUM see **ENDOTHELIUM, VASCULAR**

CAPILLARY PERMEABILITY

Clinical studies of alveolar-capillary permeability using technetium-99m DTPA aerosol. Sundram FX. **Ann Nucl Med** 1995 Nov;9(4):171–8 (26 ref.)
Proteins abnormally filtered throughout glomerular capillary have an intrinsic renal toxicity. Remuzzi G, et al. **Contrib Nephrol** 1996;118:164–72 (66 ref.)
Hypotheses regarding the role of pericytes in regulating movement of fluid, nutrients, and hormones across the microcirculatory endothelial barrier. Lonigro AJ, et al. **Diabetes** 1996 Jan;45 Suppl 1:S38–43 (21 ref.)
Systemic capillary leak syndrome in a child. Foeldvari I, et al. **J Pediatr** 1995 Nov;127(5):739–41 (15 ref.)
Nitric oxide affects microvascular permeability in the intact and inflamed vasculature. Kubes P. **Microcirculation** 1995 Sep;2(3):235–44 (46 ref.)
Cerebrovascular permeability to peptides: manipulations of transport systems at the blood-brain barrier. Zlokovic BV. **Pharm Res** 1995 Oct;12(10):1395–406 (72 ref.)
Advances in understanding permeability in fetal capillaries of the human placenta: a review of organization of the endothelial paracellular clefts and their junctional complexes. Leach L, et al. **Reprod Fertil Dev** 1995; 7(6):1451–6 (51 ref.)

PHYSIOLOGY

Mechanisms of increased airway microvascular permeability: role in airway inflammation and obstruction. Goldie RG, et al. **Clin Exp Pharmacol Physiol** 1995 Jun–Jul; 22(6–7):387–96 (88 ref.)
The importance of the interstitium in peritoneal transport. Flessner MF. **Perit Dial Int** 1996;16 Suppl 1:S76–9 (19 ref.)
The impact of peritoneal permeability and residual renal function on PD prescription. Harty J, et al. **Perit Dial Int** 1996;16 Suppl 1:S147–52 (18 ref.)
Pulmonary permeability oedema. Methods of estimation of pulmonary capillary permeability. Rogowski F, et al. **Rocz Akad Med Bialymst** 1994;39:7–17 (30 ref.)
Modelling the structural pathways for transcapillary exchange. Weinbaum S, et al. **Symp Soc Exp Biol** 1995; 49:323–45 (31 ref.)

CAPITAL PUNISHMENT

LEGISLATION & JURISPRUDENCE

Denouement of an execution competency case: is Perry pyrrhic? Mossman D. **Bull Am Acad Psychiatry Law** 1995; 23(2):269–84 (113 ref.)

METHODS

Execution by crucifixion. History, methods and cause of death. Holoubek JE, et al. **J Med** 1995;26(1–2):1–16 (31 ref.)

CAPITATION FEE

Surviving capitation. Dunham-Taylor J, et al. **Am J Nurs** 1996 Mar;96(3):26–9; quiz 30 (8 ref.)
Capitation for emergency physicians. Stapczynski JS. **Ann Emerg Med** 1996 Apr;27(4):501–5 (16 ref.)
Managed care contracting/capitation. Reardon TM. **Ann Thorac Surg** 1995 Nov;60(5):1500–8 (0 ref.)
Physician remuneration methods: the need for change and flexibility [editorial] Wright CJ. **Can Med Assoc J** 1996 Mar 1;154(5):678–80 (12 ref.)
Breakeven under capitation: pure and simple? Boles KE, et al. **Health Care Manage Rev** 1996 Winter;21(1):38–47 (15 ref.)

CAPNOCYTOPHAGA

ISOLATION & PURIFICATION

Capnocytophaga canimorsus septicemia: fifth report of a cat-associated infection and five other cases. Valtonen M, et al. **Eur J Clin Microbiol Infect Dis** 1995 Jun;14(6):520–3 (25 ref.)

CAPRIC ACIDS see **DECANOIC ACIDS**

CAPRINE ARTHRITIS-ENCEPHALITIS VIRUS see **ARTHRITIS-ENCEPHALITIS VIRUS, CAPRINE**

CAPRINES see **GOATS**

CAPSAICIN

ADMINISTRATION & DOSAGE

Drugs to treat the tissue complications of diabetes: peripheral neuropathy. Emanuele NV, et al. **Compr Ther** 1995 Oct; 21(10):579–82 (30 ref.)
Topical capsaicin. A review of its pharmacological properties and therapeutic potential in post-herpetic neuralgia, diabetic neuropathy and osteoarthritis. Rains C, et al. **Drugs Aging** 1995 Oct;7(4):317–28 (52 ref.)

ADVERSE EFFECTS

Capsaicin in hot chili pepper: carcinogen, co-carcinogen or anticarcinogen? Surh YJ, et al. **Food Chem Toxicol** 1996 Mar;34(3):313–6 (48 ref.)

PHARMACOLOGY

Capsaicin and pain mechanisms. Winter J, et al. **Br J Anaesth** 1995 Aug;75(2):157–68 (120 ref.)
Capsaicin-sensitive sensory-motor neurotransmission in the peripheral control of cardiovascular function. Rubino A, et al. **Cardiovasc Res** 1996 Apr;31(4):467–79 (160 ref.)
Topical capsaicin. A review of its pharmacological properties and therapeutic potential in post-herpetic neuralgia, diabetic neuropathy and osteoarthritis. Rains C, et al. **Drugs Aging** 1995 Oct;7(4):317–28 (52 ref.)
Neurogenic influences in arthritis: potential modification by capsaicin [editorial] Matucci Cerinic M, et al. **J Rheumatol** 1995 Aug;22(8):1447–9 (27 ref.)

THERAPEUTIC USE

[Topical capsaicin and joint pain: a therapeutic break-through?] Gratton N, et al. **Union Med Can** 1995 Mar;124(1):2–4 (17 ref.) **(Fre)**
[Capsaicin for arthritic pain] Niv D, et al. **Harefuah** 1996 Mar 15;130(6):415–20 (43 ref.) **(Heb)**
[Prophylactic treatment of episodic forms of cluster headache] Liaño H, et al. **Rev Neurol** 1995;23 Suppl 4:S525–9 (29 ref.) **(Spa)**

CAPSID

[COP-coated vesicles in intracellular protein transport] Kuge O, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec; 40(16):2427–35 (39 ref.) **(Jpn)**

BIOSYNTHESIS

Production of recombinant hantavirus nucleocapsid protein expressed in silkworm larvae and its use as a diagnostic

antigen in detecting antibodies in serum from infected rats. Yoshimatsu K, et al. **Lab Anim Sci** 1995 Dec;45(6):641–6 (8 ref.)

CHEMISTRY

Viruses. Liljas L. **Curr Opin Struct Biol** 1996 Apr;6(2):151–6 (40 ref.)

First glimpses at structure-function relationships of the nucleocapsid protein of retroviruses. Darlix JL, et al. **J Mol Biol** 1995 Dec 8;254(4):523–37 (140 ref.)

Functional implications of protein–protein interactions in icosahedral viruses. Johnson JE. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):27–33 (21 ref.)

[The structure and function of spherical viruses] Morimoto Y. **Seikagaku** 1995 Oct;67(10):1236–40 (15 ref.) **(Jpn)**

IMMUNOLOGY

[Sero-epidemiologic study of Epstein-Barr virus markers in patients without mononucleosis at a department for infectious diseases] Ternák G, et al. **Orv Hetil** 1995 Dec 10;136(50):2727–30 (38 ref.) (Eng. Abstr.) **(Hun)**

[Epitopes of hepatitis B virus nucleocapsid protein] Ehata T, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:148–54 (17 ref.) **(Jpn)**

PHYSIOLOGY

The role of coat proteins in the biosynthesis of secretory proteins. Salama NR, et al. **Curr Opin Cell Biol** 1995 Aug; 7(4):536–43 (54 ref.)

First glimpses at structure-function relationships of the nucleocapsid protein of retroviruses. Darlix JL, et al. **J Mol Biol** 1995 Dec 8;254(4):523–37 (140 ref.)

[The structure and function of spherical viruses] Morimoto Y. **Seikagaku** 1995 Oct;67(10):1236–40 (15 ref.) **(Jpn)**

ULTRASTRUCTURE

Computer modeling of prototypic and aberrant nucleocapsids of varicella–zoster virus. Grose C, et al. **Virology** 1995 Dec 20;214(2):321–9 (24 ref.)

CAPSID PROTEINS see **CAPSID**

CAPSULES

Microparticles with neuroactive agents. Filipović-Grčić J, et al. **J Microencapsul** 1995 Jul–Aug;12(4):343–62 (65 ref.)

CAPSULITIS, ADHESIVE see **BURSITIS**

CAPTOPRIL

ADVERSE EFFECTS

[ACE inhibitor–associated interstitial lung infiltrates (see comments)] Obergassel L, et al. **Dtsch Med Wochenschr** 1995 Sep 22;120(38):1273–7 (22 ref.) (Eng. Abstr.)
Comment in: Dtsch Med Wochenschr 1996 Jan 19;121(3):81. **(Ger)**

HISTORY

The discovery of captopril: from large animals to small molecules. Opie LH, et al. **Cardiovasc Res** 1995 Jul; 30(1):18–25 (39 ref.)

PHARMACOLOGY

Captopril. A review of its pharmacology and therapeutic efficacy after myocardial infarction and in ischaemic heart disease. Plosker GL, et al. **Drugs Aging** 1995 Sep; 7(3):226–53 (171 ref.)

THERAPEUTIC USE

Comparative effects of indapamide and captopril on blood pressure and albumin excretion rate in diabetic microalbuminuria. Donnelly R, et al. **Am J Cardiol** 1996 Feb 22;77(6):26B–30B (33 ref.)

Treatment of viral myocarditis with focus on captopril [editorial] Rezkalla SH, et al. **Am J Cardiol** 1996 Mar 15; 77(8):634–7 (41 ref.)

Captopril. A review of its pharmacology and therapeutic efficacy after myocardial infarction and in ischaemic heart disease. Plosker GL, et al. **Drugs Aging** 1995 Sep; 7(3):226–53 (171 ref.)

CARASSIUS AURATUS see **GOLDFISH**

CARASSIUS CARASSIUS see **CARP**

CARBAMATES

ADVERSE EFFECTS

Cholinesterase inhibition: complexities in interpretation. Lotti M. **Clin Chem** 1995 Dec;41(12 Pt 2):1814–8 (22 ref.)

TOXICITY

Regulatory and research issues related to cholinesterase inhibition. Padilla S. **Toxicology** 1995 Sep 1;102(1–2):215–20 (29 ref.)

CARBAMAZEPINE

ADVERSE EFFECTS

Aseptic meningitis secondary to carbamazepine therapy. Dang CT, et al. **Clin Infect Dis** 1996 Apr;22(4):729–30 (4 ref.)

[Side effects of phenytoin and carbamazepine on cognitive functioning] Pulliainen V, et al. **Duodecim** 1994; 110(14):1320–8 (44 ref.) **(Fin)**

BLOOD

[Carbamazepine] Gomita Y, et al. **Nippon Rinsho** 1995 Feb; 53 Su Pt 1:907–10 (8 ref.) **(Jpn)**

METABOLISM

Interactions of valproic acid with carbamazepine and its metabolites' concentrations, concentrations ratios, and level/dose ratios in epileptic children. Liu H, et al. **Clin Neuropharmacol** 1995 Feb;18(1):1–12 (34 ref.)

Cytochrome P450 isozymes and antiepileptic drug interactions. Levy RH. **Epilepsia** 1995;36 Suppl 5:S8–13 (13 ref.)

PHARMACOLOGY

Contingent tolerance to the anticonvulsant effects of carbamazepine: relationship to loss of endogenous adaptive mechanisms. Weiss SR, et al. **Brain Res Brain Res Rev** 1995 Mar;20(3):305–25 (96 ref.)

Interactions of valproic acid with carbamazepine and its metabolites' concentrations, concentrations ratios, and level/dose ratios in epileptic children. Liu H, et al. **Clin Neuropharmacol** 1995 Feb;18(1):1–12 (34 ref.)

THERAPEUTIC USE

Psychopharmacology in child and adolescent psychiatry: a review of the past seven years. Part II. Campbell M, et al. **J Am Acad Child Adolesc Psychiatry** 1995 Oct; 34(10):1262–72 (138 ref.)

Predictors of response to mood stabilizers. Calabrese JR, et al. **J Clin Psychopharmacol** 1996 Apr;16(2 Suppl 1):24S–31S (88 ref.)

Carbamazepine clinical pharmacology: a review. Albani F, et al. **Pharmacopsychiatry** 1995 Nov;28(6):235–44 (189 ref.)

CARBAMYL PHOSPHATE SYNTHASE (AMMONIA)

METABOLISM

The carbamoyl-phosphate synthase family and carbamate kinase: structure-function studies. Rubio V, et al. **Biochem Soc Trans** 1995 Nov;23(4):879–83 (33 ref.)

CARBAMYL PHOSPHATE SYNTHASE (GLUTAMINE)

METABOLISM

The carbamoyl-phosphate synthase family and carbamate kinase: structure-function studies. Rubio V, et al. **Biochem Soc Trans** 1995 Nov;23(4):879–83 (33 ref.)

CARBAPENEMS

ADMINISTRATION & DOSAGE

[Multicenter comparative study of meropenem vs. imipenem in the intramuscular treatment of hospital infections of the urinary tract] Tallarigo C, et al. **Minerva Urol Nefrol** 1995 Sep;47(3):147–56 (16 ref.) (Eng. Abstr.) **(Ita)**

CHEMISTRY

Recent advances in the chemistry and biology of carbapenem antibiotics. Coulton S, et al. **Prog Med Chem** 1996; 33:99–145 (181 ref.)

PHARMACOLOGY

Meropenem: a microbiological overview. Edwards JR. **J Antimicrob Chemother** 1995 Jul;36 Suppl A:1–17 (73 ref.)

THERAPEUTIC USE

[Carbapenems in pediatrics] Aujard Y. **Arch Pediatr** 1996;3 Suppl 1:298s–301s (10 ref.) **(Fre)**

CARBAZOLES

PHARMACOLOGY

Carvedilol, a novel vasodilating beta-blocker with the potential for cardiovascular organ protection. Feuerstein GZ, et al. **Eur Heart J** 1996 Apr;17 Suppl B:24–9 (24 ref.)

Cardiac adrenergic receptor effects of carvedilol. Yoshikawa T, et al. **Eur Heart J** 1996 Apr;17 Suppl B:8–16 (37 ref.)

THERAPEUTIC USE

Carvedilol for hypertension. **Drug Ther Bull** 1995 May; 33(5):39–40 (19 ref.)

Carvedilol, a novel multiple action antihypertensive agent with antioxidant activity and the potential for myocardial and vascular protection. Feuerstein GZ, et al. **Eur Heart J** 1995 Jul;16 Suppl F:38–42 (21 ref.)

[Evaluation of the antihypertensive drugs carvedilol, doxazosin and moxonidine] Dominiak P. **Wien Med Wochenschr** 1995;145(15–16):373–82 (92 ref.) (Eng. Abstr.) **(Ger)**

TOXICITY

Comparative carcinogenicity, metabolism, mutagenicity, and DNA binding of 7H-dibenzo[c,g]carbazole and dibenz[a,j]acridine. Warshawsky D, et al. **Crit Rev Toxicol** 1996;26(2):213–49 (101 ref.)

CARBOCYSTEINE

ANALOGS & DERIVATIVES

Phenotypic variation in xenobiotic metabolism and adverse environmental response: focus on sulfur-dependent detoxification pathways. McFadden SA. **Toxicology** 1996 Jul 17;111(1–3):43–65 (145 ref.)

CARBOHYDRATE ANTIGENS, TUMOR-ASSOCIATED see **ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE**

CARBOHYDRATE CONFORMATION

Carbon–proton coupling constants in the conformational analysis of sugar molecules. Tvaroska I, et al. **Adv Carbohydr Chem Biochem** 1995;51:15–61 (156 ref.)

Three-dimensional structures of oligosaccharides. Woods RJ. **Curr Opin Struct Biol** 1995 Oct;5(5):591–8 (94 ref.)

CARBOHYDRATE-DEFICIENT GLYCOPROTEIN SYNDROME

[Carbohydrate-deficient glycoprotein syndrome] Ohno K. **Nippon Rinsho** 1995 Dec;53(12):3041–9 (29 ref.) (Eng. Abstr.) **(Jpn)**

CARBOHYDRATE ISOMERASES

Molecular and industrial aspects of glucose isomerase. Bhosale SH, et al. **Microbiol Rev** 1996 Jun;60(2):280–300 (188 ref.)

CARBOHYDRATE LINKAGE see **CARBOHYDRATE CONFORMATION**

CARBOHYDRATE METABOLISM, INBORN ERRORS

GENETICS

Congenital sucrase-isomaltase deficiency. Treem WR. **J Pediatr Gastroenterol Nutr** 1995 Jul;21(1):1–14 (92 ref.)

CARBOHYDRATES

see related
DIETARY CARBOHYDRATES

[Advance in synthesis of sugar-modified nucleosides] Ohrui H. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1195–210 (76 ref.) **(Jpn)**

[Synthesis and properties of Oligonucleotides with modified sugar fragment] Yamana K. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1349–56 (12 ref.) **(Jpn)**

ANALYSIS

A review of the biological significance of carbohydrates on glycoproteins and methods for their analysis. Dennis RP. **Adv Exp Med Biol** 1995;376:1–11 (30 ref.)

Detection of carbohydrates in capillary electrophoresis. Paulus A, et al. **J Chromatogr A** 1996 Jan 12; 720(1–2):353–76 (88 ref.)

Fluorophore-assisted carbohydrate electrophoresis in the separation, analysis, and sequencing of carbohydrates. Starr CM, et al. **J Chromatogr A** 1996 Jan 12;720(1–2):295–321 (42 ref.)

Carbohydrate histochemistry of vertebrate taste organs. Witt M. **Prog Histochem Cytochem** 1996;30(4):1–168 (470 ref.)

CHEMISTRY

Carbon-13 nuclear magnetic relaxation and motional behavior of carbohydrate molecules in solution. Dais P. **Adv Carbohydr Chem Biochem** 1995;51:63–131 (160 ref.)

Carbon–proton coupling constants in the conformational analysis of sugar molecules. Tvaroska I, et al. **Adv Carbohydr Chem Biochem** 1995;51:15–61 (156 ref.)

The structural role of sugars in glycoproteins. Wyss DF, et al. **Curr Opin Biotechnol** 1996 Aug;7(4):409–16 (44 ref.)

Altered glycoprotein sugar-chain structures as possible diagnostic and prognostic markers in malignant tumors. Yoshida K, et al. **Int J Urol** 1995 Nov;2(5):281–7 (53 ref.)

IMMUNOLOGY

Monoclonal antibodies to cell-specific cell surface carbohydrates in plant cell biology and development. Pennell RI, et al. **Methods Cell Biol** 1995;49:123–41 (61 ref.)

Phenotypic variation of carbohydrate surface antigens and the pathogenesis of Haemophilus influenzae infections. Roche RJ, et al. **Trends Microbiol** 1995 Aug;3(8):304–9 (60 ref.)

ISOLATION & PURIFICATION

Separation of neutral carbohydrates by capillary electrophoresis. Honda S. **J Chromatogr A** 1996 Jan 12; 720(1–2):337–51 (44 ref.)

High-performance liquid chromatographic separation of carbohydrates on graphitized carbon columns. Koizumi K. **J Chromatogr A** 1996 Jan 12;720(1–2):119–26 (13 ref.)

Separation of negatively charged carbohydrates by capillary electrophoresis. Linhardt RJ, et al. **J Chromatogr A** 1996 Jan 12;720(1–2):323–35 (67 ref.)

METABOLISM

An introduction to glycosylation and rheumatic disease. What is the current state of play? Axford JS, et al. **Adv Exp Med Biol** 1995;376:171–7 (33 ref.)

A review of the biological significance of carbohydrates on glycoproteins and methods for their analysis. Dennis RP. **Adv Exp Med Biol** 1995;376:1–11 (30 ref.)

Studies on selectin–carbohydrate interactions. Jacob GS, et al. **Adv Exp Med Biol** 1995;376:283–90 (16 ref.)

Lectin–carbohydrate interactions in disease. T-cell recognition of IgA and IgD; mannose binding protein recognition of IgG0. Rudd P, et al. **Adv Exp Med Biol** 1995;376:147–52 (10 ref.)

Carbohydrate–protein interactions in vascular biology. Nelson RM, et al. **Ann Rev Cell Dev Biol** 1995;11:601–31 (185 ref.)

Selectin–carbohydrate interactions and the initiation of the inflammatory response. Lasky LA. **Annu Rev Biochem** 1995;64:113–39 (150 ref.)

Ca(2+)-dependent sugar recognition by animal lectins. Drickamer K. **Biochem Soc Trans** 1996 Feb;24(1):146–50 (20 ref.)

Bacterial endotoxin effects on carbohydrate utilization and transport. Spitzer JJ. **Biochem Soc Trans** 1995 Nov; 23(4):998–1002 (38 ref.)

Carbohydrate–lipid interactions during gestation and their control by insulin. Herrera E, et al. **Braz J Med Biol Res** 1994 Nov;27(11):2499–519 (74 ref.)

The IGF system in metabolism regulation. Binoux M. **Diabete Metab** 1995 Dec;21(5):330–7 (101 ref.)

Carbohydrate and amino acid metabolism in Giardia: a review. Jarroll EL, et al. **Folia Parasitol (Praha)** 1995; 42(2):81–9 (49 ref.)

Fat loading: the next magic bullet? Sherman WM, et al. **Int J Sport Nutr** 1995 Jun;5 Suppl:S1–12 (29 ref.)

Prediction of ruminal volatile fatty acids and pH within the net carbohydrate and protein system. Pitt RE, et al. **J Anim Sci** 1996 Jan;74(1):226–44 (126 ref.)

Design of the oxygen and substrate pathways. I. Model and strategy to test symmorphosis in a network structure. Taylor CR, et al. **J Exp Biol** 1996 Aug;199 (Pt 8):1643–9 (25 ref.)

Design of the oxygen and substrate pathways. VII. Different structural limits for oxygen and substrate supply to muscle mitochondria. Weibel ER, et al. **J Exp Biol** 1996 Aug;199 (Pt 8):1699–709 (18 ref.)

Carbohydrate metabolism in primary growth hormone resistance (Laron syndrome) before and during insulin-like growth factor-I treatment. Laron Z, et al. **Metabolism** 1995 Oct;44(10 Suppl 4):113–8 (41 ref.)

Cation and sugar selectivity determinants in a novel family of transport proteins. Poolman B, et al. **Mol Microbiol** 1996 Mar;19(5):911–22 (63 ref.)

Carbohydrate ingestion/supplementation or resistance exercise and training. Conley MS, et al. **Sports Med** 1996 Jan;21(1):7–17 (104 ref.)

[Protein–carbohydrate recognition. Foundation and medical application with illustrations of tumor lectin studies] Gabius HJ, et al. **Naturwissenschaften** 1995 Dec;82(12):533–43 (162 ref.) (Eng. Abstr.) **(Ger)**

[Role of essential trace elements in the disturbance of carbohydrate metabolism] Kimura K. **Nippon Rinsho** 1996 Jan;54(1):79–84 (20 ref.) (Eng. Abstr.) **(Jpn)**

PHARMACOKINETICS

Implications of altering the rate of carbohydrate absorption from the gastrointestinal tract. Jenkins DJ, et al. **Clin Invest Med** 1995 Aug;18(4):296–302 (57 ref.)

PHYSIOLOGY

Carbohydrate-and heparin-binding proteins in mammalian fertilization. Töpfer-Petersen E, et al. **Andrologia** 1995 Nov–Dec;27(6):303–24 (226 ref.)

From legumes to leukocytes: biological roles for sulfated carbohydrates. Hooper LV, et al. **FASEB J** 1996 Aug; 10(10):1137–46 (88 ref.)

Glycosyltransferase mutants: key to new insights in glycobiology. Stanley P, et al. **FASEB J** 1995 Nov; 9(14):1436–44 (48 ref.)

Carbohydrates, branched-chain amino acids, and endurance: the central fatigue hypothesis. Davis JM. **Int J Sport Nutr** 1995 Jun;5 Suppl:S29–38 (42 ref.)

CARBOLINES

METABOLISM

Genotoxic potential of beta-carbolines: a review. de Meester C. **Mutat Res** 1995 Oct;339(3):139–53 (93 ref.)

TOXICITY

Genotoxic potential of beta-carbolines: a review. de Meester C. **Mutat Res** 1995 Oct;339(3):139–53 (93 ref.)

CARBOMONOXYHEMOGLOBIN see **CARBOXYHEMOGLOBIN**

CARBON

The methodological problems of multinational epidemiological studies with particular reference to carbon black studies. Gardiner K. **Occup Med (Oxf)** 1995 Oct; 45(5):247–55 (39 ref.)

[Biological study of fullerene C60] Huang WD, et al. **Sheng Li Ko Hsueh Chin Chan** 1995 Oct;26(4):367–9 (10 ref.) **(Chi)**

ADMINISTRATION & DOSAGE

[Break in the trend of treatment of acute poisoning. Ventricular lavage may be substituted by active carbon] Kulling P, et al. **Lakartidningen** 1995 Oct 4;92(40):3676, 3683 (33 ref.) **(Swe)**

CHEMISTRY

Carbon–proton coupling constants in the conformational analysis of sugar molecules. Tvaroska I, et al. **Adv Carbohydr Chem Biochem** 1995;51:15–61 (156 ref.)

METABOLISM

The role of CcpA transcriptional regulator in carbon metabolism in Bacillus subtilis. Henkin TM. **FEMS Microbiol Lett** 1996 Jan 1;135(1):9–15 (35 ref.)

Protein adsorption on low temperature isotropic carbon: V. How is it related to its blood compatibility? Feng L, et al. **J Biomater Sci Polym Ed** 1995;7(5):439–52 (104 ref.)

CARBON DIOXIDE

see related
HYPERCAPNIA

BLOOD

Low blood flow extracorporeal carbon dioxide removal (ECCO2R): a review of the concept and a case report. Habashi NM, et al. **Intensive Care Med** 1995 Jul;21(7):594–7 (33 ref.)

Permissive hypercapnia in ARDS: just do it? [editorial; comment] Lewandowski K. **Intensive Care Med** 1996 Mar; 22(3):179–81 (13 ref.) Comment on: Intensive Care Med 1996 Mar;22(3):182–91.

[Lactate versus intramucosal pCO2 or pH?] Mertzlufft F. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Oct; 30 Suppl 1:S27–33 (41 ref.) **(Ger)**

[Arterial carbon dioxide tension] Matsuzaki K. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:792–5 (5 ref.) **(Jpn)**

METABOLISM

Simulation of intraluminal gas transport processes in the microcirculation. Hellums JD, et al. **Ann Biomed Eng** 1996 Jan–Feb;24(1):1–24 (97 ref.)

Carbon dioxide recovery in ready biodegradation tests: mass transfer and kinetic considerations. Larson RJ, et al. **Chemosphere** 1996 Sep;33(6):1195–210 (16 ref.)

Getting rid of carbon dioxide during exercise [editorial] Jones NL, et al. **Clin Sci (Colch)** 1996 May;90(5):323–35 (92 ref.)

Carbon dioxide formation and elimination in man. Recent theories and possible consequences. Wiklund L. **Ups J Med Sci** 1996;101(1):35–67 (71 ref.)

CARBON DISULFIDE

ADVERSE EFFECTS

[Ischemic heart disease and occupational exposure to chemical substances. Review of the literature] Waissmann W, et al. **Arq Bras Cardiol** 1995 May;64(5):477–82 (87 ref.) **(Por)**

CARBON MONOXIDE

Carbon monoxide and carboxyhemoglobin. Vreman HJ, et al. **Adv Pediatr** 1995;42:303–25 (0 ref.)

Gaseous transmitters as new agents in neuroendocrine regulation. Costa A, et al. **J Endocrinol** 1996 May; 149(2):199–207 (80 ref.)

ADVERSE EFFECTS

Health effects of outdoor air pollution. Part 2. Committee of the Environmental and Occupational Health Assembly of the American Thoracic Society. **Am J Respir Crit Care Med** 1996 Feb;153(2):477–98 (226 ref.)

METABOLISM

Gases as chemical messengers in the carotid body. Role of nitric oxide and carbon monoxide in chemoreception. Prabhakar NR. **Adv Exp Med Biol** 1995;393:309–12 (14 ref.)

CO dehydrogenase. Ferry JG. **Annu Rev Microbiol** 1995; 49:305–33 (132 ref.)

Kinetic pathways and barriers for ligand binding to myoglobin. Olson JS, et al. **J Biol Chem** 1996 Jul 26; 271(30):17593–6 (28 ref.)

[Biological role of carbon monoxide in nervous system function] Borowicz KK, et al. **Postepy Hig Med Dosw** 1996; 50(1):81–94 (79 ref.) (Eng. Abstr.) **(Pol)**

CARBON MONOXIDE POISONING

COMPLICATIONS

Myocardial infarction with normal coronary artery after carbon monoxide exposure: a case report. Lee D, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1996 May;57(5):355–9 (21 ref.)

DIAGNOSIS

Carbon monoxide poisoning: easy to treat but difficult to recognise. Balzan MV, et al. **Postgrad Med J** 1996 Aug; 72(850):470–3 (58 ref.)

[Magnetic resonance in delayed postanoxic encephalopathy following acute carbon monoxide poisoning. A case report] Pagnan L, et al. **Radiol Med (Torino)** 1996 Mar;91(3):309–11 (20 ref.) **(Ita)**

THERAPY

Carbon monoxide and carboxyhemoglobin. Vreman HJ, et al. **Adv Pediatr** 1995;42:303–25 (0 ref.)

CARBON TETRACHLORIDE

TOXICITY

A review of the role of tissue repair as an adaptive strategy: why low doses are often non-toxic and why high doses can be fatal. Calabrese EJ, et al. **Food Chem Toxicol** 1996 Mar;34(3):301–11 (49 ref.)

Efficient tissue repair underlies the resiliency of postnatally developing rats to chlordecone + CCl4 hepatotoxicity. Dalu A, et al. **Toxicology** 1996 Jul 17;111(1–3):29–42 (41 ref.)

CARBONATE DEHYDRATASE

[The catalytic mechanism of carbonic anhydrase] Furuki T, et al. **Tanpakushitsu Kakusan Koso** 1995 Sep;40(12):1835–45 (46 ref.) **(Jpn)**

DEFICIENCY

Human carbonic anhydrases and carbonic anhydrase deficiencies. Sly WS, et al. **Annu Rev Biochem** 1995; 64:375–401 (177 ref.)

DRUG EFFECTS

Do KCa channels and carbonic anhydrase play a role in thiazide-induced hyperglycaemia? Pickkers P, et al. **J Hum Hypertens** 1995 Aug;9(8):691–3 (22 ref.)

METABOLISM

Human carbonic anhydrases and carbonic anhydrase deficiencies. Sly WS, et al. **Annu Rev Biochem** 1995; 64:375–401 (177 ref.)

PHYSIOLOGY

Multiple roles of carbonic anhydrase in cellular transport and metabolism. Henry RP. **Annu Rev Physiol** 1996; 58:523–38 (108 ref.)

Carbonic anhydrase in the alimentary tract. Roles of the different isozymes and salivary factors in the maintenance of optimal conditions in the gastrointestinal canal. Parkkila S, et al. **Scand J Gastroenterol** 1996 Apr;31(4):305–17 (171 ref.)

CARBONATE DEHYDRATASE INHIBITORS see **CARBONIC ANHYDRASE INHIBITORS**

CARBONATE DEHYDRATASE ISOENZYMES see **CARBONATE DEHYDRATASE**

CARBONIC ANHYDRASE see **CARBONATE DEHYDRATASE**

CARBONIC ANHYDRASE INHIBITORS

see related
DIURETICS

CARBONIC ANHYDRASE INHIBITORS

THERAPEUTIC USE

[Topical carbonic anhydrase inhibitors in the treatment of glaucoma] Bayer A, et al. **J Fr Ophtalmol** 1996;19(5):357–62 (30 ref.) (Eng. Abstr.) **(Fre)**

CARBONIC ANHYDRASE ISOENZYMES see **CARBONATE DEHYDRATASE**

CARBONIC ANHYDRIDE see **CARBON DIOXIDE**

CARBOPLATIN

[Cisplatin and carboplatin—update] Geffen DB, et al. **Harefuah** 1995 Aug;129(3–4):131–5 (40 ref.) **(Heb)**

ADMINISTRATION & DOSAGE

Carboplatin versus cisplatin in ovarian cancer. Alberts DS. **Semin Oncol** 1995 Oct;22(5 Suppl 12):88–90 (6 ref.)

ADVERSE EFFECTS

Comparative adverse effect profiles of platinum drugs. McKeage MJ. **Drug Saf** 1995 Oct;13(4):228–44 (154 ref.)

Pathophysiology, severity, pattern, and risk factors for carboplatin-induced emesis. du Bois A, et al. **Oncology** 1996 Jun;53 Suppl 1:46–50 (29 ref.)

Amifostine and chemotherapy-related thrombocytopenia. Budd GT. **Semin Oncol** 1996 Aug;23(4 Suppl 8):49–52 (31 ref.)

THERAPEUTIC USE

Radiation and concurrent carboplatin administration in locally advanced head and neck cancer. A Hellenic Cooperative Oncology Group Study. Fountzilas G, et al. **Tumori** 1995 Sep–Oct;81(5):354–8 (19 ref.)

CARBOXY-LYASES

GENETICS

Solventogenic enzymes of Clostridium acetobutylicum: catalytic properties, genetic organization, and transcriptional regulation. Dürre P, et al. **FEMS Microbiol Rev** 1995 Oct;17(3):251–62 (90 ref.)

METABOLISM

Biogenic amines: their importance in foods. Silla Santos MH. **Int J Food Microbiol** 1996 Apr;29(2–3):213–31 (140 ref.)

CARBOXYDISMUTASE see **RIBULOSEBIPHOSPHATE CARBOXYLASE**

1-CARBOXYGLUTAMIC ACID

[Gas6: a ligand for receptor tyrosine kinase containing gamma-carboxyglutamic acids] Nakano T. **Seikagaku** 1996 Apr;68(4):299–302 (11 ref.) **(Jpn)**

CARBOXYHEMOGLOBIN

ANALYSIS

[Carboxyhemoglobin] Ohba Y. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:180–2 (7 ref.) **(Jpn)**

PHYSIOLOGY

Carbon monoxide and carboxyhemoglobin. Vreman HJ, et al. **Adv Pediatr** 1995;42:303–25 (0 ref.)

CARBOXYL (ACID) PROTEINASES see **ASPARTIC PROTEINASES**

CARBOXYLASE DEFICIENCY, MULTIPLE see **MULTIPLE CARBOXYLASE DEFICIENCY**

CARBOXYLESTERASES see **CARBOXYLIC ESTER HYDROLASES**

CARBOXYLIC ACIDS

ANALYSIS

Application of tandem mass spectrometry for the analysis of long-chain carboxylic acids. Kuksis A, et al. **J Chromatogr B Biomed Appl** 1995 Sep 15;671(1–2):35–70 (116 ref.)

Use of derivatization to improve the chromatographic properties and detection selectivity of physiologically important carboxylic acids. Toyo'oka T. **J Chromatogr B Biomed Appl** 1995 Sep 15;671(1–2):91–112 (127 ref.)

CARBOXYLIC ESTER HYDROLASES

BLOOD

[Arylesterase (ArE)] Ikeda K. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:412–4 (15 ref.) **(Jpn)**

[Isoenzyme of nonspecific esterase in hemopoietic cells] Sasaki R. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:239–42 (10 ref.) **(Jpn)**

CHEMISTRY

Acyl glycerol hydrolases: inhibitors, interface and catalysis. Cambillau C, et al. **Curr Opin Struct Biol** 1996 Aug; 6(4):449–55 (25 ref.)

Molecular aspects of carboxylesterase isoforms in comparison with other esterases. Satoh T, et al. **Toxicol Lett** 1995 Dec; 82–83:439–45 (17 ref.)

GENETICS

Molecular genetic basis of red cell markers and its forensic application. Ikemoto S, et al. **Forensic Sci Int** 1996 Jun 28;80(1–2):147–61 (42 ref.)

METABOLISM

Neuropathy target esterase (NTE) and organophosphorus-induced delayed polyneuropathy (OPIDP): recent advances. Johnson MK, et al. **Toxicol Lett** 1995 Dec;82–83:459–63 (24 ref.)

CARBOXYMETHYLCYSTEINE see **CARBOCYSTEINE**

CARBOXYPEPTIDASE TRANSPEPTIDASE

METABOLISM

The role of penicillin-binding proteins in penicillin resistance of Streptococcus pneumoniae. Hakenbeck R, et al. **Dev Biol Stand** 1995;85:115–23 (35 ref.)

CARBOXYPEPTIDASES

[Galactosialidosis—protective protein and related enzymes] Hirasawa M. **Nippon Rinsho** 1995 Dec;53(12):2967–72 (22 ref.) (Eng. Abstr.) **(Jpn)**

ISOLATION & PURIFICATION

Production and utilization of detyrosinated tubulin in developing Artemia larvae: evidence for a tubulin-reactive carboxypeptidase. Xiang H, et al. **Biochem Cell Biol** 1995 Sep–Oct;73(9–10):673–85 (82 ref.)

METABOLISM

[Mechanisms of regulation and the biological role of carboxypeptidase H—a neuropeptide-processing enzyme] Vernigora AN, et al. **Biokhimiia** 1995 Dec;60(12):1953–63 (124 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

[Lysosomal enzymes, sphingolipid activator proteins, and protective protein] Suzuki Y. **Nippon Rinsho** 1995 Dec; 53(12):2887–91 (7 ref.) (Eng. Abstr.) **(Jpn)**

CARCINOEMBRYONIC ANTIGEN

ANALYSIS

Carcinoembryonic antigen in the evaluation of therapy of primary and metastatic colorectal cancer. Adams WJ, et al. **Aust N Z J Surg** 1996 Aug;66(8):515–9 (70 ref.)

[Carcino-fetal antigens] Endo Y. **Nippon Rinsho** 1996 Jun; 54(6):1499–504 (17 ref.) (Eng. Abstr.) **(Jpn)**

BLOOD

Marked elevation of plasma carcinoembryonic antigen and stomach carcinoma. Horie Y, et al. **Cancer** 1996 May 15; 77(10):1991–7 (21 ref.)

The use of prognostic markers in surgery for colorectal cancer. Northover J. **Eur J Cancer** 1995 Jul–Aug; 31A(7–8):1207–9 (36 ref.)

DIAGNOSTIC USE

Management of recurrent colorectal cancer: another look at carcinoembryonic antigen-detected recurrence [see comments] Vauthey JN, et al. **Dig Dis** 1996 Jan–Feb; 14(1):5–13 (48 ref.) Comment in: Dig Dis 1996 Jan–Feb;14(1):1–4.

CARCINOGEN MARKERS see **TUMOR MARKERS, BIOLOGICAL**

CARCINOGENICITY TESTS

see related
MUTAGENICITY TESTS

Sixth plot of the carcinogenic potency database: results of animal bioassays published in the General Literature 1989 to 1990 and by the National Toxicology Program 1990 to 1993. Gold LS, et al. **Environ Health Perspect** 1995 Nov; 103 Suppl 8:3–122 (37 ref.)

The evaluation of potential human carcinogens: a histopathologist's point of view. Greaves P. **Exp Toxicol Pathol** 1996 Feb;48(2–3):169–74 (17 ref.)

The effects of dietary restriction on drug testing and toxicity. Hart RW, et al. **Exp Toxicol Pathol** 1996 Feb;48(2–3):121–7 (33 ref.)

The effects of overfeeding and moderate dietary restriction on Sprague-Dawley rat survival, pathology, carcinogenicity, and the toxicity of pharmaceutical agents. Keenan KP, et al. **Exp Toxicol Pathol** 1996 Feb; 48(2–3):139–44 (24 ref.)

Are lifespan rodent carcinogenicity studies defensible for pharmaceutical agents? Monro A. **Exp Toxicol Pathol** 1996 Feb;48(2–3):155–66 (70 ref.)

Human protection against non-genotoxic carcinogens in the US without the Delaney Clause. Weisburger JH. **Exp Toxicol Pathol** 1996 Feb;48(2–3):201–8 (41 ref.)

DNA adducts in human carcinogenesis: etiological relevance and structure-activity relationship. Bartsch H. **Mutat Res** 1996 Jun;340(2–3):67–79 (67 ref.)

Validation of the SOS/umu test using test results of 486 chemicals and comparison with the Ames test and carcinogenicity data. Reifferscheid G, et al. **Mutat Res** 1996 Aug 12;369(3–4):129–45 (120 ref.)

Methyl tertiary butyl ether (MTBE)—evaluation of MTBE carcinogenicity studies. Rudo KM. **Toxicol Ind Health** 1995 Mar–Apr;11(2):167–73 (14 ref.)

METHODS

Medium-term liver and multi-organ carcinogenesis bioassays for carcinogens and chemopreventive agents. Ito N, et al. **Exp Toxicol Pathol** 1996 Feb;48(2–3):113–9 (40 ref.)

Chemical carcinogen mechanisms of action and implications for testing methodology. Williams GM, et al. **Exp Toxicol Pathol** 1996 Feb;48(2–3):101–11 (55 ref.)

Principles underlying dose selection for, and extrapolation from, the carcinogen bioassay: dose influences mechanism. Counts JL, et al. **Regul Toxicol Pharmacol** 1995 Jun; 21(3):418–21 (39 ref.)

STANDARDS

Risk assessment: the default conservatism controversy. Barnard RC. **Regul Toxicol Pharmacol** 1995 Jun;21(3):431–8 (14 ref.)

STATISTICS & NUMERICAL DATA

A case study of cancer data set combinations for PCBs. Vater ST, et al. **Regul Toxicol Pharmacol** 1995 Aug;22(1):2–10 (26 ref.)

CARCINOGENS

see related
ANTICARCINOGENIC AGENTS
COCARCINOGENESIS
MUTAGENS
ONCOGENIC VIRUSES

Review of occupational lung carcinogens. Steenland K, et al. **Am J Ind Med** 1996 May;29(5):474–90 (167 ref.)

Nitrosamines and vitamins. Reed PI. **Bibl Nutr Dieta** 1995; (52):30–42 (63 ref.)

Metal carcinogenesis in total joint arthroplasty. Animal models. Lewis CG, et al. **Clin Orthop** 1996 Aug;(329 Suppl):S264–8 (37 ref.)

Capsaicin in hot chili pepper: carcinogen, co-carcinogen or anticarcinogen? Surh YJ, et al. **Food Chem Toxicol** 1996 Mar;34(3):313–6 (48 ref.)

p53 proteins and aflatoxin b1: the good, the bad, and the ugly [editorial] Liang TJ. **Hepatology** 1995 Oct;22(4 Pt 1):1330–2 (21 ref.)

Metal ion interactions with DNA: considerations on structure, stability, and effects from metal ion binding. Bregadze VG. **Met Ions Biol Syst** 1996;32:419–51 (44 ref.)

Metal replacement in DNA-binding zinc finger proteins and its relevance to mutagenicity and carcinogenicity through free radical generation. Sarkar B. **Nutrition** 1995 Sep–Oct; 11(5 Suppl):646–9 (17 ref.)

Estrogen as a carcinogen: the genetics and molecular biology of human endometrial carcinoma. Boyd J. **Prog Clin Biol Res** 1996;394:151–73 (162 ref.)

Transplacental hormonal carcinogenesis: diethylstilbestrol as an example. Newbold RR, et al. **Prog Clin Biol Res** 1996; 394:131–47 (37 ref.)

ADVERSE EFFECTS

Chemical methods for assessing systemic exposure to dietary heterocyclic amines in man. Davies DS, et al. **Arch Toxicol Suppl** 1996;18:251–8 (29 ref.)

Individual susceptibility to occupational toxicants: practical consequences for risk management. Norseth T. **Arch Toxicol Suppl** 1996;18:367–78 (37 ref.)

Malignant mesothelioma in Pilbara Aborigines. Musk AW, et al. **Aust J Public Health** 1995 Oct;19(5):520–2 (10 ref.)

Significance of individual sensitivity to chemicals: elucidation of host susceptibility by use of biomarkers in environmental health research. Cullen MR, et al. **Clin Chem** 1995 Dec; 41(12 Pt 2):1809–13 (21 ref.)

Biomarkers as tools in human health risk assessment. Greim H, et al. **Clin Chem** 1995 Dec;41(12 Pt 2):1804–8 (13 ref.)

Epidemiology of cancer by tobacco products and the significance of TSNA. Gupta PC, et al. **Crit Rev Toxicol** 1996;26(2):183–98 (81 ref.)

Risk estimation—an overview: disease risk estimation based upon animal bioassays. Gaylor DW. **Drug Metab Rev** 1996 Feb–May;28(1–2):9–27 (39 ref.)

Bioassay designs for validating biologically based mathematical models of carcinogenesis for risk assessment. Kodell RL. **Drug Metab Rev** 1996 Feb–May;28(1–2):219–23 (6 ref.)

Nonhormonal drugs and cancer. Stolley PD, et al. **Environ Health Perspect** 1995 Nov;103 Suppl 8:191–6 (114 ref.)
Overview of preventable industrial causes of occupational cancer. Ward E. **Environ Health Perspect** 1995 Nov;103 Suppl 8:197–203 (44 ref.)
Butyrate and colorectal cancer in animals and in humans (mini–symposium: butyrate and colorectal cancer). Clausen MR. **Eur J Cancer Prev** 1995 Dec;4(6):483–90 (104 ref.)
Dietary contribution to genotoxic risk and its control. Lindsay DG. **Food Chem Toxicol** 1996 Apr;34(4):423–31 (61 ref.)
Quantitative risk assessment and the limitations of the linearized multistage model. Lovell DP, et al. **Hum Exp Toxicol** 1996 Feb;15(2):87–104 (50 ref.)
Occupational cancer in developed and developing countries. Vineis P, et al. **Int J Cancer** 1995 Sep 15;62(6):655–60 (32 ref.)
Tissue dosimetry, pharmacokinetic modeling, and interspecies scaling factors. Andersen ME, et al. **Risk Anal** 1995 Aug;15(4):533–7 (25 ref.)
Tamoxifen––breast cancer preventive or human carcinogen? Clute E. **Toxicol Ind Health** 1995 Sep–Oct;11(5):503–10 (12 ref.)
ATSDR evaluation of health effects of chemicals. II. Mirex and chlordecone: health effects, toxicokinetics, human exposure, and environmental fate. Faroon O, et al. **Toxicol Ind Health** 1995;11(6):1–203 (681 ref.)
[Advances in the study on biological effects of diesel exhaust] Lu Y, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1995 Sep;29(5):305–6 (15 ref.) **(Chi)**
[Do employees in the rubber industry have an increased risk of laryngeal cancer?] Tisch M, et al. **HNO** 1995 Nov; 43(11):649–53 (24 ref.) (Eng. Abstr.) **(Ger)**
[Glutathione S–transferase as a metabolic biomarker for predisposition to lung neoplasms induced by chemical carcinogens] Lutz W, et al. **Med Pr** 1995;46(5):497–503 (14 ref.) (Eng. Abstr.) **(Pol)**
[Oxidative stress as a basic mechanism of the carcinogenic effect of man made mineral fibers on the human body] Lutz W, et al. **Med Pr** 1995;46(3):275–84 (18 ref.) (Eng. Abstr.) **(Pol)**

ANALYSIS

Quantification of endogenous carcinogens. The ethylene oxide paradox. Bolt HM. **Biochem Pharmacol** 1996 Jul 12; 52(1):1–5 (51 ref.)
Formation and analysis of tobacco–specific N–nitrosamines. Brunnemann KD, et al. **Crit Rev Toxicol** 1996;26(2):121–37 (43 ref.)
Childhood cancer: overview of incidence trends and environmental carcinogens. Zahm SH, et al. **Environ Health Perspect** 1995 Sep;103 Suppl 6:177–84 (143 ref.)
Development and application of non–invasive biomarkers for carcinogen–DNA adduct analysis in occupationally exposed populations. Talaska G, et al. **Toxicology** 1996 Jul 17;111(1–3):207–12 (17 ref.)
[Reference values in biological monitoring of occupational exposure to mutagens and carcinogens] Clonfero E, et al. **G Ital Med Lav** 1994 Jan–Nov;16(1–6):25–9 (43 ref.) (Eng. Abstr.) **(Ita)**

ANTAGONISTS & INHIBITORS

Chemoprevention of cancer. Wattenberg LW. **Prev Med** 1996 Jan–Feb;25(1):44–5 (11 ref.)

CHEMISTRY

Chemical carcinogen mechanisms of action and implications for testing methodology. Williams GM, et al. **Exp Toxicol Pathol** 1996 Feb;48(2–3):101–11 (55 ref.)
Quantitative structure––activity relationship (QSAR) studies of mutagens and carcinogens. Benigni R, et al. **Med Res Rev** 1996 May;16(3):267–84 (85 ref.)
Influence of soil half–life on risk assessment of carcinogens. Borgert CJ, et al. **Regul Toxicol Pharmacol** 1995 Oct; 22(2):143–51 (24 ref.)

CLASSIFICATION

Carcinogen classification systems: similarities and differences. Sanner T, et al. **Regul Toxicol Pharmacol** 1996 Apr; 23(2):128–38 (16 ref.)

HISTORY

The 37 year history of the Delaney Clause. Weisburger JH. **Exp Toxicol Pathol** 1996 Feb;48(2–3):183–8 (21 ref.)

METABOLISM

Formation and processing of reactive metabolites of the heterocyclic amines. Alexander J. **Arch Toxicol Suppl** 1996; 18:275–85 (52 ref.)
Enzymic and interindividual differences in the human metabolism of heterocyclic amines. Boobis AR, et al. **Arch Toxicol Suppl** 1996;18:286–302 (65 ref.)
The role of adduct site–specific mutagenesis in understanding how carcinogen–DNA adducts cause mutations: perspective, prospects and problems. Loechler EL. **Carcinogenesis** 1996 May;17(5):895–902 (70 ref.)
Recent studies on mechanisms of bioactivation and detoxification of 4–(methylnitrosamino)–1–(3–pyridyl)–1–butanone (NNK), a tobacco–specific lung carcinogen. Hecht SS. **Crit Rev Toxicol** 1996;26(2):163–81 (83 ref.)
Endogenous formation of nitrosamines and oxidative DNA–damaging agents in tobacco users. Nair J, et al. **Crit Rev Toxicol** 1996;26(2):149–61 (55 ref.)
The role of peroxidase–catalyzed activation of aromatic amines in breast cancer. Josephy PD. **Mutagenesis** 1996 Jan;11(1):3–7 (65 ref.)
Selective chemisorption and detoxification of aflatoxins by phyllosilicate clay. Phillips TD, et al. **Nat Toxins** 1995; 3(4):204–13; discussion 221 (59 ref.)
The procarcinogen hypothesis for bladder cancer: activities of individual drug metabolizing enzymes as risk factors. Branch RA, et al. **Pharmacogenetics** 1995;5 Spec No:S97–102 (26 ref.)
Role of cytochrome P4501A2 in chemical carcinogenesis: implications for human variability in expression and enzyme activity. Eaton DL, et al. **Pharmacogenetics** 1995 Oct; 5(5):259–74 (128 ref.)
The CYP2A gene subfamily: species differences, regulation, catalytic activities and role in chemical carcinogenesis. Fernandez–Salguero P, et al. **Pharmacogenetics** 1995;5 Spec No:S123–8 (56 ref.)
Assessment of cancer susceptibility in humans by use of genetic polymorphisms in carcinogen metabolism. Ikawa S, et al. **Pharmacogenetics** 1995;5 Spec No:S154–60 (42 ref.)
Metabolic polymorphisms and carcinogen–DNA adduct formation in human populations. Kaderlik KR, et al. **Pharmacogenetics** 1995;5 Spec No:S108–17 (112 ref.)
Biological relevance and consequences of chemical– or metal–induced DNA cross–linking. Paustenbach DJ, et al. **Proc Soc Exp Biol Med** 1996 Mar;211(3):211–7 (62 ref.)
Monitoring of human exposure to carcinogens through DNA and protein adduct determination. Farmer PB. **Toxicol Lett** 1995 Dec;82–83:757–62 (24 ref.)
Genetic susceptibility and carcinogen–DNA adduct formation in human urinary bladder carcinogenesis. Kadlubar FF, et al. **Toxicol Lett** 1995 Dec;82–83:627–32 (19 ref.)

PHARMACOKINETICS

Gastric mucosal protection against penetration of carcinogens into the mucosa. Sørbye H, et al. **Scand J Gastroenterol** 1995 Oct;30(10):929–34 (91 ref.)
Expression of exposure in negative carcinogenicity studies: dose/body weight, dose/body surface area, or plasma concentrations? Monro A, et al. **Toxicol Pathol** 1995 Mar–Apr;23(2):187–98 (69 ref.)
Use of quantitative modelling in methylene chloride risk assessment. Rhomberg L. **Toxicology** 1995 Sep 1; 102(1–2):95–114 (58 ref.)

PHARMACOLOGY

Chemical carcinogen mechanisms of action and implications for testing methodology. Williams GM, et al. **Exp Toxicol Pathol** 1996 Feb;48(2–3):101–11 (55 ref.)
A possible role in chemical carcinogenesis for epigenetic, heritable changes in gene expression. MacLeod MC. **Mol Carcinog** 1996 Apr;15(4):241–50 (58 ref.)
[Fjord–region polycyclic aromatic hydrocarbons: carcinogenic properties and mechanism of action] Likhachev AI, et al. **Vopr Onkol** 1996;42(1):23–33 (69 ref.) **(Rus)**

STANDARDS

Risk assessment of carcinogens in food with special consideration of non–genotoxic carcinogens. Scientific arguments for use of risk assessment and for changing the Delaney Clause specifically. Williams GM, et al. **Exp Toxicol Pathol** 1996 Feb;48(2–3):209–15 (21 ref.)

TOXICITY

Extrapolation of heterocyclic amine carcinogenesis data from rodents and nonhuman primates to humans. Adamson RH, et al. **Arch Toxicol Suppl** 1996;18:303–18 (56 ref.)
Alkylation of DNA and its aftermath. Lawley PD. **Bioessays** 1995 Jun;17(6):561–8 (54 ref.)
Role of oxidative stress in non–genotoxic carcinogenesis with special reference to liver tumors induced by peroxisome proliferators. Sai–Kato K, et al. **Biomed Environ Sci** 1995 Sep;8(3):269–79 (64 ref.)
The role of adduct site–specific mutagenesis in understanding how carcinogen–DNA adducts cause mutations: perspective, prospects and problems. Loechler EL. **Carcinogenesis** 1996 May;17(5):895–902 (70 ref.)
Interaction of bulky chemical carcinogens with DNA in chromatin. MacLeod MC. **Carcinogenesis** 1995 Sep; 16(9):2009–14 (90 ref.)
A conundrum in molecular toxicology: molecular and biological changes during neoplastic transformation of human cells. Milo GE, et al. **Cell Biol Toxicol** 1995 Dec; 11(6):329–45 (32 ref.)
The biological significance of tobacco–specific N–nitrosamines: smoking and adenocarcinoma of the lung. Hoffmann D, et al. **Crit Rev Toxicol** 1996;26(2):199–211 (76 ref.)
Comparative carcinogenicity, metabolism, mutagenicity, and DNA binding of 7H–dibenzo[c,g]carbazole and dibenz[a,j]acridine. Warshawsky D, et al. **Crit Rev Toxicol** 1996;26(2):213–49 (101 ref.)
The effects of near ultraviolet radiation on the toxic effects of polycyclic aromatic hydrocarbons in animals and plants: a review. Arfsten DP, et al. **Ecotoxicol Environ Saf** 1996 Feb;33(1):1–24 (109 ref.)
Sixth plot of the carcinogenic potency database: results of animal bioassays published in the General Literature 1989 to 1990 and by the National Toxicology Program 1990 to 1993. Gold LS, et al. **Environ Health Perspect** 1995 Nov; 103 Suppl 8:3–122 (37 ref.)
Proliferation markers. Iatropoulos MJ, et al. **Exp Toxicol Pathol** 1996 Feb;48(2–3):175–81 (31 ref.)
Medium–term liver and multi–organ carcinogenesis bioassays for carcinogens and chemopreventive agents. Ito N, et al. **Exp Toxicol Pathol** 1996 Feb;48(2–3):113–9 (40 ref.)
Epigenetic carcinogens: evaluation and risk assessment. Williams GM, et al. **Exp Toxicol Pathol** 1996 Feb; 48(2–3):189–95 (55 ref.)
Urinary bladder carcinogenesis: implications for risk assessment. Rodent Bladder Carcinogenesis Working Group. **Food Chem Toxicol** 1995 Sep;33(9):797–802 (32 ref.)
Effects of stones and other physical factors on the induction of rodent bladder cancer. Clayson DB, et al. **Food Chem Toxicol** 1995 Sep;33(9):771–84 (142 ref.)
Comparative methods of toxicity testing. Consensus document following an International Life Sciences Institute–ILSI Europe Workshop held in May 1995. Huggett AC, et al. **Food Chem Toxicol** 1996 Feb; 34(2):183–92 (34 ref.)
Genotoxicity in the rodent urinary bladder. King C, et al. **Food Chem Toxicol** 1995 Sep;33(9):757–69 (73 ref.)
Urinary bladder carcinogenesis: a working group approach to risk assessment. Neumann DA, et al. **Food Chem Toxicol** 1995 Sep;33(9):701–4 (17 ref.)
Is ingested inorganic arsenic a "threshold" carcinogen? Abernathy CO, et al. **Fundam Appl Toxicol** 1996 Feb; 29(2):168–75 (59 ref.)
The maximum tolerated dose for inhalation bioassays: toxicity vs overload. Morrow PE, et al. **Fundam Appl Toxicol** 1996 Feb;29(2):155–67 (69 ref.)
Variability in gene expression and tumor formation within genetically homogeneous animal populations in bioassays. Wolff GL. **Fundam Appl Toxicol** 1996 Feb;29(2):176–84 (30 ref.)
Bromodeoxyuridine: a diagnostic tool in biology and medicine, Part II: Oncology, chemotherapy and carcinogenesis. Dolbeare F. **Histochem J** 1995 Dec; 27(12):923–64 (468 ref.)
Experimental models for carcinogenesis in the house musk shrew, Suncus murinus, Insectivora. Tsubura A, et al. **Histol Histopathol** 1995 Oct;10(4):1047–55 (69 ref.)
Calcium–cell cycle regulator, differentiator, killer, chemopreventor, and maybe, tumor promoter. Whitfield JF, et al. **J Cell Biochem Suppl** 1995;22:74–91 (38 ref.)
Enhancement of tumor growth by drugs with some common molecular actions. LaBella FS, et al. **Mol Carcinog** 1996 Jun;16(2):68–76 (91 ref.)
Series: current issues in mutagenesis and carcinogenesis, No. 65. The genotoxicity and carcinogenicity of paracetamol: a regulatory (re)view. Bergman K, et al. **Mutat Res** 1996 Feb 1;349(2):263–88 (103 ref.)
The micronucleus test and NTP rodent carcinogens: not so many false negatives. Galloway SM. **Mutat Res** 1996 Jun 10;352(1–2):185–8 (5 ref.)
The micronucleus test: its value as a predictor of rodent carcinogens versus its value in risk assessment. Gocke E. **Mutat Res** 1996 Jun 10;352(1–2):189–90 (7 ref.)
PPAR: a mediator of peroxisome proliferator action. Green S. **Mutat Res** 1995 Dec;333(1–2):101–9 (65 ref.)
Protein kinase C and skin tumor promotion. Marks F, et al. **Mutat Res** 1995 Dec;333(1–2):161–72 (100 ref.)
Protein serine/threonine phosphatases as binding proteins for okadaic acid. Nagao M, et al. **Mutat Res** 1995 Dec; 333(1–2):173–9 (33 ref.)
Receptor–mediated events and the evaluation of the Environmental Protection Agency (EPA) of dioxin risks. Sewall CH, et al. **Mutat Res** 1995 Dec;333(1–2):111–22 (54 ref.)
DNA damage and repair in mutagenesis and carcinogenesis: implications of structure–activity relationships for cross–species extrapolation. Vogel EW, et al. **Mutat Res** 1996 Jun 12;353(1–2):177–218 (125 ref.)
Nongenotoxic carcinogens: development of detection methods based on mechanisms: a European project. Yamasaki H, et al. **Mutat Res** 1996 Jun 12;353(1–2):47–63 (74 ref.)
The CYP2A gene subfamily: species differences, regulation, catalytic activities and role in chemical carcinogenesis. Fernandez–Salguero P, et al. **Pharmacogenetics** 1995;5 Spec No:S123–8 (56 ref.)
Induction of cytochrome P450 isoforms by carcinogenic aromatic amines and carcinogenic susceptibility of rodent animals. Hashimoto Y, et al. **Pharmacogenetics** 1995;5 Spec No:S80–3 (22 ref.)
The potential role of oxidative stress in nongenotoxic carcinogenesis in the mouse liver. Bachowski S, et al. **Prog Clin Biol Res** 1995;391:385–96 (48 ref.)
Mechanisms of estrogen–associated carcinogenesis. Barrett JC, et al. **Prog Clin Biol Res** 1996;394:105–11 (38 ref.)
A decision tree approach for carcinogen risk assessment. Butterworth BE, et al. **Prog Clin Biol Res** 1995;391:49–70

(52 ref.)
Peroxisome proliferators: potential role of altered hepatocyte growth and differentiation in tumor development. Cattley RC, et al. **Prog Clin Biol Res** 1995;391:295–303 (55 ref.)
Risk assessment for carcinogenesis promoting agents: need for a weight of all the evidence approach. Clayson DB. **Prog Clin Biol Res** 1995;391:359–67 (49 ref.)
Hypomethylation of DNA: a possible epigenetic mechanism involved in tumor promotion. Counts JL, et al. **Prog Clin Biol Res** 1995;391:81–101 (112 ref.)
Genetic factors controlling responsiveness to skin tumor promotion in mice. DiGiovanni J. **Prog Clin Biol Res** 1995; 391:195–212 (61 ref.)
The pro–inflammatory and hyperplasiogenic action of interleukin–1 alpha in mouse skin. Fischer SM, et al. **Prog Clin Biol Res** 1995;391:161–77 (66 ref.)
A transgenic mouse model (TG.AC) for skin carcinogenesis: inducible transgene expression as a second critical event. Hansen LA, et al. **Prog Clin Biol Res** 1995;391:223–35 (34 ref.)
Chemically induced cancers in hormonal organs of laboratory animals and of humans. Huff J. **Prog Clin Biol Res** 1996; 394:77–102 (96 ref.)
Mechanisms of chemically induced thyroid follicular carcinogenesis. Kanno J, et al. **Prog Clin Biol Res** 1996; 394:353–98 (176 ref.)
Role of reactive intermediates in tumor promotion and progression. Kensler T, et al. **Prog Clin Biol Res** 1995; 391:103–16 (51 ref.)
Phenobarbital mouse liver tumors: implications of hepatic tumor promotion for cancer risk assessment. McClain RM. **Prog Clin Biol Res** 1995;391:325–36 (35 ref.)
HGF in liver regeneration and tumor promotion. Michalopoulos GK. **Prog Clin Biol Res** 1995;391:179–85 (29 ref.)
Skin carcinogenesis: characteristics, mechanisms, and prevention. Slaga TJ, et al. **Prog Clin Biol Res** 1995; 391:1–20 (43 ref.)
Calcium, cell death, and tumor promotion. Trump BF, et al. **Prog Clin Biol Res** 1995;391:121–31 (49 ref.)
Transforming growth factor–beta s in mammary tumorigenesis: promoters or antipromoters? Wakefield LM, et al. **Prog Clin Biol Res** 1995;391:133–48 (56 ref.)
Mechanistic considerations in risk assessment for epigenetic tumor–promoting carcinogens. Williams GM, et al. **Prog Clin Biol Res** 1995;391:369–83 (69 ref.)
The role of growth factors in mouse skin tumor promotion and premalignant progression. Yuspa SH, et al. **Prog Clin Biol Res** 1995;391:39–48 (43 ref.)
Risk assessment: the default conservatism controversy. Barnard RC. **Regul Toxicol Pharmacol** 1995 Jun;21(3):431–8 (14 ref.)
Influence of soil half–life on risk assessment of carcinogens. Borgert CJ, et al. **Regul Toxicol Pharmacol** 1995 Oct; 22(2):143–51 (24 ref.)
Principles underlying dose selection for, and extrapolation from, the carcinogen bioassay: dose influences mechanism. Counts JL, et al. **Regul Toxicol Pharmacol** 1995 Jun; 21(3):418–21 (39 ref.)
Measures of cell replication in risk/safety assessment of xenobiotic–induced, nongenotoxic carcinogenesis. Jones HB, et al. **Regul Toxicol Pharmacol** 1996 Apr;23(2):117–27 (103 ref.)
Significance of DNA adducts at low dose: shortening the time to spontaneous tumor occurrence. Lutz WK, et al. **Regul Toxicol Pharmacol** 1996 Feb;23(1 Pt 1):29–34 (40 ref.)
Endogenous production of DNA adducts. Nath RG, et al. **Regul Toxicol Pharmacol** 1996 Feb;23(1 Pt 1):22–8 (34 ref.)
Implications of arsenic genotoxicity for dose response of carcinogenic effects. Rudel R, et al. **Regul Toxicol Pharmacol** 1996 Apr;23(2):87–105 (55 ref.)
DNA damage: chemistry, repair, and mutagenic potential. Singer B. **Regul Toxicol Pharmacol** 1996 Feb;23(1 Pt 1):2–13 (43 ref.)
A case study of cancer data set combinations for PCBs. Vater ST, et al. **Regul Toxicol Pharmacol** 1995 Aug;22(1):2–10 (26 ref.)
International safety assessment of pesticides: dithiocarbamate pesticides, ETU, and PTU—a review and update. Vettorazzi G, et al. **Teratog Carcinog Mutagen** 1995–96; 15(6):313–37 (88 ref.)
Health evaluation of 1,4–dioxane. DeRosa CT, et al. **Toxicol Ind Health** 1996 Jan–Feb;12(1):1–43 (132 ref.)
Methyl tertiary butyl ether (MTBE)—evaluation of MTBE carcinogenicity studies. Rudo KM. **Toxicol Ind Health** 1995 Mar–Apr;11(2):167–73 (14 ref.)
Beware of a new carcinogenic risk: promotion of promoters. Bounias M, et al. **Toxicol Lett** 1995 Oct;80(1–3):19–24 (61 ref.)
Role of cell proliferation in regenerative and neoplastic disease. Cohen SM. **Toxicol Lett** 1995 Dec;82–83:15–21 (20 ref.)
Cell proliferation as a determining factor for the carcinogenicity of chemicals: studies with mutagenic carcinogens and mutagenic noncarcinogens. Cunningham ML, et al. **Toxicol Lett** 1995 Dec;82–83:9–14 (25 ref.)
Molecular epidemiology and human risk monitoring. Groopman JD, et al. **Toxicol Lett** 1995 Dec;82–83:763–9 (33 ref.)
Role of blocked gap junctional intercellular communication in non–genotoxic carcinogenesis. Mesnil M, et al. **Toxicol Lett** 1995 Dec;82–83:701–6 (27 ref.)
Dose–response relationships for carcinogens. Swenberg JA, et al. **Toxicol Lett** 1995 Dec;82–83:751–6 (15 ref.)
Development of structure–activity relationship rules for predicting carcinogenic potential of chemicals. Woo YT, et al. **Toxicol Lett** 1995 Sep;79(1–3):219–28 (18 ref.)
Expression of exposure in negative carcinogenicity studies: dose/body weight, dose/body surface area, or plasma concentrations? Monro A, et al. **Toxicol Pathol** 1995 Mar–Apr;23(2):187–98 (69 ref.)
Negative selection in hepatic tumor promotion in relation to cancer risk assessment. Andersen ME, et al. **Toxicology** 1995 Sep 1;102(1–2):223–37 (82 ref.)
Quantitative cancer assessment for vinyl chloride: indications of early–life sensitivity. Cogliano VJ, et al. **Toxicology** 1996 Jul 17;111(1–3):21–8 (11 ref.)
Cell proliferation in the bladder and implications for cancer risk assessment. Cohen SM. **Toxicology** 1995 Sep 1; 102(1–2):149–59 (24 ref.)
Comparison of experimental and theoretical parameters of the Moolgavkar–Venzon–Knudson incidence function for the stages of initiation and promotion in rat hepatocarcinogenesis. Dragan YP, et al. **Toxicology** 1995 Sep 1;102(1–2):161–75 (65 ref.)
Human interindividual variability in susceptibility to toxic effects: from annoying detail to a central determinant of risk. Hattis D. **Toxicology** 1996 Jul 17;111(1–3):5–14 (37 ref.)
Biochemical mechanisms and cancer risk assessment models for dioxin. Kohn MC. **Toxicology** 1995 Sep 1; 102(1–2):133–8 (31 ref.)
Risk assessment and biological mechanisms: lessons learned, future opportunities. McClellan RO. **Toxicology** 1995 Sep 1;102(1–2):239–58 (48 ref.)
[Strategies for evaluating carcinogenic substances] Henschler D. **Zentralbl Hyg Umweltmed** 1995 Apr;197(1–3):180–7 (6 ref.) (Eng. Abstr.) **(Ger)**
[Effect of BBN on the small intestine transplanted to the urinary bladder of rat] Wu B, et al. **Hinyokika Kiyo** 1995 Sep;41(9):665–8 (16 ref.) (Eng. Abstr.) **(Jpn)**

CARCINOGENS, ENVIRONMENTAL

ADVERSE EFFECTS

Breast cancer and environmental risk factors: epidemiological and experimental findings. Wolff MS, et al. **Annu Rev Pharmacol Toxicol** 1996;36:573–96 (116 ref.)
A toxicologist's view of cancer risk assessment. Rozman KK, et al. **Drug Metab Rev** 1996 Feb–May;28(1–2):29–52 (27 ref.)
Reality versus extrapolation: an academic perspective of cancer risk regulation. Waddell WJ. **Drug Metab Rev** 1996 Feb–May;28(1–2):181–95 (32 ref.)
Effects of estrogenic chemicals on development. Jones LA, et al. **Environ Health Perspect** 1995 Oct;103 Suppl 7:63–7 (27 ref.)
Implications for risk assessment of suggested nongenotoxic mechanisms of chemical carcinogenesis. Melnick RL, et al. **Environ Health Perspect** 1996 Mar;104 Suppl 1:123–34 (122 ref.)
Molecular epidemiology and prevention of cancer. Perera FP. **Environ Health Perspect** 1995 Nov;103 Suppl 8:233–6 (33 ref.)
Scientific challenges in environmental carcinogenesis. Hoffmann D, et al. **Prev Med** 1996 Jan–Feb;25(1):14–22 (85 ref.)
A decision tree approach for carcinogen risk assessment. Butterworth BE, et al. **Prog Clin Biol Res** 1995;391:49–70 (52 ref.)
The instability of tumor promotion in relation to human cancer risk. Pitot HC, et al. **Prog Clin Biol Res** 1995; 391:21–38 (120 ref.)
[Environment and oncology] Frentzel–Beyme R. **Arch Gynecol Obstet** 1995;257(1–4):228–39 (14 ref.) **(Ger)**

METABOLISM

Fumonisin generation [editorial] ApSimon JW, et al. **Nat Toxins** 1996;4(1):1–2 (16 ref.)
The implications for risk assessment of measuring the relative contribution to exposure from occupation, environment and lifestyle: hemoglobin adducts from amino– and nitro–arenes. Neumann HG, et al. **Toxicol Lett** 1995 Dec; 82–83:771–8 (20 ref.)

TOXICITY

Reducing uncertainty in risk assessment by using specific knowledge to replace default options. McClellan RO. **Drug Metab Rev** 1996 Feb–May;28(1–2):149–79 (64 ref.)
Fish models for environmental carcinogenesis: the rainbow trout. Bailey GS, et al. **Environ Health Perspect** 1996 Mar; 104 Suppl 1:5–21 (174 ref.)
Mutagenic nitroarenes, diesel emissions, particulate–induced mutations and cancer: an essay on cancer–causation by a moving target. Rosenkranz HS. **Mutat Res** 1996 Feb; 367(2):65–72 (85 ref.)
Fumonisins: their implications for human and animal health. Marasas WF. **Nat Toxins** 1995;3(4):193–8; discussion 221 (65 ref.)
Evidence for disruption of sphingolipid metabolism as a contributing factor in the toxicity and carcinogenicity of fumonisins. Riley RT, et al. **Nat Toxins** 1996;4(1):3–15 (77 ref.)

CARCINOID see **CARCINOID TUMOR**

CARCINOID, GOBLET CELL see **CARCINOID TUMOR**

CARCINOID HEART DISEASE

PHYSIOPATHOLOGY

[A rare cause of an operable cardiac lesion: carcinoid cardiopathy] Defraigne JO, et al. **Rev Med Liege** 1996 Jul; 51(7):468–78 (52 ref.) **(Fre)**

CARCINOID TUMOR

[Carcinoid of the gallbladder] Kawaguchi M, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):261–4 (12 ref.) **(Jpn)**
[Primary hepatic carcinoid tumor] Shima K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):450–2 (8 ref.) **(Jpn)**

COMPLICATIONS

[Watermelon stomach and gastric carcinoid tumor in a cirrhotic patient] Oliveira CV, et al. **Arq Gastroenterol** 1995 Apr–Jun;32(2):66–70 (34 ref.) (Eng. Abstr.) **(Por)**

DIAGNOSIS

Small bowel carcinoid: review of a single institution experience and review of the literature. Box JC, et al. **Am Surg** 1996 Apr;62(4):280–6 (40 ref.)
Endocrine tumors of the gastrointestinal tract. Perry RR, et al. **Annu Rev Med** 1996;47:57–68 (33 ref.)
[Bronchus carcinoid tumor in the Tessin canton, retrospective analysis of 13 years and literature review] John H, et al. **Schweiz Med Wochenschr** 1996 Aug 6; 126(31–32):1339–46 (20 ref.) (Eng. Abstr.) **(Ger)**
[A carcinoid with cecal localization. Apropos a case] Chisari A, et al. **Minerva Chir** 1996 Jan–Feb;51(1–2):51–7 (17 ref.) (Eng. Abstr.) **(Ita)**
[Gastric carcinoid. A clinical case and review of the literature] Capece G, et al. **Minerva Gastroenterol Dietol** 1996 Mar;42(1):45–9 (11 ref.) (Eng. Abstr.) **(Ita)**
[A functioning carcinoid tumor with liver involvement without the associated carcinoid syndrome] Sánchez A, et al. **Gastroenterol Hepatol** 1995 Nov;18(9):468–70 (7 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Octreotide treatment of carcinoid syndrome: analysis of published dose–titration data. Harris AG, et al. **Aliment Pharmacol Ther** 1995 Aug;9(4):387–94 (83 ref.)

ETIOLOGY

[Neuropsychiatric symptoms in vitamin B12 deficiency and microcarcinoidosis. The complications of chronic atrophic gastritis] Ossege LM, et al. **Dtsch Med Wochenschr** 1996 Jun 7;121(23):758–62 (25 ref.) (Eng. Abstr.) **(Ger)**
[Neurofibromatosis (von Recklinghausen disease) and carcinoid tumor in Vater's ampulla] Simon L, et al. **Orv Hetil** 1995 Oct 15;136(42):2287–92 (34 ref.) (Eng. Abstr.) **(Hun)**

METABOLISM

[A case of ACTH–producing thymic carcinoid tumor with Cushing syndrome] Nishimura H, et al. **Kyobu Geka** 1996 Feb;49(2):99–104 (20 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Neuroendocrine insights from the laboratory to the clinic. Ahlman H, et al. **Am J Surg** 1996 Jul;172(1):61–7 (40 ref.)
Carcinoid of the pancreas: clinical characteristics and morphological features. Maurer CA, et al. **Eur J Cancer** 1996 Jun;32A(7):1109–16 (55 ref.)
Primary ovarian carcinoid tumors. Davis KP, et al. **Gynecol Oncol** 1996 May;61(2):259–65 (46 ref.)
Increased incidence of second primary malignancy in patients with carcinoid tumors: case report and literature review. Rivadeneira DE, et al. **J Natl Med Assoc** 1996 May; 88(5):310–2 (12 ref.)
Endocrine tumours of the stomach. Bordi C. **Pathol Res Pract** 1995 May;191(4):373–80 (33 ref.)
[A case of goblet cell carcinoid of the appendix] Kamada T, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 May; 93(5):367–72 (16 ref.) **(Jpn)**
[Carcinoid lung tumors: clinico–morphologic characteristics, diagnosis] Samsonov VA. **Arkh Patol** 1995 Jul–Aug; 57(4):20–4 (32 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

[A rare cause of an operable cardiac lesion: carcinoid cardiopathy] Defraigne JO, et al. **Rev Med Liege** 1996 Jul; 51(7):468–78 (52 ref.) **(Fre)**

SECONDARY

[Treatment of metastatic carcinoid tumors with interferon-alpha. Five cases] Votte A, et al. **Presse Med** 1996 Jan 20;25(2):63-7 (30 ref.) (Eng. Abstr.) **(Fre)**

SECRETION

Primary carcinoid tumor of the liver: report of four resected cases including one with gastrin production. Krishnamurthy SC, et al. **J Surg Oncol** 1996 Jul; 62(3):218-21 (19 ref.)

SURGERY

Primary ovarian carcinoid tumors. Davis KP, et al. **Gynecol Oncol** 1996 May;61(2):259-65 (46 ref.)

Primary carcinoid tumor of the liver: report of four resected cases including one with gastrin production. Krishnamurthy SC, et al. **J Surg Oncol** 1996 Jul; 62(3):218-21 (19 ref.)

Carcinoid tumor of the gallbladder: report of a case. Khetan N, et al. **Surg Today** 1995;25(12):1047-9 (25 ref.)

[Carcinoid of the major duodenal papilla] Kalotov E, et al. **Khirurgiia (Sofiia)** 1995;48(4):55-9 (11 ref.) **(Bul)**

[Abdominal carcinoid: various locations and clinical course] Rossi V, et al. **G Chir** 1995 Oct;16(10):429-36 (32 ref.) (Eng. Abstr.) **(Ita)**

THERAPY

[Treatment of metastatic carcinoid tumors with interferon-alpha. Five cases] Votte A, et al. **Presse Med** 1996 Jan 20;25(2):63-7 (30 ref.) (Eng. Abstr.) **(Fre)**

ULTRASONOGRAPHY

Carcinoid tumor: an extremely unusual presacral lesion. Report of a case. Edelstein PS, et al. **Dis Colon Rectum** 1996 Aug;39(8):938-42 (16 ref.)

URINE

The clinical and laboratory correlates of an increased urinary 5-hydroxyindoleacetic acid. Tormey WP, et al. **Postgrad Med J** 1995 Sep;71(839):542-5 (16 ref.)

CARCINOMA

Endometrial carcinoma. Rose PG. **N Engl J Med** 1996 Aug 29;335(9):640-9 (100 ref.)

Early detection and treatment of oesophageal and gastric cancer. The Rotterdam Oesophageal Tumour Study Group. Siersema PD, et al. **Neth J Med** 1995 Aug; 47(2):76-86 (69 ref.)

[Molecular biology of epithelial ovarian carcinoma] Piura B, et al. **Harefuah** 1995 Nov 1;129(9):351-7 (42 ref.) **(Heb)**

[Intramucosal carcinoma of extrahepatic choledochus] Katagiri K, et al. **Ryoikibetsu Shokogun Shirizu** 1996; (9):95-8 (10 ref.) **(Jpn)**

[Undifferentiated carcinoma] Kinami Y, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):341-4 (20 ref.) **(Jpn)**

[Undifferentiated hepatic carcinoma] Shijo H, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):515-7 (16 ref.) **(Jpn)**

[Carcinosarcoma and so-called carcinosarcoma of the gallbladder] Taniguchi H, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):270-2 (13 ref.) **(Jpn)**

[Carcinoma of the hilar bile ducts] Tsuyuguchi T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):435-7 (14 ref.) **(Jpn)**

BLOOD SUPPLY

Antibody-directed targeting of the vasculature of solid tumors. Thorpe PE, et al. **Breast Cancer Res Treat** 1995; 36(2):237-51 (55 ref.)

Quantitative microvessel density. A staging and prognostic marker for human prostatic carcinoma. Brawer MK. **Cancer** 1996 Jul 15;78(2):345-9 (25 ref.)

CLASSIFICATION

[Classification of ovarian tumors based on embryogenesis] Minh HN, et al. **Arch Anat Cytol Pathol** 1995;43(3):126-39 (17 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

[Spontaneous perforation of the small intestine in primary lung carcinoma] Kolarov I, et al. **Khirurgiia (Sofiia)** 1995; 48(6):47-9 (0 ref.) **(Bul)**

DIAGNOSIS

Adrenal carcinoma in a patient with Gardner's syndrome: imaging findings. Traill Z, et al. **AJR Am J Roentgenol** 1995 Dec;165(6):1460-1 (8 ref.)

Cytomegalovirus colitis mimicking colon carcinoma in an HIV-negative patient with chronic renal failure. Falagas ME, et al. **Am J Gastroenterol** 1996 Jan;91(1):168-9 (11 ref.)

Carcinoma of the pancreatic head area. Epidemiology, natural history and clinical findings. Frontera D, et al. **Rays** 1995 Jul-Sep;20(3):226-36 (66 ref.) **(Eng, Ita)**

[Thyroid cancer, its diagnosis and surgical treatment] Abdeluakhab M, et al. **Khirurgiia (Sofiia)** 1995;48(2):39-43 (0 ref.) **(Bul)**

[Clinical use of endorectal coil MR in the study of prostatic pathology with special reference to hyperplasia and carcinoma] Gualdi GF, et al. **Clin Ter** 1996 Jan-Feb; 147(1-2):51-66 (29 ref.) (Eng. Abstr.) **(Ita)**

[The diagnosis and treatment of meningeal carcinomatosis] Aparicio Urtasun J, et al. **Rev Clin Esp** 1995 Dec; 195(12):856-63 (71 ref.) **(Spa)**

DRUG THERAPY

Gn-RH agonists in the treatment of prostatic carcinoma. Vacher P. **Biomed Pharmacother** 1995;49(7-8):325-31 (60 ref.)

Treatment approaches for metastatic cancer of the prostate based on recent molecular evidence. Middleman MN, et al. **Cancer Treat Rev** 1996 Mar;22(2):105-18 (61 ref.)

Current drug treatment guidelines for epithelial ovarian cancer. Lorigan PC, et al. **Drugs** 1996 Apr;51(4):571-84 (65 ref.)

Bolus mitomycin C and 5-FU with sequential radiation for poor-prognosis locally advanced cervical cancer. Denehy TR, et al. **Gynecol Oncol** 1996 Jan;60(1):64-71 (21 ref.)

Chemotherapy treatment of chyloperitoneum and peritoneal carcinomatosis due to cervical cancer--review of literature. Keung YK, et al. **Gynecol Oncol** 1996 Jun;61(3):448-50 (11 ref.)

Androgen receptor mediated growth control of breast cancer and endometrial cancer modulated by antiandrogen- and androgen-like steroids. Hackenberg R, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1-6 Spec No):113-7 (56 ref.)

Adjuvant therapy of gastric cancer: the Japanese experience. Fukushima M. **Semin Oncol** 1996 Jun;23(3):369-78 (52 ref.)

The role of ifosfamide and systemic therapy in the management of carcinoma of the cervix. Thigpen T, et al. **Semin Oncol** 1996 Jun;23(3 Suppl 6):56-64 (52 ref.)

The role of paclitaxel in the management of coelomic epithelial carcinoma of the ovary: a review with emphasis on the Gynecologic Oncology Group experience. Thigpen T, et al. **Semin Oncol** 1995 Dec;22(6 Suppl 14):23-31 (30 ref.)

Adjuvant therapy for colorectal cancer--is there a place for a Northern Ireland study? Wilson RH, et al. **Ulster Med J** 1994 Apr;63(1):44-51 (41 ref.)

ENZYMOLOGY

The control and biological importance of intratumoural aromatase in breast cancer. Dowsett M, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1-6 Spec No):145-50 (22 ref.)

EPIDEMIOLOGY

Carcinoma of the pancreatic head area. Epidemiology, natural history and clinical findings. Frontera D, et al. **Rays** 1995 Jul-Sep;20(3):226-36 (66 ref.) **(Eng, Ita)**

[Screening of undifferentiated carcinoma of the nasopharynx] Sasco AJ. **Bull Cancer (Paris)** 1996 May;83(5):344-51 (70 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Changing concepts in the pathogenesis and management of thyroid carcinoma. Gagel RF, et al. **CA Cancer J Clin** 1996 Sep-Oct;46(5):261-83 (128 ref.)

The consequences of hypergastrinemia. Creutzfeldt W. **Yale J Biol Med** 1994 May-Aug;67(3-4):181-94 (63 ref.)

[The etiology of vulvar carcinoma--still an enigma] Bornstein J, et al. **Harefuah** 1995 Jun 15;128(12):793-7 (48 ref.) **(Heb)**

GENETICS

Molecular defects in thyroid carcinomas: role of the RET oncogene in thyroid neoplastic transformation. Santoro M, et al. **Eur J Endocrinol** 1995 Nov;133(5):513-22 (114 ref.)

Genetic alterations in breast cancer. Bièche I, et al. **Genes Chromosomes Cancer** 1995 Dec;14(4):227-51 (190 ref.)

[Multiple endocrine neoplasia type 2A, type 2B and familial medullary thyroid carcinoma syndrome] Obara T, et al. **Nippon Rinsho** 1995 Nov;53(11):2708-15 (19 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

[Value of anti-Epstein-Barr antibody detection in the diagnosis and management of undifferentiated carcinoma of the nasopharynx] Mazeron MC. **Bull Cancer Radiother** 1996;83(1):3-7 (29 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Growth factors and their receptors in neoplastic mammary glands. Rudland PS, et al. **Biomed Pharmacother** 1995; 49(9):389-99 (95 ref.)

MORTALITY

[The prognostic factors in endometrial carcinoma (EC)] Gorchev G. **Akush Ginekol (Sofiia)** 1995;34(2):51-3 (32 ref.) **(Bul)**

[Prognostic factors in prostatic carcinoma treated with radical radiotherapy: stages A, B, and C] Rodríguez Villalba S, et al. **Actas Urol Esp** 1996 Apr;20(4):336-45 (46 ref.) (Eng. Abstr.) **(Spa)**

PATHOLOGY

Tumor-like lesions of the prostate gland [editorial; comment] Young RH. **Am J Clin Pathol** 1995 Dec;104(6):607-10 (41 ref.) Comment on: Am J Clin Pathol 1995 Dec;104(6):620-6.

Extramedullary plasmacytoma mimicking primary colonic carcinoma in a patient with Crohn's disease. Case report and literature review. Ligato S, et al. **Arch Pathol Lab Med** 1996 Mar;120(3):279-82 (32 ref.)

Prospective origins of prostate carcinoma. Prostatic intraepithelial neoplasia and atypical adenomatous hyperplasia. Bostwick DG. **Cancer** 1996 Jul 15;78(2):330-6 (67 ref.)

Neuroendocrine differentiation in prostatic malignancy. di Sant'Agnese PA, et al. **Cancer** 1996 Jul 15;78(2):357-61 (32 ref.)

Pathologic staging of prostate carcinoma. What are the issues? Grignon DJ, et al. **Cancer** 1996 Jul 15;78(2):337-40 (29 ref.)

Current prognostic factors for prostate carcinoma. Montie JE. **Cancer** 1996 Jul 15;78(2):341-4 (24 ref.)

Flat adenoma, flat carcinoma, and de novo carcinoma of the colon [editorial; comment] Owen DA. **Cancer** 1996 Jan 1;77(1):3-6 (40 ref.) Comment on: Cancer 1996 Jan 1;77(1):44-50.

Advances in endometrial pathology. Sherman ME, et al. **Clin Lab Med** 1995 Sep;15(3):517-43 (45 ref.)

Model systems of carcinoma cell dispersion. Boyer B, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 1):179-94 (85 ref.)

Radiation treatment effects in cervical cytology. Powers CN. **Diagn Cytopathol** 1995 Jul;13(1):75-80 (18 ref.)

Primary staging of urinary bladder carcinoma: the role of MRI and a comparison with CT. Barentsz JO, et al. **Eur Radiol** 1996;6(2):129-33 (49 ref.)

Carcinomas of the pituitary: definition and review of the literature. Lübke D, et al. **Gen Diagn Pathol** 1995 Oct; 141(2):81-92 (83 ref.)

Early de novo ovarian cancer and cancer developing in benign ovarian lesions. Scully RE. **Int J Gynaecol Obstet** 1995 Jul;49 Suppl:S9-15 (13 ref.)

Pathology in focus. Spindle-cell carcinoma of the nasal septum. Ahluwalia H, et al. **J Laryngol Otol** 1996 Mar; 110(3):284-7 (26 ref.)

Role of growth factors, steroid and peptide hormones in the regulation of human prostatic tumor growth. Motta M, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1-6 Spec No):107-11 (36 ref.)

Angiosarcoma-like neoplasms of epithelial organs: true endothelial tumors or variants of carcinoma? Ritter JH, et al. **Semin Diagn Pathol** 1995 Aug;12(3):270-82 (74 ref.)

Observations of aggressive, small, flat, and depressed colon cancer. Report of three cases. Kasumi A, et al. **Surg Endosc** 1995 Jun;9(6):690-4 (19 ref.)

Ectopic adrenocorticotropin syndrome associated with undifferentiated carcinoma of the colon showing multidirectional neuroendocrine, exocrine, and squamous differentiation. Onishi R, et al. **Virchows Arch** 1996 Feb; 427(5):537-41 (14 ref.)

[Extemporaneous histologic examination of cutaneous carcinoma of the face] Barrellier P, et al. **Rev Stomatol Chir Maxillofac** 1995;96(5):329-34 (20 ref.) (Eng. Abstr.) **(Fre)**

[Hepatocellular nodular hyperplasias, adenomas and carcinomas] Altmann HW. **Verh Dtsch Ges Pathol** 1995; 79:84-108 (144 ref.) (Eng. Abstr.) **(Ger)**

[A mucinous ovarian tumor with foci of anaplastic carcinoma] Buzzi A, et al. **Minerva Ginecol** 1996 Apr; 48(4):163-6 (5 ref.) (Eng. Abstr.) **(Ita)**

[Carcinoma of the prostate, stage C] Zattoni F, et al. **Minerva Urol Nefrol** 1995 Dec;47(4):197-201 (32 ref.) **(Ita)**

[Epithelial-cystic nevus of the conjunctiva (Parinaud's dermo-epithelioma)] Cernea P, et al. **Oftalmologia** 1996 Jan-Mar;40(1):58-62 (8 ref.) (Eng. Abstr.) **(Rum)**

PHYSIOPATHOLOGY

Factors controlling growth, motility, and morphogenesis of normal and malignant epithelial cells. Birchmeier C, et al. **Int Rev Cytol** 1995;160:221-66 (280 ref.)

PREVENTION & CONTROL

Screening high-risk groups for colorectal neoplasia. Hardcastle JD, et al. **Am J Gastroenterol** 1996 May; 91(5):850-2 (34 ref.)

[The secondary prevention of colorectal carcinoma by polyp removal] Riemann JF. **Strahlenther Onkol** 1995 Nov; 171(11):611-4 (21 ref.) (Eng. Abstr.) **(Ger)**

RADIOTHERAPY

Effects of cranial irradiation on hearing acuity: a review of the literature. Sataloff RT, et al. **Am J Otol** 1994 Nov; 15(6):772-80 (28 ref.)

Bolus mitomycin C and 5-FU with sequential radiation for poor-prognosis locally advanced cervical cancer. Denehy TR, et al. **Gynecol Oncol** 1996 Jan;60(1):64-71 (21 ref.)
Radiotherapy for carcinoma of the pancreas. Thomas PR. **Semin Oncol** 1996 Apr;23(2):213-9 (52 ref.)
Adjuvant therapy for colorectal cancer—is there a place for a Northern Ireland study? Wilson RH, et al. **Ulster Med J** 1994 Apr;63(1):44-51 (41 ref.)
[Radiotherapy of cutaneous cervical-facial carcinomas] Tordiglione M, et al. **Acta Otorhinolaryngol Ital** 1995 Jun; 15(3):168-78; discussion 179 (18 ref.) (Eng. Abstr.) **(Ita)**
[Prognostic factors in prostatic carcinoma treated with radical radiotherapy: stages A, B, and C] Rodríguez Villalba S, et al. **Actas Urol Esp** 1996 Apr;20(4):336-45 (46 ref.) (Eng. Abstr.) **(Spa)**

SECONDARY

Treatment approaches for metastatic cancer of the prostate based on recent molecular evidence. Middleman MN, et al. **Cancer Treat Rev** 1996 Mar;22(2):105-18 (61 ref.)
Biological characteristics of micrometastatic carcinoma cells in bone marrow. Braun S, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 1):163-77 (55 ref.)
Epithelial ovarian carcinoma metastatic to the central nervous system: a report on two cases with review of literature. Sood A, et al. **Gynecol Oncol** 1996 Jul; 62(1):113-8 (36 ref.)
[Distant metastases originating from tumors of the larynx and hypopharynx] Traserra J, et al. **Rev Laryngol Otol Rhinol (Bord)** 1989;110(3):267-71 (16 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Changing concepts in the pathogenesis and management of thyroid carcinoma. Gagel RF, et al. **CA Cancer J Clin** 1996 Sep-Oct;46(5):261-83 (128 ref.)
Surgery in ovarian cancer: the concept of cytoreductive surgery. Peter A, et al. **Curr Opin Obstet Gynecol** 1996 Feb;8(1):8-11 (15 ref.)
Hepatic cryosurgery for metastatic colorectal carcinoma. Brandt BT, et al. **Oncol Nurs Forum** 1996 Jan-Feb; 23(1):29-36; quiz 37-8 (20 ref.)
Adjuvant therapy of gastric cancer: the Japanese experience. Fukushima M. **Semin Oncol** 1996 Jun;23(3):369-78 (52 ref.)
Surgical management of pancreatic carcinoma. McGrath PC, et al. **Semin Oncol** 1996 Apr;23(2):200-12 (109 ref.)
Surgical treatment of laryngeal cancer. Hamaker RC, et al. **Semin Speech Lang** 1995 Aug;16(3):221-32 (12 ref.)
Applications of laser technology in breast cancer therapy. Lanzafame RJ. **Semin Surg Oncol** 1995 Jul-Aug; 11(4):328-32 (40 ref.)
Laparoscopic surgery for bladder carcinoma. Parra RO, et al. **Semin Surg Oncol** 1996 Mar-Apr;12(2):145-52 (38 ref.)
[Thyroid cancer, its diagnosis and surgical treatment] Abdeluakhab M, et al. **Khirurgiia (Sofiia)** 1995;48(2):39-43 (0 ref.) **(Bul)**

THERAPY

Immunoconjugates and immunotoxins for therapy of carcinomas. Hellström I, et al. **Adv Pharmacol** 1995; 33:349-88 (159 ref.)
Targeting the epidermal growth factor receptor for therapy of carcinomas. Davies DE, et al. **Biochem Pharmacol** 1996 May 3;51(9):1101-10 (125 ref.)
Recent advances in the treatment of thyroid carcinoma [editorial] Wells SA Jr. **CA Cancer J Clin** 1996 Sep-Oct; 46(5):258-60 (16 ref.)
[Therapeutic approach to epithelial cancer of the ovary at CHU Sart Tilman. Conclusions of the interdisciplinary meeting of 22 March 1995. Consensus Group] Jerusalem G, et al. **Rev Med Liege** 1995 Nov;50(11):469-71 (9 ref.) **(Fre)**
[Aftercare in patients with colorectal carcinomas] Mezger J, et al. **Dtsch Med Wochenschr** 1995 Nov 10; 120(45):1549-54 (44 ref.) **(Ger)**
[The postoperative therapy of epithelial ovarian carcinoma. Has systemic cytostasis replaced percutaneous radiation?] Souchon R, et al. **Strahlenther Onkol** 1995 Nov; 171(11):630-40 (83 ref.) (Eng. Abstr.) **(Ger)**

ULTRASONOGRAPHY

Intraportal tumor thrombus of gallbladder carcinoma: detection with intravascular ultrasonography. Kaneko T, et al. **Am J Gastroenterol** 1996 Jun;91(6):1268-9 (8 ref.)
Endoscopic ultrasonography. Pollack BJ, et al. **Semin Oncol** 1996 Jun;23(3):336-46 (83 ref.)

CARCINOMA, ACINAR CELL

SECONDARY

Case report: pleural encasement secondary to acinar adenocarcinoma of the submandibular gland. Hynes J, et al. **Br J Radiol** 1996 Mar;69(819):276-7 (12 ref.)

CARCINOMA, ADENOID CYSTIC

DIAGNOSIS

Basal cell (monomorphic) and minimally pleomorphic adenomas of the salivary glands. Distinction from the solid (anaplastic) type of adenoid cystic carcinoma in fine-needle aspiration. Stanley MW, et al. **Am J Clin Pathol** 1996 Jul; 106(1):35-41 (35 ref.)
Intracranial adenoid cystic carcinoma: case report and review of the literature. Alleyne CH, et al. **Surg Neurol** 1996 Mar; 45(3):265-71 (49 ref.)

PATHOLOGY

Magnetic resonance imaging of massive intracranial invasion by an ethmoidal adenoid cystic carcinoma (cylindroma). Veillon BJ, et al. **South Med J** 1996 Mar;89(3):321-3 (10 ref.)

SURGERY

Adenoid cystic carcinoma of Bartholin's gland: a review of the literature and report of a patient. DePasquale SE, et al. **Gynecol Oncol** 1996 Apr;61(1):122-5 (32 ref.)

CARCINOMA, ADENOSQUAMOUS

[Cancer of the anal canal] Gérard JP, et al. **Bull Cancer Radiother** 1990;77(1):23-31 (41 ref.) **(Fre)**
[Adenosquamous carcinoma of the liver] Hayashi M, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):405-7 (18 ref.) **(Jpn)**
[Adenoacanthoma, adenosquamous carcinoma of the extrahepatic bile duct] Kimoto E, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):47-9 (36 ref.) **(Jpn)**

DIAGNOSIS

[Primary malignant neoplasms of the female genitalia] Saraiva J, et al. **Acta Med Port** 1995 Oct;8(10):585-8 (11 ref.) (Eng. Abstr.) **(Por)**

PATHOLOGY

Early gastric cancer of adenosquamous carcinoma type: report of a case and review of literature. Yoshida K, et al. **Jpn J Clin Oncol** 1996 Aug;26(4):252-7 (21 ref.)

CARCINOMA, ADRENAL CORTICAL

COMPLICATIONS

Isolated clinical syndrome of primary aldosteronism in a patient with adrenocortical carcinoma. Case report and review of the literature. Weingärtner K, et al. **Urol Int** 1995;55(4):232-5 (15 ref.)

CARCINOMA, ALVEOLAR see **ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR**

CARCINOMA, ANAPLASTIC see **CARCINOMA**

CARCINOMA, BASAL CELL

Clinical histopathological characteristics of basal cell carcinoma in Japanese patients. Kikuchi A, et al. **Arch Dermatol** 1996 Mar;132(3):320-4 (24 ref.)
Aggressive basal cell carcinoma of head and neck areas. Vico P, et al. **Eur J Surg Oncol** 1995 Oct;21(5):490-7 (25 ref.)
Basal cell carcinoma. Goldberg LH. **Lancet** 1996 Mar 9; 347(9002):663-7 (29 ref.)

DIAGNOSIS

Nonmelanoma skin cancer. Epstein JH. **Compr Ther** 1996 Mar;22(3):179-82 (17 ref.)
[Incident light microscopic characterization of vascular patterns in skin tumors] Kreusch J, et al. **Hautarzt** 1996 Apr;47(4):264-72 (21 ref.) (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

The epidemiology of non-melanoma skin cancer: who, why and what can we do about it. Marks R. **J Dermatol** 1995 Nov;22(11):853-7 (27 ref.)
Risk factors for basal cell carcinoma: a case-control study. Maia M, et al. **Rev Saude Publica** 1995 Feb;29(1):27-37 (35 ref.)
[Are skin tumors on the increase?] Böni R, et al. **Schweiz Med Wochenschr** 1995 Sep 2;125(35):1619-24 (50 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Basal cell carcinoma due to radiotherapy for carcinoma of the cervix. Copas P, et al. **South Med J** 1995 Nov; 88(11):1161-2 (12 ref.)

GENETICS

Is human patched the gatekeeper of common skin cancers? [news; comment] Sidransky D. **Nat Genet** 1996 Sep; 14(1):7-8 (11 ref.) Comment on: Nat Genet 1996 Sep;14(1):78-81.
The Gorlin syndrome gene: a tumor suppressor active in basal cell carcinogenesis and embryonic development. Bale AE, et al. **Proc Assoc Am Physicians** 1995 Jul;107(2):253-7 (35 ref.)

PATHOLOGY

Sebomatricoma: a unifying term that encompasses all benign neoplasms with sebaceous differentiation. Sáchez Yus E, et al. **Am J Dermatopathol** 1995 Jun;17(3):213-21 (22 ref.)
Disseminated cutaneous Cryptococcus clinically mimicking basal cell carcinoma [letter] Murakawa GJ, et al. **Dermatol Surg** 1995 Nov;21(11):992-3 (8 ref.)
Basal cell carcinoma. Identification and treatment of the high-risk patient. Randle HW. **Dermatol Surg** 1996 Mar; 22(3):255-61 (44 ref.)
Linear basal cell carcinoma. da Silva MO, et al. **Int J Dermatol** 1995 Jul;34(7):488 (6 ref.)

PREVENTION & CONTROL

Retinoids in cancer chemoprevention. Clinical trials with the synthetic analogue fenretinide. Costa A, et al. **Ann N Y Acad Sci** 1995 Sep 30;768:148-62 (49 ref.)
Controlled clinical trials with fenretinide in breast cancer, basal cell carcinoma and oral leukoplakia. De Palo G, et al. **J Cell Biochem Suppl** 1995;22:11-7 (16 ref.)

SURGERY

Cryosurgery of malignant and premalignant diseases of the skin: a simple approach. Sinclair RD, et al. **Australas J Dermatol** 1995 Aug;36(3):133-42 (60 ref.)
[Micrographic surgery. A current methodological assessment] Kopke LF, et al. **Hautarzt** 1995 Sep; 46(9):607-14 (52 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Basal cell carcinoma. Identification and treatment of the high-risk patient. Randle HW. **Dermatol Surg** 1996 Mar; 22(3):255-61 (44 ref.)

CARCINOMA, BASAL CELL, PIGMENTED see **CARCINOMA, BASAL CELL**

CARCINOMA, BASOSQUAMOUS

PATHOLOGY

Basaloid-squamous cell carcinoma of the bronchus. Report of a case with review of the literature. Lin O, et al. **Arch Pathol Lab Med** 1995 Dec;119(12):1167-70 (16 ref.)

CARCINOMA, BRONCHIAL see **CARCINOMA, BRONCHOGENIC**

CARCINOMA, BRONCHIOLAR see **ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR**

CARCINOMA, BRONCHIOLO-ALVEOLAR see **ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR**

CARCINOMA, BRONCHOGENIC

COMPLICATIONS

Glomerulonephritis associated with malignant diseases of non-renal origin. A report of three cases and a review of the literature. Wagrowska-Danilewicz M, et al. **Pol J Pathol** 1995;46(3):195-8 (20 ref.)

DIAGNOSIS

Future diagnostic procedures. Lam S, et al. **Chest Surg Clin N Am** 1996 May;6(2):363-80 (81 ref.)
Bilateral patellar metastases as the clinical presentation of bronchogenic adenocarcinoma. Pauzner R, et al. **J Rheumatol** 1996 May;23(5):939-41 (22 ref.)
[Bronchogenic carcinoma and human immunodeficiency virus infection] Carrasquer C, et al. **Arch Bronconeumol** 1995 Aug-Sep;31(7):362-4 (15 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Future therapeutic procedures. Edell ES. **Chest Surg Clin N Am** 1996 May;6(2):381-95 (93 ref.)
Photodynamic therapy. Its use in the management of bronchogenic carcinoma. Edell ES, et al. **Clin Chest Med** 1995 Sep;16(3):455-63 (103 ref.)

PATHOLOGY

The staging of lung cancer by bronchoscopic transbronchial needle aspiration. Harrow EM, et al. **Chest Surg Clin N Am** 1996 May;6(2):223-35 (35 ref.)
[False Merkel cell tumor of the gingival mucosa disclosed by small cell bronchial carcinoma] Paume P, et al. **Rev Stomatol Chir Maxillofac** 1995;96(6):352-5 (14 ref.) (Eng. Abstr.) **(Fre)**

RADIOTHERAPY

Endoscopic brachytherapy. Spratling L, et al. **Chest Surg Clin N Am** 1996 May;6(2):293-304 (17 ref.)
Endobronchial brachytherapy. Villanueva AG, et al. **Clin Chest Med** 1995 Sep;16(3):445-54 (45 ref.)

SECONDARY

[Skin metastases, unusual presentation of lung cancer] Jurado Gámez B, et al. **An Med Interna** 1995 Jul;12(7):346-8 (15

ref.) (Eng. Abstr.) (Spa)

SURGERY

Future therapeutic procedures. Edell ES.
Chest Surg Clin N Am 1996 May;6(2):381–95 (93 ref.)
Laser bronchoscopy. Ramser ER, et al. **Clin Chest Med** 1995 Sep;16(3):415–26 (66 ref.)

CARCINOMA, COLLOID see **ADENOCARCINOMA, MUCINOUS**

CARCINOMA, CRIBRIFORM see **ADENOCARCINOMA**

CARCINOMA, DUCTAL see **CARCINOMA, INFILTRATING DUCT**

CARCINOMA, EMBRYONAL

DIAGNOSIS

A case of microscopic testicular tumour. Shoji N, et al. **Int Urol Nephrol** 1995;27(2):189–91 (5 ref.)
[Embryonal carcinoma and anaplastic seminoma of the testis: diagnostic difficulties] Vallat AV, et al.
Arch Anat Cytol Pathol 1996;44(2–3):109–12 (10 ref.) (Eng. Abstr.) (Fre)

DRUG THERAPY

Effects of taxol on the polymerization and posttranslational modification of class III beta-tubulin in P19 embryonal carcinoma cells. Laferrière NB, et al. **Biochem Cell Biol** 1995 Sep–Oct;73(9–10):687–94 (36 ref.)

GENETICS

[Correlation between p-53 expression and clinical resistance in testicular cancer] Hanna E, et al. **Orv Hetil** 1996 Jan 14;137(2):59–64 (26 ref.) (Eng. Abstr.) (Hun)

CARCINOMA, ENDOMETRIOID

DIAGNOSIS

[Primary malignant neoplasms of the female genitalia] Saraiva J, et al. **Acta Med Port** 1995 Oct;8(10):585–8 (11 ref.) (Eng. Abstr.) (Por)

PREVENTION & CONTROL

Endometrial cancer chemoprevention: implications of diverse pathways of carcinogenesis. Sherman ME, et al.
J Cell Biochem Suppl 1995;23:160–4 (27 ref.)

CARCINOMA, EPIDERMOID see **CARCINOMA, SQUAMOUS CELL**

CARCINOMA, GIANT CELL

COMPLICATIONS

Tuberous sclerosis with a brain tumor. Chaudhary D, et al. **Indian Pediatr** 1995 Feb;32(2):235–8 (13 ref.)

DIAGNOSIS

[Transitional-cell sarcomatoid carcinoma of the renal pelvis with osteoclast-type giant cells. Review of the literature] Meseguer García P, et al. **Actas Urol Esp** 1996 Jan; 20(1):63–7 (26 ref.) (Eng. Abstr.) (Spa)

CARCINOMA, GRANULAR CELL see **ADENOCARCINOMA**

CARCINOMA, HEPATOCELLULAR

Recent advances in clinical research of hepatocellular carcinoma in China. Tang Z. **Chin Med J (Engl)** 1995 Aug; 108(8):568–70 (0 ref.)
Hepatocellular carcinoma: clinical features, evaluation and treatment. Khurshid H, et al. **JPMA J Pak Med Assoc** 1995 May;45(5):136–43 (85 ref.)
[Prognostic factors of hepatocellular carcinoma: a multivariate analysis in 113 patients] Ychou M, et al.
Bull Cancer (Paris) 1995 Nov;82(11):971–4 (11 ref.) (Eng. Abstr.) (Fre)
[Hepatocellular carcinoma (HCC)] Ebara M.
Ryoikibetsu Shokogun Shirizu 1995;(7):363–6 (10 ref.) (Jpn)
[Sclerosing hepatic carcinoma] Kakita A, et al.
Ryoikibetsu Shokogun Shirizu 1995;(7):467–9 (11 ref.) (Jpn)
[Hepatocellular carcinoma of nodular type] Kanamaru T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):446–9 (17 ref.) (Jpn)
[Hepatocellular carcinoma of specific developmental type (massive type, pedunculated type, extrahepatic type, diffuse type, and intra-bile duct developmental type)] Nakanishi T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):495–7 (11 ref.) (Jpn)
[Fibrolamellar carcinoma of the liver] Nakano M.
Ryoikibetsu Shokogun Shirizu 1995;(7):269–72 (20 ref.) (Jpn)
[Combined hepatocellular and cholangiocarcinoma] Omagari K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):473–5 (14 ref.) (Jpn)
[Borderline lesions of adenomatous hyperplasia and hepatocellular carcinoma] Sakon M, et al.
Ryoikibetsu Shokogun Shirizu 1995;(7):441–5 (14 ref.) (Jpn)
[Ectopic liver and ectopic hepatocellular carcinoma] Sasaki K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):282–4 (14 ref.) (Jpn)
[Paraneoplastic syndrome of hepatocellular carcinoma] Tagawa K, et al. **Ryoikibetsu Shokogun Shirizu** 1995; (7):453–5 (13 ref.) (Jpn)
[Well-differentiated hepatocellular carcinoma] Umeshita K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):470–2 (11 ref.) (Jpn)
[Hepatocellular carcinoma originated in the caudate lobe] Yamasaki S, et al. **Ryoikibetsu Shokogun Shirizu** 1995; (7):507–10 (2 ref.) (Jpn)

BLOOD SUPPLY

Blood supply of early hepatocellular carcinoma. Bhattacharya S, et al. **Semin Liver Dis** 1995 Nov; 15(4):390–401 (96 ref.)

CHEMICALLY INDUCED

Hepatocellular carcinoma associated with anabolic steroid therapy: report of a case and review of the Japanese literature. Kosaka A, et al. **J Gastroenterol** 1996 Jun; 31(3):450–4 (24 ref.)
[Liver neoplasms due to Thorotrast] Ukida M.
Ryoikibetsu Shokogun Shirizu 1995;(7):501–3 (19 ref.) (Jpn)

COMPLICATIONS

Spontaneous rupture of hepatocellular carcinoma. Zhu LX, et al. **Br J Surg** 1996 May;83(5):602–7 (33 ref.)
Long term survival after obstruction of the common bile duct by ductal hepatocellular carcinoma. Jan YY, et al. **Eur J Surg** 1995 Oct;161(10):771–4 (17 ref.)
[Cholangiocellular carcinoma associated with liver cirrhosis] Suzuki Y, et al. **Ryoikibetsu Shokogun Shirizu** 1995; (7):357–9 (20 ref.) (Jpn)
[Hepatocarcinoma associated to fatty liver degeneration. Report of a clinical case] Pacheco R, et al. **G E N** 1995 Jul–Sep;49(3):234–7 (16 ref.) (Eng. Abstr.) (Spa)

DIAGNOSIS

Screening for hepatocellular carcinoma: a regained enthusiasm due to new therapeutic options? Henrion J, et al. **Acta Gastroenterol Belg** 1995 Sep–Dec;58(5–6):426–32 (28 ref.)
Hepatocellular carcinoma: update on diagnosis and treatment. Ramsey WH, et al. **Dig Dis** 1995 Mar–Apr;13(2):81–91 (65 ref.)
Carbohydrate-based measurements on alpha-fetoprotein in the early diagnosis of hepatocellular carcinoma. Aoyagi Y. **Glycoconj J** 1995 Jun;12(3):194–9 (66 ref.)
Secondary prevention of hepatocellular carcinoma. Tang ZY, et al. **J Gastroenterol Hepatol** 1995 Nov–Dec;10(6):683–90 (85 ref.)
Radiologic diagnosis of hepatocellular carcinoma. Ishiguchi T, et al. **Semin Surg Oncol** 1996 May–Jun;12(3):164–9 (17 ref.)
[Changed diagnosis and treatment of hepatocellular carcinoma] van Nieuwkerk CM, et al.
Ned Tijdschr Geneeskd 1996 Apr 27;140(17):922–6 (39 ref.) (Dut)
[Inflammatory pseudotumor of the liver. Case report of a rare differential diagnosis of hepatocellular carcinoma] Strohm WD, et al. **Z Gastroenterol** 1996 Feb;34(2):132–7 (45 ref.) (Eng. Abstr.) (Ger)
[Early diagnosis of hepatocellular carcinoma by serum AFP and PIVKA-II analysis] Aoyagi Y, et al.
Nippon Naika Gakkai Zasshi 1995 Dec 10;84(12):2003–7 (5 ref.) (Jpn)
[Early diagnosis of hepatocellular carcinoma using computed tomography and magnetic resonance imaging] Moriyama N. **Nippon Naika Gakkai Zasshi** 1995 Dec 10; 84(12):1997–2002 (4 ref.) (Jpn)
[A case of cranial metastasis of hepatocellular carcinoma] Shibukawa M, et al. **No To Shinkei** 1995 Nov; 47(11):1087–91 (28 ref.) (Eng. Abstr.) (Jpn)
[Use of morphometry and DNA flow cytometry in the differential diagnosis, prognosis and treatment of primary tumors of the liver (review of the literature)] Pimenova EL, et al. **Klin Lab Diagn** 1996 Mar–Apr;(2):7–11 (47 ref.) (Rus)
[Leukocytoclastic vasculitis as the form of presentation of hepatocarcinoma] Sánchez-Angulo JI, et al.
Gastroenterol Hepatol 1996 May;19(5):255–8 (35 ref.) (Eng. Abstr.) (Spa)

DRUG THERAPY

[Chemotherapy of hepatocellular carcinoma] Okada S.
Nippon Naika Gakkai Zasshi 1995 Dec 10;84(12):2028–31 (5 ref.) (Jpn)
[Percutaneous ethanol injection therapy of hepatoma] Shiina S, et al. **Nippon Naika Gakkai Zasshi** 1995 Dec 10; 84(12):2008–11 (5 ref.) (Jpn)

EPIDEMIOLOGY

Epidemiology of hepatocellular carcinoma. Colombo M. **Ital J Gastroenterol** 1995 Mar;27(2):83–7 (31 ref.)
[Primary liver tumors in children] Vos A, et al.
Ned Tijdschr Geneeskd 1995 Sep 23;139(38):1918–22 (35 ref.) (Dut)
[Epidemiology of hepatocellular carcinoma] Okuda K.
Gan To Kagaku Ryoho 1996 Aug;23(9):1105–15 (101 ref.) (Eng. Abstr.) (Jpn)
[High risk group of patients with hepatitis C virus infection developing hepatocellular carcinoma] Yokosuka O, et al.
Nippon Naika Gakkai Zasshi 1995 Dec 10;84(12):1975–9 (5 ref.) (Jpn)

ETIOLOGY

Alcohol, hepatotropic viruses, and hepatocellular carcinoma [editorial] Nalpas B, et al. **Alcohol Clin Exp Res** 1995 Oct; 19(5):1089–95 (96 ref.)
Hepatocellular carcinoma and African iron overload. Gangaidzo IT, et al. **Gut** 1995 Nov;37(5):727–30 (53 ref.)
Hepatocarcinogenesis in rodents and humans. Kitagawa T, et al. **J Cancer Res Clin Oncol** 1995;121(9–10):511–5 (39 ref.)
Etiology, screening, and treatment of hepatocellular carcinoma. Khakoo SI, et al. **Med Clin North Am** 1996 Sep;80(5):1121–45 (151 ref.)
Pathogenesis of hepatocellular carcinoma: a review from the viewpoint of molecular analysis. Kasai Y, et al.
Semin Surg Oncol 1996 May–Jun;12(3):155–9 (40 ref.)
Hepatocellular carcinoma--carcinogenesis updated. Yap I. **Singapore Med J** 1995 Dec;36(6):597–9 (63 ref.)
[Natural history of hepatitis C virus infection] Marcellin P, et al. **Pathol Biol (Paris)** 1995 Oct;43(8):669–73 (34 ref.) (Eng. Abstr.) (Fre)
[Hepatocellular carcinoma] Propst A, et al.
Schweiz Med Wochenschr 1995 Nov 4;125(44):2137–42 (15 ref.) (Eng. Abstr.) (Ger)
[High risk group of patients with hepatitis B virus infection developing hepatocellular carcinoma] Koike K.
Nippon Naika Gakkai Zasshi 1995 Dec 10;84(12):1980–4 (5 ref.) (Jpn)
[Prediction of high risk group of patients with hepatitis-C-virus type liver cirrhosis developing to liver neoplasm] Tarao K, et al. **Nippon Naika Gakkai Zasshi** 1995 Dec 10;84(12):1985–91 (5 ref.) (Jpn)
[Influence of heavy drinking for the development of hepatocellular carcinoma in type C cirrhosis] Chiba T, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:731–5 (23 ref.) (Jpn)
[Molecular mechanism of HBV hepatocarcinogenesis] Koike K. **Nippon Rinsho** 1995 Oct;53 Suppl:65–74 (37 ref.) (Jpn)
[Clinicopathological studies on juvenile hepatocellular carcinoma with hepatitis B virus infection--background factors, tumor spread and prognosis after hepatic resection] Yokoi H, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:698–703 (16 ref.) (Jpn)
[Hepatocellular carcinoma of accessory liver] Kakita A, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):279–81 (19 ref.) (Jpn)

GENETICS

Tumour suppressor p53 and Rb genes in human hepatocellular carcinoma. Lin Y, et al.
Ann Acad Med Singapore 1996 Jan;25(1):22–30 (72 ref.)
Immunochemical and genetic analysis of the p53 gene in liver preneoplastic nodules from aflatoxin-induced rats in one year. Liu YP, et al. **Ann Acad Med Singapore** 1996 Jan; 25(1):31–6 (51 ref.)
Report of a complex karyotype in recurrent metastatic fibrolamellar hepatocellular carcinoma and a review of hepatocellular carcinoma cytogenetics. Lowichik A, et al. **Cancer Genet Cytogenet** 1996 Jun;88(2):170–4 (42 ref.)
Altered retinoic acid receptors. de Thé H. **FASEB J** 1996 Jul;10(9):955–60 (43 ref.)
p53 proteins and aflatoxin b1: the good, the bad, and the ugly [editorial] Liang TJ. **Hepatology** 1995 Oct;22(4 Pt 1):1330–2 (21 ref.)
Pathogenesis of hepatocellular carcinoma: a review from the viewpoint of molecular analysis. Kasai Y, et al.
Semin Surg Oncol 1996 May–Jun;12(3):155–9 (40 ref.)
[Molecular biological characteristics of model cells of hepatitis B virus (HBV)-induced direct hepatocellular carcinogenesis] Baba M, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:97–103 (22 ref.) (Jpn)
[Use of morphometry and DNA flow cytometry in the differential diagnosis, prognosis and treatment of primary tumors of the liver (review of the literature)] Pimenova EL, et al. **Klin Lab Diagn** 1996 Mar–Apr;(2):7–11 (47 ref.) (Rus)

METABOLISM

[Alpha-fetoprotein producing hepatocellular carcinoma, AT-III producing hepatocellular carcinoma] Nakamura K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):265–8 (11 ref.) (Jpn)

PATHOLOGY

Analysis of liver development, regeneration, and carcinogenesis by genetic marking studies. Ponder KP.

FASEB J 1996 May;10(7):673–82 (59 ref.)
Hepatocellular carcinoma metastatic to bones (Case report with review of literature). Doval DC, et al. **Indian J Cancer** 1995 Mar;32(1):31–5 (25 ref.)
Mucin–producing adenoma associated with pancreas divisum and hepatic hilar carcinoma: an autopsy case. Origuchi N, et al. **J Gastroenterol** 1996 Jun;31(3):455–9 (40 ref.)
Preneoplastic conditions of the liver. Riegler JL. **Semin Gastrointest Dis** 1996 Apr;7(2):74–87 (79 ref.)
Macroregenerative (dysplastic) nodules and hepatocarcinogenesis: theoretical and clinical considerations. Theise ND. **Semin Liver Dis** 1995 Nov; 15(4):360–71 (51 ref.)
[Retrospect and recent progress of pathology of hepatobiliary system] Zhu S, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1995 Aug;24(4):217–20 (22 ref.) **(Chi)**
[Current approach to hepatic carcinogenesis. From cirrhosis to hepatocellular carcinoma] Le Bail B, et al. **Ann Pathol** 1995;15(5):332–47 (92 ref.) **(Fre)**
[Choledochus carcinoma in choledochal cyst—a rarity. Presentation of the disease with a case report] Stalder PA, et al. **Swiss Surg** 1996;(3):123–6 (34 ref.) (Eng. Abstr.) **(Ger)**
[Hepatocellular nodular hyperplasias, adenomas and carcinomas] Altmann HW. **Verh Dtsch Ges Pathol** 1995; 79:84–108 (144 ref.) (Eng. Abstr.) **(Ger)**
[Sequential cellular and molecular changes during hepatocarcinogenesis] Bannasch P. **Verh Dtsch Ges Pathol** 1995;79:72–83 (65 ref.) (Eng. Abstr.) **(Ger)**
[Prognostic factors in liver tumors] Wittekind C. **Verh Dtsch Ges Pathol** 1995;79:109–15 (61 ref.) (Eng. Abstr.) **(Ger)**
[Precancerous stages of hepatocellular carcinoma] Tanikawa K. **Gan To Kagaku Ryoho** 1995 Dec;22(14):2055–61 (29 ref.) (Eng. Abstr.) **(Jpn)**
[Clinicopathological studies on juvenile hepatocellular carcinoma with hepatitis B virus infection—background factors, tumor spread and prognosis after hepatic resection] Yokoi H, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:698–703 (16 ref.) **(Jpn)**
[Hepatocellular carcinoma (scirrhous type)] Hirooka N, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):367–70 (8 ref.) **(Jpn)**
[Extrahepatic intrabile duct tumor growth of hepatocellular carcinoma] Kashihara T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):57–60 (20 ref.) **(Jpn)**
[Hepatocellular carcinoma in adenomatous hyperplasia] Shiga J. **Ryoikibetsu Shokogun Shirizu** 1995;(7):371–3 (7 ref.) **(Jpn)**

PHYSIOPATHOLOGY

[Sequential cellular and molecular changes during hepatocarcinogenesis] Bannasch P. **Verh Dtsch Ges Pathol** 1995;79:72–83 (65 ref.) (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

Primary prevention of hepatocellular carcinoma. Yu SZ. **J Gastroenterol Hepatol** 1995 Nov–Dec;10(6):674–82 (24 ref.)
Etiology, screening, and treatment of hepatocellular carcinoma. Khakoo SI, et al. **Med Clin North Am** 1996 Sep;80(5):1121–45 (151 ref.)
[Preventive use of retinoids for occurrence of liver neoplasm] Muto Y. **Nippon Naika Gakkai Zasshi** 1995 Dec 10; 84(12):2032–7 (5 ref.) **(Jpn)**
[Does interferon therapy on type C liver cirrhosis prevent the occurrence of hepatocellular carcinoma?] Harada H, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:754–8 (17 ref.) **(Jpn)**

RADIOTHERAPY

[Radiotherapy of hepatocellular carcinoma] Tanaka N, et al. **Nippon Naika Gakkai Zasshi** 1995 Dec 10;84(12):2019–23 (7 ref.) **(Jpn)**

SECONDARY

[Renal metastasis originating from liver cancer] Fukushima M, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 Mar; 87(3):710–3 (8 ref.) (Eng. Abstr.) **(Jpn)**
[A rare case of cranial metastasis from hepatocellular carcinoma] Momoji J, et al. **No Shinkei Geka** 1995 Nov; 23(11):997–1002 (25 ref.) (Eng. Abstr.) **(Jpn)**

SURGERY

Repeated liver resection for recurrent liver cancer. Neeleman N, et al. **Br J Surg** 1996 Jul;83(7):893–901 (73 ref.)
Experimental and clinical study on hepatobiliary surgery in China. Wu M. **Chin Med J (Engl)** 1996 Feb;109(2):131–3 (19 ref.)
Primary and secondary hepatic malignancies. Gallinger S, et al. **Curr Opin Gen Surg** 1993;:257–64 (47 ref.)
Resection of a fibrolamellar carcinoma of the liver originating in the caudate lobe. Machado MC, et al. **Hepatogastroenterology** 1995 Nov–Dec;42(6):993–5 (21 ref.)
Advances in hepatic resection and results for hepatocellular carcinoma. Nonami T, et al. **Semin Surg Oncol** 1996 May–Jun;12(3):183–8 (51 ref.)
Liver transplantation and hepatocellular carcinoma. Yokoyama I, et al. **Semin Surg Oncol** 1996 May–Jun; 12(3):212–6 (30 ref.)
Hepatocellular carcinoma associated with lupoid hepatitis: a review of Japanese reports. Sakaguchi T, et al. **Surg Today** 1995;25(9):838–42 (18 ref.)
[Resections of recurrence in the liver of primary and secondary liver cancers] Herfarth C, et al. **Chirurg** 1995 Oct;66(10):949–58 (78 ref.) (Eng. Abstr.) **(Ger)**
[Microwave coagulation therapy of hepatocellular carcinoma] Seki T, et al. **Nippon Naika Gakkai Zasshi** 1995 Dec 10;84(12):2024–7 (5 ref.) **(Jpn)**
[A simultaneous operation for esophageal and cholangiocellular carcinomas—a case of report] Kudo T, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Oct; 92(10):1789–93 (12 ref.) **(Jpn)**

THERAPY

Delayed anoxic pseudolobular necrosis (terminal hepatic necrosis) after chemo–lipiodolization for hepatocellular carcinoma. Kozakai I, et al. **Am J Gastroenterol** 1996 Jun; 91(6):1263–5 (8 ref.)
Hepatocellular carcinoma: update on diagnosis and treatment. Ramsey WH, et al. **Dig Dis** 1995 Mar–Apr;13(2):81–91 (65 ref.)
Why can't we cure primary liver cancer? [editorial] Johnson PJ. **Eur J Cancer** 1995 Sep;31A(10):1562–4 (19 ref.)
Update on regional treatments for hepatobiliary malignancies. Curley SA. **Gan To Kagaku Ryoho** 1995 Sep;22(11):1437–52 (23 ref.)
Secondary prevention of hepatocellular carcinoma. Tang ZY, et al. **J Gastroenterol Hepatol** 1995 Nov–Dec;10(6):683–90 (85 ref.)
p53 gene therapy in vivo of herpatocellular and liver metastatic colorectal cancer. Bookstein R, et al. **Semin Oncol** 1996 Feb;23(1):66–77 (109 ref.)
Non–invasive loco–regional therapy for hepatocellular carcinoma. Tanikawa K. **Semin Surg Oncol** 1996 May–Jun; 12(3):189–92 (15 ref.)
[Treatment of hepatocellular carcinoma in the presence of liver cirrhosis] Ducreux M, et al. **J Chir (Paris)** 1995 Jun–Jul;132(6–7):279–86 (60 ref.) (Eng. Abstr.) **(Fre)**
[Current status of treatment for small hepatocellular carcinoma] Yokoi H, et al. **Gan To Kagaku Ryoho** 1996 Jun;23(7):855–61 (21 ref.) (Eng. Abstr.) **(Jpn)**
[TAE therapy of hepatocellular carcinoma] Kudo M. **Nippon Naika Gakkai Zasshi** 1995 Dec 10;84(12):2012–8 (7 ref.) **(Jpn)**

ULTRASONOGRAPHY

[Ultrasonographic screening of hepatocellular carcinoma] Majima Y. **Nippon Naika Gakkai Zasshi** 1995 Dec 10; 84(12):1992–6 (4 ref.) **(Jpn)**

VIROLOGY

Hepatitis B virus and hepatocellular carcinoma. Ren EC. **Ann Acad Med Singapore** 1996 Jan;25(1):17–21 (52 ref.)
Hepatitis C virus and hepatocellular carcinoma. Colombo M, et al. **Clin Exp Rheumatol** 1995 Nov–Dec;13 Suppl 13:S23–7 (49 ref.)
In vitro transformation by hepatitis B virus DNA. Schaefer S, et al. **Intervirology** 1995;38(3–4):143–54 (112 ref.)
Hepatitis C virus as a causative agent of hepatocellular carcinoma. Shimotohno K. **Intervirology** 1995; 38(3–4):162–9 (55 ref.)
[HCV genome in type C hepatocellular carcinoma] Yamada G. **Nippon Rinsho** 1995 Sep;53 Suppl:777–81 (13 ref.) **(Jpn)**

CARCINOMA, HYPERNEPHROID see **CARCINOMA, RENAL CELL**

CARCINOMA IN SITU

Vulval intraepithelial neoplasia [editorial] Jebakumar S, et al. **Int J STD AIDS** 1996 Jan–Feb;7(1):10–3 (45 ref.)
Ductal carcinoma in situ. Margolese RG. **Recent Results Cancer Res** 1996;140:131–8 (25 ref.)

CHEMISTRY

Molecular analysis of premalignant and carcinoma in situ lesions of the human breast. Steeg PS, et al. **Am J Pathol** 1996 Sep;149(3):733–8 (49 ref.)

DIAGNOSIS

Future diagnostic procedures. Lam S, et al. **Chest Surg Clin N Am** 1996 May;6(2):363–80 (81 ref.)
Current methods of assessing and treating carcinoma in situ of the bladder with or without involvement of the prostatic urethra. Kurth KH, et al. **Int J Urol** 1995 Jun;2 Suppl 2:8–22 (124 ref.)
Contemporary diagnostic approaches for nonpalpable carcinoma of the breast: the role of the radiologist. Schepps B, et al. **R I Med** 1995 Sep;78(9):239–41 (19 ref.)
[Adenoma of Vater's ampulla without clinical or analytical expression (letter)] Moreira VF, et al. **Rev Clin Esp** 1996 May;196(5):343–4 (11 ref.) **(Spa)**

DRUG THERAPY

[Place of endovesical "BCG Therapy" in superficial tumors of the bladder] Zerbib M. **J Urol (Paris)** 1995;101(2):59–63 (30 ref.) (Eng. Abstr.) **(Fre)**

EPIDEMIOLOGY

Risk of dysplasia in anal condyloma. Metcalf AM, et al. **Surgery** 1995 Oct;118(4):724–6 (14 ref.)

ETIOLOGY

Effectiveness of vaginal Papanicolaou smear screening after total hysterectomy for benign disease. Fetters MD, et al. **JAMA** 1996 Mar 27;275(12):940–7 (90 ref.)

PATHOLOGY

The minimally abnormal Papanicolaou smear. Brotzman GL, et al. **Am Fam Physician** 1996 Mar;53(4):1154–62 (39 ref.)
The pathology of ductal carcinoma in situ of the breast. Bobrow LG, et al. **Clin Oncol (R Coll Radiol)** 1995; 7(4):232–5 (40 ref.)
The pathology of vulvar neoplasia. Lininger RA, et al. **Curr Opin Obstet Gynecol** 1996 Feb;8(1):63–8 (28 ref.)
Ductal carcinoma in situ of the breast: progress and controversy. Swallow CJ, et al. **Curr Probl Surg** 1996 Jul; 33(7):553–600 (171 ref.)
Adequacy of conization margins in adenocarcinoma in situ of the cervix as a predictor of residual disease. Im DD, et al. **Gynecol Oncol** 1995 Nov;59(2):179–82 (20 ref.)
Cervical intraepithelial neoplasia. Crum CP, et al. **J Cell Biochem Suppl** 1995;23:71–9 (44 ref.)
Computer–assisted pathology of intraepithelial adenocarcinoma and related lesions: 3–D distribution, structural aberration and discrimination. Takahashi T, et al. **J Cell Biochem Suppl** 1995;23:25–32 (16 ref.)
Malignant and premalignant change in odontogenic cysts. Fanibunda K, et al. **J Oral Maxillofac Surg** 1995 Dec; 53(12):1469–72 (19 ref.)
Papillomas of the breast. A histologic spectrum including atypical hyperplasia and carcinoma in situ. McKinney CD, et al. **Pathol Annu** 1995;30 Pt 2:137–78 (47 ref.)
Duct carcinoma in situ: biological implications for clinical practice. Lagios MD. **Semin Oncol** 1996 Feb;23(1 Suppl 2):6–11 (31 ref.)

PREVENTION & CONTROL

Surrogate endpoint biomarkers for cervical cancer chemopreventive trials. Ruffin MT 4th, et al. **J Cell Biochem Suppl** 1995;23:113–24 (98 ref.)
Endometrial cancer chemoprevention: implications of diverse pathways of carcinogenesis. Sherman ME, et al. **J Cell Biochem Suppl** 1995;23:160–4 (27 ref.)

SURGERY

Breast conservation therapy in the management of invasive and in situ carcinoma. Masko GB, et al. **R I Med** 1995 Sep;78(9):246–9 (18 ref.)
Duct carcinoma in situ: biological implications for clinical practice. Lagios MD. **Semin Oncol** 1996 Feb;23(1 Suppl 2):6–11 (31 ref.)

THERAPY

Ductal carcinoma in situ of the breast: progress and controversy. Swallow CJ, et al. **Curr Probl Surg** 1996 Jul; 33(7):553–600 (171 ref.)
Current methods of assessing and treating carcinoma in situ of the bladder with or without involvement of the prostatic urethra. Kurth KH, et al. **Int J Urol** 1995 Jun;2 Suppl 2:8–22 (124 ref.)
Carcinoma in situ and treatment options. Erton M, et al. **Int Urol Nephrol** 1996;28(1):33–42 (25 ref.)
BCG immunotherapy for transitional–cell carcinoma in situ of the bladder. Lamm DL. **Oncology (Huntingt)** 1995 Oct; 9(10):947–52, 955, discussion 955–65 (51 ref.)
Management of in situ carcinoma of the breast: lobular and ductal origin. White RE, et al. **R I Med** 1995 Sep; 78(9):242–5 (27 ref.)
Controversies in the treatment of ductal carcinoma in situ. Hughes KS, et al. **Surg Clin North Am** 1996 Apr; 76(2):243–65 (76 ref.)
Current management of ductal carcinoma in situ [see comments] Barth A, et al. **West J Med** 1995 Oct; 163(4):360–6 (78 ref.) Comment in: West J Med 1995 Oct;163(4):390–2.

CARCINOMA, INFILTRATING DUCT

Ductal carcinoma in situ. Margolese RG. **Recent Results Cancer Res** 1996;140:131–8 (25 ref.)
[Intraductal cancer of the breast in women under age 35 years] Sananes S, et al. **Bull Cancer (Paris)** 1996 May; 83(5):395–9 (34 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Contemporary diagnostic approaches for nonpalpable carcinoma of the breast: the role of the radiologist. Schepps B, et al. **R I Med** 1995 Sep;78(9):239–41 (19 ref.)

PATHOLOGY

The pathology of ductal carcinoma in situ of the breast. Bobrow LG, et al. **Clin Oncol (R Coll Radiol)** 1995; 7(4):232–5 (40 ref.)

Ductal carcinoma in situ of the breast: progress and controversy. Swallow CJ, et al. **Curr Probl Surg** 1996 Jul; 33(7):553–600 (171 ref.)

Hepar lobatum carcinomatosum due to chemotherapy of a metastatic breast carcinoma. Uhlmann F, et al. **Gen Diagn Pathol** 1996 Mar;141(3–4):279–84 (21 ref.)

Coexistence of nipple duct adenoma and breast carcinoma: a clinicopathologic study of five cases and review of the literature. Jones MW, et al. **Mod Pathol** 1995 Aug; 8(6):633–6 (13 ref.)

Simultaneous multifocal polymorphous low-grade adenocarcinoma. Report of two cases. Clayton JR, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1995 Jul;80(1):71–7 (31 ref.)

Duct carcinoma in situ: biological implications for clinical practice. Lagios MD. **Semin Oncol** 1996 Feb;23(1 Suppl 2):6–11 (31 ref.)

[Tarsal metastases from breast carcinoma: a case report and review of the literature] Sandomenico F, et al. **Radiol Med (Torino)** 1996 Mar;91(3):306–8 (16 ref.) **(Ita)**

RADIOTHERAPY

Low-grade dermal angiosarcoma of the breast following radiotherapy. Bolin DJ, et al. **Am Surg** 1996 Aug; 62(8):668–72 (19 ref.)

Radiation-induced sarcoma of the breast. Mason RW, et al. **J Am Osteopath Assoc** 1996 Jun;96(6):368–70 (15 ref.)

SECONDARY

Breast carcinoma metastatic to paranasal sinuses. Austin JR, et al. **Head Neck** 1995 Mar–Apr;17(2):161–5 (20 ref.)

Malignant joint effusions secondary to solid tumor metastasis. Munn RK, et al. **J Rheumatol** 1995 May;22(5):973–5 (15 ref.)

Submandibular gland metastasis of breast carcinoma: a case report and review of the literature. Vessecchia G, et al. **Virchows Arch** 1995;427(3):349–51 (25 ref.)

[Tarsal metastases from breast carcinoma: a case report and review of the literature] Sandomenico F, et al. **Radiol Med (Torino)** 1996 Mar;91(3):306–8 (16 ref.) **(Ita)**

SURGERY

Breast conservation therapy in the management of invasive and in situ carcinoma. Masko GB, et al. **R I Med** 1995 Sep;78(9):246–9 (18 ref.)

Duct carcinoma in situ: biological implications for clinical practice. Lagios MD. **Semin Oncol** 1996 Feb;23(1 Suppl 2):6–11 (31 ref.)

THERAPY

Ductal carcinoma in situ of the breast: progress and controversy. Swallow CJ, et al. **Curr Probl Surg** 1996 Jul; 33(7):553–600 (171 ref.)

Management of in situ carcinoma of the breast: lobular and ductal origin. White RE, et al. **R I Med** 1995 Sep; 78(9):242–5 (27 ref.)

Controversies in the treatment of ductal carcinoma in situ. Hughes KS, et al. **Surg Clin North Am** 1996 Apr; 76(2):243–65 (76 ref.)

Current management of ductal carcinoma in situ [see comments] Barth A, et al. **West J Med** 1995 Oct; 163(4):360–6 (78 ref.) Comment in: West J Med 1995 Oct;163(4):390–2.

VIROLOGY

Mammary tumors induced by polyomavirus. Fluck MM, et al. **Breast Cancer Res Treat** 1996;39(1):45–56 (49 ref.)

CARCINOMA, INTRAEPITHELIAL see **CARCINOMA IN SITU**

CARCINOMA, LARGE CELL

COMPLICATIONS

[Clinical analysis of lung cancer in patients with chondromatous hamartoma] Umemori Y, et al. **Kyobu Geka** 1995 Nov;48(12):1061–4 (11 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

[Bronchogenic carcinoma and human immunodeficiency virus infection] Carrasquer C, et al. **Arch Bronconeumol** 1995 Aug–Sep;31(7):362–4 (15 ref.) (Eng. Abstr.) **(Spa)**

[Large-cell lung carcinoma producing chorionic gonadotropin hormone: the difficulty in its differential diagnosis from choriocarcinoma] Cremades Romero MJ, et al. **Arch Bronconeumol** 1996 May;32(5):253–5 (10 ref.) (Eng. Abstr.) **(Spa)**

SECRETION

[Large-cell lung carcinoma producing chorionic gonadotropin hormone: the difficulty in its differential diagnosis from choriocarcinoma] Cremades Romero MJ, et al. **Arch Bronconeumol** 1996 May;32(5):253–5 (10 ref.) (Eng. Abstr.) **(Spa)**

CARCINOMA, LOBULAR

DIAGNOSIS

[Magnetic resonance in a case of lobular adenocarcinoma of the breast] Dalpiaz G, et al. **Radiol Med (Torino)** 1996 Apr;91(4):475–7 (12 ref.) **(Ita)**

[Invasive lobular carcinoma of the breast with a 10-year evolution] da Fonseca CR, et al. **Acta Med Port** 1995 Mar; 8(3):157–9 (13 ref.) (Eng. Abstr.) **(Por)**

PATHOLOGY

Simultaneous multifocal polymorphous low-grade adenocarcinoma. Report of two cases. Clayton JR, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1995 Jul;80(1):71–7 (31 ref.)

Arguments against routine contralateral mastectomy or undirected biopsy for invasive lobular breast cancer. Lee JS, et al. **Surgery** 1995 Oct;118(4):640–7; discussion 647–8 (22 ref.)

SURGERY

Arguments against routine contralateral mastectomy or undirected biopsy for invasive lobular breast cancer. Lee JS, et al. **Surgery** 1995 Oct;118(4):640–7; discussion 647–8 (22 ref.)

THERAPY

Management of in situ carcinoma of the breast: lobular and ductal origin. White RE, et al. **R I Med** 1995 Sep; 78(9):242–5 (27 ref.)

CARCINOMA, MEDULLARY

see related
MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A
MULTIPLE ENDOCRINE NEOPLASIA TYPE 2B

Medullary thyroid carcinoma: recent advances and management update. Marsh DJ, et al. **Thyroid** 1995 Oct; 5(5):407–24 (188 ref.)

BLOOD

[Hypercalcitoninemia in conditions other than medullary cancers of the thyroid] Niccoli P, et al. **Ann Endocrinol (Paris)** 1996;57(1):15–21 (53 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

[The assessment of solitary osteolytic bone lesions in breast carcinoma. A special case report] Mose S, et al. **Strahlenther Onkol** 1996 Jan;172(1):43–6 (16 ref.) (Eng. Abstr.) **(Ger)**

DIAGNOSIS

Preoperative endocrine tumor localization utilizing a cost-effective approach. Leight GS Jr, et al. **Curr Opin Gen Surg** 1993;:108–14 (19 ref.)

Diagnostic problems in medullary carcinoma of the thyroid. Bussolati G, et al. **Pathol Res Pract** 1995 May;191(4):332–44 (64 ref.)

[Cushing's syndrome associated with a metastatic medullary carcinoma of the thyroid. A report of 2 cases and a review of the literature] Martínez Díaz-Guerra G, et al. **Rev Clin Esp** 1995 Dec;195(12):849–52 (63 ref.) (Eng. Abstr.) **(Spa)**

EPIDEMIOLOGY

[Medullary cancer of the thyroid gland in France in 1995] Modigliani E. **Ann Endocrinol (Paris)** 1996;57(1):3–7 (14 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma. Cote GJ, et al. **Baillieres Clin Endocrinol Metab** 1995 Jul; 9(3):609–30 (64 ref.)

Molecular analysis of mutations in thyroid tumors with TGGE. Simon D, et al. **Exp Clin Endocrinol Diabetes** 1995; 103(5):275–9 (36 ref.)

RET gene and its implications for cancer. Goodfellow PJ, et al. **J Natl Cancer Inst** 1995 Oct 18;87(20):1515–23 (71 ref.)

[Analysis of the RET gene and medullary cancer of the thyroid. Contribution to the diagnosis and treatment] Schuffenecker I, et al. **Ann Endocrinol (Paris)** 1996; 57(1):9–14 (27 ref.) (Eng. Abstr.) **(Fre)**

[Expression of the MDR1 gene in five human cell lines of medullary thyroid cancer and reversion of the resistance to doxorubicine by ciclosporin A and verapamil] Massart C, et al. **Bull Cancer (Paris)** 1996 Jan;83(1):39–45 (32 ref.) (Eng. Abstr.) **(Fre)**

[The direct gene test in familial medullary thyroid gland carcinoma and in MEN syndromes. Detection of mutations in the ret proto-oncogene saves screening studies] Stuhrmann M. **Fortschr Med** 1995 Dec 20;113(35–36):503–6 (23 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

Medullary carcinoma of the thyroid: subtypes and current management. Randolph GW. **Compr Ther** 1996 Apr; 22(4):203–10 (30 ref.)

[Detection of residual lesions and metastases of medullary thyroid cancer] Murat A. **Ann Endocrinol (Paris)** 1996; 57(1):27–32 (33 ref.) (Eng. Abstr.) **(Fre)**

RADIOGRAPHY

[A woman with a unilateral adrenal mass. The adrenal metastasis of a medullary carcinoma of the thyroid] Maroto P, et al. **Rev Clin Esp** 1995 Dec;195(12):847–8 (5 ref.) **(Spa)**

SECONDARY

Medullary carcinoma of the thyroid metastatic to the temporal bone. **Redleaf MI, et al. J Laryngol Otol** 1995 Dec;109(12):1200–3 (15 ref.)

[A woman with a unilateral adrenal mass. The adrenal metastasis of a medullary carcinoma of the thyroid] Maroto P, et al. **Rev Clin Esp** 1995 Dec;195(12):847–8 (5 ref.) **(Spa)**

[Cushing's syndrome associated with a metastatic medullary carcinoma of the thyroid. A report of 2 cases and a review of the literature] Martínez Díaz-Guerra G, et al. **Rev Clin Esp** 1995 Dec;195(12):849–52 (63 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

Recent advances in the treatment of thyroid carcinoma [editorial] Wells SA Jr. **CA Cancer J Clin** 1996 Sep–Oct; 46(5):258–60 (16 ref.)

[Role of non surgical therapeutics in the treatment of patients with medullary cancer of the thyroid] Guliana JM. **Ann Endocrinol (Paris)** 1996;57(1):33–40 (41 ref.) (Eng. Abstr.) **(Fre)**

CARCINOMA, MERKEL CELL

DIAGNOSIS

Merkel cell carcinoma. O'Connor WJ, et al. **Dermatol Surg** 1996 Mar;22(3):262–7 (21 ref.)

PATHOLOGY

Vulvar Merkel cell tumor with glandular and squamous differentiation. Scurry J, et al. **Gynecol Oncol** 1996 Aug; 62(2):292–7 (15 ref.)

[Primary cutaneous neuroendocrine carcinoma (Merkel tumor). Clinical and therapeutic update apropos of 4 cases] Bassereau G, et al. **Ann Otolaryngol Chir Cervicofac** 1995; 112(3):123–8 (39 ref.) (Eng. Abstr.) **(Fre)**

[False Merkel cell tumor of the gingival mucosa disclosed by small cell bronchial carcinoma] Paume P, et al. **Rev Stomatol Chir Maxillofac** 1995;96(6):352–5 (14 ref.) (Eng. Abstr.) **(Fre)**

SECONDARY

Metastatic merkel cell tumour to the bladder. Woo HH, et al. **Int Urol Nephrol** 1995;27(3):301–5 (13 ref.)

CARCINOMA, MUCINOUS see **ADENOCARCINOMA, MUCINOUS**

CARCINOMA, MUCOEPIDERMOID

[Mucoepidermoid carcinoma of the liver or the intrahepatic bile duct] Sasaki Y, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):426–8 (13 ref.) **(Jpn)**

GENETICS

A mucoepidermoid carcinoma of minor salivary gland with t(11;19)(q21;p13.1) as the only karyotypic abnormality. El-Naggar AK, et al. **Cancer Genet Cytogenet** 1996 Mar; 87(1):29–33 (35 ref.)

PATHOLOGY

Composite follicular variant of papillary carcinoma and mucoepidermoid carcinoma of the thyroid. Report of a case and review of the literature. Miranda RN, et al. **Am J Surg Pathol** 1995 Oct;19(10):1209–15 (23 ref.)

Primary mucoepidermoid carcinoma of the thyroid gland: a report of six cases and a review of the literature of a follicular epithelial-derived tumor. Wenig BM, et al. **Hum Pathol** 1995 Oct;26(10):1099–108 (44 ref.)

SURGERY

Mucoepidermoid carcinoma of the pancreas: report of a case. Onoda N, et al. **Surg Today** 1995;25(9):843–7 (16 ref.)

CARCINOMA, NEUROENDOCRINE

Mixed adenocarcinoma and neuroendocrine carcinoma arising in the urachus. A case report and review of the literature. Munichor M, et al. **Eur Urol** 1995;28(4):345–7 (22 ref.)

CARCINOMA, NEUROENDOCRINE

ENZYMOLOGY

Neuroendocrine tumors of the liver and pancreas associated with elevated serum prostatic acid phosphatase. Kaneko Y, et al. **Intern Med** 1995 Sep;34(9):886–91 (35 ref.)

PATHOLOGY

Endocrine tumours of the stomach. Bordi C. **Pathol Res Pract** 1995 May;191(4):373–80 (33 ref.)

CARCINOMA, NON-SMALL-CELL LUNG

see related
ADENOCARCINOMA
CARCINOMA, LARGE CELL
CARCINOMA, SMALL CELL
CARCINOMA, SQUAMOUS CELL

Update in the treatment and molecular biology of non-small cell lung cancer. Erlich R, et al. **Compr Ther** 1995 Aug; 21(8):445–57 (76 ref.)

COMPLICATIONS

Hypertrophic pulmonary osteoarthropathy: is there a role for radiotherapy to symptomatic sites? Case report and literature review. Roos DE. **Acta Oncol** 1996;35(1):101–3 (16 ref.)

Lung cancer in patients with bullous disease. Zulueta JJ, et al. **Am J Respir Crit Care Med** 1996 Aug;154(2 Pt 1):519–22 (28 ref.)

DIAGNOSIS

Molecular and biological factors in the prognosis of non-small cell lung cancer. Kanters SD, et al. **Eur Respir J** 1995 Aug;8(8):1389–97 (89 ref.)

Biological prognostic factors in non-small cell lung cancer. Scagliotti GV, et al. **Lung Cancer** 1995 Apr;12 Suppl 1:S13–25 (70 ref.)

Prognostic factors in NSCLC. Recent experiences. van Zandwijk N, et al. **Lung Cancer** 1995 Apr;12 Suppl 1:S27–33 (30 ref.)

DRUG THERAPY

Adjuvant and neo-adjuvant chemotherapy in non-small cell carcinoma. Cullen MH. **Ann Oncol** 1995;6 Suppl 1:43–7; discussion 47–8 (23 ref.)

Is there a role for chemotherapy of non-small cell lung cancer? Hansen HH. **Ann Oncol** 1995;6 Suppl 1:79–82 (23 ref.)

Dealing with initial chemotherapy doses: a new basis for treatment optimisation in limited small-cell lung cancer. Le Cesne A, et al. **Ann Oncol** 1995;6 Suppl 3:S53–6 (26 ref.)

New drugs in the treatment of non-small cell lung cancer. Steward WP, et al. **Ann Oncol** 1995;6 Suppl 1:49–54 (38 ref.)

Chemotherapy in non-small cell lung cancer. Thatcher N, et al. **Ann Oncol** 1995;6 Suppl 1:83–94; discussion 94–5 (97 ref.)

Vinorelbine: a new antineoplastic drug for the treatment of non-small-cell lung cancer. Jones SF, et al. **Ann Pharmacother** 1996 May;30(5):501–6 (29 ref.)

Current chemotherapy of advanced non-small cell lung cancer. Abratt RP. **Anticancer Drugs** 1995 Dec;6 Suppl 6:15–8 (29 ref.)

Docetaxel: meeting the challenge of non-small cell lung cancer management. Le Chevalier T. **Anticancer Drugs** 1995 Jul;6 Suppl 4:13–7 (23 ref.)

Phase II trials of single-agent activity of gemcitabine in patients with advanced non-small cell lung cancer: an overview. Shepherd FA. **Anticancer Drugs** 1995 Dec;6 Suppl 6:19–25 (13 ref.)

Symptomatic benefit from gemcitabine and other chemotherapy in advanced non-small cell lung cancer: changes in performance status and tumour-related symptoms. Thatcher N, et al. **Anticancer Drugs** 1995 Dec; 6 Suppl 6:39–48 (68 ref.)

Promising new agents in the treatment of non-small cell lung cancer. Edelman, MJ, et al. **Cancer Chemother Pharmacol** 1996;37(5):385–93 (96 ref.)

Aggressive vs nonaggressive therapy for metastatic NSCLC. Thatcher N, et al. **Chest** 1996 May;109(5 Suppl):87S–92S (52 ref.)

Camptothecin analogues in the treatment of non-small cell lung cancer. Ardizzoni A. **Lung Cancer** 1995 Apr;12 Suppl 1:S177–85 (19 ref.)

Scheduling of chemotherapy and radiotherapy in locally advanced non-small cell lung cancer. Bishop JF. **Lung Cancer** 1995 Jun;12 Suppl 2:S53–61 (52 ref.)

New chemotherapy agents in the treatment of advanced non-small cell lung cancer: an update including data from the Seventh World Conference on Lung Cancer. Comis RL, et al. **Lung Cancer** 1995 Jun;12 Suppl 2:S63–99 (163 ref.)

Trials with mitomycin, ifosfamide and cisplatin in non-small cell lung cancer. Cullen MH. **Lung Cancer** 1995 Apr;12 Suppl 1:S95–106 (12 ref.)

New drugs in non-small cell lung cancer. An overview. Giaccone G. **Lung Cancer** 1995 Apr;12 Suppl 1:S155–62 (35 ref.)

Edatrexate studies in non-small cell lung cancer. Gralla RJ. **Lung Cancer** 1995 Apr;12 Suppl 1:S187–91 (21 ref.)

Neoadjuvant chemotherapy of locally advanced non-small cell lung cancer. Pujol JL, et al. **Lung Cancer** 1995 Apr; 12 Suppl 1:S107–18 (46 ref.)

Gemcitabine in non-small cell lung cancer. Sørensen JB. **Lung Cancer** 1995 Apr;12 Suppl 1:S173–5 (8 ref.)

Combined-modality therapy for advanced non-small cell lung cancer: paclitaxel and thoracic irradiation. Choy H, et al. **Semin Oncol** 1995 Dec;22(6 Suppl 15):38–44 (41 ref.)

Update: vinorelbine (navelbine) in non-small cell lung cancer. Crawford J. **Semin Oncol** 1996 Apr;23(2 Suppl 5):2–7 (24 ref.)

Ifosfamide in non-small cell lung cancer. Johnson DH. **Semin Oncol** 1996 Jun;23(3 Suppl 6):7–10 (27 ref.)

Neoadjuvant chemotherapy in stage IIIa non-small cell lung cancer. Milroy R, et al. **Thorax** 1995 Sep;50 Suppl 1:S25–30 (54 ref.)

Resection of stage III non-small cell lung cancer following induction therapy. Rusch VW. **World J Surg** 1995 Nov-Dec;19(6):817–22 (35 ref.)

[Role of chemotherapy in non-small cell lung carcinoma] Giaccone G, et al. **Ned Tijdschr Geneeskd** 1996 May 25; 140(21):1111–4 (21 ref.) **(Dut)**

[Localized small-cell lung cancers: prospects of concomitant radiochemotherapy] Reboul F, et al. **Bull Cancer (Paris)** 1995 Dec;82(12):996–1004 (53 ref.) (Eng. Abstr.) **(Fre)**

[Role of hematopoietic growth factors in bronchial cancerology] Lemarié E, et al. **Rev Mal Respir** 1995; 12(5):429–34 (31 ref.) (Eng. Abstr.) **(Fre)**

[Value of chemotherapy in multi-modal treatment of non-small-cell bronchial carcinoma] Thomas M, et al. **Dtsch Med Wochenschr** 1995 Nov 24;120(47):1627–30 (25 ref.) **(Ger)**

[Chemotherapy of gastrointestinal carcinomas and non-small-cell pulmonary carcinoma: a controversy] Fey MF, et al. **Schweiz Med Wochenschr** 1996 May 18; 126(20):872–8 (26 ref.) (Eng. Abstr.) **(Ger)**

GENETICS

Pathways of chromosome alteration in human epithelial cancers. Dutrillaux B. **Adv Cancer Res** 1995;67:59–82 (80 ref.)

Molecular genetic tumor markers in the early diagnosis and screening of non-small-cell lung cancer. Jacobson DR, et al. **Ann Oncol** 1995;6 Suppl 3:S3–8 (44 ref.)

METABOLISM

Nuclear p53 overexpression is an independent prognostic parameter in node-negative non-small cell lung carcinoma. Dalquen P, et al. **J Pathol** 1996 Jan;178(1):53–8 (41 ref.)

PATHOLOGY

Lung pathology: the molecular genetics of non-small cell lung cancer. Fong KM, et al. **Pathology** 1995 Oct; 27(4):295–301 (161 ref.)

RADIOTHERAPY

Local irradiation alone for peripheral stage I lung cancer: could we omit the elective regional nodal irradiation? Krol AD, et al. **Int J Radiat Oncol Biol Phys** 1996 Jan 15; 34(2):297–302 (20 ref.)

Scheduling of chemotherapy and radiotherapy in locally advanced non-small cell lung cancer. Bishop JF. **Lung Cancer** 1995 Jun;12 Suppl 2:S53–61 (52 ref.)

Radiotherapy in non-small cell lung cancer: optimal doses and schedules. Schaake-Koning C. **Lung Cancer** 1995 Apr; 12 Suppl 1:S119–23 (17 ref.)

A palliative accelerated irradiation regimen (PAIR) for advanced non-small-cell lung cancer (NSCLC). Nestle U, et al. **Radiother Oncol** 1996 Mar;38(3):195–203 (48 ref.)

Combined-modality therapy for advanced non-small cell lung cancer: paclitaxel and thoracic irradiation. Choy H, et al. **Semin Oncol** 1995 Dec;22(6 Suppl 15):38–44 (41 ref.)

[Localized small-cell lung cancers: prospects of concomitant radiochemotherapy] Reboul F, et al. **Bull Cancer (Paris)** 1995 Dec;82(12):996–1004 (53 ref.) (Eng. Abstr.) **(Fre)**

SECONDARY

Long-term survival following surgical treatment of solitary brain metastasis in non-small cell lung cancer. Shahidi H, et al. **Chest** 1996 Jan;109(1):271–6 (53 ref.)

SURGERY

Long-term survival following surgical treatment of solitary brain metastasis in non-small cell lung cancer. Shahidi H, et al. **Chest** 1996 Jan;109(1):271–6 (53 ref.)

The messages from recently completed surgical trials on lung cancer. Goldstraw P, et al. **Eur J Surg Oncol** 1996 Feb; 22(1):1–4 (13 ref.)

Lung cancer surgery: questions for future trials. Rocmans PA. **Eur J Surg Oncol** 1996 Feb;22(1):9–12 (14 ref.)

New prognostic factors in resectable non-small cell lung cancer. Smit EF, et al. **Thorax** 1996 Jun;51(6):638–46 (95 ref.)

[New techniques in thoracic surgery. I] Andreassian B. **Presse Med** 1995 Jun 24;24(23):1078–83 (53 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Endobronchial treatment modalities in thoracic oncology [see comments] Baas P, et al. **Ann Oncol** 1995 Jul;6(6):523–31 (85 ref.) Comment in: Ann Oncol 1995 Nov;6(9):951–2.

Induction or concomitant chemotherapy and radiotherapy for non-small-cell lung cancer: myth or reality. Van Houtte P. **Ann Oncol** 1995;6 Suppl 3:S37–40 (21 ref.)

Multimodality therapy in stage III non-small cell lung cancer. Edelman MJ, et al. **Ann Thorac Surg** 1996 May; 61(5):1564–72 (60 ref.)

Biological treatment of NSCLC. The need for conclusive studies. Jassem J. **Chest** 1996 May;109(5 Suppl):119S–124S (61 ref.)

Ongoing clinical trials in lung cancer. Giaccone G, et al. **Eur J Surg Oncol** 1996 Feb;22(1):4–9 (24 ref.)

Locally advanced non-small cell lung cancer: do we know the questions? A survey of randomized trials from 1966–1993. Brundage MD, et al. **J Clin Epidemiol** 1996 Feb;49(2):183–92 (39 ref.)

Perioperative therapy for locoregional nonsmall-cell lung cancer. Takita H. **J Surg Oncol** 1996 May;62(1):65–74 (51 ref.)

Combined modality treatment for stage III non-small cell lung cancer. Bonomi P. **Lung Cancer** 1995 Jun;12 Suppl 2:S41–52 (44 ref.)

Biological response modifiers. Calabresi F, et al. **Lung Cancer** 1995 Apr;12 Suppl 1:S193–8 (28 ref.)

New chemotherapy agents in the treatment of advanced non-small cell lung cancer: an update including data from the Seventh World Conference on Lung Cancer. Comis RL, et al. **Lung Cancer** 1995 Jun;12 Suppl 2:S63–99 (163 ref.)

Neoadjuvant (induction) treatment for non-small cell lung cancer. Ginsberg RJ. **Lung Cancer** 1995 Jun;12 Suppl 2:S33–40 (22 ref.)

Multimodality therapy in unresected stage III non-small cell lung cancer: the American Cooperative Groups' Experience. Green MR. **Lung Cancer** 1995 Apr;12 Suppl 1:S87–94 (20 ref.)

An historical perspective of multi-modality treatment for resectable non-small cell lung cancer. Jaklitsch MT, et al. **Lung Cancer** 1995 Jun;12 Suppl 2:S17–32 (56 ref.)

Therapy of non-small cell lung cancer. Klastersky J. **Lung Cancer** 1995 Apr;12 Suppl 1:S133–45 (38 ref.)

Effectiveness and toxicity of preoperative therapy in stage IIIA non-small cell lung cancer including the Memorial Sloan-Kettering experience with induction MVP in patients with bulky mediastinal lymph node metastases (Clinical N2). Kris MG, et al. **Lung Cancer** 1995 Apr;12 Suppl 1:S47–57 (38 ref.)

Impact of chemotherapy on survival in locally advanced non-small cell lung cancer: the Gustave-Roussy experience. Le Cesne A, et al. **Lung Cancer** 1995 Apr;12 Suppl 1:S79–85 (25 ref.)

Future directions in non-small cell lung cancer. A personal view. Ruckdeschel JC. **Lung Cancer** 1995 Jun;12 Suppl 2:S147–52 (36 ref.)

Perioperative therapy of non-small cell lung cancer: a review of adjuvant and neoadjuvant approaches. Friedland DM, et al. **Semin Oncol** 1995 Dec;22(6):571–81 (41 ref.)

[The role of adjuvant therapy in the management of pN2 non-small-cell carcinoma of the lung] Chella A, et al. **Minerva Chir** 1995 Dec;50(12):1029–38 (40 ref.) (Eng. Abstr.) **(Ita)**

CARCINOMA, OAT CELL see **CARCINOMA, SMALL CELL**

CARCINOMA, PAPILLARY

Papillary thyroid carcinoma. Etiology, assessment, and therapy. Ain KB. **Endocrinol Metab Clin North Am** 1995 Dec;24(4):711–60 (350 ref.)

Management of papillary thyroid cancer. Vassilopoulou-Sellin R. **Oncology (Huntingt)** 1995 Feb; 9(2):145–51; discussion 151–2, 154, 157 (50 ref.)

[Papillary extrahepatic bile duct carcinoma, invasive papillary extrahepatic bile duct carcinoma] Nomoto S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):88–91 (12 ref.) **(Jpn)**

DIAGNOSIS

[Papillary carcinoma of the choroid plexus: apropos 3 cases] González San Segundo C, et al. **An Med Interna** 1996 May; 13(5):239–42 (22 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

[Complications of intravesical mitomycin chemotherapy, apropos of 2 clinical case reports] Pouya M, et al. **Acta Urol Belg** 1996 Mar;64(1):47–53 (24 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

[Papillary carcinoma on the site of a thyroglossal duct cyst: report of a case] Essakalli HL, et al. **Rev Laryngol Otol Rhinol (Bord)** 1995;116(3):213–6 (19 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Molecular analysis of mutations in thyroid tumors with

TGGE. Simon D, et al. **Exp Clin Endocrinol Diabetes** 1995; 103(5):275–9 (36 ref.)

IMMUNOLOGY

The immune response to papillary thyroid cancer [editorial; comment] Baker JR Jr. **J Clin Endocrinol Metab** 1995 Dec; 80(12):3419–20 (15 ref.) Comment on: J Clin Endocrinol Metab 1995 Dec;80(12):3421–4.

MORTALITY

[Survival potentials of patients with papillary carcinoma of the thyroid gland in Hungary] Esik O, et al. **Orv Hetil** 1996 May 19;137(20):1067–78 (50 ref.) (Eng. Abstr.) **(Hun)**

PATHOLOGY

Papillary carcinoma arising in a thyroglossal duct cyst: a case report and literature review. Hilger AW, et al. **J Laryngol Otol** 1995 Nov;109(11):1124–7 (15 ref.)

Controversies in the diagnosis and management of thyroid cancer. Thomas MJ. **J Otolaryngol** 1996 Feb;25(1):20–2 (11 ref.)

Papillary carcinoma of the thyroid gland with fibromatosis-like stroma: a case report and review of the literature. Mizukami Y, et al. **Mod Pathol** 1995 May; 8(4):366–70 (4 ref.)

Papillary thyroid cancer: a pediatric perspective. Flannery TK, et al. **Pediatrics** 1996 Sep;98(3 Pt 1):464–6 (23 ref.)

[Solid and papillary tumor of the pancreas] Spay G, et al. **Chirurgie** 1994–95;120(12):107–10 (33 ref.) (Eng. Abstr.) **(Fre)**

[Papillary carcinoma arising in thyroglossal duct cyst: a case report and review of the literature] Sorrenti G, et al. **Acta Otorhinolaryngol Ital** 1995 Dec;15(6):460–4 (40 ref.) (Eng. Abstr.) **(Ita)**

SURGERY

Concurrent papillary and squamous carcinoma in a thyroglossal duct cyst: a case report [see comments] Kwan WB, et al. **Can J Surg** 1996 Aug;39(4):328–32 (20 ref.) Comment in: Can J Surg 1996 Aug;39(4):263–4. Comment in: Can J Surg 1996 Aug;39(4):340.

The role of total thyroidectomy in the management of differentiated thyroid cancer. Stephenson BM, et al. **Curr Opin Gen Surg** 1994;:53–9 (61 ref.)

Optimal surgery for papillary thyroid carcinoma. Udelsman R, et al. **World J Surg** 1996 Jan;20(1):88–93 (65 ref.)

[Prospective therapy study in differentiated thyroid carcinoma] Gemsenjäger E, et al. **Schweiz Med Wochenschr** 1995 Nov 18;125(46):2226–36 (41 ref.) (Eng. Abstr.) **(Ger)**

[Thyroid carcinoma in hyperthyroid syndromes] Ragni F, et al. **G Chir** 1996 Apr;17(4):158–65 (26 ref.) (Eng. Abstr.) **(Ita)**

THERAPY

Treatment of vaginal recurrence in endometrial cancer. A review. Møller LA, et al. **Acta Obstet Gynecol Scand** 1996 Jan;75(1):1–7 (45 ref.)

Recent advances in the treatment of thyroid carcinoma [editorial] Wells SA Jr. **CA Cancer J Clin** 1996 Sep–Oct; 46(5):258–60 (16 ref.)

CARCINOMA, PAPILLARY, FOLLICULAR

PATHOLOGY

Composite follicular variant of papillary carcinoma and mucoepidermoid carcinoma of the thyroid. Report of a case and review of the literature. Miranda RN, et al. **Am J Surg Pathol** 1995 Oct;19(10):1209–15 (23 ref.)

[Current anatomopathological aspects of differentiated thyroid cancers of follicular (vesicular) origin: value and necessity of a common language] Franc B. **Ann Chir** 1995; 49(10):909–21 (65 ref.) (Eng. Abstr.) **(Fre)**

[Papillary carcinoma arising in thyroglossal duct cyst: a case report and review of the literature] Sorrenti G, et al. **Acta Otorhinolaryngol Ital** 1995 Dec;15(6):460–4 (40 ref.) (Eng. Abstr.) **(Ita)**

RADIOTHERAPY

Chronic myeloid leukaemia following 131I treatment for thyroid carcinoma: a report of two cases and review of the literature. Shimon I, et al. **Clin Endocrinol (Oxf)** 1995 Nov;43(5):651–4 (21 ref.)

CARCINOMA, PLANOCELLULAR see CARCINOMA, SQUAMOUS CELL

CARCINOMA, RENAL CELL

ABC of urology. Urological malignancy—III: Renal and testicular carcinoma. Dawson C, et al. **BMJ** 1996 May 4; 312(7039):1146–8 (4 ref.)

Renal-cell carcinoma. Motzer RJ, et al. **N Engl J Med** 1996 Sep 19;335(12):865–75 (150 ref.)

[Renal cell carcinoma. Significance of prognostic factors & current treatment] Fiori E, et al. **G Chir** 1995 Nov–Dec; 16(11–12):517–23 (108 ref.) (Eng. Abstr.) **(Ita)**

BLOOD SUPPLY

[Invasion, metastasis and angiogenesis of renal cell carcinoma] Tsukamoto T. **Nippon Hinyokika Gakkai Zasshi** 1996 Jan;87(1):1–12 (82 ref.) **(Jpn)**

COMPLICATIONS

[Tumors outside of the central nervous system in Von Hippel–Lindau disease] Veltman GA, et al. **Ned Tijdschr Geneeskd** 1996 Apr 13;140(15):823–6 (33 ref.) **(Dut)**

DIAGNOSIS

Observation of small incidentally detected renal masses. Bosniak MA. **Semin Urol Oncol** 1995 Nov;13(4):267–72 (18 ref.)

Diagnosis and prognosis of renal-cell tumors: a molecular approach. Wilhelm M, et al. **World J Urol** 1995;13(3):143–8 (17 ref.)

[A case of genitourinary double cancers detected by health screening] Ito T, et al. **Hinyokika Kiyo** 1996 Jun; 42(6):461–4 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Renal cell carcinoma in childhood: a case report] Sato T, et al. **Hinyokika Kiyo** 1996 Jun;42(6):439–41 (9 ref.) (Eng. Abstr.) **(Jpn)**

[Diagnosis and treatment of renal cell carcinoma accompanying the cystic lesion] Terachi T. **Hinyokika Kiyo** 1995 Sep;41(9):697–701 (12 ref.) (Eng. Abstr.) **(Jpn)**

[Lumbago-sciatica syndrome as the first manifestation of metastatic renal adenocarcinoma] Amat Cecilia M, et al. **Actas Urol Esp** 1996 Jan;20(1):54–8 (7 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Long-lasting complete remission of pulmonary metastases consequent to renal cell carcinoma obtained with interferon-beta therapy: review of the literature and a case report. Scoponi C, et al. **Tumori** 1995 May–Jun;81(3):201–3 (24 ref.)

ETIOLOGY

Renal cortical neoplasm in a child with dialysis-acquired cystic kidney disease. Gentle DL, et al. **Urology** 1996 Feb; 47(2):254–5 (5 ref.)

[Tumorigenesis of kidney tubule] Ishikawa I. **Nippon Rinsho** 1995 Aug;53(8):1900–7 (20 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Cytogenetic investigation of synchronous bilateral renal tumors. Dal Cin P, et al. **Cancer Genet Cytogenet** 1996 Jul 1;89(1):57–60 (25 ref.)

Von Hippel-Lindau disease and sporadic renal cell carcinoma. Zbar B. **Cancer Surv** 1995;25:219–32 (32 ref.)

Distinct Xp11.2 breakpoints in two renal cell carcinomas exhibiting X;autosome translocations. Dijkhuizen T, et al. **Genes Chromosomes Cancer** 1995 Sep;14(1):43–50 (20 ref.)

Familial renal cell carcinoma: review of recent molecular genetics. Yao M, et al. **Int J Urol** 1995 May;2(2):61–70 (134 ref.)

[Hippel-Lindau syndrome and sporadic renal cell carcinomas. Pathogenesis, morphologic spectrum and molecular genetics] Brauch H, et al. **Pathologe** 1995 Sep; 16(5):321–7 (41 ref.) (Eng. Abstr.) **(Ger)**

[Traditional and future criteria for progression in renal cell carcinoma. Molecular biology and clinical aspects] Pomer S, et al. **Urologe A** 1996 May;35(3):254–62 (57 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

Current management of renal cell carcinoma. Sokoloff MH, et al. **CA Cancer J Clin** 1996 Sep–Oct;46(5):284–302 (121 ref.)

Imaging in the staging of renal cell carcinoma. Reznek RH. **Eur Radiol** 1996;6(2):120–8 (61 ref.)

The role of ultrastructural pathology in the diagnosis of epithelial and unusual renal tumors. Herrera GA, et al. **Ultrastruct Pathol** 1996 Jan–Feb;20(1):7–26 (68 ref.)

[Double cancers of renal cell carcinoma and testicular seminoma: a case report] Nozawa M, et al. **Hinyokika Kiyo** 1995 Dec;41(12):999–1002 (17 ref.) (Eng. Abstr.) **(Jpn)**

SECONDARY

Single institution experience with recombinant gamma-interferon in the treatment of patients with metastatic renal cell carcinoma. Mani S, et al. **Am J Clin Oncol** 1996 Apr;19(2):149–53 (26 ref.)

Recombinant beta-interferon in the treatment of patients with metastatic renal cell carcinoma. Mani S, et al. **Am J Clin Oncol** 1996 Apr;19(2):187–9 (19 ref.)

Various features and surgical approach of solitary pancreatic metastasis from renal cell carcinoma. Fabre JM, et al. **Eur J Surg Oncol** 1995 Dec;21(6):683–6 (47 ref.)

Solitary pancreatic metastasis occurring eight years after nephrectomy for renal cell carcinoma. A case report and surgical review. Hirota T, et al. **Int J Pancreatol** 1996 Apr; 19(2):145–53 (63 ref.)

Solitary contralateral psoas metastasis 14 years after radical nephrectomy for organ confined renal cell carcinoma. Linn JF, et al. **J Urol** 1996 Jul;156(1):173 (2 ref.)

Late presentation of a solitary metastasis of renal cell carcinoma as an obstructive duodenal mass. Toh SK, et al. **Postgrad Med J** 1996 Mar;72(845):178–9 (10 ref.)

Metastatic renal cell carcinoma to ampulla of Vater: an unusual lesion amenable to surgical resection. Leslie KA, et al. **Surgery** 1996 Mar;119(3):349–51 (14 ref.)

Late solitary cerebral metastasis from renal cell carcinoma: a case report and review of the literature. Jubelirer SJ. **W V Med J** 1996 Jan–Feb;92(1):26–7 (28 ref.)

[A rare form of heart metastasis: hypernephroma. Successful surgical treatment] Minale C, et al. **Z Kardiol** 1995 Aug; 84(8):643–7 (7 ref.) (Eng. Abstr.) **(Ger)**

[Renal cell carcinoma with solitary asynchronous adrenal metastasis] Maeda Y, et al. **Hinyokika Kiyo** 1996 Jan; 42(1):39–42 (22 ref.) (Eng. Abstr.) **(Jpn)**

[A case of solitary metastasis from renal cell carcinoma to the thyroid gland] Muramoto M, et al. **Hinyokika Kiyo** 1996 Feb;42(2):123–5 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Invasion, metastasis and angiogenesis of renal cell carcinoma] Tsukamoto T. **Nippon Hinyokika Gakkai Zasshi** 1996 Jan;87(1):1–12 (82 ref.) **(Jpn)**

[The surgical opportunity in metastatic lesions of renal-cell carcinoma after a response to adjuvant immunotherapy] Olivier C, et al. **Actas Urol Esp** 1995 Mar;19(3):203–10 (27 ref.) (Eng. Abstr.) **(Spa)**

SURGERY

Nephrectomy for metastatic renal cell carcinoma and surgery for distant metastases. Van Poppel H, et al. **Acta Urol Belg** 1996 May;64(2):11–7 (45 ref.)

Laparoscopic extirpation of renal cell cancer: feasibility, questions, and concerns. Nakada SY, et al. **Semin Surg Oncol** 1996 Mar–Apr;12(2):100–12 (34 ref.)

Surgical technique and morbidity of elective partial nephrectomy. Campbell SC, et al. **Semin Urol Oncol** 1995 Nov;13(4):281–7 (27 ref.)

Rationale for total nephrectomy for suspected renal cell carcinoma. Marsh CL, et al. **Semin Urol Oncol** 1995 Nov; 13(4):273–80 (65 ref.)

Clinical experience with nephron-sparing surgery in the presence of a normal contralateral kidney. Steinbach F, et al. **Semin Urol Oncol** 1995 Nov;13(4):288–91 (18 ref.)

Current controversies in nephron-sparing surgery for renal-cell carcinoma. Steinbach F, et al. **World J Urol** 1995; 13(3):163–5 (29 ref.)

[Conservative surgery in cancer of the kidney] Ferrière JM, et al. **Presse Med** 1995 Oct 28;24(32):1507–8 (10 ref.) (Eng. Abstr.) **(Fre)**

[The surgical opportunity in metastatic lesions of renal-cell carcinoma after a response to adjuvant immunotherapy] Olivier C, et al. **Actas Urol Esp** 1995 Mar;19(3):203–10 (27 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

Metastatic renal cell carcinoma: systemic treatment. Abi-Aad AS, et al. **Acta Urol Belg** 1996 May;64(2):3–8 (26 ref.)

Recombinant beta-interferon in the treatment of patients with metastatic renal cell carcinoma. Mani S, et al. **Am J Clin Oncol** 1996 Apr;19(2):187–9 (19 ref.)

Single institution experience with recombinant gamma-interferon in the treatment of patients with metastatic renal cell carcinoma. Mani S, et al. **Am J Clin Oncol** 1996 Apr;19(2):149–53 (26 ref.)

Medical treatment of advanced renal cell carcinoma: present options and future directions. Canobbio L, et al. **Cancer Treat Rev** 1996 Mar;22(2):85–104 (123 ref.)

Gene therapy on renal-cell carcinoma: magic bullet or tragic insanity? Mickisch GH. **World J Urol** 1995;13(3):178–85 (37 ref.)

ULTRASTRUCTURE

The role of ultrastructural pathology in the diagnosis of epithelial and unusual renal tumors. Herrera GA, et al. **Ultrastruct Pathol** 1996 Jan–Feb;20(1):7–26 (68 ref.)

CARCINOMA, RESERVE CELL see CARCINOMA, SMALL CELL

CARCINOMA, ROUND CELL see CARCINOMA, SMALL CELL

CARCINOMA, SIGNET RING CELL

Primary signet ring cell carcinoma of the urinary bladder. Review of the literature and report of two cases. Erdoğru T, et al. **Urol Int** 1995;55(1):34–7 (23 ref.)

[Signet ring cell carcinoma of the intrahepatic bile duct] Saito K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):395–7 (14 ref.) **(Jpn)**

BLOOD

Marked elevation of plasma carcinoembryonic antigen and stomach carcinoma. Horie Y, et al. **Cancer** 1996 May 15; 77(10):1991–7 (21 ref.)

CARCINOMA, SIGNET RING CELL

COMPLICATIONS

[A case of gastric cancer associated with esophageal-hiatus hernia presenting with upside down stomach] Satoh K, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Jan;93(1):26-9 (12 ref.) **(Jpn)**

PATHOLOGY

Signet ring cell carcinoma in hyperplastic polyp. Zea-Iriarte WL, et al. **Scand J Gastroenterol** 1995 Jun;30(6):604-8 (26 ref.)

[A case of signet-ring cell gastric cancer appearing an elevated type] Takahashi N, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Jan;93(1):30-3 (17 ref.) **(Jpn)**

SECONDARY

Tonsillar metastasis from adenocarcinoma of the stomach. Benito I, et al. **J Laryngol Otol** 1996 Mar;110(3):291-3 (15 ref.)

CARCINOMA, SKIN APPENDAGE

PATHOLOGY

Microcystic adnexal carcinoma. Case report and review of the literature. Billingsley EM, et al. **Arch Otolaryngol Head Neck Surg** 1996 Feb;122(2):179-82 (20 ref.)

Pathologic quiz case 1. Microcystic adnexal carcinoma (MAC). Hunt JT, et al. **Arch Otolaryngol Head Neck Surg** 1995 Dec;121(12):1430-3 (27 ref.)

[Microcystic adnexal carcinoma of the skin. An underestimated tumor] Rank C, et al. **Hautarzt** 1996 Apr; 47(4):284-8 (31 ref.) (Eng. Abstr.) **(Ger)**

CARCINOMA, SMALL CELL

see related
CARCINOMA, NON-SMALL-CELL LUNG

Small cell lung cancer: biological and therapeutic aspects. Kristensen CA, et al. **Crit Rev Oncol Hematol** 1996 Jan; 22(1):27-60 (373 ref.)

Small cell carcinoma of the bladder and prostate. Abbas F, et al. **Urology** 1995 Nov;46(5):617-30 (114 ref.)

[Oat cell carcinoma of the gallbladder] Todoroki T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):251-5 (11 ref.) **(Jpn)**

COMPLICATIONS

Clinical characteristics of synchronous multiple lung cancer associated with idiopathic pulmonary fibrosis. A review of Japanese cases [see comments] Mizushima Y, et al. **Chest** 1995 Nov;108(5):1272-7 (37 ref.) Comment in: Chest 1995 Nov;108(5):1193-4.

[Paraneoplastic syndromes of the nervous system and muscles during the course of small cell lung carcinoma] Joachimowicz-Jaśkowiak E. **Pneumonol Pol** 1990 Nov-Dec;58(11-12):647-50 (21 ref.) **(Pol)**

DIAGNOSIS

A case of small cell carcinoma of the uterine cervix presenting Cushing's syndrome. Hashi A, et al. **Gynecol Oncol** 1996 Jun;61(3):427-31 (14 ref.)

[Desmoplastic small round cell tumors in adults: a new entity] Farhat F, et al. **Bull Cancer (Paris)** 1995 Aug;82(8):665-73 (39 ref.) (Eng. Abstr.) **(Fre)**

[Small cell tumor of the uterine neck] Emerich J, et al. **Ginekol Pol** 1996 Apr;67(4):215-20 (28 ref.) (Eng. Abstr.) **(Pol)**

DRUG THERAPY

The importance of dose and schedule in chemotherapy for small cell lung cancer. Ranson M, et al. **Anticancer Drugs** 1995 Oct;6 Suppl 5:53-63 (112 ref.)

New drugs for the management of lung cancer. Giaccone G. **Br J Hosp Med** 1996 May 15-Jun 4;55(10):634-8 (45 ref.)

Long-term follow-up of a randomised trial of combined chemoradiotherapy induction treatment, with and without maintenance chemotherapy in patients with small cell carcinoma of the lung. Beith JM, et al. **Eur J Cancer** 1996 Mar;32A(3):438-43 (21 ref.)

Colony-stimulating factors as an adjunct to chemotherapy in small cell lung cancer. Urban T, et al. **Eur Respir J** 1996 Mar;9(3):596-602 (66 ref.)

Carboplatin/etoposide combination chemotherapy in the treatment of poor prognosis patients with small cell lung cancer. Carney DN. **Lung Cancer** 1995 Jun;12 Suppl 3:S77-83 (10 ref.)

New drugs for treating small cell lung cancer. Ettinger DS. **Lung Cancer** 1995 Jun;12 Suppl 3:S53-61 (20 ref.)

Oral therapy for small cell lung cancer. Postmus PE, et al. **Lung Cancer** 1995 Jun;12 Suppl 3:S63-70 (29 ref.)

Combined platinum etoposide with radiation therapy in limited stage small cell lung cancer: an effective treatment strategy. Turrisi AT 3rd. **Lung Cancer** 1995 Jun;12 Suppl 3:S41-51 (26 ref.)

Ifosfamide in the treatment of small cell lung cancer. Ettinger DS. **Semin Oncol** 1996 Jun;23(3 Suppl 6):2-6 (20 ref.)

The role of ifosfamide in small cell lung cancer. Loehrer PJ Sr. **Semin Oncol** 1996 Jun;23(3 Suppl 7):40-4 (29 ref.)

[Therapeutic role of coagulation in small cell lung cancers] LeBeau B. **Rev Mal Respir** 1996;13(1):21-6 (41 ref.) (Eng. Abstr.) **(Fre)**

[Role of hematopoietic growth factors in bronchial cancerology] Lemarié E, et al. **Rev Mal Respir** 1995; 12(5):429-34 (31 ref.) (Eng. Abstr.) **(Fre)**

[Chemotherapy of small cell lung cancer] Komiya T, et al. **Gan To Kagaku Ryoho** 1996 Aug;23(9):1116-23 (36 ref.) (Eng. Abstr.) **(Jpn)**

EPIDEMIOLOGY

Small cell carcinoma of gallbladder: report of two cases. Muraina OI, et al. **Am J Gastroenterol** 1996 Apr;91(4):792-4 (9 ref.)

GENETICS

Biology of small cell lung cancer. Johnson BE, et al. **Lung Cancer** 1995 Jun;12 Suppl 3:S5-16 (88 ref.)

IMMUNOLOGY

Immunopathology of the Lambert-Eaton myasthenic syndrome. Lang B, et al. **Springer Semin Immunopathol** 1995;17(1):3-15 (69 ref.)

PATHOLOGY

Extrapulmonary small cell cancer. Vrouvas J, et al. **Clin Oncol (R Coll Radiol)** 1995;7(6):377-81 (59 ref.)

Immunopathology of the Lambert-Eaton myasthenic syndrome. Lang B, et al. **Springer Semin Immunopathol** 1995;17(1):3-15 (69 ref.)

[False Merkel cell tumor of the gingival mucosa disclosed by small cell bronchial carcinoma] Paume P, et al. **Rev Stomatol Chir Maxillofac** 1995;96(6):352-5 (14 ref.) (Eng. Abstr.) **(Fre)**

RADIOGRAPHY

Imaging of small cell carcinoma of the oesophagus. Fenlon HM, et al. **Clin Radiol** 1995 Sep;50(9):634-8 (33 ref.)

Carboplatin/etoposide combination chemotherapy in the treatment of poor prognosis patients with small cell lung cancer. Carney DN. **Lung Cancer** 1995 Jun;12 Suppl 3:S77-83 (10 ref.)

Roentgenographically occult small-cell lung cancer: case report and review of the literature. Sekine I, et al. **Mayo Clin Proc** 1996 May;71(5):481-4 (15 ref.)

Small-cell carcinoma of the esophagus: radiographic findings. Levine MS, et al. **Radiology** 1996 Jun;199(3):703-5 (18 ref.)

RADIONUCLIDE IMAGING

Imaging and staging of small-cell lung cancer: is there a future role for octreotide scintigraphy? Stokkel MP, et al. **Br J Clin Pract** 1995 Sep-Oct;49(5):235-8 (41 ref.)

RADIOTHERAPY

Long-term follow-up of a randomised trial of combined chemoradiotherapy induction treatment, with and without maintenance chemotherapy in patients with small cell carcinoma of the lung. Beith JM, et al. **Eur J Cancer** 1996 Mar;32A(3):438-43 (21 ref.)

Combined platinum etoposide with radiation therapy in limited stage small cell lung cancer: an effective treatment strategy. Turrisi AT 3rd. **Lung Cancer** 1995 Jun;12 Suppl 3:S41-51 (26 ref.)

SECONDARY

Pineal and suprasellar metastasis of lung cancer: case report and review of the literature. Izumihara A, et al. **Comput Med Imaging Graph** 1995 Sep-Oct;19(5):435-7 (14 ref.)

Prophylactic cranial irradiation in small cell lung cancer--an update. Kristjansen PE, et al. **Lung Cancer** 1995 Jun;12 Suppl 3:S23-40 (82 ref.)

SURGERY

The role of surgery in small cell carcinoma of the lung (SCLC). Holmes EC. **Lung Cancer** 1995 Jun;12 Suppl 3:S17-21 (9 ref.)

[New techniques in thoracic surgery. I] Andreassian B. **Presse Med** 1995 Jun 24;24(23):1078-83 (53 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Extensive-disease small-cell lung cancer: the thrill of victory; the agony of defeat. Aisner J. **J Clin Oncol** 1996 Feb; 14(2):658-65 (70 ref.)

Future directions in the management of small cell lung cancer. Johnson DH. **Lung Cancer** 1995 Jun;12 Suppl 3:S71-5 (39 ref.)

[Mega-dose chemotherapy with peripheral blood stem cell transplantation (PBS-CT) for small cell lung cancer (SCLC)] Chou T, et al. **Gan To Kagaku Ryoho** 1995 Oct; 22(12):1741-8 (14 ref.) (Eng. Abstr.) **(Jpn)**

ULTRASTRUCTURE

[Primary microcytoma of the larynx. Case report, ultrastructural study and review of the literature] Nirchio V, et al. **Pathologica** 1995 Apr;87(2):171-4 (17 ref.) (Eng. Abstr.) **(Ita)**

CARCINOMA, SMALL CELL LUNG see **CARCINOMA, SMALL CELL**

CARCINOMA, SPINDLE-CELL see **CARCINOMA**

CARCINOMA, SQUAMOUS see **CARCINOMA, SQUAMOUS CELL**

CARCINOMA, SQUAMOUS CELL

Second primary malignancies in the head and neck cancer patient. Sturgis EM, et al. **Ann Otol Rhinol Laryngol** 1995 Dec;104(12):946-54 (97 ref.)

ABC of Urology. Urological malignancy--II: Urothelial tumours. Dawson C, et al. **BMJ** 1996 Apr 27; 312(7038):1090-4 (0 ref.)

Lip cancer: a review. Awde JD, et al. **J Can Dent Assoc** 1996 Aug;62(8):634-6 (22 ref.)

Cancer of the tongue [see comments] Leong IT, et al. **J Can Dent Assoc** 1995 Sep;61(9):792-6 (28 ref.) Comment in: J Can Dent Assoc 1995 Nov;61(11):922, 944.

Hypopharyngeal carcinoma. Mansfield EL, et al. **J La State Med Soc** 1995 Nov;147(11):489-92 (12 ref.)

Squamous cell carcinoma. Marks R. **Lancet** 1996 Mar 16; 347(9003):735-8 (30 ref.)

Squamous cell carcinoma in the ovary of a 14-year-old girl. Khanfar NM, et al. **Mayo Clin Proc** 1996 Apr;71(4):380-3 (22 ref.)

Vulvar squamous cell carcinoma. Ansink A. **Semin Dermatol** 1996 Mar;15(1):51-9 (103 ref.)

[Cancer of the anal canal] Gérard JP, et al. **Bull Cancer Radiother** 1990;77(1):23-31 (41 ref.) **(Fre)**

[Prognostic factors in squamous cell carcinoma of the head and neck] Horiuchi M, et al. **Gan To Kagaku Ryoho** 1996 Jun;23(7):949-56 (42 ref.) (Eng. Abstr.) **(Jpn)**

[Squamous cell carcinoma of the extrahepatic bile duct] Funakawa T, et al. **Ryoikibetsu Shokogun Shirizu** 1996; (9):61-3 (21 ref.) **(Jpn)**

[Squamous cell carcinoma of the intrahepatic bile duct] Saito K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):417-9 (15 ref.) **(Jpn)**

[Adenosquamous cell carcinoma of the gallbladder] Shimoi K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):314-7 (21 ref.) **(Jpn)**

[Squamous cell carcinoma of the gallbladder] Shimoi K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):338-40 (16 ref.) **(Jpn)**

[Anal cancer. A review] Tanum G. **Tidsskr Nor Laegeforen** 1996 May 20;116(13):1567-70 (31 ref.) (Eng. Abstr.) **(Nor)**

BLOOD SUPPLY

[The significance of invasion and vessel permeation in squamous cell carcinoma of the uterine cervix with invasion to a depth of 3 mm or less] Otsuka I, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Nov; 47(11):1261-7 (26 ref.) (Eng. Abstr.) **(Jpn)**

CHEMICALLY INDUCED

Arsenic in Dermatology. Maloney ME. **Dermatol Surg** 1996 Mar;22(3):301-4 (31 ref.)

COMPLICATIONS

Acute renal failure secondary to solid tumor renal metastases: case report and review of the literature. Manning EC, et al. **Am J Kidney Dis** 1996 Feb;27(2):284-91 (30 ref.)

Squamous cell carcinoma in thyroglossal duct cyst. Deshpande A, et al. **J Laryngol Otol** 1995 Oct; 109(10):1001-4 (13 ref.)

Carcinoma of the uterine cervix presenting as superior vena cava syndrome: report of three cases and a review of literature. Biswal BM, et al. **J Obstet Gynaecol** 1995 Oct; 21(5):437-42 (13 ref.)

[Paraneoplastic pyoderma gangrenosum (letter)] Bayle-Lebey P, et al. **Ann Med Interne (Paris)** 1995; 146(8):585-7 (12 ref.) **(Fre)**

[Squamous cell carcinoma of the renal pelvis associated with renal stones in a patient with chronic renal failure: a case report and a review of the Japanese literature] Nakamura Y, et al. **Hinyokika Kiyo** 1996 Jun;42(6):451-5 (13 ref.) (Eng. Abstr.) **(Jpn)**

[Squamous cell carcinoma of the lung associated with palmo-plantar hyperkeratosis] Nomori H, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Jan;34(1):76-9 (15 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Squamous cell carcinoma-associated antigens used in novel strategies for the detection and treatment of minimal residual head and neck cancer. van Dongen GA, et al. **Anticancer Res** 1996 Jul-Aug;16(4C):2409-13 (41 ref.)

Early diagnosis of asymptomatic oral and oropharyngeal squamous cancers. Mashberg A, et al. **CA Cancer J Clin** 1995 Nov-Dec;45(6):328-51 (58 ref.)

Nonmelanoma skin cancer. Epstein JH. **Compr Ther** 1996 Mar;22(3):179–82 (17 ref.)
Multimodality imaging of cervical adenopathies. Giron J, et al. **Eur J Radiol** 1996 Feb;21(3):159–66 (21 ref.)
Diagnosis of head and neck cancer. Hilal EY. **J Med Liban** 1994;42(4):212–5 (12 ref.)
Metastatic squamous cell carcinoma of the hand and review of the literature. Foley SJ, et al. **J R Army Med Corps** 1995 Jun;141(2):102–4 (8 ref.)
[Sellar metastases simulating the Tolosa–Hunt syndrome] Aprile I, et al. **Radiol Med (Torino)** 1996 Mar;91(3):311–3 (9 ref.) **(Ita)**
[Clinico–pathological predictive indicators in squamous cell carcinoma of the head and neck] Horiuchi M. **Gan To Kagaku Ryoho** 1996 Feb;23(3):257–64 (28 ref.) (Eng. Abstr.) **(Jpn)**
[Primary intracranial malignant epidermoid—case report] Fuse T, et al. **No To Shinkei** 1995 Oct;47(10):997–1001 (14 ref.) (Eng. Abstr.) **(Jpn)**

DIET THERAPY

[Prevention of second primary cancer with vitamin supplementation in patients treated for head and neck cancers] Bairati I, et al. **Bull Cancer Radiother** 1996; 83(1):12–6 (37 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

Chemotherapy in locally advanced head and neck cancer: a critical reappraisal. Jassem J, et al. **Cancer Treat Rev** 1995 Sep;21(5):447–62 (106 ref.)
Prolonged continuous infusion cisplatin and 5–fluorouracil with radiation for locally advanced carcinoma of the vulva. Eifel PJ, et al. **Gynecol Oncol** 1995 Oct;59(1):51–6 (22 ref.)
Primary squamous cell carcinoma of the endometrium: a first report of adjuvant chemoradiation. Kennedy AS, et al. **Gynecol Oncol** 1995 Oct;59(1):117–23 (61 ref.)
Preoperative concomitant radiochemotherapy in squamous cell carcinoma of the esophagus: results of a study of 56 patients. Malhaire JP, et al. **Int J Radiat Oncol Biol Phys** 1996 Jan 15;34(2):429–37 (52 ref.)
Mechanisms of resistance of human tumours to anticancer drugs of the platinum family: a review. Ferguson PJ. **J Otolaryngol** 1995 Aug;24(4):242–52 (100 ref.)
The platinum compounds and paclitaxel in the management of carcinomas of the endometrium and uterine cervix. Thigpen T, et al. **Semin Oncol** 1995 Oct;22(5 Suppl 12):67–75 (25 ref.)
[Concomitant radiochemotherapy with cisplatin (CDDP), 5–fluorouracil (5–FU) and mitomycin C (MMC) in locally advanced carcinoma of the oropharynx. Results of a phase II trial] Berger C, et al. **Bull Cancer (Paris)** 1995 Dec; 82(12):1044–51 (38 ref.) (Eng. Abstr.) **(Fre)**
[Is there a place for chemotherapy in the initial treatment of cervical cancer? Review of the literature] Lhommé C, et al. **Bull Cancer (Paris)** 1996 Apr;83(4):276–92 (67 ref.) (Eng. Abstr.) **(Fre)**
[Current knowledge on the action of retinoids in carcinoma of the head and neck] Dolivet G, et al. **Rev Laryngol Otol Rhinol (Bord)** 1996;117(1):19–26 (34 ref.) (Eng. Abstr.) **(Fre)**
[An elderly case of squamous cell lung cancer showing partial response by daily administration of oral etoposide] Fukabori T, et al. **Gan To Kagaku Ryoho** 1996 Aug; 23(9):1187–90 (12 ref.) (Eng. Abstr.) **(Jpn)**
[Chemotherapy of head and neck cancer] Kohno N, et al. **Gan To Kagaku Ryoho** 1996 Feb;23(3):277–82 (33 ref.) (Eng. Abstr.) **(Jpn)**

EPIDEMIOLOGY

The changing epidemiology of smoking and lung cancer histology. Wynder EL, et al. **Environ Health Perspect** 1995 Nov;103 Suppl 8:143–8 (67 ref.)
Hereditary and environmental risk factors; clinical and laboratory risk matters for head and neck, especially oral, cancer and precancer. Johnson NW, et al. **Eur J Cancer Prev** 1996 Feb;5(1):5–17 (139 ref.)
Human bladder cancer: evidence for a potential irritation–induced mechanism. Burin GJ, et al. **Food Chem Toxicol** 1995 Sep;33(9):785–95 (86 ref.)
The epidemiology of non–melanoma skin cancer: who, why and what can we do about it. Marks R. **J Dermatol** 1995 Nov;22(11):853–7 (27 ref.)
Risk of dysplasia in anal condyloma. Metcalf AM, et al. **Surgery** 1995 Oct;118(4):724–6 (14 ref.)
[Are skin tumors on the increase?] Böni R, et al. **Schweiz Med Wochenschr** 1995 Sep 2;125(35):1619–24 (50 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Human bladder cancer: evidence for a potential irritation–induced mechanism. Burin GJ, et al. **Food Chem Toxicol** 1995 Sep;33(9):785–95 (86 ref.)
Laryngeal squamous carcinoma associated with longstanding localised amyloidosis. A case report. Navani SS, et al. **Indian J Cancer** 1995 Mar;32(1):43–5 (7 ref.)
Squamous cell carcinoma complicating perianal hidradenitis suppurativa. Pérez–Diaz D, et al. **Int J Colorectal Dis** 1995; 10(4):225–8 (23 ref.)
[P53 protein and human papillomavirus oncogenes in carcinogenesis of the uterine cervix] Toledo–Cuevas EM, et al. **Rev Invest Clin** 1996 Jan–Feb;48(1):59–68 (42 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

Genomic instability in squamous cell carcinoma of the head and neck. Field JK. **Anticancer Res** 1996 Jul–Aug; 16(4C):2421–31 (122 ref.)
Transgenic mice and squamous multistage skin carcinogenesis. Brown K, et al. **Cancer Metastasis Rev** 1995 Jun;14(2):113–24 (112 ref.)
Molecular alterations in head and neck squamous cell carcinoma. Bron L, et al. **Clin Otolaryngol** 1995 Aug; 20(4):291–8 (86 ref.)
Molecular changes in oral cancer may reflect aetiology and ethnic origin. Paterson IC, et al. **Eur J Cancer B Oral Oncol** 1996 May;32B(3):150–3 (60 ref.)
Hereditary and environmental risk factors; clinical and laboratory risk matters for head and neck, especially oral, cancer and precancer. Johnson NW, et al. **Eur J Cancer Prev** 1996 Feb;5(1):5–17 (139 ref.)
[A familial form of epidermoid carcinoma of the conjunctiva] Lam A, et al. **J Fr Ophtalmol** 1996;19(2):143–8 (25 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Causes of immunosuppression in squamous cell carcinoma of the head and neck. Wustrow TP, et al. **Anticancer Res** 1996 Jul–Aug;16(4C):2433–68 (714 ref.)
[Tumor–rejection antigens expressed on human squamous cell carcinoma] Itoh K, et al. **Hum Cell** 1995 Dec;8(4):149–54 (7 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

AFP–producing squamous cell carcinoma of the lung in an adolescent. Asamura H, et al. **Jpn J Clin Oncol** 1996 Apr; 26(2):103–6 (12 ref.)

PATHOLOGY

The minimally abnormal Papanicolaou smear. Brotzman GL, et al. **Am Fam Physician** 1996 Mar;53(4):1154–62 (39 ref.)
Basaloid squamous cell carcinoma of the head and neck: clinicopathological features and differential diagnosis. Barnes L, et al. **Ann Otol Rhinol Laryngol** 1996 Jan; 105(1):75–82 (40 ref.)
Mucosal adenoid squamous cell carcinoma of the head and neck. Ferlito A, et al. **Ann Otol Rhinol Laryngol** 1996 May; 105(5):409–13 (18 ref.)
Patterns of recurrence in squamous cell carcinoma of the anal canal. Luna–Pérez P, et al. **Arch Med Res** 1995 Autumn;26(3):213–9 (20 ref.)
Porocarcinoma of the heel. A case report with unusual histologic features. D'Amato MS, et al. **Cancer** 1996 Aug 15;78(4):751–7 (27 ref.)
Invasive periorbital squamous cell carcinoma [letter] Lopez–Avila A, et al. **Clin Exp Dermatol** 1995 Jul; 20(4):358–9 (4 ref.)
The pathology of cervical cancer. Walsh CB, et al. **Clin Obstet Gynecol** 1995 Sep;38(3):653–61 (16 ref.)
Molecular alterations in head and neck squamous cell carcinoma. Bron L, et al. **Clin Otolaryngol** 1995 Aug; 20(4):291–8 (86 ref.)
Benign to malignant progression in cervical squamous epithelium. Ehrmann RL. **Compr Ther** 1996 Feb; 22(2):67–75 (43 ref.)
The pathology of vulvar neoplasia. Lininger RA, et al. **Curr Opin Obstet Gynecol** 1996 Feb;8(1):63–8 (28 ref.)
Prognostic factors in squamous cell cancer of the vulva and the implications for treatment. van der Velden J, et al. **Curr Opin Obstet Gynecol** 1996 Feb;8(1):3–7 (36 ref.)
The many faces of squamous cell carcinoma. Bernstein SC, et al. **Dermatol Surg** 1996 Mar;22(3):243–54 (99 ref.)
Multiple malignant melanoma and squamous–cell carcinoma in a burn scar. Ikeda I, et al. **Dermatology** 1995; 191(4):328–32 (20 ref.)
Squamous cell carcinoma arising from mature cystic teratoma: a report of three cases. Bontis J, et al. **Eur J Gynaecol Oncol** 1996;17(1):49–52 (20 ref.)
Squamous cell carcinoma of the endometrium: a report of eight cases and a review of the literature. Goodman A, et al. **Gynecol Oncol** 1996 Apr;61(1):54–60 (55 ref.)
Vulvar Merkel cell tumor with glandular and squamous differentiation. Scurry J, et al. **Gynecol Oncol** 1996 Aug; 62(2):292–7 (15 ref.)
Cell adhesion and regulatory molecules involved in tumor formation, hemostasis, and wound healing. Van Waes C. **Head Neck** 1995 Mar–Apr;17(2):140–7 (18 ref.)
Squamous cell carcinoma of the penis. Micali G, et al. **J Am Acad Dermatol** 1996 Sep;35(3 Pt 1):432–51 (219 ref.)
Intraoral sebaceous carcinoma. Abuzeid M, et al. **J Laryngol Otol** 1996 May;110(5):500–2 (27 ref.)
Laryngeal carcinoma ex–papilloma in a non–irradiated, non–smoking patient: a clinical record and review of the literature. Hasan S, et al. **J Laryngol Otol** 1995 Aug; 109(8):762–6 (33 ref.)
Malignant and premalignant change in odontogenic cysts. Fanibunda K, et al. **J Oral Maxillofac Surg** 1995 Dec; 53(12):1469–72 (19 ref.)
Management of a carcinoma of the tongue during pregnancy: report of case. Lasaridis N, et al. **J Oral Maxillofac Surg** 1996 Feb;54(2):221–4 (16 ref.)
p53–positive squamous cell carcinoma originating from an odontogenic cyst. McDonald AR, et al. **J Oral Maxillofac Surg** 1996 Feb;54(2):216–8 (9 ref.)
Simultaneous malignant melanoma and squamous cell carcinoma of the oral cavity: a case report. Nakahara H, et al. **J Oral Maxillofac Surg** 1995 Dec;53(12):1455–7 (12 ref.)
Squamous cell carcinoma arising in association with an orthokeratinized odontogenic keratocyst. Report of a case. Yoshida H, et al. **J Oral Maxillofac Surg** 1996 May; 54(5):647–51 (25 ref.)
Carcinoma of the tongue in a long–term survivor of clear cell sarcoma of the kidney. Ferbend P, et al. **Pediatr Pathol Lab Med** 1995 Mar–Apr;15(2):327–32 (22 ref.)
Squamous cell carcinoma of the tongue in a child with Fanconi anemia: a case report and review of the literature. Somers GR, et al. **Pediatr Pathol Lab Med** 1995 Jul–Aug; 15(4):597–607 (62 ref.)
Primary squamous cell carcinoma of the breast. Weigel RJ, et al. **South Med J** 1996 May;89(5):511–5 (33 ref.)
[Papillary carcinoma arising in thyroglossal duct cyst: a case report and review of the literature] Sorrenti G, et al. **Acta Otorhinolaryngol Ital** 1995 Dec;15(6):460–4 (40 ref.) (Eng. Abstr.) **(Ita)**
[Reevaluation of precancerous lesion of squamous cell carcinoma] Sumiyoshi K, et al. **Gan To Kagaku Ryoho** 1995 Dec;22(14):2038–42 (16 ref.) (Eng. Abstr.) **(Jpn)**
[Primary squamous cell carcinoma of the prostate: a case report] Okamoto T, et al. **Hinyokika Kiyo** 1996 Jan; 42(1):67–70 (12 ref.) (Eng. Abstr.) **(Jpn)**
[Double–primary cancer of the lung and trachea] Kishiro I, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Feb; 34(2):216–9 (13 ref.) (Eng. Abstr.) **(Jpn)**
[The significance of invasion and vessel permeation in squamous cell carcinoma of the uterine cervix with invasion to a depth of 3 mm or less] Otsuka I, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Nov; 47(11):1261–7 (26 ref.) (Eng. Abstr.) **(Jpn)**

RADIOGRAPHY

Radiology of the central airways. Worrell JA. **Otolaryngol Clin North Am** 1995 Aug;28(4):701–20 (23 ref.)

RADIOTHERAPY

Pre versus post–operative radiotherapy of resectable squamous cell carcinoma of the head and neck. Wennerberg J. **Acta Otolaryngol (Stockh)** 1995 Jul;115(4):465–74 (63 ref.)
Spontaneous rupture of the urinary bladder: a late complication of radiotherapy—case report and review of the literature. Addar MH, et al. **Gynecol Oncol** 1996 Aug; 62(2):314–6 (16 ref.)
Prolonged continuous infusion cisplatin and 5–fluorouracil with radiation for locally advanced carcinoma of the vulva. Eifel PJ, et al. **Gynecol Oncol** 1995 Oct;59(1):51–6 (22 ref.)
Primary squamous cell carcinoma of the endometrium: a first report of adjuvant chemoradiation. Kennedy AS, et al. **Gynecol Oncol** 1995 Oct;59(1):117–23 (61 ref.)
Squamous cell carcinoma of the pharyngeal walls treated with radiotherapy. Chang L, et al. **Int J Radiat Oncol Biol Phys** 1996 Jun 1;35(3):477–83 (16 ref.)
Preoperative concomitant radiochemotherapy in squamous cell carcinoma of the esophagus: results of a study of 56 patients. Malhaire JP, et al. **Int J Radiat Oncol Biol Phys** 1996 Jan 15;34(2):429–37 (52 ref.)
Basal cell carcinoma due to radiotherapy for carcinoma of the cervix. Copas P, et al. **South Med J** 1995 Nov; 88(11):1161–2 (12 ref.)
[Concomitant radiochemotherapy with cisplatin (CDDP), 5–fluorouracil (5–FU) and mitomycin C (MMC) in locally advanced carcinoma of the oropharynx. Results of a phase II trial] Berger C, et al. **Bull Cancer (Paris)** 1995 Dec; 82(12):1044–51 (38 ref.) (Eng. Abstr.) **(Fre)**
[ORL brachytherapy. Brachytherapy of epidermoid carcinoma of the oral cavity] Haie–Meder C, et al. **Bull Cancer Radiother** 1995;82(2):186–90 (42 ref.) **(Fre)**
[ORL brachytherapy. Brachytherapy of squamous cell carcinoma of the oropharynx] Hoffstetter S. **Bull Cancer Radiother** 1995;82(2):191–8 (53 ref.) **(Fre)**
[ORL brachytherapy. Focus on brachytherapy for squamous cell carcinoma of the oral cavity and pharynx] Mazeron JJ. **Bull Cancer Radiother** 1995;82(2):179–85 (68 ref.) **(Fre)**
[Time factor and curietherapy: the example of epidermoid carcinoma of the mobile tongue] Mazeron JJ, et al. **Bull Cancer Radiother** 1990;77(1):15–22 (34 ref.) (Eng. Abstr.) **(Fre)**
[Place of iridium 192 implantation in irradiation of T1–T2 squamous cell carcinoma of the velopharyngeal arch] Mazeron JJ, et al. **Bull Cancer Radiother** 1996;83(1):47–53 (43 ref.) (Eng. Abstr.) **(Fre)**
[Value of the combination of external radiotherapy and curietherapy in carcinoma of the velo–tonsillar region. Statistical study of a series of 361 patients] Pernot M, et al. **Bull Cancer Radiother** 1996;83(1):40–6 (32 ref.) (Eng. Abstr.) **(Fre)**

SECONDARY

Acute renal failure secondary to solid tumor renal metastases: case report and review of the literature. Manning EC, et al. **Am J Kidney Dis** 1996 Feb;27(2):284–91 (30 ref.)
Skin metastases from a laryngeal carcinoma: report of a case. Debois JM. **Cutis** 1996 Apr;57(4):264–6 (14 ref.)
Cutaneous metastases from squamous cell carcinoma of the vulva. A case report and review of the literature. Tobias DH, et al. **Eur J Gynaecol Oncol** 1995;16(5):382–6 (8 ref.)
Recurrent squamous cell carcinoma in a rectus abdominis neovagina. Carlson JW, et al. **Gynecol Oncol** 1995 Oct; 59(1):159–61 (17 ref.)
Intradural metastasis to the cauda equina from carcinoma of the anus. Cho DY, et al. **Spine** 1995 Nov 1;20(21):2341–4 (15 ref.)
[Sellar metastases simulating the Tolosa–Hunt syndrome] Aprile I, et al. **Radiol Med (Torino)** 1996 Mar;91(3):311–3 (9 ref.) **(Ita)**
[A case of breast metastasis of esophageal squamous cell carcinoma] Meloni GB, et al. **Radiol Med (Torino)** 1996 Jun;91(6):812–4 (7 ref.) **(Ita)**

SURGERY

Pre versus post-operative radiotherapy of resectable squamous cell carcinoma of the head and neck. Wennerberg J. **Acta Otolaryngol (Stockh)** 1995 Jul;115(4):465–74 (63 ref.)
Concurrent papillary and squamous carcinoma in a thyroglossal duct cyst: a case report [see comments] Kwan WB, et al. **Can J Surg** 1996 Aug;39(4):328–32 (20 ref.) Comment in: Can J Surg 1996 Aug;39(4):263–4. Comment in: Can J Surg 1996 Aug;39(4):340.
Primary squamous cell carcinoma of the endometrium. Aikins JK, et al. **Int J Gynaecol Obstet** 1995 Jul;50(1):55–60 (32 ref.)
Management of carcinoma of the supraglottic larynx: evolution, current concepts, and future trends. Myers EN, et al. **Laryngoscope** 1996 May;106(5 Pt 1):559–67 (46 ref.)
Primary intracranial squamous cell carcinomas: report of two cases. Nishio S, et al. **Neurosurgery** 1995 Aug;37(2):329–32 (35 ref.)
Can the morbidity of esophagectomy be reduced by the thoracoscopic approach? Gossot D, et al. **Surg Endosc** 1995 Oct;9(10):1113–5 (14 ref.)
[The musculus pectoralis major rib flap. Personal experiences with 7 cases] Koch A, et al. **Chirurg** 1996 Mar;67(3):273–7 (26 ref.) (Eng. Abstr.) **(Ger)**
-Therapy of vulvar carcinoma in the early stages- Gitsch G. **Geburtshilfe Frauenheilkd** 1996 Feb;56(2):63–9 (66 ref.) (Eng. Abstr.) **(Ger)**
[Therapy of preinvasive vulvar neoplasia--standardized or individual?] Schnürch HG, et al. **Zentralbl Gynakol** 1996; 118(6):345–9 (30 ref.) (Eng. Abstr.) **(Ger)**
[Resection of the posterior mediastinal gastric tube used in reconstruction after radical surgery for esophageal cancer--case reports] Hashimoto M, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Jul;43(7):1016–22 (19 ref.) (Eng. Abstr.) **(Jpn)**
[A simultaneous operation for esophageal and cholangiocellular carcinomas--a case of report] Kudo T, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Oct; 92(10):1789–93 (12 ref.) **(Jpn)**

THERAPY

Sites of failure and times to failure in carcinoma of the vulva treated conservatively: a Gynecologic Oncology Group study. Stehman FB, et al. **Am J Obstet Gynecol** 1996 Apr; 174(4):1128–32; discussion 1132–3 (5 ref.)
Radiotherapy-chemotherapy combinations in head and neck squamous cell carcinoma: overview of randomized trials. Bourhis J, et al. **Anticancer Res** 1996 Jul–Aug; 16(4C):2397–402 (78 ref.)
Predicting response to therapy of squamous cell carcinoma of the head and neck (review). Wennerberg J. **Anticancer Res** 1996 Jul–Aug;16(4C):2389–96 (90 ref.)
Concurrent radiation therapy and chemotherapy followed by esophagectomy for localized esophageal carcinoma. Bates BA, et al. **J Clin Oncol** 1996 Jan;14(1):156–63 (48 ref.)
Unknown primary of the head and neck. Talmi YP, et al. **J Laryngol Otol** 1996 Apr;110(4):353–6 (12 ref.)
Head and neck cancer: state of the art. Atiyah RA. **J Med Liban** 1994;42(4):216–20 (22 ref.)
Retropharyngeal abscess after radiation therapy and cis-platinum, 5-fluorouracil treatment for nasopharyngeal carcinoma with collagen disease: report of two patients and a review of the literature. Hareyama M, et al. **Jpn J Clin Oncol** 1996 Jun;26(3):189–93 (15 ref.)
Cancer of the uterine cervix. Cannistra SA, et al. **N Engl J Med** 1996 Apr 18;334(16):1030–8 (100 ref.)
[Malignant tumors of the petrous bone. Apropos of 25 cases] Depondt J, et al. **Ann Otolaryngol Chir Cervicofac** 1995; 112(7):309–16 (11 ref.) (Eng. Abstr.) **(Fre)**
[Statistical study of a series of 672 cases of carcinoma of the uterine cervix. Results and complications according to age and modalities of treatment] Pernot M, et al. **Bull Cancer (Paris)** 1995 Jul;82(7):568–81 (66 ref.) (Eng. Abstr.) **(Fre)**
[Comparison of concomitant radiotherapy and chemotherapy with radiotherapy alone in advanced cancers of the head and neck: results of a randomized trial] Haddad E, et al. **Bull Cancer Radiother** 1996;83(2):97–103 (35 ref.) (Eng. Abstr.) **(Fre)**
[Retrospective study of 136 cases of epidermoid carcinoma of the base of the tongue treated at the Alexis Vautrin Centre 1978–1992] Hoffstetter S, et al. **Bull Cancer Radiother** 1996;83(2):90–6 (11 ref.) (Eng. Abstr.) **(Fre)**
[Current perspectives in the treatment of epidermoid cancer of the esophagus (editorial)] Lozach P. **Presse Med** 1995 Jun 24;24(23):1059–61 (10 ref.) (Eng. Abstr.) **(Fre)**

ULTRASONOGRAPHY

[Contribution of echography in the detection of lymph node diseases in epidermoid carcinoma of the larynx: therapeutic implications] Heitzmann P, et al. **Ann Otolaryngol Chir Cervicofac** 1995;112(5):229–33 (15 ref.) (Eng. Abstr.) **(Fre)**

VETERINARY

Feline cutaneous and subcutaneous neoplasms. Fox LE. **Vet Clin North Am Small Anim Pract** 1995 Jul;25(4):961–79 (138 ref.)

VIROLOGY

Recurrent laryngeal papillomatosis developing into laryngeal carcinoma with human papilloma virus (HPV) type 18: a case report. Sakakura A, et al. **J Laryngol Otol** 1996 Jan; 110(1):75–7 (18 ref.)
Do human papillomaviruses have a role in the pathogenesis of bladder carcinoma? Mvula M, et al. **J Urol** 1996 Feb; 155(2):471–4 (24 ref.)

CARCINOMA, THYMIC see THYMOMA

CARCINOMA, TRANSITIONAL CELL

ABC of Urology. Urological malignancy--II: Urothelial tumours. Dawson C, et al. **BMJ** 1996 Apr 27; 312(7038):1090–4 (0 ref.)
Transitional cell carcinoma of the bladder in the pediatric patient. Hoenig DM, et al. **J Urol** 1996 Jul;156(1):203–5 (23 ref.)
[Urachal adenocarcinoma associated with urothelial tumor of the bladder. Report of a case] Payen E, et al. **Prog Urol** 1996 Apr;6(2):288–91 (13 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

[Cerebral metastasis as the form of presentation of a basaloid carcinoma of the esophagus] Carvalho IR, et al. **Acta Med Port** 1995 Sep;8(9):505–9 (9 ref.) (Eng. Abstr.) **(Por)**
[Transitional-cell sarcomatoid carcinoma of the renal pelvis with osteoclast-type giant cells. Review of the literature] Meseguer García P, et al. **Actas Urol Esp** 1996 Jan; 20(1):63–7 (26 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Chemotherapy for advanced bladder carcinoma: new molecules and regimens. Abi-Aad AS. **Acta Urol Belg** 1996 May;64(2):43–5 (19 ref.)
Cisplatin-based chemotherapy in renal transplant recipients. A case report and a review of the literature. Benisovich VI, et al. **Cancer** 1996 Jan 1;77(1):160–3 (22 ref.)
The role of chemotherapy in the management of the patient with T3b bladder cancer. Millikan R, et al. **Semin Urol Oncol** 1996 May;14(2):81–5 (23 ref.)
[Complications of intravesical mitomycin chemotherapy, apropos of 2 clinical case reports] Pouya M, et al. **Acta Urol Belg** 1996 Mar;64(1):47–53 (24 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Recent advances in the study of molecular biology of bladder cancer in China. Gu F. **Chin Med J (Engl)** 1996 Feb; 109(2):126–9 (26 ref.)
Familial transitional cell carcinoma [see comments] Kiemeney LA, et al. **J Urol** 1996 Sep;156(3):867–72 (73 ref.) Comment in: J Urol 1996 Sep;156(3):961.

PATHOLOGY

Basaloid squamous cell carcinoma of the head and neck: clinicopathological features and differential diagnosis. Barnes L, et al. **Ann Otol Rhinol Laryngol** 1996 Jan; 105(1):75–82 (40 ref.)
What is the biology of invasion and metastasis in bladder cancer? Kakizoe T, et al. **Int J Urol** 1995 Jun;2 Suppl 2:58–63 (57 ref.)
[Transitional cell carcinoma of the ureter and cyclophosphamide: apropos of a case] Ponsot Y, et al. **Prog Urol** 1995 Sep;5(4):578–9 (8 ref.) (Eng. Abstr.) **(Fre)**

RADIOTHERAPY

Radiotherapy for stage T3b transitional cell carcinoma of the bladder. Pollack A, et al. **Semin Urol Oncol** 1996 May; 14(2):86–95 (63 ref.)

SECONDARY

Annular constriction of the rectum secondary to transitional cell carcinoma of the bladder. Langenstroer P, et al. **Urology** 1996 Mar;47(3):442–4 (6 ref.)
[Asynchronous metastases solely to the bilateral adrenal glands from bladder cancer: a case report] Watanabe J, et al. **Hinyokika Kiyo** 1996 Jan;42(1):63–6 (7 ref.) (Eng. Abstr.) **(Jpn)**
[Cerebral metastasis as the form of presentation of a basaloid carcinoma of the esophagus] Carvalho IR, et al. **Acta Med Port** 1995 Sep;8(9):505–9 (9 ref.) (Eng. Abstr.) **(Por)**
[Skin metastasis from transitional cell carcinoma of the bladder] Alvarez Castelo LM, et al. **Arch Esp Urol** 1995 Sep;48(7):749–50 (9 ref.) (Eng. Abstr.) **(Spa)**

SURGERY

Laparoscopic approaches to transitional cell carcinomas of the upper urinary tract. Patel A, et al. **Semin Surg Oncol** 1996 Mar–Apr;12(2):113–20 (12 ref.)
Bladder preservation and continent urinary diversion in T3b transitional cell carcinoma of the bladder. Cespedes RD, et al. **Semin Urol Oncol** 1996 May;14(2):103–11 (56 ref.)
Radical cystectomy for stage T3b bladder cancer. Hall CM, et al. **Semin Urol Oncol** 1996 May;14(2):73–80 (33 ref.)
The use of neobladders in women undergoing cystectomy for transitional-cell cancer. Stenzl A, et al. **World J Urol** 1996;14(1):15–21 (37 ref.)
[Prognostic factors of survival in infiltrating urothelial bladder carcinoma. A retrospective study of 158 patients treated by radical cystectomy] Thieblemont C, et al. **Bull Cancer (Paris)** 1996 Feb;83(2):139–46 (35 ref.) (Eng. Abstr.) **(Fre)**
[Definitive endourological treatment in urothelial tumors of the upper urinary tract] Rodríguez Rodríguez R, et al. **Arch Esp Urol** 1995 Nov;48(9):937–43 (41 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

Carcinoma in situ and treatment options. Erton M, et al. **Int Urol Nephrol** 1996;28(1):33–42 (25 ref.)
BCG immunotherapy for transitional-cell carcinoma in situ of the bladder. Lamm DL. **Oncology (Huntingt)** 1995 Oct; 9(10):947–52, 955, discussion 955–65 (51 ref.)

VIROLOGY

Do human papillomaviruses have a role in the pathogenesis of bladder carcinoma? Mvula M, et al. **J Urol** 1996 Feb; 155(2):471–4 (24 ref.)

CARCINOMA, TUBULAR see ADENOCARCINOMA

CARCINOMA, UNDIFFERENTIATED see CARCINOMA

CARCINOMA, VERRUCOUS

Verrucous carcinoma of the bladder. Blackmore CC, et al. **Abdom Imaging** 1995 Sep–Oct;20(5):480–2 (8 ref.)
Verrucous carcinoma of the mouth. Jordan RC. **J Can Dent Assoc** 1995 Sep;61(9):797–801 (34 ref.)

PATHOLOGY

Verrucous carcinoma of the renal pelvis: case presentation and review of the literature. Sheaff M, et al. **Virchows Arch** 1996 Aug;428(6):375–9 (22 ref.)

SURGERY

Long-term survival in a patient with verrucous carcinoma of the esophagus. Malik AB, et al. **Am J Gastroenterol** 1996 May;91(5):1031–3 (29 ref.)

VIROLOGY

[A Buschke and Lowenstein tumor in a female patient] Reichenbach I, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(5):491–5 (16 ref.) (Eng. Abstr.) **(Fre)**

CARCINOMATOSIS see CARCINOMA

CARCINOSARCOMA

DIAGNOSIS

[Bladder carcinosarcoma. A clinical case] Pena Outeiriño JM, et al. **Actas Urol Esp** 1995 Mar;19(3):234–7 (11 ref.) (Eng. Abstr.) **(Spa)**

PATHOLOGY

Carcinosarcoma of the urinary bladder--case report and literature review. Swaminathan I, et al. **Ann Acad Med Singapore** 1995 Jul;24(4):640–3 (15 ref.)
Carcinosarcoma arising in eccrine spiradenoma of the breast. Report of a case and review of the literature. Saboorian MH, et al. **Arch Pathol Lab Med** 1996 May;120(5):501–4 (19 ref.)

CARDENOLIDES

ADVERSE EFFECTS

Oleander toxicity: an examination of human and animal toxic exposures. Langford SD, et al. **Toxicology** 1996 May 3; 109(1):1–13 (76 ref.)

CARDIA

SURGERY

Oesophageal substitution. Isolauri J. **Ann Chir Gynaecol** 1995; 84(2):241–6 (30 ref.)

CARDIAC ARREST see **HEART ARREST**

CARDIAC ARREST, INDUCED see **HEART ARREST, INDUCED**

CARDIAC COMPLEXES, PREMATURE

DIAGNOSIS

[Intrauterine diagnosis and therapy of fetal arrhythmias] Gembruch U, et al. **Gynakologe** 1995 Oct;28(5):329–45 (69 ref.) **(Ger)**

CARDIAC DEPRESSANTS see **ANTI-ARRHYTHMIA AGENTS**

CARDIAC ELECTROVERSION see **ELECTRIC COUNTERSHOCK**

CARDIAC GLYCOSIDES

ADVERSE EFFECTS

Oleander toxicity: an examination of human and animal toxic exposures. Langford SD, et al. **Toxicology** 1996 May 3; 109(1):1–13 (76 ref.)

CHEMICAL SYNTHESIS

[Synthesis of lactone ring-containing bioactive natural products. Cardiotonic steroids, naphthoquinone antibiotics, and tetronic acid ionophore antibiotics] Yoshii E. **Yakugaku Zasshi** 1996 Jan;116(1):1–20 (45 ref.) (Eng. Abstr.) **(Jpn)**

CARDIAC HYPERTROPHY see **HEART HYPERTROPHY**

CARDIAC NEUROSIS see **NEUROCIRCULATORY ASTHENIA**

CARDIAC OUTPUT

Noninvasive measurement of cardiac output. Wilson AF. **Cardiologia** 1995 Aug;40(8):551–9 (77 ref.)

PHYSIOLOGY

The thermodilution method for the clinical assessment of cardiac output. Jansen JR. **Intensive Care Med** 1995 Aug; 21(8):691–7 (44 ref.)

Cardiac output in normal pregnancy: a critical review. van Oppen AC, et al. **Obstet Gynecol** 1996 Feb;87(2):310–8 (81 ref.)

CARDIAC OUTPUT, LOW

DIAGNOSIS

[Pharmacologic tests in cardiac decompensation] Perini G, et al. **G Ital Cardiol** 1995 Dec;25(12):1635–41 (25 ref.) **(Ita)**

DRUG THERAPY

Inotropic agents in the treatment of postoperative low cardiac output syndrome. Husedžinović I, et al. **Acta Med Croatica** 1995;49(4–5):201–5 (55 ref.)

Is it safe to prescribe digoxin after acute myocardial infarction? Update on continued controversy [editorial] Leor J, et al. **Am Heart J** 1995 Dec;130(6):1322–6 (47 ref.)

ACE inhibitors for the prevention and treatment of heart failure: why are they under-used? Cleland JG. **J Hum Hypertens** 1995 Jun;9(6):435–42 (47 ref.)

Angiotensin II receptor blockers: novel therapy for heart failure? Munger MA, et al. **Pharmacotherapy** 1996 Mar–Apr;16(2 Pt 2):59S–68S (86 ref.)

Evolving role of calcium channel blockers in heart failure. Pieper JA. **Pharmacotherapy** 1996 Mar–Apr;16(2 Pt 2):43S–49S (26 ref.)

Evolving concepts in the treatment of heart failure: should new inotropic agents carry promise or paranoia? Young JB. **Pharmacotherapy** 1996 Mar–Apr;16(2 Pt 2):78S–84S (25 ref.)

ETIOLOGY

Delayed right heart failure following lung transplantation. Kirshbom PM, et al. **Chest** 1996 Feb;109(2):575–7 (9 ref.)

Pathophysiology of heart failure: changing perceptions. Patterson JH, et al. **Pharmacotherapy** 1996 Mar–Apr;16(2 Pt 2):27S–36S (26 ref.)

METABOLISM

Mineralocorticoid receptor blockade in chronic heart failure. Struthers AD. **J Hum Hypertens** 1995 Jun;9(6):443–6 (21 ref.)

Calcium transport proteins in the nonfailing and failing heart: gene expression and function. Wankerl M, et al. **J Mol Med** 1995 Oct;73(10):487–96 (92 ref.)

PATHOLOGY

Molecular and cellular biology of the senescent hypertrophied and failing heart. Swynghedauw B, et al. **Am J Cardiol** 1995 Nov 2;76(13):2D–7D (21 ref.)

PHYSIOPATHOLOGY

Cellular mechanisms of contractile dysfunction in human heart failure. Davies CH, et al. **Eur Heart J** 1996 Feb; 17(2):189–98 (137 ref.)

Pathophysiology of heart failure: changing perceptions. Patterson JH, et al. **Pharmacotherapy** 1996 Mar–Apr;16(2 Pt 2):27S–36S (26 ref.)

PREVENTION & CONTROL

ACE inhibitors for the prevention and treatment of heart failure: why are they under-used? Cleland JG. **J Hum Hypertens** 1995 Jun;9(6):435–42 (47 ref.)

THERAPY

[Circulatory assistance in cardiac decompensation: when and how] Gavazzi A, et al. **G Ital Cardiol** 1995 Dec; 25(12):1627–33 (20 ref.) **(Ita)**

[Treatment of acute heart failure up-to-date] Tanaka K, et al. **Nippon Ika Daigaku Zasshi** 1996 Jun;63(3):233–7 (5 ref.) **(Jpn)**

ULTRASONOGRAPHY

[Use of contrast echocardiography in coronary insufficiency] Morcerf FA. **Arq Bras Cardiol** 1995 Apr;64(4):373–82 (66 ref.) **(Por)**

CARDIAC PACEMAKER, ARTIFICIAL see **PACEMAKER, ARTIFICIAL**

CARDIAC PACING, ARTIFICIAL

see related
PACEMAKER, ARTIFICIAL

Implantable cardioverter-defibrillator: present and future indications. Block M, et al. **Arch Mal Coeur Vaiss** 1996 Feb;89 Spec No 1:141–7 (61 ref.)

New indications for permanent cardiac pacing. Alagona P Jr. **Curr Opin Cardiol** 1996 Jan;11(1):9–15 (53 ref.)

Cost benefit analysis of single and dual chamber pacing for sick sinus syndrome and atrioventricular block. An economic sensitivity analysis of the literature [see comments] Sutton R, et al. **Eur Heart J** 1996 Apr; 17(4):574–82 (46 ref.) Comment in: Eur Heart J 1996 Apr;17(4):495–6.

Cardiac pacing during neurocardiogenic (vasovagal) syncope. Sra JS, et al. **J Cardiovasc Electrophysiol** 1995 Sep;6(9):751–60 (45 ref.)

Cardiac pacing [see comments] Kusumoto FM, et al. **N Engl J Med** 1996 Jan 11;334(2):89–97 (53 ref.) Comment in: N Engl J Med 1996 May 30;334(22):1476–7.

[Permanent cardiac pacing. Present possibilities and perspectives] Novák M. **Cas Lek Cesk** 1996 Jun 12; 135(12):367–73 (59 ref.) (Eng. Abstr.) **(Cze)**

[Transient entrainment of tachycardia] Grolleau R, et al. **Arch Mal Coeur Vaiss** 1995 Dec;88 Spec No 5:63–70 (33 ref.) (Eng. Abstr.) **(Fre)**

METHODS

Antitachycardia pacing: an overview. Horwood L, et al. **Am J Crit Care** 1995 Sep;4(5):397–404 (10 ref.)

Pacing and atrial fibrillation. Kerr CR, et al. **Can J Cardiol** 1996 Jan;12 Suppl A:36A–39A (31 ref.)

Issues in cardiac pacing: optimising pacemaker therapy [editorial] Gambhir DS. **Indian Heart J** 1996 Mar–Apr; 48(2):115–7 (32 ref.)

[New indications for cardiac pacing] Davy JM, et al. **Arch Mal Coeur Vaiss** 1995 Dec;88 Spec No 5:55–62 (43 ref.) (Eng. Abstr.) **(Fre)**

[Value of cardiac pacing in hypertrophic obstructive cardiomyopathy refractory to medical treatment] Gras D, et al. **Arch Mal Coeur Vaiss** 1995 Apr;88(4 Suppl):577–83 (20 ref.) (Eng. Abstr.) **(Fre)**

[The esophageal approach in rhythmology] Mabo P, et al. **Arch Mal Coeur Vaiss** 1995 Dec;88 Spec No 5:43–7 (29 ref.) (Eng. Abstr.) **(Fre)**

[Acute and chronic sequential atrioventricular pacing in patients with obstructive-type hypertrophic myocardiopathy resistant to medical therapy] Rodrigues JC, et al. **Rev Port Cardiol** 1995 Sep;14(9):637–41 (22 ref.) (Eng. Abstr.) **(Por)**

CARDIAC RUPTURE see **HEART RUPTURE**

CARDIAC RUPTURE, TRAUMATIC see **HEART INJURIES**

CARDIAC STIMULANTS see **CARDIOTONIC AGENTS**

CARDIAC SUDDEN DEATH see **DEATH, SUDDEN, CARDIAC**

CARDIAC TAMPONADE

DIAGNOSIS

Pericardial effusion and tamponade: evaluation, imaging modalities, and management. Chong HH, et al. **Compr Ther** 1995 Jul;21(7):378–85 (35 ref.)

Cardiac tamponade as the initial presentation of bronchioloalveolar cell carcinoma. Hourany J, et al. **Tenn Med** 1996 Jul;89(7):247–8 (12 ref.)

ETIOLOGY

Tension pneumopericardium following blunt injury. Capizzi PJ, et al. **J Trauma** 1995 Oct;39(4):775–80 (80 ref.)

[Mediastinal malignant schwannoma disclosed by pericardial tamponade in von Recklinghausen disease] Soulami S, et al. **Ann Cardiol Angeiol (Paris)** 1995 Oct;44(8):418–21 (11 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Pericardial effusion and tamponade: evaluation, imaging modalities, and management. Chong HH, et al. **Compr Ther** 1995 Jul;21(7):378–85 (35 ref.)

Cardiovascular shock. Rodgers KG. **Emerg Med Clin North Am** 1995 Nov;13(4):793–810 (61 ref.)

CARDIAC TRANSPLANTATION see **HEART TRANSPLANTATION**

CARDIAC VOLUME

PHYSIOLOGY

[Trans-thoracic 3D echocardiography reconstruction for left ventricular volume determination] Kupferwasser I, et al. **Herz** 1995 Aug;20(4):243–51 (53 ref.) (Eng. Abstr.) **(Ger)**

CARDIOLIPINS

see related
ANTIBODIES, ANTICARDIOLIPIN
ANTIPHOSPHOLIPID SYNDROME

CARDIOLOGY

see related
CARDIOVASCULAR DISEASES
HEART DISEASES
VASCULAR DISEASES

Solving nomenclature problems in cardiology. II. Updating terminology in clinical cardiology. Constant J. **Cardiology** 1995;86(5):361–4 (9 ref.)

Digital storage and transmission of cardiovascular images: what are the costs, benefits and timetable for conversion? Thomas JD, et al. **Heart** 1996 Jul;76(1):13–7 (13 ref.)

Artificial neural networks: current status in cardiovascular medicine. Itchhaporia D, et al. **J Am Coll Cardiol** 1996 Aug;28(2):515–21 (39 ref.)

[Prevention of coronary disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension] Pyörälä K, et al. **Cardiologia** 1996 Feb;41(2):149–82 (192 ref.) **(Ita)**

[How to read a scientific article? 5. How to choose a treatment?] Demichelis B, et al. **G Ital Cardiol** 1995 Oct; 25(10):1339–50 (55 ref.) **(Ita)**

TRENDS

Currently available hypolipidaemic drugs and future therapeutic developments. Farmer JA, et al. **Baillieres Clin Endocrinol Metab** 1995 Oct;9(4):825–47 (59 ref.)

Evolution of blockade of the renin-angiotensin system. Johnston CI, et al. **J Hum Hypertens** 1995 Jun;9(6):375–80 (46 ref.)

Recent advances in cardiology. Forman DE, et al. **Med Health R I** 1996 May;79(5):165–74 (67 ref.)

CARDIOLOGY SERVICE, HOSPITAL

STANDARDS

27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 8. Organization of preventive cardiology service. Pearson TA, et al. **J Am Coll Cardiol** 1996 Apr;27(5):1039–47 (71 ref.)

CARDIOMYOPATHIES see **MYOCARDIAL DISEASES**

CARDIOMYOPATHY, ALCOHOLIC

ETIOLOGY

[Cardiovascular impact of alcoholism] Faintuch JJ. **Rev Hosp Clin Fac Med Sao Paulo** 1995 Jan-Feb;50(1):76-9 (47 ref.) (Eng. Abstr.) **(Por)**

PHYSIOPATHOLOGY

Protein synthesis in the heart in vivo, its measurement and patho-physiological alterations. Preedy VR, et al. **Int J Cardiol** 1995 Jun 30;50(2):95-106 (48 ref.)

CARDIOMYOPATHY, CHAGAS see CHAGAS CARDIOMYOPATHY

CARDIOMYOPATHY, CONGESTIVE

Peripartum cardiomyopathy. Lampert MB, et al. **Am Heart J** 1995 Oct;130(4):860-70 (80 ref.)

DIAGNOSIS

Dilated cardiomyopathy. Burch M, et al. **Arch Dis Child** 1996 Jun;74(6):479-81 (20 ref.)

[Clinical aspects and follow-up in dilated cardiomyopathy] Grünig E, et al. **Z Kardiol** 1995;84 Suppl 4:39-40 (78 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Immunosuppressive treatment for myocarditis and dilated cardiomyopathy. Maisch B, et al. **Eur Heart J** 1995 Dec; 16 Suppl O:153-61 (81 ref.)

[Dilated cardiomyopathy--diagnosis and conservative therapy] Fruhwald FM, et al. **Acta Med Austriaca** 1995; 22(5):90-3 (27 ref.) (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

The epidemiology of infectious myocarditis, lymphocytic myocarditis and dilated cardiomyopathy. Friman G, et al. **Eur Heart J** 1995 Dec;16 Suppl O:36-41 (85 ref.)

ETIOLOGY

Tachycardiomyopathy: mechanisms and clinical implications. Fenelon G, et al. **Pacing Clin Electrophysiol** 1996 Jan; 19(1):95-106 (76 ref.)

GENETICS

Molecular and clinical aspects of inherited cardiomyopathies. Durand JB, et al. **Ann Med** 1995 Jun;27(3):311-7 (38 ref.)

A carrier of Duchenne muscular dystrophy with dilated cardiomyopathy but no skeletal muscle symptom. Kinoshita H, et al. **Brain Dev** 1995 May-Jun;17(3):202-5 (11 ref.)

[Genetics of dilated cardiomyopathies] Mestroni L, et al. **G Ital Cardiol** 1995 Nov;25(11):1469-73 (23 ref.) **(Ita)**

PHYSIOPATHOLOGY

Cell death in the failing heart: role of an unnatural growth response to overload. Katz AM. **Clin Cardiol** 1995 Sep;18(9 Suppl 4):IV36-44 (129 ref.)

RADIONUCLIDE IMAGING

Non-invasive detection of myocyte necrosis in myocarditis and dilated cardiomyopathy with radiolabelled antimyosin. Khaw BA, et al. **Eur Heart J** 1995 Dec;16 Suppl O:119-23 (16 ref.)

SURGERY

Intraoperative transoesophageal echocardiography for implantation of a pulsatile left ventricular assist device. George SJ, et al. **Br J Anaesth** 1995 Dec;75(6):794-7 (9 ref.)

THERAPY

Can we treat dilated cardiomyopathy using a left ventricular assist device? [editorial] Tayama E, et al. **Artif Organs** 1996 Mar;20(3):197-201 (57 ref.)

Immunomodulating agents for the management of heart failure with myocarditis and cardiomyopathy--lessons from animal experiments. Matsumori A, et al. **Eur Heart J** 1995 Dec;16 Suppl O:140-3 (10 ref.)

Shifting the paradigm for the treatment of dilated cardiomyopathy. Sole MJ. **Eur Heart J** 1995 Dec;16 Suppl O:176-9 (25 ref.)

[Post-partum cardiomyopathy: medical aspects, role of heart transplantation] Bertrand E. **Arch Mal Coeur Vaiss** 1995 Nov;88(11):1635-40 (42 ref.) (Eng. Abstr.) **(Fre)**

[New indications for cardiac pacing] Davy JM, et al. **Arch Mal Coeur Vaiss** 1995 Dec;88 Spec No 5:55-62 (43 ref.) (Eng. Abstr.) **(Fre)**

VIROLOGY

The role of transgenic knockout models in defining the pathogenesis of viral heart disease. Liu P, et al. **Eur Heart J** 1995 Dec;16 Suppl O:25-7 (28 ref.)

Genetics of coxsackievirus B cardiovirulence and inflammatory heart muscle disease. Tracy S, et al. **Trends Microbiol** 1996 May;4(5):175-9 (38 ref.)

CARDIOMYOPATHY, DILATED see CARDIOMYOPATHY, CONGESTIVE

CARDIOMYOPATHY, HYPERTROPHIC

Myocardial hypertrophy--Part II. Brink AJ, et al. **S Afr Med J** 1996 Apr;86 Suppl 2:C104-10 (52 ref.)

[Cardiomyopathies (VII). Natural history of hypertrophic cardiomyopathy] Sáenz de la Calzada C, et al. **Rev Esp Cardiol** 1996 Mar;49(3):214-25 (86 ref.) (Eng. Abstr.) **(Spa)**

CHEMICALLY INDUCED

[Hypertrophic cardiomyopathy in a low-birth-weight newborn treated with dexamethasone] Villa Alcázar M, et al. **An Esp Pediatr** 1996 Apr;44(4):393-4 (20 ref.) **(Spa)**

CLASSIFICATION

[Myocardiopathies (III). The classification and morphological patterns of hypertrophic myocardiopathy] Penas Lado M. **Rev Esp Cardiol** 1995 Nov;48(11):754-61 (51 ref.) (Eng. Abstr.) **(Spa)**

COMPLICATIONS

Risk assessment and prevention of sudden cardiac death in hypertrophic cardiomyopathy. Slade AK, et al. **Arch Mal Coeur Vaiss** 1996 Feb;89 Spec No 1:37-49 (74 ref.)

DIAGNOSIS

Hypertrophic cardiomyopathy: functional aspects by tagged magnetic resonance imaging. Beyar R. **Adv Exp Med Biol** 1995;382:293-301 (28 ref.)

Hypertrophic cardiomyopathy in old agers. Definitions and general considerations. Stănescu C. **Rom J Intern Med** 1995 Jul-Dec;33(3-4):133-9 (16 ref.)

[A double ventricular obstruction in a case of hypertrophic cardiomyopathy] Giordano G, et al. **Cardiologia** 1995 Aug; 40(8):611-3 (7 ref.) (Eng. Abstr.) **(Ita)**

[Role of noninvasive techniques (electrocardiogram, Holter, tilt-table test, nuclear magnetic resonance, isotopes) in the evaluation of patients with hypertrophic cardiomyopathies] Candell Riera J. **Rev Esp Cardiol** 1995 Dec;48(12):828-36 (71 ref.) (Eng. Abstr.) **(Spa)**

[Apical hypertrophic myocardiopathy and multiple fistulae between the coronary vessels and the left ventricle] Monmeneu JV, et al. **Rev Esp Cardiol** 1995 Nov; 48(11):768-70 (10 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Adrenergic beta-blocking agents in congestive heart failure due to idiopathic dilated cardiomyopathy. Waagstein F. **Eur Heart J** 1995 Dec;16 Suppl O:128-32 (37 ref.)

ETIOLOGY

[Myocardiopathy in POEMS syndrome (letter)] Gacon PH, et al. **Ann Med Interne (Paris)** 1996;147(2):124-6 (16 ref.) **(Fre)**

[Hypertrophic responses to mechanical stretch in cardiac myocytes] Yamazaki T, et al. **Tanpakushitsu Kakusan Koso** 1996 Jan;41(1):14-8 (8 ref.) **(Jpn)**

GENETICS

Molecular and clinical aspects of inherited cardiomyopathies. Durand JB, et al. **Ann Med** 1995 Jun;27(3):311-7 (38 ref.)

Familial hypertrophic cardiomyopathy: a genetic model of cardiac hypertrophy. Watkins H, et al. **Hum Mol Genet** 1995;4 Spec No:1721-7 (59 ref.)

[Hypertrophic cardiomyopathy] Friart A. **Rev Med Brux** 1995 Jul-Aug;16(4):182-4 (10 ref.) (Eng. Abstr.) **(Fre)**

[Myocardiopathies (II). Genetic changes in the etiopathogenesis of hypertrophic myocardiopathy. The therapeutic prospects] Reyes Engel A, et al. **Rev Esp Cardiol** 1995 Oct;48(10):677-85 (56 ref.) (Eng. Abstr.) **(Spa)**

MORTALITY

Sudden cardiac death in hypertrophic cardiomyopathy: risk evaluation. Mittal SR. **Int J Cardiol** 1995 Nov 10;52(1):1-4 (31 ref.)

[Cardiomyopathies. VIII. Sudden death in hypertrophic cardiomyopathy] Alfonso F. **Rev Esp Cardiol** 1996 Apr; 49(4):288-304 (166 ref.) (Eng. Abstr.) **(Spa)**

PATHOLOGY

Cellular basis of ventricular remodeling after myocardial infarction in rats. Olivetti G, et al. **Cardioscience** 1995 Jun; 6(2):101-6 (29 ref.)

[Myocardiopathies (III). The classification and morphological patterns of hypertrophic myocardiopathy] Penas Lado M. **Rev Esp Cardiol** 1995 Nov;48(11):754-61 (51 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

The renin-angiotensin-aldosterone system and myocardial collagen matrix remodelling in congestive heart failure. Brilla CG, et al. **Eur Heart J** 1995 Dec;16 Suppl O:107-9 (24 ref.)

The cardiomyopathy of overload: an unnatural growth response. Katz AM. **Eur Heart J** 1995 Dec;16 Suppl O:110-4 (73 ref.)

[Hypertrophic cardiomyopathy: spontaneous course] Seiler C. **Schweiz Med Wochenschr** 1995 Oct 14;125(41):1931-9 (55 ref.) (Eng. Abstr.) **(Ger)**

[Sudden death in hypertrophic myocardiopathy] Cardim N, et al. **Rev Port Cardiol** 1995 Sep;14(9):655-9 (54 ref.) (Eng. Abstr.) **(Por)**

[Hemodynamic and electrophysiologic changes in hypertrophic cardiomyopathy] López Gil M, et al. **Rev Esp Cardiol** 1996 Jan;49(1):56-68 (109 ref.) (Eng. Abstr.) **(Spa)**

[A paradoxical intraventricular gradient in a patient with atypical hypertrophic myocardiopathy] Penas Lado M, et al. **Rev Esp Cardiol** 1995 Oct;48(10):686-9 (10 ref.) (Eng. Abstr.) **(Spa)**

SURGERY

[Hypertrophic obstructive cardiomyopathy: surgical treatment] Schulte HD, et al. **Schweiz Med Wochenschr** 1995 Oct 14;125(41):1940-9 (18 ref.) (Eng. Abstr.) **(Ger)**

[Myocardiopathies. IX. Surgical treatment of hypertrophic obstructive myocardiopathy: is it an underestimated alternative?] Herreros J, et al. **Rev Esp Cardiol** 1996 May; 49(5):372-80 (87 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

Management of hypertrophic cardiomyopathy. Elliott PM, et al. **Br J Hosp Med** 1996 Apr 3-16;55(7):419-23 (15 ref.)

[New indications for cardiac pacing] Davy JM, et al. **Arch Mal Coeur Vaiss** 1995 Dec;88 Spec No 5:55-62 (43 ref.) (Eng. Abstr.) **(Fre)**

[The treatment of obstructive hypertrophic myocardiopathy refractory to medical therapy] Cardim N, et al. **Rev Port Cardiol** 1995 Dec;14(12):1051-5, 989 (32 ref.) (Eng. Abstr.) **(Por)**

[Acute and chronic sequential atrioventricular pacing in patients with obstructive-type hypertrophic myocardiopathy resistant to medical therapy] Rodrigues JC, et al. **Rev Port Cardiol** 1995 Sep;14(9):637-41 (22 ref.) (Eng. Abstr.) **(Por)**

CARDIOMYOPATHY, HYPERTROPHIC OBSTRUCTIVE see CARDIOMYOPATHY, HYPERTROPHIC

CARDIOMYOPLASTY

Skeletal muscle ventricles: frontiers in 1995. Isoda S, et al. **Artif Organs** 1996 Feb;20(2):114-9 (33 ref.)

INSTRUMENTATION

[Biomechanical heart and cardiovascular support] Lange R, et al. **Zentralbl Chir** 1996;121(4):263-77 (121 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Cardiomyoplasty--the beginning of a new era. Bolotin G, et al. **Isr J Med Sci** 1996 May;32(5):321-6 (40 ref.)

CARDIOMYOPLASTY, DYNAMIC see CARDIOMYOPLASTY

CARDIOPLEGIA see HEART ARREST, INDUCED

CARDIOPLEGIC SOLUTIONS

The scientific basis for hypocalcemic cardioplegia and reperfusion in cardiac surgery. Chen RH. **Ann Thorac Surg** 1996 Sep;62(3):910-4 (57 ref.)

THERAPEUTIC USE

Physiological and cellular mechanisms of myocardial protection. Krukenkamp IB, et al. **Am J Surg** 1996 Jul; 172(1):79-84 (21 ref.)

CARDIOPULMONARY ARREST see HEART ARREST

CARDIOPULMONARY BYPASS

Cardioprotective effect of desferrioxamine. Bel A, et al. **Acta Haematol** 1996;95(1):63-5 (21 ref.)

The role of the hemostasis laboratory in cardiopulmonary bypass surgery [editorial] Brandt JT. **Am J Clin Pathol** 1996 Jul;106(1):3-5 (26 ref.)

Cardiopulmonary bypass for resuscitation after penetrating cardiac trauma. Karmy-Jones R, et al. **Ann Thorac Surg** 1996 Apr;61(4):1244-5 (5 ref.)

Acute aortic dissection in a patient with osteogenesis imperfecta [see comments] Moriyama Y, et al. **Ann Thorac Surg** 1995 Nov;60(5):1397-9 (8 ref.) Comment in: Ann Thorac Surg 1996 Apr;61(4):1294.

Cardiopulmonary bypass during pregnancy. Parry AJ, et al. **Ann Thorac Surg** 1996 Jun;61(6):1865-9 (47 ref.)

Cardiopulmonary bypass in pregnancy. Pomini F, et al. **Ann Thorac Surg** 1996 Jan;61(1):259–68 (65 ref.)
Pharmacokinetics of analgesics, sedatives and anaesthetic agents during cardiopulmonary bypass. Gedney JA, et al. **Br J Anaesth** 1995 Sep;75(3):344–51 (74 ref.)
Use of cardiopulmonary bypass during bronchoscopy following sand aspiration. A case report. Mellema JD, et al. **Chest** 1995 Oct;108(4):1176–7 (6 ref.)
Myocardial ischemia after cardiopulmonary bypass. Jain U. **J Card Surg** 1995 Jul;10(4 Suppl):520–6 (97 ref.)
The management of temperature during cardiopulmonary bypass: effect on neuropsychological outcome. Nathan HJ, et al. **J Card Surg** 1995 Jul;10(4 Suppl):481–7 (50 ref.)
Determinants of cerebral perfusion during cardiopulmonary bypass. O'Dwyer C, et al. **J Cardiothorac Vasc Anesth** 1996 Jan;10(1):54–64; quiz 65 (142 ref.)
Perfluorocarbon emulsions and cardiopulmonary bypass: a technique for the future. Spiess BD, et al. **J Cardiothorac Vasc Anesth** 1996 Jan;10(1):83–89; quiz 89–90 (65 ref.)
Neuromonitoring during hypothermic cardiopulmonary bypass. Gombotz H. **J Neurosurg Anesthesiol** 1995 Oct; 7(4):289–96 (82 ref.)
[Biocompatibility and extracorporeal circulation] Camici M. **Clin Ter** 1995 Nov;146(11):713–9 (30 ref.) (Eng. Abstr.) **(Ita)**
[Mediastinal malignant tumor resection and superior vena cava revascularization. Resection of invasive thymoma with growth into the superior vena cava and right atrium using cardiopulmonary bypass] **Nippon Kyobu Geka Gakkai Zasshi** 1995 May;43(5):717–9 (4 ref.) **(Jpn)**

ADVERSE EFFECTS

The inflammatory response to cardiopulmonary bypass and its impact on postoperative myocardial function. Menasché P. **Curr Opin Cardiol** 1995 Nov;10(6):597–604 (59 ref.)
Cerebrovascular assessment of the high-risk patient: the role of transcranial Doppler ultrasound. Doblar DD. **J Cardiothorac Vasc Anesth** 1996 Jan;10(1):3–14 (116 ref.)
Neuropsychologic dysfunction after cardiac surgery: what is the problem? Gill R, et al. **J Cardiothorac Vasc Anesth** 1996 Jan;10(1):91–8 (62 ref.)
Normothermic versus hypothermic cardiopulmonary bypass: central nervous system outcomes. McLean RF, et al. **J Cardiothorac Vasc Anesth** 1996 Jan;10(1):45–52; quiz 52–3 (114 ref.)
Techniques for avoiding neurologic injury during adult cardiac surgery. Utley JR. **J Cardiothorac Vasc Anesth** 1996 Jan;10(1):38–43; quiz 43–4 (43 ref.)
Cardiopulmonary bypass and the central nervous system: potential for cerebral protection. Newman MF, et al. **J Clin Anesth** 1996 May;8(3 Suppl):53S–60S (70 ref.)
Studies of hypoxemic/reoxygenation injury: I. Linkage between cardiac function and oxidant damage. Buckberg GD. **J Thorac Cardiovasc Surg** 1995 Oct;110(4 Pt 2):1164–70 (47 ref.)
Air embolism during cardiopulmonary bypass. Kurusz M, et al. **Perfusion** 1995 Nov;10(6):361–91 (389 ref.)
[Heart surgery, cardiopulmonary bypass and inflammatory response. I. Changes in hemostasis and complement] Parolari A, et al. **G Ital Cardiol** 1996 Apr;26(4):431–46 (121 ref.) (Eng. Abstr.) **(Ita)**

INSTRUMENTATION

Heparin-bonded surfaces in extracorporeal membrane oxygenation for cardiac support. von Segesser LK. **Ann Thorac Surg** 1996 Jan;61(1):330–5; discussion 340–1 (28 ref.)

METHODS

Current methods to reduce the adverse haematological consequences of cardiopulmonary bypass. John LC, et al. **Br J Clin Pract** 1996 Jun;50(4):203–6 (66 ref.)
Con: glucose priming solutions should not be used for cardiopulmonary bypass. Hindman B. **J Cardiothorac Vasc Anesth** 1995 Oct;9(5):605–7 (39 ref.)
Pro: glucose priming solutions should be used for cardiopulmonary bypass. Metz S. **J Cardiothorac Vasc Anesth** 1995 Oct;9(5):603–4 (25 ref.)

CARDIOPULMONARY RESUSCITATION

The mystery of bradyasystole during cardiac arrest. Ornato JP, et al. **Ann Emerg Med** 1996 May;27(5):576–87 (233 ref.)
Global brain ischemia and reperfusion. White BC, et al. **Ann Emerg Med** 1996 May;27(5):588–94 (48 ref.)
The revolution and evolution of prehospital cardiac care. Eisenberg MS, et al. **Arch Intern Med** 1996 Aug 12–26; 156(15):1611–9 (43 ref.)
Advanced cardiac life support: update on recent guidelines and a look at the future. Tucker KJ, et al. **Clin Cardiol** 1995 Sep;18(9):497–504 (64 ref.)
Emergency cardiac care. Moral, legal, and ethical considerations. Peskin RM, et al. **Dent Clin North Am** 1995 Jul;39(3):677–88 (35 ref.)
Paediatric cardiopulmonary resuscitation. Richmond CE, et al. **Paediatr Anaesth** 1995;5(1):11–27 (173 ref.)
Discussing cardiopulmonary resuscitation with patients and relatives. Stewart K. **Postgrad Med J** 1995 Oct; 71(840):585–9 (30 ref.)
[Pharmacological routes of administration in circulatory collapse] Kristensen BB, et al. **Ugeskr Laeger** 1995 Dec 4;157(49):6864–8 (35 ref.) (Eng. Abstr.) **(Dan)**
[History of respiratory intensive care with reference to first aid for nearly-drowned persons] Leveau P. **Ann Fr Anesth Reanim** 1996;15(1):86–100 (57 ref.) (Eng. Abstr.) **(Fre)**
[Routes for drug administration during cardiopulmonary resuscitation] Kerz T, et al. **Anaesthesist** 1996 Jun; 45(6):550–65 (175 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Risk of acquiring AIDS from salivary exchange through cardiopulmonary resuscitation courses and mouth-to-mouth resuscitation. Sun D, et al. **Semin Dermatol** 1995 Sep;14(3):205–11 (76 ref.)

METHODS

Newer methods of improving blood flow during CPR. Halperin HR, et al. **Ann Emerg Med** 1996 May;27(5):553–62 (69 ref.)
Reassessing the need for ventilation during CPR. Idris AH. **Ann Emerg Med** 1996 May;27(5):569–75 (52 ref.)
Resuscitation from severe hemorrhage. Shoemaker WC, et al. **Crit Care Med** 1996 Feb;24(2 Suppl):S12–23 (76 ref.)
Cardiopulmonary resuscitation. Barton CW, et al. **Emerg Med Clin North Am** 1995 Nov;13(4):811–29 (101 ref.)
Current concepts in airway management for cardiopulmonary resuscitation. Reed AP. **Mayo Clin Proc** 1995 Dec;70(12):1172–84 (111 ref.)
[Resuscitation in multiple trauma] Berger K, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Apr; 31(3):187–90 (23 ref.) (Eng. Abstr.) **(Ger)**
[Resuscitation by active compression and decompression] Dirks B. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Aug; 30(5):309–12 (10 ref.) **(Ger)**
[Active compression-decompression in cardiopulmonary resuscitation] Degrazia RC, et al. **Arq Bras Cardiol** 1995 Jul;65(1):73–6 (76 ref.) **(Por)**

TRENDS

Variations in cardiopulmonary resuscitation techniques: past, present and future. Shultz JJ, et al. **Can J Cardiol** 1995 Nov;11(10):873–80 (49 ref.)

CARDIOSPASM see **ESOPHAGEAL ACHALASIA**

CARDIOTOCOGRAPHY

Intelligent fetal heart rate computer systems in intrapartum surveillance. Greene KR. **Curr Opin Obstet Gynecol** 1996 Apr;8(2):123–7 (19 ref.)
Fetal monitoring by combined CTG and FBA. Goeschen K. **J Perinat Med** 1996;24(1):37–41 (8 ref.)
Comments on past and present situation of intensive monitoring of the fetus during labor. Saling E. **J Perinat Med** 1996;24(1):7–13 (13 ref.)
[Intrauterine diagnosis and therapy of fetal arrhythmias] Gembruch U, et al. **Gynakologe** 1995 Oct;28(5):329–45 (69 ref.) **(Ger)**

METHODS

Antenatal assessment using the FECG obtained via abdominal electrodes. Crowe JA, et al. **J Perinat Med** 1996; 24(1):43–53 (13 ref.)

STATISTICS & NUMERICAL DATA

Improvements in computerized fetal heart rate analysis antepartum. Dawes GS, et al. **J Perinat Med** 1996; 24(1):25–36 (38 ref.)
Why has conventional intrapartum cardiotocography not given the expected results? Larsen JF. **J Perinat Med** 1996; 24(1):15–23 (42 ref.)

CARDIOTONIC AGENTS

ADMINISTRATION & DOSAGE

[Efficacy and problems of cardiotonic agents viewed from physiopathology of chronic congestive heart failure] Asanoi H, et al. **Nippon Naika Gakkai Zasshi** 1995 Sep 10;84(9):1465–9 (19 ref.) **(Jpn)**

ADVERSE EFFECTS

Vesnarinone-induced granulocytopenia: incidence in Japan and recommendations for safety. Furusawa S, et al. **J Clin Pharmacol** 1996 May;36(5):477–81 (13 ref.)
Electrophysiologic and proarrhythmic effects of intravenous inotropic agents. Tisdale JE, et al. **Prog Cardiovasc Dis** 1995 Sep-Oct;38(2):167–80 (104 ref.)
Oleander toxicity: an examination of human and animal toxic exposures. Langford SD, et al. **Toxicology** 1996 May 3; 109(1):1–13 (76 ref.)

BLOOD

Endogenous ouabain, sodium balance and blood pressure: a review and a hypothesis [see comments] Hamlyn JM, et al. **J Hypertens** 1996 Feb;14(2):151–67 (136 ref.) Comment in: J Hypertens 1996 Feb;14(2):169–71.
Endogenous ouabain, sodium balance and blood pressure [comment] Pidgeon GB, et al. **J Hypertens** 1996 Feb; 14(2):169–71 (28 ref.) Comment on: J Hypertens 1996 Feb;14(2):151–67.
[Digoxin] Kotaki H, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:950–3 (10 ref.) **(Jpn)**
[Digitoxin] Yamamoto K, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:945–9 (12 ref.) **(Jpn)**

CHEMICAL SYNTHESIS

[Synthesis of lactone ring-containing bioactive natural products. Cardiotonic steroids, naphthoquinone antibiotics, and tetronic acid ionophore antibiotics] Yoshii E. **Yakugaku Zasshi** 1996 Jan;116(1):1–20 (45 ref.) (Eng. Abstr.) **(Jpn)**

CONTRAINDICATIONS

Is it safe to prescribe digoxin after acute myocardial infarction? Update on continued controversy [editorial] Leor J, et al. **Am Heart J** 1995 Dec;130(6):1322–6 (47 ref.)

DIAGNOSTIC USE

Pharmacological stress electrocardiography--when is it indicated? Davies J. **Br J Clin Pract Symp Suppl** 1995 Nov; 82:2–5 (3 ref.)
Pharmacological stress echocardiography--practical considerations. Schröder K. **Br J Clin Pract Symp Suppl** 1995 Nov;82:6–9 (6 ref.)
Assessment of myocardial viability by dobutamine echocardiography. Cheirif J, et al. **Coron Artery Dis** 1995 Aug;6(8):600–5 (30 ref.)
[Stress ultrasonography with dobutamine in the diagnosis of coronary disease] Brochet E, et al. **Presse Med** 1995 Dec 9;24(38):1800–5 (25 ref.) (Eng. Abstr.) **(Fre)**
[Pharmacologic tests in cardiac decompensation] Perini G, et al. **G Ital Cardiol** 1995 Dec;25(12):1635–41 (25 ref.) **(Ita)**

PHARMACOLOGY

Milrinone: basic and clinical pharmacology and acute and chronic management. Shipley JB, et al. **Am J Med Sci** 1996 Jun;311(6):286–91 (36 ref.)

THERAPEUTIC USE

Inotropic agents in the treatment of postoperative low cardiac output syndrome. Husedžinović I, et al. **Acta Med Croatica** 1995;49(4–5):201–5 (55 ref.)
Digoxin in clinical practice: sorting out the facts. Doi SA, et al. **Br J Clin Pract** 1995 Sep-Oct;49(5):257–61 (73 ref.)
Activation of ATP-sensitive potassium channels: a novel pharmacological approach to myocardial protection? Hearse DJ. **Cardiovasc Res** 1995 Jul;30(1):1–17 (94 ref.)
Inotropic therapy for the failing myocardium [see comments] Shipley JB, et al. **Clin Cardiol** 1995 Nov;18(11):615–9 (18 ref.) Comment in: Clin Cardiol 1996 Mar;19(3):162.
Inotropic therapy for systolic heart failure. Wagoner LE, et al. **Compr Ther** 1995 Jul;21(7):367–77 (57 ref.)
Is it time to reposition vasopressors and inotropes in sepsis? Rudis MI, et al. **Crit Care Med** 1996 Mar;24(3):525–37 (74 ref.)
Digoxin in the treatment of patients with chronic heart failure. Its place in therapy. Uretsky BF. **Drugs Aging** 1995 Jul;7(1):1–9 (44 ref.)
Improvement in cardiac myocyte function by biological effects of medical therapy: a new concept in the treatment of heart failure. Bristow MR, et al. **Eur Heart J** 1995 Jul; 16 Suppl F:20–31 (93 ref.)
Digitalis--friend or foe? Erdmann E. **Eur Heart J** 1995 Jul; 16 Suppl F:16–9 (18 ref.)
Evolving concepts in the treatment of heart failure: should new inotropic agents carry promise or paranoia? Young JB. **Pharmacotherapy** 1996 Mar-Apr;16(2 Pt 2):78S–84S (25 ref.)
[Calcium sensitizers] Nieminen MS, et al. **Duodecim** 1995; 111(8):779–87 (56 ref.) **(Fin)**
[Treatment of heart failure] Bounhoure JP, et al. **Presse Med** 1996 Jun 29;25(23):1076–82 (22 ref.) (Eng. Abstr.) **(Fre)**
[Digitalis in atrial fibrillation. Still relevant treatment or an old-fashioned therapy?] Gjesdal K. **Tidsskr Nor Laegeforen** 1996 Mar 20;116(8):973–5 (39 ref.) (Eng. Abstr.) **(Nor)**

CARDIOTONIC STEROIDS see **CARDIAC GLYCOSIDES**

CARDIOVASCULAR AGENTS

ADMINISTRATION & DOSAGE

Titrating cardiovascular drugs. Marcus FI. **Clin Chem** 1996 Aug;42(8 Pt 2):1312–5 (17 ref.)
Drug profiles: maximizing therapeutic effectiveness. Porter LA, et al. **J Cardiovasc Nurs** 1995 Oct;10(1):64–72 (29 ref.)
[Chronobiology and chronopharmacology of cardiovascular diseases] Lemmer B. **Wien Med Wochenschr** 1995;

145(17-18):445-7 (29 ref.) (Eng. Abstr.) **(Ger)**
[Drug and instrumental therapeutic approaches for prevention of restenosis] Höfling B, et al. **Z Kardiol** 1995; 84 Suppl 4:151-8 (36 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

[Drug therapy in advanced age] Scholz H. **Med Monatsschr Pharm** 1996 May;19(5):132-9 (32 ref.) **(Ger)**

ANALYSIS

Capillary electrophoresis of cardiovascular drugs. Nguyen NT, et al. **J Chromatogr A** 1996 May 31;735(1-2):123-50 (95 ref.)

BLOOD

Titrating cardiovascular drugs. Marcus FI. **Clin Chem** 1996 Aug;42(8 Pt 2):1312-5 (17 ref.)

CHEMISTRY

4-quinolones as potential cardiovascular agents. Davies RV, et al. **Prog Med Chem** 1995;32:115-55 (78 ref.)

PHARMACOKINETICS

Pharmacokinetic optimisation of drug therapy in elderly patients. Parker BM, et al. **Drugs Aging** 1995 Jul;7(1):10-8 (38 ref.)
Relevance of the pharmacokinetic profile in the treatment of angina pectoris: the need for 24 h control. Tamargo J, et al. **Eur Heart J** 1995 Jul;16 Suppl E:57-61 (33 ref.)

PHARMACOLOGY

Nitric oxide donors: a continuing opportunity in drug design. Hanson SR, et al. **Adv Pharmacol** 1995;34:383-98 (28 ref.)
Pharmacologic drugs for controlled hypotension. Testa LD, et al. **J Clin Anesth** 1995 Jun;7(4):326-37 (64 ref.)
[Nitric oxide in the mechanism of the action of cardiovascular agents] Chekman IS, et al. **Lik Sprava** 1995 May-Jun; (3-6):36-40 (40 ref.) **(Ukr)**

THERAPEUTIC USE

Heart rate reduction in the treatment of chronic stable angina pectoris: experiences with a sinus node inhibitor [editorial] Frishman WH, et al. **Am Heart J** 1996 Jan;131(1):204-10 (63 ref.)
Prognosis of patients with stable angina pectoris on antianginal drug therapy. Hjemdahl P, et al. **Am J Cardiol** 1996 Jun 20;77(16):6D-15D (67 ref.)
Update on cardiovascular drugs and elders [see comments] Redeker NS, et al. **Am J Nurs** 1995 Sep;95(9):34-40; quiz 41 (9 ref.) Comment in: Am J Nurs 1995 Dec;95(12):17.
Medical treatment of pulmonary hypertension. McGoon MD. **Cardiologia** 1995 Aug;40(8):561-77 (128 ref.)
Treatment for survivors of acute myocardial infarction: what have we learned from large intervention trials? Julian DG. **Cardiovasc Drugs Ther** 1995 Aug;9 Suppl 3:495-502 (35 ref.)
Therapeutic use of n-3 fatty acids for vascular disease and thrombosis. Goodnight SH, et al. **Chest** 1995 Oct;108(4 Suppl):302S-304S (36 ref.)
Management of postmyocardial infarction in the elderly patient. Forman R, et al. **Clin Geriatr Med** 1996 Feb; 12(1):169-80 (57 ref.)
Cardiotoxicity and cardioprotection during chemotherapy. Hochster H, et al. **Curr Opin Oncol** 1995 Jul;7(4):304-9 (37 ref.)
Are antianginal drugs effective in secondary prevention after myocardial infarction? Julian DG. **Eur Heart J** 1995 Jul; 16 Suppl E:38-40 (13 ref.)
Are antianginal drugs effective in post-myocardial infarction secondary prevention? Sleight P. **Eur Heart J** 1995 Jul;16 Suppl E:36-7 (11 ref.)
Relevance of the pharmacokinetic profile in the treatment of angina pectoris: the need for 24 h control. Tamargo J, et al. **Eur Heart J** 1995 Jul;16 Suppl E:57-61 (33 ref.)
Pharmacological treatment for myocardial infarction Part 2: Implications of clinical trials of other adjunctive therapies. Avezum A Jr, et al. **Indian Heart J** 1995 Mar-Apr; 47(2):95-105 (60 ref.)
Maximizing therapy in the advanced heart failure patient. Moser DK. **J Cardiovasc Nurs** 1996 Jan;10(2):29-46 (62 ref.)
Pharmacologic approaches to the treatment of atherosclerotic arterial obstruction. Capron L. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S40-3 (15 ref.)
Pharmacologic treatment of venous leg ulcers. Dormandy JA. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S61-5 (29 ref.)
Angiopeptin: experimental and clinical studies of inhibition of myointimal proliferation. Foegh ML, et al. **Kidney Int Suppl** 1995 Dec;52:S18-22 (47 ref.)
Current trends in cardiovascular pharmacology. Ciccone CD. **Phys Ther** 1996 May;76(5):481-97 (184 ref.)
Stable ischemic heart disease. Using stress and imaging procedures to direct therapy. Lavie CJ, et al. **Postgrad Med** 1996 Feb;99(2):63-6, 73-4, 77-81 passim (23 ref.)
[Current therapeutics 1990-1995 in the cardiovascular field] Scheen AJ. **Rev Med Liege** 1995 Aug;50(8):317-22 (28 ref.) **(Fre)**
[Chronic cardiac insufficiency: current treatment and future outlook] Reuge L, et al. **Rev Med Suisse Romande** 1996 Jun;116(6):441-50 (34 ref.) **(Fre)**
[Cardiac insufficiency: therapeutic aspects in the elderly person] Perrenoud JJ. **Schweiz Rundsch Med Prax** 1996 Feb 6;85(6):164-7 (19 ref.) (Eng. Abstr.) **(Fre)**
[Dilated cardiomyopathy--diagnosis and conservative therapy] Fruhwald FM, et al. **Acta Med Austriaca** 1995; 22(5):90-3 (27 ref.) (Eng. Abstr.) **(Ger)**
[Therapeutic measures following acute myocardial infarct: differential use of PTCA, surgery and drugs] Noll G, et al. **Schweiz Med Wochenschr** 1996 Feb 3;126(5):164-76 (81 ref.) (Eng. Abstr.) **(Ger)**
[Drug therapy of cardiac insufficiency: status 1995] Rickenbacher P, et al. **Schweiz Med Wochenschr** 1996 May 25;126(21):933-45 (161 ref.) (Eng. Abstr.) **(Ger)**
[Drug therapy in angina pectoris] Follath F. **Schweiz Rundsch Med Prax** 1995 Oct 17;84(42):1186-9 (22 ref.) (Eng. Abstr.) **(Ger)**
[The effect of cardiovascular agents on the hemostatic system in myocardial ischemia] Denisova SV, et al. **Eksp Klin Farmakol** 1995 Jul-Aug;58(4):63-8 (82 ref.) **(Rus)**

CARDIOVASCULAR DISEASE (SPECIALTY) see **CARDIOLOGY**

CARDIOVASCULAR DISEASES

Effect of weight on cardiovascular disease. Kannel WB, et al. **Am J Clin Nutr** 1996 Mar;63(3 Suppl):419S-422S (20 ref.)
Clinical misconceptions dispelled by epidemiological research. Kannel WB. **Circulation** 1995 Dec 1; 92(11):3350-60 (108 ref.)
Gender differences in cardiovascular outcomes. Hartz RS. **Int J Fertil Menopausal Stud** 1996 Mar-Apr;41(2):101-8 (37 ref.)
Depot medroxyprogesterone acetate contraception in women with medical problems. Frederiksen MC. **J Reprod Med** 1996 May;41(5 Suppl):414-8 (32 ref.)
[Autonomic nervous systems and cardiovascular diseases] Inoue H. **Nippon Naika Gakkai Zasshi** 1996 Mar 10; 85(3):428-31 (8 ref.) **(Jpn)**

BLOOD

von Willebrand factor and its relevance to cardiovascular disorders. Lip GY, et al. **Br Heart J** 1995 Dec;74(6):580-3 (28 ref.)
Haemorheological consequences of chronic cigarette smoking. Ernst E. **J Cardiovasc Risk** 1995 Oct;2(5):435-9 (70 ref.)
Fibrinogen and cardiovascular risk. Heinrich J, et al. **J Cardiovasc Risk** 1995 Jun;2(3):197-205 (88 ref.)
Hyperhomocysteinemia as a risk factor for cardiovascular disease in patients undergoing hemodialysis. Friedman JA, et al. **Nutr Rev** 1995 Jul;53(7):197-201 (17 ref.)
Prospective studies of homocysteine and cardiovascular disease. Verhoef P, et al. **Nutr Rev** 1995 Oct;53(10):283-8 (19 ref.)
The role of endothelin-1 in cardiovascular physiology and pathophysiology. Webb DJ, et al. **Scott Med J** 1995 Jun; 40(3):69-71 (26 ref.)
[Hyperhomocysteinemia] Sobra J. **Cas Lek Cesk** 1996 May 2;135(9):266-9 (31 ref.) (Eng. Abstr.) **(Cze)**

CHEMICALLY INDUCED

Cardiovascular toxicity with cancer chemotherapy. Frishman WH, et al. **Curr Probl Cardiol** 1996 Apr;21(4):225-86 (227 ref.)

COMPLICATIONS

Evaluating cardiac risk in noncardiac surgery patients. Bronson DL, et al. **Cleve Clin J Med** 1995 Nov-Dec; 62(6):391-400 (39 ref.)
The clinical spectrum of neurocardiogenic syncope. Sutton R, et al. **J Cardiovasc Electrophysiol** 1995 Jul;6(7):569-76 (66 ref.)
Microalbuminuria as a marker of cardiovascular and renal disease in essential hypertension. Bigazzi R, et al. **Nephrol Dial Transplant** 1995;10 Suppl 6:10-4 (58 ref.)
Sleep-related breathing disorders. 7. Sleep and breathing problems in general medicine. Calverley PM. **Thorax** 1995 Dec;50(12):1311-6 (98 ref.)
[Heart and thyroid] Klein M, et al. **Ann Endocrinol (Paris)** 1995;56(5):473-86 (176 ref.) (Eng. Abstr.) **(Fre)**
-Anticoagulant drugs- Gulba DC. **Herz** 1996 Feb; 21(1):12-27 (164 ref.) (Eng. Abstr.) **(Ger)**
-New aspects in antithrombotic therapy--platelet inhibitors- Terres W, et al. **Herz** 1996 Feb;21(1):1-11 (89 ref.) (Eng. Abstr.) **(Ger)**

DIAGNOSIS

Syncope: diagnosis of cardiac and noncardiac causes. Farrehi PM, et al. **Geriatrics** 1995 Nov;50(11):24-30 (19 ref.)
Role of exercise in the management of cardiovascular disease in children and youth. Tomassoni TL. **Med Sci Sports Exerc** 1996 Apr;28(4):406-13 (66 ref.)
[Diabetic cardiovascular neuropathy] Luft D. **Z Arztl Fortbild (Jena)** 1996 Apr;90(2):139-43 (38 ref.) (Eng. Abstr.) **(Ger)**
[Activated factor VII as a new cardiovascular risk factor of atherothrombotic disease] Kario K, et al. **Rinsho Byori** 1995 Dec;43(12):1201-8 (28 ref.) (Eng. Abstr.) **(Jpn)**
[Exercise testing in cardiac patients] Koike A, et al. **Rinsho Byori** 1995 Aug;43(8):820-7 (19 ref.) (Eng. Abstr.) **(Jpn)**

DIET THERAPY

[Garlic (Allium sativum)--a potent medicinal plant] Resch KL, et al. **Fortschr Med** 1995 Jul 20;113(20-21):311-5 (43 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Beneficial actions of nitrates in cardiovascular disease. Abrams J. **Am J Cardiol** 1996 May 30;77(13):31C-7C (29 ref.)
Organic nitrates: new formulations and their clinical advantages. Parker JA. **Am J Cardiol** 1996 May 30; 77(13):38C-40C (23 ref.)
Chronobiology and chronotherapeutics. Applications to cardiovascular medicine. Smolensky MH. **Am J Hypertens** 1996 Apr;9(4 Pt 3):11S-21S (68 ref.)
Angiotensin receptors and their therapeutic implications. Griendling KK, et al. **Annu Rev Pharmacol Toxicol** 1996; 36:281-306 (135 ref.)
The place of beta-blockers in cardiovascular medicine. Cruickshank JM. **Cardiologia** 1995 Nov;40(11):829-43 (81 ref.)
Coadministration of calcium antagonists and ACE inhibitors--is a skeptic convinced?: a personal view. Campbell RW. **Cardiovasc Drugs Ther** 1995 Aug;9 Suppl 3:525-8 (33 ref.)
Vascular protective effects of ACE inhibitors and calcium antagonists: theoretical basis for a combination therapy in hypertension and other cardiovascular diseases. Lüscher TF, et al. **Cardiovasc Drugs Ther** 1995 Aug;9 Suppl 3:509-23 (89 ref.)
Angiotensin II receptor antagonists in heart failure: rationale and design of the evaluation of losartan in the elderly (ELITE) trial. Pitt B, et al. **Cardiovasc Drugs Ther** 1995 Oct;9(5):693-700 (80 ref.)
The role of angiogenic cytokines in cardiovascular disease. Isner JM. **Clin Immunol Immunopathol** 1996 Sep;80(3 Pt 2):S82-91 (87 ref.)
Amlodipine. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease [published erratum appears in Drugs 1995 Nov;50(5):896] Haria M, et al. **Drugs** 1995 Sep;50(3):560-86 (196 ref.)
Alteplase. A reappraisal of its pharmacology and therapeutic use in vascular disorders other than acute myocardial infarction. Wagstaff AJ, et al. **Drugs** 1995 Aug; 50(2):289-316 (185 ref.)
Transcription factors as drug targets: opportunities for therapeutic selectivity. Butt TR, et al. **Gene Expr** 1995; 4(6):319-36 (137 ref.)
Beta-blockers and their effects on protein metabolism and resting energy expenditure. Lamont LS. **J Cardpulm Rehabil** 1995 May-Jun;15(3):183-5 (21 ref.)
New advances in the pharmacologic approach to circulatory shock. Chernow B. **J Clin Anesth** 1996 May;8(3 Suppl):67S-69S (15 ref.)
A practical guide to thrombolysis. Gordon I. **Practitioner** 1995 Nov;239(1556):676-8 (10 ref.)
Thyroid hormone therapy in cardiovascular disease. Klemperer JD, et al. **Prog Cardiovasc Dis** 1996 Jan-Feb; 38(4):329-36 (69 ref.)
[Phytotherapeutic aspects of diseases of the cardiovascular system. 5. Saponins and possibilities of their use in prevention and therapy] Purmová J, et al. **Ceska Slov Farm** 1995 Oct;44(5):246-51 (53 ref.) (Eng. Abstr.) **(Cze)**
[Are beta-blockers really depressogenic?] Pélissolo A, et al. **Ann Med Psychol (Paris)** 1995 Aug-Sep;153(7):441-7 (26 ref.) (Eng. Abstr.) **(Fre)**
[Calcium antagonists in cardiovascular diseases] Thuillez C. **Arch Mal Coeur Vaiss** 1995 Sep;88 Spec No 4:9-12 (22 ref.) (Eng. Abstr.) **(Fre)**
[Current therapeutics 1990-1995 in the cardiovascular field] Scheen AJ. **Rev Med Liege** 1995 Aug;50(8):317-22 (28 ref.) **(Fre)**
[Arterial wall: a new pharmacological and therapeutic target?] Laurent S, et al. **Therapie** 1995 Jul-Aug; 50(4):387-98 (73 ref.) (Eng. Abstr.) **(Fre)**
[Drug therapy in advanced age] Scholz H. **Med Monatsschr Pharm** 1996 May;19(5):132-9 (32 ref.) **(Ger)**
[Recent molecular and pharmacologic aspects of ACE inhibitors] Köppel H, et al. **Wien Med Wochenschr** 1995; 145(23):633-7 (20 ref.) (Eng. Abstr.) **(Ger)**

ECONOMICS

Economic comparison of drug and lifestyle treatment of cardiovascular risk factors in high-risk patients. Millar JA. **Clin Exp Pharmacol Physiol** 1995 Mar;22(3):217-9 (22 ref.)

ENZYMOLOGY

Matrix metalloproteinases and cardiovascular disease.

Dollery CM, et al. **Circ Res** 1995 Nov;77(5):863–8 (49 ref.)
Nitric oxide synthases: regulation in disease. Wong GK, et al. **Nephrol Dial Transplant** 1996 Jan;11(1):215–20 (62 ref.)

EPIDEMIOLOGY

Stratification of vascular risk in hypertension and therapeutic perspective. Simon A, et al. **Am J Hypertens** 1995 Oct;8(10 Pt 2):45S–48S (18 ref.)
Health effects of outdoor air pollution. Committee of the Environmental and Occupational Health Assembly of the American Thoracic Society.
Am J Respir Crit Care Med 1996 Jan;153(1):3–50 (578 ref.)
Sociodemographic variation in the prevalence of cardiovascular disease. Reeder BA, et al. **Can J Cardiol** 1996 Mar;12(3):271–7 (49 ref.)
Epidemiologic aspects of circadian patterns of cardiovascular disease and triggers of acute cardiac events. Goldberg RJ. **Cardiol Clin** 1996 May;14(2):175–84 (40 ref.)
Monitoring cardiovascular disease in Zimbabwe: a review of needs and options. Razum O. **Cent Afr J Med** 1996 Apr; 42(4):120–4 (23 ref.)
Cardiovascular disease epidemiology: a journey from the past into the future. Epstein FH. **Circulation** 1996 May 1; 93(9):1755–64 (83 ref.)
The cardiovascular risk associated with impaired glucose tolerance. Jarrett RJ. **Diabet Med** 1996;13(3 Suppl 2):S15–9 (25 ref.)
Testosterone and risk factors for cardiovascular disease in men. Barrett–Connor EL. **Diabete Metab** 1995 Jun; 21(3):156–61 (41 ref.)
Associations between insulin levels and cardiovascular disease are confounded by comorbidity. McKeigue P, et al. **Diabetes Care** 1995 Sep;18(9):1294–8 (54 ref.)
Psychiatric illness and cardiovascular disease risk. Hayward C. **Epidemiol Rev** 1995;17(1):129–38 (138 ref.)
Clustering of cardiovascular risk factors in Australian adolescents: association with dietary excesses and deficiencies. Milligan RA, et al. **J Cardiovasc Risk** 1995 Dec;2(6):515–23 (50 ref.)
Cardiovascular disease in Mississippi. Jones ES, et al.
J Miss State Med Assoc 1995 Sep;36(9):265–9 (21 ref.)
Hyperhomocysteinemia as a risk factor for cardiovascular disease in patients undergoing hemodialysis. Friedman JA, et al. **Nutr Rev** 1995 Jul;53(7):197–201 (17 ref.)
Analysis of psychophysiological mechanism with cardiovascular risks. Băban A, et al. **Rom J Physiol** 1993 Jul–Dec;30(3–4):223–9 (49 ref.)
[Nutrition and metabolic syndrome] Hauner H.
Internist (Berl) 1995 Nov;36(11):1040–5 (37 ref.) **(Ger)**
[PLasma lipids and cardiovascular risk: lesions in the community] Farinaro E, et al. **Ann Ital Med Int** 1995 Oct; 10 Suppl:31S–34S (33 ref.) (Eng. Abstr.) **(Ita)**

ETHNOLOGY

Hypertension and other cardiac risk factors among Asian Indians. Venkata C, et al. **Am J Hypertens** 1995 Dec;8(12 Pt 2):124s–127s (14 ref.)

ETIOLOGY

Hypertension and other cardiovascular risk factors in women. Wenger NK. **Am J Hypertens** 1995 Dec;8(12 Pt 2):94s–99s (40 ref.)
Rationale to study the early natural history of heart disease: the Bogalusa Heart Study. Berenson GS, et al.
Am J Med Sci 1995 Dec;310 Suppl 1:S22–8 (37 ref.)
The importance of body fat distribution in early life. Freedman DS. **Am J Med Sci** 1995 Dec;310 Suppl 1:S72–6 (47 ref.)
Understanding the development of behavior risk factors for cardiovascular disease in youth: the Bogalusa Heart Study. Hunter SM, et al. **Am J Med Sci** 1995 Dec;310 Suppl 1:S114–8 (24 ref.)
Concept of bridging the gap from youth to adulthood. Kannel WB, et al. **Am J Med Sci** 1995 Dec;310 Suppl 1:S15–21 (19 ref.)
Obesity studies in Bogalusa. Webber LS, et al.
Am J Med Sci 1995 Dec;310 Suppl 1:S53–61 (35 ref.)
Cardiovascular complications of diabetes mellitus: what we know and what we need to know about their prevention. Savage PJ. **Ann Intern Med** 1996 Jan 1;124(1 Pt 2):123–6 (29 ref.)
Do non–insulin–dependent diabetes mellitus and cardiovascular disease share common antecedents? Stern MP. **Ann Intern Med** 1996 Jan 1;124(1 Pt 2):110–6 (90 ref.)
Passive smoking and cardiovascular risk. Kritz H, et al.
Arch Intern Med 1995 Oct 9;155(18):1942–8 (53 ref.)
Mechanisms of cardiovascular injury in renal disease. Rabelink TJ, et al. **Blood Purif** 1996;14(1):67–74 (64 ref.)
Anorexia nervosa and the heart. Cooke RA, et al.
Br J Hosp Med 1995 Oct 4–17;54(7):313–7 (41 ref.)
Nutritional aspects of changes in disease patterns in the Western Pacific region. Cavalli–Sforza LT, et al.
Bull World Health Organ 1996;74(3):307–18 (51 ref.)
Quantifying cardiovascular risk in hypertension. Alderman MH. **Cardiol Clin** 1995 Nov;13(4):519–27 (38 ref.)
Recent insights into dietary fats and cardiovascular disease. Dimmitt SB. **Clin Exp Pharmacol Physiol** 1995 Mar; 22(3):204–8 (43 ref.)
New World syndrome in Western Australian aborigines. Gracey M. **Clin Exp Pharmacol Physiol** 1995 Mar; 22(3):220–5 (38 ref.)
Ambulatory blood pressure monitoring for evaluating the relationships between lifestyle, hypertension and cardiovascular risk. Pickering TG, et al.
Clin Exp Pharmacol Physiol 1995 Mar;22(3):226–31 (58 ref.)
Consensus development meeting 1995: combined oral contraceptives and cardiovascular disease. The Consensus Statement issued after the Second European Conference on Sex Steroids and Metabolism, Amsterdam, November 1995. Writing Committee. **Gynecol Endocrinol** 1996 Feb; 10(1):1–5 (7 ref.)
Framingham study insights into hypertensive risk of cardiovascular disease. Kannel WB. **Hypertens Res** 1995 Sep;18(3):181–96 (65 ref.)
Diabetes mellitus and associated hypertension, vascular disease, and nephropathy. An update. Sowers JR, et al. **Hypertension** 1995 Dec;26(6 Pt 1):869–79 (59 ref.)
Evolution of the understanding of the role of exercise in obesity and its complications. Björntorp P.
Int J Obes Relat Metab Disord 1995 Oct;19 Suppl 4:S1–4 (15 ref.)
Antioxidants, oxidants and free radical stress in cardiovascular disease. Singh RB, et al.
J Assoc Physicians India 1996 Jan;44(1):43–8 (55 ref.)
The android woman––a risky condition. Björntorp P.
J Intern Med 1996 Feb;239(2):105–10 (38 ref.)
The Department of Health Cardiovascular Review Group and public health policy: an alternative view [see comments] Gurr MI, et al. **J R Soc Health** 1995 Oct; 115(5):279–81 (20 ref.) Comment in: J R Soc Health 1996 Apr;116(2):121–2.
Cigarette smoking and cardiovascular disease. Jeremy JY, et al. **J R Soc Health** 1995 Oct;115(5):289–95 (62 ref.)
Early determinants of adult metabolic regulation: effects of infant nutrition on adult lipid and lipoprotein metabolism. McGill HC Jr, et al. **Nutr Rev** 1996 Feb;54(2 Pt 2):S31–40 (52 ref.)
Cardiovascular disease in peritoneal dialysis. Prichard S, et al. **Perit Dial Int** 1996;16 Suppl 1:S19–22 (33 ref.)
Smoking and cardiovascular disease. Yarnell JW. **QJM** 1996 Jul;89(7):493–8 (83 ref.)
[Obstructive sleep apnea syndrome and cardiovascular diseases] Théolade R, et al. **Ann Cardiol Angeiol (Paris)** 1995 Nov;44(9):507–16 (63 ref.) (Eng. Abstr.) **(Fre)**
[The pancreatic heart] Cananau S, et al.
Rev Med Suisse Romande 1995 Sep;115(9):693–705 (0 ref.) **(Fre)**
[Heart, brain and hypertension] Lüscher TF, et al.
Schweiz Med Wochenschr 1996 Aug 24;126(34):1449–56 (43 ref.) (Eng. Abstr.) **(Ger)**
[Sleep apnea and cardiovascular risk] Schäfer H, et al.
Z Kardiol 1995 Nov;84(11):871–84 (112 ref.) (Eng. Abstr.) **(Ger)**
[The cardiovascular risk of essential arterial hypertension: general concepts] Gallo P. **Ann Ig** 1994 Jul–Dec; 6(4–6):501–9 (43 ref.) (Eng. Abstr.) **(Ita)**
[Fibrinogen as a cardiovascular risk factor] Giannasi G, et al. **Minerva Cardioangiol** 1995 May;43(5):169–75 (100 ref.) (Eng. Abstr.) **(Ita)**
[Countermeasure for patients with cardiovascular diseases due to hemodialysis] Tabei K, et al.
Nippon Naika Gakkai Zasshi 1995 Oct 10;84(10):1678–84 (5 ref.) **(Jpn)**
[Homocysteine––an independent risk factor of premature vascular disease] Mansoor MA, et al.
Tidsskr Nor Laegeforen 1996 May 30;116(14):1663–7 (41 ref.) **(Nor)**
[Arterial hypertension, left ventricular hypertrophy and cardiovascular risk (editorial)] Nogueira JB.
Acta Med Port 1995 Dec;8(12):663–6 (30 ref.) **(Por)**

GENETICS

Strategies for studying cardiovascular phenotypes in genetically manipulated mice. Becker KD, et al.
Hypertension 1996 Mar;27(3 Pt 2):495–501 (66 ref.)
Molecular biology of angiotensin receptors and their role in human cardiovascular disease. Regitz–Zagrosek V, et al. **J Mol Med** 1996 May;74(5):233–51 (229 ref.)
[A transgenic animal model: new possibilities for cardiovascular research] Franz WM, et al. **Z Kardiol** 1995; 84 Suppl 4:17–32 (105 ref.) (Eng. Abstr.) **(Ger)**
[Angiotensin receptors––organ and subtype specific regulation in cardiovascular diseases by modulation of the renin–angiotensin system. Studies of the rat model and in human myocardium] Regitz–Zagrosek V, et al.
Z Kardiol 1995;84 Suppl 4:61–9 (34 ref.) (Eng. Abstr.) **(Ger)**
[Experimental approaches for gene therapy modification of vascular remodeling] von der Leyen HE, et al.
Z Kardiol 1995 Oct;84(10):791–7 (62 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Anticardiolipin antibodies and cardiovascular disease [see comments] Muir KW. **J R Soc Med** 1995 Aug;88(8):433–6 (53 ref.) Comment in: J R Soc Med 1996 Feb;89(2):119.

METABOLISM

Cardiovascular (biochemical assessment of reperfusion). Van Lente F. **Anal Chem** 1995 Jun 15;67(12):379R–382R (41 ref.)
Nitric oxide in cardiovascular diseases. Nava E, et al.
Ann Med 1995 Jun;27(3):343–51 (82 ref.)
Stress–activated protein kinases in cardiovascular disease. Force T, et al. **Circ Res** 1996 Jun;78(6):947–53 (39 ref.)

MORTALITY

Does weight cycling present a health risk? Jeffery RW.
Am J Clin Nutr 1996 Mar;63(3 Suppl):452S–455S (16 ref.)
Causes of death in autosomal dominant polycystic kidney disease. Fick GM, et al. **J Am Soc Nephrol** 1995 Jun; 5(12):2048–56 (81 ref.)
Why are lipids not predictive of cardiovascular death in the dialysis patient? Ritz E. **Miner Electrolyte Metab** 1996; 22(1–3):9–12 (25 ref.)
Hypertension, cardiovascular complications and survival in diabetic patients on maintenance haemodialysis. Ritz E, et al. **Nephrol Dial Transplant** 1995;10 Suppl 7:43–6 (9 ref.)
[Effect of fetal and neonatal growth on the occurrence of some diseases in adults] Jendryczko A, et al.
Ginekol Pol 1996 Jan;67(1):34–6 (11 ref.) (Eng. Abstr.) **(Pol)**

PATHOLOGY

Structural changes in cardiovascular disease. Cohn JN.
Am J Cardiol 1995 Nov 24;76(15):34E–37E (36 ref.)
Magnetic resonance of the heart and great vessels. de Roos A, et al. **Nat Med** 1995 Jul;1(7):711–3 (6 ref.)

PHYSIOPATHOLOGY

Do non–insulin–dependent diabetes mellitus and cardiovascular disease share common antecedents? Stern MP. **Ann Intern Med** 1996 Jan 1;124(1 Pt 2):110–6 (90 ref.)
Endogenous nitric oxide in cardiovascular disease and transplantation. Dusting GJ, et al. **Ann Med** 1995 Jun; 27(3):395–406 (123 ref.)
Hemoconcentration and stress: a review of physiological mechanisms and relevance for cardiovascular disease risk. Allen MT, et al. **Biol Psychol** 1995 Aug;41(1):1–27 (125 ref.)
Epidemiologic aspects of circadian patterns of cardiovascular disease and triggers of acute cardiac events. Goldberg RJ. **Cardiol Clin** 1996 May;14(2):175–84 (40 ref.)
Hemostatic factors as triggers of cardiovascular events. Rosito GB, et al. **Cardiol Clin** 1996 May;14(2):239–50 (95 ref.)
Ventricular remodeling. Maisch B. **Cardiology** 1996;87 Suppl 1:2–10 (22 ref.)
Assessment of the microcirculation in cardiovascular disease. Struijker–Boudier HA, et al. **Clin Sci (Colch)** 1996 Aug; 91(2):131–9 (75 ref.)
Testosterone and risk factors for cardiovascular disease in men. Barrett–Connor EL. **Diabete Metab** 1995 Jun; 21(3):156–61 (41 ref.)
The insulin resistance syndrome revisited. Haffner SM.
Diabetes Care 1996 Mar;19(3):275–7 (43 ref.)
Sulphonylurea treatment of NIDDM patients with cardiovascular disease: a mixed blessing? Leibowitz G, et al. **Diabetologia** 1996 May;39(5):503–14 (140 ref.)
Assessment of the cardiovascular effects of stress. Engler MB, et al. **J Cardiovasc Nurs** 1995 Oct;10(1):51–63 (85 ref.)
Sympathetic nervous system: contribution to human hypertension and related cardiovascular diseases. Esler M. **J Cardiovasc Pharmacol** 1995;26 Suppl 2:S24–8 (32 ref.)
Genes and physiology: molecular physiology in genetically engineered animals. Chien KR. **J Clin Invest** 1996 Feb 15; 97(4):901–9 (66 ref.)
Role of angiotensin II in blood pressure regulation and in the pathophysiology of cardiovascular disorders. Fyhrquist F, et al. **J Hum Hypertens** 1995 Nov;9 Suppl 5:S19–24 (50 ref.)
Renin–angiotensin–aldosterone system for blood pressure and electrolyte homeostasis and its involvement in hypertension, in congestive heart failure and in associated cardiovascular damage (myocardial infarction and stroke). Laragh JH. **J Hum Hypertens** 1995 Jun;9(6):385–90 (47 ref.)
Resistance vessel growth and remodelling: cause or consequence in cardiovascular disease. Mulvany MJ.
J Hum Hypertens 1995 Jun;9(6):479–85 (43 ref.)
Bioenergetics in the pathogenesis, progression and treatment of cardiovascular disorders. Tanner HA.
Med Hypotheses 1995 May;44(5):347–58 (82 ref.)
Endothelin and endothelin antagonists: potential role in cardiovascular and renal disease. Noll G, et al.
Mol Cell Biochem 1996 Apr 12–26;157(1–2):259–67 (105 ref.)
Cellular effects of calcium channel blockers on vascular cells. Haller H. **Nephrol Dial Transplant** 1995 Oct;10 Suppl 9:3–8 (60 ref.)
Visceral fat accumulation and cardiovascular disease. Matsuzawa Y, et al. **Obes Res** 1995 Dec;3 Suppl 5:645S–647S (11 ref.)
The role of coronary microvascular dysfunction in the genesis of cardiovascular diseases. Parodi O, et al.
Q J Nucl Med 1996 Mar;40(1):9–16 (56 ref.)
[Endothelin––a cardiovascular regulatory peptide. II. Outline of its pathophysiologic activity] Lisý O. **Cesk Fysiol** 1995 Sep;44(3):152–7 (45 ref.) (Eng. Abstr.) **(Cze)**
[Serotonin and cardiovascular diseases] Reneman RS, et al.
Ned Tijdschr Geneeskd 1995 Oct 14;139(41):2080–4 (55 ref.) **(Dut)**
[The effect of smoking and of smoking cessation on

pathophysiological mechanisms of cardiovascular diseases] van den Berkmortel FW, et al. **Ned Tijdschr Geneeskd** 1996 Aug 24;140(34):1712–6 (47 ref.) **(Dut)**

[Homocysteine: relations to ischemic cardiovascular diseases] Piolot A, et al. **Rev Med Interne** 1996;17(1):34–45 (143 ref.) (Eng. Abstr.) **(Fre)**

[Sleep-related apnea disorders and associated cardiovascular diseases] Konermann M, et al. **Med Klin** 1995 Aug 15; 90(8):480–5 (60 ref.) **(Ger)**

[Cardiopulmonary involvement in thyroid gland diseases] Hellermann J, et al. **Pneumologie** 1996 May;50(5):375–80 (48 ref.) (Eng. Abstr.) **(Ger)**

[Sleep apnea syndrome, arterial hypertension and cardiovascular risks] Russi EW, et al. **Schweiz Med Wochenschr** 1995 Nov 25;125(47):2267–72 (36 ref.) (Eng. Abstr.) **(Ger)**

[Chronobiology and chronopharmacology of cardiovascular diseases] Lemmer B. **Wien Med Wochenschr** 1995; 145(17–18):445–7 (29 ref.) (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

Cardioprotection and antihypertensive therapy: the key importance of addressing the associated coronary risk factors (the Framingham experience). Kannel WB. **Am J Cardiol** 1996 Feb 22;77(6):6B–11B (19 ref.)

Antioxidant vitamin–cardiovascular disease hypothesis is still promising, but still unproven: the need for randomized trials. Hennekens CH, et al. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1377S–1380S (26 ref.)

Epidemiologic evidence of a role of carotenoids in cardiovascular disease prevention. Kohlmeier L, et al. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1370S–1376S (38 ref.)

Cardioprotective potential of antihypertensives. Hansson L. **Am J Hypertens** 1995 Oct;8(10 Pt 2):49S–52S (20 ref.)

The role of the pediatrician in the promotion of cardiovascular health. Bronfin DR, et al. **Am J Med Sci** 1995 Dec;310 Suppl 1:S42–7 (43 ref.)

The benefits of physical activity in childhood. Harsha DW. **Am J Med Sci** 1995 Dec;310 Suppl 1:S109–13 (22 ref.)

Roles of nurses and health workers in cardiovascular health promotion. Hill MN, et al. **Am J Med Sci** 1995 Dec;310 Suppl 1:S123–6 (16 ref.)

Health ahead—the Heart Smart Family approach to prevention of cardiovascular disease. Johnson CC, et al. **Am J Med Sci** 1995 Dec;310 Suppl 1:S127–32 (24 ref.)

Absolute cardiovascular risk: the basis for deciding to treat. Alderman MH. **Am J Nephrol** 1996;16(3):182–9 (40 ref.)

The antioxidant vitamins and cardiovascular disease. A critical review of epidemiologic and clinical trial data [see comments] Jha P, et al. **Ann Intern Med** 1995 Dec 1; 123(11):860–72 (55 ref.) Comment in: Ann Intern Med 1995 Dec 1;123(11):887.

Cardiovascular complications of diabetes mellitus: what we know and what we need to know about their prevention. Savage PJ. **Ann Intern Med** 1996 Jan 1;124(1 Pt 2):123–6 (29 ref.)

Cardiovascular disease and vitamins. Concurrent correction of 'suboptimal' plasma antioxidant levels may, as important part of 'optimal' nutrition, help to prevent early stages of cardiovascular disease and cancer, respectively. Gey KF. **Bibl Nutr Dieta** 1995;(52):75–91 (58 ref.)

Postmenopausal oestrogens and arteries. Vyas S, et al. **Br J Obstet Gynaecol** 1995 Dec;102(12):942–6 (30 ref.)

Hormone replacement therapy and cardiovascular disease: the case for a randomized controlled trial. Vickers MR, et al. **Ciba Found Symp** 1995;191:150–60; discussion 160–4 (31 ref.)

Can the kidney prevent cardiovascular diseases? Rodicio JL. **Clin Exp Hypertens** 1996 Apr–May;18(3–4):501–11 (31 ref.)

Assessment of nutrition and physical activity education programmes in children. Burke V, et al. **Clin Exp Pharmacol Physiol** 1995 Mar;22(3):212–6 (33 ref.)

Mechanisms for reduction of cardiovascular risk by regular exercise. Jennings GL. **Clin Exp Pharmacol Physiol** 1995 Mar;22(3):209–11 (24 ref.)

Free radicals, oxidative stress, oxidized low density lipoprotein (LDL), and the heart: antioxidants and other strategies to limit cardiovascular damage. Sinatra ST, et al. **Conn Med** 1995 Oct;59(10):579–88 (94 ref.)

Long-term aspirin in the prevention of cardiovascular disorders. Recent developments and variations on a theme. Catella-Lawson F, et al. **Drug Saf** 1995 Aug;13(2):69–75 (53 ref.)

Community programmes for cardiovascular disease prevention in changing societies [editorial; comment] Pyörälä K. **Eur Heart J** 1995 Jun;16(6):723–5 (10 ref.) Comment on: Eur Heart J 1995 Jun;16(6):752–60.

Prevention of cardiovascular disease: from biomedical research to health policy. Muntoni S. **Eur J Epidemiol** 1995 Oct;11(5):485–94 (74 ref.)

Lipid lowering in the young [editorial] Thompson GR. **Heart** 1996 Jul;76(1):1–2 (17 ref.)

The case for postmenopausal hormone therapy. Speroff L. **Hosp Pract (Off Ed)** 1996 Feb 15;31(2):75–89 (13 ref.)

Is HRT indicated for the prevention of cardiovascular disease? Samsioe G. **Int J Fertil Menopausal Stud** 1995;40 Suppl 1:33–9 (17 ref.)

Cardiovascular disease in women: implications of hormone replacement therapy. Sarrel PM. **Int J Fertil Menopausal Stud** 1996 Mar–Apr;41(2):90–3 (20 ref.)

The Mediterranean diet and cardiovascular disease. Hiser E. **J Cardpulm Rehabil** 1995 May–Jun;15(3):179–82 (22 ref.)

Benefit/risk of estrogen therapy in cardiovascular disease: current knowledge and future challenges. Chow MS. **J Clin Pharmacol** 1995 Sep;35(9 Suppl):11S–17S (14 ref.)

Is cardiovascular screening in primary care worthwhile? Coope JR. **J Hum Hypertens** 1995 Oct;9(10):785–6 (20 ref.)

Hormone replacement therapy and cardiovascular risk: the cardiovascular physicians' viewpoint. Lip GY, et al. **J Intern Med** 1995 Nov;238(5):389–99 (88 ref.)

The Department of Health Cardiovascular Review Group and public health policy: an alternative view [see comments] Gurr MI, et al. **J R Soc Health** 1995 Oct; 115(5):279–81 (20 ref.) Comment in: J R Soc Health 1996 Apr;116(2):121–2.

The menopause, hormone replacement, and cardiovascular disease: the epidemiologic evidence. Barrett-Connor E. **Maturitas** 1996 Mar;23(2):227–34 (57 ref.)

The importance of vitamin E in reducing cardiovascular risk. Abbey M. **Nutr Rev** 1995 Sep;53(9 Pt 2):S28–32 (44 ref.)

Community programs for obesity prevention: the Minnesota Heart Health Program. Jeffery RW. **Obes Res** 1995 Sep; 3 Suppl 2:283s–288s (21 ref.)

Non-invasive blood pressure monitoring in man. Portaluppi F. **Pathol Biol (Paris)** 1996 Mar;44(3):196–200 (80 ref.)

Physical activity in the prevention of cardiovascular disease. Francis K. **Phys Ther** 1996 May;76(5):456–68 (106 ref.)

Cardiovascular risk-factor reduction in elderly patients with cardiac disease. Williams MA. **Phys Ther** 1996 May; 76(5):469–80 (103 ref.)

The importance of tight blood glucose control in diabetes [editorial] Andersson DK. **Scand J Prim Health Care** 1995 Jun;13(2):81–2 (12 ref.)

Clinical trials of primary and secondary prevention of thrombosis and restenosis. Vermylen J. **Thromb Haemost** 1995 Jul;74(1):377–81 (54 ref.)

Estrogen replacement therapy in the elderly. Paganini-Hill A. **Zentralbl Gynakol** 1996;118(5):255–61 (41 ref.)

[Phytotherapeutic aspects of diseases of the cardiovascular system. 5. Saponins and possibilities of their use in prevention and therapy] Purmová J, et al. **Ceska Slov Farm** 1995 Oct;44(5):246–51 (53 ref.) (Eng. Abstr.) **(Cze)**

[Physical exercise and its effects on the cardiovascular system in elderly subjects] Arroyo JF, et al. **Schweiz Rundsch Med Prax** 1996 Feb 6;85(6):172–5 (29 ref.) (Eng. Abstr.) **(Fre)**

[Health promotion in the heart of Quebec and Canada: the ever present influence of the North Karelia model] Paradis G, et al. **Union Med Can** 1995 Sep;124(2):1–6 (19 ref.) **(Fre)**

[Estrogens in menopause—therapy and prevention. III. Estrogen replacement in menopause: uses and risks in prevention and therapy of cardiovascular diseases] Reincke M, et al. **Internist (Berl)** 1996 Apr;37(4):410–5; discussion 415 (20 ref.) **(Ger)**

[Nutrition-related prevention studies in children and adolescents on a population level—concepts, methods, outcome] Kersting M, et al. **Z Arztl Fortbild (Jena)** 1996 Feb;90(1):25–31 (34 ref.) (Eng. Abstr.) **(Ger)**

[Hormone replacement therapy and the cardiovascular system: on the role of hemostasis] Winkler UH. **Zentralbl Gynakol** 1995;117(10):510–5 (34 ref.) (Eng. Abstr.) **(Ger)**

[Treatment when blood pressure rises or falls in hypertension—new considerations for optimal prevention of cardiovascular damage] Zimlichman R. **Harefuah** 1996 Mar 15;130(6):404–6 (11 ref.) **(Heb)**

[Echocardiographic examinations for mass-screening of cardiovascular abnormalities] Sato H, et al. **Rinsho Byori** 1995 Nov;43(11):1108–12 (11 ref.) (Eng. Abstr.) **(Jpn)**

[The role of nutrition in the development of circulatory system diseases] Szponar L, et al. **Wiad Lek** 1994 Oct; 47(19–20):771–8 (50 ref.) (Eng. Abstr.) **(Pol)**

[Cardiovascular disease and hormone replacement therapy] Aldrighi JM, et al. **Arq Bras Cardiol** 1995 Sep;65(3):249–54 (72 ref.) **(Por)**

PSYCHOLOGY

Stress management for the cardiovascular patient: a look at current treatment and trends. Ulmer D. **Prog Cardiovasc Nurs** 1996 Winter;11(1):21–9 (31 ref.)

[The impact of psychological factors on the treatment of somatic diseases. The situation today, as exemplified by cardiovascular disorders and cancer] Blomhoff S, et al. **Tidsskr Nor Laegeforen** 1995 Sep 30;115(23):2893–5 (31 ref.) (Eng. Abstr.) **(Nor)**

RADIOGRAPHY

Cardiovascular radiography. Hemphill RR, et al. **Emerg Med Clin North Am** 1995 Nov;13(4):855–85 (21 ref.)

REHABILITATION

Assessment of quality of life in recovery settings. Kinney MR. **J Cardiovasc Nurs** 1995 Oct;10(1):88–96 (41 ref.)

Exercise intensity prescription in cardiovascular disease. Theoretical basis for anaerobic threshold determination. Gordon NF, et al. **J Cardpulm Rehabil** 1995 May–Jun; 15(3):193–6 (20 ref.)

Cardiac rehabilitation based on group light exercise and discussion. An Australian hospital model. Hare DL, et al. **J Cardpulm Rehabil** 1995 May–Jun;15(3):186–92 (27 ref.)

Arguments in favor of screening for diabetes in cardiac rehabilitation. Maki KC, et al. **J Cardpulm Rehabil** 1995 Mar–Apr;15(2):97–102 (41 ref.)

Role of exercise in the management of cardiovascular disease in children and youth. Tomassoni TL. **Med Sci Sports Exerc** 1996 Apr;28(4):406–13 (66 ref.)

Women's compliance with cardiac rehabilitation programs. Ginzel AR. **Prog Cardiovasc Nurs** 1996 Winter;11(1):30–5 (38 ref.)

[Sports and rehabilitation in old age] Niederhauser HU. **Schweiz Rundsch Med Prax** 1995 Oct 31;84(44):1259–64 (30 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

[Cardiorespiratory system adaptation after surgical correction of intracardiac hemodynamics] Shevchenko IuL. **Fiziol Cheloveka** 1996 Mar–Apr;22(2):20–4 (14 ref.) **(Rus)**

THERAPY

Vascular gene therapy. Flugelman MY. **Adv Exp Med Biol** 1995;382:269–77 (25 ref.)

Economic comparison of drug and lifestyle treatment of cardiovascular risk factors in high-risk patients. Millar JA. **Clin Exp Pharmacol Physiol** 1995 Mar;22(3):217–9 (22 ref.)

Novel strategy of gene therapy in cardiovascular disease with HVJ-liposome method. Morishita R, et al. **Contrib Nephrol** 1996;118:254–64 (26 ref.)

Gene therapy for cardiovascular diseases. Bauters C. **Eur Heart J** 1995 Sep;16(9):1166–8 (17 ref.)

Cardiovascular diseases in women: an equal opportunity killer. Morgan NA, et al. **J Am Pharm Assoc (Wash)** 1996 Jun;NS36(6):360–9 (98 ref.)

Bioenergetics in the pathogenesis, progression and treatment of cardiovascular disorders. Tanner HA. **Med Hypotheses** 1995 May;44(5):347–58 (82 ref.)

[Circulatory support. I. Indications and description of systems] Defraigne JO, et al. **Rev Med Liege** 1996 Apr; 51(4):295–306 (0 ref.) **(Fre)**

ULTRASONOGRAPHY

Emergency medicine applications of echocardiography. Wellford AL, et al. **Emerg Med Clin North Am** 1995 Nov; 13(4):831–54 (72 ref.)

VETERINARY

[Sedation and anesthesia in dogs and cats with cardiovascular diseases. I. Anesthesia plan considering risk assessment, hemodynamic effects of drugs and monitoring] Skarda RT, et al. **Schweiz Arch Tierheilkd** 1995;137(7):312–21 (13 ref.) (Eng. Abstr.) **(Ger)**

CARDIOVASCULAR SYSTEM

Physical activity and cardiovascular health. NIH Consensus Development Panel on Physical Activity and Cardiovascular Health. **JAMA** 1996 Jul 17;276(3):241–6 (0 ref.)

DRUG EFFECTS

Cardiovascular and autonomic effects of sevoflurane. Ebert TJ. **Acta Anaesthesiol Belg** 1996;47(1):15–21 (22 ref.)

Cardiovascular responses to sevoflurane: a review. Ebert TJ, et al. **Anesth Analg** 1995 Dec;81(6 Suppl):S11–22 (43 ref.)

Cardiovascular structural alterations in hypertension: effect of treatment. Agabiti-Rosei E, et al. **Clin Exp Hypertens** 1996 Apr–May;18(3–4):513–22 (42 ref.)

Cardiovascular toxicity with cancer chemotherapy. Frishman WH, et al. **Curr Probl Cardiol** 1996 Apr;21(4):225–86 (227 ref.)

Carvedilol, a novel vasodilating beta-blocker with the potential for cardiovascular organ protection. Feuerstein GZ, et al. **Eur Heart J** 1996 Apr;17 Suppl B:24–9 (24 ref.)

Pharmacological characterisation and autoradiographic localisation of dopamine receptor subtypes in the cardiovascular system and in the kidney. Amenta F, et al. **Hypertens Res** 1995 Jun;18 Suppl 1:S23–7 (10 ref.)

Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group. Jaillon P, et al. **J Antimicrob Chemother** 1996 May;37 Suppl A:161–7 (4 ref.)

Cardiovascular effects of androgenic-anabolic steroids. Melchert RB, et al. **Med Sci Sports Exerc** 1995 Sep; 27(9):1252–62 (114 ref.)

The role of endothelin-1 in cardiovascular physiology and pathophysiology. Webb DJ, et al. **Scott Med J** 1995 Jun; 40(3):69–71 (26 ref.)

[The cardiovascular effects of alcohol] Estruch R. **Med Clin (Barc)** 1995 Nov 11;105(16):628–35 (80 ref.) **(Spa)**

EMBRYOLOGY

Early embryonic vascular development. Baldwin HS. **Cardiovasc Res** 1996 Feb;31 Spec No:E34–45 (98 ref.)

Cardiovascular morphogenesis in zebrafish. Weinstein BM, et al. **Cardiovasc Res** 1996 Feb;31 Spec No:E17–24 (39 ref.)

Primitive-streak origin and state of commitment of cells of the cardiovascular system in avian and mammalian

embryos. Schoenwolf GC, et al. **Cell Mol Biol Res** 1995; 41(4):233–40 (54 ref.)

INJURIES

Electrical injuries: current concepts. Leibovici D, et al. **Injury** 1995 Nov;26(9):623–7 (33 ref.)

INNERVATION

c-fos expression as a marker of central cardiovascular neurons. Dun NJ, et al. **Biol Signals** 1995 May–Jun; 4(3):117–23 (25 ref.)

Sympathetic reflex regulation of the peripheral circulation in humans. Jacobsen TN. **Dan Med Bull** 1996 Apr; 43(2):126–40 (148 ref.)

Contribution of the cerebellar vermis to cardiovascular control. Ghelarducci B, et al. **J Auton Nerv Syst** 1996 Jan 5;56(3):149–56 (51 ref.)

Neurochemical modulation of cardiovascular control in the nucleus tractus solitarius. Lawrence AJ, et al. **Prog Neurobiol** 1996 Jan;48(1):21–53 (500 ref.)

METABOLISM

Insulin-like growth factor I and its binding proteins in the cardiovascular system. Delafontaine P. **Cardiovasc Res** 1995 Dec;30(6):825–34 (162 ref.)

Endothelin receptor subtypes and their role in transmembrane signaling mechanisms. Sokolovsky M. **Pharmacol Ther** 1995;68(3):435–71 (208 ref.)

Nitric oxide and its role in the cardiovascular system. Loscalzo J, et al. **Prog Cardiovasc Dis** 1995 Sep–Oct; 38(2):87–104 (171 ref.)

PATHOLOGY

Cardiovascular structural alterations in hypertension: effect of treatment. Agabiti-Rosei E, et al. **Clin Exp Hypertens** 1996 Apr–May;18(3–4):513–22 (42 ref.)

PHYSIOLOGY

Cellular and molecular mechanisms of cardiovascular aging. Molecular pharmacological implications. Miyamoto A, et al. **Ann N Y Acad Sci** 1996 Jun 15;786:283–93 (58 ref.)

Cardiovascular function of the paraventricular nucleus of the hypothalamus. Coote JH. **Biol Signals** 1995 May–Jun; 4(3):142–9 (31 ref.)

New aspects of the role of histamine in cardiovascular function: identification, characterization, and potential pathophysiological importance of H3 receptors. Göthert M, et al. **Can J Physiol Pharmacol** 1995 May;73(5):558–64 (23 ref.)

Angiotensin II as a modulator of cardiovascular autonomic control. Townend JN. **Cardiologia** 1996 Mar;41(3):217–25 (83 ref.)

Cardiovascular protection by oestrogen is partly mediated through modulation of autonomic nervous function. Du XJ, et al. **Cardiovasc Res** 1995 Aug;30(2):161–5 (57 ref.)

Capsaicin-sensitive sensory-motor neurotransmission in the peripheral control of cardiovascular function. Rubino A, et al. **Cardiovasc Res** 1996 Apr;31(4):467–79 (160 ref.)

Cardiopulmonary physiology and pathophysiology as a consequence of laparoscopic surgery. Sharma KC, et al. **Chest** 1996 Sep;110(3):810–5 (76 ref.)

Mechanisms for reduction of cardiovascular risk by regular exercise. Jennings GL. **Clin Exp Pharmacol Physiol** 1995 Mar;22(3):209–11 (24 ref.)

Normal cardiopulmonary physiology during pregnancy. Crapo RO. **Clin Obstet Gynecol** 1996 Mar;39(1):3–16 (54 ref.)

Potassium channels in the cardiovascular system. Pogátsa G. **Diabetes Res Clin Pract** 1995 Aug;28 Suppl:S91–8 (48 ref.)

Autonomic cardiovascular control in pregnancy. Ekholm EM, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Jan; 64(1):29–36 (75 ref.)

The cardiovascular responses to feeding in man. Kearney MT, et al. **Exp Physiol** 1995 Sep;80(5):683–700 (78 ref.)

Endothelial control of the cardiovascular system: recent advances. Griendling KK, et al. **FASEB J** 1996 Feb; 10(2):283–92 (60 ref.)

Beta 3-adrenoceptors in the cardiovascular system. Berlan M, et al. **Fundam Clin Pharmacol** 1995;9(3):234–9 (39 ref.)

Endothelium-dependent regulation of the cardiovascular system. Shimokawa H, et al. **Intern Med** 1995 Oct; 34(10):939–46 (105 ref.)

Calcium channel diversity in the cardiovascular system. Katz AM. **J Am Coll Cardiol** 1996 Aug;28(2):522–9 (65 ref.)

Estrogen and cardiovascular function after menopause. Samaan SA, et al. **J Am Coll Cardiol** 1995 Nov 15; 26(6):1403–10 (77 ref.)

Contribution of the cerebellar vermis to cardiovascular control. Ghelarducci B, et al. **J Auton Nerv Syst** 1996 Jan 5;56(3):149–56 (51 ref.)

Distribution and molecular forms of urotensin II and its role in cardiovascular regulation in vertebrates. Conlon JM, et al. **J Exp Zool** 1996 Jun 1–15;275(2–3):226–38 (92 ref.)

Gravity, blood circulation, and the adaptation of form and function in lower vertebrates. Lillywhite HB. **J Exp Zool** 1996 Jun 1–15;275(2–3):217–25 (37 ref.)

Epilogue: comparative cardiovascular biology of lower vertebrates. Muñoz-Chápuli R, et al. **J Exp Zool** 1996 Jun 1–15;275(2–3):249–51 (16 ref.)

Evidence for cardiovascular effects of prorenin. Sealey JE. **J Hum Hypertens** 1995 Jun;9(6):381–4 (32 ref.)

Protein tyrosine phosphorylation in cardiovascular system. Srivastava AK. **Mol Cell Biochem** 1995 Aug–Sep; 149–150:87–94 (90 ref.)

Estrogen: effects on the cardiovascular tree. Wild RA. **Obstet Gynecol** 1996 Feb;87(2 Suppl):27S–35S (70 ref.)

Modulation of cardiovascular control mechanisms and their interaction. Persson PB. **Physiol Rev** 1996 Jan; 76(1):193–244 (792 ref.)

Neurotransmitters involved in the central regulation of the cardiovascular system. McCall RB. **Prog Drug Res** 1996; 46:43–113 (484 ref.)

Neurochemical modulation of cardiovascular control in the nucleus tractus solitarius. Lawrence AJ, et al. **Prog Neurobiol** 1996 Jan;48(1):21–53 (500 ref.)

Central neural organization and control of sympathetic nervous system in mammals. Sun MK. **Prog Neurobiol** 1995 Oct;47(3):157–233 (1200 ref.)

The role of cardiovascular reactivity as a mediator of hypertension in African Americans. Falkner B. **Semin Nephrol** 1996 Mar;16(2):117–25 (52 ref.)

Thyroid status and exercise tolerance. Cardiovascular and metabolic considerations. McAllister RM, et al. **Sports Med** 1995 Sep;20(3):189–98 (64 ref.)

[Cardiovascular evaluation in athletic children] Sluysmans T, et al. **Arch Pediatr** 1995 Nov;2(11):1101–15 (106 ref.) (Eng. Abstr.) **(Fre)**

[Natural estrogens and the cardiovascular system] Bader A, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(3):233–7 (38 ref.) (Eng. Abstr.) **(Fre)**

[Cardiovascular function during laparoscopies] Berg K, et al. **Dtsch Med Wochenschr** 1995 Nov 10;120(45):1561–7 (49 ref.) **(Ger)**

[Cardiovascular response to physical exercise] Iacono A, et al. **Cardiologia** 1996 Mar;41(3):241–50 (82 ref.) **(Ita)**

[Cardiovascular interaction and anesthesia] Hoka S. **Masui** 1995;44 Suppl:S52–8 (15 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Baroreflexes and cardiovascular regulation in hypertension. Head GA. **J Cardiovasc Pharmacol** 1995;26 Suppl 2:S7–16 (86 ref.)

The cardiopulmonary system and movement dysfunction. Peel C. **Phys Ther** 1996 May;76(5):448–55 (34 ref.)

[Nitric oxide: the endogenous nitrate in the cardiovascular system] Tschudi MR, et al. **Herz** 1996 Jun;21 Suppl 1:50–60 (104 ref.) (Eng. Abstr.) **(Ger)**

[Cardiorespiratory system adaptation after surgical correction of intracardiac hemodynamics] Shevchenko IuL. **Fiziol Cheloveka** 1996 Mar–Apr;22(2):20–4 (14 ref.) **(Rus)**

CARDIOVERSION see **ELECTRIC COUNTERSHOCK**

CARDIOVERTER-DEFIBRILLATORS, IMPLANTABLE see **DEFIBRILLATORS, IMPLANTABLE**

CARDIOVIRUS INFECTIONS

THERAPY

Immunomodulating agents for the management of heart failure with myocarditis and cardiomyopathy—lessons from animal experiments. Matsumori A, et al. **Eur Heart J** 1995 Dec;16 Suppl O:140–3 (10 ref.)

CAREER CHOICE

Decline of U.S. medical student career choice of psychiatry and what to do about it. Sierles FS, et al. **Am J Psychiatry** 1995 Oct;152(10):1416–26 (127 ref.)

Practice-building seminars in chiropractic: a Petit Bourgeois response to biomedical domination. Baer HA. **Med Anthropol Q** 1996 Mar;10(1):29–44 (45 ref.)

CAREER LADDERS see **CAREER MOBILITY**

CAREER MOBILITY

Gender differences in career progress in nursing: towards a non-essentialist structural theory. Ratcliffe P. **J Adv Nurs** 1996 Feb;23(2):389–95 (48 ref.)

Practice-building seminars in chiropractic: a Petit Bourgeois response to biomedical domination. Baer HA. **Med Anthropol Q** 1996 Mar;10(1):29–44 (45 ref.)

CAREGIVERS

Caring for older people. Carers. Travers AF. **BMJ** 1996 Aug 24;313(7055):482–6 (6 ref.)

A review of the historical and social processes contributing to care and caregiving in Chinese families. Holroyd EA, et al. **J Adv Nurs** 1995 Sep;22(3):473–9 (39 ref.)

Believing and dreaming to improve cancer care. Given BA. **Oncol Nurs Forum** 1995 Jul;22(6):929–40 (36 ref.)

Explication of the construct of shared care and the prevention of pressure ulcers in home health care. Sebern MD. **Res Nurs Health** 1996 Jun;19(3):183–92 (50 ref.)

Concerns about analgesics among patients and family caregivers in a hospice setting. Ward SE, et al. **Res Nurs Health** 1996 Jun;19(3):205–11 (31 ref.)

PSYCHOLOGY

Caring for the lay caregiver. Ruppert RA. **Am J Nurs** 1996 Mar;96(3):40–5; quiz 46 (6 ref.)

Quality of life and caregiving in technological home care. Smith CE. **Annu Rev Nurs Res** 1996;14:95–118 (141 ref.)

Futile care or caregiver frustration? A practical approach. Civetta JM. **Crit Care Med** 1996 Feb;24(2):346–51 (13 ref.)

Helping the relatives of patients with cancer [editorial; comment] Fallowfield L. **Eur J Cancer** 1995 Oct; 31A(11):1731–2 (13 ref.) Comment on: Eur J Cancer 1995 Oct;31A(11):1736–40.

Anticipatory grief and AIDS: strategies for intervening with caregivers. Walker RJ, et al. **Health Soc Work** 1996 Feb; 21(1):49–57 (43 ref.)

Relationship between elderly carers and the older adult with learning disabilities: an overview of the literature. Maggs C, et al. **J Adv Nurs** 1996 Feb;23(2):243–51 (56 ref.)

At the bedside. Influencing a patient's religious beliefs: mandate or no-man's land? Howe EG. **J Clin Ethics** 1995 Fall;6(3):194–201 (29 ref.)

Implementing feminist perspectives in clinical care. Howe EG. **J Clin Ethics** 1996 Spring;7(1):2–12 (40 ref.)

Perinatally transmitted HIV infection. Supporting the helpers. Burr CK. **Nurs Clin North Am** 1996 Mar; 31(1):243–51 (21 ref.)

Family caregiver role acquisition: role-making through situated interaction. Schumacher KL. **Sch Inq Nurs Pract** 1995 Fall;9(3):211–26; discussion 227–9 (76 ref.)

STATISTICS & NUMERICAL DATA

Psychiatric and physical morbidity effects of dementia caregiving: prevalence, correlates, and causes. Schulz R, et al. **Gerontologist** 1995 Dec;35(6):771–91 (90 ref.)

CARIES, DENTAL see **DENTAL CARIES**

CARIES, ROOT see **ROOT CARIES**

CARING see **EMPATHY**

CARIOGENIC AGENTS

see related
DIET, CARIOGENIC

CARIOSTATIC AGENTS

see related
FLUORIDATION

ADMINISTRATION & DOSAGE

What is the effective concentration of fluoride? Ismail AI. **Community Dent Oral Epidemiol** 1995 Aug;23(4):246–51 (51 ref.)

CARMUSTINE

THERAPEUTIC USE

Topical treatment of early cutaneous T-cell lymphoma. Ramsay DL, et al. **Hematol Oncol Clin North Am** 1995 Oct;9(5):1031–56 (84 ref.)

CARNITINE

ANALOGS & DERIVATIVES

Acylcarnitines in intermediary metabolism. Sewell AC, et al. **Eur J Pediatr** 1995 Nov;154(11):871–7 (55 ref.)

ANALYSIS

[Carnitine] Kono N. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:510–3 (10 ref.) **(Jpn)**

BIOSYNTHESIS

Biosynthesis and metabolism of carnitine. Carter AL, et al. **J Child Neurol** 1995 Nov;10 Suppl 2:S3–7 (51 ref.)

DEFICIENCY

Carnitine disorders. Stanley CA. **Adv Pediatr** 1995;42:209–42 (24 ref.)

METABOLISM

Carnitine disorders. Stanley CA. **Adv Pediatr** 1995;42:209–42 (24 ref.)

L-Carnitine. Walter JH. **Arch Dis Child** 1996 Jun;74(6):475–8 (99 ref.)

Carnitine in neonatal nutrition. Borum PR. **J Child Neurol** 1995 Nov;10 Suppl 2:S25–31 (51 ref.)

Biosynthesis and metabolism of carnitine. Carter AL, et al. **J Child Neurol** 1995 Nov;10 Suppl 2:S3–7 (51 ref.)

Carnitine deficiency in epilepsy: Risk factors and treatment. Coulter DL. **J Child Neurol** 1995 Nov;10 Suppl 2:S32–9 (90 ref.)

Carnitine in human immunodeficiency virus type 1 infection/acquired immune deficiency syndrome. Mintz M. **J Child Neurol** 1995 Nov;10 Suppl 2:S40–4 (50 ref.)

Primary and secondary carnitine deficiency syndromes. Pons

CARNITINE

R, et al. **J Child Neurol** 1995 Nov;10 Suppl 2:S8–24 (149 ref.)

PHARMACOLOGY

Antioxidants, carnitine, and choline as putative ergogenic aids. Kanter MM, et al. **Int J Sport Nutr** 1995 Jun;5 Suppl:S120–31 (73 ref.)

PHYSIOLOGY

Carnitine—a known compound, a novel function in neural cells. Nałęcz KA, et al. **Acta Neurobiol Exp (Warsz)** 1996; 56(2):597–609 (86 ref.)

THERAPEUTIC USE

L-carnitine in dialysed patients: the choice of dosage regimen. Berard E, et al. **Int J Clin Pharmacol Res** 1995; 15(3):127–33 (43 ref.)

[Carnitine: vitamin or doping?] Krähenbühl S. **Ther Umsch** 1995 Oct;52(10):687–92 (28 ref.) (Eng. Abstr.) **(Ger)**

CARNITINE ACYLTRANSFERASES

PHYSIOLOGY

Microsomal carnitine acyltransferases. Broadway NM, et al. **Biochem Soc Trans** 1995 Aug;23(3):490–4 (49 ref.)

CARNITINE PALMITOYLTRANSFERASE

ANTAGONISTS & INHIBITORS

Malonyl-CoA and carnitine palmitoyltransferase I: an expanding partnership. McGarry JD. **Biochem Soc Trans** 1995 Aug;23(3):481–5 (29 ref.)

DEFICIENCY

Carnitine palmitoyltransferase deficiency in a college athlete: a case report and literature review. Faigel HC. **J Am Coll Health** 1995 Sep;44(2):51–4 (40 ref.)

[Recurrent myoglobinuria in a girl due to carnitine palmitoyltransferase deficiency] Carrasco Marina LL, et al. **An Esp Pediatr** 1996 Jan;44(1):67–9 (15 ref.) **(Spa)**

METABOLISM

Malonyl-CoA and carnitine palmitoyltransferase I: an expanding partnership. McGarry JD. **Biochem Soc Trans** 1995 Aug;23(3):481–5 (29 ref.)

CARNIVORA

METABOLISM

Felinine: a urinary amino acid of Felidae. Hendriks WH, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1995 Dec; 112(4):581–8 (33 ref.)

PARASITOLOGY

Ancylostoma genettae, A. protelesis, A. somaliense: three new species from wild Carnivora in the Somali Republic. Macchioni G. **Parassitologia** 1995 Dec;37(2–3):219–28 (26 ref.)

VIROLOGY

Coadaptation and immunodeficiency virus: lessons from the Felidae. Carpenter MA, et al. **Curr Opin Genet Dev** 1995 Dec;5(6):739–45 (53 ref.)

CARNOSINE

PHYSIOLOGY

Carnosine: a novel peptide regulator of intracellular calcium and contractility in cardiac muscle. Zaloga GP, et al. **New Horiz** 1996 Feb;4(1):26–35 (92 ref.)

CAROLI'S DISEASE

[Caroli disease and hepatobiliary fibropolycystic disease] Okazaki K, et al. **Ryoikibetsu Shokogun Shirizu** 1995; (8):73–6 (20 ref.) **(Jpn)**

[Congenital cystic dilatation of the intrahepatic bile ducts (Caroli's disease)] Suto T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):559–61 (14 ref.) **(Jpn)**

CAROTENE

ADMINISTRATION & DOSAGE

Considerations of the scientific substantiation for antioxidant vitamins and beta-carotene in disease prevention. Blumberg JB. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1521S–1526S (59 ref.)

Evidence from cancer intervention and biomarker studies and the development of biochemical markers. Bowen PE, et al. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1403S–1409S (54 ref.)

Antioxidants in oral cancer prevention. Garewal H. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1410S–1416S (54 ref.)

Antioxidant vitamin-cardiovascular disease hypothesis is still promising, but still unproven: the need for randomized trials. Hennekens CH, et al. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1377S–1380S (26 ref.)

Epidemiologic evidence of a role of carotenoids in cardiovascular disease prevention. Kohlmeier L, et al. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1370S–1376S (38 ref.)

Prevention of cervical intraepithelial neoplasia and cervical cancer. Meyskens FL Jr, et al. **Am J Clin Nutr** 1995 Dec; 62(6 Suppl):1417S–1419S (24 ref.)

Relations among aging, antioxidant status, and cataract. Taylor A, et al. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1439S–1447S (80 ref.)

Epidemiologic evidence for beta-carotene and cancer prevention. van Poppel G, et al. **Am J Clin Nutr** 1995 Dec; 62(6 Suppl):1393S–1402S (127 ref.)

What accounts for the association of vegetables and fruits with lower incidence of cancers and coronary heart disease? [editorial; comment] Omenn GS. **Ann Epidemiol** 1995 Jul;5(4):333–5 (12 ref.) Comment on: Ann Epidemiol 1995 Jul;5(4):255–60. Comment on: Ann Epidemiol 1995 Jul;5(4):261–9.

[Antioxidative vitamins and cataracts in the elderly] Heseker H. **Z Ernahrungswiss** 1995 Sep;34(3):167–76 (68 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Safety of antioxidant vitamins and beta-carotene. Diplock AT. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1510S–1516S (56 ref.)

PHARMACOLOGY

Antioxidants and immune response in aged persons: overview of present evidence. Meydani SN, et al. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1462S–1476S (146 ref.)

Vitamins E and C, beta-carotene, and other carotenoids as antioxidants. Sies H, et al. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1315S–1321S (87 ref.)

Antioxidant agents and colorectal carcinogenesis: role of beta-carotene, vitamin E and vitamin C. Pappalardo G, et al. **Tumori** 1996 Jan–Feb;82(1):6–11 (88 ref.)

PHYSIOLOGY

The antioxidant vitamins and cardiovascular disease. A critical review of epidemiologic and clinical trial data [see comments] Jha P, et al. **Ann Intern Med** 1995 Dec 1; 123(11):860–72 (55 ref.) Comment in: Ann Intern Med 1995 Dec 1;123(11):887.

Effect of vitamin E, vitamin C and beta-carotene on LDL oxidation and atherosclerosis. Jialal I, et al. **Can J Cardiol** 1995 Oct;11 Suppl G:97G–103G (97 ref.)

THERAPEUTIC USE

Beta-carotene, carotenoids, and disease prevention in humans. Mayne ST. **FASEB J** 1996 May;10(7):690–701 (70 ref.)

Intermediate cancer biomarkers and their use in beta-carotene studies in humans. Gerster H. **Int J Vitam Nutr Res** 1996;66(1):3–18 (83 ref.)

beta-carotene and cancer chemoprevention. Buring JE, et al. **J Cell Biochem Suppl** 1995;22:226–30 (37 ref.)

[Vitamin A derivatives and prevention of bronchial cancers] Thiberville L, et al. **Rev Mal Respir** 1996;13(2):193–5 (19 ref.) **(Fre)**

CAROTENOIDS

Microbial carotenoids. Johnson EA, et al. **Adv Biochem Eng Biotechnol** 1996;53:119–78 (339 ref.)

ADMINISTRATION & DOSAGE

Evidence for protection against age-related macular degeneration by carotenoids and antioxidant vitamins. Snodderly DM. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1448S–1461S (153 ref.)

BIOSYNTHESIS

Carotenoids 2: Genetics and molecular biology of carotenoid pigment biosynthesis. Armstrong GA, et al. **FASEB J** 1996 Feb;10(2):228–37 (64 ref.)

[Carotenoid biosynthetic pathway elucidated at the gene level] Misawa N. **Tanpakushitsu Kakusan Koso** 1996 Apr; 41(4):337–46 (47 ref.) **(Jpn)**

BLOOD

[Carotenoids] Onogi N, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:684–7 (14 ref.) **(Jpn)**

CHEMISTRY

Structure and properties of carotenoids in relation to function. Britton G. **FASEB J** 1995 Dec;9(15):1551–8 (31 ref.)

METABOLISM

Light-mediated conversion of nitrogen dioxide to nitric oxide by carotenoids. Cooney RV, et al. **Environ Health Perspect** 1994 May;102(5):460–2 (33 ref.)

Absorption, metabolism, and transport of carotenoids. Parker RS. **FASEB J** 1996 Apr;10(5):542–51 (74 ref.)

PHARMACOLOGY

Vitamins E and C, beta-carotene, and other carotenoids as antioxidants. Sies H, et al. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1315S–1321S (87 ref.)

Plant carotenoids and related molecules: important dietary antioxidants. Krinsky NI. **Biochem Soc Symp** 1995; 61:117–26 (47 ref.)

Saffron chemoprevention in biology and medicine: a review. Nair SC, et al. **Cancer Biother** 1995 Winter;10(4):257–64 (41 ref.)

Benefits and liabilities of vitamin A and carotenoids. Olson JA. **J Nutr** 1996 Apr;126(4 Suppl):1208S–12S (30 ref.)

The dual roles of nutrients as antioxidants and prooxidants: their effects on tumor cell growth. Schwartz JL. **J Nutr** 1996 Apr;126(4 Suppl):1221S–7S (42 ref.)

PHYSIOLOGY

Structure and properties of carotenoids in relation to function. Britton G. **FASEB J** 1995 Dec;9(15):1551–8 (31 ref.)

Carotenoids 3: in vivo function of carotenoids in higher plants. Demmig-Adams B, et al. **FASEB J** 1996 Mar; 10(4):403–12 (57 ref.)

Introduction: the colorful, fascinating world of the carotenoids: important physiologic modulators. Olson JA, et al. **FASEB J** 1995 Dec;9(15):1547–50 (31 ref.)

Update on the biological characteristics of the antioxidant micronutrients: vitamin C, vitamin E, and the carotenoids. Rock CL, et al. **J Am Diet Assoc** 1996 Jul;96(7):693–702; quiz 703–4 (128 ref.)

Parasites and carotenoid-based signal intensity: how general should the relationship be? Shykoff JA, et al. **Naturwissenschaften** 1996 Mar;83(3):113–21 (66 ref.)

THERAPEUTIC USE

Beta-carotene, carotenoids, and disease prevention in humans. Mayne ST. **FASEB J** 1996 May;10(7):690–701 (70 ref.)

Epidemiologic studies of antioxidants and cancer in humans. Flagg EW, et al. **J Am Coll Nutr** 1995 Oct;14(5):419–27 (88 ref.)

CAROTID ARTERIES

INJURIES

Carotid artery pseudoaneurysm and pellet embolism to the middle cerebral artery following a shotgun wound of the neck. Cogbill TH, et al. **J Trauma** 1995 Oct;39(4):763–7 (16 ref.)

The management of penetrating vascular injuries. Day JD, et al. **Neurosurg Clin N Am** 1995 Oct;6(4):799–808 (59 ref.)

PATHOLOGY

MR angiography of the extracranial carotid arteries. Rosovsky MA, et al. **Magn Reson Imaging Clin N Am** 1995 Aug;3(3):439–54 (43 ref.)

SURGERY

The cavernous carotid artery: preservation is the best means of reconstruction. Bowles AP Jr, et al. **Clin Neurosurg** 1995; 42:154–70 (41 ref.)

Techniques of carotid reconstruction. Fukushima T. **Clin Neurosurg** 1995;42:119–34 (24 ref.)

Neurophysiologic monitoring during cranial base surgery: is it necessary? Sekhar LN, et al. **Clin Neurosurg** 1995; 42:180–202 (37 ref.)

CAROTID ARTERY, COMMON

SURGERY

Ligation of the common carotid artery for the management of a mycotic pseudoaneurysm of an extracranial internal carotid artery. A case report and review of the literature. Lueg EA, et al. **Int J Pediatr Otorhinolaryngol** 1995 Aug; 33(1):67–74 (21 ref.)

CAROTID ARTERY DISEASES

COMPLICATIONS

[Raeder's syndrome (the paratrigeminal syndrome): its etiology related to carotid artery dissection. A case report] Monti L, et al. **Radiol Med (Torino)** 1996 Apr;91(4):473–5 (16 ref.) **(Ita)**

DIAGNOSIS

Dissection of the internal carotid and vertebral arteries: imaging features. Provenzale JM. **AJR Am J Roentgenol** 1995 Nov;165(5):1099–104 (53 ref.)

Spontaneous extracranial carotid artery dissection in

children. Patel H, et al. **Pediatr Neurol** 1995 Jul;13(1):55–60 (26 ref.)

[Characteristics and influence of different clinical forms on the development and prognosis of carotid sinus syndrome. Apropos of 215 cases] Graux P, et al. **Arch Mal Coeur Vaiss** 1995 Jul;88(7):999–1006 (29 ref.) (Eng. Abstr.) **(Fre)**

[Clinical evaluation and neurological ultrasonography in 60 cases of carotid dissection] Despland PA, et al. **Rev Med Suisse Romande** 1996 Aug;116(8):591–6 (29 ref.) **(Fre)**

[Dissection of the carotid artery and vertebral artery--diagnosis and therapy] Sperling W, et al. **Fortschr Neurol Psychiatr** 1996 Apr;64(4):153–60 (37 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

[Acute carotid occlusion: thrombolytic treatment] Maiza D, et al. **J Mal Vasc** 1996;21 Suppl A:83–9 (10 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Carotid–jugular arteriovenous fistula: a complication of temporary hemodialysis catheter. el–Shahawy MA, et al. **Am J Nephrol** 1995;15(4):332–6 (51 ref.)

PHYSIOPATHOLOGY

The P300 and vascular dementia: not quite ready for prime time [editorial; comment] Bergethon PR, et al. **J Am Geriatr Soc** 1995 Nov;43(11):1311–3 (14 ref.) Comment on: J Am Geriatr Soc 1995 Nov;43(11):1228–36.

RADIOGRAPHY

Angiographic workup of a carotid cavernous sinus fistula (CCF) or what information does the interventionalist need for treatment? [see comments] Debrun GM. **Surg Neurol** 1995 Jul;44(1):75–9 (18 ref.) Comment in: Surg Neurol 1996 Aug;46(2):193.

SURGERY

Ligation of the common carotid artery for the management of a mycotic pseudoaneurysm of an extracranial internal carotid artery. A case report and review of the literature. Lueg EA, et al. **Int J Pediatr Otorhinolaryngol** 1995 Aug; 33(1):67–74 (21 ref.)

THERAPY

Interventional neuroradiology of the head and neck. Hurst RW. **Neuroimaging Clin N Am** 1996 May;6(2):473–95 (38 ref.)

ULTRASONOGRAPHY

Ultrasonographic carotid plaque morphology in predicting stroke risk. Geroulakos G, et al. **Br J Surg** 1996 May; 83(5):582–7 (44 ref.)

CAROTID ARTERY, EXTERNAL

SURGERY

External carotid endarterectomy with internal carotid artery transposition flap angioplasty for symptomatic internal carotid artery occlusion. Harris LM, et al. **Cardiovasc Surg** 1995 Dec;3(6):625–9 (33 ref.)

CAROTID ARTERY, INTERNAL

ABNORMALITIES

Carotid–cavernous sinus fistula and aneurysmal rupture associated with fibromuscular dysplasia. A case report. Hirai T, et al. **Acta Radiol** 1996 Jan;37(1):49–51 (8 ref.)

Imaging quiz case 1. Ectopic internal carotid artery (ICA) within the petrous temporal bone. Saada AA, et al. **Arch Otolaryngol Head Neck Surg** 1996 Jul;122(7):792, 794 (10 ref.)

[Paradoxical aggravation of carotid cavernous fistula] Muraine M, et al. **J Fr Ophtalmol** 1996;19(1):51–4 (12 ref.) (Eng. Abstr.) **(Fre)**

INJURIES

Traumatic bilateral carotid–cavernous fistulas treated with detachable balloon. A case report. Kim JK, et al. **Acta Radiol** 1996 Jan;37(1):46–8 (6 ref.)

PATHOLOGY

Reevaluation of duplex criteria for diagnosis of high–grade carotid artery stenosis: when do we need angiography and when can we operate without angiography? Karacagil S, et al. **Int Angiol** 1995 Dec;14(4):410–4 (14 ref.)

PHYSIOPATHOLOGY

Anomalous internal carotid artery–anterior cerebral artery anastomosis associated with fenestration and cerebral aneurysm. Fujimura M, et al. **Neurol Med Chir (Tokyo)** 1996 Apr;36(4):229–33 (26 ref.)

False traumatic aneurysm of the dorsal wall of the supraclinoid internal carotid artery--case report. Saito K, et al. **Neurol Med Chir (Tokyo)** 1995 Dec;35(12):886–91 (26 ref.)

SURGERY

External carotid endarterectomy with internal carotid artery transposition flap angioplasty for symptomatic internal carotid artery occlusion. Harris LM, et al. **Cardiovasc Surg** 1995 Dec;3(6):625–9 (33 ref.)

[The effect of angioplasty on cerebral vasomotor reactivity in patients with important stenosis of the internal carotid artery] Arenas C, et al. **Rev Neurol** 1996 Feb;24(126):224–6 (12 ref.) (Eng. Abstr.) **(Spa)**

CAROTID ARTERY STENOSIS see **CAROTID STENOSIS**

CAROTID ARTERY THROMBOSIS

ULTRASONOGRAPHY

[Importance of ischemic heart disease in patients with carotid arteriosclerosis and lower extremity arteriopathy. Results of a prospective study] Racco F, et al. **Minerva Cardioangiol** 1995 Sep;43(9):345–54 (32 ref.) (Eng. Abstr.) **(Ita)**

CAROTID BODY

see related
CAROTID BODY TUMOR

BLOOD SUPPLY

The role of nitric oxide in carotid chemoreception. Wang ZZ, et al. **Biol Signals** 1995 May–Jun;4(3):109–16 (28 ref.)

CYTOLOGY

Possible role of coupling between glomus cells in carotid body chemoreception. Eyzaguirre C, et al. **Biol Signals** 1995 Sep–Oct;4(5):263–70 (30 ref.)

PHYSIOLOGY

Oxygen sensing in the carotid body. Gonzalez C, et al. **Biol Signals** 1995 Sep–Oct;4(5):245–56 (59 ref.)

Carotid body O2 chemoreception: respiratory and nonrespiratory aspects. Lahiri S. **Biol Signals** 1995 Sep–Oct; 4(5):257–62 (22 ref.)

The role of nitric oxide in carotid chemoreception. Wang ZZ, et al. **Biol Signals** 1995 May–Jun;4(3):109–16 (28 ref.)

PHYSIOPATHOLOGY

Increase in carotid body sensitivity during sustained hypoxia. Bisgard GE. **Biol Signals** 1995 Sep–Oct;4(5):292–7 (43 ref.)

CAROTID BODY TUMOR

SURGERY

Functional carotid body tumor: report of a case and a review of the literature. Ikejiri K, et al. **Surgery** 1996 Feb; 119(2):222–5 (5 ref.)

[Cervical paragangliomas. Results apropos of a series of 33 patients] Guerrier B, et al. **J Chir (Paris)** 1995 Jun–Jul; 132(6–7):287–94 (34 ref.) (Eng. Abstr.) **(Fre)**

CAROTID ENDARTERECTOMY see **ENDARTERECTOMY, CAROTID**

CAROTID SINUS

see related
PRESSORECEPTORS

[Characteristics and influence of different clinical forms on the development and prognosis of carotid sinus syndrome. Apropos of 215 cases] Graux P, et al. **Arch Mal Coeur Vaiss** 1995 Jul;88(7):999–1006 (29 ref.) (Eng. Abstr.) **(Fre)**

ULTRASTRUCTURE

Elastin and mechanoreceptor mechanisms with special reference to the mammalian carotid sinus. Kimani JK. **Ciba Found Symp** 1995;192:215–30; discussion 230–6 (68 ref.)

CAROTID STENOSIS

see related
ENDARTERECTOMY, CAROTID

CLASSIFICATION

Angiographic and duplex grading of internal carotid stenosis: can we overcome the confusion? Nicolaides AN, et al. **J Endovasc Surg** 1996 May;3(2):158–65 (32 ref.)

COMPLICATIONS

Prevention of stroke caused by carotid bifurcation stenosis [see comments] Santilli JD, et al. **Am Fam Physician** 1996 Feb 1;53(2):549–56, 559–60 (21 ref.) Comment in: Am Fam Physician 1996 Feb 1;53(2):486, 491.

[Neurofibromatosis associated with multiple intracranial vascular lesions: stenosis of the internal carotid artery and peripheral aneurysm of the Heubner's artery; report of a case] Sasaki J, et al. **No Shinkei Geka** 1995 Sep;23(9):813–7 (22 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Asymptomatic carotid stenosis: surgery's the answer, but that's not the question. Frey JL. **Ann Neurol** 1996 Mar; 39(3):405–6 (18 ref.)

Reevaluation of duplex criteria for diagnosis of high–grade carotid artery stenosis: when do we need angiography and when can we operate without angiography? Karacagil S, et al. **Int Angiol** 1995 Dec;14(4):410–4 (14 ref.)

Progress in evaluating carotid artery stenosis. Norris JW, et al. **J Vasc Surg** 1995 Nov;22(5):637–8 (14 ref.)

MR angiography in carotid stenosis. A clinical prospective. Lamparello PJ, et al. **Magn Reson Imaging Clin N Am** 1995 Aug;3(3):455–65 (33 ref.)

[The evaluation of 3DFT time–of–flight MR–angiography versus angiography in the study of carotid atheromatous lesions with a review of the literature] Auffray–Calvier E, et al. **J Neuroradiol** 1995 Dec;22(4):272–87 (30 ref.) (Eng. Abstr.) **(Fre)**

[The diagnosis of carotid stenosis] Scheffler P, et al. **Dtsch Med Wochenschr** 1996 Jun 7;121(23):765–8 (10 ref.) **(Ger)**

MICROBIOLOGY

Invasive aspergilloma of the frontal base causing internal carotid artery occlusion. Satoh H, et al. **Surg Neurol** 1995 Nov;44(5):483–8 (30 ref.)

PHYSIOPATHOLOGY

A systematic comparison of the risks of stroke and death due to carotid endarterectomy for symptomatic and asymptomatic stenosis. Rothwell PM, et al. **Stroke** 1996 Feb;27(2):266–9 (37 ref.)

RADIOGRAPHY

Angiographic and duplex grading of internal carotid stenosis: can we overcome the confusion? Nicolaides AN, et al. **J Endovasc Surg** 1996 May;3(2):158–65 (32 ref.)

SURGERY

Carotid endarterectomy--when to do it, how to do it? Steiger HJ. **Acta Neurochir (Wien)** 1995;137(3–4):121–7 (65 ref.)

The dilemma of surgical treatment for patients with asymptomatic carotid disease [comment] Barnett HJ, et al. **Ann Intern Med** 1995 Nov 1;123(9):723–5 (22 ref.) Comment on: Ann Intern Med 1995 Nov 1;123(9):649–55. Comment on: Ann Intern Med 1995 Nov 1;123(9):729.

Asymptomatic carotid stenosis: surgery's the answer, but that's not the question. Frey JL. **Ann Neurol** 1996 Mar; 39(3):405–6 (18 ref.)

Surgical management of carotid stenosis. Halliday A. **Ann R Coll Surg Engl** 1995 Sep;77(5):323–4 (19 ref.)

Carotid endarterectomy: emerging indications. Meldrum HE, et al. **Baillieres Clin Neurol** 1995 Aug;4(2):339–55 (41 ref.)

External carotid endarterectomy with internal carotid artery transposition flap angioplasty for symptomatic internal carotid artery occlusion. Harris LM, et al. **Cardiovasc Surg** 1995 Dec;3(6):625–9 (33 ref.)

Carotid Dacron patch angioplasty: immediate and long–term results of a prospective series. Perler BA, et al. **Cardiovasc Surg** 1995 Dec;3(6):631–6 (43 ref.)

Update on carotid endarterectomy. Barnett HJ, et al. **Curr Opin Cardiol** 1995 Sep;10(5):511–6 (28 ref.)

Randomized clinical trial results define operative indications in symptomatic and asymptomatic carotid endarterectomy patients. Hobson RW 2nd. **Curr Opin Gen Surg** 1994; :265–71 (50 ref.)

Controversies in the management of carotid stenosis. Macdonald RL. **J Neurosci Nurs** 1996 Apr;28(2):93–8 (33 ref.)

Who needs carotid endarterectomy? Fox A, et al. **Practitioner** 1996 Jan;240(1558):29–32 (4 ref.)

A systematic comparison of the risks of stroke and death due to carotid endarterectomy for symptomatic and asymptomatic stenosis. Rothwell PM, et al. **Stroke** 1996 Feb;27(2):266–9 (37 ref.)

A systematic review of the risks of stroke and death due to endarterectomy for symptomatic carotid stenosis. Rothwell PM, et al. **Stroke** 1996 Feb;27(2):260–5 (68 ref.)

[Current status of carotid surgery] Branchereau A, et al. **Chirurgie** 1994–95;120(10):572–81 (68 ref.) (Eng. Abstr.) **(Fre)**

[Should asymptomatic carotid stenosis be operated on? (editorial)] Bousser MG. **Rev Neurol (Paris)** 1995 Jun–Jul; 151(6–7):363–7 (41 ref.) (Eng. Abstr.) **(Fre)**

[Management of patients with carotid stenosis and coronary heart disease] Fleisch M, et al. **Schweiz Med Wochenschr** 1995 Oct 28;125(43):2053–61 (68 ref.) (Eng. Abstr.) **(Ger)**

[Treatment of symptomatic carotid stenosis] von Segesser LK. **Schweiz Med Wochenschr** 1995 Oct 28;125(43):2033–9 (26 ref.) (Eng. Abstr.) **(Ger)**

[Carotid thromboendarterectomy: personal experience and review of the literature] Tedesco M, et al. **Ann Ital Chir** 1995 May–Jun;66(3):313–8 (22 ref.) (Eng. Abstr.) **(Ita)**

[The effect of angioplasty on cerebral vasomotor reactivity

CAROTID STENOSIS

in patients with important stenosis of the internal carotid artery] Arenas C, et al. **Rev Neurol** 1996 Feb;24(126):224–6 (12 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

Medical compared with surgical treatment of asymptomatic carotid artery stenosis [comment] [see comments] Brott T, et al. **Ann Intern Med** 1995 Nov 1;123(9):720–2 (21 ref.) Comment on: Ann Intern Med 1995 Nov 1;123(9):649–55. Comment on: Ann Intern Med 1995 Nov 1;123(9):729. Comment in: Ann Intern Med 1995 Nov 1;123(9):649–55.

Indications for carotid artery stenting: a preview of the potential derived from early clinical experience [editorial] Diethrich EB. **J Endovasc Surg** 1996 May;3(2):132–9 (15 ref.)

Percutaneous techniques for endoluminal carotid interventions. Diethrich EB, et al. **J Endovasc Surg** 1996 May;3(2):182–202 (8 ref.)

Complications associated with extracranial carotid artery interventions. Dorros G. **J Endovasc Surg** 1996 May; 3(2):166–70 (15 ref.)

Anesthesia for carotid stent procedures. Kharrazi MR. **J Endovasc Surg** 1996 May;3(2):211–6 (8 ref.)

Patient preparation and monitoring for carotid stenting: the operating room nurse's perspective. Plat S, et al. **J Endovasc Surg** 1996 May;3(2):224–7 (6 ref.)

[Therapy of carotid stenosis] Scheffler P, et al. **Dtsch Med Wochenschr** 1996 Jun 14;121(24):799–802 (12 ref.) **(Ger)**

[Value of interventional angiology in carotid stenosis] Zanella FE. **Schweiz Med Wochenschr** 1995 Oct 28;125(43):2046–52 (33 ref.) (Eng. Abstr.) **(Ger)**

ULTRASONOGRAPHY

Intravascular ultrasound assessment in carotid interventions. Reid DB, et al. **J Endovasc Surg** 1996 May;3(2):203–10 (9 ref.)

Ultrasonography for diagnosis and management of carotid artery atherosclerosis. A position paper of the American Society of Neuroimaging. Weinberger J, et al. **J Neuroimaging** 1995 Oct;5(4):237–43 (42 ref.)

[Cerebrovascular ultrasound diagnosis] Baumgartner RW, et al. **Ther Umsch** 1996 Jul;53(7):528–34 (44 ref.) (Eng. Abstr.) **(Ger)**

[Importance of ischemic heart disease in patients with carotid arteriosclerosis and lower extremity arteriopathy. Results of a prospective study] Racco F, et al. **Minerva Cardioangiol** 1995 Sep;43(9):345–54 (32 ref.) (Eng. Abstr.) **(Ita)**

CARP

PHYSIOLOGY

Role of membrane lipids in temperature acclimatization of carp. Buda C, et al. **Arch Tierernahr** 1996;49(1):61–2 (7 ref.)

Protein sparing effect and nutritive significance of lipid supplementation in carp diets. Steffens W. **Arch Tierernahr** 1996;49(1):93–8 (52 ref.)

Lipid nutritional pathology in farmed fish. Tacon AG. **Arch Tierernahr** 1996;49(1):33–9 (71 ref.)

Essential fatty acid requirements in carp. Takeuchi T. **Arch Tierernahr** 1996;49(1):23–32 (29 ref.)

CARPAL BONES

Analysis of carpal instability: I. Description of the scheme. Larsen CF, et al. **J Hand Surg [Am]** 1995 Sep;20(5):757–64 (84 ref.)

The issue of vascularity in fractures and non-union of the scaphoid. Büchler U, et al. **J Hand Surg [Br]** 1995 Dec; 20(6):726–35 (86 ref.)

Idiopathic avascular necrosis of the scaphoid in a child. Jensen CH, et al. **Scand J Plast Reconstr Surg Hand Surg** 1995 Dec; 29(4):359–60 (6 ref.)

INJURIES

Recurrent locking of the wrist due to dorsal midcarpal subluxation. Craigen MA. **J Bone Joint Surg Br** 1996 Jul; 78(4):664–6 (5 ref.)

Unusual capitate fracture: a case report. Volk AG, et al. **J Hand Surg [Am]** 1995 Jul;20(4):581–2 (5 ref.)

Complex carpal dislocation. Irwin LR, et al. **J Hand Surg [Br]** 1995 Dec;20(6):746–9 (15 ref.)

[Fracture of the lunatotriquetrum bone in the triquetral part. Case report and review of the literature] Höcker K, et al. **Handchir Mikrochir Plast Chir** 1995 Sep;27(5):254–7 (45 ref.) (Eng. Abstr.) **(Ger)**

[Injuries of the bifurcate ligament] Ruland WO, et al. **Unfallchirurg** 1995 Dec;98(12):640–4 (5 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

Avascular necrosis of carpal bones. Golimbu CN, et al. **Magn Reson Imaging Clin N Am** 1995 May;3(2):281–303 (74 ref.)

RADIOGRAPHY

Primary subacute osteomyelitis of the wrist in children. De Smet L, et al. **Acta Orthop Belg** 1995;61(4):282–5 (16 ref.)

ULTRASONOGRAPHY

[Giant-cell tumor of the carpal tunnel, a color Doppler echographic study. A case report] Chiodi E, et al. **Radiol Med (Torino)** 1996 Jan–Feb;91(1–2):125–7 (9 ref.) **(Ita)**

CARPAL TUNNEL SYNDROME

Carpal tunnel syndrome. Kulick RG. **Orthop Clin North Am** 1996 Apr;27(2):345–54 (78 ref.)

DIAGNOSIS

Value of clinical provocative tests in carpal tunnel syndrome. De Smet L, et al. **Acta Orthop Belg** 1995;61(3):177–82 (26 ref.)

Anomalous flexor digitorum superficialis presenting as a painful palmar mass: a case report. Grant SD, et al. **Clin Anat** 1995;8(6):432–3 (6 ref.)

General principles and use of electrodiagnostic studies in carpal and cubital tunnel syndromes. With special, attention to pitfalls and interpretation. Hilburn JW. **Hand Clin** 1996 May;12(2):205–21 (64 ref.)

Carpal tunnel syndrome. MR imaging diagnosis. Mesgarzadeh M, et al. **Magn Reson Imaging Clin N Am** 1995 May;3(2):249–64 (45 ref.)

DRUG THERAPY

Vitamin B6 (pyridoxine) therapy for carpal tunnel syndrome. Jacobson MD, et al. **Hand Clin** 1996 May;12(2):253–7 (38 ref.)

ETIOLOGY

Carpal tunnel syndrome in children and adolescents with no history of trauma. al-Qattan MM, et al. **J Hand Surg [Br]** 1996 Feb;21(1):108–11 (38 ref.)

MICROBIOLOGY

Median nerve compression at the wrist due to intracarpal canal sepsis. Flynn JM, et al. **J Hand Surg [Am]** 1995 Sep; 20(5):864–7 (18 ref.)

PHYSIOPATHOLOGY

Personal factors and blood volume movement in causation of median neuropathy at the carpal tunnel. A commentary. Radecki P. **Am J Phys Med Rehabil** 1996 May–Jun; 75(3):235–8 (27 ref.)

The pathophysiology of carpal tunnel syndrome. Kerwin G, et al. **Hand Clin** 1996 May;12(2):243–51 (55 ref.)

SURGERY

A multicenter prospective review of 640 endoscopic carpal tunnel releases using the transbursal and extrabursal chow techniques. Nagle DJ, et al. **Arthroscopy** 1996 Apr; 12(2):139–43 (12 ref.)

Endoscopic carpal tunnel release. Sellers DS. **Clin Plast Surg** 1995 Oct;22(4):775–80 (27 ref.)

Reoperation for carpal tunnel syndrome. Cobb TK, et al. **Hand Clin** 1996 May;12(2):313–23 (64 ref.)

Pitfalls of endoscopic carpal tunnel release. Einhorn N, et al. **Orthop Clin North Am** 1996 Apr;27(2):373–80 (74 ref.)

Newer techniques of carpal tunnel release. Mirza MA, et al. **Orthop Clin North Am** 1996 Apr;27(2):355–71 (61 ref.)

CARRAGEENAN

Carrageenans and their use in meat products. Trius A, et al. **Crit Rev Food Sci Nutr** 1996 Jan;36(1–2):69–85 (71 ref.)

CARRIER PROTEINS

The kidney sodium–calcium exchanger. Lytton J, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:58–72 (30 ref.)

Phylogenetic, structural and functional characteristics of the Na–K–Cl cotransporter family. Park JH, et al. **J Membr Biol** 1996 Feb;149(3):161–8 (37 ref.)

MYC family ties [news; comment] Schmidt EV. **Nat Genet** 1996 Sep;14(1):8–10 (25 ref.) Comment on: Nat Genet 1996 Sep;14(1):69–77.

ANALYSIS

Localization of the Na(+)-Ca2+ exchanger in vascular smooth muscle, and in neurons and astrocytes. Juhaszova M, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:318–35 (31 ref.)

Identification and characterization of a widely expressed phosphate transporter/retrovirus receptor family. Kavanaugh MP, et al. **Kidney Int** 1996 Apr;49(4):959–63 (23 ref.)

Development of imaging agents for the dopamine transporter. Carroll FI, et al. **Med Res Rev** 1995 Sep;15(5):419–44 (144 ref.)

ANTAGONISTS & INHIBITORS

Mechanism of XIP in cardiac sarcolemmal vesicles. Hale CC. **Ann N Y Acad Sci** 1996 Apr 15;779:171–81 (7 ref.)

Antisense oligodeoxynucleotides directed against the Na–Ca exchanger mRNA. Promising tools for studies on the cellular and molecular level. Niggli E, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:93–102 (33 ref.)

BLOOD

Na–Ca exchange in circulating blood cells. Gardner JP, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:502–14 (27 ref.)

Plasma lipid transfer proteins. Tall A. **Annu Rev Biochem** 1995;64:235–57 (119 ref.)

[Lipid transfer protein] Sasaki N. **Nippon Rinsho** 1995 Feb; 53 Su Pt 1:665–73 (60 ref.) **(Jpn)**

[Growth hormone-binding protein] Takeda S, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:346–50 (27 ref.) **(Jpn)**

CHEMISTRY

Expression of Na(+)-Ca2+ exchanger with modified C-terminal hydrophobic domains and enhanced activity. Gabellini N, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:110–4 (9 ref.)

A new splicing variant in the frog heart sarcolemmal Na–Ca exchanger creates a putative ATP-binding site. Iwata T, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:37–45 (34 ref.)

Mutagenesis studies of the cardiac Na(+)-Ca2+ exchanger. Nicoll DA, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:86–92 (14 ref.)

The structural basis of Na(+)-Ca2+ exchange activity. Rahamimoff H, et al. **Ann N Y Acad Sci** 1996 Apr 15; 779:29–36 (16 ref.)

The lipocalin protein family: structure and function. Flower DR. **Biochem J** 1996 Aug 15;318 (Pt 1):1–14 (149 ref.)

Structure–function relationships in the FK506-binding protein (FKBP) family of peptidylprolyl cis–trans isomerases. Kay JE. **Biochem J** 1996 Mar 1;314 (Pt 2):361–85 (308 ref.)

Ca(2+)-dependent sugar recognition by animal lectins. Drickamer K. **Biochem Soc Trans** 1996 Feb;24(1):146–50 (20 ref.)

Mitochondrial metabolite transporters. Palmieri F, et al. **Biochim Biophys Acta** 1996 Jul 18;1275(1–2):127–32 (25 ref.)

Molecular characterization of the epithelial Na–K–Cl cotransporter isoforms. Payne JA, et al. **Curr Opin Cell Biol** 1995 Aug;7(4):493–503 (73 ref.)

EP-GP and the lipocalin VEGh, two different human salivary 20-kDa proteins. Schenkels LC, et al. **J Dent Res** 1995 Sep;74(9):1543–50 (80 ref.)

5-Lipoxygenase-activating protein (FLAP). Vickers PJ. **J Lipid Mediat Cell Signal** 1995 Oct;12(2–3):185–94 (46 ref.)

Structural and functional aspects of the phosphate carrier from mitochondria. Krämer R. **Kidney Int** 1996 Apr; 49(4):947–52 (55 ref.)

Structure and function of the natural-resistance-associated macrophage protein (Nramp1), a candidate protein for infectious and autoimmune disease susceptibility. Blackwell JM. **Mol Med Today** 1996 May;2(5):205–11 (38 ref.)

The PTR family: a new group of peptide transporters. Steiner HY, et al. **Mol Microbiol** 1995 Jun;16(5):825–34 (59 ref.)

Receptor (immunophilin-binding) assay for immunosuppressive drugs. Soldin SJ. **Ther Drug Monit** 1995 Dec;17(6):574–6 (18 ref.)

[Midkine in relation to development and pathological status of the nervous system] Muramatsu T. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1995 Jun; 15(3):275–9 (26 ref.) (Eng. Abstr.) **(Jpn)**

DRUG EFFECTS

Serotonin binding proteins "SBP": target proteins and tool for in vitro neurotoxicity studies. Del Río MJ, et al. **Gen Pharmacol** 1995 Dec;26(8):1633–41 (74 ref.)

GENETICS

Rat and human bile acid binders are members of the monomeric reductase gene family. Stolz A, et al. **Adv Exp Med Biol** 1995;372:269–80 (56 ref.)

A chondrodysplasia family produced by mutations in the diastrophic dysplasia sulfate transporter gene: genotype/phenotype correlations. Superti-Furga A, et al. **Am J Med Genet** 1996 May 3;63(1):144–7 (28 ref.)

Modulatory actions of corticotropin-releasing factor-binding protein. Behan DP, et al. **Ann N Y Acad Sci** 1996 Mar 22;780:81–95 (55 ref.)

Sulfate transport in chondrodysplasia. Hästbacka J, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:131–6 (29 ref.)

Molecular biological studies of the cardiac sodium–calcium exchanger. Kraev A, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:103–9 (20 ref.)

The molecular biology of the Na(+)-Ca2+ exchanger and its functional roles in heart, smooth muscle cells, neurons, glia, lymphocytes, and nonexcitable cells. Lederer WJ, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:7–17 (60 ref.)

Mutagenesis studies of the cardiac Na(+)-Ca2+ exchanger. Nicoll DA, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:86–92 (14 ref.)

Antisense oligodeoxynucleotides directed against the Na–Ca exchanger mRNA. Promising tools for studies on the cellular and molecular level. Niggli E, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:93–102 (33 ref.)

Molecular regulation of the Na(+)-Ca2+ exchanger. Philipson KD, et al. **Ann N Y Acad Sci** 1996 Apr 15; 779:20–8 (15 ref.)

Sodium–calcium exchange and calcium homeostasis in

transfected Chinese hamster ovary cells. Reeves JP, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:73–85 (27 ref.)

Alternative splicing of the Na(+)–Ca2+ exchanger gene, NCX1. Schulze DH, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:46–57 (32 ref.)

Regulation of expression of sodium–calcium exchanger and plasma membrane calcium ATPase by protein kinases, glucocorticoids, and growth factors. Smith JB, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:258–71 (36 ref.)

A family of chondrodysplasias caused by mutations in the diastrophic dysplasia sulfate transporter gene and associated with impaired sulfation of proteoglycans. Superti-Furga A, et al. **Ann N Y Acad Sci** 1996 Jun 8; 785:195–201 (26 ref.)

p16INK4A as a human tumor suppressor. Shapiro GI, et al. **Biochim Biophys Acta** 1996 Mar 18;1242(3):165–9 (59 ref.)

CDKN2A (p16INK4A) somatic and germline mutations. Smith-Sørensen B, et al. **Hum Mutat** 1996;7(4):294–303 (81 ref.)

High-level bacterial expression of mitochondrial transport proteins. Kaplan RS. **J Bioenerg Biomembr** 1996 Feb; 28(1):41–7 (23 ref.)

Natural resistance to infection with intracellular parasites: molecular genetics identifies Nramp1 as the Bcg/Ity/Lsh locus. Vidal S, et al. **J Leukoc Biol** 1995 Oct;58(4):382–90 (61 ref.)

Modulation of renal Na–Pi cotransport by hormones acting via genomic mechanism and by metabolic factors. Dousa TP. **Kidney Int** 1996 Apr;49(4):997–1004 (52 ref.)

MYC family ties [news; comment] Schmidt EV. **Nat Genet** 1996 Sep;14(1):8–10 (25 ref.) Comment on: Nat Genet 1996 Sep;14(1):69–77.

p16INK4a: a gene with a dual capacity to encode unrelated proteins that inhibit cell cycle progression. Larsen CJ. **Oncogene** 1996 May 16;12(10):2041–4 (37 ref.)

Urea transport and Kidd blood groups. Cartron JP, et al. **Transfus Clin Biol** 1995;2(4):309–15 (24 ref.)

[Cholesteryl ester transfer protein (CETP) deficiency and increased HDL cholesterol levels (hyperalphalipoproteinemia)] Inazu A, et al. **Rinsho Byori** 1996 Apr;44(4):322–6 (15 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Transferrin receptors of Neisseria meningitidis: promising candidates for a broadly cross-protective vaccine. Ala'Aldeen DA. **J Med Microbiol** 1996 Apr;44(4):237–43 (40 ref.)

Comparison of purified 12 kDa and recombinant 15 kDa Fasciola hepatica antigens related to a Schistosoma mansoni fatty acid binding protein. Hillyer GV. **Mem Inst Oswaldo Cruz** 1995 Mar–Apr;90(2):249–53 (17 ref.)

METABOLISM

Lactate/proton co-transport in skeletal muscle: regulation and importance for pH homeostasis. Juel C. **Acta Physiol Scand** 1996 Mar;156(3):369–74 (29 ref.)

Analysis and modeling of substrate uptake and product release by prokaryotic and eukaryotic cells. Krämer R. **Adv Biochem Eng Biotechnol** 1996;54:31–74 (147 ref.)

Lectin–carbohydrate interactions in disease. T-cell recognition of IgA and IgD; mannose binding protein recognition of IgG0. Rudd P, et al. **Adv Exp Med Biol** 1995;376:147–52 (10 ref.)

The dopamine transporter. The cloned target site of parkinsonism-inducing toxins and of drugs of abuse. Pifl C, et al. **Adv Neurol** 1996;69:235–8 (9 ref.)

Modulatory actions of corticotropin-releasing factor-binding protein. Behan DP, et al. **Ann N Y Acad Sci** 1996 Mar 22;780:81–95 (55 ref.)

Na–Ca exchange and Ca fluxes during contraction and relaxation in mammalian ventricular muscle. Bers DM, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:430–42 (31 ref.)

High affinity choline transporter status in Alzheimer's disease tissue from rapid autopsy. Bissette G, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:197–204 (12 ref.)

The roles of the sodium and calcium current in triggering calcium release from the sarcoplasmic reticulum. Cannell MB, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:443–50 (21 ref.)

Action potential duration modulates calcium influx, Na(+)-Ca2+ exchange, and intracellular calcium release in rat ventricular myocytes. Clark RB, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:417–29 (51 ref.)

Release of catecholamines and enkephalin peptides induced by reversal of the Na(+)-Ca2+ exchanger in chromaffin cells. Duarte EP, et al. **Ann N Y Acad Sci** 1996 Apr 15; 779:391–4 (6 ref.)

Expression of Na(+)–Ca2+ exchanger with modified C-terminal hydrophobic domains and enhanced activity. Gabellini N, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:110–4 (9 ref.)

Regulation of sodium–calcium exchange in intact myocytes by ATP and calcium. Haworth RA, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:464–79 (42 ref.)

Kinetics and mechanism: modulation of ion transport in the cardiac sarcolemma sodium–calcium exchanger by protons, monovalent, ions, and temperature. Khananshvili D, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:217–35 (37 ref.)

Calcium in the cardiac diadic cleft. Implications for sodium–calcium exchange. Langer GA, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:408–16 (24 ref.)

Evidence that reverse Na–Ca exchange can trigger SR calcium release. Litwin S, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:451–63 (20 ref.)

The sodium–calcium exchanger and glutamate-induced calcium loads in aged hippocampal neurons in vitro. Mills LR. **Ann N Y Acad Sci** 1996 Apr 15;779:379–90 (39 ref.)

Sodium–calcium exchange and calcium homeostasis in transfected Chinese hamster ovary cells. Reeves JP, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:73–85 (27 ref.)

Turnover rate and number of Na(+)–Ca2+, K+ exchange sites in retinal photoreceptors. Rispoli G, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:346–55 (26 ref.)

Na–Ca exchange in Ca2+ signaling and neurohormone secretion. Secretory vesicle contributions in adrenal chromaffin cells. Schneider AS, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:356–65 (17 ref.)

Regulation of the bovine retinal rod Na–Ca+K exchanger. Schnetkamp PP, et al. **Ann N Y Acad Sci** 1996 Apr 15; 779:336–45 (24 ref.)

Na(+)–Ca2+ exchange in anoxic/ischemic injury of CNS myelinated axons. Stys PK, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:366–78 (41 ref.)

Receptor-mediated protein sorting to the vacuole in yeast: roles for a protein kinase, a lipid kinase and GTP-binding proteins. Stack JH, et al. **Ann Rev Cell Dev Biol** 1995; 11:1–33 (146 ref.)

Molecular mechanisms of NaCl cotransport. Kaplan MR, et al. **Annu Rev Physiol** 1996;58:649–68 (92 ref.)

Biochemistry of proteins that bind and metabolize juvenile hormones. Prestwich GD, et al. **Arch Insect Biochem Physiol** 1996;32(3–4):407–19 (39 ref.)

Structure–function relationships in the FK506-binding protein (FKBP) family of peptidylprolyl cis–trans isomerases. Kay JE. **Biochem J** 1996 Mar 1;314 (Pt 2):361–85 (308 ref.)

Ca(2+)-dependent sugar recognition by animal lectins. Drickamer K. **Biochem Soc Trans** 1996 Feb;24(1):146–50 (20 ref.)

The role of Na–Ca exchange current in the cardiac action potential. Janvier NC, et al. **Cardiovasc Res** 1996 Jul; 32(1):69–84 (74 ref.)

Calcium homeostasis in vertebrate retinal rod outer segments. Schnetkamp PP. **Cell Calcium** 1995 Oct;18(4):322–30 (54 ref.)

Riboflavin binding proteins and flavin assimilation in insects. Miller SG, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1995 Mar; 110(3):467–75 (48 ref.)

Intracellular signalling. New directions for phosphatidylinositol transfer. Martin T. **Curr Biol** 1995 Sep 1;5(9):990–2 (13 ref.)

Protein folding. Prolyl isomerases join the fold. Schmid FX. **Curr Biol** 1995 Sep 1;5(9):993–4 (12 ref.)

Aquaporin water channels: unanswered questions and unresolved controversies. Agre P, et al. **Curr Opin Cell Biol** 1995 Aug;7(4):472–83 (84 ref.)

Phospholipid metabolism and membrane dynamics. Alb JG, et al. **Curr Opin Cell Biol** 1996 Aug;8(4):534–41 (46 ref.)

Cell volume regulated transporters of compatible osmolytes. Kwon HM, et al. **Curr Opin Cell Biol** 1995 Aug;7(4):465–71 (48 ref.)

Sodium cotransporters. Wright EM, et al. **Curr Opin Cell Biol** 1996 Aug;8(4):468–73 (49 ref.)

Cholesteryl ester transfer proteins, reverse cholesterol transport, and atherosclerosis. Bruce C, et al. **Curr Opin Lipidol** 1995 Oct;6(5):306–11 (47 ref.)

Amino acid transporters. Kinne RK. **Curr Opin Nephrol Hypertens** 1995 Sep;4(5):412–5 (36 ref.)

The role of penicillin-binding proteins in penicillin resistance of Streptococcus pneumoniae. Hakenbeck R, et al. **Dev Biol Stand** 1995;85:115–23 (35 ref.)

The Escherichia coli trigger factor. Hesterkamp T, et al. **FEBS Lett** 1996 Jun 24;389(1):32–4 (21 ref.)

Corticotropin releasing factor (CRF) binding protein: a novel regulator of CRF and related peptides. Behan DP, et al. **Front Neuroendocrinol** 1995 Oct;16(4):362–82 (87 ref.)

Role of transport proteins in bioartificial liver assist systems. Mitzner S, et al. **Int J Artif Organs** 1996 Jan;19(1):49–52 (6 ref.)

Nuclear matrix acceptor binding sites for steroid hormone receptors: a candidate nuclear matrix acceptor protein. Lauber AH, et al. **Int Rev Cytol** 1995;162B:337–76 (178 ref.)

The Duffy antigen receptor for chemokines: structural analysis and expression in the brain. Horuk R, et al. **J Leukoc Biol** 1996 Jan;59(1):29–38 (28 ref.)

5-Lipoxygenase-activating protein (FLAP). Vickers PJ. **J Lipid Mediat Cell Signal** 1995 Oct;12(2–3):185–94 (46 ref.)

Renal Na/Pi-cotransporters. Biber J, et al. **Kidney Int** 1996 Apr;49(4):981–5 (33 ref.)

Modulation of renal Na–Pi cotransport by hormones acting via genomic mechanism and by metabolic factors. Dousa TP. **Kidney Int** 1996 Apr;49(4):997–1004 (52 ref.)

The SMR family: a novel family of multidrug efflux proteins involved with the efflux of lipophilic drugs. Paulsen IT, et al. **Mol Microbiol** 1996 Mar;19(6):1167–75 (64 ref.)

Cation and sugar selectivity determinants in a novel family of transport proteins. Poolman B, et al. **Mol Microbiol** 1996 Mar;19(5):911–22 (63 ref.)

The PTR family: a new group of peptide transporters. Steiner HY, et al. **Mol Microbiol** 1995 Jun;16(5):825–34 (59 ref.)

Protein serine/threonine phosphatases as binding proteins for okadaic acid. Nagao M, et al. **Mutat Res** 1995 Dec; 333(1–2):173–9 (33 ref.)

Protein-mediated facilitated uptake processes for fatty acids, bilirubin, and other amphipathic compounds [see comments] Fitscher BA, et al. **Proc Soc Exp Biol Med** 1996 May;212(1):15–23 (99 ref.) Comment in: Proc Soc Exp Biol Med 1996 May;212(1):1–4.

Iron metabolism in eukaryotes: Mars and Venus at it again [comment] Kaplan J, et al. **Science** 1996 Mar 15; 271(5255):1510–2 (25 ref.) Comment on: Science 1996 Mar 15;271(5255):1552–7.

Post-translational protein translocation: not all hsc70s are created equal. Brodsky JL. **Trends Biochem Sci** 1996 Apr; 21(4):122–6 (40 ref.)

[Functional significance of diazepam binding inhibitor (DBI) in establishment of alcohol dependence] Katsura M, et al. **Nippon Yakurigaku Zasshi** 1995 Sep;106(3):217–27 (50 ref.) (Eng. Abstr.) **(Jpn)**

[Sidedness of biomembrane: asymmetrical distribution and flip-flop of phospholipids across lipid bilayer] Anzai K. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(16):2418–26 (93 ref.) **(Jpn)**

[Oligomeric assemblies of transport adenosine triphosphatases in a membrane bilayer] Boldyrev AA. **Zh Evol Biokhim Fiziol** 1995 Jul–Aug;31(4):375–86 (45 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Carbohydrate-and heparin-binding proteins in mammalian fertilization. Töpfer-Petersen E, et al. **Andrologia** 1995 Nov–Dec;27(6):303–24 (226 ref.)

Na–Ca exchange studies in sarcolemmal skeletal muscle. Gonzalez-Serratos H, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:556–60 (11 ref.)

The cardiac Na–Ca exchanger in giant membrane patches. Hilgemann DW. **Ann N Y Acad Sci** 1996 Apr 15;779:136–58 (28 ref.)

The molecular biology of the Na(+)–Ca2+ exchanger and its functional roles in heart, smooth muscle cells, neurons, glia, lymphocytes, and nonexcitable cells. Lederer WJ, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:7–17 (60 ref.)

Multiple functional states of the cardiac Na(+)–Ca2+ exchanger. Whole-cell, native-excised, and cloned-excised properties. Matsuoka S, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:159–70 (17 ref.)

The exchanger and cardiac hypertrophy. Menick DR, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:489–501 (18 ref.)

Functional roles of sodium–calcium exchange in normal and abnormal cardiac rhythm. Noble D, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:480–8 (17 ref.)

Voltage dependence of Na–Ca exchange in barnacle muscle cells. I. Na–Na exchange activated by alpha-chymotrypsin. Rasgado-Flores H, et al. **Ann N Y Acad Sci** 1996 Apr 15; 779:236–48 (28 ref.)

Coreceptors and adapter proteins in T-cell signaling. Ravichandran KS, et al. **Ann N Y Acad Sci** 1995 Sep 7; 766:117–33 (91 ref.)

Molecular mechanisms of renal apical Na/phosphate cotransport. Murer H, et al. **Annu Rev Physiol** 1996; 58:607–18 (48 ref.)

Molecular and pharmacologic targeting of angiogenesis factors—the example of pleiotrophin. Czubayko F, et al. **Breast Cancer Res Treat** 1995;36(2):157–68 (68 ref.)

Fascins, a family of actin bundling proteins. Edwards RA, et al. **Cell Motil Cytoskeleton** 1995;32(1):1–9 (48 ref.)

Fatty acid binding protein in locust and mammalian muscle. Comparison of structure, function and regulation. Haunerland NH. **Comp Biochem Physiol B Biochem Mol Biol** 1994 Oct–Nov; 109(2–3):199–208 (49 ref.)

Microvillus assembly. Not actin alone. Fath KR, et al. **Curr Biol** 1995 Jun 1;5(6):591–3 (22 ref.)

Photomorphogenesis. Seeing the light in plant development. Terzaghi WB, et al. **Curr Biol** 1995 May 1;5(5):466–8 (11 ref.)

Growth hormone axis in cushing's syndrome. Wajchenberg BL, et al. **Horm Res** 1996;45(1–2):99–107 (36 ref.)

Electrophysiological insights of type I and II Na/Pi transporters. Busch AE, et al. **Kidney Int** 1996 Apr; 49(4):986–7 (11 ref.)

Inositolpolyphosphates and their binding proteins—a short review. Huisamen B, et al. **Mol Cell Biochem** 1996 Apr 12–26;157(1–2):229–32 (29 ref.)

The role of anti-sigma factors in gene regulation. Brown KL, et al. **Mol Microbiol** 1995 May;16(3):397–404 (49 ref.)

The psychobiological regulation of social cooperation [comment] Cloninger CR. **Nat Med** 1995 Jul;1(7):623–5 (21 ref.) Comment on: Nat Med 1995 Jul;1(7):654–7.

Immunophilins and the nervous system. Snyder SH, et al. **Nat Med** 1995 Jan;1(1):32–7 (82 ref.)

Corticotropin releasing factor and its binding protein. Lowry PJ, et al. **Pharmacol Biochem Behav** 1996 May;54(1):305–8 (47 ref.)

Regulation of protein transport to the nucleus: central role of phosphorylation. Jans DA, et al. **Physiol Rev** 1996 Jul; 76(3):651–85 (400 ref.)

Cellular functions of immunophilins. Marks AR. **Physiol Rev** 1996 Jul;76(3):631–49 (161 ref.)

Fatty acid transport and fatty acid-binding proteins.

CARRIER PROTEINS

Veerkamp JH. **Proc Nutr Soc** 1995 Mar;54(1):23–37 (75 ref.)

Nucleobase and nucleoside transport in mammalian cells. Kraupp M, et al. **Wien Klin Wochenschr** 1995; 107(22):677–80 (36 ref.)

An overview of membrane transport proteins in Saccharomyces cerevisiae. Andre B. **Yeast** 1995 Dec; 11(16):1575–611 (258 ref.)

[Growth hormone receptor and binding protein: roles in cellular responsiveness to growth hormone] Maes M, et al. **Ann Endocrinol (Paris)** 1995;56(4):253–8 (47 ref.) (Eng. Abstr.) **(Fre)**

[The dopamine transporter: characterization and physiopathologic implications] Thibaut F, et al. **Encephale** 1995 Nov–Dec;21(6):445–51 (35 ref.) (Eng. Abstr.) **(Fre)**

[Platelet collagen receptors] Kralisz U. **Postepy Biochem** 1995;41(3):188–94 (78 ref.) **(Pol)**

[Flippases—phospholipid transporting proteins] Pulaski L. **Postepy Biochem** 1995;41(2):131–8 (78 ref.) **(Pol)**

CARRIER STATE

The significance of nasal carriage of Staphylococcus aureus and the incidence of postoperative wound infection. Wenzel RP, et al. **J Hosp Infect** 1995 Sep;31(1):13–24 (52 ref.)

[Pathogenic mechanism of fulminant hepatic failure in HBs Ag carrier after withdrawal of cytotoxic chemotherapy] Inoue K, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:467–72 (22 ref.) **(Jpn)**

[Hepatitis virus carrier] Nakajima S, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):54–7 (14 ref.) **(Jpn)**

[The pathogenetic characteristics of the development of a bacterial carrier state] Bukharin OV, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Mar–Apr; (2):98–101 (42 ref.) **(Rus)**

IMMUNOLOGY

[Precore region mutation in anti-HBe antibody positive asymptomatic healthy carriers] Fukuda R. **Nippon Rinsho** 1995 Oct;53 Suppl:189–94 (16 ref.) **(Jpn)**

TRANSMISSION

[Mechanisms and factors for development of HBV asymptomatic carrier] Tanaka Y, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:394–400 (21 ref.) **(Jpn)**

VIROLOGY

[Precore/core mutation and clinical course of chronic hepatitis B virus infection from the view point of asymptomatic carriers] Fujiwara K, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:401–5 (20 ref.) **(Jpn)**

[Changes in precore and core region of hepatitis B virus during the course of chronic hepatitis B virus carriers] Hamasaki K, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:411–4 (9 ref.) **(Jpn)**

CARRIERS, GENETIC see **HETEROZYGOTE**

CARRIERS, GENETIC, DETECTION see **HETEROZYGOTE DETECTION**

CARRION'S DISEASE see **BARTONELLA INFECTIONS**

CARSICKNESS see **MOTION SICKNESS**

CARTILAGE

see related
CHONDROITIN
LARYNGEAL CARTILAGES

Myelopathy associated with fibrocartilaginous emboli (FE): review and two suspected cases. McLean JM, et al. **Surg Neurol** 1995 Sep;44(3):228–34; discussion 234–5 (46 ref.)

ABNORMALITIES

Congenital tracheal cartilaginous sleeve. Lin SY, et al. **Laryngoscope** 1995 Nov;105(11):1213–9 (17 ref.)

CYTOLOGY

Role of material surfaces in regulating bone and cartilage cell response. Boyan BD, et al. **Biomaterials** 1996 Jan; 17(2):137–46 (94 ref.)

Osteoblast and chondroblast differentiation. Aubin JE, et al. **Bone** 1995 Aug;17(2 Suppl):77S–83S (56 ref.)

EMBRYOLOGY

A new subclass of helix-loop-helix transcription factors expressed in paraxial mesoderm and chondrogenic cell lineages. Olson EN, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:108–18 (30 ref.)

GROWTH & DEVELOPMENT

Basicranial synchondroses and the mandibular condyle in craniofacial growth. Rönning O. **Acta Odontol Scand** 1995 Jun;53(3):162–6 (42 ref.)

Discovery and clinical applications of bone morphogenetic proteins. Vukičević S, et al. **Eur J Clin Chem Clin Biochem** 1995 Oct;33(10):661–71 (81 ref.)

METABOLISM

Mutations in the cartilage oligomeric matrix protein (COMP) gene in pseudoachondroplasia and multiple epiphyseal dysplasia. Cohn DH, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:188–94 (18 ref.)

Cartilage matrix molecules in serum and synovial fluid. Simkin PA, et al. **Curr Opin Rheumatol** 1995 Jul;7(4):346–51 (28 ref.)

PHYSIOLOGY

Role of cartilage collagens in formation of the skeleton. Olsen BR. **Ann N Y Acad Sci** 1996 Jun 8;785:124–30 (30 ref.)

PHYSIOPATHOLOGY

Cartilage wound healing. An overview. Silver FH, et al. **Otolaryngol Clin North Am** 1995 Oct;28(5):847–64 (81 ref.)

TRANSPLANTATION

[Tissue engineering: artificial tissue replacement containing vital components] Sittinger M. **Laryngorhinootologie** 1995 Nov;74(11):695–9 (33 ref.) (Eng. Abstr.) **(Ger)**

ULTRASTRUCTURE

Ultrastructural organic–inorganic relationships in calcified tissues: cartilage and bone vs. enamel. Bonucci E. **Connect Tissue Res** 1995;33(1–3):157–62 (67 ref.)

CARTILAGE, ARTICULAR

ANATOMY & HISTOLOGY

MR imaging of the menisci. Fundamentals of anatomy and pathology. Firooznia H, et al. **Magn Reson Imaging Clin N Am** 1994 Aug;2(3):325–47 (46 ref.)

MR imaging of the triangular fibrocartilage complex. Totterman SM, et al. **Magn Reson Imaging Clin N Am** 1995 May;3(2):213–28 (24 ref.)

Emerging applications of magnetic resonance imaging in the evaluation of articular cartilage. Peterfy CG, et al. **Radiol Clin North Am** 1996 Mar;34(2):195–213, ix (63 ref.)

BLOOD SUPPLY

Microvascular architecture and exchange in synovial joints. Levick JR. **Microcirculation** 1995 Sep;2(3):217–33 (92 ref.)

CYTOLOGY

The chondrocyte, architect of cartilage. Biomechanics, structure, function and molecular biology of cartilage matrix macromolecules. Muir H. **Bioessays** 1995 Dec; 17(12):1039–48 (79 ref.)

[The cellular aspects of the development of synovial joints and articular cartilage] Archer CW, et al. **Ontogenez** 1995 Jul–Aug;26(4):259–69 (42 ref.) (Eng. Abstr.) **(Rus)**

EMBRYOLOGY

Tenascin-C and the development of articular cartilage. Pacifici M. **Matrix Biol** 1995 Dec;14(9):689–98 (54 ref.)

INJURIES

Magnetic resonance imaging of bone marrow and osteochondral injury. Vellet D. **Magn Reson Imaging Clin N Am** 1994 Aug;2(3):413–23 (22 ref.)

Rehabilitation following arthroscopic meniscectomy. St-Pierre DM. **Sports Med** 1995 Nov;20(5):338–47 (147 ref.)

METABOLISM

Changes in chondroitin sulphate structure induced by joint disease. Hardingham T. **Acta Orthop Scand Suppl** 1995 Oct; 266:107–10 (13 ref.)

The structure, biochemistry, and metabolism of osteoarthritic cartilage: a review of the literature. Dijkgraaf LC, et al. **J Oral Maxillofac Surg** 1995 Oct;53(10):1182–92 (36 ref.)

PATHOLOGY

The structure, biochemistry, and metabolism of osteoarthritic cartilage: a review of the literature. Dijkgraaf LC, et al. **J Oral Maxillofac Surg** 1995 Oct;53(10):1182–92 (36 ref.)

Magnetic resonance imaging of the meniscus. Advanced concepts. Fitzgerald SW. **Magn Reson Imaging Clin N Am** 1994 Aug;2(3):349–64 (49 ref.)

Meniscal disorders. Orbach S. **N Y State Dent J** 1996 Apr; 62(4):24–31 (0 ref.)

[Biophysical bases of the effects of holmium laser on articular cartilage and their impact on clinical application technics] Gerber BE, et al. **Orthopade** 1996 Feb;25(1):21–9 (37 ref.) (Eng. Abstr.) **(Ger)**

[Comparative histomorphometry of subchondral bone density and articular cartilage thickness in the tibial head in early human arthritis] Böhringer ME, et al. **Z Orthop Ihre Grenzgeb** 1995 Jul–Aug;133(4):291–302 (61 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Application of finite elements to the stress analysis of articular cartilage. Goldsmith AA, et al. **Med Eng Phys** 1996 Mar; 18(2):89–98 (44 ref.)

PHYSIOPATHOLOGY

A re-evaluation of the importance of disc position in temporomandibular disorders. Dolwick MF, et al. **Aust Dent J** 1996 Jun;41(3):184–7 (46 ref.)

SURGERY

Rehabilitation following arthroscopic meniscectomy. St-Pierre DM. **Sports Med** 1995 Nov;20(5):338–47 (147 ref.)

CARTILAGE DISEASES

see related
ELLIS-VAN CREVELD SYNDROME
EPIPHYSES, SLIPPED
OSTEOCHONDRITIS

DIAGNOSIS

MR imaging of the triangular fibrocartilage complex. Totterman SM, et al. **Magn Reson Imaging Clin N Am** 1995 May;3(2):213–28 (24 ref.)

Emerging applications of magnetic resonance imaging in the evaluation of articular cartilage. Peterfy CG, et al. **Radiol Clin North Am** 1996 Mar;34(2):195–213, ix (63 ref.)

[Cartilaginous tumors and other cutaneous lesions] Cribier B, et al. **Ann Dermatol Venereol** 1996;123(1):40–52 (80 ref.) **(Fre)**

CARTILAGE, EPIPHYSEAL see **GROWTH PLATE**

CASE-BASE STUDIES see **CASE-CONTROL STUDIES**

CASE-COMPARISON STUDIES see **CASE-CONTROL STUDIES**

CASE-CONTROL STUDIES

Case-control studies of screening efficacy: the use of persons newly diagnosed with cancer who later sustain an unfavorable outcome. Weiss NS, et al. **Am J Epidemiol** 1996 Feb 15;143(4):319–22 (4 ref.)

Risk factors and their identification second part: study designs for identification of risk factors. Balkau B, et al. **Diabete Metab** 1995 Jun;21(3):225–31 (17 ref.)

Design issues in case-control studies. Wacholder S. **Stat Methods Med Res** 1995 Dec;4(4):293–309 (102 ref.)

Sample size determination in epidemiologic studies. Wickramaratne PJ. **Stat Methods Med Res** 1995 Dec; 4(4):311–37 (53 ref.)

CASE MANAGEMENT

see related
MANAGED CARE PROGRAMS

Case management. Lamb GS. **Annu Rev Nurs Res** 1995; 13:117–36 (46 ref.)

Substance abuse and HIV pregnancy. Sprauve ME. **Clin Obstet Gynecol** 1996 Jun;39(2):316–32 (98 ref.)

27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 7. Evaluation and management of risk factors for the individual patient (case management). Swan HJ, et al. **J Am Coll Cardiol** 1996 Apr;27(5):1030–9 (37 ref.)

Practical management of eating disorders. Doyle MM. **Proc Nutr Soc** 1996 Nov;54(3):711–9 (29 ref.)

Assertive community treatment and case management for schizophrenia. Scott JE, et al. **Schizophr Bull** 1995; 21(4):657–68 (56 ref.)

Endoscopic management of ulcer disease. Fleischer D. **Yale J Biol Med** 1994 May–Aug;67(3–4):167–72 (37 ref.)

Medical management of esophageal reflux. Hirschowitz BI. **Yale J Biol Med** 1994 May–Aug;67(3–4):223–31 (35 ref.)

Zollinger-Ellison syndrome: past, present and future controversies. Jensen RT. **Yale J Biol Med** 1994 May–Aug; 67(3–4):195–214 (108 ref.)

LEGISLATION & JURISPRUDENCE

Youth Evaluation Services (YES): assessment, systems of referral, and treatment effects. Del Boca FK, et al. **NIDA Res Monogr** 1995;156:325–40 (11 ref.)

ORGANIZATION & ADMINISTRATION

Families of young technology-dependent children and the social worker. Bradley RH, et al. **Soc Work Health Care** 1995;21(1):23–37 (41 ref.)

CASE MANAGEMENT, INSURANCE see **MANAGED CARE PROGRAMS**

CASE MIX see **DIAGNOSIS-RELATED GROUPS**

CASE-REFERENT STUDIES see **CASE-CONTROL STUDIES**

CASEINS

CHEMISTRY

Antibacterial and immunostimulating casein-derived substances from milk: casecidin, isracidin peptides. Lahov E, et al. **Food Chem Toxicol** 1996 Jan;34(1):131-45 (49 ref.)

ULTRASTRUCTURE

Practical aspects of electron microscopy in cheese research. Kaláb M. **Adv Exp Med Biol** 1995;367:247-76 (136 ref.)

CASSAVA

CHEMISTRY

Cyanide detoxification in cassava for food and feed uses. Padmaja G. **Crit Rev Food Sci Nutr** 1995 Jul;35(4):299-339 (133 ref.)

CASSIA

see related
SENNA

CASTE see **SOCIAL CLASS**

CASTLEMAN'S DISEASE see **GIANT LYMPH NODE HYPERPLASIA**

CASTLEMAN'S TUMOR see **GIANT LYMPH NODE HYPERPLASIA**

CASTOR see **RODENTIA**

CASTRATION

VETERINARY

Surgical neutering and nonsurgical alternatives. Bloomberg MS. **J Am Vet Med Assoc** 1996 Feb 15;208(4):517-9 (21 ref.)

CASTRATION, FEMALE see **OVARIECTOMY**

CASTRATION, MALE see **ORCHIECTOMY**

CASTS, SURGICAL

Biomechanics of soft-tissue growth and remodeling with plaster casting. Bell-Krotoski JA, et al. **J Hand Ther** 1995 Apr-Jun;8(2):131-7 (16 ref.)

Instrumentational posterior fusion for atlanto-axial subluxation in a young child with Down's syndrome--case report. Kohno M, et al. **Neurol Med Chir (Tokyo)** 1995 Oct;35(10):753-8 (22 ref.)

Total contact casting for diabetic neuropathic ulcers. Sinacore DR. **Phys Ther** 1996 Mar;76(3):296-301 (29 ref.)

CAT DISEASES

Aetiology, prevalence and diagnosis of deafness in dogs and cats [see comments] Strain GM. **Br Vet J** 1996 Jan; 152(1):17-36 (81 ref.) Comment in: Br Vet J 1996 Jan;152(1):13-5.

Uveitis in dogs and cats: guidelines for the practitioner. Goodhead AD. **J S Afr Vet Assoc** 1996 Mar;67(1):12-9 (22 ref.)

Chylothorax in the dog and cat: a review. Birchard SJ, et al. **Lymphology** 1995 Jun;28(2):64-72 (53 ref.)

Diagnosis and treatment of conjunctival and corneal diseases. Nasisse MP. **Vet Q** 1995 Apr;17 Suppl 1:S42-3 (0 ref.)

CHEMICALLY INDUCED

The cat, the flea, and pesticides. Logas DB.
Vet Clin North Am Small Anim Pract 1995 Jul;25(4):801-11 (60 ref.)

Benzodiazepine poisoning in companion animals. Bertini S, et al. **Vet Hum Toxicol** 1995 Dec;37(6):559-62 (24 ref.)

CLASSIFICATION

Feline lower urinary tract disorders. Definition of terms and concepts. Osborne CA, et al.
Vet Clin North Am Small Anim Pract 1996 Mar; 26(2):169-79 (16 ref.)

CONGENITAL

Inherited and congenital diseases of the feline lower urinary tract. Kruger JM, et al.
Vet Clin North Am Small Anim Pract 1996 Mar; 26(2):265-79 (45 ref.)

DIAGNOSIS

Interstitial cystitis in cats. Buffington CA, et al.
Vet Clin North Am Small Anim Pract 1996 Mar; 26(2):317-26 (36 ref.)

Feline cutaneous and subcutaneous neoplasms. Fox LE.
Vet Clin North Am Small Anim Pract 1995 Jul;25(4):961-79 (138 ref.)

Diagnostic imaging of the feline lower urinary tract. Johnston GR, et al. **Vet Clin North Am Small Anim Pract** 1996 Mar; 26(2):401-15 (9 ref.)

Cystocentesis. Diagnostic and therapeutic considerations. Kruger JM, et al.
Vet Clin North Am Small Anim Pract 1996 Mar; 26(2):353-61 (14 ref.)

Bacterial urinary tract infections. Lees GE.
Vet Clin North Am Small Anim Pract 1996 Mar; 26(2):297-304 (12 ref.)

Overview of diagnosis of feline lower urinary tract disorders. Lulich JP, et al. **Vet Clin North Am Small Anim Pract** 1996 Mar;26(2):339-52 (3 ref.)

Diagnostic procedures in feline dermatology. Noxon JO.
Vet Clin North Am Small Anim Pract 1995 Jul;25(4):779-99 (14 ref.)

Focal and generalized alopecia. O'Dair HA, et al.
Vet Clin North Am Small Anim Pract 1995 Jul;25(4):851-70 (87 ref.)

Feline crystalluria. Detection and interpretation. Osborne CA, et al. **Vet Clin North Am Small Anim Pract** 1996 Mar; 26(2):369-91 (3 ref.)

The role of tonometry in the clinical management of the glaucomas in companion animals. Gelatt KN. **Vet Q** 1995 Apr;17 Suppl 1:S45 (0 ref.)

Dyspnea: how to solve the problem. Venker-van Haagen AJ. **Vet Q** 1995 Apr;17 Suppl 1:S7-8 (0 ref.)

DRUG THERAPY

Treating moderate and severe pain in small animals. Brock N. **Can Vet J** 1995 Oct;36(10):658-60 (3 ref.)

Therapy for feline dermatoses. Messinger LM.
Vet Clin North Am Small Anim Pract 1995 Jul; 25(4):981-1005 (126 ref.)

Feline dermatophytosis. Recent advances and recommendations for therapy. Moriello KA, et al.
Vet Clin North Am Small Anim Pract 1995 Jul;25(4):901-21 (49 ref.)

EPIDEMIOLOGY

Hemostatic disorders in cats: a retrospective study and review of the literature. Peterson JL, et al. **J Vet Intern Med** 1995 Sep-Oct;9(5):298-303 (56 ref.)

Fungal infections of the feline lower urinary tract. Lulich JP, et al. **Vet Clin North Am Small Anim Pract** 1996 Mar; 26(2):309-15 (10 ref.)

Cowpox in cats and man. Bennett M, et al. **Vet Q** 1995 Apr; 17 Suppl 1:S16 (4 ref.)

ETIOLOGY

Nodules and draining tracts. Beale KM.
Vet Clin North Am Small Anim Pract 1995 Jul; 25(4):887-900 (50 ref.)

Systemic diseases with cutaneous manifestations. Merchant SR, et al. **Vet Clin North Am Small Anim Pract** 1995 Jul; 25(4):945-59 (56 ref.)

Feline urolithiasis. Etiology and pathophysiology. Osborne CA, et al. **Vet Clin North Am Small Anim Pract** 1996 Mar; 26(2):217-32 (37 ref.)

Feline urethral plugs. Etiology and pathophysiology. Osborne CA, et al.
Vet Clin North Am Small Anim Pract 1996 Mar; 26(2):233-53 (15 ref.)

GENETICS

Inherited and congenital diseases of the feline lower urinary tract. Kruger JM, et al.
Vet Clin North Am Small Anim Pract 1996 Mar; 26(2):265-79 (45 ref.)

METABOLISM

Urolith analysis. Submission, methods, and interpretation. Ulrich LK, et al. **Vet Clin North Am Small Anim Pract** 1996 Mar;26(2):393-400 (5 ref.)

MICROBIOLOGY

Feline tuberculosis: a literature review and discussion of 19 cases caused by an unusual mycobacterial variant. Gunn-Moore DA, et al. **Vet Rec** 1996 Jan 20;138(3):53-8 (38 ref.)

PATHOLOGY

Erosive and ulcerative skin disease. Angarano DW.
Vet Clin North Am Small Anim Pract 1995 Jul;25(4):871-85 (35 ref.)

Nodules and draining tracts. Beale KM.
Vet Clin North Am Small Anim Pract 1995 Jul; 25(4):887-900 (50 ref.)

Facial, pedal, and other regional dermatoses. Foil CS.
Vet Clin North Am Small Anim Pract 1995 Jul;25(4):923-44 (64 ref.)

Systemic diseases with cutaneous manifestations. Merchant SR, et al. **Vet Clin North Am Small Anim Pract** 1995 Jul; 25(4):945-59 (56 ref.)

Selected feline eosinophilic skin diseases. Power HT, et al. **Vet Clin North Am Small Anim Pract** 1995 Jul;25(4):833-50 (30 ref.)

Exudative, crusting, and scaling dermatoses. Sousa CA.
Vet Clin North Am Small Anim Pract 1995 Jul;25(4):813-31 (23 ref.)

Biliary cystadenoma of cats. Adler R, et al. **Vet Pathol** 1995 Jul;32(4):415-8 (23 ref.)

PHYSIOPATHOLOGY

Central nervous system tumors. Gavin PR, et al.
Semin Vet Med Surg (Small Anim) 1995 Aug;10(3):180-9 (32 ref.)

Detrusor-sphincter dyssynergia. Barsanti JA, et al.
Vet Clin North Am Small Anim Pract 1996 Mar; 26(2):327-38 (32 ref.)

Pathophysiology of urethral obstruction. Bartges JW, et al.
Vet Clin North Am Small Anim Pract 1996 Mar; 26(2):255-64 (18 ref.)

Interstitial cystitis in cats. Buffington CA, et al.
Vet Clin North Am Small Anim Pract 1996 Mar; 26(2):317-26 (36 ref.)

Biologic behavior of feline lower urinary tract diseases. Lulich JP, et al. **Vet Clin North Am Small Anim Pract** 1996 Mar;26(2):207-15 (13 ref.)

Feline urolithiasis. Etiology and pathophysiology. Osborne CA, et al. **Vet Clin North Am Small Anim Pract** 1996 Mar; 26(2):217-32 (37 ref.)

Feline urethral plugs. Etiology and pathophysiology. Osborne CA, et al.
Vet Clin North Am Small Anim Pract 1996 Mar; 26(2):233-53 (15 ref.)

Feline asthma syndrome. Corcoran BM, et al. **Vet Q** 1995 Apr;17 Suppl 1:S15-6 (3 ref.)

Circulatory disorders of the liver in dogs and cats. van den Ingh TS, et al. **Vet Q** 1995 Jun;17(2):70-6 (40 ref.)

Skin disorders in cats. Willemse A. **Vet Q** 1995 Apr;17 Suppl 1:S40-1 (8 ref.)

[Sedation and anesthesia in dogs and cats with cardiovascular diseases. I. Anesthesia plan considering risk assessment, hemodynamic effects of drugs and monitoring] Skarda RT, et al. **Schweiz Arch Tierheilkd** 1995;137(7):312-21 (13 ref.) (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

Advances in feline health research: impact of recent developments in vaccinology on feline welfare. Richards JR. **J Am Vet Med Assoc** 1996 Feb 15;208(4):505-10 (30 ref.)

The cat, the flea, and pesticides. Logas DB.
Vet Clin North Am Small Anim Pract 1995 Jul;25(4):801-11 (60 ref.)

[Immunity--technical aspects of vaccines. I. Immunoprophylaxis in dogs and cats] Overgaauw PA. **Tijdschr Diergeneeskd** 1996 Feb 15;121(4):90-5 (0 ref.) (Eng. Abstr.) **(Dut)**

[Vaccination in practice. II. Immunoprophylaxis in dogs and cats] Overgaauw PA. **Tijdschr Diergeneeskd** 1996 Feb 15; 121(4):95-101 (0 ref.) **(Dut)**

[Vaccination failures. III. Postvaccinal complications and immunization schedules. Immunoprophylaxis in dogs and cats] Overgaauw PA. **Tijdschr Diergeneeskd** 1996 Feb 15; 121(4):101-5 (60 ref.) **(Dut)**

RADIOTHERAPY

Radiation therapy for head and neck cancers. Gillette SM, et al. **Semin Vet Med Surg (Small Anim)** 1995 Aug; 10(3):168-72 (28 ref.)

Radiation therapy of thoracic and abdominal tumors. LaRue SM, et al. **Semin Vet Med Surg (Small Anim)** 1995 Aug; 10(3):190-6 (32 ref.)

Palliative radiation therapy. Thrall DE, et al.
Semin Vet Med Surg (Small Anim) 1995 Aug;10(3):205-8 (14 ref.)

SURGERY

The treatment of hernias. Bellenger CR. **Vet Q** 1995 Apr; 17 Suppl 1:S2-4 (11 ref.)

THERAPY

Endodontics of dogs and cats: an alternative to extraction. Clarke DE. **Aust Vet J** 1995 Oct;72(10):383-9 (57 ref.)

Combining radiation therapy with other treatment modalities. LaRue SM, et al. **Semin Vet Med Surg (Small Anim)** 1995 Aug;10(3):197-204 (14 ref.)

Soft-tissue sarcomas. Thrall DE, et al.
Semin Vet Med Surg (Small Anim) 1995 Aug;10(3):173-9 (45 ref.)

Use of blood and blood components in canine and feline patients with hemostatic disorders. de Gopegui RR, et al. **Vet Clin North Am Small Anim Pract** 1995 Nov; 25(6):1387-402 (69 ref.)

Feline transfusion medicine. Blood types and their clinical importance. Griot-Wenk ME, et al.
Vet Clin North Am Small Anim Pract 1995 Nov; 25(6):1305-22 (35 ref.)

Transfusion therapy in emergency and critical care medicine. Kirby R. **Vet Clin North Am Small Anim Pract** 1995 Nov; 25(6):1365-86 (25 ref.)

Cystocentesis. Diagnostic and therapeutic considerations. Kruger JM, et al.
Vet Clin North Am Small Anim Pract 1996 Mar; 26(2):353-61 (14 ref.)

Hematopoietic growth factors: frontiers for cure. Ogilvie

GK. **Vet Clin North Am Small Anim Pract** 1995 Nov; 25(6):1441–56 (23 ref.)
Autotransfusion in the emergency patient. Purvis D. **Vet Clin North Am Small Anim Pract** 1995 Nov; 25(6):1291–304 (59 ref.)
The role of blood component therapy in the management of canine and feline patients with cancer. Rudloff E. **Vet Clin North Am Small Anim Pract** 1995 Nov; 25(6):1403–16 (72 ref.)
Blood substitutes: oxygen–carrying acellular fluids. Wohl JS, et al. **Vet Clin North Am Small Anim Pract** 1995 Nov; 25(6):1417–40 (120 ref.)

TRANSMISSION

Population medicine and infectious diseases. Hoskins JD. **J Am Vet Med Assoc** 1996 Feb 15;208(4):510–2 (7 ref.)

URINE

Feline crystalluria. Detection and interpretation. Osborne CA, et al. **Vet Clin North Am Small Anim Pract** 1996 Mar; 26(2):369–91 (3 ref.)

VIROLOGY

Viral infections of the feline urinary tract. Kruger JM, et al. **Vet Clin North Am Small Anim Pract** 1996 Mar; 26(2):281–96 (77 ref.)

CAT ENZYME see **CHLORAMPHENICOL ACETYLTRANSFERASE**

CAT LEUKEMIA VIRUS see **LEUKEMIA VIRUS, FELINE**

CAT SCAN, RADIONUCLIDE see **TOMOGRAPHY, EMISSION-COMPUTED**

CAT SCAN, X-RAY see **TOMOGRAPHY, X-RAY COMPUTED**

CAT SCANNERS, X-RAY see **TOMOGRAPHY SCANNERS, X-RAY COMPUTED**

CAT-SCRATCH DISEASE

Cat–scratch disease. Midani S, et al. **Adv Pediatr** 1996; 43:397–422 (97 ref.)
Benign lymphoproliferative disorders. Shaffer S. **Semin Oncol Nurs** 1996 Feb;12(1):28–37 (44 ref.)
[Bartonella (Rochalimaea) infections: cat–scratch disease and bacillary angiomatosis] Sander A, et al. **Dtsch Med Wochenschr** 1996 Jan 19;121(3):65–9 (47 ref.) **(Ger)**

DIAGNOSIS

Bartonella (Rochalimaea) infections: beyond cat scratch. Schwartzman W. **Annu Rev Med** 1996;47:355–64 (26 ref.)
Neurologic complications of Bartonella henselae infection. Marra CM. **Curr Opin Neurol** 1995 Jun;8(3):164–9 (65 ref.)
Systemic cat scratch disease: hepatic and splenic involvement about 3 pediatric cases. Destuynder O, et al. **Eur J Pediatr Surg** 1995 Dec;5(6):365–8 (43 ref.)
Fever, abdominal pain and an intracranial mass. Wong M, et al. **Pediatr Infect Dis J** 1995 Aug;14(8):725–8 (18 ref.)
[Cat–scratch disease presenting as a pseudotumor. Imaging by x–ray computed tomography and MRI] Leblan I, et al. **J Radiol** 1995 Sep;76(9):601–4 (19 ref.) (Eng. Abstr.) **(Fre)**
[Cat scratch disease. Atypical forms] Bourrillon A, et al. **Presse Med** 1996 Mar 23;25(10):503–7 (51 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

[Cat scratch disease. Bartonella henselae antibodies and DNA detection in regional lymphadenopathy] Heizmann WR, et al. **Dtsch Med Wochenschr** 1996 May 10;121(19):622–6 (33 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

[Cat scratch disease in immunocompetent children] Leclainche L, et al. **Arch Pediatr** 1996 Apr;3(4):378–82 (41 ref.) (Eng. Abstr.) **(Fre)**
[Cat scratch disease. Bartonella henselae antibodies and DNA detection in regional lymphadenopathy] Heizmann WR, et al. **Dtsch Med Wochenschr** 1996 May 10;121(19):622–6 (33 ref.) (Eng. Abstr.) **(Ger)**

MICROBIOLOGY

New pathogens, and diseases old and new. I) Afipia felis and Rochalimaea. II) Parvovirus B 19. III) herpesvirus 6. Zannolli R, et al. **Panminerva Med** 1995 Dec;37(4):238–47 (111 ref.)
[Cat–scratch disease and other infections caused by Bartonella species] Schellekens JF. **Ned Tijdschr Geneeskd** 1996 Jan 20;140(3):144–7 (25 ref.) (Eng. Abstr.) **(Dut)**
[Cat scratch disease caused by Bartonella henselae] Sölder B, et al. **Immun Infekt** 1995 Dec;23(6):228–31 (25 ref.) (Eng. Abstr.) **(Ger)**

CATABOLIC GENE ACTIVATORS see **CYCLIC AMP RECEPTOR PROTEIN**

CATABOLITE ACTIVATOR PROTEIN see **CYCLIC AMP RECEPTOR PROTEIN**

CATABOLITE GENE ACTIVATOR PROTEIN see **CYCLIC AMP RECEPTOR PROTEIN**

CATABOLITE GENE ACTIVATOR PROTEINS see **CYCLIC AMP RECEPTOR PROTEIN**

CATALASE

BLOOD

[Catalase] Murakami K, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:358–60 (7 ref.) **(Jpn)**

GENETICS

Regulation of hydroperoxidase (catalase) expression in Escherichia coli. Schellhorn HE. **FEMS Microbiol Lett** 1995 Sep 1;131(2):113–9 (25 ref.)

CATALYSIS

Catalytic metals, ascorbate and free radicals: combinations to avoid. Buettner GR, et al. **Radiat Res** 1996 May; 145(5):532–41 (79 ref.)
New designs of macroporous polymers and supports: from separation to biocatalysis. Svec F, et al. **Science** 1996 Jul 12;273(5272):205–11 (48 ref.)
[The origin and early development of biological catalysts] Masinovský Z. **Cas Lek Cesk** 1995 Oct 4;134(19):607–10 (26 ref.) (Eng. Abstr.) **(Cze)**

CATALYTIC ANTIBODIES see **ANTIBODIES, CATALYTIC**

CATAPLEXY

see related
NARCOLEPSY

DIAGNOSIS

Clinical aspects and features of cataplexy. Guilleminault C, et al. **Adv Neurol** 1995;67:65–77 (47 ref.)

PHYSIOPATHOLOGY

Clinical aspects and features of cataplexy. Guilleminault C, et al. **Adv Neurol** 1995;67:65–77 (47 ref.)
Physiology of REM sleep, cataplexy, and sleep paralysis. Hishikawa Y, et al. **Adv Neurol** 1995;67:245–71 (125 ref.)

CATARACT

Infantile Cataracts. Lambert SR, et al. **Surv Ophthalmol** 1996 May–Jun;40(6):427–58 (291 ref.)
[Progresses in ophthalmology in China, 1995] Zhang S. **Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):755–7 (0 ref.) **(Chi)**

COMPLICATIONS

Strategic issues in preventing cataract blindness in developing countries. Ellwein LB, et al. **Bull World Health Organ** 1995; 73(5):681–90 (21 ref.)
Surgical management of coexisting cataract and glaucoma. Schuman JS. **Ophthalmic Surg Lasers** 1996 Jan;27(1):45–59 (27 ref.)

CONGENITAL

A nine–month–old boy with microcephaly, cataracts, intracerebral calcifications and dysmorphic signs: an additional observation of an autosomal recessive congenital infection–like syndrome? Wieczorek D, et al. **Genet Couns** 1995;6(4):297–302 (18 ref.)
Principles and paradigms of pediatric cataract management. Basti S, et al. **Indian J Ophthalmol** 1995 Dec;43(4):159–76 (110 ref.)
Simultaneous surgery for bilateral pediatric cataracts. Zwaan J. **Ophthalmic Surg Lasers** 1996 Jan;27(1):15–20 (28 ref.)

EPIDEMIOLOGY

Blindness due to cataract: epidemiology and prevention. Javitt JC, et al. **Annu Rev Public Health** 1996;17:159–77 (109 ref.)
Epidemiological studies of sunlight and cataract: the critical factor of ultraviolet exposure geometry [see comments] Sliney DH. **Ophthalmic Epidemiol** 1994 Jun;1(2):107–19 (33 ref.) Comment in: Int J Food Sci Nutr 1994 Jun;1(2):63–5.

ETIOLOGY

Cataract: current management. Ficker L. **Br J Hosp Med** 1996 May 15–Jun 4;55(10):607–10 (15 ref.)
Risk factors for age–related cataracts. Hodge WG, et al. **Epidemiol Rev** 1995;17(2):336–46 (62 ref.)
Recent developments in vision research: light damage in cataract. McCarty CA, et al. **Invest Ophthalmol Vis Sci** 1996 Aug;37(9):1720–3 (14 ref.)
Transgenic mice: models for the study of cataractogenesis. A minireview. Bloemendal H, et al. **Ophthalmic Res** 1996; 28 Suppl 1:1–7 (23 ref.)
Cataract mutations as a tool for developmental geneticists. Graw J. **Ophthalmic Res** 1996;28 Suppl 1:8–18 (62 ref.)
Capsulotomy. Murrill CA, et al. **Optom Clin** 1995;4(4):69–83 (58 ref.)
Cholesterol and cataracts. Cenedella RJ. **Surv Ophthalmol** 1996 Jan–Feb;40(4):320–37 (158 ref.)
[Visual and sensory results of surgical treatment of cataract in children. Apropos of 135 cases] Lesueur L, et al. **J Fr Ophtalmol** 1995;18(11):667–77 (28 ref.) (Eng. Abstr.) **(Fre)**
[The oxidative stress in the cataract formation] Obara Y. **Nippon Ganka Gakkai Zasshi** 1995 Dec;99(12):1303–41 (83 ref.) (Eng. Abstr.) **(Jpn)**
[Biochemical aspects of the development of lens opacity] Jarmak A. **Klin Oczna** 1995 Nov–Dec;97(11–12):348–52 (46 ref.) (Eng. Abstr.) **(Pol)**

GENETICS

The clinical and genetic heterogeneity of autosomal dominant cataract. Ionides A, et al. **Acta Ophthalmol Scand Suppl** 1996;(219):40–1 (14 ref.)

PHYSIOPATHOLOGY

[The physiopathology of primary cataract] Stănilă A. **Oftalmologia** 1995 Oct–Dec;39(4):302–6 (10 ref.) (Eng. Abstr.) **(Rum)**

PREVENTION & CONTROL

Relations among aging, antioxidant status, and cataract. Taylor A, et al. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1439S–1447S (80 ref.)
Antioxidants and age–related eye disease. Current and future perspectives. Christen WG, et al. **Ann Epidemiol** 1996 Jan; 6(1):60–6 (79 ref.)
Blindness due to cataract: epidemiology and prevention. Javitt JC, et al. **Annu Rev Public Health** 1996;17:159–77 (109 ref.)
[Antioxidative vitamins and cataracts in the elderly] Heseker H. **Z Ernahrungswiss** 1995 Sep;34(3):167–76 (68 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Intraocular lens implantation in patients with juvenile rheumatoid arthritis–associated uveitis: an unresolved management issue [editorial; comment] Holland GN. **Am J Ophthalmol** 1996 Aug;122(2):255–7 (10 ref.) Comment on: Am J Ophthalmol 1996 Aug;122(2):161–70.
Intraocular lens implantation in patients with juvenile rheumatoid arthritis [see comments] Probst LE, et al. **Am J Ophthalmol** 1996 Aug;122(2):161–70 (24 ref.) Comment in: Am J Ophthalmol 1996 Aug;122(2):255–7.

VETERINARY

Current concepts in the management of canine cataract: a survey of techniques used by surgeons in Britain, Europe and the USA and a review of recent literature. Williams DL, et al. **Vet Rec** 1996 Apr 13;138(15):347–53 (70 ref.)

CATARACT EXTRACTION

see related
APHAKIA, POSTCATARACT
LENSES, INTRAOCULAR

Cataract: current management. Ficker L. **Br J Hosp Med** 1996 May 15–Jun 4;55(10):607–10 (15 ref.)
Strategic issues in preventing cataract blindness in developing countries. Ellwein LB, et al. **Bull World Health Organ** 1995; 73(5):681–90 (21 ref.)
Cataract extraction in patients with chronic posterior uveitis. Tabbara KF, et al. **Int Ophthalmol Clin** 1995 Spring; 35(2):121–31 (19 ref.)
Cataract surgery in Fuchs' heterochromic uveitis: past, present, and future. Jones NP. **J Cataract Refract Surg** 1996 Mar;22(2):261–8 (41 ref.)
Surgical management of coexisting cataract and glaucoma. Schuman JS. **Ophthalmic Surg Lasers** 1996 Jan;27(1):45–59 (27 ref.)
Simultaneous surgery for bilateral pediatric cataracts. Zwaan J. **Ophthalmic Surg Lasers** 1996 Jan;27(1):15–20 (28 ref.)
[Repercussions of cataract surgery on the development of diabetic retinopathy] Comhaire–Poutchinian Y. **Bull Soc Belge Ophtalmol** 1995;256:115–23 (32 ref.) (Eng. Abstr.) **(Fre)**
[Visual and sensory results of surgical treatment of cataract in children. Apropos of 135 cases] Lesueur L, et al. **J Fr Ophtalmol** 1995;18(11):667–77 (28 ref.) (Eng. Abstr.) **(Fre)**
[Principal factors affecting postoperative astigmatism after cataract extraction] Naim Dzheries Dzhadalla Kalkikh. **Vestn Oftalmol** 1995 Jul–Sep;111(3):34–6 (49 ref.) **(Rus)**

ADVERSE EFFECTS

Clinical syndrome of endocapsular hematoma: presentation of a collected series and review of the literature. Hagan JC 3rd, et al. **J Cataract Refract Surg** 1996 Apr;22(3):379–84 (18 ref.)
Flexible open–loop anterior chamber intraocular lens

implantation after posterior capsule complications in extracapsular cataract extraction. Rattigan SM, et al. **J Cataract Refract Surg** 1996 Mar;22(2):243–6 (10 ref.)
Capsulotomy. Murrill CA, et al. **Optom Clin** 1995;4(4):69–83 (58 ref.)
[Corneal edema, a complication of cataract surgery] Chercota V. **Oftalmologia** 1995 Oct–Dec;39(4):343–8 (9 ref.) (Eng. Abstr.) **(Rum)**

METHODS

Aqueous contamination during small incision cataract surgery: a lesson in study design [editorial; comment] Towler H. **Br J Ophthalmol** 1995 Oct;79(10):873 (12 ref.) Comment on: Br J Ophthalmol 1995 Oct;79(10):878–80.
Differentiated treatment of secondary cataract following extracapsular cataract operation. Adank AM, et al. **Bull Soc Belge Ophtalmol** 1994;254:37–40 (18 ref.)
Principles and paradigms of pediatric cataract management. Basti S, et al. **Indian J Ophthalmol** 1995 Dec;43(4):159–76 (110 ref.)

VETERINARY

Current concepts in the management of canine cataract: a survey of techniques used by surgeons in Britain, Europe and the USA and a review of recent literature. Williams DL, et al. **Vet Rec** 1996 Apr 13;138(15):347–53 (70 ref.)

CATARRHINA see **CERCOPITHECIDAE**

CATATONIA

CHEMICALLY INDUCED

Neuroleptic malignant syndrome and catatonia: one entity or two? [editorial] Fink M. **Biol Psychiatry** 1996 Jan 1; 39(1):1–4 (30 ref.)

COMPLICATIONS

Epidemiology and pathoetiology of neurological syndromes with hyperthermia. Di Rosa AE, et al. **Funct Neurol** 1995 May–Jun;10(3):111–9 (49 ref.)

CATECHOL ESTROGENS see **ESTROGENS, CATECHOL**

CATECHOL METHYLTRANSFERASE

ANTAGONISTS & INHIBITORS

Effects of catechol-O-methyltransferase (COMT) inhibition on the pharmacokinetics of L-DOPA. Nutt JG. **Adv Neurol** 1996;69:493–6 (15 ref.)
Induction of cytotoxicity in melanoma cells through inhibition of catechol-O-methyltransferase. Smit NP, et al. **Biochem Pharmacol** 1995 Dec 22;50(12):1955–62 (68 ref.)

PHYSIOLOGY

The role of monoamine oxidase and catechol O-methyltransferase in dopaminergic neurotransmission. Napolitano A, et al. **J Neural Transm Suppl** 1995;45:35–45 (60 ref.)

CATECHOLAMINES

ANALYSIS

[Catecholamine (CA)] Oishi S, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:507–10 (8 ref.) **(Jpn)**

BLOOD

Acute reversal of pheochromocytoma-induced catecholamine cardiomyopathy. Nanda AS, et al. **Clin Cardiol** 1995 Jul;18(7):421–3 (8 ref.)

DIAGNOSTIC USE

Pharmacological stress electrocardiography—when is it indicated? Davies J. **Br J Clin Pract Symp Suppl** 1995 Nov; 82:2–5 (3 ref.)
Nuclear cardiology studies—principles for stress modality selection. Underwood R. **Br J Clin Pract Symp Suppl** 1995 Nov;82:10–2 (9 ref.)

METABOLISM

Aging is associated in the 344/N Fischer rat with decreased stress responsivity of central and peripheral catecholaminergic systems and impairment of the hypothalamic-pituitary-adrenal axis. Cizza G, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:491–511 (68 ref.)
Stress, aging, and memory. Involvement of peripheral catecholamines. Mabry TR, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:512–22 (53 ref.)
Role of catecholamines and sympathetic activation as a risk factor for coronary artery disease. Amadi A, et al. **J Cardiovasc Risk** 1995 Jun;2(3):222–8 (66 ref.)
The role of catecholamines on intercellular coupling, myocardial cell synchronization and self ventricular defibrillation. Manoach M, et al. **Mol Cell Biochem** 1995 Jun 7–21;147(1–2):181–5 (63 ref.)

PHARMACOLOGY

Differential activation of beta 1-, beta 2- and beta 3-adrenoceptors by catecholamines in white and brown adipocytes. Galitzky J, et al. **Fundam Clin Pharmacol** 1995; 9(4):324–31 (54 ref.)

PHYSIOLOGY

Molecular biology of catecholamine neurons in relation to Parkinson's disease. Nagatsu T, et al. **Adv Neurol** 1996; 69:147–52 (22 ref.)
Sympathoadrenal system in stress. Interaction with the hypothalamic-pituitary-adrenocortical system. Kvetňanský R, et al. **Ann N Y Acad Sci** 1995 Dec 29; 771:131–58 (158 ref.)
Involvement of brain catecholamines and acetylcholine in growth hormone hypersecretory states. Pathophysiological, diagnostic and therapeutic implications. Müller EE, et al. **Drugs** 1995 Nov; 50(5):805–37 (285 ref.)
Is there a third peripheral catecholaminergic system? Endogenous dopamine as an autocrine/paracrine substance derived from plasma DOPA and inactivated by conjugation. Goldstein DS, et al. **Hypertens Res** 1995 Jun; 18 Suppl 1:S93–9 (76 ref.)
Bulbospinal catecholamine neurones and sympathetic pattern generation. Coote JH, et al. **J Physiol Pharmacol** 1995 Sep; 46(3):259–71 (50 ref.)
[Regulatory factors in food intake: overview] Aou S, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:19–25 (20 ref.) **(Jpn)**
[Pathogenesis of visceral fat accumulation] Keno Y, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:121–6 (20 ref.) **(Jpn)**
[Role of catecholamines in adipocyte metabolism] Nagasaka Y, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:106–10 (13 ref.) **(Jpn)**
[Role of biogenic amines (catecholamines, histamine, serotonin, etc.) in food intake] Tsujii S. **Nippon Rinsho** 1995 Jun;53 Suppl:33–9 (20 ref.) **(Jpn)**

SECRETION

Release of catecholamines and enkephalin peptides induced by reversal of the Na(+)-Ca2+ exchanger in chromaffin cells. Duarte EP, et al. **Ann N Y Acad Sci** 1996 Apr 15; 779:391–4 (6 ref.)
Na-Ca exchange in Ca2+ signaling and neurohormone secretion. Secretory vesicle contributions in adrenal chromaffin cells. Schneider AS, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:356–65 (17 ref.)
Mechanisms of catecholamine secretion from adrenal chromaffin cells. Burgoyne RD. **J Physiol Pharmacol** 1995 Sep;46(3):273–83 (45 ref.)

THERAPEUTIC USE

Effects of catecholamines on regional perfusion and oxygenation in critically ill patients. Meier-Hellmann A, et al. **Acta Anaesthesiol Scand Suppl** 1995;107:239–48 (106 ref.)
[What are the advances in the treatment of acute kidney failure? (editorial)] Brivet F, et al. **Presse Med** 1996 Feb 17;25(6):227–9 (13 ref.) (Eng. Abstr.) **(Fre)**

CATFISH, CHANNEL see **ICTALURIDAE**

CATHARTICS

see related
DIETARY FIBER

ADVERSE EFFECTS

Complications of laxative abuse. Baker EH, et al. **Annu Rev Med** 1996;47:127–34 (20 ref.)

PHARMACOLOGY

[The mechanism of action of sennosides] Lemli J. **Ann Gastroenterol Hepatol (Paris)** 1996 Mar–Apr; 32(2):109–12 (29 ref.) (Eng. Abstr.) **(Fre)**
[Mechanism of action of sennosides] Lemli J. **Bull Acad Natl Med** 1995 Nov;179(8):1605–11 (29 ref.) (Eng. Abstr.) **(Fre)**

THERAPEUTIC USE

Lactulose in clinical use. Ray J, et al. **Trop Gastroenterol** 1996 Apr–Jun;17(2):12–4 (11 ref.)

CATHEPSIN D

BIOSYNTHESIS

Cathepsin E and cathepsin D: biosynthesis, processing and subcellular location. Yamamoto K. **Adv Exp Med Biol** 1995; 362:223–9 (22 ref.)

METABOLISM

Cathepsin D and breast cancer [see comments] Westley BR, et al. **Eur J Cancer** 1996 Jan;32A(1):15–24 (78 ref.) Comment in: Eur J Cancer 1996 Jan;32A(1):7–8.

CATHEPSINS

BIOSYNTHESIS

Cathepsin E and cathepsin D: biosynthesis, processing and subcellular location. Yamamoto K. **Adv Exp Med Biol** 1995; 362:223–9 (22 ref.)

CHEMISTRY

[Structure and function of cathepsin e, a candidate for processing proteinases] Kageyama T. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(4):347–55 (49 ref.) **(Jpn)**

PHYSIOLOGY

Platelet activation by polymorphonuclear leukocytes: role of cathepsin G and P-selectin. Cerletti C, et al. **Thromb Haemost** 1995 Jul;74(1):218–23 (82 ref.)
[Structure and function of cathepsin e, a candidate for processing proteinases] Kageyama T. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(4):347–55 (49 ref.) **(Jpn)**

CATHETER ABLATION

Localization of the origin of the atrioventricular junctional rhythm induced during selective ablation of slow-pathway conduction in patients with atrioventricular node reentrant tachycardia. Yu JC, et al. **Am Heart J** 1996 May; 131(5):937–46 (45 ref.)
Results of radiofrequency catheter ablation for atrial flutter. Saxon LA, et al. **Am J Cardiol** 1996 May 1;77(11):1014–6 (18 ref.)
The present role of radiofrequency catheter ablation in the management of cardiac arrhythmias. Kay GN, et al. **Am J Med** 1996 Mar;100(3):344–56 (23 ref.)
Radiofrequency ablation of arrhythmias in the pediatric patient. Moak JP. **Curr Opin Cardiol** 1996 Jan;11(1):81–92 (47 ref.)
Future prospects of antiarrhythmic treatment based on experimental studies. Janse MJ. **Eur Heart J** 1995 Aug;16 Suppl G:2–6 (44 ref.)
Radiofrequency ablation--what is left? Zipes DP. **Eur Heart J** 1995 Aug;16 Suppl G:24–7 (13 ref.)
Nonpharmacologic approaches to the treatment of atrial fibrillation and atrial flutter. Baker BM, et al. **J Cardiovasc Electrophysiol** 1995 Oct;6(10 Pt 2):972–8 (66 ref.)
Future ablation concepts of tachyarrhythmias. Chen SA, et al. **J Cardiovasc Electrophysiol** 1995 Oct;6(10 Pt 1):852–62 (99 ref.)
Catheter ablation for the treatment of paroxysmal supraventricular tachycardia. Naccarelli GV, et al. **J Cardiovasc Electrophysiol** 1995 Oct;6(10 Pt 2):951–61 (47 ref.)
Ventricular tachycardia after myocardial infarction: from arrhythmia surgery to catheter ablation. Stevenson WG. **J Cardiovasc Electrophysiol** 1995 Oct;6(10 Pt 2):942–50 (52 ref.)
Wolff-Parkinson-White syndrome and radiofrequency ablation. Lai N, et al. **J Fam Pract** 1995 Nov;41(5):497–500 (19 ref.)
[Biophysical basis and cardiac lesions caused by different techniques of cardiac arrhythmia ablation] Lévy S. **Arch Mal Coeur Vaiss** 1995 Oct;88(10):1465–9 (28 ref.) (Eng. Abstr.) **(Fre)**
[Permanent junctional reciprocating tachycardia: a little-known clinical entity curable with radiofrequency ablation] Menafoglio A, et al. **Schweiz Med Wochenschr** 1995 Oct 21;125(42):1980–8 (43 ref.) (Eng. Abstr.) **(Fre)**
[Lausanne experience in radiofrequency percutaneous ablation of the slow pathway in nodal tachycardia] Menafoglio A, et al. **Schweiz Med Wochenschr** 1996 May 25;126(21):915–23 (45 ref.) (Eng. Abstr.) **(Fre)**
[Radiofrequency ablation in permanent ectopic left atrial tachycardia] Schmitt C, et al. **Dtsch Med Wochenschr** 1995 Nov 10;120(45):1538–42 (13 ref.) (Eng. Abstr.) **(Ger)**
[Treatment of supraventricular tachyarrhythmias: drugs or ablation?] Chimienti M, et al. **G Ital Cardiol** 1996 Feb; 26(2):213–26 (80 ref.) **(Ita)**
[Auricular flutter associated with an interatrial septal aneurysm submitted to radiofrequency ablation] Araya Gómez V, et al. **Arch Inst Cardiol Mex** 1995 May–Jun; 65(3):245–54 (17 ref.) (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Delayed effects of radiofrequency energy: mechanisms and clinical implications. Fenelon G, et al. **Pacing Clin Electrophysiol** 1996 Apr;19(4 Pt 1):484–9 (31 ref.)

INSTRUMENTATION

Advances in catheter ablation. Stafford PJ, et al. **Br J Hosp Med** 1996 Jan 17–Feb 6;55(1–2):44–6 (34 ref.)
[High frequency current catheter ablation in ventricular tachycardia] Haverkamp W, et al. **Z Kardiol** 1995;84 Suppl 2:83–102 (138 ref.) (Eng. Abstr.) **(Ger)**
[High frequency current catheter ablation in treatment of supraventricular and atrioventricular tachycardia] Hindricks G, et al. **Z Kardiol** 1995;84 Suppl 2:103–21 (88 ref.) (Eng. Abstr.) **(Ger)**

CATHETER ABLATION

METHODS

Surgical treatment of ventricular tachycardia. Indications and results. Pagé PL. **Arch Mal Coeur Vaiss** 1996 Feb;89 Spec No 1:115–21 (24 ref.)

Nonpharmacological therapy of atrial fibrillation. Klein GJ, et al. **Can J Cardiol** 1996 Jan;12 Suppl A:49A–50A (18 ref.)

Radiofrequency catheter ablation for AV nodal reentrant tachycardias (AVNRT). Shah DC, et al. **Indian Heart J** 1996 May–Jun;48(3):231–9 (37 ref.)

[Radiofrequency ablation of the atrioventricular accessory pathways. Value of unipolar and bipolar recordings] Aliot E, et al. **Arch Mal Coeur Vaiss** 1996 Feb;89 Spec No 1:89–97 (35 ref.) (Eng. Abstr.) **(Fre)**

[Atrial insertion of accessory pathways in permanent reciprocating junctional tachycardia] Elbaz M, et al. **Arch Mal Coeur Vaiss** 1995 Oct;88(10):1399–405 (39 ref.) (Eng. Abstr.) **(Fre)**

[Endocavitary ablation of nodal reentrant tachycardia] Jais P, et al. **Arch Mal Coeur Vaiss** 1996 Feb;89 Spec No 1:83–7 (32 ref.) (Eng. Abstr.) **(Fre)**

[Value of mapping in surgical treatment of ventricular tachycardia] Lacroix D, et al. **Arch Mal Coeur Vaiss** 1996 Feb;89 Spec No 1:109–13 (20 ref.) (Eng. Abstr.) **(Fre)**

[Radiofrequency ablation: physical bases and principles] Lavergne T, et al. **Arch Mal Coeur Vaiss** 1996 Feb;89 Spec No 1:57–63 (35 ref.) (Eng. Abstr.) **(Fre)**

[Survival after His bundle ablation for supraventricular arrhythmia. A 10-years experience in 317 consecutive patients] Poquet F, et al. **Arch Mal Coeur Vaiss** 1995 Nov; 88(11):1593–600 (31 ref.) (Eng. Abstr.) **(Fre)**

[Catheter ablation and modulation of the atrioventricular junction; current aspects] Robert F, et al. **Arch Mal Coeur Vaiss** 1996 Feb;89 Spec No 1:65–73 (50 ref.) (Eng. Abstr.) **(Fre)**

[Ablation of arrhythmia disorders: endocavitary catheter surgery. 2 decades of cardia electrophysiology] Fontaine G. **Bull Mem Acad R Med Belg** 1995;150(10–11):380–414 (33 ref.) **(Fre)**

[Biophysical basis and clinical use of catheter guided electric high frequency ablation in treatment of cardiac arrhythmias] Stanke A. **Pol Tyg Lek** 1995 Sep; 50(36–39):90–4 (35 ref.) **(Pol)**

STANDARDS

[Indications for electrophysiological studies and catheter ablation of cardiac arrhythmias. Recommendations of the Department of Arrhythmias and Clinical Electrophysiology of the Brazilian Society of Cardiology] Sosa EA, et al. **Arq Bras Cardiol** 1995 Feb;64(2):149–51 (1 ref.) **(Por)**

UTILIZATION

Endometrial ablation: indications and preliminary diagnostic hysteroscopy. Taylor PJ, et al. **Baillieres Clin Obstet Gynaecol** 1995 Jun;9(2):251–60 (18 ref.)

CATHETER ABLATION, ELECTRIC see **CATHETER ABLATION**

CATHETER ABLATION, PERCUTANEOUS see **CATHETER ABLATION**

CATHETER ABLATION, RADIOFREQUENCY see **CATHETER ABLATION**

CATHETER ABLATION, TRANSVENOUS see **CATHETER ABLATION**

CATHETERIZATION

see related
CATHETERS, INDWELLING

Assessing patient comfort: local infiltration of lidocaine during femoral sheath removal. Bowden SM, et al. **Am J Crit Care** 1995 Sep;4(5):368–9 (4 ref.)

Esophageal dilatation. Nostrant TT. **Dig Dis** 1995 Nov–Dec; 13(6):337–55 (93 ref.)

Interventional radiology and cross sectional imaging in venous access. Perry LJ, et al. **Surg Oncol Clin N Am** 1995 Jul;4(3):505–35 (82 ref.)

ADVERSE EFFECTS

Peritoneal access. Bhatla B, et al. **J Postgrad Med** 1994 Jul–Sep;40(3):170–8 (50 ref.)

INSTRUMENTATION

[Analysis of the efficacy of the large mono-canalicular intubation stent in the treatment of lacrimation caused by congenital obstruction of the lacrimal ducts in infants] Ruban JM, et al. **J Fr Ophtalmol** 1995;18(5):377–83 (11 ref.) (Eng. Abstr.) **(Fre)**

METHODS

Tubal cannulation. Valle RF. **Obstet Gynecol Clin North Am** 1995 Sep;22(3):519–40 (48 ref.)

CATHETERIZATION, BALLOON see **BALLOON DILATATION**

CATHETERIZATION, BRONCHIAL see **CATHETERIZATION, PERIPHERAL**

CATHETERIZATION, CARDIAC see **HEART CATHETERIZATION**

CATHETERIZATION, CENTRAL VENOUS

Central venous catheter infection with Rhodotorula minuta in a patient with AIDS taking suppressive doses of fluconazole. Goldani LZ, et al. **J Med Vet Mycol** 1995 Jul–Aug;33(4):267–70 (22 ref.)

Central venous catheters. An overview of Food and Drug Administration activities. Scott WL. **Surg Oncol Clin N Am** 1995 Jul;4(3):377–93 (41 ref.)

Lessons from vascular access procedures for hemodialysis. Shaffer D. **Surg Oncol Clin N Am** 1995 Jul;4(3):537–48 (70 ref.)

ADVERSE EFFECTS

Carotid–jugular arteriovenous fistula: a complication of temporary hemodialysis catheter. el-Shahawy MA, et al. **Am J Nephrol** 1995;15(4):332–6 (51 ref.)

Bacteriology, safety and prevention of infection associated with continuous intravenous infusions. Mermel LA. **Blood Coagul Fibrinolysis** 1996 Mar;7 Suppl 1:S45–51 (81 ref.)

Intravascular device-related infections in cancer patients. Raad II, et al. **Cancer Treat Res** 1995;79:211–31 (149 ref.)

Candida albicans septic thrombosis of the right atrium is associated with a central venous catheter. Kentos A, et al. **Clin Infect Dis** 1995 Aug;21(2):440–2 (18 ref.)

Complications associated with the use of central venous access devices. Whitman ED. **Curr Probl Surg** 1996 Apr; 33(4):309–78 (188 ref.)

Intravascular device-related infections in critically ill patients. Pittet D, et al. **J Chemother** 1995 Jul;7 Suppl 3:55–66 (91 ref.)

Catheter-associated fungemia due to Wangiella (Exophiala) dermatitidis. Nachman S, et al. **J Clin Microbiol** 1996 Apr; 34(4):1011–3 (10 ref.)

Pathogenesis of sepsis with central venous catheter use: alternate locus-related versus central venous catheter-related sepsis. Chathas MK, et al. **J Obstet Gynecol Neonatal Nurs** 1995 Oct;24(8):725–33 (27 ref.)

Migration of jugular or subclavian venous catheters into inferior tributaries of the brachiocephalic veins or into the azygos vein, with possible complications. Currarino G. **Pediatr Radiol** 1996 Jul;26(7):439–49 (52 ref.)

Rare complications of vascular access devices. Ingle RJ. **Semin Oncol Nurs** 1995 Aug;11(3):184–93 (79 ref.)

Management of infection and occlusion associated with vascular access devices. Rumsey KA, et al. **Semin Oncol Nurs** 1995 Aug;11(3):174–83 (59 ref.)

Catheter sepsis: the central venous line Achilles' heel. Wiener ES. **Semin Pediatr Surg** 1995 Nov;4(4):207–14 (56 ref.)

Central venous catheter related thrombosis. Lowell JA, et al. **Surg Oncol Clin N Am** 1995 Jul;4(3):479–92 (68 ref.)

[Infections related to central venous catheters] Nielsen J, et al. **Ugeskr Laeger** 1996 Feb 5;158(6):764–8 (40 ref.) (Eng. Abstr.) **(Dan)**

[Therapeutic attitude in postcatheterization symptomatic stenosis of the subclavian vein] Frikha I, et al. **Ann Cardiol Angeiol (Paris)** 1996 Mar;45(3):127–31 (39 ref.) (Eng. Abstr.) **(Fre)**

[Diaphragmatic paralysis after the catheterization of the internal jugular vein] Sánchez Castilla M, et al. **Nutr Hosp** 1995 Nov–Dec;10(6):377–8 (7 ref.) (Eng. Abstr.) **(Spa)**

INSTRUMENTATION

Central venous catheter-related infections: pathogenesis, predictors, and prevention. Hoppe B. **Heart Lung** 1995 Jul–Aug;24(4):333–9; quiz 339–41 (85 ref.)

The use of access devices in cancer pain control. Brant JM. **Semin Oncol Nurs** 1995 Aug;11(3):203–12 (44 ref.)

Comparison of vascular access devices. Hadaway LC. **Semin Oncol Nurs** 1995 Aug;11(3):154–66 (44 ref.)

A review of peripherally inserted central venous catheters in oncology patients. Cunningham RS, et al. **Surg Oncol Clin N Am** 1995 Jul;4(3):429–41 (27 ref.)

Central venous access catheters. Shapiro CL. **Surg Oncol Clin N Am** 1995 Jul;4(3):443–51 (22 ref.)

[Blood specimen collection from central venous catheters—reliable also for blood coagulation analysis?] Werner W, et al. **Z Arztl Fortbild (Jena)** 1995 Dec; 89(7):739–41 (6 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Difficult access problems. Gorman RC, et al. **Surg Oncol Clin N Am** 1995 Jul;4(3):453–72 (62 ref.)

NURSING

Patient education and compliance issues associated with access devices. McDermott MK. **Semin Oncol Nurs** 1995 Aug;11(3):221–6 (19 ref.)

CATHETERIZATION, HEART see **HEART CATHETERIZATION**

CATHETERIZATION, PERIPHERAL

The use of gauze versus transparent dressings for peripheral intravenous catheter sites. Pettit DM, et al. **Nurs Clin North Am** 1995 Sep;30(3):495–506 (15 ref.)

[Catheterization therapy of thromboembolic arterial occlusions of the lower extremities] Staněk F, et al. **Cas Lek Cesk** 1995 Aug 2;134(15):471–3 (28 ref.) (Eng. Abstr.) **(Cze)**

[French Society of Anesthesia and Intensive Care. Arterial catheterization and invasive measurement of blood pressure in anesthesia and intensive care in adults] **Ann Fr Anesth Reanim** 1995;14(5):444–53 (6611 ref.) (Eng. Abstr.) **(Fre)**

ADVERSE EFFECTS

Intravascular device-related infections in critically ill patients. Pittet D, et al. **J Chemother** 1995 Jul;7 Suppl 3:55–66 (91 ref.)

Rare complications of vascular access devices. Ingle RJ. **Semin Oncol Nurs** 1995 Aug;11(3):184–93 (79 ref.)

Management of infection and occlusion associated with vascular access devices. Rumsey KA, et al. **Semin Oncol Nurs** 1995 Aug;11(3):174–83 (59 ref.)

[Urokinase in a premature infant: its use in a case of right atrial thrombosis secondary to catheterization of the umbilical vein] Colnaghi C, et al. **Pediatr Med Chir** 1995 May–Jun;17(3):275–7 (10 ref.) (Eng. Abstr.) **(Ita)**

INSTRUMENTATION

The use of access devices in cancer pain control. Brant JM. **Semin Oncol Nurs** 1995 Aug;11(3):203–12 (44 ref.)

Comparison of vascular access devices. Hadaway LC. **Semin Oncol Nurs** 1995 Aug;11(3):154–66 (44 ref.)

Selection of vascular access devices and nursing care. Winslow MN, et al. **Semin Oncol Nurs** 1995 Aug; 11(3):167–73 (37 ref.)

Peripheral access options. Ryder MA. **Surg Oncol Clin N Am** 1995 Jul;4(3):395–427 (181 ref.)

NURSING

Patient education and compliance issues associated with access devices. McDermott MK. **Semin Oncol Nurs** 1995 Aug;11(3):221–6 (19 ref.)

Selection of vascular access devices and nursing care. Winslow MN, et al. **Semin Oncol Nurs** 1995 Aug; 11(3):167–73 (37 ref.)

CATHETERIZATION, PERIPHERAL ARTERIAL see **CATHETERIZATION, PERIPHERAL**

CATHETERIZATION, PERIPHERAL VENOUS see **CATHETERIZATION, PERIPHERAL**

CATHETERIZATION, PULMONARY ARTERY see **CATHETERIZATION, SWAN-GANZ**

CATHETERIZATION, SWAN-GANZ

see related
PULMONARY WEDGE PRESSURE

ADVERSE EFFECTS

Swan–Ganz catheter induced pulmonary artery perforation during cardiac surgery concerning two cases. Sekkal S, et al. **J Cardiovasc Surg (Torino)** 1996 Jun;37(3):313–7 (33 ref.)

Complications of Swan–Ganz catheterization for hemodynamic monitoring in patients with subarachnoid hemorrhage. Rosenwasser RH, et al. **Neurosurgery** 1995 Nov;37(5):872–5; discussion 875–6 (21 ref.)

CATHETERIZATION, URETERAL see **URINARY CATHETERIZATION**

CATHETERIZATION, URETHRAL see **URINARY CATHETERIZATION**

CATHETERIZATION, URINARY see **URINARY CATHETERIZATION**

CATHETERS, INDWELLING

see related
INFUSION PUMPS, IMPLANTABLE

Pathogenesis and prevention of catheter-related septicemia. Sitges-Serra A, et al. **Am J Infect Control** 1995 Oct; 23(5):310–6 (45 ref.)

Central venous catheter-related infections: pathogenesis, predictors, and prevention. Hoppe B. **Heart Lung** 1995 Jul–Aug;24(4):333–9; quiz 339–41 (85 ref.)

Peritoneal dialysis catheter complications. Bernardini J. **Perit Dial Int** 1996;16 Suppl 1:S486–71 (42 ref.)

Significance, epidemiology, and prevention of peritoneal dialysis catheter infections. Burkart JM. **Perit Dial Int** 1996;

16 Suppl 1:S340-6 (38 ref.)
Peritoneoscopic placement of Swan neck peritoneal dialysis catheters. Copley JB, et al. **Perit Dial Int** 1996;16 Suppl 1:S330-2 (18 ref.)
Implantation techniques for peritoneal dialysis catheters. Cruz C. **Perit Dial Int** 1996;16 Suppl 1:S319-21 (14 ref.)
The peritoneal access. Lee HB, et al. **Perit Dial Int** 1996;16 Suppl 1:S322-6 (24 ref.)
Exit-site care. Piraino B. **Perit Dial Int** 1996;16 Suppl 1:S336-9 (28 ref.)
Arterial, peritoneal, and intraventricular access devices. Almadrones L, et al. **Semin Oncol Nurs** 1995 Aug; 11(3):194-202 (23 ref.)
The use of access devices in cancer pain control. Brant JM. **Semin Oncol Nurs** 1995 Aug;11(3):203-12 (44 ref.)
Comparison of vascular access devices. Hadaway LC. **Semin Oncol Nurs** 1995 Aug;11(3):154-66 (44 ref.)
Selection of vascular access devices and nursing care. Winslow MN, et al. **Semin Oncol Nurs** 1995 Aug; 11(3):167-73 (37 ref.)
A review of peripherally inserted central venous catheters in oncology patients. Cunningham RS, et al. **Surg Oncol Clin N Am** 1995 Jul;4(3):429-41 (27 ref.)
Venous access device options. Labow CA. **Surg Oncol Clin N Am** 1995 Jul;4(3):473-8 (11 ref.)
Interventional radiology and cross sectional imaging in venous access. Perry LJ, et al. **Surg Oncol Clin N Am** 1995 Jul;4(3):505-35 (82 ref.)
Peripheral access options. Ryder MA. **Surg Oncol Clin N Am** 1995 Jul;4(3):395-427 (181 ref.)
Central venous catheters. An overview of Food and Drug Administration activities. Scott WL. **Surg Oncol Clin N Am** 1995 Jul;4(3):377-93 (41 ref.)
Lessons from vascular access procedures for hemodialysis. Shaffer D. **Surg Oncol Clin N Am** 1995 Jul;4(3):537-48 (70 ref.)
Central venous access catheters. Shapiro CL. **Surg Oncol Clin N Am** 1995 Jul;4(3):443-51 (22 ref.)
The autoperfusion balloon catheter with special attention to its use as a bail-out device. Bonnier JJ. **Z Kardiol** 1995; 84 Suppl 2:79-82 (17 ref.)
[Pulmonary artery catheter. Theory and practice] Versprille A. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May;31(1 Suppl):S9-16 (22 ref.) **(Ger)**
[Current strategies in patients with urinary diversion, 2: Upper urinary tract] Moll F. **Z Arztl Fortbild (Jena)** 1996 May;90(3):241-8 (22 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Management of catheter-related infections. Piraino B. **Am J Kidney Dis** 1996 May;27(5):754-8 (33 ref.)
Infections complicating tunneled intraspinal catheter systems used to treat chronic pain. Byers K, et al. **Clin Infect Dis** 1995 Aug;21(2):403-8 (30 ref.)
Complications associated with the use of central venous access devices. Whitman ED. **Curr Probl Surg** 1996 Apr; 33(4):309-78 (188 ref.)
Rare complications of vascular access devices. Ingle RJ. **Semin Oncol Nurs** 1995 Aug;11(3):184-93 (79 ref.)
Management of infection and occlusion associated with vascular access devices. Rumsey KA, et al. **Semin Oncol Nurs** 1995 Aug;11(3):174-83 (59 ref.)
Vascular catheter related infections in cancer patients. Farr BM. **Surg Oncol Clin N Am** 1995 Jul;4(3):493-503 (83 ref.)
[Fibrinolysis of deep venous thrombosis on implantable perfusion devices. Apropos of a consecutive series of 57 cases of thrombosis and 32 cases of fibrinolysis] Pucheu A, et al. **Bull Cancer (Paris)** 1996 Apr;83(4):293-9 (33 ref.) (Eng. Abstr.) **(Fre)**

ECONOMICS

Percutaneous nephrostomy using hospital modified catheters for cost containment. Ahmed I, et al. **East Afr Med J** 1995 Jun;72(6):391-3 (17 ref.)

SUPPLY & DISTRIBUTION

Percutaneous nephrostomy using hospital modified catheters for cost containment. Ahmed I, et al. **East Afr Med J** 1995 Jun;72(6):391-3 (17 ref.)

CATHODE see **ELECTRODES**

CATHODE RAY TUBE DISPLAY see **DATA DISPLAY**

CATHOLICISM

The Good Samaritan and the "Good Death": Catholic reflections on euthanasia. Doerflinger RM. **Issues Law Med** 1995 Fall;11(2):149-58 (31 ref.)

CATION EXCHANGE RESINS

ADVERSE EFFECTS

Cecal perforation associated with sodium polystyrene sulfonate-sorbitol enemas in a 650 gram infant with hyperkalemia. Bennett LN, et al. **Am J Perinatol** 1996 Apr; 13(3):167-70 (12 ref.)

CATION EXCHANGERS see **CATION EXCHANGE RESINS**

CATION PUMPS see **ION PUMPS**

CATIONS

Regulation of nitric oxide synthase: role of oxygen radicals and cations in nitric oxide formation. Mittal CK, et al. **Adv Pharmacol** 1995;34:235-50 (50 ref.)

CHEMISTRY

Fragmentation reactions of aromatic cation radicals: a tool for the detection of electron transfer mechanisms in biomimetic and enzymatic oxidations. Baciocchi E. **Xenobiotica** 1995 Jul;25(7):653-66 (37 ref.)

METABOLISM

Cation and sugar selectivity determinants in a novel family of transport proteins. Poolman B, et al. **Mol Microbiol** 1996 Mar;19(5):911-22 (63 ref.)
Cation-pi interactions in chemistry and biology: a new view of benzene, Phe, Tyr, and Trp. Dougherty DA. **Science** 1996 Jan 12;271(5246):163-8 (66 ref.)
Central role of radical cations in metabolic activation of polycyclic aromatic hydrocarbons. Cavalieri EL, et al. **Xenobiotica** 1995 Jul;25(7):677-88 (49 ref.)
Aminium cation radical mechanism proposed for monoamine oxidase B catalysis: are there alternatives? Edmondson DE. **Xenobiotica** 1995 Jul;25(7):735-53 (53 ref.)
Radical cation intermediates in N-dealkylation reactions. Guengerich FP, et al. **Xenobiotica** 1995 Jul;25(7):689-709 (138 ref.)

PHARMACOLOGY

Ionic control of sperm function. Fraser LR. **Reprod Fertil Dev** 1995;7(4):905-25 (169 ref.)

CATS

Septic shock due to Pasteurella multocida subspecies multocida in a previously healthy woman [letter] Ruiz-Irastorza G, et al. **Clin Infect Dis** 1995 Jul;21(1):232-4 (13 ref.)
Cat allergy. Ferguson BJ. **Ear Nose Throat J** 1995 Oct; 74(10):677, 680 (9 ref.)
Dog, cat, and human bites: a review. Griego RD, et al. **J Am Acad Dermatol** 1995 Dec;33(6):1019-29 (115 ref.)
Animal shelter issues. Luke C. **J Am Vet Med Assoc** 1996 Feb 15;208(4):524-7 (1 ref.)
Feral cats in the United Kingdom. Remfry J. **J Am Vet Med Assoc** 1996 Feb 15;208(4):520-3 (10 ref.)
Cats and their people: a (nearly) perfect relationship. Zasloff RL. **J Am Vet Med Assoc** 1996 Feb 15;208(4):512-6 (29 ref.)
[A case of Pasteurella multocida subsp. multocida septicemia due to cat bites in liver cirrhosis patient] Shimizu T, et al. **Kansenshogaku Zasshi** 1995 Nov;69(11):1302-6 (11 ref.) (Eng. Abstr.) **(Jpn)**

ANATOMY & HISTOLOGY

Applied anatomy and physiology of the feline lower urinary tract. Fletcher TF. **Vet Clin North Am Small Anim Pract** 1996 Mar; 26(2):181-96 (40 ref.)

BLOOD

Modern veterinary blood banking practices and their applications in companion animal practice. Feldman BF, et al. **Vet Clin North Am Small Anim Pract** 1995 Nov; 25(6):1231-43 (14 ref.)
Feline transfusion medicine. Blood types and their clinical importance. Griot-Wenk ME, et al. **Vet Clin North Am Small Anim Pract** 1995 Nov; 25(6):1305-22 (35 ref.)
Blood components. Collection, processing, and storage. Schneider A. **Vet Clin North Am Small Anim Pract** 1995 Nov;25(6):1245-61 (24 ref.)
Selection of anticoagulant-preservatives for canine and feline blood storage. Wardrop KJ. **Vet Clin North Am Small Anim Pract** 1995 Nov; 25(6):1263-76 (50 ref.)

METABOLISM

Monoamine oxidase: distribution in the cat brain studied by enzyme- and immunohistochemistry: recent progress. Kitahama K, et al. **Prog Neurobiol** 1994 Jan;42(1):53-78 (189 ref.)

MICROBIOLOGY

Exposure to domestic cats: risk factor for Pasteurella multocida peritonitis in liver cirrhosis? Koch CA, et al. **Am J Gastroenterol** 1996 Jul;91(7):1447-9 (29 ref.)

PHYSIOLOGY

Feline behavior and welfare. Landsberg G. **J Am Vet Med Assoc** 1996 Feb 15;208(4):502-5 (9 ref.)
The domestic cat: perspective on the nature and diversity of cats. Miller J. **J Am Vet Med Assoc** 1996 Feb 15; 208(4):498-502 (4 ref.)
Healing responses of the lower urinary tract. Degner DA, et al. **Vet Clin North Am Small Anim Pract** 1996 Mar; 26(2):197-206 (41 ref.)
Applied anatomy and physiology of the feline lower urinary tract. Fletcher TF. **Vet Clin North Am Small Anim Pract** 1996 Mar; 26(2):181-96 (40 ref.)
Grooming. McDonough S. **Vet Clin North Am Small Anim Pract** 1995 Jul;25(4):767-78 (9 ref.)

SURGERY

Surgical neutering and nonsurgical alternatives. Bloomberg MS. **J Am Vet Med Assoc** 1996 Feb 15;208(4):517-9 (21 ref.)

URINE

Measurement of the influence of diet on feline urinary pH. Allen TA. **Vet Clin North Am Small Anim Pract** 1996 Mar; 26(2):363-8 (6 ref.)
Feline crystalluria. Detection and interpretation. Osborne CA, et al. **Vet Clin North Am Small Anim Pract** 1996 Mar; 26(2):369-91 (3 ref.)

VIROLOGY

Coadaptation and immunodeficiency virus: lessons from the Felidae. Carpenter MA, et al. **Curr Opin Genet Dev** 1995 Dec;5(6):739-45 (53 ref.)

CATTLE

The history of IRM and SPA. Corah LR. **Vet Clin North Am Food Anim Pract** 1995 Jul;11(2):191-8 (8 ref.)
Measuring financial performance: an overview of financial statements. Dalsted NL. **Vet Clin North Am Food Anim Pract** 1995 Jul;11(2):293-311 (2 ref.)
SPA: marketing and financial performance measures for the cow-calf enterprise. Gutierrez PH. **Vet Clin North Am Food Anim Pract** 1995 Jul;11(2):313-60 (3 ref.)
Standardized performance analysis. Hamilton ED. **Vet Clin North Am Food Anim Pract** 1995 Jul;11(2):199-213 (2 ref.)
NCA-IRM desk record. Kniffen D. **Vet Clin North Am Food Anim Pract** 1995 Jul;11(2):215-78 (0 ref.)
Farm Financial Standards. McGrann JM. **Vet Clin North Am Food Anim Pract** 1995 Jul;11(2):279-91 (3 ref.)
Stocker/feeder cattle standardized performance analysis. McGrann JM, et al. **Vet Clin North Am Food Anim Pract** 1995 Jul;11(2):361-73 (3 ref.)
Seedstock beef cattle: SPA. McGrann JM, et al. **Vet Clin North Am Food Anim Pract** 1995 Jul;11(2):375-88 (2 ref.)
A review of post transport mortality among younger calves. Knowles TG. **Vet Rec** 1995 Oct 14;137(16):406-7 (17 ref.)

BLOOD

The response of various hematologic parameters in the young bovine subjected to multiple phlebotomies. Harper SB, et al. **ASAIO J** 1994 Jul-Sep;40(3):M816-25 (128 ref.)

EMBRYOLOGY

Fetal bovine bladder: physiology and pharmacology. Koo HP, et al. **Adv Exp Med Biol** 1995;385:251-3 (16 ref.)
Strategies for the isolation and characterization of bovine embryonic stem cells. Cherny RA, et al. **Reprod Fertil Dev** 1994;6(5):569-75 (30 ref.)
Systems for production of calves from cultured bovine embryonic cells. First NL, et al. **Reprod Fertil Dev** 1994; 6(5):553-62 (35 ref.)

GENETICS

Bovine genome mapping: evolutionary inference and the power of comparative genomics. Womack JE, et al. **Curr Opin Genet Dev** 1995 Dec;5(6):725-33 (35 ref.)
Testing for undesirable traits in cattle: an Australian perspective. Healy PJ. **J Anim Sci** 1996 Apr;74(4):917-22 (32 ref.)
Challenges and progress in the production of transgenic cattle. Eyestone WH. **Reprod Fertil Dev** 1994;6(5):647-52 (37 ref.)

GROWTH & DEVELOPMENT

Desirable characteristics of forage legumes for improving protein utilization in ruminants. Broderick GA. **J Anim Sci** 1995 Sep;73(9):2760-73 (60 ref.)
Feeding behavior and management factors during the transition period in dairy cattle. Grant RJ, et al. **J Anim Sci** 1995 Sep;73(9):2791-803 (86 ref.)
Review of some aspects of growth and development of feedlot cattle. Owens FN, et al. **J Anim Sci** 1995 Oct; 73(10):3152-72 (112 ref.)

INJURIES

Treatment of fractures of the tibia and radius-ulna by external coaptation. Adams SB, et al.

CATTLE

Vet Clin North Am Food Anim Pract 1996 Mar;12(1):181–98 (15 ref.)
Stifle injuries in cattle. Ducharme NG.
Vet Clin North Am Food Anim Pract 1996 Mar;12(1):59–84 (42 ref.)
Fractures and luxations of the pelvis and proximal femur. Hull BL. **Vet Clin North Am Food Anim Pract** 1996 Mar; 12(1):47–58 (25 ref.)
Fractures of the femur. Trostle SS, et al.
Vet Clin North Am Food Anim Pract 1996 Mar;12(1):169–80 (16 ref.)
Metacarpal and metatarsal fractures in cattle. Tulleners EP.
Vet Clin North Am Food Anim Pract 1996 Mar; 12(1):199–209 (13 ref.)

METABOLISM

Regulation of organic nutrient metabolism during transition from late pregnancy to early lactation. Bell AW.
J Anim Sci 1995 Sep;73(9):2804–19 (117 ref.)
Impact of changes in organic nutrient metabolism on feeding the transition dairy cow. Grummer RR. **J Anim Sci** 1995 Sep;73(9):2820–33 (81 ref.)
A review of dietary vitamin E supplementation for improvement of beef quality. Liu Q, et al. **J Anim Sci** 1995 Oct;73(10):3131–40 (81 ref.)
Prediction of ruminal volatile fatty acids and pH within the net carbohydrate and protein system. Pitt RE, et al.
J Anim Sci 1996 Jan;74(1):226–44 (126 ref.)

PARASITOLOGY

Recent acquisitions on tick and tick-borne disease resistance in N'dama (Bos taurus) and Gobra zebu (Bos indicus) cattle. Mattioli RC, et al. **Parassitologia** 1995 Apr;37(1):63–7 (40 ref.)

PHYSIOLOGY

The effects of lactation on the fertility of dairy cows. Macmillan KL, et al. **Aust Vet J** 1996 Apr;73(4):141–7 (56 ref.)
Synchronization of ovarian follicular waves with a gonadotropin-releasing hormone agonist to increase the precision of estrus in cattle: a review. Twagiramungu H, et al. **J Anim Sci** 1995 Oct;73(10):3141–51 (87 ref.)
Quantitative aspects of blood and amino acid flows in cattle. Lescoat P, et al. **Reprod Nutr Dev** 1996;36(2):137–74 (158 ref.)
[Reproductive medicine in transition: new developments in embryo transfer] Binder H, et al.
Schweiz Arch Tierheilkd 1996;138(5):245–50 (18 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Diagnosis and management of tendon disorders in cattle. Anderson DE, et al.
Vet Clin North Am Food Anim Pract 1996 Mar;12(1):85–116 (111 ref.)
Amputation and prosthesis. St. Jean G.
Vet Clin North Am Food Anim Pract 1996 Mar;12(1):249–61 (13 ref.)

CATTLE DISEASES

Strategies to interrupt the development of Anaplasma marginale in its tick vector. The effect of bovine-derived antibodies. Kocan KM, et al. **Ann N Y Acad Sci** 1996 Jul 23;791:157–65 (57 ref.)
Bovine fat necrosis (Lipomatosis): an overview. el-Sebaie A, et al. **Berl Munch Tierarztl Wochenschr** 1995 Nov; 108(11):427–30 (49 ref.)
Costs of major parasites to the Australian livestock industries. McLeod RS. **Int J Parasitol** 1995 Nov;25(11):1363–7 (25 ref.)
Australian-Indonesian collaboration in veterinary arbovirology—a review. Daniels PW, et al.
Vet Microbiol 1995 Sep;46(1–3):151–74 (108 ref.)
Recent advances in the understanding of Jembrana disease. Wilcox GE, et al. **Vet Microbiol** 1995 Sep;46(1–3):249–55 (23 ref.)
[Right displacement of the abomasum in cattle. 1. Pathogenesis, clinical course and prognosis] Kümper H. **Tierarztl Prax** 1995 Aug;23(4):351–9 (30 ref.) (Eng. Abstr.) **(Ger)**

CHEMICALLY INDUCED

Toxicology of oil field pollutants in cattle: a review. Coppock RW, et al. **Vet Hum Toxicol** 1995 Dec;37(6):569–76 (59 ref.)
A review of nonpesticide phosphate ester-induced neurotoxicity in cattle. Coppock RW, et al.
Vet Hum Toxicol 1995 Dec;37(6):576–9 (20 ref.)

DIAGNOSIS

Testing for undesirable traits in cattle: an Australian perspective. Healy PJ. **J Anim Sci** 1996 Apr;74(4):917–22 (32 ref.)
Uses of serology for the diagnosis of contagious bovine pleuropneumonia. Rurangirwa FR. **Rev Sci Tech** 1995 Sep; 14(3):603–9 (30 ref.)
Diagnosis and management of tendon disorders in cattle. Anderson DE, et al.
Vet Clin North Am Food Anim Pract 1996 Mar;12(1):85–116 (111 ref.)
Clinical applications of radiography and ancillary imaging. O'Brien RT, et al.
Vet Clin North Am Food Anim Pract 1996 Mar;12(1):263–75 (7 ref.)
[Complement fixation reaction for the serologic diagnosis of bovine contagious pleuropneumonia: application and interpretation of the results] Regalia J. **Rev Sci Tech** 1995 Sep;14(3):631–44 (11 ref.) (Eng. Abstr.) **(Fre)**

EPIDEMIOLOGY

Recent acquisitions on tick and tick-borne disease resistance in N'dama (Bos taurus) and Gobra zebu (Bos indicus) cattle. Mattioli RC, et al. **Parassitologia** 1995 Apr;37(1):63–7 (40 ref.)
Overview and epidemiology of contagious bovine pleuropneumonia in Africa. Masiga WN, et al.
Rev Sci Tech 1995 Sep;14(3):611–30 (26 ref.)

ETIOLOGY

Lameness, lesions of the claw of the dairy cow and subclinical laminitis [editorial; comment] Logue D. **Br Vet J** 1995 Jul-Aug;151(4):343–6 (16 ref.) Comment on: Br Vet J 1995 Jul-Aug;151(4):391–9.
Abomasal displacement in the bovine—a review on character, occurrence, aetiology and pathogenesis. Geishauser T. **Zentralbl Veterinarmed A** 1995 Jun; 42(4):229–51 (253 ref.)

GENETICS

Testing for undesirable traits in cattle: an Australian perspective. Healy PJ. **J Anim Sci** 1996 Apr;74(4):917–22 (32 ref.)

IMMUNOLOGY

Effect of chemoprophylaxis on immunity to gastrointestinal nematodes in cattle. Vercruysse J, et al.
Verh K Acad Geneeskd Belg 1996;58(1):51–60 (18 ref.)

MICROBIOLOGY

Mycoplasma mycoides subspecies mycoides (small colony variant): the agent of contagious bovine pleuropneumonia and member of the "Mycoplasma mycoides cluster". Nicholas RA, et al. **J Comp Pathol** 1995 Jul;113(1):1–27 (122 ref.)
Fusobacterium necrophorum infections: virulence factors, pathogenic mechanism and control measures. Tan ZL, et al. **Vet Res Commun** 1996;20(2):113–40 (156 ref.)

PARASITOLOGY

Development of a vaccine strategy against human and bovine schistosomiasis. Background and update. Capron A, et al. **Mem Inst Oswaldo Cruz** 1995 Mar-Apr;90(2):235–40 (29 ref.)

PREVENTION & CONTROL

DNA immunization with bovine herpesvirus-1 genes. Babiuk LA, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:47–63 (56 ref.)
Group A rotavirus veterinary vaccines. Saif LJ, et al.
J Infect Dis 1996 Sep;174 Suppl 1:S98–106 (81 ref.)
Contagious bovine pleuropneumonia vaccines: the need for improvements. Rweyemamu MM, et al. **Rev Sci Tech** 1995 Sep;14(3):593–601 (14 ref.)
[Vaccination strategies for contagious bovine pleuropneumonia in Africa] Sylla D, et al.
Rev Sci Tech 1995 Sep;14(3):577–92 (8 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Surgical management of digit disorders in cattle. Desrochers A, et al. **Vet Clin North Am Food Anim Pract** 1996 Mar; 12(1):277–98 (45 ref.)
Arthroscopy in food animal practice. Gaughan EM.
Vet Clin North Am Food Anim Pract 1996 Mar;12(1):233–47 (11 ref.)
[Inguinal and scrotal hernias in steers] Brouwers EA, et al. **Tijdschr Diergeneeskd** 1996 Jan 1;121(1):2–5 (20 ref.) (Eng. Abstr.) **(Dut)**

THERAPY

Diagnosis and management of tendon disorders in cattle. Anderson DE, et al.
Vet Clin North Am Food Anim Pract 1996 Mar;12(1):85–116 (111 ref.)

CATTLE LEUKEMIA VIRUS see **LEUKEMIA VIRUS, BOVINE**

CATTLE PLAGUE see **RINDERPEST**

CATU VIRUS see **BUNYAVIRUS**

CAUCASOID RACE

see related
WHITES

Racial disparities in preterm births. The role of urogenital infections [see comments] Fiscella K. **Public Health Rep** 1996 Mar-Apr;111(2):104–13 (15 ref.) Comment in: Public Health Rep 1996 Mar-Apr;111(2):114–5.

GENETICS

HLA-B27 and its subtypes in world populations [editorial] Khan MA. **Curr Opin Rheumatol** 1995 Jul;7(4):263–9 (94 ref.)

CAUDA EQUINA

Paraganglioma of the cauda equina. A case report and review of the literature. Bak J, et al. **APMIS** 1996 Mar; 104(3):234–40 (29 ref.)
Complications of spinal manipulation: a comprehensive review of the literature. Assendelft WJ, et al.
J Fam Pract 1996 May;42(5):475–80 (41 ref.)
Cauda equina compression by epidural lipomatosis in obesity. Effectiveness of weight reduction. Pouchot J, et al.
J Rheumatol 1995 Sep;22(9):1771–5 (20 ref.)
Intradural metastasis to the cauda equina from carcinoma of the anus. Cho DY, et al. **Spine** 1995 Nov 1;20(21):2341–4 (15 ref.)

ABNORMALITIES

[Prenatal diagnosis of three caudal regression syndromes associated with maternal diabetes] Houfflin V, et al.
J Gynecol Obstet Biol Reprod (Paris) 1996;25(4):389–95 (40 ref.) (Eng. Abstr.) **(Fre)**

CAUDATA see **URODELA**

CAUDATE NUCLEUS

ANATOMY & HISTOLOGY

Normal caudate nucleus in obsessive-compulsive disorder assessed by quantitative neuroimaging. Aylward EH, et al.
Arch Gen Psychiatry 1996 Jul;53(7):577–84 (48 ref.)

CAULOBACTER

PHYSIOLOGY

Regulation of asymmetry and polarity during the Caulobacter cell cycle. Jenal U, et al.
Adv Enzymol Relat Areas Mol Biol 1995;71:1–39 (156 ref.)

CAUSALGIA

[Causalgia in the light of new findings] Magdić B, et al.
Vojnosanit Pregl 1995 Sep-Oct;52(5):489–94 (36 ref.) **(Scr)**

CLASSIFICATION

Reflex sympathetic dystrophy: changing concepts and taxonomy. Stanton-Hicks M, et al. **Pain** 1995 Oct; 63(1):127–33 (38 ref.)

CAUSALITY

Causal thinking, biomarkers, and mechanisms of carcinogenesis. Vineis P, et al. **J Clin Epidemiol** 1996 Sep; 49(9):951–6 (44 ref.)
Assigning causation in disease: beyond Koch's postulates. Sutter MC. **Perspect Biol Med** 1996 Summer;39(4):581–92 (24 ref.)
A reader's guide to the evaluation of causation. Podrebarac T, et al. **Postgrad Med J** 1996 Mar;72(845):131–6 (19 ref.)
Definitions of attributable risk—revisited. Gefeller O.
Public Health Rev 1995;23(4):343–55 (47 ref.)

CAUSATION see **CAUSALITY**

CAUSE OF DEATH

Accidents involving older people: a review of the literature. Lilley JM, et al. **Age Ageing** 1995 Jul;24(4):346–65 (153 ref.)
Fatal asthma. FitzGerald JM, et al. **Annu Rev Med** 1996; 47:161–8 (32 ref.)
On the need for more expertise in death investigation (and a National Office of Death Investigation Affairs?) [editorial] Hanzlick R. **Arch Pathol Lab Med** 1996 Apr; 120(4):329–32 (26 ref.)
Study on electrocution death by low-voltage. Zhang P, et al. **Forensic Sci Int** 1995 Dec 18;76(2):115–9 (4 ref.)
Physical fitness, mortality and obesity. Barlow CE, et al.
Int J Obes Relat Metab Disord 1995 Oct;19 Suppl 4:S41–4 (14 ref.)
Causes of death in autosomal dominant polycystic kidney disease. Fick GM, et al. **J Am Soc Nephrol** 1995 Jun; 5(12):2048–56 (81 ref.)
'Inaccuracy' in death certification—where are we now? Maudsley G, et al. **J Public Health Med** 1996 Mar; 18(1):59–66 (88 ref.)
Death registration and cause-of-death statements. Hanzlick R. **Leg Med** 1995;:117–45 (50 ref.)
A review of diagnostic inaccuracy. Kingsford DP.
Med Sci Law 1995 Oct;35(4):347–51 (31 ref.)

CAUSTICS

ADVERSE EFFECTS

Corrosive ingestions. Lovejoy FH Jr, et al. **Pediatr Rev** 1995 Dec;16(12):473–4 (7 ref.)

CAUTERY

see related
ELECTROCOAGULATION

CAVERNITIS, FIBROUS see **PENILE INDURATION**

CAVERNOUS SINUS

Uncommon complications of odontogenic infections. Ferrera PC, et al. **Am J Emerg Med** 1996 May;14(3):317–22 (49 ref.)

ABNORMALITIES

Carotid–cavernous sinus fistula and aneurysmal rupture associated with fibromuscular dysplasia. A case report. Hirai T, et al. **Acta Radiol** 1996 Jan;37(1):49–51 (8 ref.)
Dural arteriovenous fistulas of superior sagittal sinus: case report and review of literature. Kurl S, et al. **Surg Neurol** 1996 Mar;45(3):250–5 (23 ref.)
[Paradoxical aggravation of carotid cavernous fistula] Muraine M, et al. **J Fr Ophtalmol** 1996;19(1):51–4 (12 ref.) (Eng. Abstr.) **(Fre)**

INJURIES

Traumatic bilateral carotid–cavernous fistulas treated with detachable balloon. A case report. Kim JK, et al. **Acta Radiol** 1996 Jan;37(1):46–8 (6 ref.)
Endovascular surgical approach to intracranial vascular diseases. Higashida RT, et al. **J Endovasc Surg** 1996 May; 3(2):146–57 (57 ref.)

RADIOGRAPHY

Angiographic workup of a carotid cavernous sinus fistula (CCF) or what information does the interventionalist need for treatment? [see comments] Debrun GM. **Surg Neurol** 1995 Jul;44(1):75–9 (18 ref.) Comment in: Surg Neurol 1996 Aug;46(2):193.

SURGERY

The cavernous carotid artery: preservation is the best means of reconstruction. Bowles AP Jr, et al. **Clin Neurosurg** 1995; 42:154–70 (41 ref.)
Techniques of carotid reconstruction. Fukushima T. **Clin Neurosurg** 1995;42:119–34 (24 ref.)
Primary cavernous sinus malignant lymphoma treated by gamma knife radiosurgery: case report and review of the literature. Nakatomi H, et al. **Surg Neurol** 1996 Sep; 46(3):272–8; discussion 278–9 (15 ref.)
[Surgical techniques for aneurysms in and around the cavernous sinus] Ohnishi H. **No Shinkei Geka** 1995 Nov; 23(11):955–62 (12 ref.) **(Jpn)**

CAVH see **HEMOFILTRATION**

CAVUS DEFORMITY see **FOOT DEFORMITIES**

CCK RECEPTORS see **RECEPTORS, CHOLECYSTOKININ**

CCK-8 see **SINCALIDE**

CD-ROM

ABC of medical computing. CD ROMS, multimedia, and optical storage systems. Millman A, et al. **BMJ** 1995 Sep 9;311(7006):675–8 (0 ref.)

CD1 ANTIGENS see **ANTIGENS, CD1**

CD2 ANTIGENS see **ANTIGENS, CD2**

CD3 ANTIGENS see **ANTIGENS, CD3**

CD3 COMPLEX see **ANTIGENS, CD3**

CD4 ANTIGENS see **ANTIGENS, CD4**

CD4 LYMPHOCYTE COUNT

Protracted cutaneous disorders in association with low CD4+ lymphocyte counts. Kurwa HA, et al. **Br J Dermatol** 1995 Oct;133(4):625–9 (19 ref.)
Rethinking CD4+ T cell counts for individuals who recently seroconverted to human immunodeficiency virus. Weiss PJ, et al. **Clin Infect Dis** 1995 Sep;21(3):666–8 (17 ref.)

CD4 MOLECULE see **ANTIGENS, CD4**

CD4-POSITIVE T-LYMPHOCYTES

see related
ACQUIRED IMMUNODEFICIENCY SYNDROME
ANTIGENS, CD4

T-LYMPHOCYTOPENIA, IDIOPATHIC CD4-POSITIVE

Differentiation and tolerance of CD4+ T lymphocytes. Abbas AK, et al. **Ciba Found Symp** 1995;195:7–13; discussion 13–9 (36 ref.)

CYTOLOGY

Differentiation of subsets of CD4+ and CD8+ T cells. Mosmann TR, et al. **Ciba Found Symp** 1995;195:42–50; discussion 50–4 (49 ref.)
Regulation of CD4+ T cell differentiation. Nakamura T, et al. **Ciba Found Symp** 1995;195:154–68; discussion 168–72 (39 ref.)
The molecular jury: deciding whether immature thymocytes should live or die [comment] Vukmanović S. **J Exp Med** 1996 Aug 1;184(2):305–9 (60 ref.) Comment on: J Exp Med 1996 Aug 1;184(2):531–7.

DRUG EFFECTS

Lymphoid cell resistance to glucocorticoids in HIV infection. Kawa SK, et al. **J Steroid Biochem Mol Biol** 1996 Mar; 57(5–6):259–63 (68 ref.)
Cyclosporine-induced apoptosis in CD4+ T lymphocytes and computer-simulated analysis: modeling a treatment scenario for HIV infection. Huss R, et al. **Res Immunol** 1995 Feb;146(2):101–8 (32 ref.)

IMMUNOLOGY

From cell activation to cell depletion. The programmed cell death hypothesis of AIDS pathogenesis. Ameisen JC. **Adv Exp Med Biol** 1995;374:139–63 (159 ref.)
The role of surface CD4 in HIV-induced apoptosis. Corbeil J, et al. **Adv Exp Med Biol** 1995;374:91–9 (59 ref.)
CD4+ and CD8+ T lymphocyte activation in HIV infection. Implications for immune pathogenesis and therapy. Laurence J. **Adv Exp Med Biol** 1995;374:1–15 (74 ref.)
Positive selection of thymocytes. Fink PJ, et al. **Adv Immunol** 1995;59:99–133 (144 ref.)
Cytokines, differentiation and functions of subsets of CD4 and CD8 T cells. Mosmann TR. **Behring Inst Mitt** 1995 Jun;(96):1–6 (34 ref.)
Autoimmune mechanisms of depletion of CD4 cells in HIV infection. Dalgleish AG. **Br J Haematol** 1995 Nov; 91(3):525–34 (106 ref.)
The role of subsets of CD4+ T cells in autoimmunity. Fowell D, et al. **Ciba Found Symp** 1995;195:173–82; discussion 182–8 (42 ref.)
Evidence for cell-mediated hypersensitivity as an important pathogenetic mechanism in food intolerance. MacDonald TT. **Clin Exp Allergy** 1995 Jul;25 Suppl 1:10–3 (41 ref.)
Quality standard for the enumeration of CD4+ lymphocytes in adults and adolescents infected with human immunodeficiency virus. Gross PA, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S126–7 (7 ref.)
Quality standard for the enumeration of CD4+ lymphocytes in infants and children exposed to or infected with human immunodeficiency virus. Wilfert CM, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S134–5 (10 ref.)
Positive selection of T cells. Fowlkes BJ, et al. **Curr Opin Immunol** 1995 Apr;7(2):188–95 (54 ref.)
Role of B7 signaling in the differentiation of naive CD4+ T cells to effector interleukin-4–producing T helper cells. Gause WC, et al. **Immunol Res** 1995;14(3):176–88 (84 ref.)
The role of CD4+ tumor-infiltrating lymphocytes in human solid tumors. Goedegebuure PS, et al. **Immunol Res** 1995; 14(2):119–31 (56 ref.)
Mechanism and biological significance of CD4-mediated cytotoxicity. Hahn S, et al. **Immunol Rev** 1995 Aug; 146:57–79 (140 ref.)
The contrasting roles of CD4+ T cells in intracellular infections in humans: leishmaniasis as an example. Kemp M, et al. **Immunol Today** 1996 Jan;17(1):13–6 (37 ref.)
Regulation of CD4 T cell reactivity to self and non-self. Lo D, et al. **Int Rev Immunol** 1995;13(2):147–60 (38 ref.)
CD4/CD8 lineage commitment: back to instruction? von Boehmer H. **J Exp Med** 1996 Mar 1;183(3):713–5 (22 ref.)
[Dendritic cells and tumor cell therapy] Pioche C, et al. **Pathol Biol (Paris)** 1995 Dec;43(10):904–9 (43 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Programmed death of T cells in the course of HIV infection. Meyaard L, et al. **Adv Exp Med Biol** 1995;374:115–20 (27 ref.)

PHYSIOLOGY

MHC class I-selected CD4–CD8–TCR alpha beta+ T cells: an important source of IL-4. Leite-de-Moraes MC, et al. **Braz J Med Biol Res** 1995 Aug;28(8):903–5 (28 ref.)

VIROLOGY

Hepatitis C virus-specific T lymphocyte responses. Rice CM, et al. **Curr Opin Immunol** 1995 Aug;7(4):532–8 (79 ref.)

CD4-POSITIVE T-LYMPHOCYTOPENIA, IDIOPATHIC see **T-LYMPHOCYTOPENIA, IDIOPATHIC CD4-POSITIVE**

CD4 RECEPTORS see **ANTIGENS, CD4**

CD7 ANTIGENS see **ANTIGENS, CD7**

CD8 ANTIGENS see **ANTIGENS, CD8**

CD8-POSITIVE T-LYMPHOCYTES

see related
ANTIGENS, CD8

CYTOLOGY

Differentiation of subsets of CD4+ and CD8+ T cells. Mosmann TR, et al. **Ciba Found Symp** 1995;195:42–50; discussion 50–4 (49 ref.)
The molecular jury: deciding whether immature thymocytes should live or die [comment] Vukmanović S. **J Exp Med** 1996 Aug 1;184(2):305–9 (60 ref.) Comment on: J Exp Med 1996 Aug 1;184(2):531–7.

IMMUNOLOGY

CD4+ and CD8+ T lymphocyte activation in HIV infection. Implications for immune pathogenesis and therapy. Laurence J. **Adv Exp Med Biol** 1995;374:1–15 (74 ref.)
Positive selection of thymocytes. Fink PJ, et al. **Adv Immunol** 1995;59:99–133 (144 ref.)
Cytotoxic lymphocyte-mediated immunotherapy. Smyth MJ, et al. **Aust N Z J Med** 1995 Dec;25(6):852–8 (57 ref.)
Cytokines, differentiation and functions of subsets of CD4 and CD8 T cells. Mosmann TR. **Behring Inst Mitt** 1995 Jun;(96):1–6 (34 ref.)
Listeria monocytogenes: a live vector able to deliver heterologous protein within the cytosol and to drive a CD8 dependent T cell response. Goossens PL, et al. **Biologicals** 1995 Jun;23(2):135–43 (92 ref.)
Positive selection of T cells. Fowlkes BJ, et al. **Curr Opin Immunol** 1995 Apr;7(2):188–95 (54 ref.)
CD4/CD8 lineage commitment: back to instruction? von Boehmer H. **J Exp Med** 1996 Mar 1;183(3):713–5 (22 ref.)

PHYSIOLOGY

T-cell-mediated ganglionitis associated with acute sensory neuronopathy. Hainfellner JA, et al. **Ann Neurol** 1996 Apr; 39(4):543–7 (20 ref.)
MHC class I-selected CD4–CD8–TCR alpha beta+ T cells: an important source of IL-4. Leite-de-Moraes MC, et al. **Braz J Med Biol Res** 1995 Aug;28(8):903–5 (28 ref.)

VIROLOGY

Hepatitis C virus-specific T lymphocyte responses. Rice CM, et al. **Curr Opin Immunol** 1995 Aug;7(4):532–8 (79 ref.)

CD10 ANTIGENS see **MEMBRANE METALLO-ENDOPEPTIDASE**

CD11 ANTIGENS see **ANTIGENS, CD11**

CD11A ANTIGEN see **LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1**

CD13 ANTIGENS see **ANTIGENS, CD13**

CD14 ANTIGENS see **ANTIGENS, CD14**

CD15 ANTIGENS see **ANTIGENS, CD15**

CD16 ANTIGENS see **RECEPTORS, IGG**

CD18 ANTIGENS see **ANTIGENS, CD18**

CD19 ANTIGENS see **ANTIGENS, CD19**

CD23 ANTIGENS see **RECEPTORS, IGE**

CD25 ANTIGENS see **RECEPTORS, INTERLEUKIN-2**

CD26 ANTIGENS see **ANTIGENS, CD26**

CD27 ANTIGENS see **ANTIGENS, CD27**

CD28 ANTIGENS see **ANTIGENS, CD28**

CD30 ANTIGENS see **ANTIGENS, CD30**

CD30-POSITIVE ANAPLASTIC LARGE-CELL LYMPHOMA see **LYMPHOMA, LARGE-CELL, KI-1**

CD32 ANTIGENS see **RECEPTORS, IGG**

CD34 ANTIGENS see **ANTIGENS, CD34**

CD36 ANTIGENS see **ANTIGENS, CD36**

CD40 ANTIGENS see **ANTIGENS, CD40**

CD41 ANTIGENS see **PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX**

CD42A ANTIGENS see **PLATELET GLYCOPROTEIN**

CD42A ANTIGENS

GPIB-IX COMPLEX

CD42B ANTIGENS see **PLATELET GLYCOPROTEIN GPIB-IX COMPLEX**

CD42C ANTIGENS see **PLATELET GLYCOPROTEIN GPIB-IX COMPLEX**

CD42D ANTIGENS see **PLATELET GLYCOPROTEIN GPIB-IX COMPLEX**

CD44 ANTIGENS see **ANTIGENS, CD44**

CD45 ANTIGENS see **ANTIGENS, CD45**

CD45R ANTIGENS see **ANTIGENS, CD45**

CD45RA ANTIGENS see **ANTIGENS, CD45**

CD45RO ANTIGENS see **ANTIGENS, CD45**

CD54 ANTIGENS see **INTERCELLULAR ADHESION MOLECULE-1**

CD55 ANTIGENS see **ANTIGENS, CD55**

CD57 ANTIGENS see **ANTIGENS, CD57**

CD59 ANTIGENS see **ANTIGENS, CD59**

CD62E ANTIGENS see **E-SELECTIN**

CD62L ANTIGENS see **L-SELECTIN**

CD62P ANTIGENS see **P-SELECTIN**

CD64 ANTIGENS see **RECEPTORS, IGG**

CD73 ANTIGENS see **5'-NUCLEOTIDASE**

CD80 ANTIGENS see **ANTIGENS, CD80**

CD95 ANTIGENS see **ANTIGENS, CD95**

CD106 ANTIGENS see **VASCULAR CELL ADHESION MOLECULE-1**

CD117 ANTIGENS see **PROTO-ONCOGENE PROTEINS C-KIT**

CDW121A ANTIGENS see **RECEPTORS, INTERLEUKIN-1**

CDW121B ANTIGENS see **RECEPTORS, INTERLEUKIN-1**

CD122 ANTIGENS see **RECEPTORS, INTERLEUKIN-2**

CDC GENES see **GENES, CDC**

CDC PROTEINS see **CELL CYCLE PROTEINS**

CDC2 PROTEIN KINASE see **PROTEIN P34CDC2**

CDK PROTEINS see **CYCLIN-DEPENDENT KINASES**

CDNA see **DNA, COMPLEMENTARY**

CDNA PROBES see **DNA, COMPLEMENTARY**

CDP CHOLINE see **CYTIDINE DIPHOSPHATE CHOLINE**

CEBIDAE

PARASITOLOGY

Simian malaria at two sites in the Brazilian Amazon. I--The infection rates of Plasmodium brasilianum in non-human primates. Lourenço-de-Oliveira R, et al. **Mem Inst Oswaldo Cruz** 1995 May-Jun;90(3):331-9 (70 ref.)

CECAL DISEASES

CHEMICALLY INDUCED

Colonic ulceration associated with nonsteroidal anti-inflammatory drugs. Report of three cases. Kaufman HL, et al. **Dis Colon Rectum** 1996 Jun;39(6):705-10 (36 ref.)

COMPLICATIONS

[Acute solitary diverticulitis of the cecum, a rare cause of acute abdomen. Apropos of 9 cases and review of the literature] Villalba Caballero R, et al. **J Chir (Paris)** 1995 Jun-Jul;132(6-7):299-304 (25 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

[Post-appendectomy fistulas of the cecum. Apropos of 22 cases] Genier F, et al. **J Chir (Paris)** 1995 Oct;132(10):393-8 (17 ref.) (Eng. Abstr.) **(Fre)**

RADIOGRAPHY

Dilemma of an inverted cecal diverticulum simulating a pedunculated polyp: CT appearance. Posner R, et al. **Abdom Imaging** 1995 Sep-Oct;20(5):440-1 (5 ref.)

CECAL NEOPLASMS

DIAGNOSIS

[A carcinoid with cecal localization. Apropos a case] Chisari A, et al. **Minerva Chir** 1996 Jan-Feb;51(1-2):51-7 (17 ref.) (Eng. Abstr.) **(Ita)**

[Angiolipoma of the cecum] Saroglia G, et al. **Minerva Chir** 1996 Jan-Feb;51(1-2):59-62 (5 ref.) (Eng. Abstr.) **(Ita)**

PATHOLOGY

Malignant mixed müllerian tumor of the extraovarian secondary müllerian system. Report of two cases and review of the English literature. Mira JL, et al. **Arch Pathol Lab Med** 1995 Nov;119(11):1044-9 (31 ref.)

SECONDARY

[Adenocarcinoma of the appendix. A propos of a case complicated by double local and parietal recurrence] de Souza N, et al. **J Chir (Paris)** 1996 Jun;133(4):159-61 (10 ref.) (Eng. Abstr.) **(Fre)**

CECUM

Cecal perforation associated with sodium polystyrene sulfonate-sorbitol enemas in a 650 gram infant with hyperkalemia. Bennett LN, et al. **Am J Perinatol** 1996 Apr;13(3):167-70 (12 ref.)

ABNORMALITIES

Mobile cecum syndrome: a report of two cases. Lee YJ, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1996 May;57(5):380-3 (8 ref.)

Intestinal obstruction caused by duplication of the caecum. Oudshoorn JH, et al. **Eur J Pediatr** 1996 Apr;155(4):338-40 (18 ref.)

PHYSIOLOGY

Selective retention of fluid digesta in the hindgut of bandicoots and other marsupial caecum fermenters. Hume ID, et al. **DTW Dtsch Tierarztl Wochenschr** 1995 Apr;102(4):150-1 (14 ref.)

CEFACLOR

THERAPEUTIC USE

[Azithromycin, pharmacodynamic evaluation in animal models] Lagrange PH. **Pathol Biol (Paris)** 1995 Jun;43(6):515-23 (37 ref.) (Eng. Abstr.) **(Fre)**

CEFOTAXIME

ADMINISTRATION & DOSAGE

Review and reassessment of dosing schedules for cefotaxime in selected medical indications. Young LS. **Diagn Microbiol Infect Dis** 1995 May-Jun;22(1-2):147-54 (11 ref.)

ANALOGS & DERIVATIVES

Gonorrhoea: single-dose oral treatment. Kohl PK, et al. **Curr Probl Dermatol** 1996;24:82-9 (29 ref.)

Cefotaxime and desacetylcefotaxime antimicrobial interactions. The clinical relevance of enhanced activity: a review. Jones RN. **Diagn Microbiol Infect Dis** 1995 May-Jun;22(1-2):19-33 (79 ref.)

Pharmacokinetics of cefotaxime and desacetylcefotaxime in the young. Kearns GL, et al. **Diagn Microbiol Infect Dis** 1995 May-Jun;22(1-2):97-104 (45 ref.)

Pharmacodynamic (kinetic) considerations in the treatment of moderately severe infections with cefotaxime. Turnidge JD. **Diagn Microbiol Infect Dis** 1995 May-Jun;22(1-2):57-69 (94 ref.)

ANTAGONISTS & INHIBITORS

[Meningitis due to cefotaxime-resistant Streptococcus pneumoniae] Martín Fontelos P, et al. **An Esp Pediatr** 1996 Apr;44(4):395-6 (24 ref.) **(Spa)**

PHARMACOKINETICS

Pharmacokinetics of cefotaxime in dialysis patients. Andrassy K. **Diagn Microbiol Infect Dis** 1995 May-Jun;22(1-2):85-7 (11 ref.)

Pharmacokinetics of cefotaxime and desacetylcefotaxime in the young. Kearns GL, et al. **Diagn Microbiol Infect Dis** 1995 May-Jun;22(1-2):97-104 (45 ref.)

Pharmacodynamic (kinetic) considerations in the treatment of moderately severe infections with cefotaxime. Turnidge JD. **Diagn Microbiol Infect Dis** 1995 May-Jun;22(1-2):57-69 (94 ref.)

PHARMACOLOGY

Antimicrobial activity of cefotaxime tested against infrequently isolated pathogenic species (unusual pathogens). Cormican MG, et al. **Diagn Microbiol Infect Dis** 1995 May-Jun;22(1-2):43-8 (46 ref.)

Cefotaxime and desacetylcefotaxime antimicrobial interactions. The clinical relevance of enhanced activity: a review. Jones RN. **Diagn Microbiol Infect Dis** 1995 May-Jun;22(1-2):19-33 (79 ref.)

THERAPEUTIC USE

Cefotaxime use in pediatric infections. Dajani AS. **Diagn Microbiol Infect Dis** 1995 May-Jun;22(1-2):105-10 (19 ref.)

Experience with cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis. Rimola A, et al. **Diagn Microbiol Infect Dis** 1995 May-Jun;22(1-2):141-5 (30 ref.)

The role of cefotaxime in the treatment of surgical infections. Wittmann DH. **Diagn Microbiol Infect Dis** 1995 May-Jun;22(1-2):173-82 (67 ref.)

Drug utilisation review (DUR) of the third generation cephalosporins. Focus on ceftriaxone, ceftazidime and cefotaxime. Adu A, et al. **Drugs** 1995 Sep;50(3):423-39 (109 ref.)

CEFOTIAM

ADVERSE EFFECTS

Cefotiam-induced contact urticaria syndrome: an occupational condition in Japanese nurses. Shimizu S, et al. **Dermatology** 1996;192(2):174-6 (19 ref.)

CEFTAZIDIME

PHARMACOLOGY

[Specificities of antibacterial activity of zwitterionic 7-methoxyimino cephems (cephalosporins of fourth generation)] Pechère JC. **Pathol Biol (Paris)** 1996 Feb;44(2):99-105 (26 ref.) (Eng. Abstr.) **(Fre)**

THERAPEUTIC USE

Drug utilisation review (DUR) of the third generation cephalosporins. Focus on ceftriaxone, ceftazidime and cefotaxime. Adu A, et al. **Drugs** 1995 Sep;50(3):423-39 (109 ref.)

Cure of a solitary brainstem abscess with antibiotic therapy: case report. Fulgham JR, et al. **Neurology** 1996 May;46(5):1451-4 (10 ref.)

CEFTIZOXIME

ANALOGS & DERIVATIVES

[Cefpodoxime] **Enferm Infecc Microbiol Clin** 1995 Aug-Sep;13(7):437-8 (0 ref.) **(Spa)**

CEFTIZOXIME SODIUM see **CEFTIZOXIME**

CEFTRIAXONE

THERAPEUTIC USE

Drug utilisation review (DUR) of the third generation cephalosporins. Focus on ceftriaxone, ceftazidime and cefotaxime. Adu A, et al. **Drugs** 1995 Sep;50(3):423-39 (109 ref.)

CELEBES APE see **MACACA**

CELIAC ARTERY

Aneurysms of the pancreaticoduodenal artery associated with occlusion of the celiac artery. Uher P, et al. **Abdom Imaging** 1995 Sep-Oct;20(5):470-3 (22 ref.)

Angioplasty for the treatment of visceral ischemia. Hallisey MJ, et al. **J Vasc Interv Radiol** 1995 Sep-Oct;6(5):785-91 (26 ref.)

[Benign schwannoma of the celiac tripod simulating a pancreatic neoplasm] Cedolini C, et al. **Minerva Chir** 1996 Jan-Feb;51(1-2):47-9 (15 ref.) (Eng. Abstr.) **(Ita)**

CELIAC DISEASE

Gluten-sensitive enteropathy. Luchetti R, et al. **Ann Ist Super Sanita** 1995;31(3):323-36 (157 ref.)

Human models: Whipple's disease, coeliac disease and jejunoileal bypass. Utsinger PD, et al. **Baillieres Clin Rheumatol** 1996 Feb;10(1):77-103 (129 ref.)

Gluten-sensitive enteropathy. Troncone R, et al. **Pediatr Clin North Am** 1996 Apr;43(2):355-73 (106 ref.)

[Characteristics of celiac disease in children] Schmitz J. **Gastroenterol Clin Biol** 1996;20(5 Pt 2):B42-49 (50 ref.) **(Fre)**

COMPLICATIONS

Hepatic steatosis revealing celiac disease: a case complicated by transitory liver failure [letter] Cassagnou M, et al.

Am J Gastroenterol 1996 Jun;91(6):1291–2 (8 ref.)
Neurological complications of celiac disease: a rare but continuing problem. Muller AF, et al.
Am J Gastroenterol 1996 Jul;91(7):1430–5 (28 ref.)
The major complications of coeliac disease. Wright DH.
Baillieres Clin Gastroenterol 1995 Jun;9(2):351–69 (65 ref.)
Progressive myoclonic ataxia associated with coeliac disease. The myoclonus is of cortical origin, but the pathology is in the cerebellum. Bhatia KP, et al. **Brain** 1995 Oct;118 (Pt 5):1087–93 (14 ref.)
Lymphoma in coeliac disease. Mathus-Vliegen EM.
J R Soc Med 1995 Dec;88(12):672–7 (64 ref.)
[Intestinal malabsorption, celiac disease and associated lymphoma: from symptoms to diagnosis] Gasbarrini G, et al. **Riv Eur Sci Med Farmacol** 1994 Sep-Dec;16 Suppl 1:39–68 (115 ref.) (Eng. Abstr.) **(Ita)**

DIAGNOSIS

An unusual association: celiac disease and Becker muscular dystrophy. Meini A, et al. **Am J Gastroenterol** 1996 Jul; 91(7):1459–60 (11 ref.)
Coeliac disease in adults. Corazza GR, et al.
Baillieres Clin Gastroenterol 1995 Jun;9(2):329–50 (105 ref.)
Coeliac disease research and clinical practice: maintaining momentum into the twenty-first century. Ferguson A.
Baillieres Clin Gastroenterol 1995 Jun;9(2):395–412 (41 ref.)
Dermatitis herpetiformis. Fry L.
Baillieres Clin Gastroenterol 1995 Jun;9(2):371–93 (65 ref.)
Coeliac disease in childhood. Littlewood JM.
Baillieres Clin Gastroenterol 1995 Jun;9(2):295–327 (125 ref.)
Coeliac disease: looking out for easily reversible morbidity. Dickinson RJ. **Practitioner** 1996 Mar;240(1560):194–7 (2 ref.)
[Endemic sprue: its first diagnosis based on bleeding complications] Heidinger K, et al.
Dtsch Med Wochenschr 1995 Nov 10;120(45):1543–6 (10 ref.) (Eng. Abstr.) **(Ger)**
[Celiac disease and cystic fibrosis: a rare association] López Rodríguez MJ, et al. **An Esp Pediatr** 1996 Apr;44(4):383–4 (16 ref.) **(Spa)**

DIET THERAPY

[Diet in celiac disease] Karvonen AL. **Duodecim** 1994; 110(13):1275–8 (5 ref.) **(Fin)**

ETIOLOGY

The precipitating factor in coeliac disease. Wieser H.
Baillieres Clin Gastroenterol 1995 Jun;9(2):191–207 (63 ref.)

IMMUNOLOGY

Serology of coeliac disease: early diagnosis and therapeutic impact. Mascart-Lemone F, et al.
Acta Gastroenterol Belg 1995 Sep-Dec;58(5–6):388–96 (40 ref.)
The immunology of coeliac disease. Goggins M, et al.
Ann Med Interne (Paris) 1996;147(1):40–8 (118 ref.)
Active immunity or tolerance to foods in patients with celiac disease or inflammatory bowel disease. Ferguson A, et al.
Ann N Y Acad Sci 1996 Feb 13;778:202–16 (25 ref.)
The humoral immune system in coeliac disease. Mäki M.
Baillieres Clin Gastroenterol 1995 Jun;9(2):231–49 (115 ref.)
The gluten-host interaction. Tighe MR, et al.
Baillieres Clin Gastroenterol 1995 Jun;9(2):211–30 (42 ref.)
T-cell responses and cellular immunity in coeliac disease. Trejdosiewicz LK, et al. **Baillieres Clin Gastroenterol** 1995 Jun;9(2):251–72 (160 ref.)
Absorption and presentation of antigens by epithelial cells of the small intestine: hypotheses and predictions relating to the pathogenesis of coeliac disease. Mayrhofer G.
Immunol Cell Biol 1995 Oct;73(5):433–9 (63 ref.)

PATHOLOGY

Morphology of the mucosal lesion in gluten sensitivity. Marsh MN, et al. **Baillieres Clin Gastroenterol** 1995 Jun; 9(2):273–93 (60 ref.)
Cavitation of mesenteric lymph nodes: a rare complication of coeliac disease, associated with a poor outcome. Howat AJ, et al. **Histopathology** 1995 Oct;27(4):349–54 (8 ref.)

CELIAC GANGLIA see **GANGLIA, SYMPATHETIC**

CELIOSCOPY see **LAPAROSCOPY**

CELIPROLOL

THERAPEUTIC USE

Celiprolol. An evaluation of its pharmacological properties and clinical efficacy in the management of hypertension and angina pectoris. Dunn CJ, et al. **Drugs Aging** 1995 Nov; 7(5):394–411 (111 ref.)

CELL ADHESION

Fibronectin and cell adhesion: specificity of integrin-ligand interaction. Aota S, et al.
Adv Enzymol Relat Areas Mol Biol 1995;70:1–21 (81 ref.)
The molecular architecture of focal adhesions. Jockusch BM, et al. **Ann Rev Cell Dev Biol** 1995;11:379–416 (291 ref.)
Adhesion mechanisms in liver metastasis formation. Kemperman H, et al. **Cancer Surv** 1995;24:67–79 (54 ref.)
The body language of cells: the intimate connection between cell adhesion and behavior. Klymkowsky MW, et al.
Cell 1995 Oct 6;83(1):5–8 (25 ref.)
Adhesion molecules as targets for the treatment of autoimmune diseases. Oppenheimer-Marks N, et al.
Clin Immunol Immunopathol 1996 Jun;79(3):203–10 (58 ref.)
Lymphocyte adhesion to endothelium. Dianzani U, et al.
Crit Rev Immunol 1995;15(2):167–200 (258 ref.)
Cell adhesion in the life cycle of Dictyostelium. Bozzaro S, et al. **Experientia** 1995 Dec 18;51(12):1175–88 (129 ref.)
The osteoclast clear zone is a specialized cell-extracellular matrix adhesion structure. Väänänen HK, et al.
J Cell Sci 1995 Aug;108 (Pt 8):2729–32 (39 ref.)
Involvement of CD44 and its variant isoforms in membrane-cytoskeleton interaction, cell adhesion and tumor metastasis. Bourrguignon LY, et al. **J Neurooncol** 1995 Dec;26(3):201–8 (44 ref.)
Migration and adhesion assays. Lallier T.
Methods Cell Biol 1996;51:285–99 (3 ref.)
Binding of extracellular matrix proteins by microbes. Ljungh A, et al. **Methods Enzymol** 1995;253:501–14 (50 ref.)

GENETICS

Altered adhesions in ras-transformed breast epithelial cells. Kinch MS, et al. **Biochem Soc Trans** 1995 Aug;23(3):446–50 (43 ref.)
Adhesion and direct integrin engagement differentially regulate gene transcription, transcript stabilization and translation. Mondal K, et al. **Biochem Soc Trans** 1995 Aug; 23(3):460–4 (39 ref.)

IMMUNOLOGY

Defective cell-cell adhesion in the epidermis. Stanley JR. **Ciba Found Symp** 1995;189:107–20; discussion 120–3, 174–6 (64 ref.)
T-lymphocyte interactions with endothelium and extracellular matrix. Hunt SW 3rd, et al.
Crit Rev Oral Biol Med 1996;7(1):59–86 (199 ref.)
The beta 7 integrins in mucosal homing and retention. Shaw SK, et al. **Semin Immunol** 1995 Oct;7(5):335–42 (45 ref.)
[Adhesion molecules in bronchial asthma] Fal AM, et al.
Pneumonol Alergol Pol 1995;63(9–10):577–80 (23 ref.) **(Pol)**

PHYSIOLOGY

Molecular interactions in the submembrane plaque of cell-cell and cell-matrix adhesions. Geiger B, et al.
Acta Anat (Basel) 1995;154(1):46–62 (181 ref.)
Adhesion molecules in health and disease. Faull RJ.
Aust N Z J Med 1995 Dec;25(6):720–30 (86 ref.)
Biological specificity and measurable physical properties of cell surface receptors and their possible role in signal transduction through the cytoskeleton. Forgacs G.
Biochem Cell Biol 1995 Jul-Aug;73(7–8):317–26 (50 ref.)
Cellular adhesiveness, contractility, and traction: stick, grip, and slip control. Opas M. **Biochem Cell Biol** 1995 Jul-Aug; 73(7–8):311–6 (80 ref.)
Cell-matrix adhesion: structure and regulation. Hemmings L, et al. **Biochem Soc Trans** 1995 Aug;23(3):619–26 (75 ref.)
Adhesion and direct integrin engagement differentially regulate gene transcription, transcript stabilization and translation. Mondal K, et al. **Biochem Soc Trans** 1995 Aug; 23(3):460–4 (39 ref.)
Rho, rac and cdc42 GTPases: regulators of actin structures, cell adhesion and motility. Nobes CD, et al.
Biochem Soc Trans 1995 Aug;23(3):456–9 (16 ref.)
Cell adhesion: the molecular basis of tissue architecture and morphogenesis. Gumbiner BM. **Cell** 1996 Feb 9; 84(3):345–57 (72 ref.)
Protein tyrosine phosphatases as adhesion receptors. Brady-Kalnay SM, et al. **Curr Opin Cell Biol** 1995 Oct; 7(5):650–7 (58 ref.)
Inhibition of cell adhesion by anti-adhesive molecules. Chiquet-Ehrismann R. **Curr Opin Cell Biol** 1995 Oct; 7(5):715–9 (46 ref.)
Adhesion in cell migration. Huttenlocher A, et al.
Curr Opin Cell Biol 1995 Oct;7(5):697–706 (137 ref.)
New insights into membrane dynamics from the analysis of cell surface interactions by physical methods. Sheets ED, et al. **Curr Opin Cell Biol** 1995 Oct;7(5):707–14 (65 ref.)
Morphogenetic roles of classic cadherins. Takeichi M.
Curr Opin Cell Biol 1995 Oct;7(5):619–27 (72 ref.)
Common principles in cell adhesion. Ruoslahti E, et al.
Exp Cell Res 1996 Aug 25;227(1):1–11 (147 ref.)
Cell surface chondroitin sulfate proteoglycans in tumor cell adhesion, motility and invasion. Iida J, et al.
Semin Cancer Biol 1996 Jun;7(3):155–62 (64 ref.)
Pathophysiological aspects of VLA-4 interactions and possibilities for therapeutical interventions. Kuijpers TW.
Springer Semin Immunopathol 1995;16(4):379–89 (89 ref.)
The adhesion cascade and anti-adhesion therapy: an overview. Sharar SR, et al.
Springer Semin Immunopathol 1995;16(4):359–78 (139 ref.)
Gap junction communication and cell adhesion in development. DeHaan RL. **Zygote** 1994 Aug;2(3):183–8 (71 ref.)
[Mosaic proteins] Zak I. **Postepy Biochem** 1995;41(2):120–30 (81 ref.) **(Pol)**

CELL ADHESION MOLECULE, NEURAL see **NCAM**

CELL-ADHESION MOLECULE RECEPTORS see **INTEGRINS**

CELL ADHESION MOLECULES

see related
INTEGRINS
The role of cellular adhesion molecules in surgery. Breidahl AF, et al. **Aust N Z J Surg** 1995 Dec;65(12):838–47 (54 ref.)
Cell adhesion molecules. 1: immunoglobulin superfamily. Brümmendorf T, et al. **Protein Profile** 1994;1(9):951–1058 (925 ref.)
[CD22: a cell adhesion molecule that displays alpha 2-6-linked sialic acid-binding lectin activity] Hanasaki K. **Seikagaku** 1995 Aug;67(8):1040–7 (15 ref.) **(Jpn)**

ANALYSIS

Adhesion molecules in cutaneous inflammation. Barker JN. **Ciba Found Symp** 1995;189:91–101; discussion 101–6 (38 ref.)
CD31 immunoreactivity in mesenchymal neoplasms of the skin and subcutis: report of 145 cases and review of putative immunohistologic markers of endothelial differentiation. DeYoung BR, et al. **J Cutan Pathol** 1995 Jun;22(3):215–22 (45 ref.)
Assays for measuring soluble cellular adhesion molecules and soluble cytokine receptors. Meager A, et al.
J Immunol Methods 1996 May 27;191(2):97–112 (146 ref.)
Adhesion molecules as markers of acute cellular rejection of renal allografts. Truong L, et al. **Transplant Proc** 1996 Feb;28(1):519–22 (31 ref.)

BIOSYNTHESIS

Early metastasis of human solid tumours: expression of cell adhesion molecules. Pantel K, et al. **Ciba Found Symp** 1995; 189:157–70; discussion 170–3, 174–6 (62 ref.)
All-trans retinoic acid (ATRA) and the regulation of adhesion molecules in acute myeloid leukemia. Di Noto R, et al. **Leuk Lymphoma** 1996 Apr;21(3–4):201–9 (74 ref.)
Expression of thrombospondin-1 in cancer: a role in tumor progression. Qian X, et al. **Proc Soc Exp Biol Med** 1996 Jul;212(3):199–207 (96 ref.)

BLOOD

[Circulating adhesion molecules and diseases] Ma L, et al.
Chung Hua Nei Ko Tsa Chih 1995 Jun;34(6):416–9 (20 ref.) **(Chi)**

CHEMISTRY

Structure and function of adhesion receptors in leukocyte trafficking. Hogg N, et al. **Immunol Today** 1995 Jul; 16(7):327–30 (42 ref.)
Cell adhesion molecules 1: immunoglobulin superfamily. Brümmendorf T, et al. **Protein Profile** 1995;2(9):963–108 (1278 ref.)
Conformational changes in adhesive proteins modulate their adhesive function. Ugarova T, et al. **Thromb Haemost** 1995 Jul;74(1):253–7 (58 ref.)

DRUG EFFECTS

Influence of different volume therapies and pentoxifylline infusion on circulating soluble adhesion molecules in critically ill patients. Boldt J, et al. **Crit Care Med** 1996 Mar;24(3):385–91 (39 ref.)

GENETICS

Developmental control of N-CAM expression by Hox and Pax gene products. Edelman GM, et al.
Philos Trans R Soc Lond B Biol Sci 1995 Sep 29; 349(1329):305–12 (33 ref.)
Modular cis-regulatory organization of developmentally expressed genes: two genes transcribed territorially in the sea urchin embryo, and additional examples. Kirchhamer CV, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3; 93(18):9322–8 (67 ref.)

IMMUNOLOGY

Pemphigus: autoimmunity to epidermal cell adhesion molecules. Amagai M. **Adv Dermatol** 1996;11:319–52; discussion 353 (166 ref.)
Adhesion molecules in host defense. Etzioni A.
Clin Diagn Lab Immunol 1994 Jan;1(1):1–4 (41 ref.)
T-lymphocyte interactions with endothelium and extracellular matrix. Hunt SW 3rd, et al.
Crit Rev Oral Biol Med 1996;7(1):59–86 (199 ref.)
Studies of patients with anti-epiligrin cicatricial pemphigoid. Yancey KB, et al. **J Dermatol** 1995 Nov;22(11):829–35 (25 ref.)
[ICAM-3, the role and significance of leukocyte interactions] Matysiak W, et al. **Pol Arch Med Wewn** 1996 Jan; 95(1):79–86 (35 ref.) **(Pol)**

METABOLISM

Integrin-mediated signaling in normal and malignant cells: a role of protein tyrosine kinases. Malik RK, et al.
Biochim Biophys Acta 1996 Jun 7;1287(2-3):73–6 (61 ref.)

Convergent signalling in the action of integrins, neuropeptides, growth factors and oncogenes. Rozengurt E. **Cancer Surv** 1995;24:81–96 (49 ref.)
Adhesion molecules and cell surface receptors in the heart transplant-associated arteriosclerosis. Hinek A. **Folia Histochem Cytobiol** 1996;34(1):3–19 (140 ref.)
pp125FAK in the focal adhesion. Otey CA. **Int Rev Cytol** 1996;167:161–83 (85 ref.)
The focal adhesion kinase. Schaller MD. **J Endocrinol** 1996 Jul;150(1):1–7 (88 ref.)
Flow-dependent regulation of gene expression in vascular endothelial cells. Ando J, et al. **Jpn Heart J** 1996 Jan; 37(1):19–32 (40 ref.)
[Clinical application of adhesion molecules] Okumura Y. **Nippon Geka Gakkai Zasshi** 1995 Aug;96(8):525–8 (8 ref.) **(Jpn)**

PHYSIOLOGY

Molecular interactions in the submembrane plaque of cell–cell and cell–matrix adhesions. Geiger B, et al. **Acta Anat (Basel)** 1995;154(1):46–62 (181 ref.)
Cell–cell adhesion molecules in epithelial–mesenchymal transformations. Prieto AL, et al. **Acta Anat (Basel)** 1995; 154(1):21–33 (176 ref.)
Suppression of experimental glomerulonephritis by interference with T- or B-cell activation signals or adhesion molecules. Andres G, et al. **Adv Nephrol Necker Hosp** 1995;24:91–105 (51 ref.)
Adhesion molecules in allergy. Passalacqua G, et al. **Allerg Immunol (Paris)** 1996 Feb;28(2):34–8 (37 ref.)
Cellular adhesion molecules. Newly identified mediators of angiogenesis. Polverini PJ. **Am J Pathol** 1996 Apr; 148(4):1023–9 (83 ref.)
Adhesion molecules in health and disease. Faull RJ. **Aust N Z J Med** 1995 Dec;25(6):720–30 (86 ref.)
Axonal growth mediated by cell adhesion molecules requires activation of fibroblast growth factor receptors. Saffell JL, et al. **Biochem Soc Trans** 1995 Aug;23(3):469–70 (12 ref.)
Membrane adhesion and other functions for the myelin basic proteins. Staugaitis SM, et al. **Bioessays** 1996 Jan;18(1):13–8 (45 ref.)
Cell adhesion molecules: an overview [editorial] Laffón A, et al. **Br J Rheumatol** 1995 Dec;34(12):1101–2 (14 ref.)
Adhesion molecules as determinants of disease: from molecular biology to surgical research. Menger MD, et al. **Br J Surg** 1996 May;83(5):588–601 (229 ref.)
Leukocyte adhesion molecules. Chapman PT, et al. **Br Med Bull** 1995 Apr;51(2):296–311 (80 ref.)
Role of integrins as signal transducing cell adhesion molecules in human cutaneous melanoma. Danen EH, et al. **Cancer Surv** 1995;24:43–65 (130 ref.)
The role of ICAM expression in immunity and disease. Simmons DL. **Cancer Surv** 1995;24:141–55 (58 ref.)
The body language of cells: the intimate connection between cell adhesion and behavior. Klymkowsky MW, et al. **Cell** 1995 Oct 6;83(1):5–8 (25 ref.)
Defective cell–cell adhesion in the epidermis. Stanley JR. **Ciba Found Symp** 1995;189:107–20; discussion 120–3, 174–6 (64 ref.)
Adhesion molecules as therapeutic targets in the treatment of allergic and immunologically mediated diseases. Kavanaugh A. **Clin Immunol Immunopathol** 1996 Sep;80(3 Pt 2):S15–22 (37 ref.)
Adhesion molecules as targets for the treatment of autoimmune diseases. Oppenheimer-Marks N, et al. **Clin Immunol Immunopathol** 1996 Jun;79(3):203–10 (58 ref.)
Cell adhesion molecules as morphoregulators. Cunningham BA. **Curr Opin Cell Biol** 1995 Oct;7(5):628–33 (60 ref.)
Lu-ECAM-1 and DPP IV in lung metastasis. Elble RC, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 1):107–22 (77 ref.)
MUC18: A cell adhesion molecule with a potential role in tumor growth and tumor cell dissemination. Johnson JP, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 1):95–105 (25 ref.)
The role of cell adhesion molecules in the development of IDDM: implications for pathogenesis and therapy. Yang XD, et al. **Diabetes** 1996 Jun;45(6):705–10 (61 ref.)
Adhesion molecules in inflammatory and neoplastic intestinal diseases. Pedersen G, et al. **Dig Dis** 1995 Sep–Oct; 13(5):322–36 (103 ref.)
Extracellular matrix and cell adhesion molecules in nephrogenesis. Ekblom P. **Exp Nephrol** 1996 Mar–Apr; 4(2):92–6 (30 ref.)
PSF and CMF, autocrine factors that regulate gene expression during growth and early development of Dictyostelium. Clarke M, et al. **Experientia** 1995 Dec 18; 51(12):1124–34 (60 ref.)
Biological functions of cell adhesion molecules in breast cancer. Narita T, et al. **Gan To Kagaku Ryoho** 1996 Mar; 23 Suppl 1:56–60 (9 ref.)
Cell adhesion and regulatory molecules involved in tumor formation, hemostasis, and wound healing. Van Waes C. **Head Neck** 1995 Mar–Apr;17(2):140–7 (18 ref.)
What is the epidermal intercellular cement and why is it important? Stanley JR. **J Dermatol** 1995 Nov;22(11):836–8 (9 ref.)
Cellular adhesion molecules in rheumatoid arthritis: regulation by cytokines and possible clinical importance. Szekanecz Z, et al. **J Investig Med** 1996 Apr;44(4):124–35 (164 ref.)
Regulation and selectivity of leukocyte emigration. Schleiffenbaum B, et al. **J Lab Clin Med** 1996 Feb; 127(2):151–68 (251 ref.)
Regulation of leukocyte adhesion and signaling in inflammation and disease. Wahl SM, et al. **J Leukoc Biol** 1996 Jun;59(6):789–96 (94 ref.)
Fak and focal adhesions. Martin GM. **Jpn J Cancer Res** 1996 Mar;87(3):inside front cover (34 ref.)
Adhesion molecules in renal disease. Dal Canton A. **Kidney Int** 1995 Dec;48(6):1687–96 (100 ref.)
Regulation of human B cell lymphopoiesis by adhesion molecules and cytokines. Ryan DH, et al. **Leuk Lymphoma** 1995 May;17(5–6):375–89 (137 ref.)
PECAM-1: its expression and function as a cell adhesion molecule on hemopoietic and endothelial cells. Watt SM, et al. **Leuk Lymphoma** 1995 Apr;17(3–4):229–44 (85 ref.)
The latest fashions in skin disease. Carroll JM, et al. **Mol Med** 1995 Jan;1(2):123–6 (29 ref.)
Adhesion molecules—Part I. Frenette PS, et al. **N Engl J Med** 1996 Jun 6;334(23):1526–9 (0 ref.)
Adhesion molecules—Part II: Blood vessels and blood cells. Frenette PS, et al. **N Engl J Med** 1996 Jul 4;335(1):43–5 (0 ref.)
Adhesive interactions in the hematopoietic system: regulation by cytokines. Fernández M, et al. **Proc Soc Exp Biol Med** 1996 Sep;212(4):313–23 (136 ref.)
Role of adhesion molecules in the pathogenesis of rheumatoid arthritis. Liao HX, et al. **Rheum Dis Clin North Am** 1995 Aug;21(3):715–40 (150 ref.)
Integrins, selectins and CAMs—the 'glue of life'. Froese S, et al. **S Afr Med J** 1994 Nov;84(11):759–64 (27 ref.)
The adhesion cascade and anti-adhesion therapy: an overview. Sharar SR, et al. **Springer Semin Immunopathol** 1995;16(4):359–78 (139 ref.)
Blocking of adhesion molecules in vivo as anti-inflammatory therapy. Ward PA, et al. **Ther Immunol** 1994 Jun; 1(3):165–71 (22 ref.)
Cell–adhesion molecules, glucocorticoids and long-term-memory formation. Rose SP. **Trends Neurosci** 1995 Nov;18(11):502–6 (46 ref.)
[Occurrence and significance of different adhesion molecules—review] Mätz-Rensing K, et al. **Berl Munch Tierarztl Wochenschr** 1995 Aug;108(8):294–8 (46 ref.) (Eng. Abstr.) **(Ger)**
[Adhesion molecules in dermato-oncology] Dommann SN. **Hautarzt** 1996 Mar;47(3):169–71 (16 ref.) (Eng. Abstr.) **(Ger)**
[Adhesion molecules in the development of inflammatory processes— clinical and investigational implications] Naftali T, et al. **Harefuah** 1996 Feb 1;130(3):182–5 (26 ref.) **(Heb)**
[Carbohydrate antigens as cell adhesion molecules] Kannagi R. **Nippon Geka Gakkai Zasshi** 1996 Feb;97(2):131–9 (43 ref.) (Eng. Abstr.) **(Jpn)**
[Participation of the adhesion molecules in the development of inflammatory response] Farsky SP, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1995 Jan–Feb;50(1):80–9 (147 ref.) (Eng. Abstr.) **(Por)**
[Adhesion molecules in leukocyte and endothelium interactions] Horváthová M. **Bratisl Lek Listy** 1995 Apr; 96(4):217–22 (48 ref.) (Eng. Abstr.) **(Slo)**
[Lymphocytic migration and related adhesion molecules] Hajos SE. **Rev Argent Microbiol** 1995 Jan–Mar;27(1):38–55 (43 ref.) **(Spa)**

THERAPEUTIC USE

Adhesion molecules and liver transplantation: new strategies for therapeutic intervention. Adams DH. **J Hepatol** 1995 Aug;23(2):225–31 (58 ref.)

CELL ADHESION MOLECULES, NEURONAL

BIOSYNTHESIS

Induced expression of adhesion molecules following focal brain ischemia. Wang X, et al. **J Neurotrauma** 1995 Oct; 12(5):825–32 (44 ref.)

CELL AGING

see related
CELL DEATH

Origins of G1 arrest in senescent human fibroblasts. Stein GH, et al. **Bioessays** 1995 Jun;17(6):537–43 (66 ref.)
Mitochondrial water loss and aging of cells. von Zglinicki T, et al. **Cell Biochem Funct** 1995 Sep;13(3):181–7 (48 ref.)
Cellular senescence and cancer. Barrett JC, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:411–8 (67 ref.)
Models of initiation of replicative senescence by loss of telomeric DNA. Allsopp RC. **Exp Gerontol** 1996 Jan–Apr; 31(1–2):235–43 (47 ref.)
A prospective view on phosphatases and replicative senescence. Bernier L, et al. **Exp Gerontol** 1996 Jan–Apr; 31(1–2):13–9 (30 ref.)
Coming of age in culture. Campisi J, et al. **Exp Gerontol** 1996 Jan–Apr;31(1–2):7–12 (22 ref.)
Molecular markers of senescence in fibroblast-like cultures. Cristofalo VJ, et al. **Exp Gerontol** 1996 Jan–Apr; 31(1–2):111–23 (124 ref.)
Prohibitin and the senescent phenotype. Dell'Orco RT, et al. **Exp Gerontol** 1996 Jan–Apr;31(1–2):245–52 (46 ref.)
Insights on immunological aging derived from the T lymphocyte cellular senescence model. Effros RB. **Exp Gerontol** 1996 Jan–Apr;31(1–2):21–7 (46 ref.)
Replicative senescence: considerations relating to the stability of heterochromatin domains. Howard BH. **Exp Gerontol** 1996 Jan–Apr;31(1–2):281–93 (79 ref.)
Escape from senescence in human keratinocyte cultures. Littlefield JW. **Exp Gerontol** 1996 Jan–Apr;31(1–2):29–32 (30 ref.)
Proliferative cell senescence, transformation, and the recombination potential of the genome. Macieira-Coelho A. **Exp Gerontol** 1996 Jan–Apr;31(1–2):227–34 (28 ref.)
The role of DNA damage in cellular aging: is it time for a reassessment? Norwood TH, et al. **Exp Gerontol** 1996 Jan–Apr;31(1–2):61–8 (68 ref.)
From telomere loss to p53 induction and activation of a DNA-damage pathway at senescence: the telomere loss/DNA damage model of cell aging. Vaziri H, et al. **Exp Gerontol** 1996 Jan–Apr;31(1–2):295–301 (42 ref.)
Replicative senescence: implications for in vivo aging and tumor suppression. Smith JR, et al. **Science** 1996 Jul 5; 273(5271):63–7 (52 ref.)
[Oxidative stress and cell aging] Hervonen A. **Duodecim** 1994; 110(17):1653–8 (33 ref.) **(Fin)**

GENETICS

Molecular genetic approaches to the study of cellular senescence. Goletz TJ, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:59–66 (88 ref.)
[Gene expression during replicative senescence] Ide T. **Tanpakushitsu Kakusan Koso** 1996 Mar;41(3):228–36 (57 ref.) **(Jpn)**
[Mapping of a senescent gene on human chromosome 7] Nakabayashi K, et al. **Tanpakushitsu Kakusan Koso** 1996 Mar;41(3):237–44 (31 ref.) **(Jpn)**

PHYSIOLOGY

Endless quest. Holliday R. **Bioessays** 1996 Jan;18(1):3–5 (26 ref.)
Molecular and cell biology of replicative senescence. Dimri GP, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:67–73 (28 ref.)
Lineage, migration, and fate determination of postnatal subventricular zone cells in the mammalian CNS. Goldman JE. **J Neurooncol** 1995;24(1):61–4 (15 ref.)

CELL ANOXIA see **CELL HYPOXIA**

CELL COMMUNICATION

see related
INTERCELLULAR JUNCTIONS
SECOND MESSENGER SYSTEMS
SIGNAL TRANSDUCTION

Possible role of coupling between glomus cells in carotid body chemoreception. Eyzaguirre C, et al. **Biol Signals** 1995 Sep–Oct;4(5):263–70 (30 ref.)
Axon guidance molecules. Keynes R, et al. **Cell** 1995 Oct 20;83(2):161–9 (60 ref.)
The body language of cells: the intimate connection between cell adhesion and behavior. Klymkowsky MW, et al. **Cell** 1995 Oct 6;83(1):5–8 (25 ref.)
Analysis of lymphocyte costimulation in vivo using transgenic and 'knockout' mice. Sharpe AH. **Curr Opin Immunol** 1995 Jun;7(3):389–95 (55 ref.)
Plasma-membrane-bound macromolecules are dynamically aggregated to form non-random codistribution patterns of selected functional elements. Do pattern recognition processes govern antigen presentation and intercellular interactions? Vereb G, et al. **J Mol Recognit** 1995 Jul–Aug; 8(4):237–46 (78 ref.)
Metabolic coupling between glia and neurons. Tascopoulos M, et al. **J Neurosci** 1996 Feb 1;16(3):877–85 (98 ref.)
Unique growth properties of neonatal pulmonary vascular cells: importance of time- and site-specific responses, cell–cell interaction, and synergy. Dempsey EC, et al. **J Perinatol** 1996 Mar–Apr;16(2 Pt 2 Su):S2–11 (67 ref.)
Cell–cell interactions in the testis of teleosts and elasmobranchs. Loir M, et al. **Microsc Res Tech** 1995 Dec 15;32(6):533–52 (93 ref.)
Anterior pituitary cells: getting to know their neighbors. Perez FM, et al. **Mol Cell Endocrinol** 1995 Jun;111(2):C1–6 (41 ref.)
Intercellular communication and carcinogenesis. Yamasaki H, et al. **Mutat Res** 1995 Dec;333(1–2):181–8 (49 ref.)
Intercellular communication in the brain: wiring versus volume transmission. Agnati LF, et al. **Neuroscience** 1995 Dec;69(3):711–26 (159 ref.)
Plasmodesmata: plant channels for molecules on the move [see comments] Zambryski P. **Science** 1995 Dec 22; 270(5244):1943–4 (15 ref.) Comment in: Science 1995 Dec 22;270(5244):1980–3. Comment in: Science 1995 Dec 22;270(5244):1983–5.
Role of blocked gap junctional intercellular communication in non-genotoxic carcinogenesis. Mesnil M, et al. **Toxicol Lett** 1995 Dec;82–83:701–6 (27 ref.)
Cell–cell interactions and oocyte growth. Canipari R. **Zygote** 1994 Nov;2(4):343–5 (31 ref.)
[Receptors—one component of intercellular communication pathways] Mysliveček J. **Cesk Fysiol** 1996 Jun;45(2):99–111 (38 ref.) (Eng. Abstr.) **(Cze)**

DRUG EFFECTS

The Gerhard Zbinden Memorial Lecture. Alteration of cell signalling in chemical toxicity. Nicotera P. **Arch Toxicol Suppl** 1996;18:3–11 (46 ref.)

Modulation of gap junctional intercellular communication by phosphorylation: effects of growth factors, kinase activators and phosphatase inhibitors. Mikalsen SO, et al. **Prog Clin Biol Res** 1995;391:425–38 (72 ref.)

IMMUNOLOGY

T-cell recognition of antigen. A process controlled by transient intermolecular interactions. Boniface JJ, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:62–9 (34 ref.)

Adhesion molecules in host defense. Etzioni A. **Clin Diagn Lab Immunol** 1994 Jan;1(1):1–4 (41 ref.)

Interplay of T cells and cytokines in the context of enzymatically modified extracellular matrix. Gilat D, et al. **Immunol Today** 1996 Jan;17(1):16–20 (40 ref.)

Thymocyte–stromal–cell interactions and T–cell selection. Owen JJ, et al. **Immunol Today** 1995 Jul;16(7):336–8 (9 ref.)

Immune–neuroendocrine interactions. Savino W, et al. **Immunol Today** 1995 Jul;16(7):318–22 (27 ref.)

PHYSIOLOGY

Rational problems associated with the development of cellular approaches in controlling HIV spread. Bourinbaiar AS, et al. **Adv Exp Med Biol** 1995;374:71–89 (142 ref.)

Role of material surfaces in regulating bone and cartilage cell response. Boyan BD, et al. **Biomaterials** 1996 Jan; 17(2):137–46 (94 ref.)

Intracellular signalling mechanisms of interleukin 1 and tumour necrosis factor: possible targets for therapy. Saklatvala J. **Br Med Bull** 1995 Apr;51(2):402–18 (69 ref.)

Talking through walls: signaling in plant development. Dangl JL, et al. **Cell** 1995 Dec 29;83(7):1071–7 (35 ref.)

The gap junction communication channel. Kumar NM, et al. **Cell** 1996 Feb 9;84(3):381–8 (61 ref.)

Emerging multipotent aspects of hepatocyte growth factor. Matsumoto K, et al. **J Biochem (Tokyo)** 1996 Apr; 119(4):591–600 (139 ref.)

ADAM, a novel family of membrane proteins containing A Disintegrin And Metalloprotease domain: multipotential functions in cell–cell and cell–matrix interactions. Wolfsberg TG, et al. **J Cell Biol** 1995 Oct;131(2):275–8 (22 ref.)

Structural and molecular determinants of intercellular coupling in cardiac myocytes. Kanter HL, et al. **Microsc Res Tech** 1995 Aug 1;31(5):357–63 (32 ref.)

Ocular lens gap junctions: protein expression, assembly, and structure–function analysis. Kistler J, et al. **Microsc Res Tech** 1995 Aug 1;31(5):347–56 (60 ref.)

Cell–context signalling. Pennell RI, et al. **Philos Trans R Soc Lond B Biol Sci** 1995 Oct 30; 350(1331):87–93 (48 ref.)

Alterations in cell signaling and related effector functions in T lymphocytes in burn/trauma/septic injuries [editorial] Sayeed MM. **Shock** 1996 Mar;5(3):157–66 (111 ref.)

Gap junction communication and cell adhesion in development. DeHaan RL. **Zygote** 1994 Aug;2(3):183–8 (71 ref.)

[The vascular bed of the skin. Integration site of endogenous and exogenous stimuli] Heckmann M. **Hautarzt** 1996 Jun; 47(6):417–21 (37 ref.) (Eng. Abstr.) **(Ger)**

CELL COMPARTMENTATION

Synaptic targeting of glutamate receptors. Ehlers MD, et al. **Curr Opin Cell Biol** 1996 Aug;8(4):484–9 (54 ref.)

Biogenesis of mitochondrial proteins. Lill R, et al. **Curr Opin Cell Biol** 1996 Aug;8(4):505–12 (62 ref.)

Convergence of model systems for peroxisome biogenesis. Subramani S. **Curr Opin Cell Biol** 1996 Aug;8(4):513–8 (52 ref.)

Compartmentalization of specific pre–mRNA metabolism: an emerging view. Moen PT Jr, et al. **Hum Mol Genet** 1995; 4 Spec No:1779–89 (80 ref.)

PHYSIOLOGY

Regulation of organelle biogenesis. Nunnari J, et al. **Cell** 1996 Feb 9;84(3):389–94 (73 ref.)

Phosphate metabolism: contribution of different cellular compartments. Dennis VW. **Kidney Int** 1996 Apr; 49(4):938–42 (33 ref.)

[Low–grade non–Hodgkin's lymphomas and their cytofunctional correlation with peripheral compartments of normal lymphoid tissue] Sánchez Fayos J, et al. **Rev Clin Esp** 1995 Dec;195(12):864–72 (47 ref.) **(Spa)**

CELL COUNT

see related
BLOOD CELL COUNT
SPERM COUNT

METHODS

Methods for determining numbers of cells and synapses: a case for more uniform standards of review. Coggeshall RE, et al. **J Comp Neurol** 1996 Jan 1;364(1):6–15 (30 ref.)

CELL CULTURE

Interest and limits of human tissue and cell use in pharmacotoxicology. Potier M, et al. **Cell Biol Toxicol** 1995 Aug;11(3–4):133–9 (30 ref.)

Cellular engineering—prospects for sensing and processing. Rolfe P. **Technol Health Care** 1996 Apr;4(1):9–13 (7 ref.)

METHODS

In vitro modeling of the bone/implant interface. Davies JE. **Anat Rec** 1996 Jun;245(2):426–45 (94 ref.)

Culture methods for the detection of minimal tumor contamination of hematopoietic harvests: a review. Sharp JG, et al. **J Hematother** 1995 Jun;4(3):141–8 (53 ref.)

Retinal cultures. Finlay D, et al. **Methods Cell Biol** 1996; 51:265–83 (23 ref.)

Basic culture methods. Lewis JA, et al. **Methods Cell Biol** 1995;48:3–29 (35 ref.)

CELL CYCLE

Cell cycle control in fission yeast and mammals: identification of new regulatory mechanisms. Okayama H, et al. **Adv Cancer Res** 1996;69:17–62 (246 ref.)

Cell cycle–related protein kinases and T cell death. Lahti JM, et al. **Adv Exp Med Biol** 1995;376:247–58 (84 ref.)

Cell growth signal transduction is quantal. Smith KA. **Ann N Y Acad Sci** 1995 Sep 7;766:263–71 (27 ref.)

Cell cycle regulation in Aspergillus by two protein kinases. Osmani SA, et al. **Biochem J** 1996 Aug 1;317 (Pt 3):633–41 (127 ref.)

E2F and the molecular mechanisms of early cell–cycle control. La Thangue NB. **Biochem Soc Trans** 1996 Feb; 24(1):54–9 (29 ref.)

Cyclin from sea urchins to HeLas: making the human cell cycle. Pines J. **Biochem Soc Trans** 1996 Feb;24(1):15–33 (235 ref.)

Calcium signalling and cell proliferation. Berridge MJ. **Bioessays** 1995 Jun;17(6):491–500 (71 ref.)

Tumour suppressors, kinases and clamps: how p53 regulates the cell cycle in response to DNA damage. Cox LS, et al. **Bioessays** 1995 Jun;17(6):501–8 (98 ref.)

Cell shape and chromosome partition in prokaryotes or, why E. coli is rod–shaped and haploid. Donachie WD, et al. **Bioessays** 1995 Jun;17(6):569–76 (32 ref.)

Cyclin–dependent protein kinases: key regulators of the eukaryotic cell cycle. Nigg EA. **Bioessays** 1995 Jun; 17(6):471–80 (95 ref.)

Cell death suffers a TKO. Osborne BA, et al. **Bioessays** 1995 Jun;17(6):557–9 (13 ref.)

Drosophila development pulls the strings of the cell cycle. Reed BH. **Bioessays** 1995 Jun;17(6):553–6 (23 ref.)

Stopped for repairs. Sanchez Y, et al. **Bioessays** 1995 Jun; 17(6):545–8 (27 ref.)

Origins of G1 arrest in senescent human fibroblasts. Stein GH, et al. **Bioessays** 1995 Jun;17(6):537–43 (66 ref.)

Human papillomavirus E6 and E7: proteins which deregulate the cell cycle. Tommasino M, et al. **Bioessays** 1995 Jun; 17(6):509–18 (62 ref.)

Overview of controls in the Escherichia coli cell cycle. Vinella D, et al. **Bioessays** 1995 Jun;17(6):527–36 (87 ref.)

G1 regulation and checkpoints operating around START in fission yeast. Woollard A, et al. **Bioessays** 1995 Jun; 17(6):481–90 (65 ref.)

Cell cycle control mechanisms and their role in cardiac growth. McGill CJ, et al. **Cardiovasc Res** 1995 Oct; 30(4):557–69 (182 ref.)

Mother and daughter are doing fine: asymmetric cell division in yeast [comment] Amon A. **Cell** 1996 Mar 8;84(5):651–4 (20 ref.) Comment on: Cell 1996 Mar 8;84(5):687–97. Comment on: Cell 1996 Mar 8;84(5):699–709. Comment on: Cell 1996 Mar 8;84(5):711–22.

A signaling pathway to translational control. Brown EJ, et al. **Cell** 1996 Aug 23;86(4):517–20 (20 ref.)

The cancer cell and the cell cycle clock. Hatakeyama M, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:1–10 (79 ref.)

Phosphorylation of transcription factors and control of the cell cycle. Boulikas T. **Crit Rev Eukaryot Gene Expr** 1995; 5(1):1–77 (524 ref.)

Cyclins, cyclin–dependent kinases and cdk inhibitors: implications in cell cycle control and cancer. MacLachlan TK, et al. **Crit Rev Eukaryot Gene Expr** 1995;5(2):127–56 (235 ref.)

Cell regulation. Innocent bystanders or chosen collaborators? Poon RY, et al. **Curr Biol** 1995 Nov 1;5(11):1243–7 (34 ref.)

Regulation of the cell cycle following DNA damage in normal and Ataxia telangiectasia cells. Lohrer HD. **Experientia** 1996 Apr 15;52(4):316–28 (186 ref.)

The stimulation of Na,K,Cl cotransport and of system A for neutral amino acid transport is a mechanism for cell volume increase during the cell cycle. Bussolati O, et al. **FASEB J** 1996 Jun;10(8):920–6 (49 ref.)

DNA damage and cell cycle checkpoints. Kaufmann WK, et al. **FASEB J** 1996 Feb;10(2):238–47 (44 ref.)

The biochemistry of programmed cell death. Kroemer G, et al. **FASEB J** 1995 Oct;9(13):1277–87 (84 ref.)

Nuclear matrix and the cell cycle. Loidl P, et al. **Int Rev Cytol** 1995;162B:377–403 (125 ref.)

Cell cycle regulation of membrane phospholipid metabolism. Jackowski S. **J Biol Chem** 1996 Aug 23;271(34):20219–22 (69 ref.)

Stepwise assembly of initiation complexes at budding yeast replication origins during the cell cycle. Diffley JF, et al. **J Cell Sci Suppl** 1995;19:67–72 (25 ref.)

Commitment to division in ciliate cell cycles. Adl SM, et al. **J Eukaryot Microbiol** 1996 Mar–Apr;43(2):77–86 (138 ref.)

Mantle cell lymphoma: a lymphoproliferative disorder associated with aberrant function of the cell cycle. Garcia–Conde J, et al. **Leukemia** 1996 Jun;10 Suppl 2:s78–83 (22 ref.)

Cell cycle arrest in response to DNA damage: lessons from yeast. Siede W. **Mutat Res** 1995 Sep;337(2):73–84 (100 ref.)

In and out of the plant cell cycle. Hirt H. **Plant Mol Biol** 1996 Jun;31(3):459–64 (29 ref.)

Mammalian G1 cyclins and cell cycle progression. Sherr CJ. **Proc Assoc Am Physicians** 1995 Jul;107(2):181–6 (57 ref.)

Cell cycle factors in the human oocyte and the intracytoplasmic injection of spermatozoa. Edwards RG. **Reprod Fertil Dev** 1995;7(2):143–53 (86 ref.)

PIK–related kinases: DNA repair, recombination, and cell cycle checkpoints. Keith CT, et al. **Science** 1995 Oct 6; 270(5233):50–1 (22 ref.)

Chromosomal control of meiotic cell division. McKim KS, et al. **Science** 1995 Dec 8;270(5242):1595–601 (53 ref.)

Cellular responses to DNA damage: cell–cycle checkpoints, apoptosis and the roles of p53 and ATM. Enoch T, et al. **Trends Biochem Sci** 1995 Oct;20(10):426–30 (45 ref.)

Multiple facets of the modulation of growth by cAMP. Roger PP, et al. **Vitam Horm** 1995;51:59–191 (801 ref.)

Meiotic cycle checkpoints in mammalian oocytes. Fulka J Jr, et al. **Zygote** 1994 Nov;2(4):351–4 (19 ref.)

Calcium and cell cycle control in early embryos. Wilding M. **Zygote** 1996 Feb;4(1):1–6 (69 ref.)

[Control of liver proliferation: structural, functional and molecular aspects] **Rabes HM. Verh Dtsch Ges Pathol** 1995; 79:61–71 (50 ref.) (Eng. Abstr.) **(Ger)**

[The cell cycle and the tumor suppressor genes] Kobayashi H. **Rinsho Byori** 1996 Jan;44(1):3–11 (35 ref.) (Eng. Abstr.) **(Jpn)**

[Change in certain physical characteristics of cells at various stages of the cell cycle] Samollova OP, et al. **Biofizika** 1995 Mar–Apr;40(2):383–8 (21 ref.) (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

The cell cycle as therapeutic target. Broxmeyer H. **Cancer Invest** 1995;13(6):617–24 (38 ref.)

Calcium–cell cycle regulator, differentiator, killer, chemopreventor, and maybe, tumor promoter. Whitfield JF, et al. **J Cell Biochem Suppl** 1995;22:74–91 (38 ref.)

Inhibitors of cyclin–dependent kinase and cancer. Biggs JR, et al. **J Mol Med** 1995 Oct;73(10):509–14 (58 ref.)

[Cell cycle regulation by anticancer agent] Nomoto T, et al. **Gan To Kagaku Ryoho** 1995 Oct;22(12):1719–23 (20 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

DNA damage responses: p53 induction, cell cycle perturbations, and apoptosis. Canman CE, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:277–86 (53 ref.)

Cell cycle checkpoints, genomic integrity, and cancer. Hartwell L, et al. **Cold Spring Harb Symp Quant Biol** 1994; 59:259–63 (30 ref.)

Role of a cell cycle regulator in hereditary and sporadic cancer. Kamb A. **Cold Spring Harb Symp Quant Biol** 1994; 59:39–47 (58 ref.)

Mammalian DNA damage–inducible genes associated with growth arrest and apoptosis. Smith ML, et al. **Mutat Res** 1996 Jun;340(2–3):109–24 (143 ref.)

Transcriptional activation of thymidine kinase, a marker for cell cycle control. Dou QP, et al. **Prog Nucleic Acid Res Mol Biol** 1996;53:197–217 (92 ref.)

[Cell cycle analysis of temperature sensitive mutants for cell growth] Nishimoto T. **Hum Cell** 1995 Sep;8(3):89–94 (20 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

The role of the cell cycle in HIV–1 infection. Zack JA. **Adv Exp Med Biol** 1995;374:27–31 (26 ref.)

The cell cycle and regulation of cancer cell growth. Leake R. **Ann N Y Acad Sci** 1996 Apr 30;784:252–62 (25 ref.)

Roles of ubiquitinylation in proteolysis and cellular regulation. Wilkinson KD. **Annu Rev Nutr** 1995;15:161–89 (136 ref.)

Cell proliferation–associated nuclear antigen defined by antibody Ki–67: a new kind of cell cycle–maintaining proteins. Duchrow M, et al. **Arch Immunol Ther Exp (Warsz)** 1995;43(2):117–21 (30 ref.)

Cell cycle regulation by the retinoblastoma family of growth inhibitory proteins. Beijersbergen RL, et al. **Biochim Biophys Acta** 1996 Jun 7;1287(2–3):103–20 (223 ref.)

Histone H4, the cell cycle and a question of integrity. Turner BM. **Bioessays** 1995 Dec;17(12):1013–5 (18 ref.)

Frontier questions about sister chromatid separation in anaphase. Yanagida M. **Bioessays** 1995 Jun;17(6):519–26 (70 ref.)

Steroidal regulation of cell cycle progression. Sutherland RL, et al. **Ciba Found Symp** 1995;191:218–28; discussion 228–34 (29 ref.)

DNA replication. Once, and only once. Li JJ. **Curr Biol** 1995

May 1;5(5):472–5 (24 ref.)
Starting the cell cycle: what's the point? Cross FR. **Curr Opin Cell Biol** 1995 Dec;7(6):790–7 (60 ref.)
The self–destructive personality of a cell cycle in transition. Deshaies RJ. **Curr Opin Cell Biol** 1995 Dec;7(6):781–9 (64 ref.)
Apoptosis and the cell cycle. Evan GI, et al. **Curr Opin Cell Biol** 1995 Dec;7(6):825–34 (84 ref.)
Budding yeast morphogenesis: signalling, cytoskeleton and cell cycle. Kron SJ, et al. **Curr Opin Cell Biol** 1995 Dec; 7(6):845–55 (84 ref.)
Plugging it in: signaling circuits and the yeast cell cycle. Wittenberg C, et al. **Curr Opin Cell Biol** 1996 Apr; 8(2):223–30 (55 ref.)
Cell cycle control of eukaryotic DNA replication. Kearsey SE, et al. **Curr Opin Genet Dev** 1996 Apr;6(2):208–14 (58 ref.)
Intermediate filament organization, reorganization, and function in the clawed frog Xenopus. Klymkowsky MW. **Curr Top Dev Biol** 1995;31:455–86 (140 ref.)
Sea urchin microtubules. Suprenant KA, et al. **Curr Top Dev Biol** 1995;31:65–99 (206 ref.)
The cellular effects of E2F overexpression. Adams PD, et al. **Curr Top Microbiol Immunol** 1996;208:79–93 (94 ref.)
Cyclin kinase inhibitors add a new dimension to cell cycle control. Yeudall WA, et al. **Eur J Cancer B Oral Oncol** 1995 Sep;31B(5):291–8 (102 ref.)
Control of cell cycle regulated histone genes during proliferation and differentiation. Stein JL, et al. **Int J Obes Relat Metab Disord** 1996 Mar;20 Suppl 3:S84–90 (67 ref.)
TGF–beta: receptors and cell cycle arrest. Saltis J. **Mol Cell Endocrinol** 1996 Feb 5;116(2):227–32 (61 ref.)
The phosphofructokinase–uncharged tRNA interaction in metabolic and cell cycle control: an interpretive review. Rabinovitz M. **Nucleic Acids Symp Ser** 1995;(33):182–9 (53 ref.)
The role of protein phosphatase type–2A in the Xenopus cell cycle: initiation of the G2/M transition. Lee TH. **Semin Cancer Biol** 1995 Aug;6(4):203–9 (39 ref.)
Control and activity of type–1 serine/threonine protein phosphatase during the cell cycle. Ludlow JW, et al. **Semin Cancer Biol** 1995 Aug;6(4):195–202 (42 ref.)
DNA structure checkpoints in fission yeast. Carr AM. **Semin Cell Biol** 1995 Apr;6(2):65–72 (33 ref.)
Cyclins of the fission yeast Schizosaccharomyces pombe. Fisher D, et al. **Semin Cell Biol** 1995 Apr;6(2):73–8 (38 ref.)
Structuring cell–cycle biology [comment] Levine K, et al. **Structure** 1995 Nov 15;3(11):1131–4 (52 ref.) Comment on: Structure 1995 Nov 15;3(11):1235–47.
[Recent problems on the endocrine and chemotherapy] Nishiya I, et al. **Hum Cell** 1995 Sep;8(3):107–14 (39 ref.) (Eng. Abstr.) **(Jpn)**
[Regulation of the cell cycle—involvement of protein inhibitors of cyclin–dependent kinases] Grzelakowska–Sztabert B. **Postepy Biochem** 1995; 41(2):80–93 (161 ref.) **(Pol)**

RADIATION EFFECTS

From targets to genes: a brief history of radiosensitivity. Steel GG. **Phys Med Biol** 1996 Feb;41(2):205–22 (84 ref.)
Cell cycle checkpoints and repair of ionizing radiation damage. Liu VF, et al. **Stem Cells (Dayt)** 1995 May;13 Suppl 1:117–28 (93 ref.)

CELL CYCLE GENES see **GENES, CDC**

CELL CYCLE PROTEINS

see related
PHOSPHOPROTEIN PHOSPHATASE
PROTEIN KINASES

[DNA replication licensing factor: MCM protein family] Takisawa H, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr; 41(4):356–61 (24 ref.) **(Jpn)**

GENETICS

Regulation of cellular proliferation effects on alteration of normal signaling pathways. Malkin D. **Med Pediatr Oncol Suppl** 1996;1:20–4 (25 ref.)

METABOLISM

DNA replication. Almost licensed. Ford C, et al. **Curr Biol** 1995 Sep 1;5(9):1009–12 (23 ref.)
Regulatory interactions among E2Fs and cell cycle control proteins. Cobrinik D. **Curr Top Microbiol Immunol** 1996; 208:31–61 (146 ref.)

PHYSIOLOGY

A signaling pathway to translational control. Brown EJ, et al. **Cell** 1996 Aug 23;86(4):517–20 (20 ref.)
Septin scaffolds and cleavage planes in Saccharomyces. Chant J. **Cell** 1996 Jan 26;84(2):187–90 (22 ref.)
Cell cycle regulatory proteins are targets for induced differentiation of transformed cells: Molecular and clinical studies employing hybrid polar compounds. Marks PA, et al. **Int J Hematol** 1996 Jan;63(1):1–17 (152 ref.)

CELL–CYCLE REGULATORY PROTEINS see **CELL CYCLE PROTEINS**

CELL DEATH

see related
APOPTOSIS
NECROSIS

Intraislet expression of inducible nitric oxide synthase and islet cell death. Kolb–Bachofen V. **Biochem Soc Trans** 1996 Feb;24(1):233–4 (14 ref.)
The permeability transition pore. Control points of a cyclosporin A–sensitive mitochondrial channel involved in cell death. Bernardi P. **Biochim Biophys Acta** 1996 Jul 18; 1275(1–2):5–9 (43 ref.)
Cell death suffers a TKO. Osborne BA, et al. **Bioessays** 1995 Jun;17(6):557–9 (13 ref.)
Neuronal death after perinatal asphyxia. de Haan HH, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Aug;61(2):123–7 (46 ref.)
Apoptosis, programmed cell death in the central nervous system. Maslińska D, et al. **Folia Neuropathol** 1995; 33(2):69–76 (76 ref.)
Cell death in cortical development: How much? Why? So what? Voyvodic JT. **Neuron** 1996 Apr;16(4):693–6 (16 ref.)
Calcium–mediated cell injury and cell death. Trump BF, et al. **New Horiz** 1996 Feb;4(1):139–50 (38 ref.)

DRUG EFFECTS

Calcium, cell death, and tumor promotion. Trump BF, et al. **Prog Clin Biol Res** 1995;391:121–31 (49 ref.)
[Agents inducing cell death of the vascular wall] Munsch B, et al. **Ann Biol Clin (Paris)** 1995;53(9):473–80 (88 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Molecular thanatopsis: a discourse on the BCL2 family and cell death. Yang E, et al. **Blood** 1996 Jul 15;88(2):386–401 (150 ref.)
The medical significance of physiological cell death. Häcker G, et al. **Med Res Rev** 1995 Jul;15(4):299–311 (100 ref.)

IMMUNOLOGY

Cell injury mediated by autoantibodies to intracellular antigens. Reichlin M. **Clin Immunol Immunopathol** 1995 Sep;76(3 Pt 1):215–9 (31 ref.)
The P2Z purinoceptor: an intriguing role in immunity, inflammation and cell death. Di Virgilio F. **Immunol Today** 1995 Nov;16(11):524–8 (37 ref.)

PHYSIOLOGY

Mechanisms of cell injury and death. Cobb JP, et al. **Br J Anaesth** 1996 Jul;77(1):3–10 (36 ref.)
The medical significance of physiological cell death. Häcker G, et al. **Med Res Rev** 1995 Jul;15(4):299–311 (100 ref.)
Physiology of cell survival and cell death: implications for organ conservation. Lang F, et al. **Nephrol Dial Transplant** 1995;10(9):1551–5 (62 ref.)
Cell death in normo– and teratogenesis. I. Cell death in normogenesis. Sandor S, et al. **Rom J Morphol Embryol** 1994 Jul–Dec;40(3–4):69–81 (79 ref.)
Cell death in normo– and teratogenesis. II. Cell death in teratogenesis. Sandor S, et al. **Rom J Morphol Embryol** 1994 Jul–Dec;40(3–4):83–91 (67 ref.)
Thymocyte and T cell apoptosis: is all death created equal? King LB, et al. **Thymus** 1994–95;23(3–4):209–30 (123 ref.)

RADIATION EFFECTS

Relationship between DNA damage, rejoining and cell killing by radiation in mammalian cells. Núñez MI, et al. **Radiother Oncol** 1996 May;39(2):155–65 (102 ref.)

CELL DEATH, PROGRAMMED see **APOPTOSIS**

CELL DEGRANULATION

see related
EXOCYTOSIS

The secretion of preformed granules by macrophages and neutrophils. Tapper H. **J Leukoc Biol** 1996 May; 59(5):613–22 (128 ref.)

IMMUNOLOGY

Eosinophils in allergy: role in disease, degranulation, and cytokines. Martin LB, et al. **Int Arch Allergy Immunol** 1996 Mar;109(3):207–15 (147 ref.)

CELL DENSITY see **CELL COUNT**

CELL DIFFERENTIATION

see related
ANTIGENS, DIFFERENTIATION

Nuclear inositol lipid cycle and differentiation. Cocco L, et al. **Adv Enzyme Regul** 1995;35:23–33 (31 ref.)
Positive selection of thymocytes. Fink PJ, et al. **Adv Immunol** 1995;59:99–133 (144 ref.)
Definition of signals for neuronal differentiation. Obermeier A, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:1–17 (55 ref.)
The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation. Schoonjans K, et al. **Biochim Biophys Acta** 1996 Jul 26;1302(2):93–109 (259 ref.)
The retinoblastoma protein as a fundamental mediator of growth and differentiation signals. Chen PL, et al. **Crit Rev Eukaryot Gene Expr** 1995;5(1):79–95 (114 ref.)
Intestinal epithelial cell differentiation: new insights from mice, flies and nematodes. Simon TC, et al. **Curr Opin Genet Dev** 1995 Oct;5(5):577–86 (56 ref.)
Regulation of adipocyte gene expression and differentiation by peroxisome proliferator activated receptor gamma. Tontonoz P, et al. **Curr Opin Genet Dev** 1995 Oct; 5(5):571–6 (51 ref.)
Cell differentiation in acute myeloid leukemia. Olsson I, et al. **Eur J Haematol** 1996 Jul;57(1):1–16 (122 ref.)
Liver–enriched transcription factors and hepatocyte differentiation. Cereghini S. **FASEB J** 1996 Feb; 10(2):267–82 (101 ref.)
bcl–2: role in epithelial differentiation and oncogenesis. Lu QL, et al. **Hum Pathol** 1996 Feb;27(2):102–10 (85 ref.)
Characterization of Pref–1 and its inhibitory role in adipocyte differentiation. Smas CM, et al. **Int J Obes Relat Metab Disord** 1996 Mar;20 Suppl 3:S65–72 (44 ref.)
Cell division and differentiation in avian embryos: techniques for study of early neurogenesis and myogenesis. Sechrist J, et al. **Methods Cell Biol** 1996;51:301–29 (57 ref.)
Constructing the cerebral cortex: neurogenesis and fate determination. McConnell SK. **Neuron** 1995 Oct; 15(4):761–8 (70 ref.)
Studies of in vitro differentiation with embryonic stem cells. Pedersen RA. **Reprod Fertil Dev** 1994;6(5):543–52 (139 ref.)
From uncommitted to committed embryonic cells: opportunities for their study and manipulation. Wales RG. **Reprod Fertil Dev** 1995;7(5):983–96 (203 ref.)
A new turn (or two) for twist [comment] Michelson AM. **Science** 1996 Jun 7;272(5267):1449–50 (15 ref.) Comment on: Science 1996 Jun 7;272(5267):1476–80. Comment on: Science 1996 Jun 7;272(5267):1481–4.
A toxicologic pathologist's view of apoptosis or I used to call it necrobiosis, but now I'm singing the apoptosis blues [see comments] Levin S. **Toxicol Pathol** 1995 Jul–Aug; 23(4):533–9 (34 ref.) Comment in: Toxicol Pathol 1995 Sep–Oct;23(5):617–21.
[Establishment of immortalized cell lines with differentiation phenotypes from the transgenic mice harboring temperature–sensitive SV40 T–antigen gene] Obinata M. **Seikagaku** 1995 Dec;67(12):1391–6 (11 ref.) **(Jpn)**

DRUG EFFECTS

Influence of growth factors on neuronal differentiation. Birling MC, et al. **Curr Opin Cell Biol** 1995 Dec;7(6):878–84 (66 ref.)
Gene expression and neuroblastoma cell differentiation in response to retinoic acid: differential effects of 9–cis and all–trans retinoic acid. Redfern CP, et al. **Eur J Cancer** 1995;31A(4):486–94 (73 ref.)
The insulin/Ras pathway of adipocytic differentiation of 3T3 L1 cells: dissociation between Raf–1 kinase and the MAPK/RSK cascade. Porras A, et al. **Int J Obes Relat Metab Disord** 1996 Mar;20 Suppl 3:S43–51 (47 ref.)
Regulation of differentiation pathway of skeletal mesenchymal cells in cell lines by transforming growth factor–beta superfamily. Yamaguchi A. **Semin Cell Biol** 1995 Jun;6(3):165–73 (53 ref.)
[Cellular growth factors (see comments)] Chettab A, et al. **Rev Mal Respir** 1996;13(2):117–21 (50 ref.) Comment in: Rev Mal Respir 1996;13(2):93–4. **(Fre)**
[On the novel differentiation–apoptosis inducers in tumor cells] Nakaya K. **Tanpakushitsu Kakusan Koso** 1996 Feb; 41(2):119–26 (38 ref.) **(Jpn)**

GENETICS

The Max transcription factor network: involvement of Mad in differentiation and an approach to identification of target genes. Hurlin PJ, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:109–16 (42 ref.)
Positive selection of T cells. Fowlkes BJ, et al. **Curr Opin Immunol** 1995 Apr;7(2):188–95 (54 ref.)
Chromosome behavior in cell differentiation: a field ripe for exploration? Therman E. **Genetics** 1995 Nov; 141(3):799–804 (41 ref.)
Leukaemogenic progression: the importance of differentiation and associated genetic events. Ho ES, et al. **Immunol Cell Biol** 1995 Jun;73(3):193–7 (52 ref.)
The regulation of stearoyl–CoA desaturase (SCD). Ntambi JM. **Prog Lipid Res** 1995;34(2):139–50 (130 ref.)
Transdifferentiation induced by gene transfer. Boukamp P. **Semin Cell Biol** 1995 Jun;6(3):157–63 (35 ref.)

IMMUNOLOGY

Self–tolerance checkpoints in B lymphocyte development. Goodnow CC, et al. **Adv Immunol** 1995;59:279–368 (475 ref.)
Positive and negative selection events during B lymphopoiesis. Melchers F, et al. **Curr Opin Immunol** 1995 Apr;7(2):214–27 (119 ref.)
Extrathymic T cell differentiation. Rocha B, et al. **Curr Opin Immunol** 1995 Apr;7(2):235–42 (55 ref.)

Cytokine production and requirements during T-cell development. Zlotnik A, et al. **Curr Opin Immunol** 1995 Apr;7(2):206–13 (53 ref.)
Life and death in germinal centers (redux). Kelsoe G. **Immunity** 1996 Feb;4(2):107–11 (102 ref.)
Expanding the role of Peyer's patches in B-cell ontogeny. Griebel PJ, et al. **Immunol Today** 1996 Jan;17(1):30–9 (76 ref.)
Tolerance sensitivity of immature-stage B cells: can developmentally regulated B cell antigen receptor (BCR) signal transduction play a role? Monroe JG. **J Immunol** 1996 Apr 15;156(8):2657–60 (38 ref.)
The role of the thymus during T-lymphocyte development in vitro. Anderson G, et al. **Semin Immunol** 1995 Jun; 7(3):177–83 (49 ref.)
B-lymphoid potential in pre-liver mouse embryo. Godin I, et al. **Semin Immunol** 1995 Jun;7(3):131–41 (70 ref.)
In-vitro models of B-lineage commitment. Kee BL, et al. **Semin Immunol** 1995 Jun;7(3):143–54 (115 ref.)
Lymphohematopoietic development from embryonic stem cells in vitro. Nakano T. **Semin Immunol** 1995 Jun; 7(3):197–203 (26 ref.)
In-vitro models of stroma-dependent lymphopoiesis. Péault B. **Semin Immunol** 1995 Jun;7(3):169–75 (76 ref.)
Development of human NK cells from the immature cell precursors. Poggi A, et al. **Semin Immunol** 1995 Apr; 7(2):61–6 (19 ref.)
In-vitro analyses of mechanisms of B-cell development. Rolink A, et al. **Semin Immunol** 1995 Jun;7(3):155–67 (72 ref.)

PHYSIOLOGY

The Max transcription factor network: involvement of Mad in differentiation and an approach to identification of target genes. Hurlin PJ, et al.
Cold Spring Harb Symp Quant Biol 1994;59:109–16 (42 ref.)
Control of adipocyte differentiation by CCAAT/enhancer binding protein alpha (C/EBP alpha). Lane MD, et al.
Int J Obes Relat Metab Disord 1996 Mar;20 Suppl 3:S91–6 (16 ref.)
Endocrine and paracrine negative regulators of adipose differentiation. Serrero G, et al.
Int J Obes Relat Metab Disord 1996 Mar;20 Suppl 3:S58–64 (33 ref.)
Control of cell cycle regulated histone genes during proliferation and differentiation. Stein JL, et al.
Int J Obes Relat Metab Disord 1996 Mar;20 Suppl 3:S84–90 (67 ref.)
The role of growth factors in vascular cell development and differentiation. Moses MA, et al. **Int Rev Cytol** 1995; 161:1–48 (315 ref.)
Clonal selection and learning in the antibody system. Rajewsky K. **Nature** 1996 Jun 27;381(6585):751–8 (182 ref.)
Cellular aspects of callosal connections and their development. Innocenti GM, et al. **Neuropsychologia** 1995 Aug;33(8):961–87 (99 ref.)
Modulation of biological tyrosine reactions by tyrosine phosphorylation. Gmeiner BM, et al.
Wien Klin Wochenschr 1995;107(22):687–9 (12 ref.)
[Role of glyoxalases and methylglyoxal in cell proliferation and differentiation] Piskorska D, et al.
Postepy Hig Med Dosw 1995;49(3):433–44 (56 ref.) (Eng. Abstr.) **(Pol)**

RADIATION EFFECTS

Review: a major component of radiation action: interference with intracellular control of differentiation. von Wangenheim KH, et al. **Int J Radiat Biol** 1995 Oct; 68(4):369–88 (145 ref.)

CELL DIVISION

see related
CELL CYCLE PROTEINS
GENES, CDC

Cell growth signal transduction is quantal. Smith KA.
Ann N Y Acad Sci 1995 Sep 7;766:263–71 (27 ref.)
Thrombin and its receptor in growth control. Van Obberghen-Schilling E, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:431–41 (85 ref.)
p53 in growth control and neoplasia. Gottlieb TM, et al. **Biochim Biophys Acta** 1996 Jun 7;1287(2–3):77–102 (357 ref.)
Negative regulation of cell growth by TGF beta. Polyak K. **Biochim Biophys Acta** 1996 Mar 18;1242(3):185–99 (244 ref.)
Calcium signalling and cell proliferation. Berridge MJ.
Bioessays 1995 Jun;17(6):491–500 (71 ref.)
Mother and daughter are doing fine: asymmetric cell division in yeast [comment] Amon A. **Cell** 1996 Mar 8;84(5):651–4 (20 ref.) Comment on: Cell 1996 Mar 8;84(5):687–97. Comment on: Cell 1996 Mar 8;84(5):699–709. Comment on: Cell 1996 Mar 8;84(5):711–22.
The retinoblastoma protein as a fundamental mediator of growth and differentiation signals. Chen PL, et al.
Crit Rev Eukaryot Gene Expr 1995;5(1):79–95 (114 ref.)
Cell division. Bud-site selection is only skin deep. Sanders SL, et al. **Curr Biol** 1995 Nov 1;5(11):1213–5 (25 ref.)
Cell proliferation and development of the Malpighian tubules in Drosophila melanogaster. Skaer H. **Exp Nephrol** 1996 Mar–Apr;4(2):119–26 (30 ref.)
Mismatch repair as an important source of new mutations in non-dividing cells. MacPhee DG. **Experientia** 1996 Apr 15;52(4):357–63 (30 ref.)
Mitogenic signal transduction in human breast cancer cells. Strobl JS, et al. **Gen Pharmacol** 1995 Dec;26(8):1643–9 (39 ref.)
Regulation of the interferon system and cell growth by the IRF transcription factors. Taniguchi T, et al.
J Cancer Res Clin Oncol 1995;121(9–10):516–20 (34 ref.)
Cell division and differentiation in avian embryos: techniques for study of early neurogenesis and myogenesis. Sechrist J, et al. **Methods Cell Biol** 1996;51:301–29 (57 ref.)
Roles of proteasomes in cell growth. Ichihara A, et al.
Mol Biol Rep 1995;21(1):49–52 (46 ref.)
A collection of cortical crescents: asymmetric protein localization in CNS precursor cells. Doe CQ, et al.
Neuron 1995 Nov;15(5):991–5 (31 ref.)
Cross-linking of cell surface receptors as a trigger or cell apoptosis and proliferation. Korystov YN.
Scanning Microsc 1995 Sep;9(3):757–62 (55 ref.)
Regulating cell proliferation: as easy as APC [comment] Peifer M. **Science** 1996 May 17;272(5264):974–5 (16 ref.) Comment on: Nature 1996 May 17;272(5264):1020–3. Comment on: Nature 1996 May 17;272(5264):1023–6.
Replicative senescence: implications for in vivo aging and tumor suppression. Smith JR, et al. **Science** 1996 Jul 5; 273(5271):63–7 (52 ref.)
Role of cell proliferation at early stages of hepatocarcinogenesis. Schwarz M, et al. **Toxicol Lett** 1995 Dec;82–83:27–32 (17 ref.)
Multiple facets of the modulation of growth by cAMP. Roger PP, et al. **Vitam Horm** 1995;51:59–191 (801 ref.)

DRUG EFFECTS

Evidence that iodolactones are the mediators of growth inhibition by iodine on the thyroid. Gärtner R, et al.
Acta Med Austriaca 1996;23(1–2):47–51 (34 ref.)
Proliferation markers. Iatropoulos MJ, et al.
Exp Toxicol Pathol 1996 Feb;48(2–3):175–81 (31 ref.)
In vitro studies to assess biocompatibility of peritoneal dialysis solutions: strengths and limitations. Breborowicz A, et al. **Perit Dial Int** 1996;16 Suppl 1:S119–23 (28 ref.)
Effect of different buffers on the biocompatibility of CAPD solutions. Schambye HT. **Perit Dial Int** 1996;16 Suppl 1:S130–6 (48 ref.)
The role of regenerative cell proliferation in chloroform-induced cancer. Butterworth BE, et al.
Toxicol Lett 1995 Dec;82–83:23–6 (27 ref.)
Role of cell proliferation in regenerative and neoplastic disease. Cohen SM. **Toxicol Lett** 1995 Dec;82–83:15–21 (20 ref.)
Cell proliferation as a determining factor for the carcinogenicity of chemicals: studies with mutagenic carcinogens and mutagenic noncarcinogens. Cunningham ML, et al. **Toxicol Lett** 1995 Dec;82–83:9–14 (25 ref.)
[Cellular growth factors (see comments)] Chettab A, et al.
Rev Mal Respir 1996;13(2):117–21 (50 ref.) Comment in: Rev Mal Respir 1996;13(2):93–4. **(Fre)**

GENETICS

Clinical implications of the p53 gene. Sidransky D, et al.
Annu Rev Med 1996;47:285–301 (89 ref.)
Connexin genes and cell growth control. Yamasaki H, et al.
Arch Toxicol Suppl 1996;18:105–14 (40 ref.)
Src and the control of cell division. Taylor SJ, et al.
Bioessays 1996 Jan;18(1):9–11 (40 ref.)
Transgenic and gene knockout mice in cancer research. Viney JL. **Cancer Metastasis Rev** 1995 Jun;14(2):77–90 (81 ref.)
Organelle inheritance. Warren G, et al. **Cell** 1996 Feb 9; 84(3):395–400 (75 ref.)
Regulation of cellular proliferation effects on alteration of normal signaling pathways. Malkin D.
Med Pediatr Oncol Suppl 1996;1:20–4 (25 ref.)
[Gene expression during replicative senescence] Ide T.
Tanpakushitsu Kakusan Koso 1996 Mar;41(3):228–36 (57 ref.) **(Jpn)**
[Genes for cellular mortality] Mitsui Y, et al.
Tanpakushitsu Kakusan Koso 1996 Mar;41(3):211–9 (44 ref.) **(Jpn)**

PHYSIOLOGY

Cavernous angioma associated with oligo-astrocytoma-like proliferation. Report of two cases and review of the literature with a reappraisal of the term "angioglioma". Palma L, et al. **Acta Neurochir (Wien)** 1995;133(3–4):169–73 (36 ref.)
Platelet-derived growth factor. Distinct signal transduction pathways associated with migration versus proliferation. Bornfeldt KE, et al. **Ann N Y Acad Sci** 1995 Sep 7; 766:416–30 (67 ref.)
Vesicle transport during cell growth and in the maintenance of cell polarity. Futerman AH, et al.
Biochem Soc Trans 1995 Aug;23(3):530–4 (40 ref.)
Phosphoinositide 3-kinase and the regulation of cell growth. Carpenter CL, et al. **Biochim Biophys Acta** 1996 Aug 8; 1288(1):M11–6 (65 ref.)
Microsatellite instability and a TGF beta receptor: clues to a growth control pathway. Benson JR, et al. **Bioessays** 1995 Dec;17(12):1009–12 (34 ref.)
How fission yeast fission in the middle. Chang F, et al.
Cell 1996 Jan 26;84(2):191–4 (20 ref.)
Septin scaffolds and cleavage planes in Saccharomyces. Chant J. **Cell** 1996 Jan 26;84(2):187–90 (22 ref.)
How do bacteria decide where to divide? Rothfield LI, et al. **Cell** 1996 Jan 26;84(2):183–6 (20 ref.)
Organelle inheritance. Warren G, et al. **Cell** 1996 Feb 9; 84(3):395–400 (75 ref.)
Cleavage plane specification in C. elegans: how to divide the spoils. White J, et al. **Cell** 1996 Jan 26;84(2):195–8 (17 ref.)
Molecular and cell biology of replicative senescence. Dimri GP, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:67–73 (28 ref.)
Inflammation. They're not just for clots anymore. Esmon CT. **Curr Biol** 1995 Jul 1;5(7):743–6 (15 ref.)
The renin-angiotensin-aldosterone system and myocardial collagen matrix remodelling in congestive heart failure. Brilla CG, et al. **Eur Heart J** 1995 Dec;16 Suppl O:107–9 (24 ref.)
The cardiomyopathy of overload: an unnatural growth response. Katz AM. **Eur Heart J** 1995 Dec;16 Suppl O:110–4 (73 ref.)
The roles of tissue inhibitors of metalloproteinases in tissue remodelling and cell growth. Edwards DR, et al.
Int J Obes Relat Metab Disord 1996 Mar;20 Suppl 3:S9–15 (59 ref.)
Control of cell cycle regulated histone genes during proliferation and differentiation. Stein JL, et al.
Int J Obes Relat Metab Disord 1996 Mar;20 Suppl 3:S84–90 (67 ref.)
The role of growth factors in vascular cell development and differentiation. Moses MA, et al. **Int Rev Cytol** 1995; 161:1–48 (315 ref.)
The prognostic significance of intimal proliferation in cardiac allograft vasculopathy: a paradigm shift. Mehra MR, et al. **J Heart Lung Transplant** 1995 Nov–Dec;14(6 Pt 2):S207–11 (20 ref.)
Insulin-like growth factor-I receptor. Its role in cell proliferation, apoptosis, and tumorigenicity. Rubin R, et al. **Lab Invest** 1995 Sep;73(3):311–31 (274 ref.)
Redox signalling and the control of cell growth and death. Powis G, et al. **Pharmacol Ther** 1995;68(1):149–73 (240 ref.)
The control of septum formation and cytokinesis in fission yeast. Simanis V. **Semin Cell Biol** 1995 Apr;6(2):79–87 (43 ref.)
Control of cell proliferation by heparan sulfate and heparin-binding growth factors. Vlodavsky I, et al.
Thromb Haemost 1995 Jul;74(1):534–40 (33 ref.)
Modulation of biological tyrosine reactions by tyrosine phosphorylation. Gmeiner BM, et al.
Wien Klin Wochenschr 1995;107(22):687–9 (12 ref.)
[Structure of chromatin and cell cycle. 3.] Santisteban MS.
Pathol Biol (Paris) 1995 Sep;43(7):639–64 (597 ref.) (Eng. Abstr.) **(Fre)**
[Past, present, and future problems in lymphoid regulation of nonlymphoid cell proliferation] Babaeva AG.
Biull Eksp Biol Med 1995 Sep;120(9):230–4 (35 ref.) **(Rus)**

CELL DIVISION CYCLE GENES see **GENES, CDC**

CELL DIVISION CYCLE PROTEINS see **CELL CYCLE PROTEINS**

CELL FRACTIONATION

see related
SUBCELLULAR FRACTIONS

CELL FUSION

see related
HYBRID CELLS

Site directed mutagenesis of the murine coronavirus spike protein. Effects on fusion. Bos EC, et al.
Adv Exp Med Biol 1995;380:283–6 (14 ref.)
MHVR-independent cell-cell spread of mouse hepatitis virus infection requires neutral pH fusion. Nash TC, et al.
Adv Exp Med Biol 1995;380:351–7 (8 ref.)

CELL GROWTH see **CELL DIVISION**

CELL GROWTH INHIBITORS see **GROWTH INHIBITORS**

CELL HYPOXIA

[Hypoxic factor and its significance in the onset of gastroduodenal diseases] Pogromov AP, et al.
Klin Med (Mosk) 1996;74(1):3–7 (117 ref.) **(Rus)**

GENETICS

Hypoxia-inducible gene expression. Fandrey J.
Respir Physiol 1995 Jul;101(1):1–10 (47 ref.)

PHYSIOLOGY

The effects of hypoxia on drug-metabolizing enzymes. Woodroofe AJ, et al. **Drug Metab Rev** 1995;27(3):471–95 (73 ref.)
Unifying theory of hypoxia tolerance: molecular/metabolic defense and rescue mechanisms for surviving oxygen lack.

CELL HYPOXIA

Hochachka PW, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9493–8 (63 ref.)
Hypoxia–inducible gene expression. Fandrey J. **Respir Physiol** 1995 Jul;101(1):1–10 (47 ref.)
[Scintigraphic evaluation of the ischemically damaged myocardium in patients with reduced left ventricular function. From clinical aspects to the cell] Schwaiger M, et al. **Z Kardiol** 1995;84 Suppl 4:115–23 (65 ref.) (Eng. Abstr.) **(Ger)**

CELL ISOLATION see **CELL SEPARATION**

CELL JUNCTIONS see **INTERCELLULAR JUNCTIONS**

CELL LINE

Production of monoclonal antibodies in COS and CHO cells. Trill JJ, et al. **Curr Opin Biotechnol** 1995 Oct;6(5):553–60 (53 ref.)

DRUG EFFECTS

Human cell lines in pharmacotoxicology. An introduction to a panel discussion. Batt AM, et al. **Cell Biol Toxicol** 1995 Aug;11(3–4):179–85 (31 ref.)

CELL LINE, TRANSFORMED

see related
CELL TRANSFORMATION, NEOPLASTIC
CELL TRANSFORMATION, VIRAL

CELL LINE, TUMOR see **TUMOR CELLS, CULTURED**

CELL LINEAGE

The polyclonal origin of myocyte lineages. Mikawa T, et al. **Annu Rev Physiol** 1996;58:509–21 (76 ref.)
Genetic tagging of cells and cell layers for studies of plant development. Spena A, et al. **Methods Cell Biol** 1995; 49:331–54 (110 ref.)

CELL-MEDIATED IMMUNITY see **IMMUNITY, CELLULAR**

CELL-MEDIATED LYMPHOLYTIC CELLS see **T-LYMPHOCYTES, CYTOTOXIC**

CELL MEMBRANE

see related
INTRACELLULAR MEMBRANES
MEMBRANE FUSION
MEMBRANE GLYCOPROTEINS
MEMBRANE LIPIDS
MEMBRANE POTENTIALS
MEMBRANE PROTEINS
NUCLEAR MEMBRANE
SYNAPTIC MEMBRANES

CHEMISTRY

A comparison of the transmembrane domains of Golgi and plasma membrane proteins. Munro S. **Biochem Soc Trans** 1995 Aug;23(3):527–30 (28 ref.)
The purification of membranes by affinity partitioning. Persson A, et al. **FASEB J** 1995 Oct;9(13):1304–10 (48 ref.)

DRUG EFFECTS

The surface glycoconjugates of parasitic protozoa: potential targets for new drugs. McConville MJ. **Aust N Z J Med** 1995 Dec;25(6):768–76 (40 ref.)
Narcosis due to environmental pollutants in aquatic organisms: residue–based toxicity, mechanisms, and membrane burdens. van Wezel AP, et al. **Crit Rev Toxicol** 1995;25(3):255–79 (94 ref.)
Membrane transport of nucleobases: interaction with inhibitors. Kraupp M, et al. **Gen Pharmacol** 1995 Oct; 26(6):1185–90 (29 ref.)

ENZYMOLOGY

Cell surface beta 1,4–galactosyltransferase. A signal transducing receptor? Dubois DH, et al. **Adv Exp Med Biol** 1995;376:105–14 (72 ref.)
Membrane sectors of F– and V–type H+–transporting ATPases. Fillingame RH. **Curr Opin Struct Biol** 1996 Aug; 6(4):491–8 (58 ref.)

METABOLISM

Analysis and modeling of substrate uptake and product release by prokaryotic and eukaryotic cells. Krämer R. **Adv Biochem Eng Biotechnol** 1996;54:31–74 (147 ref.)
Staphylococcal alpha–toxin, streptolysin–O, and Escherichia coli hemolysin: prototypes of pore–forming bacterial cytolysins. Bhakdi S, et al. **Arch Microbiol** 1996 Feb; 165(2):73–9 (45 ref.)
Capacitative calcium entry [see comments] Berridge MJ. **Biochem J** 1995 Nov 15;312 (Pt 1):1–11 (126 ref.) Comment in: Biochem J 1996 Mar 15;314 (Pt 3):1054–6.
Further evidence for multitopological localization of mammalian porin (VDAC) in the plasmalemma forming part of a chloride channel complex affected in cystic fibrosis and encephalomyopathy. Reymann S, et al. **Biochem Mol Med** 1995 Apr;54(2):75–87 (74 ref.)
Translocation of folded proteins across bacterial outer membranes: a novel secretory phenomenon. Hirst TR, et al. **Biochem Soc Trans** 1995 Nov;23(4):985–91 (46 ref.)
Transport of proteins across membranes—a paradigm in transition. Isenman L, et al. **Biochim Biophys Acta** 1995 Dec 20;1241(3):341–70 (207 ref.)
The role of the MDR protein in altered drug translocation across tumor cell membranes. Roepe PD. **Biochim Biophys Acta** 1995 Dec 20;1241(3):385–405 (135 ref.)
Electric fields at the plasma membrane level: a neglected element in the mechanisms of cell signalling. Olivotto M, et al. **Bioessays** 1996 Jun;18(6):495–504 (70 ref.)
The 1994 G. Malcolm Brown Lecture. Biological barriers and medicine. Goresky CA. **Clin Invest Med** 1995 Dec; 18(6):484–501 (23 ref.)
Steroid hormones. Membrane transporters of steroid hormones. Thompson EB. **Curr Biol** 1995 Jul 1;5(7):730–2 (12 ref.)
Receptor signalling and the regulation of endocytic membrane transport. Seaman MN, et al. **Curr Opin Cell Biol** 1996 Aug;8(4):549–56 (67 ref.)
How peptides cross biological membranes [editorial] Nussberger S, et al. **Exp Nephrol** 1995 Jul–Aug;3(4):211–8 (37 ref.)
Oxidant stress and endothelial membrane transport. Elliott SJ, et al. **Free Radic Biol Med** 1995 Nov;19(5):649–58 (98 ref.)
Cell cycle regulation of membrane phospholipid metabolism. Jackowski S. **J Biol Chem** 1996 Aug 23;271(34):20219–22 (69 ref.)
Membrane energization by proton pumps is important for compartmentalization of drugs and toxins: a new type of active transport. Moriyama Y. **J Exp Biol** 1996 Jul;199 (Pt 7):1447–54 (70 ref.)
Colicin import and pore formation: a system for studying protein transport across membranes? Lazdunski CJ. **Mol Microbiol** 1995 Jun;16(6):1059–66 (84 ref.)
How do long–chain free fatty acids cross cell membranes? [comment] Berk PD. **Proc Soc Exp Biol Med** 1996 May; 212(1):1–4 (33 ref.) Comment on: Proc Soc Exp Biol Med 1996 May;212(1):5–14. Comment on: Proc Soc Exp Biol Med 1996 May;212(1):15–23.
Fatty acids enter cells by simple diffusion [see comments] Zakim D. **Proc Soc Exp Biol Med** 1996 May;212(1):5–14 (53 ref.) Comment in: Proc Soc Exp Biol Med 1996 May;212(1):1–4.
Extracellular matrix signaling from the cellular membrane skeleton to the nuclear skeleton: a model of gene regulation. Lelièvre S, et al. **Recent Prog Horm Res** 1996;51:417–32 (54 ref.)
Phosphoinositides as regulators in membrane traffic. De Camilli P, et al. **Science** 1996 Mar 15;271(5255):1533–9 (74 ref.)
Protein sorting by transport vesicles. Rothman JE, et al. **Science** 1996 Apr 12;272(5259):227–34 (86 ref.)
Common principles of protein translocation across membranes. Schatz G, et al. **Science** 1996 Mar 15; 271(5255):1519–26 (60 ref.)
Coat proteins and vesicle budding. Schekman R, et al. **Science** 1996 Mar 15;271(5255):1526–33 (83 ref.)
The control of septum formation and cytokinesis in fission yeast. Simanis V. **Semin Cell Biol** 1995 Apr;6(2):79–87 (43 ref.)
Molecular recognition between membrane–spanning polypeptides. Shai Y. **Trends Biochem Sci** 1995 Nov; 20(11):460–4 (42 ref.)
[Aggrephores and aquaporins] Verbavatz JM. **C R Seances Soc Biol Fil** 1995;189(2):191–7 (34 ref.) (Eng. Abstr.) **(Fre)**
[Protein translocation machinery—how far it has been elucidated by membrane reconstitution approach] Watanabe M. **Seikagaku** 1995 Dec;67(12):1401–6 (18 ref.) **(Jpn)**

PHYSIOLOGY

Involvement of heat shock proteins and cellular membranes in the development of thermotolerance. Jóźwiak Z. **Arch Immunol Ther Exp (Warsz)** 1994;42(4):247–52 (70 ref.)
Membrane molecules and macrophage endocytosis: scavenger receptor and macrosialin as markers of plasma–membrane and vacuolar functions. da Silva RP, et al. **Biochem Soc Trans** 1996 Feb;24(1):220–4 (17 ref.)
Lipids and membrane function in green algae. Thompson GA Jr. **Biochim Biophys Acta** 1996 Jul 12;1302(1):17–45 (183 ref.)
Moving membrane up to the front of migrating cells. Bretscher MS. **Cell** 1996 May 17;85(4):465–7 (18 ref.)
Membrane dynamics in endocytosis. Robinson MS, et al. **Cell** 1996 Jan 12;84(1):13–21 (22 ref.)
The plasma membrane calcium pump—a physiological perspective on its regulation. Monteith GR, et al. **Cell Calcium** 1995 Dec;18(6):459–70 (113 ref.)
Cell surface organization by the membrane skeleton. Kusumi A, et al. **Curr Opin Cell Biol** 1996 Aug;8(4):566–74 (76 ref.)
Caveolae and caveolins. Parton RG. **Curr Opin Cell Biol** 1996 Aug;8(4):542–8 (60 ref.)
Cell surface hydrophobicity and medically important fungi. Hazen KC, et al. **Curr Top Med Mycol** 1995;6:1–31 (157 ref.)
Membrane mechanisms and intracellular signalling in cell volume regulation. Hoffmann EK, et al. **Int Rev Cytol** 1995; 161:173–262 (500 ref.)
Lipids in biological membrane fusion. Chernomordik L, et al. **J Membr Biol** 1995 Jul;146(1):1–14 (143 ref.)
Role of translocases in the generation of phosphatidylserine asymmetry. Diaz C, et al. **J Membr Biol** 1996 May; 151(1):1–9 (99 ref.)
Optical methods to measure membrane transport processes. Verkman AS. **J Membr Biol** 1995 Nov;148(2):99–110 (87 ref.)
Involvement of CD44 and its variant isoforms in membrane–cytoskeleton interaction, cell adhesion and tumor metastasis. Bourrguignon LY, et al. **J Neurooncol** 1995 Dec;26(3):201–8 (44 ref.)
Photophysical properties of porphyrins in biological membranes. Ricchelli F. **J Photochem Photobiol B** 1995 Aug;29(2–3):109–18 (94 ref.)
Electroporation theory. Concepts and mechanisms. Weaver JC. **Methods Mol Biol** 1995;47:1–26 (64 ref.)
Electroporation theory. Concepts and mechanisms. Weaver JC. **Methods Mol Biol** 1995;55:3–28 (64 ref.)
Cellular microbiology emerging. Cossart P, et al. **Science** 1996 Jan 19;271(5247):315–6 (22 ref.)
Biophysical mechanisms of cell membrane damage in electrical shock. Lee RC, et al. **Semin Neurol** 1995 Dec; 15(4):367–74 (28 ref.)
[Physiological importance of plasmalemmal caveola] Fujimoto T. **Seikagaku** 1995 Dec;67(12):1396–401 (15 ref.) **(Jpn)**

RADIATION EFFECTS

Utility of biological membranes as indicators for radiation exposure: alterations in membrane structure and function over time. Dainiak N, et al. **Stem Cells (Dayt)** 1995 May; 13 Suppl 1:142–52 (43 ref.)

ULTRASTRUCTURE

Structural organization of the cell surface of pathogenic protozoa. De Souza W. **Micron** 1995;26(5):405–30 (156 ref.)
A structural vignette common to voltage sensors and conduction pores: canaliculi. Goldstein SA. **Neuron** 1996 Apr;16(4):717–22 (52 ref.)

VIROLOGY

Influenza viruses and cell membranes. Skehel JJ, et al. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 2):S13–5 (20 ref.)

CELL MEMBRANE LIPIDS see **MEMBRANE LIPIDS**

CELL MEMBRANE PERMEABILITY

Intestinal permeability in Crohn's disease. Franchimont D, et al. **Acta Gastroenterol Belg** 1996 Jan–Mar;59(1):15–9 (35 ref.)
Cytokine patterns in the effluent of continuous ambulatory peritoneal dialysis: relationship to peritoneal permeability. Zemel D, et al. **Blood Purif** 1996;14(2):198–216 (171 ref.)
Diffusional water permeability of mammalian red blood cells. Benga G, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1995 Dec; 112(4):653–9 (54 ref.)

PHYSIOLOGY

Regulation of tight–junction permeability during nutrient absorption across the intestinal epithelium. Ballard ST, et al. **Annu Rev Nutr** 1995;15:35–55 (105 ref.)
Airway permeability. Persson CG, et al. **Clin Exp Allergy** 1995 Sep;25(9):807–14 (56 ref.)
Aquaporin water channels: unanswered questions and unresolved controversies. Agre P, et al. **Curr Opin Cell Biol** 1995 Aug;7(4):472–83 (84 ref.)
Nucleobase and nucleoside transport in mammalian cells. Kraupp M, et al. **Wien Klin Wochenschr** 1995; 107(22):677–80 (36 ref.)

CELL MEMBRANE PROTEINS see **MEMBRANE PROTEINS**

CELL MOVEMENT

Lymphocyte migration following bone marrow transplantation. Sackstein R. **Ann N Y Acad Sci** 1995 Dec 29;770:177–88 (65 ref.)
Traffic of hematogenous cells through the central nervous system. Williams KC, et al. **Curr Top Microbiol Immunol** 1995;202:221–45 (156 ref.)
Stimulation and regulation of tumor cell motility in invasion and metastasis. Levine MD, et al. **EXS** 1995;74:157–79 (135 ref.)
Specificity of hematopoietic stem cell homing. Hardy CL, et al. **Hematol Oncol** 1996 Mar;14(1):17–27 (69 ref.)
Shape oscillations of human neutrophil leukocytes: characterization and relationship to cell motility. Ehrengruber MU, et al. **J Exp Biol** 1996 Apr;199 (Pt 4):741–7 (46 ref.)
Hyaluronan: RHAMM mediated cell locomotion and signaling in tumorigenesis. Hall CL, et al. **J Neurooncol** 1995 Dec;26(3):221–9 (84 ref.)

Manipulations of neural crest cells or their migratory pathways. Bronner-Fraser M. **Methods Cell Biol** 1996; 51:61–79 (17 ref.)
Migration and adhesion assays. Lallier T. **Methods Cell Biol** 1996;51:285–99 (3 ref.)
Radial versus tangential migration of neuronal clones in the developing cerebral cortex [comment] Rakic P. **Proc Natl Acad Sci U S A** 1995 Dec 5;92(25):11323–7 (61 ref.) Comment on: Proc Natl Acad Sci U S A 1995 Dec 5;92(25):11676–80.
[Morphological analysis of NCAM-180 deficient mouse brain—polysialic acid moiety and neuronal migration] Ono K. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2188–96 (44 ref.) **(Jpn)**
[Lymphocytic migration and related adhesion molecules] Hajos SE. **Rev Argent Microbiol** 1995 Jan–Mar;27(1):38–55 (43 ref.) **(Spa)**

IMMUNOLOGY

The gut associated addressins: lymphocyte homing in the gut. De Keyser F, et al. **Baillieres Clin Rheumatol** 1996 Feb;10(1):25–39 (65 ref.)
Structure and function of adhesion receptors in leukocyte trafficking. Hogg N, et al. **Immunol Today** 1995 Jul; 16(7):327–30 (42 ref.)
The beta 7 integrins in mucosal homing and retention. Shaw SK, et al. **Semin Immunol** 1995 Oct;7(5):335–42 (45 ref.)
VLA-4 and lymphocyte trafficking in immune-inflammatory states: novel therapeutic approaches in allograft arteriopathy. Molossi S, et al. **Springer Semin Immunopathol** 1995;16(4):443–65 (225 ref.)

PHYSIOLOGY

Cellular adhesiveness, contractility, and traction: stick, grip, and slip control. Opas M. **Biochem Cell Biol** 1995 Jul–Aug; 73(7–8):311–6 (80 ref.)
The role of actin filament barbed-end exposure in cytoskeletal dynamics and cell motility. Barkalow K, et al. **Biochem Soc Trans** 1995 Aug;23(3):451–6 (40 ref.)
Rho, rac and cdc42 GTPases: regulators of actin structures, cell adhesion and motility. Nobes CD, et al. **Biochem Soc Trans** 1995 Aug;23(3):456–9 (16 ref.)
The thymic nurse cell complex: an in vitro model for extracellular matrix-mediated intrathymic T cell migration. Villa-Verde DM, et al. **Braz J Med Biol Res** 1995 Aug; 28(8):907–12 (35 ref.)
Growth factor regulation of integrin-mediated cell motility. Matsumoto K, et al. **Cancer Metastasis Rev** 1995 Sep; 14(3):205–17 (89 ref.)
Moving membrane up to the front of migrating cells. Bretscher MS. **Cell** 1996 May 17;85(4):465–7 (18 ref.)
Cell migration: a physically integrated molecular process. Lauffenburger DA, et al. **Cell** 1996 Feb 9;84(3):359–69 (103 ref.)
Actin-based cell motility and cell locomotion. Mitchison TJ, et al. **Cell** 1996 Feb 9;84(3):371–9 (76 ref.)
Regulation of ciliary beat frequency by a dynein light chain. Hamasaki T, et al. **Cell Motil Cytoskeleton** 1995;32(2):121–4 (27 ref.)
Biophysical aspects and modelling of ciliary motility. Holwill ME, et al. **Cell Motil Cytoskeleton** 1995;32(2):114–20 (31 ref.)
Actin cytoskeleton. Setting the pace of cell movement. Barkalow K, et al. **Curr Biol** 1995 Sep 1;5(9):1000–2 (11 ref.)
Adhesion in cell migration. Huttenlocher A, et al. **Curr Opin Cell Biol** 1995 Oct;7(5):697–706 (137 ref.)
Cytoskeleton in teleost eggs and early embryos: contributions to cytoarchitecture and motile events. Hart NH, et al. **Curr Top Dev Biol** 1995;31:343–81 (144 ref.)
The use of computers in understanding how animal cells crawl. Soll DR. **Int Rev Cytol** 1995;163:43–104 (118 ref.)
Lineage, migration, and fate determination of postnatal subventricular zone cells in the mammalian CNS. Goldman JE. **J Neurooncol** 1995;24(1):61–4 (15 ref.)
New insights into directed cell migration: characteristics and mechanisms. Gruler H. **Nouv Rev Fr Hematol** 1995; 37(5):255–65 (43 ref.)
Role of adhesion molecules in the pathogenesis of rheumatoid arthritis. Liao HX, et al. **Rheum Dis Clin North Am** 1995 Aug;21(3):715–40 (150 ref.)
Rapid epithelial restitution in the stomach: an updated perspective. Lacy ER. **Scand J Gastroenterol Suppl** 1995; 210:6–8 (18 ref.)
Cell surface chondroitin sulfate proteoglycans in tumor cell adhesion, motility and invasion. Iida J, et al. **Semin Cancer Biol** 1996 Jun;7(3):155–62 (64 ref.)
Alpha 4-integrin-dependent emigration of monocytes. Chuluyan HE, et al. **Springer Semin Immunopathol** 1995; 16(4):391–404 (82 ref.)
[The function of antigen presentation of dendritic cells] Péguet-Navarro J. **Pathol Biol (Paris)** 1995 Dec; 43(10):863–70 (54 ref.) (Eng. Abstr.) **(Fre)**
[Adhesion and migration of epidermal dendritic cells] Staquet MJ. **Pathol Biol (Paris)** 1995 Dec;43(10):858–62 (41 ref.) (Eng. Abstr.) **(Fre)**

CELL NUCLEOLUS

METABOLISM

The small nucleolar RNAs. Maxwell ES, et al. **Annu Rev Biochem** 1995;64:897–934 (196 ref.)
Small RNA chaperones for ribosome biogenesis. Steitz JA, et al. **Science** 1995 Dec 8;270(5242):1626–7 (16 ref.)
Small nucleolar RNAs guide ribosomal RNA methylation. Tollervey D. **Science** 1996 Aug 23;273(5278):1056–7 (13 ref.)

PHYSIOLOGY

The nucleolus. Shaw PJ, et al. **Ann Rev Cell Dev Biol** 1995; 11:93–121 (202 ref.)

CELL NUCLEUS

see related
CELL COMPARTMENTATION

Can nucleated erythrocytes found in maternal venous blood be used in the noninvasive prenatal diagnosis of fetal chromosome abnormalities? Slunga-Tallberg A, et al. **Eur J Hum Genet** 1995;3(4):264–70 (46 ref.)
The nuclear status of human sperm cells. Dadoune JP. **Micron** 1995;26(4):323–45 (182 ref.)
Theory and practice of stereological techniques applied to the estimation of cell number and nuclear volume in the testis. Wreford NG. **Microsc Res Tech** 1995 Dec 1; 32(5):423–36 (48 ref.)

CHEMISTRY

The dynamic properties and possible functions of nuclear lamins. Moir RD, et al. **Int Rev Cytol** 1995;162B:141–82 (190 ref.)
Molecular analysis of the coiled body. Bohmann K, et al. **J Cell Sci Suppl** 1995;19:107–13 (64 ref.)

ENZYMOLOGY

Biochemical properties and function of poly(ADP-ribose) glycohydrolase. Desnoyers S, et al. **Biochimie** 1995; 77(6):433–8 (44 ref.)

GENETICS

Contributions of nuclear architecture to transcriptional control. Stein GS, et al. **Int Rev Cytol** 1995;162A:251–78 (196 ref.)
The nuclear response to cAMP: role of transcription factor CREM. Lalli E, et al. **Philos Trans R Soc Lond B Biol Sci** 1996 Feb 29; 351(1336):201–9 (50 ref.)

IMMUNOLOGY

Nuclear changes in the cytotoxic T lymphocyte-induced model of apoptosis. Sellins KS, et al. **Immunol Rev** 1995 Aug;146:241–66 (104 ref.)

METABOLISM

Nuclear inositol lipid cycle and differentiation. Cocco L, et al. **Adv Enzyme Regul** 1995;35:23–33 (31 ref.)
The regulation of protein transport to the nucleus by phosphorylation. Jans DA. **Biochem J** 1995 Nov 1;311 (Pt 3):705–16 (169 ref.)
The signal transduction pathway leading from the toll receptor to nuclear localization of dorsal transcription factor. Gay NJ, et al. **Biochem Soc Trans** 1996 Feb; 24(1):35–8 (26 ref.)
Importins/karyopherins meet nucleoporins. Hurt EC. **Cell** 1996 Feb 23;84(4):509–15 (44 ref.)
Regulation of nuclear calcium concentration. Meyer T, et al. **Ciba Found Symp** 1995;188:252–62; discussion 262–6 (32 ref.)
HIV-1 virology. Simply Marvelous nuclear transport. Goldfarb DS. **Curr Biol** 1995 Jun 1;5(6):570–3 (19 ref.)
Transcriptional control by protein phosphorylation: signal transmission from the cell surface to the nucleus. Karin M, et al. **Curr Biol** 1995 Jul 1;5(7):747–57 (102 ref.)
Protein translocation: nuclear export—out of the dark. Moore MS. **Curr Biol** 1996 Feb 1;6(2):137–40 (20 ref.)
Nuclear pores and macromolecular assemblies involved in nucleocytoplasmic transport. Stewart M, et al. **Curr Opin Struct Biol** 1996 Apr;6(2):162–5 (43 ref.)
Protein import into the nucleus. Schlenstedt G. **FEBS Lett** 1996 Jun 24;389(1):75–9 (89 ref.)
Intracellular structure and nucleocytoplasmic transport. Agutter PS. **Int Rev Cytol** 1995;162B:183–224 (182 ref.)
Targeting and association of proteins with functional domains in the nucleus: the insoluble solution. Leonhardt H, et al. **Int Rev Cytol** 1995;162B:303–35 (161 ref.)
The architectural organization of nuclear metabolism. Nickerson JA, et al. **Int Rev Cytol** 1995;162A:67–123 (303 ref.)
Protein kinases in the control of mitosis: focus on nucleocytoplasmic trafficking. Gallant P, et al. **J Cell Sci Suppl** 1995;19:21–8 (86 ref.)
Extracellular matrix signaling from the cellular membrane skeleton to the nuclear skeleton: a model of gene regulation. Lelièvre S, et al. **Recent Prog Horm Res** 1996;51:417–32 (54 ref.)
Nucleocytoplasmic transport. Görlich D, et al. **Science** 1996 Mar 15;271(5255):1513–8 (77 ref.)
Nucleocytoplasmic shuttling of steroid receptors. Defranco DB, et al. **Vitam Horm** 1995;51:315–38 (86 ref.)

PATHOLOGY

Nuclear texture measurements in image cytometry. Doudkine A, et al. **Pathologica** 1995 Jun;87(3):286–99 (26 ref.)

PHYSIOLOGY

Protein import into the nucleus: an integrated view. Hicks GR, et al. **Ann Rev Cell Dev Biol** 1995;11:155–88 (230 ref.)
The structural basis of nuclear function. Jackson DA, et al. **Int Rev Cytol** 1995;162A:125–49 (121 ref.)
Molecular analysis of the coiled body. Bohmann K, et al. **J Cell Sci Suppl** 1995;19:107–13 (64 ref.)
Stability of the mammalian sperm nucleus. Yanagimachi R. **Zygote** 1994 Nov;2(4):383–4 (15 ref.)
[Nuclear bodies—their structure and function in the correction of malignant differentiation in neoplastic cells] Hod I. **Harefuah** 1996 Apr 15;130(8):527–31 (26 ref.) **(Heb)**

TRANSPLANTATION

Germ-line therapy to cure mitochondrial disease: protocol and ethics of in vitro ovum nuclear transplantation. Rubenstein DS, et al. **Camb Q Healthc Ethics** 1995 Summer; 4(3):316–39 (101 ref.)
Nuclear transplantation in mammalian eggs and embryos. Sun FZ, et al. **Curr Top Dev Biol** 1995;30:147–76 (137 ref.)
Progress in cloning embryos from domesticated livestock. Prather RS. **Proc Soc Exp Biol Med** 1996 May;212(1):38–43 (68 ref.)

ULTRASTRUCTURE

Impact of rearrangements on function and position of chromosomes in the interphase nucleus and on human genetic disorders. Qumsiyeh MB. **Chromosome Res** 1995 Dec;3(8):455–65 (157 ref.)
The polytene nucleus in morphological, cytochemical, and functional studies of messenger RNA transcription, processing, and transportation. Vázquez Nin GH, et al. **Eur J Histochem** 1996;40(1):7–16 (116 ref.)
Intracellular structure and nucleocytoplasmic transport. Agutter PS. **Int Rev Cytol** 1995;162B:183–224 (182 ref.)
The structural basis of nuclear function. Jackson DA, et al. **Int Rev Cytol** 1995;162A:125–49 (121 ref.)
Targeting and association of proteins with functional domains in the nucleus: the insoluble solution. Leonhardt H, et al. **Int Rev Cytol** 1995;162B:303–35 (161 ref.)
The architectural organization of nuclear metabolism. Nickerson JA, et al. **Int Rev Cytol** 1995;162A:67–123 (303 ref.)
Contributions of nuclear architecture to transcriptional control. Stein GS, et al. **Int Rev Cytol** 1995;162A:251–78 (196 ref.)
Nuclear ultrastructures associated with the RNA synthesis and processing. Raška I. **J Cell Biochem** 1995 Sep; 59(1):11–26 (46 ref.)
A chromomeric model for nuclear and chromosome structure. Cook PR. **J Cell Sci** 1995 Sep;108 (Pt 9):2927–35 (71 ref.)
On the structure of replication and transcription factories. Hughes TA, et al. **J Cell Sci Suppl** 1995;19:59–65 (64 ref.)
Stability of the mammalian sperm nucleus. Yanagimachi R. **Zygote** 1994 Nov;2(4):383–4 (15 ref.)
[Nuclear bodies—their structure and function in the correction of malignant differentiation in neoplastic cells] Hod I. **Harefuah** 1996 Apr 15;130(8):527–31 (26 ref.) **(Heb)**
[The formation of the karyosphere in the oogenesis of insects and amphibians] Gruzova MN, et al. **Tsitologiia** 1995; 37(8):744–69 (156 ref.) (Eng. Abstr.) **(Rus)**
[A morphofunctional analysis of the nuclear apparatus of the nonapeptidergic neurosecretory cells in the vertebrate hypothalamus] Polenov AL, et al. **Tsitologiia** 1996; 38(1):28–38 (55 ref.) (Eng. Abstr.) **(Rus)**

VIROLOGY

Nuclear organization of replication and gene expression in adenovirus-infected cells. Bridge E, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 1):99–117 (86 ref.)

CELL NUMBER see **CELL COUNT**

CELL POLARITY

Plasticity in epithelial polarity of renal intercalated cells: targeting of the H(+)-ATPase and band 3. Al-Awqati Q. **Am J Physiol** 1996 Jun;270(6 Pt 1):C1571–80 (67 ref.)
Virus entry and release in polarized epithelial cells. Compans RW. **Curr Top Microbiol Immunol** 1995;202:209–19 (54 ref.)
Neuronal polarity: giving neurons heads and tails. Prochiantz A. **Neuron** 1995 Oct;15(4):743–6 (26 ref.)

GENETICS

Disruption of polarized function in hepatocytes. Chipman JK, et al. **Arch Toxicol Suppl** 1996;18:115–26 (61 ref.)

CELL POLARITY

PHYSIOLOGY

Vesicle transport during cell growth and in the maintenance of cell polarity. Futerman AH, et al. **Biochem Soc Trans** 1995 Aug;23(3):530–4 (40 ref.)
Origins of cell polarity. Drubin DG, et al. **Cell** 1996 Feb 9;84(3):335–44 (89 ref.)
Cell polarity. The importance of being polar. Glotzer M, et al. **Curr Biol** 1995 Oct 1;5(10):1102–5 (21 ref.)
Generation of cell polarity in yeast. Chant J. **Curr Opin Cell Biol** 1996 Aug;8(4):557–65 (56 ref.)
Development of cell polarity in budding yeast. Govindan B, et al. **J Exp Zool** 1995 Dec 1;273(5):401–24 (209 ref.)
Mechanisms of neuronal polarity. Cid-Arregui A, et al. **Neurobiol Aging** 1995 May–Jun;16(3):239–43; discussion 243–6 (61 ref.)
Epithelial cell polarity: new perspectives. Le Gall AH, et al. **Semin Nephrol** 1995 Jul;15(4):272–84 (107 ref.)

CELL RESPIRATION

see related
OXYGEN CONSUMPTION

CELL SEGREGATION see **CELL SEPARATION**

CELL SENESCENCE see **CELL AGING**

CELL SEPARATION

see related
BLOOD COMPONENT REMOVAL
PLASMAPHERESIS

Purification and expansion of human hematopoietic stem/progenitor cells. Civin CI, et al. **Ann N Y Acad Sci** 1995 Dec 29;770:91–8 (53 ref.)

INSTRUMENTATION

[Current status of the plasmapheresis problem] Kalinin NN. **Gematol Transfuziol** 1995 Mar–Apr;40(2):46–8 (12 ref.) **(Rus)**

METHODS

Detection and isolation of rare cells. Radbruch A, et al. **Curr Opin Immunol** 1995 Apr;7(2):270–3 (22 ref.)
Umbilical cord blood as a source of hematopoietic stem cells: from research to clinical application. Almici C, et al. **Haematologica** 1995 Sep–Oct;80(5):473–9 (53 ref.)
CD34 cell separation: from basic research to clinical applications. Nadali G, et al. **Int J Clin Lab Res** 1995; 25(3):121–7 (39 ref.)
Isolating fetal nucleated red blood cells from maternal blood: the Baylor experience—1995. Simpson JL, et al. **Prenat Diagn** 1995 Oct;15(10):907–12 (19 ref.)
Strategies for the isolation and characterization of bovine embryonic stem cells. Cherny RA, et al. **Reprod Fertil Dev** 1994;6(5):569–75 (30 ref.)
Platelet production in the Old World—and the New. Murphy S, et al. **Transfusion** 1996 Aug;36(8):751–4 (30 ref.)
[Detection of hematopoietic stem cells using automated blood cell counter and flow cytometry] Takekawa K, et al. **Rinsho Byori** 1995 Jul;Suppl 99:117–22 (20 ref.) **(Jpn)**

CELL SHAPE see **CELL SIZE**

CELL SIZE

Shape oscillations of human neutrophil leukocytes: characterization and relationship to cell motility. Ehrengruber MU, et al. **J Exp Biol** 1996 Apr;199 (Pt 4):741–7 (46 ref.)
Cell shape determination: a pivotal role for Rho [comment] Bussey H. **Science** 1996 Apr 12;272(5259):224–5 (12 ref.)
Comment on: Science 1996 Apr 12;272(5259):277–9.
Comment on: Science 1996 Apr 12;272(5259):279–81.

PHYSIOLOGY

The role of cellular hydration in the regulation of cell function. Häussinger D. **Biochem J** 1996 Feb 1;313 (Pt 3):697–710 (170 ref.)
Membrane mechanisms and intracellular signalling in cell volume regulation. Hoffmann EK, et al. **Int Rev Cytol** 1995; 161:173–262 (500 ref.)
Social control of cell size: males and females are different. Fernald RD. **Prog Brain Res** 1995;105:171–7 (23 ref.)
[Changes in cell volume and modulation of their metabolism] Lietz T. **Postepy Biochem** 1996;42(1):49–56 (100 ref.) **(Pol)**

CELL SURFACE ANTIGENS see **ANTIGENS, SURFACE**

CELL SURFACE GLYCOPROTEINS see **MEMBRANE GLYCOPROTEINS**

CELL SURFACE PROTEINS see **MEMBRANE PROTEINS**

CELL SURFACE RECEPTORS see **RECEPTORS, CELL SURFACE**

CELL SURVIVAL

Enhanced cell survival and tumorigenesis. Cory S, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:365–75 (82 ref.)
Hierarchical control of lymphocyte survival. Boise LH, et al. **Science** 1996 Oct 4;274(5284):67–8 (17 ref.)

DRUG EFFECTS

In vitro studies to assess biocompatibility of peritoneal dialysis solutions: strengths and limitations. Breborowicz A, et al. **Perit Dial Int** 1996;16 Suppl 1:S119–23 (28 ref.)
Effect of different buffers on the biocompatibility of CAPD solutions. Schambye HT. **Perit Dial Int** 1996;16 Suppl 1:S130–6 (48 ref.)
Role of Fenton chemistry in thiol-induced toxicity and apoptosis. Held KD, et al. **Radiat Res** 1996 May; 145(5):542–53 (81 ref.)

GENETICS

Role of recombination enzymes in mammalian cell survival. Edelmann W, et al. **Proc Natl Acad Sci U S A** 1996 Jun 25;93(13):6225–7 (25 ref.)

IMMUNOLOGY

Life and death during lymphocyte development and function: evidence for two distinct killing mechanisms. Strasser A. **Curr Opin Immunol** 1995 Apr;7(2):228–34 (97 ref.)

PHYSIOLOGY

Physiology of cell survival and cell death: implications for organ conservation. Lang F, et al. **Nephrol Dial Transplant** 1995;10(9):1551–5 (62 ref.)
[Apoptosis—programmed cell death] Baumgartner-Parzer SM. **Wien Klin Wochenschr** 1996;108(11):311–20 (122 ref.) (Eng. Abstr.) **(Ger)**

RADIATION EFFECTS

From targets to genes: a brief history of radiosensitivity. Steel GG. **Phys Med Biol** 1996 Feb;41(2):205–22 (84 ref.)

CELL TRANSFORMATION, NEOPLASTIC

see related
ANTIGENS, DIFFERENTIATION

The role of estrogen in mammary carcinogenesis. Fishman J, et al. **Ann N Y Acad Sci** 1995 Sep 30;768:91–100 (31 ref.)
The role of the insulin-like growth factor-I receptor in cancer. LeRoith D, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:402–8 (30 ref.)
How can carcinogenesis be inhibited? Smith TJ, et al. **Ann N Y Acad Sci** 1995 Sep 30;768:82–90 (67 ref.)
Tumour heterogeneity and clonality—an old theme revisited. Fey MF, et al. **Ann Oncol** 1996 Feb;7(2):121–8 (88 ref.)
Glycerophosphoinositols as potential markers of ras-induced transformation and novel second messengers. Corda D, et al. **Anticancer Res** 1996 May–Jun;16(3B):1341–50 (86 ref.)
Ubiquitin in signal transduction and cell transformation. Isaksson A, et al. **Biochim Biophys Acta** 1996 Aug 8; 1288(1):F21–9 (73 ref.)
Melanoma formation in Xiphophorus: a model system for the role of receptor tyrosine kinases in tumorigenesis. Malitschek B, et al. **Bioessays** 1995 Dec;17(12):1017–23 (39 ref.)
Telomerase, cell immortality, and cancer. Harley CB, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:307–15 (72 ref.)
Proliferative cell senescence, transformation, and the recombination potential of the genome. Macieira-Coelho A. **Exp Gerontol** 1996 Jan–Apr;31(1–2):227–34 (28 ref.)
Epithelial–mesenchymal transitions in development and tumor progression. Birchmeier W, et al. **EXS** 1995;74:1–15 (93 ref.)
bcl-2: role in epithelial differentiation and oncogenesis. Lu QL, et al. **Hum Pathol** 1996 Feb;27(2):102–10 (85 ref.)
DNA methylation and polyamines in embryonic development and cancer. Heby O. **Int J Dev Biol** 1995 Oct;39(5):737–57 (169 ref.)
Some characteristics of neoplastic cell transformation in transgenic mice. Shvemberger IN, et al. **Int Rev Cytol** 1996; 164:37–90 (198 ref.)
Hyaluronan: RHAMM mediated cell locomotion and signaling in tumorigenesis. Hall CL, et al. **J Neurooncol** 1995 Dec;26(3):221–9 (84 ref.)
Molecular events in lung cancer. Roth JA. **Lung Cancer** 1995 Jun;12 Suppl 2:S3–15 (51 ref.)
Reversal of malignancy by the adenovirus E1a gene. Frisch SM. **Mutat Res** 1996 Feb 19;350(1):261–6 (31 ref.)
Cellular changes involved in conversion of normal to malignant breast: importance of the stromal reaction. Rønnov-Jessen L, et al. **Physiol Rev** 1996 Jan;76(1):69–125 (630 ref.)
Studies on the expression of T-(Gal beta (1–3) GalNAc alpha 1-O-R) and T-like antigens in normal and pathologic human and rat urothelium. Langkilde NC. **Scand J Urol Nephrol Suppl** 1995;176:7–46 (188 ref.)
[Choledochus carcinoma in choledochal cyst—a rarity. Presentation of the disease with a case report] Stalder PA, et al. **Swiss Surg** 1996;(3):123–6 (34 ref.) (Eng. Abstr.) **(Ger)**
[Sequential cellular and molecular changes during hepatocarcinogenesis] Bannasch P. **Verh Dtsch Ges Pathol** 1995;79:72–83 (65 ref.) (Eng. Abstr.) **(Ger)**
[Growth factors in liver regeneration and hepatocarcinogenesis] Schirmacher P, et al. **Verh Dtsch Ges Pathol** 1995;79:55–60 (47 ref.) (Eng. Abstr.) **(Ger)**
[Cyclin D1 in oncogenesis] Hosokawa Y. **Seikagaku** 1996 Mar;68(3):201–5 (15 ref.) **(Jpn)**
[The significance of tumor suppressor genes and viral oncoproteins in the onset of malignant cell transformation] Bojić I, et al. **Vojnosanit Pregl** 1995 Jul–Aug;52(4):371–6 (42 ref.) **(Scr)**
[Human oncogenic viruses. New findings] Pavan JV, et al. **Rev Fac Cien Med Univ Nac Cordoba** 1995;53(1):37–44 (35 ref.) **(Spa)**
[Molecular bases of papillomavirus and polyomavirus carcinogenesis] Taja-Chayeb L, et al. **Salud Publica Mex** 1996 Jan–Feb;38(1):47–57 (40 ref.) (Eng. Abstr.) **(Spa)**

CHEMICALLY INDUCED

A conundrum in molecular toxicology: molecular and biological changes during neoplastic transformation of human cells. Milo GE, et al. **Cell Biol Toxicol** 1995 Dec; 11(6):329–45 (32 ref.)

CHEMISTRY

Adhesion receptors in malignant transformation and dissemination of gastrointestinal tumors. Streit M, et al. **J Mol Med** 1996 May;74(5):253–68 (140 ref.)

DRUG EFFECTS

[Cellular growth factors and cancer (see comments)] Martinet Y, et al. **Rev Mal Respir** 1996;13(2):123–6 (12 ref.)
Comment in: Rev Mal Respir 1996;13(2):93–4. **(Fre)**

GENETICS

PAX and HOX in neoplasia. Stuart ET, et al. **Adv Genet** 1995;33:255–74 (92 ref.)
Clinical implications of the p53 gene. Sidransky D, et al. **Annu Rev Med** 1996;47:285–301 (89 ref.)
The cbl oncogene: a novel substrate of protein tyrosine kinases. Langdon WY. **Aust N Z J Med** 1995 Dec; 25(6):859–64 (19 ref.)
Altered adhesions in ras-transformed breast epithelial cells. Kinch MS, et al. **Biochem Soc Trans** 1995 Aug;23(3):446–50 (43 ref.)
Alterations in DNA methylation may play a variety of roles in carcinogenesis. Counts JL, et al. **Cell** 1995 Oct 6; 83(1):13–5 (18 ref.)
Molecular genetics of dysplasia in ulcerative colitis. Benhattar J, et al. **Eur J Cancer** 1995 Jul–Aug; 31A(7–8):1171–3 (15 ref.)
DCC: linking tumour suppressor genes and altered cell surface interactions in cancer? Cho KR, et al. **Eur J Cancer** 1995 Jul–Aug;31A(7–8):1055–60 (47 ref.)
Molecular defects in thyroid carcinomas: role of the RET oncogene in thyroid neoplastic transformation. Santoro M, et al. **Eur J Endocrinol** 1995 Nov;133(5):513–22 (114 ref.)
Gene regulation by NF-M and Myb during differentiation and leukemic transformation. Kowenz-Leutz E, et al. **Immunobiology** 1995 Jul;193(2–4):356–62 (15 ref.)
Leukaemogenic progression: the importance of differentiation and associated genetic events. Ho ES, et al. **Immunol Cell Biol** 1995 Jun;73(3):193–7 (52 ref.)
Biomarkers in the endometrium. Berchuck A. **J Cell Biochem Suppl** 1995;23:174–8 (32 ref.)
Fak and focal adhesions. Martin GM. **Jpn J Cancer Res** 1996 Mar;87(3):inside front cover (34 ref.)
Cancer progression and p53. Carson DA, et al. **Lancet** 1995 Oct 14;346(8981):1009–11 (23 ref.)
The molecular biology of brain tumors. Barker FG 2nd, et al. **Neurol Clin** 1995 Nov;13(4):701–21 (170 ref.)
The role of growth factor receptors in central nervous system development and neoplasia. Weiner HL. **Neurosurgery** 1995 Aug;37(2):179–93; discussion 193–4 (187 ref.)
Tumor suppressor genes: at the crossroads of molecular carcinogenesis, molecular epidemiology, and human risk assessment. Harris CC. **Prev Med** 1996 Jan–Feb;25(1):10–2 (33 ref.)
[Biology of solid cancers: breast cancer as an example. First part: genetic systems implicated in carcinogenesis] Bièche I, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996; 25(2):131–41 (37 ref.) (Eng. Abstr.) **(Fre)**
[Biology of solid cancers: breast cancer as an example. Second part: gene disregulation in breast cancer] Bièche I, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996; 25(2):142–52 (65 ref.) (Eng. Abstr.) **(Fre)**
[Hippel-Lindau syndrome and sporadic renal cell carcinomas. Pathogenesis, morphologic spectrum and molecular genetics] Brauch H, et al. **Pathologe** 1995 Sep; 16(5):321–7 (41 ref.) (Eng. Abstr.) **(Ger)**
[Tumor suppressor gene p53. Theoretical principles and their significance for pathology] Poremba C, et al. **Pathologe** 1996 May;17(3):181–8 (62 ref.) (Eng. Abstr.) **(Ger)**

METABOLISM

Alterations in glycoconjugates related to the transformation

grade of human uroepithelial cell lines. Ugorski M, et al. **Arch Immunol Ther Exp (Warsz)** 1995;43(3-4):161-6 (42 ref.)

Recent studies on mechanisms of bioactivation and detoxification of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), a tobacco-specific lung carcinogen. Hecht SS. **Crit Rev Toxicol** 1996;26(2):163-81 (83 ref.)

Role of oxygen free radicals in cancer development. Dreher D, et al. **Eur J Cancer** 1996 Jan;32A(1):30-8 (115 ref.)

Role of bile acids in colorectal carcinogenesis. Nagengast FM, et al. **Eur J Cancer** 1995 Jul-Aug;31A(7-8):1067-70 (44 ref.)

Role of short-chain fatty acids in the prevention of colorectal cancer. Scheppach W, et al. **Eur J Cancer** 1995 Jul-Aug; 31A(7-8):1077-80 (29 ref.)

Biomarkers in the ovary. Berchuck A. **J Cell Biochem Suppl** 1995;23:223-6 (20 ref.)

Interactions between Ras and Raf: key regulatory proteins in cellular transformation. Marshall M. **Mol Reprod Dev** 1995 Dec;42(4):493-9 (24 ref.)

PATHOLOGY

Cavernous angioma associated with oligo-astrocytoma-like proliferation. Report of two cases and review of the literature with a reappraisal of the term "angioglioma". Palma L, et al. **Acta Neurochir (Wien)** 1995;133(3-4):169-73 (36 ref.)

Carcinosarcoma arising in eccrine spiradenoma of the breast. Report of a case and review of the literature. Saboorian MH, et al. **Arch Pathol Lab Med** 1996 May;120(5):501-4 (19 ref.)

Malignant transformation in endometriosis of the urinary bladder: case report of clear cell adenocarcinoma. Balat O, et al. **Eur J Gynaecol Oncol** 1996;17(1):13-6 (14 ref.)

Elimination of transformed cells by normal cells: a novel concept for the control of carcinogenesis. Bauer G. **Histol Histopathol** 1996 Jan;11(1):237-55 (152 ref.)

The neuroepithelial stem cell concept: implications for neuro-oncology. Brüstle O, et al. **J Neurooncol** 1995; 24(1):57-9 (17 ref.)

Insulin-like growth factor-I receptor. Its role in cell proliferation, apoptosis, and tumorigenicity. Rubin R, et al. **Lab Invest** 1995 Sep;73(3):311-31 (274 ref.)

Preneoplastic transformation of human mammary epithelial cells. Band V. **Semin Cancer Biol** 1995 Jun;6(3):185-92 (50 ref.)

Gastric carcinoma arising from a hyperplasiogenic polyp with a diameter of less than 2 centimeters. Gschwantler M, et al. **Z Gastroenterol** 1995 Oct;33(10):610-2 (15 ref.)

[The malignant transformation of leukoplakia of the oral cavity. A review of the literature and clinical case reports] Colella G, et al. **Minerva Stomatol** 1995 Jun;44(6):291-300 (62 ref.) (Eng. Abstr.) **(Ita)**

RADIATION EFFECTS

Enhanced risks of cancer from protracted exposures to X- or gamma-rays: a radiobiological model of radiation-induced breast cancer [editorial] Elkind MM. **Br J Cancer** 1996 Jan;73(2):133-8 (54 ref.)

CELL TRANSFORMATION, VIRAL

Modulation of gene expression by adenovirus transformation. Zantema A, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 3):1-23 (158 ref.)

SV40-mediated immortalization of human fibroblasts. Ozer HL, et al. **Exp Gerontol** 1996 Jan-Apr;31(1-2):303-10 (30 ref.)

Cellular transformation by human T-cell leukemia virus type I. Ressler S, et al. **FEMS Microbiol Lett** 1996 Jul 1; 140(2-3):99-109 (60 ref.)

[Gene structure and transformation mechanism of HTLV-I] Matsumoto K. **Nippon Rinsho** 1995 Nov;53(11):2837-45 (21 ref.) (Eng. Abstr.) **(Jpn)**

[Molecular bases of papillomavirus and polyomavirus carcinogenesis] Taja-Chayeb L, et al. **Salud Publica Mex** 1996 Jan-Feb;38(1):47-57 (40 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

Role of kinases in HTLV-I transformation. Xu X, et al. **J Investig Med** 1996 Apr;44(4):113-23 (169 ref.)

PHYSIOLOGY

Assessing the role of E1A in the differential oncogenicity of group A and group C human adenoviruses. Williams J, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 3):149-75 (134 ref.)

CELL TRANSPLANTATION

see related
BLOOD COMPONENT TRANSFUSION
TRANSPLANTATION IMMUNOLOGY

Immunobiology of cellular transplantation. Gill RG, et al. **Cell Transplant** 1995 Jul-Aug;4(4):361-70 (90 ref.)

Endothelial cell transplantation. Williams SK. **Cell Transplant** 1995 Jul-Aug;4(4):401-10 (42 ref.)

The mechanism of clinical effectiveness of human fetal liver cell transfusion. Wu Z. **Chin Med J (Engl)** 1995 Sep; 108(9):650-2 (8 ref.)

Cell sources for bioartificial liver support. Stange J, et al. **Int J Artif Organs** 1996 Jan;19(1):14-7 (25 ref.)

Hepatocyte encapsulation--initial intentions and new aspects for its use in bioartificial liver support. Stange J, et al. **Int J Artif Organs** 1996 Jan;19(1):45-8 (26 ref.)

Rationale for intrastriatal grafting of striatal neuroblasts in patients with Huntington's disease. Peschanski M, et al. **Neuroscience** 1995 Sep;68(2):273-85 (159 ref.)

[Cell and gene transfers for therapeutic use into the central nervous system] Peschanski M. **Ann Endocrinol (Paris)** 1995;56(6):575-7 (17 ref.) (Eng. Abstr.) **(Fre)**

[Use of cultured fibroblasts for restoration of skin in severe burns] Sarkisov DS, et al. **Biull Eksp Biol Med** 1995 Jun; 119(6):566-70 (28 ref.) **(Rus)**

[Hepatocyte transplantation: current status] Arranz Caso JA, et al. **Med Clin (Barc)** 1996 Jan 13;106(1):27-35 (144 ref.) **(Spa)**

INSTRUMENTATION

Implantable biohybrid artificial organs. Colton CK. **Cell Transplant** 1995 Jul-Aug;4(4):415-36 (72 ref.)

LEGISLATION & JURISPRUDENCE

Cell transplantation and Federal regulation. Noguchi PD. **Cell Transplant** 1995 Jul-Aug;4(4):411-4 (4 ref.)

METHODS

Commentary on the present state of knowledge for myoblast transfer therapy [comment] Grounds MD. **Cell Transplant** 1996 May-Jun;5(3):431-3 (14 ref.) Comment on: Cell Transplant 1996 May-Jun;5(3):421-9.

PHYSIOLOGY

Glial cell transplantation and remyelination of the central nervous system. Duncan ID. **Neuropathol Appl Neurobiol** 1996 Apr;22(2):87-100 (100 ref.)

TRENDS

Use of mammalian liver cells for artificial liver support. Jauregui HO, et al. **Cell Transplant** 1996 May-Jun; 5(3):353-67 (130 ref.)

CELL VIABILITY see **CELL SURVIVAL**

CELL WALL

[A new serine protease zymogen activated by components of the fungal cell wall] Muta T. **Seikagaku** 1995 Aug; 67(8):1032-6 (15 ref.) **(Jpn)**

CHEMISTRY

Mycobacterium tuberculosis cell envelope. Lee RE, et al. **Curr Top Microbiol Immunol** 1996;215:1-27 (68 ref.)

METABOLISM

Molecular basis of cell integrity and morphogenesis in Saccharomyces cerevisiae. Cid VJ, et al. **Microbiol Rev** 1995 Sep;59(3):345-86 (463 ref.)

The control of septum formation and cytokinesis in fission yeast. Simanis V. **Semin Cell Biol** 1995 Apr;6(2):79-87 (43 ref.)

CELLOBIASES see **BETA-GLUCOSIDASE**

CELLS

Replicative senescence: an old lives' tale? Campisi J. **Cell** 1996 Feb 23;84(4):497-500 (25 ref.)

CHEMISTRY

[Reality in analysis of calcium ion concentration in single cell] Hayashi H, et al. **Nippon Seirigaku Zasshi** 1995; 57(11):441-50 (25 ref.) **(Jpn)**

[Optical measurement of intracellular calcium concentration] Konishi M, et al. **Nippon Seirigaku Zasshi** 1995;57(7):313-24 (23 ref.) **(Jpn)**

[Instruments used for measurement of intracellular calcium ions] Miyakawa A. **Nippon Seirigaku Zasshi** 1995; 57(10):401-17 (18 ref.) **(Jpn)**

[Basic study of calcium ion indicator for measurement of intracellular calcium ion] Ogawa Y, et al. **Nippon Seirigaku Zasshi** 1995;57(8-9):365-74 (54 ref.) **(Jpn)**

CYTOLOGY

Size control: the regulation of cell numbers in animal development. Raff MC. **Cell** 1996 Jul 26;86(2):173-5 (20 ref.)

Cytoarchitecture and cell growth control. Slack JK, et al. **Cell Motil Cytoskeleton** 1996;33(2):83-7 (24 ref.)

DRUG EFFECTS

The mechanisms responsible for the PTH-induced rise in cytosolic calcium in various cells are not uniform. Massry SG, et al. **Miner Electrolyte Metab** 1995;21(1-3):13-28 (75 ref.)

Calmodulin: effects of cell stimuli and drugs on cellular activation. Gnegy ME. **Prog Drug Res** 1995;45:33-65 (248 ref.)

ENZYMOLOGY

Expression and expressional control of nitric oxide synthases in various cell types. Förstermann U, et al. **Adv Pharmacol** 1995;34:171-86 (102 ref.)

Detecting enzymatic activity in cells using fluorogenic substrates. Haugland RP. **Biotech Histochem** 1995 Sep; 70(5):243-51 (17 ref.)

Novel functions of phosphatidylinositol 3-kinase in terminally differentiated cells. Nakanishi S, et al. **Cell Signal** 1995 Aug;7(6):545-57 (127 ref.)

Redox signalling and the control of cell growth and death. Powis G, et al. **Pharmacol Ther** 1995;68(1):149-73 (240 ref.)

[Kinetic analysis of enzyme reactions within cells] Nakae Y, et al. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(13):1927-35 (80 ref.) **(Jpn)**

METABOLISM

Reaction engineering methods to study intracellular metabolite concentrations. Weuster-Botz D, et al. **Adv Biochem Eng Biotechnol** 1996;54:75-108 (62 ref.)

Downregulation of cellular metabolism during environmental stress: mechanisms and implications. Hand SC, et al. **Annu Rev Physiol** 1996;58:539-63 (165 ref.)

Cellular water content and volume regulation in animal cells. Katz U. **Cell Biochem Funct** 1995 Sep;13(3):189-93 (23 ref.)

Overview of iron metabolism. Uchida T. **Int J Hematol** 1995 Dec;62(4):193-202 (74 ref.)

The fates of proteins in cells. Bohley P. **Naturwissenschaften** 1995 Dec;82(12):544-50 (112 ref.)

[Role of free radicals and antioxidants in the cell defense system] Antila E. **Duodecim** 1994;110(17):1611-9 (27 ref.) **(Fin)**

[Cell damage as reason for the formation of unsaturated fatty acid hydroperoxides] Hölzel C, et al. **Naturwissenschaften** 1995 Oct;82(10):452-60 (74 ref.) (Eng. Abstr.) **(Ger)**

PARASITOLOGY

Intracellular survival of protozoan parasites with special reference to Leishmania spp., Toxoplasma gondii and Trypanosoma cruzi. Mauël J. **Adv Parasitol** 1996;38:1-51 (250 ref.)

PATHOLOGY

[Cell damage as reason for the formation of unsaturated fatty acid hydroperoxides] Hölzel C, et al. **Naturwissenschaften** 1995 Oct;82(10):452-60 (74 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Angiotensin II in cell growth and matrix production. Hsueh WA, et al. **Adv Exp Med Biol** 1995;377:217-23 (49 ref.)

Cellular and molecular physiology of volume-sensitive anion channels. Strange K, et al. **Am J Physiol** 1996 Mar;270(3 Pt 1):C711-30 (146 ref.)

Micro-osmosis in gels, cells and enzymes. Wiggins PM. **Cell Biochem Funct** 1995 Sep;13(3):165-72 (54 ref.)

Somatostatin and its receptor. Introduction. Reichlin S. **Ciba Found Symp** 1995;190:1-6 (38 ref.)

Lipid mediator networks in cell signaling: update and impact of cytokines. Serhan CN, et al. **FASEB J** 1996 Aug; 10(10):1147-58 (62 ref.)

Membrane mechanisms and intracellular signalling in cell volume regulation. Hoffmann EK, et al. **Int Rev Cytol** 1995; 161:173-262 (500 ref.)

The role of growth factors in vascular cell development and differentiation. Moses MA, et al. **Int Rev Cytol** 1995; 161:1-48 (315 ref.)

The resting membrane potential of cells are measures of electrical work, not of ionic currents. Veech RL, et al. **Integr Physiol Behav Sci** 1995 Sep-Dec;30(4):283-307 (46 ref.)

Functional role of glycosphingolipids in cell recognition and signaling. Hakomori S, et al. **J Biochem (Tokyo)** 1995 Dec; 118(6):1091-103 (123 ref.)

The role of Notch in lateral inhibition and cell fate specification. Chitnis AB. **Mol Cell Neurosci** 1995 Aug; 6(4):311-21 (70 ref.)

Regulation of cell volume in health and disease. McManus ML, et al. **N Engl J Med** 1995 Nov 9;333(19):1260-6 (53 ref.)

Thoughts over cell biology: a commentary. Henics T. **Physiol Chem Phys Med NMR** 1995;27(2):139-44 (49 ref.)

[Regulation of cell function by level of hydration] Häussinger D. **Naturwissenschaften** 1996 Jun;83(6):264-71 (39 ref.) (Eng. Abstr.) **(Ger)**

[Cellular mechanisms of circadian clocks] Roenneberg T, et al. **Wien Med Wochenschr** 1995;145(17-18):385-9 (74 ref.) (Eng. Abstr.) **(Ger)**

[SA channels are mechanosensors of cells?] Sokabe M, et al. **Tanpakushitsu Kakusan Koso** 1996 Jan;41(1):2-13 (43 ref.) **(Jpn)**

[The general principles of cellular gravisensing] Tairbekov MG. **Izv Akad Nauk Ser Biol** 1996 Mar-Apr;(2):133-40 (41 ref.) (Eng. Abstr.) **(Rus)**

CELLS

[The formation and development of the denaturation theory of injuries and irritation] Aleksandrov VIa. **Tsitologiia** 1995; 37(12):1101–22 (124 ref.) (Eng. Abstr.) **(Rus)**

RADIATION EFFECTS

Mapping of mammalian genomes with radiation (Goss and Harris) hybrids. Leach RJ, et al. **Adv Genet** 1995;33:63–99 (82 ref.)
Cells, stress and EMFs. Smith O. **Nat Med** 1996 Jan;2(1):23–4 (13 ref.)
Cellular mechanisms of protection and repair induced by radiation exposure and their consequences for cell system responses. Feinendegen LE, et al. **Stem Cells (Dayt)** 1995 May;13 Suppl 1:7–20 (46 ref.)
[The concept of the biological action of low doses of ionizing radiation on cells] Geras'kin SA. **Radiats Biol Radioecol** 1995 Sep–Oct;35(5):571–80 (34 ref.) (Eng. Abstr.) **(Rus)**

ULTRASTRUCTURE

Biological atomic force microscopy: from microns to nanometers and beyond. Shao Z, et al. **Ann Rev Cell Dev Biol** 1995;11:241–65 (134 ref.)
Cell rounding with "rip off" detachment. Sit KH. **Histol Histopathol** 1996 Jan;11(1):215–27 (125 ref.)

CELLS, CULTURED

see related
CELL CULTURE

Micromass cultures of limb and other mesenchyme. Daniels K, et al. **Methods Cell Biol** 1996;51:237–47 (24 ref.)
Autonomic and sensory neuron cultures. Nishi R. **Methods Cell Biol** 1996;51:249–63 (11 ref.)
Cell systems for use in studies on the relationship between foreign compound metabolism and toxicity. Oesch F, et al. **Pharmacol Toxicol** 1995 May;76(5):325–7 (16 ref.)
[Simple detection of the contamination in animal cell cultures] Harasawa R, et al. **Tanpakushitsu Kakusan Koso** 1995 Nov;40(15):2361–8 (15 ref.) **(Jpn)**

CELLS, IMMOBILIZED

[Immobilization in alginate gels] Jankovský M, et al. **Vet Med (Praha)** 1996 May;41(5):159–64 (60 ref.) (Eng. Abstr.) **(Cze)**

CELLULAR INCLUSIONS see **INCLUSION BODIES**

CELLULAR NEUROBIOLOGY see **NEUROBIOLOGY**

CELLULAR PROTO-ONCOGENE PROTEINS see **PROTO-ONCOGENE PROTEINS**

CELLULASE

METABOLISM

Cellulose hydrolysis by bacteria and fungi. Tomme P, et al. **Adv Microb Physiol** 1995;37:1–81 (367 ref.)

CELLULITIS

Streptococcal infections of skin and soft tissues [see comments] Bisno AL, et al. **N Engl J Med** 1996 Jan 25; 334(4):240–5 (51 ref.) Comment in: N Engl J Med 1996 May 30;334(22):1478.
[Gastric phlegmon] Kurguzov OP, et al. **Khirurgiia (Mosk)** 1995;(6):52–5 (76 ref.) **(Rus)**

CHEMICALLY INDUCED

Injectable silicone: cause of facial nodules, cellulitis, ulceration, and migration. Rapaport MJ, et al. **Aesthetic Plast Surg** 1996 May–Jun;20(3):267–76 (34 ref.)

DIAGNOSIS

Streptococcal gangrene of the eyelids and orbit. Shayegani A, et al. **Am J Ophthalmol** 1995 Dec;120(6):784–92 (49 ref.)
Wells' syndrome in childhood: case report and review of the literature. Anderson CR, et al. **J Am Acad Dermatol** 1995 Nov;33(5 Pt 2):857–64 (19 ref.)
Necrotising soft tissue infections as a complication of chickenpox. Nathan S, et al. **Singapore Med J** 1995 Dec; 36(6):656–60 (11 ref.)

EPIDEMIOLOGY

[Soft-tissue infection caused by Aeromonas hydrophila] Ramos JM, et al. **Enferm Infecc Microbiol Clin** 1995 Oct; 13(8):469–72 (27 ref.) (Eng. Abstr.) **(Spa)**

RADIOGRAPHY

CT evaluation of soft tissue and muscle infection and inflammation: a systematic compartmental approach. Beauchamp NJ Jr, et al. **Skeletal Radiol** 1995 Jul; 24(5):317–24 (8 ref.)

CELLULOSE

see related
PAPER

CHEMISTRY

The development of advanced cellulosic fibres. Woodings CR. **Int J Biol Macromol** 1995 Dec;17(6):305–9 (31 ref.)

METABOLISM

Cellulose hydrolysis by bacteria and fungi. Tomme P, et al. **Adv Microb Physiol** 1995;37:1–81 (367 ref.)
Cellulose degradation in anaerobic environments. Leschine SB. **Annu Rev Microbiol** 1995;49:399–426 (194 ref.)
Lignocellulose degradation by Phanerochaete chrysosporium: gene families and gene expression for a complex process. Broda P, et al. **Mol Microbiol** 1996 Mar; 19(5):923–32 (78 ref.)

CEMENTOBLASTS see **DENTAL CEMENTUM**

CEMENTUM see **DENTAL CEMENTUM**

CENSUS see **DEMOGRAPHY**

CENTENARIANS see **AGED, 80 AND OVER**

CENTRAL NERVOUS SYSTEM

ABNORMALITIES

Occipital encephalocele and MURCS association: case report and review of central nervous system anomalies in MURCS patients. Lin HJ, et al. **Am J Med Genet** 1996 Jan 2; 61(1):59–62 (23 ref.)

ANATOMY & HISTOLOGY

Anatomy and electrophysiology of fast central synapses lead to a structural model for long-term potentiation. Edwards FA. **Physiol Rev** 1995 Oct;75(4):759–87 (200 ref.)

BLOOD SUPPLY

Vasculitis of the central nervous system. Calabrese LH. **Rheum Dis Clin North Am** 1995 Nov;21(4):1059–76 (89 ref.)

CHEMISTRY

Growth factors in the CNS and their effects on oligodendroglia. Kahn MA, et al. **Prog Brain Res** 1995; 105:145–69 (152 ref.)
Stress proteins: their role in the normal central nervous system and in disease states, especially multiple sclerosis. Birnbaum G. **Springer Semin Immunopathol** 1995; 17(1):107–18 (75 ref.)

CYTOLOGY

Microglia: the effector cell for reconstitution of the central nervous system following bone marrow transplantation for lysosomal and peroxisomal storage diseases. Krivit W, et al. **Cell Transplant** 1995 Jul–Aug;4(4):385–92 (71 ref.)
Traffic of hematogenous cells through the central nervous system. Williams KC, et al. **Curr Top Microbiol Immunol** 1995;202:221–45 (156 ref.)
Neuropeptide messenger plasticity in the CNS neurons following axotomy. Palkovits M. **Mol Neurobiol** 1995 Apr–Jun;10(2–3):91–103 (48 ref.)
A collection of cortical crescents: asymmetric protein localization in CNS precursor cells. Doe CQ, et al. **Neuron** 1995 Nov;15(5):991–5 (31 ref.)

DRUG EFFECTS

Physiological and toxicological actions of nitric oxide in the central nervous system. Dawson VL, et al. **Adv Pharmacol** 1995;34:323–42 (73 ref.)
Muscarinic signaling in the central nervous system. Recent developments and anesthetic implications. Durieux ME. **Anesthesiology** 1996 Jan;84(1):173–89 (171 ref.)
CNS effects and abuse liability of anabolic–androgenic steroids. Lukas SE. **Annu Rev Pharmacol Toxicol** 1996; 36:333–57 (125 ref.)
Lipid vs protein theories of alcohol action in the nervous system. Peoples RW, et al. **Annu Rev Pharmacol Toxicol** 1996;36:185–201 (112 ref.)
Introduction to functional teratology. Dencker L. **Arch Toxicol Suppl** 1996;18:51–6 (10 ref.)
Teratogenic effects of alcohol: current status of animal research and in vitro models. Guerri C. **Arch Toxicol Suppl** 1996;18:71–80 (55 ref.)
Neurosteroids: synthesis and functions in the central and peripheral nervous systems. Schumacher M, et al. **Ciba Found Symp** 1995;191:90–106; discussion 106–12 (50 ref.)
New central mediators as targets of centrally acting antihypertensive drugs. van Zwieten PA. **Clin Exp Hypertens** 1996 Apr–May;18(3–4):291–303 (38 ref.)
Involvement of cytoskeletal proteins in the mechanisms of organophosphorus ester-induced delayed neurotoxicity. Abou-Donia MB. **Clin Exp Pharmacol Physiol** 1995 May; 22(5):358–9 (5 ref.)
Serotonin: current understanding and the way forward. Dinan TG. **Int Clin Psychopharmacol** 1996 Mar;11 Suppl 1:19–21 (10 ref.)
Benzodiazepine side effects: role of pharmacokinetics and pharmacodynamics. Vgontzas AN, et al. **Pharmacology** 1995 Oct;51(4):205–23 (196 ref.)
A physiological role for GABAB receptors and the effects of baclofen in the mammalian central nervous system. Misgeld U, et al. **Prog Neurobiol** 1995 Jul;46(4):423–62 (412 ref.)
Neurotoxicity modeling for risk assessment. Kodell RL, et al. **Regul Toxicol Pharmacol** 1995 Aug;22(1):24–9 (10 ref.)

EMBRYOLOGY

Spindle orientation and asymmetric localization in Drosophila: both inscuteable? Doe CQ. **Cell** 1996 Sep 6; 86(5):695–7 (16 ref.)
Determination events in the nervous system of the vertebrate embryo. Bally-Cuif L, et al. **Curr Opin Genet Dev** 1995 Aug;5(4):450–8 (70 ref.)
Cadherin expression in the developing vertebrate CNS: from neuromeres to brain nuclei and neural circuits. Redies C. **Exp Cell Res** 1995 Oct;220(2):243–56 (187 ref.)
Sonic hedgehog: a common signal for ventral patterning along the rostrocaudal axis of the neural tube. Ericson J, et al. **Int J Dev Biol** 1995 Oct;39(5):809–16 (45 ref.)
Strategies for the generation of neuronal diversity in the developing central nervous system. McConnell SK. **J Neurosci** 1995 Nov;15(11):6987–98 (126 ref.)
Genetic mechanisms of early neurogenesis in Drosophila melanogaster. Campos-Ortega JA. **Mol Neurobiol** 1995 Apr–Jun;10(2–3):75–89 (97 ref.)
Apoptosis in the developing CNS. Naruse I, et al. **Prog Neurobiol** 1995 Oct;47(2):135–55 (152 ref.)
Induction and patterning of the vertebrate nervous system. Kelly OG, et al. **Trends Genet** 1995 Jul;11(7):273–8 (62 ref.)

ENZYMOLOGY

Transcription of the human neuronal nitric oxide synthase gene in the central nervous system is mediated by multiple promoters. Young AP, et al. **Adv Pharmacol** 1995;34:91–112 (51 ref.)
Inducible nitric oxide synthase in the central nervous system. Sparrow JR. **J Mol Neurosci** 1994–95;5(4):219–29 (95 ref.)

GROWTH & DEVELOPMENT

Expression of heparin-binding growth factors and their receptors in neural development. Wanaka A. **Kaibogaku Zasshi** 1995 Dec;70(6):512–20 (17 ref.)

IMMUNOLOGY

Immune surveillance and autoantigen recognition in the central nervous system. Sedgwick JD. **Aust N Z J Med** 1995 Dec;25(6):784–92 (46 ref.)
Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system. Steinman L. **Cell** 1996 May 3;85(3):299–302 (31 ref.)
Complement biosynthesis in the central nervous system. Barnum SR. **Crit Rev Oral Biol Med** 1995;6(2):132–46 (112 ref.)
The influence of cytokines on the central nervous system of transgenic mice. Geiger K, et al. **Curr Top Microbiol Immunol** 1996;206:101–17 (104 ref.)
The role of macrophage subpopulations in autoimmune disease of the central nervous system. Bauer J, et al. **Histochem J** 1996 Feb;28(2):83–97 (104 ref.)
Interpreting MHC class I expression and class I/class II reciprocity in the CNS: reconciling divergent findings. Lampson LA. **Microsc Res Tech** 1995 Nov 1;32(4):267–85 (101 ref.)
Multiple sclerosis: a unique immunopathological syndrome of the central nervous system. Hunter SF, et al. **Springer Semin Immunopathol** 1995;17(1):89–105 (105 ref.)
CNS antigen presentation. Hart MN, et al. **Trends Neurosci** 1995 Nov;18(11):475–81 (56 ref.)

INJURIES

Neural injury repair: hope for the future as barriers to effective CNS regeneration become clearer. Jackowski A. **Br J Neurosurg** 1995;9(3):303–17 (149 ref.)

METABOLISM

Calcium dynamics in the central nervous system. DeCoster MA. **Adv Neuroimmunol** 1995;5(3):233–9 (68 ref.)
Pharmacologic evidence for D2 dopamine receptor heterogeneity. Missale C, et al. **Adv Neurol** 1996;69:245–51 (39 ref.)
Nitric oxide in the central nervous system. Paakkari I, et al. **Ann Med** 1995 Jun;27(3):369–77 (96 ref.)
Persistent sodium current in mammalian central neurons. Crill WE. **Annu Rev Physiol** 1996;58:349–62 (77 ref.)
Low-threshold calcium currents in central nervous system neurons. Huguenard JR. **Annu Rev Physiol** 1996;58:329–48 (111 ref.)
Use of non-radioactive probes for mRNA detection by in situ hybridization: interests and applications in the central nervous system. Le Moine C, et al. **Cell Mol Biol (Noisy-le-grand)** 1995 Nov;41(7):917–23 (37 ref.)
A reappraisal of ganglioside GD3 expression in the CNS. Goldman JE, et al. **Glia** 1996 Apr;16(4):291–5 (39 ref.)
Serotonin: current understanding and the way forward. Dinan TG. **Int Clin Psychopharmacol** 1996 Mar;11 Suppl 1:19–21 (10 ref.)

Distribution and pharmacology of alpha 2-adrenoceptors in the central nervous system. MacDonald E, et al. **J Physiol Pharmacol** 1995 Sep;46(3):241-58 (104 ref.)
Genetic variation of CNS receptors--a new perspective for pharmacogenetics. Propping P, et al. **Pharmacogenetics** 1995 Oct;5(5):318-25 (75 ref.)
GABAB receptors. Kerr DI, et al. **Pharmacol Ther** 1995; 67(2):187-246 (584 ref.)
Gene expression of serotonergic neurons in the central nervous system: molecular and developmental analysis. Joh TH, et al. **Prog Brain Res** 1995;105:43-52 (31 ref.)
Nitric oxide: a radical neurotransmitter in the central nervous system. Vincent SR. **Prog Neurobiol** 1994 Jan;42(1):129-60 (485 ref.)
[Free radicals in the central nervous system] Rokyta R, et al. **Cesk Fysiol** 1996 Mar;45(1):4-12 (34 ref.) (Eng. Abstr.) **(Cze)**

MICROBIOLOGY

Entry of pathogens into the central nervous system. Tuomanen E. **FEMS Microbiol Rev** 1996 Jul;18(4):289-99 (42 ref.)

PATHOLOGY

Multiple sclerosis: a unique immunopathological syndrome of the central nervous system. Hunter SF, et al. **Springer Semin Immunopathol** 1995;17(1):89-105 (105 ref.)
[Multiple system atrophy with Lewy bodies] Tison F, et al. **Rev Neurol (Paris)** 1995 Jun-Jul;151(6-7):398-403 (35 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Evolutionary ancient roles of serotonin: long-lasting regulation of activity and development. Turlejski K. **Acta Neurobiol Exp (Warsz)** 1996;56(2):619-36 (138 ref.)
Clinical and experimental evaluation of cranial TENS in the U.S.: a review. Taylor DN. **Acupunct Electrother Res** 1995 Apr-Jul;20(2):117-32 (45 ref.)
New model for the regulation of energy balance and adiposity by the central nervous system. Kaiyala KJ, et al. **Am J Clin Nutr** 1995 Nov;62(5 Suppl):1123S-1134S (130 ref.)
Proenkephalin gene regulation in the neuroendocrine hypothalamus: a model of gene regulation in the CNS. Borsook D, et al. **Am J Physiol** 1995 Sep;269(3 Pt 1):E393-408 (203 ref.)
Muscarinic signaling in the central nervous system. Recent developments and anesthetic implications. Durieux ME. **Anesthesiology** 1996 Jan;84(1):173-89 (171 ref.)
Mechanisms and functions of serotonin neuronal systems: opportunities for neuropeptide interactions. Fuller RW. **Ann N Y Acad Sci** 1996 Mar 22;780:176-84 (61 ref.)
Tubulin expression and axonal transport in injured and regenerating neurons in the adult mammalian central nervous system. Fournier AE, et al. **Biochem Cell Biol** 1995 Sep-Oct;73(9-10):659-64 (39 ref.)
Axonal regeneration. Brecknell JE, et al. **Biol Rev Camb Philos Soc** 1996 May;71(2):227-55 (260 ref.)
Regeneration in the vertebrate central nervous system: phylogeny, ontogeny, and mechanisms. Larner AJ, et al. **Biol Rev Camb Philos Soc** 1995 Nov;70(4):597-619 (159 ref.)
Clustering membrane proteins: It's all coming together with the PSD-95/SAP90 protein family. Gomperts SN. **Cell** 1996 Mar 8;84(5):659-62 (20 ref.)
New central mediators as targets of centrally acting antihypertensive drugs. van Zwieten PA. **Clin Exp Hypertens** 1996 Apr-May;18(3-4):291-303 (38 ref.)
Schwann cells and the regrowth of axons in the mammalian CNS: a review of transplantation studies in the rat visual system. Harvey AR, et al. **Clin Exp Pharmacol Physiol** 1995 Aug;22(8):569-79 (77 ref.)
Good vibrations? Respiratory rhythms in the central control of blood pressure. Pilowsky P. **Clin Exp Pharmacol Physiol** 1995 Sep;22(9):594-604 (90 ref.)
Inhibition of cell adhesion by anti-adhesive molecules. Chiquet-Ehrismann R. **Curr Opin Cell Biol** 1995 Oct; 7(5):715-9 (46 ref.)
Regeneration in the adult mammalian CNS: guided by development. Aubert I, et al. **Curr Opin Neurobiol** 1995 Oct;5(5):625-35 (118 ref.)
Thyrotropin releasing hormone. Occurrence and role outside the central nervous system. Iversen E. **Dan Med Bull** 1995 Jun;42(3):257-68 (216 ref.)
Apoptosis, programmed cell death in the central nervous system. Maślińska D, et al. **Folia Neuropathol** 1995; 33(2):69-76 (76 ref.)
Growth hormone and its receptors in the central nervous system--location and functional significance. Nyberg F, et al. **Horm Res** 1996;45(1-2):18-22 (28 ref.)
Regulation and function of central nervous system chemokines. Glabinski AR, et al. **Int J Dev Neurosci** 1995 Jun-Jul;13(3-4):153-65 (120 ref.)
Regulation of GABAA receptor function and gene expression in the central nervous system. Morrow AL. **Int Rev Neurobiol** 1995;38:1-41 (275 ref.)
Neuromonitoring during hypothermic cardiopulmonary bypass. Gombotz H. **J Neurosurg Anesthesiol** 1995 Oct; 7(4):289-96 (82 ref.)
Modulation of NMDA and dopaminergic neurotransmissions by sigma ligands: possible implications for the treatment of psychiatric disorders. Debonnel G, et al. **Life Sci** 1996; 58(9):721-34 (179 ref.)
Physiological relevance and functional potential of central nervous system-derived cell lines. Whittemore SR, et al. **Mol Neurobiol** 1996 Feb;12(1):13-38 (165 ref.)
Multiple roles of platelet-activating factor in the nervous system. Bussolino F, et al. **Neurochem Int** 1995 May; 26(5):425-33 (75 ref.)
Cytokines in the central nervous system: regulatory roles in neuronal function, cell death and repair. Sei Y, et al. **Neuroimmunomodulation** 1995 May-Jun;2(3):121-33 (159 ref.)
Nicotinic receptors in the development and modulation of CNS synapses. Role LW, et al. **Neuron** 1996 Jun; 16(6):1077-85 (132 ref.)
Glial cell transplantation and remyelination of the central nervous system. Duncan ID. **Neuropathol Appl Neurobiol** 1996 Apr;22(2):87-100 (100 ref.)
Purinergic inhibition of neurotransmitter release in the central nervous system. Ribeiro JA. **Pharmacol Toxicol** 1995 Nov; 77(5):299-305 (68 ref.)
Anatomy and electrophysiology of fast central synapses lead to a structural model for long-term potentiation. Edwards FA. **Physiol Rev** 1995 Oct;75(4):759-87 (200 ref.)
Neuronal calcium channels encoded by the alpha 1A subunit and their contribution to excitatory synaptic transmission in the CNS. Wheeler DB, et al. **Prog Brain Res** 1995; 105:65-78 (51 ref.)
The concept of trophic units in the central nervous system. Agnati LF, et al. **Prog Neurobiol** 1995 Aug;46(6):561-74 (140 ref.)
Use of voltage-sensitive dyes and optical recordings in the central nervous system. Ebner TJ, et al. **Prog Neurobiol** 1995 Aug;46(5):463-506 (242 ref.)
Neurotransmitters in the CNS control of breathing. Bonham AC. **Respir Physiol** 1995 Sep;101(3):219-30 (40 ref.)
Suprapontine influences on the micturition reflex. Torrens M. **Scand J Urol Nephrol Suppl** 1995;175:11-3 (24 ref.)
Dietary calcium intake: effects on central blood pressure control. Pörsti I, et al. **Semin Nephrol** 1995 Nov; 15(6):550-63 (176 ref.)
Retrograde signaling at GABAA-receptor synapses in the mammalian CNS. Alger BE, et al. **Trends Neurosci** 1995 Aug;18(8):333-40 (42 ref.)
[Androgens and feminine behavior] Kerdelhue B, et al. **Contracept Fertil Sex** 1996 May;24(5):407-12 (28 ref.) (Eng. Abstr.) **(Fre)**
[Function of endogenous opioid peptides and sex steroids at the level of the central nervous system] Bidzińska B, et al. **Postepy Hig Med Dosw** 1995;49(4):523-30 (44 ref.) (Eng. Abstr.) **(Pol)**
[The central effects of interoceptive signalization] Zakharzhevskii VB. **Fiziol Zh Im I M Sechenova** 1995 Sep; 81(9):1-12 (64 ref.) **(Rus)**
[The evolution of the synapses in the vertebrate central nervous system (a topical paper)] Motorina MV. **Zh Evol Biokhim Fiziol** 1995 Jan-Feb;31(1):3-13 (68 ref.) (Eng. Abstr.) **(Rus)**
[Neurotoxicity of excitatory amino acids and the central nervous system] Martos JM, et al. **Rev Clin Esp** 1996 Feb; 196(2):113-8 (102 ref.) **(Spa)**
[Progesterone and its metabolites in central nervous system function] Camacho-Arroyo I, et al. **Rev Invest Clin** 1995 Jul-Aug;47(4):329-40 (118 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

Neurobiology of muscle fatigue. Advances and issues. Gandevia SC, et al. **Adv Exp Med Biol** 1995;384:515-25 (31 ref.)
Neurophysiology of opioid poorly responsive pain. Dickenson AH. **Cancer Surv** 1994;21:5-16 (49 ref.)
Electrophysiological alterations of the central nervous system in diabetes mellitus. Di Mario U, et al. **Diabetes Metab Rev** 1995 Oct;11(3):259-77 (153 ref.)
Experimental strategies to promote central nervous system remyelination in multiple sclerosis: insights gained from the Theiler's virus model system. Miller DJ, et al. **J Neurosci Res** 1995 Jun 15;41(3):291-6 (40 ref.)

RADIOGRAPHY

[3D-CT of the central nervous system] Machida T. **No To Shinkei** 1996 Jul;48(7):607-12 (8 ref.) **(Jpn)**

SURGERY

[Nerve transplantation in the central nervous system: a strategy for inducing nerve fiber regeneration in lesions of the brain and spinal cord] Gauthier P, et al. **Rev Neurol (Paris)** 1996 Feb;152(2):106-15 (62 ref.) (Eng. Abstr.) **(Fre)**

ULTRASTRUCTURE

An analysis of contemporary morphological concepts of synaptic remodelling in the CNS: perforated synapses revisited. Jones DG, et al. **Rev Neurosci** 1995 Jul-Sep; 6(3):177-219 (174 ref.)

VIROLOGY

Neurovirulence of pseudorabies virus. Card JP, et al. **Crit Rev Neurobiol** 1995;9(2-3):137-62 (125 ref.)
HIV interactions with cells of the nervous system. Dubois-Dalcq M, et al. **Curr Opin Neurobiol** 1995 Oct; 5(5):647-55 (65 ref.)
[How does HIV-1 and other retroviruses affect the nervous system?] Elovaara I. **Duodecim** 1995;111(9):826-35 (40 ref.) **(Fin)**

CENTRAL NERVOUS SYSTEM AGENTS

ADMINISTRATION & DOSAGE

Microparticles with neuroactive agents. Filipović-Grčić J, et al. **J Microencapsul** 1995 Jul-Aug;12(4):343-62 (65 ref.)

ADVERSE EFFECTS

Drug-induced seizures in the elderly. Causative agents and optimal management. Franson KL, et al. **Drugs Aging** 1995 Jul;7(1):38-48 (78 ref.)

THERAPEUTIC USE

Identifying a neurobiologic basis for drug therapy in TMDs. Denucci DJ, et al. **J Am Dent Assoc** 1996 May; 127(5):581-93 (80 ref.)
[Therapy of idiopathic and uremic restless legs syndrome] Trenkwalder C, et al. **Nervenarzt** 1996 Apr;67(4):265-76 (79 ref.) (Eng. Abstr.) **(Ger)**

CENTRAL NERVOUS SYSTEM DEPRESSANTS

METABOLISM

Fundamental studies on alcohol dependence and disposition. Komura S, et al. **Forensic Sci Int** 1996 Jun 28; 80(1-2):99-107 (37 ref.)

PHARMACOLOGY

Role of acetaldehyde in the actions of ethanol on the brain--a review. Hunt WA. **Alcohol** 1996 Mar-Apr;13(2):147-51 (66 ref.)

CENTRAL NERVOUS SYSTEM DISEASES

The definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. **J Auton Nerv Syst** 1996 Apr 20;58(1-2):123-4 (1 ref.)

CHEMICALLY INDUCED

Physiological and toxicological actions of nitric oxide in the central nervous system. Dawson VL, et al. **Adv Pharmacol** 1995;34:323-42 (73 ref.)
CNS adverse events associated with antimalarial agents. Fact or fiction? Phillips-Howard PA, et al. **Drug Saf** 1995 Jun; 12(6):370-83 (77 ref.)

COMPLICATIONS

Central nervous system disease in primary Sjögren's syndrome. De Backer H, et al. **Acta Neurol Belg** 1995; 95(3):142-6 (36 ref.)
Primary angiitis of the central nervous system associated with Hodgkin's disease. Yuen RW, et al. **Arch Pathol Lab Med** 1996 Jun;120(6):573-6 (22 ref.)
Investigation of visual loss: neuro-ophthalmology from a neurologist's perspective. Lueck CJ. **J Neurol Neurosurg Psychiatry** 1996 Mar;60(3):275-80 (48 ref.)
Disorders of the central and autonomic nervous systems as a cause for emesis in infants. Johns DW. **Semin Pediatr Surg** 1995 Aug;4(3):152-6 (37 ref.)
The aetiologies of epilepsy in tropical Africa. Adamolekun B. **Trop Geogr Med** 1995;47(3):115-7 (29 ref.)
[Nontraumatic coma in extramural practice] Enrico JF, et al. **Schweiz Rundsch Med Prax** 1995 Nov 7;84(45):1321-30 (16 ref.) (Eng. Abstr.) **(Fre)**
[Obesity due to central nervous system diseases] Sakuragawa N. **Nippon Rinsho** 1995 Jun;53 Suppl:415-8 (16 ref.) **(Jpn)**

CONGENITAL

The diagnosis of congenital infections: contemporary strategies. Souza IE, et al. **J Child Neurol** 1995 Jul; 10(4):271-82 (89 ref.)

DIAGNOSIS

[Neurocysticercosis] Brouwer RE, et al. **Ned Tijdschr Geneeskd** 1995 Dec 30;139(52):2721-5 (45 ref.) **(Dut)**
[Neurocysticercosis: pediatric aspects] Grill J, et al. **Arch Pediatr** 1996 Apr;3(4):360-8 (53 ref.) (Eng. Abstr.) **(Fre)**
[Sarcoidosis of the central nervous system: clinical and radiological polymorphism] de Seze J, et al. **Rev Med Interne** 1996;17(6):482-7 (38 ref.) (Eng. Abstr.)

(Fre)
[Molecular genetic analysis--a new stage in the study of hereditary diseases of the central nervous system] Ivanova-Smolenskaia IA, et al. **Vestn Ross Akad Med Nauk** 1996;(4):6-10 (45 ref.) (Eng. Abstr.) (Rus)

DRUG THERAPY

Cholinergic channel activators: novel opportunities for the treatment of CNS disorders. Sullivan JP, et al. **Proc West Pharmacol Soc** 1995;38:127-30 (29 ref.)

EPIDEMIOLOGY

Arboviruses causing neurological disorders in the central nervous system. Dobler G. **Arch Virol Suppl** 1996;11:33-40 (18 ref.)

ETIOLOGY

Cytokine involvement in central nervous system disease. Implications from transgenic mice. Campbell IL, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:301-12 (52 ref.)
Overview of neuroimmune stress interactions. Implications for susceptibility to inflammatory disease. Sternberg EM, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:364-71 (53 ref.)
Central and peripheral nervous complications of dental treatment. Rosaitti EO. **Arq Neuropsiquiatr** 1995 Sep; 53(3-A):513-7 (33 ref.)
Arboviruses and the central nervous system. Griffin DE. **Springer Semin Immunopathol** 1995;17(2-3):121-32 (79 ref.)
[Acute hepatic porphyria and its neurological syndrome] Bont A, et al. **Schweiz Med Wochenschr** 1996 Jan 9; 126(1-2):6-14 (45 ref.) (Eng. Abstr.) (Ger)
[Neuro-psychiatric involvement in primary Sjögren's syndrome] Sagawa A, et al. **Nippon Rinsho** 1995 Oct; 53(10):2563-7 (13 ref.) (Eng. Abstr.) (Jpn)
[Central nervous system involvement in the acquired immunodeficiency syndrome] Gavura VV. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995; 95(2):96-100 (87 ref.) (Rus)

GENETICS

CNS genetic disorders: loss of function, gain of function, or something else? Martin JB. **Curr Opin Neurobiol** 1995 Oct;5(5):669-73 (36 ref.)
AP-1 transcription factor complexes in CNS disorders and development. Pennypacker KR. **J Fla Med Assoc** 1995 Aug;82(8):551-4 (26 ref.)
Genetically engineered animal models of human neurodegenerative diseases. Higgins LS, et al. **Neurodegeneration** 1995 Jun;4(2):117-29 (49 ref.)
Preliminary characterization of the central nervous system in partial trisomy 16 mice. Holtzman DM, et al. **Prog Clin Biol Res** 1995;393:227-40 (32 ref.)
[Infection of the mouse by Theiler's virus; a model for the study of demyelinating diseases of the central nervous system] Brahic M. **Bull Acad Natl Med** 1996 Feb; 180(2):305-15; discussion 315-6 (27 ref.) (Eng. Abstr.) (Fre)
[Dynamic mutations--a newly detected category of mutations which is the basis for certain neurologic diseases] Mardešić D. **Lijec Vjesn** 1995 Jul-Aug;117(7-8):184-8 (23 ref.) (Eng. Abstr.) (Scr)

IMMUNOLOGY

Arboviruses and the central nervous system. Griffin DE. **Springer Semin Immunopathol** 1995;17(2-3):121-32 (79 ref.)

METABOLISM

The biochemical basis of the neuropathy in cobalamin deficiency. Weir DG, et al. **Baillieres Clin Haematol** 1995 Sep;8(3):479-97 (103 ref.)
Neurotrophic factors in central nervous system trauma. Mocchetti I, et al. **J Neurotrauma** 1995 Oct;12(5):853-70 (186 ref.)

PARASITOLOGY

Neurocysticercosis--an update. Maiti B. **J Assoc Physicians India** 1995 Jul;43(7):477-82 (30 ref.)

PATHOLOGY

Opportunistic infections of the central nervous system in children with HIV infection: report of 9 autopsy cases and review of literature. Wrzolek MA, et al. **Clin Neuropathol** 1995 Jul-Aug;14(4):187-96 (41 ref.)
Glial inclusions in CNS degenerative diseases. Chin SS, et al. **J Neuropathol Exp Neurol** 1996 May;55(5):499-508 (78 ref.)
Chronic lymphocytic leukemia and the central nervous system: a clinical and pathological study. Cramer SC, et al. **Neurology** 1996 Jan;46(1):19-25 (67 ref.)
[Fast Spin Echo sequences in neuroradiology: technical features, semiology, and applications] Scarabino T, et al. **Radiol Med (Torino)** 1996 May;91(5):519-25 (36 ref.) (Ita)

PHYSIOPATHOLOGY

Factors controlling coronavirus infections and disease of the central nervous system. A review. Dales S. **Adv Exp Med Biol** 1995;380:13-22 (24 ref.)
Fatigue brought on by malfunction of the central and peripheral nervous systems. McComas AJ, et al. **Adv Exp Med Biol** 1995;384:495-512 (59 ref.)
Clinical impact of cytomegalovirus infections of the nervous system in patients with AIDS. McCutchan JA. **Clin Infect Dis** 1995 Oct;21 Suppl 2:S196-201 (42 ref.)
Involvement of endogenous benzodiazepine receptor ligands in brain disorders: therapeutic potential for benzodiazepine antagonists? Polc P. **Med Hypotheses** 1995 Jun;44(6):439-46 (51 ref.)
Chronic lymphocytic leukemia and the central nervous system: a clinical and pathological study. Cramer SC, et al. **Neurology** 1996 Jan;46(1):19-25 (67 ref.)

PREVENTION & CONTROL

Cardiopulmonary bypass and the central nervous system: potential for cerebral protection. Newman MF, et al. **J Clin Anesth** 1996 May;8(3 Suppl):53S-60S (70 ref.)
[Indications for psychological examination in diagnosis, certification and prevention of occupational diseases] Waszkowska M. **Med Pr** 1995;46(5):505-8 (14 ref.) (Eng. Abstr.) (Pol)

THERAPY

Bone marrow transplantation for metabolic diseases. Parkman R, et al. **Cancer Treat Res** 1995;76:87-96 (33 ref.)
Core temperature control in the management of CNS lesions. Raps EC, et al. **Clin Neuropharmacol** 1995 Apr;18(2):159-64 (41 ref.)
Gene therapy in the central nervous system: direct versus indirect gene delivery. Ridet JL, et al. **J Neurosci Res** 1995 Oct 15;42(3):287-93 (64 ref.)
Grafting of genetically manipulated cells into adult brain: toward graft-gene therapy. Uchida K, et al. **Kelo J Med** 1996 Jun;45(2):81-9 (40 ref.)
[Anti-sense in medicine and central nervous system disorders] Cohen H, et al. **Harefuah** 1996 Apr 1;130(7):500-2 (14 ref.) (Heb)

VETERINARY

The collection and analysis of cerebrospinal fluid as an aid to diagnosis in ruminant neurological disease. Scott PR. **Br Vet J** 1995 Nov-Dec;151(6):603-14 (39 ref.)

VIROLOGY

Factors controlling coronavirus infections and disease of the central nervous system. A review. Dales S. **Adv Exp Med Biol** 1995;380:13-22 (24 ref.)
Arboviruses causing neurological disorders in the central nervous system. Dobler G. **Arch Virol Suppl** 1996;11:33-40 (18 ref.)
[Zoster and the nervous system] Malin JP. **Dtsch Med Wochenschr** 1996 May 10;121(19):635-8 (22 ref.) (Ger)

CENTRAL NERVOUS SYSTEM NEOPLASMS

DIAGNOSIS

Primary central nervous system lymphoma in immunocompetent patients. Ferreri AJ, et al. **Cancer Treat Rev** 1995 Sep;21(5):415-46 (229 ref.)

DRUG THERAPY

Immunotoxins for central nervous system malignancy. Youle RJ. **Semin Cancer Biol** 1996 Apr;7(2):65-70 (36 ref.)

EPIDEMIOLOGY

Epidemiology of primary CNS neoplasms. Preston-Martin S. **Neurol Clin** 1996 May;14(2):273-90 (49 ref.)

METABOLISM

Cytokines and tumors of the central nervous system. Van Meir EG. **Glia** 1995 Nov;15(3):264-88 (205 ref.)
Expression of the CD44 adhesion molecule in tumours of the central and peripheral nervous system. Baltuch GH, et al. **J Neurooncol** 1995 Dec;26(3):191-8 (62 ref.)
Neuropeptides in neuroblastomas and ganglioneuromas. Kogner P. **Prog Brain Res** 1995;104:325-38 (99 ref.)

PATHOLOGY

Revising the World Health Organization (WHO) Blue Book--Histological typing of tumours of the central nervous system. Burger PC. **J Neurooncol** 1995;24(1):3-7 (24 ref.)
Primary central nervous system lymphomas--new pathological developments. Jellinger KA, et al. **J Neurooncol** 1995;24(1):33-6 (23 ref.)

SECONDARY

Remission of acromegaly caused by pituitary carcinoma after surgical excision of growth hormone-secreting metastasis detected by 111-indium pentetreotide scan. Greenman Y, et al. **J Clin Endocrinol Metab** 1996 Apr;81(4):1628-33 (29 ref.)

SURGERY

Remission of acromegaly caused by pituitary carcinoma after surgical excision of growth hormone-secreting metastasis detected by 111-indium pentetreotide scan. Greenman Y, et al. **J Clin Endocrinol Metab** 1996 Apr;81(4):1628-33 (29 ref.)

THERAPY

Primary central nervous system lymphoma in immunocompetent patients. Ferreri AJ, et al. **Cancer Treat Rev** 1995 Sep;21(5):415-46 (229 ref.)
New therapies of primary CNS lymphomas and oligodendrogliomas. Macdonald DR. **J Neurooncol** 1995; 24(1):97-101 (26 ref.)

VETERINARY

Central nervous system tumors. Gavin PR, et al. **Semin Vet Med Surg (Small Anim)** 1995 Aug;10(3):180-9 (32 ref.)

CENTRAL NERVOUS SYSTEM STIMULANTS

Methamphetamine and driving impairment. Logan BK. **J Forensic Sci** 1996 May;41(3):457-64 (37 ref.)
In vivo analysis of the role of dopamine in stimulant and opiate self-administration. Gratton A. **J Psychiatry Neurosci** 1996 Jul;21(4):264-79 (120 ref.)

ADMINISTRATION & DOSAGE

[Abuse of alcohol and central nervous system stimulants. A growing problem in developing countries] Eide AH, et al. **Lakartidningen** 1995 Nov 29;92(48):4569-71 (31 ref.) (Swe)

PHARMACOLOGY

Caffeine and performance. Spriet LL. **Int J Sport Nutr** 1995 Jun;5 Suppl:S84-99 (56 ref.)

THERAPEUTIC USE

The run on Ritalin. Attention deficit disorder and stimulant treatment in the 1990s. Diller LH. **Hastings Cent Rep** 1996 Mar-Apr;26(2):12-8 (45 ref.)
Neuroendocrine responses to methylphenidate and d-amphetamine: applications to attention-deficit disorder. Lurie S, et al. **J Neuropsychiatry Clin Neurosci** 1991 Winter; 3(1):41-50 (70 ref.)
[Experimental and clinical pharmacology of psychostimulants] Bourin M, et al. **Can J Psychiatry** 1995 Sep;40(7):401-10 (108 ref.) (Eng. Abstr.) (Fre)

CENTRAL RETINAL ARTERY see **RETINAL ARTERY**

CENTRAL RETINAL ARTERY OCCLUSION see **RETINAL ARTERY OCCLUSION**

CENTRAL RETINAL VEIN see **RETINAL VEIN**

CENTRAL VENOUS CATHETERIZATION see **CATHETERIZATION, CENTRAL VENOUS**

CENTRALLY ACTING MUSCLE RELAXANTS see **MUSCLE RELAXANTS, CENTRAL**

CENTRIC RELATION

New definition for relating occlusion to varying conditions of the temporomandibular joint. Dawson PE. **J Prosthet Dent** 1995 Dec;74(6):619-27 (39 ref.)

CENTROMERE

GENETICS

The elusive centromere: sequence divergence and functional conservation. Sunkel CE, et al. **Curr Opin Genet Dev** 1995 Dec;5(6):756-67 (68 ref.)
Variability of clinical and immunological phenotype in immunodeficiency-centromeric instability-facial anomalies syndrome. Report of two new patients and review of the literature. Franceschini P, et al. **Eur J Pediatr** 1995 Oct; 154(10):840-6 (21 ref.)

PHYSIOLOGY

The elusive centromere: sequence divergence and functional conservation. Sunkel CE, et al. **Curr Opin Genet Dev** 1995 Dec;5(6):756-67 (68 ref.)
The centromere: hub of chromosomal activities. Pluta AF, et al. **Science** 1995 Dec 8;270(5242):1591-4 (83 ref.)
The centromere: kinetochore complex. Vig BK. **Southeast Asian J Trop Med Public Health** 1995;26 Suppl 1:68-76 (48 ref.)
Centromere activation. Brown W, et al. **Trends Genet** 1995 Sep;11(9):337-9 (8 ref.)

CENTROSOME

PHYSIOLOGY

The sperm centrosome during fertilization in mammals: implications for fertility and reproduction. Navara CS, et al. **Reprod Fertil Dev** 1995;7(4):747–54 (30 ref.)

ULTRASTRUCTURE

Confocal immunofluorescence microscopy of microtubules, microtubule-associated proteins, and microtubule-organizing centers during amphibian oogenesis and early development. Gard DL, et al. **Curr Top Dev Biol** 1995;31:383–431 (137 ref.)

CENURIASIS see **CESTODE INFECTIONS**

CEPHALIN-KAOLIN COAGULATION TIME see **PARTIAL THROMBOPLASTIN TIME**

CEPHALINS see **PHOSPHATIDYLETHANOLAMINES**

CEPHALOMETRY

see related

CRANIOMETRY

Evaluation of cervical spine abnormalities on cephalometric radiographs. Vastardis H, et al. **Am J Orthod Dentofacial Orthop** 1996 Jun;109(6):581–8 (34 ref.)

Digital imaging of cephalometric radiography, Part 1: Advantages and limitations of digital imaging. Forsyth DB, et al. **Angle Orthod** 1996;66(1):37–42 (29 ref.)

[Predictive soft tissue factors in bimaxillary operations] Steinhäuser EW, et al. **Fortschr Kiefer Gesichtschir** 1995; 40:50–7 (31 ref.) **(Ger)**

METHODS

Cephalometric analysis of Deutero-Malay Indonesians. Munandar S, et al. **Aust Dent J** 1995 Dec;40(6):381–8 (38 ref.)

CEPHALOPELVIC DISPROPORTION see **LABOR COMPLICATIONS**

CEPHALOPELVIC PROPORTION see **PELVIMETRY**

CEPHALOPELVIMETRY see **PELVIMETRY**

CEPHALOSPORINS

[Cephalosporins: 4 generations of structural evolution] Sader HS, et al. **Rev Assoc Med Bras** 1995 Mar–Apr;41(2):144–50 (58 ref.) **(Por)**

ADMINISTRATION & DOSAGE

Review and reassessment of dosing schedules for cefotaxime in selected medical indications. Young LS. **Diagn Microbiol Infect Dis** 1995 May–Jun;22(1–2):147–54 (11 ref.)

Once-a-day cephalosporins: reality or myth? Scaglione F, et al. **J Chemother** 1995 May;7 Suppl 1:13–5 (22 ref.)

Hematogenous osteomyelitis of the calcaneus in children: surgical treatment and use of implanted antibiotic beads. Kelsey R, et al. **J Foot Ankle Surg** 1995 Nov–Dec; 34(6):547–55; discussion 594 (26 ref.)

ADVERSE EFFECTS

Tolerability of oral cephalosporins. Lepper H, et al. **Antibiot Chemother** 1995;47:160–82 (100 ref.)

Cefotiam-induced contact urticaria syndrome: an occupational condition in Japanese nurses. Shimizu S, et al. **Dermatology** 1996;192(2):174–6 (19 ref.)

ANALYSIS

[Concentration of cephems in sputum from patients with pulmonary infection: relationship between MICs of pathogenic bacteria, levels of antibiotic and efficacy] Rikitomi N. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:1020–3 (10 ref.) **(Jpn)**

ANTAGONISTS & INHIBITORS

[Meningitis due to cefotaxime-resistant Streptococcus pneumoniae] Martin Fontelos P, et al. **An Esp Pediatr** 1996 Apr;44(4):395–6 (24 ref.) **(Spa)**

CEREBROSPINAL FLUID

Diffusion of 3-quaternary ammonium cephem antibiotics into cerebrospinal fluid of patients with bacterial meningitis. Modai J. **J Chemother** 1996 Feb;8 Suppl 2:83–90 (12 ref.)

CHEMICAL SYNTHESIS

The chemistry and structure-activity relationships of C3-quaternary ammonium cephem antibiotics. Laws A, et al. **J Chemother** 1996 Feb;8 Suppl 2:7–22 (49 ref.)

CHEMISTRY

Systematics of beta-lactams: chemical properties and structure activity relationship of oral cephalosporins. Kees F, et al. **Antibiot Chemother** 1995;47:1–7 (13 ref.)

Cycloaddition and related reactions of cephalosporin antibiotics. Pitlik J. **Bioorg Med Chem** 1995 Sep; 3(9):1157–81 (150 ref.)

PHARMACOKINETICS

The pharmacokinetic profile of a new generation of parenteral cephalosporin. Rybak M. **Am J Med** 1996 Jun 24;100(6A):39S–44S (29 ref.)

Clinical pharmacokinetics of oral cephalosporins. Stoeckel K, et al. **Antibiot Chemother** 1995;47:34–71 (151 ref.)

Pharmacokinetics of cefotaxime in dialysis patients. Andrassy K. **Diagn Microbiol Infect Dis** 1995 May–Jun;22(1–2):85–7 (11 ref.)

Pharmacokinetics of cefotaxime and desacetylcefotaxime in the young. Kearns GL, et al. **Diagn Microbiol Infect Dis** 1995 May–Jun;22(1–2):97–104 (45 ref.)

Pharmacodynamic (kinetic) considerations in the treatment of moderately severe infections with cefotaxime. Turnidge JD. **Diagn Microbiol Infect Dis** 1995 May–Jun; 22(1–2):57–69 (94 ref.)

The penetration of novel intravenous cephalosporins into the lung. Baldwin DR. **J Chemother** 1996 Feb;8 Suppl 2:71–82 (89 ref.)

Tissue penetration of the fourth generation parenteral cephalosporins. Wise R. **J Chemother** 1996 Feb;8 Suppl 2:63–70 (38 ref.)

Pharmacokinetics of ceftibuten in children. Barr WH, et al. **Pediatr Infect Dis J** 1995 Jul;14(7 Suppl):S93–101 (30 ref.)

PHARMACOLOGY

Bacteriologic and clinical applications of a new extended-spectrum parenteral cephalosporin. Segreti J, et al. **Am J Med** 1996 Jun 24;100(6A):45S–51S (56 ref.)

Microbiology of oral cephalosporins. Cullmann W. **Antibiot Chemother** 1995;47:72–109 (143 ref.)

Pharmacology and toxicology of oral cephalosporins. Gialdroni Grassi G. **Antibiot Chemother** 1995;47:8–33 (135 ref.)

Systematics of beta-lactams: chemical properties and structure activity relationship of oral cephalosporins. Kees F, et al. **Antibiot Chemother** 1995;47:1–7 (13 ref.)

Antimicrobial activity of cefotaxime tested against infrequently isolated pathogenic species (unusual pathogens). Cormican MG, et al. **Diagn Microbiol Infect Dis** 1995 May–Jun;22(1–2):43–8 (46 ref.)

Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Craig WA. **Diagn Microbiol Infect Dis** 1995 May–Jun;22(1–2):89–96 (31 ref.)

Cefotaxime and desacetylcefotaxime antimicrobial interactions. The clinical relevance of enhanced activity: a review. Jones RN. **Diagn Microbiol Infect Dis** 1995 May–Jun;22(1–2):19–33 (79 ref.)

Drug utilisation review (DUR) of the third generation cephalosporins. Focus on ceftriaxone, ceftazidime and cefotaxime. Adu A, et al. **Drugs** 1995 Sep;50(3):423–39 (109 ref.)

Laboratory assessment of antibacterial activity of zwitterionic 7-methoxyimino cephalosporins. Pechère JC, et al. **J Antimicrob Chemother** 1995 Nov;36(5):757–71 (52 ref.)

In vitro activity of fourth generation cephalosporins against enterobacteriaceae producing extended-spectrum beta-lactamases. Sanders CC. **J Chemother** 1996 Feb;8 Suppl 2:57–62 (26 ref.)

Ceftibuten: a review of antimicrobial activity, spectrum and other microbiologic features. Jones RN. **Pediatr Infect Dis J** 1995 Jul;14(7 Suppl):S77–83 (36 ref.)

Ceftibuten: minimal inhibitory concentrations, postantibiotic effect and beta-lactamase stability—a rationale for dosing programs. Neu HC. **Pediatr Infect Dis J** 1995 Jul;14(7 Suppl):S88–92 (29 ref.)

[Specificities of antibacterial activity of zwitterionic 7-methoxyimino cephems (cephalosporins of fourth generation] Pechère JC. **Pathol Biol (Paris)** 1996 Feb; 44(2):99–105 (26 ref.) (Eng. Abstr.) **(Fre)**

THERAPEUTIC USE

Oral cephalosporins: clinical results in urinary tract infections. Giamarellou H. **Antibiot Chemother** 1995; 47:145–59 (46 ref.)

Oral cephalosporins in upper respiratory infections. Leibovitz E, et al. **Antibiot Chemother** 1995;47:110–22 (106 ref.)

Oral cephalosporins: clinical results in lower respiratory tract infections. Pozzi E, et al. **Antibiot Chemother** 1995; 47:123–44 (100 ref.)

Cefotaxime use in pediatric infections. Dajani AS. **Diagn Microbiol Infect Dis** 1995 May–Jun;22(1–2):105–10 (19 ref.)

Cephalosporin-metronidazole combinations in the management of intra-abdominal infections. Nicolau DP, et al. **Diagn Microbiol Infect Dis** 1995 May–Jun; 22(1–2):189–94 (28 ref.)

Experience with cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis. Rimola A, et al. **Diagn Microbiol Infect Dis** 1995 May–Jun;22(1–2):141–5 (30 ref.)

The role of cefotaxime in the treatment of surgical infections. Wittmann DH. **Diagn Microbiol Infect Dis** 1995 May–Jun; 22(1–2):173–82 (67 ref.)

Drug utilisation review (DUR) of the third generation cephalosporins. Focus on ceftriaxone, ceftazidime and cefotaxime. Adu A, et al. **Drugs** 1995 Sep;50(3):423–39 (109 ref.)

A guide to the treatment of lower respiratory tract infections. Vogel F. **Drugs** 1995 Jul;50(1):62–72 (56 ref.)

The newer cephalosporins. Aztreonam and imipenem. Ennis DM, et al. **Infect Dis Clin North Am** 1995 Sep;9(3):687–713 (123 ref.)

Clinical experience with the fourth generation cephalosporins. Giamarellou H. **J Chemother** 1996 Feb;8 Suppl 2:91–104 (30 ref.)

The position of recently developed broad-spectrum cephem antibiotics in bacterial septicemia. Shah PM. **J Chemother** 1996 Feb;8 Suppl 2:105–11 (17 ref.)

Worldwide safety experience with ceftibuten pediatric suspension. Reidenberg BE. **Pediatr Infect Dis J** 1995 Jul; 14(7 Suppl):S130–3 (22 ref.)

Evaluation of penicillins, cephalosporins, and macrolides for therapy of streptococcal pharyngitis. Shulman ST. **Pediatrics** 1996 Jun;97(6 Pt 2):955–9 (34 ref.)

[Treatment of commonly occurring skin infections] Hyry H, et al. **Duodecim** 1995;111(8):697–702 (15 ref.) **(Fin)**

TOXICITY

Pharmacology and toxicology of oral cephalosporins. Gialdroni Grassi G. **Antibiot Chemother** 1995;47:8–33 (135 ref.)

CEPHALOSPORIUM see **ACREMONIUM**

CEPHALOTAXINE ALKALOIDS see **HARRINGTONINES**

CEPHALOTAXUS ALKALOIDS see **HARRINGTONINES**

CERAMICS

Effect of varying etching times on the bond strength of ceramic brackets. Olsen ME, et al. **Am J Orthod Dentofacial Orthop** 1996 Apr;109(4):403–9 (49 ref.)

The use of ceramic in prosthetic hip surgery. The state of the art. Toni A, et al. **Chir Organi Mov** 1995 Apr–Jun; 80(2):125–37 (65 ref.) **(Eng, Ita)**

Spontaneous fracture of the ceramic ball in a ceramic-polyethylene total hip arthroplasty. Michaud RJ, et al. **J Arthroplasty** 1995 Dec;10(6):863–7 (27 ref.)

[Scanning electron microscopy in the study of surface treatment methods used in the repair of porcelain-fused-to-metal restorations] Hegedús C, et al. **Fogorv Sz** 1995 Apr;88(4):133–9 (32 ref.) (Eng. Abstr.) **(Hun)**

ANALYSIS

[Refractory ceramic fibers, kinds, health effects after exposure, TLVs] Woźniak H, et al. **Med Pr** 1996; 47(4):393–9 (17 ref.) (Eng. Abstr.) **(Pol)**

CERAMIDES

IMMUNOLOGY

Ceramide signalling and the immune response. Ballou LR, et al. **Biochim Biophys Acta** 1996 Jun 11;1301(3):273–87 (134 ref.)

PHYSIOLOGY

Ceramide signalling and the immune response. Ballou LR, et al. **Biochim Biophys Acta** 1996 Jun 11;1301(3):273–87 (134 ref.)

Ceramide: a potential second messenger in the nervous system. Chao MV. **Mol Cell Neurosci** 1995 Apr;6(2):91–6 (55 ref.)

Ceramide: an intracellular mediator of apoptosis and growth suppression. Saba JD, et al. **Philos Trans R Soc Lond B Biol Sci** 1996 Feb 29; 351(1336):233–40; discussion 240–1 (40 ref.)

CERASTES see **VIPERIDAE**

CERATITIS CAPITATA see **DIPTERA**

CERATOPOGONIDAE

Culicoides variipennis and bluetongue disease. Research on arthropod-borne animal diseases for control and prevention in the year 2000. Tabachnick WJ, et al. **Ann N Y Acad Sci** 1996 Jul 23;791:219–26 (30 ref.)

Culicoides variipennis and bluetongue-virus epidemiology in the United States. Tabachnick WJ. **Annu Rev Entomol** 1996; 41:23–43 (135 ref.)

VIROLOGY

Handling small arbovirus vectors safely during biosafety level 3 containment: Culicoides variipennis sonorensis (Diptera:Ceratopogonidae) and exotic bluetongue viruses. Hunt GJ, et al. **J Med Entomol** 1996 May;33(3):271–7 (17

CERATOPOGONIDAE

ref.)
Veterinary arbovirus vectors in Australia--a retrospective. Muller MJ. **Vet Microbiol** 1995 Sep;46(1-3):101-16 (67 ref.)

CERCOPITHECIDAE

PHYSIOLOGY

Colour vision. Dalton's eyes and monkey genes. Tovée MJ. **Curr Biol** 1995 Jun 1;5(6):583-6 (16 ref.)

CEREALS

Grain dust, endotoxin, and airflow obstruction. Schwartz DA. **Chest** 1996 Mar;109(3 Suppl):57S-63S (51 ref.)
Whole grain intake and cancer: a review of the literature. Jacobs DR Jr, et al. **Nutr Cancer** 1995;24(3):221-9 (35 ref.)
Total nutrient intake and ready-to-eat cereal consumption of children and young adults in the Bogalusa Heart Study. Nicklas TA, et al. **Nutr Rev** 1995 Sep;53(9 Pt 2):S39-45 (41 ref.)

ADVERSE EFFECTS

The gluten-host interaction. Tighe MR, et al.
Baillieres Clin Gastroenterol 1995 Jun;9(2):211-30 (42 ref.)
The precipitating factor in coeliac disease. Wieser H.
Baillieres Clin Gastroenterol 1995 Jun;9(2):191-207 (63 ref.)

GENETICS

Cereal genome evolution: pastoral pursuits with 'Lego' genomes. Moore G. **Curr Opin Genet Dev** 1995 Dec; 5(6):717-24 (65 ref.)
Transformation of cereals by microprojectile bombardment of immature inflorescence and scutellum tissues. Barcelo P, et al. **Methods Mol Biol** 1995;49:113-23 (22 ref.)

MICROBIOLOGY

Mycotoxicosis--humankind's greatest affliction? Campbell GD. **Nutr Health** 1996;10(4):323-9 (13 ref.)

CEREBELLAR ATAXIA

ETIOLOGY

[Campylobacter jejuni and autoimmune-mediated neurologic diseases: pathogenesis of Guillain-Barré syndrome and Fisher's syndrome] Yuki N. **Nippon Saikingaku Zasshi** 1995 Oct;50(4):991-1003 (41 ref.) **(Jpn)**

GENETICS

Molecular genetic analyses of myelin deficiency and cerebellar ataxia. Mikoshiba K, et al. **Prog Brain Res** 1995; 105:23-41 (89 ref.)

CEREBELLAR DISEASES

Craniospinal arachnoid cyst: case report] Fukushima Y, et al. **No Shinkei Geka** 1996 Jan;24(1):75-9 (14 ref.) (Eng. Abstr.) **(Jpn)**

CHEMICALLY INDUCED

Cerebellar lithium toxicity: a review of recent literature and tentative pathophysiology. Grignon S, et al. **Therapie** 1996 Mar-Apr;51(2):101-6 (33 ref.)

COMPLICATIONS

Unexpected sudden death in a young pregnant woman: unusual presentation of neurosarcoidosis. Maisel JA, et al. **Ann Emerg Med** 1996 Jul;28(1):94-7 (12 ref.)

ETIOLOGY

Amyloid angiopathy-related cerebellar hemorrhage. Cuny E, et al. **Surg Neurol** 1996 Sep;46(3):235-9 (22 ref.)

IMMUNOLOGY

[Pure cerebellar syndrome associated with anti-Hu antibodies] Pradat PF, et al. **Rev Neurol (Paris)** 1995 May; 151(5):341-3 (12 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

[Physiopathology of cerebellar symptoms: from Holmes to our times (editorial)] Manto M. **Acta Neurol Belg** 1995 Dec; 95(4):193-6 (24 ref.) **(Fre)**

SURGERY

Cerebellar mutism: report of seven cases and review of the literature. Erşahin Y, et al. **Neurosurgery** 1996 Jan; 38(1):60-5;discussion 66 (30 ref.)

CEREBELLAR NEOPLASMS

[Hemangioblastoma and von Hippel-Lindau disease] Matsumoto K, et al. **Nippon Rinsho** 1995 Nov;53(11):2672-7 (12 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Primary T-cell lymphoma of the cerebellum. A case report. Kleopa K, et al. **J Neurooncol** 1996 Mar;27(3):225-30 (28 ref.)
Medulloblastoma in adults. Sheikh BY, et al.
J Neurosurg Sci 1994 Dec;38(4):229-34 (21 ref.)
[Lhermitte-Duclos disease: is MRI diagnosis feasible?] Lemercier-Bertout C, et al. **Rev Neurol (Paris)** 1995 May; 151(5):327-31 (13 ref.) **(Fre)**
[Cortical function in 107 patients with supratentorial expanding mass. Pre- and postoperative study] Bucciero A, et al. **Minerva Med** 1995 Oct;86(10):403-7 (15 ref.) (Eng. Abstr.) **(Ita)**

PATHOLOGY

Medullocytoma (lipidized medulloblastoma). A cerebellar neoplasm of adults with favorable prognosis. Giangaspero F, et al. **Am J Surg Pathol** 1996 Jun;20(6):656-64 (29 ref.)
Lipomatous medulloblastoma in adults. A distinct clinicopathological entity. Soylemezoglu F, et al.
Am J Surg Pathol 1996 Apr;20(4):413-8 (33 ref.)

PHYSIOPATHOLOGY

Hemifacial seizures and cerebellar ganglioglioma: an epilepsy syndrome of infancy with seizures of cerebellar origin. Harvey AS, et al. **Ann Neurol** 1996 Jul;40(1):91-8 (7 ref.)

RADIOTHERAPY

An audit of craniospinal irradiation for medulloblastoma in Newcastle 1970-1992. Tinkler D, et al.
Clin Oncol (R Coll Radiol) 1995;7(3):179-83 (21 ref.)
Radiation-induced meningioma in children: report of two cases and review of the literature. Starshak RJ.
Pediatr Radiol 1996;26(8):537-41 (30 ref.)

SURGERY

Neurophysiological monitoring of cranial nerves during posterior fossa surgery. Broggi G, et al.
Acta Neurochir Suppl (Wien) 1995;64:35-9 (16 ref.)
Cerebellar mutism: report of seven cases and review of the literature. Erşahin Y, et al. **Neurosurgery** 1996 Jan; 38(1):60-5;discussion 66 (30 ref.)
Primary intracranial squamous cell carcinomas: report of two cases. Nishio S, et al. **Neurosurgery** 1995 Aug;37(2):329-32 (35 ref.)
Mutism and pseudobulbar symptoms after resection of posterior fossa tumors in children: incidence and pathophysiology. Pollack IF, et al. **Neurosurgery** 1995 Nov; 37(5):885-93 (39 ref.)
Transient cerebellar mutism after posterior fossa surgery in children. Van Calenbergh F, et al. **Neurosurgery** 1995 Nov; 37(5):894-8 (32 ref.)

CEREBELLAR NUCLEI

PATHOLOGY

A rare case of idiopathic hypoparathyroidism with varied neurological manifestations. Abe S, et al. **Intern Med** 1996 Feb;35(2):129-34 (37 ref.)
[Clinical picture of DRPLA] Naito H. **No To Shinkei** 1995 Oct;47(10):931-8 (35 ref.) **(Jpn)**
[Neuropathology of dentatorubral-pallidoluysian atrophy and Machado-Joseph disease] Takahashi H, et al.
No To Shinkei 1995 Oct;47(10):947-53 (34 ref.) **(Jpn)**
[How was the gene for dentatorubral-pallidoluysian atrophy discovered?] Tsuji S, et al. **No To Shinkei** 1996 Apr; 48(4):323-8 (27 ref.) **(Jpn)**

PHYSIOLOGY

Ocular motor systems. Part 2: Nuclear and supranuclear systems. Skarf B. **J Neuroophthalmol** 1995 Sep; 15(3):191-201 (74 ref.)

CEREBELLUM

ABNORMALITIES

Atrioventricular canal and 3C (cranio-cerebello-cardiac) syndrome [letter; comment] Digilio MC, et al.
Am J Med Genet 1995 Jul 31;58(1):97-8 (15 ref.) Comment on: Am J Med Genet 1994 Aug 1;52(1):66-9.

BLOOD SUPPLY

A rare case of the posterior inferior cerebellar artery. Cavdar S, et al. **Acta Anat (Basel)** 1995;152(3):234-6 (19 ref.)
Peripheral aneurysms of the anterior inferior cerebellar artery. Case report and review of literature. Spallone A, et al. **Br J Neurosurg** 1995;9(4):537-41 (38 ref.)
[Superficial temporal artery to superior cerebellar artery anastomosis via the presigmoid retrolabyrinthine transtentorial approach] Ito M, et al. **No Shinkei Geka** 1995 Oct;23(10):869-74 (20 ref.) **(Jpn)**

ENZYMOLOGY

Aldolase C/zebrin II and the regionalization of the cerebellum. Hawkes R, et al. **J Mol Neurosci** 1995; 6(3):147-58 (75 ref.)

PATHOLOGY

Progressive myoclonic ataxia associated with coeliac disease. The myoclonus is of cortical origin, but the pathology is in the cerebellum. Bhatia KP, et al. **Brain** 1995 Oct;118 (Pt 5):1087-93 (14 ref.)
The relationship of multiple system atrophy to sporadic olivopontocerebellar atrophy and other forms of idiopathic late-onset cerebellar atrophy. Gilman S, et al.
Neurology 1996 May;46(5):1197-9 (40 ref.)

PHYSIOLOGY

Modulation of inhibitory synapses in the mammalian brain. Marty A, et al. **Curr Opin Neurobiol** 1995 Jun;5(3):335-41 (38 ref.)
Role of the cerebellum in movement control and adaptation. Robinson FR. **Curr Opin Neurobiol** 1995 Dec;5(6):755-62 (49 ref.)
Contribution of the cerebellar vermis to cardiovascular control. Ghelarducci B, et al. **J Auton Nerv Syst** 1996 Jan 5;56(3):149-56 (51 ref.)
Cerebellar contributions to cognition. Fiez JA. **Neuron** 1996 Jan;16(1):13-5 (23 ref.)
The role of the cerebello-thalamo-cortical pathway in skilled movement. Horne MK, et al. **Prog Neurobiol** 1995 Jun; 46(2-3):199-213 (150 ref.)
The cerebellum: a neuronal learning machine? Raymond JL, et al. **Science** 1996 May 24;272(5265):1126-31 (49 ref.)
Cerebellar long-term depression might normalize excitation of Purkinje cells: a hypothesis. De Schutter E.
Trends Neurosci 1995 Jul;18(7):291-5 (79 ref.)

PHYSIOPATHOLOGY

Hemifacial seizures and cerebellar ganglioglioma: an epilepsy syndrome of infancy with seizures of cerebellar origin. Harvey AS, et al. **Ann Neurol** 1996 Jul;40(1):91-8 (7 ref.)
Neurologic intensive care unit management and economic issues. Sundrani S. **Neurol Clin** 1995 Aug;13(3):679-93 (57 ref.)
Proximal ligation of large distal posterior inferior cerebellar artery aneurysm. Yamaguchi N, et al.
Neurol Med Chir (Tokyo) 1996 Jan;36(1):31-5 (20 ref.)

CEREBRAL AMYLOID ANGIOPATHY

COMPLICATIONS

Amyloid angiopathy-related cerebellar hemorrhage. Cuny E, et al. **Surg Neurol** 1996 Sep;46(3):235-9 (22 ref.)

GENETICS

Leptomeningeal amyloid and variant transthyretins [comment] Benson MD. **Am J Pathol** 1996 Feb; 148(2):351-4 (19 ref.) Comment on: Am J Pathol 1996 Feb;148(2):361-6.

PATHOLOGY

Pathology of the vessels in cerebral amyloid angiopathy. Liberski PP, et al. **Folia Neuropathol** 1995;33(4):207-14 (68 ref.)
Primary angiitis of the central nervous system associated with cerebral amyloid angiopathy: report of two cases and review of the literature. Fountain NB, et al. **Neurology** 1996 Jan;46(1):190-7 (39 ref.)

CEREBRAL ANEURYSM

Giant intracranial aneurysms in two sisters: case report. Kato S, et al. **Surg Neurol** 1996 Sep;46(3):240-6 (52 ref.)

COMPLICATIONS

Innovations in aneurysmal subarachnoid hemorrhage: intracisternal t-PA for the prevention of vasospasm. Bell TE, et al. **J Neurosci Nurs** 1996 Apr;28(2):107-13 (37 ref.)
Management of aneurysmal subarachnoid hemorrhage. Miller J, et al. **Neurol Clin** 1995 Aug;13(3):451-78 (112 ref.)
Is Marfan syndrome associated with symptomatic intracranial aneurysms? van den Berg JS, et al. **Stroke** 1996 Jan; 27(1):10-2 (35 ref.)
Systemic multiple aneurysms of the intracranial arteries and visceral arteries: case report. Fuse T, et al. **Surg Neurol** 1996 Sep;46(3):258-61; discussion 261-2 (13 ref.)
[A case of de novo aneurysm of the distal posterior inferior cerebellar artery with intraventricular hemorrhage] Kojima A, et al. **No Shinkei Geka** 1996 May;24(5):469-73 (10 ref.) (Eng. Abstr.) **(Jpn)**
[Neurofibromatosis associated with multiple intracranial vascular lesions: stenosis of the internal carotid artery and peripheral aneurysm of the Heubner's artery; report of a case] Sasaki J, et al. **No Shinkei Geka** 1995 Sep;23(9):813-7 (22 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Distinction of masses involving the sella and suprasellar space: specificity of imaging features. Donovan JL, et al. **AJR Am J Roentgenol** 1996 Sep;167(3):597-603 (69 ref.)
Intracranial aneurysms. Puskar G, et al.
Magn Reson Imaging Clin N Am 1995 Aug;3(3):467-83 (52 ref.)
Spontaneous extracranial carotid artery dissection in children. Patel H, et al. **Pediatr Neurol** 1995 Jul;13(1):55-60 (26 ref.)
[Dissection of the carotid artery and vertebral artery--diagnosis and therapy] Sperling W, et al.

Fortschr Neurol Psychiatr 1996 Apr;64(4):153–60 (37 ref.) (Eng. Abstr.) **(Ger)**

[Cerebral artery dissection] Sturzenegger M, et al. **Ther Umsch** 1996 Jul;53(7):544–51 (32 ref.) (Eng. Abstr.) **(Ger)**

[Giant intracranial aneurysms: a case history assessment of the correlation between etiopathogenetic hypothesis and magnetic resonance imaging] Manfrè L, et al. **Radiol Med (Torino)** 1995 Dec;90(6):822–5 (12 ref.) (Eng. Abstr.) **(Ita)**

[Dolichoectatic intracranial arteries. Advances in images and therapeutics] Casas Parera I, et al. **Medicina (B Aires)** 1995; 55(1):59–68 (62 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

ADPKD–associated intracranial aneurysm: new insights and unanswered questions. Pirson Y, et al. **Contrib Nephrol** 1995;115:53–8 (21 ref.)

[Giant intracranial aneurysms: a case history assessment of the correlation between etiopathogenetic hypothesis and magnetic resonance imaging] Manfrè L, et al. **Radiol Med (Torino)** 1995 Dec;90(6):822–5 (12 ref.) (Eng. Abstr.) **(Ita)**

PATHOLOGY

Anatomy of segmental duplication in the human basilar artery. Possible site of aneurysm formation. De Caro R, et al. **Clin Neuropathol** 1995 Nov–Dec;14(6):303–9 (35 ref.)

PHYSIOPATHOLOGY

Energetic and spatial constraints of arterial networks. Rossitti S. **Arq Neuropsiquiatr** 1995 Jun;53(2):333–41 (48 ref.)

False traumatic aneurysm of the dorsal wall of the supraclinoid internal carotid artery—case report. Saito K, et al. **Neurol Med Chir (Tokyo)** 1995 Dec;35(12):886–91 (26 ref.)

Proximal ligation of large distal posterior inferior cerebellar artery aneurysm. Yamaguchi N, et al. **Neurol Med Chir (Tokyo)** 1996 Jan;36(1):31–5 (20 ref.)

Complications of Swan–Ganz catheterization for hemodynamic monitoring in patients with subarachnoid hemorrhage. Rosenwasser RH, et al. **Neurosurgery** 1995 Nov;37(5):872–5; discussion 875–6 (21 ref.)

RADIOGRAPHY

Natural history of giant intracranial aneurysms and indications for intervention. Barrow DL, et al. **Clin Neurosurg** 1995;42:214–44 (106 ref.)

Ruptured aneurysm at the origin of duplication of the middle cerebral artery—case report. Koyama S, et al. **Neurol Med Chir (Tokyo)** 1995 Sep;35(9):671–3 (24 ref.)

SURGERY

Perioperative management of aneurysmal subarachnoid hemorrhage: Part 2. Postoperative management. McGrath BJ, et al. **Anesth Analg** 1995 Dec;81(6):1295–302 (94 ref.)

Ensuring adequate cerebral perfusion during aneurysm surgery [editorial] Miller JD. **Br J Anaesth** 1995 Nov; 75(5):518–9 (12 ref.)

Anaesthesia for cerebral aneurysm surgery. Nathanson M, et al. **Br J Hosp Med** 1995 Oct 18–31;54(8):405–8 (12 ref.)

Peripheral aneurysms of the anterior inferior cerebellar artery. Case report and review of literature. Spallone A, et al. **Br J Neurosurg** 1995;9(4):537–41 (38 ref.)

Surgical management of giant intracranial aneurysms: experience with 171 patients. Lawton MT, et al. **Clin Neurosurg** 1995;42:245–66 (74 ref.)

Endovascular surgical approach to intracranial vascular diseases. Higashida RT, et al. **J Endovasc Surg** 1996 May; 3(2):146–57 (57 ref.)

Aneurysmal subarachnoid hemorrhage in a patient with bilateral A1 fenestrations associated with an azygos anterior cerebral artery. Case report and literature review. Friedlander RM, et al. **J Neurosurg** 1996 Apr;84(4):681–4 (33 ref.)

Proximal ligation of large distal posterior inferior cerebellar artery aneurysm. Yamaguchi N, et al. **Neurol Med Chir (Tokyo)** 1996 Jan;36(1):31–5 (20 ref.)

Ruptured dissecting aneurysm of the peripheral anterior cerebral artery—case report. Yano H, et al. **Neurol Med Chir (Tokyo)** 1995 Jul;35(7):450–3 (17 ref.)

Management of traumatic aneurysms caused by high-velocity missile head wounds. Aarabi B. **Neurosurg Clin N Am** 1995 Oct;6(4):775–97 (263 ref.)

Postsurgical development of dural arteriovenous malformations after transpetrosal and transtentorial operations: case report. Sasaki T, et al. **Neurosurgery** 1995 Oct;37(4):820–4; discussion 824–5 (14 ref.)

[A case of anterior cerebral artery dissecting aneurysm] Araki T, et al. **No Shinkei Geka** 1996 Jan;24(1):87–91 (19 ref.) (Eng. Abstr.) **(Jpn)**

[Surgical treatment of aneurysms at basilar artery and posterior cerebral artery associated with moyamoya disease: a case report] Kawaguti T, et al. **No Shinkei Geka** 1995 Sep;23(9):807–11 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Profound hypothermia and circulatory arrest in cerebral aneurysm surgery] Nagao S. **No Shinkei Geka** 1996 Jun; 24(6):507–15 (70 ref.) **(Jpn)**

[BA top aneurysm] Nagata I, et al. **No Shinkei Geka** 1996 Jun;24(6):517–22 (12 ref.) **(Jpn)**

[Surgical techniques for aneurysms in and around the cavernous sinus] Ohnishi H. **No Shinkei Geka** 1995 Nov; 23(11):955–62 (12 ref.) **(Jpn)**

[The surgical treatment of an aneurysm with a carotid–ophthalmic location] Krylov VV, et al. **Zh Vopr Neirokhir Im N N Burdenko** 1995 Jul–Sep;(3):31–2 (24 ref.) **(Rus)**

THERAPY

Interventional neuroradiology. Pelz DM. **Baillieres Clin Neurol** 1995 Aug;4(2):297–315 (60 ref.)

Endovascular management of giant intracranial aneurysms. Standard SC, et al. **Clin Neurosurg** 1995;42:267–93 (92 ref.)

ULTRASONOGRAPHY

Prenatal diagnosis of cerebral arteriovenous malformation using color Doppler ultrasonography: case report and review of the literature. Sepulveda W, et al. **Ultrasound Obstet Gynecol** 1995 Oct;6(4):282–6 (30 ref.)

CEREBRAL ANGIOGRAPHY

Interventional neuroradiology. Pelz DM. **Baillieres Clin Neurol** 1995 Aug;4(2):297–315 (60 ref.)

Hyperhomocysteinaemia; with reference to its neuroradiological aspects. van den Berg M, et al. **Neuroradiology** 1995 Jul;37(5):403–11 (78 ref.)

ADVERSE EFFECTS

[A case of pituitary adenoma progressing to pituitary apoplexy on the occasion of cerebral angiography] Suga T, et al. **No Shinkei Geka** 1996 May;24(5):475–9 (12 ref.) (Eng. Abstr.) **(Jpn)**

METHODS

[Role of magnetic resonance imaging in cerebral venous thrombosis] Bousser MG. **J Mal Vasc** 1995;20(3):189–93 (21 ref.) (Eng. Abstr.) **(Fre)**

CEREBRAL ANOXIA

Hypoxic and ischemic central nervous system disorders in infants and children. Johnston MV, et al. **Adv Pediatr** 1995; 42:1–45 (178 ref.)

COMPLICATIONS

[Cerebral hypoxic and ischemic damage in newborn infants: cellular mechanisms and role of excitatory amino acids] Cortey A. **Arch Pediatr** 1995 Dec;2(12):1192–9 (44 ref.) (Eng. Abstr.) **(Fre)**

CONGENITAL

–Prenatal diagnosis of brain damage in the fetus– Dürig P. **Arch Gynecol Obstet** 1995;256 Suppl:S43–9 (46 ref.) **(Ger)**

DIAGNOSIS

[Magnetic resonance in delayed postanoxic encephalopathy following acute carbon monoxide poisoning. A case report] Pagnan L, et al. **Radiol Med (Torino)** 1996 Mar;91(3):309–11 (20 ref.) **(Ita)**

ETIOLOGY

Cerebral resuscitation from cardiac arrest: treatment potentials. Gisvold SE, et al. **Crit Care Med** 1996 Feb;24(2 Suppl):S69–80 (79 ref.)

Cerebral resuscitation from cardiac arrest: pathophysiologic mechanisms. Vaagenes P, et al. **Crit Care Med** 1996 Feb; 24(2 Suppl):S57–68 (103 ref.)

Secondary brain insults after head injury: clinical perspectives. Chesnut RM. **New Horiz** 1995 Aug; 3(3):366–75 (44 ref.)

The management of renal failure in patients at risk of cerebral edema/hypoxia. Davenport A. **New Horiz** 1995 Nov; 3(4):717–24 (54 ref.)

–Perinatal asphyxia of the neonate at term– Fawer CL. **Arch Gynecol Obstet** 1995;256 Suppl:S61–70 (13 ref.) **(Fre)**

METABOLISM

Nitric oxide in the central nervous system. Paakkari I, et al. **Ann Med** 1995 Jun;27(3):369–77 (96 ref.)

[Cerebral hypoxic and ischemic damage in newborn infants: cellular mechanisms and role of excitatory amino acids] Cortey A. **Arch Pediatr** 1995 Dec;2(12):1192–9 (44 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Breath-holding spells. Breningstall GN. **Pediatr Neurol** 1996 Feb;14(2):91–7 (35 ref.)

Near infrared spectroscopy: methodological principles and clinical application in preterm infants. Bernert G, et al. **Wien Klin Wochenschr** 1995;107(19):569–73 (36 ref.)

[Cerebral resuscitation: pathophysiological limitations and therapeutic possibilities (editorial)] Strebel S. **Schweiz Rundsch Med Prax** 1996 Jan 16;85(3):35–8 (33 ref.) **(Ger)**

[Pathophysiology of hypoxia–ischemia in the developing brain] Yoshioka H, et al. **No To Shinkei** 1996 Jul; 48(7):613–20 (50 ref.) **(Jpn)**

PREVENTION & CONTROL

Neuroprotective properties of the uncompetitive NMDA receptor antagonist remacemide hydrochloride. Palmer GC, et al. **Ann N Y Acad Sci** 1995 Sep 15;765:236–47; discussion 248 (38 ref.)

Dexamethasone and the prevention of neonatal hypoxic–ischemic brain damage. Tuor UI. **Ann N Y Acad Sci** 1995 Sep 15;765:179–95; discussion 196–7 (97 ref.)

Pathophysiology of postischemic hypoxia and cerebral protection: implications of the almitrine and raubasine combination. Chan P. **Eur Neurol** 1995;35 Suppl 1:23–7 (41 ref.)

THERAPY

Cerebral resuscitation from cardiac arrest: treatment potentials. Gisvold SE, et al. **Crit Care Med** 1996 Feb;24(2 Suppl):S69–80 (79 ref.)

Cerebral resuscitation from cardiac arrest: pathophysiologic mechanisms. Vaagenes P, et al. **Crit Care Med** 1996 Feb; 24(2 Suppl):S57–68 (103 ref.)

CEREBRAL ARTERIES

see related

CEREBRAL ANGIOGRAPHY

Energetic and spatial constraints of arterial networks. Rossitti S. **Arq Neuropsiquiatr** 1995 Jun;53(2):333–41 (48 ref.)

[Surgical treatment of aneurysms at basilar artery and posterior cerebral artery associated with moyamoya disease: a case report] Kawaguti T, et al. **No Shinkei Geka** 1995 Sep;23(9):807–11 (15 ref.) (Eng. Abstr.) **(Jpn)**

[The moyamoya syndrome secondary to fibromuscular dysplasia of the middle cerebral artery] Verdú Pérez A, et al. **An Esp Pediatr** 1996 Jul;45(1):99–100 (12 ref.) **(Spa)**

ABNORMALITIES

Ruptured aneurysm at the origin of duplication of the middle cerebral artery—case report. Koyama S, et al. **Neurol Med Chir (Tokyo)** 1995 Sep;35(9):671–3 (24 ref.)

ANATOMY & HISTOLOGY

Microsurgical anatomy of the posterior choroidal arteries. Vinas FC, et al. **Neurol Res** 1995 Oct;17(5):334–44 (34 ref.)

INNERVATION

The physiology of the cerebrovascular parasympathetic innervation. Branston NM. **Br J Neurosurg** 1995; 9(3):319–29 (25 ref.)

Nitroxidergic nerves and hypertension. Toda N. **Hypertens Res** 1995 Mar;18(1):19–26 (68 ref.)

Nitroxidergic nerve: regulation of vascular tone and blood flow in the brain. Toda N, et al. **J Hypertens** 1996 Apr; 14(4):423–34 (127 ref.)

Innervation of cerebral arteries by nerves containing 5–hydroxytryptamine and noradrenaline. Lincoln J. **Pharmacol Ther** 1995;68(3):473–501 (256 ref.)

PATHOLOGY

Amyloid beta–protein induces the cerebrovascular cellular pathology of Alzheimer's disease and related disorders. Van Nostrand WE, et al. **Ann N Y Acad Sci** 1996 Jan 17; 777:297–302 (19 ref.)

Cocaine–associated intracranial hemorrhage: absence of vasculitis in 14 cases. Aggarwal SK, et al. **Neurology** 1996 Jun;46(6):1741–3 (10 ref.)

[An autopsy case of "diffuse neurofibrillary tangles with calcification", multiple infarctions and hyaline arteriosclerosis] Arai T, et al. **No To Shinkei** 1996 Jan; 48(1):69–76 (26 ref.) (Eng. Abstr.) **(Jpn)**

[Dolichoectatic intracranial arteries. Advances in images and therapeutics] Casas Parera I, et al. **Medicina (B Aires)** 1995; 55(1):59–68 (62 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

Calcium channels in cerebral arteries. Alborch E, et al. **Pharmacol Ther** 1995;68(1):1–34 (187 ref.)

PHYSIOPATHOLOGY

Ruptured aneurysm of the distal posterior inferior cerebellar artery in a neonate—case report. Hosotani K, et al. **Neurol Med Chir (Tokyo)** 1995 Dec;35(12):892–5 (11 ref.)

Spontaneous dissecting aneurysm of the anterior cerebral artery: report of two cases. Koyama S, et al. **Surg Neurol** 1996 Jul;46(1):55–61 (15 ref.)

[The significance of so-called "high-intensity transient signals" (HITS) during transcranial Doppler sonography] Sliwka U, et al. **Dtsch Med Wochenschr** 1995 Dec 1; 120(48):1667–70 (28 ref.) **(Ger)**

[Non-inflammatory arteriopathies] Alvarez-Sabín J. **Rev Neurol** 1995;23 Suppl 1:S33–40 (52 ref.) **(Spa)**

CEREBRAL ARTERIES

RADIOGRAPHY

Carotid artery pseudoaneurysm and pellet embolism to the middle cerebral artery following a shotgun wound of the neck. Cogbill TH, et al. **J Trauma** 1995 Oct;39(4):763–7 (16 ref.)

SURGERY

Treatment of ruptured cerebral aneurysm in moyamoya disease. Kodama N, et al. **Surg Neurol** 1996 Jul;46(1):62–6 (12 ref.)

[Early reperfusion as a rationale from of therapy in ischemic stroke] Garcia JH. **Rev Neurol** 1995 Sep–Oct; 23(123):1067–73 (40 ref.) (Eng. Abstr.) **(Spa)**

CEREBRAL ARTERIOSCLEROSIS

see related
DEMENTIA, VASCULAR

ULTRASONOGRAPHY

Ultrasonography for diagnosis and management of carotid artery atherosclerosis. A position paper of the American Society of Neuroimaging. Weinberger J, et al. **J Neuroimaging** 1995 Oct;5(4):237–43 (42 ref.)

CEREBRAL ARTERIOVENOUS MALFORMATIONS

COMPLICATIONS

Combined malformation of the Vein of Galen and of spinal vessels: endovascular embolization. Hammen A, et al. **Clin Neuropathol** 1995 Jul–Aug;14(4):233–6 (15 ref.)

Headache as a symptom of organic diseases. Edmeads JG. **Curr Opin Neurol** 1995 Jun;8(3):233–6 (32 ref.)

Intramedullary haemorrhage due to AVM located within the medulla oblongata in a three year old child. Case report. Maggi G, et al. **J Neurosurg Sci** 1994 Dec;38(4):255–8 (15 ref.)

[What to do in a 60-year-old HIV-positive woman with a cerebral arteriovenous malformation? Decision analysis (see comments)] Dippel DW, et al. **Ned Tijdschr Geneeskd** 1995 Nov 18;139(46):2362–9 (52 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1996 Feb 17;140(7):386–7. **(Dut)**

[Multiple dural arteriovenous shunts presenting as subarachnoid hemorrhage: a case report] Nimura K, et al. **No Shinkei Geka** 1995 Sep;23(9):819–24 (22 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Isolated cerebral intraaxial varix. Kelly KJ, et al. **AJNR Am J Neuroradiol** 1995 Sep;16(8):1633–5 (10 ref.)

Vascular malformations. Marks MP. **Magn Reson Imaging Clin N Am** 1995 Aug;3(3):485–91 (25 ref.)

Spontaneous disappearance of a cerebral arteriovenous malformation. Shimizu K, et al. **Neurol Med Chir (Tokyo)** 1996 Jan;36(1):26–30 (25 ref.)

Dural arteriovenous fistulas of superior sagittal sinus: case report and review of literature. Kurl S, et al. **Surg Neurol** 1996 Mar;45(3):250–5 (23 ref.)

GENETICS

Familial arteriovenous malformations in children. Brilli RJ, et al. **Pediatr Emerg Care** 1995 Dec;11(6):376–8 (14 ref.)

MORTALITY

Cure, morbidity, and mortality associated with embolization of brain arteriovenous malformations: a review of 1246 patients in 32 series over a 35-year period. Frizzel RT, et al. **Neurosurgery** 1995 Dec;37(6):1031–9; discussion 1039–40 (56 ref.)

PATHOLOGY

Developmental failures of blood vessels within central nervous system. Rafalowska J. **Folia Neuropathol** 1995; 33(4):201–6 (46 ref.)

PHYSIOPATHOLOGY

Embryological basis of some aspects of cerebral vascular fistulas and malformations. Mullan S, et al. **J Neurosurg** 1996 Jul;85(1):1–8 (20 ref.)

SURGERY

Complications after multidisciplinary treatment of cerebral arteriovenous malformations. Deruty R, et al. **Acta Neurochir (Wien)** 1996;138(2):119–31 (46 ref.)

Brain stem surgery [editorial] Jackowski A. **Br J Neurosurg** 1995;9(5):581–4 (32 ref.)

Microsurgical treatment of arteriovenous malformations in critical areas of the brain. O'Laoire SA. **Br J Neurosurg** 1995;9(3):347–60 (60 ref.)

Radiosurgery for arteriovenous malformations. Friedman WA. **Clin Neurosurg** 1995;42:328–47 (43 ref.)

Surgical treatment of intracranial arteriovenous malformations with an analysis of cost–effectiveness. Nussbaum ES, et al. **Clin Neurosurg** 1995;42:348–69 (65 ref.)

Vascular lesions of the cranial base. Shin JH, et al. **Clin Plast Surg** 1995 Jul;22(3):531–42 (21 ref.)

Stereotactic radiosurgery for postgeniculate visual pathway arteriovenous malformations. Pollock BE, et al. **J Neurosurg** 1996 Mar;84(3):437–41 (29 ref.)

Arteriovenous malformation associated with a large cyst—case report. Hatashita S, et al. **Neurol Med Chir (Tokyo)** 1995 Jun;35(6):377–9 (8 ref.)

Intracranial cavernous malformations: lesion behavior and management strategies. Maraire JN, et al. **Neurosurgery** 1995 Oct;37(4):591–605 (123 ref.)

Childhood dural arteriovenous fistulae of the posterior dural sinuses: three case reports and literature review. Morita A, et al. **Neurosurgery** 1995 Dec;37(6):1193–9; discussion 1199–200 (34 ref.)

[Radiosurgery by linear accelerators in the treatment of 84 arteriovenous malformations] Schlienger M, et al. **Bull Cancer (Paris)** 1995 Dec;82 Suppl 5:581s–585s (25 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Role of transarterial embolization in the management of cerebral arteriovenous malformations. Wikholm G. **Acta Radiol Suppl** 1996;404:1–25 (118 ref.)

Interventional neuroradiology. Pelz DM. **Baillieres Clin Neurol** 1995 Aug;4(2):297–315 (60 ref.)

Therapy of AVMs: a decision analysis. Fisher WS 3rd. **Clin Neurosurg** 1995;42:294–312 (31 ref.)

Cure, morbidity, and mortality associated with embolization of brain arteriovenous malformations: a review of 1246 patients in 32 series over a 35-year period. Frizzel RT, et al. **Neurosurgery** 1995 Dec;37(6):1031–9; discussion 1039–40 (56 ref.)

[What to do in a 60-year-old HIV-positive woman with a cerebral arteriovenous malformation? Decision analysis (see comments)] Dippel DW, et al. **Ned Tijdschr Geneeskd** 1995 Nov 18;139(46):2362–9 (52 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1996 Feb 17;140(7):386–7. **(Dut)**

[Therapeutic risk in multidisciplinary approach of cerebral arteriovenous malformations] Deruty R, et al. **Neurochirurgie** 1996;42(1):35–43 (46 ref.) (Eng. Abstr.) **(Fre)**

CEREBRAL ARTERY DISEASES

COMPLICATIONS

Subarachnoid haemorrhage and myths about saccular aneurysms. Weller RO. **J Clin Pathol** 1995 Dec; 48(12):1078–81 (29 ref.)

DIAGNOSIS

[Vasculitis] Berlit P. **Ther Umsch** 1996 Jul;53(7):559–67 (36 ref.) (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

[Risk factors and prevention of cerebral artery disease] Diener HC. **Internist (Berl)** 1995 Sep;36(9):868–74 (30 ref.) **(Ger)**

CEREBRAL CORTEX

see related
ELECTROENCEPHALOGRAPHY

ABNORMALITIES

Cortical maldevelopment, anti–psychotic drugs, and schizophrenia: a search for common ground. Weinberger DR, et al. **Schizophr Res** 1995 Aug 1;16(2):87–110 (215 ref.)

Wiring, dysmorphogenesis and epilepsy: a hypothesis. Sisodiya SM. **Seizure** 1995 Sep;4(3):169–85 (89 ref.)

[Classification and pathogenesis of cerebral cortical malformations] Takashima S, et al. **No To Hattatsu** 1996 Jan;28(1):14–22 (22 ref.) (Eng. Abstr.) **(Jpn)**

[The congenital bilateral perisylvian syndrome: a report of 2 new cases] Vaquerizo Madrid J, et al. **An Esp Pediatr** 1996 Jun;44(6):617–9 (11 ref.) **(Spa)**

ANATOMY & HISTOLOGY

Anatomical evidence concerning the role of the thalamus in corticocortical communication: a brief review. Guillery RW. **J Anat** 1995 Dec;187 (Pt 3):583–92 (69 ref.)

Homology in the evolution of the cerebral hemispheres. The case of reptilian dorsal ventricular ridge and its possible correspondence with mammalian neocortex. Aboitiz F. **J Hirnforsch** 1995;36(4):461–72 (84 ref.)

Numbers, time and neocortical neuronogenesis: a general developmental and evolutionary model. Caviness VS Jr, et al. **Trends Neurosci** 1995 Sep;18(9):379–83 (24 ref.)

[The development of human cerebral cortex] Marín–Padilla M. **Rev Neurol** 1995;23 Suppl 3:S261–8 (37 ref.) **(Spa)**

CYTOLOGY

Proliferative events in the cerebral ventricular zone. Caviness VS Jr, et al. **Brain Dev** 1995 May–Jun;17(3):159–63 (36 ref.)

The usual suspects: GABA and glutamate may regulate proliferation in the neocortex. LaMantia AS. **Neuron** 1995 Dec;15(6):1223–5 (25 ref.)

Constructing the cerebral cortex: neurogenesis and fate determination. McConnell SK. **Neuron** 1995 Oct; 15(4):761–8 (70 ref.)

Integrator or coincidence detector? The role of the cortical neuron revisited. König P, et al. **Trends Neurosci** 1996 Apr; 19(4):130–7 (45 ref.)

A small step for the cell, a giant leap for mankind: a hypothesis of neocortical expansion during evolution. Rakic P. **Trends Neurosci** 1995 Sep;18(9):383–8 (59 ref.)

DRUG EFFECTS

Propofol. An update of its use in anaesthesia and conscious sedation. Bryson HM, et al. **Drugs** 1995 Sep;50(3):513–59 (622 ref.)

[Glutamatergic hypothesis of schizophrenia: psychoses induced by phencyclidine and cortical–subcortical imbalance] Krebs MO. **Encephale** 1995 Sep–Oct; 21(5):581–8 (52 ref.) (Eng. Abstr.) **(Fre)**

EMBRYOLOGY

Proliferative events in the cerebral ventricular zone. Caviness VS Jr, et al. **Brain Dev** 1995 May–Jun;17(3):159–63 (36 ref.)

Role of the subplate neurons in specification of neocortical areas. Woźniak W. **Folia Morphol (Warsz)** 1995;54(3):141–5 (26 ref.)

Radial versus tangential migration of neuronal clones in the developing cerebral cortex [comment] Rakic P. **Proc Natl Acad Sci U S A** 1995 Dec 5;92(25):11323–7 (61 ref.) Comment on: Proc Natl Acad Sci U S A 1995 Dec 5;92(25):11676–80.

Plasticity and commitment in the developing cerebral cortex. McConnell SK. **Prog Brain Res** 1995;105:129–43 (107 ref.)

GROWTH & DEVELOPMENT

Neurotransmitter receptors in the developing cerebral cortex. Lidow MS, et al. **Crit Rev Neurobiol** 1995;9(4):395–418 (162 ref.)

Constructing the cerebral cortex: neurogenesis and fate determination. McConnell SK. **Neuron** 1995 Oct; 15(4):761–8 (70 ref.)

Cell death in cortical development: How much? Why? So what? Voyvodic JT. **Neuron** 1996 Apr;16(4):693–6 (16 ref.)

[Development of visual perception in early childhood] Farber DA, et al. **Fiziol Cheloveka** 1995 Sep–Oct;21(5):162–71 (92 ref.) **(Rus)**

METABOLISM

Neurotransmitter receptors in the developing cerebral cortex. Lidow MS, et al. **Crit Rev Neurobiol** 1995;9(4):395–418 (162 ref.)

Induced expression of adhesion molecules following focal brain ischemia. Wang X, et al. **J Neurotrauma** 1995 Oct; 12(5):825–32 (44 ref.)

GM2 ganglioside and pyramidal neuron dendritogenesis. Walkley SU, et al. **Neurochem Res** 1995 Nov; 20(11):1287–99 (115 ref.)

Neuropeptide changes in cortical and deep gray structures in Alzheimer's disease. Roeske LC, et al. **Rev Neurosci** 1995 Oct–Dec;6(4):317–28 (156 ref.)

PATHOLOGY

Neuropathology of the cortex in amyotrophic lateral sclerosis with dementia. Pellissier JF, et al. **Adv Neurol** 1995; 68:139–41 (41 ref.)

The cortical neuritic dystrophy of Alzheimer's disease: nature, significance, and possible pathogenesis. Larner AJ. **Dementia** 1995 Jul–Aug;6(4):218–24 (84 ref.)

Hippocampal and neocortical involvement in normal brain aging and dementia: morphological and neurochemical profile of the vulnerable circuits. Hof PR, et al. **J Am Geriatr Soc** 1996 Jul;44(7):857–64 (83 ref.)

[Anarthria, progressive apraxia and extrapyramidal syndrome: an uncommon clinical form of corticobasal degeneration? A case studied by HMPAO Tc99m single–photon emission tomography] Fayet G, et al. **Rev Neurol (Paris)** 1995 Apr;151(4):247–50 (14 ref.) (Eng. Abstr.) **(Fre)**

[Characterization of gestural disorders in primary progressive apraxia: diagnostic and nosographic contribution] Habib M, et al. **Rev Neurol (Paris)** 1995 Oct;151(10):541–51 (29 ref.) (Eng. Abstr.) **(Fre)**

[Corticobasal degeneration: clinical features] Ueno E. **No To Shinkei** 1996 Jun;48(6):505–12 (42 ref.) **(Jpn)**

[Neuropathology of corticobasal degeneration] Wakabayashi K, et al. **No To Shinkei** 1996 Jun;48(6):521–32 (88 ref.) **(Jpn)**

PHYSIOLOGY

Development of oscillatory activity in the limbic cortex in vitro. Konopacki J. **Acta Neurobiol Exp (Warsz)** 1996; 56(1):407–21 (51 ref.)

No–go potential in the prefrontal cortex and electrical stimulation of its loci in monkeys. Sasaki K. **Adv Neurol** 1995;67:131–41 (20 ref.)

The limbic system of tetrapods: a comparative analysis of cortical and amygdalar populations. Bruce LL, et al. **Brain Behav Evol** 1995;46(4–5):224–34 (90 ref.)

The evolution of isocortex. Kaas JH. **Brain Behav Evol** 1995; 46(4–5):187–96 (52 ref.)
The evolution of ideas concerning the function of the neocortex. Mountcastle V. **Cereb Cortex** 1995 Jul–Aug; 5(4):289–95 (19 ref.)
Neural networks. Sleep and memory. Sejnowski TJ. **Curr Biol** 1995 Aug 1;5(8):832–4 (14 ref.)
Localization of functional regions of human mesial cortex by somatosensory evoked potential recording and by cortical stimulation. Allison T, et al. **Electroencephalogr Clin Neurophysiol** 1996 Mar; 100(2):126–40 (62 ref.)
Regulation of normal proliferation in the developing cerebrum potential actions of trophic factors. Caviness VS Jr, et al. **Exp Neurol** 1996 Feb;137(2):357–66 (79 ref.)
Anatomical evidence concerning the role of the thalamus in corticocortical communication: a brief review. Guillery RW. **J Anat** 1995 Dec;187 (Pt 3):583–92 (69 ref.)
Clinical neurophysiology of cortical sensorimotor function: yesterday, today, and tomorrow. Aminoff MJ. **J Clin Neurophysiol** 1996 May;13(3):219–26 (60 ref.)
The critical period for long-term potentiation in primary sensory cortex. Fox K. **Neuron** 1995 Sep;15(3):485–8 (21 ref.)
The mental and the neural: psychological and neural studies of mental rotation and memory scanning. Georgopoulos AP, et al. **Neuropsychologia** 1995 Nov;33(11):1531–47 (25 ref.)
Activation by GABAb, reduction of the intracellular concentration of Ca++, and inhibition of protein kinases are possible mechanisms of the long-term posttetanic modification of the efficiency of inhibitory transmission in the new cortex. Silʹkis IG. **Neurosci Behav Physiol** 1996 Jan–Feb;26(1):88–97 (41 ref.)
The role of the cerebello-thalamo-cortical pathway in skilled movement. Horne MK, et al. **Prog Neurobiol** 1995 Jun; 46(2–3):199–213 (150 ref.)
The temporal relationship between the brainstem and primary cortical auditory evoked potentials. Shaw NA. **Prog Neurobiol** 1995 Oct;47(2):95–103 (66 ref.)
Development and plasticity of cortical processing architectures. Singer W. **Science** 1995 Nov 3; 270(5237):758–64 (66 ref.)
Functional brain imaging studies of cortical mechanisms for memory. Ungerleider LG. **Science** 1995 Nov 3; 270(5237):769–75 (94 ref.)
Behind the optic nerve: an inside view of the primate visual system. Van Essen DC. **Trans Am Ophthalmol Soc** 1995; 93:123–33 (2 ref.)
Exuberant development of connections, and its possible permissive role in cortical evolution. Innocenti GM. **Trends Neurosci** 1995 Sep;18(9):397–402 (57 ref.)
Grasping objects: the cortical mechanisms of visuomotor transformation. Jeannerod M, et al. **Trends Neurosci** 1995 Jul;18(7):314–20 (43 ref.)
The organization of neocortex in mammals: are species differences really so different? Krubitzer L. **Trends Neurosci** 1995 Sep;18(9):408–17 (66 ref.)
How do thalamic axons find their way to the cortex? Molnár Z, et al. **Trends Neurosci** 1995 Sep;18(9):389–97 (54 ref.)
The emergence and evolution of mammalian neocortex. Northcutt RG, et al. **Trends Neurosci** 1995 Sep;18(9):373–9 (51 ref.)
[Neurophysiological mechanisms of the cortical–subcortical interrelationships in the organization of behavior] Shuvaev VT, et al. **Fiziol Zh Im I M Sechenova** 1995 Aug; 81(8):110–20 (29 ref.) (Eng. Abstr.) **(Rus)**
[The role of subcortical structures in the conditioning process] Suvorov NF. **Fiziol Zh Im I M Sechenova** 1995 Nov;81(11):82–93 (54 ref.) **(Rus)**
[Neurotransmitters and cerebral development: physiologic and physiopathologic aspects] Legido A. **Rev Neurol** 1995; 23 Suppl 3:S269–77 (100 ref.) **(Spa)**
[The development of human cerebral cortex] Marín-Padilla M. **Rev Neurol** 1995;23 Suppl 3:S261–8 (37 ref.) **(Spa)**

PHYSIOPATHOLOGY

Pathophysiology of negative myoclonus and asterixis. Shibasaki H. **Adv Neurol** 1995;67:199–209 (34 ref.)
Deficient habituation of evoked cortical potentials in migraine: a link between brain biology, behavior and trigeminovascular activation? Schoenen J. **Biomed Pharmacother** 1996;50(2):71–8 (78 ref.)
Primary (idiopathic) generalized epilepsy and underlying mechanisms. Niedermeyer E. **Clin Electroencephalogr** 1996 Jan;27(1):1–21 (147 ref.)
Some aspects of higher motor disorders and their relationship to movement disorders associated with disease of subcortical nuclei [editorial] Thompson PD, et al. **Curr Opin Neurol** 1995 Aug;8(4):303–5 (6 ref.)
Synaesthesia: reconciling the subjective with the objective. Harrison J, et al. **Endeavour** 1995;19(4):157–60 (20 ref.)
Schizophrenia: a disease of heteromodal association cortex? Pearlson GD, et al. **Neuropsychopharmacology** 1996 Jan; 14(1):1–17 (172 ref.)
Ischemia and lesion induced imbalances in cortical function. Luhmann HJ. **Prog Neurobiol** 1996 Feb;48(2):131–66 (415 ref.)
[Cortical function in 107 patients with supratentorial expanding mass. Pre- and postoperative study] Bucciero A, et al. **Minerva Med** 1995 Oct;86(10):403–7 (15 ref.) (Eng. Abstr.) **(Ita)**
[Evoked potentials and headache] Giubelli D, et al. **Minerva Med** 1995 Sep;86(9):367–78 (39 ref.) (Eng. Abstr.) **(Ita)**

SURGERY

Microelectrode monitoring of cortical and subcortical structures during stereotactic surgery. Lozano AM, et al. **Acta Neurochir Suppl (Wien)** 1995;64:30–4 (19 ref.)

CEREBRAL DOMINANCE see **DOMINANCE, CEREBRAL**

CEREBRAL EDEMA see **BRAIN EDEMA**

CEREBRAL EMBOLISM AND THROMBOSIS

see related
CEREBRAL INFARCTION

BLOOD

[Homocysteinemia as a risk factor for cerebrovascular disorders. The role of age and homocysteine levels] Reis RP, et al. **Acta Med Port** 1996 Jan;9(1):15–20 (43 ref.) (Eng. Abstr.) **(Por)**

COMPLICATIONS

[A case of transient amnesia caused by cerebral thrombophlebitis: contribution of neuroimaging to physiopathogenesis of transient amnesia] Attarian S, et al. **Rev Neurol (Paris)** 1995 Oct;151(10):552–8 (32 ref.) (Eng. Abstr.) **(Fre)**
[Cerebral venous thrombosis and arterial infarction in pregnancy and puerperium. A series of 60 cases] Ben Hamouda-M'Rad I, et al. **Rev Neurol (Paris)** 1995 Oct; 151(10):563–8 (29 ref.) (Eng. Abstr.) **(Fre)**
[Cardiogenic cerebral embolism] Rubio F, et al. **Rev Neurol** 1995;23 Suppl 1:S53–60 (98 ref.) **(Spa)**

DIAGNOSIS

Isolated cortical venous thrombosis—discrepancy between clinical features and neuroradiologic findings. A case report. Chang YJ, et al. **Angiology** 1995 Dec;46(12):1133–8 (19 ref.)

DRUG THERAPY

Thrombolytic therapy for brain attack. Macabasco AC, et al. **J Neurosci Nurs** 1995 Jun;27(3):138–49; quiz 150–1 (24 ref.)
[Thrombolysis in stroke] Diener HC, et al. **Internist (Berl)** 1996 Jun;37(6):613–8 (26 ref.) **(Ger)**

ETIOLOGY

Cardioembolic stroke. Brickner ME. **Am J Med** 1996 Apr; 100(4):465–74 (92 ref.)
The proximal aorta: a source of stroke. Jones EF, et al. **Baillieres Clin Neurol** 1995 Aug;4(2):207–20 (45 ref.)
Aortic atheromatosis and risks of cerebral embolization. Barbut D, et al. **J Cardiothorac Vasc Anesth** 1996 Jan; 10(1):24–9; quiz 29–30 (72 ref.)
Cerebral emboli and cognitive outcome after cardiac surgery. Stump DA, et al. **J Cardiothorac Vasc Anesth** 1996 Jan; 10(1):113–8; quiz 118–9 (43 ref.)
Cardioembolism as a source of cerebrovascular events. Hennerici MG. **J Heart Valve Dis** 1995 Mar;4(2):121–6 (23 ref.)
[Atherosclerotic disease of the aorta: a source of thromboembolism] Gur H, et al. **Harefuah** 1996 Mar 1; 130(5):339–43 (34 ref.) **(Heb)**
[Cerebrovascular manifestations of gastrointestinal diseases] González JL, et al. **Rev Neurol** 1995;23 Suppl 1:S91–4 (43 ref.) **(Spa)**
[Ictus, pregnancy and contraception] Pareja A, et al. **Rev Neurol** 1995;23 Suppl 1:S87–90 (27 ref.) **(Spa)**

MORTALITY

[Parma Stroke Data Bank: embolic stroke] Tonelli C, et al. **Minerva Med** 1995 Nov;86(11):459–66 (76 ref.) (Eng. Abstr.) **(Ita)**

PHYSIOPATHOLOGY

[Cerebrovascular manifestations of gastrointestinal diseases] González JL, et al. **Rev Neurol** 1995;23 Suppl 1:S91–4 (43 ref.) **(Spa)**

PREVENTION & CONTROL

[Preventive treatment of cerebrovascular accidents of arterial origin] Castillo V, et al. **Schweiz Rundsch Med Prax** 1996 Feb 6;85(6):159–63 (33 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Interventional neuroradiology. Pelz DM. **Baillieres Clin Neurol** 1995 Aug;4(2):297–315 (60 ref.)

ULTRASONOGRAPHY

High-intensity transient signals: evolution or revolution in understanding cerebral embolism? [editorial] Hennerici M. **Eur Neurol** 1995;35(5):249–53 (42 ref.)
[Detection of cardiac embolism by transcranial Doppler] Pettelot G, et al. **Ann Cardiol Angeiol (Paris)** 1996 Jan; 45(1):34–8 (19 ref.) (Eng. Abstr.) **(Fre)**
[Circulating cerebral microemboli. Detection with transcranial Doppler ultrasound] Thiel A, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Apr; 31(3):127–31 (41 ref.) (Eng. Abstr.) **(Ger)**

CEREBRAL HEMORRHAGE

Epidemiology of intracerebral hemorrhage. Thrift AG, et al. **Epidemiol Rev** 1995;17(2):361–81 (185 ref.)

CHEMICALLY INDUCED

Cocaine-associated intracranial hemorrhage: absence of vasculitis in 14 cases. Aggarwal SK, et al. **Neurology** 1996 Jun;46(6):1741–3 (10 ref.)

COMPLICATIONS

Unilateral spatial neglect due to a haemorrhagic contusion in the right frontal lobe. Maeshima S, et al. **J Neurol** 1995 Oct;242(10):613–7 (15 ref.)
Fibrosarcomatous metastasis the central nervous system with overt hemorrhage: case report and review of the literature. Jeffery DR, et al. **J Neurol Sci** 1995 Dec;134(1–2):207–9 (8 ref.)

DIAGNOSIS

A new application for near-infrared spectroscopy: detection of delayed intracranial hematomas after head injury. Robertson CS, et al. **J Neurotrauma** 1995 Aug; 12(4):591–600 (64 ref.)
Spontaneous clivus hematoma: case report and literature review. Tomaras C, et al. **Neurosurgery** 1995 Jul; 37(1):123–4 (5 ref.)

ENZYMOLOGY

Matrix metalloproteinases in brain injury. Rosenberg GA. **J Neurotrauma** 1995 Oct;12(5):833–42 (69 ref.)

ETIOLOGY

Intracerebral haemorrhage. Kase CS. **Baillieres Clin Neurol** 1995 Aug;4(2):247–78 (90 ref.)
Case report: Pontine haemorrhage following iohexol lumbar myelography. Yeh YF, et al. **Br J Radiol** 1996 Apr; 69(820):368–70 (28 ref.)
A new application for near-infrared spectroscopy: detection of delayed intracranial hematomas after head injury. Robertson CS, et al. **J Neurotrauma** 1995 Aug; 12(4):591–600 (64 ref.)
Intracerebral hemorrhage after carotid endarterectomy associated with ipsilateral fibrinoid necrosis: a consequence of the hyperperfusion syndrome? Mansoor GA, et al. **J Vasc Surg** 1996 Jan;23(1):147–51 (20 ref.)
Familial arteriovenous malformations in children. Brilli RJ, et al. **Pediatr Emerg Care** 1995 Dec;11(6):376–8 (14 ref.)
Amyloid angiopathy-related cerebellar hemorrhage. Cuny E, et al. **Surg Neurol** 1996 Sep;46(3):235–9 (22 ref.)
[Fetal cerebral accident due to massive fetomaternal hemorrhage. A case report] Lionnet C, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(5):553–6 (18 ref.) (Eng. Abstr.) **(Fre)**
[A case of de novo aneurysm of the distal posterior inferior cerebellar artery with intraventricular hemorrhage] Kojima A, et al. **No Shinkei Geka** 1996 May;24(5):469–73 (10 ref.) (Eng. Abstr.) **(Jpn)**
[A case of primary intracranial malignant fibrous histiocytoma associated with peritumoral hemorrhage] Matsuzaki K, et al. **No Shinkei Geka** 1996 Jun;24(6):557–62 (22 ref.) (Eng. Abstr.) **(Jpn)**
[A case of erythroleukemia found after multiple cerebral hemorrhage] Izumi M, et al. **Rinsho Shinkeigaku** 1996 Jan; 36(1):58–60 (7 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Neuroimaging in head injury. Gean AD, et al. **New Horiz** 1995 Aug;3(3):549–61 (43 ref.)
[Vascular stroke of the brain stem. Study of 21 cases] Leal Filho MB, et al. **Arq Neuropsiquiatr** 1995 Mar;53(1):75–81 (17 ref.) (Eng. Abstr.) **(Por)**

PHYSIOPATHOLOGY

Intracerebral haemorrhage. MacKenzie JM. **J Clin Pathol** 1996 May;49(5):360–4 (61 ref.)
[Intracerebral hemorrhages] Schütz H. **Ther Umsch** 1996 Jul; 53(7):590–6 (51 ref.) (Eng. Abstr.) **(Ger)**
[Current aspects of premature labor] Briese V. **Zentralbl Gynakol** 1995;117(8):393–401 (47 ref.) (Eng. Abstr.) **(Ger)**
[Hematological changes and cerebrovascular disorders] Abellán MT, et al. **Rev Neurol** 1995 Sep–Oct; 23(123):993–1007 (97 ref.) (Eng. Abstr.) **(Spa)**
[Intraventricular hemorrhage in a newborn] Koenigsberger MR, et al. **Rev Neurol** 1995;23 Suppl 3:S285–8 (59 ref.) **(Spa)**

PREVENTION & CONTROL

Prophylactic indomethacin: systematic review and

CEREBRAL HEMORRHAGE

meta-analysis. Fowlie PW.
Arch Dis Child Fetal Neonatal Ed 1996 Mar;74(2):F81-7 (35 ref.)
Prevention of intraventricular hemorrhage in preterm infants. Wells JT, et al. **Early Hum Dev** 1995 Aug 18;42(3):209-33 (179 ref.)
[Characteristics of delivery of the small premature infant] Schneider H, et al. **Arch Gynecol Obstet** 1995; 257(1-4):462-71 (51 ref.) **(Ger)**

SURGERY

Brain stem surgery [editorial] Jackowski A.
Br J Neurosurg 1995;9(5):581-4 (32 ref.)
Expanding intracerebral hematoma from pituitary adenoma: case report. Wakai S, et al. **Neurosurgery** 1995 Oct; 37(4):807-8; discussion 808-9 (2 ref.)

CEREBRAL INFARCTION

CHEMICALLY INDUCED

[Multiple cerebral infarction after treatment with cisplatin] Komatsumoto S, et al. **Rinsho Shinkeigaku** 1996 Mar; 36(3):499-502 (9 ref.) (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

Frontal abnormalities in a patient with obsessive-compulsive disorder: the role of structural lesions in obsessive-compulsive behavior. Swoboda KJ, et al. **Neurology** 1995 Dec;45(12):2130-4 (25 ref.)
[Cerebral venous thrombosis and arterial infarction in pregnancy and puerperium. A series of 60 cases] Ben Hamouda-M'Rad I, et al. **Rev Neurol (Paris)** 1995 Oct; 151(10):563-8 (29 ref.) (Eng. Abstr.) **(Fre)**
[Akinetic mutism with right hemiplegia caused by infarction in the territory of the left anterior cerebral artery] Lechevalier B, et al. **Rev Neurol (Paris)** 1996 Mar; 152(3):181-9 (27 ref.) (Eng. Abstr.) **(Fre)**
[See-saw nystagmus. Clinical aspects, diagnosis, pathophysiology: observations in 2 patients] Endres M, et al. **Nervenarzt** 1996 Jun;67(6):484-9 (41 ref.) (Eng. Abstr.) **(Ger)**
[A case of hemichorea presenting with inattention and denial of involuntary movement] Ichikawa H, et al. **Rinsho Shinkeigaku** 1995 Nov;35(11):1230-4 (15 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Diffusion weighted imaging for acute cerebral infarction. Schäbitz WR, et al. **Neurol Res** 1995 Aug;17(4):270-4 (53 ref.)
[Results of magnetic resonance imaging in the acute phase of cerebral infarction] Berry I, et al. **J Mal Vasc** 1995; 20(3):184-8 (31 ref.) (Eng. Abstr.) **(Fre)**
[Lacunar cerebral infarction in a young woman] Hofbauer LC, et al. **Dtsch Med Wochenschr** 1995 Dec 22; 120(51-52):1777-82 (30 ref.) (Eng. Abstr.) **(Ger)**
[Clinical procedures in brain infarct and differential diagnosis] Mattle HP, et al. **Ther Umsch** 1996 Jul;53(7):507-11 (16 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Ischemic stroke: treatment on the horizon. Giroux C, et al. **Eur Neurol** 1996;36(2):61-4 (12 ref.)
[Thrombolysis in stroke] Diener HC, et al. **Internist (Berl)** 1996 Jun;37(6):613-8 (26 ref.) **(Ger)**
[Treatment of ischemic cerebral infarct with glycerine] Winter R, et al. **Nervenarzt** 1995 Aug;66(8):596-602 (63 ref.) (Eng. Abstr.) **(Ger)**
[Acetyl-salicylic acid and trifusal in the prevention of atherothrombotic stroke] Alvarez Sabín J. **Rev Neurol** 1995 Sep-Oct;23(123):1091-5 (36 ref.) **(Spa)**

ETIOLOGY

[Etiology and mechanism in cerebral infarction] Castillo V, et al. **Schweiz Med Wochenschr** 1996 Mar 23;126(12):489-92 (20 ref.) (Eng. Abstr.) **(Fre)**
[Favorable prognosis in a case of recurrent cerebral infarctions caused by chronic disseminated intravascular coagulation due to ovarian carcinoma] Izumi M, et al. **No To Shinkei** 1996 Jun;48(6):581-5 (16 ref.) (Eng. Abstr.) **(Jpn)**

MORTALITY

[Parma Stroke Data Bank: embolic stroke] Tonelli C, et al. **Minerva Med** 1995 Nov;86(11):459-66 (76 ref.) (Eng. Abstr.) **(Ita)**

PATHOLOGY

Ischemic stroke and incomplete infarction. Garcia JH, et al. **Stroke** 1996 Apr;27(4):761-5 (48 ref.)

PHYSIOPATHOLOGY

Correlation between proto-oncogene, fibroblast growth factor and adaptive response in brain infarct. Liu HM. **Prog Brain Res** 1995;105:239-44 (44 ref.)
Ischemic stroke and incomplete infarction. Garcia JH, et al. **Stroke** 1996 Apr;27(4):761-5 (48 ref.)
[Non-valvular atrial fibrillation and cerebral infarction] Martín R. **Rev Neurol** 1995 Mar-Apr;23(120):370-6 (81 ref.) (Eng. Abstr.) **(Spa)**

PREVENTION & CONTROL

Anticoagulation for prevention of cerebral infarcts following subarachnoid hemorrhage. Wang DZ, et al. **Surg Neurol** 1995 Sep;44(3):270-4 (22 ref.)
[High dosage acetylsalicylic acid administration for prevention of acute cerebral ischemia] Hartmann A. **Nervenarzt** 1995 Dec;66(12):886-9; discussion 885 (18 ref.) (Eng. Abstr.) **(Ger)**
[Aspirin dosage for prevention of cerebral infarct: arguments for low dosage] Hennerici MG, et al. **Nervenarzt** 1995 Dec; 66(12):890-4; discussion 885 (38 ref.) (Eng. Abstr.) **(Ger)**
[Prevention of cerebral infarction] Tanahashi N, et al. **Nippon Naika Gakkai Zasshi** 1995 Oct 10;84(10):1744-8 (19 ref.) **(Jpn)**
[Acetyl-salicylic acid and trifusal in the prevention of atherothrombotic stroke] Alvarez Sabín J. **Rev Neurol** 1995 Sep-Oct;23(123):1091-5 (36 ref.) **(Spa)**

REHABILITATION

Recovery from aphasia. Farmer LJ.
J Miss State Med Assoc 1996 Aug;37(8):690-3 (52 ref.)

THERAPY

The penumbra, therapeutic time window and acute ischaemic stroke. Fisher M, et al. **Baillieres Clin Neurol** 1995 Aug; 4(2):279-95 (85 ref.)
Critical care of acute ischemic stroke. Hacke W, et al. **Intensive Care Med** 1995 Oct;21(10):856-62 (44 ref.)
[Management of a cerebral infarction in the acute stage] Vuadens P, et al. **Rev Med Suisse Romande** 1996 Aug; 116(8):583-6 (24 ref.) **(Fre)**
[Acute therapy and prevention of ischemic cerebral infarct] von Maravić M. **Z Arztl Fortbild (Jena)** 1995 Dec; 89(7):711-8 (0 ref.) (Eng. Abstr.) **(Ger)**

CEREBRAL ISCHEMIA

Hypoxic and ischemic central nervous system disorders in infants and children. Johnston MV, et al. **Adv Pediatr** 1995; 42:1-45 (178 ref.)

COMPLICATIONS

[Cerebral hypoxic and ischemic damage in newborn infants: cellular mechanisms and role of excitatory amino acids] Cortey A. **Arch Pediatr** 1995 Dec;2(12):1192-9 (44 ref.) (Eng. Abstr.) **(Fre)**
[Psychiatric diseases and ictus] Aguilar M, et al. **Rev Neurol** 1995;23 Suppl 1:S113-22 (128 ref.) **(Spa)**
[Cerebral ischemia and respiratory diseases] Castillo J, et al. **Rev Neurol** 1995;23 Suppl 1:S61-9 (81 ref.) **(Spa)**

DIAGNOSIS

Markers of cerebral ischemia after cardiac surgery. Johnsson P. **J Cardiothorac Vasc Anesth** 1996 Jan;10(1):120-6 (67 ref.)
Stroke and ischemia. Siewert B, et al. **Magn Reson Imaging Clin N Am** 1995 Aug;3(3):529-40 (90 ref.)
[Neuroradiologic findings in arterial cerebral ischemia] Jansen O, et al. **Radiologe** 1995 Nov;35(11):779-90 (33 ref.) (Eng. Abstr.) **(Ger)**
[Several results of studies on initial manifestations of insufficiency of cerebral circulation] Manvelov LS. **Klin Med (Mosk)** 1995;73(5):28-31 (16 ref.) **(Rus)**

DRUG THERAPY

Clinical potential for the use of neuroprotective agents. A brief overview. Trembly B. **Ann N Y Acad Sci** 1995 Sep 15;765:1-20; discussion 26-7 (87 ref.)
Thrombolysis in ischemic stroke: double or quits? [editorial] van Gijn J. **Circulation** 1996 May 1;93(9):1616-7 (21 ref.)
Medical therapy for ischemic stroke. Silver B, et al. **Clin Neuropharmacol** 1996 Apr;19(2):101-28 (272 ref.)
Development of HU-211 as a neuroprotectant for ischemic brain damage. Biegon A, et al. **Neurol Res** 1995 Aug; 17(4):275-80 (27 ref.)
Citicoline (CDP-choline): mechanisms of action and effects in ischemic brain injury. D'Orlando KJ, et al. **Neurol Res** 1995 Aug;17(4):281-4 (21 ref.)
Pharmacological modulation of voltage-gated Na+ channels: a rational and effective strategy against ischemic brain damage. Urenjak J, et al. **Pharmacol Rev** 1996 Mar; 48(1):21-67 (670 ref.)
[Treatment of ischemic cerebral infarct with glycerine] Winter R, et al. **Nervenarzt** 1995 Aug;66(8):596-602 (63 ref.) (Eng. Abstr.) **(Ger)**
[Therapy and prevention of cerebral ischemia] Mattle HP, et al. **Ther Umsch** 1996 Jul;53(7):573-84 (68 ref.) (Eng. Abstr.) **(Ger)**
[Early reperfusion as a rationale from of therapy in ischemic stroke] Garcia JH. **Rev Neurol** 1995 Sep-Oct; 23(123):1067-73 (40 ref.) (Eng. Abstr.) **(Spa)**
[Preventive neuroprotection] Martín R. **Rev Neurol** 1995 Jan-Feb;23(119):30-2 (47 ref.) **(Spa)**

ENZYMOLOGY

Protein serine/threonine kinases (PKA, PKC and CaMKII) involved in ischemic brain pathology. Domańska-Janik K. **Acta Neurobiol Exp (Warsz)** 1996;56(2):579-85 (44 ref.)

ETIOLOGY

Global brain ischemia and reperfusion. White BC, et al. **Ann Emerg Med** 1996 May;27(5):588-94 (48 ref.)
Mechanisms of cerebral ischemia: intracellular cascades and therapeutic interventions. Small DL, et al. **J Cardiothorac Vasc Anesth** 1996 Jan;10(1):139-46 (51 ref.)
Umbilical cord ulceration as a cause of hypoxic-ischemic encephalopathy: report of a case and review of the literature. Khurana A, et al. **J Perinatol** 1995 Sep-Oct; 15(5):423-5 (21 ref.)
Cerebral ischemia in patients with hepatitis C virus infection and mixed cryoglobulinemia. Petty GW, et al. **Mayo Clin Proc** 1996 Jul;71(7):671-8 (57 ref.)
Role of oxidants in ischemic brain damage. Chan PH. **Stroke** 1996 Jun;27(6):1124-9 (56 ref.)
[Ischemic cerebrovascular complications in Rendu-Osler disease: a case] Albucher JF, et al. **Rev Neurol (Paris)** 1996 Apr;152(4):283-7 (11 ref.) (Eng. Abstr.) **(Fre)**
[Ischemic stroke in the young adult (see comments)] Gandolfo C, et al. **Ann Ital Med Int** 1996 Jan-Mar; 11(1):33-8 (50 ref.) (Eng. Abstr.) Comment in: Ann Ital Med Int 1996 Jan-Mar;11(1):5-7. **(Ita)**
[Obesity as a risk factor of ischemic brain disease (prospective study)] Ogawa M. **Nippon Rinsho** 1995 Jun;53 Suppl:276-80 (15 ref.) **(Jpn)**
[Ictus, pregnancy and contraception] Pareja A, et al. **Rev Neurol** 1995;23 Suppl 1:S87-90 (27 ref.) **(Spa)**
[Cephalic fibromuscular dysplasia and stroke in infancy: a case report] and review of literature] Romera-López J, et al. **Rev Neurol** 1996 Jun;24(130):650-2 (11 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

Genes for ischaemic stroke: strategies for their detection. Sharma P. **J Hypertens** 1996 Mar;14(3):277-85 (62 ref.)

METABOLISM

Calcium transients in brain ischemia: role in neuronal injury. Lazarewicz JW. **Acta Neurobiol Exp (Warsz)** 1996; 56(1):299-311 (113 ref.)
Nitric oxide in the central nervous system. Paakkari I, et al. **Ann Med** 1995 Jun;27(3):369-77 (96 ref.)
Inhibition of lipid peroxidation in central nervous system trauma and ischemia. Hall ED. **J Neurol Sci** 1995 Dec;134 Suppl:79-83 (44 ref.)
Cerebral metabolic rate and hypothermia: their relationship with ischemic neurologic injury. Lanier WL. **J Neurosurg Anesthesiol** 1995 Jul;7(3):216-21 (31 ref.)
Calcium-related damage in ischemia. Kristián T, et al. **Life Sci** 1996;59(5-6):357-67 (104 ref.)
Glucose modulation of ischemic brain injury: review and clinical recommendations. Wass CT, et al. **Mayo Clin Proc** 1996 Aug;71(8):801-12 (108 ref.)
Cerebral metabolic management. Robertson CS, et al. **New Horiz** 1995 Aug;3(3):410-22 (97 ref.)
Gene expression in astrocytes during and after ischemia. Yu AC, et al. **Prog Brain Res** 1995;105:245-53 (50 ref.)
[Heat shock protein 70 and perinatal hypoxic-ischemic brain damage] Chang YQ, et al. **Sheng Li Ko Hsueh Chin Chan** 1995 Jul;26(3):267-9 (10 ref.) **(Chi)**
[Cerebral hypoxic and ischemic damage in newborn infants: cellular mechanisms and role of excitatory amino acids] Cortey A. **Arch Pediatr** 1995 Dec;2(12):1192-9 (44 ref.) (Eng. Abstr.) **(Fre)**
[Nitric oxide: implication in excitotoxicity and cerebral ischemia] Demerlé-Pallardy C, et al. **C R Seances Soc Biol Fil** 1995;189(6):1059-68 (49 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Protein serine/threonine kinases (PKA, PKC and CaMKII) involved in ischemic brain pathology. Domańska-Janik K. **Acta Neurobiol Exp (Warsz)** 1996;56(2):579-85 (44 ref.)
Calcium transients in brain ischemia: role in neuronal injury. Lazarewicz JW. **Acta Neurobiol Exp (Warsz)** 1996; 56(1):299-311 (113 ref.)
Diffusion and perfusion MR imaging of cerebral ischemia. Hossmann KA, et al. **Cerebrovasc Brain Metab Rev** 1995 Fall;7(3):187-217 (150 ref.)
Cerebral metabolic rate and hypothermia: their relationship with ischemic neurologic injury. Lanier WL. **J Neurosurg Anesthesiol** 1995 Jul;7(3):216-21 (31 ref.)
Neuronal apoptosis: current understanding of molecular mechanisms and potential role in ischemic brain injury. Johnson EM JR, et al. **J Neurotrauma** 1995 Oct; 12(5):843-52 (102 ref.)
Mechanisms of secondary brain damage in global and focal ischemia: a speculative synthesis. Siesjö BK, et al. **J Neurotrauma** 1995 Oct;12(5):943-56 (113 ref.)
Reactive microglia in cerebral ischaemia: an early mediator of tissue damage? Gehrmann J, et al. **Neuropathol Appl Neurobiol** 1995 Aug;21(4):277-89 (104 ref.)
[Vascular stroke of the brain stem. Study of 21 cases] Leal

Filho MB, et al. **Arq Neuropsiquiatr** 1995 Mar;53(1):75–81 (17 ref.) (Eng. Abstr.) **(Por)**

PHYSIOPATHOLOGY

The ischaemic penumbra: twenty years on. Obrenovitch TP. **Cerebrovasc Brain Metab Rev** 1995 Winter;7(4):297–323 (260 ref.)

Hypothetical roles of angiogenesis, osmotic swelling, and ischemia in high-altitude cerebral edema. Severinghaus JW. **J Appl Physiol** 1995 Aug;79(2):375–9 (68 ref.)

Neurocritical care for acute ischemic stroke. Hund E, et al. **Neurol Clin** 1995 Aug;13(3):511–27 (87 ref.)

Regulatory mechanism of stress response in mammalian nervous system during cerebral ischaemia or after heat shock. Higashi T, et al. **Neuropathol Appl Neurobiol** 1995 Dec;21(6):480–3 (19 ref.)

Normal and abnormal calcium homeostasis in neurons: a basis for the pathophysiology of traumatic and ischemic central nervous system injury. Tymianski M, et al. **Neurosurgery** 1996 Jun;38(6):1176–95 (300 ref.)

Cerebral blood flow in severe clinical head injury. Bouma GJ, et al. **New Horiz** 1995 Aug;3(3):384–94 (52 ref.)

Enhanced vulnerability to secondary ischemic insults after experimental traumatic brain injury. DeWitt DS, et al. **New Horiz** 1995 Aug;3(3):376–83 (66 ref.)

Ischemia and lesion induced imbalances in cortical function. Luhmann HJ. **Prog Neurobiol** 1996 Feb;48(2):131–66 (415 ref.)

[Pathophysiology of hypoxia-ischemia in the developing brain] Yoshioka H, et al. **No To Shinkei** 1996 Jul; 48(7):613–20 (50 ref.) **(Jpn)**

[The importance of clinical hemorheology in the study of cerebral blood flow in normal conditions and in cerebrovascular ischemia] Melaragno Filho R. **Arq Neuropsiquiatr** 1995 Mar;53(1):157–68 (85 ref.) (Eng. Abstr.) **(Por)**

[A cerebral accident: ictus is a medical emergency] Castillo J. **Rev Neurol** 1995 Mar–Apr;23(120):322–3 (22 ref.) **(Spa)**

[Molecular factors of cerebral hypoxia–ischemia] Macaya A, et al. **Rev Neurol** 1996 Jul;24(131):855–64 (84 ref.) (Eng. Abstr.) **(Spa)**

PREVENTION & CONTROL

Dexamethasone and the prevention of neonatal hypoxic–ischemic brain damage. Tuor UI. **Ann N Y Acad Sci** 1995 Sep 15;765:179–95; discussion 196–7 (97 ref.)

Protection of the brain after aneurysmal rupture. Weir B. **Can J Neurol Sci** 1995 Aug;22(3):177–86 (73 ref.)

Ticlopidine. A review of its pharmacology, clinical efficacy and tolerability in the prevention of cerebral ischaemia and stroke. Noble S, et al. **Drugs Aging** 1996 Mar;8(3):214–32 (125 ref.)

Techniques for avoiding neurologic injury during adult cardiac surgery. Utley JR. **J Cardiothorac Vasc Anesth** 1996 Jan;10(1):38–43; quiz 43–4 (43 ref.)

Pharmacologic therapy: promising clinical investigations. Marshall LF, et al. **New Horiz** 1995 Aug;3(3):573–80 (30 ref.)

Possibilities of brain protection with tirilazad after cardiac arrest. Sterz F, et al. **Semin Thromb Hemost** 1996; 22(1):105–12 (37 ref.)

Aspirin in ischemic cerebrovascular disease. How strong is the case for a different dosing regimen? [see comments] Patrono C, et al. **Stroke** 1996 Apr;27(4):756–60 (36 ref.) Comment in: Stroke 1996 Apr;27(4):585–7. Comment in: Stroke 1996 Apr;27(4):588–92.

[Therapy and prevention of cerebral ischemia] Mattle HP, et al. **Ther Umsch** 1996 Jul;53(7):573–84 (68 ref.) (Eng. Abstr.) **(Ger)**

[Brain protection—update] Sakabe T, et al. **Masui** 1995;44 Suppl:S45–51 (27 ref.) **(Jpn)**

[Cerebral protection] Cottrell JE. **Anesteziol Reanimatol** 1996 Mar–Apr;(2):81–5 (75 ref.) (Eng. Abstr.) **(Rus)**

REHABILITATION

[A cerebral accident: ictus is a medical emergency] Castillo J. **Rev Neurol** 1995 Mar–Apr;23(120):322–3 (22 ref.) **(Spa)**

SURGERY

[Early reperfusion as a rationale from of therapy in ischemic stroke] Garcia JH. **Rev Neurol** 1995 Sep–Oct; 23(123):1067–73 (40 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

The penumbra, therapeutic time window and acute ischaemic stroke. Fisher M, et al. **Baillieres Clin Neurol** 1995 Aug; 4(2):279–95 (85 ref.)

Critical care of acute ischemic stroke. Hacke W, et al. **Intensive Care Med** 1995 Oct;21(10):856–62 (44 ref.)

[Intensive care in acute ischemia] Steiner T, et al. **Ther Umsch** 1996 Jul;53(7):568–72 (15 ref.) (Eng. Abstr.) **(Ger)**

[Acute therapy and prevention of ischemic cerebral infarct] von Maravić M. **Z Arztl Fortbild (Jena)** 1995 Dec; 89(7):711–8 (0 ref.) (Eng. Abstr.) **(Ger)**

CEREBRAL ISCHEMIA, TRANSIENT

Cerebral arterial spasm—a clinical review. Dorsch NW. **Br J Neurosurg** 1995;9(3):403–12 (34 ref.)

COMPLICATIONS

Stroke prevention: the emerging strategies. McCrory DC, et al. **Hosp Pract (Off Ed)** 1996 Mar 15; 31(3):123–8,131–2,134 (8 ref.)

DIAGNOSIS

[Response to 6 questions apropos transient cerebral ischemia] Sternon J. **Rev Med Brux** 1996 Feb;17(1):11–6 (22 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

Pathophysiology of postischemic hypoxia and cerebral protection: implications of the almitrine and raubasine combination. Chan P. **Eur Neurol** 1995;35 Suppl 1:23–7 (41 ref.)

Pharmacological strategies in the treatment of cerebral ischemia. O'Neill M, et al. **Eur Neurol** 1995;35 Suppl 1:28–36 (88 ref.)

Calpain as a novel target for treating acute neurodegenerative disorders. Bartus RT, et al. **Neurol Res** 1995 Aug; 17(4):249–58 (40 ref.)

ETIOLOGY

Innovations in aneurysmal subarachnoid hemorrhage: intracisternal t-PA for the prevention of vasospasm. Bell TE, et al. **J Neurosci Nurs** 1996 Apr;28(2):107–13 (37 ref.)

Posttraumatic cerebral arterial spasm. Martin NA, et al. **J Neurotrauma** 1995 Oct;12(5):897–901 (22 ref.)

Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors. Skop BP, et al. **Psychosomatics** 1996 Jan–Feb;37(1):12–6 (41 ref.)

[Atrial septal aneurysm. Report of two clinical cases and review of the literature] Perrotta S, et al. **Minerva Cardioangiol** 1995 Jul–Aug;43(7–8):339–43 (23 ref.) (Eng. Abstr.) **(Ita)**

[Cerebral vasospasm following subarachnoid hemorrhage as studied from the mechanism of physiological smooth muscle contraction] Sakaki S, et al. **No Shinkei Geka** 1996 Jan;24(1):19–28 (34 ref.) **(Jpn)**

METABOLISM

Free radicals and intracellular events associated with cerebrovascular spasm. Cook DA, et al. **Cardiovasc Res** 1995 Oct;30(4):493–500 (112 ref.)

Induced expression of adhesion molecules following focal brain ischemia. Wang X, et al. **J Neurotrauma** 1995 Oct; 12(5):825–32 (44 ref.)

Calcium, energy metabolism and the development of selective neuronal loss following short-term cerebral ischemia. Sims NR. **Metab Brain Dis** 1995 Sep; 10(3):191–217 (168 ref.)

PATHOLOGY

Mechanisms of secondary brain damage in global and focal ischemia: a speculative synthesis. Siesjö BK, et al. **J Neurotrauma** 1995 Oct;12(5):943–56 (113 ref.)

Calcium, energy metabolism and the development of selective neuronal loss following short-term cerebral ischemia. Sims NR. **Metab Brain Dis** 1995 Sep; 10(3):191–217 (168 ref.)

Diffusion-weighted NMR imaging: application to experimental focal cerebral ischemia. Hoehn-Berlage M. **NMR Biomed** 1995 Nov–Dec;8(7–8):345–58 (103 ref.)

PHYSIOPATHOLOGY

Glutamate excitotoxicity in transient global cerebral ischemia. Paschen W. **Acta Neurobiol Exp (Warsz)** 1996; 56(1):313–22 (68 ref.)

The pathophysiology of cerebral vasospasm. Weir B. **Br J Neurosurg** 1995;9(3):375–90 (57 ref.)

False traumatic aneurysm of the dorsal wall of the supraclinoid internal carotid artery—case report. Saito K, et al. **Neurol Med Chir (Tokyo)** 1995 Dec;35(12):886–91 (26 ref.)

[Low cerebral output, transient ischemic attack and syncope] Berger JP. **Rev Med Suisse Romande** 1996 Aug; 116(8):597–604 (23 ref.) **(Fre)**

PREVENTION & CONTROL

Neuroprotective use-dependent blockers of Na+ and Ca2+ channels controlling presynaptic release of glutamate. Goldin SM, et al. **Ann N Y Acad Sci** 1995 Sep 15;765:210–29 (59 ref.)

Prophylactic pharmacologic neuroprotection against focal cerebral ischemia. Jonas S. **Ann N Y Acad Sci** 1995 Sep 15;765:21–5; discussion 26–7 (9 ref.)

Neuroprotective properties of the uncompetitive NMDA receptor antagonist remacemide hydrochloride. Palmer GC, et al. **Ann N Y Acad Sci** 1995 Sep 15;765:236–47; discussion 248 (38 ref.)

[High dosage acetylsalicylic acid administration for prevention of acute cerebral ischemia] Hartmann A. **Nervenarzt** 1995 Dec;66(12):886–9; discussion 885 (18 ref.) (Eng. Abstr.) **(Ger)**

[Aspirin dosage for prevention of cerebral infarct: arguments for low dosage] Hennerici MG, et al. **Nervenarzt** 1995 Dec; 66(12):890–4; discussion 885 (38 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Management of cerebral vasospasm in the 1990s. Klebanoff LM, et al. **Clin Neuropharmacol** 1995 Apr;18(2):127–37 (55 ref.)

Management of transient ischemic attacks. Adams HP Jr, et al. **Compr Ther** 1995 Jul;21(7):355–61 (15 ref.)

[Acute therapy and prevention of ischemic cerebral infarct] von Maravić M. **Z Arztl Fortbild (Jena)** 1995 Dec; 89(7):711–8 (0 ref.) (Eng. Abstr.) **(Ger)**

CEREBRAL PALSY

CLASSIFICATION

[Motor deficiencies in children: for a nosologic clarification in epidemiological studies] Cans C, et al. **Arch Pediatr** 1996 Jan;3(1):75–80 (20 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

Classification of eating impairments based on eating efficiency in children with cerebral palsy. Gisel EG, et al. **Dysphagia** 1995 Fall;10(4):268–74 (38 ref.)

DIAGNOSIS

[Significance of intrapartum hypoxia for cerebral long-term morbidity] Schneider H. **Z Geburtshilfe Neonatol** 1996 Mar–Apr;200(2):43–9 (47 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Cerebral palsy: a paradigm for developmental disabilities. Pellegrino L. **Dev Med Child Neurol** 1995 Sep;37(9):834–9 (17 ref.)

The origins of cerebral palsy. Australian and New Zealand Perinatal Societies. **J Paediatr Child Health** 1995 Aug; 31(4):284–9 (39 ref.)

Cerebral palsy. Taft LT. **Pediatr Rev** 1995 Nov;16(11):411–8; quiz 418 (12 ref.)

[Cerebral palsy and perinatal asphyxia in full term newborn infants] Bréart G, et al. **Arch Pediatr** 1996 Jan;3(1):70–4 (15 ref.) (Eng. Abstr.) **(Fre)**

[Perinatal risk factors and motor deficiency due to cerebral palsy] Rumeau-Rouquette C, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(2):119–23 (24 ref.) (Eng. Abstr.) **(Fre)**

-Neonatal asphyxia as the cause of brain damage in children?- Schneider H. **Arch Gynecol Obstet** 1995;256 Suppl:S32–42 (75 ref.) (Eng. Abstr.) **(Ger)**

REHABILITATION

Prognosis for ambulation in cerebral palsy. Sala DA, et al. **Dev Med Child Neurol** 1995 Nov;37(11):1020–6 (9 ref.)

SURGERY

Cerebral palsy: orthopaedic management. Renshaw TS, et al. **Instr Course Lect** 1996;45:475–90 (79 ref.)

THERAPY

Review of research on therapeutic interventions for children with cerebral palsy. Hur JJ. **Acta Neurol Scand** 1995 Jun; 91(6):423–32 (40 ref.)

CEREBRAL PEDUNCLE see **MESENCEPHALON**

CEREBRAL REVASCULARIZATION

METHODS

[Superficial temporal artery to superior cerebellar artery anastomosis via the presigmoid retrolabyrinthine transtentorial approach] Ito M, et al. **No Shinkei Geka** 1995 Oct;23(10):869–74 (20 ref.) **(Jpn)**

CEREBRAL SCLEROSIS, DIFFUSE

GENETICS

The proteolipid protein gene: double, double, ... and trouble [editorial] Hodes ME, et al. **Am J Hum Genet** 1996 Jul; 59(1):12–5 (27 ref.)

CEREBRAL VASOSPASM see **CEREBRAL ISCHEMIA, TRANSIENT**

CEREBRAL VEINS

see related

CEREBRAL ANGIOGRAPHY

Isolated cortical venous thrombosis—discrepancy between clinical features and neuroradiologic findings. A case report. Chang YJ, et al. **Angiology** 1995 Dec;46(12):1133–8 (19 ref.)

[Role of magnetic resonance imaging in cerebral venous thrombosis] Bousser MG. **J Mal Vasc** 1995;20(3):189–93 (21 ref.) (Eng. Abstr.) **(Fre)**

CEREBRAL VEINS

ABNORMALITIES

Combined malformation of the Vein of Galen and of spinal vessels: endovascular embolization. Hammen A, et al. **Clin Neuropathol** 1995 Jul-Aug;14(4):233-6 (15 ref.)

Prenatal diagnosis of cerebral arteriovenous malformation using color Doppler ultrasonography: case report and review of the literature. Sepulveda W, et al. **Ultrasound Obstet Gynecol** 1995 Oct;6(4):282-6 (30 ref.)

INNERVATION

The physiology of the cerebrovascular parasympathetic innervation. Branston NM. **Br J Neurosurg** 1995; 9(3):319-29 (25 ref.)

PATHOLOGY

Amyloid beta-protein induces the cerebrovascular cellular pathology of Alzheimer's disease and related disorders. Van Nostrand WE, et al. **Ann N Y Acad Sci** 1996 Jan 17; 777:297-302 (19 ref.)

Thrombosis of the deep venous drainage of the brain in adults. Analysis of seven cases with review of the literature. Crawford SC, et al. **Arch Neurol** 1995 Nov;52(11):1101-8 (23 ref.)

ULTRASONOGRAPHY

Prenatal diagnosis of cerebral arteriovenous malformation using color Doppler ultrasonography: case report and review of the literature. Sepulveda W, et al. **Ultrasound Obstet Gynecol** 1995 Oct;6(4):282-6 (30 ref.)

CEREBRAL VENTRICLE NEOPLASMS

Intraventricular supratentorial tumors in children. Tortori-Donati P, et al. **Rays** 1996 Jan-Mar;21(1):26-49 (35 ref.) **(Eng, Ita)**

DIAGNOSIS

Intraventricular neurocytoma. Ng P, et al. **Australas Radiol** 1996 May;40(2):125-33 (27 ref.)

PATHOLOGY

Intraventricular neurocytoma: a report of two cases. Radhakrishnan VV, et al. **Indian J Cancer** 1994 Sep; 31(3):198-202 (11 ref.)

SURGERY

Giant central neurocytoma with tetraventricular and extra-axial extension. Case report. Roche PH, et al. **Acta Neurochir (Wien)** 1995;133(1-2):95-100 (33 ref.)

CEREBRAL VENTRICLES

see related
INJECTIONS, INTRAVENTRICULAR
VENTRICULOSTOMY

Familial bilateral periventricular nodular heterotopia mimics tuberous sclerosis. Jardine PE, et al. **Arch Dis Child** 1996 Mar;74(3):244-6 (13 ref.)

Tempting fate and commitment in the developing forebrain. Barbe MF. **Neuron** 1996 Jan;16(1):1-4 (16 ref.)

[Fetal cerebral accident due to massive fetomaternal hemorrhage. A case report] Lionnet C, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(5):553-6 (18 ref.) (Eng. Abstr.) **(Fre)**

[A case of de novo aneurysm of the distal posterior inferior cerebellar artery with intraventricular hemorrhage] Kojima A, et al. **No Shinkei Geka** 1996 May;24(5):469-73 (10 ref.) (Eng. Abstr.) **(Jpn)**

[A case of cysticercosis of the third ventricle] El'iashevich GP. **Lik Sprava** 1995 Jul-Aug;(7-8):131-2 (9 ref.) **(Rus)**

ABNORMALITIES

Cavernous malformations of the third ventricle. Sinson G, et al. **Neurosurgery** 1995 Jul;37(1):37-42 (20 ref.)

Nonprogressive congenital unilateral ventriculomegaly. Tsao PN, et al. **Pediatr Neurol** 1996 Jan;14(1):66-8 (15 ref.)

ANATOMY & HISTOLOGY

Homology in the evolution of the cerebral hemispheres. The case of reptilian dorsal ventricular ridge and its possible correspondence with mammalian neocortex. Aboitiz F. **J Hirnforsch** 1995;36(4):461-72 (84 ref.)

CYTOLOGY

Proliferative events in the cerebral ventricular zone. Caviness VS Jr, et al. **Brain Dev** 1995 May-Jun;17(3):159-63 (36 ref.)

EMBRYOLOGY

Proliferative events in the cerebral ventricular zone. Caviness VS Jr, et al. **Brain Dev** 1995 May-Jun;17(3):159-63 (36 ref.)

PHYSIOLOGY

Anteroventral wall of the third ventricle and dorsal lamina terminalis: headquarters for control of body fluid homeostasis? McKinley MJ, et al. **Clin Exp Pharmacol Physiol** 1996 Apr;23(4):271-81 (96 ref.)

PHYSIOPATHOLOGY

Spontaneous periodic hypothermia. Kloos RT. **Medicine (Baltimore)** 1995 Sep;74(5):268-80 (131 ref.)

[Intraventricular hemorrhage in a newborn] Koenigsberger MR, et al. **Rev Neurol** 1995;23 Suppl 3:S285-8 (59 ref.) **(Spa)**

SURGERY

Arachnoid cyst within the fourth ventricle--a case report. Nadkarni T, et al. **Br J Neurosurg** 1995;9(5):675-8 (10 ref.)

Cavernous malformations of the third ventricle. Sinson G, et al. **Neurosurgery** 1995 Jul;37(1):37-42 (20 ref.)

CEREBROHEPATORENAL SYNDROME see **ZELLWEGER SYNDROME**

CEREBROSIDE-SULFATASE

see related
LEUKODYSTROPHY, METACHROMATIC

CEREBROSPINAL FLUID

see related
BLOOD-BRAIN BARRIER

[Traumatic spinothoracic cerebrospinal fluid fistula] Löw R, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1995 Nov;163(5):454-6 (9 ref.) **(Ger)**

PHYSIOLOGY

Cerebrospinal fluid. Thompson EJ. **J Neurol Neurosurg Psychiatry** 1995 Oct;59(4):349-57 (58 ref.)

Anatomical pathways for lymphatic drainage of the brain and their pathological significance. Kida S, et al. **Neuropathol Appl Neurobiol** 1995 Jun;21(3):181-4 (17 ref.)

Physiology and immunology of lymphatic drainage of interstitial and cerebrospinal fluid from the brain. Knopf PM, et al. **Neuropathol Appl Neurobiol** 1995 Jun; 21(3):175-80 (16 ref.)

CEREBROSPINAL FLUID PRESSURE

see related
INTRACRANIAL PRESSURE

Regional cerebral blood flow, white matter abnormalities, and cerebrospinal fluid hydrodynamics in patients with idiopathic adult hydrocephalus syndrome. Kristensen B, et al. **J Neurol Neurosurg Psychiatry** 1996 Mar;60(3):282-8 (41 ref.)

CEREBROSPINAL FLUID SHUNTS

Hydrocephalus and shunts in children with brain tumors. Ryan JA, et al. **J Pediatr Oncol Nurs** 1995 Oct;12(4):223-9 (19 ref.)

Lumboperitoneal shunt for the treatment of pseudotumor cerebri. Eggenberger ER, et al. **Neurology** 1996 Jun; 46(6):1524-30 (49 ref.)

ADVERSE EFFECTS

Cerebrospinal fluid shunt infections. Hanekom WA, et al. **Adv Pediatr Infect Dis** 1996;11:29-54 (90 ref.)

Cerebrospinal fluid shunt complications: an emergency medicine perspective. Key CB, et al. **Pediatr Emerg Care** 1995 Oct;11(5):265-73 (56 ref.)

METHODS

Surgical indication and results of foramen magnum decompression versus syringosubarachnoid shunting for syringomyelia associated with Chiari I malformation. Hida K, et al. **Neurosurgery** 1995 Oct;37(4):673-8; discussion 678-9 (33 ref.)

CEREBROSPINAL RHINORRHEA

SURGERY

[Endonasal treatment of iatrogenic or spontaneous cerebrospinal rhinorrhea of the anterior cranial fossa] Coiffier T, et al. **Ann Otolaryngol Chir Cervicofac** 1995; 112(8):367-73 (48 ref.) (Eng. Abstr.) **(Fre)**

CEREBROVASCULAR CIRCULATION

Near infra-red spectroscopy [editorial] Harris DN. **Anaesthesia** 1995 Dec;50(12):1015-6 (19 ref.)

Ensuring adequate cerebral perfusion during aneurysm surgery [editorial] Miller JD. **Br J Anaesth** 1995 Nov; 75(5):518-9 (12 ref.)

Cerebral blood flow and brain function in hypertension. Fujishima M, et al. **Hypertens Res** 1995 Jun;18(2):111-7 (23 ref.)

Cerebral perfusion and hypothermic circulatory arrest. Chanyi S. **J Cardiothorac Vasc Anesth** 1996 Jan;10(1):75-81; quiz 81-2 (47 ref.)

Cerebrovascular assessment of the high-risk patient: the role of transcranial Doppler ultrasound. Doblar DD. **J Cardiothorac Vasc Anesth** 1996 Jan;10(1):3-14 (116 ref.)

The role of neuromonitoring in cardiovascular surgery. Edmonds HL Jr, et al. **J Cardiothorac Vasc Anesth** 1996 Jan;10(1):15-23 (51 ref.)

Determinants of cerebral perfusion during cardiopulmonary bypass. O'Dwyer C, et al. **J Cardiothorac Vasc Anesth** 1996 Jan;10(1):54-64; quiz 65 (142 ref.)

Nitroxidergic nerve: regulation of vascular tone and blood flow in the brain. Toda N, et al. **J Hypertens** 1996 Apr; 14(4):423-34 (127 ref.)

Regional cerebral blood flow, white matter abnormalities, and cerebrospinal fluid hydrodynamics in patients with idiopathic adult hydrocephalus syndrome. Kristensen B, et al. **J Neurol Neurosurg Psychiatry** 1996 Mar;60(3):282-8 (41 ref.)

Mechanical characteristics of vascular tissue and their role in brain injury modeling: a review. Vossoughi J, et al. **J Neurotrauma** 1995 Aug;12(4):755-63 (52 ref.)

Cerebral blood flow in severe clinical head injury. Bouma GJ, et al. **New Horiz** 1995 Aug;3(3):384-94 (52 ref.)

Hemodynamic management of brain-injured patients. Tonnesen AS. **New Horiz** 1995 Aug;3(3):499-505 (33 ref.)

Cerebrovascular permeability to peptides: manipulations of transport systems at the blood-brain barrier. Zlokovic BV. **Pharm Res** 1995 Oct;12(10):1395-406 (72 ref.)

[Low cerebral output, transient ischemic attack and syncope] Berger JP. **Rev Med Suisse Romande** 1996 Aug; 116(8):597-604 (23 ref.) **(Fre)**

[The blood-brain barrier: a specialty of cerebral microcirculation systems] Wolf S, et al. **Naturwissenschaften** 1996 Jul;83(7):302-11 (41 ref.) **(Ger)**

DRUG EFFECTS

The role of angiotensin receptor subtypes in cerebrovascular regulation in the rat. Näveri L. **Acta Physiol Scand Suppl** 1995;630:1-48 (170 ref.)

Vascular aspects of oestrogen. Collins P. **Maturitas** 1996 Mar; 23(2):217-26 (97 ref.)

Cerebral blood flow in untreated and treated hypertension. Strandgaard S, et al. **Neth J Med** 1995 Oct;47(4):180-4 (32 ref.)

Fetal cerebral vascular effects of cocaine exposure. Schreiber MD. **NIDA Res Monogr** 1995;158:67-87 (50 ref.)

Cholinergic and vasoactive intestinal polypeptidergic innervation of the cerebral arteries. Dauphin F, et al. **Pharmacol Ther** 1995;67(3):385-417 (274 ref.)

[Effects of analgesia and sedation on cerebrovascular circulation, cerebral blood volume, cerebral metabolism and intracranial pressure] Werner C. **Anaesthesist** 1995 Dec; 44 Suppl 3:S566-72 (83 ref.) (Eng. Abstr.) **(Ger)**

[Means for the pharmacological regulation of the cerebral blood circulation] Mirzoian RS. **Eksp Klin Farmakol** 1995 Jul-Aug;58(4):3-7 (30 ref.) **(Rus)**

PHYSIOLOGY

Transcranial Doppler ultrasound for cerebral perfusion. Jørgensen LG. **Acta Physiol Scand Suppl** 1995;625:1-44 (215 ref.)

The role of angiotensin receptor subtypes in cerebrovascular regulation in the rat. Näveri L. **Acta Physiol Scand Suppl** 1995;630:1-48 (170 ref.)

Cerebral blood flow in the newborn infant. Pryds O, et al. **Arch Dis Child Fetal Neonatal Ed** 1996 Jan;74(1):F63-9 (57 ref.)

Neurogenic control of the cerebral circulation. Branston NM. **Cerebrovasc Brain Metab Rev** 1995 Winter;7(4):338-49 (61 ref.)

Coupling of brain activity and cerebral blood flow: basis of functional neuroimaging. Villringer A, et al. **Cerebrovasc Brain Metab Rev** 1995 Fall;7(3):240-76 (268 ref.)

Nitric oxide and cerebral blood flow: an update. Watkins LD. **Cerebrovasc Brain Metab Rev** 1995 Winter; 7(4):324-337 (99 ref.)

The vascularization of the developing human brain. Dąmbska M. **Folia Neuropathol** 1995;33(4):189-93 (29 ref.)

Failure at task-specific regional brain activation: new conceptualization of a disease entity. Wexler BE. **J Neuropsychiatry Clin Neurosci** 1991 Winter;3(1):94-8 (20 ref.)

Cerebral hemodynamic disturbances following penetrating craniocerebral injury and their influence on outcome. Kordestani RK, et al. **Neurosurg Clin N Am** 1995 Oct; 6(4):657-67 (68 ref.)

Introduction to cerebral perfusion pressure management. Rosner MJ. **Neurosurg Clin N Am** 1995 Oct;6(4):761-73 (99 ref.)

Intracranial pressure and cerebral perfusion pressure in severe head injury. Lang EW, et al. **New Horiz** 1995 Aug; 3(3):400-9 (98 ref.)

Transcranial Doppler measurements. Newell DW. **New Horiz** 1995 Aug;3(3):423-30 (69 ref.)

Evaluation of cerebral blood flow and hemodynamic reserve in symptomatic moyamoya disease using stable Xenon-CT blood flow. Horowitz M, et al. **Surg Neurol** 1995 Sep; 44(3):251-61; discussion 262 (75 ref.)

[The importance of clinical hemorheology in the study of cerebral blood flow in normal conditions and in cerebrovascular ischemia] Melaragno Filho R. **Arq Neuropsiquiatr** 1995 Mar;53(1):157-68 (85 ref.) (Eng.

Abstr.) **(Por)**

[The significance of the pulsator factor for the functioning of the cerebral circulatory system (a brief review)] Vainshtein GB, et al. **Fiziol Zh Im I M Sechenova** 1995 Jun;81(6):54–8 (28 ref.) **(Rus)**

CEREBROVASCULAR DISORDERS

Risk factors for cerebrovascular disease and the role of coagulation and fibrinolysis. Catto AJ, et al. **Blood Coagul Fibrinolysis** 1995 Sep;6(6):497–510 (173 ref.)

Cerebrovascular disease in women. Knepper LE, et al. **Cardiology** 1995;86(4):339–48 (97 ref.)

Stroke in children. Nicolaides P, et al. **Dev Med Child Neurol** 1996 Feb;38(2):172–80 (67 ref.)

[Progresses in neurology in China, 1995] Jiang D, et al. **Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):723–4 (0 ref.) **(Chi)**

BLOOD

[Hematological changes and cerebrovascular disorders] Abellán MT, et al. **Rev Neurol** 1995 Sep–Oct; 23(123):993–1007 (97 ref.) (Eng. Abstr.) **(Spa)**

CHEMICALLY INDUCED

How to have a stroke at an early age: the effects of crack, cocaine and other illicit drugs. Blank-Reid C. **J Neurosci Nurs** 1996 Feb;28(1):19–27 (29 ref.)

[Cocaine abuse--with special reference to cerebrovascular complications] Lalouschek W, et al. **Wien Klin Wochenschr** 1995;107(17):516–21 (65 ref.) (Eng. Abstr.) **(Ger)**

COMPLICATIONS

Headache as a symptom of organic diseases. Edmeads JG. **Curr Opin Neurol** 1995 Jun;8(3):233–6 (32 ref.)

Treatment of post-stroke hypertension. A practical guide. O'Connell JE, et al. **Drugs Aging** 1996 Jun;8(6):408–15 (50 ref.)

Vertical gaze paralysis and intermittent unresponsiveness in a patient with a thalamomesencephalic stroke. Beversdorf DQ, et al. **J Neuroophthalmol** 1995 Dec;15(4):230–5 (21 ref.)

Understanding central post-stroke pain. Segatore M. **J Neurosci Nurs** 1996 Feb;28(1):28–35 (74 ref.)

The management of central post-stroke pain. Bowsher D. **Postgrad Med J** 1995 Oct;71(840):598–604 (36 ref.)

Complications and medical comorbidities of stroke. MacWalter RS, et al. **Scott Med J** 1995 Oct;40(5):134–7 (61 ref.)

AIDS and cerebrovascular disease. Pinto AN. **Stroke** 1996 Mar;27(3):538–43 (61 ref.)

Effects of cerebrovascular accident on micturition. Burney TL, et al. **Urol Clin North Am** 1996 Aug;23(3):483–90 (33 ref.)

[What is left of vascular dementia?] Ghika J, et al. **Rev Med Suisse Romande** 1996 Aug;116(8):635–8 (16 ref.) **(Fre)**

[Neuromuscular involvement and cerebrovascular accidents] Kuntzer T, et al. **Rev Med Suisse Romande** 1996 Aug; 116(8):605–9 (31 ref.) **(Fre)**

[Migraine and cerebrovascular accidents] Nater B. **Rev Med Suisse Romande** 1996 Aug;116(8):587–9 (14 ref.) **(Fre)**

[Pain in the upper extremity after a stroke] Marchuk G, et al. **Lik Sprava** 1995 May–Jun;(5–6):55–61 (108 ref.) (Eng. Abstr.) **(Rus)**

[The moyamoya syndrome secondary to fibromuscular dysplasia of the middle cerebral artery] Verdú Pérez A, et al. **An Esp Pediatr** 1996 Jul;45(1):99–100 (12 ref.) **(Spa)**

[Clinical aspects of vascular epilepsy in aging] Carod FJ, et al. **Rev Neurol** 1995 Nov–Dec;23(124):1314–7 (11 ref.) **(Spa)**

[Prevention of migrainous infarction] Leira R. **Rev Neurol** 1995;23 Suppl 2:S219–25 (109 ref.) **(Spa)**

DIAGNOSIS

A proposal for an integrated multidisciplinary assessment battery in elderly stroke patients. Kalra L. **Aging (Milano)** 1995 Jun;7(3):197–201 (57 ref.)

Unusual appearance of intracranial fibromuscular dysplasia. A case report. Belen D, et al. **Angiology** 1996 Jun; 47(6):627–32 (21 ref.)

Diagnosis and treatment of concomitant hypertension and stroke. Kenton EJ 3rd. **J Natl Med Assoc** 1996 Jun; 88(6):364–8 (25 ref.)

Cognitive status as a predictor of right hemisphere stroke outcomes. Sisson RA. **J Neurosci Nurs** 1995 Jun; 27(3):152–6 (19 ref.)

Stroke and ischemia. Siewert B, et al. **Magn Reson Imaging Clin N Am** 1995 Aug;3(3):529–40 (90 ref.)

Diagnosis and therapeutic aspects of stroke. Lees KR, et al. **Neth J Med** 1995 Oct;47(4):195–8 (22 ref.)

Ventilatory management in critical neurologic illness. Borel CO, et al. **Neurol Clin** 1995 Aug;13(3):627–44 (79 ref.)

Cocaine-induced cerebrovascular impairment: challenges to neuropsychological assessment. Strickland TL, et al. **Neuropsychol Rev** 1995 Mar;5(1):69–79 (38 ref.)

[Current aspects in cerebrovascular neuroradiology] Maeder P, et al. **Rev Med Suisse Romande** 1996 Aug;116(8):611–9 (27 ref.) **(Fre)**

[Behçet disease with primary involvement of the cerebral vessels] Proebstle TM, et al. **Dtsch Med Wochenschr** 1996 Jan 5;121(1–2):16–20 (19 ref.) (Eng. Abstr.) **(Ger)**

[Neuroradiological studies and findings in stroke] Forsting M, et al. **Ther Umsch** 1996 Jul;53(7):535–43 (20 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Clinical potential for the use of neuroprotective agents. A brief overview. Trembly B. **Ann N Y Acad Sci** 1995 Sep 15;765:1–20; discussion 26–7 (87 ref.)

Secondary prevention of stroke [editorial] Chambers BR. **Aust N Z J Med** 1995 Oct;25(5):465–8 (18 ref.)

Pharmacological therapy for acute stroke: the future. Panayiotou BN, et al. **Br J Clin Pract** 1995 Nov–Dec; 49(6):314–7 (66 ref.)

Antithrombotic therapy for cerebrovascular disorders. An update. Sherman DG, et al. **Chest** 1995 Oct;108(4 Suppl):444S–456S (203 ref.)

Medical therapy for ischemic stroke. Silver B, et al. **Clin Neuropharmacol** 1996 Apr;19(2):101–28 (272 ref.)

Lazaroids. CNS pharmacology and current research. Clark WM, et al. **Drugs** 1995 Dec;50(6):971–83 (64 ref.)

Pentoxifylline (oxpentifylline). A review of its therapeutic efficacy in the management of peripheral vascular and cerebrovascular disorders. Frampton JE, et al. **Drugs Aging** 1995 Dec;7(6):480–503 (150 ref.)

Quantitative electroencephalography in aging brain and cerebrovascular disease: the effects of almitrine-raubasine. Sebban C. **Eur Neurol** 1995;35 Suppl 1:37–42 (16 ref.)

Diagnosis and treatment of concomitant hypertension and stroke. Kenton EJ 3rd. **J Natl Med Assoc** 1996 Jun; 88(6):364–8 (25 ref.)

Therapeutic effects of endothelin receptor antagonists in stroke. Barone FC, et al. **Neurol Res** 1995 Aug;17(4):259–64 (70 ref.)

Microglia as a unique cellular target in the treatment of stroke: potential neurotoxic mediators produced by activated microglia. Wood PL. **Neurol Res** 1995 Aug; 17(4):242–8 (104 ref.)

Emerging treatments for stroke in humans. Koroshetz WJ, et al. **Trends Pharmacol Sci** 1996 Jun;17(6):227–33 (57 ref.)

[Thrombolytic therapy in ischemic cerebrovascular accidents] Hommel M, et al. **Schweiz Rundsch Med Prax** 1995 Sep 19;84(38):1025–31 (59 ref.) (Eng. Abstr.) **(Fre)**

[Antihypertensive therapy in stroke: acute therapy, primary and secondary prevention] Brainin M. **Acta Med Austriaca** 1995;22(3):54–7 (36 ref.) (Eng. Abstr.) **(Ger)**

[Emergency drug therapy of cerebrovascular disease] Kobayashi S. **Nippon Naika Gakkai Zasshi** 1995 Nov 10; 84(11):1832–6 (7 ref.) **(Jpn)**

[Antithrombotic therapy in cerebrovascular disorders] Dahl T, et al. **Tidsskr Nor Laegeforen** 1995 Sep 30; 115(23):2909–12 (50 ref.) (Eng. Abstr.) **(Nor)**

[Guidelines for the management of acute cerebrovascular disease in patients] Alonso de Leciñana M, et al. **Rev Neurol** 1995 Mar–Apr;23(120):363–9 (54 ref.) (Eng. Abstr.) **(Spa)**

EPIDEMIOLOGY

Case-control and cohort studies of moderate alcohol consumption and stroke. Camargo CA Jr. **Clin Chim Acta** 1996 Mar 15;246(1–2):107–19 (41 ref.)

Hypertension, coronary artery and cerebrovascular diseases in the population. Has epidemiology changed in the last decades? Pessina AC, et al. **Clin Exp Hypertens** 1996 Apr–May;18(3–4):363–70 (18 ref.)

Epidemiology of cerebrovascular disease: stroke epidemic in Japan. Shimamoto T, et al. **J Epidemiol** 1996 Aug;6(3 Suppl):S43–7 (37 ref.)

Ethnic differences in stroke: black-white differences in the United States population. SECORDS Investigators. Southeastern Consortium on Racial Differences in Stroke. Gaines K, et al. **Neuroepidemiology** 1995;14(5):209–39 (194 ref.)

Clinical epidemiology of stroke. Thompson DW, et al. **Neurol Clin** 1996 May;14(2):309–15 (33 ref.)

A systematic comparison of the risks of stroke and death due to carotid endarterectomy for symptomatic and asymptomatic stenosis. Rothwell PM, et al. **Stroke** 1996 Feb;27(2):266–9 (37 ref.)

A systematic review of the risks of stroke and death due to endarterectomy for symptomatic carotid stenosis. Rothwell PM, et al. **Stroke** 1996 Feb;27(2):260–5 (68 ref.)

Comparing stroke incidence worldwide: what makes studies comparable? Sudlow CL, et al. **Stroke** 1996 Mar; 27(3):550–8 (84 ref.)

[Epidemiology and risk factors in stroke] Leonhardt G, et al. **Ther Umsch** 1996 Jul;53(7):512–8 (25 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Association between stroke and atrial septal aneurysm assessed by transesophageal echocardiography in a cardiologic population. Ossemann M, et al. **Acta Neurol Belg** 1995;95(3):170–7 (49 ref.)

Cardioembolic stroke. Brickner ME. **Am J Med** 1996 Apr; 100(4):465–74 (92 ref.)

Cerebrovascular complications in Ehlers-Danlos syndrome type IV. North KN, et al. **Ann Neurol** 1995 Dec;38(6):960–4 (28 ref.)

Ultrasonographic carotid plaque morphology in predicting stroke risk. Geroulakos G, et al. **Br J Surg** 1996 May; 83(5):582–7 (44 ref.)

Prognosis of individuals with atrial fibrillation. Laupacis A, et al. **Can J Cardiol** 1996 Jan;12 Suppl A:14A–16A (22 ref.)

Transesophageal echocardiography in diagnosing cardioembolic stroke. Husain AM, et al. **Clin Cardiol** 1995 Dec;18(12):705–8 (14 ref.)

Alcohol, hypertension, coronary disease and stroke. Lip GY, et al. **Clin Exp Pharmacol Physiol** 1995 Mar;22(3):189–94 (66 ref.)

Vascular pathology in the elderly. Hsu CY, et al. **Eur Neurol** 1995;35 Suppl 1:2–4 (20 ref.)

Complications associated with extracranial carotid artery interventions. Dorros G. **J Endovasc Surg** 1996 May; 3(2):166–70 (15 ref.)

Estrogen replacement therapy and stroke. Paganini-Hill A. **Prog Cardiovasc Dis** 1995 Nov–Dec;38(3):223–42 (85 ref.)

Stroke in Williams syndrome. Wollack JB, et al. **Stroke** 1996 Jan;27(1):143–6 (20 ref.)

[Clinical evaluation and neurological ultrasonography in 60 cases of carotid dissection] Despland PA, et al. **Rev Med Suisse Romande** 1996 Aug;116(8):591–6 (29 ref.) **(Fre)**

[Diagnosis and treatment of cerebrovascular accidents of cardioembolic origin] Ricou FJ, et al. **Schweiz Rundsch Med Prax** 1996 Feb 6;85(6):155–8 (25 ref.) (Eng. Abstr.) **(Fre)**

[Heart, brain and hypertension] Lüscher TF, et al. **Schweiz Med Wochenschr** 1996 Aug 24;126(34):1449–56 (43 ref.) (Eng. Abstr.) **(Ger)**

[Epidemiology and risk factors in stroke] Leonhardt G, et al. **Ther Umsch** 1996 Jul;53(7):512–8 (25 ref.) (Eng. Abstr.) **(Ger)**

[Ischemic stroke in the young adult (see comments)] Gandolfo C, et al. **Ann Ital Med Int** 1996 Jan–Mar; 11(1):33–8 (50 ref.) (Eng. Abstr.) Comment in: Ann Ital Med Int 1996 Jan–Mar;11(1):5–7. **(Ita)**

[Countermeasure for patients with cerebrovascular disorders due to hemodialysis] Hirakata H. **Nippon Naika Gakkai Zasshi** 1995 Oct 10;84(10):1685–90 (9 ref.) **(Jpn)**

[Cerebral circulatory disorder, ischemic cerebrovascular disease in obesity] Nagatsuka K. **Nippon Rinsho** 1995 Jun; 53 Suppl:338–42 (12 ref.) **(Jpn)**

[Diabetes mellitus and stroke] Man'kovskiĭ BN. **Lik Sprava** 1995 Jul–Aug;(7–8):78–83 (55 ref.) **(Rus)**

[Metabolic changes and cerebrovascular disease] Dávalos A. **Rev Neurol** 1995;23 Suppl 1:S128–30 (30 ref.) **(Spa)**

[Iatrogenic cerebrovascular disease] Rey A, et al. **Rev Neurol** 1995;23 Suppl 1:S131–46 (200 ref.) **(Spa)**

[Mitochondrial diseases and cerebrovascular pathology] Vivancos J, et al. **Rev Neurol** 1995;23 Suppl 1:S106–12 (39 ref.) **(Spa)**

GENETICS

The genetics of cerebrovascular disease. Brass LM, et al. **Baillieres Clin Neurol** 1995 Aug;4(2):221–45 (145 ref.)

MORTALITY

[Parma Stroke Data Bank: embolic stroke] Tonelli C, et al. **Minerva Med** 1995 Nov;86(11):459–66 (76 ref.) (Eng. Abstr.) **(Ita)**

NURSING

Neurodevelopmental treatment: application to nursing and effects on the hemiplegic stroke patient. Hafsteinsdóttir TB. **J Neurosci Nurs** 1996 Feb;28(1):36–47 (45 ref.)

PATHOLOGY

Clinical stroke syndromes: clinical-anatomical correlations. Gavrilescu T, et al. **Cerebrovasc Brain Metab Rev** 1995 Fall;7(3):218–39 (101 ref.)

Selected histochemical and immunocytochemical markers of biological activity of brain blood vessels. Kałuża J. **Folia Neuropathol** 1995;33(4):195–200 (32 ref.)

Developmental failures of blood vessels within central nervous system. Rafałowska J. **Folia Neuropathol** 1995; 33(4):201–6 (46 ref.)

Ischemic stroke and incomplete infarction. Garcia JH, et al. **Stroke** 1996 Apr;27(4):761–5 (48 ref.)

[Retrospect and prospect of neuropathology in China] Xu Q, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1995 Aug; 24(4):248–51 (16 ref.) **(Chi)**

PHYSIOPATHOLOGY

Mechanisms underlying functional recovery following stroke. Lee RG, et al. **Can J Neurol Sci** 1995 Nov;22(4):257–63 (46 ref.)

Hemorheology in cerebrovascular accident: an overview. Hussain MA, et al. **J Assoc Physicians India** 1995 Apr; 43(4):283–6 (35 ref.)

Predicting perioperative stroke. Kim J, et al. **J Neurosurg Anesthesiol** 1995 Jul;7(3):211–5 (24 ref.)

Neurologic intensive care unit management and economic issues. Sundrani S. **Neurol Clin** 1995 Aug;13(3):679–93 (57 ref.)
Innervation of cerebral arteries by nerves containing 5–hydroxytryptamine and noradrenaline. Lincoln J. **Pharmacol Ther** 1995;68(3):473–501 (256 ref.)
Neurological manifestations of acute posterior multifocal placoid pigment epitheliopathy. Comu S, et al. **Stroke** 1996 May;27(5):996–1001 (38 ref.)
Ischemic stroke and incomplete infarction. Garcia JH, et al. **Stroke** 1996 Apr;27(4):761–5 (48 ref.)
[Clinical symptoms and stroke syndrome] Bassetti C, et al. **Ther Umsch** 1996 Jul;53(7):519–27 (39 ref.) (Eng. Abstr.) **(Ger)**
[Stroke units: modality, structure, organization and utilization] Díez–Tejedor E, et al. **Rev Neurol** 1995 Mar–Apr;23(120):377–80 (21 ref.) **(Spa)**
[Stroke units] Matías–Guiu J. **Rev Neurol** 1995 Mar–Apr; 23(120):324–5 (26 ref.) **(Spa)**
[Arterial hypertension and cerebrovascular disease] Matías–Guiu J, et al. **Rev Neurol** 1995;23 Suppl 1:S50–2 (24 ref.) **(Spa)**

PREVENTION & CONTROL

Risk factors and differential antihypertensive therapies. Os I. **Acta Med Austriaca** 1995;22(3):45–7 (31 ref.)
Carotid endarterectomy—when to do it, how to do it? Steiger HJ. **Acta Neurochir (Wien)** 1995;137(3–4):121–7 (65 ref.)
Prevention of stroke caused by carotid bifurcation stenosis [see comments] Santilli JD, et al. **Am Fam Physician** 1996 Feb 1;53(2):549–56, 559–60 (21 ref.) Comment in: Am Fam Physician 1996 Feb 1;53(2):486, 491.
Atrial fibrillation, anticoagulation, and stroke. Morley J, et al. **Am J Cardiol** 1996 Jan 25;77(3):38A–44A (29 ref.)
The dilemma of surgical treatment for patients with asymptomatic carotid disease [comment] Barnett HJ, et al. **Ann Intern Med** 1995 Nov 1;123(9):723–5 (22 ref.) Comment on: Ann Intern Med 1995 Nov 1;123(9):649–55. Comment on: Ann Intern Med 1995 Nov 1;123(9):729.
Medical compared with surgical treatment of asymptomatic carotid artery stenosis [comment] [see comments] Brott T, et al. **Ann Intern Med** 1995 Nov 1;123(9):720–2 (21 ref.) Comment on: Ann Intern Med 1995 Nov 1;123(9):649–55. Comment on: Ann Intern Med 1995 Nov 1;123(9):729. Comment in: Ann Intern Med 1995 Nov 1;123(9):649–55.
Strategies for neuroprotection with glutamate antagonists. Extrapolating from evidence taken from the first stroke and head injury studies. Bullock R. **Ann N Y Acad Sci** 1995 Sep 15;765:272–8; discussion 298 (11 ref.)
Surgical management of carotid stenosis. Halliday A. **Ann R Coll Surg Engl** 1995 Sep;77(5):323–4 (19 ref.)
Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation [see comments] Blackshear JL, et al. **Ann Thorac Surg** 1996 Feb;61(2):755–9 (59 ref.) Comment in: Ann Thorac Surg 1996 Feb;61(2):515.
Secondary prevention of stroke [editorial] Chambers BR. **Aust N Z J Med** 1995 Oct;25(5):465–8 (18 ref.)
Risk factors and primary prevention of stroke [editorial] Stewart–Wynne EG, et al. **Aust N Z J Med** 1995 Jun; 25(3):191–4 (24 ref.)
Potential beneficial effects of urapidil in primary and secondary prevention of stroke. Späh F, et al. **Blood Press** 1995;Suppl 3:62–7 (49 ref.)
Antithrombotic therapy in atrial fibrillation. Turpie AG, et al. **Can Fam Physician** 1996 Jul;42:1341–5 (16 ref.)
Antithrombotic therapy in atrial fibrillation. Connolly SJ, et al. **Can J Cardiol** 1996 Jan;12 Suppl A:17A–20A (13 ref.)
Primary and secondary prevention of stroke. MacMahon S, et al. **Clin Exp Hypertens** 1996 Apr–May;18(3–4):537–46 (16 ref.)
Ticlopidine. A review of its pharmacology, clinical efficacy and tolerability in the prevention of cerebral ischaemia and stroke. Noble S, et al. **Drugs Aging** 1996 Mar;8(3):214–32 (125 ref.)
Stroke prevention: the emerging strategies. McCrory DC, et al. **Hosp Pract (Off Ed)** 1996 Mar 15; 31(3):123–8,131–2,134 (8 ref.)
Primary prevention of stroke [see comments] Bronner LL, et al. **N Engl J Med** 1995 Nov 23;333(21):1392–400 (142 ref.) Comment in: N Engl J Med 1996 Apr 25;334(17):1138; discussion 1139. Comment in: N Engl J Med 1996 Apr 25;334(17):1138–9.
Effectiveness versus efficacy of treatment of hypertension for stroke prevention. Whisnant JP. **Neurology** 1996 Feb; 46(2):301–7 (22 ref.)
Non–invasive blood pressure monitoring in man. Portaluppi F. **Pathol Biol (Paris)** 1996 Mar;44(3):196–200 (80 ref.)
Who needs carotid endarterectomy? Fox A, et al. **Practitioner** 1996 Jan;240(1558):29–32 (4 ref.)
Blood pressure lowering for the primary and secondary prevention of coronary and cerebrovascular disease. MacMahon S, et al. **Schweiz Med Wochenschr** 1995 Dec 26;125(51–52):2479–86 (28 ref.)
Aspirin dose in stroke prevention: beautiful hypotheses slain by ugly facts [editorial; comment] Barnett HJ, et al. **Stroke** 1996 Apr;27(4):588–92 (60 ref.) Comment on: Stroke 1996 Apr;27(4):756–60.
Aspirin wars: the optimal dose of aspirin prevent stroke [editorial; comment] Hart RG, et al. **Stroke** 1996 Apr; 27(4):585–7 (45 ref.) Comment on: Stroke 1996 Apr;27(4):756–60.
Aspirin in ischemic cerebrovascular disease. How strong is the case for a different dosing regimen? [see comments] Patrono C, et al. **Stroke** 1996 Apr;27(4):756–60 (36 ref.) Comment in: Stroke 1996 Apr;27(4):585–7. Comment in: Stroke 1996 Apr;27(4):588–92.
[Antithrombotic agents and prevention of cerebrovascular accidents] Dewarrat A, et al. **Rev Med Suisse Romande** 1996 Aug;116(8):629–34 (38 ref.) (Eng. Abstr.) **(Fre)**
[Estrogen–gestagen substitution in geriatric gynecology. Long–term prevention for the third segment of life after menopause] Lauritzen C. **Fortschr Med** 1996 May 30; 114(15):187–90 (0 ref.) (Eng. Abstr.) **(Ger)**
[Risk factors and prevention of cerebral artery disease] Diener HC. **Internist (Berl)** 1995 Sep;36(9):868–74 (30 ref.) **(Ger)**
[Current status of primary and secondary prevention of cerebral apoplexy] Zippel C. **Wien Med Wochenschr** 1995; 145(19–20):537–41 (35 ref.) (Eng. Abstr.) **(Ger)**
[Metabolic tolerance of isradipine. Evaluation after three months of therapy] Panuccio D, et al. **Clin Ter** 1995 Nov; 146(11):729–36 (82 ref.) (Eng. Abstr.) **(Ita)**
[Prevention of migrainous infarction] Leira R. **Rev Neurol** 1995;23 Suppl 2:S219–25 (109 ref.) **(Spa)**

PSYCHOLOGY

Epidemiology and treatment of post–stroke depression. Gustafson Y, et al. **Drugs Aging** 1995 Oct;7(4):298–309 (45 ref.)
Human development in the context of aging and chronic illness: the role of attachment in Alzheimer's disease and stroke. Wright LK, et al. **Int J Aging Hum Dev** 1995; 41(2):133–50 (82 ref.)

REHABILITATION

Recovery from stroke: rehabilitation. Speach DP, et al. **Baillieres Clin Neurol** 1995 Aug;4(2):317–38 (115 ref.)
Benefits of aerobic exercise after stroke. Potempa K, et al. **Sports Med** 1996 May;21(5):337–46 (57 ref.)
[Many chronic problems in CVA patients at home] Hochstenbach JB, et al. **Ned Tijdschr Geneeskd** 1996 Jun 1;140(22):1182–6 (34 ref.) (Eng. Abstr.) **(Dut)**
[Stroke rehabilitation] Kallanranta T. **Duodecim** 1994; 110(15):1419–30 (76 ref.) **(Fin)**
[Guidelines for the management of acute cerebrovascular disease in patients] Alonso de Leciñana M, et al. **Rev Neurol** 1995 Mar–Apr;23(120):363–9 (54 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

Endovascular therapy for surgical diseases of the cranial base. Chaloupka JC, et al. **Clin Plast Surg** 1995 Jul;22(3):417–50 (193 ref.)
Stroke is an emergency. Futrell N, et al. **Dis Mon** 1996 Apr; 42(4):199–264 (198 ref.)
Acute stroke. Naradzay JF, et al. **Emerg Med Clin North Am** 1996 Feb;14(1):197–216 (123 ref.)
Carotid angioplasty and stenting: is endovascular treatment for cerebrovascular disease justified [editorial] Bergeron P. **J Endovasc Surg** 1996 May;3(2):129–31 (12 ref.)
Management of transient ischaemic attacks and stroke. Humphrey PR. **Postgrad Med J** 1995 Oct;71(840):577–84 (35 ref.)
Stroke: therapeutic window. Popa G. **Rom J Neurol Psychiatry** 1995 Jan–Mar;33(1):37–49 (16 ref.)
[Which treatment for patients with cerebrovascular accident and patent foramen ovale?] Devuyst G, et al. **Rev Med Suisse Romande** 1996 Aug;116(8):639–43 (30 ref.) **(Fre)**
[Countermeasure for patients with cerebrovascular disorders due to hemodialysis] Hirakata H. **Nippon Naika Gakkai Zasshi** 1995 Oct 10;84(10):1685–90 (9 ref.) **(Jpn)**

ULTRASONOGRAPHY

[Transcranial Doppler and color duplex ultrasound. Familiar and new uses] Baumgartner RW, et al. **Ultraschall Med** 1996 Apr;17(2):50–4 (50 ref.) (Eng. Abstr.) **(Ger)**
[Importance of cerebrovascular reactivity testing in diabetes mellitus] Fülesdi B, et al. **Orv Hetil** 1995 Nov 12; 136(46):2497–500 (35 ref.) (Eng. Abstr.) **(Hun)**

CEREBRUM see **BRAIN**

CERIUM

ADVERSE EFFECTS

Rare earth (cerium oxide) pneumoconiosis: analytical scanning electron microscopy and literature review. McDonald JW, et al. **Mod Pathol** 1995 Oct;8(8):859–65 (24 ref.)

CEROID

METABOLISM

Lipofuscin and ceroid pigments in aging and brain pathology. A review. I. Biochemical and morphological properties. Riga D, et al. **Rom J Neurol Psychiatry** 1995 Apr–Jun; 33(2):121–36 (107 ref.)

CEROID–LIPOFUSCINOSIS, NEURONAL see **NEURONAL CEROID–LIPOFUSCINOSIS**

CERTIFICATION

see related
ACCREDITATION

Certified nurse midwives: over twenty years of military service. Davis LJ. **Mil Med** 1995 Aug;160(8):401–4 (20 ref.)
Focus on quantitative methods. Determining cut–off scores. Goodwin LD. **Res Nurs Health** 1996 Jun;19(3):249–56 (60 ref.)

ORGANIZATION & ADMINISTRATION

Regulation of advanced nursing practice: Part Two—Certification. Spencer–Cisek P, et al. **Oncol Nurs Forum** 1995 Sep;22(8 Suppl):39–42 (12 ref.)

TRENDS

[Evolution and current status of certification of specialists in Mexico] Espinosa de los Reyes VM. **Gac Med Mex** 1995 Jan–Feb;131(1):72–82 (31 ref.) **(Spa)**

CERULENIN

PHARMACOLOGY

Identification of new drug targets in Mycobacterium avium and Mycobacterium tuberculosis. Rastogi N, et al. **Res Microbiol** 1996 Jan–Feb;147(1–2):97–105 (36 ref.)

CERULOPLASMIN

ANALYSIS

[Ceruloplasmin] Terao T. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:220–3 (16 ref.) **(Jpn)**

METABOLISM

Iron metabolism in eukaryotes: Mars and Venus at it again [comment] Kaplan J, et al. **Science** 1996 Mar 15; 271(5255):1510–2 (25 ref.) Comment on: Science 1996 Mar 15;271(5255):1552–7.

PHYSIOLOGY

The iron–copper connection: the link to ceruloplasmin grows stronger. Harris ED. **Nutr Rev** 1995 Jun;53(6):170–3 (12 ref.)

CERUMEN

PHYSIOLOGY

[Dimorphism of cerumen, facts and theory] Meyer zum Gottesberge A, et al. **Laryngorhinootologie** 1995 Oct; 74(10):606–10 (36 ref.) (Eng. Abstr.) **(Ger)**

CERVICAL INTRAEPITHELIAL NEOPLASIA

see related
CERVIX NEOPLASMS

Cervical intraepithelial neoplasia in pregnancy. Harper DM, et al. **J Fam Pract** 1996 Jan;42(1):79–83 (27 ref.)

CLASSIFICATION

Spontaneous evolution of intraepithelial lesions according to the grade and type of the implicated human papillomavirus (HPV). Syrjänen KJ. **Eur J Obstet Gynecol Reprod Biol** 1996 Mar;65(1):45–53 (98 ref.)

MICROBIOLOGY

[Association of Chlamydia trachomatis and human papilloma virus as predisposing factors in cervical intraepithelial neoplasia] González Sánchez JL, et al. **Ginecol Obstet Mex** 1995 Oct;63:422–6 (30 ref.) (Eng. Abstr.) **(Spa)**

PATHOLOGY

Cervical intraepithelial neoplasia: false negative smears. Allen SM. **Br J Biomed Sci** 1996 Jun;53(2):152–6 (36 ref.)
Endocervical curettage has no place in the routine management of women with cervical intraepithelial neoplasia: debate. Ferenczy A. **Clin Obstet Gynecol** 1995 Sep;38(3):644–8 (9 ref.)
Every woman with an abnormal cervical smear should be referred for treatment: debate. Flannelly G, et al. **Clin Obstet Gynecol** 1995 Sep;38(3):585–91 (20 ref.)
Cervical neoplasia: are adjunctive tests to cervical cytology worthwhile? Greenberg MD, et al. **Clin Obstet Gynecol** 1995 Sep;38(3):600–9 (24 ref.)
Endocervical curettage: a technique in search of an indication?: debate. Noller KL. **Clin Obstet Gynecol** 1995 Sep;38(3):649–52 (2 ref.)
Every woman with an abnormal cervical smear should not be referred for colposcopy: debate. Prendiville W, et al.

Clin Obstet Gynecol 1995 Sep;38(3):592–9 (16 ref.)
The pathology of cervical cancer. Walsh CB, et al.
Clin Obstet Gynecol 1995 Sep;38(3):653–61 (16 ref.)
[Blue nevus of the endocervix] Di Renzi F, et al.
Minerva Ginecol 1995 Jul–Aug;47(7–8):331–4 (23 ref.) (Eng. Abstr.) **(Ita)**

PREVENTION & CONTROL

Prevention of cervical intraepithelial neoplasia and cervical cancer. Meyskens FL Jr, et al. **Am J Clin Nutr** 1995 Dec; 62(6 Suppl):1417S–1419S (24 ref.)

SURGERY

Management of patients with high grade squamous intraepithelial lesions. Ferenczy A. **Cancer** 1995 Nov 15; 76(10 Suppl):1928–33 (38 ref.)
Large loop excision of the transformation zone. Prendiville W. **Clin Obstet Gynecol** 1995 Sep;38(3):622–39 (41 ref.)
The case for early intervention ('see and treat') in patients with dyskaryosis on routine cervical screening. Murdoch JB. **Int J STD AIDS** 1995 Nov–Dec;6(6):415–7 (15 ref.)

VIROLOGY

Cervical intraepithelial neoplasia, cervical cancer, and HPV. Holly EA. **Annu Rev Public Health** 1996;17:69–84 (96 ref.)
Spontaneous evolution of intraepithelial lesions according to the grade and type of the implicated human papillomavirus (HPV). Syrjänen KJ.
Eur J Obstet Gynecol Reprod Biol 1996 Mar;65(1):45–53 (98 ref.)

CERVICAL RIB SYNDROME

DIAGNOSIS

[The superior thoracic outlet compression syndrome: a report of a case in childhood with complete cervical rib] Nedbal M, et al. **Pediatr Med Chir** 1995 May–Jun;17(3):261–3 (22 ref.) (Eng. Abstr.) **(Ita)**

CERVICAL SMEARS see VAGINAL SMEARS

CERVICAL VERTEBRAE

Atlanto-axial subluxation and cervical osteomyelitis: two unusual complications of adenoidectomy. Baker LL, et al.
Ann Otol Rhinol Laryngol 1996 Apr;105(4):295–9 (12 ref.)
Chordoma of the lower cervical spine. D'Haen B, et al.
Clin Neurol Neurosurg 1995 Aug;97(3):245–8 (20 ref.)
Cervical spondylotic myelopathy. Cates JR, et al.
J Manipulative Physiol Ther 1995 Sep;18(7):471–5 (23 ref.)
A risk assessment of cervical manipulation vs. NSAIDs for the treatment of neck pain. Dabbs V, et al.
J Manipulative Physiol Ther 1995 Oct;18(8):530–6 (43 ref.)
Cervical discogenic syndrome: a cause of chronic head and neck pain. Senter BS. **J Miss State Med Assoc** 1995 Aug; 36(8):231–4 (15 ref.)
Inflammatory and infectious processes of the cervical spine. Ruiz A, et al. **Neuroimaging Clin N Am** 1995 Aug; 5(3):401–25 (80 ref.)
Cervical spine tumors. Sevick RJ.
Neuroimaging Clin N Am 1995 Aug;5(3):385–400 (66 ref.)
Cervical spine infections. Ghanayem AJ, et al.
Orthop Clin North Am 1996 Jan;27(1):53–67 (92 ref.)
Multifocal metachronous epidural abscesses of the spine. A case report. Chow GH, et al. **Spine** 1996 May 1; 21(9):1094–7 (11 ref.)
[A rare case of chondroid chordoma of the cervical spine] Sarrazin JL, et al. **J Radiol** 1996 Feb;77(2):141–4 (13 ref.) (Eng. Abstr.) **(Fre)**
[Manual medicine in otorhinolaryngology. Theoretical principles— clinical practice—principles of therapy and prevention] Seifert K. **Laryngorhinootologie** 1995 Oct; 74(10):583–90 (38 ref.) (Eng. Abstr.) **(Ger)**

ABNORMALITIES

Evaluation of cervical spine abnormalities on cephalometric radiographs. Vastardis H, et al.
Am J Orthod Dentofacial Orthop 1996 Jun;109(6):581–8 (34 ref.)
Craniovertebral junction anomalies in inherited disorders: part of the syndrome or caused by the disorder? Crockard HA, et al. **Eur J Pediatr** 1995 Jul;154(7):504–12 (48 ref.)
Cervical spondylolysis: three levels of simultaneous involvement. Yochum TR, et al.
J Manipulative Physiol Ther 1995 Jul–Aug;18(6):411–5 (10 ref.)
Congenital anomalies of the cervical spine. Smoker WR.
Neuroimaging Clin N Am 1995 Aug;5(3):427–49 (126 ref.)

INJURIES

What is the evidence for an organic lesion in whiplash injury? Gargan MF. **J Psychosom Res** 1995 Aug;39(6):777–81 (27 ref.)
Cervical spine fractures. Hughes SP.
J R Coll Surg Edinb 1995 Oct;40(5):337–41 (16 ref.)
Vertebrobasilar thrombosis associated with nonpenetrating cervical spine trauma. Prabhu V, et al. **J Trauma** 1996 Jan; 40(1):130–7 (59 ref.)
Imaging evaluation of cervical spine trauma. Cornelius RS, et al. **Neuroimaging Clin N Am** 1995 Aug;5(3):451–63 (51 ref.)
Imaging of cervical spine trauma. Tehranzadeh J, et al.
Semin Ultrasound CT MR 1996 Apr;17(2):93–104 (51 ref.)
Traumatic atlantoaxial rotatory subluxation and dislocation. Moore KR, et al. **Spine** 1995 Sep 1;20(17):1928–30 (10 ref.)
Spine update. Impaired cognitive functioning after whiplash injury of the cervical spine. Radanov BP, et al. **Spine** 1996 Feb 1;21(3):392–7 (26 ref.)
[Clinical aspects and neurologic expert assessment in sequelae of whiplash injury to the cervical spine] Jenzer G.
Nervenarzt 1995 Oct;66(10):730–5 (30 ref.) (Eng. Abstr.) **(Ger)**
[Injuries of the cervical spine. Diagnosis and surgical treatment] Illgner A, et al. **Unfallchirurg** 1996 May; 99(5):351–67; quiz 367 (10 ref.) **(Ger)**

PATHOLOGY

CT and MR imaging of vertebral osteoblastoma. A report of two cases. Ozkal E, et al. **Clin Imaging** 1996 Jan–Mar; 20(1):37–41 (13 ref.)
MR1 of giant cell tumor of the tendon sheath in the cervical spine. Bui–Mansfield LT, et al.
J Comput Assist Tomogr 1996 Jan–Feb;20(1):113–5 (6 ref.)
Paget sarcoma of the cervical vertebrae: an autopsy case report and review of the literature. Matsukuma S, et al.
Pathol Int 1995 Nov;45(11):885–9 (27 ref.)

PHYSIOPATHOLOGY

Cervical ventral epithelial cyst treated by anterior corpectomy—case report. Fujimoto K, et al.
Neurol Med Chir (Tokyo) 1996 May;36(5):321–5 (14 ref.)
Orthopedic conditions of the cervical spine and shoulder. Epps HR, et al. **Pediatr Clin North Am** 1996 Aug; 43(4):919–31 (37 ref.)

RADIOGRAPHY

Radiographic evaluation of the upper cervical spine in rheumatoid arthritis: a retrospective analysis. Kuhr M, et al. **Eur Spine J** 1996;5(2):107–11 (30 ref.)
Computed tomography and myelography in the evaluation of cervical degenerative disease. Russell EJ.
Neuroimaging Clin N Am 1995 Aug;5(3):329–48 (83 ref.)
Calcification of cervical ganglia: case report. Casolin AL, et al. **Neuroradiology** 1995 Aug;37(6):468–70 (19 ref.)
Complications of cervical discography: analysis of 4400 diagnostic disc injections. Zeidman SM, et al.
Neurosurgery 1995 Sep;37(3):414–7 (14 ref.)
Tuberculosis of the cervical spine. Lukhele M.
S Afr Med J 1996 May;86(5):553–6 (8 ref.)

SURGERY

Anterior decompressive microsurgery and osteosynthesis for the treatment of multi-segmental cervical spondylosis. Pathophysiological considerations, surgical indication, results and complications: a survey. Seifert V.
Acta Neurochir (Wien) 1995;135(3–4):105–21 (108 ref.)
In the rheumatoid patient: surgery to the cervical spine. Casey AT, et al. **Br J Rheumatol** 1995 Nov;34(11):1079–86 (48 ref.)
The anterior approach to the cervical spine. Bell GR.
Neuroimaging Clin N Am 1995 Aug;5(3):465–79 (41 ref.)
Cervical ventral epithelial cyst treated by anterior corpectomy—case report. Fujimoto K, et al.
Neurol Med Chir (Tokyo) 1996 May;36(5):321–5 (14 ref.)
Surgical management of cervical rheumatoid problems. Crockard HA. **Spine** 1995 Dec 1;20(23):2584–90 (40 ref.)
Complications of posterior cervical plating. Heller JG, et al. **Spine** 1995 Nov 15;20(22):2442–8 (21 ref.)

CERVICITIS

DIAGNOSIS

[Chlamydia infections in gynecology and obstetrics] Dieterle S. **Geburtshilfe Frauenheilkd** 1995 Sep;55(9):510–7 (65 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Chlamydia trachomatis: a major cause of mucopurulent cervicitis and pelvic inflammatory disease in women. Paavonen J. **Curr Probl Dermatol** 1996;24:110–22 (78 ref.)

CERVIX DISEASES

PATHOLOGY

The abnormal Papanicolaou smear. McIntyre-Seltman K.
Med Clin North Am 1995 Nov;79(6):1427–42 (49 ref.)

CERVIX DYSPLASIA

see related
CERVICAL NEOPLASMS

PREVENTION & CONTROL

Nutrient antioxidants in the pathogenesis and prevention of cervical dysplasias and cancer. Romney SL, et al.
J Cell Biochem Suppl 1995;23:96–103 (45 ref.)

CERVIX INCOMPETENCE

SURGERY

Prevention of preterm birth. Owen P, et al.
Baillieres Clin Obstet Gynaecol 1995 Sep;9(3):465–79 (96 ref.)
[Are there still indications for cerclage in 1995?] Dufour P, et al. **Rev Fr Gynecol Obstet** 1995 Oct;90(10):423–30 (26 ref.) (Eng. Abstr.) **(Fre)**

ULTRASONOGRAPHY

Sonography in the evaluation of the cervix during pregnancy. Guzman ER, et al. **Curr Opin Obstet Gynecol** 1996 Apr; 8(2):99–105 (16 ref.)

CERVIX MUCUS

CHEMISTRY

Biochemical changes in the cervical mucus after application of laminaria tent. El Maradny E, et al.
Acta Obstet Gynecol Scand 1996 Mar;75(3):203–7 (35 ref.)

PHYSIOLOGY

[Clinical study of ovulatory cervical mucus] Chrétien FC, et al. **Contracept Fertil Sex** 1996 May;24(5):359–67 (18 ref.) **(Fre)**

CERVIX NEOPLASMS

see related
CERVICAL INTRAEPITHELIAL NEOPLASIA
CERVIX DYSPLASIA

Cervical intraepithelial neoplasia in pregnancy. Harper DM, et al. **J Fam Pract** 1996 Jan;42(1):79–83 (27 ref.)

BLOOD SUPPLY

[The significance of invasion and vessel permeation in squamous cell carcinoma of the uterine cervix with invasion to a depth of 3 mm or less] Otsuka I, et al.
Nippon Sanka Fujinka Gakkai Zasshi 1995 Nov; 47(11):1261–7 (26 ref.) (Eng. Abstr.) **(Jpn)**

CHEMICALLY INDUCED

Postmenopausal estrogens and progestogens and the incidence of gynecologic cancer. Weiss NS, et al.
Maturitas 1996 Mar;23(2):235–9 (43 ref.)

COMPLICATIONS

AIDS-associated malignancies. Krown SE.
Cancer Chemother Biol Response Modif 1996;16:441–61 (141 ref.)
Carcinoma of the male breast: a sexually transmitted disease? Amir H, et al. **East Afr Med J** 1996 Mar;73(3):187–90 (32 ref.)
Carcinoma of the uterine cervix presenting as superior vena cava syndrome: report of three cases and a review of literature. Biswal BM, et al. **J Obstet Gynaecol** 1995 Oct; 21(5):437–42 (13 ref.)

DIAGNOSIS

Cervical cancer: how often—and why—to screen older women. Mandelblatt JS, et al. **Geriatrics** 1996 Jun; 51(6):45–8; quiz 49 (33 ref.)
A case of small cell carcinoma of the uterine cervix presenting Cushing's syndrome. Hashi A, et al.
Gynecol Oncol 1996 Jun;61(3):427–31 (14 ref.)
Magnetic resonance imaging applications in uterine cervical cancer. Mezrich R. **Magn Reson Imaging Clin N Am** 1994 May;2(2):211–43 (60 ref.)
[The cytological screening problems in cancer of the cervix uteri] Khristova L. **Akush Ginekol (Sofiia)** 1994;33(2):39–40 (14 ref.) **(Bul)**
[Choroid metastasis in a patient with adenocarcinoma of the cervix. A case report] Wiegel T, et al.
Strahlenther Onkol 1995 Sep;171(9):539–42 (16 ref.) (Eng. Abstr.) **(Ger)**
[Small cell tumor of the uterine neck] Emerich J, et al.
Ginekol Pol 1996 Apr;67(4):215–20 (28 ref.) (Eng. Abstr.) **(Pol)**
[Primary malignant neoplasms of the female genitalia] Saraiva J, et al. **Acta Med Port** 1995 Oct;8(10):585–8 (11 ref.) (Eng. Abstr.) **(Por)**

DRUG THERAPY

Does adjuvant chemotherapy change the prognosis of cervical cancer? Morton GC, et al.
Curr Opin Obstet Gynecol 1996 Feb;8(1):17–20 (26 ref.)
Bolus mitomycin C and 5-FU with sequential radiation for poor-prognosis locally advanced cervical cancer. Denehy TR, et al. **Gynecol Oncol** 1996 Jan;60(1):64–71 (21 ref.)
Neoadjuvant chemotherapy for locally advanced cervical cancer—where does it stand?: a review. Edelmann DZ, et al. **Obstet Gynecol Surv** 1996 May;51(5):305–13 (63 ref.)
The role of ifosfamide and systemic therapy in the management of carcinoma of the cervix. Thigpen T, et al. **Semin Oncol** 1996 Jun;23(3 Suppl 6):56–64 (52 ref.)
The platinum compounds and paclitaxel in the management

of carcinomas of the endometrium and uterine cervix. Thigpen T, et al. **Semin Oncol** 1995 Oct;22(5 Suppl 12):67–75 (25 ref.)

The potential role of amifostine in conjunction with cisplatin in the treatment of locally advanced carcinoma of the cervix. Wadler S, et al. **Semin Oncol** 1996 Aug;23(4 Suppl 8):64–8 (33 ref.)

[Is there a place for chemotherapy in the initial treatment of cervical cancer? Review of the literature] Lhommé C, et al. **Bull Cancer (Paris)** 1996 Apr;83(4):276–92 (67 ref.) (Eng. Abstr.) **(Fre)**

[Photodynamic therapy (PDT) for early cervical cancer] Muroya T, et al. **Gan To Kagaku Ryoho** 1996 Jan; 23(1):47–56 (10 ref.) (Eng. Abstr.) **(Jpn)**

EPIDEMIOLOGY

Cervical cancer survival in a high risk urban population. Thoms WW, et al. **Cancer** 1995 Dec 15;76(12):2518–23 (26 ref.)

ETIOLOGY

The epidemiology of cervical carcinogenesis. Schiffman MH, et al. **Cancer** 1995 Nov 15;76(10 Suppl):1888–901 (165 ref.)

Pathogenesis of cancer of the cervix. Zur Hausen H, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:623–8 (55 ref.)

[P53 protein and human papillomavirus oncogenes in carcinogenesis of the uterine cervix] Toledo-Cuevas EM, et al. **Rev Invest Clin** 1996 Jan–Feb;48(1):59–68 (42 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

Molecular biology of cervical cancer and its precursors. Park TW, et al. **Cancer** 1995 Nov 15;76(10 Suppl):1902–13 (90 ref.)

[Cellular and molecular pathogenesis of cancer of the cervix] Monsonego J. **Contracept Fertil Sex** 1995 Dec; 23(12):731–40 (63 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Immunity to human papillomavirus-associated cervical neoplasia. Stern PL. **Adv Cancer Res** 1996;69:175–211 (187 ref.)

MORTALITY

Human papillomavirus type 18: association with poor prognosis in early stage cervical cancer [see comments] Burger RA, et al. **J Natl Cancer Inst** 1996 Oct 2; 88(19):1361–8 (42 ref.) Comment in: J Natl Cancer Inst 1996 Oct 2;88(19):1331–2.

PATHOLOGY

The minimally abnormal Papanicolaou smear. Brotzman GL, et al. **Am Fam Physician** 1996 Mar;53(4):1154–62 (39 ref.)

Malignant mesonephric neoplasms of the uterine cervix. A report of eight cases, including four with a malignant spindle cell component. Clement PB, et al. **Am J Surg Pathol** 1995 Oct;19(10):1158–71 (43 ref.)

Cervical intraepithelial neoplasia: false negative smears. Allen SM. **Br J Biomed Sci** 1996 Jun;53(2):152–6 (36 ref.)

Surgical pathology of the uterine cervix. Diagnostic problems and controversies. Sickel JZ. **Clin Lab Med** 1995 Sep; 15(3):493–516 (74 ref.)

Endocervical curettage has no place in the routine management of women with cervical intraepithelial neoplasia: debate. Ferenczy A. **Clin Obstet Gynecol** 1995 Sep;38(3):644–8 (9 ref.)

Every woman with an abnormal cervical smear should be referred for treatment: debate. Flannelly G, et al. **Clin Obstet Gynecol** 1995 Sep;38(3):585–91 (20 ref.)

Cervical neoplasia: are adjunctive tests to cervical cytology worthwhile? Greenberg MD, et al. **Clin Obstet Gynecol** 1995 Sep;38(3):600–9 (24 ref.)

Endocervical curettage: a technique in search of an indication?: debate. Noller KL. **Clin Obstet Gynecol** 1995 Sep;38(3):649–52 (2 ref.)

Every woman with an abnormal cervical smear should not be referred for colposcopy: debate. Prendiville W, et al. **Clin Obstet Gynecol** 1995 Sep;38(3):592–9 (16 ref.)

Modern image capture and data collection technology. Shafi MI, et al. **Clin Obstet Gynecol** 1995 Sep;38(3):640–3 (9 ref.)

The pathology of cervical cancer. Walsh CB, et al. **Clin Obstet Gynecol** 1995 Sep;38(3):653–61 (16 ref.)

Benign to malignant progression in cervical squamous epithelium. Ehrmann RL. **Compr Ther** 1996 Feb; 22(2):67–75 (43 ref.)

The pathology of cervical neoplasia. Ostör AG, et al. **Curr Opin Obstet Gynecol** 1996 Feb;8(1):69–73 (40 ref.)

Radiation treatment effects in cervical cytology. Powers CN. **Diagn Cytopathol** 1995 Jul;13(1):75–80 (18 ref.)

Carcinomatous meningitis complicating cervical cancer: a clinicopathologic study and literature review. Aboulafia DM, et al. **Gynecol Oncol** 1996 Feb;60(2):313–8 (19 ref.)

Adequacy of conization margins in adenocarcinoma in situ of the cervix as a predictor of residual disease. Im DD, et al. **Gynecol Oncol** 1995 Nov;59(2):179–82 (20 ref.)

Pericardial metastasis in carcinoma of the uterine cervix. Jamshed A, et al. **Gynecol Oncol** 1996 Jun;61(3):451–3 (16 ref.)

Chemotherapy treatment of chyloperitoneum and peritoneal carcinomatosis due to cervical cancer—review of literature. Keung YK, et al. **Gynecol Oncol** 1996 Jun;61(3):448–50 (11 ref.)

Benign cervical leiomyoma leading to disseminated fatal malignancy. O'Connell MP, et al. **Gynecol Oncol** 1996 Jul; 62(1):119–22 (5 ref.)

Lymph node metastases, cell type, age, HPV status and type, neoadjuvant chemotherapy and treatment failures in cervical cancer. Elliott P. **Int J Gynaecol Obstet** 1995 Jul; 49 Suppl:S17–25 (39 ref.)

Cervical intraepithelial neoplasia. Crum CP, et al. **J Cell Biochem Suppl** 1995;23:71–9 (44 ref.)

Image cytometry and chemoprevention in cervical cancer. Palcic B, et al. **J Cell Biochem Suppl** 1995;23:43–54 (18 ref.)

Stage IA carcinoma of the cervix revisited. Benedet JL, et al. **Obstet Gynecol** 1996 Jun;87(6):1052–9 (26 ref.)

Pandora's box or Ariadne's thread? Definition and prognostic significance of microinvasion in the uterine cervix. Squamous lesions. Ostör AG. **Pathol Annu** 1995;30 Pt 2:103–36 (129 ref.)

Müllerian adenosarcoma of the cervix: differential diagnosis, histogenesis and review of the literature. García-Rostán y P erez GM, et al. **Pathol Int** 1995 Nov;45(11):890–4 (30 ref.)

[Recent advances in gynecological pathology in China] Huang S. **Chung Hua Ping Li Hsueh Tsa Chih** 1995 Aug; 24(4):228–31 (20 ref.) **(Chi)**

[Blue nevus of the endocervix] Di Renzi F, et al. **Minerva Ginecol** 1995 Jul–Aug;47(7–8):331–4 (23 ref.) (Eng. Abstr.) **(Ita)**

[The significance of invasion and vessel permeation in squamous cell carcinoma of the uterine cervix with invasion to a depth of 3 mm or less] Otsuka I, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Nov; 47(11):1261–7 (26 ref.) (Eng. Abstr.) **(Jpn)**

PREVENTION & CONTROL

Prevention of cervical intraepithelial neoplasia and cervical cancer. Meyskens FL Jr, et al. **Am J Clin Nutr** 1995 Dec; 62(6 Suppl):1417S–1419S (24 ref.)

The quality of cervical cancer screening: a primary care perspective. Curtis P, et al. **Am J Med Qual** 1996 Spring; 11(1):11–7 (49 ref.)

Cervical cancer screening: meeting the needs of minority ethnic women. Luke K. **Br J Cancer** 1996 Sep;74 Suppl 29:S47–50 (11 ref.)

Cervical cancer screening: are the 1989 recommendations still valid? National Workshop on Screening for Cancer of the Cervix [see comments] Parboosingh EJ, et al. **Can Med Assoc J** 1996 Jun 15;154(12):1847–53 (18 ref.) Comment in: Can Med Assoc J 1996 Jun 15;154(12):1867–9.

Chemoprevention trials and surrogate end point biomarkers in the cervix. Mitchell MF, et al. **Cancer** 1995 Nov 15;76(10 Suppl):1956–77 (227 ref.)

Screening. The next century. Richart RM. **Cancer** 1995 Nov 15;76(10 Suppl):1919–27 (36 ref.)

Multinational approaches to cervical cancer screening: a review. Lovejoy NC. **Cancer Nurs** 1996 Apr;19(2):126–34 (42 ref.)

Assessing the effectiveness of cervical screening. Wilson S, et al. **Clin Obstet Gynecol** 1995 Sep;38(3):577–84 (36 ref.)

Cytologic screening for cervix cancer: each year or each 3 years? Dubois G. **Eur J Obstet Gynecol Reprod Biol** 1996 Mar;65(1):57–9 (14 ref.)

Virologic screening. Schneider A. **Eur J Obstet Gynecol Reprod Biol** 1996 Mar;65(1):61–3 (23 ref.)

Cervical cancer: how often—and why—to screen older women. Mandelblatt JS, et al. **Geriatrics** 1996 Jun; 51(6):45–8; quiz 49 (33 ref.)

A review of cervical cancer and cervical screening: implications for nursing practice. Ibbotson T, et al. **J Adv Nurs** 1995 Oct;22(4):745–52 (59 ref.)

Strategies for phase II cancer chemoprevention trials: cervix, endometrium, and ovary. Kelloff GJ, et al. **J Cell Biochem Suppl** 1995;23:1–9 (51 ref.)

Chemoprevention trials in the cervix: design, feasibility, and recruitment. Mitchell MF, et al. **J Cell Biochem Suppl** 1995; 23:104–12 (43 ref.)

Perspective on cervical cancer: why prevent? Morrow CP, et al. **J Cell Biochem Suppl** 1995;23:61–70 (24 ref.)

Image cytometry and chemoprevention in cervical cancer. Palcic B, et al. **J Cell Biochem Suppl** 1995;23:43–54 (18 ref.)

Nutrient antioxidants in the pathogenesis and prevention of cervical dysplasias and cancer. Romney SL, et al. **J Cell Biochem Suppl** 1995;23:96–103 (45 ref.)

Surrogate endpoint biomarkers for cervical cancer chemopreventive trials. Ruffin MT 4th, et al. **J Cell Biochem Suppl** 1995;23:113–24 (98 ref.)

Screening for cervical cancer. Guidozzi F. **Obstet Gynecol Surv** 1996 Apr;51(4):247–52 (46 ref.)

[Role of the general physician in a screening strategy for cancer of the cervix uteri] Boüüaert C, et al. **Rev Med Liege** 1995 Dec;50(12):517–24 (37 ref.) **(Fre)**

RADIOTHERAPY

Altered fractionation and extended-field irradiation of carcinoma of the cervix. Marcial VA, et al. **Cancer** 1995 Nov 15;76(10 Suppl):2152–8 (24 ref.)

Spontaneous rupture of the urinary bladder: a late complication of radiotherapy—case report and review of the literature. Addar MH, et al. **Gynecol Oncol** 1996 Aug; 62(2):314–6 (16 ref.)

Bolus mitomycin C and 5-FU with sequential radiation for poor-prognosis locally advanced cervical cancer. Denehy TR, et al. **Gynecol Oncol** 1996 Jan;60(1):64–71 (21 ref.)

The potential role of amifostine in conjunction with cisplatin in the treatment of locally advanced carcinoma of the cervix. Wadler S, et al. **Semin Oncol** 1996 Aug;23(4 Suppl 8):64–8 (33 ref.)

Basal cell carcinoma due to radiotherapy for carcinoma of the cervix. Copas P, et al. **South Med J** 1995 Nov; 88(11):1161–2 (12 ref.)

SURGERY

Management of patients with high grade squamous intraepithelial lesions. Ferenczy A. **Cancer** 1995 Nov 15; 76(10 Suppl):1928–33 (38 ref.)

Large loop excision of the transformation zone. Prendiville W. **Clin Obstet Gynecol** 1995 Sep;38(3):622–39 (41 ref.)

Laparoscopic lymphadenectomy. Melendez TD, et al. **Curr Opin Obstet Gynecol** 1995 Aug;7(4):307–10 (20 ref.)

The case for early intervention ('see and treat') in patients with dyskaryosis on routine cervical screening. Murdoch JB. **Int J STD AIDS** 1995 Nov–Dec;6(6):415–7 (15 ref.)

[Future prospects of surgical gynecology in treatment of cervix carcinoma] Höckel M. **Gynakol Geburtshilfliche Rundsch** 1995;35(3):133–8 (35 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Cancer of the uterine cervix. Cannistra SA, et al. **N Engl J Med** 1996 Apr 18;334(16):1030–8 (100 ref.)

Human papillomaviruses: their clinical significance in the management of cervical carcinoma [see comments] Hines JF, et al. **Oncology (Huntingt)** 1995 Apr;9(4):279–85; discussion 286–8, 291 (50 ref.) Comment in: Oncology (Huntingt) 1995 Aug;9(8):702.

[Statistical study of a series of 672 cases of carcinoma of the uterine cervix. Results and complications according to age and modalities of treatment] Pernot M, et al. **Bull Cancer (Paris)** 1995 Jul;82(7):568–81 (66 ref.) (Eng. Abstr.) **(Fre)**

ULTRASONOGRAPHY

[Ultrasound studies in afterloading therapy of uterine malignancy] Günter HH, et al. **Ultraschall Med** 1995 Aug; 16(4):162–6 (20 ref.) (Eng. Abstr.) **(Ger)**

VIROLOGY

Bilateral primary ovarian squamous cell carcinoma associated with human papilloma virus infection and vulvar and cervical intraepithelial neoplasia. A case report with review of the literature. Mai KT, et al. **Am J Surg Pathol** 1996 Jun;20(6):767–72 (23 ref.)

Human papillomaviruses, cervical cancer and the developing world. Birley HD. **Ann Trop Med Parasitol** 1995 Oct; 89(5):453–63 (69 ref.)

Cervical intraepithelial neoplasia, cervical cancer, and HPV. Holly EA. **Annu Rev Public Health** 1996;17:69–84 (96 ref.)

Perinatal acquisition of cervical cancer-associated papillomaviruses. Cason J. **Br J Obstet Gynaecol** 1996 Sep; 103(9):853–8 (66 ref.)

Pathobiology of human papillomavirus. Prasad CJ. **Clin Lab Med** 1995 Sep;15(3):685–704 (81 ref.)

Cervical cancer: is herpes simplex virus type II a cofactor? Jones C. **Clin Microbiol Rev** 1995 Oct;8(4):549–56 (122 ref.)

Virologic screening. Schneider A. **Eur J Obstet Gynecol Reprod Biol** 1996 Mar;65(1):61–3 (23 ref.)

The molecular biology of cervical cancer. Münger K. **J Cell Biochem Suppl** 1995;23:55–60 (36 ref.)

Human papillomavirus type 18: association with poor prognosis in early stage cervical cancer [see comments] Burger RA, et al. **J Natl Cancer Inst** 1996 Oct 2; 88(19):1361–8 (42 ref.) Comment in: J Natl Cancer Inst 1996 Oct 2;88(19):1331–2.

Do human papillomaviruses have a role in the pathogenesis of bladder carcinoma? Mvula M, et al. **J Urol** 1996 Feb; 155(2):471–4 (24 ref.)

Human papillomaviruses: their clinical significance in the management of cervical carcinoma [see comments] Hines JF, et al. **Oncology (Huntingt)** 1995 Apr;9(4):279–85; discussion 286–8, 291 (50 ref.) Comment in: Oncology (Huntingt) 1995 Aug;9(8):702.

[Cellular and molecular pathogenesis of cancer of the cervix] Monsonego J. **Contracept Fertil Sex** 1995 Dec; 23(12):731–40 (63 ref.) (Eng. Abstr.) **(Fre)**

CERVIX UTERI

see related
COLPOSCOPY

ANATOMY & HISTOLOGY

The colposcopic examination. Johnson BA. **Am Fam Physician** 1996 Jun;53(8):2473–82, 2487–8 (17 ref.)

Anatomy and physiology of cervical ripening. Leppert PC.

Clin Obstet Gynecol 1995 Jun;38(2):267–79 (21 ref.)

DRUG EFFECTS

Outpatient cervical ripening. Sawai SK, et al.
Clin Obstet Gynecol 1995 Jun;38(2):301–9 (23 ref.)

MICROBIOLOGY

Impact of variation in endocervical specimen collection and testing techniques on frequency of false-positive and false-negative Chlamydia detection results. Kellogg JA. Am J Clin Pathol 1995 Nov;104(5):554–9 (65 ref.)

PATHOLOGY

Surgical pathology of the uterine cervix. Diagnostic problems and controversies. Sickel JZ. Clin Lab Med 1995 Sep; 15(3):493–516 (74 ref.)

Benign to malignant progression in cervical squamous epithelium. Ehrmann RL. Compr Ther 1996 Feb; 22(2):67–75 (43 ref.)

PHYSIOLOGY

Cervical assessment. Fuentes A, et al.
Clin Obstet Gynecol 1995 Jun;38(2):224–31 (22 ref.)

Anatomy and physiology of cervical ripening. Leppert PC. Clin Obstet Gynecol 1995 Jun;38(2):267–79 (21 ref.)

Relaxin used to produce the cervical ripening of labor. Weiss G. Clin Obstet Gynecol 1995 Jun;38(2):293–300 (16 ref.)

SURGERY

Surgical pathology of the uterine cervix. Diagnostic problems and controversies. Sickel JZ. Clin Lab Med 1995 Sep; 15(3):493–516 (74 ref.)

[Contra cervix extirpation] Semm K.
Arch Gynecol Obstet 1995;257(1–4):362–71 (25 ref.) (Ger)

ULTRASONOGRAPHY

Sonography in the evaluation of the cervix during pregnancy. Guzman ER, et al. Curr Opin Obstet Gynecol 1996 Apr; 8(2):99–105 (16 ref.)

CESAREAN SECTION

see related
VAGINAL BIRTH AFTER CESAREAN

Preserving the pelvic floor and perineum during childbirth—elective caesarean section? Sultan AH, et al. Br J Obstet Gynaecol 1996 Aug;103(8):731–4 (21 ref.)

Previous cesarean delivery and the risk of ectopic pregnancy. Kendrick JS, et al. Obstet Gynecol 1996 Feb;87(2):297–301 (19 ref.)

[Delivery of women with cicatricial uterus] Haddad S, et al. Presse Med 1996 May 18;25(17):813–7 (23 ref.) (Eng. Abstr.) (Fre)

[Characteristics of delivery of the small premature infant] Schneider H, et al. Arch Gynecol Obstet 1995; 257(1–4):462–71 (51 ref.) (Ger)

[Endometriosis of the abdominal wall. A report of a case secondary to cesarean section] Capanna A, et al.
G Chir 1995 Aug–Sep;16(8–9):352–6 (19 ref.) (Eng. Abstr.) (Ita)

[Temperature changes and thermoregulatory responses during epidural anesthesia in women undergoing cesarean delivery] Negishi C, et al. Masui 1996 May;45(5):558–64 (17 ref.) (Eng. Abstr.) (Jpn)

ADVERSE EFFECTS

Recurrence of herpes simplex virus blepharitis after cesarean section and epidural morphine. James CF. Anesth Analg 1996 May;82(5):1094–6 (17 ref.)

Gas embolism complicating obstetric or gynecologic procedures. Case reports and review of the literature. Mushkat Y, et al. Eur J Obstet Gynecol Reprod Biol 1995 Nov;63(1):97–103 (54 ref.)

Midtrimester uterine rupture. A case report. Levrant SG, et al. J Reprod Med 1996 Mar;41(3):186–90 (28 ref.)

[Retrospective study of postoperative infectious morbidity following cesarean section] Di Lieto A, et al.
Minerva Ginecol 1996 Mar;48(3):85–92 (45 ref.) (Eng. Abstr.) (Ita)

METHODS

Anaesthesia for caesarean section (epidural and general): effects on the neonate. Dick WF.
Eur J Obstet Gynecol Reprod Biol 1995 May;59 Suppl:S61–7 (42 ref.)

CESIUM RADIOISOTOPES

ADVERSE EFFECTS

[The results of multiyear research on fish populations from reservoirs falling within the area of the Kyshtym accident (a review)] Fetisov AN. Radiats Biol Radioecol 1995 Sep–Oct;35(5):751–8 (19 ref.) (Eng. Abstr.) (Rus)

CESTODA

CLASSIFICATION

Cestode systematics: any progress? Mariaux J.
Int J Parasitol 1996 Mar;26(3):231–43 (114 ref.)

ISOLATION & PURIFICATION

Studies on the helminth parasites of birds from Egypt: 1–trematoda and cestoda. Ashour AA, et al.
J Egypt Soc Parasitol 1996 Apr;26(1):207–16 (24 ref.)

CESTODE INFECTIONS

VETERINARY

Studies on the helminth parasites of birds from Egypt: 1–trematoda and cestoda. Ashour AA, et al.
J Egypt Soc Parasitol 1996 Apr;26(1):207–16 (24 ref.)

CETACEA

Morbilliviruses and morbillivirus diseases of marine mammals. de Swart RL, et al. Infect Agents Dis 1995 Sep; 4(3):125–30 (61 ref.)

METABOLISM

Epidemiological analysis of persistent organochlorine contaminants in cetaceans. Colborn T, et al.
Rev Environ Contam Toxicol 1996;146:91–172 (247 ref.)

CFTR PROTEIN see **CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR**

CGMP-DEPENDENT PROTEIN KINASES see **CYCLIC GMP-DEPENDENT PROTEIN KINASES**

CGRP RECEPTORS see **RECEPTORS, CALCITONIN GENE-RELATED PEPTIDE**

CHAGAS CARDIOMYOPATHY

Chagas' heart disease. Hagar JM, et al.
Curr Probl Cardiol 1995 Dec;20(12):825–924 (299 ref.)

COMPLICATIONS

Lesions of mediastinal paraganglia in chronic chagasic cardiomyopathy: cause of sudden death? [editorial] Ramos SG, et al. Am Heart J 1996 Feb;131(2):417–20 (32 ref.)

Thromboembolism in chronic Chagas' heart disease. Braga JC, et al. Rev Paul Med 1995 Mar–Apr;113(2):862–6 (29 ref.)

[Mitral subvalvular aneurysm of probable chagasic etiology] García Hernández N, et al. Arch Inst Cardiol Mex 1995 May–Jun;65(3):265–9 (20 ref.) (Eng. Abstr.) (Spa)

DIAGNOSIS

The undetermined form of Chagas' heart disease: concept and forensic implications. Barretto AC, et al.
Rev Paul Med 1995 Mar–Apr;113(2):797–801 (20 ref.)

Laboratory diagnosis of Chagas' heart disease. Ferreira AW, et al. Rev Paul Med 1995 Mar–Apr;113(2):767–71 (21 ref.)

Electrocardiography in Chagas' heart disease. Garzon SA, et al. Rev Paul Med 1995 Mar–Apr;113(2):802–13 (17 ref.)

Holter monitoring in Chagas' heart disease. Grupi CJ, et al. Rev Paul Med 1995 Mar–Apr;113(2):835–40 (40 ref.)

Magnetic resonance imaging in Chagas' heart disease. Kalil Filho R, et al. Rev Paul Med 1995 Mar–Apr;113(2):880–3 (11 ref.)

DRUG THERAPY

Medical treatment of cardiac arrhythmias in Chagas' heart disease. de Paola AA, et al. Rev Paul Med 1995 Mar–Apr; 113(2):858–61 (29 ref.)

Etiological treatment of acute and chronic Chagas' heart disease. Fragata Filho AA, et al. Rev Paul Med 1995 Mar–Apr;113(2):867–72 (11 ref.)

EPIDEMIOLOGY

Epidemiology of Chagas' heart disease. Wanderley DM, et al. Rev Paul Med 1995 Mar–Apr;113(2):742–9 (35 ref.)

ETIOLOGY

Participation of autonomic nervous system in the pathogenesis of Chagas disease. Sterin-Borda LJ, et al. Acta Physiol Pharmacol Ther Latinoam 1994;44(4):109–23 (89 ref.)

Pathogenesis of chronic Chagas' myocarditis. Rossi MA. Rev Paul Med 1995 Mar–Apr;113(2):750–6 (53 ref.)

[Unified hypothesis about the pathogenesis of chronic Chagas cardiopathy. Therapeutic implications] Rossi MA, et al. Arq Bras Cardiol 1995 Mar;64(3):255–60 (82 ref.) (Por)

IMMUNOLOGY

Autoimmunity in Chagas' heart disease. Cunha-Neto E, et al. Rev Paul Med 1995 Mar–Apr;113(2):757–66 (39 ref.)

MORTALITY

[Sudden death in patients with chagasic myocarditis] Fuenmayor AJ, et al. Arch Inst Cardiol Mex 1996 Mar–Apr;66(2):157–61 (18 ref.) (Eng. Abstr.) (Spa)

PARASITOLOGY

[Chagas disease. Importance of the parasite in the pathogenesis of the cardiac chronic disease] Higuchi ML. Arq Bras Cardiol 1995 Mar;64(3):251–4 (46 ref.) (Por)

PATHOLOGY

Coronary microvascular abnormalities in Chagas' disease [editorial] Rossi MA, et al. Am Heart J 1996 Jul;132(1 Pt 1):207–10 (49 ref.)

Endomyocardial biopsy in Chagas' heart disease: pathogenetic contributions. Higuchi MD. Rev Paul Med 1995 Mar–Apr;113(2):821–5 (21 ref.)

The apical ventricular lesion in Chagas' heart disease. Nogueira EA, et al. Rev Paul Med 1995 Mar–Apr; 113(2):785–90 (31 ref.)

[Chronic Chagas cardiopathy as a model for an insight on the pathogenesis of arrhythmogenic right ventricular cardiomyopathy (editorial)] Rossi MA. Arq Bras Cardiol 1995 Jul;65(1):3–5 (39 ref.) (Por)

[Acute Chagas cardiopathy. A systematic study of the intracardiac excitatory-conduction and autonomic nervous systems in an autochthonous case in Acre] Rocha A, et al. Rev Soc Bras Med Trop 1996 Jul–Aug;29(4):367–71 (12 ref.) (Eng. Abstr.) (Por)

PHYSIOPATHOLOGY

Functional alterations of the autonomic nervous system in Chagas' heart disease. Amorim DD, et al.
Rev Paul Med 1995 Mar–Apr;113(2):772–84 (75 ref.)

Signal-averaged electrocardiogram in chronic Chagas' heart disease. de Moraes AP, et al. Rev Paul Med 1995 Mar–Apr; 113(2):851–7 (26 ref.)

Ventricular function in Chagas' heart disease. Maciel BC, et al. Rev Paul Med 1995 Mar–Apr;113(2):814–20 (43 ref.)

Natural history of chronic Chagas' heart disease: prognosis factors. Mady C, et al. Rev Paul Med 1995 Mar–Apr; 113(2):791–6 (19 ref.)

Studies of the coronary circulation in Chagas' heart disease. Marin-Neto JA, et al. Rev Paul Med 1995 Mar–Apr; 113(2):826–34 (48 ref.)

Electrophysiologic study in chronic Chagas' heart disease. Scanavacca M, et al. Rev Paul Med 1995 Mar–Apr; 113(2):841–50 (45 ref.)

SURGERY

Heart transplantation for Chagas' cardiomyopathy. Blanche C, et al. Ann Thorac Surg 1995 Nov;60(5):1406–8; discussion 1408–9 (12 ref.)

Heart transplants for patients with Chagas' heart disease. Bocchi EA. Rev Paul Med 1995 Mar–Apr;113(2):873–9 (29 ref.)

CHAGAS DISEASE

DRUG THERAPY

Plant metabolites active against Trypanosoma cruzi. Sepúlveda-Boza S, et al. Planta Med 1996 Apr;62(2):98–105 (63 ref.)

EPIDEMIOLOGY

[Trypanosoma cruzi in French Guinea: review of accumulated data since 1940] Raccurt CP.
Med Trop (Mars) 1996;56(1):79–87 (49 ref.) (Eng. Abstr.) (Fre)

IMMUNOLOGY

Apoptosis as a cause of T-cell unresponsiveness in experimental Chagas' disease. Lopes MF, et al.
Braz J Med Biol Res 1995 Aug;28(8):913–8 (35 ref.)

[Role of cytokines in resistance and pathology in Trypanosoma cruzi infection] Laucella SA, et al.
Rev Argent Microbiol 1996 Apr–Jun;28(2):99–109 (81 ref.) (Eng. Abstr.) (Spa)

CHALCONE

THERAPEUTIC USE

Chalcones, myo-inositol and other novel inhibitors of pulmonary carcinogenesis. Wattenberg L.
J Cell Biochem Suppl 1995;22:162–8 (40 ref.)

CHALONES see **GROWTH INHIBITORS**

CHAMPUS see **HEALTH BENEFIT PLANS, EMPLOYEE**

CHANCRE

TRANSMISSION

Congenital and acquired early childhood syphilis. Rubins S, et al. Cutis 1995 Sep;56(3):132–6 (47 ref.)

CHANCROID

DIAGNOSIS

Chancroid and Haemophilus ducreyi: an update. Trees DL, et al. **Clin Microbiol Rev** 1995 Jul;8(3):357–75 (170 ref.)
Chancroid: new developments in an old disease. Marrazzo JM, et al. **Curr Clin Top Infect Dis** 1995;15:129–52 (83 ref.)
Chancroid. Eichmann A. **Curr Probl Dermatol** 1996;24:20–4 (21 ref.)

DRUG THERAPY

Chancroid: new developments in an old disease. Marrazzo JM, et al. **Curr Clin Top Infect Dis** 1995;15:129–52 (83 ref.)
Chancroid. Abeck D, et al. **Curr Probl Dermatol** 1996;24:90–6 (32 ref.)
Treatment of chancroid with azithromycin. Ballard RC, et al. **Int J STD AIDS** 1996;7 Suppl 1:9–12 (16 ref.)

MICROBIOLOGY

Chancroid and Haemophilus ducreyi: an update. Trees DL, et al. **Clin Microbiol Rev** 1995 Jul;8(3):357–75 (170 ref.)

CHANGUINOLA VIRUS see **ORBIVIRUS**

CHANNEL BLOCKERS, CALCIUM see **CALCIUM CHANNEL BLOCKERS**

CHANNEL CATFISH see **ICTALURIDAE**

CHAOS THEORY see **NONLINEAR DYNAMICS**

CHAPERONES, MOLECULAR see **MOLECULAR CHAPERONES**

CHAPERONIN 60

IMMUNOLOGY

Atherosclerosis as an autoimmune condition. Kleindienst R, et al. **Isr J Med Sci** 1995 Oct;31(10):596–9 (26 ref.)

CHAPERONIN 60 (GROEL) see **GROEL PROTEIN**

CHAPERONINS

METABOLISM

The 67 kDa spliced variant of beta-galactosidase serves as a reusable protective chaperone for tropoelastin. Hinek A. **Ciba Found Symp** 1995;192:185–91; discussion 191–6 (30 ref.)
Protein folding in the cell: competing models of chaperonin function. Ellis RJ, et al. **FASEB J** 1996 Jan;10(1):20–6 (43 ref.)
Thermolabile folding intermediates: inclusion body precursors and chaperonin substrates. King J, et al. **FASEB J** 1996 Jan;10(1):57–66 (63 ref.)
A quantitative assessment of the role of the chaperonin proteins in protein folding in vivo. Lorimer GH. **FASEB J** 1996 Jan;10(1):5–9 (43 ref.)
Chaperonin-mediated folding of actin and tubulin. Lewis SA, et al. **J Cell Biol** 1996 Jan;132(1–2):1–4 (32 ref.)
Chaperonins in phage display of antibody fragments. Söderlind E, et al. **Methods Mol Biol** 1995;51:343–53 (28 ref.)

PHYSIOLOGY

Molecular chaperones in cellular protein folding. Hartl FU. **Nature** 1996 Jun 13;381(6583):571–9 (154 ref.)
The fates of proteins in cells. Bohley P. **Naturwissenschaften** 1995 Dec;82(12):544–50 (112 ref.)

CHARCOAL

METABOLISM

Evaluation of the US pharmacopeia adsorption tests for activated charcoals and proposals for changes. Cooney DO. **Vet Hum Toxicol** 1995 Aug;37(4):371–7 (11 ref.)

CHARCOT-MARIE DISEASE

CLASSIFICATION

[Is there a single form of Charcot-Marie-Tooth disease, or are there several variations? A classification difficulty] Ben Hamida M, et al. **Rev Neurol (Paris)** 1995 Apr;151(4):221–4 (35 ref.) **(Fre)**

DIAGNOSIS

DNA diagnostics for Charcot-Marie-Tooth disease and related inherited neuropathies [editorial; comment] Lupski JR. **Clin Chem** 1996 Jul;42(7):995–8 (46 ref.) Comment on: Clin Chem 1996 Jul;42(7):1021–5.
[Contribution of molecular genetics to the diagnosis of Charcot-Marie-Tooth disease] Goldber-Stern H, et al. **Harefuah** 1995 Jun 1;128(11):700–3 (45 ref.) **(Heb)**

GENETICS

X-linked dominant Charcot-Marie-Tooth disease and other potential gap-junction diseases of the nervous system [see comments] Spray DC, et al. **Trends Neurosci** 1995 Jun; 18(6):256–62 (92 ref.) Comment in: Trends Neurosci 1995 Dec;18(12):520–1.

CHARCOT-MARIE-TOOTH DISEASE see **CHARCOT-MARIE DISEASE**

CHARCOT'S JOINT see **ARTHROPATHY, NEUROGENIC**

CHARGE NURSES see **NURSING, SUPERVISORY**

CHEEK

Eosinophilic granuloma of soft tissue: a case report and literature review. Kim YG, et al. **J Oral Maxillofac Surg** 1996 Mar;54(3):353–7 (12 ref.)

ANATOMY & HISTOLOGY

The buccal pad of fat: a review. Tostevin PM, et al. **Clin Anat** 1995;8(6):403–6 (35 ref.)

PATHOLOGY

Spindle cell lipoma of the oral cavity. Tosios K, et al. **Int J Oral Maxillofac Surg** 1995 Oct;24(5):363–4 (10 ref.)

CHEESE

Immunolocalization and microstructure of milk proteins and fat mimetics in reduced fat cheese. Armbruster BL, et al. **Adv Exp Med Biol** 1995;367:277–94 (47 ref.)
Contribution of milk-clotting enzymes and plasmin to cheese ripening. Farkye NY. **Adv Exp Med Biol** 1995;367:195–207 (64 ref.)
Biogenesis of flavour compounds in cheese. Fox PF, et al. **Adv Exp Med Biol** 1995;367:59–98 (302 ref.)
Nutritional aspects of reduced-fat cheese. Holsinger VH. **Adv Exp Med Biol** 1995;367:339–44 (12 ref.)
Overview: cheese chemistry and rheology. Holsinger VH, et al. **Adv Exp Med Biol** 1995;367:1–6 (15 ref.)
Practical aspects of electron microscopy in cheese research. Kalàb M. **Adv Exp Med Biol** 1995;367:247–76 (136 ref.)
Whey proteins in cheese--an overview. Lelièvre J. **Adv Exp Med Biol** 1995;367:359–65 (34 ref.)
Time-temperature effects on microbial, chemical and sensory changes during cooling and aging of cheddar cheese. Torres JA, et al. **Adv Exp Med Biol** 1995;367:123–59 (95 ref.)
Cheese: physical, biochemical, and nutritional aspects. Fox PF, et al. **Adv Food Nutr Res** 1996;39:163–328 (712 ref.)

ANALYSIS

Methods for assessing proteolysis in cheese during maturation. Fox PF, et al. **Adv Exp Med Biol** 1995; 367:161–94 (244 ref.)
Chemical species in cheese and their origin in milk components. Hill AR. **Adv Exp Med Biol** 1995;367:43–58 (75 ref.)

MICROBIOLOGY

Contribution of lactic acid bacteria to cheese ripening. Steele JL. **Adv Exp Med Biol** 1995;367:209–20 (43 ref.)

STANDARDS

Improving the sensory characteristics of reduced-fat cheese. Mistry VV. **Adv Exp Med Biol** 1995;367:371–82 (19 ref.)
Bitterness in cheese: a review. Habibi-Najafi MB, et al. **Crit Rev Food Sci Nutr** 1996 May;36(5):397–411 (98 ref.)

CHEILITIS

CHEMICALLY INDUCED

Allergic contact cheilitis. Ophaswongse S, et al. **Contact Dermatitis** 1995 Dec;33(6):365–70 (51 ref.)

COMPLICATIONS

Co-occurrence of plasma cell orificial mucositis and plasmoacanthoma. Report of a case and review of the literature. van de Kerkhof PC, et al. **Dermatology** 1995; 191(1):53–5 (21 ref.)

CHEILITIS GRANULOMATOSA see **MELKERSSON-ROSENTHAL SYNDROME**

CHELATING AGENTS

see related
ANTIDOTES
IRON CHELATES

Radiation protection and radiation recovery with essential metalloelement chelates. Sorenson JR, et al. **Proc Soc Exp Biol Med** 1995 Dec;210(3):191–204 (97 ref.)

PHARMACOLOGY

Mobilizers of stored cadmium. Bláha K, et al. **Arch Toxicol Suppl** 1996;18:195–201 (24 ref.)
Comparative efficacy and toxicity of desferrioxamine, deferiprone and other iron and aluminium chelating drugs. Kontoghiorghes GJ. **Toxicol Lett** 1995 Oct;80(1–3):1–18 (151 ref.)

THERAPEUTIC USE

Chemical, pharmacological, toxicological and therapeutic advances of deferiprone (L1) and other iron and aluminium chelators. Kontoghiorghes GJ. **Arch Toxicol Suppl** 1996; 18:202–14 (56 ref.)
Practical recommendations and new therapies for Wilson's disease. Brewer GJ. **Drugs** 1995 Aug;50(2):240–9 (46 ref.)
The use of chelating agents in occupational lead poisoning. Porru S, et al. **Occup Med (Oxf)** 1996 Feb;46(1):41–8 (34 ref.)
Chelation therapy in beta-thalassemia: the benefits and limitations of desferrioxamine. Giardina PJ, et al. **Semin Hematol** 1995 Oct;32(4):304–12 (93 ref.)
[A wine pitcher, cause of lead poisoning] Jouglard J, et al. **Presse Med** 1996 Feb 17;25(6):243–6 (8 ref.) (Eng. Abstr.) **(Fre)**

TOXICITY

Comparative efficacy and toxicity of desferrioxamine, deferiprone and other iron and aluminium chelating drugs. Kontoghiorghes GJ. **Toxicol Lett** 1995 Oct;80(1–3):1–18 (151 ref.)

CHELATION THERAPY

The use of chelating agents in occupational lead poisoning. Porru S, et al. **Occup Med (Oxf)** 1996 Feb;46(1):41–8 (34 ref.)
Chelation therapy in beta-thalassemia: the benefits and limitations of desferrioxamine. Giardina PJ, et al. **Semin Hematol** 1995 Oct;32(4):304–12 (93 ref.)

METHODS

Prevention and treatment of aluminum toxicity including chelation therapy: status and research needs. Yokel RA, et al. **J Toxicol Environ Health** 1996 Aug 30;48(6):667–83 (90 ref.)

CHELIDONIUM see **PLANTS, MEDICINAL**

CHEMEXFOLIATION

Dermabrasion, chemabrasion, and laserabrasion. Historical perspectives, modern dermabrasion techniques, and future trends. Fulton JE Jr. **Dermatol Surg** 1996 Jul;22(7):619–28 (52 ref.)

CHEMICAL FACE PEELING see **CHEMEXFOLIATION**

CHEMICAL INDUSTRY

Reproductive effects in birds exposed to pesticides and industrial chemicals. Fry DM. **Environ Health Perspect** 1995 Oct;103 Suppl 7:165–71 (85 ref.)
[Refractory ceramic fibers, kinds, health effects after exposure, TLVs] Woźniak H, et al. **Med Pr** 1996; 47(4):393–9 (17 ref.) (Eng. Abstr.) **(Pol)**

ECONOMICS

Alcian blue. Now you see it, now you don't. Scott JE. **Eur J Oral Sci** 1996 Feb;104(1):2–9 (17 ref.)

CHEMICAL MODELS see **MODELS, CHEMICAL**

CHEMICAL SHIFT IMAGING see **NUCLEAR MAGNETIC RESONANCE**

CHEMICAL VACCINES see **VACCINES, SYNTHETIC**

CHEMICAL WARFARE AGENTS

see related
TEAR GASES

[General characteristic and toxicity of VX] Inoue N, et al. **Fukuoka Igaku Zasshi** 1995 Nov;86(11):405–10 (10 ref.) **(Jpn)**

CHEMICAL WATER POLLUTION see **WATER POLLUTION, CHEMICAL**

CHEMILUMINESCENCE

Analytical applications of liquid phase chemiluminescence reactions--a review. Bowie AR, et al. **J Biolumin Chemilumin** 1996 Mar-Apr;11(2):61–90 (160 ref.)
Chemiluminescence in drug assay. Calokerinos AC, et al. **J Pharm Biomed Anal** 1995 Aug;13(9):1063–71 (122 ref.)
[Free radicals and natural or synthetic chemiluminescent systems] Torreilles J, et al. **C R Seances Soc Biol Fil** 1995; 189(6):1149–70 (40 ref.) (Eng. Abstr.) **(Fre)**
[The assay of enzyme activity in EIA--colorimetric, fluorometric and luminometric method] Maeda M. **Nippon Rinsho** 1995 Sep;53(9):2198–202 (16 ref.) (Eng. Abstr.) **(Jpn)**
[Characteristics of various labeled chemiluminescent compounds] Uji Y, et al. **Nippon Rinsho** 1995 Sep;

53(9):2175–82 (15 ref.) (Eng. Abstr.) **(Jpn)**

CHEMISTRY

see related
BRAIN CHEMISTRY

CHEMISTRY, ANALYTICAL

see related
CHEMISTRY, CLINICAL

METHODS

Analytical applications of liquid phase chemiluminescence reactions—a review. Bowie AR, et al. **J Biolumin Chemilumin** 1996 Mar–Apr;11(2):61–90 (160 ref.)

[Instrumental analysis of trace elements] Mattiello G, et al. **Ann Ist Super Sanita** 1995;31(2):233–7 (10 ref.) (Eng. Abstr.) **(Ita)**

[Assessment of factors causing pre-analytic variabililty] Minoia C. **Ann Ist Super Sanita** 1995;31(2):225–32 (13 ref.) (Eng. Abstr.) **(Ita)**

STANDARDS

[Reference materials and trace element analysis] Gallorini M, et al. **Ann Ist Super Sanita** 1995;31(2):255–9 (11 ref.) (Eng. Abstr.) **(Ita)**

[Quality control for trace elements in occupational and environmental medicine] Morisi G, et al. **Ann Ist Super Sanita** 1995;31(2):245–54 (8 ref.) (Eng. Abstr.) **(Ita)**

CHEMISTRY, BIOINORGANIC

METHODS

[Handling of biological material before trace element determination] Caroli S, et al. **Ann Ist Super Sanita** 1995; 31(2):219–24 (15 ref.) (Eng. Abstr.) **(Ita)**

[Instrumental analysis of trace elements] Mattiello G, et al. **Ann Ist Super Sanita** 1995;31(2):233–7 (10 ref.) (Eng. Abstr.) **(Ita)**

[Assessment of factors causing pre-analytic variabililty] Minoia C. **Ann Ist Super Sanita** 1995;31(2):225–32 (13 ref.) (Eng. Abstr.) **(Ita)**

STANDARDS

[Reference materials and trace element analysis] Gallorini M, et al. **Ann Ist Super Sanita** 1995;31(2):255–9 (11 ref.) (Eng. Abstr.) **(Ita)**

CHEMISTRY, CLINICAL

Chemiluminescence and bioluminescence. Kricka LJ. **Anal Chem** 1995 Jun 15;67(12):499R–502R (98 ref.)

Cardiovascular (biochemical assessment of reperfusion). Van Lente F. **Anal Chem** 1995 Jun 15;67(12):379R–382R (41 ref.)

Role of the clinical toxicologist in court. Chamberlain RT. **Clin Chem** 1996 Aug;42(8 Pt 2):1337–41 (29 ref.)

Low-density lipoprotein oxidation, antioxidants, and atherosclerosis: a clinical biochemistry perspective. Jialal I, et al. **Clin Chem** 1996 Apr;42(4):498–506 (92 ref.)

The clinical interface—a British physician's view. Neuberger J, et al. **Clin Chim Acta** 1996 Apr 15;248(1):11–8 (9 ref.)

INSTRUMENTATION

Use of artificial intelligence in analytical systems for the clinical laboratory. Place JF, et al. **Clin Biochem** 1995 Aug; 28(4):373–89 (84 ref.)

METHODS

A practical approach to the laboratory diagnosis of dyslipidemia. Jialal I. **Am J Clin Pathol** 1996 Jul; 106(1):128–38 (33 ref.)

Capillary electrophoresis. Xu Y. **Anal Chem** 1995 Jun 15; 67(12):463R–473R (162 ref.)

Use of artificial intelligence in analytical systems for the clinical laboratory. Place JF, et al. **Clin Biochem** 1995 Aug; 28(4):373–89 (84 ref.)

Immunosensors: technology and opportunities in laboratory medicine. Morgan CL, et al. **Clin Chem** 1996 Feb; 42(2):193–209 (186 ref.)

STANDARDS

The need for accuracy in laboratory medicine. Büttner J. **Eur J Clin Chem Clin Biochem** 1995 Dec;33(12):981–8 (38 ref.)

Analytical specifications of reference methods compilation and critical discussion (from the members of the European EQA-Organizers Working Group B). Stöckl D, et al. **Eur J Clin Chem Clin Biochem** 1996 Apr;34(4):319–37 (221 ref.)

Analytical quality specifications for reference methods and operating specifications for networks of reference laboratories. discussion paper from the members of the external quality assessment (EQA) Working Group B1) on target values in EQAS. Thienpont L, et al. **Eur J Clin Chem Clin Biochem** 1995 Dec;33(12):949–57 (52 ref.)

TRENDS

Technological trends in clinical laboratory science. Burtis CA. **Clin Biochem** 1995 Jun;28(3):213–9 (77 ref.)

[PCR: principles and prospects in clinical biology] Billiald P, et al. **Ann Pharm Fr** 1995;53(4):155–62 (79 ref.) (Eng. Abstr.) **(Fre)**

CHEMISTRY, ORGANIC

METHODS

Biocatalytic syntheses of aromatics from D-glucose: renewable microbial sources of aromatic compounds. Frost JW, et al. **Annu Rev Microbiol** 1995;49:557–79 (81 ref.)

Molecular trees: a new branch of chemistry [comment] Bell TW. **Science** 1996 Feb 23;271(5252):1077–8 (19 ref.) Comment on: Science 1996 Feb 23;271(5252):1095–8.

CHEMISTRY, PHARMACEUTICAL

see related
BIOPHARMACEUTICS
DRUG COMPOUNDING

Risk analysis in the manufacture of veterinary biologicals. Moreau Y. **Rev Sci Tech** 1995 Dec;14(4):937–50 (10 ref.)

[Synthetic enantiomers of drugs] Knabe J. **Pharm Unserer Zeit** 1995 Nov;24(6):324–30 (24 ref.) **(Ger)**

INSTRUMENTATION

Dielectric relaxation spectroscopy and some applications in the pharmaceutical sciences. Smith G, et al. **J Pharm Sci** 1995 Sep;84(9):1029–44 (150 ref.)

METHODS

The potential of electroanalytical techniques in pharmaceutical analysis. Kauffmann JM, et al. **Acta Pharm Hung** 1996 Mar;66(2):57–64 (80 ref.)

Determination of drug-related impurities by capillary electrophoresis. Altria KD. **J Chromatogr A** 1996 May 31; 735(1–2):43–56 (58 ref.)

Pharmaceutical solids: a strategic approach to regulatory considerations. Byrn S, et al. **Pharm Res** 1995 Jul; 12(7):945–54 (22 ref.)

Considerations in the design of toxicokinetic programs. Cayen MN. **Toxicol Pathol** 1995 Mar–Apr;23(2):148–57 (48 ref.)

STANDARDS

Peer review in toxicologic pathology. Ward JM, et al. **Toxicol Pathol** 1995 Mar–Apr;23(2):226–34 (26 ref.)

TRENDS

Frontiers in the development of new medicines in relation to clinical pharmacology. Dollery CT. **Pharmacol Toxicol** 1995 May;76(5):334–8 (11 ref.)

CHEMISTRY, PHYSICAL

INSTRUMENTATION

[Measurements of density and partial specific volume] Gekko K. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(16):2461–5 (11 ref.) **(Jpn)**

CHEMODECTOMA see PARAGANGLIOMA, EXTRA-ADRENAL

CHEMOEMBOLIZATION, THERAPEUTIC

Non-invasive loco-regional therapy for hepatocellular carcinoma. Tanikawa K. **Semin Surg Oncol** 1996 May–Jun; 12(3):189–92 (15 ref.)

ADVERSE EFFECTS

Delayed anoxic pseudolobular necrosis (terminal hepatic necrosis) after chemo-lipiodolization for hepatocellular carcinoma. Kozakai I, et al. **Am J Gastroenterol** 1996 Jun; 91(6):1263–5 (8 ref.)

CHEMOKINES

see related
CHEMOTAXIS, LEUKOCYTE

Cytokines, chemokines, T cells and allergy [editorial] Frew AJ. **Clin Exp Allergy** 1996 Jan;26(1):2–4 (29 ref.)

GENETICS

Genetic approaches to study chemokine function. Lira SA. **J Leukoc Biol** 1996 Jan;59(1):45–52 (53 ref.)

New members of the chemokine receptor gene family. Raport CJ, et al. **J Leukoc Biol** 1996 Jan;59(1):18–23 (33 ref.)

IMMUNOLOGY

Chemokines and the allergic response. Kaplan AP, et al. **Exp Dermatol** 1995 Aug;4(4 Pt 2):260–5 (36 ref.)

"The good, the bad, and the ugly." The role of chemokines in models of human disease. Strieter RM, et al. **J Immunol** 1996 May 15;156(10):3583–6 (33 ref.)

METABOLISM

Regulation and expression of chemokines: potential role in glomerulonephritis. Brown Z, et al. **J Leukoc Biol** 1996 Jan;59(1):75–80 (43 ref.)

The Duffy antigen receptor for chemokines: structural analysis and expression in the brain. Horuk R, et al. **J Leukoc Biol** 1996 Jan;59(1):29–38 (28 ref.)

New members of the chemokine receptor gene family. Raport CJ, et al. **J Leukoc Biol** 1996 Jan;59(1):18–23 (33 ref.)

Some aspects of IL-8 pathophysiology. III: Chemokine interaction with endothelial cells. Rot A, et al. **J Leukoc Biol** 1996 Jan;59(1):39–44 (34 ref.)

Selectivity and antagonism of chemokine receptors. Wells TN, et al. **J Leukoc Biol** 1996 Jan;59(1):53–60 (25 ref.)

Cloning and characterization of human chemokine receptors. Power CA, et al. **Trends Pharmacol Sci** 1996 Jun; 17(6):209–13 (4 ref.)

PHARMACOLOGY

Relationship of histamine-releasing factors and histamine-releasing inhibitory factors to chemokine group of cytokine. Kuna P, et al. **Allergy Asthma Proc** 1996 Jan–Feb;17(1):5–11 (38 ref.)

Beta chemokines costimulate lymphocyte cytolysis, proliferation, and lymphokine production. Taub DD, et al. **J Leukoc Biol** 1996 Jan;59(1):81–9 (33 ref.)

PHYSIOLOGY

Chemokines and renal disease. Wenzel UO, et al. **Am J Kidney Dis** 1995 Dec;26(6):982–94 (111 ref.)

Chemokine receptors and HIV-1: an attractive pair? Bates P. **Cell** 1996 Jul 12;86(1):1–3 (15 ref.)

Chemokines, a family of chemotactic cytokines. Graves DT, et al. **Crit Rev Oral Biol Med** 1995;6(2):109–18 (106 ref.)

Chemotactic and suppressor cytokine networks. Thompson K, et al. **Hepatogastroenterology** 1996 Jan–Feb;43(7):15–31 (132 ref.)

Regulation and function of central nervous system chemokines. Glabinski AR, et al. **Int J Dev Neurosci** 1995 Jun–Jul;13(3–4):153–65 (120 ref.)

Chemokines active on eosinophils: potential roles in allergic inflammation [comment] Kita H, et al. **J Exp Med** 1996 Jun 1;183(6):2421–6 (60 ref.) Comment on: J Exp Med 1996 Jun 1;183(6):2437–48.

Chemoattractants attract HIV researchers [comment] Moore JP, et al. **J Exp Med** 1996 Aug 1;184(2):311–3 (35 ref.) Comment on: J Exp Med 1996 Aug 1;184(2):569–77.

Chemokines as inhibitors of hematopoietic progenitors [editorial; comment] VerFaillie CM. **J Lab Clin Med** 1996 Feb;127(2):148–50 (16 ref.) Comment on: J Lab Clin Med 1996 Feb;127(2):179–85.

The role of chemokines in inflammatory joint disease. Kunkel SL, et al. **J Leukoc Biol** 1996 Jan;59(1):6–12 (26 ref.)

Genetic approaches to study chemokine function. Lira SA. **J Leukoc Biol** 1996 Jan;59(1):45–52 (53 ref.)

Activation and regulation of chemokines in allergic airway inflammation. Lukacs NW, et al. **J Leukoc Biol** 1996 Jan; 59(1):13–7 (34 ref.)

Role of eosinophil-chemotactic C-C chemokines in cutaneous inflammation. Schröder JM, et al. **J Leukoc Biol** 1996 Jan;59(1):1–5 (24 ref.)

Expression and regulation of chemokines in bacterial pneumonia. Standiford TJ, et al. **J Leukoc Biol** 1996 Jan; 59(1):24–8 (33 ref.)

The chemokines: cytokines that direct leukocyte migration. Negus RP. **J R Soc Med** 1996 Jun;89(6):312–4 (37 ref.)

The role of CXC chemokines as regulators of angiogenesis. Strieter RM, et al. **Shock** 1995 Sep;4(3):155–60 (87 ref.)

Chemokines, inflammation and the immune system. Taub DD, et al. **Ther Immunol** 1994 Aug;1(4):229–46 (190 ref.)

CHEMOLYSIS, INTERVERTEBRAL DISK see INTERVERTEBRAL DISK CHEMOLYSIS

CHEMONUCLEOLYSIS see INTERVERTEBRAL DISK CHEMOLYSIS

CHEMOPREVENTION

see related
ANTICARCINOGENIC AGENTS

4-Hydroxyphenylretinamide in the chemoprevention of cancer. Naik HR, et al. **Adv Pharmacol** 1995;33:315–47 (98 ref.)

Chemoprophylaxis for the prevention of bacterial and fungal infections. Donnelly JP. **Cancer Treat Res** 1995;79:45–81 (276 ref.)

Intermediate cancer biomarkers and their use in beta-carotene studies in humans. Gerster H. **Int J Vitam Nutr Res** 1996;66(1):3–18 (83 ref.)

Chemoprevention of cancer. Greenwald P. **Sci Am** 1996 Sep; 275(3):96–9 (0 ref.)

CHEMOPROPHYLAXIS see CHEMOPREVENTION

CHEMORECEPTORS

PHYSIOLOGY

Gases as chemical messengers in the carotid body. Role of nitric oxide and carbon monoxide in chemoreception. Prabhakar NR. **Adv Exp Med Biol** 1995;393:309–12 (14 ref.)
The role of nitric oxide in carotid chemoreception. Wang ZZ, et al. **Biol Signals** 1995 May–Jun;4(3):109–16 (28 ref.)
Contribution of acid–base changes to control of breathing during exercise. Forster HV, et al. **Can J Appl Physiol** 1995 Sep;20(3):380–94 (97 ref.)
Unraveling chemosensory diversity. Buck LB. **Cell** 1995 Nov 3;83(3):349–52 (17 ref.)
Baroreflex and chemoreflex control of fetal hormone secretion. Wood CE. **Reprod Fertil Dev** 1995;7(3):479–89 (94 ref.)
[Regulatory factors in food intake: glucoreceptor neuron and gluco–sensitive neuron] Aou S, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:26–32 (20 ref.) **(Jpn)**

ULTRASTRUCTURE

[The vomeronasal organ—a rediscovered sensory organ] Trotier D, et al. **Tidsskr Nor Laegeforen** 1996 Jan 10; 116(1):47–51 (35 ref.) (Eng. Abstr.) **(Nor)**

CHEMOSYMPATHECTOMY see **SYMPATHECTOMY, CHEMICAL**

CHEMOTACTIC CYTOKINES see **CHEMOKINES**

CHEMOTACTIC FACTOR, MACROPHAGE-DERIVED see **INTERLEUKIN-8**

CHEMOTACTIC FACTOR, NEUTROPHIL, MONOCYTE-DERIVED see **INTERLEUKIN-8**

CHEMOTACTIC FACTORS

see related
PHEROMONES

CHEMISTRY

Human monocyte chemotactic proteins–2 and –3: structural and functional comparison with MCP–1. Proost P, et al. **J Leukoc Biol** 1996 Jan;59(1):67–74 (118 ref.)

IMMUNOLOGY

[Histamine releasing factors and chemotactic factors in evaluation of mucosal inflammation in bronchial asthma] Kuna P, et al. **Pneumonol Alergol Pol** 1995;63(5–6):322–7 (29 ref.) **(Pol)**

METABOLISM

Duffy and receptors for P. vivax and chemotactic peptides. Pogo AO, et al. **Transfus Clin Biol** 1995;2(4):269–76 (29 ref.)

PHYSIOLOGY

Regulation and selectivity of leukocyte emigration. Schleiffenbaum B, et al. **J Lab Clin Med** 1996 Feb; 127(2):151–68 (251 ref.)
Human monocyte chemotactic proteins–2 and –3: structural and functional comparison with MCP–1. Proost P, et al. **J Leukoc Biol** 1996 Jan;59(1):67–74 (118 ref.)

CHEMOTACTIC FACTORS, EOSINOPHIL

PHYSIOLOGY

Role of eosinophil–chemotactic C–C chemokines in cutaneous inflammation. Schröder JM, et al. **J Leukoc Biol** 1996 Jan;59(1):1–5 (24 ref.)

CHEMOTACTIC FACTORS, MACROPHAGE

ANALYSIS

[Macrophage chemotactic factor (MCF)] Takahashi M, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:819–21 (9 ref.) **(Jpn)**

CHEMOTAXINS see **CHEMOTACTIC FACTORS**

CHEMOTAXIS

see related
CHEMORECEPTORS
CHEMOTACTIC FACTORS

Transduction of the chemotactic cAMP signal across the plasma membrane of Dictyostelium cells. Van Haastert PJ. **Experientia** 1995 Dec 18;51(12):1144–54 (72 ref.)
[Bacterial chemotactic transducer–type protein family] Kuroda A, et al. **Tanpakushitsu Kakusan Koso** 1996 Feb; 41(2):146–53 (33 ref.) **(Jpn)**

PHYSIOLOGY

Platelet–derived growth factor. Distinct signal transduction pathways associated with migration versus proliferation. Bornfeldt KE, et al. **Ann N Y Acad Sci** 1995 Sep 7; 766:416–30 (67 ref.)
How bacteria sense and swim. Blair DF. **Annu Rev Microbiol** 1995;49:489–522 (197 ref.)
Neuronal target recognition. Garrity PA, et al. **Cell** 1995 Oct 20;83(2):177–85 (70 ref.)
Making the connection: cytoskeletal rearrangements during growth cone guidance. Tanaka E, et al. **Cell** 1995 Oct 20; 83(2):171–6 (40 ref.)
Regulation of interaction between signaling protein CheY and flagellar motor during bacterial chemotaxis. Barak R, et al. **Curr Top Cell Regul** 1996;34:137–58 (156 ref.)
Chemotaxis in Bacillus subtilis: how bacteria monitor environmental signals. Garrity LF, et al. **Pharmacol Ther** 1995;68(1):87–104 (85 ref.)

CHEMOTAXIS, LEUKOCYTE

T lymphocyte chemotaxis and skin diseases. Tan J, et al. **Exp Dermatol** 1995 Oct;4(5):281–90 (87 ref.)
Regulation and selectivity of leukocyte emigration. Schleiffenbaum B, et al. **J Lab Clin Med** 1996 Feb; 127(2):151–68 (251 ref.)
Microcephaly, characteristic facies, joint abnormalities, and deficient leucocyte chemotaxis: a further case of the syndrome of Say et al. Perandones C, et al. **J Med Genet** 1996 Mar;33(3):227–9 (7 ref.)
Chemokines, inflammation and the immune system. Taub DD, et al. **Ther Immunol** 1994 Aug;1(4):229–46 (190 ref.)

PHYSIOLOGY

Calcium signalling during chemotaxis. Fay FS, et al. **Ciba Found Symp** 1995;188:121–35; discussion 136–40 (34 ref.)
The chemokines: cytokines that direct leukocyte migration. Negus RP. **J R Soc Med** 1996 Jun;89(6):312–4 (37 ref.)
Alpha 4–integrin–dependent emigration of monocytes. Chuluyan HE, et al. **Springer Semin Immunopathol** 1995; 16(4):391–404 (82 ref.)

CHEMOTHERAPY see **DRUG THERAPY**

CHEMOTHERAPY, ADJUVANT

The adjuvant therapy of pemphigus. An update. Bystryn JC, et al. **Arch Dermatol** 1996 Feb;132(2):203–12 (89 ref.)
Adjuvant therapy for resectable gastric adenocarcinoma: preoperative and postoperative chemotherapy trials. Leach SD, et al. **J Infus Chemother** 1995 Summer;5(3):104–11 (46 ref.)
[Adjuvant systemic chemotherapy in colon cancer] Raskov HH. **Ugeskr Laeger** 1996 Feb 26;158(9):1222–7 (36 ref.) (Eng. Abstr.) **(Dan)**
[The role of adjuvant therapy in the management of pN2 non–small–cell carcinoma of the lung] Chella A, et al. **Minerva Chir** 1995 Dec;50(12):1029–38 (40 ref.) (Eng. Abstr.) **(Ita)**

ADVERSE EFFECTS

Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. Bines J, et al. **J Clin Oncol** 1996 May;14(5):1718–29 (91 ref.)

ECONOMICS

Cost effectiveness and other assessments of adjuvant therapies for early breast cancer. Hillner BE, et al. **Oncology (Huntingt)** 1995 Nov;9(11 Suppl):129–34 (18 ref.)

METHODS

Induction (neo–adjuvant) chemotherapy: systemic and arterial delivery techniques and their clinical applications. Stephens FO. **Aust N Z J Surg** 1995 Oct;65(10):699–707 (57 ref.)

CHENIC ACID see **CHENODEOXYCHOLIC ACID**

CHENODEOXYCHOLATE see **CHENODEOXYCHOLIC ACID**

CHENODEOXYCHOLIC ACID

PHARMACOKINETICS

Clinical pharmacokinetics of therapeutic bile acids. Crosignani A, et al. **Clin Pharmacokinet** 1996 May; 30(5):333–58 (156 ref.)

CHENODEOXYCHOLYLTAURINE see **TAUROCHENODEOXYCHOLIC ACID**

CHENODIOL see **CHENODEOXYCHOLIC ACID**

CHERUBISM

DIAGNOSIS

Cherubism: diagnostic imaging and review of the literature in Japan. Hitomi G, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 May;81(5):623–8 (24 ref.)

PATHOLOGY

Cherubism in a patient with Noonan's syndrome. Addante RR, et al. **J Oral Maxillofac Surg** 1996 Feb;54(2):210–3 (15 ref.)

CHEST see **THORAX**

CHEST INJURIES see **THORACIC INJURIES**

CHEST PAIN

see related
ANGINA PECTORIS

Noncardiac chest pain and abdominal pain. Ho K. **Ann Emerg Med** 1996 Apr;27(4):457–60 (24 ref.)
Characterization and identification of women with angina pectoris. Holdright DR, et al. **Eur Heart J** 1996 Apr; 17(4):510–7 (70 ref.)

DIAGNOSIS

Detection of myocardial ischemia. Jain A, et al. **Curr Probl Cardiol** 1995 Nov;20(11):773–824 (112 ref.)
The role of CK–MB in chest pain decision–making. Hedges JR. **J Accid Emerg Med** 1995 Jun;12(2):101–6 (39 ref.)
[Noncardiac chest pain—a disease of the esophagus?] Lux G, et al. **Dtsch Med Wochenschr** 1995 Dec 15; 120(50):1748–55 (71 ref.) **(Ger)**

ETIOLOGY

Adolescent chest pain. Anzai AK, et al. **Am Fam Physician** 1996 Apr;53(5):1682–90 (16 ref.)
Chest pain in children. Leung AK, et al. **Can Fam Physician** 1996 Jun;42:1156–60, 1163–4 (27 ref.)
Ambulatory esophageal manometry in the evaluation of unexplained chest pain. Leite LP, et al. **Dig Dis** 1995 May–Jun;13(3):145–52 (15 ref.)
Advances in the use of ancillary diagnostic testing in the emergency department evaluation of chest pain. Stack LB, et al. **Emerg Med Clin North Am** 1995 Nov;13(4):713–33 (75 ref.)
Acute outpatient care and comprehensive management of acute myocardial ischemia in chest pain emergency departments. Bahr RD. **Md Med J** 1995 Sep;44(9):691–3 (9 ref.)
[Heart–related chest pain without manifest coronary disease] Hartikainen J, et al. **Nord Med** 1995;110(8–9):216–20 (12 ref.) (Eng. Abstr.) **(Swe)**

PSYCHOLOGY

Psychological aspects of non–cardiac chest pain. Serlie AW, et al. **Psychother Psychosom** 1995;64(2):62–73 (57 ref.)

THERAPY

Using prediction models and cost–effectiveness analysis to improve clinical decisions: emergency department patients with acute chest pain. Goldman L. **Proc Assoc Am Physicians** 1995 Oct;107(3):329–33 (22 ref.)

CHEWING see **MASTICATION**

CHEWING TOBACCO see **TOBACCO, SMOKELESS**

CH'I KUNG see **BREATHING EXERCISES**

CHIARI'S SYNDROME see **HEPATIC VEIN THROMBOSIS**

CHIASMA OPTICUM see **OPTIC CHIASM**

CHICANOS see **MEXICAN AMERICANS**

CHICK EMBRYO

Quail–chick transplantations. Le Douarin N, et al. **Methods Cell Biol** 1996;51:23–59 (105 ref.)
Gene transfer using replication–defective retroviral and adenoviral vectors. Leber SM, et al. **Methods Cell Biol** 1996;51:161–83 (42 ref.)
In situ hybridization analysis of chick embryos in whole mount and tissue sections. Nieto MA, et al. **Methods Cell Biol** 1996;51:219–35 (9 ref.)
[Chick embryo culture and manipulation of early avian embryo] Naito M. **Tanpakushitsu Kakusan Koso** 1995 Oct; 40(14):2025–34 (51 ref.) **(Jpn)**

ANATOMY & HISTOLOGY

Embryo slices. Hotary KB, et al. **Methods Cell Biol** 1996; 51:109–24 (14 ref.)

METABOLISM

Manipulating gene expression with replication–competent retroviruses. Morgan BA, et al. **Methods Cell Biol** 1996; 51:185–218 (25 ref.)

PHYSIOLOGY

Neurotrophins and their receptors in chicken neuronal development. Hallböok F, et al. **Int J Dev Biol** 1995 Oct; 39(5):855–68 (115 ref.)

Egg proteins: what are their functions? Stevens L. **Sci Prog** 1996;79 (Pt 1):65–87 (25 ref.)

ULTRASTRUCTURE

Morphology and significance of programmed cell death in the developing limb bud of the vertebrate embryo. Hurle JM, et al. **Microsc Res Tech** 1996 Jun 15;34(3):236–46 (86 ref.)

CHICKENPOX

COMPLICATIONS

Chickenpox in pregnancy: how dangerous? Venkatesan P. **Practitioner** 1996 Apr;240(1561):256–9 (5 ref.)

Necrotising soft tissue infections as a complication of chickenpox. Nathan S, et al. **Singapore Med J** 1995 Dec; 36(6):656–60 (11 ref.)

Primary varicella–zoster–induced rhabdomyolysis. Will MJ, et al. **South Med J** 1996 Sep;89(9):915–20 (15 ref.)

[Childhood cancer and chickenpox. Principles of management] Lidin–Janson G, et al. **Lakartidningen** 1996 Jun 19;93(25):2434–6 (19 ref.) **(Swe)**

CONGENITAL

[Congenital varicella. Problems with prenatal diagnosis after an early, primary maternal infection] Lécuru F, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(6):618–21 (24 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

[Congenital varicella. Problems with prenatal diagnosis after an early, primary maternal infection] Lécuru F, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(6):618–21 (24 ref.) (Eng. Abstr.) **(Fre)**

[Prenatal diagnosis of fetal varicella in the second trimester of pregnancy] Pons JC, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(8):829–38 (59 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

Treatment of acyclovir–resistant herpes simplex and varicella zoster virus infections. Safrin S. **Adv Exp Med Biol** 1996; 394:59–66 (44 ref.)

EPIDEMIOLOGY

[Varicella in pregnancy] Lécuru F, et al. **Presse Med** 1995 Oct 7;24(29):1352–7 (23 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Efficacy, immunogenicity, safety, and use of live attenuated chickenpox vaccine. Krause PR, et al. **J Pediatr** 1995 Oct; 127(4):518–25 (39 ref.)

NURSING

Varicella zoster virus: trends and treatment. Braun I. **MCN Am J Matern Child Nurs** 1996 Jul–Aug;21(4):187–90 (15 ref.)

PHYSIOPATHOLOGY

[Can outcome of varicella pneumonia be predicted in a non–immunosuppressed patient?] Jeanfaivre T, et al. **Rev Pneumol Clin** 1995;51(6):348–50 (15 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

Varicella vaccine [editorial] Moffitt JE, et al. **Ann Allergy Asthma Immunol** 1996 May;76(5):381–3 (29 ref.)

Efficacy, immunogenicity, safety, and use of live attenuated chickenpox vaccine. Krause PR, et al. **J Pediatr** 1995 Oct; 127(4):518–25 (39 ref.)

Development of live attenuated varicella vaccine. Gershon AA. **Proc Assoc Am Physicians** 1995 Oct;107(3):365–8 (31 ref.)

CHICKENPOX VIRUS see HERPESVIRUS 3, HUMAN

CHICKENS

[Infectious coryza: review of diagnostic methods and vaccines] Blackall PJ, et al. **Rev Argent Microbiol** 1995 Jul–Sep;27(3):156–74 (62 ref.) **(Spa)**

PHYSIOLOGY

Nutritional and physiological characteristics in germ–free chickens. Furuse M, et al. **Comp Biochem Physiol A Physiol** 1994 Nov;109(3):547–56 (68 ref.)

CHIKUNGUNYA VIRUS

What is the potential for future outbreaks of chikungunya, dengue and yellow fever in southern Africa? [editorial] Jupp PG, et al. **S Afr Med J** 1996 Jan;86(1):35–7 (20 ref.)

CHILBLAINS

PATHOLOGY

Violaceous rash of dorsal fingers in a woman. Diagnosis: chilblain lupus erythematosus (perniosis). Fisher DA, et al. **Arch Dermatol** 1996 Apr;132(4):459, 462 (8 ref.)

CHILD ABUSE

Child abuse, sudden infant death syndrome, and psychosocial development. Botash AS, et al. **Curr Opin Pediatr** 1996 Apr;8(2):195–200 (29 ref.)

The abused patient. Dym H. **Dent Clin North Am** 1995 Jul; 39(3):621–35 (22 ref.)

How accurately can bruises be aged in abused children? Literature review and synthesis. Schwartz AJ, et al. **Pediatrics** 1996 Feb;97(2):254–7 (46 ref.)

[Behind closed doors—the hidden epidemic] Megiddo D. **Harefuah** 1996 Mar 1;130(5):337–9 (19 ref.) **(Heb)**

DIAGNOSIS

Orofacial manifestations of child abuse and neglect. Jessee SA. **Am Fam Physician** 1995 Nov 1;52(6):1829–34 (38 ref.)

The time interval between lethal infant shaking and onset of symptoms. A review of the shaken baby syndrome literature. Nashelsky MB, et al. **Am J Forensic Med Pathol** 1995 Jun;16(2):154–7 (28 ref.)

Screening for child abuse: problems and possibilities. Doueck HJ. **Appl Nurs Res** 1995 Nov;8(4):191–8 (53 ref.)

Two new otolaryngologic findings in child abuse. Drake AF, et al. **Arch Otolaryngol Head Neck Surg** 1995 Dec; 121(12):1417–20 (11 ref.)

Munchausen syndrome by proxy. Child abuse in the medical system. Donald T, et al. **Arch Pediatr Adolesc Med** 1996 Jul;150(7):753–8 (22 ref.)

Genetic and congenital defect conditions that mimic child abuse. Wardinsky TD. **J Fam Pract** 1995 Oct;41(4):377–83 (26 ref.)

Hypothermia in shaken infant syndrome. Wahl NG, et al. **Pediatr Emerg Care** 1995 Aug;11(4):233–4 (18 ref.)

LEGISLATION & JURISPRUDENCE

Legal issues affecting dentistry's role in preventing child abuse and neglect. Mouden LD, et al. **J Am Dent Assoc** 1995 Aug;126(8):1173–80 (63 ref.)

PREVENTION & CONTROL

Preserving families at risk of child abuse and neglect: the role of the helping alliance [see comments] Dore MM, et al. **Child Abuse Negl** 1996 Apr;20(4):349–61 (80 ref.) Comment in: Child Abuse Negl 1996 Apr;20(4):345–7.

Legal issues affecting dentistry's role in preventing child abuse and neglect. Mouden LD, et al. **J Am Dent Assoc** 1995 Aug;126(8):1173–80 (63 ref.)

PSYCHOLOGY

Neural Mechanisms in dissociative amnesia for childhood abuse: relevance to the current controversy surrounding the "false memory syndrome". Bremner JD, et al. **Am J Psychiatry** 1996 Jul;153(7 Suppl):71–82 (124 ref.)

Treating the traumatic memories of patients with dissociative identity disorder. Kluft RP. **Am J Psychiatry** 1996 Jul;153(7 Suppl):103–10 (77 ref.)

A representational perspective of child abuse and prevention: internal working models of attachment and caregiving. George C. **Child Abuse Negl** 1996 May;20(5):411–24 (62 ref.)

Violence: the scientific medical perspective. Pincus JH. **Isr J Med Sci** 1996 Jul;32(7):511–4 (24 ref.)

The sociocognitive model of dissociative identity disorder: a reexamination of the evidence. Gleaves DH. **Psychol Bull** 1996 Jul;120(1):42–59 (150 ref.)

STATISTICS & NUMERICAL DATA

Estimating the occurrence of child maltreatment and risk–factor effects: benefits of a mixed–design strategy in epidemiologic research. Bertolli J, et al. **Child Abuse Negl** 1995 Aug;19(8):1007–16 (39 ref.)

CHILD ABUSE, SEXUAL

Child sexual abuse. Romans S, et al. **Curr Opin Pediatr** 1995 Aug;7(4):405–9 (55 ref.)

DIAGNOSIS

Interviewing the young child sexual abuse victim. Lewin L. **J Psychosoc Nurs Ment Health Serv** 1995 Jul;33(7):5–10 (26 ref.)

Psychological science and the use of anatomically detailed dolls in child sexual–abuse assessments. Koocher GP, et al. **Psychol Bull** 1995 Sep;118(2):199–222 (160 ref.)

LEGISLATION & JURISPRUDENCE

Mendacious moms or devious dads? Some perplexing issues in child custody/sexual abuse allegation disputes. Penfold PS. **Can J Psychiatry** 1995 Aug;40(6):337–41 (38 ref.)

The False Memory Syndrome debate—will the victim please stand up? Choiniere M. **J Contemp Health Law Policy** 1996 Spring;12(2):675–700 (201 ref.)

PSYCHOLOGY

Cultural psychopathology and the "false memory syndrome" debates: a view from psychoanalysis. Berger LS. **Am J Psychother** 1996 Spring;50(2):167–77 (41 ref.)

Repressed memories: some clinical data contributing toward its elucidation. Martínez–Taboas A. **Am J Psychother** 1996 Spring;50(2):217–30 (47 ref.)

Sexual abuse of children: prevalence, effects, and treatment. Cosentino CE, et al. **Ann N Y Acad Sci** 1996 Jun 18; 789:45–65 (119 ref.)

Child sexual abuse: initial effects. Kelley SJ. **Annu Rev Nurs Res** 1995;13:63–85 (65 ref.)

Assessment of sexual abuse and trauma: clinical measures. Miller TW, et al. **Child Psychiatry Hum Dev** 1995 Fall; 26(1):3–10 (20 ref.)

Research on the treatment of sexually abused children: a review and recommendations. Finkelhor D, et al. **J Am Acad Child Adolesc Psychiatry** 1995 Nov; 34(11):1408–23 (76 ref.)

Case study: sexual abuse of boys by females. Peluso E, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Jan;35(1):51–4 (31 ref.)

Child and adolescent sex abuse perpetrators: a review of the research literature. Vizard E, et al. **J Child Psychol Psychiatry** 1995 Jul;36(5):731–56 (115 ref.)

Factors influencing recall of childhood sexual abuse. Rogers ML. **J Trauma Stress** 1995 Oct;8(4):691–716 (115 ref.)

Trauma, traumatic memory, and research: where do we go from here? Wolfe J. **J Trauma Stress** 1995 Oct;8(4):717–26 (5 ref.)

CHILD ADVOCACY

Environmental health during childhood: pediatrician advocacy. Carlson JE, et al. **Pediatr Ann** 1995 Dec; 24(12):624, 626–8 (19 ref.)

CHILD BEHAVIOR

Childhood behavior problems. Novak LL. **Am Fam Physician** 1996 Jan;53(1):257–62, 267–9 (08 ref.)

Parents' attributions for their children's behavior. Miller SA. **Child Dev** 1995 Dec;66(6):1557–84 (110 ref.)

[Psychosomatic pain in children—a psychomuscular stress reaction?] Alfvén G. **Nord Med** 1995;110(11):275–9 (15 ref.) (Eng. Abstr.) **(Swe)**

DRUG EFFECTS

A review of important elements in sedation study methodology. Wilson S. **Pediatr Dent** 1995 Nov–Dec; 17(7):406–12 (57 ref.)

CHILD BEHAVIOR DISORDERS

Psychiatric disorders in pre–schoolers. Kong DS. **Singapore Med J** 1995 Jun;36(3):318–21 (48 ref.)

CLASSIFICATION

Classification of child and adolescent psychopathology. Cantwell DP. **J Child Psychol Psychiatry** 1996 Jan; 37(1):3–12 (80 ref.)

DIAGNOSIS

The role of comorbidity in the differential diagnosis of young children with deviant behavior. Demb HB. **J Dev Behav Pediatr** 1995 Jun;16(3 Suppl):S3–6 (30 ref.)

The Child and Adolescent Psychiatric Assessment (CAPA). Angold A, et al. **Psychol Med** 1995 Jul;25(4):739–53 (35 ref.)

DRUG THERAPY

Psychopharmacology in child and adolescent psychiatry: a review of the past seven years. Part II. Campbell M, et al. **J Am Acad Child Adolesc Psychiatry** 1995 Oct; 34(10):1262–72 (138 ref.)

EPIDEMIOLOGY

Developmental epidemiology. Angold A, et al. **Epidemiol Rev** 1995;17(1):74–82 (126 ref.)

Psychiatric sequelae of low birth weight. Breslau N. **Epidemiol Rev** 1995;17(1):96–106 (70 ref.)

ETIOLOGY

[Fetal alcohol syndrome: an unrecognized cause of intellectual handicap and problem behavior in The Netherlands] van Balkom ID, et al. **Ned Tijdschr Geneeskd** 1996 Mar 16;140(11):592–5 (37 ref.) **(Dut)**

[Organic hyperactivity] Yelin B. **Rev Neurol** 1995;23 Suppl 3:S314–7 (36 ref.) **(Spa)**

PREVENTION & CONTROL

Violence in children: the scope for prevention. Graham P. **Arch Dis Child** 1996 Mar;74(3):185–7 (23 ref.)

Violence among children and adolescents and the role of

the pediatrician. Dukarm CP, et al. **Bull N Y Acad Med** 1995 Summer;72(1):5–15 (38 ref.)

Developmental and behavioral issues in childhood injury prevention. Rivara FP. **J Dev Behav Pediatr** 1995 Oct; 16(5):362–70 (79 ref.)

PSYCHOLOGY

Executive functions and developmental psychopathology. Pennington BF, et al. **J Child Psychol Psychiatry** 1996 Jan; 37(1):51–87 (225 ref.)

Attachment and risk for psychopathology: the early years. Crittenden PM. **J Dev Behav Pediatr** 1995 Jun;16(3 Suppl):S12–6 (16 ref.)

Aggressive behavior in childhood and early adolescence: an ecological-developmental perspective on youth violence. Fraser MW. **Soc Work** 1996 Jul;41(4):347–61 (120 ref.)

REHABILITATION

[Neuropedagogic aspects of children with acquired craniocerebral trauma--an overview] Vandermeulen JA, et al. **Rehabilitation (Stuttg)** 1995 Aug;34(3):139–47 (140 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Intensive interventions in conduct disorders. Bailey VF. **Arch Dis Child** 1996 Apr;74(4):352–6 (41 ref.)

The acute management of aggressive behaviour in hospitalized children and adolescents. Measham TJ. **Can J Psychiatry** 1995 Aug;40(6):330–6 (30 ref.)

Improving the transition from basic efficacy research to effectiveness studies: methodological issues and procedures. Clarke GN. **J Consult Clin Psychol** 1995 Oct;63(5):718–25 (50 ref.)

Bridging the gap between laboratory and clinic in child and adolescent psychotherapy. Weisz JR, et al. **J Consult Clin Psychol** 1995 Oct;63(5):688–701 (70 ref.)

[Psychotherapy research and child psychotherapy practice] Märtens M, et al. **Prax Kinderpsychol Kinderpsychiatr** 1995 Oct;44(8):302–21 (250 ref.) (Eng. Abstr.) **(Ger)**

CHILD CARE

see related
CHILD REARING
INFANT CARE

PSYCHOLOGY

Child rearing beliefs in the African-American community: implications for culturally competent pediatric care. Yoos HL, et al. **J Pediatr Nurs** 1995 Dec;10(6):343–53 (73 ref.)

STANDARDS

Making a difference for children: the medical community's role in improving child care. Reisman B. **J Am Med Wom Assoc** 1995 Sep-Oct;50(5):170–4 (21 ref.)

CHILD CUSTODY

The case of the switched embryos. Robertson JA. **Hastings Cent Rep** 1995 Nov-Dec;25(6):13–9 (24 ref.)

Divorce and custody: the rights, needs, and obligations of mothers, fathers, and children. Maccoby EE. **Nebr Symp Motiv** 1995;42:135–72 (58 ref.)

LEGISLATION & JURISPRUDENCE

Mendacious moms or devious dads? Some perplexing issues in child custody/sexual abuse allegation disputes. Penfold PS. **Can J Psychiatry** 1995 Aug;40(6):337–41 (38 ref.)

CHILD DAY CARE CENTERS

The role of the family physician in the day care setting. Olsen CG, et al. **Am Fam Physician** 1996 Sep 15;54(4):1257–65, 1267–8 (32 ref.)

Out-of-home day care and health. Roberts I. **Arch Dis Child** 1996 Jan;74(1):73–6 (16 ref.)

The child with HIV in day care and school. Gross EJ, et al. **Nurs Clin North Am** 1996 Mar;31(1):231–41 (24 ref.)

CHILD DEVELOPMENT

see related
GROWTH
MOTOR SKILLS
PERSONALITY DEVELOPMENT

Out-of-home day care and health. Roberts I. **Arch Dis Child** 1996 Jan;74(1):73–6 (16 ref.)

Developmental monitoring in primary care. Goldfarb CE, et al. **Can Fam Physician** 1996 Aug;42:1527–32, 1535–6 (22 ref.)

The preschool "passage". An overview of dental health. Johnsen DC. **Dent Clin North Am** 1995 Oct;39(4):695–707 (23 ref.)

Personality development. Managing behavior of the cooperative preschool child. Pinkham JR. **Dent Clin North Am** 1995 Oct;39(4):771–87 (32 ref.)

Growth, growth hormone and cognitive functions. Sartorio A, et al. **Horm Res** 1996;45(1–2):23–9 (61 ref.)

Internal regulation and the evolution of normal growth as the basis for prevention of obesity in children. Satter EM. **J Am Diet Assoc** 1996 Sep;96(9):860–4 (35 ref.)

Say it once again: effects of repeated questions on children's event recall. Fivush R, et al. **J Trauma Stress** 1995 Oct; 8(4):555–80 (75 ref.)

Children's long-term retention of salient personal experiences. Ornstein PA. **J Trauma Stress** 1995 Oct; 8(4):581–605 (60 ref.)

Long-term retention of memory for preverbal experience: evidence and implications. Nelson K. **Memory** 1994 Dec; 2(4):467–75 (5 ref.)

Integrating family-centered developmental assessment and intervention into routine care in the neonatal intensive care unit. McGrath JM, et al. **Nurs Clin North Am** 1996 Jun; 31(2):367–86 (104 ref.)

Intestinal motility during ontogeny and intestinal pseudo-obstruction in children. Milla PJ. **Pediatr Clin North Am** 1996 Apr;43(2):511–32 (72 ref.)

Divorce: consequences for children. Emery RE, et al. **Pediatr Rev** 1995 Aug;16(8):306–10 (8 ref.)

The relationship between breast-feeding and infant health and development. Forsyth JS. **Proc Nutr Soc** 1995 Jul; 54(2):407–18 (45 ref.)

[Children with speech disorders] Rantala SL. **Duodecim** 1995; 111(6):567–72 (12 ref.) **(Fin)**

[Polyunsaturated fatty acids and cerebral-sensory development in infants (editorial)] Ghisolfi J. **Arch Pediatr** 1995 Sep;2(9):825–30 (15 ref.) **(Fre)**

[Etiology and physiopathology of obesity: childhood obesity] Murata M. **Nippon Naika Gakkai Zasshi** 1995 Aug 10; 84(8):1236–40 (13 ref.) **(Jpn)**

DRUG EFFECTS

Developmental neurotoxicology in the neonate--effects of pesticides and polychlorinated organic substances. Eriksson P. **Arch Toxicol Suppl** 1996;18:81–8 (26 ref.)

Developmental toxicity risk assessment: consensus building, hypothesis formulation, and focused research. Kimmel CA. **Drug Metab Rev** 1996 Feb-May;28(1–2):85–103 (51 ref.)

Review of the multiple chemical exposure factors which may disturb human behavioral development. Liu G, et al. **Soz Praventivmed** 1995;40(4):209–17 (69 ref.)

Kids are different: developmental variability in toxicology. Graeter LJ, et al. **Toxicology** 1996 Jul 17;111(1–3):15–20 (20 ref.)

PHYSIOLOGY

Neurodevelopmental variation in school-aged children. Tanner JL. **Compr Ther** 1995 Sep;21(9):499–506 (17 ref.)

Normal sleep architecture in infants and children. Kahn A, et al. **J Clin Neurophysiol** 1996 May;13(3):184–97 (100 ref.)

The Nutrition Society 1994 Silver Medal Lecture. Pregnancy, parturition and neonatal development: interactions between nutrition and thyroid hormones. Symonds ME. **Proc Nutr Soc** 1995 Jul;54(2):329–43 (97 ref.)

Breastfeeding for optimal mental development. The alpha and the omega in human milk. de Andraca I, et al. **World Rev Nutr Diet** 1995;78:1–27 (74 ref.)

[Effect of fetal and neonatal growth on the occurrence of some diseases in adults] Jendryczko A, et al. **Ginekol Pol** 1996 Jan;67(1):34–6 (11 ref.) (Eng. Abstr.) **(Pol)**

CHILD DEVELOPMENT DEVIATIONS see **DEVELOPMENTAL DISABILITIES**

CHILD DEVELOPMENT DISORDERS see **DEVELOPMENTAL DISABILITIES**

CHILD DEVELOPMENT DISORDERS, PERVASIVE

Psychiatric disorders in pre-schoolers. Kong DS. **Singapore Med J** 1995 Jun;36(3):318–21 (48 ref.)

DRUG THERAPY

Psychopharmacology in child and adolescent psychiatry: a review of the past seven years. Part I. Campbell M, et al. **J Am Acad Child Adolesc Psychiatry** 1995 Sep; 34(9):1124–32 (132 ref.)

PATHOLOGY

Brief report: neuroanatomic observations of the brain in pervasive developmental disorders. Bauman ML. **J Autism Dev Disord** 1996 Apr;26(2):199–203 (18 ref.)

PSYCHOLOGY

[Reflections on international adoption] Laurent A, et al. **Ann Med Psychol (Paris)** 1995 Oct;153(8):528–30; discussion 531 (2 ref.) (Eng. Abstr.) **(Fre)**

CHILD DEVELOPMENT DISORDERS, SPECIFIC see **DEVELOPMENTAL DISABILITIES**

CHILD, EXCEPTIONAL

see related
EARLY INTERVENTION (EDUCATION)

CHILD HEALTH see **CHILD WELFARE**

CHILD HEALTH SERVICES

History and present organization of pediatric oncology in Germany. Hertl M. **Pediatr Hematol Oncol** 1995 Jul-Aug; 12(4):325–31 (10 ref.)

ECONOMICS

Technology seduction: lost opportunities in child health? Stanley FJ, et al. **J Paediatr Child Health** 1995 Aug; 31(4):302–6 (26 ref.)

ORGANIZATION & ADMINISTRATION

Meeting the needs of minority ethnic communities. Webb E. **Arch Dis Child** 1996 Mar;74(3):264–7 (49 ref.)

Rethinking the organization of children's programs: lessons from the elderly. Grason H, et al. **Milbank Q** 1995; 73(4):565–97 (37 ref.)

Families of young technology-dependent children and the social worker. Bradley RH, et al. **Soc Work Health Care** 1995;21(1):23–37 (41 ref.)

The impact of HIV-1 infection on child health in sub-Saharan Africa: the burden on the health services. Walraven G, et al. **Trop Med Int Health** 1996 Feb;1(1):3–14 (87 ref.)

STANDARDS

[Is now the time to evaluate the function of child health clinics? (editorial)] Saarelma O. **Duodecim** 1994; 110(18):1677–8 (12 ref.) **(Fin)**

TRENDS

[Progresses in child health in China, 1995] Yie G. **Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):754–5 (0 ref.) **(Chi)**

CHILD, HOSPITALIZED

[Pain in hospitalized children] Foussat C, et al. **Arch Pediatr** 1995 Nov;2(11):1097–100 (14 ref.) (Eng. Abstr.) **(Fre)**

PSYCHOLOGY

The acute management of aggressive behaviour in hospitalized children and adolescents. Measham TJ. **Can J Psychiatry** 1995 Aug;40(6):330–6 (30 ref.)

The changing profile of acute childhood illness: a need for the development of family nursing knowledge. Rennick JE. **J Adv Nurs** 1995 Aug;22(2):258–66 (57 ref.)

Evolution of parental stress and coping processes: a framework for critical care practice. LaMontagne LL, et al. **J Pediatr Nurs** 1995 Aug;10(4):212–8 (13 ref.)

CHILD MOLESTATION, SEXUAL see **CHILD ABUSE, SEXUAL**

CHILD NEGLECT see **CHILD ABUSE**

CHILD NUTRITION

see related
ADOLESCENT NUTRITION
INFANT NUTRITION

Importance of dietary fiber in childhood. Williams CL. **J Am Diet Assoc** 1995 Oct;95(10):1140–6, 1149; quiz 1147–8 (77 ref.)

Dietary guidelines in perspective. Harper AE. **J Nutr** 1996 Apr;126(4 Suppl):1042S–8S (51 ref.)

Considerations about dietary fat restrictions for children. Lifshitz F, et al. **J Nutr** 1996 Apr;126(4 Suppl):1031S–41S (93 ref.)

Nutritional management of persistent diarrhea in childhood: a perspective from the developing world. Bhutta ZA, et al. **J Pediatr Gastroenterol Nutr** 1996 Jan;22(1):17–37 (210 ref.)

Nutrition recommendations update: dietary fats and children. **Nutr Rev** 1995 Dec;53(12):367–75 (55 ref.)

Early nutrition and later physical work capacity. Haas JD, et al. **Nutr Rev** 1996 Feb;54(2 Pt 2):S41–8 (22 ref.)

Reproductive performance and nutrition during childhood. Martorell R, et al. **Nutr Rev** 1996 Apr;54(4 Pt 2):S15–21 (15 ref.)

Chronic nonspecific diarrhea of childhood: pathophysiology and management. Kneepkens CM, et al. **Pediatr Clin North Am** 1996 Apr;43(2):375–90 (103 ref.)

An effective procedure for changing food preferences in 5–7-year-old children. Horne PJ, et al. **Proc Nutr Soc** 1995 Jul;54(2):441–52 (61 ref.)

[Interactions between drugs and food in pediatric age] Paci A, et al. **Pediatr Med Chir** 1996 Jan-Feb;18(1):47–52 (25 ref.) (Eng. Abstr.) **(Ita)**

CHILD NUTRITION DISORDERS

see related
INFANT NUTRITION DISORDERS

ETIOLOGY

Zinc deficiency [editorial] Bhaskaram P. **Indian Pediatr** 1995 Nov;32(11):1153–6 (15 ref.)

Gastrointestinal and nutritional problems in children with

immunodeficiency and AIDS. Winter H, et al. **Pediatr Clin North Am** 1996 Apr;43(2):573–90 (40 ref.)

CHILD OF IMPAIRED PARENTS

Inconsistencies in the literature on collegiate adult children of alcoholics: factors to consider for African Americans. Rodney HE. **J Am Coll Health** 1996 Jul;45(1):19–25 (58 ref.)

PSYCHOLOGY

Children of alcoholic parents. A review. Steinhausen HC. **Eur Child Adolesc Psychiatry** 1995 Jul;4(3):143–52 (55 ref.)

Child and adolescent sex abuse perpetrators: a review of the research literature. Vizard E, et al. **J Child Psychol Psychiatry** 1995 Jul;36(5):731–56 (115 ref.)

[Induced delusional disorder in childhood and adolescence] Zillessen KE, et al. **Z Kinder Jugenpsychiatr** 1996 Jun; 24(2):117–26 (43 ref.) **(Ger)**

CHILD, PRESCHOOL

The preschool "passage". An overview of dental health. Johnsen DC. **Dent Clin North Am** 1995 Oct;39(4):695–707 (23 ref.)

Preschool children. Need and use of dental services. Waldman HB. **Dent Clin North Am** 1995 Oct;39(4):887–96 (33 ref.)

CHILD PSYCHIATRY

[Infantile autism in France in 1994] Golse B. **Psychiatr Enfant** 1995;38(2):463–76 (23 ref.) (Eng. Abstr.) **(Fre)**

[Reflections on transference, countertransference, session frequency and the analytic process] Holder A. **Psychiatr Enfant** 1995;38(2):603–23 (5 ref.) (Eng. Abstr.) **(Fre)**

[Considerations on the diagnosis of infantile anorexia] Robin D, et al. **Psychiatr Enfant** 1995;38(1):365–401 (54 ref.) (Eng. Abstr.) **(Fre)**

CHILD PSYCHOLOGY

see related
CHILD DEVELOPMENT

What do infants recall of their lives? Memory for specific events by one- to two-year-olds. Bauer PJ. **Am Psychol** 1996 Jan;51(1):29–41 (75 ref.)

Origins and early development of perception, action, and representation. Bertenthal BI. **Annu Rev Psychol** 1996; 47:431–59 (150 ref.)

Predictors of outcome in child psychoanalysis: a retrospective study of 763 cases at the Anna Freud Centre. Fonagy P, et al. **J Am Psychoanal Assoc** 1996;44(1):27–77 (90 ref.)

Psychosocial problems in refugee children exposed to war. McCloskey LA, et al. **Pediatrics** 1996 Mar;97(3):394–7 (36 ref.)

Contingency detection and the contingent organization of behavior in interactions: implications for socioemotional development in infancy. Tarabulsy GM, et al. **Psychol Bull** 1996 Jul;120(1):25–41 (110 ref.)

[Depression amd depressive feelings in childhood and adolescence—problems in diagnosis and assessment] Solantaus T. **Duodecim** 1994;110(3):239–51 (69 ref.) **(Fin)**

CHILD REARING

see related
PARENTING

PSYCHOLOGY

Child rearing beliefs in the African-American community: implications for culturally competent pediatric care. Yoos HL, et al. **J Pediatr Nurs** 1995 Dec;10(6):343–53 (73 ref.)

CHILD WELFARE

see related
FOSTER HOME CARE

Pervasive media violence. Schooler C, et al. **Annu Rev Public Health** 1996;17:275–98 (216 ref.)

Preserving families at risk of child abuse and neglect: the role of the helping alliance [see comments] Dore MM, et al. **Child Abuse Negl** 1996 Apr;20(4):349–61 (80 ref.) Comment in: Child Abuse Negl 1996 Apr;20(4):345–7.

Case studies of environmental risks to children. Goldman LR. **Future Child** 1995 Summer-Fall;5(2):27–33 (15 ref.)

Environmental policy and children's health. Landrigan PJ, et al. **Future Child** 1995 Summer-Fall;5(2):34–52 (33 ref.)

Making a difference for children: the medical community's role in improving child care. Reisman B. **J Am Med Wom Assoc** 1995 Sep-Oct;50(5):170–4 (21 ref.)

Involuntary smoking and the health of children. Samet JM. **Md Med J** 1995 Oct;44(10):774–8 (24 ref.)

Growing up in a socially toxic environment: life for children and families in the 1990s. Garbarino J. **Nebr Symp Motiv** 1995;42:1–20 (37 ref.)

Divorce and custody: the rights, needs, and obligations of mothers, fathers, and children. Maccoby EE. **Nebr Symp Motiv** 1995;42:135–72 (58 ref.)

Overview of perinatally transmitted HIV infection. Boland M. **Nurs Clin North Am** 1996 Mar;31(1):155–64 (36 ref.)

Looking toward the twenty-first century. The role of nursing research in care of children and families affected by HIV. Sherwen LN, et al. **Nurs Clin North Am** 1996 Mar; 31(1):165–78 (35 ref.)

Infants and young children in orphanages: one view from pediatrics and child psychiatry. Frank DA, et al. **Pediatrics** 1996 Apr;97(4):569–78 (173 ref.)

Psychopathology among children placed in family foster care. Pilowsky D. **Psychiatr Serv** 1995 Sep;46(9):906–10 (32 ref.)

Dispelling the myth that 50 percent of U.S. schoolchildren have never had a cavity. Edelstein BL, et al. **Public Health Rep** 1995 Sep-Oct;110(5):522–30; discussion 521, 531–3 (46 ref.)

The impact of HIV-1 infection on child health in sub-Saharan Africa: the burden on the health services. Walraven G, et al. **Trop Med Int Health** 1996 Feb;1(1):3–14 (87 ref.)

LEGISLATION & JURISPRUDENCE

Irreversible error: the power and prejudice of female genital mutilation. Annas CL. **J Contemp Health Law Policy** 1996 Spring;12(2):325–53 (217 ref.)

Consent to medical treatment by older children in English & Scottish law. Bissett-Johnson A, et al. **J Contemp Health Law Policy** 1996 Spring;12(2):449–73 (117 ref.)

Accreditation of those who arrange adoptions under the Hague Convention on intercountry adoption as a means of protecting, through private international law, the rights of children. Pierce WL. **J Contemp Health Law Policy** 1996 Spring;12(2):535–61 (31 ref.)

STATISTICS & NUMERICAL DATA

Child health statistical review, 1995. Platt MJ, et al. **Arch Dis Child** 1995 Dec;73(6):541–8 (12 ref.)

TRENDS

Welfare reform and children's health. Geltman PL, et al. **Arch Pediatr Adolesc Med** 1996 Apr;150(4):384–9 (64 ref.)

CHILDBIRTH see **LABOR**

CHILDBIRTH AT HOME see **HOME CHILDBIRTH**

CHILDREN OF IMPAIRED PARENTS see **CHILD OF IMPAIRED PARENTS**

CHIMERA

see related
ANIMALS, TRANSGENIC

Quail-chick transplantations. Le Douarin N, et al. **Methods Cell Biol** 1996;51:23–59 (105 ref.)

Chimerism and thoracic organ transplantation. Gammie JS, et al. **Semin Thorac Cardiovasc Surg** 1996 Apr;8(2):149–55 (45 ref.)

GENETICS

Man and the chimaera. Selective versus neutral oxytocin evolution. Acher R, et al. **Adv Exp Med Biol** 1995; 395:615–27 (59 ref.)

CHIMERA, TRANSPLANTATION see **TRANSPLANTATION CHIMERA**

CHIMERIC PROTEINS

[Construction and clinical application of chimeric antibodies] Kuroki M, et al. **Nippon Rinsho** 1995 Dec;53(12):3122–31 (23 ref.) (Eng. Abstr.) **(Jpn)**

THERAPEUTIC USE

Monoclonal antibody therapy of cancer. Jurcic JG, et al. **Cancer Chemother Biol Response Modif** 1996;16:168–88 (124 ref.)

CHIMERIC TOXINS see **IMMUNOTOXINS**

CHIMPANZEE CORYZA AGENT see **RESPIRATORY SYNCYTIAL VIRUSES**

CHIN

SURGERY

The stability of facial osteotomies. 3. Chin advancement. Hoffman GR, et al. **Aust Dent J** 1995 Oct;40(5):289–95 (28 ref.)

The stability of facial osteotomies. Part 6. Chin setback. Hoffman GR, et al. **Aust Dent J** 1996 Jun;41(3):178–83 (21 ref.)

CHINCAP, ORTHODONTIC see **EXTRAORAL TRACTION APPLIANCES**

CHINESE AMERICANS see **ASIAN AMERICANS**

CHINESE HERBAL DRUGS see **DRUGS, CHINESE HERBAL**

CHINESE MEDICINE, TRADITIONAL see **MEDICINE, CHINESE TRADITIONAL**

CHIRONEX VENOMS see **CNIDARIAN VENOMS**

CHIROPODY see **PODIATRY**

CHIROPOTES see **CEBIDAE**

CHIROPRACTIC

see related
MANIPULATION, ORTHOPEDIC

Impact of varying panel membership on ratings of appropriateness in consensus panels: a comparison of a multi- and single disciplinary panel. Coulter I, et al. **Health Serv Res** 1995 Oct;30(4):577–91 (34 ref.)

MUJA: manipulation under joint anesthesia/analgesia: a treatment approach for recalcitrant low back pain of synovial joint origin. Dreyfuss P, et al. **J Manipulative Physiol Ther** 1995 Oct;18(8):537–46 (107 ref.)

Somatic dysfunction and the phenomenon of visceral disease simulation: a probable explanation for the apparent effectiveness of somatic therapy in patients presumed to be suffering from true visceral disease. Nansel D, et al. **J Manipulative Physiol Ther** 1995 Jul-Aug;18(6):379–97 (351 ref.)

[Manual medicine in otorhinolaryngology. Theoretical principles— clinical practice—principles of therapy and prevention] Seifert K. **Laryngorhinootologie** 1995 Oct; 74(10):583–90 (38 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

A risk assessment of cervical manipulation vs. NSAIDs for the treatment of neck pain. Dabbs V, et al. **J Manipulative Physiol Ther** 1995 Oct;18(8):530–6 (43 ref.)

EDUCATION

Medical schools, the social contract and population medicine: McMaster revisited. Coulter ID, et al. **J Manipulative Physiol Ther** 1995 Oct;18(8):554–8 (25 ref.)

TRENDS

Practice-building seminars in chiropractic: a Petit Bourgeois response to biomedical domination. Baer HA. **Med Anthropol Q** 1996 Mar;10(1):29–44 (45 ref.)

UTILIZATION

Preliminary findings of analysis of chiropractic utilization and cost in the workers' compensation system of New South Wales, Australia. Tuchin PJ, et al. **J Manipulative Physiol Ther** 1995 Oct;18(8):503–11 (57 ref.)

CHIROPTERA

Representation of perceptual dimensions of insect prey during terminal pursuit by echolocating bats. Simmons JA, et al. **Biol Bull** 1996 Aug;191(1):109–21 (56 ref.)

[Considerations on human rabies transmitted by bats] Schneider MC, et al. **Salud Publica Mex** 1995 Jul-Aug; 37(4):354–62 (36 ref.) (Eng. Abstr.) **(Spa)**

PARASITOLOGY

[Trematode parasites of Italian bats] Ricci M. **Parassitologia** 1995 Dec;37(2-3):199–214 (32 ref.) (Eng. Abstr.) **(Ita)**

CHITIN

BIOSYNTHESIS

Molecular and genetic control of chitin biosynthesis in fungi. Ruiz-Herrera J, et al. **Arch Med Res** 1995 Autumn; 26(3):315–21 (23 ref.)

Does DG42 synthesize hyaluronan or chitin?: A controversy about oligosaccharides in vertebrate development. Varki A. **Proc Natl Acad Sci U S A** 1996 May 14;93(10):4523–5 (53 ref.)

CHITINASE

CHEMISTRY

Oviductins possess chitinase- and mucin-like domains: a lead in the search for the biological function of these oviduct-specific ZP-associating glycoproteins. Malette B, et al. **Mol Reprod Dev** 1995 Jul;41(3):384–97 (145 ref.)

Chitinases, chitosanases, and lysozymes can be divided into procaryotic and eucaryotic families sharing a conserved core. Monzingo AF, et al. **Nat Struct Biol** 1996 Feb; 3(2):133–40 (27 ref.)

CHLAMYDIA

CHEMISTRY

Disulfide cross-linked envelope proteins: the functional equivalent of peptidoglycan in chlamydiae? Hatch TP. **J Bacteriol** 1996 Jan;178(1):1-5 (49 ref.)

PATHOGENICITY

Acute pharyngitis: etiology and diagnosis. Bisno AL. **Pediatrics** 1996 Jun;97(6 Pt 2):949-54 (76 ref.)

CHLAMYDIA INFECTIONS

Chlamydia trachomatis infection update [see comments] Heath CB, et al. **Am Fam Physician** 1995 Oct;52(5):1455-62 (17 ref.) Comment in: Am Fam Physician 1996 Mar;53(4):1085.

[Progresses in prenatal medicine in China, 1995] Zhou Z. **Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):748-9 (0 ref.) **(Chi)**

[Chlamydia trachomatis] Ottesen M. **Ugeskr Laeger** 1996 Feb 5;158(6):751-5 (40 ref.) (Eng. Abstr.) **(Dan)**

[Natural history of Chlamydia infections] Orfila J, et al. **Rev Med Interne** 1996;17 Suppl 1:29S-32S (53 ref.) **(Fre)**

COMPLICATIONS

[Perihepatitis] Iwata N, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):463-5 (20 ref.) **(Jpn)**

[Fitz-Hugh-Curtis syndrome] Sakai H, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):430-3 (7 ref.) **(Jpn)**

DIAGNOSIS

Impact of variation in endocervical specimen collection and testing techniques on frequency of false-positive and false-negative Chlamydia detection results. Kellogg JA. **Am J Clin Pathol** 1995 Nov;104(5):554-9 (65 ref.)

DNA amplification assays: a new standard for diagnosis of Chlamydia trachomatis infections. Quinn TC. **Ann Acad Med Singapore** 1995 Jul;24(4):627-33 (52 ref.)

General practice update: chlamydia infection in women. Oakeshott P, et al. **Br J Gen Pract** 1995 Nov;45(400):615-20 (74 ref.)

Modern diagnosis and management of genital Chlamydia trachomatis infection [see comments] Robinson AJ, et al. **Br J Hosp Med** 1996 Apr 3-16;55(7):388-93 (31 ref.) Comment in: Br J Hosp Med 1996 Apr 3-16;55(7):386-7.

Keeping up with new technology: new approaches to diagnosis of Chlamydia infection. LeBar WD. **Clin Chem** 1996 May;42(5):809-12 (28 ref.)

Pneumonia due to Chlamydia pneumoniae: prevalence, clinical features, diagnosis, and treatment. Kauppinen M, et al. **Clin Infect Dis** 1995 Dec;21 Suppl 3:S244-52 (120 ref.)

Chlamydia pneumoniae (TWAR). Kuo CC, et al. **Clin Microbiol Rev** 1995 Oct;8(4):451-61 (147 ref.)

Chlamydia trachomatis infections in women. Schubiner H, et al. **Curr Probl Dermatol** 1996;24:25-33 (62 ref.)

Tests for infection with Chlamydia trachomatis. Taylor-Robinson D. **Int J STD AIDS** 1996 Jan-Feb;7(1):19-25; quiz 26 (42 ref.)

The discrepancy in discrepant analysis. Hadgu A. **Lancet** 1996 Aug 31;348(9027):592-3 (7 ref.)

Chlamydia: testing for the silent threat to fertility. Radcliffe K. **Practitioner** 1996 Apr;240(1561):260-3 (8 ref.)

Chlamydia pneumoniae: defining the clinical spectrum of infection requires precise laboratory diagnosis. Bourke SJ, et al. **Thorax** 1995 Sep;50 Suppl 1:S43-8 (50 ref.)

[Clinical manifestations of Chlamydia pneumoniae infections] Gaillat J. **Rev Med Interne** 1996;17 Suppl 1:41S-44S (35 ref.) **(Fre)**

[Chlamydia infections in gynecology and obstetrics] Dieterle S. **Geburtshilfe Frauenheilkd** 1995 Sep;55(9):510-7 (65 ref.) (Eng. Abstr.) **(Ger)**

[Chlamydia pneumoniae infection associated with autoimmune hemolytic anemia due to warm antibodies] Belda J, et al. **Arch Bronconeumol** 1996 May;32(5):251-2 (7 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Nongonococcal urethritis. Nickel P, et al. **Curr Probl Dermatol** 1996;24:97-104 (34 ref.)

Chlamydia trachomatis: a major cause of mucopurulent cervicitis and pelvic inflammatory disease in women. Paavonen J. **Curr Probl Dermatol** 1996;24:110-22 (78 ref.)

[Azithromycin and genital infections] Micoud M, et al. **Pathol Biol (Paris)** 1995 Jun;43(6):542-6 (19 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

The immunobiology and immunopathology of chlamydial infections. Ward ME. **APMIS** 1995 Nov;103(11):769-96 (200 ref.)

MICROBIOLOGY

Chlamydia pneumoniae (TWAR). Kuo CC, et al. **Clin Microbiol Rev** 1995 Oct;8(4):451-61 (147 ref.)

Chlamydia in coronary plaques--hidden culprit or harmless hobo? Capron L. **Nat Med** 1996 Aug;2(8):856-7 (9 ref.)

[Association of Chlamydia trachomatis and human papilloma virus as predisposing factors in cervical intraepithelial neoplasia] González Sánchez JL, et al. **Ginecol Obstet Mex** 1995 Oct;63:422-6 (30 ref.) (Eng. Abstr.) **(Spa)**

PATHOLOGY

The immunobiology and immunopathology of chlamydial infections. Ward ME. **APMIS** 1995 Nov;103(11):769-96 (200 ref.)

PREVENTION & CONTROL

[Indications for testing for sexually transmitted Chlamydia trachomatis infections] Aavitsland P, et al. **Tidsskr Nor Laegeforen** 1995 Oct 20;115(25):3141-4 (42 ref.) (Eng. Abstr.) **(Nor)**

CHLAMYDIA PNEUMONIAE

Pneumonia due to Chlamydia pneumoniae: prevalence, clinical features, diagnosis, and treatment. Kauppinen M, et al. **Clin Infect Dis** 1995 Dec;21 Suppl 3:S244-52 (120 ref.)

Chlamydia pneumoniae (TWAR). Kuo CC, et al. **Clin Microbiol Rev** 1995 Oct;8(4):451-61 (147 ref.)

Chlamydia pneumoniae: defining the clinical spectrum of infection requires precise laboratory diagnosis. Bourke SJ, et al. **Thorax** 1995 Sep;50 Suppl 1:S43-8 (50 ref.)

[Clinical manifestations of Chlamydia pneumoniae infections] Gaillat J. **Rev Med Interne** 1996;17 Suppl 1:41S-44S (35 ref.) **(Fre)**

IMMUNOLOGY

[Chlamydia pneumoniae infection associated with autoimmune hemolytic anemia due to warm antibodies] Belda J, et al. **Arch Bronconeumol** 1996 May;32(5):251-2 (7 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

Chlamydia in coronary plaques--hidden culprit or harmless hobo? Capron L. **Nat Med** 1996 Aug;2(8):856-7 (9 ref.)

CHLAMYDIA PSITTACI

Chlamydia psittaci infections: a review with emphasis on avian chlamydiosis. Vanrompay D, et al. **Vet Microbiol** 1995 Jul;45(2-3):93-119 (237 ref.)

ISOLATION & PURIFICATION

[A case of fulminant psittacosis necessitating mechanical ventilation diagnosed by chlamydial isolation form BALF] Taniguchi H, et al. **Kansenshogaku Zasshi** 1995 Dec;69(12):1396-401 (9 ref.) (Eng. Abstr.) **(Jpn)**

CHLAMYDIA TRACHOMATIS

Chlamydia trachomatis infection update [see comments] Heath CB, et al. **Am Fam Physician** 1995 Oct;52(5):1455-62 (17 ref.) Comment in: Am Fam Physician 1996 Mar;53(4):1085.

Modern diagnosis and management of genital Chlamydia trachomatis infection [see comments] Robinson AJ, et al. **Br J Hosp Med** 1996 Apr 3-16;55(7):388-93 (31 ref.) Comment in: Br J Hosp Med 1996 Apr 3-16;55(7):386-7.

Keeping up with new technology: new approaches to diagnosis of Chlamydia infection. LeBar WD. **Clin Chem** 1996 May;42(5):809-12 (28 ref.)

Nongonococcal urethritis. Nickel P, et al. **Curr Probl Dermatol** 1996;24:97-104 (34 ref.)

Chlamydia trachomatis infections in women. Schubiner H, et al. **Curr Probl Dermatol** 1996;24:25-33 (62 ref.)

Tests for infection with Chlamydia trachomatis. Taylor-Robinson D. **Int J STD AIDS** 1996 Jan-Feb;7(1):19-25; quiz 26 (42 ref.)

[Chlamydia trachomatis infection in women] Suchet JH. **Rev Med Interne** 1996;17 Suppl 1:36S-38S (18 ref.) **(Fre)**

[Chlamydia infections in gynecology and obstetrics] Dieterle S. **Geburtshilfe Frauenheilkd** 1995 Sep;55(9):510-7 (65 ref.) (Eng. Abstr.) **(Ger)**

[Perihepatitis] Iwata N, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):463-5 (20 ref.) **(Jpn)**

[Indications for testing for sexually transmitted Chlamydia trachomatis infections] Aavitsland P, et al. **Tidsskr Nor Laegeforen** 1995 Oct 20;115(25):3141-4 (42 ref.) (Eng. Abstr.) **(Nor)**

[Association of Chlamydia trachomatis and human papilloma virus as predisposing factors in cervical intraepithelial neoplasia] González Sánchez JL, et al. **Ginecol Obstet Mex** 1995 Oct;63:422-6 (30 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

DNA amplification assays: a new standard for diagnosis of Chlamydia trachomatis infections. Quinn TC. **Ann Acad Med Singapore** 1995 Jul;24(4):627-33 (52 ref.)

ISOLATION & PURIFICATION

[Chlamydia trachomatis] Ottesen M. **Ugeskr Laeger** 1996 Feb 5;158(6):751-5 (40 ref.) (Eng. Abstr.) **(Dan)**

CHLAMYDOMONAS

GENETICS

Exploring the function of inner and outer dynein arms with Chlamydomonas mutants. Kamiya R. **Cell Motil Cytoskeleton** 1995;32(2):98-102 (34 ref.)

PHYSIOLOGY

Flagellar kinesins: new moves with an old beat. Bernstein M. **Cell Motil Cytoskeleton** 1995;32(2):125-8 (27 ref.)

Regulation of dynein-driven microtubule sliding by an axonemal kinase and phosphatase in Chlamydomonas flagella. Habermacher G, et al. **Cell Motil Cytoskeleton** 1995;32(2):106-9 (23 ref.)

CHLAMYDOMONAS REINHARDTII

PHYSIOLOGY

Flagellar assembly in two hundred and fifty easy-to-follow steps. Dutcher SK. **Trends Genet** 1995 Oct;11(10):398-404 (62 ref.)

CHLOASMA see **MELANOSIS**

CHLORAMBUCIL

ADVERSE EFFECTS

[Delayed allergic reaction to Chlorambucil (Leukeran). Case report and literature review] Torricelli R, et al. **Schweiz Med Wochenschr** 1995 Oct 7;125(40):1870-3 (10 ref.) (Eng. Abstr.) **(Ger)**

CHLORAMIPHENE see **CLOMIPHENE**

CHLORAMPHENICOL

ADVERSE EFFECTS

Chloramphenicol eye drops: a dangerous drug? Diamond J, et al. **Practitioner** 1995 Oct;239(1555):608-11 (15 ref.)

BIOSYNTHESIS

Chloramphenicol. Vining LC, et al. **Biotechnology** 1995; 28:505-30 (80 ref.)

CHLORAMPHENICOL ACETYLTRANSFERASE

ANALYSIS

Chloramphenicol acetyl transferase assay. Davey MR, et al. **Methods Mol Biol** 1995;49:143-8 (11 ref.)

CHLORANIL

ANALOGS & DERIVATIVES

Oxidative DNA lesions in V79 cells mediated by pentachlorophenol metabolites. Dahlhaus M, et al. **Arch Toxicol** 1996;70(7):457-60 (39 ref.)

TOXICITY

Oxidative DNA lesions in V79 cells mediated by pentachlorophenol metabolites. Dahlhaus M, et al. **Arch Toxicol** 1996;70(7):457-60 (39 ref.)

CHLORDECONE

ADVERSE EFFECTS

ATSDR evaluation of health effects of chemicals. II. Mirex and chlordecone: health effects, toxicokinetics, human exposure, and environmental fate. Faroon O, et al. **Toxicol Ind Health** 1995;11(6):1-203 (681 ref.)

TOXICITY

A review of the role of tissue repair as an adaptive strategy: why low doses are often non-toxic and why high doses can be fatal. Calabrese EJ, et al. **Food Chem Toxicol** 1996 Mar;34(3):301-11 (49 ref.)

Efficient tissue repair underlies the resiliency of postnatally developing rats to chlordecone + CCl_4 hepatotoxicity. Dalu A, et al. **Toxicology** 1996 Jul 17;111(1-3):29-42 (41 ref.)

CHLORETHAZINE see **MECHLORETHAMINE**

CHLORHEXIDINE

ADMINISTRATION & DOSAGE

An analysis of bacteremias during dental extractions. A double-blind, placebo-controlled study of chlorhexidine. Lockhart PB. **Arch Intern Med** 1996 Mar 11;156(5):513-20

(67 ref.)

CHLORIDE CHANNELS

ANTAGONISTS & INHIBITORS

Development of chloride channel modulators. Singh AK, et al. **Kidney Int** 1995 Oct;48(4):985–93 (18 ref.)

CHEMISTRY

Further evidence for multitopological localization of mammalian porin (VDAC) in the plasmalemma forming part of a chloride channel complex affected in cystic fibrosis and encephalomyopathy. Reymann S, et al. **Biochem Mol Med** 1995 Apr;54(2):75–87 (74 ref.)

DRUG EFFECTS

Steroid anesthetics: old compounds, new drugs. Sear JW. **J Clin Anesth** 1996 May;8(3 Suppl):91S–98S (70 ref.)

Neurosteroids: molecular mechanisms of action and psychopharmacological significance. Rupprecht R, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1–6 Spec No):163–8 (50 ref.)

GENETICS

Cystic fibrosis: basic chemical and cellular mechanisms. Stern M, et al. **Br J Hosp Med** 1996 Mar 6–19;55(5):237–40 (22 ref.)

METABOLISM

Further evidence for multitopological localization of mammalian porin (VDAC) in the plasmalemma forming part of a chloride channel complex affected in cystic fibrosis and encephalomyopathy. Reymann S, et al. **Biochem Mol Med** 1995 Apr;54(2):75–87 (74 ref.)

Aspects of calcium-activated chloride currents: a neuronal perspective. Scott RH, et al. **Pharmacol Ther** 1995 Jun; 66(3):535–65 (178 ref.)

PHYSIOLOGY

Cellular and molecular physiology of volume-sensitive anion channels. Strange K, et al. **Am J Physiol** 1996 Mar;270(3 Pt 1):C711–30 (146 ref.)

Chloride channels of intracellular organelles. al-Awqati Q. **Curr Opin Cell Biol** 1995 Aug;7(4):504–8 (50 ref.)

Chloride transport across kidney epithelia through CLC chloride channels. Uchida S, et al. **Nippon Jinzo Gakkai Shi** 1996 Jul;38(7):285–9 (17 ref.)

CHLORIDES

BLOOD

[Chloride] Kinouchi T. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:758–61 (17 ref.) **(Jpn)**

METABOLISM

Molecular characterization of the epithelial Na-K-Cl cotransporter isoforms. Payne JA, et al. **Curr Opin Cell Biol** 1995 Aug;7(4):493–503 (73 ref.)

Renal chloride-bicarbonate exchangers. Godinich MJ, et al. **Curr Opin Nephrol Hypertens** 1995 Sep;4(5):398–401 (34 ref.)

The stimulation of Na,K,Cl cotransport and of system A for neutral amino acid transport is a mechanism for cell volume increase during the cell cycle. Bussolati O, et al. **FASEB J** 1996 Jun;10(8):920–6 (49 ref.)

Anions, membrane resistance and ventricular fibrillation. Curtis MJ, et al. **J Basic Clin Physiol Pharmacol** 1994 Jan-Mar;5(1):19–26 (24 ref.)

Chloride transport across kidney epithelia through CLC chloride channels. Uchida S, et al. **Nippon Jinzo Gakkai Shi** 1996 Jul;38(7):285–9 (17 ref.)

CHLORIMIPRAMINE see **CLOMIPRAMINE**

CHLORINATED HYDROCARBONS see **HYDROCARBONS, CHLORINATED**

CHLORINE

[Chlorination and ozonation of contaminants in water environment and role of free radicals] Hamada A. **Yakugaku Zasshi** 1995 Oct;115(10):790–804 (52 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Reductive dechlorination of tetrachloroethene by a high rate anaerobic microbial consortium. Zinder SH, et al. **Environ Health Perspect** 1995 Jun;103 Suppl 5:5–7 (12 ref.)

CHLORMETHIAZOLE

THERAPEUTIC USE

The management of alcohol withdrawal using chlormethiazole. Morgan MY. **Alcohol Alcohol** 1995 Nov; 30(6):771–4 (21 ref.)

CHLORMETHINE see **MECHLORETHAMINE**

2-CHLOROACETOPHENONE see **OMEGA-CHLOROACETOPHENONE**

2-CHLORODEOXYADENOSINE see **CLADRIBINE**

2-CHLORO-2'-DEOXYADENOSINE see **CLADRIBINE**

CHLOROETHYLENE see **VINYL CHLORIDE**

CHLOROETHYLENE POLYMER see **POLYVINYL CHLORIDE**

CHLOROFLUOROCARBONS

TOXICITY

Toxicology of chlorofluorocarbon replacements. Dekant W. **Environ Health Perspect** 1996 Mar;104 Suppl 1:75–83 (78 ref.)

CHLOROFORM

TOXICITY

The role of regenerative cell proliferation in chloroform-induced cancer. Butterworth BE, et al. **Toxicol Lett** 1995 Dec;82–83:23–6 (27 ref.)

CHLOROPHENYL GABA see **BACLOFEN**

CHLOROPHYLL

see related
PHOTOSYNTHESIS

BIOSYNTHESIS

Evolution of chlorophyll biosynthesis--the challenge to survive photooxidation. Reinbothe S, et al. **Cell** 1996 Sep 6;86(5):703–5 (14 ref.)

The regulation of enzymes involved in chlorophyll biosynthesis. Reinbothe S, et al. **Eur J Biochem** 1996 Apr 15;237(2):323–43 (312 ref.)

Glutamate transfer RNA: a cofactor for heme and chlorophyll biosynthesis. Madan Kumar A, et al. **Indian J Biochem Biophys** 1996 Feb;33(1):30–4 (31 ref.)

[Chlorophyll biogenesis] Tanaka A, et al. **Tanpakushitsu Kakusan Koso** 1996 Feb;41(2):136–45 (82 ref.) **(Jpn)**

CHLOROPHYLLIDES

PHARMACOLOGY

Activity profiles of antimutagens: in vitro and in vivo data. Waters MD, et al. **Mutat Res** 1996 Feb 19;350(1):109–29 (117 ref.)

CHLOROPHYTA see **ALGAE, GREEN**

CHLOROPLAST COUPLING FACTOR see **H(+)-TRANSPORTING ATP SYNTHASE**

CHLOROPLAST RNA see **RNA, CHLOROPLAST**

CHLOROPLASTS

see related
PHOTOSYNTHESIS

GENETICS

Uniparental inheritance of mitochondrial and chloroplast genes: mechanisms and evolution. Birky CW Jr. **Proc Natl Acad Sci U S A** 1995 Dec 5;92(25):11331–8 (96 ref.)

METABOLISM

Shedding light on the chloroplast protein import machinery. Schnell DJ. **Cell** 1995 Nov 17;83(4):521–4 (14 ref.)

Targeting of foreign proteins to the chloroplast. Napier JA. **Methods Mol Biol** 1995;49:369–76 (20 ref.)

PHYSIOLOGY

RNA editing in plant organelles: a fertile field. Gray MW. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8157–9 (53 ref.)

CHLOROQUINE

HISTORY

Localized permanent epidemics: the genesis of chloroquine resistance in Plasmodium falciparum. Verdrager J. **Southeast Asian J Trop Med Public Health** 1995 Mar; 26(1):23–8 (18 ref.)

THERAPEUTIC USE

[Decision making policies on the utilization of antimalarials in response to a modification of chloroquine efficacy. Applications to Africa] Baudon D. **Med Trop (Mars)** 1995; 55(4 Suppl):37–40 (5 ref.) (Eng. Abstr.) **(Fre)**

CHLOROSIS see **ANEMIA, HYPOCHROMIC**

CHLORPYRIFOS

TOXICITY

Ectoxicology of chlorpyrifos. Barron MG, et al. **Rev Environ Contam Toxicol** 1995;144:1–93 (337 ref.)

CHO CELLS

IMMUNOLOGY

Production of monoclonal antibodies in COS and CHO cells. Trill JJ, et al. **Curr Opin Biotechnol** 1995 Oct;6(5):553–60 (53 ref.)

METABOLISM

Depolarization-induced 86Rb+ efflux in CHO cells expressing a recombinant potassium channel. Hu W, et al. **J Pharmacol Toxicol Methods** 1995 Sep;34(1):1–7 (83 ref.)

CHOANAL ATRESIA

CLASSIFICATION

Choanal atresia: a new anatomic classification and clinical management applications. Brown OE, et al. **Laryngoscope** 1996 Jan;106(1 Pt 1):97–101 (31 ref.)

SURGERY

Choanal atresia: a new anatomic classification and clinical management applications. Brown OE, et al. **Laryngoscope** 1996 Jan;106(1 Pt 1):97–101 (31 ref.)

CHOICE BEHAVIOR

Health promotion and the "ideology of choice". Lowenberg JS. **Public Health Nurs** 1995 Oct;12(5):319–23 (37 ref.)

PHYSIOLOGY

Looking for 'fresh' food: diet and lone parents. Dowler E, et al. **Proc Nutr Soc** 1996 Nov;54(3):759–69 (22 ref.)

Social influences on food choice and dietary change: a sociological attitude. Murcott A. **Proc Nutr Soc** 1996 Nov; 54(3):729–35 (13 ref.)

CHOKED DISK see **PAPILLEDEMA**

CHOKING see **AIRWAY OBSTRUCTION**

CHOLAGOGUES AND CHOLERETICS

PHARMACOKINETICS

Clinical pharmacokinetics of therapeutic bile acids. Crosignani A, et al. **Clin Pharmacokinet** 1996 May; 30(5):333–58 (156 ref.)

PHARMACOLOGY

Anethole dithiolethione: biochemical considerations. Christen MO. **Methods Enzymol** 1995;252:316–23 (40 ref.)

THERAPEUTIC USE

Drug-induced vanishing bile duct syndrome: response to ursodiol. O'Brien CB, et al. **Am J Gastroenterol** 1996 Jul; 91(7):1456–7 (10 ref.)

[Bile acids and their therapeutic use in children] Lacaille F. **Arch Pediatr** 1995 Dec;2(12):1200–8 (57 ref.) (Eng. Abstr.) **(Fre)**

[Primary biliary cirrhosis and ursodeoxycholic acid therapy] Makino I. **Nippon Naika Gakkai Zasshi** 1996 Mar 10; 85(3):399–403 (10 ref.) **(Jpn)**

CHOLANGIOCARCINOMA

Extrahepatic biliary cystadenomas and cystadenocarcinoma. Report of seven cases and review of the literature. Davies W, et al. **Ann Surg** 1995 Nov;222(5):619–25 (20 ref.)

[Cholangiocarcinoma] Komatsu M, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):398–401 (12 ref.) **(Jpn)**

[Combined hepatocellular and cholangiocarcinoma] Omagari K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):473–5 (14 ref.) **(Jpn)**

[Mucinous cholangiocarcinoma, mucus producing carcinoma] Sakamoto H, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):414–6 (17 ref.) **(Jpn)**

[Intrahepatic sarcomatoid cholangiocarcinoma] Sasaki M, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):408–10 (14 ref.) **(Jpn)**

[Mucinous cholangiocarcinoma] Sasaki M, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):423–5 (15 ref.) **(Jpn)**

[Peripheral type of cholangiocarcinoma without intrahepatic bile duct dilatation] Sugiura N, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):498–500 (9 ref.) **(Jpn)**

[Liver adenoma and hepatobiliary cystadenoma] Takahama T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):387–91 (7

ref.) (Jpn)
[Cholangiocellular carcinoma (intrahepatic bile duct carcinoma)] Tarao K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):476–9 (10 ref.) (Jpn)
[Cholangiocarcinoma] Biesa I, et al. **G E N** 1995 Jan–Mar; 49(1):90–100 (89 ref.) (Eng. Abstr.) (Spa)

COMPLICATIONS

[A case of cholangiocarcinoma with temporary subsegmental fatty liver and intrahepatic portal aneurysm] Miyanaga O, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Sep; 92(9):1297–303 (9 ref.) (Jpn)
[A case of the hypoplasia of the hepatic left lobe complicated with cholangiocarcinoma] Suzuki T, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Apr;93(4):276–81 (20 ref.) (Jpn)
[Cholangiocellular carcinoma associated with liver cirrhosis] Suzuki Y, et al. **Ryoikibetsu Shokogun Shirizu** 1995; (7):357–9 (20 ref.) (Jpn)

EPIDEMIOLOGY

Relationships between sclerosing cholangitis, inflammatory bowel disease, and cancer in patients undergoing liver transplantation. Knechtle SJ, et al. **Surgery** 1995 Oct; 118(4):615–9; discussion 619–20 (18 ref.)

METABOLISM

[Ectopic hormone producing cholangiocarcinoma] Kawanami C, et al. **Ryoikibetsu Shokogun Shirizu** 1996; (9):99–102 (14 ref.) (Jpn)

PATHOLOGY

Clinico-pathological findings of asymptomatic intrahepatic cholangiocellular carcinoma: report of two cases and review of the literature. Chijiiwa K, et al. **Eur J Surg Oncol** 1996 Apr;22(2):186–8 (15 ref.)
[Choledochus carcinoma in choledochal cyst—a rarity. Presentation of the disease with a case report] Stalder PA, et al. **Swiss Surg** 1996;(3):123–6 (34 ref.) (Eng. Abstr.) (Ger)

SECONDARY

[Renal metastasis originating from liver cancer] Fukushima M, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 Mar; 87(3):710–3 (8 ref.) (Eng. Abstr.) (Jpn)

SURGERY

[Percutaneous treatment of malignant stenoses of the hilum] Bonnel D, et al. **Gastroenterol Clin Biol** 1995 Jun–Jul; 19(6–7):564–71 (24 ref.) (Eng. Abstr.) (Fre)
[Treatment of tumoral stenoses of the hepatic hilum (editorial)] Valette PJ. **Gastroenterol Clin Biol** 1995 Jun–Jul;19(6–7):561–3 (17 ref.) (Fre)
[A simultaneous operation for esophageal and cholangiocellular carcinomas—a case of report] Kudo T, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Oct; 92(10):1789–93 (12 ref.) (Jpn)

THERAPY

[Results of endoscopic biliary drainage in primary tumors of the common bile duct (cholangiocarcinoma)] Costamagna G, et al. **Chir Ital** 1995;47(1):18–23 (20 ref.) (Eng. Abstr.) (Ita)

CHOLANGIOGRAPHY

INSTRUMENTATION

MR cholangiopancreatography. Reinhold C, et al. **Abdom Imaging** 1996 Mar–Apr;21(2):105–16 (35 ref.)
Helical CT cholangiography. Stockberger SM, et al. **Abdom Imaging** 1996 Mar–Apr;21(2):98–104 (17 ref.)

METHODS

Carcinoma of the pancreatic head area. Diagnostic imaging. Direct cholangiography: PTC. Cotroneo AR, et al. **Rays** 1995 Jul–Sep;20(3):280–8 (11 ref.) (Eng, Ita)

CHOLANGIOMA see **ADENOMA, BILE DUCT**

CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE

see related
SPHINCTEROTOMY, ENDOSCOPIC

The role of ERCP in choledocholithiasis. Lo SK, et al. **Abdom Imaging** 1996 Mar–Apr;21(2):120–32 (185 ref.)
Endoscopic diagnosis and management of biliary complications following orthotopic liver transplantation. Gholson CF, et al. **Dig Dis Sci** 1996 Jun;41(6):1045–53 (49 ref.)
Carcinoma of the pancreatic head area. Diagnostic imaging. Direct cholangiography: ERCP. Costamagna G, et al. **Rays** 1995 Jul–Sep;20(3):269–79 (17 ref.) (Eng, Ita)
[Results of endoscopic biliary drainage in primary tumors of the common bile duct (cholangiocarcinoma)] Costamagna G, et al. **Chir Ital** 1995;47(1):18–23 (20 ref.) (Eng. Abstr.) (Ita)
[The role of ERCP in the diagnosis and therapy of Mirizzi's syndrome. Apropos a clinical case] De Monti M, et al. **Minerva Gastroenterol Dietol** 1996 Mar;42(1):39–43 (18 ref.) (Eng. Abstr.) (Ita)
[The role of emergency therapeutic endoscopic retrograde cholangiopancreatography in acute biliary pancreatitis] Moreira Vicente V, et al. **Rev Clin Esp** 1995 Sep; 195(9):645–8 (56 ref.) (Spa)

ADVERSE EFFECTS

Cystic duct perforation as a complication of endoscopic stone extraction. Manbeck MA, et al. **Am J Gastroenterol** 1996 Mar;91(3):592–4 (12 ref.)
Complications related to diagnostic and therapeutic endoscopic retrograde cholangiopancreatography. Aliperti G. **Gastrointest Endosc Clin N Am** 1996 Apr;6(2):379–407 (220 ref.)
[Antibiotic prophylaxis and endoscopic retrograde cholangiopancreatography] Le Dreau G, et al. **Gastroenterol Clin Biol** 1996 Feb;20(1):55–63 (100 ref.) (Fre)

METHODS

Safe laparoendoscopic approach to biliary pancreatitis in older patients. McGrath MF, et al. **Arch Surg** 1996 Aug; 131(8):826–31; discussion 831–3 (21 ref.)

CHOLANGITIS

[Extrahepatic cholangitis] Murakami K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):5–7 (19 ref.) (Jpn)
[Acute obstructive suppurative cholangitis] Nakai T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):8–10 (19 ref.) (Jpn)
[Eosinophilic cholangitis] Tazawa J. **Ryoikibetsu Shokogun Shirizu** 1996;(9):17–9 (18 ref.) (Jpn)
[Oriental cholangiohepatitis] Uchiyama K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):134–6 (13 ref.) (Jpn)

COMPLICATIONS

[Inflammatory hepatic cyst] Kurumi Y, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):83–6 (20 ref.) (Jpn)

ETIOLOGY

Bacillus subtilis as a cause of cholangitis in polycystic kidney and liver disease [letter] Wallet F, et al. **Am J Gastroenterol** 1996 Jul;91(7):1477–8 (11 ref.)
Cholangitis: pathogenesis, diagnosis, and treatment. Hanau LH, et al. **Curr Clin Top Infect Dis** 1995;15:153–78 (253 ref.)
Cholangitis associated with paroxysmal nocturnal hemoglobinuria: another instance of ischemic cholangiopathy? Le Thi Huong D, et al. **Gastroenterology** 1995 Oct;109(4):1338–43 (52 ref.)

IMMUNOLOGY

[Intrahepatic cholangitis with presumably immunologic bases] Klinge O. **Verh Dtsch Ges Pathol** 1995;79:198–232 (128 ref.) (Eng. Abstr.) (Ger)

MICROBIOLOGY

Stenotrophomonas maltophilia: an unusual cause of biliary sepsis. Papadakis KA, et al. **Clin Infect Dis** 1995 Oct; 21(4):1032–4 (9 ref.)

PATHOLOGY

[Intrahepatic cholangitis with presumably immunologic bases] Klinge O. **Verh Dtsch Ges Pathol** 1995;79:198–232 (128 ref.) (Eng. Abstr.) (Ger)

SURGERY

Biliary infections. Roslyn JJ. **Curr Opin Gen Surg** 1993; :265–70 (33 ref.)

THERAPY

Cholangitis: pathogenesis, diagnosis, and treatment. Hanau LH, et al. **Curr Clin Top Infect Dis** 1995;15:153–78 (253 ref.)

CHOLANGITIS, CHRONIC NONSUPPURATIVE DESTRUCTIVE see **LIVER CIRRHOSIS, BILIARY**

CHOLANGITIS, SCLEROSING

[Primary sclerosing cholangitis (PSC)] Oda M, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):555–9 (20 ref.) (Jpn)
[Sclerosing cholangitis (primary, secondary)] Oda M, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):11–6 (25 ref.) (Jpn)
[Extrahepatic cholestatic syndrome in childhood] Tazawa Y. **Ryoikibetsu Shokogun Shirizu** 1996;(9):159–62 (19 ref.) (Jpn)
[Autoimmune diseases of the liver, III. Primary sclerosing cholangitis] Garassini Serra MA, et al. **G E N** 1995 Apr–Jun;49(2):170–8 (59 ref.) (Eng. Abstr.) (Spa)

COMPLICATIONS

Temporary resolution of obstructive jaundice during ursodeoxycholic acid therapy in a patient with primary sclerosing cholangitis and a dominant biliary stricture. Fracchia M, et al. **Ital J Gastroenterol** 1995 Oct–Nov; 27(8):430–5 (38 ref.)

DIAGNOSIS

Recognizing primary biliary cirrhosis and primary sclerosing cholangitis. Buckley SE, et al. **Am Fam Physician** 1996 Jan;53(1):195–200 (11 ref.)

DRUG THERAPY

Temporary resolution of obstructive jaundice during ursodeoxycholic acid therapy in a patient with primary sclerosing cholangitis and a dominant biliary stricture. Fracchia M, et al. **Ital J Gastroenterol** 1995 Oct–Nov; 27(8):430–5 (38 ref.)

EPIDEMIOLOGY

Relationships between sclerosing cholangitis, inflammatory bowel disease, and cancer in patients undergoing liver transplantation. Knechtle SJ, et al. **Surgery** 1995 Oct; 118(4):615–9; discussion 619–20 (18 ref.)

ETIOLOGY

[Liver dysfunction in patients with inflammatory bowel disease—with special reference to primary sclerosing cholangitis] Kakei N, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):301–4 (8 ref.) (Jpn)

IMMUNOLOGY

[Primary sclerosing cholangitis (PSC)—humoral immune phenomena, pathogenetic aspects and therapeutic possibilities] Hopf U, et al. **Z Gastroenterol** 1993 Feb;31 Suppl 2:106–10 (31 ref.) (Eng. Abstr.) (Ger)

SURGERY

Surgery for sclerosing cholangitis. Braasch JW. **Curr Opin Gen Surg** 1994;:156–60 (17 ref.)

CHOLECALCIFEROL

see related
RECEPTORS, CALCITRIOL

ANALOGS & DERIVATIVES

Vitamin D3 analogues. Kragballe K. **Dermatol Clin** 1995 Oct; 13(4):835–9 (37 ref.)

DEFICIENCY

Noncalcemic actions of 1,25-dihydroxyvitamin D3 and clinical applications. Holick MF. **Bone** 1995 Aug;17(2 Suppl):107S–111S (36 ref.)

THERAPEUTIC USE

Vitamin D3 analogues. Kragballe K. **Dermatol Clin** 1995 Oct; 13(4):835–9 (37 ref.)
Vitamin D3 as a possible chemopreventive and therapeutic agent of cancers. DeLuca HF. **Jpn J Cancer Res** 1996 Apr; 87(4):inside front cover (10 ref.)
[Administration of vitamin D3 and its active metabolites in the prevention and treatment of osteoporosis] Lips P. **Ned Tijdschr Geneeskd** 1996 Jan 13;140(2):65–8 (34 ref.) (Dut)

CHOLECALCIFEROL RECEPTORS see **RECEPTORS, CALCITRIOL**

CHOLECYSTECTOMY

see related
POSTCHOLECYSTECTOMY SYNDROME

ADVERSE EFFECTS

[Antibiotic prophylaxis in biliary surgery] Gondret R, et al. **Ann Chir** 1995;49(6):493–9 (52 ref.) (Eng. Abstr.) (Fre)

CHOLECYSTECTOMY, CELIOSCOPIC see **CHOLECYSTECTOMY, LAPAROSCOPIC**

CHOLECYSTECTOMY, LAPAROSCOPIC

Changing indications for laparoscopic cholecystectomy. Stones without symptoms and symptoms without stones. Schwesinger WH, et al. **Surg Clin North Am** 1996 Jun; 76(3):493–504 (76 ref.)
Laparoscopic cholecystectomy in pregnancy. A report of 6 cases and review of the literature. Wishner JD, et al. **Surg Endosc** 1996 Mar;10(3):314–8 (29 ref.)
Laparoscopic cholecystectomy for gallbladder torsion. Schroder DM, et al. **Surg Laparosc Endosc** 1995 Aug;

5(4):330–4 (39 ref.)
Laparoscopic cholecystectomy during pregnancy. Lanzafame RJ. **Surgery** 1995 Oct;118(4):627–31; discussion 631–3 (28 ref.)
[Anesthesiologic procedures in laparoscopic cholecystectomy] Wilhelm W, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Nov; 30(7):450–4 (18 ref.) **(Ger)**
[Laparoscopic cholecystectomy in pregnancy. A description of 2 cases and review of the literature] Lang RD, et al. **Chirurg** 1995 Dec;66(12):1225–9 (49 ref.) (Eng. Abstr.) **(Ger)**
[Implantation metastases following laparoscopic cholecystectomy in gallbladder carcinoma] Buhr J, et al. **Dtsch Med Wochenschr** 1996 Jan 19;121(3):57–61; discussion 61–2 (36 ref.) (Eng. Abstr.) **(Ger)**
[Laparoscopic cholecystectomy for gallbladder stones] Farello G, et al. **Chir Ital** 1995;47(1):24–43 (75 ref.) (Eng. Abstr.) **(Ita)**

ADVERSE EFFECTS

Endoscopic approaches to common bile duct injuries. Ponsky JL. **Surg Clin North Am** 1996 Jun;76(3):505–13 (11 ref.)
The spilled stone. A potential danger after laparoscopic cholecystectomy. Targarona EM, et al. **Surg Endosc** 1995 Jul;9(7):768–73 (69 ref.)
[Laparoscopic cholecystectomy causing injury to biliary tracts. Analysis of the results of 26,440 operations in Hungary] Ihász M, et al. **Orv Hetil** 1996 May 5; 137(18):955–63 (29 ref.) (Eng. Abstr.) **(Hun)**
[Endoscopic management of bile leakage following laparoscopic cholecystectomy] Lakatos L, et al. **Orv Hetil** 1996 Mar 17;137(11):569–75 (47 ref.) (Eng. Abstr.) **(Hun)**

ECONOMICS

Managing gallbladder disease in a cost-effective manner. Orlando R 3rd, et al. **Surg Clin North Am** 1996 Feb; 76(1):117–28 (36 ref.)
[Economic evaluation of health. Principles--example of laparoscopic cholecystectomy] de Pouvourville G. **Ann Chir** 1995;49(10):881–8 (11 ref.) (Eng. Abstr.) **(Fre)**

INSTRUMENTATION

Laparoscopic and endoscopic management of common bile duct stones. Pitcher DE, et al. **Curr Opin Gen Surg** 1994; :203–7 (17 ref.)
[Laparoscopic therapy of choledocholithiasis] Rechner J, et al. **Zentralbl Chir** 1996;121(4):278–82 (22 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Safe laparoendoscopic approach to biliary pancreatitis in older patients. McGrath MF, et al. **Arch Surg** 1996 Aug; 131(8):826–31; discussion 831–3 (21 ref.)
Biliary surgery. Leichter RF, et al. **Curr Opin Gen Surg** 1993; :271–6 (36 ref.)
Peritonitis biliaris: some aspects of its origin. Vomela J, et al. **Rocz Akad Med Bialymst** 1995;40(1):58–64 (24 ref.)
[Laparoscopic cholecystectomy in 1994. Results of the survey of the SFCERO on 4624 cases] Collet D. **Ann Chir** 1996; 50(3):241–51 (42 ref.) (Eng. Abstr.) **(Fre)**
[Indications and modalities of cholecystectomy in cholelithiasis. Study Group of Cholecystectomy, under the aegis of the National Agency for the Development of Medical Evaluation] **Gastroenterol Clin Biol** 1995 Aug–Sep; 19(8–9):707–17 (29 ref.) **(Fre)**
["500 consecutive cases of laparoscopic cholecystectomy". Argument for the association to endoscopic sphincterotomy: analysis] Lagrange M. **J Chir (Paris)** 1996 Apr;133(2):65–71 (13 ref.) (Eng. Abstr.) **(Fre)**

CHOLECYSTITIS

[Acute cholecystitis] Hayashi M. **Ryoikibetsu Shokogun Shirizu** 1996;(9):206–9 (7 ref.) **(Jpn)**
[Cholecystitis] Hayashi M. **Ryoikibetsu Shokogun Shirizu** 1996;(9):216–8 (5 ref.) **(Jpn)**
[Chronic cholecystitis] Hayashi M. **Ryoikibetsu Shokogun Shirizu** 1996;(9):228–30 (5 ref.) **(Jpn)**
[Xanthogranulomatous cholecystitis] Iwamoto S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):196–8 (10 ref.) **(Jpn)**
[Acalculous cholecystitis] Kimura W, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):231–3 (11 ref.) **(Jpn)**
[Granulation polyp of the gallbladder, inflammation of the Rokitansky-Aschoff sinus] Liao CM, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):321–3 (6 ref.) **(Jpn)**
[Emphysematous cholecystitis] Nagami H, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):202–5 (16 ref.) **(Jpn)**
[Metaplastic cholecystitis] Ozeki Y, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):199–201 (12 ref.) **(Jpn)**
[Mirizzi's syndrome, pseudo-lesion of bile duct due to the disorder of the cystic duct] Takifuji K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):146–8 (7 ref.) **(Jpn)**

COMPLICATIONS

Liver abscess secondary to intrahepatic perforation of the gallbladder, presenting as a liver mass. Bakalakos EA, et al. **Am J Gastroenterol** 1996 Aug;91(8):1644–6 (12 ref.)
[HIV (human immunodeficiency virus) disease and AIDS (acquired immunodeficiency syndrome)] Fujii T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):255–7 (10 ref.) **(Jpn)**

DIAGNOSIS

[Gangrenous cholecystitis] Kano N, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):193–5 (18 ref.) **(Jpn)**
[Fibroxanthogranulomatous inflammation] Kitamra T. **Ryoikibetsu Shokogun Shirizu** 1996;(9):290–1 (8 ref.) **(Jpn)**

ETIOLOGY

Acute cholecystitis resulting from hemobilia after tru-cut biopsy: a case report and brief review of the literature. Counihan TC, et al. **Am Surg** 1996 Sep;62(9):757–8 (5 ref.)
Gunshot cholecystitis. Petersen JM, et al. **J Clin Gastroenterol** 1995 Dec;21(4):320–2 (17 ref.)
[Postoperative acute cholecystitis] Nakajima Y, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):213–5 (7 ref.) **(Jpn)**
[Ischemic cholecystitis] Takahashi M, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):210–2 (22 ref.) **(Jpn)**

MICROBIOLOGY

Emphysematous cholecystitis. Lindsey I, et al. **Aust N Z J Surg** 1996 Apr;66(4):267–8 (14 ref.)
Acute cholecystitis caused by Campylobacter jejuni. Landau Z, et al. **Isr J Med Sci** 1995 Nov;31(11):696–7 (6 ref.)

PATHOLOGY

Chronic cholecystitis with features of diffuse inflammatory pseudotumour: a clinico-pathological case study and review of the literature. Corsi A, et al. **Ital J Gastroenterol** 1995 Jun;27(5):252–5 (30 ref.)
Gallbladder adenocarcinoma, acalculous chronic lymphoplasmacytic cholecystitis, ulcerative colitis. Herzog K, et al. **Mod Pathol** 1996 Mar;9(3):194–8 (26 ref.)
[Lymph follicular cholecystitis] Nakashiro H, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):234–6 (5 ref.) **(Jpn)**

RADIONUCLIDE IMAGING

[Hepatobiliary radionuclide imaging. Clinical applications] Zerbib E. **Ann Chir** 1995;49(7):637–43 (35 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Biliary infections. Roslyn JJ. **Curr Opin Gen Surg** 1993; :265–70 (33 ref.)
Laparoscopic cholecystectomy during pregnancy. Lanzafame RJ. **Surgery** 1995 Oct;118(4):627–31; discussion 631–3 (28 ref.)
[Laparoscopic cholecystectomy in pregnancy. A description of 2 cases and review of the literature] Lang RD, et al. **Chirurg** 1995 Dec;66(12):1225–9 (49 ref.) (Eng. Abstr.) **(Ger)**

ULTRASONOGRAPHY

[Ultrasound of stress cholecystitis--diagnosis and differential diagnosis] Macheiner P, et al. **Z Gastroenterol** 1996 Jan; 34(1):21–6 (36 ref.) (Eng. Abstr.) **(Ger)**

CHOLECYSTOKININ

see related
GASTROINTESTINAL AGENTS
RECEPTORS, CHOLECYSTOKININ

BLOOD

[Cholecystokinin-pancreozymin (CCK-PZ)] Iwata Y, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:644–7 (19 ref.) **(Jpn)**

CLASSIFICATION

Opioid and anti-opioid peptides. Cesselin F. **Fundam Clin Pharmacol** 1995;9(5):409–33 (316 ref.)

GENETICS

[Messenger RNA of duodenal cholecystokinin: thanks to endoscopy... (editorial)] Chayvialle JA. **Gastroenterol Clin Biol** 1995 Aug–Sep;19(8–9):657–8 (13 ref.) **(Fre)**

PHARMACOLOGY

Cholecystokinin modulation of serotonergic control of feeding behavior. Cooper SJ. **Ann N Y Acad Sci** 1996 Mar 22;780:213–22 (49 ref.)
Opioid and anti-opioid peptides. Cesselin F. **Fundam Clin Pharmacol** 1995;9(5):409–33 (316 ref.)

PHYSIOLOGY

Cholecystokinin and anxiety: promises and pitfalls. Rodgers RJ, et al. **Crit Rev Neurobiol** 1995;9(4):345–69 (202 ref.)
Cholecystokinin in psychiatric research: a time for cautious excitement. Abelson JL. **J Psychiatr Res** 1995 Sep–Oct; 29(5):389–96 (60 ref.)

SECRETION

Regulation of cholecystokinin secretion by intraluminal releasing factors. Liddle RA. **Am J Physiol** 1995 Sep;269(3 Pt 1):G319–27 (78 ref.)

CHOLECYSTOKININ OCTAPEPTIDE see **SINCALIDE**

CHOLECYSTOKININ OCTAPEPTIDE RECEPTORS see **RECEPTORS, CHOLECYSTOKININ**

CHOLECYSTOKININ-PANCREOZYMIN RECEPTORS see **RECEPTORS, CHOLECYSTOKININ**

CHOLECYSTOKININ RECEPTORS see **RECEPTORS, CHOLECYSTOKININ**

CHOLEDOCHAL CYST

COMPLICATIONS

Choledochocele-containing stones. Tajiri H. **Am J Gastroenterol** 1996 May;91(5):1046–8 (10 ref.)
[Asymptomatic choledochal cyst] Hollerbach S, et al. **Dtsch Med Wochenschr** 1996 Mar 1;121(9):269–74 (16 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

[Choledochus carcinoma in choledochal cyst--a rarity. Presentation of the disease with a case report] Stalder PA, et al. **Swiss Surg** 1996;(3):123–6 (34 ref.) (Eng. Abstr.) **(Ger)**
[Congenital bile duct dilatation, congenital biliary dilatation] Miyazaki I, et al. **Ryoikibetsu Shokogun Shirizu** 1996; (9):118–26 (52 ref.) **(Jpn)**

SURGERY

Prenatally diagnosed choledochal cysts: observation or early surgery? Lugo-Vicente HL. **J Pediatr Surg** 1995 Sep; 30(9):1288–90 (24 ref.)
Choledochocele: changing trends in diagnosis and management. Masetti R, et al. **Surg Today** 1996;26(4):281–5 (14 ref.)

ULTRASONOGRAPHY

Prenatal diagnosis of a choledochal cyst: a case report and review of the literature. Benhidjeb T, et al. **Am J Perinatol** 1996 May;13(4):207–10 (20 ref.)
Prenatally diagnosed choledochal cysts: observation or early surgery? Lugo-Vicente HL. **J Pediatr Surg** 1995 Sep; 30(9):1288–90 (24 ref.)

CHOLEDOCHOLITHIASIS see **COMMON BILE DUCT CALCULI**

CHOLEDOCHUS see **COMMON BILE DUCT**

CHOLELITHIASIS

Incidental diagnosis of asymptomatic neonatal cholelithiasis: case report and literature review. Morad Y, et al. **J Perinatol** 1995 Jul–Aug;15(4):314–7 (24 ref.)
Cholesterol gallstone formation in man and potential treatments of the gallbladder motility defect. Portincasa P, et al. **Scand J Gastroenterol Suppl** 1995;212:63–78 (294 ref.)
[Limy bile] Ise H, et al. **Ryoikibetsu Shokogun Shirizu** 1996; (9):489–91 (17 ref.) **(Jpn)**
[Cholecysto-choledocholithiasis] Kashima K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):516–8 (15 ref.) **(Jpn)**
[Extra-hepatic cholangiolithiasis-choledocholithiasis] Kashima K, et al. **Ryoikibetsu Shokogun Shirizu** 1996; (9):142–5 (15 ref.) **(Jpn)**
[Cholecystocholedocholithiasis] Sai J, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):412–4 (17 ref.) **(Jpn)**
[Calcified gallstone] Saito K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):408–11 (13 ref.) **(Jpn)**
[Confluence stone] Takagi I, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):397–99 (19 ref.) **(Jpn)**
[Mirizzi's syndrome, pseudo-lesion of bile duct due to the disorder of the cystic duct] Takifuji K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):146–8 (7 ref.) **(Jpn)**

CHEMISTRY

[Cholesterol gallstone--symptoms, diagnosis and treatments] Abei M, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):400–3

(7 ref.) **(Jpn)**

[Rare gallstone (calcium carbonate calculus)] Goto K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):418–20 (11 ref.) **(Jpn)**

[Pigment stone (black stones, calcium bilirubinate stones)] Ise H, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):404–7 (18 ref.) **(Jpn)**

COMPLICATIONS

Cystic duct perforation as a complication of endoscopic stone extraction. Manbeck MA, et al. **Am J Gastroenterol** 1996 Mar;91(3):592–4 (12 ref.)

Choledochocele–containing stones. Tajiri H. **Am J Gastroenterol** 1996 May;91(5):1046–8 (10 ref.)

Gallstone pancreatitis: an update. Wassef W, et al. **Gastroenterologist** 1996 Mar;4(1):70–5 (66 ref.)

[Hepatic echinococcosis with gallstones of the echinococcal cavity] Kuntz C, et al. **Dtsch Med Wochenschr** 1995 Dec 8;120(49):1699–702 (13 ref.) (Eng. Abstr.) **(Ger)**

[Gallstone ileus] Numata M, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):503–5 (8 ref.) **(Jpn)**

[Biliary pancreatitis] Yamaguchi A, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):506–8 (5 ref.) **(Jpn)**

[Internal biliary fistula: study of 13 cases and review of the literature] Machado MA, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1995 Jan–Feb;50(1):45–8 (17 ref.) (Eng. Abstr.) **(Por)**

DIAGNOSIS

[The role of ERCP in the diagnosis and therapy of Mirizzi's syndrome. Apropos a clinical case] De Monti M, et al. **Minerva Gastroenterol Dietol** 1996 Mar;42(1):39–43 (18 ref.) (Eng. Abstr.) **(Ita)**

[Gas–containing gallstones] Kurosaki A, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):394–6 (11 ref.) **(Jpn)**

ETIOLOGY

A radical view of gallstone aetiogenesis. Braganza JM, et al. **Med Hypotheses** 1995 Nov;45(5):510–6 (62 ref.)

[Diseases of the biliary system in obesity] Takikawa H, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:349–53 (21 ref.) **(Jpn)**

[Cholelithiasis following gastrectomy] Miyazaki I, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):388–90 (26 ref.) **(Jpn)**

[Cholecystolithiasis with ascariasis] Shibayama K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):391–3 (19 ref.) **(Jpn)**

[Impaired gallbladder motility—an underestimated pathogenetic factor of gallstones] Jonderko K. **Przegl Lek** 1995;52(7):358–64 (102 ref.) **(Pol)**

PHYSIOPATHOLOGY

Gallbladder motility, gallstones, and the surgeon. Patankar R, et al. **Dig Dis Sci** 1995 Nov;40(11):2323–35 (188 ref.)

[Silent stone] Simizu T. **Ryoikibetsu Shokogun Shirizu** 1996;(9):421–4 (20 ref.) **(Jpn)**

PREVENTION & CONTROL

[Antibiotic prophylaxis in biliary surgery] Gondret R, et al. **Ann Chir** 1995;49(6):493–9 (52 ref.) (Eng. Abstr.) **(Fre)**

RADIOGRAPHY

Endoscopic stenting of gallbladder for symptomatic cholelithiasis in patients with end–stage liver disease awaiting orthotopic liver transplantation. Shrestha R, et al. **Am J Gastroenterol** 1996 Mar;91(3):595–8 (21 ref.)

[Pseudostone of the gallbladder] Kubota Y, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):415–7 (3 ref.) **(Jpn)**

SURGERY

The management of intrahepatic stones. Cheung KL, et al. **Adv Surg** 1996;29:111–29 (108 ref.)

Biliary surgery. Leichter RF, et al. **Curr Opin Gen Surg** 1993; :271–6 (36 ref.)

Gallbladder motility, gallstones, and the surgeon. Patankar R, et al. **Dig Dis Sci** 1995 Nov;40(11):2323–35 (188 ref.)

Changing indications for laparoscopic cholecystectomy. Stones without symptoms and symptoms without stones. Schwesinger WH, et al. **Surg Clin North Am** 1996 Jun; 76(3):493–504 (76 ref.)

The spilled stone. A potential danger after laparoscopic cholecystectomy. Targarona EM, et al. **Surg Endosc** 1995 Jul;9(7):768–73 (69 ref.)

Laparoscopic cholecystectomy in pregnancy. A report of 6 cases and review of the literature. Wishner JD, et al. **Surg Endosc** 1996 Mar;10(3):314–8 (29 ref.)

[Laparoscopic cholecystectomy in 1994. Results of the survey of the SFCERO on 4624 cases] Collet D. **Ann Chir** 1996; 50(3):241–51 (42 ref.) (Eng. Abstr.) **(Fre)**

[Indications and modalities of cholecystectomy in cholelithiasis. Study Group of Cholecystectomy, under the aegis of the National Agency for the Development of Medical Evaluation] **Gastroenterol Clin Biol** 1995 Aug–Sep; 19(8–9):707–17 (29 ref.) **(Fre)**

["500 consecutive cases of laparoscopic cholecystectomy". Argument for the association to endoscopic sphincterotomy: analysis] Lagrange M. **J Chir (Paris)** 1996 Apr;133(2):65–71 (13 ref.) (Eng. Abstr.) **(Fre)**

[Laparoscopic cholecystectomy in pregnancy. A description of 2 cases and review of the literature] Lang RD, et al. **Chirurg** 1995 Dec;66(12):1225–9 (49 ref.) (Eng. Abstr.) **(Ger)**

[Laparoscopic cholecystectomy for gallbladder stones] Farello G, et al. **Chir Ital** 1995;47(1):24–43 (75 ref.) (Eng. Abstr.) **(Ita)**

THERAPY

Extracorporeal gall bladder lithotripsy—a review of tissue and cellular effects. Stephenson TJ. **J Pathol** 1996 May; 179(1):4–9 (51 ref.)

What should I do about my patient's gall stones? Dennison AR, et al. **Postgrad Med J** 1995 Dec;71(842):725–9 (103 ref.)

[When should gallstones be treated?] Kiviluoto T, et al. **Duodecim** 1994;110(20):1869–74 (29 ref.) **(Fin)**

[Role of extracorporeal shock wave lithotripsy in the treatment of common bile duct and intrahepatic calculi] Dagenais M, et al. **Ann Chir** 1995;49(8):659–63 (15 ref.) (Eng. Abstr.) **(Fre)**

ULTRASONOGRAPHY

Laparoscopic resection of a large hepatic tumor. Ferzli G, et al. **Surg Endosc** 1995 Jun;9(6):733–5 (9 ref.)

CHOLELITHIASIS, COMMON BILE DUCT see **COMMON BILE DUCT CALCULI**

CHOLERA

Cholera: its story in Africa with special reference to Kenya and other east African countries. Waiyaki PG. **East Afr Med J** 1996 Jan;73(1):40–3 (19 ref.)

COMPLICATIONS

Herman Award Lecture, 1995: infection–induced malnutrition—from cholera to cytokines. Beisel WR. **Am J Clin Nutr** 1995 Oct;62(4):813–9 (91 ref.)

Mechanism and treatment of diarrhoea due to Vibrio cholerae and Escherichia coli: roles of drugs and prostaglandins. Rabbani GH. **Dan Med Bull** 1996 Apr;43(2):173–85 (169 ref.)

EPIDEMIOLOGY

Cholera in the United States. Hellinger WC, et al. **Dig Dis** 1995 May–Jun;13(3):190–8 (31 ref.)

[Epidemic of cholera due to a new serogroup Vibrio cholerae O139 Bengal] Shimada T, et al. **Nippon Saikingaku Zasshi** 1995 Oct;50(4):1005–17 (70 ref.) **(Jpn)**

[World cholera pandemics as mono– and polycyclic phenomena] Arutiunov IuI. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Mar–Apr; (2):113–7 (26 ref.) **(Rus)**

MICROBIOLOGY

An ace up the sleeve of the cholera bacterium. Richardson SH, et al. **Nat Med** 1996 Aug;2(8):853–5 (8 ref.)

THERAPY

Practical guidelines for the treatment of cholera. Seas C, et al. **Drugs** 1996 Jun;51(6):966–73 (24 ref.)

CHOLERA TOXIN

Cholera toxin B subunit as transmucosal carrier–delivery and immunomodulating system for induction of antiinfectious and antipathological immunity. Czerkinsky C, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:185–93 (32 ref.)

GENETICS

Molecular engineering of cholera toxin. Burnette WN, et al. **Adv Exp Med Biol** 1995;371B:1513–8 (43 ref.)

IMMUNOLOGY

Molecular engineering of cholera toxin. Burnette WN, et al. **Adv Exp Med Biol** 1995;371B:1513–8 (43 ref.)

TOXICITY

Mechanism of action of cholera toxin & other toxins. Ganguly NK, et al. **Indian J Med Res** 1996 Jul;104:28–37 (84 ref.)

CHOLERA VACCINE

ADMINISTRATION & DOSAGE

Oral vaccines against cholera and enterotoxigenic Escherichia coli diarrhea. Svennerholm AM, et al. **Adv Exp Med Biol** 1995;371B:1623–8 (19 ref.)

IMMUNOLOGY

Strategies for production of a potential candidate vaccine for cholera. Ghosh A, et al. **Indian J Med Res** 1996 Jul; 104:60–75 (111 ref.)

ISOLATION & PURIFICATION

Why do we not yet have a suitable vaccine against cholera? Finkelstein RA. **Adv Exp Med Biol** 1995;371B:1633–40 (61 ref.)

CHOLERAGEN see **CHOLERA TOXIN**

CHOLERAGENOID see **CHOLERA TOXIN**

CHOLERETICS see **CHOLAGOGUES AND CHOLERETICS**

CHOLESTANOLS

METABOLISM

Green light for steroid hormones [comment] Russell DW. **Science** 1996 Apr 19;272(5260):370–1 (7 ref.) Comment on: Science 1996 Apr 19;272(5260):398–401.

CHOLESTASIS

Inflammatory and immunologic effects of obstructive jaundice: pathogenesis and treatment. Kimmings AN, et al. **J Am Coll Surg** 1995 Dec;181(6):567–81 (186 ref.)

Chronic cholestasis of infancy. Whitington PF. **Pediatr Clin North Am** 1996 Feb;43(1):1–26 (84 ref.)

[Post operative bile duct stricture] Hoshino M, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):155–8 (8 ref.) **(Jpn)**

[Biliary sludge] Itakura J, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):509–11 (11 ref.) **(Jpn)**

[Acute obstructive suppurative cholangitis] Nakai T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):8–10 (19 ref.) **(Jpn)**

[Mirizzi's syndrome, pseudo–lesion of bile duct due to the disorder of the cystic duct] Takifuji K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):146–8 (7 ref.) **(Jpn)**

[Cystic duct syndrome] Yamakawa T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):441–3 (10 ref.) **(Jpn)**

CHEMICALLY INDUCED

Flucloxacillin associated cholestatic hepatitis. An Australian and Swedish epidemic? Devereaux BM, et al. **Eur J Clin Pharmacol** 1995;49(1–2):81–5 (30 ref.)

[Drug–induced cholestasis] Kawada N, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):45–8 (9 ref.) **(Jpn)**

[Toxic cholestatic hepatitis due to phenytoin] de la Serna Higuera C, et al. **Gastroenterol Hepatol** 1995 Nov; 18(9):471–3 (11 ref.) (Eng. Abstr.) **(Spa)**

COMPLICATIONS

Medical therapy of pruritus of cholestasis. Luketic VA, et al. **Gastroenterologist** 1995 Sep;3(3):257–60 (11 ref.)

Ductular reaction in the liver. Desmet V, et al. **Pathol Res Pract** 1995 Jul;191(6):513–24 (153 ref.)

Pruritus of chronic cholestasis. Raiford DS. **QJM** 1995 Sep; 88(9):603–7 (34 ref.)

The pruritus of cholestasis. Bergasa NV. **Semin Dermatol** 1995 Dec;14(4):302–12 (86 ref.)

[Secondary biliary cirrhosis] Ohsuga M, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):200–2 (9 ref.) **(Jpn)**

[Aminoglycoside nephrotoxicity and obstructive jaundice (editorial)] Lucena MI, et al. **Med Clin (Barc)** 1995 Oct 14;105(12):457–60 (55 ref.) **(Spa)**

DRUG THERAPY

[Ursodeoxycholic acid: an alternative in the treatment of chronic cholestasis] Parés A, et al. **Gastroenterol Hepatol** 1996 Feb;19(2):58–67 (110 ref.) **(Spa)**

ECONOMICS

Malignant obstructive jaundice. Evaluation and management. Rossi RL, et al. **Surg Clin North Am** 1996 Feb;76(1):63–70 (18 ref.)

ETIOLOGY

Idiopathic fibrosing pancreatitis: a rare cause of obstructive jaundice in children. Amerson JL, et al. **Am Surg** 1996 Apr;62(4):295–9 (09 ref.)

Liver and biliary tract changes and injury associated with total parenteral nutrition: pathogenesis and prevention. Briones ER, et al. **J Am Coll Nutr** 1995 Jun;14(3):219–28 (119 ref.)

[Lemmel's syndrome caused by a giant diverticulum in the third portion of the duodenum, report of a case] Hirano A, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Nov; 92(11):1863–70 (11 ref.) **(Jpn)**

PATHOLOGY

Histopathology of cholestasis. Desmet VJ.

Verh Dtsch Ges Pathol 1995;79:233–40 (44 ref.)
[Histologic diagnosis of neonatal cholestasis] Hadchouel M, et al. **Ann Pathol** 1995;15(5):357–64 (37 ref.) **(Fre)**
[Hepatic neoductules] Fischer HP, et al.
Verh Dtsch Ges Pathol 1995;79:36–46 (42 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Bile secretion--models, mechanisms, and malfunctions. A perspective on the development of modern cellular and molecular concepts of bile secretion and cholestasis. Boyer JL. **J Gastroenterol** 1996 Jun;31(3):475–81 (78 ref.)

RADIOGRAPHY

[Icterus--sometimes something is wrong: the rupture of an echinococcal cyst into the biliary tract] Bücker A, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Jul;165(1):88–90 (10 ref.) **(Ger)**

SURGERY

The role of preoperative biliary decompression in obstructive jaundice. Nakeeb A, et al. **Hepatogastroenterology** 1995 Jul–Aug;42(4):332–7 (26 ref.)
[Stenting or operation in malignant or benign stenoses: where are the limits?--from the viewpoint of the surgeon] Schoenberg MH, et al. **Bildgebung** 1995 Oct;62 Suppl 2:73–6 (13 ref.) **(Ger)**

THERAPY

Malignant obstructive jaundice. Evaluation and management. Rossi RL, et al. **Surg Clin North Am** 1996 Feb;76(1):63–70 (18 ref.)
[Plastic prostheses or self-expanding stents--is there an ideal drainage? Pro metal] Hochberger J, et al. **Bildgebung** 1995 Oct;62 Suppl 2:59–63 (22 ref.) **(Ger)**
[Plastic prostheses or self-expanding stents--is there an ideal drainage? Pro synthetics] Soehendra N, et al.
Bildgebung 1995 Oct;62 Suppl 2:55–8 (23 ref.) **(Ger)**

ULTRASONOGRAPHY

Endoscopic ultrasonography in pancreatobiliary disease using radial instruments. Buscail L.
Gastrointest Endosc Clin N Am 1995 Oct;5(4):781–7 (25 ref.)

CHOLESTASIS, EXTRAHEPATIC see **BILE DUCT OBSTRUCTION, EXTRAHEPATIC**

CHOLESTASIS, INTRAHEPATIC

[Nielsen syndrome] Fujisawa T.
Ryoikibetsu Shokogun Shirizu 1995;(7):539–41 (9 ref.) **(Jpn)**
[Intrahepatic cholestasis in infants and children] Iitsuka T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):585–9 (13 ref.) **(Jpn)**
[Summerskill syndrome] Kimura A, et al.
Ryoikibetsu Shokogun Shirizu 1995;(7):542–3 (14 ref.) **(Jpn)**
[Inspissated bile syndrome] Kondo M, et al.
Ryoikibetsu Shokogun Shirizu 1996;(9):524–7 (18 ref.) **(Jpn)**
[Aagenaes syndrome] Nittono H, et al.
Ryoikibetsu Shokogun Shirizu 1995;(7):521–2 (5 ref.) **(Jpn)**
[Byler disease] Okaniwa M. **Ryoikibetsu Shokogun Shirizu** 1995;(7):531–4 (19 ref.) **(Jpn)**
[Intrahepatic cholestasis in internal medicine] Sakisaka S, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):580–4 (5 ref.) **(Jpn)**

CHEMICALLY INDUCED

Canalicular cholestasis due to amiodarone toxicity. A definite diagnosis obtained by electron microscopy. Macarri G, et al. **Ital J Gastroenterol** 1995 Oct–Nov;27(8):436–8 (18 ref.)
[Cholestatic hepatitis and amoxicillin–clavulanic acid combination. Personnel case report and literature review] Watteeuw G, et al. **Rev Med Brux** 1995 Dec;16(6):391–3 (11 ref.) (Eng. Abstr.) **(Fre)**
[Trimethoprim–sulfamethoxazole–induced cholestatic hepatitis. Clinico–immunological demonstration of its allergic origin] Cario E, et al. **Dtsch Med Wochenschr** 1996 Feb 2;121(5):129–32 (10 ref.) (Eng. Abstr.) **(Ger)**

DIAGNOSIS

MR cholangiopancreatography. Reinhold C, et al.
Abdom Imaging 1996 Mar–Apr;21(2):105–16 (35 ref.)
Diagnosis and therapy of cholestatic liver disease. Pasha TM, et al. **Med Clin North Am** 1996 Sep;80(5):995–1019 (108 ref.)
[Rational laboratory diagnosis of cholestasis syndrome] Nilius R, et al. **Z Gastroenterol** 1993 Feb;31 Suppl 2:33–8 (24 ref.) (Eng. Abstr.) **(Ger)**

ETHNOLOGY

[Microfilament dysfunction (severe familial cholestasis in North American Indian children)] Terazawa S.
Ryoikibetsu Shokogun Shirizu 1995;(7):535–8 (12 ref.) **(Jpn)**

ETIOLOGY

Obstructive jaundice due to multiple hepatic peribiliary cysts. Stevens W, et al. **Am J Gastroenterol** 1996 Jan;91(1):155–7 (5 ref.)
[Inspissated bile syndrome] Isobe K, et al.
Ryoikibetsu Shokogun Shirizu 1995;(8):578–81 (18 ref.) **(Jpn)**
[Cholestasis in congenital heart diseases (hypoplastic left heart syndrome, aortic coarctation)] Konno T.
Ryoikibetsu Shokogun Shirizu 1995;(7):571–3 (9 ref.) **(Jpn)**
[Postoperative liver damage, postoperative jaundice, and benign postoperative cholestasis] Ouchi K, et al.
Ryoikibetsu Shokogun Shirizu 1995;(8):538–40 (6 ref.) **(Jpn)**
[Intrahepatic cholestasis associated with neonatal small intestinal obstruction] Tajiri H, et al.
Ryoikibetsu Shokogun Shirizu 1995;(7):569–70 (9 ref.) **(Jpn)**

GENETICS

Arthrogryposis, renal dysfunction and cholestasis syndrome: report of five patients from three Italian families. Di Rocco M, et al. **Eur J Pediatr** 1995 Oct;154(10):835–9 (8 ref.)
[Familial benign chronic intrahepatic cholestasis] Tazawa Y.
Ryoikibetsu Shokogun Shirizu 1995;(7):547–9 (10 ref.) **(Jpn)**

METABOLISM

Hepatocellular cholestasis: pathobiology and histological outcome. Green RM, et al. **Semin Liver Dis** 1995 Nov; 15(4):372–89 (217 ref.)

PATHOLOGY

Canalicular cholestasis due to amiodarone toxicity. A definite diagnosis obtained by electron microscopy. Macarri G, et al. **Ital J Gastroenterol** 1995 Oct–Nov;27(8):436–8 (18 ref.)
Hepatocellular cholestasis: pathobiology and histological outcome. Green RM, et al. **Semin Liver Dis** 1995 Nov; 15(4):372–89 (217 ref.)

PHYSIOPATHOLOGY

Cholestasis: pathophysiology and pathobiochemistry. Krell H, et al. **Z Gastroenterol** 1993 Feb;31 Suppl 2:11–5 (58 ref.)
[Cholestatic erythrohepatic protoporphyria: porphyrin metabolism before and after liver transplantation] Doss MO, et al. **Z Gastroenterol** 1993 Feb;31 Suppl 2:85–9 (31 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

[Percutaneous treatment of malignant stenoses of the hilum] Bonnel D, et al. **Gastroenterol Clin Biol** 1995 Jun–Jul; 19(6–7):564–71 (24 ref.) (Eng. Abstr.) **(Fre)**
[Treatment of tumoral stenoses of the hepatic hilum (editorial)] Valette PJ. **Gastroenterol Clin Biol** 1995 Jun–Jul;19(6–7):561–3 (17 ref.) **(Fre)**

THERAPY

Diagnosis and therapy of cholestatic liver disease. Pasha TM, et al. **Med Clin North Am** 1996 Sep;80(5):995–1019 (108 ref.)

ULTRASONOGRAPHY

[Status of ultrasound diagnosis in differential cholestasis diagnosis] Busse HJ, et al. **Z Gastroenterol** 1993 Feb;31 Suppl 2:39–41 (25 ref.) (Eng. Abstr.) **(Ger)**

CHOLESTEATOMA

ETIOLOGY

Fibrous dysplasia of the temporal bone: ten new cases demonstrating the spectrum of otologic sequelae. Megerian CA, et al. **Am J Otol** 1995 Jul;16(4):408–19 (49 ref.)

PHYSIOPATHOLOGY

Preservation of cochlear function after extensive labyrinthine destruction. Ars B, et al. **Am J Otol** 1996 Jan;17(1):40–5 (49 ref.)

SURGERY

A surgical solution for the difficult chronic ear. Jackson CG, et al. **Am J Otol** 1996 Jan;17(1):7–14 (8 ref.)

CHOLESTEATOMA, MIDDLE EAR

COMPLICATIONS

Labyrinthine fistulae. Vantrappen G, et al.
Acta Otorhinolaryngol Belg 1996;50(1):63–8 (13 ref.)

CONGENITAL

[Congenital cholesteatoma and associated ossicular malformations] el Jerrari A, et al.
Ann Otolaryngol Chir Cervicofac 1995;112(6):258–61 (22 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Epitympanic compartment surgical considerations: reevaluation. Palva T, et al. **Am J Otol** 1995 Jul; 16(4):505–13 (24 ref.)

PHYSIOPATHOLOGY

High levels of fibronectin in the stroma of aural cholesteatoma. Schilling V, et al. **Am J Otolaryngol** 1995 Jul–Aug;16(4):232–5 (28 ref.)

SURGERY

[Audiometric results of 81 ossiculoplasties after tympanoplasty with closed technique in chronic cholesteatomatous otitis] Caprio D, et al.
Ann Otolaryngol Chir Cervicofac 1995;112(3):107–17 (16 ref.) (Eng. Abstr.) **(Fre)**
[Modern aspects of tympanoplasty. An overview] Helms J. **Laryngorhinootologie** 1995 Aug;74(8):465–7 (14 ref.) (Eng. Abstr.) **(Ger)**

CHOLESTEROL

see related
EMBOLISM, CHOLESTEROL
HYPERCHOLESTEROLEMIA

Calcium pyrophosphate crystal deposition disease and other crystal deposition diseases. Fam AG.
Curr Opin Rheumatol 1995 Jul;7(4):364–8 (32 ref.)

ANALYSIS

Chromatographic methods in the analysis of cholesterol and related lipids. Hoving EB.
J Chromatogr B Biomed Appl 1995 Sep 15;671(1–2):341–62 (113 ref.)
[Cholesterol gallstone--symptoms, diagnosis and treatments] Abei M, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):400–3 (7 ref.) **(Jpn)**

BIOSYNTHESIS

Oxylanosterols as modifiers of cholesterol biosynthesis. Trzaskos JM. **Prog Lipid Res** 1995;34(2):99–116 (28 ref.)

BLOOD

What benefit can be derived from treating normocholesterolemic patients with coronary artery disease? Brown G, et al. **Am J Cardiol** 1995 Sep 28; 76(9):93C–97C (20 ref.)
Range of serum cholesterol values in the population developing coronary artery disease. Kannel WB.
Am J Cardiol 1995 Sep 28;76(9):69C–77C (47 ref.)
Cholesterol screening in asymptomatic adults, revisited. Part 2 [see comments] Garber AM, et al. **Ann Intern Med** 1996 Mar 1;124(5):518–31 (121 ref.) Comment in: Ann Intern Med 1996 Mar 1;124(5):505–8. Comment in: Ann Intern Med 1996 Mar 1;124(5):513–4.
Cholesterol reduction: weighing the benefits and risks. Gaziano JM, et al. **Ann Intern Med** 1996 May 15; 124(10):914–8 (29 ref.)
The genetic determinants of plasma cholesterol and response to diet. Humphries SE, et al.
Baillieres Clin Endocrinol Metab 1995 Oct;9(4):797–823 (148 ref.)
Role of dietary fish protein in the regulation of plasma lipids. Jacques H, et al. **Can J Cardiol** 1995 Oct;11 Suppl G:63G–71G (45 ref.)
Anticarcinogenic, hypocholesterolemic, and antagonistic activities of Lactobacillus acidophilus. Mital BK, et al.
Crit Rev Microbiol 1995;21(3):175–214 (371 ref.)
The 4S study. Implications for prescribing. van Boven AJ, et al. **Drugs** 1996 Apr;51(4):507–14 (55 ref.)
Dietary fibre and plasma lipids. Truswell AS.
Eur J Clin Nutr 1995 Oct;49 Suppl 3:S105–9 (30 ref.)
Cholesterol in patients with coronary heart disease: how low should we go? Rubins HB. **J Gen Intern Med** 1995 Aug; 10(8):464–71 (45 ref.)
Should cholesterol be measured in all hypertensives? Haq IU, et al. **J Hum Hypertens** 1995 Jun;9(6):417–21 (41 ref.)
Cholesterol and psychological well-being. Wardle J.
J Psychosom Res 1995 Jul;39(5):549–62 (72 ref.)
Why are lipids not predictive of cardiovascular death in the dialysis patient? Ritz E. **Miner Electrolyte Metab** 1996; 22(1–3):9–12 (25 ref.)
The effects of dietary change on serum cholesterol. Haq IU, et al. **Proc Nutr Soc** 1996 Nov;54(3):601–16 (80 ref.)
Atherosclerotic lesions in humans--plaque stabilization and regression. Kritz H, et al. **Wien Klin Wochenschr** 1995; 107(18):555–66 (60 ref.)
ACAT/CEH and ACEH/LAL: two key enzymes in hepatic cellular cholesterol homeostasis and their involvement in genetic disorders. Schmitz G, et al. **Z Gastroenterol** 1996 Jun;34 Suppl 3:68–72 (19 ref.)
[Decrease in plasma cholesterol and regression of atherosclerosis] Wang Y, et al.
Chung Hua Nei Ko Tsa Chih 1995 Aug;34(8):561–4 (21 ref.) **(Chi)**
[Drug therapy of hypercholesterolemia] Schwandt P, et al. **Wien Klin Wochenschr** 1995;107(18):544–8 (64 ref.) (Eng. Abstr.) **(Ger)**
[1995 consensus guidelines for cholesterol. Society of

Physicians in Vienna] Sinzinger H, et al. **Wien Klin Wochenschr** 1995;107(18):537–9 (5 ref.) **(Ger)**

[Radical therapy of refractory hyperlipidemia: extracorporeal cholesterol elimination] Kostner KM. **Wien Med Wochenschr** 1994;144(12–13):333–5 (13 ref.) (Eng. Abstr.) **(Ger)**

[Reverse cholesterol transport] Schmidt HH, et al. **Z Gastroenterol** 1996 Jun;34(6):386–91 (69 ref.) **(Ger)**

[Cholesterol] Uji Y, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:615–6 (7 ref.) **(Jpn)**

[Low concentration level of total serum cholesterol as a risk factor for suicidal and aggressive behavior] Ainiyet J, et al. **Psychiatr Pol** 1996 May–Jun;30(3):499–509 (31 ref.) (Eng. Abstr.) **(Pol)**

[The value of the treatment of dyslipidemias in the prognosis of patients with coronary artery disease] Giannini SD, et al. **Arq Bras Cardiol** 1995 Sep;65(3):297–9 (42 ref.) **(Por)**

[The effect of a reduction in plasma cholesterol on the evolution of coronary disease] Fernández-Avilés F, et al. **Rev Esp Cardiol** 1995;48 Suppl 5:43–51 (36 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

The genetic determinants of plasma cholesterol and response to diet. Humphries SE, et al. **Baillieres Clin Endocrinol Metab** 1995 Oct;9(4):797–823 (148 ref.)

IMMUNOLOGY

Anticholesterol antibodies and plaque formation. Ordovas JM. **Nutr Rev** 1996 Apr;54(4 Pt 1):124–7 (28 ref.)

ISOLATION & PURIFICATION

Cholesterol nucleation in bile. Holzbach RT. **Ital J Gastroenterol** 1995 Mar;27(2):101–5 (38 ref.)

METABOLISM

Is reverse cholesterol transport a misnomer for suggesting its role in the prevention of atheroma formation? Quintão EC. **Atherosclerosis** 1995 Jul;116(1):1–14 (162 ref.)

Role of the steroidogenic acute regulatory protein (StAR) in steroidogenesis. Stocco DM, et al. **Biochem Pharmacol** 1996 Feb 9;51(3):197–205 (125 ref.)

Phospholipid vesicles and other cholesterol carriers in bile. Gilat T, et al. **Biochim Biophys Acta** 1996 Jun 10; 1286(2):95–115 (108 ref.)

Cholesteryl ester transfer proteins, reverse cholesterol transport, and atherosclerosis. Bruce C, et al. **Curr Opin Lipidol** 1995 Oct;6(5):306–11 (47 ref.)

Structure of cholesterol–containing particles accumulating in atherosclerotic lesions and the mechanisms of their derivation. Hoff HF, et al. **Curr Opin Lipidol** 1995 Oct; 6(5):317–25 (91 ref.)

Apolipoprotein A–I–containing lipoproteins and atherosclerosis. Leroy A, et al. **Curr Opin Lipidol** 1995 Oct; 6(5):281–5 (36 ref.)

Anatomical heterogeneity of the intestinal mucosa and cholesterol homeostasis. A review of studies with normal and genetically hypercholesterolemic (RICO) Rat. Lutton C. **Digestion** 1996;57(1):1–10 (40 ref.)

Suggested sterol–binding mechanisms of dietary fibre based on ileostomy studies. Andersson H. **Eur J Clin Nutr** 1995 Oct;49 Suppl 3:S173–7 (39 ref.)

Cholesterol homeostasis: role of the LDL receptor. Javitt NB. **FASEB J** 1995 Oct;9(13):1378–81 (30 ref.)

Cholesterol and the coronary endothelium. Knight CJ, et al. **J Cardiovasc Risk** 1995 Jun;2(3):180–8 (60 ref.)

Cholesterol gallstone formation in man and potential treatments of the gallbladder motility defect. Portincasa P, et al. **Scand J Gastroenterol Suppl** 1995;212:63–78 (294 ref.)

Cholesterol and cataracts. Cenedella RJ. **Surv Ophthalmol** 1996 Jan–Feb;40(4):320–37 (158 ref.)

[From cholesterol to oxysterols. Current data] Luu B. **C R Seances Soc Biol Fil** 1995;189(5):827–37 (28 ref.) (Eng. Abstr.) **(Fre)**

[Insulin, diabetes and cholesterol metabolism] Monnier L, et al. **C R Seances Soc Biol Fil** 1995;189(5):919–31 (27 ref.) (Eng. Abstr.) **(Fre)**

[Cholesterosis (cholesterolosis) of the gallbladder] Noda A, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):444–7 (10 ref.) **(Jpn)**

[Cholesterol polyp] Taira A, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):280–2 (8 ref.) **(Jpn)**

[Transport of cholesterol by high density lipoproteins from the standpoint of protein biochemistry] Titov VN. **Vopr Med Khim** 1995 May–Jun;41(3):2–8 (85 ref.) **(Rus)**

[Hepatic metabolism of cholesterol] García Mediavilla V, et al. **Nutr Hosp** 1996 Jan–Feb;11(1):37–42 (43 ref.) (Eng. Abstr.) **(Spa)**

PHARMACOLOGY

Biological effects of oxysterols: current status. Guardiola F, et al. **Food Chem Toxicol** 1996 Feb;34(2):193–211 (215 ref.)

CHOLESTEROL ACYLTRANSFERASE

GENETICS

ACAT/CEH and ACEH/LAL: two key enzymes in hepatic cellular cholesterol homeostasis and their involvement in genetic disorders. Schmitz G, et al. **Z Gastroenterol** 1996 Jun;34 Suppl 3:68–72 (19 ref.)

CHOLESTEROL DESMOLASE

METABOLISM

Mitochondrial specificity of the early steps in steroidogenesis. Miller WL. **J Steroid Biochem Mol Biol** 1995 Dec; 55(5–6):607–16 (114 ref.)

CHOLESTEROL, DIETARY

see related
HYPERCHOLESTEROLEMIA
HYPERCHOLESTEROLEMIA, FAMILIAL

ADMINISTRATION & DOSAGE

Dietary cholesterol and the optimal diet for reducing risk of atherosclerosis. McNamara DJ. **Can J Cardiol** 1995 Oct; 11 Suppl G:123G–126G (13 ref.)

[Dietary treatment of hypercholesterolemia] Richter WO. **Wien Klin Wochenschr** 1995;107(18):549–54 (83 ref.) (Eng. Abstr.) **(Ger)**

BLOOD

Apolipoprotein E polymorphism and dietary plasma cholesterol response. Tikkanen M, et al. **Can J Cardiol** 1995 Oct;11 Suppl G:93G–96G (25 ref.)

CHOLESTEROL EMBOLISM see **EMBOLISM, CHOLESTEROL**

CHOLESTEROL ESTER STORAGE DISEASE

[Acid lipase deficiency: Wolman disease and cholesteryl ester storage disease] Tanaka A. **Nippon Rinsho** 1995 Dec; 53(12):3004–8 (10 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

ACAT/CEH and ACEH/LAL: two key enzymes in hepatic cellular cholesterol homeostasis and their involvement in genetic disorders. Schmitz G, et al. **Z Gastroenterol** 1996 Jun;34 Suppl 3:68–72 (19 ref.)

CHOLESTEROL ESTERS

BIOSYNTHESIS

The stimulation of the cholesterol esterification pathway by atherogenic lipoproteins in macrophages. Tabas I. **Curr Opin Lipidol** 1995 Oct;6(5):260–8 (112 ref.)

BLOOD

[Reverse cholesterol transport] Schmidt HH, et al. **Z Gastroenterol** 1996 Jun;34(6):386–91 (69 ref.) **(Ger)**

[Role of cholesterol esters in triglyceride transport] Titov VN. **Biokhimiia** 1995 Sep;60(9):1371–81 (40 ref.) (Eng. Abstr.) **(Rus)**

METABOLISM

A docking receptor for HDL cholesterol esters [comment] Steinberg D. **Science** 1996 Jan 26;271(5248):460–1 (15 ref.) Comment on: Science 1996 Jan 26;271(5248):518–20.

CHOLESTEROL HDL see **LIPOPROTEINS, HDL CHOLESTEROL**

CHOLESTEROL INHIBITORS see **ANTICHOLESTEREMIC AGENTS**

CHOLESTEROL LDL see **LIPOPROTEINS, LDL CHOLESTEROL**

CHOLESTEROL SIDE–CHAIN CLEAVAGE ENZYME see **CHOLESTEROL DESMOLASE**

CHOLINE

ANALOGS & DERIVATIVES

The AF64A model of cholinergic hypofunction: an update. Hanin I. **Life Sci** 1996;58(22):1955–64 (66 ref.)

BIOSYNTHESIS

Regulatory mechanisms of choline production. Freeman JJ. **Life Sci** 1996;58(22):1921–7 (40 ref.)

METABOLISM

Continuing the search for cholinergic factors in cognitive dysfunction. Russell RW. **Life Sci** 1996;58(22):1965–70 (15 ref.)

PHARMACOLOGY

Antioxidants, carnitine, and choline as putative ergogenic aids. Kanter MM, et al. **Int J Sport Nutr** 1995 Jun;5 Suppl:S120–31 (73 ref.)

CHOLINE ACETYLASE see **CHOLINE ACETYLTRANSFERASE**

CHOLINE ACETYLTRANSFERASE

METABOLISM

Cholinergic signaling in the rat pineal gland. Laitinen JT, et al. **Cell Mol Neurobiol** 1995 Apr;15(2):177–92 (72 ref.)

Overexpression of choline acetyltransferase reconstitutes discrete acetylcholine release in some but not all synapse formation–defective neuroblastoma cells. Zhong ZG, et al. **J Physiol Paris** 1995;89(3):137–45 (40 ref.)

CHOLINE CHLORIDE DIHYDROGEN PHOSPHATE see **PHOSPHORYLCHOLINE**

CHOLINE DEFICIENCY

METABOLISM

New insight into the biochemical pathology of liver in choline deficiency. Ghoshal AK. **Crit Rev Biochem Mol Biol** 1995;30(4):263–73 (42 ref.)

The AF64A model of cholinergic hypofunction: an update. Hanin I. **Life Sci** 1996;58(22):1955–64 (66 ref.)

CHOLINE KINASE

[Biological roles of choline kinase] Uchida T. **Seikagaku** 1996 Mar;68(3):205–10 (20 ref.) **(Jpn)**

CHOLINE PHOSPHATE CHLORIDE see **PHOSPHORYLCHOLINE**

CHOLINERGIC AGENTS

see related
BOTULINUM TOXINS

IMMUNOLOGY

Cholinergic–specific glycoconjugates. Whittaker VP, et al. **Neurochem Res** 1995 Nov;20(11):1377–87 (47 ref.)

THERAPEUTIC USE

Clinical heterogeneity: responders to cholinergic therapy. Eagger SA, et al. **Alzheimer Dis Assoc Disord** 1995;9 Suppl 2:37–42 (72 ref.)

TOXICITY

Potential animal model of multiple chemical sensitivity with cholinergic supersensitivity. Overstreet DH, et al. **Toxicology** 1996 Jul 17;111(1–3):119–34 (101 ref.)

CHOLINERGIC AGONISTS

THERAPEUTIC USE

The pharmacotherapy of Alzheimer's disease based on the cholinergic hypothesis: an update. Weinstock M. **Neurodegeneration** 1995 Dec;4(4):349–56 (82 ref.)

[Dementias: present situation and future perspectives (III). Neurological, therapeutic, psychosocial aspects and patient care] Espert R, et al. **Rev Neurol** 1995 Jan–Feb; 23(119):86–95 (138 ref.) (Eng. Abstr.) **(Spa)**

CHOLINERGIC AGONISTS, MUSCARINIC see **MUSCARINIC AGONISTS**

CHOLINERGIC ANTAGONISTS

ADMINISTRATION & DOSAGE

[Bladder dysfunctions in encephalomyelitis disseminata—drug and interventional therapeutic options] Zwergel U, et al. **Fortschr Neurol Psychiatr** 1995 Dec; 63(12):495–503 (125 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Acetylcholine and hallucinations: disease–related compared to drug–induced alterations in human consciousness. Perry EK, et al. **Brain Cogn** 1995 Aug;28(3):240–58 (65 ref.)

PHARMACOLOGY

Acetylcholine and hallucinations: disease–related compared to drug–induced alterations in human consciousness. Perry EK, et al. **Brain Cogn** 1995 Aug;28(3):240–58 (65 ref.)

Noncompetitive inhibitors of the acetylcholine receptor help paint a picture of its ion channel. Eterovic VA, et al. **P R Health Sci J** 1995 Sep;14(3):199–209 (71 ref.)

THERAPEUTIC USE

Drug therapy of peptic ulcer disease. Ching CK, et al. **Br J Hosp Med** 1995 Jul 12–Aug 15;54(2–3):101–6 (39 ref.)

The pharmacological treatment of Menière's disease. Brookes

GB. **Clin Otolaryngol** 1996 Feb;21(1):3–11 (78 ref.)
Infantile colic: natural history and treatment. Lehtonen LA, et al. **Curr Probl Pediatr** 1996 Mar;26(3):79–85 (78 ref.)

CHOLINERGIC-BLOCKING AGENTS see **CHOLINERGIC ANTAGONISTS**

CHOLINERGIC FIBERS

DRUG EFFECTS

Cognitive enhancement. New strategies for stimulating cholinergic, glutamatergic, and nitric oxide systems. Ingram DK, et al. **Ann N Y Acad Sci** 1996 Jun 15; 786:348–61 (80 ref.)

PHYSIOLOGY

A computational model of cholinergic disruption of septohippocampal activity in classical eyeblink conditioning. Myers CE, et al. **Neurobiol Learn Mem** 1996 Jul;66(1):51–66 (90 ref.)

CHOLINERGIC RECEPTORS see **RECEPTORS, CHOLINERGIC**

CHOLINESTERASE INHIBITORS

see related
INSECTICIDES, ORGANOPHOSPHATE
INSECTICIDES, ORGANOTHIOPHOSPHATE

ADVERSE EFFECTS

Cholinesterase inhibition: complexities in interpretation. Lotti M. **Clin Chem** 1995 Dec;41(12 Pt 2):1814–8 (22 ref.)
Neuropsychopathological changes by organophosphorus compounds—a review. Eyer P. **Hum Exp Toxicol** 1995 Nov;14(11):857–64 (76 ref.)

PHARMACOKINETICS

Clinical pharmacokinetics of drugs for Alzheimer's disease. Parnetti L. **Clin Pharmacokinet** 1995 Aug;29(2):110–29 (111 ref.)

PHARMACOLOGY

The pharmacology of galanthamine and its analogues. Harvey AL. **Pharmacol Ther** 1995;68(1):113–28 (100 ref.)
Structural bases for the specificity of cholinesterase catalysis and inhibition. Taylor P, et al. **Toxicol Lett** 1995 Dec; 82–83:453–8 (20 ref.)

POISONING

A review of nonpesticide phosphate ester–induced neurotoxicity in cattle. Coppock RW, et al.
Vet Hum Toxicol 1995 Dec;37(6):576–9 (20 ref.)

THERAPEUTIC USE

Clinical pharmacokinetics of drugs for Alzheimer's disease. Parnetti L. **Clin Pharmacokinet** 1995 Aug;29(2):110–29 (111 ref.)
Alzheimer's disease: the role of tacrine therapy. Jogerst G. **Iowa Med** 1995 Oct;85(10):409–11 (0 ref.)
The pharmacotherapy of Alzheimer's disease based on the cholinergic hypothesis: an update. Weinstock M.
Neurodegeneration 1995 Dec;4(4):349–56 (82 ref.)
[New therapeutic prospects in Alzheimer disease] Rouhart F. **Rev Med Interne** 1995;16(11):860–3 (28 ref.) (Eng. Abstr.) **(Fre)**
[Dementias: present situation and future perspectives (III). Neurological, therapeutic, psychosocial aspects and patient care] Espert R, et al. **Rev Neurol** 1995 Jan–Feb; 23(119):86–95 (138 ref.) (Eng. Abstr.) **(Spa)**

TOXICITY

Engineering of human cholinesterases explains and predicts diverse consequences of administration of various drugs and poisons. Schwarz M, et al. **Pharmacol Ther** 1995; 67(2):283–322 (198 ref.)
Effects of myotoxins on skeletal muscle fibers. Khan MA. **Prog Neurobiol** 1995 Aug;46(5):541–60 (230 ref.)
Regulatory and research issues related to cholinesterase inhibition. Padilla S. **Toxicology** 1995 Sep 1;102(1–2):215–20 (29 ref.)

CHOLINESTERASES

BLOOD

Catalytic properties and distribution profiles of paraoxonase and cholinesterase phenotypes in human sera. Reiner E, et al. **Toxicol Lett** 1995 Dec;82–83:447–52 (24 ref.)
[Cholinesterase] Nakamura S. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:292–5 (16 ref.) **(Jpn)**

CHEMISTRY

Structural bases for the specificity of cholinesterase catalysis and inhibition. Taylor P, et al. **Toxicol Lett** 1995 Dec; 82–83:453–8 (20 ref.)

DRUG EFFECTS

The study of interactive effects of pollutants: a biomarker approach. Johnston G. **Sci Total Environ** 1995 Oct 27; 171(1–3):205–12 (18 ref.)

GENETICS

Genetic predisposition in occupational toxicology. Bolt HM. **Arch Toxicol Suppl** 1996;18:362–6 (32 ref.)
Engineering of human cholinesterases explains and predicts diverse consequences of administration of various drugs and poisons. Schwarz M, et al. **Pharmacol Ther** 1995; 67(2):283–322 (198 ref.)

PHYSIOLOGY

Novel functions of cholinesterases in development, physiology and disease. Layer PG, et al.
Prog Histochem Cytochem 1995;29(3):1–94 (465 ref.)

CHOLINOCEPTIVE SITES see **RECEPTORS, CHOLINERGIC**

CHOLINOCEPTORS see **RECEPTORS, CHOLINERGIC**

CHOLINOLYTICS see **CHOLINERGIC ANTAGONISTS**

CHOLINOMIMETICS see **CHOLINERGIC AGENTS**

CHONDRITIS, COSTAL see **TIETZE'S SYNDROME**

CHONDROBLASTOMA

SURGERY

Chondromyxoid fibroma of a metacarpal: a case report and review of the literature. Strauch RJ, et al.
J Hand Surg [Am] 1996 Mar;21(2):293–5 (6 ref.)

CHONDROCALCINOSIS

Calcium pyrophosphate crystal deposition disease and other crystal deposition diseases. Fam AG.
Curr Opin Rheumatol 1995 Jul;7(4):364–8 (32 ref.)
Calcium pyrophosphate dihydrate crystal deposition disease revisited. Steinbach LS, et al. **Radiology** 1996 Jul;200(1):1–9 (74 ref.)

CHONDRODYSPLASIA, HEREDITARY DEFORMING see **EXOSTOSES, MULTIPLE HEREDITARY**

CHONDRODYSPLASIA PUNCTATA

CHEMICALLY INDUCED

Prenatal exposure to phenytoin, facial development, and a possible role for vitamin K. Howe AM, et al.
Am J Med Genet 1995 Sep 11;58(3):238–44 (52 ref.)

GENETICS

Chondrodysplasia punctata: case report and literature review of patients with heart lesions. Fourie DT.
Pediatr Cardiol 1995 Sep–Oct;16(5):247–50 (33 ref.)

CHONDRODYSPLASIA PUNCTATA, RHIZOMELIC

PATHOLOGY

Rhizomelic chondrodysplasia punctata: report of a case with review of the literature and correlation with other peroxisomal disorders. Agamanolis DP, et al.
Pediatr Pathol Lab Med 1995 May–Jun;15(3):503–13 (25 ref.)

CHONDRODYSTROPHIA CALCIFICANS CONGENITA see **CHONDRODYSPLASIA PUNCTATA**

CHONDROECTODERMAL DYSPLASIA see **ELLIS-VAN CREVELD SYNDROME**

CHONDROITIN

BIOSYNTHESIS

Cell surface chondroitin sulfate proteoglycans in tumor cell adhesion, motility and invasion. Iida J, et al.
Semin Cancer Biol 1996 Jun;7(3):155–62 (64 ref.)

CHONDROITIN SULFATE A see **CHONDROITIN SULFATES**

CHONDROITIN SULFATE B see **DERMATAN SULFATE**

CHONDROITIN SULFATE C see **CHONDROITIN SULFATES**

CHONDROITIN SULFATES

ANALYSIS

Anabolic and catabolic markers of proteoglycan metabolism in osteoarthritis. Caterson B, et al.
Acta Orthop Scand Suppl 1995 Oct;266:121–4 (32 ref.)

CHEMISTRY

Changes in chondroitin sulphate structure induced by joint disease. Hardingham T. **Acta Orthop Scand Suppl** 1995 Oct; 266:107–10 (13 ref.)

IMMUNOLOGY

Immunology of chondroitin/dermatan sulfate. Hascall VC, et al. **Adv Exp Med Biol** 1995;376:205–16 (34 ref.)

CHONDROMA

DIAGNOSIS

Soft tissue chondroma of the neck: a case report and review of the literature. Kamysz JW, et al. **Pediatr Radiol** 1996; 26(2):145–7 (14 ref.)

PATHOLOGY

Childhood soft tissue chondroma: a case report. Pollock L, et al. **Pediatr Pathol Lab Med** 1995 May–Jun;15(3):437–41 (6 ref.)

CHONDROMATOSIS, SYNOVIAL

Synovial osteochondromatosis. Crotty JM, et al.
Radiol Clin North Am 1996 Mar;34(2):327–42, xi (71 ref.)

SURGERY

[Reichel syndrome. A case report with review of the literature] Kotter A, et al. **Chirurg** 1996 May;67(5):556–9 (36 ref.) (Eng. Abstr.) **(Ger)**

ULTRASONOGRAPHY

Synovial osteochondromatosis of the distal radioulnar joint: ultrasound diagnosis. Leekam RN, et al.
J Clin Ultrasound 1996 May;24(4):207–8 (10 ref.)

CHONDROSARCOMA

DIAGNOSIS

[Cartilaginous tumors and other cutaneous lesions] Cribier B, et al. **Ann Dermatol Venereol** 1996;123(1):40–52 (80 ref.) **(Fre)**

GENETICS

t(9;22)(q22–31;q11–12) is a consistent marker of extraskeletal myxoid chondrosarcoma: evaluation of three cases. Sciot R, et al. **Mod Pathol** 1995 Sep;8(7):765–8 (19 ref.)

PATHOLOGY

Chondrosarcoma: a review. Springfield DS, et al.
Instr Course Lect 1996;45:417–24 (38 ref.)

SURGERY

[Chondrosarcoma of the skull base. Apropos of sphenotemporal localization and review of the literature] Roche PH, et al. **Neurochirurgie** 1995;41(5):353–8 (34 ref.) (Eng. Abstr.) **(Fre)**

CHONDROSARCOMA, MESENCHYMAL

Mesenchymal chondrosarcoma of the foot, an unusual location: case report and review of the literature. Sans M, et al. **Med Pediatr Oncol** 1996 Feb;26(2):139–42 (12 ref.)

PATHOLOGY

Mesenchymal chondrosarcoma: a clinicopathologic and flow cytometric study of 13 cases presenting in the central nervous system. Rushing EJ, et al. **Cancer** 1996 May 1; 77(9):1884–91 (36 ref.)

CHONDROSTEOMA see **OSTEOCHONDROMA**

CHORDAE TENDINEAE

Papillary fibroelastoma of the mitral valve. A rare cause of embolic events. Colucci V, et al. **Tex Heart Inst J** 1995; 22(4):327–31 (31 ref.)

INJURIES

[Morphological study by transesophageal echocardiography and clinical aspects of ruptured chordae tendineae in the elderly] Benhalima B, et al. **Arch Mal Coeur Vaiss** 1995 Mar;88(3):345–52 (29 ref.) (Eng. Abstr.) **(Fre)**

CHORDATA

GENETICS

Hox genes and chordate evolution. Holland PW, et al.
Dev Biol 1996 Feb 1;173(2):382–95 (75 ref.)

GROWTH & DEVELOPMENT

Chasing tails in ascidians: developmental insights into the

origin and evolution of chordates. Satoh N, et al. **Trends Genet** 1995 Sep;11(9):354–9 (44 ref.)

CHORDOMA

Chondroid chordoma of the lateral skull base. Kaufman BA, et al. **Pediatr Neurosurg** 1995;23(3):159–65 (44 ref.)

DIAGNOSIS

Chordoma of the lower cervical spine. D'Haen B, et al. **Clin Neurol Neurosurg** 1995 Aug;97(3):245–8 (20 ref.)

DRUG THERAPY

Chemotherapeutic treatment of malignant chordoma in children. Scimeca PG, et al. **J Pediatr Hematol Oncol** 1996 May;18(2):237–40 (10 ref.)

PATHOLOGY

Chordoid tumor: a light, electron microscopic, and immunohistochemical study. Carstens PH. **Ultrastruct Pathol** 1995 Jul–Aug;19(4):291–5 (22 ref.)

[A rare case of chondroid chordoma of the cervical spine] Sarrazin JL, et al. **J Radiol** 1996 Feb;77(2):141–4 (13 ref.) (Eng. Abstr.) **(Fre)**

SECONDARY

Sacrococcygeal chordoma metastatic to the brain with review of the literature. Hall WA, et al. **J Neurooncol** 1995; 25(2):155–9 (16 ref.)

SURGERY

Radical resection of anterior skull base tumors. Lawton MT, et al. **Clin Neurosurg** 1995;42:43–70 (62 ref.)

Cranial chordomas in children and adolescents. Borba LA, et al. **J Neurosurg** 1996 Apr;84(4):584–91 (57 ref.)

CHOREA

COMPLICATIONS

[Sydenham rheumatic chorea] Rodríguez Ormazabal J. **Rev Neurol** 1995;23 Suppl 3:S334–8 (79 ref.) **(Spa)**

DIAGNOSIS

[Chorea and athetosis in childhood] Fernández-Alvarez E. **Rev Neurol** 1995;23 Suppl 3:S330–3 (59 ref.) **(Spa)**

[Sydenham rheumatic chorea] Rodríguez Ormazabal J. **Rev Neurol** 1995;23 Suppl 3:S334–8 (79 ref.) **(Spa)**

GENETICS

[Choreoacanthocytosis. A neurologic-hematologic syndrome] Hiersemenzel LP, et al. **Nervenarzt** 1996 Jun; 67(6):490–5 (39 ref.) (Eng. Abstr.) **(Ger)**

PSYCHOLOGY

[A case of hemichorea presenting with inattention and denial of involuntary movement] Ichikawa H, et al. **Rinsho Shinkeigaku** 1995 Nov;35(11):1230–4 (15 ref.) (Eng. Abstr.) **(Jpn)**

CHOREA, HEREDITARY see HUNTINGTON'S DISEASE

CHORIOAMNIONITIS

COMPLICATIONS

Delayed interval delivery after intrauterine infection and immature birth of twin 1—a case report and literature review. de Jong MW, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Nov;63(1):91–4 (29 ref.)

Sepsis during pregnancy. Simpson KR. **J Obstet Gynecol Neonatal Nurs** 1995 Jul–Aug;24(6):550–6 (26 ref.)

ETHNOLOGY

Race, perinatal outcome, and amniotic infection. Fiscella K. **Obstet Gynecol Surv** 1996 Jan;51(1):60–6 (54 ref.)

IMMUNOLOGY

[Intra-amniotic infection, cytokines and premature labor] Baumann P, et al. **Wien Klin Wochenschr** 1995; 107(20):598–607 (102 ref.) (Eng. Abstr.) **(Ger)**

MICROBIOLOGY

[Does asymptomatic amniotic infection in the second trimester really exist?] Montuclard B, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(2):186–91 (17 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

[Prevention of infection and therapy of premature labor] Martius J. **Arch Gynecol Obstet** 1995;257(1–4):451–7 (35 ref.) **(Ger)**

CHORIOANGIOMA see HEMANGIOMA

CHORIOCARCINOMA

[Primary hepatic choriocarcinoma] Takemori Y, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):378–80 (18 ref.) **(Jpn)**

DIAGNOSIS

A case of microscopic testicular tumour. Shoji N, et al. **Int Urol Nephrol** 1995;27(2):189–91 (5 ref.)

[Choriocarcinoma] Wierzchniewska A, et al. **Ginekol Pol** 1995 Sep;66(9):537–40 (23 ref.) (Eng. Abstr.) **(Pol)**

[Large-cell lung carcinoma producing chorionic gonadotropin hormone: the difficulty in its differential diagnosis from choriocarcinoma] Cremades Romero MJ, et al. **Arch Bronconeumol** 1996 May;32(5):253–5 (10 ref.) (Eng. Abstr.) **(Spa)**

SECONDARY

Choriocarcinoma presenting as a breast lump. Fowler CA, et al. **Eur J Surg Oncol** 1995 Oct;21(5):576–8 (14 ref.)

SURGERY

Resection of an unsuspected primary pulmonary choriocarcinoma. Canver CC, et al. **Ann Thorac Surg** 1996 Apr;61(4):1249–51 (8 ref.)

[Primary retroperitoneal pure choriocarcinoma] Okubo Y, et al. **Nippon Hinyokika Gakkai Zasshi** 1995 Dec; 86(12):1784–8 (14 ref.) (Eng. Abstr.) **(Jpn)**

THERAPY

[Choriocarcinoma] Wierzchniewska A, et al. **Ginekol Pol** 1995 Sep;66(9):537–40 (23 ref.) (Eng. Abstr.) **(Pol)**

CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN

ANALYSIS

Clinical applications of urinary gonadotropin peptides (UGP) in gynecologic oncology. Schwartz PE, et al. **Anticancer Res** 1996 Jul–Aug;16(4B):2135–9 (35 ref.)

CHORIONIC GONADOTROPIN RECEPTORS see RECEPTORS, LH

CHORIONIC SOMATOMAMMOTROPIN, HUMAN see PLACENTAL LACTOGEN

CHORIONIC VILLI SAMPLING

-Amniocentesis or chorionic villi sampling--when and why?- Hebisch G. **Arch Gynecol Obstet** 1995;256 Suppl:S182–92 (17 ref.) **(Ger)**

METHODS

[Reliability of invasive prenatal diagnosis in the first trimester in comparison with standard amniocentesis] Crombach G, et al. **Gynakologe** 1995 Oct;28(5):302–14 (93 ref.) **(Ger)**

CHORIORETINITIS

ETIOLOGY

[Chorioretinal manifestations in AIDS] Snyers B, et al. **J Fr Ophtalmol** 1995;18(10):634–44 (76 ref.) **(Fre)**

PARASITOLOGY

Reactivation toxoplasmic retinochoroiditis in patients undergoing bone marrow transplantation: is there a role for chemoprophylaxis? Peacock JE Jr, et al. **Bone Marrow Transplant** 1995 Jun;15(6):983–7 (23 ref.)

Ocular toxoplasmosis: toxoplasmic retinochoroiditis. Tabbara KF. **Int Ophthalmol Clin** 1995 Spring;35(2):15–29 (29 ref.)

CHORISTOMA

Ectopic ureter opening into the seminal vesicle in an infant: a case report and review of the Japanese literature. Terai A, et al. **Int J Urol** 1995 May;2(2):128–31 (17 ref.)

[Ectopic lingual thyroid. Apropos of 3 cases] Maurice N, et al. **Ann Otolaryngol Chir Cervicofac** 1995;112(8):399–405 (24 ref.) (Eng. Abstr.) **(Fre)**

[Ciliated hepatic foregut cyst and hepatic foregut cyst] Kakita A, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):128–31 (19 ref.) **(Jpn)**

[Heterotopic tissues in the gallbladder (heterotopic gastric mucosa, heterotopic intestinal epithelium, heterotopic pancreatic tissue and ectopic liver in the gallbladder] Kodama T, et al. **Ryoikibetsu Shokogun Shirizu** 1996; (9):360–2 (17 ref.) **(Jpn)**

[Ectopic liver] Okanoue T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):151–3 (19 ref.) **(Jpn)**

[Ectopic liver and ectopic hepatocellular carcinoma] Sasaki K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):282–4 (14 ref.) **(Jpn)**

DIAGNOSIS

Familial bilateral periventricular nodular heterotopia mimics tuberous sclerosis. Jardine PE, et al. **Arch Dis Child** 1996 Mar;74(3):244–6 (13 ref.)

Ectopic thyroid tissue presenting as a midline neck mass. Damiano A, et al. **Int J Pediatr Otorhinolaryngol** 1996 Jan; 34(1–2):141–8 (12 ref.)

[Choristoma of the gastric mucosa: report of a case] Fernandes M, et al. **Rev Laryngol Otol Rhinol (Bord)** 1995; 116(5):347–9 (09 ref.) (Eng. Abstr.) **(Fre)**

[A case of intrapancreatic accessory spleen with epidermoid cyst] Kanemaki N, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Aug;92(8):1212–6 (12 ref.) **(Jpn)**

[Cystic ectopic pituitary adenoma: report of a case] Akimoto J, et al. **No To Shinkei** 1995 Nov;47(11):1092–7 (12 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Gastric gland heterotopia with extensive lymphoid stroma: a gastric lymphoepithelial cyst. Delvaux S, et al. **Am J Gastroenterol** 1996 Mar;91(3):599–601 (17 ref.)

Salivary gland choristoma of the middle ear: report of a case and review of the literature. Hinni ML, et al. **Ear Nose Throat J** 1996 Jul;75(7):422–4 (17 ref.)

Osseous choristoma of the tongue. Wei Cheong Ngeow, et al. **J Nihon Univ Sch Dent** 1996 Mar;38(1):49–51 (3 ref.)

[Anomalous positions of the gallbladder] Higashi S. **Ryoikibetsu Shokogun Shirizu** 1996;(9):363–6 (13 ref.) **(Jpn)**

[Hepatic ciliated cyst] Ohmoto K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):99–101 (15 ref.) **(Jpn)**

[Salivary gland heterotopia in the bone tissue of the mandible] Afanas'ev VV, et al. **Stomatologiia (Mosk)** 1995;74(2):69–70 (8 ref.) (Eng. Abstr.) **(Rus)**

SURGERY

[Atopic stomach polyp as the cause of invagination of Meckel's diverticulum] Schütter FW, et al. **Chirurg** 1995 Oct;66(10):1016–8 (24 ref.) (Eng. Abstr.) **(Ger)**

CHOROID

BLOOD SUPPLY

Indocyanine green angiography. Can it help preserve the vision of our patients? [editorial; comment] Bressler NM, et al. **Arch Ophthalmol** 1996 Jun;114(6):747–9 (30 ref.) Comment on: Arch Ophthalmol 1996 Jun;114(6):693–7.

Submacular surgery. Are randomized trials necessary? [editorial] Bressler NM. **Arch Ophthalmol** 1995 Dec; 113(12):1557–60 (31 ref.)

Indocyanine green angiography. Owens SL. **Br J Ophthalmol** 1996 Mar;80(3):263–6 (50 ref.)

Treatment of choroidal neovascularization: updated information from recent macular photocoagulation study group reports. Zimmer-Galler IE, et al. **Int Ophthalmol Clin** 1995 Fall;35(4):37–57 (13 ref.)

[Effective mechanisms of laser photocoagulation for neovascularization in diabetic retinopathy] Funatsu H, et al. **Nippon Ganka Gakkai Zasshi** 1996 May;100(5):339–49 (64 ref.) (Eng. Abstr.) **(Jpn)**

CHOROID DISEASES

COMPLICATIONS

[Central serous chorioretinopathy in a pregnant woman] Khairallah M, et al. **J Fr Ophtalmol** 1996;19(3):216–21 (14 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Indocyanine green angiography. Lim JI, et al. **Int Ophthalmol Clin** 1995 Fall;35(4):59–70 (49 ref.)

MEWDS, MFC, PIC, AMN, AIBSE, and AZOOR: one disease or many? [editorial] Jampol LM, et al. **Retina** 1995; 15(5):373–8 (21 ref.)

[AIDS: infections of the retina and choroid] Schimkat M, et al. **Bildgebung** 1995 Dec;62(4):288–301 (100 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Neurological manifestations of acute posterior multifocal placoid pigment epitheliopathy. Comu S, et al. **Stroke** 1996 May;27(5):996–1001 (38 ref.)

CHOROID NEOPLASMS

DIAGNOSIS

[The clinical and anatomicopathological aspects in malignant choroid melanoma] Stefan C. **Oftalmologia** 1996 Apr–Jun; 40(2):105–14 (64 ref.) (Eng. Abstr.) **(Rum)**

[Choroidal metastases as the form of presentation of 2 bronchiolo-alveolar carcinomas] de Frutos Arribas JF, et al. **Rev Clin Esp** 1995 Dec;195(12):853–5 (19 ref.) (Eng. Abstr.) **(Spa)**

PATHOLOGY

Metastatic choroidal melanoma to the contralateral orbit 40 years after enucleation. Coupland SE, et al.

Arch Ophthalmol 1996 Jun;114(6):751–6 (27 ref.)
[Colobomatous fossette of the optic papilla and juxtapapillary choroidal malignant melanoma] Chercota V, et al. **Oftalmologia** 1995 Oct–Dec;39(4):307–10 (9 ref.) (Eng. Abstr.) **(Rum)**

SECONDARY

Neonatal hepatoblastoma metastatic to the choroid and iris. Endo EG, et al. **Arch Ophthalmol** 1996 Jun;114(6):757–61 (24 ref.)
[Bilateral choroidal metastases of pancreatic carcinoma] Castillo J, et al. **J Fr Ophtalmol** 1995;18(12):795–8 (6 ref.) (Eng. Abstr.) **(Fre)**
[Choroid metastasis in a patient with adenocarcinoma of the cervix. A case report] Wiegel T, et al. **Strahlenther Onkol** 1995 Sep;171(9):539–42 (16 ref.) (Eng. Abstr.) **(Ger)**
[Choroidal metastases as the form of presentation of 2 bronchiolo–alveolar carcinomas] de Frutos Arribas JF, et al. **Rev Clin Esp** 1995 Dec;195(12):853–5 (19 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

No one knows the preferred management for choroidal melanoma [editorial] Fine SL. **Am J Ophthalmol** 1996 Jul; 122(1):106–8 (11 ref.)

CHOROID PLEXUS

[Amniocentesis and single choroid plexus cyst. Current status] Morales–Roselló J, et al. **Rev Fr Gynecol Obstet** 1995 Oct;90(10):412–6 (30 ref.) (Eng. Abstr.) **(Fre)**

BLOOD SUPPLY

Microsurgical anatomy of the posterior choroidal arteries. Vinas FC, et al. **Neurol Res** 1995 Oct;17(5):334–44 (34 ref.)

CHOROID PLEXUS NEOPLASMS

DIAGNOSIS

[Papillary carcinoma of the choroid plexus: apropos 3 cases] González San Segundo C, et al. **An Med Interna** 1996 May; 13(5):239–42 (22 ref.) (Eng. Abstr.) **(Spa)**

SECONDARY

Solitary metastasis to the choroid plexus of the lateral ventricle. Report of three cases and a review of the literature. Kohno M, et al. **J Neurooncol** 1996 Jan; 27(1):47–52 (19 ref.)

CHOROIDEREMIA

GENETICS

[Choroideremia: in the trace of a new protein family] Sankila EM. **Duodecim** 1994;110(7):687–93 (29 ref.) **(Fin)**

CHOROIDITIS

see related
CHORIORETINITIS

Serpiginous choroiditis. Ciulla TA, et al. **Int Ophthalmol Clin** 1996 Winter;36(1):135–43 (38 ref.)

DIAGNOSIS

Serpiginous (geographical) choroiditis. Abu el–Asrar AM. **Int Ophthalmol Clin** 1995 Spring;35(2):87–91 (24 ref.)

CHRIST–SIEMENS–TOURAINE SYNDROME see **ECTODERMAL DYSPLASIA**

CHRISTIANITY

Nonoperative management of a splenic tear in a Jehovah's Witness with hemophilia. Zieg PM, et al. **J Trauma** 1996 Feb;40(2):299–301 (21 ref.)

PSYCHOLOGY

Stress, stigmatization and psychosomatic purpuras. Panconesi E, et al. **Int Angiol** 1995 Jun;14(2):130–7 (51 ref.)

CHRISTMAS DISEASE

SURGERY

Orthotopic liver transplantation in hemophilia B: a case report. Kadry Z, et al. **Transpl Int** 1995;8(6):485–7 (26 ref.)

THERAPY

Improved safety from plasma derivatives: purification and viral elimination characteristics of mononine. Feldman F, et al. **Acta Haematol** 1995;94 Suppl 1:25–32; discussion 33–4 (13 ref.)
High–purity factor IX concentrates for treatment of hemophilia B: relative purity and thrombogenic potential. Limentani SA, et al. **Acta Haematol** 1995;94 Suppl 1:12–7 (24 ref.)
In vivo models of thrombogenic potential: usefulness and limitations. MacGregor I, et al. **Acta Haematol** 1995;94 Suppl 1:18–23; discussion 24 (25 ref.)
Continuous infusion of factor concentrates: review of use in hemophilia A and demonstration of safety and efficacy in hemophilia B. Martinowitz UP, et al. **Acta Haematol** 1995;94 Suppl 1:35–42 (30 ref.)
The need for highly purified products to treat hemophilia B. Scharrer I. **Acta Haematol** 1995;94 Suppl 1:2–7 (44 ref.)
Biosynthesis of factor IX: implications for gene therapy. Furie BC, et al. **Thromb Haemost** 1995 Jul;74(1):274–7 (60 ref.)

CHRISTMAS FACTOR see **FACTOR IX**

CHROMAFFIN GRANULES

ENZYMOLOGY

Proenkephalin–processing enzymes in chromaffin granules: model for neuropeptide biosynthesis. Hook VY, et al. **Ann N Y Acad Sci** 1996 Mar 22;780:121–33 (22 ref.)

METABOLISM

Release of catecholamines and enkephalin peptides induced by reversal of the Na(+)-Ca2+ exchanger in chromaffin cells. Duarte EP, et al. **Ann N Y Acad Sci** 1996 Apr 15; 779:391–4 (6 ref.)

PHYSIOLOGY

Na–Ca exchange in Ca2+ signaling and neurohormone secretion. Secretory vesicle contributions in adrenal chromaffin cells. Schneider AS, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:356–65 (17 ref.)

CHROMAFFIN SYSTEM

PHYSIOLOGY

Mechanisms of catecholamine secretion from adrenal chromaffin cells. Burgoyne RD. **J Physiol Pharmacol** 1995 Sep;46(3):273–83 (45 ref.)
Facilitation of Ca2+ current in excitable cells. Dolphin AC. **Trends Neurosci** 1996 Jan;19(1):35–43 (95 ref.)

ULTRASTRUCTURE

The interchromatin granules. Thiry M. **Histol Histopathol** 1995 Oct;10(4):1035–45 (86 ref.)

CHROMATES

ADVERSE EFFECTS

[Persistent reactive airway dysfunction syndrome after exposure to chromate] Nagasaka Y, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Jul;33(7):759–64 (16 ref.) (Eng. Abstr.) **(Jpn)**

CHROMATIDS

see related
SISTER CHROMATID EXCHANGE

PHYSIOLOGY

Frontier questions about sister chromatid separation in anaphase. Yanagida M. **Bioessays** 1995 Jun;17(6):519–26 (70 ref.)

ULTRASTRUCTURE

The bond between sisters [comment] Sekelsky JJ, et al. **Cell** 1995 Oct 20;83(2):157–60 (23 ref.) Comment on: Cell 1995 Oct 20;83(2):247–56.

CHROMATIN

Genetic and molecular analysis of the gypsy chromatin insulator of Drosophila. Gdula DA, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9378–83 (43 ref.)
[Granulocyte abnormal chromatin clumping syndrome: report of a new case and review of the literature] Esteve J, et al. **Sangre (Barc)** 1995 Aug;40(4):327–30 (22 ref.) (Eng. Abstr.) **(Spa)**

CHEMISTRY

Chromatin unfolds. Felsenfeld G. **Cell** 1996 Jul 12;86(1):13–9 (45 ref.)
Chromatin structure and RNA polymerase II connection: implications for transcription. Struhl K. **Cell** 1996 Jan 26; 84(2):179–82 (15 ref.)
Histones and chromatin structure in hyperthermophilic Archaea. Grayling RA, et al. **FEMS Microbiol Rev** 1996 May;18(2–3):203–13 (29 ref.)
Scaffold/matrix–attached regions: structural properties creating transcriptionally active loci. Bode J, et al. **Int Rev Cytol** 1995;162A:389–454 (230 ref.)
Chromatin domains and prediction of MAR sequences. Boulikas T. **Int Rev Cytol** 1995;162A:279–388 (478 ref.)
[Structure of chromatin and cell cycle. 3.] Santisteban MS. **Pathol Biol (Paris)** 1995 Sep;43(7):639–64 (597 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Targeting chromatin disruption: Transcription regulators that acetylate histones. Wolffe AP, et al. **Cell** 1996 Mar 22; 84(6):817–9 (15 ref.)
Multiple SWItches to turn on chromatin? Peterson CL. **Curr Opin Genet Dev** 1996 Apr;6(2):171–5 (36 ref.)
Epigenetic regulation of gene expression: the effect of altered chromatin structure from yeast to mammals. Hendrich BD, et al. **Hum Mol Genet** 1995;4 Spec No:1765–77 (188 ref.)
Drosophila chromatin and transcription. Becker PB. **Semin Cell Biol** 1995 Aug;6(4):185–90 (50 ref.)
The HMG–14/–17 chromosomal protein family: architectural elements that enhance transcription from chromatin templates. Bustin M, et al. **Semin Cell Biol** 1995 Aug; 6(4):247–55 (39 ref.)
Chromatin and transcriptional activity in early Xenopus development. Landsberger N, et al. **Semin Cell Biol** 1995 Aug;6(4):191–9 (65 ref.)
Role of chromatin structure in zygotic gene activation in the mammalian embryo. Schultz RM, et al. **Semin Cell Biol** 1995 Aug;6(4):201–8 (52 ref.)

METABOLISM

Interaction of bulky chemical carcinogens with DNA in chromatin. MacLeod MC. **Carcinogenesis** 1995 Sep; 16(9):2009–14 (90 ref.)
Special HATs for special occasions: linking histone acetylation to chromatin assembly and gene activation. Brownell JE, et al. **Curr Opin Genet Dev** 1996 Apr; 6(2):176–84 (83 ref.)
Chromatin and transcription. Edmondson DG, et al. **FASEB J** 1996 Aug;10(10):1173–82 (59 ref.)
Interaction of steroid hormone receptors with transcription factors involves chromatin remodelling. Beato M, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1–6 Spec No):47–59 (144 ref.)
Depletion of nuclear poly(ADP–ribose) polymerase by antisense RNA expression: influence on genomic stability, chromatin organization, DNA repair, and DNA replication. Simbulan–Rosenthal CM, et al. **Prog Nucleic Acid Res Mol Biol** 1996;55:135–56 (68 ref.)
Histone acetylation in chromatin and chromosomes. Turner BM, et al. **Semin Cell Biol** 1995 Aug;6(4):229–36 (60 ref.)

PHYSIOLOGY

Chromatin structure and transcriptional activity of MAG gene. Konat GW. **Acta Neurobiol Exp (Warsz)** 1996; 56(1):281–5 (25 ref.)
Chromatin unfolds. Felsenfeld G. **Cell** 1996 Jul 12;86(1):13–9 (45 ref.)
Transcriptional control by steroid hormones: the role of chromatin. Truss M, et al. **Ciba Found Symp** 1995;191:7–17; discussion 17–23 (45 ref.)
Centromeric chromatin. Histone deviants. Wolffe AP. **Curr Biol** 1995 May 1;5(5):452–4 (14 ref.)
Chromatin complexes regulating gene expression in Drosophila. Pirrotta V. **Curr Opin Genet Dev** 1995 Aug; 5(4):466–72 (57 ref.)
The nuclear matrix and the regulation of chromatin organization and function. Davie JR. **Int Rev Cytol** 1995; 162A:191–250 (353 ref.)
The regulation of euchromatin and heterochromatin by histones in yeast. Grunstein M, et al. **J Cell Sci Suppl** 1995; 19:29–36 (65 ref.)
Sex chromatin in lepidoptera. Traut W, et al. **Q Rev Biol** 1996 Jun;71(2):239–56 (71 ref.)

ULTRASTRUCTURE

Chromatin structure and transcriptional activity of MAG gene. Konat GW. **Acta Neurobiol Exp (Warsz)** 1996; 56(1):281–5 (25 ref.)
Developmental roles for chromatin and chromosomal structure. Patterton D, et al. **Dev Biol** 1996 Jan 10; 173(1):2–13 (140 ref.)
Repression and activation by multiprotein complexes that alter chromatin structure. Kingston RE, et al. **Genes Dev** 1996 Apr 15;10(8):905–20 (145 ref.)
The nuclear matrix and the regulation of chromatin organization and function. Davie JR. **Int Rev Cytol** 1995; 162A:191–250 (353 ref.)
Chromatin structure and gene expression. Felsenfeld G, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9384–8 (19 ref.)
Scanning force microscopy of chromatin. Fritzsche W, et al. **Scanning Microsc** 1995 Sep;9(3):729–37; discussion 738–9 (66 ref.)

CHROMATOGRAPHY

Use of multivariate mathematical methods for the evaluation of retention data matrices. Cserháti T, et al. **Adv Chromatogr** 1996;36:1–63 (118 ref.)

METHODS

Chromatography in the downstream processing of biotechnological products. Freitag R, et al. **Adv Biochem Eng Biotechnol** 1996;53:17–59 (383 ref.)
Methods for the determination of beta–agonists in biological matrices. A review. Boyd D, et al. **Analyst** 1996 Jan; 121(1):1R–10R (115 ref.)

CHROMATOGRAPHY

Expanded bed chromatography and radial flow column chromatography: the approaches for adsorption chromatography of biomolecules on industrial scale. Ambedkar SS, et al. **Hindustan Antibiot Bull** 1994 Aug-Nov;36(3-4):164-72 (22 ref.)

New trends in downstream processing of biotechnological products. Patkar AY, et al. **Hindustan Antibiot Bull** 1994 Aug-Nov;36(3-4):141-56 (64 ref.)

Micellar electrokinetic chromatography perspectives in drug analysis. Nishi H, et al. **J Chromatogr A** 1996 May 31; 735(1-2):3-27 (243 ref.)

Enantiomer separation of drugs by electrokinetic chromatography. Nishi H. **J Chromatogr A** 1996 May 31; 735(1-2):57-76 (151 ref.)

Chromatographic techniques for the characterization of proteins. Holthuis JJ, et al. **Pharm Biotechnol** 1995;7:243-99 (144 ref.)

[Uses of analytic type countercurrent chromatography] Liao P, et al. **Chung Kuo Chung Yao Tsa Chih** 1995 Sep; 20(9):569-70 (20 ref.) **(Chi)**

[Quantitative analysis of oxidative base damage in DNA] Zastawny TH. **Postepy Hig Med Dosw** 1995;49(5):609-30 (74 ref.) (Eng. Abstr.) **(Pol)**

CHROMATOGRAPHY, AFFINITY

Fractionation of glycoprotein-derived oligosaccharides by affinity chromatography using immobilized lectin columns. Endo T. **J Chromatogr A** 1996 Jan 12;720(1-2):251-61 (66 ref.)

CHROMATOGRAPHY, GAS

Derivatization reactions for the determination of amines by gas chromatography and their applications in environmental analysis. Kataoka H. **J Chromatogr A** 1996 May 10;733(1-2):19-34 (178 ref.)

METHODS

Gas chromatographic analysis of fatty acid methyl esters. Eder K. **J Chromatogr B Biomed Appl** 1995 Sep 15; 671(1-2):113-31 (140 ref.)

CHROMATOGRAPHY, GAS-LIQUID see **CHROMATOGRAPHY, GAS**

CHROMATOGRAPHY, GAS-LIQUID-MASS SPECTROMETRY see **MASS FRAGMENTOGRAPHY**

CHROMATOGRAPHY, GAS-MASS SPECTROMETRY see **MASS FRAGMENTOGRAPHY**

CHROMATOGRAPHY, HIGH PERFORMANCE LIQUID see **CHROMATOGRAPHY, HIGH PRESSURE LIQUID**

CHROMATOGRAPHY, HIGH PRESSURE LIQUID

The development and application of coupled HPLC-NMR spectroscopy. Lindon JC, et al. **Adv Chromatogr** 1996; 36:315-82 (70 ref.)

Peptide chemistry: development of high performance liquid chromatography and capillary zone electrophoresis. Miller C, et al. **Biopolymers** 1996;40(3):265-317 (124 ref.)

High-performance liquid chromatographic analysis of glycosaminoglycan-derived oligosaccharides. Imanari T, et al. **J Chromatogr A** 1996 Jan 12;720(1-2):275-93 (134 ref.)

High-performance liquid chromatographic separation of carbohydrates on graphitized carbon columns. Koizumi K. **J Chromatogr A** 1996 Jan 12;720(1-2):119-26 (13 ref.)

Three-dimensional mapping of N-linked oligosaccharides using anion-exchange, hydrophobic and hydrophilic interaction modes of high-performance liquid chromatography. Takahashi N. **J Chromatogr A** 1996 Jan 12;720(1-2):217-25 (20 ref.)

[HPLC analysis of non-steroidal antirheumatic agents in biological material. I. Salicylates] Sochor J, et al. **Ceska Slov Farm** 1996 Feb;45(1):8-13 (54 ref.) (Eng. Abstr.) **(Cze)**

METHODS

Microdialysis sampling for pharmacological studies: HPLC and CE analysis. Lunte SM, et al. **Adv Chromatogr** 1996; 36:383-432 (73 ref.)

High-performance liquid chromatography of phosphatidic acid. Abidi SL, et al. **J Chromatogr B Biomed Appl** 1995 Sep 15;671(1-2):281-97 (100 ref.)

Use of derivatization to improve the chromatographic properties and detection selectivity of physiologically important carboxylic acids. Toyo'oka T. **J Chromatogr B Biomed Appl** 1995 Sep 15;671(1-2):91-112 (127 ref.)

High-performance liquid chromatographic analysis of corticosteroids. Volin P. **J Chromatogr B Biomed Appl** 1995 Sep 15;671(1-2):319-40 (162 ref.)

Principles and methods for the analysis and purification of synthetic deoxyribonucleotides by high-performance liquid chromatography. Warren WJ, et al. **Mol Biotechnol** 1995 Oct;4(2):179-99 (24 ref.)

New designs of macroporous polymers and supports: from separation to biocatalysis. Svec F, et al. **Science** 1996 Jul 12;273(5272):205-11 (48 ref.)

[Determination of serum or plasma alpha-tocopherol by high performance liquid chromatography: optimization of operative models] Jezequel-Cuer M, et al. **Ann Biol Clin (Paris)** 1995;53(6):343-52 (34 ref.) (Eng. Abstr.) **(Fre)**

[Reversed-phase high-performance liquid chromatograph--application to serum aluminium monitoring] Hoshino H, et al. **Nippon Rinsho** 1996 Jan; 54(1):215-20 (9 ref.) (Eng. Abstr.) **(Jpn)**

STANDARDS

A systematic review and critical comparison of internal standards for the routine liquid chromatographic assay of amiodarone and desethylamiodarone. Pollak PT. **Ther Drug Monit** 1996 Apr;18(2):168-78 (53 ref.)

CHROMATOGRAPHY, HIGH SPEED LIQUID see **CHROMATOGRAPHY, HIGH PRESSURE LIQUID**

CHROMATOGRAPHY, LIQUID

Analysis of drugs of abuse in biological fluids by liquid chromatography. Binder SR. **Adv Chromatogr** 1996; 36:201-71 (413 ref.)

Future prospects for the analysis of complex biological systems using micro-column liquid chromatography-electrospray tandem mass spectrometry. Yates JR 3rd, et al. **Analyst** 1996 Jul;121(7):65R-76R (66 ref.)

METHODS

Electrochemical detection of biomolecules in liquid chromatography and capillary electrophoresis. Chen JG, et al. **Adv Chromatogr** 1996;36:273-313 (60 ref.)

Use of liquid chromatography for the determination of interactions between bioactive compounds. Cserháti T, et al. **Biomed Chromatogr** 1995 Jul-Aug;9(4):157-61 (72 ref.)

CHROMATOGRAPHY, LIQUID, HIGH PRESSURE see **CHROMATOGRAPHY, HIGH PRESSURE LIQUID**

CHROMATOGRAPHY, MASS see **MASS FRAGMENTOGRAPHY**

CHROMATOGRAPHY, THIN LAYER

High-resolution thin-layer chromatography of gangliosides. Müthing J. **J Chromatogr A** 1996 Jan 12;720(1-2):3-25 (234 ref.)

METHODS

Thin-layer chromatographic procedures for lipid separation. Touchstone JC. **J Chromatogr B Biomed Appl** 1995 Sep 15;671(1-2):169-95 (128 ref.)

CHROMATOPHORES

see related
PIGMENTATION

CHROMIUM

ANALYSIS

[Chromium] Wada O, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:830-5 (5 ref.) **(Jpn)**

PHARMACOKINETICS

A prediction of chromium(III) accumulation in humans from chromium dietary supplements. Stearns DM, et al. **FASEB J** 1995 Dec;9(15):1650-7 (49 ref.)

PBK modeling for metals. Examples with lead, uranium, and chromium. O'Flaherty EJ. **Toxicol Lett** 1995 Dec; 82-83:367-72 (6 ref.)

PHARMACOLOGY

Chromium and other insulin sensitizers may enhance glucagon secretion: implications for hypoglycemia and weight control. McCarty MF. **Med Hypotheses** 1996 Feb; 46(2):77-80 (35 ref.)

CHROMIUM ALLOYS

see related
DENTAL MATERIALS

Cobalt chromium molybdenum metal combination for modular hip prostheses. Schmidt M, et al. **Clin Orthop** 1996 Aug;(329 Suppl):S35-47 (32 ref.)

METABOLISM

Distribution of cobalt chromium wear and corrosion products and biologic reactions. Merritt K, et al. **Clin Orthop** 1996 Aug;(329 Suppl):S233-43 (71 ref.)

CHROMIUM-COBALT ALLOYS see **CHROMIUM ALLOYS**

CHROMIUM-NICKEL ALLOYS see **CHROMIUM ALLOYS**

CHROMOBLASTOMYCOSIS

Chromomycosis. Bayles MA. **Curr Top Med Mycol** 1995; 6:221-43 (98 ref.)

CHROMOGRANINS

BLOOD

[Chromogranin A] Sato J. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:547-9 (9 ref.) **(Jpn)**

PHYSIOLOGY

Chromogranin A: current status as a precursor for bioactive peptides and a granulogenic/sorting factor in the regulated secretory pathway. Iacangelo AL, et al. **Regul Pept** 1995 Aug 22;58(3):65-88 (175 ref.)

CHROMOMYCOSIS see **CHROMOBLASTOMYCOSIS**

CHROMOPLASTS see **PLASTIDS**

CHROMOSOMAL PROBES see **DNA PROBES**

CHROMOSOMAL PROTEINS, NON-HISTONE

PHYSIOLOGY

The SMC proteins and the coming of age of the chromosome scaffold hypothesis. Saitoh N, et al. **Bioessays** 1995 Sep; 17(9):759-66 (54 ref.)

CHROMOSOMAL RNA see **RNA, NUCLEAR**

CHROMOSOMAL TRANSLOCATION see **TRANSLOCATION (GENETICS)**

CHROMOSOME ABERRATIONS

Pathways of chromosome alteration in human epithelial cancers. Dutrillaux B. **Adv Cancer Res** 1995;67:59-82 (80 ref.)

Oncogenic role of "master" transcription factors in human leukemias and sarcomas: a developmental model. Look AT. **Adv Cancer Res** 1995;67:25-57 (162 ref.)

Cytogenetics and molecular genetics of bone and soft tissue tumors. Mandahl N. **Adv Cancer Res** 1996;69:63-99 (143 ref.)

Duplication of 7p: further delineation of the phenotype and restriction of the critical region to the distal part of the short arm. Reish O, et al. **Am J Med Genet** 1996 Jan 2; 61(1):21-5 (33 ref.)

Isodicentric (X)(q13) in haematological malignancies: presentation of five new cases, application of fluorescence in situ hybridization (FISH) and review of the literature. Dierlamm J, et al. **Br J Haematol** 1995 Dec;91(4):885-91 (23 ref.)

Multiple myeloma: almost all patients are cytogenetically abnormal. Zandecki M, et al. **Br J Haematol** 1996 Aug; 94(2):217-27 (86 ref.)

Influence of sex on cytogenetic end points: evidence from a large human sample and review of the literature. Bonassi S, et al. **Cancer Epidemiol Biomarkers Prev** 1995 Sep; 4(6):671-9 (77 ref.)

Cytogenetic investigation of synchronous bilateral renal tumors. Dal Cin P, et al. **Cancer Genet Cytogenet** 1996 Jul 1;89(1):57-60 (25 ref.)

A new cytogenetic subgroup in tenosynovial giant cell tumors (nodular tenosynovitis) is characterized by involvement of 16q24. Dal Cin P, et al. **Cancer Genet Cytogenet** 1996 Mar;87(1):85-7 (5 ref.)

Dicentric (1;15) in myeloid disorders. Michaux L, et al. **Cancer Genet Cytogenet** 1996 May;88(1):86-9 (10 ref.)

Impact of rearrangements on function and position of chromosomes in the interphase nucleus and on human genetic disorders. Qumsiyeh MB. **Chromosome Res** 1995 Dec;3(8):455-65 (157 ref.)

Fluorescence in situ hybridization: powerful molecular tool for cancer prognosis. Fox JL, et al. **Clin Chem** 1995 Nov; 41(11):1554-9 (11 ref.)

Some cytogenetic and molecular aspects of cancer therapy. Sandberg AA, et al. **Compr Ther** 1996 Feb;22(2):76-80 (11 ref.)

Cytogenetics and experimental models of sarcomas. Bridge JA. **Curr Opin Oncol** 1995 Jul;7(4):333-9 (49 ref.)

ICF syndrome (immunodeficiency, centromeric instability and facial anomalies): investigation of heterochromatin abnormalities and review of clinical outcome. Brown DC, et al. **Hum Genet** 1995 Oct;96(4):411-6 (15 ref.)

Uniparental disomy in humans: development of an imprinting map and its implications for prenatal diagnosis. Ledbetter DH, et al. **Hum Mol Genet** 1995;4 Spec No:1757-64 (100 ref.)

Genetic anomaly and ICSI. Chandley AC, et al. **Hum Reprod** 1996 May;11(5):930-2 (26 ref.)

Is ICSI associated with risks of genetic disease? Implications for counselling, practice and research. Persson JW, et al. **Hum Reprod** 1996 May;11(5):921-4 (30 ref.)

Micro-assisted fertilization and sperm chromosome

abnormalities. Rosenbusch B, et al. **Hum Reprod** 1996 May; 11(5):928–30 (29 ref.)
Cytogenetics of human spermatozoa: what about the reproductive relevance of structural chromosome aberrations? Rosenbusch BE. **J Assist Reprod Genet** 1995 Jul;12(6):375–83 (53 ref.)
Abnormalities of retinoblastoma gene expression in hematological malignancies. Zhu YM, et al. **Leuk Lymphoma** 1995 Jun;18(1–2):61–7 (80 ref.)
Emergence of novel transient clonal chromosomal bone marrow changes in remission of acute lymphoblastic leukemia. Andreasson P, et al. **Leukemia** 1996 Feb; 10(2):378–83 (14 ref.)
Quantification of low-level radiation exposure by conventional chromosome aberration analysis. Bauchinger M. **Mutat Res** 1995 Oct;339(3):177–89 (61 ref.)
Genetic, cytogenetic, and carcinogenic effects of radon: a review. Jostes RF. **Mutat Res** 1996 Jun;340(2–3):125–39 (87 ref.)
The molecular biology of brain tumors. Barker FG 2nd, et al. **Neurol Clin** 1995 Nov;13(4):701–21 (170 ref.)
Genetic polymorphisms of drug-metabolizing enzymes and lung cancer susceptibility. Kawajiri K, et al. **Pharmacogenetics** 1995;5 Spec No:S70–3 (17 ref.)
The molecular biology of myeloproliferative disorders as revealed by chromosomal abnormalities. Zeleznik-Le NJ, et al. **Semin Hematol** 1995 Jul;32(3):201–19 (137 ref.)
Identification of genetic imbalances in malignant lymphoma using comparative genomic hybridization. Bentz M, et al. **Stem Cells** 1995 Dec;13 Suppl 3:83–7 (19 ref.)
Diagnosis and monitoring of chromosome aberrations in hematological malignancies by fluorescence in situ hybridization. Döhner H, et al. **Stem Cells** 1995 Dec;13 Suppl 3:76–82 (28 ref.)
The clinical significance of p53 aberrations in human tumours. Bosari S, et al. **Virchows Arch** 1995;427(3):229–41 (158 ref.)
[Myelodysplastic syndrome; current insights in pathogenesis and treatment] Soepenberg O, et al. **Ned Tijdschr Geneeskd** 1995 Oct 21;139(42):2130–5 (57 ref.) **(Dut)**
[Cytogenetic abnormalities in sperm: a risk factor for application of medical reproduction techniques?] Rosenbusch B, et al. **Geburtshilfe Frauenheilkd** 1995 Sep; 55(9):518–25 (40 ref.) (Eng. Abstr.) **(Ger)**
[Severe hereditary retinal diseases in childhood] Lorenz B. **Ther Umsch** 1996 Jan;53(1):7–19 (13 ref.) (Eng. Abstr.) **(Ger)**
[Genomic imprinting and human pathology. 2.] Cirillo Silengo M, et al. **Pediatr Med Chir** 1995 Sep–Oct; 17(5):389–94 (41 ref.) (Eng. Abstr.) **(Ita)**
[Neoplasias in hematopoietic tissues] Kamada N, et al. **Nippon Rinsho** 1996 Jun;54(6):1626–30 (5 ref.) (Eng. Abstr.) **(Jpn)**
[Genetic abnormalities in B cell neoplasms: special reference to diffuse large cell lymphoma] Ohno H, et al. **Rinsho Ketsueki** 1996 May;37(5):404–7 (10 ref.) **(Jpn)**

GENETICS

Evaluation of phenotypic alteration by microcell-mediated chromosome transfer. Hunt JD. **Anal Biochem** 1996 Jul 1;238(2):107–16 (92 ref.)
Chromosomal aberrations in musculoskeletal tumours: clinical importance. Rydholm A. **J Bone Joint Surg Br** 1996 May;78(3):501–6 (7 ref.)
Cytogenetics and molecular biology of soft tissue tumors. Fletcher JA. **Monogr Pathol** 1996;38:37–64 (126 ref.)
[Karyotyping in couples with subfertility and infertility] Stora de Novion H. **Contracept Fertil Sex** 1995 Nov;23(11):655–9 (39 ref.) **(Fre)**
[Comparative genomic hybridization in pathology. A new molecular cytogenetic method] Störkel S, et al. **Pathologe** 1996 May;17(3):189–94 (19 ref.) (Eng. Abstr.) **(Ger)**
[Traditional and future criteria for progression in renal cell carcinoma. Molecular biology and clinical aspects] Pomer S, et al. **Urologe A** 1996 May;35(3):254–62 (57 ref.) (Eng. Abstr.) **(Ger)**
[Specific chromosome aberrations in human soft-tissue tumors and their diagnostic significance] Mrózek K, et al. **Pol Tyg Lek** 1995 Sep;50(36–39):85–9 (30 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOLOGY

Potential sources of multiple mutations in human cancers. Christians FC, et al. **Prev Med** 1995 Jul;24(4):329–32 (37 ref.)

CHROMOSOME ABNORMALITIES

see related
KARYOTYPING
MENTAL RETARDATION

Primary adrenal lymphoma with chromosomal abnormalities. Sasagawa I, et al. **Acta Haematol** 1995;94(3):156–62 (34 ref.)
Absence makes the search grow longer [editorial; comment] Dobyns WB. **Am J Hum Genet** 1996 Jan;58(1):7–16 (121 ref.) Comment on: Am J Hum Genet 1996 Jan;58(1):28–34.
Chromosomal duplications in bacteria, fruit flies, and humans. Lupski JR, et al. **Am J Hum Genet** 1996 Jan;58(1):21–7 (79 ref.)
Clinical and cytogenetic findings in seven cases of inverted duplication of 8p with evidence of a telomeric deletion using fluorescence in situ hybridization [see comments] Guo WJ, et al. **Am J Med Genet** 1995 Sep 11;58(3):230–6 (20 ref.) Comment in: Am J Med Genet 1995 Sep 11;58(3):237.
Neuroblastoma in a boy with MCA/MR syndrome, deletion 11q, and duplication 12q. Koiffmann CP, et al. **Am J Med Genet** 1995 Jul 31;58(1):46–9 (18 ref.)
Clinical dysmorphology beyond developmental genetics: recent advances in some human developmental genes. Lacombe D. **Ann Genet** 1995;38(3):137–44 (59 ref.)
Genetics of embryonal tumours of childhood: retinoblastoma, Wilms' tumour and neuroblastoma. Brodeur GM. **Cancer Surv** 1995;25:67–99 (209 ref.)
The genetic basis for mental retardation. Raynham H, et al. **QJM** 1996 Mar;89(3):169–75 (51 ref.)
[Primary macroglobulinemia with t(11;18) (q21;q21)] Hirase N, et al. **Rinsho Ketsueki** 1996 Apr;37(4):340–5 (17 ref.) (Eng. Abstr.) **(Jpn)**
[Chromosomal abnormalities] Tsuda M. **Ryoikibetsu Shokogun Shirizu** 1995;(8):348–51 (15 ref.) **(Jpn)**

CHEMICALLY INDUCED

DNA topoisomerase inhibitors. Capranico G, et al. **Cancer Chemother Biol Response Modif** 1996;16:68–87 (94 ref.)
Effects of estrogenic chemicals on development. Jones LA, et al. **Environ Health Perspect** 1995 Oct;103 Suppl 7:63–7 (27 ref.)

DIAGNOSIS

Cytogenetics and its prognostic value in myelodysplastic syndromes. Verhoef GE, et al. **Acta Haematol** 1996; 95(2):95–101 (55 ref.)
Detection of a subtle rearrangement of chromosome 22 using molecular techniques. Biesecker LG, et al. **Am J Med Genet** 1995 Sep 25;58(4):389–94 (15 ref.)
Can nucleated erythrocytes found in maternal venous blood be used in the noninvasive prenatal diagnosis of fetal chromosome abnormalities? Slunga-Tallberg A, et al. **Eur J Hum Genet** 1995;3(4):264–70 (46 ref.)
Medical genetics in Singapore. Tay JS. **Southeast Asian J Trop Med Public Health** 1995;26 Suppl 1:19–25 (32 ref.)
[Improved prenatal diagnostic possibilities for congenital abnormalities and chromosomal disorders. Advantages and disadvantages of screening and diagnostic methods] Nørgaard-Pedersen B, et al. **Ugeskr Laeger** 1996 Feb 26; 158(9):1201–7 (29 ref.) (Eng. Abstr.) **(Dan)**
[Karyotyping in couples with subfertility and infertility] Stora de Novion H. **Contracept Fertil Sex** 1995 Nov;23(11):655–9 (39 ref.) **(Fre)**
[Amniocentesis and single choroid plexus cyst. Current status] Morales-Roselló J, et al. **Rev Fr Gynecol Obstet** 1995 Oct;90(10):412–6 (30 ref.) (Eng. Abstr.) **(Fre)**
–Amniocentesis or chorionic villi sampling—when and why?– Hebisch G. **Arch Gynecol Obstet** 1995;256 Suppl:S182–92 (17 ref.) **(Ger)**
[Reliability of invasive prenatal diagnosis in the first trimester in comparison with standard amniocentesis] Crombach G, et al. **Gynakologe** 1995 Oct;28(5):302–14 (93 ref.) **(Ger)**
[Noninvasive prenatal diagnosis of fetal cells in maternal blood] Tutschek B, et al. **Gynakologe** 1995 Oct; 28(5):289–301 (74 ref.) **(Ger)**

EPIDEMIOLOGY

Prevalence of fetal facial cleft at different stages of pregnancy. Snijders RJ, et al. **Ultrasound Obstet Gynecol** 1995 Nov;6(5):327–9 (11 ref.)

ETIOLOGY

[Alagille syndrome in 1995. Clinical and genetic data] Deleuze JF, et al. **Gastroenterol Clin Biol** 1995 Jun–Jul; 19(6–7):587–96 (103 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

The origin of numerical chromosome abnormalities. Jacobs PA, et al. **Adv Genet** 1995;33:101–33 (66 ref.)
New mechanisms for genetic disease and nontraditional modes of inheritance. Langlois S, et al. **Adv Pediatr** 1995; 42:91–111 (60 ref.)
Inversion duplication of the short arm of chromosome 8: clinical data on seven patients and review of the literature. de Die-Smulders CE, et al. **Am J Med Genet** 1995 Nov 20;59(3):369–74 (16 ref.)
Familial partial duplication (1)(p21p31). Hoechstetter L, et al. **Am J Med Genet** 1995 Nov 20;59(3):291–4 (8 ref.)
Uniparental isodisomy of chromosome 14 in two cases: an abnormal child and a normal adult. Papenhausen PR, et al. **Am J Med Genet** 1995 Nov 20;59(3):271–5 (30 ref.)
DiGeorge syndrome and related syndromes associated with 22q11.2 deletions. A review. Demczuk S, et al. **Ann Genet** 1995;38(2):59–76 (183 ref.)
Trinucleotide instability: a repeating theme in human inherited disorders. Gusella JF, et al. **Annu Rev Med** 1996; 47:201–9 (18 ref.)
Impact of rearrangements on function and position of chromosomes in the interphase nucleus and on human genetic disorders. Qumsiyeh MB. **Chromosome Res** 1995 Dec;3(8):455–65 (157 ref.)
Inherited ataxias. Harding AE. **Curr Opin Neurol** 1995 Aug; 8(4):306–9 (27 ref.)
Variability of clinical and immunological phenotype in immunodeficiency-centromeric instability-facial anomalies syndrome. Report of two new patients and review of the literature. Franceschini P, et al. **Eur J Pediatr** 1995 Oct; 154(10):840–6 (21 ref.)
Floating-Harbor syndrome: description of a further patient, review of the literature, and suggestion of autosomal dominant inheritance. Lacombe D, et al. **Eur J Pediatr** 1995 Aug;154(8):658–61 (9 ref.)
A distinct phenotype associated with partial trisomy 10q due to proximal direct duplication 10q11 —> q223? van Buggenhout G, et al. **Genet Couns** 1996;7(1):53–9 (14 ref.)
Zimmermann-Laband syndrome in a patient with severe mental retardation. Van Buggenhout GJ, et al. **Genet Couns** 1995;6(4):321–7 (15 ref.)
The helix-loop-helix gene SCL: implicated in T-cell acute lymphoblastic leukaemia and in normal haematopoietic development. Robb L, et al. **Int J Biochem Cell Biol** 1996 Jun;28(6):609–18 (84 ref.)
Molecular basis of genetic instability of triplet repeats. Wells RD. **J Biol Chem** 1996 Feb 9;271(6):2875–8 (49 ref.)
Prenatal and postnatal growth failure associated with maternal heterodisomy for chromosome 7. Langlois S, et al. **J Med Genet** 1995 Nov;32(11):871–5 (25 ref.)
Genetic alterations in gliomas. Collins VP. **J Neurooncol** 1995;24(1):37–8 (10 ref.)
Molecular cytogenetic quantitation of gains and losses of genetic material from human gliomas. Feuerstein BG, et al. **J Neurooncol** 1995;24(1):47–55 (23 ref.)
Chromosome 17 abnormalities and inactivation of the p53 gene in chronic myeloid leukemia and their prognostic significance. Nakai H, et al. **Leuk Lymphoma** 1995 Oct; 19(3–4):213–21 (58 ref.)
The alpha-thalassemia/mental retardation syndromes. Gibbons RJ, et al. **Medicine (Baltimore)** 1996 Mar; 75(2):45–52 (32 ref.)
Origins and evolution of Huntington disease chromosomes. Andrew SE, et al. **Neurodegeneration** 1995 Sep;4(3):239–44 (50 ref.)
Chondrodysplasia punctata: case report and literature review of patients with heart lesions. Fourie DT. **Pediatr Cardiol** 1995 Sep–Oct;16(5):247–50 (33 ref.)
Association of infantile neuroaxonal dystrophy and osteopetrosis: a rare autosomal recessive disorder. Rees H, et al. **Pediatr Neurosurg** 1995;22(6):321–7 (36 ref.)
[Risks of intracytoplasmatic sperm cell injection for offspring?] Hollanders JM, et al. **Ned Tijdschr Geneeskd** 1996 Jan 6;140(1):9–11 (20 ref.) **(Dut)**
[Genetics of colorectal cancers (editorial)] Pocard M, et al. **Ann Chir** 1996;50(3):211–6 (19 ref.) **(Fre)**
[Uniparental disomy: a review of causes and clinical sequelae] Engel E. **Ann Genet** 1995;38(3):113–36 (166 ref.) (Eng. Abstr.) **(Fre)**
[Ectopic pregnancy: factors related to ovum anomalies?] Bouyer J, et al. **Rev Epidemiol Sante Publique** 1996 Apr; 44(2):101–10 (48 ref.) (Eng. Abstr.) **(Fre)**
[Mutation of G proteins] Trüeb RM. **Hautarzt** 1995 Sep; 46(9):603–6 (15 ref.) (Eng. Abstr.) **(Ger)**
[Genomic imprinting and human pathology. 2.] Cirillo Silengo M, et al. **Pediatr Med Chir** 1995 Sep–Oct; 17(5):389–94 (41 ref.) (Eng. Abstr.) **(Ita)**

PATHOLOGY

Asbestos and mesothelioma: genetic lessons from a tragedy [comment] Knudson A. **Proc Natl Acad Sci U S A** 1995 Nov 21;92(24):10819–20 (21 ref.) Comment on: Proc Natl Acad Sci U S A 1995 Nov 21;92(24):10854–8.

PREVENTION & CONTROL

[Maternal serum screening for detection of fetal chromosome abnormalities] Holzgreve W, et al. **Gynakologe** 1995 Oct; 28(5):280–8 (44 ref.) **(Ger)**

ULTRASONOGRAPHY

First-trimester ultrasound screening for chromosomal defects. Snijders RJ, et al. **Ultrasound Obstet Gynecol** 1996 Mar;7(3):216–26 (58 ref.)

CHROMOSOME DELETION

see related
GENE DELETION

Genetics of murine lung tumors. Dragani TA, et al. **Adv Cancer Res** 1995;67:83–112 (181 ref.)
Menkes and Wilson diseases. Monaco AP, et al. **Adv Genet** 1995;33:233–53 (91 ref.)
Terminal deletion of the long arm of chromosome 3 [46,XX,del(3)(q27—>qter)]. Chitayat D, et al. **Am J Med Genet** 1996 Jan 2;61(1):45–8 (8 ref.)
Interstitial deletion (6)q13q15. Gershoni-Baruch R, et al. **Am J Med Genet** 1996 Apr 24;62(4):345–7 (18 ref.)
Clinical and cytogenetic findings in seven cases of inverted duplication of 8p with evidence of a telomeric deletion using fluorescence in situ hybridization [see comments] Guo WJ, et al. **Am J Med Genet** 1995 Sep 11;58(3):230–6 (20 ref.) Comment in: Am J Med Genet 1995 Sep 11;58(3):237.

CHROMOSOME DELETION

Two craniosynostotic patients with 11q deletions, and review of 48 cases. Lewanda AF, et al. **Am J Med Genet** 1995 Nov 6;59(2):193–8 (46 ref.)

Hereditary spherocytic anemia with deletion of the short arm of chromosome 8. Okamoto N, et al. **Am J Med Genet** 1995 Sep 11;58(3):225–9 (14 ref.)

Hunter–McAlpine craniosynostosis phenotype associated with skeletal anomalies and interstitial deletion of chromosome 17q. Thomas JA, et al. **Am J Med Genet** 1996 Apr 24;62(4):372–5 (8 ref.)

DiGeorge syndrome and related syndromes associated with 22q11.2 deletions. A review. Demczuk S, et al. **Ann Genet** 1995;38(2):59–76 (183 ref.)

DiGeorge syndrome and partial monosomy 10p: case report and review. Schuffenhauer S, et al. **Ann Genet** 1995; 38(3):162–7 (39 ref.)

Genomic imprinting and cancer. Brenton JD, et al. **Cancer Surv** 1995;25:161–71 (68 ref.)

Recent advances in the molecular genetics of malignant melanoma. Haluska FG, et al. **Cancer Surv** 1995;25:277–92 (72 ref.)

Molecular genetics of prostate cancer. Isaacs WB. **Cancer Surv** 1995;25:357–79 (133 ref.)

Molecular genetics of sporadic and familial breast cancer. Jones KA, et al. **Cancer Surv** 1995;25:315–34 (135 ref.)

Clinical phenotype associated with terminal 2q37 deletion. Conrad B, et al. **Clin Genet** 1995 Sep;48(3):134–9 (16 ref.)

Partial deletion 11q: report of a case with a large terminal deletion 11q21–qter without loss of telomeric sequences, and review of the literature. Hertz JM, et al. **Clin Genet** 1995 May;47(5):231–5 (19 ref.)

Cytogenetic and molecular cytogenetic studies of a case of interstitial deletion of proximal 15q. Tonk V, et al. **Clin Genet** 1995 Sep;48(3):151–5 (15 ref.)

Interstitial deletion of 8p: report of two patients and review of the literature. Tsukahara M, et al. **Clin Genet** 1995 Jul; 48(1):41–5 (27 ref.)

1p36: every subband a suppressor? Versteeg R, et al. **Eur J Cancer** 1995;31A(4):538–41 (27 ref.)

Clinical features of nine males with molecularly defined deletions of the Y chromosome long arm. Salo P, et al. **J Med Genet** 1995 Sep;32(9):711–5 (37 ref.)

Molecular analysis of the 5q– chromosome. Nagarajan L. **Leuk Lymphoma** 1995 May;17(5–6):361–6 (37 ref.)

Ophthalmic manifestations of Smith–Magenis syndrome. Chen RM, et al. **Ophthalmology** 1996 Jul;103(7):1084–91 (29 ref.)

Partial deletion of chromosome 6p: autopsy findings in a premature infant and review of the literature. Alashari M, et al. **Pediatr Pathol Lab Med** 1995 Nov–Dec;15(6):941–7 (20 ref.)

The azoospermia factor (AZF) of the human Y chromosome in Yq11: function and analysis in spermatogenesis. Vogt PH, et al. **Reprod Fertil Dev** 1995;7(4):685–93 (56 ref.)

[Molecular genetic research on Duchenne–Becker myodystrophy. The correlation of the severity of the disease with the type of deletion] Badalian LO, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995;95(6):90–2 (35 ref.) **(Rus)**

CHROMOSOME FRAGILE SITES

see related
FRAGILE X SYNDROME

The molecular basis of fragile sites in human chromosomes. Sutherland GR, et al. **Curr Opin Genet Dev** 1995 Jun; 5(3):323–7 (40 ref.)

Trinucleotide repeat expansion and human disease. Hummerich H, et al. **Electrophoresis** 1995 Sep; 16(9):1698–704 (92 ref.)

The 5,6-double bond of pyrimidine nucleosides, a fragile site in nucleic acids. Hayatsu H. **J Biochem (Tokyo)** 1996 Mar; 119(3):391–5 (62 ref.)

CHROMOSOME MAPPING

see related
POLYMORPHISM, RESTRICTION FRAGMENT LENGTH

Genetics of murine lung tumors. Dragani TA, et al. **Adv Cancer Res** 1995;67:83–112 (181 ref.)

Mapping of mammalian genomes with radiation (Goss and Harris) hybrids. Leach RJ, et al. **Adv Genet** 1995;33:63–99 (82 ref.)

Strategies for mapping and identifying quantitative trait loci specifying behavioral responses to alcohol. Buck KJ. **Alcohol Clin Exp Res** 1995 Aug;19(4):795–801 (57 ref.)

Chromosomal locations and modes of action of genes of the retinoid (vitamin A) system support their involvement in the etiology of schizophrenia. Goodman AB. **Am J Med Genet** 1995 Aug 14;60(4):335–48 (216 ref.)

A complete map of the human immunoglobulin VH locus. Tomlinson IM, et al. **Ann N Y Acad Sci** 1995 Sep 29; 764:43–6 (12 ref.)

German population data on the loci low-density-lipoprotein receptor, glycophorin A, hemoglobin gamma G, D7S8 and group-specific component. Huckenbeck W, et al. **Anthropol Anz** 1995 Sep;53(3):193–8 (14 ref.)

Do imprinted genes have few and small introns? Haig D. **Bioessays** 1996 May;18(5):351–3 (21 ref.)

Genetics of chromosome 11: loci for pediatric and adult malignancies, developmental disorders, and other diseases. Nowak NJ, et al. **Cancer Invest** 1995;13(6):646–59 (78 ref.)

Molecular genetics of prostate cancer. Isaacs WB. **Cancer Surv** 1995;25:357–79 (133 ref.)

Linkage homology for bronchial hyperresponsiveness between DNA markers on human chromosome 5q31–q33 and mouse chromosome 13. Levitt RC, et al. **Clin Exp Allergy** 1995 Nov;25 Suppl 2:61–3 (21 ref.)

Introduction to positional cloning. Papadopoulos N. **Clin Exp Allergy** 1995 Nov;25 Suppl 2:116–8 (16 ref.)

Mapping and cloning hereditary deafness genes. Cremers FP, et al. **Curr Opin Genet Dev** 1995 Jun;5(3):371–5 (55 ref.)

Comparative maps: the mammalian jigsaw puzzle. Eppig JT, et al. **Curr Opin Genet Dev** 1995 Dec;5(6):709–16 (52 ref.)

Mapping genes for psychiatric disorders and behavioral traits. McInnes LA, et al. **Curr Opin Genet Dev** 1995 Jun; 5(3):376–81 (41 ref.)

Positional cloning reaches maturity. Nelson DL. **Curr Opin Genet Dev** 1995 Jun;5(3):298–303 (32 ref.)

Bovine genome mapping: evolutionary inference and the power of comparative genomics. Womack JE, et al. **Curr Opin Genet Dev** 1995 Dec;5(6):725–33 (35 ref.)

Genetics of autoimmune disease. Merriman TR, et al. **Curr Opin Immunol** 1995 Dec;7(6):786–92 (69 ref.)

Progress in Alzheimer's disease genetics. Schellenberg GD. **Curr Opin Neurol** 1995 Aug;8(4):262–7 (68 ref.)

Physical and genetic maps of the chromosome of the Lactococcus lactis subsp. lactis strain IL1403 and Lactococcus lactis subsp. cremoris strain MG1363. Le Bourgeois P, et al. **Dev Biol Stand** 1995;85:597–603 (33 ref.)

Physical map of Streptococcus mutans GS-5 chromosome. Zuccon FM, et al. **Dev Biol Stand** 1995;85:403–7 (14 ref.)

The genetics of the NOD mouse. Baxter AG, et al. **Diabetes Metab Rev** 1995 Dec;11(4):315–35 (102 ref.)

Human/mouse homology relationships. DeBry RW, et al. **Genomics** 1996 May 1;33(3):337–51 (46 ref.)

The use of discordant sibling pairs for finding genetic loci linked to obesity: practical considerations. Allison DB. **Int J Obes Relat Metab Disord** 1996 Jun;20(6):553–60 (54 ref.)

Polycystic kidney disease. 1: Identification and analysis of the primary defect [editorial] Harris PC, et al. **J Am Soc Nephrol** 1995 Oct;6(4):1125–33 (72 ref.)

Identifying the genes for human hypertension. Hingorani AD, et al. **Nephrol Dial Transplant** 1996 Apr;11(4):575–86 (133 ref.)

Current status of the human obesity gene map. Bouchard C, et al. **Obes Res** 1996 Jan;4(1):81–90 (56 ref.)

The nematode Caenorhabditis elegans and its genome. Hodgkin J, et al. **Science** 1995 Oct 20;270(5235):410–4 (25 ref.)

Clinical and molecular cytogenetics and gene mapping: principles and techniques. Francke U. **Southeast Asian J Trop Med Public Health** 1995;26 Suppl 1:34–43 (48 ref.)

FISH as a tool for genome mapping and positional cloning. Inazawa J. **Southeast Asian J Trop Med Public Health** 1995; 26 Suppl 1:86–8 (19 ref.)

Livestock QTLs—bringing home the bacon? Haley CS. **Trends Genet** 1995 Dec;11(12):488–92 (27 ref.)

QTL mapping in rice. McCouch SR, et al. **Trends Genet** 1995 Dec;11(12):482–7 (58 ref.)

Mapping and manipulating quantitative traits in maize. Stuber CW. **Trends Genet** 1995 Dec;11(12):477–81 (46 ref.)

[Conversion of zinc finger protein to artificial site-specific nuclease: application to chromosome mapping and sequencing] Nagaoka M, et al. **Nippon Rinsho** 1995 Oct; 53(10):2589–96 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Positional cloning of the putative gene responsible for transient abnormal myelopoiesis and that for multiple cartilaginous exostoses] Niikawa N. **Rinsho Byori** 1996 Jan; 44(1):13–8 (6 ref.) (Eng. Abstr.) **(Jpn)**

[Mapping of a senescent gene on human chromosome 7] Nakabayashi K, et al. **Tanpakushitsu Kakusan Koso** 1996 Mar;41(3):237–44 (31 ref.) **(Jpn)**

[Slide PCR for gene mapping] Yoshida MC. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):652–5 (3 ref.) **(Jpn)**

[Intraspecific genetic diversity: monitoring and principles of conservation] Altukhov IuP. **Genetika** 1995 Oct; 31(10):1333–57 (110 ref.) (Eng. Abstr.) **(Rus)**

METHODS

Mapping human chromosomes. Bently DR, et al. **Curr Opin Genet Dev** 1995 Jun;5(3):328–34 (51 ref.)

Novel approaches to linkage mapping. Sheffield VC, et al. **Curr Opin Genet Dev** 1995 Jun;5(3):335–41 (49 ref.)

Genetic mapping with polymorphic sequence-tagged sites. Williams BD. **Methods Cell Biol** 1995;48:81–96 (20 ref.)

Searching for complex disease genes: can it be made any easier? Baron M. **Psychiatr Genet** 1995 Summer;5(2):89–91 (26 ref.)

TRENDS

[The high fork of genome programs (editorial)] Weissenbach J. **C R Acad Sci III** 1996 Apr;319(4):247–8 (11 ref.) **(Fre)**

CHROMOSOME MARKERS see **GENETIC MARKERS**

CHROMOSOME 1 see **CHROMOSOMES, HUMAN, PAIR 1**

CHROMOSOME 2 see **CHROMOSOMES, HUMAN, PAIR 2**

CHROMOSOME 3 see **CHROMOSOMES, HUMAN, PAIR 3**

CHROMOSOME 4 see **CHROMOSOMES, HUMAN, PAIR 4**

CHROMOSOME 5 see **CHROMOSOMES, HUMAN, PAIR 5**

CHROMOSOME 6 see **CHROMOSOMES, HUMAN, PAIR 6**

CHROMOSOME 7 see **CHROMOSOMES, HUMAN, PAIR 7**

CHROMOSOME 8 see **CHROMOSOMES, HUMAN, PAIR 8**

CHROMOSOME 9 see **CHROMOSOMES, HUMAN, PAIR 9**

CHROMOSOME 10 see **CHROMOSOMES, HUMAN, PAIR 10**

CHROMOSOME 11 see **CHROMOSOMES, HUMAN, PAIR 11**

CHROMOSOME 12 see **CHROMOSOMES, HUMAN, PAIR 12**

CHROMOSOME 13 see **CHROMOSOMES, HUMAN, PAIR 13**

CHROMOSOME 14 see **CHROMOSOMES, HUMAN, PAIR 14**

CHROMOSOME 15 see **CHROMOSOMES, HUMAN, PAIR 15**

CHROMOSOME 16 see **CHROMOSOMES, HUMAN, PAIR 16**

CHROMOSOME 17 see **CHROMOSOMES, HUMAN, PAIR 17**

CHROMOSOME 18 see **CHROMOSOMES, HUMAN, PAIR 18**

CHROMOSOME 19 see **CHROMOSOMES, HUMAN, PAIR 19**

CHROMOSOME 20 see **CHROMOSOMES, HUMAN, PAIR 20**

CHROMOSOME 21 see **CHROMOSOMES, HUMAN, PAIR 21**

CHROMOSOME 22 see **CHROMOSOMES, HUMAN, PAIR 22**

CHROMOSOMES

see related
KARYOTYPING

Chromosomal position effects and the modulation of transgene expression. Clark AJ, et al. **Reprod Fertil Dev** 1994;6(5):589–98 (49 ref.)

[Genetics of dilated cardiomyopathies] Mestroni L, et al. **G Ital Cardiol** 1995 Nov;25(11):1469–73 (23 ref.) **(Ita)**

[Loop-domain organization of genes in eukaryotic chromosomes] Glazkov MV. **Mol Biol (Mosk)** 1995 Sep–Oct;29(5):965–82 (118 ref.) **(Rus)**

CHEMISTRY

Boundary and insulator elements in chromosomes. Gerasimova TI, et al. **Curr Opin Genet Dev** 1996 Apr; 6(2):185–92 (42 ref.)

Biochemical and genetic dissection of mitotic chromosome condensation. Hirano T. **Trends Biochem Sci** 1995 Sep; 20(9):357–61 (32 ref.)

GENETICS

Mammalian artificial chromosomes: a new tool for gene therapy. Huxley C. **Gene Ther** 1994 Jan;1(1):7–12 (56 ref.)

Selective distribution of histone H1 variants and high mobility group proteins in chromosomes. Grossbach U. **Semin Cell Biol** 1995 Aug;6(4):237–46 (62 ref.)

Biochemical and genetic dissection of mitotic chromosome condensation. Hirano T. **Trends Biochem Sci** 1995 Sep; 20(9):357–61 (32 ref.)

METABOLISM

Histone acetylation in chromatin and chromosomes. Turner BM, et al. **Semin Cell Biol** 1995 Aug;6(4):229–36 (60 ref.)

[The role of incomplete terminal repair of chromosomal DNA in the aging of neurons and postmitotic organisms] Olovnikov AM. **Izv Akad Nauk Ser Biol** 1995 Jul–Aug; (4):504–7 (12 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Chromosomes take an active role in spindle assembly. Waters JC, et al. **Bioessays** 1995 Nov;17(11):911–4 (32 ref.)
Regulation of chromosomal replication in E. coli: sequestration and beyond. Crooke E. **Cell** 1995 Sep 22; 82(6):877–80 (18 ref.)
Do changes in chromosomes cause aging? Guarente L. **Cell** 1996 Jul 12;86(1):9–12 (21 ref.)
Chromosome behavior in cell differentiation: a field ripe for exploration? Therman E. **Genetics** 1995 Nov; 141(3):799–804 (41 ref.)
Going mobile: microtubule motors and chromosome segregation. Barton NR, et al. **Proc Natl Acad Sci U S A** 1996 Mar 5;93(5):1735–42 (139 ref.)
Meiosis: how could it work? Kleckner N. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8167–74 (103 ref.)
Chromosomal control of meiotic cell division. McKim KS, et al. **Science** 1995 Dec 8;270(5242):1595–601 (53 ref.)
The centromere: hub of chromosomal activities. Pluta AF, et al. **Science** 1995 Dec 8;270(5242):1591–4 (83 ref.)

RADIATION EFFECTS

Quantification of low-level radiation exposure by conventional chromosome aberration analysis. Bauchinger M. **Mutat Res** 1995 Oct;339(3):177–89 (61 ref.)

ULTRASTRUCTURE

The SMC proteins and the coming of age of the chromosome scaffold hypothesis. Saitoh N, et al. **Bioessays** 1995 Sep; 17(9):759–66 (54 ref.)
Developmental roles for chromatin and chromosomal structure. Patterton D, et al. **Dev Biol** 1996 Jan 10; 173(1):2–13 (140 ref.)
A chromomeric model for nuclear and chromosome structure. Cook PR. **J Cell Sci** 1995 Sep;108 (Pt 9):2927–35 (71 ref.)
[The role of disulfide bridges of the residual protein in chromosomal DNA organization] Struchkov VA, et al. **Biofizika** 1995 Mar-Apr;40(2):296–316 (96 ref.) (Eng. Abstr.) **(Rus)**
[The formation of the karyosphere in the oogenesis of insects and amphibians] Gruzova MN, et al. **Tsitologiia** 1995; 37(8):744–69 (156 ref.) (Eng. Abstr.) **(Rus)**

CHROMOSOMES B see CHROMOSOMES, HUMAN, 4–5

CHROMOSOMES, BACTERIAL

CHEMISTRY

Structure and partitioning of bacterial DNA: determined by a balance of compaction and expansion forces? Woldringh CL, et al. **FEMS Microbiol Lett** 1995 Sep 15;131(3):235–42 (46 ref.)

GENETICS

Physical and genetic maps of the chromosome of the Lactococcus lactis subsp. lactis strain IL1403 and Lactococcus lactis subsp. cremoris strain MG1363. Le Bourgeois P, et al. **Dev Biol Stand** 1995;85:597–603 (33 ref.)
Physical map of Streptococcus mutans GS-5 chromosome. Zuccon FM, et al. **Dev Biol Stand** 1995;85:403–7 (14 ref.)

METABOLISM

Hypothesis: chromosome separation in Escherichia coli involves autocatalytic gene expression, transertion and membrane–domain formation. Norris V. **Mol Microbiol** 1995 Jun;16(6):1051–7 (71 ref.)

PHYSIOLOGY

Cell shape and chromosome partition in prokaryotes or, why E. coli is rod-shaped and haploid. Donachie WD, et al. **Bioessays** 1995 Jun;17(6):569–76 (32 ref.)

ULTRASTRUCTURE

Cell shape and chromosome partition in prokaryotes or, why E. coli is rod-shaped and haploid. Donachie WD, et al. **Bioessays** 1995 Jun;17(6):569–76 (32 ref.)

CHROMOSOMES C see CHROMOSOMES, HUMAN, 6–12

CHROMOSOMES, FUNGAL

Structure and function of kinetochores in budding yeast. Hyman AA, et al. **Ann Rev Cell Dev Biol** 1995;11:471–95 (97 ref.)
Elements of chromosome structure and function in fission yeast. Allshire RC. **Semin Cell Biol** 1995 Apr;6(2):55–64 (74 ref.)
The chromosome ends of Saccharomyces cerevisiae. Louis EJ. **Yeast** 1995 Dec;11(16):1553–73 (157 ref.)

GENETICS

Chromosome–length polymorphism in fungi. Zolan ME. **Microbiol Rev** 1995 Dec;59(4):686–98 (145 ref.)

CHROMOSOMES, HUMAN

The origin of numerical chromosome abnormalities. Jacobs PA, et al. **Adv Genet** 1995;33:101–33 (66 ref.)
Nucleotide excision repair: variations associated with cancer development and speciation. Cleaver JE, et al. **Cancer Surv** 1995;25:125–42 (76 ref.)
Genetics and malignant progression of human brain tumours. Furnari FB, et al. **Cancer Surv** 1995;25:233–75 (312 ref.)
Molecular genetics of sporadic and familial breast cancer. Jones KA, et al. **Cancer Surv** 1995;25:315–34 (135 ref.)
Role of transgenic mice in identification and characterization of tumour suppressor genes. Sharan SK, et al. **Cancer Surv** 1995;25:143–59 (103 ref.)
Human/mouse homology relationships. DeBry RW, et al. **Genomics** 1996 May 1;33(3):337–51 (46 ref.)
Molecular cytogenetics and the myelodysplastic syndromes [comment] Anastasi J. **Leuk Res** 1996 Jul;20(7):559–62 (38 ref.) Comment on: Leuk Res 1996 Jul;20(7):551–7.
The coloring of cytogenetics. Speicher MR, et al. **Nat Med** 1996 Sep;2(9):1046–8 (18 ref.)
Microsatellite instability in human cancer. Speicher MR. **Oncol Res** 1995;7(6):267–75 (87 ref.)
Chromosome manipulation: a systematic approach toward understanding human chromosome structure and function [comment] Willard HF. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):6847–50 (28 ref.) Comment on: Proc Natl Acad Sci U S A 1996 Jul 9;93(14):7125–30.
Clinical and molecular cytogenetics and gene mapping: principles and techniques. Francke U. **Southeast Asian J Trop Med Public Health** 1995;26 Suppl 1:34–43 (48 ref.)
Multifactorial inheritance in type 1 diabetes. Cordell HJ, et al. **Trends Genet** 1995 Dec;11(12):499–504 (52 ref.)
Polygenic disease: methods for mapping complex disease traits. Weeks DE, et al. **Trends Genet** 1995 Dec; 11(12):513–9 (110 ref.)
[Human familial autosomal reciprocal translocations] Cohen O, et al. **Ann Genet** 1995;38(4):177–86 (37 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Mapping human chromosomes. Bently DR, et al. **Curr Opin Genet Dev** 1995 Jun;5(3):328–34 (51 ref.)
The molecular basis of fragile sites in human chromosomes. Sutherland GR, et al. **Curr Opin Genet Dev** 1995 Jun; 5(3):323–7 (40 ref.)
Paracentric inversions: a review. Madan K. **Hum Genet** 1995 Nov;96(5):503–15 (109 ref.)

PHYSIOLOGY

Impact of rearrangements on function and position of chromosomes in the interphase nucleus and on human genetic disorders. Qumsiyeh MB. **Chromosome Res** 1995 Dec;3(8):455–65 (157 ref.)

ULTRASTRUCTURE

Impact of rearrangements on function and position of chromosomes in the interphase nucleus and on human genetic disorders. Qumsiyeh MB. **Chromosome Res** 1995 Dec;3(8):455–65 (157 ref.)

CHROMOSOMES, HUMAN, PAIR 1

Dicentric (1;15) in myeloid disorders. Michaux L, et al. **Cancer Genet Cytogenet** 1996 May;88(1):86–9 (10 ref.)
Translocation (Y;1)(q12;q12) in hematologic malignancies. Report on two new cases, FISH characterization, and review of the literature. Michaux L, et al. **Cancer Genet Cytogenet** 1996 Jan;86(1):35–8 (13 ref.)
der(1;15)(q10;10): a nonrandom chromosomal abnormality of myeloid neoplasia. Wong KF, et al. **Cancer Genet Cytogenet** 1995 Sep;83(2):144–7 (12 ref.)
1p36: every subband a suppressor? Versteeg R, et al. **Eur J Cancer** 1995;31A(4):538–41 (27 ref.)
Familial hypertrophic cardiomyopathy: a genetic model of cardiac hypertrophy. Watkins H, et al. **Hum Mol Genet** 1995;4 Spec No:1721–7 (59 ref.)

ULTRASTRUCTURE

Familial partial duplication (1)(p21p31). Hoechstetter L, et al. **Am J Med Genet** 1995 Nov 20;59(3):291–4 (8 ref.)

CHROMOSOMES, HUMAN, PAIR 2

Clinical phenotype associated with terminal 2q37 deletion. Conrad B, et al. **Clin Genet** 1995 Sep;48(3):134–9 (16 ref.)

GENETICS

t(2;5) translocations in anaplastic large cell lymphomas and Hodgkin's disease [editorial; comment] Herbst H. **J Pathol** 1996 Feb;178(2):113–5 (22 ref.) Comment on: J Pathol 1996 Feb;178(2):128–32.

CHROMOSOMES, HUMAN, PAIR 3

Terminal deletion of the long arm of chromosome 3 [46,XX,del(3)(q27-->qter)]. Chitayat D, et al. **Am J Med Genet** 1996 Jan 2;61(1):45–8 (8 ref.)
Molecular characterization of trisomic segment 3p24.1-->3pter: a case with review of the literature. Conte RA, et al. **Clin Genet** 1995 Jul;48(1):49–53 (37 ref.)

CHROMOSOMES, HUMAN, PAIR 4

Origins and evolution of Huntington disease chromosomes. Andrew SE, et al. **Neurodegeneration** 1995 Sep;4(3):239–44 (50 ref.)

CHROMOSOMES, HUMAN, PAIR 5

A chondrodysplasia family produced by mutations in the diastrophic dysplasia sulfate transporter gene: genotype/phenotype correlations. Superti-Furga A, et al. **Am J Med Genet** 1996 May 3;63(1):144–7 (28 ref.)
Myelodysplastic syndrome with t(5;12)(q31;p12–p13) and eosinophilia: a pediatric case with review of literature. Pellier I, et al. **J Pediatr Hematol Oncol** 1996 Aug; 18(3):285–8 (19 ref.)
Molecular analysis of the 5q- chromosome. Nagarajan L. **Leuk Lymphoma** 1995 May;17(5–6):361–6 (37 ref.)

GENETICS

Linkage homology for bronchial hyperresponsiveness between DNA markers on human chromosome 5q31–q33 and mouse chromosome 13. Levitt RC, et al. **Clin Exp Allergy** 1995 Nov;25 Suppl 2:61–3 (21 ref.)
t(2;5) translocations in anaplastic large cell lymphomas and Hodgkin's disease [editorial; comment] Herbst H. **J Pathol** 1996 Feb;178(2):113–5 (22 ref.) Comment on: J Pathol 1996 Feb;178(2):128–32.

CHROMOSOMES, HUMAN, PAIR 6

Interstitial deletion (6)q13q15. Gershoni-Baruch R, et al. **Am J Med Genet** 1996 Apr 24;62(4):345–7 (18 ref.)
Reflections on the evidence for a vulnerability locus for schizophrenia on chromosome 6p24–22 [editorial] Kendler KS, et al. **Am J Med Genet** 1996 Apr 9;67(2):124–6 (27 ref.)
Interstitial deletion of the long arm of chromosome 6 associated with unusual limb anomalies: report of two new patients and review of the literature. Pandya A, et al. **Am J Med Genet** 1995 Oct 23;59(1):38–43 (22 ref.)
The search for IDDM susceptibility genes: the next generation. Owerbach D, et al. **Diabetes** 1996 May; 45(5):544–51 (79 ref.)
Multifactorial inheritance in type 1 diabetes. Cordell HJ, et al. **Trends Genet** 1995 Dec;11(12):499–504 (52 ref.)

GENETICS

A new myeloproliferative disorder associated with chromosomal translocations involving 8p11: a review [see comments] Macdonald D, et al. **Leukemia** 1995 Oct; 9(10):1628–30 (30 ref.) Comment in: Leukemia 1996 Jul;10(7):1252–3.
Partial deletion of chromosome 6p: autopsy findings in a premature infant and review of the literature. Alashari M, et al. **Pediatr Pathol Lab Med** 1995 Nov-Dec;15(6):941–7 (20 ref.)

CHROMOSOMES, HUMAN, PAIR 7

Duplication of 7p: further delineation of the phenotype and restriction of the critical region to the distal part of the short arm. Reish O, et al. **Am J Med Genet** 1996 Jan 2; 61(1):21–5 (33 ref.)
[Hereditary hematopoietic malignancy with emphasis of juvenile chronic myelogenous leukemia and 7 monosomy syndrome] Hayashi Y. **Nippon Rinsho** 1995 Nov; 53(11):2737–41 (21 ref.) (Eng. Abstr.) **(Jpn)**
[Mapping of a senescent gene on human chromosome 7] Nakabayashi K, et al. **Tanpakushitsu Kakusan Koso** 1996 Mar;41(3):237–44 (31 ref.) **(Jpn)**

GENETICS

Prenatal and postnatal growth failure associated with maternal heterodisomy for chromosome 7. Langlois S, et al. **J Med Genet** 1995 Nov;32(11):871–5 (25 ref.)

PHYSIOLOGY

Cytogenetic, molecular and functional evidence for novel tumor suppressor genes on the long arm of human chromosome 7. Zenklusen JC, et al. **Mol Carcinog** 1996 Mar;15(3):167–75 (142 ref.)

CHROMOSOMES, HUMAN, PAIR 8

Primary adrenal lymphoma with chromosomal abnormalities. Sasagawa I, et al. **Acta Haematol** 1995;94(3):156–62 (34 ref.)
Clinical and cytogenetic findings in seven cases of inverted duplication of 8p with evidence of a telomeric deletion using fluorescence in situ hybridization [see comments] Guo WJ, et al. **Am J Med Genet** 1995 Sep 11;58(3):230–6 (20 ref.) Comment in: Am J Med Genet 1995 Sep 11;58(3):237.
Hereditary spherocytic anemia with deletion of the short arm of chromosome 8. Okamoto N, et al. **Am J Med Genet** 1995 Sep 11;58(3):225–9 (14 ref.)
Trisomy 8 and 20 in desmoid tumors and breast cancer: more than a casual coincidence? [letter; comment] Rohen G, et

al. **Cancer Genet Cytogenet** 1996 Jan;86(1):92 (9 ref.) Comment on: Cancer Genet Cytogenet 1995 Feb;79(2):139–43.

Molecular genetics of prostate cancer. Isaacs WB. **Cancer Surv** 1995;25:357–79 (133 ref.)

Interstitial deletion of 8p: report of two patients and review of the literature. Tsukahara M, et al. **Clin Genet** 1995 Jul; 48(1):41–5 (27 ref.)

Mosaic "tetrasomy" 8p: case report and review of the literature. Winters J, et al. **Clin Genet** 1995 Oct;48(4):195–8 (9 ref.)

Transcriptional regulation by the t(8;21) fusion protein, AML–1/ETO. Hiebert SW, et al. **Curr Top Microbiol Immunol** 1996;211:253–8 (19 ref.)

Philadelphia chromosome–negative cells with trisomy 8 after busulfan and interferon treatment of Ph1–positive chronic myelogenous leukemia. Izumi T, et al. **Int J Hematol** 1996 Jul;64(1):73–7 (17 ref.)

[Therapy–related leukemia with t(8;21) initially diagnosed as MDS (RAEB in T)] Hanamura A, et al. **Rinsho Ketsueki** 1995 Aug;36(8):755–61 (15 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

A new myeloproliferative disorder associated with chromosomal translocations involving 8p11: a review [see comments] Macdonald D, et al. **Leukemia** 1995 Oct; 9(10):1628–30 (30 ref.) Comment in: Leukemia 1996 Jul;10(7):1252–3.

ULTRASTRUCTURE

Inversion duplication of the short arm of chromosome 8: clinical data on seven patients and review of the literature. de Die–Smulders CE, et al. **Am J Med Genet** 1995 Nov 20;59(3):369–74 (16 ref.)

Therapy–related acute leukemia associated with t(11q23) after primary acute myeloid leukemia with t(8;21): a report of two cases [letter] Roulston D, et al. **Blood** 1995 Nov 1;86(9):3613–4 (7 ref.)

CHROMOSOMES, HUMAN, PAIR 9

PAX and HOX in neoplasia. Stuart ET, et al. **Adv Genet** 1995;33:255–74 (92 ref.)

Mosaic vs. nonmosaic trisomy 9: report of a liveborn infant evaluated by fluorescence in situ hybridization and review of the literature. Cantú ES, et al. **Am J Med Genet** 1996 Apr 24;62(4):330–5 (39 ref.)

Recent advances in the molecular genetics of malignant melanoma. Haluska FG, et al. **Cancer Surv** 1995;25:277–92 (72 ref.)

Molecular cytogenetic studies of duplication 9q32–>q34.3 inserted into 9q13. Hou JW, et al. **Clin Genet** 1995 Sep; 48(3):148–50 (9 ref.)

Prenatal diagnosis of trisomy 9. Six cases and a review of the literature. Saura R, et al. **Prenat Diagn** 1995 Jul; 15(7):609–14 (25 ref.)

GENETICS

A new myeloproliferative disorder associated with chromosomal translocations involving 8p11: a review [see comments] Macdonald D, et al. **Leukemia** 1995 Oct; 9(10):1628–30 (30 ref.) Comment in: Leukemia 1996 Jul;10(7):1252–3.

t(9;22)(q22–31;q11–12) is a consistent marker of extraskeletal myxoid chondrosarcoma: evaluation of three cases. Sciot R, et al. **Mod Pathol** 1995 Sep;8(7):765–8 (19 ref.)

The expanding world of trinucleotide repeats [comment] Warren ST. **Science** 1996 Mar 8;271(5254):1374–5 (7 ref.) Comment on: Science 1996 Mar 8;271(5254):1423–7.

CHROMOSOMES, HUMAN, PAIR 10

DiGeorge syndrome and partial monosomy 10p: case report and review. Schuffenhauer S, et al. **Ann Genet** 1995; 38(3):162–7 (39 ref.)

A distinct phenotype associated with partial trisomy 10q due to proximal direct duplication 10q11 –> q223? van Buggenhout G, et al. **Genet Couns** 1996;7(1):53–9 (14 ref.)

Small extra ring chromosome derived from chromosome 10p: clinical report and characterisation by FISH. Blennow E, et al. **J Med Genet** 1996 May;33(5):399–402 (30 ref.)

ULTRASTRUCTURE

An angiomyoma with t(X;10)(q22;q23.2). Sonobe H, et al. **Cancer Genet Cytogenet** 1996 Aug;90(1):54–6 (17 ref.)

CHROMOSOMES, HUMAN, PAIR 11

Neuroblastoma in a boy with MCA/MR syndrome, deletion 11q, and duplication 12q. Koiffmann CP, et al. **Am J Med Genet** 1995 Jul 31;58(1):46–9 (18 ref.)

A mucoepidermoid carcinoma of minor salivary gland with t(11;19)(q21;p13.1) as the only karyotypic abnormality. El–Naggar AK, et al. **Cancer Genet Cytogenet** 1996 Mar; 87(1):29–33 (35 ref.)

Partial deletion 11q: report of a case with a large terminal deletion 11q21–qter without loss of telomeric sequences, and review of the literature. Hertz JM, et al. **Clin Genet** 1995 May;47(5):231–5 (19 ref.)

Ataxia–telangiectasia: closer to unraveling the mystery. Shiloh Y. **Eur J Hum Genet** 1995;3(2):116–38 (259 ref.)

Retinoic acid regulatory pathways, chromosomal translocations, and acute promyelocytic leukemia. Chen Z, et al. **Genes Chromosomes Cancer** 1996 Mar;15(3):147–56 (123 ref.)

11q23 rearrangements in acute leukemia. Rubnitz JE, et al. **Leukemia** 1996 Jan;10(1):74–82 (75 ref.)

[Primary macroglobulinemia with t(11;18) (q21;q21)] Hirase N, et al. **Rinsho Ketsueki** 1996 Apr;37(4):340–5 (17 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Two craniosynostotic patients with 11q deletions, and review of 48 cases. Lewanda AF, et al. **Am J Med Genet** 1995 Nov 6;59(2):193–8 (46 ref.)

Genetics of chromosome 11: loci for pediatric and adult malignancies, developmental disorders, and other diseases. Nowak NJ, et al. **Cancer Invest** 1995;13(6):646–59 (78 ref.)

11q and high–affinity IgE receptor in asthma and allergy. Cookson WO. **Clin Exp Allergy** 1995 Nov;25 Suppl 2:71–3; discussion 95–6 (23 ref.)

The cyclin D1/PRAD1 oncogene in human neoplasia. Arnold A. **J Investig Med** 1995 Dec;43(6):543–9 (44 ref.)

A new myeloproliferative disorder associated with chromosomal translocations involving 8p11: a review [see comments] Macdonald D, et al. **Leukemia** 1995 Oct; 9(10):1628–30 (30 ref.) Comment in: Leukemia 1996 Jul;10(7):1252–3.

ULTRASTRUCTURE

Therapy–related acute leukemia associated with t(11q23) after primary acute myeloid leukemia with t(8;21): a report of two cases [letter] Roulston D, et al. **Blood** 1995 Nov 1;86(9):3613–4 (7 ref.)

CHROMOSOMES, HUMAN, PAIR 12

Cytogenetic and molecular analysis in trisomy 12p. Allen TL, et al. **Am J Med Genet** 1996 May 3;63(1):250–6 (33 ref.)

Neuroblastoma in a boy with MCA/MR syndrome, deletion 11q, and duplication 12q. Koiffmann CP, et al. **Am J Med Genet** 1995 Jul 31;58(1):46–9 (18 ref.)

Clinical and molecular cytogenetic observations in three cases of "trisomy 12p syndrome". Rauch A, et al. **Am J Med Genet** 1996 May 3;63(1):243–9 (26 ref.)

Chromosome 12–linked autosomal dominant scapuloperoneal muscular dystrophy. Wilhelmsen KC, et al. **Ann Neurol** 1996 Apr;39(4):507–20 (75 ref.)

Myelodysplastic syndrome with t(5;12)(q31;p12–p13) and eosinophilia: a pediatric case with review of literature. Pellier I, et al. **J Pediatr Hematol Oncol** 1996 Aug; 18(3):285–8 (19 ref.)

Reviews of chromosome studies in urological tumors. III. Cytogenetics and genes in testicular tumors. Sandberg AA, et al. **J Urol** 1996 May;155(5):1531–56 (254 ref.)

CHROMOSOMES, HUMAN, PAIR 13

Fetal exomphalos and chromosomal defects: relationship to maternal age and gestation. Snijders RJ, et al. **Ultrasound Obstet Gynecol** 1995 Oct;6(4):250–5 (30 ref.)

CHROMOSOMES, HUMAN, PAIR 14

Hunter–McAlpine craniosynostosis phenotype associated with skeletal anomalies and interstitial deletion of chromosome 17q. Thomas JA, et al. **Am J Med Genet** 1996 Apr 24;62(4):372–5 (8 ref.)

Familial hypertrophic cardiomyopathy: a genetic model of cardiac hypertrophy. Watkins H, et al. **Hum Mol Genet** 1995;4 Spec No:1721–7 (59 ref.)

[Phenotype of familial forms of early–onset Alzheimer's disease linked to chromosome 14. Clinical and neuropsychological characteristics of a large group] Hannequin D, et al. **Rev Neurol (Paris)** 1995 Dec; 151(12):682–90 (74 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Uniparental isodisomy of chromosome 14 in two cases: an abnormal child and a normal adult. Papenhausen PR, et al. **Am J Med Genet** 1995 Nov 20;59(3):271–5 (30 ref.)

CHROMOSOMES, HUMAN, PAIR 15

Absence makes the search grow longer [editorial; comment] Dobyns WB. **Am J Hum Genet** 1996 Jan;58(1):7–16 (121 ref.) Comment on: Am J Hum Genet 1996 Jan;58(1):28–34.

Dicentric (1;15) in myeloid disorders. Michaux L, et al. **Cancer Genet Cytogenet** 1996 May;88(1):86–9 (10 ref.)

Trisomy 15 in hematological malignancies: six cases and review of the literature. Smith SR, et al. **Cancer Genet Cytogenet** 1996 Jul 1;89(1):27–30 (19 ref.)

der(1;15)(q10;10): a nonrandom chromosomal abnormality of myeloid neoplasia. Wong KF, et al. **Cancer Genet Cytogenet** 1995 Sep;83(2):144–7 (12 ref.)

Cytogenetic and molecular cytogenetic studies of a case of interstitial deletion of proximal 15q. Tonk V, et al. **Clin Genet** 1995 Sep;48(3):151–5 (15 ref.)

Retinoic acid regulatory pathways, chromosomal translocations, and acute promyelocytic leukemia. Chen Z, et al. **Genes Chromosomes Cancer** 1996 Mar;15(3):147–56 (123 ref.)

Familial hypertrophic cardiomyopathy: a genetic model of cardiac hypertrophy. Watkins H, et al. **Hum Mol Genet** 1995;4 Spec No:1721–7 (59 ref.)

GENETICS

[Autosomal recessive limb–girdle muscular dystrophy probably linked to chromosome 15] Noguera Moya A, et al. **An Esp Pediatr** 1996 Mar;44(3):267–9 (17 ref.) **(Spa)**

CHROMOSOMES, HUMAN, PAIR 16

A new cytogenetic subgroup in tenosynovial giant cell tumors (nodular tenosynovitis) is characterized by involvement of 16q24. Dal Cin P, et al. **Cancer Genet Cytogenet** 1996 Mar;87(1):85–7 (5 ref.)

Acute non–lymphoblastic leukaemia with t(16;21): case report with a review of the literature. Hiyoshi M, et al. **Clin Lab Haematol** 1995 Sep;17(3):243–6 (15 ref.)

Transforming properties of the leukemic inv(16) fusion gene CBFB–MYH11. Hajra A, et al. **Curr Top Microbiol Immunol** 1996;211:289–98 (23 ref.)

Autosomal dominant polycystic kidney disease: molecular analysis. Harris PC, et al. **Hum Mol Genet** 1995;4 Spec No:1745–9 (45 ref.)

The alpha–thalassemia/mental retardation syndromes. Gibbons RJ, et al. **Medicine (Baltimore)** 1996 Mar; 75(2):45–52 (32 ref.)

Identification of a gene for autosomal dominant polycystic kidney disease: implications for understanding the pathogenesis and treatment of the disease. Harris PC. **Nephrol Dial Transplant** 1996 Feb;11(2):258–62 (60 ref.)

CHROMOSOMES, HUMAN, PAIR 17

Germline mutations in the TP53 gene. Eeles RA. **Cancer Surv** 1995;25:101–24 (106 ref.)

Retinoic acid regulatory pathways, chromosomal translocations, and acute promyelocytic leukemia. Chen Z, et al. **Genes Chromosomes Cancer** 1996 Mar;15(3):147–56 (123 ref.)

Chromosome 17 abnormalities and inactivation of the p53 gene in chronic myeloid leukemia and their prognostic significance. Nakai H, et al. **Leuk Lymphoma** 1995 Oct; 19(3–4):213–21 (58 ref.)

GENETICS

Ophthalmic manifestations of Smith–Magenis syndrome. Chen RM, et al. **Ophthalmology** 1996 Jul;103(7):1084–91 (29 ref.)

CHROMOSOMES, HUMAN, PAIR 18

Clinical and molecular cytogenetics and gene mapping: principles and techniques. Francke U. **Southeast Asian J Trop Med Public Health** 1995;26 Suppl 1:34–43 (48 ref.)

Fetal exomphalos and chromosomal defects: relationship to maternal age and gestation. Snijders RJ, et al. **Ultrasound Obstet Gynecol** 1995 Oct;6(4):250–5 (30 ref.)

[Primary macroglobulinemia with t(11;18) (q21;q21)] Hirase N, et al. **Rinsho Ketsueki** 1996 Apr;37(4):340–5 (17 ref.) (Eng. Abstr.) **(Jpn)**

CHROMOSOMES, HUMAN, PAIR 19

A mucoepidermoid carcinoma of minor salivary gland with t(11;19)(q21;p13.1) as the only karyotypic abnormality. El–Naggar AK, et al. **Cancer Genet Cytogenet** 1996 Mar; 87(1):29–33 (35 ref.)

The CYP2A gene subfamily: species differences, regulation, catalytic activities and role in chemical carcinogenesis. Fernandez–Salguero P, et al. **Pharmacogenetics** 1995;5 Spec No:S123–8 (56 ref.)

CHROMOSOMES, HUMAN, PAIR 20

Trisomy 8 and 20 in desmoid tumors and breast cancer: more than a casual coincidence? [letter; comment] Rohen G, et al. **Cancer Genet Cytogenet** 1996 Jan;86(1):92 (9 ref.) Comment on: Cancer Genet Cytogenet 1995 Feb;79(2):139–43.

[Alagille syndrome in 1995. Clinical and genetic data] Deleuze JF, et al. **Gastroenterol Clin Biol** 1995 Jun–Jul; 19(6–7):587–96 (103 ref.) (Eng. Abstr.) **(Fre)**

CHROMOSOMES, HUMAN, PAIR 21

Transient leukemia with trisomy 21: description of a case and review of the literature. Bhatt S, et al. **Am J Med Genet** 1995 Sep 25;58(4):310–4 (23 ref.)

Monosomy 21q: two cases of del(21q) and review of the literature. Huret JL, et al. **Clin Genet** 1995 Sep;48(3):140–7 (60 ref.)

Acute non–lymphoblastic leukaemia with t(16;21): case report with a review of the literature. Hiyoshi M, et al. **Clin Lab Haematol** 1995 Sep;17(3):243–6 (15 ref.)

Transcriptional regulation by the t(8;21) fusion protein, AML–1/ETO. Hiebert SW, et al. **Curr Top Microbiol Immunol** 1996;211:253–8 (19 ref.)

Transgenic models for chromosome 21 gene dosage effects.

Groner Y. **Prog Clin Biol Res** 1995;393:193–212 (40 ref.)
The integrated map of human chromosome 21. Patterson D. **Prog Clin Biol Res** 1995;393:43–55 (35 ref.)
[Therapy-related leukemia with t(8;21) initially diagnosed as MDS (RAEB in T)] Hanamura A, et al. **Rinsho Ketsueki** 1995 Aug;36(8):755–61 (15 ref.) (Eng. Abstr.) **(Jpn)**

ULTRASTRUCTURE

Therapy-related acute leukemia associated with t(11q23) after primary acute myeloid leukemia with t(8;21): a report of two cases [letter] Roulston D, et al. **Blood** 1995 Nov 1;86(9):3613–4 (7 ref.)

CHROMOSOMES, HUMAN, PAIR 22

see related
PHILADELPHIA CHROMOSOME
Chromosome 22: a model with implications for diagnostic imaging. Starshak RJ. **AJR Am J Roentgenol** 1996 Aug; 167(2):315–24 (62 ref.)
Risk of fetal mosaicism when placental mosaicism is diagnosed by chorionic villus sampling. Phillips OP, et al. **Am J Obstet Gynecol** 1996 Mar;174(3):850–5 (24 ref.)

GENETICS

How many breaks do we need to CATCH on 22q11? [editorial] Dallapiccola B, et al. **Am J Hum Genet** 1996 Jul;59(1):7–11 (53 ref.)
t(9;22)(q22–31;q11–12) is a consistent marker of extraskeletal myxoid chondrosarcoma: evaluation of three cases. Sciot R, et al. **Mod Pathol** 1995 Sep;8(7):765–8 (19 ref.)

ULTRASTRUCTURE

Detection of a subtle rearrangement of chromosome 22 using molecular techniques. Biesecker LG, et al. **Am J Med Genet** 1995 Sep 25;58(4):389–94 (15 ref.)
DiGeorge syndrome and related syndromes associated with 22q11.2 deletions. A review. Demczuk S, et al. **Ann Genet** 1995;38(2):59–76 (183 ref.)

CHROMOSOMES, HUMAN, 4–5

The genetic background of craniosynostosis syndromes. Heutink P, et al. **Eur J Hum Genet** 1995;3(5):312–23 (70 ref.)

CHROMOSOMES, HUMAN, 6–12

The genetic background of craniosynostosis syndromes. Heutink P, et al. **Eur J Hum Genet** 1995;3(5):312–23 (70 ref.)

CHROMOSOMES, RING see **RING CHROMOSOMES**

CHROMOSOMES, YEAST ARTIFICIAL

Germ line transmission of yeast artificial chromosomes in transgenic mice. Montoliu L, et al. **Reprod Fertil Dev** 1994; 6(5):577–84 (44 ref.)
[YAC-modification system for analyzing gene regulation] Koide T. **Seikagaku** 1996 Feb;68(2):137–42 (15 ref.) **(Jpn)**

GENETICS

YAC transgenics and the study of genetics and human disease. Lamb BT, et al. **Curr Opin Genet Dev** 1995 Jun; 5(3):342–8 (54 ref.)
YAC transgenic mice in the study of the genetic basis of Down syndrome. Cabin DE, et al. **Prog Clin Biol Res** 1995; 393:213–26 (28 ref.)

CHRONIC DISEASE

Anorexia during acute and chronic disease. Plata-Salamán CR. **Nutrition** 1996 Feb;12(2):69–78 (147 ref.)
Strategies for potential manipulation of anorexia during acute and chronic disease. Plata-Salamán CR. **Nutrition** 1995 Sep–Oct;11(5 Suppl):702–4 (39 ref.)
Physical fitness in children with juvenile rheumatoid arthritis and other chronic pediatric illnesses. Singsen BH. **Pediatr Clin North Am** 1995 Oct;42(5):1035–50 (61 ref.)

ECONOMICS

The medical costs attributable to meat consumption [see comments] Barnard ND, et al. **Prev Med** 1995 Nov; 24(6):646–55 (105 ref.) Comment in: Prev Med 1995 Nov;24(6):565–7.

EPIDEMIOLOGY

Management of depression in patients with coexisting medical illness. Nesse RE, et al. **Am Fam Physician** 1996 May 1; 53(6):2125–33 (20 ref.)
Menopause: its epidemiology and potential association with chronic diseases. Sowers MR, et al. **Epidemiol Rev** 1995; 17(2):287–302 (208 ref.)
Behavioral risk factors related to chronic diseases in ethnic minorities. Myers HF, et al. **Health Psychol** 1995 Dec; 14(7):613–21 (65 ref.)
The law of halves. Herman J. **J Clin Epidemiol** 1996 May; 49(5):595–8 (40 ref.)
Genetic and aging epidemiology. The merging of two disciplines. Cauley JA, et al. **Neurol Clin** 1996 May; 14(2):467–75 (53 ref.)

NURSING

Smoking cessation interventions in chronic illness. Wewers ME, et al. **Annu Rev Nurs Res** 1996;14:75–93 (55 ref.)
Social support: some pragmatic implications for health care professionals. Keeling DI, et al. **J Adv Nurs** 1996 Jan; 23(1):76–81 (36 ref.)
Spiritual care of the school-age child with a chronic condition. Fulton RA, et al. **J Pediatr Nurs** 1995 Aug; 10(4):224–31 (56 ref.)

PSYCHOLOGY

Harnessing the power of the placebo effect and renaming it "remembered wellness". Benson H, et al. **Annu Rev Med** 1996;47:193–9 (18 ref.)
Risk and resilience among children and youth with disabilities. Patterson J, et al. **Arch Pediatr Adolesc Med** 1996 Jul;150(7):692–8 (115 ref.)
Anxiety in medically ill older patients: a review and update. Hocking LB, et al. **Int J Psychiatry Med** 1995;25(3):221–38 (74 ref.)
Chronic illness and the family life-cycle. Newby NM. **J Adv Nurs** 1996 Apr;23(4):786–91 (29 ref.)
Sociological dimensions of illness behavior. Mechanic D. **Soc Sci Med** 1995 Nov;41(9):1207–16 (54 ref.)
[Psychological and psychiatric problems in chronic somatic patients; recommendations for future studies and implications for care] Poppelaars CA, et al. **Ned Tijdschr Geneeskd** 1996 Feb 24;140(8):415–8 (32 ref.) **(Dut)**

REHABILITATION

[Sports as a preventive and rehabilitational measure for the elderly] Dorner H. **Fortschr Med** 1996 May 30; 114(15):183–6 (25 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Update on cellular transplantation into the CNS as a novel therapy for chronic pain. Czech KA, et al. **Prog Neurobiol** 1995 Aug;46(5):507–29 (126 ref.)
[Therapeutic compliance in adolescents with chronic disease] Alvin P, et al. **Arch Pediatr** 1995 Sep;2(9):874–82 (86 ref.) (Eng. Abstr.) **(Fre)**
[Significance of support groups in the integrated management of chronically ill patients] Rodriguez-Agudelo Y, et al. **Gac Med Mex** 1995 May–Jun;131(3):329–34 (20 ref.) (Eng. Abstr.) **(Spa)**

CHRONIC FATIGUE SYNDROME see **FATIGUE SYNDROME, CHRONIC**

CHRONIC ILLNESS see **CHRONIC DISEASE**

CHRONIC LIMITATION OF ACTIVITY see **ACTIVITIES OF DAILY LIVING**

CHRONIC OBSTRUCTIVE PULMONARY DISEASE see **LUNG DISEASES, OBSTRUCTIVE**

CHRONOBIOLOGY

Chronobiology and chronotherapeutics. Applications to cardiovascular medicine. Smolensky MH. **Am J Hypertens** 1996 Apr;9(4 Pt 3):11S–21S (68 ref.)
Current concepts for chronochemotherapy of cancer. Laerum OD, et al. **J Infus Chemother** 1995;5(3 Suppl 1):159–70 (189 ref.)
Pulmonary thromboembolism: current concepts and chronobiological perspectives. Manfredini R, et al. **Panminerva Med** 1995 Mar;37(1):38–43 (62 ref.)
Circadian rhythms and cancer chemotherapy. Focan C. **Pharmacol Ther** 1995;67(1):1–52 (289 ref.)
[Temporal organization and information in biological systems] Romanov IuA. **Aviakosm Ekolog Med** 1995; 29(4):4–9 (44 ref.) (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

Rationales to consider the use of melatonin as a chrono-oncotherapeutic drug. Bartsch C, et al. **In Vivo** 1995 Jul–Aug;9(4):305–9 (62 ref.)
Marker rhythms for cancer chronotherapy. From laboratory animals to human beings. Focan C. **In Vivo** 1995 Jul–Aug; 9(4):283–98 (113 ref.)

PHYSIOLOGY

Circasemiseptan (about-half-weekly) and/or circaseptan (about-weekly) pattern in human mitotic activity? Blank M, et al. **In Vivo** 1995 Jul–Aug;9(4):391–4 (49 ref.)
The week in phylogeny and ontogeny: opportunities for oncology. Halberg F. **In Vivo** 1995 Jul–Aug;9(4):269–78 (92 ref.)

CHRONOTROPISM, CARDIAC see **HEART RATE**

CHRYSOTILE see **ASBESTOS, SERPENTINE**

CHUNG I HSUEH see **MEDICINE, CHINESE TRADITIONAL**

CHURG-STRAUSS SYNDROME

Polyarteritis nodosa, microscopic polyangiitis, and Churg–Strauss syndrome. Clinical aspects and treatment. Lhote F, et al. **Rheum Dis Clin North Am** 1995 Nov; 21(4):911–47 (132 ref.)

COMPLICATIONS

[Necrotic purpura of the head disclosing Churg-Strauss syndrome] Ly S, et al. **Ann Dermatol Venereol** 1995; 122(3):94–6 (17 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

[Churg–Strauss syndrome. A differential diagnosis in chronic polypoid sinusitis] Trittel C, et al. **Laryngorhinootologie** 1995 Sep;74(9):577–80 (23 ref.) (Eng. Abstr.) **(Ger)**
[ANCA-associated vasculitis (Wegener's granulomatosis, Churg–Strauss syndrome, microscopic polyangiitis). 2. Diagnostic procedure (see comments)] de Groot K, et al. **Z Rheumatol** 1995 Sep–Oct;54(5):291–302 (59 ref.) (Eng. Abstr.) Comment in: Z Rheumatol 1995 Sep–Oct;54(5):277–8. **(Ger)**
[Churg–Strauss vasculitis: recall and update] Prados C, et al. **Med Clin (Barc)** 1996 Jun 8;107(2):62–8 (69 ref.) **(Spa)**
[Non-giant cell temporal arteritis as a manifestation of Churg–Strauss syndrome. Presentation of a case and review of literature] Serrano-Castro PJ, et al. **Neurologia** 1996 Feb; 11(2):82–4 (16 ref.) (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

[ANCA-associated vasculitis (Wegener's granulomatosis, Churg–Strauss syndrome, microscopic polyangiitis). 1. Systemic aspects, pathogenesis and clinical aspects (see comments)] Gross WL, et al. **Z Rheumatol** 1995 Sep–Oct; 54(5):279–90 (22 ref.) (Eng. Abstr.) Comment in: Z Rheumatol 1995 Sep–Oct;54(5):277–8. **(Ger)**

THERAPY

[ANCA-associated vasculitis (Wegener's granulomatosis, Churg–Strauss syndrome, microscopic polyangiitis). 3. Therapeutic procedure (see comments)] Reinhold-Keller E, et al. **Z Rheumatol** 1995 Sep–Oct;54(5):303–9 (30 ref.) (Eng. Abstr.) Comment in: Z Rheumatol 1995 Sep–Oct;54(5):277–8. **(Ger)**

CHYLOMICRONS

BLOOD

[Chylomicron] Shimazu N, et al. **Nippon Rinsho** 1995 Feb; 53 Su Pt 1:658–61 (20 ref.) **(Jpn)**

METABOLISM

Chylomicron assembly and catabolism: role of apolipoproteins and receptors. Hussain MM, et al. **Biochim Biophys Acta** 1996 May 20;1300(3):151–70 (313 ref.)
Chylomicron remnants: hepatic receptors and metabolism. Havel RJ. **Curr Opin Lipidol** 1995 Oct;6(5):312–6 (41 ref.)
[Liver mechanisms for the elimination of lipoproteins of intestinal origin] Khallou J, et al. **C R Seances Soc Biol Fil** 1995;189(5):899–904 (22 ref.) (Eng. Abstr.) **(Fre)**

CHYLOPERICARDIUM see **PERICARDIAL EFFUSION**

CHYLOPERITONEUM

DIET THERAPY

Lymphangioleiomyomatosis, chylous ascites, and diet. Calvo E, et al. **Dig Dis Sci** 1996 Mar;41(3):591–3 (8 ref.)

DRUG THERAPY

Chemotherapy treatment of chyloperitoneum and peritoneal carcinomatosis due to cervical cancer--review of literature. Keung YK, et al. **Gynecol Oncol** 1996 Jun;61(3):448–50 (11 ref.)

VETERINARY

Chylothorax and chylous ascites in a dog with mediastinal lymphangiosarcoma. Myers NC 3rd, et al. **J Am Anim Hosp Assoc** 1996 May–Jun;32(3):263–9 (32 ref.)

CHYLOTHORAX

DIAGNOSIS

Diagnosis and management of chylothorax. Miller JI Jr. **Chest Surg Clin N Am** 1996 Feb;6(1):139–48 (8 ref.)

SURGERY

Early thoracic duct ligation for postoperative chylothorax. Sieczka EM, et al. **J Surg Oncol** 1996 Jan;61(1):56–60 (27 ref.)

CHYLOTHORAX

THERAPY

Diagnosis and management of chylothorax. Miller JI Jr. **Chest Surg Clin N Am** 1996 Feb;6(1):139–48 (8 ref.)

VETERINARY

Chylothorax and chylous ascites in a dog with mediastinal lymphangiosarcoma. Myers NC 3rd, et al. **J Am Anim Hosp Assoc** 1996 May–Jun;32(3):263–9 (32 ref.)

Chylothorax in the dog and cat: a review. Birchard SJ, et al. **Lymphology** 1995 Jun;28(2):64–72 (53 ref.)

CHYLOUS ASCITES see **CHYLOPERITONEUM**

CHYMOPAPAIN

THERAPEUTIC USE

Chemonucleolysis. Nordby EJ, et al. **Spine** 1996 May 1; 21(9):1102–5 (14 ref.)

CHYMOSIN

METABOLISM

Contribution of milk–clotting enzymes and plasmin to cheese ripening. Farkye NY. **Adv Exp Med Biol** 1995;367:195–207 (64 ref.)

CHYMOTRYPSIN

[Direct analysis of the peptide bond cleavage by rapid quenching method] Shibuya N, et al. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(13):1959–62 (3 ref.) **(Jpn)**

ANALYSIS

[Chymotrypsin] Katoh M. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:323–5 (9 ref.) **(Jpn)**

PHARMACOLOGY

Voltage dependence of Na–Ca exchange in barnacle muscle cells. I. Na–Na exchange activated by alpha–chymotrypsin. Rasgado–Flores H, et al. **Ann N Y Acad Sci** 1996 Apr 15; 779:236–48 (28 ref.)

CI–581 see **KETAMINE**

CICATRIX

see related
KELOID

COMPLICATIONS

Midtrimester uterine rupture. A case report. Levrant SG, et al. **J Reprod Med** 1996 Mar;41(3):186–90 (28 ref.)

ETIOLOGY

[The cicatrization of corneal wounds] Spineanu L. **Oftalmologia** 1995 Oct–Dec;39(4):356–60 (6 ref.) (Eng. Abstr.) **(Rum)**

PATHOLOGY

Multiple malignant melanoma and squamous–cell carcinoma in a burn scar. Ikeda I, et al. **Dermatology** 1995; 191(4):328–32 (20 ref.)

PHYSIOPATHOLOGY

Scar formation: the spectral nature of fetal and adult wound repair. Ferguson MW, et al. **Plast Reconstr Surg** 1996 Apr; 97(4):854–60 (42 ref.)

SURGERY

Management of scar contractures, hypertrophic scars, and keloids. Sherris DA, et al. **Otolaryngol Clin North Am** 1995 Oct;28(5):1057–68 (29 ref.)

[Progressive pneumoperitoneum in treatment of inguinal and scar hernias. Results of animal experiments and clinical applications] Willis S, et al. **Langenbecks Arch Chir** 1996; 381(3):132–7 (37 ref.) (Eng. Abstr.) **(Ger)**

CICATRIX, HYPERTROPHIC

see related
KELOID

Aetiology and management of hypertrophic scars and keloids. O'Sullivan ST, et al. **Ann R Coll Surg Engl** 1996 May;78(3 (Pt 1)):168–75 (100 ref.)

METABOLISM

[Collagen metabolism in hypertrophic and keloid scars] Del'vig AA. **Vestn Ross Akad Med Nauk** 1995;(12):41–5 (34 ref.) (Eng. Abstr.) **(Rus)**

SURGERY

Management of scar contractures, hypertrophic scars, and keloids. Sherris DA, et al. **Otolaryngol Clin North Am** 1995 Oct;28(5):1057–68 (29 ref.)

CILIA

see related
EPITHELIUM

PHYSIOLOGY

Role of cilia in human health. Afzelius BA. **Cell Motil Cytoskeleton** 1995;32(2):95–7 (17 ref.)

Biophysical aspects and modelling of ciliary motility. Holwill ME, et al. **Cell Motil Cytoskeleton** 1995;32(2):114–20 (31 ref.)

Structural and functional hierarchy of eukaryotic cilia and flagella. Omoto CK. **Eur J Histochem** 1995;39(2):85–90 (53 ref.)

Situs inversus and ciliary abnormalities. What is the connection? Afzelius BA. **Int J Dev Biol** 1995 Oct; 39(5):839–44 (57 ref.)

ULTRASTRUCTURE

Structural and functional hierarchy of eukaryotic cilia and flagella. Omoto CK. **Eur J Histochem** 1995;39(2):85–90 (53 ref.)

CILIARY BODY

see related
TRABECULECTOMY

ULTRASTRUCTURE

Ciliary body. Tamm ER, et al. **Microsc Res Tech** 1996 Apr 1;33(5):390–439 (201 ref.)

CILIARY DYSKINESIA see **CILIARY MOTILITY DISORDERS**

CILIARY MOTILITY DISORDERS

DIAGNOSIS

[Primary ciliary dyskinesia, immotile cilia syndrome, and Kartagener syndrome: diagnostic criteria] Dombi VH, et al. **Schweiz Med Wochenschr** 1996 Mar 16;126(11):421–33 (129 ref.) (Eng. Abstr.) **(Ger)**

CILIATA see **CILIOPHORA**

CILIOPHORA

Eosinophilic colitis and hepatitis in a horse with colonic intramucosal ciliated protozoa. French RA, et al. **Vet Pathol** 1996 Mar;33(2):235–8 (10 ref.)

CYTOLOGY

Commitment to division in ciliate cell cycles. Adl SM, et al. **J Eukaryot Microbiol** 1996 Mar–Apr;43(2):77–86 (138 ref.)

PHYSIOLOGY

Chemical signaling in ciliates. Luporini P, et al. **J Eukaryot Microbiol** 1995 May–Jun;42(3):208–12 (30 ref.)

CIMETIDINE

THERAPEUTIC USE

A plasma cell variant of Castleman's disease treated successfully with cimetidine. Case report and review of the literature. Barbounis V, et al. **Anticancer Res** 1996 Jan–Feb;16(1):545–7 (21 ref.)

Prophylaxis for stress–related gastrointestinal hemorrhage: a cost effectiveness analysis. Ben–Menachem T, et al. **Crit Care Med** 1996 Feb;24(2):338–45 (59 ref.)

[Therapeutic management of duodenal ulcer except in emergency cases: antisecretory treatment] Ruszniewski P. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S53–S57 (48 ref.) **(Fre)**

CINE–CT see **TOMOGRAPHY, X–RAY COMPUTED**

CINE MAGNETIC RESONANCE IMAGING see **MAGNETIC RESONANCE IMAGING, CINE**

CINE MRI see **MAGNETIC RESONANCE IMAGING, CINE**

CINEFLUOROGRAPHY see **CINERADIOGRAPHY**

CINERADIOGRAPHY

[Radiologic differential diagnosis of neurologically–induced deglutition disorders] Wuttge–Hanning A, et al. **Radiologe** 1995 Oct;35(10):733–40 (16 ref.) (Eng. Abstr.) **(Ger)**

INSTRUMENTATION

[Videocinematography of swallowing. Indications, methodology and findings] Pokieser P, et al. **Radiologe** 1995 Oct;35(10):703–11 (9 ref.) (Eng. Abstr.) **(Ger)**

CINGULATE GYRUS see **GYRUS CINGULI**

CINNAMATES

PHARMACOLOGY

Identification of new drug targets in Mycobacterium avium and Mycobacterium tuberculosis. Rastogi N, et al. **Res Microbiol** 1996 Jan–Feb;147(1–2):97–105 (36 ref.)

THERAPEUTIC USE

Methoclocinnamox: a mu partial agonist with pharmacotherapeutic potential for heroin abuse. Woods JH, et al. **NIDA Res Monogr** 1995;147:195–219 (29 ref.)

CIPROFLOXACIN

PHARMACOLOGY

Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability. Davis R, et al. **Drugs** 1996 Jun;51(6):1019–74 (517 ref.)

THERAPEUTIC USE

Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability. Davis R, et al. **Drugs** 1996 Jun;51(6):1019–74 (517 ref.)

Lower respiratory tract infection therapy—the role of ciprofloxacin. Ball AP, et al. **J Int Med Res** 1995 Sep–Oct; 23(5):315–27 (55 ref.)

CIRCADIAN RHYTHM

see related
PHOTOPERIOD

Chronobiology. Implications for cancer chemotherapy. Bjarnason GA. **Acta Oncol** 1995;34(5):615–24 (120 ref.)

The pathophysiology of the onset of morning cardiovascular events. Johnstone MT, et al. **Am J Hypertens** 1996 Apr; 9(4 Pt 3):22S–28S (45 ref.)

A chronotherapeutic approach to the management of hypertension. White WB. **Am J Hypertens** 1996 Apr;9(4 Pt 3):29S–33S (27 ref.)

The pineal gland and cancer. Ronco AL, et al. **Anticancer Res** 1996 Jul–Aug;16(4A):2033–9 (68 ref.)

Locomotor activity and non–photic influences on circadian clocks. Mrosovsky N. **Biol Rev Camb Philos Soc** 1996 Aug; 71(3):343–72 (128 ref.)

Travel statement on jet lag. Paulson E. **Can Med Assoc J** 1996 Jul 1;155(1):61–6 (17 ref.) **(Eng, Fre)**

Epidemiologic aspects of circadian patterns of cardiovascular disease and triggers of acute cardiac events. Goldberg RJ. **Cardiol Clin** 1996 May;14(2):175–84 (40 ref.)

Practical implications of circadian variations in thrombolytic and antithrombotic activities. Kurnik PB. **Cardiol Clin** 1996 May;14(2):251–62 (31 ref.)

Circadian patterns and triggers of sudden cardiac death. Peters RW. **Cardiol Clin** 1996 May;14(2):185–94 (42 ref.)

Chronobiology and chronotherapy of asthma. Pincus DJ, et al. **Clin Chest Med** 1995 Dec;16(4):699–713 (62 ref.)

An unusual case of mixed sclerosing bone dystrophy presenting with morning stiffness and joint swelling in childhood: a case report. Foeldvari I, et al. **Clin Exp Rheumatol** 1995 Jul–Aug;13(4):525–8 (19 ref.)

Nocturnal hypoglycaemia in patients with insulin–dependent diabetes mellitus. Bendtson I. **Dan Med Bull** 1995 Jun; 42(3):269–84 (172 ref.)

Chronomodulation of chemotherapy against metastatic colorectal cancer. International Organization for Cancer Chronotherapy. Lévi F, et al. **Eur J Cancer** 1995 Jul–Aug; 31A(7–8):1264–70 (43 ref.)

Hematopoiesis occurs in rhythms. Laerum OD. **Exp Hematol** 1995 Oct;23(11):1145–7 (38 ref.)

Treatment of delayed sleep phase syndrome. Regestein QR, et al. **Gen Hosp Psychiatry** 1995 Sep;17(5):335–45 (69 ref.)

Chronobiological aspects of pulmonary thromboembolism. Manfredini R, et al. **Int J Cardiol** 1995 Nov 10;52(1):31–7 (98 ref.)

Circadian rhythms and the onset of acute myocardial infarction. Thompson DR, et al. **J Cardiovasc Risk** 1995 Dec;2(6):491–3 (12 ref.)

Sundown syndrome: etiology and management. Burney–Puckett M. **J Psychosoc Nurs Ment Health Serv** 1996 May;34(5):40–3 (15 ref.)

A model for circadian oscillations in the Drosophila period protein (PER). Goldbeter A. **Proc R Soc Lond B Biol Sci** 1995 Sep 22;261(1362):319–24 (46 ref.)

Effect of chronic stress associated with unemployment on salivary cortisol: overall cortisol levels, diurnal rhythm, and acute stress reactivity. Ockenfels MC, et al. **Psychosom Med** 1995 Sep–Oct;57(5):460–7 (61 ref.)

Influence of time of day on psychological responses to exercise. A review. Trine MR, et al. **Sports Med** 1995 Nov; 20(5):328–37 (69 ref.)

[Melatonin—the hormone of darkness] Kancheva RL, et al. **Cas Lek Cesk** 1996 Apr 17;135(8):231–5 (43 ref.) (Eng. Abstr.) **(Cze)**

[Shift work systems from the chronobiological viewpoint] **Knauth P. Wien Med Wochenschr** 1995;145(17–18):406–10 (31 ref.) (Eng. Abstr.) **(Ger)**

[Disorders of the circadian sleep-wake rhythm--diagnostic and therapeutic principles] Mayer G, et al. **Wien Med Wochenschr** 1995;145(17-18):423-30 (38 ref.) (Eng. Abstr.) **(Ger)**

[Therapy of emotional disturbance by manipulation of the biological clocks] Nagayama H. **Seishin Shinkeigaku Zasshi** 1995;97(8):575-85 (61 ref.) **(Jpn)**

DRUG EFFECTS

Use of melatonin in circadian rhythm disorders and following phase shifts. Skene DJ, et al. **Acta Neurobiol Exp (Warsz)** 1996;56(1):359-62 (23 ref.)

Melatonin as a chronobiotic: PROS and CONS. Steinlechner S. **Acta Neurobiol Exp (Warsz)** 1996;56(1):363-72 (64 ref.)

Pharmacological and genetic approaches for the study of circadian rhythms in mammals. Turek FW, et al. **Front Neuroendocrinol** 1995 Jul;16(3):191-223 (181 ref.)

Practical relevance of the 24-hour trough: peak ratio of antihypertensive drugs. Zannad F. **J Hypertens Suppl** 1995 Aug;13(2):S109-12 (41 ref.)

[Therapy of jet lag] Samel A, et al. **Wien Med Wochenschr** 1995;145(17-18):458-60 (21 ref.) (Eng. Abstr.) **(Ger)**

GENETICS

The circadian clock: from molecules to behaviour. Florez JC, et al. **Ann Med** 1995 Aug;27(4):481-90 (84 ref.)

Light, immediate-early genes, and circadian rhythms. Kornhauser JM, et al. **Behav Genet** 1996 May;26(3):221-40 (120 ref.)

Molecular control of circadian rhythms. Rosbash M. **Curr Opin Genet Dev** 1995 Oct;5(5):662-8 (67 ref.)

Pharmacological and genetic approaches for the study of circadian rhythms in mammals. Turek FW, et al. **Front Neuroendocrinol** 1995 Jul;16(3):191-223 (181 ref.)

Circadian rhythms: peering into the molecular clockwork. Hastings M. **J Neuroendocrinol** 1995 May;7(5):331-40 (62 ref.)

period and timeless tango: a dance of two clock genes. Reppert SM, et al. **Neuron** 1995 Nov;15(5):983-6 (23 ref.)

Molecular biological approach to the circadian clock mechanism. Ishida N. **Neurosci Res** 1995 Oct;23(3):231-40 (96 ref.)

IMMUNOLOGY

The role of airway inflammation in the pathophysiology of nocturnal asthma. Oosterhoff Y, et al. **Clin Exp Allergy** 1995 Oct;25(10):915-21 (39 ref.)

PHYSIOLOGY

Towards a molecular biology of the circadian clock and sleep of mammals. Shiromani PJ, et al. **Adv Neuroimmunol** 1995; 5(2):217-30 (89 ref.)

Biorhythms and the biological clock involvement of melatonin and the pineal gland in life and disease. Nir I. **Biomed Environ Sci** 1995 Jun;8(2):90-105 (54 ref.)

New models in vogue for circadian clocks. Kay SA, et al. **Cell** 1995 Nov 3;83(3):361-4 (20 ref.)

Molecular genetic analysis of circadian rhythms in vertebrates and invertebrates. Sehgal A. **Curr Opin Neurobiol** 1995 Dec;5(6):824-31 (73 ref.)

Marker rhythms for cancer chronotherapy. From laboratory animals to human beings. Focan C. **In Vivo** 1995 Jul-Aug; 9(4):283-98 (113 ref.)

Diurnal physiologic processes and circadian variation of acute myocardial infarction. Feng DL, et al. **J Cardiovasc Risk** 1995 Dec;2(6):494-8 (43 ref.)

A circadian perspective on myocardial ischaemia. Gnecchi-Ruscone T, et al. **J Cardiovasc Risk** 1995 Dec; 2(6):505-9 (73 ref.)

Circadian rhythms and the onset of myocardial infarction: clinical implications. Purcell H, et al. **J Cardiovasc Risk** 1995 Dec;2(6):510-4 (34 ref.)

The laboratory assessment of daytime sleepiness in childhood. Kotagal S, et al. **J Clin Neurophysiol** 1996 May; 13(3):208-18 (50 ref.)

Circadian rhythm sleep disorders: a brief review with special reference to long-term follow-up. Ohta T. **Nagoya J Med Sci** 1995 Dec;58(3-4):83-93 (30 ref.)

Changes in circadian rhythms and sleep quality with aging: mechanisms and interventions. Myers BL, et al. **Neurosci Biobehav Rev** 1995 Winter;19(4):553-71 (318 ref.)

Non-invasive blood pressure monitoring in man. Portaluppi F. **Pathol Biol (Paris)** 1996 Mar;44(3):196-200 (80 ref.)

Circadian rhythms and cancer chemotherapy. Focan C. **Pharmacol Ther** 1995;67(1):1-52 (289 ref.)

Biological rhythms in pain and in the effects of opioid analgesics. Labrecque G, et al. **Pharmacol Ther** 1995; 68(1):129-47 (80 ref.)

Principles of rhythmic motor pattern generation. Marder E, et al. **Physiol Rev** 1996 Jul;76(3):687-717 (327 ref.)

Circadian variation in sports performance. Atkinson G, et al. **Sports Med** 1996 Apr;21(4):292-312 (122 ref.)

Use of nocturnal penile tumescence and rigidity in the evaluation of male erectile dysfunction. Levine LA, et al. **Urol Clin North Am** 1995 Nov;22(4):775-88 (58 ref.)

[Circadian rhythm in the sensitivity of target systems to drugs: an underestimated phenomenon] Reinberg AE. **Bull Acad Natl Med** 1996 Mar;180(3):533-43; discussion 544-7 (31 ref.) (Eng. Abstr.) **(Fre)**

[Secretion of thyrotropin during states of wakefulness and sleep. Physiological data and clinical applications] Goichot B, et al. **Presse Med** 1996 Jun 15;25(21):980-4 (25 ref.) (Eng. Abstr.) **(Fre)**

[Ontogenesis of sleep-wakefulness regulation] Hinckel P, et al. **Psychother Psychosom Med Psychol** 1995 Nov; 45(11):367-72 (27 ref.) (Eng. Abstr.) **(Ger)**

[Concepts and models of sleep regulation] Achermann P, et al. **Wien Med Wochenschr** 1995;145(17-18):402-6 (40 ref.) (Eng. Abstr.) **(Ger)**

[Interaction of epileptic seizures and biological rhythms] Bülau P, et al. **Wien Med Wochenschr** 1995; 145(17-18):448-51 (37 ref.) (Eng. Abstr.) **(Ger)**

[Chronobiology and chronopharmacology of cardiovascular diseases] Lemmer B. **Wien Med Wochenschr** 1995; 145(17-18):445-7 (29 ref.) (Eng. Abstr.) **(Ger)**

[Chronobiological health of the circadian system: examples for disorders of the sleep-waking rhythm] Moog R. **Wien Med Wochenschr** 1995;145(17-18):452-3 (18 ref.) (Eng. Abstr.) **(Ger)**

[Chronobiological viewpoints of respiratory regulation] Raschke F. **Wien Med Wochenschr** 1995;145(17-18):435-9 (16 ref.) (Eng. Abstr.) **(Ger)**

[Cellular mechanisms of circadian clocks] Roenneberg T, et al. **Wien Med Wochenschr** 1995;145(17-18):385-9 (74 ref.) (Eng. Abstr.) **(Ger)**

[Pulsatile hormone secretion for control of target organs] Schöfl C, et al. **Wien Med Wochenschr** 1995; 145(17-18):431-5 (23 ref.) (Eng. Abstr.) **(Ger)**

[Diurnal blood pressure rhythm in patients with hypertension] Dabrowska E, et al. **Pol Arch Med Wewn** 1996 Feb;95(2):147-52 (48 ref.) **(Pol)**

[The complex interaction of the hypothalamic suprachiasmatic nuclei with the epiphysis and corpus striatum--a functionally unified system for regulating circadian behavioral fluctuations] Arushanian EB. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1996 Jan-Feb; 46(1):15-22 (44 ref.) (Eng. Abstr.) **(Rus)**

CIRCLE OF WILLIS

ANATOMY & HISTOLOGY

[Anatomy of the circle of Willis with 3D time of flight magnetic resonance angiography and analysis of partitions] Brunereau L, et al. **J Radiol** 1995 Sep;76(9):573-7 (19 ref.) (Eng. Abstr.) **(Fre)**

CIRCULAR DICHROISM

Structural information on proteins from circular dichroism spectroscopy possibilities and limitations. Bloemendal M, et al. **Pharm Biotechnol** 1995;7:65-100 (112 ref.)

[Circular dichroism of proteins: recent developments in analysis and prediction] Woody RW, et al. **Tanpakushitsu Kakusan Koso** 1996 Jan;41(1):56-69 (120 ref.) **(Jpn)**

CIRCUMCISION

ABC of general surgery in children. Problems with the penis and prepuce [see comments] Davenport M. **BMJ** 1996 Feb 3;312(7026):299-301 (0 ref.) Comment in: BMJ 1996 May 11;312(7040):1230-1.

Neonatal circumcision revisited. Fetus and Newborn Committee, Canadian Paediatric Society. **Can Med Assoc J** 1996 Mar 15;154(6):769-80 (122 ref.)

Neonatal circumcision: an end to the controversy? Roberts JA. **South Med J** 1996 Feb;89(2):167-71 (37 ref.)

ADVERSE EFFECTS

Treating complications of circumcision. Baskin LS, et al. **Pediatr Emerg Care** 1996 Feb;12(1):62-8 (33 ref.)

INSTRUMENTATION

Use of the Mogen clamp for neonatal circumcision. Reynolds RD. **Am Fam Physician** 1996 Jul;54(1):177-82 (11 ref.)

CIRCUMCISION, FEMALE

Irreversible error: the power and prejudice of female genital mutilation. Annas CL. **J Contemp Health Law Policy** 1996 Spring;12(2):325-53 (217 ref.)

ETHNOLOGY

Judging the other. Responding to traditional female genital surgeries. Lane SD, et al. **Hastings Cent Rep** 1996 May-Jun; 26(3):31-40 (61 ref.)

[Study of a custom in Somalia: the circumcision of girls] Bayoudh F, et al. **Med Trop (Mars)** 1995;55(3):238-42 (15 ref.) (Eng. Abstr.) **(Fre)**

STATISTICS & NUMERICAL DATA

[Study of a custom in Somalia: the circumcision of girls] Bayoudh F, et al. **Med Trop (Mars)** 1995;55(3):238-42 (15 ref.) (Eng. Abstr.) **(Fre)**

CIRRHOSIS see **FIBROSIS**

CIRRHOSIS, LIVER see **LIVER CIRRHOSIS**

CISPLATIN

[Cisplatin and carboplatin--update] Geffen DB, et al. **Harefuah** 1995 Aug;129(3-4):131-5 (40 ref.) **(Heb)**

ADMINISTRATION & DOSAGE

Carboplatin versus cisplatin in ovarian cancer. Alberts DS. **Semin Oncol** 1995 Oct;22(5 Suppl 12):88-90 (6 ref.)

Combination regimens of paclitaxel and the platinum drugs as first-line regimens for ovarian cancer. Ozols RF. **Semin Oncol** 1995 Dec;22(6 Suppl 15):1-6 (17 ref.)

[Treatment for hormone-refractory or relapsing prostatic cancer] Hirao Y, et al. **Gan To Kagaku Ryoho** 1996 Mar; 23(4):418-26 (17 ref.) (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Comparative adverse effect profiles of platinum drugs. McKeage MJ. **Drug Saf** 1995 Oct;13(4):228-44 (154 ref.)

Mutagenic and carcinogenic properties of platinum-based anticancer drugs. Sanderson BJ, et al. **Mutat Res** 1996 Aug 17;355(1-2):59-70 (59 ref.)

Management of cisplatin-induced delayed emesis. Hesketh P. **Oncology** 1996 Jun;53 Suppl 1:73-7 (14 ref.)

Optimal control of acute cisplatin-induced emesis. Verweij J, et al. **Oncology** 1996 Jun;53 Suppl 1:56-64 (80 ref.)

[Prevention and treatment of toxic and adverse effects of cisplatin] Deng C, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1995 Jun;30(6):376-9 (30 ref.) **(Chi)**

[Efficacy of ondansetron in acute and delayed cisplatin-induced nausea and vomiting] Depierre A. **Bull Cancer (Paris)** 1996 Feb;83(2):147-53 (29 ref.) (Eng. Abstr.) **(Fre)**

[Leukoencephalopathy under cisplatin therapy] David-Götting I, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1995 Nov;163(5):460-1 (0 ref.) **(Ger)**

[Multiple cerebral infarction after treatment with cisplatin] Komatsumoto S, et al. **Rinsho Shinkeigaku** 1996 Mar; 36(3):499-502 (9 ref.) (Eng. Abstr.) **(Jpn)**

ANALOGS & DERIVATIVES

Cisplatin and derived anticancer drugs: mechanism and current status of DNA binding. Bloemink MJ, et al. **Met Ions Biol Syst** 1996;32:641-85 (191 ref.)

CHEMISTRY

Cisplatin and derived anticancer drugs: mechanism and current status of DNA binding. Bloemink MJ, et al. **Met Ions Biol Syst** 1996;32:641-85 (191 ref.)

Current status of structure-activity relationships of platinum anticancer drugs: activation of the trans geometry. Farrell N. **Met Ions Biol Syst** 1996;32:603-39 (104 ref.)

Trans-diammineplatinum(II): what makes it different from cis-DDP? Coordination chemistry of a neglected relative of cisplatin and its interaction with nucleic acids. Lippert B. **Met Ions Biol Syst** 1996;33:105-41 (153 ref.)

METABOLISM

Proteins that bind to and mediate the biological activity of platinum anticancer drug-DNA adducts. Whitehead JP, et al. **Met Ions Biol Syst** 1996;32:687-726 (111 ref.)

PHARMACOKINETICS

Insights into mechanisms of cisplatin resistance and potential for its clinical reversal. Gosland M, et al. **Pharmacotherapy** 1996 Jan-Feb;16(1):16-39 (200 ref.)

PHARMACOLOGY

Cisplatin. Dabholkar M, et al. **Cancer Chemother Biol Response Modif** 1996;16:88-110 (101 ref.)

THERAPEUTIC USE

Cisplatin-based chemotherapy in renal transplant recipients. A case report and a review of the literature. Benisovich VI, et al. **Cancer** 1996 Jan 1;77(1):160-3 (22 ref.)

Cisplatin plus radiation therapy. Wheeler RH, et al. **J Infus Chemother** 1995 Spring;5(2):61-6 (46 ref.)

The potential role of amifostine in conjunction with cisplatin in the treatment of locally advanced carcinoma of the cervix. Wadler S, et al. **Semin Oncol** 1996 Aug;23(4 Suppl 8):64-8 (33 ref.)

Cisplatin and DNA repair in cancer chemotherapy. Zamble DB, et al. **Trends Biochem Sci** 1995 Oct;20(10):435-9 (33 ref.)

[Cisplatin and radiotherapy: towards a new therapeutic system?] Reboul F, et al. **Bull Cancer Radiother** 1990; 77(2):95-100 (28 ref.) **(Fre)**

TOXICITY

Strategies to prevent nephrotoxicity of anticancer drugs. Skinner R. **Curr Opin Oncol** 1995 Jul;7(4):310-5 (38 ref.)

Current status of structure-activity relationships of platinum anticancer drugs: activation of the trans geometry. Farrell N. **Met Ions Biol Syst** 1996;32:603-39 (104 ref.)

[Cisplatin resistance in a murine leukemia cell line associated with defect of apoptosis] Segal-Bendirdjian E, et al.

CISPLATIN

Bull Cancer (Paris) 1996 May;83(5):371–8 (37 ref.) (Eng. Abstr.) (Fre)

CISTERNA CHYLI see **THORACIC DUCT**

CISTERNA MAGNA

see related
VENTRICULOSTOMY

Innovations in aneurysmal subarachnoid hemorrhage: intracisternal t-PA for the prevention of vasospasm. Bell TE, et al. **J Neurosci Nurs** 1996 Apr;28(2):107–13 (37 ref.)

CISTERNOGRAPHY, MYELOGRAPHIC see **MYELOGRAPHY**

CISTRON see **GENES, STRUCTURAL**

CITALOPRAM

ADVERSE EFFECTS

Does selectivity matter? Deakin JFW.
Int Clin Psychopharmacol 1996 Mar;11 Suppl 1:13–7 (12 ref.)

The safety and tolerability of citalopram. Muldoon C.
Int Clin Psychopharmacol 1996 Mar;11 Suppl 1:35–40 (17 ref.)

PHARMACOKINETICS

Pharmacology and pharmacokinetics of citalopram and other SSRIs. Baumann P. **Int Clin Psychopharmacol** 1996 Mar; 11 Suppl 1:5–11 (62 ref.)

PHARMACOLOGY

Pharmacology and pharmacokinetics of citalopram and other SSRIs. Baumann P. **Int Clin Psychopharmacol** 1996 Mar; 11 Suppl 1:5–11 (62 ref.)

Does selectivity matter? Deakin JFW.
Int Clin Psychopharmacol 1996 Mar;11 Suppl 1:13–7 (12 ref.)

Serotonin: current understanding and the way forward. Dinan TG. **Int Clin Psychopharmacol** 1996 Mar;11 Suppl 1:19–21 (10 ref.)

THERAPEUTIC USE

Scandinavian experience with citalopram in the elderly. Gottfries CG. **Int Clin Psychopharmacol** 1996 Mar;11 Suppl 1:41–4 (14 ref.)

The antidepressant efficacy of citalopram. Montgomery SA, et al. **Int Clin Psychopharmacol** 1996 Mar;11 Suppl 1:29–33 (9 ref.)

CITICOLINE see **CYTIDINE DIPHOSPHATE CHOLINE**

CITRATES

BLOOD

[Citric acid] Isshiki G, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:597–9 (18 ref.) (Jpn)

METABOLISM

Proposed role for a combination of citric acid and ascorbic acid in the production of dietary iron overload: a fundamental cause of disease. Crawford RD.
Biochem Mol Med 1995 Feb;54(1):1–11 (77 ref.)

PHARMACOLOGY

Effects of bicarbonate, citrate, and phosphate loading on performance. Horswill CA. **Int J Sport Nutr** 1995 Jun;5 Suppl:S111–9 (49 ref.)

Inhibition of citrate lyase may aid aerobic endurance. McCarty MF. **Med Hypotheses** 1995 Sep;45(3):247–54 (77 ref.)

CITROVORUM FACTOR see **LEUCOVORIN**

CITRUS FRUITS

Blood pressure-lowering effect of adding grapefruit juice to nifedipine and terazosin in a patient with severe renovascular hypertension. Pisarik P. **Arch Fam Med** 1996 Jul-Aug;5(7):413–6 (17 ref.)

CITY HOSPITALS see **HOSPITALS, URBAN**

CIVIL DEFENSE

Effective emergency management: reconsidering the bureaucratic approach. Neal DM, et al. **Disasters** 1995 Dec; 19(4):327–37 (48 ref.)

CIVIL RIGHTS

The maternal-fetal rights dilemma: honoring a woman's choice of medical care during pregnancy. Arch RR.
J Contemp Health Law Policy 1996 Spring;12(2):637–73 (255 ref.)

Legal recognition of transsexuals in Australia. Finlay H.
J Contemp Health Law Policy 1996 Spring;12(2):503–33 (95 ref.)

Absolving a deadly sin: a medical and legal argument for including obesity as a disability under the Americans with Disabilities Act. Kuss CL.
J Contemp Health Law Policy 1996 Spring;12(2):563–605 (335 ref.)

Legal status of the mentally disabled person in South African law. Oosthuizen H, et al. **Med Law** 1995;14(7–8):601–9 (9 ref.)

Stigma, labelling and psychiatric misdiagnosis: origins and outcomes. Witztum E, et al. **Med Law** 1995;14(7–8):659–69 (27 ref.)

CLADOSPORIUM

Chromomycosis. Bayles MA. **Curr Top Med Mycol** 1995; 6:221–43 (98 ref.)

GENETICS

Cf9 and Avr9, two major players in the gene-for-gene game. de Wit PJ. **Trends Microbiol** 1995 Jul;3(7):251–2 (15 ref.)

CLADOSPORIUM WERNECKII see **EXOPHIALA**

CLADRIBINE

METABOLISM

On the phosphorylation of 2-chlorodeoxyadenosine (CdA) and its correlation with clinical response in leukemia treatment. Arnér ES. **Leuk Lymphoma** 1996 Apr; 21(3–4):225–31 (64 ref.)

PHARMACOKINETICS

2-Chloro-2'-deoxyadenosine--clinical, biochemical and pharmacokinetic considerations. Liliemark J, et al.
Arch Immunol Ther Exp (Warsz) 1994;42(1):7–10 (19 ref.)

PHARMACOLOGY

Cladribine (2-chloro-2'-deoxyadenosine): new perspectives in clinical immunosuppression. Górski A, et al.
Arch Immunol Ther Exp (Warsz) 1994;42(1):11–2 (10 ref.)

Discovery, mechanism and expected clinical significance of selective cytotoxicity of 2-chloro-2'-deoxyadenosine (2-CdA). Grieb P. **Arch Immunol Ther Exp (Warsz)** 1994; 42(1):1–5 (34 ref.)

On the phosphorylation of 2-chlorodeoxyadenosine (CdA) and its correlation with clinical response in leukemia treatment. Arnér ES. **Leuk Lymphoma** 1996 Apr; 21(3–4):225–31 (64 ref.)

THERAPEUTIC USE

2-Chloro-2'-deoxyadenosine [editorial] Delannoy A, et al. **Acta Clin Belg** 1995;50(4):193–6 (10 ref.)

2-Chloro-2'-deoxyadenosine--clinical, biochemical and pharmacokinetic considerations. Liliemark J, et al.
Arch Immunol Ther Exp (Warsz) 1994;42(1):7–10 (19 ref.)

The role of cladribine in the treatment of lymphoid malignancies. Nelson MC, et al. **Oncol Nurs Forum** 1995 Oct;22(9):1395–400 (22 ref.)

CLAIMS REVIEW see **INSURANCE CLAIM REVIEW**

CLAIRVOYANCE see **PARAPSYCHOLOGY**

CLARITHROMYCIN

[Clarithromycin] Schouenborg P. **Ugeskr Laeger** 1996 May 13;158(20):2870–3 (31 ref.) (Dan)

ADMINISTRATION & DOSAGE

[Clarithromycin combined with pyrimethamine in cerebral toxoplasmosis--a a report of 2 cases] Dalston MO, et al. **Rev Soc Bras Med Trop** 1995 Oct-Dec;28(4):409–13 (11 ref.) (Eng. Abstr.) (Por)

PHARMACOLOGY

Ribosomal drug resistance in mycobacteria. Sander P, et al. **Res Microbiol** 1996 Jan-Feb;147(1–2):59–67 (73 ref.)

[Azithromycin: critical points] Philippon A, et al.
Pathol Biol (Paris) 1995 Jun;43(6):488–97 (55 ref.) (Eng. Abstr.) (Fre)

THERAPEUTIC USE

Clarithromycin for treatment of Helicobacter pylori infections. Graham DY. **Eur J Gastroenterol Hepatol** 1995 Aug;7 Suppl 1:S55–8 (46 ref.)

The newer macrolides. Azithromycin and clarithromycin. Zuckerman JM, et al. **Infect Dis Clin North Am** 1995 Sep; 9(3):731–45 (66 ref.)

Treatment and prophylaxis of Mycobacterium avium complex. Young LS. **Int J STD AIDS** 1996;7 Suppl 1:23–7 (15 ref.)

Strategies for Helicobacter pylori eradication in 1995: a review of international and Belgian experience. Deltenre M, et al. **J Physiol Pharmacol** 1996 Mar;47(1):59–69 (66 ref.)

Clarithromycin against Mycobacterium avium complex infections. Heifets LB. **Tuber Lung Dis** 1996 Feb; 77(1):19–26 (105 ref.)

[How to eradicate Helicobacter pylori in 1995? Critical review of available treatments] Deltenre M, et al.
Gastroenterol Clin Biol 1996 Jan;20(1 Pt 2):S44–S52 (122 ref.) (Fre)

CLASS I ANTIGENS see **HISTOCOMPATIBILITY ANTIGENS CLASS I**

CLASS I GENES see **GENES, MHC CLASS I**

CLASS I HEPARIN-BINDING GROWTH FACTOR see **FIBROBLAST GROWTH FACTOR, ACIDIC**

CLASS II ANTIGENS see **HISTOCOMPATIBILITY ANTIGENS CLASS II**

CLASS II GENES see **GENES, MHC CLASS II**

CLASS II HEPARIN-BINDING GROWTH FACTOR see **FIBROBLAST GROWTH FACTOR, BASIC**

CLASS II HUMAN ANTIGENS see **HLA-D ANTIGENS**

CLASS SWITCHING see **IMMUNOGLOBULIN CLASS SWITCHING**

CLASSICAL COMPLEMENT PATHWAY see **COMPLEMENT PATHWAY, CLASSICAL**

CLASSIFICATION

Arbitrarily amplified DNA in systematics and phylogenetics. Schierwater B. **Electrophoresis** 1995 Sep;16(9):1643–7 (45 ref.)

Definitions of quality of life: a taxonomy. Farquhar M.
J Adv Nurs 1995 Sep;22(3):502–8 (41 ref.)

CLASTOGENS see **MUTAGENS**

CLATHRIN

PHYSIOLOGY

The emergence of clathrin-independent pinocytic pathways. Lamaze C, et al. **Curr Opin Cell Biol** 1995 Aug;7(4):573–80 (55 ref.)

Coated vesicles: a diversity of form and function. Schmid SL, et al. **FASEB J** 1995 Nov;9(14):1445–53 (70 ref.)

CLAUSTROPHOBIA see **PHOBIC DISORDERS**

CLAUSTRUM see **BASAL GANGLIA**

CLAVICLE

Congenital clavicular pseudoarthrosis associated with vascular thoracic outlet syndrome: case presentation and review of the literature. Hahn K, et al.
Cathet Cardiovasc Diagn 1995 Aug;35(4):321–7 (30 ref.)

RADIOGRAPHY

Osteitis condensans of the clavicle: does fibrocartilage play a role? A report of two cases with spontaneous clinical and roentgenographic resolution. Berthelot JM, et al.
Rev Rhum Engl Ed 1995 Jul-Sep;62(7–8):501–6 (54 ref.)

CLAVULANIC ACIDS

ADVERSE EFFECTS

[Acute pancreatitis associated with hepatotoxicity induced by amoxicillin-clavulanic acid] Galindo C, et al.
Rev Esp Enferm Dig 1995 Aug;87(8):597–600 (23 ref.) (Eng. Abstr.) (Spa)

CLAW see **HOOF AND CLAW**

CLEAN ROOMS see **ENVIRONMENT, CONTROLLED**

CLEANSING AGENTS see **DETERGENTS**

CLEAVAGE, CELL see **CELL DIVISION**

CLEAVAGE STAGE, OVUM

see related
CELL DIVISION

PHYSIOLOGY

Sea urchin microtubules. Suprenant KA, et al.
Curr Top Dev Biol 1995;31:65–99 (206 ref.)

CLEFT LIP

The EEC syndrome: a literature study. Roelfsema NM, et al. **Clin Dysmorphol** 1996 Apr;5(2):115–27 (124 ref.)

COMPLICATIONS

Intranasal tooth in a patient with a cleft lip and alveolus. Yeung KH, et al. **Cleft Palate Craniofac J** 1996 Mar;

33(2):157-9 (30 ref.)
The residual cleft lip nasal deformity. An anatomic approach. Rifley W, et al. **Clin Plast Surg** 1996 Jan;23(1):81-92 (67 ref.)

PATHOLOGY

Van der Woude syndrome. Kulkarni ML, et al. **Ann Dent** 1995 Summer-Fall;54(1-2):34-5 (7 ref.)
[The Hay-Wells syndrome, its incidence in Spain and a review of the literature] Martínez-Frías ML, et al. **An Esp Pediatr** 1996 Jul;45(1):101-4 (24 ref.) **(Spa)**

SURGERY

Alternative donor site for alveolar bone grafting in adults with cleft lip and palate. So LL, et al. **Angle Orthod** 1996; 66(1):9-16 (64 ref.)

THERAPY

Management of cleft lip and palate. Habel A, et al. **Arch Dis Child** 1996 Apr;74(4):360-6 (25 ref.)
Maxillary orthopedics in the presurgical management of infants with cleft lip and palate. Sierra FJ, et al. **Pediatr Dent** 1995 Nov-Dec;17(7):419-23 (24 ref.)

CLEFT PALATE

The EEC syndrome: a literature study. Roelfsema NM, et al. **Clin Dysmorphol** 1996 Apr;5(2):115-27 (124 ref.)

CHEMICALLY INDUCED

Review of the interaction between TCDD and glucocorticoids in embryonic palate. Abbott BD. **Toxicology** 1995 Dec 28;105(2-3):365-73 (86 ref.)

COMPLICATIONS

Palatal mucoperiosteal expansion as an adjunct to palatal fistula repair: case report and review of the literature. Van Damme PA, et al. **Cleft Palate Craniofac J** 1996 May; 33(3):255-7 (10 ref.)
Intranasal tooth in a patient with a cleft lip and alveolus. Yeung KH, et al. **Cleft Palate Craniofac J** 1996 Mar; 33(2):157-9 (30 ref.)

EPIDEMIOLOGY

Prevalence of fetal facial cleft at different stages of pregnancy. Snijders RJ, et al. **Ultrasound Obstet Gynecol** 1995 Nov;6(5):327-9 (11 ref.)

PATHOLOGY

Van der Woude syndrome. Kulkarni ML, et al. **Ann Dent** 1995 Summer-Fall;54(1-2):34-5 (7 ref.)
[The Hay-Wells syndrome, its incidence in Spain and a review of the literature] Martínez-Frías ML, et al. **An Esp Pediatr** 1996 Jul;45(1):101-4 (24 ref.) **(Spa)**

PHYSIOPATHOLOGY

Cleft palate speech dissected: a review of current knowledge and analysis. Wyatt R, et al. **Br J Plast Surg** 1996 Apr; 49(3):143-9 (32 ref.)

SURGERY

Alternative donor site for alveolar bone grafting in adults with cleft lip and palate. So LL, et al. **Angle Orthod** 1996; 66(1):9-16 (64 ref.)
Ethical issues in the case of surgical repair of cleft palate. Berkowitz S. **Cleft Palate Craniofac J** 1995 Jul;32(4):271-6; discussion 277-81 (66 ref.)
Alveolar cleft bone grafting (Part I): Primary bone grafting. Eppley BL. **J Oral Maxillofac Surg** 1996 Jan;54(1):74-82 (23 ref.)
Alveolar cleft bone grafting (Part II): Secondary bone grafting. Ochs MW. **J Oral Maxillofac Surg** 1996 Jan; 54(1):83-8 (37 ref.)
Submucous cleft palate: diagnostic methods and outcomes of surgical treatment. Gosain AK, et al. **Plast Reconstr Surg** 1996 Jun;97(7):1497-509 (102 ref.)

THERAPY

Management of cleft lip and palate. Habel A, et al. **Arch Dis Child** 1996 Apr;74(4):360-6 (25 ref.)
Maxillary orthopedics in the presurgical management of infants with cleft lip and palate. Sierra FJ, et al. **Pediatr Dent** 1995 Nov-Dec;17(7):419-23 (24 ref.)

CLEFT PALATE PROSTHESIS see **PALATAL OBTURATORS**

CLEIDOCRANIAL DYSOSTOSIS see **CLEIDOCRANIAL DYSPLASIA**

CLEIDOCRANIAL DYSPLASIA

COMPLICATIONS

Autotransplantation in cleidocranial dysplasia: case report with 5-year follow-up. Halazonetis J, et al. **J Oral Maxillofac Surg** 1995 Dec;53(12):1472-5 (10 ref.)

CLENBUTEROL

THERAPEUTIC USE

Clenbuterol: a substitute for anabolic steroids? Prather ID, et al. **Med Sci Sports Exerc** 1995 Aug;27(8):1118-21 (24 ref.)

CLERAMBAULT SYNDROME see **ORGANIC MENTAL DISORDERS, PSYCHOTIC**

CLETHRIONOMYS see **MICROTINAE**

CLIMACTERIC

The climacteric in The Netherlands: a review of Dutch studies on epidemiology, attitudes and use of hormone replacement therapy. Barentsen R. **Eur J Obstet Gynecol Reprod Biol** 1996 Apr;64 Suppl:S7-11 (22 ref.)
Review of the endometrial safety during intravaginal treatment with estriol. Vooijs GP, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Sep;62(1):101-6 (50 ref.)

DRUG EFFECTS

The effects of estradiol valerate plus medroxyprogesterone acetate and conjugated estrogens plus medrogestone on climacteric symptoms and metabolic variables in perimenopausal women. Egarter C, et al. **Acta Obstet Gynecol Scand** 1996 Apr;75(4):386-93 (40 ref.)
Psychological and sexual symptoms associated with the menopause and the effects of hormone replacement therapy. Pearce J, et al. **Br J Psychiatry** 1995 Aug; 167(2):163-73 (60 ref.)
Norethindrone--a review of therapeutic applications. Taitel HF, et al. **Int J Fertil Menopausal Stud** 1995 Jul-Aug; 40(4):207-23 (64 ref.)
Hormone replacement therapy and vaginal bleeds. Theoretical aspects and clinical management. Samsioe G. **Zentralbl Gynakol** 1996;118(4):181-7 (28 ref.)
[Current trends in hormone therapy during menopause and postmenopause] Suhonen S. **Duodecim** 1994;110(10):1011-8 (35 ref.) **(Fin)**
-Hormone substitution in postmenopause- Keller PJ. **Arch Gynecol Obstet** 1995;256 Suppl:S193-7 (6 ref.) **(Ger)**
[Estrogens in menopause--therapy and prevention. II. Estrogens and osteoporosis] Hüfner M. **Internist (Berl)** 1996 Apr;37(4):405-9 (50 ref.) **(Ger)**
[Estrogens in menopause--therapy and prevention. III. Estrogen replacement in menopause: uses and risks in prevention and therapy of cardiovascular diseases] Reincke M, et al. **Internist (Berl)** 1996 Apr;37(4):410-5; discussion 415 (20 ref.) **(Ger)**
[Estrogens in menopause--therapy and prevention. I. Hormone substitution in climacteric and postmenopause] Wuttke W. **Internist (Berl)** 1996 Apr;37(4):402-5 (50 ref.) **(Ger)**
[Gestagens and hormone substitution] Klinger G. **Zentralbl Gynakol** 1995;117 Suppl:25-9 (0 ref.) **(Ger)**
[Long-term hormone replacement and risk of breast carcinoma: current status. On behalf of the German Menopause Society and the Professional Society of Gynecologic Endocrinology and Reproductive Medicine of the German Society of Gynecology and Obstetrics] Kuhl H, et al. **Zentralbl Gynakol** 1995;117(10):549-53 (35 ref.) **(Ger)**
[Transdermal and oral hormone substitution with estrogens: a comparison] Schindler AE. **Zentralbl Gynakol** 1995; 117(10):504-7 (27 ref.) (Eng. Abstr.) **(Ger)**
[Prevention of cardiovascular diseases by hormone replacement in postmenopause] Windler E. **Zentralbl Gynakol** 1996;118(4):188-97 (77 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Norethindrone--a review of therapeutic applications. Taitel HF, et al. **Int J Fertil Menopausal Stud** 1995 Jul-Aug; 40(4):207-23 (64 ref.)
[Andropause: myth or reality?] Tomer Y, et al. **Harefuah** 1995 Jun 15;128(12):785-8 (51 ref.) **(Heb)**

PSYCHOLOGY

[Psychiatric manifestations in climacteric. Diagnostic difficulties and therapeutic possibilities] Nijs P, et al. **Gynakologe** 1995 Dec;28(6):420-5 (22 ref.) **(Ger)**

CLIMATE

see related
ACCLIMATIZATION

The potential health impacts of climate change: an overview. Kovats S, et al. **Med War** 1995 Oct-Dec;11(4):168-78 (28 ref.)
Climate change and human health: possible communicable disease consequences in the United Kingdom. Rowland MG. **Med War** 1995 Oct-Dec;11(4):188-94 (19 ref.)
Polycythemia vera--a climatological disease. Berlin NI. **Trans Am Clin Climatol Assoc** 1994;106:25-36; discussion 36-7 (33 ref.)
The Jeremiah Metzger Lecture on the climate of cities. Bondurant S. **Trans Am Clin Climatol Assoc** 1995; 107:189-212 (32 ref.)
[Dermatologic climate therapy--definition, indications and public health necessity] Vocks E, et al. **Rehabilitation (Stuttg)** 1995 Aug;34(3):148-53 (21 ref.) (Eng. Abstr.) **(Ger)**
[Immunophysiologic mechanisms of adaptation to extreme conditions] Novikov VS. **Fiziol Cheloveka** 1996 Mar-Apr; 22(2):25-34 (44 ref.) **(Rus)**

CLINICAL CLERKSHIP

METHODS

Learner-centered strategies in clerkship education. Curry RH, et al. **Am J Med** 1996 Jun;100(6):589-95 (34 ref.)

CLINICAL COMPETENCE

Moral competency. Cassidy VR. **Annu Rev Nurs Res** 1996; 14:181-204 (94 ref.)
The impact of multiskilling on quality of care. Holzemer WL. **Int Nurs Rev** 1996 Jan-Feb;43(1):21-5 (32 ref.)
An explanation of the differences between expert and novice performance in the administration of an intramuscular injection of an analgesic agent to a patient in pain. Noyes J. **J Adv Nurs** 1995 Oct;22(4):800-7 (61 ref.)
Intuition and expertise: comments on the Benner debate. Paley J. **J Adv Nurs** 1996 Apr;23(4):665-71 (38 ref.)
Cultural competence--an essential hybrid for delivering high quality care in the 1990's and beyond. Lavizzo-Mourey RJ, et al. **Trans Am Clin Climatol Assoc** 1995;107:226-35; discussion 236-7 (40 ref.)
[Does learning new knowledge and discarding old knowledge go too slowly?] Olesen F. **Nord Med** 1996 Apr; 111(4):119-22 (15 ref.) **(Dan)**
[Competence of diagnosis: chronic generalized infection, caused by hepatitis virus (B, C) (editorial)] Serov VV, et al. **Arkh Patol** 1995 Jul-Aug;57(4):3-5 (20 ref.) **(Rus)**
[Learning clinical medicine] Lifshitz A. **Gac Med Mex** 1995 Sep-Dec;131(5-6):571-6 (15 ref.) (Eng. Abstr.) **(Spa)**
[The clinician up to date. A danger for the patient?] García Martín M, et al. **Med Clin (Barc)** 1995 Nov 11;105(16):622-7 (51 ref.) **(Spa)**

LEGISLATION & JURISPRUDENCE

Credibility: the key to the successful physician witness. Marshall JC. **Surv Ophthalmol** 1995 Jul-Aug;40(1):69-72 (14 ref.)

STANDARDS

Neglected conflicts in the discipline of nursing: perceptions of the importance and value of practical skill. Bjørk IT. **J Adv Nurs** 1995 Jul;22(1):7-12 (44 ref.)
Critical thinking and intuitive nursing practice. Paul RW, et al. **J Adv Nurs** 1995 Jul;22(1):40-7 (5 ref.)
HIV infection. What nurses need to know. The consumer perspective. Schietinger H, et al. **Nurs Clin North Am** 1996 Mar;31(1):137-52 (21 ref.)
Documentation and outcomes of advanced nursing practice. Boyle DM. **Oncol Nurs Forum** 1995 Sep;22(8 Suppl):11-7 (57 ref.)
Self-efficacy in pediatric resuscitation: implications for education and performance. Maibach EW, et al. **Pediatrics** 1996 Jan;97(1):94-9 (33 ref.)

CLINICAL ENGINEERING see **BIOMEDICAL ENGINEERING**

CLINICAL ETHICS see **ETHICS, MEDICAL**

CLINICAL INFORMATICS see **MEDICAL INFORMATICS**

CLINICAL INVESTIGATOR see **RESEARCH PERSONNEL**

CLINICAL INVESTIGATORS see **RESEARCH PERSONNEL**

CLINICAL LABORATORY INFORMATION SYSTEMS

Integrating instruments and the laboratory information system. Chou D. **Am J Clin Pathol** 1996 Apr;105(4 Suppl 1):S60-4 (10 ref.)
The satellite laboratory and point-of-care testing. Integration of information. Jacobs E, et al. **Am J Clin Pathol** 1995 Oct;104(4 Suppl 1):S33-9 (17 ref.)
Internet: road to heaven or hell for the clinical laboratory? Chou D. **Clin Chem** 1996 May;42(5):827-30 (26 ref.)
[Laboratory systematization] Murakami S. **Rinsho Byori** 1995 Oct;43(10):994-8 (4 ref.) (Eng. Abstr.) **(Jpn)**

STANDARDS

Software standards and the laboratory information system. Aller RD. **Am J Clin Pathol** 1996 Apr;105(4 Suppl 1):S48-53 (15 ref.)
Closing the clinical laboratory testing loop with information technology. Connelly DP, et al. **Am J Clin Pathol** 1996

Apr;105(4 Suppl 1):S40–7 (23 ref.)
Software regression testing and quality assurance. Weilert M. **Am J Clin Pathol** 1996 Apr;105(4 Suppl 1):S10–6 (8 ref.)

CLINICAL LADDERS see **CAREER MOBILITY**

CLINICAL MARKERS see **BIOLOGICAL MARKERS**

CLINICAL MEDICINE

Refocusing on history-taking skills during internal medicine training. Schechter GP, et al. **Am J Med** 1996 Aug; 101(2):210–6 (54 ref.)
The need for evidence-based medicine. Sackett DL, et al. **J R Soc Med** 1995 Nov;88(11):620–4 (22 ref.)
Application of artificial neural networks to clinical medicine [see comments] Baxt WG. **Lancet** 1995 Oct 28; 346(8983):1135–8 (61 ref.) Comment in: Lancet 1995 Dec 2;346(8988):1501. Comment in: Lancet 1995 Dec 23–30;346(8991–8992):1712.
[How to read a scientific article? 5. How to choose a treatment?] Demichelis B, et al. **G Ital Cardiol** 1995 Oct; 25(10):1339–50 (55 ref.) **(Ita)**
[Decision making and informed consent in clinical medicine] Sakurai T. **Nippon Igaku Hoshasen Gakkai Zasshi** 1995 Oct; 55(13):459–62 (15 ref.) (Eng. Abstr.) **(Jpn)**

EDUCATION

How should subspecialists be trained for clinical careers? McFadden D. **Am J Med** 1996 Jul;101(1):1–4 (12 ref.)
[Learning clinical medicine] Lifshitz A. **Gac Med Mex** 1995 Sep-Dec;131(5–6):571–6 (15 ref.) (Eng. Abstr.) **(Spa)**

METHODS

Epidemiologic and clinical challenges in reviving the necropsy. Feinstein AR. **Arch Pathol Lab Med** 1996 Aug; 120(8):749–52 (11 ref.)
On the need for evidence-based medicine. Sackett DL, et al. **J Public Health Med** 1995 Sep;17(3):330–4 (22 ref.)

CLINICAL NURSE SPECIALISTS see **NURSE CLINICIANS**

CLINICAL NURSING RESEARCH

Delirium intervention research in acute care settings. Cronin-Stubbs D. **Annu Rev Nurs Res** 1996;14:57–73 (35 ref.)
Psychoneuroimmunological studies in HIV disease. McCain NL, et al. **Annu Rev Nurs Res** 1996;14:23–55 (75 ref.)
Blood pressure. Thomas SA, et al. **Annu Rev Nurs Res** 1996; 14:3–22 (87 ref.)
The organization of clinical supervision within the nursing profession: a review of the literature. Fowler J. **J Adv Nurs** 1996 Mar;23(3):471–8 (44 ref.)
The changing profile of acute childhood illness: a need for the development of family nursing knowledge. Rennick JE. **J Adv Nurs** 1995 Aug;22(2):258–66 (57 ref.)
Models and processes of research utilization. White JM, et al. **Nurs Clin North Am** 1995 Sep;30(3):409–20 (27 ref.)
Obtaining "informed" consent from the elderly. Alt-White AC. **West J Nurs Res** 1995 Dec;17(6):700–5 (12 ref.)

ORGANIZATION & ADMINISTRATION

Nursing development units: an opportunity for evaluation. Draper J. **J Adv Nurs** 1996 Feb;23(2):267–71 (24 ref.)
Using computerized clinical nursing data bases for nursing research. Nail LM, et al. **J Prof Nurs** 1996 Jul-Aug; 12(4):197–206 (28 ref.)
[INSERM clinical research network on sickle cell anemia: a tool for therapeutic care and research] Girot R. **Arch Pediatr** 1996;3 Suppl 1:321s–323s (9 ref.) **(Fre)**

CLINICAL PATHOLOGY see **PATHOLOGY, CLINICAL**

CLINICAL PATHWAYS see **CRITICAL PATHWAYS**

CLINICAL PHARMACOLOGY see **PHARMACOLOGY, CLINICAL**

CLINICAL PHARMACY SERVICE see **PHARMACY SERVICE, HOSPITAL**

CLINICAL PRACTICE NURSING RESEARCH see **CLINICAL NURSING RESEARCH**

CLINICAL PRACTICE PATTERNS see **PHYSICIAN'S PRACTICE PATTERNS**

CLINICAL PRACTICE VARIATIONS see **PHYSICIAN'S PRACTICE PATTERNS**

CLINICAL PROTOCOLS

see related
PATIENT SELECTION

Protocols for clinical care. Herbert SI, et al. **Comput Methods Programs Biomed** 1995 Sep-Oct; 48(1–2):21–6 (11 ref.)
Clinical application of gene transfer. Herrmann F. **J Mol Med** 1996 Apr;74(4):213–21 (120 ref.)
Medical management of severe head injury: present and future. Chesnut RM. **New Horiz** 1995 Aug;3(3):581–93 (45 ref.)
Latex allergy precautions. A research-based protocol. Steelman VM. **Nurs Clin North Am** 1995 Sep;30(3):475–93 (85 ref.)
[Drug treatment of chronic obstructive pulmonary disease] van Herwaarden CL, et al. **Ned Tijdschr Geneeskd** 1996 Apr 6;140(14):761–5 (35 ref.) **(Dut)**
[Chronic cardiac insufficiency: current treatment and future outlook] Reuge L, et al. **Rev Med Suisse Romande** 1996 Jun;116(6):441–50 (34 ref.) **(Fre)**
[Therapy recommendations for the use of intravenously applicable immunoglobulins] Marschner JP, et al. **Med Klin** 1996 Mar 15;91(3):141–7 (78 ref.) **(Ger)**
[Neurocutaneous disorders with achromic spots. Tuberous sclerosis of Bourneville. Diagnostic criteria and follow-up protocol] Prats-Viñas JM. **Rev Neurol** 1996 Sep; 24(133):1056–9 (7 ref.) **(Spa)**

CLINICAL SKILLS see **CLINICAL COMPETENCE**

CLINICAL TRIAL OVERVIEWS see **META-ANALYSIS**

CLINICAL TRIALS

see related
DRUG APPROVAL
META-ANALYSIS

A critique of the double-blind clinical trial. Part 2. Kiene H. **Altern Ther Health Med** 1996 Mar;2(2):59–64 (36 ref.)
Clinical trials in osteoarthritis [editorial] March LM, et al. **Ann Rheum Dis** 1996 Aug;55(8):491–3 (27 ref.)
Submacular surgery. Are randomized trials necessary? [editorial] Bressler NM. **Arch Ophthalmol** 1995 Dec; 113(12):1557–60 (31 ref.)
Drug trials in neuropathy. Hughes RA, et al. **Baillieres Clin Neurol** 1995 Nov;4(3):607–27 (87 ref.)
Design and assessment of clinical trials on continuous infusion. Schulman S, et al. **Blood Coagul Fibrinolysis** 1996 Mar;7 Suppl 1:S7–9 (8 ref.)
Clinical trial design for evaluating combination therapies. Paulus HE. **Br J Rheumatol** 1995 Nov;34 Suppl 2:92–5 (26 ref.)
Report of the National Eye Institute/Industry workshop on Clinical Trials in Dry Eyes. Lemp MA. **CLAO J** 1995 Oct; 21(4):221–32 (106 ref.)
Evidence based critical care medicine; what is it and what can it do for us? Evidence Based Medicine in Critical Care Group. Cook DJ, et al. **Crit Care Med** 1996 Feb;24(2):334–7 (46 ref.)
Clinical trials of diabetic neuropathy: past, present, and future. Pfeifer MA, et al. **Diabetes** 1995 Dec;44(12):1355–61 (51 ref.)
From trial outcomes to clinical practice. **Drug Ther Bull** 1996 May;34(5):38–40 (4 ref.)
How reliable are clinical trials? The importance of the criteria for early termination. Schwartz PJ. **Eur Heart J** 1995 Aug; 16 Suppl G:37–45 (29 ref.)
Recent clinical trials of pain control: impact on quality of life. Ahmedzai S. **Eur J Cancer** 1995;31A Suppl 6:S2–7 (31 ref.)
The role of clinical trials in assessing optimal treatment of cutaneous melanoma not extending beyond the regional nodes. Cascinelli N. **Eur J Surg Oncol** 1996 Apr;22(2):123–7 (49 ref.)
Open trials in cutaneous malignant melanoma. Rudenstam CM. **Eur J Surg Oncol** 1996 Apr;22(2):128–30 (8 ref.)
Understanding and evaluating clinical trials. Bigby M, et al. **J Am Acad Dermatol** 1996 Apr;34(4):555–90; quiz 591–3 (168 ref.)
Screening for ovarian cancer: what are the optimal surrogate endpoints for clinical trials? Karlan BY. **J Cell Biochem Suppl** 1995;23:227–32 (40 ref.)
Surrogate endpoint biomarkers for cervical cancer chemopreventive trials. Ruffin MT 4th, et al. **J Cell Biochem Suppl** 1995;23:113–24 (98 ref.)
The hidden truth: what do the clinical trials really tell us about BP control? Ruilope LM. **J Hum Hypertens** 1995 Jul;9 Suppl 2:S3–7 (13 ref.)
What have we learned from clinical trials in congestive heart failure? Swedberg K. **J Intern Med** 1996 Apr;239(4):307–8 (13 ref.)
Clinical application of gene transfer. Herrmann F. **J Mol Med** 1996 Apr;74(4):213–21 (120 ref.)
Recruiting minorities into clinical trials: toward a participant-friendly system [see comments] Swanson GM, et al. **J Natl Cancer Inst** 1995 Dec 6;87(23):1747–59 (107 ref.) Comment in: J Natl Cancer Inst 1996 Mar 20;88(6):377.
Minority inclusion in clinical trials issues and potential strategies. Brawley OW, et al. **J Natl Cancer Inst Monogr** 1995;(17):55–7 (18 ref.)
Measuring success in clinical gene therapy research. Culver KW. **Mol Med Today** 1996 Jun;2(6):234–6 (11 ref.)
HIV infection. Clinical research. Considerations for prospective participants. Hutchins SA, et al. **Nurs Clin North Am** 1996 Mar;31(1):125–35 (17 ref.)
An overview of radiotherapy trials for the treatment of brain metastases. Berk L. **Oncology (Huntingt)** 1995 Nov; 9(11):1205–12; discussion 1212–6, 1219 (26 ref.)
New anticancer agents in clinical development. Eckardt J, et al. **Oncology (Huntingt)** 1995 Nov;9(11):1191–9 (0 ref.)
Focus on qualitative methods: Using qualitative methods in intervention studies. Sandelowski M. **Res Nurs Health** 1996 Aug;19(4):359–64 (39 ref.)
Ethical aspects of prevention. Tomatis L. **Scand J Work Environ Health** 1995 Aug;21(4):245–51 (44 ref.)
Clinical trials of primary and secondary prevention of thrombosis and restenosis. Vermylen J. **Thromb Haemost** 1995 Jul;74(1):377–81 (54 ref.)
[DSM IV and research. The problem of clinical trials] Boyer P. **Encephale** 1995 Dec;21 Spec No 5:41–6 (3 ref.) (Eng. Abstr.) **(Fre)**
[Clinical trials in Israel—the need for good clinical practice guidelines] Garty N. **Harefuah** 1996 Feb 15;130(4):253–5 (4 ref.) **(Heb)**
[Current status and problems in clinical trial for new anticancer drug in Japan] Fukuoka M. **Gan To Kagaku Ryoho** 1996 Jan;23(2):141–5 (5 ref.) (Eng. Abstr.) **(Jpn)**
[Problems in conducting clinical trials for cancer patients] Kondo M. **Gan To Kagaku Ryoho** 1996 Jan;23(2):151–5 (6 ref.) (Eng. Abstr.) **(Jpn)**
[The guideline for clinical trials proposed by Japan Society for Cancer Therapy (JSCT)] Kurihara M. **Gan To Kagaku Ryoho** 1996 Jan;23(2):156–65 (10 ref.) (Eng. Abstr.) **(Jpn)**
[Has the clinical trials in Japan been accepted by the society?] Saijo S, et al. **Gan To Kagaku Ryoho** 1996 Jan;23(2):129–35 (5 ref.) (Eng. Abstr.) **(Jpn)**
[Getting informed consent in clinical trials on Japanese cancer patients] Sasako M. **Gan To Kagaku Ryoho** 1996 Jan;23(2):146–50 (3 ref.) (Eng. Abstr.) **(Jpn)**
[The importance of scientific clinical trials] Shimada Y. **Gan To Kagaku Ryoho** 1996 Jan;23(2):136–40 (2 ref.) (Eng. Abstr.) **(Jpn)**
[Concomitant therapies in the clinical trial in Alzheimer's disease] Bermejo F, et al. **Rev Neurol** 1995 Jan-Feb; 23(119):118–24 (81 ref.) (Eng. Abstr.) **(Spa)**
[Methodological aspects and discrepancies in the clinical trials in Alzheimer's disease] Borja J, et al. **Rev Neurol** 1995 Jan-Feb;23(119):125–8 (30 ref.) (Eng. Abstr.) **(Spa)**
[Clinical trials in the Alzheimer's disease: evaluation of the therapeutic response] Frank A, et al. **Rev Neurol** 1995 Jan-Feb;23(119):111–7 (41 ref.) (Eng. Abstr.) **(Spa)**

ECONOMICS

Economic analysis alongside clinical trials: practical considerations. The Economics Workgroup. Drummond M, et al. **J Rheumatol** 1995 Jul;22(7):1418–9 (4 ref.)

LEGISLATION & JURISPRUDENCE

Informed consent issues in international research concerns. Porter JP. **Camb Q Healthc Ethics** 1996 Spring;5(2):237–43 (25 ref.)

METHODS

Correlation between viral load measurements and outcome in clinical trials of antiviral drugs. Schooley RT. **AIDS** 1995 Dec;9 Suppl 2:S15–S19 (21 ref.)
A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma. Rothenberg ML, et al. **Cancer** 1996 Aug 1;78(3 Suppl):627–32 (48 ref.)
Early-phase clinical trials in migraine: efficacy, safety and dose-finding. Pilgrim AJ. **Cephalalgia** 1995 Oct;15 Suppl 15:10–3 (13 ref.)
Clinical trials and quality of life assessment: the nurses' viewpoint. Molin C, et al. **Eur J Cancer** 1995;31A Suppl 6:S8–10 (25 ref.)
The design of clinical trials for new therapies in bladder cancer. Is it time for new strategies? De Mulder PH, et al. **Int J Urol** 1995 Jun;2 Suppl 2:113–6 (18 ref.)
Viral phenotype and genotype as markers in clinical trials. Katzenstein DA. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995;10 Suppl 2:S25–34 (89 ref.)
Current HIV clinical trial design issues. Lange JM. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995;10 Suppl 1:S47–51 (24 ref.)
Potential criteria for cohort selection in chemoprevention trials of epithelial ovarian cancer. Baker VV. **J Cell Biochem Suppl** 1995;23:243–6 (19 ref.)
Methodologic issues regarding outcome measures for clinical drug trials of psychiatric complications in dementia. Teri L, et al. **J Geriatr Psychiatry Neurol** 1995 Oct;8 Suppl 1:S8–17 (63 ref.)
Chronic renal allograft rejection and clinical trial design. Kasiske BL, et al. **Kidney Int Suppl** 1995 Dec;52:S116–9 (12 ref.)
Intervention research. Tijssen JG. **Neth J Med** 1995 Aug; 47(2):87–92 (14 ref.)
Clinical research in neurology. From observation to experimentation. Marshall FJ, et al. **Neurol Clin** 1996 May; 14(2):451–66 (61 ref.)
Antiemetic study methodology: recommendations for future studies. Olver IN. **Oncology** 1996 Jun;53 Suppl 1:96–101 (32 ref.)
Classics in Spine. Surgery literature revisited. Bessette L, et al. **Spine** 1996 Feb 1;21(3):259–63 (13 ref.)
Critical reading of the meta-analysis of clinical trials. Nony

P, et al. **Therapie** 1995 Jul-Aug;50(4):339-51 (67 ref.)
[Methodology of the evaluation of antiemetics] Bergmann JF. **Bull Cancer (Paris)** 1995 Dec;82(12):1062-6 (18 ref.) (Eng. Abstr.) **(Fre)**

STANDARDS

Standards for veterinary clinical trials. Boothe DM, et al. **Adv Vet Sci Comp Med** 1995;39:191-252 (46 ref.)
A consideration of ethical issues in the design of clinical trials. Weymuller EA Jr. **Am J Otolaryngol** 1996 Jan-Feb; 17(1):2-11 (26 ref.)
How to do it. Get patients' consent to enter clinical trials [see comments] Wager E, et al. **BMJ** 1995 Sep 16; 311(7007):734-7 (36 ref.) Comment in: BMJ 1996 Jan 20;312(7024):185-6. Comment in: BMJ 1996 Jan 20;312(7024):186. Comment in: BMJ 1996 Mar 30;312(7034):847.
Ethical issues in clinical trials. Claessens MT, et al. **Br J Urol** 1995 Nov;76 Suppl 2:29-36 (39 ref.)
Clinical trials: relevance of correlation between treatment responses. Cleophas TJ. **Eur J Clin Pharmacol** 1996; 50(1-2):1-6 (14 ref.)
Evaluation of clinical trials of agents and procedures to prevent caries and periodontal disease: choosing products and recommending procedures. Addy M. **Int Dent J** 1995 Jun;45(3):185-96 (57 ref.)
World Federation of Neurology Research Group on Neuromuscular Diseases Subcommittee on Motor Neuron Disease. Airlie House guidelines. Therapeutic trials in amyotrophic lateral sclerosis. Airlie House "Therapeutic Trials in ALS" Workshop Contributors. **J Neurol Sci** 1995 May;129 Suppl:1-10 (0 ref.)
MDR1 reversal: criteria for clinical trials designed to overcome the multidrug resistance phenotype. Hegewisch-Becker S. **Leukemia** 1996 Jul;10 Suppl 3:S32-S38 (53 ref.)
Methodology of clinical trials in hand osteoarthritis. Issues and proposals. Maheu E, et al. **Rev Rhum Engl Ed** 1995 Jun;62(6 Suppl 1):55S-62S (22 ref.)
Analytic requirements for immunosuppressive drugs in clinical trials. Shaw LM, et al. **Ther Drug Monit** 1995 Dec; 17(6):577-83 (31 ref.)
[Quality control in clinical trials] Fukushima M. **Gan To Kagaku Ryoho** 1996 Jan;23(2):172-82 (11 ref.) (Eng. Abstr.) **(Jpn)**

STATISTICS & NUMERICAL DATA

MRC quality of life studies using a daily diary card--practical lessons learned from cancer trials. Fayers P. **Qual Life Res** 1995 Aug;4(4):343-52 (42 ref.)
Planning and revising the sample size for a trial. Gould AL. **Stat Med** 1995 May 15-30;14(9-10):1039-51; discussion 1053-5 (15 ref.)

TRENDS

Autopsy. A crucial component of human clinical investigation. Kaufman SR. **Arch Pathol Lab Med** 1996 Aug;120(8):767-70 (43 ref.)

CLINICAL TRIALS, CONTROLLED see **CONTROLLED CLINICAL TRIALS**

CLINICAL TRIALS, PHASE I

Gene therapy for cystic fibrosis in humans by liposome-mediated DNA transfer: the production of resources and the regulatory process. Caplen NJ, et al. **Gene Ther** 1994 Mar;1(2):139-47 (21 ref.)
Pediatric phase I drug tolerance: a review and comparison of recent adult and pediatric phase I trials. Carlson L, et al. **J Pediatr Hematol Oncol** 1996 Aug;18(3):250-6 (83 ref.)
Paclitaxel couplets with cyclophosphamide or cisplatin in metastatic breast cancer. Tolcher AW. **Semin Oncol** 1996 Feb;23(1 Suppl 1):37-43 (22 ref.)
[Clinical phase I studies in oncology and hematology. Concepts, implementation and ethical considerations] Hanauske AR. **Med Klin** 1996 Apr 12;91 Suppl 3:68-70 (28 ref.) **(Ger)**
[Combination phase I trials] Masuda N. **Gan To Kagaku Ryoho** 1996 Jan;23(2):219-25 (13 ref.) (Eng. Abstr.) **(Jpn)**
[Current status of phase I and phase II trials--experience in Habikino from 1988 to 1994] Masuda N, et al. **Gan To Kagaku Ryoho** 1996 Jan;23(2):166-71 (14 ref.) (Eng. Abstr.) **(Jpn)**
[Early clinical trials in ECTG. Early Clinical Trial Group] Ogawa M. **Gan To Kagaku Ryoho** 1996 Jan;23(2):238-41 (13 ref.) (Eng. Abstr.) **(Jpn)**
[Informed consent in phase I trial] Shimada Y. **Gan To Kagaku Ryoho** 1996 Jan;23(2):226-30 (2 ref.) (Eng. Abstr.) **(Jpn)**

STANDARDS

An overview of pharmacoepidemiology. Wertheimer AL, et al. **Pharm World Sci** 1995 May 26;17(3):61-6 (13 ref.)

CLINICAL TRIALS, PHASE II

Paclitaxel couplets with cyclophosphamide or cisplatin in metastatic breast cancer. Tolcher AW. **Semin Oncol** 1996 Feb;23(1 Suppl 1):37-43 (22 ref.)
[Current status of phase I and phase II trials--experience in Habikino from 1988 to 1994] Masuda N, et al. **Gan To Kagaku Ryoho** 1996 Jan;23(2):166-71 (14 ref.) (Eng. Abstr.) **(Jpn)**

ECONOMICS

A phase II chemoprevention trial design to identify surrogate endpoint biomarkers in breast cancer. Dhingra K. **J Cell Biochem Suppl** 1995;23:19-24 (27 ref.)

STANDARDS

An overview of pharmacoepidemiology. Wertheimer AL, et al. **Pharm World Sci** 1995 May 26;17(3):61-6 (13 ref.)

STATISTICS & NUMERICAL DATA

Design of clinical antiepileptic drug trials. Binnie CD. **Seizure** 1995 Sep;4(3):187-92 (14 ref.)

CLINICAL TRIALS, PHASE III

Reducing patient eligibility criteria in cancer clinical trials. George SL. **J Clin Oncol** 1996 Apr;14(4):1364-70 (24 ref.)

ECONOMICS

Economic analysis during phase III clinical trials: who, what, when, where, and why? Bennett CL, et al. **Oncology (Huntingt)** 1995 Nov;9(11 Suppl):169-75 (17 ref.)

METHODS

Surrogate end points in clinical trials: are we being misled? Fleming TR, et al. **Ann Intern Med** 1996 Oct 1; 125(7):605-13 (79 ref.)
Quality-of-life research in the Pediatric Oncology Group: 1991-1995. Bradlyn AS, et al. **J Natl Cancer Inst Monogr** 1996;(20):49-53 (21 ref.)
Trial-related quality of life: using quality-of-life assessment to distinguish among cancer therapies. Gotay CC. **J Natl Cancer Inst Monogr** 1996;(20):1-6 (44 ref.)

STANDARDS

Surrogate end points in clinical trials: are we being misled? Fleming TR, et al. **Ann Intern Med** 1996 Oct 1; 125(7):605-13 (79 ref.)
An overview of pharmacoepidemiology. Wertheimer AL, et al. **Pharm World Sci** 1995 May 26;17(3):61-6 (13 ref.)

CLINICAL TRIALS, RANDOMIZED see **RANDOMIZED CONTROLLED TRIALS**

CLINICS, FREE-STANDING see **AMBULATORY CARE FACILITIES**

CLITORIDECTOMY see **CIRCUMCISION, FEMALE**

CLODRONATE see **CLODRONIC ACID**

CLODRONIC ACID

THERAPEUTIC USE

Clodronate and other bisphosphonates as supportive therapy in osteolysis due to malignancy. Elomaa I, et al. **Acta Oncol** 1995;34(5):629-36 (81 ref.)
Use of clodronate in multiple myeloma. Jantunen E, et al. **Leuk Lymphoma** 1995 Oct;19(3-4):207-11 (29 ref.)
[Metastatic bone lesions in solid tumors and possible use of clodronate (Bonephos) in clinical oncology] Moiseenko VM, et al. **Vopr Onkol** 1996;42(2):17-30 (93 ref.) **(Rus)**

CLOFIBRATE

ADVERSE EFFECTS

[Peroxisome proliferators and hepatocarcinogenesis] Tamura H. **Seikagaku** 1995 Aug;67(8):1044-7 (15 ref.) **(Jpn)**

CLOMIFENE see **CLOMIPHENE**

CLOMIPHENE

PHARMACOLOGY

Pharmacological interventions for the induction of ovulation. Collins JA, et al. **Drugs** 1995 Sep;50(3):480-94 (91 ref.)

CLOMIPRAMINE

THERAPEUTIC USE

Neuropsychiatry of obsessive-compulsive disorder in children and adolescents. March JS, et al. **Compr Ther** 1995 Sep;21(9):507-12 (71 ref.)

CLONAL ABORTION see **CLONAL DELETION**

CLONAL ANERGY

Induction of anergy in Th1 lymphocytes by oral tolerance. Importance of antigen dosage and frequency of feeding. Friedman A. **Ann N Y Acad Sci** 1996 Feb 13;778:103-10 (47 ref.)
Signalling events in the anergy induction of T helper 1 cells. Sloan-Lancaster J, et al. **Ciba Found Symp** 1995;195:189-96; discussion 196-202 (33 ref.)
Clonal anergy of B cells: a flexible, reversible, and quantitative concept [comment] Nossal GJ. **J Exp Med** 1996 May 1;183(5):1953-6 (27 ref.) Comment on: J Exp Med 1996 May 1;183(5):2313-28.
Models of T cell anergy: is there a common molecular mechanism? [comment] Schwartz RH. **J Exp Med** 1996 Jul 1;184(1):1-8 (69 ref.) Comment on: J Exp Med 1996 Jul 1;184(1):19-29.
Anergy as a mechanism of peripheral T cell tolerance. Quill H. **J Immunol** 1996 Feb 15;156(4):1325-7 (36 ref.)

IMMUNOLOGY

The critical role of CD28 signalling in the prevention of human T-cell anergy. Boussiotis VA, et al. **Res Immunol** 1995 Mar-Apr;146(3):140-9 (72 ref.)

CLONAL DELETION

see related
APOPTOSIS

Autoantigen-induced deletion of peripheral self-reactive T cells. Miller JF. **Int Rev Immunol** 1995;13(2):107-14 (47 ref.)
Central tolerance of T cells. Sprent J. **Int Rev Immunol** 1995; 13(2):95-105 (85 ref.)

IMMUNOLOGY

Intrathymic and extrathymic clonal deletion of T cells. Sprent J, et al. **Curr Opin Immunol** 1995 Apr;7(2):196-205 (118 ref.)

CLONAZEPAM

BLOOD

[Clonazepam, nitrazepam, diazepam] Yasuda K. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:911-4 (19 ref.) **(Jpn)**

THERAPEUTIC USE

Clonazepam-sensitive intermittent dystonic tremor. Davis TL, et al. **South Med J** 1995 Oct;88(10):1069-71 (16 ref.)

CLONE CELLS

Ethical and policy issues in human embryo twinning. Bonnicksen AL. **Camb Q Healthc Ethics** 1995 Summer; 4(3):268-84 (94 ref.)

CLONES see **CLONE CELLS**

CLONIDINE

ANALOGS & DERIVATIVES

Three autacoids--endogenous digitalis-like factor, clonidine-displacing substance, and quinidine-like immunoreactivity. Kölbel F, et al. **Sb Lek** 1995; 96(4):405-15 (65 ref.)

POISONING

Poisoning with anti-hypertensive drugs: methyldopa and clonidine. Zarifis J, et al. **J Hum Hypertens** 1995 Oct; 9(10):787-90 (31 ref.)

THERAPEUTIC USE

Is clonidine an effective smoking cessation therapy? Gourlay SG, et al. **Drugs** 1995 Aug;50(2):197-207 (83 ref.)

CLONING, MOLECULAR

see related
DNA, RECOMBINANT
GENETIC ENGINEERING
RECOMBINANT FUSION PROTEINS

The immunotherapy of solid cancers based on cloning the genes encoding tumor-rejection antigens. Rosenberg SA. **Annu Rev Med** 1996;47:481-91 (38 ref.)
Molecular cloning of the von Hippel-Lindau tumor suppressor gene and its role in renal carcinoma. Gnarra JR, et al. **Biochim Biophys Acta** 1996 Mar 18;1242(3):201-10 (60 ref.)
Gene fusion expression systems in Escherichia coli. LaVallie ER, et al. **Curr Opin Biotechnol** 1995 Oct;6(5):501-6 (47 ref.)
Mapping and cloning hereditary deafness genes. Cremers FP, et al. **Curr Opin Genet Dev** 1995 Jun;5(3):371-5 (55 ref.)
Cytogenetics and experimental models of sarcomas. Bridge JA. **Curr Opin Oncol** 1995 Jul;7(4):333-9 (49 ref.)
Progress in cloning embryos from domesticated livestock. Prather RS. **Proc Soc Exp Biol Med** 1996 May;212(1):38-43 (68 ref.)
Gene fusions encoding chimaeric transcription factors in solid tumours. Sorensen PH, et al. **Semin Cancer Biol** 1996 Feb; 7(1):3-14 (100 ref.)
[Significance of clonality study in hematological diseases]

CLONING, MOLECULAR

Karasawa M. **Nippon Naika Gakkai Zasshi** 1995 Nov 10; 84(11):1934–8 (12 ref.) **(Jpn)**
[Positional cloning of the putative gene responsible for transient abnormal myelopoiesis and that for multiple cartilaginous exostoses] Niikawa N. **Rinsho Byori** 1996 Jan; 44(1):13–8 (6 ref.) (Eng. Abstr.) **(Jpn)**

METHODS

Production of antibody fragments in Escherichia coli. Harrison JS, et al. **Ann N Y Acad Sci** 1996 May 15; 782:143–58 (81 ref.)
Introduction to positional cloning. Papadopoulos N. **Clin Exp Allergy** 1995 Nov;25 Suppl 2:116–8 (16 ref.)
Developments in expression cloning. Seed B. **Curr Opin Biotechnol** 1995 Oct;6(5):567–73 (76 ref.)
Positional cloning reaches maturity. Nelson DL. **Curr Opin Genet Dev** 1995 Jun;5(3):298–303 (32 ref.)
Recent advances in differential display. Liang P, et al. **Curr Opin Immunol** 1995 Apr;7(2):274–80 (41 ref.)
Expression cloning of the epithelial sodium channel. Canessa CM, et al. **Kidney Int** 1995 Oct;48(4):950–5 (29 ref.)
[TA cloning: a rapid and efficient method for cloning of the PCR products] Yasuda J. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):518–21 (7 ref.) **(Jpn)**

CLONING VECTORS see **GENETIC VECTORS**

CLONOGENIC CELL ASSAY see **COLONY-FORMING UNITS ASSAY**

CLONOGENIC CELL ASSAY, TUMOR see **TUMOR STEM CELL ASSAY**

CLONORCHIASIS

[Clonorchiasis] Kawashima T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):70–2 (6 ref.) **(Jpn)**

CLORANFENICOL see **CHLORAMPHENICOL**

CLOSED-CIRCUIT ANESTHESIA see **ANESTHESIA, CLOSED-CIRCUIT**

CLOSED COHORT STUDIES see **COHORT STUDIES**

CLOSTEROVIRUS

GENETICS

[Structure and function of RNA from closterovirus genomes] Agranovskaĭ AA. **Mol Biol (Mosk)** 1995 Nov–Dec; 29(6):1265–85 (121 ref.) **(Rus)**

CLOSTRIDIAL NEUROTOXIN see **TETANUS TOXIN**

CLOSTRIDIUM

CLASSIFICATION

A second case of infant botulism type F caused by Clostridium baratii. Paisley JW, et al. **Pediatr Infect Dis J** 1995 Oct;14(10):912–4 (17 ref.)

ENZYMOLOGY

Alcohol dehydrogenase: multiplicity and relatedness in the solvent-producing clostridia. Chen JS. **FEMS Microbiol Rev** 1995 Oct;17(3):263–73 (44 ref.)
Solventogenic enzymes of Clostridium acetobutylicum: catalytic properties, genetic organization, and transcriptional regulation. Dürre P, et al. **FEMS Microbiol Rev** 1995 Oct;17(3):251–62 (90 ref.)

GENETICS

Expression of heat shock genes in Clostridium acetobutylicum. Bahl H, et al. **FEMS Microbiol Rev** 1995 Oct;17(3):341–8 (38 ref.)
Chemotherapeutic tumour targeting using clostridial spores. Minton NP, et al. **FEMS Microbiol Rev** 1995 Oct; 17(3):357–64 (40 ref.)
Molecular genetics and the initiation of solventogenesis in Clostridium beijerinckii (formerly Clostridium acetobutylicum) NCIMB 8052. Wilkinson SR, et al. **FEMS Microbiol Rev** 1995 Oct;17(3):275–85 (69 ref.)
Regulation of nitrogen metabolism, starch utilisation and the beta-hbd-adh1 gene cluster in Clostridium acetobutylicum. Woods DR, et al. **FEMS Microbiol Rev** 1995 Oct; 17(3):299–306 (29 ref.)

GROWTH & DEVELOPMENT

Growth of clostridia and preparation of their neurotoxins. Shone CC, et al. **Curr Top Microbiol Immunol** 1995; 195:143–60 (56 ref.)

ISOLATION & PURIFICATION

Bacillus piliformis infection (Tyzzer's disease) in a patient infected with HIV-1: confirmation with 16S ribosomal RNA sequence analysis. Smith KJ, et al. **J Am Acad Dermatol** 1996 Feb;34(2 Pt 2):343–8 (18 ref.)

PATHOGENICITY

Ecology of neurotoxigenic strains of clostridia. Popoff MR. **Curr Top Microbiol Immunol** 1995;195:1–29 (113 ref.)

PHYSIOLOGY

Sigma factor and sporulation genes in Clostridium. Sauer U, et al. **FEMS Microbiol Rev** 1995 Oct;17(3):331–40 (82 ref.)

CLOSTRIDIUM BOTULINUM

see related
BOTULINUM TOXINS

CLASSIFICATION

The typing of botulinal neurotoxins. Giménez DF, et al. **Int J Food Microbiol** 1995 Sep;27(1):1–9 (16 ref.)

ENZYMOLOGY

Studies on the active-site structure of C3-like exoenzymes: involvement of glutamic acid in catalysis of ADP-ribosylation. Aktories K, et al. **Biochimie** 1995; 77(5):326–32 (62 ref.)

CLOSTRIDIUM BOTULINUM TOXINS see **BOTULINUM TOXINS**

CLOSTRIDIUM DIFFICILE

see related
ENTEROCOLITIS, PSEUDOMEMBRANOUS

Bacteremia due to Clostridium difficile: case report and review of extraintestinal C. difficile infections. Feldman RJ, et al. **Clin Infect Dis** 1995 Jun;20(6):1560–2 (39 ref.)
Clostridium difficile-associated diarrhea and colitis. Gerding DN, et al. **Infect Control Hosp Epidemiol** 1995 Aug; 16(8):459–77 (195 ref.)
Clostridium difficile--associated diarrhoeal diseases: an overview. Niyogi SK. **J Indian Med Assoc** 1995 Mar; 93(3):105–7 (29 ref.)
Antibiotic-induced colitis. Devenyi AG. **Semin Pediatr Surg** 1995 Nov;4(4):215–20 (39 ref.)
[Clostridium difficile-associated diarrhea--an increasing problem. Reduce the administration of antibiotics and improve hygiene!] Svenungsson B. **Lakartidningen** 1996 Aug 28;93(35):2931–4 (67 ref.) **(Swe)**

ISOLATION & PURIFICATION

Clostridium difficile colitis: recent therapeutical and immunological considerations. Delmée M, et al. **Acta Gastroenterol Belg** 1995 May–Aug;58(3–4):313–7 (17 ref.)
Update on diagnosis of Clostridium difficile-associated diarrhea. DeMaio J, et al. **Curr Clin Top Infect Dis** 1995; 15:97–114 (139 ref.)

CLOSTRIDIUM ENTEROCOLITIS see **ENTEROCOLITIS, PSEUDOMEMBRANOUS**

CLOSTRIDIUM INFECTIONS

Clostridium difficile-associated diarrhea and colitis. Gerding DN, et al. **Infect Control Hosp Epidemiol** 1995 Aug; 16(8):459–77 (195 ref.)
Clostridium difficile--associated diarrhoeal diseases: an overview. Niyogi SK. **J Indian Med Assoc** 1995 Mar; 93(3):105–7 (29 ref.)
Primary Clostridium septicum aortitis: a rare cause of necrotizing suprarenal aortic infection. A case report and review of the literature. Sailors DM, et al. **J Vasc Surg** 1996 Apr;23(4):714–8 (24 ref.)

DIAGNOSIS

Bacillus piliformis infection (Tyzzer's disease) in a patient infected with HIV-1: confirmation with 16S ribosomal RNA sequence analysis. Smith KJ, et al. **J Am Acad Dermatol** 1996 Feb;34(2 Pt 2):343–8 (18 ref.)

ETIOLOGY

Clostridium innocuum endocarditis. Cutrona AF, et al. **Clin Infect Dis** 1995 Nov;21(5):1306–7 (17 ref.)
Clostridial meningitis as a result of craniocerebral arrow injury. Neal G, et al. **J Trauma** 1996 Mar;40(3):476–80 (23 ref.)

MICROBIOLOGY

Clostridium difficile colitis: recent therapeutical and immunological considerations. Delmée M, et al. **Acta Gastroenterol Belg** 1995 May–Aug;58(3–4):313–7 (17 ref.)
Double clostridial mycotic aneurysms of the aorta. Messa CA 3rd, et al. **Cardiovasc Surg** 1995 Dec;3(6):687–92 (28 ref.)
Clostridial disease of the gut. Borriello SP. **Clin Infect Dis** 1995 Jun;20 Suppl 2:S242–50 (135 ref.)

CLOSTRIDIUM PERFRINGENS

Emphysematous cholecystitis. Lindsey I, et al. **Aust N Z J Surg** 1996 Apr;66(4):267–8 (14 ref.)
Diffuse pneumocephalus due to meningitis: CT findings. Goyal M, et al. **Pediatr Radiol** 1996;26(4):278–9 (5 ref.)

METABOLISM

[Regulation of the toxin production in Clostridium perfringens] Shimizu T. **Nippon Saikingaku Zasshi** 1995 Jul; 50(3):737–44 (27 ref.) **(Jpn)**

CLOSTRIDIUM TETANI

see related
TETANUS TOXIN

CLOSTRIDIUM TETANI TOXIN see **TETANUS TOXIN**

CLOSTRIDIUM WELCHII see **CLOSTRIDIUM PERFRINGENS**

CLOUSTON'S SYNDROME see **ECTODERMAL DYSPLASIA**

CLOVE see **SPICES**

CLOZAPINE

ADVERSE EFFECTS

Clozapine-induced neuroleptic malignant syndrome: review and report of new cases. Sachdev P, et al. **J Clin Psychopharmacol** 1995 Oct;15(5):365–71 (29 ref.)
Novel versus conventional antipsychotic drugs. Love RC. **Pharmacotherapy** 1996 Jan–Feb;16(1 Pt 2):6–10 (24 ref.)
[Agranulocytosis caused by clozapine: the importance of leukocyte monitoring and efficacy of hematopoietic growth factors] van Melick EJ, et al. **Ned Tijdschr Geneeskd** 1995 Nov 25;139(47):2437–40 (18 ref.) (Eng. Abstr.) **(Dut)**
[Current aspects of the use of clozapine in the Châlons-sur-Marne Psychiatric Hospital: intestinal occlusion with clozapine] Théret L, et al. **Ann Med Psychol (Paris)** 1995 Aug–Sep;153(7):474–7 (24 ref.) (Eng. Abstr.) **(Fre)**

PHARMACOKINETICS

Pharmacokinetics of clozapine and risperidone: a review of recent literature. Byerly MJ, et al. **J Clin Psychopharmacol** 1996 Apr;16(2):177–87 (78 ref.)

PHARMACOLOGY

New insights into the biology of schizophrenia through the mechanism of action of clozapine. Brunello N, et al. **Neuropsychopharmacology** 1995 Nov;13(3):177–213 (400 ref.)

THERAPEUTIC USE

Effectiveness of clozapine in hospitalised people with chronic neuroleptic-resistant schizophrenia. Avnon M, et al. **Br J Psychiatry** 1995 Dec;167(6):760–4 (15 ref.)
Clozapine as a treatment for psychosis in Parkinson's disease: a review. Musser WS, et al. **J Neuropsychiatry Clin Neurosci** 1996 Winter;8(1):1–9 (52 ref.)
Clozapine: efficacy and safety. Buchanan RW. **Schizophr Bull** 1995;21(4):579–91 (80 ref.)
[Dopamine D4-receptor variants, schizophrenia and clozapine therapy] Ewald HL, et al. **Ugeskr Laeger** 1996 Jun 17;158(25):3601–3 (17 ref.) (Eng. Abstr.) **(Dan)**
[Value of clozapine in treatment of psychotic disorder in Parkinson disease] Abbar M, et al. **Encephale** 1996 Jan–Feb; 22(1):53–63 (46 ref.) (Eng. Abstr.) **(Fre)**
[Clozapine in the treatment of mental manifestations of Parkinson disease] Diederich N, et al. **Rev Neurol (Paris)** 1995 Apr;151(4):251–7 (54 ref.) (Eng. Abstr.) **(Fre)**

CLUBBED FINGERS see **OSTEOARTHROPATHY, SECONDARY HYPERTROPHIC**

CLUBFOOT

SURGERY

Clubfoot controversies: complications and causes for failure. Crawford AH, et al. **Instr Course Lect** 1996;45:339–46 (65 ref.)

THERAPY

Clubfoot controversies: complications and causes for failure. Crawford AH, et al. **Instr Course Lect** 1996;45:339–46 (65 ref.)

CLUSTER ANALYSIS

Accounting for cluster randomization: a review of primary prevention trials, 1990 through 1993. Simpson JM, et al. **Am J Public Health** 1995 Oct;85(10):1378–83 (43 ref.)
The analysis of disease clusters, Part I: State of the art. Jacquez GM, et al. **Infect Control Hosp Epidemiol** 1996 May;17(5):319–27 (35 ref.)
Using cluster analysis for medical resource decision making. Dilts D, et al. **Med Decis Making** 1995 Oct–Dec;

15(4):333–47 (72 ref.)
Spatial statistical methods in environmental epidemiology: a critique. Elliott P, et al. **Stat Methods Med Res** 1995 Jun;4(2):137–59 (114 ref.)

CLUSTER HEADACHE

Cluster headache: a review. Connors MJ.
J Am Osteopath Assoc 1995 Sep;95(9):533–9 (45 ref.)
[Cluster headache] Alberca R. **Rev Clin Esp** 1995 Sep;195(2 Spec No):36–40 (27 ref.) **(Spa)**

COMPLICATIONS

[Pathogenicity of cluster headache] Láinez JM, et al.
Rev Neurol 1995;23 Suppl 4:S492–9 (121 ref.) **(Spa)**

DIAGNOSIS

Advances in cluster headache management. Lewis TA, et al. **Cleve Clin J Med** 1996 Jul–Aug;63(4):237–44 (35 ref.)
The management of migraine and cluster headaches. Diamond S. **Compr Ther** 1995 Sep;21(9):492–8 (27 ref.)
[Diagnosis and differential diagnosis] Martínez-Lage JM, et al. **Rev Neurol** 1995;23 Suppl 4:S506–13 (25 ref.) **(Spa)**
[Cluster headache. Definition and diagnostic criteria] Noya M. **Rev Neurol** 1995;23 Suppl 4:S479–81 (14 ref.) **(Spa)**

DRUG THERAPY

Treatment of cluster headache: clinical trials, design and results. Ekbom K. **Cephalalgia** 1995 Oct;15 Suppl 15:33–6 (35 ref.)
Migraine and cluster headache—their management with sumatriptan: a critical review of the current clinical experience. Wilkinson M, et al. **Cephalalgia** 1995 Oct; 15(5):337–57 (166 ref.)
[Prophylactic treatment of chronic cluster headache] Alberca R. **Rev Neurol** 1995;23 Suppl 4:S530–4 (55 ref.) **(Spa)**
[Sumatriptan ++ in the treatment of migraine and cluster headache] Láinez JM, et al. **Rev Neurol** 1995;23 Suppl 2:S166–78 (127 ref.) **(Spa)**
[Prophylactic treatment of episodic forms of cluster headache] Liaño H, et al. **Rev Neurol** 1995;23 Suppl 4:S525–9 (29 ref.) **(Spa)**
[Symptomatic treatment of cluster headache] Titus F. **Rev Neurol** 1995;23 Suppl 4:S519–24 (46 ref.) **(Spa)**

EPIDEMIOLOGY

[Epidemiological and etiological data on cluster headache] Leira R. **Rev Neurol** 1995;23 Suppl 4:S482–6 (87 ref.) **(Spa)**

ETIOLOGY

[Epidemiological and etiological data on cluster headache] Leira R. **Rev Neurol** 1995;23 Suppl 4:S482–6 (87 ref.) **(Spa)**

HISTORY

[Historical aspects and synonymy of cluster headache] Balcells M. **Rev Neurol** 1995;23 Suppl 4:S473–8 (47 ref.) **(Spa)**

MICROBIOLOGY

Clusterlike headache. A case of sphenoidal aspergilloma. Zanchin G, et al. **Headache** 1995 Sep;35(8):494–7 (20 ref.)

PHYSIOPATHOLOGY

Putative neuroimmunological mechanisms in cluster headache. An integrated hypothesis. Martelletti P, et al. **Headache** 1996 May;36(5):312–5 (44 ref.)
[Evolutive forms] Alberca R. **Rev Neurol** 1995;23 Suppl 4:S514–8 (34 ref.) **(Spa)**
[Clinical features of cluster headache attack] Gómez-Aranda F, et al. **Rev Neurol** 1995;23 Suppl 4:S500–5 (37 ref.) **(Spa)**
[Atypical forms of cluster headache] Navarro A, et al. **Rev Neurol** 1995;23 Suppl 4:S540–3 (36 ref.) **(Spa)**
[Cluster headache: anatomical and physiopathological basis of pain] Pascual-Gómez J. **Rev Neurol** 1995;23 Suppl 4:S487–91 (40 ref.) **(Spa)**

SURGERY

Resolution of chronic cluster headache after resection of a tentorial meningioma: case report [see comments] Taub E, et al. **Neurosurgery** 1995 Aug;37(2):319–21; discussion 321–2 (27 ref.) Comment in: Neurosurgery 1996 Apr;38(4):849–50.

THERAPY

Advances in cluster headache management. Lewis TA, et al. **Cleve Clin J Med** 1996 Jul–Aug;63(4):237–44 (35 ref.)
The management of migraine and cluster headaches. Diamond S. **Compr Ther** 1995 Sep;21(9):492–8 (27 ref.)
Treatment of cluster headache and its variants. Stovner LJ, et al. **Curr Opin Neurol** 1995 Jun;8(3):243–7 (44 ref.)

CLUSTERING see **CLUSTER ANALYSIS**

CNIDARIA

CHEMISTRY

Understanding, improving and using green fluorescent proteins. Cubitt AB, et al. **Trends Biochem Sci** 1995 Nov; 20(11):448–55 (43 ref.)

EMBRYOLOGY

Cytoskeleton and ctenophore development. Houliston E, et al. **Curr Top Dev Biol** 1995;31:41–63 (401 ref.)

GROWTH & DEVELOPMENT

Synchronous multispecific spawning on coral reefs: potential for hybridization and roles of gamete recognition. Babcock R. **Reprod Fertil Dev** 1995;7(4):943–50 (74 ref.)

METABOLISM

Peptides in the nervous systems of cnidarians: structure, function, and biosynthesis. Grimmelikhuijzen CJ, et al. **Int Rev Cytol** 1996;167:37–89 (124 ref.)

ULTRASTRUCTURE

Cytoskeleton and ctenophore development. Houliston E, et al. **Curr Top Dev Biol** 1995;31:41–63 (401 ref.)

CNIDARIAN VENOMS

CHEMISTRY

Lophozozymus pictor toxin: a fluorescent structural isomer of palytoxin. Lau CO, et al. **Toxicon** 1995 Oct;33(10):1373–7 (18 ref.)

CO-DERGOCRINE see **DIHYDROERGOTOXINE**

CO-DERGOCRINE MESYLATE see **ERGOLOID MESYLATES**

COA see **COENZYME A**

COAGULANTS

see related
BLOOD COAGULATION FACTORS

COAGULATION FACTORS see **BLOOD COAGULATION FACTORS**

COAGULATION TIME, WHOLE BLOOD see **WHOLE BLOOD COAGULATION TIME**

COAL MINING

see related
PNEUMOCONIOSIS
SILICOSIS

COAL TAR

Natural selection of PAH-degrading bacterial guilds at coal-tar disposal sites. Ghiorse WC, et al.
Environ Health Perspect 1995 Jun;103 Suppl 5:107–11 (15 ref.)

COAT PROTEINS see **CAPSID**

COATED PITS, CELL-MEMBRANE

see related
CLATHRIN

COATED VESICLES

METABOLISM

Vesicle biogenesis: the coat connection [comment] Mallabiabarrena A, et al. **Cell** 1995 Dec 1;83(5):667–9 (21 ref.) Comment on: Cell 1995 Dec 1;83(5):703–13.
Coat proteins and vesicle budding. Schekman R, et al. **Science** 1996 Mar 15;271(5255):1526–33 (83 ref.)

PHYSIOLOGY

Vesicle transport during cell growth and in the maintenance of cell polarity. Futerman AH, et al.
Biochem Soc Trans 1995 Aug;23(3):530–4 (40 ref.)
Coated vesicles: a diversity of form and function. Schmid SL, et al. **FASEB J** 1995 Nov;9(14):1445–53 (70 ref.)
[COP-coated vesicles in intracellular protein transport] Kuge O, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec; 40(16):2427–35 (39 ref.) **(Jpn)**

COBALAMIN see **VITAMIN B 12**

COBALT

ANALYSIS

[Cobalt] Nomoto S. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:854–7 (9 ref.) **(Jpn)**

COBALT-CHROMIUM ALLOYS see **CHROMIUM ALLOYS**

COCAINE

Cardiac arrest in cocaine users. Karch SB.
Am J Emerg Med 1996 Jan;14(1):79–81 (30 ref.)
Buprenorphine as a pharmacotherapy for cocaine abuse: a review of the evidence. Compton PA, et al.
J Addict Dis 1995;14(3):97–114 (56 ref.)
Recent changes in the etiology of hearing disorders: perinatal drug exposure. Gerber SE, et al. **J Am Acad Audiol** 1995 Sep;6(5):371–7 (50 ref.)
A model for pharmacological research-treatment of cocaine dependence. Montoya ID, et al. **J Subst Abuse Treat** 1995 Nov-Dec;12(6):415–21 (44 ref.)
Chronic intestinal ischemia caused by intravenous cocaine use: report of two cases and review of the literature. Myers SI, et al. **J Vasc Surg** 1996 Apr;23(4):724–9 (23 ref.)
A review of the effects of dopaminergic agents on humans, animals, and drug-seeking behavior, and its implications for medication development.Focus on GBR 12909. Rothman RB, et al. **Mol Neurobiol** 1995 Aug-Dec; 11(1-3):1–19 (130 ref.)
Management of cocaine abuse and dependence. Mendelson JH, et al. **N Engl J Med** 1996 Apr 11;334(15):965–72 (122 ref.)
Pharmacological and behavioral treatment of cocaine addiction: animal models. Carroll ME.
NIDA Res Monogr 1994;145:113–30 (26 ref.)
Use of rodent self-administration models to develop pharmacotherapies for cocaine abuse. Dworkin SI, et al. **NIDA Res Monogr** 1994;145:88–112 (65 ref.)
Cocaine self-administration research: treatment implications. Foltin RW, et al. **NIDA Res Monogr** 1994;145:139–62 (38 ref.)
Species-, gender-, and pregnancy-related differences in the pharmacokinetics and pharmacodynamics of cocaine. Morishima HO, et al. **NIDA Res Monogr** 1995;158:2–21 (52 ref.)
Pharmacogenetics of cocaine: a critical review. Morse AC, et al. **Pharmacogenetics** 1995 Aug;5(4):183–92 (80 ref.)
Ethnicity and psychotherapy. A component in the treatment of cocaine addiction in African Americans. Foulks EF, et al. **Psychiatr Clin North Am** 1995 Sep;18(3):607–20 (59 ref.)
Cocaine using during pregnancy and low birth weight: the impact of prenatal care and drug treatment. Chazotte C, et al. **Semin Perinatol** 1995 Aug;19(4):293–300 (40 ref.)
[Cocaine abuse and mental disease] Glyngdal P.
Ugeskr Laeger 1996 Aug 12;158(33):4638–42 (39 ref.) (Eng. Abstr.) **(Dan)**

ADVERSE EFFECTS

Cocaine-associated agitated delirium and the neuroleptic malignant syndrome. Wetli CV, et al.
Am J Emerg Med 1996 Jul;14(4):425–8 (18 ref.)
CNS effects and abuse liability of anabolic-androgenic steroids. Lukas SE. **Annu Rev Pharmacol Toxicol** 1996; 36:333–57 (125 ref.)
How to have a stroke at an early age: the effects of crack, cocaine and other illicit drugs. Blank-Reid C.
J Neurosci Nurs 1996 Feb;28(1):19–27 (29 ref.)
Cocaine-associated myocardial infarction. Hollander JE.
J R Soc Med 1996 Aug;89(8):443–7 (69 ref.)
The management of cocaine-associated myocardial ischemia [see comments] Hollander JE. **N Engl J Med** 1995 Nov 9;333(19):1267–72 (66 ref.) Comment in: N Engl J Med 1996 Feb 22;334(8):535; discussion 536–7. Comment in: N Engl J Med 1996 Feb 22;334(8):535–6; discussion 536–7. Comment in: N Engl J Med 1996 Feb 22;334(8):536; discussion 536–7.
Cocaine-associated intracranial hemorrhage: absence of vasculitis in 14 cases. Aggarwal SK, et al. **Neurology** 1996 Jun;46(6):1741–3 (10 ref.)
Cocaine-induced cerebrovascular impairment: challenges to neuropsychological assessment. Strickland TL, et al.
Neuropsychol Rev 1995 Mar;5(1):69–79 (38 ref.)
Neurobiological mechanisms underlying the acquisition and expression of incentive motivation by cocaine-associated stimuli: relationship to craving. Pert A.
NIDA Res Monogr 1994;145:163–90 (70 ref.)
Cocaine reward and cocaine craving: the role of dopamine in perspective. Wise RA. **NIDA Res Monogr** 1994; 145:191–206 (92 ref.)
Overview of the effects of abuse and drugs on pregnancy and offspring. Zuckerman B, et al. **NIDA Res Monogr** 1995; 149:16–38 (89 ref.)
Cocaine-associated cerebral vasculitis. Merkel PA, et al. **Semin Arthritis Rheum** 1995 Dec;25(3):172–83 (82 ref.)
[Cocaine abuse—with special reference to cerebrovascular complications] Lalouschek W, et al.
Wien Klin Wochenschr 1995;107(17):516–21 (65 ref.) (Eng. Abstr.) **(Ger)**
[Main cardiotoxic drugs] Pettirossi G, et al. **Clin Ter** 1996 Jan-Feb;147(1-2):67–77 (34 ref.) (Eng. Abstr.) **(Ita)**
[Cocaine-induced neurological complications] García Castaño J, et al. **An Med Interna** 1996 Apr;13(4):198–201 (33 ref.) (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

A shot in the arm for cocaine addiction. Slusher BS, et al.

COCAINE

Nat Med 1996 Jan;2(1):26–7 (13 ref.)

PHARMACOLOGY

Addictive drugs as reinforcers: multiple partial actions on memory systems. White NM. **Addiction** 1996 Jul; 91(7):921–49; discussion 951–65 (304 ref.)

Behavioral sensitization and tolerance to cocaine and the occupation of dopamine receptors by dopamine. Martin-Iverson MT, et al. **Mol Neurobiol** 1995 Aug–Dec; 11(1–3):31–46 (69 ref.)

Prenatal cocaine produces biochemical and functional changes in brain serotonin systems in rat progeny. Battaglia G, et al. **NIDA Res Monogr** 1995;158:115–48 (56 ref.)

Effects of cocaine on fetal brain metabolism and behavioral state in the sheep model. Burchfield DJ. **NIDA Res Monogr** 1995;158:58–66 (30 ref.)

Neurobehavioral pharmacology of cocaine: role for serotonin in its locomotor and discriminative stimulus effects. Cunningham KA, et al. **NIDA Res Monogr** 1994;145:40–66 (95 ref.)

Role for the mesocortical dopamine system in the motivating effects of cocaine. Koob GF, et al. **NIDA Res Monogr** 1994;145:1–18 (44 ref.)

Dopamine, a common substrate for the rewarding effects of brain stimulation reward, cocaine, and morphine. Kornetsky C, et al. **NIDA Res Monogr** 1994;145:19–39 (66 ref.)

Effects of morphine and cocaine on breathing control in neonatal animals: a minireview. Olsen GD, et al. **NIDA Res Monogr** 1995;158:22–39 (106 ref.)

A review of the effects of dopaminergic agents in humans: implications for medication development. Rothman RB. **NIDA Res Monogr** 1994;145:67–87 (73 ref.)

Fetal cerebral vascular effects of cocaine exposure. Schreiber MD. **NIDA Res Monogr** 1995;158:67–87 (50 ref.)

Effects of prenatal morphine and cocaine on postnatal behaviors and brain neurotransmitters. Vathy I. **NIDA Res Monogr** 1995;158:88–114 (118 ref.)

TOXICITY

Cocaine during pregnancy: a critical review of the literature. Offidani C, et al. **Minerva Ginecol** 1995 Sep;47(9):381–90 (40 ref.)

COCARCINOGENESIS

Transgenic approaches to the analysis of ras and p53 function in multistage carcinogenesis. Kemp CJ, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:427–34 (50 ref.)

Defining the steps in a multistep mouse model for mammary carcinogenesis. Varmus HE, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:491–9 (55 ref.)

Capsaicin in hot chili pepper: carcinogen, co-carcinogen or anticarcinogen? Surh YJ, et al. **Food Chem Toxicol** 1996 Mar;34(3):313–6 (48 ref.)

Observations on vitamin K deficiency in the fetus and newborn: has nature made a mistake? Israels LG, et al. **Semin Thromb Hemost** 1995;21(4):357–63 (36 ref.)

COCCIDIOIDOMYCOSIS

DIAGNOSIS

Coccidioidomycosis: the other great imitator. Cardone JS, et al. **Cutis** 1995 Jul;56(1):33–6 (13 ref.)

PREVENTION & CONTROL

Opportunistic coccidioidomycosis in patients infected with human immunodeficiency virus: prevention issues and priorities. McNeil MM, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S111–3 (19 ref.)

COCCIDIOSIS

DRUG THERAPY

Chemotherapy of human and animal coccidioses: state and perspectives. Haberkorn A. **Parasitol Res** 1996;82(3):193–9 (97 ref.)

ETIOLOGY

Cyclospora in patients with traveller's diarrhea. Gascon J, et al. **Scand J Infect Dis** 1995;27(5):511–4 (18 ref.)

IMMUNOLOGY

Cytokines and immunological control of Eimeria spp. Ovington KS, et al. **Int J Parasitol** 1995 Nov; 25(11):1331–51 (114 ref.)

PARASITOLOGY

A 'new' parasite: human infection with Cyclospora cayetanensis. Chiodini PL. **Trans R Soc Trop Med Hyg** 1994 Jul–Aug;88(4):369–71 (18 ref.)

PREVENTION & CONTROL

Cytokines and immunological control of Eimeria spp. Ovington KS, et al. **Int J Parasitol** 1995 Nov; 25(11):1331–51 (114 ref.)

COCCYGEAL REGION see **SACROCOCCYGEAL REGION**

COCCYX

ABNORMALITIES

[The caudal regression syndrome] Méndez Bustelo MJ, et al. **An Esp Pediatr** 1996 Apr;44(4):405–8 (23 ref.) **(Spa)**

PATHOLOGY

Malignant sacrococcygeal germ cell tumour in an adult. Smithers BM, et al. **Aust N Z J Surg** 1996 Mar;66(3):185–9 (25 ref.)

COCHLEA

see related
OTOACOUSTIC EMISSIONS, SPONTANEOUS

DRUG EFFECTS

Auditory and vestibular functions after single or combined exposure to toluene: a review. Morata TC, et al. **Arch Toxicol** 1995;69(7):431–43 (106 ref.)

METABOLISM

Chemical synaptic transmission in the cochlea. Puel JL. **Prog Neurobiol** 1995 Dec;47(6):449–76 (251 ref.)

PHYSIOLOGY

Preservation of cochlear function after extensive labyrinthine destruction. Ars B, et al. **Am J Otol** 1996 Jan;17(1):40–5 (49 ref.)

Ionic conductances and hair cell tuning in the turtle cochlea. Art JJ, et al. **Ann N Y Acad Sci** 1996 Jun 19;781:103–22 (27 ref.)

Functional development of auditory sensitivity in the fetus and neonate. Sohmer H, et al. **J Basic Clin Physiol Pharmacol** 1995;6(2):95–108 (74 ref.)

Cholinergic and purinergic signalling in outer hair cells of mammalian cochlea. Heilbronn E, et al. **Neurochem Int** 1995 Oct-Nov;27(4–5):301–11 (79 ref.)

A faster transduction mechanism for the cochlear amplifier? Kolston PJ. **Trends Neurosci** 1995 Oct;18(10):427–9 (21 ref.)

PHYSIOPATHOLOGY

Tinnitus and otoacoustic emissions. Ceranic BJ, et al. **Clin Otolaryngol** 1995 Jun;20(3):192–200 (89 ref.)

Perceptual consequences of cochlear hearing loss and their implications for the design of hearing aids. Moore BC. **Ear Hear** 1996 Apr;17(2):133–61 (200 ref.)

COCHLEAR IMPLANT

The dispute concerning the benefits to be expected from cochlear implantation of young deaf children [letter] Lane H. **Am J Otol** 1995 May;16(3):393–9 (41 ref.)

Mechanical and acoustic analysis of middle ear reconstruction. Rosowski JJ, et al. **Am J Otol** 1995 Jul; 16(4):486–97 (56 ref.)

New processing strategies in cochlear implantation. Wilson BS, et al. **Am J Otol** 1995 Sep;16(5):669–75 (23 ref.)

NIH consensus conference. Cochlear implants in adults and children. **JAMA** 1995 Dec 27;274(24):1955–61 (0 ref.)

Cochlear implants in adults and children. **NIH Consens Statement** 1995 May 15–17;13(2):1–30 (0 ref.)

Cochlear implants: a modern miracle. Proops D. **Practitioner** 1996 Jan;240(1558):38–40 (2 ref.)

[NIH Consensus Conference on cochlear implants in adults and children, 15 to 17 May 1995] Albegger KW. **HNO** 1996 Mar;44(3):118 (0 ref.) **(Ger)**

[The implantable middle ear hearing aid] Niehaus HH. **HNO** 1995 Dec;43(12):697–701 (27 ref.) **(Ger)**

[Current status and aspect of cochlear implant] Komune S. **Fukuoka Igaku Zasshi** 1995 Dec;86(12):425–31 (5 ref.) **(Jpn)**

ECONOMICS

Cost effectiveness of the multichannel cochlear implant. Wyatt JR, et al. **Am J Otol** 1995 Jan;16(1):52–62 (53 ref.)

STANDARDS

Cochlear implants: it's time to rethink [editorial] [see comments] House WF. **Am J Otol** 1994 Sep;15(5):573–87 (31 ref.) Comment in: Am J Otol 1995 Jan;16(1):118–9; discussion 119–20. Comment in: Am J Otol 1995 Jan;16(1):120–1; discussion 122–3. Comment in: Am J Otol 1995 Jan;16(1):121–2; discussion 122–3. Comment in: Am J Otol 1995 Jan;16(1):123–4. Comment in: Am J Otol 1995 May;16(3):399–402.

COCHLEAR NERVE

SURGERY

[Establishment of the criteria to evaluate intraoperative changes of brainstem auditory evoked potentials during microvascular decompression and acoustic neurinoma excision] Sekiya T, et al. **No Shinkei Geka** 1996 May; 24(5):431–6 (55 ref.) (Eng. Abstr.) **(Jpn)**

COCHLEAR PROSTHESIS see **COCHLEAR IMPLANT**

COCHLIOBOLUS see **ASCOMYCETES**

COCKAYNE SYNDROME

GENETICS

Xeroderma pigmentosum and molecular cloning of DNA repair genes. Boulikas T. **Anticancer Res** 1996 Mar–Apr; 16(2):693–708 (161 ref.)

COCKAYNE-TOURAINE DISEASE see **EPIDERMOLYSIS BULLOSA DYSTROPHICA**

COCKROACHES

GENETICS

kdr-Type resistance in insects with special reference to the German cockroach, Blattella germanica. Scott JG, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1994 Oct-Nov; 109(2–3):191–8 (68 ref.)

IMMUNOLOGY

[Cockroach allergy: a study of its prevalence using skin tests with commercial extracts] Cuesta C, et al. **Allergol Immunopathol (Madr)** 1995 Nov–Dec; 23(6):295–300 (34 ref.) (Eng. Abstr.) **(Spa)**

CODEINE

METABOLISM

The pharmacogenetics of codeine hypoalgesia. Sindrup SH, et al. **Pharmacogenetics** 1995 Dec;5(6):335–46 (91 ref.)

PHARMACOLOGY

The pharmacogenetics of codeine hypoalgesia. Sindrup SH, et al. **Pharmacogenetics** 1995 Dec;5(6):335–46 (91 ref.)

CODON

Effects of rare codon clusters on high-level expression of heterologous proteins in Escherichia coli. Kane JF. **Curr Opin Biotechnol** 1995 Oct;6(5):494–500 (26 ref.)

DNA sequence evolution: the sounds of silence. Sharp PM, et al. **Philos Trans R Soc Lond B Biol Sci** 1995 Sep 29; 349(1329):241–7 (54 ref.)

GENETICS

[A case of variant Gerstmann-Sträussler-Scheinker disease with the mutation of codon P105L] Kubo M, et al. **Rinsho Shinkeigaku** 1995 Aug;35(8):873–7 (9 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Van Pel A, et al. **Immunol Rev** 1995 Jun; 145:229–50 (92 ref.)

CODON, INITIATOR

see related
PEPTIDE CHAIN INITIATION
TRANSLATION, GENETIC

CODON, NONSENSE

When cells stop making sense: effects of nonsense codons on RNA metabolism in vertebrate cells. Maquat LE. **RNA** 1995 Jul;1(5):453–65 (110 ref.)

CODON, STOP see **CODON, TERMINATOR**

CODON, TERMINATOR

see related
TRANSLATION, GENETIC

Premature termination codon mutations in the type VII collagen gene (COL7A1) underlie severe recessive dystrophic epidermolysis bullosa. Uitto J, et al. **Proc Assoc Am Physicians** 1995 Jul;107(2):245–52 (30 ref.)

The end in sight: terminating translation in eukaryotes. Stansfield I, et al. **Trends Biochem Sci** 1995 Dec; 20(12):489–91 (17 ref.)

CODON, UNASSIGNED see **CODON, NONSENSE**

COELENTERATA see **CNIDARIA**

COELENTERATE VENOMS see **CNIDARIAN VENOMS**

COENDOU see **RODENTIA**

COENURIASIS see **CESTODE INFECTIONS**

COENZYME I see **NAD**

COENZYME II see NADP

COENZYME A

METABOLISM

Palmitoylcarnitine, a surface-active metabolite. Goñi FM, et al. **FEBS Lett** 1996 Jul 15;390(1):1-5 (45 ref.)

COENZYME A SYNTHETASES

METABOLISM

Coenzyme A ligases involved in anaerobic biodegradation of aromatic compounds. Villemur R. **Can J Microbiol** 1995 Oct;41(10):855-61 (49 ref.)

COENZYME M see MESNA

COENZYME Q see UBIQUINONE

COENZYMES

ISOLATION & PURIFICATION

Immobilization of enzymes/coenzymes for molecular electronics applications. Phadke RS. **Biosystems** 1995; 35(2-3):179-82 (14 ref.)

METABOLISM

Transcriptional activation. A holistic view of the complex. Carey MF. **Curr Biol** 1995 Sep 1;5(9):1003-5 (19 ref.)

Biogenesis of novel quinone coenzymes. Tanizawa K. **J Biochem (Tokyo)** 1995 Oct;118(4):671-8 (52 ref.)

COERCION

Coercion and commitment: understanding involuntary mental hospital admission. Monahan J, et al. **Int J Law Psychiatry** 1995 Summer;18(3):249-63 (75 ref.)

Crime, disorder and legal pressure as a result of addiction problems in The Netherlands. Wolters RD. **Med Law** 1995; 14(7-8):521-9 (28 ref.)

COFFEA see COFFEE

COFFEE

see related
CAFFEINE

Dose-response relationship between coffee and the risk of pancreas cancer. Nishi M, et al. **Jpn J Clin Oncol** 1996 Feb;26(1):42-8 (38 ref.)

COGNITION

Cognitive functioning in "diffuse" pathology. Role of prefrontal and limbic structures. Boller F, et al. **Ann N Y Acad Sci** 1995 Dec 15;769:23-39 (51 ref.)

Social and cognitive approaches to depression: towards a new synthesis. Champion LA, et al. **Br J Clin Psychol** 1995 Nov;34 (Pt 4):485-503 (96 ref.)

Growth, growth hormone and cognitive functions. Sartorio A, et al. **Horm Res** 1996;45(1-2):23-9 (61 ref.)

The cognitive component of nursing assessment: an analysis. Crow RA, et al. **J Adv Nurs** 1995 Aug;22(2):206-12 (44 ref.)

On the battle between behavior and cognition: lessons from physicists and pragmatists. Corrigan PW. **J Behav Ther Exp Psychiatry** 1995 Sep;26(3):209-14 (44 ref.)

Causation and complexity: old lessons, new crusades [comment] Layng TV. **J Behav Ther Exp Psychiatry** 1995 Sep;26(3):249-58 (50 ref.) Comment on: J Behav Ther Exp Psychiatry 1995 Sep;26(3):179-90.

Cerebral emboli and cognitive outcome after cardiac surgery. Stump DA, et al. **J Cardiothorac Vasc Anesth** 1996 Jan; 10(1):113-8; quiz 118-9 (43 ref.)

Process dissociation, single-process theories, and recognition memory. Ratcliff R, et al. **J Exp Psychol Gen** 1995 Dec; 124(4):352-74 (41 ref.)

Prediction of recovery from traumatic brain injury. Levin HS. **J Neurotrauma** 1995 Oct;12(5):913-22 (44 ref.)

Tasks and timing in the perception of linguistic anomaly. Fodor JD, et al. **J Psycholinguist Res** 1996 Jan;25(1):25-57 (36 ref.)

Interference in short-term memory: the magical number two (or three) in sentence processing. Lewis RL. **J Psycholinguist Res** 1996 Jan;25(1):93-115 (80 ref.)

Proper names and how they are learned. La Palme Reyes M, et al. **Memory** 1993 Dec;1(4):433-55 (32 ref.)

Testing cognition may contribute to the diagnosis of movement disorders. Pillon B, et al. **Neurology** 1996 Feb; 46(2):329-34 (75 ref.)

Applying cognitive-social theory to health-protective behavior: breast self-examination in cancer screening. Miller SM, et al. **Psychol Bull** 1996 Jan;119(1):70-94 (263 ref.)

Motivated closing of the mind: "seizing" and "freezing". Kruglanski AW, et al. **Psychol Rev** 1996 Apr;103(2):263-83 (92 ref.)

The processing-speed theory of adult age differences in cognition. Salthouse TA. **Psychol Rev** 1996 Jul; 103(3):403-28 (110 ref.)

Cognitive dissonance reduction as constraint satisfaction. Shultz TR, et al. **Psychol Rev** 1996 Apr;103(2):219-40 (64 ref.)

["Kukia poimi ja kukia kana, te sepele nistä ja omaiesi ana"--developmental dyslexia] Haapanen ML. **Duodecim** 1995;111(6):573-8 (27 ref.) **(Fin)**

[Is the mind located in the brain?] Louhiala P. **Duodecim** 1994;110(1):35-41 (22 ref.) **(Fin)**

[Neuropsychology of musical identification] Lechevalier B, et al. **Rev Neurol (Paris)** 1995 Aug-Sep;151(8-9):505-10 (32 ref.) (Eng. Abstr.) **(Fre)**

[Cognitive-behavioral therapy for obesity--with special reference to binge eating disorder] Komaki G. **Nippon Rinsho** 1995 Jun;53 Suppl:468-74 (14 ref.) **(Jpn)**

DRUG EFFECTS

Cognitive enhancement. New strategies for stimulating cholinergic, glutamatergic, and nitric oxide systems. Ingram DK, et al. **Ann N Y Acad Sci** 1996 Jun 15; 786:348-61 (80 ref.)

The neurobehavioural toxicology and teratology of lead. Winneke G, et al. **Arch Toxicol Suppl** 1996;18:57-70 (60 ref.)

Effects of neuroleptic medications on the cognition of patients with schizophrenia: a review of recent studies. Goldberg TE, et al. **J Clin Psychiatry** 1996;57 Suppl 9:62-5 (23 ref.)

Spatial cognition in humans: possible modulation by androgens and estrogens. Hampson E. **J Psychiatry Neurosci** 1995 Nov;20(5):397-404 (66 ref.)

Cognitive effects of vigabatrin: a review. Monaco F. **Neurology** 1996 Jul;47(1 Suppl 1):S6-11 (71 ref.)

Effects of antidepressants on cognitive functions: a review. Amado-Boccara I, et al. **Neurosci Biobehav Rev** 1995 Fall; 19(3):479-93 (68 ref.)

PHYSIOLOGY

Preliminary process theory: towards an integrated account of the psychophysiology of cognitive processes. Barry RJ. **Acta Neurobiol Exp (Warsz)** 1996;56(1):469-84 (24 ref.)

Neurocognitive studies in patients with supplementary sensorimotor area lesions. Burton DB, et al. **Adv Neurol** 1996;70:249-61 (58 ref.)

The role of nutrition in the development of normal cognition. Kretchmer N, et al. **Am J Clin Nutr** 1996 Jun; 63(6):997S-1001S (52 ref.)

Brain imaging and cognitive neuroscience. Toward strong inference in attributing function to structure. Sarter M, et al. **Am Psychol** 1996 Jan;51(1):13-21 (75 ref.)

Neuronal models of prefrontal cortical functions. Dehaene S, et al. **Ann N Y Acad Sci** 1995 Dec 15;769:305-19 (37 ref.)

Toward a cognitive account of frontal lobe function: simulating frontal lobe deficits in normal subjects. Dunbar K, et al. **Ann N Y Acad Sci** 1995 Dec 15;769:289-304 (34 ref.)

Temporal processing. Fuster JM. **Ann N Y Acad Sci** 1995 Dec 15;769:173-81 (19 ref.)

Forms of reasoning: insight into prefrontal functions? Holyoak KJ, et al. **Ann N Y Acad Sci** 1995 Dec 15; 769:253-63 (55 ref.)

Re-examining the role of executive functions in routine action production. Schwartz MF. **Ann N Y Acad Sci** 1995 Dec 15;769:321-35 (51 ref.)

Glucose regulation and cognitive functions: relation to Alzheimer's disease and diabetes. Messier C, et al. **Behav Brain Res** 1996 Feb;75(1-2):1-11 (127 ref.)

Cognitive functions of the basal forebrain cholinergic system in monkeys: memory or attention? Voytko ML. **Behav Brain Res** 1996 Feb;75(1-2):13-25 (123 ref.)

Cognitive and biological determinants of P300: an integrative review. Polich J, et al. **Biol Psychol** 1995 Oct;41(2):103-46 (257 ref.)

Large-scale cortical networks and cognition. Bressler SL. **Brain Res Brain Res Rev** 1995 Mar;20(3):288-304 (191 ref.)

Neurodevelopmental variation in school-aged children. Tanner JL. **Compr Ther** 1995 Sep;21(9):499-506 (17 ref.)

Animal models of cognitive function. Decker MW. **Crit Rev Neurobiol** 1995;9(4):321-43 (244 ref.)

Does breakfast make a difference in school? Pollitt E. **J Am Diet Assoc** 1995 Oct;95(10):1134-9 (24 ref.)

Do animals have cognitive maps? Bennett AT. **J Exp Biol** 1996 Jan;199 (Pt 1):219-24 (57 ref.)

Computations on metric maps in mammals: getting oriented and choosing a multi-destination route. Gallistel CR, et al. **J Exp Biol** 1996 Jan;199 (Pt 1):211-7 (47 ref.)

Deciphering the hippocampal polyglot: the hippocampus as a path integration system. McNaughton BL, et al. **J Exp Biol** 1996 Jan;199 (Pt 1):173-85 (56 ref.)

Some considerations on estimating event-related brain signals. Krieger S, et al. **J Neural Transm Gen Sect** 1995; 99(1-3):103-29 (72 ref.)

What do connectionism and social psychology offer each other? Smith ER. **J Pers Soc Psychol** 1996 May; 70(5):893-912 (132 ref.)

Cerebellar contributions to cognition. Fiez JA. **Neuron** 1996 Jan;16(1):13-5 (23 ref.)

The cognitive neuroscience of mental imagery. Kosslyn SM, et al. **Neuropsychologia** 1995 Nov;33(11):1335-44 (21 ref.)

Anatomic basis of cognitive-emotional interactions in the primate prefrontal cortex. Barbas H. **Neurosci Biobehav Rev** 1995 Fall;19(3):499-510 (155 ref.)

Serotonergic modulation of cholinergic function in the central nervous system: cognitive implications. Cassel JC, et al. **Neuroscience** 1995 Nov;69(1):1-41 (261 ref.)

Luminance and chromatic contrast effects on reading and object recognition in low vision: a review of the literature. Eperjesi F, et al. **Ophthalmic Physiol Opt** 1995 Nov; 15(6):561-8 (20 ref.)

The attentional control of pain: methodological and theoretical concerns. Eccleston C. **Pain** 1995 Oct; 63(1):3-10 (45 ref.)

A cognitive science perspective on kindling and episode sensitization in recurrent affective disorder. Segal ZV, et al. **Psychol Med** 1996 Mar;26(2):371-80 (70 ref.)

The role of visual and cognitive processes in the control of eye movement. Kowler E. **Rev Oculomot Res** 1990; 4:1-70 (255 ref.)

Eye movements in visual search: cognitive, perceptual and motor control aspects. Viviani P. **Rev Oculomot Res** 1990; 4:353-93 (235 ref.)

Mapping cognitive brain function with modern high-resolution electroencephalography. Gevins A, et al. **Trends Neurosci** 1995 Oct;18(10):429-36 (48 ref.)

Theory of mind: evolutionary history of a cognitive specialization. Povinelli DJ, et al. **Trends Neurosci** 1995 Sep;18(9):418-24 (58 ref.)

[The question of cognitive activity in twins] Bak F. **Acta Genet Med Gemellol (Roma)** 1994;43(3-4):193-206 (30 ref.) **(Fre)**

[Cognitive evoked potentials in children: normal and abnormal development] Taylor MJ, et al. **Neurophysiol Clin** 1995;25(3):130-45 (110 ref.) (Eng. Abstr.) **(Fre)**

COGNITION DISORDERS

Symptom management: loss of concentration. Cimprich B. **Semin Oncol Nurs** 1995 Nov;11(4):279-88 (80 ref.)

CHEMICALLY INDUCED

Cognitive and behavioral effects of antiepileptic drugs. Devinsky O. **Epilepsia** 1995;36 Suppl 2:S46-65 (106 ref.)

Cognitive side-effects of chronic antiepileptic drug treatment: a review of 25 years of research. Vermeulen J, et al. **Epilepsy Res** 1995 Oct;22(2):65-95 (130 ref.)

Salicylism from topical salicylates: review of the literature. Brubacher JR, et al. **J Toxicol Clin Toxicol** 1996; 34(4):431-6 (31 ref.)

[Tolerance of neuroleptics, deficit syndrome and cognitive functions] Kahn JP. **Encephale** 1996 Jun;22 Spec No 2:49-54 (35 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Defining neuropsychological dysfunction after coronary artery bypass grafting [see comments] Mahanna EP, et al. **Ann Thorac Surg** 1996 May;61(5):1342-7 (41 ref.) Comment in: Ann Thorac Surg 1996 May;61(5):1295-6.

Neuropsychology of multiple sclerosis. Rao SM. **Curr Opin Neurol** 1995 Jun;8(3):216-20 (44 ref.)

Brain electrical activity (quantitative EEG and bit-mapping neurocognitive CNV components), psychometrics and clinical findings in presenile subjects with initial mild cognitive decline or probable Alzheimer-type dementia. Zappoli R, et al. **Ital J Neurol Sci** 1995 Sep;16(6):341-76 (177 ref.)

Cognitive status as a predictor of right hemisphere stroke outcomes. Sisson RA. **J Neurosci Nurs** 1995 Jun; 27(3):152-6 (19 ref.)

Vascular risk factors and atherosclerosis as risk factors for cognitive decline and dementia [editorial] Prince MJ. **J Psychosom Res** 1995 Jul;39(5):525-30 (31 ref.)

Detecting the malingering of cognitive deficits: an update. Haines ME, et al. **Neuropsychol Rev** 1995 Jun;5(2):125-48 (82 ref.)

Assessing cognitive function in schizophrenics and patients with Alzheimer's disease. Mohs RC. **Schizophr Res** 1995 Sep;17(1):115-21 (65 ref.)

Facial processing in schizophrenia and delusional misidentification: cognitive neuropsychiatric approaches. Phillips ML, et al. **Schizophr Res** 1995 Sep;17(1):109-14 (45 ref.)

[Cognition disorders in obsessive disorder] Amado-Boccara I, et al. **Encephale** 1989 May-Jun;15(3):319-23 (22 ref.) (Eng. Abstr.) **(Fre)**

[Presentation by the GRECO group of the French adaptation of a cognitive assessment scale used in Alzheimer type dementia] Puel M, et al. **Presse Med** 1996 Jun 22; 25(22):1028-32 (14 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

Cognitive impairment in elderly people. Predisposing factors and implications for experimental drug studies. Jolles J, et al. **Drugs Aging** 1995 Dec;7(6):459-79 (176 ref.)

Antidepressants and cognitive impairment in the elderly. Oxman TE. **J Clin Psychiatry** 1996;57 Suppl 5:38-44 (59 ref.)

Cognitive impairment as a target for pharmacological treatment in schizophrenia. Davidson M, et al. **Schizophr Res** 1995 Sep;17(1):123-9 (55 ref.)

COGNITION DISORDERS

[Possibilities and limits of therapy of cognition disorders in the elderly] Hoyer S. **Z Gerontol Geriatr** 1995 Nov-Dec; 28(6):457-62 (56 ref.) (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

Psychiatric sequelae of low birth weight. Breslau N. **Epidemiol Rev** 1995;17(1):96-106 (70 ref.)

ETIOLOGY

One person's view of iron deficiency, development, and cognitive function [see comments] Beard J. **Am J Clin Nutr** 1995 Oct;62(4):709-10 (21 ref.) Comment in: Am J Clin Nutr 1996 Jul;64(1):120-1.

Cognitive problems in the elderly. Dal Forno G, et al. **Curr Opin Neurol** 1995 Aug;8(4):256-61 (44 ref.)

Neurocognitive disorders in HIV-1 infection. HNRC Group. HIV Neurobehavioral Research Center. Grant I, et al. **Curr Top Microbiol Immunol** 1995;202:11-32 (77 ref.)

Do cognitive changes of Parkinson's disease result from dopamine depletion? Dubois B, et al. **J Neural Transm Suppl** 1995;45:27-34 (28 ref.)

Anatomic correlates of psychological events related to temporolimbic epilepsy. Tackenberg JN, et al. **J Neurosci Nurs** 1996 Apr;28(2):73-81 (51 ref.)

Timing and vulnerability in research on malnutrition and cognition. Pollitt E. **Nutr Rev** 1996 Feb;54(2 Pt 2):S49-55 (15 ref.)

Spine update. Impaired cognitive functioning after whiplash injury of the cervical spine. Radanov BP, et al. **Spine** 1996 Feb 1;21(3):392-7 (26 ref.)

[Mental confusion syndromes in oncology] Reich MG, et al. **Bull Cancer (Paris)** 1996 Feb;83(2):115-28 (73 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Continuing the search for cholinergic factors in cognitive dysfunction. Russell RW. **Life Sci** 1996;58(22):1965-70 (15 ref.)

NURSING

Cognitive effects of electroconvulsive therapy: a clinical review for nurses. Durr AL, et al. **Convuls Ther** 1995 Sep; 11(3):192-201 (33 ref.)

PATHOLOGY

Cognitive impairment in elderly schizophrenia: a dementia (still) lacking distinctive histopathology. Arnold SE, et al. **Schizophr Bull** 1996;22(1):5-9 (30 ref.)

PHYSIOPATHOLOGY

Testing cognition may contribute to the diagnosis of movement disorders. Pillon B, et al. **Neurology** 1996 Feb; 46(2):329-34 (75 ref.)

Canine cognitive dysfunction as a model for human age-related cognitive decline, dementia and Alzheimer's disease: clinical presentation, cognitive testing, pathology and response to l-deprenyl therapy. Ruehl WW, et al. **Prog Brain Res** 1995;106:217-25 (32 ref.)

The anatomy of melancholia: does frontal-subcortical pathophysiology underpin its psychomotor and cognitive manifestations? [editorial] Austin MP, et al. **Psychol Med** 1995 Jul;25(4):665-72 (90 ref.)

PSYCHOLOGY

Traumatic brain injury, cognitive and emotional dysfunction. Impact of clinical neuropsychology research. Emilien G, et al. **Acta Neurol Belg** 1996 Jun;96(2):89-101 (73 ref.)

The cognitive syndrome of progressive supranuclear palsy. Dubois B, et al. **Adv Neurol** 1996;69:399-403 (17 ref.)

Cognitive deficit associated with rheumatic diseases: neuropsychological perspectives. Carbotte RM, et al. **Arthritis Rheum** 1995 Oct;38(10):1363-74 (92 ref.)

ECT and non-memory cognition: a review. Calev A, et al. **Br J Clin Psychol** 1995 Nov;34 (Pt 4):505-15 (60 ref.)

Cognitive impairment in elderly people. Predisposing factors and implications for experimental drug studies. Jolles J, et al. **Drugs Aging** 1995 Dec;7(6):459-79 (176 ref.)

REHABILITATION

[Neuropedagogic aspects of children with acquired craniocerebral trauma--an overview] Vandermeulen JA, et al. **Rehabilitation (Stuttg)** 1995 Aug;34(3):139-47 (140 ref.) (Eng. Abstr.) **(Ger)**

COGNITIVE DISSONANCE

[Cognitive distortion in the affirmation of self. Various observations] Masson A, et al. **Rev Med Liege** 1995 Sep; 50(9):390-5 (21 ref.) **(Fre)**

COGNITIVE ENHANCERS see **NOOTROPIC AGENTS**

COGNITIVE THERAPY

The management of drug-resistant, persistent and unpleasant auditory hallucinations. Lecompte D. **Acta Psychiatr Belg** 1996 Jan-Feb;96(1):21-9 (21 ref.)

Research update on the psychosocial treatment of schizophrenia. Penn DL, et al. **Am J Psychiatry** 1996 May; 153(5):607-17 (89 ref.)

Cognitive behaviour therapy in children and adolescents. Kaplan CA, et al. **Arch Dis Child** 1995 Nov;73(5):472-5 (41 ref.)

Treatment strategies for anxiety, stress, and developmental conflict during reproduction [see comments] Lederman RP. **Behav Med** 1995 Fall;21(3):113-22 (69 ref.) Comment in: Behav Med 1996 Fall;21(3):123-9.

The neuropsychology of depression and its implications for cognitive therapy. Crews WD Jr, et al. **Neuropsychol Rev** 1995 Jun;5(2):81-123 (156 ref.)

The sociocognitive model of dissociative identity disorder: a reexamination of the evidence. Gleaves DH. **Psychol Bull** 1996 Jul;120(1):42-59 (150 ref.)

Preventing relapse in weight control: a discussion of cognitive and behavioral strategies. Turner LW, et al. **Psychol Rep** 1995 Oct;77(2):651-6 (25 ref.)

METHODS

Theoretical foundations of cognitive-behavior therapy for anxiety and depression. Brewin CR. **Annu Rev Psychol** 1996;47:33-57 (90 ref.)

Correcting faulty appraisals of obsessional thoughts. Freeston MH, et al. **Behav Res Ther** 1996 May-Jun;34(5-6):433-46 (52 ref.)

Obsessive-compulsive disorder. Diagnosis and management. Ladouceur R, et al. **Can Fam Physician** 1996 Jun; 42:1169-72, 1175-8 (23 ref.)

Interrupting the binge-purge cycle in bulimia: the use of planned binges. Steel ZP, et al. **Int J Eat Disord** 1995 Nov; 18(3):199-208 (46 ref.)

Cognitive therapy of affective disorders: a review. Scott J. **J Affect Disord** 1996 Feb 12;37(1):1-11 (75 ref.)

Issues in the transportability of treatment: the case of anxiety disorders in youths. Kendall PC, et al. **J Consult Clin Psychol** 1995 Oct;63(5):702-8 (60 ref.)

Social phobia: diagnostic issues and review of cognitive behavioral treatment strategies. Juster HR, et al. **Prog Behav Modif** 1996;30:74-98 (90 ref.)

Functional analysis in behavior therapy. Kohlenberg RJ, et al. **Prog Behav Modif** 1996;30:1-24 (120 ref.)

Cognitive behavioral strategies in athletic performance enhancement. Meyers AW, et al. **Prog Behav Modif** 1996; 30:137-64 (140 ref.)

Cognitive-behavior therapy for generalized anxiety disorder. Harvey AG, et al. **Psychiatr Clin North Am** 1995 Dec; 18(4):859-70 (55 ref.)

Social phobia. Longitudinal course and long-term outcome of cognitive-behavioral treatment. Juster HR, et al. **Psychiatr Clin North Am** 1995 Dec;18(4):821-42 (77 ref.)

Cognitive-behavior therapy and the longitudinal course of panic disorder. Otto MW, et al. **Psychiatr Clin North Am** 1995 Dec;18(4):803-20 (78 ref.)

Psychotherapy for panic disorder. Shear MK. **Psychiatr Q** 1995 Winter;66(4):321-8 (16 ref.)

[Cognitive experimental approach to anxiety disorders] Azaïs F. **Encephale** 1995 Sep-Oct;21(5):597-607 (35 ref.) (Eng. Abstr.) **(Fre)**

COHORT ANALYSIS see **COHORT STUDIES**

COHORT STUDIES

Risk factors and their identification second part: study designs for identification of risk factors. Balkau B, et al. **Diabete Metab** 1995 Jun;21(3):225-31 (17 ref.)

Cohort analysis of mortality rates as an historical or narrative technique [see comments] Case RA. **J Epidemiol Community Health** 1996 Apr;50(2):114-24 (34 ref.) Comment in: J Epidemiol Community Health 1996 Apr;50(2):125-6.

Design issues in cohort studies. Prentice RL. **Stat Methods Med Res** 1995 Dec;4(4):273-92 (94 ref.)

Sample size determination in epidemiologic studies. Wickramaratne PJ. **Stat Methods Med Res** 1995 Dec; 4(4):311-37 (53 ref.)

COIN LESION, PULMONARY

DIAGNOSIS

[Solitary pulmonary nodule] Tukiainen P, et al. **Duodecim** 1994;110(8):831-8 (15 ref.) **(Fin)**

PATHOLOGY

Transbronchial needle aspiration and percutaneous needle aspiration for staging and diagnosis of lung cancer. Wang KP. **Clin Chest Med** 1995 Sep;16(3):535-52 (26 ref.)

Diagnosing the indeterminate pulmonary nodule: percutaneous biopsy versus thoracoscopy. Mitruka S, et al. **Surgery** 1995 Oct;118(4):676-84 (25 ref.)

RADIOGRAPHY

The solitary pulmonary nodule. Is it malignant or benign? Dholakia S, et al. **Postgrad Med** 1996 Feb;99(2):246-50 (4 ref.)

COITUS

Pathways of influence on fifth and eighth graders' reports about having had sexual intercourse. Porter CP, et al. **Res Nurs Health** 1996 Jun;19(3):193-204 (55 ref.)

Coitally--related morbidities in the non-pregnant female. Babarinsa IA, et al. **West Afr J Med** 1995 Jul-Sep; 14(3):141-6 (63 ref.)

[Does coitus have an effect on the course of pregnancy?] Kurki T. **Duodecim** 1994;110(18):1681-5 (32 ref.) **(Fin)**

[Hemoperitoneum due to coitus without vaginal lesions] Brühwiler H, et al. **Schweiz Med Wochenschr** 1995 Sep 2;125(35):1634-7 (14 ref.) (Eng. Abstr.) **(Ger)**

COITUS INTERRUPTUS

Withdrawal: a review of the literature and an agenda for research [see comments] Rogow D, et al. **Stud Fam Plann** 1995 May-Jun;26(3):140-53 (92 ref.) Comment in: Stud Fam Plann 1995 Sep-Oct;26(5):305-6.

COLCHICINE

[Colchicine] Le Hello C. **Ann Med Interne (Paris)** 1996; 147(3):185-211 (329 ref.) **(Fre)**

PHARMACOKINETICS

[Colchicine: recent data on pharmacokinetics and clinical pharmacology] Chappey O, et al. **Rev Med Interne** 1995; 16(10):782-9 (76 ref.) (Eng. Abstr.) **(Fre)**

PHARMACOLOGY

[Experimental pharmacology of hard tissue research] Ohya K. **Kokubyo Gakkai Zasshi** 1995 Dec;62(4):473-82 (31 ref.) **(Jpn)**

THERAPEUTIC USE

An evidence based appraisal of the management of nontophaceous interval gout [editorial] [see comments] Ferraz MB. **J Rheumatol** 1995 Sep;22(9):1618-9 (26 ref.) Comment in: J Rheumatol 1995 Sep;22(9):1621-3.

[Colchicine in familial Mediterranean fever: practical problems and their solutions] Ben-Chetrit E, et al. **Harefuah** 1995 Nov 15;129(10):413-6 (31 ref.) **(Heb)**

COLD

see related
CRYOPRESERVATION
CRYOSURGERY
CRYOTHERAPY
HYPOTHERMIA
HYPOTHERMIA, INDUCED

Molecular responses to drought and cold stress. Shinozaki K, et al. **Curr Opin Biotechnol** 1996 Apr;7(2):161-7 (64 ref.)

A review of heart rate and blood pressure responses in the cold in healthy subjects and coronary artery disease patients. Emmett JD. **J Cardpulm Rehabil** 1995 Jan-Feb; 15(1):19-24 (47 ref.)

ADVERSE EFFECTS

The respiratory system in a cold environment. Giesbrecht GG. **Aviat Space Environ Med** 1995 Sep;66(9):890-902 (163 ref.)

Exercise- and cold-induced asthma. Giesbrecht GG, et al. **Can J Appl Physiol** 1995 Sep;20(3):300-14 (100 ref.)

[Dermatoses and winter sports] Letawe C, et al. **Rev Med Liege** 1995 Nov;50(11):477-9 (12 ref.) **(Fre)**

COLD AGGLUTININ DISEASE see **ANEMIA, HEMOLYTIC, AUTOIMMUNE**

COLD, COMMON see **COMMON COLD**

COLD-INSOLUBLE GLOBULINS see **FIBRONECTINS**

COLD THERAPY see **CRYOTHERAPY**

COLECTOMY

Effect of some abdominal surgical operations on small bowel motility in humans: our experience. Bassotti G, et al. **J Clin Gastroenterol** 1995 Oct;21(3):211-6 (86 ref.)

Trocar site tumor recurrence after laparoscopic-assisted colectomy. Fodera M, et al. **J Laparoendosc Surg** 1995 Aug; 5(4):259-62 (12 ref.)

Surgical options for familial adenomatous polyposis. Ambroze WL Jr, et al. **Semin Surg Oncol** 1995 Nov-Dec; 11(6):423-7 (27 ref.)

Laparoscopic colon resection. Schirmer BD. **Surg Clin North Am** 1996 Jun;76(3):571-83 (32 ref.)

ADVERSE EFFECTS

Laparoscopic colon resection for cancer--an unfavorable view. Bertagnolli MM, et al. **Adv Surg** 1996;29:155-64 (46 ref.)

Abdominal wall metastasis and peritoneal carcinomatosis after laparoscopic-assisted colectomy for colon cancer. Jacquet P, et al. **Eur J Surg Oncol** 1995 Oct;21(5):568-70 (25 ref.)

INSTRUMENTATION

Controversies regarding laparoscopic colectomy for malignant diseases. Ota DM, et al. **Curr Opin Gen Surg**

1994;:208-13 (22 ref.)

METHODS

Laparoscopic colon resection for cancer--a favorable view. Ota DM. **Adv Surg** 1996;29:141-53 (16 ref.)
Colorectal stapled anastomoses. Experiences and results. Hansen O, et al. **Dis Colon Rectum** 1996 Jan;39(1):30-6 (39 ref.)
Results of colectomy for severe slow transit constipation. Lubowski DZ, et al. **Dis Colon Rectum** 1996 Jan;39(1):23-9 (23 ref.)
Minimally invasive colectomy in elderly patients. Peters WR, et al. **Surg Laparosc Endosc** 1995 Dec;5(6):477-9 (15 ref.)
[Preternatural anus?] Obertop H. **Ned Tijdschr Geneeskd** 1996 Apr 6;140(14):755-7 (29 ref.) **(Dut)**

COLIC

DIAGNOSIS

Infantile colic: natural history and treatment. Lehtonen LA, et al. **Curr Probl Pediatr** 1996 Mar;26(3):79-85 (78 ref.)

ETIOLOGY

Buckshot colic: case report and review of the literature [see comments] Fildes JJ, et al. **J Trauma** 1995 Dec;39(6):1181-4 (27 ref.) Comment in: J Trauma 1996 Jun;40(6):1054.
Gastrointestinal gas formation and infantile colic. Sferra TJ, et al. **Pediatr Clin North Am** 1996 Apr;43(2):489-510 (116 ref.)

THERAPY

Renal colic. Cordell WH. **Ann Emerg Med** 1996 Apr; 27(4):451-3 (11 ref.)
ABC of Urology. Urological emergencies in general practice [see comments] Dawson C, et al. **BMJ** 1996 Mar 30; 312(7034):838-40 (0 ref.) Comment in: BMJ 1996 Jul 13;313(7049):112; discussion 112-3.
Infantile colic: natural history and treatment. Lehtonen LA, et al. **Curr Probl Pediatr** 1996 Mar;26(3):79-85 (78 ref.)
[Strategy changes in the treatment of ureteral lithiasis and nephritic colic] González Enguita C, et al. **Actas Urol Esp** 1996 Apr;20(4):351-60 (35 ref.) (Eng. Abstr.) **(Spa)**

COLICINES see **COLICINS**

COLICINS

BIOSYNTHESIS

Microcins. Moreno F, et al. **Biotechnology** 1995;28:307-21 (58 ref.)

CHEMISTRY

Ion channel forming colicins. Stroud R. **Curr Opin Struct Biol** 1995 Aug;5(4):514-20 (27 ref.)

METABOLISM

Ion channel forming colicins. Stroud R. **Curr Opin Struct Biol** 1995 Aug;5(4):514-20 (27 ref.)
The biology of E colicins: paradigms and paradoxes. James R, et al. **Microbiology** 1996 Jul;142 (Pt 7):1569-80 (84 ref.)
Colicin import and pore formation: a system for studying protein transport across membranes? Lazdunski CJ. **Mol Microbiol** 1995 Jun;16(6):1059-66 (84 ref.)

COLIFORM BACILLI see **ENTEROBACTERIACEAE**

COLIPHAGE LAMBDA see **BACTERIOPHAGE LAMBDA**

COLIPHAGE M13 see **BACTERIOPHAGE M13**

COLIPHAGE MU see **BACTERIOPHAGE MU**

COLIPHAGE T4 see **BACTERIOPHAGE T4**

COLITIS

Collagenous colitis: pathogenesis and management. Halaby IA, et al. **Dis Colon Rectum** 1996 May;39(5):573-8 (61 ref.)
Inflammatory diseases of the colon. Narrowing a wide field of symptoms and possible causes. Tooson JD, et al. **Postgrad Med** 1995 Nov;98(5):46-8, 54, 57-8 passim (23 ref.)
[Toxic colitis from the viewpoint of the surgeon] Antoš F. **Rozhl Chir** 1995 May;74(4):155-8 (11 ref.) (Eng. Abstr.) **(Cze)**

CHEMICALLY INDUCED

Disinfectant colitis. Rinse as well as you wash [editorial] Ryan CK, et al. **J Clin Gastroenterol** 1995 Jul;21(1):6-9 (23 ref.)

DIAGNOSIS

Cytomegalovirus colitis mimicking colon carcinoma in an HIV-negative patient with chronic renal failure. Falagas ME, et al. **Am J Gastroenterol** 1996 Jan;91(1):168-9 (11 ref.)
Are collagenous colitis and lymphocytic colitis distinct syndromes? Jackson BK. **Dig Dis** 1995 Sep-Oct; 13(5):301-11 (46 ref.)

ETIOLOGY

Fulminant herpes colitis in a patient with Crohn's disease. el-Serag HB, et al. **J Clin Gastroenterol** 1996 Apr; 22(3):220-3 (41 ref.)
[Diversion colitis] Cayla JM, et al. **Gastroenterol Clin Biol** 1995 Aug-Sep;19(8-9):685-8 (27 ref.) **(Fre)**
[Ischemic colitis after vascular surgery reconstruction of an abdominal aortic aneurysm] Kaiser MM, et al. **Chirurg** 1996 Apr;67(4):380-6 (30 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Animal models of intestinal and joint inflammation. Sartor RB, et al. **Baillieres Clin Rheumatol** 1996 Feb;10(1):55-76 (54 ref.)

METABOLISM

Deposits of eosinophil granule proteins in eosinophilic cholecystitis and eosinophilic colitis associated with hypereosinophilic syndrome. Tajima K, et al. **Dig Dis Sci** 1996 Feb;41(2):282-8 (25 ref.)

MICROBIOLOGY

Clostridium difficile colitis: recent therapeutical and immunological considerations. Delmée M, et al. **Acta Gastroenterol Belg** 1995 May-Aug;58(3-4):313-7 (17 ref.)
Infectious colitides in patients with acquired immunodeficiency syndrome. Mosenkis BN, et al. **Gastroenterologist** 1995 Sep;3(3):241-8 (72 ref.)
Clostridium difficile-associated diarrhea and colitis. Gerding DN, et al. **Infect Control Hosp Epidemiol** 1995 Aug; 16(8):459-77 (195 ref.)

PATHOLOGY

Postirradiation colitis cystica profunda. Case report and literature review. Ng WK, et al. **Arch Pathol Lab Med** 1995 Dec;119(12):1170-3 (17 ref.)
Animal models of intestinal and joint inflammation. Sartor RB, et al. **Baillieres Clin Rheumatol** 1996 Feb;10(1):55-76 (54 ref.)

VETERINARY

Eosinophilic colitis and hepatitis in a horse with colonic intramucosal ciliated protozoa. French RA, et al. **Vet Pathol** 1996 Mar;33(2):235-8 (10 ref.)

VIROLOGY

Herpes simplex virus (HSV) colitis in a bone marrow transplant recipient. Naik HR, et al. **Bone Marrow Transplant** 1996 Feb;17(2):285-6 (11 ref.)

COLITIS, AMEBIC see **DYSENTERY, AMEBIC**

COLITIS, GRANULOMATOUS see **CROHN DISEASE**

COLITIS, ISCHEMIC

Ischemic colitis. Gandhi SK, et al. **Dis Colon Rectum** 1996 Jan;39(1):88-100 (84 ref.)
[Ischemic colitis in young patients] Apelland T, et al. **Tidsskr Nor Laegeforen** 1996 May 20;116(13):1571-2 (16 ref.) (Eng. Abstr.) **(Nor)**

COLITIS, MUCOUS see **COLONIC DISEASES, FUNCTIONAL**

COLITIS, PSEUDOMEMBRANOUS see **ENTEROCOLITIS, PSEUDOMEMBRANOUS**

COLITIS, ULCERATIVE

Unifying hypothesis for inflammatory bowel disease and associated colon cancer: sticking the pieces together with sugar. Rhodes JM. **Lancet** 1996 Jan 6;347(8993):40-4 (49 ref.)
Ulcerative colitis in children. Kirschner BS. **Pediatr Clin North Am** 1996 Feb;43(1):235-54 (115 ref.)
[Ulcerative colitis and Crohn disease] Asakura H. **Nippon Naika Gakkai Zasshi** 1996 Mar 10;85(3):408-11 (10 ref.) **(Jpn)**

BLOOD

Anti-endothelial cell antibodies in sera from patients with inflammatory bowel disease. Aldebert D, et al. **Gastroenterol Clin Biol** 1995 Nov;19(11):867-70 (20 ref.)
Circulating neutrophils from patients with ulcerative colitis have a normal respiratory burst. Haydek JM, et al. **Inflammation** 1995 Dec;19(6):701-15 (42 ref.)

COMPLICATIONS

Immune thrombocytopenic purpura in three patients with preexisting ulcerative colitis. Yoshida EM, et al. **Am J Gastroenterol** 1996 Jun;91(6):1232-5 (22 ref.)
Colonic cancer surveillance in ulcerative colitis is not essential for every patient. Axon AT. **Eur J Cancer** 1995 Jul-Aug;31A(7-8):1183-6 (31 ref.)
Is colonoscopic cancer surveillance in ulcerative colitis essential for every patient? Lennard-Jones JE. **Eur J Cancer** 1995 Jul-Aug;31A(7-8):1178-82 (28 ref.)
Grading of dysplasia. Riddell RH. **Eur J Cancer** 1995 Jul-Aug;31A(7-8):1169-70 (14 ref.)
Premalignant changes in ulcerative colitis. Nixon JB, et al. **Semin Surg Oncol** 1995 Nov-Dec;11(6):386-93 (52 ref.)
The complete heart-block--an extraintestinal manifestation of ulcerative colitis. Maeder HU. **Z Gastroenterol** 1996 Jan; 34(1):27-9 (9 ref.)
[Lymphomas of the colon complicating hemorrhagic rectocolitis] Baron P, et al. **Gastroenterol Clin Biol** 1995 Nov;19(11):935-9 (32 ref.) (Eng. Abstr.) **(Fre)**
[Specific respiratory manifestations associated with hemorrhagic rectocolitis. Analysis of a case and review of the literature] Lagier E, et al. **Gastroenterol Clin Biol** 1996;20(4):397-400 (28 ref.) (Eng. Abstr.) **(Fre)**
[Bronchiectasis in hemorrhagic rectocolitis. Apropos of a case] Jrad IB, et al. **Rev Pneumol Clin** 1995;51(5):288-90 (11 ref.) (Eng. Abstr.) **(Fre)**
[Hepatic changes in patients with nonspecific ulcerative colitis] Pontes RM, et al. **Arq Gastroenterol** 1995 Apr-Jun; 32(2):48-53 (62 ref.) (Eng. Abstr.) **(Por)**
[Cerebrovascular manifestations of gastrointestinal diseases] González JL, et al. **Rev Neurol** 1995;23 Suppl 1:S91-4 (43 ref.) **(Spa)**

DIAGNOSIS

[Thrombosis in the small branches of the superior mesenteric artery in the early stages of essential thrombocythemia] Adorján T, et al. **Orv Hetil** 1996 Mar 10;137(10):527-9 (28 ref.) (Eng. Abstr.) **(Hun)**
[Use of a scoring index for evaluating disease activity of Leśniowski-Crohn disease and ulcerative colitis in children] Ryżko J, et al. **Pediatr Pol** 1995 Jul;70(7):585-9 (9 ref.) (Eng. Abstr.) **(Pol)**

DRUG THERAPY

Antioxidant properties of 5-aminosalicylic acid: potential mechanism for its protective effect in ulcerative colitis. Miles AM, et al. **Adv Exp Med Biol** 1995;371B:1317-21 (20 ref.)
Budesonide. A review of its pharmacological properties and therapeutic efficacy in inflammatory bowel disease. Spencer CM, et al. **Drugs** 1995 Nov;50(5):854-72 (51 ref.)
Inflammatory bowel disease. Hanauer SB. **N Engl J Med** 1996 Mar 28;334(13):841-8 (111 ref.)
[Cyclosporine A and chronic inflammatory diseases of the digestive tract] Brazier F, et al. **Gastroenterol Clin Biol** 1995 May;19(5):494-504 (118 ref.) **(Fre)**
[5-aminosalicylic acid and chronic inflammatory bowel diseases in children] Klotz U. **Klin Padiatr** 1995 Sep-Oct; 207(5):285-7 (18 ref.) (Eng. Abstr.) **(Ger)**
[Advances in the topical steroid treatment of inflammatory bowel diseases] Díaz Blasco J, et al. **Rev Esp Enferm Dig** 1995 Nov;87(11):802-7 (62 ref.) **(Spa)**

EPIDEMIOLOGY

Epidemiology of inflammatory bowel disease: an update. Russel MG, et al. **Scand J Gastroenterol** 1996 May; 31(5):417-27 (190 ref.)

ETIOLOGY

Environmental risk factors in inflammatory bowel disease. Koutroubakis I, et al. **Hepatogastroenterology** 1996 Mar-Apr;43(8):381-93 (125 ref.)
[Type I hypersensitivity reactions and etiopathogenesis of hemorrhagic rectocolitis] Leprince E, et al. **Presse Med** 1995 Dec 16-23;24(39):1902-6 (58 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Molecular genetics of dysplasia in ulcerative colitis. Benhattar J, et al. **Eur J Cancer** 1995 Jul-Aug; 31A(7-8):1171-3 (15 ref.)
[Genetics and chronic idiopathic inflammatory diseases of the intestines] Reimund JM, et al. **Ann Med Interne (Paris)** 1996;147(3):178-84 (38 ref.) **(Fre)**
[Genetics of inflammatory bowel diseases] Hugot JP, et al. **Gastroenterol Clin Biol** 1995 Nov;19(11):890-8 (125 ref.) **(Fre)**

IMMUNOLOGY

Immunology of inflammatory bowel disease--an update. Jewell DP. **J Gastroenterol** 1995 Nov;30 Suppl 8:78-82 (43 ref.)
From basic advances to therapeutic strategies in ulcerative colitis [editorial] Shanahan F. **QJM** 1995 Sep;88(9):599-602 (32 ref.)
[Crohn disease, hemorrhagic rectocolitis: antibodies and humans (editorial)] Duclos B. **Gastroenterol Clin Biol** 1995 Nov;19(11):865-6 (21 ref.) **(Fre)**

[Characteristics of HLA II antigen expression in the rectal mucosa of children suffering form ulcerative colitis and Crohn disease] Hacsek G, et al. **Orv Hetil** 1995 Oct 15; 136(42):2279–82 (25 ref.) (Eng. Abstr.) **(Hun)**

METABOLISM

Cytokines and inflammatory bowel disease. Radford-Smith G, et al. **Baillieres Clin Gastroenterol** 1996 Mar; 10(1):151–64 (64 ref.)

[Butyrate and hemorrhagic rectocolitis] Flourié B, et al. **Gastroenterol Clin Biol** 1995 Jun-Jul;19(6–7):619–24 (51 ref.) **(Fre)**

MICROBIOLOGY

Escherichia coli O157:H7 infections: a frequent cause of bloody diarrhea and the hemolytic–uremic syndrome. Cohen MB. **Adv Pediatr** 1996;43:171–207 (187 ref.)

PATHOLOGY

Gallbladder adenocarcinoma, acalculous chronic lymphoplasmacytic cholecystitis, ulcerative colitis. Herzog K, et al. **Mod Pathol** 1996 Mar;9(3):194–8 (26 ref.)

Obstructive colitis: an analysis of 50 cases and a review of the literature. Gratama S, et al. **Pathology** 1995 Oct; 27(4):324–9 (30 ref.)

PREVENTION & CONTROL

[Connection between smoking and reduced risk of ulcerative colitis. Does nicotine mediate a protective effect?] Nilsson A. **Lakartidningen** 1995 Dec 13;92(50):4788–92 (20 ref.) **(Swe)**

PSYCHOLOGY

[Quality of life in chronic inflammatory bowel diseases] Bregenzer N, et al. **Med Klin** 1996 Jun 15;91(6):396–401 (36 ref.) **(Ger)**

RADIOGRAPHY

CT features of ulcerative colitis and Crohn's disease. Gore RM, et al. **AJR Am J Roentgenol** 1996 Jul;167(1):3–15 (86 ref.)

RADIONUCLIDE IMAGING

Review article: quantitative leucocyte scanning in the assessment of inflammatory bowel disease activity and its response to therapy. Weldon MJ, et al. **Aliment Pharmacol Ther** 1996 Apr;10(2):123–32 (70 ref.)

SURGERY

Perianal inflammatory conditions in inflammatory bowel disease. Stein BL, et al. **Curr Opin Gen Surg** 1993;:141–6 (17 ref.)

Surgical choices in colitis care. Bui A. **Practitioner** 1996 Mar; 240(1560):178–82 (5 ref.)

[Surgical treatment of ulcero-hemorrhagic rectocolitis] Dozois RR, et al. **Ann Chir** 1995;49(7):628–36 (60 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Inflammatory bowel disease. Bowling TE. **Eur J Gastroenterol Hepatol** 1995 Jun;7(6):521–7 (45 ref.)

Medical treatment of inflammatory bowel disease. Singhal A, et al. **J Assoc Physicians India** 1995 Sep;43(9):627–31 (32 ref.)

[Treatment and recurrence prevention ulcerative colitis] Schölmerich J. **Internist (Berl)** 1995 Dec;36(12):1124–32 (70 ref.) **(Ger)**

[Ulcerative colitis: medical treatment] Otero Regino W, et al. **Rev Gastroenterol Peru** 1995 Sep–Dec;15(3):282–9 (36 ref.) (Eng. Abstr.) **(Spa)**

COLLABORATION see COOPERATIVE BEHAVIOR

COLLAGEN

The alpha chains of type IV collagen. Zhou J, et al. **Contrib Nephrol** 1996;117:80–104 (96 ref.)

Isolated collagenoma: a case report with a review of connective tissue nevi of the collagen type. Gautam RK, et al. **J Dermatol** 1996 Jul;23(7):476–8 (22 ref.)

Extracellular matrix. 1: fibril-forming collagens. Kadler K. **Protein Profile** 1994;1(5):519–638 (3411 ref.)

Extracellular matrix 1: Fibril-forming collagens. Kadler K. **Protein Profile** 1995;2(5):491–619 (3619 ref.)

[Interstitial collagen matrix and its relationship with expansion of acute myocardial infarction] Matsubara BB, et al. **Arq Bras Cardiol** 1995 Jun;64(6):559–63 (39 ref.) **(Por)**

ADMINISTRATION & DOSAGE

Evidence that type II collagen feeding can induce a durable therapeutic response in some patients with rheumatoid arthritis. Trentham DE. **Ann N Y Acad Sci** 1996 Feb 13; 778:306–14 (15 ref.)

ADVERSE EFFECTS

[Pros and cons of use of collagenated arterial prostheses] Barral X, et al. **J Mal Vasc** 1996;21 Suppl A:36–40 (11 ref.) (Eng. Abstr.) **(Fre)**

ANALYSIS

The specificity of collagen cross-links as markers of bone and connective tissue degradation. Eyre DR. **Acta Orthop Scand Suppl** 1995 Oct;266:166–70 (23 ref.)

Collagen crosslinks in metabolic bone disease. Robins SP. **Acta Orthop Scand Suppl** 1995 Oct;266:171–5 (28 ref.)

[Collagen, procollagen peptide] Mizuta T. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:182–5 (16 ref.) **(Jpn)**

BIOSYNTHESIS

Collagen propeptides as indicators of collagen assembly. Risteli J, et al. **Acta Orthop Scand Suppl** 1995 Oct;266:183–8 (18 ref.)

Role of protein kinase C and cyclic AMP/protein kinase A in high glucose-stimulated transcriptional activation of collagen alpha 1 (IV) in glomerular mesangial cells. Ziyadeh FN, et al. **J Diabetes Complications** 1995 Oct–Dec; 9(4):255–61 (35 ref.)

A proposed sequence of reactions leading to collagen biosynthesis, fibrosis, and hypertension in alcoholics. Brecher AS, et al. **J Investig Med** 1996 Feb;44(2):36–41 (107 ref.)

BLOOD

[Type IV collagen] Mizuta T. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:258–61 (13 ref.) **(Jpn)**

CHEMISTRY

[Collagens in intestinal smooth muscles] Le Blay G, et al. **Gastroenterol Clin Biol** 1996 Mar;20(2):185–92 (49 ref.) **(Fre)**

CLASSIFICATION

Collagen types in the middle ear mucosa. Nerlich AG. **Eur Arch Otorhinolaryngol** 1995;252(7):443–6; discussion 447–9 (25 ref.)

DEFICIENCY

Cardiac malformation in two infants with hypochondrogenesis. Potocki L, et al. **Am J Med Genet** 1995 Nov 20;59(3):295–9 (17 ref.)

GENETICS

Molecular defects in the chondrodysplasias. Rimoin DL. **Am J Med Genet** 1996 May 3;63(1):106–10 (35 ref.)

Progress in human chondrodysplasias: molecular genetics. Horton WA. **Ann N Y Acad Sci** 1996 Jun 8;785:150–9 (44 ref.)

Collagens: molecular biology, diseases, and potentials for therapy. Prockop DJ, et al. **Annu Rev Biochem** 1995; 64:403–34 (248 ref.)

Mutations in collagen genes resulting in metaphyseal and epiphyseal dysplasias. Olsen BR. **Bone** 1995 Aug;17(2 Suppl):45S–49S (30 ref.)

Molecular signalling mechanisms controlling growth and function of cardiac fibroblasts. Booz GW, et al. **Cardiovasc Res** 1995 Oct;30(4):537–43 (57 ref.)

Mutations in Alport syndrome associated with diffuse esophageal leiomyomatosis. Antignac C, et al. **Contrib Nephrol** 1996;117:172–82 (37 ref.)

The type IV collagen gene family. Heikkilä P, et al. **Contrib Nephrol** 1996;117:105–29 (74 ref.)

New approaches to the DNA diagnosis of Alport syndrome. Renieri A, et al. **Contrib Nephrol** 1996;117:183–97 (50 ref.)

Mutations in type IV collagen genes and Alport phenotypes. Tryggvason K. **Contrib Nephrol** 1996;117:154–71 (58 ref.)

Role of protein kinase C and cyclic AMP/protein kinase A in high glucose-stimulated transcriptional activation of collagen alpha 1 (IV) in glomerular mesangial cells. Ziyadeh FN, et al. **J Diabetes Complications** 1995 Oct–Dec; 9(4):255–61 (35 ref.)

Another look at collagen V and XI molecules. Fichard A, et al. **Matrix Biol** 1995 Jul;14(7):515–31 (156 ref.)

Premature termination codon mutations in the type VII collagen gene (COL7A1) underlie severe recessive dystrophic epidermolysis bullosa. Uitto J, et al. **Proc Assoc Am Physicians** 1995 Jul;107(2):245–52 (30 ref.)

The Ehlers-Danlos syndrome: a heritable collagen disorder as cause of bleeding. de Paepe A. **Thromb Haemost** 1996 Mar;75(3):379–86 (75 ref.)

[Ehlers-Danlos syndromes. Clinical, genetic and molecular aspects] Germain D. **Ann Dermatol Venereol** 1995; 122(4):187–204 (91 ref.) (Eng. Abstr.) **(Fre)**

[Collagen genes and skeletal disorders] Kimura T, et al. **Ryumachi** 1995 Jun;35(3):600–8 (39 ref.) **(Jpn)**

[Type IV collagen: gene expression, supramolecular aggregates, and role in human diseases] Ninomiya Y. **Seikagaku** 1995 Nov;67(11):1301–7 (15 ref.) **(Jpn)**

IMMUNOLOGY

Arthritis: animal models of oral tolerance. Staines NA, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:297–305 (14 ref.)

Evidence that type II collagen feeding can induce a durable therapeutic response in some patients with rheumatoid arthritis. Trentham DE. **Ann N Y Acad Sci** 1996 Feb 13; 778:306–14 (15 ref.)

Identification of the alpha 3 chain of type IV collagen as the common autoantigen in antibasement membrane disease and Goodpasture syndrome. Kalluri R, et al. **J Am Soc Nephrol** 1995 Oct;6(4):1178–85 (64 ref.)

METABOLISM

Collagen II turnover in joint diseases. Poole AR, et al. **Acta Orthop Scand Suppl** 1995 Oct;266:88–91 (28 ref.)

Is collagen remodeling associated with bladder obstruction? Ehrlich HP. **Adv Exp Med Biol** 1995;385:143–9; discussion 179–84 (30 ref.)

Ventricular remodeling in heart failure: the role of myocardial collagen. Janicki JS, et al. **Adv Exp Med Biol** 1995;382:239–45 (27 ref.)

Role of angiotensin II and prostaglandin E2 in regulating cardiac fibroblast collagen turnover. Brilla CG, et al. **Am J Cardiol** 1995 Nov 2;76(13):8D–13D (42 ref.)

A family with two sisters with collagenofibrotic glomerulonephropathy. Tamura H, et al. **Am J Kidney Dis** 1996 Apr;27(4):588–95 (23 ref.)

Dynamics of matrix turnover during pathologic remodeling of the extracellular matrix [comment] Stetler-Stevenson WG. **Am J Pathol** 1996 May;148(5):1345–50 (34 ref.) Comment on: Am J Pathol 1996 May;148(5):1639–48.

Collagens: molecular biology, diseases, and potentials for therapy. Prockop DJ, et al. **Annu Rev Biochem** 1995; 64:403–34 (248 ref.)

Collagen fibril formation. Kadler KE, et al. **Biochem J** 1996 May 15;316 (Pt 1):1–11 (105 ref.)

Spontaneous disappearance of intraepidermal type VII collagen in a patient with dystrophic epidermolysis bullosa. Hatta N, et al. **Br J Dermatol** 1995 Oct;133(4):619–24 (17 ref.)

Proteinases and inhibitors. Cawston TE. **Br Med Bull** 1995 Apr;51(2):385–401 (65 ref.)

Immunohistologic findings in Alport syndrome. Kashtan CE, et al. **Contrib Nephrol** 1996;117:142–53 (58 ref.)

New insights into the function of collagens from genetic analysis. Olsen BR. **Curr Opin Cell Biol** 1995 Oct;7(5):720–7 (59 ref.)

The mechanism of collagen cross-linking in diabetes: a puzzle nearing resolution. Monnier VM, et al. **Diabetes** 1996 Jul; 45 Suppl 3:S67–72 (106 ref.)

Collagen turnover and its regulation in the normal and hypertrophying heart. Bishop JE, et al. **Eur Heart J** 1995 May;16 Suppl C:38–44 (43 ref.)

The renin-angiotensin-aldosterone system and myocardial collagen matrix remodelling in congestive heart failure. Brilla CG, et al. **Eur Heart J** 1995 Dec;16 Suppl O:107–9 (24 ref.)

Hypertensive heart disease: cardioreparation by reversal of interstitial collagen in patients. Motz W, et al. **Eur Heart J** 1995 May;16 Suppl C:69–73 (45 ref.)

Collagen/collagenase interaction: does the enzyme mimic the conformation of its own substrate? De Souza SJ, et al. **FASEB J** 1996 Jun;10(8):927–30 (18 ref.)

Bacterial collagenases and collagen-degrading enzymes and their potential role in human disease. Harrington DJ. **Infect Immun** 1996 Jun;64(6):1885–91 (82 ref.)

Extracellular matrix, supramolecular organisation and shape. Scott JE. **J Anat** 1995 Oct;187 (Pt 2):259–69 (21 ref.)

Detection of hepatic fibrogenesis: a review of available techniques. Wu J, et al. **Scand J Gastroenterol** 1995 Sep; 30(9):817–25 (78 ref.)

Platelet adhesion to collagen. Sixma JJ, et al. **Thromb Haemost** 1995 Jul;74(1):454–9 (75 ref.)

Hsp47: a collagen-specific molecular chaperone. Nagata K. **Trends Biochem Sci** 1996 Jan;21(1):22–6 (29 ref.)

[Biochemical markers of bone turnover in urine—pyridinoline, deoxypyridinoline and aminoterminal cross-links of type I collagen] Hayashi Y. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:523–6 (7 ref.) **(Jpn)**

[Metabolic disturbances and collagen distribution in interstitial pulmonary fibrosis] Siemińska A. **Pneumonol Alergol Pol** 1995;63(7–8):446–52 (40 ref.) **(Pol)**

[Collagen metabolism in hypertrophic and keloid scars] Del'vig AA. **Vestn Ross Akad Med Nauk** 1995;(12):41–5 (34 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

The collagens and their urologic implications. Macarak EJ, et al. **Adv Exp Med Biol** 1995;385:173–7; discussion 179–84 (25 ref.)

Role of cartilage collagens in formation of the skeleton. Olsen BR. **Ann N Y Acad Sci** 1996 Jun 8;785:124–30 (30 ref.)

The chondrocyte, architect of cartilage. Biomechanics, structure, function and molecular biology of cartilage matrix macromolecules. Muir H. **Bioessays** 1995 Dec; 17(12):1039–48 (79 ref.)

Another look at collagen V and XI molecules. Fichard A, et al. **Matrix Biol** 1995 Jul;14(7):515–31 (156 ref.)

Role of collagen in soft connective tissue wound healing. Oryan A. **Transplant Proc** 1995 Oct;27(5):2759–61 (34 ref.)

[Tissue localization and possible function of type VI collagen] Kobayashi M. **Kaibogaku Zasshi** 1995 Aug;70(4):298–306 (26 ref.) (Eng. Abstr.) **(Jpn)**

ULTRASTRUCTURE

Collagen fibril formation. Kadler KE, et al. **Biochem J** 1996 May 15;316 (Pt 1):1–11 (105 ref.)

COLLAGEN DISEASES

[Recent topics on collagen diseases] Kano S. **Nippon Naika Gakkai Zasshi** 1996 Mar 10;85(3):412–6 (5 ref.) **(Jpn)**

CLASSIFICATION

[Diagnostic and classification criteria in rheumatology: collagenoses] Zuber M, et al. **Dtsch Med Wochenschr** 1996 Jul 12;121(28–29):913–8 (26 ref.) **(Ger)**

COMPLICATIONS

Peripheral ulcerative keratitis in the collagen vascular diseases. Gregory JK, et al. **Int Ophthalmol Clin** 1996 Winter;36(1):21–30 (37 ref.)

Retropharyngeal abscess after radiation therapy and cis-platinum, 5-fluorouracil treatment for nasopharyngeal carcinoma with collagen disease: report of two patients and a review of the literature. Hareyama M, et al. **Jpn J Clin Oncol** 1996 Jun;26(3):189–93 (15 ref.)

Gastrointestinal manifestations of collagen-vascular diseases. Bassel K, et al. **Semin Gastrointest Dis** 1995 Oct;6(4):228–40 (124 ref.)

[Tubulointerstitial nephropathy secondary to collagen-vascular diseases] Yamada A. **Nippon Rinsho** 1995 Aug;53(8):1969–73 (19 ref.) (Eng. Abstr.) **(Jpn)**

[Collagen diseases and vasculitis] Takasaki Y. **Ryoikibetsu Shokogun Shirizu** 1995;(8):329–32 (19 ref.) **(Jpn)**

[Metabolic disturbances and collagen distribution in interstitial pulmonary fibrosis] Siemińska A. **Pneumonol Alergol Pol** 1995;63(7–8):446–52 (40 ref.) **(Pol)**

DIAGNOSIS

Fibrogenesis imperfecta ossium. Carr AJ, et al. **J Bone Joint Surg Br** 1995 Sep;77(5):820–9 (22 ref.)

Collagen vascular diseases. Corley DE, et al. **Semin Respir Infect** 1995 Jun;10(2):78–85 (18 ref.)

[Diagnostic and classification criteria in rheumatology: collagenoses] Zuber M, et al. **Dtsch Med Wochenschr** 1996 Jul 12;121(28–29):913–8 (26 ref.) **(Ger)**

DRUG THERAPY

[Emergency therapy of collagen diseases and their complications] Ichikawa Y, et al. **Nippon Naika Gakkai Zasshi** 1995 Nov 10;84(11):1865–9 (5 ref.) **(Jpn)**

GENETICS

Collagens: molecular biology, diseases, and potentials for therapy. Prockop DJ, et al. **Annu Rev Biochem** 1995; 64:403–34 (248 ref.)

[Genetical aspects of collagen disease] Takeuchi F. **Ryumachi** 1995 Oct;35(5):827–52 (250 ref.) **(Jpn)**

IMMUNOLOGY

[Role of antigen specific T-cell in collagen diseases] Yamamoto K. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Feb;18(1):1–13 (40 ref.) **(Jpn)**

PATHOLOGY

Fibroelastolytic patterns of intrinsic skin aging: pseudoxanthoma-elasticum-like papillary dermal elastolysis and white fibrous papulosis of the neck. Rongioletti F, et al. **Dermatology** 1995;191(1):19–24 (32 ref.)

[Interstitial lung involvement in collagen diseases with special reference to bronchoalveolar lavage and lung biopsy] Witt C, et al. **Pneumologie** 1995 Sep;49(9):487–91 (64 ref.) **(Ger)**

COLLAGEN TYPE I see **COLLAGEN**

COLLAGEN TYPE II see **COLLAGEN**

COLLAGEN TYPE III see **COLLAGEN**

COLLAGEN TYPE IV see **COLLAGEN**

COLLAGEN TYPE V see **COLLAGEN**

COLLAGEN TYPE VI see **COLLAGEN**

COLLAGEN TYPE VII see **COLLAGEN**

COLLAGEN TYPE VIII see **COLLAGEN**

COLLAGEN TYPE IX see **COLLAGEN**

COLLAGEN TYPE X see **COLLAGEN**

COLLAGEN TYPE XI see **COLLAGEN**

COLLAGEN TYPE XII see **COLLAGEN**

COLLAGEN TYPE XIII see **COLLAGEN**

COLLAGENASES

BLOOD

[Collagenase] Murawaki Y, et al. **Nippon Rinsho** 1995 Feb; 53 Su Pt 1:380–2 (12 ref.) **(Jpn)**

CHEMISTRY

A helping hand for collagenases: the haemopexin-like domain. Bode W. **Structure** 1995 Jun 15;3(6):527–30 (49 ref.)

METABOLISM

Stromal-epithelial interaction in type IV collagenase expression and activation: The role in cancer metastasis. Shi YE, et al. **EXS** 1995;74:215–34 (98 ref.)

Collagen/collagenase interaction: does the enzyme mimic the conformation of its own substrate? De Souza SJ, et al. **FASEB J** 1996 Jun;10(8):927–30 (18 ref.)

A helping hand for collagenases: the haemopexin-like domain. Bode W. **Structure** 1995 Jun 15;3(6):527–30 (49 ref.)

PHYSIOLOGY

Bacterial collagenases and collagen-degrading enzymes and their potential role in human disease. Harrington DJ. **Infect Immun** 1996 Jun;64(6):1885–91 (82 ref.)

COLLATERAL CIRCULATION

see related
ANGIOGENESIS FACTOR
NEOVASCULARIZATION, PHYSIOLOGIC

COLLATERAL LIGAMENTS

INJURIES

Gamekeeper's thumb: ulnar collateral ligament injury. Richard JR. **Am Fam Physician** 1996 Apr;53(5):1775–81 (12 ref.)

COLLES' FRACTURE

SURGERY

Operative treatment of intraarticular distal radial fractures. Lipton HA, et al. **Clin Orthop** 1996 Jun;(327):110–24 (91 ref.)

External fixation of the wrist. Pennig D, et al. **Injury** 1996 Jan;27(1):1–15 (108 ref.)

COLLICULUS, INFERIOR see **INFERIOR COLLICULUS**

COLLICULUS, SUPERIOR see **SUPERIOR COLLICULUS**

COLLOIDS

CHEMISTRY

Measuring colloidal and macromolecular properties by FFF. Giddings JC. **Anal Chem** 1995 Oct 1;67(19):592A–598A (33 ref.)

THERAPEUTIC USE

The use of colloids in clinical practice. Cone A. **Br J Hosp Med** 1995 Aug 16–Sep 5;54(4):155–9 (20 ref.)

COLOBOMA

COMPLICATIONS

Glaucoma and findings simulating glaucoma in the Rubinstein-Taybi syndrome. Brei TJ, et al. **J Pediatr Ophthalmol Strabismus** 1995 Jul–Aug; 32(4):248–52 (56 ref.)

DIAGNOSIS

Oculoauriculofrontonasal syndrome: report of another case and review of differential diagnosis. Toriello HV, et al. **Clin Dysmorphol** 1995 Oct;4(4):338–46 (25 ref.)

PATHOLOGY

[Colobomatous fossette of the optic papilla and juxtapapillary choroidal malignant melanoma] Chercota V, et al. **Oftalmologia** 1995 Oct–Dec;39(4):307–10 (9 ref.) (Eng. Abstr.) **(Rum)**

COLON

see related
COLECTOMY
COLONOSCOPY
COLOSTOMY

Butyrate and the colonocyte. Implications for neoplasia. Velázquez OC, et al. **Dig Dis Sci** 1996 Apr;41(4):727–39 (117 ref.)

ABNORMALITIES

Colonic atresia combined with Hirschsprung's disease: a diagnostic and therapeutic challenge. Kim PC, et al. **J Pediatr Surg** 1995 Aug;30(8):1216–7 (8 ref.)

Colonic duplication: an unusual cause of enterovesical fistula. Payne CE, et al. **Urology** 1995 Nov;46(5):726–8 (10 ref.)

BLOOD SUPPLY

Shock-associated right colon ischemia and necrosis. Ludwig KA, et al. **J Trauma** 1995 Dec;39(6):1171–4 (28 ref.)

[Ischemic colitis after vascular surgery reconstruction of an abdominal aortic aneurysm] Kaiser MM, et al. **Chirurg** 1996 Apr;67(4):380–6 (30 ref.) (Eng. Abstr.) **(Ger)**

[Recurrent bleeding from colonic varices in portal hypertension. The successful prevention of recurrence by the implantation of a transjugular intrahepatic stent-shunt (TIPS)] Allgaier HP, et al. **Dtsch Med Wochenschr** 1995 Dec 22;120(51–52):1773–6 (29 ref.) (Eng. Abstr.) **(Ger)**

[Angiodysplasia of the right colon and aortic stenosis. A case report] Arcidiacono G, et al. **Minerva Cardioangiol** 1996 Apr;44(4):173–7 (25 ref.) (Eng. Abstr.) **(Ita)**

CYTOLOGY

Colorectal cell kinetics. Gilliland R, et al. **Br J Surg** 1996 Jun;83(6):739–49 (181 ref.)

Structural characterization of colonic cell types and correlation with specific functions. Colony PC. **Dig Dis Sci** 1996 Jan;41(1):88–104 (137 ref.)

DRUG EFFECTS

Nonsteroidal anti-inflammatory drugs: gastroduodenal injury and beyond. Bernsdorff KR, et al. **Dig Dis** 1995 Jul–Aug; 13(4):251–66 (134 ref.)

INJURIES

A review of intestinal injury from blunt abdominal trauma. Munns J, et al. **Aust N Z J Surg** 1995 Dec;65(12):857–60 (15 ref.)

[The surgical procedure in injuries to the colon] Sheianov SD, et al. **Vestn Khir Im I I Grek** 1995;154(3):115–9 (48 ref.) **(Rus)**

INNERVATION

Neuronal intestinal dysplasia: a role for surgery? Lugo-Vicente HL. **Bol Asoc Med P R** 1995 Mar–Apr; 87(3–4):60–3 (29 ref.)

METABOLISM

Colonic fluid handling in health & acute diarrhoeal diseases. Ramakrishna BS. **Indian J Med Res** 1996 Jul;104:52–9 (47 ref.)

[Butyrate and hemorrhagic rectocolitis] Flourié B, et al. **Gastroenterol Clin Biol** 1995 Jun–Jul;19(6–7):619–24 (51 ref.) **(Fre)**

[Ion transport in the colon] Caprilli R, et al. **Minerva Gastroenterol Dietol** 1995 Dec;41(4):289–301 (52 ref.) (Eng. Abstr.) **(Ita)**

MICROBIOLOGY

Bacterial fermentation of complex carbohydrate in the human colon. Hill MJ. **Eur J Cancer Prev** 1995 Oct;4(5):353–8 (23 ref.)

[Hydrogen metabolism in the large intestine--physiology and clinical implications] Christl SU, et al. **Z Gastroenterol** 1995 Jul;33(7):408–13 (66 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

Use of pancreatic enzyme supplements for patients with cystic fibrosis in the context of fibrosing colonopathy. Consensus Committee. Borowitz DS, et al. **J Pediatr** 1995 Nov;127(5):681–4 (22 ref.)

Colonoscopic biopsy and polypectomy. Pierzchajlo RP. **Prim Care** 1995 Sep;22(3):451–70 (78 ref.)

Colorectal adenocarcinoma: staging and histopathology. Johnson RD, et al. **Semin Roentgenol** 1996 Apr; 31(2):94–102 (36 ref.)

Role of apoptosis in biology and pathology: resistance to apoptosis in colon carcinogenesis. Payne CM, et al. **Ultrastruct Pathol** 1995 Jul–Aug;19(4):221–48 (246 ref.)

[A case of segmental aganglionosis localized descending colon] Moriya H, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Jan;93(1):39–44 (9 ref.) **(Jpn)**

PHYSIOLOGY

Structural characterization of colonic cell types and correlation with specific functions. Colony PC. **Dig Dis Sci** 1996 Jan;41(1):88–104 (137 ref.)

Selective retention of fluid digesta in the hindgut of bandicoots and other marsupial caecum fermenters. Hume ID, et al. **DTW Dtsch Tierarztl Wochenschr** 1995 Apr; 102(4):150–1 (14 ref.)

Colonic motility in health and disease. O'Brien MD, et al. **Gastroenterol Clin North Am** 1996 Mar;25(1):147–62 (62 ref.)

Human colonic motility: physiological aspects. Bassotti G, et al. **Int J Colorectal Dis** 1995;10(3):173–80 (138 ref.)

Involvement of nitric oxide in neuromuscular transmission

in canine proximal colon. Shuttleworth CW, et al. **Proc Soc Exp Biol Med** 1996 Jan;211(1):16–23 (50 ref.)
[Neurohormonal control of gallbladder motility by intra–ileal and intracolonic nutrients—a review] Niebergall–Roth E, et al. **Berl Munch Tierarztl Wochenschr** 1996 Mar; 109(3):87–94 (110 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Intestinal responses induced by enteral feeding. Bowling TE, et al. **Nutrition** 1995 May–Jun;11(3):304–7 (67 ref.)

RADIATION EFFECTS

Postirradiation colitis cystica profunda. Case report and literature review. Ng WK, et al. **Arch Pathol Lab Med** 1995 Dec;119(12):1170–3 (17 ref.)

SURGERY

Current controversies in laparoscopic colorectal surgery [editorial] Agachan F, et al. **G Chir** 1996 Mar;17(3):77–83 (67 ref.)
[The surgical procedure in injuries to the colon] Sheianov SD, et al. **Vestn Khir Im I I Grek** 1995;154(3):115–9 (48 ref.) **(Rus)**
[Coloanal anastomosis (Parks operation) in the treatment of acute radiation rectitis] San Martin S, et al. **Rev Med Chil** 1995 Mar;123(3):321–5 (15 ref.) (Eng. Abstr.) **(Spa)**

TRANSPLANTATION

Oesophageal substitution. Isolauri J. **Ann Chir Gynaecol** 1995; 84(2):241–6 (30 ref.)
Malignant tumor developed in colon–esophagus. Altorjay A, et al. **Hepatogastroenterology** 1995 Nov–Dec;42(6):797–9 (19 ref.)

COLON AND RECTAL SURGERY (SPECIALTY)

METHODS

Radioimmunoguided surgery and colorectal cancer. Aftab F, et al. **Eur J Surg Oncol** 1996 Aug;22(4):381–8 (81 ref.)

TRENDS

What's new in colon and rectal surgery. Abel ME. **J Am Coll Surg** 1996 Feb;182(2):89–92 (21 ref.)

COLON, IRRITABLE see **COLONIC DISEASES, FUNCTIONAL**

COLONIC AGANGLIONOSIS see **HIRSCHSPRUNG DISEASE**

COLONIC DISEASES

Colonic actinomycosis: report of a case and review of the literature. Kaya E, et al. **Surg Today** 1995;25(10):923–6 (12 ref.)

CHEMICALLY INDUCED

Nonsteroidal anti–inflammatory drug–induced colonic strictures: two cases and literature review. Gargot D, et al. **Am J Gastroenterol** 1995 Nov;90(11):2035–8 (18 ref.)
Fibrosing colonopathy in cystic fibrosis. Smyth RL. **Arch Dis Child** 1996 May;74(5):464–8 (24 ref.)
Fibrosing colonopathy: recent advances. Dodge JA. **J R Soc Med** 1996;89 Suppl 27:19–23 (18 ref.)
[Nonsteroidal antirheumatic drugs and acetylsalicylic acid: adverse effects distal to the duodenum] Gut A, et al. **Schweiz Med Wochenschr** 1996 Apr 13;126(15):616–25 (95 ref.) (Eng. Abstr.) **(Ger)**

COMPLICATIONS

Massive rectal bleeding from colonic tuberculosis. Monkemuller KE, et al. **Am J Gastroenterol** 1996 Jul; 91(7):1439–41 (22 ref.)
[Colonic pseudo–obstruction caused by digestive amyloidosis in a chronic hemodialyzed patient. Apropos of a case] Tiffet O, et al. **Ann Chir** 1996;50(3):279–82 (11 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Gastrointestinal tuberculosis in renal transplantation: a case report and review. Ahsan N, et al. **Clin Transplant** 1995 Aug;9(4):349–52 (19 ref.)

ETIOLOGY

Colocutaneous fistula: a rare and silent complication of percutaneous endoscopic gastrostomy. Siddique I, et al. **Dig Dis Sci** 1996 Feb;41(2):301–4 (14 ref.)
Angiodysplasia as the cause of massive lower gastrointestinal hemorrhage in a young adult. Report of a case. Greason KL, et al. **Dis Colon Rectum** 1996 Jun;39(6):702–4 (12 ref.)
Colocutaneous fistula as a complication of PEG tube placement. Kilmartin C, et al. **J Fam Pract** 1996 Jul; 43(1):76–8 (10 ref.)
Subclinical colonic thickening. Oades PJ, et al. **J R Soc Med** 1996;89 Suppl 27:24–30 (44 ref.)
Colonic duplication: an unusual cause of enterovesical fistula. Payne CE, et al. **Urology** 1995 Nov;46(5):726–8 (10 ref.)
[Spontaneous colonic perforations revealing Ehlers–Danlos syndrome type IV] Henry C, et al. **Arch Pediatr** 1995 Nov; 2(11):1067–72 (19 ref.) (Eng. Abstr.) **(Fre)**
[Ano–rectal and colonic complications of suppositories and enemas] de Parades V, et al. **Gastroenterol Clin Biol** 1996; 20(5):446–52 (118 ref.) **(Fre)**
[Inflammatory pseudotumor of the intestine caused by necrotizing vasculitis in the course of Horton disease] Fontaney F, et al. **Gastroenterol Clin Biol** 1995 Nov; 19(11):940–3 (25 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Glycosylation patterns of mucins in colonic disease. Corfield AP, et al. **Biochem Soc Trans** 1995 Nov;23(4):840–5 (42 ref.)

MICROBIOLOGY

Gastrointestinal tuberculosis in renal transplantation: a case report and review. Ahsan N, et al. **Clin Transplant** 1995 Aug;9(4):349–52 (19 ref.)
Intestinal histoplasmosis in AIDS patients: report of three cases observed in France and review of the literature. Trylesinski A, et al. **Eur J Gastroenterol Hepatol** 1995 Jul; 7(7):679–83 (23 ref.)

PATHOLOGY

[Necrotizing panniculitis of the colon—a rare form of mesenterial panniculitis] Herzig R, et al. **Swiss Surg** 1996; (3):131–3 (17 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Colonic volvulus. Frizelle EA, et al. **Adv Surg** 1996;29:131–9 (36 ref.)
Technique of sacral hernia repair. Kaplan LJ, et al. **Am Surg** 1996 Sep;62(9):762–4 (4 ref.)
Prophylaxis in bowel surgery. Nichols RL, et al. **Curr Clin Top Infect Dis** 1995;15:76–96 (89 ref.)
Colorectal stapled anastomoses. Experiences and results. Hansen O, et al. **Dis Colon Rectum** 1996 Jan;39(1):30–6 (39 ref.)
[Colon volvulus] Monteferrante E, et al. **Minerva Chir** 1995 Dec;50(12):1085–8 (12 ref.) (Eng. Abstr.) **(Ita)**

ULTRASONOGRAPHY

[Established indications for endosonography of the rectum and colon] Feifel G, et al. **Bildgebung** 1995 Oct;62 Suppl 2:40–6 (40 ref.) **(Ger)**

COLONIC DISEASES, FUNCTIONAL

DIAGNOSIS

The challenge of irritable bowel syndrome. Bonis PA, et al. **Am Fam Physician** 1996 Mar;53(4):1229–36 (52 ref.)
When to investigate and treat IBS symptoms. Barnes J. **Practitioner** 1996 Mar;240(1560):184–7 (3 ref.)

ETIOLOGY

[Irritable bowel syndrome] Julkunen R. **Duodecim** 1994; 110(20):1927–33 (25 ref.) **(Fin)**

PHYSIOPATHOLOGY

Colonic motility in health and disease. O'Brien MD, et al. **Gastroenterol Clin North Am** 1996 Mar;25(1):147–62 (62 ref.)

PSYCHOLOGY

[Recent psychosomatic contributions to the pathogenesis and therapy of irritable colon (irritable bowel syndrome)] Csef H. **Z Gastroenterol** 1996 Apr;34(4):250–5 (102 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

The challenge of irritable bowel syndrome. Bonis PA, et al. **Am Fam Physician** 1996 Mar;53(4):1229–36 (52 ref.)
Psychological treatments for irritable bowel syndrome: a critique of controlled treatment trials. Talley NJ, et al. **Am J Gastroenterol** 1996 Feb;91(2):277–83 (34 ref.)

COLONIC NEOPLASMS

Recent study on colorectal cancer in China. Zheng S. **Chin Med J (Engl)** 1996 Mar;109(3):182–5 (19 ref.)
Butyrate and the colonocyte. Implications for neoplasia. Velázquez OC, et al. **Dig Dis Sci** 1996 Apr;41(4):727–39 (117 ref.)

COMPLICATIONS

A systematic review of the association between Barrett's esophagus and colon neoplasms [see comments] Howden CW, et al. **Am J Gastroenterol** 1995 Oct;90(10):1814–9 (29 ref.) Comment in: Am J Gastroenterol 1996 May;91(5):1056–7.
Life–threatening lower intestinal bleeding leading to discovery of a colonic paraganglioma [letter] Velitchkov NG, et al. **Dis Colon Rectum** 1996 Aug;39(8):943–5 (4 ref.)

DIAGNOSIS

Cytomegalovirus colitis mimicking colon carcinoma in an HIV–negative patient with chronic renal failure. Falagas ME, et al. **Am J Gastroenterol** 1996 Jan;91(1):168–9 (11 ref.)
Colorectal neoplasms. Screening can save lives. Truszkowski JA, et al. **Postgrad Med** 1995 Nov;98(5):97–9, 103–6, 109–12 (20 ref.)
Screening for colon cancer: a review of current and future strategies. Weinberg DS, et al. **Semin Oncol** 1995 Oct; 22(5):433–47 (138 ref.)
[Determination of the activated proto–oncogene (Ki–ras) in feces. A new laboratory analysis for early diagnosis of colorectal cancer] Koornstra JJ, et al. **Tidsskr Nor Laegeforen** 1995 Oct 30;115(26):3266–70 (42 ref.) (Eng. Abstr.) **(Nor)**

DRUG THERAPY

The chemotherapy of colon cancer. Connors TA, et al. **Eur J Cancer** 1995 Jul–Aug;31A(7–8):1373–8 (30 ref.)
An overview of adjuvant therapy for colorectal cancer. Haller DG. **Eur J Cancer** 1995 Jul–Aug;31A(7–8):1255–63 (47 ref.)
Biochemical modulation of fluoropyrimidines: is there an optimal (6R,S) leucovorin dose and schedule? [editorial; comment] Doroshow JH. **J Natl Cancer Inst** 1996 Apr 3; 88(7):393–5 (24 ref.) Comment on: J Natl Cancer Inst 1996 Apr 3;88(7):430–6.
Adjuvant therapy of colon cancer: towards a new consensus [editorial] Blijham GH. **Neth J Med** 1996 Jul;49(1):1–3 (19 ref.)
Adjuvant chemotherapy for colon and rectal cancer. Fuchs CS, et al. **Semin Oncol** 1995 Oct;22(5):472–87 (132 ref.)
[Adjuvant systemic chemotherapy in colon cancer] Raskov HH. **Ugeskr Laeger** 1996 Feb 26;158(9):1222–7 (36 ref.) (Eng. Abstr.) **(Dan)**
[Colon cancer and vitamin D—in vivo growth inhibition of colon cancer by a fluorinated analogue of 1,25–(OH)2D3, DD–003] Tanaka N, et al. **Seikagaku** 1996 Mar;68(3):214–9 (19 ref.) **(Jpn)**
[Adjuvant chemotherapy of colonic cancer] Shparyk IaV, et al. **Klin Khir** 1995;(6):38–41 (32 ref.) **(Ukr)**

EPIDEMIOLOGY

Who is susceptible to cancers of the breast, colon, and prostate? Willett WC. **Ann N Y Acad Sci** 1995 Sep 30; 768:1–11 (45 ref.)
Diet, nutrition, and avoidable cancer. Willett WC. **Environ Health Perspect** 1995 Nov;103 Suppl 8:165–70 (58 ref.)
Epidemiology of fibre, resistant starch and colorectal cancer. Kritchevsky D. **Eur J Cancer Prev** 1995 Oct;4(5):345–52 (65 ref.)
[Calcium and colon cancer] Liberman–Insel V, et al. **Harefuah** 1996 Jan 15;130(2):129–31 (20 ref.) **(Heb)**

ETIOLOGY

Who is susceptible to cancers of the breast, colon, and prostate? Willett WC. **Ann N Y Acad Sci** 1995 Sep 30; 768:1–11 (45 ref.)
Colonic cancer surveillance in ulcerative colitis is not essential for every patient. Axon AT. **Eur J Cancer** 1995 Jul–Aug;31A(7–8):1183–6 (31 ref.)
Risk factors for colon neoplasia—epidemiology and biology. Potter JD. **Eur J Cancer** 1995 Jul–Aug;31A(7–8):1033–8 (96 ref.)
Butyrate and colorectal cancer in animals and in humans (mini–symposium: butyrate and colorectal cancer). Clausen MR. **Eur J Cancer Prev** 1995 Dec;4(6):483–90 (104 ref.)
Unifying hypothesis for inflammatory bowel disease and associated colon cancer: sticking the pieces together with sugar. Rhodes JM. **Lancet** 1996 Jan 6;347(8993):40–4 (49 ref.)
Folate, epithelial dysplasia and colon cancer. Kim Y, et al. **Proc Assoc Am Physicians** 1995 Jul;107(2):218–27 (81 ref.)
[Lymphomas of the colon complicating hemorrhagic rectocolitis] Baron P, et al. **Gastroenterol Clin Biol** 1995 Nov;19(11):935–9 (32 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Genetic counselling and testing for susceptibility to breast, ovarian and colon cancer: where are we today? Cole DE, et al. **Can Med Assoc J** 1996 Jan 15;154(2):149–55 (56 ref.)
Genetic counseling for familial cancer risk. Weitzel JN. **Hosp Pract (Off Ed)** 1996 Feb 15;31(2):57–69 (17 ref.)
Familial risk and colon cancer. Burt RW. **Int J Cancer** 1996 Feb 20;69(1):44–6 (20 ref.)
Translational research on hereditary colon, breast, and ovarian cancers. Li FP. **J Natl Cancer Inst Monogr** 1995; (17):1–4 (26 ref.)
Colorectal cancer: molecular genetic studies and their future clinical applications. Fearon ER. **Med Pediatr Oncol Suppl** 1996;1:35–40 (57 ref.)
Molecular biology of colon polyps and colon cancer. Allen , JI. **Semin Surg Oncol** 1995 Nov–Dec;11(6):399–405 (22 ref.)
Premalignant changes in ulcerative colitis. Nixon JB, et al. **Semin Surg Oncol** 1995 Nov–Dec;11(6):386–93 (52 ref.)
[Prognostic factors of colon cancer from a molecular biology standpoint] Mori M, et al. **Gan To Kagaku Ryoho** 1996 Jul;23(8):982–9 (51 ref.) (Eng. Abstr.) **(Jpn)**

[Hereditary solitary adenoma] Yoshikawa R, et al. **Nippon Rinsho** 1995 Nov;53(11):2734–6 (12 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Butyrate and markers of neoplastic change in the colon. Johnson IT. **Eur J Cancer Prev** 1995 Oct;4(5):365–71 (64 ref.)

Oestrogen and colonic epithelial cell growth. Singh S, et al. **Gut** 1995 Dec;37(6):737–9 (42 ref.)

MORTALITY

Body weight and colon cancer. Shike M. **Am J Clin Nutr** 1996 Mar;63(3 Suppl):442S–444S (30 ref.)

Synchronous colon primaries have the same prognosis as solitary colon cancers. Passman MA, et al. **Dis Colon Rectum** 1996 Mar;39(3):329–34 (42 ref.)

PATHOLOGY

Extramedullary plasmacytoma mimicking primary colonic carcinoma in a patient with Crohn's disease. Case report and literature review. Ligato S, et al. **Arch Pathol Lab Med** 1996 Mar;120(3):279–82 (32 ref.)

Flat adenoma, flat carcinoma, and de novo carcinoma of the colon [editorial; comment] Owen DA. **Cancer** 1996 Jan 1;77(1):3–6 (40 ref.) Comment on: Cancer 1996 Jan 1;77(1):44–50.

Heterotopic ossification in adenocarcinoma of the colon. Hui Y, et al. **Chin Med J (Engl)** 1995 Oct;108(10):798–800 (2 ref.)

Molecular mechanisms for organ-specific colon carcinoma metastasis. Radinsky R. **Eur J Cancer** 1995 Jul–Aug; 31A(7–8):1091–5 (28 ref.)

Grading of dysplasia. Riddell RH. **Eur J Cancer** 1995 Jul–Aug;31A(7–8):1169–70 (14 ref.)

The short-chain fatty acid butyrate induces apoptosis in colorectal tumour cell lines. Hague A, et al. **Eur J Cancer Prev** 1995 Oct;4(5):359–64 (36 ref.)

Butyrate and colonic cytokinetics: differences between in vitro and in vivo studies. Lupton JR. **Eur J Cancer Prev** 1995 Oct;4(5):373–8 (67 ref.)

Abdominal wall metastasis and peritoneal carcinomatosis after laparoscopic-assisted colectomy for colon cancer. Jacquet P, et al. **Eur J Surg Oncol** 1995 Oct;21(5):568–70 (25 ref.)

Primary tumour staging of gastric and colorectal cancer. Bruneton JN, et al. **Eur Radiol** 1996;6(2):140–6 (45 ref.)

Premalignant changes in ulcerative colitis. Nixon JB, et al. **Semin Surg Oncol** 1995 Nov–Dec;11(6):386–93 (52 ref.)

Observations of aggressive, small, flat, and depressed colon cancer. Report of three cases. Kasumi A, et al. **Surg Endosc** 1995 Jun;9(6):690–4 (19 ref.)

Role of apoptosis in biology and pathology: resistance to apoptosis in colon carcinogenesis. Payne CM, et al. **Ultrastruct Pathol** 1995 Jul–Aug;19(4):221–48 (246 ref.)

Ectopic adrenocorticotropin syndrome associated with undifferentiated carcinoma of the colon showing multidirectional neuroendocrine, exocrine, and squamous differentiation. Onishi R, et al. **Virchows Arch** 1996 Feb; 427(5):537–41 (14 ref.)

[A case of schwannoma in the transverse colon] Hoshi S. **Nippon Shokakibyo Gakkai Zasshi** 1995 Sep;92(9):1289–92 (10 ref.) **(Jpn)**

[Streptococcus bovis in a surgical wound and a colonic neoplasm] Martínez Mas E, et al. **Gastroenterol Hepatol** 1995 Nov;18(9):474–6 (19 ref.) (Eng. Abstr.) **(Spa)**

PREVENTION & CONTROL

Strategies for colon cancer prevention. Lipkin M. **Ann N Y Acad Sci** 1995 Sep 30;768:170–9 (10 ref.)

Genetic counselling and testing for susceptibility to breast, ovarian and colon cancer: where are we today? Cole DE, et al. **Can Med Assoc J** 1996 Jan 15;154(2):149–55 (56 ref.)

Pharmacologic prevention of colonic neoplasms. Effects of calcium, vitamins, omega fatty acids, and nonsteroidal anti-inflammatory drugs. Eastwood GL. **Dig Dis** 1996 Mar–Apr;14(2):119–28 (124 ref.)

Calcium, why and how much? Palmieri GM. **Miner Electrolyte Metab** 1995;21(1–3):236–41 (44 ref.)

Chemoprevention of colon cancer by minor dietary constituents and their synthetic analogues. Reddy BS. **Prev Med** 1996 Jan–Feb;25(1):48–50 (13 ref.)

The tumor promoter receptor protein kinase C: a novel target for chemoprevention and therapy of human colon cancer. O'Brian CA, et al. **Prog Clin Biol Res** 1995;391:117–20 (20 ref.)

The women's health initiative: will it resolve the issues? Michels KB, et al. **Recent Results Cancer Res** 1996; 140:295–305 (53 ref.)

The role of lactic acid bacteria in colon cancer prevention. Rafter JJ. **Scand J Gastroenterol** 1995 Jun;30(6):497–502 (56 ref.)

Colonoscopic polypectomy: indication, technique, and therapeutic implications. Greene FL. **Semin Surg Oncol** 1995 Nov–Dec;11(6):416–22 (19 ref.)

[Screening for colon cancer] Järvinen HJ, et al. **Duodecim** 1994;110(20):1919–24 (33 ref.) **(Fin)**

RADIOGRAPHY

[Acute respiratory failure and multiple pulmonary nodules. Pulmonary metastases of colonic adenocarcinoma] Cordero PJ, et al. **Rev Clin Esp** 1995 Dec;195(12):845–6 (7 ref.) **(Spa)**

RADIONUCLIDE IMAGING

Radiolabeled monoclonal antibodies. Brumley CL, et al. **AORN J** 1995 Sep;62(3):343–50, 353–5; quiz 356–8, 361–2 (12 ref.)

RADIOTHERAPY

Adjuvant radiation therapy for colon cancer. Minsky BD. **Cancer Treat Rev** 1995 Sep;21(5):407–14 (18 ref.)

The current role of radiotherapy in colorectal cancer. Aleman BM, et al. **Eur J Cancer** 1995 Jul–Aug; 31A(7–8):1333–9 (28 ref.)

[Concomitant preoperative radiochemotherapy for rectal cancers] Bosset JF, et al. **Ann Chir** 1996;50(4):302–10; discussion 311 (53 ref.) (Eng. Abstr.) **(Fre)**

SECONDARY

Annular constriction of the rectum secondary to transitional cell carcinoma of the bladder. Langenstroer P, et al. **Urology** 1996 Mar;47(3):442–4 (6 ref.)

SURGERY

Adjuvant radiation therapy for colon cancer. Minsky BD. **Cancer Treat Rev** 1995 Sep;21(5):407–14 (18 ref.)

Controversies regarding laparoscopic colectomy for malignant diseases. Ota DM, et al. **Curr Opin Gen Surg** 1994;:208–13 (22 ref.)

Synchronous colon primaries have the same prognosis as solitary colon cancers. Passman MA, et al. **Dis Colon Rectum** 1996 Mar;39(3):329–34 (42 ref.)

Role of laparoscopic techniques in colorectal cancer surgery. Milsom JW, et al. **Oncology (Huntingt)** 1995 May; 9(5):393–8; discussion 398–9, 403–4, 409 (23 ref.)

THERAPY

Adjuvant therapy of colon cancer. Shulman K, et al. **Semin Oncol** 1995 Dec;22(6):600–10 (108 ref.)

COLONIC POLYPS

Inherited syndromes of colon polyps. Box JC, et al. **Semin Surg Oncol** 1995 Nov–Dec;11(6):394–8 (24 ref.)

COMPLICATIONS

Bleeding from polypoid colonic arteriovenous malformations. Koziara FJ, et al. **Am J Gastroenterol** 1996 Mar;91(3):584–6 (6 ref.)

DIAGNOSIS

Endoscopic evaluation of colon polyps. VanDerWerken BS, et al. **Semin Roentgenol** 1996 Apr;31(2):118–24 (43 ref.)

GENETICS

Molecular biology of colon polyps and colon cancer. Allen JI. **Semin Surg Oncol** 1995 Nov–Dec;11(6):399–405 (22 ref.)

PATHOLOGY

Polyps: the pathologist's perspective Mitros FA. **Semin Surg Oncol** 1995 Nov–Dec;11(6):379–85 (23 ref.)

PREVENTION & CONTROL

Colorectal cancer and polyps: clinical decisions for screening, early diagnosis, and surveillance of high-risk groups. Bond JH. **Compr Ther** 1996 Feb;22(2):100–6 (47 ref.)

RADIOGRAPHY

Barium enema: colorectal polyps and carcinoma. Ott DJ. **Semin Roentgenol** 1996 Apr;31(2):125–41 (64 ref.)

SURGERY

Colonic tattooing with India ink: benefits, risks, and alternatives. Nizam R, et al. **Am J Gastroenterol** 1996 Sep; 91(9):1804–8 (26 ref.)

Pitfalls in polypectomy: from gene to cure. Waye JD. **Eur J Cancer** 1995 Jul–Aug;31A(7–8):1133–7 (15 ref.)

Colonoscopic biopsy and polypectomy. Pierzchajlo RP. **Prim Care** 1995 Sep;22(3):451–70 (78 ref.)

Colonoscopic polypectomy: indication, technique, and therapeutic implications. Greene FL. **Semin Surg Oncol** 1995 Nov–Dec;11(6):416–22 (19 ref.)

[The secondary prevention of colorectal carcinoma by polyp removal] Riemann JF. **Strahlenther Onkol** 1995 Nov; 171(11):611–4 (21 ref.) (Eng. Abstr.) **(Ger)**

[Endoscopic resection of colorectal lesions—technique and indication] Kato M. **Hokkaido Igaku Zasshi** 1995 May; 70(3):365–9 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Colonoscopy after polypectomy. A valuable follow-up] Fasth S. **Lakartidningen** 1996 Apr 10;93(15):1419–21 (15 ref.) **(Swe)**

COLONIC PSEUDO-OBSTRUCTION

CHEMICALLY INDUCED

Acute pseudo-obstruction of the colon (Ogilvie's syndrome) resulting from combination tocolytic therapy. Pecha RE, et al. **Am J Gastroenterol** 1996 Jun;91(6):1265–6 (13 ref.)

ETIOLOGY

[Colonic pseudo-obstruction caused by digestive amyloidosis in a chronic hemodialyzed patient. Apropos of a case] Tiffet O, et al. **Ann Chir** 1996;50(3):279–82 (11 ref.) (Eng. Abstr.) **(Fre)**

COLONOSCOPY

Giant sigmoid diverticulum: report of two cases and endoscopic recognition. Mehta DC, et al. **Am J Gastroenterol** 1996 Jun;91(6):1269–71 (11 ref.)

A case of Trichuris trichiura infection diagnosed by colonoscopy. Yoshida M, et al. **Am J Gastroenterol** 1996 Jan;91(1):161–2 (7 ref.)

Colonoscopy preps: what's best? [editorial; comment] Keeffe EB. **Gastrointest Endosc** 1996 May;43(5):524–8 (30 ref.) Comment on: Gastrointest Endosc 1996 May;43(5):463–6. Comment on: Gastrointest Endosc 1996 May;43(5):467–9.

Disinfectant colitis. Rinse as well as you wash [editorial] Ryan CK, et al. **J Clin Gastroenterol** 1995 Jul;21(1):6–9 (23 ref.)

Bowel preparation before colonoscopy. Choosing the best lavage regimen. Tooson JD, et al. **Postgrad Med** 1996 Aug; 100(2):203–4, 207–12, 214 (30 ref.)

Privileges, credentialing, and liability. Musallam LS. **Prim Care** 1995 Sep;22(3):491–8 (12 ref.)

Drugs and sedation for colonoscopy. Phillips MS. **Prim Care** 1995 Sep;22(3):433–43 (33 ref.)

Colonoscopic biopsy and polypectomy. Pierzchajlo RP. **Prim Care** 1995 Sep;22(3):451–70 (78 ref.)

Colonoscopy. Robinson R. **Prim Care** 1995 Sep;22(3):399–409 (48 ref.)

Endoscopic evaluation of colon polyps. VanDerWerken BS, et al. **Semin Roentgenol** 1996 Apr;31(2):118–24 (43 ref.)

Colonoscopic polypectomy: indication, technique, and therapeutic implications. Greene FL. **Semin Surg Oncol** 1995 Nov–Dec;11(6):416–22 (19 ref.)

[Endoscopic resection of colorectal lesions—technique and indication] Kato M. **Hokkaido Igaku Zasshi** 1995 May; 70(3):365–9 (11 ref.) (Eng. Abstr.) **(Jpn)**

[The importance of colonoscopy in the early detection of colorectal cancer] Nahas SC. **Rev Hosp Clin Fac Med Sao Paulo** 1995 Mar–Apr; 50(2):125–8 (46 ref.) (Eng. Abstr.) **(Por)**

[Colonoscopy after polypectomy. A valuable follow-up] Fasth S. **Lakartidningen** 1996 Apr 10;93(15):1419–21 (15 ref.) **(Swe)**

ADVERSE EFFECTS

Complications of colonoscopy and flexible sigmoidoscopy. Waye JD, et al. **Gastrointest Endosc Clin N Am** 1996 Apr; 6(2):343–77 (138 ref.)

HISTORY

[Colonoscopy: diagnostic and treatment methods] Nahas SC. **Rev Hosp Clin Fac Med Sao Paulo** 1995 May–Jun; 50(3):154–9 (44 ref.) (Eng. Abstr.) **(Por)**

INSTRUMENTATION

Cleaning and disinfection of lower gastrointestinal endoscopes. Tremain SC. **Prim Care** 1995 Sep;22(3):471–8 (9 ref.)

METHODS

Anal endosonography in faecal incontinence [editorial] Bartram C. **Endoscopy** 1996 Feb;28(2):259–60 (26 ref.)

Insertion techniques. Hopper WJ. **Prim Care** 1995 Sep; 22(3):411–31 (8 ref.)

Screening for colon cancer: a review of current and future strategies. Weinberg DS, et al. **Semin Oncol** 1995 Oct; 22(5):433–47 (138 ref.)

COLONY-FORMING UNITS see **STEM CELLS**

COLONY-FORMING UNITS ASSAY

METHODS

[Hemopoietic colony formation in semisolid and liquid culture system] Ikebuchi K. **Rinsho Byori** 1995 Jul;Suppl 99:123–35 (14 ref.) **(Jpn)**

[Splenic colony forming method] Suzuki K, et al. **Rinsho Byori** 1995 Jul;Suppl 99:136–8 (12 ref.) **(Jpn)**

COLONY-FORMING UNITS ASSAY, TUMOR see **TUMOR STEM CELL ASSAY**

COLONY-FORMING UNITS, ERYTHROID see **ERYTHROID PROGENITOR CELLS**

COLONY-FORMING UNITS, HEMATOPOIETIC see **HEMATOPOIETIC STEM CELLS**

COLONY-FORMING UNITS, NEOPLASTIC see **TUMOR STEM CELLS**

COLONY-STIMULATING FACTOR, GRANULOCYTE-MACROPHAGE see **GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR**

COLONY-STIMULATING FACTOR, MACROPHAGE see **MACROPHAGE COLONY-STIMULATING FACTOR**

COLONY-STIMULATING FACTOR, MAST-CELL see **INTERLEUKIN-3**

COLONY-STIMULATING FACTOR, MULTIPOTENTIAL see **INTERLEUKIN-3**

COLONY-STIMULATING FACTOR RECEPTORS see **RECEPTORS, COLONY-STIMULATING FACTOR**

COLONY-STIMULATING FACTOR 2 ALPHA see **INTERLEUKIN-3**

COLONY-STIMULATING FACTORS

see related
RECEPTORS, COLONY-STIMULATING FACTOR

BIOSYNTHESIS

Interleukins and colony stimulating factors in human myeloid leukemia cell lines. Hassan HT, et al. **Leuk Lymphoma** 1995 Dec;20(1-2):1-15 (196 ref.)

THERAPEUTIC USE

The cell cycle as therapeutic target. Broxmeyer H. **Cancer Invest** 1995;13(6):617-24 (38 ref.)

Colony-stimulating factors: current applications and perspectives. Bron D, et al. **Cancer Treat Res** 1995; 79:245-54 (63 ref.)

Colony-stimulating factors as an adjunct to chemotherapy in small cell lung cancer. Urban T, et al. **Eur Respir J** 1996 Mar;9(3):596-602 (66 ref.)

Use of growth factors during induction therapy for acute myeloid leukemia. Rowe JM. **Leukemia** 1996 Apr;10 Suppl 1:S40-3 (10 ref.)

COLOPROCTECTOMY, RESTORATIVE see **PROCTOCOLECTOMY, RESTORATIVE**

COLOR

There's more to colour than meets the eye. Cowey A, et al. **Behav Brain Res** 1995 Nov;71(1-2):89-100 (78 ref.)

Colour thresholding in video imaging. Fermin CD, et al. **J Anat** 1995 Jun;186 (Pt 3):469-81 (21 ref.)

Luminance and chromatic contrast effects on reading and object recognition in low vision: a review of the literature. Eperjesi F, et al. **Ophthalmic Physiol Opt** 1995 Nov; 15(6):561-8 (20 ref.)

COLOR BLINDNESS see **COLOR VISION DEFECTS**

COLOR FLOW ECHOCARDIOGRAPHY see **ECHOCARDIOGRAPHY, DOPPLER, COLOR**

COLOR PERCEPTION

see related
COLOR VISION DEFECTS

The emotional Stroop task and psychopathology. Williams JM, et al. **Psychol Bull** 1996 Jul;120(1):3-24 (95 ref.)

GENETICS

Molecular genetics of human color vision. Deeb SS, et al. **Behav Genet** 1996 May;26(3):195-207 (60 ref.)

Molecular basis for tetrachromatic color vision. Okano T, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1995 Nov;112(3):405-14 (52 ref.)

Colour vision. Dalton's eyes and monkey genes. Tovée MJ. **Curr Biol** 1995 Jun 1;5(6):583-6 (16 ref.)

PHYSIOLOGY

There's more to colour than meets the eye. Cowey A, et al. **Behav Brain Res** 1995 Nov;71(1-2):89-100 (78 ref.)

Colour vision. Adapting to change. Walsh V. **Curr Biol** 1995 Jul 1;5(7):703-5 (10 ref.)

Synaesthesia: reconciling the subjective with the objective. Harrison J, et al. **Endeavour** 1995;19(4):157-60 (20 ref.)

Circuitry for color coding in the primate retina. Dacey DM. **Proc Natl Acad Sci U S A** 1996 Jan 23;93(2):582-8 (55 ref.)

Primate photopigments and primate color vision. Jacobs GH. **Proc Natl Acad Sci U S A** 1996 Jan 23;93(2):577-81 (61 ref.)

Separating colour and luminance information in the visual system. Kingdom FA, et al. **Spat Vis** 1995;9(2):191-219 (77 ref.)

COLOR VISION see **COLOR PERCEPTION**

COLOR VISION DEFECTS

ETIOLOGY

[The pathogenesis of diabetic dyschromatopsia] Gheorghiu M. **Oftalmologia** 1996 Jan-Mar;40(1):11-5 (15 ref.) (Eng. Abstr.) **(Rum)**

GENETICS

Colour vision. Dalton's eyes and monkey genes. Tovée MJ. **Curr Biol** 1995 Jun 1;5(6):583-6 (16 ref.)

COLORECTAL NEOPLASMS

see related
GENES, DCC

Liver metastases from colorectal cancer: lessons from past and present clinical studies. Taylor I. **Br J Surg** 1996 Apr; 83(4):456-60 (35 ref.)

CD44 in colon cancer. Herrlich P, et al. **Eur J Cancer** 1995 Jul-Aug;31A(7-8):1110-2 (32 ref.)

Colorectal cancer: hepatic-directed therapy--the role of surgery, regional chemotherapy, and novel modalities. Busch E, et al. **Semin Oncol** 1995 Oct;22(5):494-508 (110 ref.)

Colorectal cancer biology: clinical implications. Johnston PG, et al. **Semin Oncol** 1995 Oct;22(5):418-32 (112 ref.)

Colorectal cancer: etiologic and clinical aspects. Richards F 2nd, et al. **Semin Roentgenol** 1996 Apr;31(2):103-10 (51 ref.)

[Muir-Torre syndrome] Yoshikawa R, et al. **Nippon Rinsho** 1995 Nov;53(11):2803-6 (11 ref.) (Eng. Abstr.) **(Jpn)**

BLOOD

[Pharmacology of regional chemotherapy of colorectal liver metastases] Schalhorn A, et al. **Zentralbl Chir** 1995; 120(10):764-8 (15 ref.) (Eng. Abstr.) **(Ger)**

CHEMISTRY

Fibrinolysis components as prognostic markers in breast cancer and colorectal carcinoma. Gandolfo GM, et al. **Anticancer Res** 1996 Jul-Aug;16(4B):2155-9 (37 ref.)

COMPLICATIONS

Rectal bleeding: when is it right to refer? Thompson M, et al. **Practitioner** 1996 Mar;240(1560):198-200 (9 ref.)

DIAGNOSIS

TAG-72 expression and its role in the biological evaluation of human colorectal cancer. Guadagni F, et al. **Anticancer Res** 1996 Jul-Aug;16(4B):2141-8 (71 ref.)

A simple mucus test for cancer screening. Shamsuddin AM. **Anticancer Res** 1996 Jul-Aug;16(4B):2193-9 (57 ref.)

College of American Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors. Report of the Colorectal Cancer Working Group. Fielding LP, et al. **Arch Pathol Lab Med** 1995 Dec;119(12):1115-21 (58 ref.)

Management of recurrent colorectal cancer: another look at carcinoembryonic antigen-detected recurrence [see comments] Vauthey JN, et al. **Dig Dis** 1996 Jan-Feb; 14(1):5-13 (48 ref.) Comment in: Dig Dis 1996 Jan-Feb;14(1):1-4.

Radiology in the detection and prevention of colorectal cancer. Stevenson G. **Eur J Cancer** 1995 Jul-Aug; 31A(7-8):1121-6 (55 ref.)

Early detection research program at the NCI. Srivastava S, et al. **Int J Cancer** 1996 Feb 20;69(1):35-7 (24 ref.)

Colorectal cancer screening: present strategies and future prospects [see comments] Marshall JB. **Postgrad Med** 1996 Mar;99(3):253-64 (37 ref.) Comment in: Postgrad Med 1996 Jun;99(6):43-4. Comment in: Postgrad Med 1996 Jul;100(1):50, 52.

New imaging techniques in colorectal cancer. Tempero M, et al. **Semin Oncol** 1995 Oct;22(5):448-71 (178 ref.)

Integrated imaging in colorectal cancer. Ott DJ, et al. **Semin Roentgenol** 1996 Apr;31(2):166-9 (34 ref.)

Magnetic resonance imaging of colorectal cancer. Zagoria RJ, et al. **Semin Roentgenol** 1996 Apr;31(2):162-5 (11 ref.)

[Endoscopic diagnosis and treatment of flat colorectal neoplastic lesions] Saurin JC. **Gastroenterol Clin Biol** 1996; 20(5 Pt 2):B152-8 (44 ref.) **(Fre)**

[Genetic diagnosis of colorectal cancer] Itoh F, et al. **Hokkaido Igaku Zasshi** 1996 Jan;71(1):9-14 (18 ref.) (Eng. Abstr.) **(Jpn)**

[The importance of colonoscopy in the early detection of colorectal cancer] Nahas SC. **Rev Hosp Clin Fac Med Sao Paulo** 1995 Mar-Apr; 50(2):125-8 (46 ref.) (Eng. Abstr.) **(Por)**

DRUG THERAPY

Adjuvant chemotherapy for colorectal cancer. Kerr DJ, et al. **Br J Hosp Med** 1996 Mar 6-19;55(5):259-62 (17 ref.)

Chemotherapy of metastatic bowel cancer. Ross PJ, et al. **Br J Hosp Med** 1996 Mar 6-19;55(5):263-6 (20 ref.)

Arterial therapy of hepatic colorectal metastases. Vauthey JN, et al. **Br J Surg** 1996 Apr;83(4):447-55 (104 ref.)

Cancers of the large bowel and hepatobiliary tract. Vaughn DJ, et al. **Cancer Chemother Biol Response Modif** 1996; 16:495-510 (63 ref.)

CPT-11 (irinotecan) in the treatment of colorectal cancer. Armand JP, et al. **Eur J Cancer** 1995 Jul-Aug; 31A(7-8):1283-7 (41 ref.)

Thymidylate synthase inhibition, a dead end? [editorial] Herrmann R. **Eur J Cancer** 1995 Nov;31A(12):1919-20 (7 ref.)

ZD1694 (Tomudex): a new thymidylate synthase inhibitor with activity in colorectal cancer. Jackman AL, et al. **Eur J Cancer** 1995 Jul-Aug;31A(7-8):1277-82 (30 ref.)

Role of leucovorin dosing and administration schedule. Jolivet J. **Eur J Cancer** 1995 Jul-Aug;31A(7-8):1311-5 (52 ref.)

Chronomodulation of chemotherapy against metastatic colorectal cancer. International Organization for Cancer Chronotherapy. Lévi F, et al. **Eur J Cancer** 1995 Jul-Aug; 31A(7-8):1264-70 (43 ref.)

Locoregional chemotherapy for adjuvant treatment of colorectal adenocarcinoma. Penna C, et al. **Eur J Cancer** 1996 Jun;32A(7):1117-22 (47 ref.)

Current chemotherapeutic possibilities in the treatment of colorectal cancer. van Triest B, et al. **Eur J Cancer** 1995 Jul-Aug;31A(7-8):1193-7 (29 ref.)

Biochemical modulation of fluoropyrimidines: is there an optimal (6R,S) leucovorin dose and schedule? [editorial; comment] Doroshow JH. **J Natl Cancer Inst** 1996 Apr 3; 88(7):393-5 (24 ref.) Comment on: J Natl Cancer Inst 1996 Apr 3;88(7):430-6.

Prognostic variable in patients with advanced colorectal cancer treated with fluorouracil and leucovorin-based chemotherapy. Fountzilas G, et al. **Med Pediatr Oncol** 1996 May;26(5):305-17 (45 ref.)

Role of chemotherapy for advanced colorectal cancer: new opportunities. Bleiberg H. **Semin Oncol** 1996 Feb;23(1 Suppl 3):42-50 (71 ref.)

Metastatic colorectal cancer: advances in biochemical modulation and new drug development. Meropol NJ, et al. **Semin Oncol** 1995 Oct;22(5):509-24 (153 ref.)

CPT-11 in the treatment of colorectal cancer: clinical efficacy and safety profile. Rougier P, et al. **Semin Oncol** 1996 Feb;23(1 Suppl 3):34-41 (35 ref.)

Clinical development of new fluoropyrimidines: a major improvement in colorectal cancer treatment? Colleoni M, et al. **Tumori** 1995 Sep-Oct;81(5):303-7 (44 ref.)

Radiotherapy and combined chemo-radiotherapy of rectal cancer. Zucali R. **Tumori** 1995 May-Jun;81(3 Suppl):74-7 (29 ref.)

Adjuvant therapy for colorectal cancer--is there a place for a Northern Ireland study? Wilson RH, et al. **Ulster Med J** 1994 Apr;63(1):44-51 (41 ref.)

[Immunotherapy of colorectal cancers] Bécouarn Y, et al. **Gastroenterol Clin Biol** 1996 Feb;20(1):20-32 (106 ref.) **(Fre)**

[Results of resection and adjuvant therapy of liver metastases of primary colorectal tumors--a review of the literature] Lorenz M, et al. **Zentralbl Chir** 1995;120(10):769-79 (74 ref.) (Eng. Abstr.) **(Ger)**

[Regional adjuvant therapy in colorectal liver metastases: requirements for clinical therapy studies from the statistical viewpoint (see comments)] Müller HH, et al. **Zentralbl Chir** 1995;120(10):755-9 (10 ref.) (Eng. Abstr.) Comment in: Zentralbl Chir 1995;120(10):753-4. **(Ger)**

[Recent advance in chemotherapy for advanced colorectal cancer] Aiba K. **Gan To Kagaku Ryoho** 1996 Apr; 23(5):535-48 (83 ref.) (Eng. Abstr.) **(Jpn)**

[Progress of adjuvant chemotherapy in colon cancer] Toge T. **Gan To Kagaku Ryoho** 1996 Apr;23(5):554-9 (30 ref.) (Eng. Abstr.) **(Jpn)**

[Chemotherapy in colorectal cancer. Recommendations of the Norwegian Gastrointestinal Cancer Group] Tveit KM, et al. **Tidsskr Nor Laegeforen** 1996 Jan 30;116(3):357-60 (31 ref.) (Eng. Abstr.) **(Nor)**

[Regional adjuvant chemotherapy in colorectal cancer] Shparyk IaV, et al. **Klin Khir** 1995;(9-10):41-5 (38 ref.) **(Ukr)**

ECONOMICS

Screening for colon cancer: economics and related considerations. Gelfand DW. **Semin Roentgenol** 1996 Apr; 31(2):170-6 (17 ref.)

EPIDEMIOLOGY

Colorectal cancer and intake of dietary fibre. A summary of the epidemiological evidence. Kaaks R, et al. **Eur J Clin Nutr** 1995 Oct;49 Suppl 3:S10-7 (56 ref.)

Short-chain fatty acids and colorectal cancer. Vernia P, et al. **Eur J Clin Nutr** 1995 Oct;49 Suppl 3:S18-21 (20 ref.)

Principal cancers among women: breast, lung and colorectal. Rozenberg S, et al. **Int J Fertil Menopausal Stud** 1996 Mar-Apr;41(2):166-71 (33 ref.)

Genetic epidemiology of colorectal cancer. Presciuttini S, et al. **Tumori** 1996 Mar-Apr;82(2):107-13 (58 ref.)

ETHNOLOGY

Molecular changes of colorectal cancer in Singapore. Goh HS, et al. **Ann Acad Med Singapore** 1996 Jan;25(1):3-10 (93 ref.)

ETIOLOGY

Malignancy in Crohn's disease. Bernstein D, et al.

Am J Gastroenterol 1996 Mar;91(3):434–40 (107 ref.)
In vitro models for studying colorectal carcinogenesis: cellular and molecular events including APC and Rb cleavage in the control of proliferation, differentiation and apoptosis. Williams AC, et al. **Biochim Biophys Acta** 1996 Aug 8;1288(1):F9–19 (91 ref.)
Colorectal cancer and the intersection between basic and clinical research. Vogelstein B, et al.
Cold Spring Harb Symp Quant Biol 1994;59:517–21 (32 ref.)
Is colonoscopic cancer surveillance in ulcerative colitis essential for every patient? Lennard-Jones JE.
Eur J Cancer 1995 Jul–Aug;31A(7–8):1178–82 (28 ref.)
Role of bile acids in colorectal carcinogenesis. Nagengast FM, et al. **Eur J Cancer** 1995 Jul–Aug;31A(7–8):1067–70 (44 ref.)
Endoscopic appearance of dysplasia and cancer in inflammatory bowel disease. Tytgat GN, et al.
Eur J Cancer 1995 Jul–Aug;31A(7–8):1174–7 (41 ref.)
Colorectal cancer and intake of dietary fibre. A summary of the epidemiological evidence. Kaaks R, et al.
Eur J Clin Nutr 1995 Oct;49 Suppl 3:S10–7 (56 ref.)
Short-chain fatty acids and colorectal cancer. Vernia P, et al. **Eur J Clin Nutr** 1995 Oct;49 Suppl 3:S18–21 (20 ref.)
The causes of ordinary colorectal adenomas: the key to the control of colorectal cancer? [see comments] Kune GA, et al. **J R Soc Med** 1995 Nov;88(11):625–8 (32 ref.) Comment in: J R Soc Med 1996 Apr;89(4):237.
Controversies about the genetic model of colorectal tumorigenesis. Waliszewski P. **Pol J Pathol** 1995; 46(4):239–43 (48 ref.)
[New aspects in the etiopathogenesis of colorectal cancer] Iarŭmov N. **Khirurgiia (Sofiia)** 1995;48(4):46–51 (9 ref.) (Eng. Abstr.) **(Bul)**
[Etiology of colorectal cancer] Matos Villalobos M. G E N 1994 Oct–Dec;48(4):264–72 (76 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

Pathways of chromosome alteration in human epithelial cancers. Dutrillaux B. **Adv Cancer Res** 1995;67:59–82 (80 ref.)
Molecular changes of colorectal cancer in Singapore. Goh HS, et al. **Ann Acad Med Singapore** 1996 Jan;25(1):3–10 (93 ref.)
p53 and prognosis in colorectal cancer. Smith DR, et al. **Ann Acad Med Singapore** 1996 Jan;25(1):107–12 (97 ref.)
Colorectal adenoma progression and genetic change: is there a link? Jass JR. **Ann Med** 1995 Jun;27(3):301–6 (40 ref.)
Molecular genetics of colorectal cancer. Fearon ER.
Ann N Y Acad Sci 1995 Sep 30;768:101–10 (60 ref.)
Is mucinous carcinoma of the colorectum a distinct genetic entity? Hanski C. **Br J Cancer** 1995 Dec;72(6):1350–6 (124 ref.)
Molecular genetic basis of colorectal cancer susceptibility. Cunningham C, et al. **Br J Surg** 1996 Mar;83(3):321–9 (78 ref.)
Emergent issues in the genetics of intestinal neoplasia. Dove WF, et al. **Cancer Surv** 1995;25:335–55 (98 ref.)
The deleted in colorectal cancer (DCC) gene: a candidate tumour suppressor gene encoding a cell surface protein with similarity to neural cell adhesion molecules. Fearon ER, et al. **Cancer Surv** 1995;24:3–17 (58 ref.)
Molecular biology and colorectal cancer: genetic alterations, inherited syndromes, and applications to colon cancer screening. O'Brien BL, et al. **Dig Dis** 1995 May–Jun; 13(3):182–9 (47 ref.)
Genetic and environmental factors in colorectal carcinogenesis. Zimbalist EH, et al. **Dig Dis** 1995 Nov–Dec; 13(6):365–78 (119 ref.)
Molecular genetics of dysplasia in ulcerative colitis. Benhattar J, et al. **Eur J Cancer** 1995 Jul–Aug; 31A(7–8):1171–3 (15 ref.)
DCC: linking tumour suppressor genes and altered cell surface interactions in cancer? Cho KR, et al.
Eur J Cancer 1995 Jul–Aug;31A(7–8):1055–60 (47 ref.)
Genetic epidemiology of colorectal cancer. Petersen GM.
Eur J Cancer 1995 Jul–Aug;31A(7–8):1047–50 (33 ref.)
Screening for clonal genetic alterations. Sidransky D.
Eur J Cancer 1995 Jul–Aug;31A(7–8):1127–9 (23 ref.)
Roles of the DNA mismatch repair genes in colorectal tumorigenesis. Boland CR. **Int J Cancer** 1996 Feb 20; 69(1):47–9 (14 ref.)
The adenomatous polyposis coli gene and human cancers. Nakamura Y. **J Cancer Res Clin Oncol** 1995; 121(9–10):529–34 (63 ref.)
National Cancer Institute Workshop on Genetic Screening for Colorectal Cancer. Rossi SC, et al.
J Natl Cancer Inst 1996 Mar 20;88(6):331–9 (49 ref.)
Microsatellite instability and hereditary non-polyposis colon cancer [editorial] Peltomäki P. **J Pathol** 1995 Aug; 176(4):329–30 (26 ref.)
Controversies about the genetic model of colorectal tumorigenesis. Waliszewski P. **Pol J Pathol** 1995; 46(4):239–43 (48 ref.)
Multistep carcinogenesis in colorectal cancers. Takami K, et al. **Southeast Asian J Trop Med Public Health** 1995;26 Suppl 1:190–6 (28 ref.)
Genetic epidemiology of colorectal cancer. Presciuttini S, et al. **Tumori** 1996 Mar–Apr;82(2):107–13 (58 ref.)
[Genetics of colorectal cancers (editorial)] Pocard M, et al. **Ann Chir** 1996;50(3):211–6 (19 ref.) **(Fre)**
[Prognostic value of genetic changes in colorectal cancers] Laurent-Puig P. **Gastroenterol Clin Biol** 1996;20(5 Pt 2):B27–35 (69 ref.) **(Fre)**
[Precancerous lesion in colorectal cancer] Nagawa H, et al. **Gan To Kagaku Ryoho** 1995 Dec;22(14):2043–7 (19 ref.) (Eng. Abstr.) **(Jpn)**
[Genetic basis of tumors of the colon] Spaventi R. **Lijec Vjesn** 1995 Nov–Dec;117(11–12):285–93 (107 ref.) (Eng. Abstr.) **(Ser)**

IMMUNOLOGY

The human leucocyte antigen complex: its role in colorectal cancer. Ngoi SS, et al. **Ann Acad Med Singapore** 1996 Jan; 25(1):11–6 (34 ref.)
[Carbohydrate antigens in carcinoma invasion and metastasis] Izumi Y, et al. **Nippon Geka Gakkai Zasshi** 1996 Feb; 97(2):140–4 (13 ref.) (Eng. Abstr.) **(Jpn)**
[Prognosis of colorectal cancer and sialyl-lea antigen] Watanabe M, et al. **Nippon Geka Gakkai Zasshi** 1996 Feb; 97(2):177–81 (13 ref.) **(Jpn)**

METABOLISM

MDR1/P-glycoprotein expression in colorectal cancer. Linn SC, et al. **Eur J Cancer** 1995 Jul–Aug;31A(7–8):1291–4 (30 ref.)
Intermediate biomarkers in the colorectal tumor progression. Risio M, et al. **Tumori** 1995 May–Jun;81(3 Suppl):16–8 (19 ref.)

MORTALITY

Can mortality from colorectal cancer be reduced? Winawer SJ. **Ann N Y Acad Sci** 1995 Sep 30;768:60–7 (36 ref.)
Prognostic value of plasminogen activators and their inhibitors in colorectal cancer. Verspaget HW, et al.
Eur J Cancer 1995 Jul–Aug;31A(7–8):1105–9 (28 ref.)

PATHOLOGY

Exfoliated tumour cells and locally recurrent colorectal cancer. Basha G, et al. **Acta Chir Belg** 1996 Apr;96(2):66–70 (41 ref.)
Prognostic value of pathological characteristics of colorectal cancer. Bosman FT. **Eur J Cancer** 1995 Jul–Aug; 31A(7–8):1216–21 (30 ref.)
Regional chemotherapy of colorectal cancer. Kemeny NE. **Eur J Cancer** 1995 Jul–Aug;31A(7–8):1271–6 (45 ref.)
Treatment of colorectal cancer metastases confined to the liver. Vahrmeijer AL, et al. **Eur J Cancer** 1995 Jul–Aug; 31A(7–8):1238–42 (43 ref.)
Planning of liver surgery using three dimensional imaging techniques. van Leeuwen MS, et al. **Eur J Cancer** 1995 Jul–Aug;31A(7–8):1212–5 (16 ref.)
The vascularity of colorectal liver metastases. Shankar A, et al. **Eur J Surg Oncol** 1996 Aug;22(4):389–96 (88 ref.)
Repeated hepatic resections for recurrent metastasis of colorectal cancer. Gazzaniga GM, et al.
Hepatogastroenterology 1995 Jul–Aug;42(4):383–6 (19 ref.)
Hepatic cryosurgery for metastatic colorectal carcinoma. Brandt BT, et al. **Oncol Nurs Forum** 1996 Jan–Feb; 23(1):29–36; quiz 37–8 (20 ref.)
Colorectal liver metastases. Burke D, et al.
Postgrad Med J 1996 Aug;72(850):464–9 (53 ref.)
Colorectal adenocarcinoma: staging and histopathology. Johnson RD, et al. **Semin Roentgenol** 1996 Apr; 31(2):94–102 (36 ref.)
Immunodiagnosis and immunotherapy of isolated tumor cells disseminated to bone marrow of patients with colorectal cancer. Braun S, et al. **Tumori** 1995 May–Jun;81(3 Suppl):78–83 (51 ref.)
Intermediate biomarkers in the colorectal tumor progression. Risio M, et al. **Tumori** 1995 May–Jun;81(3 Suppl):16–8 (19 ref.)
[Tumor staging and follow-up care in rectosigmoid carcinoma: colonoscopic endosonography compared to CT, MRI and endorectal MRI] Meyenberger C, et al. **Schweiz Rundsch Med Prax** 1996 May 7;85(19):622–31 (44 ref.) (Eng. Abstr.) **(Ger)**
[Classification and documentation of liver metastases of colorectal carcinomas] Wittekind C. **Zentralbl Chir** 1995; 120(10):760–3 (18 ref.) (Eng. Abstr.) **(Ger)**
[Prognostic factors of colorectal cancer concerning metastases] Yamaguchi S, et al. **Gan To Kagaku Ryoho** 1996 Apr;23(5):529–33 (17 ref.) (Eng. Abstr.) **(Jpn)**
[Comparative study on biological difference between gastric cancer and colorectal cancer] Mai M, et al.
Nippon Geka Gakkai Zasshi 1996 Apr;97(4):263–8 (24 ref.) (Eng. Abstr.) **(Jpn)**
[Current status of the regional treatment of hepatic metastasis from colorectal carcinoma] de Castro Carpeño J, et al. **Rev Clin Esp** 1995 Aug;195(8):565–70 (79 ref.) **(Spa)**

PHYSIOPATHOLOGY

Growth factors in colorectal tumorigenesis. Van Laethem JL, et al. **Acta Gastroenterol Belg** 1995 May–Aug; 58(3–4):274–9 (22 ref.)
Adhesion molecules in inflammatory and neoplastic intestinal diseases. Pedersen G, et al. **Dig Dis** 1995 Sep–Oct; 13(5):322–36 (103 ref.)

PREVENTION & CONTROL

Screening high-risk groups for colorectal neoplasia. Hardcastle JD, et al. **Am J Gastroenterol** 1996 May; 91(5):850–2 (34 ref.)
Lessons from the follow-up of patients with large colorectal adenomas: be or not be, that is the question [editorial; comment] Neugut AI, et al. **Am J Gastroenterol** 1996 Mar; 91(3):420–2 (45 ref.) Comment on: Am J Gastroenterol 1996 Mar;91(3):448–54.
Contributions of molecular genetics to the clinical management of colorectal cancer. Sterm HS.
Am J Surg 1996 Jan;171(1):10–5 (45 ref.)
Adherence to colorectal cancer screening. A brief overview. Vernon SW. **Ann N Y Acad Sci** 1995 Sep 30;768:292–5 (19 ref.)
Can mortality from colorectal cancer be reduced? Winawer SJ. **Ann N Y Acad Sci** 1995 Sep 30;768:60–7 (36 ref.)
Colorectal cancer: surgical prophylaxis and chemoprevention [see comments] Nugent KP. **Ann R Coll Surg Engl** 1995 Sep;77(5):372–6 (55 ref.) Comment in: Ann R Coll Surg Engl 1996 Mar;78(2):154–5.
Fecal occult blood screening for colorectal cancer. Van Dam J, et al. **Arch Intern Med** 1995 Dec 11–25;155(22):2389–402 (96 ref.)
Genetic and cellular changes in colorectal cancer: proposed targets of chemopreventive agents. Greenwald P, et al.
Cancer Epidemiol Biomarkers Prev 1995 Oct–Nov; 4(7):691–702 (175 ref.)
Colorectal cancer and polyps: clinical decisions for screening, early diagnosis, and surveillance of high-risk groups. Bond JH. **Compr Ther** 1996 Feb;22(2):100–6 (47 ref.)
Screening for colorectal cancer. Mandel JS.
Curr Opin Gen Surg 1994;:79–84 (27 ref.)
Colorectal cancer: future population screening for early colorectal cancer. Blum HE. **Eur J Cancer** 1995 Jul–Aug; 31A(7–8):1369–72 (35 ref.)
Interference with the adenoma-carcinoma sequence. Bond JH. **Eur J Cancer** 1995 Jul–Aug;31A(7–8):1115–7 (30 ref.)
The role of nonsteroidal anti-inflammatory drugs in colorectal cancer prevention. Giardiello FM, et al.
Eur J Cancer 1995 Jul–Aug;31A(7–8):1071–6 (55 ref.)
Calcium and vitamin D: possible protective agents against colorectal cancer? Kleibeuker JH, et al. **Eur J Cancer** 1995 Jul–Aug;31A(7–8):1081–4 (33 ref.)
Chemo- and dietary prevention of colorectal cancer. Schatzkin A, et al. **Eur J Cancer** 1995 Jul–Aug; 31A(7–8):1198–204 (31 ref.)
Role of short-chain fatty acids in the prevention of colorectal cancer. Scheppach W, et al. **Eur J Cancer** 1995 Jul–Aug; 31A(7–8):1077–80 (29 ref.)
Early detection research program at the NCI. Srivastava S, et al. **Int J Cancer** 1996 Feb 20;69(1):35–7 (24 ref.)
Calcium and the prevention of colon cancer. Lipkin M, et al. **J Cell Biochem Suppl** 1995;22:65–73 (54 ref.)
Colorectal cancer: the role of screening and surveillance. Westergaard H. **J Investig Med** 1996 Jun;44(5):216–27 (104 ref.)
Colorectal cancer screening. Ferrante JM.
Med Clin North Am 1996 Jan;80(1):27–43 (63 ref.)
Screening for colorectal cancer, 1996 [see comments] Macrae FA. **Med J Aust** 1996 Jul 15;165(2):102–5 (42 ref.) Comment in: Med J Aust 1996 Jul 15;165(2):68–9.
Studies on the role of specific dietary fibres in protection against colorectal cancer. Ferguson LR, et al.
Mutat Res 1996 Feb 19;350(1):173–84 (67 ref.)
Prevention of gastrointestinal cancer—the potential role of NSAIDs in colorectal cancer. Luk GD.
Schweiz Med Wochenschr 1996 May 11;126(19):801–12 (125 ref.)
Prevention of colorectal cancer by screening flexible sigmoidoscopy: possible role of the primary care physician. Abbas Z, et al. **Scott Med J** 1995 Jun;40(3):67–9 (41 ref.)
Screening for colon cancer: economics and related considerations. Gelfand DW. **Semin Roentgenol** 1996 Apr; 31(2):170–6 (17 ref.)
Diet and chemoprevention of colon polyps and colorectal cancer. Nixon DW. **Semin Surg Oncol** 1995 Nov–Dec; 11(6):411–5 (34 ref.)
Determinants of persistent compliance with screening for colorectal cancer. Neilson AR, et al. **Soc Sci Med** 1995 Aug;41(3):365–74 (36 ref.)
Screening of average-risk individuals for colorectal cancer and postoperative evaluation of patients with colorectal cancer. Nelson RL. **Surg Clin North Am** 1996 Feb; 76(1):35–45 (36 ref.)
Antioxidant agents and colorectal carcinogenesis: role of beta-carotene, vitamin E and vitamin C. Pappalardo G, et al. **Tumori** 1996 Jan–Feb;82(1):6–11 (88 ref.)
[Test for occult blood in feces: a method for reducing the mortality from colorectal cancer? (editorial)] Faivre J, et al. **Gastroenterol Clin Biol** 1996;20(3):225–7 (15 ref.) **(Fre)**
[The secondary prevention of colorectal carcinoma by polyp removal] Riemann JF. **Strahlenther Onkol** 1995 Nov; 171(11):611–4 (21 ref.) (Eng. Abstr.) **(Ger)**
[Primary and secondary prevention of colorectal tumors] Yoshida Y. **Nippon Naika Gakkai Zasshi** 1995 Sep 10; 84(9):1380–7 (8 ref.) **(Jpn)**

RADIOGRAPHY

Barium enema: colorectal polyps and carcinoma. Ott DJ.
Semin Roentgenol 1996 Apr;31(2):125–41 (64 ref.)
Computed tomography evaluation of colorectal carcinoma. Scharling ES, et al. **Semin Roentgenol** 1996 Apr;

31(2):142–53 (69 ref.)

RADIONUCLIDE IMAGING

Radio-immunotargeting in colorectal carcinoma. Rutgers EJ. **Eur J Cancer** 1995 Jul–Aug;31A(7–8):1243–7 (28 ref.)
Radiolabelled monoclonal antibodies in tumour imaging and therapy: out of fashion? Delaloye AB, et al. **Eur J Nucl Med** 1995 Jun;22(6):571–80 (106 ref.)
Radioimmunoguided surgery and colorectal cancer. Aftab F, et al. **Eur J Surg Oncol** 1996 Aug;22(4):381–8 (81 ref.)
[Methodology and clinical usefulness of radioimmunoimaging using radiolabeled monoclonal antibodies] Endo K, et al. **Nippon Rinsho** 1996 Jun;54(6):1604–9 (12 ref.) (Eng. Abstr.) **(Jpn)**

RADIOTHERAPY

Radiolabelled monoclonal antibodies in tumour imaging and therapy: out of fashion? Delaloye AB, et al. **Eur J Nucl Med** 1995 Jun;22(6):571–80 (106 ref.)
Past, present, and future of intraoperative irradiation for colorectal cancer [editorial] Gunderson LL. **Int J Radiat Oncol Biol Phys** 1996 Feb 1;34(3):741–4 (12 ref.)
Radiotherapy and combined chemo-radiotherapy of rectal cancer. Zucali R. **Tumori** 1995 May–Jun;81(3 Suppl):74–7 (29 ref.)
Adjuvant therapy for colorectal cancer—is there a place for a Northern Ireland study? Wilson RH, et al. **Ulster Med J** 1994 Apr;63(1):44–51 (41 ref.)

SECONDARY

Arterial therapy of hepatic colorectal metastases. Vauthey JN, et al. **Br J Surg** 1996 Apr;83(4):447–55 (104 ref.)

SURGERY

Exfoliated tumour cells and locally recurrent colorectal cancer. Basha G, et al. **Acta Chir Belg** 1996 Apr;96(2):66–70 (41 ref.)
Laparoscopic colon resection for cancer—an unfavorable view. Bertagnolli MM, et al. **Adv Surg** 1996;29:155–64 (46 ref.)
Laparoscopic colon resection for cancer—a favorable view. Ota DM. **Adv Surg** 1996;29:141–53 (16 ref.)
Local excision of rectal tumours. Banerjee AK, et al. **Br J Surg** 1995 Sep;82(9):1165–73 (110 ref.)
Stapling instruments for intestinal anastomosis in colorectal surgery. Moran BJ. **Br J Surg** 1996 Jul;83(7):902–9 (76 ref.)
Follow-up after polypectomy: consensus? Bond JH. **Eur J Cancer** 1995 Jul–Aug;31A(7–8):1141–4 (28 ref.)
Developments in colorectal cancer surgery. Jeekel J. **Eur J Cancer** 1995 Jul–Aug;31A(7–8):1379–81 (13 ref.)
Intra-operative ultrasound in detection of liver metastases. Meijer S, et al. **Eur J Cancer** 1995 Jul–Aug; 31A(7–8):1210–1 (10 ref.)
The use of prognostic markers in surgery for colorectal cancer. Northover J. **Eur J Cancer** 1995 Jul–Aug; 31A(7–8):1207–9 (36 ref.)
Radioimmunoguided surgery and colorectal cancer. Aftab F, et al. **Eur J Surg Oncol** 1996 Aug;22(4):381–8 (81 ref.)
Past, present, and future of intraoperative irradiation for colorectal cancer [editorial] Gunderson LL. **Int J Radiat Oncol Biol Phys** 1996 Feb 1;34(3):741–4 (12 ref.)
Surgical concepts in the treatment of colorectal cancer. Loggie BW. **Semin Roentgenol** 1996 Apr;31(2):111–7 (42 ref.)
Radioimmunoguided Surgery system improves survival for patients with recurrent colorectal cancer. Bertsch DJ, et al. **Surgery** 1995 Oct;118(4):634–8; discussion 638–9 (9 ref.)
Current perspectives on repeat hepatic resection for colorectal carcinoma: a review. Wanebo HJ, et al. **Surgery** 1996 Apr;119(4):361–71 (70 ref.)
Surgical technique and colorectal cancer: impaction on local recurrence and survival. Averbach AM, et al. **Tumori** 1995 May–Jun;81(3 Suppl):65–71 (75 ref.)
The use of drains in elective surgery for colorectal cancer: always, never or selectively? Averbach AM, et al. **Tumori** 1995 May–Jun;81(3 Suppl):89–97 (24 ref.)
[Preternatural anus?] Obertop H. **Ned Tijdschr Geneeskd** 1996 Apr 6;140(14):755–7 (29 ref.) **(Dut)**
[Surgery of colorectal cancer by laparoscopic approach] Boulez J. **Ann Chir** 1996;50(3):219–30 (45 ref.) **(Fre)**
[Is celioscopic surgery for colorectal cancer currently justified?] Pélissier EP, et al. **Gastroenterol Clin Biol** 1996; 20(4):374–8 (38 ref.) **(Fre)**
[Resections of recurrence in the liver of primary and secondary liver cancers] Herfarth C, et al. **Chirurg** 1995 Oct;66(10):949–58 (78 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Carcinoembryonic antigen in the evaluation of therapy of primary and metastatic colorectal cancer. Adams WJ, et al. **Aust N Z J Surg** 1996 Aug;66(8):515–9 (70 ref.)
Treatment principles in advanced colorectal cancer. Zalcberg JR, et al. **Aust N Z J Surg** 1996 Apr;66(4):202–5 (30 ref.)
Principles of adjuvant therapy [see comments] Dawson JW, et al. **Br J Hosp Med** 1995 Sep 20–Oct 3;54(6):249–54 (25 ref.) Comment in: Br J Hosp Med 1995 Sep 20–Oct 3;54(6):248.
Adjuvant therapy for colorectal cancer. Stamatakis J, et al. **Br J Hosp Med** 1995 Sep 20–Oct 3;54(6):259–63 (32 ref.)
Immunological and biochemical modulation in the treatment of advanced colorectal cancer: update and future directions. Hilgenfeld RU, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 3):217–40 (93 ref.)
Radiotherapy and hyperthermia. González González D, et al. **Eur J Cancer** 1995 Jul–Aug;31A(7–8):1351–5 (27 ref.)
The role of interferon-alpha as a modulator of fluorouracil and leucovorin. Grem JL, et al. **Eur J Cancer** 1995 Jul–Aug;31A(7–8):1316–20 (29 ref.)
The role of biological response modifiers in the management of patients with colorectal cancer. Wagstaff J. **Eur J Cancer** 1995 Jul–Aug;31A(7–8):1323–5 (29 ref.)
p53 gene therapy in vivo of herpatocellular and liver metastatic colorectal cancer. Bookstein R, et al. **Semin Oncol** 1996 Feb;23(1):66–77 (109 ref.)
Treatment and follow-up of large bowel adenoma. Rossini FP, et al. **Tumori** 1995 May–Jun;81(3 Suppl):38–44 (61 ref.)
Follow-up of colorectal cancer. Sugarbaker PH. **Tumori** 1995 May–Jun;81(3 Suppl):126–34 (64 ref.)
[Aftercare in patients with colorectal carcinomas] Mezger J, et al. **Dtsch Med Wochenschr** 1995 Nov 10; 120(45):1549–54 (44 ref.) **(Ger)**
[Sense and nonsense in after-care of colorectal carcinoma] Schölmerich J. **Med Klin** 1996 Jun 15;91(6):420–7 (53 ref.) **(Ger)**
[Adjuvant therapy of liver metastases: active specific immunotherapy] Hagmüller E, et al. **Zentralbl Chir** 1995; 120(10):780–5 (37 ref.) (Eng. Abstr.) **(Ger)**
[Neoadjuvant therapy for colorectal cancer] Kotake K, et al. **Gan To Kagaku Ryoho** 1995 Nov;22(13):1886–92 (41 ref.) (Eng. Abstr.) **(Jpn)**
[Advances in the treatment of colorectal cancer] Maehara Y, et al. **Gan To Kagaku Ryoho** 1996 Apr;23(5):517–28 (143 ref.) (Eng. Abstr.) **(Jpn)**

ULTRASONOGRAPHY

[Established indications for endosonography of the rectum and colon] Feifel G, et al. **Bildgebung** 1995 Oct;62 Suppl 2:40–6 (40 ref.) **(Ger)**

COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS

Hereditary nonpolyposis colorectal cancer: review of clinical, molecular genetics, and counseling aspects. Bellacosa A, et al. **Am J Med Genet** 1996 Apr 24;62(4):353–64 (115 ref.)
[Hereditary non-polyposis colon carcinoma. Syndrome of the cancer family—a neglected disease] Sahm SW, et al. **Dtsch Med Wochenschr** 1995 Nov 24;120(47):1631–5 (36 ref.) **(Ger)**
[Hereditary non-polyposis colorectal cancer (HNPCC)] Ushio K, et al. **Nippon Rinsho** 1995 Nov;53(11):2790–6 (13 ref.) (Eng. Abstr.) **(Jpn)**
[Muir–Torre syndrome] Yoshikawa R, et al. **Nippon Rinsho** 1995 Nov;53(11):2803–6 (11 ref.) (Eng. Abstr.) **(Jpn)**
[Hereditary nonpolyposis colorectal cancer. Lynch syndrome] Luna Pérez P, et al. **Rev Gastroenterol Mex** 1995 Jul–Sep;60(3):169–74 (44 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Use of molecular methods in the early diagnosis of familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer. Khine K, et al. **Ann Acad Med Singapore** 1996 Jan;25(1):64–70 (88 ref.)
The emerging role of the physician in genetic counselling and testing for heritable breast, ovarian and colon cancer. Taylor KM, et al. **Can Med Assoc J** 1996 Apr 15; 154(8):1155–8 (23 ref.)
Clinical aspects and management of hereditary non-polyposis colorectal cancer (HNPCC). Bertario L, et al. **Tumori** 1996 Mar–Apr;82(2):117–21 (33 ref.)

EPIDEMIOLOGY

Descriptive epidemiology of hereditary non-polyposis colorectal cancer. Ponz de Leon M. **Tumori** 1996 Mar–Apr; 82(2):102–6 (30 ref.)

GENETICS

Human mismatch repair genes and their association with hereditary non-polyposis colon cancer. Kolodner RD, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:331–8 (79 ref.)
Update on the differential diagnosis, surveillance and management of hereditary non-polyposis colorectal cancer. Lynch HT, et al. **Eur J Cancer** 1995 Jul–Aug; 31A(7–8):1039–46 (43 ref.)
DNA mismatch repair and cancer. Chung DC, et al. **Gastroenterology** 1995 Nov;109(5):1685–99 (109 ref.)
Genetic screening for colorectal cancer and intervention. Alberts DS, et al. **Int J Cancer** 1996 Feb 20;69(1):62–3 (10 ref.)
Use of gene tests to detect hereditary predisposition to cancer: what do we know about cost effectiveness? Brown ML, et al. **Int J Cancer** 1996 Feb 20;69(1):55–7 (17 ref.)
Identification of DNA mismatch repair gene mutations in hereditary nonpolyposis colon cancer patients. Luce MC, et al. **Int J Cancer** 1996 Feb 20;69(1):50–2 (25 ref.)
Overview of natural history, pathology, molecular genetics and management of HNPCC (Lynch Syndrome). Lynch HT, et al. **Int J Cancer** 1996 Feb 20;69(1):38–43 (51 ref.)
Genetic counseling and predictive testing for colorectal cancer risk. Petersen GM. **Int J Cancer** 1996 Feb 20; 69(1):53–4 (12 ref.)
Molecular mechanisms underlying hereditary nonpolyposis colorectal carcinoma. Rhyu MS. **J Natl Cancer Inst** 1996 Mar 6;88(5):240–51 (126 ref.)
Molecular genetics of hereditary non-polyposis colorectal cancer (HNPCC). Cama A, et al. **Tumori** 1996 Mar–Apr; 82(2):122–35 (107 ref.)
Genetic counseling in hereditary non-polyposis colorectal cancer. Heouaine A, et al. **Tumori** 1996 Mar–Apr; 82(2):136–42 (31 ref.)
[Hereditary nonpolyposis colorectal cancers] Caplin S, et al. **Schweiz Rundsch Med Prax** 1996 Aug 27;85(35):1041–5 (68 ref.) (Eng. Abstr.) **(Fre)**
[Hereditary nonpolyposis colorectal cancer: genetics and prospective molecular screening] Hutter P, et al. **Schweiz Rundsch Med Prax** 1996 Aug 27;85(35):1046–51 (20 ref.) (Eng. Abstr.) **(Fre)**
[Familial colorectal and breast carcinoma—genetic counseling and presymptomatic diagnosis] Müller H, et al. **Ther Umsch** 1995 Dec;52(12):826–34 (55 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

Overview of natural history, pathology, molecular genetics and management of HNPCC (Lynch Syndrome). Lynch HT, et al. **Int J Cancer** 1996 Feb 20;69(1):38–43 (51 ref.)
Hereditary nonpolyposis colorectal cancer and colonic adenomas: aggressive adenomas? Lynch HT, et al. **Semin Surg Oncol** 1995 Nov–Dec;11(6):406–10 (24 ref.)
Pathologic features of hereditary non-polyposis colorectal cancer. Messerini L, et al. **Tumori** 1996 Mar–Apr; 82(2):114–6 (16 ref.)

PREVENTION & CONTROL

Colorectal cancer and polyps: clinical decisions for screening, early diagnosis, and surveillance of high-risk groups. Bond JH. **Compr Ther** 1996 Feb;22(2):100–6 (47 ref.)
Genetic screening for colorectal cancer and intervention. Alberts DS, et al. **Int J Cancer** 1996 Feb 20;69(1):62–3 (10 ref.)
Genetic counseling and predictive testing for colorectal cancer risk. Petersen GM. **Int J Cancer** 1996 Feb 20; 69(1):53–4 (12 ref.)

PSYCHOLOGY

Genetic counseling in hereditary non-polyposis colorectal cancer. Heouaine A, et al. **Tumori** 1996 Mar–Apr; 82(2):136–42 (31 ref.)

THERAPY

Clinical aspects and management of hereditary non-polyposis colorectal cancer (HNPCC). Bertario L, et al. **Tumori** 1996 Mar–Apr;82(2):117–21 (33 ref.)

COLORIMETRY

[The assay of enzyme activity in EIA—colorimetric, fluorometric and luminometric method] Maeda M. **Nippon Rinsho** 1995 Sep;53(9):2198–202 (16 ref.) (Eng. Abstr.) **(Jpn)**

COLORING AGENTS see **DYES**

COLOSTOMY

[Preternatural anus?] Obertop H. **Ned Tijdschr Geneeskd** 1996 Apr 6;140(14):755–7 (29 ref.) **(Dut)**

ADVERSE EFFECTS

The morbidity of defunctioning stomata. Chen F, et al. **Aust N Z J Surg** 1996 Apr;66(4):218–21 (25 ref.)
Colostomy closure. Ochsner Clinic experience. Khoury DA, et al. **Dis Colon Rectum** 1996 Jun;39(6):605–9 (24 ref.)

METHODS

Laparoscopic colostomy for a gunshot wound to the rectum. Namias N, et al. **J Laparoendosc Surg** 1995 Aug;5(4):251–3 (17 ref.)

COLOSTRAL IGA see **IGA, SECRETORY**

COLOSTRUM

IMMUNOLOGY

Human milk and intestinal host defense in newborns: an update. Xanthou M, et al. **Adv Pediatr** 1995;42:171–208 (169 ref.)

COLPOHYSTERECTOMY see **HYSTERECTOMY, VAGINAL**

COLPOSCOPY

The colposcopic examination. Johnson BA.

Am Fam Physician 1996 Jun;53(8):2473–82, 2487–8 (17 ref.)
Endocervical curettage: a technique in search of an indication?: debate. Noller KL. **Clin Obstet Gynecol** 1995 Sep;38(3):649–52 (2 ref.)
Every woman with an abnormal cervical smear should not be referred for colposcopy: debate. Prendiville W, et al. **Clin Obstet Gynecol** 1995 Sep;38(3):592–9 (16 ref.)

METHODS

Large loop excision of the transformation zone. Prendiville W. **Clin Obstet Gynecol** 1995 Sep;38(3):622–39 (41 ref.)
Modern image capture and data collection technology. Shafi MI, et al. **Clin Obstet Gynecol** 1995 Sep;38(3):640–3 (9 ref.)

STANDARDS

Endocervical curettage has no place in the routine management of women with cervical intraepithelial neoplasia: debate. Ferenczy A. **Clin Obstet Gynecol** 1995 Sep;38(3):644–8 (9 ref.)

COMA

see related
PERSISTENT VEGETATIVE STATE

Myxedema coma in the elderly [published erratum appears in J Am Board Fam Pract 1995 Nov–Dec;8(6):502] Olsen CG. **J Am Board Fam Pract** 1995 Sep–Oct;8(5):376–83 (51 ref.)
Coma. Smith MC. **Lijec Vjesn** 1995 Jun;117 Suppl 2:46–9 (18 ref.)

DIAGNOSIS

Fever, convulsions and coma in scleromyxedema: a "dermato–neuro syndrome". River Y, et al. **Neurology** 1996 Jun;46(6):1778–9 (7 ref.)

ETIOLOGY

Vertical gaze paralysis and intermittent unresponsiveness in a patient with a thalamomesencephalic stroke. Beversdorf DQ, et al. **J Neuroophthalmol** 1995 Dec;15(4):230–5 (21 ref.)
[Nontraumatic coma in extramural practice] Enrico JF, et al. **Schweiz Rundsch Med Prax** 1995 Nov 7;84(45):1321–30 (16 ref.) (Eng. Abstr.) **(Fre)**
[Ketoacidotic coma in an infant as the form of onset of a mitochondrial 2–methylacetoacetyl–CoA thiolase deficiency] Yeste Fernández D, et al. **An Esp Pediatr** 1996 Jun;44(6):620–2 (9 ref.) **(Spa)**

THERAPY

Can healthcare providers obtain judicial intervention against surrogates who demand "medically inappropriate" life support for incompetent patients? [see comments] Cantor NL. **Crit Care Med** 1996 May;24(5):883–7 (28 ref.)
Comment in: Crit Care Med 1996 May;24(5):730–2.

COMA, HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC see **HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC COMA**

COMBAT DISORDERS

PSYCHOLOGY

Psychosocial problems in refugee children exposed to war. McCloskey LA, et al. **Pediatrics** 1996 Mar;97(3):394–7 (36 ref.)

THERAPY

Critical interaction therapy: couples therapy in combat–related posttraumatic stress disorder. Johnson DR, et al. **Fam Process** 1995 Dec;34(4):401–12 (16 ref.)

COMBINATION CHEMOTHERAPY see **DRUG THERAPY, COMBINATION**

COMBINATIONS, ANTIBIOTIC see **ANTIBIOTICS, COMBINED**

COMBINED CARBOXYLASE DEFICIENCY see **MULTIPLE CARBOXYLASE DEFICIENCY**

COMBINED MODALITY THERAPY

see related
ANTINEOPLASTIC AGENTS, COMBINED

COMBINING SITE see **BINDING SITES**

COMMERCE

see related
ANTITRUST LAWS
ECONOMIC COMPETITION
INDUSTRY

Scrapie: the risk of its introduction and effects on trade. MacDiarmid SC. **Aust Vet J** 1996 May;73(5):161–4 (21 ref.)
Commerce in transplantation in Third World countries. Chugh KS, et al. **Kidney Int** 1996 May;49(5):1181–6 (34 ref.)
Risk analysis for the importation of veterinary biologicals into the United States of America. Roth HJ, et al. **Rev Sci Tech** 1995 Dec;14(4):1061–72 (6 ref.)

LEGISLATION & JURISPRUDENCE

Legal & ethical safeguards: protection of society's most vulnerable participants in a commercialized organ transplantation system. Banks GJ. **Am J Law Med** 1995; 21(1):45–110 (505 ref.)
A North American model to contain the spread of Aedes albopictus through tire legislation. Novak RJ. **Parassitologia** 1995 Dec;37(2–3):129–39 (17 ref.)

TRENDS

Prospects for expanded mohair and cashmere production and processing in the United States of America. Lupton CJ. **J Anim Sci** 1996 May;74(5):1164–72 (18 ref.)

COMMITMENT OF MENTALLY ILL

see related
PATIENT ADVOCACY

LEGISLATION & JURISPRUDENCE

Psychopathy—a clinical and legal dilemma [editorial] Reed J. **Br J Psychiatry** 1996 Jan;168(1):4–9 (20 ref.)
Coercion and commitment: understanding involuntary mental hospital admission. Monahan J, et al. **Int J Law Psychiatry** 1995 Summer;18(3):249–63 (75 ref.)
New legislation on civil commitment in Hungary. Dósa A. **Med Law** 1995;14(7–8):581–7 (15 ref.)
A biopsychosocial rationale for coerced community treatment in the management of schizophrenia. Geller JL. **Psychiatr Q** 1995 Fall;66(3):219–35 (58 ref.)
[Compliance with psychiatric legal ordinance section 63 StGB. Legal principles—current status—treatment concepts—perspectives] Nedopil N, et al. **Nervenarzt** 1995 Nov;66(11):793–801 (38 ref.) (Eng. Abstr.) **(Ger)**

COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGENS see **MEMBRANE METALLO–ENDOPEPTIDASE**

COMMON BILE DUCT

[Confluence stone] Takagi I, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):397–99 (19 ref.) **(Jpn)**

ABNORMALITIES

[Duplication of extra–hepatic biliary duct (duplication of common hepatic duct, duplication of cystic duct, duplication of common bile duct)] Nakagawara G, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):111–3 (15 ref.) **(Jpn)**

EMBRYOLOGY

[Congenital dilatation of the common bile duct in an adult] Gruttadauria G, et al. **Chir Ital** 1995;47(1):50–4 (22 ref.) (Eng. Abstr.) **(Ita)**

INJURIES

Endoscopic approaches to common bile duct injuries. Ponsky JL. **Surg Clin North Am** 1996 Jun;76(3):505–13 (11 ref.)

PATHOLOGY

[Congenital dilatation of the common bile duct in an adult] Gruttadauria G, et al. **Chir Ital** 1995;47(1):50–4 (22 ref.) (Eng. Abstr.) **(Ita)**
[Annular stricture of the common hepatic duct] Ashida H, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):167–9 (8 ref.) **(Jpn)**
[Septum formation of the common bile duct] Tsutsumi Y, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):170–2 (19 ref.) **(Jpn)**

RADIOGRAPHY

[An impassable iatrogenic lesion of the common bile duct at its junction: its recanalization via a combined percutaneous–endoscopic approach. A case] Ferro C, et al. **Radiol Med (Torino)** 1996 Apr;91(4):488–91 (16 ref.) **(Ita)**

SURGERY

Endoscopic approaches to common bile duct injuries. Ponsky JL. **Surg Clin North Am** 1996 Jun;76(3):505–13 (11 ref.)

COMMON BILE DUCT CALCULI

[Cholecysto–choledocholithiasis] Kashima K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):516–8 (15 ref.) **(Jpn)**
[Extra–hepatic cholangiolithiasis–choledocholithiasis] Kashima K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):142–5 (15 ref.) **(Jpn)**
[Cholecystocholedocholithiasis] Sai J, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):412–4 (17 ref.) **(Jpn)**

COMPLICATIONS

Safe laparoendoscopic approach to biliary pancreatitis in older patients. McGrath MF, et al. **Arch Surg** 1996 Aug; 131(8):826–31; discussion 831–3 (21 ref.)
[Biliary ileus. A report of 2 cases] Ottenello M, et al. **Minerva Chir** 1996 Jan–Feb;51(1–2):67–9 (18 ref.) (Eng. Abstr.) **(Ita)**

DIAGNOSIS

MR cholangiopancreatography. Reinhold C, et al. **Abdom Imaging** 1996 Mar–Apr;21(2):105–16 (35 ref.)

ETIOLOGY

[Choledochal calculosis due to a suture thread] Lo Casto RM, et al. **Minerva Chir** 1996 Jan–Feb;51(1–2):63–5 (11 ref.) (Eng. Abstr.) **(Ita)**

PREVENTION & CONTROL

[Antibiotic prophylaxis in biliary surgery] Gondret R, et al. **Ann Chir** 1995;49(6):493–9 (52 ref.) (Eng. Abstr.) **(Fre)**

RADIOGRAPHY

The role of ERCP in choledocholithiasis. Lo SK, et al. **Abdom Imaging** 1996 Mar–Apr;21(2):120–32 (185 ref.)
Helical CT cholangiography. Stockberger SM, et al. **Abdom Imaging** 1996 Mar–Apr;21(2):98–104 (17 ref.)

SURGERY

The current management of common bile duct stones. Jones DB, et al. **Adv Surg** 1996;29:271–89 (54 ref.)
Choledocholithiasis in anomalous biliary system. Leung LC, et al. **Aust N Z J Surg** 1996 Jun;66(6):416–7 (5 ref.)
Biliary surgery. Leichter RF, et al. **Curr Opin Gen Surg** 1993; :271–6 (36 ref.)
Laparoscopic and endoscopic management of common bile duct stones. Pitcher DE, et al. **Curr Opin Gen Surg** 1994; :203–7 (17 ref.)
Biliary endoprostheses in elderly patients with endoscopically irretrievable common bile duct stones: report on 117 patients [see comments] Bergman JJ, et al. **Gastrointest Endosc** 1995 Sep;42(3):195–201 (24 ref.)
Comment in: Gastrointest Endosc 1995 Sep;42(3):272–3.
[Laparoscopic cholecystectomy in 1994. Results of the survey of the SFCERO on 4624 cases] Collet D. **Ann Chir** 1996; 50(3):241–51 (42 ref.) (Eng. Abstr.) **(Fre)**
[Indications and modalities of cholecystectomy in cholelithiasis. Study Group of Cholecystectomy, under the aegis of the National Agency for the Development of Medical Evaluation] **Gastroenterol Clin Biol** 1995 Aug–Sep; 19(8–9):707–17 (29 ref.) **(Fre)**
["500 consecutive cases of laparoscopic cholecystectomy". Argument for the association to endoscopic sphincterotomy: analysis] Lagrange M. **J Chir (Paris)** 1996 Apr;133(2):65–71 (13 ref.) (Eng. Abstr.) **(Fre)**
[Laparoscopic therapy of choledocholithiasis] Rechner J, et al. **Zentralbl Chir** 1996;121(4):278–82 (22 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

[Role of extracorporeal shock wave lithotripsy in the treatment of common bile duct and intrahepatic calculi] Dagenais M, et al. **Ann Chir** 1995;49(8):659–63 (15 ref.) (Eng. Abstr.) **(Fre)**

ULTRASONOGRAPHY

Usefulness of endoscopic ultrasonography in the diagnosis of choledocholithiasis. Palazzo L, et al. **Abdom Imaging** 1996 Mar–Apr;21(2):93–7 (51 ref.)
[Ultrasonic laparoscopy in digestive diseases] Catheline JM, et al. **Ann Chir** 1996;50(1):51–7 (30 ref.) (Eng. Abstr.) **(Fre)**

COMMON BILE DUCT CYST see **CHOLEDOCHAL CYST**

COMMON BILE DUCT DISEASES

[Mirizzi's syndrome, pseudo–lesion of bile duct due to the disorder of the cystic duct] Takifuji K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):146–8 (7 ref.) **(Jpn)**
[Septum formation of the common bile duct] Tsutsumi Y, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):170–2 (19 ref.) **(Jpn)**
[Parapapillary choledochoduodenal fistula] Uetsuji S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):528–9 (14 ref.) **(Jpn)**

CLASSIFICATION

[Benign elevated lesions of the common bile duct] Kashima K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):173–5 (13 ref.) **(Jpn)**

DIAGNOSIS

[Annular stricture of the common hepatic duct] Ashida H, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):167–9 (8 ref.) **(Jpn)**

COMMON BILE DUCT DISEASES

ETIOLOGY

Long term survival after obstruction of the common bile duct by ductal hepatocellular carcinoma. Jan YY, et al. **Eur J Surg** 1995 Oct;161(10):771–4 (17 ref.)

[Lemmel's syndrome caused by a giant diverticulum in the third portion of the duodenum, report of a case] Hirano A, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Nov; 92(11):1863–70 (11 ref.) **(Jpn)**

PATHOLOGY

Ductular reaction in the liver. Desmet V, et al. **Pathol Res Pract** 1995 Jul;191(6):513–24 (153 ref.)

PHYSIOPATHOLOGY

[Sphincter of Oddi dysfunction] Jonas Y, et al. **Harefuah** 1996 Apr 1;130(7):486–90 (34 ref.) **(Heb)**

RADIOGRAPHY

[Icterus—sometimes something is wrong: the rupture of an echinococcal cyst into the biliary tract] Bücker A, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Jul;165(1):88–90 (10 ref.) **(Ger)**

SURGERY

[Endoscopic management of benign strictures of the common bile duct] Orosz P, et al. **Orv Hetil** 1996 Feb 11; 137(6):291–4 (31 ref.) (Eng. Abstr.) **(Hun)**

COMMON BILE DUCT NEOPLASMS

Periampullary tumours: report of two cases. Kassa E. **East Afr Med J** 1996 May;73(5):333–5 (17 ref.)

[Cholangiocarcinoma] Blesa I, et al. **G E N** 1995 Jan–Mar; 49(1):90–100 (89 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

MR cholangiopancreatography. Reinhold C, et al. **Abdom Imaging** 1996 Mar–Apr;21(2):105–16 (35 ref.)

[Prospects of early immunocytochemical diagnosis in periampullary tumors (a review of foreign literature)] Kubyshkin VA, et al. **Khirurgiia (Mosk)** 1995;(6):50–2 (42 ref.) **(Rus)**

[Adenoma of Vater's ampulla without clinical or analytical expression (letter)] Moreira VF, et al. **Rev Clin Esp** 1996 May;196(5):343–4 (11 ref.) **(Spa)**

EPIDEMIOLOGY

[7 cases of carcinoma of the distal choledochus] Gómez-Méndez TJ, et al. **Rev Invest Clin** 1995 Jul–Aug; 47(4):291–5 (11 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

[Neurofibromatosis (von Recklinghausen disease) and carcinoid tumor in Vater's ampulla] Simon L, et al. **Orv Hetil** 1995 Oct 15;136(42):2287–92 (34 ref.) (Eng. Abstr.) **(Hun)**

PATHOLOGY

[Choledochus carcinoma in choledochal cyst—a rarity. Presentation of the disease with a case report] Stalder PA, et al. **Swiss Surg** 1996;(3):123–6 (34 ref.) (Eng. Abstr.) **(Ger)**

SECONDARY

Metastatic renal cell carcinoma to ampulla of Vater: an unusual lesion amenable to surgical resection. Leslie KA, et al. **Surgery** 1996 Mar;119(3):349–51 (14 ref.)

SURGERY

Is local excision of pT1-ampullary carcinomas justified? Klein P, et al. **Eur J Surg Oncol** 1996 Aug;22(4):366–71 (24 ref.)

Vater's papilla and periampullary area villous adenoma: personal experience about nine cases and review of the literature. Motton G, et al. **Hepatogastroenterology** 1996 Mar–Apr;43(8):448–55 (77 ref.)

Metastatic renal cell carcinoma to ampulla of Vater: an unusual lesion amenable to surgical resection. Leslie KA, et al. **Surgery** 1996 Mar;119(3):349–51 (14 ref.)

[Carcinoid of the major duodenal papilla] Kalotov E, et al. **Khirurgiia (Sofiia)** 1995;48(4):55–9 (11 ref.) **(Bul)**

THERAPY

[Hepatobiliary stenting in malignant and benign stenosis—which approach is the best? Endoscopic approach] Jung M, et al. **Bildgebung** 1995 Oct;62 Suppl 2:47–52 (24 ref.) **(Ger)**

[Results of endoscopic biliary drainage in primary tumors of the common bile duct (cholangiocarcinoma)] Costamagna G, et al. **Chir Ital** 1995;47(1):18–23 (20 ref.) (Eng. Abstr.) **(Ita)**

COMMON COLD

The common cold. Lorber B. **J Gen Intern Med** 1996 Apr; 11(4):229–36 (70 ref.)

Anaesthesia in children with viral respiratory tract infections. Van der Walt J. **Paediatr Anaesth** 1995;5(4):257–62 (25 ref.)

COMPLICATIONS

The effects of rhinovirus infections on allergic airway responses. Gern JE, et al. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 2):S40–5 (40 ref.)

DRUG THERAPY

Antihistamines and the common cold. A review and critique of the literature. Luks D, et al. **J Gen Intern Med** 1996 Apr;11(4):240–4 (27 ref.)

Cold, cough, and allergy medications: uses and abuses. Katcher ML. **Pediatr Rev** 1996 Jan;17(1):12–7 (11 ref.)

THERAPY

Reducing demand for physician visits through public education: a look at the pilot cold-and-flu campaign in London, Ontario. Brown EM, et al. **Can Med Assoc J** 1996 Mar 15;154(6):835–40 (21 ref.)

VIROLOGY

Rhinovirus infection of the normal human airway. Gwaltney JM Jr. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 2):S36–9 (35 ref.)

COMMON COLD VIRUS see **RHINOVIRUS**

COMMON FIMBRIAE see **FIMBRIAE, BACTERIAL**

COMMON HEPATIC DUCT see **HEPATIC DUCT, COMMON**

COMMON MARKET see **EUROPEAN ECONOMIC COMMUNITY**

COMMON PILI see **FIMBRIAE, BACTERIAL**

COMMON VARIABLE IMMUNODEFICIENCY

COMPLICATIONS

[Frequent airway infections (clinical conference)] Hohage H, et al. **Schweiz Rundsch Med Prax** 1995 Nov 14; 84(46):1358–63 (56 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Evidence for a generalized signaling abnormality in B cells from patients with common variable immunodeficiency. Eisenstein EM, et al. **Adv Exp Med Biol** 1995;371B:699–704 (11 ref.)

Common variable immunodeficiency: clinical aspects and recent progress in identifying the immunological defect(s). Eibl MM, et al. **Folia Microbiol (Praha)** 1995;40(4):360–6 (49 ref.)

PATHOLOGY

Enterocolitis in infantile common variable immunodeficiency. A case report and review of the literature. John HA, et al. **Dig Dis Sci** 1996 Mar;41(3):621–3 (9 ref.)

COMMUNICABLE DISEASE CONTACT TRACING see **CONTACT TRACING**

COMMUNICABLE DISEASE CONTROL

see related
DISEASE RESERVOIRS
DISEASE VECTORS
INFECTION CONTROL

Vaccination policies and practices [see comments] Henderson DA. **Aust J Public Health** 1995 Dec;19(6):634–8 (5 ref.) Comment in: Aust J Public Health 1995 Dec;19(6):545–6.

Infectious disease transmission through cell, tissue, and organ transplantation: reducing the risk through donor selection. Eastlund T. **Cell Transplant** 1995 Sep–Oct;4(5):455–77 (223 ref.)

Global aspects of vaccination. Ada G. **Int Arch Allergy Immunol** 1995 Dec;108(4):304–8 (13 ref.)

Fight against infectious diseases. Soda K, et al. **J Epidemiol** 1996 Aug;6(3 Suppl):S61–6 (9 ref.)

The US Arctic Investigations Program: infectious disease prevention and control research in Alaska. Wainwright RB. **Lancet** 1996 Feb 24;347(9000):517–20 (52 ref.)

The emergence of "emerging diseases": a lesson in holistic epidemiology. Kilbourne ED. **Mt Sinai J Med** 1996 May–Sep;63(3–4):159–66 (31 ref.)

Infectious disease testing for blood transfusions [news] **Oncology (Huntingt)** 1995 Nov;9(11):1141–2 (0 ref.)

Changing patterns of communicable disease: who is turning the kaleidoscope? Waltner-Toews D. **Perspect Biol Med** 1995 Autumn;39(1):43–55 (22 ref.)

Not by drugs alone: the fight against parasitic helminths. Evans AC, et al. **World Health Forum** 1995;16(3):258–61 (10 ref.)

[Advances in the research on nucleic acid vaccines] Lu F, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1995 Sep; 29(5):303–4 (20 ref.) **(Chi)**

[Antibodies as medication] Kurki P, et al. **Duodecim** 1995; 111(8):788–96 (29 ref.) **(Fin)**

[Consensus report: tissue handling in suspected Creutzfeldt-Jakob disease and other spongiform encephalopathies (prion diseases) in the human.European Union Biomed-1 Concerted Action] Budka H, et al. **Pathologe** 1996 Mar;17(2):171–5 (16 ref.) (Eng. Abstr.) **(Ger)**

[Infectious diseases from the hygienic viewpoint with special reference to environmental infections—a retrospective and prospective view] Exner M. **Zentralbl Hyg Umweltmed** 1995 Apr;197(1–3):134–61 (79 ref.) (Eng. Abstr.) **(Ger)**

[Communicable diseases in Norway. Epidemiological status and future challenge for prevention of the most important diseases] Lystad A, et al. **Tidsskr Nor Laegeforen** 1995 Sep 30;115(23):2899–903 (29 ref.) (Eng. Abstr.) **(Nor)**

LEGISLATION & JURISPRUDENCE

A national consensus on guidelines for establishment of a post-exposure notification protocol for emergency responders. Laboratory Centre for Disease Control, Health Protection Branch, Health Canada. **Can Commun Dis Rep** 1995 Oct 15;21(19):169–80 (5 ref.) **(Eng, Fre)**

Legal considerations in infectious diseases and dentistry. Burris S. **Dent Clin North Am** 1996 Apr;40(2):425–35 (62 ref.)

METHODS

Control of infections in schools. McMillan JA. **Pediatr Rev** 1995 Aug;16(8):283–8; quiz 289 (19 ref.)

Disinfection and wildlife. Corn JL, et al. **Rev Sci Tech** 1995 Jun;14(2):455–68 (17 ref.)

Disinfection procedures for personnel and vehicles entering and leaving contaminated premises. Ford WB. **Rev Sci Tech** 1995 Jun;14(2):393–401 (10 ref.)

[Immunization in preterm and term infants] Bernatowska-Matuszkiewicz E, et al. **Pediatr Pol** 1995 Sep; 70(9):759–63 (20 ref.) (Eng. Abstr.) **(Pol)**

STANDARDS

Infectious disease testing for blood transfusions. NIH Consensus Development Panel on Infectious Disease Testing for Blood Transfusions. **JAMA** 1995 Nov 1; 274(17):1374–9 (0 ref.)

Recommended biocontainment features for research and diagnostic facilities where animal pathogens are used. First International Veterinary Biosafety Workshop. Barbeito MS, et al. **Rev Sci Tech** 1995 Sep;14(3):873–87 (8 ref.)

Environmental considerations of disinfectants used in agriculture. Bruins G, et al. **Rev Sci Tech** 1995 Mar; 14(1):81–94 (15 ref.)

TRENDS

Immunization among African American children: implications for social work. Copeland VC. **Health Soc Work** 1996 May;21(2):105–14 (70 ref.)

COMMUNICABLE DISEASES

see related
DISEASE RESERVOIRS

Mexican contributions to the knowledge of infectious diseases, published in Spanish. Gutiérrez G. **Arch Med Res** 1995;26 Spec No:S27–9 (22 ref.)

The impact of infectious diseases on the health of U.S. troops deployed to the Persian Gulf during operations Desert Shield and Desert Storm. Hyams KC, et al. **Clin Infect Dis** 1995 Jun;20(6):1497–504 (69 ref.)

Primary care for women. Management of common problems of the head and neck. Phillips LP, et al. **J Nurse Midwifery** 1996 Mar–Apr;41(2):101–16 (55 ref.)

Control of infections in schools. McMillan JA. **Pediatr Rev** 1995 Aug;16(8):283–8; quiz 289 (19 ref.)

DIAGNOSIS

Detection of infectious disease agents in tissue by immunocytochemistry. Bacchi CE, et al. **Braz J Med Biol Res** 1994 Dec;27(12):2803–20 (52 ref.)

Recognizing and treating new and emerging infections encountered in everyday practice. Gordon SM. **Cleve Clin J Med** 1996 May–Jun;63(3):172–8 (24 ref.)

Sequence-based identification of microbial pathogens: a reconsideration of Koch's postulates. Fredericks DN, et al. **Clin Microbiol Rev** 1996 Jan;9(1):18–33 (119 ref.)

The polymerase chain reaction: a revolutionary new procedure for the laboratory diagnosis of infectious disease. Buck GE. **J Ky Med Assoc** 1996 Apr;94(4):148–52 (23 ref.)

The use of molecular biology techniques for diagnostic microbiology and hospital epidemiology. Low DE, et al. **New Horiz** 1995 May;3(2):161–9 (84 ref.)

Infectious disease testing for blood transfusions. **NIH Consens Statement** 1995 Jan 9–11;13(1):1–27 (0 ref.)

DRUG THERAPY

Lipid formulations of amphotericin B. Less toxicity but at what economic cost? Tollemar J, et al. **Drug Saf** 1995 Oct; 13(4):207–18 (86 ref.)

Ciprofloxacin. An updated review of its pharmacology,

therapeutic efficacy and tolerability. Davis R, et al. **Drugs** 1996 Jun;51(6):1019–74 (517 ref.)
Macrolide antibiotics in paediatric infectious diseases. Guay DR. **Drugs** 1996 Apr;51(4):515–36 (205 ref.)
Review: granulocyte colony-stimulating factor—role and relationships in infectious diseases. Dale DC, et al. **J Infect Dis** 1995 Oct;172(4):1061–75 (204 ref.)
[Clinical infectiology—I. Diagnosis, pathogen spectrum and resistance] Schrappe M. **Med Klin** 1996 Apr 1;91 Suppl 1:166–75 (157 ref.) **(Ger)**

EPIDEMIOLOGY

Addressing the challenges of emerging infectious disease. Pinner RW. **Am J Med Sci** 1996 Jan;311(1):3–8 (23 ref.)
Quarterly communicable disease review October to December 1994. From the PHLS Communicable Disease Surveillance Centre. **J Public Health Med** 1995 Jun; 17(2):230–7 (50 ref.)
Climate change and global infectious disease threats. Jackson EK. **Med J Aust** 1995 Dec 4–18;163(11–12):570–4 (67 ref.)
The emergence of "emerging diseases": a lesson in holistic epidemiology. Kilbourne ED. **Mt Sinai J Med** 1996 May-Sep;63(3–4):159–66 (31 ref.)
Changing patterns of communicable disease: who is turning the kaleidoscope? Waltner-Toews D. **Perspect Biol Med** 1995 Autumn;39(1):43–55 (22 ref.)
Spatial heterogeneity, nonlinear dynamics and chaos in infectious diseases. Grenfell BT, et al. **Stat Methods Med Res** 1995 Jun;4(2):160–83 (82 ref.)
[Infectious diseases from the hygienic viewpoint with special reference to environmental infections—a retrospective and prospective view] Exner M. **Zentralbl Hyg Umweltmed** 1995 Apr;197(1–3):134–61 (79 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Infectious disease emergencies in disasters. Howard MJ, et al. **Emerg Med Clin North Am** 1996 May;14(2):413–28 (87 ref.)
Women at risk for infection: the woman who is chemically dependent. Kendig S. **J Obstet Gynecol Neonatal Nurs** 1995 Oct;24(8):776–81 (38 ref.)
Climate change and human health: possible communicable disease consequences in the United Kingdom. Rowland MG. **Med War** 1995 Oct-Dec;11(4):188–94 (19 ref.)
Transfusion-transmitted infections in the newborn. Delage G. **Transfus Med Rev** 1995 Jul;9(3):271–6 (62 ref.)

IMMUNOLOGY

Risk assessment for the harmful effects of UVB radiation on the immunological resistance to infectious diseases. Van Loveren H, et al. **Arch Toxicol Suppl** 1996;18:21–8 (19 ref.)
Nitric oxide in infectious and autoimmune diseases. Liew FY. **Ciba Found Symp** 1995;195:234–9; discussion 239–44 (26 ref.)
T cell subsets in infectious and autoimmune diseases. Introduction. Mitchison NA. **Ciba Found Symp** 1995; 195:1–5; discussion 5–6 (9 ref.)
Host factors affecting disease transmission. Muzyka BC. **Dent Clin North Am** 1996 Apr;40(2):263–75 (28 ref.)

MICROBIOLOGY

[Modern methods and means for the rapid determination of the sensitivity of the causative agents of dangerous infectious diseases to antibiotics and chemical preparations] D'iakov SI, et al. **Voen Med Zh** 1996 Mar;317(3):44–7 (17 ref.) **(Rus)**

PHYSIOPATHOLOGY

The protective role of the hypothalamic-pituitary-adrenal axis against lethality produced by immune, infectious, and inflammatory stress. Kapcala LP, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:419–37 (87 ref.)

THERAPY

Do monoclonal antibodies and anticytokines still have a future in infectious diseases? Cohen J, et al. **Am J Med** 1995 Dec 29;99(6A):45S–52S; discussion 52S–53S (36 ref.)
Recognizing and treating new and emerging infections encountered in everyday practice. Gordon SM. **Cleve Clin J Med** 1996 May-Jun;63(3):172–8 (24 ref.)
Infectious disease indications for hyperbaric oxygen therapy. Brown RB, et al. **Compr Ther** 1995 Nov;21(11):663–7 (17 ref.)

TRANSMISSION

Health hazards to humans associated with domestic pets. Plaut M, et al. **Annu Rev Public Health** 1996;17:221–45 (87 ref.)
A national consensus on guidelines for establishment of a post-exposure notification protocol for emergency responders. Laboratory Centre for Disease Control, Health Protection Branch, Health Canada. **Can Commun Dis Rep** 1995 Oct 15;21(19):169–80 (5 ref.) **(Eng, Fre)**
Host factors affecting disease transmission. Muzyka BC. **Dent Clin North Am** 1996 Apr;40(2):263–75 (28 ref.)
Postexposure protocol. Younai FS. **Dent Clin North Am** 1996 Apr;40(2):457–86 (118 ref.)
Population medicine and infectious diseases. Hoskins JD. **J Am Vet Med Assoc** 1996 Feb 15;208(4):510–2 (7 ref.)
Infectious disease testing for blood transfusions [news] **Oncology (Huntingt)** 1995 Nov;9(11):1141–2 (0 ref.)

VETERINARY

Green turtle fibropapillomatosis: challenges to assessing the role of environmental cofactors. Herbst LH, et al. **Environ Health Perspect** 1995 May;103 Suppl 4:27–30 (37 ref.)
Advances in feline health research: impact of recent developments in vaccinology on feline welfare. Richards JR. **J Am Vet Med Assoc** 1996 Feb 15;208(4):505–10 (30 ref.)
Evolutionary pressures in the spread and persistence of infectious agents in vertebrate populations. Anderson RM. **Parasitology** 1995;111 Suppl:S15–31 (69 ref.)
Introduction: ecological impact of parasitism on wildlife host populations. Grenfell BT, et al. **Parasitology** 1995;111 Suppl:S3–14 (185 ref.)
Disinfection and wildlife. Corn JL, et al. **Rev Sci Tech** 1995 Jun;14(2):455–68 (17 ref.)
Disinfection of stockyards. Fotheringham VJ. **Rev Sci Tech** 1995 Jun;14(2):293–307 (21 ref.)
Disinfection of farrowing pens. Owen JM. **Rev Sci Tech** 1995 Jun;14(2):381–91 (18 ref.)
Disinfection in aquaculture. Torgersen Y, et al. **Rev Sci Tech** 1995 Jun;14(2):419–34 (39 ref.)
Systemic diseases with cutaneous manifestations. Merchant SR, et al. **Vet Clin North Am Small Anim Pract** 1995 Jul; 25(4):945–59 (56 ref.)

COMMUNICATION

Treating patients from other cultures. Orr RD. **Am Fam Physician** 1996 May 1;53(6):2004–6 (22 ref.)
Overweight and health: communications challenges and opportunities. Rippe JM. **Am J Clin Nutr** 1996 Mar;63(3 Suppl):470S–473S (32 ref.)
The clinical interface—a British physician's view. Neuberger J, et al. **Clin Chim Acta** 1996 Apr 15;248(1):11–8 (9 ref.)
Critical interaction therapy: couples therapy in combat-related posttraumatic stress disorder. Johnson DR, et al. **Fam Process** 1995 Dec;34(4):401–12 (16 ref.)
Effects of information-giving and communication during orthodontic consultation and treatment. Part 3: Optimized orthodontist-patient communication. Witt E, et al. **Fortschr Kieferorthop** 1996 Jun;57(3):154–67 (55 ref.) **(Eng, Ger)**
A selective review of the literature on nurse-patient communication: has the patient's contribution been neglected? Jarrett N, et al. **J Adv Nurs** 1995 Jul;22(1):72–8 (51 ref.)
Theoretical and practical considerations on the use of reassurance in the nursing management of anxious patients. Teasdale K. **J Adv Nurs** 1995 Jul;22(1):79–86 (61 ref.)
Poster presentation: an effective means of scientific communication. Harikrishnan KM, et al. **J Assoc Physicians India** 1995 Aug;43(8):546–7 (4 ref.)
Matching verbal repertoires: understanding the contingencies of practice in order to functionally communicate with clinicians. Montgomery RW, et al. **J Behav Ther Exp Psychiatry** 1995 Jun;26(2):99–105 (29 ref.)
Communication with cancer patients: does it matter? Butow PN, et al. **J Palliat Care** 1995 Winter;11(4):34–8 (50 ref.)
Breaking bad news. A review of the literature. Ptacek JT, et al. **JAMA** 1996 Aug 14;276(6):496–502 (83 ref.)
Communication breakdown: a preventable cause of acute renal failure in a newborn infant [see comments] Craig JC, et al. **Med J Aust** 1996 Jun 3;164(11):663–4 (8 ref.)
Comment in: Med J Aust 1996 Jun 3;164(11):645–6.
Risk communication: a tool for behavior change. McCallum DB. **NIDA Res Monogr** 1995;155:65–89 (27 ref.)
Communicating emerging scientific information. **Nutr Rev** 1996 May;54(5):153–7 (2 ref.)
Discussing the diagnosis and prognosis with cancer patients. Bennett M, et al. **Postgrad Med J** 1996 Jan;72(843):25–9 (14 ref.)
Telling parents their child has severe congenital anomalies. Ryan S. **Postgrad Med J** 1995 Sep;71(839):529–33 (14 ref.)
Communication issues in breast imaging. D'Orsi CJ, et al. **Radiol Clin North Am** 1995 Nov;33(6):1231–45 (31 ref.)
[Communication of bad information: general indications and guidelines] Saltini A, et al. **Recenti Prog Med** 1995 Oct; 86(10):409–17 (12 ref.) (Eng. Abstr.) **(Ita)**
[Communication of bad facts. To inform or not to inform the patient: a choice between 2 alternatives?] Saltini A. **Recenti Prog Med** 1995 Sep;86(9):359–66 (40 ref.) (Eng. Abstr.) **(Ita)**
[The neurobiological bases of acoustical communication. A comparative physiological review of structures and mechanisms] Vartanian IA, et al. **Zh Evol Biokhim Fiziol** 1995 Sep-Dec;31(5–6):677–84 (33 ref.) **(Rus)**

COMMUNICATION AIDS FOR DISABLED

[Technology for the diagnosis and rehabilitation of patients with dysphonia] Vilkman E, et al. **Duodecim** 1995; 111(6):549–53 (10 ref.) **(Fin)**

COMMUNICATION AIDS FOR HANDICAPPED see **COMMUNICATION AIDS FOR DISABLED**

COMMUNICATION BOARDS see **COMMUNICATION AIDS FOR DISABLED**

COMMUNICATION, SATELLITE see **SATELLITE COMMUNICATIONS**

COMMUNICATIVE DISORDERS

THERAPY

Speech and language therapy: does it work? Enderby P, et al. **BMJ** 1996 Jun 29;312(7047):1655–8 (34 ref.)

COMMUNITY-ACQUIRED INFECTIONS

see related
CROSS INFECTION

The pneumococcal problem. Obaro SK, et al. **BMJ** 1996 Jun 15;312(7045):1521–5 (49 ref.)
Community-acquired pneumonia: an update. Meeker DP, et al. **Cleve Clin J Med** 1996 Jan-Feb;63(1):16–30 (97 ref.)
Severe community-acquired pneumonia. Leeper KV Jr. **Semin Respir Infect** 1996 Jun;11(2):96–108 (82 ref.)

DRUG THERAPY

[Azithromycin and bronchopulmonary infections] Leophonte P. **Pathol Biol (Paris)** 1995 Jun;43(6):534–41 (38 ref.) (Eng. Abstr.) **(Fre)**

EPIDEMIOLOGY

Inner-city tuberculosis in the USA. McGowan JE Jr, et al. **J Hosp Infect** 1995 Jun;30 Suppl:282–95 (65 ref.)

THERAPY

Treatment of community-acquired urinary tract infections. Perdue BE, et al. **Am Pharm** 1995 Dec;NS35(12):37–45 (51 ref.)

COMMUNITY ACTION see **CONSUMER PARTICIPATION**

COMMUNITY CARE NETWORKS see **COMMUNITY NETWORKS**

COMMUNITY HEALTH AIDES

Challenging old notions of professionalism: how can nurses work with paraprofessional ethnic health workers? Fuller J. **J Adv Nurs** 1995 Sep;22(3):465–72 (44 ref.)

COMMUNITY HEALTH CARES see **COMMUNITY HEALTH SERVICES**

COMMUNITY HEALTH EDUCATION see **HEALTH EDUCATION**

COMMUNITY HEALTH NETWORKS see **COMMUNITY NETWORKS**

COMMUNITY HEALTH NURSING

Approaches to community needs assessment: a literature review. Billings JR, et al. **J Adv Nurs** 1995 Oct;22(4):721–30 (100 ref.)
The use of the Nominal Group Technique in research with community nurses. Carney O, et al. **J Adv Nurs** 1996 May; 23(5):1024–9 (13 ref.)
Explication of the construct of shared care and the prevention of pressure ulcers in home health care. Sebern MD. **Res Nurs Health** 1996 Jun;19(3):183–92 (50 ref.)

ORGANIZATION & ADMINISTRATION

Coming to voice: the power of emancipatory community interventions. Drevdahl D. **ANS Adv Nurs Sci** 1995 Dec; 18(2):13–24 (50 ref.)
The development of community psychiatric nursing: a professional project? Godin P. **J Adv Nurs** 1996 May; 23(5):925–34 (60 ref.)

TRENDS

Sensitizing nurses for a changing environmental health role. Tiedje LB, et al. **Public Health Nurs** 1995 Dec;12(6):359–65 (34 ref.)

COMMUNITY HEALTH PLANNING

see related
COMMUNITY HEALTH SERVICES

Behaviour change in practice: population strategies. Wiseman MJ. **Int J Obes Relat Metab Disord** 1996 Feb;20 Suppl 1:S31–3 (14 ref.)
Technology assessment. Old, new, and needs-based. Tugwell P, et al. **Int J Technol Assess Health Care** 1995 Fall; 11(4):650–62 (39 ref.)

COMMUNITY HEALTH PLANNING

METHODS

Paradigms lost: toward a new understanding of community participation in health programmes. Rifkin SB. **Acta Trop** 1996 Apr;61(2):79–92 (53 ref.)

COMMUNITY HEALTH SERVICES

Paradigms lost: toward a new understanding of community participation in health programmes. Rifkin SB. **Acta Trop** 1996 Apr;61(2):79–92 (53 ref.)

Roles of nurses and health workers in cardiovascular health promotion. Hill MN, et al. **Am J Med Sci** 1995 Dec;310 Suppl 1:S123–6 (16 ref.)

Educating pediatric residents in community settings. DeWitt TG, et al. **Curr Opin Pediatr** 1995 Oct;7(5):489–93 (26 ref.)

Community-oriented primary care programs. Bailey RN. **J Am Optom Assoc** 1995 Oct;66(10):631–3 (7 ref.)

Building community capacity for health promotion: a challenge for public health nurses. Kang R. **Public Health Nurs** 1995 Oct;12(5):312–8 (24 ref.)

LEGISLATION & JURISPRUDENCE

[Background and prospects of the Community Health Act] Aoyama H. **Nippon Eiseigaku Zasshi** 1996 Feb; 50(6):1026–35 (14 ref.) (Eng. Abstr.) **(Jpn)**

ORGANIZATION & ADMINISTRATION

Community-based approaches for the prevention of alcohol, tobacco, and other drug use. Aguirre-Molina M, et al. **Annu Rev Public Health** 1996;17:337–58 (121 ref.)

A contextual approach for understanding individual autonomy in managed community long-term care. Capitman J, et al. **Gerontologist** 1995 Aug;35(4):533–40 (55 ref.)

Sustaining interventions in community systems: on the relationship between researchers and communities. Altman DG. **Health Psychol** 1995 Nov;14(6):526–36 (72 ref.)

Approaches to community needs assessment: a literature review. Billings JR, et al. **J Adv Nurs** 1995 Oct;22(4):721–30 (100 ref.)

Reaching out to the African American community through innovative strategies. Robinson KD, et al. **Oncol Nurs Forum** 1995 Oct;22(9):1383–91 (28 ref.)

Problems with public health outreach. Azzarto J. **Soc Work Health Care** 1995;22(1):57–67 (20 ref.)

[Health promotion in the heart of Quebec and Canada: the ever present influence of the North Karelia model] Paradis G, et al. **Union Med Can** 1995 Sep;124(2):1–6 (19 ref.) **(Fre)**

STANDARDS

Care of patients with epilepsy in the community: will new initiatives address old problems? [see comments] Thapar AK. **Br J Gen Pract** 1996 Jan;46(402):37–42 (69 ref.) Comment in: Br J Gen Pract 1996 Jan;46(402):3–4.

Toward comprehensive obesity prevention programs in Native American communities. Broussard BA, et al. **Obes Res** 1995 Sep;3 Suppl 2:289s–297s (50 ref.)

Community programs for obesity prevention: the Minnesota Heart Health Program. Jeffery RW. **Obes Res** 1995 Sep; 3 Suppl 2:283s–288s (21 ref.)

TRENDS

Strengthening individual and community capacity to prevent disease and promote health: in search of relevant theories and principles. Freudenberg N, et al. **Health Educ Q** 1995 Aug;22(3):290–306 (83 ref.)

Mental health nurses working purposefully with people with serious and enduring mental illness—an international perspective. Gournay K. **Int J Nurs Stud** 1995 Aug; 32(4):341–52 (68 ref.)

COMMUNITY MEDICINE

Community programmes for cardiovascular disease prevention in changing societies [editorial; comment] Pyörälä K. **Eur Heart J** 1995 Jun;16(6):723–5 (10 ref.) Comment on: Eur Heart J 1995 Jun;16(6):752–60.

EDUCATION

Controversies in community based education. Ogunbode O. **West Afr J Med** 1996 Jan–Mar;15(1):18–23 (15 ref.)

ORGANIZATION & ADMINISTRATION

Community medicine: an urban model. Deuschle KW, et al. **J Community Health** 1995 Dec;20(6):459–72 (37 ref.)

COMMUNITY MENTAL HEALTH SERVICES

In search of effective programs to address students' emotional distress and behavioral problems. Part II: Critique of school- and community-based programs. Wassef A, et al. **Adolescence** 1995 Winter;30(120):757–77 (29 ref.)

PTSD diagnosis and treatment for mental health clinicians. Friedman MJ. **Community Ment Health J** 1996 Apr; 32(2):173–89; discussion 191–3 (50 ref.)

Assertive community treatment: an update of randomized trials. Burns BJ, et al. **Psychiatr Serv** 1995 Jul;46(7):669–75 (46 ref.)

Use of a token economy with seriously mentally ill patients: criticisms and misconceptions. Corrigan PW. **Psychiatr Serv** 1995 Dec;46(12):1258–63 (52 ref.)

Assertive community treatment and case management for schizophrenia. Scott JE, et al. **Schizophr Bull** 1995; 21(4):657–68 (56 ref.)

ECONOMICS

Rural mental health coverage under health care reform. Shelton DA, et al. **Community Ment Health J** 1995 Dec; 31(6):539–52 (33 ref.)

Estimated societal costs of assertive community mental health care. Wolff N, et al. **Psychiatr Serv** 1995 Sep;46(9):898–906 (29 ref.)

LEGISLATION & JURISPRUDENCE

A biopsychosocial rationale for coerced community treatment in the management of schizophrenia. Geller JL. **Psychiatr Q** 1995 Fall;66(3):219–35 (58 ref.)

MANPOWER

Human resource issues in rural mental health services. Merwin EI, et al. **Community Ment Health J** 1995 Dec; 31(6):525–37 (38 ref.)

ORGANIZATION & ADMINISTRATION

Community care of patients with schizophrenia: the role of the primary health care team. King M, et al. **Br J Gen Pract** 1996 Apr;46(405):231–7 (89 ref.)

Geropsychiatric public sector nursing: placement challenges. Fuller K, et al. **J Psychosoc Nurs Ment Health Serv** 1995 Aug;33(8):20–2 (6 ref.)

Housing for persons with co-occurring mental and addictive disorders. Osher FC, et al. **New Dir Ment Health Serv** 1996 Summer;(70):53–64 (37 ref.)

STANDARDS

Critical issues in reforming rural mental health service delivery. Blank MB, et al. **Community Ment Health J** 1995 Dec;31(6):511–24 (46 ref.)

TRENDS

Managed care in the public mental health system. Cuffel BJ, et al. **Community Ment Health J** 1996 Apr;32(2):109–24 (42 ref.)

Dealing with drug misuse. Gabbay MB. **J R Soc Health** 1995 Dec;115(6):391–4 (14 ref.)

UTILIZATION

Critical issues in reforming rural mental health service delivery. Blank MB, et al. **Community Ment Health J** 1995 Dec;31(6):511–24 (46 ref.)

Local knowledge and rural mental health reform. Hill CE, et al. **Community Ment Health J** 1995 Dec;31(6):553–68 (48 ref.)

COMMUNITY NETWORKS

ORGANIZATION & ADMINISTRATION

[INSERM clinical research network on sickle cell anemia: a tool for therapeutic care and research] Girot R. **Arch Pediatr** 1996;3 Suppl 1:321s–323s (9 ref.) **(Fre)**

TRENDS

Mergers, networking, and vertical integration: managed care and investor-owned hospitals. Brown M. **Health Care Manage Rev** 1996 Winter;21(1):29–37 (7 ref.)

COMMUNITY PERIODONTAL INDEX OF TREATMENT NEEDS see **PERIODONTAL INDEX**

COMMUNITY PHARMACY SERVICES

ECONOMICS

Compensation for cognitive services in the community pharmacy. Braden LL. **Am Pharm** 1995 Mar; NS35(3):58–65; quiz 65–6 (7 ref.)

COMORBIDITY

Comorbidity risk parameters associated with advanced breast cancer and systemic disease. Management of nonbreast disease. Graves TA, et al. **Surg Oncol Clin N Am** 1995 Oct;4(4):633–56 (110 ref.)

[Confusional states in the elderly—an underdiagnosed syndrome with a poor prognosis] Pitkälä K. **Nord Med** 1996 Jun;111(6):184–8 (15 ref.) (Eng. Abstr.) **(Swe)**

COMPACT DISK READ-ONLY MEMORY see **CD-ROM**

COMPARTMENT SYNDROMES

see related
NERVE COMPRESSION SYNDROMES

Volkmann's ischemic contracture of the foot and ankle: evaluation and treatment of established deformity. Santi MD, et al. **Foot Ankle Int** 1995 Jun;16(6):368–77 (72 ref.)

COMPLICATIONS

Calcific myonecrosis following compartment syndrome: report of two cases, review of the literature, and recommendations for treatment. Snyder BJ, et al. **J Trauma** 1995 Oct;39(4):792–5 (6 ref.)

DIAGNOSIS

Exertional compartment syndromes of the lower extremity. Schepsis AA, et al. **Curr Opin Rheumatol** 1996 Mar; 8(2):143–7 (9 ref.)

PHYSIOPATHOLOGY

The abdominal compartment syndrome. Burch JM, et al. **Surg Clin North Am** 1996 Aug;76(4):833–42 (35 ref.)

SURGERY

Lower leg overuse injuries in athletes. Järvinen M. **Knee Surg Sports Traumatol Arthrosc** 1993;1(2):126–30 (33 ref.)

COMPETENCE, CLINICAL see **CLINICAL COMPETENCE**

COMPETENCE, IMMUNOLOGIC see **IMMUNOCOMPETENCE**

COMPETENCE, PROFESSIONAL see **PROFESSIONAL COMPETENCE**

COMPETENCY-BASED EDUCATION

STANDARDS

Another look at competency-based education in dietetics. Chambers DW, et al. **J Am Diet Assoc** 1996 Jun;96(6):614–7 (25 ref.)

COMPETENCY, MENTAL see **MENTAL COMPETENCY**

COMPETITION, ECONOMIC see **ECONOMIC COMPETITION**

COMPETITIVE BEHAVIOR

More than just a game: research developments and issues in competitive anxiety in sport. Jones G. **Br J Psychol** 1995 Nov;86 (Pt 4):449–78 (190 ref.)

COMPETITIVE MEDICAL PLANS

see related
PREFERRED PROVIDER ORGANIZATIONS

LEGISLATION & JURISPRUDENCE

Physician-run health plans and antitrust. American College of Physicians. **Ann Intern Med** 1996 Jul 1;125(1):59–65 (20 ref.)

COMPLEMENT

see related
RECEPTORS, COMPLEMENT

ANALYSIS

Clinical utility of complement assessment. Ahmed AE, et al. **Clin Diagn Lab Immunol** 1995 Sep;2(5):509–17 (93 ref.)

BIOSYNTHESIS

Complement biosynthesis in the central nervous system. Barnum SR. **Crit Rev Oral Biol Med** 1995;6(2):132–46 (112 ref.)

DEFICIENCY

Genetic deficiencies of complement. Lokki ML, et al. **Ann Med** 1995 Aug;27(4):451–9 (113 ref.)

Clinical utility of complement assessment. Ahmed AE, et al. **Clin Diagn Lab Immunol** 1995 Sep;2(5):509–17 (93 ref.)

[Complement deficiencies] Meri S. **Duodecim** 1994; 110(2):185–94 (35 ref.) **(Fin)**

IMMUNOLOGY

A "complement-ary" AIDS vaccine. Dierich MP, et al. **Nat Med** 1996 Feb;2(2):153–5 (26 ref.)

[Expression and role of complement regulatory proteins on human gametes and pre-implantation embryos] Fénichel P, et al. **Contracept Fertil Sex** 1995 Sep;23(9):576–80 (50 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Complement fragments and cytokines: production and removal as consequences of hemofiltration. Journois D. **Contrib Nephrol** 1995;116:80–5 (23 ref.)

PHYSIOLOGY

Intervention in the complement system: a therapeutic strategy in inflammation. Morgan BP. **Biochem Soc Trans** 1996 Feb;

24(1):224–9 (43 ref.)
Michael Mason Prize Essay 1995. Complement, immune complexes and systemic lupus erythematosus. Davies KA. **Br J Rheumatol** 1996 Jan;35(1):5–23 (69 ref.)
Physiology and pathophysiology of complement: progress and trends. Morgan BP. **Crit Rev Clin Lab Sci** 1995; 32(3):265–98 (217 ref.)
Contradictory roles for antibody and complement in the interaction of Brucella abortus with its host. Hoffmann EM, et al. **Crit Rev Microbiol** 1995;21(3):153–63 (50 ref.)
Complement system in coronary heart disease: a review. Gardinali M, et al. **Immunopharmacology** 1995 Aug; 30(2):105–17 (91 ref.)
The antiphospholipid syndrome and SLE: is there a clue in the link between complement and coagulation? Merrill JT, et al. **Lupus** 1996 Feb;5(1):6–10 (63 ref.)

COMPLEMENT 1 ESTERASE INHIBITORS see **COMPLEMENT 1 INACTIVATORS**

COMPLEMENT 1 INACTIVATORS

ANALYSIS

[C1-inhibitor (C1-INH)] Sakata T, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:402–4 (13 ref.) **(Jpn)**

COMPLEMENT 1 INHIBITORS see **COMPLEMENT 1 INACTIVATORS**

COMPLEMENT 1Q

ANALYSIS

Pan-nephritis (glomerulonephritis, arteriolitis, and tubulointerstitial nephritis) associated with predominant mesangial C1q deposition and hypocomplementemia: a variant type of C1q nephropathy? Imai H, et al. **Am J Kidney Dis** 1996 Apr;27(4):583–7 (15 ref.)

COMPLEMENT 2

DEFICIENCY

Multifocal stenosing ulcerations of the small intestine revealing vasculitis associated with C2 deficiency. Perlemuter G, et al. **Gastroenterology** 1996 May; 110(5):1628–32 (23 ref.)

COMPLEMENT 4

DEFICIENCY

Recurrent hematuria: a novel clinical presentation of hereditary complete complement C4 deficiency. Lhotta K, et al. **Am J Kidney Dis** 1996 Mar;27(3):424–7 (10 ref.)

COMPLEMENT 5

IMMUNOLOGY

Complement-specific antibodies: designing novel anti-inflammatories. Matis LA, et al. **Nat Med** 1995 Aug; 1(8):839–42 (18 ref.)

COMPLEMENT ACTIVATION

Intervention in the complement system: a therapeutic strategy in inflammation. Morgan BP. **Biochem Soc Trans** 1996 Feb; 24(1):224–9 (43 ref.)
Clinical utility of complement assessment. Ahmed AE, et al. **Clin Diagn Lab Immunol** 1995 Sep;2(5):509–17 (93 ref.)
Activation of the complement system by pathogenic fungi. Kozel TR. **Clin Microbiol Rev** 1996 Jan;9(1):34–46 (109 ref.)
Human regulator of complement activation (RCA) gene family proteins and their relationship to microbial infection. Seya T. **Microbiol Immunol** 1995;39(5):295–305 (82 ref.)
The generation of transgenic pigs as potential organ donors for humans. Cozzi E, et al. **Nat Med** 1995 Sep;1(9):964–6 (30 ref.)
Complement inhibitory therapeutics and xenotransplantation. Ryan US. **Nat Med** 1995 Sep;1(9):967–8 (19 ref.)
[Heart surgery, cardiopulmonary bypass and inflammatory response. I. Changes in hemostasis and complement] Parolari A, et al. **G Ital Cardiol** 1996 Apr;26(4):431–46 (121 ref.) (Eng. Abstr.) **(Ita)**

GENETICS

Human regulator of complement activation (RCA) gene family proteins and their relationship to microbial infection. Seya T. **Microbiol Immunol** 1995;39(5):295–305 (82 ref.)

PHYSIOLOGY

Physiology and pathophysiology of complement: progress and trends. Morgan BP. **Crit Rev Clin Lab Sci** 1995; 32(3):265–98 (217 ref.)

COMPLEMENT COMPLEX C5B-9 see **COMPLEMENT MEMBRANE ATTACK COMPLEX**

COMPLEMENT FIXATION TESTS

VETERINARY

[Complement fixation reaction for the serologic diagnosis of bovine contagious pleuropneumonia: application and interpretation of the results] Regalla J. **Rev Sci Tech** 1995 Sep;14(3):631–44 (11 ref.) (Eng. Abstr.) **(Fre)**

COMPLEMENT INACTIVATORS

THERAPEUTIC USE

Complement inhibitory therapeutics and xenotransplantation. Ryan US. **Nat Med** 1995 Sep;1(9):967–8 (19 ref.)

COMPLEMENT INHIBITORS see **COMPLEMENT INACTIVATORS**

COMPLEMENT MEMBRANE ATTACK COMPLEX

PHYSIOLOGY

Induction of cellular procoagulant activity by the membrane attack complex of complement. Sims PJ, et al. **Semin Cell Biol** 1995 Oct;6(5):275–82 (63 ref.)

COMPLEMENT PATHWAY, CLASSICAL

DRUG EFFECTS

Coagulation inhibitor substitution during sepsis. Fourrier F, et al. **Intensive Care Med** 1995 Nov;21 Suppl 2:S264–8 (34 ref.)

COMPLEMENT PROTEINS see **COMPLEMENT**

COMPLEMENT RECEPTORS see **RECEPTORS, COMPLEMENT**

COMPLEMENTARITY-DETERMINING REGION see **IMMUNOGLOBULIN VARIABLE REGION**

COMPLEMENTARY DNA see **DNA, COMPLEMENTARY**

COMPLEMENTARY MEDICINE see **ALTERNATIVE MEDICINE**

COMPLEX III see **UBIQUINOL-CYTOCHROME-C REDUCTASE**

COMPLEXONS see **CHELATING AGENTS**

COMPLIANT BEHAVIOR see **COOPERATIVE BEHAVIOR**

COMPOSITE RESINS

Current trends in dental composites. Ferracane JL. **Crit Rev Oral Biol Med** 1995;6(4):302–18 (118 ref.)
[Current status of adhesive resin restorations] Tagami J. **Kokubyo Gakkai Zasshi** 1996 Mar;63(1):1–7 (28 ref.) **(Jpn)**

CHEMISTRY

Clinical guidelines for photocuring restorative resins. Caughman WF, et al. **J Am Dent Assoc** 1995 Sep; 126(9):1280–2, 1284, 1286 (15 ref.)

COMPREHENSIVE HEALTH CARE

ECONOMICS

The cost of comprehensive preventive medical services for adolescents. Gans JE, et al. **Arch Pediatr Adolesc Med** 1995 Nov;149(11):1226–34 (52 ref.)

METHODS

Enhancing perinatal outcome in homeless women: the challenge of providing comprehensive health care. Beal AC, et al. **Semin Perinatol** 1995 Aug;19(4):307–13 (19 ref.)

ORGANIZATION & ADMINISTRATION

Management of non-insulin-dependent diabetes mellitus. The United Kingdom experience. Keen H. **Ann Intern Med** 1996 Jan 1;124(1 Pt 2):156–9 (10 ref.)
Rethinking the organization of children's programs: lessons from the elderly. Grason H, et al. **Milbank Q** 1995; 73(4):565–97 (37 ref.)

TRENDS

[Organization of cardiologic rehabilitation in central Europe: retrospect, present, future outlook] Halhuber MJ. **Wien Klin Wochenschr** 1995;107(24):756–9 (6 ref.) (Eng. Abstr.) **(Ger)**

COMPREHENSIVE HEALTH PLANNING see **REGIONAL HEALTH PLANNING**

COMPREHENSIVE HEALTH PLANS, STATE see **STATE HEALTH PLANS**

COMPULSIVE BEHAVIOR

see related
OBSESSIVE-COMPULSIVE DISORDER

GENETICS

The D2 dopamine receptor gene as a determinant of reward deficiency syndrome. Blum K, et al. **J R Soc Med** 1996 Jul;89(7):396–400 (66 ref.)

COMPUTED TOMOGRAPHY SCANNERS, X-RAY see **TOMOGRAPHY SCANNERS, X-RAY COMPUTED**

COMPUTER-AIDED DESIGN

Generation of new-lead structures in computer-aided drug design. Cohen NC, et al. **Prog Drug Res** 1995;45:205–43 (139 ref.)
[Computer-designed site-specific drugs--myth or reality?] Taskinen J. **Duodecim** 1995;111(8):799–806 (25 ref.) **(Fin)**

TRENDS

Update on computer-aided drug design. Jackson RC. **Curr Opin Biotechnol** 1995 Dec;6(6):646–51 (48 ref.)

COMPUTER-AIDED MANUFACTURING see **COMPUTER-AIDED DESIGN**

COMPUTER ARCHITECTURE see **COMPUTER SYSTEMS**

COMPUTER-ASSISTED DECISION MAKING see **DECISION MAKING, COMPUTER-ASSISTED**

COMPUTER-ASSISTED DESIGN see **COMPUTER-AIDED DESIGN**

COMPUTER-ASSISTED DIAGNOSIS see **DIAGNOSIS, COMPUTER-ASSISTED**

COMPUTER-ASSISTED DRUG THERAPY see **DRUG THERAPY, COMPUTER-ASSISTED**

COMPUTER-ASSISTED IMAGE PROCESSING see **IMAGE PROCESSING, COMPUTER-ASSISTED**

COMPUTER-ASSISTED INSTRUCTION

The use of computers in the teaching of biochemistry: support for learning the qualitative differences. McAleese R. **Biochem Soc Trans** 1996 Feb;24(1):293–7 (19 ref.)
Deciding among interactive multimedia technologies. Locatis C. **J Biocommun** 1995;22(2):2–7 (20 ref.)
Educational challenges. Jaffe CC, et al. **Radiol Clin North Am** 1996 May;34(3):629–46 (13 ref.)

INSTRUMENTATION

[PC applications in routine practice, science and teaching. What computer peripherals are useful?] Knopp MV, et al. **Radiologe** 1995 Sep;35(9):620–4 (3 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Medical education by satellite: the EuroTransMed experience. Young HL. **J Audiov Media Med** 1995 Jun; 18(2):75–8 (0 ref.)

COMPUTER-ASSISTED MANUFACTURING see **COMPUTER-AIDED DESIGN**

COMPUTER-ASSISTED RADIOTHERAPY PLANNING see **RADIOTHERAPY PLANNING, COMPUTER-ASSISTED**

COMPUTER-ASSISTED THERAPY see **THERAPY, COMPUTER-ASSISTED**

COMPUTER COMMUNICATION NETWORKS

Accessing and using the Internet's World Wide Web for emergency physicians. Yamamoto LG, et al. **Am J Emerg Med** 1996 May;14(3):302–8 (10 ref.)
The Internet and the future of psychiatry. Huang MP, et al. **Am J Psychiatry** 1996 Jul;153(7):861–9 (67 ref.)
Medical information: from Surgeon General to superhighway. Deering CM, et al. **Ann Trop Med Parasitol** 1995 Dec;89(6):579–91 (20 ref.)
Medical resources and the internet. Making the connection. Kramer JM, et al. **Arch Intern Med** 1996 Apr 22; 156(8):833–42 (13 ref.)
On-line resources for pediatricians. Spooner SA. **Arch Pediatr Adolesc Med** 1995 Oct;149(10):1160–8 (23 ref.)
Internet on-ramp. Searching the Internet. Horton RM. **Biotechniques** 1996 Mar;20(3):406–8 (0 ref.)
ABC of medical computing. Hospital based computer

systems. Lee N, et al. **BMJ** 1995 Oct 14;311(7011):1013–6 (0 ref.)
Introducing the Internet. Pallen M. **BMJ** 1995 Nov 25; 311(7017):1422–4 (25 ref.)
Electronic mail [see comments] Pallen M. **BMJ** 1995 Dec 2;311(7018):1487–90 (25 ref.) Comment in: BMJ 1996 Apr 13;312(7036):977.
Guide to the Internet. The world wide web [see comments] Pallen M. **BMJ** 1995 Dec 9;311(7019):1552–6 (32 ref.) Comment in: BMJ 1996 Apr 13;312(7036):977.
Internet: road to heaven or hell for the clinical laboratory? Chou D. **Clin Chem** 1996 May;42(5):827–30 (26 ref.)
The Internet and the pediatrician: should there be a connection? Fikar CR. **Clin Pediatr (Phila)** 1996 May; 35(5):229–35 (19 ref.)
Internet for the allergist. Bell T. **J Asthma** 1996;33(3):143–8 (6 ref.)
On-line food and nutrition information resources. Institute of Food Science and Technology. **Nutr Rev** 1996 May; 54(5):158 (0 ref.)
Networks for electronic radiology. Blaine GJ, et al. **Radiol Clin North Am** 1996 May;34(3):505–24 (31 ref.)
Teleradiology: the practice of radiology enters Cyberspace. Coons T. **Radiol Technol** 1995 Nov–Dec;67(2):125–40; quiz 141–4 (33 ref.)
A graphical interface for searching the human genome. Adler D. **Trends Genet** 1995 Oct;11(10):416–7 (0 ref.)
[Internet—an introduction not only for the physician] Schäfer N. **Z Arztl Fortbild (Jena)** 1996 Feb;90(1):33–42 (21 ref.) (Eng. Abstr.) **(Ger)**
[A pediatrician's guide to the Internet] Dollberg S. **Harefuah** 1995 Dec 15;129(12):559–64 (1 ref.) **(Heb)**
[The Internet and clinical medicine. An introduction to the biomedical information services available in electronic form on the "net of all nets"] Tringali M, et al. **Recenti Prog Med** 1996 May;87(5):237–49 (11 ref.) (Eng. Abstr.) **(Ita)**
[Toward virtual life from bioinformatics] Sugawara H. **Tanpakushitsu Kakusan Koso** 1995 Sep;40(12):1809–21 (15 ref.) **(Jpn)**

CLASSIFICATION

Exploring the functions of World Wide Web–based electronic medical record systems [see comments] Kohane IS. **MD Comput** 1996 Jul–Aug;13(4):339–46 (28 ref.) Comment in: MD Comput 1996 Jul–Aug;13(4):295–7.

ORGANIZATION & ADMINISTRATION

Computers and networks in medical and healthcare systems. Egan GF, et al. **Comput Biol Med** 1995 May;25(3):355–65 (25 ref.)
Creating a nursing home page on the World Wide Web. Shellenbarger T, et al. **Comput Nurs** 1996 Jul–Aug; 14(4):239–45 (15 ref.)
Exploring the functions of World Wide Web–based electronic medical record systems [see comments] Kohane IS. **MD Comput** 1996 Jul–Aug;13(4):339–46 (28 ref.) Comment in: MD Comput 1996 Jul–Aug;13(4):295–7.

COMPUTER DATA PROCESSING see **AUTOMATIC DATA PROCESSING**

COMPUTER GRAPHICS

MRC image processing programs. Crowther RA, et al. **J Struct Biol** 1996 Jan–Feb;116(1):9–16 (31 ref.)
A new representation of knowledge concerning human anatomy and function. Höhne KH, et al. **Nat Med** 1995 Jun;1(6):506–11 (33 ref.)
Image representations for visual learning. Beymer D, et al. **Science** 1996 Jun 28;272(5270):1905–9 (61 ref.)

COMPUTER HARDWARE see **COMPUTERS**

COMPUTER LITERACY

[Internet—an introduction not only for the physician] Schäfer N. **Z Arztl Fortbild (Jena)** 1996 Feb;90(1):33–42 (21 ref.) (Eng. Abstr.) **(Ger)**

COMPUTER MODELS see **COMPUTER SIMULATION**

COMPUTER NETWORK MANAGEMENT see **COMPUTER COMMUNICATION NETWORKS**

COMPUTER PERIPHERALS

ABC of medical computing. Adaptive computer technology. Poole CJ, et al. **BMJ** 1995 Oct 28;311(7013):1149–51 (0 ref.)
[PC applications in routine practice, science and teaching. What computer peripherals are useful?] Knopp MV, et al. **Radiologe** 1995 Sep;35(9):620–4 (3 ref.) (Eng. Abstr.) **(Ger)**

COMPUTER PROGRAMS see **SOFTWARE**

COMPUTER REASONING see **ARTIFICIAL INTELLIGENCE**

COMPUTER SECURITY

Privacy, confidentiality, and electronic medical records. Barrows RC Jr, et al. **J Am Med Inform Assoc** 1996 Mar–Apr;3(2):139–48 (42 ref.)
Confidentiality of HIV medical records: the computer age. Byrd CM, et al. **Prog Cardiovasc Nurs** 1995 Fall; 10(4):39–43, 45 (17 ref.)

COMPUTER SIMULATION

see related
MODELS, THEORETICAL

New computational models of the respiratory oscillator in mammals. Smith JC. **Adv Exp Med Biol** 1995;393:7–13 (10 ref.)
Control of intermittent ventilation in lower vertebrates. A computer dynamic model. Topor ZL, et al. **Adv Exp Med Biol** 1995;393:21–2 (4 ref.)
A spinal circuitry simulator as a teaching tool for neuromuscular physiology. Maw S, et al. **Am J Physiol** 1996 Jun;270(6 Pt 3):S50–68 (25 ref.)
A computer model of prefrontal cortex function. Levinson R. **Ann N Y Acad Sci** 1995 Dec 15;769:381–8 (9 ref.)
Computer modeling of adaptive depression. Webster C. **Behav Sci** 1995 Oct;40(4):314–30 (52 ref.)
Simulations of enzymic reactions. Mulholland AJ, et al. **Biochem Soc Trans** 1996 Feb;24(1):247–54 (56 ref.)
Brownian dynamics simulations of enzyme–substrate encounter. Wade RC. **Biochem Soc Trans** 1996 Feb; 24(1):254–9 (29 ref.)
Virtual reality in anaesthesia. Burt DE. **Br J Anaesth** 1995 Oct;75(4):472–80 (20 ref.)
Biophysical aspects and modelling of ciliary motility. Holwill ME, et al. **Cell Motil Cytoskeleton** 1995;32(2):114–20 (31 ref.)
Modeling mutations and homologous proteins. Sali A. **Curr Opin Biotechnol** 1995 Aug;6(4):437–51 (222 ref.)
Modeling protein–ligand complexes. Bamborough P, et al. **Curr Opin Struct Biol** 1996 Apr;6(2):236–41 (54 ref.)
Novel methods for molecular dynamics simulations. Elber R. **Curr Opin Struct Biol** 1996 Apr;6(2):232–5 (29 ref.)
Structure–derived potentials and protein simulations. Jernigan RL, et al. **Curr Opin Struct Biol** 1996 Apr; 6(2):195–209 (92 ref.)
Mean–field minimization methods for biological macromolecules. Koehl P, et al. **Curr Opin Struct Biol** 1996 Apr;6(2):222–6 (36 ref.)
Simulating DNA at low resolution. Olson WK. **Curr Opin Struct Biol** 1996 Apr;6(2):242–56 (76 ref.)
Modeling side–chain conformation. Vásquez M. **Curr Opin Struct Biol** 1996 Apr;6(2):217–21 (53 ref.)
A computer model for time–based simulation of electrophoresis systems with freely defined initial and boundary conditions. Schafer–Nielsen C. **Electrophoresis** 1995 Aug;16(8):1369–76 (13 ref.)
Protein folding by a biased Monte Carlo procedure in the dihedral angle space. Lee B, et al. **FASEB J** 1996 Jan; 10(1):119–25 (43 ref.)
Simulation of spatial learning in the Morris water maze by a neural network model of the hippocampal formation and nucleus accumbens. Brown MA, et al. **Hippocampus** 1995; 5(3):171–88 (73 ref.)
Computer models: killing mosquitoes with information. Roberts FC. **J Am Mosq Control Assoc** 1995 Jun;11(2 Pt 2):284–9 (10 ref.)
Computer simulation of the upper extremities. Buford WL Jr, et al. **J Hand Ther** 1995 Apr–Jun;8(2):167–74 (33 ref.)
Simulation modelling for resource allocation and planning in the health sector. Lehaney B, et al. **J R Soc Health** 1995 Dec;115(6):382–5 (47 ref.)
Advances in computational image processing for microscopy. Carragher B, et al. **J Struct Biol** 1996 Jan–Feb;116(1):2–8 (35 ref.)
The micrograph data processing program. Smith PR, et al. **J Struct Biol** 1996 Jan–Feb;116(1):35–40 (28 ref.)
A new generation of the IMAGIC image processing system. van Heel M, et al. **J Struct Biol** 1996 Jan–Feb;116(1):17–24 (58 ref.)
Mathematical and computer models in epidemiology. Massad E. **MD Comput** 1996 Mar–Apr;13(2):147–54 (31 ref.)
A new representation of knowledge concerning human anatomy and function. Höhne KH, et al. **Nat Med** 1995 Jun;1(6):506–11 (33 ref.)
The cost of managing lung cancer in Canada. Evans WK, et al. **Oncology (Huntingt)** 1995 Nov;9(11 Suppl):147–53 (37 ref.)
Current techniques in three–dimensional CT simulation and radiation treatment planning. Stephenson JA, et al. **Oncology (Huntingt)** 1995 Nov;9(11):1225–32, 1235; discussion 1235–40 (26 ref.)
Cyclosporine–induced apoptosis in CD4+ T lymphocytes and computer–simulated analysis: modeling a treatment scenario for HIV infection. Huss R, et al. **Res Immunol** 1995 Feb;146(2):101–8 (32 ref.)
Effects of local connectivity on striatal function: stimulation and analysis of a model. Wickens JR, et al. **Synapse** 1995 Aug;20(4):281–98 (84 ref.)
Medicine in virtual environments. Dumay AC. **Technol Health Care** 1995 Oct;3(2):75–89 (87 ref.)
Physiologically based pharmacokinetic models: mathematical fundamentals and simulation implementations. Hoang K. **Toxicol Lett** 1995 Sep;79(1–3):99–106 (20 ref.)
Structure–activity relationships and computer–assisted analysis of respiratory sensitization potential. Karol MH, et al. **Toxicol Lett** 1996 Aug;86(2–3):187–91 (10 ref.)
Role of computational chemistry in support of hazard identification (ID): mechanism–based SARs. Richard AM. **Toxicol Lett** 1995 Sep;79(1–3):115–22 (31 ref.)
Toxicity prediction from metabolic pathway modelling. Jackson RC. **Toxicology** 1995 Sep 1;102(1–2):197–205 (23 ref.)
Computer modeling in urology. Kattan MW, et al. **Urology** 1996 Jan;47(1):14–21 (33 ref.)
Computer modeling of prototypic and aberrant nucleocapsids of varicella–zoster virus. Grose C, et al. **Virology** 1995 Dec 20;214(2):321–9 (24 ref.)
Natural problems for stereoscopic depth perception in virtual environments. Wann JP, et al. **Vision Res** 1995 Oct; 35(19):2731–6 (23 ref.)
[Evaluation of the proliferative potential of residual tumor. Verification of parametric methods by computer simulation] Ivankov AA, et al. **Vopr Onkol** 1996;42(1):34–9 (14 ref.) **(Rus)**

COMPUTER SOFTWARE see **SOFTWARE**

COMPUTER STORAGE DEVICES

Image storage. Venables CW. **Gastroenterologist** 1995 Dec; 3(4):268–72 (7 ref.)
Digital storage and transmission of cardiovascular images: what are the costs, benefits and timetable for conversion? Thomas JD, et al. **Heart** 1996 Jul;76(1):13–7 (13 ref.)

COMPUTER SYSTEMS

Closing the clinical laboratory testing loop with information technology. Connelly DP, et al. **Am J Clin Pathol** 1996 Apr;105(4 Suppl 1):S40–7 (23 ref.)
ABC of medical computing. Computers in general practice—II [see comments] Millman A, et al. **BMJ** 1995 Sep 30;311(7009):864–7 (0 ref.) Comment in: BMJ 1996 Jan 27;312(7025):254.
ABC of medical computing. Computers in general practice—III. Millman A, et al. **BMJ** 1995 Oct 7; 311(7010):938–41 (0 ref.)
Virtual reality in anaesthesia. Burt DE. **Br J Anaesth** 1995 Oct;75(4):472–80 (20 ref.)
Principles of development and design of microsystems. Wagner B. **Endosc Surg Allied Technol** 1995 Aug;3(4):204–9 (26 ref.)
Deciding among interactive multimedia technologies. Locatis C. **J Biocommun** 1995;22(2):2–7 (20 ref.)
Validation of computer–related systems.Parenteral Drug Association. **PDA J Pharm Sci Technol** 1995 Jan–Feb;49 Suppl 1:S1–17 (41 ref.)
Radiology systems architecture. Deibel SR, et al. **Radiol Clin North Am** 1996 May;34(3):681–96 (17 ref.)
[Computer systems in medical practice. I. The aims, difficulties and implementation of computerization in health care organizations] Michalak J. **Med Pr** 1995;46(5):509–16 (12 ref.) (Eng. Abstr.) **(Pol)**

ECONOMICS

What value do computers provide to NHS hospitals? [see comments] Lock C. **BMJ** 1996 Jun 1;312(7043):1407–10 (65 ref.) Comment in: BMJ 1996 Jun 1;312(7043):1371–2.

UTILIZATION

ABC of medical computing. Using computers in clinical audit. Kinn S, et al. **BMJ** 1995 Sep 16;311(7007):739–42 (0 ref.)
Has general practitioner computing made a difference to patient care? A systematic review of published reports. Sullivan F, et al. **BMJ** 1995 Sep 30;311(7009):848–52 (56 ref.)

COMPUTER SYSTEMS DEVELOPMENT see **COMPUTER SYSTEMS**

COMPUTER SYSTEMS EVALUATION see **COMPUTER SYSTEMS**

COMPUTER SYSTEMS ORGANIZATION see **COMPUTER SYSTEMS**

COMPUTER TERMINALS

Magnetic fields of video display terminals and pregnancy outcome. Lindbohm ML, et al. **J Occup Environ Med** 1995 Aug;37(8):952–6 (30 ref.)

COMPUTER USER TRAINING

Creating a nursing home page on the World Wide Web. Shellenbarger T, et al. **Comput Nurs** 1996 Jul–Aug; 14(4):239–45 (15 ref.)

COMPUTER VIRUSES see **COMPUTER SECURITY**

COMPUTER VISION SYSTEMS see **ARTIFICIAL INTELLIGENCE**

COMPUTERIZED EMISSION TOMOGRAPHY see **TOMOGRAPHY, EMISSION-COMPUTED**

COMPUTERIZED MEDICAL RECORDS SYSTEMS see **MEDICAL RECORDS SYSTEMS, COMPUTERIZED**

COMPUTERIZED TOMOGRAPHY, X-RAY see **TOMOGRAPHY, X-RAY COMPUTED**

COMPUTERS

see related
ATTITUDE TO COMPUTERS
AUTOMATIC DATA PROCESSING

The promise of computerized feedback systems for diabetes care. McDonald CJ, et al. **Ann Intern Med** 1996 Jan 1;124(1 Pt 2):170–4 (37 ref.)
Psychophysiology and adaptive automation. Byrne EA, et al. **Biol Psychol** 1996 Feb 5;42(3):249–68 (75 ref.)
ABC of medical computing. Computers in general practice—I. Millman A, et al. **BMJ** 1995 Sep 23; 311(7008):800–2 (0 ref.)
ABC of medical computing. Keeping your computer healthy and legal. Millman A. **BMJ** 1995 Nov 11;311(7015):1289–93 (0 ref.)
Intravenous drug delivery systems: toward an intravenous "vaporizer". Egan TD. **J Clin Anesth** 1996 May;8(3 Suppl):8S–14S (38 ref.)
Specifying dual-detector gamma cameras and associated computer systems. Tindale WB. **Nucl Med Commun** 1995 Jul;16(7):534–8 (4 ref.)
Limits of natural science: brain research and computers. Stieve H. **Z Naturforsch [C]** 1995 May–Jun;50(5–6):317–36 (86 ref.)
[Technology for the diagnosis and rehabilitation of patients with dysphonia] Vilkman E, et al. **Duodecim** 1995; 111(6):549–53 (10 ref.) **(Fin)**

COMPUTERS, DIGITAL see **COMPUTERS**

COMPUTERS, PERSONAL see **MICROCOMPUTERS**

CONCENTRATION see **ATTENTION**

CONCEPT FORMATION

Origins and early development of perception, action, and representation. Bertenthal BI. **Annu Rev Psychol** 1996; 47:431–59 (150 ref.)

CONCEPTION see **FERTILIZATION**

CONCHAE NASALES see **TURBINATES**

CONCURRENT REVIEW

ORGANIZATION & ADMINISTRATION

Appropriateness of admissions: the French experience. Lang T, et al. **Int J Qual Health Care** 1995 Sep;7(3):233–8 (16 ref.)

CONCURRENT STUDIES see **COHORT STUDIES**

CONDITIONING (PSYCHOLOGY)

PHYSIOLOGY

The use of conditioning to probe for CNS pathways that regulate fever and NK cell activity. Hiramoto R, et al. **Int J Neurosci** 1996 Feb;84(1–4):229–45 (55 ref.)
Delayed protection of the heart against ischaemia. Parratt JR, et al. **Trends Pharmacol Sci** 1995 Oct;16(10):351–5 (52 ref.)

CONDITIONING, CLASSICAL

Mechanisms of conditioned immunomodulation. Lysle DT, et al. **Int J Immunopharmacol** 1995 Aug;17(8):641–7 (54 ref.)
Models, mechanisms and management of anticipatory nausea and emesis. Morrow GR, et al. **Oncology** 1996 Jun;53 Suppl 1:4–7 (12 ref.)

PHYSIOLOGY

A computational model of cholinergic disruption of septohippocampal activity in classical eyeblink conditioning. Myers CE, et al. **Neurobiol Learn Mem** 1996 Jul;66(1):51–66 (90 ref.)
[The development of I. P. Pavlov's concepts of the food center] Kassil' VG. **Fiziol Zh Im I M Sechenova** 1995 Nov; 81(11):18–29 (49 ref.) **(Rus)**
[The role of subcortical structures in the conditioning process] Suvorov NF. **Fiziol Zh Im I M Sechenova** 1995 Nov;81(11):82–93 (54 ref.) **(Rus)**
[The temporal factors in behavioral response conditioning] Zieliński K. **Fiziol Zh Im I M Sechenova** 1995 Nov; 81(11):30–42 (53 ref.) **(Rus)**

CONDITIONING, EYELID

PHYSIOLOGY

A computational model of cholinergic disruption of septohippocampal activity in classical eyeblink conditioning. Myers CE, et al. **Neurobiol Learn Mem** 1996 Jul;66(1):51–66 (90 ref.)

CONDITIONING, OPERANT

PHYSIOLOGY

Repeated acquisition of response sequences: the analysis of behavior in transition. Cohn J, et al. **Neurosci Biobehav Rev** 1995 Fall;19(3):397–406 (46 ref.)
Neurobiological mechanisms underlying the acquisition and expression of incentive motivation by cocaine-associated stimuli: relationship to craving. Pert A. **NIDA Res Monogr** 1994;145:163–90 (70 ref.)
Amygdala role in conditioned associative learning. Ono T, et al. **Prog Neurobiol** 1995 Jul;46(4):401–22 (142 ref.)

CONDITIONING THERAPY see **BEHAVIOR THERAPY**

CONDOMS

The male polyurethane condom: a review of current knowledge. Rosenberg MJ, et al. **Contraception** 1996 Mar; 53(3):141–6 (18 ref.)
Condom availability and prevention issues for adolescents. Spingarn RW. **Curr Opin Pediatr** 1995 Aug;7(4):360–5 (53 ref.)
[Effectiveness of condoms in the prevention of HIV infection in partners of seropositive subjects] Guillén Grima F, et al. **Med Clin (Barc)** 1995 Oct 28;105(14):541–8 (99 ref.) **(Spa)**

STANDARDS

Interaction of condom design and user techniques and condom acceptability. Gerofi J, et al. **Contraception** 1995 Oct;52(4):223–8 (8 ref.)

STATISTICS & NUMERICAL DATA

Condom use among female commercial sex workers in Nevada's legal brothels [see comments] Albert AE, et al. **Am J Public Health** 1995 Nov;85(11):1514–20 (50 ref.) Comment in: Am J Public Health 1995 Nov;85(11):1485–8.

UTILIZATION

Interaction of condom design and user techniques and condom acceptability. Gerofi J, et al. **Contraception** 1995 Oct;52(4):223–8 (8 ref.)
Adolescent condom use, the health belief model, and the prevention of sexually transmitted disease. Hiltabiddle SJ. **J Obstet Gynecol Neonatal Nurs** 1996 Jan;25(1):61–6 (36 ref.)

CONDUCT DISORDERS, CHILD see **CHILD BEHAVIOR DISORDERS**

CONDUCTION-BLOCKING ANESTHETICS see **ANESTHETICS, LOCAL**

CONDYLOMATA ACUMINATA

COMPLICATIONS

[A Buschke and Lowenstein tumor in a female patient] Reichenbach I, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(5):491–5 (16 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Condyloma acuminatum of the bladder: radiologic findings. Levine CD, et al. **AJR Am J Roentgenol** 1995 Dec; 165(6):1467–8 (3 ref.)
[Condylomata acuminata in children: a case report, update and management protocol] Niguez Carbonell JC, et al. **An Esp Pediatr** 1996 Mar;44(3):292–4 (20 ref.) **(Spa)**

DRUG THERAPY

Podophyllotoxin in the treatment of genital warts. Beutner KR. **Curr Probl Dermatol** 1996;24:227–32 (23 ref.)

ETIOLOGY

Human papilloma virus infection of the vulva. Beutner KR. **Semin Dermatol** 1996 Mar;15(1):2–7 (63 ref.)

PATHOLOGY

Perianal lymphangioma circumscriptum mistaken for genital warts. Darmstadt GL. **Pediatrics** 1996 Sep;98(3 Pt 1):461–3 (18 ref.)
Risk of dysplasia in anal condyloma. Metcalf AM, et al. **Surgery** 1995 Oct;118(4):724–6 (14 ref.)

THERAPY

Current therapy for recurrent and extensive anal warts. Congilosi SM, et al. **Dis Colon Rectum** 1995 Oct; 38(10):1101–7 (51 ref.)
Medical therapy of genital human papilloma virus-related disease. Lacey CJ, et al. **Int J STD AIDS** 1995 Nov–Dec; 6(6):399–407 (45 ref.)
Identifying and treating genital warts. Woolley P. **Practitioner** 1995 Sep;239(1554):542–6 (11 ref.)

CONE PHOTORECEPTORS see **CONES (RETINA)**

CONES (RETINA)

PHYSIOLOGY

Ca2+ flux in retinal rod and cone outer segments: differences in Ca2+ selectivity of the cGMP-gated ion channels and Ca2+ clearance rates. Korenbrot JI. **Cell Calcium** 1995 Oct;18(4):285–300 (75 ref.)
Rods, cones and calcium. McNaughton PA. **Cell Calcium** 1995 Oct;18(4):275–84 (66 ref.)
Primate photopigments and primate color vision. Jacobs GH. **Proc Natl Acad Sci U S A** 1996 Jan 23;93(2):577–81 (61 ref.)

CONFERENCES see **CONGRESSES**

CONFIDENCE INTERVALS

Euclidean distance matrix analysis: confidence intervals for form and growth differences. Lele S, et al. **Am J Phys Anthropol** 1995 Sep;98(1):73–86 (28 ref.)

CONFIDENTIALITY

Genetic privacy: from the laboratory to the legislature. Andrews LB. **Genome Res** 1995 Oct;5(3):209–13 (17 ref.)
Confidentiality in group psychotherapy: empirical findings and the law. Roback HB, et al. **Int J Group Psychother** 1996 Jan;46(1):117–35 (38 ref.)
Privacy, confidentiality, and electronic medical records. Barrows RC Jr, et al. **J Am Med Inform Assoc** 1996 Mar–Apr;3(2):139–48 (42 ref.)
Childhood immunization registries. A national review of public health information systems and the protection of privacy [see comments] Gostin LO, et al. **JAMA** 1995 Dec 13;274(22):1793–9 (76 ref.) Comment in: JAMA 1996 May 1;275(17):1312–3.

LEGISLATION & JURISPRUDENCE

Preserving confidentiality in occupational medical practice. McCunney RJ. **Am Fam Physician** 1996 Apr;53(5):1751–60 (19 ref.)
In camera inspections of privileged records in sexual assault trials: balancing defendants' rights and state interests under Massachusetts's Bishop Test. Crowley EM. **Am J Law Med** 1995;21(1):131–64 (313 ref.)
Confidentiality of HIV medical records: the computer age. Byrd CM, et al. **Prog Cardiovasc Nurs** 1995 Fall; 10(4):39–43, 45 (17 ref.)
[Is legislation needed in the treatment of infertility? (editorial)] Hovatta O. **Duodecim** 1994;110(2):123–6 (11 ref.) **(Fin)**

CONFLICT (PSYCHOLOGY)

Management of conflict: do nurses/women handle it differently? Valentine PE. **J Adv Nurs** 1995 Jul;22(1):142–9 (77 ref.)
Behavioral treatment of depression in the context of marital discord. Beach SR, et al. **Prog Behav Modif** 1996;30:99–122 (110 ref.)

CONFLICT OF INTEREST

LEGISLATION & JURISPRUDENCE

Medical futility and implications for physician autonomy. Daar JF. **Am J Law Med** 1995;21(2–3):221–40 (117 ref.)
Conflicts of interest in Canadian health care law. Dickens BM. **Am J Law Med** 1995;21(2–3):259–80 (152 ref.)
Strains in the fiduciary metaphor: divided physician loyalties and obligations in a changing health care system. Rodwin MA. **Am J Law Med** 1995;21(2–3):241–57 (108 ref.)
Medicaid physician participation: patients, poverty, and physician self-interest. Watson SD. **Am J Law Med** 1995; 21(2–3):191–220 (232 ref.)

CONFOCAL MICROSCOPY see **MICROSCOPY, CONFOCAL**

CONFOCAL MICROSCOPY, SCANNING LASER see **MICROSCOPY, CONFOCAL**

CONFORMITY, SOCIAL see **SOCIAL CONFORMITY**

CONFOUNDING FACTORS (EPIDEMIOLOGY)

Adjusting survival curves for confounders: a review and a new method. Nieto FJ, et al. **Am J Epidemiol** 1996 May 15;143(10):1059–68 (25 ref.)
Matching. Costanza MC. **Prev Med** 1995 Sep;24(5):425–33 (14 ref.)

CONFUSION

DIAGNOSIS

[A diabetic woman with a picture of temporospatial disorientation, nausea and vomiting] Urbano García J, et al. **Rev Clin Esp** 1996 May;196(5):333–4, 338 (6 ref.) **(Spa)**

[Confusional states in the elderly—an underdiagnosed syndrome with a poor prognosis] Pitkälä K. **Nord Med** 1996 Jun;111(6):184–8 (15 ref.) (Eng. Abstr.) **(Swe)**

ETIOLOGY

Sundown syndrome: etiology and management. Burney-Puckett M. **J Psychosoc Nurs Ment Health Serv** 1996 May;34(5):40–3 (15 ref.)

Cryptococcal meningitis and confusional psychosis. A case report and literature review. Sa'adah MA, et al. **Trop Geogr Med** 1995;47(5):224–6 (20 ref.)

NURSING

Nursing strategies for acute confusion in elders. Foreman MD, et al. **Am J Nurs** 1996 Apr;96(4):44–51; quiz 51–2 (17 ref.)

PSYCHOLOGY

Possible mechanisms for reducing memory confusion during sleep. Gardner-Medwin AR, et al. **Behav Brain Res** 1995 Jul-Aug;69(1-2):167–75 (24 ref.)

THERAPY

Sundown syndrome: etiology and management. Burney-Puckett M. **J Psychosoc Nurs Ment Health Serv** 1996 May;34(5):40–3 (15 ref.)

[Effectiveness of validation. A literature study] Schrijnemaekers VJ, et al. **Tijdschr Gerontol Geriatr** 1995 Oct;26(5):205–13 (37 ref.) (Eng. Abstr.) **(Dut)**

CONGENITAL DEFECTS see **ABNORMALITIES**

CONGENITAL ICHTHYOSIFORM ERYTHRODERMA see **ICHTHYOSIFORM ERYTHRODERMA, CONGENITAL**

CONGESTIVE CARDIOMYOPATHY see **CARDIOMYOPATHY, CONGESTIVE**

CONGRESSES

The U.S.-Japan Cooperative Cancer Research Program: some highlights of seminars, interdisciplinary program area, 1981–1996. Miller RW. **Jpn J Cancer Res** 1996 Mar; 87(3):221–6 (20 ref.)

STANDARDS

Drug companies and continuing medical education. Bickell NA. **J Gen Intern Med** 1995 Jul;10(7):392–4 (9 ref.)

CONISATION see **CONIZATION**

CONIZATION

METHODS

Adequacy of conization margins in adenocarcinoma in situ of the cervix as a predictor of residual disease. Im DD, et al. **Gynecol Oncol** 1995 Nov;59(2):179–82 (20 ref.)

CONJUGATED ESTROGENS see **ESTROGENS, CONJUGATED**

CONJUGATION, GENETIC

DNA processing reactions in bacterial conjugation. Lanka E, et al. **Annu Rev Biochem** 1995;64:141–69 (187 ref.)

Conjugative transposition. Scott JR, et al. **Annu Rev Microbiol** 1995;49:367–97 (108 ref.)

The conjugative transposon Tn916 of Enterococcus faecalis: structural analysis and some key factors involved in movement. Clewell DB, et al. **Dev Biol Stand** 1995;85:11–7 (28 ref.)

In the driver's seat: the Bacteroides conjugative transposons and the elements they mobilize. Salyers AA, et al. **J Bacteriol** 1995 Oct;177(20):5727–31 (22 ref.)

CONJUNCTIVA

ANATOMY & HISTOLOGY

Conjunctiva. Nichols BA. **Microsc Res Tech** 1996 Mar 1; 33(4):296–319 (61 ref.)

BLOOD SUPPLY

Visualization of microcirculatory disorders in haemorrhagic fever with renal syndrome. Sirotin BZ, et al. **Nephrol Dial Transplant** 1996 Apr;11(4):721–2 (6 ref.)

[State of microcirculation in the bulbar conjunctiva in retinal thrombosis of patients with hypertension and diabetes mellitus] Polunin GS, et al. **Vesta Oftalmol** 1996 Jan-Mar; 112(1):51–3 (60 ref.) **(Rus)**

CONJUNCTIVAL DISEASES

PATHOLOGY

Pathological case of the month. Synthetic fiber granuloma (Teddy Bear Granuloma). Lueder GT, et al. **Arch Pediatr Adolesc Med** 1996 Mar;150(3):327–8 (5 ref.)

VETERINARY

Diagnosis and treatment of conjunctival and corneal diseases. Nasisse MP. **Vet Q** 1995 Apr;17 Suppl 1:S42–3 (0 ref.)

CONJUNCTIVAL NEOPLASMS

GENETICS

[A familial form of epidermoid carcinoma of the conjunctiva] Lam A, et al. **J Fr Ophtalmol** 1996;19(2):143–8 (25 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

[Epithelial-cystic nevus of the conjunctiva (Parinaud's dermo-epithelioma)] Cernea P, et al. **Oftalmologia** 1996 Jan-Mar;40(1):58–62 (8 ref.) (Eng. Abstr.) **(Rum)**

CONJUNCTIVITIS

DIAGNOSIS

[Diagnosis and treatment of conjunctivitis] Ehlers N, et al. **Nord Med** 1996 Mar;111(3):74–6, 83 (15 ref.) (Eng. Abstr.) **(Dan)**

DRUG THERAPY

[Diagnosis and treatment of conjunctivitis] Ehlers N, et al. **Nord Med** 1996 Mar;111(3):74–6, 83 (15 ref.) (Eng. Abstr.) **(Dan)**

ETIOLOGY

[Arachnids as risk factors in occupational exposure] Dutkiewicz J. **Wiad Parazytol** 1995;41(3):253–66 (48 ref.) (Eng. Abstr.) **(Pol)**

PATHOLOGY

Infections of the eyelid, lacrimal system, conjunctiva, and cornea. Durand M, et al. **Curr Clin Top Infect Dis** 1996; 16:125–50 (150 ref.)

THERAPY

Low-dose methotrexate as an adjunctive therapy with surgery for ectropion complicating dermatomyositis. Abernethy ML, et al. **Dermatology** 1996;192(2):153–5 (14 ref.)

CONJUNCTIVITIS, ALLERGIC

Vernal keratoconjunctivitis. Colby K, et al. **Int Ophthalmol Clin** 1996 Winter;36(1):15–20 (26 ref.)

DRUG THERAPY

A critical look at ocular allergy drugs. Joseph Titi M. **Am Fam Physician** 1996 Jun;53(8):2637–42, 2645–6 (22 ref.)

Lodoxamide in vernal keratoconjunctivitis. Lee S, et al. **Ann Pharmacother** 1996 May;30(5):535–7 (19 ref.)

A review of the causes and treatment of bacterial and allergic conjunctivitis. Friedlaender MH. **Clin Ther** 1995 Sep–Oct; 17(5):800–10; discussion 779 (213 ref.)

Therapeutic options in ocular allergic disease. Hingorani M, et al. **Drugs** 1995 Aug;50(2):208–21 (167 ref.)

Levocabastine. An update of its pharmacology, clinical efficacy and tolerability in the topical treatment of allergic rhinitis and conjunctivitis. Noble S, et al. **Drugs** 1995 Dec; 50(6):1032–49 (60 ref.)

ETIOLOGY

A review of the causes and treatment of bacterial and allergic conjunctivitis. Friedlaender MH. **Clin Ther** 1995 Sep–Oct; 17(5):800–10; discussion 779 (213 ref.)

THERAPY

Management of ocular allergy. Friedlaender MH. **Ann Allergy Asthma Immunol** 1995 Sep;75(3):212–22; quiz 223–4 (64 ref.)

Atopic disease, rhinitis and conjunctivitis, and upper respiratory infections. Wood RA, et al. **Curr Opin Pediatr** 1995 Oct;7(5):615–27 (63 ref.)

CONJUNCTIVITIS, ATOPIC see **CONJUNCTIVITIS, ALLERGIC**

CONJUNCTIVITIS, BACTERIAL

[Diagnosis and treatment of conjuncitivitis] Ehlers N, et al. **Ugeskr Laeger** 1996 Jan 1;158(1):34–7 (20 ref.) (Eng. Abstr.) **(Dan)**

DRUG THERAPY

A review of the causes and treatment of bacterial and allergic conjunctivitis. Friedlaender MH. **Clin Ther** 1995 Sep–Oct; 17(5):800–10; discussion 779 (213 ref.)

ETIOLOGY

A review of the causes and treatment of bacterial and allergic conjunctivitis. Friedlaender MH. **Clin Ther** 1995 Sep–Oct; 17(5):800–10; discussion 779 (213 ref.)

CONJUNCTIVITIS, GIANT PAPILLARY see **CONJUNCTIVITIS, ALLERGIC**

CONJUNCTIVITIS, MUCOPURULENT see **CONJUNCTIVITIS, BACTERIAL**

CONJUNCTIVITIS, PURULENT see **CONJUNCTIVITIS, BACTERIAL**

CONJUNCTIVITIS, VERNAL see **CONJUNCTIVITIS, ALLERGIC**

CONJUNCTIVITIS, VIRAL

[Diagnosis and treatment of conjuncitivitis] Ehlers N, et al. **Ugeskr Laeger** 1996 Jan 1;158(1):34–7 (20 ref.) (Eng. Abstr.) **(Dan)**

CONNECTING PEPTIDE see **C-PEPTIDE**

CONNECTIONIST MODELS see **NEURAL NETWORKS (COMPUTER)**

CONNECTIVE TISSUE

see related
CELLULITIS
COLLAGEN

CHEMISTRY

Fibrillin-containing microfibrils: structure and function in health and disease. Kielty CM, et al. **Int J Biochem Cell Biol** 1995 Aug;27(8):747–60 (70 ref.)

CYTOLOGY

Induction of soft connective tissue formation by various prosthetic implants. Oryan A. **Transplant Proc** 1995 Oct; 27(5):2754–5 (23 ref.)

DRUG EFFECTS

Effects of streptozotocin-induced diabetes on postpneumonectomy lung growth and connective tissue levels. Ofulue AF, et al. **Pediatr Pulmonol** 1995 Jun; 19(6):365–70 (29 ref.)

GROWTH & DEVELOPMENT

Biomechanics of soft-tissue growth and remodeling with plaster casting. Bell-Krotoski JA, et al. **J Hand Ther** 1995 Apr-Jun;8(2):131–7 (16 ref.)

METABOLISM

Connective tissue metabolism including cytokines in scleroderma. Postlethwaite AE. **Curr Opin Rheumatol** 1995 Nov;7(6):535–40 (41 ref.)

PHYSIOLOGY

Interactions of connective tissue cells with the extracellular matrix. Horton MA. **Bone** 1995 Aug;17(2 Suppl):51S–53S (20 ref.)

Mechanosensitive connective tissue: potential influence on heart rhythm. Kohl P, et al. **Cardiovasc Res** 1996 Jul; 32(1):62–8 (63 ref.)

Role of collagen in soft connective tissue wound healing. Oryan A. **Transplant Proc** 1995 Oct;27(5):2759–61 (34 ref.)

PHYSIOPATHOLOGY

Role of collagen in soft connective tissue wound healing. Oryan A. **Transplant Proc** 1995 Oct;27(5):2759–61 (34 ref.)

RADIATION EFFECTS

Initiation of non-neoplastic late effects: the role of endothelium and connective tissue. Rezvani M, et al. **Stem Cells (Dayt)** 1995 May;13 Suppl 1:248–56 (72 ref.)

RADIOGRAPHY

[Imaging of connective tissue formations of the sub-umbilical anterior abdominal wall] Roy C, et al. **Ann Radiol (Paris)** 1995;38(7-8):389–95 (20 ref.) (Eng. Abstr.) **(Fre)**

CONNECTIVE TISSUE DISEASE, MIXED see **MIXED CONNECTIVE TISSUE DISEASE**

CONNECTIVE TISSUE DISEASES

see related
BONE DISEASES, DEVELOPMENTAL

COLLAGEN DISEASES

The connective tissue diseases and the overall influence of gender. Lahita RG. **Int J Fertil Menopausal Stud** 1996 Mar-Apr;41(2):156-65 (121 ref.)

CHEMICALLY INDUCED

Silicone breast implants and connective-tissue diseases [editorial; comment] Valesini G, et al. **Clin Exp Rheumatol** 1995 Jul-Aug;13(4):421-3 (18 ref.) Comment on: Clin Exp Rheumatol 1995 Jul-aug;13(4):521-3.

A critical assessment of the relationship between silicone breast implants and connective tissue diseases. Wong O. **Regul Toxicol Pharmacol** 1996 Feb;23(1 Pt 1):74-85 (60 ref.)

CLASSIFICATION

[Mixed connective tissue disease -- thirty three years of uncertainty] George J, et al. **Harefuah** 1996 Jan 15; 130(2):99-104 (37 ref.) **(Heb)**

COMPLICATIONS

Vasculitis associated with connective tissue disorders. Bacon PA, et al. **Rheum Dis Clin North Am** 1995 Nov; 21(4):1077-96 (107 ref.)

Gastrointestinal manifestations of collagen-vascular diseases. Bassel K, et al. **Semin Gastrointest Dis** 1995 Oct;6(4):228-40 (124 ref.)

[Systemic diseases and infections: current questions] Lortholary O, et al. **Presse Med** 1996 Mar 2-9;25(8):370-5, 377-8 (96 ref.) (Eng. Abstr.) **(Fre)**

CONGENITAL

Congenital contractural arachnodactyly. Kulkarni ML, et al. **Indian Pediatr** 1995 Jan;32(1):82-7 (14 ref.)

DIAGNOSIS

Overlapping syndromes, undifferentiated connective tissue disease, and other fibrosing conditions. Kallenberg CG. **Curr Opin Rheumatol** 1995 Nov;7(6):568-73 (42 ref.)

Significance of the anti-Ro (SS-A) antibody in evaluation of patients with cutaneous manifestations of a connective tissue disease. Provost TT, et al. **J Am Acad Dermatol** 1996 Aug;35(2 Pt 1):147-69; quiz 170-2 (213 ref.)

Reflex sympathetic dystrophy. Cooke E. **Practitioner** 1995 Sep;239(1554):521-3 (2 ref.)

ETIOLOGY

Silica-associated connective tissue disease. A study of 24 cases. Koeger AC, et al. **Medicine (Baltimore)** 1995 Sep; 74(5):221-37 (122 ref.)

GENETICS

Piezogenic pedal papules in two family members. Gibney MD, et al. **Cutis** 1996 Apr;57(4):260-2 (12 ref.)

[Gene errors as a cause of rare and common connective tissue diseases] Ala-Kokko L, et al. **Duodecim** 1994;110(7):731-9 (43 ref.) **(Fin)**

PHYSIOPATHOLOGY

The specificity of collagen cross-links as markers of bone and connective tissue degradation. Eyre DR. **Acta Orthop Scand Suppl** 1995 Oct;266:166-70 (23 ref.)

THERAPY

Managing painful upper limb disorders. Pearson R. **Practitioner** 1995 Sep;239(1554):514-6, 518, 520 (3 ref.)

CONNEXIN 43

ANALYSIS

New insights into myocardial arrhythmogenesis: distribution of gap-junctional coupling in normal, ischaemic and hypertrophied human hearts. Peters NS. **Clin Sci (Colch)** 1996 Jun;90(6):447-52 (56 ref.)

CONNEXINS

CHEMISTRY

Structure of gap junction intercellular channels. Yeager M, et al. **Curr Opin Struct Biol** 1996 Apr;6(2):183-92 (78 ref.)

Connections with connexins: the molecular basis of direct intercellular signaling. Bruzzone R, et al. **Eur J Biochem** 1996 May 15;238(1):1-27 (535 ref.)

GENETICS

Connexin genes and cell growth control. Yamasaki H, et al. **Arch Toxicol Suppl** 1996;18:105-14 (40 ref.)

Role of connexin genes in growth control. Yamasaki H, et al. **Carcinogenesis** 1996 Jun;17(6):1199-213 (194 ref.)

METABOLISM

The connexin family of intercellular channel forming proteins. White TW, et al. **Kidney Int** 1995 Oct; 48(4):1148-57 (121 ref.)

Myocardial gap junction organization in ischemia and infarction. Peters NS. **Microsc Res Tech** 1995 Aug 1; 31(5):375-86 (95 ref.)

PHYSIOLOGY

Cardiac intercellular communication: consequences of connexin distribution and diversity. Beyer EC, et al. **Braz J Med Biol Res** 1995 Apr;28(4):415-25 (62 ref.)

Role of connexin genes in growth control. Yamasaki H, et al. **Carcinogenesis** 1996 Jun;17(6):1199-213 (194 ref.)

New functions for gap junctions. Paul DL. **Curr Opin Cell Biol** 1995 Oct;7(5):665-72 (36 ref.)

Connections with connexins: the molecular basis of direct intercellular signaling. Bruzzone R, et al. **Eur J Biochem** 1996 May 15;238(1):1-27 (535 ref.)

Modelling the structural pathways for transcapillary exchange. Weinbaum S, et al. **Symp Soc Exp Biol** 1995; 49:323-45 (31 ref.)

ULTRASTRUCTURE

Gap junctions in blood forming tissues. Rosendaal M. **Microsc Res Tech** 1995 Aug 1;31(5):396-407 (70 ref.)

CONN'S DISEASE see **HYPERALDOSTERONISM**

CONRADI-HUNERMANN SYNDROME see **CHONDRODYSPLASIA PUNCTATA**

CONSCIOUS SEDATION

Reversal of conscious sedation by flumazenil: current status and future prospects. McCloy RF. **Acta Anaesthesiol Scand Suppl** 1995;108:35-42 (51 ref.)

Sedation. Murphy MF. **Ann Emerg Med** 1996 Apr; 27(4):461-3 (20 ref.)

Propofol. An update of its use in anaesthesia and conscious sedation. Bryson HM, et al. **Drugs** 1995 Sep;50(3):513-59 (622 ref.)

The EEG as a monitor of sedation: encouraging progress. Veselis RA. **J Clin Anesth** 1996 May;8(3 Suppl):81S-87S (69 ref.)

Sedation with benzodiazepines. Gempeler F, et al. **Middle East J Anesthesiol** 1995 Jun;13(2):117-45 (73 ref.)

Clinical aspects of nurse anesthesia practice. Sedation and monitored anesthesia care. Booth M. **Nurs Clin North Am** 1996 Sep;31(3):667-82 (14 ref.)

A review of important elements in sedation study methodology. Wilson S. **Pediatr Dent** 1995 Nov-Dec; 17(7):406-12 (57 ref.)

Review of monitors and monitoring during sedation with emphasis on clinical applications. Wilson S. **Pediatr Dent** 1995 Nov-Dec;17(7):413-8 (14 ref.)

[Gamma-hydroxybutyric acid--significance for anesthesia and intensive care medicine?] Kleinschmidt S, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Nov; 30(7):393-402 (59 ref.) (Eng. Abstr.) **(Ger)**

[Sedation in endoscopy] Pérez-Piqueras J, et al. **Rev Esp Enferm Dig** 1995 Oct;87(10):725-30 (95 ref.) **(Spa)**

ADVERSE EFFECTS

Complications associated with sedative and neuromuscular blocking drugs in critically ill patients. Prielipp RC, et al. **Crit Care Clin** 1995 Oct;11(4):983-1003 (79 ref.)

Complications of conscious sedation. Benjamin SB. **Gastrointest Endosc Clin N Am** 1996 Apr;6(2):277-86 (18 ref.)

ECONOMICS

The cost of sedating and paralyzing the critically ill patient. Cheng EY. **Crit Care Clin** 1995 Oct;11(4):1005-19 (29 ref.)

METHODS

Anaesthesia for cardioversion. Stoneham MD. **Anaesthesia** 1996 Jun;51(6):565-70 (69 ref.)

Methods for monitoring the level of sedation. Avramov MN, et al. **Crit Care Clin** 1995 Oct;11(4):803-26 (75 ref.)

Optimal intravenous dosing strategies for sedatives and analgesics in the intensive care unit. Barr J, et al. **Crit Care Clin** 1995 Oct;11(4):827-47 (64 ref.)

Use of neuromuscular blocking drugs in the critically ill patient. Coursin DB, et al. **Crit Care Clin** 1995 Oct; 11(4):957-81 (94 ref.)

Sedation of the agitated, critically ill patient without an artificial airway. Durbin CG Jr. **Crit Care Clin** 1995 Oct; 11(4):913-36 (86 ref.)

Inhalational anesthetics in the intensive care unit. Kong KL. **Crit Care Clin** 1995 Oct;11(4):887-902 (74 ref.)

Barbiturates, neuroleptics, and propofol for sedation. Lund N, et al. **Crit Care Clin** 1995 Oct;11(4):875-86 (38 ref.)

Sedation for the mechanically ventilated patient. Mazzeo AJ. **Crit Care Clin** 1995 Oct;11(4):937-55 (56 ref.)

Opioids and benzodiazepines. Murray MJ, et al. **Crit Care Clin** 1995 Oct;11(4):849-73 (91 ref.)

Advantages and disadvantages of combining sedative agents. Stoltzfus DP. **Crit Care Clin** 1995 Oct;11(4):903-12 (26 ref.)

Patients requiring sedation. Tung A, et al. **Crit Care Clin** 1995 Oct;11(4):791-802 (45 ref.)

Patient-controlled intraoperative sedation. Herrick IA. **J Clin Anesth** 1996 May;8(3 Suppl):73S-75S (13 ref.)

Monitored anesthesia care: how much sedation, how much analgesia? Smith I. **J Clin Anesth** 1996 May;8(3 Suppl):76S-80S (19 ref.)

Use of intravenous sedation for wisdom tooth surgery on aircraft carriers. Hooley JR, et al. **Mil Med** 1995 Aug; 160(8):398-400 (17 ref.)

[Sedation and analgesia in children] Carbajal R, et al. **Arch Pediatr** 1995 Nov;2(11):1089-96 (27 ref.) (Eng. Abstr.) **(Fre)**

[Sedation of the patient in critical condition] Castillo J. **Rev Esp Anestesiol Reanim** 1995 Dec;42(10):432-5 quiz answer 440 (25 ref.) **(Spa)**

CONSCIOUSNESS

see related
UNCONSCIOUSNESS

Promoting a sense of connectedness among individuals by scientifically demonstrating the existence of a planetary consciousness? Andrews S. **Altern Ther Health Med** 1996 May;2(3):39-45 (107 ref.)

Consciousness and the natural method. Flanagan O. **Neuropsychologia** 1995 Sep;33(9):1103-15 (26 ref.)

On the origin of consciousness, a postulate and its corollary. Cabanac M. **Neurosci Biobehav Rev** 1996;20(1):33-40 (50 ref.)

[Awareness during general anesthesia. Definition, incidence, clinical relevance, causes, avoidance and medicolegal aspects] Schwender D, et al. **Anaesthesist** 1995 Nov; 44(11):743-54 (84 ref.) (Eng. Abstr.) **(Ger)**

[Pictures of the psyche. Imaging the highest functions of the brain: consciousness, language, emotions, is now possible] Ingvar DH. **Lakartidningen** 1995 Dec 20;92(51-52):4885-9 (20 ref.) **(Swe)**

DRUG EFFECTS

An information processing theory of anaesthesia. Flohr H. **Neuropsychologia** 1995 Sep;33(9):1169-80 (74 ref.)

PHYSIOLOGY

Mind and consciousness during sleep. Bosinelli M. **Behav Brain Res** 1995 Jul-Aug;69(1-2):195-201 (53 ref.)

Layer I of primary sensory neocortex: where top-down converges upon bottom-up. Cauller L. **Behav Brain Res** 1995 Nov;71(1-2):163-70 (52 ref.)

Sensations and brain processes. Flohr H. **Behav Brain Res** 1995 Nov;71(1-2):157-61 (13 ref.)

Visual perception and phenomenal consciousness. Stoerig P, et al. **Behav Brain Res** 1995 Nov;71(1-2):147-56 (69 ref.)

The problem of animal consciousness in relation to neuropsychology. Weiskrantz L. **Behav Brain Res** 1995 Nov;71(1-2):171-5 (17 ref.)

On the neurophysiology of consciousness: Part II. Constraining the semantic problem [see comments] Bogen JE. **Conscious Cogn** 1995 Jun;4(2):137-58 (100 ref.) Comment in: Conscious Cogn 1995 Jun;4(2):159-62. Comment in: Conscious Cogn 1995 Jun;4(2):163-6. Comment in: Conscious Cogn 1995 Jun;4(2):167-71. Comment in: Conscious Cogn 1995 Jun;4(2):172-93.

On the neurophysiology of consciousness: I. An overview. Bogen JE. **Conscious Cogn** 1995 Mar;4(1):52-62 (70 ref.)

Thalamic contributions to attention and consciousness [comment] Newman J. **Conscious Cogn** 1995 Jun; 4(2):172-93 (65 ref.) Comment on: Conscious Cogn 1995 Jun;4(2):137-58.

Penetrating gunshots to the head and lack of immediate incapacitation. I. Wound ballistics and mechanisms of incapacitation. Karger B. **Int J Legal Med** 1995; 108(2):53-61 (90 ref.)

Consciousness: perspectives from symbolic and connectionist AI. Bechtel W. **Neuropsychologia** 1995 Sep;33(9):1075-86 (37 ref.)

An introduction to the biology of consciousness. Delacour J. **Neuropsychologia** 1995 Sep;33(9):1061-74 (55 ref.)

The neurobiology of human consciousness: an evolutionary approach. Donald M. **Neuropsychologia** 1995 Sep; 33(9):1087-102 (74 ref.)

Dopamine release in the nucleus accumbens: the perspective from aberrations of consciousness in schizophrenia. Gray JA. **Neuropsychologia** 1995 Sep;33(9):1143-53 (53 ref.)

Conscious and pre-conscious processes as seen from the standpoint of sleep-waking cycle neurophysiology. Paré D, et al. **Neuropsychologia** 1995 Sep;33(9):1155-68 (98 ref.)

Memory and consciousness: a selective review of issues and data. Rugg MD. **Neuropsychologia** 1995 Sep;33(9):1131-41 (66 ref.)

CONSCIOUSNESS DISORDERS

CHEMICALLY INDUCED

Hyponatremia with consciousness disturbance caused by omeprazole administration. A case report and literature review. Shiba S, et al. **Dig Dis Sci** 1996 Aug;41(8):1615-7 (5 ref.)

ETIOLOGY

[Severe metabolic alkalosis with a consciousness disorder] Niederstadt C, et al. **Dtsch Med Wochenschr** 1996 Aug 2; 121(31-32):978-82 (19 ref.) (Eng. Abstr.) **(Ger)**

CONSENSUS DEVELOPMENT CONFERENCES

Impact of varying panel membership on ratings of appropriateness in consensus panels: a comparison of a multi- and single disciplinary panel. Coulter I, et al. **Health Serv Res** 1995 Oct;30(4):577-91 (34 ref.)

[Advantages and inconveniences of consensus conferences] Tournaire M, et al. **Contracept Fertil Sex** 1995 Oct; 23(10):587-9 (7 ref.) **(Fre)**

CONSENSUS WORKSHOPS see **CONSENSUS DEVELOPMENT CONFERENCES**

CONSERVATION OF NATURAL RESOURCES

see related
ECOLOGY

Wildlife, people and development: veterinary contributions to wildlife health and resource management in Africa. Kock MD. **Trop Anim Health Prod** 1996 Feb;28(1):68-80 (28 ref.)

TRENDS

Toxicity testing with communities: microcosms, mesocosms, and whole-system manipulations. Cairns J Jr, et al. **Rev Environ Contam Toxicol** 1996;147:45-69 (97 ref.)

CONSERVED SEQUENCE

A class act: conservation of homeodomain protein functions. Manak JR, et al. **Dev Suppl** 1994;:61-77 (230 ref.)

Chitinases, chitosanases, and lysozymes can be divided into procaryotic and eucaryotic families sharing a conserved core. Monzingo AF, et al. **Nat Struct Biol** 1996 Feb; 3(2):133-40 (27 ref.)

[Highly conserved secondary structures predicted in 5' noncoding region of HCV: a possible connection to viral replication] Katayama K, et al. **Nippon Rinsho** 1995 Sep; 53 Suppl:43-50 (19 ref.) **(Jpn)**

CONSTIPATION

Idiopathic constipation [editorial] O'Toole D, et al. **Ir Med J** 1996 May-Jun;89(3):88, 90-1 (36 ref.)

Constipation and fecal incontinence in the elderly population. Romero Y, et al. **Mayo Clin Proc** 1996 Jan;71(1):81-92 (73 ref.)

Encopresis and soiling. Loening-Baucke V. **Pediatr Clin North Am** 1996 Feb;43(1):279-98 (71 ref.)

Functional colonic and anorectal disorders. Detecting and overcoming causes of constipation and fecal incontinence. Rao SS. **Postgrad Med** 1995 Nov;98(5):115-9, 124-6 (40 ref.)

Constipation and diarrhea: the neglected symptoms. Wright PS, et al. **Semin Oncol Nurs** 1995 Nov;11(4):289-97 (87 ref.)

DIAGNOSIS

Diagnosis and treatment of constipation. Mellgren A. **Eur J Surg** 1995 Sep;161(9):623-34 (96 ref.)

DRUG THERAPY

Cisapride for the treatment of chronic idiopathic constipation. Gardner VY, et al. **Ann Pharmacother** 1995 Nov;29(11):1161-3 (12 ref.)

ETIOLOGY

[Chronic idiopathic constipation in adults. Pathogenesis and treatment] Bouhnik Y, et al. **Ann Gastroenterol Hepatol (Paris)** 1996 Mar-Apr; 32(2):89-96 (40 ref.) (Eng. Abstr.) **(Fre)**

[Constipation in children: from symptoms of Hirschsprung disease to chronic intestinal pseudo-obstruction syndromes] Goulet O. **Gastroenterol Clin Biol** 1996;20(5 Pt 2):B56-62 (39 ref.) **(Fre)**

PHYSIOPATHOLOGY

Colonic motility in health and disease. O'Brien MD, et al. **Gastroenterol Clin North Am** 1996 Mar;25(1):147-62 (62 ref.)

Anorectal and pelvic floor function. Relevance of continence, incontinence, and constipation. Sagar PM, et al. **Gastroenterol Clin North Am** 1996 Mar;25(1):163-82 (102 ref.)

Chronic idiopathic constipation: pathophysiology and treatment. Velio P, et al. **J Clin Gastroenterol** 1996 Apr; 22(3):190-6 (92 ref.)

SURGERY

Continence disorders. Grotz RL, et al. **Curr Opin Gen Surg** 1993;:147-56 (54 ref.)

Results of colectomy for severe slow transit constipation. Lubowski DZ, et al. **Dis Colon Rectum** 1996 Jan;39(1):23-9 (23 ref.)

THERAPY

Current approaches to the management of constipation. Sykes NP. **Cancer Surv** 1994;21:137-46 (52 ref.)

Biofeedback training in children with functional constipation. A critical review. Loening-Baucke V. **Dig Dis Sci** 1996 Jan;41(1):65-71 (31 ref.)

Diagnosis and treatment of constipation. Mellgren A. **Eur J Surg** 1995 Sep;161(9):623-34 (96 ref.)

Chronic idiopathic constipation: pathophysiology and treatment. Velio P, et al. **J Clin Gastroenterol** 1996 Apr; 22(3):190-6 (92 ref.)

CONSTRICTIVE PERICARDITIS see **PERICARDITIS, CONSTRICTIVE**

CONSULTANTS

Organizational and psychological consultation in collegiate sports medicine groups. Anderson MB, et al. **J Am Coll Health** 1995 Sep;44(2):63-9 (18 ref.)

The role of the consultation-liaison nurse. Caring for patients with AIDS dementia complex. Price N. **J Psychosoc Nurs Ment Health Serv** 1995 Dec;33(12):31-4 (14 ref.)

CONSULTATION see **REFERRAL AND CONSULTATION**

CONSUMER ADVOCACY

Media strategies for community health advocacy. Woodruff K. **Prim Care** 1995 Dec;22(4):805-15 (29 ref.)

Regulating assisted reproductive technologies: public health, consumer protection, and public resources. Wilcox LS, et al. **Womens Health Issues** 1996 May-Jun;6(3):175-80 (22 ref.)

LEGISLATION & JURISPRUDENCE

Public citizen opposition to spinal implant fixation. Yuan HA. **J Spinal Disord** 1995 Oct;8(5):413-8 (17 ref.)

CONSUMER INVOLVEMENT see **CONSUMER PARTICIPATION**

CONSUMER PARTICIPATION

Community involvement in the control of Aedes aegypti. Gubler DJ, et al. **Acta Trop** 1996 Apr;61(2):169-79 (21 ref.)

Paradigms lost: toward a new understanding of community participation in health programmes. Rifkin SB. **Acta Trop** 1996 Apr;61(2):79-92 (53 ref.)

Healthy Cities: toward worldwide health promotion. Flynn BC. **Annu Rev Public Health** 1996;17:299-309 (59 ref.)

Involving the public: practical and ethical issues. Jacobson B, et al. **Br Med Bull** 1995 Oct;51(4):869-75 (16 ref.)

Information for public choice. McIver S. **Br Med Bull** 1995 Oct;51(4):900-13 (29 ref.)

Improving the use of information in medical effectiveness research. Phillips KA, et al. **Int J Qual Health Care** 1996 Feb;8(1):21-30 (96 ref.)

Linking quality improvement with primary health care. Sukati NA. **Int Nurs Rev** 1995 Jul-Aug;42(4):109-14, 124 (36 ref.)

Social theory, social action, and intervention research: implications for cancer prevention among Latinos. Flores ET, et al. **J Natl Cancer Inst Monogr** 1995;(18):101-8 (53 ref.)

The future of graduate education in nursing: scholarship, the health of communities, and health care reform. Hall JM, et al. **J Prof Nurs** 1995 Nov-Dec;11(6):332-8 (22 ref.)

Media strategies for community health advocacy. Woodruff K. **Prim Care** 1995 Dec;22(4):805-15 (29 ref.)

Building community capacity for health promotion: a challenge for public health nurses. Kang R. **Public Health Nurs** 1995 Oct;12(5):312-8 (24 ref.)

METHODS

Coming to voice: the power of emancipatory community interventions. Drevdahl D. **ANS Adv Nurs Sci** 1995 Dec; 18(2):13-24 (50 ref.)

Health policy planning: a look at consumer involvement in Nova Scotia. Sullivan MJ, et al. **Can J Public Health** 1995 Sep-Oct;86(5):317-20 (26 ref.)

CONSUMER PREFERENCE see **CONSUMER SATISFACTION**

CONSUMER PRICE INDEX see **ECONOMICS**

CONSUMER PRODUCT SAFETY

The safety and hazards of blood-derived drugs. Grabenstein JD. **Am J Health Syst Pharm** 1995 Nov 1;52(21):2448-52 (27 ref.)

Could changes in the wheelchair delivery system improve safety? [see comments] Kirby RL, et al. **Can Med Assoc J** 1995 Dec 1;153(11):1585-91 (40 ref.) Comment in: Can Med Assoc J 1996 Mar 15;154(6):762, 764.

Evaluation of the safety of sodium pectate as a food ingredient. Borzelleca JF, et al. **Food Chem Toxicol** 1996 Jan;34(1):21-5 (18 ref.)

The present safety assessment of deet. Osimitz TG, et al. **J Am Mosq Control Assoc** 1995 Jun;11(2 Pt 2):274-8 (24 ref.)

LEGISLATION & JURISPRUDENCE

Home HIV testing and conflicts with state HIV testing regulations. Fabbri WO. **Am J Law Med** 1995;21(4):419-44 (230 ref.)

STANDARDS

Salmonellae and food safety. Tietjen M, et al. **Crit Rev Microbiol** 1995;21(1):53-83 (104 ref.)

Washington's experience and recommendations Re: Anticoagulant rodenticides. Morrissey B, et al. **Vet Hum Toxicol** 1995 Aug;37(4):362-3 (4 ref.)

CONSUMER SATISFACTION

Anticipating public reaction to the use of genetic engineering in infant nutrition. Hoban TJ 4th. **Am J Clin Nutr** 1996 Apr;63(4):657S-62S (8 ref.)

The effectiveness of psychotherapy. The Consumer Reports study. Seligman ME. **Am Psychol** 1995 Dec;50(12):965-74 (11 ref.)

Contracting and choice. Carruthers I. **Br Med Bull** 1995 Oct; 51(4):914-26 (0 ref.)

Interaction of condom design and user techniques and condom acceptability. Gerofi J, et al. **Contraception** 1995 Oct;52(4):223-8 (8 ref.)

Consumer concerns about modern technology in agriculture: considerations for undergraduate and graduate teaching. Weber GM, et al. **J Anim Sci** 1995 Sep;73(9):2727-32 (16 ref.)

CONSUMPTION COAGULOPATHY see **DISSEMINATED INTRAVASCULAR COAGULATION**

CONTACT DERMATITIS see **DERMATITIS, CONTACT**

CONTACT LENSES

AIDS and the contact lens practice. Slonim CB. **CLAO J** 1995 Oct;21(4):233-5 (19 ref.)

ADVERSE EFFECTS

Contact lens wear by hospital health care staff: is there cause for concern? Hay J, et al. **J Hosp Infect** 1995 Jun;30 Suppl:275-81 (40 ref.)

CONTACT TRACING

Pitfalls in contact tracing and early diagnosis of childhood tuberculosis. Clark JE, et al. **BMJ** 1996 Jul 27; 313(7051):221-2 (6 ref.)

Prevention of recurrent pelvic infection by contact tracing: a commonsense approach. Robinson AJ, et al. **Br J Obstet Gynaecol** 1996 Sep;103(9):859-61 (21 ref.)

LEGISLATION & JURISPRUDENCE

The risk of domestic violence and women with HIV infection: implications for partner notification, public policy, and the law. Rothenberg KH, et al. **Am J Public Health** 1995 Nov;85(11):1569-76 (98 ref.)

CONTAINMENT OF BIOHAZARDS

Handling small arbovirus vectors safely during biosafety level 3 containment: Culicoides variipennis sonorensis (Diptera:Ceratopogonidae) and exotic bluetongue viruses. Hunt GJ, et al. **J Med Entomol** 1996 May;33(3):271-7 (17 ref.)

METHODS

Safety requirements for maintenance and distribution of transgenic mice susceptible to human viruses: the example of poliovirus-susceptible transgenic mice. Ghendon Y, et al. **Curr Top Microbiol Immunol** 1996;206:327-40 (31 ref.)

STANDARDS

Laboratory-associated infections and biosafety. Sewell DL. **Clin Microbiol Rev** 1995 Jul;8(3):389-405 (158 ref.)

CONTINENT URINARY RESERVOIRS see **URINARY RESERVOIRS, CONTINENT**

CONTINGENT NEGATIVE VARIATION

The neurophysiology of sexual desire, with particular reference to paedophilia. Howard RC. **Ann Acad Med Singapore** 1995 Sep;24(5):724-7 (11 ref.)

Brain electrical activity (quantitative EEG and bit-mapping neurocognitive CNV components), psychometrics and clinical findings in presenile subjects with initial mild cognitive decline or probable Alzheimer-type dementia. Zappoli R, et al. **Ital J Neurol Sci** 1995 Sep;16(6):341-76 (177 ref.)

[The use of the contingent negative wave in neurology and psychiatry] Vein AM, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995; 95(4):99-102 (79 ref.) **(Rus)**

PHYSIOLOGY

Single-trial readiness potentials and fatigue. Popivanov D, et al. **Adv Exp Med Biol** 1995;384:295-304 (26 ref.)
Generation of contingent negative variation in the supplementary sensorimotor area. Ikeda A, et al. **Adv Neurol** 1996;70:153-9 (44 ref.)
Eyeglass MEDRETE: practical considerations (a user's guide). Dreher RJ, et al. **Mil Med** 1996 Jun;161(6):334-8 (4 ref.)

CONTINUED STAY REVIEW see **CONCURRENT REVIEW**

CONTINUING CARE RETIREMENT CENTERS see **HOUSING FOR THE ELDERLY**

CONTINUITY OF PATIENT CARE

Cystic fibrosis: transition from paediatric to adult physician's care [editorial] Landau LI. **Thorax** 1995 Oct;50(10):1031-2 (6 ref.)
[Wrong beds and wrong care] Hertogh CM, et al. **Ned Tijdschr Geneeskd** 1996 Apr 20;140(16):868-70 (18 ref.) **(Dut)**

LEGISLATION & JURISPRUDENCE

Emergency room follow-up care and malpractice liability. Morgan D. **J Leg Med** 1995 Sep;16(3):373-406 (143 ref.)

ORGANIZATION & ADMINISTRATION

The medical director in the multi-level long-term care facility. Applebaum GE. **Clin Geriatr Med** 1995 Aug; 11(3):359-72 (4 ref.)
The acute and long-term care interface. Integrating the continuum. Phillips-Harris C, et al. **Clin Geriatr Med** 1995 Aug;11(3):481-501 (24 ref.)
Bridging the gap between hospital and home for premature infants in Malawi. Mbweza E. **Int Nurs Rev** 1996 Mar-Apr; 43(2):53-7 (19 ref.)
Pediatric and family HIV. Psychosocial concerns across the continuum of disease. Lewis SL, et al. **Nurs Clin North Am** 1996 Mar;31(1):221-30 (29 ref.)

CONTINUOUS PASSIVE MOTION THERAPY see **MOTION THERAPY, CONTINUOUS PASSIVE**

CONTINUOUS QUALITY MANAGEMENT see **TOTAL QUALITY MANAGEMENT**

CONTINUUM OF CARE see **CONTINUITY OF PATIENT CARE**

CONTOUR PERCEPTION see **FORM PERCEPTION**

CONTRACEPTION

see related
FAMILY PLANNING

Contraception, unintended pregnancies, and sexually transmitted diseases: why isn't a simple solution possible? Cates W Jr. **Am J Epidemiol** 1996 Feb 15;143(4):311-8 (30 ref.)
Barriers to conception and disease. Donovan B. **Ann Acad Med Singapore** 1995 Jul;24(4):608-14 (73 ref.)
Immunosuppressive mechanisms in semen: implications for contraception. Kelly RW. **Hum Reprod** 1995 Jul; 10(7):1686-93 (137 ref.)
Contraception for women with health problems. Corson SL. **Int J Fertil Menopausal Stud** 1996 Mar-Apr;41(2):77-84 (28 ref.)
Sequelae of premature sexual life [comment] Creatsas G. **J R Soc Med** 1995 Jul;88(7):369-71 (12 ref.) Comment on: J R Soc Med 1995 Jul;88(7):384-8.
Contraception. A clinical review for the internist. Kaunitz AM, et al. **Med Clin North Am** 1995 Nov;79(6):1377-409 (156 ref.)
Office gynecology for the primary care physician, part I: vaginitis, the Papanicolaou smear, contraception, and postmenopausal estrogen replacement. Reife CM. **Med Clin North Am** 1996 Mar;80(2):299-319 (63 ref.)
Through the patient's eyes: strategies toward more successful contraception. Delbanco TL, et al. **Obstet Gynecol** 1996 Sep;88(3 Suppl):41S-47S (31 ref.)
Physician-patient interaction in reproductive counseling. Lipkin M Jr. **Obstet Gynecol** 1996 Sep;88(3 Suppl):31S-40S (51 ref.)
Contraception in diabetic women. Kjos SL. **Obstet Gynecol Clin North Am** 1996 Mar;23(1):243-58 (64 ref.)
[Fertility] Tica V. **Contracept Fertil Sex** 1996 Mar; 24(3):173-83 (110 ref.) **(Fre)**

METHODS

Natural family planning. Geerling JH. **Am Fam Physician** 1995 Nov 1;52(6):1749-56, 1759-60 (33 ref.)
Long-acting contraceptive options. Kaunitz AM. **Int J Fertil Menopausal Stud** 1996 Mar-Apr;41(2):69-76 (54 ref.)
Women, contraception and STDs including HIV [editorial] Carlin EM, et al. **Int J STD AIDS** 1995 Nov-Dec; 6(6):373-86 (234 ref.)
The perimenopause and contraception. Shaaban MM. **Maturitas** 1996 Mar;23(2):181-92 (77 ref.)
Contraceptive methods: do Hispanic adolescents and their family planning care providers think about contraceptive methods the same way? Erickson PI. **Med Anthropol** 1996 May;17(1):65-82 (53 ref.)
The diaphragm: barrier contraception has a new social role. Tagg PI. **Nurse Pract** 1995 Dec;20(12):36, 39-42 (24 ref.)
Withdrawal: a review of the literature and an agenda for research [see comments] Rogow D, et al. **Stud Fam Plann** 1995 May-Jun;26(3):140-53 (92 ref.) Comment in: Stud Fam Plann 1995 Sep-Oct;26(5):305-6.
[Breast feeding: which contraceptive method?] Codaccioni X, et al. **Rev Fr Gynecol Obstet** 1995 May-Jun; 90(5-6):302-5 (7 ref.) (Eng. Abstr.) **(Fre)**

STATISTICS & NUMERICAL DATA

The perimenopause and contraception. Shaaban MM. **Maturitas** 1996 Mar;23(2):181-92 (77 ref.)

UTILIZATION

Reproductive decision-making and determinants of contraceptive use in HIV-infected women. Williams HA, et al. **Clin Obstet Gynecol** 1996 Jun;39(2):333-43 (40 ref.)

CONTRACEPTION BEHAVIOR

Factors affecting the consistent use of barrier methods of contraception. Beckman LJ, et al. **Obstet Gynecol** 1996 Sep; 88(3 Suppl):65S-71S (26 ref.)
Compliance with contraceptives and other treatments. Cramer JA. **Obstet Gynecol** 1996 Sep;88(3 Suppl):4S-12S (42 ref.)
Through the patient's eyes: strategies toward more successful contraception. Delbanco TL, et al. **Obstet Gynecol** 1996 Sep;88(3 Suppl):41S-47S (31 ref.)
Adolescent contraceptive behavior: the impact of the provider and the structure of clinic-based programs. Jaccard J. **Obstet Gynecol** 1996 Sep;88(3 Suppl):57S-64S (68 ref.)
How effective are contraceptives? The determination and measurement of pregnancy rates. Potter LS. **Obstet Gynecol** 1996 Sep;88(3 Suppl):13S-23S (51 ref.)

CONTRACEPTION, IMMUNOLOGIC

Vaccination for birth control. Dirnhofer S, et al. **Int Arch Allergy Immunol** 1995 Dec;108(4):350-4 (36 ref.)
Virus-vectored immunocontraception for control of wild rabbits: identification of target antigens and construction of recombinant viruses. Holland MK, et al. **Reprod Fertil Dev** 1994;6(5):631-42 (61 ref.)
Sperm antigens and immunocontraception. Kerr LE. **Reprod Fertil Dev** 1995;7(4):825-30 (74 ref.)

METHODS

Targeting the zona pellucida for immunocontraception: a minireview. Tesarik J. **Hum Reprod** 1995 Dec;10 Suppl 2:132-9 (35 ref.)
[Immuno-contraceptive vaccines] Kochanowska IE, et al. **Postepy Hig Med Dosw** 1995;49(4):451-68 (73 ref.) (Eng. Abstr.) **(Pol)**

TRENDS

Immunization to regulate fertility: biological and cultural frameworks. Schrater AF. **Soc Sci Med** 1995 Sep; 41(5):657-71 (85 ref.)

CONTRACEPTIVE AGENTS

Still waiting for the contraceptive revolution. Klitsch M. **Fam Plann Perspect** 1995 Nov-Dec;27(6):246-53 (68 ref.)

IMMUNOLOGY

Synthetic hormone/growth factor subunit vaccine with application to antifertility and cancer. Snyder LL, et al. **Pharm Biotechnol** 1995;6:907-30 (145 ref.)

PHARMACOLOGY

Antiprogestins: mechanism of action and contraceptive potential. Spitz IM, et al. **Annu Rev Pharmacol Toxicol** 1996;36:47-81 (161 ref.)
Mifepristone: a potential contraceptive. Heikinheimo O, et al. **Clin Obstet Gynecol** 1996 Jun;39(2):461-8 (20 ref.)

CONTRACEPTIVE AGENTS, FEMALE

Materials, methods and results of the Norplant training program. Bromham DR, et al. **Adv Contracept** 1995 Sep; 11(3):255-62 (4 ref.)
The combined use of prostaglandin and antiprogestin in human fertility control. Baulieu EE. **Eur J Obstet Gynecol Reprod Biol** 1996 Mar;65(1):115-9 (42 ref.)
Contraception for women with health problems. Corson SL. **Int J Fertil Menopausal Stud** 1996 Mar-Apr;41(2):77-84 (28 ref.)
Long-acting contraceptive options. Kaunitz AM. **Int J Fertil Menopausal Stud** 1996 Mar-Apr;41(2):69-76 (54 ref.)
Use of depot medroxyprogesterone acetate contraception in adolescents. Davis AJ. **J Reprod Med** 1996 May;41(5 Suppl):407-13 (15 ref.)
Depot medroxyprogesterone acetate contraception in women with medical problems. Frederiksen MC. **J Reprod Med** 1996 May;41(5 Suppl):414-8 (32 ref.)

ADMINISTRATION & DOSAGE

[Levonorgestrel capsules: a big leap forward in intrauterine contraception] Hamerlynck JV. **Ned Tijdschr Geneeskd** 1996 Jun 8;140(23):1212-4 (17 ref.) **(Dut)**

ADVERSE EFFECTS

Depot medroxyprogesterone acetate contraception and the risk of breast and gynecologic cancer. Kaunitz AM. **J Reprod Med** 1996 May;41(5 Suppl):419-27 (38 ref.)
Counseling issues and management of side effects for women using depot medroxyprogesterone acetate contraception. Nelson AL. **J Reprod Med** 1996 May;41(5 Suppl):391-400 (27 ref.)
Depot medroxyprogesterone acetate contraception. Metabolic parameters and mood changes. Westhoff C. **J Reprod Med** 1996 May;41(5 Suppl):401-6 (28 ref.)

PHARMACOKINETICS

Pharmacokinetics of depot medroxyprogesterone acetate contraception. Mishell DR Jr. **J Reprod Med** 1996 May; 41(5 Suppl):381-90 (11 ref.)

PHARMACOLOGY

Implantable levonorgestrel contraception: 4 years of experience with Norplant. Hatasaka H. **Clin Obstet Gynecol** 1995 Dec;38(4):859-71 (26 ref.)
The contraceptive use of depot medroxyprogesterone acetate. Hickey M, et al. **Clin Obstet Gynecol** 1995 Dec; 38(4):849-58 (20 ref.)

STANDARDS

The progestin-only pills and the levonorgestrel-releasing IUD: two progestin-only contraceptives. Chi IC. **Clin Obstet Gynecol** 1995 Dec;38(4):872-89 (71 ref.)
Levonorgestrel-releasing IUD as a method of contraception with therapeutic properties. Luukkainen T, et al. **Contraception** 1995 Nov;52(5):269-76 (41 ref.)

THERAPEUTIC USE

Levonorgestrel-releasing IUD as a method of contraception with therapeutic properties. Luukkainen T, et al. **Contraception** 1995 Nov;52(5):269-76 (41 ref.)
Noncontraceptive benefits and therapeutic uses of depot medroxyprogesterone acetate. Cullins VE. **J Reprod Med** 1996 May;41(5 Suppl):428-33 (57 ref.)

CONTRACEPTIVE AGENTS, MALE

The myth of a male pill [see comments] Potts M. **Nat Med** 1996 Apr;2(4):398-9 (9 ref.) Comment in: Nat Med 1996 Jul;2(7):722.

THERAPEUTIC USE

Hormonal male contraception: progress and prospects for the 21st century. Handelsman DJ. **Aust N Z J Med** 1995 Dec;25(6):808-16 (54 ref.)

CONTRACEPTIVE DEVICES

Still waiting for the contraceptive revolution. Klitsch M. **Fam Plann Perspect** 1995 Nov-Dec;27(6):246-53 (68 ref.)

UTILIZATION

Factors affecting the consistent use of barrier methods of contraception. Beckman LJ, et al. **Obstet Gynecol** 1996 Sep; 88(3 Suppl):65S-71S (26 ref.)

CONTRACEPTIVE DEVICES, FEMALE

More on women and the prevention of HIV infection [editorial; comment] Stein ZA. **Am J Public Health** 1995 Nov;85(11):1485-8 (44 ref.) Comment on: Am J Public Health 1995 Nov;85(11):1514-20. Comment on: Am J Public Health 1995 Nov;85(11):1521-5. Comment on: Am J Public Health 1995 Nov;85(11):1526-30.
The diaphragm: barrier contraception has a new social role. Tagg PI. **Nurse Pract** 1995 Dec;20(12):36, 39-42 (24 ref.)

CONTRACEPTIVE DEVICES, INTRAUTERINE see **INTRAUTERINE DEVICES**

CONTRACEPTIVE DEVICES, MALE

STANDARDS

Interaction of condom design and user techniques and condom acceptability. Gerofi J, et al. **Contraception** 1995 Oct;52(4):223-8 (8 ref.)

UTILIZATION

Interaction of condom design and user techniques and

condom acceptability. Gerofi J, et al. **Contraception** 1995 Oct;52(4):223–8 (8 ref.)

CONTRACEPTIVES, ORAL

The pill. The controversy continues. Lidegaard O, et al. **Acta Obstet Gynecol Scand** 1996 Feb;75(2):93–7 (10 ref.)
Desogestrel, norgestimate, and gestodene: the newer progestins. Kaplan B. **Ann Pharmacother** 1995 Jul–Aug; 29(7–8):736–42 (51 ref.)
Compliance and oral contraceptives: a review. Rosenberg MJ, et al. **Contraception** 1995 Sep;52(3):137–41 (35 ref.)
Compliance with contraceptives and other treatments. Cramer JA. **Obstet Gynecol** 1996 Sep;88(3 Suppl):4S–12S (42 ref.)

ADMINISTRATION & DOSAGE

How much compliance is enough? Urquhart J. **Pharm Res** 1996 Jan;13(1):10–1 (17 ref.)

ADVERSE EFFECTS

Women, hormones and blood pressure. Khaw KT. **Can J Cardiol** 1996 Jun;12 Suppl D:9D–12D (16 ref.)
Oral contraceptives and thrombotic diseases: impact of new epidemiological studies [editorial] Lidegaard O, et al. **Contraception** 1996 Mar;53(3):135–9 (13 ref.)
[Risk of thromboembolism and oral contraceptives] Lê MG. **Contracept Fertil Sex** 1996 May;24(5):378–83 (7 ref.) (Eng. Abstr.) **(Fre)**
[A new generation of oral contraceptives and venous thromboembolic diseases: unexpected results!] Scarabin PY. **Rev Epidemiol Sante Publique** 1996 Apr;44(2):188–9 (7 ref.) **(Fre)**
[Significance of hereditary thrombophilia for risk of thrombosis with oral contraceptives] Bauersachs R, et al. **Zentralbl Gynakol** 1996;118(5):262–70 (53 ref.) (Eng. Abstr.) **(Ger)**
[Main cardiotoxic drugs] Pettirossi G, et al. **Clin Ter** 1996 Jan–Feb;147(1–2):67–77 (34 ref.) (Eng. Abstr.) **(Ita)**
[Ictus, pregnancy and contraception] Pareja A, et al. **Rev Neurol** 1995;23 Suppl 1:S87–90 (27 ref.) **(Spa)**

PHARMACOLOGY

Norgestimate. Corson SL. **Clin Obstet Gynecol** 1995 Dec; 38(4):841–8 (25 ref.)

THERAPEUTIC USE

Bone-sparing properties of oral contraceptives. DeCherney A. **Am J Obstet Gynecol** 1996 Jan;174(1 Pt 1):15–20 (25 ref.)
[Oral contraception—benefits and risks] Braendle W. **Arch Gynecol Obstet** 1995;257(1–4):532–6 (23 ref.) **(Ger)**
[Sex hormones, glycolipid metabolism, and atherogenesis] Sarubbi B, et al. **Minerva Med** 1995 Jun;86(6):265–73 (67 ref.) (Eng. Abstr.) **(Ita)**

CONTRACEPTIVES, ORAL, COMBINED

Consensus development meeting 1995: combined oral contraceptives and cardiovascular disease. The Consensus Statement issued after the Second European Conference on Sex Steroids and Metabolism, Amsterdam, November 1995. Writing Committee. **Gynecol Endocrinol** 1996 Feb; 10(1):1–5 (7 ref.)
How effective are contraceptives? The determination and measurement of pregnancy rates. Potter LS. **Obstet Gynecol** 1996 Sep;88(3 Suppl):13S–23S (51 ref.)

ADMINISTRATION & DOSAGE

[Lowering the steroid dose in oral contraception and risk of functional ovarian cysts] Mayenga JM, et al. **Contracept Fertil Sex** 1995 Jul–Aug;23(7–8):439–41 (11 ref.) **(Fre)**

ADVERSE EFFECTS

Consensus development meeting 1995: combined oral contraceptives and cardiovascular disease. The Consensus Statement issued after the Second European Conference on Sex Steroids and Metabolism, Amsterdam, November 1995. Writing Committee. **Gynecol Endocrinol** 1996 Feb; 10(1):1–5 (7 ref.)
Advances in oral hormonal contraception. Elstein M, et al. **Zentralbl Gynakol** 1995;117(11):559–65 (57 ref.)
[Lowering the steroid dose in oral contraception and risk of functional ovarian cysts] Mayenga JM, et al. **Contracept Fertil Sex** 1995 Jul–Aug;23(7–8):439–41 (11 ref.) **(Fre)**

PHARMACOLOGY

Gestodene. A review of its pharmacology, efficacy and tolerability in combined contraceptive preparations. Wilde MI, et al. **Drugs** 1995 Aug;50(2):364–95 (128 ref.)

STANDARDS

Combined oral contraceptives: do we know all of their effects? Hannaford PC. **Contraception** 1995 Jun;51(6):325–7 (35 ref.)

CONTRACEPTIVES, ORAL, HORMONAL

[35 years of estrogen-progestagen pills: where is the vascular risk?] Gaspard U. **Rev Med Liege** 1996 Jan;51(1):133–8 (15 ref.) **(Fre)**

ADMINISTRATION & DOSAGE

[Lowering the steroid dose in oral contraception and risk of functional ovarian cysts] Mayenga JM, et al. **Contracept Fertil Sex** 1995 Jul–Aug;23(7–8):439–41 (11 ref.) **(Fre)**

ADVERSE EFFECTS

Oral contraceptives and cancer. A review of the evidence. La Vecchia C, et al. **Drug Saf** 1996 Apr;14(4):260–72 (100 ref.)
[Lowering the steroid dose in oral contraception and risk of functional ovarian cysts] Mayenga JM, et al. **Contracept Fertil Sex** 1995 Jul–Aug;23(7–8):439–41 (11 ref.) **(Fre)**
[APC (activated protein C) resistance and oral contraceptives] Kreis I, et al. **Geburtshilfe Frauenheilkd** 1996 May;56(5):231–3 (21 ref.) (Eng. Abstr.) **(Ger)**
[The regression of a hepatocellular adenoma after the withdrawal of hormonal contraception] Daldrup HE, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1995 Nov;163(5):449–51 (12 ref.) **(Ger)**

CONTRACEPTIVES, ORAL, SYNTHETIC

Progestogens, progesterone antagonists, progesterone, and androgens: synthesis, classification, and uses. Peterson CM. **Clin Obstet Gynecol** 1995 Dec;38(4):813–20 (13 ref.)

BLOOD

[Synthetic steroids] Miyazaki S. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:1036–9 (19 ref.) **(Jpn)**

PHARMACOLOGY

Clinical applications of the antiprogestins. Kettel LM. **Clin Obstet Gynecol** 1995 Dec;38(4):921–34 (56 ref.)
Gestodene-containing contraceptives. Kuhl H, et al. **Clin Obstet Gynecol** 1995 Dec;38(4):829–40 (32 ref.)
Desogestrel. Stone SC. **Clin Obstet Gynecol** 1995 Dec; 38(4):821–8 (39 ref.)
Designer contraceptive pills. Hsueh AJ. **Hum Reprod** 1995 Aug;10(8):1997–2000 (26 ref.)

CONTRACEPTIVES, POSTCOITAL

ADMINISTRATION & DOSAGE

The Yuzpe regimen of emergency contraception: how long after the morning after? Trussell J, et al. **Obstet Gynecol** 1996 Jul;88(1):150–4 (19 ref.)

STANDARDS

Consensus statement on emergency contraception. **Contraception** 1995 Oct;52(4):211–3 (6 ref.)

SUPPLY & DISTRIBUTION

Expanding access to emergency contraception in developing countries. Ellertson C, et al. **Stud Fam Plann** 1995 Sep–Oct; 26(5):251–63 (70 ref.)

CONTRACEPTIVES, POSTCOITAL, HORMONAL

ADMINISTRATION & DOSAGE

Emergency contraception in the United Kingdom and The Netherlands. Glasier A, et al. **Fam Plann Perspect** 1996 Mar–Apr;28(2):49–51 (17 ref.)
The effectiveness of the Yuzpe regimen of emergency contraception. Trussell J, et al. **Fam Plann Perspect** 1996 Mar–Apr;28(2):58–64, 87 (30 ref.)
Research on new methods of emergency contraception. von Hertzen H, et al. **Fam Plann Perspect** 1996 Mar–Apr; 28(2):52–7, 88 (59 ref.)

CONTRACEPTIVES, POSTCOITAL, SYNTHETIC

ADMINISTRATION & DOSAGE

The effectiveness of the Yuzpe regimen of emergency contraception. Trussell J, et al. **Fam Plann Perspect** 1996 Mar–Apr;28(2):58–64, 87 (30 ref.)
Research on new methods of emergency contraception. von Hertzen H, et al. **Fam Plann Perspect** 1996 Mar–Apr; 28(2):52–7, 88 (59 ref.)

CONTRACT SERVICES

Contracting and choice. Carruthers I. **Br Med Bull** 1995 Oct; 51(4):914–26 (0 ref.)
Market testing specialist health promotion services—a test case for an imaginative public health presence in purchasing. Whitelaw S, et al. **J Public Health Med** 1995 Jun;17(2):211–6 (22 ref.)

ECONOMICS

The managed care contract: implementation in radiation oncology. Bruner DW. **Oncol Nurs Forum** 1996 Apr; 23(3):451–4 (21 ref.)

ORGANIZATION & ADMINISTRATION

Population-centered and patient-focused purchasing: the U.K. experience. Ham C. **Milbank Q** 1996;74(2):191–214 (58 ref.)

STANDARDS

Managed care contracting/capitation. Reardon TM. **Ann Thorac Surg** 1995 Nov;60(5):1500–8 (0 ref.)

CONTRACTILE PROTEINS

GENETICS

Contractile protein phenotypic variation during development. Murphy AM. **Cardiovasc Res** 1996 Feb;31 Spec No:E25–33 (106 ref.)
Inherited disorders of contractile proteins in skeletal and cardiac muscle. Laing NG. **Curr Opin Neurol** 1995 Oct; 8(5):391–6 (50 ref.)

PHYSIOLOGY

Contractile proteins and their response to bladder outlet obstruction. Chacko S, et al. **Adv Exp Med Biol** 1995; 385:55–63; discussion 75–9 (111 ref.)
Yeast motor proteins. Streiblová E, et al. **Folia Microbiol (Praha)** 1995;40(6):571–82 (59 ref.)

CONTRACTURE

Congenital contractural arachnodactyly. Kulkarni ML, et al. **Indian Pediatr** 1995 Jan;32(1):82–7 (14 ref.)

PATHOLOGY

Pathological infrapatellar plica: a report of two cases and literature review. Kim SJ, et al. **Arthroscopy** 1996 Apr; 12(2):236–9 (18 ref.)

SURGERY

Management of scar contractures, hypertrophic scars, and keloids. Sherris DA, et al. **Otolaryngol Clin North Am** 1995 Oct;28(5):1057–68 (29 ref.)

CONTRAST MEDIA

see related
EXTRAVASATION OF DIAGNOSTIC AND THERAPEUTIC MATERIALS

Visipaque—a step forward. A historical review. Almen T. **Acta Radiol Suppl** 1995;399:2–18 (48 ref.)
Diagnosis of myocardial stunning: a new use for myocardial contrast and dobutamine echocardiography. Cheirif J. **Am J Card Imaging** 1995 Oct;9(4):261–8 (51 ref.)
Why do we need contrast agents for ultrasound? Cosgrove D. **Clin Radiol** 1996 Feb;51 Suppl 1:1–4 (20 ref.)
Contrast echocardiography. Nihoyannopoulos P. **Clin Radiol** 1996 Feb;51 Suppl 1:28–30 (12 ref.)
Contrast-enhanced MR imaging. Schima W, et al. **Clin Radiol** 1996 Apr;51(4):235–44 (108 ref.)
Gadolinium-enhanced breast MRI. Kelcz F, et al. **Crit Rev Diagn Imaging** 1995;36(4):287–338 (41 ref.)
Myocardial contrast echocardiography in acute myocardial infarction. Pathophysiological background and clinical applications. Iliceto S, et al. **Eur Heart J** 1996 Mar; 17(3):344–53 (68 ref.)
The non-ionic isotonic contrast agents. Perspectives and controversies. Dawson P. **Eur Radiol** 1996;6 Suppl 2:S20–4 (17 ref.)
Novel MR image contrast mechanisms in epilepsy. Tofts PS. **Magn Reson Imaging** 1995;13(8):1099–106 (67 ref.)
Gastrointestinal contrast agents for MR imaging. Brown JJ. **Magn Reson Imaging Clin N Am** 1996 Feb;4(1):25–35 (43 ref.)
Liver. III: Gadolinium-based hepatobiliary contrast agents (Gd-EOB-DTPA and Gd-BOPTA/Dimeg). Giovagnoni A, et al. **Magn Reson Imaging Clin N Am** 1996 Feb; 4(1):61–72 (34 ref.)
Targeted contrast agents in MR imaging. Gupta H, et al. **Magn Reson Imaging Clin N Am** 1996 Feb;4(1):171–84 (78 ref.)
Sensitivity of contrast-enhanced MR imaging of the breast. Heywang-Koebrunner SH, et al. **Magn Reson Imaging Clin N Am** 1994 Nov;2(4):527–38 (32 ref.)
Contrast-enhanced MR imaging of the kidneys and adrenal glands. Huch Böni RA, et al. **Magn Reson Imaging Clin N Am** 1996 Feb;4(1):101–31 (61 ref.)
Contrast-enhanced MR imaging of the pancreas. Kettritz U, et al. **Magn Reson Imaging Clin N Am** 1996 Feb;4(1):87–100 (62 ref.)
Liver I: Currently available gadolinium chelates. Mitchell

DG. **Magn Reson Imaging Clin N Am** 1996 Feb;4(1):37–51 (15 ref.)
Contrast-enhanced MR imaging of gynecologic disorders. Outwater EK. **Magn Reson Imaging Clin N Am** 1996 Feb; 4(1):133–51 (84 ref.)
Liver. II: Iron oxide-based reticuloendothelial contrast agents for MR imaging. Clinical review. Petersein J, et al. **Magn Reson Imaging Clin N Am** 1996 Feb;4(1):53–60 (38 ref.)
The specificity of contrast-enhanced breast MR imaging. Piccoli CW. **Magn Reson Imaging Clin N Am** 1994 Nov; 2(4):557–71 (75 ref.)
Body MR angiography with gadolinium contrast agents. Prince MR. **Magn Reson Imaging Clin N Am** 1996 Feb; 4(1):11–24 (28 ref.)
Mangafodipir trisodium injection (Mn-DPDP). A contrast agent for abdominal MR imaging. Rofsky NM, et al. **Magn Reson Imaging Clin N Am** 1996 Feb;4(1):73–85 (49 ref.)
Contrast-enhanced MR imaging of the bladder and prostate. Siegelman ES, et al. **Magn Reson Imaging Clin N Am** 1996 Feb;4(1):153–69 (61 ref.)
Basic principles of MR contrast agents. Wolf GL, et al. **Magn Reson Imaging Clin N Am** 1996 Feb;4(1):1–10 (52 ref.)
Tracers and contrast agents in cardiovascular imaging: present and future. Marmion M, et al. **Q J Nucl Med** 1996 Mar;40(1):121–31 (43 ref.)
Selective use of radiographic low-osmolality contrast media in the 1990s. Ellis JH, et al. **Radiology** 1996 Aug; 200(2):297–311 (178 ref.)
Barium enema: colorectal polyps and carcinoma. Ott DJ. **Semin Roentgenol** 1996 Apr;31(2):125–41 (64 ref.)
[Detection of liver tumors] Rummeny EJ, et al. **Radiologe** 1995 Nov;35(11 Suppl 2):S252–8 (29 ref.) (Eng. Abstr.) **(Ger)**
[Gadolinium-DTPA (Magnevist) as contrast medium for galactography] Kaltenborn H, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1995 Nov;163(5):457–9 (14 ref.) **(Ger)**
[Lymph node diagnosis with imaging methods. An overview with special reference to recent developments in the area of MR contrast media] Mohr U, et al. **Z Lymphol** 1996 Jun;20(1):15–20 (59 ref.) (Eng. Abstr.) **(Ger)**
[The magnetic resonance assessment of craniofacial fibrous dysplasia. The completion of the study with gadolinium administration and magnetic resonance angiography] Di Girolamo M, et al. **Radiol Med (Torino)** 1996 Mar; 91(3):313–6 (10 ref.) **(Ita)**
[Contrast media for computerized and magnetic resonance tomography. Basic principles] Rinck PA, et al. **Vestn Rentgenol Radiol** 1995 Nov-Dec;(6):52–9 (22 ref.) (Eng. Abstr.) **(Rus)**

ADMINISTRATION & DOSAGE

Liposomes as delivery agents for medical imaging. Torchilin VP. **Mol Med Today** 1996 Jun;2(6):242–9 (36 ref.)
[Contrast medium administration in spiral computed tomography: the results of a consensus conference. Institute for Radiodiagnosis, Regensburg] Feuerbach S, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Feb;164(2):158–65 (23 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Reducing arrhythmogenic effects in the isolated heart enriching roentgen contrast media with electrolytes. Survey and present state. Besjakov J, et al. **Acta Radiol Suppl** 1995;399:115–21 (53 ref.)
Biochemical and morphological effects of contrast media on the kidney. Dobrota M, et al. **Acta Radiol Suppl** 1995; 399:196–203 (42 ref.)
Main results of the first comparative clinical studies on Visipaque. Grynne BH, et al. **Acta Radiol Suppl** 1995; 399:265–70 (23 ref.)
Cardiac electrophysiology, arrhythmogenic mechanisms and roentgen contrast media. Jacobsen EA, et al. **Acta Radiol Suppl** 1995;399:105–14 (60 ref.)
Sodium-calcium relationships and cardiac function during coronary bolus perfusion. Jynge P, et al. **Acta Radiol Suppl** 1995;399:122–34 (74 ref.)
Vasodilatative and vasoconstrictive effects of angiography contrast media. Karstoft J, et al. **Acta Radiol Suppl** 1995; 399:164–9 (41 ref.)
Adverse reactions in myelography. Maly P, et al. **Acta Radiol Suppl** 1995;399:230–7 (61 ref.)
A review of coronary arteriography- and contrast media-induced ventricular fibrillation. Morris TW. **Acta Radiol Suppl** 1995;399:100–4 (49 ref.)
Effects of iodinated contrast media on peripheral blood flow. Pugh ND, et al. **Acta Radiol Suppl** 1995;399:155–63 (64 ref.)
Contrast media effects on hemostatic and thrombotic parameters. Possible consequences for practical techniques and prophylactic measures. Stormorken H, et al. **Acta Radiol Suppl** 1995;399:173–81 (67 ref.)
Noncardiogenic pulmonary edema due to radiocontrast media [clinical conference] Ramesh S, et al. **Ann Allergy Asthma Immunol** 1995 Oct;75(4):308–10 (10 ref.)
Case report: Pontine haemorrhage following iohexol lumbar myelography. Yeh YF, et al. **Br J Radiol** 1996 Apr; 69(820):368–70 (28 ref.)
Contrast media-associated nephrotoxicity. Rudnick MR, et al. **Curr Opin Nephrol Hypertens** 1996 Mar;5(2):127–33 (83 ref.)
Role of mast cells, basophils and their mediators in adverse reactions to general anesthetics and radiocontrast media. Genovese A, et al. **Int Arch Allergy Immunol** 1996 May; 110(1):13–22 (102 ref.)
Reliability of experimental models of iodinated contrast media-induced acute renal failure. From methodological considerations to pathophysiology. Idée JM, et al. **Invest Radiol** 1996 Apr;31(4):230–41 (96 ref.)
Contrast media nephropathy. Mallat SG. **J Med Liban** 1995; 43(1):26–9 (44 ref.)
Treatment of adverse reactions to radiographic contrast media in adults. Cohan RH, et al. **Radiol Clin North Am** 1996 Sep;34(5):1055–76 (105 ref.)
[The endorem tolerance profile] Laniado M, et al. **Radiologe** 1995 Nov;35(11 Suppl 2):S266–70 (16 ref.) (Eng. Abstr.) **(Ger)**
[Contrast agent retention in a jejunal diverticulum and small-intestine volvulus] Hüppe T, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1995 Nov;163(5):443–5 (10 ref.) **(Ger)**
[How should informed consent for an invasive radiologic procedure be phrased in order that responsibility for contrast agent reactions be blamed on the patient himself] Barzilai M. **Harefuah** 1995 Jun 1;128(11):732–4 (33 ref.) **(Heb)**
[Anaphylactoid reactions to radiocontrast media] Confino-Cohen R, et al. **Harefuah** 1995 Jul;129(1-2):55–7 (17 ref.) **(Heb)**
[Iodinated contrast media: adverse reactions, prevention and treatment] Konen E, et al. **Harefuah** 1995 Jun 1; 128(11):719–23 (35 ref.) **(Heb)**
[Liver neoplasms due to Thorotrast] Ukida M. **Ryoikibetsu Shokogun Shirizu** 1995;(7):501–3 (19 ref.) **(Jpn)**

PHARMACOKINETICS

Intestinal permeability measurements – a new application for water soluble contrast media? Andersen R, et al. **Acta Radiol Suppl** 1995;399:247–52 (42 ref.)
MR mammography with pharmacokinetic mapping for monitoring of breast cancer treatment during neoadjuvant therapy. Knopp MV, et al. **Magn Reson Imaging Clin N Am** 1994 Nov;2(4):633–58 (42 ref.)

PHARMACOLOGY

Roentgen contrast media and fibrinolysis. Brosstad F, et al. **Acta Radiol Suppl** 1995;399:185–7 (7 ref.)
Pharmacologic profile of iobitridol, a nonionic iodinated contrast medium. Idee JM, et al. **Acta Radiol Suppl** 1996; 400:35–48 (44 ref.)
Haemodynamic and rheological effects of contrast media: the role of viscosity and osmolality. Pugh ND. **Eur Radiol** 1996;6 Suppl 2:S13–5 (12 ref.)

TOXICITY

Effects of contrast media on renal epithelial cells in culture. Andersen KJ, et al. **Acta Radiol Suppl** 1995;399:213–8 (40 ref.)
Neurotoxicity of water-soluble contrast media. Torvik A, et al. **Acta Radiol Suppl** 1995;399:221–9 (101 ref.)
Sodium-calcium balance in coronary angiography and experimental experience with iodixanol. Jynge P. **Eur Radiol** 1996;6 Suppl 2:S8–12 (19 ref.)
A toxicologic risk for using manganese complexes? A literature survey of existing data through several medical specialties. Misselwitz B, et al. **Invest Radiol** 1995 Oct; 30(10):611–20 (120 ref.)

CONTRAST SENSITIVITY

[Contrast sensitivity] Liška V. **Cesk Slov Oftalmol** 1996 Feb; 52(1):39–43 (0 ref.) **(Cze)**

PHYSIOLOGY

The role of eye movement in the detection of contrast and spatial detail. Steinman RM, et al. **Rev Oculomot Res** 1990; 4:115–212 (176 ref.)

CONTROLLED CLINICAL TRIALS

A simple analysis of crossover studies with one-group interaction. Cleophas TJ. **Int J Clin Pharmacol Ther** 1995 Jun;33(6):322–7 (25 ref.)
Formulae and tables for the determination of sample sizes and power in clinical trials for testing differences in proportions for the two-sample design: a review. Sahai H, et al. **Stat Med** 1996 Jan 15;15(1):1–21 (96 ref.)

ECONOMICS

Economic analysis alongside clinical trials: problems and potential. Drummond M. **J Rheumatol** 1995 Jul; 22(7):1403–7 (15 ref.)
OMERACT II: the biologics perspective. Strand V. **J Rheumatol** 1995 Jul;22(7):1415–7 (24 ref.)

LEGISLATION & JURISPRUDENCE

How important is consent for controlled clinical trials? MacKinnon B. **Camb Q Healthc Ethics** 1996 Spring; 5(2):221–7 (6 ref.)

STANDARDS

Psychological treatments for irritable bowel syndrome: a critique of controlled treatment trials. Talley NJ, et al. **Am J Gastroenterol** 1996 Feb;91(2):277–83 (34 ref.)

STATISTICS & NUMERICAL DATA

Design of clinical antiepileptic drug trials. Binnie CD. **Seizure** 1995 Sep;4(3):187–92 (14 ref.)

CONTROLLED CLINICAL TRIALS, RANDOMIZED see **RANDOMIZED CONTROLLED TRIALS**

CONTUSIONS

PATHOLOGY

How accurately can bruises be aged in abused children? Literature review and synthesis. Schwartz AJ, et al. **Pediatrics** 1996 Feb;97(2):254–7 (46 ref.)

PHYSIOPATHOLOGY

Experimental pulmonary contusion: review of the literature and description of a new porcine model. Cohn SM, et al. **J Trauma** 1996 Sep;41(3):565–71 (43 ref.)

CONVALESCENCE

Postacute brain injury rehabilitation. Malec JF, et al. **Arch Phys Med Rehabil** 1996 Feb;77(2):198–207 (140 ref.)
Complications and medical comorbidities of stroke. MacWalter RS, et al. **Scott Med J** 1995 Oct;40(5):134–7 (61 ref.)

PSYCHOLOGY

Social support: some pragmatic implications for health care professionals. Keeling DI, et al. **J Adv Nurs** 1996 Jan; 23(1):76–81 (36 ref.)

CONVECTION

Convective mass transfer in hemodialysis. Jaffrin MY. **Artif Organs** 1995 Nov;19(11):1162–71 (12 ref.)

CONVERGENCE, OCULAR

Spasm of the near reflex: a spectrum of anomalies. Goldstein JH, et al. **Surv Ophthalmol** 1996 Jan-Feb;40(4):269–78 (50 ref.)

PHYSIOLOGY

Neuronal circuitry controlling the near response. Mays LE, et al. **Curr Opin Neurobiol** 1995 Dec;5(6):763–8 (29 ref.)

CONVERGENT STRABISMUS see **ESOTROPIA**

CONVERSION DISORDER

[Conversion nonepileptic seizures] Amir I, et al. **Harefuah** 1996 Feb 15;130(4):272–7 (37 ref.) **(Heb)**

DIAGNOSIS

[Hysteria, dissociation and conversion. A review of concepts, classification and diagnostic instruments] Spitzer C, et al. **Psychiatr Prax** 1996 Mar;23(2):63–8 (55 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Psychogenic seizures. Lesser RP. **Neurology** 1996 Jun; 46(6):1499–507 (84 ref.)

PSYCHOLOGY

True auditory hallucinations as a conversion symptom. Nakaya M. **Psychopathology** 1995;28(4):214–9 (14 ref.)

CONVULSIONS

see related
ANTICONVULSANTS
ECLAMPSIA
EPILEPSY
KINDLING (NEUROLOGY)

CHEMICALLY INDUCED

[Encephalopathy, convulsions and hypopotassemia in theophylline poisoning: a case analysis] Suárez Ortega S, et al. **Arch Bronconeumol** 1995 Aug-Sep;31(7):368–70 (23 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Fever, convulsions and coma in scleromyxedema: a "dermato-neuro syndrome". River Y, et al. **Neurology** 1996 Jun;46(6):1778–9 (7 ref.)

CONVULSIONS

ETIOLOGY

Convulsive syncope in the aviation environment. Voge VM, et al. **Aviat Space Environ Med** 1995 Dec;66(12):1198–204 (45 ref.)

CONVULSIONS, FEBRILE

Febrile seizures: a decision-making analysis. Freeman JM, et al. **Am Fam Physician** 1995 Oct;52(5):1401–6, 1409–10 (17 ref.)

Febrile seizures: an update. Singhi PD, et al. **Indian Pediatr** 1995 May;32(5):564–72 (43 ref.)

CHEMICALLY INDUCED

Case series analysis of adverse reactions to vaccines: a comparative evaluation. Farrington CP, et al. **Am J Epidemiol** 1996 Jun 1;143(11):1165–73 (18 ref.)

EPIDEMIOLOGY

Case series analysis of adverse reactions to vaccines: a comparative evaluation. Farrington CP, et al. **Am J Epidemiol** 1996 Jun 1;143(11):1165–73 (18 ref.)

CONVULSIVE THERAPY, ELECTRIC see **ELECTROCONVULSIVE THERAPY**

COOPERATIVE BEHAVIOR

see related

COMMUNITY NETWORKS

Compliance with handwashing and barrier precautions. Larson E, et al. **J Hosp Infect** 1995 Jun;30 Suppl:88–106 (81 ref.)

The psychobiological regulation of social cooperation [comment] Cloninger CR. **Nat Med** 1995 Jul;1(7):623–5 (21 ref.) Comment on: Nat Med 1995 Jul;1(7):654–7.

Perspectives on collaboration and infrastructure development: industry perspectives. Knaak JB. **Toxicol Lett** 1995 Sep;79(1–3):305–12 (32 ref.)

Perspectives on collaboration and infrastructure development among government, academia, and industry. O'Flaherty EJ. **Toxicol Lett** 1995 Sep;79(1–3):297–8 (0 ref.)

NIEHS perspectives on collaboration among government, academia, and industry. Olden K. **Toxicol Lett** 1995 Sep; 79(1–3):287–9 (0 ref.)

COPD see **LUNG DISEASES, OBSTRUCTIVE**

COPING BEHAVIOR see **ADAPTATION, PSYCHOLOGICAL**

COPPER

see related

CERULOPLASMIN

Nucleic acid chemistry of the cuprous complexes of 1,10-phenanthroline and derivatives. Sigman DS, et al. **Met Ions Biol Syst** 1996;33:485–513 (60 ref.)

[Inherited neurological disease--relationship between an essential trace elements and Wilson/Menkes disease] Ozawa M, et al. **Nippon Rinsho** 1996 Jan;54(1):117–22 (18 ref.) (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Limits of metabolic tolerance to copper and biological basis for present recommendations and regulations. Olivares M, et al. **Am J Clin Nutr** 1996 May;63(5):846S–52S (76 ref.)

Present interpretation of the role of copper in Indian childhood cirrhosis. Pandit A, et al. **Am J Clin Nutr** 1996 May;63(5):830S–5S (59 ref.)

Wilson disease and idiopathic copper toxicosis. Scheinberg IH, et al. **Am J Clin Nutr** 1996 May;63(5):842S–5S (34 ref.)

Metal-induced hepatotoxicity. Britton RS. **Semin Liver Dis** 1996 Feb;16(1):3–12 (105 ref.)

Wilson disease: genetic basis of copper toxicity and natural history. Schilsky ML. **Semin Liver Dis** 1996 Feb; 16(1):83–95 (92 ref.)

ANALYSIS

Copper regulatory level in drinking-water as proposed by Sidhu et al. Fitzgerald DJ. **Regul Toxicol Pharmacol** 1996 Apr;23(2):173–5 (9 ref.)

BLOOD

[Copper] Nishi Y. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:815–8 (14 ref.) **(Jpn)**

CHEMISTRY

Copper biochemistry and molecular biology. Linder MC, et al. **Am J Clin Nutr** 1996 May;63(5):797S–811S (109 ref.)

'As prepared' forms of fully oxidised haem/Cu terminal oxidases. Moody AJ. **Biochim Biophys Acta** 1996 Aug 7; 1276(1):6–20 (119 ref.)

DEFICIENCY

Copper: not too little, not too much, but just right. Based on the triennial Pewterers Lecture delivered at the National Hospital for Neurology, London, on 23 March 1995. Walshe JM. **J R Coll Physicians Lond** 1995 Jul–Aug; 29(4):280–8 (57 ref.)

Hypothesis: the possible role of magnesium and copper deficiency in retinopathy of prematurity. Caddell JL. **Magnes Res** 1995 Sep;8(3):261–70 (81 ref.)

Hepatic transdifferentiation in the pancreas. Rao MS, et al. **Semin Cell Biol** 1995 Jun;6(3):151–6 (53 ref.)

METABOLISM

Menkes and Wilson diseases. Monaco AP, et al. **Adv Genet** 1995;33:233–53 (91 ref.)

Copper/zinc superoxide dismutase mutations and free radical damage in amyotrophic lateral sclerosis. Hosler BA, et al. **Adv Neurol** 1995;68:41–6 (24 ref.)

Copper biochemistry and molecular biology. Linder MC, et al. **Am J Clin Nutr** 1996 May;63(5):797S–811S (109 ref.)

Liver copper storage and transport during development: implications for cytotoxicity. Luza SC, et al. **Am J Clin Nutr** 1996 May;63(5):812S–20S (105 ref.)

Copper: not too little, not too much, but just right. Based on the triennial Pewterers Lecture delivered at the National Hospital for Neurology, London, on 23 March 1995. Walshe JM. **J R Coll Physicians Lond** 1995 Jul–Aug; 29(4):280–8 (57 ref.)

Copper and zinc metabolism in health and disease: speciation and interactions. Bremner I, et al. **Proc Nutr Soc** 1995 Jul; 54(2):489–99 (60 ref.)

Disordered copper metabolism in LEC rats, an animal model of Wilson disease: roles of metallothionein. Suzuki KT. **Res Commun Mol Pathol Pharmacol** 1995 Aug;89(2):221–40 (69 ref.)

PHARMACOKINETICS

Bioavailability of copper. Lönnerdal B. **Am J Clin Nutr** 1996 May;63(5):821S–9S (121 ref.)

Cellular copper transport. Vulpe CD, et al. **Annu Rev Nutr** 1995;15:293–322 (195 ref.)

PHYSIOLOGY

Copper as an essential nutrient. Olivares M, et al. **Am J Clin Nutr** 1996 May;63(5):791S–6S (101 ref.)

The iron–copper connection: the link to ceruloplasmin grows stronger. Harris ED. **Nutr Rev** 1995 Jun;53(6):170–3 (12 ref.)

STANDARDS

Micronutrients (magnesium, zinc, and copper): are mineral supplements needed for athletes? Lukaski HC. **Int J Sport Nutr** 1995 Jun;5 Suppl:S74–83 (37 ref.)

TOXICITY

Genetic and molecular basis for copper toxicity. Harris ZL, et al. **Am J Clin Nutr** 1996 May;63(5):836S–41S (53 ref.)

COPPER RADIOISOTOPES

DIAGNOSTIC USE

Neuropeptide receptors in health and disease: the molecular basis for in vivo imaging. Reubi JC. **J Nucl Med** 1995 Oct; 36(10):1825–35 (61 ref.)

COPROPORPHYRIA, HEREDITARY see **PORPHYRIA, HEPATIC**

COPROPORPHYRINOGEN OXIDASE

GENETICS

Molecular abnormalities of coproporphyrinogen oxidase in patients with hereditary coproporphyria. Grandchamp B, et al. **J Bioenerg Biomembr** 1995 Apr;27(2):215–9 (22 ref.)

COPROPORPHYRINOGENASE see **COPROPORPHYRINOGEN OXIDASE**

COPULATION

c-Fos expression as a tool to search for the neurobiological base of the sexual behaviour of males. Bialy M, et al. **Acta Neurobiol Exp (Warsz)** 1996;56(2):567–77 (52 ref.)

PHYSIOLOGY

Studies on clasper movement of Anopheles species. Kang W, et al. **Indian J Malariol** 1995 Mar;32(1):37–41 (12 ref.)

COPULINS see **SEX ATTRACTANTS**

COR PULMONALE see **PULMONARY HEART DISEASE**

CORAL SNAKE see **ELAPIDAE**

CORD BLOOD see **FETAL BLOOD**

CORDOCENTESIS

Use of cordocentesis in the management of preterm or growth-restricted fetuses with abnormal monitoring. Shalev E, et al. **Obstet Gynecol Surv** 1995 Dec; 50(12):839–44 (55 ref.)

METHODS

Cordocentesis. Westgren M, et al. **Gynecol Obstet Invest** 1995;40(4):227–30 (17 ref.)

CORE PROTEINS, VIRAL see **VIRAL CORE PROTEINS**

CORN

GENETICS

The Mutator transposable element system of maize. Bennetzen JL. **Curr Top Microbiol Immunol** 1996; 204:195–229 (134 ref.)

DNA methylation and activity of the maize Spm transposable element. Fedoroff NV. **Curr Top Microbiol Immunol** 1995; 197:143–64 (54 ref.)

The En/Spm transposable element of maize. Gierl A. **Curr Top Microbiol Immunol** 1996;204:145–59 (57 ref.)

The maize transposable element activator (Ac). Kunze R. **Curr Top Microbiol Immunol** 1996;204:161–94 (195 ref.)

Paramutation in maize and related allelic interactions. Patterson GI, et al. **Curr Top Microbiol Immunol** 1995; 197:121–41 (94 ref.)

The gene for pyruvate, orthophosphate dikinase in C4 plants: structure, regulation and evolution. Matsuoka M. **Plant Cell Physiol** 1995 Sep;36(6):937–43 (55 ref.)

Infertility treatment: a nuclear restorer gene in maize [comment] Levings CS 3rd. **Science** 1996 May 31; 272(5266):1279–80 (16 ref.) Comment on: Science 1996 May 31;272(5266):1334–6.

Mapping and manipulating quantitative traits in maize. Stuber CW. **Trends Genet** 1995 Dec;11(12):477–81 (46 ref.)

METABOLISM

The role of the Opaque2 transcriptional factor in the regulation of protein accumulation and amino acid metabolism in maize seeds. Yunes JA, et al. **An Acad Bras Cienc** 1994;66 Su 1 (Pt 2):227–37; quiz 237–8 (60 ref.)

URF13, a ligand-gated, pore-forming receptor for T-toxin in the inner membrane of cms-T mitochondria. Rhoads DM, et al. **J Bioenerg Biomembr** 1995 Aug;27(4):437–45 (52 ref.)

CORNEA

see related

ENDOTHELIUM, CORNEAL
KERATECTOMY, PHOTOREFRACTIVE, EXCIMER LASER
KERATOTOMY, RADIAL

A review of methods for storage of corneas for keratoplasty. Basu PK. **Indian J Ophthalmol** 1995 Jun;43(2):55–8 (30 ref.)

ANATOMY & HISTOLOGY

PAR Corneal Topography System (PAR CTS): the clinical application of close-range photogrammetry. Belin MW, et al. **Optom Vis Sci** 1995 Nov;72(11):828–37 (16 ref.)

DRUG EFFECTS

Cornea and external disease. Holland SP. **Can J Ophthalmol** 1995 Oct;30(6):296–7 (15 ref.)

ENZYMOLOGY

Activation of the phospholipase/cyclooxygenase cascade in the rabbit cornea by platelet-activating factor is challenged by PAF receptor antagonists. Hurst JS, et al. **J Ocul Pharmacol Ther** 1995 Fall;11(3):329–37 (39 ref.)

INJURIES

Corneal abrasions: diagnosis and management. Torok PG, et al. **Am Fam Physician** 1996 Jun;53(8):2521–9, 2532 (26 ref.)

Sight-threatening complications after radial keratotomy [editorial; comment] McDonnell PJ. **Arch Ophthalmol** 1996 Feb;114(2):211–2 (5 ref.) Comment on: Arch Ophthalmol 1996 Feb;114(2):129–34.

Ruptured globes following radial and hexagonal keratotomy surgery [see comments] Vinger PF, et al. **Arch Ophthalmol** 1996 Feb;114(2):129–34 (51 ref.) Comment in: Arch Ophthalmol 1996 Feb;114(2):211–2.

[The cicatrization of corneal wounds] Spineanu L. **Oftalmologia** 1995 Oct–Dec;39(4):356–60 (6 ref.) (Eng. Abstr.) **(Rum)**

METABOLISM

Class 3 aldehyde dehydrogenase. A northern perspective in the land down under. Feimer J, et al. **Adv Exp Med Biol** 1995;372:137–41 (12 ref.)

PATHOLOGY

[Indications of penetrating keratoplasty from a histopathological study of 1129 corneal buttons (from 1982 to 1991)] Leger F, et al. **J Fr Ophtalmol** 1995;18(5):331–7 (16 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Primary corneal graft failure. A national reporting system

[editorial; comment] Brightbill FS. **Arch Ophthalmol** 1995 Dec;113(12):1554–5 (9 ref.) Comment on: Arch Ophthalmol 1995 Dec;113(12):1497–502.
Cornea and external disease. Holland SP.
Can J Ophthalmol 1995 Oct;30(6):296–7 (15 ref.)
Do topical corticosteroids have a role following excimer laser photorefractive keratectomy? [see comments] Corbett MC, et al. **J Refract Surg** 1995 Sep–Oct;11(5):380–7 (64 ref.) Comment in: J Refract Surg 1995 Sep–Oct;11(5):339–40.
Intraocular lens power calculation for eyes after refractive keratotomy. Hoffer KJ. **J Refract Surg** 1995 Nov–Dec; 11(6):490–3 (4 ref.)
Barraquer Lecture. Refractive surgery: myth versus reality. Salz J. **J Refract Surg** 1995 Jul–Aug;11(4):284–300 (46 ref.)
Evaluating new refractive surgical procedures: free market madness versus regulatory rigor mortis [editorial] Waring GO 3rd. **J Refract Surg** 1995 Sep–Oct;11(5):335–9 (26 ref.)
Automated lamellar keratoplasty. American Academy of Ophthalmology [see comments] **Ophthalmology** 1996 May; 103(5):852–61 (15 ref.) Comment in: Ophthalmology 1996 May;103(5):703–4.
Photorefractive and phototherapeutic procedures. LaRussa FP, et al. **Optom Clin** 1995;4(4):51–67 (30 ref.)
How predictable are the results of excimer laser photorefractive keratectomy? A review. Grosvenor T. **Optom Vis Sci** 1995 Oct;72(10):698–712 (55 ref.)
[Clinical progress in the therapy of myopia with excimer laser keratotomy] Zhu RY, et al.
Chung Hua Yen Ko Tsa Chih 1995 May;31(3):221–5 (31 ref.) **(Chi)**
[Artificial cornea] Renard G. **Bull Acad Natl Med** 1996 Mar; 180(3):659–65; discussion 665–8 (14 ref.) (Eng. Abstr.) **(Fre)**
[Complication of keratoprosthesis of posterior fixation: retroprosthetic membranes. Apropos of 4 cases] Mortemousque B, et al. **J Fr Ophtalmol** 1995;18(10):608–13 (23 ref.) (Eng. Abstr.) **(Fre)**

ULTRASTRUCTURE

Ultrastructure of the human cornea. Beuerman RW, et al. **Microsc Res Tech** 1996 Mar 1;33(4):320–35 (51 ref.)

CORNEAL DISEASES

COMPLICATIONS

Glaucoma and findings simulating glaucoma in the Rubinstein–Taybi syndrome. Brei TJ, et al.
J Pediatr Ophthalmol Strabismus 1995 Jul–Aug; 32(4):248–52 (56 ref.)

DIAGNOSIS

Recurrent corneal erosions. Management by the primary care physician. Weinstock FJ, et al. **Postgrad Med** 1995 Nov; 98(5):155, 159–60 (8 ref.)

IMMUNOLOGY

[Autoimmune diseases of the peripheral cornea. Immunopathology, clinical aspects and therapy] Pleyer U, et al. **Klin Monatsbl Augenheilkd** 1996 Feb;208(2):73–81 (45 ref.) (Eng. Abstr.) **(Ger)**

MICROBIOLOGY

Corneal phaeohyphomycosis due to Exserohilum rostratum. A case report and brief review. Kanungo R, et al.
Acta Ophthalmol Scand 1996 Apr;74(2):197–9 (21 ref.)

PATHOLOGY

Pyogenic granuloma of the cornea: report of a case and review of the literature. Mietz H, et al.
Graefes Arch Clin Exp Ophthalmol 1996 Feb;234(2):131–6 (22 ref.)

PREVENTION & CONTROL

Transplantation of corneal tissue from donors with diseases of the central nervous system [see comments] Hogan RN, et al. **Cornea** 1995 Nov;14(6):547–53 (67 ref.) Comment in: Cornea 1995 Nov;14(6):545–6.

SURGERY

The Bowman Lecture. Naumann GO. **Eye** 1995;9 (Pt 4):395–421 (227 ref.)
[Indications of penetrating keratoplasty from a histopathological study of 1129 corneal buttons (from 1982 to 1991)] Leger F, et al. **J Fr Ophtalmol** 1995;18(5):331–7 (16 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Cornea and external disease. Holland SP.
Can J Ophthalmol 1995 Oct;30(6):296–7 (15 ref.)

VETERINARY

Diagnosis and treatment of conjunctival and corneal diseases. Nasisse MP. **Vet Q** 1995 Apr;17 Suppl 1:S42–3 (0 ref.)

CORNEAL EDEMA

ETIOLOGY

[Corneal edema, a complication of cataract surgery] Chercota V. **Oftalmologia** 1995 Oct–Dec;39(4):343–8 (9 ref.) (Eng. Abstr.) **(Rum)**

CORNEAL ENDOTHELIUM see **ENDOTHELIUM, CORNEAL**

CORNEAL OPACITY

GENETICS

Two novel molecular defects in the LCAT gene are associated with fish eye disease. Kuivenhoven JA, et al. **Arterioscler Thromb Vasc Biol** 1996 Feb;16(2):294–303 (33 ref.)

CORNEAL STROMA

SURGERY

Changing concepts in excimer laser corneal surgery [editorial] Waring GO 3rd. **J Refract Surg** 1995 May–Jun; 11(3 Suppl):S224–6 (7 ref.)

CORNEAL TRANSPLANTATION

Transplantation of corneal tissue from donors with diseases of the central nervous system [see comments] Hogan RN, et al. **Cornea** 1995 Nov;14(6):547–53 (67 ref.) Comment in: Cornea 1995 Nov;14(6):545–6.
The Bowman Lecture. Naumann GO. **Eye** 1995;9 (Pt 4):395–421 (227 ref.)

ADVERSE EFFECTS

[A case of keratitis due to Mycobacterium chelonae] Duchesne B, et al. **Bull Soc Belge Ophtalmol** 1994;254:59–62 (10 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

The mechanisms of corneal graft failure in the rat. Katami M. **Eye** 1995;9 (Pt 2):197–207 (38 ref.)
Histocompatibility antigens. Taylor CJ, et al. **Eye** 1995;9 (Pt 2):173–9 (81 ref.)
HLA–DR matching in corneal transplantation. Systematic review of published evidence. Corneal Transplant Follow–up Study Collaborators. Gore SM, et al.
Transplantation 1995 Nov 15;60(9):1033–9 (24 ref.)

METHODS

Automated lamellar keratoplasty. American Academy of Ophthalmology [see comments] **Ophthalmology** 1996 May; 103(5):852–61 (15 ref.) Comment in: Ophthalmology 1996 May;103(5):703–4.

CORNEAL ULCER

Mooren's ulcer. Chow CY, et al. **Int Ophthalmol Clin** 1996 Winter;36(1):1–13 (56 ref.)

COMPLICATIONS

Peripheral ulcerative keratitis in the collagen vascular diseases. Gregory JK, et al. **Int Ophthalmol Clin** 1996 Winter;36(1):21–30 (37 ref.)

DIAGNOSIS

[The ocular manifestations in Felty's syndrome] Giuri S. **Oftalmologia** 1996 Jan–Mar;40(1):51–7 (28 ref.) (Eng. Abstr.) **(Rum)**

CORNS see **CALLOSITIES**

CORNU AMMONIS see **HIPPOCAMPUS**

CORONARY ANEURYSM

ETIOLOGY

Coronary pseudoaneurysm after angioplasty. Flum DR, et al. **Am Surg** 1995 Dec;61(12):1035–8 (40 ref.)

RADIOGRAPHY

Coronary artery aneurysms. Report of two cases and review of the literature. Dagalp Z, et al. **Angiology** 1996 Feb; 47(2):197–201 (12 ref.)

THERAPY

The autoperfusion balloon catheter with special attention to its use as a bail–out device. Bonnier JJ. **Z Kardiol** 1995; 84 Suppl 2:79–82 (17 ref.)

CORONARY ANGIOGRAPHY

Are there gender differences or issues related to angiographic imaging of the coronary arteries? Bell MR.
Am J Card Imaging 1996 Jan;10(1):44–53 (57 ref.)
Angiographic trials of lipid–lowering therapy: end of an era? Thompson GR. **Br Heart J** 1995 Oct;74(4):343–7 (27 ref.)
Role of angiography. Anderson HV. **Cardiol Clin** 1995 Aug; 13(3):407–19 (57 ref.)
Right coronary artery pseudo–transection due to mechanical straightening during coronary angioplasty. Blankenship JC. **Cathet Cardiovasc Diagn** 1995 Sep;36(1):43–5 (7 ref.)
Our preoccupation with coronary luminology. The dissociation between clinical and angiographic findings in ischemic heart disease. Topol EJ, et al. **Circulation** 1995 Oct 15;92(8):2333–42 (85 ref.)
The role of coronary angiography after thrombolysis. Aguirre FV, et al. **Curr Opin Cardiol** 1995 Jul;10(4):381–8 (58 ref.)
Regression or stabilization of atherosclerosis means regression or stabilization of what we don't see in the arteriogram. Fuster V, et al. **Eur Heart J** 1995 Jul;16 Suppl E:6–12 (47 ref.)
The descending septal branch (Bonapace's branch). A case report and literature review of this often forgotten branch. First description in vivo. Said M, et al. **Eur Heart J** 1995 Oct;16(10):1443–7 (43 ref.)
Sodium–calcium balance in coronary angiography and experimental experience with iodixanol. Jynge P.
Eur Radiol 1996;6 Suppl 2:S8–12 (19 ref.)
Coronary arteriography in estrogen–treated postmenopausal women. Sullivan JM. **Prog Cardiovasc Dis** 1995 Nov–Dec; 38(3):211–22 (34 ref.)
[Coronary artery disease in octogenarians: contribution of coronary angiography and evaluation of therapeutic possibilities] Elbaz M, et al. **Arch Mal Coeur Vaiss** 1995 Oct;88(10):1391–8 (27 ref.) (Eng. Abstr.) **(Fre)**
[Coronary fistula in adults. Review with reference to personal experience] Zanchin L, et al. **Schweiz Med Wochenschr** 1996 Feb 24;126(8):299–307 (77 ref.) (Eng. Abstr.) **(Ger)**
[The relationship between clinical events and the angiographic lesions in coronary atherosclerosis. Hypolipemic treatment and plaque stabilization] Castro Beiras A, et al. **Rev Esp Cardiol** 1995;48 Suppl 5:23–30 (47 ref.) (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Sodium–calcium relationships and cardiac function during coronary bolus perfusion. Jynge P, et al.
Acta Radiol Suppl 1995;399:122–34 (74 ref.)
A review of coronary arteriography– and contrast media–induced ventricular fibrillation. Morris TW.
Acta Radiol Suppl 1995;399:100–4 (49 ref.)
Transient cortical blindness following bypass graft angiography. A case report. Kamata J, et al. **Angiology** 1995 Oct;46(10):937–46 (33 ref.)

INSTRUMENTATION

Intravenous coronary angiography with dichromography using synchrotron radiation. Hamm CW, et al. **Herz** 1996 Apr;21(2):127–31 (13 ref.)
Non–invasive visualization of coronary arteries with and without calcification by electron beam computed tomography. Schmermund A, et al. **Herz** 1996 Apr; 21(2):118–26 (49 ref.)

METHODS

New concepts for interpretation of intracoronary velocity and pressure tracings. Di Mario C, et al. **Br Heart J** 1995 Nov;74(5):485–92 (49 ref.)

CORONARY ANGIOPLASTY, TRANSLUMINAL BALLOON see **ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY**

CORONARY ARTERIOSCLEROSIS

see related
ATHERECTOMY, CORONARY

Arterial thrombosis for the clinician. Pathobiology and emerging concepts. Becker RC. **Cardiol Clin** 1995 Aug; 13(3):295–310 (168 ref.)

BLOOD

The influence of pretreatment low density lipoprotein cholesterol concentrations on the effect of hypocholesterolemic therapy on coronary atherosclerosis in angiographic trials. Harvard Atherosclerosis Reversibility Project Research Group. Sacks FM, et al. **Am J Cardiol** 1995 Sep 28;76(9):78C–85C (30 ref.)
Individuality of lipemic responses to diet. McGill HC Jr, et al. **Can J Cardiol** 1995 Oct;11 Suppl G:15G–27G (184 ref.)

COMPLICATIONS

Elucidation of the role of plaque instability and rupture in acute coronary events. Fuster V. **Am J Cardiol** 1995 Sep 28;76(9):24C–33C (81 ref.)
Thrombosis in ischemic heart disease. Ambrose JA, et al. **Arch Intern Med** 1996 Jul 8;156(13):1382–94 (166 ref.)
Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death. Farb A, et al. **Circulation** 1996 Apr 1; 93(7):1354–63 (46 ref.)
Morphological and functional significance of findings in unstable atherothrombotic plaque underlying acute

coronary syndromes: a review. Baroldi G. **Int J Cardiol** 1995 Aug;49 Suppl:S3–9 (18 ref.)

Presence of thrombosis in coronary atherosclerotic plaques. Escaned J, et al. **J Cardiovasc Risk** 1995 Jun;2(3):189–96 (106 ref.)

The contribution of thrombosis to the clinical expression of coronary atherosclerosis. Davies MJ. **Thromb Res** 1996 Apr 1;82(1):1–32 (137 ref.)

[Aneurysms of the left ventricle without atheromatous coronary artery disease. Apropos of 2 cases] Obadia JF, et al. **Arch Mal Coeur Vaiss** 1996 Jun;89(6):755–9 (10 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Vascular risk factors and atherosclerosis as risk factors for cognitive decline and dementia [editorial] Prince MJ. **J Psychosom Res** 1995 Jul;39(5):525–30 (31 ref.)

DIET THERAPY

Optimal diet for reducing the risk of arteriosclerosis. Jenkins DJ. **Can J Cardiol** 1995 Oct;11 Suppl G:118G–122G (55 ref.)

Individuality of lipemic responses to diet. McGill HC Jr, et al. **Can J Cardiol** 1995 Oct;11 Suppl G:15G–27G (184 ref.)

Dietary cholesterol and the optimal diet for reducing risk of atherosclerosis. McNamara DJ. **Can J Cardiol** 1995 Oct; 11 Suppl G:123G–126G (13 ref.)

DRUG THERAPY

Lipid lowering and coronary risk. Gotto AM Jr. **Isr J Med Sci** 1996 Jun;32(6):355–9 (27 ref.)

Impact of converting enzyme inhibitors and calcium entry blockers on cardiac allograft vasculopathy: from bench to bedside. Mehra MR, et al. **J Heart Lung Transplant** 1995 Nov–Dec;14(6 Pt 2):S246–9 (16 ref.)

[Local drug administration systems, preclinical and clinical use: perspectives and limitations] Gonschior P, et al. **Z Kardiol** 1996 Mar;85(3):155–65 (59 ref.) (Eng. Abstr.) **(Ger)**

[The relationship between clinical events and the angiographic lesions in coronary atherosclerosis. Hypolipemic treatment and plaque stabilization] Castro Beiras A, et al. **Rev Esp Cardiol** 1995;48 Suppl 5:23–30 (47 ref.) (Eng. Abstr.) **(Spa)**

EPIDEMIOLOGY

Are there gender differences regarding coronary artery calcification. Kung S, et al. **Am J Card Imaging** 1996 Jan; 10(1):72–7 (60 ref.)

ETIOLOGY

New aspects of risk factors for the development of atherosclerosis, including small low-density lipoprotein, homocyst(e)ine, and lipoprotein(a). Superko HR. **Curr Opin Cardiol** 1995 Jul;10(4):347–54 (91 ref.)

Homocysteine and coronary atherosclerosis. Mayer EL, et al. **J Am Coll Cardiol** 1996 Mar 1;27(3):517–27 (127 ref.)

Cholesterol and the coronary endothelium. Knight CJ, et al. **J Cardiovasc Risk** 1995 Jun;2(3):180–8 (60 ref.)

Recent insights into the mechanisms of iatrogenic arteriosclerosis [editorial] Ferns GA, et al. **J Pathol** 1995 Aug;176(4):331–2 (15 ref.)

[The importance of the dyslipidemia–arterial hypertension link in coronary atherosclerosis] Diament J, et al. **Arq Bras Cardiol** 1995 Sep;65(3):279–82 (35 ref.) **(Por)**

[Ischemic heart disease and occupational exposure to chemical substances. Review of the literature] Waissmann W, et al. **Arq Bras Cardiol** 1995 May;64(5):477–82 (87 ref.) **(Por)**

IMMUNOLOGY

The role of histoincompatibility in cardiac allograft vasculopathy. Costanzo MR. **J Heart Lung Transplant** 1995 Nov–Dec;14(6 Pt 2):S180–4 (19 ref.)

Acute rejection: culprit or coincidence in the pathogenesis of cardiac graft vascular disease? Hauptman PJ, et al. **J Heart Lung Transplant** 1995 Nov–Dec;14(6 Pt 2):S173–80 (55 ref.)

Macrophages and transplant arteriosclerosis: known and novel molecules. Russell ME. **J Heart Lung Transplant** 1995 Nov–Dec;14(6 Pt 2):S111–5 (31 ref.)

METABOLISM

Effect of vitamin E, vitamin C and beta-carotene on LDL oxidation and atherosclerosis. Jialal I, et al. **Can J Cardiol** 1995 Oct;11 Suppl G:97G–103G (97 ref.)

The role of endothelin in coronary atherosclerosis. Mathew V, et al. **Mayo Clin Proc** 1996 Aug;71(8):769–77 (76 ref.)

Anti-oxidants and coronary heart disease. Ubbink JB, et al. **S Afr Med J** 1995 Dec;85(12):1279–81 (46 ref.)

[Lipoproteins, antioxidants, and coronary cardiopathy] Guimarães AC. **Arq Bras Cardiol** 1995 Sep;65(3):289–95 (31 ref.) **(Por)**

MORTALITY

[Cholesterolemia reduction and mortality. Critical analysis] Feitosa GS. **Arq Bras Cardiol** 1995 Sep;65(3):301–4 (43 ref.) **(Por)**

PATHOLOGY

Progression and regression of the atherosclerotic plaque. de Feyter PJ, et al. **Eur Heart J** 1995 Aug;16 Suppl I:26–30 (32 ref.)

The prognostic significance of intimal proliferation in cardiac allograft vasculopathy: a paradigm shift. Mehra MR, et al. **J Heart Lung Transplant** 1995 Nov–Dec;14(6 Pt 2):S207–11 (20 ref.)

Cell biology of restenosis post-angioplasty. Badimon L, et al. **Z Kardiol** 1995;84 Suppl 4:145–9 (25 ref.)

How vessels narrow. Schwartz SM. **Z Kardiol** 1995;84 Suppl 4:129–35 (58 ref.)

PHYSIOPATHOLOGY

Pathophysiology of coronary artery disease. Fernández-Ortiz A, et al. **Clin Geriatr Med** 1996 Feb;12(1):1–21 (151 ref.)

Significance of defective endothelial signal transduction in impaired endothelium-dependent relaxation in atherosclerosis. Shimokawa H, et al. **Gerontology** 1995;41 Suppl 1:28–33 (19 ref.)

[Coronary endothelial dysfunction and graft atheromatosis following heart transplantation] Vassalli G. **Schweiz Med Wochenschr** 1995 Oct 14;125(41):1923–30 (51 ref.) (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

Benefits of exogenous oestrogen in inhibiting stress-related coronary artery atherosclerosis. Clarkson TB, et al. **Br J Obstet Gynaecol** 1996 May;103 Suppl 13:73–8; discussion 78–9 (40 ref.)

Optimal diet for reducing the risk of arteriosclerosis. Jenkins DJ. **Can J Cardiol** 1995 Oct;11 Suppl G:118G–122G (55 ref.)

Dietary cholesterol and the optimal diet for reducing risk of atherosclerosis. McNamara DJ. **Can J Cardiol** 1995 Oct; 11 Suppl G:123G–126G (13 ref.)

The role of lipid management by diet and exercise in the progression, stabilization, and regression of coronary artery atherosclerosis. LaFontaine T. **J Cardpulm Rehabil** 1995 Jul–Aug;15(4):262–8 (26 ref.)

[Prevention of coronary atherosclerosis. Determination and evaluation of lipid metabolism values] Cremer P, et al. **Fortschr Med** 1995 Nov 20;113(32):453–8 (18 ref.) (Eng. Abstr.) **(Ger)**

[Nutrition in prevention of coronary heart disease] Hrboticky N, et al. **Z Arztl Fortbild (Jena)** 1996 Feb;90(1):11–8 (27 ref.) (Eng. Abstr.) **(Ger)**

[Metabolic tolerance of isradipine. Evaluation after three months of therapy] Panuccio D, et al. **Clin Ter** 1995 Nov; 146(11):729–36 (82 ref.) (Eng. Abstr.) **(Ita)**

RADIOGRAPHY

Ultrafast computed tomography for detection of coronary artery calcification. Fusman B, et al. **Am J Card Imaging** 1995 Jul;9(3):206–12 (43 ref.)

Regression or stabilization of atherosclerosis means regression or stabilization of what we don't see in the arteriogram. Fuster V, et al. **Eur Heart J** 1995 Jul;16 Suppl E:6–12 (47 ref.)

[The relationship between clinical events and the angiographic lesions in coronary atherosclerosis. Hypolipemic treatment and plaque stabilization] Castro Beiras A, et al. **Rev Esp Cardiol** 1995;48 Suppl 5:23–30 (47 ref.) (Eng. Abstr.) **(Spa)**

REHABILITATION

[Benefits and risks of physical activity in patient with coronary heart disease] Gohlke H. **Wien Klin Wochenschr** 1995;107(24):760–5 (29 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Atherectomy (directional, rotational, extractional) and its role in percutaneous revascularization. Kaufmann UP, et al. **Curr Opin Cardiol** 1995 Jul;10(4):412–9 (53 ref.)

[Treatment policy in coronary sclerosis in The Netherlands: suitable and less suitable indications for invasive interventions] Rigter H, et al. **Ned Tijdschr Geneeskd** 1996 Aug 3;140(31):1584–7 (14 ref.) **(Dut)**

THERAPY

Right coronary artery pseudo-transection due to mechanical straightening during coronary angioplasty. Blankenship JC. **Cathet Cardiovasc Diagn** 1995 Sep;36(1):43–5 (7 ref.)

Clinical investigations of the arrest and reversal of coronary artery disease. Farmer JA, et al. **Coron Artery Dis** 1995 Jun;6(6):457–65 (40 ref.)

Atherosclerotic heart disease in the elderly. Keller NM, et al. **Curr Opin Cardiol** 1995 Jul;10(4):427–33 (77 ref.)

Regression of atherosclerosis. Does it occur and does it have clinical meaning? Brown BG, et al. **Eur Heart J** 1995 Jul; 16 Suppl E:2–5 (29 ref.)

Regression or stabilization of atherosclerosis means regression or stabilization of what we don't see in the arteriogram. Fuster V, et al. **Eur Heart J** 1995 Jul;16 Suppl E:6–12 (47 ref.)

Fish oil and antioxidants after heart transplantation: future strategies or eye of newt and wing of bat revisited? Young JB. **J Heart Lung Transplant** 1995 Nov–Dec;14(6 Pt 2):S250–4 (29 ref.)

The three processes leading to post PTCA restenosis: dependence on the lesion substrate. Fuster V, et al. **Thromb Haemost** 1995 Jul;74(1):552–9 (55 ref.)

Interrelation between atherosclerosis and restenosis. Kranzhöfer R, et al. **Z Kardiol** 1995;84 Suppl 4:125–8 (28 ref.)

[15 years of coronary angioplasty: focus on the different techniques] Dupouy P, et al. **Ann Cardiol Angeiol (Paris)** 1995 Oct;44(8):433–7 (31 ref.) (Eng. Abstr.) **(Fre)**

-Anticoagulation after intracoronary stent implantation- Bode C, et al. **Herz** 1996 Feb;21(1):60–3 (21 ref.) (Eng. Abstr.) **(Ger)**

-Differential antithrombotic therapy in patients with low and high PTCA risk- Silber S, et al. **Herz** 1996 Feb;21(1):44–59 (213 ref.) (Eng. Abstr.) **(Ger)**

[Clinical aspects and therapy of unstable angina pectoris] Rupprecht HJ, et al. **Med Klin** 1996 Jun 15;91(6):366–71 (54 ref.) **(Ger)**

[Alternative methods in interventional therapy of coronary heart disease] Erbel R, et al. **Z Kardiol** 1995;84 Suppl 2:53–64 (72 ref.) (Eng. Abstr.) **(Ger)**

[Drug and instrumental therapeutic approaches for prevention of restenosis] Höfling B, et al. **Z Kardiol** 1995; 84 Suppl 4:151–8 (36 ref.) (Eng. Abstr.) **(Ger)**

CORONARY ARTERY BYPASS

Roles of percutaneous transluminal coronary angioplasty and bypass graft surgery for the treatment of coronary artery disease. Cishek MB, et al. **Am Heart J** 1996 May; 131(5):1012–7 (58 ref.)

Transient cortical blindness following bypass graft angiography. A case report. Kamata J, et al. **Angiology** 1995 Oct;46(10):937–46 (33 ref.)

Aprotinin [see comments] Robert S, et al. **Ann Pharmacother** 1996 Apr;30(4):372–80 (68 ref.) Comment in: Ann Pharmacother 1996 Apr;30(4):407–8.

Combined valve replacement and coronary bypass grafting in osteogenesis imperfecta [see comments] Almassi GH, et al. **Ann Thorac Surg** 1995 Nov;60(5):1395–7 (15 ref.) Comment in: Ann Thorac Surg 1996 Apr;61(4):1294.

Defining neuropsychological dysfunction after coronary artery bypass grafting [see comments] Mahanna EP, et al. **Ann Thorac Surg** 1996 May;61(5):1342–7 (41 ref.) Comment in: Ann Thorac Surg 1996 May;61(5):1295–6.

Quality of life, bypass surgery and the elderly. Page SA, et al. **Can J Cardiol** 1995 Oct;11(9):777–82 (29 ref.)

Coronary angioplasty and surgical revascularization: emerging concepts. Philippides GJ, et al. **Cardiology** 1995; 86(4):324–38 (53 ref.)

Effect of residential cardiac rehabilitation following bypass surgery. Observations in Switzerland. Dubach P, et al. **Chest** 1995 Nov;108(5):1434–9 (16 ref.)

Mediastinitis after coronary artery bypass graft surgery. Risk factors and long-term survival. Milano CA, et al. **Circulation** 1995 Oct 15;92(8):2245–51 (18 ref.)

Vascular reactivity of arterial coronary artery bypass grafts—implications for their performance. Dzimiri N, et al. **Clin Cardiol** 1996 Mar;19(3):165–71 (63 ref.)

Coronary bypass surgery in the elderly. Cheitlin MD. **Clin Geriatr Med** 1996 Feb;12(1):195–205 (40 ref.)

Role of leukotrienes in coronary artery surgery. Allen SP, et al. **Curr Opin Cardiol** 1995 Nov;10(6):605–13 (93 ref.)

Molecular biology of graft occlusion. Callow AD. **Curr Opin Cardiol** 1995 Nov;10(6):569–76 (56 ref.)

Recent reports on long-term results of coronary artery bypass grafting. Hannan RL, et al. **Curr Opin Cardiol** 1995 Nov;10(6):549–55 (34 ref.)

Coronary angioplasty versus coronary surgery in the management of angina. Rickards AF, et al. **Curr Opin Cardiol** 1995 Jul;10(4):399–403 (15 ref.)

Aprotinin in patients having coronary artery bypass graft surgery. Royston D. **Curr Opin Cardiol** 1995 Nov; 10(6):591–6 (50 ref.)

Intravascular stents: current applications. Bailey SR, et al. **Curr Probl Cardiol** 1995 Sep;20(9):614–78 (191 ref.)

The management of patients with stable angina and multivessel disease. PTCA or coronary bypass surgery? Gersh BJ. **Eur Heart J** 1995 Jul;16 Suppl E:32–5 (20 ref.)

Multivessel angioplasty versus bypass surgery. A case for PTCA. Grines CL, et al. **Eur Heart J** 1995 Jul;16 Suppl E:29–31 (13 ref.)

Subacute stent thrombosis: evolving issues and current concepts. Mak KH, et al. **J Am Coll Cardiol** 1996 Feb; 27(2):494–503 (102 ref.)

Comparison of medical treatment, coronary angioplasty and coronary artery bypass surgery in patients with chronic stable angina. Gogna A, et al. **J Assoc Physicians India** 1995 Aug;43(8):548–52 (33 ref.)

Clinical aspects of preconditioning and implications for the cardiac surgeon. Kloner RA, et al. **J Card Surg** 1995 Jul; 10(4 Suppl):369–75 (38 ref.)

Con: The choice of muscle relaxants is not important in cardiac surgery [comment] Fleming N. **J Cardiothorac Vasc Anesth** 1995 Dec;9(6):772–4 (20 ref.) Comment on: J Cardiothorac Vasc Anesth 1995 Dec;9(6):786–71.

Safety issues regarding early extubation after coronary artery bypass surgery. Higgins TL. **J Cardiothorac Vasc Anesth** 1995 Oct;9(5 Suppl 1):24–9

(52 ref.)
Pro: The choice of muscle relaxants is important in cardiac surgery. Hudson RJ, et al. **J Cardiothorac Vasc Anesth** 1995 Dec;9(6):768–71 (38 ref.)
Three-dimensional intracoronary ultrasound imaging. Methodology and clinical relevance for the assessment of coronary arteries and bypass grafts. Von Birgelen C, et al. **J Cardiovasc Surg (Torino)** 1996 Apr;37(2):129–39 (100 ref.)
Thallium imaging in management of post-revascularization patients. Alazraki P, et al. **Q J Nucl Med** 1996 Mar; 40(1):85–90 (26 ref.)
Myocardial protection for coronary artery bypass in patients with acute myocardial infarction: resuscitation of ischemic myocardium. Brown WM 3rd, et al.
Semin Thorac Cardiovasc Surg 1995 Oct;7(4):191–7 (84 ref.)
Surgical intervention in acute myocardial infarction: an historical perspective [see comments] Coleman WS, et al. **Semin Thorac Cardiovasc Surg** 1995 Oct;7(4):176–83 (45 ref.) Comment in: Semin Thorac Cardiovasc Surg 1995 Oct;7(4):174–5.
Operative therapy for mitral insufficiency from coronary artery disease. Galloway AC, et al.
Semin Thorac Cardiovasc Surg 1995 Oct;7(4):227–32 (33 ref.)
Intermittent ischemia of the heart. Flameng W.
Transplant Proc 1995 Oct;27(5):2791–2 (12 ref.)
[Treatment policy in coronary sclerosis in The Netherlands: suitable and less suitable indications for invasive interventions] Rigter H, et al. **Ned Tijdschr Geneeskd** 1996 Aug 3;140(31):1584–7 (14 ref.) **(Dut)**
[Angioplasty or bypass for multitruncal coronary disease. Viewpoint of the cardiologist] Urban P.
Schweiz Med Wochenschr 1995 Oct 28;125(43):2062–6 (30 ref.) (Eng. Abstr.) **(Fre)**
[Coronary arteries and coronary artery bypass in CT: options, limitations and perspectives] Steiner P. **Aktuelle Radiol** 1995 Sep;5(5):283–9 (28 ref.) (Eng. Abstr.) **(Ger)**
[Risk predictors and secondary prevention after PTCA and bypass operations] Gulba DC, et al. **Internist (Berl)** 1995 Sep;36(9):891–901 (82 ref.) **(Ger)**
[Therapeutic measures following acute myocardial infarct: differential use of PTCA, surgery and drugs] Noll G, et al. **Schweiz Med Wochenschr** 1996 Feb 3;126(5):164–76 (81 ref.) (Eng. Abstr.) **(Ger)**
[Surgical or percutaneous revascularization in multi-vessel coronary disease] Zingone B. **G Ital Cardiol** 1995 Dec; 25(12):1607–19 (123 ref.) (Eng. Abstr.) **(Ita)**
[Quality of life after an episode of myocardial infarct] Borrello G, et al. **Minerva Cardioangiol** 1995 Jul–Aug; 43(7–8):315–27 (39 ref.) (Eng. Abstr.) **(Ita)**
[Coronary artery bypass grafting for a patient with left ventricular ejection fraction of 16%: a case report and review of the Japanese literature] Aiba M, et al.
Kyobu Geka 1995 Sep;48(10):861–4 (10 ref.) (Eng. Abstr.) **(Jpn)**
[Surgery for WPW syndrome with concomitant CABG: a case report] Ueda T, et al. **Kyobu Geka** 1996 Apr; 49(4):331–3 (5 ref.) (Eng. Abstr.) **(Jpn)**
[Papillary muscle rupture complicating acute myocardial infarction—treatment with mitral valve replacement and coronary bypass surgery in acute phase] Kyo S, et al.
Nippon Kyobu Geka Gakkai Zasshi 1996 Jun;44(6):874–81 (23 ref.) (Eng. Abstr.) **(Jpn)**
[Radiation-induced coronary ostial stenosis, a case of redo coronary bypass for the restenosis following patch angioplasty] Takewa Y, et al.
Nippon Kyobu Geka Gakkai Zasshi 1996 Feb;44(2):220–5 (16 ref.) (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Iatrogenic aorto-coronary venous fistula as a complication of coronary artery bypass surgery: patient report and review of the literature. Calkins JB Jr, et al.
Cathet Cardiovasc Diagn 1996 Jan;37(1):55–9 (19 ref.)
Adverse neurologic events: risks of intracardiac versus extracardiac surgery. Nussmeier NA.
J Cardiothorac Vasc Anesth 1996 Jan;10(1):31–7 (86 ref.)
Recent insights into the mechanisms of iatrogenic arteriosclerosis [editorial] Ferns GA, et al. **J Pathol** 1995 Aug;176(4):331–2 (15 ref.)

METHODS

Conduit options in coronary artery bypass surgery. Canver CC. **Chest** 1995 Oct;108(4):1150–5 (43 ref.)
Developments in surgical techniques for coronary revascularization. Alfieri O, et al. **Curr Opin Cardiol** 1995 Nov;10(6):556–61 (24 ref.)
Vein graft failure. Mills NL, et al. **Curr Opin Cardiol** 1995 Nov;10(6):562–8 (16 ref.)
The use of autologous saphenous vein grafts for isolated left anterior descending coronary artery revascularization. Pomar JL. **Eur Heart J** 1995 Jul;16 Suppl E:26–8 (20 ref.)
Arterial and venous conduits for coronary artery bypass. A current review. Cooper GJ, et al.
Eur J Cardiothorac Surg 1996;10(2):129–40 (197 ref.)
Percutaneous coronary revascularization versus coronary bypass surgery in multivessel disease. Banka VS, et al.
Indian Heart J 1996 Jan–Feb;48(1):73–7 (24 ref.)
[Arterial coronary bypass] Bical O. **Presse Med** 1995 Dec 9;24(38):1814–8 (22 ref.) (Eng. Abstr.) **(Fre)**

MORTALITY

Potentiation of vasculopathy by insulin: implications from an NHLBI clinical alert [editorial] Sobel BE.
Circulation 1996 May 1;93(9):1613–5 (20 ref.)

REHABILITATION

Diagnostic and functional exercise testing: test selection and interpretation. Franklin BA. **J Cardiovasc Nurs** 1995 Oct; 10(1):8–29 (57 ref.)
[Rehabilitation of the patient with coronary bypass] Quarenghi F. **Cardiologia** 1995 Nov;40(11):869–71 (14 ref.) **(Ita)**

CORONARY ARTERY DISEASE see **CORONARY DISEASE**

CORONARY ARTERY VASOSPASM see **CORONARY VASOSPASM**

CORONARY ATHERECTOMY see **ATHERECTOMY, CORONARY**

CORONARY ATHEROSCLEROSIS see **CORONARY ARTERIOSCLEROSIS**

CORONARY CIRCULATION

Coronary microvascular abnormalities in Chagas' disease [editorial] Rossi MA, et al. **Am Heart J** 1996 Jul;132(1 Pt 1):207–10 (49 ref.)
The elusive difference between hibernation and stunning in patients. Ambrosio G. **Basic Res Cardiol** 1995 Jul–Aug; 90(4):297–9 (14 ref.)
New concepts for interpretation of intracoronary velocity and pressure tracings. Di Mario C, et al. **Br Heart J** 1995 Nov;74(5):485–92 (49 ref.)
Right-to-left flow through a patent foramen ovale in acute right ventricular infarction. Two case reports and a proposal for management. Amsel BJ, et al. **Chest** 1995 Nov; 108(5):1468–71 (23 ref.)
Remodelling of the coronary arteries after thrombolysis. Davies GJ. **Eur Heart J** 1995 Aug;16 Suppl I:31–2 (12 ref.)
Coronary reserve in experimental myocardial hypertrophy. Gosse P, et al. **Eur Heart J** 1995 Aug;16 Suppl I:22–5 (28 ref.)
Local regulation of the coronary circulation in health and disease: role of nitric oxide and endothelin. Lüscher TF, et al. **Eur Heart J** 1995 May;16 Suppl C:51–8 (120 ref.)
Modulation of coronary autoregulatory responses by endothelium-derived nitric oxide. Canty JM Jr, et al.
Int J Cardiol 1995 Jul;50(3):207–15 (27 ref.)
Ultrasonography characterization of heart morphology and blood flow of lower vertebrates. Coucelo J, et al.
J Exp Zool 1996 Jun 1–15;275(2–3):73–82 (19 ref.)
A glimpse of the coronary microcirculation with myocardial contrast echocardiography. Kaul S. **J Investig Med** 1995 Aug;43(4):345–61 (45 ref.)
Increased protection of the ischemic myocardium by decreased aortic pressure. Nakamura Y, et al.
Jpn Heart J 1995 Nov;36(6):689–97 (34 ref.)
Detection of myocardial viability with 99mTc-labelled myocardial perfusion agents. Bisi G, et al.
Q J Nucl Med 1996 Mar;40(1):68–75 (60 ref.)
Quantitative assessment of myocardial perfusion: is it of clinical relevance? Stollfuss JC, et al. **Q J Nucl Med** 1996 Mar;40(1):76–84 (61 ref.)
The vascular biology of heart and lung preservation for transplantation. Pinsky DJ. **Thromb Haemost** 1995 Jul; 74(1):58–65 (50 ref.)
[Endothelial function and coronary microcirculation in arterial hypertension] Salvetti A. **Cardiologia** 1996 Apr; 41(4):319–25 (41 ref.) **(Ita)**

PHYSIOLOGY

Myocardial preconditioning promises to be a novel approach to the treatment of ischemic heart disease. Cohen MV, et al. **Annu Rev Med** 1996;47:21–9 (52 ref.)
Marine propellers: the latest topics. Kubo H.
Artif Organs 1996 Feb;20(2):109–13 (9 ref.)
Long-term ventricular wall actuation: can and should it be systematically explored? Melvin DB, et al. **Artif Organs** 1996 Jan;20(1):63–8 (13 ref.)
Glossary: methods for the measurement of coronary blood flow and myocardial perfusion. Sakka SG, et al.
Basic Res Cardiol 1996 Mar–Apr;91(2):155–78 (197 ref.)
The importance of early patency after acute myocardial infarction. Grover A, et al. **Curr Opin Cardiol** 1995 Jul; 10(4):361–6 (29 ref.)
Coronary reserve: concept and physiological variations. Bourdarias JP. **Eur Heart J** 1995 Aug;16 Suppl I:2–6 (34 ref.)
The impact of myocardial blood flow quantitation with PET on the understanding of cardiac diseases. Camici PG, et al. **Eur Heart J** 1996 Jan;17(1):25–34 (95 ref.)
Coronary vascular reserve in humans: a critical review of methods of evaluation and of interpretation of the results. Nitenberg A, et al. **Eur Heart J** 1995 Aug;16 Suppl I:7–21 (140 ref.)
Studies of the coronary circulation in Chagas' heart disease. Marin-Neto JA, et al. **Rev Paul Med** 1995 Mar–Apr; 113(2):826–34 (48 ref.)
Interrelation between atherosclerosis and restenosis. Kranzhöfer R, et al. **Z Kardiol** 1995;84 Suppl 4:125–8 (28 ref.)
Metabolic aspects of hibernating myocardium. Pantely GA, et al. **Z Kardiol** 1995;84 Suppl 4:101–5 (25 ref.)
[Coronary microangiopathy in hypertensive heart disease: pathogenesis, diagnosis and therapy] Motz W, et al.
Herz 1995 Dec;20(6):355–64 (52 ref.) (Eng. Abstr.) **(Ger)**
[Pathophysiology of the "hibernating" myocardium] Schulz R, et al. **Z Kardiol** 1995;84 Suppl 4:91–100 (40 ref.) (Eng. Abstr.) **(Ger)**
[The coronary circulation, renin-angiotensin system and ACE inhibition] Campa PP. **Cardiologia** 1995 Sep; 40(9):635–41 (97 ref.) **(Ita)**

CORONARY DISEASE

see related
ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY
CORONARY ARTERY BYPASS
MYOCARDIAL REVASCULARIZATION

Sex-specific differences in coronary artery disease risk factors, evaluation, and treatment: have they been adequately evaluated? Fetters JK, et al. **Am Heart J** 1996 Apr;131(4):796–813 (190 ref.)
Assessment of cardiac risk in noncardiac surgery. Forgosh LB, et al. **Clin Cardiol** 1995 Oct;18(10):556–62 (45 ref.)
Dyslipidemia and coronary artery disease in the elderly. LaRosa JC. **Clin Geriatr Med** 1996 Feb;12(1):33–40 (34 ref.)
Hypertension and coronary artery disease in the elderly. Messerli FH, et al. **Clin Geriatr Med** 1996 Feb;12(1):41–56 (88 ref.)
Coronary artery disease in women. Legato MJ.
Int J Fertil Menopausal Stud 1996 Mar–Apr;41(2):94–100 (41 ref.)
Coronary heart disease in women. Gender differences and effects of menopause. Villablanca AC. **Postgrad Med** 1996 Sep;100(3):191–6, 201–2 (25 ref.)
[Cardiologic progress in China, 1995] Chen S.
Chung Hua I Hsueh Tsa Chih 1995 Dec;75(12):715–6 (0 ref.) **(Chi)**
[Value of dobutamine echocardiography in the detection of coronary disease in heart transplant patient. Groupe de Recherche VACOMED] Derumeaux G, et al.
Arch Mal Coeur Vaiss 1996 Jun;89(6):687–94 (30 ref.) (Eng. Abstr.) **(Fre)**
[Transplant vasculopathy following heart transplantation] Weis M, et al. **Dtsch Med Wochenschr** 1995 Sep 29; 120(39):1327–33 (50 ref.) **(Ger)**

BLOOD

Range of serum cholesterol values in the population developing coronary artery disease. Kannel WB.
Am J Cardiol 1995 Sep 28;76(9):69C–77C (47 ref.)
Metabolic abnormalities in cardiac ischemia. Walsh MF, et al. **Cardiol Clin** 1995 Nov;13(4):529–38 (155 ref.)
Complement system in coronary heart disease: a review. Gardinali M, et al. **Immunopharmacology** 1995 Aug; 30(2):105–17 (91 ref.)
Cholesterol in patients with coronary heart disease: how low should we go? Rubins HB. **J Gen Intern Med** 1995 Aug; 10(8):464–71 (45 ref.)
Postprandial triacylglycerolaemia—nutritional implications. Roche HM, et al. **Prog Lipid Res** 1995;34(3):249–66 (110 ref.)
[Is plasma lipoprotein (a) level a reliable indicator predicting restenosis after angioplasty?] Bussière JL, et al.
Arch Mal Coeur Vaiss 1996 Apr;89(4):425–9 (24 ref.) (Eng. Abstr.) **(Fre)**
[Blood coagulation and fibrinolysis in patients with acute coronary syndrome] Ogawa H, et al.
Nippon Naika Gakkai Zasshi 1995 Oct 10;84(10):1755–9 (12 ref.) **(Jpn)**
[The effect of a reduction in plasma cholesterol on the evolution of coronary disease] Fernández-Avilés F, et al.
Rev Esp Cardiol 1995;48 Suppl 5:43–51 (36 ref.) (Eng. Abstr.) **(Spa)**

COMPLICATIONS

Noncardiac surgery in the cardiac patient: what is the question? [see comments] Bodenheimer MM.
Ann Intern Med 1996 Apr 15;124(8):763–6 (22 ref.) Comment in: Ann Intern Med 1996 Apr 15;124(8):767–72.
Screening for cardiac disease in patients having noncardiac surgery [comment] Fleisher LA, et al. **Ann Intern Med** 1996 Apr 15;124(8):767–72 (20 ref.) Comment on: Ann Intern Med 1996 Apr 15;124(8):763–6.
Diabetes mellitus and coronary heart disease in the elderly. Vokonas PS, et al. **Clin Geriatr Med** 1996 Feb;12(1):69–78 (56 ref.)
The interface of hypertension and ischemic heart disease. Pell AC, et al. **Curr Opin Cardiol** 1995 Sep;10(5):473–9 (42 ref.)
Operative therapy for mitral insufficiency from coronary artery disease. Galloway AC, et al.
Semin Thorac Cardiovasc Surg 1995 Oct;7(4):227–32 (33 ref.)

CORONARY DISEASE

DIAGNOSIS

Diagnosis of coronary artery disease in women: roles of three dimensional imaging with magnetic resonance or positron emission tomography. Patterson RE, et al. **Am J Card Imaging** 1996 Jan;10(1):78–88 (86 ref.)

New concepts for interpretation of intracoronary velocity and pressure tracings. Di Mario C, et al. **Br Heart J** 1995 Nov;74(5):485–92 (49 ref.)

Lipoprotein(a) as a marker for coronary heart disease. Duriez P, et al. **Br J Clin Pract Symp Suppl** 1996 Jan;77A:54–61 (72 ref.)

Review of rationale for diagnostic modalities in combination. Lahiri A. **Br J Clin Pract Symp Suppl** 1995 Nov;82:13–5 (6 ref.)

Magnetic resonance imaging in coronary artery disease. van der Wall EE, et al. **Circulation** 1995 Nov 1;92(9):2723–39 (198 ref.)

Progression and regression of coronary artery disease--linkage of clinical, pathologic, and angiographic findings. Matsuda Y, et al. **Clin Cardiol** 1995 Jul;18(7):412–7 (41 ref.)

Stress testing for coronary artery disease in the elderly. Schulman SP, et al. **Clin Geriatr Med** 1996 Feb; 12(1):101–19 (98 ref.)

Clinical manifestations and diagnosis of coronary artery disease. Tresch DD, et al. **Clin Geriatr Med** 1996 Feb; 12(1):89–100 (55 ref.)

Are increased plasma non-esterified fatty acid concentrations a risk marker for coronary heart disease and other chronic diseases? [editorial] Frayn KN, et al. **Clin Sci (Colch)** 1996 Apr;90(4):243–53 (129 ref.)

New invasive techniques of assessment of the physiological significance of coronary stenoses in humans. Di Mario C, et al. **Eur Heart J** 1995 Aug;16 Suppl I:104–14 (68 ref.)

Gender bias in the diagnosis and treatment of coronary artery disease. Beery TA. **Heart Lung** 1995 Nov-Dec;24(6):427–35 (64 ref.)

Coronary artery imaging by magnetic resonance. Scheidegger MB, et al. **Herz** 1996 Apr;21(2):90–6 (20 ref.)

Coronary imaging using MRI. van Rossum AC, et al. **Herz** 1996 Apr;21(2):97–105 (38 ref.)

The evaluation of chest pain in women. Douglas PS, et al. **N Engl J Med** 1996 May 16;334(20):1311–5 (55 ref.)

Preoperative assessment of patients with known or suspected coronary disease. Mangano DT, et al. **N Engl J Med** 1995 Dec 28;333(26):1750–6 (55 ref.)

Coronary artery disease in the geriatric population. Keller NM, et al. **Prog Cardiovasc Dis** 1996 Mar-Apr;38(5):407–18 (92 ref.)

Tracers and contrast agents in cardiovascular imaging: present and future. Marmion M, et al. **Q J Nucl Med** 1996 Mar;40(1):121–31 (43 ref.)

Nuclear medicine techniques and magnetic resonance imaging in coronary artery disease. Pauwels E, et al. **Q J Nucl Med** 1996 Mar;40(1):132–41 (63 ref.)

[Detection of multivessel lesions after myocardial infarction. Improvement of the predictive value of early exercise stress test by discriminant analysis] Leroy F, et al. **Arch Mal Coeur Vaiss** 1996 Feb;89(2):193–200 (31 ref.) (Eng. Abstr.) **(Fre)**

[Restenosis after angioplasty. Diagnosis and treatment] Steg PG, et al. **Presse Med** 1995 Dec 9;24(38):1825–30 (31 ref.) (Eng. Abstr.) **(Fre)**

[Stress echocardiography versus myocardial scintigraphy: comparative value in coronary heart disease] Silber S. **Herz** 1996 Apr;21(2):136–41 (68 ref.) **(Ger)**

[Intracoronary ultrasound: scientific aspects and clinical possibilities] Rickenbacher P, et al. **Schweiz Rundsch Med Prax** 1996 Mar 12;85(11):320–8 (153 ref.) (Eng. Abstr.) **(Ger)**

[Apical hypertrophic myocardiopathy and multiple fistulae between the coronary vessels and the left ventricle] Monmeneu JV, et al. **Rev Esp Cardiol** 1995 Nov; 48(11):768–70 (10 ref.) (Eng. Abstr.) **(Spa)**

DIET THERAPY

Diet in the prevention and treatment of atherosclerosis. A perspective for the elderly. Srinath U, et al. **Clin Geriatr Med** 1995 Nov;11(4):591–611 (46 ref.)

DRUG THERAPY

What benefit can be derived from treating normocholesterolemic patients with coronary artery disease? Brown G, et al. **Am J Cardiol** 1995 Sep 28; 76(9):93C–97C (20 ref.)

Anti-ischemic intervention as prognosis improvement in patients with coronary artery disease, with special focus on verapamil. Jespersen CM. **Am J Cardiol** 1996 Jun 20; 77(16):32D–36D (64 ref.)

Response of hypertensive left ventricular hypertrophy and coronary microvascular disease to calcium antagonists. Vogt M, et al. **Am J Cardiol** 1995 Nov 2;76(13):24D–30D (52 ref.)

Update on cardiovascular drugs and elders [see comments] Redeker NS, et al. **Am J Nurs** 1995 Sep;95(9):34–40; quiz 41 (9 ref.) Comment in: Am J Nurs 1995 Dec;95(12):17.

Beta-blockers in hypertensive and coronary heart disease. Goldstein S. **Arch Intern Med** 1996 Jun 24;156(12):1267–76 (89 ref.)

Antithrombotic agents in coronary artery disease. Cairns JA, et al. **Chest** 1995 Oct;108(4 Suppl):380S–400S (155 ref.)

Coronary thrombolysis. Cairns JA, et al. **Chest** 1995 Oct; 108(4 Suppl):401S–423S (141 ref.)

The 4S study. Implications for prescribing. van Boven AJ, et al. **Drugs** 1996 Apr;51(4):507–14 (55 ref.)

Advances in antithrombotic drug therapy for coronary artery disease. Rihal CS, et al. **Eur Heart J** 1995 Jul;16 Suppl D:10–21 (107 ref.)

New thrombin inhibiting strategies for coronary artery disease. Shah PK, et al. **Indian Heart J** 1995 Jul-Aug; 47(4):381–6 (41 ref.)

Ongoing clinical trials of angiotensin-converting enzyme inhibitors for treatment of coronary artery disease in patients with preserved left ventricular function. Pepine CJ. **J Am Coll Cardiol** 1996 Apr;27(5):1048–52 (14 ref.)

Modification of coronary artery disease using antithrombotic therapy. Drake-Holland AJ. **J Cardiovasc Risk** 1995 Jun; 2(3):229–33 (47 ref.)

The promise of new genetically engineered plasminogen activators. Cutler D, et al. **J Vasc Interv Radiol** 1995 Nov-Dec;6(6 Pt 2 Su):3S–7S (16 ref.)

Clinical and economic lessons from studies of coronary thrombolysis. Mark DB. **J Vasc Interv Radiol** 1995 Nov-Dec;6(6 Pt 2 Su):94S–101S (27 ref.)

Pharmacologic prevention of coronary artery disease. What do clinical trials show? Milani RV, et al. **Postgrad Med** 1996 Feb;99(2):109–12, 115–20 (38 ref.)

Calcium channel antagonists in the treatment of coronary artery disease: fundamental pharmacological properties relevant to clinical use. Opie LH. **Prog Cardiovasc Dis** 1996 Jan-Feb;38(4):273–90 (93 ref.)

Aspirin in ischemic cerebrovascular disease. How strong is the case for a different dosing regimen? [see comments] Patrono C, et al. **Stroke** 1996 Apr;27(4):756–60 (36 ref.) Comment in: Stroke 1996 Apr;27(4):585–7. Comment in: Stroke 1996 Apr;27(4):588–92.

[Controlled clinical studies of tolerance development and dosing problems in nitrate therapy] Abshagen U. **Herz** 1996 Jun;21 Suppl 1:23–30 (18 ref.) (Eng. Abstr.) **(Ger)**

[Use of nitrates in coronary heart disease including acute myocardial infarct] Auch-Schwelk W. **Herz** 1996 Jun;21 Suppl 1:31–4 (34 ref.) (Eng. Abstr.) **(Ger)**

[Characteristics of angina pectoris therapy with nitrates] Silber S. **Herz** 1996 Jun;21 Suppl 1:4–22 (331 ref.) (Eng. Abstr.) **(Ger)**

[Symptomatic therapy refractory myocardial ischemia in coronary heart disease. Chronic intermittent urokinase therapy and invasive therapeutic measures] Leschke M, et al. **Internist (Berl)** 1996 Jun;37(6):597–606 (50 ref.) **(Ger)**

[Effects of adenosine on the heart--therapeutic and diagnostic possibilities] Stark U, et al. **Wien Klin Wochenschr** 1996;108(12):343–51 (61 ref.) (Eng. Abstr.) **(Ger)**

[Local drug administration systems, preclinical and clinical use: perspectives and limitations] Gonschior P, et al. **Z Kardiol** 1996 Mar;85(3):155–65 (59 ref.) (Eng. Abstr.) **(Ger)**

[Angiotensin converting enzyme inhibitors in ischemic heart disease] Takáč M, et al. **Vnitr Lek** 1996 Apr;42(4):290–6 (62 ref.) (Eng. Abstr.) **(Slo)**

[The practical aspects of lipid management in secondary prevention] de Teresa Galván E, et al. **Rev Esp Cardiol** 1995;48 Suppl 5:52–6 (16 ref.) (Eng. Abstr.) **(Spa)**

ECONOMICS

Cost-effectiveness of alternative interventions for the prevention and treatment of coronary heart disease. Crowley S, et al. **Aust J Public Health** 1995 Aug; 19(4):336–46 (77 ref.)

Cost-effectiveness in clinical cardiology. Part 1: Coronary artery disease and congestive heart failure. Willens HJ, et al. **Chest** 1996 May;109(5):1359–69 (60 ref.)

Cost-effectiveness of accepted measures for intervention in coronary heart disease. Kuntz KM, et al. **Coron Artery Dis** 1995 Jun;6(6):472–8 (40 ref.)

27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 6. Cost effectiveness of assessment and management of risk factors. Goldman L, et al. **J Am Coll Cardiol** 1996 Apr;27(5):1020–30 (51 ref.)

EPIDEMIOLOGY

Are there gender differences or issues related to angiographic imaging of the coronary arteries? Bell MR. **Am J Card Imaging** 1996 Jan;10(1):44–53 (57 ref.)

Are there gender differences related to stress or pharmacological echocardiography? Crouse LJ, et al. **Am J Card Imaging** 1996 Jan;10(1):65–71 (29 ref.)

Gender-related imaging issues in assessment of coronary artery disease by nuclear techniques. Grover-McKay M. **Am J Card Imaging** 1996 Jan;10(1):54–64 (67 ref.)

Diagnosis of coronary artery disease in women: roles of three dimensional imaging with magnetic resonance or positron emission tomography. Patterson RE, et al. **Am J Card Imaging** 1996 Jan;10(1):78–88 (86 ref.)

High density lipoproteins and coronary heart disease. Barter PJ, et al. **Atherosclerosis** 1996 Mar;121(1):1–12 (96 ref.)

Controlling coronary risk through nutrition. Nestel PJ. **Can J Cardiol** 1995 Oct;11 Suppl G:9G–14G (19 ref.)

Coronary artery disease in women: a population-based perspective. Pagley PR, et al. **Cardiology** 1995;86(4):265–9 (24 ref.)

Alcohol and coronary heart disease: consistent relationship and public health implications. Criqui MH. **Clin Chim Acta** 1996 Mar 15;246(1-2):51–7 (27 ref.)

Hypertension, coronary artery and cerebrovascular diseases in the population. Has epidemiology changed in the last decades? Pessina AC, et al. **Clin Exp Hypertens** 1996 Apr-May;18(3-4):363–70 (18 ref.)

Clinical and epidemiologic predictors of recurrent coronary artery disease. Mathew J, et al. **Coron Artery Dis** 1995 Jun; 6(6):447–56 (58 ref.)

Coronary risk factors and their modification: lipids, smoking, hypertension, estrogen, and the elderly. Abrams J, et al. **Curr Probl Cardiol** 1995 Aug;20(8):533–610 (192 ref.)

27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 2. Clinical epidemiology: the conceptual basis for interpreting risk factors. Furberg CD, et al. **J Am Coll Cardiol** 1996 Apr;27(5):976–8 (15 ref.)

The hypothetical epidemic of coronary heart disease and atherosclerosis. Stehbens WE. **Med Hypotheses** 1995 Nov; 45(5):449–54 (55 ref.)

The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. Grodstein F, et al. **Prog Cardiovasc Dis** 1995 Nov-Dec;38(3):199–210 (86 ref.)

Fatty acid composition of adipose tissue in humans. Implications for the dietary fat-serum cholesterol-CHD issue. Seidelin KN. **Prog Lipid Res** 1995;34(3):199–217 (158 ref.)

ETHNOLOGY

Coronary artery disease among South Asians: identification of a high risk population [editorial] Jolly KS, et al. **Can J Cardiol** 1996 Jun;12(6):569–71 (32 ref.)

Special features of coronary heart disease in people of the Indian sub-continent. Vardan S, et al. **Indian Heart J** 1995 Jul-Aug;47(4):399–407 (126 ref.)

ETIOLOGY

Coronary artery obstruction caused by perivalvular abscess in aortic valve endocarditis. Schlaifer JD, et al. **Am Heart J** 1996 Feb;131(2):413–6 (8 ref.)

Elucidation of the role of plaque instability and rupture in acute coronary events. Fuster V. **Am J Cardiol** 1995 Sep 28;76(9):24C–33C (81 ref.)

Systolic ventricular dysfunction and heart failure due to coronary microangiopathy in hypertensive heart disease. Vogt M, et al. **Am J Cardiol** 1995 Nov 2;76(13):48D–53D (34 ref.)

Alcohol consumption and coronary heart disease: good habits may be more important than just good wine [see comments] Rimm EB. **Am J Epidemiol** 1996 Jun 1;143(11):1094–8; discussion 1099 (39 ref.) Comment in: Am J Epidemiol 1996 Jun 1;143(1):1089–93.

Nutritional ecogenetics: homocysteine-related arteriosclerotic vascular disease, neural tube defects, and folic acid [editorial; comment] Motulsky AG. **Am J Hum Genet** 1996 Jan;58(1):17–20 (28 ref.) Comment on: Am J Hum Genet 1996 Jan;58(1):35–41.

Childhood lipoprotein profiles and implications for adult coronary artery disease: the Bogalusa Heart Study. Srinivasan SR, et al. **Am J Med Sci** 1995 Dec;310 Suppl 1:S62–7 (36 ref.)

From the discovery of risk factors for coronary artery disease to the application of preventive measures. Wynder EL. **Am J Med Sci** 1995 Dec;310 Suppl 1:S119–22 (20 ref.)

Role of hypertension in coronary artery disease. Weber MA. **Am J Nephrol** 1996;16(3):210–6 (45 ref.)

Coronary pseudoaneurysm after angioplasty. Flum DR, et al. **Am Surg** 1995 Dec;61(12):1035–8 (40 ref.)

Atherogenic and anti-atherogenic factors in the human diet. Addis PB, et al. **Biochem Soc Symp** 1995;61:259–71 (64 ref.)

Risk factor management: the cardiologist's perspective. Jackson G. **Br J Clin Pract Symp Suppl** 1996 Jan;77A:33–9 (9 ref.)

Dyslipidaemia and coronary heart disease: nature vs nurture. Hegele RA. **Br J Hosp Med** 1995 Aug 16-Sep 5;54(4):143–6 (15 ref.)

Metabolic and cardiovascular characteristics of hypertension. Familial aspects. Neutel JM, et al. **Cardiol Clin** 1995 Nov; 13(4):539–47 (31 ref.)

Prevention and practical aspects of triggering of cardiovascular events. Tofler GH, et al. **Cardiol Clin** 1996 May;14(2):309–12 (22 ref.)

Left ventricular hypertrophy and diastolic dysfunction: their relation to coronary heart disease. Störk T, et al. **Cardiovasc Drugs Ther** 1995 Aug;9 Suppl 3:533–7 (33 ref.)

Traumatic fistula between the left anterior descending coronary artery and a left ventricular pseudoaneurysm. Haapanen YT, et al. **Cardiovasc Intervent Radiol** 1996 Jul-Aug;19(4):272–4 (11 ref.)

Alcohol, hypertension, coronary disease and stroke. Lip GY, et al. **Clin Exp Pharmacol Physiol** 1995 Mar;22(3):189–94 (66 ref.)

Postprandial state and atherosclerosis. Ebenbichler CF, et al. **Curr Opin Lipidol** 1995 Oct;6(5):286–90 (37 ref.)

Triglycerides and coronary risk. Shepherd J, et al. **Isr J Med Sci** 1996 Jun;32(6):345–55 (38 ref.)

Sequelae of Kawasaki disease in adolescents and young adults. Burns JC, et al. **J Am Coll Cardiol** 1996 Jul; 28(1):253–7 (76 ref.)

27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 3. Spectrum of risk factors for coronary heart disease. Pasternak RC, et al. **J Am Coll Cardiol** 1996 Apr;27(5):978–90 (155 ref.)

Thrombosis as a unitary hypothesis of cardiovascular risk. Noble MI. **J Cardiovasc Risk** 1995 Jun;2(3):177–9 (12 ref.)

Tumor embolism to LAD during pneumonectomy. A case report. Shah R, et al. **J Cardiovasc Surg (Torino)** 1996 Jun; 37(3):319–21 (13 ref.)

Multiple risk factors for coronary heart disease in patients with hypertension. Kaplan NM. **J Hypertens Suppl** 1995 Aug;13(2):S1–5 (30 ref.)

Stress, smoking, and the cardiovascular system. Pomerleau OF, et al. **J Subst Abuse** 1989;1(3):331–43 (50 ref.)

Thrombogenic and lipid risk factors in hypertension and coronary artery disease. Ding YA. **Jpn Circ J** 1996 Feb; 60(2):75–84 (41 ref.)

Growth in utero and coronary heart disease. Barker DJ. **Nutr Rev** 1996 Feb;54(2 Pt 2):S1–7 (40 ref.)

Homocysteine--an atherogenic and a thrombogenic factor? Ubbink JB. **Nutr Rev** 1995 Nov;53(11):323–5 (18 ref.)

[Coronary artery disease in patients with aortic abdominal aneurysm. Apropos of a consecutive series of 172 cases] Langanay T, et al. **Arch Mal Coeur Vaiss** 1996 Feb; 89(2):211–8 (30 ref.) (Eng. Abstr.) **(Fre)**

[Coronary disease and diabetes] Passa P, et al. **Diabete Metab** 1995 Dec;21(6):446–51 (19 ref.) **(Fre)**

[Diabetic cardiopathy (editorial)] Mattioli G. **Cardiologia** 1995 Aug;40(8):535–9 (15 ref.) **(Ita)**

[Radiation-induced coronary ostial stenosis, a case of redo coronary bypass for the restenosis following patch angioplasty] Takewa Y, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Feb;44(2):220–5 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Graft vascular disease. Its pathogenesis and diagnosis] Muñoz Aguilera R, et al. **Rev Esp Cardiol** 1995;48 Suppl 7:115–28 (164 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

[The Finnish genes of coronary heart disease] Kontula K, et al. **Duodecim** 1994;110(7):721–9 (43 ref.) **(Fin)**

[Lipoprotein(a)--atherogenic waste product of evolution?] Kronenberg F, et al. **Wien Med Wochenschr** 1994; 144(12–13):324–30 (68 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Role of antibody and indirect antigen presentation in transplant-associated coronary artery vasculopathy. Rose ML. **J Heart Lung Transplant** 1996 Apr;15(4):342–9 (75 ref.)

METABOLISM

Triglycerides and coronary risk. Shepherd J, et al. **Isr J Med Sci** 1996 Jun;32(6):345–55 (38 ref.)

Homocysteine as a risk factor for coronary artery disease. Meleady RA, et al. **J Cardiovasc Risk** 1995 Jun;2(3):216–21 (52 ref.)

Lipoprotein (a): a prothrombotic risk factor for coronary artery disease. Seed M, et al. **J Cardiovasc Risk** 1995 Jun; 2(3):206–15 (67 ref.)

MORTALITY

Patterns of aspirin use in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study. Shahar E, et al. **Am Heart J** 1996 May;131(5):915–22 (37 ref.)

Vitamin intake in Great Britain: association with mortality rates for coronary heart disease. Ashwell M, et al. **Bibl Nutr Dieta** 1995;(52):128–36 (9 ref.)

Review of moderate alcohol consumption and reduced risk of coronary heart disease: is the effect due to beer, wine, or spirits. Rimm EB, et al. **BMJ** 1996 Mar 23; 312(7033):731–6 (57 ref.)

[Decrease in coronary heart disease mortality in 1974–1992 largely explainable by changes in cholesterol and smoking risk factors (see comments)] Oei LT, et al. **Ned Tijdschr Geneeskd** 1995 Nov 11;139(45):2309–14 (31 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1995 Dec 30;139(52):2756–7. **(Dut)**

NURSING

Risk profile screening. Froelicher ES, et al. **J Cardiovasc Nurs** 1995 Oct;10(1):30–50 (89 ref.)

PATHOLOGY

Induction of tissue inhibitor of metalloproteinase and its mitogenic response to endothelial cells in human atherosclerotic and restenotic lesions. Tyagi SC, et al. **Can J Cardiol** 1996 Apr;12(4):353–62 (42 ref.)

Mechanisms and prevention of restenosis: from experimental models to clinical practice. Bauters C, et al. **Cardiovasc Res** 1996 Jun;31(6):835–46 (181 ref.)

Fibromuscular dysplasia of coronary arteries as a rare cause of death. Zack F, et al. **Int J Legal Med** 1996;108(4):215–8 (18 ref.)

Cardiac allograft vasculopathy: the central pathogenetic role of ischemia-induced endothelial cell injury. Day JD, et al. **J Heart Lung Transplant** 1995 Nov-Dec;14(6 Pt 2):S142–9 (84 ref.)

The pathogenesis of graft vascular disease: implications of vascular remodeling. Gibbons GH. **J Heart Lung Transplant** 1995 Nov-Dec;14(6 Pt 2):S149–58 (59 ref.)

The three mechanisms for coronary artery disease progression: insights into future management. McLaughlin MA, et al. **Mt Sinai J Med** 1995 Sep;62(4):265–74 (63 ref.)

[Surgical or percutaneous revascularization in multi-vessel coronary disease] Zingone B. **G Ital Cardiol** 1995 Dec; 25(12):1607–19 (123 ref.) (Eng. Abstr.) **(Ita)**

PHYSIOPATHOLOGY

Alcohol, coronary disease, and hypertension. Klatsky AL. **Annu Rev Med** 1996;47:149–60 (95 ref.)

Hemodynamic changes as triggers of cardiovascular events. Deedwania PC. **Cardiol Clin** 1996 May;14(2):229–38 (57 ref.)

Circadian patterns and triggers of sudden cardiac death. Peters RW. **Cardiol Clin** 1996 May;14(2):185–94 (42 ref.)

The role of thrombin and thrombin inhibitors in coronary angioplasty. Ali MN, et al. **Chest** 1995 Nov;108(5):1409–19 (78 ref.)

Smoking and coronary artery disease. Tresch DD, et al. **Clin Geriatr Med** 1996 Feb;12(1):23–32 (58 ref.)

Diabetic cardiomyopathy. A unique entity or a complication of coronary artery disease? Bell DS. **Diabetes Care** 1995 May;18(5):708–14 (79 ref.)

Local regulation of the coronary circulation in health and disease: role of nitric oxide and endothelin. Lüscher TF, et al. **Eur Heart J** 1995 May;16 Suppl C:51–8 (120 ref.)

Coronary artery disease: prevention of progression and prevention of events. Simoons ML, et al. **Eur Heart J** 1995 Jun;16(6):729–33 (21 ref.)

Potential mechanisms promoting restenosis in diabetic patients. Aronson D, et al. **J Am Coll Cardiol** 1996 Mar 1;27(3):528–35 (103 ref.)

27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 1. Pathogenesis of coronary disease: the biologic role of risk factors. Fuster V, et al. **J Am Coll Cardiol** 1996 Apr;27(5):964–76 (82 ref.)

Baroreflex sensitivity. La Rovere MT, et al. **J Cardiovasc Electrophysiol** 1995 Sep;6(9):761–74 (86 ref.)

Role of catecholamines and sympathetic activation as a risk factor for coronary artery disease. Amadi A, et al. **J Cardiovasc Risk** 1995 Jun;2(3):222–8 (66 ref.)

A review of heart rate and blood pressure responses in the cold in healthy subjects and coronary artery disease patients. Emmett JD. **J Cardpulm Rehabil** 1995 Jan-Feb; 15(1):19–24 (47 ref.)

Hypertension and coronary artery disease: cause and effect. McInnes GT. **J Hypertens Suppl** 1995 Aug;13(2):S49–56 (77 ref.)

Aspirin in ischemic cerebrovascular disease. How strong is the case for a different dosing regimen? [see comments] Patrono C, et al. **Stroke** 1996 Apr;27(4):756–60 (36 ref.) Comment in: Stroke 1996 Apr;27(4):585–7. Comment in: Stroke 1996 Apr;27(4):588–92.

Intermittent ischemia of the heart. Flameng W. **Transplant Proc** 1995 Oct;27(5):2791–2 (12 ref.)

[The effect of menopause on risk factors for ischemic diseases] de Kleijn MJ, et al. **Ned Tijdschr Geneeskd** 1996 Mar 2;140(9):478–82 (45 ref.) **(Dut)**

[Restenosis: physiopathology, treatments and prevention] Lafont A, et al. **Ann Cardiol Angeiol (Paris)** 1995 Sep; 44(7):349–53 (31 ref.) (Eng. Abstr.) **(Fre)**

[Asymptomatic ischemia--an important part of the spectrum of coronary disease] Rutishauser W, et al. **Schweiz Rundsch Med Prax** 1995 Oct 17;84(42):1181–5 (28 ref.) (Eng. Abstr.) **(Fre)**

[Late ventricular potentials: significance, electrophysiology and clinical importance in coronary disease] Zimmermann M. **Schweiz Rundsch Med Prax** 1996 Apr 30;85(18):604–12 (51 ref.) (Eng. Abstr.) **(Fre)**

[Pharmacology of nitrates and other NO donors] Dendorfer A. **Herz** 1996 Jun;21 Suppl 1:38–49 (54 ref.) (Eng. Abstr.) **(Ger)**

[Coronary microangiopathy in hypertensive heart disease: pathogenesis, diagnosis and therapy] Motz W, et al. **Herz** 1995 Dec;20(6):355–64 (52 ref.) (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

Risk factors and differential antihypertensive therapies. Os I. **Acta Med Austriaca** 1995;22(3):45–7 (31 ref.)

Remodeling cardiac rehabilitation into secondary prevention programs. Merz CN, et al. **Am Heart J** 1996 Aug;132(2 (Pt 1)):418–27 (56 ref.)

Extending the benefit of lipid-regulating therapy to primary prevention. Jones PH, et al. **Am J Cardiol** 1995 Sep 28; 76(9):118C–121C (17 ref.)

Cardioprotection and antihypertensive therapy: the key importance of addressing the associated coronary risk factors (the Framingham experience). Kannel WB. **Am J Cardiol** 1996 Feb 22;77(6):6B–11B (19 ref.)

Epidemiologic evidence for vitamin E in prevention of cardiovascular disease. Stampfer MJ, et al. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1365S–1369S (27 ref.)

The coronary artery disease paradox. Black HR. **Am J Hypertens** 1996 Apr;9(4 Pt 3):2S–10S (66 ref.)

What accounts for the association of vegetables and fruits with lower incidence of cancers and coronary heart disease? [editorial; comment] Omenn GS. **Ann Epidemiol** 1995 Jul;5(4):333–5 (12 ref.) Comment on: Ann Epidemiol 1995 Jul;5(4):255–60. Comment on: Ann Epidemiol 1995 Jul;5(4):261–9.

Lowering risk without lowering cholesterol: implications for national cholesterol policy. Avins AL, et al. **Ann Intern Med** 1996 Sep 15;125(6):502–6 (35 ref.)

Cholesterol screening in asymptomatic adults, revisited. Part 2 [see comments] Garber AM, et al. **Ann Intern Med** 1996 Mar 1;124(5):518–31 (121 ref.) Comment in: Ann Intern Med 1996 Mar 1;124(5):505–8. Comment in: Ann Intern Med 1996 Mar 1;124(5):513–4.

Cholesterol reduction: weighing the benefits and risks. Gaziano JM, et al. **Ann Intern Med** 1996 May 15; 124(10):914–8 (29 ref.)

The cholesterol controversy [see comments] Geurian KL. **Ann Pharmacother** 1996 May;30(5):495–500 (60 ref.) Comment in: Ann Pharmacother 1996 May;30(5):539–42.

Cholesterol-lowering therapy: is there really a controversy? [comment] Jungnickel PW. **Ann Pharmacother** 1996 May; 30(5):539–42 (33 ref.) Comment on: Ann Pharmacother 1996 May;30(5):495–500.

Meta-analysis, clinical trials, and transferability of research results into practice. The case of cholesterol-lowering interventions in the secondary prevention of coronary heart disease. Marchioli R, et al. **Arch Intern Med** 1996 Jun 10; 156(11):1158–72 (163 ref.)

Cost-effectiveness of alternative interventions for the prevention and treatment of coronary heart disease. Crowley S, et al. **Aust J Public Health** 1995 Aug; 19(4):336–46 (77 ref.)

Angiographic trials of lipid-lowering therapy: end of an era? Thompson GR. **Br Heart J** 1995 Oct;74(4):343–7 (27 ref.)

Prevention of both osteoporosis and coronary heart disease in primary care. Waine C. **Br J Clin Pract** 1996 Jan-Feb; 50(1):44–6 (12 ref.)

Lipid management: past, present, and future. Betteridge DJ. **Br J Clin Pract Symp Suppl** 1996 Jan;77A:1–10 (49 ref.)

Fluvastatin for the prevention of restenosis after coronary balloon angioplasty: angiographic and methodological background of the fluvastatin angioplasty restenosis trial. Foley DP, et al. **Br J Clin Pract Symp Suppl** 1996 Jan; 77A:40–53 (53 ref.)

The patient at risk: who should we be treating? Shviro I, et al. **Br J Clin Pract Symp Suppl** 1996 Jan;77A:24–7 (25 ref.)

Hormone replacement therapy and cardiovascular disease: the human model. Sullivan JM. **Br J Obstet Gynaecol** 1996 May;103 Suppl 13:59–65; discussion 66–7 (34 ref.)

Dietary fibre, complex carbohydrate and coronary artery disease. Anderson JW. **Can J Cardiol** 1995 Oct;11 Suppl G:55G–62G (98 ref.)

Controlling coronary risk through nutrition. Nestel PJ. **Can J Cardiol** 1995 Oct;11 Suppl G:9G–14G (19 ref.)

Sympathetic nervous system as a coronary risk factor in hypertension. Julius S, et al. **Cardiologia** 1996 Apr; 41(4):309–17 (85 ref.)

Primary prevention of coronary heart disease in women. Meilahn EN, et al. **Cardiology** 1995;86(4):286–98 (134 ref.)

Coronary heart disease in African Americans: primary and secondary prevention. Clark LT, et al. **Cleve Clin J Med** 1995 Sep-Oct;62(5):285–92 (52 ref.)

Lipid-regulating and antiatherosclerotic therapy: current options and future approaches. Gotto AM Jr. **Cleve Clin J Med** 1996 Jan-Feb;63(1):31–41 (48 ref.)

Nonlipid primary and secondary prevention strategies for coronary heart disease. Maron DJ. **Clin Cardiol** 1996 May; 19(5):419–23 (36 ref.)

Alcohol and coronary heart disease: the evidence for a protective effect. Kannel WB, et al. **Clin Chim Acta** 1996 Mar 15;246(1–2):59–76 (44 ref.)

Physical inactivity and coronary heart disease in elderly patients. Wenger NK. **Clin Geriatr Med** 1996 Feb; 12(1):79–88 (88 ref.)

Coronary risk factors and their modification: lipids, smoking, hypertension, estrogen, and the elderly. Abrams J, et al. **Curr Probl Cardiol** 1995 Aug;20(8):533–610 (192 ref.)

Cholesterol screening in children. Benuck I. **Curr Probl Pediatr** 1995 Sep;25(8):254–60 (45 ref.)

Prevention of macrovascular disease: absolute proof or absolute risk? [editorial] [see comments] Durrington PN. **Diabet Med** 1995 Jul;12(7):561–2 (12 ref.) Comment in: Diabet Med 1996 Mar;13(3):284–5.

Aspirin for primary prevention of coronary disease. Fuster V, et al. **Eur Heart J** 1995 Jul;16 Suppl E:16–20 (23 ref.)

Alcohol and coronary heart disease. Shaper AG. **Eur Heart J** 1995 Dec;16(12):1760–4 (20 ref.)

Coronary artery disease: prevention of progression and prevention of events. Simoons ML, et al. **Eur Heart J** 1995 Jun;16(6):729–33 (21 ref.)

Mechanisms whereby oestrogens influence arterial health. Stevenson JC. **Eur J Obstet Gynecol Reprod Biol** 1996 Mar; 65(1):39–42 (30 ref.)

Hypertension and CHD risk: whither alpha-1 blockers? Pandit RB. **Indian Heart J** 1996 May-Jun;48(3):265–71 (41 ref.)

Exercise and the prevention of dyslipidemia and coronary heart disease. Després JP, et al. **Int J Obes Relat Metab Disord** 1995 Oct;19 Suppl 4:S45–51

(72 ref.)
The women's health agenda: evolution of hormone replacement therapy as treatment and prophylaxis for coronary artery disease. King KM, et al. **J Adv Nurs** 1996 May;23(5):984–91 (39 ref.)
27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 5. Stratification of patients into high, medium and low risk subgroups for purposes of risk factor management. Califf RM, et al. **J Am Coll Cardiol** 1996 Apr; 27(5):1007–19 (68 ref.)
27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 4. Efficacy of risk factor management. Forrester JS, et al. **J Am Coll Cardiol** 1996 Apr; 27(5):991–1006 (163 ref.)
27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 8. Organization of preventive cardiology service. Pearson TA, et al. **J Am Coll Cardiol** 1996 Apr;27(5):1039–47 (71 ref.)
27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 7. Evaluation and management of risk factors for the individual patient (case management). Swan HJ, et al. **J Am Coll Cardiol** 1996 Apr;27(5):1030–9 (37 ref.)
Primary prevention of coronary artery disease. St. Pierre M, et al. **J Ark Med Soc** 1996 Jul;93(2):89–91 (14 ref.)
Physical activity and cardiovascular risk. Hardman A. **J Cardiovasc Risk** 1995 Aug;2(4):285–8 (17 ref.)
Epidemiology of physical activity, physical fitness and coronary heart disease. Whaley MH, et al. **J Cardiovasc Risk** 1995 Aug;2(4):289–95 (38 ref.)
Treating elevated cholesterol levels: the great Satan in perspective. Gibaldi M, et al. **J Clin Pharmacol** 1996 Mar; 36(3):189–97 (45 ref.)
Reduction of tobacco health hazards in continuing users: individual behavioral and public health approaches. Kozlowski LT. **J Subst Abuse** 1989;1(3):345–57 (50 ref.)
Phytoestrogens—a short review. Knight DC, et al. **Maturitas** 1995 Nov;22(3):167–75 (89 ref.)
Dietary antioxidants in disease prevention. Gordon M. **Nat Prod Rep** 1996 Aug;13(4):265–73 (130 ref.)
Pharmacologic prevention of coronary artery disease. What do clinical trials show? Milani RV, et al. **Postgrad Med** 1996 Feb;99(2):109–12, 115–20 (38 ref.)
Lifestyle change for coronary artery disease. What to tell patients. O'Keefe JH Jr, et al. **Postgrad Med** 1996 Feb; 99(2):89–92, 95–6, 102–6 (34 ref.)
Hyperlipidemia. When does treatment make a difference? Wise GR, et al. **Postgrad Med** 1996 Jul;100(1):138–49 (17 ref.)
The nonhuman primate model of the relationship between gonadal steroids and coronary heart disease. Clarkson TB, et al. **Prog Cardiovasc Dis** 1995 Nov–Dec;38(3):189–98 (34 ref.)
The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. Grodstein F, et al. **Prog Cardiovasc Dis** 1995 Nov–Dec;38(3):199–210 (86 ref.)
Blood pressure lowering for the primary and secondary prevention of coronary and cerebrovascular disease. MacMahon S, et al. **Schweiz Med Wochenschr** 1995 Dec 26;125(51–52):2479–86 (28 ref.)
[Prevention of coronary disease in clinical practice. Guidelines of the working group of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension] Pyörälä K, et al. **Arch Mal Coeur Vaiss** 1995 Oct;88(10 Suppl):1493–542 (192 ref.) **(Fre)**
[Hormone replacement therapy in menopausal women previously treated for breast cancer (editorial)] This P. **Presse Med** 1996 Feb 3;25(4):141–4 (25 ref.) (Eng. Abstr.) **(Fre)**
[Antihypertensive therapy and coronary heart disease: significance of the effect of concomitant cardiovascular risk factors] Huber K, et al. **Acta Med Austriaca** 1995; 22(3):48–51 (47 ref.) (Eng. Abstr.) **(Ger)**
[Estrogen-gestagen substitution in geriatric gynecology. Long-term prevention for the third segment of life after menopause] Lauritzen C. **Fortschr Med** 1996 May 30; 114(15):187–90 (0 ref.) (Eng. Abstr.) **(Ger)**
[Risk predictors and secondary prevention after PTCA and bypass operations] Gulba DC, et al. **Internist (Berl)** 1995 Sep;36(9):891–901 (82 ref.) **(Ger)**
[Secondary prevention of coronary heart disease with lipid lowering drugs. Evaluating outcome eliminates the controversy] Pedersen TR. **Internist (Berl)** 1995 Dec; 36(12):1174–8 (32 ref.) **(Ger)**
[Risk predictors and primary prevention of coronary heart disease] Stenzinger W. **Internist (Berl)** 1995 Sep; 36(9):875–82 (56 ref.) **(Ger)**
[Hypertension and coronary heart disease. Global risk moderation through control of body weight] Suter PM, et al. **Schweiz Rundsch Med Prax** 1996 Jan 30;85(5):113–6 (18 ref.) (Eng. Abstr.) **(Ger)**
[Blood thinning in heart patients] Meier B. **Ther Umsch** 1995 Oct;52(10):661–71 (55 ref.) (Eng. Abstr.) **(Ger)**
[Prevention of cardiovascular diseases by hormone replacement in postmenopause] Windler E. **Zentralbl Gynakol** 1996;118(4):188–97 (77 ref.) (Eng. Abstr.) **(Ger)**
[The role of physical activity in the prevention of certain internal diseases] Jákó P. **Orv Hetil** 1995 Oct 29; 136(44):2379–83 (44 ref.) (Eng. Abstr.) **(Hun)**
[Introduction to ischemic preconditioning of the heart] Della Bella D. **Cardiologia** 1996 Apr;41(4):331–42 (77 ref.) **(Ita)**
[Prevention of coronary disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension] Pyörälä K, et al. **Cardiologia** 1996 Feb;41(2):149–82 (192 ref.) **(Ita)**
[Can vitamin E prevent development of coronary heart disease?] Nguyen KN, et al. **Tidsskr Nor Laegeforen** 1996 Mar 30;116(9):1109–13 (61 ref.) (Eng. Abstr.) **(Nor)**
[Menopause, hormonal replacement therapy, and coronary disease] Gebara OC, et al. **Arq Bras Cardiol** 1995 Apr; 64(4):355–8 (40 ref.) **(Por)**
[Why the cardiologists should be interested in lipids?] López-Sendón JL, et al. **Rev Esp Cardiol** 1995;48 Suppl 2:23–32 (61 ref.) (Eng. Abstr.) **(Spa)**
[The control of cholesterol in the prevention of coronary cardiopathy] Vintró IB. **Rev Esp Salud Publica** 1995 Nov–Dec;69(6):439–43 (21 ref.) **(Spa)**

PSYCHOLOGY

Life-threatening cardiovascular consequences of anger in patients with coronary heart disease. Verrier RL, et al. **Cardiol Clin** 1996 May;14(2):289–307 (112 ref.)

RADIOGRAPHY

Are there gender differences or issues related to angiographic imaging of the coronary arteries? Bell MR. **Am J Card Imaging** 1996 Jan;10(1):44–53 (57 ref.)
Ultrafast computed tomography for detection of coronary artery calcification. Fusman B, et al. **Am J Card Imaging** 1995 Jul;9(3):206–12 (43 ref.)
Intravenous coronary angiography with dichromography using synchrotron radiation. Hamm CW, et al. **Herz** 1996 Apr;21(2):127–31 (13 ref.)
Non-invasive visualization of coronary arteries with and without calcification by electron beam computed tomography. Schmermund A, et al. **Herz** 1996 Apr; 21(2):118–26 (49 ref.)
Electron beam computed tomography and coronary artery disease: scanning for coronary artery calcification. Rumberger JA, et al. **Mayo Clin Proc** 1996 Apr; 71(4):369–77 (30 ref.)
Coronary arteriography in estrogen-treated postmenopausal women. Sullivan JM. **Prog Cardiovasc Dis** 1995 Nov–Dec; 38(3):211–22 (34 ref.)
Single coronary artery: a case report and review of current literature. Barendra C, et al. **Singapore Med J** 1995 Jun; 36(3):335–7 (16 ref.)
[Coronary arteries and coronary artery bypass in CT: options, limitations and perspectives] Steiner P. **Aktuelle Radiol** 1995 Sep;5(5):283–9 (28 ref.) (Eng. Abstr.) **(Ger)**
[Coronary fistula in adults. Review with reference to personal experience] Zanchin L, et al. **Schweiz Med Wochenschr** 1996 Feb 24;126(8):299–307 (77 ref.) (Eng. Abstr.) **(Ger)**

RADIONUCLIDE IMAGING

Gender-related imaging issues in assessment of coronary artery disease by nuclear techniques. Grover-McKay M. **Am J Card Imaging** 1996 Jan;10(1):54–64 (67 ref.)
The current status of clinical PET imaging. Cook GJ, et al. **Clin Radiol** 1996 Sep;51(9):603–13 (108 ref.)
What is the current status of quantification and nuclear medicine in cardiology? Hör G. **Eur J Nucl Med** 1996 Jul; 23(7):815–51 (483 ref.)
Thallium imaging in management of post-revascularization patients. Alazraki P, et al. **Q J Nucl Med** 1996 Mar; 40(1):85–90 (26 ref.)
Detection of myocardial viability with 99mTc-labelled myocardial perfusion agents. Bisi G, et al. **Q J Nucl Med** 1996 Mar;40(1):68–75 (60 ref.)
Quantitative assessment of myocardial perfusion: is it of clinical relevance? Stollfuss JC, et al. **Q J Nucl Med** 1996 Mar;40(1):76–84 (61 ref.)
Nuclear cardiology and echocardiography for the assessment of myocardial viability. Tarolo GL, et al. **Q J Nucl Med** 1996 Mar;40(1):91–107 (124 ref.)
[Continuous ambulatory measurement of left ventricular function by an isotopic method] Millaire A. **Arch Mal Coeur Vaiss** 1995 Oct;88(10):1453–63 (30 ref.) (Eng. Abstr.) **(Fre)**
[Scintigraphic evaluation of the ischemically damaged myocardium in patients with reduced left ventricular function. From clinical aspects to the cell] Schwaiger M, et al. **Z Kardiol** 1995;84 Suppl 4:115–23 (65 ref.) (Eng. Abstr.) **(Ger)**

REHABILITATION

Remodeling cardiac rehabilitation into secondary prevention programs. Merz CN, et al. **Am Heart J** 1996 Aug;132(2 (Pt 1)):418–27 (56 ref.)
Effect of residential cardiac rehabilitation following bypass surgery. Observations in Switzerland. Dubach P, et al. **Chest** 1995 Nov;108(5):1434–9 (16 ref.)
Exercise training for coronary artery disease in the elderly. Brechue WF, et al. **Clin Geriatr Med** 1996 Feb;12(1):207–29 (91 ref.)
Diagnostic and functional exercise testing: test selection and interpretation. Franklin BA. **J Cardiovasc Nurs** 1995 Oct; 10(1):8–29 (57 ref.)

SURGERY

Management of restenosis after coronary intervention. Dangas G, et al. **Am Heart J** 1996 Aug;132(2 (Pt 1)):428–36 (58 ref.)
Matching to guide the design and predict the outcome of randomized atherectomy trials [editorial] Umans VA, et al. **Am Heart J** 1995 Nov;130(5):1135–43 (48 ref.)
Transient cortical blindness following bypass graft angiography. A case report. Kamata J, et al. **Angiology** 1995 Oct;46(10):937–46 (33 ref.)
Combined valve replacement and coronary bypass grafting in osteogenesis imperfecta [see comments] Almassi GH, et al. **Ann Thorac Surg** 1995 Nov;60(5):1395–7 (15 ref.) Comment in: Ann Thorac Surg 1996 Apr;61(4):1294.
Repair of an aneurysm of the left main coronary artery. Lepojärvi M, et al. **Ann Thorac Surg** 1996 Apr;61(4):1247–9 (11 ref.)
Coronary bypass surgery in the elderly. Cheitlin MD. **Clin Geriatr Med** 1996 Feb;12(1):195–205 (40 ref.)
Intravascular stents: current applications. Bailey SR, et al. **Curr Probl Cardiol** 1995 Sep;20(9):614–78 (191 ref.)
The management of patients with stable angina and multivessel disease. PTCA or coronary bypass surgery? Gersh BJ. **Eur Heart J** 1995 Jul;16 Suppl E:32–5 (20 ref.)
The use of the internal mammary artery for revascularization of the left anterior descending coronary artery. Puga J. **Eur Heart J** 1995 Jul;16 Suppl E:21–5 (11 ref.)
Percutaneous revascularization strategies. Usefulness in ischemic coronary artery disease. Garratt KN. **Postgrad Med** 1996 Feb;99(2):125–6, 129–31, 135–7 (30 ref.)
The surgical management of allograft coronary disease: a paradigm shift. Miller LW, et al. **Semin Thorac Cardiovasc Surg** 1996 Apr;8(2):133–8 (54 ref.)
Complete revascularization with internal thoracic artery grafts. Tector AJ, et al. **Semin Thorac Cardiovasc Surg** 1996 Jan;8(1):29–41 (67 ref.)
[Excimer laser assisted angioplasty. Immediate results in the treatment of complex coronary lesions] Escojido H, et al. **Arch Mal Coeur Vaiss** 1996 Apr;89(4):407–15 (29 ref.) (Eng. Abstr.) **(Fre)**
[Interventional cardiology] Kappenberger L, et al. **Schweiz Rundsch Med Prax** 1995 Oct 17;84(42):1190–3 (10 ref.) (Eng. Abstr.) **(Fre)**
[Management of patients with carotid stenosis and coronary heart disease] Fleisch M, et al. **Schweiz Med Wochenschr** 1995 Oct 28;125(43):2053–61 (68 ref.) (Eng. Abstr.) **(Ger)**
[Coronary artery bypass grafting for a patient with left ventricular ejection fraction of 16%: a case report and review of the Japanese literature] Aiba M, et al. **Kyobu Geka** 1995 Sep;48(10):861–4 (10 ref.) (Eng. Abstr.) **(Jpn)**
[Radiation-induced coronary ostial stenosis, a case of redo coronary bypass for the restenosis following patch angioplasty] Takewa Y, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Feb;44(2):220–5 (16 ref.) (Eng. Abstr.) **(Jpn)**

THERAPY

Roles of percutaneous transluminal coronary angioplasty and bypass graft surgery for the treatment of coronary artery disease. Cishek MB, et al. **Am Heart J** 1996 May; 131(5):1012–7 (58 ref.)
Use of calcium channel antagonists in myocardial revascularization procedures. Califf RM, et al. **Am J Cardiol** 1996 Jun 20;77(16):26D–31D (28 ref.)
Role of polymers in improving the results of stenting in coronary arteries. Peng T, et al. **Biomaterials** 1996 Apr; 17(7):685–94 (90 ref.)
Cost-effectiveness in clinical cardiology. Part 1: Coronary artery disease and congestive heart failure. Willens HJ, et al. **Chest** 1996 May;109(5):1359–69 (60 ref.)
Applications of bio-techniques on treatment of cardiovascular diseases. Tang J, et al. **Chin Med J (Engl)** 1996 Feb;109(2):108–10 (0 ref.)
Intracoronary stenting. From concept to custom. Ruygrok PN, et al. **Circulation** 1996 Sep 1;94(5):882–90 (49 ref.)
Potentiation of vasculopathy by insulin: implications from an NHLBI clinical alert [editorial] Sobel BE. **Circulation** 1996 May 1;93(9):1613–5 (20 ref.)
Restenosis—an open file. Gottsauner-Wolf M, et al. **Clin Cardiol** 1996 May;19(5):347–56 (118 ref.)
Restenosis following coronary angioplasty: clinical presentations and therapeutic options. Levine GN, et al. **Clin Cardiol** 1995 Dec;18(12):693–703 (80 ref.)
Percutaneous transluminal coronary angioplasty in the elderly. Thompson RC, et al. **Clin Geriatr Med** 1996 Feb; 12(1):181–94 (106 ref.)
Clinical importance of determining the presence of myocardial viability. Cheirif J, et al. **Coron Artery Dis** 1995 Aug;6(8):597–9 (14 ref.)
Cost-effectiveness of accepted measures for intervention in coronary heart disease. Kuntz KM, et al. **Coron Artery Dis** 1995 Jun;6(6):472–8 (40 ref.)
Risk factor intervention and coronary artery disease: clinical

strategies. Vogel RA. **Coron Artery Dis** 1995 Jun; 6(6):466–71 (59 ref.)

Restenosis after coronary angioplasty. Hamon M, et al. **Eur Heart J** 1995 Aug;16 Suppl 1:33–48 (163 ref.)

Gender bias in the diagnosis and treatment of coronary artery disease. Beery TA. **Heart Lung** 1995 Nov–Dec;24(6):427–35 (64 ref.)

Percutaneous coronary revascularization versus coronary bypass surgery in multivessel disease. Banka VS, et al. **Indian Heart J** 1996 Jan–Feb;48(1):73–7 (24 ref.)

New devices in interventional cardiology: present and future. Beyar R. **Isr J Med Sci** 1996 Jul;32(7):515–25 (42 ref.)

Antisense approach to restenosis. Simons M. **Jpn Circ J** 1996 Jan;60(1):1–9 (50 ref.)

Prevention of late lumen loss after coronary angioplasty by photodynamic therapy: role of activated neutrophils. Sluiter W, et al. **Mol Cell Biochem** 1996 Apr 12–26; 157(1–2):233–8 (44 ref.)

Management of diabetic pregnancy complicated by coronary artery disease and neuropathy. Hagay Z, et al. **Obstet Gynecol Clin North Am** 1996 Mar;23(1):205–20 (38 ref.)

The autoperfusion balloon catheter with special attention to its use as a bail-out device. Bonnier JJ. **Z Kardiol** 1995; 84 Suppl 2:79–82 (17 ref.)

Coronary stents. Sigwart U. **Z Kardiol** 1995;84 Suppl 2:65–77 (75 ref.)

[Current status in the gene therapy of coronary restenosis after interventional therapy] Huo F, et al. **Chung Hua Nei Ko Tsa Chih** 1995 May;34(5):350–2 (20 ref.) **(Chi)**

[Progress in the interventional therapy of coronary disease] Wang L, et al. **Chung Hua Nei Ko Tsa Chih** 1995 May; 34(5):347–9 (17 ref.) **(Chi)**

[Is plasma lipoprotein (a) level a reliable indicator predicting restenosis after angioplasty?] Bussière JL, et al. **Arch Mal Coeur Vaiss** 1996 Apr;89(4):425–9 (24 ref.) (Eng. Abstr.) **(Fre)**

[Coronary artery disease in octogenarians: contribution of coronary angiography and evaluation of therapeutic possibilities] Elbaz M, et al. **Arch Mal Coeur Vaiss** 1995 Oct;88(10):1391–8 (27 ref.) (Eng. Abstr.) **(Fre)**

[Mechanisms of restenosis after coronary angioplasty] Leclercq F, et al. **Arch Mal Coeur Vaiss** 1996 Mar; 89(3):359–65 (42 ref.) (Eng. Abstr.) **(Fre)**

[The secondary prevention of coronary disease] Krémer R. **Rom J Intern Med** 1995 Jul–Dec;33(3–4):125–31 (20 ref.) **(Fre)**

[Angioplasty or bypass for multitruncal coronary disease. Viewpoint of the cardiologist] Urban P. **Schweiz Med Wochenschr** 1995 Oct 28;125(43):2062–6 (30 ref.) (Eng. Abstr.) **(Fre)**

[Coronary angioplasty in elderly patients] Eeckhout E, et al. **Schweiz Rundsch Med Prax** 1996 Feb 6;85(6):168–71 (18 ref.) (Eng. Abstr.) **(Fre)**

[Gene therapy concepts in coronary stenoses] Schott E, et al. **Internist (Berl)** 1996 Apr;37(4):350–9 (69 ref.) **(Ger)**

[Cardiology update—II] Trappe HJ. **Med Klin** 1996 Apr 1; 91 Suppl 1:128–39 (139 ref.) **(Ger)**

[Cardiology update—II] Trappe HJ. **Med Klin** 1995 Oct 15; 90(10):567–78 (139 ref.) **(Ger)**

[Modifying increased plasma cholesterol levels in secondary prevention of coronary heart disease] Jost S, et al. **Z Kardiol** 1995 Aug;84(8):577–95 (159 ref.) (Eng. Abstr.) **(Ger)**

[PTCA or alternative techniques? Balloon angioplasty remains dominant] Reifart N. **Z Kardiol** 1995;84 Suppl 2:43–52 (30 ref.) (Eng. Abstr.) **(Ger)**

[Ticlopidine in coronary artery diseases] Porter T, et al. **Harefuah** 1995 Nov 15;129(10):427–30 (26 ref.) **(Heb)**

[Surgical or percutaneous revascularization in multi-vessel coronary disease] Zingone B. **G Ital Cardiol** 1995 Dec; 25(12):1607–19 (123 ref.) (Eng. Abstr.) **(Ita)**

[Gene therapy for cardiovascular disease] Morishita R, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2739–45 (26 ref.) **(Jpn)**

[The value of the treatment of dyslipidemias in the prognosis of patients with coronary artery disease] Giannini SD, et al. **Arq Bras Cardiol** 1995 Sep;65(3):297–9 (42 ref.) **(Por)**

[Angioplasty, surgical, or clinical treatment. Therapeutic options for obstructive coronary artery disease (editorial)] Hueb WA, et al. **Arq Bras Cardiol** 1995 Jul;65(1):7–10 (28 ref.) **(Por)**

ULTRASONOGRAPHY

Are there gender differences related to stress or pharmacological echocardiography? Crouse LJ, et al. **Am J Card Imaging** 1996 Jan;10(1):65–71 (29 ref.)

Understanding intravascular ultrasound. Strimike C. **Am J Nurs** 1996 Jun;96(6):40–3; quiz 44 (11 ref.)

Assessing the physiologic significance of coronary artery disease: role of Doppler methodology. Schlaifer JD, et al. **Clin Cardiol** 1996 Mar;19(3):172–8 (38 ref.)

Assessment of myocardial viability by dobutamine echocardiography. Cheirif J, et al. **Coron Artery Dis** 1995 Aug;6(8):600–5 (30 ref.)

Intracoronary Doppler flow velocity measurements for the evaluation and treatment of coronary artery disease. Bach RG, et al. **Curr Opin Cardiol** 1995 Jul;10(4):434–42 (35 ref.)

Recent advances in stress echocardiography. Marwick TH. **Curr Opin Cardiol** 1995 Nov;10(6):619–25 (40 ref.)

Intravascular ultrasound for evaluation of coronary arteries. Görge G, et al. **Herz** 1996 Apr;21(2):78–89 (82 ref.)

Three-dimensional reconstruction of coronary arteries with intravascular ultrasound. von Birgelen C, et al. **Herz** 1995 Aug;20(4):277–89 (85 ref.)

Intravascular ultrasound: clinical applications. Jain A, et al. **Indian Heart J** 1995 Mar–Apr;47(2):151–7 (75 ref.)

Three-dimensional intracoronary ultrasound imaging. Methodology and clinical relevance for the assessment of coronary arteries and bypass grafts. Von Birgelen C, et al. **J Cardiovasc Surg (Torino)** 1996 Apr;37(2):129–39 (100 ref.)

[Stress ultrasonography with dobutamine in the diagnosis of coronary disease] Brochet E, et al. **Presse Med** 1995 Dec 9;24(38):1800–5 (25 ref.) (Eng. Abstr.) **(Fre)**

–Practical implementation of stress echocardiography—what should be monitored?– Beckmann S, et al. **Herz** 1996 Feb; 21(1):65–70; discussion 64 (18 ref.) **(Ger)**

[Diagnosis of coronary heart disease using echocardiography 3D reconstructions. Diagnosis of global and regional left ventricular function] Buck T, et al. **Herz** 1995 Aug; 20(4):252–62 (57 ref.) (Eng. Abstr.) **(Ger)**

[Stress echocardiography. Rise of a new method] Mathias Júnior W. **Arq Bras Cardiol** 1995 Apr;64(4):401–8 (43 ref.) **(Por)**

CORONARY HEART DISEASE see **CORONARY DISEASE**

CORONARY OCCLUSION see **CORONARY DISEASE**

CORONARY-PRONE PERSONALITY see **TYPE A PERSONALITY**

CORONARY REPERFUSION see **MYOCARDIAL REPERFUSION**

CORONARY STENOSIS see **CORONARY DISEASE**

CORONARY THROMBOSIS

Arterial thrombosis for the clinician. Pathobiology and emerging concepts. Becker RC. **Cardiol Clin** 1995 Aug; 13(3):295–310 (168 ref.)

COMPLICATIONS

Morphological and functional significance of findings in unstable atherothrombotic plaque underlying acute coronary syndromes: a review. Baroldi G. **Int J Cardiol** 1995 Aug;49 Suppl:S3–9 (18 ref.)

Thrombosis as a unitary hypothesis of cardiovascular risk. Noble MI. **J Cardiovasc Risk** 1995 Jun;2(3):177–9 (12 ref.)

DRUG THERAPY

Antiplatelet and anticoagulant use after myocardial infarction. Almony GT, et al. **Clin Cardiol** 1996 May; 19(5):357–65 (109 ref.)

Platelet glycoprotein IIb/IIIa receptor antagonists in coronary artery disease. Lefkovits J, et al. **Eur Heart J** 1996 Jan;17(1):9–18 (81 ref.)

–New perspectives in therapy of unstable angina– Hamm CW. **Herz** 1996 Feb;21(1):37–43 (69 ref.) (Eng. Abstr.) **(Ger)**

–Differential antithrombotic therapy in patients with low and high PTCA risk– Silber S, et al. **Herz** 1996 Feb;21(1):44–59 (213 ref.) (Eng. Abstr.) **(Ger)**

[Symptomatic therapy refractory myocardial ischemia in coronary heart disease. Chronic intermittent urokinase therapy and invasive therapeutic measures] Leschke M, et al. **Internist (Berl)** 1996 Jun;37(6):597–606 (50 ref.) **(Ger)**

ETIOLOGY

Acute stent thrombosis associated with exercise testing after successful percutaneous transluminal coronary angioplasty. Samuels B, et al. **Am Heart J** 1995 Nov;130(5):1120–2 (15 ref.)

Thrombosis in ischemic heart disease. Ambrose JA, et al. **Arch Intern Med** 1996 Jul 8;156(13):1382–94 (166 ref.)

Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death. Farb A, et al. **Circulation** 1996 Apr 1; 93(7):1354–63 (46 ref.)

Subacute stent thrombosis: evolving issues and current concepts. Mak KH, et al. **J Am Coll Cardiol** 1996 Feb; 27(2):494–503 (102 ref.)

Presence of thrombosis in coronary atherosclerotic plaques. Escaned J, et al. **J Cardiovasc Risk** 1995 Jun;2(3):189–96 (106 ref.)

[Dyslipidemia and blood coagulation] Serrano Júnior CV, et al. **Arq Bras Cardiol** 1995 Sep;65(3):273–7 (46 ref.) **(Por)**

MICROBIOLOGY

Candida albicans septic thrombosis of the right atrium is associated with a central venous catheter. Kentos A, et al. **Clin Infect Dis** 1995 Aug;21(2):440–2 (18 ref.)

PHYSIOPATHOLOGY

The pathophysiology of the onset of morning cardiovascular events. Johnstone MT, et al. **Am J Hypertens** 1996 Apr; 9(4 Pt 3):22S–28S (45 ref.)

PREVENTION & CONTROL

Thrombosis and embolism. Horn EH. **Baillieres Clin Obstet Gynaecol** 1995 Sep;9(3):595–618 (95 ref.)

–Anticoagulation after intracoronary stent implantation– Bode C, et al. **Herz** 1996 Feb;21(1):60–3 (21 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

[New aspects of blood coagulation inhibitory therapy within the scope of percutaneous transluminal coronary angioplasty (PTCA)] Schächinger V, et al. **Z Kardiol** 1995 Sep;84(9):651–67 (152 ref.) (Eng. Abstr.) **(Ger)**

ULTRASONOGRAPHY

[Transesophageal echocardiography. Indications and clinical impact] Campos Filho O. **Arq Bras Cardiol** 1995 Apr; 64(4):383–9 (47 ref.) **(Por)**

CORONARY VASOSPASM

COMPLICATIONS

Migraine and angina pectoris by coronary artery spasm. Lafitte C, et al. **Headache** 1996 May;36(5):332–4 (14 ref.)

DIAGNOSIS

[Reflections of an expert committee of the French Society of Cardiology on the use of methylergometrine maleate (Methergin) for the detection of abnormal coronary vasomotricity] Lablanche JM, et al. **Arch Mal Coeur Vaiss** 1995 Feb;88(2):247–53 (53 ref.) **(Fre)**

DRUG THERAPY

Calcium channel antagonists in the management of anginal syndromes: changing concepts in relation to the role of coronary vasospasm. Opie LH. **Prog Cardiovasc Dis** 1996 Jan–Feb;38(4):291–314 (154 ref.)

ETIOLOGY

[Clinical study and physiopathology of coronary vasospasm] Yasue H. **Nippon Naika Gakkai Zasshi** 1995 Sep 10; 84(9):1407–15 (16 ref.) **(Jpn)**

[Current views on the clinical significance of coronary artery spasm] Siembab L, et al. **Przegl Lek** 1995;52(8):395–9 (20 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOPATHOLOGY

[Clinical study and physiopathology of coronary vasospasm] Yasue H. **Nippon Naika Gakkai Zasshi** 1995 Sep 10; 84(9):1407–15 (16 ref.) **(Jpn)**

CORONARY VESSEL ANOMALIES

Anomalous origin of coronary artery in association with aorticopulmonary window. D'Souza VJ, et al. **Pediatr Cardiol** 1996 Sep–Oct;17(5):316–8 (12 ref.)

COMPLICATIONS

[Atresia of the left coronary artery: a case in a marathon runner. Review of the literature] Bouchiat C, et al. **Arch Mal Coeur Vaiss** 1996 Apr;89(4):485–7 (10 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

[Bilateral coronary fistula: a case report and review] Vanselow B, et al. **Z Kardiol** 1996 Mar;85(3):214–20 (45 ref.) (Eng. Abstr.) **(Ger)**

[A retroaortic anomalous left coronary artery] Barriales Villa R, et al. **Rev Esp Cardiol** 1995 Oct;48(10):690–2 (8 ref.) (Eng. Abstr.) **(Spa)**

PATHOLOGY

Multiple fistulas between coronary and pulmonary arteries. Van Dam DW, et al. **Eur J Cardiothorac Surg** 1995; 9(12):707–8 (10 ref.)

RADIOGRAPHY

The descending septal branch (Bonapace's branch). A case report and literature review of this often forgotten branch. First description in vivo. Said M, et al. **Eur Heart J** 1995 Oct;16(10):1443–7 (43 ref.)

Single coronary artery: a case report and review of current literature. Barendra C, et al. **Singapore Med J** 1995 Jun; 36(3):335–7 (16 ref.)

SURGERY

[A case report of bentall type operation for annuloaortic ectasia with anomalous origin of the right coronary artery complicated by aortic dissection] Hirai M, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Jul;43(7):1044–9 (20 ref.) (Eng. Abstr.) **(Jpn)**

CORONARY VESSELS

Iatrogenic aorto–coronary venous fistula as a complication

of coronary artery bypass surgery: patient report and review of the literature. Calkins JB Jr, et al. **Cathet Cardiovasc Diagn** 1996 Jan;37(1):55–9 (19 ref.)
Control of coronary angiogenesis. Schaper W. **Eur Heart J** 1995 May;16 Suppl C:66–8 (16 ref.)
Coronary angioscopy: exploring new frontiers. Shaw D, et al. **Indian Heart J** 1995 May–Jun;47(3):269–73 (51 ref.)
Stents for intracoronary placement: current status and future directions. Eeckhout E, et al. **J Am Coll Cardiol** 1996 Mar 15;27(4):757–65 (96 ref.)
Coronary artery stents. American College of Cardiology. Pepine CJ, et al. **J Am Coll Cardiol** 1996 Sep;28(3):782–94 (55 ref.)

ANATOMY & HISTOLOGY

Coronary MR angiography. Duerinckx AJ. **Magn Reson Imaging Clin N Am** 1996 May;4(2):361–418 (222 ref.)
MR angiography of the coronary arteries. Duerinckx AJ. **Top Magn Reson Imaging** 1995 Fall;7(4):267–85 (103 ref.)
[Vascularization of the sinus node in the Black African] Yangni-Angate H, et al. **West Afr J Med** 1995 Jul–Sep; 14(3):181–3 (6 ref.) (Eng. Abstr.) **(Fre)**
[Intracoronary ultrasound: scientific aspects and clinical possibilities] Rickenbacher P, et al. **Schweiz Rundsch Med Prax** 1996 Mar 12;85(11):320–8 (153 ref.) (Eng. Abstr.) **(Ger)**
[Critical analysis of the clinical and surgical importance of the variations in the origin of the sinoatrial node artery of the human heart] Caetano AG, et al. **Rev Assoc Med Bras** 1995 Mar–Apr;41(2):94–102 (88 ref.) (Eng. Abstr.) **(Por)**

DRUG EFFECTS

Nuclear cardiology studies—principles for stress modality selection. Underwood R. **Br J Clin Pract Symp Suppl** 1995 Nov;82:10–2 (9 ref.)

EMBRYOLOGY

Formation of the coronary vasculature: a brief review. Tomanek RJ. **Cardiovasc Res** 1996 Feb;31 Spec No:E46–51 (53 ref.)

ENZYMOLOGY

Modulation of protein kinase C by adenosine: involvement of adenosine A1 receptor–pertussis toxin sensitive nucleotide binding protein system. Marala RB, et al. **Mol Cell Biochem** 1995 Aug–Sep;149–150:51–8 (56 ref.)

GROWTH & DEVELOPMENT

Postnatal growth of the heart and its blood vessels. Hudlicka O, et al. **J Vasc Res** 1996 Jul–Aug;33(4):266–87 (265 ref.)

METABOLISM

Endothelial cells, nitric oxide and ischaemic preconditioning. Parratt JR, et al. **Basic Res Cardiol** 1996 Jan–Feb; 91(1):27–30 (14 ref.)
Cholesterol and the coronary endothelium. Knight CJ, et al. **J Cardiovasc Risk** 1995 Jun;2(3):180–8 (60 ref.)

PATHOLOGY

Coronary microvascular abnormalities in Chagas' disease [editorial] Rossi MA, et al. **Am Heart J** 1996 Jul;132(1 Pt 1):207–10 (49 ref.)
Novel techniques of coronary artery imaging. Ge J, et al. **Curr Opin Cardiol** 1995 Nov;10(6):626–33 (56 ref.)
Coronary artery imaging by magnetic resonance. Scheidegger MB, et al. **Herz** 1996 Apr;21(2):90–6 (20 ref.)
Coronary imaging using MRI. van Rossum AC, et al. **Herz** 1996 Apr;21(2):97–105 (38 ref.)
Coronary ventricular fistula as a complication of PTCA: a case report and literature review. el-Omar MM, et al. **Int J Cardiol** 1995 Sep;51(2):113–6 (10 ref.)
Magnetic resonance angiography and flow quantification of coronary arteries. Edelman RR, et al. **Magn Reson Imaging Clin N Am** 1993 Dec;1(2):339–47 (48 ref.)
Prevention of late lumen loss after coronary angioplasty by photodynamic therapy: role of activated neutrophils. Sluiter W, et al. **Mol Cell Biochem** 1996 Apr 12–26; 157(1–2):233–8 (44 ref.)
Magnetic resonance of the heart and great vessels. de Roos A, et al. **Nat Med** 1995 Jul;1(7):711–3 (6 ref.)
VLA-4 and lymphocyte trafficking in immune-inflammatory states: novel therapeutic approaches in allograft arteriopathy. Molossi S, et al. **Springer Semin Immunopathol** 1995;16(4):443–65 (225 ref.)
How vessels narrow. Schwartz SM. **Z Kardiol** 1995;84 Suppl 4:129–35 (58 ref.)
[Surgical or percutaneous revascularization in multi-vessel coronary disease] Zingone B. **G Ital Cardiol** 1995 Dec; 25(12):1607–19 (123 ref.) (Eng. Abstr.) **(Ita)**

PHYSIOLOGY

Glossary: methods for the measurement of coronary blood flow and myocardial perfusion. Sakka SG, et al. **Basic Res Cardiol** 1996 Mar–Apr;91(2):155–78 (197 ref.)
Role of polymers in improving the results of stenting in coronary arteries. Peng T, et al. **Biomaterials** 1996 Apr; 17(7):685–94 (90 ref.)
Endothelium-mediated control of coronary vascular tone after chronic exercise training. Laughlin MH. **Med Sci Sports Exerc** 1995 Aug;27(8):1135–44 (34 ref.)
Paracrine functions of the coronary vascular endothelium. Fleming I, et al. **Mol Cell Biochem** 1996 Apr 12–26; 157(1–2):137–45 (49 ref.)

PHYSIOPATHOLOGY

Is stunned myocardium ischemic on a microvascular level? Becker LC. **Basic Res Cardiol** 1995 Jul–Aug;90(4):282–4 (11 ref.)
Coronary vasomotion of the stunned myocardium. Mandinov L, et al. **Basic Res Cardiol** 1995 Jul–Aug;90(4):288–90 (11 ref.)
Intermittent ischemia of the heart. Flameng W. **Transplant Proc** 1995 Oct;27(5):2791–2 (12 ref.)
[The role of coronary vasomotoricity in ischemic cardiopathy: fluctuating preconceptions (editorial)] Maseri A, et al. **Cardiologia** 1996 Jan;41(1):19–30 (132 ref.) **(Ita)**
[Endothelial function and coronary microcirculation in arterial hypertension] Salvetti A. **Cardiologia** 1996 Apr; 41(4):319–25 (41 ref.) **(Ita)**
[Ischemic cardiopathy in women: the role of estrogens in the coronary vascular wall and in syndrome X] Gaxiola E, et al. **Arch Inst Cardiol Mex** 1995 Sep–Oct;65(5):461–7 (61 ref.) **(Spa)**

SURGERY

The use of autologous saphenous vein grafts for isolated left anterior descending coronary artery revascularization. Pomar JL. **Eur Heart J** 1995 Jul;16 Suppl E:26–8 (20 ref.)

ULTRASONOGRAPHY

Assessment of transplant arteriopathy by intracoronary two-dimensional ultrasound imaging and coronary flow velocity. Wolford T, et al. **Cathet Cardiovasc Diagn** 1995 Aug;35(4):335–42 (35 ref.)
Three-dimensional reconstruction of coronary arteries with intravascular ultrasound. von Birgelen C, et al. **Herz** 1995 Aug;20(4):277–89 (85 ref.)
Intravascular ultrasound: clinical applications. Jain A, et al. **Indian Heart J** 1995 Mar–Apr;47(2):151–7 (75 ref.)
Three-dimensional intracoronary ultrasound imaging. Methodology and clinical relevance for the assessment of coronary arteries and bypass grafts. Von Birgelen C, et al. **J Cardiovasc Surg (Torino)** 1996 Apr;37(2):129–39 (100 ref.)
A glimpse of the coronary microcirculation with myocardial contrast echocardiography. Kaul S. **J Investig Med** 1995 Aug;43(4):345–61 (45 ref.)
[The evaluation of the acute recoil of the Palmaz-Schatz stent using echography. A case report] Maiello L, et al. **Cardiologia** 1996 Jun;41(6):559–62 (10 ref.) (Eng. Abstr.) **(Ita)**
[Use of contrast echocardiography in coronary insufficiency] Morcerf FA. **Arq Bras Cardiol** 1995 Apr;64(4):373–82 (66 ref.) **(Por)**

CORONAVIRUS

ENZYMOLOGY

Proteolytic processing of the arterivirus replicase. Snijder E, et al. **Adv Exp Med Biol** 1995;380:443–51 (28 ref.)

GENETICS

Transcription, replication, recombination, and engineering of coronavirus genes. Lai MM. **Adv Exp Med Biol** 1995; 380:463–71 (29 ref.)
Coronaviruses use discontinuous extension for synthesis of subgenome-length negative strands. Sawicki SG, et al. **Adv Exp Med Biol** 1995;380:499–506 (21 ref.)
Regulation of transcription of coronaviruses. van Marle G, et al. **Adv Exp Med Biol** 1995;380:507–10 (23 ref.)

IMMUNOLOGY

Development of protection against coronavirus induced diseases. A review. Enjuanes L, et al. **Adv Exp Med Biol** 1995;380:197–211 (108 ref.)
Immunopathological aspects of coronavirus infections. Wege H. **Springer Semin Immunopathol** 1995;17(2–3):133–48 (111 ref.)

PATHOGENICITY

Immunopathological aspects of coronavirus infections. Wege H. **Springer Semin Immunopathol** 1995;17(2–3):133–48 (111 ref.)

PHYSIOLOGY

Factors controlling coronavirus infections and disease of the central nervous system. A review. Dales S. **Adv Exp Med Biol** 1995;380:13–22 (24 ref.)
Coronaviruses use discontinuous extension for synthesis of subgenome-length negative strands. Sawicki SG, et al. **Adv Exp Med Biol** 1995;380:499–506 (21 ref.)
Coronavirus infection of polarized epithelial cells. Rossen JW, et al. **Trends Microbiol** 1995 Dec;3(12):486–90 (27 ref.)

CORONAVIRUS INFECTIONS

ETIOLOGY

Immunopathological aspects of coronavirus infections. Wege H. **Springer Semin Immunopathol** 1995;17(2–3):133–48 (111 ref.)

IMMUNOLOGY

Genetic resistance to coronavirus infection. A review. Buschman E, et al. **Adv Exp Med Biol** 1995;380:1–11 (52 ref.)
Development of protection against coronavirus induced diseases. A review. Enjuanes L, et al. **Adv Exp Med Biol** 1995;380:197–211 (108 ref.)
Immunopathological aspects of coronavirus infections. Wege H. **Springer Semin Immunopathol** 1995;17(2–3):133–48 (111 ref.)

PHYSIOPATHOLOGY

Factors controlling coronavirus infections and disease of the central nervous system. A review. Dales S. **Adv Exp Med Biol** 1995;380:13–22 (24 ref.)
Spread of MHV-JHM from nasal cavity to white matter of spinal cord. Transneuronal movement and involvement of astrocytes. Perlman S, et al. **Adv Exp Med Biol** 1995; 380:73–8 (21 ref.)

VETERINARY

[Mouse hepatitis virus] Homberger FR. **Schweiz Arch Tierheilkd** 1996;138(4):183–8 (10 ref.) (Eng. Abstr.) **(Ger)**

CORONERS AND MEDICAL EXAMINERS

The role of medical examiners and coroners in public health surveillance and epidemiologic research. Hanzlick R, et al. **Annu Rev Public Health** 1996;17:383–409 (85 ref.)

STANDARDS

On the need for more expertise in death investigation (and a National Office of Death Investigation Affairs?) [editorial] Hanzlick R. **Arch Pathol Lab Med** 1996 Apr; 120(4):329–32 (26 ref.)

CORPORA QUADRIGEMINA

SURGERY

Burr hole neuroendoscopic fenestration of quadrigeminal cistern arachnoid cyst: technical case report. Ruge JR, et al. **Neurosurgery** 1996 Apr;38(4):830–7 (32 ref.)

CORPORATE CULTURE see **ORGANIZATIONAL CULTURE**

CORPUS CALLOSUM

[Contribution of position emission tomography in a case of Marchiafava Bignami disease: Morel's laminar sclerosis?] Logak M, et al. **Rev Neurol (Paris)** 1996 Jan;152(1):47–50 (10 ref.) (Eng. Abstr.) **(Fre)**

ABNORMALITIES

Absence makes the search grow longer [editorial; comment] Dobyns WB. **Am J Hum Genet** 1996 Jan;58(1):7–16 (121 ref.) Comment on: Am J Hum Genet 1996 Jan;58(1):28–34.
Agenesis and lipoma of corpus callosum. Case report. Silva DF, et al. **Arq Neuropsiquiatr** 1995 Sep;53(3–B):667–70 (34 ref.)
Association of infantile neuroaxonal dystrophy and osteopetrosis: a rare autosomal recessive disorder. Rees H, et al. **Pediatr Neurosurg** 1995;22(6):321–7 (36 ref.)
[Corpus callosum agenesis and parasagittal interhemispheric cyst] Doffe L, et al. **J Radiol** 1996 Jun;77(6):427–30 (15 ref.) (Eng. Abstr.) **(Fre)**

CYTOLOGY

Cellular aspects of callosal connections and their development. Innocenti GM, et al. **Neuropsychologia** 1995 Aug;33(8):961–87 (99 ref.)

PHYSIOLOGY

Corpus callosum and simple visuomotor integration. Berlucchi G, et al. **Neuropsychologia** 1995 Aug; 33(8):923–36 (74 ref.)

PHYSIOPATHOLOGY

Visual integration in the split brain. Corballis MC. **Neuropsychologia** 1995 Aug;33(8):937–59 (78 ref.)

CORPUS CARDIACUM see **NEUROSECRETORY SYSTEMS**

CORPUS LUTEUM

METABOLISM

Regulation of oxytocin expression in the bovine corpus luteum. Orphan receptors and the oxytocin promoter. Walther N, et al. **Adv Exp Med Biol** 1995;395:79–90 (63 ref.)

PHYSIOLOGY

Luteotropic and luteolytic effects of oxytocin in the porcine corpus luteum. Wuttke W, et al. **Adv Exp Med Biol** 1995; 395:495–506 (42 ref.)

Endometrial responses to corpus luteum products in cycles with induced ovulation: theoretical and practical considerations. Seppälä M, et al. **Hum Reprod** 1995 Dec; 10 Suppl 2:67–76 (101 ref.)

The control of prostaglandin production by the endometrium in relation to luteolysis and menstruation. Poyser NL. **Prostaglandins Leukot Essent Fatty Acids** 1995 Sep; 53(3):147–95 (500 ref.)

A comparative study of the corpus luteum. Gemmell RT. **Reprod Fertil Dev** 1995;7(3):303–12 (83 ref.)

CORPUS LUTEUM CYST see **OVARIAN CYSTS**

CORPUS LUTEUM MAINTENANCE

DRUG EFFECTS

[Gestagens and corpus luteum insufficiency] Rothe K. **Zentralbl Gynakol** 1995;117 Suppl:2–5 (24 ref.) **(Ger)**

CORPUS STRIATUM

CYTOLOGY

Mechanisms of neuronal plasticity as analyzed at the single cell level. Eberwine J, et al. **Prog Brain Res** 1995; 105:117–26 (18 ref.)

DRUG EFFECTS

Neurotoxicity, drugs and abuse, and the CuZn-superoxide dismutase transgenic mice. Cadet JL, et al. **Mol Neurobiol** 1995 Aug–Dec;11(1–3):155–63 (49 ref.)

[Glutamatergic hypothesis of schizophrenia: psychoses induced by phencyclidine and cortical-subcortical imbalance] Krebs MO. **Encephale** 1995 Sep–Oct; 21(5):581–8 (52 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Parkinson's disease and free radicals. Mechanism of neurodegeneration and neuroprotection. Kondo T. **Ann N Y Acad Sci** 1996 Jun 15;786:206–16 (35 ref.)

Anatomical localization and regulation of somatostatin gene expression in the basal ganglia and its clinical implications. Chesselet MF, et al. **Ciba Found Symp** 1995;190:51–9; discussion 59–64 (47 ref.)

PET studies of the striatal dopaminergic system in Parkinson's disease (PD). Piccini P, et al. **J Neural Transm Suppl** 1995;45:123–31 (57 ref.)

Behavioral sensitization and tolerance to cocaine and the occupation of dopamine receptors by dopamine. Martin-Iverson MT, et al. **Mol Neurobiol** 1995 Aug–Dec; 11(1–3):31–46 (69 ref.)

PHYSIOLOGY

Analogical transfer in sequence learning. Human and neural-network models of frontostriatal function. Dominey PF, et al. **Ann N Y Acad Sci** 1995 Dec 15;769:369–73 (5 ref.)

Dopamine regulation of transcription factor-target interactions in rat striatum. Hyman SE, et al. **Chem Senses** 1995 Apr;20(2):257–60 (24 ref.)

The modulation of dopamine receptors in rat striatum. Stefani A, et al. **J Neural Transm Suppl** 1995;45:61–6 (24 ref.)

Effects of local connectivity on striatal function: stimulation and analysis of a model. Wickens JR, et al. **Synapse** 1995 Aug;20(4):281–98 (84 ref.)

[The complex interaction of the hypothalamic suprachiasmatic nuclei with the epiphysis and corpus striatum—a functionally unified system for regulating circadian behavioral fluctuations] Arushanian EB. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1996 Jan–Feb; 46(1):15–22 (44 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Multiple system atrophy. Quinn N, et al. **Curr Opin Neurol** 1995 Aug;8(4):323–6 (28 ref.)

TRANSPLANTATION

Core Assessment Program for Intracerebral Transplantation in Huntington's Disease (CAPIT-HD). Quinn N, et al. **Mov Disord** 1996 Mar;11(2):143–50 (44 ref.)

Tempting fate and commitment in the developing forebrain. Barbe MF. **Neuron** 1996 Jan;16(1):1–4 (16 ref.)

CORRESPONDENCE COURSES see **EDUCATION**

CORRIDOR DISEASE see **THEILERIASIS**

CORROSION

Corrosion and other electrochemical aspects of biomaterials. Bundy KJ. **Crit Rev Biomed Eng** 1994;22(3–4):139–251 (1712 ref.)

CORTEXOLONE see **CORTODOXONE**

CORTEXONE see **DESOXYCORTICOSTERONE**

CORTICAL DESYNCHRONIZATION see **CORTICAL SYNCHRONIZATION**

CORTICAL SYNCHRONIZATION

Synchronization and cooperative interaction in brain activity. Kozhedub RG. **Neurosci Behav Physiol** 1995 Nov–Dec; 25(6):517–30 (129 ref.)

CORTICOIDS see **ADRENAL CORTEX HORMONES**

CORTICOSPINAL TRACTS see **PYRAMIDAL TRACTS**

CORTICOSTEROID-BINDING GLOBULIN see **TRANSCORTIN**

CORTICOSTEROID RECEPTORS see **RECEPTORS, STEROID**

CORTICOSTEROIDS see **ADRENAL CORTEX HORMONES**

CORTICOSTERONE

BIOSYNTHESIS

Neuropeptides in the adrenal gland: distribution, localization of receptors, and effects on steroid hormone synthesis. Tóth IE, et al. **Endocr Res** 1995 Feb–May;21(1–2):39–51 (135 ref.)

BLOOD

[Corticosterone] Murase H. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:448–51 (20 ref.) **(Jpn)**

METABOLISM

Potential interactions between nimodipine and adrenal hormones. Isaacson RL, et al. **Ann N Y Acad Sci** 1995 Sep 15;765:134–42; discussion 160–2 (29 ref.)

PHYSIOLOGY

Insulin, corticosterone and the autonomic nervous system in animal obesities: a viewpoint. Jeanrenaud B. **Diabetologia** 1995 Aug;38(8):998–1002 (61 ref.)

CORTICOTROPIN

see related
RECEPTORS, CORTICOTROPIN

ANALOGS & DERIVATIVES

ACTH-related peptides: receptors and signal transduction systems involved in their neurotrophic and neuroprotective actions. Hol EM, et al. **Peptides** 1995;16(5):979–93 (150 ref.)

BIOSYNTHESIS

[A case of ACTH-producing thymic carcinoid tumor with Cushing syndrome] Nishimura H, et al. **Kyobu Geka** 1996 Feb;49(2):99–104 (20 ref.) (Eng. Abstr.) **(Jpn)**

BLOOD

Alcohol stimulates ACTH secretion in the rat: mechanisms of action and interactions with other stimuli. Rivier C. **Alcohol Clin Exp Res** 1996 Apr;20(2):240–54 (207 ref.)

[Adrenocorticotropic hormone (ACTH)] Suda T. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:278–81 (10 ref.) **(Jpn)**

METABOLISM

Permeability of the blood-brain barrier to melanocortins. Banks WA, et al. **Peptides** 1995;16(6):1157–61 (70 ref.)

[Role of hormonal exploration in avoiding of the failures of anterior pituitary gland surgery in Cushing disease] Bachelot I, et al. **Ann Endocrinol (Paris)** 1995;56(6):620–4 (15 ref.) (Eng. Abstr.) **(Fre)**

PHARMACOLOGY

Extrapulmonary effects of antenatally administered steroids. Padbury JF, et al. **J Pediatr** 1996 Feb;128(2):167–72 (61 ref.)

PHYSIOLOGY

Calcium uptake by ACTH-stimulated lymphocytes: what is the physiological significance? Clarke BL. **Adv Neuroimmunol** 1995;5(3):271–81 (48 ref.)

ACTH-related peptides: receptors and signal transduction systems involved in their neurotrophic and neuroprotective actions. Hol EM, et al. **Peptides** 1995;16(5):979–93 (150 ref.)

[Regulation of corticotropic function in stressful situations] Paulmyer-Lacroix O, et al. **Ann Endocrinol (Paris)** 1995; 56(4):245–51 (36 ref.) (Eng. Abstr.) **(Fre)**

SECRETION

Central regulation of ACTH release in stress. Assenmacher I, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:41–54 (81 ref.)

A case of small cell carcinoma of the uterine cervix presenting Cushing's syndrome. Hashi A, et al. **Gynecol Oncol** 1996 Jun;61(3):427–31 (14 ref.)

Current topic: the placental corticotrophin-releasing hormone–adrenocorticotrophin axis. Challis JR, et al. **Placenta** 1995 Sep;16(6):481–502 (98 ref.)

CORTICOTROPIN RECEPTORS see **RECEPTORS, CORTICOTROPIN**

CORTICOTROPIN-RELEASING FACTOR see **CORTICOTROPIN-RELEASING HORMONE**

CORTICOTROPIN-RELEASING HORMONE

see related
RECEPTORS, CORTICOTROPIN-RELEASING HORMONE

ANALYSIS

[Corticotropin-releasing hormone (CRH)] Yamamoto K, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:333–6 (16 ref.) **(Jpn)**

BIOSYNTHESIS

CRH overproduction in transgenic mice: behavioral and immune system modulation. Stenzel-Poore MP, et al. **Ann N Y Acad Sci** 1996 Mar 22;780:36–48 (70 ref.)

Current topic: the placental corticotrophin-releasing hormone–adrenocorticotrophin axis. Challis JR, et al. **Placenta** 1995 Sep;16(6):481–502 (98 ref.)

CEREBROSPINAL FLUID

Postmortem and cerebrospinal fluid studies of corticotropin-releasing factor in humans. Hartline KM, et al. **Ann N Y Acad Sci** 1996 Mar 22;780:96–105 (44 ref.)

DEFICIENCY

Production of corticotropin-releasing hormone-deficient mice by targeted mutation in embryonic stem cells. Muglia L, et al. **Ann N Y Acad Sci** 1996 Mar 22;780:49–59 (36 ref.)

GENETICS

Production of corticotropin-releasing hormone-deficient mice by targeted mutation in embryonic stem cells. Muglia L, et al. **Ann N Y Acad Sci** 1996 Mar 22;780:49–59 (36 ref.)

METABOLISM

Modulatory actions of corticotropin-releasing factor-binding protein. Behan DP, et al. **Ann N Y Acad Sci** 1996 Mar 22;780:81–95 (55 ref.)

Local expression of corticotropin-releasing hormone in inflammatory arthritis. Crofford LJ, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:459–71 (63 ref.)

Corticotropin releasing hormone in the pathophysiology of melancholic and atypical depression and in the mechanism of action of antidepressant drugs. Gold PW, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:716–29 (53 ref.)

Postmortem and cerebrospinal fluid studies of corticotropin-releasing factor in humans. Hartline KM, et al. **Ann N Y Acad Sci** 1996 Mar 22;780:96–105 (44 ref.)

Corticotropin releasing factor (CRF) binding protein: a novel regulator of CRF and related peptides. Behan DP, et al. **Front Neuroendocrinol** 1995 Oct;16(4):362–82 (87 ref.)

PHYSIOLOGY

Corticotropin-releasing hormone involvement in stressor-induced alterations in sleep and in the regulation of waking. Opp MR. **Adv Neuroimmunol** 1995;5(2):127–43 (100 ref.)

A role for CRH and the sympathetic nervous system in stress-induced immunosuppression. Friedman EM, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:396–418 (125 ref.)

The role of CRF in behavioral aspects of stress. Heinrichs SC, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:92–104 (63 ref.)

The role of prostaglandins in blastocyst implantation. Psychoyos A, et al. **Hum Reprod** 1995 Dec;10 Suppl 2:30–42 (105 ref.)

Molecular mechanisms and neural pathways mediating the influence of interleukin-1 on the activity of neuroendocrine CRF motoneurons in the rat. Rivest S. **Int J Dev Neurosci** 1995 Jun–Jul;13(3–4):135–46 (96 ref.)

Exercise and the neurobiological control of food intake and energy expenditure. Richard D. **Int J Obes Relat Metab Disord** 1995 Oct;19 Suppl 4:S73–9 (78 ref.)

Corticotropin-releasing factor (CRF) and stress-related reproductive failure: the brain as a state of the art or the

ovary as a novel clue? Nappi RE, et al. **J Endocrinol Invest** 1995 Dec;18(11):872–80 (89 ref.)

Corticotropin releasing factor and its binding protein. Lowry PJ, et al. **Pharmacol Biochem Behav** 1996 May;54(1):305–8 (47 ref.)

[Corticotropin–releasing hormone in pregnancy] Sun G. **Sheng Li Ko Hsueh Chin Chan** 1995 Jul;26(3):270–2 (10 ref.) **(Chi)**

SECRETION

Neurotransmitter regulation of the hypothalamic corticotropin–releasing hormone neuron. Calogero AE. **Ann N Y Acad Sci** 1995 Dec 29;771:31–40 (68 ref.)

CORTICOTROPIN RELEASING-HORMONE RECEPTORS see **RECEPTORS, CORTICOTROPIN-RELEASING HORMONE**

CORTICOTROPIN-RELEASING HORMONE-41 see **CORTICOTROPIN-RELEASING HORMONE**

CORTISOL see **HYDROCORTISONE**

CORTODOXONE

ANALOGS & DERIVATIVES

[Urinary tetrahydro–11–deoxycortisol (THS)] Okatani Y. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:499–501 (7 ref.) **(Jpn)**

BLOOD

[11–Deoxycortisol] Okatani Y. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:441–3 (11 ref.) **(Jpn)**

[21–Deoxycortisol] Okatani Y. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:444–7 (7 ref.) **(Jpn)**

CORYNEBACTERIACEAE see **ACTINOMYCETALES**

CORYNEBACTERIUM

CLASSIFICATION

Misidentification of toxigenic Corynebacterium diphtheriae as a Corynebacterium species with low virulence in a child with endocarditis. Pennie RA, et al. **J Clin Microbiol** 1996 May;34(5):1275–6 (18 ref.)

Corynebacterium CDC group JK (Corynebacterium jeikeium) sepsis in haematological patients: a report of three cases and a systematic literature review. van der Lelie H, et al. **Scand J Infect Dis** 1995;27(6):581–4 (36 ref.)

GENETICS

Transport mutants and transport genes of Corynebacterium glutamicum. Eggeling L, et al. **Ann N Y Acad Sci** 1996 May 15;782:191–201 (32 ref.)

METABOLISM

Transport mutants and transport genes of Corynebacterium glutamicum. Eggeling L, et al. **Ann N Y Acad Sci** 1996 May 15;782:191–201 (32 ref.)

Construction of L–lysine–, L–threonine–, and L–isoleucine–overproducing strains of Corynebacterium glutamicum. Sahm H, et al. **Ann N Y Acad Sci** 1996 May 15;782:25–39 (34 ref.)

CORYNEBACTERIUM ACNES see **PROPIONIBACTERIUM ACNES**

CORYNEBACTERIUM DIPHTHERIAE

see related
DIPHTHERIA TOXIN

CLASSIFICATION

Misidentification of toxigenic Corynebacterium diphtheriae as a Corynebacterium species with low virulence in a child with endocarditis. Pennie RA, et al. **J Clin Microbiol** 1996 May;34(5):1275–6 (18 ref.)

METABOLISM

Treatment of infection caused by toxigenic and non–toxigenic strains of Corynebacterium diphtheriae. Wilson AP. **J Antimicrob Chemother** 1995 Jun;35(6):717–20 (33 ref.)

CORYNEBACTERIUM DIPHTHERIAE TOXIN see **DIPHTHERIA TOXIN**

CORYNEBACTERIUM EQUI see **RHODOCOCCUS EQUI**

CORYNEBACTERIUM INFECTIONS

ETIOLOGY

Corynebacterium CDC group JK (Corynebacterium jeikeium) sepsis in haematological patients: a report of three cases and a systematic literature review. van der Lelie H, et al. **Scand J Infect Dis** 1995;27(6):581–4 (36 ref.)

CORYNEBACTERIUM PARVUM see **PROPIONIBACTERIUM ACNES**

CORYNEFORM GROUP see **ACTINOMYCETALES**

CORYZA, ACUTE see **COMMON COLD**

CORYZA VIRUSES see **RHINOVIRUS**

COSMETIC SURGERY see **SURGERY, PLASTIC**

COSMETICS

ADVERSE EFFECTS

Adverse contact reactions to sculptured acrylic nails: 4 case reports and a literature review. Freeman S, et al. **Contact Dermatitis** 1995 Dec;33(6):381–5 (48 ref.)

ANALYSIS

Determination of allantoin in biological, cosmetic, and pharmaceutical samples. Chen XB, et al. **J AOAC Int** 1996 May–Jun;79(3):628–35 (56 ref.)

PHARMACOLOGY

Cosmeceuticals. A proposal for rational definition, evaluation, and regulation [editorial] Vermeer BJ, et al. **Arch Dermatol** 1996 Mar;132(3):337–40 (23 ref.)

COSMETICS, HAIR see **HAIR PREPARATIONS**

COSMIC RADIATION

Issues in protection from galactic cosmic rays. Wilson JW, et al. **Radiat Environ Biophys** 1995 Nov;34(4):217–22 (17 ref.)

COSMIDS

see related
CLONING, MOLECULAR

COST-BENEFIT ANALYSIS

Cost–effectiveness analysis: what is it and how will it influence neurology. Holloway RG. **Ann Neurol** 1996 Jun; 39(6):818–23 (32 ref.)

Intra–operative neurophysiologic monitoring in neurosurgery: benefits, efficacy, and cost–effectiveness. Møller AR. **Clin Neurosurg** 1995;42:171–9 (8 ref.)

Surgical treatment of intracranial arteriovenous malformations with an analysis of cost–effectiveness. Nussbaum ES, et al. **Clin Neurosurg** 1995;42:348–69 (65 ref.)

Sensitivity analysis in economic evaluation: a review of published studies. Briggs A, et al. **Health Econ** 1995 Sep–Oct;4(5):355–71 (109 ref.)

The economics and cost–effectiveness of critical care medicine. Chalfin DB, et al. **Intensive Care Med** 1995 Nov; 21(11):952–61 (67 ref.)

Understanding the essentials of economic evaluation. Schmid GP. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995; 10 Suppl 4:S6–13 (7 ref.)

ECONOMICS

Specific considerations for cost–effectiveness studies in AIDS. Bozzette SA. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995;10 Suppl 4:S23–7 (14 ref.)

Design and assessment of cost–effectiveness studies in AIDS populations. Simpson KN. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995;10 Suppl 4:S28–32 (17 ref.)

METHODS

Pharmacoeconomic studies. Pitfalls and problems. De Graeve D, et al. **Int J Technol Assess Health Care** 1996 Winter; 12(1):22–30 (27 ref.)

STANDARDS

Working toward a common currency: is standardization of cost–effectiveness analysis possible? Luce BR. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995;10 Suppl 4:S19–22 (18 ref.)

TRENDS

Evaluating the cost–effectiveness of pharmacologic therapy: where we've been and where we're going. Epstein AM. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995;10 Suppl 4:S1–5 (6 ref.)

Cost–effectiveness: from whose perspective? Hillman AL. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995;10 Suppl 4:S14–8 (9 ref.)

COST-BENEFIT DATA see **COST-BENEFIT ANALYSIS**

COST CONTAINMENT see **COST CONTROL**

COST CONTROL

Impact of cost cutting on laboratories: new business strategies for laboratories. Ash KO. **Clin Chem** 1996 May;42(5):822–6 (6 ref.)

How to evaluate and implement new technologies in an era of managed care and cost containment. Koch DD. **Clin Chem** 1996 May;42(5):797–802 (34 ref.)

Cost containment through nutrition intervention. Tucker HN, et al. **Nutr Rev** 1996 Apr;54(4 Pt 1):111–21 (58 ref.)

METHODS

Re–minding our Ps and Qs: medical cost controls in Canada. Barer ML, et al. **Health Aff (Millwood)** 1996 Summer; 15(2):216–34 (34 ref.)

Can managed care plans control health care costs? Zwanziger J, et al. **Health Aff (Millwood)** 1996 Summer;15(2):185–99 (22 ref.)

COST EFFECTIVENESS see **COST-BENEFIT ANALYSIS**

COST OF ILLNESS

see related
QUALITY OF LIFE

Social and economic effects of body weight in the United States. Wolf AM, et al. **Am J Clin Nutr** 1996 Mar;63(3 Suppl):466S–469S (19 ref.)

Disability as a public health outcome in the aging population. Guralnik JM, et al. **Annu Rev Public Health** 1996;17:25–46 (98 ref.)

The Lyme disease controversy. Social and financial costs of misdiagnosis and mismanagement. Sigal LH. **Arch Intern Med** 1996 Jul 22;156(14):1493–500 (30 ref.)

The economic cost and social and psychological impact of musculoskeletal conditions. National Arthritis Data Work Groups. Yelin E, et al. **Arthritis Rheum** 1995 Oct; 38(10):1351–62 (68 ref.)

Economics of hypertension control. World Hypertension League. **Bull World Health Organ** 1995;73(4):417–24 (43 ref.)

The cost–effective way forward for the management of the patient with heart failure. Giles T. **Cardiology** 1996;87 Suppl 1:33–9 (15 ref.)

The underestimated long term medical and economic consequences of rheumatoid arthritis. Pincus T. **Drugs** 1995; 50 Suppl 1:1–14 (80 ref.)

Can improved quality of care reduce the costs of managing angina pectoris? Cleland JG. **Eur Heart J** 1996 Mar;17 Suppl A:29–40 (74 ref.)

Psychiatric and physical morbidity effects of dementia caregiving: prevalence, correlates, and causes. Schulz R, et al. **Gerontologist** 1995 Dec;35(6):771–91 (90 ref.)

Estimating costs of mental health and substance abuse coverage. Frank RG, et al. **Health Aff (Millwood)** 1995 Fall;14(3):102–15 (17 ref.)

The cost of the illness that defies [editorial] Howlett M, et al. **Postgrad Med J** 1995 Dec;71(842):705–6 (15 ref.)

Quality of life and cost of therapy in reflux disease. Glise H. **Scand J Gastroenterol Suppl** 1995;210:38–42 (33 ref.)

The impact of HIV–1 infection on child health in sub–Saharan Africa: the burden on the health services. Walraven G, et al. **Trop Med Int Health** 1996 Feb;1(1):3–14 (87 ref.)

COST SAVINGS

STATISTICS & NUMERICAL DATA

Cost savings at the end of life. What do the data show? Emanuel EJ. **JAMA** 1996 Jun 26;275(24):1907–14 (42 ref.)

COST SHARING

see related
HEALTH BENEFIT PLANS, EMPLOYEE
MANAGED CARE PROGRAMS

The role of employee flexible spending accounts in health care financing. Schweitzer M, et al. **Am J Public Health** 1996 Aug;86(8 Pt 1):1079–81 (15 ref.)

COSTAL CHONDRITIS see **TIETZE'S SYNDROME**

COSTEN'S SYNDROME see **TEMPOROMANDIBULAR JOINT SYNDROME**

COSTS AND COST ANALYSIS

Cost–effectiveness analysis: what is it and how will it influence neurology. Holloway RG. **Ann Neurol** 1996 Jun; 39(6):818–23 (32 ref.)

Economic dimensions of slip and fall injuries. Englander F, et al. **J Forensic Sci** 1996 Sep;41(5):733–46 (42 ref.)

COSTS, DIRECT SERVICE see **DIRECT SERVICE COSTS**

COSYNTHASE see **UROPORPHYRINOGEN III SYNTHASE**

COT DEATH see **SUDDEN INFANT DEATH**

COTURNIX

The sexually dimorphic medial preoptic nucleus of quail: a key brain area mediating steroid action on male sexual

behavior. Panzica GC, et al. **Front Neuroendocrinol** 1996 Jan;17(1):51–125 (287 ref.)

EMBRYOLOGY

Quail–chick transplantations. Le Douarin N, et al. **Methods Cell Biol** 1996;51:23–59 (105 ref.)

PHYSIOLOGY

Effects of testosterone and its metabolites on aromatase-immunoreactive cells in the quail brain: relationship with the activation of male reproductive behavior. Balthazart J, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1–6 Spec No):185–200 (125 ref.)

COUGH

see related
ANTITUSSIVE AGENTS
EXPECTORANTS

Cough in children. Schidlow DV. **J Asthma** 1996;33(2):81–7 (18 ref.)
[Cough variant asthma] Hirata K, et al. **Nippon Naika Gakkai Zasshi** 1996 Feb 10;85(2):240–4 (5 ref.) **(Jpn)**

CHEMICALLY INDUCED

Putative mechanisms of cough after treatment with angiotensin converting enzyme inhibitors. Semple PF. **J Hypertens Suppl** 1995 Sep;13 Suppl 3:S17–21 (38 ref.)
[Cough as an adverse effect during angiotensin-converting enzyme inhibitor therapy] Adamek L, et al. **Pol Arch Med Wewn** 1996 Mar;95(3):254–60 (33 ref.) **(Pol)**

COMPLICATIONS

Cough, exertional, and sexual headaches: an analysis of 72 benign and symptomatic cases. Pascual J, et al. **Neurology** 1996 Jun;46(6):1520–4 (19 ref.)

DIAGNOSIS

Objective assessment of cough. Piirilä P, et al. **Eur Respir J** 1995 Nov;8(11):1949–56 (93 ref.)
Chronic persistent cough: diagnosis and treatment update. Corrao WM. **Pediatr Ann** 1996 Mar;25(3):162–8 (21 ref.)
[Cough—work-up and therapy] Zellweger JP, et al. **Schweiz Med Wochenschr** 1995 Nov 11;125(45):2194–200 (28 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Chronic persistent cough: diagnosis and treatment update. Corrao WM. **Pediatr Ann** 1996 Mar;25(3):162–8 (21 ref.)
Cold, cough, and allergy medications: uses and abuses. Katcher ML. **Pediatr Rev** 1996 Jan;17(1):12–7 (11 ref.)

ETIOLOGY

Excluding gastroesophageal reflux disease as the cause of chronic cough [editorial] Johnston BT, et al. **J Clin Gastroenterol** 1996 Apr;22(3):168–9 (13 ref.)
Cough and asthma in children. Newson T, et al. **Pediatr Ann** 1996 Mar;25(3):156–8, 161 (29 ref.)

PHYSIOPATHOLOGY

Neurophysiology of the cough reflex. Widdicombe JG. **Eur Respir J** 1995 Jul;8(7):1193–202 (98 ref.)

COUMARINS

see related
ANTICOAGULANTS

ADVERSE EFFECTS

Antenatal drugs affecting vitamin K status of the fetus and the newborn. Astedt B. **Semin Thromb Hemost** 1995; 21(4):364–70 (84 ref.)

THERAPEUTIC USE

[Anticoagulation in cardiology] Meier B. **Ann Cardiol Angeiol (Paris)** 1995 Dec;44(10):567–77 (53 ref.) (Eng. Abstr.) **(Fre)**

COUMARONES see **BENZOFURANS**

COUNSELING

Suicide and AIDS: problem identification during counselling. Miller R. **AIDS Care** 1995;7 Suppl 2:5199–205 (18 ref.)
A multi-factor account of disability after brain injury: implications for neuropsychological counselling. Montgomery GK. **Brain Inj** 1995 Jul;9(5):453–69 (45 ref.)
Counseling issues and management of side effects for women using depot medroxyprogesterone acetate contraception. Nelson AL. **J Reprod Med** 1996 May;41(5 Suppl):391–400 (27 ref.)
Physician–patient interaction in reproductive counseling. Lipkin M Jr. **Obstet Gynecol** 1996 Sep;88(3 Suppl):31S–40S (51 ref.)
Incorporating effective smoking prevention and cessation counseling into practice. Klein JD. **Pediatr Ann** 1995 Dec; 24(12):646–52 (31 ref.)
Client counseling in orthopedic emergencies. Brackenridge SS, et al. **Vet Clin North Am Small Anim Pract** 1995 Sep; 25(5):1047–58 (7 ref.)
[Family counseling in primary health care: a systemic approach] Jarabo Crespo Y, et al. **Aten Primaria** 1995 Nov 30;16(9):557–62 (27 ref.) **(Spa)**

METHODS

Directive counseling on long-acting contraception. Moskowitz E, et al. **Am J Public Health** 1996 Jun; 86(6):787–90 (24 ref.)
Advanced counseling techniques: integrating assessment and intervention. Foster SL, et al. **Am Pharm** 1995 Oct; NS35(10):40–8; quiz 48–50 (10 ref.)
Ethical reasoning in clinical genetics: a survey of cases and methods. Callahan TC, et al. **J Clin Ethics** 1995 Fall; 6(3):248–53 (23 ref.)
Delayed reporting of sexual assault. Implications for counseling. Plumbo MA. **J Nurse Midwifery** 1995 Sep–Oct; 40(5):424–7 (9 ref.)
Smoking cessation counseling in adults and children: the clinician's role. Adams JA. **Md Med J** 1995 Oct; 44(10):779–87 (26 ref.)
Counseling patients about therapy for localized prostate cancer. Middleton RG. **Semin Urol Oncol** 1995 Aug; 13(3):187–90 (8 ref.)

STATISTICS & NUMERICAL DATA

Physicians' prevention counseling behaviors: current status and future directions [editorial; comment] Frank E, et al. **Prev Med** 1995 Nov;24(6):543–5 (26 ref.) Comment on: Prev Med 1995 Nov;24(6):546–2.

COUNSELING, SEX see **SEX COUNSELING**

COUNTERIRRITANTS see **IRRITANTS**

COUNTERPULSATION

see related
HEART-ASSIST DEVICES

COUNTERTRANSFERENCE (PSYCHOLOGY)

Enactments: an evolving dyadic concept of acting out. Frayn DH. **Am J Psychother** 1996 Spring;50(2):194–207 (35 ref.)
Countertransference as instrument and obstacle: a comprehensive and descriptive framework. Bouchard MA, et al. **Psychoanal Q** 1995 Oct;64(4):717–45 (36 ref.)

COUPLING FACTOR 1 see **H(+)-TRANSPORTING ATP SYNTHASE**

COURTSHIP

Male and female sexual victimization in dating relationships: gender differences in coercion techniques and outcomes. Waldner-Haugrud LK, et al. **Violence Vict** 1995 Fall; 10(3):203–15 (23 ref.)

COWDEN'S DISEASE see **HAMARTOMA SYNDROME, MULTIPLE**

COWDRIA

CLASSIFICATION

Uncharacterized Ehrlichia spp. may contribute to clinical heartwater. Allsopp BA, et al. **Ann N Y Acad Sci** 1996 Jul 23;791:17–23 (24 ref.)

COWDRIA RUMINANTIUM see **COWDRIA**

COWPOX

EPIDEMIOLOGY

Cowpox in cats and man. Bennett M, et al. **Vet Q** 1995 Apr; 17 Suppl 1:S16 (4 ref.)

COXA see **HIP**

COXARTHROSIS see **OSTEOARTHRITIS, HIP**

COXIELLA BURNETII

[Q fever and Coxiella burnetii] Oda H, et al. **Nippon Saikingaku Zasshi** 1995 Jul;50(3):703–15 (84 ref.) **(Jpn)**

PHYSIOLOGY

Cohabitation of Leishmania amazonensis and Coxiella burnetii. Rabinovitch M, et al. **Trends Microbiol** 1996 Apr; 4(4):158–61 (32 ref.)

COXSACKIE B VIRUSES see **COXSACKIEVIRUSES B**

COXSACKIEVIRUS INFECTIONS

VIROLOGY

The role of transgenic knockout models in defining the pathogenesis of viral heart disease. Liu P, et al. **Eur Heart J** 1995 Dec;16 Suppl O:25–7 (28 ref.)
Genetics of coxsackievirus B cardiovirulence and inflammatory heart muscle disease. Tracy S, et al. **Trends Microbiol** 1996 May;4(5):175–9 (38 ref.)

COXSACKIEVIRUSES B

GENETICS

The role of transgenic knockout models in defining the pathogenesis of viral heart disease. Liu P, et al. **Eur Heart J** 1995 Dec;16 Suppl O:25–7 (28 ref.)
Genetics of coxsackievirus B cardiovirulence and inflammatory heart muscle disease. Tracy S, et al. **Trends Microbiol** 1996 May;4(5):175–9 (38 ref.)

PATHOGENICITY

Genetics of coxsackievirus B cardiovirulence and inflammatory heart muscle disease. Tracy S, et al. **Trends Microbiol** 1996 May;4(5):175–9 (38 ref.)

CPEO see **OPHTHALMOPLEGIA, CHRONIC PROGRESSIVE EXTERNAL**

CPITN see **PERIODONTAL INDEX**

CPM THERAPY see **MOTION THERAPY, CONTINUOUS PASSIVE**

CPN60 see **CHAPERONIN 60**

CPR see **CARDIOPULMONARY RESUSCITATION**

CRAB-EATING MONKEY see **MACACA FASCICULARIS**

CRABS, HORSESHOE see **HORSESHOE CRABS**

CRACK COCAINE

Crack cocaine abuse: an epidemic with many public health consequences. Cornish JW, et al. **Annu Rev Public Health** 1996;17:259–73 (54 ref.)
HIV/AIDS risks among male, heterosexual noninjecting drug users who exchange crack for sex. Inciardi JA. **NIDA Res Monogr** 1994;143:26–40 (66 ref.)

ADVERSE EFFECTS

Prenatal cocaine exposure. Consequences for child and family. Eyler FD, et al. **J Fla Med Assoc** 1995 Sep; 82(9):603–6 (52 ref.)
How to have a stroke at an early age: the effects of crack, cocaine and other illicit drugs. Blank-Reid C. **J Neurosci Nurs** 1996 Feb;28(1):19–27 (29 ref.)

CRACKLES see **RESPIRATORY SOUNDS**

CRAMP see **MUSCLE CRAMP**

CRANIAL FOSSA, POSTERIOR

INJURIES

Acute traumatic posterior fossa subdural haematomas. Borzone M, et al. **Acta Neurochir (Wien)** 1995;135(1–2):32–7 (9 ref.)

PATHOLOGY

Neuroepithelial cyst of the posterior fossa: two case reports with radiologic-pathologic correlation. Goh RH, et al. **Can Assoc Radiol J** 1996 Apr;47(2):126–31 (12 ref.)

CRANIAL IRRADIATION

An audit of craniospinal irradiation for medulloblastoma in Newcastle 1970–1992. Tinkler D, et al. **Clin Oncol (R Coll Radiol)** 1995;7(3):179–83 (21 ref.)
The efficacy of cranial irradiation in ovarian cancer metastatic to the brain: analysis of 32 cases. Corn BW, et al. **Obstet Gynecol** 1995 Dec;86(6):955–9 (17 ref.)

ADVERSE EFFECTS

Case report: late aggressive meningioma following prophylactic cranial irradiation for acute lymphoblastic leukaemia. Stein ME, et al. **Br J Radiol** 1995 Oct; 68(814):1123–5 (13 ref.)
An unusual case of hypersomnolence syndrome. Gandhi MK, et al. **Clin Lab Haematol** 1995 Sep;17(3):247–50 (14 ref.)
Central nervous system toxicity of cancer therapy in children. Moore IM. **J Pediatr Oncol Nurs** 1995 Oct;12(4):203–10; discussion 211 (50 ref.)
Radiation-induced meningioma in children: report of two cases and review of the literature. Starshak RJ. **Pediatr Radiol** 1996;26(8):537–41 (30 ref.)

CRANIAL NERVE DISEASES

ETIOLOGY

Simultaneous, multiple cranial neuropathies in diabetes mellitus. Eshbaugh CG, et al. **J Neuroophthalmol** 1995 Dec; 15(4):219–24 (23 ref.)

SURGERY

Neurophysiological monitoring of cranial nerves during posterior fossa surgery. Broggi G, et al. **Acta Neurochir Suppl (Wien)** 1995;64:35–9 (16 ref.)

CRANIAL NERVE NEOPLASMS

Intratemporal facial nerve perineurioma. Li D, et al. **Laryngoscope** 1996 Mar;106(3 Pt 1):328–33 (39 ref.)

Neoplasms of the optic–chiasmatic region. Bozzao A, et al. **Rays** 1996 Jan–Mar;21(1):50–69 (24 ref.) **(Eng, Ita)**

Neurinoma of the trigeminal root and atypical trigeminal neuralgia: case report and review of the literature. Tancioni F, et al. **Surg Neurol** 1995 Jul;44(1):36–42 (29 ref.)

DIAGNOSIS

Meningioma of the optic nerve sheath. Ortiz O, et al. **AJNR Am J Neuroradiol** 1996 May;17(5):901–6 (13 ref.)

Functioning glomus vagale tumor: report of case. Guiral H, et al. **J Oral Maxillofac Surg** 1996 Feb;54(2):227–30 (12 ref.)

Trigeminal neuropathy: evaluation with MR imaging. Majoie CB, et al. **Radiographics** 1995 Jul;15(4):795–811 (33 ref.)

PATHOLOGY

Rapid growth of an optic nerve ganglioglioma in a patient with neurofibromatosis 1. Sadun F, et al. **Ophthalmology** 1996 May;103(5):794–9 (41 ref.)

SECONDARY

Pineal germinoma with cranial nerve metastasis. Incesu L, et al. **Radiol Med (Torino)** 1996 Apr;91(4):471–2 (11 ref.)

SURGERY

Cavernous malformations of the optic chiasma. Shibuya M, et al. **Acta Neurochir (Wien)** 1995;136(1–2):29–36 (26 ref.)

Vestibular schwannoma and the only hearing ear. Bhatia S, et al. **J Laryngol Otol** 1996 Apr;110(4):366–9 (18 ref.)

Postsurgical development of dural arteriovenous malformations after transpetrosal and transtentorial operations: case report. Sasaki T, et al. **Neurosurgery** 1995 Oct;37(4):820–4; discussion 824–5 (14 ref.)

[Mediastinal schwannoma originating from the intrathoracic vagal nerve—a case report and review of the literature] Ohtaki A, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Sep;43(9):1675–9 (19 ref.) (Eng. Abstr.) **(Jpn)**

CRANIAL NERVES

INJURIES

Neurophysiological monitoring of cranial nerves during posterior fossa surgery. Broggi G, et al. **Acta Neurochir Suppl (Wien)** 1995;64:35–9 (16 ref.)

PHYSIOPATHOLOGY

[Cerebrovascular manifestations of infectious diseases] Martínez Vázquez F, et al. **Rev Neurol** 1995;23 Suppl 1:S11–21 (88 ref.) **(Spa)**

CRANIAL SINUS THROMBOSIS see **SINUS THROMBOSIS**

CRANIAL SINUSES

SURGERY

Childhood dural arteriovenous fistulae of the posterior dural sinuses: three case reports and literature review. Morita A, et al. **Neurosurgery** 1995 Dec;37(6):1193–9; discussion 1199–200 (34 ref.)

CRANIAL SUTURES

[Chondrosarcoma of the skull base. Apropos of sphenotemporal localization and review of the literature] Roche PH, et al. **Neurochirurgie** 1995;41(5):353–8 (34 ref.) (Eng. Abstr.) **(Fre)**

GROWTH & DEVELOPMENT

Basicranial synchondroses and the mandibular condyle in craniofacial growth. Rönning O. **Acta Odontol Scand** 1995 Jun;53(3):162–6 (42 ref.)

PHYSIOLOGY

The role of sutures in normal and abnormal craniofacial growth. Persson M. **Acta Odontol Scand** 1995 Jun; 53(3):152–61 (87 ref.)

CRANIOFACIAL DYSOSTOSIS

DIAGNOSIS

Atrioventricular canal and 3C (cranio–cerebello–cardiac) syndrome [letter; comment] Digilio MC, et al. **Am J Med Genet** 1995 Jul 31;58(1):97–8 (15 ref.) Comment on: Am J Med Genet 1994 Aug 1;52(1):66–9.

ETIOLOGY

[Advances in the understanding of the etiopathogenesis of non syndromic craniostenoses and therapeutic approaches] Czorny A, et al. **Ann Chir Plast Esthet** 1995 Dec; 40(6):657–65 (22 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Novel FGFR2 mutations in Crouzon and Jackson–Weiss syndromes show allelic heterogeneity and phenotypic variability. Park WJ, et al. **Hum Mol Genet** 1995 Jul; 4(7):1229–33 (18 ref.)

Molecular genetics and craniofacial surgery. Mulliken JB, et al. **Plast Reconstr Surg** 1996 Mar;97(3):666–75 (71 ref.)

PATHOLOGY

[Cerebro–oculofacial dysplasia associated with vertebral changes] Munteanu G, et al. **Oftalmologia** 1995 Oct–Dec; 39(4):316–21 (10 ref.) (Eng. Abstr.) **(Rum)**

PHYSIOPATHOLOGY

[Standard electromyographic and kinesiographic parameters in a sample of healthy population] Manni A, et al. **Minerva Stomatol** 1995 Sep;44(9):411–9 (29 ref.) (Eng. Abstr.) **(Ita)**

SURGERY

[Craniofacial surgery] Lyberg T. **Tidsskr Nor Laegeforen** 1996 Jan 20;116(2):230–4 (22 ref.) (Eng. Abstr.) **(Nor)**

CRANIOLOGY

see related
CEPHALOMETRY
CRANIOMETRY

CRANIOMETRY

see related
CEPHALOMETRY

Superimposition and reconstruction in forensic facial identification: a survey. Aulsebrook WA, et al. **Forensic Sci Int** 1995 Oct 30;75(2–3):101–20 (230 ref.)

CRANIOPHARYNGIOMA

DIAGNOSIS

Distinction of masses involving the sella and suprasellar space: specificity of imaging features. Donovan JL, et al. **AJR Am J Roentgenol** 1996 Sep;167(3):597–603 (69 ref.)

CRANIOSYNOSTOSES

ETIOLOGY

[Advances in the understanding of the etiopathogenesis of non syndromic craniostenoses and therapeutic approaches] Czorny A, et al. **Ann Chir Plast Esthet** 1995 Dec; 40(6):657–65 (22 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Is there a Baller–Gerold syndrome? [editorial; comment] Cohen MM Jr, et al. **Am J Med Genet** 1996 Jan 2;61(1):63–4 (38 ref.) Comment on: Am J Med Genet 1996 Jan 2;61(1):65–7.

Two craniosynostotic patients with 11q deletions, and review of 48 cases. Lewanda AF, et al. **Am J Med Genet** 1995 Nov 6;59(2):193–8 (46 ref.)

Hunter–McAlpine craniosynostosis phenotype associated with skeletal anomalies and interstitial deletion of chromosome 17q. Thomas JA, et al. **Am J Med Genet** 1996 Apr 24;62(4):372–5 (8 ref.)

Fibroblast growth factor receptor–2 mutations in craniosynostosis. Malcolm S, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:164–70 (29 ref.)

The genetic background of craniosynostosis syndromes. Heutink P, et al. **Eur J Hum Genet** 1995;3(5):312–23 (70 ref.)

Novel FGFR2 mutations in Crouzon and Jackson–Weiss syndromes show allelic heterogeneity and phenotypic variability. Park WJ, et al. **Hum Mol Genet** 1995 Jul; 4(7):1229–33 (18 ref.)

Pfeiffer type cardiocranial syndrome: a third case report. Williamson–Kruse L, et al. **J Med Genet** 1995 Nov; 32(11):901–3 (5 ref.)

Molecular genetics and craniofacial surgery. Mulliken JB, et al. **Plast Reconstr Surg** 1996 Mar;97(3):666–75 (71 ref.)

PATHOLOGY

Patient with craniosynostosis and marfanoid phenotype (Shprintzen–Goldberg syndrome) and cloverleaf skull. Saal HM, et al. **Am J Med Genet** 1995 Jul 17;57(4):573–8 (16 ref.)

Perspectives on craniofacial asymmetry. V. The craniosynostoses. Cohen MM Jr. **Int J Oral Maxillofac Surg** 1995 Jun;24(3):191–4 (24 ref.)

PHYSIOPATHOLOGY

The role of sutures in normal and abnormal craniofacial growth. Persson M. **Acta Odontol Scand** 1995 Jun; 53(3):152–61 (87 ref.)

SURGERY

Unilateral coronal synostosis (anterior plagiocephaly): current clinical perspectives. Posnick JC. **Ann Plast Surg** 1996 Apr;36(4):430–47 (97 ref.)

[Surgery of craniofacial abnormalities] Mühling J, et al. **Fortschr Kiefer Gesichtschir** 1995;40:72–7 (67 ref.) **(Ger)**

CRANIOTOMY

ADVERSE EFFECTS

Intrasellar abscess following transsphenoidal surgery. Henegar MM, et al. **Surg Neurol** 1996 Feb;45(2):183–8 (24 ref.)

METHODS

The maxillofacial surgeon and cranial base surgery. Vaughan ED. **Br J Oral Maxillofac Surg** 1996 Feb;34(1):4–17 (18 ref.)

Pitfalls in the pterional approach to the parasellar area (review). Aydin IH, et al. **Minim Invasive Neurosurg** 1995 Dec;38(4):146–52 (25 ref.)

Postsurgical development of dural arteriovenous malformations after transpetrosal and transtentorial operations: case report. Sasaki T, et al. **Neurosurgery** 1995 Oct;37(4):820–4; discussion 824–5 (14 ref.)

[Long–term results of the surgical treatment of spheno–orbital osteomeningioma] Gaillard S, et al. **Neurochirurgie** 1995;41(6):391–7 (34 ref.) (Eng. Abstr.) **(Fre)**

[Surgery of craniofacial abnormalities] Mühling J, et al. **Fortschr Kiefer Gesichtschir** 1995;40:72–7 (67 ref.) **(Ger)**

[Dura–plasty in intracranial operations] Ernestus RI, et al. **Zentralbl Neurochir** 1995;56(3):106–10 (20 ref.) (Eng. Abstr.) **(Ger)**

CRANIUM see **SKULL**

CRATAEGUS see **PLANTS, MEDICINAL**

CRD–401 see **DILTIAZEM**

CREATINE

PHARMACOLOGY

Creatine and its application as an ergogenic aid. Greenhaff PL. **Int J Sport Nutr** 1995 Jun;5 Suppl:S100–10 (33 ref.)

CREATINE KINASE

BLOOD

New biochemical markers for myocardial cell injury. Hamm CW, et al. **Curr Opin Cardiol** 1995 Jul;10(4):355–60 (42 ref.)

[Rhabdomyolysis and Q fever (letter)] Alberto Navarro L, et al. **Enferm Infecc Microbiol Clin** 1996 Feb;14(2):129–30 (9 ref.) **(Spa)**

METABOLISM

Variations of muscle mitochondrial creatine kinase activity in mitochondrial diseases. Bouzidi MF, et al. **Biochim Biophys Acta** 1996 Jun 7;1316(2):61–70 (45 ref.)

PHYSIOLOGY

Metabolic control and metabolic capacity: two aspects of creatine kinase functioning in the cells. Saks VA, et al. **Biochim Biophys Acta** 1996 Jun 13;1274(3):81–8 (57 ref.)

CREATINE KINASE ISOENZYMES

BLOOD

New biochemical markers for myocardial cell injury. Hamm CW, et al. **Curr Opin Cardiol** 1995 Jul;10(4):355–60 (42 ref.)

The role of CK–MB in chest pain decision–making. Hedges JR. **J Accid Emerg Med** 1995 Jun;12(2):101–6 (39 ref.)

CREATINE KINASE ISOZYMES see **CREATINE KINASE ISOENZYMES**

CREATINE PHOSPHOKINASE see **CREATINE KINASE**

CREATININE

ANALYSIS

[Creatine] Kojima S, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:460–3 (10 ref.) **(Jpn)**

[Creatinine and its clinical significance] Yoshimura M, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:464–8 (11 ref.) **(Jpn)**

BLOOD

Serum creatinine and urea: make the most of these simple test. Isles CG, et al. **Br J Hosp Med** 1996 Apr 17–30; 55(8):513–6 (3 ref.)

Colonoscopy preps: what's best? [editorial; comment] Keeffe EB. **Gastrointest Endosc** 1996 May;43(5):524–8 (30 ref.) Comment on: Gastrointest Endosc 1996 May;43(5):463–6. Comment on: Gastrointest Endosc 1996 May;43(5):467–9.

How to reach optimal creatinine clearances in automated peritoneal dialysis. Durand PY, et al. **Perit Dial Int** 1996; 16 Suppl 1:S167–70 (14 ref.)

The impact of peritoneal permeability and residual renal function on PD prescription. Harty J, et al. **Perit Dial Int** 1996;16 Suppl 1:S147–52 (18 ref.)

METABOLISM

Conventional measurement of renal function utilizing serum creatinine, creatinine clearance, inulin and para-aminohippuric acid clearance. Toto RD. **Curr Opin Nephrol Hypertens** 1995 Nov;4(6):505–9; discussion 503–4 (21 ref.)

CREATIVENESS

[Anna, Irma and Dora—the key to the mothers in the creation of psychoanalysis] King V. **Psyche (Stuttg)** 1995 Sep–Oct; 49(9–10):838–66 (60 ref.) (Eng. Abstr.) **(Ger)**

[The neurobiological bases of creativity] Simonov PV. **Fiziol Zh Im I M Sechenova** 1995 Nov;81(11):1–9 (35 ref.) **(Rus)**

CREB PROTEIN see DNA-BINDING PROTEIN, CYCLIC AMP-RESPONSIVE

CREDENTIALING

Privileges, credentialing, and liability. Musallam LS. **Prim Care** 1995 Sep;22(3):491–8 (12 ref.)

CREEPING ERUPTION see LARVA MIGRANS

CREPIS see HERBS

CREST SYNDROME

COMPLICATIONS

Reversible cardiogenic shock in an angry woman—case report and review of the literature. Kovacs KA, et al. **Can J Cardiol** 1996 Jul;12(7):689–93 (52 ref.)

CRETINISM

CONGENITAL

Compound W: a potential marker in maternal serum for assessing fetal thyroid function. Wu SY, et al. **Compr Ther** 1995 Oct;21(10):594–6 (17 ref.)

ETIOLOGY

Role of goitrogens in iodine deficiency disorders & brain development. Rao PS, et al. **Indian J Med Res** 1995 Nov; 102:223–6 (16 ref.)

CREUTZFELDT-JAKOB SYNDROME

DIAGNOSIS

[Creutzfeldt-Jakob disease—a human prion disease] Buchwald E, et al. **Nord Med** 1996 Jun;111(6):180–3 (14 ref.) (Eng. Abstr.) **(Dan)**

[Spongiform encephalopathy in cattle and humans] Wientjens DP, et al. **Ned Tijdschr Geneeskd** 1996 Jun 15; 140(24):1252–4 (20 ref.) **(Dut)**

[Prion-type pathologies: from scrapie to prion-related dementias. On the borderline between veterinary and human pathology] Domich L. **Rev Neurol** 1996 Jul; 24(131):785–802 (250 ref.) **(Spa)**

EPIDEMIOLOGY

Risk factors for Creutzfeldt-Jakob disease: a reanalysis of case-control studies. Wientjens DP, et al. **Neurology** 1996 May;46(5):1287–91 (28 ref.)

ETIOLOGY

Bovine spongiform encephalopathy and Creutzfeldt-Jakob disease: implications for physicians [see comments] MacKnight C, et al. **Can Med Assoc J** 1996 Sep 1; 155(5):529–36 (107 ref.) Comment in: Can Med Assoc J 1996 Sep 1;155(5):549–51.

Risk factors for Creutzfeldt-Jakob disease: a reanalysis of case-control studies. Wientjens DP, et al. **Neurology** 1996 May;46(5):1287–91 (28 ref.)

[Hypophyseal growth hormone and Creutzfeldt-Jakob disease in The Netherlands. Ad hoc Commission Creutzfeldt-Jakob-disease of the Dutch Growth Foundation] Rikken B, et al. **Ned Tijdschr Geneeskd** 1996 Jun 1;140(22):1163–5 (17 ref.) **(Dut)**

[Bovine spongiform encephalopathy and Creutzfeldt-Jakob disease. Current questions] Brugère-Picoux J. **Bull Acad Natl Med** 1996 Feb;180(2):291–9; discussion 300–3 (38 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Fatal familial insomnia and familial Creutzfeldt-Jakob disease: a tale of two diseases with the same genetic mutation. Gambetti P. **Curr Top Microbiol Immunol** 1996; 207:19–25 (17 ref.)

Transmissibility of Creutzfeldt-Jakob disease and related disorders. Collins SJ, et al. **Sci Prog** 1995;78 (Pt 3):217–27 (30 ref.)

PATHOLOGY

[Consensus report: tissue handling in suspected Creutzfeldt-Jakob disease and other spongiform encephalopathies (prion diseases) in the human.European Union Biomed-1 Concerted Action] Budka H, et al. **Pathologe** 1996 Mar;17(2):171–5 (16 ref.) (Eng. Abstr.) **(Ger)**

TRANSMISSION

Creutzfeldt-Jakob disease and bovine spongiform encephalopathy: any connection? [see comments] Almond JW, et al. **BMJ** 1995 Nov 25;311(7017):1415–21 (14 ref.) Comment in: BMJ 1996 Jan 20;312(7024):180. Comment in: BMJ 1996 Jan 20;312(7024):181. Comment in: BMJ 1996 Jul 20;313(7050):171–2.

Tissue handling in suspected Creutzfeldt-Jakob disease (CJD) and other human spongiform encephalopathies (prion diseases). Budka H, et al. **Brain Pathol** 1995 Jul; 5(3):319–22 (20 ref.)

Proposed link between transmissible spongiform encephalopathies of man and animals [see comments] Diringer H. **Lancet** 1995 Nov 4;346(8984):1208–10 (20 ref.) Comment in: Lancet 1996 Jan 6;347(8993):65–6.

Iatrogenic and zoonotic Creutzfeldt-Jakob disease: the Australian perspective. Collins S, et al. **Med J Aust** 1996 May 20;164(10):598–602 (35 ref.)

[Creutzfeldt-Jakob disease: in praise of madness (bovine)] Petrosillo N, et al. **Recenti Prog Med** 1996 May; 87(5):193–203 (103 ref.) **(Ita)**

CRF-41 see CORTICOTROPIN-RELEASING HORMONE

CRH RECEPTORS see RECEPTORS, CORTICOTROPIN-RELEASING HORMONE

CRIB DEATH see SUDDEN INFANT DEATH

CRIBRIFORM PLATE see ETHMOID BONE

CRICETIDAE see MICROTINAE

CRICETINAE see HAMSTERS

CRICETUS see HAMSTERS

CRIGLER-NAJJAR SYNDROME

METABOLISM

[Crigler-Najjar syndrome (types I and II)] Tazuma S, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):421–3 (15 ref.) **(Jpn)**

CRIME

[Epilepsy and delinquent behavior] Arías Horcajadas F, et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1995 Sep–Oct;23(5):235–40 (33 ref.) (Eng. Abstr.) **(Spa)**

PREVENTION & CONTROL

Crime, disorder and legal pressure as a result of addiction problems in The Netherlands. Wolters RD. **Med Law** 1995; 14(7–8):521–9 (28 ref.)

STATISTICS & NUMERICAL DATA

Violence, crime, and mental illness. How strong a link? [editorial] Marzuk PM. **Arch Gen Psychiatry** 1996 Jun; 53(6):481–6 (51 ref.)

CRIMINAL JUSTICE see CRIMINAL LAW

CRIMINAL LAW

What price the concept of psychopathic disorder? Prins H. **Med Sci Law** 1995 Oct;35(4):307–15 (56 ref.)

Male rape: the impact of a legal definition on the clinical area. Rogers P. **Med Sci Law** 1995 Oct;35(4):303–6 (14 ref.)

Technology transfer in the criminal justice field: implications for substance abuse. Gendreau P. **NIDA Res Monogr** 1995; 155:198–208 (35 ref.)

HISTORY

The evolution and definition of the concept of 'automatism' in Canadian case law. Jang D, et al. **Med Law** 1995; 14(3–4):221–38 (22 ref.)

CRIMINAL PSYCHOLOGY

Violence: the scientific medical perspective. Pincus JH. **Isr J Med Sci** 1996 Jul;32(7):511–4 (24 ref.)

CRIMINOLOGY

Epidemiology of illicit and abused drugs in the general population, emergency department drug-related episodes, and arrestees. Rouse BA. **Clin Chem** 1996 Aug;42(8 Pt 2):1330–6 (9 ref.)

CRIPPLED see DISABLED

CRISIS INTERVENTION

Preventing suicide in women and men. Lester D. **Crisis** 1995; 16(2):79–84 (33 ref.)

[Psychiatric emergencies and crises in gynecology] Gaebel W, et al. **Gynakologe** 1995 Dec;28(6):403–11 (19 ref.) **(Ger)**

METHODS

[Emergency situations in hypertension] Nagy V, et al. **Orv Hetil** 1996 Apr 28;137(17):913–21 (55 ref.) (Eng. Abstr.) **(Hun)**

CRITICAL CARE

see related
INTENSIVE CARE

Critical care profiling for informed treatment of severely ill patients. Shirey TL. **Am J Clin Pathol** 1995 Oct;104(4 Suppl 1):S79–87 (77 ref.)

Physiology and regulation. Ionized calcium, magnesium and lactate measurements in critical care settings. Toffaletti J. **Am J Clin Pathol** 1995 Oct;104(4 Suppl 1):S88–94 (20 ref.)

Managing agitation in critically ill patients. Harvey MA. **Am J Crit Care** 1996 Jan;5(1):7–16; quiz 17–8 (72 ref.)

Management of profound hypothermia. Antretter H, et al. **Br J Hosp Med** 1995 Sep 6–19;54(5):215–20 (26 ref.)

Standards of evidence for the safety and effectiveness of critical care monitoring devices and related interventions. Coalition for Critical Care Excellence: Consensus Conference on Physiologic Monitoring Devices. **Crit Care Med** 1995 Oct;23(10):1756–63 (12 ref.)

Evidence based critical care medicine; what is it and what can it do for us? Evidence Based Medicine in Critical Care Group. Cook DJ, et al. **Crit Care Med** 1996 Feb;24(2):334–7 (46 ref.)

A model for technology assessment as applied to closed loop infusion systems. Technology Assessment Task Force of the Society of Critical Care Medicine. Jastremski M, et al. **Crit Care Med** 1995 Oct;23(10):1745–55 (105 ref.)

Multiple organ failure. Buchman TG. **Curr Opin Gen Surg** 1993;:26–31 (30 ref.)

Malnutrition, injury, and the host immune response: nutrient substitution. Gallagher HJ, et al. **Curr Opin Gen Surg** 1993; :92–104 (116 ref.)

Acute myocardial infarction: pre-hospital and in-hospital management. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. **Eur Heart J** 1996 Jan;17(1):43–63 (127 ref.)

Dangling: a review of relevant physiology, research, and practice. Winslow EH, et al. **Heart Lung** 1995 Jul–Aug; 24(4):263–72 (35 ref.)

Technology and the lifeworld of critical care nursing. Walters AJ. **J Adv Nurs** 1995 Aug;22(2):338–46 (26 ref.)

Active cooling during anesthesia and critical care. Illievich UM, et al. **J Neurosurg Anesthesiol** 1996 Jan;8(1):78–82 (56 ref.)

Continuous hemofiltration: nursing perspectives in critical care. Baldwin IC, et al. **New Horiz** 1995 Nov;3(4):738–47 (34 ref.)

Monitoring of O2 transport and tissue oxygenation in paediatric critical care. Hüttemann E, et al. **Paediatr Anaesth** 1995;5(5):281–6 (54 ref.)

Transfusion therapy in emergency and critical care medicine. Kirby R. **Vet Clin North Am Small Anim Pract** 1995 Nov; 25(6):1365–86 (25 ref.)

[Indications for the use of magnesium in anesthesia and intensive care] Delhumeau A, et al. **Ann Fr Anesth Reanim** 1995;14(5):406–16 (113 ref.) (Eng. Abstr.) **(Fre)**

[Snake bites] Vincent JL, et al. **Rev Med Brux** 1995 Nov; 16(5):349–52 (12 ref.) (Eng. Abstr.) **(Fre)**

[Recommendations for initial diagnosis and therapy in acute blood coagulation disorders] Sütterlin R, et al. **Anaesthesiol Reanim** 1996;21(3):76–80 (24 ref.) (Eng. Abstr.) **(Ger)**

[Principles of analgesia and sedation] Behne M. **Anaesthesist** 1995 Dec;44 Suppl 3:S535–9 (21 ref.) (Eng. Abstr.) **(Ger)**

[Clinical aspects of acute lung failure in adults (ARDS)] Lewandowski K, et al. **Anaesthesist** 1996 Jan;45(1):1–18 (85 ref.) (Eng. Abstr.) **(Ger)**

[VO2 and DO2 during cardiogenic shock and infection] Beale R. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May;31(1 Suppl):S22–5 (19 ref.) **(Ger)**

[Continuous monitoring of minute cardiac volume] Jansen JR. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May;31(1 Suppl):S30–4 (26 ref.) **(Ger)**

[Gamma-hydroxybutyric acid--significance for anesthesia and intensive care medicine?] Kleinschmidt S, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Nov; 30(7):393–402 (59 ref.) (Eng. Abstr.) **(Ger)**

[Imaging methods in intensive care] Habscheid W. **Bildgebung** 1996 Mar;63(1):4–21 (113 ref.) (Eng. Abstr.) **(Ger)**

[Thyrotoxic crisis. Pitfalls in diagnosis--intensive therapy] Hehrmann R. **Fortschr Med** 1996 Apr 10;114(10):114–7 (18 ref.) (Eng. Abstr.) **(Ger)**

ECONOMICS

Economic evaluations in the critical care literature: do they help us improve the efficiency of our unit? Heyland DK, et al. **Crit Care Med** 1996 Sep;24(9):1591–8 (46 ref.)

The economics and cost-effectiveness of critical care medicine. Chalfin DB, et al. **Intensive Care Med** 1995 Nov; 21(11):952–61 (67 ref.)

METHODS

Critical care of children with acute brain injury. Greenwald BM, et al. **Adv Pediatr** 1995;42:47–89 (135 ref.)

Echocardiography assessment of left ventricular function in the critically ill. McLean AS. **Anaesth Intensive Care** 1996 Feb;24(1):60–5 (40 ref.)

Impact of the resin blood culture medium on the treatment of critically ill patients. Levin PD, et al. **Crit Care Med** 1996 May;24(5):797–801 (24 ref.)

Management of nutrition in the critically ill patient. Kudsk KA, et al. **Curr Opin Gen Surg** 1994;:24–9 (15 ref.)

Evaluation of hepatic function. Ozawa K, et al. **Curr Opin Gen Surg** 1994;:17–23 (31 ref.)

The management of acute respiratory failure. Shanley CJ, et al. **Curr Opin Gen Surg** 1994;:7–16 (82 ref.)

Gastrointestinal bleeding. Talbot-Stern JK. **Emerg Med Clin North Am** 1996 Feb;14(1):173–84 (31 ref.)

Traumatic brain injury. Zink BJ. **Emerg Med Clin North Am** 1996 Feb;14(1):115–50 (149 ref.)

Critical care of acute ischemic stroke. Hacke W, et al. **Intensive Care Med** 1995 Oct;21(10):856–62 (44 ref.)

New advances in the pharmacologic approach to circulatory shock. Chernow B. **J Clin Anesth** 1996 May;8(3 Suppl):67S–69S (15 ref.)

Antioxidant therapy in critical care medicine. Tanswell AK, et al. **New Horiz** 1995 May;3(2):330–41 (140 ref.)

[Liver transplantation as school for visceral surgery--experiences for perioperative management] Neuhaus P, et al. **Chirurg** 1996 Apr;67(4):341–7 (31 ref.) (Eng. Abstr.) **(Ger)**

[New developments in clinical therapy of shock] Walz M, et al. **Chirurg** 1995 Nov;66(11):1040–9 (59 ref.) (Eng. Abstr.) **(Ger)**

[Sedation of the patient in critical condition] Castillo J. **Rev Esp Anestesiol Reanim** 1995 Dec;42(10):432–5 quiz answer 440 (25 ref.) **(Spa)**

ORGANIZATION & ADMINISTRATION

Critical care medicine: opportunities and strategies for improvement. Cohen IL, et al. **Jt Comm J Qual Improv** 1996 Feb;22(2):85–103 (97 ref.)

TRENDS

The current and future status of critical care testing and patient monitoring. Kost GJ, et al. **Am J Clin Pathol** 1995 Oct;104(4 Suppl 1):S2–17 (202 ref.)

What's new in critical care and metabolism. Rice CL. **J Am Coll Surg** 1996 Feb;182(2):93–9 (69 ref.)

CRITICAL ILLNESS

Effects of catecholamines on regional perfusion and oxygenation in critically ill patients. Meier-Hellmann A, et al. **Acta Anaesthesiol Scand Suppl** 1995;107:239–48 (106 ref.)

The role of flumazenil in the critically ill. Park GR, et al. **Acta Anaesthesiol Scand Suppl** 1995;108:23–34 (120 ref.)

Lactate levels in critically ill patients. Vincent JL. **Acta Anaesthesiol Scand Suppl** 1995;107:261–6 (29 ref.)

Quantifying pulmonary oxygen transfer deficits in critically ill patients. Wandrup JH. **Acta Anaesthesiol Scand Suppl** 1995;107:37–44 (54 ref.)

Monitoring pulmonary artery wedge pressure in medical patients. Sharma S, et al. **Am Fam Physician** 1996 Sep 1; 54(3):1039–49 (39 ref.)

Physiology and regulation. Ionized calcium, magnesium and lactate measurements in critical care settings. Toffaletti J. **Am J Clin Pathol** 1995 Oct;104(4 Suppl 1):S88–94 (20 ref.)

Ethical considerations of ensuring an informed and autonomous consent in research involving critically ill patients. Silverman HJ. **Am J Respir Crit Care Med** 1996 Sep;154(3 Pt 1):582–6 (34 ref.)

Neurologic complications in critically ill patients. Wijdicks EF. **Anesth Analg** 1996 Aug;83(2):411–9 (60 ref.)

Determinants of intestinal barrier failure in critical illness. Aranow JS, et al. **Br J Anaesth** 1996 Jul;77(1):71–81 (170 ref.)

Molecular mechanisms of drug metabolism in the critically ill. Park GR. **Br J Anaesth** 1996 Jul;77(1):32–49 (160 ref.)

Micronutrients in critical illness. Demling RH, et al. **Crit Care Clin** 1995 Jul;11(3):651–73 (40 ref.)

Metabolic responses of the critically ill patient. Kinney JM. **Crit Care Clin** 1995 Jul;11(3):569–85 (66 ref.)

Nutritional assessment in the critically ill. Manning EM, et al. **Crit Care Clin** 1995 Jul;11(3):603–34 (110 ref.)

Theories and assumptions on energy expenditure. Determinations in the clinical setting. Molina P, et al. **Crit Care Clin** 1995 Jul;11(3):587–601 (53 ref.)

Influence of different volume therapies and pentoxifylline infusion on circulating soluble adhesion molecules in critically ill patients. Boldt J, et al. **Crit Care Med** 1996 Mar;24(3):385–91 (39 ref.)

Sedation for the critically ill neurologic patient. Mirski MA, et al. **Crit Care Med** 1995 Dec;23(12):2038–53 (124 ref.)

Anterior pituitary function during critical illness and dopamine treatment. Van den Berghe G, et al. **Crit Care Med** 1996 Sep;24(9):1580–90 (178 ref.)

Sepsis in the critically ill patient. Baker CC, et al. **Curr Probl Surg** 1995 Dec;32(12):1013–83 (341 ref.)

Indirect calorimetry in critically ill patients: role of the clinical dietitian in interpreting results. Porter C, et al. **J Am Diet Assoc** 1996 Jan;96(1):49–57 (38 ref.)

Factors affecting drug metabolism in critically ill patients. Woodrooffe AJ, et al. **Middle East J Anesthesiol** 1995 Feb; 13(1):3–22 (71 ref.)

Ethics and the care of critically ill infants and children. American Academy of Pediatrics Committee on Bioethics. **Pediatrics** 1996 Jul;98(1):149–52 (58 ref.)

Stress ulcer prophylaxis. Do critically ill patients need it? DePriest JL. **Postgrad Med** 1995 Oct;98(4):159–61, 165–6, 168 (23 ref.)

The insulin-like growth factors in critical illness: pathophysiology and therapeutic potential. Holly JM. **Proc Nutr Soc** 1995 Jul;54(2):591–9 (56 ref.)

[Transport of critically ill patients] Ben Abraham R, et al. **Harefuah** 1996 Apr 1;130(7):474–8 (14 ref.) **(Heb)**

THERAPY

Critical care profiling for informed treatment of severely ill patients. Shirey TL. **Am J Clin Pathol** 1995 Oct;104(4 Suppl 1):S79–87 (77 ref.)

Nutrition and immunonutrition. O'Leary MJ, et al. **Br J Anaesth** 1996 Jul;77(1):118–27 (102 ref.)

Protein and amino acids in nutritional support. McNurlan MA, et al. **Crit Care Clin** 1995 Jul;11(3):635–50 (114 ref.)

Maximizing oxygen delivery in critically ill patients: a methodologic appraisal of the evidence. Heyland DK, et al. **Crit Care Med** 1996 Mar;24(3):517–24 (42 ref.)

Triage of critically ill patients: an overview of interventions. Rady MY. **Emerg Med Clin North Am** 1996 Feb;14(1):13–33 (91 ref.)

CRITICAL PATHWAYS

Standardizing care delivery for infants and children with common congenital cardiac lesions. Allen HD, et al. **Curr Opin Pediatr** 1995 Oct;7(5):601–5 (33 ref.)

Critical pathways for the future: MR imaging and digital mammography. Newstead GM, et al. **Radiographics** 1995 Jul;15(4):951–62 (40 ref.)

CROCIDOLITE ASBESTOS see **ASBESTOS, CROCIDOLITE**

CROHN DISEASE

Unifying hypothesis for inflammatory bowel disease and associated colon cancer: sticking the pieces together with sugar. Rhodes JM. **Lancet** 1996 Jan 6;347(8993):40–4 (49 ref.)

Crohn's disease in children. Hyams JS. **Pediatr Clin North Am** 1996 Feb;43(1):255–77 (65 ref.)

[Ulcerative colitis and Crohn disease] Asakura H. **Nippon Naika Gakkai Zasshi** 1996 Mar 10;85(3):408–11 (10 ref.) **(Jpn)**

BLOOD

Anti-endothelial cell antibodies in sera from patients with inflammatory bowel disease. Aldebert D, et al. **Gastroenterol Clin Biol** 1995 Nov;19(11):867–70 (20 ref.)

CHEMICALLY INDUCED

Colonoscopy preps: what's best? [editorial; comment] Keeffe EB. **Gastrointest Endosc** 1996 May;43(5):524–8 (30 ref.) Comment on: Gastrointest Endosc 1996 May;43(5):463–6. Comment on: Gastrointest Endosc 1996 May;43(5):467–9.

COMPLICATIONS

Malignancy in Crohn's disease. Bernstein D, et al. **Am J Gastroenterol** 1996 Mar;91(3):434–40 (107 ref.)

Crohn's disease complicating male genitourinary tract without overlying cutaneous involvement. Minocha A, et al. **Am J Gastroenterol** 1996 Jul;91(7):1463–4 (9 ref.)

Localized epidermolysis bullosa acquisita of the esophagus in a patient with Crohn's disease. Schattenkirchner S, et al. **Am J Gastroenterol** 1996 Aug;91(8):1657–9 (15 ref.)

Metastatic Crohn's disease. Report of 3 cases with special reference to histopathologic findings. Hackzell-Bradley M, et al. **Arch Dermatol** 1996 Aug;132(8):928–32 (22 ref.)

Extramedullary plasmacytoma mimicking primary colonic carcinoma in a patient with Crohn's disease. Case report and literature review. Ligato S, et al. **Arch Pathol Lab Med** 1996 Mar;120(3):279–82 (32 ref.)

Management of rectourethral fistulas in Crohn's disease. Santoro GA, et al. **Int J Colorectal Dis** 1995;10(4):183–8 (47 ref.)

Fulminant herpes colitis in a patient with Crohn's disease. el-Serag HB, et al. **J Clin Gastroenterol** 1996 Apr; 22(3):220–3 (41 ref.)

[Sweet syndrome associated with Crohn disease] Ly S, et al. **Rev Med Interne** 1995;16(12):931–3 (18 ref.) (Eng. Abstr.) **(Fre)**

[Perforation in Crohn's ileitis and its impact on the natural history of the disease. Note 1. Pathogenic process of the event, its relationship with intestinal obstruction, and its immediate consequences] Tonelli P. **Ann Ital Chir** 1995 May-Jun;66(3):335–47 (24 ref.) (Eng. Abstr.) **(Ita)**

[Cerebrovascular manifestations of gastrointestinal diseases] González JL, et al. **Rev Neurol** 1995;23 Suppl 1:S91–4 (43 ref.) **(Spa)**

DIAGNOSIS

Does Crohn's disease need differentiation from tuberculosis? Jayanthi V, et al. **J Gastroenterol Hepatol** 1996 Feb; 11(2):183–6 (42 ref.)

[Use of a scoring index for evaluating disease activity of Leśniowski-Crohn disease and ulcerative colitis in children] Ryżko J, et al. **Pediatr Pol** 1995 Jul;70(7):585–9 (9 ref.) (Eng. Abstr.) **(Pol)**

DRUG THERAPY

Leukocyte-endothelial cell interactions: potential targets for mesalazine in Crohn's disease. Wakefield AJ, et al. **Adv Exp Med Biol** 1995;371B:1307–11 (72 ref.)

Budesonide. A review of its pharmacological properties and therapeutic efficacy in inflammatory bowel disease. Spencer CM, et al. **Drugs** 1995 Nov;50(5):854–72 (51 ref.)

Inflammatory bowel disease. Hanauer SB. **N Engl J Med** 1996 Mar 28;334(13):841–8 (111 ref.)

[Cyclosporine A and chronic inflammatory diseases of the digestive tract] Brazier F, et al. **Gastroenterol Clin Biol** 1995 May;19(5):494–504 (118 ref.) **(Fre)**

[Crohn disease: prevention and drug therapy] Gross V, et al. **Chirurg** 1995 Aug;66(8):757–63 (42 ref.) (Eng. Abstr.) **(Ger)**

[5-aminosalicylic acid and chronic inflammatory bowel diseases in children] Klotz U. **Klin Padiatr** 1995 Sep-Oct; 207(5):285–7 (18 ref.) (Eng. Abstr.) **(Ger)**

[Current orientation on medical therapy of Crohn disease] Grassi M, et al. **Clin Ter** 1995 Nov;146(11):737–45 (132 ref.) (Eng. Abstr.) **(Ita)**

[Advances in the topical steroid treatment of inflammatory bowel diseases] Diaz Blasco J, et al. **Rev Esp Enferm Dig** 1995 Nov;87(11):802–7 (62 ref.) **(Spa)**

EPIDEMIOLOGY

Epidemiology of inflammatory bowel disease: an update. Russel MG, et al. **Scand J Gastroenterol** 1996 May; 31(5):417–27 (190 ref.)

ETIOLOGY

Environmental risk factors in inflammatory bowel disease. Koutroubakis I, et al. **Hepatogastroenterology** 1996 Mar-Apr;43(8):381–93 (125 ref.)

GENETICS

[Genetics and chronic idiopathic inflammatory diseases of the intestines] Reimund JM, et al. **Ann Med Interne (Paris)** 1996;147(3):178–84 (38 ref.) **(Fre)**

[Genetics of Crohn disease: a complex model] Colombel JF, et al. **Gastroenterol Clin Biol** 1996;20(5 Pt 2):B15–20 (45 ref.) **(Fre)**

[Genetics of inflammatory bowel diseases] Hugot JP, et al. **Gastroenterol Clin Biol** 1995 Nov;19(11):890–8 (125 ref.) **(Fre)**

IMMUNOLOGY

Immunology of inflammatory bowel disease--an update. Jewell DP. **J Gastroenterol** 1995 Nov;30 Suppl 8:78–82 (43 ref.)

[Crohn disease, hemorrhagic rectocolitis: antibodies and humans (editorial)] Duclos B. **Gastroenterol Clin Biol** 1995 Nov;19(11):865–6 (21 ref.) **(Fre)**

[Characteristics of HLA II antigen expression in the rectal mucosa of children suffering form ulcerative colitis and Crohn disease] Hacsek G, et al. **Orv Hetil** 1995 Oct 15; 136(42):2279–82 (25 ref.) (Eng. Abstr.) **(Hun)**

METABOLISM

Cytokines and inflammatory bowel disease. Radford-Smith G, et al. **Baillieres Clin Gastroenterol** 1996 Mar; 10(1):151–64 (64 ref.)

PATHOLOGY

Crohn's disease of the vulva. Vettraino IM, et al. **Am J Dermatopathol** 1995 Aug;17(4):410–3 (10 ref.)

Perianal Crohn's disease in children and adolescents. Tolia V. **Am J Gastroenterol** 1996 May;91(5):922–6 (32 ref.)

Vulvitis granulomatosa: a cryptogenic chronic inflammatory

hypertrophy of vulvar labia related to cheilitis granulomatosa and Crohn's disease. Guerrieri C, et al. **Int J Gynecol Pathol** 1995 Oct;14(4):352–9 (62 ref.)

PHYSIOPATHOLOGY

Intestinal permeability in Crohn's disease. Franchimont D, et al. **Acta Gastroenterol Belg** 1996 Jan–Mar;59(1):15–9 (35 ref.)

PSYCHOLOGY

[Quality of life in chronic inflammatory bowel diseases] Bregenzer N, et al. **Med Klin** 1996 Jun 15;91(6):396–401 (36 ref.) **(Ger)**

RADIOGRAPHY

CT features of ulcerative colitis and Crohn's disease. Gore RM, et al. **AJR Am J Roentgenol** 1996 Jul;167(1):3–15 (86 ref.)

RADIONUCLIDE IMAGING

Review article: quantitative leucocyte scanning in the assessment of inflammatory bowel disease activity and its response to therapy. Weldon MJ, et al. **Aliment Pharmacol Ther** 1996 Apr;10(2):123–32 (70 ref.)

SURGERY

Perianal inflammatory conditions in inflammatory bowel disease. Stein BL, et al. **Curr Opin Gen Surg** 1993;:141–6 (17 ref.)

[Surgery in Crohn's disease] Halme L. **Duodecim** 1994; 110(21):2017–21 (10 ref.) **(Fin)**

[Surgical therapy of recurrent Crohn disease] Buhr HJ, et al. **Chirurg** 1995 Aug;66(8):764–73 (35 ref.) (Eng. Abstr.) **(Ger)**

[Recurrent Crohn disease—definition and diagnosis] Köhne G, et al. **Chirurg** 1995 Aug;66(8):745–50 (31 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Inflammatory bowel disease. Bowling TE. **Eur J Gastroenterol Hepatol** 1995 Jun;7(6):521–7 (45 ref.)

Medical treatment of inflammatory bowel disease. Singhal A, et al. **J Assoc Physicians India** 1995 Sep;43(9):627–31 (32 ref.)

Nutritional support in Crohn's disease: current status and future directions. O'Morain C, et al. **J Gastroenterol** 1995 Nov;30 Suppl 8:102–7 (32 ref.)

[Treatment of Crohn disease in children] Cezard JP, et al. **Gastroenterol Clin Biol** 1996;20(5 Pt 2):B50–55 (55 ref.) **(Fre)**

CROMOLYN SODIUM

ADMINISTRATION & DOSAGE

Inhaled sodium cromoglycate. Holgate ST. **Respir Med** 1996 Aug;90(7):387–90 (45 ref.)

THERAPEUTIC USE

Oral sodium cromoglycate: its use in the management of food allergy. Edwards AM. **Clin Exp Allergy** 1995 Jul;25 Suppl 1:31–3 (30 ref.)

CRONKHITE–CANADA SYNDROME see **INTESTINAL POLYPS**

CROP, AVIAN

SECRETION

Regulation of pigeon cropmilk secretion and parental behaviors by prolactin. Horseman ND, et al. **Annu Rev Nutr** 1995;15:213–38 (130 ref.)

CROPS, AGRICULTURAL

Site-specific integrated pest management for high value crops: sample units for map generation using the Colorado potato beetle (Coleoptera: Chrysomelidae) as a model system. Weisz R, et al. **J Econ Entomol** 1995 Oct; 88(5):1069–80 (36 ref.)

CROSS-CULTURAL COMPARISON

Management of epilepsy in Hungary. Halász P. **Acta Neurol Scand Suppl** 1995;162:24–6 (2 ref.)

Recent developments in the epidemiology of epilepsy. Hauser WA. **Acta Neurol Scand Suppl** 1995;162:17–21 (31 ref.)

Fatal asthma. FitzGerald JM, et al. **Annu Rev Med** 1996; 47:161–8 (32 ref.)

Athletic knee injuries. Similarities and differences between Asian and Western experience. Maffulli N, et al. **Clin Orthop** 1996 Feb;(323):98–105 (90 ref.)

Cultural challenges to the psychiatric enterprise. Fabrega H Jr. **Compr Psychiatry** 1995 Sep–Oct;36(5):377–83 (48 ref.)

Interpreting culture and psychopathology: primitivist themes in cross-cultural debate. Lucas RH, et al. **Cult Med Psychiatry** 1995 Sep;19(3):287–326 (115 ref.)

Emergency contraception in the United Kingdom and The Netherlands. Glasier A, et al. **Fam Plann Perspect** 1996 Mar–Apr;28(2):49–51 (17 ref.)

The international political economy of food: a global crisis. Friedmann H. **Int J Health Serv** 1995;25(3):511–38 (55 ref.)

Cross-cultural perspectives on menopause. Robinson G. **J Nerv Ment Dis** 1996 Aug;184(8):453–8 (23 ref.)

Social networks and family violence in cross-cultural perspective. Korbin JE. **Nebr Symp Motiv** 1995;42:107–34 (92 ref.)

Tuberculosis and HIV infection worldwide. Murray JF. **Pneumologie** 1995 Dec;49 Suppl 3:653–6 (22 ref.)

Syringe-mediated drug sharing among injecting drug users: patterns, social context and implications for transmission of blood-borne pathogens. Grund JP, et al. **Soc Sci Med** 1996 Mar;42(5):691–703 (89 ref.)

Elderly mental health in the developing world. Levkoff SE, et al. **Soc Sci Med** 1995 Oct;41(7):983–1003 (178 ref.)

Abortion law and practice in China: an overview with comparisons to the United States. Rigdon SM. **Soc Sci Med** 1996 Feb;42(4):543–60 (96 ref.)

Theory and methodology in premenstrual syndrome research. Walker A. **Soc Sci Med** 1995 Sep;41(6):793–800 (56 ref.)

[Transcultural symptomatology. Its expression in family practice] Ferron M. **Can Fam Physician** 1995 Oct; 41:1718–25 (20 ref.) (Eng. Abstr.) **(Fre)**

[Epidemiology of the use of anxiolytic and hypnotic drugs in France and in the world] Pélissolo A, et al. **Encephale** 1996 May–Jun;22(3):187–96 (68 ref.) (Eng. Abstr.) **(Fre)**

[Does AIDS influence the epidemiology of tuberculosis?] Ferlinz R, et al. **Pneumologie** 1995 Aug;49(8):449–54 (7 ref.) **(Ger)**

CROSS INFECTION

see related
COMMUNITY-ACQUIRED INFECTIONS
DISEASE TRANSMISSION, PATIENT-TO-PROFESSIONAL
DISEASE TRANSMISSION, PROFESSIONAL-TO-PATIENT
INFECTION CONTROL

Emerging and reemerging microbial threats. Nosocomial fungal infections. Henderson VJ, et al. **Arch Surg** 1996 Mar; 131(3):330–7 (57 ref.)

Infection, the gut and the development of the multiple organ dysfunction syndrome. Nieuwenhuijzen GA, et al. **Eur J Surg** 1996 Apr;162(4):259–73 (185 ref.)

Nosocomial pneumonia: trying to make sense of the literature. Broughton WA, et al. **Postgrad Med** 1996 Mar; 99(3):221–31, 235–6, 241–2 (31 ref.)

Nosocomial pneumonia. Lipchik RJ, et al. **Radiol Clin North Am** 1996 Jan;34(1):47–58 (69 ref.)

[Application of PCR to hospital epidemiology] Tokue Y, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):705–7 (14 ref.) **(Jpn)**

COMPLICATIONS

Diagnosis and treatment of nosocomial pneumonia. Bonten MJ, et al. **Br J Hosp Med** 1995 Oct 4–17;54(7):335–40 (25 ref.)

DIAGNOSIS

Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies. A consensus statement, American Thoracic Society, November 1995. **Am J Respir Crit Care Med** 1996 May;153(5):1711–25 (110 ref.)

Diagnosis and treatment of nosocomial pneumonia in patients in intensive care units. Chastre J, et al. **Clin Infect Dis** 1995 Dec;21 Suppl 3:S226–37 (61 ref.)

The use of molecular biology techniques for diagnostic microbiology and hospital epidemiology. Low DE, et al. **New Horiz** 1995 May;3(2):161–9 (84 ref.)

Diagnosis of pulmonary infections in mechanically ventilated patients. Chastre J, et al. **Semin Respir Infect** 1996 Jun; 11(2):65–76 (58 ref.)

Differential diagnosis of fever and pulmonary densities in mechanically ventilated patients. Louthan FB, et al. **Semin Respir Infect** 1996 Jun;11(2):77–95 (136 ref.)

Nosocomial pneumonia during mechanical ventilation: problems with diagnostic criteria [editorial] Brun-Buisson C. **Thorax** 1995 Nov;50(11):1128–30 (27 ref.)

[Nosocomial pneumonia] Jébrak G, et al. **Presse Med** 1996 Jun 8;25(20):944–50 (25 ref.) (Eng. Abstr.) **(Fre)**

[Hospital pneumonia due to Xanthomonas maltophilia and AIDS (letter)] Sitges M, et al. **Arch Bronconeumol** 1996 May;32(5):259–60 (6 ref.) **(Spa)**

DRUG THERAPY

Diagnosis and treatment of nosocomial pneumonia in patients in intensive care units. Chastre J, et al. **Clin Infect Dis** 1995 Dec;21 Suppl 3:S226–37 (61 ref.)

Current perspectives on glycopeptide resistance. Woodford N, et al. **Clin Microbiol Rev** 1995 Oct;8(4):585–615 (429 ref.)

[Multicenter comparative study of meropenem vs. imipenem in the intramuscular treatment of hospital infections of the urinary tract] Tallarigo C, et al. **Minerva Urol Nefrol** 1995 Sep;47(3):147–56 (16 ref.) (Eng. Abstr.) **(Ita)**

EPIDEMIOLOGY

Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Jarvis WR. **Clin Infect Dis** 1995 Jun; 20(6):1526–30 (21 ref.)

Current perspectives on glycopeptide resistance. Woodford N, et al. **Clin Microbiol Rev** 1995 Oct;8(4):585–615 (429 ref.)

Nosocomial candidiasis: epidemiology and drug resistance. Mahayni R, et al. **Infect Agents Dis** 1995 Dec;4(4):248–53 (72 ref.)

The analysis of disease clusters, Part I: State of the art. Jacquez GM, et al. **Infect Control Hosp Epidemiol** 1996 May;17(5):319–27 (35 ref.)

Respiratory syncytial virus bronchiolitis: clinical aspects and epidemiology. Boeck KD. **Monaldi Arch Chest Dis** 1996 Jun;51(3):210–3 (28 ref.)

[Epidemiology of Clostridium difficile nosocomial infections] Barbut F, et al. **Presse Med** 1996 Mar 2–9;25(8):385–92 (33 ref.) (Eng. Abstr.) **(Fre)**

[K-antigen as a marker of Klebsiella pneumoniae and its use in clinical and epidemiological analysis (literature review)] Priamukhina NS, et al. **Klin Lab Diagn** 1996 Mar–Apr; (2):47–9 (29 ref.) **(Rus)**

[Multiple nosocomial infections: more of the same (editorial; comment)] Barrasa Villar JI. **Med Clin (Barc)** 1996 Jun 8;107(2):53–5 (36 ref.) Comment on: Med Clin (Barc) 1996 Jun 8;107(2):41–4. **(Spa)**

ETIOLOGY

Nosocomial candidiasis: emerging species, reservoirs, and modes of transmission. Pfaller MA. **Clin Infect Dis** 1996 May;22 Suppl 2:S89–94 (74 ref.)

Central venous catheter-related infections: pathogenesis, predictors, and prevention. Hoppe B. **Heart Lung** 1995 Jul–Aug;24(4):333–9; quiz 339–41 (85 ref.)

Nosocomial colonization and infection in persons infected with human immunodeficiency virus. Craven DE, et al. **Infect Control Hosp Epidemiol** 1996 May;17(5):304–18 (90 ref.)

[Hepatitis C virus infection in hemodialysis] Simon N. **Pathol Biol (Paris)** 1995 Oct;43(8):735–40 (33 ref.) (Eng. Abstr.) **(Fre)**

[Nosocomial infections: a problem in ambulatory practice] Francioli P. **Rev Med Suisse Romande** 1996 May; 116(5):371–7 (5 ref.) **(Fre)**

[Pneumonia in patients on the mechanical respirator] Ben-Abraham R, et al. **Harefuah** 1995 Jul;129(1–2):46–51 (35 ref.) **(Heb)**

MICROBIOLOGY

Impact of changing pathogens and antimicrobial susceptibility patterns in the treatment of serious infections in hospitalized patients. Jones RN. **Am J Med** 1996 Jun 24;100(6A):3S–12S (53 ref.)

Epidemiology of mycobacterial diseases. Portaels F. **Clin Dermatol** 1995 May–Jun;13(3):207–22 (117 ref.)

Resistant nosocomial gram-negative bacillary pathogens: Acinetobacter baumannii, Xanthomonas maltophilia, and Pseudomonas cepacia. Fang FC, et al. **Curr Clin Top Infect Dis** 1996;16:52–83 (363 ref.)

The role of colonization in the pathogenesis of nosocomial infections. Bonten MJ, et al. **Infect Control Hosp Epidemiol** 1996 Mar;17(3):193–200 (69 ref.)

Clostridium difficile-associated diarrhea and colitis. Gerding DN, et al. **Infect Control Hosp Epidemiol** 1995 Aug; 16(8):459–77 (195 ref.)

Basic microbiologic support for hospital epidemiology. McGowan JEJr, et al. **Infect Control Hosp Epidemiol** 1996 May;17(5):298–303 (30 ref.)

Etiology and risk factors of adult pneumonia. Ginesu F, et al. **J Chemother** 1995 Aug;7(4):277–85 (32 ref.)

Emerging resistance in Enterococcus spp. Heath CH, et al. **Med J Aust** 1996 Jan 15;164(2):116–20 (44 ref.)

Nosocomial bacteremia due to Acinetobacter baumannii. Clinical features, epidemiology, and predictors of mortality. Seifert H, et al. **Medicine (Baltimore)** 1995 Nov;74(6):340–9 (46 ref.)

[Nosocomial infections caused by anaerobes] García-Rodríguez JA, et al. **Enferm Infecc Microbiol Clin** 1995 Aug–Sep;13(7):429–34 (21 ref.) **(Spa)**

[Clostridium difficile-associated diarrhea—an increasing problem. Reduce the administration of antibiotics and improve hygiene!] Svenungsson B. **Lakartidningen** 1996 Aug 28;93(35):2931–4 (67 ref.) **(Swe)**

PREVENTION & CONTROL

APIC guideline for handwashing and hand antisepsis in health care settings. Larson EL. **Am J Infect Control** 1995 Aug;23(4):251–69 (239 ref.)

Vancomycin-resistant Staphylococcus aureus: perspectives on measures needed for control. Edmond MB, et al. **Ann Intern Med** 1996 Feb 1;124(3):329–34 (53 ref.)

Infection control for oncology. Wiblin RT, et al. **Cancer Treat Res** 1995;79:83–100 (115 ref.)

The endoscope and infection transmission: the problems and how to avoid them. Benjamin SB. **Cleve Clin J Med** 1995 Sep–Oct;62(5):279–80 (2 ref.)

Nosocomial tuberculosis: new progress in control and

prevention. McGowan JE Jr. **Clin Infect Dis** 1995 Sep; 21(3):489–505 (153 ref.)
Prophylactic use of the new quinolones for prevention of nosocomial infection in the intensive care unit. Potgieter PD, et al. **Drugs** 1995;49 Suppl 2:86–91 (34 ref.)
The role of colonization in the pathogenesis of nosocomial infections. Bonten MJ, et al. **Infect Control Hosp Epidemiol** 1996 Mar;17(3):193–200 (69 ref.)
The epidemiology of colonization. Jarvis WR. **Infect Control Hosp Epidemiol** 1996 Jan;17(1):47–52 (43 ref.)
High-level disinfection or "sterilization" of endoscopes? Muscarella LF. **Infect Control Hosp Epidemiol** 1996 Mar; 17(3):183–7 (61 ref.)
Selective decontamination of the digestive tract: indications and problems [editorial] Lode H, et al. **Infection** 1995 May–Jun;23(3):129–32 (31 ref.)
The impact of surveys on hospital infection. Emmerson AM. **J Hosp Infect** 1995 Jun;30 Suppl:421–40 (68 ref.)
Hospital-acquired tuberculosis. deWit D. **Med J Aust** 1995 Oct 16;163(8):428–31 (43 ref.)
Managing HIV. Part 7: Professional issues. 7.1 HIV infection control in medical practice. Mitchell DH, et al. **Med J Aust** 1996 Jul 15;165(2):86–9 (19 ref.)
Cleaning and disinfection of lower gastrointestinal endoscopes. Tremain SC. **Prim Care** 1995 Sep;22(3):471–8 (9 ref.)
Stress ulcer prophylaxis: gastrointestinal bleeding and nosocomial pneumonia. Best evidence synthesis. Cook DJ. **Scand J Gastroenterol Suppl** 1995;210:48–52 (38 ref.)
[Preventing transmission of infection in endoscopy: hygienic maintainance of flexible endoscopes and measures for personal protection] Leiss O, et al. **Leber Magen Darm** 1995 Dec;25(6):251–7 (25 ref.) (Eng. Abstr.) **(Ger)**
[Principles and practice of control of hospital infection] Ohta M, et al. **Nippon Saikingaku Zasshi** 1995 Jul;50(3):765–75 (7 ref.) **(Jpn)**
[Hospital management and the role of clinical microbiology laboratory for preventing nosocomial infection] Ichiyama S. **Rinsho Byori** 1995 Oct;43(10):1005–9 (4 ref.) (Eng. Abstr.) **(Jpn)**
[Hospital hygiene and the medicosocial problems of preserving human health in medical institutions] Znamenskii AV, et al. **Voen Med Zh** 1995 Jul;(7):55–60, 80 (23 ref.) (Eng. Abstr.) **(Rus)**
[Nosocomial infection (editorial)] Ezpeleta C, et al. **Rev Clin Esp** 1996 May;196(5):273–6 (29 ref.) **(Spa)**

TRANSMISSION

Continuing investigation and controversy regarding risk of transmission of infection via dental handpieces. Epstein JB, et al. **J Can Dent Assoc** 1996 Jun;62(6):485–91 (53 ref.)
Nosocomial acquisition of Escherichia coli by infants delivered in hospitals. Fujita K, et al. **J Hosp Infect** 1996 Apr;32(4):277–81 (23 ref.)
The environmental risk factors associated with medical and dental equipment in the transmission of Burkholderia (Pseudomonas) cepacia in cystic fibrosis patients. Pankhurst CL, et al. **J Hosp Infect** 1996 Apr;32(4):249–55 (32 ref.)
[Transmission of infection in oral medicine. Evaluation of the risk of transmission in the office surgery] Vacher C, et al. **Rev Stomatol Chir Maxillofac** 1996;97(2):121–4 (7 ref.) (Eng. Abstr.) **(Fre)**
[Risk of infection in endoscopy] Leiss O, et al. **Leber Magen Darm** 1995 Sep;25(5):198–202 (27 ref.) (Eng. Abstr.) **(Ger)**

CROSS-LINKING REAGENTS

Cross-linking reconsidered: binding and cross-linking fields and the cellular response. Sulzer B, et al. **Biophys J** 1996 Mar;70(3):1154–68 (60 ref.)

PHARMACOLOGY

Toward the production of bispecific antibody fragments for clinical applications. Carter P, et al. **J Hematother** 1995 Oct;4(5):463–70 (63 ref.)

CROSS-OVER STUDIES

A simple analysis of crossover studies with one-group interaction. Cleophas TJ. **Int J Clin Pharmacol Ther** 1995 Jun;33(6):322–7 (25 ref.)

CROSS-SECTIONAL STUDIES

Risk factors and their identification second part: study designs for identification of risk factors. Balkau B, et al. **Diabete Metab** 1995 Jun;21(3):225–31 (17 ref.)

CROSS-TRANSFUSION, INTRAUTERINE see **FETOFETAL TRANSFUSION**

CROSSBITE see **MALOCCLUSION**

CROSSES, GENETIC

see related
CONJUGATION, GENETIC
HYBRIDIZATION
TRANSFORMATION, GENETIC

Genetic contributions to lupus-like disease in (NZB x NZW)F1 mice. Drake CG, et al. **Immunol Rev** 1995 Apr; 144:51–74 (59 ref.)
Hybrid resistance: 'negative' and 'positive' signaling of murine natural killer cells. Bennett M, et al. **Semin Immunol** 1995 Apr;7(2):121–7 (24 ref.)

CROSSING OVER (GENETICS)

Is the synaptonemal complex a disjunction machine? Maguire MP. **J Hered** 1995 Sep–Oct;86(5):330–40 (91 ref.)
Meiosis: how could it work? Kleckner N. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8167–74 (103 ref.)

CROSSMATCHING, BLOOD see **BLOOD GROUPING AND CROSSMATCHING**

CROSSMATCHING, TISSUE see **HISTOCOMPATIBILITY TESTING**

CROTALID VENOMS

CHEMISTRY

Phospholipase A2 myotoxins from Bothrops snake venoms. Gutiérrez JM, et al. **Toxicon** 1995 Nov;33(11):1405–24 (129 ref.)

TOXICITY

In vitro activity of BaH1, the main hemorrhagic toxin of Bothrops asper snake venom on bovine endothelial cells. Borkow G, et al. **Toxicon** 1995 Oct;33(10):1387–91 (23 ref.)

CROTALIDS see **VIPERIDAE**

CROTON OIL

see related
PHORBOL ESTERS

CROUP

Acute laryngotracheitis. Sinha V, et al. **Indian Pediatr** 1995 Jul;32(7):821–5 (17 ref.)

CROUP-ASSOCIATED VIRUS see **PARAINFLUENZA VIRUS TYPE 2**

CROUZON'S DISEASE see **CRANIOFACIAL DYSOSTOSIS**

CROW-FUKASE SYNDROME see **POEMS SYNDROME**

CROWN COMPOUNDS see **ETHERS, CYCLIC**

CROWNS

[Scanning electron microscopy in the study of surface treatment methods used in the repair of porcelain-fused-to-metal restorations] Hegedús C, et al. **Fogorv Sz** 1995 Apr;88(4):133–9 (32 ref.) (Eng. Abstr.) **(Hun)**
[Discussion on the location of the artificial crown margin] Hasegawa S. **Kokubyo Gakkai Zasshi** 1995 Sep; 62(3):373–80 (39 ref.) **(Jpn)**

CRST SYNDROME see **CREST SYNDROME**

CRUCIATE LIGAMENT, ANTERIOR see **ANTERIOR CRUCIATE LIGAMENT**

CRUCIATE LIGAMENT, POSTERIOR see **POSTERIOR CRUCIATE LIGAMENT**

CRUDE OIL see **PETROLEUM**

CRUOR see **POSTMORTEM CHANGES**

CRUSH SYNDROME

PHYSIOPATHOLOGY

[Hemodynamic profile and serum cytokines in crush syndrome. Analogy with severe burns] Gueugniaud PY, et al. **Presse Med** 1996 Mar 16;25(9):449–51 (16 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

[Concept for the management of combined bone-soft tissue defects of the lower extremity] Amgwerd MG, et al. **Swiss Surg** 1995;(2):90–5 (30 ref.) (Eng. Abstr.) **(Ger)**

CRUSTACEA

see related
SHELLFISH

CHEMISTRY

Molecular biology of neurohormone precursors in the eyestalk of Crustacea. De Kleijn DP, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1995 Dec; 112(4):573–9 (32 ref.)

CRYING

Infantile colic: natural history and treatment. Lehtonen LA, et al. **Curr Probl Pediatr** 1996 Mar;26(3):79–85 (78 ref.)

CRYOABLATION see **CRYOSURGERY**

CRYOANESTHESIA see **HYPOTHERMIA, INDUCED**

CRYOFIXATION see **CRYOPRESERVATION**

CRYOGLOBULINEMIA

CLASSIFICATION

Classification of the cryoglobulinemic syndrome. Invernizzi F, et al. **Clin Exp Rheumatol** 1995 Nov–Dec;13 Suppl 13:S123–8 (34 ref.)

COMPLICATIONS

Cryoglobulinemia: recent findings in cutaneous and extracutaneous manifestations. Davis MD, et al. **Int J Dermatol** 1996 Apr;35(4):240–8 (50 ref.)

DIAGNOSIS

Cerebral ischemia in patients with hepatitis C virus infection and mixed cryoglobulinemia. Petty GW, et al. **Mayo Clin Proc** 1996 Jul;71(7):671–8 (57 ref.)

ETIOLOGY

Hepatitis C virus infection, cryoglobulinemia, and glomerulonephritis. Schifferli JA, et al. **Adv Nephrol Necker Hosp** 1995;24:107–29 (88 ref.)
[Extrahepatic manifestations of hepatitis A virus infection] Maïga MY, et al. **Gastroenterol Clin Biol** 1996;20(4):346–52 (110 ref.) **(Fre)**
[Extrahepatic manifestations related to hepatitis C virus] Opolon P, et al. **Pathol Biol (Paris)** 1995 Oct;43(8):709–15 (59 ref.) (Eng. Abstr.) **(Fre)**
[Mixed cryoglobulinemia in hepatitis C virus infection] Musset L, et al. **Presse Med** 1996 Apr 6;25(12):595–8 (22 ref.) (Eng. Abstr.) **(Fre)**
[Mixed cryoglobulinemia and the hepatitis C virus (editorial)] Bulfoni A. **Minerva Med** 1995 May;86(5):193–8 (37 ref.) (Eng. Abstr.) **(Ita)**
[Cryoglobulinemia and its significance in hepatitis C virus infection] Kanoh T. **Ryoikibetsu Shokogun Shirizu** 1995; (8):321–4 (20 ref.) **(Jpn)**

IMMUNOLOGY

Humoral immune response and natural killer activity in patients with mixed cryoglobulinemia. Gabrielli A, et al. **Clin Exp Rheumatol** 1995 Nov–Dec;13 Suppl 13:S95–9 (21 ref.)
Cross-reactive idiotypes on cryoprecipitating monoclonal IgMk rheumatoid factors. Sinico RA, et al. **Clin Exp Rheumatol** 1995 Nov–Dec;13 Suppl 13:S105–7 (8 ref.)
Sjögren's syndrome, mixed cryoglobulinaemia and the monoclonal gammopathies. Vitali C, et al. **Clin Exp Rheumatol** 1996 Jan–Feb;14 Suppl 14:S59–63 (44 ref.)

THERAPY

Guidelines for the management of essential mixed cryoglobulinemia. Tavoni A, et al. **Clin Exp Rheumatol** 1995 Nov–Dec;13 Suppl 13:S191–5 (35 ref.)

VIROLOGY

Etiopathogenetic role of hepatitis C virus in mixed cryoglobulinemia, chronic liver diseases and lymphomas. Ferri C, et al. **Clin Exp Rheumatol** 1995 Nov–Dec;13 Suppl 13:S135–40 (49 ref.)
Viruses and cryoglobulinemia. Galli M. **Clin Exp Rheumatol** 1995 Nov–Dec;13 Suppl 13:S63–70 (66 ref.)
Hepatitis C virus: from biology to clinical practice. Monteverde A, et al. **Clin Exp Rheumatol** 1995 Nov–Dec; 13 Suppl 13:S205–10 (9 ref.)

CRYOGLOBULINS

CLASSIFICATION

Immunochemical characterization of the cryoglobulins: pathophysiologic implications. Merlini G, et al. **Clin Exp Rheumatol** 1995 Nov–Dec;13 Suppl 13:S71–3 (15 ref.)

CRYOPRESERVATION

Use of cryopreserved bone marrow in unrelated allogeneic transplantation. Stockschläder M, et al. **Bone Marrow Transplant** 1996 Feb;17(2):197–9 (18 ref.)
Hydrosalpinx affects the implantation of previously cryopreserved embryos. Akman MA, et al. **Hum Reprod** 1996 May;11(5):1013–4 (8 ref.)

Strategies in frozen donor semen procreation. Le Lannou D, et al. **Hum Reprod** 1995 Jul;10(7):1765–74 (90 ref.)
A review of methods for storage of corneas for keratoplasty. Basu PK. **Indian J Ophthalmol** 1995 Jun;43(2):55–8 (30 ref.)
Stem cell cryopreservation. Gorlin J. **J Infus Chemother** 1996 Winter;6(1):23–7 (24 ref.)
Recent developments and concepts in the cryopreservation of spermatozoa and the assessment of their post-thawing function. Watson PF. **Reprod Fertil Dev** 1995;7(4):871–91 (155 ref.)
[Neuronal transplantation in animal models of Parkinson disease: in vivo voltammetry, tissue cryopreservation and immunology] Sautter J, et al. **Zentralbl Neurochir** 1995; 56(4):161–7 (28 ref.) (Eng. Abstr.) **(Ger)**
[Anti-hemophilia drugs: from cryoprecipitate to factor VIII concentrates of high purity] Gutsalo AE, et al. **Ukr Biokhim Zh** 1995 Jan–Feb;67(1):3–13 (62 ref.) (Eng. Abstr.) **(Rus)**

METHODS

Methods of isolation and cryopreservation of stem cells from cord blood. Quillen K, et al. **J Hematother** 1996 Apr; 5(2):153–5 (12 ref.)
Storage of haemopoietic stem cells for autologous bone marrow transplantation. Raju GM, et al. **Natl Med J India** 1995 Sep–Oct;8(5):216–21 (82 ref.)
[The creation of genetic cryobanks and the use of the methods of developmental biology as a means for preserving rare animal species. I. The cryopreservation of the sperm of wild mammals] Rott NN. **Ontogenez** 1995 Jul–Aug;26(4):270–81 (59 ref.) (Eng. Abstr.) **(Rus)**

VETERINARY

Morphology and biochemistry of in-vitro produced bovine embryos: implications for their cryopreservation. Massip A, et al. **Hum Reprod** 1995 Nov;10(11):3004–11 (79 ref.)

CRYOSURGERY

Cryosurgery of malignant and premalignant diseases of the skin: a simple approach. Sinclair RD, et al. **Australas J Dermatol** 1995 Aug;36(3):133–42 (60 ref.)
Future therapeutic procedures. Edell ES. **Chest Surg Clin N Am** 1996 May;6(2):381–95 (93 ref.)
Hepatic cryosurgery for metastatic colorectal carcinoma. Brandt BT, et al. **Oncol Nurs Forum** 1996 Jan–Feb; 23(1):29–36; quiz 37–8 (20 ref.)

ADVERSE EFFECTS

Macular epiretinal membrane formation and treated retinal breaks. Saran BR, et al. **Am J Ophthalmol** 1995 Oct; 120(4):480–5 (27 ref.)
Venous gas embolism during cryosurgery for bone tumors. Schreuder HW, et al. **J Surg Oncol** 1995 Nov;60(3):196–200 (11 ref.)

METHODS

Liver cryosurgery. McMasters KM, et al. **J Ky Med Assoc** 1996 Jun;94(6):222–9 (55 ref.)
Cryosurgery of the prostate: techniques and pitfalls. Zippe CD. **Urol Clin North Am** 1996 Feb;23(1):147–63 (11 ref.)

CRYOTHERAPY

see related
HYPOTHERMIA, INDUCED

Eruptive pyogenic granulomas: a successfully treated patient and review of the literature. Shah M, et al. **Br J Dermatol** 1995 Nov;133(5):795–6 (27 ref.)
Cryotherapy for tracheobronchial disorders. Maiwand MO, et al. **Clin Chest Med** 1995 Sep;16(3):427–43 (57 ref.)
Recurrent melanoma of the hard palate treated by en bloc excision and reconstruction with an autologous palatal bone graft subjected to cryotherapy and a buccal mucosal flap. Rosales J, et al. **J Oral Maxillofac Surg** 1995 Oct; 53(10):1218–20 (16 ref.)

METHODS

Hepatic cryotherapy for metastatic liver tumours. McCall JL, et al. **Br J Hosp Med** 1995 Oct 18–31;54(8):378–81 (26 ref.)

CRYPTOCOCCOSIS

Cutaneous Cryptococcus infection and AIDS. Report of 12 cases and review of the literature. Murakawa GJ, et al. **Arch Dermatol** 1996 May;132(5):545–8 (36 ref.)
Opportunistic fungal infections in patients with HIV disease: combating cryptococcosis and histoplasmosis. Kirchner JT. **Postgrad Med** 1996 Jun;99(6):209–16 (34 ref.)
[Hepatic cryptococcosis] Ito A. **Ryoikibetsu Shokogun Shirizu** 1995;(7):73–4 (6 ref.) **(Jpn)**

COMPLICATIONS

Cryptococcosis in the era of AIDS—100 years after the discovery of Cryptococcus neoformans. Mitchell TG, et al. **Clin Microbiol Rev** 1995 Oct;8(4):515–48 (529 ref.)
[Primary cutaneous cryptococcosis and bacterial pneumonia caused by Pseudomonas aeruginosa in AIDS: clinical case and review of the literature] Dronda F, et al. **Enferm Infecc Microbiol Clin** 1996 Feb;14(2):101–5 (35 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Cryptococcal infection of the breast. Goldman M, et al. **Clin Infect Dis** 1995 Nov;21(5):1166–9 (19 ref.)
Cell wall polysaccharides of pathogenic yeasts. Fukazawa Y, et al. **Curr Top Med Mycol** 1995;6:189–219 (166 ref.)
Cryptococcosis of the larynx. Isaacson JE, et al. **Otolaryngol Head Neck Surg** 1996 Jan;114(1):106–9 (10 ref.)
[Pulmonary cryptococcosis—a pathology of the future?] Mihălţan F. **Pneumoftiziologia** 1995 Jan–Jun;44(1–2):71–5 (57 ref.) **(Rum)**

DRUG THERAPY

Cryptococcosis in the era of AIDS—100 years after the discovery of Cryptococcus neoformans. Mitchell TG, et al. **Clin Microbiol Rev** 1995 Oct;8(4):515–48 (529 ref.)

EPIDEMIOLOGY

Cirrhosis: a risk factor for cryptococcal peritonitis. Mabee CL, et al. **Am J Gastroenterol** 1995 Nov;90(11):2042–5 (20 ref.)
Emergence of cryptococcal disease: epidemiologic perspectives 100 years after its discovery. Hajjeh RA, et al. **Epidemiol Rev** 1995;17(2):303–20 (203 ref.)

ETIOLOGY

[Cryptococcal whitlow in a HIV positive patient] Verneuil L, et al. **Ann Dermatol Venereol** 1995;122(10):688–91 (29 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Antibody immunity and invasive fungal infections. Casadevall A. **Infect Immun** 1995 Nov;63(11):4211–8 (133 ref.)

MICROBIOLOGY

Emergence of cryptococcal disease: epidemiologic perspectives 100 years after its discovery. Hajjeh RA, et al. **Epidemiol Rev** 1995;17(2):303–20 (203 ref.)

PATHOLOGY

Disseminated cutaneous Cryptococcus clinically mimicking basal cell carcinoma [letter] Murakawa GJ, et al. **Dermatol Surg** 1995 Nov;21(11):992–3 (8 ref.)

PREVENTION & CONTROL

Prospects for preventing cryptococcosis in persons infected with human immunodeficiency virus. Pinner RW, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S103–7 (46 ref.)

CRYPTOCOCCUS

CLASSIFICATION

Emergence of cryptococcal disease: epidemiologic perspectives 100 years after its discovery. Hajjeh RA, et al. **Epidemiol Rev** 1995;17(2):303–20 (203 ref.)

CRYPTOCOCCUS NEOFORMANS

GROWTH & DEVELOPMENT

Cryptococcosis in the era of AIDS—100 years after the discovery of Cryptococcus neoformans. Mitchell TG, et al. **Clin Microbiol Rev** 1995 Oct;8(4):515–48 (529 ref.)

PATHOGENICITY

Virulence factors of Cryptococcus neoformans. Kozel TR. **Trends Microbiol** 1995 Aug;3(8):295–9 (53 ref.)

CRYPTORCHIDISM

ABC of general paediatric surgery. Inguinal hernia, hydrocele, and the undescended testis. Davenport M. **BMJ** 1996 Mar 2;312(7030):564–7 (0 ref.)
Undescended testes: screening and early operation. Gordon N. **Br J Clin Pract** 1995 Nov–Dec;49(6):318–20 (30 ref.)
[Cryptorchidism: current views (editorial)] Jannini EA, et al. **Minerva Endocrinol** 1995 Dec;20(4):201–10 (53 ref.) (Eng. Abstr.) **(Ita)**

COMPLICATIONS

A child with an intra-abdominal testicular teratoma: a case report and review of prepubertal cryptorchid germ cell tumors. Brown IR, et al. **Urology** 1995 Dec;46(6):863–6 (27 ref.)
Testicular seminoma originating in an undescended testis in a renal allograft recipient. Modlin CS, et al. **Urology** 1996 Jul;48(1):145–8 (9 ref.)
[A case of testicular tumor associated with the contralateral undescended testis] Ueda H, et al. **Hinyokika Kiyo** 1995 Dec;41(12):1015–8 (20 ref.) (Eng. Abstr.) **(Jpn)**
[Cryptorchidism and testicular cancer] Pereira Arias JG, et al. **Arch Esp Urol** 1995 Nov;48(9):959–61 (12 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Laparoscopy for nonpalpable testis in childhood: is inguinal exploration necessary when vas and vessels are not seen? Arnbjörnsson E, et al. **Eur J Pediatr Surg** 1996 Feb;6(1):7–9 (19 ref.)
Cancer and male infertility. Meirow D, et al. **Hum Reprod** 1995 Aug;10(8):2017–22 (59 ref.)

ETIOLOGY

Normal testicular descent and the aetiology of cryptorchidism. Hutson JM, et al. **Adv Anat Embryol Cell Biol** 1996;132:1–56 (174 ref.)
The pathogenesis of cryptorchidism and splenogonadal fusion: a new hypothesis. Cortes D, et al. **Br J Urol** 1996 Feb;77(2):285–90 (24 ref.)

PHYSIOPATHOLOGY

[Cryptorchism—assessment from an andrologic viewpoint] Weidner W, et al. **Urologe A** 1996 Mar;35(2):111–4 (31 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

[Current status of laparoscopic surgery in pediatric urology] Fuchs GJ, et al. **Urologe A** 1996 May;35(3):175–84 (62 ref.) (Eng. Abstr.) **(Ger)**

CRYPTOSPORIDIOSIS

[Liver cryptosporidiosis] Ito A, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):75–8 (13 ref.) **(Jpn)**

DRUG THERAPY

Human cryptosporidiosis. Hoepelman IM. **Int J STD AIDS** 1996;7 Suppl 1:28–33 (71 ref.)

EPIDEMIOLOGY

[Cryptosporidiosis in humans. Review] Chacín-Bonilla L. **Invest Clin** 1995 Dec;36(4):207–50 (240 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

Cryptosporidium related diarrhoea. Das P. **Indian J Med Res** 1996 Jul;104:86–95 (132 ref.)

PREVENTION & CONTROL

Cryptosporidiosis: sources of infection and guidelines for prevention. Juranek DD. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S57–61 (52 ref.)

CRYPTOSPORIDIUM

GENETICS

Genetic variability in parasites and host-parasite interactions. Thompson RC, et al. **Parasitology** 1996;112 Suppl:S7–22 (118 ref.)
[Advances in the study of molecular biology in Cryptosporidium] Ma L, et al. **Chung Kuo Chi Sheng Chung Hsueh Yu Chi Sheng Chung Ping Tsa Chih** 1995;13(2):145–9 (20 ref.) **(Chi)**

CRYPTOSPORIDIUM PARVUM

Human cryptosporidiosis. Hoepelman IM. **Int J STD AIDS** 1996;7 Suppl 1:28–33 (71 ref.)

CRYSTALLINS

CHEMISTRY

Stability and folding of ultrastable proteins: eye lens crystallins and enzymes from thermophiles. Jaenicke R. **FASEB J** 1996 Jan;10(1):84–92 (50 ref.)
alpha-Crystallins, versatile stress-proteins. Boelens WC, et al. **Mol Biol Rep** 1995;21(2):75–80 (87 ref.)

GENETICS

Lens development and crystallin gene expression: many roles for Pax-6. Cvekl A, et al. **Bioessays** 1996 Aug;18(8):621–30 (72 ref.)
Lens crystallins of invertebrates—diversity and recruitment from detoxification enzymes and novel proteins. Tomarev SI, et al. **Eur J Biochem** 1996 Feb 1;235(3):449–65 (225 ref.)

METABOLISM

Lens crystallins of invertebrates—diversity and recruitment from detoxification enzymes and novel proteins. Tomarev SI, et al. **Eur J Biochem** 1996 Feb 1;235(3):449–65 (225 ref.)

ULTRASTRUCTURE

Ocular lens gap junctions: protein expression, assembly, and structure-function analysis. Kistler J, et al. **Microsc Res Tech** 1995 Aug 1;31(5):347–56 (60 ref.)

CRYSTALLIZATION

Crystal-induced arthritis: an overview. Schumacher HR. **Am J Med** 1996 Feb 26;100(2A):46S–52S (22 ref.)
Imaging of arthropathies. Crystal disease. Uri DS, et al. **Radiol Clin North Am** 1996 Mar;34(2):359–74, xi (48 ref.)
The science of macromolecular crystallization. McPherson A, et al. **Structure** 1995 Aug 15;3(8):759–68 (90 ref.)

CRYSTALLOGRAPHY, X-RAY

Protein crystallography in Australia. Parker MW. **Aust N Z J Med** 1995 Dec;25(6):876–82 (40 ref.)
Protein engineering as a tool for crystallography. Price SR, et al. **Curr Opin Biotechnol** 1995 Aug;6(4):425–30 (40 ref.)
X-ray crystal structures of animal lectins. Rini JM. **Curr Opin Struct Biol** 1995 Oct;5(5):617–21 (36 ref.)
Density modification in x-ray crystallography. Podjarny AD, et al. **Methods Mol Biol** 1996;56:205–26 (88 ref.)
Crystallographic methods and protocols. Introduction. Sanderson MR. **Methods Mol Biol** 1996;56:1–21 (70 ref.)
Thermal diffuse X-ray scattering and its contribution to understanding protein dynamics. Thüne T, et al. **Prog Biophys Mol Biol** 1995;63(3):251–76 (60 ref.)
Where freedom is given, liberties are taken. Kleywegt GJ, et al. **Structure** 1995 Jun 15;3(6):535–40 (34 ref.)
[Shed light on the molecular structure of the respiratory chain: X-ray crystal structure analysis of cytochrome c oxidase] Kato H. **Tanpakushitsu Kakusan Koso** 1995 Nov; 40(15):2340–1 (4 ref.) **(Jpn)**

METHODS

Laue crystallography. It's show time. Farber GK. **Curr Biol** 1995 Oct 1;5(10):1088–90 (13 ref.)
Recent developments for crystallographic refinement of macromolecules. Brünger AT. **Methods Mol Biol** 1996; 56:245–66 (81 ref.)
Molecular replacement using known structural information. Tickle IJ, et al. **Methods Mol Biol** 1996;56:173–203 (92 ref.)
Diffuse scattering in protein crystallography. Benoit JP, et al. **Q Rev Biophys** 1995 May;28(2):131–69 (92 ref.)
The use of antibody fragments for crystallization and structure determinations. Kovari LC, et al. **Structure** 1995 Dec 15;3(12):1291–3 (34 ref.)
The science of macromolecular crystallization. McPherson A, et al. **Structure** 1995 Aug 15;3(8):759–68 (90 ref.)

CSF-1 see **MACROPHAGE COLONY-STIMULATING FACTOR**

CSF-GM see **GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR**

CSF-M see **MACROPHAGE COLONY-STIMULATING FACTOR**

CTG, ANTEPARTUM see **CARDIOTOCOGRAPHY**

CU-ZN SUPEROXIDE DISMUTASE see **SUPEROXIDE DISMUTASE**

CUBAN AMERICANS see **HISPANIC AMERICANS**

CUBITAL TUNNEL SYNDROME see **ULNAR NERVE COMPRESSION SYNDROME**

CUES

Covert orienting to non-informative cues: reaction time studies. Tassinari G, et al. **Behav Brain Res** 1995 Nov; 71(1–2):101–12 (58 ref.)

CUFF, ROTATOR see **ROTATOR CUFF**

CUL-DE-SAC, DOUGLAS' see **DOUGLAS' POUCH**

CULICIDAE

Biocontrol from a mosquito control director's point of view. Beidler EJ. **J Am Mosq Control Assoc** 1995 Jun;11(2 Pt 2):258–9 (6 ref.)
Regulatory factors affecting larval mosquito populations in container and pool habitats: implications for biological control. Washburn JO. **J Am Mosq Control Assoc** 1995 Jun;11(2 Pt 2):279–83 (13 ref.)
[Hazards of insect vectors of parasites: from theory to practice] Alvar Ezquerra JP. **An R Acad Nac Med (Madr)** 1995;112(3):617–45; discussion 646 (93 ref.) **(Spa)**

MICROBIOLOGY

Some environmental and biological factors influencing the activity of entomopathogenic Bacillus on mosquito larvae in Brazil. Consoli RA, et al. **Mem Inst Oswaldo Cruz** 1995 Jan–Feb;90(1):121–4 (55 ref.)

CULICOIDES see **CERATOPOGONIDAE**

CULTURAL CHARACTERISTICS

see related
CROSS-CULTURAL COMPARISON

Women and AIDS in Zambia: a review of the psychosocial factors implicated in the transmission of HIV. Campbell T, et al. **AIDS Care** 1995;7(3):365–73 (26 ref.)
Latinos and mutual support group: a case for considering culture. Simoni JM, et al. **Am J Orthopsychiatry** 1995 Jul; 65(3):440–5 (26 ref.)
Pain assessment and ethnicity. Todd KH. **Ann Emerg Med** 1996 Apr;27(4):421–3 (28 ref.)
Judging the other. Responding to traditional female genital surgeries. Lane SD, et al. **Hastings Cent Rep** 1996 May–Jun; 26(3):31–40 (61 ref.)
A review of the historical and social processes contributing to care and caregiving in Chinese families. Holroyd EA, et al. **J Adv Nurs** 1995 Sep;22(3):473–9 (39 ref.)
Child rearing beliefs in the African-American community: implications for culturally competent pediatric care. Yoos HL, et al. **J Pediatr Nurs** 1995 Dec;10(6):343–53 (73 ref.)
The social and cultural context of menopause. Kaufert PA. **Maturitas** 1996 Mar;23(2):169–80 (49 ref.)
Immunization to regulate fertility: biological and cultural frameworks. Schrater AF. **Soc Sci Med** 1995 Sep; 41(5):657–71 (85 ref.)
Cultural competence—an essential hybrid for delivering high quality care in the 1990's and beyond. Lavizzo-Mourey RJ, et al. **Trans Am Clin Climatol Assoc** 1995;107:226–35; discussion 236–7 (40 ref.)

CULTURAL DEPRIVATION

Drugs and deprivation. Pearson G. **J R Soc Health** 1996 Apr;116(2):113–6 (40 ref.)

CULTURAL DISADVANTAGEMENT see **CULTURAL DEPRIVATION**

CULTURAL DIVERSITY

Treating patients from other cultures. Orr RD. **Am Fam Physician** 1996 May 1;53(6):2004–6 (22 ref.)
The value of curiosity and naiveté for the cross-cultural psychotherapist. Dyche L, et al. **Fam Process** 1995 Dec; 34(4):389–99 (33 ref.)
Training to think culturally: a multidimensional comparative framework. Falicov CJ. **Fam Process** 1995 Dec; 34(4):373–88 (56 ref.)
Nutritional status outcomes for children: ethnic, cultural, and environmental contexts. Bronner YL. **J Am Diet Assoc** 1996 Sep;96(9):891–903 (88 ref.)
Cultural aspects of pain in childbearing women. Weber SE. **J Obstet Gynecol Neonatal Nurs** 1996 Jan;25(1):67–72 (20 ref.)
Who is our consumer? Shaping nursing programs to meet emerging needs. Norbeck JS. **J Prof Nurs** 1995 Nov–Dec; 11(6):325–31 (9 ref.)
Assessing, diagnosing and treating culturally diverse individuals: a Hispanic perspective. Ruiz P. **Psychiatr Q** 1995 Winter;66(4):329–41 (34 ref.)

CULTURE

see related
CROSS-CULTURAL COMPARISON

Cultural-societal roots of violence. The examples of genocidal violence and of contemporary youth violence in the United States. Staub E. **Am Psychol** 1996 Feb; 51(2):117–32 (122 ref.)
HIV/AIDS in the context of culture: selection of ethnocultural communities for study in Canada. Cappon P, et al. **Can J Public Health** 1996 May–Jun;87 Suppl 1:S11–4, S11–5 (50 ref.) **(Eng, Fre)**
Comment: the neglect of culture in psychiatric nosology: the case of culture bound syndromes. Aderibigbe YA, et al. **Int J Soc Psychiatry** 1995 Winter;41(4):235–41 (50 ref.)
The essential elements of culturally sensitive psychiatric services. Bhui K, et al. **Int J Soc Psychiatry** 1995 Winter; 41(4):242–56 (83 ref.)
Postmodernism, health and illness. Mitchell DP. **J Adv Nurs** 1996 Jan;23(1):201–5 (28 ref.)
Psychosocial/cultural issues in medicine and psychiatry: treating African Americans. Carter JH. **J Natl Med Assoc** 1995 Dec;87(12):857–60 (18 ref.)
The experience of maternity in a woman's life. Simkin P. **J Obstet Gynecol Neonatal Nurs** 1996 Mar–Apr; 25(3):247–52 (12 ref.)
Somatization in Hispanics. Hulme PA. **J Psychosoc Nurs Ment Health Serv** 1996 Mar;34(3):33–7 (14 ref.)
Drug use, AIDS, and ethnography: advanced ethnographic research methods exploring the HIV epidemic. Trotter RT 2nd. **NIDA Res Monogr** 1995;157:38–64 (10 ref.)
Culture and psychiatric diagnosis. Impact on DSM-IV and ICD-10. Alarcon RD. **Psychiatr Clin North Am** 1995 Sep; 18(3):449–65 (80 ref.)
Sociocultural and therapeutic perspectives on violence. Blue HC, et al. **Psychiatr Clin North Am** 1995 Sep;18(3):571–87 (103 ref.)
Transcultural aspects of dissociative and somatoform disorders. Escobar JI. **Psychiatr Clin North Am** 1995 Sep; 18(3):555–69 (45 ref.)
Ethnicity and psychotherapy. A component in the treatment of cocaine addiction in African Americans. Foulks EF, et al. **Psychiatr Clin North Am** 1995 Sep;18(3):607–20 (59 ref.)
A cultural perspective on family theory and therapy. Kaslow NJ, et al. **Psychiatr Clin North Am** 1995 Sep;18(3):621–33 (34 ref.)
The cultural context of anxiety disorders. Kirmayer LJ, et al. **Psychiatr Clin North Am** 1995 Sep;18(3):503–21 (88 ref.)
Culture-bound syndromes. Levine RE, et al. **Psychiatr Clin North Am** 1995 Sep;18(3):523–36 (41 ref.)
Cultural psychiatry. Theoretical, clinical, and research issues. Lewis-Fernández R, et al. **Psychiatr Clin North Am** 1995 Sep;18(3):433–48 (88 ref.)
Cultural considerations in the assessment and treatment of religious and spiritual problems. Lukoff D, et al. **Psychiatr Clin North Am** 1995 Sep;18(3):467–85 (93 ref.)
Culture and major depression. Current challenges in the diagnosis of mood disorders. Manson SM. **Psychiatr Clin North Am** 1995 Sep;18(3):487–501 (95 ref.)
Cultural formulation and comprehensive diagnosis. Clinical and research perspectives. Mezzich JE. **Psychiatr Clin North Am** 1995 Sep;18(3):649–57 (26 ref.)
Eating disorders and disordered eating in different cultures. Weiss MG. **Psychiatr Clin North Am** 1995 Sep;18(3):537–53 (75 ref.)
Cultural aspects of substance abuse and alcoholism. Assessment and management. Westermeyer J. **Psychiatr Clin North Am** 1995 Sep;18(3):589–605 (68 ref.)
Culture in treatment, culture as treatment. A critical appraisal of developments in addictions programs for indigenous North Americans and Australians. Brady M. **Soc Sci Med** 1995 Dec;41(11):1487–98 (78 ref.)
Health-related quality of life between naturalism and hermeneutics. Rosenberg R. **Soc Sci Med** 1995 Nov; 41(10):1411–5 (17 ref.)
Rethinking the label: who benefits from the PMS construct? Gurevich M. **Women Health** 1995;23(2):67–98 (102 ref.)

CULTURE MEDIA

STANDARDS

Impact of the resin blood culture medium on the treatment of critically ill patients. Levin PD, et al. **Crit Care Med** 1996 May;24(5):797–801 (24 ref.)

CULTURED CELLS see **CELLS, CULTURED**

CULTURED TUMOR CELLS see **TUMOR CELLS, CULTURED**

CUMULATIVE SURVIVAL RATE see **SURVIVAL RATE**

CUMULATIVE TRAUMA DISORDERS see **REPETITION STRAIN INJURY**

CURARE-LIKE AGENTS see **NEUROMUSCULAR NONDEPOLARIZING AGENTS**

CURARIFORM DRUGS see **NEUROMUSCULAR NONDEPOLARIZING AGENTS**

CURETTAGE

see related
DILATATION AND CURETTAGE

METHODS

Desmoplastic fibroma. Aggressive curettage as a surgical alternative for treatment. Nishida J, et al. **Clin Orthop** 1995 Nov;(320):142–8 (27 ref.)

STANDARDS

Endocervical curettage has no place in the routine management of women with cervical intraepithelial neoplasia: debate. Ferenczy A. **Clin Obstet Gynecol** 1995 Sep;38(3):644–8 (9 ref.)
Endocervical curettage: a technique in search of an indication?: debate. Noller KL. **Clin Obstet Gynecol** 1995 Sep;38(3):649–52 (2 ref.)

CURIETHERAPY see **BRACHYTHERAPY**

CURIOSITY see **EXPLORATORY BEHAVIOR**

CURRICULUM

Caring for the lay caregiver. Ruppert RA. **Am J Nurs** 1996 Mar;96(3):40–5; quiz 46 (6 ref.)
On the need for ethics curricula in epidemiology. Coughlin SS, et al. **Epidemiology** 1995 Sep;6(5):566–7 (31 ref.)
The evolution and status of genetics education in nursing in the United States 1983–1995. Anderson GW. **Image J Nurs Sch** 1996 Summer;28(2):101–6 (40 ref.)
A sharing in critical thought by nursing faculty. Hendricks-Thomas J, et al. **J Adv Nurs** 1995 Sep; 22(3):594–9 (35 ref.)
[Essays on current molecular genetics for lecture courses for students of the Biology Department at Moscow State University] Sverdlov ED. **Mol Gen Mikrobiol Virusol** 1995 Oct–Dec;(4):3–19 (28 ref.) **(Rus)**

STANDARDS

Basic surgical training. 2: Interactions with the undergraduate

medical curriculum. Willan P. **Clin Anat** 1996;9(3):167–70 (1 ref.)
Design elements of professional ethics courses. Spafford MM, et al. **Optom Vis Sci** 1995 Oct;72(10):741–52 (59 ref.)

TRENDS

A historical decline of educational perioperative clinical experiences. Wagner VD, et al. **AORN J** 1995 Nov; 62(5):771–2, 775–80, 782 (46 ref.)

CURRICULUM, PROBLEM-BASED see **PROBLEM-BASED LEARNING**

CUSHING'S SYNDROME

Cushing's disease and pregnancy: report of six cases. Chico A, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Jan; 64(1):143–6 (20 ref.)

COMPLICATIONS

[Endocrine obesity] Inoue S, et al. **Nippon Rinsho** 1995 Jun; 53 Suppl:419–24 (16 ref.) **(Jpn)**

DIAGNOSIS

Differential diagnosis and management of Cushing's syndrome. Tsigos C, et al. **Annu Rev Med** 1996;47:443–61 (52 ref.)
Adrenal incidentaloma: subclinical Cushing's syndrome. Newell-Price J, et al. **Postgrad Med J** 1996 Apr; 72(846):207–10 (27 ref.)
[Cushing's syndrome; optimalization of the diagnosis] de Herder WW, et al. **Ned Tijdschr Geneeskd** 1996 Jul 13; 140(28):1449–54 (21 ref.) **(Dut)**
[Cushing's syndrome associated with a metastatic medullary carcinoma of the thyroid. A report of 2 cases and a review of the literature] Martínez Díaz-Guerra G, et al. **Rev Clin Esp** 1995 Dec;195(12):849–52 (63 ref.) (Eng. Abstr.) **(Spa)**
[Cushing's syndrome: review of a national caseload] Contreras P, et al. **Rev Med Chil** 1995 Mar;123(3):350–62 (31 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Mifepristone: treatment of Cushing's syndrome. Sartor O, et al. **Clin Obstet Gynecol** 1996 Jun;39(2):506–10 (12 ref.)

ETIOLOGY

Differential diagnosis and treatment of steroid-induced affective syndromes. Pies R. **Gen Hosp Psychiatry** 1995 Sep;17(5):353–61 (27 ref.)
A case of small cell carcinoma of the uterine cervix presenting Cushing's syndrome. Hashi A, et al. **Gynecol Oncol** 1996 Jun;61(3):427–31 (14 ref.)
[Food-dependent Cushing syndrome: a new entity of organic hypercorticism] Matejka G, et al. **Rev Med Interne** 1996; 17(6):461–6 (23 ref.) (Eng. Abstr.) **(Fre)**
[A case of ACTH-producing thymic carcinoid tumor with Cushing syndrome] Nishimura H, et al. **Kyobu Geka** 1996 Feb;49(2):99–104 (20 ref.) (Eng. Abstr.) **(Jpn)**

MORTALITY

[Cushing's syndrome is still a potentially fatal disease] Kreze A. **Bratisl Lek Listy** 1995 Nov;96(11):605–8 (25 ref.) (Eng. Abstr.) **(Slo)**

PHYSIOPATHOLOGY

CRH overproduction in transgenic mice: behavioral and immune system modulation. Stenzel-Poore MP, et al. **Ann N Y Acad Sci** 1996 Mar 22;780:36–48 (70 ref.)
Growth hormone axis in cushing's syndrome. Wajchenberg BL, et al. **Horm Res** 1996;45(1–2):99–107 (36 ref.)
[Role of hormonal receptor abnormalities in the physiopathology of adrenocortical tumors] Lacroix A. **Ann Endocrinol (Paris)** 1995;56(6):614–6 (21 ref.) **(Fre)**

SURGERY

Assessment of cure after transsphenoidal surgery for Cushing's disease. McCance DR, et al. **Clin Endocrinol (Oxf)** 1996 Jan;44(1):1–6 (27 ref.)
Factors influencing the immediate and late outcome of Cushing's disease treated by transsphenoidal surgery: a retrospective study by the European Cushing's Disease Survey Group [see comments] Bochicchio D, et al. **J Clin Endocrinol Metab** 1995 Nov;80(11):3114–20 (43 ref.) Comment in: J Clin Endocrinol Metab 1995 Nov;80(11):3111–3.
[Role of hormonal exploration in avoiding of the failures of anterior pituitary gland surgery in Cushing disease] Bachelot I, et al. **Ann Endocrinol (Paris)** 1995;56(6):620–4 (15 ref.) (Eng. Abstr.) **(Fre)**

CUSPID

PATHOLOGY

The impacted maxillary canine: I. Review of concepts. Kuftinec MM, et al. **ASDC J Dent Child** 1995 Sep-Oct; 62(5):317–24 (42 ref.)
The impacted maxillary canine: II. Clinical approaches and solutions. Kuftinec MM, et al. **ASDC J Dent Child** 1995 Sep-Oct;62(5):325–34 (37 ref.)

CUSTODY, CHILD see **CHILD CUSTODY**

CUSTOMS see **CULTURE**

CUTANEOUS FISTULA

[Biliary fistula (postoperative, spontaneous)] Ohta T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):500–2 (6 ref.) **(Jpn)**

COMPLICATIONS

Epididymocutaneous fistula in a patient with the acquired immunodeficiency syndrome and Marfan's syndrome. Weiner DM, et al. **Urology** 1996 May;47(5):766–8 (14 ref.)

CONGENITAL

Congenital urethrocutaneous fistula: a case report and literature review, with a nomenclature proposal. Karnak I, et al. **J Pediatr Surg** 1995 Oct;30(10):1504–5 (7 ref.)
[Mento-sternal fistulae. Review of the literature. Apropos of 4 cases] Sfeir R, et al. **Ann Chir Plast Esthet** 1995 Apr; 40(2):176–81 (19 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Uncommon complications of odontogenic infections. Ferrera PC, et al. **Am J Emerg Med** 1996 May;14(3):317–22 (49 ref.)
Colocutaneous fistula: a rare and silent complication of percutaneous endoscopic gastrostomy. Siddique I, et al. **Dig Dis Sci** 1996 Feb;41(2):301–4 (14 ref.)
Colocutaneous fistula as a complication of PEG tube placement. Kilmartin C, et al. **J Fam Pract** 1996 Jul; 43(1):76–8 (10 ref.)
[Odontogenic sinusitis with cutaneous fistulization. A case report] Garbarino R, et al. **Minerva Stomatol** 1995 Jun; 44(6):319–23 (18 ref.) (Eng. Abstr.) **(Ita)**

SURGERY

Surgical treatment of complications 45 years after extraperiosteal pneumonolysis and plombage using acrylic resin balls for cavitary pulmonary tuberculosis. Thomas GE, et al. **Chest** 1995 Oct;108(4):1163–4 (8 ref.)

CUTANEOUS LARVA MIGRANS see **LARVA MIGRANS**

CUTIS ELASTICA see **EHLERS-DANLOS SYNDROME**

CUTIS LAXA

see related
EHLERS-DANLOS SYNDROME

COMPLICATIONS

Cutis laxa acquisita associated with multiple myeloma: a case report and review of the literature. McCarty MJ, et al. **Cutis** 1996 Apr;57(4):267–70 (30 ref.)

CX43 see **CONNEXIN 43**

CYANATES

METABOLISM

Carbamylation of proteins and atherogenesis in renal failure. Roxborough HE, et al. **Med Hypotheses** 1995 Aug; 45(2):125–8 (28 ref.)

CYANIDES

Cyanide detoxification in cassava for food and feed uses. Padmaja G. **Crit Rev Food Sci Nutr** 1995 Jul;35(4):299–339 (133 ref.)

ADVERSE EFFECTS

Chemistry, toxicology, and human health risk of cyanide compounds in soils at former manufactured gas plant sites. Shifrin NS, et al. **Regul Toxicol Pharmacol** 1996 Apr; 23(2):106–16 (50 ref.)

POISONING

Carbohydrate tolerance in patients with tropical ataxic neuropathy—A human model of chronic cyanide intoxication. Famuyiwa OO, et al. **Afr J Med Med Sci** 1995 Jun;24(2):151–7 (28 ref.)

TOXICITY

Modification of cyanide toxicodynamics: mechanistic based antidote development. Isom GE, et al. **Toxicol Lett** 1995 Dec;82–83:795–9 (14 ref.)

CYANOACRYLATES

Removal of superglue from the external ear using acetone: case report and literature review. Abadir WF, et al. **J Laryngol Otol** 1995 Dec;109(12):1219–21 (5 ref.)

CYANOBACTERIA

[Cyanobacteria, their toxins and health risks] Thébault I, et al. **Med Trop (Mars)** 1995;55(4):375–80 (43 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

The molecular regulation of the reductive pentose phosphate pathway in Proteobacteria and Cyanobacteria. Gibson JL, et al. **Arch Microbiol** 1996 Sep;166(3):141–50 (69 ref.)

CYANOCOBALAMIN see **VITAMIN B 12**

CYANOPHYCEAE see **CYANOBACTERIA**

CYANOSIS

[Acrocyanosis] Edelstein S, et al. **Harefuah** 1995 Jun 15; 128(12):803–6 (16 ref.) **(Heb)**

CHEMICALLY INDUCED

A case of acute dapsone poisoning: toxicological data and review of the literature. Tracqui A, et al. **J Anal Toxicol** 1995 Jul-Aug;19(4):229–35 (72 ref.)

ETIOLOGY

[Cyanosis] Oertel R, et al. **Internist (Berl)** 1995 Oct; 36(10):1019–30 (8 ref.) **(Ger)**

PHYSIOPATHOLOGY

Breath-holding spells. Breningstall GN. **Pediatr Neurol** 1996 Feb;14(2):91–7 (35 ref.)

CYBERNETICS

Transplant information transfer and analysis in cyberspace. Merion RM. **Transplant Proc** 1996 Aug;28(4):2026–8 (3 ref.)

METHODS

Mediatophore and other presynaptic proteins. A cybernetic linking at the active zone. Dunant Y, et al. **J Physiol Paris** 1995;89(3):147–56 (68 ref.)

CYCLIC AMP

Multiple facets of the modulation of growth by cAMP. Roger PP, et al. **Vitam Horm** 1995;51:59–191 (801 ref.)

ANALYSIS

Immunosuppressive retroviral peptides: cAMP and cytokine patterns. Haraguchi S, et al. **Immunol Today** 1995 Dec; 16(12):595–603 (97 ref.)
[Cyclic AMP (cAMP)] Okuya S, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:726–8 (8 ref.) **(Jpn)**

METABOLISM

Compartmentalization of cyclic AMP phosphodiesterases, signalling 'crosstalk', desensitization and the phosphorylation of Gi-2 add cell specific personalization to the control of the levels of the second messenger cyclic AMP. Houslay MD. **Adv Enzyme Regul** 1995;35:303–38 (68 ref.)
Transcription factors responsive to cAMP. Sassone-Corsi P. **Ann Rev Cell Dev Biol** 1995;11:355–77 (73 ref.)
Endothelin receptor heterogeneity, G-proteins, and signaling via cAMP and cGMP cascades. Sokolovsky M. **Cell Mol Neurobiol** 1995 Oct;15(5):561–71 (40 ref.)
Regulation of multidrug resistance through the cAMP and EGF signalling pathways. Rohlff C, et al. **Cell Signal** 1995 Jul;7(5):431–43 (131 ref.)
Signal transduction: regulation of cAMP concentration in cardiac muscle by calmodulin-dependent cyclic nucleotide phosphodiesterase. Sharma RK. **Mol Cell Biochem** 1995 Aug-Sep;149–150:241–7 (23 ref.)
Gating by cyclic AMP: expanded role for an old signaling pathway. Iyengar R. **Science** 1996 Jan 26;271(5248):461–3 (17 ref.)
Myocardial contractile response and IP3, cAMP and cGMP interrelationships. Martinussen HJ. **Ups J Med Sci** 1996; 101(1):1–33 (142 ref.)

PHARMACOLOGY

cAMP-dependent regulation of gene transcription by cAMP response element-binding protein and cAMP response element modulator. Habener JF, et al. **Vitam Horm** 1995; 51:1–57 (196 ref.)

PHYSIOLOGY

Regulation of astrocyte cell biology by the cAMP/protein kinase A signaling pathway. Huneycutt BS, et al. **Adv Neuroimmunol** 1995;5(3):261–9 (45 ref.)
Cyclic nucleotide-gated ion channels: an extended family with diverse functions. Finn JT, et al. **Annu Rev Physiol** 1996;58:395–426 (246 ref.)
Role of cyclic AMP in the actions of cannabinoid receptors. Childers SR, et al. **Biochem Pharmacol** 1996 Sep 27; 52(6):819–27 (68 ref.)
The 1994 Upjohn Award Lecture. Molecular and genetic approaches to the study of signal transduction in the

adrenal cortex. Schimmer BP. **Can J Physiol Pharmacol** 1995 Aug;73(8):1097–107 (83 ref.)
Family of cyclic nucleotide gated ion channels. Kaupp UB. **Curr Opin Neurobiol** 1995 Aug;5(4):434–42 (92 ref.)
Dual role of cAMP during Dictyostelium development. Reymond CD, et al. **Experientia** 1995 Dec 18; 51(12):1166–74 (88 ref.)
Transduction of the chemotactic cAMP signal across the plasma membrane of Dictyostelium cells. Van Haastert PJ. **Experientia** 1995 Dec 18;51(12):1144–54 (72 ref.)
Adaptation to life at micromolar nutrient levels: the regulation of Escherichia coli glucose transport by endoinduction and cAMP. Ferenci T. **FEMS Microbiol Rev** 1996 Jul;18(4):301–17 (92 ref.)
The nuclear response to cAMP: role of transcription factor CREM. Lalli E, et al. **Philos Trans R Soc Lond B Biol Sci** 1996 Feb 29; 351(1336):201–9 (50 ref.)
Cross talk between cyclic AMP and the polyphosphoinositide signaling cascade in iris sphincter and other nonvascular smooth muscle. Abdel-Latif AA. **Proc Soc Exp Biol Med** 1996 Feb;211(2):163–77 (126 ref.)
Cyclic AMP, the reluctant messenger in plants. Bolwell GP. **Trends Biochem Sci** 1995 Dec;20(12):492–5 (43 ref.)

CYCLIC AMP-DEPENDENT PROTEIN KINASES

CHEMISTRY

Conservation, evolution, and specificity in cellular control by protein phosphorylation. Hofer HW. **Experientia** 1996 May 15;52(5):449–54 (27 ref.)
Detergent binding to unmyristylated protein kinase A—structural implications for the role of myristate. Sowadski JM, et al. **J Bioenerg Biomembr** 1996 Feb; 28(1):7–12 (27 ref.)

DRUG EFFECTS

Modulation of gap junctional intercellular communication by phosphorylation: effects of growth factors, kinase activators and phosphatase inhibitors. Mikalsen SO, et al. **Prog Clin Biol Res** 1995;391:425–38 (72 ref.)

METABOLISM

Protein serine/threonine kinases (PKA, PKC and CaMKII) involved in ischemic brain pathology. Domańska-Janik K. **Acta Neurobiol Exp (Warsz)** 1996;56(2):579–85 (44 ref.)
Conservation, evolution, and specificity in cellular control by protein phosphorylation. Hofer HW. **Experientia** 1996 May 15;52(5):449–54 (27 ref.)
How do protein kinases discriminate between serine/threonine and tyrosine? Structural insights from the insulin receptor protein-tyrosine kinase. Taylor SS, et al. **FASEB J** 1995 Oct;9(13):1255–66 (41 ref.)
Detergent binding to unmyristylated protein kinase A—structural implications for the role of myristate. Sowadski JM, et al. **J Bioenerg Biomembr** 1996 Feb; 28(1):7–12 (27 ref.)
Role of protein kinase C and cyclic AMP/protein kinase A in high glucose-stimulated transcriptional activation of collagen alpha 1 (IV) in glomerular mesangial cells. Ziyadeh FN, et al. **J Diabetes Complications** 1995 Oct-Dec; 9(4):255–61 (35 ref.)

PHYSIOLOGY

Regulation of astrocyte cell biology by the cAMP/protein kinase A signaling pathway. Huneycutt BS, et al. **Adv Neuroimmunol** 1995;5(3):261–9 (45 ref.)
cGMP signaling through cAMP- and cGMP-dependent protein kinases. Lincoln TM, et al. **Adv Pharmacol** 1995; 34:305–22 (68 ref.)
Regulation of dynein-driven microtubule sliding by an axonemal kinase and phosphatase in Chlamydomonas flagella. Habermacher G, et al. **Cell Motil Cytoskeleton** 1995;32(2):106–9 (23 ref.)
Morphogenetic signalling. Responses to hedgehog. Kalderon D. **Curr Biol** 1995 Jun 1;5(6):580–2 (15 ref.)

3',5'-CYCLIC AMP 5'-NUCLEOTIDOHYDROLASE see **3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE**

3',5'-CYCLIC-AMP PHOSPHODIESTERASE see **3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE**

CYCLIC AMP RECEPTOR PROTEIN

METABOLISM

Morbidity and mortality in hemodialysis: the role of schedules. Berland Y, et al. **Artif Organs** 1995 Aug; 19(8):827–31 (24 ref.)

CYCLIC GMP

ANALYSIS

[Cyclic GMP (cGMP)] Okuya S, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:729–31 (9 ref.) **(Jpn)**

METABOLISM

Endothelin receptor heterogeneity, G-proteins, and signaling via cAMP and cGMP cascades. Sokolovsky M. **Cell Mol Neurobiol** 1995 Oct;15(5):561–71 (40 ref.)
The renal cGMP-gated cation channel: its molecular structure and physiological role. McCoy DE, et al. **Kidney Int** 1995 Oct;48(4):1125–33 (77 ref.)
Myocardial contractile response and IP3, cAMP and cGMP interrelationships. Martinussen HJ. **Ups J Med Sci** 1996; 101(1):1–33 (142 ref.)

PHARMACOLOGY

Type III cGMP-inhibited cyclic nucleotide phosphodiesterases (PDE3 gene family). Manganiello VC, et al. **Cell Signal** 1995 Jul;7(5):445–55 (106 ref.)

PHYSIOLOGY

cGMP signaling through cAMP- and cGMP-dependent protein kinases. Lincoln TM, et al. **Adv Pharmacol** 1995; 34:305–22 (68 ref.)
Nitric oxide and cGMP signaling. McDonald LJ, et al. **Adv Pharmacol** 1995;34:263–75 (49 ref.)
Nitric oxide: a neural messenger. Jaffrey SR, et al. **Ann Rev Cell Dev Biol** 1995;11:417–40 (167 ref.)
Cyclic nucleotide-gated ion channels: an extended family with diverse functions. Finn JT, et al. **Annu Rev Physiol** 1996;58:395–426 (246 ref.)
Do nitric oxide and cGMP play a role in calcium cycling? Milbourne EA, et al. **Cell Calcium** 1995 Sep;18(3):207–13 (43 ref.)
Endothelium-dependent hyperpolarization. Beyond nitric oxide and cyclic GMP. Cohen RA, et al. **Circulation** 1995 Dec 1;92(11):3337–49 (211 ref.)
Family of cyclic nucleotide gated ion channels. Kaupp UB. **Curr Opin Neurobiol** 1995 Aug;5(4):434–42 (92 ref.)
Oxygen-radical/nitric oxide mediate calcium-dependent hormone action on cyclic GMP system: a novel concept in signal transduction mechanisms. Mittal CK. **Mol Cell Biochem** 1995 Aug-Sep;149–150:257–62 (37 ref.)
Nitric oxide and cyclic GMP signaling. McDonald LJ, et al. **Proc Soc Exp Biol Med** 1996 Jan;211(1):1–6 (42 ref.)

CYCLIC GMP-DEPENDENT PROTEIN KINASES

METABOLISM

Signalling by cGMP-dependent protein kinases. Vaandrager AB, et al. **Mol Cell Biochem** 1996 Apr 12–26;157(1–2):23–30 (67 ref.)

PHYSIOLOGY

cGMP signaling through cAMP- and cGMP-dependent protein kinases. Lincoln TM, et al. **Adv Pharmacol** 1995; 34:305–22 (68 ref.)

3',5'-CYCLIC GMP 5'-NUCLEOTIDOHYDROLASE see **3',5'-CYCLIC-GMP PHOSPHODIESTERASE**

3',5'-CYCLIC-GMP PHOSPHODIESTERASE

GENETICS

Diversity in cyclic nucleotide phosphodiesterase isoenzyme families. Manganiello VC, et al. **Arch Biochem Biophys** 1995 Sep 10;322(1):1–13 (156 ref.)

PHYSIOLOGY

Type III cyclic nucleotide phosphodiesterases and insulin action. Manganiello VC, et al. **Curr Top Cell Regul** 1996; 34:63–100 (265 ref.)

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE

GENETICS

Diversity in cyclic nucleotide phosphodiesterase isoenzyme families. Manganiello VC, et al. **Arch Biochem Biophys** 1995 Sep 10;322(1):1–13 (156 ref.)

METABOLISM

Type III cGMP-inhibited cyclic nucleotide phosphodiesterases (PDE3 gene family). Manganiello VC, et al. **Cell Signal** 1995 Jul;7(5):445–55 (106 ref.)
Signal transduction: regulation of cAMP concentration in cardiac muscle by calmodulin-dependent cyclic nucleotide phosphodiesterase. Sharma RK. **Mol Cell Biochem** 1995 Aug-Sep;149–150:241–7 (23 ref.)
Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Beavo JA. **Physiol Rev** 1995 Oct; 75(4):725–48 (179 ref.)

PHYSIOLOGY

Type III cyclic nucleotide phosphodiesterases and insulin action. Manganiello VC, et al. **Curr Top Cell Regul** 1996; 34:63–100 (265 ref.)

2',3'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES

PHYSIOLOGY

[Progress in the study of cyclic nucleotide phosphodiesterases] Zhou HL, et al. **Sheng Li Ko Hsueh Chin Chan** 1995 Jul;26(3):213–7 (16 ref.) (Eng. Abstr.) **(Chi)**

CYCLIC SOMATOSTATIN see **SOMATOSTATIN**

CYCLICITY see **PERIODICITY**

CYCLIN A see **CYCLINS**

CYCLIN B see **CYCLINS**

CYCLIN-DEPENDENT KINASES

Cyclins, cyclin-dependent kinases and cdk inhibitors: implications in cell cycle control and cancer. MacLachlan TK, et al. **Crit Rev Eukaryot Gene Expr** 1995;5(2):127–56 (235 ref.)

ANTAGONISTS & INHIBITORS

Why are there so many CDK inhibitors? Xiong Y. **Biochim Biophys Acta** 1996 Aug 8;1288(1):01–5 (65 ref.)
Cyclins, Cdks, and cyclin kinase inhibitors. Roberts JM, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:31–8 (62 ref.)
Inhibitors of cyclin-dependent kinase and cancer. Biggs JR, et al. **J Mol Med** 1995 Oct;73(10):509–14 (58 ref.)
Molecular foundations of cancer: new targets for intervention. Karp JE, et al. **Nat Med** 1995 Apr;1(4):309–20 (121 ref.)
[Regulation of the cell cycle—involvement of protein inhibitors of cyclin-dependent kinases] Grzelakowska-Sztabert B. **Postepy Biochem** 1995; 41(2):80–93 (161 ref.) **(Pol)**

CHEMISTRY

Structuring cell-cycle biology [comment] Levine K, et al. **Structure** 1995 Nov 15;3(11):1131–4 (52 ref.) Comment on: Structure 1995 Nov 15;3(11):1235–47.

GENETICS

Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Hall M, et al. **Adv Cancer Res** 1996;68:67–108 (219 ref.)

METABOLISM

Cyclin-dependent protein kinases: key regulators of the eukaryotic cell cycle. Nigg EA. **Bioessays** 1995 Jun; 17(6):471–80 (95 ref.)
Origins of G1 arrest in senescent human fibroblasts. Stein GH, et al. **Bioessays** 1995 Jun;17(6):537–43 (66 ref.)
G1 regulation and checkpoints operating around START in fission yeast. Woollard A, et al. **Bioessays** 1995 Jun; 17(6):481–90 (65 ref.)
Cyclins, Cdks, and cyclin kinase inhibitors. Roberts JM, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:31–8 (62 ref.)
D-type cyclins and their cyclin-dependent kinases: G1 phase integrators of the mitogenic response. Sherr CJ, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:11–9 (86 ref.)
Cell regulation. Innocent bystanders or chosen collaborators? Poon RY, et al. **Curr Biol** 1995 Nov 1;5(11):1243–7 (34 ref.)
Cyclin dependent kinase regulation. Lees E. **Curr Opin Cell Biol** 1995 Dec;7(6):773–80 (102 ref.)
[Cyclin dependent kinases. From molecular biology to pathology] Wołowiec D. **Postepy Hig Med Dosw** 1995; 49(2):221–35 (80 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOLOGY

Regulating S phase: CDKs, licensing and proteolysis. Wuarin J, et al. **Cell** 1996 Jun 14;85(6):785–7 (19 ref.)
[Cell cycle regulation by anticancer agent] Nomoto T, et al. **Gan To Kagaku Ryoho** 1995 Oct;22(12):1719–23 (20 ref.) (Eng. Abstr.) **(Jpn)**

CYCLINS

see related
MATURATION-PROMOTING FACTOR

Cyclins, cyclin-dependent kinases and cdk inhibitors: implications in cell cycle control and cancer. MacLachlan TK, et al. **Crit Rev Eukaryot Gene Expr** 1995;5(2):127–56 (235 ref.)
[Cyclin D1 in oncogenesis] Hosokawa Y. **Seikagaku** 1996 Mar;68(3):201–5 (15 ref.) **(Jpn)**

ANTAGONISTS & INHIBITORS

Molecular foundations of cancer: new targets for intervention. Karp JE, et al. **Nat Med** 1995 Apr;1(4):309–20 (121 ref.)

BIOSYNTHESIS

A yeast transcription factor activating G1 cyclin expression has similarity to bacterial signal transduction proteins. Johnston LH, et al. **Biochem Soc Trans** 1996 Feb; 24(1):49–54 (26 ref.)

CHEMISTRY

Structuring cell–cycle biology [comment] Levine K, et al. **Structure** 1995 Nov 15;3(11):1131–4 (52 ref.) Comment on: Structure 1995 Nov 15;3(11):1235–47.

GENETICS

Expression and regulation of cyclin genes in breast cancer. Sutherland RL, et al. **Acta Oncol** 1995;34(5):651–6 (25 ref.)
Genetic alterations of cyclins, cyclin–dependent kinases, and Cdk inhibitors in human cancer. Hall M, et al. **Adv Cancer Res** 1996;68:67–108 (219 ref.)
The cyclin D1/PRAD1 oncogene in human neoplasia. Arnold A. **J Investig Med** 1995 Dec;43(6):543–9 (44 ref.)

METABOLISM

Cell cycle regulation by the retinoblastoma family of growth inhibitory proteins. Beijersbergen RL, et al. **Biochim Biophys Acta** 1996 Jun 7;1287(2–3):103–20 (223 ref.)
Origins of G1 arrest in senescent human fibroblasts. Stein GH, et al. **Bioessays** 1995 Jun;17(6):537–43 (66 ref.)
Cyclins, Cdks, and cyclin kinase inhibitors. Roberts JM, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:31–8 (62 ref.)
D–type cyclins and their cyclin–dependent kinases: G1 phase integrators of the mitogenic response. Sherr CJ, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:11–9 (86 ref.)
Cell cycle. The only way out of mitosis. Glotzer M. **Curr Biol** 1995 Sep 1;5(9):970–2 (26 ref.)
Cell regulation. Innocent bystanders or chosen collaborators? Poon RY, et al. **Curr Biol** 1995 Nov 1;5(11):1243–7 (34 ref.)

PHYSIOLOGY

Cyclin from sea urchins to HeLas: making the human cell cycle. Pines J. **Biochem Soc Trans** 1996 Feb;24(1):15–33 (235 ref.)
Happenstance, circumstance or enemy action: cyclin D1 in breast, eye and brain. Schmidt EV. **Bioessays** 1996 Jan; 18(1):6–8 (29 ref.)
Cyclin kinase inhibitors add a new dimension to cell cycle control. Yeudall WA, et al. **Eur J Cancer B Oral Oncol** 1995 Sep;31B(5):291–8 (102 ref.)
Mammalian G1 cyclins and cell cycle progression. Sherr CJ. **Proc Assoc Am Physicians** 1995 Jul;107(2):181–6 (57 ref.)
Cyclins of the fission yeast Schizosaccharomyces pombe. Fisher D, et al. **Semin Cell Biol** 1995 Apr;6(2):73–8 (38 ref.)
[Structure of chromatin and cell cycle. 3.] Santisteban MS. **Pathol Biol (Paris)** 1995 Sep;43(7):639–64 (597 ref.) (Eng. Abstr.) **(Fre)**
[Regulation of the cell cycle––involvement of protein inhibitors of cyclin–dependent kinases] Grzelakowska–Sztabert B. **Postepy Biochem** 1995; 41(2):80–93 (161 ref.) **(Pol)**

CYCLITIS, HETEROCHROMIC see **IRIDOCYCLITIS**

CYCLOBUTANES

THERAPEUTIC USE

Sibutramine: a novel new agent for obesity treatment. Ryan DH, et al. **Obes Res** 1995 Nov;3 Suppl 4:553S–559S (29 ref.)

CYCLOHEXANES

TOXICITY

Assessment of follicle destruction in chemical–induced ovarian toxicity. Hoyer PB, et al. **Annu Rev Pharmacol Toxicol** 1996;36:307–31 (122 ref.)

CYCLOHEXANOLS

ADVERSE EFFECTS

Cardiovascular safety in depressed patients: focus on venlafaxine. Feighner JP. **J Clin Psychiatry** 1995 Dec; 56(12):574–9 (44 ref.)

THERAPEUTIC USE

Nefazodone and venlafaxine: two new agents for the treatment of depression. Goldberg RJ. **J Fam Pract** 1995 Dec;41(6):591–4 (19 ref.)
Therapeutic options for treating major depression, and the role of venlafaxine. Scott MA, et al. **Pharmacotherapy** 1996 May–Jun;16(3):352–65 (91 ref.)

CYCLOOXYGENASE see **PROSTAGLANDIN–ENDOPEROXIDE SYNTHASE**

CYCLOOXYGENASE INHIBITORS

see related **ANTI–INFLAMMATORY AGENTS, NON–STEROIDAL**

ADVERSE EFFECTS

[Sensitivity to acetylsalicylic acid] Elverland HH. **Tidsskr Nor Laegeforen** 1996 Feb 28;116(6):754–6 (22 ref.) (Eng. Abstr.) **(Nor)**

PHARMACOLOGY

Inflammation, reproduction, cancer and all that.... The regulation and role of the inducible prostaglandin synthase. Herschman HR, et al. **Bioessays** 1995 Dec;17(12):1031–7 (65 ref.)
Pharmacology of meloxicam, a new non–steroidal anti–inflammatory drug with an improved safety profile through preferential inhibition of COX–2. Engelhardt G. **Br J Rheumatol** 1996 Apr;35 Suppl 1:4–12 (69 ref.)
Constitutive cyclooxygenase (COX–1) and inducible cyclooxygenase (COX–2): rationale for selective inhibition and progress to date. Griswold DE, et al. **Med Res Rev** 1996 Mar;16(2):181–206 (143 ref.)
Aspirin––now we can see it. Allen KN. **Nat Med** 1995 Sep; 1(9):882–3 (13 ref.)
Mechanism of action of anti–inflammatory drugs. Vane JR, et al. **Scand J Rheumatol Suppl** 1996;102:9–21 (75 ref.)

THERAPEUTIC USE

Innovative treatment approaches for rheumatoid arthritis. New cyclo–oxygenase and cytokine inhibitors. Richardson CE, et al. **Baillieres Clin Rheumatol** 1995 Nov;9(4):731–58 (73 ref.)
[Can nitrogen monoxide replace aspirin in the prevention of preeclampsia?] Ohl J, et al. **Contracept Fertil Sex** 1996 Apr;24(4):259–61 (16 ref.) **(Fre)**
[Aspirin during pregnancy. Indications and modalities of prescription after the publication of the later trials] Uzan S, et al. **Presse Med** 1996 Jan 6–13;25(1):31–6 (30 ref.) (Eng. Abstr.) **(Fre)**

CYCLOPARAFFINS

CHEMICAL SYNTHESIS

[Synthesis of novel nucleosides: carbocyclic nucleosides] Katagiri N, et al. **Tanpakushitsu Kakusan Koso** 1994 Jul; 40(10):1219–31 (54 ref.) **(Jpn)**

CYCLOPHOSPHAMIDE

ADMINISTRATION & DOSAGE

Complete remission of multicentric reticulohistiocytosis with combination therapy of steroid, cyclophosphamide, and low–dose pulse methotrexate. Case report, review of the literature, and proposal for treatment. Liang GC, et al. **Arthritis Rheum** 1996 Jan;39(1):171–4 (15 ref.)
Oral therapy for small cell lung cancer. Postmus PE, et al. **Lung Cancer** 1995 Jun;12 Suppl 3:S63–70 (29 ref.)
Mononeuritis multiplex in systemic lupus erythematosus: response to pulse intravenous cyclophosphamide. Martinez–Taboada VM, et al. **Lupus** 1996 Feb;5(1):74–6 (21 ref.)
[Cicatricial pemphigoid––a therapeutic problem] Axt M, et al. **Hautarzt** 1995 Sep;46(9):620–7 (32 ref.) (Eng. Abstr.) **(Ger)**
[Pulse–dose cyclophosphamide therapy for steroid–refractory autoimmune neurological diseases] Watanabe T, et al. **Rinsho Shinkeigaku** 1995 Jun;35(6):611–6 (30 ref.) (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Efficacy of mesna for prevention of hemorrhagic cystitis after high–dose cyclophosphamide therapy. Haselberger MB, et al. **Ann Pharmacother** 1995 Sep;29(9):918–21 (21 ref.)
Optimal control of cyclophosphamide–induced emesis. Stewart A. **Oncology** 1996 Jun;53 Suppl 1:32–8 (38 ref.)
[Transitional cell carcinoma of the ureter and cyclophosphamide: apropos of a case] Ponsot Y, et al. **Prog Urol** 1995 Sep;5(4):578–9 (8 ref.) (Eng. Abstr.) **(Fre)**
[Two cases of therapy–related myelodysplastic syndrome] Takahashi A, et al. **Rinsho Ketsueki** 1996 Jan;37(1):53–9 (16 ref.) (Eng. Abstr.) **(Jpn)**
[Extramedullary toxicity in bone marrow transplantation using busulfan and cyclophosphamide conditioning] Pascual MJ, et al. **Sangre (Barc)** 1995 Jun;40(3):191–7 (31 ref.) (Eng. Abstr.) **(Spa)**

PHARMACOLOGY

Brain tumor gene therapy in mice with a novel "suicide" gene: the cyclophosphamide–activating CYP2B1 gene. Chiocca EA. **Clin Neurosurg** 1995;42:370–82 (49 ref.)
Immunological tolerance to xenogeneic grafts induced by cyclophosphamide in adult animals. Chernyakhovskaya IYu, et al. **Folia Biol (Praha)** 1994;40(6):371–80 (33 ref.)

THERAPEUTIC USE

Cyclophosphamide therapy of medulloblastoma: from the laboratory to the clinic and back again (and again and again). Friedman HS, et al. **J Neurooncol** 1995;24(1):103–8 (21 ref.)
[Felty syndrome: a therapy–resistant variant of chronic rheumatoid arthritis? 2 case reports and literature review] Brücker R, et al. **Schweiz Rundsch Med Prax** 1996 Apr 16;85(16):534–40 (38 ref.) (Eng. Abstr.) **(Ger)**
[New treatments for multiple sclerosis] Masdeu JC. **Rev Neurol** 1996 Jun;24(130):708–11 (38 ref.) **(Spa)**

CYCLOSPORIN A see **CYCLOSPORINE**

CYCLOSPORINE

Clinical use of cyclosporin in rheumatoid arthritis. Richardson C, et al. **Drugs** 1995;50 Suppl 1:26–36 (53 ref.)
The panorama of cyclosporin research. Balakrishnan K, et al. **J Basic Microbiol** 1996;36(2):121–47 (292 ref.)

ADMINISTRATION & DOSAGE

Combination therapy with cyclosporin in rheumatoid arthritis. Yocum DE. **Drugs** 1995;50 Suppl 1:37–40 (20 ref.)

ADVERSE EFFECTS

Neurophysiologic evaluation of cyclosporine toxicity associated with bone marrow transplantation. Edwards LL, et al. **Acta Neurol Scand** 1995 Nov;92(5):423–9 (11 ref.)
Cyclosporine in the treatment of rheumatoid arthritis. Stein CM. **Bull Rheum Dis** 1995 Nov;44(7):1–4 (11 ref.)
Morphologic features of cyclosporin nephrotoxicity. D'Agati VD. **Contrib Nephrol** 1995;114:84–110 (93 ref.)
Complications of cyclosporin therapy. Hoyer PF. **Contrib Nephrol** 1995;114:111–23 (61 ref.)
Hypertension after cardiac transplantation: pathophysiology and management. Sander M, et al. **Curr Opin Nephrol Hypertens** 1995 Sep;4(5):443–51 (125 ref.)
Safety aspects of cyclosporin in rheumatoid arthritis. Dijkmans BA. **Drugs** 1995;50 Suppl 1:41–7 (37 ref.)
The differential diagnosis between rejection and cyclosporine toxicity. Mihatsch MJ, et al. **Kidney Int Suppl** 1995 Dec; 52:S63–9 (9 ref.)
Cyclosporine–induced renal dysfunction in experimental animals and humans. Remuzzi G, et al. **Kidney Int Suppl** 1995 Dec;52:S70–4 (49 ref.)
The role of calcium–channel antagonists in solid organ transplantation. Huntress JD, et al. **New Horiz** 1996 Feb; 4(1):129–33 (30 ref.)
Chronic cyclosporine nephropathy in renal transplantation. Bennett WM, et al. **Transplant Proc** 1996 Aug;28(4):2100–3 (29 ref.)
Renovascular elements of the cyclosporine injury. Curtis JJ. **Transplant Proc** 1996 Aug;28(4):2094–6 (18 ref.)
[Hair–like hyperkeratoses in patients with kidney transplants. A new cyclosporin side–effect] Izakovic J, et al. **Hautarzt** 1995 Dec;46(12):841–6 (45 ref.) (Eng. Abstr.) **(Ger)**

BLOOD

Cyclosporin A: analytical methodology and factors affecting therapeutic drug monitoring. Holt DW, et al. **Ther Drug Monit** 1995 Dec;17(6):625–30 (29 ref.)
Cyclosporine A: clinical experience and therapeutic drug monitoring. Lindholm A. **Ther Drug Monit** 1995 Dec; 17(6):631–7 (46 ref.)
Lake Louise Consensus Conference on cyclosporin monitoring in organ transplantation: report of the consensus panel. Oellerich M, et al. **Ther Drug Monit** 1995 Dec; 17(6):642–54 (47 ref.)
[Cyclosporine] Yuhki Y, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:1056–9 (13 ref.) **(Jpn)**

METABOLISM

Some new aspects of molecular mechanisms of cyclosporin A effect on immune response. Zav'yalov VP, et al. **APMIS** 1995 Jun;103(6):401–15 (121 ref.)
Alternative cyclosporine metabolic pathways and toxicity. Christians U, et al. **Clin Biochem** 1995 Dec;28(6):547–59 (94 ref.)
Drug interactions in transplantation. Seifeldin R. **Clin Ther** 1995 Nov–Dec;17(6):1043–61 (102 ref.)

PHARMACOKINETICS

Challenges in cyclosporine therapy: the role of therapeutic monitoring by area under the curve monitoring. Kahan BD, et al. **Ther Drug Monit** 1995 Dec;17(6):621–4 (15 ref.)
Pharmacokinetic considerations in the therapeutic application of cyclosporine in renal transplantation. Kahan BD. **Transplant Proc** 1996 Aug;28(4):2143–6 (26 ref.)
Cyclosporine pharmacology. Lee JI, et al. **Transplant Proc** 1996 Aug;28(4):2156–8 (20 ref.)
Neoral in liver transplantation. Levy GA, et al. **Transplant Proc** 1996 Apr;28(2):1019–21 (9 ref.)

PHARMACOLOGY

Inhibition of T lymphocyte activation and apoptotic cell death by cyclosporin A and tacrolimus (FK506). Its

relevance to therapy of HIV infection. Thomson AW, et al. **Adv Exp Med Biol** 1995;374:211–6 (46 ref.)
The actions of cyclosporin A and FK506 on T-lymphocyte activation. Mattila PS. **Biochem Soc Trans** 1996 Feb; 24(1):45–9 (40 ref.)
The permeability transition pore. Control points of a cyclosporin A–sensitive mitochondrial channel involved in cell death. Bernardi P. **Biochim Biophys Acta** 1996 Jul 18; 1275(1–2):5–9 (43 ref.)
The mechanism of action of cyclosporin A and FK506. Ho S, et al. **Clin Immunol Immunopathol** 1996 Sep;80(3 Pt 2):S40–5 (31 ref.)
Molecular mechanisms of immunosuppression by cyclosporine, FK506, and rapamycin. Cardenas ME, et al. **Curr Opin Nephrol Hypertens** 1995 Nov;4(6):472–7 (83 ref.)
Mechanisms of action of immunosuppressive agents: cyclosporin A, FK506, and rapamycin. Bierer BE. **Proc Assoc Am Physicians** 1995 Apr;107(1):28–40 (135 ref.)
Cyclosporine-induced apoptosis in CD4+ T lymphocytes and computer-simulated analysis: modeling a treatment scenario for HIV infection. Huss R, et al. **Res Immunol** 1995 Feb;146(2):101–8 (32 ref.)
Immunoregulatory and fibrogenic activities of cyclosporine: a unifying hypothesis based on transforming growth factor-beta expression. Khanna A, et al. **Transplant Proc** 1996 Aug;28(4):2015–8 (38 ref.)
[Expression of the MDR1 gene in five human cell lines of medullary thyroid cancer and reversion of the resistance to doxorubicine by ciclosporin A and verapamil] Massart C, et al. **Bull Cancer (Paris)** 1996 Jan;83(1):39–45 (32 ref.) (Eng. Abstr.) **(Fre)**
[The mechanism of action of cyclosporine: something more than immunosuppression?] Losa García JE, et al. **Rev Clin Esp** 1996 May;196(5):313–21 (78 ref.) **(Spa)**

THERAPEUTIC USE

My thoughts on using cyclosporine in the treatment of inflammatory bowel disease [editorial; comment] Korelitz BI. **Am J Gastroenterol** 1995 Dec;90(12):2085–6 (17 ref.) Comment on: Am J Gastroenterol 1995 Dec;90(12):2093–6.
A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Sandborn WJ. **Am J Gastroenterol** 1996 Mar;91(3):423–33 (65 ref.)
Innovative treatment approaches for rheumatoid arthritis. Cyclosporin, leflunomide and nitrogen mustard. Furst DE. **Baillieres Clin Rheumatol** 1995 Nov;9(4):711–29 (41 ref.)
Cyclosporine in the treatment of rheumatoid arthritis. Stein CM. **Bull Rheum Dis** 1995 Nov;44(7):1–4 (11 ref.)
Cisplatin-based chemotherapy in renal transplant recipients. A case report and a review of the literature. Benisovich VI, et al. **Cancer** 1996 Jan 1;77(1):160–3 (22 ref.)
Optimizing the use of cyclosporine in renal transplantation. Sketris I, et al. **Clin Biochem** 1995 Jun;28(3):195–211 (182 ref.)
Mechanism of action of cyclosporin in rheumatoid arthritis. Bentin J. **Clin Rheumatol** 1995 Sep;14 Suppl 2:22–5 (50 ref.)
Cyclosporine in rheumatoid arthritis: an overview. Førre O. **Clin Rheumatol** 1995 Sep;14 Suppl 2:33–6 (20 ref.)
Use of cyclosporin in membranous and mesangioproliferative (IgA) nephropathy. Cattran DC. **Contrib Nephrol** 1995; 114:49–58 (47 ref.)
Use of cyclosporin in the treatment of idiopathic nephrotic syndrome in adults. Meyrier A. **Contrib Nephrol** 1995; 114:28–48 (47 ref.)
Use of cyclosporin in lupus nephritis. Radhakrishnan J, et al. **Contrib Nephrol** 1995;114:59–72 (53 ref.)
Cyclosporin in steroid-resistant idiopathic nephrotic syndrome. Tejani A, et al. **Contrib Nephrol** 1995;114:73–7 (32 ref.)
Cyclosporine: what clinicians need to know. Koo J, et al. **Dermatol Clin** 1995 Oct;13(4):897–907 (69 ref.)
Cyclosporin. A review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral). Noble S, et al. **Drugs** 1995 Nov; 50(5):924–41 (60 ref.)
Clinical use of cyclosporin in rheumatoid arthritis. Richardson C, et al. **Drugs** 1995;50 Suppl 1:26–36 (53 ref.)
International consensus recommendations on cyclosporin use in rheumatoid arthritis. Tugwell P. **Drugs** 1995;50 Suppl 1:48–56 (32 ref.)
Treatment of aplastic anaemia with antilymphocyte globulin and cyclosporin. Marsh JC, et al. **Int J Hematol** 1995 Oct; 62(3):133–44 (79 ref.)
Long-term use of cyclosporine A does not adversely impact on clinical outcomes following renal transplantation. Lewis RM. **Kidney Int Suppl** 1995 Dec;52:S75–8 (35 ref.)
Cyclosporine in rheumatoid arthritis. Yocum DE, et al. **Rheum Dis Clin North Am** 1995 Aug;21(3):835–44 (57 ref.)
Challenges in cyclosporine therapy: the role of therapeutic monitoring by area under the curve monitoring. Kahan BD, et al. **Ther Drug Monit** 1995 Dec;17(6):621–4 (15 ref.)
Cyclosporine A: clinical experience and therapeutic drug monitoring. Lindholm A. **Ther Drug Monit** 1995 Dec; 17(6):631–7 (46 ref.)
Therapeutic drug monitoring of cyclosporin G. Yatscoff RW, et al. **Ther Drug Monit** 1995 Dec;17(6):655–9 (28 ref.)
Neoral in liver transplantation. Jamieson NV, et al. **Transplant Proc** 1996 Aug;28(4):2229–31 (35 ref.)
Pharmacokinetic considerations in the therapeutic application of cyclosporine in renal transplantation. Kahan BD. **Transplant Proc** 1996 Aug;28(4):2143–6 (26 ref.)
Neoral therapy in liver transplantation. Levy GA. **Transplant Proc** 1996 Aug;28(4):2225–8 (27 ref.)
Neoral in liver transplantation. Levy GA, et al. **Transplant Proc** 1996 Apr;28(2):1019–21 (9 ref.)
An overview of the first decade of cyclosporine. Stiller CR. **Transplant Proc** 1996 Aug;28(4):2005–12 (3 ref.)
Chronic renal allograft function under cyclosporin treatment. Leuven Collaborative Group for Transplantation. Vanrenterghem Y, et al. **Transplant Proc** 1996 Aug; 28(4):2097–9 (11 ref.)
[Advances in transplantation biology and transplantation of vital organs in the era of immunosuppression with cyclosporin A] Hökl J, et al. **Cas Lek Cesk** 1995 Dec 13; 134(24):775–8 (21 ref.) (Eng. Abstr.) **(Cze)**
[Cyclosporine A and chronic inflammatory diseases of the digestive tract] Brazier F, et al. **Gastroenterol Clin Biol** 1995 May;19(5):494–504 (118 ref.) **(Fre)**
[Cyclosporin and diffuse alveolar interstitial lung disease] Losa García JE, et al. **Arch Bronconeumol** 1996 Jun-Jul; 32(6):302–6 (65 ref.) **(Spa)**

TOXICITY

Alternative cyclosporine metabolic pathways and toxicity. Christians U, et al. **Clin Biochem** 1995 Dec;28(6):547–59 (94 ref.)
Pathogenesis of drug-induced gingival overgrowth. A review of studies in the rat model. Nishikawa S, et al. **J Periodontol** 1996 May;67(5):463–71 (94 ref.)

CYCLOSPORINS

BIOSYNTHESIS

Biosynthesis and mechanism of action of cyclosporins. Lawen A. **Prog Med Chem** 1996;33:53–97 (179 ref.)

METABOLISM

Cyclophilin and gag in HIV-1 replication and pathogenesis. Franke EK, et al. **Adv Exp Med Biol** 1995;374:217–28 (122 ref.)

THERAPEUTIC USE

Cyclosporine in the treatment of idiopathic nephrosis. Niaudet P. **Indian Pediatr** 1995 Dec;32(12):1317–21 (17 ref.)
[Resistance to chemotherapy in cancers of the kidney and therapeutic perspectives] Oudard S, et al. **J Urol (Paris)** 1995;101(3):122–4 (25 ref.) (Eng. Abstr.) **(Fre)**

CYLINDROMA see **CARCINOMA, ADENOID CYSTIC**

CYNOMOLGUS MONKEY see **MACACA FASCICULARIS**

CYPOVIRUS see **REOVIRIDAE**

CYPRINODONTID see **CYPRINODONTIFORMES**

CYPRINODONTIFORMES

Melanoma formation in Xiphophorus: a model system for the role of receptor tyrosine kinases in tumorigenesis. Malitschek B, et al. **Bioessays** 1995 Dec;17(12):1017–23 (39 ref.)

CYPRINUS see **CARP**

CYST, LYMPHATIC see **LYMPHOCELE**

CYSTADENOCARCINOMA

Extrahepatic biliary cystadenomas and cystadenocarcinoma. Report of seven cases and review of the literature. Davies W, et al. **Ann Surg** 1995 Nov;222(5):619–25 (20 ref.)
[Liver adenoma and hepatobiliary cystadenoma] Takahama T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):387–91 (7 ref.) **(Jpn)**

MORTALITY

[Possibilities and limitations of curative resections in cancers of the pancreas] Klempnauer J, et al. **J Chir (Paris)** 1996 May;133(3):117–22 (27 ref.) (Eng. Abstr.) **(Fre)**

CYSTADENOCARCINOMA, MUCINOUS

DIAGNOSIS

[Primary malignant neoplasms of the female genitalia] Saraiva J, et al. **Acta Med Port** 1995 Oct;8(10):585–8 (11 ref.) (Eng. Abstr.) **(Por)**

PATHOLOGY

Primary retroperitoneal mucinous cystadenocarcinoma of low malignant potential: a case report and literature review. Pearl ML, et al. **Gynecol Oncol** 1996 Apr;61(1):150–2 (16 ref.)

CYSTADENOCARCINOMA, PAPILLARY

[Serious papillary endometrial adenocarcinoma] Zhang G, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1996 Jan;31(1):48–51 (25 ref.) **(Chi)**

CYSTADENOMA

Extrahepatic biliary cystadenomas and cystadenocarcinoma. Report of seven cases and review of the literature. Davies W, et al. **Ann Surg** 1995 Nov;222(5):619–25 (20 ref.)
[Adenoma, cyst adenoma of the extrahepatic bile duct] Shiga J. **Ryoikibetsu Shokogun Shirizu** 1996;(9):53–6 (21 ref.) **(Jpn)**

DIAGNOSIS

[A giant unifocal biliary cystadenoma: a chance finding in a young asymptomatic athlete] Busoni F, et al. **Radiol Med (Torino)** 1996 Apr;91(4):480–2 (12 ref.) **(Ita)**
[Cystadenoma of the seminal vesicles. A case report] D'Erme M, et al. **Radiol Med (Torino)** 1996 Mar;91(3):322–4 (8 ref.) **(Ita)**

PATHOLOGY

Laryngeal oncocytic cystadenomas. Eight cases and a literature review. Brandwein M, et al. **Arch Otolaryngol Head Neck Surg** 1995 Nov; 121(11):1302–5 (38 ref.)

VETERINARY

Biliary cystadenoma of cats. Adler R, et al. **Vet Pathol** 1995 Jul;32(4):415–8 (23 ref.)

CYSTADENOMA LYMPHOMATOSUM, PAPILLARY see **ADENOLYMPHOMA**

CYSTADENOMA, MUCINOUS

PATHOLOGY

Thyroid carcinoma originating in a teratoma of the ovary. Ferrer J, et al. **Eur J Gynaecol Oncol** 1995;16(5):396–402 (24 ref.)
[A mucinous ovarian tumor with foci of anaplastic carcinoma] Buzzi A, et al. **Minerva Ginecol** 1996 Apr; 48(4):163–6 (5 ref.) (Eng. Abstr.) **(Ita)**

SECRETION

Mucin-producing neoplasms of the pancreas. Intraductal papillary and mucinous cystic neoplasms. Shyr YM, et al. **Ann Surg** 1996 Feb;223(2):141–6 (27 ref.)

CYSTADENOMA, PAPILLARY

CHEMISTRY

Solid and cystic papillary neoplasm of the pancreas: a clinico-cytopathologic and immunocytochemical study of five new cases diagnosed by fine-needle aspiration cytology and a review of the literature. Pelosi G, et al. **Diagn Cytopathol** 1995 Oct;13(3):233–46 (106 ref.)

DIAGNOSIS

[A solid epithelial papillary-cystic pancreatic tumor. A report of a clinical case and review of the literature] Chávez M, et al. **Rev Gastroenterol Peru** 1996 Jan-Apr;16(1):64–71 (29 ref.) (Eng. Abstr.) **(Spa)**

PATHOLOGY

Solid and cystic papillary neoplasm of the pancreas: a clinico-cytopathologic and immunocytochemical study of five new cases diagnosed by fine-needle aspiration cytology and a review of the literature. Pelosi G, et al. **Diagn Cytopathol** 1995 Oct;13(3):233–46 (106 ref.)

CYSTADENOMA, SEROUS

PATHOLOGY

A case of macrocystic serous cystadenoma of the pancreas. Mori K, et al. **Int J Pancreatol** 1995 Feb;17(1):91–3 (8 ref.)

CYSTATHIONINE BETA-SYNTHASE

see related
HOMOCYSTINURIA

CYSTATINS, KININOGEN see **KININOGENS**

CYSTEAMINE

THERAPEUTIC USE

Recent advances in the treatment of cystinosis. Schneider JA, et al. **J Inherit Metab Dis** 1995;18(4):387–97 (18 ref.)

CYSTECTOMY

see related
URINARY DIVERSION

Bladder preservation--a prospect for patients with urinary bladder cancer. Sternberg CN. **Acta Oncol** 1995; 34(5):589–97; discusion 588 (72 ref.)

What are the risks of cystectomy and the advances in perioperative care? Montie JE, et al. **Int J Urol** 1995 Jun; 2 Suppl 2:89–104 (78 ref.)
Which patients are suitable for continent diversion or bladder substitution following cystectomy or other definitive local treatment? Skinner DG, et al. **Int J Urol** 1995 Jun;2 Suppl 2:105–12 (105 ref.)
Radical cystectomy for stage T3b bladder cancer. Hall CM, et al. **Semin Urol Oncol** 1996 May;14(2):73–80 (33 ref.)
The use of neobladders in women undergoing cystectomy for transitional-cell cancer. Stenzl A, et al. **World J Urol** 1996;14(1):15–21 (37 ref.)
[Prognostic factors of survival in infiltrating urothelial bladder carcinoma. A retrospective study of 158 patients treated by radical cystectomy] Thieblemont C, et al. **Bull Cancer (Paris)** 1996 Feb;83(2):139–46 (35 ref.) (Eng. Abstr.) **(Fre)**

CYSTEINAMINE see **CYSTEAMINE**

CYSTEINE

ANALOGS & DERIVATIVES

Felinine: a urinary amino acid of Felidae. Hendriks WH, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1995 Dec; 112(4):581–8 (33 ref.)

CHEMISTRY

Oxidative folding of cystine-rich peptides vs regioselective cysteine pairing strategies. Moroder L, et al. **Biopolymers** 1996;40(2):207–34 (206 ref.)
The picornaviral 3C proteinases: cysteine nucleophiles in serine proteinase folds. Malcolm BA. **Protein Sci** 1995 Aug; 4(8):1439–45 (65 ref.)

CYSTEINE ENDOPEPTIDASES see **CYSTEINE PROTEINASES**

CYSTEINE PROTEASES see **CYSTEINE PROTEINASES**

CYSTEINE PROTEINASES

[Lactacystin: a tool for elucidation of proteasome functions] Omura S, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr; 41(4):327–36 (57 ref.) **(Jpn)**

BIOSYNTHESIS

Necessary but not sufficient: the role of glucocorticoids in the acidosis-induced increase in levels of mRNAs encoding proteins of the ATP-dependent proteolytic pathway in rat muscle. Price SR, et al. **Miner Electrolyte Metab** 1996; 22(1–3):72–5 (14 ref.)

CEREBROSPINAL FLUID

Neuropeptide converting and processing enzymes in the spinal cord and cerebrospinal fluid. Persson S, et al. **Prog Brain Res** 1995;104:111–30 (195 ref.)

CHEMISTRY

Proteasome: from structure to function. Stock D, et al. **Curr Opin Biotechnol** 1996 Aug;7(4):376–85 (75 ref.)
Molecular biology of proteasomes. Tanaka K. **Mol Biol Rep** 1995;21(1):21–6 (54 ref.)
The picornaviral 3C proteinases: cysteine nucleophiles in serine proteinase folds. Malcolm BA. **Protein Sci** 1995 Aug; 4(8):1439–45 (65 ref.)

GENETICS

Porphyromonas gingivalis: a proteinase/gene accounting audit. Potempa J, et al. **Trends Microbiol** 1995 Nov; 3(11):430–4 (30 ref.)

IMMUNOLOGY

ICE family proteases: mediators of all apoptotic cell death? Henkart PA. **Immunity** 1996 Mar;4(3):195–201 (52 ref.)

METABOLISM

Proenkephalin-processing enzymes in chromaffin granules: model for neuropeptide biosynthesis. Hook VY, et al. **Ann N Y Acad Sci** 1996 Mar 22;780:121–33 (22 ref.)
New concepts regarding the pathogenesis of amebiasis. Reed SL. **Clin Infect Dis** 1995 Oct;21 Suppl 2:S182–5 (39 ref.)
Cytokine-processing enzymes. Stopping the cuts. Dinarello CA, et al. **Curr Biol** 1995 Jun 1;5(6):587–90 (34 ref.)
Proteolysis. The proteasome: a protein-degrading organelle? Rubin DM, et al. **Curr Biol** 1995 Aug 1;5(8):854–8 (32 ref.)
Adenovirus endopeptidase and its role in virus infection. Weber JM. **Curr Top Microbiol Immunol** 1995;199 (Pt 1):227–35 (36 ref.)
The 20S/26S proteasomal pathway of protein degradation in muscle tissue. Dahlmann B, et al. **Mol Biol Rep** 1995; 21(1):57–62 (88 ref.)
Catalytic components of proteasomes and the regulation of proteinase activity. Rivett AJ, et al. **Mol Biol Rep** 1995; 21(1):35–41 (55 ref.)
Multicatalytic proteinase in fish muscle. Sánchez JJ, et al. **Mol Biol Rep** 1995;21(1):63–9 (31 ref.)
Relationships between proteasomes and RNA. Schmid HP, et al. **Mol Biol Rep** 1995;21(1):43–7 (46 ref.)
Proteolytic activity of proteasome on myofibrillar structures. Taylor RG, et al. **Mol Biol Rep** 1995;21(1):71–3 (19 ref.)

PHYSIOLOGY

Selective protein degradation: a journey's end within the proteasome. Jentsch S, et al. **Cell** 1995 Sep 22;82(6):881–4 (22 ref.)
Proteasome: from structure to function. Stock D, et al. **Curr Opin Biotechnol** 1996 Aug;7(4):376–85 (75 ref.)
Regulatory features of multicatalytic and 26S proteases. Hoffman L, et al. **Curr Top Cell Regul** 1996;34:1–32 (192 ref.)
Life, death, and the pursuit of apoptosis. White E. **Genes Dev** 1996 Jan 1;10(1):1–15 (191 ref.)
Mechanistic aspects of NF-kappa B regulation: the emerging role of phosphorylation and proteolysis. Finco TS, et al. **Immunity** 1995 Sep;3(3):263–72 (100 ref.)
Potyviral HC-Pro: a multifunctional protein. Maia IG, et al. **J Gen Virol** 1996 Jul;77 (Pt 7):1335–41 (51 ref.)
Proteasome and class I antigen processing and presentation. Belich MP, et al. **Mol Biol Rep** 1995;21(1):53–6 (39 ref.)
Proteasomes of the yeast S. cerevisiae: genes, structure and functions. Hilt W, et al. **Mol Biol Rep** 1995;21(1):3–10 (74 ref.)
Roles of proteasomes in cell growth. Ichihara A, et al. **Mol Biol Rep** 1995;21(1):49–52 (46 ref.)

CYSTIC DISEASE OF BREAST see **FIBROCYSTIC DISEASE OF BREAST**

CYSTIC DUCT

[Neoplasms of the cystic duct] Nakamura S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):265–9 (26 ref.) **(Jpn)**

[Confluence stone] Takagi I, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):397–99 (19 ref.) **(Jpn)**

[Mirizzi's syndrome, pseudo-lesion of bile duct due to the disorder of the cystic duct] Takifuji K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):146–8 (7 ref.) **(Jpn)**

[Cystic duct syndrome] Yamakawa T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):441–3 (10 ref.) **(Jpn)**

ABNORMALITIES

[Duplication of extra-hepatic biliary duct (duplication of common hepatic duct, duplication of cystic duct, duplication of common bile duct)] Nakagawara G, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):111–3 (15 ref.) **(Jpn)**

[Low junction of the cystic duct] Nakagawara G, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):136–8 (13 ref.) **(Jpn)**

INJURIES

Cystic duct perforation as a complication of endoscopic stone extraction. Manbeck MA, et al. **Am J Gastroenterol** 1996 Mar;91(3):592–4 (12 ref.)

CYSTIC FIBROSIS

see related
CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR

Cystic fibrosis: pathogenesis, pulmonary infection, and treatment. Moss RB. **Clin Infect Dis** 1995 Oct;21(4):839–49; quiz 850–1 (27 ref.)
Pregnancy in patients with cystic fibrosis. Hilman BC, et al. **Clin Obstet Gynecol** 1996 Mar;39(1):70–86 (54 ref.)
Cystic fibrosis. Gastrointestinal complications and gene therapy. Shalon LB, et al. **Pediatr Clin North Am** 1996 Feb;43(1):157–96 (147 ref.)
[Cystic fibrosis in adults: the new approach to an old disease] Lázaro MT, et al. **Rev Clin Esp** 1995 Sep;195(9):633–40 (95 ref.) **(Spa)**

COMPLICATIONS

Cystic fibrosis and the sinonasal tract. Batsakis JG, et al. **Ann Otol Rhinol Laryngol** 1996 Apr;105(4):329–30 (9 ref.)
Cystic fibrosis and the pseudomonads. Wright KC. **Br J Biomed Sci** 1996 Jun;53(2):140–5 (51 ref.)
Pulmonary complications of cystic fibrosis in adults. Shah RM, et al. **Crit Rev Diagn Imaging** 1995;36(6):441–77 (46 ref.)
Drug management of noninfective complications of cystic fibrosis. Sanchez I, et al. **Drugs** 1995 Oct;50(4):626–35 (40 ref.)
The environmental risk factors associated with medical and dental equipment in the transmission of Burkholderia (Pseudomonas) cepacia in cystic fibrosis patients. Pankhurst CL, et al. **J Hosp Infect** 1996 Apr;32(4):249–55 (32 ref.)
Role of corticosteroids in cystic fibrosis lung disease. Balfour-Lynn IM, et al. **J R Soc Med** 1996;89 Suppl 27:8–13 (37 ref.)
Liver transplantation for hepatic cirrhosis in cystic fibrosis. Noble-Jamieson G, et al. **J R Soc Med** 1996;89 Suppl 27:31–7 (24 ref.)
Subclinical colonic thickening. Oades PJ, et al. **J R Soc Med** 1996;89 Suppl 27:24–30 (44 ref.)
Cancer risk in patients with cystic fibrosis: the European data. CF/CSG Group. Schöni MH, et al. **J R Soc Med** 1996; 89 Suppl 27:38–43 (4 ref.)
Syringomyelia and chiari malformation presenting as scoliosis in cystic fibrosis. Rusakow LS, et al. **Pediatr Pulmonol** 1995 May;19(5):317–8 (10 ref.)
Commentary: unusual manifestations of aspergillosis [comment] Denning DW. **Thorax** 1995 Jul;50(7):812–3 (23 ref.) Comment on: Thorax 1995 Jul;50(7):805–6. Comment on: Thorax 1995 Jul;50(7):807–8. Comment on: Thorax 1995 Jul;50(7):809–10. Comment on: Thorax 1995 Jul;50(7):810–1.
Pseudomonas aeruginosa, mucoidy and the chronic infection phenotype in cystic fibrosis. Deretic V, et al. **Trends Microbiol** 1995 Sep;3(9):351–6 (59 ref.)
[Cystic fibrosis and Burkholderia (formerly Pseudomonas) cepacia: an increasing clinical and psychosocial problem] Horrevorts AM, et al. **Ned Tijdschr Geneeskd** 1995 Nov 18;139(46):2343–6 (31 ref.) **(Dut)**
[Pathogenesis and diagnosis of bacterial airway infections in patients with cystic fibrosis] Möller AV, et al. **Ned Tijdschr Geneeskd** 1995 Nov 18;139(46):2346–9 (28 ref.) **(Dut)**
[Prevention and therapy of airway infections in patients with cystic fibrosis] Möller AV, et al. **Ned Tijdschr Geneeskd** 1995 Nov 18;139(46):2350–3 (26 ref.) **(Dut)**
[Cystic fibrosis in adults] Durieu I, et al. **Presse Med** 1995 Dec 16–23;24(39):1882–7 (23 ref.) (Eng. Abstr.) **(Fre)**
[Bronchopulmonary aspergillosis and mucoviscidosis] Baculard A, et al. **Rev Pneumol Clin** 1995;51(3):160–3 (29 ref.) (Eng. Abstr.) **(Fre)**
[Digestive disease in cystic fibrosis] Carrasco S, et al. **Gastroenterol Hepatol** 1996 Jun-Jul;19(6):320–5 (37 ref.) **(Spa)**

DIAGNOSIS

Preimplantation genetic diagnosis of cystic fibrosis (delta F508). Ao A, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Mar;65(1):7–10 (23 ref.)
Shwachman-Diamond syndrome: the clinical imitator of cystic fibrosis. Lozada-Muñoz L, et al. **P R Health Sci J** 1995 Dec;14(4):275–7 (15 ref.)
[Celiac disease and cystic fibrosis: a rare association] López Rodríguez MJ, et al. **An Esp Pediatr** 1996 Apr;44(4):383–4 (16 ref.) **(Spa)**

DIET THERAPY

Nutritional management of cystic fibrosis. MacDonald A. **Arch Dis Child** 1996 Jan;74(1):81–7 (71 ref.)

DRUG THERAPY

Effectiveness of bronchodilators in cystic fibrosis. Cropp GJ. **Am J Med** 1996 Jan 29;100(1A):19S–29S (38 ref.)
Fibrosing colonopathy in cystic fibrosis. Smyth RL. **Arch Dis Child** 1996 May;74(5):464–8 (24 ref.)
Dornase alfa for cystic fibrosis. **Drug Ther Bull** 1995 Feb; 33(2):15–6 (5 ref.)
DNase trials in cystic fibrosis. Hodson ME, et al. **Eur Respir J** 1995 Oct;8(10):1786–91 (26 ref.)
Inhalation of antibiotics in cystic fibrosis. Touw DJ, et al. **Eur Respir J** 1995 Sep;8(9):1594–604 (65 ref.)
Aerosolized dornase alpha (rhDNase) in cystic fibrosis. Bates RD, et al. **J Clin Pharm Ther** 1995 Dec;20(6):313–5 (19 ref.)
Use of pancreatic enzyme supplements for patients with cystic fibrosis in the context of fibrosing colonopathy. Consensus Committee. Borowitz DS, et al. **J Pediatr** 1995 Nov;127(5):681–4 (22 ref.)
Fibrosing colonopathy: recent advances. Dodge JA. **J R Soc Med** 1996;89 Suppl 27:19–23 (18 ref.)
Nebulizers in cystic fibrosis. Hambleton G, et al. **J R Soc Med** 1996;89 Suppl 27:14–8 (4 ref.)
New treatment strategies in cystic fibrosis: rhDNase. Shah PL, et al. **Monaldi Arch Chest Dis** 1996 Apr;51(2):125–9 (27 ref.)
Dornase alfa: a new option in the management of cystic fibrosis. Witt DM, et al. **Pharmacotherapy** 1996 Jan-Feb; 16(1):40–8 (24 ref.)
[Gene therapy of mucoviscidosis with liposomes] Lehn P, et al. **Arch Pediatr** 1996;3 Suppl 1:88s–92s (20 ref.) **(Fre)**
[New pharmacological approaches: rhDNase] Tournier G, et al. **Rev Pneumol Clin** 1995;51(3):193–200 (40 ref.) (Eng. Abstr.) **(Fre)**

EPIDEMIOLOGY

Cystic fibrosis in Russia: background and a model for future collaboration with the West. Kapranov N, et al. **J R Soc Med** 1996;89 Suppl 27:44–7 (0 ref.)
[Epidemiological data. Neonatal and prenatal screening] Farriaux JP, et al. **Rev Pneumol Clin** 1995;51(3):109–14 (41 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Cystic fibrosis: basic chemical and cellular mechanisms. Stern M, et al. **Br J Hosp Med** 1996 Mar 6–19;55(5):237–40 (22 ref.)

CYSTIC FIBROSIS

Preimplantation genetic diagnosis of cystic fibrosis (delta F508). Ao A, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Mar;65(1):7–10 (23 ref.)

Gene therapy for cystic fibrosis: challenges and future directions. Wilson JM. **J Clin Invest** 1995 Dec; 96(6):2547–54 (85 ref.)

Gene therapy for cystic fibrosis. Alton EW. **J Inherit Metab Dis** 1995;18(4):501–7 (17 ref.)

Carrier screening in the community. Brock DJ. **J Inherit Metab Dis** 1995;18(4):525–32 (12 ref.)

Development of mouse models for cystic fibrosis. Dorin JR. **J Inherit Metab Dis** 1995;18(4):495–500 (24 ref.)

Cystic fibrosis: five years beyond the gene. Porteous DJ. **J Inherit Metab Dis** 1995;18(4):491–4 (16 ref.)

Treatment of cystic fibrosis based on understanding CFTR. Smith AE. **J Inherit Metab Dis** 1995;18(4):508–16 (25 ref.)

New pharmaceutical approaches to the treatment of cystic fibrosis [comment] Delaney SJ, et al. **Nat Med** 1996 Apr; 2(4):392–3 (14 ref.) Comment on: Nat Med 1996 Apr;2(4):467–9.

Cystic fibrosis: genetics and clinical applications. Corrado G, et al. **Riv Eur Sci Med Farmacol** 1995 Mar–Jun; 17(2–3):67–76 (89 ref.)

Inherited liver diseases in adults. Kumar A, et al. **West J Med** 1995 Oct;163(4):382–6 (20 ref.)

Cystic fibrosis in adults. From researcher to practitioner [see comments] Marelich GP, et al. **West J Med** 1996 Apr; 164(4):321–34 (147 ref.) Comment in: West J Med 1996 Apr;164(4):361–2.

[Molecular basis of cystic fibrosis and congenital bilateral agenesis of vas deferens] Bienvenu T, et al. **Contracept Fertil Sex** 1996 Jun;24(6):495–500 (31 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Further evidence for multitopological localization of mammalian porin (VDAC) in the plasmalemma forming part of a chloride channel complex affected in cystic fibrosis and encephalomyopathy. Reymann S, et al. **Biochem Mol Med** 1995 Apr;54(2):75–87 (74 ref.)

Cystic fibrosis: five years beyond the gene. Porteous DJ. **J Inherit Metab Dis** 1995;18(4):491–4 (16 ref.)

[Mucoviscidosis and nutrition] Munck A. **Rev Pneumol Clin** 1995;51(3):145–50 (28 ref.) (Eng. Abstr.) **(Fre)**

MICROBIOLOGY

Characteristics of Bordetella hinzii strains isolated from a cystic fibrosis patient over a 3-year period. Funke G, et al. **J Clin Microbiol** 1996 Apr;34(4):966–9 (17 ref.)

Heat-shock proteins in host–pathogen interactions: implications for cystic fibrosis. Polla BS, et al. **Trends Microbiol** 1995 Oct;3(10):392–6 (51 ref.)

PATHOLOGY

[Congenital cystic fibrosis] Sakai T. **Ryoikibetsu Shokogun Shirizu** 1995;(8):370 (1 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Reproductive health in young people with cystic fibrosis. Sawyer SM. **Curr Opin Pediatr** 1995 Aug;7(4):376–80 (46 ref.)

Development of mouse models for cystic fibrosis. Dorin JR. **J Inherit Metab Dis** 1995;18(4):495–500 (24 ref.)

[CFTR protein and molecular mechanisms of pulmonary involvement in cystic fibrosis] Chinet T. **Rev Pneumol Clin** 1995;51(3):122–9 (87 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

[Outcome of cystic fibrosis children screened at birth] Brouard J, et al. **Rev Mal Respir** 1996;13(1):79–80 (21 ref.) **(Fre)**

PSYCHOLOGY

Family and parental functioning in cystic fibrosis. Ievers CE, et al. **J Dev Behav Pediatr** 1996 Feb;17(1):48–55 (45 ref.)

RADIOGRAPHY

Radiology of the central airways. Worrell JA. **Otolaryngol Clin North Am** 1995 Aug;28(4):701–20 (23 ref.)

REHABILITATION

[Kinesitherapy for mucoviscidosis] Wils J, et al. **Rev Pneumol Clin** 1995;51(3):164–74 (71 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Lung transplantation for cystic fibrosis: special considerations. Kotloff RM, et al. **Chest** 1996 Mar; 109(3):787–98 (74 ref.)

Sinusitis in patients with cystic fibrosis. Hui Y, et al. **Eur Arch Otorhinolaryngol** 1995;252(4):191–6 (44 ref.)

[Pulmonary and cardiopulmonary transplantation in mucoviscidosis] Haloun A, et al. **Rev Pneumol Clin** 1995; 51(3):207–14 (47 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Treatment of cystic fibrosis in adults. Hamer L, et al. **Am Fam Physician** 1996 Sep 15;54(4):1291–7 (23 ref.)

Cystic fibrosis: adult clinical aspects. Conway SP. **Br J Hosp Med** 1996 Mar 6–19;55(5):248–52 (20 ref.)

Gene therapy for cystic fibrosis: current issues. Southern KW. **Br J Hosp Med** 1996 Apr 17–30;55(8):495–9 (19 ref.)

Cystic fibrosis: paediatric aspects. Wallis C. **Br J Hosp Med** 1996 Mar 6–19;55(5):241–7 (32 ref.)

Gene therapy for cystic fibrosis. Rosenfeld MA, et al. **Chest** 1996 Jan;109(1):241–52 (103 ref.)

Gene therapy for cystic fibrosis in humans by liposome-mediated DNA transfer: the production of resources and the regulatory process. Caplen NJ, et al. **Gene Ther** 1994 Mar;1(2):139–47 (21 ref.)

Gene therapy for cystic fibrosis: challenges and future directions. Wilson JM. **J Clin Invest** 1995 Dec; 96(6):2547–54 (85 ref.)

Gene therapy for cystic fibrosis. Alton EW. **J Inherit Metab Dis** 1995;18(4):501–7 (17 ref.)

Treatment of cystic fibrosis based on understanding CFTR. Smith AE. **J Inherit Metab Dis** 1995;18(4):508–16 (25 ref.)

Transferring to adult health care: experiences of adolescents with cystic fibrosis. Russell MT, et al. **J Pediatr Nurs** 1996 Aug;11(4):262–8 (44 ref.)

Towards gene therapy for cystic fibrosis. Alton EW. **J Pharm Pharmacol** 1995 May;47(5):351–4 (18 ref.)

Therapeutic implications of recent advances in cystic fibrosis. White KR, et al. **MCN Am J Matern Child Nurs** 1995 Nov–Dec;20(6):304–8 (32 ref.)

Management of pulmonary disease in patients with cystic fibrosis. Ramsey BW. **N Engl J Med** 1996 Jul 18; 335(3):179–88 (96 ref.)

Cystic fibrosis: transition from paediatric to adult physician's care [editorial] Landau LI. **Thorax** 1995 Oct;50(10):1031–2 (6 ref.)

Cystic fibrosis therapy—where we are and how we got there [editorial; comment] Gruenert DC. **West J Med** 1996 Apr; 164(4):361–2 (14 ref.) Comment on: West J Med 1996 Apr;164(4):321–34.

[Gene therapy for hereditary and acquired human diseases] Mehtali M, et al. **Ann Endocrinol (Paris)** 1995;56(6):571–4 (15 ref.) (Eng. Abstr.) **(Fre)**

[Mucoviscidosis: in children and adults] Hubert D, et al. **Rev Pneumol Clin** 1995;51(3):137–44 (33 ref.) (Eng. Abstr.) **(Fre)**

[Gene therapy in mucoviscidosis] Schatz C, et al. **Rev Pneumol Clin** 1995;51(3):201–6 (33 ref.) (Eng. Abstr.) **(Fre)**

[Therapy of cystic fibrosis in adulthood—current and future management] Bargon J, et al. **Pneumologie** 1995 Nov; 49(11):573–83 (98 ref.) **(Ger)**

[New therapeutic modalities for pulmonary disease in cystic fibrosis] Virgilis D, et al. **Harefuah** 1995 Dec 15; 129(12):569–72 (36 ref.) **(Heb)**

CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR

ADMINISTRATION & DOSAGE

[Gene therapy of mucoviscidosis with liposomes] Lehn P, et al. **Arch Pediatr** 1996;3 Suppl 1:88s–92s (20 ref.) **(Fre)**

GENETICS

Cystic fibrosis: five years beyond the gene. Porteous DJ. **J Inherit Metab Dis** 1995;18(4):491–4 (16 ref.)

Treatment of cystic fibrosis based on understanding CFTR. Smith AE. **J Inherit Metab Dis** 1995;18(4):508–16 (25 ref.)

New pharmaceutical approaches to the treatment of cystic fibrosis [comment] Delaney SJ, et al. **Nat Med** 1996 Apr; 2(4):392–3 (14 ref.) Comment on: Nat Med 1996 Apr;2(4):467–9.

[Gene therapy of mucoviscidosis with liposomes] Lehn P, et al. **Arch Pediatr** 1996;3 Suppl 1:88s–92s (20 ref.) **(Fre)**

METABOLISM

Cystic fibrosis: five years beyond the gene. Porteous DJ. **J Inherit Metab Dis** 1995;18(4):491–4 (16 ref.)

Treatment of cystic fibrosis based on understanding CFTR. Smith AE. **J Inherit Metab Dis** 1995;18(4):508–16 (25 ref.)

PHYSIOLOGY

[CFTR protein and molecular mechanisms of pulmonary involvement in cystic fibrosis] Chinet T. **Rev Pneumol Clin** 1995;51(3):122–9 (87 ref.) (Eng. Abstr.) **(Fre)**

CYSTICERCOSIS

Neurocysticercosis—an update. Maiti B. **J Assoc Physicians India** 1995 Jul;43(7):477–82 (30 ref.)

Recent developments in cestode research. Webbe G. **Trans R Soc Trop Med Hyg** 1995 Jul–Aug;89(4):345–6, 353 (35 ref.)

DIAGNOSIS

Distinctive serial magnetic resonance changes in a young woman with rapidly evolved neurocysticercosis, with positron emission tomography results. Nagayama M, et al. **J Neuroimaging** 1996 Jul;6(3):198–201 (15 ref.)

[Neurocysticercosis] Brouwer RE, et al. **Ned Tijdschr Geneeskd** 1995 Dec 30;139(52):2721–5 (45 ref.) **(Dut)**

[Neurocysticercosis: pediatric aspects] Grill J, et al. **Arch Pediatr** 1996 Apr;3(4):360–8 (53 ref.) (Eng. Abstr.) **(Fre)**

[A case of cysticercosis of the third ventricle] El'iashevich GP. **Lik Sprava** 1995 Jul–Aug;(7–8):131–2 (9 ref.) **(Rus)**

EPIDEMIOLOGY

Detection, screening and community epidemiology of taeniid cestode zoonoses: cystic echinococcosis, alveolar echinococcosis and neurocysticercosis. Craig PS, et al. **Adv Parasitol** 1996;38:169–250 (365 ref.)

[The prevalence of Taenia solum taeniasis and cysticercosis] Bessonov AS. **Med Parazitol (Mosk)** 1995 Apr–Jun; (2):47–51 (43 ref.) **(Rus)**

PARASITOLOGY

Cysticercosis. Sotelo J, et al. **Curr Clin Top Infect Dis** 1996; 16:240–59 (109 ref.)

PATHOLOGY

[Occurrence of cysticercosis in autopsies performed in Uberlandia, Minas Gerais, Brazil] Costa-Cruz JM, et al. **Arq Neuropsiquiatr** 1995 Jun;53(2):227–32 (25 ref.) (Eng. Abstr.) **(Por)**

PHYSIOPATHOLOGY

Magnetoencephalographic features in neurocysticercosis. Morioka T, et al. **Surg Neurol** 1996 Feb;45(2):176–81; discussion 181–2 (46 ref.)

PREVENTION & CONTROL

Detection, screening and community epidemiology of taeniid cestode zoonoses: cystic echinococcosis, alveolar echinococcosis and neurocysticercosis. Craig PS, et al. **Adv Parasitol** 1996;38:169–250 (365 ref.)

SURGERY

Tremor as the result of shunt obstruction: four patients with cysticercosis and secondary parkinsonism: report of four cases. Keane JR. **Neurosurgery** 1995 Sep;37(3):520–2 (3 ref.)

CYSTINE

Cystine knots. Isaacs NW. **Curr Opin Struct Biol** 1995 Jun; 5(3):391–5 (22 ref.)

ANALYSIS

Oxidative folding of cystine-rich peptides vs regioselective cysteine pairing strategies. Moroder L, et al. **Biopolymers** 1996;40(2):207–34 (206 ref.)

[The dissolution of cystine lithiasis with n-acetylcysteine] Benítez Navio J, et al. **Arch Esp Urol** 1995 Nov;48(9):944–8 (13 ref.) (Eng. Abstr.) **(Spa)**

CHEMISTRY

Structure of IgA: facts and gaps in our data on disulfide bonds. Biewenga J. **Adv Exp Med Biol** 1995;371A:575–9 (18 ref.)

CYSTINE ARYLAMIDASE see **OXYTOCINASE**

CYSTINOSIS

[Lysosomal membrane transport disorders—cystinosis and sialic acid storage disorders (Salla disease, ISSD)] Yano T, et al. **Nippon Rinsho** 1995 Dec;53(12):3068–71 (5 ref.) (Eng. Abstr.) **(Jpn)**

[Cystinosis] Wada Y. **Ryoikibetsu Shokogun Shirizu** 1995; (8):337–40 (8 ref.) **(Jpn)**

DRUG THERAPY

Recent advances in the treatment of cystinosis. Schneider JA, et al. **J Inherit Metab Dis** 1995;18(4):387–97 (18 ref.)

GENETICS

Cystinosis. Thoene JG. **J Inherit Metab Dis** 1995;18(4):380–6 (17 ref.)

METABOLISM

Cystinosis. Thoene JG. **J Inherit Metab Dis** 1995;18(4):380–6 (17 ref.)

CYSTINURIA

GENETICS

[Advancements in the genetics of cystinuria] Rousaud F, et al. **Ann Urol (Paris)** 1995;29(6–7):346–50 (40 ref.) (Eng. Abstr.) **(Fre)**

CYSTITIS

Eosinophilic granulomatous cystitis in children. Ladocsi LT, et al. **Urology** 1995 Nov;46(5):732–5 (22 ref.)

[Chronic cystitis] Danilenko VR. **Urol Nefrol (Mosk)** 1995 Jul–Aug;(4):49–53 (85 ref.) **(Rus)**

CHEMICALLY INDUCED

Intravesical thiotepa–induced eosinophilic cystitis. Choe JM, et al. **Urology** 1995 Nov;46(5):729–31 (15 ref.)

[Bladder retraction, a complication of chemoprophylaxis of superficial bladder cancer using intravesical mitomycin C. Apropos of a case and review of the literature] Punga–Maole ML, et al. **Prog Urol** 1995 Sep;5(4):580–5 (39 ref.) (Eng. Abstr.) **(Fre)**

CLASSIFICATION

[Eosinophilic cystitis: a single anatomopathologic entity and three different presentation forms. Proposed classification] Server Pastor G, et al. **Actas Urol Esp** 1996 Feb; 20(2):155–61 (37 ref.) (Eng. Abstr.) **(Spa)**

COMPLICATIONS

[Spontaneous bladder perforation secondary to bacterial cystitis. Cause of acute abdomen in diabetic elderly] Rodríguez Rodríguez A, et al. **Actas Urol Esp** 1995 May; 19(5):393–7 (14 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

[Female urology: new advances in 1995] Chassagne S, et al. **J Urol (Paris)** 1996;102(1):33–9 (32 ref.) **(Fre)**

MICROBIOLOGY

[Treatment of cystitis in women] Lobel B. **Presse Med** 1995 Oct 28;24(32):1527–9 (9 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

[Proliferative cystitis forming tumorous lesion: a case report] Inaba Y, et al. **Hinyokika Kiyo** 1995 Aug;41(8):617–20 (17 ref.) (Eng. Abstr.) **(Jpn)**

PREVENTION & CONTROL

Efficacy of mesna for prevention of hemorrhagic cystitis after high–dose cyclophosphamide therapy. Haselberger MB, et al. **Ann Pharmacother** 1995 Sep;29(9):918–21 (21 ref.)

Oral administration of mesna with ifosfamide. Goren MP. **Semin Oncol** 1996 Jun;23(3 Suppl 6):91–6 (51 ref.)

[Prevention of frequent cystitis in otherwise healthy women] Baerheim A, et al. **Tidsskr Nor Laegeforen** 1996 Mar 10; 116(7):841–3 (50 ref.) (Eng. Abstr.) **(Nor)**

CYSTITIS, CHRONIC INTERSTITIAL see **CYSTITIS, INTERSTITIAL**

CYSTITIS, INTERSTITIAL

Interstitial cystitis—still an enigma after 80 years. Toozs–Hobson P, et al. **Br J Obstet Gynaecol** 1996 Jul; 103(7):621–4 (44 ref.)

Interstitial cystitis. When urgency and frequency mean more than routine inflammation. Mobley DF, et al. **Postgrad Med** 1996 May;99(5):201–4, 207–8, 214 (16 ref.)

[Diagnostic and therapeutic approaches to interstitial cystitis] Golomb J. **Harefuah** 1996 Feb 15;130(4):267–71 (43 ref.) **(Heb)**

DIAGNOSIS

[Interstitial cystitis: new concepts on etiology and diagnosis] Haab F, et al. **Prog Urol** 1995 Nov;5(5):653–60 (73 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

[A case of lupus cystitis successfully treated with corticosteroid accompanied by gastrointestinal symptoms] Sato M, et al. **Ryumachi** 1995 Oct;35(5):814–20 (38 ref.) (Eng. Abstr.) **(Jpn)**

EPIDEMIOLOGY

Lupus cystitis in the Japanese [editorial; comment] Koike T, et al. **Intern Med** 1996 Feb;35(2):87–8 (14 ref.) Comment on: Intern Med 1996 Feb;35(2):155–8.

ETIOLOGY

[Interstitial cystitis: new concepts on etiology and diagnosis] Haab F, et al. **Prog Urol** 1995 Nov;5(5):653–60 (73 ref.) (Eng. Abstr.) **(Fre)**

VETERINARY

Interstitial cystitis in cats. Buffington CA, et al. **Vet Clin North Am Small Anim Pract** 1996 Mar; 26(2):317–26 (36 ref.)

CYSTOCELE see **BLADDER DISEASES**

CYSTOSARCOMA PHYLLODES see **PHYLLODES TUMOR**

CYSTOSTOMY

METHODS

[Lich–Gregoir ureteroneocystostomy: experience of a North–American pediatric center] Leblanc B, et al. **Ann Chir** 1995;49(8):685–8 (17 ref.) (Eng. Abstr.) **(Fre)**

CYSTS

Polycystic liver disease. Torres VE. **Contrib Nephrol** 1995; 115:44–52 (31 ref.)

[Cystic ectasia of the rete testis: apropos of a case] Poddevin F, et al. **J Urol (Paris)** 1996;102(2):92–4 (10 ref.) (Eng. Abstr.) **(Fre)**

[Simple hepatic cyst] Kodama M, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):132–5 (23 ref.) **(Jpn)**

[Retention cyst of the gallbladder] Yamada M, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):456–8 (15 ref.) **(Jpn)**

CLASSIFICATION

[Benign polycystic liver disease] Kuronuma Y, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):144–6 (17 ref.) **(Jpn)**

[Liver cysts (cystic liver diseases)] Ohmoto K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):136–43 (40 ref.) **(Jpn)**

COMPLICATIONS

Obstructive jaundice due to multiple hepatic peribiliary cysts. Stevens W, et al. **Am J Gastroenterol** 1996 Jan;91(1):155–7 (5 ref.)

Duodenal duplication cyst with massive gastrointestinal bleeding. Rubin RB, et al. **J Clin Gastroenterol** 1995 Jul; 21(1):72–4 (20 ref.)

Autosomal dominant polycystic liver disease as an etiology for hemoperitoneum during CCPD. Rutecki GW, et al. **Perit Dial Int** 1995 Oct–Dec;15(8):367–9 (11 ref.)

A symptomatic testicular cyst in a patient with von Hippel–Lindau disease. Brown JA, et al. **Urology** 1996 Sep; 48(3):494–5 (9 ref.)

Cystic dysplasia of the testis: an unusual cause of a pediatric scrotal mass. Zaragoza MR, et al. **Urology** 1996 Feb; 47(2):244–7 (12 ref.)

[Pulmonary infection due to Mycobacterium szulgai associated with multiple bullous disease of the lung] Mori K, et al. **Kekkaku** 1995 Sep;70(9):511–6 (12 ref.) (Eng. Abstr.) **(Jpn)**

[Infected liver cysts] Kiryu Y, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):94–8 (19 ref.) **(Jpn)**

[Inflammatory hepatic cyst] Kurumi Y, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):83–6 (20 ref.) **(Jpn)**

CONGENITAL

Congenital vallecular cyst: a cause of failure to thrive. Oluwole M. **Br J Clin Pract** 1996 Apr–May;50(3):170 (9 ref.)

Prostatic cyst. An unusual but important finding in male urogenital dysfunction. Zhu JP, et al. **Scand J Urol Nephrol** 1995 Sep;29(3):345–9 (30 ref.)

[Clinical and surgical aspects of cysts and fistulae of the nose in children. Apropos of 37 cases] Ducroz V, et al. **Ann Otolaryngol Chir Cervicofac** 1995;112(5):218–24 (33 ref.) (Eng. Abstr.) **(Fre)**

[Corpus callosum agenesis and parasagittal interhemispheric cyst] Doffe L, et al. **J Radiol** 1996 Jun;77(6):427–30 (15 ref.) (Eng. Abstr.) **(Fre)**

[Polycystic liver disease] Furukawa R, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):102–5 (20 ref.) **(Jpn)**

[Congenital liver cysts (solitary and multiple)] Kakita A, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):125–7 (18 ref.) **(Jpn)**

[Ciliated hepatic foregut cyst and hepatic foregut cyst] Kakita A, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):128–31 (19 ref.) **(Jpn)**

[Fibropolycystic disease] Mizuta T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):120–4 (20 ref.) **(Jpn)**

[Fibropolycystic disease of the liver] Okazaki K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):90–3 (13 ref.) **(Jpn)**

DIAGNOSIS

Neuroepithelial cyst of the posterior fossa: two case reports with radiologic–pathologic correlation. Goh RH, et al. **Can Assoc Radiol J** 1996 Apr;47(2):126–31 (12 ref.)

Cyst of the medial meniscus: observation of two cases. Tigani D, et al. **Chir Organi Mov** 1995 Oct–Dec;80(4):449–52 (14 ref.) **(Eng, Ita)**

An unusual presentation of intestinal duplication with a literature review. Otter MI, et al. **Dig Dis Sci** 1996 Mar; 41(3):627–9 (14 ref.)

Scoliosis as the first sign of a cystic spinal cord lesion. Samuelsson L, et al. **Eur Spine J** 1995;4(5):284–90 (41 ref.)

Ganglia and cysts around joints. Steiner E, et al. **Radiol Clin North Am** 1996 Mar;34(2):395–425, xi–xii (127 ref.)

Cystic adventitial disease of the popliteal artery—a case of young boy. Ishibashi S, et al. **Tohoku J Exp Med** 1995 Jul;176(3):173–80 (20 ref.)

[Imaging of ciliated hepatic or biliary cysts. 4 cases] Benlolo D, et al. **Gastroenterol Clin Biol** 1996;20(5):497–501 (10 ref.) (Eng. Abstr.) **(Fre)**

[Amniocentesis and single choroid plexus cyst. Current status] Morales–Roselló J, et al. **Rev Fr Gynecol Obstet** 1995 Oct;90(10):412–6 (30 ref.) (Eng. Abstr.) **(Fre)**

[Hemospermia associated with a urogenital sinus cyst: diagnostic contribution of MRI. Report a case] Cinque T, et al. **Radiol Med (Torino)** 1995 Dec;90(6):840–2 (8 ref.) **(Ita)**

[Solitary non–parasitic liver cyst] Kuronuma Y, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):113–5 (9 ref.) **(Jpn)**

[Cystic pyeloureteritis. A review of the literature in the period of 1946–1994 and a report of a new case] Romero Pérez P, et al. **Actas Urol Esp** 1995 Mar;19(3):252–7 (20 ref.) (Eng. Abstr.) **(Spa)**

[Retroperitoneal cystic masses associated with an elevation of serum amylase] Azuara Muslera MV, et al. **Rev Clin Esp** 1995 Oct;195(10):723–5 (20 ref.) **(Spa)**

EMBRYOLOGY

Fetal porencephaly: a review of etiology, diagnosis, and prognosis. Eller KM, et al. **Obstet Gynecol Surv** 1995 Sep; 50(9):684–7 (14 ref.)

ETIOLOGY

Subcutaneous pretibial cyst formation associated with anterior cruciate ligament allografts: a report of four cases and literature review. Victoroff BN, et al. **Arthroscopy** 1995 Aug;11(4):486–94 (25 ref.)

Traumatic pneumatoceles in an infant: case report and review of the literature. Schimpl G, et al. **Eur J Pediatr Surg** 1996 Apr;6(2):104–6 (14 ref.)

A complex cystic dysplastic urogenital anomaly—an odd presentation. Singh G, et al. **Int Urol Nephrol** 1995; 27(6):687–90 (5 ref.)

Inflammatory pseudocyst associated with trisomy 21 and Hirschsprung's disease. DuBois JJ, et al. **Mil Med** 1995 Sep;160(9):477–9 (28 ref.)

[Traumatic hepatic cyst] Kurumi Y, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):87–9 (17 ref.) **(Jpn)**

[Parasitic cyst of the liver] Ohmoto K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):109–12 (18 ref.) **(Jpn)**

[Hepatic biloma] Watanabe H, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):106–8 (22 ref.) **(Jpn)**

PATHOLOGY

Gastric gland heterotopia with extensive lymphoid stroma: a gastric lymphoepithelial cyst. Delvaux S, et al. **Am J Gastroenterol** 1996 Mar;91(3):599–601 (17 ref.)

Postirradiation colitis cystica profunda. Case report and literature review. Ng WK, et al. **Arch Pathol Lab Med** 1995 Dec;119(12):1170–3 (17 ref.)

Testicular cysts: a case report and review of a recent Tripler experience. Gange SN, et al. **Hawaii Med J** 1995 Jul; 54(7):678–9 (15 ref.)

The Ivemark syndrome: prenatal diagnosis of an uncommon cystic renal lesion with heterogeneous associations. Larson RS, et al. **Pediatr Nephrol** 1995 Oct;9(5):594–8 (16 ref.)

Solitary nonparasitic cysts of the liver: the Boston Children's Hospital experience. Donovan MJ, et al. **Pediatr Pathol Lab Med** 1995 May–Jun;15(3):419–28 (30 ref.)

Cystic dysplasia of the testis: a report of three cases and review of the literature. Loo CK, et al. **Pediatr Pathol Lab Med** 1995 Nov–Dec;15(6):885–93 (9 ref.)

Unilateral polycystic (dysgenetic) disease of the parotid gland. Ortiz–Hidalgo C, et al. **South Med J** 1995 Nov; 88(11):1173–5 (9 ref.)

[Pseudocystic ureteritis. Apropos of a case] Joual A, et al. **Ann Urol (Paris)** 1995;29(5):284–6 (7 ref.) (Eng. Abstr.) **(Fre)**

[Our experience with parotid cysts] Assimakopoulos D, et al. **Rev Stomatol Chir Maxillofac** 1995;96(5):313–6 (21 ref.) (Eng. Abstr.) **(Fre)**

[Hepatic hilar cyst with or without cirrhosis] Fukusato T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):77–9 (11 ref.) **(Jpn)**

[Intra–hepatic biliary cyst] Motoo Y, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):80–2 (12 ref.) **(Jpn)**

[Cystic hepatic neoplasm] Ohmoto K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):116–9 (20 ref.) **(Jpn)**

[Hepatic ciliated cyst] Ohmoto K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):99–101 (15 ref.) **(Jpn)**

[Epithelial–cystic nevus of the conjunctiva (Parinaud's dermo–epithelioma)] Cernea P, et al. **Oftalmologia** 1996 Jan–Mar;40(1):58–62 (8 ref.) (Eng. Abstr.) **(Rum)**

[A giant adrenal mass: the anatomicopathological surprise finding] Mármol Navarro S, et al. **Arch Esp Urol** 1995 Nov;

48(9):949–51 (8 ref.) (Eng. Abstr.) **(Spa)**
[A cystic lymphoepithelial lesion of the parotid in HIV-1-infected patients] Calderón-Osuna E, et al. **Med Clin (Barc)** 1995 Oct 14;105(12):461–3 (10 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

Cervical ventral epithelial cyst treated by anterior corpectomy—case report. Fujimoto K, et al. **Neurol Med Chir (Tokyo)** 1996 May;36(5):321–5 (14 ref.)

RADIOGRAPHY

[Esophageal duplications: role of computed tomography. Apropos of 2 cases] Jouini S, et al. **Ann Radiol (Paris)** 1995; 38(7–8):418–25 (22 ref.) (Eng. Abstr.) **(Fre)**
[A case of intramural cyst in the gallbladder] Fujisawa T, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Sep; 92(9):1309–14 (14 ref.) **(Jpn)**

SURGERY

Laparoscopic fenestration of giant posterolateral liver cyst. Watson DI, et al. **J Laparoendosc Surg** 1995 Aug;5(4):255–7 (7 ref.)
Cervical ventral epithelial cyst treated by anterior corpectomy—case report. Fujimoto K, et al. **Neurol Med Chir (Tokyo)** 1996 May;36(5):321–5 (14 ref.)
Arteriovenous malformation associated with a large cyst—case report. Hatashita S, et al. **Neurol Med Chir (Tokyo)** 1995 Jun;35(6):377–9 (8 ref.)
[Orthotopic liver transplantation in therapy of advanced polycystic liver disease] Klupp J, et al. **Chirurg** 1996 May; 67(5):515–21 (25 ref.) (Eng. Abstr.) **(Ger)**
[Urethral parameatal cysts. Report of two cases and review of the literature] Di Cello V, et al. **Minerva Urol Nefrol** 1995 Sep;47(3):137–9 (6 ref.) (Eng. Abstr.) **(Ita)**

THERAPY

[Splenic cyst. Review of the literature and report of 2 cases] de Melo VA, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1995 Sep–Oct;50(5):289–93 (40 ref.) (Eng. Abstr.) **(Por)**

ULTRASONOGRAPHY

A case of varix dilatation of the umbilical vein and review of the literature. Babay ZA, et al. **Fetal Diagn Ther** 1996 May–Jun;11(3):221–3 (10 ref.)
Demonstration of cystic adventitial disease by intravascular ultrasound imaging. Koppensteiner R, et al. **J Vasc Surg** 1996 Mar;23(3):534–6 (9 ref.)
[Ultrasound diagnosis, follow-up and therapy of cystic degeneration of the adventitia. 2 case reports and review of the literature] Schäberle W, et al. **Ultraschall Med** 1996 Jun;17(3):131–7 (39 ref.) (Eng. Abstr.) **(Ger)**

CYSTS, HYDATID see **ECHINOCOCCOSIS**

CYSTYL AMINOPEPTIDASE see **OXYTOCINASE**

CYTAPHERESIS

see related
IMMUNOTHERAPY, ADOPTIVE

CYTARABINE

[Design of antitumor 2'-deoxy-(2'-C-substituted) cytidines] Matsuda A. **Tanpakushitsu Kakusan Koso** 1994 Jul; 40(10):1232–41 (18 ref.) **(Jpn)**

ADMINISTRATION & DOSAGE

Errors involving pediatric patients receiving chemotherapy: a literature review. Trinkle R, et al. **Med Pediatr Oncol** 1996 May;26(5):344–51 (47 ref.)
[Bases for intravenous administration of cytosine arabinoside in the treatment of adult acute myeloid leukemia] Thomas X, et al. **Bull Cancer (Paris)** 1995 Nov;82(11):911–22 (57 ref.) (Eng. Abstr.) **(Fre)**

PHARMACOKINETICS

Intracellular pharmacodynamics in leukemia therapy. Gandhi V, et al. **Rinsho Ketsueki** 1996 May;37(5):369–79 (44 ref.)

THERAPEUTIC USE

High-dose chemotherapy in adult acute myeloid leukemia: rationale and results. Stasi R, et al. **Leuk Res** 1996 Jul; 20(7):535–49 (70 ref.)
Does it matter how remission is achieved in acute leukemia? Bishop JF. **Leukemia** 1996 Apr;10 Suppl 1:S7–9 (6 ref.)
Treatment of acute myeloid leukemia with antecedent myelodysplastic syndrome. Larson RA. **Leukemia** 1996 Apr;10 Suppl 1:S23–5 (7 ref.)
Postremission therapy of acute myeloid leukemia in older adults. Schiller GJ. **Leukemia** 1996 Apr;10 Suppl 1:S18–20 (19 ref.)

CYTIDINE AMINOHYDROLASE see **CYTIDINE DEAMINASE**

CYTIDINE DEAMINASE

GENETICS

Apolipoprotein B mRNA editing protein: a tool for dissecting lipoprotein metabolism and a potential therapeutic gene for hypercholesterolemia. Chan L, et al. **Z Gastroenterol** 1996 Jun;34 Suppl 3:31–2 (16 ref.)

CYTIDINE DIPHOSPHATE CHOLINE

PHARMACOLOGY

CDP-choline: pharmacological and clinical review. Secades JJ, et al. **Methods Find Exp Clin Pharmacol** 1995 Oct;17 Suppl B:2–54 (239 ref.)

THERAPEUTIC USE

CDP-choline: pharmacological and clinical review. Secades JJ, et al. **Methods Find Exp Clin Pharmacol** 1995 Oct;17 Suppl B:2–54 (239 ref.)
Citicoline (CDP-choline): mechanisms of action and effects in ischemic brain injury. D'Orlando KJ, et al. **Neurol Res** 1995 Aug;17(4):281–4 (21 ref.)

CYTIDYLATE PHOSPHATASE see **5'-NUCLEOTIDASE**

CYTOCHEMISTRY see **HISTOCYTOCHEMISTRY**

CYTOCHROME AA3 see **CYTOCHROME-C OXIDASE**

CYTOCHROME B

CHEMISTRY

A compilation of mutations located in the cytochrome b subunit of the bacterial and mitochondrial bc1 complex. Brasseur G, et al. **Biochim Biophys Acta** 1996 Jul 18; 1275(1–2):61–9 (45 ref.)

DEFICIENCY

Mutations in the X-linked and autosomal recessive forms of chronic granulomatous disease. Roos D, et al. **Blood** 1996 Mar 1;87(5):1663–81 (151 ref.)

METABOLISM

Structure of human phagocyte cytochrome b and its relationship to microbicidal superoxide production. Jesaitis AJ. **J Immunol** 1995 Oct 1;155(7):3286–8 (57 ref.)

CYTOCHROME B5

CHEMISTRY

Electron transfer from cytochrome b5 to cytochrome c. Durham B, et al. **J Bioenerg Biomembr** 1995 Jun; 27(3):331–40 (52 ref.)
Experimental and theoretical analysis of the interaction between cytochrome c and cytochrome b5. Mauk AG, et al. **J Bioenerg Biomembr** 1995 Jun;27(3):311–30 (78 ref.)

METABOLISM

Electron transfer from cytochrome b5 to cytochrome c. Durham B, et al. **J Bioenerg Biomembr** 1995 Jun; 27(3):331–40 (52 ref.)
Experimental and theoretical analysis of the interaction between cytochrome c and cytochrome b5. Mauk AG, et al. **J Bioenerg Biomembr** 1995 Jun;27(3):311–30 (78 ref.)
[Cytochrome b5 reductase] Takeshita M, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:225–8 (16 ref.) **(Jpn)**

CYTOCHROME BC1 COMPLEX see **UBIQUINOL-CYTOCHROME-C REDUCTASE**

CYTOCHROME C

CHEMISTRY

Flavocytochrome b2-cytochrome c interactions: the electron transfer reaction revisited. Capeillere-Blandin C. **Biochimie** 1995;77(7–8):516–30 (107 ref.)
Electron transfer in ruthenium-modified proteins. Bjerrum MJ, et al. **J Bioenerg Biomembr** 1995 Jun;27(3):295–302 (39 ref.)
Electron transfer from cytochrome b5 to cytochrome c. Durham B, et al. **J Bioenerg Biomembr** 1995 Jun; 27(3):331–40 (52 ref.)
Experimental and theoretical analysis of the interaction between cytochrome c and cytochrome b5. Mauk AG, et al. **J Bioenerg Biomembr** 1995 Jun;27(3):311–30 (78 ref.)
Electron transfer between cytochrome c and cytochrome c peroxidase. Millett F, et al. **J Bioenerg Biomembr** 1995 Jun; 27(3):341–51 (53 ref.)

METABOLISM

Electron transfer in ruthenium-modified proteins. Bjerrum MJ, et al. **J Bioenerg Biomembr** 1995 Jun;27(3):295–302 (39 ref.)
Electron transfer from cytochrome b5 to cytochrome c. Durham B, et al. **J Bioenerg Biomembr** 1995 Jun; 27(3):331–40 (52 ref.)
Experimental and theoretical analysis of the interaction between cytochrome c and cytochrome b5. Mauk AG, et al. **J Bioenerg Biomembr** 1995 Jun;27(3):311–30 (78 ref.)
Electron transfer between cytochrome c and cytochrome c peroxidase. Millett F, et al. **J Bioenerg Biomembr** 1995 Jun; 27(3):341–51 (53 ref.)

CYTOCHROME-C OXIDASE

CHEMISTRY

Cytochrome c oxidase: chemistry of a molecular machine. Musser SM, et al. **Adv Enzymol Relat Areas Mol Biol** 1995; 71:79–208 (392 ref.)
Internal electron-transfer reactions in cytochrome c oxidase. Brzezinski P. **Biochemistry** 1996 May 7;35(18):5612–5 (33 ref.)
'As prepared' forms of fully oxidised haem/Cu terminal oxidases. Moody AJ. **Biochim Biophys Acta** 1996 Aug 7; 1276(1):6–20 (119 ref.)
Electron transfer and proton pumping in cytochrome oxidase. Brunori M, et al. **Biochimie** 1995;77(7–8):668–76 (58 ref.)
Cytochrome c oxidase. Ostermeier C, et al. **Curr Opin Struct Biol** 1996 Aug;6(4):460–6 (49 ref.)
The currents of life: the terminal electron-transfer complex of respiration [comment] Ramirez BE, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):11949–51 (27 ref.) Comment on: Proc Natl Acad Sci U S A 1995 Dec 19;92(26):11955–9.
Functional significance of cytochrome c oxidase structure. Scott RA. **Structure** 1995 Oct 15;3(10):981–6 (26 ref.)
[Shed light on the molecular structure of the respiratory chain: X-ray crystal structure analysis of cytochrome c oxidase] Kato H. **Tanpakushitsu Kakusan Koso** 1995 Nov; 40(15):2340–1 (4 ref.) **(Jpn)**

ISOLATION & PURIFICATION

'As prepared' forms of fully oxidised haem/Cu terminal oxidases. Moody AJ. **Biochim Biophys Acta** 1996 Aug 7; 1276(1):6–20 (119 ref.)

METABOLISM

Cytochrome c oxidase: chemistry of a molecular machine. Musser SM, et al. **Adv Enzymol Relat Areas Mol Biol** 1995; 71:79–208 (392 ref.)
Internal electron-transfer reactions in cytochrome c oxidase. Brzezinski P. **Biochemistry** 1996 May 7;35(18):5612–5 (33 ref.)
Molecular aspects of the electron transfer system which participates in the oxidation of ferrous ion by Thiobacillus ferrooxidans. Yamanaka T, et al. **FEMS Microbiol Rev** 1995 Dec;17(4):401–13 (50 ref.)
The currents of life: the terminal electron-transfer complex of respiration [comment] Ramirez BE, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):11949–51 (27 ref.) Comment on: Proc Natl Acad Sci U S A 1995 Dec 19;92(26):11955–9.

CYTOCHROME-C PEROXIDASE

CHEMISTRY

Electron transfer between cytochrome c and cytochrome c peroxidase. Millett F, et al. **J Bioenerg Biomembr** 1995 Jun; 27(3):341–51 (53 ref.)

METABOLISM

Electron transfer between cytochrome c and cytochrome c peroxidase. Millett F, et al. **J Bioenerg Biomembr** 1995 Jun; 27(3):341–51 (53 ref.)

CYTOCHROME C REDUCTASE see **NADH DEHYDROGENASE**

CYTOCHROME OXIDASE see **CYTOCHROME-C OXIDASE**

CYTOCHROME P-450

[Metabolic enzymes of neurotoxin: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and Parkinson's disease] Wu RF, et al. **Seikagaku** 1995 Nov; 67(11):1307–11 (15 ref.) **(Jpn)**

ANALYSIS

Induction of cytochrome P-450 in the Norway rat, Rattus norvegicus, following exposure to potential environmental contaminants. Nims RW, et al. **J Toxicol Environ Health** 1995 Nov;46(3):271–92 (133 ref.)
Localization and characterization of cytochrome P450 in the brain. In vivo and in vitro investigations on phenytoin- and phenobarbital-inducible isoforms. Volk B, et al. **Toxicol Lett** 1995 Dec;82–83:655–62 (11 ref.)

ANTAGONISTS & INHIBITORS

Newer antidepressants and the cytochrome P450 system. Nemeroff CB, et al. **Am J Psychiatry** 1996 Mar; 153(3):311–20 (101 ref.)
Topical beta-adrenergic antagonists and quinidine. A risky

interaction [editorial] Higginbotham EJ. **Arch Ophthalmol** 1996 Jun;114(6):745–6 (7 ref.)

Drug interactions and the cytochrome P450 system. The role of cytochrome P450 1A2. Brøsen K. **Clin Pharmacokinet** 1995;29 Suppl 1:20–5 (20 ref.)

Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6. Ereshefsky L, et al. **Clin Pharmacokinet** 1995;29 Suppl 1:10–8; discussion 18–9 (38 ref.)

Are pharmacokinetic drug interactions with the SSRIs an issue? Brøsen K. **Int Clin Psychopharmacol** 1996 Mar;11 Suppl 1:23–7 (9 ref.)

Cytochrome P450 monooxygenases and interactions of psychotropic drugs: a five-year update. Shen WW. **Int J Psychiatry Med** 1995;25(3):277–90 (78 ref.)

Serotonin selective reuptake inhibitor drug interactions and the cytochrome P450 system. Ereshefsky L, et al. **J Clin Psychiatry** 1996;57 Suppl 8:17–24; discussion 25 (78 ref.)

P450 inhibitors of use in medical treatment: focus on mechanisms of action. Vanden Bossche H, et al. **Pharmacol Ther** 1995;67(1):79–100 (155 ref.)

Inhibition of biotransformation by nitric oxide (NO) overproduction and toxic consequences. Stadler J, et al. **Toxicol Lett** 1995 Dec;82–83:215–9 (26 ref.)

BIOSYNTHESIS

Introduction: basal and inducible expression of cytochromes P450 and related enzymes. Prough RA. **FASEB J** 1996 Jun;10(8):807–8 (18 ref.)

Cytochromes P450 5: induction of cytochrome P4501A1: a model for analyzing mammalian gene transcription. Whitlock JP Jr, et al. **FASEB J** 1996 Jun;10(8):809–18 (44 ref.)

Induction of cytochrome P-450 in the Norway rat, Rattus norvegicus, following exposure to potential environmental contaminants. Nims RW, et al. **J Toxicol Environ Health** 1995 Nov;46(3):271–92 (133 ref.)

Polymorphic forms of the Ah receptor and induction of the CYP1A1 gene. Fujii–Kuriyama Y, et al. **Pharmacogenetics** 1995;5 Spec No:S149–53 (30 ref.)

Induction of cytochrome P450 isoforms by carcinogenic aromatic amines and carcinogenic susceptibility of rodent animals. Hashimoto Y, et al. **Pharmacogenetics** 1995;5 Spec No:S80–3 (22 ref.)

Genetically engineered yeast cells and their applications. Pompon D, et al. **Toxicol Lett** 1995 Dec;82–83:815–22 (14 ref.)

Genetically engineered bacterial cells and applications. Waterman MR, et al. **Toxicol Lett** 1995 Dec;82–83:807–13 (27 ref.)

CHEMISTRY

NADPH–P-450 reductase: structural and functional comparisons of the eukaryotic and prokaryotic isoforms. Sevrioukova IF, et al. **Biochimie** 1995;77(7–8):562–72 (59 ref.)

Artificial P450/reductase fusion enzymes: what can we learn from their structures? Yabusaki Y. **Biochimie** 1995; 77(7–8):594–603 (51 ref.)

P450s: structural similarities and functional differences. Graham–Lorence S, et al. **FASEB J** 1996 Feb;10(2):206–14 (50 ref.)

Structural flexibility and functional versatility of mammalian P450 enzymes. Negishi M, et al. **FASEB J** 1996 May; 10(7):683–9 (34 ref.)

Structural domains of P450–containing monooxygenase systems. Degtyarenko KN. **Protein Eng** 1995 Aug; 8(8):737–47 (119 ref.)

Cytochrome P450: structure, function, and generation of reactive oxygen species. Bernhardt R. **Rev Physiol Biochem Pharmacol** 1996;127:137–221 (483 ref.)

DRUG EFFECTS

The P-450 system. Definition and relevance to the use of antidepressants in medical practice. Goldberg RJ. **Arch Fam Med** 1996 Jul–Aug;5(7):406–12 (104 ref.)

Antidepressant drug interactions and the cytochrome P450 system: a critical appraisal. Riesenman C. **Pharmacotherapy** 1995 Nov–Dec;15(6 Pt 2):84S–99S (78 ref.)

GENETICS

The molecular biology of xenobiotic enzymes and the predisposition to idiopathic Parkinson's disease. Ho SL, et al. **Adv Neurol** 1996;69:53–60 (36 ref.)

Gene–environment interaction in parkinson's disease. The case of CYP2D6 gene polymorphism. Landi MT, et al. **Adv Neurol** 1996;69:61–72 (80 ref.)

Metabolic polymorphisms and cancer susceptibility. Smith G, et al. **Cancer Surv** 1995;25:27–65 (249 ref.)

Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Bertilsson L. **Clin Pharmacokinet** 1995 Sep;29(3):192–209 (103 ref.)

Molecular genetics of cytochrome P450 IID. Anomalies of drug metabolism. Jacqz–Aigrain E, et al. **Clin Rev Allergy Immunol** 1995 Fall;13(3):211–21 (50 ref.)

Human drug–metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer. Nebert DW, et al. **DNA Cell Biol** 1996 Apr;15(4):273–80 (96 ref.)

Constitutive expression of hepatic cytochrome P450 genes. Gonzalez FJ, et al. **FASEB J** 1996 Aug;10(10):1112–7 (49 ref.)

Lung cancer and CYP2D6 (the debrisoquine polymorphism): sources of heterogeneity in the proposed association. Caporaso N, et al. **Pharmacogenetics** 1995;5 Spec No:S129–34 (44 ref.)

The CYP2A gene subfamily: species differences, regulation, catalytic activities and role in chemical carcinogenesis. Fernandez–Salguero P, et al. **Pharmacogenetics** 1995;5 Spec No:S123–8 (56 ref.)

Polymorphic forms of the Ah receptor and induction of the CYP1A1 gene. Fujii–Kuriyama Y, et al. **Pharmacogenetics** 1995;5 Spec No:S149–53 (30 ref.)

Assessment of cancer susceptibility in humans by use of genetic polymorphisms in carcinogen metabolism. Ikawa S, et al. **Pharmacogenetics** 1995;5 Spec No:S154–60 (42 ref.)

Genetic polymorphisms of drug–metabolizing enzymes and lung cancer susceptibility. Kawajiri K, et al. **Pharmacogenetics** 1995;5 Spec No:S70–3 (17 ref.)

P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Nelson DR, et al. **Pharmacogenetics** 1996 Feb;6(1):1–42 (270 ref.)

Transcriptional regulation of the genes encoding the cytochrome P–450 steroid hydroxylases. Parker KL, et al. **Vitam Horm** 1995;51:339–70 (121 ref.)

METABOLISM

The molecular biology of xenobiotic enzymes and the predisposition to idiopathic Parkinson's disease. Ho SL, et al. **Adv Neurol** 1996;69:53–60 (36 ref.)

Gene–environment interaction in parkinson's disease. The case of CYP2D6 gene polymorphism. Landi MT, et al. **Adv Neurol** 1996;69:61–72 (80 ref.)

Enzymic and interindividual differences in the human metabolism of heterocyclic amines. Boobis AR, et al. **Arch Toxicol Suppl** 1996;18:286–302 (65 ref.)

On the mechanism of nitric oxide formation upon oxidative cleavage of C = N(OH) bonds by NO–synthases and cytochromes P450. Mansuy D, et al. **Biochimie** 1995; 77(7–8):661–7 (28 ref.)

The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. Kivistö KT, et al. **Br J Clin Pharmacol** 1995 Dec;40(6):523–30 (73 ref.)

Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Bertilsson L. **Clin Pharmacokinet** 1995 Sep;29(3):192–209 (103 ref.)

Prostaglandin–metabolizing enzymes during pregnancy: characterization of NAD(+)–dependent prostaglandin dehydrogenase, carbonyl reductase, and cytochrome P450–dependent prostaglandin omega–hydroxylase. Okita RT, et al. **Crit Rev Biochem Mol Biol** 1996 Apr; 31(2):101–26 (100 ref.)

The 1994 Bernard B. Brodie Award Lecture. Structure, mechanism, and inhibition of cytochrome P450. Ortiz de Montellano PR. **Drug Metab Dispos** 1995 Nov; 23(11):1181–7 (61 ref.)

Clinical importance of hepatic cytochrome P450 in drug metabolism. Spatzenegger M, et al. **Drug Metab Rev** 1995; 27(3):397–417 (146 ref.)

The effects of hypoxia on drug–metabolizing enzymes. Woodrooffe AJ, et al. **Drug Metab Rev** 1995;27(3):471–95 (73 ref.)

Gender effects in pharmacokinetics and pharmacodynamics. Harris RZ, et al. **Drugs** 1995 Aug;50(2):222–39 (170 ref.)

Routes and regulation of NADPH production in steroidogenic mitochondria. Hanukoglu I, et al. **Endocr Res** 1995 Feb–May;21(1–2):231–41 (46 ref.)

Cytochrome P450 proteins and potential utilization in biodegradation. Guengerich FP. **Environ Health Perspect** 1995 Jun;103 Suppl 5:25–8 (27 ref.)

Structural flexibility and functional versatility of mammalian P450 enzymes. Negishi M, et al. **FASEB J** 1996 May; 10(7):683–9 (34 ref.)

Cytochrome P450 in the brain: neuroendocrine functions. Warner M, et al. **Front Neuroendocrinol** 1995 Jul; 16(3):224–36 (50 ref.)

Some aspects of the role of cytochrome P–450 isozymes in the N–oxidative transformation of secondary and tertiary amine compounds. Hlavica P, et al. **J Biochem Toxicol** 1995 Oct;10(5):275–285 (86 ref.)

Role of reactive metabolites in drug–induced hepatitis. Pessayre D. **J Hepatol** 1995;23 Suppl 1:16–24 (39 ref.)

Renal cytochrome P450. Schwartzman ML, et al. **J Lipid Mediat Cell Signal** 1995 Oct;12(2–3):229–42 (58 ref.)

Prostacyclin and thromboxane synthases. Tanabe T, et al. **J Lipid Mediat Cell Signal** 1995 Oct;12(2–3):243–55 (67 ref.)

Recent progress in enzymology and molecular biology of enzymes involved in vitamin D metabolism. Okuda K, et al. **J Lipid Res** 1995 Aug;36(8):1641–52 (89 ref.)

The procarcinogen hypothesis for bladder cancer: activities of individual drug metabolizing enzymes as risk factors. Branch RA, et al. **Pharmacogenetics** 1995;5 Spec No:S97–102 (26 ref.)

Role of cytochrome P4501A2 in chemical carcinogenesis: implications for human variability in expression and enzyme activity. Eaton DL, et al. **Pharmacogenetics** 1995 Oct; 5(5):259–74 (128 ref.)

The role of cytochrome P450 enzymes in hepatic and extrahepatic human drug toxicity. Park BK, et al. **Pharmacol Ther** 1995;68(3):385–424 (369 ref.)

Pesticide–metabolizing enzymes. Hodgson E, et al. **Toxicol Lett** 1995 Dec;82–83:73–81 (41 ref.)

Substrates of human hepatic cytochrome P450 3A4. Li AP, et al. **Toxicology** 1995 Dec 15;104(1–3):1–8 (37 ref.)

Risk assessment: toxicity from chemical exposure resulting from enhanced expression of CYP2E1. Raucy JL. **Toxicology** 1995 Dec 28;105(2–3):217–24 (48 ref.)

On the mechanism of amine oxidations by P450. Karki SB, et al. **Xenobiotica** 1995 Jul;25(7):711–24 (55 ref.)

[Cytochrome P–450 isoenzymes as predictors of drug interactions] Pelkonen O. **Duodecim** 1994;110(17):1575–9 (19 ref.) **(Fin)**

[Role of human cytochrome P–450 enzymes in the metabolism of xenobiotics] Monostory K, et al. **Acta Pharm Hung** 1995 Sep;65(5):147–56 (94 ref.) (Eng. Abstr.) **(Hun)**

[Cytochrome P–450 in tumors and during carcinogenesis] Kobliakov VA. **Biokhimiia** 1995 Nov;60(11):1747–64 (122 ref.) (Eng. Abstr.) **(Rus)**

[Polymorphism of enzymes involved in drug metabolism: gene structure and enzymatic activity] Krynetskii EI. **Mol Biol (Mosk)** 1996 Jan–Feb;30(1):33–42 (58 ref.) **(Rus)**

PHARMACOKINETICS

Cytochrome P450 isozymes and antiepileptic drug interactions. Levy RH. **Epilepsia** 1995;36 Suppl 5:S8–13 (13 ref.)

PHYSIOLOGY

Cytochromes and psychotropic drug interactions [editorial] Taylor D, et al. **Br J Psychiatry** 1996 May;168(5):529–32 (30 ref.)

Drug interactions and the cytochrome P450 system. The role of cytochrome P450 2C19. Flockhart DA. **Clin Pharmacokinet** 1995;29 Suppl 1:45–52 (51 ref.)

Metabolism of drugs by cytochrome P450 3A isoforms. Implications for drug interactions in psychopharmacology. von Moltke LL, et al. **Clin Pharmacokinet** 1995;29 Suppl 1:33–43; discussion 43–4 (66 ref.)

Cytochromes P450 and drug toxicity. Immunological consequences. Mansuy D. **Clin Rev Allergy Immunol** 1995 Fall;13(3):201–9 (12 ref.)

Cytochrome P450 2: peroxidative reactions of diversozymes. Coon MJ, et al. **FASEB J** 1996 Mar;10(4):428–34 (42 ref.)

The remarkable P450s: a historical overview of these versatile hemeprotein catalysts. Estabrook RW. **FASEB J** 1996 Feb; 10(2):202–4 (29 ref.)

The emerging role of cytochrome P450 3A in psychopharmacology. Ketter TA, et al. **J Clin Psychopharmacol** 1995 Dec;15(6):387–98 (173 ref.)

P450–dependent enzymes as targets for prostate cancer therapy. De Coster R, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1–6 Spec No):133–43 (101 ref.)

Cytochrome P450 isoenzymes—importance for the internist. Kerremans AL. **Neth J Med** 1996 Jun;48(6):237–43 (36 ref.)

Cytochrome P450: structure, function, and generation of reactive oxygen species. Bernhardt R. **Rev Physiol Biochem Pharmacol** 1996;127:137–221 (483 ref.)

Genetic implications in the metabolism and toxicity of mycotoxins. Neal GE. **Toxicol Lett** 1995 Dec;82–83:861–7 (25 ref.)

Xenobiotic metabolism in brain. Ravindranath V, et al. **Toxicol Lett** 1995 Dec;82–83:633–8 (19 ref.)

[Cytochrome P450–dependent monooxygenase system and anesthetics] Chen TL, et al. **Acta Anaesthesiol Sin** 1995 Sep;33(3):185–94 (64 ref.) (Eng. Abstr.) **(Chi)**

CYTOCHROME P-450(11 BETA) see **STEROID 11-HYDROXYLASE**

CYTOCHROME P-450(AROM) see **AROMATASE**

CYTOCHROME P-450(C-21) see **STEROID 21-HYDROXYLASE**

CYTOCHROME P-450(SCC) see **CHOLESTEROL DESMOLASE**

CYTOCHROME REDUCTASES

BLOOD

[Cytochrome b5 reductase] Takeshita M, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:225–8 (16 ref.) **(Jpn)**

CYTODIAGNOSIS

Applications of flow cytometric DNA analysis to diagnostic cytology. Cibas ES. **Diagn Cytopathol** 1995 Aug; 13(2):166–71 (50 ref.)

METHODS

[Rapid cytology] Shibata H, et al. **Rinsho Byori** 1995 Oct; 43(10):1024–7 (2 ref.) (Eng. Abstr.) **(Jpn)**

CYTOFLUOROMETRY, FLOW see **FLOW CYTOMETRY**

CYTOGENETICS

see related
CHROMOSOME ABNORMALITIES
CHROMOSOME MAPPING
KARYOTYPING

Clinical and molecular cytogenetics and gene mapping: principles and techniques. Francke U. **Southeast Asian J Trop Med Public Health** 1995;26 Suppl 1:34–43 (48 ref.)

Cytogenetics research in radiation biology. Bender MA. **Stem Cells (Dayt)** 1995 May;13 Suppl 1:172–81 (49 ref.)

METHODS

Chromosome painting in mammals as an approach to comparative genomics. Wienberg J, et al. **Curr Opin Genet Dev** 1995 Dec;5(6):792–7 (36 ref.)

Cytogenetics and molecular biology of soft tissue tumors. Fletcher JA. **Monogr Pathol** 1996;38:37–64 (126 ref.)

Molecular cytogenetics: unraveling of the genetic composition of individual cells by fluorescence in situ hybridization and digital imaging microscopy. Tanke HJ, et al. **World J Urol** 1995;13(3):138–42 (19 ref.)

STATISTICS & NUMERICAL DATA

Sister chromatid exchanges (SCEs) and high frequency cells (HFCs) in human population studies: principles of their analysis. Lazutka JR. **Mutat Res** 1995 Oct;331(2):229–31 (12 ref.)

TRENDS

Recent advances in cytometry, cytogenetics and molecular genetics of thyroid tumours and tumour-like lesions. Soares P, et al. **Pathol Res Pract** 1995 May;191(4):304–17 (141 ref.)

CYTOHISTOLOGICAL PREPARATION TECHNIQUES see **HISTOCYTOLOGICAL PREPARATION TECHNIQUES**

CYTOKERATIN see **KERATIN**

CYTOKINE RECEPTORS see **RECEPTORS, CYTOKINE**

CYTOKINES

Cytokines: a primer for plastic surgeons. Remick DG. **Ann Plast Surg** 1995 Nov;35(5):549–59 (30 ref.)

The role of cytokines in blood transfusion reactions. Muylle L. **Blood Rev** 1995 Jun;9(2):77–83 (74 ref.)

Cytokines and cytokine measurements in a clinical laboratory. Whiteside TL. **Clin Diagn Lab Immunol** 1994 May; 1(3):257–60 (24 ref.)

Human mast cell cytokines. Bradding P. **Clin Exp Allergy** 1996 Jan;26(1):13–9 (56 ref.)

Cytokines, chemokines, T cells and allergy [editorial] Frew AJ. **Clin Exp Allergy** 1996 Jan;26(1):2–4 (29 ref.)

St. John Dermatological Society Oration, 1994. Immune responses in leprosy, cytokines and new archetypes for dermatology. Rea TH. **Clin Exp Dermatol** 1995 Mar; 20(2):89–97 (48 ref.)

Are cytokines associated with neuropsychiatric syndromes in humans? Hickie I, et al. **Int J Immunopharmacol** 1995 Aug;17(8):677–83 (27 ref.)

Endocrine, paracrine and autocrine actions of prolactin on immune cells. Matera L. **Life Sci** 1996;59(8):599–614 (173 ref.)

[Cytokines in ophthalmology] Yamashita H. **Nippon Ganka Gakkai Zasshi** 1995 Oct;99(10):1109–10 (5 ref.) **(Jpn)**

[Are cytokines factors for host defense against infection?] Imanishi J. **Nippon Saikingaku Zasshi** 1995 Jul; 50(3):793–801 (8 ref.) **(Jpn)**

ADMINISTRATION & DOSAGE

Site-specific delivery of cytokines in cancer. Klingemann HG, et al. **Mol Med Today** 1996 Apr;2(4):154–9 (38 ref.)

ADVERSE EFFECTS

Clinical toxicity of cytokines used as haemopoietic growth factors. Vial T, et al. **Drug Saf** 1995 Dec;13(6):371–406 (236 ref.)

Immune-mediated side-effects of cytokines in humans. Vial T, et al. **Toxicology** 1995 Dec 20;105(1):31–57 (239 ref.)

ANALYSIS

Factors affecting the measurement of cytokines in biological fluids: implications for their clinical measurement. Heney D, et al. **Ann Clin Biochem** 1995 Jul;32 (Pt 4):358–68 (62 ref.)

Cytokines and gastrointestinal disease mechanisms. Przemioslo RT, et al. **Baillieres Clin Gastroenterol** 1996 Mar;10(1):17–32 (73 ref.)

Cytokines and inflammatory bowel disease. Radford-Smith G, et al. **Baillieres Clin Gastroenterol** 1996 Mar; 10(1):151–64 (64 ref.)

Immunosuppressive retroviral peptides: cAMP and cytokine patterns. Haraguchi S, et al. **Immunol Today** 1995 Dec; 16(12):595–603 (97 ref.)

Detection of human cytokines in situ using antibody and probe based methods. Hoefakker S, et al. **J Immunol Methods** 1995 Sep 25;185(2):149–75 (159 ref.)

Immunoassays for detecting cytokines: what are they really measuring? Mire-Sluis AR, et al. **J Immunol Methods** 1995 Oct 26;186(2):157–60 (15 ref.)

Reverse transcription polymerase chain reaction for cytokines in the mixed lymphocyte culture. Is there a role in renal transplantation? [editorial] Danzer SG, et al. **Nephrol Dial Transplant** 1996 Jul;11(7):1246–7 (10 ref.)

Determination of lymphocyte subsets and cytokine levels in cynomolgus monkeys. Verdier F, et al. **Toxicology** 1995 Dec 20;105(1):81–90 (27 ref.)

[Enzyme immunoassay for cytokines] Aoki C, et al. **Nippon Rinsho** 1995 Sep;53(9):2290–5 (10 ref.) (Eng. Abstr.) **(Jpn)**

ANTAGONISTS & INHIBITORS

Cytokine inhibitors and graft-versus-host disease. Ferrara JL. **Ann N Y Acad Sci** 1995 Dec 29;770:227–36 (38 ref.)

Innovative treatment approaches for rheumatoid arthritis. New cyclo-oxygenase and cytokine inhibitors. Richardson CE, et al. **Baillieres Clin Rheumatol** 1995 Nov;9(4):731–58 (73 ref.)

A perspective on anti-cytokine and anti-T cell-directed therapies in rheumatoid arthritis. Maini RN. **Clin Exp Rheumatol** 1995 Sep-Oct;13 Suppl 12:S35–40 (40 ref.)

Pro- and antiinflammatory cytokine balance in rheumatoid arthritis. Miossec P. **Clin Exp Rheumatol** 1995 Sep-Oct;13 Suppl 12:S13–6 (16 ref.)

Glucocorticosteroid inhibition of cytokine production: relevance to antiallergic actions. Schwiebert LA, et al. **J Allergy Clin Immunol** 1996 Jan;97(1 Pt 2):143–52 (105 ref.)

Cytokine antagonists: new ideas for the management of Graves' ophthalmopathy [editorial; comment] Bartalena L, et al. **J Clin Endocrinol Metab** 1996 Feb;81(2):446–8 (15 ref.) Comment on: J Clin Endocrinol Metab 1996 Feb;81(2):449–52.

Cytokines and their antagonists in myeloid disorders. Estrov Z, et al. **Semin Hematol** 1995 Jul;32(3):220–31 (124 ref.)

[Cytokine inhibitors in intensive care] Villard J, et al. **Rev Mal Respir** 1995;12(4):335–42 (66 ref.) (Eng. Abstr.) **(Fre)**

BIOSYNTHESIS

Does DHEAS restore immune competence in aged animals through its capacity to function as a natural modulator of peroxisome activities? Spencer NF, et al. **Ann N Y Acad Sci** 1995 Dec 29;774:200–16 (129 ref.)

Glomerular hypertension and progressive renal disease: the interplay of mesangial cell stretch, cytokine formation and extracellular matrix synthesis. Cortes P, et al. **Contrib Nephrol** 1996;118:229–33 (14 ref.)

Cytokine-processing enzymes. Stopping the cuts. Dinarello CA, et al. **Curr Biol** 1995 Jun 1;5(6):587–90 (34 ref.)

Cytokines and transplantation: Th1/Th2 regulation of the immune response to solid organ transplants in the adult. Dallman MJ. **Curr Opin Immunol** 1995 Oct;7(5):632–8 (54 ref.)

Role and modulation of T-cell cytokines in allergy. Daser A, et al. **Curr Opin Immunol** 1995 Dec;7(6):762–70 (61 ref.)

Cytokine production and requirements during T-cell development. Zlotnik A, et al. **Curr Opin Immunol** 1995 Apr;7(2):206–13 (53 ref.)

The impact of cytokines on high dose chemotherapy followed by transplantation of purified and ex vivo expanded peripheral blood stem cells: achieving a state of minimal residual disease for tumor immunotherapy with cytokine gene transfected cells [editorial] Mertelsmann R. **Eur Cytokine Netw** 1995 Mar-Apr;6(2):79–82 (12 ref.)

Mouse mast cell cytokine production: rôle in cutaneous inflammatory and immunological responses. Galli SJ, et al. **Exp Dermatol** 1995 Aug;4(4 Pt 2):240–9 (73 ref.)

Cytokine production pathway in the elderly. Caruso C, et al. **Immunol Res** 1996;15(1):84–90 (52 ref.)

Production and modulation of T-cell cytokines in atopic allergy. Kapsenberg ML, et al. **Int Arch Allergy Immunol** 1996 Jun;110(2):107–13 (68 ref.)

The eosinophil: a cytokine-producing cell? [editorial] Kita H. **J Allergy Clin Immunol** 1996 Apr;97(4):889–92 (20 ref.)

Alveolar macrophages as a cell source of cytokine hyperproduction in HIV-related interstitial lung disease. Agostini C, et al. **J Leukoc Biol** 1995 Nov;58(5):495–500 (37 ref.)

Dendritic cells from different tissues induce production of different T cell cytokine profiles. Everson MP, et al. **J Leukoc Biol** 1996 Apr;59(4):494–8 (31 ref.)

Role of CSB/p38/RK stress response kinase in LPS and cytokine signaling mechanisms. Lee JC, et al. **J Leukoc Biol** 1996 Feb;59(2):152–7 (62 ref.)

Novel insight into molecular mechanism of endotoxin shock: biochemical analysis of LPS receptor signaling in a cell-free system targeting NF-kappaB and regulation of cytokine production/action through beta2 integrin in vivo. Mukaida N, et al. **J Leukoc Biol** 1996 Feb;59(2):145–51 (42 ref.)

Modulation of inflammation and cytokine production by dietary (n-3) fatty acids. Blok WL, et al. **J Nutr** 1996 Jun; 126(6):1515–33 (131 ref.)

Bacterial modulins: a novel class of virulence factors which cause host tissue pathology by inducing cytokine synthesis. Henderson B, et al. **Microbiol Rev** 1996 Jun;60(2):316–41 (260 ref.)

Cell stress genes and acute CNS injury. McIntosh TK, et al. **Neuropathol Appl Neurobiol** 1995 Dec;21(6):477–9 (27 ref.)

Renal transplant fine needle aspiration and cytokine gene expression. Nast CC. **Pediatr Nephrol** 1995;9 Suppl:S56–60 (31 ref.)

Alpha 4 integrin-induced cytokine production and eosinophil function. Broide DH. **Springer Semin Immunopathol** 1995; 16(4):405–15 (85 ref.)

Relationships between B cell cytokine production in secondary lymphoid follicles and apoptosis of germinal center B lymphocytes. Pistoia V, et al. **Stem Cells (Dayt)** 1995 Sep;13(5):487–500 (105 ref.)

Epithelial cytokine responses and mucosal cytokine networks. Hedges SR, et al. **Trends Microbiol** 1995 Jul; 3(7):266–70 (69 ref.)

[The IgA immune system for mucosal vaccine: role of levels one and two Th2 cytokine producing T cells] Shimaoka M, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Feb; 19(1):114–8 (15 ref.) **(Jpn)**

[Ectopic cytokine syndrome] Yamaguchi K, et al. **Nippon Naika Gakkai Zasshi** 1996 Mar 10;85(3):328–32 (15 ref.) **(Jpn)**

BLOOD

Plasma concentrations of cytokines, their soluble receptors, and antioxidant vitamins can predict the development of multiple organ failure in patients at risk. Borrelli E, et al. **Crit Care Med** 1996 Mar;24(3):392–7 (38 ref.)

Eosinophils in allergy: role in disease, degranulation, and cytokines. Martin LB, et al. **Int Arch Allergy Immunol** 1996 Mar;109(3):207–15 (147 ref.)

[Hemodynamic profile and serum cytokines in crush syndrome. Analogy with severe burns] Gueugniaud PY, et al. **Presse Med** 1996 Mar 16;25(9):449–51 (16 ref.) (Eng. Abstr.) **(Fre)**

[Cytokines and pancreatic diseases] Böcker U, et al. **Dtsch Med Wochenschr** 1995 Nov 10;120(45):1555–60 (50 ref.) **(Ger)**

CHEMISTRY

Structural aspects of cytokine/receptor interactions. Nicola NA. **Ann N Y Acad Sci** 1995 Sep 7;766:253–62 (23 ref.)

Reference databases of cytokine structure and function. Casciari JJ, et al. **Cancer Chemother Biol Response Modif** 1996;16:315–46 (103 ref.)

CLASSIFICATION

[Classification of cytokines in the cyclic morphofunctioning and the gestational endometrium] Ciobotaru C. **Rom J Morphol Embryol** 1995 Jan-Jun;41(1-2):23–37 (7 ref.) **(Fre)**

GENETICS

A genetic approach to idiotypic vaccination for B cell lymphoma. Stevenson FK, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:212–26 (23 ref.)

The effects of cytokine gene transfer into tumors on host cell infiltration and regression. McBride WH, et al. **Anticancer Res** 1996 May-Jun;16(3A):1139–43 (32 ref.)

A genetic approach for the analysis of cytokine function in vivo. Müller W. **Behring Inst Mitt** 1995 Jun;(96):95–6 (10 ref.)

Gene therapy of rheumatoid arthritis via cytokine regulation: future perspectives. Chernajovsky Y, et al. **Br Med Bull** 1995 Apr;51(2):503–16 (41 ref.)

Tumor cells engineered to produce cytokines or cofactors as cellular vaccines: do animal studies really support clinical trials? Colombo MP, et al. **Cancer Immunol Immunother** 1995 Nov;41(5):265–70 (66 ref.)

Preventing abnormalities in signal transduction of T cells in cancer: the promise of cytokine gene therapy. Zier K, et al. **Immunol Today** 1996 Jan;17(1):39–45 (62 ref.)

Cytokine gene regulation by viral gene products. Geist LJ, et al. **J Lab Clin Med** 1995 Dec;126(6):517–20 (40 ref.)

Regulation of cytokine gene expression by reactive oxygen and reactive nitrogen intermediates. Remick DG, et al. **J Leukoc Biol** 1996 Apr;59(4):471–5 (34 ref.)

Reverse transcription polymerase chain reaction for cytokines in the mixed lymphocyte culture. Is there a role in renal transplantation? [editorial] Danzer SG, et al. **Nephrol Dial Transplant** 1996 Jul;11(7):1246–7 (10 ref.)

In situ cytokine gene transfection using vaccinia virus vectors. Lattime EC, et al. **Semin Oncol** 1996 Feb; 23(1):88–100 (98 ref.)

[Cytokine gene expression in the liver of chronic hepatitis C] Fukuda R. **Nippon Rinsho** 1995 Sep;53 Suppl:629–34 (14 ref.) **(Jpn)**

[Cytokine mRNA expression in the labial glands of patients with Sjögren's syndrome] Ohyama Y, et al. **Nippon Rinsho** 1995 Oct;53(10):2412–7 (13 ref.) (Eng. Abstr.) **(Jpn)**

[Gene therapy of glioma using cytokine] Ikeda H, et al. **No To Shinkei** 1995 Sep;47(9):835–43 (47 ref.) **(Jpn)**

[Immunogene therapy of cancer using cytokine genes] Hanada K, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec;

40(17):2688–93 (23 ref.) **(Jpn)**

[Cytokine gene therapy for malignant brain tumors] Mizuno M, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec; 40(17):2709–12 (13 ref.) **(Jpn)**

[Gene therapy for diabetes: various approaches including adoptive transfer of cytokine gene–transduced lymphocytes] Moritani M, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2746–52 (23 ref.) **(Jpn)**

IMMUNOLOGY

The Janus protein tyrosine kinase family and its role in cytokine signaling. Ihle JN. **Adv Immunol** 1995;60:1–35 (230 ref.)

Mast–cell–leukocyte cytokine cascades in allergic inflammation. Galli SJ, et al. **Allergy** 1995 Nov; 50(11):851–62 (129 ref.)

The role of cytokines and neuroendocrine hormones in cutaneous immunity and inflammation. Luger TA, et al. **Allergy** 1995 Apr;50(4):292–302 (119 ref.)

The role of mast cells and basophils in immunoregulation. Nolte H. **Allergy Asthma Proc** 1996 Jan–Feb;17(1):17–21 (13 ref.)

Do monoclonal antibodies and anticytokines still have a future in infectious diseases? Cohen J, et al. **Am J Med** 1995 Dec 29;99(6A):45S–52S; discussion 52S–53S (36 ref.)

The role of Th1 and Th2 cells for mucosal IgA responses. Yamamoto M, et al. **Ann N Y Acad Sci** 1996 Feb 13; 778:64–71 (39 ref.)

Human cytokine autoantibodies. Characteristics, test procedures and possible physiological and clinical significance. Hansen MB. **APMIS Suppl** 1996;59:1–33 (258 ref.)

Sepsis and cytokines: current status. Blackwell TS, et al. **Br J Anaesth** 1996 Jul;77(1):110–7 (72 ref.)

An overview of pathophysiological theories in Plasmodium falciparum cerebral malaria with the special reference to the role of cytokines. Kotłowski A. **Bull Inst Marit Trop Med Gdynia** 1993–94;44–45(1–4):103–8 (37 ref.)

"Kinoids": the basis for anticytokine immunization and their use in HIV infection. Bizzini B, et al. **Cell Mol Biol (Noisy–le–grand)** 1995 May;41(3):351–6 (38 ref.)

T cells and cytokines in intracellular bacterial infections: experiences with Mycobacterium bovis BCG. Kaufmann SH, et al. **Ciba Found Symp** 1995;195:123–32; discussion 132–6 (33 ref.)

Role for CD30 antigen in human T helper 2–type responses. Romagnani S. **Ciba Found Symp** 1995;195:55–62; discussion 62–7 (43 ref.)

Cytokines in immune regulation/pathogenesis in HIV infection. Shearer GM, et al. **Ciba Found Symp** 1995; 195:142–7; discussion 147–53 (44 ref.)

The immune response: the efferent arm. Horowitz MC, et al. **Clin Orthop** 1996 May;(326):25–34 (45 ref.)

Glia, cytokines, and neurotoxicity. Chao CC, et al. **Crit Rev Neurobiol** 1995;9(2–3):189–205 (249 ref.)

The cytokine network in sarcoidosis. Müller–Quernheim J. **Eur Cytokine Netw** 1996 Jan–Mar;7(1):13–26 (142 ref.)

Functions of T–cell subsets and cytokines in mycobacterial infections. Munk ME, et al. **Eur Respir J Suppl** 1995 Sep; 20:668s–675s (91 ref.)

Viral evasion of cytokine–mediated host defense mechanisms. Gribaudo G, et al. **G Batteriol Virol Immunol** 1994 Jan–Dec;86(1–12):3–10 (41 ref.)

Critical influences of the cytokine orchestration on the outcome of myelin antigen–specific T–cell autoimmunity in experimental autoimmune encephalomyelitis and multiple sclerosis. Olsson T. **Immunol Rev** 1995 Apr; 144:245–68 (169 ref.)

Interplay of T cells and cytokines in the context of enzymatically modified extracellular matrix. Gilat D, et al. **Immunol Today** 1996 Jan;17(1):16–20 (40 ref.)

Cytokine circuits in tuberculosis. Toossi Z. **Infect Agents Dis** 1996 Mar;5(2):98–107 (94 ref.)

Cytokines in the acquired immunodeficiency syndrome and other infectious diseases. Poli G, et al. **Int J Clin Lab Res** 1995;25(3):128–34 (58 ref.)

The role of natural killer cells in the treatment of chronic myeloid leukemia. Silla LM, et al. **J Hematother** 1995 Aug; 4(4):269–79 (103 ref.)

T cell and cytokine basis of host variability in response to intestinal nematode infections. Grencis RK. **Parasitology** 1996;112 Suppl:S31–7 (45 ref.)

The role of epidermal cytokines in the generation of cutaneous immune reactions and ultraviolet radiation–induced immune suppression. Ullrich SE. **Photochem Photobiol** 1995 Sep;62(3):389–401 (99 ref.)

Autoantibodies to cytokines in inflammatory joint disorders [editorial] Jouvenne P, et al. **Rev Rhum Engl Ed** 1995 Oct; 62(9):541–5 (20 ref.)

Human host response to Mycobacterium tuberculosis. Rom WN, et al. **Schweiz Med Wochenschr** 1995 Nov 11; 125(45):2178–85 (46 ref.)

Cells and cytokines in the pathogenesis of MAIDS, a retrovirus–induced immunodeficiency syndrome of mice. Morse HC 3rd, et al. **Springer Semin Immunopathol** 1995; 17(2–3):231–45 (66 ref.)

Pro–inflammatory cytokines in a ruminant model: pathophysiological, pharmacological, and therapeutic aspects. van Miert AS. **Vet Q** 1995 Jun;17(2):41–50 (167 ref.)

[Cytokine measurements from patient specimens] Varkila K, et al. **Duodecim** 1994;110(2):195–201 (43 ref.) **(Fin)**

[Regulation by maternally derived cytokines of pre–implantation development and uterine receptiveness] Stewart CL, et al. **Contracept Fertil Sex** 1995 Sep; 23(9):555–61 (37 ref.) (Eng. Abstr.) **(Fre)**

[The function of antigen presentation of dendritic cells] Péguet–Navarro J. **Pathol Biol (Paris)** 1995 Dec; 43(10):863–70 (54 ref.) (Eng. Abstr.) **(Fre)**

[The role of cytokines in viral infections] Cavallo R, et al. **G Batteriol Virol Immunol** 1994 Jan–Dec;86(1–12):65–78 (44 ref.) (Eng. Abstr.) **(Ita)**

[Cytokines and nonviral infections] Grabchenko NI, et al. **Mikrobiol Z** 1995 Nov–Dec;57(6):63–78 (99 ref.) (Eng. Abstr.) **(Rus)**

ISOLATION & PURIFICATION

[Cytokine measurements from patient specimens] Varkila K, et al. **Duodecim** 1994;110(2):195–201 (43 ref.) **(Fin)**

METABOLISM

AIDS–related non–Hodgkin's lymphomas: molecular genetics, viral infection and cytokine deregulation. Gaidano G, et al. **Acta Haematol** 1996;95(3–4):193–8 (32 ref.)

Herman Award Lecture, 1995: infection–induced malnutrition––from cholera to cytokines. Beisel WR. **Am J Clin Nutr** 1995 Oct;62(4):813–9 (91 ref.)

T–cell subsets and their cytokine profiles in transplantation and tolerance. Groux H, et al. **Ann N Y Acad Sci** 1995 Dec 29;770:141–8 (27 ref.)

Structural aspects of cytokine/receptor interactions. Nicola NA. **Ann N Y Acad Sci** 1995 Sep 7;766:253–62 (23 ref.)

Modulatory effects of selenium and strontium salts on keratinocyte–derived inflammatory cytokines. Celerier P, et al. **Arch Dermatol Res** 1995;287(7):680–2 (11 ref.)

Cytokines, adhesion molecules (E–selectin and VCAM–1) and graft–versus–host disease. Lange A, et al. **Arch Immunol Ther Exp (Warsz)** 1995;43(2):99–105 (23 ref.)

Cytokines in human lung fibrosis. Martinet Y, et al. **Arch Toxicol Suppl** 1996;18:127–39 (39 ref.)

Soluble cytokine receptors. Heaney ML, et al. **Blood** 1996 Feb 1;87(3):847–57 (146 ref.)

Placental isoferritin: a new biomarker from conception to delivery. Maymon R, et al. **Br J Obstet Gynaecol** 1996 Apr;103(4):301–5 (29 ref.)

Cytokine expression in chronic inflammatory disease. Brennan FM, et al. **Br Med Bull** 1995 Apr;51(2):368–84 (60 ref.)

Mediators, cytokines, and growth factors in liver–lung interactions. Panos RJ, et al. **Clin Chest Med** 1996 Mar; 17(1):151–69 (220 ref.)

Complement fragments and cytokines: production and removal as consequences of hemofiltration. Journois D. **Contrib Nephrol** 1995;116:80–5 (23 ref.)

Hodgkin's disease: a cytokine–producing tumor––a review. Gruss HJ, et al. **Crit Rev Oncog** 1994;5(5):473–538 (356 ref.)

Cytokines in Alzheimer's disease and multiple sclerosis. Patterson PH. **Curr Opin Neurobiol** 1995 Oct;5(5):642–6 (44 ref.)

Connective tissue metabolism including cytokines in scleroderma. Postlethwaite AE. **Curr Opin Rheumatol** 1995 Nov;7(6):535–40 (41 ref.)

Cytokines, modified lipoproteins, and arteriosclerosis in diabetes. Lopes–Virella MF, et al. **Diabetes** 1996 Jul;45 Suppl 3:S40–4 (49 ref.)

Cytokines and tumors of the central nervous system. Van Meir EG. **Glia** 1995 Nov;15(3):264–88 (205 ref.)

Cytokines, fibrinolysis and vasculitis. Teofoli P, et al. **Int Angiol** 1995 Jun;14(2):125–9 (51 ref.)

Keratinocyte–derived cytokines and UVB–induced immunosuppression. Kondo S, et al. **J Dermatol** 1995 Nov; 22(11):888–93 (45 ref.)

UVB–dependent modulation of epidermal cytokine network: roles in UVB–induced depletion of Langerhans cells and dendritic epidermal T cells. Takashima A. **J Dermatol** 1995 Nov;22(11):876–87 (100 ref.)

Production and function of cytokines in natural and acquired immunity to Candida albicans infection. Ashman RB, et al. **Microbiol Rev** 1995 Dec;59(4):646–72 (367 ref.)

DNA repair and cytokines in antimutagenesis and anticarcinogenesis. Yarosh DB, et al. **Mutat Res** 1996 Feb 19;350(1):255–60 (28 ref.)

Balance between pro–inflammatory cytokines and their specific inhibitors in patients on dialysis. Pereira BJ. **Nephrol Dial Transplant** 1995;10 Suppl 7:27–32 (55 ref.)

Induction by cytokines of the pattern of pituitary hormone secretion in infection. McCann SM, et al. **Neuroimmunomodulation** 1994 Jan;1(1):2–13 (50 ref.)

Interactions between nutrients and the immune system. Grimble RF. **Nutr Health** 1995;10(3):191–200 (15 ref.)

STATs find that hanging together can be stimulating [comment] Leung S, et al. **Science** 1996 Aug 9; 273(5276):750–1 (19 ref.) Comment on: Science 1996 Aug 9;273(5276):794–7.

Hypothesis: compartmentalization of cytokines in intraabdominal infection. Schein M, et al. **Surgery** 1996 Jun; 119(6):694–700 (80 ref.)

[Exploration of cytokines in inflammation in biological fluids] Bienvenu J. **C R Seances Soc Biol Fil** 1995;189(4):545–55 (19 ref.) (Eng. Abstr.) **(Fre)**

[Cytokines in inflammation] Cavaillon JM. **C R Seances Soc Biol Fil** 1995;189(4):531–44 (61 ref.) (Eng. Abstr.) **(Fre)**

[Cytokine gene expression in the liver of chronic hepatitis B] Fukuda R. **Nippon Rinsho** 1995 Oct;53 Suppl:223–7 (17 ref.) **(Jpn)**

[Interaction of cytokines with cellular receptors] Danilkovich AV, et al. **Biokhimiia** 1995 Sep;60(9):1382–95 (102 ref.) (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

Cytokines in the regulation of basophil effector functions. Cieslewicz G, et al. **Allergy Asthma Proc** 1996 Jan–Feb; 17(1):13–6 (31 ref.)

Cytokine signal transduction through a homo– or heterodimer of gp130. Kishimoto T, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:224–34 (22 ref.)

Haemopoietic stem cell inhibition: potential for dose intensification. Marshall E. **Eur J Cancer** 1995 Sep; 31A(10):1586–91 (92 ref.)

Hematopoietic stem cell cytokine response. Lowry PA. **J Cell Biochem** 1995 Aug;58(4):410–5 (29 ref.)

Induction by cytokines of the pattern of pituitary hormone secretion in infection. McCann SM, et al. **Neuroimmunomodulation** 1994 Jan;1(1):2–13 (50 ref.)

Cytokines as vaccine adjuvants. Current status and potential applications. Dong P, et al. **Pharm Biotechnol** 1995;6:625–43 (122 ref.)

Cytokines as immunological adjuvants. Heath AW. **Pharm Biotechnol** 1995;6:645–58 (66 ref.)

Cytokine–containing liposomes as adjuvants for subunit vaccines. Lachman LB, et al. **Pharm Biotechnol** 1995; 6:659–71 (37 ref.)

PHYSIOLOGY

Sleep regulation: interactions among cytokines and classical neurotransmitters. Grazia de Simoni M, et al. **Adv Neuroimmunol** 1995;5(2):189–200 (61 ref.)

Cytokines in sleep regulation. Krueger JM, et al. **Adv Neuroimmunol** 1995;5(2):171–88 (85 ref.)

Interactions between cytokines and nitric oxide. Liew FY. **Adv Neuroimmunol** 1995;5(2):201–9 (49 ref.)

Role of immune activation and cytokine expression in HIV–1–associated neurologic diseases. Yoshioka M, et al. **Adv Neuroimmunol** 1995;5(3):335–58 (190 ref.)

Cytokine function: a study in biologic diversity. Cohen MC, et al. **Am J Clin Pathol** 1996 May;105(5):589–98 (125 ref.)

Cytokine signaling in mesothelial cells: receptor expression closes the autocrine loop. Gerwin BI. **Am J Respir Cell Mol Biol** 1996 Jun;14(6):505–7 (27 ref.)

Regulation of APP expression, biogenesis and metabolism by extracellular matrix and cytokines. Beyreuther K, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:74–6 (17 ref.)

Cytokine signal transduction through a homo– or heterodimer of gp130. Kishimoto T, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:224–34 (22 ref.)

The stress–activated protein kinases. A novel ERK subfamily responsive to cellular stress and inflammatory cytokines. Kyriakis JM, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:303–19 (48 ref.)

Mechanism of action of cytokines to induce the pattern of pituitary hormone secretion in infection. McCann SM, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:386–95 (29 ref.)

Regulation of iron metabolism: translational effects mediated by iron, heme, and cytokines. Mascotti DP, et al. **Annu Rev Nutr** 1995;15:239–61 (143 ref.)

Cytokine regulation of monocyte recruitment. Mantovani A, et al. **Arch Immunol Ther Exp (Warsz)** 1995;43(2):149–52 (21 ref.)

Cytokines: sources, receptors and signalling. Barrett KE. **Baillieres Clin Gastroenterol** 1996 Mar;10(1):1–15 (60 ref.)

Growth factors and ulcerative gastrointestinal disease. Playford RJ, et al. **Baillieres Clin Gastroenterol** 1996 Mar; 10(1):135–49 (60 ref.)

Cytokines, differentiation and functions of subsets of CD4 and CD8 T cells. Mosmann TR. **Behring Inst Mitt** 1995 Jun;(96):1–6 (34 ref.)

A genetic approach for the analysis of cytokine function in vivo. Müller W. **Behring Inst Mitt** 1995 Jun;(96):95–6 (10 ref.)

Cytokine regulation of matrix metalloproteinase activity and its regulatory dysfunction in disease. Ries C, et al. **Biol Chem Hoppe Seyler** 1995 Jun;376(6):345–55 (100 ref.)

Role of cytokines in bone resorption. Manolagas SC. **Bone** 1995 Aug;17(2 Suppl):63S–67S (45 ref.)

The effects of cytokines and growth factors on osteoblastic cells. Mundy GR, et al. **Bone** 1995 Aug;17(2 Suppl):71S–75S (41 ref.)

Towards cytokine insight in sight. Rosenbaum JT. **Br J Ophthalmol** 1995 Nov;79(11):970–1 (15 ref.)

Role of cytokines and growth factors in promoting the local recurrence of breast cancer. Reid SE, et al. **Br J Surg** 1996 Mar;83(3):313–20 (97 ref.)

Molecular and pharmacologic targeting of angiogenesis factors––the example of pleiotrophin. Czubayko F, et al. **Breast Cancer Res Treat** 1995;36(2):157–68 (68 ref.)

Reference databases of cytokine structure and function. Casciari JJ, et al. **Cancer Chemother Biol Response Modif** 1996;16:315–46 (103 ref.)

Recombinant hematopoietic growth factors in bone marrow transplantation. Nemunaitis J. **Cancer Treat Res** 1995; 76:225–48 (151 ref.)

Sex steroids, cytokines and the bone marrow: new concepts on the pathogenesis of osteoporosis. Manolagas SC, et al. **Ciba Found Symp** 1995;191:187–96; discussion 197–202 (45 ref.)

Immunological control in primary biliary cirrhosis: the cytokine story [editorial] O'Donohue J, et al. **Clin Exp Immunol** 1996 Aug;105(2):199–201 (25 ref.)

Pro- and antiinflammatory cytokine balance in rheumatoid arthritis. Miossec P. **Clin Exp Rheumatol** 1995 Sep–Oct;13 Suppl 12:S13–6 (16 ref.)

Cytokines and skeletal physiology. Goldring SR, et al. **Clin Orthop** 1996 Mar;(324):13–23 (67 ref.)

Cytokines in rheumatoid arthritis. Houssiau FA. **Clin Rheumatol** 1995 Sep;14 Suppl 2:10–3 (21 ref.)

Interaction of inflammatory cytokines and erythropoeitin in iron metabolism and erythropoiesis in anaemia of chronic disease. Jongen-Lavrencic M, et al. **Clin Rheumatol** 1995 Sep;14(5):519–25 (93 ref.)

Interaction between nutrients, pro-inflammatory cytokines and inflammation [editorial] Grimble RF. **Clin Sci (Colch)** 1996 Aug;91(2):121–30 (102 ref.)

Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: what we do and do not know about cytokine regulation. Bone RC. **Crit Care Med** 1996 Jan;24(1):163–72 (87 ref.)

Cytokines and neuronal differentiation. Mehler MF, et al. **Crit Rev Neurobiol** 1995;9(4):419–46 (291 ref.)

AIDS. Viruses, cytokines and Kaposi's sarcoma. Ganem D. **Curr Biol** 1995 May 1;5(5):469–71 (17 ref.)

T-cell subsets. Who does the polarizing? Swain SL. **Curr Biol** 1995 Aug 1;5(8):849–51 (25 ref.)

Cytokine regulation of granuloma formation in schistosomiasis. Wynn TA, et al. **Curr Opin Immunol** 1995 Aug;7(4):505–11 (61 ref.)

Lymphocytes, cytokines, inflammation, and immune trafficking. Tsokos GC. **Curr Opin Rheumatol** 1995 Sep; 7(5):376–83 (84 ref.)

Cytokines as mediators in the pathogenesis of septic shock. Dinarello CA. **Curr Top Microbiol Immunol** 1996; 216:133–65 (160 ref.)

The influence of cytokines on the central nervous system of transgenic mice. Geiger K, et al. **Curr Top Microbiol Immunol** 1996;206:101–17 (104 ref.)

Transgenic models to assess the neuropathogenic potential of HIV-1 proteins and cytokines. Mucke L, et al. **Curr Top Microbiol Immunol** 1995;202:187–205 (98 ref.)

Molecular control of development in normal and leukemic myeloid cells by cytokines, tumor suppressor and oncogenes. Sachs L. **Curr Top Microbiol Immunol** 1996; 211:3–5 (18 ref.)

Role of cytokines and platelet-activating factor in inflammatory bowel disease. Implications for therapy. Nassif A, et al. **Dis Colon Rectum** 1996 Feb;39(2):217–23 (66 ref.)

Cytokines and the endocrine system. II. Roles in substrate metabolism, modulation of thyroidal and pancreatic endocrine cell functions and autoimmune endocrine diseases. Mandrup-Poulsen T, et al. **Eur J Endocrinol** 1996 Jan;134(1):21–30 (174 ref.)

Cytokines and the endocrine system. I. The immunoendocrine network. Mandrup-Poulsen T, et al. **Eur J Endocrinol** 1995 Dec;133(6):660–71 (109 ref.)

Paracrine mechanism of ovarian regulation. Dor J, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Mar;65(1):25–8 (26 ref.)

Mast cells in the cytokine network: the what, where from and what for. Czarnetzki BM, et al. **Exp Dermatol** 1995 Aug;4(4 Pt 2):221–6 (43 ref.)

Cytokines involved in growth and differentiation of human basophils and mast cells. Valent P. **Exp Dermatol** 1995 Aug; 4(4 Pt 2):255–9 (40 ref.)

Tumor-stromal cytokine interactions in ovarian neoplasms. Kacinski BM. **EXS** 1995;74:181–90 (59 ref.)

Keratinocyte growth factor as a cytokine that mediates mesenchymal–epithelial interaction. Rubin JS, et al. **EXS** 1995;74:191–214 (90 ref.)

Fibroblast subpopulations as accelerators of tumor progression: the role of migration stimulating factor. Schor SL. **EXS** 1995;74:273–96 (80 ref.)

Liver regeneration. 2. Role of growth factors and cytokines in hepatic regeneration. Fausto N, et al. **FASEB J** 1995 Dec;9(15):1527–36 (68 ref.)

Lipid mediator networks in cell signaling: update and impact of cytokines. Serhan CN, et al. **FASEB J** 1996 Aug; 10(10):1147–58 (62 ref.)

Chemotactic and suppressor cytokine networks. Thompson K, et al. **Hepatogastroenterology** 1996 Jan–Feb;43(7):15–31 (132 ref.)

Actions of cytokines on the immune response and viral interactions: an overview. Peters M. **Hepatology** 1996 Apr; 23(4):909–16 (79 ref.)

Cytokine mediated effects in mucosal immunity. Kramer DR, et al. **Immunol Cell Biol** 1995 Oct;73(5):389–96 (71 ref.)

Cytokine receptors encoded by poxviruses: a lesson in cytokine biology. Alcami A, et al. **Immunol Today** 1995 Oct;16(10):474–8 (39 ref.)

Cytokines and fever. Luheshi G, et al. **Int Arch Allergy Immunol** 1996 Apr;109(4):301–7 (30 ref.)

Role of cytokines in patients on dialysis [editorial] Pereira BJ, et al. **Int J Artif Organs** 1995 Jun;18(6):293–304 (101 ref.)

Transforming growth factor-beta 1: a lesion-associated cytokine of the nervous system. Kiefer R, et al. **Int J Dev Neurosci** 1995 Jun–Jul;13(3–4):331–9 (54 ref.)

Neurotrophins and cytokines—intermediaries between the immune and nervous systems. Otten U, et al. **Int J Dev Neurosci** 1995 Jun–Jul;13(3–4):147–51 (48 ref.)

Cytokines in neurodegeneration and repair. Rothwell NJ, et al. **Int J Dev Neurosci** 1995 Jun–Jul;13(3–4):179–85 (52 ref.)

Novel insights into the biology of myelodysplastic syndromes: excessive apoptosis and the role of cytokines. Raza A, et al. **Int J Hematol** 1996 Jun;63(4):265–78 (52 ref.)

Immune network and autoimmunity. George J, et al. **Intern Med** 1996 Jan;35(1):3–9 (49 ref.)

Epidermal cytokines in allergic contact dermatitis. Kondo S, et al. **J Am Acad Dermatol** 1995 Nov;33(5 Pt 1):786–800 (194 ref.)

Cytokines and thrombosis. Dosquet C, et al. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S13–9 (65 ref.)

Cytokines regulate vascular functions related to stability of the atherosclerotic plaque. Libby P, et al. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S9–12 (23 ref.)

Cytokines, phagocytes, and pentoxifylline. Mandell GL. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S20–2 (7 ref.)

Hematopoietic stem cell cytokine response. Lowry PA. **J Cell Biochem** 1995 Aug;58(4):410–5 (29 ref.)

Is interleukin 17, an inducible cytokine that stimulates production of other cytokines, merely a redundant player in a sea of other biomolecules? [comment] Broxmeyer HE. **J Exp Med** 1996 Jun 1;183(6):2411–5 (43 ref.) Comment on: J Exp Med 1996 Jun 1;183(6):2593–603.

Is IL-6 both a cytokine and a neurotrophic factor? [comment] Wagner JA. **J Exp Med** 1996 Jun 1;183(6):2417–9 (28 ref.) Comment on: J Exp Med 1996 Jun 1;183(6):2627–34.

Cytokines in aging and muscle homeostasis. Cannon JG. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:120–3 (39 ref.)

Dysregulation of cytokines during graft-versus-host disease. Krenger W, et al. **J Hematother** 1996 Feb;5(1):3–14 (136 ref.)

Review: nomenclature and biologic significance of cytokines involved in inflammation and the host immune response. Liles WC, et al. **J Infect Dis** 1995 Dec;172(6):1573–80 (63 ref.)

Acute lung injury: the role of cytokines in the elicitation of neutrophils [published erratum appears in J Investig Med 1995 Apr;43(2):204] Strieter RM, et al. **J Investig Med** 1994 Dec;42(4):640–51 (109 ref.)

Cellular adhesion molecules in rheumatoid arthritis: regulation by cytokines and possible clinical importance. Szekanecz Z, et al. **J Investig Med** 1996 Apr;44(4):124–35 (164 ref.)

The inflammatory response in interleukin-1 beta-deficient mice: comparison with other cytokine-related knock-out mice. Fantuzzi G, et al. **J Leukoc Biol** 1996 Apr; 59(4):489–93 (41 ref.)

Gene transfer for cytokine functional studies in the lung: the multifunctional role of GM-CSF in pulmonary inflammation. Xing Z, et al. **J Leukoc Biol** 1996 Apr; 59(4):481–8 (55 ref.)

Gp130, a shared signal transducing receptor component for hematopoietic and neuropoietic cytokines. Taga T. **J Neurochem** 1996 Jul;67(1):1–10 (90 ref.)

The role of cytokines in wound healing. Slavin J. **J Pathol** 1996 Jan;178(1):5–10 (50 ref.)

Regulation of human B cell lymphopoiesis by adhesion molecules and cytokines. Ryan DH, et al. **Leuk Lymphoma** 1995 May;17(5–6):375–89 (137 ref.)

Autocrine and paracrine regulation of neoplastic cell growth in hairy cell leukemia. Schmid M, et al. **Leuk Lymphoma** 1995 May;17(5–6):401–10 (127 ref.)

Control of apoptosis in hematopoiesis and leukemia by cytokines, tumor suppressor and oncogenes. Lotem J, et al. **Leukemia** 1996 Jun;10(6):925–31 (131 ref.)

Regulation of human immunodeficiency virus type 1 and cytokine gene expression in myeloid cells by NF-kappa B/Rel transcription factors. Roulston A, et al. **Microbiol Rev** 1995 Sep;59(3):481–505 (481 ref.)

Role of atherogenic lipoproteins in cytokine-mediated renovascular injury. Kirschenbaum MA, et al. **Miner Electrolyte Metab** 1996;22(1–3):47–50 (20 ref.)

The role of cytokines in inflammatory glomerular injury. Lakkis FG, et al. **Miner Electrolyte Metab** 1995; 21(4–5):250–61 (116 ref.)

The pathogenesis of tubulointerstitial disease associated with glomerulonephritis: the glomerular cytokine theory. Pichler R, et al. **Miner Electrolyte Metab** 1995; 21(4–5):317–27 (140 ref.)

Are cytokines responsible for the asthmatic state of the airways? Kips JC, et al. **Monaldi Arch Chest Dis** 1996 Jun; 51(3):223–7 (52 ref.)

The role of cytokines in human lung fibrosis. Vaillant P, et al. **Monaldi Arch Chest Dis** 1996 Apr;51(2):145–52 (49 ref.)

Progression of renal failure: what is the role of cytokines? Floege J, et al. **Nephrol Dial Transplant** 1995;10(9):1575–86 (161 ref.)

Cytokines and growth factors in renal disease. Noronha IL, et al. **Nephrol Dial Transplant** 1995;10(6):775–86 (156 ref.)

Roles of cytokines in the neural-immune interactions: modulation of NMDA responses by IFN-alpha. Katafuchi T, et al. **Neurobiology (Bp)** 1995;3(3–4):319–27 (39 ref.)

Sleep, microbes and cytokines. Krueger JM, et al. **Neuroimmunomodulation** 1994 Mar–Apr;1(2):100–9 (121 ref.)

Cytokines in the central nervous system: regulatory roles in neuronal function, cell death and repair. Sei Y, et al. **Neuroimmunomodulation** 1995 May–Jun;2(3):121–33 (159 ref.)

Cytokines and food intake: the relevance of the immune system to the student of ingestive behavior. Weingarten HP. **Neurosci Biobehav Rev** 1996;20(1):163–70 (90 ref.)

Cytokine responses in leprosy lesions. Modlin RL. **Nippon Rai Gakkai Zasshi** 1995 Jul;64(2):85–8 (14 ref.)

Cytokines and feeding suppression: an integrative view from neurologic to molecular levels. Plata-Salamán CR. **Nutrition** 1995 Sep–Oct;11(5 Suppl):674–7 (26 ref.)

Immune activation: the role of pro-inflammatory cytokines in inflammation, illness responses and pathological pain states. Watkins LR, et al. **Pain** 1995 Dec;63(3):289–302 (135 ref.)

The cytokine network controlling peritoneal inflammation. Topley N. **Perit Dial Int** 1995;15(7 Suppl):S35–9; discussion S39–40 (39 ref.)

Activation of the HPA axis by immune insults: roles and interactions of cytokines, eicosanoids, glucocorticoids. Buckingham JC, et al. **Pharmacol Biochem Behav** 1996 May; 54(1):285–98 (138 ref.)

Janus kinases in cytokine signalling. Ihle JN. **Philos Trans R Soc Lond B Biol Sci** 1996 Feb 29; 351(1336):159–66 (120 ref.)

The IRS-signalling system in insulin and cytokine action. White MF. **Philos Trans R Soc Lond B Biol Sci** 1996 Feb 29;351(1336):181–9 (80 ref.)

Viruses, cytokines, antigens, and autoimmunity. Gianani R, et al. **Proc Natl Acad Sci U S A** 1996 Mar 19;93(6):2257–9 (43 ref.)

Regulation of gut glutamine metabolism: role of hormones and cytokines. Abumrad NN, et al. **Proc Nutr Soc** 1995 Jul;54(2):525–33 (33 ref.)

Adhesive interactions in the hematopoietic system: regulation by cytokines. Fernández M, et al. **Proc Soc Exp Biol Med** 1996 Sep;212(4):313–23 (136 ref.)

Cytokines and nitric oxide in islet inflammation and diabetes. McDaniel ML, et al. **Proc Soc Exp Biol Med** 1996 Jan; 211(1):24–32 (41 ref.)

Cytokines and osteoporosis [editorial] Cohen-Solal M, et al. **Rev Rhum Engl Ed** 1996 Feb;63(2):83–6 (19 ref.)

Cytokines and their antagonists in myeloid disorders. Estrov Z, et al. **Semin Hematol** 1995 Jul;32(3):220–31 (124 ref.)

The Janus protein tyrosine kinases in hematopoietic cytokine signaling. Ihle JN. **Semin Immunol** 1995 Aug;7(4):247–54 (57 ref.)

Potential roles for endothelins in systemic inflammatory response syndrome with a particular relationship to cytokines. Battistini B, et al. **Shock** 1996 Mar;5(3):167–83 (181 ref.)

Cytokine regulation of chemical sensitization. Kimber I, et al. **Toxicol Lett** 1995 Dec;82–83:491–6 (29 ref.)

Role of proinflammatory cytokines in a toxic response: application of cytokine knockout mice in toxicological research. Ryffel B. **Toxicol Lett** 1995 Dec;82–83:477–82 (33 ref.)

Cytokine knockout mice: possible application in toxicological research. Ryffel B. **Toxicology** 1995 Dec 20;105(1):69–80 (55 ref.)

[Growth factors and cytokines as messengers of hormonal effects] Ilvesmäki V, et al. **Duodecim** 1994;110(10):949–57 (53 ref.) **(Fin)**

[Darier's erythema annulare centrifugum of neonatal onset with a 15 years' follow-up. Efficacy of interferon and role of cytokines] Guillet MH, et al. **Ann Dermatol Venereol** 1995;122(6–7):422–6 (31 ref.) (Eng. Abstr.) **(Fre)**

[Physiopathology of symptoms of malaria. Role of cytokines, cytoadherence and premunition] Hommel M. **Presse Med** 1996 Jan 20;25(2):70–6 (54 ref.) (Eng. Abstr.) **(Fre)**

[Classification of cytokines in the cyclic morphofunctioning and the gestational endometrium] Ciobotaru C. **Rom J Morphol Embryol** 1995 Jan–Jun;41(1–2):23–37 (7 ref.) **(Fre)**

[Cytokines in chronic inflammatory intestinal diseases] Neurath MF, et al. **Dtsch Med Wochenschr** 1996 May 31; 121(22):735–41 (48 ref.) **(Ger)**

[Cytokines: biology and therapeutic relevance] Roeb E, et al. **Dtsch Med Wochenschr** 1996 Jun 14;121(24):803–9 (36 ref.) **(Ger)**

[Clinical and immunobiological observations on the inflammatory activity of sarcoidosis] Müller-Quernheim J. **Pneumologie** 1996 Jan;50(1):40–8 (101 ref.) **(Ger)**

[Intra-amniotic infection, cytokines and premature labor] Baumann P, et al. **Wien Klin Wochenschr** 1995; 107(20):598–607 (102 ref.) (Eng. Abstr.) **(Ger)**

[Leishmania-macrophage interactions: role of cytokines and molecules co-involved in killing] Faliero SM, et al. **Parassitologia** 1995 Apr;37(1):5–15 (126 ref.) (Eng. Abstr.) **(Ita)**

[Correlation between the nervous system and immune system] Katafuchi T. **Fukuoka Igaku Zasshi** 1996 Jun;87(6):127–32 (3 ref.) **(Jpn)**

[Cytokines and growth of cancers] Tachibana M. **Hum Cell** 1995 Dec;8(4):215–6 (18 ref.) **(Jpn)**

[The mechanism of induction and expression of protective immunity with special reference to the role of cytokines] Mitsuyama M. **Kekkaku** 1995 Nov;70(11):651–7 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Cytokines during the perisurgical period] Kawamura T. **Masui** 1996 May;45(5):536–46 (29 ref.) (Eng. Abstr.) **(Jpn)**

[Role of cytokines in pathophysiology of asthma] Ishioka S. **Nippon Naika Gakkai Zasshi** 1996 Feb 10;85(2):184–8 (5 ref.) **(Jpn)**

[Role of cytokines in etiological mechanism of congestive heart failure] Sasayama S, et al. **Nippon Naika Gakkai Zasshi** 1995 Sep 10;84(9):1459–64 (25 ref.) **(Jpn)**

[Recent development in immunology of leprosy: roles of immunoregulatory cytokines in the establishment of immuno–unresponsiveness to M. leprae in leprosy patients] Tomioka H. **Nippon Rai Gakkai Zasshi** 1995 Jul;64(2):69–84 (37 ref.) **(Jpn)**

[Role of cytokines in regulation of food intake and appetite] Shimizu H. **Nippon Rinsho** 1995 Jun;53 Suppl:58–63 (39 ref.) **(Jpn)**

[Induction of cytotoxic T cells specific for HCV–NS5 and cytokine] Shirai M, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:163–9 (17 ref.) **(Jpn)**

[Attempts to elucidate the reasons why mycobacterial infections are generally intractable] Tomioka H. **Nippon Saikingaku Zasshi** 1995 Jul;50(3):687–701 (50 ref.) **(Jpn)**

[The role of cytokines and growth factors in pathogenesis and progression of glomerulonephritis] Wągrowska–Danilewicz M, et al. **Pol Arch Med Wewn** 1996 May;95(5):493–6 (74 ref.) **(Pol)**

[The role of free radicals in pathogenesis of insulin dependent diabetes mellitus] Komosińska K, et al. **Postepy Hig Med Dosw** 1995;49(6):733–46 (64 ref.) (Eng. Abstr.) **(Pol)**

[Cytokines in persons infected with HIV and patients with AIDS] Piasecki E. **Postepy Hig Med Dosw** 1995; 49(1):125–35 (46 ref.) (Eng. Abstr.) **(Pol)**

[Role of cytokines in resistance and pathology in Trypanosoma cruzi infection] Laucella SA, et al. **Rev Argent Microbiol** 1996 Apr–Jun;28(2):99–109 (81 ref.) (Eng. Abstr.) **(Spa)**

SECRETION

Effect of peritoneal dialysis on cytokine production by peritoneal cells. Topley N, et al. **Blood Purif** 1996; 14(2):188–97 (62 ref.)

Cytokine patterns in the effluent of continuous ambulatory peritoneal dialysis: relationship to peritoneal permeability. Zemel D, et al. **Blood Purif** 1996;14(2):198–216 (171 ref.)

Cytokine secretion by human mast cells. Krüger–Krasagakes S, et al. **Exp Dermatol** 1995 Aug;4(4 Pt 2):250–4 (26 ref.)

Th1 and Th2 subsets: paradigms lost? Kelso A. **Immunol Today** 1995 Aug;16(8):374–9 (41 ref.)

THERAPEUTIC USE

Cytokines in the treatment of malignancies. Jákó J, et al. **Acta Med Hung** 1994;50(3–4):257–73 (50 ref.)

Cytokine therapy of HIV infection. Sneller MC. **Adv Exp Med Biol** 1996;394:411–9 (54 ref.)

Cytokines in stem cell transplantation. Stewart FM. **Ann N Y Acad Sci** 1995 Dec 29;770:53–69 (62 ref.)

Cytokines and immunological monitoring. Kopp WC, et al. **Cancer Chemother Biol Response Modif** 1996;16:189–238 (203 ref.)

"Kinoids": the basis for anticytokine immunization and their use in HIV infection. Bizzini B, et al. **Cell Mol Biol (Noisy–le–grand)** 1995 May;41(3):351–6 (38 ref.)

The role of angiogenic cytokines in cardiovascular disease. Isner JM. **Clin Immunol Immunopathol** 1996 Sep;80(3 Pt 2):S82–91 (87 ref.)

The new generation of recombinant human hematopoietic cytokines. Hunt P, et al. **Curr Opin Biotechnol** 1995 Dec; 6(6):692–7 (45 ref.)

Therapeutic strategies for cytokines. Dutcher JP. **Curr Opin Oncol** 1995 Nov;7(6):566–71 (76 ref.)

Influence of local cytokines on tumor metastasis: using cytokine gene–transfected tumor cells as experimental models. Qin Z, et al. **Curr Top Microbiol Immunol** 1996; 213 (Pt 3):55–64 (27 ref.)

The impact of cytokines on high dose chemotherapy followed by transplantation of purified and ex vivo expanded peripheral blood stem cells: achieving a state of minimal residual disease for tumor immunotherapy with cytokine gene transfected cells [editorial] Mertelsmann R. **Eur Cytokine Netw** 1995 Mar–Apr;6(2):79–82 (12 ref.)

Cytokine treatment of mast–cell–mediated skin diseases. Luger TA. **Exp Dermatol** 1995 Aug;4(4 Pt 2):277–80 (39 ref.)

The thrombocytopenia of cancer. Prospects for effective cytokine therapy. Kaushansky K. **Hematol Oncol Clin North Am** 1996 Apr;10(2):431–55 (167 ref.)

Cytokines and immunological control of Eimeria spp. Ovington KS, et al. **Int J Parasitol** 1995 Nov; 25(11):1331–51 (114 ref.)

Cytokines and bone marrow transplantation. Takaku F. **J Cancer Res Clin Oncol** 1995;121(12):701–9 (88 ref.)

Immunotherapy and immunoprophylaxis in bone marrow transplantation. Barnes RA. **J Hosp Infect** 1995 Jun;30 Suppl:223–31 (53 ref.)

Interferons and other cytokines in head and neck cancer. Hamasaki VK, et al. **Med Oncol** 1995 Mar;12(1):23–33 (64 ref.)

[Treatment of inflammation with anti–inflammatory cytokines: example in models of auto–immune diseases] Bessis N, et al. **C R Seances Soc Biol Fil** 1995;189(4):579–90 (33 ref.) (Eng. Abstr.) **(Fre)**

[Immunotherapy of colorectal cancers] Bécouarn Y, et al. **Gastroenterol Clin Biol** 1996 Feb;20(1):20–32 (106 ref.) **(Fre)**

[Interferons in the therapy of solid tumors] Tomao S, et al. **Clin Ter** 1995 Aug–Sep;146(8–9):491–502 (96 ref.) (Eng. Abstr.) **(Ita)**

[Treatment with growth factors and cytokines in hematologic diseases] Waage A, et al. **Tidsskr Nor Laegeforen** 1996 May 10;116(12):1465–9 (33 ref.) (Eng. Abstr.) **(Nor)**

TOXICITY

Neuropathogenic actions of cytokines assessed in transgenic mice. Campbell IL. **Int J Dev Neurosci** 1995 Jun–Jul; 13(3–4):275–84 (68 ref.)

CYTOKINES, CHEMOTACTIC see **CHEMOKINES**

CYTOKINESIS see **CELL DIVISION**

CYTOKINETICS see **CELL CYCLE**

CYTOLOGICAL TECHNIQUES

see related
CYTODIAGNOSIS

Root border cells as tools in plant cell studies. Brigham LA, et al. **Methods Cell Biol** 1995;49:377–87 (20 ref.)

Manipulation of pollen grains for gametophytic and sporophytic types of growth. Raghavan V. **Methods Cell Biol** 1995;49:367–75 (11 ref.)

Cell optical displacement assay (CODA)—measurements of cytoskeletal tension in living plant cells with a laser optical trap. Schindler M. **Methods Cell Biol** 1995;49:71–84 (44 ref.)

Role of cytology in intraoperative diagnosis. A practical guide. Czerniak B, et al. **Pathol Annu** 1995;30 Pt 2:83–102 (52 ref.)

[Preparation of apical and basolateral membranes from small intestinal epithelium. Methodologic aspects] Usatiuk PV, et al. **Ukr Biokhim Zh** 1995 Sep–Oct;67(5):16–24 (94 ref.) (Eng. Abstr.) **(Ukr)**

TRENDS

Update of immunocytochemistry in cytopathology. van Hoeven KH, et al. **Pathol Annu** 1995;30 Pt 2:245–67 (84 ref.)

CYTOLOGY

see related
CELLS

CYTOMEGALIC INCLUSION DISEASE see **CYTOMEGALOVIRUS INFECTIONS**

CYTOMEGALOVIRUS

Transfusion–transmitted cytomegalovirus: the part–time pathogen. Gunter KC. **Pediatr Pathol Lab Med** 1995 May–Jun;15(3):515–34 (100 ref.)

DRUG EFFECTS

Cytomegalovirus: genetics of drug resistance. Biron KK. **Adv Exp Med Biol** 1996;394:135–43 (43 ref.)

Molecular detection of human cytomegalovirus and determination of genotypic ganciclovir resistance in clinical specimens. Spector SA, et al. **Clin Infect Dis** 1995 Oct;21 Suppl 2:S170–3 (22 ref.)

Drug resistance in cytomegalovirus: current knowledge and implications for patient management. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996;12 Suppl 1:S1–22 (81 ref.)

[Active antiviral agents against human cytomegalovirus and their use in pediatrics] Mazeron MC, et al. **Arch Pediatr** 1996;3 Suppl 1:309s–311s (12 ref.) **(Fre)**

GENETICS

Cytomegalovirus: genetics of drug resistance. Biron KK. **Adv Exp Med Biol** 1996;394:135–43 (43 ref.)

Cytomegalovirus genes: their structure and function. Stenberg RM, et al. **Scand J Infect Dis Suppl** 1995;99:3–6 (42 ref.)

IMMUNOLOGY

Immunoprophylaxis against cytomegalovirus disease. Adler SP. **Scand J Infect Dis Suppl** 1995;99:105–9 (41 ref.)

Searching for antibodies specific for human cytomegalovirus: is it diagnostically useful? When and how. Landini MP, et al. **Scand J Infect Dis Suppl** 1995;99:18–23 (43 ref.)

ISOLATION & PURIFICATION

Cytomegalovirus as precipitating factor of acute bacterial sinusitis in an immunocompetent patient. A case report. Morre TD, et al. **Acta Otorhinolaryngol Belg** 1996; 50(1):37–40 (20 ref.)

Cytomegalovirus and atherosclerosis. Melnick JL, et al. **Bioessays** 1995 Oct;17(10):899–903 (28 ref.)

Molecular detection of human cytomegalovirus and determination of genotypic ganciclovir resistance in clinical specimens. Spector SA, et al. **Clin Infect Dis** 1995 Oct;21 Suppl 2:S170–3 (22 ref.)

Detection of human cytomegalovirus DNA: how, when and where? Gerna G, et al. **Scand J Infect Dis Suppl** 1995; 99:11–5 (46 ref.)

The cytomegalovirus antigenemia assay: a plea for standardization. The TH, et al. **Scand J Infect Dis Suppl** 1995;99:25–9 (31 ref.)

PATHOGENICITY

Pathogenicity: animal models. Bruggeman CA, et al. **Scand J Infect Dis Suppl** 1995;99:43–50 (64 ref.)

Cytomegalovirus persistence in macrophages and endothelial cells. Fish KN, et al. **Scand J Infect Dis Suppl** 1995;99:34–40 (54 ref.)

Deletion mutants in human cytomegalovirus glycoprotein US9 are impaired in cell–cell transmission and in altering tight junctions of polarized human retinal pigment epithelial cells. Pereira L, et al. **Scand J Infect Dis Suppl** 1995;99:82–7 (42 ref.)

PHYSIOLOGY

Cytomegalovirus latency and latency–specific transcription in hematopoietic progenitors. Kondo K, et al. **Scand J Infect Dis Suppl** 1995;99:63–7 (24 ref.)

CYTOMEGALOVIRUS INFECTIONS

Cytomegalovirus encephalitis. Arribas JR, et al. **Ann Intern Med** 1996 Oct 1;125(7):577–87 (133 ref.)

Advances in the management of AIDS–related cytomegalovirus retinitis [see comments] Masur H, et al. **Ann Intern Med** 1996 Jul 15;125(2):126–36 (69 ref.) Comment in: Ann Intern Med 1996 Jul 15;125(2):144–5.

Pathogenicity: animal models. Bruggeman CA, et al. **Scand J Infect Dis Suppl** 1995;99:43–50 (64 ref.)

BLOOD

Cytomegalovirus as a cause of pancytopenia. Almeida–Porada GD, et al. **Leuk Lymphoma** 1996 Apr; 21(3–4):217–23 (59 ref.)

COMPLICATIONS

Management of cytomegalovirus disease. Danner SA. **AIDS** 1995 Dec;9 Suppl 2:S3–S8 (16 ref.)

Cytomegalovirus and atherosclerosis. Melnick JL, et al. **Bioessays** 1995 Oct;17(10):899–903 (28 ref.)

[Liver, biliary tracts and human immunodeficiency virus infection. 2: hepatobiliary complications of AIDS] Vuitton DA, et al. **Gastroenterol Clin Biol** 1996;20(3):281–93 (146 ref.) **(Fre)**

[Left vocal cord paralysis in cytomegalovirus multifocal neuropathy in a patient with HIV infection] de La Blanchardiere A, et al. **Presse Med** 1996 Jan 27;25(3):106–7 (7 ref.) (Eng. Abstr.) **(Fre)**

[Clinical classification of adult T–cell leukemia and its complications] Tamura K. **Rinsho Byori** 1996 Jan; 44(1):19–23 (7 ref.) (Eng. Abstr.) **(Jpn)**

CONGENITAL

Congenital cytomegalovirus infection and disease. Demmler GJ. **Adv Pediatr Infect Dis** 1996;11:135–62 (130 ref.)

Congenital cytomegalovirus infection. Daniel Y, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Nov;63(1):7–16 (121 ref.)

DIAGNOSIS

Cytomegalovirus colitis mimicking colon carcinoma in an HIV–negative patient with chronic renal failure. Falagas ME, et al. **Am J Gastroenterol** 1996 Jan;91(1):168–9 (11 ref.)

Cytomegalovirus sinusitis. A new manifestation of AIDS. Marks SC, et al. **Arch Otolaryngol Head Neck Surg** 1996 Jul;122(7):789–91 (11 ref.)

Molecular detection of human cytomegalovirus and determination of genotypic ganciclovir resistance in clinical specimens. Spector SA, et al. **Clin Infect Dis** 1995 Oct;21 Suppl 2:S170–3 (22 ref.)

Neurologic opportunistic infections. Clifford DB. **Curr Opin Neurol** 1995 Jun;8(3):175–8 (32 ref.)

Detection of human cytomegalovirus DNA: how, when and where? Gerna G, et al. **Scand J Infect Dis Suppl** 1995; 99:11–5 (46 ref.)

Searching for antibodies specific for human cytomegalovirus: is it diagnostically useful? When and how. Landini MP, et al. **Scand J Infect Dis Suppl** 1995;99:18–23 (43 ref.)

The cytomegalovirus antigenemia assay: a plea for standardization. The TH, et al. **Scand J Infect Dis Suppl** 1995;99:25–9 (31 ref.)

Cytomegalovirus pneumonia: presentation, diagnosis, and

treatment. Ljungman P. **Semin Respir Infect** 1995 Dec; 10(4):209–15 (44 ref.)
[Clinical presentation of primary cytomegalovirus infection in a non-immunodepressed adult] Robert JP, et al. **Rev Med Suisse Romande** 1996 May;116(5):379–84 (30 ref.) (Eng. Abstr.) **(Fre)**
[Cytomegalovirus pneumopathies. What role should be given to cytomegaloviruses isolated from blood and bronchoalveolar lavage fluid in AIDS and from organ and bone marrow grafts?] Blot F, et al. **Rev Pneumol Clin** 1995; 51(6):309–20 (102 ref.) (Eng. Abstr.) **(Fre)**
[CMV infection and cytomegalovirus disease in immunodepressed patients] Mustafa MM. **Pediatr Pol** 1995 May;70(5):443–7 (42 ref.) **(Pol)**

DRUG THERAPY

Oral ganciclovir for cytomegalovirus infections. Follansbee SE, et al. **Adv Exp Med Biol** 1996;394:93–103 (10 ref.)
Management of cytomegalovirus disease. Danner SA. **AIDS** 1995 Dec;9 Suppl 2:S3–S8 (16 ref.)
Cytomegalovirus retinitis in AIDS: natural history, diagnosis, and treatment. Dunn JP, et al. **AIDS Clin Rev** 1995–96; :99–129 (120 ref.)
Management of cytomegalovirus infection. The Jefferiss Wing Therapeutics and Protocols Group. Fisher M, et al. **Int J STD AIDS** 1995 Sep–Oct;6(5):313–9 (28 ref.)
Drug resistance in cytomegalovirus: current knowledge and implications for patient management. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996;12 Suppl 1:S1–22 (81 ref.)
Ganciclovir. Crumpacker CS. **N Engl J Med** 1996 Sep 5; 335(10):721–9 (86 ref.)
Update (1995) on clinical trials of antiviral therapy and prophylaxis for AIDS-related cytomegalovirus disease. Jacobson MA. **Scand J Infect Dis Suppl** 1995;99:96–9 (25 ref.)
Prevention and treatment of cytomegalovirus disease in thoracic organ transplant patients: evidence for a beneficial effect of hyperimmune globulin. Valantine HA. **Transplant Proc** 1995 Oct;27(5 Suppl 1):49–57 (62 ref.)
[Cytomegalovirus disease in the AIDS patient. The current status of therapy and the outlook] Stoehr A, et al. **Dtsch Med Wochenschr** 1995 Dec 22;120(51–52):1785–8 (39 ref.) **(Ger)**
[A case of Guillain-Barré syndrome associated with anti-GM2 antibody due to cytomegalovirus infection--special reference to the effect of ganciclovir] Niwa K, et al. **Rinsho Shinkeigaku** 1995 Jun;35(6):652–6 (18 ref.) (Eng. Abstr.) **(Jpn)**

EPIDEMIOLOGY

Cytomegalovirus infection in marrow transplantation. Boeckh M, et al. **Cancer Treat Res** 1995;76:97–136 (203 ref.)
Recurrent cytomegalovirus disease in solid-organ transplant recipients. Falagas ME, et al. **Transplant Proc** 1995 Oct; 27(5 Suppl 1):34–7 (23 ref.)
[The epidemiology of cytomegalovirus infection] Rădulescu A, et al. **Bacteriol Virusol Parazitol Epidemiol** 1995 Jan–Mar;40(1):31–6 (11 ref.) **(Rum)**

ETIOLOGY

Cytomegalovirus infection in organ transplant recipients. Hibberd PL, et al. **Infect Dis Clin North Am** 1995 Dec; 9(4):863–77 (87 ref.)
[The significance of cytomegalovirus infection in the period after a heart transplant] Manito N, et al. **Rev Esp Cardiol** 1995;48 Suppl 7:108–14 (36 ref.) (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

Syndromes induced by cytomegalovirus infection. Price P, et al. **Clin Immunol Immunopathol** 1996 Sep;80(3 Pt 1):215–24 (92 ref.)
Cytomegalovirus latency and latency-specific transcription in hematopoietic progenitors. Kondo K, et al. **Scand J Infect Dis Suppl** 1995;99:63–7 (24 ref.)
The role of CD8+, CD57+ cells in human cytomegalovirus and other viral infections. Wang EC, et al. **Scand J Infect Dis Suppl** 1995;99:69–77 (78 ref.)
Pathogenesis of cytomegalovirus pneumonia in immunocompromised hosts. Riddell SR. **Semin Respir Infect** 1995 Dec;10(4):199–208 (71 ref.)

PATHOLOGY

[Pathologic anatomy of cytomegalovirus encephalomyelitis and varicella-zona virus encephalomyelitis] Henin D, et al. **J Neuroradiol** 1995 Sep;22(3):180–3 (14 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Clinical impact of cytomegalovirus infections of the nervous system in patients with AIDS. McCutchan JA. **Clin Infect Dis** 1995 Oct;21 Suppl 2:S196–201 (42 ref.)

PREVENTION & CONTROL

Prophylaxis and treatment of CMV infections in transplantation. Zaia JA. **Adv Exp Med Biol** 1996; 394:117–34 (72 ref.)
Current prospects for immunization against cytomegaloviral disease. Adler SP. **Infect Agents Dis** 1996 Jan;5(1):29–35 (55 ref.)
Cytomegalovirus infection in the bone marrow transplant recipient. Zaia JA, et al. **Infect Dis Clin North Am** 1995 Dec;9(4):879–900 (95 ref.)
Preventive care in obstetrics: toxoplasmosis, cytomegalovirus, and hepatitis B. Ledger WJ. **J Matern Fetal Med** 1996 May–Jun;5(3):100–5 (26 ref.)
Immunoprophylaxis against cytomegalovirus disease. Adler SP. **Scand J Infect Dis Suppl** 1995;99:105–9 (41 ref.)
Prophylactic cytomegalovirus management strategies. Martin M. **Transplant Proc** 1995 Oct;27(5 Suppl 1):23–7 (30 ref.)
Prevention and treatment of cytomegalovirus disease in thoracic organ transplant patients: evidence for a beneficial effect of hyperimmune globulin. Valantine HA. **Transplant Proc** 1995 Oct;27(5 Suppl 1):49–57 (62 ref.)
Cytomegalovirus prophylaxis in solid organ transplant recipients. Patel R, et al. **Transplantation** 1996 May 15; 61(9):1279–89 (58 ref.)
[Prevention of cytomegalovirus in organ transplantation] Aguado JM. **Rev Clin Esp** 1996 Apr;196(4):240–7 (118 ref.) **(Spa)**

THERAPY

Immunotherapy of CMV infections. Paar DP, et al. **Adv Exp Med Biol** 1996;394:145–51 (20 ref.)
Prophylaxis and treatment of CMV infections in transplantation. Zaia JA. **Adv Exp Med Biol** 1996; 394:117–34 (72 ref.)
Cytomegalovirus pneumonia: presentation, diagnosis, and treatment. Ljungman P. **Semin Respir Infect** 1995 Dec; 10(4):209–15 (44 ref.)
Role of immunoglobulins and new antivirals in treatment of cytomegalovirus infection. Paya CV. **Transplant Proc** 1995 Oct;27(5 Suppl 1):28–30 (21 ref.)

TRANSMISSION

Transfusion-transmitted cytomegalovirus: the part-time pathogen. Gunter KC. **Pediatr Pathol Lab Med** 1995 May–Jun;15(3):515–34 (100 ref.)
Transfusion-dependent thalassemia: viral complications (epidemiology and follow-up). de Montalembert M, et al. **Semin Hematol** 1995 Oct;32(4):280–7 (46 ref.)
[The problem of cytomegalovirus infection in military blood transfusions] Shevchenko IuL, et al. **Voen Med Zh** 1995 Nov;(11):27–31, 80 (18 ref.) (Eng. Abstr.) **(Rus)**

VIROLOGY

Cytomegalovirus as precipitating factor of acute bacterial sinusitis in an immunocompetent patient. A case report. Morre TD, et al. **Acta Otorhinolaryngol Belg** 1996; 50(1):37–40 (20 ref.)
Cytomegalovirus persistence in macrophages and endothelial cells. Fish KN, et al. **Scand J Infect Dis Suppl** 1995;99:34–40 (54 ref.)

CYTOMEGALOVIRUS RETINITIS

Cytomegalovirus retinitis in patients with AIDS: current status. Luckie AP. **Med J Aust** 1995 Nov 6;163(9):489–92 (24 ref.)
Deletion mutants in human cytomegalovirus glycoprotein US9 are impaired in cell–cell transmission and in altering tight junctions of polarized human retinal pigment epithelial cells. Pereira L, et al. **Scand J Infect Dis Suppl** 1995;99:82–7 (42 ref.)
[Chorioretinal manifestations in AIDS] Snyers B, et al. **J Fr Ophtalmol** 1995;18(10):634–44 (76 ref.) **(Fre)**

DRUG THERAPY

Current management of cytomegalovirus retinitis in AIDS update on ganciclovir and foscarnet for CMV infections. Jacobson MA. **Adv Exp Med Biol** 1996;394:85–92 (28 ref.)
Controversies in the treatment of cytomegalovirus retinitis: foscarnet versus ganciclovir. Jabs DA. **Infect Agents Dis** 1995 Sep;4(3):131–42 (63 ref.)
Oral ganciclovir: a new option for patients with CMV retinitis [editorial] Fisher M, et al. **Int J STD AIDS** 1996 Jan–Feb;7(1):1–3 (19 ref.)

ETIOLOGY

Acquired immunodeficiency syndrome and the eye--1996 [editorial] Jabs DA. **Arch Ophthalmol** 1996 Jul;114(7):863–6 (61 ref.)

PATHOLOGY

A foveal-sparing pattern of cytomegalovirus retinitis in the acquired immunodeficiency syndrome. Luckie AP, et al. **Aust N Z J Ophthalmol** 1996 Feb;24(1):53–9 (23 ref.)

CYTOMETRY, FLOW see **FLOW CYTOMETRY**

CYTOMETRY, IMAGE see **IMAGE CYTOMETRY**

CYTOPATHOGENIC EFFECT, VIRAL

see related
PLAQUE ASSAY

CYTOPLASM

Intracytoplasmic sperm injection--what kind of reproduction is being assisted? De Jonge CJ, et al. **Hum Reprod** 1995 Oct;10(10):2518–20 (11 ref.)
Intracytoplasmic sperm injection--is there a need for an animal model, especially in assessing the genetic risks involved? Ng SC, et al. **Hum Reprod** 1995 Oct; 10(10):2523–5 (26 ref.)
Intracytoplasmic sperm injection (ICSI): potential genetic concerns. Patrizio P. **Hum Reprod** 1995 Oct;10(10):2520–3 (26 ref.)
Intracytoplasmic sperm injection three years after the birth of the first ICSI child. Van Steirteghem A, et al. **Hum Reprod** 1995 Oct;10(10):2527–8 (16 ref.)
Is an animal model needed for intracytoplasmic sperm injection (ICSI) and other assisted reproduction technologies? Yanagimachi R. **Hum Reprod** 1995 Oct; 10(10):2525–6 (11 ref.)

ENZYMOLOGY

The Btk subfamily of cytoplasmic tyrosine kinases: structure, regulation and function. Rawlings DJ, et al. **Semin Immunol** 1995 Aug;7(4):237–46 (81 ref.)

GENETICS

Sorting of messenger RNAs in the cytoplasm: mRNA localization and the cytoskeleton. Hesketh JE. **Exp Cell Res** 1996 Jun 15;225(2):219–36 (123 ref.)

IMMUNOLOGY

Anti-neutrophil cytoplasmic antibodies in generalized autoimmune diseases. Schnabel A, et al. **Int Arch Allergy Immunol** 1996 Mar;109(3):201–6 (32 ref.)
[Cytoplasmic islet cell antibodies and GAD antibodies in diagnosis of diabetes] Bieg S, et al. **Med Klin** 1995 Oct 15;90(10):594–8 (48 ref.) **(Ger)**
[Autoantibodies against neutrophil cytoplasm and their significance in the classification of systemic vasculitis] Fijałkowska-Morawska J, et al. **Przegl Lek** 1995; 52(6):318–22 (20 ref.) (Eng. Abstr.) **(Pol)**

METABOLISM

Nuclear pores and macromolecular assemblies involved in nucleocytoplasmic transport. Stewart M, et al. **Curr Opin Struct Biol** 1996 Apr;6(2):162–5 (43 ref.)
Intracellular structure and nucleocytoplasmic transport. Agutter PS. **Int Rev Cytol** 1995;162B:183–224 (182 ref.)
Nucleocytoplasmic transport. Görlich D, et al. **Science** 1996 Mar 15;271(5255):1513–8 (77 ref.)
Plasmodesmata: plant channels for molecules on the move [see comments] Zambryski P. **Science** 1995 Dec 22; 270(5244):1943–4 (15 ref.) Comment in: Science 1995 Dec 22;270(5244):1980–3. Comment in: Science 1995 Dec 22;270(5244):1983–5.
Nucleocytoplasmic shuttling of steroid receptors. Defranco DB, et al. **Vitam Horm** 1995;51:315–38 (86 ref.)

ULTRASTRUCTURE

On the real structure of the cytoplasmic matrix: learning from the embedment-free electron microscopy. Kondo H. **Arch Histol Cytol** 1995 Oct;58(4):397–415 (64 ref.)
Cytoskeleton, cellular signals, and cytoplasmic localization in Chaetopterus embryos. Eckberg WR, et al. **Curr Top Dev Biol** 1995;31:5–39 (100 ref.)
Cytoskeleton and ctenophore development. Houliston E, et al. **Curr Top Dev Biol** 1995;31:41–63 (401 ref.)
Intracellular structure and nucleocytoplasmic transport. Agutter PS. **Int Rev Cytol** 1995;162B:183–224 (182 ref.)
Ribosome-lamella complexes in sinus histiocytes [letter] Eyden BP, et al. **Ultrastruct Pathol** 1995 Nov–Dec; 19(6):511–5 (65 ref.)

CYTOPLASMIC AND NUCLEAR RECEPTORS see **RECEPTORS, CYTOPLASMIC AND NUCLEAR**

CYTOPLASMIC FILAMENTS see **CYTOSKELETON**

CYTOPLASMIC GRANULES

see related
CELL DEGRANULATION
Secretory vesicles of human neutrophils. Sengeløv H. **Eur J Haematol Suppl** 1996;58:1–24 (136 ref.)

GENETICS

Coordinate regulation of neutrophil secondary granule protein gene expression. Khanna-Gupta A, et al. **Curr Top Microbiol Immunol** 1996;211:165–71 (20 ref.)

PHYSIOLOGY

The biological significance of storage granules in rat parathyroid cells. Setoguti T, et al. **Microsc Res Tech** 1995 Oct 1;32(2):148–63 (81 ref.)

ULTRASTRUCTURE

Trans-Golgi network (TGN) of different cell types: three-dimensional structural characteristics and variability. Clermont Y, et al. **Anat Rec** 1995 Jul;242(3):289–301 (79

ref.)
The interchromatin granules. Thiry M. **Histol Histopathol** 1995 Oct;10(4):1035–45 (86 ref.)

CYTOPLASMIC INCLUSIONS see **INCLUSION BODIES**

CYTOPLASMIC POLYHEDROSIS VIRUSES see **REOVIRIDAE**

CYTOSINE

ANALOGS & DERIVATIVES

A preclinical and clinical overview of the nucleotide-based antiviral agent cidofovir (HPMPC). Lalezari JP, et al. **Adv Exp Med Biol** 1996;394:105–15 (26 ref.)
DNA methylation errors and cancer. Jones PA. **Cancer Res** 1996 Jun 1;56(11):2463–7 (60 ref.)
Prevention of DNA 5-methylcytosine reutilization in human cells. Vilpo JA, et al. **Somat Cell Mol Genet** 1995 Jul; 21(4):285–8 (28 ref.)

CYTOSINE ARABINOSIDE see **CYTARABINE**

CYTOSKELETAL FILAMENTS see **CYTOSKELETON**

CYTOSKELETAL PROTEINS

[Dystrophin, dystrophin-associated protein and dystrophinopathy] Ozawa E. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1995 Jun; 15(3):289–93 (15 ref.) (Eng. Abstr.) **(Jpn)**
[Cytoskeletal SH3 proteins] Maruta H, et al. **Seikagaku** 1995 Oct;67(10):1210–7 (32 ref.) **(Jpn)**

ANALYSIS

Spindle orientation and asymmetric localization in Drosophila: both inscuteable? Doe CQ. **Cell** 1996 Sep 6; 86(5):695–7 (16 ref.)

GENETICS

Muscular dystrophies: diseases of the dystrophin-glycoprotein complex [comment] Worton R. **Science** 1995 Nov 3;270(5237):755–6 (15 ref.) Comment on: Science 1995 Nov 3;270(5237):819–22.

METABOLISM

Involvement of cytoskeletal proteins in the mechanisms of organophosphorus ester-induced delayed neurotoxicity. Abou-Donia MB. **Clin Exp Pharmacol Physiol** 1995 May; 22(5):358–9 (5 ref.)
Dystrophin-glycoprotein complex: molecular organization and critical roles in skeletal muscle. Sunada Y, et al. **Curr Opin Neurol** 1995 Oct;8(5):379–84 (40 ref.)
Monoamines, cytoskeletal elements and psychiatric disorders: a neurochemical fugue. Harris J, et al. **Prog Brain Res** 1995; 106:241–8 (54 ref.)

PHYSIOLOGY

Molecular interactions in the submembrane plaque of cell-cell and cell-matrix adhesions. Geiger B, et al. **Acta Anat (Basel)** 1995;154(1):46–62 (181 ref.)
E-cadherin and its associated protein catenins, cancer invasion and metastasis. Jiang WG. **Br J Surg** 1996 Apr; 83(4):437–46 (138 ref.)
Adherens junction proteins in tumour progression. Birchmeier W, et al. **Cancer Surv** 1995;24:129–40 (68 ref.)
Signal transduction of beta-catenin. Gumbiner BM. **Curr Opin Cell Biol** 1995 Oct;7(5):634–40 (51 ref.)
The E-cadherin/catenin complex in invasion and metastasis. Bracke ME, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 1):123–61 (350 ref.)
What is the epidermal intercellular cement and why is it important? Stanley JR. **J Dermatol** 1995 Nov;22(11):836–8 (9 ref.)
Developmental expression and possible role of perinuclear theca proteins in mammalian spermatozoa. Oko RJ. **Reprod Fertil Dev** 1995;7(4):777–97 (26 ref.)
Regulating cell proliferation: as easy as APC [comment] Peifer M. **Science** 1996 May 17;272(5264):974–5 (16 ref.) Comment on: Nature 1996 May 17;272(5264):1020–3. Comment on: Nature 1996 May 17;272(5264):1023–6.
Role of signalling and cytoskeletal rearrangements in the pathogenesis of Entamoeba histolytica. Guillén N. **Trends Microbiol** 1996 May;4(5):191–7 (47 ref.)
[VLA and alpha6, beta4 integrins. Expression in normal and neoplastic human tissues] Hofman P, et al. **Arch Anat Cytol Pathol** 1995;43(3–6):309–24 (112 ref.) (Eng. Abstr.) **(Fre)**

CYTOSKELETON

Cell optical displacement assay (CODA)--measurements of cytoskeletal tension in living plant cells with a laser optical trap. Schindler M. **Methods Cell Biol** 1995;49:71–84 (44 ref.)
Evolution of a dynamic cytoskeleton. Mitchison TJ. **Philos Trans R Soc Lond B Biol Sci** 1995 Sep 29; 349(1329):299–304 (18 ref.)

CHEMISTRY

The anatomy of a molecular giant: how the sarcomere cytoskeleton is assembled from immunoglobulin superfamily molecules. Fürst DO, et al. **J Mol Cell Cardiol** 1995 Apr;27(4):951–9 (76 ref.)
[The cytoskeleton of muscle cells] Dąbrowska R, et al. **Postepy Biochem** 1995;41(3):165–74 (156 ref.) **(Pol)**

GENETICS

Sorting of messenger RNAs in the cytoplasm: mRNA localization and the cytoskeleton. Hesketh JE. **Exp Cell Res** 1996 Jun 15;225(2):219–36 (123 ref.)
[Cytoskeleton and differentiation. Genetic regulation of intermediate filaments in the neuromuscular system] Li Z, et al. **Arch Inst Pasteur Tunis** 1994 Jul-Oct;71(3–4):419–30 (48 ref.) **(Fre)**

METABOLISM

Acetylcholine receptors and the cytoskeletal connection. Phillips WD. **Clin Exp Pharmacol Physiol** 1995 Dec; 22(12):961–5 (40 ref.)
Disruption of the cytoskeleton in Alzheimer's disease. Lee VM. **Curr Opin Neurobiol** 1995 Oct;5(5):663–8 (43 ref.)
Actin-membrane cytoskeletal dynamics in early sea urchin development. Bonder EM, et al. **Curr Top Dev Biol** 1995; 31:101–37 (131 ref.)
Cytoskeletal derangements following central nervous system injury: modulation by neurotrophic gene transfection. Hayes RL, et al. **J Neurotrauma** 1995 Oct;12(5):933–41 (58 ref.)
Role of the actin cytoskeleton on epithelial Na+ channel regulation. Cantiello HF. **Kidney Int** 1995 Oct;48(4):970–84 (91 ref.)
Regulation of the actin cytoskeleton by inositol phospholipid pathways. Kandzari DE, et al. **Subcell Biochem** 1996; 26:97–114 (91 ref.)
[Abnormality of cytoskeletons and their phosphorylation in Alzheimer's disease] Nakamura Y, et al. **Seikagaku** 1996 Feb;68(2):133–6 (25 ref.) **(Jpn)**

PHYSIOLOGY

Thin filament-mediated regulation of cardiac contraction. Tobacman LS. **Annu Rev Physiol** 1996;58:447–81 (207 ref.)
Biological specificity and measurable physical properties of cell surface receptors and their possible role in signal transduction through the cytoskeleton. Forgacs G. **Biochem Cell Biol** 1995 Jul-Aug;73(7–8):317–26 (50 ref.)
The role of actin filament barbed-end exposure in cytoskeletal dynamics and cell motility. Barkalow K, et al. **Biochem Soc Trans** 1995 Aug;23(3):451–6 (40 ref.)
Making the connection: cytoskeletal rearrangements during growth cone guidance. Tanaka E, et al. **Cell** 1995 Oct 20; 83(2):171–6 (40 ref.)
Budding yeast morphogenesis: signalling, cytoskeleton and cell cycle. Kron SJ, et al. **Curr Opin Cell Biol** 1995 Dec; 7(6):845–55 (84 ref.)
Cell surface organization by the membrane skeleton. Kusumi A, et al. **Curr Opin Cell Biol** 1996 Aug;8(4):566–74 (76 ref.)
Integrin transmembrane signaling and cytoskeletal control. Yamada KM, et al. **Curr Opin Cell Biol** 1995 Oct;7(5):681–9 (84 ref.)
Axis formation during amphibian oogenesis: reevaluating the role of the cytoskeleton. Gard DL. **Curr Top Dev Biol** 1995; 30:215–52 (122 ref.)
Role of the actin cytoskeleton in early Drosophila development. Miller KG. **Curr Top Dev Biol** 1995; 31:167–96 (59 ref.)
Mammalian model systems for exploring cytoskeletal dynamics during fertilization. Navara CS, et al. **Curr Top Dev Biol** 1995;31:321–42 (54 ref.)
RNA localization and the cytoskeleton in Drosophila oocytes. Pokrywka NJ. **Curr Top Dev Biol** 1995;31:139–66 (49 ref.)
Role of the cytoskeleton in the generation of spatial patterns in Tubifex eggs. Shimizu T. **Curr Top Dev Biol** 1995; 31:197–235 (57 ref.)
The Dictyostelium cytoskeleton. Noegel AA, et al. **Experientia** 1995 Dec 18;51(12):1135–43 (135 ref.)
Multisubunit receptors in the immune system and their association with the cytoskeleton: in search of functional significance. Caplan S, et al. **Immunol Res** 1995; 14(2):98–118 (150 ref.)
Involvement of CD44 and its variant isoforms in membrane-cytoskeleton interaction, cell adhesion and tumor metastasis. Bourrguignon LY, et al. **J Neurooncol** 1995 Dec;26(3):201–8 (44 ref.)
Cellular microbiology emerging. Cossart P, et al. **Science** 1996 Jan 19;271(5247):315–6 (22 ref.)
The role of the cytoskeleton in renal development. Bacallao R. **Semin Nephrol** 1995 Jul;15(4):285–90 (61 ref.)
[Participation of the cytoskeleton in the physiology of the endometrium] Durán Reyes G, et al. **Ginecol Obstet Mex** 1995 Nov;63:467–73 (30 ref.) (Eng. Abstr.) **(Spa)**

ULTRASTRUCTURE

Cellular signaling pathways and cytoskeletal organization. Kosik KS, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:114–20 (28 ref.)
Cytoskeleton, cellular signals, and cytoplasmic localization in Chaetopterus embryos. Eckberg WR, et al. **Curr Top Dev Biol** 1995;31:5–39 (100 ref.)
Cytoskeleton in teleost eggs and early embryos: contributions to cytoarchitecture and motile events. Hart NH, et al. **Curr Top Dev Biol** 1995;31:343–81 (144 ref.)
Development and evolution of an egg cytoskeletal domain in ascidians. Jeffery WR. **Curr Top Dev Biol** 1995;31:243–76 (77 ref.)
Cortical cytoskeleton of the Xenopus oocyte, egg, and early embryo. Larabell CA. **Curr Top Dev Biol** 1995;31:433–53 (72 ref.)
Cytoskeletal changes in osteoclasts during the resorption cycle. Lakkakorpi PT, et al. **Microsc Res Tech** 1996 Feb 1;33(2):171–81 (90 ref.)

CYTOSOL

DRUG EFFECTS

The mechanisms responsible for the PTH-induced rise in cytosolic calcium in various cells are not uniform. Massry SG, et al. **Miner Electrolyte Metab** 1995;21(1–3):13–28 (75 ref.)

ENZYMOLOGY

Constitutive and overexpressed human cytosolic class-3 aldehyde dehydrogenases in normal and neoplastic cells/secretions. Sladek NE, et al. **Adv Exp Med Biol** 1995; 372:103–14 (41 ref.)
Cytosolic phospholipase A2. Clark JD, et al. **J Lipid Mediat Cell Signal** 1995 Oct;12(2–3):83–117 (139 ref.)

METABOLISM

Rat and human bile acid binders are members of the monomeric reductase gene family. Stolz A, et al. **Adv Exp Med Biol** 1995;372:269–80 (56 ref.)
Is an elevated concentration of acinar cytosolic free ionised calcium the trigger for acute pancreatitis? Ward JB, et al. **Lancet** 1995 Oct 14;346(8981):1016–9 (42 ref.)
Cytosolic and mitochondrial calcium in synaptosomes during aging. Satrústegui J, et al. **Life Sci** 1996;59(5–6):429–34 (33 ref.)

CYTOSOL AMINOPEPTIDASE see **LEUCINE AMINOPEPTIDASE**

CYTOSOLIC AND NUCLEAR RECEPTORS see **RECEPTORS, CYTOPLASMIC AND NUCLEAR**

CYTOSTATIC AGENTS see **ANTINEOPLASTIC AGENTS**

CYTOTACTIN see **TENASCIN**

CYTOTAXINOGENS see **CHEMOTACTIC FACTORS**

CYTOTAXINS see **CHEMOTACTIC FACTORS**

CYTOTOXIC ANTIBIOTICS see **ANTIBIOTICS, ANTINEOPLASTIC**

CYTOTOXIC T-LYMPHOCYTES see **T-LYMPHOCYTES, CYTOTOXIC**

CYTOTOXICITY, ANTIBODY-DEPENDENT CELL see **ANTIBODY-DEPENDENT CELL CYTOTOXICITY**

CYTOTOXICITY, IMMUNOLOGIC

see related
ANTIBODIES, BISPECIFIC
COMPLEMENT MEMBRANE ATTACK COMPLEX
KILLER CELLS, LYMPHOKINE-ACTIVATED
KILLER CELLS, NATURAL
T-LYMPHOCYTES, CYTOTOXIC

C-type lectins of natural killer cells: carbohydrate ligands and role in tumour cell lysis. Bezouška K. **Biochem Soc Trans** 1996 Feb;24(1):156–61 (24 ref.)
Dual mechanisms of lymphocyte-mediated cytotoxicity serve to control and deliver the immune response. Smyth MJ. **Bioessays** 1995 Oct;17(10):891–8 (70 ref.)
Redirection of cellular cytotoxicity. A two-step approach using recombinant single-chain Fv molecules. George AJ, et al. **Cell Biophys** 1995 Jun;26(3):153–65 (39 ref.)
Role of human natural killer cells in health and disease. Whiteside TL, et al. **Clin Diagn Lab Immunol** 1994 Mar; 1(2):125–33 (76 ref.)
Role of extracellular ATP and P1 and P2 classes of purinergic receptors in T-cell development and cytotoxic T lymphocyte effector functions. Apasov S, et al. **Immunol Rev** 1995 Aug;146:5–19 (40 ref.)
PELs and the perforin and granzyme independent mechanism of CTL-mediated lysis. Berke G. **Immunol Rev** 1995 Aug; 146:21–31 (52 ref.)
Molecular pathways of CTL-mediated cytotoxicity. Clark WR, et al. **Immunol Rev** 1995 Aug;146:33–44 (37 ref.)
Fas bridging cell death and cytotoxicity: the reaper connection. Golstein P, et al. **Immunol Rev** 1995 Aug; 146:45–56 (58 ref.)
Lymphocyte-mediated cytotoxicity in vitro and in vivo:

mechanisms and significance. Kägi D, et al. **Immunol Rev** 1995 Aug;146:95–115 (102 ref.)
Perforin and lymphocyte-mediated cytolysis. Liu CC, et al. **Immunol Rev** 1995 Aug;146:145–75 (155 ref.)
Molecular interactions in the activation of effector and precursor cytotoxic T lymphocytes. Mescher MF. **Immunol Rev** 1995 Aug;146:177–210 (108 ref.)
Nuclear changes in the cytotoxic T lymphocyte-induced model of apoptosis. Sellins KS, et al. **Immunol Rev** 1995 Aug;146:241–66 (104 ref.)
Granzyme B plays a critical role in cytotoxic lymphocyte-induced apoptosis. Shresta S, et al. **Immunol Rev** 1995 Aug;146:211–21 (32 ref.)
Fas-mediated cytotoxicity—a new immunoregulatory and pathogenic function of Th1 CD4+ T cells. Yagita H, et al. **Immunol Rev** 1995 Aug;146:223–39 (71 ref.)
Unlocking the secrets of CTL and NK cells. Berke G. **Immunol Today** 1995 Jul;16(7):343–6 (14 ref.)
Cell-mediated cytotoxicity in perforin-less mice. Clark WR, et al. **Int Rev Immunol** 1995;13(1):1–14 (39 ref.)
Inhibitory effects of class I molecules on murine NK cells: speculations on function, specificity and self-tolerance. Raulet DH, et al. **Semin Immunol** 1995 Apr;7(2):103–7 (24 ref.)
Natural killer cells wear different hats: effector cells of innate resistance and regulatory cells of adaptive immunity and of hematopoiesis. Trinchieri G. **Semin Immunol** 1995 Apr; 7(2):83–8 (43 ref.)
Tumor-directed cytotoxicity in multiple myeloma—the basis for an experimental treatment approach with interleukin 2. Peest D, et al. **Stem Cells (Dayt)** 1995 Aug;13 Suppl 2:72–6 (20 ref.)

GENETICS

Induction of lytic pathways in T cell clones derived from wild-type or protein tyrosine kinase Fyn mutant mice. Lancki DW, et al. **Immunol Rev** 1995 Aug;146:117–44 (56 ref.)

IMMUNOLOGY

Mechanism and biological significance of CD4-mediated cytotoxicity. Hahn S, et al. **Immunol Rev** 1995 Aug; 146:57–79 (140 ref.)
Alternative triggering molecules and single chain bispecific antibodies. Segal DM, et al. **J Hematother** 1995 Oct; 4(5):377–82 (31 ref.)

CYTOTOXICITY TESTS, IMMUNOLOGIC

METHODS

Immune function assays. Nicklin S. **Methods Mol Biol** 1995; 43:245–56 (10 ref.)

CYTOTOXIN-ANTIBODY CONJUGATES see **IMMUNOTOXINS**

2,4-D see **2,4-DICHLOROPHENOXYACETIC ACID**

D4T see **STAVUDINE**

D-145 see **MEMANTINE**

DAIRY PRODUCTS

[Biomedical aspects of the use of milk whey in nutrition (review)] Lind AR, et al. **Vopr Pitan** 1995;(6):29–33 (45 ref.) (Eng. Abstr.) **(Rus)**

STANDARDS

Do dairy products improve bone density in adolescent girls? Kerstetter JE. **Nutr Rev** 1995 Nov;53(11):328–32 (26 ref.)

TOXICITY

Preclinical drug metabolism programs for food-producing animals. Clement RP. **Toxicol Pathol** 1995 Mar–Apr; 23(2):209–16 (7 ref.)

DAIRYING

METHODS

Feeding behavior and management factors during the transition period in dairy cattle. Grant RJ, et al. **J Anim Sci** 1995 Sep;73(9):2791–803 (86 ref.)

STANDARDS

Use of disinfectants in open-air dairying. Hutchinson RE. **Rev Sci Tech** 1995 Jun;14(2):261–72 (46 ref.)
Disinfection in the dairy parlour. Saran A. **Rev Sci Tech** 1995 Mar;14(1):207–24 (31 ref.)

TRENDS

Status and prospects of the dairy goat industry in the United States. Haenlein GF. **J Anim Sci** 1996 May;74(5):1173–81 (29 ref.)

DALTEPARIN see **TEDELPARIN**

DANAZOL

PHARMACOLOGY

Danazol and plasma lipoprotein metabolism. Shepherd J. **Int J Gynaecol Obstet** 1995 Sep;50 Suppl 1:S23–6 (17 ref.)

THERAPEUTIC USE

The impact of bone loss in women with endometriosis. Stevenson JC. **Int J Gynaecol Obstet** 1995 Sep;50 Suppl 1:S11–5 (26 ref.)
[Treatment of idiopathic thrombocytopenic purpura with danazol] Ruberto E, et al. **Sangre (Barc)** 1995 Aug; 40(4):307–10 (18 ref.) (Eng. Abstr.) **(Spa)**

DANCING

INJURIES

Lower extremity musculoskeletal problems in dancers. Schon LC, et al. **Curr Opin Rheumatol** 1996 Mar;8(2):130–42 (43 ref.)

DANE PARTICLE see **HEPATITIS B VIRUS**

DANGEROUS BEHAVIOR

Psychosis and violence: the case for a content analysis of psychotic experience. Junginger J. **Schizophr Bull** 1996; 22(1):91–103 (50 ref.)

DANTROLENE

THERAPEUTIC USE

Management of suspected neuroleptic malignant syndrome. Velamoor VR, et al. **Can J Psychiatry** 1995 Nov; 40(9):545–50 (33 ref.)
[The neuroleptic malignant syndrome in an adolescent. Its treatment with dantrolene, bromocryptin and diazepam] Real Rodríguez B, et al. **An Esp Pediatr** 1996 Jan;44(1):60–2 (20 ref.) **(Spa)**

DAPHNIA

PHYSIOLOGY

Commentary on effects of anthropogenic and natural organic chemicals on development, swimming behavior, and reproduction of Daphnia, a key member of aquatic ecosystems. Dodson SI, et al. **Environ Health Perspect** 1995 May;103 Suppl 4:7–11 (60 ref.)

DAPSONE

ADMINISTRATION & DOSAGE

[Cicatricial pemphigoid—a therapeutic problem] Axt M, et al. **Hautarzt** 1995 Sep;46(9):620–7 (32 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Dapsone toxicity: some current perspectives. Coleman MD. **Gen Pharmacol** 1995 Nov;26(7):1461–7 (51 ref.)
[Hypersensitivity syndrome caused by dapsone. Transient circulating clone T] Bocquet H, et al. **Ann Dermatol Venereol** 1995;122(8):514–6 (14 ref.) (Eng. Abstr.) **(Fre)**

POISONING

A case of acute dapsone poisoning: toxicological data and review of the literature. Tracqui A, et al. **J Anal Toxicol** 1995 Jul–Aug;19(4):229–35 (72 ref.)

DARK ADAPTATION

[Zinc-deficient disorders of sense organs—dark adaptation, taste and smell disorders] Tomita H. **Nippon Rinsho** 1996 Jan;54(1):141–7 (40 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Beta wave of the scotopic (rod) electroretinogram as a measure of the activity of human on-bipolar cells. Hood DC, et al. **J Opt Soc Am A** 1996 Mar;13(3):623–33 (54 ref.)

DATA ANALYSIS, STATISTICAL see **DATA INTERPRETATION, STATISTICAL**

DATA COLLECTION

Application of computers in diabetes care—a review. I. Computers for data collection and interpretation. Lehmann ED, et al. **Med Inf (Lond)** 1995 Oct–Dec;20(4):281–302 (142 ref.)
Spatial statistical methods in environmental epidemiology: a critique. Elliott P, et al. **Stat Methods Med Res** 1995 Jun;4(2):137–59 (114 ref.)

METHODS

An in-depth study of triangulation. Dootson S. **J Adv Nurs** 1995 Jul;22(1):183–7 (27 ref.)
Using health care records as sources of data for research. vonKoss Krowchuk H, et al. **J Nurs Meas** 1995 Summer; 3(1):3–12 (21 ref.)
Research practice and data management. van Es GA. **Neth J Med** 1996 Jan;48(1):38–44 (7 ref.)
Methods for assessing sperm motility, morphology, and counts in the rat, rabbit, and dog: a consensus report. ILSI Risk Science Institute Expert Working Group on Sperm Evaluation. Seed J, et al. **Reprod Toxicol** 1996 May–Jun; 10(3):237–44 (30 ref.)
Study design for epidemiologic studies with measurement error. Holford TR, et al. **Stat Methods Med Res** 1995 Dec; 4(4):339–58 (43 ref.)

STANDARDS

International Poison Information Center data collection capabilities. Krenzelok EP, et al. **Vet Hum Toxicol** 1995 Jun;37(3):246–8 (3 ref.)

DATA DISPLAY

Differential display RT-PCR for identifying novel gene expression in the lung. Sunday ME. **Am J Physiol** 1995 Sep;269(3 Pt 1):L273–84 (72 ref.)

DATA INTERPRETATION, STATISTICAL

Understanding research synthesis (meta-analysis). Mosteller F, et al. **Annu Rev Public Health** 1996;17:1–23 (91 ref.)
Quantitative analyses of scientific literature and their validity for judging Latin American production [comment] Spinak E. **Bull Pan Am Health Organ** 1995 Dec;29(4):352–9; discussion 359–60 (25 ref.) Comment on: Bull Pan Am Health Organ 1995 Mar;29(1):87–95.
Interpreting results from thrombolytic megatrials: distinguishing fact from fiction. Brophy JM. **Can J Cardiol** 1996 Jan;12(1):89–92 (22 ref.)
Prevention. How much harm? How much benefit? 1. Influence of reporting methods on perception of benefits [see comments] Marshall KG. **Can Med Assoc J** 1996 May 15;154(10):1493–9 (56 ref.) Comment in: Can Med Assoc J 1996 May 15;154(10):1510–2.
Advances in strategies for minimizing and adjusting for survey nonresponse. Kessler RC, et al. **Epidemiol Rev** 1995; 17(1):192–204 (67 ref.)
Quantitative methods in nursing research. Abrams KR, et al. **J Adv Nurs** 1996 May;23(5):1008–15 (26 ref.)
Deprivation indices: their interpretation and use in relation to health. Carstairs V. **J Epidemiol Community Health** 1995 Dec;49 Suppl 2:S3–8 (27 ref.)
Statistical methods and strategies for working with large data bases. Marshall G, et al. **Med Care** 1995 Oct;33(10 Suppl):OS35–42 (20 ref.)
Application of computers in diabetes care—a review. I. Computers for data collection and interpretation. Lehmann ED, et al. **Med Inf (Lond)** 1995 Oct–Dec;20(4):281–302 (142 ref.)
Correction for the design effect in school-based substance use and abuse prevention research: sample size requirements and analysis considerations. Dielman TE. **NIDA Res Monogr** 1994;139:115–25 (38 ref.)
The rough and ready jackknife. Resnick B. **Nurs Res** 1996 May–Jun;45(3):185–8 (19 ref.)
Risk assessment for carcinogenesis promoting agents: need for a weight of all the evidence approach. Clayson DB. **Prog Clin Biol Res** 1995;391:359–67 (49 ref.)
Considerations of quantitative data on organ sizes and cell numbers and sizes in Down syndrome. Landing BH, et al. **Prog Clin Biol Res** 1995;393:177–91 (36 ref.)
Model selection techniques for the covariance matrix for incomplete longitudinal data. Grady JJ, et al. **Stat Med** 1995 Jul 15;14(13):1397–416 (20 ref.)
Statistical approaches to human brain mapping by functional magnetic resonance imaging. Lange N. **Stat Med** 1996 Feb 28;15(4):389–428 (93 ref.)
Formulae and tables for the determination of sample sizes and power in clinical trials for testing differences in proportions for the two-sample design: a review. Sahai H, et al. **Stat Med** 1996 Jan 15;15(1):1–21 (96 ref.)
Spatial statistical methods in environmental epidemiology: a critique. Elliott P, et al. **Stat Methods Med Res** 1995 Jun;4(2):137–59 (114 ref.)
The analysis of the EEG. Gasser T, et al. **Stat Methods Med Res** 1996 Mar;5(1):67–99 (95 ref.)
Isobolographic analysis of interactions: an update on applications and utility. Gessner PK. **Toxicology** 1995 Dec 28;105(2–3):161–79 (33 ref.)
[Evaluating correctly the validity of a rating scale: the numerous pitfalls to avoid] Fermanian J. **Rev Epidemiol Sante Publique** 1996 Jun;44(3):278–86 (19 ref.) (Eng. Abstr.) **(Fre)**
[Interpretation of negative results in research in health sciences] Ramalle-Gómara E, et al. **Aten Primaria** 1995 Nov 30;16(9):564–70 (49 ref.) **(Spa)**

DATA POOLING see **META-ANALYSIS**

DATA PROCESSING, AUTOMATIC see **AUTOMATIC DATA PROCESSING**

DATA PROTECTION see **COMPUTER SECURITY**

DATA SECURITY see **COMPUTER SECURITY**

DATA SYSTEMS see **INFORMATION SYSTEMS**

DATABANKS see **DATABASES, FACTUAL**

DATABANKS, FACTUAL see **DATABASES, FACTUAL**

DATABASE MANAGEMENT SYSTEMS

Patient data management systems in anaesthesia: an emerging technology. Weiss YG, et al. **Can J Anaesth** 1995 Oct; 42(10):914–21 (32 ref.)

ORGANIZATION & ADMINISTRATION

Bibliography database managers. A comparative review. Nicoll LH, et al. **Comput Nurs** 1996 Jan–Feb;14(1):45–56 (3 ref.)

Using computerized clinical nursing data bases for nursing research. Nail LM, et al. **J Prof Nurs** 1996 Jul–Aug; 12(4):197–206 (28 ref.)

DATABASES see **INFORMATION SYSTEMS**

DATABASES, BIBLIOGRAPHIC

[Use of computer base MEDIP in retrieving information on occupational medicine and hygiene] Przyluska J. **Med Pr** 1996;47(2):183–8 (5 ref.) (Eng. Abstr.) **(Pol)**

DATABASES, DISTRIBUTED see **COMPUTER COMMUNICATION NETWORKS**

DATABASES, FACTUAL

Food sampling strategies for energy intake estimates. Holden JM. **Am J Clin Nutr** 1995 Nov;62(5 Suppl):1151S–1157S (31 ref.)

Developing a quality improvement database using health insurance data: a guided tour with application to Medicare's National Claims History file. Parente ST, et al. **Am J Med Qual** 1995 Winter;10(4):162–76 (21 ref.)

Optimizing cardiothoracic surgery information for a managed care environment. Denton TA, et al. **Ann Thorac Surg** 1995 Nov;60(5):1522–5 (22 ref.)

Quality initiatives and the power of the database: what they are and how they run. Grover FL, et al. **Ann Thorac Surg** 1995 Nov;60(5):1514–21 (15 ref.)

Quality initiatives and the power of the database: where we stand. Kouchoukos NT. **Ann Thorac Surg** 1995 Nov; 60(5):1526–9 (13 ref.)

Reference databases of cytokine structure and function. Casciari JJ, et al. **Cancer Chemother Biol Response Modif** 1996;16:315–46 (103 ref.)

Computer systems in dysmorphology. Evans CD. **Clin Dysmorphol** 1995 Jul;4(3):185–201 (34 ref.)

Taking a bite out of CRISP. Strategies on using and conducting searches in the Computer Retrieval of Information on Scientific Projects database. Bair AH, et al. **Comput Nurs** 1996 Jul–Aug;14(4):218–24; quiz 225–6 (10 ref.)

Pitfalls of protein sequence analysis. Rost B, et al. **Curr Opin Biotechnol** 1996 Aug;7(4):457–61 (12 ref.)

Sixth plot of the carcinogenic potency database: results of animal bioassays published in the General Literature 1989 to 1990 and by the National Toxicology Program 1990 to 1993. Gold LS, et al. **Environ Health Perspect** 1995 Nov; 103 Suppl 8:3–122 (37 ref.)

Molecular cloning of eukaryotic glycoprotein and glycolipid glycosyltransferases: a survey. Field MC, et al. **Glycobiology** 1995 Jul;5(5):463–72 (142 ref.)

Programs, databases, and expert systems for human geneticists—a survey. Fischer C, et al. **Hum Genet** 1996 Feb;97(2):129–37 (103 ref.)

BTKbase: a database of XLA-causing mutations. International Study Group. Vihinen M, et al. **Immunol Today** 1995 Oct;16(10):460–5 (39 ref.)

Privacy, confidentiality, and electronic medical records. Barrows RC Jr, et al. **J Am Med Inform Assoc** 1996 Mar–Apr;3(2):139–48 (42 ref.)

Peptide, peptidomimetic, and organic synthetic combinatorial libraries. Eichler J, et al. **Med Res Rev** 1995 Nov; 15(6):481–96 (67 ref.)

Surfing the DNA databases for K+ channels nets yet more diversity. Salkoff L, et al. **Neuron** 1995 Sep;15(3):489–92 (35 ref.)

Are database-derived potentials valid for scoring both forward and inverted protein folding? Rooman MJ, et al. **Protein Eng** 1995 Sep;8(9):849–58 (82 ref.)

Mapping the protein universe. Holm L, et al. **Science** 1996 Aug 2;273(5275):595–603 (36 ref.)

ATSDR's information databases to support human health risk assessment of hazardous substances. Agency for Toxic Substances and Disease Registry. Johnson BL. **Toxicol Lett** 1995 Sep;79(1–3):11–6 (0 ref.)

A graphical interface for searching the human genome. Adler D. **Trends Genet** 1995 Oct;11(10):416–7 (0 ref.)

[Parma Stroke Data Bank: embolic stroke] Tonelli C, et al. **Minerva Med** 1995 Nov;86(11):459–66 (76 ref.) (Eng. Abstr.) **(Ita)**

[Development of information biology] Tateno Y. **Tanpakushitsu Kakusan Koso** 1995 Sep;40(12):1803–8 (16 ref.) **(Jpn)**

STANDARDS

Quantitative analyses of scientific literature and their validity for judging Latin American production [comment] Spinak E. **Bull Pan Am Health Organ** 1995 Dec;29(4):352–9; discussion 359–60 (25 ref.) Comment on: Bull Pan Am Health Organ 1995 Mar;29(1):87–95.

DATURA see **STRAMONIUM**

DAY CARE CENTERS FOR CHILDREN see **CHILD DAY CARE CENTERS**

DAY DREAMS see **FANTASY**

DAY SURGERY see **AMBULATORY SURGERY**

D-D CARBOXYPEPTIDASE see **CARBOXYPEPTIDASE TRANSPEPTIDASE**

DDAVP see **DESMOPRESSIN**

DDC (ANTIVIRAL) see **ZALCITABINE**

DDI (ANTIVIRAL) see **DIDANOSINE**

DDT

kdr-Type resistance in insects with special reference to the German cockroach, Blattella germanica. Scott JG, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1994 Oct–Nov; 109(2–3):191–8 (68 ref.)

DE LANGE'S SYNDROME

ETIOLOGY

A further report of Brachmann–de Lange syndrome in two sibs with normal parents. Krajewska-Walasek M, et al. **Clin Genet** 1995 Jun;47(6):324–7 (9 ref.)

DE TONI–DEBRE–FANCONI SYNDROME see **FANCONI SYNDROME**

DEAF-MUTISM see **DEAFNESS**

DEAFNESS

see related
HEARING AIDS

The dispute concerning the benefits to be expected from cochlear implantation of young deaf children [letter] Lane H. **Am J Otol** 1995 May;16(3):393–9 (41 ref.)

CONGENITAL

[Malformation of the internal ear and recurrent meningitis: radio-surgical correlations] Ruaux C, et al. **Ann Otolaryngol Chir Cervicofac** 1995;112(3):118–22 (21 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Bilateral evoked otoacoustic emissions in a child with bilateral profound hearing loss. Laccourreye L, et al. **Ann Otol Rhinol Laryngol** 1996 Apr;105(4):286–8 (15 ref.)

ETIOLOGY

Complications of the gamma knife. Wiet RJ, et al. **Arch Otolaryngol Head Neck Surg** 1996 Apr;122(4):414–6 (13 ref.)

GENETICS

Juberg-Marsidi syndrome: report of an additional case. Tsukahara M, et al. **Am J Med Genet** 1995 Sep 25; 58(4):353–5 (7 ref.)

Transgenic insertional mutagenesis. Applications to inner-ear genetics. Friedman RA. **Arch Otolaryngol Head Neck Surg** 1996 Mar;122(3):252–7 (55 ref.)

Hearing. A gene for deaf ears? Ashmore J. **Curr Biol** 1995 Jul 1;5(7):716–8 (12 ref.)

Mapping and cloning hereditary deafness genes. Cremers FP, et al. **Curr Opin Genet Dev** 1995 Jun;5(3):371–5 (55 ref.)

Maternally inherited diabetes and deafness: a new diabetes subtype. Maassen JA, et al. **Diabetologia** 1996 Apr; 39(4):375–82 (53 ref.)

Deaf and dizzy mice with mutated myosin motors. Gillespie PG. **Nat Med** 1996 Jan;2(1):27–9 (13 ref.)

REHABILITATION

Cost effectiveness of the multichannel cochlear implant. Wyatt JR, et al. **Am J Otol** 1995 Jan;16(1):52–62 (53 ref.)

[NIH Consensus Conference on cochlear implants in adults and children, 15 to 17 May 1995] Albegger KW. **HNO** 1996 Mar;44(3):118 (0 ref.) **(Ger)**

[The implantable middle ear hearing aid] Niehaus HH. **HNO** 1995 Dec;43(12):697–701 (27 ref.) **(Ger)**

SURGERY

Cochlear implants: a modern miracle. Proops D. **Practitioner** 1996 Jan;240(1558):38–40 (2 ref.)

VETERINARY

Aetiology, prevalence and diagnosis of deafness in dogs and cats [see comments] Strain GM. **Br Vet J** 1996 Jan; 152(1):17–36 (81 ref.) Comment in: Br Vet J 1996 Jan;152(1):13–5.

DEAFNESS, CONDUCTIVE see **HEARING LOSS, CONDUCTIVE**

DEAFNESS, PARTIAL see **HEARING LOSS, PARTIAL**

DEAFNESS, SENSORINEURAL see **DEAFNESS**

DEAFNESS, SUDDEN

Sudden sensorineural hearing loss: an otologic emergency. Gulya AJ. **Compr Ther** 1996 Apr;22(4):217–21 (14 ref.)

DEALKYLATION

Radical cation intermediates in N-dealkylation reactions. Guengerich FP, et al. **Xenobiotica** 1995 Jul;25(7):689–709 (138 ref.)

DEAMINO ARGININE VASOPRESSIN see **DESMOPRESSIN**

DEATH

see related
ATTITUDE TO DEATH
BEREAVEMENT
CAUSE OF DEATH
HOMICIDE
INFANTICIDE
SUICIDE
TERMINAL CARE

Defining and redefining death. Ott BB. **Am J Crit Care** 1995 Nov;4(6):476–80 (28 ref.)

Redefining death in America, 1968. Stevens ML. **Caduceus** 1995 Winter;11(3):207–19 (41 ref.)

Death and dying and recognizing approaching death. Long MC. **Clin Geriatr Med** 1996 May;12(2):359–68 (25 ref.)

Nonheart-beating donors: the Maastricht experience. Daemen JW, et al. **Clin Transpl** 1994;:303–16 (59 ref.)

Near-death experiences. Blackmore SJ. **J R Soc Med** 1996 Feb;89(2):73–6 (44 ref.)

DEATH, ASSISTED see **SUICIDE, ASSISTED**

DEATH CERTIFICATES

'Inaccuracy' in death certification—where are we now? Maudsley G, et al. **J Public Health Med** 1996 Mar; 18(1):59–66 (88 ref.)

Death registration and cause-of-death statements. Hanzlick R. **Leg Med** 1995;:117–45 (50 ref.)

DEATH PENALTY see **CAPITAL PUNISHMENT**

DEATH RATE see **MORTALITY**

DEATH, SUDDEN

see related
RESUSCITATION
SUDDEN INFANT DEATH

Medicolegal investigative system and sudden death in Scandinavia. Saukko P. **Nippon Hoigaku Zasshi** 1995 Dec; 49(6):458–65 (7 ref.)

ETIOLOGY

Exertional collapse and sudden death associated with sickle cell trait. Kerle KK, et al. **Am Fam Physician** 1996 Jul; 54(1):237–40 (18 ref.)

Unexpected sudden death in a young pregnant woman: unusual presentation of neurosarcoidosis. Maisel JA, et al. **Ann Emerg Med** 1996 Jul;28(1):94–7 (12 ref.)

Diuretics and risk of sudden death in hypertension—evidence and potential implications. Hoes AW, et al. **Clin Exp Hypertens** 1996 Apr–May;18(3–4):523–35 (22 ref.)

Sudden death caused by testicular germ cell tumour. Dada MA, et al. **Med Sci Law** 1995 Oct;35(4):357–9 (12 ref.)

Air embolism during cardiopulmonary bypass. Kurusz M, et al. **Perfusion** 1995 Nov;10(6):361–91 (389 ref.)

[Death or uncertain cause] Wilkens H, et al. **Z Arztl Fortbild (Jena)** 1995 Dec;89(7):719–23 (19 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

[Sudden unexpected natural death from a viewpoint of forensic pathology] Takatsu A. **Nippon Hoigaku Zasshi** 1995 Dec;49(6):432–46 (37 ref.) (Eng. Abstr.) **(Jpn)**

DEATH, SUDDEN, CARDIAC

Impact of aborted sudden cardiac death on survivors and

their spouses: the phenomenon of different reference points. Doolittle ND, et al. **Am J Crit Care** 1995 Sep;4(5):389–96 (24 ref.)

Sudden death and physical activity in athletes and nonathletes. Jensen-Urstad M. **Scand J Med Sci Sports** 1995 Oct;5(5):279–84 (46 ref.)

[Sudden cardiac death: definition, mechanisms and risk factors] Evéquoz D, et al. **Schweiz Rundsch Med Prax** 1996 Feb 13;85(7):188–96 (56 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Lesions of mediastinal paraganglia in chronic chagasic cardiomyopathy: cause of sudden death? [editorial] Ramos SG, et al. **Am Heart J** 1996 Feb;131(2):417–20 (32 ref.)

Cardiac arrest in cocaine users. Karch SB. **Am J Emerg Med** 1996 Jan;14(1):79–81 (30 ref.)

Triggers for sudden cardiac death in the athlete. Maron BJ. **Cardiol Clin** 1996 May;14(2):195–210 (97 ref.)

Physical exertion as a trigger of myocardial infarction and sudden cardiac death. Mittleman MA, et al. **Cardiol Clin** 1996 May;14(2):263–70 (47 ref.)

Circadian patterns and triggers of sudden cardiac death. Peters RW. **Cardiol Clin** 1996 May;14(2):185–94 (42 ref.)

Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death. Farb A, et al. **Circulation** 1996 Apr 1; 93(7):1354–63 (46 ref.)

Ventricular tachyarrhythmias, myocardial ischemia, and sudden cardiac death in patients with hypertensive heart disease. Zehender M, et al. **Clin Cardiol** 1995 Jul; 18(7):377–83 (84 ref.)

Right bundle branch block, persistent ST-segment elevation in V1–V3 and sudden cardiac death: always a distinct syndrome? D'Onofrio A, et al. **G Ital Cardiol** 1995 Sep; 25(9):1171–5 (12 ref.)

Management strategies in patients at high risk of sudden cardiac death following myocardial infarction. Sra J, et al. **Indian Heart J** 1995 Mar-Apr;47(2):158–62 (37 ref.)

Morphological and functional significance of findings in unstable atherothrombotic plaque underlying acute coronary syndromes: a review. Baroldi G. **Int J Cardiol** 1995 Aug;49 Suppl:S3–9 (18 ref.)

Autonomic nervous system and sudden cardiac death. Barron HV, et al. **J Am Coll Cardiol** 1996 Apr;27(5):1053–60 (42 ref.)

Visceral larva migrans induced eosinophilic cardiac pseudotumor: a cause of sudden death in a child. Boschetti A, et al. **J Forensic Sci** 1995 Nov;40(6):1097–9 (12 ref.)

Structural and non-structural disease underlying high-risk cardiac arrhythmias relevant to sports medicine. Rossi L. **J Sports Med Phys Fitness** 1995 Jun;35(2):79–86 (29 ref.)

Sudden death from cardiac causes in children and young adults. Liberthson RR. **N Engl J Med** 1996 Apr 18; 334(16):1039–44 (52 ref.)

Electrocardiographic predictors in the ESVEM trial: unsustained ventricular tachycardia, heart period variability, and the signal-averaged electrocardiogram. Anderson KP, et al. **Prog Cardiovasc Dis** 1996 May-Jun; 38(6):463–88 (89 ref.)

[Prognostic factors after sustained ventricular fibrillation or tachycardia. A multivariate study apropos of 160 cases] Fleurant E, et al. **Arch Mal Coeur Vaiss** 1996 Apr; 89(4):435–44 (31 ref.) (Eng. Abstr.) **(Fre)**

[Sudden death] Grégoire JM. **Rev Med Brux** 1996 Jun; 17(3):107–13 (52 ref.) (Eng. Abstr.) **(Fre)**

[Risk stratification following myocardial infarct] Buser PT, et al. **Schweiz Med Wochenschr** 1996 Jun 8;126(23):1011–22 (57 ref.) (Eng. Abstr.) **(Ger)**

[Death or uncertain cause] Wilkens H, et al. **Z Arztl Fortbild (Jena)** 1995 Dec;89(7):719–23 (19 ref.) (Eng. Abstr.) **(Ger)**

[How do you want to die? The therapeutic options in ventricular tachyarrhythmia at the end of the anti-arrhythmia drug era] Seipel L. **Z Kardiol** 1995 Oct; 84(10):787–90 (38 ref.) **(Ger)**

[Sudden death in hypertrophic myocardiopathy] Cardim N, et al. **Rev Port Cardiol** 1995 Sep;14(9):655–9 (54 ref.) (Eng. Abstr.) **(Por)**

[Sudden death in patients with chagasic myocarditis] Fuenmayor AJ, et al. **Arch Inst Cardiol Mex** 1996 Mar-Apr;66(2):157–61 (18 ref.) (Eng. Abstr.) **(Spa)**

[Cardiomyopathies. VIII. Sudden death in hypertrophic cardiomyopathy] Alfonso F. **Rev Esp Cardiol** 1996 Apr; 49(4):288–304 (166 ref.) (Eng. Abstr.) **(Spa)**

PATHOLOGY

[Youthful sudden cardiac death and the Kawasaki syndrome. An anatomopathological case report] Nappo A, et al. **Minerva Cardioangiol** 1996 Mar;44(3):127–32 (14 ref.) (Eng. Abstr.) **(Ita)**

PREVENTION & CONTROL

Prospects for genetic manipulation of cardiac excitability. Lawrence JH, et al. **Adv Exp Med Biol** 1995;382:41–8 (44 ref.)

Risk assessment and prevention of sudden cardiac death in hypertrophic cardiomyopathy. Slade AK, et al. **Arch Mal Coeur Vaiss** 1996 Feb;89 Spec No 1:37–49 (74 ref.)

The implantable cardiac defibrillator. Kamalvand K, et al. **Br J Hosp Med** 1996 Jan 17–Feb 6;55(1-2):37–41 (16 ref.)

Sudden cardiac death. How to reduce the number of victims? Wellens HJ, et al. **Eur Heart J** 1995 Aug;16 Suppl G:7–9 (30 ref.)

Sudden cardiac death in hypertrophic cardiomyopathy: risk evaluation. Mittal SR. **Int J Cardiol** 1995 Nov 10;52(1):1–4 (31 ref.)

Anions, membrane resistance and ventricular fibrillation. Curtis MJ, et al. **J Basic Clin Physiol Pharmacol** 1994 Jan-Mar;5(1):19–26 (24 ref.)

How can we facilitate spontaneous termination of ventricular fibrillation and prevent sudden cardiac death? A working hypothesis. Manoach M, et al. **J Cardiovasc Electrophysiol** 1995 Jul;6(7):584–9 (58 ref.)

Expanding indications for the use of Class III agents in patients at high risk for sudden death. Singh BN. **J Cardiovasc Electrophysiol** 1995 Oct;6(10 Pt 2):887–900 (47 ref.)

Prevention of cardiac sudden death by N-3 fatty acids: a review of the evidence. Leaf A, et al. **J Intern Med** 1996 Jul;240(1):5–12 (32 ref.)

[Which patients at risk of sudden death after myocardial infarction? Critical study of prognostic factors] Aliot E, et al. **Arch Mal Coeur Vaiss** 1995 Aug;88 Spec No 3:37–44 (51 ref.) (Eng. Abstr.) **(Fre)**

[Cardiovascular evaluation in athletic children] Sluysmans T, et al. **Arch Pediatr** 1995 Nov;2(11):1101–15 (106 ref.) (Eng. Abstr.) **(Fre)**

[Sudden cardiac death and immediate defibrillation by trained lay persons] Theissen K. **Dtsch Med Wochenschr** 1996 Apr 12;121(15):463–4 (18 ref.) **(Ger)**

[Implantable defibrillators--current status of guidelines. Recognized and possible indications--prerequisites] Andresen D. **Fortschr Med** 1996 Apr 20;114(11):128–32 (0 ref.) (Eng. Abstr.) **(Ger)**

[Implantable cardioverter-defibrillator] Fuhrer J. **Schweiz Rundsch Med Prax** 1996 May 14;85(20):655–62 (19 ref.) (Eng. Abstr.) **(Ger)**

[Automated implantable cardioverter/defibrillators. Indications for implantation and clinical results] Ulbricht LJ, et al. **Z Kardiol** 1995;84 Suppl 2:127–36 (96 ref.) (Eng. Abstr.) **(Ger)**

[Implantable cardioverter-defibrillator: prevention of sudden cardiac death and impact on survival in patients with malignant ventricular arrhythmias] Occhetta E, et al. **Cardiologia** 1995 Jun;40(6):419–25 (35 ref.) **(Ita)**

[The current status of the prevention and treatment of sudden death] Pedrote A, et al. **Rev Esp Cardiol** 1995 Nov; 48(11):710–21 (149 ref.) (Eng. Abstr.) **(Spa)**

DEATH WITH DIGNITY see **RIGHT TO DIE**

DEBRIDEMENT

Pseudallescheria boydii in an immunocompromised host. Successful treatment with debridement and itraconazole. Ruxin TA, et al. **Arch Dermatol** 1996 Apr;132(4):382–4 (23 ref.)

METHODS

Update on management of chronic osteomyelitis: report of four cases. Fasika OM, et al. **East Afr Med J** 1995 Sep; 72(9):611–2 (9 ref.)

DECAMETHONIUM COMPOUNDS

see related
NEUROMUSCULAR DEPOLARIZING AGENTS

DECANOATES

METABOLISM

Production of rhamnolipid biosurfactants. Ochsner UA, et al. **Adv Biochem Eng Biotechnol** 1996;53:89–118 (70 ref.)

DECANOIC ACIDS

DIAGNOSTIC USE

[Image diagnosis of heart diseases using new radioisotope compounds] Nishimural T. **Nippon Naika Gakkai Zasshi** 1995 Sep 10;84(9):1564–8 (8 ref.) **(Jpn)**

DECARBOXYLASES see **CARBOXY-LYASES**

DECAVANADATE see **VANADATES**

DECAY-ACCELERATING FACTOR see **ANTIGENS, CD55**

DECAYED, MISSING, AND FILLED TEETH see **DMF INDEX**

DECEPTION see **LYING**

DECIDUA

METABOLISM

Synthesis and metabolism of oxytocin in late gestation in human decidua. Mitchell BF, et al. **Adv Exp Med Biol** 1995; 395:365–80 (69 ref.)

Oxytocin synthesis and metabolism in human decidua. Mitchell BF. **Reprod Fertil Dev** 1995;7(3):319–21 (12 ref.)

PHYSIOLOGY

Decidua in human implantation. Loke YW, et al. **Hum Reprod** 1995 Dec;10 Suppl 2:14–21 (62 ref.)

DECIDUAL CELL REACTION see **OVUM IMPLANTATION**

DECISION ANALYSIS see **DECISION SUPPORT TECHNIQUES**

DECISION MAKING

see related
DECISION SUPPORT TECHNIQUES
POLICY MAKING

Directive counseling on long-acting contraception. Moskowitz E, et al. **Am J Public Health** 1996 Jun; 86(6):787–90 (24 ref.)

Ethical considerations of ensuring an informed and autonomous consent in research involving critically ill patients. Silverman HJ. **Am J Respir Crit Care Med** 1996 Sep;154(3 Pt 1):582–6 (34 ref.)

Triage: techniques and applications in decision making. Kennedy K, et al. **Ann Emerg Med** 1996 Aug;28(2):136–44 (74 ref.)

Who are the donors in organ donation? The family's perspective in mandated choice. Klassen AC, et al. **Ann Intern Med** 1996 Jul 1;125(1):70–3 (14 ref.)

Mandated choice for organ donation: time to give it a try. Spital A. **Ann Intern Med** 1996 Jul 1;125(1):66–9 (33 ref.)

Decision factors influencing hormone replacement therapy. Rozenberg S, et al. **Br J Obstet Gynaecol** 1996 May;103 Suppl 13:92–7; discussion 97–8 (45 ref.)

Choices in health care: a contribution from The Netherlands. van de Ven WP. **Br Med Bull** 1995 Oct;51(4):781–90 (7 ref.)

Decision-making capacity for informed consent in the older population. Christensen K, et al. **Bull Am Acad Psychiatry Law** 1995;23(3):353–65 (27 ref.)

Reproductive decision-making and determinants of contraceptive use in HIV-infected women. Williams HA, et al. **Clin Obstet Gynecol** 1996 Jun;39(2):333–43 (40 ref.)

Can healthcare providers obtain judicial intervention against surrogates who demand "medically inappropriate" life support for incompetent patients? [see comments] Cantor NL. **Crit Care Med** 1996 May;24(5):883–7 (28 ref.) Comment in: Crit Care Med 1996 May;24(5):730–2.

Futile care or caregiver frustration? A practical approach. Civetta JM. **Crit Care Med** 1996 Feb;24(2):346–51 (13 ref.)

Terminating life-sustaining treatment of the demented. Callahan D. **Hastings Cent Rep** 1995 Nov-Dec;25(6):25–31 (11 ref.)

Decision-making situations in health care. Murdach AD. **Health Soc Work** 1995 Aug;20(3):187–91 (37 ref.)

When the patient chooses: describing unaided decisions in health care. Pierce PF. **Hum Factors** 1996 Jun;38(2):278–87 (30 ref.)

The evolution of FDA policy on silicone breast implants: a case study of politics, bureaucracy, and business in the process of decision-making. Palley HA. **Int J Health Serv** 1995;25(4):573–91 (61 ref.)

Group decision making. Palazzolo C. **J Am Vet Med Assoc** 1996 Aug 1;209(3):566–9 (11 ref.)

Managed care: "new moves, moral uncertainty, and a radical attitude. Howe EG. **J Clin Ethics** 1995 Winter;6(4):290–305 (57 ref.)

Integration of emerging designs for the practice and management of nursing. Blouin AS, et al. **J Nurs Adm** 1996 Mar;26(3):38–46 (54 ref.)

Implant prosthodontic treatment options for the edentulous patient. Zarb GA, et al. **J Oral Rehabil** 1995 Aug; 22(8):661–71 (17 ref.)

Restructuring the principle of medical futility. Smith GP 2nd. **J Palliat Care** 1995 Autumn;11(3):9–16 (40 ref.)

Variation in dentists' clinical decisions. Bader JD, et al. **J Public Health Dent** 1995 Summer;55(3):181–8 (67 ref.)

Challenges for clinical decision making in the management of osteoarthritis of the knee [editorial; comment] Williams MH. **J Rheumatol** 1996 Apr;23(4):586–9 (63 ref.) Comment on: J Rheumatol 1996 Apr;23(4):730–8.

The person-trade-off approach to valuing health care programs [see comments] Nord E. **Med Decis Making** 1995 Jul-Sep;15(3):201–8 (32 ref.) Comment in: Med Decis Making 1995 Jul-Sep;15(3):287–8.

Methods for combining experts' probability assessments. Jacobs RA. **Neural Comput** 1995 Sep;7(5):867–88 (51 ref.)

Ethical decision making in managing trauma. Ratzan SC. **Neurosurg Clin N Am** 1995 Oct;6(4):809–16 (12 ref.)

Defining neurotoxicity in a decision-making context. Tilson HA, et al. **Neurotoxicology** 1995 Summer;16(2):363–75 (49 ref.)

Towards informed decisions about prenatal testing: a review [see comments] Marteau TM. **Prenat Diagn** 1995 Dec; 15(13):1215–26 (75 ref.) Comment in: Prenat Diagn 1995 Dec;15(13):1209–13.

Screening for disease, cost-effectiveness, and guidelines. Meyer DL. **Prim Care** 1995 Dec;22(4):591–9 (18 ref.)

Using prediction models and cost-effectiveness analysis to improve clinical decisions: emergency department patients

with acute chest pain. Goldman L.
Proc Assoc Am Physicians 1995 Oct;107(3):329–33 (22 ref.)
Mental competence and the question of beneficent intervention. Checkland D, et al. **Theor Med** 1996 Jun; 17(2):121–34 (43 ref.)
Decision making in ruminant orthopedics. Fessler JF, et al. **Vet Clin North Am Food Anim Pract** 1996 Mar;12(1):1–18 (58 ref.)
Fracture management decisions. Roush JK.
Vet Clin North Am Small Anim Pract 1995 Sep; 25(5):1059–72 (19 ref.)
[Decision making and informed consent in clinical medicine] Sakurai T. **Nippon Igaku Hoshasen Gakkai Zasshi** 1995 Oct; 55(13):459–62 (15 ref.) (Eng. Abstr.) **(Jpn)**
[Current clinical problems in evaluating microbiological and pharmacological data] Aguado JM.
Enferm Infecc Microbiol Clin 1995 Oct;13(8):477–81 (11 ref.) **(Spa)**

DECISION MAKING, COMPUTER-ASSISTED

Medical informatics and pediatrics. Decision-support systems. Johnson KB, et al. **Arch Pediatr Adolesc Med** 1995 Dec;149(12):1371–80 (74 ref.)
Invited review: computer aids for decision-making in diagnostic radiology—a literature review. Taylor P.
Br J Radiol 1995 Sep;68(813):945–57 (55 ref.)
Protocols for clinical care. Herbert SI, et al.
Comput Methods Programs Biomed 1995 Sep-Oct; 48(1–2):21–6 (11 ref.)
Clinical decision support—how, when and for whom. Wigertz O. **Comput Methods Programs Biomed** 1995 Sep–Oct;48(1–2):15–20 (25 ref.)
Bridging theory and practice: cognitive science and medical informatics. Patel VL, et al. **Medinfo** 1995;8 Pt 2:1278–82 (26 ref.)

DECISION MAKING, ORGANIZATIONAL

see related
DECISION SUPPORT TECHNIQUES
POLICY MAKING
Policy and procedure development and implementation. Levenson SA. **Clin Geriatr Med** 1995 Aug;11(3):449–65 (8 ref.)
Owned vertical integration and health care: promise and performance. Walston SL, et al.
Health Care Manage Rev 1996 Winter;21(1):83–92 (59 ref.)
The research basis of health care decision making. Ingram N. **J Adv Nurs** 1996 Apr;23(4):692–6 (18 ref.)
Managed care and total quality management: a necessary integration. Phoon J, et al. **J Nurs Care Qual** 1996 Jan; 10(2):25–32 (22 ref.)
[Decision making policies on the utilization of antimalarials in response to a modification of chloroquine efficacy. Applications to Africa] Baudon D. **Med Trop (Mars)** 1995; 55(4 Suppl):37–40 (5 ref.) (Eng. Abstr.) **(Fre)**

DECISION MODELING see **DECISION SUPPORT TECHNIQUES**

DECISION SUPPORT SYSTEMS, MANAGEMENT

Information systems and strategic management. Austin CJ, et al. **Health Care Manage Rev** 1995 Summer;20(3):26–33; discussion 34–42 (17 ref.)

DECISION SUPPORT TECHNIQUES

Febrile seizures: a decision-making analysis. Freeman JM, et al. **Am Fam Physician** 1995 Oct;52(5):1401–6, 1409–10 (17 ref.)
Artificial neural networks for decision support in clinical medicine. Forsström JJ, et al. **Ann Med** 1995 Oct; 27(5):509–17 (72 ref.)
Diagnosis of vascular trauma. Modrall JG, et al.
Ann Vasc Surg 1995 Jul;9(4):415–21 (61 ref.)
Making decisions about antithrombotic therapy in heart disease. Decision analytic and cost-effectiveness issues. Eckman MH, et al. **Chest** 1995 Oct;108(4 Suppl):457S–470S (64 ref.)
Therapy of AVMs: a decision analysis. Fisher WS 3rd.
Clin Neurosurg 1995;42:294–312 (31 ref.)
Decision-support systems in dentistry. White SC.
J Dent Educ 1996 Jan;60(1):47–63 (141 ref.)
Using cluster analysis for medical resource decision making. Dilts D, et al. **Med Decis Making** 1995 Oct–Dec; 15(4):333–47 (72 ref.)
Justifying prenatal screening and genetic amniocentesis programs by cost-effectiveness analyses: a re-evaluation. Ganiats TG. **Med Decis Making** 1996 Jan–Mar;16(1):45–50 (61 ref.)
Application of computers in diabetes care—a review. II. Computers for decision support and education. Lehmann ED, et al. **Med Inf (Lond)** 1995 Oct–Dec;20(4):303–29 (147 ref.)
Diagnostic reasoning in neurology. Gifford DR, et al.
Neurol Clin 1996 Feb;14(1):223–38 (59 ref.)
Diagnostic and prognostic decision support systems. Bartels PH, et al. **Pathologica** 1995 Jun;87(3):221–36 (33 ref.)
Clinical applications of Bayesian belief networks in pathology. Hamilton PW, et al. **Pathologica** 1995 Jun; 87(3):237–45 (11 ref.)
Decision aids in radiology. Kahn CE Jr.
Radiol Clin North Am 1996 May;34(3):607–28 (106 ref.)
Risk analysis systems for veterinary biologicals: a regulator's tool box. Osborne CG, et al. **Rev Sci Tech** 1995 Dec; 14(4):925–35 (8 ref.)
[Contribution of biology to the therapeutic decision: cancer of the breast in 1995] Chinot O, et al.
Bull Cancer Radiother 1995;82(2):225–37 (62 ref.) **(Fre)**

DECISION THEORY

Patient satisfaction and normative decision theory. Brennan PF. **J Am Med Inform Assoc** 1995 Jul–Aug;2(4):250–9 (34 ref.)

DECISION TREES

Allogenic bone marrow transplantation or chemotherapy for patients with acute myeloid leukemia in first complete remission: a decision analysis approach. Hertenstein B, et al. **Ann Hematol** 1996 Apr;72(4):223–30 (47 ref.)
Management after a first myocardial infarction. Flapan AD. **Hosp Pract (Off Ed)** 1996 May 15;31(5):133–7, 141–6 (11 ref.)
Comparison of "accelerated" tissue plasminogen activator with streptokinase for treatment of suspected myocardial infarction [see comments] Kellett J, et al.
Med Decis Making 1995 Oct–Dec;15(4):297–310 (145 ref.)
Comment in: Med Decis Making 1995 Oct–Dec;15(4):395–6.
Clinical decision theory: the threshold concept. Habbema JD. **Neth J Med** 1995 Dec;47(6):302–7 (7 ref.)
An algorithmic approach to cancer pain management. Hudzinski DM. **Nurs Clin North Am** 1995 Dec;30(4):711–23 (11 ref.)
A decision tree approach for carcinogen risk assessment. Butterworth BE, et al. **Prog Clin Biol Res** 1995;391:49–70 (52 ref.)
[Decision trees in psychiatric therapy] Dantchev N.
Encephale 1996 May–Jun;22(3):205–14 (14 ref.) (Eng. Abstr.) **(Fre)**

DECOMPRESSION SICKNESS

PHYSIOPATHOLOGY
Somatosensory evoked potentials in acute neurological decompression illness. Murrison A, et al. **J Neurol** 1995 Oct;242(10):669–76 (22 ref.)

DECONGESTANTS see **NASAL DECONGESTANTS**

DECUBITUS ULCER

PREVENTION & CONTROL
A review of pressure damage prevention strategies. Land L. **J Adv Nurs** 1995 Aug;22(2):329–37 (68 ref.)
Explication of the construct of shared care and the prevention of pressure ulcers in home health care. Sebern MD.
Res Nurs Health 1996 Jun;19(3):183–92 (50 ref.)

DECUSSATION, PYRAMIDAL see **PYRAMIDAL TRACTS**

DEER

PHYSIOLOGY
Interferon, the oxytocin receptor and the maternal recognition of pregnancy in ruminants and non-ruminants: a comparative approach. Flint AP. **Reprod Fertil Dev** 1995; 7(3):313–8 (31 ref.)
[The systems organization of the breeding behavior of the moose in its natural habitat] Bogomolova EM, et al.
Usp Fiziol Nauk 1995 Oct–Dec;26(4):48–74 (47 ref.) (Eng. Abstr.) **(Rus)**

DEET

The present safety assessment of deet. Osimitz TG, et al. **J Am Mosq Control Assoc** 1995 Jun;11(2 Pt 2):274–8 (24 ref.)

DEFECATION

see related
CONSTIPATION
DIARRHEA
ENCOPRESIS
FECAL INCONTINENCE
Systemic diseases causing disorders of defecation and continence. Wald A. **Semin Gastrointest Dis** 1995 Oct; 6(4):194–202 (55 ref.)
[The 3rd national workshop on defecography: the functional radiology of (neo) rectal ampullae (ileal reservoir, colo-anal anastomosis, continent perineal colostomy)] Piloni V, et al. **Radiol Med (Torino)** 1996 Jan–Feb;91(1–2):66–72 (34 ref.) (Eng. Abstr.) **(Ita)**

PHYSIOLOGY
Clinical and physiological aspects of ileal pouch-anal anastomosis. Salemans JM, et al.
Scand J Gastroenterol Suppl 1995;212:3–12 (98 ref.)

DEFECTIVE INTERFERING PARTICLES see **DEFECTIVE VIRUSES**

DEFECTIVE INTERFERING VIRUSES see **DEFECTIVE VIRUSES**

DEFECTIVE VIRUSES

GENETICS
Minireview: the herpes simplex virus amplicon—a versatile defective virus vector. Frenkel N, et al. **Gene Ther** 1994; 1 Suppl 1:S40–6 (44 ref.)
A defective HIV-1 vector for gene transfer to human lymphocytes. Parolin C, et al. **J Mol Med** 1995 Jun; 73(6):279–88 (176 ref.)

DEFENSE MECHANISMS

Ideological singularity as a defense against clinical complexity. Schultz-Ross RA. **Am J Psychother** 1995 Fall; 49(4):540–7 (35 ref.)
The destructiveness of perfectionism. Implications for the treatment of depression. Blatt SJ. **Am Psychol** 1995 Dec; 50(12):1003–20 (175 ref.)
Central tachykinins: mediators of defence reaction and stress reactions. Culman J, et al. **Can J Physiol Pharmacol** 1995 Jul;73(7):885–91 (54 ref.)
Relation of threatened egotism to violence and aggression: the dark side of high self-esteem. Baumeister RF, et al. **Psychol Rev** 1996 Jan;103(1):5–33 (175 ref.)
[Between idealization and devaluation—problems and perspectives of theoretical analyses of female homo- and heterosexuality] Flaake K. **Psyche (Stuttg)** 1995 Sep–Oct; 49(9–10):867–85 (70 ref.) (Eng. Abstr.) **(Ger)**
[Transsexual wish and and cis-sexual defense] Sigusch V. **Psyche (Stuttg)** 1995 Sep–Oct;49(9–10):811–37 (75 ref.) (Eng. Abstr.) **(Ger)**

DEFEROXAMINE

ADVERSE EFFECTS
Antidotes: benefits and risks. Proudfoot AT. **Toxicol Lett** 1995 Dec;82–83:779–83 (20 ref.)

PHARMACOLOGY
Comparative efficacy and toxicity of desferrioxamine, deferiprone and other iron and aluminium chelating drugs. Kontoghiorghes GJ. **Toxicol Lett** 1995 Oct;80(1–3):1–18 (151 ref.)

THERAPEUTIC USE
Cardioprotective effect of desferrioxamine. Bel A, et al.
Acta Haematol 1996;95(1):63–5 (21 ref.)
Role of deferoxamine in tumor therapy. Donfrancesco A, et al. **Acta Haematol** 1996;95(1):66–9 (16 ref.)
Myocardial protection in the occlusion/reperfusion dog model: the role of ischemic necrosis vs reperfusion injury. Chagas AC, et al. **Braz J Med Biol Res** 1995 Sep; 28(9):951–9 (40 ref.)
Risks of parenteral deferoxamine for acute iron poisoning. Howland MA. **J Toxicol Clin Toxicol** 1996;34(5):491–7 (50 ref.)
Benefits of parenteral deferoxamine for acute iron poisoning. Tenenbein M. **J Toxicol Clin Toxicol** 1996;34(5):485–9 (36 ref.)
Prevention and treatment of aluminum toxicity including chelation therapy: status and research needs. Yokel RA, et al. **J Toxicol Environ Health** 1996 Aug 30;48(6):667–83 (90 ref.)
Chelation therapy in beta-thalassemia: the benefits and limitations of desferrioxamine. Giardina PJ, et al.
Semin Hematol 1995 Oct;32(4):304–12 (93 ref.)

TOXICITY
Comparative efficacy and toxicity of desferrioxamine, deferiprone and other iron and aluminium chelating drugs. Kontoghiorghes GJ. **Toxicol Lett** 1995 Oct;80(1–3):1–18 (151 ref.)

DEFIBRILLATION, ELECTRIC see **ELECTRIC COUNTERSHOCK**

DEFIBRILLATORS, IMPLANTABLE

Evolution of the management of malignant ventricular tachyarrhythmias: the roles of drug therapy and implantable defibrillators [editorial] Kim SG.
Am Heart J 1995 Nov;130(5):1144–50 (59 ref.)
Drug therapy versus implantation of a cardiac defibrillator for the treatment of malignant arrhythmias in left ventricular dysfunction [editorial] Mannino MM, et al.
Am Heart J 1996 Jun;131(6):1251–9 (44 ref.)

Interactions between pharmacologic and nonpharmacologic antiarrhythmic therapy. Greene HL. **Am J Cardiol** 1996 Aug 29;78(4A):61–6 (49 ref.)

Prospective trials of implantable cardioverter defibrillators versus drugs: are they addressing the right question? [editorial] Josephson M, et al. **Am J Cardiol** 1996 Apr 15; 77(10):859–63 (29 ref.)

Antitachycardia pacing: an overview. Horwood L, et al. **Am J Crit Care** 1995 Sep;4(5):397–404 (10 ref.)

The current status of the implantable cardioverter defibrillator. Gillis AM. **Annu Rev Med** 1996;47:85–93 (20 ref.)

Implantable cardioverter–defibrillator: present and future indications. Block M, et al. **Arch Mal Coeur Vaiss** 1996 Feb;89 Spec No 1:141–7 (61 ref.)

The implantable cardiac defibrillator. Kamalvand K, et al. **Br J Hosp Med** 1996 Jan 17–Feb 6;55(1–2):37–41 (16 ref.)

The patient with a pacemaker or related device. Bourke ME. **Can J Anaesth** 1996 May;43(5 Pt 2):R24–41 (28 ref.) **(Eng, Fre)**

Interactions between antiarrhythmic drugs and implantable cardioverter–defibrillators. Dougherty AH. **Curr Opin Cardiol** 1996 Jan;11(1):2–8 (25 ref.)

Implantable cardioverter–defibrillator advances. Lerman RD, et al. **Curr Opin Cardiol** 1996 Jan;11(1):16–22 (65 ref.)

Management of cardiac arrest survivors: drugs or devices. Madan N, et al. **Indian Heart J** 1995 Jul–Aug;47(4):387–93 (38 ref.)

Drugs versus devices: contemporary practice in light of contemporary trials. Epstein AE. **J Cardiovasc Electrophysiol** 1995 Oct;6(10 Pt 2):937–41 (32 ref.)

Implantable atrial defibrillators [see comments] Hillsley RE, et al. **J Cardiovasc Electrophysiol** 1995 Aug;6(8):634–48 (107 ref.) Comment in: J Cardiovasc Electrophysiol 1995 Aug;6(8):649–51.

Benefits and lessons learned from stored electrogram information in implantable defibrillators. Marchlinski FE, et al. **J Cardiovasc Electrophysiol** 1995 Oct;6(10 Pt 1):832–51 (29 ref.)

Management of intracardiac device recalls: a consensus conference. Participants of the Consensus Conference. North American Society of Cardiac Pacing and Electrophysiology (NASPE). Goldman BS, et al. **Pacing Clin Electrophysiol** 1996 Jan;19(1):7–17 (14 ref.)

Nonpharmacological therapy for malignant ventricular arrhythmias: implantable defibrillator trials. Saksena S, et al. **Prog Cardiovasc Dis** 1996 May–Jun;38(6):429–44 (90 ref.)

Implanted cardioverter–defibrillators are preferable to drugs as primary therapy in sustained ventricular tachyarrhythmias. Saksena S, et al. **Prog Cardiovasc Dis** 1996 May–Jun;38(6):445–54 (51 ref.)

[Atrial fibrillation and flutter in children and young adults with congenital cardiopathies] Gow RM. **Can J Cardiol** 1996 Feb;12 Suppl A:43A–48A (40 ref.) **(Fre)**

[Auricular fibrillation: future orientation] Kerr CR, et al. **Can J Cardiol** 1996 Feb;12 Suppl A:59A–62A (32 ref.) **(Fre)**

[Cardiac stimulation and atrial fibrillation] Kerr CR, et al. **Can J Cardiol** 1996 Feb;12 Suppl A:34A–37A (31 ref.) **(Fre)**

[Implantable defibrillators—current status of guidelines. Recognized and possible indications—prerequisites] Andresen D. **Fortschr Med** 1996 Apr 20;114(11):128–32 (0 ref.) (Eng. Abstr.) **(Ger)**

[Simplified implantation of defibrillators] Alt E, et al. **Herz** 1995 Dec;20(6):414–9 (44 ref.) **(Ger)**

[Implantable cardioverter–defibrillator] Fuhrer J. **Schweiz Rundsch Med Prax** 1996 May 14;85(20):655–62 (19 ref.) (Eng. Abstr.) **(Ger)**

[How do you want to die? The therapeutic options in ventricular tachyarrhythmia at the end of the anti–arrhythmia drug era] Seipel L. **Z Kardiol** 1995 Oct; 84(10):787–90 (38 ref.) **(Ger)**

[Automated implantable cardioverter/defibrillators. Indications for implantation and clinical results] Ulbricht LJ, et al. **Z Kardiol** 1995;84 Suppl 2:127–36 (96 ref.) (Eng. Abstr.) **(Ger)**

[Management of patients with sustained ventricular arrhythmia: anti–arrhythmia agents or defibrillator?] Cappato R, et al. **Cardiologia** 1996 Feb;41(2):95–105 (75 ref.) **(Ita)**

[Implantable cardioverter–defibrillator: prevention of sudden cardiac death and impact on survival in patients with malignant ventricular arrhythmias] Occhetta E, et al. **Cardiologia** 1995 Jun;40(6):419–25 (35 ref.) **(Ita)**

ADVERSE EFFECTS

Defibrillator patch electrode constriction: an underrecognized entity [see comments] Barrington WW, et al. **Ann Thorac Surg** 1995 Oct;60(4):1112–5; discussion 1115–6 (11 ref.) Comment in: Ann Thorac Surg 1996 Mar;61(3):1042.

Twiddler's syndrome complicating a transvenous defibrillator lead system. de Buitleir M, et al. **Chest** 1996 May; 109(5):1391–4 (8 ref.)

CONTRAINDICATIONS

Implantable defibrillators are preferable to pharmacologic therapy for patients with ventricular tachyarrhythmias: an antagonist's viewpoint. Anderson J. **Prog Cardiovasc Dis** 1996 Mar–Apr;38(5):393–400 (32 ref.)

DEFICIENCY DISEASES

DRUG THERAPY

The treatment of zinc deficiency is an immunotherapy [editorial] Hadden JW. **Int J Immunopharmacol** 1995 Sep; 17(9):697–701 (37 ref.)

ETIOLOGY

The feeding of patients in hospital: a review. McGlone PC, et al. **J R Soc Health** 1995 Oct;115(5):282–8 (49 ref.)

[Pathologic states related to alcoholism] Manso CF. **Acta Med Port** 1995 Dec;8(12):711–7 (107 ref.) (Eng. Abstr.) **(Por)**

IMMUNOLOGY

The treatment of zinc deficiency is an immunotherapy [editorial] Hadden JW. **Int J Immunopharmacol** 1995 Sep; 17(9):697–701 (37 ref.)

VETERINARY

Lipid nutritional pathology in farmed fish. Tacon AG. **Arch Tierernahr** 1996;49(1):33–9 (71 ref.)

DEFORMITIES see ABNORMALITIES

DEGLUTITION

Corrosive ingestions. Lovejoy FH Jr, et al. **Pediatr Rev** 1995 Dec;16(12):473–4 (7 ref.)

PHYSIOLOGY

Swallowing and esophageal function in Parkinson's disease. Johnston BT, et al. **Am J Gastroenterol** 1995 Oct; 90(10):1741–6 (54 ref.)

Neural regulation of swallowing in the dog. Venker–van Haagen AJ. **Vet Q** 1995 Apr;17 Suppl 1:S7 (1 ref.)

[Clinico–instrumental assessment of swallowing in head injury rehabilitation] Zanardi L, et al. **Minerva Anestesiol** 1995 Nov;61(11):463–70 (26 ref.) (Eng. Abstr.) **(Ita)**

DEGLUTITION DISORDERS

Anorexia, cachexia, and dysphagia: the symptom experience. Grant MM, et al. **Semin Oncol Nurs** 1995 Nov;11(4):266–71 (32 ref.)

CLASSIFICATION

Classification of eating impairments based on eating efficiency in children with cerebral palsy. Gisel EG, et al. **Dysphagia** 1995 Fall;10(4):268–74 (38 ref.)

COMPLICATIONS

Pharyngeal and swallowing disorders in infants. Jolley SG, et al. **Semin Pediatr Surg** 1995 Aug;4(3):157–65 (38 ref.)

DIAGNOSIS

Dysphagia in the elderly. Paterson WG. **Can Fam Physician** 1996 May;42:925–32 (42 ref.)

Esophageal dysphagia as the sole symptom in type I Chiari malformation. Elta GH, et al. **Dig Dis Sci** 1996 Mar; 41(3):512–5 (11 ref.)

[The pharyngoesophageal segment] Ekberg O, et al. **Radiologe** 1995 Oct;35(10):689–92 (22 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Diagnostic imaging in the evaluation of dysphagia. Barloon TJ, et al. **Am Fam Physician** 1996 Feb 1;53(2):535–46 (22 ref.)

Low–amplitude distal esophageal spasm as a cause of severe dysphagia for solid food. Breumelhof R, et al. **Am J Gastroenterol** 1996 Jan;91(1):143–6 (14 ref.)

Severe dysphagia, dysmotility, and unusual saccular dilation (diverticulum) of the esophagus following excision of an asymptomatic congenital cyst. Mahajan RJ, et al. **Am J Gastroenterol** 1996 Jun;91(6):1254–8 (23 ref.)

Achalasia. A possible late cause of postpolio dysphagia. Benini L, et al. **Dig Dis Sci** 1996 Mar;41(3):516–8 (20 ref.)

Oropharyngeal dysphagia due to iatrogenic neurological dysfunction. Buchholz DW. **Dysphagia** 1995 Fall; 10(4):248–54 (51 ref.)

Dysphagia after pharyngolaryngeal cancer surgery. Part II: Implications for reconstructive procedures. Herberhold C, et al. **Dysphagia** 1995 Fall;10(4):279–81 (28 ref.)

Pathological pharyngo–esophageal interactions. Massey BT. **Dysphagia** 1995 Fall;10(4):232–4 (21 ref.)

Dysphagia after pharyngolaryngeal cancer surgery. Part I: Pathophysiology of postsurgical deglutition. Walther EK. **Dysphagia** 1995 Fall;10(4):275–8 (25 ref.)

Prolonged dysphagia after orthognathic surgery: report of a case and review of the literature. Nagler RM, et al. **J Oral Maxillofac Surg** 1996 Apr;54(4):523–5 (21 ref.)

PATHOLOGY

[Anatomy and pathophysiology of deglutition disorders] Rabischong P. **Radiologe** 1995 Oct;35(10):679–88 (43 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Swallowing and esophageal function in Parkinson's disease. Johnston BT, et al. **Am J Gastroenterol** 1995 Oct; 90(10):1741–6 (54 ref.)

Subglottic air pressure: a key component of swallowing efficiency. Eibling DE, et al. **Ann Otol Rhinol Laryngol** 1996 Apr;105(4):253–8 (19 ref.)

Oropharyngeal dysphagia due to iatrogenic neurological dysfunction. Buchholz DW. **Dysphagia** 1995 Fall; 10(4):248–54 (51 ref.)

Cricopharyngeal myotomy may be effective treatment for selected patients with neurogenic oropharyngeal dysphagia. Buchholz DW. **Dysphagia** 1995 Fall;10(4):255–8 (20 ref.)

Pathological pharyngo–esophageal interactions. Massey BT. **Dysphagia** 1995 Fall;10(4):232–4 (21 ref.)

RADIOGRAPHY

[Simultaneous video radiography and "solid state" intraluminal pharyngeal manometry during barium swallow; video manometry] Olsson R, et al. **Radiologe** 1995 Oct;35(10):753–8 (46 ref.) (Eng. Abstr.) **(Ger)**

[Videocinematography of swallowing. Indications, methodology and findings] Pokieser P, et al. **Radiologe** 1995 Oct;35(10):703–11 (9 ref.) (Eng. Abstr.) **(Ger)**

[Functional disorders of the esophagus. Radiologic diagnosis] Schima W, et al. **Radiologe** 1995 Oct;35(10):693–702 (64 ref.) (Eng. Abstr.) **(Ger)**

[Radiologic differential diagnosis of neurologically–induced deglutition disorders] Wuttge–Hanning A, et al. **Radiologe** 1995 Oct;35(10):733–40 (16 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Oropharyngeal dysphagia and disorders of the upper esopharyngeal sphincter. Duranceau A. **Ann Chir Gynaecol** 1995;84(2):225–33 (15 ref.)

Pharyngoesophageal swallowing disorders. Jamieson JR. **Curr Opin Gen Surg** 1993;:189–94 (33 ref.)

Esophageal tissue band transected with hot biopsy forceps. Su AY, et al. **Dig Dis Sci** 1995 Oct;40(10):2197–9 (7 ref.)

Cricopharyngeal myotomy may be effective treatment for selected patients with neurogenic oropharyngeal dysphagia. Buchholz DW. **Dysphagia** 1995 Fall;10(4):255–8 (20 ref.)

THERAPY

Palliation of malignant dysphagia from oesophageal cancer. Ellul JP, et al. **Br J Hosp Med** 1996 Mar 6–19;55(5):272–4 (15 ref.)

Dysphagia in the elderly. Paterson WG. **Can Fam Physician** 1996 May;42:925–32 (42 ref.)

Efficacy of behavioral treatment for oropharyngeal dysphagia. Langmore SE. **Dysphagia** 1995 Fall; 10(4):259–62 (43 ref.)

Efficacy in dysphagia. Rosenbek JC. **Dysphagia** 1995 Fall; 10(4):263–7 (22 ref.)

Laser therapy in the palliation of dysphagia in oesophageal malignancy. Lewis–Jones CM, et al. **Palliat Med** 1995 Oct; 9(4):327–30 (15 ref.)

DEGUS see RODENTIA

DEHYDRATASES see HYDRO–LYASES

DEHYDRATION

see related
FLUID THERAPY
REHYDRATION SOLUTIONS

Patient–induced dehydration—can it ever be therapeutic? Smith SA. **Oncol Nurs Forum** 1995 Nov–Dec; 22(10):1487–91 (20 ref.)

THERAPY

Utility of clysis for hydration in nursing home residents. Hussain NA, et al. **J Am Geriatr Soc** 1996 Aug;44(8):969–73 (20 ref.)

DEHYDROBENZPERIDOL see DROPERIDOL

DEHYDROBILIRUBIN see BILIVERDINE

DEHYDROCORTISONE see PREDNISONE

DEHYDROEPIANDROSTERONE see PRASTERONE

DEHYDROGENASES see OXIDOREDUCTASES

DEHYDROISOANDROSTERONE see PRASTERONE

11–DEHYDROPROSTAGLANDIN F2ALPHA see PROSTAGLANDIN D2

DEINSTITUTIONALIZATION

[Evaluation of autonomy in chronic mental patients. Problems, assessment tools, results] Leguay D. **Encephale** 1995 Nov–Dec;21(6):425–35 (98 ref.) (Eng.

Abstr.) (Fre)

LEGISLATION & JURISPRUDENCE

[Social legislative and structural deficits of ambulatory management of chronic psychiatric and handicapped patients] Rössler W, et al. **Nervenarzt** 1995 Nov; 66(11):802–10 (34 ref.) (Eng. Abstr.) (Ger)

DEJERINE-SOTTAS DISEASE see **NEUROPATHIES, HEREDITARY MOTOR AND SENSORY**

DELAYED-ACTION PREPARATIONS

[Studies on development of pharmaceutical preparation with the purpose of improving controlled-release and bioavailability] Goto S. **Yakugaku Zasshi** 1995 Nov; 115(11):871–91 (26 ref.) (Eng. Abstr.) (Jpn)

DELAYED EFFECTS, PRENATAL EXPOSURE see **PRENATAL EXPOSURE DELAYED EFFECTS**

DELIRIUM

Delirium. Quick recognition, careful evaluation, and appropriate treatment. Casey DA, et al. **Postgrad Med** 1996 Jul;100(1):121–4, 128, 133–4 (10 ref.)

CHEMICALLY INDUCED

Cocaine-associated agitated delirium and the neuroleptic malignant syndrome. Wetli CV, et al. **Am J Emerg Med** 1996 Jul;14(4):425–8 (18 ref.)

Delirium associated with acyclovir treatment in a patient with renal failure. Revankar SG, et al. **Clin Infect Dis** 1995 Aug;21(2):435–6 (14 ref.)

The neuropsychiatric complications of corticosteroid therapy. Vincent FM. **Compr Ther** 1995 Sep;21(9):524–8 (22 ref.)

Meperidine associated mental status changes in a patient with chronic renal failure. Stock SL, et al. **J Fla Med Assoc** 1996 May;83(5):315–9 (16 ref.)

DIAGNOSIS

Delirium in elderly patients: evaluation and management. Rummans TA, et al. **Mayo Clin Proc** 1995 Oct; 70(10):989–98 (55 ref.)

Brain failure in older patients. Uncovering treatable causes of a diminished ability to think. Paist SS 3rd, et al. **Postgrad Med** 1996 May;99(5):125–8, 130–4, 136 (7 ref.)

[Delirium: occurrence, diagnosis and therapy] Radanov BP, et al. **Schweiz Rundsch Med Prax** 1995 Nov 14; 84(46):1335–41 (38 ref.) (Eng. Abstr.) (Ger)

NURSING

Delirium intervention research in acute care settings. Cronin-Stubbs D. **Annu Rev Nurs Res** 1996;14:57–73 (35 ref.)

THERAPY

Delirium in elderly patients: evaluation and management. Rummans TA, et al. **Mayo Clin Proc** 1995 Oct; 70(10):989–98 (55 ref.)

DELIRIUM TREMENS see **ALCOHOL WITHDRAWAL DELIRIUM**

DELIVERY

see related
BIRTH INJURIES
DYSTOCIA

The use of ultrasonography in the labor and delivery suite. Benito CW, et al. **Clin Perinatol** 1996 Mar;23(1):117–39 (87 ref.)

Intrapartum management of multiple gestations. Houlihan C, et al. **Clin Perinatol** 1996 Mar;23(1):91–116 (92 ref.)

The role of prostaglandins in labor and delivery. O'Brien WF. **Clin Perinatol** 1995 Dec;22(4):973–84 (40 ref.)

Forcep deliveries. Thompson JP. **Clin Perinatol** 1995 Dec; 22(4):953–72 (14 ref.)

The experience of maternity in a woman's life. Simkin P. **J Obstet Gynecol Neonatal Nurs** 1996 Mar–Apr; 25(3):247–52 (12 ref.)

Protecting the pelvic floor: obstetric management to prevent incontinence and pelvic organ prolapse. Handa VL, et al. **Obstet Gynecol** 1996 Sep;88(3):470–8 (46 ref.)

Spontaneous intrauterine linear skull fracture: a rare complication of spontaneous vaginal delivery. Heise RH, et al. **Obstet Gynecol** 1996 May;87(5 Pt 2):851–4 (15 ref.)

[Delivery of women with cicatricial uterus] Haddad S, et al. **Presse Med** 1996 May 18;25(17):813–7 (23 ref.) (Eng. Abstr.) (Fre)

[Effect of pregnancy and delivery on genuine stress incontinence] Zilberman B, et al. **Harefuah** 1995 Jul; 129(1–2):43–6 (21 ref.) (Heb)

[Postterm pregnancy--importance of this problem in modern obstetrics] Chazan B, et al. **Ginekol Pol** 1996 Mar; 67(3):148–56 (20 ref.) (Eng. Abstr.) (Pol)

ADVERSE EFFECTS

Maternal sequelae of childbirth [editorial] Reynolds F. **Br J Anaesth** 1995 Nov;75(5):515–7 (26 ref.)

METHODS

Delivery of the premature infant. Bottoms S. **Clin Obstet Gynecol** 1995 Dec;38(4):780–9 (26 ref.)

Abnormal fetal presentations. Gimovsky M, et al. **Curr Opin Obstet Gynecol** 1995 Dec;7(6):482–5 (15 ref.)

Monoamniotic twin pregnancies. Review of the literature, and a case report with vaginal delivery. Dubecq F, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Jun;66(2):183–6 (15 ref.)

Effects of epidural analgesia on the progress of labor and the mode of delivery. Finster M. **Eur J Obstet Gynecol Reprod Biol** 1995 May;59 Suppl:S31–3 (35 ref.)

The Zavanelli maneuver for fetal shoulder dystocia. Three cases with poor outcomes. Spellacy WN. **J Reprod Med** 1995 Jul;40(7):543–4 (7 ref.)

[Labor and delivery in twin pregnancy] Wirthner D, et al. **Rev Med Suisse Romande** 1996 Apr;116(4):255–60 (49 ref.) (Fre)

NURSING

Nursing support of the laboring woman. Hodnett E. **J Obstet Gynecol Neonatal Nurs** 1996 Mar–Apr; 25(3):257–64 (11 ref.)

DELIVERY, ABDOMINAL see **CESAREAN SECTION**

DELIVERY, HOME see **HOME CHILDBIRTH**

DELIVERY OF DENTAL CARE see **DELIVERY OF HEALTH CARE**

DELIVERY OF HEALTH CARE

see related
CONSUMER PARTICIPATION

Computerized geriatric assessment for geriatric care management. De Vore PA. **Aging (Milano)** 1995 Jun; 7(3):194–6 (22 ref.)

Managed health care. Managing the risks of laboratory testing in an integrated delivery system. Cooney MM. **Am J Clin Pathol** 1995 Oct;104(4 Suppl 1):S50–3 (14 ref.)

Using hub technology to facilitate information system integration in a health-care enterprise. Gendler SM, et al. **Am J Clin Pathol** 1996 Apr;105(4 Suppl 1):S25–32 (5 ref.)

Cancer and ethnic minorities--the Department of Health's perspective. Bahl V. **Br J Cancer** 1996 Sep;74 Suppl 29:S2–10 (28 ref.)

Spain: an explanatory model of supply and utilization of human resources of the health care system. Alfonso Sanchez JL, et al. **Cah Sociol Demogr Med** 1995 Oct–Dec; 35(3–4):227–61 (79 ref.)

The winds of change. Roski RA. **Clin Neurosurg** 1995;42:1–14 (8 ref.)

Medicine in transition: strategies for change. Vogel DE. **Clin Neurosurg** 1995;42:23–9 (0 ref.)

Australian healthcare: a smart card for a clever country. Morris S, et al. **Int J Biomed Comput** 1995 Oct;40(2):101–5 (14 ref.)

Shifting boundaries in professional care. Hopkins A, et al. **J R Soc Med** 1996 Jul;89(7):364–71 (36 ref.)

Understanding American health-care and health-care reform [see comments] Johnson D. **J R Soc Med** 1995 Nov; 88(11):652P–656P (8 ref.) Comment in: J R Soc Med 1996 Mar;89(3):179.

The impact of molecular medicine on health services. Jones R. **Nat Med** 1996 Sep;2(9):959–60 (11 ref.)

Clinical issues in therapeutic communities. Carroll JF. **NIDA Res Monogr** 1994;144:268–79 (9 ref.)

Service delivery strategies for treating high-risk youth: delinquents, homeless, runaways, and sexual minorities. Farrow JA. **NIDA Res Monogr** 1995;156:39–48 (23 ref.)

An analysis of the women's health movement and its impact on the delivery of health care within the United States. Geary MS. **Nurse Pract** 1995 Nov;20(11 Pt 1):24, 27–8, 30–1, passim (45 ref.)

[A brief review of the debate over social inequalities in health] Doz JF, et al. **Aten Primaria** 1996 May 31; 17(9):585–9 (40 ref.) (Spa)

ECONOMICS

The economics of reimbursement and technological change in cancer care [see comments] Kesteloot K. **Eur J Cancer** 1995;31A(9):1406–9 (22 ref.) Comment in: Eur J Cancer 1995;31A(9):1387.

European School of Oncology Advisory report to the Commission of the European Communities for the "Europe Against Cancer Programme" cost-effectiveness in cancer care [see comments] Williams C, et al. **Eur J Cancer** 1995; 31A(9):1410–24 (77 ref.) Comment in: Eur J Cancer 1995;31A(9):1387.

Perspectives in health economics [editorial] Phelps CE. **Health Econ** 1995 Sep–Oct;4(5):335–53 (44 ref.)

Principles of economic evaluation for health care programs. O'Brien B. **J Rheumatol** 1995 Jul;22(7):1399–402 (18 ref.)

Observations on renal replacement services in Russia, Belarus and Lithuania. Boesken WH, et al. **Nephrol Dial Transplant** 1995 Nov;10(11):2013–6 (5 ref.)

LEGISLATION & JURISPRUDENCE

[Help or hinderniss? The effect of legal norms on the physician–patient relationship] Ulsenheimer K. **Geburtshilfe Frauenheilkd** 1995 Sep;55(9):M110–9 (113 ref.) (Ger)

ORGANIZATION & ADMINISTRATION

The current state of health care in the former Soviet Union: implications for health care policy and reform [see comments] Barr DA, et al. **Am J Public Health** 1996 Mar; 86(3):307–12 (61 ref.) Comment in: Am J Public Health 1996 Mar;86(3):321–3.

A systematic overview of the effectiveness of home visiting as a delivery strategy for public health nursing interventions. Ciliska D, et al. **Can J Public Health** 1996 May–Jun;87(3):193–8 (17 ref.)

Behavioral medicine, clinical health psychology, and cost offset. Friedman R, et al. **Health Psychol** 1995 Nov; 14(6):509–18 (52 ref.)

Ethnic minorities, health care systems, and behavior. Penn NE, et al. **Health Psychol** 1995 Dec;14(7):641–6 (40 ref.)

Health care and nursing in Romania. Lakey CK, et al. **J Adv Nurs** 1996 May;23(5):1045–9 (20 ref.)

Domestic violence: changing theory, changing practice. Warshaw C. **J Am Med Womens Assoc** 1996 May–Jul; 51(3):87–91, 100 (70 ref.)

How cardiac rehabilitation is being influenced by changes in health-care delivery. Froelicher VF, et al. **J Cardpulm Rehabil** 1996 May–Jun;16(3):151–9 (24 ref.)

Through the lenses of organizational sociology: the role of organizational theory and research in conceptualizing and examining our health care system. Flood AB, et al. **J Health Soc Behav** 1995;Spec No:154–69 (95 ref.)

Transforming prenatal care: reflections on the past and present with implications for the future. Maloni JA, et al. **J Obstet Gynecol Neonatal Nurs** 1996 Jan;25(1):17–23 (51 ref.)

Certified nurse midwives: over twenty years of military service. Davis LJ. **Mil Med** 1995 Aug;160(8):401–4 (20 ref.)

The Dutch health care system: lessons for reform in the United States. Jackson JL. **South Med J** 1996 Jun; 89(6):567–72 (31 ref.)

Improving the quality of care for persons with HIV infection in sub-Saharan Africa. Colebunders R, et al. **Trop Geogr Med** 1995;47(2):78–81 (26 ref.)

STANDARDS

Observations on renal replacement services in Russia, Belarus and Lithuania. Boesken WH, et al. **Nephrol Dial Transplant** 1995 Nov;10(11):2013–6 (5 ref.)

Quo vademus? A review of the regulatory environment. Huss H, et al. **Qual Assur** 1995 Sep;4(3):181–6 (6 ref.)

STATISTICS & NUMERICAL DATA

Delivery systems for preschool children. Crall JJ. **Dent Clin North Am** 1995 Oct;39(4):897–907 (22 ref.)

TRENDS

Professional dynamics and the changing nature of medical work. Hafferty FW, et al. **J Health Soc Behav** 1995;Spec No:132–53 (130 ref.)

The preparation of advanced practice nurses. Current issues. O'Flynn AI. **Nurs Clin North Am** 1996 Sep;31(3):429–38 (20 ref.)

Enhancing coverage and sustainability of vaccination programs: an explanatory framework with special reference to India. Streefland PH. **Soc Sci Med** 1995 Sep;41(5):647–56 (53 ref.)

The outlook of the Tekhne Iatrike and the Medical Act to the third millenium. Araya RF. **Theor Med** 1996 Jun; 17(2):163–73 (46 ref.)

Cultural competence--an essential hybrid for delivering high quality care in the 1990's and beyond. Lavizzo-Mourey RJ, et al. **Trans Am Clin Climatol Assoc** 1995;107:226–35; discussion 236–7 (40 ref.)

[Conceptual approaches in quality evaluation, quality promotion and quality assurance] Gebert AJ. **Swiss Surg** 1995;(1):8–14 (83 ref.) (Eng. Abstr.) (Ger)

[Health care system in the 21st century] Endo H. **Masui** 1995; 44 Suppl:S12–6 (0 ref.) (Jpn)

DELIVERY OF HEALTH CARE, INTEGRATED

Owned vertical integration and health care: promise and performance. Walston SL, et al. **Health Care Manage Rev** 1996 Winter;21(1):83–92 (59 ref.)

ORGANIZATION & ADMINISTRATION

The acute and long-term care interface. Integrating the continuum. Phillips-Harris C, et al. **Clin Geriatr Med** 1995 Aug;11(3):481–501 (24 ref.)

The problematic fit of diagnosis and strategy for medical group stakeholders--including IDS/Ns. Blair JD, et al. **Health Care Manage Rev** 1996 Winter;21(1):7–28 (21 ref.)

The leadership dance. Ehrat KS, et al. **J Nurs Adm** 1996 Apr;26(4):13–5 (14 ref.)

Integration of health care delivery. Report of a WHO Study Group. **World Health Organ Tech Rep Ser** 1996;861:1–68

DELIVERY OF HEALTH CARE, INTEGRATED

(61 ref.)

TRENDS

The challenge of managing laboratory information in a managed care environment. Friedman BA.
Am J Clin Pathol 1996 Apr;105(4 Suppl 1):S3-9 (23 ref.)
Mergers, networking, and vertical integration: managed care and investor-owned hospitals. Brown M.
Health Care Manage Rev 1996 Winter;21(1):29-37 (7 ref.)

DELIVERY ROOMS

Nosocomial acquisition of Escherichia coli by infants delivered in hospitals. Fujita K, et al. **J Hosp Infect** 1996 Apr;32(4):277-81 (23 ref.)

DELIVERY, VACUUM EXTRACTION see **VACUUM EXTRACTION, OBSTETRICAL**

DELPHI TECHNIQUE

[Professional profile of primary health care personnel. A Delphi study] Molina Durán F, et al. **Aten Primaria** 1996 Jan;17(1):24-32 (21 ref.) (Eng. Abstr.) **(Spa)**

DELTA AGENT

GENETICS

The molecular biology of hepatitis delta virus. Lai MM.
Annu Rev Biochem 1995;64:259-86 (132 ref.)
Substitution rates in hepatitis delta virus. Krushkal J, et al.
J Mol Evol 1995 Dec;41(6):721-6 (31 ref.)
Regulation of the hepatitis delta virus ribozymes: to cleave or not to cleave? Lazinski DW, et al. **RNA** 1995 May; 1(3):225-33 (70 ref.)
[Divergence and heterogeneity of HDV-RNA sequences in Japan] Imazeki F. **Nippon Rinsho** 1995 Oct;53 Suppl:752-8 (20 ref.) **(Jpn)**
[Molecular biological study of hepatitis delta virus] Kamahora T. **Nippon Rinsho** 1995 Oct;53 Suppl:743-51 (47 ref.) **(Jpn)**

DELTA HEPATITIS see **DELTA INFECTION**

DELTA INFECTION

[Clinical aspects of hepatitis D virus infection] Ogata N, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:768-78 (30 ref.) **(Jpn)**

[Delta hepatitis] Matsuda S, et al.
Ryoikibetsu Shokogun Shirizu 1995;(7):127-30 (10 ref.) **(Jpn)**

COMPLICATIONS

Role of hepatitis C virus in dual and triple hepatitis virus infection. Liaw YF. **Hepatology** 1995 Oct;22(4 Pt 1):1101-8 (84 ref.)
Acute exacerbation and superinfection in patients with chronic viral hepatitis. Liaw YF. **J Formos Med Assoc** 1995 Sep;94(9):521-8 (78 ref.)
[Liver, biliary tracts and human immunodeficiency virus infection. 1: liver, HIV and hepatitis B, C and D viruses] Vuitton DA, et al. **Gastroenterol Clin Biol** 1996; 20(3):269-80 (146 ref.) **(Fre)**

EPIDEMIOLOGY

Hepatitis B and hepatitis delta virus infection in South America. Torres JR. **Gut** 1996;38 Suppl 2:S48-55 (82 ref.)
[Epidemiology of hepatitis delta virus infection] Iwanami E, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:759-67 (22 ref.) **(Jpn)**

PATHOLOGY

[Pathology of liver graft viral reinfection] Reynès M, et al.
Ann Pathol 1995;15(5):396-402 (40 ref.) **(Fre)**

DELTA RECEPTORS see **RECEPTORS, OPIOID, DELTA**

DELTA RHYTHM

Observations on delta homeostasis, the one-stimulus model of NREM-REM alternation and the neurobiologic implications of experimental dream studies. Feinberg I, et al. **Behav Brain Res** 1995 Jul-Aug;69(1-2):97-108 (56 ref.)

DELTA SLEEP-INDUCING PEPTIDE

PHYSIOLOGY

[The role of the delta sleep-inducing peptide in the formation of neuropathological syndromes] Shandra AA, et al.
Fiziol Zh Im I M Sechenova 1995 Sep;81(9):13-24 (56 ref.) (Eng. Abstr.) **(Rus)**

DELTA SUPERINFECTION see **DELTA INFECTION**

DELTA(9)-THC see **TETRAHYDROCANNABINOL**

DELTA VIRUS see **DELTA AGENT**

DELUSIONS

DIAGNOSIS

Facial processing in schizophrenia and delusional misidentification: cognitive neuropsychiatric approaches. Phillips ML, et al. **Schizophr Res** 1995 Sep;17(1):109-14 (45 ref.)
[Stability of positive/negative symptoms in schizophrenia] Ribeyre JM, et al. **Encephale** 1996 Jun;22 Spec No 2:29-31 (11 ref.) (Eng. Abstr.) **(Fre)**
[Diagnosis of Taijin-Kyofu and social phobia] Kasahara T. **Seishin Shinkeigaku Zasshi** 1995;97(5):357-66 (47 ref.) **(Jpn)**

DRUG THERAPY

Late-life delusional depression: acute and long-term treatment. Meyers BS. **Int Psychogeriatr** 1995;7 Suppl:113-24 (73 ref.)

ETIOLOGY

[Conference at the Salpêtrière. April 1994 . Familial dementia and onirism in a 63-year-old woman] Laurent B, et al. **Rev Neurol (Paris)** 1995 Jun-Jul;151(6-7):420-8 (50 ref.) **(Fre)**
[The pathogenesis of persecutory delusions in the light of the attribution theory] Wojnar M, et al. **Psychiatr Pol** 1995 Sep-Oct;29(5):665-74 (26 ref.) (Eng. Abstr.) **(Pol)**

PSYCHOLOGY

Dementia and guns [see comments] Mendez MF.
J Am Geriatr Soc 1996 Apr;44(4):409-10 (10 ref.) Comment in: J Am Geriatr Soc 1996 Apr;44(4):467-9.
Dangerous delusional misidentification and homicide. Silva JA, et al. **J Forensic Sci** 1996 Jul;41(4):641-4 (32 ref.)
[Delusions and imagination] Schmidt-Degenhard M.
Fortschr Neurol Psychiatr 1995 Sep;63(9):350-7 (57 ref.) (Eng. Abstr.) **(Ger)**
[Othello syndrome--jealousy and jealous delusions as symptoms of psychiatric disorders] Soyka M.
Fortschr Neurol Psychiatr 1995 Dec;63(12):487-94 (93 ref.) (Eng. Abstr.) **(Ger)**
[Induced delusional disorder in childhood and adolescence] Zillessen KE, et al. **Z Kinder Jugenpsychiatr** 1996 Jun; 24(2):117-26 (43 ref.) **(Ger)**

THERAPY

An overview of treatment in paranoia/delusional disorder. Munro A, et al. **Can J Psychiatry** 1995 Dec;40(10):616-22 (132 ref.)

DEMENTIA

[Subcortical dementia] Sellal F. **Rev Med Interne** 1996; 17(5):419-24 (26 ref.) (Eng. Abstr.) **(Fre)**
[Subcortical dementia: is a revision of the concept necessary?] Godefroy O, et al. **Rev Neurol (Paris)** 1995 Dec; 151(12):675-81 (91 ref.) (Eng. Abstr.) **(Fre)**
[Progressive aphasia without dementia--the onset of an atrophic process of the brain] Kadykov AS, et al.
Zh Nevropatol Psikhiatr Im S S Korsakova 1996;96(1):42-4 (11 ref.) (Eng. Abstr.) **(Rus)**

CHEMICALLY INDUCED

The neuropsychiatric complications of corticosteroid therapy. Vincent FM. **Compr Ther** 1995 Sep;21(9):524-8 (22 ref.)

CLASSIFICATION

[Are the concepts of dementia according to DSM-4 and ICD-10 similar? Some theoretical aspects] Heinik J.
Harefuah 1996 Mar 15;130(6):409-13 (32 ref.) **(Heb)**

COMPLICATIONS

Difficult dementia: six steps to control problem behaviors. Banazak DA. **Geriatrics** 1996 Feb;51(2):36-42 (16 ref.)
Dementia: diagnosis and emergency behavioral complications. Tueth MJ. **J Emerg Med** 1995 Jul-Aug; 13(4):519-25 (38 ref.)
Sundown syndrome: etiology and management. Burney-Puckett M.
J Psychosoc Nurs Ment Health Serv 1996 May;34(5):40-3 (15 ref.)
Management of dementia-related behavioral disturbances: a nonpharmacologic approach. Carlson DL, et al.
Mayo Clin Proc 1995 Nov;70(11):1108-15 (41 ref.)
[Frontal type dementia and amyotrophic lateral sclerosis. 3 cases with (HmPAO Tc99m) single-photon emission tomography study] Vercelletto M, et al.
Rev Neurol (Paris) 1995 Nov;151(11):640-7 (43 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Review: Binswanger's disease, leukoaraiosis and dementia [letter; comment] Hasan M, et al. **Age Ageing** 1995 Sep; 24(5):454 (4 ref.) Comment on: Age Ageing 1994 Jan;23(1):75-81.
A flexible system of detection for Alzheimer's disease and related dementias. Gurland BJ, et al. **Aging (Milano)** 1995 Jun;7(3):165-72 (18 ref.)
Molecular and functional magnetic resonance neuroimaging for the study of dementia. Gilberto González R.
Ann N Y Acad Sci 1996 Jan 17;777:37-48 (29 ref.)
Alzheimer's disease: an update. Sandson TA, et al.
Compr Ther 1995 Sep;21(9):480-5 (41 ref.)
Staging methods for the assessment of dementia: Perspectives. Cohen-Mansfield J, et al. **J Clin Psychiatry** 1996 May; 57(5):190-8 (57 ref.)
Agitation as a possible expression of generalized anxiety disorder in demented elderly patients: toward a treatment approach. Mintzer JE, et al. **J Clin Psychiatry** 1996;57 Suppl 7:55-63; discussion 73-5 (79 ref.)
Dementia: diagnosis and emergency behavioral complications. Tueth MJ. **J Emerg Med** 1995 Jul-Aug; 13(4):519-25 (38 ref.)
Dementia: diagnosis and evaluation [see comments] Fleming KC, et al. **Mayo Clin Proc** 1995 Nov;70(11):1093-107 (97 ref.) Comment in: Mayo Clin Proc 1996 Aug;71(8):821.
Evaluation of dementia. Geldmacher DS, et al.
N Engl J Med 1996 Aug 1;335(5):330-6 (39 ref.)
Brain failure in older patients. Uncovering treatable causes of a diminished ability to think. Paist SS 3rd, et al.
Postgrad Med 1996 May;99(5):125-8, 130-4, 136 (7 ref.)
[Dementias: current situation and future perspectives] Espert R, et al. **Rev Neurol** 1995 Jan-Feb;23(119):70-6 (90 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Treatment of the elderly suffering from psychosis and dementia. Sunderland T. **J Clin Psychiatry** 1996;57 Suppl 9:53-6 (30 ref.)
Methodologic issues regarding outcome measures for clinical drug trials of psychiatric complications in dementia. Teri L, et al. **J Geriatr Psychiatry Neurol** 1995 Oct;8 Suppl 1:S8-17 (63 ref.)
Clozapine as a treatment for psychosis in Parkinson's disease: a review. Musser WS, et al.
J Neuropsychiatry Clin Neurosci 1996 Winter;8(1):1-9 (52 ref.)
Pharmacologic therapies in dementia. Fleming KC, et al.
Mayo Clin Proc 1995 Nov;70(11):1116-23 (47 ref.)
[Dementias: present situation and future perspectives (III). Neurological, therapeutic, psychosocial aspects and patient care] Espert R, et al. **Rev Neurol** 1995 Jan-Feb; 23(119):86-95 (138 ref.) (Eng. Abstr.) **(Spa)**

EPIDEMIOLOGY

Epidemiology of the dementias: recent developments and new approaches. van Duijn CM.
J Neurol Neurosurg Psychiatry 1996 May;60(5):478-88 (153 ref.)
[Dementias: current situation and future perspectives] Espert R, et al. **Rev Neurol** 1995 Jan-Feb;23(119):70-6 (90 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

Intravascular malignant lymphomatosis: a cause of subacute dementia. Treves TA, et al. **Dementia** 1995 Sep-Oct; 6(5):286-93 (107 ref.)
Charles Bonnet syndrome: an early marker for dementia? [see comments] Pliskin NH, et al. **J Am Geriatr Soc** 1996 Sep;44(9):1055-61 (43 ref.) Comment in: J Am Geriatr Soc 1996 Sep;44(9):1128-9.
Clozapine as a treatment for psychosis in Parkinson's disease: a review. Musser WS, et al.
J Neuropsychiatry Clin Neurosci 1996 Winter;8(1):1-9 (52 ref.)
[Progressive lupus dementia. 2 cases with or without antiphospholipid antibodies] Robin C, et al.
Rev Neurol (Paris) 1995 Dec;151(12):699-707 (48 ref.) (Eng. Abstr.) **(Fre)**
[Necrotizing herpes simplex encephalitis as the cause of a progressive dementia syndrome] Zachhuber C, et al.
Dtsch Med Wochenschr 1995 Sep 22;120(38):1278-82 (19 ref.) (Eng. Abstr.) **(Ger)**

GENETICS

Prions, beta-sheets and transmissible dementias: is there still something missing? Liberski PP.
Acta Neuropathol (Berl) 1995;90(2):113-25 (202 ref.)
Dynamic mutations and psychiatric genetics [editorial] O'Donovan MC, et al. **Psychol Med** 1996 Jan;26(1):1-6 (30 ref.)

NURSING

Delirium intervention research in acute care settings. Cronin-Stubbs D. **Annu Rev Nurs Res** 1996;14:57-73 (35 ref.)

PATHOLOGY

The new neuropathology of degenerative frontotemporal dementias. Jackson M, et al. **Acta Neuropathol (Berl)** 1996; 91(2):127-34 (38 ref.)
Prions, beta-sheets and transmissible dementias: is there still something missing? Liberski PP.
Acta Neuropathol (Berl) 1995;90(2):113-25 (202 ref.)
Neuropathology of the cortex in amyotrophic lateral sclerosis with dementia. Pellissier JF, et al. **Adv Neurol** 1995;

68:139–41 (41 ref.)
Lewy body disease and dementia. A review. Kalra S, et al. **Arch Intern Med** 1996 Mar 11;156(5):487–93 (62 ref.)
Making the diagnosis of mixed and non-Alzheimer's dementias. Hansen LA, et al. **Arch Pathol Lab Med** 1995 Nov;119(11):1023–31 (34 ref.)
Methodological problems and clinical relevance of structural neuroimaging in dementia research. Lang CJ. **J Neural Transm Gen Sect** 1995;99(1–3):131–43 (45 ref.)
Frontotemporal dementia: a clinicopathological review of four postmortem studies. Hooten WM, et al. **J Neuropsychiatry Clin Neurosci** 1996 Winter;8(1):10–9 (65 ref.)

PHYSIOPATHOLOGY

Syndromes of language dissolution in aging and dementia. Kirshner HS, et al. **Compr Ther** 1995 Sep;21(9):519–23 (30 ref.)
The P300 and vascular dementia: not quite ready for prime time [editorial; comment] Bergethon PR, et al. **J Am Geriatr Soc** 1995 Nov;43(11):1311–3 (14 ref.) Comment on: J Am Geriatr Soc 1995 Nov;43(11):1228–36.
[Dementias: present situation and future perspectives (II). Biological markers] Espert R, et al. **Rev Neurol** 1995 Jan–Feb;23(119):77–85 (107 ref.) (Eng. Abstr.) **(Spa)**

PSYCHOLOGY

Review: diogenes syndrome. Cooney C, et al. **Age Ageing** 1995 Sep;24(5):451–3 (14 ref.)
Neuropsychological aspects of frontotemporal degeneration. Neary D. **Ann N Y Acad Sci** 1995 Dec 15;769:15–22 (31 ref.)
Dementia and guns [see comments] Mendez MF. **J Am Geriatr Soc** 1996 Apr;44(4):409–10 (10 ref.) Comment in: J Am Geriatr Soc 1996 Apr;44(4):467–9.
Anticonvulsant and other non-neuroleptic treatment of agitation in dementia. Tariot PN, et al. **J Geriatr Psychiatry Neurol** 1995 Oct;8 Suppl 1:S28–39 (103 ref.)
Methodologic issues regarding outcome measures for clinical drug trials of psychiatric complications in dementia. Teri L, et al. **J Geriatr Psychiatry Neurol** 1995 Oct;8 Suppl 1:S8–17 (63 ref.)
[Dementias: present situation and future perspectives (III). Neurological, therapeutic, psychosocial aspects and patient care] Espert R, et al. **Rev Neurol** 1995 Jan–Feb; 23(119):86–95 (138 ref.) (Eng. Abstr.) **(Spa)**

RADIOGRAPHY

Methodological problems and clinical relevance of structural neuroimaging in dementia research. Lang CJ. **J Neural Transm Gen Sect** 1995;99(1–3):131–43 (45 ref.)

THERAPY

Terminating life-sustaining treatment of the demented. Callahan D. **Hastings Cent Rep** 1995 Nov–Dec;25(6):25–31 (11 ref.)
Dworkin on dementia. Elegant theory, questionable policy. Dresser R. **Hastings Cent Rep** 1995 Nov–Dec;25(6):32–8 (17 ref.)
[Toward a treatment for dementia] Ghika J. **Schweiz Rundsch Med Prax** 1995 Sep 19;84(38):1050–3 (47 ref.) (Eng. Abstr.) **(Fre)**

DEMENTIA, MULTI-INFARCT

PATHOLOGY

[Cadasil—a new model for subcortical dementia] Davous P, et al. **Rev Neurol (Paris)** 1995 Nov;151(11):634–9 (31 ref.) (Eng. Abstr.) **(Fre)**
[An autopsy case of "diffuse neurofibrillary tangles with calcification", multiple infarctions and hyaline arteriosclerosis] Arai T, et al. **No To Shinkei** 1996 Jan; 48(1):69–76 (26 ref.) (Eng. Abstr.) **(Jpn)**

DEMENTIA PRAECOX see SCHIZOPHRENIA

DEMENTIA, PRESENILE

DIAGNOSIS

Neurodegenerative disorders with extensive tau pathology: a comparative study and review. Feany MB, et al. **Ann Neurol** 1996 Aug;40(2):139–48 (93 ref.)
Brain electrical activity (quantitative EEG and bit-mapping neurocognitive CNV components), psychometrics and clinical findings in presenile subjects with initial mild cognitive decline or probable Alzheimer-type dementia. Zappoli R, et al. **Ital J Neurol Sci** 1995 Sep;16(6):341–76 (177 ref.)

PHYSIOPATHOLOGY

Utility of auditory P300 in detection of presenile dementia. Filipović SR, et al. **J Neurol Sci** 1995 Aug;131(2):150–5 (25 ref.)

DEMENTIA, PRIMARY DEGENERATIVE, PRESENILE see DEMENTIA, PRESENILE

DEMENTIA, PRIMARY DEGENERATIVE, SENILE see DEMENTIA, SENILE

DEMENTIA, SENILE

DIAGNOSIS

Non-Alzheimer's disease amyloidoses of the nervous system. Castaño EM, et al. **Curr Opin Neurol** 1995 Aug;8(4):279–85 (57 ref.)
Human prion diseases. Parchi P, et al. **Curr Opin Neurol** 1995 Aug;8(4):286–93 (55 ref.)
Diagnostic testing and dementia. Sandson TA, et al. **Neurol Clin** 1996 Feb;14(1):45–59 (145 ref.)

EPIDEMIOLOGY

Epidemiology of mental disorders in middle age and late life: conceptual issues. Gallo JJ. **Epidemiol Rev** 1995;17(1):83–94 (171 ref.)
Psychiatric and physical morbidity effects of dementia caregiving: prevalence, correlates, and causes. Schulz R, et al. **Gerontologist** 1995 Dec;35(6):771–91 (90 ref.)
Elderly mental health in the developing world. Levkoff SE, et al. **Soc Sci Med** 1995 Oct;41(7):983–1003 (178 ref.)

ETIOLOGY

Review: cobalamin deficiency and mental impairment in elderly people. van Goor L, et al. **Age Ageing** 1995 Nov; 24(6):536–42 (80 ref.)
Cognitive problems in the elderly. Dal Forno G, et al. **Curr Opin Neurol** 1995 Aug;8(4):256–61 (44 ref.)
[Diagnostic imaging in senile dementia. Exclusion of specific treatable causes also in the elderly] Herholz K. **Fortschr Med** 1995 Oct 20;113(29):413–7 (6 ref.) (Eng. Abstr.) **(Ger)**

GENETICS

Genes and recent developments in the epidemiology of Alzheimer's disease and related dementia. Breitner JC, et al. **Epidemiol Rev** 1995;17(1):39–47 (99 ref.)

PATHOLOGY

The canine as an animal model of human aging and dementia. Cummings BJ, et al. **Neurobiol Aging** 1996 Mar–Apr; 17(2):259–68 (106 ref.)
Cognitive impairment in elderly schizophrenia: a dementia (still) lacking distinctive histopathology. Arnold SE, et al. **Schizophr Bull** 1996;22(1):5–9 (30 ref.)

PHYSIOPATHOLOGY

[Light therapy can restore a disturbed sleep/wake rhythm in dementia: but what is the basis of its efficacy?] Beullens J. **Tijdschr Gerontol Geriatr** 1995 Dec;26(6):264–9 (40 ref.) (Eng. Abstr.) **(Dut)**

DEMENTIA, VASCULAR

Vascular dementia. Amar K, et al. **BMJ** 1996 Jan 27; 312(7025):227–31 (65 ref.)

DIAGNOSIS

Vascular cognitive impairment: a new approach to vascular dementia. Bowler JV, et al. **Baillieres Clin Neurol** 1995 Aug;4(2):357–76 (75 ref.)
Vascular risk factors and atherosclerosis as risk factors for cognitive decline and dementia [editorial] Prince MJ. **J Psychosom Res** 1995 Jul;39(5):525–30 (31 ref.)
Assessing vascular dementia. Forette F, et al. **Neth J Med** 1995 Oct;47(4):185–94 (90 ref.)
[Magnetic resonance imaging in vascular dementia] Leys D, et al. **J Mal Vasc** 1995;20(3):194–202 (73 ref.) (Eng. Abstr.) **(Fre)**
[Patchy changes in white matter in cranial computerized and magnetic resonance tomography—significance for (differential) diagnosis of dementia of the Alzheimer type and vascular dementia] Stoppe G, et al. **Fortschr Neurol Psychiatr** 1995 Nov;63(11):425–40 (150 ref.) (Eng. Abstr.) **(Ger)**
[Some problems in giving notice of the name of a disease: with special reference to Alzheimer's disease and vascular dementia] Hirai S. **No To Shinkei** 1996 May;48(5):431–5 (3 ref.) **(Jpn)**

DRUG THERAPY

HWA 285 (propentofylline)—a new compound for the treatment of both vascular dementia and dementia of the Alzheimer type. Rother M, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:404–9 (23 ref.)

EPIDEMIOLOGY

Epidemiology of vascular dementia. Hébert R, et al. **Neuroepidemiology** 1995;14(5):240–57 (75 ref.)

ETIOLOGY

[What is left of vascular dementia?] Ghika J, et al. **Rev Med Suisse Romande** 1996 Aug;116(8):635–8 (16 ref.) **(Fre)**
[The pathogenesis of vascular dementia] Medvedev AV. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995; 95(5):95–100 (93 ref.) **(Rus)**

DEMENTIAS, TRANSMISSIBLE see PRION DISEASES

4-DEMETHOXYDAUNORUBICIN see IDARUBICIN

DEMETHYL EPIPODOPHYLLOTOXIN ETHYLIDINE GLUCOSIDE see ETOPOSIDE

N-DEMETHYLASES see OXIDOREDUCTASES, N-DEMETHYLATING

DEMOGRAPHY

The demography of menopause. Hill K. **Maturitas** 1996 Mar; 23(2):113–27 (18 ref.)

DEMYELINATING DISEASES

COMPLICATIONS

Membranous glomerulonephritis associated with inflammatory demyelinating peripheral neuropathies. Panjwani M, et al. **Am J Kidney Dis** 1996 Feb;27(2):279–83 (20 ref.)

DIAGNOSIS

Mycoplasma pneumoniae infection associated with an acute brainstem syndrome. Pellegrini M, et al. **Acta Neurol Scand** 1996 Feb–Mar;93(2–3):203–6 (10 ref.)
The electrophysiology of axonal and demyelinating polyneuropathies. Cornblath DR. **Baillieres Clin Neurol** 1996 Mar;5(1):107–13 (37 ref.)
Acute disseminated encephalomyelitis and isolated central nervous system demyelinative syndromes. Tselis AC, et al. **Curr Opin Neurol** 1995 Jun;8(3):227–9 (19 ref.)
Axonal CIDP: a premature concept? Feasby TE. **Muscle Nerve** 1996 Mar;19(3):372–4 (16 ref.)
[Electrophysiological diagnosis and therapy of peripheral nerve demyelinating diseases] Kimura J. **Nippon Naika Gakkai Zasshi** 1996 Mar 10;85(3):389–92 (10 ref.) **(Jpn)**

GENETICS

Glial transplants: an in vivo analysis of extrinsic and intrinsic determinants of dysmyelination in genetic variants. Lachapelle F. **Brain Pathol** 1995 Jul;5(3):289–99 (103 ref.)
Molecular anatomy and genetics of myelin proteins in the peripheral nervous system. Snipes GJ, et al. **J Anat** 1995 Jun;186 (Pt 3):483–94 (120 ref.)
Dysmyelination in class I MHC transgenic mice. Turnley AM, et al. **Microsc Res Tech** 1995 Nov 1;32(4):286–94 (64 ref.)
[Infection of the mouse by Theiler's virus; a model for the study of demyelinating diseases of the central nervous system] Brahic M. **Bull Acad Natl Med** 1996 Feb; 180(2):305–15; discussion 315–6 (27 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Spontaneous and induced remyelination in multiple sclerosis and the Theiler's virus model of central nervous system demyelination. Miller DJ, et al. **Microsc Res Tech** 1995 Oct 15;32(3):230–45 (119 ref.)

PHYSIOPATHOLOGY

Experimental autoimmune encephalomyelitis in rodents as a model for human demyelinating disease [see comments] Swanborg RH. **Clin Immunol Immunopathol** 1995 Oct; 77(1):4–13 (99 ref.) Comment in: Clin Immunol Immunopathol 1995 Oct;77(1):3.
The cell biology of myelin degeneration and regeneration in the peripheral nervous system. Goodrum JF, et al. **J Neuropathol Exp Neurol** 1996 Sep;55(9):943–53 (47 ref.)

RADIONUCLIDE IMAGING

[Contribution of position emission tomography in a case of Marchiafava Bignami disease: Morel's laminar sclerosis?] Logak M, et al. **Rev Neurol (Paris)** 1996 Jan;152(1):47–50 (10 ref.) (Eng. Abstr.) **(Fre)**

REHABILITATION

[Demyelinating diseases and physical treatment methods] Strelkova NI, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1996 Jan–Feb;(1):41–4 (24 ref.) **(Rus)**

SURGERY

Glial cell transplants: experimental therapies of myelin diseases. Duncan ID, et al. **Brain Pathol** 1995 Jul; 5(3):301–10 (77 ref.)

VETERINARY

The neurobiology of canine distemper virus infection. Vandevelde M, et al. **Vet Microbiol** 1995 May; 44(2–4):271–80 (57 ref.)

DEMYELINATION see DEMYELINATING DISEASES

DENDRITES

PHYSIOLOGY

Dendritic integration in mammalian neurons, a century after Cajal. Yuste R, et al. **Neuron** 1996 Apr;16(4):701–16 (208 ref.)

Dendritic spines for neuroprotection: a hypothesis. Segal M. **Trends Neurosci** 1995 Nov;18(11):468–71 (33 ref.)

[Signal transduction systems of nerve growth cone: effects of anesthetics on the machinery] Saito S, et al. **Masui** 1995; 44 Suppl:S113–8 (15 ref.) **(Jpn)**

ULTRASTRUCTURE

GM2 ganglioside and pyramidal neuron dendritogenesis. Walkley SU, et al. **Neurochem Res** 1995 Nov; 20(11):1287–99 (115 ref.)

DENDRITIC CELLS

The mononuclear phagocyte–dendritic cell dichotomy: myths, facts, and a revised concept. Goerdt S, et al. **Clin Exp Immunol** 1996 Jul;105(1):1–9 (143 ref.)

Follicular dendritic cells in malignant lymphomas. Petrasch S. **Curr Top Microbiol Immunol** 1995;201:189–203 (60 ref.)

A theory of follicular dendritic cell origin. Szakal AK, et al. **Curr Top Microbiol Immunol** 1995;201:1–13 (39 ref.)

CYTOLOGY

The interdependence of lymphocyte, stromal cell, and follicular dendritic cell maturation. Clark EA. **Adv Exp Med Biol** 1995;378:285–8 (26 ref.)

Population dynamics and functions of respiratory tract dendritic cells in the rat. Holt PG, et al. **Adv Exp Med Biol** 1995;378:177–81 (22 ref.)

Multiple lines of evidence favoring a bone marrow derivation of follicular dendritic cells (FDCs). Szakal AK, et al. **Adv Exp Med Biol** 1995;378:267–72 (29 ref.)

Immune cell traffic from blood through the normal human skin to lymphatics. Olszewski WL, et al. **Clin Dermatol** 1995 Sep–Oct;13(5):473–83 (29 ref.)

Pathways of dendritic cell differentiation and development. Roake JA. **Eye** 1995;9 (Pt 2):161–6 (61 ref.)

A fresh morphological and functional look at dermal dendritic cells. Nestle FO, et al. **J Cutan Pathol** 1995 Oct; 22(5):385–93 (71 ref.)

IMMUNOLOGY

Stimulation of human anti-viral CD8+ cytolytic T lymphocytes by dendritic cells. Bhardwaj N, et al. **Adv Exp Med Biol** 1995;378:375–9 (35 ref.)

Preferential entry and productive infection of CD4 expressing lymphoid dendritic cells by macrophage–tropic HIV–1. Cameron PU, et al. **Adv Exp Med Biol** 1995;378:429–33 (24 ref.)

Dendritic cells as stimulator cells of MHC class I–restricted immune responses. Elbe A, et al. **Adv Exp Med Biol** 1995; 378:341–5 (35 ref.)

Dendritic cells "in vivo": their role in the initiation of intestinal immune responses. Liu L, et al. **Adv Exp Med Biol** 1995;371A:271–4 (5 ref.)

Dendritic cells seclude Leishmania parasites that persist in cured mice—a role in the maintenance of T–cell memory? Moll H, et al. **Adv Exp Med Biol** 1995;378:507–9 (13 ref.)

Functional and ultrastructural aspects of antigen processing by dendritic cells. Ossevoort MA, et al. **Adv Exp Med Biol** 1995;378:227–31 (24 ref.)

Multiple lines of evidence favoring a bone marrow derivation of follicular dendritic cells (FDCs). Szakal AK, et al. **Adv Exp Med Biol** 1995;378:267–72 (29 ref.)

The dendritic cell lineage: a ubiquitous antigen–presenting organization. Massard G, et al. **Ann Thorac Surg** 1996 Jan; 61(1):252–8 (67 ref.)

Presentation of self peptides by dendritic cells: possible implications for the pathogenesis of rheumatoid arthritis. Thomas R, et al. **Arthritis Rheum** 1996 Feb;39(2):183–90 (85 ref.)

Role of follicular dendritic cells in the regulation of B cell proliferation. Freedman AS, et al. **Curr Top Microbiol Immunol** 1995;201:83–92 (45 ref.)

Regulation of human B cell activation by follicular dendritic cell and T cell signals. Grouard G, et al. **Curr Top Microbiol Immunol** 1995;201:105–17 (55 ref.)

Follicular dendritic cells: origin and function. Heinen E, et al. **Curr Top Microbiol Immunol** 1995;201:15–47 (200 ref.)

Follicular dendritic cells: antigen retention, B cell activation, and cytokine production. Kosco–Vilbois MH, et al. **Curr Top Microbiol Immunol** 1995;201:69–82 (30 ref.)

Murine follicular dendritic cells: accessory activities in vitro. Tew JG, et al. **Curr Top Microbiol Immunol** 1995; 201:93–104 (50 ref.)

Mechanism of immune complex trapping by follicular dendritic cells. Van den Berg TK, et al. **Curr Top Microbiol Immunol** 1995;201:49–67 (110 ref.)

Dendritic cells and immune–based therapies. Steinman RM. **Exp Hematol** 1996 Jul;24(8):859–62 (16 ref.)

The biology of airway dendritic cells. McWilliam AS, et al. **Immunol Cell Biol** 1995 Oct;73(5):405–13 (35 ref.)

Dendritic cells: a major story unfolds. Stingl G, et al. **Immunol Today** 1995 Jul;16(7):330–3 (32 ref.)

Dendritic cells and the replication of HIV–1. Cameron P, et al. **J Leukoc Biol** 1996 Feb;59(2):158–71 (194 ref.)

[Cells of the dendritic lineage are key cells in the immune response (editorial)] Soler P. **Ann Pathol** 1995;15(4):235–7 (22 ref.) **(Fre)**

[Role of Langerhans cells in the physiopathology of atopic dermatitis] Bieber T. **Pathol Biol (Paris)** 1995 Dec; 43(10):871–5 (39 ref.) (Eng. Abstr.) **(Fre)**

[Dendritic cells and immune function in cancer] Chaux P. **Pathol Biol (Paris)** 1995 Dec;43(10):897–903 (53 ref.) (Eng. Abstr.) **(Fre)**

[Dendritic cells and tumor cell therapy] Pioche C, et al. **Pathol Biol (Paris)** 1995 Dec;43(10):904–9 (43 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Mechanism of immune complex trapping by follicular dendritic cells. Van den Berg TK, et al. **Curr Top Microbiol Immunol** 1995;201:49–67 (110 ref.)

PARASITOLOGY

Dendritic cells seclude Leishmania parasites that persist in cured mice—a role in the maintenance of T–cell memory? Moll H, et al. **Adv Exp Med Biol** 1995;378:507–9 (13 ref.)

PHYSIOLOGY

Population dynamics and functions of respiratory tract dendritic cells in the rat. Holt PG, et al. **Adv Exp Med Biol** 1995;378:177–81 (22 ref.)

Probing dendritic function with patch pipettes. Stuart G, et al. **Curr Opin Neurobiol** 1995 Jun;5(3):389–94 (27 ref.)

A fresh morphological and functional look at dermal dendritic cells. Nestle FO, et al. **J Cutan Pathol** 1995 Oct; 22(5):385–93 (71 ref.)

Dendritic cells from different tissues induce production of different T cell cytokine profiles. Everson MP, et al. **J Leukoc Biol** 1996 Apr;59(4):494–8 (31 ref.)

Microchimerism, dendritic cell progenitors and transplantation tolerance. Thomson AW, et al. **Stem Cells (Dayt)** 1995 Nov;13(6):622–39 (119 ref.)

[In vitro differenciation and functions of dendritic cells obtained from CD34+ hematopoietic progenitors] Dubois B, et al. **Pathol Biol (Paris)** 1995 Dec;43(10):829–40 (88 ref.) (Eng. Abstr.) **(Fre)**

[Follicular dendritic cells: phenotype, origin and functions] Heinen E. **Pathol Biol (Paris)** 1995 Dec;43(10):848–57 (43 ref.) (Eng. Abstr.) **(Fre)**

[The function of antigen presentation of dendritic cells] Péguet–Navarro J. **Pathol Biol (Paris)** 1995 Dec; 43(10):863–70 (54 ref.) (Eng. Abstr.) **(Fre)**

RADIATION EFFECTS

UVB–dependent modulation of epidermal cytokine network: roles in UVB–induced depletion of Langerhans cells and dendritic epidermal T cells. Takashima A. **J Dermatol** 1995 Nov;22(11):876–87 (100 ref.)

ULTRASTRUCTURE

[Digestive dendritic cells] Terris B, et al. **Ann Pathol** 1995; 15(4):260–8 (106 ref.) **(Fre)**

VIROLOGY

Preferential entry and productive infection of CD4 expressing lymphoid dendritic cells by macrophage–tropic HIV–1. Cameron PU, et al. **Adv Exp Med Biol** 1995;378:429–33 (24 ref.)

Dendritic cell–T cell conjugates that migrate from normal human skin are an explosive site of infection for HIV–1. Pope M, et al. **Adv Exp Med Biol** 1995;378:457–60 (36 ref.)

Follicular dendritic cells and infection by human immunodeficiency virus type 1—a crucial target cell and virus reservoir. Schuurman HJ, et al. **Curr Top Microbiol Immunol** 1995;201:161–88 (170 ref.)

Follicular dendritic cells initiate and maintain infection of the germinal centers by human immunodeficiency virus. Tenner–Racz K, et al. **Curr Top Microbiol Immunol** 1995; 201:141–59 (110 ref.)

[Dendritic cells of spleen and blood and HIV–1 infection] Hosmalin A. **Pathol Biol (Paris)** 1995 Dec;43(10):889–96 (54 ref.) (Eng. Abstr.) **(Fre)**

DENDRITIC CELLS, FOLLICULAR see **DENDRITIC CELLS**

DENDROASPIS see **ELAPIDAE**

DENERVATION

Neuropeptide messenger plasticity in the CNS neurons following axotomy. Palkovits M. **Mol Neurobiol** 1995 Apr–Jun;10(2–3):91–103 (48 ref.)

DENERVATION, PARASYMPATHETIC see **PARASYMPATHECTOMY**

DENERVATION, SYMPATHETIC see **SYMPATHECTOMY**

DENERVATION, SYMPATHETIC, CHEMICAL see **SYMPATHECTOMY, CHEMICAL**

DENGUE

DIAGNOSIS

[Dengue and hemorrhagic dengue: the clinical aspects] Martínez–Torres E. **Salud Publica Mex** 1995;37 Suppl:S29–44 (107 ref.) (Eng. Abstr.) **(Spa)**

EPIDEMIOLOGY

Arboviruses as imported disease agents: the need for increased awareness. Gubler DJ. **Arch Virol Suppl** 1996; 11:21–32 (29 ref.)

Review of the factors modulating dengue transmission. Kuno G. **Epidemiol Rev** 1995;17(2):321–35 (162 ref.)

What is the potential for future outbreaks of chikungunya, dengue and yellow fever in southern Africa? [editorial] Jupp PG, et al. **S Afr Med J** 1996 Jan;86(1):35–7 (20 ref.)

PREVENTION & CONTROL

Community involvement in the control of Aedes aegypti. Gubler DJ, et al. **Acta Trop** 1996 Apr;61(2):169–79 (21 ref.)

TRANSMISSION

Review of the factors modulating dengue transmission. Kuno G. **Epidemiol Rev** 1995;17(2):321–35 (162 ref.)

[The role of the Aedes aegypti vector in the epidemiology of dengue in Mexico] Fernández–Salas I, et al. **Salud Publica Mex** 1995;37 Suppl:S45–52 (17 ref.) (Eng. Abstr.) **(Spa)**

[Vectors of dengue in Mexico: a critical review)] Ibáñez–Bernal S, et al. **Salud Publica Mex** 1995;37 Suppl:S53–63 (34 ref.) (Eng. Abstr.) **(Spa)**

DENGUE VIRUS

Global distribution and continuing spread of Aedes albopictus. Knudsen AB. **Parassitologia** 1995 Dec; 37(2–3):91–7 (44 ref.)

History and updating on the spread of Aedes albopictus in Italy. Romi R. **Parassitologia** 1995 Dec;37(2–3):99–103 (16 ref.)

DENIAL (PSYCHOLOGY)

The neurology of alcoholic denial: implications for assessment and treatment. Duffy JD. **Can J Psychiatry** 1995 Jun;40(5):257–63 (30 ref.)

[A case of hemichorea presenting with inattention and denial of involuntary movement] Ichikawa H, et al. **Rinsho Shinkeigaku** 1995 Nov;35(11):1230–4 (15 ref.) (Eng. Abstr.) **(Jpn)**

DENS AXIS see **ODONTOID PROCESS**

DENSITOMETRY

METHODS

[Densitometry (hydrostatic weighing) for measurement of human body fat mass] Koda M, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:165–9 (11 ref.) **(Jpn)**

DENSITOMETRY, X-RAY

Body composition by DXA: tried and true? Kohrt WM. **Med Sci Sports Exerc** 1995 Oct;27(10):1349–53 (34 ref.)

[Dual photon absorptiometry, dual energy X–ray absorptiometry for analysis of body fat mass] Itabashi A. **Nippon Rinsho** 1995 Jun;53 Suppl:174–8 (11 ref.) **(Jpn)**

INSTRUMENTATION

Bone densitometry: patients with end–stage renal disease. Erlichman M, et al. **Health Technol Assess** 1996 Mar; (8):1–27 (174 ref.)

METHODS

Bone absorptiometry: a critical appraisal of various methods. Slosman DO, et al. **Acta Paediatr Suppl** 1995 Sep;411:9–11 (7 ref.)

Prediction of body composition in elderly men over 75 years of age. Fuller NJ, et al. **Ann Hum Biol** 1996 Mar–Apr; 23(2):127–47 (64 ref.)

DENTAL ABRASION see **TOOTH ABRASION**

DENTAL ACID ETCHING see **ACID ETCHING, DENTAL**

DENTAL ALLOYS

[Scanning electron microscopy in the study of surface treatment methods used in the repair of porcelain–fused–to–metal restorations] Hegedús C, et al. **Fogorv Sz** 1995 Apr;88(4):133–9 (32 ref.) (Eng. Abstr.) **(Hun)**

CHEMISTRY

Biological effects of palladium and risk of using palladium in dental casting alloys. Wataha JC, et al. **J Oral Rehabil** 1996 May;23(5):309–20 (53 ref.)

DENTAL AMALGAM

ADVERSE EFFECTS

Dental amalgam: toxicological evaluation and health risk assessment. Levy M. **J Can Dent Assoc** 1995 Aug; 61(8):667–8, 671–4 (46 ref.)

[Allergies to dental prostheses and to amalgam: various data from the literature] Dejobert Y, et al. **Rev Stomatol Chir Maxillofac** 1995;96(4):243–6 (16 ref.) **(Fre)**

[Amalgam allergy and amalgam controversy] Lübbe J, et al. **Schweiz Med Wochenschr** 1996 Apr 20;126(16):661–5 (48 ref.) (Eng. Abstr.) **(Ger)**

CHEMISTRY

Setting reactions in dental amalgam. Part 1. Phases and microstructures between one hour and one week. Mitchell RJ, et al. **Crit Rev Oral Biol Med** 1996;7(1):12–22 (97 ref.)

Setting reactions in dental amalgam. Part 2. The kinetics of amalgamation. Okabe T, et al. **Crit Rev Oral Biol Med** 1996;7(1):23–35 (84 ref.)

TOXICITY

[Amalgam and the toxicological risks of mercury. A review of the argument] Marchi A, et al. **Minerva Stomatol** 1995 Jun;44(6):311–8 (44 ref.) (Eng. Abstr.) **(Ita)**

DENTAL ANESTHESIA see **ANESTHESIA, DENTAL**

DENTAL ANXIETY

PHYSIOPATHOLOGY

Anxiety. Its manifestation and role in the dental patient. Boorin MR. **Dent Clin North Am** 1995 Jul;39(3):523–39 (47 ref.)

PREVENTION & CONTROL

Managing behavior of precooperative children. Nathan JE. **Dent Clin North Am** 1995 Oct;39(4):789–816 (39 ref.)

PSYCHOLOGY

A model of pain and anxiety associated with acute stressors: distress in dental procedures. Litt MD. **Behav Res Ther** 1996 May–Jun;34(5–6):459–76 (100 ref.)

THERAPY

Theoretical concepts and practical applications of hypnosis in the treatment of children and adolescents with dental fear and anxiety. Shaw AJ, et al. **Br Dent J** 1996 Jan 6; 180(1):11–6 (28 ref.)

DENTAL ARCH

PHYSIOPATHOLOGY

The role of the shortened dental arch concept in the management of reduced dentitions. Allen PF, et al. **Br Dent J** 1995 Nov 11;179(9):355–7 (24 ref.)

RADIOGRAPHY

Diagnostic imaging in dental implantology. Frederiksen NL. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1995 Nov;80(5):540–54 (48 ref.)

DENTAL ATTRITION see **TOOTH ABRASION**

DENTAL BONDING

Effect of varying etching times on the bond strength of ceramic brackets. Olsen ME, et al. **Am J Orthod Dentofacial Orthop** 1996 Apr;109(4):403–9 (49 ref.)

Does resin based dentine bonding work? Söderholm KJ. **Int Dent J** 1995 Dec;45(6):371–81 (74 ref.)

Designs of bond strength tests for metal–ceramic complexes: review of the literature. Hammad IA, et al. **J Prosthet Dent** 1996 Jun;75(6):602–8 (44 ref.)

DENTAL BRIDGEWORK see **DENTURE, PARTIAL**

DENTAL CARE

Acute cardiac care in dental practice. Assael LA. **Dent Clin North Am** 1995 Jul;39(3):555–65 (11 ref.)

Emergency management of hypoglycemia and hyperglycemia. Bavitz JB. **Dent Clin North Am** 1995 Jul; 39(3):587–94 (13 ref.)

Management of immediate allergic reactions. Becker DE. **Dent Clin North Am** 1995 Jul;39(3):577–86 (41 ref.)

The poisoned patient. Toxicologic emergencies. Norris LH, et al. **Dent Clin North Am** 1995 Jul;39(3):595–619 (72 ref.)

Emergency cardiac care. Moral, legal, and ethical considerations. Peskin RM, et al. **Dent Clin North Am** 1995 Jul;39(3):677–88 (35 ref.)

Neurologic emergencies. Piecuch JF, et al. **Dent Clin North Am** 1995 Jul;39(3):567–75 (13 ref.)

Resuscitation of the pediatric patient. Rosenberg MB, et al. **Dent Clin North Am** 1995 Jul;39(3):663–76 (26 ref.)

Assessment of the medical emergency. Saef SH. **Dent Clin North Am** 1995 Jul;39(3):487–99 (20 ref.)

Respiratory emergencies in the dental office. Shafer DM. **Dent Clin North Am** 1995 Jul;39(3):541–54 (12 ref.)

[General ambulatory anesthesia in oral medicine and maxillofacial surgery] Boufflers E, et al. **Rev Stomatol Chir Maxillofac** 1995;96(4):247–58 (22 ref.) **(Fre)**

ADVERSE EFFECTS

Central and peripheral nervous complications of dental treatment. Rossitti EO. **Arq Neuropsiquiatr** 1995 Sep; 53(3–A):513–7 (33 ref.)

ORGANIZATION & ADMINISTRATION

Oral health and dental care in Hong Kong. Schwarz E, et al. **Int Dent J** 1995 Jun;45(3):169–76 (20 ref.)

PSYCHOLOGY

Variation in dentists' clinical decisions. Bader JD, et al. **J Public Health Dent** 1995 Summer;55(3):181–8 (67 ref.)

DENTAL CARE FOR AGED

The tooth wear index: a flawed epidemiological tool in an ageing population group. Donachie MA, et al. **Community Dent Oral Epidemiol** 1996 Apr;24(2):152–8 (28 ref.)

Differential diagnosis of jaw pain in the elderly. Sandler NA, et al. **J Am Dent Assoc** 1995 Sep;126(9):1263–72 (40 ref.)

METHODS

The role of the shortened dental arch concept in the management of reduced dentitions. Allen PF, et al. **Br Dent J** 1995 Nov 11;179(9):355–7 (24 ref.)

DENTAL CARE FOR CHILDREN

Periodontal and soft-tissue abnormalities. Delaney JE. **Dent Clin North Am** 1995 Oct;39(4):837–50 (14 ref.)

Dental practice considerations. Griffin AP, et al. **Dent Clin North Am** 1995 Oct;39(4):861–75 (14 ref.)

Habits affecting dental and maxillofacial growth and development. Josell SD. **Dent Clin North Am** 1995 Oct; 39(4):851–60 (32 ref.)

Management of trauma in the child and adolescent. Camp JH. **Pediatr Dent** 1995 Sep–Oct;17(5):379–86 (12 ref.)

LEGISLATION & JURISPRUDENCE

Oral health policies and programs affecting the preschool child. Casamassimo PS. **Dent Clin North Am** 1995 Oct; 39(4):877–85 (23 ref.)

METHODS

Restorative dentistry for preschool children. Croll TP. **Dent Clin North Am** 1995 Oct;39(4):737–70 (35 ref.)

Traumatic injuries in the preschool child. Harding AM, et al. **Dent Clin North Am** 1995 Oct;39(4):817–35 (37 ref.)

Dental caries risk assessment and prevention. Tinanoff N. **Dent Clin North Am** 1995 Oct;39(4):709–19 (36 ref.)

PSYCHOLOGY

Managing behavior of precooperative children. Nathan JE. **Dent Clin North Am** 1995 Oct;39(4):789–816 (39 ref.)

Personality development. Managing behavior of the cooperative preschool child. Pinkham JR. **Dent Clin North Am** 1995 Oct;39(4):771–87 (32 ref.)

STATISTICS & NUMERICAL DATA

Delivery systems for preschool children. Crall JJ. **Dent Clin North Am** 1995 Oct;39(4):897–907 (22 ref.)

TRENDS

The preschool "passage". An overview of dental health. Johnsen DC. **Dent Clin North Am** 1995 Oct;39(4):695–707 (23 ref.)

UTILIZATION

Preschool children. Need and use of dental services. Waldman HB. **Dent Clin North Am** 1995 Oct;39(4):887–96 (33 ref.)

DENTAL CARE FOR CHRONICALLY ILL

The role of the dentist in the era of AIDS. Glick M. **Dent Clin North Am** 1996 Apr;40(2):343–57 (52 ref.)

Dental considerations for the patient with renal disease receiving hemodialysis. De Rossi SS, et al. **J Am Dent Assoc** 1996 Feb;127(2):211–9 (52 ref.)

Angina: an update for dentistry. Herman WW, et al. **J Am Dent Assoc** 1996 Jan;127(1):98–104 (62 ref.)

Managing patients who have seizure disorders: dental and medical issues. Sanders BJ, et al. **J Am Dent Assoc** 1995 Dec;126(12):1641–7 (18 ref.)

Surgical management of patients on warfarin sodium. Beirne OR, et al. **J Oral Maxillofac Surg** 1996 Sep;54(9):1115–8 (18 ref.)

[Oro-dental manifestations of leukemia in children] Nikoui M, et al. **J Can Dent Assoc** 1996 May;62(5):443–6, 449–50 (41 ref.) (Eng. Abstr.) **(Fre)**

[The arterial pressure problem in dental practice] Abraham-Inpyain L, et al. **Stomatologiia (Mosk)** 1996; 75(1):37–9 (40 ref.) (Eng. Abstr.) **(Rus)**

LEGISLATION & JURISPRUDENCE

Legal considerations in infectious diseases and dentistry. Burris S. **Dent Clin North Am** 1996 Apr;40(2):425–35 (62 ref.)

DENTAL CARE FOR DISABLED

see related
DENTAL CARE FOR CHRONICALLY ILL

DENTAL CARIES

see related
CARIOSTATIC AGENTS
DIET, CARIOGENIC
ROOT CARIES

DIAGNOSIS

[Approximal and smooth-surface caries. Their diagnosis and therapeutic principles] Lussi A, et al. **Schweiz Monatsschr Zahnmed** 1995;105(11):1438–45 (20 ref.) **(Ger, Fre)**

EPIDEMIOLOGY

Dental caries risk assessment and prevention. Tinanoff N. **Dent Clin North Am** 1995 Oct;39(4):709–19 (36 ref.)

Description and epidemiology of nursing caries. Milnes AR. **J Public Health Dent** 1996 Winter;56(1):38–50 (59 ref.)

Research recommendations: pleas for enhanced research efforts to impact the epidemic of dental disease in infants. Weinstein P. **J Public Health Dent** 1996 Winter;56(1):55–9 (35 ref.)

Dispelling the myth that 50 percent of U.S. schoolchildren have never had a cavity. Edelstein BL, et al. **Public Health Rep** 1995 Sep–Oct;110(5):522–30; discussion 521, 531–3 (46 ref.)

ETIOLOGY

An overview of caries risk assessment, and its potential utility. Moss ME, et al. **J Dent Educ** 1995 Oct;59(10):932–40 (42 ref.)

Cariogenicity depends more on diet than the prevailing mutans streptococcal species. van Palenstein Helderman WH, et al. **J Dent Res** 1996 Jan;75(1):535–45 (115 ref.)

GENETICS

Genetic influences in caries and periodontal diseases. Hassell TM, et al. **Crit Rev Oral Biol Med** 1995;6(4):319–42 (203 ref.)

MICROBIOLOGY

Dental caries is a transmissible infectious disease: the Keyes and Fitzgerald revolution. Tanzer JM. **J Dent Res** 1995 Sep;74(9):1536–42 (38 ref.)

Susceptibility of oral bacterial biofilms to antimicrobial agents. Wilson M. **J Med Microbiol** 1996 Feb;44(2):79–87 (54 ref.)

Etiology of nursing caries: a microbiologic perspective. Berkowitz R. **J Public Health Dent** 1996 Winter;56(1):51–4 (48 ref.)

PREVENTION & CONTROL

Should we use milk fluoridation? A review. Mariño R. **Bull Pan Am Health Organ** 1995 Dec;29(4):287–98 (71 ref.)

What is the effective concentration of fluoride? Ismail AI. **Community Dent Oral Epidemiol** 1995 Aug;23(4):246–51 (51 ref.)

Dental caries risk assessment and prevention. Tinanoff N. **Dent Clin North Am** 1995 Oct;39(4):709–19 (36 ref.)

Evaluation of clinical trials of agents and procedures to prevent caries and periodontal disease: choosing products and recommending procedures. Addy M. **Int Dent J** 1995 Jun;45(3):185–96 (57 ref.)

The role of fluoride toothpastes in the prevention of dental caries. Bowen WH. **J R Soc Med** 1995 Sep;88(9):505–7 (16 ref.)

[Discussion on the location of the artificial crown margin] Hasegawa S. **Kokubyo Gakkai Zasshi** 1995 Sep; 62(3):373–80 (39 ref.) **(Jpn)**

[Cariostatic mechanisms of fluoride and its effects on human beings] Sato T, et al. **Nippon Rinsho** 1996 Jan;54(1):67–72 (11 ref.) (Eng. Abstr.) **(Jpn)**

RADIOGRAPHY

Current trends in radiographic caries imaging. Wenzel A. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1995 Nov;80(5):527–39 (149 ref.)

DENTAL CEMENTUM

CYTOLOGY

Expression and role of epidermal growth factor receptors during differentiation of cementoblasts, osteoblasts, and periodontal ligament fibroblasts in the rat. Cho MI, et al. **Anat Rec** 1996 Jun;245(2):342–60 (69 ref.)

GROWTH & DEVELOPMENT

Cementogenesis reviewed: a comparison between human premolars and rodent molars. Bosshardt DD, et al. **Anat Rec** 1996 Jun;245(2):267–92 (141 ref.)

PHYSIOLOGY

Role of two mineral-associated adhesion molecules, osteopontin and bone sialoprotein, during cementogenesis. MacNeil RL, et al. **Connect Tissue Res** 1995;33(1–3):1–7 (87 ref.)

DENTAL CENTRIC RELATION see **CENTRIC RELATION**

DENTAL CROWNS see **CROWNS**

DENTAL DECAY see **DENTAL CARIES**

DENTAL DEVICES, HOME CARE

see related
TOOTHBRUSHING

DENTAL EDUCATION see **EDUCATION, DENTAL**

DENTAL EDUCATION, GRADUATE see **EDUCATION, DENTAL, GRADUATE**

DENTAL ENAMEL

see related
AMELOBLASTS
AMELOGENESIS

DRUG EFFECTS

[Experimental pharmacology of hard tissue research] Ohya K. **Kokubyo Gakkai Zasshi** 1995 Dec;62(4):473–82 (31 ref.) **(Jpn)**

EMBRYOLOGY

Molecular mechanisms of dental enamel formation. Simmer JP, et al. **Crit Rev Oral Biol Med** 1995;6(2):84–108 (194 ref.)

GROWTH & DEVELOPMENT

[Molecular structure and function of matrix proteins in developing enamel—amelogenin and enamelin] Sasaki S. **Kokubyo Gakkai Zasshi** 1995 Sep;62(3):347–72 (141 ref.) **(Jpn)**

METABOLISM

Recent observations on enamel crystal formation during mammalian amelogenesis. Aoba T. **Anat Rec** 1996 Jun; 245(2):208–18 (74 ref.)

Enamel mineralization and the role of ameloblasts in calcium transport. Takano Y. **Connect Tissue Res** 1995; 33(1–3):127–37 (74 ref.)

PATHOLOGY

Induction of osteodentin and abortive enamel in adenomatoid odontogenic tumor. Takeda Y. **Ann Dent** 1995 Summer–Fall;54(1–2):61–3 (13 ref.)

PHYSIOLOGY

[A discussion of 2 remarkable schools] Ivanova EN. **Stomatologiia (Mosk)** 1995;74(4):74–6 (20 ref.) (Eng. Abstr.) **(Rus)**

ULTRASTRUCTURE

Ultrastructural organic–inorganic relationships in calcified tissues: cartilage and bone vs. enamel. Bonucci E. **Connect Tissue Res** 1995;33(1–3):157–62 (67 ref.)

DENTAL ENAMEL PROTEINS

[Molecular structure and function of matrix proteins in developing enamel—amelogenin and enamelin] Sasaki S. **Kokubyo Gakkai Zasshi** 1995 Sep;62(3):347–72 (141 ref.) **(Jpn)**

CHEMISTRY

A review of the aggregation properties of a recombinant amelogenin. Moradian-Oldak J, et al. **Connect Tissue Res** 1995;32(1–4):125–30 (35 ref.)

[Molecular structure and function of matrix proteins in developing enamel—amelogenin and enamelin] Sasaki S. **Kokubyo Gakkai Zasshi** 1995 Sep;62(3):347–72 (141 ref.) **(Jpn)**

GENETICS

Recent advances in amelogenin biochemistry. Fincham AG, et al. **Connect Tissue Res** 1995;32(1–4):119–24 (75 ref.)

PHYSIOLOGY

Enamel matrix proteins and ameloblast biology. Deutsch D, et al. **Connect Tissue Res** 1995;32(1–4):97–107 (123 ref.)

[Molecular structure and function of matrix proteins in developing enamel—amelogenin and enamelin] Sasaki S. **Kokubyo Gakkai Zasshi** 1995 Sep;62(3):347–72 (141 ref.) **(Jpn)**

DENTAL EQUIPMENT

Dental unit water contamination. Peters E, et al. **J Can Dent Assoc** 1996 Jun;62(6):492–5 (41 ref.)

DENTAL FEAR see **DENTAL ANXIETY**

DENTAL FILLINGS, PERMANENT see **DENTAL RESTORATION, PERMANENT**

DENTAL FISSURES

DIAGNOSIS

[Fissure caries. Their diagnosis and therapeutic principles] Lussi A, et al. **Schweiz Monatsschr Zahnmed** 1995; 105(9):1164–73 (21 ref.) **(Ger, Fre)**

DENTAL FOCAL INFECTION see **FOCAL INFECTION, DENTAL**

DENTAL HEALTH SERVICES

Research issues related to the oral health status of aging veterans. Gibson G, et al. **Med Care** 1995 Nov;33(11 Suppl):NS45–56 (46 ref.)

STANDARDS

Quality and effectiveness issues related to oral health. Antczak-Bouckoms A. **Med Care** 1995 Nov;33(11 Suppl):NS123–42 (60 ref.)

Functionally dependent veterans. Issues related to providing and improving their oral health care. Henry RG. **Med Care** 1995 Nov;33(11 Suppl):NS143–63 (82 ref.)

SUPPLY & DISTRIBUTION

Delivery systems for preschool children. Crall JJ. **Dent Clin North Am** 1995 Oct;39(4):897–907 (22 ref.)

UTILIZATION

Access to and patterns of use of oral health care among elderly veterans. Gilbert GH. **Med Care** 1995 Nov;33(11 Suppl):NS78–89 (58 ref.)

DENTAL HEALTH SURVEYS

Oral health, health, and health-related quality of life. Gift HC, et al. **Med Care** 1995 Nov;33(11 Suppl):NS57–77 (95 ref.)

Dental problems in the offshore oil and gas industry: a review. Duffy B. **Occup Med (Oxf)** 1996 Feb;46(1):79–83 (8 ref.)

[Oral disease epidemiologic illness indices and oral health measures—traditional concepts are supplemented by new socio-dental indicators] Strippel H. **Gesundheitswesen** 1996 Mar;58(3):162–8 (50 ref.) (Eng. Abstr.) **(Ger)**

DENTAL HIGH-SPEED EQUIPMENT

[Transmission of infection in oral medicine. Evaluation of the risk of transmission in the office surgery] Vacher C, et al. **Rev Stomatol Chir Maxillofac** 1996;97(2):121–4 (7 ref.) (Eng. Abstr.) **(Fre)**

STANDARDS

Dental air turbine handpiece performance testing. Dyson JE, et al. **Aust Dent J** 1995 Oct;40(5):330–8 (53 ref.)

DENTAL HYGIENE see **ORAL HYGIENE**

DENTAL IMPLANTATION, ENDOSSEOUS

Soft and hard tissue response to endosseous dental implants. Listgarten MA. **Anat Rec** 1996 Jun;245(2):410–25 (154 ref.)

Dental restorations using titanium osseointegrated dental implants. McEwen DR, et al. **AORN J** 1995 Aug; 62(2):189–91, 193–8, 201–5; quiz 207–9 (14 ref.)

Osseointegrated implants: a review of the literature. Shearer BH. **Int Dent J** 1995 Aug;45(4):261–6 (25 ref.)

The reverse-torque test: a clinical report. Sullivan DY, et al. **Int J Oral Maxillofac Implants** 1996 Mar–Apr; 11(2):179–85 (15 ref.)

Implant prosthodontic treatment options for the edentulous patient. Zarb GA, et al. **J Oral Rehabil** 1995 Aug; 22(8):661–71 (17 ref.)

A conceptual framework for understanding outcomes of oral implant therapy. Guckes AD, et al. **J Prosthet Dent** 1996 Jun;75(6):633–9 (76 ref.)

Diagnostic imaging in dental implantology. Frederiksen NL. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1995 Nov;80(5):540–54 (48 ref.)

Dental implants and dental CT software programs. Abrahams JJ, et al. **Semin Ultrasound CT MR** 1995 Dec;16(6):468–86 (21 ref.)

DENTAL IMPLANTATION, OSSEOINTEGRATED see **DENTAL IMPLANTATION, ENDOSSEOUS**

DENTAL IMPLANTS

In vitro modeling of the bone/implant interface. Davies JE. **Anat Rec** 1996 Jun;245(2):426–45 (94 ref.)

Osseointegrated implants: a review of the literature. Shearer BH. **Int Dent J** 1995 Aug;45(4):261–6 (25 ref.)

Evaluation of the clinical predictability of hydroxyapatite-coated endosseous dental implants: a review of the literature. Biesbrock AR, et al. **Int J Oral Maxillofac Implants** 1995 Nov–Dec;10(6):712–20 (63 ref.)

The reverse-torque test: a clinical report. Sullivan DY, et al. **Int J Oral Maxillofac Implants** 1996 Mar–Apr; 11(2):179–85 (15 ref.)

A conceptual framework for understanding outcomes of oral implant therapy. Guckes AD, et al. **J Prosthet Dent** 1996 Jun;75(6):633–9 (76 ref.)

Temporomandibular joint and dental imaging. Westesson PL. **Neuroimaging Clin N Am** 1996 May;6(2):333–55 (31 ref.)

[Dental implants—indications and long-term outcome] Kniha H, et al. **Fortschr Med** 1996 Mar 30;114(9):99–103 (8 ref.) (Eng. Abstr.) **(Ger)**

[Maintenance therapy: an indispensible complement to periodontal treatment and the surgical implant] Fanali S, et al. **Minerva Stomatol** 1995 May;44(5):245–55 (89 ref.) (Eng. Abstr.) **(Ita)**

DENTAL IMPRESSION MATERIALS

see related
SILICONE ELASTOMERS

A survey of the methods of disinfection of dental impressions used in dental hospitals in the United Kingdom. Blair FM, et al. **Br Dent J** 1996 May 25;180(10):369–75 (26 ref.)

ADVERSE EFFECTS

Foreign body aspiration in dentistry: a review. Cameron SM, et al. **J Am Dent Assoc** 1996 Aug;127(8):1224–9 (30 ref.)

THERAPEUTIC USE

[Impressions and esthetic rehabilitation. The preparatory work, clinical procedures and materials] Magne P, et al. **Schweiz Monatsschr Zahnmed** 1995;105(10):1302–16 (33 ref.) **(Fre, Ger)**

DENTAL IMPRESSION TECHNIQUE

Trouble-shooting dual arch impressions. Kaplowitz GJ. **J Am Dent Assoc** 1996 Feb;127(2):234–40 (24 ref.)

[Impressions and esthetic rehabilitation. The preparatory work, clinical procedures and materials] Magne P, et al. **Schweiz Monatsschr Zahnmed** 1995;105(10):1302–16 (33 ref.) **(Fre, Ger)**

ADVERSE EFFECTS

Foreign body aspiration in dentistry: a review. Cameron SM, et al. **J Am Dent Assoc** 1996 Aug;127(8):1224–9 (30 ref.)

DENTAL INSTRUMENTS

Continuing investigation and controversy regarding risk of transmission of infection via dental handpieces. Epstein JB, et al. **J Can Dent Assoc** 1996 Jun;62(6):485–91 (53 ref.)

DENTAL MATERIALS

see related
DENTAL BONDING

Current trends in dental composites. Ferracane JL. **Crit Rev Oral Biol Med** 1995;6(4):302–18 (118 ref.)

Denture base materials. Phoenix RD. **Dent Clin North Am** 1996 Jan;40(1):113–20 (21 ref.)

Dental materials: 1994 literature review. Brown D, et al. **J Dent** 1996 May;24(3):153–84 (334 ref.)

DENTAL MEDICAID PROGRAM see **MEDICAID**

DENTAL OCCLUSION

see related
JAW RELATION RECORD
MALOCCLUSION

Complete denture occlusion. Lang BR. **Dent Clin North Am** 1996 Jan;40(1):85–101 (40 ref.)

Factors to consider in selecting an occlusal concept for patients with implants in the edentulous mandible. Wismeijer D, et al. **J Prosthet Dent** 1995 Oct;74(4):380–4 (26 ref.)

Occlusal vertical dimension in prosthodontics. Chou TM, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1996 May;

12(5):260–6 (34 ref.)
[Gnathologic concepts and their practical role in dentistry] Fazekas A, et al. **Fogorv Sz** 1996 Feb;89(2):39–49 (26 ref.) **(Hun)**

[Standard electromyographic and kinesiographic parameters in a sample of healthy population] Manni A, et al. **Minerva Stomatol** 1995 Sep;44(9):411–9 (29 ref.) (Eng. Abstr.) **(Ita)**

DENTAL OCCLUSION, TRAUMATIC

COMPLICATIONS

Experimental occlusal interferences. Part I. A review. Christensen LV, et al. **J Oral Rehabil** 1995 Jul;22(7):515–20 (21 ref.)

DENTAL OFFICES

Biofilm and the dental office. Shearer BG. **J Am Dent Assoc** 1996 Feb;127(2):181–9 (49 ref.)

DENTAL PHOBIA see DENTAL ANXIETY

DENTAL PLAQUE

PREVENTION & CONTROL

Rationale of mechanical plaque control. Westfelt E. **J Clin Periodontol** 1996 Mar;23(3 Pt 2):263–7 (54 ref.)
[Mechanical and chemical plaque control] Schiffner U. **Schweiz Monatsschr Zahnmed** 1995;105(12):1576–85 (41 ref.) **(Ger, Fre)**

DENTAL PROSTHESIS

see related
DENTURES

ADVERSE EFFECTS

[Allergies to dental prostheses and to amalgam: various data from the literature] Dejobert Y, et al. **Rev Stomatol Chir Maxillofac** 1995;96(4):243–6 (16 ref.) **(Fre)**

DENTAL PROSTHESIS DESIGN

Factors to consider for predictable post and core build-ups of endodontically treated teeth. Part I: Basic theoretical concepts. Manning KE, et al. **J Can Dent Assoc** 1995 Aug; 61(8):685–8, 690, 693–5 (40 ref.)
Factors to consider for predictable post and core build-ups of endodontically treated teeth. Part II: Clinical application of basic concepts. Manning KE, et al. **J Can Dent Assoc** 1995 Aug;61(8):696–701, 703, 705–7 (46 ref.)

DENTAL PROSTHESIS, IMPLANT-SUPPORTED

Dental restorations using titanium osseointegrated dental implants. McEwen DR, et al. **AORN J** 1995 Aug; 62(2):189–91, 193–8, 201–5; quiz 207–9 (14 ref.)
Implant prosthodontic treatment options for the edentulous patient. Zarb GA, et al. **J Oral Rehabil** 1995 Aug; 22(8):661–71 (17 ref.)
Factors to consider in selecting an occlusal concept for patients with implants in the edentulous mandible. Wismeijer D, et al. **J Prosthet Dent** 1995 Oct;74(4):380–4 (26 ref.)

DENTAL PROSTHESIS, SURGICAL see DENTAL IMPLANTS

DENTAL PULP

see related
PULPECTOMY

BLOOD SUPPLY

Microvascular architecture and exchange in teeth. Matthews B, et al. **Microcirculation** 1995 Dec;2(4):305–13 (50 ref.)

INNERVATION

Neural elements in dental pulp and dentin. Nair PN. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1995 Dec;80(6):710–9 (69 ref.)

PHYSIOLOGY

[A discussion of 2 remarkable schools] Ivanova EN. **Stomatologiia (Mosk)** 1995;74(4):74–6 (20 ref.) (Eng. Abstr.) **(Rus)**

DENTAL PULP DISEASES

DRUG THERAPY

A new biological approach to vital pulp therapy. Rutherford B, et al. **Crit Rev Oral Biol Med** 1995;6(3):218–29 (93 ref.)

VETERINARY

Endodontics of dogs and cats: an alternative to extraction. Clarke DE. **Aust Vet J** 1995 Oct;72(10):383–9 (57 ref.)

DENTAL RADIOGRAPHY see RADIOGRAPHY, DENTAL

DENTAL RESEARCH

An overview of self-reported outcome assessment in dental research. Reisine S. **J Dent Educ** 1996 Jun;60(6):488–93 (25 ref.)
The role of the AADR in promoting research integrity: perspectives and consensus statements. Bebeau MJ, et al. **J Dent Res** 1996 Feb;75(2):856–60 (9 ref.)

STANDARDS

Evaluation of clinical trials of agents and procedures to prevent caries and periodontal disease: choosing products and recommending procedures. Addy M. **Int Dent J** 1995 Jun;45(3):185–96 (57 ref.)

DENTAL RESTORATION, PERMANENT

see related
ACRYLIC RESINS
DENTAL MATERIALS

Stress-induced cervical lesions: review of advances in the past 10 years. Lee WC, et al. **J Prosthet Dent** 1996 May; 75(5):487–94 (65 ref.)

METHODS

Restorative dentistry for preschool children. Croll TP. **Dent Clin North Am** 1995 Oct;39(4):737–70 (35 ref.)

STANDARDS

[Scanning electron microscopy in the study of surface treatment methods used in the repair of porcelain-fused-to-metal restorations] Hegedús C, et al. **Fogorv Sz** 1995 Apr;88(4):133–9 (32 ref.) (Eng. Abstr.) **(Hun)**

TRENDS

Changing paradigms in restorative dentistry. Löe H. **J Am Coll Dent** 1995 Fall;62(3):31–6 (37 ref.)

DENTAL RESTORATION, TEMPORARY

see related
ACRYLIC RESINS
DENTAL MATERIALS

DENTAL STAFF

Occupational health and safety emergencies. Goupil MT. **Dent Clin North Am** 1995 Jul;39(3):637–47 (69 ref.)

DENTAL STRESS ANALYSIS

Stress-induced cervical lesions: review of advances in the past 10 years. Lee WC, et al. **J Prosthet Dent** 1996 May; 75(5):487–94 (65 ref.)

METHODS

Designs of bond strength tests for metal-ceramic complexes: review of the literature. Hammad IA, et al. **J Prosthet Dent** 1996 Jun;75(6):602–8 (44 ref.)

DENTAL WHITE SPOTS see DENTAL CARIES

DENTATE GYRUS

ANATOMY & HISTOLOGY

Connection matrix of the hippocampal formation: I. The dentate gyrus. Patton PE, et al. **Hippocampus** 1995; 5(4):245–86 (410 ref.)

DENTATE NUCLEUS see CEREBELLAR NUCLEI

DENTIFRICES

see related
MOUTHWASHES

Hydrogen peroxide: a review of its use in dentistry. Marshall MV, et al. **J Periodontol** 1995 Sep;66(9):786–96 (100 ref.)

THERAPEUTIC USE

[Micro-abrasions of enamel: an alternative to the elimination of superficial demineralization and decalcification] Tudts M, et al. **Rev Belge Med Dent** 1996;51(3):54–71 (55 ref.) (Eng. Abstr.) **(Fre)**

DENTIN

see related
ODONTOBLASTS

Does resin based dentine bonding work? Söderholm KJ. **Int Dent J** 1995 Dec;45(6):371–81 (74 ref.)

CHEMISTRY

Lipids in predentine and dentine. Goldberg M, et al. **Connect Tissue Res** 1995;33(1–3):105–14 (56 ref.)

INNERVATION

Update on the concepts and probable role of peptidergic nerves in dentine sensitivity and pain mechanisms. Ngassapa DN. **East Afr Med J** 1996 Apr;73(4):268–70 (29 ref.)
Neural elements in dental pulp and dentin. Nair PN. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1995 Dec;80(6):710–9 (69 ref.)

METABOLISM

Dentin mineralization and the role of odontoblasts in calcium transport. Linde A. **Connect Tissue Res** 1995;33(1–3):163–70 (46 ref.)

PATHOLOGY

Induction of osteodentin and abortive enamel in adenomatoid odontogenic tumor. Takeda Y. **Ann Dent** 1995 Summer-Fall;54(1–2):61–3 (13 ref.)
Pre-eruptive resorption of dentin in the primary and permanent dentitions: case reports and literature review. Seow WK, et al. **Pediatr Dent** 1996 Jan–Feb;18(1):67–71 (24 ref.)

PHYSIOLOGY

Dentin matrix proteins and dentinogenesis. Butler WT. **Connect Tissue Res** 1995;33(1–3):59–65 (48 ref.)

ULTRASONOGRAPHY

[Micromorphological aspects of dentin] Goracci G, et al. **Minerva Stomatol** 1995 Sep;44(9):377–87 (52 ref.) (Eng. Abstr.) **(Ita)**

ULTRASTRUCTURE

Ultrastructure of dentin matrix in heritable dentin defects. Waltimo J, et al. **Scanning Microsc** 1995 Mar;9(1):185–97; discussion 197–8 (89 ref.)

DENTIN-BONDING AGENTS

Dentin bonding system. Part I: Literature review. Miyazaki M, et al. **Biomed Mater Eng** 1996;6(1):15–31 (129 ref.)
[Current status of adhesive resin restorations] Tagami J. **Kokubyo Gakkai Zasshi** 1996 Mar;63(1):1–7 (28 ref.) **(Jpn)**

CHEMISTRY

Dentin bonding system. Part II: Effect of crosshead speed. Oshida Y, et al. **Biomed Mater Eng** 1996;6(2):87–100 (106 ref.)
Does resin based dentine bonding work? Söderholm KJ. **Int Dent J** 1995 Dec;45(6):371–81 (74 ref.)

DENTIN DYSPLASIA

PATHOLOGY

Ultrastructure of dentin matrix in heritable dentin defects. Waltimo J, et al. **Scanning Microsc** 1995 Mar;9(1):185–97; discussion 197–8 (89 ref.)

DENTIN SENSITIVITY

PHYSIOPATHOLOGY

Update on the concepts and probable role of peptidergic nerves in dentine sensitivity and pain mechanisms. Ngassapa DN. **East Afr Med J** 1996 Apr;73(4):268–70 (29 ref.)
Neural elements in dental pulp and dentin. Nair PN. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1995 Dec;80(6):710–9 (69 ref.)

DENTINOGENESIS

Dentin matrix proteins and dentinogenesis. Butler WT. **Connect Tissue Res** 1995;33(1–3):59–65 (48 ref.)
Dentin mineralization and the role of odontoblasts in calcium transport. Linde A. **Connect Tissue Res** 1995;33(1–3):163–70 (46 ref.)

DENTINOGENESIS IMPERFECTA

PATHOLOGY

Ultrastructure of dentin matrix in heritable dentin defects. Waltimo J, et al. **Scanning Microsc** 1995 Mar;9(1):185–97; discussion 197–8 (89 ref.)

DENTIST-PATIENT RELATIONS

Managing behavior of precooperative children. Nathan JE. **Dent Clin North Am** 1995 Oct;39(4):789–816 (39 ref.)

DENTIST-PATIENT RELATIONS

Personality development. Managing behavior of the cooperative preschool child. Pinkham JR. **Dent Clin North Am** 1995 Oct;39(4):771–87 (32 ref.)

Effects of information-giving and communication during orthodontic consultation and treatment. Part 3: Optimized orthodontist-patient communication. Witt E, et al. **Fortschr Kieferorthop** 1996 Jun;57(3):154–67 (55 ref.) **(Eng, Ger)**

Chronic alcoholism: an important condition in the dentist-patient relationship. Robb ND, et al. **J Dent** 1996 Jan–Mar;24(1–2):17–24 (45 ref.)

DENTISTRY

see related
DENTAL EQUIPMENT
DENTAL INSTRUMENTS
EDUCATION, DENTAL

Preventive dentistry and the family physician. Clark MM, et al. **Am Fam Physician** 1996 Feb 1;53(2):619–26, 631–2 (30 ref.)

Gastrodontology: a clinical perspective worth consideration [editorial] Siegel MA. **Am J Gastroenterol** 1996 Jan; 91(1):1–2 (35 ref.)

Tuberculosis: a re-emerging problem for health care workers. Bagg J. **Br Dent J** 1996 May 25;180(10):376–81 (47 ref.)

Issues of latex safety in dentistry. Field EA, et al. **Br Dent J** 1995 Oct 7;179(7):247–53 (51 ref.)

Common infectious diseases. Bagg J. **Dent Clin North Am** 1996 Apr;40(2):385–93 (33 ref.)

Hepatitis B virus infection. Current status in dentistry. Cottone JA, et al. **Dent Clin North Am** 1996 Apr; 40(2):293–307 (62 ref.)

Dental health care workers at risk. Garfunkel AA, et al. **Dent Clin North Am** 1996 Apr;40(2):277–91 (44 ref.)

Infection control. Miller CH. **Dent Clin North Am** 1996 Apr; 40(2):437–56 (38 ref.)

Hepatitis C virus infection. Molinari JA. **Dent Clin North Am** 1996 Apr;40(2):309–25 (77 ref.)

Tuberculosis. Phelan JA, et al. **Dent Clin North Am** 1996 Apr;40(2):327–41 (35 ref.)

Syphilis and gonorrhea. Siegel MA. **Dent Clin North Am** 1996 Apr;40(2):369–83 (34 ref.)

Postexposure protocol. Younai FS. **Dent Clin North Am** 1996 Apr;40(2):457–86 (118 ref.)

Legal issues affecting dentistry's role in preventing child abuse and neglect. Mouden LD, et al. **J Am Dent Assoc** 1995 Aug;126(8):1173–80 (63 ref.)

Practice parameters in dentistry: where do we stand? Shugars DA, et al. **J Am Dent Assoc** 1995 Aug;126(8):1134–43 (36 ref.)

Human bites to the hand. Carr MM. **J Can Dent Assoc** 1995 Sep;61(9):782–4 (32 ref.)

STANDARDS

Dental practice parameters. Parameters for 12 oral health conditions. Adopted by the American Dental Association House of Delegates. October 1995. **J Am Dent Assoc** 1996 Jan;Suppl:iS–iiS, 1S–36S (0 ref.)

DENTISTRY FOR AGED see **DENTAL CARE FOR AGED**

DENTISTRY FOR CHILDREN see **DENTAL CARE FOR CHILDREN**

DENTISTRY FOR CHRONICALLY ILL see **DENTAL CARE FOR CHRONICALLY ILL**

DENTISTRY, OPERATIVE

INSTRUMENTATION

[30 years of experience in using lasers in dentistry] Prokhonchukov AA. **Stomatologiia (Mosk)** 1995; 74(4):68–73 (25 ref.) **(Rus)**

DENTISTRY, PEDIATRIC see **PEDIATRIC DENTISTRY**

DENTISTS

Hepatitis C virus (HCV)—an occupational risk to dentists? Porter SR, et al. **Br Dent J** 1996 Jun 22;180(12):473–4 (21 ref.)

The abused patient. Dym H. **Dent Clin North Am** 1995 Jul; 39(3):621–35 (22 ref.)

The role of the dentist in the era of AIDS. Glick M. **Dent Clin North Am** 1996 Apr;40(2):343–57 (52 ref.)

Occupational health and safety emergencies. Goupil MT. **Dent Clin North Am** 1995 Jul;39(3):637–47 (69 ref.)

Metastatic squamous cell carcinoma of the hand and review of the literature. Foley SJ, et al. **J R Army Med Corps** 1995 Jun;141(2):102–4 (8 ref.)

PSYCHOLOGY

Variation in dentists' clinical decisions. Bader JD, et al. **J Public Health Dent** 1995 Summer;55(3):181–8 (67 ref.)

STATISTICS & NUMERICAL DATA

Controlling the production of dentists. Waldman HB. **Ann Dent** 1995 Summer–Fall;54(1–2):18–21 (11 ref.)

DENTITION

The role of the shortened dental arch concept in the management of reduced dentitions. Allen PF, et al. **Br Dent J** 1995 Nov 11;179(9):355–7 (24 ref.)

Anatomy of the jaw, dentition, and related regions. Abrahams JJ, et al. **Semin Ultrasound CT MR** 1995 Dec;16(6):453–67 (13 ref.)

DENTITION, MIXED

see related
SERIAL EXTRACTION

DENTITION, PRIMARY

see related
TOOTH, DECIDUOUS

DENTOALVEOLAR ABSCESS, APICAL see **PERIAPICAL ABSCESS**

DENTURE BASES

Denture base materials. Phoenix RD. **Dent Clin North Am** 1996 Jan;40(1):113–20 (21 ref.)

DENTURE, COMPLETE

Complete-denture esthetics. Engelmeier RL. **Dent Clin North Am** 1996 Jan;40(1):71–84 (26 ref.)

Complete dentures for the obturator patient. King GE, et al. **Dent Clin North Am** 1996 Jan;40(1):217–37 (26 ref.)

Complete denture occlusion. Lang BR. **Dent Clin North Am** 1996 Jan;40(1):85–101 (40 ref.)

Complete-denture therapy for the geriatric patient. Lloyd PM. **Dent Clin North Am** 1996 Jan;40(1):239–54 (40 ref.)

DENTURE, COMPLETE, LOWER

ADVERSE EFFECTS

Differential diagnosis of jaw pain in the elderly. Sandler NA, et al. **J Am Dent Assoc** 1995 Sep;126(9):1263–72 (40 ref.)

DENTURE DESIGN

Complete-denture esthetics. Engelmeier RL. **Dent Clin North Am** 1996 Jan;40(1):71–84 (26 ref.)

Prosthodontic treatment for the Applegate-Kennedy class V partially edentulous patient. Shifman A, et al. **J Prosthet Dent** 1996 Aug;76(2):212–8 (39 ref.)

Factors to consider in selecting an occlusal concept for patients with implants in the edentulous mandible. Wismeijer D, et al. **J Prosthet Dent** 1995 Oct;74(4):380–4 (26 ref.)

DENTURE, IMPLANT-SUPPORTED see **DENTAL PROSTHESIS, IMPLANT-SUPPORTED**

DENTURE LINERS

see related
SILICONE ELASTOMERS

DENTURE, OVERLAY

Factors to consider in selecting an occlusal concept for patients with implants in the edentulous mandible. Wismeijer D, et al. **J Prosthet Dent** 1995 Oct;74(4):380–4 (26 ref.)

DENTURE, PARTIAL

Prosthodontic treatment for the Applegate-Kennedy class V partially edentulous patient. Shifman A, et al. **J Prosthet Dent** 1996 Aug;76(2):212–8 (39 ref.)

DENTURE, PARTIAL, FIXED, RESIN-BONDED

[Resin-bonded bridges. A genuine alternative therapy for private practice or a long-term temporary measure?] Otto T. **Schweiz Monatsschr Zahnmed** 1995;105(12):1552–9 (24 ref.) **(Ger, Fre)**

DENTURE, PARTIAL, REMOVABLE

[Treatment plan for removable partial prostheses] Maes J, et al. **Rev Belge Med Dent** 1995;50(4):37–52 (47 ref.) (Eng. Abstr.) **(Fre)**

DENTURE, PARTIAL, TEMPORARY

[Resin-bonded bridges. A genuine alternative therapy for private practice or a long-term temporary measure?] Otto T. **Schweiz Monatsschr Zahnmed** 1995;105(12):1552–9 (24 ref.) **(Ger, Fre)**

DENTURE RETENTION

METHODS

Denture fixatives—an update for general dental practice. Jagger DC, et al. **Br Dent J** 1996 Apr 20;180(8):311–3 (18 ref.)

Denture adhesives: changing attitudes. Grasso JE. **J Am Dent Assoc** 1996 Jan;127(1):90–6 (36 ref.)

DENTURE STABILITY see **DENTURE RETENTION**

DENTURES

Restoration of the partially edentulous mouth—a comparison of overdentures, removable partial dentures, fixed partial dentures and implant treatment. Budtz-Jörgensen E. **J Dent** 1996 Jul;24(4):237–44 (89 ref.)

DEONTOLOGICAL ETHICS see **ETHICS**

DEOXYCORTICOSTERONE see **DESOXYCORTICOSTERONE**

11-DEOXYCORTISOL see **CORTODOXONE**

DEOXYCYTIDINE

ANALOGS & DERIVATIVES

Current chemotherapy of advanced non-small cell lung cancer. Abratt RP. **Anticancer Drugs** 1995 Dec;6 Suppl 6:15–8 (29 ref.)

Preclinical characteristics of gemcitabine. Plunkett W, et al. **Anticancer Drugs** 1995 Dec;6 Suppl 6:7–13 (33 ref.)

Phase II trials of single-agent activity of gemcitabine in patients with advanced non-small cell lung cancer: an overview. Shepherd FA. **Anticancer Drugs** 1995 Dec;6 Suppl 6:19–25 (13 ref.)

Symptomatic benefit from gemcitabine and other chemotherapy in advanced non-small cell lung cancer: changes in performance status and tumour-related symptoms. Thatcher N, et al. **Anticancer Drugs** 1995 Dec; 6 Suppl 6:39–48 (68 ref.)

Safety profile of gemcitabine. Tonato M, et al. **Anticancer Drugs** 1995 Dec;6 Suppl 6:27–32 (11 ref.)

Activity of gemcitabine in patients with advanced pancreatic carcinoma. A review. Moore M. **Cancer** 1996 Aug 1;78(3 Suppl):633–8 (21 ref.)

Clinical, toxicological and pharmacological aspects of gemcitabine. Guchelaar HJ, et al. **Cancer Treat Rev** 1996 Jan;22(1):15–31 (54 ref.)

Gemcitabine in non-small cell lung cancer. Sørensen JB. **Lung Cancer** 1995 Apr;12 Suppl 1:S173–5 (8 ref.)

Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Plunkett W, et al. **Semin Oncol** 1995 Aug; 22(4 Suppl 11):3–10 (26 ref.)

DEOXYCYTIDINE KINASE

METABOLISM

Mammalian deoxyribonucleoside kinases. Arnér ES, et al. **Pharmacol Ther** 1995;67(2):155–86 (241 ref.)

DEOXYDINUCLEOSIDE PHOSPHATES see **DINUCLEOSIDE PHOSPHATES**

DEOXYEPHEDRINE see **METHAMPHETAMINE**

DEOXYGLUCOSE

ANALOGS & DERIVATIVES

FDG uptake within regionally stunned myocardium. McFalls EO, et al. **Am J Card Imaging** 1995 Oct;9(4):269–74 (30 ref.)

Fluorine-18-fluorodeoxyglucose PET to determine regional cerebral glucose utilization: a re-examination. Schmidt KC, et al. **J Nucl Med** 1996 Feb;37(2):394–9 (42 ref.)

Iodine-123-labeled glucose analogs: prospects for a single-photon-emitting analog of fluorine-18-labeled deoxyglucose [editorial; comment] Gatley SJ. **Nucl Med Biol** 1995 Oct;22(7):829–35 (49 ref.) Comment on: Nucl Med Biol 1995 Oct;22(7):875–85.

[Positron-emission tomography: role of 18F-fluorodeoxyglucose (18FDG) imaging in oncology] Lagrange JL, et al. **Bull Cancer (Paris)** 1995 Aug; 82(8):611–22 (118 ref.) (Eng. Abstr.) **(Fre)**

BLOOD

[1,5-Anhydroglucitol (1,5 AG)] Yamanouchi T. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:553–6 (5 ref.) **(Jpn)**

METABOLISM

D1/D2 actions of dopaminergic drugs studied with [14C]-2-deoxyglucose autoradiography. Trugman JM. **Prog Neuropsychopharmacol Biol Psychiatry** 1995 Sep; 19(5):795–810 (35 ref.)

DEOXYRIBODIPYRIMIDINE PHOTOLYASE see **DNA PHOTOLYASE**

DEOXYRIBONUCLEASE I

CHEMISTRY

Trinucleotide models for DNA bending propensity: comparison of models based on DNaseI digestion and nucleosome packaging data. Brukner I, et al. **J Biomol Struct Dyn** 1995 Oct;13(2):309–17 (28 ref.)

PHARMACOLOGY

[New pharmacological approaches: rhDNase] Tournier G, et al. **Rev Pneumol Clin** 1995;51(3):193–200 (40 ref.) (Eng. Abstr.) **(Fre)**

THERAPEUTIC USE

Dornase alfa for cystic fibrosis. **Drug Ther Bull** 1995 Feb; 33(2):15–6 (5 ref.)

Aerosolized dornase alpha (rhDNase) in cystic fibrosis. Bates RD, et al. **J Clin Pharm Ther** 1995 Dec;20(6):313–5 (19 ref.)

New treatment strategies in cystic fibrosis: rhDNase. Shah PL, et al. **Monaldi Arch Chest Dis** 1996 Apr;51(2):125–9 (27 ref.)

Dornase alfa: a new option in the management of cystic fibrosis. Witt DM, et al. **Pharmacotherapy** 1996 Jan–Feb; 16(1):40–8 (24 ref.)

DEOXYRIBONUCLEASES

[Molecular design of artificial nucleases] Komiyama M, et al. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1438–43 (43 ref.) **(Jpn)**

ANALYSIS

[Isozymes of DNase I] Kishi K, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:450–3 (20 ref.) **(Jpn)**

CHEMICAL SYNTHESIS

Sequence–specific and hydrolytic scission of DNA and RNA by lanthanide complex–oligoDNA hybrids. Komiyama M. **J Biochem (Tokyo)** 1995 Oct;118(4):665–70 (46 ref.)

THERAPEUTIC USE

DNase trials in cystic fibrosis. Hodson ME, et al. **Eur Respir J** 1995 Oct;8(10):1786–91 (26 ref.)

DEOXYRIBONUCLEIC ACID see **DNA**

DEOXYTHYMIDINE KINASE see **THYMIDINE KINASE**

DEOXYURSOCHOLIC ACID see **URSODEOXYCHOLIC ACID**

DEPARTMENT OF AGRICULTURE (U.S.) see **UNITED STATES DEPARTMENT OF AGRICULTURE**

DEPENDENCY (PSYCHOLOGY)

Issues in personality as diathesis for depression: the case of sociotropy–dependency and autonomy–self–criticism. Coyne JC, et al. **Psychol Bull** 1995 Nov;118(3):358–78 (125 ref.)

DEPENDOVIRUS

Adeno–associated virus vectors for gene therapy. Flotte TR, et al. **Gene Ther** 1995 Aug;2(6):357–62 (59 ref.)

[Adeno–associated virus (AAV) vectors] Tamayose K, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2532–8 (24 ref.) **(Jpn)**

GENETICS

Adenovirus and adeno–associated virus as vectors for gene therapy. Berns KI, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:95–104 (48 ref.)

Strategies for efficient gene transfer into hematopoietic cells. The use of adeno–associated virus vectors in gene therapy. Chatterjee S, et al. **Ann N Y Acad Sci** 1995 Dec 29; 770:79–90 (40 ref.)

DEPO–MEDROXYPROGESTERONE ACETATE see **MEDROXYPROGESTERONE 17–ACETATE**

DEPOLARIZING MUSCLE RELAXANTS see **NEUROMUSCULAR DEPOLARIZING AGENTS**

DEPOT PREPARATIONS see **DELAYED–ACTION PREPARATIONS**

DEPRENALIN see **SELEGILINE**

DEPRENIL see **SELEGILINE**

DEPRENYL see **SELEGILINE**

DEPRESSION

see related
ANTIDEPRESSIVE AGENTS

Computer modeling of adaptive depression. Webster C. **Behav Sci** 1995 Oct;40(4):314–30 (52 ref.)

Advances in the study of mood disorders in childhood and adolescence. Fennig S, et al. **Curr Opin Pediatr** 1995 Aug; 7(4):401–4 (17 ref.)

Adult depression. A treatable condition. Ames DA. **N C Med J** 1995 Oct;56(10):497–500 (0 ref.)

Depression and HIV. A nursing perspective on a complex relationship. McEnany GW, et al. **Nurs Clin North Am** 1996 Mar;31(1):57–80 (103 ref.)

Brain serotonin, carbohydrate–craving, obesity and depression. Wurtman RJ, et al. **Obes Res** 1995 Nov;3 Suppl 4:477S–480S (34 ref.)

CHEMICALLY INDUCED

[Tolerance of neuroleptics, deficit syndrome and cognitive functions] Kahn JP. **Encephale** 1996 Jun;22 Spec No 2:49–54 (35 ref.) (Eng. Abstr.) **(Fre)**

CLASSIFICATION

[Deficit: the value and difficulty of defining the primary or secondary character of observed symptoms] Petit M, et al. **Encephale** 1996 Jun;22 Spec No 2:13–8 (20 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

Depression, stressful events and the risk of cancer [editorial] Mathé G. **Biomed Pharmacother** 1996;50(1):1–2 (22 ref.)

DIAGNOSIS

Recognition and management of anxiety and depression in elderly patients [see comments] Martin LM, et al. **Mayo Clin Proc** 1995 Oct;70(10):999–1006 (09 ref.) Comment in: Mayo Clin Proc 1996 Apr;71(4):424.

Clues to depression in primary care practice. el–Mallakh RS, et al. **Postgrad Med** 1996 Jul;100(1):85–8, 93–6 (20 ref.)

[Methodological problems of depression research (see comments)] Jepsen PW. **Ugeskr Laeger** 1996 Mar 11; 158(11):1508–12 (11 ref.) (Eng. Abstr.) Comment in: Ugeskr Laeger 1996 Jun 3;158(23):3332–3. **(Dan)**

[Central concepts and problems in the diagnosis of depression] Henriksson M, et al. **Duodecim** 1994; 110(3):227–37 (56 ref.) **(Fin)**

[Stability of positive/negative symptoms in schizophrenia] Ribeyre JM, et al. **Encephale** 1996 Jun;22 Spec No 2:29–31 (11 ref.) (Eng. Abstr.) **(Fre)**

[New concepts relating to histochemistry of the serotonergic neural systems of the raphe nucleus] Villar MJ. **Acta Psiquiatr Psicol Am Lat** 1994 Dec;40(4):293–300 (36 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Interactions with drugs used in the treatment of depressive illness. D'Arcy PF, et al. **Adverse Drug React Toxicol Rev** 1995 Winter;14(4):211–31 (160 ref.)

The treatment of negative symptoms: pharmacological and methodological issues. Carpenter WT Jr. **Br J Psychiatry Suppl** 1996 May;(29):17–22 (45 ref.)

Sertraline 50 mg daily: the optimal dose in the treatment of depression. Preskorn SH, et al. **Int Clin Psychopharmacol** 1995 Sep;10(3):129–41 (55 ref.)

Administration of antidepressants, diazepam and psychomotor stimulants further confirms the utility of Flinders Sensitive Line rats as an animal model of depression. Overstreet DH, et al. **Psychopharmacology (Berl)** 1995 Sep;121(1):27–37 (62 ref.)

Thyroid hormone treatment of depression. Joffe RT, et al. **Thyroid** 1995 Jun;5(3):235–9 (33 ref.)

[Effect of adjuvant drug therapy following successful electroconvulsive therapy for therapy–resistant depression is still disappointing] Leentjens AF, et al. **Ned Tijdschr Geneeskd** 1996 Feb 3;140(5):241–3 (31 ref.) **(Dut)**

[Associated psychotropic drugs in deficit schizophrenia] Beaufils B. **Encephale** 1996 Jun;22 Spec No 2:41–3 (18 ref.) (Eng. Abstr.) **(Fre)**

[Methodological constraints in evaluating anti–deficit effects] Boyer P, et al. **Encephale** 1996 Jun;22 Spec No 2:25–7 (16 ref.) (Eng. Abstr.) **(Fre)**

[Treatment of negative symptoms in schizophrenia by amisulpride. Review of the literature] Pélissolo A, et al. **Encephale** 1996 May–Jun;22(3):215–9 (25 ref.) (Eng. Abstr.) **(Fre)**

[The place of amisulpride in the atypical neuroleptic class] Perrault G, et al. **Encephale** 1996 Jun;22 Spec No 2:3–8 (12 ref.) (Eng. Abstr.) **(Fre)**

[Incidence of the deficit form in refractory schizophrenia] Samuelian JC. **Encephale** 1996 Jun;22 Spec No 2:19–23 (30 ref.) (Eng. Abstr.) **(Fre)**

[Profile of the action of neuroleptics in deficit schizophrenia] Vanelle JM. **Encephale** 1996 Jun;22 Spec No 2:33–9 (35 ref.) (Eng. Abstr.) **(Fre)**

[Schizophrenic deficit syndrome and neurologic tolerance] Verdoux H, et al. **Encephale** 1996 Jun;22 Spec No 2:45–7 (27 ref.) (Eng. Abstr.) **(Fre)**

[New perspectives in the serotoninergic treatment for depression] Hamon M. **Therapie** 1995 Nov–Dec;50(6):505–9 (20 ref.) (Eng. Abstr.) **(Fre)**

[Drug therapy and affective disorders: state of the art] Cugurra F. **Clin Ter** 1995 Oct;146(10):577–85 (32 ref.) (Eng. Abstr.) **(Ita)**

[Sleep, depression and antidepressive treatments (2)] Arriaga F. **Acta Med Port** 1995 Mar;8(3):181–6 (73 ref.) (Eng. Abstr.) **(Por)**

[Depression, antidepressants and the biological clock] Arushanian EB, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995;95(3):85–9 (71 ref.) **(Rus)**

ECONOMICS

Pharmacoeconomic issues in the treatment of depression. Saklad SR. **Pharmacotherapy** 1995 Nov–Dec;15(6 Pt 2):76S–83S (24 ref.)

EPIDEMIOLOGY

Epidemiology and treatment of post–stroke depression. Gustafson Y, et al. **Drugs Aging** 1995 Oct;7(4):298–309 (45 ref.)

Maternal depressive symptoms and the risk of poor pregnancy outcome. Review of the literature and preliminary findings. Orr ST, et al. **Epidemiol Rev** 1995; 17(1):165–71 (34 ref.)

[How many of us are depressed? (editorial)] Lehtinen V. **Duodecim** 1994;110(3):217, 219–20 (11 ref.) **(Fin)**

ETIOLOGY

Depression following spinal cord injury. Elliott TR, et al. **Arch Phys Med Rehabil** 1996 Aug;77(8):816–23 (89 ref.)

The economic cost and social and psychological impact of musculoskeletal conditions. National Arthritis Data Work Groups. Yelin E, et al. **Arthritis Rheum** 1995 Oct; 38(10):1351–62 (68 ref.)

Depression in patients with pancreatic carcinoma. Diagnostic and treatment issues. Passik SD, et al. **Cancer** 1996 Aug 1;78(3 Suppl):615–26 (84 ref.)

GENETICS

Diagnostic and genetic issues of depression and bipolar illness. Berrettini W. **Pharmacotherapy** 1995 Nov–Dec;15(6 Pt 2):69S–75S (78 ref.)

IMMUNOLOGY

Stress and the immune system in the etiology of anxiety and depression. Leonard BE, et al. **Pharmacol Biochem Behav** 1996 May;54(1):299–303 (74 ref.)

METABOLISM

Cerebrospinal fluid 5–hydroxyindolacetic acid and aggression: a critical reappraisal of the clinical data. Tuinier S, et al. **Int Clin Psychopharmacol** 1995 Sep;10(3):147–56 (82 ref.)

PHYSIOPATHOLOGY

Corticotropin releasing hormone in the pathophysiology of melancholic and atypical depression and in the mechanism of action of antidepressant drugs. Gold PW, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:716–29 (53 ref.)

Antidepressants and hypothalamic–pituitary–adrenocortical regulation. Holsboer F, et al. **Endocr Rev** 1996 Apr; 17(2):187–205 (237 ref.)

Role of the serotonergic system in the forced swimming test. Borsini F. **Neurosci Biobehav Rev** 1995 Fall;19(3):377–95 (178 ref.)

Stress and the immune system in the etiology of anxiety and depression. Leonard BE, et al. **Pharmacol Biochem Behav** 1996 May;54(1):299–303 (74 ref.)

[Deficit schizophrenia: from pharmacology to clinical practice] Tassin JP. **Encephale** 1996 Jun;22 Spec No 2:9–12 (20 ref.) (Eng. Abstr.) **(Fre)**

PSYCHOLOGY

Recent developments in anxiety, stress, and depression. File SE. **Pharmacol Biochem Behav** 1996 May;54(1):3–12 (156 ref.)

Role of 5–HT in stress, anxiety, and depression. Graeff FG, et al. **Pharmacol Biochem Behav** 1996 May;54(1):129–41 (112 ref.)

[Depression and suicide] Isometsä E, et al. **Duodecim** 1994; 110(3):341–6 (50 ref.) **(Fin)**

[The development of susceptibility to depression and its psychodynamics] Tähkä V. **Duodecim** 1994;110(3):267–76 (20 ref.) **(Fin)**

[Depressed patients and their family] Väisänen L, et al. **Duodecim** 1994;110(3):333–8 (11 ref.) **(Fin)**

THERAPY

Ethically justified clinically comprehensive guidelines for the management of the depressed pregnant patient. Coverdale JH, et al. **Am J Obstet Gynecol** 1996 Jan;174(1 Pt 1):169–73 (25 ref.)

Epidemiology and treatment of post–stroke depression. Gustafson Y, et al. **Drugs Aging** 1995 Oct;7(4):298–309 (45 ref.)

Recognition and management of anxiety and depression in elderly patients [see comments] Martin LM, et al. **Mayo Clin Proc** 1995 Oct;70(10):999–1006 (09 ref.) Comment in: Mayo Clin Proc 1996 Apr;71(4):424.

Clues to depression in primary care practice. el–Mallakh RS,

et al. **Postgrad Med** 1996 Jul;100(1):85–8, 93–6 (20 ref.)
[Effect of adjuvant drug therapy following successful electroconvulsive therapy for therapy-resistant depression is still disappointing] Leentjens AF, et al. **Ned Tijdschr Geneeskd** 1996 Feb 3;140(5):241–3 (31 ref.) **(Dut)**

[Course and prognosis of severe depression] Isometsä E. **Duodecim** 1994;110(3):287–92 (51 ref.) **(Fin)**

DEPRESSION, BIPOLAR see **BIPOLAR DISORDER**

DEPRESSION, ENDOGENOUS see **DEPRESSIVE DISORDER**

DEPRESSION, INVOLUTIONAL

DIAGNOSIS

Late-onset schizophrenia and late paraphrenia. Riecher-Rössler A, et al. **Schizophr Bull** 1995;21(3):345–54; discussion 355–6 (80 ref.)

DEPRESSION, NEUROTIC see **DEPRESSIVE DISORDER**

DEPRESSION, POSTPARTUM

Postpartum depression: issues in clinical assessment. Horowitz JA, et al. **J Perinatol** 1995 Jul–Aug;15(4):268–78; quiz 279–80 (82 ref.)

DRUG THERAPY

Antidepressant treatment during breast-feeding. Wisner KL, et al. **Am J Psychiatry** 1996 Sep;153(9):1132–7 (52 ref.)

ETIOLOGY

Post-natal depression: the relevance of sociological approaches. Thurtle V. **J Adv Nurs** 1995 Sep;22(3):416–24 (43 ref.)
An enzyme/brain-barrier theory of psychiatric pathogenesis: unifying observations on phenylketonuria, autism, schizophrenia and postpartum psychosis. Seim AR, et al. **Med Hypotheses** 1995 Nov;45(5):498–502 (36 ref.)

PSYCHOLOGY

[Psychiatric diseases with onset in puerperium] Woitalla D, et al. **Gynakologe** 1995 Dec;28(6):434–9 (33 ref.) **(Ger)**

DEPRESSION, REACTIVE, PSYCHOTIC see **AFFECTIVE DISORDERS, PSYCHOTIC**

DEPRESSION, UNIPOLAR see **DEPRESSIVE DISORDER**

DEPRESSIVE DISORDER

Dysthymic disorder: the chronic depression. Sansone RA, et al. **Am Fam Physician** 1996 Jun;53(8):2588–96 (28 ref.)
Advances in the study of mood disorders in childhood and adolescence. Fennig S, et al. **Curr Opin Pediatr** 1995 Aug; 7(4):401–4 (17 ref.)
Depression in long-term care facilities. Masand PS. **Geriatrics** 1995 Oct;50 Suppl 1:S16–24 (43 ref.)
Advances in understanding major depressive disorder. Hagerty BM. **J Psychosoc Nurs Ment Health Serv** 1995 Nov;33(11):27–34 (30 ref.)
Dysthymic disorder: the depression that never quits. Sansone RA, et al. **Postgrad Med** 1996 Jun;99(6):233–4, 237–44, 249 (18 ref.)
Major depressive disorder. Arnold CB. **Proc Annu Meet Med Sect Am Counc Life Insur** 1995;:19–26 (15 ref.)
Serotonin receptors and their function in sleep, anxiety disorders and depression. Leonard BE. **Psychother Psychosom** 1996 Mar–Apr;65(2):66–75 (75 ref.)

BLOOD

[The biological basis of suicidal behavior: neuroendocrine and psychophysiological approach to the role of catecholamines] Pitchot W, et al. **Acta Psychiatr Belg** 1995 Jul–Oct;95(4–5):210–33 (102 ref.) (Eng. Abstr.) **(Fre)**

CHEMICALLY INDUCED

[Are beta-blockers really depressogenic?] Pélissolo A, et al. **Ann Med Psychol (Paris)** 1995 Aug–Sep;153(7):441–7 (26 ref.) (Eng. Abstr.) **(Fre)**

CLASSIFICATION

Nosology of chronic mood disorders. First MB, et al. **Psychiatr Clin North Am** 1996 Mar;19(1):29–39 (10 ref.)
[Depression in the child and adolescent] Klein R. **Encephale** 1995 Dec;21 Spec No 5:31–3 (19 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

Moclobemide safety: monitoring a newly developed product in the 1990s. Hilton S, et al. **J Clin Psychopharmacol** 1995 Aug;15(4 Suppl 2):76S–83S (28 ref.)
Feeling hopeless and helpless. When anxiety symptoms coexist with depressive disorder. Nesse RE. **Postgrad Med** 1996 Aug;100(2):163–6, 171–2, 175–7 (21 ref.)
The management of treatment-resistant depression in the medically ill. Franco-Bronson K. **Psychiatr Clin North Am** 1996 Jun;19(2):329–50 (154 ref.)
The management of treatment resistance in depressed patients with substance use disorders. Nunes EV, et al. **Psychiatr Clin North Am** 1996 Jun;19(2):311–27 (92 ref.)
The role of Axis II comorbidity in the management of patients with treatment-resistant depression. Thase ME. **Psychiatr Clin North Am** 1996 Jun;19(2):287–309 (97 ref.)
[Depressive disorders in mentally retarded children. A review of selected literature. Part II] Rola J. **Psychiatr Pol** 1996 Mar–Apr;30(2):211–9 (20 ref.) (Eng. Abstr.) **(Pol)**
[Depressive disorders in mentally retarded children. A review of selected literature. Part I] Rola J. **Psychiatr Pol** 1996 Mar–Apr;30(2):201–10 (20 ref.) (Eng. Abstr.) **(Pol)**
[Depression and obsessive-compulsive disorder cor-morbidity] Barcia D. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1996 Mar–Apr;24(2):91–6 (29 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Management of depression in patients with coexisting medical illness. Nesse RE, et al. **Am Fam Physician** 1996 May 1; 53(6):2125–33 (20 ref.)
Major depression in children and adolescents. Mirza KA, et al. **Br J Hosp Med** 1996 Jan 17–Feb 6;55(1–2):57–61 (19 ref.)
Present use of the Hamilton Depression Rating Scale: observation on method of assessment in research of depressive disorders. Snaith RP. **Br J Psychiatry** 1996 May; 168(5):594–7 (11 ref.)
Depression in old age. Is there a real decrease in prevalence? A review. Ernst C, et al. **Eur Arch Psychiatry Clin Neurosci** 1995;245(6):272–87 (199 ref.)
Recognition and differentiation of elderly depression in the clinical setting. Reynolds CF 3rd. **Geriatrics** 1995 Oct;50 Suppl 1:S6–15 (17 ref.)
The difficult elderly patient: curable hostile depression or personality disorder? Monfort JC. **Int Psychogeriatr** 1995; 7 Suppl:95–111 (50 ref.)
Presentation and course of major depressive disorder during childhood and later years of the life span. Kovacs M. **J Am Acad Child Adolesc Psychiatry** 1996 Jun;35(6):705–15 (75 ref.)
Psychotic depression. Coryell W. **J Clin Psychiatry** 1996;57 Suppl 3:27–31; discussion 49 (76 ref.)
The diagnosis and treatment of late-life depression. Rothschild AJ. **J Clin Psychiatry** 1996;57 Suppl 5:5–11 (80 ref.)
The depressions of Alzheimer's disease: sorting, pharmacotherapy, and clinical advice. Knesper DJ. **J Geriatr Psychiatry Neurol** 1995 Oct;8 Suppl 1:S40–51 (147 ref.)
Psychiatric screening in geriatric primary care: should it be for depression alone? Lish JD, et al. **J Geriatr Psychiatry Neurol** 1995 Jul;8(3):141–53 (129 ref.)
Clues to depression in primary care practice. el-Mallakh RS, et al. **Postgrad Med** 1996 Jul;100(1):85–8, 93–6 (20 ref.)
Symptomatology in dysthymic and major depressive disorder. Klein DN, et al. **Psychiatr Clin North Am** 1996 Mar;19(1):41–53 (18 ref.)
Differential diagnosis of chronic depressive disorders. McCullough JP, et al. **Psychiatr Clin North Am** 1996 Mar; 19(1):55–71 (80 ref.)
Culture and major depression. Current challenges in the diagnosis of mood disorders. Manson SM. **Psychiatr Clin North Am** 1995 Sep;18(3):487–501 (95 ref.)
Chronic mood disorder and depressive personality. Shea MT, et al. **Psychiatr Clin North Am** 1996 Mar;19(1):103–20 (42 ref.)
[Masked depression] Verster GC, et al. **S Afr Med J** 1995 Aug;85(8):759–62 (24 ref.) (Eng. Abstr.) **(Afr)**
[Methodological problems of depression research (see comments)] Jepsen PW. **Ugeskr Laeger** 1996 Mar 11; 158(11):1508–12 (11 ref.) (Eng. Abstr.) Comment in: Ugeskr Laeger 1996 Jun 3;158(23):3332–3. **(Dan)**
[Spontaneous course of depression] Azorin JM. **Encephale** 1995 Mar;21 Spec No 2:31–4 (22 ref.) (Eng. Abstr.) **(Fre)**
[Importance of DSM IV (APA) and ICD-10 (WHO) in diagnosis and treatment of mood disorders] Bourgeois M. **Encephale** 1995 Dec;21 Spec No 5:47–52 (22 ref.) (Eng. Abstr.) **(Fre)**
[Dysphoric mania and mixed states] Bourgeois M, et al. **Encephale** 1995 Dec;21 Spec No 6:21–32 (39 ref.) (Eng. Abstr.) **(Fre)**
[Anxious-excited depression: a mixed affective syndrome] Koukopoulos A, et al. **Encephale** 1995 Dec;21 Spec No 6:33–6 (21 ref.) (Eng. Abstr.) **(Fre)**
[The dysthymia concept: current and historical aspects—an overview] Brieger P, et al. **Fortschr Neurol Psychiatr** 1995 Oct;63(10):411–20 (113 ref.) (Eng. Abstr.) **(Ger)**
[Prognosis of depression] Huber M. **Versicherungsmedizin** 1996 Apr 1;48(2):49–53 (52 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Nefazodone: a new antidepressant. Ellingrod VL, et al. **Am J Health Syst Pharm** 1995 Dec 15;52(24):2799–812 (54 ref.)
Clinical implications of antidepressant drug effects on sexual function. Harvey KV, et al. **Ann Clin Psychiatry** 1995 Dec; 7(4):189–201 (107 ref.)
Discontinuation reactions following sertraline. Leiter FL, et al. **Biol Psychiatry** 1995 Nov 15;38(10):694–5 (7 ref.)
The future of antidepressants. Bourin M, et al. **Biomed Pharmacother** 1996;50(1):7–12 (53 ref.)
Recent advances in the treatment of depression. Hale AS. **Br J Hosp Med** 1996 Feb 21–Mar 5;55(4):183–6 (23 ref.)
Psychological and sexual symptoms associated with the menopause and the effects of hormone replacement therapy. Pearce J, et al. **Br J Psychiatry** 1995 Aug; 167(2):163–73 (60 ref.)
Selective serotonin reuptake inhibitors and tricyclic antidepressants in combination. Interactions and therapeutic uses. Taylor D. **Br J Psychiatry** 1995 Nov; 167(5):575–80 (38 ref.)
Akathisia: a review and case report following paroxetine treatment. Baldassano CF, et al. **Compr Psychiatry** 1996 Mar–Apr;37(2):122–4 (40 ref.)
Rational antidepressant selection in the elderly. Christensen DD. **Geriatrics** 1995 Oct;50 Suppl 1:S41–50 (41 ref.)
Principles to optimize drug treatment in the depressed elderly: practical pharmacokinetics and drug interactions. Cohen LJ. **Geriatrics** 1995 Oct;50 Suppl 1:S32–40 (33 ref.)
Benzodiazepines for depression? A review of the literature. Birkenhäger TK, et al. **Int Clin Psychopharmacol** 1995 Sep; 10(3):181–95 (73 ref.)
Scandinavian experience with citalopram in the elderly. Gottfries CG. **Int Clin Psychopharmacol** 1996 Mar;11 Suppl 1:41–4 (14 ref.)
The antidepressant efficacy of citalopram. Montgomery SA, et al. **Int Clin Psychopharmacol** 1996 Mar;11 Suppl 1:29–33 (9 ref.)
Antidepressants in geriatric depression: what difference have they made? Baldwin RC. **Int Psychogeriatr** 1995;7 Suppl:55–68 (65 ref.)
Treatment-resistant depression in the elderly. Bonner D, et al. **Int Psychogeriatr** 1995;7 Suppl:83–94 (70 ref.)
Late-life delusional depression: acute and long-term treatment. Meyers BS. **Int Psychogeriatr** 1995;7 Suppl:113–24 (73 ref.)
Maintenance therapies for late-life recurrent major depression: research and review circa 1995. Reynolds CF 3rd, et al. **Int Psychogeriatr** 1995;7 Suppl:27–39 (27 ref.)
Efficacy of acute treatment for geriatric depression. Schneider LS, et al. **Int Psychogeriatr** 1995;7 Suppl:7–25 (75 ref.)
A review of the effects of moderate alcohol intake on the treatment of anxiety and mood disorders. Castaneda R, et al. **J Clin Psychiatry** 1996 May;57(5):207–12 (82 ref.)
The pharmacologic profile of mirtazapine. de Boer T. **J Clin Psychiatry** 1996;57 Suppl 4:19–25 (48 ref.)
Cardiovascular safety in depressed patients: focus on venlafaxine. Feighner JP. **J Clin Psychiatry** 1995 Dec; 56(12):574–9 (44 ref.)
Efficacy and tolerability of antidepressant therapy in the old–old. Finkel SI. **J Clin Psychiatry** 1996;57 Suppl 5:23–8 (47 ref.)
Augmentation strategies: focus on anxiolytics. Joffe RT, et al. **J Clin Psychiatry** 1996;57 Suppl 7:25–31; discussion 32–3 (56 ref.)
Tolerability and safety: essentials in antidepressant pharmacotherapy. Lader MH. **J Clin Psychiatry** 1996;57 Suppl 2:39–44 (26 ref.)
New approaches to the treatment of depression. Leonard BE. **J Clin Psychiatry** 1996;57 Suppl 4:26–33 (67 ref.)
Efficacy in long-term treatment of depression. Montgomery SA. **J Clin Psychiatry** 1996;57 Suppl 2:24–30 (28 ref.)
Use of serotonin selective reuptake inhibitors in geriatric depression. Newhouse PA. **J Clin Psychiatry** 1996;57 Suppl 5:12–22 (79 ref.)
Antidepressants and cognitive impairment in the elderly. Oxman TE. **J Clin Psychiatry** 1996;57 Suppl 5:38–44 (59 ref.)
The diagnosis and treatment of late-life depression. Rothschild AJ. **J Clin Psychiatry** 1996;57 Suppl 5:5–11 (80 ref.)
Does intolerance or lack of response with fluoxetine predict the same will happen with sertraline? Zarate CA, et al. **J Clin Psychiatry** 1996 Feb;57(2):67–71 (23 ref.)
The behavioral toxicity of reversible inhibitors of monoamine oxidase A: laboratory and clinical investigations. Fairweather DB, et al. **J Clin Psychopharmacol** 1995 Aug; 15(4 Suppl 2):68S–75S (43 ref.)
One foot on the bandwagon? [editorial] Pies R. **J Clin Psychopharmacol** 1995 Oct;15(5):303–5 (16 ref.)
Recent clinical development with reversible and selective amine oxidase inhibitors: a valuable addition to the armamentarium. Chairman's introduction. Priest RG. **J Clin Psychopharmacol** 1995 Aug;15(4 Suppl 2):1S–3S (18 ref.)
Nefazodone and venlafaxine: two new agents for the treatment of depression. Goldberg RJ. **J Fam Pract** 1995 Dec;41(6):591–4 (19 ref.)
The depressions of Alzheimer's disease: sorting, pharmacotherapy, and clinical advice. Knesper DJ. **J Geriatr Psychiatry Neurol** 1995 Oct;8 Suppl 1:S40–51

(147 ref.)
Antidepressants for children. Is scientific support necessary? Fisher RL, et al. **J Nerv Ment Dis** 1996 Feb;184(2):99–102 (31 ref.)
New antidepressants. Kupecz D. **Nurse Pract** 1995 Sep; 20(9):64–7 (18 ref.)
Therapeutic options for treating major depression, and the role of venlafaxine. Scott MA, et al. **Pharmacotherapy** 1996 May–Jun;16(3):352–65 (91 ref.)
Management of depression. Current trends in primary care. Kuzel R. **Postgrad Med** 1996 May;99(5):179–80, 185–6, 189–92, passiM (28 ref.)
Recent developments in antidepressant agents. Claghorn J, et al. **Prog Drug Res** 1996;46:243–62 (72 ref.)
Treatment algorithms in treatment-resistant depression. Amsterdam JD, et al. **Psychiatr Clin North Am** 1996 Jun; 19(2):371–86 (72 ref.)
Definition and epidemiology of treatment-resistant depression. Fava M, et al. **Psychiatr Clin North Am** 1996 Jun;19(2):179–200 (104 ref.)
The management of treatment-resistant depression in the medically ill. Franco-Bronson K.
Psychiatr Clin North Am 1996 Jun;19(2):329–50 (154 ref.)
Pharmacotherapy for chronic depression. Friedman RA, et al. **Psychiatr Clin North Am** 1996 Mar;19(1):121–32 (31 ref.)
Treatment-resistant depression in children and adolescents. Geller B, et al. **Psychiatr Clin North Am** 1996 Jun; 19(2):253–67 (89 ref.)
The management of treatment-resistant depression in disorders on the interface of psychiatry and medicine. Fibromyalgia, chronic fatigue syndrome, migraine, irritable bowel syndrome, atypical facial pain, and premenstrual dysphoric disorder. Gruber AJ, et al.
Psychiatr Clin North Am 1996 Jun;19(2):351–69 (79 ref.)
Novel strategies for treatment-resistant depression. Hornig-Rohan M, et al. **Psychiatr Clin North Am** 1996 Jun;19(2):387–405 (133 ref.)
Management of treatment resistance in the depressed geriatric patient. Kamholz BA, et al. **Psychiatr Clin North Am** 1996 Jun;19(2):269–86 (147 ref.)
The management of treatment resistance in depressed patients with substance use disorders. Nunes EV, et al.
Psychiatr Clin North Am 1996 Jun;19(2):311–27 (92 ref.)
Management of treatment-resistant unipolar and chronically depressed patients. Reus VI. **Psychiatr Clin North Am** 1996 Jun;19(2):201–13 (134 ref.)
Management of psychotic, treatment-resistant depression. Rothschild AJ. **Psychiatr Clin North Am** 1996 Jun; 19(2):237–52 (119 ref.)
The role of Axis II comorbidity in the management of patients with treatment-resistant depression. Thase ME. **Psychiatr Clin North Am** 1996 Jun;19(2):287–309 (97 ref.)
Does thyroid hormone have a role as adjunctive therapy in depression? Jackson IM. **Thyroid** 1996 Feb;6(1):63–7 (41 ref.)
[Pharmacotherapy in resistance depression] Leština J, et al. **Ceska Slov Psychiatr** 1995 Aug;91(4):216–33 (157 ref.) (Eng. Abstr.) **(Cze)**
[Drug therapy and other biological therapies in mood disorders] Syvälahti E, et al. **Duodecim** 1994;110(3):295–304 (26 ref.) **(Fin)**
[Prediction of therapeutic response in depressive states] Radat F, et al. **Ann Med Psychol (Paris)** 1996 May;154(2):89–102 (53 ref.) (Eng. Abstr.) **(Fre)**
[Delay in the effect of antidepressive agents: pharmacologic approach] Allain H, et al. **Encephale** 1995 Mar;21 Spec No 2:9–15 (39 ref.) (Eng. Abstr.) **(Fre)**
[Practical considerations in initial treatment] Allilaire JF. **Encephale** 1995 Mar;21 Spec No 2:23–9 (0 ref.) (Eng. Abstr.) **(Fre)**
[The long-term course of depression (epidemiology and clinical aspects)] Cardot H, et al. **Encephale** 1995 Mar;21 Spec No 2:51–9 (77 ref.) (Eng. Abstr.) **(Fre)**
[Delay of the antidepressant effect: clinical studies] Escande M, et al. **Encephale** 1995 Mar;21 Spec No 2:3–8 (30 ref.) (Eng. Abstr.) **(Fre)**
[Consolidation treatment. The status in dysthymia] Hardy P. **Encephale** 1995 Mar;21 Spec No 2:39–42 (15 ref.) (Eng. Abstr.) **(Fre)**
[Initiating thymoregulator treatment] Olié JP, et al.
Encephale 1995 Mar;21 Spec No 2:71–8 (86 ref.) (Eng. Abstr.) **(Fre)**
[Efficacy of antidepressants and thymoregulators in the long-term evolution of depression] Pringuey D, et al.
Encephale 1995 Mar;21 Spec No 2:61–70 (18 ref.) (Eng. Abstr.) **(Fre)**
[Biological factors and resistance to antidepressive agents] Puech AJ, et al. **Encephale** 1995 Mar;21 Spec No 2:17–21 (25 ref.) (Eng. Abstr.) **(Fre)**
[Long-term clinical effects of antidepressive agents] Sechter D. **Encephale** 1995 Mar;21 Spec No 2:35–8 (14 ref.) (Eng. Abstr.) **(Fre)**
[Evolution of benefit-risk ratio of antidepressants] Corruble E, et al. **Therapie** 1995 Nov–Dec;50(6):515–21 (46 ref.) (Eng. Abstr.) **(Fre)**
[St. John's wort as antidepressive therapy] Ernst E. **Fortschr Med** 1995 Sep 10;113(25):354–5 (13 ref.) (Eng. Abstr.) **(Ger)**
[Value of old and new anticonvulsants in treatment of psychiatric diseases] Walden J, et al.
Fortschr Neurol Psychiatr 1995 Aug;63(8):320–35 (185 ref.) (Eng. Abstr.) **(Ger)**

ECONOMICS

Care for depression in a changing environment. Wells KB, et al. **Health Aff (Millwood)** 1995 Fall;14(3):78–89 (15 ref.)

ENZYMOLOGY

Antidepressants and drug-metabolizing enzymes--expert group report. Meyer UA, et al. **Acta Psychiatr Scand** 1996 Feb;93(2):71–9 (45 ref.)

EPIDEMIOLOGY

Recent progress in the epidemiology of major depression. Burvill PW. **Epidemiol Rev** 1995;17(1):21–31 (148 ref.)
Maternal depressive symptoms and the risk of poor pregnancy outcome. Review of the literature and preliminary findings. Orr ST, et al. **Epidemiol Rev** 1995; 17(1):165–71 (34 ref.)
Psychiatric and physical morbidity effects of dementia caregiving: prevalence, correlates, and causes. Schulz R, et al. **Gerontologist** 1995 Dec;35(6):771–91 (90 ref.)
Comorbidity of personality disorders and unipolar major depression: a review. Corruble E, et al. **J Affect Disord** 1996 Apr 12;37(2–3):157–70 (100 ref.)
Generalized anxiety and mixed anxiety-depression: association with disability and health care utilization. Roy-Byrne PP. **J Clin Psychiatry** 1996;57 Suppl 7:86–91 (33 ref.)
Definition and epidemiology of treatment-resistant depression. Fava M, et al. **Psychiatr Clin North Am** 1996 Jun;19(2):179–200 (104 ref.)
The epidemiology of fatigue and depression: a French primary-care study. Fuhrer R, et al. **Psychol Med** 1995 Sep;25(5):895–905 (51 ref.)
[Depression and smoking] Aubin HJ, et al. **Encephale** 1996 Jan–Feb;22(1):17–22 (49 ref.) (Eng. Abstr.) **(Fre)**
[Depressive disorders and interferon alpha (editorial)] Hardy P. **Gastroenterol Clin Biol** 1996;20(3):255–7 (13 ref.) **(Fre)**

ETIOLOGY

Depression associated with multiple sclerosis: an etiological conundrum. Feinstein A. **Can J Psychiatry** 1995 Dec; 40(10):573–6 (30 ref.)
Differential diagnosis and treatment of steroid-induced affective syndromes. Pies R. **Gen Hosp Psychiatry** 1995 Sep;17(5):353–61 (27 ref.)
[Depression and epilepsy] Sirota P, et al. **Harefuah** 1995 Nov 15;129(10):423–6 (44 ref.) **(Heb)**

GENETICS

[Depression and alcoholism: a potential familial-genetic relationship] Kasperowicz-Dąbrowiecka A, et al.
Psychiatr Pol 1996 Mar–Apr;30(2):281–96 (45 ref.) (Eng. Abstr.) **(Pol)**

IMMUNOLOGY

[How are psychological processes, the neuroendocrine system and immune system integrated?] Kaschka WP.
Z Klin Psychol Psychopathol Psychother 1996;44(3):280–9 (50 ref.) (Eng. Abstr.) **(Ger)**

METABOLISM

The potential role of excessive cortisol induced by HPA hyperfunction in the pathogenesis of depression. Stokes PE. **Eur Neuropsychopharmacol** 1995;5 Suppl:77–82 (48 ref.)
Serotonin: current understanding and the way forward. Dinan TG. **Int Clin Psychopharmacol** 1996 Mar;11 Suppl 1:19–21 (10 ref.)
Norepinephrine metabolism and psychoactive drugs in the endogenous depressions. 1968 [classical article] Schildkraut JJ, et al. **Pharmacopsychiatry** 1995 Sep;28 Suppl 1:24–37 (58 ref.)
[Biological factors in severe depression] Syvälahti E. **Duodecim** 1994;110(3):261–6 (18 ref.) **(Fin)**

NURSING

Theoretical and empirical considerations of resourcefulness. Zauszniewski JA. **Image J Nurs Sch** 1995 Fall;27(3):177–80 (31 ref.)

PHYSIOPATHOLOGY

Corticotropin releasing hormone in the pathophysiology of melancholic and atypical depression and in the mechanism of action of antidepressant drugs. Gold PW, et al.
Ann N Y Acad Sci 1995 Dec 29;771:716–29 (53 ref.)
Glucocorticoid receptors in depression. Pariante CM, et al. **Isr J Med Sci** 1995 Dec;31(12):705–12 (25 ref.)
Noradrenergic and serotonergic abnormalities in depression: stress-induced dysfunction? Dinan TG.
J Clin Psychiatry 1996;57 Suppl 4:14–8 (43 ref.)
Serotonin dysfunction disorders: a behavioral neurochemistry perspective. Petty F, et al. **J Clin Psychiatry** 1996;57 Suppl 8:11–6 (24 ref.)
The anatomy of melancholia: does frontal-subcortical pathophysiology underpin its psychomotor and cognitive manifestations? [editorial] Austin MP, et al.
Psychol Med 1995 Jul;25(4):665–72 (90 ref.)
A cognitive science perspective on kindling and episode sensitization in recurrent affective disorder. Segal ZV, et al. **Psychol Med** 1996 Mar;26(2):371–80 (70 ref.)
[Chronobiology of depression] Giedke H.
Wien Med Wochenschr 1995;145(17–18):411–8 (108 ref.) (Eng. Abstr.) **(Ger)**

PSYCHOLOGY

Depression in the young. Moreau D. **Ann N Y Acad Sci** 1996 Jun 18;789:31–44 (89 ref.)
Pattern integrations in young depressed women: Part I. Beeber LS. **Arch Psychiatr Nurs** 1996 Jun;10(3):151–6 (21 ref.)
Chronic fatigue syndrome. 1: Etiology and pathogenesis. Farrar DJ, et al. **Behav Med** 1995 Spring;21(1):5–16 (133 ref.)
Sleep research in depressive illness: clinical implications--a tasting menu. Kupfer DJ. **Biol Psychiatry** 1995 Sep 15; 38(6):391–403 (38 ref.)
Social and cognitive approaches to depression: towards a new synthesis. Champion LA, et al. **Br J Clin Psychol** 1995 Nov;34 (Pt 4):485–503 (96 ref.)
The paradoxical power of the depressed patient: a problem for the ranking theory of depression. Price J, et al.
Br J Med Psychol 1995 Sep;68 (Pt 3):193–206; discussion 207–22 (37 ref.)
Depression in battered women. Campbell J, et al.
J Am Med Womens Assoc 1996 May–Jul;51(3):106–10 (56 ref.)
The behavioral toxicity of reversible inhibitors of monoamine oxidase A: laboratory and clinical investigations. Fairweather DB, et al. **J Clin Psychopharmacol** 1995 Aug; 15(4 Suppl 2):68S–75S (43 ref.)
Psychosocial factors in recurrent pediatric headache. Martin SE, et al. **Pediatr Ann** 1995 Sep;24(9):464–74 (23 ref.)
Issues in personality as diathesis for depression: the case of sociotropy-dependency and autonomy-self-criticism.
Coyne JC, et al. **Psychol Bull** 1995 Nov;118(3):358–78 (125 ref.)
The emotional Stroop task and psychopathology. Williams JM, et al. **Psychol Bull** 1996 Jul;120(1):3–24 (95 ref.)
[Recurrent brief depression] Koponen H, et al. **Duodecim** 1994;110(16):1519–22 (23 ref.) **(Fin)**
[Depression amd depressive feelings in childhood and adolescence--problems in diagnosis and assessment] Solantaus T. **Duodecim** 1994;110(3):239–51 (69 ref.) **(Fin)**
[An update on mercyism and early depression: a critical review of the literature and a psychopathological hypothesis] Guedeney A. **Psychiatr Enfant** 1995; 38(1):345–63 (69 ref.) (Eng. Abstr.) **(Fre)**
[Dream recall in depressed patients] Schredl M.
Psychother Psychosom Med Psychol 1995 Dec;45(12):414–7 (29 ref.) (Eng. Abstr.) **(Ger)**
[Acoustic and optical perceptual disorders in depressive diseases--an overview of results from experimental studies] Kallert TW. **Schweiz Arch Neurol Psychiatr** 1996; 147(1):4–11 (61 ref.) (Eng. Abstr.) **(Ger)**
[Marital problems in depressive patients: a review of the literature and own clinical investigations] Zięba A, et al. **Psychiatr Pol** 1996 May–Jun;30(3):511–20 (32 ref.) (Eng. Abstr.) **(Pol)**

THERAPY

Management of depression in patients with coexisting medical illness. Nesse RE, et al. **Am Fam Physician** 1996 May 1; 53(6):2125–33 (20 ref.)
The destructiveness of perfectionism. Implications for the treatment of depression. Blatt SJ. **Am Psychol** 1995 Dec; 50(12):1003–20 (175 ref.)
Theoretical foundations of cognitive-behavior therapy for anxiety and depression. Brewin CR. **Annu Rev Psychol** 1996;47:33–57 (90 ref.)
Psychotherapy of depression. Implications for reform of the health care system. Clarkin JF, et al.
Arch Gen Psychiatry 1996 Aug;53(8):717–23 (69 ref.)
Fitting the treatment to the patient: recent advances in the practice of electroconvulsive therapy. Frukacz A, et al. **Aust N Z J Psychiatry** 1995 Sep;29(3):484–91 (24 ref.)
ECT and non-memory cognition: a review. Calev A, et al. **Br J Clin Psychol** 1995 Nov;34 (Pt 4):505–15 (60 ref.)
Psychological treatments for depression. An update [editorial] Scott J. **Br J Psychiatry** 1995 Sep;167(3):289–92 (39 ref.)
The efficacy of psychosocial treatments in primary care. A review of randomized clinical trials. Brown C, et al.
Gen Hosp Psychiatry 1995 Nov;17(6):414–24 (43 ref.)
The primary care setting: managing medical comorbidity in the elderly depressed patient. Ferentz K. **Geriatrics** 1995 Oct;50 Suppl 1:S25–31 (38 ref.)
Care for depression in a changing environment. Wells KB, et al. **Health Aff (Millwood)** 1995 Fall;14(3):78–89 (15 ref.)
Cognitive therapy of affective disorders: a review. Scott J. **J Affect Disord** 1996 Feb 12;37(1):1–11 (75 ref.)
Prolongation of ECT-induced seizures with theophylline [letter] Stewart JT. **J Am Geriatr Soc** 1996 Apr;44(4):475 (9 ref.)
Relapse and recurrence following a course of ECT: reasons for concern and strategies for further investigation. Grunhaus L, et al. **J Psychiatr Res** 1995 May–Jun; 29(3):165–72 (36 ref.)
Management of depression in the outpatient office. Salazar WH. **Med Clin North Am** 1996 Mar;80(2):431–55 (95 ref.)
The neuropsychology of depression and its implications for

DEPRESSIVE DISORDER

cognitive therapy. Crews WD Jr, et al. **Neuropsychol Rev** 1995 Jun;5(2):81–123 (156 ref.)

Clues to depression in primary care practice. el–Mallakh RS, et al. **Postgrad Med** 1996 Jul;100(1):85–8, 93–6 (20 ref.)

Behavioral treatment of depression in the context of marital discord. Beach SR, et al. **Prog Behav Modif** 1996;30:99–122 (110 ref.)

Psychosocial interventions for adolescent depression: issues, evidence, and future directions. Hoberman HM, et al. **Prog Behav Modif** 1996;30:25–73 (250 ref.)

Psychotherapy for dysthymic disorder. Markowitz JC. **Psychiatr Clin North Am** 1996 Mar;19(1):133–49 (68 ref.)

Combined medication and psychotherapy in the treatment of chronic mood disorders. Miller IW, et al. **Psychiatr Clin North Am** 1996 Mar;19(1):151–71 (70 ref.)

Recovery, chronicity, and levels of psychopathology in major depression. Mueller TI, et al. **Psychiatr Clin North Am** 1996 Mar;19(1):85–102 (52 ref.)

[Psychotherapy in depressive conditions] Huttunen MO. **Duodecim** 1994;110(3):307–19 (26 ref.) **(Fin)**

[Humoral aspects of sleep deprivation] Ebert D, et al. **Fortschr Neurol Psychiatr** 1995 Nov;63(11):441–50 (60 ref.) (Eng. Abstr.) **(Ger)**

DEPRESSIVE SYMPTOMS see **DEPRESSION**

DEPRESSIVE SYNDROME see **DEPRESSIVE DISORDER**

DEPTH PERCEPTION

PHYSIOLOGY

Dapiprazole's effect upon accommodative recovery: is it due entirely to changes in depth of field? Molinari JF, et al. **Optom Vis Sci** 1995 Aug;72(8):552–6 (18 ref.)

Binocular eye movements and the perception of depth. Collewijn H, et al. **Rev Oculomot Res** 1990;4:213–61 (169 ref.)

Natural problems for stereoscopic depth perception in virtual environments. Wann JP, et al. **Vision Res** 1995 Oct; 35(19):2731–6 (23 ref.)

DERMABRASION

Dermabrasion, chemabrasion, and laserabrasion. Historical perspectives, modern dermabrasion techniques, and future trends. Fulton JE Jr. **Dermatol Surg** 1996 Jul;22(7):619–28 (52 ref.)

DERMAL SINUS see **SPINA BIFIDA OCCULTA**

DERMATAN SULFATE

IMMUNOLOGY

Immunology of chondroitin/dermatan sulfate. Hascall VC, et al. **Adv Exp Med Biol** 1995;376:205–16 (34 ref.)

DERMATITIS

Eyelid dermatitis. A common, often confounding rash. Parkinson RW. **Postgrad Med** 1996 Aug;100(2):231–6, 239–40 (12 ref.)

DIAGNOSIS

Update on the diagnosis of lichenoid dermatitis. Boyd AS. **Adv Dermatol** 1996;11:287–315; discussion 316 (108 ref.)

[Dermatitis and neurological changes] Benitez León MD, et al. **Rev Clin Esp** 1995 Oct;195(10):717–8 (15 ref.) **(Spa)**

DRUG THERAPY

Hyaluronan receptor antagonists alter skin inflammation and fibrosis following injury. Savani RC, et al. **Proc West Pharmacol Soc** 1995;38:131–6 (68 ref.)

[Steroid-induced psychoses] Whitworth AB, et al. **Hautarzt** 1995 Sep;46(9):666–73; quiz 672 (34 ref.) **(Ger)**

ETIOLOGY

Cutaneous reactions following herpes zoster infections: report of three cases and a review of the literature. Gibney MD, et al. **Br J Dermatol** 1996 Mar;134(3):504–9 (22 ref.)

Perioral dermatitis. Hogan DJ. **Curr Probl Dermatol** 1995; 22:98–104 (51 ref.)

Rheumatoid neutrophilic dermatitis. Hassab–el–Naby HM, et al. **Int J Dermatol** 1996 Mar;35(3):207–8 (6 ref.)

Dermatitis of the vulva. Marren P, et al. **Semin Dermatol** 1996 Mar;15(1):36–41 (24 ref.)

METABOLISM

Adhesion molecules in cutaneous inflammation. Barker JN. **Ciba Found Symp** 1995;189:91–101; discussion 101–6 (38 ref.)

PHYSIOPATHOLOGY

[The vascular bed of the skin. Integration site of endogenous and exogenous stimuli] Heckmann M. **Hautarzt** 1996 Jun; 47(6):417–21 (37 ref.) (Eng. Abstr.) **(Ger)**

VETERINARY

The cat, the flea, and pesticides. Logas DB. **Vet Clin North Am Small Anim Pract** 1995 Jul;25(4):801–11 (60 ref.)

Therapy for feline dermatoses. Messinger LM. **Vet Clin North Am Small Anim Pract** 1995 Jul; 25(4):981–1005 (126 ref.)

Exudative, crusting, and scaling dermatoses. Sousa CA. **Vet Clin North Am Small Anim Pract** 1995 Jul;25(4):813–31 (23 ref.)

DERMATITIS, ACTINIC see **PHOTOSENSITIVITY DISORDERS**

DERMATITIS, ADVERSE DRUG REACTION see **DRUG ERUPTIONS**

DERMATITIS, ALLERGIC CONTACT

DIAGNOSIS

Contact allergy testing alternatives: 1996. Scheman A. **Cutis** 1996 Apr;57(4):235–40 (22 ref.)

ETIOLOGY

Contact allergy to topical corticosteroids and systemic contact dermatitis from prednisolone with tolerance of triamcinolone. Bircher AJ, et al. **Acta Derm Venereol** 1995 Nov;75(6):490–3 (38 ref.)

Early events in contact sensitivity. Katz SI, et al. **Adv Exp Med Biol** 1995;378:497–500 (12 ref.)

The immunology of nickel-induced allergic contact dermatitis. Sosroseno W. **Asian Pac J Allergy Immunol** 1995 Dec;13(2):173–81 (95 ref.)

Contact allergy to imidazoles used as antimycotic agents. Dooms–Goossens A, et al. **Contact Dermatitis** 1995 Aug; 33(2):73–7 (54 ref.)

Contact dermatitis due to imidazole antimycotics. Guidetti MS, et al. **Contact Dermatitis** 1995 Oct;33(4):282 (5 ref.)

Textile dermatitis: an update. (I). Resins, additives and fibers. Hatch KL, et al. **Contact Dermatitis** 1995 Jun;32(6):319–26 (34 ref.)

Effect of age and sex on the induction and elicitation of allergic contact dermatitis. Kwangsukstith C, et al. **Contact Dermatitis** 1995 Nov;33(5):289–98 (85 ref.)

Allergic contact cheilitis. Ophaswongse S, et al. **Contact Dermatitis** 1995 Dec;33(6):365–70 (51 ref.)

Contact allergy: animal models. Maurer T. **Curr Probl Dermatol** 1995;22:38–43 (11 ref.)

[Contact dermatoses: new antigens and current events] Castelain M. **Allerg Immunol (Paris)** 1995 Dec;27(10):363–9 (37 ref.) (Eng. Abstr.) **(Fre)**

[Cutaneous immunoallergic reactions caused by vaccines] Barbaud A, et al. **Ann Dermatol Venereol** 1995; 122(3):129–38 (120 ref.) **(Fre)**

[Contact dermatitis following cardiac pacemaker implantation] Moïni C, et al. **Arch Mal Coeur Vaiss** 1996 Feb;89(2):253–6 (12 ref.) (Eng. Abstr.) **(Fre)**

[Latex allergy] Schürer NY, et al. **Hautarzt** 1995 Oct; 46(10):742–53 (10 ref.) **(Ger)**

[Metal dermatoses I] Schwarz T, et al. **Hautarzt** 1996 Apr; 47(4):316–28; quiz 327–8 (10 ref.) **(Ger)**

IMMUNOLOGY

Studies on Langerhans cell phenotype in human afferent skin lymph from allergic contact dermatitis. Brand CU, et al. **Adv Exp Med Biol** 1995;378:523–5 (14 ref.)

Chronic finger dermatitis after trauma. Diagnosis: posttraumatic eczema with allergic contact dermatitis to neomycin, bacitracin, and topical corticosteroids. Sherertz EF. **Arch Dermatol** 1996 Apr;132(4):461, 464 (11 ref.)

The immunology of nickel-induced allergic contact dermatitis. Sosroseno W. **Asian Pac J Allergy Immunol** 1995 Dec;13(2):173–81 (95 ref.)

T cell immune responses to haptens. Structural models for allergic and autoimmune reactions. Weltzien HU, et al. **Toxicology** 1996 Feb 22;107(2):141–51 (54 ref.)

PHYSIOPATHOLOGY

Epidermal cytokines in allergic contact dermatitis. Kondo S, et al. **J Am Acad Dermatol** 1995 Nov;33(5 Pt 1):786–800 (194 ref.)

DERMATITIS, ALLERGIC ECZEMATOUS see **DERMATITIS, ALLERGIC CONTACT**

DERMATITIS, ATOPIC

Atopic eczema of adult type in Japan. Nishioka K. **Australas J Dermatol** 1996 May;37 Suppl 1:S7–9 (18 ref.)

Atopic dermatitis: an update. Rothe MJ, et al. **J Am Acad Dermatol** 1996 Jul;35(1):1–13; quiz 14–6 (123 ref.)

Atopic dermatitis. Hogan PA. **Med J Aust** 1996 Jun 17; 164(12):736–41 (27 ref.)

COMPLICATIONS

Atopic retinal detachment. Report of four cases and a review of the literature. Yoneda K, et al. **Br J Dermatol** 1995 Oct; 133(4):586–91 (78 ref.)

Coexistence of atopic dermatitis and lichen nitidus in three patients. Lestringant GG, et al. **Dermatology** 1996; 192(2):171–3 (14 ref.)

DIAGNOSIS

New concepts in atopic dermatitis. Boguniewicz M, et al. **Compr Ther** 1996 Mar;22(3):144–51 (18 ref.)

[Atopic dermatitis] Lehners–Weber C, et al. **Rev Med Liege** 1996 Jul;51(7):461–7 (54 ref.) **(Fre)**

DRUG THERAPY

Atopic eczema in children: what to do when treatment fails to work. Hogan PA. **Australas J Dermatol** 1996 Aug; 37(3):119–22; quiz 123–4 (25 ref.)

EPIDEMIOLOGY

On the definition and epidemiology of atopic dermatitis. Williams HC. **Dermatol Clin** 1995 Jul;13(3):649–57 (51 ref.)

ETIOLOGY

Pathogenesis and management of atopic dermatitis. Friedmann PS, et al. **Clin Exp Allergy** 1995 Sep; 25(9):799–806 (39 ref.)

Atopic dermatitis and delayed hypersensitivity to dust mites. Castelain M. **Clin Rev Allergy Immunol** 1995 Summer; 13(2):161–72 (53 ref.)

Atopic dermatitis: the skin as a window into the pathogenesis of chronic allergic diseases. Leung DY. **J Allergy Clin Immunol** 1995 Sep;96(3):302–18; quiz 319 (47 ref.)

Atopic dermatitis: is it an allergic disease? Halbert AR, et al. **J Am Acad Dermatol** 1995 Dec;33(6):1008–18 (114 ref.)

IMMUNOLOGY

Atopic dermatitis: new knowledge and new approaches. Kolmer HL, et al. **Hosp Pract (Off Ed)** 1995 Oct 15; 30(10):63–72 (9 ref.)

Development of childhood eczema and its classification. Oranje AP. **Pediatr Allergy Immunol** 1995;6 Suppl 7:31–5 (26 ref.)

The role of the skin in the development of chemical respiratory hypersensitivity. Kimber I. **Toxicol Lett** 1996 Aug;86(2–3):89–92 (29 ref.)

PHYSIOPATHOLOGY

Role of eosinophil-chemotactic C-C chemokines in cutaneous inflammation. Schröder JM, et al. **J Leukoc Biol** 1996 Jan;59(1):1–5 (24 ref.)

[Role of Langerhans cells in the physiopathology of atopic dermatitis] Bieber T. **Pathol Biol (Paris)** 1995 Dec; 43(10):871–5 (39 ref.) (Eng. Abstr.) **(Fre)**

REHABILITATION

[Dermatologic climate therapy—definition, indications and public health necessity] Vocks E, et al. **Rehabilitation (Stuttg)** 1995 Aug;34(3):148–53 (21 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Pathogenesis and management of atopic dermatitis. Friedmann PS, et al. **Clin Exp Allergy** 1995 Sep; 25(9):799–806 (39 ref.)

Intravenous immune globulin: an alternative therapy in steroid-dependent allergic diseases. Gelfand EW, et al. **Clin Exp Immunol** 1996 May;104 Suppl 1:61–6 (56 ref.)

[Phototherapy of atopic dermatitis] Marguery MC, et al. **Ann Dermatol Venereol** 1995;122(10):729–34 (27 ref.) **(Fre)**

DERMATITIS, CONTACT

see related
DERMATITIS, OCCUPATIONAL

DIAGNOSIS

The European standard series. European Environmental and Contact Dermatitis Research Group (EECDRG). Bruynzeel DP, et al. **Contact Dermatitis** 1995 Sep; 33(3):145–8 (16 ref.)

ETIOLOGY

Predictive molecular and genetic toxicology. Application to the detection of sensitizing potential of xenobiotics. Garrigue JL, et al. **Clin Rev Allergy Immunol** 1995 Fall; 13(3):189–200 (38 ref.)

Adverse contact reactions to sculptured acrylic nails: 4 case reports and a literature review. Freeman S, et al. **Contact Dermatitis** 1995 Dec;33(6):381–5 (48 ref.)

Immediate contact reactions. Lahti A. **Curr Probl Dermatol** 1995;22:17–23 (13 ref.)

Cefotiam-induced contact urticaria syndrome: an occupational condition in Japanese nurses. Shimizu S, et al. **Dermatology** 1996;192(2):174–6 (19 ref.)

Hepatitis, rash and eosinophilia following trichloroethylene exposure: a case report and speculation on mechanistic similarity to halothane induced hepatitis. Bond GR. **J Toxicol Clin Toxicol** 1996;34(4):461–6 (11 ref.)

How accurately can bruises be aged in abused children?

Literature review and synthesis. Schwartz AJ, et al. **Pediatrics** 1996 Feb;97(2):254–7 (46 ref.)
Plant dermatitis. Possible culprits go far beyond poison ivy. Juckett G. **Postgrad Med** 1996 Sep;100(3):159–63, 167–71 (20 ref.)
Managing contact dermatitis. Shaw S. **Practitioner** 1996 Jan; 240(1558):16–24 (0 ref.)
[Contact eczema caused by calcipotriol] Giordano-Labadie F, et al. **Ann Dermatol Venereol** 1996;123(3):196–7 (7 ref.) **(Fre)**
[Latex allergy: from contact urticaria to asthma] Helbling A. **Schweiz Rundsch Med Prax** 1996 Aug 13;85(33):978–82 (22 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Predictive molecular and genetic toxicology. Application to the detection of sensitizing potential of xenobiotics. Garrigue JL, et al. **Clin Rev Allergy Immunol** 1995 Fall; 13(3):189–200 (38 ref.)

THERAPY

Treatment of vulvar dermatoses. Zellis S, et al. **Semin Dermatol** 1996 Mar;15(1):71–6 (26 ref.)

DERMATITIS, CONTACT, ALLERGIC see **DERMATITIS, ALLERGIC CONTACT**

DERMATITIS, CONTACT, PHOTOTOXIC see **DERMATITIS, PHOTOTOXIC**

DERMATITIS, ECZEMATOUS see **ECZEMA**

DERMATITIS, EXFOLIATIVE

COMPLICATIONS

Ofuji papuloerythroderma in a patient with the acquired immunodeficiency syndrome. García-Patos V, et al. **Dermatology** 1996;192(2):164–6 (23 ref.)

CONGENITAL

Erythrokeratodermia variabilis present at birth: case report and review of the literature. Hendrix JD Jr, et al. **Pediatr Dermatol** 1995 Dec;12(4):351–4 (21 ref.)

DIAGNOSIS

Cutaneous T-cell lymphoma presenting as papuloerythroderma--a case and review of the literature. Shah M, et al. **Clin Exp Dermatol** 1995 Mar;20(2):161–3 (11 ref.)

DRUG THERAPY

Salicylism from topical salicylates: review of the literature. Brubacher JR, et al. **J Toxicol Clin Toxicol** 1996; 34(4):431–6 (31 ref.)

ETIOLOGY

[Erythrodermia] Sigurdsson V, et al. **Ned Tijdschr Geneeskd** 1996 Aug 3;140(31):1592–5 (27 ref.) **(Dut)**

DERMATITIS HERPETIFORMIS

DIAGNOSIS

Dermatitis herpetiformis. Fry L. **Baillieres Clin Gastroenterol** 1995 Jun;9(2):371–93 (65 ref.)

PATHOLOGY

Dermatitis herpetiformis associated with lichen planopilaris. Isaac M, et al. **J Am Acad Dermatol** 1995 Dec;33(6):1050–1 (3 ref.)

DERMATITIS, IRRITANT

ETIOLOGY

Surfactants and experimental irritant contact dermatitis. Effendy I, et al. **Contact Dermatitis** 1995 Oct;33(4):217–25 (86 ref.)
The sodium lauryl sulfate model: an overview. Lee CH, et al. **Contact Dermatitis** 1995 Jul;33(1):1–7 (92 ref.)
Senile lip licking [letter] Hisa T, et al. **Dermatology** 1995; 191(4):339–40 (4 ref.)
Topical iontophoretic drug delivery: pathways, principles, factors, and skin irritation. Singh J, et al. **Med Res Rev** 1996 May;16(3):285–96 (88 ref.)

IMMUNOLOGY

Rosettes of Langerhans cells and activated T cells in human skin lymph derived from irritant contact dermatitis. Brand CU, et al. **Adv Exp Med Biol** 1995;378:527–9 (17 ref.)

DERMATITIS MEDICAMENTOSA see **DRUG ERUPTIONS**

DERMATITIS, OCCUPATIONAL

ABC of work related disorders. Occupational dermatitis. White IR. **BMJ** 1996 Aug 24;313(7055):487–9 (0 ref.)
Skin hazards of the marine aquarium industry. Tong DW. **Int J Dermatol** 1996 Mar;35(3):153–8 (43 ref.)

EPIDEMIOLOGY

The epidemiology of occupational contact dermatitis. Lushniak BD. **Dermatol Clin** 1995 Jul;13(3):671–80 (66 ref.)

ETIOLOGY

Issues of latex safety in dentistry. Field EA, et al. **Br Dent J** 1995 Oct 7;179(7):247–53 (51 ref.)
Textile dermatitis: an update. (I). Resins, additives and fibers. Hatch KL, et al. **Contact Dermatitis** 1995 Jun;32(6):319–26 (34 ref.)
Cefotiam-induced contact urticaria syndrome: an occupational condition in Japanese nurses. Shimizu S, et al. **Dermatology** 1996;192(2):174–6 (19 ref.)
Hypoallergenic gloves. Field EA. **Int Dent J** 1995 Dec; 45(6):339–46 (36 ref.)
[Latex allergy] Schürer NY, et al. **Hautarzt** 1995 Oct; 46(10):742–53 (10 ref.) **(Ger)**

DERMATITIS, PHOTOTOXIC

ETIOLOGY

Methylene blue-induced phototoxicity: an unrecognized complication. Porat R, et al. **Pediatrics** 1996 May; 97(5):717–21 (19 ref.)

DERMATITIS, PRIMARY IRRITANT see **DERMATITIS, IRRITANT**

DERMATITIS, RADIATION-INDUCED see **RADIODERMATITIS**

DERMATITIS, SEBORRHEIC

MICROBIOLOGY

Seborrhoeic dermatitis and Pityrosporum yeasts. Bergbrant IM. **Curr Top Med Mycol** 1995;6:95–112 (130 ref.)

DERMATITIS SEBORRHEICA see **DERMATITIS, SEBORRHEIC**

DERMATITIS, TOXICODENDRON

Plant dermatitis. Possible culprits go far beyond poison ivy. Juckett G. **Postgrad Med** 1996 Sep;100(3):159–63, 167–71 (20 ref.)

DERMATITIS VENENATA see **DERMATITIS, CONTACT**

DERMATITIS VERRUCOSA see **CHROMOBLASTOMYCOSIS**

DERMATOFIBROMA

PATHOLOGY

Multinucleate cell angiohistiocytoma. A review and report of four cases. Cribier B, et al. **Acta Derm Venereol** 1995 Sep;75(5):337–9 (5 ref.)
Clear cell dermatofibroma. Case report of an unusual fibrohistiocytic lesion. Zelger BW, et al. **Am J Surg Pathol** 1996 Apr;20(4):483–91 (23 ref.)
[Dendritic cells in dogs and cats: models of study in human pathology] Marchal T, et al. **Pathol Biol (Paris)** 1995 Dec; 43(10):910–20 (68 ref.) (Eng. Abstr.) **(Fre)**

RADIOGRAPHY

Sclerosing haemangioma of the lung. Liam CK, et al. **Singapore Med J** 1995 Jun;36(3):333–4 (9 ref.)

DERMATOFIBROSARCOMA

PATHOLOGY

Dermatofibrosarcoma protuberans. Gloster HM Jr. **J Am Acad Dermatol** 1996 Sep;35(3 Pt 1):355–74; quiz 375–6 (176 ref.)

SURGERY

A comparison between Mohs micrographic surgery and wide surgical excision for the treatment of dermatofibrosarcoma protuberans. Gloster HM Jr, et al. **J Am Acad Dermatol** 1996 Jul;35(1):82–7 (37 ref.)

DERMATOLOGIC AGENTS

see related
ANTI-INFECTIVE AGENTS, LOCAL
Antimicrobial skin preparations for the maxillofacial region. Morgan JP 3rd, et al. **J Oral Maxillofac Surg** 1996 Jan; 54(1):89–94 (56 ref.)

ADMINISTRATION & DOSAGE

Melanin hyperpigmentation of skin: melasma, topical treatment with azelaic acid, and other therapies. Breathnach AS. **Cutis** 1996 Jan;57(1 Suppl):36–45 (73 ref.)
Efficacy and safety of topical azelaic acid (20 percent cream): an overview of results from European clinical trials and experimental reports. Graupe K, et al. **Cutis** 1996 Jan;57(1 Suppl):20–35 (53 ref.)

ADVERSE EFFECTS

Methotrexate hepatotoxicity and the role of routine liver biopsy: a collective opinion [letter] Sinclair RD, et al. **Australas J Dermatol** 1995 Nov;36(4):228–9 (5 ref.)
Minimizing complications from systemic glucocorticosteroid use. Nesbitt LT Jr. **Dermatol Clin** 1995 Oct;13(4):925–39 (56 ref.)
[Contact eczema caused by calcipotriol] Giordano-Labadie F, et al. **Ann Dermatol Venereol** 1996;123(3):196–7 (7 ref.) **(Fre)**

PHARMACOKINETICS

Challenges in evaluating bioequivalence of dermatological drug products. Shah VP. **Curr Probl Dermatol** 1995; 22:152–7 (10 ref.)

PHARMACOLOGY

Topical retinoids and cutaneous biology. Craven NM, et al. **Clin Exp Dermatol** 1996 Jan;21(1):1–10 (141 ref.)
Retinoids and sebaceous gland activity. Geiger JM. **Dermatology** 1995;191(4):305–10 (52 ref.)

THERAPEUTIC USE

Methotrexate and other chemotherapeutic agents used to treat psoriasis. Jeffes EW III, et al. **Dermatol Clin** 1995 Oct;13(4):875–90 (128 ref.)
Systemic retinoids for psoriasis. Wieder JM, et al. **Dermatol Clin** 1995 Oct;13(4):891–6 (34 ref.)
Low-dose methotrexate as an adjunctive therapy with surgery for ectropion complicating dermatomyositis. Abernethy ML, et al. **Dermatology** 1996;192(2):153–5 (14 ref.)
The concept of the acid mantle of the skin: its relevance for the choice of skin cleansers. Schmid MH, et al. **Dermatology** 1995;191(4):276–80 (27 ref.)
Topical therapy for psoriasis. Lebwohl M, et al. **Int J Dermatol** 1995 Oct;34(10):673–84 (67 ref.)
Botulinum A exotoxin use in clinical dermatology. Carruthers A, et al. **J Am Acad Dermatol** 1996 May;34(5 Pt 1):788–97 (118 ref.)
Physical enhancement of dermatologic drug delivery: iontophoresis and phonophoresis. Kassan DG, et al. **J Am Acad Dermatol** 1996 Apr;34(4):657–66 (74 ref.)
Advances in topical therapy for skin diseases. Willsteed EM. **Med J Aust** 1996 Sep 2;165(5):274–9 (25 ref.)
Calcipotriol: a new drug for topical psoriasis treatment. Kragballe K. **Pharmacol Toxicol** 1995 Oct;77(4):241–6 (41 ref.)
[Retinoids] Piérard GE, et al. **Rev Med Liege** 1996 Jan; 51(1):142–4 (13 ref.) **(Fre)**

DERMATOLOGY

see related
SKIN DISEASES
Dermatologic health services research. Chren MM. **Dermatol Clin** 1995 Jul;13(3):689–95 (40 ref.)
Dermatology at the Dead Sea spas. Even-Paz Z. **Isr J Med Sci** 1996 Jul;32 Suppl:S11–5 (23 ref.)
Dermatologic surgery personnel with AIDS. Resnik SS, et al. **Semin Dermatol** 1995 Sep;14(3):240–2 (22 ref.)
The potential role of simple dermatologic surgery techniques in transmitting HIV infection. Spencer J, et al. **Semin Dermatol** 1995 Sep;14(3):219–27 (43 ref.)

EDUCATION

Learning and teaching in dermatology. A practitioner's guide. Brodell RT, et al. **Arch Dermatol** 1996 Aug; 132(8):946–52 (85 ref.)

METHODS

Studies on development of hairless descendants of Mexican hairless dogs and their usefulness in dermatological science. Kimura T. **Exp Anim** 1996 Jan;45(1):1–13 (36 ref.)
Confocal laser scanning microscopy: a new optical microscopic technique for applications in pathology and dermatology. Fink-Puches R, et al. **J Cutan Pathol** 1995 Jun;22(3):252–9 (27 ref.)

TRENDS

Mouse mutations as animal models and biomedical tools for dermatological research. Sundberg JP, et al. **J Invest Dermatol** 1996 Feb;106(2):368–76 (170 ref.)

DERMATOLYSIS see **CUTIS LAXA**

DERMATOMEGALY see **CUTIS LAXA**

DERMATOMYCOSES

Cutaneous Cryptococcus infection and AIDS. Report of 12 cases and review of the literature. Murakawa GJ, et al. **Arch Dermatol** 1996 May;132(5):545–8 (36 ref.)
Cutaneous alternariosis in a nonimmunocompromised patient.

DERMATOMYCOSES

Saenz-Santamaria MC, et al. **Int J Dermatol** 1995 Aug; 34(8):556–7 (10 ref.)

COMPLICATIONS

Mucocutaneous histoplasmosis in AIDS. Souza Filho FJ, et al. **Br J Dermatol** 1995 Sep;133(3):472–4 (26 ref.)

Common superficial fungal infections in patients with AIDS. Aly R, et al. **Clin Infect Dis** 1996 May;22 Suppl 2:S128–32 (24 ref.)

Cutaneous manifestations of opportunistic infections in patients infected with human immunodeficiency virus. Tappero JW, et al. **Clin Microbiol Rev** 1995 Jul;8(3):440–50 (68 ref.)

[Primary cutaneous cryptococcosis and bacterial pneumonia caused by Pseudomonas aeruginosa in AIDS: clinical case and review of the literature] Dronda F, et al. **Enferm Infecc Microbiol Clin** 1996 Feb;14(2):101–5 (35 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Cutaneous mycoses in children. Elewski BE. **Br J Dermatol** 1996 Jun;134 Suppl 46:7–11: discussion 37–8 (34 ref.)

Coccidioidomycosis: the other great imitator. Cardone JS, et al. **Cutis** 1995 Jul;56(1):33–6 (13 ref.)

[3 cases of cutaneous mycosis: an analysis and the resulting conclusions] Buiuc D, et al. **Bacteriol Virusol Parazitol Epidemiol** 1995 Jan–Mar; 40(1):25–30 (13 ref.) **(Rum)**

EPIDEMIOLOGY

Dematiaceous fungal infections in China. Li R, et al. **Curr Top Med Mycol** 1995;6:283–305 (48 ref.)

Epidemiology of dermatophytes in Europe. Svejgaard EL. **Int J Dermatol** 1995 Aug;34(8):525–8 (27 ref.)

ETIOLOGY

[Cryptococcal whitlow in a HIV positive patient] Verneuil L, et al. **Ann Dermatol Venereol** 1995;122(10):688–91 (29 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Subcutaneous phaeohyphomycosis in a renal transplant recipient: a case report and review of the literature. Jha V, et al. **Am J Kidney Dis** 1996 Jul;28(1):137–9 (21 ref.)

Cutaneous defenses against dermatophytes and yeasts. Wagner DK, et al. **Clin Microbiol Rev** 1995 Jul;8(3):317–35 (284 ref.)

Cutaneous alternariosis in an immunocompromised patient. Chaidemenos GC, et al. **Cutis** 1995 Sep;56(3):145–50 (40 ref.)

MICROBIOLOGY

Neonatal Malassezia furfur pustulosis. Rapelanoro R, et al. **Arch Dermatol** 1996 Feb;132(2):190–3 (30 ref.)

A case of cutaneous phaeohyphomycosis caused by Exserohilum rostratum, its in vitro sensitivity and review of literature. Agarwal A, et al. **Mycopathologia** 1995 Jul; 131(1):9–12 (26 ref.)

PATHOLOGY

Disseminated cutaneous Cryptococcus clinically mimicking basal cell carcinoma [letter] Murakawa GJ, et al. **Dermatol Surg** 1995 Nov;21(11):992–3 (8 ref.)

[Subcutaneous phaeohyphomycosis in the state of Pará: a report of 3 cases] Arnaud MV, et al. **Rev Soc Bras Med Trop** 1996 May–Jun;29(3):271–4 (20 ref.) (Eng. Abstr.) **(Por)**

VETERINARY

Feline dermatophytosis. Recent advances and recommendations for therapy. Moriello KA, et al. **Vet Clin North Am Small Anim Pract** 1995 Jul;25(4):901–21 (49 ref.)

DERMATOMYOSITIS

[Polymyositis and dermatomyositis. Current status] Cherin P, et al. **Ann Dermatol Venereol** 1995;122(6–7):447–54 (71 ref.) **(Fre)**

CHEMICALLY INDUCED

Hydroxyurea-induced dermatomyositis-like eruption. Senet P, et al. **Br J Dermatol** 1995 Sep;133(3):455–9 (32 ref.)

COMPLICATIONS

Dermatomyositis treated with high-dose intravenous immunoglobulins and associated with panniculitis. Sabroe RA, et al. **Clin Exp Dermatol** 1995 Mar;20(2):164–7 (16 ref.)

Vesicle formation in dermatomyositis associated with gynecologic malignancies. Kubo M, et al. **J Am Acad Dermatol** 1996 Feb;34(2 Pt 2):391–4 (27 ref.)

[Dermatopolymyositis and primary biliary cirrhosis. A rare association] Rain F, et al. **Presse Med** 1996 Apr 6; 25(12):581–2 (12 ref.) (Eng. Abstr.) **(Fre)**

[An autopsy case of dermatomyositis with rapidly progressive interstitial pneumonia] Ozawa Y, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Oct;18(5):552–8 (29 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

MRS and NIRS for muscle disease evaluation. Olsen NJ, et al. **Bull Rheum Dis** 1995 Aug;44(5):4–7 (10 ref.)

Diagnosis and management of dermatomyositis. Adams-Gandhi LB, et al. **Compr Ther** 1996 Mar; 22(3):156–64 (83 ref.)

An update on juvenile dermatomyositis. Pachman LM. **Curr Opin Rheumatol** 1995 Sep;7(5):437–41 (67 ref.)

Juvenile dermatomyositis. Pathophysiology and disease expression. Pachman LM. **Pediatr Clin North Am** 1995 Oct; 42(5):1071–98 (138 ref.)

DRUG THERAPY

Dermatomyositis treated with high-dose intravenous immunoglobulins and associated with panniculitis. Sabroe RA, et al. **Clin Exp Dermatol** 1995 Mar;20(2):164–7 (16 ref.)

Low-dose methotrexate as an adjunctive therapy with surgery for ectropion complicating dermatomyositis. Abernethy ML, et al. **Dermatology** 1996;192(2):153–5 (14 ref.)

ETIOLOGY

Cutaneous manifestations of selected rheumatologic diseases. Ostezan LB, et al. **Am Fam Physician** 1996 Apr; 53(5):1625–36 (14 ref.)

IMMUNOLOGY

Photoimmunology of lupus erythematosus and dermatomyositis: a speculative review. Sontheimer RD. **Photochem Photobiol** 1996 May;63(5):583–94 (155 ref.)

PHYSIOPATHOLOGY

Juvenile dermatomyositis. Halbert AR. **Australas J Dermatol** 1996 May;37(2):106–8 (19 ref.)

THERAPY

An update on juvenile dermatomyositis. Pachman LM. **Curr Opin Rheumatol** 1995 Sep;7(5):437–41 (67 ref.)

Use of intravenous immune globulin in the therapy of children with rheumatological diseases. Roifman CM. **J Clin Immunol** 1995 Nov;15(6 Suppl):42S–51S (10 ref.)

DERMATOPHYTES

Cutaneous defenses against dermatophytes and yeasts. Wagner DK, et al. **Clin Microbiol Rev** 1995 Jul;8(3):317–35 (284 ref.)

ISOLATION & PURIFICATION

Epidemiology of dermatophytes in Europe. Svejgaard EL. **Int J Dermatol** 1995 Aug;34(8):525–8 (27 ref.)

DERMATOPHYTOSES see **DERMATOMYCOSES**

DERMATOPLASTY see **SKIN TRANSPLANTATION**

DERMATOSCLEROSIS see **SCLERODERMA, CIRCUMSCRIBED**

DERMATOSIS, NEUTROPHILIC, FEBRILE, ACUTE see **SWEET'S SYNDROME**

DERMOID see **DERMOID CYST**

DERMOID CYST

METABOLISM

The humoral hypercalcemia of benignancy. A newly appreciated syndrome [see comments] Knecht TP, et al. **Am J Clin Pathol** 1996 Apr;105(4):487–92 (42 ref.) Comment in: Am J Clin Pathol 1996 Apr;105(4):377–9.

PATHOLOGY

Hairy polyp of the tonsil. Mitchell TE, et al. **J Laryngol Otol** 1996 Jan;110(1):101–3 (16 ref.)

Dermoid cyst of the nose: a case report and review of the literature. Nocini PF, et al. **J Oral Maxillofac Surg** 1996 Mar;54(3):357–62 (21 ref.)

RADIOGRAPHY

Dermoid cyst of the ovary: computed tomography diagnosis of an unusual case. Garant M, et al. **Can Assoc Radiol J** 1996 Apr;47(2):107–10 (9 ref.)

SURGERY

Dermoid cyst of the frontal bone away from the anterior fontanel. Fujimaki T, et al. **Childs Nerv Syst** 1995 Jul; 11(7):424–7 (19 ref.)

[Granulomatous peritonitis after laparoscopic surgery of an ovarian dermoid cyst. Diagnosis, management, prevention, a case report] Huss M, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(4):365–72 (54 ref.) (Eng. Abstr.) **(Fre)**

DERMOLYSINS see **EXFOLIATINS**

DESENSITIZATION, IMMUNOLOGIC

The immunological defects in allergic asthmatic children and the working mechanisms of immunotherapy (hyposensitization) [editorial] Hsieh KH. **Acta Paediatr Sin** 1995 Nov–Dec;36(6):399–400 (25 ref.)

Treatment of autoimmune diseases by oral tolerance to autoantigens. Weiner HL, et al. **Adv Exp Med Biol** 1995; 371B:1217–23 (30 ref.)

The role of immunotherapy in allergic rhinitis/allergic asthma. Creticos PS. **Allergy Proc** 1995 Nov–Dec; 16(6):297–302 (78 ref.)

Safe allergen immunotherapy. The correct allergen, the appropriate patient, the adequate dose. Schoenwetter WF. **Postgrad Med** 1996 Aug;100(2):123–6, 131–5 (17 ref.)

ADVERSE EFFECTS

Adverse reactions associated with skin testing and immunotherapy. Lockey RF. **Allergy Proc** 1995 Nov–Dec; 16(6):293–6 (11 ref.)

METHODS

Venom immunotherapy: tolerance to a 3-day protocol of rush-immunotherapy. Díez Gómez ML, et al. **Allergol Immunopathol (Madr)** 1995 Nov–Dec;23(6):277–84 (40 ref.)

[Hyposensitization in general practice. A strategic concept] Jorde W. **HNO** 1995 Dec;43(12):741–4 (6 ref.) **(Ger)**

DESENSITIZATION, PSYCHOLOGIC

The empirical status of the clinical application of eye movement desensitization and reprocessing. Lohr JM, et al. **J Behav Ther Exp Psychiatry** 1995 Dec;26(4):285–302 (67 ref.)

DESFERRIOXAMINE see **DEFEROXAMINE**

DESICCATION

see related
FREEZE DRYING

METHODS

Control of the dehydration process in production of intermediate-moisture meat products: a review. Chang SF, et al. **Adv Food Nutr Res** 1996;39:71–161 (222 ref.)

DESIGN, EQUIPMENT see **EQUIPMENT DESIGN**

DESIGNER DRUGS

see related
STREET DRUGS

DESIPRAMINE

BLOOD

[Tricyclic antidepressants (imipramine, desipramine, amitriptyline, nortriptyline)] Yasuda K. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:934–7 (20 ref.) **(Jpn)**

DESMETHYLIMIPRAMINE see **DESIPRAMINE**

DESMIN

PHYSIOLOGY

Desmin-related neuromuscular disorders. Goebel HH. **Muscle Nerve** 1995 Nov;18(11):1306–20 (104 ref.)

DESMOID see **FIBROMATOSIS, AGGRESSIVE**

DESMOLASES see **LYASES**

DESMOPRESSIN

ADMINISTRATION & DOSAGE

Desmopressin tablet treatment in nocturnal enuresis. Stenberg A, et al. **Scand J Urol Nephrol Suppl** 1995;173:95–9 (9 ref.)

ADVERSE EFFECTS

Intranasal desmopressin-induced hyponatremia. Williford SL, et al. **Pharmacotherapy** 1996 Jan–Feb;16(1):66–74 (26 ref.)

THERAPEUTIC USE

[Desmopressin in the treatment of hemorrhagic diathesis] Haar D, et al. **Ugeskr Laeger** 1995 Nov 27;157(48):6713–5 (35 ref.) (Eng. Abstr.) **(Dan)**

DESMOSOMES

PHYSIOLOGY

Microfilament organization and wound repair in retinal pigment epithelium. Kalnins VI, et al.

Biochem Cell Biol 1995 Sep-Oct;73(9-10):709-22 (97 ref.)
Desmosomes and cancer. Garrod DR. **Cancer Surv** 1995; 24:97-111 (51 ref.)
Desmosomes and hemidesmosomes: structure and function of molecular components. Green KJ, et al. **FASEB J** 1996 Jun;10(8):871-81 (81 ref.)

DESOGESTREL

Desogestrel, norgestimate, and gestodene: the newer progestins. Kaplan B. **Ann Pharmacother** 1995 Jul-Aug; 29(7-8):736-42 (51 ref.)

PHARMACOLOGY

Desogestrel. Stone SC. **Clin Obstet Gynecol** 1995 Dec; 38(4):821-8 (39 ref.)

DESOXYCORTICOSTERONE

ANALOGS & DERIVATIVES

[11-Deoxycorticosterone (DOC), 18-hydroxy-11-deoxycorticosterone (18-OH-DOC) and 19-nor-deoxycorticosterone (19-nor-DOC)] Kinouchi T, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:452-9 (40 ref.) **(Jpn)**

ANALYSIS

[11-Deoxycorticosterone (DOC), 18-hydroxy-11-deoxycorticosterone (18-OH-DOC) and 19-nor-deoxycorticosterone (19-nor-DOC)] Kinouchi T, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:452-9 (40 ref.) **(Jpn)**

BIOSYNTHESIS

A case of deoxycorticosterone-producing adrenal adenoma. Wada N, et al. **Endocr J** 1995 Oct;42(5):637-42 (29 ref.)

11-DESOXYCORTISONE see **CORTODOXONE**

DESOXYCORTONE see **DESOXYCORTICOSTERONE**

DESOXYPHENOBARBITAL see **PRIMIDONE**

DESOXYRIBONUCLEASES see **DEOXYRIBONUCLEASES**

DESQUAMATING AGENTS see **KERATOLYTIC AGENTS**

DESTOMBES-ROSAI-DORFMAN SYNDROME see **HISTIOCYTOSIS, SINUS**

DETERGENTS

THERAPEUTIC USE

The concept of the acid mantle of the skin: its relevance for the choice of skin cleansers. Schmid MH, et al. **Dermatology** 1995;191(4):276-80 (27 ref.)

DETERMINATION OF HEALTH CARE NEEDS see **HEALTH SERVICES NEEDS AND DEMAND**

DETOXICATION, DRUG, METABOLIC see **METABOLIC DETOXICATION, DRUG**

DEUTERIUM

DIAGNOSTIC USE

[Total body water by D2O dilution] Koda M, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:170-3 (10 ref.) **(Jpn)**

DEUTERONS see **DEUTERIUM**

DEVELOPED COUNTRIES

Rheumatic fever prevention in industrializing countries: problems and approaches. Snitcowsky R. **Pediatrics** 1996 Jun;97(6 Pt 2):996-8 (12 ref.)

DEVELOPING COUNTRIES

Women and AIDS in Zambia: a review of the psychosocial factors implicated in the transmission of HIV. Campbell T, et al. **AIDS Care** 1995;7(3):365-73 (26 ref.)
Preventing opportunistic infections in human immunodeficiency virus-infected persons: implications for the developing world. Kaplan JE, et al. **Am J Trop Med Hyg** 1996 Jul;55(1):1-11 (113 ref.)
Human papillomaviruses, cervical cancer and the developing world. Birley HD. **Ann Trop Med Parasitol** 1995 Oct; 89(5):453-63 (69 ref.)
Hepatitis E: an overview. Mast EE, et al. **Annu Rev Med** 1996;47:257-66 (55 ref.)
Ethical issues in the developing world. Harrison NW, et al. **Br J Urol** 1995 Nov;76 Suppl 2:93-6 (13 ref.)
Ethical issues in renal transplantation in developing countries. Naqvi SA, et al. **Br J Urol** 1995 Nov;76 Suppl 2:97-101 (16 ref.)
Ethical issues in male sterilization in developing countries. Rizvi SA, et al. **Br J Urol** 1995 Nov;76 Suppl 2:103-5 (18 ref.)
Periconceptional folic acid and neural tube defects: public health issues. Pérez-Escamilla R. **Bull Pan Am Health Organ** 1995 Sep;29(3):250-63 (70 ref.)
Strategic issues in preventing cataract blindness in developing countries. Ellwein LB, et al. **Bull World Health Organ** 1995; 73(5):681-90 (21 ref.)
Informed consent issues in international research concerns. Porter JP. **Camb Q Healthc Ethics** 1996 Spring;5(2):237-43 (25 ref.)
Preventing diabetes mellitus; the epidemiological basis. Fernando D. **Ceylon Med J** 1995 Dec;40(4):136-8 (26 ref.)
The third age, the Third World and the third millennium. Diczfalusy E. **Contraception** 1996 Jan;53(1):1-7 (23 ref.)
Human immunodeficiency virus infection and AIDS in east Africa: challenges and possibilities for prevention and control. Mhalu FS, et al. **East Afr Med J** 1996 Jan; 73(1):13-9 (25 ref.)
Urinary tract infection. Gulati S, et al. **Indian Pediatr** 1996 Mar;33(3):211-7 (20 ref.)
Urinary tract infection [editorial] Mehta KP. **Indian Pediatr** 1996 Mar;33(3):173-6 (14 ref.)
Controlling non-insulin-dependent diabetes mellitus in developing countries. Gulliford MC. **Int J Epidemiol** 1995; 24 Suppl 1:S53-9 (69 ref.)
Ergonomics for industrially developing countries: an alternative approach. Rubio CA. **J Hum Ergol (Tokyo)** 1995 Jun;24(1):119-23 (3 ref.)
The role of nutrition in economic development. Martorell R. **Nutr Rev** 1996 Apr;54(4 Pt 2):S66-71 (35 ref.)
Iodine deficiency disorders: a public health challenge in developing countries. Ali O. **Nutrition** 1995 Sep-Oct;11(5 Suppl):517-20 (23 ref.)
A review of dietary and environmental correlates of obesity with emphasis on developing countries. Popkin BM, et al. **Obes Res** 1995 Sep;3 Suppl 2:145s-153s (69 ref.)
Screening for cervical cancer. Guidozzi F. **Obstet Gynecol Surv** 1996 Apr;51(4):247-52 (46 ref.)
Nutrition in overseas aid: the investors' perspective. Lambert J. **Proc Nutr Soc** 1995 Jul;54(2):357-60 (3 ref.)
Prosthetics in the developing world: a review of the literature. Cummings D. **Prosthet Orthot Int** 1996 Apr; 20(1):51-60 (63 ref.)
A review of the consensus conference on appropriate prosthetic technology in developing countries. Day HJ. **Prosthet Orthot Int** 1996 Apr;20(1):15-23 (0 ref.)
Risk assessment related to veterinary biologicals: specific issues in developing nations. Ward DE. **Rev Sci Tech** 1995 Dec;14(4):991-1007 (35 ref.)
Elderly mental health in the developing world. Levkoff SE, et al. **Soc Sci Med** 1995 Oct;41(7):983-1003 (178 ref.)
Vaccinations in the Third World: a consideration of community demand. Nichter M. **Soc Sci Med** 1995 Sep; 41(5):617-32 (96 ref.)
Enhancing coverage and sustainability of vaccination programs: an explanatory framework with special reference to India. Streefland PH. **Soc Sci Med** 1995 Sep;41(5):647-56 (53 ref.)
Women's education and fertility: results from 26 Demographic and Health Surveys. Castro Martin T. **Stud Fam Plann** 1995 Jul-Aug;26(4):187-202 (50 ref.)
Expanding access to emergency contraception in developing countries. Ellertson C, et al. **Stud Fam Plann** 1995 Sep-Oct; 26(5):251-63 (70 ref.)
Sexually transmitted diseases in developing countries. Mabey D. **Trans R Soc Trop Med Hyg** 1996 Mar-Apr;90(2):97-9 (7 ref.)
Improving the quality of care for persons with HIV infection in sub-Saharan Africa. Colebunders R, et al. **Trop Geogr Med** 1995;47(2):78-81 (26 ref.)
Is the lesser growth of African schoolchildren essentially prejudicial to their present and future health? Walker AR, et al. **Trop Geogr Med** 1995;47(4):145-50 (53 ref.)
The development and state of health and safety in the workplace in west Africa: perspectives from Nigeria. Asuzu MC. **West Afr J Med** 1996 Jan-Mar;15(1):36-44 (19 ref.)
[Generic drugs in developing countries] Trouiller P. **Sante** 1996 Jan-Feb;6(1):21-6 (24 ref.) (Eng. Abstr.) **(Fre)**
[The general concepts of development and the principle of sustainable development] Romanov IuA. **Aviakosm Ekolog Med** 1995;29(3):6-16 (44 ref.) (Eng. Abstr.) **(Rus)**
[Abuse of alcohol and central nervous system stimulants. A growing problem in developing countries] Eide AH, et al. **Lakartidningen** 1995 Nov 29;92(48):4569-71 (31 ref.) **(Swe)**

DEVELOPMENTAL BIOLOGY

Transgenic fish in aquaculture and developmental biology. Gong Z, et al. **Curr Top Dev Biol** 1995;30:177-214 (174 ref.)
Resynthesizing evolutionary and developmental biology. Gilbert SF, et al. **Dev Biol** 1996 Feb 1;173(2):357-72 (169 ref.)
On the importance of evolution to developmental psychobiology. Hill WL. **Dev Psychobiol** 1995 Mar; 28(2):117-29 (70 ref.)
The Drosophila Stock Centers and their implications for developmental biology. Rasmuson-Lestander A. **Int J Dev Biol** 1995 Oct;39(5):765-8 (29 ref.)
The new dysmorphology: application of insights from basic developmental biology to the understanding of human birth defects. Epstein CJ. **Proc Natl Acad Sci U S A** 1995 Sep 12;92(19):8566-73 (92 ref.)

DEVELOPMENTAL DELAY DISORDERS see **DEVELOPMENTAL DISABILITIES**

DEVELOPMENTAL DISABILITIES

Psychiatric disorders in pre-schoolers. Kong DS. **Singapore Med J** 1995 Jun;36(3):318-21 (48 ref.)

CHEMICALLY INDUCED

Neuro-behavioral effects of childhood lead exposure. vonKoss Krowchuk H. **Annu Rev Nurs Res** 1995;13:87-114 (108 ref.)
Neurobehavioral effects of developmental methylmercury exposure. Gilbert SG, et al. **Environ Health Perspect** 1995 Sep;103 Suppl 6:135-42 (107 ref.)

CLASSIFICATION

Developmental dyspraxia by any other name: are they all just clumsy children? Missiuna C, et al. **Am J Occup Ther** 1995 Jul-Aug;49(7):619-27 (71 ref.)

DIAGNOSIS

Developmental monitoring in primary care. Goldfarb CE, et al. **Can Fam Physician** 1996 Aug;42:1527-32, 1535-6 (22 ref.)
The role of comorbidity in the differential diagnosis of young children with deviant behavior. Demb HB. **J Dev Behav Pediatr** 1995 Jun;16(3 Suppl):S3-6 (30 ref.)
Developmental testing. Gilbride KE. **Pediatr Rev** 1995 Sep; 16(9):338-45 (25 ref.)

ETIOLOGY

One person's view of iron deficiency, development, and cognitive function [see comments] Beard J. **Am J Clin Nutr** 1995 Oct;62(4):709-10 (21 ref.) Comment in: Am J Clin Nutr 1996 Jul;64(1):120-1.
Prenatally drug-exposed children in out-of-home care: are we looking at the whole picture? Franck EJ. **Child Welfare** 1996 Jan-Feb;75(1):19-34 (30 ref.)
Cerebral palsy: a paradigm for developmental disabilities. Pellegrino L. **Dev Med Child Neurol** 1995 Sep;37(9):834-9 (17 ref.)
Infants with bronchopulmonary dysplasia: a developmental perspective. Mitchell SH. **J Pediatr Nurs** 1996 Jun; 11(3):145-51 (18 ref.)
[Effect of smoking on the fetus and the child during pregnancy] Gueguen C, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(8):853-9 (63 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Genetics of chromosome 11: loci for pediatric and adult malignancies, developmental disorders, and other diseases. Nowak NJ, et al. **Cancer Invest** 1995;13(6):646-59 (78 ref.)
Transcription-factor mutations and disease. Latchman DS. **N Engl J Med** 1996 Jan 4;334(1):28-33 (43 ref.)

PHYSIOPATHOLOGY

[Cognitive evoked potentials in children: normal and abnormal development] Taylor MJ, et al. **Neurophysiol Clin** 1995;25(3):130-45 (110 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

Developmental and behavioral issues in childhood injury prevention. Rivara FP. **J Dev Behav Pediatr** 1995 Oct; 16(5):362-70 (79 ref.)

PSYCHOLOGY

Attachment and risk for psychopathology: the early years. Crittenden PM. **J Dev Behav Pediatr** 1995 Jun;16(3 Suppl):S12-6 (16 ref.)
Hardiness and stress: a critical review. Huang C. **Matern Child Nurs J** 1995 Jul-Sep;23(3):82-9 (36 ref.)
[The development and learning] Evrard P, et al. **Arch Pediatr** 1996;3 Suppl 1:44s-52s (97 ref.) **(Fre)**

REHABILITATION

Motor problems in children with developmental coordination disorder: review of the literature. Willoughby C, et al. **Am J Occup Ther** 1995 Sep;49(8):787-94 (40 ref.)

SURGERY

Surgery for catastrophic localization-related epilepsy in infants. Wyllie E. **Epilepsia** 1996;37 Suppl 1:S22-5 (36 ref.)

DEVELOPMENTAL GENE EXPRESSION REGULATION see **GENE EXPRESSION REGULATION, DEVELOPMENTAL**

DEVIATION, EPISTATIC see **EPISTASIS, GENETIC**

DEVICE APPROVAL

Public citizen opposition to spinal implant fixation. Yuan HA. **J Spinal Disord** 1995 Oct;8(5):413–8 (17 ref.)

LEGISLATION & JURISPRUDENCE

The evolution of FDA policy on silicone breast implants: a case study of politics, bureaucracy, and business in the process of decision-making. Palley HA. **Int J Health Serv** 1995;25(4):573–91 (61 ref.)

A surgeon's perspective of medical device regulation. Brantigan JW. **J Spinal Disord** 1995 Oct;8(5):396–412 (74 ref.)

STANDARDS

Standards of evidence for the safety and effectiveness of critical care monitoring devices and related interventions. Coalition for Critical Care Excellence: Consensus Conference on Physiologic Monitoring Devices. **Crit Care Med** 1995 Oct;23(10):1756–63 (12 ref.)

DEVICE APPROVAL PROCESS see **DEVICE APPROVAL**

DEVICE DESIGN see **EQUIPMENT DESIGN**

DEVICE SAFETY see **EQUIPMENT SAFETY**

DEVICES see **EQUIPMENT AND SUPPLIES**

DEXAMETHASONE

ADMINISTRATION & DOSAGE

[Cicatricial pemphigoid--a therapeutic problem] Axt M, et al. **Hautarzt** 1995 Sep;46(9):620–7 (32 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

[Hypertrophic cardiomyopathy in a low-birth-weight newborn treated with dexamethasone] Villa Alcázar M, et al. **An Esp Pediatr** 1996 Apr;44(4):393–4 (20 ref.) **(Spa)**

THERAPEUTIC USE

Dexamethasone and the prevention of neonatal hypoxic-ischemic brain damage. Tuor UI. **Ann N Y Acad Sci** 1995 Sep 15;765:179–95; discussion 196–7 (97 ref.)

Possible interaction involving phenytoin, dexamethasone, and antineoplastic agents: a case report and review. Gattis WA, et al. **Ann Pharmacother** 1996 May;30(5):520–6 (20 ref.)

Adjunctive dexamethasone therapy for pediatric bacterial meningitis. Bonadio WA. **J Emerg Med** 1996 Mar-Apr; 14(2):165–72 (40 ref.)

Dexamethasone-suppressible hyperaldosteronism: clinical, biochemical and genetic relations. Connell JM, et al. **J Hum Hypertens** 1995 Jun;9(6):505–9 (19 ref.)

DEXPROPRANOLOL see **PROPRANOLOL**

DEXRAZOXANE see **RAZOXANE**

DEXTRANS

PHARMACOLOGY

[Radiation-protective action of microbial substances] Andrushchenko VN, et al. **Radiats Biol Radioecol** 1996 Mar-Apr;36(2):195–208 (95 ref.) (Eng. Abstr.) **(Rus)**

DEXTROAMPHETAMINE

THERAPEUTIC USE

Neuroendocrine responses to methylphenidate and d-amphetamine: applications to attention-deficit disorder. Lurie S, et al. **J Neuropsychiatry Clin Neurosci** 1991 Winter; 3(1):41–50 (70 ref.)

DEXTROMETHORPHAN

PHARMACOLOGY

Discriminative stimulus properties of dextromethorphan in rats. Gavend M, et al. **Biomed Pharmacother** 1995; 49(10):456–64 (59 ref.)

DEXTROSE see **GLUCOSE**

DHBV see **HEPATITIS B VIRUS, DUCK**

DHP ETHER see **DIHEMATOPORPHYRIN ETHER**

DI GUGLIELMO'S DISEASE see **LEUKEMIA, ERYTHROBLASTIC, ACUTE**

DI-N-ACETYLCHITOBIOSYL BETA-N-ACETYLGLUCOSAMINIDASE see **MANNOSYL-GLYCOPROTEIN ENDO-BETA-N-ACETYLGLUCOSAMINIDASE**

DIABETES, AUTOIMMUNE see **DIABETES MELLITUS, INSULIN-DEPENDENT**

DIABETES, BRONZE see **HEMOCHROMATOSIS**

DIABETES, GESTATIONAL

see related
PREGNANCY IN DIABETES

Diagnosis and management of gestational diabetes. Weller KA. **Am Fam Physician** 1996 May 1;53(6):2053–7; 2061–2 (21 ref.)

Role of fetal surveillance in diabetic pregnancies. Fuentes A, et al. **J Matern Fetal Med** 1996 Mar-Apr;5(2):85–8 (12 ref.)

The infant of the diabetic mother. Tyrala EE. **Obstet Gynecol Clin North Am** 1996 Mar;23(1):221–41 (89 ref.)

[Diabetes and pregnancy] Omori Y. **Nippon Naika Gakkai Zasshi** 1996 Mar 10;85(3):379–83 (8 ref.) **(Jpn)**

DIAGNOSIS

Glucose metabolism assessment in pregnancy. Garner PR. **Clin Biochem** 1995 Oct;28(5):499–502 (18 ref.)

[Gestational diabetes] Seydoux J, et al. **Rev Med Suisse Romande** 1995 Sep;115(9):647–52 (38 ref.) **(Fre)**

[Diabetes mellitus during pregnancy] Omori Y. **Nippon Naika Gakkai Zasshi** 1996 Apr 10;85(4):536–40 (6 ref.) **(Jpn)**

DRUG THERAPY

Oral hypoglycemic agents as an alternative therapy for gestational diabetes [editorial; comment] Hod M, et al. **Isr J Med Sci** 1995 Oct;31(10):640–3 (47 ref.) Comment on: Isr J Med Sci 1995 Oct;31(10):623–5.

EPIDEMIOLOGY

Is there a seasonal variation in the incidence of gestational diabetes? Moses R, et al. **Diabet Med** 1995 Jul;12(7):563–5 (10 ref.)

ETIOLOGY

Vitamin and mineral deficiencies which may predispose to glucose intolerance of pregnancy. Jovanovic-Peterson L, et al. **J Am Coll Nutr** 1996 Feb;15(1):14–20 (64 ref.)

GENETICS

The genetics and pathophysiology of type II and gestational diabetes. Csorba TR, et al. **Crit Rev Clin Lab Sci** 1995; 32(5–6):509–50 (246 ref.)

METABOLISM

Aspects of metabolism in normal and gestational diabetic pregnancy. Johnston DG, et al. **Biochem Soc Trans** 1995 Aug;23(3):512–6 (20 ref.)

Fuel metabolism in pregnancy and in gestational diabetes mellitus. Boden G. **Obstet Gynecol Clin North Am** 1996 Mar;23(1):1–10 (53 ref.)

Fuel metabolism in deviant fetal growth in offspring of diabetic women. Hod M, et al. **Obstet Gynecol Clin North Am** 1996 Mar;23(1):259–77 (105 ref.)

PHYSIOPATHOLOGY

The genetics and pathophysiology of type II and gestational diabetes. Csorba TR, et al. **Crit Rev Clin Lab Sci** 1995; 32(5–6):509–50 (246 ref.)

[Gestational diabetes and adult type of diabetes with relative insulin resistance] Forsén T, et al. **Duodecim** 1994; 110(8):808–14 (30 ref.) **(Fin)**

PREVENTION & CONTROL

Diabetes. Oats JN. **Baillieres Clin Obstet Gynaecol** 1995 Sep; 9(3):481–95 (67 ref.)

Screening and testing for gestational diabetes mellitus. Coustan DR. **Obstet Gynecol Clin North Am** 1996 Mar; 23(1):125–36 (51 ref.)

THERAPY

Management of gestational diabetes mellitus. Langer O, et al. **Obstet Gynecol Clin North Am** 1996 Mar;23(1):137–59 (89 ref.)

Gestational diabetes: ensuring a successful outcome. Davidson JA, et al. **Postgrad Med** 1996 Mar;99(3):165–72 (14 ref.)

[Gestational diabetes] Seydoux J, et al. **Rev Med Suisse Romande** 1995 Sep;115(9):647–52 (38 ref.) **(Fre)**

[Diabetes mellitus during pregnancy] Omori Y. **Nippon Naika Gakkai Zasshi** 1996 Apr 10;85(4):536–40 (6 ref.) **(Jpn)**

URINE

Microalbuminuria: prognostic and therapeutic implications in diabetic and hypertensive pregnancy. Bar J, et al. **Diabet Med** 1995 Aug;12(8):649–56 (110 ref.)

DIABETES INSIPIDUS

Diabetes insipidus. Robertson GL. **Endocrinol Metab Clin North Am** 1995 Sep;24(3):549–72 (61 ref.)

CHEMICALLY INDUCED

Nephrogenic diabetes insipidus and renal tubular acidosis secondary to foscarnet therapy. Navarro JF, et al. **Am J Kidney Dis** 1996 Mar;27(3):431–4 (16 ref.)

CONGENITAL

[Congenital diabetes insipidus. Recent advances in molecular genetics] Vantyghem MC, et al. **Presse Med** 1996 Feb 24; 25(7):299–303 (30 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Differential diagnosis and pathophysiology of diabetes insipidus. Valtin H. **Nippon Jinzo Gakkai Shi** 1995 Nov; 37(11):601–9 (6 ref.)

[Magnetic resonance in familial central diabetes insipidus: a family study] Bastida Eizaguirre M, et al. **An Esp Pediatr** 1996 Jun;44(6):537–9 (16 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

Lyphomatoid granulomatosis causing central diabetes insipidus: case report and review of the literature. Bushunow PW, et al. **Cancer Invest** 1996;14(2):112–19 (42 ref.)

[Diabetes insipidus and panhypopituitarism in an 8-year-old girl due to probable lymphocytic hypophysitis] Bastida Eizaguirre M, et al. **An Esp Pediatr** 1996 Apr;44(4):402–4 (20 ref.) **(Spa)**

GENETICS

Diabetes insipidus. Hendy GN, et al. **Baillieres Clin Endocrinol Metab** 1995 Jul;9(3):509–24 (78 ref.)

DIABETES INSIPIDUS, NEPHROGENIC

CHEMICALLY INDUCED

Nephrogenic diabetes insipidus induced by lobenzarit disodium treatment in patients with rheumatoid arthritis. Sakane N, et al. **Intern Med** 1996 Feb;35(2):119–22 (17 ref.)

Lithium-induced diabetes insipidus in a surgical patient: report of a case and review of the literature. Gray EJ, et al. **J Oral Maxillofac Surg** 1996 Jul;54(7):909–12 (20 ref.)

DIABETES MELLITUS

see related
DIABETIC DIET
GASTROPARESIS
GLUCOSE INTOLERANCE
GLYCOSYLATION END PRODUCTS, ADVANCED
SCLEREDEMA ADULTORUM

The diabetic patient: a challenge or just routine? Ralley FE. **Can J Anaesth** 1996 May;43(5 Pt 2):R14–23 (18 ref.) **(Eng, Fre)**

Hormone replacement therapy and diabetes mellitus. Dunne FP, et al. **Clin Endocrinol (Oxf)** 1996 Jun;44(6):615–20 (48 ref.)

Creation of a District Diabetes Register using the DIALOG system. Vaughan NJ, et al. **Diabet Med** 1996 Feb; 13(2):175–81 (12 ref.)

DIALOG: co-ordination of the annual review process through a District Diabetes Register linked to the FHSA database. Vaughan NJ, et al. **Diabet Med** 1996 Feb; 13(2):182–8 (11 ref.)

A clinically useful diabetes electronic medical record: lessons from the past; pointers toward the future. Gorman C, et al. **Eur J Endocrinol** 1996 Jan;134(1):31–42 (39 ref.)

Perioperative management of the diabetic patient. Peters A, et al. **Exp Clin Endocrinol Diabetes** 1995;103(4):213–8 (27 ref.)

Diabetes mellitus: its impact on women. Wishner KL. **Int J Fertil Menopausal Stud** 1996 Mar-Apr;41(2):177–86 (99 ref.)

Contraception in diabetic women. Kjos SL. **Obstet Gynecol Clin North Am** 1996 Mar;23(1):243–58 (64 ref.)

What next in the treatment of diabetes? Steel J. **Practitioner** 1996 Feb;240(1559):116–9 (5 ref.)

[Progresses in diabetology in China, 1995] Chen J. **Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):722–3 (0 ref.) **(Chi)**

[Diabetes and anesthesia: perioperative management of the diabetic patient] Brogard JM, et al. **Ann Fr Anesth Reanim** 1995;14(6):523–31 (28 ref.) **(Fre)**

BLOOD

Dyslipoproteinemias in diabetes. Steiner G. **Clin Invest Med** 1995 Aug;18(4):282–7 (23 ref.)

Cytokines, modified lipoproteins, and arteriosclerosis in diabetes. Lopes-Virella MF, et al. **Diabetes** 1996 Jul;45

Suppl 3:S40–4 (49 ref.)
Tests of glycemia in diabetes. Goldstein DE, et al. **Diabetes Care** 1995 Jun;18(6):896–909 (144 ref.)
Why use the oral glucose tolerance test? Stolk RP, et al. **Diabetes Care** 1995 Jul;18(7):1045–9 (40 ref.)
[Respective value of glycated hemoglobin and fructosamine assays in the care of diabetes mellitus] Bernard M, et al. **Ann Biol Clin (Paris)** 1995;53(6):321–7 (52 ref.) (Eng. Abstr.) **(Fre)**
[Quality of blood sugar control and late complications of diabetes] Sélam JL. **Rev Med Suisse Romande** 1995 Sep; 115(9):653–7 (25 ref.) **(Fre)**
[Heat shock proteins in diabetes mellitus] Parlapiano C, et al. **Riv Eur Sci Med Farmacol** 1995 Jan–Feb;17(1):27–33 (10 ref.) (Eng. Abstr.) **(Ita)**

CHEMICALLY INDUCED

Carbohydrate tolerance in patients with tropical ataxic neuropathy—A human model of chronic cyanide intoxication. Famuyiwa OO, et al. **Afr J Med Med Sci** 1995 Jun;24(2):151–7 (28 ref.)
Potential role of environmental genotoxic agents in diabetes mellitus and neurodegenerative diseases. Eizirik DL, et al. **Biochem Pharmacol** 1996 Jun 28;51(12):1585–91 (92 ref.)
Diabetes mellitus associated with pentamidine isethionate in diffuse cutaneous leishmaniasis. Costa JM, et al. **Rev Soc Bras Med Trop** 1995 Oct–Dec;28(4):405–7 (13 ref.)

CLASSIFICATION

Consensus statement from the International Workshop on Types of Diabetes Peculiar to the Tropics, 17–19 October 1995, in Cuttack, India. **Acta Diabetol** 1996 Mar;33(1):62–4 (0 ref.)
Maternally inherited diabetes and deafness: a new diabetes subtype. Maassen JA, et al. **Diabetologia** 1996 Apr; 39(4):375–82 (53 ref.)

COMPLICATIONS

Tight glycaemic control prevents diabetic complications [editorial] Pirart J. **Acta Clin Belg** 1995;50(6):321–5 (31 ref.)
Hypertension in patients with diabetes mellitus. Skyler JS, et al. **Am J Hypertens** 1995 Dec;8(12 Pt 2):100s–105s (60 ref.)
Review: diabetic ketoacidosis and hyperglycemic hyperosmolar nonketotic syndrome. Umpierrez GE, et al. **Am J Med Sci** 1996 May;311(5):225–33 (75 ref.)
Occupational therapy and the person with diabetes and vision impairment. Cate Y, et al. **Am J Occup Ther** 1995 Oct; 49(9):905–11 (31 ref.)
Diabetic and hypertensive heart disease. Grossman E, et al. **Ann Intern Med** 1996 Aug 15;125(4):304–10 (100 ref.)
Cardiovascular complications of diabetes mellitus: what we know and what we need to know about their prevention. Savage PJ. **Ann Intern Med** 1996 Jan 1;124(1 Pt 2):123–6 (29 ref.)
Hypomagnesemia and diabetes mellitus. A review of clinical implications. Tosiello L. **Arch Intern Med** 1996 Jun 10; 156(11):1143–8 (58 ref.)
New approaches for treatment in diabetes: aldose reductase inhibitors. Hotta N. **Biomed Pharmacother** 1995; 49(5):232–43 (168 ref.)
Diabetes mellitus and coronary heart disease in the elderly. Vokonas PS, et al. **Clin Geriatr Med** 1996 Feb;12(1):69–78 (56 ref.)
The pathological implications of protein glycation. Brownlee M. **Clin Invest Med** 1995 Aug;18(4):275–81 (22 ref.)
Glycation, oxidation, and glycoxidation reactions in the development of diabetic complications. Lyons TJ. **Contrib Nephrol** 1995;112:1–10 (42 ref.)
Hypertensive heart disease and the diabetic patient. Grossman E, et al. **Curr Opin Cardiol** 1995 Sep;10(5):458–65 (92 ref.)
Diabetic complications and the surgeon. Adams MB, et al. **Curr Probl Surg** 1996 Mar;33(3):223–98 (198 ref.)
Risk factors and their identification second part: study designs for identification of risk factors. Balkau B, et al. **Diabete Metab** 1995 Jun;21(3):225–31 (17 ref.)
Diabetes and haemochromatosis: current concepts, management and prevention. Yaouanq JM. **Diabete Metab** 1995 Dec;21(5):319–29 (71 ref.)
The role of oxidative stress in neuropathy and other diabetic complications. Van Dam PS, et al. **Diabetes Metab Rev** 1995 Oct;11(3):181–92 (72 ref.)
Diabetic gastroparesis. Farrell FJ, et al. **Dig Dis** 1995 Sep–Oct;13(5):291–300 (83 ref.)
Epidemiology of gastrointestinal complications of diabetes mellitus. Locke GR 3rd. **Eur J Gastroenterol Hepatol** 1995 Aug;7(8):711–6 (31 ref.)
Gastroparesis and dyspepsia in patients with diabetes mellitus. Mearin F, et al. **Eur J Gastroenterol Hepatol** 1995 Aug; 7(8):717–23 (42 ref.)
Diarrhoea in patients with diabetes mellitus. von der Ohe MR. **Eur J Gastroenterol Hepatol** 1995 Aug;7(8):730–6 (61 ref.)
Incontinence and anorectal dysfunction in patients with diabetes mellitus. Wald A. **Eur J Gastroenterol Hepatol** 1995 Aug;7(8):737–9 (16 ref.)
Taking control of diabetes. Jaspan JB. **Hosp Pract (Off Ed)** 1995 Oct 15;30(10):55–62 (9 ref.)
Diabetes mellitus and associated hypertension, vascular disease, and nephropathy. An update. Sowers JR, et al. **Hypertension** 1995 Dec;26(6 Pt 1):869–79 (59 ref.)
Liver disturbances in obesity and diabetes mellitus. Van Steenbergen W, et al. **Int J Obes Relat Metab Disord** 1995 Sep;19 Suppl 3:S27–36 (80 ref.)
Diabetic dyslipidemia: effects of diabetes control, diet and drug therapy. Bar-On H. **Isr J Med Sci** 1996 Jun; 32(6):397–406 (105 ref.)
Diabetic gastroparesis: a review. Nilsson PH. **J Diabetes Complications** 1996 Mar–Apr;10(2):113–22 (96 ref.)
Simultaneous, multiple cranial neuropathies in diabetes mellitus. Eshbaugh CG, et al. **J Neuroophthalmol** 1995 Dec; 15(4):219–24 (23 ref.)
Diabetes and periodontal diseases. **J Periodontol** 1996 Feb; 67(2):166–76 (127 ref.)
Pathophysiology and treatment of diabetic diarrhea. Nakamura T, et al. **J Smooth Muscle Res** 1996 Apr; 32(2):27–42 (100 ref.)
A practical guideline for management of hypertension in patients with diabetes. Fatourechi V, et al. **Mayo Clin Proc** 1996 Jan;71(1):53–8 (37 ref.)
Management choices in diabetic end-stage renal disease. Friedman EA. **Nephrol Dial Transplant** 1995;10 Suppl 7:61–9 (73 ref.)
Hypertension, cardiovascular complications and survival in diabetic patients on maintenance haemodialysis. Ritz E, et al. **Nephrol Dial Transplant** 1995;10 Suppl 7:43–6 (9 ref.)
Current considerations in patients with coexistent diabetes and hypertension. Wood MH. **Nurse Pract** 1996 Apr; 21(4):19–20, 27–31 (24 ref.)
Diabetes complications: why is glucose potentially toxic? [see comments] Porte D Jr, et al. **Science** 1996 May 3; 272(5262):699–700 (12 ref.) Comment in: Science 1996 May 3;272(5262):728–31.
Diabetic gastroparesis. Malagelada JR. **Semin Gastrointest Dis** 1995 Oct;6(4):181–6 (69 ref.)
Diabetic diarrhea. Saslow SB, et al. **Semin Gastrointest Dis** 1995 Oct;6(4):187–93 (69 ref.)
Diabetic eye disease: a primary care perspective. Frank KJ, et al. **South Med J** 1996 May;89(5):463–70 (25 ref.)
[Diabetic dyslipidemia and its treatment] Urbánek R, et al. **Vnitr Lek** 1996 Jan;42(1):26–30 (27 ref.) (Eng. Abstr.) **(Cze)**
[Arterial hypertension and diabetes. Members of the Board of Directors and Scientific Directors of ALFEDIAM] Bauduceau B, et al. **Diabetes Metab** 1996 Feb;22(1):64–76 (65 ref.) **(Fre)**
[The pancreatic heart] Cananau S, et al. **Rev Med Suisse Romande** 1995 Sep;115(9):693–705 (0 ref.) **(Fre)**
[Quality of blood sugar control and late complications of diabetes] Sélam JL. **Rev Med Suisse Romande** 1995 Sep; 115(9):653–7 (25 ref.) **(Fre)**
[Diabetes and infection] Tajeddin M, et al. **Rev Med Suisse Romande** 1995 Sep;115(9):659–65 (53 ref.) **(Fre)**
[Susceptibility to infections in diabetes—effects on metabolism] Perschel WT, et al. **Immun Infekt** 1995 Dec; 23(6):196–200 (34 ref.) (Eng. Abstr.) **(Ger)**
[Infections in diabetes mellitus] Schubert S, et al. **Immun Infekt** 1995 Dec;23(6):200–4 (57 ref.) (Eng. Abstr.) **(Ger)**
[Cigarette smoking in diabetes] Gefel D, et al. **Harefuah** 1996 Jan 1;130(1):37–40 (40 ref.) **(Heb)**
[Therapy of diabetes mellitus associated with hypertension] Katayama H. **Nippon Naika Gakkai Zasshi** 1996 Apr 10; 85(4):514–8 (10 ref.) **(Jpn)**
[Therapy of diabetes mellitus associated with liver disease] Totani E, et al. **Nippon Naika Gakkai Zasshi** 1996 Apr 10;85(4):525–9 (6 ref.) **(Jpn)**
[Therapy of diabetes mellitus associated with hyperlipidemia] Yamada N. **Nippon Naika Gakkai Zasshi** 1996 Apr 10; 85(4):519–24 (4 ref.) **(Jpn)**
[Fatty liver and diabetes mellitus] Kobayashi K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):21–3 (12 ref.) **(Jpn)**
[Diabetes mellitus and stroke] Man'kovskiĭ BN. **Lik Sprava** 1995 Jul–Aug;(7–8):78–83 (55 ref.) **(Rus)**
[Intraocular hemorrhage of diabetic etiology: current notions on pathogenesis and enzyme therapy] Evgrafov VIu, et al. **Vestn Oftalmol** 1995 Oct–Dec;111(4):35–7 (43 ref.) **(Rus)**
[State of microcirculation in the bulbar conjunctiva in retinal thrombosis of patients with hypertension and diabetes mellitus] Polunin GS, et al. **Vestn Oftalmol** 1996 Jan–Mar; 112(1):51–3 (60 ref.) **(Rus)**
[Spontaneous bladder perforation secondary to bacterial cystitis. Cause of acute abdomen in diabetic elderly] Rodriguez Rodriguez A, et al. **Actas Urol Esp** 1995 May; 19(5):393–7 (14 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Glucose monitoring as a guide to diabetes management. Critical subject review. Koch B. **Can Fam Physician** 1996 Jun;42:1142–6, 1149–52 (65 ref.)
An alternative approach to the diagnosis of diabetes with a review of the literature. Davidson MB, et al. **Diabetes Care** 1995 Jul;18(7):1065–71 (49 ref.)
Why use the oral glucose tolerance test? Stolk RP, et al. **Diabetes Care** 1995 Jul;18(7):1045–9 (40 ref.)
[Recent progress in diagnoses of diabetes and its complications] Matsuyama T. **Rinsho Byori** 1995 Dec; 43(12):1235–40 (16 ref.) (Eng. Abstr.) **(Jpn)**

DIET THERAPY

Diet and diabetes in the elderly. Fonseca V, et al. **Clin Geriatr Med** 1995 Nov;11(4):613–24 (53 ref.)
Dietary carbohydrates and glucose metabolism in diabetic patients. Parillo M, et al. **Diabete Metab** 1995 Dec; 21(6):391–401 (67 ref.)
Dietary fibre in the treatment of metabolic diseases. Rivellese AA, et al. **Eur J Clin Nutr** 1995 Oct;49 Suppl 3:S110–2 (12 ref.)

DRUG THERAPY

Diabetes and hypertension. Smolar EN. **Compr Ther** 1995 Oct;21(10):597–601 (25 ref.)
Management of hyperlipidemia in diabetes. Vinik AI, et al. **Compr Ther** 1995 Oct;21(10):602–9 (50 ref.)
The IGF system in metabolism regulation. Binoux M. **Diabete Metab** 1995 Dec;21(5):330–7 (101 ref.)
Beta-agonists as antiobesity, antidiabetic and nutrient partitioning agents. Yen TT. **Obes Res** 1995 Nov;3 Suppl 4:531S–536S (57 ref.)
[Acarbose, a glucosidase inhibitor: a new therapeutic principle in diabetes mellitus] Hermansen K, et al. **Ugeskr Laeger** 1996 Apr 29;158(18):2564–8 (33 ref.) **(Dan)**
[Beta blockers and diuretics: therapeutic drugs of first choice in diabetes mellitus and hypertension] Sawicki PT. **Wien Klin Wochenschr** 1995;107(21):629–39 (98 ref.) (Eng. Abstr.) **(Ger)**
[alpha-Glucosidase inhibitors in the therapy of diabetes mellitus] Giorgino R, et al. **Ann Ital Med Int** 1995 Oct;10 Suppl:61S–65S (45 ref.) (Eng. Abstr.) **(Ita)**
[Insulin analogs] Scaglione L, et al. **Minerva Endocrinol** 1996 Mar;21(1):27–36 (31 ref.) (Eng. Abstr.) **(Ita)**
[Pathophysiologic and clinical aspects of usefulness regarding angiotensin converting enzyme inhibitors in diabetes] Jasik M. **Pol Arch Med Wewn** 1996 Mar;95(3):261–9 (29 ref.) **(Pol)**

ECONOMICS

Diabetes in minorities: reflections on the medical dilemma and the healthcare crisis. Gavin JR 3rd. **Trans Am Clin Climatol Assoc** 1995;107:213–23; discussion 223–5 (20 ref.)

EPIDEMIOLOGY

Risk factors and their identification second part: study designs for identification of risk factors. Balkau B, et al. **Diabete Metab** 1995 Jun;21(3):225–31 (17 ref.)
Diabetes in minorities: reflections on the medical dilemma and the healthcare crisis. Gavin JR 3rd. **Trans Am Clin Climatol Assoc** 1995;107:213–23; discussion 223–5 (20 ref.)
[Obesity as a risk factor of diabetes mellitus (prospective study)] Amemiya T. **Nippon Rinsho** 1995 Jun;53 Suppl:265–70 (19 ref.) **(Jpn)**

ETIOLOGY

Amyloid fibril toxicity in Alzheimer's disease and diabetes. Lorenzo A, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:89–95 (12 ref.)
[Diabetes secondary to endocrine diseases] Löffler J, et al. **Rev Med Suisse Romande** 1995 Sep;115(9):721–6 (38 ref.) **(Fre)**
[Diabetes mellitus with endocrine diseases—the physiopathology , diagnosis and therapy] Okuda Y, et al. **Nippon Naika Gakkai Zasshi** 1996 Apr 10;85(4):530–5 (5 ref.) **(Jpn)**

GENETICS

Glucokinase mutations, insulin secretion, and diabetes mellitus. Bell GI, et al. **Annu Rev Physiol** 1996;58:171–86 (63 ref.)
Molecular genetics of diabetes mellitus. Aitman TJ, et al. **Baillieres Clin Endocrinol Metab** 1995 Jul;9(3):631–56 (146 ref.)
Maternally inherited diabetes and deafness: a new diabetes subtype. Maassen JA, et al. **Diabetologia** 1996 Apr; 39(4):375–82 (53 ref.)
[Mitochondrial gene and diabetes] Xiang K, et al. **Chung Hua Nei Ko Tsa Chih** 1995 Sep;34(9):638–40 (20 ref.) **(Chi)**
[Mitochondria gene mutation and diabetes] Kadowaki T. **Nippon Naika Gakkai Zasshi** 1996 Apr 10;85(4):573–7 (5 ref.) **(Jpn)**

IMMUNOLOGY

Cytokines, modified lipoproteins, and arteriosclerosis in diabetes. Lopes-Virella MF, et al. **Diabetes** 1996 Jul;45 Suppl 3:S40–4 (49 ref.)

METABOLISM

Glucokinase mutations, insulin secretion, and diabetes mellitus. Bell GI, et al. **Annu Rev Physiol** 1996;58:171–86 (63 ref.)
Glucose regulation and cognitive functions: relation to Alzheimer's disease and diabetes. Messier C, et al. **Behav Brain Res** 1996 Feb;75(1–2):1–11 (127 ref.)

The aetiology of diabetic neuropathy: the combined roles of metabolic and vascular defects. Stevens MJ, et al. **Diabet Med** 1995 Jul;12(7):566–79 (187 ref.)
Banting Lecture 1995. A lesson in metabolic regulation inspired by the glucokinase glucose sensor paradigm. Matschinsky FM. **Diabetes** 1996 Feb;45(2):223–41 (86 ref.)
The mechanism of collagen cross-linking in diabetes: a puzzle nearing resolution. Monnier VM, et al. **Diabetes** 1996 Jul; 45 Suppl 3:S67–72 (106 ref.)
Nuclear magnetic resonance studies of muscle and applications to exercise and diabetes. Shulman RG, et al. **Diabetes** 1996 Jan;45 Suppl 1:S93–8 (20 ref.)
[Long-term complications in diabetes mellitus: role of irreversible glycosylation products] Treskes M, et al. **Ned Tijdschr Geneeskd** 1996 Jun 22;140(25):1299–303 (52 ref.) **(Dut)**
[Insulin, diabetes and cholesterol metabolism] Monnier L, et al. **C R Seances Soc Biol Fil** 1995;189(5):919–31 (27 ref.) (Eng. Abstr.) **(Fre)**
[Effects of glycation process on the macromolecular structure of the glomerular basement membranes and on the glomerular functions in aging and diabetes mellitus] Sternberg M, et al. **C R Seances Soc Biol Fil** 1995; 189(6):967–85 (47 ref.) (Eng. Abstr.) **(Fre)**
[Alcohol and diabetes] Georgescu M, et al. **Rev Med Suisse Romande** 1995 Sep;115(9):707–11 (17 ref.) **(Fre)**
[Susceptibility to infections in diabetes—effects on metabolism] Perschel WT, et al. **Immun Infekt** 1995 Dec; 23(6):196–200 (34 ref.) (Eng. Abstr.) **(Ger)**
[Lipid metabolism and new dietetic recommendations in diabetes mellitus] Sanz París A, et al. **An Med Interna** 1996 Mar;13(3):136–45 (78 ref.) (Eng. Abstr.) **(Spa)**

PATHOLOGY

Diabetic macroangiopathy and atherosclerosis. Andresen JL, et al. **Diabetes** 1996 Jul;45 Suppl 3:S91–4 (39 ref.)

PHYSIOPATHOLOGY

Arterial compliance in hypertension and diabetes mellitus. McVeigh GE. **Am J Nephrol** 1996;16(3):217–22 (52 ref.)
Emergency management of hypoglycemia and hyperglycemia. Bavitz JB. **Dent Clin North Am** 1995 Jul; 39(3):587–94 (13 ref.)
The pathogenesis of diabetic foot problems: an overview. Boulton AJ. **Diabet Med** 1996;13 Suppl 1:S12–6 (28 ref.)
Gastric emptying in diabetes. Kong MF, et al. **Diabet Med** 1996 Feb;13(2):112–9 (65 ref.)
The aetiology of diabetic neuropathy: the combined roles of metabolic and vascular defects. Stevens MJ, et al. **Diabet Med** 1995 Jul;12(7):566–79 (187 ref.)
Biochemical and molecular mechanisms in the development of diabetic vascular complications. King GL, et al. **Diabetes** 1996 Jul;45 Suppl 3:S105–8 (26 ref.)
Mechanism on disorders of coagulation and fibrinolysis in diabetes. Matsuda T, et al. **Diabetes** 1996 Jul;45 Suppl 3:S109–10 (21 ref.)
Nutrition principles and diabetes. A role for "lente carbohydrate"? Jenkins DJ, et al. **Diabetes Care** 1995 Nov; 18(11):1491–8 (78 ref.)
Glucagon and its family revisited. Lefèbvre PJ. **Diabetes Care** 1995 May;18(5):715–30 (186 ref.)
Diabetes complications: the renal-retinal link. An epidemiological perspective. Lloyd CE, et al. **Diabetes Care** 1995 Jul;18(7):1034–6 (19 ref.)
Insulin therapy and GH-IGF-I axis disorders in diabetes: impact of glycaemic control and hepatic insulinization. Hanaire-Broutin H, et al. **Diabetes Metab** 1996 Jul; 22(4):245–50 (42 ref.)
Electrophysiological alterations of the central nervous system in diabetes mellitus. Di Mario U, et al. **Diabetes Metab Rev** 1995 Oct;11(3):259–77 (153 ref.)
Potential mechanisms promoting restenosis in diabetic patients. Aronson D, et al. **J Am Coll Cardiol** 1996 Mar 1;27(3):528–35 (103 ref.)
The pathobiology of diabetes mellitus: implications for surgeons. Kamal K, et al. **J Am Coll Surg** 1996 Sep; 183(3):271–89 (262 ref.)
The role of vanadium in the management of diabetes. Brichard SM, et al. **Trends Pharmacol Sci** 1995 Aug; 16(8):265–70 (60 ref.)
[Pathophysiologic mechanisms of early changes in renal hemodynamics in diabetes mellitus] Komers R. **Cas Lek Cesk** 1996 Mar 6;135(5):135–9 (68 ref.) (Eng. Abstr.) **(Cze)**

PREVENTION & CONTROL

Screening for diabetes in asymptomatic individuals. New Zealand Society for the Study of Diabetes. **N Z Med J** 1995 Nov 10;108(1011):464–5 (8 ref.)

PSYCHOLOGY

[Health education as a method of treating psycho-emotional disorders in patients with diabetes mellitus] Tatoń J, et al. **Pol Tyg Lek** 1996 Jan;51(1–5):46–9 (38 ref.) **(Pol)**

REHABILITATION

An integrated behavioral medicine approach to improving care of patients with diabetes mellitus. Jenkins CD. **Behav Med** 1995 Summer;21(2):53–65; discussion 66–8 (19 ref.)
Education and the diabetic foot. Edmonds ME, et al. **Diabet Med** 1996;13 Suppl 1:S61–4 (25 ref.)
Diabetes self-management education. Clement S. **Diabetes Care** 1995 Aug;18(8):1204–14 (114 ref.)

SURGERY

Pancreas transplantation for diabetes mellitus. Pirsch JD, et al. **Am J Kidney Dis** 1996 Mar;27(3):444–50 (56 ref.)
Growth factors and comprehensive surgical care of diabetic wounds. Knighton DR, et al. **Curr Opin Gen Surg** 1993; :32–9 (42 ref.)
Diabetic complications and the surgeon. Adams MB, et al. **Curr Probl Surg** 1996 Mar;33(3):223–98 (198 ref.)

THERAPY

The promise of computerized feedback systems for diabetes care. McDonald CJ, et al. **Ann Intern Med** 1996 Jan 1;124(1 Pt 2):170–4 (37 ref.)
Diabetes in the elderly: studies dispel common misconceptions. Mooradian A. **Cleve Clin J Med** 1996 Jan–Feb;63(1):5–7 (11 ref.)
Prevention of macrovascular disease: absolute proof or absolute risk? [editorial] [see comments] Durrington PN. **Diabet Med** 1995 Jul;12(7):561–2 (12 ref.) Comment in: Diabet Med 1996 Mar;13(3):284–5.
Pre-conception care of diabetes, congenital malformations, and spontaneous abortions. Kitzmiller JL, et al. **Diabetes Care** 1996 May;19(5):514–41 (324 ref.)
Taking control of diabetes. Jaspan JB. **Hosp Pract (Off Ed)** 1995 Oct 15;30(10):55–62 (9 ref.)
The application of engineering and technology in the management of diabetes. Claremont DJ. **J Med Eng Technol** 1995 Nov–Dec;19(6):205–10 (64 ref.)
Nutrition support in hospitalized patients with diabetes mellitus. McMahon MM, et al. **Mayo Clin Proc** 1996 Jun; 71(6):587–94 (9 ref.)
Preventing complications in diabetes mellitus: the role of the primary care physician. Laine C, et al. **Med Clin North Am** 1996 Mar;80(2):457–74 (96 ref.)
Treatment of the pre-azotaemic phases of kidney disease in diabetes. Viberti GC. **Nephrol Dial Transplant** 1995;10 Suppl 7:38–42 (58 ref.)
The development of healthcare services for diabetic prisoners. MacFarlane IA. **Postgrad Med J** 1996 Apr; 72(846):214–7 (15 ref.)
Diabetes mellitus—current clinical aspects. Wright JW. **Proc Annu Meet Med Sect Am Counc Life Insur** 1995;:161–9 (42 ref.)
[Endocrinology update—II] Burgstaller M, et al. **Med Klin** 1996 Apr 1;91 Suppl 1:34–44 (171 ref.) **(Ger)**

URINE

Tests of glycemia in diabetes. Goldstein DE, et al. **Diabetes Care** 1995 Jun;18(6):896–909 (144 ref.)

DIABETES MELLITUS, ADULT-ONSET see **DIABETES MELLITUS, NON-INSULIN-DEPENDENT**

DIABETES MELLITUS, BRITTLE see **DIABETES MELLITUS, INSULIN-DEPENDENT**

DIABETES MELLITUS, EXPERIMENTAL

see related
MICE, INBRED NOD

CHEMICALLY INDUCED

Effects of streptozotocin-induced diabetes on postpneumonectomy lung growth and connective tissue levels. Ofulue AF, et al. **Pediatr Pulmonol** 1995 Jun; 19(6):365–70 (29 ref.)

COMPLICATIONS

The use of neutralizing antibodies to demonstrate the role of transforming growth factor-beta and Amadori-glycated albumin as mediators of experimental diabetic kidney disease. Ziyadeh FN, et al. **Contrib Nephrol** 1996; 118:188–94 (39 ref.)

DRUG THERAPY

[alpha-Glucosidase inhibitors in the therapy of diabetes mellitus] Giorgino R, et al. **Ann Ital Med Int** 1995 Oct;10 Suppl:61S–65S (45 ref.) (Eng. Abstr.) **(Ita)**

IMMUNOLOGY

The contribution of animal models to the understanding of the pathogenesis of type 1 diabetes. Carnaud C. **Braz J Med Biol Res** 1995 Aug;28(8):925–9 (35 ref.)

METABOLISM

Determinants of glucose turnover in the pathophysiology of diabetes: an in vivo analysis in diabetic dogs. Fisher SJ, et al. **Diabetes Metab** 1996 Apr;22(2):111–21 (78 ref.)
Role of protein kinase C and cyclic AMP/protein kinase A in high glucose-stimulated transcriptional activation of collagen alpha 1 (IV) in glomerular mesangial cells. Ziyadeh FN, et al. **J Diabetes Complications** 1995 Oct–Dec; 9(4):255–61 (35 ref.)
Neuropeptide Y, the hypothalamus, and diabetes: insights into the central control of metabolism. Frankish HM, et al. **Peptides** 1995;16(4):757–71 (154 ref.)

PATHOLOGY

Retinopathy in animal models of diabetes. Engerman RL, et al. **Diabetes Metab Rev** 1995 Jul;11(2):109–20 (88 ref.)

PHYSIOPATHOLOGY

Determinants of glucose turnover in the pathophysiology of diabetes: an in vivo analysis in diabetic dogs. Fisher SJ, et al. **Diabetes Metab** 1996 Apr;22(2):111–21 (78 ref.)
Retinopathy in animal models of diabetes. Engerman RL, et al. **Diabetes Metab Rev** 1995 Jul;11(2):109–20 (88 ref.)
Current concepts of renal hemodynamics in diabetes. Anderson S, et al. **J Diabetes Complications** 1995 Oct–Dec; 9(4):304–7 (35 ref.)
Effects of experimental diabetes and insulin on smooth muscle functions. Oztürk Y, et al. **Pharmacol Rev** 1996 Mar; 48(1):69–112 (728 ref.)
The role of vanadium in the management of diabetes. Brichard SM, et al. **Trends Pharmacol Sci** 1995 Aug; 16(8):265–70 (60 ref.)

THERAPY

[Gene therapy for diabetes: various approaches including adoptive transfer of cytokine gene-transduced lymphocytes] Moritani M, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2746–52 (23 ref.) **(Jpn)**

DIABETES MELLITUS, GESTATIONAL see **DIABETES, GESTATIONAL**

DIABETES MELLITUS, INSULIN-DEPENDENT

see related
MICE, INBRED NOD

The athlete with type I diabetes: managing insulin, diet and exercise. Fahey PJ, et al. **Am Fam Physician** 1996 Apr; 53(5):1611–24 (22 ref.)
The young athlete with chronic disease. Small E, et al. **Clin Sports Med** 1995 Jul;14(3):709–26 (144 ref.)
Transient and permanent neonatal diabetes. Fösel S. **Eur J Pediatr** 1995 Dec;154(12):944–8 (105 ref.)
Role of fetal surveillance in diabetic pregnancies. Fuentes A, et al. **J Matern Fetal Med** 1996 Mar–Apr;5(2):85–8 (12 ref.)
[Identification of diabetic patients at high risk for development of retinopathy] Leibowitz E, et al. **Harefuah** 1995 Oct;129(7–8):271–3 (24 ref.) **(Heb)**
[Human leukocyte antigen (HLA) and the related diseases] Mizuki N, et al. **Nippon Naika Gakkai Zasshi** 1995 Dec 10;84(12):2091–103 (12 ref.) **(Jpn)**

BLOOD

Nocturnal hypoglycaemia in patients with insulin-dependent diabetes mellitus. Bendtson I. **Dan Med Bull** 1995 Jun; 42(3):269–84 (172 ref.)
Insulin resistance: a multifaceted metabolic syndrome. Insights gained using a low-dose insulin infusion technique. Krentz AJ, et al. **Diabet Med** 1996 Jan;13(1):30–9 (54 ref.)
Beyond glycemia. Vinik AI, et al. **Diabetes Care** 1995 Jul; 18(7):1037–41 (34 ref.)
[Zinc and diabetes mellitus] Ripa S, et al. **Minerva Med** 1995 Oct;86(10):415–21 (101 ref.) (Eng. Abstr.) **(Ita)**

COMPLICATIONS

Intensive insulin therapy in insulin-dependent diabetes mellitus, the results of the diabetes control and complications trial. Duron F. **Biomed Pharmacother** 1995; 49(6):278–82 (36 ref.)
Drugs to treat the tissue complications of diabetes: peripheral neuropathy. Emanuele NV, et al. **Compr Ther** 1995 Oct; 21(10):579–82 (30 ref.)
Are angiotensin-converting enzyme inhibitors the renal protective antihypertensive drugs of choice? [editorial] Bauer JH. **Curr Opin Nephrol Hypertens** 1995 Sep; 4(5):427–31 (23 ref.)
Is insulin really a heart disease risk factor. Wingard DL, et al. **Diabetes Care** 1995 Sep;18(9):1299–304 (45 ref.)
Tumour-induced hypoglycaemia in a patient with insulin-dependent diabetes mellitus. Svartberg J, et al. **J Intern Med** 1996 Feb;239(2):181–5 (16 ref.)
Stiff-person syndrome with anti-glutamic acid decarboxylase autoantibodies: complete remission of symptoms after intrathecal baclofen administration. Seitz RJ, et al. **J Neurol** 1995 Oct;242(10):618–22 (32 ref.)
Bilateral endogenous Escherichia coli endophthalmitis: a devastating complication in an insulin-dependent diabetic. Walmsley RS, et al. **Postgrad Med J** 1996 Jun;72(848):361–3 (10 ref.)
Non-ophthalmologic findings of the Diabetes Control and Complications Trial. Saudek CD. **Surv Ophthalmol** 1995 Sep–Oct;40(2):157–62 (33 ref.)
Pregnancy after pancreas transplantation: report of four new

cases and review of the literature. Barrou B, et al. **Transplant Proc** 1995 Dec;27(6):3043-4 (2 ref.)

[Lymphocytic mastopathy. A case report and review of the literature] Pellerin P, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(7):683-5 (10 ref.) (Eng. Abstr.) **(Fre)**

[Hypoglycemia--occurrence, causes and hormonal counterregulatory mechanisms in healthy persons and in patients with IDDM] Mokáň M. **Bratisl Lek Listy** 1995 Jun;96(6):311-6 (34 ref.) (Eng. Abstr.) **(Slo)**

DIAGNOSIS

[Cytoplasmic islet cell antibodies and GAD antibodies in diagnosis of diabetes] Bieg S, et al. **Med Klin** 1995 Oct 15;90(10):594-8 (48 ref.) **(Ger)**

[Microalbuminuria in diabetes mellitus--illness or symptom?] Müller WA. **Versicherungsmedizin** 1996 Jun 1;48(3):70-6 (84 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Intensive insulin therapy in insulin-dependent diabetes mellitus, the results of the diabetes control and complications trial. Duron F. **Biomed Pharmacother** 1995; 49(6):278-82 (36 ref.)

Angiotensin-converting enzyme inhibition in type I diabetic nephropathy. Lewis EJ. **Contrib Nephrol** 1996;118:206-13 (4 ref.)

Recombinant IGF-I therapy in insulin-dependent diabetes mellitus. Savage MO, et al. **Diabetes Metab** 1996 Jul; 22(4):257-60 (13 ref.)

Treatment with insulin infusion pumps and ketoacidotic episodes: from physiology to troubleshooting. Castillo MJ, et al. **Diabetes Metab Rev** 1995 Jul;11(2):161-77 (87 ref.)

The insulin-sparing effect of metformin in insulin-treated diabetic patients. Golay A, et al. **Diabetes Metab Rev** 1995 Sep;11 Suppl 1:S63-7 (34 ref.)

Can hypoglycaemia be predicted before its onset? Lönnroth P. **Diabetologia** 1996 May;39(5):613-4 (17 ref.)

Can hypoglycaemia be predicted before its onset? (Comment). Maggs D. **Diabetologia** 1996 May;39(5):615-7 (16 ref.)

Insulin-like growth factors (IGFs) and IGF-I treatment in the adolescent with insulin-dependent diabetes mellitus. Dunger DB, et al. **Metabolism** 1995 Oct;44(10 Suppl 4):119-23 (56 ref.)

Diabetes mellitus and traffic incidents. Veneman TF. **Neth J Med** 1996 Jan;48(1):24-8 (27 ref.)

Insulin pump therapy: acceptable alternative to injection therapy. Marcus AO, et al. **Postgrad Med** 1996 Mar; 99(3):125-32, 142-4 (22 ref.)

[The conditions, indications and contraindications of treatment of diabetes using subcutaneous infusion of insulin] Dryáková M. **Cas Lek Cesk** 1996 Jan 17;135(2):43-9 (36 ref.) (Eng. Abstr.) **(Cze)**

[Human insulin-like growth factor I and treatment in diabetes] Koivisto VA. **Duodecim** 1994; 110(23-24):2197-201 (25 ref.) **(Fin)**

[Current role of external pumps in the treatment of insulin-dependent diabetes mellitus] Selam JL, et al. **Diabete Metab** 1995 Dec;21(5):378-82 (21 ref.) **(Fre)**

EPIDEMIOLOGY

The relationship between cow's milk exposure and type 1 diabetes. Gerstein HC, et al. **Diabet Med** 1996 Jan; 13(1):23-9 (89 ref.)

Milk and type I diabetes. Scott FW, et al. **Diabetes Care** 1996 Apr;19(4):379-83 (51 ref.)

The pathogenesis and prevention of diabetes in adults. Genes, autoimmunity, and demography. Zimmet PZ. **Diabetes Care** 1995 Jul;18(7):1050-64 (142 ref.)

Exposure to superantigens as an immunogenetic explanation of type I diabetes mini-epidemics. Trucco M, et al. **J Pediatr Endocrinol Metab** 1995 Jan-Mar;8(1):3-10 (41 ref.)

[Epidemiology and molecular epidemiology of type I diabetes mellitus] Yang Z, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1995 Oct; 16(5):310-3 (19 ref.) **(Chi)**

[Hypertension and diabetes] Navalesi R, et al. **Ann Ital Med Int** 1995 Oct;10 Suppl:121S-129S (37 ref.) (Eng. Abstr.) **(Ita)**

ETIOLOGY

The contribution of insulitis to diabetes development in tumor necrosis factor transgenic mice. Flavell RA, et al. **Curr Top Microbiol Immunol** 1996;206:33-50 (72 ref.)

Virus-induced autoimmune disease: transgenic approach to mimic insulin-dependent diabetes mellitus and multiple sclerosis. Oldstone MB, et al. **Curr Top Microbiol Immunol** 1996;206:67-83 (34 ref.)

Exposure to superantigens as an immunogenetic explanation of type I diabetes mini-epidemics. Trucco M, et al. **J Pediatr Endocrinol Metab** 1995 Jan-Mar;8(1):3-10 (41 ref.)

Early infant diets and insulin-dependent diabetes. Ellis TM, et al. **Lancet** 1996 May 25;347(9013):1464-5 (20 ref.)

The estrogen connection: the etiological relationship between diabetes, cancer, rheumatoid arthritis and psychiatric disorders. Holden RJ. **Med Hypotheses** 1995 Aug; 45(2):169-89 (162 ref.)

Mechanisms of pathogenesis in diabetes mellitus. Dayhaw-Barker P. **Optom Vis Sci** 1995 Jun;72(6):417-24 (35 ref.)

Cytokines and nitric oxide in islet inflammation and diabetes. McDaniel ML, et al. **Proc Soc Exp Biol Med** 1996 Jan; 211(1):24-32 (41 ref.)

[AIDS and diabetes] Blanc MH. **Rev Med Suisse Romande** 1995 Sep;115(9):667-70 (29 ref.) **(Fre)**

GENETICS

Recent advances in the immunopathogenesis of insulin-dependent diabetes mellitus. Schatz D, et al. **Curr Opin Pediatr** 1995 Aug;7(4):459-65 (73 ref.)

Influence of T lymphocytes and major histocompatibility complex class II genes on diabetes susceptibility in the NOD mouse. Slattery RM, et al. **Curr Top Microbiol Immunol** 1996;206:51-66 (64 ref.)

Nephropathy in type 1 diabetes: the role of genetic factors. Chowdhury TA, et al. **Diabet Med** 1995 Dec; 12(12):1059-67 (61 ref.)

HLA and glutamic acid decarboxylase in human insulin-dependent diabetes mellitus. Sanjeevi CB, et al. **Diabet Med** 1996 Mar;13(3):209-17 (68 ref.)

The search for IDDM susceptibility genes: the next generation. Owerbach D, et al. **Diabetes** 1996 May; 45(5):544-51 (79 ref.)

The role of prohormone convertases in insulin biosynthesis: evidence for inherited defects in their action in man and experimental animals. Steiner DF, et al. **Diabetes Metab** 1996 Apr;22(2):94-104 (72 ref.)

The genetics of the NOD mouse. Baxter AG, et al. **Diabetes Metab Rev** 1995 Dec;11(4):315-35 (102 ref.)

Genetic susceptibility to nephropathy in insulin-dependent diabetes: from epidemiology to molecular genetics. Doria A, et al. **Diabetes Metab Rev** 1995 Dec;11(4):287-314 (213 ref.)

Twin studies in insulin dependent diabetes and other autoimmune diseases. Rowe RE, et al. **Diabetes Metab Rev** 1995 Jul;11(2):121-35 (85 ref.)

Genetic susceptibility to diabetic kidney disease: an update. Krolewski AS, et al. **J Diabetes Complications** 1995 Oct-Dec;9(4):277-81 (49 ref.)

Genetic factors in the development of diabetic nephropathy. Trevisan R, et al. **J Lab Clin Med** 1995 Oct;126(4):342-9 (63 ref.)

Genetic analysis of type 1 diabetes using whole genome approaches. Todd JA. **Proc Natl Acad Sci U S A** 1995 Sep 12;92(19):8560-5 (101 ref.)

Multifactorial inheritance in type 1 diabetes. Cordell HJ, et al. **Trends Genet** 1995 Dec;11(12):499-504 (52 ref.)

[The role of genes in the type-1 diabetes] Reijonen H, et al. **Duodecim** 1994;110(7):695-706 (54 ref.) **(Fin)**

IMMUNOLOGY

T-cell recognition of beta-cell autoantigens in insulin-dependent diabetes mellitus. Kallan AA, et al. **APMIS** 1996 Jan;104(1):3-11 (84 ref.)

The contribution of animal models to the understanding of the pathogenesis of type 1 diabetes. Carnaud C. **Braz J Med Biol Res** 1995 Aug;28(8):925-9 (35 ref.)

Insulin-dependent diabetes mellitus. Tisch R, et al. **Cell** 1996 May 3;85(3):291-7 (44 ref.)

Glutamic acid decarboxylase and other autoantigens in IDDM. Nepom GT. **Curr Opin Immunol** 1995 Dec; 7(6):825-30 (63 ref.)

Recent advances in the immunopathogenesis of insulin-dependent diabetes mellitus. Schatz D, et al. **Curr Opin Pediatr** 1995 Aug;7(4):459-65 (73 ref.)

Influence of T lymphocytes and major histocompatibility complex class II genes on diabetes susceptibility in the NOD mouse. Slattery RM, et al. **Curr Top Microbiol Immunol** 1996;206:51-66 (64 ref.)

HLA and glutamic acid decarboxylase in human insulin-dependent diabetes mellitus. Sanjeevi CB, et al. **Diabet Med** 1996 Mar;13(3):209-17 (68 ref.)

T-cell responses to autoantigens in IDDM. The search for the Holy Grail. Roep BO. **Diabetes** 1996 Sep;45(9):1147-56 (123 ref.)

Insulin-dependent diabetes mellitus as a beta-cell targeted disease of immunoregulation. Bach JF. **J Autoimmun** 1995 Aug;8(4):439-63 (172 ref.)

The clinical significance of an autoimmune response against glutamic acid decarboxylase. Ellis TM, et al. **Nat Med** 1996 Feb;2(2):148-53 (30 ref.)

Checkpoints in the progression of autoimmune disease: lessons from diabetes models. André I, et al. **Proc Natl Acad Sci U S A** 1996 Mar 19;93(6):2260-3 (67 ref.)

[Autoimmunity and glutamate decarboxylase antibodies in the pathogenesis of type I diabetes mellitus in experimental and clinical practice] Kučera P, et al. **Vnitr Lek** 1996 May; 42(5):359-67 (65 ref.) (Eng. Abstr.) **(Cze)**

[Immunological tolerance in prevention of diabetes (editorial)] Knip M. **Duodecim** 1994;110(17):1571-3 (13 ref.) **(Fin)**

[The role of free radicals in pathogenesis of insulin dependent diabetes mellitus] Komosińska K, et al. **Postepy Hig Med Dosw** 1995;49(6):733-46 (64 ref.) (Eng. Abstr.) **(Pol)**

[The characteristics of the immunogenesis and immunocorrection of diabetes mellitus] Galenok VA, et al. **Ter Arkh** 1995;67(10):7-12 (61 ref.) (Eng. Abstr.) **(Rus)**

METABOLISM

Relations of hormones and growth factors at the crossroad of pathogenesis and pharmacotherapeutics. The case of diabetes mellitus [editorial] Mathé G. **Biomed Pharmacother** 1995;49(5):221-4 (38 ref.)

Does fall in tissue glucose precede fall in blood glucose? Sternberg F, et al. **Diabetologia** 1996 May;39(5):609-12 (22 ref.)

Insulin-like growth factors (IGFs) and IGF-I treatment in the adolescent with insulin-dependent diabetes mellitus. Dunger DB, et al. **Metabolism** 1995 Oct;44(10 Suppl 4):119-23 (56 ref.)

[Behavior of pancreatic beta-cells in type I and II diabetes: clinical implications?] Waeber G. **Rev Med Suisse Romande** 1995 Sep;115(9):627-34 (37 ref.) **(Fre)**

PATHOLOGY

The pathology of the endocrine pancreas in type 1 (insulin-dependent) diabetes mellitus. Foulis AK. **APMIS** 1996 Mar;104(3):161-7 (32 ref.)

[Pathology of diabetes mellitus] Yagihashi S. **Nippon Naika Gakkai Zasshi** 1996 Apr 10;85(4):568-72 (5 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Nephropathy in type 1 diabetes: the role of genetic factors. Chowdhury TA, et al. **Diabet Med** 1995 Dec; 12(12):1059-67 (61 ref.)

The epidemiology of diabetic foot problems. Reiber GE. **Diabet Med** 1996;13 Suppl 1:S6-11 (39 ref.)

Microvascular aspects of diabetic foot disease. Tooke JE, et al. **Diabet Med** 1996;13 Suppl 1:S26-9 (14 ref.)

Hyperglycemia and diabetic kidney disease. The case for transforming growth factor-beta as a key mediator. Sharma K, et al. **Diabetes** 1995 Oct;44(10):1139-46 (124 ref.)

The role of cell adhesion molecules in the development of IDDM: implications for pathogenesis and therapy. Yang XD, et al. **Diabetes** 1996 Jun;45(6):705-10 (61 ref.)

Development and consequences of insulin resistance: lessons from animals with hyperinsulinaemia. Shafrir E. **Diabetes Metab** 1996 Apr;22(2):122-31 (63 ref.)

Genetic susceptibility to nephropathy in insulin-dependent diabetes: from epidemiology to molecular genetics. Doria A, et al. **Diabetes Metab Rev** 1995 Dec;11(4):287-314 (213 ref.)

Heparan sulphate in the pathogenesis of diabetic nephropathy. Kofoed-Enevoldsen A. **Diabetes Metab Rev** 1995 Jul;11(2):137-60 (143 ref.)

Role of insulin resistance in the pathogenesis of NIDDM. Yki-Järvinen H. **Diabetologia** 1995 Dec;38(12):1378-88 (123 ref.)

Exocrine pancreatic function in diabetes mellitus. Gröger G, et al. **Eur J Gastroenterol Hepatol** 1995 Aug;7(8):740-6 (70 ref.)

Current concepts of renal hemodynamics in diabetes. Anderson S, et al. **J Diabetes Complications** 1995 Oct-Dec; 9(4):304-7 (35 ref.)

Microalbuminuria in prediction and prevention of diabetic nephropathy in insulin-dependent diabetes mellitus patients. Mogensen CE. **J Diabetes Complications** 1995 Oct-Dec;9(4):337-49 (99 ref.)

Molecular and physiological aspects of nephropathy in type I (insulin-dependent) diabetes mellitus. Raskin GS, et al. **J Diabetes Complications** 1996 Jan-Feb;10(1):31-7 (59 ref.)

Natural course of growth hormone hypersecretion in insulin-dependent diabetes mellitus. Wurzburger MI, et al. **Med Hypotheses** 1996 Feb;46(2):145-9 (48 ref.)

Effects of experimental diabetes and insulin on smooth muscle functions. Oztürk Y, et al. **Pharmacol Rev** 1996 Mar; 48(1):69-112 (728 ref.)

Hypoglycemia-induced autonomic failure in insulin-dependent diabetes mellitus. Cryer PE. **Proc Assoc Am Physicians** 1995 Apr;107(1):67-70 (30 ref.)

[The phenomenon of hypoglycemia unawareness--definition, frequency, pathogenesis and clinical forms] Mokáň M. **Bratisl Lek Listy** 1995 Aug;96(8):413-9 (39 ref.) (Eng. Abstr.) **(Slo)**

[Diabetic nephropathy and molecular biology of the renin-angiotensin system in the diabetic kidney] Rodríguez Pérez JC, et al. **Med Clin (Barc)** 1995 Nov 25; 105(18):708-15 (103 ref.) **(Spa)**

PREVENTION & CONTROL

Tolerance induction as a therapeutic strategy for the control of autoimmune endocrine disease in mouse models. Parish NM, et al. **Immunol Rev** 1995 Apr;144:269-300 (103 ref.)

Antigen-specific therapy for autoimmune disease: prospects for the prevention of insulin-dependent diabetes. Harrison LC. **Mol Med** 1995 Nov;1(7):722-7 (34 ref.)

[Can type 1 diabetes mellitus be prevented? (editorial)] Akerblom H. **Duodecim** 1994;110(10):928-31 (19 ref.) **(Fin)**

PSYCHOLOGY

The psychological care of patients with insulin-dependent

diabetes mellitus. Jacobson AM. **N Engl J Med** 1996 May 9;334(19):1249-53 (65 ref.)

REHABILITATION

Physical activity in the treatment and prevention of diabetes. Speisberg A, et al. **Compr Ther** 1995 Oct;21(10):559-62 (59 ref.)

SURGERY

Whole-organ versus islet pancreatic transplantation. Brunicardi FC, et al. **Curr Opin Gen Surg** 1994;:179-85 (37 ref.)

Pancreas and islet transplantation in humans. Kendall DM, et al. **Diabetes Metab** 1996 Jun;22(3):157-63 (40 ref.)

Pancreas transplantation: a treatment option for insulin-dependent diabetes mellitus. Larsen JL, et al. **Diabetes Metab** 1996 Apr;22(2):139-46 (76 ref.)

The case for pancreas transplantation. Sutherland DE. **Diabetes Metab** 1996 Apr;22(2):132-8 (39 ref.)

Pancreas transplantation: an update. Sutherland DE, et al. **Diabetes Metab Rev** 1995 Dec;11(4):337-63 (218 ref.)

Pancreas transplantation. Stratta RJ, et al. **Int J Pancreatol** 1995 Feb;17(1):1-13 (85 ref.)

Transplantation in diabetes: a cell biological problem. Purrello F, et al. **J Endocrinol Invest** 1995 Apr;18(4):311-9 (72 ref.)

The patient with type II diabetes and uraemia--to transplant or not to transplant [editorial] Hirschl MM. **Nephrol Dial Transplant** 1995;10(9):1515-6 (7 ref.)

Pancreas transplantation. Stratta RJ, et al. **Ren Fail** 1995 Jul; 17(4):323-37 (85 ref.)

Pregnancy after pancreas transplantation: report of four new cases and review of the literature. Barrou B, et al. **Transplant Proc** 1995 Dec;27(6):3043-4 (2 ref.)

Long-term pancreatic function: potential benefits. Bartlett ST, et al. **Transplant Proc** 1996 Aug;28(4):2128-30 (18 ref.)

Pancreas and islet cell transplantation: now and then. Sutherland DE. **Transplant Proc** 1996 Aug;28(4):2131-3 (20 ref.)

THERAPY

Unexplained improvement in diabetes control: a wolf in sheep's clothing. Snow KJ. **Compr Ther** 1995 Oct; 21(10):590-3 (16 ref.)

Pancreas transplantation: a managed cure approach to diabetes. Stratta RJ, et al. **Curr Probl Surg** 1996 Sep; 33(9):709-808 (250 ref.)

The role of cell adhesion molecules in the development of IDDM: implications for pathogenesis and therapy. Yang XD, et al. **Diabetes** 1996 Jun;45(6):705-10 (61 ref.)

Inpatient management of adults with diabetes. Hirsch IB, et al. **Diabetes Care** 1995 Jun;18(6):870-8 (82 ref.)

Beyond glycemia. Vinik AI, et al. **Diabetes Care** 1995 Jul; 18(7):1037-41 (34 ref.)

Tolerance induction as a therapeutic strategy for the control of autoimmune endocrine disease in mouse models. Parish NM, et al. **Immunol Rev** 1995 Apr;144:269-300 (103 ref.)

Application of computers in diabetes care--a review. I. Computers for data collection and interpretation. Lehmann ED, et al. **Med Inf (Lond)** 1995 Oct-Dec;20(4):281-302 (142 ref.)

Application of computers in diabetes care--a review. II. Computers for decision support and education. Lehmann ED, et al. **Med Inf (Lond)** 1995 Oct-Dec;20(4):303-29 (147 ref.)

Management of foot problems in diabetes. Shaw JE, et al. **Perit Dial Int** 1996;16 Suppl 1:S279-82 (26 ref.)

Non-ophthalmologic findings of the Diabetes Control and Complications Trial. Saudek CD. **Surv Ophthalmol** 1995 Sep-Oct;40(2):157-62 (33 ref.)

[Acquired experience with diabetes mellitus] Ernould C, et al. **Arch Pediatr** 1996;3 Suppl 1:315s-317s (5 ref.) **(Fre)**

[Endocrinology update. II] Burgstaller M, et al. **Med Klin** 1996 Apr 10;91(4):207-17 (171 ref.) **(Ger)**

[Insulin producing cells as therapy in diabetes mellitus] Schnedl WJ, et al. **Naturwissenschaften** 1996 Jan;83(1):1-5 (41 ref.) (Eng. Abstr.) **(Ger)**

[Monitoring the pregnant diabetic patient] Heyl W, et al. **Z Geburtshilfe Neonatol** 1995 Jul-Aug;199(4):132-7 (41 ref.) (Eng. Abstr.) **(Ger)**

[Progress on clinical study and prediction of IDDM] Kida K, et al. **Nippon Naika Gakkai Zasshi** 1996 Apr 10; 85(4):502-7 (5 ref.) **(Jpn)**

[Perspectives on prevention and treatment of diabetes mellitus type I (IDDM)] Otto-Buczkowska E. **Wiad Lek** 1994 Sep;47(17-18):694-7 (27 ref.) **(Pol)**

URINE

Differing effects of antihypertensive agents on urinary albumin excretion. Weir MR. **Am J Nephrol** 1996; 16(3):237-45 (69 ref.)

[Diabetic nephropathy: significance of microalbuminuria and proteinuria in Type I and Type II diabetes mellitus] Lehmann R, et al. **Schweiz Rundsch Med Prax** 1995 Oct 31;84(44):1265-71 (53 ref.) (Eng. Abstr.) **(Ger)**

VIROLOGY

Retroviruses and diabetes in animal models: hypotheses for the induction of the disease [published erratum appears in Diabete Metab 1995 Dec;21(5):384] Signore A, et al. **Diabete Metab** 1995 Jun;21(3):147-55 (54 ref.)

A new look at viruses in type 1 diabetes. Yoon JW. **Diabetes Metab Rev** 1995 Jul;11(2):83-107 (194 ref.)

DIABETES MELLITUS, JUVENILE-ONSET see **DIABETES MELLITUS, INSULIN-DEPENDENT**

DIABETES MELLITUS, KETOSIS-PRONE see **DIABETES MELLITUS, INSULIN-DEPENDENT**

DIABETES MELLITUS, KETOSIS-RESISTANT see **DIABETES MELLITUS, NON-INSULIN-DEPENDENT**

DIABETES MELLITUS, MATURITY-ONSET see **DIABETES MELLITUS, NON-INSULIN-DEPENDENT**

DIABETES MELLITUS, NON-INSULIN-DEPENDENT

Weight and non-insulin-dependent diabetes mellitus. Pi-Sunyer FX. **Am J Clin Nutr** 1996 Mar;63(3 Suppl):426S-429S (53 ref.)

Diabetes in the elderly. Meneilly GS, et al. **Diabet Med** 1995 Nov;12(11):949-60 (158 ref.)

Seminars in Medicine of the Beth Israel Hospital, Boston. Non-insulin-dependent diabetes mellitus - a genetically programmed failure of the beta cell to compensate for insulin resistance. Polonsky KS, et al. **N Engl J Med** 1996 Mar 21;334(12):777-83 (68 ref.)

[Diabetes and pregnancy] Omori Y. **Nippon Naika Gakkai Zasshi** 1996 Mar 10;85(3):379-83 (8 ref.) **(Jpn)**

BLOOD

Hemoglobin variants recently detected in Austria. Schnedl WJ, et al. **Ann Hematol** 1995 Oct;71(4):185-7 (23 ref.)

Serum insulin, IGF-I,IGF-II and growth hormone, and left ventricular mass in noninsulin-dependent mellitus. Rabkin SW, et al. **Can J Cardiol** 1996 Mar;12(3):264-70 (52 ref.)

Hyperinsulinemia and triglyceride-rich lipoproteins. Steiner G, et al. **Diabetes** 1996 Jul;45 Suppl 3:S24-6 (29 ref.)

The pharmacological treatment of hyperglycemia in NIDDM. American Diabetes Association. **Diabetes Care** 1995 Nov;18(11):1510-8 (0 ref.)

Beyond glycemia. Vinik AI, et al. **Diabetes Care** 1995 Jul; 18(7):1037-41 (34 ref.)

[Raised blood glucose level increases risk of atherosclerosis in non-insulin-dependent diabetes (editorial)] Uusitupa M, et al. **Duodecim** 1994;110(12):1119-20 (16 ref.) **(Fin)**

[Zinc and diabetes mellitus] Ripa S, et al. **Minerva Med** 1995 Oct;86(10):415-21 (101 ref.) (Eng. Abstr.) **(Ita)**

[Calcitonin gene-related peptide in diabetes mellitus type 2: a possible etiopathogenetic role] Parlapiano C, et al. **Riv Eur Sci Med Farmacol** 1995 Jan-Feb;17(1):35-9 (46 ref.) (Eng. Abstr.) **(Ita)**

COMPLICATIONS

The natural history of renal disease in non-insulin-dependent diabetes mellitus: lessons from the Pima Indians. Nelson RG, et al. **Adv Nephrol Necker Hosp** 1995;24:145-56 (47 ref.)

Renal involvement in type II diabetes. Ritz E, et al. **Adv Nephrol Necker Hosp** 1995;24:131-43 (58 ref.)

Diabetic nephropathy in type II diabetes. Ritz E, et al. **Am J Kidney Dis** 1996 Feb;27(2):167-94 (218 ref.)

The pathophysiology of diabetic complications: how much does the glucose hypothesis explain? Nathan DM. **Ann Intern Med** 1996 Jan 1;124(1 Pt 2):86-9 (51 ref.)

Prevention of long-term complications of non-insulin-dependent diabetes mellitus. Nathan DM. **Clin Invest Med** 1995 Aug;18(4):332-9 (44 ref.)

Hyperinsulinemia and atherosclerosis. Standl E. **Clin Invest Med** 1995 Aug;18(4):261-6 (40 ref.)

Drugs to treat the tissue complications of diabetes: peripheral neuropathy. Emanuele NV, et al. **Compr Ther** 1995 Oct; 21(10):579-82 (30 ref.)

Is insulin really a heart disease risk factor. Wingard DL, et al. **Diabetes Care** 1995 Sep;18(9):1299-304 (45 ref.)

Diabetic neuropathy in elderly patients. What can be done? Belmin J, et al. **Drugs Aging** 1996 Jun;8(6):416-29 (97 ref.)

Renal transplantation in patients with type 2 diabetes mellitus. Hirschl MM. **Nephrol Dial Transplant** 1995;10 Suppl 7:58-60 (12 ref.)

[Pancreatic somatostatinoma and MEN 1. Apropos of a case. Review of the literature] Roy J, et al. **Ann Endocrinol (Paris)** 1996;57(1):71-6 (26 ref.) (Eng. Abstr.) **(Fre)**

[Risk factors of microangiopathy in patients with non-insulin dependent diabetes mellitus] Czech A, et al. **Pol Tyg Lek** 1996 Jan;51(1-5):35-6 (9 ref.) **(Pol)**

[A diabetic woman with a picture of temporospatial disorientation, nausea and vomiting] Urbano Garcia J, et al. **Rev Clin Esp** 1996 May;196(5):333-4, 338 (6 ref.) **(Spa)**

DIAGNOSIS

Screening for NIDDM in nonpregnant adults. A review of principles, screening tests, and recommendations. Engelgau MM, et al. **Diabetes Care** 1995 Dec;18(12):1606-18 (118 ref.)

[Diagnosis of the metabolic syndrome] Hanefeld M, et al. **Internist (Berl)** 1996 Jul;37(7):705-11 (32 ref.) **(Ger)**

[Microalbuminuria in diabetes mellitus--illness or symptom?] Müller WA. **Versicherungsmedizin** 1996 Jun 1;48(3):70-6 (84 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Role of metformin in type II diabetes. Epstein S. **Cleve Clin J Med** 1995 Sep-Oct;62(5):278-9 (4 ref.)

The mechanism of alpha-glucosidase inhibition in the management of diabetes. Bischoff H. **Clin Invest Med** 1995 Aug;18(4):303-11 (31 ref.)

Clinical experience with acarbose as first line therapy in NIDDM. Fölsch UR. **Clin Invest Med** 1995 Aug; 18(4):312-7 (28 ref.)

Traditional pharmacological management of non-insulin-dependent diabetes. Tattersall R. **Clin Invest Med** 1995 Aug;18(4):288-95 (23 ref.)

The pharmacological treatment of hyperglycemia in NIDDM. American Diabetes Association. **Diabetes Care** 1995 Nov;18(11):1510-8 (0 ref.)

Insulin-like growth factor-I in the therapy of non-insulin-dependent diabetes mellitus and insulin resistance. Froesch ER, et al. **Diabetes Metab** 1996 Jul; 22(4):261-7 (25 ref.)

Mechanisms of metformin action in non-insulin-dependent diabetes mellitus. Perriello G. **Diabetes Metab Rev** 1995 Sep;11 Suppl 1:S51-6 (62 ref.)

What therapy do our NIDDM patients need? Insulin releasers. Crepaldi G, et al. **Diabetes Res Clin Pract** 1995 Aug;28 Suppl:S159-65 (29 ref.)

Clinical profile of glimepiride. Draeger E. **Diabetes Res Clin Pract** 1995 Aug;28 Suppl:S139-46 (7 ref.)

Alternative therapeutic principles in the prevention of microvascular and neuropathic complications. Gries FA. **Diabetes Res Clin Pract** 1995 Aug;28 Suppl:S201-7 (12 ref.)

Insulin therapy in type II diabetes. Holman RR, et al. **Diabetes Res Clin Pract** 1995 Aug;28 Suppl:S179-84 (16 ref.)

Rationale and hurdles of inhibitors of hepatic gluconeogenesis in treatment of diabetes mellitus. Kashiwagi A. **Diabetes Res Clin Pract** 1995 Aug;28 Suppl:S195-200 (30 ref.)

Sulphonylurea treatment of NIDDM patients with cardiovascular disease: a mixed blessing? Leibowitz G, et al. **Diabetologia** 1996 May;39(5):503-14 (140 ref.)

Drug therapy of non-insulin-dependent diabetes mellitus in the elderly. Mooradian AD. **Drugs** 1996 Jun;51(6):931-41 (57 ref.)

Prevention of complications in non-insulin-dependent diabetes mellitus (NIDDM). Wolffenbuttel BH, et al. **Drugs** 1995 Aug;50(2):263-88 (264 ref.)

Diabetic vascular injury and ACE. Potential for pharmacological prevention of complications of later life. Cooper ME, et al. **Drugs Aging** 1996 Jan;8(1):38-46 (90 ref.)

Insulin treatment in elderly patients with non-insulin-dependent diabetes mellitus. A double-edged sword? Niskanen L. **Drugs Aging** 1996 Mar;8(3):183-92 (51 ref.)

Potential role of thiazolidinediones in older diabetic patients. Umeda F. **Drugs Aging** 1995 Nov;7(5):331-7 (23 ref.)

New therapeutic agents for the treatment of NIDDM. Kuehnle HF. **Exp Clin Endocrinol Diabetes** 1996; 104(2):93-101 (54 ref.)

Prospects for beta 3-adrenoceptor agonists in the treatment of obesity and diabetes. Arch JR, et al. **Int J Obes Relat Metab Disord** 1996 Mar;20(3):191-9 (90 ref.)

Oral hypoglycemic agents as an alternative therapy for gestational diabetes [editorial; comment] Hod M, et al. **Isr J Med Sci** 1995 Oct;31(10):640-3 (47 ref.) Comment on: Isr J Med Sci 1995 Oct;31(10):623-5.

Metformin: a new treatment option for non-insulin-dependent diabetes mellitus. Goo AK, et al. **J Fam Pract** 1996 Jun;42(6):612-8 (52 ref.)

Angiotensin converting enzyme inhibitors and calcium antagonists alone or combined: does the progression of diabetic renal disease differ? Bakris GL, et al. **J Hypertens Suppl** 1995 Aug;13(2):S95-101 (52 ref.)

Hypertension in the non-insulin-dependent diabetes mellitus syndrome: a critical review of therapeutic intervention. Rett K, et al. **J Hypertens Suppl** 1995 Aug;13(2):S81-5 (26 ref.)

Effects of angiotensin converting enzyme inhibitors on the progression of diabetic nephropathy. Ruilope LM. **J Hypertens Suppl** 1995 Aug;13(2):S91-3 (26 ref.)

Pharmacologic treatment options for non-insulin-dependent diabetes mellitus. Tan GH, et al. **Mayo Clin Proc** 1996 Aug; 71(8):763-8 (26 ref.)

Metformin. Bailey CJ, et al. **N Engl J Med** 1996 Feb 29; 334(9):574-9 (66 ref.)

Metformin in noninsulin-dependent diabetes mellitus. Lee AJ. **Pharmacotherapy** 1996 May-Jun;16(3):327-51 (114 ref.)

Do more diabetic patients need insulin? Page S, et al. **Practitioner** 1996 Feb;240(1559):104-8 (7 ref.)

Pathophysiologic information and therapy for non-insulin-dependent diabetes mellitus [editorial] Bressler R. **South Med J** 1996 Aug;89(8):831-3 (43 ref.)

[Human insulin-like growth factor I and treatment in diabetes] Koivisto VA. **Duodecim** 1994; 110(23-24):2197-201 (25 ref.) **(Fin)**

[Is insulin therapy sufficiently used in type II diabetes? Minimal insulin therapy, or intensified insulin therapy?] Charbonnel B. **Diabete Metab** 1995 Jun;21(3):219-24 (15 ref.) **(Fre)**

[How I treat... A Type 2 diabetic patient who has become insulin-dependent] Scheen AJ. **Rev Med Liege** 1996 Apr; 51(4):263-5 (19 ref.) **(Fre)**

[Integrated drug therapy of the metabolic syndrome] Julius U, et al. **Internist (Berl)** 1996 Jul;37(7):722-30 (32 ref.) **(Ger)**

ENZYMOLOGY

The mechanism of alpha-glucosidase inhibition in the management of diabetes. Bischoff H. **Clin Invest Med** 1995 Aug;18(4):303-11 (31 ref.)

EPIDEMIOLOGY

Epidemiologic studies on the pathogenesis of non-insulin-dependent diabetes mellitus (NIDDM). Harris MI. **Clin Invest Med** 1995 Aug;18(4):231-9 (38 ref.)

Impaired glucose tolerance--prevalence and conversion to NIDDM. Harris MI. **Diabet Med** 1996;13(3 Suppl 2):S9-11 (14 ref.)

The pathogenesis and prevention of diabetes in adults. Genes, autoimmunity, and demography. Zimmet PZ. **Diabetes Care** 1995 Jul;18(7):1050-64 (142 ref.)

NIDDM--the devastating disease. Horton ES. **Diabetes Res Clin Pract** 1995 Aug;28 Suppl:S3-11 (90 ref.)

[Nutrition and metabolic syndrome] Hauner H. **Internist (Berl)** 1995 Nov;36(11):1040-5 (37 ref.) **(Ger)**

[Epidemiology of the metabolic syndrome] Janka HU. **Internist (Berl)** 1996 Jul;37(7):681-6 (59 ref.) **(Ger)**

[Hypertension and diabetes] Navalesi R, et al. **Ann Ital Med Int** 1995 Oct;10 Suppl:121S-129S (37 ref.) (Eng. Abstr.) **(Ita)**

ETHNOLOGY

Indo-Asians with diabetes: a special case. Roshan M, et al. **Practitioner** 1996 Feb;240(1559):120-4 (14 ref.)

ETIOLOGY

Non-insulin-dependent diabetes mellitus in children and adolescents. Glaser N, et al. **Adv Pediatr** 1996;43:359-96 (264 ref.)

The pathogenesis of type II diabetes mellitus. A polygenic disease. Sacks DB, et al. **Am J Clin Pathol** 1996 Feb; 105(2):149-56 (44 ref.)

Does adult-onset diabetes mellitus begin in childhood?: the Bogalusa Heart Study. Berenson GS, et al. **Am J Med Sci** 1995 Dec;310 Suppl 1:S77-82 (20 ref.)

Do non-insulin-dependent diabetes mellitus and cardiovascular disease share common antecedents? Stern MP. **Ann Intern Med** 1996 Jan 1;124(1 Pt 2):110-6 (90 ref.)

New World syndrome in Western Australian aborigines. Gracey M. **Clin Exp Pharmacol Physiol** 1995 Mar; 22(3):220-5 (38 ref.)

Role of insulin resistance in the pathogenesis of NIDDM. Yki-Järvinen H. **Diabetologia** 1995 Dec;38(12):1378-88 (123 ref.)

Evolution of the understanding of the role of exercise in obesity and its complications. Björntorp P. **Int J Obes Relat Metab Disord** 1995 Oct;19 Suppl 4:S1-4 (15 ref.)

Psammomys obesus of the Jerusalem colony: a model for nutritionally induced, non-insulin-dependent diabetes. Shafrir E, et al. **J Basic Clin Physiol Pharmacol** 1993 Apr-Jun;4(1-2):83-99 (54 ref.)

The android woman--a risky condition. Björntorp P. **J Intern Med** 1996 Feb;239(2):105-10 (38 ref.)

The estrogen connection: the etiological relationship between diabetes, cancer, rheumatoid arthritis and psychiatric disorders. Holden RJ. **Med Hypotheses** 1995 Aug; 45(2):169-89 (162 ref.)

Mechanisms of pathogenesis in diabetes mellitus. Dayhaw-Barker P. **Optom Vis Sci** 1995 Jun;72(6):417-24 (35 ref.)

Nutritional influences on pancreatic development and potential links with non-insulin-dependent diabetes. Dahri S, et al. **Proc Nutr Soc** 1995 Jul;54(2):345-56 (32 ref.)

[Secondary disorders of lipid metabolism, metabolic syndrome and familial combined hyperlipidemia] Steinmetz A, et al. **Wien Med Wochenschr** 1994;144(12-13):299-307 (64 ref.) (Eng. Abstr.) **(Ger)**

[Mitochondrial gene abnormalities and diabetes mellitus] Kagawa Y. **Nippon Naika Gakkai Zasshi** 1995 Oct 10; 84(10):1749-54 (21 ref.) **(Jpn)**

[Obesity and the related diseases: diabetes mellitus] Kobayashi M. **Nippon Naika Gakkai Zasshi** 1995 Aug 10; 84(8):1251-5 (5 ref.) **(Jpn)**

[Progress on clinical and etiological study of NIDDM] Seino H. **Nippon Naika Gakkai Zasshi** 1996 Apr 10;85(4):508-13 (2 ref.) **(Jpn)**

[Complication of childhood obesity] Yamazaki K, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:524-8 (17 ref.) **(Jpn)**

GENETICS

Genetics of non-insulin-dependent diabetes mellitus: from genes to the disease. Froguel P, et al. **Adv Nephrol Necker Hosp** 1995;24:157-63 (46 ref.)

Genetics of non-insulin-dependent (type-II) diabetes mellitus. Kahn CR, et al. **Annu Rev Med** 1996;47:509-31 (157 ref.)

The genetics and pathophysiology of type II and gestational diabetes. Csorba TR, et al. **Crit Rev Clin Lab Sci** 1995; 32(5-6):509-50 (246 ref.)

Genetic analysis of NIDDM. The study of quantitative traits. Ghosh S, et al. **Diabetes** 1996 Jan;45(1):1-14 (152 ref.)

Candidate genes for insulin resistance. Moller DE, et al. **Diabetes Care** 1996 Apr;19(4):396-400 (45 ref.)

The role of prohormone convertases in insulin biosynthesis: evidence for inherited defects in their action in man and experimental animals. Steiner DF, et al. **Diabetes Metab** 1996 Apr;22(2):94-104 (72 ref.)

Genetics and the metabolic syndrome. Bouchard C. **Int J Obes Relat Metab Disord** 1995 May;19 Suppl 1:S52-9 (43 ref.)

Genetic susceptibility to diabetic kidney disease: an update. Krolewski AS, et al. **J Diabetes Complications** 1995 Oct-Dec;9(4):277-81 (49 ref.)

[Genetic background of the non-insulin dependent diabetes] Groop L. **Duodecim** 1994;110(7):709-18 (54 ref.) **(Fin)**

[Glucokinase: the first hit in the hunt for a gene in late-onset diabetes (editorial)] Laakso M. **Duodecim** 1994;110(1):13-5 (18 ref.) **(Fin)**

[The metabolic syndrome and chronic vascular disease. Cellular mechanisms and potential candidate genes] Haller H, et al. **Internist (Berl)** 1996 Jul;37(7):687-97 (100 ref.) **(Ger)**

[Diabetogenes; which cause type II diabetes mellitus] Murakami T, et al. **Rinsho Byori** 1995 Aug;43(8):781-5 (0 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

[The characteristics of the immunogenesis and immunocorrection of diabetes mellitus] Galenok VA, et al. **Ter Arkh** 1995;67(10):7-12 (61 ref.) (Eng. Abstr.) **(Rus)**

METABOLISM

Islet amyloid in type 2 (non-insulin-dependent) diabetes. Clark A, et al. **APMIS** 1996 Jan;104(1):12-8 (47 ref.)

Relations of hormones and growth factors at the crossroad of pathogenesis and pharmacotherapeutics. The case of diabetes mellitus [editorial] Mathé G. **Biomed Pharmacother** 1995;49(5):221-4 (38 ref.)

Clinical pharmacokinetics of metformin. Scheen AJ. **Clin Pharmacokinet** 1996 May;30(5):359-71 (74 ref.)

Regulation of hepatic glucose production in healthy subjects and patients with non-insulin-dependent diabetes mellitus. Tappy L. **Diabete Metab** 1995 Oct;21(4):233-40 (71 ref.)

Are the beta-cell signaling molecules malonyl-CoA and cystolic long-chain acyl-CoA implicated in multiple tissue defects of obesity and NIDDM? Prentki M, et al. **Diabetes** 1996 Mar;45(3):273-83 (163 ref.)

Fatty acids and insulin resistance. Boden G. **Diabetes Care** 1996 Apr;19(4):394-5 (14 ref.)

Rationale and hurdles of inhibitors of hepatic gluconeogenesis in treatment of diabetes mellitus. Kashiwagi A. **Diabetes Res Clin Pract** 1995 Aug;28 Suppl:S195-200 (30 ref.)

The esters of carboxylic nutrients as insulinotropic tools in non-insulin-dependent diabetes mellitus. Malaisse WJ. **Gen Pharmacol** 1995 Oct;26(6):1133-41 (40 ref.)

Pancreatic islet amyloid formation in patients with noninsulin-dependent diabetes mellitus. Implication for therapeutic strategy. Oosterwijk C, et al. **Int J Pancreatol** 1995 Aug;18(1):7-14 (68 ref.)

Pathophysiologic information and therapy for non-insulin-dependent diabetes mellitus [editorial] Bressler R. **South Med J** 1996 Aug;89(8):831-3 (43 ref.)

[Behavior of pancreatic beta-cells in type I and II diabetes: clinical implications?] Waeber G. **Rev Med Suisse Romande** 1995 Sep;115(9):627-34 (37 ref.) **(Fre)**

[Insulin resistance and pathogenesis of non-insulin-dependent diabetes mellitus (I)] Martinka E, et al. **Vnitr Lek** 1996 Jan; 42(1):31-6 (41 ref.) (Eng. Abstr.) **(Slo)**

PATHOLOGY

Pancreatic pathology in non-insulin dependent diabetes (NIDDM). Clark A, et al. **Diabetes Res Clin Pract** 1995 Aug;28 Suppl:S39-47 (50 ref.)

[Pathology of diabetes mellitus] Yagihashi S. **Nippon Naika Gakkai Zasshi** 1996 Apr 10;85(4):568-72 (5 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Glucose control and insulin resistance in non-insulin-dependent diabetes mellitus. Henry RR. **Ann Intern Med** 1996 Jan 1;124(1 Pt 2):97-103 (19 ref.)

The pathophysiology of diabetic complications: how much does the glucose hypothesis explain? Nathan DM. **Ann Intern Med** 1996 Jan 1;124(1 Pt 2):86-9 (51 ref.)

Do non-insulin-dependent diabetes mellitus and cardiovascular disease share common antecedents? Stern MP. **Ann Intern Med** 1996 Jan 1;124(1 Pt 2):110-6 (90 ref.)

An integrated view of beta-cell dysfunction in type-II diabetes. Poitout V, et al. **Annu Rev Med** 1996;47:69-83 (42 ref.)

Understanding the pathogenesis of type 2 diabetes: can we get off the metabolic merry-go-rounds? Proietto J, et al. **Aust N Z J Med** 1995 Dec;25(6):870-5 (33 ref.)

Benefits of exercise for type II diabetics: convergence of epidemiologic, physiologic, and molecular evidence. Bonen A. **Can J Appl Physiol** 1995 Sep;20(3):261-79 (80 ref.)

The key role of islet dysfunction in type II diabetes mellitus. Porte D Jr, et al. **Clin Invest Med** 1995 Aug;18(4):247-54 (26 ref.)

Glucose toxicity: the implications of hyperglycemia in the pathophysiology of diabetes mellitus. Rossetti L. **Clin Invest Med** 1995 Aug;18(4):255-60 (22 ref.)

The genetics and pathophysiology of type II and gestational diabetes. Csorba TR, et al. **Crit Rev Clin Lab Sci** 1995; 32(5-6):509-50 (246 ref.)

Impaired glucose tolerance--prevalence and conversion to NIDDM. Harris MI. **Diabet Med** 1996;13(3 Suppl 2):S9-11 (14 ref.)

Review of previous impaired glucose tolerance intervention studies. Melander A. **Diabet Med** 1996;13(3 Suppl 2):S20-2 (5 ref.)

The epidemiology of diabetic foot problems. Reiber GE. **Diabet Med** 1996;13 Suppl 1:S6-11 (39 ref.)

Microvascular aspects of diabetic foot disease. Tooke JE, et al. **Diabet Med** 1996;13 Suppl 1:S26-9 (14 ref.)

Alcohol and the NIDDM patient. Bell DS. **Diabetes Care** 1996 May;19(5):509-13 (60 ref.)

The insulin resistance syndrome revisited. Haffner SM. **Diabetes Care** 1996 Mar;19(3):275-7 (43 ref.)

The pathogenesis and prevention of diabetes in adults. Genes, autoimmunity, and demography. Zimmet PZ. **Diabetes Care** 1995 Jul;18(7):1050-64 (142 ref.)

Insulin action in man. Scheen AJ, et al. **Diabetes Metab** 1996 Apr;22(2):105-10 (51 ref.)

Development and consequences of insulin resistance: lessons from animals with hyperinsulinaemia. Shafrir E. **Diabetes Metab** 1996 Apr;22(2):122-31 (63 ref.)

Pathophysiology of non-insulin-dependent diabetes mellitus (NIDDM). Beck-Nielsen H, et al. **Diabetes Res Clin Pract** 1995 Aug;28 Suppl:S13-25 (21 ref.)

Insulin secretion in obese and non-obese NIDDM. Cerasi E, et al. **Diabetes Res Clin Pract** 1995 Aug;28 Suppl:S27-37 (62 ref.)

Alternative therapeutic principles in the prevention of microvascular and neuropathic complications. Gries FA. **Diabetes Res Clin Pract** 1995 Aug;28 Suppl:S201-7 (12 ref.)

Pathogenesis of insulin resistance: modulation of the insulin signal at receptor level. Kellerer M, et al. **Diabetes Res Clin Pract** 1995 Aug;28 Suppl:S173-7 (36 ref.)

Insulin deficiency and insulin resistance in the pathogenesis of NIDDM: is a divorce possible? Cerasi E. **Diabetologia** 1995 Aug;38(8):992-7 (50 ref.)

Sulphonylurea treatment of NIDDM patients with cardiovascular disease: a mixed blessing? Leibowitz G, et al. **Diabetologia** 1996 May;39(5):503-14 (140 ref.)

The pathogenesis of NIDDM: the role of the pancreatic beta cell. Zawalich WS, et al. **Diabetologia** 1995 Aug; 38(8):986-91 (41 ref.)

Mechanism of postprandial hyperglycaemia in diabetes mellitus. Dinneen SF. **Eur J Gastroenterol Hepatol** 1995 Aug;7(8):724-9 (39 ref.)

Current concepts of renal hemodynamics in diabetes. Anderson S, et al. **J Diabetes Complications** 1995 Oct-Dec; 9(4):304-7 (35 ref.)

Risk factors for non-insulin-dependent diabetes mellitus. Haffner SM. **J Hypertens Suppl** 1995 Aug;13(2):S73-6 (50 ref.)

Prognostic significance of albuminuria for the development of nephropathy. Viberti GF. **J Hypertens Suppl** 1995 Aug; 13(2):S87-9 (15 ref.)

Insulin resistance in obesity and its molecular control. Noguchi T, et al. **Obes Res** 1995 Sep;3 Suppl 2:195S-198S (20 ref.)

Effects of experimental diabetes and insulin on smooth muscle functions. Oztürk Y, et al. **Pharmacol Rev** 1996 Mar; 48(1):69-112 (728 ref.)

[Physiopathology of non-insulin-dependent diabetes] Guillausseau PJ, et al. **Ann Med Interne (Paris)** 1996; 147(2):87-92 (69 ref.) **(Fre)**

[Microalbuminuria and non-insulin-dependent diabetes: practical interpretation and therapeutic consequences] Bouhanick B, et al. **Diabete Metab** 1995 Oct;21(4):295-8 (20 ref.) **(Fre)**

[How I explore... insulin resistance in clinical practice] Scheen AJ. **Rev Med Liege** 1996 Jun;51(6):439-42 (23 ref.) **(Fre)**

[Metabolic syndrome and fatal quartet] Standl E. **Internist (Berl)** 1996 Jul;37(7):698-704 (36 ref.) **(Ger)**

[Insulin resistance and pathogenesis of non-insulin-dependent diabetes mellitus (part II)] Martinka E, et al. **Vnitr Lek** 1996 Mar;42(3):200-4 (32 ref.) (Eng. Abstr.) **(Slo)**

[Diabetic nephropathy and molecular biology of the renin-angiotensin system in the diabetic kidney] Rodríguez Pérez JC, et al. **Med Clin (Barc)** 1995 Nov 25; 105(18):708-15 (103 ref.) **(Spa)**

PREVENTION & CONTROL

Preventing diabetes mellitus; the epidemiological basis. Fernando D. **Ceylon Med J** 1995 Dec;40(4):136-8 (26 ref.)

Screening for NIDDM in nonpregnant adults. A review of principles, screening tests, and recommendations. Engelgau MM, et al. **Diabetes Care** 1995 Dec;18(12):1606-18 (118 ref.)

Controlling non-insulin-dependent diabetes mellitus in developing countries. Gulliford MC. **Int J Epidemiol** 1995; 24 Suppl 1:S53–9 (69 ref.)
Arguments in favor of screening for diabetes in cardiac rehabilitation. Maki KC, et al. **J Cardpulm Rehabil** 1995 Mar–Apr;15(2):97–102 (41 ref.)
[The role of physical activity in the prevention of certain internal diseases] Jákó P. **Orv Hetil** 1995 Oct 29; 136(44):2379–83 (44 ref.) (Eng. Abstr.) **(Hun)**

REHABILITATION

Physical activity in the treatment and prevention of diabetes. Spelsberg A, et al. **Compr Ther** 1995 Oct;21(10):559–62 (59 ref.)

THERAPY

Health care for persons with non-insulin-dependent diabetes mellitus. The German experience. Berger M, et al. **Ann Intern Med** 1996 Jan 1;124(1 Pt 2):153–5 (11 ref.)
Glucose control and insulin resistance in non-insulin-dependent diabetes mellitus. Henry RR. **Ann Intern Med** 1996 Jan 1;124(1 Pt 2):97–103 (19 ref.)
Management of non-insulin-dependent diabetes mellitus. The United Kingdom experience. Keen H. **Ann Intern Med** 1996 Jan 1;124(1 Pt 2):156–9 (10 ref.)
Unexplained improvement in diabetes control: a wolf in sheep's clothing. Snow KJ. **Compr Ther** 1995 Oct; 21(10):590–3 (16 ref.)
Inpatient management of adults with diabetes. Hirsch IB, et al. **Diabetes Care** 1995 Jun;18(6):870–8 (82 ref.)
Beyond glycemia. Vinik AI, et al. **Diabetes Care** 1995 Jul; 18(7):1037–41 (34 ref.)
NIDDM—the devastating disease. Horton ES. **Diabetes Res Clin Pract** 1995 Aug;28 Suppl:S3–11 (90 ref.)
Targets of therapy for NIDDM. Tattersall R. **Diabetes Res Clin Pract** 1995 Aug;28 Suppl:S49–55 (43 ref.)
Lessons from UK prospective diabetes study. Turner RC, et al. **Diabetes Res Clin Pract** 1995 Aug;28 Suppl:S131–7 (32 ref.)
Type II diabetes: a treatment approach for the older patient. Miller M. **Geriatrics** 1996 Aug;51(8):43–4, 47–9; quiz 50 (20 ref.)
Exercise in the management of non-insulin-dependent (type 2) diabetes mellitus. Gautier JF, et al. **Int J Obes Relat Metab Disord** 1995 Oct;19 Suppl 4:S58–61 (29 ref.)
Treatment of type II diabetes: what options have been added to traditional methods? Cefalu WT. **Postgrad Med** 1996 Mar;99(3):109–19, 122 (28 ref.)
The importance of tight blood glucose control in diabetes [editorial] Andersson DK. **Scand J Prim Health Care** 1995 Jun;13(2):81–2 (12 ref.)
[Current developments in the area of maturity onset diabetes of the young (MODY)] Tack CJ. **Ned Tijdschr Geneeskd** 1995 Oct 21;139(42):2127–9 (10 ref.) **(Dut)**
[Acarbose in therapy of diabetes] Mehnert H. **Internist (Berl)** 1995 Dec;36(12):1190–5 (21 ref.) **(Ger)**
[Non-medicamentous therapy of metabolic syndrome] Reimers CD, et al. **Internist (Berl)** 1996 Jul;37(7):712–21 (70 ref.) **(Ger)**
[Endocrinology update. II] Burgstaller M, et al. **Med Klin** 1996 Apr 10;91(4):207–17 (171 ref.) **(Ger)**

URINE

Differing effects of antihypertensive agents on urinary albumin excretion. Weir MR. **Am J Nephrol** 1996; 16(3):237–45 (69 ref.)
Microalbuminuria in non-insulin dependent diabetes mellitus [editorial; comment] Kumar S. **Diabet Med** 1995 Aug; 12(8):647–8 (11 ref.) Comment on: Diabet Med 1995 Aug;12(8):657–63.
Microalbuminuria in patients with NIDDM: an overview. Alzaid AA. **Diabetes Care** 1996 Jan;19(1):79–89 (136 ref.)
[Microalbuminuria and non-insulin-dependent diabetes: practical interpretation and therapeutic consequences] Bouhanick B, et al. **Diabete Metab** 1995 Oct;21(4):295–8 (20 ref.) **(Fre)**
[Diabetic nephropathy: significance of microalbuminuria and proteinuria in Type I and Type II diabetes mellitus] Lehmann R, et al. **Schweiz Rundsch Med Prax** 1995 Oct 31;84(44):1265–71 (53 ref.) (Eng. Abstr.) **(Ger)**

DIABETES MELLITUS, STABLE see **DIABETES MELLITUS, NON-INSULIN-DEPENDENT**

DIABETES MELLITUS, TYPE 1 see **DIABETES MELLITUS, INSULIN-DEPENDENT**

DIABETES MELLITUS, TYPE 2 see **DIABETES MELLITUS, NON-INSULIN-DEPENDENT**

DIABETES, PHOSPHATE see **HYPOPHOSPHATEMIA, FAMILIAL**

DIABETES, PREGNANCY-INDUCED see **DIABETES, GESTATIONAL**

DIABETIC ACIDOSIS see **DIABETIC KETOACIDOSIS**

DIABETIC ANGIOPATHIES

[Progress on diagnosis and therapy of diabetic angiopathies] Haranou Y, et al. **Nippon Naika Gakkai Zasshi** 1996 Apr 10;85(4):562–7 (12 ref.) **(Jpn)**
[Obesity and vascular diseases] Oikawa S, et al. **Nippon Naika Gakkai Zasshi** 1995 Aug 10;84(8):1246–50 (5 ref.) **(Jpn)**

COMPLICATIONS

Biochemical and vascular factors in the pathogenesis of diabetic neuropathy. Ward JD. **Clin Invest Med** 1995 Aug; 18(4):267–74 (67 ref.)
[Coronary disease and diabetes] Passa P, et al. **Diabete Metab** 1995 Dec;21(6):446–51 (19 ref.) **(Fre)**
[Diabetic cardiopathy (editorial)] Mattioli G. **Cardiologia** 1995 Aug;40(8):535–9 (15 ref.) **(Ita)**
[Erectile dysfunction in patients with diabetes] Franek E. **Przegl Lek** 1996;53(2):88–93 (30 ref.) (Eng. Abstr.) **(Pol)**

DIAGNOSIS

[Recent progress in diagnoses of diabetes and its complications] Matsuyama T. **Rinsho Byori** 1995 Dec; 43(12):1235–40 (16 ref.) (Eng. Abstr.) **(Jpn)**

DRUG THERAPY

Comparative effects of indapamide and captopril on blood pressure and albumin excretion rate in diabetic microalbuminuria. Donnelly R, et al. **Am J Cardiol** 1996 Feb 22;77(6):26B–30B (33 ref.)
Intervention in diabetic vascular disease by modulation of growth factors. Serri O, et al. **Metabolism** 1995 Oct;44(10 Suppl 4):83–90 (106 ref.)
[Beta blockers and diuretics: therapeutic drugs of first choice in diabetes mellitus and hypertension] Sawicki PT. **Wien Klin Wochenschr** 1995;107(21):629–39 (98 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

The vascular complications of diabetes mellitus. Gnudi A, et al. **Acta Biomed Ateneo Parmense** 1995;66(3–4):119–24 (12 ref.)
Advanced glycosylation end products in diabetic renal and vascular disease. Bucala R, et al. **Am J Kidney Dis** 1995 Dec;26(6):875–88 (114 ref.)
Hyperinsulinemia and atherosclerosis. Standl E. **Clin Invest Med** 1995 Aug;18(4):261–6 (40 ref.)
Dyslipoproteinemias in diabetes. Steiner G. **Clin Invest Med** 1995 Aug;18(4):282–7 (23 ref.)
Biochemical and molecular mechanisms in the development of diabetic vascular complications. King GL, et al. **Diabetes** 1996 Jul;45 Suppl 3:S105–8 (26 ref.)
Mechanism on disorders of coagulation and fibrinolysis in diabetes. Matsuda T, et al. **Diabetes** 1996 Jul;45 Suppl 3:S109–10 (21 ref.)
Recent progress in advanced glycation and diabetic vascular disease: role of advanced glycation end product receptors. Vlassara H, et al. **Diabetes** 1996 Jul;45 Suppl 3:S65–6 (17 ref.)
Role of insulin and proinsulin in diabetic vascular disease. Wareham NJ, et al. **Metabolism** 1995 Oct;44(10 Suppl 4):76–82 (56 ref.)
[Risk factors of microangiopathy in patients with non-insulin dependent diabetes mellitus] Czech A, et al. **Pol Tyg Lek** 1996 Jan;51(1–5):35–6 (9 ref.) **(Pol)**

IMMUNOLOGY

Cytokines, modified lipoproteins, and arteriosclerosis in diabetes. Lopes-Virella MF, et al. **Diabetes** 1996 Jul;45 Suppl 3:S40–4 (49 ref.)

PATHOLOGY

Diabetic macroangiopathy and atherosclerosis. Andresen JL, et al. **Diabetes** 1996 Jul;45 Suppl 3:S91–4 (39 ref.)

PHYSIOPATHOLOGY

Early atherogenesis in diabetes mellitus. Schaper NC. **Diabet Med** 1996;13 Suppl 1:S23–5 (30 ref.)
The aetiology of diabetic neuropathy: the combined roles of metabolic and vascular defects. Stevens MJ, et al. **Diabet Med** 1995 Jul;12(7):566–79 (187 ref.)
Diabetic cardiomyopathy. A unique entity or a complication of coronary artery disease? Bell DS. **Diabetes Care** 1995 May;18(5):708–14 (79 ref.)
Oxidative stress and diabetic vascular complications. Giugliano D, et al. **Diabetes Care** 1996 Mar;19(3):257–67 (152 ref.)
The insulin resistance syndrome revisited. Haffner SM. **Diabetes Care** 1996 Mar;19(3):275–7 (43 ref.)
Sulphonylurea treatment of NIDDM patients with cardiovascular disease: a mixed blessing? Leibowitz G, et al. **Diabetologia** 1996 May;39(5):503–14 (140 ref.)
[Vascular complications in diabetes mellitus: role of endothelial dysfunction] Stehouwer CD. **Ned Tijdschr Geneeskd** 1996 Apr 20;140(16):870–4 (27 ref.) **(Dut)**

PREVENTION & CONTROL

Prevention of long-term complications of non-insulin-dependent diabetes mellitus. Nathan DM. **Clin Invest Med** 1995 Aug;18(4):332–9 (44 ref.)
Prevention of macrovascular disease: absolute proof or absolute risk? [editorial] [see comments] Durrington PN. **Diabet Med** 1995 Jul;12(7):561–2 (12 ref.) Comment in: Diabet Med 1996 Mar;13(3):284–5.
Alternative therapeutic principles in the prevention of microvascular and neuropathic complications. Gries FA. **Diabetes Res Clin Pract** 1995 Aug;28 Suppl:S201–7 (12 ref.)
The importance of tight blood glucose control in diabetes [editorial] Andersson DK. **Scand J Prim Health Care** 1995 Jun;13(2):81–2 (12 ref.)
Non-ophthalmologic findings of the Diabetes Control and Complications Trial. Saudek CD. **Surv Ophthalmol** 1995 Sep–Oct;40(2):157–62 (33 ref.)

SURGERY

Lower extremity arterial reconstruction in patients with diabetes mellitus. Estes JM, et al. **Diabet Med** 1996;13 Suppl 1:S43–7 (17 ref.)

THERAPY

Diabetes and hypertension: prognostic and therapeutic considerations. Gilbert RE, et al. **Blood Press** 1995 Nov; 4(6):329–38 (101 ref.)
The management of hypertension in diabetes: with special reference to diabetic kidney disease. Leese GP, et al. **Diabet Med** 1996 May;13(5):401–10 (145 ref.)

ULTRASONOGRAPHY

[Importance of cerebrovascular reactivity testing in diabetes mellitus] Fülesdi B, et al. **Orv Hetil** 1995 Nov 12; 136(46):2497–500 (35 ref.) (Eng. Abstr.) **(Hun)**

DIABETIC DIET

Nutrition principles and diabetes. A role for "lente carbohydrate"? Jenkins DJ, et al. **Diabetes Care** 1995 Nov; 18(11):1491–8 (78 ref.)
[Lipid metabolism and new dietetic recommendations in diabetes mellitus] Sanz París A, et al. **An Med Interna** 1996 Mar;13(3):136–45 (78 ref.) (Eng. Abstr.) **(Spa)**

STANDARDS

International tables of glycemic index. Foster-Powell K, et al. **Am J Clin Nutr** 1995 Oct;62(4):871S–890S (79 ref.)

DIABETIC FOOT

[The ischemic diabetic foot] Tešić D. **Med Pregl** 1995; 48(7–8):235–40 (29 ref.) (Eng. Abstr.) **(Scr)**

COMPLICATIONS

Antibiotic therapy in diabetic foot infection. van der Meer JW, et al. **Diabet Med** 1996;13 Suppl 1:S48–51 (19 ref.)

DIAGNOSIS

The clinical examination of the diabetic foot in daily practise. de Heus-van Putten MA, et al. **Diabet Med** 1996;13 Suppl 1:S55–7 (17 ref.)
The use of non-invasive vascular assessment in diabetic patients with foot lesions. Takolander R, et al. **Diabet Med** 1996;13 Suppl 1:S39–42 (30 ref.)
Magnetic resonance imaging of the diabetic foot. Spaeth HJ Jr, et al. **Magn Reson Imaging Clin N Am** 1994 Feb; 2(1):123–30 (28 ref.)
Imaging the diabetic foot. Gold RH, et al. **Skeletal Radiol** 1995 Nov;24(8):563–71 (30 ref.)

EPIDEMIOLOGY

The epidemiology of diabetic foot problems. Reiber GE. **Diabet Med** 1996;13 Suppl 1:S6–11 (39 ref.)

ETIOLOGY

[Progress on diagnosis and therapy of diabetic gangrene] Saito N, et al. **Nippon Naika Gakkai Zasshi** 1996 Apr 10; 85(4):556–61 (8 ref.) **(Jpn)**

MICROBIOLOGY

Foot infections in diabetic patients: the role of anaerobes. Gerding DN. **Clin Infect Dis** 1995 Jun;20 Suppl 2:S283–8 (17 ref.)

NURSING

Performing foot screening for diabetic patients. Dorgan MB, et al. **Am J Nurs** 1995 Nov;95(11):32–6; quiz 37 (12 ref.)

PATHOLOGY

The histology of diabetic foot ulcers. Ferguson MW, et al. **Diabet Med** 1996;13 Suppl 1:S30–3 (27 ref.)

PHYSIOPATHOLOGY

The pathogenesis of diabetic foot problems: an overview. Boulton AJ. **Diabet Med** 1996;13 Suppl 1:S12–6 (28 ref.)
Biomechanical aspects of diabetic foot disease: aetiology, treatment, and prevention. Cavanagh PR, et al. **Diabet Med** 1996;13 Suppl 1:S17–22 (30 ref.)

The clinical examination of the diabetic foot in daily practise. de Heus-van Putten MA, et al. **Diabet Med** 1996;13 Suppl 1:S55-7 (17 ref.)
The Charcot joint in diabetes. Klenerman L. **Diabet Med** 1996;13 Suppl 1:S52-4 (11 ref.)
The use of non-invasive vascular assessment in diabetic patients with foot lesions. Takolander R, et al. **Diabet Med** 1996;13 Suppl 1:S39-42 (30 ref.)
Microvascular aspects of diabetic foot disease. Tooke JE, et al. **Diabet Med** 1996;13 Suppl 1:S26-9 (14 ref.)

PREVENTION & CONTROL

Education and the diabetic foot. Edmonds ME, et al. **Diabet Med** 1996;13 Suppl 1:S61-4 (25 ref.)
Preventing amputation in the patient with diabetes. Levin ME. **Disbetes Care** 1995 Oct;18(10):1383-94 (117 ref.)
[The treatment of distal neuropathy--an important means for preventing the development of diabetic gangrene] Datsun IH, et al. **Vrach Delo** 1995 Jan-Feb;(1-2):25-9 (29 ref.) **(Ukr)**

REHABILITATION

Education and the diabetic foot. Edmonds ME, et al. **Diabet Med** 1996;13 Suppl 1:S61-4 (25 ref.)

SURGERY

Growth factors and comprehensive surgical care of diabetic wounds. Knighton DR, et al. **Curr Opin Gen Surg** 1993; :32-9 (42 ref.)
Lower extremity arterial reconstruction in patients with diabetes mellitus. Estes JM, et al. **Diabet Med** 1996;13 Suppl 1:S43-7 (17 ref.)
Preventing amputation in the patient with diabetes. Levin ME. **Diabetes Care** 1995 Oct;18(10):1383-94 (117 ref.)
[Role of conservative orthopedic surgery in the treatment of the diabetic foot] Ha Van G, et al. **Diabetes Metab** 1996 Feb;22(1):80-6 (31 ref.) **(Fre)**

THERAPY

Prevention and care of diabetic foot ulcers [see comments] Birrer RB, et al. **Am Fam Physician** 1996 Feb 1; 53(2):601-11, 615-6 (28 ref.) Comment in: Am Fam Physician 1996 Jul;54(1):70. Comment in: Am Fam Physician 1996 Jul;54(1):70, 72.
Management of foot problems in diabetes. Shaw JE, et al. **Perit Dial Int** 1996;16 Suppl 1:S279-82 (26 ref.)
Total contact casting for diabetic neuropathic ulcers. Sinacore DR. **Phys Ther** 1996 Mar;76(3):296-301 (29 ref.)
Dealing with the diabetic foot. Cooke E. **Practitioner** 1996 Feb;240(1559):112-4 (5 ref.)

DIABETIC KETOACIDOSIS

Review: diabetic ketoacidosis and hyperglycemic hyperosmolar nonketotic syndrome. Umpierrez GE, et al. **Am J Med Sci** 1996 May;311(5):225-33 (75 ref.)

DRUG THERAPY

Treatment with insulin infusion pumps and ketoacidotic episodes: from physiology to troubleshooting. Castillo MJ, et al. **Diabetes Metab Rev** 1995 Jul;11(2):161-77 (87 ref.)

ETIOLOGY

Can a severe degree of ketoacidosis develop overnight? Schreiber M, et al. **J Am Soc Nephrol** 1996 Feb;7(2):192-7 (20 ref.)

PHYSIOPATHOLOGY

Treatment with insulin infusion pumps and ketoacidotic episodes: from physiology to troubleshooting. Castillo MJ, et al. **Diabetes Metab Rev** 1995 Jul;11(2):161-77 (87 ref.)

THERAPY

Management of diabetic ketoacidosis in childhood. Edge JA. **Br J Hosp Med** 1996 Apr 17-30;55(8):508-12 (21 ref.)
Diabetic ketoacidosis (DKA): treatment guidelines. Rosenbloom AL, et al. **Clin Pediatr (Phila)** 1996 May; 35(5):261-6 (15 ref.)
Management of hypoglycemia and diabetic ketoacidosis in pregnancy. Whiteman VE, et al. **Obstet Gynecol Clin North Am** 1996 Mar;23(1):87-107 (90 ref.)
Diabetic ketoacidosis and hyperosmolar nonketotic state: gaining control over extreme hyperglycemic complications. Gonzalez-Campoy JM, et al. **Postgrad Med** 1996 Jun; 99(6):143-52 (21 ref.)
[Emergency drug therapy of diabetic coma] Morita S, et al. **Nippon Naika Gakkai Zasshi** 1995 Nov 10;84(11):1843-7 (4 ref.) **(Jpn)**

DIABETIC KETOSIS see **DIABETIC KETOACIDOSIS**

DIABETIC NEPHROPATHIES

Diabetic nephropathy in type II diabetes. Ritz E, et al. **Am J Kidney Dis** 1996 Feb;27(2):167-94 (218 ref.)
Diabetes mellitus and associated hypertension, vascular disease, and nephropathy. An update. Sowers JR, et al. **Hypertension** 1995 Dec;26(6 Pt 1):869-79 (59 ref.)
[Progress on diagnosis and therapy of diabetic nephropathy] Kitsukawa R. **Nippon Naika Gakkai Zasshi** 1996 Apr 10; 85(4):546-50 (5 ref.) **(Jpn)**
[Diabetic nephropathy and molecular biology of the renin-angiotensin system in the diabetic kidney] Rodríguez Pérez JC, et al. **Med Clin (Barc)** 1995 Nov 25; 105(18):708-15 (103 ref.) **(Spa)**

COMPLICATIONS

[Eye fundus of the diabetic patient with nephropathy and hypertensive retinopathy. Macroangiopathic complications] Leys AM. **Bull Soc Belge Ophtalmol** 1995; 256:49-59 (29 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Microalbuminuria and potential confounders. A review and some observations on variability of urinary albumin excretion. Mogensen CE, et al. **Diabetes Care** 1995 Apr; 18(4):572-81 (85 ref.)
Surveillance for complications of diabetes: don't wait for symptoms before intervening. Hirsch IB. **Postgrad Med** 1996 Mar;99(3):147-55, 159-62 (24 ref.)
[Microalbuminuria in diabetes mellitus--illness or symptom?] Müller WA. **Versicherungsmedizin** 1996 Jun 1;48(3):70-6 (84 ref.) (Eng. Abstr.) **(Ger)**
[Early diagnosis and therapy of diabetic nephropathy] Shigeta Y. **Nippon Naika Gakkai Zasshi** 1996 Mar 10; 85(3):464-7 (7 ref.) **(Jpn)**

DRUG THERAPY

Comparative effects of indapamide and captopril on blood pressure and albumin excretion rate in diabetic microalbuminuria. Donnelly R, et al. **Am J Cardiol** 1996 Feb 22;77(6):26B-30B (33 ref.)
Therapeutic options in diabetic renal disease and hypertension. Savage MW, et al. **Br J Hosp Med** 1995 Nov 1-14;54(9):429-34 (26 ref.)
Angiotensin-converting enzyme inhibition in type I diabetic nephropathy. Lewis EJ. **Contrib Nephrol** 1996;118:206-13 (4 ref.)
Angiotensin converting enzyme inhibitors and calcium antagonists alone or combined: does the progression of diabetic renal disease differ? Bakris GL, et al. **J Hypertens Suppl** 1995 Aug;13(2):S95-101 (52 ref.)
Effects of angiotensin converting enzyme inhibitors on the progression of diabetic nephropathy. Ruilope LM. **J Hypertens Suppl** 1995 Aug;13(2):S91-3 (26 ref.)
Effects of ACE inhibitors and calcium antagonists alone or combined on progression of diabetic nephropathy. Lash JP, et al. **Nephrol Dial Transplant** 1995 Oct;10 Suppl 9:56-62 (52 ref.)
[ACE inhibitors and early diabetic nephropathy] Bangstad HJ, et al. **Tidsskr Nor Laegeforen** 1995 Oct 10; 115(24):3039-41 (25 ref.) (Eng. Abstr.) **(Nor)**

EPIDEMIOLOGY

Microalbuminuria in patients with NIDDM: an overview. Alzaid AA. **Diabetes Care** 1996 Jan;19(1):79-89 (136 ref.)
Diabetes complications: the renal-retinal link. An epidemiological perspective. Lloyd CE, et al. **Diabetes Care** 1995 Jul;18(7):1034-6 (19 ref.)
Genetic susceptibility to nephropathy in insulin-dependent diabetes: from epidemiology to molecular genetics. Doria A, et al. **Diabetes Metab Rev** 1995 Dec;11(4):287-314 (213 ref.)

ETIOLOGY

The natural history of renal disease in non-insulin-dependent diabetes mellitus: lessons from the Pima Indians. Nelson RG, et al. **Adv Nephrol Necker Hosp** 1995;24:145-56 (47 ref.)
Renal involvement in type II diabetes. Ritz E, et al. **Adv Nephrol Necker Hosp** 1995;24:131-43 (58 ref.)
Advanced glycosylation end products in diabetic renal and vascular disease. Bucala R, et al. **Am J Kidney Dis** 1995 Dec;26(6):875-88 (114 ref.)
The use of neutralizing antibodies to demonstrate the role of transforming growth factor-beta and Amadori-glycated albumin as mediators of experimental diabetic kidney disease. Ziyadeh FN, et al. **Contrib Nephrol** 1996; 118:188-94 (39 ref.)
Role of Amadori-modified nonenzymatically glycated serum proteins in the pathogenesis of diabetic nephropathy [editorial] Cohen MP, et al. **J Am Soc Nephrol** 1996 Feb; 7(2):183-90 (127 ref.)
Role of oxidative stress in the development of diabetic nephropathy. Ha H, et al. **Kidney Int Suppl** 1995 Sep; 51:S18-21 (59 ref.)
The role of growth hormone, insulin-like growth factors (IGFs), and IGF-binding proteins in experimental diabetic kidney disease. Flyvbjerg A, et al. **Metabolism** 1995 Oct; 44(10 Suppl 4):67-71 (62 ref.)
Mediators of hyperglycemia and the pathogenesis of matrix accumulation in diabetic renal disease. Ziyadeh FN. **Miner Electrolyte Metab** 1995;21(4-5):292-302 (157 ref.)
Diabetic renal disease: microalbuminuria, implications and intervention. Savage MW, et al. **Nutrition** 1995 Nov-Dec; 11(6):761-4 (57 ref.)
[The kidney in diabetes mellitus--new aspects on pathogenesis, diagnosis and therapy] Thaiss F, et al. **Z Arztl Fortbild (Jena)** 1996 May;90(3):199-204 (39 ref.) (Eng. Abstr.) **(Ger)**
[Contemporary view on pathophysiology and pathogenesis of diabetic nephropathy. I. Pathophysiology of diabetic nephropathy] Grzeszczak W, et al. **Pol Arch Med Wewn** 1996 May;95(5):471-8 (91 ref.) **(Pol)**
[Contemporary view on pathophysiology and pathogenesis of diabetic nephropathy. II. Pathogenesis of diabetic nephropathy] Grzeszczak W, et al. **Pol Arch Med Wewn** 1996 May;95(5):479-85 (157 ref.) **(Pol)**

GENETICS

Nephropathy in type 1 diabetes: the role of genetic factors. Chowdhury TA, et al. **Diabet Med** 1995 Dec; 12(12):1059-67 (61 ref.)
Genetic susceptibility to nephropathy in insulin-dependent diabetes: from epidemiology to molecular genetics. Doria A, et al. **Diabetes Metab Rev** 1995 Dec;11(4):287-314 (213 ref.)
Genetic susceptibility to diabetic kidney disease: an update. Krolewski AS, et al. **J Diabetes Complications** 1995 Oct-Dec;9(4):277-81 (49 ref.)
Genetic factors in the development of diabetic nephropathy. Trevisan R, et al. **J Lab Clin Med** 1995 Oct;126(4):342-9 (63 ref.)
Genetic pattern in diabetic nephropathy [editorial] Tarnow L. **Nephrol Dial Transplant** 1996 Mar;11(3):410-2 (23 ref.)

METABOLISM

Role of transforming growth factor-beta in diabetic glomerulosclerosis and renal hypertrophy. Ziyadeh FN, et al. **Kidney Int Suppl** 1995 Sep;51:S34-6 (34 ref.)
'Toxicity of glucose: is AGE the answer?' Makita Z. **Nephrol Dial Transplant** 1995;10 Suppl 7:33-7 (32 ref.)
[The pathobiochemistry of nephropathy in diabetes] Angielski S. **Klin Lab Diagn** 1995 Nov-Dec;(6):15-20 (58 ref.) **(Rus)**

PATHOLOGY

The structure of glomeruli and juxtaglomerular arterioles in the early phase of diabetic nephropathy--relationship between progression and metabolic control. Osterby R, et al. **Contrib Nephrol** 1996;118:195-205 (24 ref.)
[Approach of cellular mechanisms of glomerulosclerosis in a model of accelerated aging the obese Zucker rat] Chevalier J, et al. **C R Seances Soc Biol Fil** 1995; 189(6):987-1007 (64 ref.) (Eng. Abstr.) **(Fre)**
[Pathology of diabetes mellitus] Yagihashi S. **Nippon Naika Gakkai Zasshi** 1996 Apr 10;85(4):568-72 (5 ref.) **(Jpn)**

PHYSIOPATHOLOGY

The pathophysiology of diabetic complications: how much does the glucose hypothesis explain? Nathan DM. **Ann Intern Med** 1996 Jan 1;124(1 Pt 2):86-9 (51 ref.)
Hyperglycemia and diabetic kidney disease. The case for transforming growth factor-beta as a key mediator. Sharma K, et al. **Diabetes** 1995 Oct;44(10):1139-46 (124 ref.)
Heparan sulphate in the pathogenesis of diabetic nephropathy. Kofoed-Enevoldsen A. **Diabetes Metab Rev** 1995 Jul;11(2):137-60 (143 ref.)
Insulin-like growth factors (IGFs) and IGF-binding proteins in diabetic kidney disease. Phillip M, et al. **Isr J Med Sci** 1995 Dec;31(12):712-6 (66 ref.)
Current concepts of renal hemodynamics in diabetes. Anderson S, et al. **J Diabetes Complications** 1995 Oct-Dec; 9(4):304-7 (35 ref.)
Extracellular matrix and its interactions in the diabetic kidney: a molecular biological approach. Gilbert RE, et al. **J Diabetes Complications** 1995 Oct-Dec;9(4):252-4 (27 ref.)
Natural history of early diabetic nephropathy: what are the effects of therapeutic intervention? Melbourne Diabetic Nephropathy Study Group. Jerums G, et al. **J Diabetes Complications** 1995 Oct-Dec;9(4):308-14 (47 ref.)
Advanced glycation endproducts and diabetic nephropathy. Makita Z, et al. **J Diabetes Complications** 1995 Oct-Dec; 9(4):265-8 (26 ref.)
Microalbuminuria in prediction and prevention of diabetic nephropathy in insulin-dependent diabetes mellitus patients. Mogensen CE. **J Diabetes Complications** 1995 Oct-Dec;9(4):337-49 (99 ref.)
Molecular and physiological aspects of nephropathy in type I (insulin-dependent) diabetes mellitus. Raskin GS, et al. **J Diabetes Complications** 1996 Jan-Feb;10(1):31-7 (59 ref.)
Prognostic significance of albuminuria for the development of nephropathy. Viberti GF. **J Hypertens Suppl** 1995 Aug; 13(2):S87-9 (15 ref.)
Endothelins in diabetic kidneys. Koide H, et al. **Kidney Int Suppl** 1995 Sep;51:S45-9 (68 ref.)
Does nitric oxide, an inflammatory mediator of glomerular mesangial cells, have a role in diabetic nephropathy? Pfeilschifter J. **Kidney Int Suppl** 1995 Sep;51:S50-60 (114 ref.)
Renal functional reserve in subjects with diabetes mellitus. Jones SL, et al. **Semin Nephrol** 1995 Sep;15(5):475-81 (51 ref.)

DIABETIC NEPHROPATHIES

[Approach of cellular mechanisms of glomerulosclerosis in a model of accelerated aging the obese Zucker rat] Chevalier J, et al. **C R Seances Soc Biol Fil** 1995; 189(6):987–1007 (64 ref.) (Eng. Abstr.) **(Fre)**

[The renal tubulointerstitium in diabetes mellitus] Ueno M, et al. **Nippon Rinsho** 1995 Aug;53(8):1981–7 (23 ref.) (Eng. Abstr.) **(Jpn)**

PREVENTION & CONTROL

Prevention and treatment of diabetic nephropathy. Foote EF. **Am J Health Syst Pharm** 1995 Aug 15;52(16):1781–92 (94 ref.)

Are angiotensin-converting enzyme inhibitors the renal protective antihypertensive drugs of choice? [editorial] Bauer JH. **Curr Opin Nephrol Hypertens** 1995 Sep; 4(5):427–31 (23 ref.)

Natural history of early diabetic nephropathy: what are the effects of therapeutic intervention? Melbourne Diabetic Nephropathy Study Group. Jerums G, et al. **J Diabetes Complications** 1995 Oct–Dec;9(4):308–14 (47 ref.)

Microalbuminuria in prediction and prevention of diabetic nephropathy in insulin-dependent diabetes mellitus patients. Mogensen CE. **J Diabetes Complications** 1995 Oct–Dec;9(4):337–49 (99 ref.)

Prevention of diabetic renal disease with special reference to microalbuminuria [see comments] Mogensen CE, et al. **Lancet** 1995 Oct 21;346(8982):1080–4 (49 ref.) Comment in: Lancet 1995 Dec 16;346(8990):1638.

Renoprotection in diabetes. With special reference to insulin-dependent patients. Mogensen CE. **Schweiz Med Wochenschr** 1995 Dec 26;125(51–52):2471–8 (45 ref.)

[The feasibility and current limits in the prevention of diabetic nephropathy] Savazzi GM, et al. **Ann Ital Med Int** 1996 Jan–Mar;11(1):39–45 (40 ref.) (Eng. Abstr.) **(Ita)**

SURGERY

The case for pancreas transplantation. Sutherland DE. **Diabetes Metab** 1996 Apr;22(2):132–8 (39 ref.)

Renal transplantation in patients with type 2 diabetes mellitus. Hirschl MM. **Nephrol Dial Transplant** 1995;10 Suppl 7:58–60 (12 ref.)

The patient with type II diabetes and uraemia—to transplant or not to transplant [editorial] Hirschl MM. **Nephrol Dial Transplant** 1995;10(9):1515–6 (7 ref.)

Pancreas transplantation. Stratta RJ, et al. **Ren Fail** 1995 Jul; 17(4):323–37 (85 ref.)

[Advantages and disadvantages of combination kidney and pancreas transplantation] Marti HP, et al. **Ther Umsch** 1995 Sep;52(9):594–601 (44 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Prevention and treatment of diabetic nephropathy. Foote EF. **Am J Health Syst Pharm** 1995 Aug 15;52(16):1781–92 (94 ref.)

Why are lipids not predictive of cardiovascular death in the dialysis patient? Ritz E. **Miner Electrolyte Metab** 1996; 22(1–3):9–12 (25 ref.)

Management choices in diabetic end-stage renal disease. Friedman EA. **Nephrol Dial Transplant** 1995;10 Suppl 7:61–9 (73 ref.)

Diabetic nephropathy and pregnancy. Kitzmiller JL, et al. **Obstet Gynecol Clin North Am** 1996 Mar;23(1):173–203 (192 ref.)

Dialysis in patients with diabetic nephropathy: CAPD versus hemodialysis. Lee HB, et al. **Perit Dial Int** 1996;16 Suppl 1:S269–74 (28 ref.)

Quality of life elderly and diabetic patients on peritoneal dialysis. Nissenson AR. **Perit Dial Int** 1996;16 Suppl 1:S406–9 (33 ref.)

Peritoneal dialysis in diabetics. Optimal insulin therapy on CAPD: intraperitoneal versus subcutaneous treatment. Scarpioni L, et al. **Perit Dial Int** 1996;16 Suppl 1:S275–8 (33 ref.)

Management of foot problems in diabetes. Shaw JE, et al. **Perit Dial Int** 1996;16 Suppl 1:S279–82 (26 ref.)

[Treatment of chronic kidney failure in diabetics with peritoneal dialysis] Bednářová V, et al. **Cas Lek Cesk** 1996 May 29;135(11):340–3 (27 ref.) (Eng. Abstr.) **(Cze)**

[Renal replacement therapy of patients with chronic diabetic nephropathy] Kawaguchi Y. **Nippon Naika Gakkai Zasshi** 1995 Oct 10;84(10):1632–6 (5 ref.) **(Jpn)**

[Early diagnosis and therapy of diabetic nephropathy] Shigeta Y. **Nippon Naika Gakkai Zasshi** 1996 Mar 10; 85(3):464–7 (7 ref.) **(Jpn)**

[Considerations on the treatment of incipient diabetic nephropathy (lst of 2 parts)] Pérez Blanco FJ, et al. **An Med Interna** 1996 Apr;13(4):193–7 (91 ref.) (Eng. Abstr.) **(Spa)**

[The treatment of incipient diabetic nephropathy (2nd of 2 parts)] Pérez Blanco FJ, et al. **An Med Interna** 1996 May; 13(5):248–50 (41 ref.) (Eng. Abstr.) **(Spa)**

URINE

Differing effects of antihypertensive agents on urinary albumin excretion. Weir MR. **Am J Nephrol** 1996; 16(3):237–45 (69 ref.)

[Microalbuminuria in diabetes mellitus] van Etten RW, et al. **Ned Tijdschr Geneeskd** 1995 Sep 9;139(36):1823–8 (72 ref.) **(Dut)**

[Diabetic nephropathy: significance of microalbuminuria and proteinuria in Type I and Type II diabetes mellitus] Lehmann R, et al. **Schweiz Rundsch Med Prax** 1995 Oct 31;84(44):1265–71 (53 ref.) (Eng. Abstr.) **(Ger)**

DIABETIC NEUROPATHIES

Diabetic neuropathy in elderly patients. What can be done? Belmin J, et al. **Drugs Aging** 1996 Jun;8(6):416–29 (97 ref.)

[Diabetic neuropathy. Current concepts on etiopathogenesis, diagnosis, and treatment] Zorrilla Hernández E, et al. **Gac Med Mex** 1994 Jan–Feb;130(1):18–25 (70 ref.) (Eng. Abstr.) **(Spa)**

CHEMICALLY INDUCED

Animal models of neuropathies. Schmalbruch H, et al. **Baillieres Clin Neurol** 1996 Mar;5(1):77–105 (243 ref.)

COMPLICATIONS

Impotence in diabetes mellitus. Close CF, et al. **Diabetes Metab Rev** 1995 Oct;11(3):279–85 (49 ref.)

The role of diabetic neuropathy and high plantar pressures in the pathogenesis of foot ulceration. Katoulis EC, et al. **Horm Metab Res** 1996 Apr;28(4):159–64 (62 ref.)

[Erectile dysfunction in patients with diabetes] Franek E. **Przegl Lek** 1996;53(2):88–93 (30 ref.) (Eng. Abstr.) **(Pol)**

DIAGNOSIS

Diabetic neuropathies. Low PA, et al. **Baillieres Clin Neurol** 1995 Nov;4(3):401–25 (118 ref.)

Diagnosis and management of diabetic peripheral neuropathy. Ziegler D. **Diabet Med** 1996;13 Suppl 1:S34–8 (30 ref.)

Identifying patients with diabetes mellitus who are at risk for lower-extremity complications: use of Semmes–Weinstein monofilaments. Mueller MJ. **Phys Ther** 1996 Jan;76(1):68–71 (15 ref.)

Surveillance for complications of diabetes: don't wait for symptoms before intervening. Hirsch IB. **Postgrad Med** 1996 Mar;99(3):147–55, 159–62 (24 ref.)

[Diabetic cardiovascular neuropathy] Luft D. **Z Arztl Fortbild (Jena)** 1996 Apr;90(2):139–43 (38 ref.) (Eng. Abstr.) **(Ger)**

[Diabetic neuropathy: overview of clinical problems] Czech A, et al. **Pol Tyg Lek** 1996 Jan;51(1–5):33–4 (11 ref.) **(Pol)**

DRUG THERAPY

Peripheral diabetic neuropathy: current concepts in treatment. Calissi PT, et al. **Ann Pharmacother** 1995 Jul–Aug;29(7–8):769–77 (57 ref.)

New approaches for treatment in diabetes: aldose reductase inhibitors. Hotta N. **Biomed Pharmacother** 1995; 49(5):232–43 (168 ref.)

Topical capsaicin. A review of its pharmacological properties and therapeutic potential in post-herpetic neuralgia, diabetic neuropathy and osteoarthritis. Rains C, et al. **Drugs Aging** 1995 Oct;7(4):317–28 (52 ref.)

[Therapeutic strategies in diabetic neuropathy. Pathogenetically founded therapeutic approaches in peripheral, sensory, symmetrical neuropathy] Luft D. **Med Klin** 1996 May 15;91(5):295–301 (70 ref.) **(Ger)**

[Tolrestat in the therapy of diabetic peripheral neuropathy: is this drug really useful?] Daniele E, et al. **Clin Ter** 1995 Dec;146(12):793–99 (31 ref.) (Eng. Abstr.) **(Ita)**

ETIOLOGY

Biochemical and vascular factors in the pathogenesis of diabetic neuropathy. Ward JD. **Clin Invest Med** 1995 Aug; 18(4):267–74 (67 ref.)

The aetiology of diabetic neuropathy: the combined roles of metabolic and vascular defects. Stevens MJ, et al. **Diabet Med** 1995 Jul;12(7):566–79 (187 ref.)

Simultaneous, multiple cranial neuropathies in diabetes mellitus. Eshbaugh CG, et al. **J Neuroophthalmol** 1995 Dec; 15(4):219–24 (23 ref.)

Neurotrophins and peripheral neuropathy. Tomlinson DR, et al. **Philos Trans R Soc Lond B Biol Sci** 1996 Mar 29; 351(1338):455–62 (47 ref.)

GENETICS

Pathology and pathogenetic mechanisms of diabetic neuropathy. Yagihashi S. **Diabetes Metab Rev** 1995 Oct; 11(3):193–225 (330 ref.)

METABOLISM

The calcium hypothesis of brain aging and neurodegenerative disorders: significance in diabetic neuropathy. Biessels G, et al. **Life Sci** 1996;59(5–6):379–87 (67 ref.)

PATHOLOGY

Pathology and pathogenetic mechanisms of diabetic neuropathy. Yagihashi S. **Diabetes Metab Rev** 1995 Oct; 11(3):193–225 (330 ref.)

PHYSIOPATHOLOGY

The pathophysiology of diabetic complications: how much does the glucose hypothesis explain? Nathan DM. **Ann Intern Med** 1996 Jan 1;124(1 Pt 2):86–9 (51 ref.)

Diabetic neuropathy. Llewelyn JG. **Curr Opin Neurol** 1995 Oct;8(5):364–6 (16 ref.)

The pathogenesis of diabetic foot problems: an overview. Boulton AJ. **Diabet Med** 1996;13 Suppl 1:S12–6 (28 ref.)

Biomechanical aspects of diabetic foot disease: aetiology, treatment, and prevention. Cavanagh PR, et al. **Diabet Med** 1996;13 Suppl 1:S17–22 (30 ref.)

The Charcot joint in diabetes. Klenerman L. **Diabet Med** 1996;13 Suppl 1:S52–4 (11 ref.)

The aetiology of diabetic neuropathy: the combined roles of metabolic and vascular defects. Stevens MJ, et al. **Diabet Med** 1995 Jul;12(7):566–79 (187 ref.)

Electrophysiological alterations of the central nervous system in diabetes mellitus. Di Mario U, et al. **Diabetes Metab Rev** 1995 Oct;11(3):259–77 (153 ref.)

Diabetic autonomic neuropathy. Spallone V, et al. **Diabetes Metab Rev** 1995 Oct;11(3):227–57 (322 ref.)

The role of oxidative stress in neuropathy and other diabetic complications. Van Dam PS, et al. **Diabetes Metab Rev** 1995 Oct;11(3):181–92 (72 ref.)

Long-term pancreatic function: potential benefits. Bartlett ST, et al. **Transplant Proc** 1996 Aug;28(4):2128–30 (18 ref.)

PREVENTION & CONTROL

Beyond glycemia. Vinik AI, et al. **Diabetes Care** 1995 Jul; 18(7):1037–41 (34 ref.)

Alternative therapeutic principles in the prevention of microvascular and neuropathic complications. Gries FA. **Diabetes Res Clin Pract** 1995 Aug;28 Suppl:S201–7 (12 ref.)

[Neuro-ophthalmological problems in the diabetic patient] Boschi A. **Bull Soc Belge Ophtalmol** 1995;256:145–50 (19 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Diagnosis and management of diabetic peripheral neuropathy. Ziegler D. **Diabet Med** 1996;13 Suppl 1:S34–8 (30 ref.)

Clinical trials of diabetic neuropathy: past, present, and future. Pfeifer MA, et al. **Diabetes** 1995 Dec;44(12):1355–61 (51 ref.)

Management of diabetic pregnancy complicated by coronary artery disease and neuropathy. Hagay Z, et al. **Obstet Gynecol Clin North Am** 1996 Mar;23(1):205–20 (38 ref.)

[Progress on diagnosis and therapy of diabetic neuropathies] Matsuoka K. **Nippon Naika Gakkai Zasshi** 1996 Apr 10; 85(4):551–5 (5 ref.) **(Jpn)**

[Diabetic neuropathy: overview of clinical problems] Czech A, et al. **Pol Tyg Lek** 1996 Jan;51(1–5):33–4 (11 ref.) **(Pol)**

[The treatment of distal neuropathy—an important means for preventing the development of diabetic gangrene] Datsun IH, et al. **Vrach Delo** 1995 Jan–Feb;(1–2):25–9 (29 ref.) **(Ukr)**

DIABETIC RETINOPATHY

Diabetic retinopathy. Klein R. **Annu Rev Public Health** 1996; 17:137–58 (91 ref.)

[Diabetic retinopathy] Kalvodová B. **Cesk Oftalmol** 1995 Sep; 51(4):240–53 (0 ref.) **(Cze)**

[Physiopathology and treatment of diabetic retinopathy] Ishibashi T. **Fukuoka Igaku Zasshi** 1995 Oct;86(10):379–84 (4 ref.) **(Jpn)**

[Progress on diagnosis and therapy of diabetic retinopathy] Akiya S, et al. **Nippon Naika Gakkai Zasshi** 1996 Apr 10; 85(4):541–5 (5 ref.) **(Jpn)**

BLOOD

Diabetic retinopathy. Evans SA. **J R Soc Med** 1996 Apr; 89(4):230P–1P (11 ref.)

COMPLICATIONS

Diabetic vascular injury and ACE. Potential for pharmacological prevention of complications of later life. Cooper ME, et al. **Drugs Aging** 1996 Jan;8(1):38–46 (90 ref.)

Diabetic vitreopathy [editorial; comment] Sebag J. **Ophthalmology** 1996 Feb;103(2):205–6 (5 ref.) Comment on: Ophthalmology 1996 Feb;103(2):315–22. Comment on: Ophthalmology 1996 FEB;103(2):323–8.

[Repercussions of cataract surgery on the development of diabetic retinopathy] Comhaire-Poutchinian Y. **Bull Soc Belge Ophtalmol** 1995;256:115–23 (32 ref.) (Eng. Abstr.) **(Fre)**

[Neovascular glaucoma in the diabetic patient] Detry-Morel M. **Bull Soc Belge Ophtalmol** 1995;256:133–41 (27 ref.) (Eng. Abstr.) **(Fre)**

[Eye fundus of the diabetic patient with nephropathy and hypertensive retinopathy. Macroangiopathic complications] Leys AM. **Bull Soc Belge Ophtalmol** 1995; 256:49–59 (29 ref.) (Eng. Abstr.) **(Fre)**

[Effective mechanisms of laser photocoagulation for neovascularization in diabetic retinopathy] Funatsu H, et al. **Nippon Ganka Gakkai Zasshi** 1996 May;100(5):339–49 (64 ref.) (Eng. Abstr.) **(Jpn)**

[The pathogenesis of diabetic dyschromatopsia] Gheorghiu M. **Oftalmologia** 1996 Jan-Mar;40(1):11-5 (15 ref.) (Eng. Abstr.) **(Rum)**

DIAGNOSIS

Surveillance for complications of diabetes: don't wait for symptoms before intervening. Hirsch IB. **Postgrad Med** 1996 Mar;99(3):147-55, 159-62 (24 ref.)

Diabetic retinopathy: a review for the primary care physician. Fonseca V, et al. **South Med J** 1996 Sep;89(9):839-50 (44 ref.)

[Detection, monitoring and treatment of diabetic retinopathy. Recommendations of ALFEDIAM. Committee of above-mentioned experts and validated by the board of directors and scientific board of ALFEDIAM] Massin P, et al. **Diabetes Metab** 1996 Jun;22(3):203-9 (17 ref.) **(Fre)**

EPIDEMIOLOGY

An alternative approach to the diagnosis of diabetes with a review of the literature. Davidson MB, et al. **Diabetes Care** 1995 Jul;18(7):1065-71 (49 ref.)

Diabetes complications: the renal-retinal link. An epidemiological perspective. Lloyd CE, et al. **Diabetes Care** 1995 Jul;18(7):1034-6 (19 ref.)

ETIOLOGY

The role of growth factors in the development of diabetic retinopathy. Sharp PS. **Metabolism** 1995 Oct;44(10 Suppl 4):72-5 (58 ref.)

[Diabetic retinopathy and pregnancy] Verougstraete C. **Bull Soc Belge Ophtalmol** 1995;256:33-41 (39 ref.) (Eng. Abstr.) **(Fre)**

[Identification of diabetic patients at high risk for development of retinopathy] Leibowitz E, et al. **Harefuah** 1995 Oct;129(7-8):271-3 (24 ref.) **(Heb)**

METABOLISM

Role of glucose regulatory mechanisms in diabetic retinopathy. Knott RM, et al. **Br J Ophthalmol** 1995 Nov; 79(11):1046-9 (43 ref.)

[Diabetic retinopathy: pathogenesis, risk factors, clinical picture, classification] Malenfant M. **Bull Soc Belge Ophtalmol** 1995;256:11-23 (34 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Retinopathy in animal models of diabetes. Engerman RL, et al. **Diabetes Metab Rev** 1995 Jul;11(2):109-20 (88 ref.)

PHYSIOPATHOLOGY

The pathophysiology of diabetic complications: how much does the glucose hypothesis explain? Nathan DM. **Ann Intern Med** 1996 Jan 1;124(1 Pt 2):86-9 (51 ref.)

Vascular endothelial growth factor and retinal neovascularisation: a new therapeutic approach for diabetic retinopathy. Favard C, et al. **Diabetes Metab** 1996 Jul; 22(4):268-73 (67 ref.)

Retinopathy in animal models of diabetes. Engerman RL, et al. **Diabetes Metab Rev** 1995 Jul;11(2):109-20 (88 ref.)

Long-term pancreatic function: potential benefits. Bartlett ST, et al. **Transplant Proc** 1996 Aug;28(4):2128-30 (18 ref.)

PREVENTION & CONTROL

The management of hypertension in diabetes: with special reference to diabetic kidney disease. Leese GP, et al. **Diabet Med** 1996 May;13(5):401-10 (145 ref.)

REHABILITATION

Occupational therapy and the person with diabetes and vision impairment. Cate Y, et al. **Am J Occup Ther** 1995 Oct; 49(9):905-11 (31 ref.)

SURGERY

Lasers and liability. Classé JG. **Optom Clin** 1995;4(4):113-23 (19 ref.)

[Treatment of diabetic retinopathy. Clinical experience with various lasers. Complications associated with lasers] De Laey JJ. **Bull Soc Belge Ophtalmol** 1995;256:97-103 (24 ref.) (Eng. Abstr.) **(Fre)**

[Surgical treatment of diabetic retinopathy] Gribomont AC. **Bull Soc Belge Ophtalmol** 1995;256:105-12 (50 ref.) (Eng. Abstr.) **(Fre)**

[Proliferative diabetic retinopathy: laser photocoagulation treatment] Snyers B. **Bull Soc Belge Ophtalmol** 1995; 256:87-94 (19 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Diabetic eye disease: a primary care perspective. Frank KJ, et al. **South Med J** 1996 May;89(5):463-70 (25 ref.)

DIACETYL

CHEMISTRY

The sweet, sweet smell of diacetyl. Smith DP. **Neuron** 1996 Mar;16(3):469-71 (15 ref.)

DIACYLGLYCEROLS see DIGLYCERIDES

DIAGNOSIS

Small particles in medicine [editorial] Falkenhagen D. **Artif Organs** 1995 Aug;19(8):792-4 (32 ref.)

Naming and framing: the social construction of diagnosis and illness. Brown P. **J Health Soc Behav** 1995;Spec No:34-52 (69 ref.)

Determinants and consequences of children's coping in the medical setting: conceptualization, review, and critique. Rudolph KD, et al. **Psychol Bull** 1995 Nov;118(3):328-57 (130 ref.)

Diagnostic test studies: biotechnology assessment. Lossing AG, et al. **Surgery** 1996 Jul;120(1):1-6 (32 ref.)

[Knowing how to read a scientific article. 3. Knowing how to assess the natural history of a disease] Longo M, et al. **G Ital Cardiol** 1995 Aug;25(8):1067-75 (30 ref.) **(Ita)**

[Communication of bad facts. To inform or not to inform the patient: a choice between 2 alternatives?] Saltini A. **Recenti Prog Med** 1995 Sep;86(9):359-66 (40 ref.) (Eng. Abstr.) **(Ita)**

[Methods for DNA diagnosis in military medicine] Belokhvostov AS. **Voen Med Zh** 1995 Sep;(9):39-44, 80 (24 ref.) (Eng. Abstr.) **(Rus)**

DIAGNOSIS, COMPUTER-ASSISTED

Computerized geriatric assessment for geriatric care management. De Vore PA. **Aging (Milano)** 1995 Jun; 7(3):194-6 (22 ref.)

Medical informatics and pediatrics. Decision-support systems. Johnson KB, et al. **Arch Pediatr Adolesc Med** 1995 Dec;149(12):1371-80 (74 ref.)

Topographic concepts in computerized electrocardiology. Kneppo P, et al. **Crit Rev Biomed Eng** 1992;19(5):343-418 (240 ref.)

Computer assisted semen analysis systems: sperm motility assessment. Irvine DS. **Hum Reprod** 1995 Oct;10 Suppl 1:53-9 (43 ref.)

Computer-assisted pathology of intraepithelial adenocarcinoma and related lesions: 3-D distribution, structural aberration and discrimination. Takahashi T, et al. **J Cell Biochem Suppl** 1995;23:25-32 (16 ref.)

Decision-support systems in dentistry. White SC. **J Dent Educ** 1996 Jan;60(1):47-63 (141 ref.)

Artificial neural networks in pathology and medical laboratories [see comments] Dybowski R, et al. **Lancet** 1995 Nov 4;346(8984):1203-7 (34 ref.) Comment in: Lancet 1995 Nov 4;346(8984):1175-7. Comment in: Lancet 1995 Dec 23-30;346(8991-8992):1712.

Diagnostic and prognostic decision support systems. Bartels PH, et al. **Pathologica** 1995 Jun;87(3):221-36 (33 ref.)

Clinical applications of Bayesian belief networks in pathology. Hamilton PW, et al. **Pathologica** 1995 Jun; 87(3):237-45 (11 ref.)

Image processing and computer-aided diagnosis. Giger M, et al. **Radiol Clin North Am** 1996 May;34(3):565-96 (115 ref.)

[The treatment and teaching aspects in the computerized management of the surgical emergency (editorial)] Bonomo M, et al. **Recenti Prog Med** 1996 May;87(5):229-36 (24 ref.) **(Ita)**

[Use of fuzzy set theory in diagnostics] Bogdanik T. **Pol Arch Med Wewn** 1995 Feb;93(2):143-8 (27 ref.) **(Pol)**

METHODS

Symbiosis of nurse and machine through fuzzy logic: improved specificity of a neonatal pulse oximeter alarm. Bosque EM. **ANS Adv Nurs Sci** 1995 Dec;18(2):67-75 (60 ref.)

Unbiased stereologic techniques for practical use in diagnostic histopathology. Sørensen FB. **Pathologica** 1995 Jun;87(3):263-78 (86 ref.)

Syntactic structure analysis. van Diest PJ, et al. **Pathologica** 1995 Jun;87(3):255-62 (41 ref.)

[Computer-assisted surgery: assessment and perspectives] Demongeot J. **Chirurgie** 1994-95;120(11):19-25 (27 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS, DIFFERENTIAL

Natural history of amyotrophic lateral sclerosis. Quantification of symptoms, signs, strength, and function. Brooks BR, et al. **Adv Neurol** 1995;68:163-84 (27 ref.)

Natural history of amyotrophic lateral sclerosis. Observations with the Charing Cross Amyotrophic Lateral Sclerosis Rating Scales. Guiloff RJ, et al. **Adv Neurol** 1995;68:185-98 (28 ref.)

Natural history of amyotrophic lateral sclerosis. A discussion. Meininger V, et al. **Adv Neurol** 1995;68:199-207 (18 ref.)

Failure of the autonomic nervous system. Mitsky V, et al. **Compr Ther** 1995 Sep;21(9):529-34 (8 ref.)

Pseudoseizures: an update. Nash JL. **Compr Ther** 1995 Sep; 21(9):486-91 (29 ref.)

Alzheimer's disease: an update. Sandson TA, et al. **Compr Ther** 1995 Sep;21(9):480-5 (41 ref.)

Differential diagnosis of cyclic vomiting syndrome. Forbes D. **J Pediatr Gastroenterol Nutr** 1995;21 Suppl 1:S11-4 (42 ref.)

DIAGNOSIS, DUAL (PSYCHIATRY)

Group treatment for dually diagnosed clients. Mueser KT, et al. **New Dir Ment Health Serv** 1996 Summer;(70):33-51 (35 ref.)

DIAGNOSIS, IMMUNOLOGICAL see IMMUNOLOGIC TESTS

DIAGNOSIS, LABORATORY

Cyclophosphamide therapy of medulloblastoma: from the laboratory to the clinic and back again (and again and again). Friedman HS, et al. **J Neurooncol** 1995;24(1):103-8 (21 ref.)

Laboratory diagnosis of viral infections of the lung. Leland DS, et al. **Semin Respir Infect** 1995 Dec;10(4):189-98 (38 ref.)

[Progresses in laboratory medicine in China, 1995] Tao Q, et al. **Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):773-4 (0 ref.) **(Chi)**

[Quick Return Service in endocrinological tests] Hashimoto T. **Rinsho Byori** 1995 Oct;43(10):1034-7 (3 ref.) (Eng. Abstr.) **(Jpn)**

[The assessment of quick turnaround service in clinical laboratories] Kondoh T, et al. **Rinsho Byori** 1995 Oct; 43(10):1038-43 (1 ref.) (Eng. Abstr.) **(Jpn)**

[Rapid cytology] Shibata H, et al. **Rinsho Byori** 1995 Oct; 43(10):1024-7 (2 ref.) (Eng. Abstr.) **(Jpn)**

INSTRUMENTATION

Food and Drug Administration (FDA)'s impact on laboratory performance: FDA's perspective. Gutman S. **Clin Chem** 1996 May;42(5):786-9 (5 ref.)

METHODS

Diagnostic mycobacteriology laboratory practices. Shinnick TM, et al. **Clin Infect Dis** 1995 Aug;21(2):291-9 (56 ref.)

Preoperative laboratory evaluation. Velanovich V. **J Am Coll Surg** 1996 Jul;183(1):79-87 (75 ref.)

PCR in clinical diagnosis. Ronai Z, et al. **J Clin Lab Anal** 1995;9(4):269-83 (206 ref.)

The future of blood groups and other markers in reference laboratories. Rouger P, et al. **Transfus Clin Biol** 1995; 2(4):329-34 (8 ref.)

[Should immunohistochemistry be used to evaluate estrogen and progesterone receptors in breast cancers? (editorial)] Balaton AJ, et al. **Ann Pathol** 1996;16(2):78-80 (11 ref.) **(Fre)**

[Criteria in selection of the investigation method (literature review)] Titov VN. **Klin Lab Diagn** 1995 May-Jun;(3):54-7 (10 ref.) **(Rus)**

STANDARDS

Molecular diagnostics in the clinical laboratory: a plea for prudence! [editorial] Ieven M, et al. **Acta Clin Belg** 1995; 50(5):255-9 (33 ref.)

Laboratory turnaround time. Valenstein P. **Am J Clin Pathol** 1996 Jun;105(6):676-88 (59 ref.)

Evaluative laboratory testing. Assessing tests that assess disease activity. Ward MM. **Arthritis Rheum** 1995 Nov; 38(11):1555-63 (63 ref.)

DIAGNOSIS, NURSING see NURSING DIAGNOSIS

DIAGNOSIS, ORAL

METHODS

The use of diagnostic tests to aid clinical diagnosis [see comments] Matthews DC, et al. **J Can Dent Assoc** 1995 Sep;61(9):785-91 (18 ref.) Comment in: J Can Dent Assoc 1995 Nov;61(11):944. Comment in: J Can Dent Assoc 1995 Dec;61(12):1022. Comment in: J Can Dent Assoc 1996 Jan;62(1):6-7.

Decision-support systems in dentistry. White SC. **J Dent Educ** 1996 Jan;60(1):47-63 (141 ref.)

DIAGNOSIS, PRENATAL see PRENATAL DIAGNOSIS

DIAGNOSIS-RELATED GROUPS

[Classification systems in case-mix groups in ambulatory care. Perspectives for our primary health care] Juncosa S, et al. **Aten Primaria** 1996 Jan;17(1):76-82 (34 ref.) **(Spa)**

ECONOMICS

Case-mix measurement in medical rehabilitation. Stineman MG. **Arch Phys Med Rehabil** 1995 Dec;76(12):1163-70 (40 ref.)

DIAGNOSTIC ERRORS

Stigma, labelling and psychiatric misdiagnosis: origins and outcomes. Witztum E, et al. **Med Law** 1995;14(7-8):659-69 (27 ref.)

A review of diagnostic inaccuracy. Kingsford DP. **Med Sci Law** 1995 Oct;35(4):347-51 (31 ref.)

DIAGNOSTIC IMAGING

see related
IMAGE PROCESSING, COMPUTER-ASSISTED

Imaging of prostate cancer. Choyke PL. **Abdom Imaging** 1995 Nov-Dec;20(6):505-13 (40 ref.)

Diagnostic imaging evaluation of renovascular hypertension. King BF Jr. **Abdom Imaging** 1995 Sep-Oct;20(5):395-405 (45 ref.)

On the principles underlying the diagnosis of brain tumours--a survey article. Go KG, et al. **Acta Neurochir (Wien)** 1995;135(1-2):1-11 (31 ref.)

The role of neuroimaging in the discovery of processing stages. A review. Mulder G, et al. **Acta Psychol (Amst)** 1995 Nov;90(1-3):63-79 (66 ref.)

Chromosome 22: a model with implications for diagnostic imaging. Starshak RJ. **AJR Am J Roentgenol** 1996 Aug; 167(2):315-24 (62 ref.)

Brain imaging and cognitive neuroscience. Toward strong inference in attributing function to structure. Sarter M, et al. **Am Psychol** 1996 Jan;51(1):13-21 (75 ref.)

Imaging methods as a diagnostic tool in neuro-AIDS. A review. Arendt G. **Bildgebung** 1995 Dec;62(4):310-9 (51 ref.)

Prediction of myocardium at risk. Clinical significance during acute infarction and in evaluating subsequent prognosis. Mahmarian JJ. **Cardiol Clin** 1995 Aug;13(3):355-78 (127 ref.)

Neuroimaging and functional examination in hydrocephalus: a comment. Kang JK. **Childs Nerv Syst** 1995 Aug; 11(8):478-82 (20 ref.)

Digital imaging in dermatology. Kenet RD. **Clin Dermatol** 1995 Jul-Aug;13(4):381-92 (50 ref.)

Diagnostic imaging of the lung during pregnancy. Diethelm L, et al. **Clin Obstet Gynecol** 1996 Mar;39(1):36-55 (41 ref.)

Neonatal gastrointestinal imaging. Cumming WA, et al. **Clin Perinatol** 1996 Jun;23(2):387-407 (31 ref.)

Imaging of shoulder instability. Gusmer PB, et al. **Clin Sports Med** 1995 Oct;14(4):777-95 (26 ref.)

Novel techniques of coronary artery imaging. Ge J, et al. **Curr Opin Cardiol** 1995 Nov;10(6):626-33 (56 ref.)

Recent progress in digital image formatting and current trends in computers: their role in digital image storage and telemedicine. Commentary. Thomas JD. **Curr Opin Cardiol** 1995 Nov;10(6):615-8 (14 ref.)

New diagnostic techniques in trauma. Livingston DH. **Curr Opin Gen Surg** 1994;:35-40 (38 ref.)

Incidentally discovered adrenal tumors. Saxe A. **Curr Opin Gen Surg** 1993;:121-9 (50 ref.)

Congenital uterine malformations. Woodward PJ, et al. **Curr Probl Diagn Radiol** 1995 Sep-Oct;24(5):178-97 (51 ref.)

Multimodality imaging of osteomyelitis. Elgazzar AH, et al. **Eur J Nucl Med** 1995 Sep;22(9):1043-63 (142 ref.)

Future of functional brain imaging. Kuikka JT, et al. **Eur J Nucl Med** 1996 Jul;23(7):737-40 (26 ref.)

Multimodality imaging of cervical adenopathies. Giron J, et al. **Eur J Radiol** 1996 Feb;21(3):159-66 (21 ref.)

Primary tumour staging of gastric and colorectal cancer. Bruneton JN, et al. **Eur Radiol** 1996;6(2):140-6 (45 ref.)

Imaging of the oropharynx and oral cavity. Part II: Pathology. Lenz M, et al. **Eur Radiol** 1996;6(4):536-49 (28 ref.)

The dysmorphic lung: imaging findings. Mata JM, et al. **Eur Radiol** 1996;6(4):403-14 (56 ref.)

Imaging in the staging of renal cell carcinoma. Reznek RH. **Eur Radiol** 1996;6(2):120-8 (61 ref.)

Clinical efficacy of imaging modalities in the diagnosis of low-back pain disorders. Boos N, et al. **Eur Spine J** 1996; 5(1):2-22 (142 ref.)

Imaging: the basis for effective therapy. Chen GT, et al. **Front Radiat Ther Oncol** 1996;29:31-42 (34 ref.)

Neuroimaging in child and adolescent neuropsychiatric disorders. Peterson BS. **J Am Acad Child Adolesc Psychiatry** 1995 Dec; 34(12):1560-76 (115 ref.)

Abdominal pain in the postpartum: role of imaging. Van Hoe L, et al. **J Belge Radiol** 1995 Jun;78(3):186-9 (17 ref.)

Design and implementation of a picture archiving and communication system: the second time. Huang HK, et al. **J Digit Imaging** 1996 May;9(2):47-59 (18 ref.)

Imaging of pedal soft tissue neoplasms. Levey DS, et al. **J Foot Ankle Surg** 1995 Jul-Aug;34(4):411-8 (23 ref.)

Imaging of children with chronic renal failure. Frankel DG, et al. **J Pediatr** 1996 Aug;129(2):s33-8 (24 ref.)

Technologic considerations for breast tumor size assessment. Davis PL, et al. **Magn Reson Imaging Clin N Am** 1994 Nov;2(4):623-31 (42 ref.)

MR imaging versus alternative imaging techniques. Hodler J, et al. **Magn Reson Imaging Clin N Am** 1995 Nov; 3(4):591-608 (70 ref.)

Diagnostic tests in neuro-ophthalmology. Galetta SL, et al. **Neurol Clin** 1996 Feb;14(1):201-22 (114 ref.)

Diagnostic testing of seizure disorders. Gilliam F, et al. **Neurol Clin** 1996 Feb;14(1):61-84 (119 ref.)

Neuroradiology of brain tumors. Schwartz RB. **Neurol Clin** 1995 Nov;13(4):723-56 (59 ref.)

Use of voltage-sensitive dyes and optical recordings in the central nervous system. Ebner TJ, et al. **Prog Neurobiol** 1995 Aug;46(5):463-506 (242 ref.)

Registration of multi-modal biomedical images of the heart. Gilardi MC, et al. **Q J Nucl Med** 1996 Mar;40(1):142-50 (43 ref.)

Contemporary diagnostic approaches for nonpalpable carcinoma of the breast: the role of the radiologist. Schepps B, et al. **R I Med** 1995 Sep;78(9):239-41 (19 ref.)

Networks for electronic radiology. Blaine GJ, et al. **Radiol Clin North Am** 1996 May;34(3):505-24 (31 ref.)

Image acquisition. Sites, technologies, and approaches. Horii SC. **Radiol Clin North Am** 1996 May;34(3):469-94 (56 ref.)

Evaluation of the abdomen in sepsis of unknown origin. McDowell RK, et al. **Radiol Clin North Am** 1996 Jan; 34(1):177-90 (58 ref.)

Imaging of osteoarthritis. Preidler KW, et al. **Radiol Clin North Am** 1996 Mar;34(2):259-71, x (63 ref.)

Three-dimensional imaging, surgical planning, and image-guided therapy. Vannier MW, et al. **Radiol Clin North Am** 1996 May;34(3):545-63 (131 ref.)

Radiology's role in diagnosis of AIDS-related pathologies. Vedda RA. **Radiol Technol** 1995 Jul-Aug;66(6):365-9; quiz 370-2 (25 ref.)

Stress fractures. Anderson MW, et al. **Radiology** 1996 Apr; 199(1):1-12 (105 ref.)

Advances in tumor imaging. Giger ML, et al. **Sci Am** 1996 Sep;275(3):110-2 (0 ref.)

Adrenal cortical and medullary imaging. Freitas JE. **Semin Nucl Med** 1995 Jul;25(3):235-30 (63 ref.)

Integrated imaging in colorectal cancer. Ott DJ, et al. **Semin Roentgenol** 1996 Apr;31(2):166-9 (34 ref.)

Radiologic diagnosis of hepatocellular carcinoma. Ishiguchi T, et al. **Semin Surg Oncol** 1996 May-Jun;12(3):164-9 (17 ref.)

Radiological evaluation of infertility. Collins JI, et al. **Semin Ultrasound CT MR** 1995 Aug;16(4):304-16 (74 ref.)

Imaging of gastrointestinal neuroendocrine tumors. Gorman B, et al. **Semin Ultrasound CT MR** 1995 Aug;16(4):331-41 (46 ref.)

Thyroid and parathyroid imaging. Hopkins CR, et al. **Semin Ultrasound CT MR** 1995 Aug;16(4):279-95 (76 ref.)

Adrenal imaging. Korobkin M, et al. **Semin Ultrasound CT MR** 1995 Aug;16(4):317-30 (45 ref.)

Thoracolumbar burst fracture: evaluating stability. Petersilge CA, et al. **Semin Ultrasound CT MR** 1996 Apr;17(2):105-13 (40 ref.)

Imaging of cervical spine trauma. Tehranzadeh J, et al. **Semin Ultrasound CT MR** 1996 Apr;17(2):93-104 (51 ref.)

Imaging assessment of pubertal disorders. Zwiebel WJ, et al. **Semin Ultrasound CT MR** 1995 Aug;16(4):296-303 (18 ref.)

Imaging the diabetic foot. Gold RH, et al. **Skeletal Radiol** 1995 Nov;24(8):563-71 (30 ref.)

Multifocal vascular lesions of bone: imaging characteristics. Lomasney LM, et al. **Skeletal Radiol** 1996 Apr;25(3):255-61 (31 ref.)

Interventional radiology and cross sectional imaging in venous access. Perry LJ, et al. **Surg Oncol Clin N Am** 1995 Jul;4(3):505-35 (82 ref.)

-Possibilities and limits of imaging for evaluating breast implants- Tristant H. **Arch Gynecol Obstet** 1995;256 Suppl:S135-47 (31 ref.) **(Fre)**

[New imaging techniques in pulmonary embolism] Blum A, et al. **Arch Mal Coeur Vaiss** 1995 Nov;88(11 Suppl):1735-43 (34 ref.) (Eng. Abstr.) **(Fre)**

[Neuroimaging and neurobiology of obsessive compulsive disorder: review of recent developments in research] Huguelet P, et al. **Encephale** 1996 Jan-Feb;22(1):41-5 (29 ref.) (Eng. Abstr.) **(Fre)**

[The diagnosis of primary cerebral lymphoma in AIDS. The contribution of imaging] Laissy JP, et al. **J Neuroradiol** 1995 Sep;22(3):207-17 (25 ref.) (Eng. Abstr.) **(Fre)**

[Current aspects in cerebrovascular neuroradiology] Maeder P, et al. **Rev Med Suisse Romande** 1996 Aug;116(8):611-9 (27 ref.) **(Fre)**

[Imaging methods in intensive care] Habscheid W. **Bildgebung** 1996 Mar;63(1):4-21 (113 ref.) (Eng. Abstr.) **(Ger)**

[HIV infection: findings in liver and bile ducts] Jablonowski H. **Bildgebung** 1995 Dec;62(4):260-70 (89 ref.) (Eng. Abstr.) **(Ger)**

[AIDS: infections of the retina and choroid] Schimkat M, et al. **Bildgebung** 1995 Dec;62(4):288-301 (100 ref.) (Eng. Abstr.) **(Ger)**

[Is preoperative site diagnosis in organic hyperinsulinism from the viewpoint of the surgeon still necessary today? Results of a consecutive series and analysis of the literature] Böttger T, et al. **Chirurg** 1996 Mar;67(3):268-72 (17 ref.) (Eng. Abstr.) **(Ger)**

[Diagnostic imaging in senile dementia. Exclusion of specific treatable causes also in the elderly] Herholz K. **Fortschr Med** 1995 Oct 20;113(29):413-7 (6 ref.) (Eng. Abstr.) **(Ger)**

[Neuroradiology in ophthalmology. 2] Müller-Forell W, et al. **Ophthalmologe** 1995 Oct;92(5):757-84 (26 ref.) **(Ger)**

[Developmental anomalies and congenital diseases of the pancreas] Brambs HJ. **Radiologe** 1996 May;36(5):381-8 (56 ref.) (Eng. Abstr.) **(Ger)**

[The pharyngoesophageal segment] Ekberg O, et al. **Radiologe** 1995 Oct;35(10):689-92 (22 ref.) (Eng. Abstr.) **(Ger)**

[Appearance forms of mesenteric cyst. A case report] Gissler HM, et al. **Radiologe** 1996 Jun;36(6):503-7 (30 ref.) (Eng. Abstr.) **(Ger)**

[Anatomy and pathophysiology of deglutition disorders] Rabischong P. **Radiologe** 1995 Oct;35(10):679-88 (43 ref.) (Eng. Abstr.) **(Ger)**

[1995 literature review: diagnostic imaging of the liver] Merkle E. **Rontgenpraxis** 1996 Mar;49(3):64-70 (100 ref.) **(Ger)**

[Musculoskeletal tumors: epidemiology, clinical aspects and diagnostic requirements] Rechl H, et al. **Rontgenpraxis** 1995 Aug;48(8):217-22 (32 ref.) **(Ger)**

[Diagnosis and therapy of intra-abdominal abscesses] Rieber A. **Rontgenpraxis** 1995 Dec;48(12):335-9 (18 ref.) **(Ger)**

[Diagnosis of perianal and perirectal fistulas and abscesses] Rieber A, et al. **Rontgenpraxis** 1996 May;49(5):110-4 (20 ref.) **(Ger)**

[Radiologic diagnosis of infectious spondylitis] Wikström M, et al. **Rontgenpraxis** 1996 Apr;49(4):79-84 (30 ref.) **(Ger)**

[Renovascular hypertension] Greminger P. **Schweiz Med Wochenschr** 1996 Jul 27;126(30):1314-20 (45 ref.) (Eng. Abstr.) **(Ger)**

[Neuroradiological studies and findings in stroke] Forsting M, et al. **Ther Umsch** 1996 Jul;53(7):535-43 (20 ref.) (Eng. Abstr.) **(Ger)**

[Lymph node diagnosis with imaging methods. An overview with special reference to recent developments in the area of MR contrast media] Mohr U, et al. **Z Lymphol** 1996 Jun;20(1):15-20 (59 ref.) (Eng. Abstr.) **(Ger)**

[A working hypothesis. Multiparameter functional imaging as a possible course for radiobiology (editorial)] Cardinale AE, et al. **Radiol Med (Torino)** 1995 Sep;90(3):177-80 (26 ref.) **(Ita)**

[Imaging diagnosis in border-less age] Heshiki A. **Nippon Igaku Hoshasen Gakkai Zasshi** 1995 Oct; 55(13):463-6 (15 ref.) (Eng. Abstr.) **(Jpn)**

CLASSIFICATION

[Techniques for thyroid imaging] Hermans J. **Ann Endocrinol (Paris)** 1995;56(5):495-506 (31 ref.) (Eng. Abstr.) **(Fre)**

ECONOMICS

Preoperative endocrine tumor localization utilizing a cost-effective approach. Leight GS Jr, et al. **Curr Opin Gen Surg** 1993;:108-14 (19 ref.)

INSTRUMENTATION

A technique for interactive image-guided neurosurgical intervention in primary brain tumors. Maciunas RJ, et al. **Neurosurg Clin N Am** 1996 Apr;7(2):245-66 (111 ref.)

Vascular imaging before, during, and after endovascular repair. White RA, et al. **World J Surg** 1996 Jul-Aug; 20(6):622-9 (42 ref.)

[3-D imaging of the liver] Leppek R, et al. **Radiologe** 1995 Oct;35(10):769-77 (44 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Trends in the utilization of noninvasive cardiac diagnostic tests in Ontario from fiscal year 1989/90 to 1992/93. Chan B, et al. **Can J Cardiol** 1996 Mar;12(3):237-48 (67 ref.)

Diagnostic imaging at its centennial: the past, the present and the future [editorial] Doris CI. **Can Med Assoc J** 1995 Nov 1;153(9):1297-300 (7 ref.)

Neuroimaging in pediatric epilepsy. Kuzniecky RI. **Epilepsia** 1996;37 Suppl 1:S10-21 (77 ref.)

Dynamic neuroimaging of brain function. Simpson GV, et al. **J Clin Neurophysiol** 1995 Sep;12(5):432-49 (65 ref.)

Equipment configuration and procedures: preferences for interventional microtherapy. Grönemeyer D, et al. **J Digit Imaging** 1996 May;9(2):81-96 (31 ref.)

Liposomes as delivery agents for medical imaging. Torchilin VP. **Mol Med Today** 1996 Jun;2(6):242-9 (36 ref.)

Diagnostic testing in movement disorders. Anouti A, et al. **Neurol Clin** 1996 Feb;14(1):169-82 (61 ref.)

Diagnostic testing for the evaluation of headaches. Evans RW. **Neurol Clin** 1996 Feb;14(1):1-26 (159 ref.)

The diagnosis of multiple sclerosis. Rolak LA. **Neurol Clin** 1996 Feb;14(1):27-43 (34 ref.)

Diagnostic testing and dementia. Sandson TA, et al. **Neurol Clin** 1996 Feb;14(1):45-59 (145 ref.)

The diagnosis of infections of the spine by modern imaging techniques. Rothman SL. **Orthop Clin North Am** 1996 Jan; 27(1):15-31 (15 ref.)

New imaging techniques in colorectal cancer. Tempero M, et al. **Semin Oncol** 1995 Oct;22(5):448-71 (178 ref.)

Assessment of spinal fusion. Critical evaluation of imaging techniques. Herzog RJ, et al. **Spine** 1996 May 1; 21(9):1114-8 (5 ref.)

[Imaging of endocrine tumors of the pancreas] Thérasse E, et al. **Ann Endocrinol (Paris)** 1995;56(5):509-10 (4 ref.) **(Fre)**

[Current methods in the diagnosis of deep venous thrombosis of the lower limbs] Cappeliez O, et al. **Rev Med Brux** 1996 Jun;17(3):127-31 (19 ref.) (Eng. Abstr.) **(Fre)**

[Imaging methods in diagnosis and differential diagnosis of breast cancer] Kessler M, et al. **Bildgebung** 1995 Sep; 62(3):160-72 (58 ref.) (Eng. Abstr.) **(Ger)**

STANDARDS

Modular extension of the ACR-NEMA DICOM standard to support new diagnostic imaging modalities and services. Bidgood WD Jr, et al. **J Digit Imaging** 1996 May;9(2):67-77 (37 ref.)

TRENDS

Diagnostic imaging at its centennial: the past, the present and the future [editorial] Doris CI. **Can Med Assoc J** 1995 Nov 1;153(9):1297–300 (7 ref.)

VETERINARY

Clinical applications of radiography and ancillary imaging. O'Brien RT, et al. **Vet Clin North Am Food Anim Pract** 1996 Mar;12(1):263–75 (7 ref.)

Diagnostic imaging of the feline lower urinary tract. Johnston GR, et al. **Vet Clin North Am Small Anim Pract** 1996 Mar; 26(2):401–15 (9 ref.)

Diagnostic imaging in dogs: radiography, ultrasonography, and computed tomography for examination of the abdomen. Voorhout G. **Vet Q** 1995 Apr;17 Suppl 1:S30–1 (9 ref.)

DIAGNOSTIC REAGENT KITS see **REAGENT KITS, DIAGNOSTIC**

DIAGNOSTIC SERVICES

ORGANIZATION & ADMINISTRATION

Workflow computing. Improving management and efficiency of pathology diagnostic services. Buffone GJ, et al. **Am J Clin Pathol** 1996 Apr;105(4 Suppl 1):S17–24 (7 ref.)

DIAGNOSTIC TESTS, ROUTINE

Laboratory testing in peripheral nerve disease. Griffin JW, et al. **Neurol Clin** 1996 Feb;14(1):119–33 (58 ref.)

Diagnostic tests for the evaluation of back and neck pain. Haldeman S. **Neurol Clin** 1996 Feb;14(1):103–17 (52 ref.)

The diagnosis of multiple sclerosis. Rolak LA. **Neurol Clin** 1996 Feb;14(1):27–43 (34 ref.)

Preoperative investigations. Hannallah RS. **Paediatr Anaesth** 1995;5(5):325–9 (17 ref.)

ECONOMICS

"Routine" preoperative studies. Which studies in which patients? Marcello PW, et al. **Surg Clin North Am** 1996 Feb;76(1):11–23 (42 ref.)

STANDARDS

Preoperative screening: what tests are necessary? Jones T, et al. **Cleve Clin J Med** 1995 Nov–Dec;62(6):374–8 (39 ref.)

STATISTICS & NUMERICAL DATA

The evaluation of diagnostic tests: principles, problems, and new developments. Sox HC. **Annu Rev Med** 1996;47:463–71 (14 ref.)

VETERINARY

Applications of DNA amplification techniques in veterinary diagnostics. Pfeffer M, et al. **Vet Res Commun** 1995; 19(5):375–407 (284 ref.)

DIALYSIS, EXTRACORPOREAL see **HEMODIALYSIS**

DIALYSIS SOLUTIONS

Biocompatibility of peritoneal dialysis solutions. Breborowicz A, et al. **Am J Kidney Dis** 1996 May;27(5):738–43 (54 ref.)

What is the ideal technique for testing the biocompatibility of peritoneal dialysis solutions? [editorial] Topley N. **Perit Dial Int** 1995 Jul–Sep;15(6):205–9 (29 ref.)

ADMINISTRATION & DOSAGE

Bicarbonate: the alternative buffer for peritoneal dialysis. Passlick–Deetjen J, et al. **Perit Dial Int** 1996;16 Suppl 1:S109–13 (44 ref.)

Prescription of calcium concentration and PTH control. Ritz E, et al. **Perit Dial Int** 1996;16 Suppl 1:S300–4 (31 ref.)

ADVERSE EFFECTS

Effect of different buffers on the biocompatibility of CAPD solutions. Schambye HT. **Perit Dial Int** 1996;16 Suppl 1:S130–6 (48 ref.)

CHEMISTRY

Heat sterilization of glucose–containing fluids for peritoneal dialysis: biological consequences of chemical alterations. Wieslander AP, et al. **Perit Dial Int** 1995;15(7 Suppl):S52–9; discussion S59–60 (32 ref.)

PHARMACOKINETICS

Optimal use of glucose polymer (icodextrin) in peritoneal dialysis. Mistry CD, et al. **Perit Dial Int** 1996;16 Suppl 1:S104–8 (23 ref.)

Theoretical analysis of osmotic agents in peritoneal dialysis. What size is an ideal osmotic agent? Rippe B, et al. **Perit Dial Int** 1996;16 Suppl 1:S97–103 (18 ref.)

PHARMACOLOGY

In vitro studies on the effect of dialysis solutions on peritoneal leukocytes. Jörres A, et al. **Perit Dial Int** 1995;15(7 Suppl):S41–5; discussion S45–6 (28 ref.)

The role of TGF–beta in growth inhibition of peritoneal mesothelial cells in high–glucose dialysate. Kumano K, et al. **Perit Dial Int** 1995;15(7 Suppl):S93–5 (18 ref.)

Lactate–versus bicarbonate–based peritoneal dialysis solutions. Pedersen FB. **Perit Dial Int** 1995;15(7 Suppl):S47–50; discussion S51 (33 ref.)

THERAPEUTIC USE

The influence of dialysis time and dialyser reuse on survival. Shaldon S. **Nephrol Dial Transplant** 1995;10 Suppl 3:57–62 (51 ref.)

TOXICITY

In vitro studies to assess biocompatibility of peritoneal dialysis solutions: strengths and limitations. Breborowicz A, et al. **Perit Dial Int** 1996;16 Suppl 1:S119–23 (28 ref.)

Physiological approaches to increase biocompatibility of peritoneal dialysis. Breborowicz A, et al. **Perit Dial Int** 1995;15(7 Suppl):S76–85; discussion S85–6 (127 ref.)

Peritoneal dialysis solution biocompatibility testing in animals. Di Paolo N, et al. **Perit Dial Int** 1995;15(7 Suppl):S61–9; discussion S69–70 (40 ref.)

DIAMINE OXIDASE see **AMINE OXIDASE (COPPER–CONTAINING)**

DIAMINODIPHENYLSULFONE see **DAPSONE**

CIS–DIAMMINE(CYCLOBUTANEDICARBOXYLATO) PLATINUM II see **CARBOPLATIN**

CIS–DIAMMINEDICHLOROPLATINUM(II) see **CISPLATIN**

DIAMOND–BLACKFAN ANEMIA see **FANCONI'S ANEMIA**

DIAPER PINS see **INFANT CARE**

DIAPERS, INFANT see **INFANT CARE**

DIAPHRAGM

Primary diaphragmatic schwannoma with a typical target appearance: correlation of CT and MR imagings and histologic findings. Koyama S, et al. **J Gastroenterol** 1996 Apr;31(2):268–72 (11 ref.)

[Endometriosis of the diaphragm. Diagnostic aspects apropos of a case without pneumothorax] Witte A, et al. **Rev Med Interne** 1995;16(7):527–32 (18 ref.) (Eng. Abstr.) **(Fre)**

INJURIES

Traumatic rupture of diaphragm. Shah R, et al. **Ann Thorac Surg** 1995 Nov;60(5):1444–9 (60 ref.)

CT in blunt chest trauma: pulmonary, tracheobronchial, and diaphragmatic injuries. Kang EY, et al. **Semin Ultrasound CT MR** 1996 Apr;17(2):114–8 (39 ref.)

PHYSIOLOGY

The role of the diaphragm in lymphatic absorption from the peritoneal cavity. Abu–Hijleh MF, et al. **J Anat** 1995 Jun; 186 (Pt 3):453–67 (89 ref.)

Sub–diaphragmatic vagal afferent integration of meal–related gastrointestinal signals. Schwartz GJ, et al. **Neurosci Biobehav Rev** 1996;20(1):47–56 (31 ref.)

PHYSIOPATHOLOGY

Effect of bullectomy on diaphragm strength. Travaline JM, et al. **Am J Respir Crit Care Med** 1995 Nov;152(5 Pt 1):1697–701 (25 ref.)

DIAPHRAGMATIC EVENTRATION

ULTRASONOGRAPHY

[THe echographic diagnosis of diaphragmatic eventration in newborn infants. 2 cases] Sciacca P, et al. **Pediatr Med Chir** 1995 May–Jun;17(3):257–9 (10 ref.) (Eng. Abstr.) **(Ita)**

DIAPHRAGMATIC HERNIA see **HERNIA, DIAPHRAGMATIC**

DIAPHRAGMATIC HERNIA, TRAUMATIC see **HERNIA, DIAPHRAGMATIC, TRAUMATIC**

DIAPHRAGMATIC PARALYSIS see **RESPIRATORY PARALYSIS**

DIAPHYSEAL ACLASIS see **EXOSTOSES, MULTIPLE HEREDITARY**

DIAPHYSEAL DYSPLASIA, PROGRESSIVE

COMPLICATIONS

Hearing impairment in Engelmann disease. Higashi K, et al. **Am J Otol** 1996 Jan;17(1):26–9 (23 ref.)

DIARRHEA

see related
REHYDRATION SOLUTIONS

Evaluating the child with chronic diarrhea. Leung AK, et al. **Am Fam Physician** 1996 Feb 1;53(2):635–43 (23 ref.)

Enteropathogenic and enteroaggregative strains of Escherichia coli: clinical features of infection, epidemiology, and pathogenesis. Wanke CA. **Curr Clin Top Infect Dis** 1995;15:230–52 (116 ref.)

Chronic nonspecific diarrhea of childhood: pathophysiology and management. Kneepkens CM, et al. **Pediatr Clin North Am** 1996 Apr;43(2):375–90 (103 ref.)

Constipation and diarrhea: the neglected symptoms. Wright PS, et al. **Semin Oncol Nurs** 1995 Nov;11(4):289–97 (87 ref.)

[Epidemiology, physiopathology and treatment of travellers' diarrhea] Bouchaud O, et al. **Ann Med Interne (Paris)** 1995; 146(6):431–7 (62 ref.) **(Fre)**

[Persistent diarrhea] Sagaro González E, et al. **G E N** 1995 Jan–Mar;49(1):74–81 (54 ref.) (Eng. Abstr.) **(Spa)**

CHEMICALLY INDUCED

Complications of laxative abuse. Baker EH, et al. **Annu Rev Med** 1996;47:127–34 (20 ref.)

Diarrhea associated with parenteral vancomycin therapy [letter] Schenfeld LA, et al. **Clin Infect Dis** 1995 Jun; 20(6):1578–9 (5 ref.)

Antibiotic–induced diarrhoea. **Drug Ther Bull** 1995 Mar; 33(3):23–4 (22 ref.)

COMPLICATIONS

Diarrhea and malnutrition: a challenge for pediatricians. Gracey M. **J Pediatr Gastroenterol Nutr** 1996 Jan; 22(1):6–16 (120 ref.)

Hyperglycemia in diarrhea–associated hemolytic–uremic syndrome. Robson WL, et al. **Nephron** 1995;71(1):54–8 (21 ref.)

Electrolyte fluxes in the gut and oral rehydration solutions. Acra SA, et al. **Pediatr Clin North Am** 1996 Apr; 43(2):433–49 (64 ref.)

DIAGNOSIS

Update on diagnosis of Clostridium difficile–associated diarrhea. DeMaio J, et al. **Curr Clin Top Infect Dis** 1995; 15:97–114 (139 ref.)

DIET THERAPY

Controlling diarrhea in the HIV patient. Anastasi JK, et al. **Am J Nurs** 1996 Aug;96(8):35–41; quiz 42 (8 ref.)

DRUG THERAPY

Is there any reason to continue treating Blastocystis infections? [editorial; comment] Markell EK. **Clin Infect Dis** 1995 Jul;21(1):104–5 (11 ref.) Comment on: Clin Infect Dis 1995 Jul;21(1):97–101.

Mechanism and treatment of diarrhoea due to Vibrio cholerae and Escherichia coli: roles of drugs and prostaglandins. Rabbani GH. **Dan Med Bull** 1996 Apr;43(2):173–85 (169 ref.)

Role of quinolones in the treatment of diarrhoeal diseases. Akalin HE. **Drugs** 1995;49 Suppl 2:128–31 (31 ref.)

The new quinolones in the treatment of diarrhoea and typhoid fever. Waiz A. **Drugs** 1995;49 Suppl 2:132–5 (54 ref.)

Chronic Diarrhoea: current concepts on mechanisms and management. Farthing MJ. **Eur J Gastroenterol Hepatol** 1996 Feb;8(2):157–67 (60 ref.)

Empiric antibiotic therapy for acute infective diarrhoea in the developed world. Moss PJ, et al. **J Antimicrob Chemother** 1995 Jun;35(6):903–13 (74 ref.)

ETIOLOGY

Diarrhoea in patients with diabetes mellitus. von der Ohe MR. **Eur J Gastroenterol Hepatol** 1995 Aug;7(8):730–6 (61 ref.)

Cryptosporidium related diarrhoea. Das P. **Indian J Med Res** 1996 Jul;104:86–95 (132 ref.)

Adherence & colonization properties of Vibrio cholerae & diarrhoeagenic Escherichia coli. Ghose AC. **Indian J Med Res** 1996 Jul;104:38–51 (160 ref.)

Intestinal responses induced by enteral feeding. Bowling TE, et al. **Nutrition** 1995 May–Jun;11(3):304–7 (67 ref.)

Secretory diarrhea in children: newly recognized toxins and hormone–secreting tumors. Udall JN Jr. **Pediatr Clin North Am** 1996 Apr;43(2):333–53 (78 ref.)

Diarrhoea in the returned traveller. Ellis C. **Practitioner** 1996 Mar;240(1560):188–92 (4 ref.)

The Sir David Cuthbertson Medal Lecture. Enteral–feeding–related diarrhoea: proposed causes and possible solutions. Bowling TE. **Proc Nutr Soc** 1995 Jul; 54(2):579–90 (64 ref.)

Cyclospora in patients with traveller's diarrhea. Gascon J, et al. **Scand J Infect Dis** 1995;27(5):511–4 (18 ref.)

Diabetic diarrhea. Saslow SB, et al. **Semin Gastrointest Dis** 1995 Oct;6(4):187–93 (69 ref.)

[Pathogenesis of chronic diarrhoea after surgery for extreme

obesity] Lemieszewski A. **Pol Tyg Lek** 1996 Jan; 51(1-5):37-9 (32 ref.) **(Pol)**

METABOLISM

Reactive oxygen and nitrogen metabolites as mediators of secretory diarrhea. Gaginella TS, et al. **Gastroenterology** 1995 Dec;109(6):2019-28 (147 ref.)

Colonic fluid handling in health & acute diarrhoeal diseases. Ramakrishna BS. **Indian J Med Res** 1996 Jul;104:52-9 (47 ref.)

MICROBIOLOGY

Escherichia coli O157:H7 infections: a frequent cause of bloody diarrhea and the hemolytic-uremic syndrome. Cohen MB. **Adv Pediatr** 1996;43:171-207 (187 ref.)

Candida-associated diarrhea: a syndrome in search of credibility. Levine J, et al. **Clin Infect Dis** 1995 Oct; 21(4):881-6 (80 ref.)

Mechanism and treatment of diarrhoea due to Vibrio cholerae and Escherichia coli: roles of drugs and prostaglandins. Rabbani GH. **Dan Med Bull** 1996 Apr;43(2):173-85 (169 ref.)

Clostridium difficile-associated diarrhea and colitis. Gerding DN, et al. **Infect Control Hosp Epidemiol** 1995 Aug; 16(8):459-77 (195 ref.)

Clostridium difficile--associated diarrhoeal diseases: an overview. Niyogi SK. **J Indian Med Assoc** 1995 Mar; 93(3):105-7 (29 ref.)

Gastrointestinal manifestations of HIV infection. Sharpstone D, et al. **Lancet** 1996 Aug 10;348(9024):379-83 (50 ref.)

[Clostridium difficile-associated diarrhea--an increasing problem. Reduce the administration of antibiotics and improve hygiene!] Svenungsson B. **Lakartidningen** 1996 Aug 28;93(35):2931-4 (67 ref.) **(Swe)**

PARASITOLOGY

Blastocystis hominis and traveler's diarrhea [editorial; comment] Keystone JS. **Clin Infect Dis** 1995 Jul;21(1):102-3 (31 ref.) Comment on: Clin Infect Dis 1995 Jul;21(1):97-101.

PHYSIOPATHOLOGY

Chronic Diarrhoea: current concepts on mechanisms and management. Farthing MJ. **Eur J Gastroenterol Hepatol** 1996 Feb;8(2):157-67 (60 ref.)

Colonic motility in health and disease. O'Brien MD, et al. **Gastroenterol Clin North Am** 1996 Mar;25(1):147-62 (62 ref.)

Pathophysiology and treatment of diabetic diarrhea. Nakamura T, et al. **J Smooth Muscle Res** 1996 Apr; 32(2):27-42 (100 ref.)

New aspects of the pathophysiology and treatment of secretory diarrhoea. Hansen MB, et al. **Physiol Res** 1995; 44(2):61-78 (135 ref.)

PREVENTION & CONTROL

Passive immunity against diarrhoea. Bogstedt AK, et al. **Acta Paediatr** 1996 Feb;85(2):125-8 (20 ref.)

Oral vaccines against cholera and enterotoxigenic Escherichia coli diarrhea. Svennerholm AM, et al. **Adv Exp Med Biol** 1995;371B:1623-8 (19 ref.)

Efficacy of a quadrivalent rhesus rotavirus-based human rotavirus vaccine aimed at preventing severe rotavirus diarrhea in infants and young children. Kapikian AZ, et al. **J Infect Dis** 1996 Sep;174 Suppl 1:S65-72 (39 ref.)

New lessons for rotavirus vaccines [comment] Glass RI, et al. **Science** 1996 Apr 5;272(5258):46-8 (14 ref.) Comment on: Science 1996 Apr 5;272(5258):101-4. Comment on: Science 1996 Apr 5;272(5258):104-7.

[A vaccine against diarrhea. Soon a reality in the fight against viral gastroenteritis in both developed and developing countries] Svensson L. **Lakartidningen** 1996 Jan 31; 93(5):353-8 (26 ref.) **(Swe)**

THERAPY

Managing diarrhoea. Current thinking. Heap T. **Aust Fam Physician** 1996 Jan;25(1):38-45 (11 ref.)

Management of diarrhea induced by tumors or cancer therapy. Cascinu S. **Curr Opin Oncol** 1995 Jul;7(4):325-9 (63 ref.)

Epidemiology & management of persistent diarrhoea in children of developing countries. Bhan MK, et al. **Indian J Med Res** 1996 Jul;104:103-14 (75 ref.)

Management of acute diarrhoea. Bhattacharya SK. **Indian J Med Res** 1996 Jul;104:96-102 (48 ref.)

Current status of oral rehydration as a strategy for the control of diarrhoeal diseases. Mahalanabis D. **Indian J Med Res** 1996 Jul;104:115-24 (67 ref.)

Management of persistent diarrhoea. Bhatnagar S, et al. **J Indian Med Assoc** 1995 Jun;93(6):227-30, 234 (5 ref.)

Oral rehydration therapy programme in India: standard case management of acute watery diarrhoea. Manchanda VK. **J Indian Med Assoc** 1995 Jun;93(6):220-6 (17 ref.)

Nutritional management of persistent diarrhea in childhood: a perspective from the developing world. Bhutta ZA, et al. **J Pediatr Gastroenterol Nutr** 1996 Jan;22(1):17-37 (210 ref.)

Pathophysiology and treatment of diabetic diarrhea. Nakamura T, et al. **J Smooth Muscle Res** 1996 Apr; 32(2):27-42 (100 ref.)

Biotherapeutic agents. A neglected modality for the treatment and prevention of selected intestinal and vaginal infections [see comments] Elmer GW, et al. **JAMA** 1996 Mar 20;275(11):870-6 (81 ref.) Comment in: JAMA 1996 Jul 3;276(1):29-30.

New aspects of the pathophysiology and treatment of secretory diarrhoea. Hansen MB, et al. **Physiol Res** 1995; 44(2):61-78 (135 ref.)

The Sir David Cuthbertson Medal Lecture. Enteral-feeding-related diarrhoea: proposed causes and possible solutions. Bowling TE. **Proc Nutr Soc** 1995 Jul; 54(2):579-90 (64 ref.)

[Medical treatment of chronic radiation induced enteritis] Cosnes J. **Ann Chir** 1996;50(1):36-9 (23 ref.) (Eng. Abstr.) **(Fre)**

VETERINARY

Diagnosis and treatment of chronic diarrhea. Strombeck DR. **Vet Q** 1995 Apr;17 Suppl 1:S12-3 (0 ref.)

DIARRHEA, INFANTILE

Fever without apparent source on clinical examination, lower respiratory infections in children, other infectious diseases, and acute gastroenteritis and diarrhea of infancy and early childhood. McCarthy PL, et al. **Curr Opin Pediatr** 1996 Feb;8(1):75-93 (134 ref.)

[Autoimmune enteropathy] Lachaux A. **Arch Pediatr** 1996 Mar;3(3):261-6 (32 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

Methemoglobinemia in an infant: case report and review of the literature. Jolly BT, et al. **Pediatr Emerg Care** 1995 Oct;11(5):294-7 (22 ref.)

ETHNOLOGY

The Finnish disease heritage: a personal look. Perheentupa J. **Acta Paediatr** 1995 Oct;84(10):1094-9 (26 ref.)

ETIOLOGY

Chronic diarrhea and malabsorption. Branski D, et al. **Pediatr Clin North Am** 1996 Apr;43(2):307-31 (107 ref.)

[Methemoglobinemia, acidemia and diarrhea induced by hypersensitivity to cow's milk proteins] Catalán Muñoz M, et al. **An Esp Pediatr** 1996 Mar;44(3):295-6 (6 ref.) **(Spa)**

PREVENTION & CONTROL

Childhood diarrhea and malnutrition in Pakistan, Part III: Social policy issues. David S, et al. **J Pediatr Nurs** 1995 Aug;10(4):273-8 (35 ref.)

[A vaccine against diarrhea. Soon a reality in the fight against viral gastroenteritis in both developed and developing countries] Svensson L. **Lakartidningen** 1996 Jan 31; 93(5):353-8 (26 ref.) **(Swe)**

THERAPY

Chronic diarrhea and malabsorption. Branski D, et al. **Pediatr Clin North Am** 1996 Apr;43(2):307-31 (107 ref.)

DIARRHEA VIRUS, BOVINE VIRAL

GENETICS

Molecular biology of bovine viral diarrhea virus and its interactions with the host. Donis RO. **Vet Clin North Am Food Anim Pract** 1995 Nov; 11(3):393-423 (133 ref.)

IMMUNOLOGY

Passive immunity against diarrhoea. Bogstedt AK, et al. **Acta Paediatr** 1996 Feb;85(2):125-8 (20 ref.)

Control of bovine viral diarrhea virus infection without vaccines. Bitsch V, et al. **Vet Clin North Am Food Anim Pract** 1995 Nov;11(3):627-40 (16 ref.)

Control of bovine viral diarrhea infection by use of vaccination. Bolin SR. **Vet Clin North Am Food Anim Pract** 1995 Nov;11(3):615-25 (74 ref.)

Antigenic differences among pestiviruses. Edwards S, et al. **Vet Clin North Am Food Anim Pract** 1995 Nov;11(3):563-77 (107 ref.)

Immunology of bovine viral diarrhea virus. Potgieter LN. **Vet Clin North Am Food Anim Pract** 1995 Nov;11(3):501-20 (116 ref.)

ISOLATION & PURIFICATION

Diagnosis of bovine viral diarrhea virus infections. Brock KV. **Vet Clin North Am Food Anim Pract** 1995 Nov; 11(3):549-61 (52 ref.)

PHYSIOLOGY

The pathogenesis of mucosal disease. Bolin SR. **Vet Clin North Am Food Anim Pract** 1995 Nov; 11(3):489-500 (65 ref.)

Molecular biology of bovine viral diarrhea virus and its interactions with the host. Donis RO. **Vet Clin North Am Food Anim Pract** 1995 Nov; 11(3):393-423 (133 ref.)

Pathogenesis of intrauterine infections with bovine viral diarrhea virus. Moennig V, et al. **Vet Clin North Am Food Anim Pract** 1995 Nov;11(3):477-87 (51 ref.)

DIARRHEOGENIC TUMOR see **VIPOMA**

DIASTASE see **AMYLASES**

DIASTEMATOMYELIA see **SPINA BIFIDA OCCULTA**

DIASTOLE

Diastolic dysfunction. Tardif JC, et al. **Can J Cardiol** 1996 Apr;12(4):389-98 (73 ref.)

[Left ventricular diastolic function assessment by transthoracic Doppler echocardiography] Poulsen SH, et al. **Ugeskr Laeger** 1996 Aug 12;158(33):4631-7 (33 ref.) (Eng. Abstr.) **(Dan)**

DIATHERMY

[Treatment of hemorrhoidal peduncles with diathermy probe] Milito G, et al. **Ann Ital Chir** 1995 Nov-Dec;66(6):801-3 (14 ref.) (Eng. Abstr.) **(Ita)**

INSTRUMENTATION

Field analysis of a tape helix with embedded bio-media for microwave hyperthermia. Pathak SK, et al. **J Med Eng Technol** 1996 Jan-Feb;20(1):24-33 (23 ref.)

DIATHERMY, SURGICAL see **ELECTROCOAGULATION**

DIATHESIS see **DISEASE SUSCEPTIBILITY**

DIATRIZOATE

ADVERSE EFFECTS

Noncardiogenic pulmonary edema due to radiocontrast media [clinical conference] Ramesh S, et al. **Ann Allergy Asthma Immunol** 1995 Oct;75(4):308-10 (10 ref.)

DIAZEPAM

see related
RECEPTORS, GABA-A

BLOOD

[Clonazepam, nitrazepam, diazepam] Yasuda K. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:911-4 (19 ref.) **(Jpn)**

PHARMACOLOGY

Administration of antidepressants, diazepam and psychomotor stimulants further confirms the utility of Flinders Sensitive Line rats as an animal model of depression. Overstreet DH, et al. **Psychopharmacology (Berl)** 1995 Sep;121(1):27-37 (62 ref.)

THERAPEUTIC USE

[The neuroleptic malignant syndrome in an adolescent. Its treatment with dantrolene, bromocryptin and diazepam] Real Rodríguez B, et al. **An Esp Pediatr** 1996 Jan;44(1):60-2 (20 ref.) **(Spa)**

DIBENZOCYCLOHEPTENES

THERAPEUTIC USE

[Preventive neuroprotection] Martín R. **Rev Neurol** 1995 Jan-Feb;23(119):30-2 (47 ref.) **(Spa)**

DICARBOXYLIC ACIDS

ADMINISTRATION & DOSAGE

Melanin hyperpigmentation of skin: melasma, topical treatment with azelaic acid, and other therapies. Breathnach AS. **Cutis** 1996 Jan;57(1 Suppl):36-45 (73 ref.)

Efficacy and safety of topical azelaic acid (20 percent cream): an overview of results from European clinical trials and experimental reports. Graupe K, et al. **Cutis** 1996 Jan;57(1 Suppl):20-35 (53 ref.)

DICHLOROACETATE

THERAPEUTIC USE

The therapy of respiratory chain encephalomyopathy: a critical review of the past and current perspective. Walker UA, et al. **Acta Neurol Scand** 1995 Oct;92(4):273-80 (77 ref.)

DICHLOROACETIC ACID see **DICHLOROACETATE**

CIS-DICHLORODIAMMINEPLATINUM(II) see CISPLATIN

DICHLORODIETHYL SULFIDE see MUSTARD GAS

DICHLOROMETHANE see METHYLENE CHLORIDE

DICHLOROMETHYLENE DIPHOSPHONATE see CLODRONIC ACID

2,4-DICHLOROPHENOXYACETIC ACID

METABOLISM

Characterization of the first enzyme in 2,4-dichlorophenoxyacetic acid metabolism. Hausinger RP, et al. **Environ Health Perspect** 1995 Jun;103 Suppl 5:37-9 (8 ref.)

DICLOFENAC

ADVERSE EFFECTS

Nonsteroidal anti-inflammatory drug-induced colonic strictures: two cases and literature review. Gargot D, et al. **Am J Gastroenterol** 1995 Nov;90(11):2035-8 (18 ref.)

Diclofenac/misoprostol. A review of its pharmacology and therapeutic efficacy in painful inflammatory conditions. Davis R, et al. **Drugs Aging** 1995 Nov;7(5):372-93 (76 ref.)

Review of Arthrotec clinical data. McKenna F. **Eur J Rheumatol Inflamm** 1994;14(3 Suppl):25-9 (9 ref.)

THERAPEUTIC USE

Review of Arthrotec clinical data. McKenna F. **Eur J Rheumatol Inflamm** 1994;14(3 Suppl):25-9 (9 ref.)

DICLOPHENAC see DICLOFENAC

DICROSTONYX see MICROTINAE

DICTYOSTELIUM

CLASSIFICATION

Consensus phylogeny of Dictyostelium. Loomis WF, et al. **Experientia** 1995 Dec 18;51(12):1110-5 (34 ref.)

GENETICS

PSF and CMF, autocrine factors that regulate gene expression during growth and early development of Dictyostelium. Clarke M, et al. **Experientia** 1995 Dec 18; 51(12):1124-34 (60 ref.)

Analysis of gene function in Dictyostelium. Kuspa A, et al. **Experientia** 1995 Dec 18;51(12):1116-23 (77 ref.)

From virus to vaccine: developments using the simple eukaryote, Dictyostelium discoideum. Emslie KR, et al. **Trends Microbiol** 1995 Dec;3(12):476-9 (23 ref.)

GROWTH & DEVELOPMENT

Morphogenesis in Dictyostelium: new twists to a not-so-old tale. Williams J. **Curr Opin Genet Dev** 1995 Aug;5(4):426-31 (56 ref.)

The role of calcium in aggregation and development of Dictyostelium. Newell PC, et al. **Experientia** 1995 Dec 18; 51(12):1155-65 (104 ref.)

Dual role of cAMP during Dictyostelium development. Reymond CD, et al. **Experientia** 1995 Dec 18; 51(12):1166-74 (88 ref.)

METABOLISM

Recombinant glycoprotein production in the slime mould Dictyostelium discoideum. Williams KL, et al. **Curr Opin Biotechnol** 1995 Oct;6(5):538-42 (43 ref.)

PHYSIOLOGY

Cell adhesion in the life cycle of Dictyostelium. Bozzaro S, et al. **Experientia** 1995 Dec 18;51(12):1175-88 (129 ref.)

The Dictyostelium cytoskeleton. Noegel AA, et al. **Experientia** 1995 Dec 18;51(12):1135-43 (135 ref.)

Transduction of the chemotactic cAMP signal across the plasma membrane of Dictyostelium cells. Van Haastert PJ. **Experientia** 1995 Dec 18;51(12):1144-54 (72 ref.)

The extracellular matrix of the Dictyostelium discoideum slug. Wilkins MR, et al. **Experientia** 1995 Dec 18; 51(12):1189-96 (80 ref.)

DICTYOSTELIUM DISCOIDEUM see DICTYOSTELIUM

DICYCLOMINE

THERAPEUTIC USE

Infantile colic: natural history and treatment. Lehtonen LA, et al. **Curr Probl Pediatr** 1996 Mar;26(3):79-85 (78 ref.)

DICYCLOVERIN see DICYCLOMINE

DIDANOSINE

[Didanosine] **Enferm Infecc Microbiol Clin** 1995 Oct; 13(8):487-90 (0 ref.) **(Spa)**

THERAPEUTIC USE

The clinical use of didanosine. Kahn J. **Adv Exp Med Biol** 1996;394:245-56 (47 ref.)

Studies of zidovudine in combination with didanosine and zalcitabine. Jablonowski H. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995;10 Suppl 1:S52-6 (17 ref.)

2',3'-DIDEHYDRO-3'-DEOXYTHYMIDINE see STAVUDINE

DIDEOXYCYTIDINE see ZALCITABINE

2',3'-DIDEOXYCYTIDINE see ZALCITABINE

DIDEOXYINOSINE see DIDANOSINE

2',3'-DIDEOXYINOSINE see DIDANOSINE

DIELDRIN

TOXICITY

The species specificity of dieldrin- or phenobarbital- induced hepatocarcinogenesis: case studies with implications for human health risk assessment. Stevenson DE, et al. **Prog Clin Biol Res** 1995;391:337-45 (28 ref.)

Sodium channels and GABAA receptor-channel complex as targets of environmental toxicants. Narahashi T, et al. **Toxicol Lett** 1995 Dec;82-83:239-45 (20 ref.)

DIESEL EXHAUST see VEHICLE EMISSIONS

DIET

Diet and psychological health. Miller M. **Altern Ther Health Med** 1996 Sep;2(5):40-8 (73 ref.)

The athlete with type I diabetes: managing insulin, diet and exercise. Fahey PJ, et al. **Am Fam Physician** 1996 Apr; 53(5):1611-24 (22 ref.)

McCollum Award Lecture, 1995: diet, lifestyle, and weight maintenance. Flatt JP. **Am J Clin Nutr** 1995 Oct; 62(4):820-36 (91 ref.)

Body composition, respiratory quotient, and weight maintenance. Flatt JP. **Am J Clin Nutr** 1995 Nov;62(5 Suppl):1107S-1117S (72 ref.)

Sugar substitutes: their energy values, bulk characteristics, and potential health benefits. Levin GV, et al. **Am J Clin Nutr** 1995 Nov;62(5 Suppl):1161S-1168S (38 ref.)

Sympathetic nervous system response to intake. Welle S. **Am J Clin Nutr** 1995 Nov;62(5 Suppl):1118S-1122S (46 ref.)

Alcohol consumption and coronary heart disease: good habits may be more important than just good wine [see comments] Rimm EB. **Am J Epidemiol** 1996 Jun 1;143(11):1094-8; discussion 1099 (39 ref.) Comment in: Am J Epidemiol 1996 Jun 1;143(1):1089-93.

Dietary studies of children and young adults (1973-1988): the Bogalusa Heart Study. Nicklas TA. **Am J Med Sci** 1995 Dec;310 Suppl 1:S101-8 (37 ref.)

Induction of anergy in Th1 lymphocytes by oral tolerance. Importance of antigen dosage and frequency of feeding. Friedman A. **Ann N Y Acad Sci** 1996 Feb 13;778:103-10 (47 ref.)

The genetic determinants of plasma cholesterol and response to diet. Humphries SE, et al. **Baillieres Clin Endocrinol Metab** 1995 Oct;9(4):797-823 (148 ref.)

Vitamin intake in Great Britain: association with mortality rates for coronary heart disease. Ashwell M, et al. **Bibl Nutr Dieta** 1995;(52):128-36 (9 ref.)

Discussions in the United States about recommended daily dietary allowances in the future. Lachance PA. **Bibl Nutr Dieta** 1995;(52):158-67 (35 ref.)

Proposed role for a combination of citric acid and ascorbic acid in the production of dietary iron overload: a fundamental cause of disease. Crawford RD. **Biochem Mol Med** 1995 Feb;54(1):1-11 (77 ref.)

Plant carotenoids and related molecules: important dietary antioxidants. Krinsky NI. **Biochem Soc Symp** 1995; 61:117-26 (47 ref.)

The importance of diet and physical activity in the treatment of conditions managed in general practice. Little P, et al. **Br J Gen Pract** 1996 Mar;46(404):187-92 (122 ref.)

The preventive role of diet in prostatic disease. Morton MS, et al. **Br J Urol** 1996 Apr;77(4):481-93 (149 ref.)

Optimal diet for reducing the risk of arteriosclerosis. Jenkins DJ. **Can J Cardiol** 1995 Oct;11 Suppl G:118G-122G (55 ref.)

Dietary cholesterol and the optimal diet for reducing risk of atherosclerosis. McNamara DJ. **Can J Cardiol** 1995 Oct; 11 Suppl G:123G-126G (13 ref.)

Antioxidants in the Mediterranean diet. Mancini M, et al. **Can J Cardiol** 1995 Oct;11 Suppl G:105G-109G (20 ref.)

Diet, aging, and cancer. Goodwin JS, et al. **Clin Geriatr Med** 1995 Nov;11(4):577-89 (45 ref.)

On the presence of inulin and oligofructose as natural ingredients in the western diet. van Loo J, et al. **Crit Rev Food Sci Nutr** 1995 Nov;35(6):525-52 (102 ref.)

Diet, blood coagulation and fibrinolysis. Marckmann P. **Dan Med Bull** 1995 Nov;42(5):410-25 (275 ref.)

Diet and cancer: future etiologic research. Schatzkin A, et al. **Environ Health Perspect** 1995 Nov;103 Suppl 8:171-5 (55 ref.)

Diet, nutrition, and avoidable cancer. Willett WC. **Environ Health Perspect** 1995 Nov;103 Suppl 8:165-70 (58 ref.)

Role of bile acids in colorectal carcinogenesis. Nagengast FM, et al. **Eur J Cancer** 1995 Jul-Aug;31A(7-8):1067-70 (44 ref.)

Chemo- and dietary prevention of colorectal cancer. Schatzkin A, et al. **Eur J Cancer** 1995 Jul-Aug; 31A(7-8):1198-204 (31 ref.)

Role of short-chain fatty acids in the prevention of colorectal cancer. Scheppach W, et al. **Eur J Cancer** 1995 Jul-Aug; 31A(7-8):1077-80 (29 ref.)

Dietary restriction. Masoro EJ. **Exp Gerontol** 1995 May-Aug; 30(3-4):291-8 (27 ref.)

Lipid peroxidation: a review of causes, consequences, measurement and dietary influences. Benzie IF. **Int J Food Sci Nutr** 1996 May;47(3):233-61 (222 ref.)

Are dietary recommendations for dietary fat reduction achievable? Drummond S, et al. **Int J Food Sci Nutr** 1996 May;47(3):221-6 (37 ref.)

Energy requirements of the fat sand rat (Psammomys obesus) when consuming the saltbush, Atriplex halimus: a review. Degen AA. **J Basic Clin Physiol Pharmacol** 1993 Apr-Jun; 4(1-2):13-28 (37 ref.)

The Mediterranean diet and cardiovascular disease. Hiser E. **J Cardpulm Rehabil** 1995 May-Jun;15(3):179-82 (22 ref.)

Dietary guidelines in perspective. Harper AE. **J Nutr** 1996 Apr;126(4 Suppl):1042S-8S (51 ref.)

Dietary antioxidants in disease prevention. Gordon M. **Nat Prod Rep** 1996 Aug;13(4):265-73 (130 ref.)

Whole grain intake and cancer: a review of the literature. Jacobs DR Jr, et al. **Nutr Cancer** 1995;24(3):221-9 (35 ref.)

Disease heterogeneity: does it impact our ability to detect dietary associations with breast cancer? Slattery ML, et al. **Nutr Cancer** 1995;24(3):213-20 (72 ref.)

A fertility diet for planning pregnancy. Wynn M, et al. **Nutr Health** 1995;10(3):219-38 (50 ref.)

Early dietary influence on later immunocompetence. Hanson LA, et al. **Nutr Rev** 1996 Feb;54(2 Pt 2):S23-30 (73 ref.)

Lowered energy intake and dietary macronutrient balance: potential consequences for micronutrient status. Whitehead RG. **Nutr Rev** 1995 Sep;53(9 Pt 2):S2-8 (6 ref.)

Dietary intake and physical activity as "predictors" of weight gain in observational, prospective studies of adults. Williamson DF. **Nutr Rev** 1996 Apr;54(4 Pt 2):S101-9 (15 ref.)

Clinical applications of diet and physical activity in weight loss. Wood PD. **Nutr Rev** 1996 Apr;54(4 Pt 2):S131-5 (29 ref.)

Dietary purine nucleotides and the gastrointestinal tract. Leleiko NS, et al. **Nutrition** 1995 Nov-Dec;11(6):725-30 (44 ref.)

Dietary fiber in weaning foods of young children. Agostoni C, et al. **Pediatrics** 1995 Nov;96(5 Pt 2):1002-5 (42 ref.)

Influence of diet on tumors of hormonal tissues. Rao GN. **Prog Clin Biol Res** 1996;394:41-56 (92 ref.)

What causes cancer? Trichopoulos D, et al. **Sci Am** 1996 Sep;275(3):80-7 (0 ref.)

Role of dietary factors in the hypertension of African Americans. Adrogué HJ, et al. **Semin Nephrol** 1996 Mar; 16(2):94-101 (45 ref.)

Individual nutrient effects on length of gestation and pregnancy outcome. Murtaugh MA, et al. **Semin Perinatol** 1995 Jun;19(3):197-210 (138 ref.)

Periconceptional folic acid supplementation as a social intervention. Rose NC, et al. **Semin Perinatol** 1995 Aug; 19(4):243-54 (61 ref.)

Diet and chemoprevention of colon polyps and colorectal cancer. Nixon DW. **Semin Surg Oncol** 1995 Nov-Dec; 11(6):411-5 (34 ref.)

[Monoamine oxidase inhibitors and food precautions. A comparison of utilization in Belgian psychiatric education institutes and current findings in the literature] Mallet L, et al. **Acta Psychiatr Belg** 1996 Mar-Apr;96(2):74-100 (52 ref.) (Eng. Abstr.) **(Fre)**

[Diet and cancer: review of the epidemiologic evidence] Del Prete U, et al. **Ann Ig** 1996 Mar-Apr;8(2):213-28 (127 ref.) (Eng. Abstr.) **(Ita)**

[Interactions between drugs and food in pediatric age] Paci A, et al. **Pediatr Med Chir** 1996 Jan-Feb;18(1):47-52 (25 ref.) (Eng. Abstr.) **(Ita)**

ADVERSE EFFECTS

Colorectal cancer and intake of dietary fibre. A summary of the epidemiological evidence. Kaaks R, et al. **Eur J Clin Nutr** 1995 Oct;49 Suppl 3:S10-7 (56 ref.)

Dietary contribution to genotoxic risk and its control. Lindsay DG. **Food Chem Toxicol** 1996 Apr;34(4):423-31 (61 ref.)

"Hidden" allergens in foods. Steinman HA. **J Allergy Clin Immunol** 1996 Aug;98(2):241-50 (93 ref.)

The making of a user friendly MAOI diet. Gardner DM, et al. **J Clin Psychiatry** 1996 Mar;57(3):99-104 (53 ref.)

The influence of diet on urinary stone disease. Parivar F,

et al. **J Urol** 1996 Feb;155(2):432–40 (139 ref.)
Diet as a confounder of the association between air pollution and female lung cancer: Hong Kong studies on exposures to environmental tobacco smoke, incense, and cooking fumes as examples. Koo LC, et al. **Lung Cancer** 1996 Mar; 14 Suppl 1:S47–61 (21 ref.)
Chronic nonspecific diarrhea of childhood: pathophysiology and management. Kneepkens CM, et al. **Pediatr Clin North Am** 1996 Apr;43(2):375–90 (103 ref.)
Risks from occupational and dietary exposure to mevinphos. Cochran RC, et al. **Rev Environ Contam Toxicol** 1996; 146:1–24 (76 ref.)
[The pediatrician and cancer prevention. Dietetic factors and smoking] Ferris i Tortajada J, et al. **An Esp Pediatr** 1996 Jul;45(1):6–13 (51 ref.) (Eng. Abstr.) **(Spa)**
[Diet and migraine] Leira R, et al. **Rev Neurol** 1996 May; 24(129):534–8 (46 ref.) (Eng. Abstr.) **(Spa)**

PSYCHOLOGY

Fat, carbohydrate, and the regulation of energy intake. Rolls BJ, et al. **Am J Clin Nutr** 1995 Nov;62(5 Suppl):1086S–1095S (45 ref.)
Unrealistic optimism about diet-related risks: implications for interventions. Raats MM, et al. **Proc Nutr Soc** 1996 Nov; 54(3):737–45 (36 ref.)

STANDARDS

Diet, nutrition & cancer—the Indian scenario. Krishnaswamy K, et al. **Indian J Med Res** 1995 Nov;102:200–9 (70 ref.)
Position of the American Dietetic Association: vitamin and mineral supplementation. **J Am Diet Assoc** 1996 Jan; 96(1):73–7 (53 ref.)
Indexes of overall diet quality: a review. Kant AK. **J Am Diet Assoc** 1996 Aug;96(8):785–91 (69 ref.)
Plant wax components: a new approach to estimating intake and diet composition in herbivores. Dove H, et al. **J Nutr** 1996 Jan;126(1):13–26 (62 ref.)
Recent advances in methods of assessing dietary amino acid requirements for adult humans. Zello GA, et al. **J Nutr** 1995 Dec;125(12):2907–15 (64 ref.)
A review of dietary and environmental correlates of obesity with emphasis on developing countries. Popkin BM, et al. **Obes Res** 1995 Sep;3 Suppl 2:145s–153s (69 ref.)
Changing diet and exercise behaviors in individuals at risk for weight gain. Wing RR. **Obes Res** 1995 Sep;3 Suppl 2:277s–282s (28 ref.)
Looking for 'fresh' food: diet and lone parents. Dowler E, et al. **Proc Nutr Soc** 1996 Nov;54(3):759–69 (22 ref.)
The effects of dietary change on serum cholesterol. Haq IU, et al. **Proc Nutr Soc** 1996 Nov;54(3):601–16 (80 ref.)
Nutrient effects: post-absorptive interactions. Jéquier E. **Proc Nutr Soc** 1995 Mar;54(1):253–65 (57 ref.)
Social influences on food choice and dietary change: a sociological attitude. Murcott A. **Proc Nutr Soc** 1996 Nov; 54(3):729–35 (13 ref.)
Parental influences on children's diets. Wardle J. **Proc Nutr Soc** 1996 Nov;54(3):747–58 (63 ref.)

TRENDS

Intake of carbohydrate and its components—international comparisons, trends over time, and effects of changing to low-fat diets. Stephen AM, et al. **Am J Clin Nutr** 1995 Oct;62(4):851S–867S (378 ref.)

VETERINARY

Measurement of the influence of diet on feline urinary pH. Allen TA. **Vet Clin North Am Small Anim Pract** 1996 Mar; 26(2):363–8 (6 ref.)

DIET, ATHEROGENIC

see related
CHOLESTEROL, DIETARY

DIET, CARIOGENIC

Cariogenicity depends more on diet than the prevailing mutans streptococcal species. van Palenstein Helderman WH, et al. **J Dent Res** 1996 Jan;75(1):535–45 (115 ref.)

DIET, CHEMICALLY DEFINED see **FOOD, FORMULATED**

DIET, DIABETIC see **DIABETIC DIET**

DIET, ELEMENTAL see **FOOD, FORMULATED**

DIET, FAT-FREE see **DIET, FAT-RESTRICTED**

DIET, FAT-RESTRICTED

Improving the sensory characteristics of reduced-fat cheese. Mistry VV. **Adv Exp Med Biol** 1995;367:371–82 (19 ref.)
Diet in the prevention and treatment of atherosclerosis. A perspective for the elderly. Srinath U, et al. **Clin Geriatr Med** 1995 Nov;11(4):591–611 (46 ref.)
Lipid lowering in the young [editorial] Thompson GR. **Heart** 1996 Jul;76(1):1–2 (17 ref.)
The role of lipid management by diet and exercise in the progression, stabilization, and regression of coronary artery atherosclerosis. LaFontaine T. **J Cardpulm Rehabil** 1995 Jul–Aug;15(4):262–8 (26 ref.)
Hypercholesterolemia. Dietary advice for patients regarding meat [see comments] Keenan JM, et al. **Postgrad Med** 1995 Oct;98(4):113–4, 117–8, 120–1 passim (20 ref.) Comment in: Postgrad Med 1996 Feb;99(2):47–8.
[Dietary treatment of hypercholesterolemia] Richter WO. **Wien Klin Wochenschr** 1995;107(18):549–54 (83 ref.) (Eng. Abstr.) **(Ger)**
[Modifying increased plasma cholesterol levels in secondary prevention of coronary heart disease] Jost S, et al. **Z Kardiol** 1995 Aug;84(8):577–95 (159 ref.) (Eng. Abstr.) **(Ger)**

PSYCHOLOGY

Cholesterol and psychological well-being. Wardle J. **J Psychosom Res** 1995 Jul;39(5):549–62 (72 ref.)

DIET, FORMULA see **FOOD, FORMULATED**

DIET, LOW-FAT see **DIET, FAT-RESTRICTED**

DIET, LOW-PROTEIN see **DIET, PROTEIN-RESTRICTED**

DIET, LOW-SALT see **DIET, SODIUM-RESTRICTED**

DIET, LOW-SODIUM see **DIET, SODIUM-RESTRICTED**

DIET, PROTEIN-FREE see **DIET, PROTEIN-RESTRICTED**

DIET, PROTEIN-RESTRICTED

Low-protein diets in the treatment of chronic renal failure. Mitch WE. **J Am Coll Nutr** 1995 Aug;14(4):311–6 (34 ref.)
Effect of low-protein diets on renal disease: are non-haemodynamic factors involved? [editorial] Heidland A, et al. **Nephrol Dial Transplant** 1995;10(9):1512–4 (27 ref.)

VETERINARY

Protein sparing effect and nutritive significance of lipid supplementation in carp diets. Steffens W. **Arch Tierernahr** 1996;49(1):93–8 (52 ref.)
The hyperfiltration theory: progression of chronic renal failure and the effects of diet in dogs. Gonin-Jmaa D, et al. **J Am Vet Med Assoc** 1995 Dec 1;207(11):1411–5 (54 ref.)

DIET RECORDS

The calorie: myth, measurement, and reality. Heymsfield SB, et al. **Am J Clin Nutr** 1995 Nov;62(5 Suppl):1034S–1041S (78 ref.)

DIET, REDUCING

Diet and diabetes in the elderly. Fonseca V, et al. **Clin Geriatr Med** 1995 Nov;11(4):613–24 (53 ref.)
Exercise with or without dietary restriction and obesity treatment. Saris WH. **Int J Obes Relat Metab Disord** 1995 Oct;19 Suppl 4:S113–6 (31 ref.)
[Diet therapy of obesity] Nakamura T. **Nippon Naika Gakkai Zasshi** 1995 Aug 10;84(8):1273–8 (12 ref.) **(Jpn)**
[Diet therapy in obesity] Nakamura T, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:449–54 (12 ref.) **(Jpn)**
[Effects of one-week inpatient weight reduction program for obese persons] Ogawa K, et al. **Nippon Rinsho** 1995 Jun; 53 Suppl:501–8 (11 ref.) **(Jpn)**
[Behavioural modification for therapy of obesity] Ohno M, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:460–7 (15 ref.) **(Jpn)**
[Very low calorie diets for obesity] Tanaka S. **Nippon Rinsho** 1995 Jun;53 Suppl:495–8 (13 ref.) **(Jpn)**
[Childhood obesity: treatment and prognosis] Yamazaki K, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:529–33 (12 ref.) **(Jpn)**

PSYCHOLOGY

Psychological consequences of food restriction. Polivy J. **J Am Diet Assoc** 1996 Jun;96(6):589–92; quiz 593–4 (48 ref.)
Preventing relapse in weight control: a discussion of cognitive and behavioral strategies. Turner LW, et al. **Psychol Rep** 1995 Oct;77(2):651–6 (25 ref.)

STANDARDS

Antiaging action of caloric restriction: endocrine and metabolic aspects. Masoro EJ. **Obes Res** 1995 Sep;3 Suppl 2:241s–247s (30 ref.)
A very-low-calorie conventional Japanese diet: its implications for prevention of obesity. Sakata T. **Obes Res** 1995 Sep;3 Suppl 2:233s–239s (21 ref.)

DIET, SODIUM-RESTRICTED

The potentiality and practicality of a 'salt-free' diet for the prevention and amelioration of human disorders. Leeming RA. **Med Hypotheses** 1996 Jan;46(1):45–51 (45 ref.)

STANDARDS

Are low-sodium diets appropriate for treated hypertensive men? Fleet JC. **Nutr Rev** 1995 Oct;53(10):296–8 (10 ref.)

DIET SURVEYS

Assessment of food intakes: are we measuring what people eat? Livingstone MB. **Br J Biomed Sci** 1995 Mar; 52(1):58–67 (50 ref.)

DIET, SYNTHETIC see **FOOD, FORMULATED**

DIET THERAPY

Clinical and laboratory assessment of zinc deficiency in Dutch children. A review. Van Wouwe JP. **Biol Trace Elem Res** 1995 Aug–Sep;49(2–3):211–25 (68 ref.)

ECONOMICS

Position of The American Dietetic Association: nutrition services in managed care. Laramee SH. **J Am Diet Assoc** 1996 Apr;96(4):391–5 (55 ref.)

DIETARY CALCIUM see **CALCIUM, DIETARY**

DIETARY CARBOHYDRATES

Dietary fibre, complex carbohydrate and coronary artery disease. Anderson JW. **Can J Cardiol** 1995 Oct;11 Suppl G:55G–62G (98 ref.)
Review of previous impaired glucose tolerance intervention studies. Melander A. **Diabet Med** 1996;13(3 Suppl 2):S20–2 (5 ref.)
Nutrition principles and diabetes. A role for "lente carbohydrate"? Jenkins DJ, et al. **Diabetes Care** 1995 Nov; 18(11):1491–8 (78 ref.)
Brain serotonin, carbohydrate-craving, obesity and depression. Wurtman RJ, et al. **Obes Res** 1995 Nov;3 Suppl 4:477S–480S (34 ref.)

ADMINISTRATION & DOSAGE

Energy intake and sensory properties of food. Drewnowski A. **Am J Clin Nutr** 1995 Nov;62(5 Suppl):1081S–1085S (38 ref.)
Intake of carbohydrate and its components—international comparisons, trends over time, and effects of changing to low-fat diets. Stephen AM, et al. **Am J Clin Nutr** 1995 Oct;62(4):851S–867S (378 ref.)
Carbohydrate and obesity. Astrup A, et al. **Int J Obes Relat Metab Disord** 1995 Nov;19 Suppl 5:S27–37 (121 ref.)
Intake of sugars in relation to fatness and micronutrient adequacy. Bolton-Smith C. **Int J Obes Relat Metab Disord** 1996 Mar;20 Suppl 2:S31–3 (35 ref.)
Association of macronutrients and energy intake with hypertension. Preuss HG, et al. **J Am Coll Nutr** 1996 Feb; 15(1):21–35 (207 ref.)
Carbohydrates and exercise performance. Hargreaves M. **Nutr Rev** 1996 Apr;54(4 Pt 2):S136–9 (40 ref.)

ANALYSIS

Methods to assess glucose metabolism in humans in relation to carbohydrate and fibre in the diet. Bornet FR, et al. **Eur J Clin Nutr** 1995 Oct;49 Suppl 3:S97–104 (60 ref.)
Physical properties of polysaccharides in food. Brosio E. **Eur J Clin Nutr** 1995 Oct;49 Suppl 3:S63–7 (7 ref.)
Definition and measurement of dietary fibre. Englyst HN, et al. **Eur J Clin Nutr** 1995 Oct;49 Suppl 3:S48–62 (38 ref.)
The impact of complex carbohydrates on energy balance. Livesey G. **Eur J Clin Nutr** 1995 Oct;49 Suppl 3:S89–96 (30 ref.)
Complex carbohydrates: the science and the label. **Nutr Rev** 1995 Jul;53(7):186–93 (8 ref.)

CLASSIFICATION

International tables of glycemic index. Foster-Powell K, et al. **Am J Clin Nutr** 1995 Oct;62(4):871S–890S (79 ref.)

METABOLISM

Sugar substitutes: their energy values, bulk characteristics, and potential health benefits. Levin GV, et al. **Am J Clin Nutr** 1995 Nov;62(5 Suppl):1161S–1168S (38 ref.)
Metabolizable energy of macronutrients. Livesey G. **Am J Clin Nutr** 1995 Nov;62(5 Suppl):1135S–1142S (35 ref.)
Fat, carbohydrate, and the regulation of energy intake. Rolls BJ, et al. **Am J Clin Nutr** 1995 Nov;62(5 Suppl):1086S–1095S (45 ref.)
Digestion, absorption, and fermentation of carbohydrates in the newborn. Kien CL. **Clin Perinatol** 1996 Jun; 23(2):211–28 (143 ref.)
Effect of reduced rate of carbohydrate absorption on carbohydrate and lipid metabolism. Jenkins DJ, et al. **Eur J Clin Nutr** 1995 Oct;49 Suppl 3:S68–73 (36 ref.)
The impact of complex carbohydrates on energy balance. Livesey G. **Eur J Clin Nutr** 1995 Oct;49 Suppl 3:S89–96 (30 ref.)
Fat loading: the next magic bullet? Sherman WM, et al.

Int J Sport Nutr 1995 Jun;5 Suppl:S1-12 (29 ref.)

PHARMACOLOGY

Dietary carbohydrates and glucose metabolism in diabetic patients. Parillo M, et al. **Diabete Metab** 1995 Dec; 21(6):391-401 (67 ref.)

Manipulating carbohydrate content and sources in obesity prone subjects: effect on energy expenditure and macronutrient balance. Raben A, et al. **Int J Obes Relat Metab Disord** 1996 Mar;20 Suppl 2:S24-30 (81 ref.)

Synthesis of fat in response to alterations in diet: insights from new stable isotope methodologies. Hellerstein MK. **Lipids** 1996 Mar;31 Suppl:S117-25 (73 ref.)

STANDARDS

Dietary carbohydrate as an ergogenic aid for prolonged and brief competitions in sport. Walberg-Rankin J. **Int J Sport Nutr** 1995 Jun;5 Suppl:S13-28 (67 ref.)

DIETARY CHOLESTEROL see CHOLESTEROL, DIETARY

DIETARY FATS

Nutrient substitutes and their energy values in fat substitutes and replacers. Miraglio AM. **Am J Clin Nutr** 1995 Nov; 62(5 Suppl):1175S-1179S (22 ref.)

Transformations and effects of lipids in the rumen: three decades of research at Gent University. Demeyer DI, et al. **Arch Tierernahr** 1995;48(1-2):119-34 (41 ref.)

Probing the causes of high-fat diet hyperphagia: a mechanistic and behavioral dissection. Warwick ZS. **Neurosci Biobehav Rev** 1996;20(1):155-61 (33 ref.)

ADMINISTRATION & DOSAGE

Energy intake and sensory properties of food. Drewnowski A. **Am J Clin Nutr** 1995 Nov;62(5 Suppl):1081S-1085S (38 ref.)

Intake of carbohydrate and its components--international comparisons, trends over time, and effects of changing to low-fat diets. Stephen AM, et al. **Am J Clin Nutr** 1995 Oct;62(4):851S-867S (378 ref.)

Dietary fat content and energy density during infancy and childhood; the effect on energy intake and growth. Michaelsen KF, et al. **Eur J Clin Nutr** 1995 Jul;49(7):467-83 (75 ref.)

Are dietary recommendations for dietary fat reduction achievable? Drummond S, et al. **Int J Food Sci Nutr** 1996 May;47(3):221-6 (37 ref.)

Is breast cancer avoidable? Could dietary changes help? Walker AR, et al. **Int J Food Sci Nutr** 1995 Nov; 46(4):373-81 (78 ref.)

Fat and obesity. Weststrate JA. **Int J Obes Relat Metab Disord** 1995 Nov;19 Suppl 5:S38-43 (43 ref.)

Fat loading: the next magic bullet? Sherman WM, et al. **Int J Sport Nutr** 1995 Jun;5 Suppl:S1-12 (29 ref.)

Association of macronutrients and energy intake with hypertension. Preuss HG, et al. **J Am Coll Nutr** 1996 Feb; 15(1):21-35 (207 ref.)

Considerations about dietary fat restrictions for children. Lifshitz F, et al. **J Nutr** 1996 Apr;126(4 Suppl):1031S-41S (93 ref.)

Nutrition recommendations update: dietary fats and children. **Nutr Rev** 1995 Dec;53(12):367-75 (55 ref.)

Serotonin, eating behavior, and fat intake. Blundell JE, et al. **Obes Res** 1995 Nov;3 Suppl 4:471S-476S (61 ref.)

Understanding fat preference and consumption: applications of behavioural sciences to a nutritional problem. Mela DJ. **Proc Nutr Soc** 1995 Jul;54(2):453-64 (77 ref.)

ADVERSE EFFECTS

Recent insights into dietary fats and cardiovascular disease. Dimmitt SB. **Clin Exp Pharmacol Physiol** 1995 Mar; 22(3):204-8 (43 ref.)

Diet, blood coagulation and fibrinolysis. Marckmann P. **Dan Med Bull** 1995 Nov;42(5):410-25 (275 ref.)

The Department of Health Cardiovascular Review Group and public health policy: an alternative view [see comments] Gurr MI, et al. **J R Soc Health** 1995 Oct; 115(5):279-81 (20 ref.) Comment in: J R Soc Health 1996 Apr;116(2):121-2.

Trans fatty acids: implications for health, analytical methods, incidence in edible fats and intake (a review). Precht D, et al. **Nahrung** 1995;39(5-6):343-74 (195 ref.)

The women's health initiative: will it resolve the issues? Michels KB, et al. **Recent Results Cancer Res** 1996; 140:295-305 (53 ref.)

ANALYSIS

Characteristics of fats in Japanese diets and current recommendations. Sugano M. **Lipids** 1996 Mar;31 Suppl:S283-6 (13 ref.)

METABOLISM

McCollum Award Lecture, 1995: diet, lifestyle, and weight maintenance. Flatt JP. **Am J Clin Nutr** 1995 Oct; 62(4):820-36 (91 ref.)

Fat, carbohydrate, and the regulation of energy intake. Rolls BJ, et al. **Am J Clin Nutr** 1995 Nov;62(5 Suppl):1086S-1095S (45 ref.)

The role of stereospecific saturated fatty acid positions on lipid nutrition. Decker EA. **Nutr Rev** 1996 Apr;54(4 Pt 1):108-10 (18 ref.)

PHARMACOLOGY

Influence of dietary fatty acid composition and vitamin E on fatty acids and alpha-tocopherol in carp (Cyprinus carpio L.). Schwarz FJ. **Arch Tierernahr** 1996;49(1):63-71 (37 ref.)

Protein sparing effect and nutritive significance of lipid supplementation in carp diets. Steffens W. **Arch Tierernahr** 1996;49(1):93-8 (52 ref.)

Atherogenic and anti-atherogenic factors in the human diet. Addis PB, et al. **Biochem Soc Symp** 1995;61:259-71 (64 ref.)

Saturated fats and blood lipids: new slant on an old story. Hayes KC. **Can J Cardiol** 1995 Oct;11 Suppl G:39G-46G (48 ref.)

Effects of dietary fat on drug absorption. Zhi J, et al. **Clin Pharmacol Ther** 1995 Nov;58(5):487-91 (47 ref.)

Importance of energy density and macronutrients in the regulation of energy intake. Prentice AM, et al. **Int J Obes Relat Metab Disord** 1996 Mar;20 Suppl 2:S18-23 (27 ref.)

Fats in Indian diets and their nutritional and health implications. Ghafoorunissa. **Lipids** 1996 Mar;31 Suppl:S287-91 (29 ref.)

Impact of fat substitutes on fat intake. Miller GD, et al. **Lipids** 1996 Mar;31 Suppl:S293-6 (61 ref.)

Fats for the food industry: implications for cholesterol-lowering. Nestel P, et al. **Lipids** 1996 Mar;31 Suppl:S65-9 (10 ref.)

STANDARDS

Position paper on trans fatty acids. ASCN/AIN Task Force on Trans Fatty Acids. American Society for Clinical Nutrition and American Institute of Nutrition. **Am J Clin Nutr** 1996 May;63(5):663-70 (32 ref.)

Nutrition evaluation of dietary fat substitutes. Gershoff SN. **Nutr Rev** 1995 Nov;53(11):305-13 (63 ref.)

THERAPEUTIC USE

Alternative epilepsy therapies: the ketogenic diet, immunoglobulins, and steroids. Prasad AN, et al. **Epilepsia** 1996;37 Suppl 1:S81-95 (106 ref.)

The hyperfiltration theory: progression of chronic renal failure and the effects of diet in dogs. Gonin-Jmaa D, et al. **J Am Vet Med Assoc** 1995 Dec 1;207(11):1411-5 (54 ref.)

DIETARY FATS, UNSATURATED

The Mediterranean diet and cardiovascular disease. Hiser E. **J Cardpulm Rehabil** 1995 May-Jun;15(3):179-82 (22 ref.)

ADMINISTRATION & DOSAGE

Dietary fish oil and airways obstruction. Britton J. **Thorax** 1995 Sep;50 Suppl 1:S11-5 (28 ref.)

ANALYSIS

Lipid-based fat substitutes. Akoh CC. **Crit Rev Food Sci Nutr** 1995 Sep;35(5):405-30 (131 ref.)

METABOLISM

Eicosanoids in rheumatoid arthritis. Sperling RI. **Rheum Dis Clin North Am** 1995 Aug;21(3):741-58 (84 ref.)

PHARMACOLOGY

Antagonistic effects of dietary arachidonic acid and n-3 polyunsaturated fatty acids. Whelan J. **J Nutr** 1996 Apr; 126(4 Suppl):1086S-91S (35 ref.)

Polyunsaturated fatty acid regulation of hepatic gene transcription. Clarke SD, et al. **Lipids** 1996 Mar;31 Suppl:S7-11 (50 ref.)

Effect of dietary docosahexaenoic acid on brain composition and neural function in term infants. Gibson RA, et al. **Lipids** 1996 Mar;31 Suppl:S177-81 (28 ref.)

Effects of modulation of inflammatory and immune parameters in patients with rheumatic and inflammatory disease receiving dietary supplementation of n-3 and n-6 fatty acids. Kremer JM. **Lipids** 1996 Mar;31 Suppl:S243-7 (50 ref.)

Fats for the food industry: implications for cholesterol-lowering. Nestel P, et al. **Lipids** 1996 Mar;31 Suppl:S65-9 (10 ref.)

The significance of polyunsaturated fatty acids in cutaneous biology. Ziboh VA. **Lipids** 1996 Mar;31 Suppl:S249-53 (29 ref.)

Polyunsaturated fatty acids and signalling via phospholipase C-beta and A2 in myocardium. de Jonge HW, et al. **Mol Cell Biochem** 1996 Apr 12-26;157(1-2):199-210 (79 ref.)

[The experimental and clinical aspects of eicosapentaenoic amd docosahexaenoic acids (a review of the literature and the author's own data)] Serhiienko OO. **Lik Sprava** 1995 May-Jun;(5-6):61-6 (31 ref.) (Eng. Abstr.) **(Ukr)**

THERAPEUTIC USE

Adrenoleukodystrophy: molecular genetics, pathology, and Lorenzo's oil. Moser HW, et al. **Brain Pathol** 1995 Jul; 5(3):259-66 (72 ref.)

Komrower Lecture. Adrenoleukodystrophy: natural history, treatment and outcome. Moser HW. **J Inherit Metab Dis** 1995;18(4):435-47 (47 ref.)

DIETARY FIBER

Dietary fibre, complex carbohydrate and coronary artery disease. Anderson JW. **Can J Cardiol** 1995 Oct;11 Suppl G:55G-62G (98 ref.)

Dietary fiber: fact and fiction. Bennett WG, et al. **Dig Dis** 1996 Jan-Feb;14(1):43-58 (96 ref.)

Studies on the role of specific dietary fibres in protection against colorectal cancer. Ferguson LR, et al. **Mutat Res** 1996 Feb 19;350(1):173-84 (67 ref.)

ADMINISTRATION & DOSAGE

Gut mucosa reconditioning with species-specific lactobacilli, surfactants, pseudomucus, and fibers--an invited review. Bengmark S, et al. **Biotechnol Ther** 1994-95;5(3-4):171-94 (149 ref.)

Epidemiology of fibre, resistant starch and colorectal cancer. Kritchevsky D. **Eur J Cancer Prev** 1995 Oct;4(5):345-52 (65 ref.)

Colorectal cancer and intake of dietary fibre. A summary of the epidemiological evidence. Kaaks R, et al. **Eur J Clin Nutr** 1995 Oct;49 Suppl 3:S10-7 (56 ref.)

The diet as a source of dietary fibre. Southgate DA. **Eur J Clin Nutr** 1995 Oct;49 Suppl 3:S22-6 (20 ref.)

Short-chain fatty acids and colorectal cancer. Vernia P, et al. **Eur J Clin Nutr** 1995 Oct;49 Suppl 3:S18-21 (20 ref.)

Dietary fiber in weaning foods of young children. Agostoni C, et al. **Pediatrics** 1995 Nov;96(5 Pt 2):1002-5 (42 ref.)

An overview of the effects of dietary fiber on gastrointestinal transit. Hillemeier C. **Pediatrics** 1995 Nov;96(5 Pt 2):997-9 (13 ref.)

The role of dietary fiber in the development and treatment of childhood obesity. Kimm SY. **Pediatrics** 1995 Nov;96(5 Pt 2):1010-4 (51 ref.)

Is a high-fiber diet safe for children? Williams CL, et al. **Pediatrics** 1995 Nov;96(5 Pt 2):1014-9 (55 ref.)

ANALYSIS

Dietary fibre analysis--an overview. Asp NG. **Eur J Clin Nutr** 1995 Oct;49 Suppl 3:S42-7 (32 ref.)

Methods to assess glucose metabolism in humans in relation to carbohydrate and fibre in the diet. Bornet FR, et al. **Eur J Clin Nutr** 1995 Oct;49 Suppl 3:S97-104 (60 ref.)

In vitro studies to predict physiological effects of dietary fibre. Brighenti F, et al. **Eur J Clin Nutr** 1995 Oct;49 Suppl 3:S81-8 (38 ref.)

Definition and measurement of dietary fibre. Englyst HN, et al. **Eur J Clin Nutr** 1995 Oct;49 Suppl 3:S48-62 (38 ref.)

Bioavailability of micronutrients in a fibre-rich diet, especially related to minerals. Frølich W. **Eur J Clin Nutr** 1995 Oct;49 Suppl 3:S116-22 (44 ref.)

Dietary fibre analysis: methodological error sources. Mañas E, et al. **Eur J Clin Nutr** 1995 Oct;49 Suppl 3:S158-62 (22 ref.)

Effects of processing on dietary fibre in vegetables. Nyman M. **Eur J Clin Nutr** 1995 Oct;49 Suppl 3:S215-8 (22 ref.)

Cell-wall chemistry and architecture in relation to sources of dietary fibre. Selvendran RR, et al. **Eur J Clin Nutr** 1995 Oct;49 Suppl 3:S27-41 (40 ref.)

METABOLISM

Contribution of fiber and resistant starch to metabolizable energy. Behall KM, et al. **Am J Clin Nutr** 1995 Nov;62(5 Suppl):1158S-1160S (35 ref.)

Metabolizable energy of macronutrients. Livesey G. **Am J Clin Nutr** 1995 Nov;62(5 Suppl):1135S-1142S (35 ref.)

Bacterial fermentation of complex carbohydrate in the human colon. Hill MJ. **Eur J Cancer Prev** 1995 Oct;4(5):353-8 (23 ref.)

Suggested sterol-binding mechanisms of dietary fibre based on ileostomy studies. Andersson H. **Eur J Clin Nutr** 1995 Oct;49 Suppl 3:S173-7 (39 ref.)

In vitro studies to predict physiological effects of dietary fibre. Brighenti F, et al. **Eur J Clin Nutr** 1995 Oct;49 Suppl 3:S81-8 (38 ref.)

Dietary fibre: effect of processing and nutrient interactions. Carnovale E, et al. **Eur J Clin Nutr** 1995 Oct;49 Suppl 3:S307-11 (42 ref.)

Role of gastrointestinal motility in the delay of absorption by dietary fibre. Cherbut C. **Eur J Clin Nutr** 1995 Oct;49 Suppl 3:S74-80 (61 ref.)

Dietary fibre and drug interactions. Chiesara E, et al. **Eur J Clin Nutr** 1995 Oct;49 Suppl 3:S123-8 (47 ref.)

Interactions between large intestine fermentation and dietary calcium. Demigné C, et al. **Eur J Clin Nutr** 1995 Oct;49 Suppl 3:S235-8 (13 ref.)

Bioavailability of micronutrients in a fibre-rich diet, especially related to minerals. Frølich W. **Eur J Clin Nutr** 1995 Oct;49 Suppl 3:S116-22 (44 ref.)

Effect of reduced rate of carbohydrate absorption on carbohydrate and lipid metabolism. Jenkins DJ, et al.

DIETARY FIBER

Eur J Clin Nutr 1995 Oct;49 Suppl 3:S68–73 (36 ref.)
In vitro binding properties of dietary fibre. Kritchevsky D. **Eur J Clin Nutr** 1995 Oct;49 Suppl 3:S113–5 (18 ref.)

PHARMACOLOGY

The influence of dietary fibre on protein digestion and utilization in monogastrics. Eggum BO. **Arch Tierernahr** 1995;48(1–2):89–95 (44 ref.)
Effect of konjac fibre (glucomannan) on glucose and lipids. Doi K. **Eur J Clin Nutr** 1995 Oct;49 Suppl 3:S190–7 (18 ref.)
Dietary fibres: effects on lipid metabolism and mechanisms of action. Lairon D. **Eur J Clin Nutr** 1996 Mar;50(3):125–33 (59 ref.)

STANDARDS

Importance of dietary fiber in childhood. Williams CL. **J Am Diet Assoc** 1995 Oct;95(10):1140–6, 1149; quiz 1147–8 (77 ref.)
Whole-body fuel selection in ruminants: nutrient supply and utilization by major tissues. Ortigues I, et al. **Proc Nutr Soc** 1995 Mar;54(1):235–51 (55 ref.)

THERAPEUTIC USE

Clinical effects of a dietary fibre supplement. A review. Gatti E. **Eur J Clin Nutr** 1995 Oct;49 Suppl 3:S199–200 (12 ref.)
Dietary fibre in the treatment of metabolic diseases. Rivellese AA, et al. **Eur J Clin Nutr** 1995 Oct;49 Suppl 3:S110–2 (12 ref.)
Dietary fibre and plasma lipids. Truswell AS. **Eur J Clin Nutr** 1995 Oct;49 Suppl 3:S105–9 (30 ref.)
The role of dietary fiber in the development and treatment of childhood obesity. Kimm SY. **Pediatrics** 1995 Nov;96(5 Pt 2):1010–4 (51 ref.)
The role of fiber in the treatment of hypercholesterolemia in children and adolescents. Kwiterovich PO Jr. **Pediatrics** 1995 Nov;96(5 Pt 2):1005–9 (20 ref.)
Benefits of dietary fiber. Myth or medicine? Bennett WG, et al. **Postgrad Med** 1996 Feb;99(2):153–6, 166–8, 171–2 passim (27 ref.)

DIETARY FORMULATIONS see **FOOD, FORMULATED**

DIETARY HABITS see **FOOD HABITS**

DIETARY MODIFICATION see **FOOD HABITS**

DIETARY OILS see **DIETARY FATS, UNSATURATED**

DIETARY PHOSPHORUS see **PHOSPHORUS, DIETARY**

DIETARY POTASSIUM see **POTASSIUM, DIETARY**

DIETARY PROTEINS

The influence of dietary fibre on protein digestion and utilization in monogastrics. Eggum BO. **Arch Tierernahr** 1995;48(1–2):89–95 (44 ref.)
Dietary protein and blood pressure [see comments] Obarzanek E, et al. **JAMA** 1996 May 22–29; 275(20):1598–603 (52 ref.) Comment in: JAMA 1996 May 22–29;275(20):1604–6.
[Role of soybean proteins in human nutrition (review)] Vysotskil VG, et al. **Vopr Pitan** 1995;(5):20–7 (45 ref.) (Eng. Abstr.) **(Rus)**

ADMINISTRATION & DOSAGE

The significance of protein intake and catabolism. Flanigan MJ, et al. **Adv Ren Replace Ther** 1995 Oct;2(4):330–40 (62 ref.)
Protein sparing effect and nutritive significance of lipid supplementation in carp diets. Steffens W. **Arch Tierernahr** 1996;49(1):93–8 (52 ref.)
Protein requirements of elderly people. Campbell WW, et al. **Eur J Clin Nutr** 1996 Feb;50 Suppl 1:S180–3; discussion S183–5 (8 ref.)
Protein requirements of infants and children. Dewey KG, et al. **Eur J Clin Nutr** 1996 Feb;50 Suppl 1:S119–47; discussion S147–50 (140 ref.)
Association of macronutrients and energy intake with hypertension. Preuss HG, et al. **J Am Coll Nutr** 1996 Feb; 15(1):21–35 (207 ref.)
Dietary protein restriction and the progression of chronic renal insufficiency: a review of the literature. Holm EA, et al. **J Intern Med** 1996 Feb;239(2):99–104 (60 ref.)
Treatment of the pre-azotaemic phases of kidney disease in diabetes. Viberti GC. **Nephrol Dial Transplant** 1995;10 Suppl 7:38–42 (58 ref.)
Is increased dietary protein necessary or beneficial for individuals with a physically active lifestyle? Lemon PW. **Nutr Rev** 1996 Apr;54(4 Pt 2):S169–75 (79 ref.)
Salvage of urea-nitrogen and protein requirements. Jackson AA. **Proc Nutr Soc** 1995 Jul;54(2):535–47 (38 ref.)
Renal response to an acute oral protein load in healthy humans and in patients with renal disease or liver cirrhosis. De Santo NG, et al. **Semin Nephrol** 1995 Sep;15(5):433–48 (127 ref.)
[Diet therapy in diffuse progressive nephropathies] Ratner MI. **Klin Med (Mosk)** 1996;74(1):7–8 (11 ref.) **(Rus)**

ANALYSIS

Lipid-based fat substitutes. Akoh CC. **Crit Rev Food Sci Nutr** 1995 Sep;35(5):405–30 (131 ref.)

IMMUNOLOGY

IgG and IgA antibodies to dietary antigens in food allergy and intolerance. Barnes RM. **Clin Exp Allergy** 1995 Jul;25 Suppl 1:7–9 (39 ref.)

METABOLISM

Metabolizable energy of macronutrients. Livesey G. **Am J Clin Nutr** 1995 Nov;62(5 Suppl):1135S–1142S (35 ref.)
Nutritional assessment (protein nutriture). Spiekerman AM. **Anal Chem** 1995 Jun 15;67(12):429R–436R (80 ref.)
Protein requirements of elderly people. Campbell WW, et al. **Eur J Clin Nutr** 1996 Feb;50 Suppl 1:S180–3; discussion S183–5 (8 ref.)

PHARMACOKINETICS

Nutritional and hormonal regulation of glutathione homeostasis. Taylor CG, et al. **Curr Top Cell Regul** 1996; 34:189–208 (129 ref.)

PHARMACOLOGY

Gene expression in the intestine: the effect of dietary nucleotides. LeLeiko NS, et al. **Adv Pediatr** 1995;42:145–69 (65 ref.)
Role of dietary fish protein in the regulation of plasma lipids. Jacques H, et al. **Can J Cardiol** 1995 Oct;11 Suppl G:63G–71G (45 ref.)
Vegetarian diet components, protein and blood pressure: which nutrients are important? Beilin LJ, et al. **Clin Exp Pharmacol Physiol** 1995 Mar;22(3):195–8 (48 ref.)
Single cell protein: a promising dietary substitute. Puniya AK, et al. **Indian J Exp Biol** 1995 Aug;33(8):545–51 (101 ref.)
Nitric oxide and the renal hemodynamic response to proteins. King AJ. **Semin Nephrol** 1995 Sep;15(5):405–14 (88 ref.)

STANDARDS

Do athletes need more dietary protein and amino acids? Lemon PW. **Int J Sport Nutr** 1995 Jun;5 Suppl:S39–61 (91 ref.)
Desirable characteristics of forage legumes for improving protein utilization in ruminants. Broderick GA. **J Anim Sci** 1995 Sep;73(9):2760–73 (60 ref.)
Nutrition evaluation of dietary fat substitutes. Gershoff SN. **Nutr Rev** 1995 Nov;53(11):305–13 (63 ref.)
Whole-body fuel selection in ruminants: nutrient supply and utilization by major tissues. Ortigues I, et al. **Proc Nutr Soc** 1995 Mar;54(1):235–51 (55 ref.)
[Determination of the protein quality of food and animal feed] Bergner H. **Arch Tierernahr** 1994;45(4):293–332 (104 ref.) (Eng. Abstr.) **(Ger)**

DIETARY SERVICES

Position of The American Dietetic Association: nutrition services in managed care. Laramee SH. **J Am Diet Assoc** 1996 Apr;96(4):391–5 (55 ref.)
Nutrition services in managed care: new paradigms for dietitians. Laramee SH. **J Am Diet Assoc** 1996 Apr; 96(4):335–6 (9 ref.)

ORGANIZATION & ADMINISTRATION

Nutrition support teams: an integral part of developing a gastroenterology service. Reynolds N, et al. **Gut** 1995 Dec; 37(6):740–2 (19 ref.)

STANDARDS

The 1995 JCAHO mental health manual—an overview for dietetics professionals. Foiles RA. **J Am Diet Assoc** 1996 Apr;96(4):403–4 (6 ref.)
Applying the 1996 JCAHO nutrition care standards in a long-term-care setting. Robinson GE. **J Am Diet Assoc** 1996 Apr;96(4):400–3 (8 ref.)
Applying the 1995 JCAHO standards to dietetics practice in home care. Westbrook NH. **J Am Diet Assoc** 1996 Apr; 96(4):404–6 (5 ref.)

DIETARY SODIUM see **SODIUM, DIETARY**

DIETARY SODIUM CHLORIDE see **SODIUM CHLORIDE, DIETARY**

DIETARY SUPPLEMENTATION see **FOOD, FORTIFIED**

DIETETICS

see related
DIETARY SERVICES
FOOD SERVICE, HOSPITAL

Which formula in cow's milk protein intolerance? The dietitian's dilemma. MacDonald A. **Eur J Clin Nutr** 1995 Sep;49 Suppl 1:S56–63 (66 ref.)
Position of the American Dietetic Association: vitamin and mineral supplementation. **J Am Diet Assoc** 1996 Jan; 96(1):73–7 (53 ref.)
Position of the American Dietetic Association: food irradiation. **J Am Diet Assoc** 1996 Jan;96(1):69–72 (27 ref.)
Position of the American Dietetic Association: biotechnology and the future of food. **J Am Diet Assoc** 1995 Dec; 95(12):1429–32 (29 ref.)
Position of the American Dietetic Association: oral health and nutrition. **J Am Diet Assoc** 1996 Feb;96(2):184–9 (55 ref.)
Position of The American Dietetic Association: nutrition services in managed care. Laramee SH. **J Am Diet Assoc** 1996 Apr;96(4):391–5 (55 ref.)

EDUCATION

Another look at competency-based education in dietetics. Chambers DW, et al. **J Am Diet Assoc** 1996 Jun;96(6):614–7 (25 ref.)

METHODS

Indirect calorimetry in critically ill patients: role of the clinical dietitian in interpreting results. Porter C, et al. **J Am Diet Assoc** 1996 Jan;96(1):49–57 (38 ref.)

DIETHYLENETRIAMINE PENTAACETIC ACID see **DTPA**

DIETHYLHEXYL PHTHALATE

TOXICITY

Comparative methods of toxicity testing. Consensus document following an International Life Sciences Institute-ILSI Europe Workshop held in May 1995. Huggett AC, et al. **Food Chem Toxicol** 1996 Feb; 34(2):183–92 (34 ref.)

DIETHYLSTILBESTROL

ADVERSE EFFECTS

Transplacental hormonal carcinogenesis: diethylstilbestrol as an example. Newbold RR, et al. **Prog Clin Biol Res** 1996; 394:131–47 (37 ref.)

TOXICITY

Teratogen update: carcinogenesis and teratogenesis associated with exposure to diethylstilbestrol (DES) in utero. Mittendorf R. **Teratology** 1995 Jun;51(6):435–45 (45 ref.)

DIFFERENTIAL LEUKOCYTE COUNT see **LEUKOCYTE COUNT**

DIFFERENTIATION ANTIGENS see **ANTIGENS, DIFFERENTIATION**

DIFFERENTIATION ANTIGENS, B-CELL see **ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE**

DIFFERENTIATION ANTIGENS, HAIRY CELL LEUKEMIA see **ANTIGENS, DIFFERENTIATION**

DIFFERENTIATION ANTIGENS, LEUKOCYTE, HUMAN see **ANTIGENS, CD**

DIFFERENTIATION ANTIGENS, B-LYMPHOCYTE see **ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE**

DIFFERENTIATION ANTIGENS, MYELOMONOCYTIC see **ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC**

DIFFERENTIATION ANTIGENS, T-CELL see **ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE**

DIFFERENTIATION MARKERS see **ANTIGENS, DIFFERENTIATION**

DIFFUSE IDIOPATHIC SKELETAL HYPEROSTOSIS see **HYPEROSTOSIS, DIFFUSE IDIOPATHIC SKELETAL**

DIFFUSE LEWY BODY DISEASE see **PARKINSON DISEASE**

DIFFUSION OF INNOVATION

Cochlear implants: it's time to rethink [editorial] [see comments] House WF. **Am J Otol** 1994 Sep;15(5):573–87 (31 ref.) Comment in: Am J Otol 1995 Jan;16(1):118–9; discussion 119–20. Comment in: Am J Otol 1995 Jan;16(1):120–1; discussion 122–3. Comment in: Am J Otol 1995 Jan;16(1):121–2; discussion 122–3. Comment in: Am J Otol 1995 Jan;16(1):123–4. Comment in: Am J Otol 1995 May;16(3):399–402.
Secondary prevention of excessive alcohol use: assessing the prospects of implementation. Botelho RJ, et al. **Fam Pract** 1996 Apr;13(2):182–93 (139 ref.)
Assisted conception techniques. On what basis do health technologies become routinely available when they have been assessed as effective? Freemantle N, et al. **Int J Technol Assess Health Care** 1995 Fall;11(4):786–94 (35 ref.)

Using the evidence. A need for quantity, not quality? Hyde CJ. **Int J Technol Assess Health Care** 1996 Spring; 12(2):280–7 (41 ref.)
Processes in the creation and diffusion of nursing knowledge: an examination of the developing concept of family–centred care. Bradley SF. **J Adv Nurs** 1996 Apr; 23(4):722–7 (33 ref.)
From research to practice: one organizational model for promoting research–based practice. Kitson A, et al. **J Adv Nurs** 1996 Mar;23(3):430–40 (53 ref.)
The nursing process re–examined: enrollment and translation. Latimer J. **J Adv Nurs** 1995 Aug;22(2):213–20 (35 ref.)
Parallels and contradictions in the theory and practice of action research and nursing. Waterman H, et al. **J Adv Nurs** 1995 Oct;22(4):779–84 (35 ref.)
Informing the nursing professions about IT. Barnett DE. **Medinfo** 1995;8 Pt 2:1316–20 (7 ref.)
Acute renal replacement in the intensive care unit: now and tomorrow. Bellomo R, et al. **New Horiz** 1995 Nov; 3(4):760–7 (39 ref.)
Rethinking organization stability as a determinant for innovation adoption and diffusion. Glassman AM. **NIDA Res Monogr** 1995;155:132–46 (40 ref.)
Barriers and facilitators of research utilization. An integrative review. Funk SG, et al. **Nurs Clin North Am** 1995 Sep; 30(3):395–407 (79 ref.)
Models and processes of research utilization. White JM, et al. **Nurs Clin North Am** 1995 Sep;30(3):409–20 (27 ref.)

DIGENIC ACID see **KAINIC ACID**

DIGEORGE SYNDROME

GENETICS

How many breaks do we need to CATCH on 22q11? [editorial] Dallapiccola B, et al. **Am J Hum Genet** 1996 Jul;59(1):7–11 (53 ref.)
DiGeorge syndrome and related syndromes associated with 22q11.2 deletions. A review. Demczuk S, et al. **Ann Genet** 1995;38(2):59–76 (183 ref.)
DiGeorge syndrome and partial monosomy 10p: case report and review. Schuffenhauer S, et al. **Ann Genet** 1995; 38(3):162–7 (39 ref.)

DIGESTANTS see **GASTROINTESTINAL AGENTS**

DIGESTION

Transformations and effects of lipids in the rumen: three decades of research at Gent University. Demeyer DI, et al. **Arch Tierernahr** 1995;48(1–2):119–34 (41 ref.)
Adaptive evolution of lysozyme: changes in amino acid sequence, regulation of expression and gene number. Prager EM. **EXS** 1996;75:323–45 (75 ref.)

DRUG EFFECTS

The influence of dietary fibre on protein digestion and utilization in monogastrics. Eggum BO. **Arch Tierernahr** 1995;48(1–2):89–95 (44 ref.)

PHYSIOLOGY

The effect of Helicobacter pylori infection on gastric emptying of digestible and indigestible solids in patients with nonulcer dyspepsia. Chang CS, et al. **Am J Gastroenterol** 1996 Mar;91(3):474–9 (49 ref.)
Digestion in the newborn. Hamosh M. **Clin Perinatol** 1996 Jun;23(2):191–209 (114 ref.)
Digestion, absorption, and fermentation of carbohydrates in the newborn. Kien CL. **Clin Perinatol** 1996 Jun; 23(2):211–28 (143 ref.)
Selective retention of fluid digesta in the hindgut of bandicoots and other marsupial caecum fermenters. Hume ID, et al. **DTW Dtsch Tierarztl Wochenschr** 1995 Apr; 102(4):150–1 (14 ref.)
Characteristics of plant cell walls affecting intake and digestibility of forages by ruminants. Jung HG, et al. **J Anim Sci** 1995 Sep;73(9):2774–90 (147 ref.)
Vagal control of digestion: modulation by central neural and peripheral endocrine factors. Rogers RC, et al. **Neurosci Biobehav Rev** 1996;20(1):57–66 (91 ref.)
[The current level of the development of I. P. Pavlov's concept of digestion] Timofeeva NM. **Fiziol Zh Im I M Sechenova** 1995 Nov;81(11):112–24 (29 ref.) **(Rus)**
[The maturation of intestinal digestive enzymes in ontogeny] Timofeeva NM. **Fiziol Zh Im I M Sechenova** 1995 Jul; 81(7):1–16 (59 ref.) **(Rus)**
[A shift in types of nutrition and digestion in ontogeny] Arshavskiĭ IA, et al. **Usp Fiziol Nauk** 1996 Jan–Mar; 27(1):109–29 (95 ref.) (Eng. Abstr.) **(Rus)**

DIGESTIVE SYSTEM

CYTOLOGY

[Digestive dendritic cells] Terris B, et al. **Ann Pathol** 1995; 15(4):260–8 (106 ref.) **(Fre)**

PHYSIOLOGY

[Nitric oxide in gastroenterology] Merino Ugarte C. **Rev Gastroenterol Peru** 1995;15 Suppl 1:S101–4 (21 ref.) (Eng. Abstr.) **(Spa)**

DIGESTIVE SYSTEM DISEASES

Endoscopic ultrasound—current applications. McLean A, et al. **Clin Radiol** 1996 Feb;51(2):83–98 (103 ref.)

COMPLICATIONS

[Sweet syndrome and Yersinia enterocolitica infection. 2 cases] Neau D, et al. **Rev Med Interne** 1995;16(12):919–22 (13 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

How effective is enteroscopy? Schmit A, et al. **Acta Gastroenterol Belg** 1995 Mar–Apr;58(2):201–7 (17 ref.)

DRUG THERAPY

The clinical use of gastrointestinal hormones for alimentary tract disease. Townsend CM Jr, et al. **Adv Surg** 1996; 29:79–92 (50 ref.)
Lansoprazole—another proton pump inhibitor. **Drug Ther Bull** 1995 May;33(5):36–7 (14 ref.)

ETIOLOGY

[Digestive sites disclosing sarcoidosis] Chemlal K, et al. **Ann Med Interne (Paris)** 1996;147(2):103–6 (19 ref.) (Eng. Abstr.) **(Fre)**
[Digestive disease in cystic fibrosis] Carrasco S, et al. **Gastroenterol Hepatol** 1996 Jun–Jul;19(6):320–5 (37 ref.) **(Spa)**

PARASITOLOGY

[Multiple digestive involvement in visceral leishmaniasis in a patient with HIV infection: favourable course with itraconazole] Béchade D, et al. **Rev Med Interne** 1996; 17(3):234–7 (20 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Polypropylene mesh closure after emergency laparotomy: morbidity and outcome. Brandt CP, et al. **Surgery** 1995 Oct;118(4):736–40; discussion 740–1 (17 ref.)
[Digestive surgery using the celioscopic route. Prospects for the future] Périssat J. **Bull Acad Natl Med** 1996 Mar; 180(3):679–91; discussion 691–6 (30 ref.) (Eng. Abstr.) **(Fre)**
[Frontiers of digestive surgery using laparoscopy (editorial)] Champault G. **Gastroenterol Clin Biol** 1996;20(4):353–6 (37 ref.) **(Fre)**

DIGESTIVE SYSTEM NEOPLASMS

DIAGNOSIS

[Tumor markers: neoplasmas in digestive organs] Takami H, et al. **Nippon Rinsho** 1996 Jun;54(6):1616–20 (5 ref.) (Eng. Abstr.) **(Jpn)**
[Detection of tumor markers by genetic diagnostic methods and its clinical application] Yamamoto H, et al. **Nippon Rinsho** 1996 Jun;54(6):1574–9 (19 ref.) (Eng. Abstr.) **(Jpn)**

DRUG THERAPY

[Use of 5–fluorouracil in digestive cancer] Setiz JF, et al. **Gastroenterol Clin Biol** 1996;20(5 Pt 2):B80–88 (68 ref.) **(Fre)**

EPIDEMIOLOGY

[Muscular tumors of the digestive tract: an analysis of 53 cases] Larequi A, et al. **Rev Clin Esp** 1995 Dec; 195(12):836–40 (30 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

Alcohol as a cause of cancer. Thomas DB. **Environ Health Perspect** 1995 Nov;103 Suppl 8:153–60 (65 ref.)
The consequences of hypergastrinemia. Creutzfeldt W. **Yale J Biol Med** 1994 May–Aug;67(3–4):181–94 (63 ref.)

GENETICS

[Physiopathological and diagnostic value of genetic changes in digestive cancers] Laurent–Puig P, et al. **Gastroenterol Clin Biol** 1996;20(5 Pt 2):B21–26 (63 ref.) **(Fre)**

MICROBIOLOGY

[Helicobacter pylori as a cause of benign malignant peptic ulcer] Abou–Mouch S, et al. **Harefuah** 1995 Jun 15; 128(12):808–11 (44 ref.) **(Heb)**

RADIONUCLIDE IMAGING

[Detection of endocrine tumors of the digestive tract. Value and limitations of scintigraphy of somatostatin receptors] Le Guludec D, et al. **Presse Med** 1996 Apr 20;25(14):677–82 (27 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Port site metastasis. An unresolved problem in laparoscopic surgery. A review. Martinez J, et al. **Int Surg** 1995 Oct–Dec;80(4):315–21 (106 ref.)
[Tumor implantation in cicatrization sites following surgery for digestive cancers] Jacquet P, et al. **J Chir (Paris)** 1996 Jun;133(4):175–82 (63 ref.) (Eng. Abstr.) **(Fre)**
[Mortality after digestive cancer surgery] Isono K, et al. **Nippon Geka Gakkai Zasshi** 1995 Aug;96(8):529–38 (20 ref.) **(Jpn)**

DIGITAL RADIOGRAPHY see **RADIOGRAPHIC IMAGE ENHANCEMENT**

DIGITAL SIGNAL PROCESSING see **SIGNAL PROCESSING, COMPUTER–ASSISTED**

DIGITAL SUBTRACTION ANGIOGRAPHY see **ANGIOGRAPHY, DIGITAL SUBTRACTION**

DIGITALIS GLYCOSIDES

PHARMACOLOGY

Natriuretic hormones II. Benaksas EJ, et al. **Prog Drug Res** 1995;45:245–88 (109 ref.)

THERAPEUTIC USE

Digitalis—friend or foe? Erdmann E. **Eur Heart J** 1995 Jul; 16 Suppl F:16–9 (18 ref.)
Significance of sodium pump isoforms in digitalis therapy. McDonough AA, et al. **J Mol Cell Cardiol** 1995 Apr; 27(4):1001–9 (65 ref.)
[Therapy of heart failure. Digitalis, diuretic plus ACE inhibitor or more?] Becker H, et al. **Internist (Berl)** 1995 Dec;36(12):1117–23 (43 ref.) **(Ger)**
[Digitalis in atrial fibrillation. Still relevant treatment or an old–fashioned therapy?] Gjesdal K. **Tidsskr Nor Laegeforen** 1996 Mar 20;116(8):973–5 (39 ref.) (Eng. Abstr.) **(Nor)**

DIGITOXIN

BLOOD

[Digitoxin] Yamamoto K, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:945–9 (12 ref.) **(Jpn)**

DIGLYCERIDES

BIOSYNTHESIS

Diacylglycerol production, Ca2+ influx, and protein kinase C activation in sustained cellular responses. Rasmussen H, et al. **Endocr Rev** 1995 Oct;16(5):649–81 (268 ref.)

PHARMACOLOGY

Protein kinase D (PKD): a novel target for diacylglycerol and phorbol esters. Rozengurt E, et al. **Mutat Res** 1995 Dec;333(1–2):153–60 (47 ref.)

DIGOXIGENIN

The digoxigenin (DIG) system for non–radioactive labelling and detection of nucleic acids--an overview. Höltke HJ, et al. **Cell Mol Biol (Noisy–le–grand)** 1995 Nov; 41(7):883–905 (48 ref.)
[Detection of gene expression using digoxigenin–labeled probes] Kubota S, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):486–90 (14 ref.) **(Jpn)**

DIGOXIN

BLOOD

[Digoxin] Kotaki H, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:950–3 (10 ref.) **(Jpn)**
[Monitoring of plasma digoxin. If, when, how? Consensus of the Clinical Pharmacology Committee of Experimental Therapy at the Polish Academy of Education] **Pol Arch Med Wewn** 1996 Jan;95(1):91–4 (0 ref.) **(Pol)**

CONTRAINDICATIONS

Is it safe to prescribe digoxin after acute myocardial infarction? Update on continued controversy [editorial] Leor J, et al. **Am Heart J** 1995 Dec;130(6):1322–6 (47 ref.)

IMMUNOLOGY

[Digoxin–like immunoreactive factors. Review of the literature] Ozzola G, et al. **Minerva Med** 1995 Nov; 86(11):475–80 (42 ref.) (Eng. Abstr.) **(Ita)**

PHARMACOKINETICS

Application of saliva for drug monitoring. An in vivo model for transmembrane transport. Haeckel R, et al. **Eur J Clin Chem Clin Biochem** 1996 Mar;34(3):171–91 (179 ref.)

THERAPEUTIC USE

Digoxin in clinical practice: sorting out the facts. Doi SA,

et al. **Br J Clin Pract** 1995 Sep–Oct;49(5):257–61 (73 ref.)
Digoxin in the treatment of patients with chronic heart failure. Its place in therapy. Uretsky BF. **Drugs Aging** 1995 Jul;7(1):1–9 (44 ref.)
Is there a role for digoxin in patients with systolic dysfunction? Williamson KM. **Pharmacotherapy** 1996 Mar–Apr;16(2 Pt 2):37S–42S (27 ref.)

DIHEMATOPORPHYRIN ETHER

see related
HEMATOPORPHYRIN PHOTORADIATION

PHARMACOLOGY

Light scattering of human skin: a comparison between zinc (II)–phthalocyanine and photofrin II. Ochsner M. **J Photochem Photobiol B** 1996 Jan;32(1–2):3–9 (23 ref.)

THERAPEUTIC USE

Photodynamic therapy. Its use in the management of bronchogenic carcinoma. Edell ES, et al. **Clin Chest Med** 1995 Sep;16(3):455–63 (103 ref.)
[Photodynamic therapy of centrally located early-stage lung cancer] Furuse K. **Gan To Kagaku Ryoho** 1996 Jan; 23(1):27–30 (17 ref.) (Eng. Abstr.) **(Jpn)**
[Photodynamic therapy for multiple primary lung cancer] Konaka C, et al. **Gan To Kagaku Ryoho** 1996 Jan;23(1):31–5 (8 ref.) (Eng. Abstr.) **(Jpn)**
[Photodynamic therapy for gastric cancer] Mimura S, et al. **Gan To Kagaku Ryoho** 1996 Jan;23(1):41–6 (5 ref.) (Eng. Abstr.) **(Jpn)**
[Photodynamic therapy for esophageal cancer] Shimao H, et al. **Gan To Kagaku Ryoho** 1996 Jan;23(1):36–40 (13 ref.) (Eng. Abstr.) **(Jpn)**

5,12–DIHETE see **LEUKOTRIENE B4**

DIHYDROERGOCORNINE see **DIHYDROERGOTOXINE**

DIHYDROERGOCORNINE MESYLATE see **ERGOLOID MESYLATES**

DIHYDROERGOCRISTINE see **DIHYDROERGOTOXINE**

DIHYDROERGOCRISTINE MESYLATE see **ERGOLOID MESYLATES**

DIHYDROERGOCRYPTINE see **DIHYDROERGOTOXINE**

DIHYDROERGOCRYPTINE MESYLATE see **ERGOLOID MESYLATES**

DIHYDROERGOTAMINE

ADMINISTRATION & DOSAGE

[Migraine: dihydroergotamine nasal spray—an alternative] Beubler E. **Wien Med Wochenschr** 1995;145(14):326–31 (18 ref.) (Eng. Abstr.) **(Ger)**

THERAPEUTIC USE

[Prophylactic treatment of episodic forms of cluster headache] Liaño H, et al. **Rev Neurol** 1995;23 Suppl 4:S525–9 (29 ref.) **(Spa)**
[Symptomatic treatment of cluster headache] Titus F. **Rev Neurol** 1995;23 Suppl 4:S519–24 (46 ref.) **(Spa)**
[Treatment of the acute migraine attack] Titus F. **Rev Neurol** 1995;23 Suppl 2:S203–7 (49 ref.) **(Spa)**

DIHYDROERGOTOXINE

PHARMACOLOGY

The inhibition of peroxide formation as a possible substrate for the neuroprotective action of dihydroergocryptine. Favit A, et al. **J Neural Transm Suppl** 1995;45:297–305 (30 ref.)

THERAPEUTIC USE

Dihydroergocryptine in the treatment of Parkinson's disease. Bonuccelli U, et al. **J Neural Transm Suppl** 1995;45:239–45 (33 ref.)

DIHYDROERGOTOXINE MESYLATE see **ERGOLOID MESYLATES**

DIHYDROFOLATE DEHYDROGENASE see **TETRAHYDROFOLATE DEHYDROGENASE**

DIHYDROFOLATE REDUCTASE see **TETRAHYDROFOLATE DEHYDROGENASE**

DIHYDROPYRIDINES

THERAPEUTIC USE

Should dihydropyridines be used as first-line drugs in the treatment of hypertension? The con side [see comments] Furberg CD, et al. **Arch Intern Med** 1995 Nov 13; 155(20):2157–61 (32 ref.) Comment in: Arch Intern Med 1995 Nov 13;155(20):2145. Comment in: Arch Intern Med 1996 May 27;156(10):1115–6.
Short acting dihydropyridine (vasodilating) calcium channel blockers for hypertension: is there a risk? Beevers DG, et al. **BMJ** 1996 May 4;312(7039):1143–5 (19 ref.)
[Calcium antagonists and treatment of chronic heart failure] Lanfranchi J. **Arch Mal Coeur Vaiss** 1995 Apr;88(4 Suppl):623–31 (49 ref.) (Eng. Abstr.) **(Fre)**

DIHYDROTESTOSTERONE see **STANOLONE**

1,8–DIHYDROXY–9–ANTHRONE see **ANTHRALIN**

P–DIHYDROXYBENZENES see **HYDROQUINONES**

1 ALPHA,25–DIHYDROXYCHOLECALCIFEROL see **CALCITRIOL**

1,25–DIHYDROXYCHOLECALCIFEROL see **CALCITRIOL**

3,4–DIHYDROXYPHENYLACETIC ACID

ANALYSIS

[3,4–Dihydroxyphenylacetic acid (DOPAC)] Shigetomi S, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:537–9 (12 ref.) **(Jpn)**

DIHYDROXYPHENYLALANINE see **DOPA**

DIHYDROXYPREGNADIENES see **PREGNADIENEDIOLS**

1 ALPHA,25–DIHYDROXYVITAMIN D3 see **CALCITRIOL**

1,25–DIHYDROXYVITAMIN D3 see **CALCITRIOL**

DIIODOHYDROXYQUIN see **IODOQUINOL**

DIIODOTHYRONINES

BLOOD

Compound W: a potential marker in maternal serum for assessing fetal thyroid function. Wu SY, et al. **Compr Ther** 1995 Oct;21(10):594–6 (17 ref.)
[Di–iodothyronine (T2)] Ashizawa K, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:390–2 (15 ref.) **(Jpn)**

DIIODOTYROSINE

see related
RECEPTORS, THYROID HORMONE

DIIODOTYROSINE RECEPTORS see **RECEPTORS, THYROID HORMONE**

DIKETOBUTANE see **DIACETYL**

DIKETOPREGNENES see **PREGNENEDIONES**

DILATATION

see related
BALLOON DILATATION

DILATATION AND CURETTAGE

[Conservative therapeutic possibilities in glandular or adenomatous endometrium hyperplasia] Schindler AE. **Zentralbl Gynakol** 1996;118(6):359–64 (29 ref.) (Eng. Abstr.) **(Ger)**

DILATATION, BALLOON see **BALLOON DILATATION**

DILATATION, TRANSLUMINAL ARTERIAL see **ANGIOPLASTY, BALLOON**

DILATED CARDIOMYOPATHY see **CARDIOMYOPATHY, CONGESTIVE**

DILTIAZEM

ANALOGS & DERIVATIVES

Clentiazem and diltiazem preserve endothelium–dependent relaxation following global rat heart ischemia. Dagenais F, et al. **Can J Cardiol** 1995 Oct;11(9):816–22 (45 ref.)

PHARMACOLOGY

Clentiazem and diltiazem preserve endothelium–dependent relaxation following global rat heart ischemia. Dagenais F, et al. **Can J Cardiol** 1995 Oct;11(9):816–22 (45 ref.)

DILUTION TECHNIQUES see **INDICATOR DILUTION TECHNIQUES**

DIMERCAPTOSUCCINIC ACID see **SUCCIMER**

DIMETHOATE

POISONING

Orthodeoxia and platypnoea after acute organophosphorus poisoning reversed by CPAP: a newly described cause and review of the literature. Bouros D, et al. **Respir Med** 1995 Oct;89(9):625–8 (33 ref.)

1,3–DIMETHYL–5–AMINOADAMANTANE see **MEMANTINE**

DIMETHYLAMINOPHENAZONE see **AMINOPYRINE**

DIMETHYLCYSTEINE see **PENICILLAMINE**

DIMETHYLDIKETONE see **DIACETYL**

DIMETHYLERGOMETRIN see **METHYSERGIDE**

DIMETHYLGLYOXAL see **DIACETYL**

DIMETHYLGUANYLGUANIDINE see **METFORMIN**

DINITROGENASE see **NITROGENASE**

DINITROPHENOLS

POISONING

[A case of acute peroral poisoning by the preparation Nitrafen] Nikitin PV, et al. **Sud Med Ekspert** 1996 Jan–Mar; 39(1):33–5 (9 ref.) **(Rus)**

DINOFLAGELLIDA

ENZYMOLOGY

Rubisco rules fall; gene transfer triumphs. Palmer JD. **Bioessays** 1995 Dec;17(12):1005–8 (31 ref.)

DINOPROST

ADMINISTRATION & DOSAGE

Intraumbilical vein injection of prostaglandin F2 alpha in retained placenta. Bider D, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Jan;64(1):59–61 (13 ref.)

ANALOGS & DERIVATIVES

The isoprostanes. Current knowledge and directions for future research. Morrow JD, et al. **Biochem Pharmacol** 1996 Jan 12;51(1):1–9 (54 ref.)

ANALYSIS

[Prostaglandin F2 alpha and its metabolites] Fujimoto N, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:713–5 (7 ref.) **(Jpn)**

BIOSYNTHESIS

The control of prostaglandin production by the endometrium in relation to luteolysis and menstruation. Poyser NL. **Prostaglandins Leukot Essent Fatty Acids** 1995 Sep; 53(3):147–95 (500 ref.)

CHEMISTRY

The isoprostanes. Current knowledge and directions for future research. Morrow JD, et al. **Biochem Pharmacol** 1996 Jan 12;51(1):1–9 (54 ref.)

METABOLISM

Prostaglandin F2 alpha receptor. Sakamoto K, et al. **J Lipid Mediat Cell Signal** 1995 Oct;12(2–3):405–11 (16 ref.)
[Prostaglandin F2 alpha and its metabolites] Fujimoto N, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:713–5 (7 ref.) **(Jpn)**

PHARMACOLOGY

Endocrine and paracrine negative regulators of adipose differentiation. Serrero G, et al. **Int J Obes Relat Metab Disord** 1996 Mar;20 Suppl 3:S58–64 (33 ref.)
Synchronization of ovarian follicular waves with a gonadotropin–releasing hormone agonist to increase the precision of estrus in cattle: a review. Twagiramungu H, et al. **J Anim Sci** 1995 Oct;73(10):3141–51 (87 ref.)

DINOPROSTONE

BIOSYNTHESIS

[Role of metabolic arachidonic acid cascade and prostaglandin E2 in the pathogenesis of immunodeficiency in traumatic shock and acute hemorrhage] Pavlovskiĭ MP, et al. **Klin Khir** 1995;(4):35–8 (62 ref.) **(Ukr)**

BLOOD

[Prostaglandin E2 and its metabolites] Miyoshi T, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:706–8 (13 ref.) **(Jpn)**

METABOLISM

Prostaglandin E receptors. Negishi M, et al. **J Lipid Mediat Cell Signal** 1995 Oct;12(2–3):379–91 (57 ref.)

[Prostaglandin E2 and its metabolites] Miyoshi T, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:706–8 (13 ref.) **(Jpn)**

[Hyperprostaglandin E syndrome] Castelló Girona F, et al. **An Esp Pediatr** 1996 Mar;44(3):285–8 (10 ref.) **(Spa)**

PHARMACOLOGY

Outpatient cervical ripening. Sawai SK, et al. **Clin Obstet Gynecol** 1995 Jun;38(2):301–9 (23 ref.)

PHYSIOLOGY

Role of angiotensin II and prostaglandin E2 in regulating cardiac fibroblast collagen turnover. Brilla CG, et al. **Am J Cardiol** 1995 Nov 2;76(13):8D–13D (42 ref.)

THERAPEUTIC USE

Induction of labor by PGE2 and other local methods. Physiology, methods and guidelines for patient selection. Lyndrup J. **Dan Med Bull** 1995 Jun;42(3):227–43 (218 ref.)

DINUCLEOSIDE DIPHOSPHATES see **DINUCLEOSIDE PHOSPHATES**

DINUCLEOSIDE MONOPHOSPHATES see **DINUCLEOSIDE PHOSPHATES**

DINUCLEOSIDE OLIGOPHOSPHATES see **DINUCLEOSIDE PHOSPHATES**

DINUCLEOSIDE PHOSPHATES

GENETICS

CpG DNA: a pathogenic factor in systemic lupus erythematosus? Krieg AM. **J Clin Immunol** 1995 Nov; 15(6):284–92 (77 ref.)

METABOLISM

P2 purinergic receptors for diadenosine polyphosphates in the nervous system. Pintor J, et al. **Gen Pharmacol** 1995 Mar;26(2):229–35 (49 ref.)

DINUCLEOSIDE TETRAPHOSPHATES see **DINUCLEOSIDE PHOSPHATES**

DINUCLEOSIDE TRIPHOSPHATES see **DINUCLEOSIDE PHOSPHATES**

DINUCLEOTIDE REPEATS

Dinucleotide relative abundance extremes: a genomic signature. Karlin S, et al. **Trends Genet** 1995 Jul; 11(7):283–90 (27 ref.)

DIOCTYL PHTHALATE see **DIETHYLHEXYL PHTHALATE**

DIODOXYQUINOLINE see **IODOQUINOL**

DIOSMIN

THERAPEUTIC USE

Cellular basis of inflammation, edema and the activity of Daflon 500 mg. Friesenecker B, et al. **Int J Microcirc Clin Exp** 1995;15 Suppl 1:17–21 (44 ref.)

DIOXANES

TOXICITY

Health evaluation of 1,4-dioxane. DeRosa CT, et al. **Toxicol Ind Health** 1996 Jan-Feb;12(1):1–43 (132 ref.)

DIOXIN RECEPTORS see **RECEPTORS, ARYL HYDROCARBON**

DIOXINS

ADVERSE EFFECTS

The reproductive toxicology of Great Lakes contaminants. Foster WG. **Environ Health Perspect** 1995 Dec;103 Suppl 9:63–9 (85 ref.)

Hospitals and plastics. Dioxin prevention and medical waste incinerators. Thornton J, et al. **Public Health Rep** 1996 Jul-Aug;111(4):299–313 (121 ref.)

ANALYSIS

Comparisons of estimated human body burdens of dioxinlike chemicals and TCDD body burdens in experimentally exposed animals. DeVito MJ, et al. **Environ Health Perspect** 1995 Sep;103(9):820–31 (113 ref.)

PHARMACOKINETICS

Biologically-based models of dioxin pharmacokinetics. Buckley LA. **Toxicology** 1995 Sep 1;102(1–2):125–31 (26 ref.)

TOXICITY

The effects on mammals of pre- and postnatal environmental exposure to PCBS. The Dutch Collaborative PCB/Dioxin Study. Smits-van Prooije AE, et al. **Arch Toxicol Suppl** 1996;18:97–102 (22 ref.)

Receptor-mediated carcinogenesis: the role of biological effect modeling for risk assessment of dioxin and tamoxifen. Demby KB, et al. **Prog Clin Biol Res** 1996;394:113–29 (57 ref.)

Case studies of the use of biomarkers to assess exposures. Needham LL, et al. **Toxicol Lett** 1995 Dec;82–83:373–8 (14 ref.)

Dioxins: model chemicals for assessing receptor-mediated toxicity. DeVito MJ, et al. **Toxicology** 1995 Sep 1; 102(1–2):115–23 (72 ref.)

Biochemical mechanisms and cancer risk assessment models for dioxin. Kohn MC. **Toxicology** 1995 Sep 1; 102(1–2):133–8 (31 ref.)

DIOXOLANES

CHEMISTRY

Pentatomic cyclic agonists and muscarinic receptors: a 20 years review. Angeli P. **Farmaco** 1995 Sep;50(9):565–77 (70 ref.)

DIPEPTIDES

PHARMACOLOGY

[Discovery and pharmacological properties of selective neurokinin-receptor antagonists, FK224 and FK888] Fujii T. **Nippon Yakurigaku Zasshi** 1995 Sep;106(3):193–204 (34 ref.) (Eng. Abstr.) **(Jpn)**

THERAPEUTIC USE

The role of nitric oxide and NO-donor agents in myocardial protection from surgical ischemic-reperfusion injury. Vinten-Johansen J, et al. **Int J Cardiol** 1995 Jul; 50(3):273–81 (47 ref.)

DIPEPTIDYL AMINOPEPTIDASES see **DIPEPTIDYL PEPTIDASES**

DIPEPTIDYL-PEPTIDASE IV see **ANTIGENS, CD26**

DIPEPTIDYL PEPTIDASES

BLOOD

[Glycylproline dipeptidyl aminopeptidase (GPDAP)] Matsuda Y, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:365–8 (20 ref.) **(Jpn)**

DIPHENHYDRAMINE

What is the role of diphenhydramine in local anesthesia? [editorial; comment] Green SM. **Acad Emerg Med** 1996 Mar;3(3):198–200 (11 ref.) Comment on: Acad Emerg Med 1996 Mar;3(3):228–33.

POISONING

[An anticholinergic syndrome with hallucinatory psychosis after diphenhydramine poisoning] Lang K, et al. **Dtsch Med Wochenschr** 1995 Dec 8;120(49):1695–8 (17 ref.) (Eng. Abstr.) **(Ger)**

DIPHENYL OXIDES see **PHENYL ETHERS**

DIPHENYLACETIC ACIDS

PHARMACOLOGY

The interaction of 4-DAMP mustard with subtypes of the muscarinic receptor. Ehlert FJ. **Life Sci** 1996;58(22):1971–8 (39 ref.)

DIPHENYLBUTAZONE see **PHENYLBUTAZONE**

DIPHENYLHYDANTOIN see **PHENYTOIN**

DIPHENYLHYDRAMIN see **DIPHENHYDRAMINE**

DIPHOSPHOGLYCERIC ACIDS

BLOOD

[Red cell glycolytic intermediates] Fujii H. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:234–8 (3 ref.) **(Jpn)**

[2,3-Diphosphoglycerate (2,3-DPG)] Takagi Y, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:229–33 (8 ref.) **(Jpn)**

DIPHOSPHONATES

ADVERSE EFFECTS

Esophagitis associated with the use of alendronate [see comments] de Groen PC, et al. **N Engl J Med** 1996 Oct 3;335(14):1016–21 (17 ref.) Comment in: N Engl J Med 1996 Oct 3;335(14):1058–9. Comment in: N Engl J Med 1996 Oct 3;335(14):1069–70.

DIAGNOSTIC USE

[Bone scintigraphy and algodystrophy] Tondeur M, et al. **Rev Med Liege** 1995 Dec;50(12):510–6 (58 ref.) **(Fre)**

PHARMACOLOGY

Tiludronate: bone pharmacology and safety. Bonjour JP, et al. **Bone** 1995 Nov;17(5 Suppl):473S–477S (39 ref.)

Skeletal safety of tiludronate. Neer RM. **Bone** 1995 Nov;17(5 Suppl):501S–503S (27 ref.)

Bisphosphonates: mechanisms of action. Rodan GA, et al. **J Clin Invest** 1996 Jun 15;97(12):2692–6 (54 ref.)

[Experimental pharmacology of hard tissue research] Ohya K. **Kokubyo Gakkai Zasshi** 1995 Dec;62(4):473–82 (31 ref.) **(Jpn)**

THERAPEUTIC USE

An overview of the results of clinical trials with alendronate, a promising treatment of osteoporosis in postmenopausal women. Hirsch LJ, et al. **Ann Ital Med Int** 1995 Oct;10 Suppl:22S–28S (41 ref.)

Tiludronate: development as an osteoporosis therapy. Chesnut CH 3rd. **Bone** 1995 Nov;17(5 Suppl):517S–519S (16 ref.)

Efficacy and safety of drugs for Paget's disease of bone. Reginster JY, et al. **Bone** 1995 Nov;17(5 Suppl):485S–488S (49 ref.)

Bisphosphonates in multiple myeloma: current status; future perspectives. Jantunen E, et al. **Br J Haematol** 1996 Jun 1;93(3):501–6 (58 ref.)

The role of bisphosphonates in the prevention and treatment of osteoporosis. Reginster JY. **Clin Rheumatol** 1995 Sep;14 Suppl 3:22–5 (25 ref.)

Comparative clinical pharmacology and therapeutic use of bisphosphonates in metabolic bone diseases. Rosen CJ, et al. **Drugs** 1996 Apr;51(4):537–51 (80 ref.)

Bisphosphonates and the treatment of bone disease in the elderly. Johansen A, et al. **Drugs Aging** 1996 Feb; 8(2):113–26 (133 ref.)

[Role of bisphosphonates in the treatment of tumoral osteolysis] Claudepierre P, et al. **Ann Med Interne (Paris)** 1995;146(5):325–7 (38 ref.) **(Fre)**

[Use of bisphosphates in treatment of primary and secondary osteoporosis] Olszyński WP. **Pol Tyg Lek** 1995 Nov; 50(44–47):56–8 (6 ref.) (Eng. Abstr.) **(Pol)**

DIPHOSPHOPYRIDINE NUCLEOTIDE see **NAD**

DIPHTHERIA

DIAGNOSIS

Misidentification of toxigenic Corynebacterium diphtheriae as a Corynebacterium species with low virulence in a child with endocarditis. Pennie RA, et al. **J Clin Microbiol** 1996 May;34(5):1275–6 (18 ref.)

DRUG THERAPY

Treatment of infection caused by toxigenic and non-toxigenic strains of Corynebacterium diphtheriae. Wilson AP. **J Antimicrob Chemother** 1995 Jun;35(6):717–20 (33 ref.)

EPIDEMIOLOGY

Diphtheria: are we ready for it? Begg N, et al. **Arch Dis Child** 1995 Dec;73(6):568–72 (23 ref.)

Diphtheria: changing patterns in the developing world and the industrialized world. Galazka AM, et al. **Eur J Epidemiol** 1995 Feb;11(1):107–17 (80 ref.)

Resurgence of diphtheria. Galazka AM, et al. **Eur J Epidemiol** 1995 Feb;11(1):95–105 (49 ref.)

Current situation and control strategies for resurgence of diphtheria in newly independent states of the former Soviet Union [see comments] Hardy IR, et al. **Lancet** 1996 Jun 22;347(9017):1739–44 (35 ref.) Comment in: Lancet 1996 Aug 17;348(9025):486.

MICROBIOLOGY

Misidentification of toxigenic Corynebacterium diphtheriae as a Corynebacterium species with low virulence in a child with endocarditis. Pennie RA, et al. **J Clin Microbiol** 1996 May;34(5):1275–6 (18 ref.)

DIPHTHERIA-PERTUSSIS-TETANUS VACCINE see **DIPHTHERIA-TETANUS-PERTUSSIS VACCINE**

DIPHTHERIA-TETANUS-PERTUSSIS VACCINE

IMMUNOLOGY

[Application and development of immunity of childhood vaccines] Yang Y. **Chung Hua I Hsueh Tsa Chih** 1996 Apr; 76(4):318–9 (21 ref.) **(Chi)**

DIPHTHERIA TOXIN

BIOSYNTHESIS

Treatment of infection caused by toxigenic and non-toxigenic strains of Corynebacterium diphtheriae. Wilson AP. **J Antimicrob Chemother** 1995 Jun;35(6):717–20 (33 ref.)

THERAPEUTIC USE

Targeting diphtheria toxin to growth factor receptors. Murphy JR, et al. **Semin Cancer Biol** 1995 Oct;6(5):259–67 (64 ref.)

DIPHTHERIA TOXOID

see related
DIPHTHERIA-TETANUS-PERTUSSIS VACCINE

IMMUNOLOGY

Role of gamma delta T cells in the regulation of mucosal IgA response and oral tolerance. Fujihashi K, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:55–63 (42 ref.)

THERAPEUTIC USE

Current situation and control strategies for resurgence of diphtheria in newly independent states of the former Soviet Union [see comments] Hardy IR, et al. **Lancet** 1996 Jun 22;347(9017):1739–44 (35 ref.) Comment in: Lancet 1996 Aug 17;348(9025):486.

DIPHTHERIA VACCINE see **DIPHTHERIA TOXOID**

DIPLOCOCCUS PNEUMONIAE see **STREPTOCOCCUS PNEUMONIAE**

DIPROPYL ACETATE see **VALPROIC ACID**

DIPTERA

[Human furunculoid cutaneous myiasis caused by Dermatobia hominis (L.) diagnosed in Belgium (Diptera: Cuterebridae)] Leclerco M. **Rev Med Liege** 1996 Jun;51(6):434–8 (32 ref.) **(Fre)**

[2 cases of ocular infestation by Oestrus ovis (letter)] Boquet E, et al. **Enferm Infecc Microbiol Clin** 1995 Aug–Sep; 13(7):442–4 (9 ref.) **(Spa)**

GENETICS

Medfly transformed—official! [comment] Ashburner M. **Science** 1995 Dec 22;270(5244):1941–2 (11 ref.) Comment on: Science 1995 Dec 22;270(5244):2002–5. Comment on: Science 1995 Dec 22;270(5244):2005–8.

PHYSIOLOGY

Nineteenth century research on naturally occurring cell death and related phenomena. Clarke PG, et al. **Anat Embryol (Berl)** 1996 Feb;193(2):81–99 (143 ref.)

Flies, genes, and memory engineering. Gelperin A. **Biol Bull** 1996 Aug;191(1):139–43 (95 ref.)

VIROLOGY

The role of dipterous insects in the mechanical transmission of animal viruses. Carn VM. **Br Vet J** 1996 Jul; 152(4):377–93 (55 ref.)

DIPYLIDIASIS see **CESTODE INFECTIONS**

DIPYRIDAMOLE

DIAGNOSTIC USE

The heart in hypertension. Thinking small [editorial; comment] Cannon RO 3rd. **Am J Hypertens** 1996 Apr;9(4 Pt 1):406–8 (19 ref.) Comment on: Am J Hypertens 1996 Apr;9(4 Pt 1):361–9.

[Provocation tests in echocardiography: stress—dipyridamole—dobutamine (editorial)] Dagianti A. **Cardiologia** 1995 Jul;40(7):451–9 (69 ref.) **(Ita)**

[Echocardiography with pharmacological stress: dobutamine or dipyridamole?] Salustri A, et al. **G Ital Cardiol** 1996 Apr;26(4):447–53 (45 ref.) **(Ita)**

DIPYRINE see **AMINOPYRINE**

DIPYRONE

ADMINISTRATION & DOSAGE

[A possible association between the maternal administration of metamizole and persistent pulmonary hypertension in a newborn infant] Martí Solé JJ, et al. **An Esp Pediatr** 1996 Apr;44(4):387–8 (10 ref.) **(Spa)**

DIRECT REPEAT see **REPETITIVE SEQUENCES, NUCLEIC ACID**

DIRECT SERVICE COSTS

Economics of schizophrenia. Williams R, et al. **Can J Psychiatry** 1995 Sep;40(7 Suppl 2):S60–7 (24 ref.)

DIRECTED MOLECULAR EVOLUTION

Phage display: protein engineering by directed evolution. O'Neil KT, et al. **Curr Opin Struct Biol** 1995 Aug; 5(4):443–9 (54 ref.)

DIRECTIONAL CORONARY ATHERECTOMY see **ATHERECTOMY, CORONARY**

DIROFILARIA

GROWTH & DEVELOPMENT

Development of Dirofilaria and Setaria nematodes in Aedes albopictus. Cancrini G, et al. **Parassitologia** 1995 Dec; 37(2–3):141–5 (24 ref.)

DIROFILARIASIS

DIAGNOSIS

[Retrobulbar orbital dirofilariasis. A case report] Eligi C, et al. **Radiol Med (Torino)** 1995 Sep;90(3):334–5 (8 ref.) **(Ita)**

[A case of Dirofilaria repens migration in man] Artamonova AA, et al. **Med Parazitol (Mosk)** 1996 Jan–Mar;(1):44 (6 ref.) (Eng. Abstr.) **(Rus)**

PARASITOLOGY

Human dirofilariasis due to Dirofilaria (Nochtiella) repens: a review of world literature. Pampiglione S, et al. **Parassitologia** 1995 Dec;37(2–3):149–93 (468 ref.)

[A case of pulmonary dirofilariasis] Itoh K, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Feb;34(2):231–5 (14 ref.) (Eng. Abstr.) **(Jpn)**

DISABILITIES, DEVELOPMENTAL see **DEVELOPMENTAL DISABILITIES**

DISABILITY EVALUATION

Neurolaw: towards a new medical jurisprudence. Taylor JS. **Brain Inj** 1995 Oct;9(7):745–51 (44 ref.)

Migraine impact and functional disability. Lipton RB, et al. **Cephalalgia** 1995 Oct;15 Suppl 15:4–9 (33 ref.)

Measurement of disability after multiple injuries: the functional independence measure. Clinical review. Hetherington H, et al. **Eur J Surg** 1995 Aug;161(8):549–55 (60 ref.)

Identification and assessment of students with disabilities. Reschly DJ. **Future Child** 1996 Spring;6(1):40–53 (51 ref.)

Children who have difficulty in school: a primary pediatrician's approach. McInerny TK. **Pediatr Rev** 1995 Sep;16(9):325–32; quiz 332 (18 ref.)

Evaluation in pulmonary rehabilitation. Ambrosino N, et al. **Respir Med** 1996 Aug;90(7):395–400 (50 ref.)

Functional disability scales for back pain. Kopec JA, et al. **Spine** 1995 Sep 1;20(17):1943–9 (19 ref.)

[Diagnosis and management of neurotic occupational disorders (before pension application)] Stevens A, et al. **Nervenarzt** 1995 Nov;66(11):811–9 (42 ref.) (Eng. Abstr.) **(Ger)**

[Management and monitoring of transient work incapacity. Is the primary care model effective?] Alberquilla Menéndez-Asenjo A, et al. **Aten Primaria** 1996 Jan; 17(1):40–6 (33 ref.) (Eng. Abstr.) **(Spa)**

[Unclear pathomechanism behind neck-shoulder pain. Problem with insurance claim] Zetterberg C. **Lakartidningen** 1996 Feb 28;93(9):793–6 (68 ref.) **(Swe)**

DISABLED

see related
EARLY INTERVENTION (EDUCATION)
EDUCATION, SPECIAL
EMPLOYMENT, SUPPORTED
REHABILITATION

Disability as a public health outcome in the aging population. Guralnik JM, et al. **Annu Rev Public Health** 1996;17:25–46 (98 ref.)

Focused review: physiatric management of HIV-related disability. O'Dell MW, et al. **Arch Phys Med Rehabil** 1996 Mar;77(3 Suppl):S66–73 (59 ref.)

ABC of medical computing. Adaptive computer technology. Poole CJ, et al. **BMJ** 1995 Oct 28;311(7013):1149–51 (0 ref.)

An overview of disability. Fitzpatrick F, et al. **Br J Rheumatol** 1996 Feb;35(2):184–7 (36 ref.)

Disability and handicap in dermatology. Finlay AY, et al. **Int J Dermatol** 1996 May;35(5):305–11 (60 ref.)

The economics of independent living: efficiency, equity and ethics. O'Shea E, et al. **Int J Rehabil Res** 1996 Mar; 19(1):13–26 (28 ref.)

Generalized anxiety and mixed anxiety-depression: association with disability and health care utilization. Roy-Byrne PP. **J Clin Psychiatry** 1996;57 Suppl 7:86–91 (33 ref.)

Strength and aerobic training attenuate muscle wasting and improve resistance to the development of disability with aging. Tseng BS, et al. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:113–9 (49 ref.)

Epidemiology of disabling neurological disease: how and why does disability occur? Wade DT. **J Neurol Neurosurg Psychiatry** 1996 Sep;61(3):242–9 (77 ref.)

Functionally dependent veterans. Issues related to providing and improving their oral health care. Henry RG. **Med Care** 1995 Nov;33(11 Suppl):NS143–63 (82 ref.)

-Brain damage in infancy: mostly not intrapartum. On the etiology of mental and neurologic handicaps- Largo RH, et al. **Arch Gynecol Obstet** 1995;256 Suppl:S71–80 (18 ref.) **(Ger)**

[The disabled in the community—towards equal opportunity] Ohry A, et al. **Harefuah** 1996 Apr 1;130(7):483–5 (26 ref.) **(Heb)**

[Late complications after "permanent" disability] Ohry A, et al. **Harefuah** 1996 Jan 15;130(2):116–7 (19 ref.) **(Heb)**

CLASSIFICATION

The classification of disability. Hutchison T. **Arch Dis Child** 1995 Aug;73(2):91–3; discussion 94 (5 ref.)

Identification and assessment of students with disabilities. Reschly DJ. **Future Child** 1996 Spring;6(1):40–53 (51 ref.)

The International Classification of Impairments, Disabilities and Handicaps (ICIDH)—results and problems. Schuntermann MF. **Int J Rehabil Res** 1996 Mar;19(1):1–11 (12 ref.)

EDUCATION

The school experience of children with arthritis. Coping in the 1990s and transition into adulthood. Spencer CH, et al. **Pediatr Clin North Am** 1995 Oct;42(5):1285–98 (25 ref.)

LEGISLATION & JURISPRUDENCE

Special report: protection and advocacy: what nurses need to know. Schauer C. **Arch Psychiatr Nurs** 1995 Oct; 9(5):233–9 (15 ref.)

Special education for students with disabilities: analysis and recommendations. Terman DL, et al. **Future Child** 1996 Spring;6(1):4–24 (60 ref.)

Absolving a deadly sin: a medical and legal argument for including obesity as a disability under the Americans with Disabilities Act. Kuss CL. **J Contemp Health Law Policy** 1996 Spring;12(2):563–605 (335 ref.)

The role of the pediatrician in implementing the Americans with Disabilities Act: subject review. American Academy of Pediatrics Committee on Children with Disabilities. **Pediatrics** 1996 Jul;98(1):146–8 (09 ref.)

PSYCHOLOGY

Risk and resilience among children and youth with disabilities. Patterson J, et al. **Arch Pediatr Adolesc Med** 1996 Jul;150(7):692–8 (115 ref.)

A multi-factor account of disability after brain injury: implications for neuropsychological counselling. Montgomery GK. **Brain Inj** 1995 Jul;9(5):453–69 (45 ref.)

African American families, religion, and disability: a conceptual framework. Rogers-Dulan J, et al. **Ment Retard** 1995 Aug;33(4):226–38 (65 ref.)

Sociological dimensions of illness behavior. Mechanic D. **Soc Sci Med** 1995 Nov;41(9):1207–16 (54 ref.)

REHABILITATION

Families of young technology-dependent children and the social worker. Bradley RH, et al. **Soc Work Health Care** 1995;21(1):23–37 (41 ref.)

DISACCHARIDES

METABOLISM

Production of rhamnolipid biosurfactants. Ochsner UA, et al. **Adv Biochem Eng Biotechnol** 1996;53:89–118 (70 ref.)

DISASTER PLANNING

see related
CIVIL DEFENSE

Disaster medicine: current assessment and blueprint for the future. SAEM Disaster Medicine White Paper Subcommittee. **Acad Emerg Med** 1995 Dec;2(12):1068–76 (91 ref.)

Radiation disasters and emergency department preparedness. Fong F, et al. **Emerg Med Clin North Am** 1996 May; 14(2):349–70 (18 ref.)

Disaster planning, Part 1. Overview of hospital and emergency department planning for internal and external disasters. Lewis CP, et al. **Emerg Med Clin North Am** 1996 May;14(2):439–52 (45 ref.)

A medical disaster response to reduce immediate mortality

after an earthquake [see comments] Schultz CH, et al. **N Engl J Med** 1996 Feb 15;334(7):438–44 (53 ref.) Comment in: N Engl J Med 1996 Jun 27;334(26):1746; discussion 1747. Comment in: N Engl J Med 1996 Jun 27;334(26):1746–7.

METHODS

Disaster planning. Part II. Disaster problems, issues, and challenges identified in the research literature. Auf der Heide E. **Emerg Med Clin North Am** 1996 May; 14(2):453–80 (124 ref.)

Medical support for mass gatherings. Leonard RB. **Emerg Med Clin North Am** 1996 May;14(2):383–97 (41 ref.)

Hazardous materials. Disaster medical planning and response. Levitin HW, et al. **Emerg Med Clin North Am** 1996 May; 14(2):327–48 (56 ref.)

Public relations in disaster management and planning for emergency physicians. Friedman FD. **J Emerg Med** 1995 Sep–Oct;13(5):661–8 (25 ref.)

ORGANIZATION & ADMINISTRATION

Effective emergency management: reconsidering the bureaucratic approach. Neal DM, et al. **Disasters** 1995 Dec; 19(4):327–37 (48 ref.)

DISASTERS

Acute-phase mental health consequences of disasters: implications for triage and emergency medical services [see comments] Burkle FM Jr. **Ann Emerg Med** 1996 Aug; 28(2):119–28 (78 ref.) Comment in: Ann Emerg Med 1996 Aug;28(2):220–2.

Psychological first-aid: a practical aide-memoire. Leach J. **Aviat Space Environ Med** 1995 Jul;66(7):668–74 (22 ref.)

Urban search and rescue. Barbera JA, et al. **Emerg Med Clin North Am** 1996 May;14(2):399–412 (76 ref.)

Health care personnel in disaster response. Reversible roles or territorial imperatives? Bissell RA, et al. **Emerg Med Clin North Am** 1996 May;14(2):267–88 (66 ref.)

Management of unique clinical entities in disaster medicine. Gans L, et al. **Emerg Med Clin North Am** 1996 May; 14(2):301–26 (104 ref.)

Disaster epidemiology. Noji EK. **Emerg Med Clin North Am** 1996 May;14(2):289–300 (60 ref.)

Operational medicine in disasters. Yeskey KS, et al. **Emerg Med Clin North Am** 1996 May;14(2):429–38 (24 ref.)

Review of psychiatric epidemiologic research on disasters. Bromet E, et al. **Epidemiol Rev** 1995;17(1):113–9 (70 ref.)

Evolution of complex disasters. Burkholder BT, et al. **Lancet** 1995 Oct 14;346(8981):1012–5 (21 ref.)

DISCECTOMY see DISKECTOMY

DISCHARGE PLANNING see PATIENT DISCHARGE

DISCITIS

COMPLICATIONS

Vertebral bone destruction in sickle cell disease: infection, infarction or both. Kooy A, et al. **Neth J Med** 1996 Jun; 48(6):227–31 (11 ref.)

DIAGNOSIS

Evaluation of destructive spondyloarthropathies in hemodialysis by computerized tomographic scan and magnetic resonance imaging. Flipo RM, et al. **J Rheumatol** 1996 May;23(5):869–73 (28 ref.)

[Radiologic diagnosis of infectious spondylitis] Wikström M, et al. **Rontgenpraxis** 1996 Apr;49(4):79–84 (30 ref.) **(Ger)**

[Contiguity spondylodiscitis following percutaneous femoral artery catheterization. A case report] Mascalchi M, et al. **Radiol Med (Torino)** 1996 Mar;91(3):325–6 (9 ref.) **(Ita)**

MICROBIOLOGY

[Acute lumbago: infectious traps] Bonny O, et al. **Rev Med Suisse Romande** 1996 May;116(5):399–403 (8 ref.) **(Fre)**

RADIOGRAPHY

Complications of cervical discography: analysis of 4400 diagnostic disc injections. Zeidman SM, et al. **Neurosurgery** 1995 Sep;37(3):414–7 (14 ref.)

THERAPY

Pyogenic vertebral osteomyelitis and postsurgical disc space infections. Ozuna RM, et al. **Orthop Clin North Am** 1996 Jan;27(1):87–94 (59 ref.)

DISCLOSURE, TRUTH see TRUTH DISCLOSURE

DISCOLYSIS see INTERVERTEBRAL DISK CHEMOLYSIS

DISCRETE SUBAORTIC STENOSIS see AORTIC VALVE STENOSIS

DISCRIMINATION (PSYCHOLOGY)

PHYSIOLOGY

Task dependency of visual processing in the human visual system. Orban GA, et al. **Behav Brain Res** 1996 Apr; 76(1–2):215–23 (41 ref.)

DISCRIMINATION LEARNING

A review of simultaneous visual discrimination as a method of training octopuses. Boal JG. **Biol Rev Camb Philos Soc** 1996 May;71(2):157–90 (66 ref.)

Goodness of visual regularities: a nontransformational approach. van der Helm PA, et al. **Psychol Rev** 1996 Jul; 103(3):429–56 (95 ref.)

DRUG EFFECTS

Discriminative stimulus properties of dextromethorphan in rats. Gavend M, et al. **Biomed Pharmacother** 1995; 49(10):456–64 (59 ref.)

Neurobehavioral pharmacology of cocaine: role for serotonin in its locomotor and discriminative stimulus effects. Cunningham KA, et al. **NIDA Res Monogr** 1994;145:40–66 (95 ref.)

Drug discrimination: no evidence for tolerance to opiates. Colpaert FC. **Pharmacol Rev** 1995 Dec;47(4):605–29 (133 ref.)

DISEASE

Zinc, human diseases and aging. Fabris N, et al. **Aging (Milano)** 1995 Apr;7(2):77–93 (172 ref.)

Adhesion molecules as determinants of disease: from molecular biology to surgical research. Menger MD, et al. **Br J Surg** 1996 May;83(5):588–601 (229 ref.)

Soluble cytokine receptors in disease. Barak V. **Isr J Med Sci** 1995 Sep;31(9):565–71 (82 ref.)

Sarcopenia in aging humans: the impact of menopause and disease. Poehlman ET, et al. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:73–7 (25 ref.)

Expanding the horizon of reflection on health and disease. Khushf G. **J Med Philos** 1995 Oct;20(5):461–73 (31 ref.)

Psychosocial/cultural issues in medicine and psychiatry: treating African Americans. Carter JH. **J Natl Med Assoc** 1995 Dec;87(12):857–60 (18 ref.)

Regulation of cell volume in health and disease. McManus ML, et al. **N Engl J Med** 1995 Nov 9;333(19):1260–6 (53 ref.)

Controlling the production of interleukin-1 and tumor necrosis factor in disease. Dinarello CA. **Nutrition** 1995 Sep–Oct;11(5 Suppl):695–7 (18 ref.)

Genetic analysis of thyroid hormone receptors in development and disease. Forrest D, et al. **Recent Prog Horm Res** 1996;51:1–22 (78 ref.)

[Traditional medicine: its influence on the concepts of health and disease] Ahmed AM, et al. **Ann Ig** 1995 May–Jun; 7(3):201–8 (34 ref.) (Eng. Abstr.) **(Ita)**

ETIOLOGY

Proposed role for a combination of citric acid and ascorbic acid in the production of dietary iron overload: a fundamental cause of disease. Crawford RD. **Biochem Mol Med** 1995 Feb;54(1):1–11 (77 ref.)

The fetal and infant origins of disease. Barker DJ. **Eur J Clin Invest** 1995 Jul;25(7):457–63 (51 ref.)

Determinants of health and disease. Wolf S. **Integr Physiol Behav Sci** 1996 Jan–Mar;31(1):56–76 (75 ref.)

Social conditions as fundamental causes of disease. Link BG, et al. **J Health Soc Behav** 1995;Spec No:80–94 (90 ref.)

Somatic dysfunction and the phenomenon of visceral disease simulation: a probable explanation for the apparent effectiveness of somatic therapy in patients presumed to be suffering from true visceral disease. Nansel D, et al. **J Manipulative Physiol Ther** 1995 Jul–Aug;18(6):379–97 (351 ref.)

The potential health impacts of climate change: an overview. Kovats S, et al. **Med War** 1995 Oct–Dec;11(4):168–78 (28 ref.)

Environmental health science research and human risk assessment. Olden K, et al. **Mol Carcinog** 1995 Sep;14(1):2–9 (25 ref.)

Multiple viral pathogenicity: another paradigm in medical research? Sotelo J. **Perspect Biol Med** 1996 Summer; 39(4):507–13 (20 ref.)

Proprotein convertases and the pathophysiology of human diseases: prospective considerations. Chrétien M, et al. **Proc Assoc Am Physicians** 1995 Apr;107(1):47–66 (138 ref.)

Eicosanoids, fatty acids and neutrophils: their relevance to the pathophysiology of disease. Bates EJ. **Prostaglandins Leukot Essent Fatty Acids** 1995 Aug; 53(2):75–86 (213 ref.)

Defective protein folding as a basis of human disease. Thomas PJ, et al. **Trends Biochem Sci** 1995 Nov;20(11):456–9 (43 ref.)

PSYCHOLOGY

Illness and family functioning: theoretical and practical considerations from the primary care point of view. Tansella CZ. **Fam Pract** 1995 Jun;12(2):214–20 (14 ref.)

Naming and framing: the social construction of diagnosis and illness. Brown P. **J Health Soc Behav** 1995;Spec No:34–52 (69 ref.)

DISEASE COSTS see COST OF ILLNESS

DISEASE FREQUENCY SURVEYS see CROSS-SECTIONAL STUDIES

DISEASE MODELS, ANIMAL

Bladder function in experimental outlet obstruction: pharmacologic responses to alterations in innervation, energetics, calcium mobilization, and genetics. Levin RM, et al. **Adv Exp Med Biol** 1995;385:7–19; discussion 75–9 (61 ref.)

Electrical properties of obstructed guinea pig bladder. Mostwin JL, et al. **Adv Exp Med Biol** 1995;385:21–8; discussion 75–9 (16 ref.)

Animal models of amyotrophic lateral sclerosis. Mitsumoto H, et al. **Adv Neurol** 1995;68:73–87; discussion 89–91 (80 ref.)

Thyroiditis—a model canine autoimmune disease. Happ GM. **Adv Vet Sci Comp Med** 1995;39:97–139 (216 ref.)

Immunology of atherosclerosis: the promise of mouse models [comment] Lichtman AH, et al. **Am J Pathol** 1996 Aug; 149(2):351–7 (81 ref.) Comment on: Am J Pathol 1996 Aug;149(2):359–66.

Prevention of graft-versus-host disease. Studies in a canine model. Storb R, et al. **Ann N Y Acad Sci** 1995 Dec 29; 770:149–64 (27 ref.)

Models of antiviral resistance. Kimberlin DW, et al. **Antiviral Res** 1995 Apr;26(4):415–22 (23 ref.)

Ovine lentivirus infection: an animal model for pediatric HIV infection? de la Concha-Bermejillo A, et al. **Arch Med Res** 1995 Winter;26(4):345–54 (105 ref.)

Photoreceptor apoptosis in animal models. Implications for retinitis pigmentosa research [editorial] Wong F. **Arch Ophthalmol** 1995 Oct;113(10):1245–7 (24 ref.)

Animal models and vaccine development. Lee A. **Baillieres Clin Gastroenterol** 1995 Sep;9(3):615–32 (74 ref.)

Common methodological problems and artifacts associated with studies of myocardial stunning in vivo. Bolli R. **Basic Res Cardiol** 1995 Jul–Aug;90(4):257–62 (13 ref.)

Melanoma formation in Xiphophorus: a model system for the role of receptor tyrosine kinases in tumorigenesis. Malitschek B, et al. **Bioessays** 1995 Dec;17(12):1017–23 (39 ref.)

Perspectives of pQCT technology associated to biomechanical studies in skeletal research employing rat models. Ferretti JL. **Bone** 1995 Oct;17(4 Suppl):353S–364S (48 ref.)

Available animal models of osteopenia--small and large. Miller SC, et al. **Bone** 1995 Oct;17(4 Suppl):117S–123S (64 ref.)

Assessing bone quality--animal models in preclinical osteoporosis research. Mosekilde L. **Bone** 1995 Oct;17(4 Suppl):343S–352S (35 ref.)

Animal models of cortical porosity. Sietsema WK. **Bone** 1995 Oct;17(4 Suppl):297S–305S (19 ref.)

Transgenic mouse models of breast cancer. Amundadottir LT, et al. **Breast Cancer Res Treat** 1996;39(1):119–35 (133 ref.)

Animal models of breast cancer: their diversity and role in biomedical research. Clarke R. **Breast Cancer Res Treat** 1996;39(1):1–6 (27 ref.)

Human breast cancer cell line xenografts as models of breast cancer. The immunobiologies of recipient mice and the characteristics of several tumorigenic cell lines. Clarke R. **Breast Cancer Res Treat** 1996;39(1):69–86 (147 ref.)

Mammary tumors induced by polyomavirus. Fluck MM, et al. **Breast Cancer Res Treat** 1996;39(1):45–56 (49 ref.)

Experimentally induced mammary tumors in rats. Russo J, et al. **Breast Cancer Res Treat** 1996;39(1):7–20 (112 ref.)

Transgenic and gene knockout mice in cancer research. Viney JL. **Cancer Metastasis Rev** 1995 Jun;14(2):77–90 (81 ref.)

Transgenic models and cancer treatment. Coletta PL, et al. **Cancer Treat Rev** 1996 Nov;21(6):565–76 (79 ref.)

Animal models of human-derived cancer vaccines. Herlyn D, et al. **Cell Biophys** 1995 Aug;27(1):15–30 (56 ref.)

P-selectin knockout: a mouse model for various human diseases. Wagner DD. **Ciba Found Symp** 1995;189:2–10; discussion 10–16, 77–8 (43 ref.)

Animal models of genetic hypertension: what can we learn for human hypertension? Rubattu S, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22(12):S386–93 (48 ref.)

Animal models of human disease. Transgenic and knockout models of autoimmunity: Building a better disease? [see comments] Lo D. **Clin Immunol Immunopathol** 1996 May; 79(2):96–104 (60 ref.) Comment in: Clin Immunol Immunopathol 1996 May;79(2):93–4.

Syndromes induced by cytomegalovirus infection. Price P, et al. **Clin Immunol Immunopathol** 1996 Sep;80(3 Pt 1):215–24 (92 ref.)

Use of an animal model of trichomoniasis as a basis for understanding this disease in women. Corbeil LB. **Clin Infect Dis** 1995 Oct;21 Suppl 2:S158–61 (29 ref.)

Neurodevelopmental animal models of schizophrenia. Lillrank SM, et al. **Clin Neurosci** 1995;3(2):98–104 (88 ref.)

Perfluorocarbon-associated gas exchange improves

oxygenation, lung mechanics, and survival in a model of adult respiratory distress syndrome. Papo MC, et al. **Crit Care Med** 1996 Mar;24(3):466–74 (40 ref.)

Pharmacokinetic modeling approaches for describing the uptake, systemic distribution, and disposition of inhaled chemicals. Gargas ML, et al. **Crit Rev Toxicol** 1995; 25(3):237–54 (70 ref.)

Feline immunodeficiency virus as a model for study of lentivirus infection of the central nervous system. Henriksen SJ, et al. **Curr Top Microbiol Immunol** 1995; 202:167–86 (88 ref.)

Transgenic models to assess the neuropathogenic potential of HIV-1 proteins and cytokines. Mucke L, et al. **Curr Top Microbiol Immunol** 1995;202:187–205 (98 ref.)

Selected models of HIV-induced neurological disease. Narayan O, et al. **Curr Top Microbiol Immunol** 1995; 202:151–66 (61 ref.)

The role of transgenic knockout models in defining the pathogenesis of viral heart disease. Liu P, et al. **Eur Heart J** 1995 Dec;16 Suppl O:25–7 (28 ref.)

ApcMin: a mouse model for intestinal and mammary tumorigenesis. Moser AR, et al. **Eur J Cancer** 1995 Jul–Aug;31A(7–8):1061–4 (30 ref.)

Experimental models of inflammatory bowel disease. Elson CO, et al. **Gastroenterology** 1995 Oct;109(4):1344–67 (97 ref.)

Intracytoplasmic sperm injection—is there a need for an animal model, especially in assessing the genetic risks involved? Ng SC, et al. **Hum Reprod** 1995 Oct; 10(10):2523–5 (26 ref.)

Is an animal model needed for intracytoplasmic sperm injection (ICSI) and other assisted reproduction technologies? Yanagimachi R. **Hum Reprod** 1995 Oct; 10(10):2525–6 (11 ref.)

Chronicity of tissue-specific experimental autoimmune disease: a role for B cells? Holmdahl R, et al. **Immunol Rev** 1995 Apr;144:109–35 (164 ref.)

The Yaa gene model of systemic lupus erythematosus. Izui S, et al. **Immunol Rev** 1995 Apr;144:137–56 (62 ref.)

Research models for psoriasis: "great expectations". Wolf R, et al. **Int J Dermatol** 1995 Jul;34(7):448–55 (106 ref.)

Animal models of inflammatory bowel disease. Bhatti MA, et al. **Int J Exp Pathol** 1995 Oct;76(5):309–15 (56 ref.)

The woodchuck: an animal model for hepatitis B virus infection in man. Roggendorf M, et al. **Intervirology** 1995; 38(1–2):100–12 (111 ref.)

Chronic progressive myeloneuropathy in WKAH rats induced by HTLV-I infection as an animal model for HAM/TSP in humans. Yoshiki T. **Intervirology** 1995; 38(3–4):229–37 (40 ref.)

Use of genetically engineered mice as models for understanding human neurodegenerative disease. Andersen JK, et al. **J Am Geriatr Soc** 1996 Jun;44(6):717–22 (34 ref.)

Animal models of emmetropization: matching axial length to the focal plane. Norton TT, et al. **J Am Optom Assoc** 1995 Jul;66(7):405–14 (87 ref.)

Brief report: medial temporal lobe and autism: a putative animal model in primates. Bachevalier J. **J Autism Dev Disord** 1996 Apr;26(2):217–20 (5 ref.)

What insights into age-related changes in skeletal muscle are provided by animal models? Cartee GD. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:137–41 (43 ref.)

"The good, the bad, and the ugly." The role of chemokines in models of human disease. Strieter RM, et al. **J Immunol** 1996 May 15;156(10):3583–6 (33 ref.)

Mouse mutations as animal models and biomedical tools for dermatological research. Sundberg JP, et al. **J Invest Dermatol** 1996 Feb;106(2):368–76 (170 ref.)

Transgenic and knockout mice in the study of neurodegenerative diseases. Aguzzi A, et al. **J Mol Med** 1996 Mar;74(3):111–26 (149 ref.)

Two models for multiple sclerosis: experimental allergic encephalomyelitis and Theiler's murine encephalomyelitis virus. Tsunoda I, et al. **J Neuropathol Exp Neurol** 1996 Jun;55(6):673–86 (136 ref.)

Lithium-pilocarpine neurotoxicity: a potential model of status epilepticus. Kulkarni SK, et al. **Methods Find Exp Clin Pharmacol** 1995 Oct;17(8):551–67 (195 ref.)

Two models of multiple sclerosis: experimental allergic encephalomyelitis (EAE) and Theiler's murine encephalomyelitis virus (TMEV) infection. A pathological and immunological comparison. Dal Canto MC, et al. **Microsc Res Tech** 1995 Oct 15;32(3):215–29 (74 ref.)

Murine model of genetic demyelinating disease: the twitcher mouse. Suzuki K, et al. **Microsc Res Tech** 1995 Oct 15; 32(3):204–14 (61 ref.)

Animal models for breast cancer. Sukumar S, et al. **Mutat Res** 1995 Dec;333(1–2):37–44 (51 ref.)

Transgenic animals. Shuldiner AR. **N Engl J Med** 1996 Mar 7;334(10):653–5 (0 ref.)

A miracle enough: the power of mice. Paigen K. **Nat Med** 1995 Mar;1(3):215–20 (8 ref.)

Pharmacological and behavioral treatment of cocaine addiction: animal models. Carroll ME. **NIDA Res Monogr** 1994;145:113–30 (26 ref.)

Transgenic models for eye malformations. Götz W. **Ophthalmic Genet** 1995 Sep;16(3):85–104 (160 ref.)

Experimental models in pulmonary pathology. Kumar RK. **Pathology** 1995 Apr;27(2):130–2 (35 ref.)

Primate models of anxiety. Longitudinal perspectives. Coplan JD, et al. **Psychiatr Clin North Am** 1995 Dec;18(4):727–43 (59 ref.)

Administration of antidepressants, diazepam and psychomotor stimulants further confirms the utility of Flinders Sensitive Line rats as an animal model of depression. Overstreet DH, et al. **Psychopharmacology (Berl)** 1995 Sep;121(1):27–37 (62 ref.)

Mouse models of atherosclerosis. Breslow JL. **Science** 1996 May 3;272(5262):685–8 (26 ref.)

Rodent models for the study of etiology, prevention and treatment of breast cancer. Gould MN. **Semin Cancer Biol** 1995 Jun;6(3):147–52 (32 ref.)

Genetic and spontaneous models of inflammatory bowel disease in rodents: evidence for abnormalities in mucosal immune regulation. Powrie F, et al. **Ther Immunol** 1995 Apr;2(2):113–23 (57 ref.)

Predictive testing for respiratory sensitization in the mouse. Kimber I, et al. **Toxicol Lett** 1996 Aug;86(2–3):193–8 (31 ref.)

Predictive testing for respiratory sensitisation. Pauluhn J. **Toxicol Lett** 1996 Aug;86(2–3):177–85 (17 ref.)

Potential animal model of multiple chemical sensitivity with cholinergic supersensitivity. Overstreet DH, et al. **Toxicology** 1996 Jul 17;111(1–3):119–34 (101 ref.)

Hepatocarcinogenesis: a polygenic model of inherited predisposition to cancer. Dragani TA, et al. **Tumori** 1996 Jan–Feb;82(1):1–5 (45 ref.)

Animal models as the basis of pharmacologic intervention in trauma and sepsis patients. Redl H, et al. **World J Surg** 1996 May;20(4):487–92 (81 ref.)

[Transgenic animals in medicine] Goetz P. **Cas Lek Cesk** 1996 Feb 14;135(4):102–5 (11 ref.) (Eng. Abstr.) **(Cze)**

[Value of transgenic mouse as model for the study of human lipoprotein metabolism] Fournier N, et al. **Ann Biol Clin (Paris)** 1995;53(4):209–20 (64 ref.) (Eng. Abstr.) **(Fre)**

[Experimental models of venous thrombosis] Azougagh Oualane F, et al. **Ann Cardiol Angeiol (Paris)** 1995 Jun–Aug; 44(6):288–98 (27 ref.) (Eng. Abstr.) **(Fre)**

[Approach of cellular mechanisms of glomerulosclerosis in a model of accelerated aging the obese Zucker rat] Chevalier J, et al. **C R Seances Soc Biol Fil** 1995; 189(6):987–1007 (64 ref.) (Eng. Abstr.) **(Fre)**

[Experimental types of hypertension—models for essential hypertension in the human?] Rupp H, et al. **Herz** 1995 Oct; 20(5):315–21 (34 ref.) (Eng. Abstr.) **(Ger)**

[A transgenic animal model: new possibilities for cardiovascular research] Franz WM, et al. **Z Kardiol** 1995; 84 Suppl 4:17–32 (105 ref.) (Eng. Abstr.) **(Ger)**

[Transgenic rats as a model for investigation of the pathogenesis of hypertension] Paul M. **Z Kardiol** 1995;84 Suppl 4:55–60 (32 ref.) (Eng. Abstr.) **(Ger)**

[Trial to produce animal model of Alzheimer's disease by continuous infusion of beta-amyloid protein into the rat cerebral ventricle] Nabeshima T. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1995 Oct; 15(5):411–8 (27 ref.) (Eng. Abstr.) **(Jpn)**

[Mini review: animal model of human lysosomal storage disease] Sakiyama T. **Nippon Rinsho** 1995 Dec; 53(12):3105–11 (16 ref.) (Eng. Abstr.) **(Jpn)**

[An experimental model for gene therapy of murine retroviral leukemias] Aizaki K, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2679–85 (19 ref.) **(Jpn)**

[Overview: animal models of human diseases] Asano S. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2661–2 (3 ref.) **(Jpn)**

[Mouse model for familial adenomatous polyposis coli] Ito M, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec; 40(17):2668–73 (22 ref.) **(Jpn)**

[The model mouse for gene therapy] Katsuki M. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2663–7 (2 ref.) **(Jpn)**

[An attempt to generate a closer mouse model of familial amyloidotic polyneuropathy, an autosomal dominantly inherited disease] Maeda S, et al. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2204–13 (30 ref.) **(Jpn)**

[Animal models for muscle research and muscle diseases] Nabeshima Y. **Tanpakushitsu Kakusan Koso** 1995 Oct; 40(14):2197–203 (29 ref.) **(Jpn)**

[Gene therapy for ornithine transcarbamylase (OTC) deficient mice] Shimada T, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2674–8 (24 ref.) **(Jpn)**

[Nerve growth factor strategy and preparation of animal model for Alzheimer-type senile dementia] Nabeshima T. **Yakugaku Zasshi** 1995 Jul;115(7):499–512 (59 ref.) (Eng. Abstr.) **(Jpn)**

[Neurobiology of parkinsonism. II. Experimental models] Ponzoni S, et al. **Arq Neuropsiquiatr** 1995 Sep; 53(3-B):711–7 (33 ref.) (Eng. Abstr.) **(Por)**

DISEASE-MODIFYING ANTIRHEUMATIC DRUGS see **ANTIRHEUMATIC AGENTS**

DISEASE-MODIFYING SECOND-LINE DRUGS see **ANTIRHEUMATIC AGENTS**

DISEASE NOTIFICATION

[Cancer patient care—informed consent and disease notification] Eguchi K. **Nippon Naika Gakkai Zasshi** 1996 Mar 10;85(3):356–9 (25 ref.) **(Jpn)**

LEGISLATION & JURISPRUDENCE

A national consensus on guidelines for establishment of a post-exposure notification protocol for emergency responders. Laboratory Centre for Disease Control, Health Protection Branch, Health Canada. **Can Commun Dis Rep** 1995 Oct 15;21(19):169–80 (5 ref.) **(Eng, Fre)**

DISEASE OUTBREAKS

see related
COMMUNICABLE DISEASES

The changing epidemiology of foodborne diseases. Altekruse SF, et al. **Am J Med Sci** 1996 Jan;311(1):23–9 (50 ref.)

The reemergence of serious group A streptococcal infections and acute rheumatic fever. Bronze MS, et al. **Am J Med Sci** 1996 Jan;311(1):41–54 (92 ref.)

Australian arboviruses: at what risk New Zealand? [editorial] Weinstein P, et al. **Aust N Z J Med** 1995 Dec;25(6):666–9 (19 ref.)

AIDS-related lymphoma: an emerging epidemic. Denton AS, et al. **Br J Hosp Med** 1996 Mar 6–19;55(5):282–8 (27 ref.)

Cholera in the United States. Hellinger WC, et al. **Dig Dis** 1995 May–Jun;13(3):190–8 (31 ref.)

Cholera: its story in Africa with special reference to Kenya and other east African countries. Waiyaki PG. **East Afr Med J** 1996 Jan;73(1):40–3 (19 ref.)

Virology research and virulent human pandemics. Mims CA. **Epidemiol Infect** 1995 Dec;115(3):377–86 (49 ref.)

Heroin epidemics revisited. Hughes PH, et al. **Epidemiol Rev** 1995;17(1):66–73 (52 ref.)

Patterns and predictability in emerging infections. Morse SS. **Hosp Pract (Off Ed)** 1996 Apr 15;31(4):85–91, 96–101, 104 passim (11 ref.)

Basic microbiologic support for hospital epidemiology. McGowan JEJr, et al. **Infect Control Hosp Epidemiol** 1996 May;17(5):298–303 (30 ref.)

Syphilis makes a comeback [editorial] Drusin LM. **Int J STD AIDS** 1996 Jan–Feb;7(1):7–9 (33 ref.)

An epidemic of optic neuropathy and painful sensory neuropathy in Cuba: clinical aspects. Thomas PK, et al. **J Neurol** 1995 Oct;242(10):629–38 (53 ref.)

Exposure to superantigens as an immunogenetic explanation of type I diabetes mini-epidemics. Trucco M, et al. **J Pediatr Endocrinol Metab** 1995 Jan–Mar;8(1):3–10 (41 ref.)

Global burden of the HIV pandemic [see comments] Quinn TC. **Lancet** 1996 Jul 13;348(9020):99–106 (50 ref.) Comment in: Lancet 1996 Aug 17;348(9025):480–1.

The hypothetical epidemic of coronary heart disease and atherosclerosis. Stehbens WE. **Med Hypotheses** 1995 Nov; 45(5):449–54 (55 ref.)

Tuberculosis: what nurses need to know to help control the epidemic. Grimes DE, et al. **Nurs Outlook** 1995 Jul–Aug; 43(4):164–73 (20 ref.)

Measles outbreaks in the United States, 1987 through 1990. Hutchins S, et al. **Pediatr Infect Dis J** 1996 Jan;15(1):31–8 (40 ref.)

Space, persistence and dynamics of measles epidemics. Bolker B, et al. **Philos Trans R Soc Lond B Biol Sci** 1995 May 30;348(1325):309–20 (58 ref.)

What is the potential for future outbreaks of chikungunya, dengue and yellow fever in southern Africa? [editorial] Jupp PG, et al. **S Afr Med J** 1996 Jan;86(1):35–7 (20 ref.)

Escalating threat from tuberculosis: the third epidemic. Malin AS, et al. **Thorax** 1995 Sep;50 Suppl 1:S37–42 (38 ref.)

[Tuberculosis in low prevalence countries. Back to the future?] Pedersen JT, et al. **Ugeskr Laeger** 1995 Dec 4; 157(49):6859–63 (39 ref.) (Eng. Abstr.) **(Dan)**

[Trypanosoma cruzi in French Guinea: review of accumulated data since 1940] Raccurt CP. **Med Trop (Mars)** 1996;56(1):79–87 (49 ref.) (Eng. Abstr.) **(Fre)**

[Epidemic of type B botulism: Sion, December 1993–January 1994] Troillet N, et al. **Schweiz Med Wochenschr** 1995 Sep 30;125(39):1805–12 (18 ref.) (Eng. Abstr.) **(Fre)**

[Epidemic of cholera due to a new serogroup Vibrio cholerae O139 Bengal] Shimada T, et al. **Nippon Saikingaku Zasshi** 1995 Oct;50(4):1005–17 (70 ref.) **(Jpn)**

[The AIDS epidemic in Norway—where did it go?] Eskild A, et al. **Tidsskr Nor Laegeforen** 1996 Jan 30;116(3):382–6 (26 ref.) (Eng. Abstr.) **(Nor)**

[Increased incidence of severe Streptococcus group A infections in Noway during the last 10 years. New outbreak 1993–94] Høiby EA, et al. **Tidsskr Nor Laegeforen** 1995 Oct 20;115(25):3131–6 (44 ref.) (Eng. Abstr.) **(Nor)**

[World cholera pandemics as mono- and polycyclic phenomena] Arutiunov IuI. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Mar–Apr; (2):113–7 (26 ref.) **(Rus)**

[An outbreak of poisoning by mushrooms of the genus Omphalotus (letter)] Alguacil García GF, et al. **Med Clin (Barc)** 1996 Jun 8;107(2):75 (8 ref.) **(Spa)**

[Considerations on human rabies transmitted by bats] Schneider MC, et al. **Salud Publica Mex** 1995 Jul–Aug; 37(4):354–62 (36 ref.) (Eng. Abstr.) **(Spa)**

[Two different HIV types are known. The differences may explain mechanisms of the infection] Andersson S, et al.

Lakartidningen 1996 Jun 5;93(23):2230, 2235–6 (37 ref.) **(Swe)**
[Tularemia occurs in the whole country. A good year for rodents prepares the ground for an epidemic] Bäck E. **Lakartidningen** 1995 Oct 11;92(41):3790–3 (14 ref.) **(Swe)**

ECONOMICS

Impact and risk of foreign animal diseases. Brown CC, et al. **J Am Vet Med Assoc** 1996 Apr 1;208(7):1038–40 (16 ref.)

HISTORY

Localized permanent epidemics: the genesis of chloroquine resistance in Plasmodium falciparum. Verdrager J. **Southeast Asian J Trop Med Public Health** 1995 Mar; 26(1):23–8 (18 ref.)

PREVENTION & CONTROL

Guidelines for control of measles outbreaks in Canada (revised 1995). Advisory Committee on Epidemiology. **Can Commun Dis Rep** 1995 Nov 15;21(21):189–95 (2 ref.) **(Eng, Fre)**
Guidelines for control of measles outbreaks in Canada (revised 1995). Advisory Committee on Epidemiology. **Can Med Assoc J** 1996 Apr 15;154(8):1197–1205 (3 ref.) **(Eng, Fre)**
Yellow fever: an emerging threat for Kenya and other east African countries. Sanders EJ, et al. **East Afr Med J** 1996 Jan;73(1):10–2 (21 ref.)
Food safety: review and implications for dietitians and dietetic technicians [see comments] Ollinger-Snyder P, et al. **J Am Diet Assoc** 1996 Feb;96(2):163–8, 171; quiz 169–70 (82 ref.) Comment in: J Am Diet Assoc 1996 Aug;96(8):751.
Research recommendations: pleas for enhanced research efforts to impact the epidemic of dental disease in infants. Weinstein P. **J Public Health Dent** 1996 Winter;56(1):55–9 (35 ref.)
Current situation and control strategies for resurgence of diphtheria in newly independent states of the former Soviet Union [see comments] Hardy IR, et al. **Lancet** 1996 Jun 22;347(9017):1739–44 (35 ref.) Comment in: Lancet 1996 Aug 17;348(9025):486.
The next pandemic influenza virus? Shortridge KF. **Lancet** 1995 Nov 4;346(8984):1210–2 (10 ref.)
[Tuberculosis in France: how can the current epidemic be stopped? Conference of Experts on Tuberculosis, 15 December 1994, Paris] Bégué P, et al. **Rev Mal Respir** 1995; 12 Suppl 3:R132–57 (73 ref.) **(Fre)**

STATISTICS & NUMERICAL DATA

Yellow fever: an emerging threat for Kenya and other east African countries. Sanders EJ, et al. **East Afr Med J** 1996 Jan;73(1):10–2 (21 ref.)
Threat of Marburg and Ebola viral haemorrhagic fevers in Africa. Tukei PM. **East Afr Med J** 1996 Jan;73(1):27–31 (15 ref.)
Epidemiology of cerebrovascular disease: stroke epidemic in Japan. Shimamoto T, et al. **J Epidemiol** 1996 Aug;6(3 Suppl):S43–7 (37 ref.)
Climate change and global infectious disease threats. Jackson EK. **Med J Aust** 1995 Dec 4–18;163(11–12):570–4 (67 ref.)
Spatial heterogeneity, nonlinear dynamics and chaos in infectious diseases. Grenfell BT, et al. **Stat Methods Med Res** 1995 Jun;4(2):160–83 (82 ref.)

VETERINARY

Salmonellosis in horses [comment] Murray MJ. **J Am Vet Med Assoc** 1996 Aug 1;209(3):558–60 (10 ref.) Comment on: J Am Vet Med Assoc 1996 Aug 1;209(3):626–8. Comment on: J Am Vet Med Assoc 1996 Aug 1;209(3):629–31.
Advances in feline health research: impact of recent developments in vaccinology on feline welfare. Richards JR. **J Am Vet Med Assoc** 1996 Feb 15;208(4):505–10 (30 ref.)
Aircraft and ship disinfection. Cancellotti FM. **Rev Sci Tech** 1995 Mar;14(1):177–89 (20 ref.)
Disinfection procedures for personnel and vehicles entering and leaving contaminated premises. Ford WB. **Rev Sci Tech** 1995 Jun;14(2):393–401 (10 ref.)
Disinfection of stockyards. Fotheringham VJ. **Rev Sci Tech** 1995 Jun;14(2):293–307 (21 ref.)
Disinfection of livestock production premises. Fotheringham VJ. **Rev Sci Tech** 1995 Mar;14(1):191–205 (21 ref.)
Disinfecting poultry production premises. Meroz M, et al. **Rev Sci Tech** 1995 Jun;14(2):273–91 (27 ref.)
Risk of introducing exotic disease through importation of animals and animal products. Metcalf HE, et al. **Rev Sci Tech** 1995 Dec;14(4):951–6 (12 ref.)
Disinfection of farrowing pens. Owen JM. **Rev Sci Tech** 1995 Jun;14(2):381–91 (18 ref.)
Disinfection in aquaculture. Torgersen Y, et al. **Rev Sci Tech** 1995 Jun;14(2):419–34 (39 ref.)
Australian studies on Newcastle disease virus. The French heritage. Spradbrow PB, et al. **Vet Microbiol** 1995 Sep; 46(1–3):15–9, 1–2 (14 ref.)

DISEASE PROGRESSION

see related
PROGNOSIS

DISEASE RESERVOIRS

see related
CARRIER STATE
DISEASE VECTORS
Non-human reservoirs of Helicobacter pylori. Fox JG. **Aliment Pharmacol Ther** 1995;9 Suppl 2:93–103 (83 ref.)
Control and research on schistosomiasis in China. Chen M. **Chin Med J (Engl)** 1995 Sep;108(9):643–6 (9 ref.)
The next pandemic influenza virus? Shortridge KF. **Lancet** 1995 Nov 4;346(8984):1210–2 (10 ref.)
A North American model to contain the spread of Aedes albopictus through tire legislation. Novak RJ. **Parassitologia** 1995 Dec;37(2–3):129–39 (17 ref.)
[Epidemiological status of alveolar echinococcosis in China] Jiang CP. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1995 Aug;16(4):243–5 (16 ref.) **(Chi)**
[Protozoa as reservoirs for human bacterial pathogens] Kolodyński J. **Wiad Parazytol** 1996;42(1):37–43 (34 ref.) (Eng. Abstr.) **(Pol)**
[Ticks (Ixodidae) in zoonotic propagation of piroplasma Babesia micorti and Babesia divergens] Siński E, et al. **Wiad Parazytol** 1995;41(3):321–7 (13 ref.) (Eng. Abstr.) **(Pol)**
[The effect of economic activities altering water resources on the parasitological situation] Artamoshin AS, et al. **Med Parazitol (Mosk)** 1995 Apr–Jun;(2):51–7 (50 ref.) (Eng. Abstr.) **(Rus)**
[The problem of natural foci of plague: the search for ways for its resolution (editorial)] Lomaradskii IV, et al. **Med Parazitol (Mosk)** 1995 Oct–Dec;(4):3–9 (46 ref.) (Eng. Abstr.) **(Rus)**

DISEASE RESISTANCE see **IMMUNITY, NATURAL**

DISEASE SUSCEPTIBILITY

see related
HEMORRHAGIC DIATHESIS
Human interindividual variability in susceptibility to toxic effects: from annoying detail to a central determinant of risk. Hattis D. **Toxicology** 1996 Jul 17;111(1–3):5–14 (37 ref.)

EPIDEMIOLOGY

Obtaining information about susceptibility from the epidemiological literature. Grassman JA. **Toxicology** 1996 Jul 17;111(1–3):253–70 (104 ref.)

GENETICS

Age-specific oncogenesis: the genetics of cancer susceptibility. Malkin D. **Environ Health Perspect** 1995 Sep; 103 Suppl 6:37–9 (10 ref.)
Immunoglobulin allotypes and RFLPs in disease association. Propert D. **Exp Clin Immunogenet** 1995;12(3):198–205 (42 ref.)
The Yaa gene model of systemic lupus erythematosus. Izui S, et al. **Immunol Rev** 1995 Apr;144:137–56 (62 ref.)
Genetic susceptibility and occupational cancer. Hayes RB. **Med Lav** 1995 May–Jun;86(3):206–13 (51 ref.)
Interindividual variations in susceptibility and sensitivity: linking risk assessment and risk management. Preston RJ. **Toxicology** 1996 Jul 17;111(1–3):331–41 (42 ref.)
Xenogenetics in multifactorial disease susceptibility. Sim E, et al. **Trends Genet** 1995 Dec;11(12):509–12 (52 ref.)
[Etiology and pathogenesis of addiction] van den Brink W. **Ned Tijdschr Geneeskd** 1995 Dec 16;139(50):2606–10 (35 ref.) **(Dut)**
[Genetic predisposition for Alzheimer's disease] Staufenbiel M, et al. **Ther Umsch** 1995 Dec;52(12):821–5 (28 ref.) (Eng. Abstr.) **(Ger)**
[Significance of hereditary thrombophilia for risk of thrombosis with oral contraceptives] Bauersachs R, et al. **Zentralbl Gynakol** 1996;118(5):262–70 (53 ref.) (Eng. Abstr.) **(Ger)**

DISEASE TRANSMISSION

see related
COMMUNICABLE DISEASES
Host factors affecting disease transmission. Muzyka BC. **Dent Clin North Am** 1996 Apr;40(2):263–75 (28 ref.)

VETERINARY

Quarantine requirements for the importation of black rhinoceros from Zimbabwe into Australia. Doyle KA, et al. **Aust Vet J** 1995 Oct;72(10):364–8 (4 ref.)

DISEASE TRANSMISSION, HORIZONTAL

Importance of perinatal versus horizontal transmission of hepatitis B virus infection in China. Yao GB. **Gut** 1996;38 Suppl 2:S39–42 (16 ref.)
Hospital-acquired tuberculosis. deWit D. **Med J Aust** 1995 Oct 16;163(8):428–31 (43 ref.)
Sexual, vertical and household transmission of hepatitis C. Caldwell SH, et al. **Va Med Q** 1995 Fall;122(4):270–4 (35 ref.)

PREVENTION & CONTROL

Transplantation of corneal tissue from donors with diseases of the central nervous system [see comments] Hogan RN, et al. **Cornea** 1995 Nov;14(6):547–53 (67 ref.) Comment in: Cornea 1995 Nov;14(6):545–6.

DISEASE TRANSMISSION, PATIENT-TO-PROFESSIONAL

see related
BLOOD-BORNE PATHOGENS
Common infectious diseases. Bagg J. **Dent Clin North Am** 1996 Apr;40(2):385–93 (33 ref.)
Hepatitis B virus infection. Current status in dentistry. Cottone JA, et al. **Dent Clin North Am** 1996 Apr; 40(2):293–307 (62 ref.)
Hepatitis C virus infection. Molinari JA. **Dent Clin North Am** 1996 Apr;40(2):309–25 (77 ref.)
Tuberculosis. Phelan JA, et al. **Dent Clin North Am** 1996 Apr;40(2):327–41 (35 ref.)
Postexposure protocol. Younai FS. **Dent Clin North Am** 1996 Apr;40(2):457–86 (118 ref.)
A work-systems analysis of compliance with universal precautions among health care workers. DeJoy DM, et al. **Health Educ Q** 1996 May;23(2):159–74 (80 ref.)
Viral hazards to and from health care workers. Jeffries DJ. **J Hosp Infect** 1995 Jun;30 Suppl:140–55 (96 ref.)
Nurses: at special risk. Jackson MM, et al. **J Obstet Gynecol Neonatal Nurs** 1995 Jul–Aug;24(6):533–40 (37 ref.)
Hazards to the orthopaedic trauma surgeon: occupational exposure to HIV and viral hepatitis (a review article). Chou L, et al. **J Orthop Trauma** 1996;10(4):289–96 (46 ref.)
Managing HIV. Part 7: Professional issues. 7.1 HIV infection control in medical practice. Mitchell DH, et al. **Med J Aust** 1996 Jul 15;165(2):86–9 (19 ref.)
Human immunodeficiency virus and acquired immunodeficiency syndrome: recent developments and their implications for pediatric surgeons. Cooper A. **Semin Pediatr Surg** 1995 Nov;4(4):252–61 (88 ref.)
[Perforations and porosity of surgical gloves. Frequency, mechanism, risk] Johanet H, et al. **Ann Chir** 1996; 50(4):352–5 (35 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

AIDS and the contact lens practice. Slonim CB. **CLAO J** 1995 Oct;21(4):233–5 (19 ref.)
HIV infection in healthcare workers: risk for infection and methods of prevention. Beekmann SE, et al. **Semin Dermatol** 1995 Sep;14(3):212–8 (39 ref.)
Management of occupational exposure to HIV. Critchley SE, et al. **Semin Dermatol** 1995 Sep;14(3):235–9 (36 ref.)
The potential role of simple dermatologic surgery techniques in transmitting HIV infection. Spencer J, et al. **Semin Dermatol** 1995 Sep;14(3):219–27 (43 ref.)
Prevention of blood exposure. Body and facial protection. Fry DE, et al. **Surg Clin North Am** 1995 Dec;75(6):1141–57 (27 ref.)

DISEASE TRANSMISSION, PROFESSIONAL-TO-PATIENT

see related
BLOOD-BORNE PATHOGENS
Viral hazards to and from health care workers. Jeffries DJ. **J Hosp Infect** 1995 Jun;30 Suppl:140–55 (96 ref.)
Managing HIV. Part 7: Professional issues. 7.1 HIV infection control in medical practice. Mitchell DH, et al. **Med J Aust** 1996 Jul 15;165(2):86–9 (19 ref.)

LEGISLATION & JURISPRUDENCE

Legal considerations in infectious diseases and dentistry. Burris S. **Dent Clin North Am** 1996 Apr;40(2):425–35 (62 ref.)
Bloodborne pathogen transmission from healthcare worker to patients. Legal issues and provider perspectives. Rhodes RS, et al. **Surg Clin North Am** 1995 Dec;75(6):1205–17 (29 ref.)

PREVENTION & CONTROL

Dermatologic surgery personnel with AIDS. Resnik SS, et al. **Semin Dermatol** 1995 Sep;14(3):240–2 (22 ref.)
Preventing bloodborne pathogen transmission from health-care workers to patients. The CDC perspective. Bell DM, et al. **Surg Clin North Am** 1995 Dec;75(6):1189–203 (80 ref.)

DISEASE TRANSMISSION, VERTICAL

The sensitivity of HIV-1 DNA polymerase chain reaction in the neonatal period and the relative contributions of intra-uterine and intra-partum transmission. Dunn DT, et al. **AIDS** 1995 Sep;9(9):F7–11 (29 ref.)
Perinatal acquisition of cervical cancer-associated papillomaviruses. Cason J. **Br J Obstet Gynaecol** 1996 Sep;

103(9):853–8 (66 ref.)
Quality standard for the immunization of infants and children born to women infected with human immunodeficiency virus. Wilfert CM, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S136–7 (5 ref.)
The diagnosis and management of perinatal HIV infection. Nesheim SR. **Clin Obstet Gynecol** 1996 Jun;39(2):396–410 (84 ref.)
Determinants of perinatal HIV-1 transmission. Orloff SL, et al. **Clin Obstet Gynecol** 1996 Jun;39(2):386–95 (39 ref.)
Group B streptococcal infections in newborn infants. Zach TL. **Compr Ther** 1995 Nov;21(11):673–7 (20 ref.)
Congenital and acquired early childhood syphilis. Rubins S, et al. **Cutis** 1995 Sep;56(3):132–6 (47 ref.)
Importance of perinatal versus horizontal transmission of hepatitis B virus infection in China. Yao GB. **Gut** 1996;38 Suppl 2:S39–42 (16 ref.)
Perinatal transmission of hepatitis B virus infection and vaccination in China. Yao JL. **Gut** 1996;38 Suppl 2:S37–8 (5 ref.)
Neonatal herpes simplex virus-2 encephalitis. Irani MT, et al. **Indian Pediatr** 1995 Apr;32(4):476–80 (15 ref.)
Transmission of HIV-1 in the breast-feeding process. Black RF. **J Am Diet Assoc** 1996 Mar;96(3):267–74; quiz 275–6 (61 ref.)
Nosocomial acquisition of Escherichia coli by infants delivered in hospitals. Fujita K, et al. **J Hosp Infect** 1996 Apr;32(4):277–81 (23 ref.)
Human parvovirus B19 in pregnancy. Finch CM. **J Obstet Gynecol Neonatal Nurs** 1995 Jul–Aug;24(6):495–8 (20 ref.)
Group B streptococcus during the perinatal period. Shermer RH. **J Obstet Gynecol Neonatal Nurs** 1995 Jul–Aug; 24(6):562–6 (21 ref.)
Overview of perinatally transmitted HIV infection. Boland M. **Nurs Clin North Am** 1996 Mar;31(1):155–64 (36 ref.)
Sexual, vertical and household transmission of hepatitis C. Caldwell SH, et al. **Va Med Q** 1995 Fall;122(4):270–4 (35 ref.)
[Ultrasonic signs of fetal toxoplasmosis. Review of the literature] Abboud P, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(7):733–8 (17 ref.) (Eng. Abstr.) **(Fre)**
[Clinical study of fulminant hepatitis type B of infant caused by vertical transmission] Harada Y, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:510–5 (7 ref.) **(Jpn)**
[The viewpoints of viral vertical transmission from fetal neonatal immunologic aspects] Ichijo M. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Aug; 47(8):713–23 (0 ref.) (Eng. Abstr.) **(Jpn)**
[Human immunodeficiency virus (HIV) infection in obstetrics and gynaecology] Balsdon MJ. **Rev Chil Obstet Ginecol** 1994;59(6):476–84 (0 ref.) (Eng. Abstr.) **(Spa)**

PREVENTION & CONTROL

Prevention of neonatal septicaemia due to group B streptococci. Adriaanse AH. **Baillieres Clin Obstet Gynaecol** 1995 Sep;9(3):545–52 (33 ref.)
Infectious diseases. Gilbert GL. **Baillieres Clin Obstet Gynaecol** 1995 Sep;9(3):529–43 (63 ref.)
Quality standard for the prophylaxis of Pneumocystis carinii pneumonia in infants and children born to women infected with human immunodeficiency virus. Wilfert CM, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S132–3 (4 ref.)
Preventive care in obstetrics: toxoplasmosis, cytomegalovirus, and hepatitis B. Ledger WJ. **J Matern Fetal Med** 1996 May–Jun;5(3):100–5 (26 ref.)
Perinatal herpes: current status and obstetric management strategies. Scott LL. **Pediatr Infect Dis J** 1995 Oct; 14(10):827–32; discussion 832–5 (73 ref.)

DISEASE VECTORS

Exposure to domestic cats: risk factor for Pasteurella multocida peritonitis in liver cirrhosis? Koch CA, et al. **Am J Gastroenterol** 1996 Jul;91(7):1447–9 (29 ref.)
Vector-borne viral diseases in Sweden—a short review. Niklasson B, et al. **Arch Virol Suppl** 1996;11:49–55 (37 ref.)
Imported vector- and rodent-borne virus infections—an introduction. Schwarz TF. **Arch Virol Suppl** 1996;11:3–11 (49 ref.)
Capnocytophaga canimorsus septicemia: fifth report of a cat-associated infection and five other cases. Valtonen M, et al. **Eur J Clin Microbiol Infect Dis** 1995 Jun;14(6):520–3 (25 ref.)
Interactions between parasites and insects vectors. Hurd H. **Mem Inst Oswaldo Cruz** 1994;89 Suppl 2:27–30 (20 ref.)
Transfer of toxin genes to alternate bacterial hosts for mosquito control. Orduz S, et al. **Mem Inst Oswaldo Cruz** 1995 Jan–Feb;90(1):97–107 (88 ref.)
Control of Aedes albopictus from the perspective of North America. Nasci RS. **Parassitologia** 1995 Dec;37(2–3):123–7 (6 ref.)
Arbovirus surveillance in Italy. Verani P, et al. **Parassitologia** 1995 Dec;37(2–3):105–8 (19 ref.)
Reptile-associated salmonellosis in New York State. Ackman DM, et al. **Pediatr Infect Dis J** 1995 Nov;14(11):955–9 (22 ref.)

DISEASES IN TWINS

Distinct skeletal abnormalities in four girls with Shprintzen–Goldberg syndrome. Adès LC, et al. **Am J Med Genet** 1995 Jul 17;57(4):565–72 (13 ref.)
Simultaneous acute appendicitis in monozygotic twins: coincidence or genetic? Gurbuz AT, et al. **Am Surg** 1996 May;62(5):407–8 (6 ref.)
Twin studies in insulin dependent diabetes and other autoimmune diseases. Rowe RE, et al. **Diabetes Metab Rev** 1995 Jul;11(2):121–35 (85 ref.)
Intraoperative enteroscopy in the diagnosis of partial intestinal obstruction in infancy. Duggan C, et al. **Dig Dis Sci** 1995 Oct;40(10):2236–8 (12 ref.)
Review of the contribution of twin studies in the search for non-genetic causes of multiple sclerosis. James WH. **Neuroepidemiology** 1996;15(3):132–41 (35 ref.)
Talon cusp affecting the primary maxillary central incisors in two sets of female twins: report of two cases. Liu JF, et al. **Pediatr Dent** 1995 Sep–Oct;17(5):362–4 (16 ref.)
Monozygotic twins concordant for congenital neuroblastoma: case report and review of the literature. Boyd TK, et al. **Pediatr Pathol Lab Med** 1995 Nov–Dec; 15(6):931–40 (16 ref.)

DIAGNOSIS

[A complete congenital heart block in twins] Barquero Genovés IM, et al. **An Esp Pediatr** 1996 Feb;44(2):164–6 (37 ref.) **(Spa)**

GENETICS

MZ female twins discordant for X-linked diseases: a review. Tiberio G. **Acta Genet Med Gemellol (Roma)** 1994; 43(3–4):207–14 (28 ref.)
Folie simultanée in monozygotic twins. White TG. **Can J Psychiatry** 1995 Sep;40(7):418–20 (26 ref.)
[Genetics of inflammatory bowel diseases] Hugot JP, et al. **Gastroenterol Clin Biol** 1995 Nov;19(11):890–8 (125 ref.) **(Fre)**

DISINFECTANTS

A survey of the methods of disinfection of dental impressions used in dental hospitals in the United Kingdom. Blair FM, et al. **Br Dent J** 1996 May 25;180(10):369–75 (26 ref.)
Antiseptics and disinfectants. Current issues. Terleckyj B, et al. **J Am Podiatr Med Assoc** 1995 Aug;85(8):439–45 (32 ref.)
Writing guidelines to require disinfection. Grow AG. **Rev Sci Tech** 1995 Jun;14(2):469–77 (6 ref.)
Use of disinfectants in zoos and game parks. Heuschele WP. **Rev Sci Tech** 1995 Jun;14(2):447–54 (14 ref.)

CHEMISTRY

Chemicals used as disinfectants: active ingredients and enhancing additives. Jeffrey DJ. **Rev Sci Tech** 1995 Mar; 14(1):57–74 (9 ref.)

PHARMACOLOGY

Mycobactericidal testing of disinfectants: an update. Sattar SA, et al. **J Hosp Infect** 1995 Jun;30 Suppl:372–82 (37 ref.)
Modes of action of disinfectants. Maris P. **Rev Sci Tech** 1995 Mar;14(1):47–55 (24 ref.)
Testing disinfectants for efficacy. Tamási G. **Rev Sci Tech** 1995 Mar;14(1):75–9 (9 ref.)

DISINFECTION

Sterilization and disinfection of instruments and materials in the surgery unit and laboratory areas. Best M, et al. **Semin Dermatol** 1995 Sep;14(3):243–6 (14 ref.)
[Risk of infection in endoscopy] Leiss O, et al. **Leber Magen Darm** 1995 Sep;25(5):198–202 (27 ref.) (Eng. Abstr.) **(Ger)**
[Preventing transmission of infection in endoscopy: hygienic maintainance of flexible endoscopes and measures for personal protection] Leiss O, et al. **Leber Magen Darm** 1995 Dec;25(6):251–7 (25 ref.) (Eng. Abstr.) **(Ger)**
[Questions about re-sterilization and reuse of sterile disposable devices] Petrás G, et al. **Orv Hetil** 1995 Oct 22;136(43):2339–42 (39 ref.) (Eng. Abstr.) **(Hun)**

METHODS

HIV-1 prevention: interdisciplinary studies on the efficacy of bleach and development of prevention protocols. McCoy CB, et al. **Arch Immunol Ther Exp (Warsz)** 1995;43(1):1–9 (31 ref.)
A survey of the methods of disinfection of dental impressions used in dental hospitals in the United Kingdom. Blair FM, et al. **Br Dent J** 1996 May 25;180(10):369–75 (26 ref.)
Formaldehyde disinfection in laboratories: limitations and hazards. Cheney JE, et al. **Br J Biomed Sci** 1995 Sep; 52(3):195–201 (53 ref.)
High-level disinfection or "sterilization" of endoscopes? Muscarella LF. **Infect Control Hosp Epidemiol** 1996 Mar; 17(3):183–7 (61 ref.)
Cleaning and disinfection of lower gastrointestinal endoscopes. Tremain SC. **Prim Care** 1995 Sep;22(3):471–8 (9 ref.)

STANDARDS

Environmental considerations of disinfectants used in agriculture. Bruins G, et al. **Rev Sci Tech** 1995 Mar; 14(1):81–94 (15 ref.)
Aircraft and ship disinfection. Cancellotti FM. **Rev Sci Tech** 1995 Mar;14(1):177–89 (20 ref.)
Disinfection and wildlife. Corn JL, et al. **Rev Sci Tech** 1995 Jun;14(2):455–68 (17 ref.)
Disinfecting equine facilities. Dwyer RM. **Rev Sci Tech** 1995 Jun;14(2):403–18 (4 ref.)
Disinfection procedures for personnel and vehicles entering and leaving contaminated premises. Ford WB. **Rev Sci Tech** 1995 Jun;14(2):393–401 (10 ref.)
Disinfection of stockyards. Fotheringham VJ. **Rev Sci Tech** 1995 Jun;14(2):293–307 (21 ref.)
Disinfection of livestock production premises. Fotheringham VJ. **Rev Sci Tech** 1995 Mar;14(1):191–205 (21 ref.)
Writing guidelines to require disinfection. Grow AG. **Rev Sci Tech** 1995 Jun;14(2):469–77 (6 ref.)
Inactivation of viruses in liquid manure. Haas B, et al. **Rev Sci Tech** 1995 Jun;14(2):435–45 (28 ref.)
Use of disinfectants in zoos and game parks. Heuschele WP. **Rev Sci Tech** 1995 Jun;14(2):447–54 (14 ref.)
Disinfection of food production areas. Holah JT. **Rev Sci Tech** 1995 Jun;14(2):343–63 (55 ref.)
Use of disinfectants in open-air dairying. Hutchinson RE. **Rev Sci Tech** 1995 Jun;14(2):261–72 (46 ref.)
Disinfection of trucks and trailers. Mateost Poumian A. **Rev Sci Tech** 1995 Mar;14(1):165–76 (4 ref.) **(Eng, Spa)**
Disinfecting poultry production premises. Meroz M, et al. **Rev Sci Tech** 1995 Jun;14(2):273–91 (27 ref.)
Disinfection of farrowing pens. Owen JM. **Rev Sci Tech** 1995 Jun;14(2):381–91 (18 ref.)
Use of antimicrobial agents in official abattoirs under meat inspection in the United States of America. Patch MA. **Rev Sci Tech** 1995 Jun;14(2):309–12 (4 ref.)
Cleaning and disinfection practice in the meat industries of Europe. Salvat G, et al. **Rev Sci Tech** 1995 Jun;14(2):313–41 (19 ref.) **(Eng, Fre)**
Application of disinfectants in poultry hatcheries. Samberg Y, et al. **Rev Sci Tech** 1995 Jun;14(2):365–80 (31 ref.)
Disinfection in the dairy parlour. Saran A. **Rev Sci Tech** 1995 Mar;14(1):207–24 (31 ref.)
Testing disinfectants for efficacy. Tamási G. **Rev Sci Tech** 1995 Mar;14(1):75–9 (9 ref.)
Disinfection in aquaculture. Torgersen Y, et al. **Rev Sci Tech** 1995 Jun;14(2):419–34 (39 ref.)

DISINFECTION, HAND see **HANDWASHING**

DISK, HERNIATED see **INTERVERTEBRAL DISK DISPLACEMENT**

DISK, INTERVERTEBRAL see **INTERVERTEBRAL DISK**

DISKECTOMY

ADVERSE EFFECTS

[Imaging of the lumbar spine after diskectomy] Laredo JD, et al. **Ann Radiol (Paris)** 1995;38(4):161–8 (34 ref.) (Eng. Abstr.) **(Fre)**

METHODS

Open discectomy as treatment for herniated nucleus pulposus of the lumbar spine. Errico TJ, et al. **Spine** 1995 Aug 15; 20(16):1829–33 (26 ref.)
[Lumbar discectomy: anatomical review and surgical techniques] Ono H. **No Shinkei Geka** 1996 May; 24(5):415–29 (56 ref.) **(Jpn)**

TRENDS

Controversy in spine care. Is fusion necessary after anterior cervical discectomy? Sonntag VK, et al. **Spine** 1996 May 1;21(9):1111–3 (15 ref.)

DISLOCATIONS

Recurrent subluxation of the sacroiliac joint: diagnosis and treatment. Lippitt Ab. **Bull Hosp Jt Dis** 1995;54(2):94–102 (29 ref.)
Lisfranc's fracture-dislocation. A literature review and case presentations of tarsometatarsal joint injuries. Felder-Johnson KL, et al. **Clin Podiatr Med Surg** 1995 Oct;12(4):565–602 (61 ref.)
Traumatic atlantooccipital dislocation with survival: case report and review of the literature. Guigui P, et al. **Eur Spine J** 1995;4(4):242–7 (36 ref.)
Isolated dislocation of the radial head in an adult: case report and review of the literature. Deehan DJ, et al. **J R Coll Surg Edinb** 1995 Dec;40(6):421–3 (26 ref.)

COMPLICATIONS

Recurrent locking of the wrist due to dorsal midcarpal subluxation. Craigen MA. **J Bone Joint Surg Br** 1996 Jul; 78(4):664–6 (5 ref.)
Lumbosacral fracture-subluxation associated with bilateral fractures of the first sacral pedicles: a case report and review of the literature. Shirado O, et al. **J Orthop Trauma** 1995;9(4):354–8 (28 ref.)
Vertical fracture of the central sacral canal: plane and simple.

Hatem SF, et al. **J Trauma** 1996 Jan;40(1):138–40 (12 ref.)

DIAGNOSIS

Acute dislocations of the distal radioulnar joint. Bruckner JD, et al. **Instr Course Lect** 1996;45:27–36 (96 ref.)

ETIOLOGY

Atlanto–axial subluxation and cervical osteomyelitis: two unusual complications of adenoidectomy. **Baker LL, et al. Ann Otol Rhinol Laryngol** 1996 Apr;105(4):295–9 (12 ref.)

Noncontact knee dislocation in a female basketball player: a case report. Putukian M, et al. **Clin J Sport Med** 1995 Oct;5(4):258–61 (15 ref.)

Volar dislocation of the lunate in a weight lifter. Miller SJ, et al. **Orthopedics** 1996 Jan;19(1):61–3 (17 ref.)

Odontoid fracture and C1–C2 subluxation in psoriatic cervical spondyloarthropathy. A case report. Sosner J, et al. **Spine** 1996 Feb 15;21(4):519–21 (6 ref.)

[Intubation trauma of the larynx—a literature review with special reference to arytenoid cartilage dislocation (see comments)] Rieger A, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Jun; 31(5):281–7 (37 ref.) (Eng. Abstr.) Comment in: Anasthesiol Intensivmed Notfallmed Schmerzther 1996 Jun;31(5):279–80. **(Ger)**

GENETICS

Joint dislocation and cerebral anomalies are consistently associated with oral–facial–digital syndrome type IV. Digilio MC, et al. **Clin Genet** 1995 Sep;48(3):156–9 (11 ref.)

PATHOLOGY

Avulsion fracture of the tuberosity of the calcaneus in children. A report of four cases and review of the literature. Cole RJ, et al. **J Bone Joint Surg Am** 1995 Oct; 77(10):1568–71 (14 ref.)

PHYSIOPATHOLOGY

A re-evaluation of the importance of disc position in temporomandibular disorders. Dolwick MF, et al. **Aust Dent J** 1996 Jun;41(3):184–7 (46 ref.)

Complex carpal dislocation. Irwin LR, et al. **J Hand Surg [Br]** 1995 Dec;20(6):746–9 (15 ref.)

Internal derangement and the accessory ligaments around the temporomandibular joint. Osborn JW. **J Oral Rehabil** 1995 Oct;22(10):731–40 (33 ref.)

RADIOGRAPHY

Dislocation of the distal radioulnar joint associated with a transstyloid radiocarpal fracture dislocation. A case report and review of the literature. Stoffelen D, et al. **Acta Orthop Belg** 1996 Mar;62(1):52–5 (7 ref.)

Dislocation of the distal interphalangeal and the metacarpophalangeal joints in the same finger: a case report. Andersen MB, et al. **J Hand Surg [Am]** 1995 Jul; 20(4):574–5 (4 ref.)

Open dorsal dislocations of the index, long, ring, and small finger metacarpophalangeal joints. Fraser KE, et al. **J Hand Surg [Am]** 1995 Jul;20(4):576–7 (4 ref.)

[Patellar subluxation: where are we in 1995? (see comments)] Dupont JY. **Acta Orthop Belg** 1995;61(3):155–68 (43 ref.) (Eng. Abstr.) Comment in: Acta Orthop Belg 1996 Mar;62(1):71. **(Fre)**

[Views necessary for the traumatic wrist] Zeitoun F, et al. **Ann Radiol (Paris)** 1995;38(5):255–65 (25 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Thoracic fracture–dislocations without spinal cord injury: a case report and literature review. Liljenqvist U, et al. **Eur Spine J** 1995;4(4):252–6 (34 ref.)

Irreducible dorsal dislocation of the great toe interphalangeal joint: case report and literature review. Crosby LA, et al. **Foot Ankle Int** 1995 Sep;16(9):559–61 (7 ref.)

Acute dislocations of the distal radioulnar joint. Bruckner JD, et al. **Instr Course Lect** 1996;45:27–36 (96 ref.)

Transfibular osteotomy in the correction of ankle joint incongruity. Davis JL, et al. **J Foot Ankle Surg** 1995 Jul–Aug;34(4):389–99 (23 ref.)

Talar fracture/dislocation in the adolescent patient. Valentine BC 2nd, et al. **J Foot Ankle Surg** 1995 Jul–Aug;34(4):379–83 (11 ref.)

Intracranial reduction of an intact mandibular condyle displaced into the middle cranial fossa. Sandler NA, et al. **J Oral Maxillofac Surg** 1996 Apr;54(4):506–10 (17 ref.)

Occipitocervical fusion by Luque loop rod instrumentation in Down syndrome. Higo M, et al. **J Pediatr Orthop** 1995 Jul–Aug;15(4):539–42 (17 ref.)

Instrumentational posterior fusion for atlanto–axial subluxation in a young child with Down's syndrome—case report. Kohno M, et al. **Neurol Med Chir (Tokyo)** 1995 Oct;35(10):753–8 (22 ref.)

Traumatic atlantoaxial rotatory subluxation and dislocation. Moore KR, et al. **Spine** 1995 Sep 1;20(17):1928–30 (10 ref.)

[Injuries of the cervical spine. Diagnosis and surgical treatment] Illigner A, et al. **Unfallchirurg** 1996 May; 99(5):351–67; quiz 367 (10 ref.) **(Ger)**

[Acute isolated ventral dislocation of the head of the fibula] Kohler G, et al. **Unfallchirurg** 1996 Mar;99(3):221–2 (10 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Traumatic dislocation of the knee: a review of the literature. Ghalambor N, et al. **Bull Hosp Jt Dis** 1995;54(1):19–24 (39 ref.)

Subtalar joint dislocations. Bohay DR, et al. **Foot Ankle Int** 1995 Dec;16(12):803–8 (16 ref.)

Volar transscaphoid perilunate fracture dislocation: case report and review. Hayeems EB, et al. **J Trauma** 1996 Jun; 40(6):1031–3 (14 ref.)

VETERINARY

Stifle injuries in cattle. Ducharme NG. **Vet Clin North Am Food Anim Pract** 1996 Mar;12(1):59–84 (42 ref.)

Spinal fracture/luxation. Kirby BM. **Vet Clin North Am Small Anim Pract** 1995 Sep; 25(5):1149–74 (49 ref.)

Traumatic joint luxations in small animals. McLaughlin RM Jr. **Vet Clin North Am Small Anim Pract** 1995 Sep; 25(5):1175–96 (28 ref.)

DISODIUM CROMOGLYCATE see CROMOLYN SODIUM

DISOPROFOL see PROPOFOL

DISOPYRAMIDE

BLOOD

[Disopyramide, mexiletine, aprindine] Suzuki M. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:989–93 (25 ref.) **(Jpn)**

DISPOSABLE EQUIPMENT

Technology assessment status evaluation: disposable endoscopic accessories. American Society for Gastrointestinal Endoscopy. Kimmey MB, et al. **Gastrointest Endosc** 1995 Dec;42(6):618–9 (5 ref.)

[Questions about re-sterilization and reuse of sterile disposable devices] Petrás G, et al. **Orv Hetil** 1995 Oct 22;136(43):2339–42 (39 ref.) (Eng. Abstr.) **(Hun)**

DISSECTING ANEURYSM see ANEURYSM, DISSECTING

DISSEMINATED INTRAVASCULAR COAGULATION

Disseminated intravascular coagulation: diagnosis and treatment. Baglin T. **BMJ** 1996 Mar 16;312(7032):683–7 (28 ref.)

Management of disseminated intravascular coagulopathy. Richey ME, et al. **Clin Obstet Gynecol** 1995 Sep; 38(3):514–20 (19 ref.)

[Disseminated intravascular coagulation syndrome in surgical practice] Titova MI, et al. **Klin Med (Mosk)** 1995;73(4):20–4 (30 ref.) **(Rus)**

COMPLICATIONS

Disseminated intravascular coagulation and antithrombin III depression in acute fatty liver of pregnancy. Castro MA, et al. **Am J Obstet Gynecol** 1996 Jan;174(1 Pt 1):211–6 (13 ref.)

[Consumption coagulopathy during pregnancy: a case of afibrinogenemia during the second trimester] Debiéve F, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(8):860–2 (9 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Disseminated intravascular coagulation: objective clinical and laboratory diagnosis, treatment, and assessment of therapeutic response. Bick RL. **Semin Thromb Hemost** 1996;22(1):69–88 (181 ref.)

DRUG THERAPY

Treating disseminated intravascular coagulation. Corbett JV, et al. **MCN Am J Matern Child Nurs** 1995 Sep–Oct; 20(5):290 (9 ref.)

[Treatment of disseminated intravascular coagulation syndrome] Częstochowska E. **Pol Arch Med Wewn** 1995 May;93(5):369–71 (11 ref.) **(Pol)**

ETIOLOGY

Coagulation inhibitor substitution during sepsis. Fourrier F, et al. **Intensive Care Med** 1995 Nov;21 Suppl 2:S264–8 (34 ref.)

[A case of adult onset Still's disease complicated with adult respiratory distress syndrome and disseminated intravascular coagulation] Yokoyama M, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Apr;18(2):207–14 (31 ref.) (Eng. Abstr.) **(Jpn)**

[Favorable prognosis in a case of recurrent cerebral infarctions caused by chronic disseminated intravascular coagulation due to ovarian carcinoma] Izumi M, et al. **No To Shinkei** 1996 Jun;48(6):581–5 (16 ref.) (Eng. Abstr.) **(Jpn)**

[DIC] Matsuda T. **Ryoikibetsu Shokogun Shirizu** 1995; (8):251–4 (12 ref.) **(Jpn)**

THERAPY

Disseminated intravascular coagulation: objective clinical and laboratory diagnosis, treatment, and assessment of therapeutic response. Bick RL. **Semin Thromb Hemost** 1996;22(1):69–88 (181 ref.)

[Emergency therapy of disseminated intravascular coagulation] Yawata Y. **Nippon Naika Gakkai Zasshi** 1995 Nov 10;84(11):1858–64 (5 ref.) **(Jpn)**

DISSOCIATION see DISSOCIATIVE DISORDERS

DISSOCIATIVE DISORDERS

DIAGNOSIS

Dissociation: the clinical realities. Frankel FH. **Am J Psychiatry** 1996 Jul;153(7 Suppl):64–70 (45 ref.)

The case for a dissociative interpretation of pseudoepileptic seizures. Kuyk J, et al. **J Nerv Ment Dis** 1996 Aug; 184(8):468–74 (83 ref.)

Transcultural aspects of dissociative and somatoform disorders. Escobar JI. **Psychiatr Clin North Am** 1995 Sep; 18(3):555–69 (45 ref.)

[Hysteria, dissociation and conversion. A review of concepts, classification and diagnostic instruments] Spitzer C, et al. **Psychiatr Prax** 1996 Mar;23(2):63–8 (55 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Hypnotizability and traumatic experience: a diathesis–stress model of dissociative symptomatology. Butler LD, et al. **Am J Psychiatry** 1996 Jul;153(7 Suppl):42–63 (155 ref.)

PHYSIOPATHOLOGY

Traumatic stress and pathological dissociation. Putnam FW. **Ann N Y Acad Sci** 1995 Dec 29;771:708–15 (62 ref.)

PSYCHOLOGY

Neural Mechanisms in dissociative amnesia for childhood abuse: relevance to the current controversy surrounding the "false memory syndrome". Bremner JD, et al. **Am J Psychiatry** 1996 Jul;153(7 Suppl):71–82 (124 ref.)

Dissociation, somatization, and affect dysregulation: the complexity of adaptation of trauma. van der Kolk BA, et al. **Am J Psychiatry** 1996 Jul;153(7 Suppl):83–93 (90 ref.)

Repressed memories: some clinical data contributing toward its elucidation. Martinez–Taboas A. **Am J Psychother** 1996 Spring;50(2):217–30 (47 ref.)

Dissociation and the fragmentary nature of traumatic memories: overview and exploratory study. van der Kolk BA, et al. **J Trauma Stress** 1995 Oct;8(4):505–25 (85 ref.)

The sociocognitive model of dissociative identity disorder: a reexamination of the evidence. Gleaves DH. **Psychol Bull** 1996 Jul;120(1):42–59 (150 ref.)

THERAPY

Treating the traumatic memories of patients with dissociative identity disorder. Kluft RP. **Am J Psychiatry** 1996 Jul;153(7 Suppl):103–10 (77 ref.)

DISTEMPER

VIROLOGY

The neurobiology of canine distemper virus infection. Vandevelde M, et al. **Vet Microbiol** 1995 May; 44(2–4):271–80 (57 ref.)

DISTEMPER, CANINE see DISTEMPER

DISTEMPER VIRUS, CANINE

PATHOGENICITY

The neurobiology of canine distemper virus infection. Vandevelde M, et al. **Vet Microbiol** 1995 May; 44(2–4):271–80 (57 ref.)

DISTRIBUTED SYSTEMS see COMPUTER COMMUNICATION NETWORKS

DISULFIDES

CHEMISTRY

Disulfide cross-linked envelope proteins: the functional equivalent of peptidoglycan in chlamydiae? Hatch TP. **J Bacteriol** 1996 Jan;178(1):1–5 (49 ref.)

[The role of disulfide bridges of the residual protein in chromosomal DNA organization] Struchkov VA, et al. **Biofizika** 1995 Mar–Apr;40(2):296–316 (96 ref.) (Eng. Abstr.) **(Rus)**

METABOLISM

New disulfide bond-forming reactions for peptide and protein synthesis. Kiso Y, et al. **Braz J Med Biol Res** 1994

DISULFIDES

Dec;27(12):2733–44 (24 ref.)

DISULFIRAM

ADVERSE EFFECTS

[Liver damage attributed to the use of disulfiram] Kerkhof SC, et al. **Ned Tijdschr Geneeskd** 1995 Nov 18; 139(46):2378–81 (24 ref.) (Eng. Abstr.) **(Dut)**

THERAPEUTIC USE

How to get the best out of antabuse. Kristenson H. **Alcohol Alcohol** 1995 Nov;30(6):775–83 (47 ref.)
[What is used as a drug for problem drinking?] Heinälä P, et al. **Duodecim** 1995;111(8):761–8 (30 ref.) **(Fin)**
[Disulfiram therapy] Widenius T, et al. **Duodecim** 1994; 110(2):153–8 (10 ref.) **(Fin)**

DITHRANOL see **ANTHRALIN**

DIURESIS

see related
DIURETICS
OSMOLAR CONCENTRATION

PHYSIOLOGY

Urea recycling: an aid to the excretion of potassium during antidiuresis. Halperin ML, et al. **Nephron** 1996;72(4):507–11 (32 ref.)
Neuropeptides implicated in the control of diuresis in insects. Coast GM. **Peptides** 1996;17(2):327–36 (61 ref.)
[Molecular structure of luminal diuretic receptors] Gamba G. **Rev Invest Clin** 1995 May–Jun;47(3):231–49 (131 ref.) (Eng. Abstr.) **(Spa)**

DIURETICS

see related
CARBONIC ANHYDRASE INHIBITORS

ADVERSE EFFECTS

Diuretics and risk of sudden death in hypertension—evidence and potential implications. Hoes AW, et al. **Clin Exp Hypertens** 1996 Apr–May;18(3–4):523–35 (22 ref.)
[Concomitant therapies in the clinical trial in Alzheimer's disease] Bermejo F, et al. **Rev Neurol** 1995 Jan–Feb; 23(119):118–24 (81 ref.) (Eng. Abstr.) **(Spa)**

ANALYSIS

Capillary electrophoresis of diuretics. Riekkola ML, et al. **J Chromatogr A** 1996 May 31;735(1–2):151–64 (23 ref.)

BLOOD

[Diuretics] Orita Y, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:960–5 (9 ref.) **(Jpn)**

METABOLISM

[Molecular structure of luminal diuretic receptors] Gamba G. **Rev Invest Clin** 1995 May–Jun;47(3):231–49 (131 ref.) (Eng. Abstr.) **(Spa)**

PHARMACOLOGY

The role of continuous infusion loop diuretics. Yelton SL, et al. **Ann Pharmacother** 1995 Oct;29(10):1010–4; quiz 1060–1 (19 ref.)

THERAPEUTIC USE

Diuretics: cornerstone of antihypertensive therapy. Kaplan NM. **Am J Cardiol** 1996 Feb 22;77(6):3B–5B (22 ref.)
Can we improve diuretic response in heart failure? Trelawny JM. **Br J Hosp Med** 1996 May 15–Jun 4;55(10):616–9 (24 ref.)
Optimising diuretic therapy in elderly patients with hypertension. Cushman WC. **Drugs Aging** 1995 Aug; 7(2):88–96 (30 ref.)
Refocus on diuretics in the treatment of heart failure. Taylor SH. **Eur Heart J** 1995 Jul;16 Suppl F:7–15 (86 ref.)
Antihypertensive treatment with diuretics: antediluvian or up to date? Dorhout Mees EJ. **Nephrol Dial Transplant** 1996 Apr;11(4):587–92 (43 ref.)
[Diuretics in the neonatal period] Guignard JP, et al. **Rev Med Suisse Romande** 1995 Aug;115(8):583–90 (89 ref.) (Eng. Abstr.) **(Fre)**
[Therapy of heart failure. Digitalis, diuretic plus ACE inhibitor or more?] Becker H, et al. **Internist (Berl)** 1995 Dec;36(12):1117–23 (43 ref.) **(Ger)**
[Arterial hypertension in the elderly. Is there still room for diuretics?] Dubois D, et al. **Schweiz Rundsch Med Prax** 1996 Jan 30;85(5):117–25 (77 ref.) (Eng. Abstr.) **(Ger)**
[Beta blockers and diuretics: therapeutic drugs of first choice in diabetes mellitus and hypertension] Sawicki PT. **Wien Klin Wochenschr** 1995;107(21):629–39 (98 ref.) (Eng. Abstr.) **(Ger)**
[Diuretics and beta-blockers as the first option in the treatment of arterial hypertension] Ferreira Montero IJ, et al. **Rev Esp Cardiol** 1995;48 Suppl 4:66–71 (41 ref.) (Eng. Abstr.) **(Spa)**

DIURETICS, OSMOTIC

THERAPEUTIC USE

Mannitol and other diuretics in severe neurotrauma. Bullock R. **New Horiz** 1995 Aug;3(3):448–52 (44 ref.)

DIURETICS, SULFAMYL

Loop diuretics: comparison of torsemide, furosemide, and bumetanide. Chen BP. **Conn Med** 1996 Jun;60(6):343–5 (6 ref.)

PHARMACOLOGY

Torsemide: a new loop diuretic. Fowler SF, et al. **Am J Health Syst Pharm** 1995 Aug 15;52(16):1771–80; quiz 1814–5 (60 ref.)

THERAPEUTIC USE

Comparative effects of indapamide and captopril on blood pressure and albumin excretion rate in diabetic microalbuminuria. Donnelly R, et al. **Am J Cardiol** 1996 Feb 22;77(6):26B–30B (33 ref.)
Torsemide: a new loop diuretic. Fowler SF, et al. **Am J Health Syst Pharm** 1995 Aug 15;52(16):1771–80; quiz 1814–5 (60 ref.)
Loop diuretics and thiazides—the case for their combination in chronic renal failure [editorial] Fliser D. **Nephrol Dial Transplant** 1996 Mar;11(3):408–10 (10 ref.)
[Clinico-pharmacological approaches to the use of lasix] Kukes VG, et al. **Anesteziol Reanimatol** 1995 Sep–Oct; (5):40–4 (17 ref.) **(Rus)**

DIURETICS, THIAZIDE

see related
ANTIHYPERTENSIVE AGENTS

Low-dose thiazides in the treatment of hypertension: benefits and risks in perspective. Silverberg DS, et al. **J Hum Hypertens** 1995 Nov;9(11):869–73 (80 ref.)

ADVERSE EFFECTS

Do KCa channels and carbonic anhydrase play a role in thiazide-induced hyperglycaemia? Pickkers P, et al. **J Hum Hypertens** 1995 Aug;9(8):691–3 (22 ref.)

THERAPEUTIC USE

Treatment of hypertension in the elderly. Lever AF, et al. **J Hypertens** 1995 Jun;13(6):571–9 (44 ref.)
Loop diuretics and thiazides—the case for their combination in chronic renal failure [editorial] Fliser D. **Nephrol Dial Transplant** 1996 Mar;11(3):408–10 (10 ref.)

DIURNAL RHYTHM see **CIRCADIAN RHYTHM**

DIVALPROEX see **VALPROIC ACID**

DIVERTICULITIS

COMPLICATIONS

Jejunal diverticulitis manifesting with abdominal wall abscess. Alvarez OA, et al. **Am J Gastroenterol** 1995 Nov; 90(11):2060–2 (10 ref.)
[Acute solitary diverticulitis of the cecum, a rare cause of acute abdomen. Apropos of 9 cases and review of the literature] Villalba Caballero R, et al. **J Chir (Paris)** 1995 Jun–Jul;132(6–7):299–304 (25 ref.) (Eng. Abstr.) **(Fre)**

ULTRASONOGRAPHY

[Ultrasound morphologic spectrum of Meckel's diverticulitis—3 case reports and overview of the literature] Demharter J, et al. **Rontgenpraxis** 1996 Jun;49(6):145–8 (11 ref.) **(Ger)**

DIVERTICULITIS, COLONIC

COMPLICATIONS

Genital fistulas secondary to diverticular disease of the colon: a review. Tancer ML, et al. **Obstet Gynecol Surv** 1996 Jan; 51(1):67–73 (67 ref.)

DIAGNOSIS

[Acute sigmoid diverticulitis—current diagnosis] Gillessen A, et al. **Chirurg** 1995 Dec;66(12):1177–81 (22 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

[Pathogenesis and pathophysiology of sigmoid diverticulitis] Hoffmann P, et al. **Chirurg** 1995 Dec;66(12):1169–72 (30 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

[Thoughts on the treatment of diverticular sigmoiditis. Apropos of 191 cases] Flament JB, et al. **Chirurgie** 1994–95; 120(11):43–8; discussion 48–9 (22 ref.) (Eng. Abstr.) **(Fre)**
[Early elective surgery of acute diverticulitis of the colon] Siewert JR, et al. **Chirurg** 1995 Dec;66(12):1182–9 (32 ref.) (Eng. Abstr.) **(Ger)**

DIVERTICULOSIS see **DIVERTICULUM**

DIVERTICULOSIS, COLONIC

Giant diverticulum of the sigmoid colon. Naber A, et al. **Int J Colorectal Dis** 1995;10(3):169–72 (50 ref.)
[Diverticular disease] Vogt W, et al. **Dtsch Med Wochenschr** 1996 Mar 29;121(13):411–5 (28 ref.) **(Ger)**

DIAGNOSIS

Giant sigmoid diverticulum: report of two cases and endoscopic recognition. Mehta DC, et al. **Am J Gastroenterol** 1996 Jun;91(6):1269–71 (11 ref.)

DIVERTICULOSIS, ESOPHAGEAL see **ESOPHAGEAL DIVERTICULUM**

DIVERTICULUM

[Myocardial diverticulum of the left ventricle. Review of the literature apropos of a case] Roche R, et al. **Ann Cardiol Angeiol (Paris)** 1996 Feb;45(2):68–70 (14 ref.) (Eng. Abstr.) **(Fre)**
[Jejunal diverticulosis: report of a case and review of the literature] Clemente A, et al. **Minerva Chir** 1995 May; 50(5):497–500 (15 ref.) (Eng. Abstr.) **(Ita)**

COMPLICATIONS

Complicated jejunal diverticulosis: report of a case. Fronticelli CM, et al. **Surg Today** 1996;26(3):192–5 (10 ref.)
[Apropos of a case of nephrogenic adenoma in a urethral diverticulum in a woman] Materne R, et al. **Acta Urol Belg** 1995 Dec;63(4):13–8 (59 ref.) (Eng. Abstr.) **(Fre)**
[Lemmel's syndrome caused by a giant diverticulum in the third portion of the duodenum, report of a case] Hirano A, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Nov; 92(11):1863–70 (11 ref.) **(Jpn)**

EPIDEMIOLOGY

Perforated jejunal diverticula: an analysis of reported cases. Chendrasekhar A, et al. **Am Surg** 1995 Nov;61(11):984–8 (40 ref.)

ETIOLOGY

[A case of urethral diverticulum in a male paraplegic patient] Kawakami T, et al. **Hinyokika Kiyo** 1995 Nov; 41(11):887–90 (8 ref.) (Eng. Abstr.) **(Jpn)**

RADIOGRAPHY

Dilemma of an inverted cecal diverticulum simulating a pedunculated polyp: CT appearance. Posner R, et al. **Abdom Imaging** 1995 Sep–Oct;20(5):440–1 (5 ref.)
Ureteric pseudo-diverticula—its implications and a review of the literature on various ureteric diverticula. Tan TH. **Singapore Med J** 1995 Dec;36(6):682–3 (11 ref.)
Ureteral pseudodiverticulosis: the case for the retrograde urogram. Socher SA, et al. **Urology** 1996 Jun;47(6):924–7 (13 ref.)
[Contrast agent retention in a jejunal diverticulum and small-intestine volvulus] Hüppe T, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1995 Nov;163(5):443–5 (10 ref.) **(Ger)**

DIVING

see related
DECOMPRESSION SICKNESS

The study of the brain using PET and SPECT: implications for space and underwater neurology. Newberg AB, et al. **J Neurol Sci** 1996 Mar;136(1–2):1–9 (84 ref.)
[Underwater diving during pregnancy] Revel A, et al. **Harefuah** 1995 Jun 1;128(11):707–10 (28 ref.) **(Heb)**

INJURIES

Recreational scuba diving injuries. Clenney TL, et al. **Am Fam Physician** 1996 Apr;53(5):1761–74 (17 ref.)
[Gastric rupture secondary to barotrauma in the framework of a diving accident. Apropos of a case report and literature review] Vuilleumier H, et al. **Swiss Surg** 1995;(5):226–9 (8 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Effects of diving and hyperbaria on responses to exercise. Shiraki K, et al. **Exerc Sport Sci Rev** 1995;23:459–85 (76 ref.)

PSYCHOLOGY

Anxiety and panic in recreational scuba divers. Morgan WP. **Sports Med** 1995 Dec;20(6):398–421 (117 ref.)

DIVORCE

Divorce and custody: the rights, needs, and obligations of mothers, fathers, and children. Maccoby EE.

Nebr Symp Motiv 1995;42:135–72 (58 ref.)

PSYCHOLOGY

Divorce: consequences for children. Emery RE, et al. Pediatr Rev 1995 Aug;16(8):306–10 (8 ref.)

DIZOCILPINE see DIZOCILPINE MALEATE

DIZOCILPINE MALEATE

THERAPEUTIC USE

[Preventive neuroprotection] Martín R. Rev Neurol 1995 Jan–Feb;23(119):30–2 (47 ref.) (Spa)

DIZZINESS

DIAGNOSIS

[An infant with dizziness] Koenigsberger MR, et al. Rev Neurol 1995;23 Suppl 3:S410–7 (60 ref.) (Spa)

ETIOLOGY

Persistent dizziness following head trauma and perilymphatic fistula. Fitzgerald DC. Arch Phys Med Rehabil 1995 Nov; 76(11):1017–20 (26 ref.)

Posturography—applications and limitations in the management of the dizzy patient. Harcourt JP. Clin Otolaryngol 1995 Aug;20(4):299–302 (24 ref.)

The dizzy patient: a review of etiology, differential diagnosis, and management. Anderson DC, et al. J Am Optom Assoc 1995 Sep;66(9):545–58 (68 ref.)

Head trauma: hearing loss and dizziness. Fitzgerald DC. J Trauma 1996 Mar;40(3):488–96 (83 ref.)

Dizziness in the elderly: etiology and treatment. Burke M. Nurse Pract 1995 Dec;20(12):28, 31–5 (19 ref.)

GENETICS

Deaf and dizzy mice with mutated myosin motors. Gillespie PG. Nat Med 1996 Jan;2(1):27–9 (13 ref.)

THERAPY

Dizziness in the elderly: etiology and treatment. Burke M. Nurse Pract 1995 Dec;20(12):28, 31–5 (19 ref.)

DMARD see ANTIRHEUMATIC AGENTS

DMF INDEX

[Oral disease epidemiologic illness indices and oral health measures—traditional concepts are supplemented by new socio-dental indicators] Strippel H. Gesundheitswesen 1996 Mar;58(3):162–8 (50 ref.) (Eng. Abstr.) (Ger)

DMSA see SUCCIMER

DNA

see related
DNA PRIMERS
GENETIC CODE
NUCLEIC ACID DENATURATION
NUCLEIC ACID HYBRIDIZATION
REPETITIVE SEQUENCES, NUCLEIC ACID

DNA vaccines. McDonnell WM, et al. N Engl J Med 1996 Jan 4;334(1):42–5 (0 ref.)

DNA sequence evolution: the sounds of silence. Sharp PM, et al. Philos Trans R Soc Lond B Biol Sci 1995 Sep 29; 349(1329):241–7 (54 ref.)

[Mechanism of DNA recognition by a protooncogene product, Myb] Ogata K, et al. Seikagaku 1996 Feb; 68(2):111–28 (24 ref.) (Jpn)

[Homologous recombination and triple helix DNA] Kotani H. Tanpakushitsu Kakusan Koso 1995 Dec;40(17):2654–60 (22 ref.) (Jpn)

[Mechanisms of the recognition of homologous DNA molecules by RecA protein] Kurumizaka H, et al. Tanpakushitsu Kakusan Koso 1994 Jul;40(10):1647–55 (61 ref.) (Jpn)

[Specific DNA recognition by Myb protein] Ogata K, et al. Tanpakushitsu Kakusan Koso 1994 Jul;40(10):1592–7 (24 ref.) (Jpn)

[Structure determination of transcription factors] Shirakawa M. Tanpakushitsu Kakusan Koso 1994 Jul;40(10):1598–608 (54 ref.) (Jpn)

[Stability prediction of active structures of nucleic acids] Sugimoto N. Tanpakushitsu Kakusan Koso 1994 Jul; 40(10):1548–57 (28 ref.) (Jpn)

[Structural motifs in interactions of nucleic acids] Takenaka A, et al. Tanpakushitsu Kakusan Koso 1994 Jul; 40(10):1527–39 (129 ref.) (Jpn)

[Development of information biology] Tateno Y. Tanpakushitsu Kakusan Koso 1995 Sep;40(12):1803–8 (16 ref.) (Jpn)

ADVERSE EFFECTS

DNA, dragons and sanity. Petricciani JC, et al. Biologicals 1995 Sep;23(3):233–8 (26 ref.)

ANALYSIS

cDNA selection and other approaches in positional cloning. Parimoo S, et al. Anal Biochem 1995 Jun 10;228(1):1–17 (202 ref.)

Molecular diagnosis of Duchenne muscular dystrophy in Singapore. Low PS, et al. Ann Acad Med Singapore 1996 Jan;25(1):84–9 (18 ref.)

Is sex worth searching for? Witt M. Arch Immunol Ther Exp (Warsz) 1994;42(5–6):345–8 (31 ref.)

DNA on a chip. Ross DW. Arch Pathol Lab Med 1996 Jun; 120(6):604–5 (4 ref.)

Viral vaccines and residual cellular DNA. Horaud F. Biologicals 1995 Sep;23(3):225–8 (17 ref.)

DAPI: a DNA-specific fluorescent probe. Kapuscinski J. Biotech Histochem 1995 Sep;70(5):220–33 (184 ref.)

DNA diagnostics for Charcot-Marie-Tooth disease and related inherited neuropathies [editorial; comment] Lupski JR. Clin Chem 1996 Jul;42(7):995–8 (46 ref.) Comment on: Clin Chem 1996 Jul;42(7):1021–5.

New approaches to the DNA diagnosis of Alport syndrome. Renieri A, et al. Contrib Nephrol 1996;117:183–97 (50 ref.)

Amperometric biosensors. Heller A. Curr Opin Biotechnol 1996 Feb;7(1):50–4 (39 ref.)

Applications of flow cytometric DNA analysis to diagnostic cytology. Cibas ES. Diagn Cytopathol 1995 Aug; 13(2):166–71 (50 ref.)

Commercial automated gel electrophoresis apparatus: application to DNA, band dispersion, nonlinear Ferguson curves, and isolation. Chrambach A, et al. Electrophoresis 1995 May;16(5):713–8 (26 ref.)

Detection of mismatched bases in double stranded DNA by gel electrophoresis. Ganguly A, et al. Electrophoresis 1995 Oct;16(10):1830–5 (49 ref.)

Molecular biological studies on teeth, and inquests. Yamamoto K. Forensic Sci Int 1996 Jun 28;80(1–2):79–87 (21 ref.)

DNA methylation in early development. Razin A, et al. Hum Mol Genet 1995;4 Spec No:1751–5 (39 ref.)

Sequence-specific and hydrolytic scission of DNA and RNA by lanthanide complex-oligoDNA hybrids. Komiyama M. J Biochem (Tokyo) 1995 Oct;118(4):665–70 (46 ref.)

Capillary gel electrophoresis and antisense therapeutics. Analysis of DNA analogs. DeDionisio LA, et al. J Chromatogr A 1996 May 31;735(1–2):191–208 (32 ref.)

The myotubular myopathies: differential diagnosis of the X linked recessive, autosomal dominant, and autosomal recessive forms and present state of DNA studies. Wallgren-Pettersson C, et al. J Med Genet 1995 Sep; 32(9):673–9 (56 ref.)

Fluorescence in situ hybridization for the detection of DNA and RNA. Albertson DG, et al. Methods Cell Biol 1995; 48:339–64 (27 ref.)

Genomic DNA sequencing methods. Favello A, et al. Methods Cell Biol 1995;48:551–69 (9 ref.)

Nonradioactive probes. Isaac PG, et al. Mol Biotechnol 1995 Jun;3(3):259–65 (24 ref.)

Nucleic acid detection using non-radioactive labelling methods. Mansfield ES, et al. Mol Cell Probes 1995 Jun; 9(3):145–56 (44 ref.)

Surfing the DNA databases for K+ channels nets yet more diversity. Salkoff L, et al. Neuron 1995 Sep;15(3):489–92 (35 ref.)

DNA markers in forensic medicine. Mayr WR. Transfus Clin Biol 1995;2(4):325–8 (4 ref.)

Applications of DNA amplification techniques in veterinary diagnostics. Pfeffer M, et al. Vet Res Commun 1995; 19(5):375–407 (284 ref.)

[Prenatal diagnosis of cutaneous genetic diseases by the study of fetal DNA] Hovnanian A, et al. Ann Dermatol Venereol 1995;122(4):173–85 (151 ref.) (Eng. Abstr.) (Fre)

[Practical application of DNA-diagnosis in the Nippon Medical School Hospital] Kawanami O, et al. Nippon Ika Daigaku Zasshi 1995 Aug;62(4):401–5 (21 ref.) (Jpn)

[Quantitative PCR: DNA quantification by PCR] Yasuda J. Tanpakushitsu Kakusan Koso 1996 Apr;41(5):499–502 (14 ref.) (Jpn)

[Use of DNA analysis for determining HLA class II antigens] Brojer E. Acta Haematol Pol 1995;26(3):247–56 (30 ref.) (Eng. Abstr.) (Pol)

[Quantitative analysis of oxidative base damage in DNA] Zastawny TH. Postepy Hig Med Dosw 1995;49(5):609–30 (74 ref.) (Eng. Abstr.) (Pol)

[Methods for DNA diagnosis in military medicine] Belokhvostov AS. Voen Med Zh 1995 Sep;(9):39–44, 80 (24 ref.) (Eng. Abstr.) (Rus)

BIOSYNTHESIS

The role of p53 in regulating genomic stability when DNA and RNA synthesis are inhibited. Chernova OB, et al. Trends Biochem Sci 1995 Oct;20(10):431–4 (49 ref.)

SOS-regulated proteins in translesion DNA synthesis and mutagenesis. Walker GC. Trends Biochem Sci 1995 Oct; 20(10):416–20 (50 ref.)

[The role of incomplete terminal repair of chromosomal DNA in the aging of neurons and postmitotic organisms] Olovnikov AM. Izv Akad Nauk Ser Biol 1995 Jul–Aug; (4):504–7 (12 ref.) (Eng. Abstr.) (Rus)

[The effect of the incomplete terminal repair of the linear double-stranded DNA molecule] Olovnikov AM. Izv Akad Nauk Ser Biol 1995 Jul–Aug;(4):501–3 (12 ref.) (Eng. Abstr.) (Rus)

CHEMICAL SYNTHESIS

[Preparation of stable isotope labeled DNA oligomers: applications to the structural analysis of nucleic acids by heteronuclear multidimensional NMR spectroscopy] Ono A, et al. Tanpakushitsu Kakusan Koso 1994 Jul; 40(10):1509–17 (21 ref.) (Jpn)

CHEMISTRY

Nickel-catalyzed oxidations: from hydrocarbons to DNA. Burrows CJ, et al. Acta Chem Scand 1996 Apr;50(4):337–44 (35 ref.)

Fluorescence photobleaching in DNA sequencing. Chu B. Adv Biophys 1996;32:17–29 (81 ref.)

Multi-helical DNA-binding domains: their structures and modes of DNA-binding. Suzuki M, et al. Adv Biophys 1996; 32:31–52 (88 ref.)

DNA conformation and its changes upon binding transcription factors. Suzuki M, et al. Adv Biophys 1996; 32:53–72 (47 ref.)

Triplex DNA structures. Frank-Kamenetskii MD, et al. Annu Rev Biochem 1995;64:65–95 (212 ref.)

Force field development and conformational search strategy in the simulation of biomolecular recognition processes. Tenette C, et al. Biochem Soc Trans 1996 Feb;24(1):268–74 (43 ref.)

Peptide nucleic acids (PNA): synthesis, properties and potential applications. Hyrup B, et al. Bioorg Med Chem 1996 Jan;4(1):5–23 (66 ref.)

Simulating DNA at low resolution. Olson WK. Curr Opin Struct Biol 1996 Apr;6(2):242–56 (76 ref.)

The thermodynamics of DNA structures that contain lesions or guanine tetrads. Pilch DS, et al. Curr Opin Struct Biol 1995 Jun;5(3):334–42 (63 ref.)

Calorimetry of proteins and nucleic acids. Plum GE, et al. Curr Opin Struct Biol 1995 Oct;5(5):682–90 (71 ref.)

The design and engineering of nucleic acid nanoscale assemblies. Seeman NC. Curr Opin Struct Biol 1996 Aug; 6(4):519–26 (52 ref.)

Surface plasmon resonance and its use in biomolecular interaction analysis (BIA). Szabo A, et al. Curr Opin Struct Biol 1995 Oct;5(5):699–705 (38 ref.)

Theory of the mobility-shift assay of nonspecific protein-DNA complexes governed by conditional probabilities: the HU:DNA complex. Cann JR, et al. Electrophoresis 1995 Jun;16(6):881–7 (29 ref.)

Aggregated DNA in ethanol solution. Piškur J, et al. FEBS Lett 1995 Nov 20;375(3):174–8 (38 ref.)

A model for DNA polymerase translocation: worm-like movement of DNA within the binding cleft. Wlassoff WA, et al. FEBS Lett 1996 Jul 15;390(1):6–9 (37 ref.)

Molecular basis of genetic instability of triplet repeats. Wells RD. J Biol Chem 1996 Feb 9;271(6):2875–8 (49 ref.)

Trinucleotide models for DNA bending propensity: comparison of models based on DNaseI digestion and nucleosome packaging data. Brukner I, et al. J Biomol Struct Dyn 1995 Oct;13(2):309–17 (28 ref.)

What is the basis of sequence-directed curvature in DNAs containing A tracts? Harvey SC, et al. J Biomol Struct Dyn 1995 Oct;13(2):301–7 (55 ref.)

Prediction of function in DNA sequence analysis. Gelfand MS. J Comput Biol 1995 Spring;2(1):87–115 (449 ref.)

A useful role for "static" models in elucidating the behaviour of DNA in solution. Calladine CR, et al. J Mol Biol 1996 Apr 5;257(3):479–85 (36 ref.)

RNA recognition and cleavage by iron(II)-bleomycin. Battigello JM, et al. Met Ions Biol Syst 1996;33:593–617 (98 ref.)

Photolytic covalent binding of metal complexes to DNA. Billadeau MA, et al. Met Ions Biol Syst 1996;33:269–96 (73 ref.)

Cisplatin and derived anticancer drugs: mechanism and current status of DNA binding. Bloemink MJ, et al. Met Ions Biol Syst 1996;32:641–85 (191 ref.)

Evidences for a catalytic activity of the DNA double helix in the reaction between DNA, platinum(II), and intercalators. Boudvillain M, et al. Met Ions Biol Syst 1996; 33:87–104 (44 ref.)

Effect of metal ions on the fluorescence of dyes bound to DNA. Bregadze VG, et al. Met Ions Biol Syst 1996; 33:253–67 (20 ref.)

Metal ion interactions with DNA: considerations on structure, stability, and effects from metal ion binding. Bregadze VG. Met Ions Biol Syst 1996;32:419–51 (44 ref.)

Nickel complexes as probes of guanine sites in nucleic acid folding. Burrows CJ, et al. Met Ions Biol Syst 1996; 33:537–60 (41 ref.)

Interactions of metallopharmaceuticals with DNA. Clarke MJ, et al. Met Ions Biol Syst 1996;32:727–80 (235 ref.)

Targeting of nucleic acids by iron complexes. Draganescu A, et al. Met Ions Biol Syst 1996;33:453–84 (92 ref.)

Specific DNA cleavage by manganese(III) complexes. Gravert DJ, et al. Met Ions Biol Syst 1996;33:515–36 (32 ref.)

Electrochemically activated nucleic acid oxidation. Johnston DH, et al. Met Ions Biol Syst 1996;33:297–324 (77 ref.)

Zinc complexes as targeting agents for nucleic acids. Kimura E, et al. Met Ions Biol Syst 1996;33:29–52 (30 ref.)

Metallocene interactions with DNA and DNA-processing enzymes. Kuo LY, et al. **Met Ions Biol Syst** 1996;33:53–85 (113 ref.)

Trans-diammineplatinum(II): what makes it different from cis-DDP? Coordination chemistry of a neglected relative of cisplatin and its interaction with nucleic acids. Lippert B. **Met Ions Biol Syst** 1996;33:105–41 (153 ref.)

Synthetic metallopeptides as probes of protein–DNA interactions. Long EC, et al. **Met Ions Biol Syst** 1996; 33:427–52 (65 ref.)

Electron transfer reactions through the DNA double helix. Meade TJ. **Met Ions Biol Syst** 1996;32:453–78 (85 ref.)

DNA interactions with substitution-inert transition metal ion complexes. Nordén B, et al. **Met Ions Biol Syst** 1996; 33:177–252 (210 ref.)

Porphyrin and metalloporphyrin interactions with nucleic acids. Pasternack RF, et al. **Met Ions Biol Syst** 1996; 33:367–97 (114 ref.)

Metallobleomycin–DNA interactions: structures and reactions related to bleomycin-induced DNA damage. Petering DH, et al. **Met Ions Biol Syst** 1996;33:619–48 (92 ref.)

Selective DNA cleavage by metalloporphyrin derivatives. Pratviel G, et al. **Met Ions Biol Syst** 1996;33:399–426 (96 ref.)

Metal ions in multiple-stranded DNA. Sabat M, et al. **Met Ions Biol Syst** 1996;33:143–76 (148 ref.)

Ternary metal ion–nucleic acid base–protein complexes. Sabat M. **Met Ions Biol Syst** 1996;32:521–55 (153 ref.)

Nucleic acid chemistry of the cuprous complexes of 1,10-phenanthroline and derivatives. Sigman DS, et al. **Met Ions Biol Syst** 1996;33:485–513 (60 ref.)

NMR studies of oligonucleotide–metal ion interactions. Sletten E, et al. **Met Ions Biol Syst** 1996;32:397–418 (56 ref.)

Electron transfer between metal complexes bound to DNA: is DNA a wire? Stemp ED, et al. **Met Ions Biol Syst** 1996; 33:325–65 (75 ref.)

Proteins that bind to and mediate the biological activity of platinum anticancer drug–DNA adducts. Whitehead JP, et al. **Met Ions Biol Syst** 1996;32:687–726 (111 ref.)

Crystallography in the study of protein–DNA interactions. Brown DG, et al. **Methods Mol Biol** 1996;56:293–318 (109 ref.)

The crystallization and structure analysis of oligonucleotide sequences. Neidle S. **Methods Mol Biol** 1996;56:267–92 (82 ref.)

Refinement of protein and nucleic acid structures. Westhof E, et al. **Methods Mol Biol** 1996;56:227–44 (39 ref.)

Open complex formation by Escherichia coli RNA polymerase: the mechanism of polymerase-induced strand separation of double helical DNA. deHaseth PL, et al. **Mol Microbiol** 1995 Jun;16(5):817–24 (72 ref.)

Creation of genomic methylation patterns. Bestor TH, et al. **Nat Genet** 1996 Apr;12(4):363–7 (51 ref.)

Concerted evolution of repetitive DNA sequences in eukaryotes. Elder JF Jr, et al. **Q Rev Biol** 1995 Sep; 70(3):297–320 (146 ref.)

Analysis of the mechanism of DNA recombination using tangles. Sumners DW, et al. **Q Rev Biophys** 1995 Aug; 28(3):253–313 (85 ref.)

Transcription factor IIA: a structure with multiple functions [comment] Jacobson RH, et al. **Science** 1996 May 10; 272(5263):827–8 (11 ref.) Comment on: Science 1996 May 10;272(5263):830–6.

Intercalation, DNA kinking, and the control of transcription. Werner MH, et al. **Science** 1996 Feb 9;271(5250):778–84 (54 ref.)

Counting the calories to stay in the groove. Ladbury JE. **Structure** 1995 Jul 15;3(7):635–9 (21 ref.)

Unraveling transposition: gamma delta resolvase in complex with DNA. Mondragón A. **Structure** 1995 Aug 15; 3(8):755–8 (16 ref.)

Action at a distance: DNA-looping and initiation of transcription. Rippe K, et al. **Trends Biochem Sci** 1995 Dec; 20(12):500–6 (39 ref.)

[Stereochemical basis of DNA super-structure formation by transcription factors] Suzuki M. **Tanpakushitsu Kakusan Koso** 1996 Feb;41(2):105–18 (21 ref.) **(Jpn)**

[The role of disulfide bridges of the residual protein in chromosomal DNA organization] Struchkov VA, et al. **Biofizika** 1995 Mar–Apr;40(2):296–316 (96 ref.) (Eng. Abstr.) **(Rus)**

[A cracked state of the double-helical DNA] Volkov SN. **Mol Biol (Mosk)** 1995 Sep–Oct;29(5):1086–94 (29 ref.) **(Rus)**

DRUG EFFECTS

Oxidative DNA lesions in V79 cells mediated by pentachlorophenol metabolites. Dahlhaus M, et al. **Arch Toxicol** 1996;70(7):457–60 (39 ref.)

Alkylation of DNA and its aftermath. Lawley PD. **Bioessays** 1995 Jun;17(6):561–8 (54 ref.)

Human protection against non-genotoxic carcinogens in the US without the Delaney Clause. Weisburger JH. **Exp Toxicol Pathol** 1996 Feb;48(2–3):201–8 (41 ref.)

Risk assessment of carcinogens in food with special consideration of non-genotoxic carcinogens. Scientific arguments for use of risk assessment and for changing the Delaney Clause specifically. Williams GM, et al. **Exp Toxicol Pathol** 1996 Feb;48(2–3):209–15 (21 ref.)

Epigenetic carcinogens: evaluation and risk assessment. Williams GM, et al. **Exp Toxicol Pathol** 1996 Feb; 48(2–3):189–95 (55 ref.)

Hypomethylation of DNA: a possible epigenetic mechanism involved in tumor promotion. Counts JL, et al. **Prog Clin Biol Res** 1995;391:81–101 (112 ref.)

DNA damage: chemistry, repair, and mutagenic potential. Singer B. **Regul Toxicol Pharmacol** 1996 Feb;23(1 Pt 1):2–13 (43 ref.)

GENETICS

Alterations in DNA methylation may play a variety of roles in carcinogenesis. Counts JL, et al. **Cell** 1995 Oct 6; 83(1):13–5 (18 ref.)

Epigenetic programming of differential gene expression in development and evolution. Monk M. **Dev Genet** 1995; 17(3):188–97 (58 ref.)

Arbitrarily amplified DNA in systematics and phylogenetics. Schierwater B. **Electrophoresis** 1995 Sep;16(9):1643–7 (45 ref.)

Fluorescence in situ hybridization: a brief review. Swiger RR, et al. **Environ Mol Mutagen** 1996;27(4):245–54 (69 ref.)

The polytene nucleus in morphological, cytochemical, and functional studies of messenger RNA transcription, processing, and transportation. Vázquez Nin GH, et al. **Eur J Histochem** 1996;40(1):7–16 (116 ref.)

Fluorescent PCR: a new technique for PGD of sex and single-gene defects. Findlay I, et al. **J Assist Reprod Genet** 1996 Feb;13(2):96–103 (28 ref.)

Prediction of function in DNA sequence analysis. Gelfand MS. **J Comput Biol** 1995 Spring;2(1):87–115 (449 ref.)

Increased expression of DNA cointroduced with nuclear protein in adult rat liver. Kaneda Y, et al. **J Mol Med** 1995 Jun;73(6):289–97 (14 ref.)

DNA transformation. Mello C, et al. **Methods Cell Biol** 1995; 48:451–82 (45 ref.)

DNA technology in forensic applications. Hochmeister MN. **Mol Aspects Med** 1995;16(4):315–437 (345 ref.)

Delivery of DNA into mammalian cells by receptor-mediated endocytosis and gene therapy. Guy J, et al. **Mol Biotechnol** 1995 Jun;3(3):237–48 (60 ref.)

Creation of genomic methylation patterns. Bestor TH, et al. **Nat Genet** 1996 Apr;12(4):363–7 (51 ref.)

Expression-PCR (E-PCR): overview and applications. Lanar DE, et al. **PCR Methods Appl** 1994 Oct;4(2):S92–6 (13 ref.)

Alu: structure, origin, evolution, significance and function of one-tenth of human DNA. Schmid CW. **Prog Nucleic Acid Res Mol Biol** 1996;53:283–319 (180 ref.)

Analysis of the mechanism of DNA recombination using tangles. Sumners DW, et al. **Q Rev Biophys** 1995 Aug; 28(3):253–313 (85 ref.)

Sex preselection by flow cytometric separation of X and Y chromosome-bearing sperm based on DNA difference: a review. Johnson LA. **Reprod Fertil Dev** 1995;7(4):893–903 (47 ref.)

Dinucleotide relative abundance extremes: a genomic signature. Karlin S, et al. **Trends Genet** 1995 Jul; 11(7):283–90 (27 ref.)

[Mechanisms of nucleoside-analog mutagenesis] Negishi K, et al. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1564–70 (55 ref.) **(Jpn)**

[Single-strand conformation polymorphism (SSCP) analysis: a convenient, rapid method for detection of single-base changes in DNA] Sekiya T. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):539–45 (4 ref.) **(Jpn)**

[Structure of four-stranded telomeric DNA] Shida T. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1578–82 (27 ref.) **(Jpn)**

[Detection of rare target gene with a point mutation by improved PCR] Tada M, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):549–52 (7 ref.) **(Jpn)**

[Ancient DNA] Ueda S. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):733–7 (19 ref.) **(Jpn)**

IMMUNOLOGY

B-1 cellular origin and VH segment structure of IgG, IgA, and IgM anti-DNA autoantibodies in patients with systemic lupus erythematosus. Kasaian MT, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:410–23 (52 ref.)

Origins of anti-DNA antibodies and their implications for B-cell tolerance. Radic MZ, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:384–96 (13 ref.)

Immunologic consequences of nucleic acid therapy. Pisetsky DS. **Antisense Res Dev** 1995 Fall;5(3):219–25 (53 ref.)

Nucleic acid vaccines. Vogel FR, et al. **Clin Microbiol Rev** 1995 Jul;8(3):406–10 (32 ref.)

Idiotypic DNA vaccines against B-cell lymphoma. Stevenson FK, et al. **Immunol Rev** 1995 Jun;145:211–28 (40 ref.)

DNA vaccines: what can we expect? Siegrist CA, et al. **Infect Agents Dis** 1996 Jan;5(1):55–9 (19 ref.)

The immunologic properties of DNA. Pisetsky DS. **J Immunol** 1996 Jan 15;156(2):421–3 (37 ref.)

Novel genetic immunotoxins and intracellular antibodies for cancer therapy. Chen SY, et al. **Semin Oncol** 1996 Feb; 23(1):148–53 (55 ref.)

Genetic immunization. Ertl HC, et al. **Viral Immunol** 1996; 9(1):1–9 (40 ref.)

ISOLATION & PURIFICATION

[DNA typing of HLA] Kashiwase K, et al. **Rinsho Byori** 1995 Jul;Suppl 99:92–101 (17 ref.) **(Jpn)**

[High resolutional two-dimension electrophoresis of DNA: a refinement of RLGS method] Asakawa J. **Tanpakushitsu Kakusan Koso** 1996 Feb;41(2):170–7 (8 ref.) **(Jpn)**

[Extraction of DNA from pancreatic and/or duodenal juice] Fukayama N, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr; 41(5):466–8 (3 ref.) **(Jpn)**

[Labelling of PCR products] Makino R. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):494–8 (6 ref.) **(Jpn)**

[Isolation of DNA from cells and tissues for PCR] Sekiya T. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):453–6 (4 ref.) **(Jpn)**

[Analysis of PCR products using silver staining] Sugano K. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):491–3 (4 ref.) **(Jpn)**

METABOLISM

DNA conformation and its changes upon binding transcription factors. Suzuki M, et al. **Adv Biophys** 1996; 32:53–72 (47 ref.)

Multi-helical DNA-binding domains: their structures and modes of DNA-binding. Suzuki M, et al. **Adv Biophys** 1996; 32:31–52 (88 ref.)

The nucleic acid ligand. A new tool for molecular recognition. McGown LB, et al. **Anal Chem** 1995 Nov 1; 67(21):663A–668A (28 ref.)

Force field development and conformational search strategy in the simulation of biomolecular recognition processes. Tenette C, et al. **Biochem Soc Trans** 1996 Feb;24(1):268–74 (43 ref.)

The specificity of homeotic gene function. Mann RS. **Bioessays** 1995 Oct;17(10):855–63 (74 ref.)

DNA methylation: a potential pathway to abnormal autoreactive lupus B cells. Huck S, et al. **Clin Immunol Immunopathol** 1996 Jul;80(1):1–8 (85 ref.)

Cancer. Exploring the bowels of DNA methylation. Balmain A. **Curr Biol** 1995 Sep 1;5(9):1013–6 (33 ref.)

Protein structure. Why have six-fold symmetry? Kelman Z, et al. **Curr Biol** 1995 Nov 1;5(11):1239–42 (22 ref.)

Recombination. Pieces of the site-specific recombination puzzle. Oram M, et al. **Curr Biol** 1995 Oct 1;5(10):1106–9 (20 ref.)

Multiple roles for DNA methylation in gametic imprinting. Neumann B, et al. **Curr Opin Genet Dev** 1996 Apr; 6(2):159–63 (45 ref.)

NMR structural studies on the zinc finger domains of nuclear hormone receptors. Knegtel RM, et al. **EXS** 1995;73:279–95 (30 ref.)

Genomic simple repetitive DNAs are targets for differential binding of nuclear proteins. Epplen JT, et al. **FEBS Lett** 1996 Jun 24;389(1):92–5 (40 ref.)

A model for DNA polymerase translocation: worm-like movement of DNA within the binding cleft. Wlassoff WA, et al. **FEBS Lett** 1996 Jul 15;390(1):6–9 (37 ref.)

Regulation of the DNA binding activity of NF-kappa B. Matthews JR, et al. **Int J Biochem Cell Biol** 1995 Sep; 27(9):865–79 (130 ref.)

DNA methylation and polyamines in embryonic development and cancer. Heby O. **Int J Dev Biol** 1995 Oct;39(5):737–57 (169 ref.)

Specificity and functional significance of DNA interaction with the nuclear matrix: new approaches to clarify the old questions. Razin SV, et al. **Int Rev Cytol** 1995;162B:405–48 (142 ref.)

Mechanisms of intron mobility. Belfort M, et al. **J Biol Chem** 1995 Dec 22;270(51):30237–40 (55 ref.)

Alignment of 3 (but not 4) DNA strands within a RecA protein filament. Cox MM. **J Biol Chem** 1995 Nov 3; 270(44):26021–4 (68 ref.)

Studies of DNA methylation in animals. Bird A, et al. **J Cell Sci Suppl** 1995;19:37–9 (23 ref.)

Current status of structure–activity relationships of platinum anticancer drugs: activation of the trans geometry. Farrell N. **Met Ions Biol Syst** 1996;32:603–39 (104 ref.)

Metallocene interactions with DNA and DNA-processing enzymes. Kuo LY, et al. **Met Ions Biol Syst** 1996;33:53–85 (113 ref.)

Electron transfer reactions through the DNA double helix. Meade TJ. **Met Ions Biol Syst** 1996;32:453–78 (85 ref.)

Ternary metal ion–nucleic acid base–protein complexes. Sabat M. **Met Ions Biol Syst** 1996;32:521–55 (153 ref.)

Proteins that bind to and mediate the biological activity of platinum anticancer drug–DNA adducts. Whitehead JP, et al. **Met Ions Biol Syst** 1996;32:687–726 (111 ref.)

Crystallography in the study of protein–DNA interactions. Brown DG, et al. **Methods Mol Biol** 1996;56:293–318 (109 ref.)

Genotoxic potential of beta-carbolines: a review. de Meester C. **Mutat Res** 1995 Oct;339(3):139–53 (93 ref.)

The mutagenic properties of DNA minor-groove binding ligands. Turner PR, et al. **Mutat Res** 1996 Aug 17; 355(1–2):141–69 (116 ref.)

A new role for lactoferrin: DNA binding and transcription activation. Fleet JC. **Nutr Rev** 1995 Aug;53(8):226–7 (7 ref.)

Biological relevance and consequences of chemical- or metal-induced DNA cross-linking. Paustenbach DJ, et al. **Proc Soc Exp Biol Med** 1996 Mar;211(3):211–7 (62 ref.)

DNA methylation, molecular genetic, and linkage studies in prostate cancer. Jarrard DF, et al. **Prostate Suppl** 1996; 6:36–44 (88 ref.)
DNA recognition code of transcription factors. Suzuki M, et al. **Protein Eng** 1995 Apr;8(4):319–28 (101 ref.)
The shrewd grasp of RNA polymerase [comment] Landick R, et al. **Science** 1996 Jul 12;273(5272):202–3 (19 ref.) Comment on: Science 1996 Jul 12;273(5272):211–7.
No "End of History" for photolyases [comment] Sancar A. **Science** 1996 Apr 5;272(5258):48–9 (14 ref.) Comment on: Science 1996 Apr 5;272(5258):109–12.
Prevention of DNA 5–methylcytosine reutilization in human cells. Vilpo JA, et al. **Somat Cell Mol Genet** 1995 Jul; 21(4):285–8 (28 ref.)
Unraveling transposition: gamma delta resolvase in complex with DNA. Mondragón A. **Structure** 1995 Aug 15; 3(8):755–8 (16 ref.)
Homeodomains: together again for the first time. Tullius T. **Structure** 1995 Nov 15;3(11):1143–5 (15 ref.)
Finding prospective partners in the library: the two–hybrid system and phage display find a match. Allen JB, et al. **Trends Biochem Sci** 1995 Dec;20(12):511–6 (50 ref.)
[Design of a novel Zn finger–based DNA cutter] Kuwahara J, et al. **Tanpakushitsu Kakusan Koso** 1994 Jul; 40(10):1457–64 (21 ref.) **(Jpn)**
[Mechanism of oxidative DNA strand scission] Sugiyama H. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1444–56 (50 ref.) **(Jpn)**
[Interaction of Oct–proteins with DNA] Stepchenko AG, et al. **Mol Biol (Mosk)** 1996 May–Jun;30(3):503–13 (46 ref.) **(Rus)**

PHARMACOKINETICS

Uptake of foreign DNA by mammalian cells via the gastrointestinal tract in mice: methylation of foreign DNA—a cellular defense mechanism. Doerfler W. **Curr Top Microbiol Immunol** 1995;197:209–24 (73 ref.)

PHYSIOLOGY

The biology of left–handed Z–DNA. Herbert A, et al. **J Biol Chem** 1996 May 17;271(20):11595–8 (76 ref.)

RADIATION EFFECTS

UV and nucleic acids. Douki T, et al. **EXS** 1995;73:173–97 (126 ref.)
DNA UVB dosimeters. Regan JD, et al. **J Photochem Photobiol B** 1995 Nov;31(1–2):57–61 (19 ref.)
Genomic instability induced by ionizing radiation. Morgan WF, et al. **Radiat Res** 1996 Sep;146(3):247–58 (175 ref.)
The single cell gel electrophoresis/comet assay: a potential tool for detecting radiation–induced DNA damage in humans. Tice RR, et al. **Stem Cells (Dayt)** 1995 May;13 Suppl 1:207–14 (12 ref.)

ULTRASTRUCTURE

[Dynamics of the high order structure of giant DNA—single molecular observation by fluorescence microscopy] Oana H, et al. **Tanpakushitsu Kakusan Koso** 1994 Jul; 40(10):1558–63 (18 ref.) **(Jpn)**

DNA ADDUCTS

DNA repair: enzymatic mechanisms and relevance to drug response. Chaney SG, et al. **J Natl Cancer Inst** 1996 Oct 2;88(19):1346–60 (253 ref.)
Hemoglobin adducts for in vivo dose monitoring and cancer risk estimation. Törnqvist M, et al. **J Occup Environ Med** 1995 Sep;37(9):1077–85 (41 ref.)
Proteins that bind to and mediate the biological activity of platinum anticancer drug–DNA adducts. Whitehead JP, et al. **Met Ions Biol Syst** 1996;32:687–726 (111 ref.)
DNA adducts from chemotherapeutic agents. Lawley PD, et al. **Mutat Res** 1996 Aug 17;355(1–2):13–40 (174 ref.)

ANALYSIS

Molecular biomarkers for aflatoxins and their application to human liver cancer. Scholl P, et al. **Pharmacogenetics** 1995; 5 Spec No:S171–6 (33 ref.)
Monitoring of human exposure to carcinogens through DNA and protein adduct determination. Farmer PB. **Toxicol Lett** 1995 Dec;82–83:757–62 (24 ref.)
Development and application of non–invasive biomarkers for carcinogen–DNA adduct analysis in occupationally exposed populations. Talaska G, et al. **Toxicology** 1996 Jul 17;111(1–3):207–12 (17 ref.)

CHEMISTRY

DNA adducts in human carcinogenesis: etiological relevance and structure–activity relationship. Bartsch H. **Mutat Res** 1996 Jun;340(2–3):67–79 (67 ref.)

DRUG EFFECTS

Significance of DNA adducts at low dose: shortening the time to spontaneous tumor occurrence. Lutz WK, et al. **Regul Toxicol Pharmacol** 1996 Feb;23(1 Pt 1):29–34 (40 ref.)

METABOLISM

Comparative carcinogenicity, metabolism, mutagenicity, and DNA binding of 7H–dibenzo[c,g]carbazole and dibenz[a,j]acridine. Warshawsky D, et al. **Crit Rev Toxicol** 1996;26(2):213–49 (101 ref.)
Induction and repair of benzo[a]pyrene–DNA adducts in C57BL/6 and BALB/c mice: association with aging and longevity. Boerrigter ME, et al. **Mech Ageing Dev** 1995 Jul 28;82(1):31–50 (50 ref.)
Molecular dosimetry of chemical mutagens. Relationship between DNA adduct formation and genetic changes analyzed at the molecular level. van Zeeland AA. **Mutat Res** 1996 Jun 12;353(1–2):123–50 (96 ref.)
Metabolic polymorphisms and carcinogen–DNA adduct formation in human populations. Kaderlik KR, et al. **Pharmacogenetics** 1995;5 Spec No:S108–17 (112 ref.)
Endogenous production of DNA adducts. Nath RG, et al. **Regul Toxicol Pharmacol** 1996 Feb;23(1 Pt 1):22–8 (34 ref.)
Genetic susceptibility and carcinogen–DNA adduct formation in human urinary bladder carcinogenesis. Kadlubar FF, et al. **Toxicol Lett** 1995 Dec;82–83:627–32 (19 ref.)

TOXICITY

The role of adduct site–specific mutagenesis in understanding how carcinogen–DNA adducts cause mutations: perspective, prospects and problems. Loechler EL. **Carcinogenesis** 1996 May;17(5):895–902 (70 ref.)
A conundrum in molecular toxicology: molecular and biological changes during neoplastic transformation of human cells. Milo GE, et al. **Cell Biol Toxicol** 1995 Dec; 11(6):329–45 (32 ref.)
Relationship of DNA adducts derived from 2–acetylaminofluorene to cell proliferation and the induction of rodent liver and bladder tumors. Cohen SM, et al. **Toxicol Pathol** 1995 Mar–Apr;23(2):136–42 (21 ref.)

DNA, ANTISENSE

Use of transgenics, null mutants, and antisense approaches to study ethanol's actions. Wehner JM, et al. **Alcohol Clin Exp Res** 1995 Aug;19(4):811–20 (79 ref.)

ANALYSIS

[Antisense strategies in studies on the role of sugar chains in phenotype expression of neoplasms] Ugorski M. **Postepy Hig Med Dosw** 1995;49(1):77–84 (22 ref.) (Eng. Abstr.) **(Pol)**

DIAGNOSTIC USE

Application of antisense DNA method for the study of molecular bases of brain function and behavior. Ogawa S, et al. **Behav Genet** 1996 May;26(3):279–92 (85 ref.)

DNA, BACTERIAL

Tn10 and IS10 transposition and chromosome rearrangements: mechanism and regulation in vivo and in vitro. Kleckner N, et al. **Curr Top Microbiol Immunol** 1996; 204:49–82 (96 ref.)
Bacterial insertion sequences. Ohtsubo F, et al. **Curr Top Microbiol Immunol** 1996;204:1–26 (160 ref.)

ANALYSIS

Molecular biology in medicine: laboratory diagnosis of tuberculosis. Ling ML. **Ann Acad Med Singapore** 1996 Jan; 25(1):94–7 (26 ref.)
Detection of mycobacterial DNA in the skin. Etiologic insights and diagnostic perspectives. Degitz K. **Arch Dermatol** 1996 Jan;132(1):71–5 (58 ref.)
Polymerase chain reaction of Borrelia burgdorferi flagellin gene in Shulman syndrome. Hashimoto Y, et al. **Dermatology** 1996;192(2):136–9 (26 ref.)
The unique DNA topology and DNA topoisomerases of hyperthermophilic archaea. Forterre P, et al. **FEMS Microbiol Rev** 1996 May;18(2–3):237–48 (47 ref.)
Interpreting chromosomal DNA restriction patterns produced by pulsed–field gel electrophoresis: criteria for bacterial strain typing. Tenover FC, et al. **J Clin Microbiol** 1995 Sep;33(9):2233–9 (48 ref.)
Novel strategies for the detection of drug resistance in Mycobacterium tuberculosis. Telenti A, et al. **Res Microbiol** 1996 Jan–Feb;147(1–2):73–9 (34 ref.)
[Aseptic meningitis. Demonstration of bacterial DNA in cerebrospinal fluid by gene amplification] Salord F, et al. **Ann Fr Anesth Reanim** 1995;14(4):320–5 (28 ref.) (Eng. Abstr.) **(Fre)**

BIOSYNTHESIS

Collapse and repair of replication forks in Escherichia coli. Kuzminov A. **Mol Microbiol** 1995 May;16(3):373–84 (102 ref.)

CHEMISTRY

Structure and partitioning of bacterial DNA: determined by a balance of compaction and expansion forces? Woldringh CL, et al. **FEMS Microbiol Lett** 1995 Sep 15;131(3):235–42 (46 ref.)
Relaxing and unwinding on Holliday: DNA helicase–mediated branch migration. Adams DE, et al. **Mutat Res** 1995 Nov;337(3):149–59 (70 ref.)
Novel PTS proteins revealed by bacterial genome sequencing: a unique fructose–specific phosphoryl transfer protein with two HPr–like domains in Haemophilus influenzae. Reizer J, et al. **Res Microbiol** 1996 May; 147(4):209–15 (29 ref.)
[beta–Lactamases of Branhamella catarrhalis and their phenotypic implications] Chaïbi EB, et al. **Res Microbiol** 1995 Nov–Dec;146(9):761–71 (40 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

DNA processing reactions in bacterial conjugation. Lanka E, et al. **Annu Rev Biochem** 1995;64:141–69 (187 ref.)
CpG DNA: a pathogenic factor in systemic lupus erythematosus? Krieg AM. **J Clin Immunol** 1995 Nov; 15(6):284–92 (77 ref.)
Old and new concepts for the role of chi in bacterial recombination. Stahl F, et al. **J Hered** 1995 Sep–Oct; 86(5):327–9 (48 ref.)
New approaches to typing and identification of bacteria using the 16S–23S rDNA spacer region. Gürtler V, et al. **Microbiology** 1996 Jan;142 (Pt 1):3–16 (100 ref.)

IMMUNOLOGY

Immunological properties of bacterial DNA. Pisetsky DS, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:152–63 (33 ref.)

ISOLATION & PURIFICATION

[Cat scratch disease. Bartonella henselae antibodies and DNA detection in regional lymphadenopathy] Heizmann WR, et al. **Dtsch Med Wochenschr** 1996 May 10;121(19):622–6 (33 ref.) (Eng. Abstr.) **(Ger)**

METABOLISM

DNA processing reactions in bacterial conjugation. Lanka E, et al. **Annu Rev Biochem** 1995;64:141–69 (187 ref.)

PHYSIOLOGY

Regulation of chromosomal replication in E. coli: sequestration and beyond. Crooke E. **Cell** 1995 Sep 22; 82(6):877–80 (18 ref.)

DNA–BINDING PROTEIN, CYCLIC AMP–RESPONSIVE

[Regulation of gene expression through phosphorylation of transcription factors] Hagiwara M. **Seikagaku** 1995 Dec; 67(12):1388–91 (11 ref.) **(Jpn)**

METABOLISM

Transcription factors responsive to cAMP. Sassone–Corsi P. **Ann Rev Cell Dev Biol** 1995;11:355–77 (73 ref.)

PHYSIOLOGY

Memory mechanisms. Photographic memory in flies. Goda Y. **Curr Biol** 1995 Aug 1;5(8):852–3 (11 ref.)
Shaking out the cause of addiction [comment] Hyman SE. **Science** 1996 Aug 2;273(5275):611–2 (5 ref.) Comment on: Science 1996 Aug 2;273(5275):657–9.
cAMP–dependent regulation of gene transcription by cAMP response element–binding protein and cAMP response element modulator. Habener JF, et al. **Vitam Horm** 1995; 51:1–57 (196 ref.)

RADIATION EFFECTS

Both ATF–2 and c–Jun are phosphorylated by stress–activated protein kinases in response to UV irradiation. Wilhelm D, et al. **Immunobiology** 1995 Jul; 193(2–4):143–8 (22 ref.)

DNA–BINDING PROTEINS

see related
DNA REPLICATION
HELIX–LOOP–HELIX MOTIFS
LEUCINE ZIPPERS
ZINC FINGERS

Designing DNA–binding proteins on the surface of filamentous phage. Choo Y, et al. **Curr Opin Biotechnol** 1995 Aug;6(4):431–6 (23 ref.)
The genetic basis of murine and human sex determination: a review. McElreavey K, et al. **Heredity** 1995 Dec;75 (Pt 6):599–611 (82 ref.)
The nuclear factor IL–4 (NF–IL4). Köhler I, et al. **Immunobiology** 1995 Jul;193(2–4):273–80 (23 ref.)
The C/EBP family of transcription factors. Wedel A, et al. **Immunobiology** 1995 Jul;193(2–4):171–85 (100 ref.)
Nucleoid proteins. Hayat MA, et al. **Micron** 1995; 26(5):461–80 (220 ref.)
Transcription factors. 1: bZIP proteins. Hurst HC. **Protein Profile** 1994;1(2):123–68 (471 ref.)
[Biological significance of nuclear matrix attachment regions (MAR) and tissue specific MAR–DNA binding proteins] Kohwi Y, et al. **Seikagaku** 1995 Sep;67(9):1115–27 (28 ref.) **(Jpn)**
[Sex differentiation and Ad4BP] Morohashi K. **Seikagaku** 1995 Oct;67(10):1195–209 (56 ref.) **(Jpn)**
[HN7–3/fork head (winged–helix) transcription factor family in dorso–ventral pattern formation of vertebrate embryos]

Sasaki H. **Seikagaku** 1995 Oct;67(10):1218–21 (15 ref.) **(Jpn)**

[Specific DNA recognition by Myb protein] Ogata K, et al. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1592–7 (24 ref.) **(Jpn)**

ANALYSIS

Does the Wilms' tumour suppressor gene, WT1, play roles in both splicing and transcription? Charlieu JP, et al. **J Cell Sci Suppl** 1995;19:95–9 (20 ref.)

BIOSYNTHESIS

Heat shock transcription factors: structure and regulation. Wu C. **Ann Rev Cell Dev Biol** 1995;11:441–69 (157 ref.)

New perspectives on eye evolution. Halder G, et al. **Curr Opin Genet Dev** 1995 Oct;5(5):602–9 (68 ref.)

Sex differentiation — gonadogenesis and novel genes. Nordqvist K. **Int J Dev Biol** 1995 Oct;39(5):727–36 (76 ref.)

CHEMISTRY

Multi-helical DNA-binding domains: their structures and modes of DNA-binding. Suzuki M, et al. **Adv Biophys** 1996; 32:31–52 (88 ref.)

Heat shock transcription factors: structure and regulation. Wu C. **Ann Rev Cell Dev Biol** 1995;11:441–69 (157 ref.)

Structure-function relationships in the FK506-binding protein (FKBP) family of peptidylprolyl cis-trans isomerases. Kay JE. **Biochem J** 1996 Mar 1;314 (Pt 2):361–85 (308 ref.)

Protein structure. Why have six-fold symmetry? Kelman Z, et al. **Curr Biol** 1995 Nov 1;5(11):1239–42 (22 ref.)

Theory of the mobility-shift assay of nonspecific protein-DNA complexes governed by conditional probabilities: the HU:DNA complex. Cann JR, et al. **Electrophoresis** 1995 Jun;16(6):881–7 (29 ref.)

Trinucleotide models for DNA bending propensity: comparison of models based on DNaseI digestion and nucleosome packaging data. Brukner I, et al. **J Biomol Struct Dyn** 1995 Oct;13(2):309–17 (28 ref.)

Structural alterations in the transcription factor PEBP2/CBF linked to four different types of leukemia. Ito Y. **J Cancer Res Clin Oncol** 1996;122(5):266–74 (46 ref.)

Molecular conjugates: a targeted gene delivery vector for molecular medicine. Cristiano RJ, et al. **J Mol Med** 1995 Oct;73(10):479–86 (45 ref.)

Targeting of nucleic acids by iron complexes. Draganescu A, et al. **Met Ions Biol Syst** 1996;33:453–84 (92 ref.)

Synthetic metallopeptides as probes of protein-DNA interactions. Long EC, et al. **Met Ions Biol Syst** 1996; 33:427–52 (65 ref.)

Ternary metal ion-nucleic acid base-protein complexes. Sabat M. **Met Ions Biol Syst** 1996;32:521–55 (153 ref.)

Metal replacement in DNA-binding zinc finger proteins and its relevance to mutagenicity and carcinogenicity through free radical generation. Sarkar B. **Nutrition** 1995 Sep–Oct; 11(5 Suppl):646–9 (17 ref.)

Transcription factors 2: helix-loop-helix. Littlewood TD, et al. **Protein Profile** 1994;1(6):635–709 (1097 ref.)

Transcription factor IIA: a structure with multiple functions [comment] Jacobson RH, et al. **Science** 1996 May 10; 272(5263):827–8 (11 ref.) Comment on: Science 1996 May 10;272(5263):830–6.

hSRY: molecular gender bender. Bramham J, et al. **Structure** 1995 Jul 15;3(7):631–3 (19 ref.)

Receptor (immunophilin-binding) assay for immunosuppressive drugs. Soldin SJ. **Ther Drug Monit** 1995 Dec;17(6):574–6 (18 ref.)

[Structure determination of transcription factors] Shirakawa M. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1598–608 (54 ref.) **(Jpn)**

DRUG EFFECTS

Positive regulation of the nuclear activator CREM by the mitogen-induced p70 S6 kinase. de Groot RP, et al. **Immunobiology** 1995 Jul;193(2–4):155–60 (9 ref.)

GENETICS

PAX and HOX in neoplasia. Stuart ET, et al. **Adv Genet** 1995;33:255–74 (92 ref.)

The proteolipid protein gene: double, double, ... and trouble [editorial] Hodes ME, et al. **Am J Hum Genet** 1996 Jul; 59(1):12–5 (27 ref.)

Mutations in PAX3 that cause Waardenburg syndrome type I: ten new mutations and review of the literature. Baldwin CT, et al. **Am J Med Genet** 1995 Aug 28;58(2):115–22 (16 ref.)

Pax genes and skeletal development. Balling R, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:27–33 (29 ref.)

The TEL gene and human leukemia. Golub TR, et al. **Biochim Biophys Acta** 1996 Aug 8;1288(1):M7–10 (27 ref.)

MHox and vertebrate skeletogenesis: the long and the short of it. Brickell PM. **Bioessays** 1995 Sep;17(9):750–3 (31 ref.)

Genetics of aniridia and anterior segment dysgenesis. Churchill A, et al. **Br J Ophthalmol** 1996 Jul;80(7):669–73 (53 ref.)

BCL-6 and the molecular pathogenesis of B-cell lymphoma. Dalla-Favera R, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:117–23 (49 ref.)

The hepatocyte nuclear factor-3/forkhead transcription regulatory family in development, inflammation, and neoplasia. Hromas R, et al. **Crit Rev Oncol Hematol** 1995 Aug;20(1–2):129–40 (64 ref.)

RNA processing. Wilms' tumour—the splicing connection? Lamond AI. **Curr Biol** 1995 Aug 1;5(8):862–5 (10 ref.)

Muscle development. Making Drosophila muscle. Taylor MV. **Curr Biol** 1995 Jul 1;5(7):740–2 (14 ref.)

Involvement of the TEL gene in hematologic malignancy by diverse molecular genetic mechanisms. Golub TR, et al. **Curr Top Microbiol Immunol** 1996;211:279–88 (21 ref.)

Molecular analysis of Evi1, a zinc finger oncogene involved in myeloid leukemia. Lopingco MC, et al. **Curr Top Microbiol Immunol** 1996;211:211–22 (63 ref.)

The Tc1/mariner transposon family. Plasterk RH. **Curr Top Microbiol Immunol** 1996;204:125–43 (98 ref.)

The mycN/max protein complex in neuroblastoma. Short review. Wenzel A, et al. **Eur J Cancer** 1995;31A(4):516–9 (40 ref.)

Roles of Paxgenes in nephrogenesis. Rothenpieler UW. **Exp Nephrol** 1996 Mar–Apr;4(2):86–91 (35 ref.)

PAX genes: what's new in developmental biology and cancer? Stuart ET, et al. **Hum Mol Genet** 1995;4 Spec No:1717–20 (52 ref.)

The helix-loop-helix gene SCL: implicated in T-cell acute lymphoblastic leukaemia and in normal haematopoietic development. Robb L, et al. **Int J Biochem Cell Biol** 1996 Jun;28(6):609–18 (84 ref.)

Increased expression of DNA cointroduced with nuclear protein in adult rat liver. Kaneda Y, et al. **J Mol Med** 1995 Jun;73(6):289–97 (14 ref.)

HRX gene rearrangement in secondary acute lymphoblastic leukemia. Kobayashi Y, et al. **Leuk Lymphoma** 1995 May; 17(5–6):391–9 (71 ref.)

Developmental control of N-CAM expression by Hox and Pax gene products. Edelman GM, et al. **Philos Trans R Soc Lond B Biol Sci** 1995 Sep 29; 349(1329):305–12 (33 ref.)

The nuclear response to cAMP: role of transcription factor CREM. Lalli E, et al. **Philos Trans R Soc Lond B Biol Sci** 1996 Feb 29; 351(1336):201–9 (50 ref.)

The gene responsible for adrenal hypoplasia congenita, DAX-1, encodes a nuclear hormone receptor that defines a new class within the superfamily. Burris TP, et al. **Recent Prog Horm Res** 1996;51:241–59; discussion 259–60 (94 ref.)

Pax6: more than meets the eye. Hanson I, et al. **Trends Genet** 1995 Jul;11(7):268–72 (41 ref.)

Insight into the microphthalmia gene. Moore KJ. **Trends Genet** 1995 Nov;11(11):442–8 (41 ref.)

[Inducible regulatable promoter—ionizing radiation-inducible promoter EGR-1] Ohno T. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2624–30 (25 ref.) **(Jpn)**

[Structure and properties of transcription IIIA from Xenopus laevis] Wyszko E, et al. **Postepy Biochem** 1995;41(2):102–9 (56 ref.) **(Pol)**

[Initiation of DNA replication in Streptomyces; organizational comparison of the oriC region in prokaryotic organisms] Zakrzewska-Czerwińska J. **Postepy Hig Med Dosw** 1995;49(1):149–60 (43 ref.) (Eng. Abstr.) **(Pol)**

IMMUNOLOGY

The Ku autoantigen: cast in a new light. Robinson A. **Can Med Assoc J** 1996 Jun 15;154(12):1871–3 (8 ref.)

METABOLISM

Multi-helical DNA-binding domains: their structures and modes of DNA-binding. Suzuki M, et al. **Adv Biophys** 1996; 32:31–52 (88 ref.)

Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Schindler C, et al. **Annu Rev Biochem** 1995;64:621–51 (145 ref.)

Leucine-responsive regulatory protein: a global regulator of gene expression in E. coli. Newman EB, et al. **Annu Rev Microbiol** 1995;49:747–75 (122 ref.)

Multiple steps in the regulation of transcription-factor level and activity. Calkhoven CF, et al. **Biochem J** 1996 Jul 15; 317 (Pt 2):329–42 (269 ref.)

Structure-function relationships in the FK506-binding protein (FKBP) family of peptidylprolyl cis-trans isomerases. Kay JE. **Biochem J** 1996 Mar 1;314 (Pt 2):361–85 (308 ref.)

A yeast transcription factor activating G1 cyclin expression has similarity to bacterial signal transduction proteins. Johnston LH, et al. **Biochem Soc Trans** 1996 Feb; 24(1):49–54 (26 ref.)

Thrombopoietin induces tyrosine phosphorylation of Stat3 and Stat5 in human blood platelets. Miyakawa Y, et al. **Blood** 1996 Jan 15;87(2):439–46 (36 ref.)

STATs: signal transducers and activators of transcription. Ihle JN. **Cell** 1996 Feb 9;84(3):331–4 (20 ref.)

The Max transcription factor network: involvement of Mad in differentiation and an approach to identification of target genes. Hurlin PJ, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:109–16 (42 ref.)

Chromatin. Nucleosome assembly during DNA replication. Krude T. **Curr Biol** 1995 Nov 1;5(11):1232–4 (17 ref.)

Recombination. Pieces of the site-specific recombination puzzle. Oram M, et al. **Curr Biol** 1995 Oct 1;5(10):1106–9 (20 ref.)

The role of BSAP (Pax-5) in B-cell development. Busslinger M, et al. **Curr Opin Genet Dev** 1995 Oct;5(5):595–601 (53 ref.)

C/EBP alpha. a critical regulator of genes governing integrative metabolic processes. Darlington GJ, et al. **Curr Opin Genet Dev** 1995 Oct;5(5):565–70 (37 ref.)

Transcriptional regulation by the t(8;21) fusion protein, AML-1/ETO. Hiebert SW, et al. **Curr Top Microbiol Immunol** 1996;211:253–8 (19 ref.)

Regulation of muscle differentiation by the MEF2 family of MADS box transcription factors. Olson EN, et al. **Dev Biol** 1995 Nov;172(1):2–14 (102 ref.)

Genomic simple repetitive DNAs are targets for differential binding of nuclear proteins. Epplen JT, et al. **FEBS Lett** 1996 Jun 24;389(1):92–5 (40 ref.)

Nuclear matrix acceptor binding sites for steroid hormone receptors: a candidate nuclear matrix acceptor protein. Lauber AH, et al. **Int Rev Cytol** 1995;162B:337–76 (178 ref.)

The RuvABC proteins and Holliday junction processing in Escherichia coli. West SC. **J Bacteriol** 1996 Mar; 178(5):1237–41 (59 ref.)

Stepwise assembly of initiation complexes at budding yeast replication origins during the cell cycle. Diffley JF, et al. **J Cell Sci Suppl** 1995;19:67–72 (25 ref.)

B cell lineage-specific activator protein (BSAP). A player at multiple stages of B cell development. Michaelson JS, et al. **J Immunol** 1996 Apr 1;156(7):2349–51 (50 ref.)

The PI/PTB domain: a new protein interaction domain involved in growth factor receptor signaling. Margolis B. **J Lab Clin Med** 1996 Sep;128(3):235–41 (66 ref.)

Ternary metal ion-nucleic acid base-protein complexes. Sabat M. **Met Ions Biol Syst** 1996;32:521–55 (153 ref.)

In vivo footprinting of protein-DNA interactions. Paul AL, et al. **Methods Cell Biol** 1995;49:391–400 (14 ref.)

Crystallography in the study of protein-DNA interactions. Brown DG, et al. **Methods Mol Biol** 1996;56:293–318 (109 ref.)

Single-stranded DNA binding protein encoded by the filamentous bacteriophage M13: structural and functional characteristics. Stassen AP, et al. **Mol Biol Rep** 1994–95; 20(3):109–27 (101 ref.)

New insights into p53 function from structural studies. Arrowsmith CH, et al. **Oncogene** 1996 Apr 4;12(7):1379–85 (59 ref.)

Role of recombination enzymes in mammalian cell survival. Edelmann W, et al. **Proc Natl Acad Sci U S A** 1996 Jun 25;93(13):6225–7 (25 ref.)

Transcription factors 2: helix-loop-helix. Littlewood TD, et al. **Protein Profile** 1994;1(6):635–709 (1097 ref.)

Intercalation, DNA kinking, and the control of transcription. Werner MH, et al. **Science** 1996 Feb 9;271(5250):778–84 (54 ref.)

The G-box: a ubiquitous regulatory DNA element in plants bound by the GBF family of bZIP proteins. Menkens AE, et al. **Trends Biochem Sci** 1995 Dec;20(12):506–10 (39 ref.)

[Interaction of Oct-proteins with DNA] Stepchenko AG, et al. **Mol Biol (Mosk)** 1996 May–Jun;30(3):503–13 (46 ref.) **(Rus)**

PHYSIOLOGY

The role of the Opaque2 transcriptional factor in the regulation of protein accumulation and amino acid metabolism in maize seeds. Yunes JA, et al. **An Acad Bras Cienc** 1994;66 Su 1 (Pt 2):227–37; quiz 237–8 (60 ref.)

Mechanisms for the prevention of damage to DNA in spores of Bacillus species. Setlow P. **Annu Rev Microbiol** 1995; 49:29–54 (91 ref.)

Lens development and crystallin gene expression: many roles for Pax-6. Cvekl A, et al. **Bioessays** 1996 Aug;18(8):621–30 (72 ref.)

Nonsteroid nuclear receptors: what are genetic studies telling us about their role in real life? Kastner P, et al. **Cell** 1995 Dec 15;83(6):859–69 (71 ref.)

TGFbeta signaling: receptors, transducers, and Mad proteins. Massagué J. **Cell** 1996 Jun 28;85(7):947–50 (20 ref.)

Oestrogen-responsive finger protein suggests a transcriptional cascade of steroid hormone regulation. **Ciba Found Symp** 1995;191:43–51 (18 ref.)

Lymphopoiesis. Transcription factors controlling B-cell development. Desiderio S. **Curr Biol** 1995 Jun 1;5(6):605–8 (20 ref.)

Boundary and insulator elements in chromosomes. Gerasimova TI, et al. **Curr Opin Genet Dev** 1996 Apr; 6(2):185–92 (42 ref.)

Multiple SWItches to turn on chromatin? Peterson CL. **Curr Opin Genet Dev** 1996 Apr;6(2):171–5 (36 ref.)

The role of brahma and related proteins in transcription and development. Tamkun JW. **Curr Opin Genet Dev** 1995 Aug; 5(4):473–7 (51 ref.)

The TATA box binding protein. Burley SK. **Curr Opin Struct Biol** 1996 Feb;6(1):69–75 (38 ref.)

Hematopoietic transcriptional regulation by the myeloid zinc finger gene, MZF-1. Hromas R, et al. **Curr Top Microbiol Immunol** 1996;211:159–64 (15 ref.)

Terminal myeloid gene expression and differentiation requires the transcription factor PU.1. Simon MC, et al. **Curr Top Microbiol Immunol** 1996;211:113–9 (26 ref.)

Function of PU.1 (Spi-1), C/EBP, and AML1 in early myelopoiesis: regulation of multiple myeloid CSF receptor

promoters. Zhang DE, et al.
Curr Top Microbiol Immunol 1996;211:137–47 (61 ref.)
The Jak–STAT pathway: specific signal transduction from the cell membrane to the nucleus. Heim MH.
Eur J Clin Invest 1996 Jan;26(1):1–12 (133 ref.)
The role of CcpA transcriptional regulator in carbon metabolism in Bacillus subtilis. Henkin TM.
FEMS Microbiol Lett 1996 Jan 1;135(1):9–15 (35 ref.)
NF–Y, IRF–2, and C/EBP proteins are involved in regulation of human IL–4 gene expression. Li–Weber M, et al. **Immunobiology** 1995 Jul;193(2–4):263–7 (9 ref.)
The inducible transcription factor NF–AT plays an important role in the activation of the murine interleukin–4 promoter. Schneider G, et al. **Immunobiology** 1995 Jul; 193(2–4):268–72 (14 ref.)
BSAP: a key regulator of B–cell development and differentiation. Neurath MF, et al. **Immunol Today** 1995 Dec;16(12):564–9 (22 ref.)
Control of adipocyte differentiation by CCAAT/enhancer binding protein alpha (C/EBP alpha). Lane MD, et al.
Int J Obes Relat Metab Disord 1996 Mar;20 Suppl 3:S91–6 (16 ref.)
Regulation of the interferon system and cell growth by the IRF transcription factors. Taniguchi T, et al.
J Cancer Res Clin Oncol 1995;121(9–10):516–20 (34 ref.)
The role of early growth response gene 1 (egr–1) in regulation of the immune response. McMahon SB, et al.
J Leukoc Biol 1996 Aug;60(2):159–66 (101 ref.)
The role of transcription factors in the pituitary expression of the glycoprotein hormone alpha–subunit gene. Aylwin SJ, et al. **J Mol Endocrinol** 1995 Dec;15(3):221–31 (82 ref.)
Chicken ovalbumin upstream promoter–transcription factors and their regulation. Qiu Y, et al.
J Steroid Biochem Mol Biol 1996 Jan;56(1–6 Spec No):81–5 (30 ref.)
Enhancement of nuclear receptor transcriptional signalling. Renkawitz R, et al. **J Steroid Biochem Mol Biol** 1996 Jan; 56(1–6 Spec No):39–45 (29 ref.)
Identification and characterization of transcriptional regulatory elements of the human aromatase cytochrome P450 gene (CYP19). Toda K, et al.
J Steroid Biochem Mol Biol 1996 Jan;56(1–6 Spec No):151–9 (22 ref.)
Immunophilins and the nervous system. Snyder SH, et al. **Nat Med** 1995 Jan;1(1):32–7 (82 ref.)
Cellular functions of immunophilins. Marks AR.
Physiol Rev 1996 Jul;76(3):631–49 (161 ref.)
Metamorphosis in Drosophila: from molecular biology to mutants. Bender M. **Trends Genet** 1995 Sep;11(9):335–6 (21 ref.)
cAMP–dependent regulation of gene transcription by cAMP response element–binding protein and cAMP response element modulator. Habener JF, et al. **Vitam Horm** 1995; 51:1–57 (196 ref.)

DNA, CIRCULAR

GENETICS

The structure and replication of kinetoplast DNA. Shapiro TA, et al. **Annu Rev Microbiol** 1995;49:117–43 (126 ref.)

DNA, COMPLEMENTARY

Interpreting cDNA sequences: some insights from studies on translation. Kozak M. **Mamm Genome** 1996 Aug; 7(8):563–74 (258 ref.)

ANALYSIS

Large–scale complementary DNA sequencing methods. Fulton LL, et al. **Methods Cell Biol** 1995;48:571–82 (10 ref.)

BIOSYNTHESIS

[Molecular mechanisms of directing biosynthesis of nucleic acids. Theoretical study of complementary base pair recognition by DNA polymerases] Poltev VI, et al.
Mol Biol (Mosk) 1995 Sep–Oct;29(5):1011–22 (28 ref.) **(Rus)**

CHEMISTRY

Cloning and functional characterization of extracellular Ca(2+)–sensing receptors from parathyroid and kidney. Brown EM, et al. **Bone** 1995 Aug;17(2 Suppl):7S–11S (30 ref.)
Toward a more complete molecular description of the osteoclast. Horne WC. **Bone** 1995 Aug;17(2):107–9 (14 ref.)

GENETICS

cDNA selection and other approaches in positional cloning. Parimoo S, et al. **Anal Biochem** 1995 Jun 10;228(1):1–17 (202 ref.)
Revolutions in rapid amplification of cDNA ends: new strategies for polymerase chain reaction cloning of full–length cDNA ends. Schaefer BC. **Anal Biochem** 1995 May 20;227(2):255–73 (79 ref.)
Gene expression and vascular smooth muscle cell phenotype. Weissberg PL, et al. **Blood Press Suppl** 1995;2:68–73 (19 ref.)
Retrohoming: cDNA–mediated mobility of group II introns requires a catalytic RNA. Curcio MJ, et al. **Cell** 1996 Jan 12;84(1):9–12 (15 ref.)
[Hypermethylation and inactivity of hepatitis C virus cDNA transgene in transgenic mice] Kato T, et al.
Nippon Rinsho 1995 Sep;53 Suppl:95–9 (16 ref.) **(Jpn)**
[Cloning of the holocarboxylase synthetase cDNA and identification of mutations prevalent in Japanese HCS–deficient patients] Narisawa K, et al.
Nippon Rinsho 1996 Jan;54(1):259–67 (14 ref.) (Eng. Abstr.) **(Jpn)**

DNA CYTOSINE–5–METHYLASE see **DNA (CYTOSINE–5–)–METHYLTRANSFERASE**

DNA (CYTOSINE–5–)–METHYLTRANSFERASE

METABOLISM

DNA methylation and activity of the maize Spm transposable element. Fedoroff NV. **Curr Top Microbiol Immunol** 1995; 197:143–64 (54 ref.)
DNA methylation and polyamines in embryonic development and cancer. Heby O. **Int J Dev Biol** 1995 Oct;39(5):737–57 (169 ref.)

PHYSIOLOGY

Alterations in DNA methylation may play a variety of roles in carcinogenesis. Counts JL, et al. **Cell** 1995 Oct 6; 83(1):13–5 (18 ref.)

DNA DAMAGE

DNA lesion–recognizing proteins and the p53 connection. Boulikas T. **Anticancer Res** 1996 Jan–Feb;16(1):225–42 (187 ref.)
DNA damage in folate deficiency. Blount BC, et al.
Baillieres Clin Haematol 1995 Sep;8(3):461–78 (75 ref.)
Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer. Wiseman H, et al. **Biochem J** 1996 Jan 1;313 (Pt 1):17–29 (213 ref.)
Mitochondrial damage as a source of diseases and aging: a strategy of how to fight these. Zorov DB.
Biochim Biophys Acta 1996 Jul 18;1275(1–2):10–5 (48 ref.)
NAD and poly(ADP–ribose) regulation of proteins involved in response to cellular stress and DNA damage. Berger NA, et al. **Biochimie** 1995;77(5):364–7 (16 ref.)
Role of poly(ADP–ribose) polymerase in cell–cycle checkpoint mechanisms following gamma–irradiation. Masutani M, et al. **Biochimie** 1995;77(6):462–5 (24 ref.)
Progress in identifying clinical relevance of inhibition, stimulation and measurements of poly ADP–ribosylation. Pero RW, et al. **Biochimie** 1995;77(5):385–93 (45 ref.)
Tumour suppressors, kinases and clamps: how p53 regulates the cell cycle in response to DNA damage. Cox LS, et al. **Bioessays** 1995 Jun;17(6):501–8 (98 ref.)
Alkylation of DNA and its aftermath. Lawley PD.
Bioessays 1995 Jun;17(6):561–8 (54 ref.)
Stopped for repairs. Sanchez Y, et al. **Bioessays** 1995 Jun; 17(6):545–8 (27 ref.)
Ataxia–telangiectasia and cellular responses to DNA damage. Meyn MS. **Cancer Res** 1995 Dec 15;55(24):5991–6001 (148 ref.)
Interaction of bulky chemical carcinogens with DNA in chromatin. MacLeod MC. **Carcinogenesis** 1995 Sep; 16(9):2009–14 (90 ref.)
DNA damage responses: p53 induction, cell cycle perturbations, and apoptosis. Canman CE, et al.
Cold Spring Harb Symp Quant Biol 1994;59:277–86 (53 ref.)
Endogenous formation of nitrosamines and oxidative DNA–damaging agents in tobacco users. Nair J, et al.
Crit Rev Toxicol 1996;26(2):149–61 (55 ref.)
Models of initiation of replicative senescence by loss of telomeric DNA. Allsopp RC. **Exp Gerontol** 1996 Jan–Apr; 31(1–2):235–43 (47 ref.)
The role of DNA damage in cellular aging: is it time for a reassessment? Norwood TH, et al. **Exp Gerontol** 1996 Jan–Apr;31(1–2):61–8 (68 ref.)
From telomere loss to p53 induction and activation of a DNA–damage pathway at senescence: the telomere loss/DNA damage model of cell aging. Vaziri H, et al. **Exp Gerontol** 1996 Jan–Apr;31(1–2):295–301 (42 ref.)
Regulation of the cell cycle following DNA damage in normal and Ataxia telangiectasia cells. Lohrer HD.
Experientia 1996 Apr 15;52(4):316–28 (186 ref.)
UV and nucleic acids. Douki T, et al. **EXS** 1995;73:173–97 (126 ref.)
DNA damage and cell cycle checkpoints. Kaufmann WK, et al. **FASEB J** 1996 Feb;10(2):238–47 (44 ref.)
A prediction of chromium(III) accumulation in humans from chromium dietary supplements. Stearns DM, et al.
FASEB J 1995 Dec;9(15):1650–7 (49 ref.)
Late effects of treatment for Wilms tumor. Green DM, et al. **Hematol Oncol Clin North Am** 1995 Dec;9(6):1317–27 (83 ref.)
Recognition and processing of damaged DNA. Lindahl T. **J Cell Sci Suppl** 1995;19:73–7 (33 ref.)
Proteolysis and the biochemistry of life–or–death decisions [comment] Ashkenas J, et al. **J Exp Med** 1996 May 1; 183(5):1947–51 (34 ref.) Comment on: J Exp Med 1996 May 1;183(5):1957–64.
Apoptosis overview emphasizing the role of oxidative stress, DNA damage and signal–transduction pathways. Payne CM, et al. **Leuk Lymphoma** 1995 Sep;19(1–2):43–93 (720 ref.)
Metallobleomycin–DNA interactions: structures and reactions related to bleomycin–induced DNA damage. Petering DH, et al. **Met Ions Biol Syst** 1996;33:619–48 (92 ref.)
Collapse and repair of replication forks in Escherichia coli. Kuzminov A. **Mol Microbiol** 1995 May;16(3):373–84 (102 ref.)
Antioxidant defences against reactive oxygen species causing genetic and other damage. Anderson D. **Mutat Res** 1996 Feb 19;350(1):103–8 (46 ref.)
Genetic toxicology of four commonly used benzodiazepines: a review. Giri AK, et al. **Mutat Res** 1996 Jun; 340(2–3):93–108 (100 ref.)
Repair of ionizing–radiation damage in the radiation resistant bacterium Deinococcus radiodurans. Minton KW.
Mutat Res 1996 May 15;363(1):1–7 (34 ref.)
DNA damage and mutagenesis by radiomimetic DNA–cleaving agents: bleomycin, neocarzinostatin and other enediynes. Povirk LF. **Mutat Res** 1996 Aug 17; 355(1–2):71–89 (125 ref.)
Cell cycle arrest in response to DNA damage: lessons from yeast. Siede W. **Mutat Res** 1995 Sep;337(2):73–84 (100 ref.)
Mammalian DNA damage–inducible genes associated with growth arrest and apoptosis. Smith ML, et al.
Mutat Res 1996 Jun;340(2–3):109–24 (143 ref.)
DNA damage and repair in mutagenesis and carcinogenesis: implications of structure–activity relationships for cross–species extrapolation. Vogel EW, et al.
Mutat Res 1996 Jun 12;353(1–2):177–218 (125 ref.)
DNA damage, p53 and anticancer therapies. Milner J.
Nat Med 1995 Sep;1(9):879–80 (8 ref.)
Role of reactive intermediates in tumor promotion and progression. Kensler T, et al. **Prog Clin Biol Res** 1995; 391:103–16 (51 ref.)
Poly(ADP–ribosyl)ation as a fail–safe, transcription–independent, suicide mechanism in acutely DNA–damaged cells: a hypothesis. Nagele A.
Radiat Environ Biophys 1995 Nov;34(4):251–4 (36 ref.)
DNA damage: chemistry, repair, and mutagenic potential. Singer B. **Regul Toxicol Pharmacol** 1996 Feb;23(1 Pt 1):2–13 (43 ref.)
DNA damage profiles induced by oxidizing agents. Epe B. **Rev Physiol Biochem Pharmacol** 1996;127:223–49 (160 ref.)
p53: DNA damage, DNA repair, and apoptosis. Götz C, et al. **Rev Physiol Biochem Pharmacol** 1996;127:65–95 (230 ref.)
Cell cycle checkpoints and repair of ionizing radiation damage. Liu VF, et al. **Stem Cells (Dayt)** 1995 May;13 Suppl 1:117–28 (93 ref.)
The single cell gel electrophoresis/comet assay: a potential tool for detecting radiation–induced DNA damage in humans. Tice RR, et al. **Stem Cells (Dayt)** 1995 May;13 Suppl 1:207–14 (12 ref.)
Cellular responses to DNA damage: cell–cycle checkpoints, apoptosis and the roles of p53 and ATM. Enoch T, et al.
Trends Biochem Sci 1995 Oct;20(10):426–30 (45 ref.)
Post–translational modification of poly(ADP–ribose) polymerase induced by DNA strand breaks. Lindahl T, et al. **Trends Biochem Sci** 1995 Oct;20(10):405–11 (46 ref.)
Homologous recombination and the roles of double–strand breaks. Shinohara A, et al. **Trends Biochem Sci** 1995 Oct; 20(10):387–91 (32 ref.)
[TUNEL method rarely revealed DNA fragmentation in chronic hepatitis C] Tanaka Y. **Nippon Rinsho** 1995 Sep; 53 Suppl:192–7 (17 ref.) **(Jpn)**
[DNA lesions produced by active oxygen and their induced mutations] Kamiya H, et al.
Tanpakushitsu Kakusan Koso 1994 Jul;40(10):1571–7 (36 ref.) **(Jpn)**
[Quantitative analysis of oxidative base damage in DNA] Zastawny TH. **Postepy Hig Med Dosw** 1995;49(5):609–30 (74 ref.) (Eng. Abstr.) **(Pol)**

DRUG EFFECTS

Implications of arsenic genotoxicity for dose response of carcinogenic effects. Rudel R, et al.
Regul Toxicol Pharmacol 1996 Apr;23(2):87–105 (55 ref.)

GENETICS

Identification of mismatch repair genes and their role in the development of cancer. Fishel R, et al.
Curr Opin Genet Dev 1995 Jun;5(3):382–95 (158 ref.)
DNA damage, mutation and fine structure DNA repair in aging. Bohr VA, et al. **Mutat Res** 1995 Oct;338(1–6):25–34 (100 ref.)

PHYSIOLOGY

Mechanisms for the prevention of damage to DNA in spores of Bacillus species. Setlow P. **Annu Rev Microbiol** 1995; 49:29–54 (91 ref.)
[Interactions of proteins with damaged DNA] Widlak P.
Postepy Biochem 1995;41(3):195–200 (71 ref.) **(Pol)**

RADIATION EFFECTS

Radiation physics and radiobiology. Rossi HH.
Health Phys 1996 Jun;70(6):828–31 (7 ref.)

DNA DAMAGE

Relationship between DNA damage, rejoining and cell killing by radiation in mammalian cells. Núñez MI, et al. **Radiother Oncol** 1996 May;39(2):155–65 (102 ref.)

DNA-DEPENDENT DNA POLYMERASE III see DNA POLYMERASE III

DNA-DEPENDENT DNA POLYMERASES see DNA POLYMERASES

DNA-DEPENDENT RNA POLYMERASE I see RNA POLYMERASE I

DNA-DEPENDENT RNA POLYMERASE II see RNA POLYMERASE II

DNA-DEPENDENT RNA POLYMERASE III see RNA POLYMERASE III

DNA-DEPENDENT RNA POLYMERASES see RNA POLYMERASES

DNA, DOUBLE-STRANDED see DNA

DNA FINGERPRINTING

Statistical and genetic aspects of quality control for DNA identification. Morton NE, et al. **Electrophoresis** 1995 Sep; 16(9):1670–7 (30 ref.)

Epidemiology of tuberculosis by DNA fingerprinting. van Soolingen D, et al. **Eur Respir J Suppl** 1995 Sep; 20:649s–656s (58 ref.)

Generation of DNA probes for detection of microorganisms by polymerase chain reaction fingerprinting [editorial] Giesendorf BA, et al. **Zentralbl Bakteriol** 1996 Apr; 283(4):417–30 (47 ref.)

[AP-PCR genomic fingerprinting] Kohno T, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):629–32 (3 ref.) **(Jpn)**

METHODS

Repetitive sequence fingerprinting in the long range mapping of mammalian genomes. Hamvas RM, et al. **Electrophoresis** 1995 Sep;16(9):1602–6 (64 ref.)

DNA fingerprinting by hybridisation to oligonucleotide arrays. Southern EM. **Electrophoresis** 1995 Sep; 16(9):1539–42 (14 ref.)

Nucleic acid fingerprinting by PCR-based methods: applications to problems in aging and mutagenesis. Welsh J, et al. **Mutat Res** 1995 Oct;338(1–6):215–29 (72 ref.)

DNA fingerprinting and forensic medicine. Boonsaeng V. **Southeast Asian J Trop Med Public Health** 1995;26 Suppl 1:296–300 (26 ref.)

VETERINARY

[DNA fingerprinting in wild equid and Poitou ass breeding] Werner P, et al. **Schweiz Arch Tierheilkd** 1995;137(8):395–7 (10 ref.) **(Ger)**

DNA FOOTPRINTING

METHODS

In vivo footprinting of protein–DNA interactions. Paul AL, et al. **Methods Cell Biol** 1995;49:391–400 (14 ref.)

DNA, FUNGAL

ANALYSIS

Molecular genetic approaches to identification, epidemiology and taxonomy of non-albicans Candida species. Sullivan DJ, et al. **J Med Microbiol** 1996 Jun;44(6):399–408 (109 ref.)

CHEMISTRY

The elusive centromere: sequence divergence and functional conservation. Sunkel CE, et al. **Curr Opin Genet Dev** 1995 Dec;5(6):756–67 (68 ref.)

GENETICS

Molecular genetic technology transfer to pathogenic fungi. Goldman WE. **Arch Med Res** 1995 Winter;26(4):437–40 (14 ref.)

MIP: an epigenetic gene silencing process in Ascobolus immersus. Rossignol JL, et al. **Curr Top Microbiol Immunol** 1995;197:179–91 (32 ref.)

Genetic and epigenetic inactivation of repetitive sequences in Neurospora crassa: RIP, DNA methylation, and quelling. Singer MJ, et al. **Curr Top Microbiol Immunol** 1995; 197:165–77 (54 ref.)

Natural plasmids of filamentous fungi. Griffiths AJ. **Microbiol Rev** 1995 Dec;59(4):673–85 (102 ref.)

METABOLISM

Stepwise assembly of initiation complexes at budding yeast replication origins during the cell cycle. Diffley JF, et al. **J Cell Sci Suppl** 1995;19:67–72 (25 ref.)

A heterodimeric transcriptional repressor becomes crystal clear [comment] Andrews BJ, et al. **Science** 1995 Oct 13; 270(5234):251–3 (18 ref.) Comment on: Science 1995 Oct 13;270(5234):262–9. Comment on: Science 1995 Oct 13;270(5234):262–9. Comment on: Science 1995 Oct 13;270(5234):290–3.

ULTRASTRUCTURE

DNA structure checkpoints in fission yeast. Carr AM. **Semin Cell Biol** 1995 Apr;6(2):65–72 (33 ref.)

DNA-GYRASE see DNA TOPOISOMERASE (ATP-HYDROLYSING)

DNA HELICASES

METABOLISM

Relaxing and unwinding on Holliday: DNA helicase-mediated branch migration. Adams DE, et al. **Mutat Res** 1995 Nov;337(3):149–59 (70 ref.)

PHYSIOLOGY

DNA helicases: new breeds of translocating motors and molecular pumps. West SC. **Cell** 1996 Jul 26;86(2):177–80 (13 ref.)

DNA HELIX DESTABILIZING PROTEINS see DNA-BINDING PROTEINS

DNA, HELMINTH

GENETICS

[Large scale analysis of C. elegans cDNA] Kohara Y. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):715–20 (6 ref.) **(Jpn)**

DNA INJURY see DNA DAMAGE

DNA INSERTION ELEMENTS

see related
DNA, RECOMBINANT
MUTAGENESIS, INSERTIONAL
PLASMIDS

Evolutionary aspects, and taxonomic definition of viruses together with mobile extrachromosomal elements of relative autonomy into a special highest rank taxon (a review). Berencsi G, et al. **Acta Microbiol Immunol Hung** 1995;42(2):141–53 (154 ref.)

Molecular cytogenetic studies of duplication 9q32-->q34.3 inserted into 9q13. Hou JW, et al. **Clin Genet** 1995 Sep; 48(3):148–50 (9 ref.)

Genomic regulation of transposable elements in Drosophila. Lozovskaya ER, et al. **Curr Opin Genet Dev** 1995 Dec; 5(6):768–73 (37 ref.)

LTR-retrotransposons and MITEs: important players in the evolution of plant genomes. Wessler SR, et al. **Curr Opin Genet Dev** 1995 Dec;5(6):814–21 (65 ref.)

The Mutator transposable element system of maize. Bennetzen JL. **Curr Top Microbiol Immunol** 1996; 204:195–229 (134 ref.)

Transposon Tn7. Craig NL. **Curr Top Microbiol Immunol** 1996;204:27–48 (66 ref.)

P elements in Drosophila. Engels WR. **Curr Top Microbiol Immunol** 1996;204:103–23 (134 ref.)

The En/Spm transposable element of maize. Gierl A. **Curr Top Microbiol Immunol** 1996;204:145–59 (57 ref.)

Tn10 and IS10 transposition and chromosome rearrangements: mechanism and regulation in vivo and in vitro. Kleckner N, et al. **Curr Top Microbiol Immunol** 1996; 204:49–82 (96 ref.)

The maize transposable element activator (Ac). Kunze R. **Curr Top Microbiol Immunol** 1996;204:161–94 (195 ref.)

Transposition of phage Mu DNA. Lavoie BD, et al. **Curr Top Microbiol Immunol** 1996;204:83–102 (89 ref.)

Bacterial insertion sequences. Ohtsubo F, et al. **Curr Top Microbiol Immunol** 1996;204:1–26 (160 ref.)

The Tc1/mariner transposon family. Plasterk RH. **Curr Top Microbiol Immunol** 1996;204:125–43 (98 ref.)

The conjugative transposon Tn916 of Enterococcus faecalis: structural analysis and some key factors involved in movement. Clewell DB, et al. **Dev Biol Stand** 1995;85:11–7 (28 ref.)

In the driver's seat: the Bacteroides conjugative transposons and the elements they mobilize. Salyers AA, et al. **J Bacteriol** 1995 Oct;177(20):5727–31 (22 ref.)

Gene cassettes: a new class of mobile element. Recchia GD, et al. **Microbiology** 1995 Dec;141 (Pt 12):3015–27 (43 ref.)

Cases of ancient mobile element DNA insertions that now affect gene regulation. Britten RJ. **Mol Phylogenet Evol** 1996 Feb;5(1):13–7 (32 ref.)

DNA sequence insertion and evolutionary variation in gene regulation. Britten RJ. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9374–7 (41 ref.)

Gene disruptions using P transposable elements: an integral component of the Drosophila genome project. Spradling AC, et al. **Proc Natl Acad Sci U S A** 1995 Nov 21; 92(24):10824–30 (38 ref.)

Medfly transformed--official! [comment] Ashburner M. **Science** 1995 Dec 22;270(5244):1941–2 (11 ref.) Comment on: Science 1995 Dec 22;270(5244):2002–5. Comment on: Science 1995 Dec 22;270(5244):2005–8.

Unity in transposition reactions. Craig NL. **Science** 1995 Oct 13;270(5234):253–4 (22 ref.)

[Study on Pseudomonas transposons and molecular genetic analysis of Pseudomonas by use of transposons] Tsuda M. **Nippon Saikingaku Zasshi** 1995 Oct;50(4):947–59 (58 ref.) **(Jpn)**

GENETICS

Conjugative transposition. Scott JR, et al. **Annu Rev Microbiol** 1995;49:367–97 (108 ref.)

DNA methylation and activity of the maize Spm transposable element. Fedoroff NV. **Curr Top Microbiol Immunol** 1995; 197:143–64 (54 ref.)

Mobile genetic elements in mycobacteria. Dale JW. **Eur Respir J Suppl** 1995 Sep;20:633s–648s (100 ref.)

PHYSIOLOGY

Quality control in Mu DNA transposition [comment] Craigie R. **Cell** 1996 Apr 19;85(2):137–40 (11 ref.) Comment on: Cell 1996 Apr 19;85(2):257–69. Comment on: Cell 1996 Apr 19;85(2):271–80.

DNA transposition: from a black box to a color monitor. Grindley ND, et al. **Cell** 1995 Dec 29;83(7):1063–6 (25 ref.)

Conjugative transposons: an unusual and diverse set of integrated gene transfer elements. Salyers AA, et al. **Microbiol Rev** 1995 Dec;59(4):579–90 (86 ref.)

DNA JOINASES see POLYDEOXYRIBONUCLEOTIDE SYNTHETASES

DNA LIGASES see POLYDEOXYRIBONUCLEOTIDE SYNTHETASES

DNA MARKERS see GENETIC MARKERS

DNA MIMICRY see MOLECULAR MIMICRY

DNA, MITOCHONDRIAL

Mitochondrial DNA: molecular fossils in the nucleus. Perna NT, et al. **Curr Biol** 1996 Feb 1;6(2):128–9 (13 ref.)

[8-Oxoguanine repair system and its role in mitochondria] Kang D, et al. **Seikagaku** 1996 Apr;68(4):289–95 (22 ref.) **(Jpn)**

ANALYSIS

Mitochondrial disorders. Methods and specimen selection for diagnostic molecular pathology. Kiechle FL, et al. **Arch Pathol Lab Med** 1996 Jun;120(6):597–603 (89 ref.)

GENETICS

Mitochondrial genome mutations and kidney disease. Singh PJ, et al. **Am J Kidney Dis** 1996 Jul;28(1):140–6 (47 ref.)

The structure and replication of kinetoplast DNA. Shapiro TA, et al. **Annu Rev Microbiol** 1995;49:117–43 (126 ref.)

Germ-line therapy to cure mitochondrial disease: protocol and ethics of in vitro ovum nuclear transplantation. Rubenstein DS, et al. **Camb Q Healthc Ethics** 1995 Summer; 4(3):316–39 (101 ref.)

Mitochondrial transcription initiation: promoter structures and RNA polymerases. Tracy RL, et al. **Curr Genet** 1995 Aug;28(3):205–16 (103 ref.)

Maternally inherited diabetes and deafness: a new diabetes subtype. Maassen JA, et al. **Diabetologia** 1996 Apr; 39(4):375–82 (53 ref.)

Clinical presentations and laboratory investigations in respiratory chain deficiency. Munnich A, et al. **Eur J Pediatr** 1996 Apr;155(4):262–74 (28 ref.)

Degeneration of human oncogenes and mitochondrial genes occurs in cells that exhibit age-related pathology. Cortopassi G, et al. **Exp Gerontol** 1996 Jan-Apr; 31(1–2):253–65 (43 ref.)

Mitochondrial DNA mutations associated with aging and degenerative diseases. Ozawa T. **Exp Gerontol** 1995 May-Aug;30(3–4):269–90 (55 ref.)

Sexuality of mitochondria: fusion, recombination, and plasmids. Kawano S, et al. **Int Rev Cytol** 1995;161:49–110 (179 ref.)

Mitochondrial medicine. Luft R, et al. **J Intern Med** 1995 Nov;238(5):405–21 (119 ref.)

Genotypic selection of mitochondrial and oncogenic mutations in human tissue suggests mechanisms of age-related pathophysiology. Cortopassi G, et al. **Mutat Res** 1995 Oct;338(1–6):151–9 (43 ref.)

Human aging is associated with stochastic somatic mutations of mitochondrial DNA. Kadenbach B, et al. **Mutat Res** 1995 Oct;338(1–6):161–72 (112 ref.)

Update in molecular genetics: mitochondrial energy transduction disorders. Marzuki S, et al. **Southeast Asian J Trop Med Public Health** 1995;26 Suppl 1:155–61 (37 ref.)

[Mitochondrial gene and diabetes] Xiang K, et al. **Chung Hua Nei Ko Tsa Chih** 1995 Sep;34(9):638–40 (20 ref.) **(Chi)**

[Mitochondrial gene abnormalities and diabetes mellitus] Kagawa Y. **Nippon Naika Gakkai Zasshi** 1995 Oct 10; 84(10):1749–54 (21 ref.) **(Jpn)**

[The analysis of maternal inheritance of mitochondrial DNA in mammal] Kaneda H, et al. **Seikagaku** 1996 Apr;

68(4):282–5 (14 ref.) **(Jpn)**

[Origin of modern humans revealed by complete sequences of hominoid mitochondrial DNAs] Horai S. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):727–32 (20 ref.) **(Jpn)**

[Mitochondrial introns of fungi and their role in evolution] Shnyreva AV. **Genetika** 1995 Jul;31(7):869–76 (46 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Mitochondrial damage as a source of diseases and aging: a strategy of how to fight these. Zorov DB. **Biochim Biophys Acta** 1996 Jul 18;1275(1–2):10–5 (48 ref.)

DNA MUTATIONAL ANALYSIS

see related
POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL

The use of null mutant mice to study complex learning and memory processes. Wehner JM, et al. **Behav Genet** 1996 May;26(3):301–12 (75 ref.)

Motor neuron disease caused by mutations in superoxide dismutase 1. Wong PC, et al. **Curr Opin Neurol** 1995 Aug; 8(4):294–301 (77 ref.)

Dynamic mutations and psychiatric genetics [editorial] O'Donovan MC, et al. **Psychol Med** 1996 Jan;26(1):1–6 (30 ref.)

Mutations affecting human lipoprotein lipase gene. Antikainen M, et al. **Z Gastroenterol** 1996 Jun;34 Suppl 3:59–61 (20 ref.)

METHODS

Applications of heteroduplex analysis for mutation detection in disease genes. Glavac D, et al. **Hum Mutat** 1995; 6(4):281–7 (75 ref.)

Single-cell analysis of unstable genes. Daniels R, et al. **J Assist Reprod Genet** 1996 Feb;13(2):163–9 (28 ref.)

Fluorescent PCR: a new technique for PGD of sex and single-gene defects. Findlay I, et al. **J Assist Reprod Genet** 1996 Feb;13(2):96–103 (28 ref.)

DNA, NEOPLASM

Studies on the expression of T-(Gal beta (1–3) GalNAc alpha 1–O–R) and T-like antigens in normal and pathologic human and rat urothelium. Langkilde NC. **Scand J Urol Nephrol Suppl** 1995;176:7–46 (188 ref.)

ANALYSIS

Detection of minimal residual disease in hematopoietic tissues. Sharp JG, et al. **Ann N Y Acad Sci** 1995 Dec 29; 770:242–61 (89 ref.)

Immunophenotype and DNA cell content in multiple myeloma. San Miguel JF, et al. **Baillieres Clin Haematol** 1995 Dec;8(4):735–59 (102 ref.)

Primary intratesticular sarcoma. Immunohistochemical ultrastructural and DNA flow cytometric study of three cases with a review of the literature. Washecka RM, et al. **Cancer** 1996 Apr 15;77(8):1524–8 (26 ref.)

Nephrogenic adenoma of the bladder in renal transplant recipients: a report of 9 cases with assessment of deoxyribonucleic acid ploidy and long-term followup. Fournier G, et al. **J Urol** 1996 Jul;156(1):41–4 (21 ref.)

Primary pulmonary rhabdomyosarcoma in childhood: clinico-biologic features in two cases with review of the literature. Schiavetti A, et al. **Med Pediatr Oncol** 1996 Mar; 26(3):201–7 (26 ref.)

The value of cytometric DNA analysis as a prognostic tool in neuroendocrine neoplastic diseases. Falkmer UG, et al. **Pathol Res Pract** 1995 May;191(4):281–303 (121 ref.)

[Genetic alterations and DNA-based diagnosis in breast cancer] Matsumoto S, et al. **Nippon Geka Gakkai Zasshi** 1996 May;97(5):375–80 (30 ref.) (Eng. Abstr.) **(Jpn)**

[Use of morphometry and DNA flow cytometry in the differential diagnosis, prognosis and treatment of primary tumors of the liver (review of the literature)] Pimenova EL, et al. **Klin Lab Diagn** 1996 Mar–Apr;(2):7–11 (47 ref.) **(Rus)**

DRUG EFFECTS

Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Plunkett W, et al. **Semin Oncol** 1995 Aug; 22(4 Suppl 11):3–10 (26 ref.)

GENETICS

Molecular cytogenetic quantitation of gains and losses of genetic material from human gliomas. Feuerstein BG, et al. **J Neurooncol** 1995;24(1):47–55 (23 ref.)

Clinical application of flow cytometry to urological malignancies. Tachibana M. **Keio J Med** 1996 Jun; 45(2):73–80 (54 ref.)

Detection of chromosomal translocations in leukemia–lymphoma cells by polymerase chain reaction. Drexler HG, et al. **Leuk Lymphoma** 1995 Nov; 19(5–6):359–80 (278 ref.)

Molecular genetics of hereditary non-polyposis colorectal cancer (HNPCC). Cama A, et al. **Tumori** 1996 Mar–Apr; 82(2):122–35 (107 ref.)

[Detection of RET-proto-oncogene mutations in the diagnosis of Type 2 endocrine neoplasia (MEN 2)] Komminoth P, et al. **Schweiz Med Wochenschr** 1996 Aug 6;126(31–32):1329–38 (57 ref.) (Eng. Abstr.) **(Ger)**

[Familial colorectal and breast carcinoma—genetic counseling and presymptomatic diagnosis] Müller H, et al. **Ther Umsch** 1995 Dec;52(12):826–34 (55 ref.) (Eng. Abstr.) **(Ger)**

[Familial cancer and oncogenic factors] Ohmori M, et al. **Gan To Kagaku Ryoho** 1996 Mar;23(4):395–400 (31 ref.) (Eng. Abstr.) **(Jpn)**

[Representational difference analysis: identification of the differences between genomes] Aburatani H, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):573–9 (11 ref.) **(Jpn)**

[Detection of DNA aberrations in human cancers by AP-PCR-SSCP analysis] Okano A, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):633–7 (12 ref.) **(Jpn)**

[Molecular diagnosis of cancer by non-radioisotopic PCR/SSCP analysis] Sugano K. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):638–42 (8 ref.) **(Jpn)**

IMMUNOLOGY

Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Van Pel A, et al. **Immunol Rev** 1995 Jun; 145:229–50 (92 ref.)

ISOLATION & PURIFICATION

[Methods of DNA extraction from cells obtained by cytological techniques] Ichikawa D, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):460–2 (4 ref.) **(Jpn)**

[AP-PCR genomic fingerprinting] Kohno T, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):629–32 (3 ref.) **(Jpn)**

METABOLISM

DNA methylation errors and cancer. Jones PA. **Cancer Res** 1996 Jun 1;56(11):2463–7 (60 ref.)

Genomic imprinting, DNA methylation, and cancer. Feinberg AP, et al. **J Natl Cancer Inst Monogr** 1995; (17):21–6 (83 ref.)

RADIATION EFFECTS

Relationship between DNA damage, rejoining and cell killing by radiation in mammalian cells. Núñez MI, et al. **Radiother Oncol** 1996 May;39(2):155–65 (102 ref.)

DNA NICKING-CLOSING PROTEIN see **DNA TOPOISOMERASE**

DNA NUCLEOTIDYLEXOTRANSFERASE

ANALYSIS

[Terminal deoxynucleotidyl transferase (TdT)] Sasaki R. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:186–9 (9 ref.) **(Jpn)**

DNA NUCLEOTIDYLTRANSFERASES

CHEMISTRY

Retroviral integrases and their cousins. Rice P, et al. **Curr Opin Struct Biol** 1996 Feb;6(1):76–83 (65 ref.)

Retroviral integrase, putting the pieces together. Andrake MD, et al. **J Biol Chem** 1996 Aug 16;271(33):19633–6 (59 ref.)

GENETICS

DNA-dependent protein kinase defects are linked to deficiencies in DNA repair and V(D)J recombination. Finnie NJ, et al. **Philos Trans R Soc Lond B Biol Sci** 1996 Feb 29;351(1336):173–9 (50 ref.)

METABOLISM

V(D)J recombination: double-strand break repair gene products used in the joining mechanism. Weaver D, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:99–111 (48 ref.)

HIV-1 virology. Simply Marvelous nuclear transport. Goldfarb DS. **Curr Biol** 1995 Jun 1;5(6):570–3 (19 ref.)

Recombination. Pieces of the site-specific recombination puzzle. Oram M, et al. **Curr Biol** 1995 Oct 1;5(10):1106–9 (20 ref.)

DNA PHOTOLYASE

METABOLISM

No "End of History" for photolyases [comment] Sancar A. **Science** 1996 Apr 5;272(5258):48–9 (14 ref.) Comment on: Science 1996 Apr 5;272(5258):109–12.

DNA PHOTOREACTIVATING ENZYME see **DNA PHOTOLYASE**

DNA, PLANT

The Mutator transposable element system of maize. Bennetzen JL. **Curr Top Microbiol Immunol** 1996; 204:195–229 (134 ref.)

The En/Spm transposable element of maize. Gierl A. **Curr Top Microbiol Immunol** 1996;204:145–59 (57 ref.)

The maize transposable element activator (Ac). Kunze R. **Curr Top Microbiol Immunol** 1996;204:161–94 (195 ref.)

CHEMISTRY

The G-box: a ubiquitous regulatory DNA element in plants bound by the GBF family of bZIP proteins. Menkens AE, et al. **Trends Biochem Sci** 1995 Dec;20(12):506–10 (39 ref.)

GENETICS

Suppression of flavonoid flower pigmentation genes in Petunia hybrida by the introduction of antisense and sense genes. de Lange P, et al. **Curr Top Microbiol Immunol** 1995; 197:57–75 (88 ref.)

DNA methylation and activity of the maize Spm transposable element. Fedoroff NV. **Curr Top Microbiol Immunol** 1995; 197:143–64 (54 ref.)

DNA methylation and transgene silencing in Petunia hybrida. Meyer P. **Curr Top Microbiol Immunol** 1995;197:15–28 (61 ref.)

METABOLISM

In vivo footprinting of protein-DNA interactions. Paul AL, et al. **Methods Cell Biol** 1995;49:391–400 (14 ref.)

DNA POLYMERASE GAMMA see **DNA POLYMERASE III**

DNA POLYMERASE, RNA-DIRECTED see **RNA-DIRECTED DNA POLYMERASE**

DNA POLYMERASE III

CHEMISTRY

DNA polymerase III holoenzyme: structure and function of a chromosomal replicating machine. Kelman Z, et al. **Annu Rev Biochem** 1995;64:171–200 (153 ref.)

Structural and functional similarities of prokaryotic and eukaryotic DNA polymerase sliding clamps. Kelman Z, et al. **Nucleic Acids Res** 1995 Sep 25;23(18):3613–20 (41 ref.)

METABOLISM

DNA polymerase III holoenzyme: structure and function of a chromosomal replicating machine. Kelman Z, et al. **Annu Rev Biochem** 1995;64:171–200 (153 ref.)

DNA polymerase III: running rings around the fork. Herendeen DR, et al. **Cell** 1996 Jan 12;84(1):5–8 (18 ref.)

DNA POLYMERASES

[Thermostable DNA Polymerases and PCR] Ishino Y. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):429–36 (42 ref.) **(Jpn)**

[TA cloning: a rapid and efficient method for cloning of the PCR products] Yasuda J. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):518–21 (7 ref.) **(Jpn)**

ANTAGONISTS & INHIBITORS

Nucleic acid chemistry of the cuprous complexes of 1,10-phenanthroline and derivatives. Sigman DS, et al. **Met Ions Biol Syst** 1996;33:485–513 (60 ref.)

BLOOD

[Hepatitis B virus-specific DNA polymerase activity as a sensitive marker of viral replication] Matsuura K, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:275–83 (19 ref.) **(Jpn)**

CHEMISTRY

A model for DNA polymerase translocation: worm-like movement of DNA within the binding cleft. Wlassoff WA, et al. **FEBS Lett** 1996 Jul 15;390(1):6–9 (37 ref.)

Polymerase structures and function: variations on a theme? Joyce CM, et al. **J Bacteriol** 1995 Nov;177(22):6321–9 (47 ref.)

What is the orientation of DNA polymerases on their templates? Hughes SH, et al. **J Virol** 1996 May; 70(5):2679–83 (34 ref.)

GENETICS

[Pre-symptomatic diagnosis of Huntington disease by polymerase chain reaction] Tóth T, et al. **Orv Hetil** 1996 Mar 3;137(9):451–4 (25 ref.) (Eng. Abstr.) **(Hun)**

METABOLISM

A model for DNA polymerase translocation: worm-like movement of DNA within the binding cleft. Wlassoff WA, et al. **FEBS Lett** 1996 Jul 15;390(1):6–9 (37 ref.)

What is the orientation of DNA polymerases on their templates? Hughes SH, et al. **J Virol** 1996 May; 70(5):2679–83 (34 ref.)

Metallocene interactions with DNA and DNA-processing

DNA POLYMERASES

enzymes. Kuo LY, et al. **Met Ions Biol Syst** 1996;33:53–85 (113 ref.)

[Molecular mechanisms of directing biosynthesis of nucleic acids. Theoretical study of complementary base pair recognition by DNA polymerases] Poltev VI, et al. **Mol Biol (Mosk)** 1995 Sep–Oct;29(5):1011–22 (28 ref.) **(Rus)**

PHYSIOLOGY

Relating structure to function in phi29 DNA polymerase. Blanco L, et al. **J Biol Chem** 1996 Apr 12;271(15):8509–12 (46 ref.)

DNA PRIMERS

[Method of determining optimal PCR primers] Mitsuhashi M. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):439–45 (8 ref.) **(Jpn)**

CHEMICAL SYNTHESIS

[Primer for PCR method, synthesis and purification] Kawase Y. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):446–52 (20 ref.) **(Jpn)**

ISOLATION & PURIFICATION

[Primer for PCR method, synthesis and purification] Kawase Y. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):446–52 (20 ref.) **(Jpn)**

DNA PROBES

Construction and application of human chromosomal specific DNA probe pools. Li L. **Chin Med J (Engl)** 1996 Feb; 109(2):112–3 (4 ref.)

Northern analysis and nucleic acid probes. Sabelli PA, et al. **Methods Mol Biol** 1995;49:213–28 (32 ref.)

Nucleic acid detection using non-radioactive labelling methods. Mansfield ES, et al. **Mol Cell Probes** 1995 Jun; 9(3):145–56 (44 ref.)

Generation of DNA probes for detection of microorganisms by polymerase chain reaction fingerprinting [editorial] Giesendorf BA, et al. **Zentralbl Bakteriol** 1996 Apr; 283(4):417–30 (47 ref.)

[Serum levels of HCV-RNA determined by branched DNA (bDNA) probe assay in chronic hepatitis C] Osada T, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:287–93 (13 ref.) **(Jpn)**

[Detection of Mycoplasma pneumoniae by using polymerase chain reaction and nonradioactive DNA probes] Yamashita K, et al. **Rinsho Byori** 1995 Dec;43(12):1251–5 (17 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSTIC USE

[Genetic methods of diagnosing tuberculosis] Krychniak-Soszka A. **Pneumonol Alergol Pol** 1996; 64(1–2):102–5 (32 ref.) **(Pol)**

DNA PROBES, HISTOCOMPATIBILITY ANTIGEN see **DNA PROBES, HLA**

DNA PROBES, HLA

[PCR-SSOP (sequence specific oligonucleotide probe) method] Yasunaga S, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):553–5 (3 ref.) **(Jpn)**

DNA, PROTOZOAN

ANALYSIS

[The utilization of molecular biological tools in the study of malaria transmission: example of programs conducted in Senegal] Fontenille D, et al. **Med Trop (Mars)** 1995;55(4 Suppl):52–5 (15 ref.) (Eng. Abstr.) **(Fre)**

CHEMISTRY

A glutathione reductase-like flavoenzyme of the malaria parasite Plasmodium falciparum: structural considerations based on the DNA sequence. Becker K, et al. **Biochem Soc Trans** 1996 Feb;24(1):67–72 (37 ref.)

GENETICS

The structure and replication of kinetoplast DNA. Shapiro TA, et al. **Annu Rev Microbiol** 1995;49:117–43 (126 ref.)

METABOLISM

Mitosis and genome partition in trypanosomes. Solari AJ. **Biocell** 1995 Aug;19(2):65–84 (77 ref.)

DNA REARRANGEMENT see **GENE REARRANGEMENT**

DNA, RECOMBINANT

see related
GENETIC ENGINEERING
GENETIC VECTORS

DNA immunization with bovine herpesvirus-1 genes. Babiuk LA, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:47–63 (56 ref.)

Adenovirus and adeno-associated virus as vectors for gene therapy. Berns KI, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:95–104 (48 ref.)

Obtaining marketing authorization for nucleic acid vaccines in the European Union. Cichutek K. **Ann N Y Acad Sci** 1995 Nov 27;772:178–85 (15 ref.)

Use of plasmid DNA for direct gene transfer and immunization. Davis HL, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:21–9 (29 ref.)

Assuring the safety and efficacy of DNA vaccines. Griffiths E. **Ann N Y Acad Sci** 1995 Nov 27;772:164–9 (10 ref.)

DNA vectors. Precedents and safety. Hilleman MR. **Ann N Y Acad Sci** 1995 Nov 27;772:1–14 (52 ref.)

Nucleic acid malaria vaccines. Current status and potential. Hoffman SL, et al. **Ann N Y Acad Sci** 1995 Nov 27; 772:88–94 (11 ref.)

Prospects for gene therapy with direct injection of polynucleotides. Kass-Eisler A, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:232–40 (33 ref.)

Overview of DNA vaccines. Liu MA. **Ann N Y Acad Sci** 1995 Nov 27;772:15–20 (28 ref.)

Regulatory issues in the use of DNA vaccines. Minor PD. **Ann N Y Acad Sci** 1995 Nov 27;772:170–7 (29 ref.)

Direct gene transfer for treatment of human cancer. Nabel GJ, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:227–31 (40 ref.)

A genetic approach to idiotypic vaccination for B cell lymphoma. Stevenson FK, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:212–26 (23 ref.)

DNA-mediated immunization to the hepatitis B surface antigen. Activation and entrainment of the immune response. Whalen RG, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:64–76 (31 ref.)

Recombinant technique and gonadotropins production: new era in reproductive medicine. Shoham Z, et al. **Fertil Steril** 1996 Aug;66(2):187–201 (137 ref.)

Regulation of Agrobacterium gene manipulation. Dewhurst F. **Methods Mol Biol** 1995;44:369–91 (33 ref.)

Chromosomal position effects and the modulation of transgene expression. Clark AJ, et al. **Reprod Fertil Dev** 1994;6(5):589–98 (49 ref.)

ADMINISTRATION & DOSAGE

Protective efficacy of intramuscular immunization with naked DNA. Donnelly JJ, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:40–6 (26 ref.)

Improved cationic lipid formulations for in vivo gene therapy. Felgner PL, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:126–39 (51 ref.)

ADVERSE EFFECTS

Risk potential of the chromosomal insertion of foreign DNA. Kurth R. **Ann N Y Acad Sci** 1995 Nov 27;772:140–51 (25 ref.)

GENETICS

Potential DNA vaccine integration into host cell genome. Nichols WW, et al. **Ann N Y Acad Sci** 1995 Nov 27; 772:30–9 (8 ref.)

Recent developments and perspectives of biotechnology-derived products. Thomas JA. **Toxicology** 1995 Dec 20;105(1):7–22 (31 ref.)

IMMUNOLOGY

Immunological properties of bacterial DNA. Pisetsky DS, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:152–63 (33 ref.)

THERAPEUTIC USE

Gene therapy for cystic fibrosis in humans by liposome-mediated DNA transfer: the production of resources and the regulatory process. Caplen NJ, et al. **Gene Ther** 1994 Mar;1(2):139–47 (21 ref.)

DNA RECOMBINANT PROTEINS see **RECOMBINANT PROTEINS**

DNA RELAXING ENZYME see **DNA TOPOISOMERASE**

DNA REPAIR

see related
PYRIMIDINE DIMERS

V(D)J recombination: double-strand break repair gene products used in the joining mechanism. Weaver D, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:99–111 (48 ref.)

DNA lesion-recognizing proteins and the p53 connection. Boulikas T. **Anticancer Res** 1996 Jan–Feb;16(1):225–42 (187 ref.)

Xeroderma pigmentosum and molecular cloning of DNA repair genes. Boulikas T. **Anticancer Res** 1996 Mar–Apr; 16(2):693–708 (161 ref.)

Mammalian nucleotide excision repair. Ma L, et al. **Biochim Biophys Acta** 1995 Dec 18;1242(2):137–63 (261 ref.)

Progress in identifying clinical relevance of inhibition, stimulation and measurements of poly ADP-ribosylation. Pero RW, et al. **Biochimie** 1995;77(5):385–93 (45 ref.)

Menage à trois: double strand break repair, V(D)J recombination and DNA-PK. Jeggo PA, et al. **Bioessays** 1995 Nov;17(11):949–57 (67 ref.)

Stopped for repairs. Sanchez Y, et al. **Bioessays** 1995 Jun; 17(6):545–8 (27 ref.)

Cisplatin. Dabholkar M, et al. **Cancer Chemother Biol Response Modif** 1996;16:88–110 (101 ref.)

Ataxia-telangiectasia and cellular responses to DNA damage. Meyn MS. **Cancer Res** 1995 Dec 15;55(24):5991–6001 (148 ref.)

Nucleotide excision repair: variations associated with cancer development and speciation. Cleaver JE, et al. **Cancer Surv** 1995;25:125–42 (76 ref.)

Enzyme structures. DNA repair flips out. Demple B. **Curr Biol** 1995 Jul 1;5(7):719–21 (11 ref.)

DNA repair. Nucleotide excision-repair in the test tube. Jaspers NG, et al. **Curr Biol** 1995 Jul 1;5(7):700–2 (23 ref.)

DNA excision repair and transcription: implications for genome evolution. Sullivan DT. **Curr Opin Genet Dev** 1995 Dec;5(6):786–91 (55 ref.)

DNA-replication fidelity, mismatch repair and genome instability in cancer cells. Umar A, et al. **Eur J Biochem** 1996 Jun 1;238(2):297–307 (81 ref.)

Mismatch repair as an important source of new mutations in non-dividing cells. MacPhee DG. **Experientia** 1996 Apr 15;52(4):357–63 (30 ref.)

Biochemistry and genetics of eukaryotic mismatch repair. Kolodner R. **Genes Dev** 1996 Jun 15;10(12):1433–42 (85 ref.)

DNA-repair methyltransferase as a molecular device for preventing mutation and cancer. Sekiguchi M, et al. **J Cancer Res Clin Oncol** 1996;122(4):199–206 (64 ref.)

Molecular mechanisms underlying hereditary nonpolyposis colorectal carcinoma. Rhyu MS. **J Natl Cancer Inst** 1996 Mar 6;88(5):240–51 (126 ref.)

Induction and repair of benzo[a]pyrene-DNA adducts in C57BL/6 and BALB/c mice: association with aging and longevity. Boerrigter ME, et al. **Mech Ageing Dev** 1995 Jul 28;82(1):31–50 (50 ref.)

Relaxing and unwinding on Holliday: DNA helicase-mediated branch migration. Adams DE, et al. **Mutat Res** 1995 Nov;337(3):149–59 (70 ref.)

Repair of ionizing-radiation damage in the radiation resistant bacterium Deinococcus radiodurans. Minton KW. **Mutat Res** 1996 May 15;363(1):1–7 (34 ref.)

Evidence that mammalian cells possess homologous recombinational repair pathways. Thompson LH. **Mutat Res** 1996 Jun 12;363(2):77–88 (119 ref.)

DNA damage and repair in mutagenesis and carcinogenesis: implications of structure-activity relationships for cross-species extrapolation. Vogel EW, et al. **Mutat Res** 1996 Jun 12;353(1–2):177–218 (125 ref.)

DNA repair and cytokines in antimutagenesis and anticarcinogenesis. Yarosh DB, et al. **Mutat Res** 1996 Feb 19;350(1):255–60 (28 ref.)

Depletion of nuclear poly(ADP-ribose) polymerase by antisense RNA expression: influence on genomic stability, chromatin organization, DNA repair, and DNA replication. Simbulan-Rosenthal CM, et al. **Prog Nucleic Acid Res Mol Biol** 1996;55:135–56 (68 ref.)

DNA damage: chemistry, repair, and mutagenic potential. Singer B. **Regul Toxicol Pharmacol** 1996 Feb;23(1 Pt 1):2–13 (43 ref.)

PIK-related kinases: DNA repair, recombination, and cell cycle checkpoints. Keith CT, et al. **Science** 1995 Oct 6; 270(5233):50–1 (22 ref.)

Microsatellite instability and DNA mismatch repair in human cancer. Karran P. **Semin Cancer Biol** 1996 Feb;7(1):15–24 (72 ref.)

Cell cycle checkpoints and repair of ionizing radiation damage. Liu VF, et al. **Stem Cells (Dayt)** 1995 May;13 Suppl 1:117–28 (93 ref.)

DNA double-strand break repair and V(D)J recombination: involvement of DNA-PK. Jackson SP, et al. **Trends Biochem Sci** 1995 Oct;20(10):412–5 (41 ref.)

Mismatch repair: mechanisms and relationship to cancer susceptibility. Kolodner RD. **Trends Biochem Sci** 1995 Oct; 20(10):397–401 (49 ref.)

Nucleotide excision repair and the link with transcription. Lehmann AR. **Trends Biochem Sci** 1995 Oct;20(10):402–5 (29 ref.)

DNA repair in three dimensions. Pearl LH, et al. **Trends Biochem Sci** 1995 Oct;20(10):421–6 (32 ref.)

The base excision repair pathway. Seeberg E, et al. **Trends Biochem Sci** 1995 Oct;20(10):391–7 (50 ref.)

Homologous recombination and the roles of double-strand breaks. Shinohara A, et al. **Trends Biochem Sci** 1995 Oct; 20(10):387–91 (32 ref.)

Cisplatin and DNA repair in cancer chemotherapy. Zamble DB, et al. **Trends Biochem Sci** 1995 Oct;20(10):435–9 (33 ref.)

[8-Oxoguanine repair system and its role in mitochondria] Kang D, et al. **Seikagaku** 1996 Apr;68(4):289–95 (22 ref.) **(Jpn)**

[Nucleotide excision repair in human cells. Biochemistry and implications in diseases] Aarsaether N, et al. **Tidsskr Nor Laegeforen** 1995 Sep 20;115(22):2786–9 (26 ref.) (Eng. Abstr.) **(Nor)**

[Oxidative damage repair of DNA in prokaryotes] Zastawny TH. **Postepy Biochem** 1996;42(1):31–41 (118 ref.) **(Pol)**

DRUG EFFECTS

The role of inhibitors of poly(ADP-ribose) polymerase as

resistance-modifying agents in cancer therapy. Griffin RJ, et al. **Biochimie** 1995;77(6):408–22 (84 ref.)
DNA repair: enzymatic mechanisms and relevance to drug response. Chaney SG, et al. **J Natl Cancer Inst** 1996 Oct 2;88(19):1346–60 (253 ref.)

GENETICS

DNA repair fine structure and its relations to genomic instability. Bohr VA. **Carcinogenesis** 1995 Dec; 16(12):2885–92 (85 ref.)
Variability in DNA repair and individual susceptibility to genotoxins. Kyrtopoulos SA. **Clin Chem** 1995 Dec;41(12 Pt 2):1848–53 (51 ref.)
Human mismatch repair genes and their association with hereditary non-polyposis colon cancer. Kolodner RD, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:331–8 (79 ref.)
DNA repair and transcription. Bhatia PK, et al. **Curr Opin Genet Dev** 1996 Apr;6(2):146–50 (60 ref.)
Identification of mismatch repair genes and their role in the development of cancer. Fishel R, et al. **Curr Opin Genet Dev** 1995 Jun;5(3):382–95 (158 ref.)
DNA mismatch repair and cancer. Chung DC, et al. **Gastroenterology** 1995 Nov;109(5):1685–99 (109 ref.)
Roles of the DNA mismatch repair genes in colorectal tumorigenesis. Boland CR. **Int J Cancer** 1996 Feb 20; 69(1):47–9 (14 ref.)
Identification of DNA mismatch repair gene mutations in hereditary nonpolyposis colon cancer patients. Luce MC, et al. **Int J Cancer** 1996 Feb 20;69(1):50–2 (25 ref.)
DNA damage, mutation and fine structure DNA repair in aging. Bohr VA, et al. **Mutat Res** 1995 Oct;338(1–6):25–34 (100 ref.)
Molecular biology of DNA repair in the fission yeast Schizosaccharomyces pombe. Lehmann AR. **Mutat Res** 1996 Aug 8;363(3):147–61 (102 ref.)
DNA damage, p53 and anticancer therapies. Milner J. **Nat Med** 1995 Sep;1(9):879–80 (8 ref.)
[Mice with targeted DNA repair genes] Tanaka K. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2214–22 (10 ref.) **(Jpn)**

IMMUNOLOGY

The Ku autoantigen: cast in a new light. Robinson A. **Can Med Assoc J** 1996 Jun 15;154(12):1871–3 (8 ref.)

PHYSIOLOGY

DNA–mismatch repair. The intricacies of eukaryotic spell–checking. Kunkel TA. **Curr Biol** 1995 Oct 1; 5(10):1091–4 (25 ref.)
Recognition and processing of damaged DNA. Lindahl T. **J Cell Sci Suppl** 1995;19:73–7 (33 ref.)
DNA repair deficiency in systemic lupus erythematosus; cause or consequence of disease and implications for management. Herrick AL, et al. **Lupus** 1995 Dec;4(6):423–4 (11 ref.)
Collapse and repair of replication forks in Escherichia coli. Kuzminov A. **Mol Microbiol** 1995 May;16(3):373–84 (102 ref.)
DNA–dependent protein kinase defects are linked to deficiencies in DNA repair and V(D)J recombination. Finnie NJ, et al. **Philos Trans R Soc Lond B Biol Sci** 1996 Feb 29;351(1336):173–9 (50 ref.)
p53: DNA damage, DNA repair, and apoptosis. Götz C, et al. **Rev Physiol Biochem Pharmacol** 1996;127:65–95 (230 ref.)
What to do at an end: DNA double–strand–break repair. Weaver DT. **Trends Genet** 1995 Oct;11(10):388–92 (51 ref.)
[Repair of O6–methylguanine–DNA] Sledziewska–Gójska EW. **Postepy Biochem** 1996;42(1):21–30 (132 ref.) **(Pol)**
[The role of incomplete terminal repair of chromosomal DNA in the aging of neurons and postmitotic organisms] Olovnikov AM. **Izv Akad Nauk Ser Biol** 1995 Jul–Aug; (4):504–7 (12 ref.) (Eng. Abstr.) **(Rus)**
[The effect of the incomplete terminal repair of the linear double–stranded DNA molecule] Olovnikov AM. **Izv Akad Nauk Ser Biol** 1995 Jul–Aug;(4):501–3 (12 ref.) (Eng. Abstr.) **(Rus)**

RADIATION EFFECTS

Relationship between DNA damage, rejoining and cell killing by radiation in mammalian cells. Núñez MI, et al. **Radiother Oncol** 1996 May;39(2):155–65 (102 ref.)

DNA REPAIR ENZYMES see **POLYDEOXYRIBONUCLEOTIDE SYNTHETASES**

DNA REPETITIOUS REGION see **REPETITIVE SEQUENCES, NUCLEIC ACID**

DNA REPLICATION

see related
DNA HELICASES
DNA TOPOISOMERASE
VIRUS REPLICATION

Silencing and heritable domains of gene expression. Loo S, et al. **Ann Rev Cell Dev Biol** 1995;11:519–48 (113 ref.)
The structure and replication of kinetoplast DNA. Shapiro TA, et al. **Annu Rev Microbiol** 1995;49:117–43 (126 ref.)
Cyclin–dependent protein kinases: key regulators of the eukaryotic cell cycle. Nigg EA. **Bioessays** 1995 Jun; 17(6):471–80 (95 ref.)
Stopped for repairs. Sanchez Y, et al. **Bioessays** 1995 Jun; 17(6):545–8 (27 ref.)
Overview of controls in the Escherichia coli cell cycle. Vinella D, et al. **Bioessays** 1995 Jun;17(6):527–36 (87 ref.)
Chromatin. Nucleosome assembly during DNA replication. Krude T. **Curr Biol** 1995 Nov 1;5(11):1232–4 (17 ref.)
Molecular interactions during adenovirus DNA replication. Hay RT, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 2):31–48 (114 ref.)
Expression, nuclear transport, and phosphorylation of adenovirus DNA replication proteins. Ramachandra M, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 2):50–88 (262 ref.)
Adenovirus DNA replication. Van der Vliet PC. **Curr Top Microbiol Immunol** 1995;199 (Pt 2):1–30 (147 ref.)
Homologous recombination in the replicative cycle of adenovirus and its relationship to DNA replication. Young CS. **Curr Top Microbiol Immunol** 1995;199 (Pt 2):89–108 (75 ref.)
DNA–replication fidelity, mismatch repair and genome instability in cancer cells. Umar A, et al. **Eur J Biochem** 1996 Jun 1;238(2):297–307 (81 ref.)
Structure and partitioning of bacterial DNA: determined by a balance of compaction and expansion forces? Woldringh CL, et al. **FEMS Microbiol Lett** 1995 Sep 15;131(3):235–42 (46 ref.)
Primase structure and function. Griep MA. **Indian J Biochem Biophys** 1995 Aug;32(4):171–8 (64 ref.)
Origins of replication and the nuclear matrix: the DHFR domain as a paradigm. Dijkwel PA, et al. **Int Rev Cytol** 1995;162A:455–84 (180 ref.)
On the structure of replication and transcription factories. Hughes TA, et al. **J Cell Sci Suppl** 1995;19:59–65 (64 ref.)
Replication of baculovirus DNA. Kool M, et al. **J Gen Virol** 1995 Sep;76 (Pt 9):2103–18 (150 ref.)
Microsatellite instability in human cancer. Speicher MR. **Oncol Res** 1995;7(6):267–75 (87 ref.)
Minute virus of mice cis–acting sequences required for genome replication and the role of the trans–acting viral protein, NS–1. Astell CR, et al. **Prog Nucleic Acid Res Mol Biol** 1996;55:245–85 (116 ref.)
Regulation of synthesis of ribonucleotide reductase and relationship to DNA replication in various systems. Greenberg GR, et al. **Prog Nucleic Acid Res Mol Biol** 1996; 53:345–95 (158 ref.)
Depletion of nuclear poly(ADP–ribose) polymerase by antisense RNA expression: influence on genomic stability, chromatin organization, DNA repair, and DNA replication. Simbulan–Rosenthal CM, et al. **Prog Nucleic Acid Res Mol Biol** 1996;55:135–56 (68 ref.)
The centromere: kinetochore complex. Vig BK. **Southeast Asian J Trop Med Public Health** 1995;26 Suppl 1:68–76 (48 ref.)
The initiation of DNA replication in the budding yeast cell division cycle. Diffley JF. **Yeast** 1995 Dec;11(16):1651–70 (163 ref.)
[Eukaryotic DNA replication: analysis of reconstitution of SV40 DNA replication] Waga S. **Seikagaku** 1995 Sep; 67(9):1142–8 (19 ref.) **(Jpn)**
[DNA replication licensing factor: MCM protein family] Takisawa H, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr; 41(4):356–61 (24 ref.) **(Jpn)**

GENETICS

Quality control in Mu DNA transposition [comment] Craigie R. **Cell** 1996 Apr 19;85(2):137–40 (11 ref.) Comment on: Cell 1996 Apr 19;85(2):257–69. Comment on: Cell 1996 Apr 19;85(2):271–80.
Recombination by replication. Kogoma T. **Cell** 1996 May 31;85(5):625–7 (17 ref.)
Defects in replication fidelity of simple repeated sequences reveal a new mutator mechanism for oncogenesis. Perucho M, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:339–48 (63 ref.)
Microsatellite instability and hereditary non–polyposis colon cancer [editorial] Peltomäki P. **J Pathol** 1995 Aug; 176(4):329–30 (26 ref.)

PHYSIOLOGY

Endless quest. Holliday R. **Bioessays** 1996 Jan;18(1):3–5 (26 ref.)
DNA replication. Almost licensed. Ford C, et al. **Curr Biol** 1995 Sep 1;5(9):1009–12 (23 ref.)
DNA replication. Once, and only once. Li JJ. **Curr Biol** 1995 May 1;5(5):472–5 (24 ref.)
Cell cycle control of eukaryotic DNA replication. Kearsey SE, et al. **Curr Opin Genet Dev** 1996 Apr;6(2):208–14 (58 ref.)
Stepwise assembly of initiation complexes at budding yeast replication origins during the cell cycle. Diffley JF, et al. **J Cell Sci Suppl** 1995;19:67–72 (25 ref.)
Collapse and repair of replication forks in Escherichia coli. Kuzminov A. **Mol Microbiol** 1995 May;16(3):373–84 (102 ref.)
[Initiation of DNA replication in Streptomyces; organizational comparison of the oriC region in prokaryotic organisms] Zakrzewska–Czerwińska J. **Postepy Hig Med Dosw** 1995;49(1):149–60 (43 ref.) (Eng. Abstr.) **(Pol)**

DNA RESTRICTION ENZYMES

see related
POLYMORPHISM, RESTRICTION FRAGMENT LENGTH
RESTRICTION MAPPING

[Conversion of zinc finger protein to artificial site–specific nuclease: application to chromosome mapping and sequencing] Nagaoka M, et al. **Nippon Rinsho** 1995 Oct; 53(10):2589–96 (10 ref.) (Eng. Abstr.) **(Jpn)**

DNA, RIBOSOMAL

see related
TRANSCRIPTION, GENETIC

Regulation of ribosomal DNA transcription during neonatal cardiomyocyte hypertrophy. Hannan RD, et al. **Cardiovasc Res** 1995 Oct;30(4):501–10 (135 ref.)

CHEMISTRY

A review of the use of ribosomal DNA (rDNA) to differentiate among cryptic Anopheles species. Collins FH, et al. **Insect Mol Biol** 1996 Feb;5(1):1–9 (55 ref.)

GENETICS

Species specificity of transcription by RNA polymerase I. Heix J, et al. **Curr Opin Genet Dev** 1995 Oct;5(5):652–6 (26 ref.)
Molecular identification of nanoplanktonic protists based on small subunit ribosomal RNA gene sequences for ecological studies. Lim EL. **J Eukaryot Microbiol** 1996 Mar–Apr; 43(2):101–6 (47 ref.)
New approaches to typing and identification of bacteria using the 16S–23S rDNA spacer region. Gürtler V, et al. **Microbiology** 1996 Jan;142 (Pt 1):3–16 (100 ref.)

DNA, SATELLITE

GENETICS

Microsatellite instability and hereditary non–polyposis colon cancer [editorial] Peltomäki P. **J Pathol** 1995 Aug; 176(4):329–30 (26 ref.)
Microsatellite instability in human cancer. Speicher MR. **Oncol Res** 1995;7(6):267–75 (87 ref.)

PHYSIOLOGY

Centromere activation. Brown W, et al. **Trends Genet** 1995 Sep;11(9):337–9 (8 ref.)

DNA SEQUENCE see **BASE SEQUENCE**

DNA SEQUENCE ANALYSIS see **SEQUENCE ANALYSIS, DNA**

DNA, SINGLE–STRANDED

[Unusual single–stranded DNA structures: extraordinarily thermo–stable mini–hairpin] Hirao I, et al. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1583–91 (21 ref.) **(Jpn)**

ANALYSIS

Novel strategies for the detection of drug resistance in Mycobacterium tuberculosis. Telenti A, et al. **Res Microbiol** 1996 Jan–Feb;147(1–2):73–9 (34 ref.)

METABOLISM

Single–stranded DNA binding protein encoded by the filamentous bacteriophage M13: structural and functional characteristics. Stassen AP, et al. **Mol Biol Rep** 1994–95; 20(3):109–27 (101 ref.)
Getting down to the core of homologous recombination [comment] Stasiak A. **Science** 1996 May 10;272(5263):828–9 (9 ref.) Comment on: Science 1996 May 10;272(5263):868–72.

DNA, SPACER see **DNA, RIBOSOMAL**

DNA, SUPERCOILED see **DNA, SUPERHELICAL**

DNA, SUPERHELICAL

CHEMISTRY

Open complex formation by Escherichia coli RNA polymerase: the mechanism of polymerase–induced strand separation of double helical DNA. deHaseth PL, et al. **Mol Microbiol** 1995 Jun;16(5):817–24 (72 ref.)

METABOLISM

Getting down to the core of homologous recombination [comment] Stasiak A. **Science** 1996 May 10;272(5263):828–9 (9 ref.) Comment on: Science 1996 May 10;272(5263):868–72.

DNA, SUPERTWISTED see **DNA, SUPERHELICAL**

DNA TOPOISOMERASE

ANTAGONISTS & INHIBITORS

DNA topoisomerase inhibitors. Capranico G, et al. **Cancer Chemother Biol Response Modif** 1996;16:68–87 (94 ref.)

CPT-11 (irinotecan) in the treatment of colorectal cancer. Armand JP, et al. **Eur J Cancer** 1995 Jul-Aug; 31A(7–8):1283–7 (41 ref.)

Antitopoisomerase drug action and resistance. Nitiss JL, et al. **Eur J Cancer** 1996 Jun;32A(6):958–66 (115 ref.)

Mechanisms of resistance to topoisomerases poisons. Prost S. **Gen Pharmacol** 1995 Dec;26(8):1673–84 (88 ref.)

Mutagenicity of anticancer drugs that inhibit topoisomerase enzymes. Ferguson LR, et al. **Mutat Res** 1996 Aug 17; 355(1–2):91–101 (81 ref.)

CPT-11: clinical experience in phase I studies. Armand JP. **Semin Oncol** 1996 Feb;23(1 Suppl 3):27–33 (22 ref.)

Preclinical evaluation of CPT-11 and its active metabolite SN-38. Lavelle F, et al. **Semin Oncol** 1996 Feb;23(1 Suppl 3):11–20 (44 ref.)

Eukaryotic DNA topoisomerase I: genome gatekeeper and its intruders, camptothecins. Pommier Y. **Semin Oncol** 1996 Feb;23(1 Suppl 3):3–10 (87 ref.)

CPT-11: an original spectrum of clinical activity. Rothenberg ML. **Semin Oncol** 1996 Feb;23(1 Suppl 3):21–6 (38 ref.)

CPT-11 in the treatment of colorectal cancer: clinical efficacy and safety profile. Rougier P, et al. **Semin Oncol** 1996 Feb;23(1 Suppl 3):34–41 (35 ref.)

Mechanism of action of DNA topoisomerase inhibitors. Binaschi M, et al. **Stem Cells (Dayt)** 1995 Jul;13(4):369–79 (103 ref.)

[Topoisomerase I inhibitors. Review of phase II trials with irinotecan (CPT-11) and topotecan] Bonneterre J. **Bull Cancer (Paris)** 1995 Aug;82(8):623–8 (52 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Anti-topoisomerase-I and clinical findings in systemic sclerosis (scleroderma). Shoenfeld Y, et al. **Isr J Med Sci** 1996 Jul;32(7):537–42 (32 ref.)

METABOLISM

The unique DNA topology and DNA topoisomerases of hyperthermophilic archaea. Forterre P, et al. **FEMS Microbiol Rev** 1996 May;18(2–3):237–48 (47 ref.)

Metallocene interactions with DNA and DNA-processing enzymes. Kuo LY, et al. **Met Ions Biol Syst** 1996;33:53–85 (113 ref.)

Molecular, cellular, and clinical aspects of the pharmacology of 20(S)camptothecin and its derivatives. Rivory LP, et al. **Pharmacol Ther** 1995;68(2):269–96 (170 ref.)

DNA TOPOISOMERASE (ATP-HYDROLYSING)

ANTAGONISTS & INHIBITORS

Therapy-related acute promyelocytic leukemia with t(15;17)(q22;q12) following chemotherapy with drugs targeting DNA topoisomerase II. A report of two cases and a review of the literature [see comments] Hoffmann L, et al. **Ann Oncol** 1995 Oct;6(8):781–8 (32 ref.) Comment in: Ann Oncol 1995 Oct;6(8):751–3.

Molecular mechanisms of drug inhibition of DNA gyrase. Lewis RJ, et al. **Bioessays** 1996 Aug;18(8):661–71 (73 ref.)

Therapy-related acute leukemia associated with t(11q23) after primary acute myeloid leukemia with t(8;21): a report of two cases [letter] Roulston D, et al. **Blood** 1995 Nov 1;86(9):3613–4 (7 ref.)

Quinolone mode of action. Hooper DC. **Drugs** 1995;49 Suppl 2:10–5 (32 ref.)

Mechanisms of resistance to topoisomerases poisons. Prost S. **Gen Pharmacol** 1995 Dec;26(8):1673–84 (88 ref.)

Function of topoisomerase II and the consequences of inhibition. Davies SM. **Med Pediatr Oncol Suppl** 1996; 1:12–9 (83 ref.)

[Mechanism of action and resistance to fluoroquinolones] Alarcón T, et al. **Enferm Infecc Microbiol Clin** 1996 Feb; 14(2):111–7 (83 ref.) **(Spa)**

CHEMISTRY

Recent developments in DNA topoisomerase II structure and mechanism. Berger JM, et al. **Curr Opin Struct Biol** 1996 Feb;6(1):84–90 (67 ref.)

GENETICS

Human DNA topoisomerase II: biochemistry and role in chemotherapy resistance (review). Withoff S, et al. **Anticancer Res** 1996 Jul-Aug;16(4A):1867–80 (184 ref.)

DNA topoisomerase II mutations and resistance to anti-tumor drugs. Vassetzky YS, et al. **Bioessays** 1995 Sep; 17(9):767–74 (66 ref.)

METABOLISM

Human DNA topoisomerase II: biochemistry and role in chemotherapy resistance (review). Withoff S, et al. **Anticancer Res** 1996 Jul-Aug;16(4A):1867–80 (184 ref.)

The unique DNA topology and DNA topoisomerases of hyperthermophilic archaea. Forterre P, et al. **FEMS Microbiol Rev** 1996 May;18(2–3):237–48 (47 ref.)

PHYSIOLOGY

Function of topoisomerase II and the consequences of inhibition. Davies SM. **Med Pediatr Oncol Suppl** 1996; 1:12–9 (83 ref.)

DNA TOPOISOMERASE I see **DNA TOPOISOMERASE**

DNA TOPOISOMERASE II see **DNA TOPOISOMERASE (ATP-HYDROLYSING)**

DNA TUMOR VIRUSES

[The current view of molecular biology of DNA tumor virus] Wada T, et al. **Tanpakushitsu Kakusan Koso** 1996 May; 41(6):793–9 (14 ref.) **(Jpn)**

IMMUNOLOGY

Cellular immunity against DNA tumour viruses: possibilities for peptide-based vaccines and immune escape. Toes RE, et al. **Biochem Soc Trans** 1995 Aug;23(3):692–6 (52 ref.)

METABOLISM

Use of the E2F transcription factor by DNA tumor virus regulatory proteins. Cress WD, et al. **Curr Top Microbiol Immunol** 1996;208:63–78 (112 ref.)

DNA UNTWISTING ENZYME see **DNA TOPOISOMERASE**

DNA UNTWISTING PROTEIN see **DNA TOPOISOMERASE**

DNA UNWINDING PROTEINS see **DNA HELICASES**

DNA, VIRAL

Rhinoviruses and cells: molecular aspects. Rowlands DJ. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 2):S31–5 (41 ref.)

Interspecies transmission of influenza viruses. Webster RG, et al. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 2):S25–30 (27 ref.)

The mechanism of adenovirus DNA integration: studies in a cell-free system. Fechteler K, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 2):109–37 (122 ref.)

Transposition of phage Mu DNA. Lavoie BD, et al. **Curr Top Microbiol Immunol** 1996;204:83–102 (89 ref.)

Selective encapsidation of adenovirus DNA. Schmid SI, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 1):67–80 (45 ref.)

Cytomegalovirus genes: their structure and function. Stenberg RM, et al. **Scand J Infect Dis Suppl** 1995;99:3–6 (42 ref.)

ANALYSIS

No detection of HTLV-I proviral DNA in lesional skin biopsies from Swiss and German patients with cutaneous T-cell lymphoma. Böni R, et al. **Br J Dermatol** 1996 Feb; 134(2):282–4 (20 ref.)

Recurrent laryngeal papillomatosis developing into laryngeal carcinoma with human papilloma virus (HPV) type 18: a case report. Sakakura A, et al. **J Laryngol Otol** 1996 Jan; 110(1):75–7 (18 ref.)

Unsuccessful effort to detect human papillomavirus DNA in urinary bladder cancers by the polymerase chain reaction and in situ hybridization. Sano T, et al. **Pathol Int** 1995 Jul;45(7):506–12 (32 ref.)

[Diagnosis of contagious diseases in animals using PCR] Hofmann MA, et al. **Schweiz Arch Tierheilkd** 1995; 137(12):531–6 (9 ref.) (Eng. Abstr.) **(Ger)**

[Quantitative assay of HBV-DNA] Shimoda K, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:284–91 (5 ref.) **(Jpn)**

[In situ PCR detection of HTLV-1 provirus in spinal cord lesions with HAM/TSP] Izumo S, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):656–9 (16 ref.) **(Jpn)**

[Hepatitis C virus] Kato N, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):676–80 (19 ref.) **(Jpn)**

[Analysis of HTLV-1 expression in vivo] Saito M, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):681–5 (13 ref.) **(Jpn)**

[Novel molecular technology for HIV detection and analysis] Tamatsukuri S, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):686–95 (36 ref.) **(Jpn)**

BIOSYNTHESIS

Molecular interactions during adenovirus DNA replication. Hay RT, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 2):31–48 (114 ref.)

Expression, nuclear transport, and phosphorylation of adenovirus DNA replication proteins. Ramachandra M, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 2):50–88 (262 ref.)

Adenovirus DNA replication. Van der Vliet PC. **Curr Top Microbiol Immunol** 1995;199 (Pt 2):1–30 (147 ref.)

Homologous recombination in the replicative cycle of adenovirus and its relationship to DNA replication. Young CS. **Curr Top Microbiol Immunol** 1995;199 (Pt 2):89–108 (75 ref.)

Replication of baculovirus DNA. Kool M, et al. **J Gen Virol** 1995 Sep;76 (Pt 9):2103–18 (150 ref.)

Minute virus of mice cis-acting sequences required for genome replication and the role of the trans-acting viral protein, NS-1. Astell CR, et al. **Prog Nucleic Acid Res Mol Biol** 1996;55:245–85 (116 ref.)

[Eukaryotic DNA replication: analysis of reconstitution of SV40 DNA replication] Waga S. **Seikagaku** 1995 Sep; 67(9):1142–8 (19 ref.) **(Jpn)**

BLOOD

Measuring viral load in the clinical setting. Harrigan R. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995;10 Suppl 1:S34–40 (26 ref.)

CHEMISTRY

[The structure and function of HBV-DNA] Mitamura K. **Nippon Rinsho** 1995 Oct;53 Suppl:13–27 (47 ref.) **(Jpn)**

GENETICS

The sensitivity of HIV-1 DNA polymerase chain reaction in the neonatal period and the relative contributions of intra-uterine and intra-partum transmission. Dunn DT, et al. **AIDS** 1995 Sep;9(9):F7–11 (29 ref.)

Quality control in Mu DNA transposition [comment] Craigie R. **Cell** 1996 Apr 19;85(2):137–40 (11 ref.) Comment on: Cell 1996 Apr 19;85(2):257–69. Comment on: Cell 1996 Apr 19;85(2):271–80.

In vitro transformation by hepatitis B virus DNA. Schaefer S, et al. **Intervirology** 1995;38(3–4):143–54 (112 ref.)

Primary adult T cell leukemia of bone: two patients with primary bone lesion showing monoclonal integration of HTLV-I proviral DNA. Takemoto S, et al. **Leukemia** 1996 Feb;10(2):333–7 (24 ref.)

Noncoding control region of naturally occurring BK virus variants: sequence comparison and functional analysis. Moens U, et al. **Virus Genes** 1995;10(3):261–75 (112 ref.)

[Cellular proteins binding to the hot spot of DNA recombination on the HBV-DNA sequence] Kajino K, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:94–6 (8 ref.) **(Jpn)**

[Transactivation function of X gene-cellular gene fusion product or 3' truncated pre S2/S gene cellular gene fusion product from integrated hepatitis B virus DNA] Mita E, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:89–93 (15 ref.) **(Jpn)**

[Hepatitis B infections show a variety of clinical pictures. Variations in viral DNA is a possible explanation] Kidd-Ljunggren K. **Lakartidningen** 1996 Mar 27; 93(13):1212–6 (28 ref.) **(Swe)**

IMMUNOLOGY

DNA-mediated immunization: prospects for hepatitis B vaccination. Michel ML. **Res Virol** 1995 Jul-Aug; 146(4):261–5 (28 ref.)

ISOLATION & PURIFICATION

JCV-DNA and BKV-DNA in the CNS tissue and CSF of AIDS patients and normal subjects. Study of 41 cases and review of the literature. Vago L, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Jun 1;12(2):139–46 (43 ref.)

Detection of human cytomegalovirus DNA: how, when and where? Gerna G, et al. **Scand J Infect Dis Suppl** 1995; 99:11–5 (46 ref.)

[Detection and typing of HPV genome: consensus PCR method] Yamashita T, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):664–8 (21 ref.) **(Jpn)**

METABOLISM

DNA packaging and cutting by phage terminases: control in phage T4 by a synaptic mechanism. Black LW. **Bioessays** 1995 Dec;17(12):1025–30 (55 ref.)

Virus DNA packaging: the strategy used by phage lambda. Catalano CE, et al. **Mol Microbiol** 1995 Jun;16(6):1075–86 (87 ref.)

PHYSIOLOGY

[The structure and function of HBV-DNA] Mitamura K. **Nippon Rinsho** 1995 Oct;53 Suppl:13–27 (47 ref.) **(Jpn)**

DNA VIRUSES

see related
DNA, VIRAL

New strategies of immune modulation by DNA viruses. McFadden G, et al. **Transplant Proc** 1996 Aug;28(4):2085–8 (32 ref.)

GENETICS

The use of DNA viruses as vectors for gene therapy. Ali M, et al. **Gene Ther** 1994 Nov;1(6):367–84 (179 ref.)

ISOLATION & PURIFICATION

[Procedures of viral identification in respiratory infections] Aspa J, et al. **Arch Bronconeumol** 1995 Nov;31(9):470–80 (132 ref.) **(Spa)**

PHYSIOLOGY

Comparison of packaging strategy in retroviruses and pararetroviruses. Mesnard JM, et al. **Virology** 1995 Oct 20; 213(1):1–6 (62 ref.)

DNAASE see **DEOXYRIBONUCLEASES**

DNASE see **DEOXYRIBONUCLEASES**

DNASE I see **DEOXYRIBONUCLEASE I**

DO-NOT-RESUSCITATE ORDERS see **RESUSCITATION ORDERS**

DOBUTAMINE

DIAGNOSTIC USE

Diagnosis of myocardial stunning: a new use for myocardial contrast and dobutamine echocardiography. Cheirif J. **Am J Card Imaging** 1995 Oct;9(4):261–8 (51 ref.)

Assessment of myocardial viability by dobutamine echocardiography. Cheirif J, et al. **Coron Artery Dis** 1995 Aug;6(8):600–5 (30 ref.)

Dobutamine stress echocardiography. Stănescu C. **Rom J Intern Med** 1995 Jan–Jun;33(1–2):3–11 (26 ref.)

[Value of dobutamine echocardiography in the detection of coronary disease in heart transplant patient. Groupe de Recherche VACOMED] Derumeaux G, et al. **Arch Mal Coeur Vaiss** 1996 Jun;89(6):687–94 (30 ref.) (Eng. Abstr.) **(Fre)**

[Study of myocardial viability after recent infarction by echocardiography under dobutamine. Evidence of stunned myocardium] Guéret P, et al. **Arch Mal Coeur Vaiss** 1995 Aug;88 Spec No 3:13–7 (19 ref.) (Eng. Abstr.) **(Fre)**

[Stress ultrasonography with dobutamine in the diagnosis of coronary disease] Brochet E, et al. **Presse Med** 1995 Dec 9;24(38):1800–5 (25 ref.) (Eng. Abstr.) **(Fre)**

[Provocation tests in echocardiography: stress—dipyridamole—dobutamine (editorial)] Dagianti A. **Cardiologia** 1995 Jul;40(7):451–9 (69 ref.) **(Ita)**

[Echocardiography with pharmacological stress: dobutamine or dipyridamole?] Salustri A, et al. **G Ital Cardiol** 1996 Apr;26(4):447–53 (45 ref.) **(Ita)**

DOCA see **DESOXYCORTICOSTERONE**

DOCOSAHEXAENOATE see **DOCOSAHEXAENOIC ACIDS**

DOCOSAHEXAENOIC ACIDS

PHARMACOLOGY

Effect of dietary docosahexaenoic acid on brain composition and neural function in term infants. Gibson RA, et al. **Lipids** 1996 Mar;31 Suppl:S177–81 (28 ref.)

[The experimental and clinical aspects of eicosapentaenoic amd docosahexaenoic acids (a review of the literature and the author's own data)] Serhiienko OO. **Lik Sprava** 1995 May–Jun;(5–6):61–6 (31 ref.) (Eng. Abstr.) **(Ukr)**

DOCOSAHEXENOIC ACIDS see **DOCOSAHEXAENOIC ACIDS**

DOCOSENOIC ACIDS see **ERUCIC ACIDS**

DOCTOR-PATIENT RELATIONS see **PHYSICIAN-PATIENT RELATIONS**

DOCUMENTATION

see related
RECORDS

Service documentation and the biomedical engineer: results of a survey. Goffin K, et al. **Biomed Instrum Technol** 1996 May–Jun;30(3):223–35 (24 ref.)

Documentation and outcomes of advanced nursing practice. Boyle DM. **Oncol Nurs Forum** 1995 Sep;22(8 Suppl):11–7 (57 ref.)

METHODS

[Classification and documentation of liver metastases of colorectal carcinomas] Wittekind C. **Zentralbl Chir** 1995; 120(10):760–3 (18 ref.) (Eng. Abstr.) **(Ger)**

DOG DISEASES

Aetiology, prevalence and diagnosis of deafness in dogs and cats [see comments] Strain GM. **Br Vet J** 1996 Jan; 152(1):17–36 (81 ref.) Comment in: Br Vet J 1996 Jan;152(1):13–5.

Treatment of canine hip dysplasia: a review. Remedios AM, et al. **Can Vet J** 1995 Aug;36(8):503–9 (73 ref.)

Uveitis in dogs and cats: guidelines for the practitioner. Goodhead AD. **J S Afr Vet Assoc** 1996 Mar;67(1):12–9 (22 ref.)

Hypoglycemia in four dogs with smooth muscle tumors. Beaudry D, et al. **J Vet Intern Med** 1995 Nov–Dec; 9(6):415–8 (25 ref.)

Chylothorax in the dog and cat: a review. Birchard SJ, et al. **Lymphology** 1995 Jun;28(2):64–72 (53 ref.)

Diagnosis and treatment of conjunctival and corneal diseases. Nasisse MP. **Vet Q** 1995 Apr;17 Suppl 1:S42–3 (0 ref.)

[Urinary incontinence in castrated female dogs. 2. Therapy] Blendinger C, et al. **Tierarztl Prax** 1995 Aug;23(4):402–6 (30 ref.) (Eng. Abstr.) **(Ger)**

[Seizure disorders in the dog. 1. Clinical features and differential diagnosis] Fischer A. **Tierarztl Prax** 1995 Dec; 23(6):596–602 (30 ref.) (Eng. Abstr.) **(Ger)**

CHEMICALLY INDUCED

Benzodiazepine poisoning in companion animals. Bertini S, et al. **Vet Hum Toxicol** 1995 Dec;37(6):559–62 (24 ref.)

Cisapride toxicosis in dogs. Volmer PA. **Vet Hum Toxicol** 1996 Apr;38(2):118–20 (20 ref.)

DIAGNOSIS

Ocular and orbital porcupine quills in the dog: a review and case series. Grahn BH, et al. **Can Vet J** 1995 Aug; 36(8):488–93 (24 ref.)

Diagnosis and treatment of porto-systemic shunts. Bellenger CR, et al. **Vet Q** 1995 Apr;17 Suppl 1:S4–5 (6 ref.)

The differential diagnosis of polyuria/polydipsia in dogs. Belshaw BE. **Vet Q** 1995 Apr;17 Suppl 1:S19–21 (0 ref.)

The role of tonometry in the clinical management of the glaucomas in companion animals. Gelatt KN. **Vet Q** 1995 Apr;17 Suppl 1:S45 (0 ref.)

Dyspnea: how to solve the problem. Venker-van Haagen AJ. **Vet Q** 1995 Apr;17 Suppl 1:S7–8 (0 ref.)

[Testicular tumors in dogs: a literature review] Peters MA, et al. **Tijdschr Diergeneeskd** 1996 Jan 15;121(2):36–8 (47 ref.) (Eng. Abstr.) **(Dut)**

[Significance of electroencephalography for the diagnosis of seizures in dogs] Schütt-Mast I, et al. **Tierarztl Prax** 1996 Apr;24(2):129–36 (6 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Treating moderate and severe pain in small animals. Brock N. **Can Vet J** 1995 Oct;36(10):658–60 (3 ref.)

Treatment of acute isoniazid overdose in dogs. Villar D, et al. **Vet Hum Toxicol** 1995 Oct;37(5):473–7 (50 ref.)

EPIDEMIOLOGY

Estimating disease prevalence with health surveys and genetic screening. Dodds WJ. **Adv Vet Sci Comp Med** 1995; 39:29–96 (125 ref.)

Rabies: the emergence of a microbial threat. Borus P. **East Afr Med J** 1996 Jan;73(1):32–4 (12 ref.)

ETIOLOGY

Chylothorax and chylous ascites in a dog with mediastinal lymphangiosarcoma. Myers NC 3rd, et al. **J Am Anim Hosp Assoc** 1996 May–Jun;32(3):263–9 (32 ref.)

GENETICS

Estimating disease prevalence with health surveys and genetic screening. Dodds WJ. **Adv Vet Sci Comp Med** 1995; 39:29–96 (125 ref.)

Recent advances in understanding the spectrum of canine generalised progressive retinal atrophy. Clements PJ, et al. **J Small Anim Pract** 1996 Apr;37(4):155–62 (54 ref.)

IMMUNOLOGY

Thyroiditis—a model canine autoimmune disease. Happ GM. **Adv Vet Sci Comp Med** 1995;39:97–139 (216 ref.)

PARASITOLOGY

Spirocerca lupi infection in the dog: aberrant migration. Harrus S, et al. **J Am Anim Hosp Assoc** 1996 Mar–Apr; 32(2):125–30 (29 ref.)

PATHOLOGY

Calcinosis circumscripta in the footpad of a dog. Joffe DJ. **Can Vet J** 1996 Mar;37(3):161–2 (11 ref.)

Aggressive, undifferentiated sarcoma with widespread metastasis in a six-month-old Neopolitan mastiff. Sanders NA, et al. **J Am Anim Hosp Assoc** 1996 Mar–Apr; 32(2):97–101 (18 ref.)

PHYSIOPATHOLOGY

The hyperfiltration theory: progression of chronic renal failure and the effects of diet in dogs. Gonin-Jmaa D, et al. **J Am Vet Med Assoc** 1995 Dec 1;207(11):1411–5 (54 ref.)

Central nervous system tumors. Gavin PR, et al. **Semin Vet Med Surg (Small Anim)** 1995 Aug;10(3):180–9 (32 ref.)

Circulatory disorders of the liver in dogs and cats. van den Ingh TS, et al. **Vet Q** 1995 Jun;17(2):70–6 (40 ref.)

[Sedation and anesthesia in dogs and cats with cardiovascular diseases. I. Anesthesia plan considering risk assessment, hemodynamic effects of drugs and monitoring] Skarda RT, et al. **Schweiz Arch Tierheilkd** 1995;137(7):312–21 (13 ref.) (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

[Vaccination failures. III. Postvaccinal complications and immunization schedules. Immunoprophylaxis in dogs and cats] Overgaauw PA. **Tijdschr Diergeneeskd** 1996 Feb 15; 121(4):101–5 (60 ref.) **(Dut)**

[Immunity—technical aspects of vaccines. I. Immunoprophylaxis in dogs and cats] Overgaauw PA. **Tijdschr Diergeneeskd** 1996 Feb 15;121(4):90–5 (0 ref.) (Eng. Abstr.) **(Dut)**

[Vaccination in practice. II. Immunoprophylaxis in dogs and cats] Overgaauw PA. **Tijdschr Diergeneeskd** 1996 Feb 15; 121(4):95–101 (0 ref.) **(Dut)**

RADIOTHERAPY

Normal tissue tolerance and management of radiation injury. Gillette EL, et al. **Semin Vet Med Surg (Small Anim)** 1995 Aug;10(3):209–13 (12 ref.)

Radiation therapy for head and neck cancers. Gillette SM, et al. **Semin Vet Med Surg (Small Anim)** 1995 Aug; 10(3):168–72 (28 ref.)

Radiation therapy of thoracic and abdominal tumors. LaRue SM, et al. **Semin Vet Med Surg (Small Anim)** 1995 Aug; 10(3):190–6 (32 ref.)

Palliative radiation therapy. Thrall DE, et al. **Semin Vet Med Surg (Small Anim)** 1995 Aug;10(3):205–8 (14 ref.)

SURGERY

Canine cemented total hip replacements: state of the art. Olmstead ML. **J Small Anim Pract** 1995 Sep;36(9):395–9 (13 ref.)

Diagnosis and treatment of porto-systemic shunts. Bellenger CR, et al. **Vet Q** 1995 Apr;17 Suppl 1:S4–5 (6 ref.)

The treatment of hernias. Bellenger CR. **Vet Q** 1995 Apr; 17 Suppl 1:S2–4 (11 ref.)

Current concepts in the management of canine cataract: a survey of techniques used by surgeons in Britain, Europe and the USA and a review of recent literature. Williams DL, et al. **Vet Rec** 1996 Apr 13;138(15):347–53 (70 ref.)

THERAPY

Endodontics of dogs and cats: an alternative to extraction. Clarke DE. **Aust Vet J** 1995 Oct;72(10):383–9 (57 ref.)

Cervicofacial Actinomyces viscosus infection in a Brazilian fila: a case report and literature review. Donohue DE, et al. **J Am Anim Hosp Assoc** 1995 Nov–Dec;31(6):501–5 (20 ref.)

Supportive treatment of canine babesiosis. Jacobson LS, et al. **J S Afr Vet Assoc** 1995 Jun;66(2):95–105 (128 ref.)

Combining radiation therapy with other treatment modalities. LaRue SM, et al. **Semin Vet Med Surg (Small Anim)** 1995 Aug;10(3):197–204 (14 ref.)

Soft-tissue sarcomas. Thrall DE, et al. **Semin Vet Med Surg (Small Anim)** 1995 Aug;10(3):173–9 (45 ref.)

Canine transfusion reactions and their management. Harrell KA, et al. **Vet Clin North Am Small Anim Pract** 1995 Nov; 25(6):1333–64 (63 ref.)

Transfusion therapy in emergency and critical care medicine. Kirby R. **Vet Clin North Am Small Anim Pract** 1995 Nov; 25(6):1365–86 (25 ref.)

Hematopoietic growth factors: frontiers for cure. Ogilvie GK. **Vet Clin North Am Small Anim Pract** 1995 Nov; 25(6):1441–56 (23 ref.)

Autotransfusion in the emergency patient. Purvis D. **Vet Clin North Am Small Anim Pract** 1995 Nov; 25(6):1291–304 (59 ref.)

The role of blood component therapy in the management of canine and feline patients with cancer. Rudloff E. **Vet Clin North Am Small Anim Pract** 1995 Nov; 25(6):1403–16 (72 ref.)

Blood substitutes: oxygen-carrying acellular fluids. Wohl JS, et al. **Vet Clin North Am Small Anim Pract** 1995 Nov; 25(6):1417–40 (120 ref.)

ULTRASONOGRAPHY

Echocardiography in dogs. Tiemessen I. **Vet Q** 1995 Apr;17 Suppl 1:S34–5 (1 ref.)

[Doppler echocardiography of heart valve defects in the dog] Schneider M, et al. **Tierarztl Prax** 1996 Apr;24(2):177–89 (19 ref.) (Eng. Abstr.) **(Ger)**

DOGS

Dog, cat, and human bites: a review. Griego RD, et al. **J Am Acad Dermatol** 1995 Dec;33(6):1019–29 (115 ref.)

Severe dog bites in children. Brogan TV, et al. **Pediatrics** 1995 Nov;96(5 Pt 1):947–50 (19 ref.)

Diagnostic imaging in dogs: radiography, ultrasonography, and computed tomography for examination of the abdomen. Voorhout G. **Vet Q** 1995 Apr;17 Suppl 1:S30–1 (9 ref.)

[Dog bites: publications on risk factors, infections, antibiotics and primary wound closure (see comments)] de Melker HE, et al. **Ned Tijdschr Geneeskd** 1996 Mar 30; 140(13):709–13 (41 ref.) (Eng. Abstr.) Comment in: Ned Tijdschr Geneeskd 1996 Jun 1;140(22):1202–3. **(Dut)**

DOGS

BLOOD

Modern veterinary blood banking practices and their applications in companion animal practice. Feldman BF, et al. **Vet Clin North Am Small Anim Pract** 1995 Nov; 25(6):1231–43 (14 ref.)

Canine blood groups and their importance in veterinary transfusion medicine. Hale AS. **Vet Clin North Am Small Anim Pract** 1995 Nov; 25(6):1323–32 (22 ref.)

Blood components. Collection, processing, and storage. Schneider A. **Vet Clin North Am Small Anim Pract** 1995 Nov;25(6):1245–61 (24 ref.)

Selection of anticoagulant–preservatives for canine and feline blood storage. Wardrop KJ. **Vet Clin North Am Small Anim Pract** 1995 Nov; 25(6):1263–76 (50 ref.)

IMMUNOLOGY

Thyroiditis—a model canine autoimmune disease. Happ GM. **Adv Vet Sci Comp Med** 1995;39:97–139 (216 ref.)

PHYSIOLOGY

Vision in dogs. Miller PE, et al. **J Am Vet Med Assoc** 1995 Dec 15;207(12):1623–34 (68 ref.)

The canine as an animal model of human aging and dementia. Cummings BJ, et al. **Neurobiol Aging** 1996 Mar–Apr; 17(2):259–68 (106 ref.)

Neural regulation of swallowing in the dog. Venker–van Haagen AJ. **Vet Q** 1995 Apr;17 Suppl 1:S7 (1 ref.)

DOLICHOL PHOSPHATES

PHYSIOLOGY

[Dolichol–coupled biosynthesis of an oligosaccharide precursor for N–glycosylated proteins in the rough endoplasmic reticulum] Shpakov AO. **Ukr Biokhim Zh** 1995 Mar–Apr;67(2):3–17 (87 ref.) (Eng. Abstr.) **(Rus)**

DOLPHINS

METABOLISM

Environmental pollutants in marine mammals from the Norwegian coast and Arctic. Skaare JU. **Sci Total Environ** 1996 Jul 16;186(1–2):25–7 (12 ref.)

DOMESTIC VIOLENCE

SAFE questions: overcoming barriers to the detection of domestic violence. Neufeld B. **Am Fam Physician** 1996 Jun; 53(8):2575–80, 2582 (32 ref.)

Sexual and physical abuse and gastrointestinal illness. Review and recommendations [see comments] Drossman DA, et al. **Ann Intern Med** 1995 Nov 15;123(10):782–94 (99 ref.) Comment in: Ann Intern Med 1995 Nov 15;123(10):774–81. Comment in: Ann Intern Med 1996 Sep 1;125(5):426; discussion 426–7.

Invisible victims: battered women in psychiatric and medical emergency rooms. Keller LE. **Bull Menninger Clin** 1996 Winter;60(1):1–21 (52 ref.)

The abused patient. Dym H. **Dent Clin North Am** 1995 Jul; 39(3):621–35 (22 ref.)

Domestic violence. Do you know when and how to intervene? Steiner RP, et al. **Postgrad Med** 1996 Jul; 100(1):103–6, 111–4, 116 (19 ref.)

A model for the classification and diagnosis of relational disorders. Committee on the Family, Group for the Advancement of Psychiatry. **Psychiatr Serv** 1995 Sep; 46(9):926–31 (61 ref.)

[Behind closed doors—the hidden epidemic] Megiddo D. **Harefuah** 1996 Mar 1;130(5):337–9 (19 ref.) **(Heb)**

ETHNOLOGY

Social networks and family violence in cross–cultural perspective. Korbin JE. **Nebr Symp Motiv** 1995;42:107–34 (92 ref.)

LEGISLATION & JURISPRUDENCE

The risk of domestic violence and women with HIV infection: implications for partner notification, public policy, and the law. Rothenberg KH, et al. **Am J Public Health** 1995 Nov;85(11):1569–76 (98 ref.)

Domestic violence: legal issues for health care practitioners and institutions. Hyman A. **J Am Med Womens Assoc** 1996 May–Jul;51(3):101–5 (27 ref.)

PREVENTION & CONTROL

Violence in intimate relationships and the practicing internist: new "disease" or new agenda? [comment] [see comments] Alpert EJ. **Ann Intern Med** 1995 Nov 15;123(10):774–81 (33 ref.) Comment on: Ann Intern Med 1995 Nov 15;123(10):737–46. Comment on: Ann Intern Med 1995 Nov 15;123(10):782–94. Comment on: Ann Intern Med 1995 Nov 15;123(10):800–2. Comment on: Ann Intern Med 1995 Nov 15;123(10):804–5. Comment in: Ann Intern Med 1996 Sep 1;125(5):426; discussion 426–7.

Helping the vulnerable or condoning control within the family: where is nursing? Cody A. **J Adv Nurs** 1996 May; 23(5):882–6 (51 ref.)

Guidelines for doctors on identifying and helping their patients who batter. Adams D. **J Am Med Womens Assoc** 1996 May–Jul;51(3):123–6 (22 ref.)

Woman abuse and pediatrics: expanding the web of detection. Barkan SE, et al. **J Am Med Womens Assoc** 1996 May–Jul; 51(3):96–100 (81 ref.)

Domestic violence: changing theory, changing practice. Warshaw C. **J Am Med Womens Assoc** 1996 May–Jul; 51(3):87–91, 100 (70 ref.)

Policy issues for improving institutional response to domestic violence. Langford DR. **J Nurs Adm** 1996 Jan;26(1):39–45 (29 ref.)

Family violence: practical recommendations for physicians and the medical community. Buel SM, et al. **Womens Health Issues** 1995 Winter;5(4):158–72 (24 ref.)

DOMICILIARY CARE see HOME CARE SERVICES

DOMINANCE, CEREBRAL

see related
APHASIA

Cognitive status as a predictor of right hemisphere stroke outcomes. Sisson RA. **J Neurosci Nurs** 1995 Jun; 27(3):152–6 (19 ref.)

[Cortical function in 107 patients with supratentorial expanding mass. Pre– and postoperative study] Bucciero A, et al. **Minerva Med** 1995 Oct;86(10):403–7 (15 ref.) (Eng. Abstr.) **(Ita)**

GENETICS

In defence of the right shift theory. Annett M. **Percept Mot Skills** 1996 Feb;82(1):115–37 (62 ref.)

PHYSIOLOGY

Cerebral laterality in affect and affective illness: a review. Mandal MK, et al. **J Psychol** 1996 Jul;130(4):447–59 (80 ref.)

Corpus callosum and simple visuomotor integration. Berlucchi G, et al. **Neuropsychologia** 1995 Aug; 33(8):923–36 (74 ref.)

Visual integration in the split brain. Corballis MC. **Neuropsychologia** 1995 Aug;33(8):937–59 (78 ref.)

Cellular aspects of callosal connections and their development. Innocenti GM, et al. **Neuropsychologia** 1995 Aug;33(8):961–87 (99 ref.)

Early onset bilateral calcifications and epilepsy. Nunes ML, et al. **Pediatr Neurol** 1995 Jul;13(1):80–2 (11 ref.)

Nonprogressive congenital unilateral ventriculomegaly. Tsao PN, et al. **Pediatr Neurol** 1996 Jan;14(1):66–8 (15 ref.)

[The specific features of the work of the visual mechanisms in the right and left hemispheres of the human brain] Krol' VM. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1995 Nov–Dec; 45(6):1075–84 (35 ref.) (Eng. Abstr.) **(Rus)**

DOPA

ANALOGS & DERIVATIVES

Fluorodopa PET scanning in Parkinson's disease. Snow BJ. **Adv Neurol** 1996;69:449–57 (73 ref.)

Biogenesis of novel quinone coenzymes. Tanizawa K. **J Biochem (Tokyo)** 1995 Oct;118(4):671–8 (52 ref.)

Copper amine oxidase: a novel use for a tyrosine [comment] Fontecave M, et al. **Structure** 1995 Nov 15;3(11):1127–9 (22 ref.) Comment on: Structure 1995 Nov 15;3(11):1171–84.

ANALYSIS

[3,4–Dihydroxyphenylalanine (DOPA)] Shigetomi S, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:516–9 (16 ref.) **(Jpn)**

BLOOD

Is there a third peripheral catecholaminergic system? Endogenous dopamine as an autocrine/paracrine substance derived from plasma DOPA and inactivated by conjugation. Goldstein DS, et al. **Hypertens Res** 1995 Jun; 18 Suppl 1:S93–9 (76 ref.)

PHYSIOLOGY

Function and significance of the renal DOPA/DA system. Armando I, et al. **Acta Physiol Pharmacol Ther Latinoam** 1995;45(3):135–46 (111 ref.)

L–DOPA see LEVODOPA

DOPA DECARBOXYLASE

GENETICS

The Wilhelmine E. Key 1992 Invitational lecture. Phenotypic analysis of the Dopa decarboxylase gene cluster mutants in Drosophila melanogaster. Wright TR. **J Hered** 1996 May–Jun;87(3):175–90 (99 ref.)

DOPA OXIDASE see MONOPHENOL MONOOXYGENASE

DOPAC see 3,4–DIHYDROXYPHENYLACETIC ACID

DOPAMINE

see related
DOPAMINE AGENTS
RECEPTORS, DOPAMINE

ADMINISTRATION & DOSAGE

[Is preventive perioperative dopamine administration of value?] Bund M, et al. **Anaesthesiol Reanim** 1995; 20(3):76–81 (45 ref.) (Eng. Abstr.) **(Ger)**

ANALOGS & DERIVATIVES

Dopexamine after cardiac surgery. **Drug Ther Bull** 1995 Apr; 33(4):30–2 (17 ref.)

ANALYSIS

Diagnostic significance of dopamine estimation using plasma and urine in patients with adrenal and renal insufficiency, renal transplantation and hypertension. Yoshimura M, et al. **Hypertens Res** 1995 Jun;18 Suppl 1:S87–92 (31 ref.)

BIOSYNTHESIS

Function and significance of the renal DOPA/DA system. Armando I, et al. **Acta Physiol Pharmacol Ther Latinoam** 1995;45(3):135–46 (111 ref.)

BLOOD

Plasma free dopamine: physiological variability and pathophysiological significance. Miura Y, et al. **Hypertens Res** 1995 Jun;18 Suppl 1:S65–72 (47 ref.)

GENETICS

Genetic determinants of dopaminergic activity: potential role in blood pressure regulation. Kuchel O. **Hypertens Res** 1995 Jun;18 Suppl 1:S1–10 (72 ref.)

METABOLISM

The dopamine transporter. The cloned target site of parkinsonism–inducing toxins and of drugs of abuse. Pifl C, et al. **Adv Neurol** 1996;69:235–8 (9 ref.)

Clinical assessment of sympathetic responses to stress. Goldstein DS. **Ann N Y Acad Sci** 1995 Dec 29;771:570–93 (144 ref.)

Pathophysiological basis of vulnerability to drug abuse: role of an interaction between stress, glucocorticoids, and dopaminergic neurons. Piazza PV, et al. **Annu Rev Pharmacol Toxicol** 1996;36:359–78 (117 ref.)

Opioid receptor types and subtypes: the delta receptor as a model. Zaki PA, et al. **Annu Rev Pharmacol Toxicol** 1996; 36:379–401 (94 ref.)

Neurotransmitter systems in schizophrenia. Reynolds GP. **Int Rev Neurobiol** 1995;38:305–39 (144 ref.)

PET studies of the striatal dopaminergic system in Parkinson's disease (PD). Piccini P, et al. **J Neural Transm Suppl** 1995;45:123–31 (57 ref.)

Chromaffin cell survival and host dopaminergic fiber recovery in a patient with Parkinson's disease treated by cografts of adrenal medulla and pretransected peripheral nerve. Case report. Date I, et al. **J Neurosurg** 1996 Apr; 84(4):685–9 (33 ref.)

Behavioral sensitization and tolerance to cocaine and the occupation of dopamine receptors by dopamine. Martin–Iverson MT, et al. **Mol Neurobiol** 1995 Aug–Dec; 11(1–3):31–46 (69 ref.)

A review of the effects of dopaminergic agents on humans, animals, and drug–seeking behavior, and its implications for medication development.Focus on GBR 12909. Rothman RB, et al. **Mol Neurobiol** 1995 Aug–Dec; 11(1–3):1–19 (130 ref.)

Dopamine–derived 6,7–dihydroxy–1,2,3,4–tetrahydroisoquinolines; oxidation and neurotoxicity. Naoi M, et al. **Prog Brain Res** 1995; 106:227–39 (42 ref.)

The role of dopamine in epilepsy. Starr MS. **Synapse** 1996 Feb;22(2):159–94 (462 ref.)

[Parkinson disease and the neuronal dopamine uptake complex] Costentin J. **Ann Pharm Fr** 1995;53(4):145–54 (87 ref.) (Eng. Abstr.) **(Fre)**

[Neuronal transplantation in animal models of Parkinson disease: in vivo voltammetry, tissue cryopreservation and immunology] Sautter J, et al. **Zentralbl Neurochir** 1995; 56(4):161–7 (28 ref.) (Eng. Abstr.) **(Ger)**

PHARMACOLOGY

Dopamine–induced, genotoxic activation of programmed cell death. A role in nigrostriatal neuronal degeneration in Parkinson's disease? Ziv I, et al. **Adv Neurol** 1996;69:229–33 (26 ref.)

Aminotetralin drugs and D3 receptor functions. What may partially selective D3 receptor ligands tell us about dopamine D3 receptor functions? Lévesque D. **Biochem Pharmacol** 1996 Aug 23;52(4):511–8 (102 ref.)

Anterior pituitary function during critical illness and dopamine treatment. Van den Berghe G, et al. **Crit Care Med** 1996 Sep;24(9):1580–90 (178 ref.)

Comparison of the effect of dopamine in primate arteries and

veins. Okamura T, et al. **Hypertens Res** 1995 Jun;18 Suppl 1:S35-7 (19 ref.)
[Dopamine and the kidney--renal sparing effect: fact or fiction?] Yussim E, et al. **Harefuah** 1996 Apr 1;130(7):480-3 (26 ref.) **(Heb)**

PHYSIOLOGY

Is dopaminergic cell death accompanied by concomitant nerve plasticity? Anglade P, et al. **Adv Neurol** 1996; 69:195-208 (96 ref.)
Contribution of dopaminergic and glutamatergic mechanisms to the pathogenesis of motor response complications in Parkinson's disease. Chase TN, et al. **Adv Neurol** 1996; 69:497-501 (30 ref.)
Functional positron emission tomographic studies of striatal dopaminergic activity. Changes induced by drugs and nigrostriatal degeneration. Tedroff J, et al. **Adv Neurol** 1996;69:443-8 (31 ref.)
Dopamine receptor signaling defects in spontaneous hypertension. Jose PA, et al. **Am J Hypertens** 1996 Apr; 9(4 Pt 1):400-5 (53 ref.)
Serotonin-dopamine interaction and its relevance to schizophrenia. Kapur S, et al. **Am J Psychiatry** 1996 Apr; 153(4):466-76 (140 ref.)
The role of mesolimbic dopaminergic and retrohippocampal afferents to the nucleus accumbens in latent inhibition: implications for schizophrenia. Gray JA, et al. **Behav Brain Res** 1995 Nov;71(1-2):19-31 (80 ref.)
Dopamine regulation of transcription factor-target interactions in rat striatum. Hyman SE, et al. **Chem Senses** 1995 Apr;20(2):257-60 (24 ref.)
Is there a third peripheral catecholaminergic system? Endogenous dopamine as an autocrine/paracrine substance derived from plasma DOPA and inactivated by conjugation. Goldstein DS, et al. **Hypertens Res** 1995 Jun; 18 Suppl 1:S93-9 (76 ref.)
Role for endogenous dopamine in modulating sympathetic-adrenal activity in humans. Mannelli M, et al. **Hypertens Res** 1995 Jun;18 Suppl 1:S79-86 (92 ref.)
Plasma free dopamine: physiological variability and pathophysiological significance. Miura Y, et al. **Hypertens Res** 1995 Jun;18 Suppl 1:S65-72 (47 ref.)
Studies on the nature of the antagonistic actions of dopamine and 5-hydroxytryptamine in renal tissues. Soares-da-Silva P, et al. **Hypertens Res** 1995 Jun;18 Suppl 1:S47-51 (21 ref.)
Effects of picotesla flux electromagnetic fields on dopaminergic transmission in Tourette's syndrome. Sandyk R. **Int J Neurosci** 1996 Feb;84(1-4):187-94 (95 ref.)
Biologic markers and neurochemical correlates of agitation and psychosis in dementia. Kirby M, et al. **J Geriatr Psychiatry Neurol** 1995 Oct;8 Suppl 1:S2-7 (63 ref.)
Do cognitive changes of Parkinson's disease result from dopamine depletion? Dubois B, et al. **J Neural Transm Suppl** 1995;45:27-34 (28 ref.)
The role of monoamine oxidase and catechol O-methyltransferase in dopaminergic neurotransmission. Napolitano A, et al. **J Neural Transm Suppl** 1995;45:35-45 (60 ref.)
Basic research in substantia nigra and ventral tegmental area: clinical implications. Stratta F, et al. **J Neural Transm Suppl** 1995;45:47-55 (65 ref.)
The behavioral neurochemistry of motivation: methodological and conceptual issues in studies of the dynamic activity of nucleus accumbens dopamine. Salamone JD. **J Neurosci Methods** 1996 Feb;64(2):137-49 (152 ref.)
In vivo analysis of the role of dopamine in stimulant and opiate self-administration. Gratton A. **J Psychiatry Neurosci** 1996 Jul;21(4):264-79 (120 ref.)
Modulation of NMDA and dopaminergic neurotransmissions by sigma ligands: possible implications for the treatment of psychiatric disorders. Debonnel G, et al. **Life Sci** 1996; 58(9):721-34 (179 ref.)
Dopamine, serotonin and tachykinin in self-injurious behavior. Sivam SP. **Life Sci** 1996 May 24;58(26):2367-75 (66 ref.)
Optimal physical performance in athletes: key roles of dopamine in a specific neurotransmitter/hormonal mechanism. Gilbert C. **Mech Ageing Dev** 1995 Oct 13; 84(2):83-102 (85 ref.)
Manganese toxicity, dopaminergic dysfunction and hepatic encephalopathy. Butterworth RF, et al. **Metab Brain Dis** 1995 Dec;10(4):259-67 (37 ref.)
The psychobiological regulation of social cooperation [comment] Cloninger CR. **Nat Med** 1995 Jul;1(7):623-5 (21 ref.) Comment on: Nat Med 1995 Jul;1(7):654-7.
Functional significance of mesolimbic dopamine. Kiyatkin EA. **Neurosci Biobehav Rev** 1995 Winter;19(4):573-98 (187 ref.)
Role for the mesocortical dopamine system in the motivating effects of cocaine. Koob GF, et al. **NIDA Res Monogr** 1994;145:1-18 (44 ref.)
Cocaine reward and cocaine craving: the role of dopamine in perspective. Wise RA. **NIDA Res Monogr** 1994; 145:191-206 (92 ref.)
[Deficit schizophrenia: from pharmacology to clinical practice] Tassin JP. **Encephale** 1996 Jun;22 Spec No 2:9-12 (20 ref.) (Eng. Abstr.) **(Fre)**
[Degeneration of catecholaminergic neurons (editorial)] Chatellard-Causse C, et al. **Pathol Biol (Paris)** 1995 Sep; 43(7):577-80 (13 ref.) **(Fre)**
[Dopamine and the kidney--renal sparing effect: fact or fiction?] Yussim E, et al. **Harefuah** 1996 Apr 1;130(7):480-3 (26 ref.) **(Heb)**

THERAPEUTIC USE

Low-dose dopamine in surgical and intensive care unit patients. Bonde J, et al. **Acta Anaesthesiol Scand** 1996 Mar; 40(3):326-30 (34 ref.)
[The therapeutic effect of dopamine in acute kidney failure] Mühlbauer B. **Anaesthesist** 1996 Jul;45(7):657-69 (50 ref.) **(Ger)**
[The role of enzymatic systems in pathophysiology and pharmacotherapy of Parkinson's disease] Kuran W. **Neurol Neurochir Pol** 1995 Jul-Aug;29(4):561-8 (30 ref.) (Eng. Abstr.) **(Pol)**

DOPAMINE AGENTS

PHARMACOLOGY

A review of the effects of dopaminergic agents in humans: implications for medication development. Rothman RB. **NIDA Res Monogr** 1994;145:67-87 (73 ref.)

TOXICITY

Excitatory amino acids and MPTP toxicity. Fornai F, et al. **Adv Neurol** 1996;69:167-76 (52 ref.)

DOPAMINE AGONISTS

ADMINISTRATION & DOSAGE

[The therapy of a macroprolactinoma with the intramuscular application of a long-acting bromocriptine preparation] Kreft B, et al. **Dtsch Med Wochenschr** 1996 Jul 5; 121(27):865-8 (10 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation. Webster J. **Drug Saf** 1996 Apr; 14(4):228-38 (59 ref.)
[Retroperitoneal fibrosis secondary to treatment with L-dopa analogues for Parkinson disease] Sánchez-Chapado M, et al. **Arch Esp Urol** 1995 Dec;48(10):979-83 (28 ref.) (Eng. Abstr.) **(Spa)**

METABOLISM

D2 receptor agonists and partial agonists: relationship between receptor binding measures and functional activity. O'Boyle KM, et al. **Biochem Soc Trans** 1996 Feb; 24(1):183-8 (43 ref.)
The binding of agonists and antagonists to dopamine receptors. Strange PG. **Biochem Soc Trans** 1996 Feb; 24(1):188-92 (28 ref.)

PHARMACOKINETICS

Pharmacokinetics of apomorphine in Parkinson's disease. Gancher S. **J Neural Transm Suppl** 1995;45:137-41 (21 ref.)

PHARMACOLOGY

D2 receptor agonists and partial agonists: relationship between receptor binding measures and functional activity. O'Boyle KM, et al. **Biochem Soc Trans** 1996 Feb; 24(1):183-8 (43 ref.)
Genetics and the organization of the basal ganglia. Hitzemann R, et al. **Int Rev Neurobiol** 1995;38:43-94 (356 ref.)
DOPA-induced "peak dose" dyskinesia: clues implicating D2 receptor-mediated mechanisms using dopaminergic agonists in MPTP monkeys. Blanchet PJ, et al. **J Neural Transm Suppl** 1995;45:103-12 (52 ref.)
The inhibition of peroxide formation as a possible substrate for the neuroprotective action of dihydroergocryptine. Favit A, et al. **J Neural Transm Suppl** 1995;45:297-305 (30 ref.)
Apomorphine continuous stimulation in Parkinson's disease: receptor desensitization as a possible mechanism of reduced motor response. Maggio R, et al. **J Neural Transm Suppl** 1995;45:133-6 (22 ref.)
Dopamine receptor subtype agonists and feeding behavior. Terry P, et al. **Obes Res** 1995 Nov;3 Suppl 4:515S-523S (57 ref.)
The D-1 dopamine receptor: past, present and future an idiosyncratic review. Kebabian JW, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1995 Sep; 19(5):757-78 (44 ref.)
Behavioural pharmacology of 'D-1-like' dopamine receptors: further subtyping, new pharmacological probes and interactions with 'D-2-like' receptors. Waddington JL, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1995 Sep; 19(5):811-31 (65 ref.)
[Apomorphine] Esteban Muñoz J. **Neurologia** 1995 Oct; 10(8):330-7 (55 ref.) **(Spa)**

THERAPEUTIC USE

Preclamol. A "designer drug" in the treatment of advanced Parkinson's disease. Pirtošek Z, et al. **Adv Neurol** 1996; 69:535-40 (26 ref.)
Management of suspected neuroleptic malignant syndrome. Velamoor VR, et al. **Can J Psychiatry** 1995 Nov; 40(9):545-50 (33 ref.)
A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation. Webster J. **Drug Saf** 1996 Apr; 14(4):228-38 (59 ref.)
Dopexamine after cardiac surgery. **Drug Ther Bull** 1995 Apr; 33(4):30-2 (17 ref.)
Diagnosis and drug therapy of prolactinoma. Ciccarelli E, et al. **Drugs** 1996 Jun;51(6):954-65 (63 ref.)
Dopamine agonists in schizophrenia: a review. Benkert O, et al. **Eur Neuropsychopharmacol** 1995;5 Suppl:43-53 (68 ref.)
Dihydroergocryptine in the treatment of Parkinson's disease. Bonuccelli U, et al. **J Neural Transm Suppl** 1995;45:239-45 (33 ref.)
Ropinirole in the symptomatic treatment of Parkinson's disease. Brooks DJ, et al. **J Neural Transm Suppl** 1995; 45:231-8 (15 ref.)
Pergolide mesylate in Parkinson's disease treatment. Pezzoli G, et al. **J Neural Transm Suppl** 1995;45:203-12 (48 ref.)
Dopaminergic agonists in the treatment of Parkinson's disease: a review. Piccoli F, et al. **J Neural Transm Suppl** 1995;45:187-95 (46 ref.)
Second generation of dopamine agonists: pros and cons. Rabey JM. **J Neural Transm Suppl** 1995;45:213-24 (63 ref.)
Cocaine reward and cocaine craving: the role of dopamine in perspective. Wise RA. **NIDA Res Monogr** 1994; 145:191-206 (92 ref.)

DOPAMINE ANTAGONISTS

ADVERSE EFFECTS

Tardive syndromes and other drug-induced movement disorders. Jankovic J. **Clin Neuropharmacol** 1995 Jun; 18(3):197-214 (124 ref.)

DIAGNOSTIC USE

D2-receptor imaging with [123I]IBZM and single photon emission tomography in psychiatry: a survey of current status. Schlösser R, et al. **J Neural Transm Gen Sect** 1995; 99(1-3):173-85 (52 ref.)

METABOLISM

The binding of agonists and antagonists to dopamine receptors. Strange PG. **Biochem Soc Trans** 1996 Feb; 24(1):188-92 (28 ref.)

PHARMACOLOGY

Genetics and the organization of the basal ganglia. Hitzemann R, et al. **Int Rev Neurobiol** 1995;38:43-94 (356 ref.)
The D-1 dopamine receptor: past, present and future an idiosyncratic review. Kebabian JW, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1995 Sep; 19(5):757-78 (44 ref.)

THERAPEUTIC USE

A review of the effects of dopaminergic agents on humans, animals, and drug-seeking behavior, and its implications for medication development.Focus on GBR 12909. Rothman RB, et al. **Mol Neurobiol** 1995 Aug-Dec; 11(1-3):1-19 (130 ref.)

DOPAMINE BETA-HYDROXYLASE

BLOOD

[Dopamine-beta-hydroxylase (DBH)] Nakai T. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:550-2 (11 ref.) **(Jpn)**

DOPAMINE RECEPTOR AGONISTS see **DOPAMINE AGONISTS**

DOPAMINE RECEPTOR ANTAGONISTS see **DOPAMINE ANTAGONISTS**

DOPAMINE RECEPTORS see **RECEPTORS, DOPAMINE**

DOPAMINE D1 RECEPTORS see **RECEPTORS, DOPAMINE D1**

DOPAMINE D2 RECEPTORS see **RECEPTORS, DOPAMINE D2**

DOPAMINE REUPTAKE INHIBITORS see **DOPAMINE UPTAKE INHIBITORS**

DOPAMINE UPTAKE INHIBITORS

PHARMACOLOGY

Dopamine, a common substrate for the rewarding effects of brain stimulation reward, cocaine, and morphine. Kornetsky C, et al. **NIDA Res Monogr** 1994;145:19-39 (66 ref.)

DOPAMINE UPTAKE INHIBITORS

THERAPEUTIC USE

A review of the effects of dopaminergic agents on humans, animals, and drug-seeking behavior, and its implications for medication development.Focus on GBR 12909. Rothman RB, et al. **Mol Neurobiol** 1995 Aug-Dec; 11(1-3):1-19 (130 ref.)

DOPAMINERGIC AGONISTS see **DOPAMINE AGONISTS**

DOPAMINERGIC ANTAGONISTS see **DOPAMINE ANTAGONISTS**

DOPING IN SPORTS

Drugs in sport. MacAuley D. **BMJ** 1996 Jul 27; 313(7051):211-5 (13 ref.)

Sodium bicarbonate loading and the rules of racing [editorial; comment] Williams RB. **Br Vet J** 1995 Sep-Oct; 151(5):473-5 (6 ref.) Comment on: Br Vet J 1995 Sep-Oct;151(5):523-45.

Metabolism of anabolic androgenic steroids [see comments] Schänzer W. **Clin Chem** 1996 Jul;42(7):1001-20 (95 ref.) Comment in: Clin Chem 1996 Jul;42(7):999-1000.

[Drug screening in clinical toxicology and analytical doping control in sports] Ueki M. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:904-6 (5 ref.) **(Jpn)**

LEGISLATION & JURISPRUDENCE

Comparative analysis of European legislation on doping. Cecchi R, et al. **Med Law** 1995;14(7-8):571-9 (26 ref.)

DOPPLER ECHOCARDIOGRAPHY see **ECHOCARDIOGRAPHY, DOPPLER**

DOPPLER ECHOCARDIOGRAPHY, COLOR see **ECHOCARDIOGRAPHY, DOPPLER, COLOR**

DOPPLER-LASER FLOWMETRY see **LASER-DOPPLER FLOWMETRY**

DOPPLER SONOGRAPHY, TRANSCRANIAL see **ULTRASONOGRAPHY, DOPPLER, TRANSCRANIAL**

DOPPLER TRANSCRANIAL SONOGRAPHY see **ULTRASONOGRAPHY, DOPPLER, TRANSCRANIAL**

DOPPLER TRANSCRANIAL ULTRASONOGRAPHY see **ULTRASONOGRAPHY, DOPPLER, TRANSCRANIAL**

DOPPLER ULTRASONOGRAPHY see **ULTRASONOGRAPHY, DOPPLER**

DOPPLER ULTRASONOGRAPHY, COLOR see **ULTRASONOGRAPHY, DOPPLER, COLOR**

DOPPLER ULTRASONOGRAPHY, DUPLEX see **ULTRASONOGRAPHY, DOPPLER, DUPLEX**

DOPPLER ULTRASONOGRAPHY, TRANSCRANIAL see **ULTRASONOGRAPHY, DOPPLER, TRANSCRANIAL**

DOPPLER ULTRASOUND see **ULTRASONICS**

DORMICE see **RODENTIA**

DORSAL POSITION see **SUPINE POSITION**

DORSAL ROOT GANGLIA see **GANGLIA, SPINAL**

DORSAL ROOTS see **SPINAL NERVE ROOTS**

DOSAGE COMPENSATION (GENETICS)

MZ female twins discordant for X-linked diseases: a review. Tiberio G. **Acta Genet Med Gemellol (Roma)** 1994; 43(3-4):207-14 (28 ref.)

X chromosome inactivation, XIST, and pursuit of the X-inactivation center. Willard HF. **Cell** 1996 Jul 12; 86(1):5-7 (14 ref.)

The evolution of chromosomal sex determination and dosage compensation. Charlesworth B. **Curr Biol** 1996 Feb 1; 6(2):149-62 (113 ref.)

Genetic conflict and evolution of mammalian X-chromosome inactivation. Moore T, et al. **Dev Genet** 1995;17(3):206-11 (44 ref.)

Equality for X chromosomes [see comments] Kelley RL, et al. **Science** 1995 Dec 8;270(5242):1607-10 (49 ref.) Comment in: Science 1996 May 24;272(5265):1190-1.

DOSAGE FORMS

see related
DRUG ADMINISTRATION ROUTES

DOSE-RESPONSE RELATIONSHIP, DRUG

Approaches to meeting the criteria for fixed dose antihypertensive combinations. Focus on metoprolol. Kendall MJ. **Drugs** 1995 Sep;50(3):454-64 (51 ref.)

Biological effects of low level exposures. Calabrese EJ. **Hum Exp Toxicol** 1996 Jan;15(1):67-70 (26 ref.)

Sertraline 50 mg daily: the optimal dose in the treatment of depression. Preskorn SH, et al. **Int Clin Psychopharmacol** 1995 Sep;10(3):129-41 (55 ref.)

Are the currently recommended doses of benzathine penicillin G adequate for secondary prophylaxis of rheumatic fever? Currie BJ. **Pediatrics** 1996 Jun;97(6 Pt 2):989-91 (21 ref.)

Principles underlying dose selection for, and extrapolation from, the carcinogen bioassay: dose influences mechanism. Counts JL, et al. **Regul Toxicol Pharmacol** 1995 Jun; 21(3):418-21 (39 ref.)

Chemical mixtures: current risk assessment methodologies and future directions. Seed J, et al. **Regul Toxicol Pharmacol** 1995 Aug;22(1):76-94 (48 ref.)

Tutorial in biostatistics. Designing studies for dose response. Wong WK, et al. **Stat Med** 1996 Feb 28;15(4):343-59 (16 ref.)

The application of dosimetry models to identify key processes and parameters for default dose-response assessment approaches. Jarabek AM. **Toxicol Lett** 1995 Sep; 79(1-3):171-84 (26 ref.)

DOSE-RESPONSE RELATIONSHIP, RADIATION

Risk of radiation at low doses. Beninson D. **Health Phys** 1996 Aug;71(2):122-5 (0 ref.)

DOSIMETRY CALCULATIONS, COMPUTER-ASSISTED see **RADIOTHERAPY PLANNING, COMPUTER-ASSISTED**

DOT IMMUNOBLOTTING see **IMMUNOBLOTTING**

DOUBLE-BLIND METHOD

A critique of the double-blind clinical trial. Part 1. Kiene H. **Altern Ther Health Med** 1996 Jan;2(1):74-80 (41 ref.)

A critique of the double-blind clinical trial. Part 2. Kiene H. **Altern Ther Health Med** 1996 Mar;2(2):59-64 (36 ref.)

DOUBLE-MASKED STUDY see **DOUBLE-BLIND METHOD**

DOUBLE-STRANDED RNA see **RNA, DOUBLE-STRANDED**

DOUBLE-STRANDED RNA-BINDING PROTEINS see **RNA-BINDING PROTEINS**

DOUCHING see **IRRIGATION**

DOUGLAS' POUCH

RADIOGRAPHY

Peritoneographic diagnosis of perineal enterocele after hysterectomy. Tepetes K, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1995 Oct;163(4):367-8 (12 ref.)

DOWN-REGULATION (PHYSIOLOGY)

see related
UP-REGULATION (PHYSIOLOGY)

DRUG EFFECTS

Down regulation of Fc receptors by IVIgG. Mannhalter JW, et al. **Int Rev Immunol** 1989;5(2):173-9 (24 ref.)

PHYSIOLOGY

Downregulation of cellular metabolism during environmental stress: mechanisms and implications. Hand SC, et al. **Annu Rev Physiol** 1996;58:539-63 (165 ref.)

DOWN SYNDROME

see related
AMYLOID BETA-PROTEIN
AMYLOID BETA-PROTEIN PRECURSOR

Down's syndrome and anaesthesia. Mitchell V, et al. **Paediatr Anaesth** 1995;5(6):379-84 (49 ref.)

BLOOD

Maternal serum markers for fetal trisomy 21 screening. Muller F, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Mar;65(1):3-6 (30 ref.)

COMPLICATIONS

Milia-like idiopathic calcinosis cutis: an unusual dermatosis associated with Down syndrome. Schepis C, et al. **Br J Dermatol** 1996 Jan;134(1):143-6 (17 ref.)

Transient abnormal myelopoiesis accompanied by hepatic fibrosis in two infants with Down syndrome. Yagihashi N, et al. **J Clin Pathol** 1995 Oct;48(10):973-5 (10 ref.)

Occipitocervical fusion by Luque loop rod instrumentation in Down syndrome. Higo M, et al. **J Pediatr Orthop** 1995 Jul-Aug;15(4):539-42 (17 ref.)

Inflammatory pseudocyst associated with trisomy 21 and Hirschsprung's disease. DuBois JJ, et al. **Mil Med** 1995 Sep;160(9):477-9 (28 ref.)

Instrumentational posterior fusion for atlanto-axial subluxation in a young child with Down's syndrome--case report. Kohno M, et al. **Neurol Med Chir (Tokyo)** 1995 Oct;35(10):753-8 (22 ref.)

Posterior urethral valves in patients with Down syndrome. Kupferman JC, et al. **Pediatr Nephrol** 1996 Apr;10(2):143-6 (35 ref.)

Down syndrome and leukemia, an update. Drabkin HA, et al. **Prog Clin Biol Res** 1995;393:169-76 (14 ref.)

[Moyamoya associated with Down syndrome] Soto-Ares G, et al. **J Radiol** 1996 Jun;77(6):441-4 (14 ref.) (Eng. Abstr.) **(Fre)**

[Down syndrome: 1. Medical aspects] Decoq P, et al. **Rev Belge Med Dent** 1995;50(3):43-52 (20 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

First trimester serum screening for Down's syndrome [see comments] Wald NJ, et al. **Prenat Diagn** 1995 Dec; 15(13):1227-40 (44 ref.) Comment in: Prenat Diagn 1995 Dec;15(3):1209-13.

Antenatal screening for Down syndrome. Wald NJ. **Prog Clin Biol Res** 1995;393:27-42 (25 ref.)

Screening for Down syndrome in the first trimester. Powell KJ, et al. **Reprod Fertil Dev** 1995;7(6):1413-7 (54 ref.)

[Blood markers in the prenatal diagnosis of Down's syndrome: the triple test] Ortega-Benito JM. **Med Clin (Barc)** 1995 Sep 9;105(7):264-8 (32 ref.) **(Spa)**

ETIOLOGY

[An analysis of the causes for the occurrence of Down's syndrome and the current approaches to its prevention at the stage of mass prenatal ultrasonic and immunobiochemical screening of pregnant women] Veropotvelian NP, et al. **Tsitol Genet** 1995 Sep-Oct; 29(5):82-92 (71 ref.) (Eng. Abstr.) **(Rus)**

GENETICS

Craniovertebral junction anomalies in inherited disorders: part of the syndrome or caused by the disorder? Crockard HA, et al. **Eur J Pediatr** 1995 Jul;154(7):504-12 (48 ref.)

YAC transgenic mice in the study of the genetic basis of Down syndrome. Cabin DE, et al. **Prog Clin Biol Res** 1995; 393:213-26 (28 ref.)

Transgenic models for chromosome 21 gene dosage effects. Groner Y. **Prog Clin Biol Res** 1995;393:193-212 (40 ref.)

Preliminary characterization of the central nervous system in partial trisomy 16 mice. Holtzman DM, et al. **Prog Clin Biol Res** 1995;393:227-40 (32 ref.)

The integrated map of human chromosome 21. Patterson D. **Prog Clin Biol Res** 1995;393:43-55 (35 ref.)

Genetic determinants of Alzheimer disease. St George-Hyslop P. **Prog Clin Biol Res** 1995;393:139-45 (23 ref.)

IMMUNOLOGY

Immune dysfunction in Down's syndrome: primary immune deficiency or early senescence of the immune system? Cuadrado E, et al. **Clin Immunol Immunopathol** 1996 Mar; 78(3):209-14 (61 ref.)

A hypothesis to explain the immune defects in Down syndrome. Murphy M, et al. **Prog Clin Biol Res** 1995; 393:147-67 (48 ref.)

PATHOLOGY

Magnetic resonance imaging of the aging brain in Down syndrome. Emerson JF, et al. **Prog Clin Biol Res** 1995; 393:123-38 (28 ref.)

Considerations of quantitative data on organ sizes and cell numbers and sizes in Down syndrome. Landing BH, et al. **Prog Clin Biol Res** 1995;393:177-91 (36 ref.)

PREVENTION & CONTROL

First trimester serum screening for Down's syndrome [see comments] Wald NJ, et al. **Prenat Diagn** 1995 Dec; 15(13):1227-40 (44 ref.) Comment in: Prenat Diagn 1995 Dec;15(3):1209-13.

[Maternal serum screening for detection of fetal chromosome abnormalities] Holzgreve W, et al. **Gynakologe** 1995 Oct; 28(5):280-8 (44 ref.) **(Ger)**

[An analysis of the causes for the occurrence of Down's syndrome and the current approaches to its prevention at the stage of mass prenatal ultrasonic and immunobiochemical screening of pregnant women] Veropotvelian NP, et al. **Tsitol Genet** 1995 Sep-Oct; 29(5):82-92 (71 ref.) (Eng. Abstr.) **(Rus)**

DOWNREGULATION see **DOWN-REGULATION (PHYSIOLOGY)**

DOXAZOSIN

THERAPEUTIC USE

Doxazosin: a new approach to hypertension and benign

prostatic hyperplasia. Pool JL. **Br J Clin Pract** 1996 Apr-May;50(3):154-63 (70 ref.)
[Evaluation of the antihypertensive drugs carvedilol, doxazosin and moxonidine] Dominiak P. **Wien Med Wochenschr** 1995;145(15-16):373-82 (92 ref.) (Eng. Abstr.) **(Ger)**

DOXAZOSIN MESYLATE see **DOXAZOSIN**

DOXORUBICIN

ADMINISTRATION & DOSAGE

Liposomal doxorubicin (Doxil). Porche DJ. **J Assoc Nurses AIDS Care** 1996 Mar-Apr;7(2):55-9 (6 ref.)
Treatment of metastatic breast cancer with paclitaxel and doxorubicin. Dombernowsky P, et al. **Semin Oncol** 1995 Dec;22(6 Suppl 15):13-7 (14 ref.)

ADVERSE EFFECTS

Combination therapy with probucol prevents adriamycin-induced cardiomyopathy. Singal PK, et al. **J Mol Cell Cardiol** 1995 Apr;27(4):1055-63 (80 ref.)

PHARMACOLOGY

[Expression of the MDR1 gene in five human cell lines of medullary thyroid cancer and reversion of the resistance to doxorubicine by ciclosporin A and verapamil] Massart C, et al. **Bull Cancer (Paris)** 1996 Jan;83(1):39-45 (32 ref.) (Eng. Abstr.) **(Fre)**

DOXYLAMINE

TOXICITY

Bendectin: review of the medical literature of a comprehensively studied human nonteratogen and the most prevalent tortogen-litigen. Brent RL. **Reprod Toxicol** 1995 Jul-Aug;9(4):337-49 (178 ref.)

DPN see **NAD**

DPNASE see **NAD+ NUCLEOSIDASE**

DPT VACCINE see **DIPHTHERIA-TETANUS-PERTUSSIS VACCINE**

DRAINAGE

Treatment of complicated pleural fluid collections with image-guided drainage and intracavitary urokinase [see comments] Moulton JS, et al. **Chest** 1995 Nov; 108(5):1252-9 (20 ref.) Comment in: Chest 1995 Nov;108(5):1190-1.
The role of preoperative biliary decompression in obstructive jaundice. Nakeeb A, et al. **Hepatogastroenterology** 1995 Jul-Aug;42(4):332-7 (26 ref.)
The use of drains in elective surgery for colorectal cancer: always, never or selectively? Averbach AM, et al. **Tumori** 1995 May-Jun;81(3 Suppl):89-97 (24 ref.)
[Results of endoscopic biliary drainage in primary tumors of the common bile duct (cholangiocarcinoma)] Costamagna G, et al. **Chir Ital** 1995;47(1):18-23 (20 ref.) (Eng. Abstr.) **(Ita)**

ADVERSE EFFECTS

External abdominal hernia of mucocele of the appendix in drain-tube removal site. Bacchin P, et al. **Radiol Med (Torino)** 1995 Dec;90(6):827-9 (13 ref.)

INSTRUMENTATION

Biliary endoprostheses in elderly patients with endoscopically irretrievable common bile duct stones: report on 117 patients [see comments] Bergman JJ, et al. **Gastrointest Endosc** 1995 Sep;42(3):195-201 (24 ref.) Comment in: Gastrointest Endosc 1995 Sep;42(3):272-3.

METHODS

Abscess drainage techniques. Grant DS. **Br J Hosp Med** 1995 Nov 1-14;54(9):435-8 (14 ref.)
Large-volume paracentesis in the treatment of cirrhotic patients with refractory ascites. The role of postparacentesis plasma volume expansion. Forouzandeh B, et al. **J Clin Gastroenterol** 1996 Apr;22(3):207-10 (51 ref.)
[Percutaneous treatment of malignant stenoses of the hilum] Bonnel D, et al. **Gastroenterol Clin Biol** 1995 Jun-Jul; 19(6-7):564-71 (24 ref.) (Eng. Abstr.) **(Fre)**
[Adjuvant therapy in lymphedema] Brenke R, et al. **Z Lymphol** 1996 Jun;20(1):31-5 (10 ref.) (Eng. Abstr.) **(Ger)**

DRAINAGE, SUCTION see **SUCTION**

DREAMS

[Dream recall in depressed patients] Schredl M. **Psychother Psychosom Med Psychol** 1995 Dec;45(12):414-7 (29 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Observations on delta homeostasis, the one-stimulus model of NREM-REM alternation and the neurobiologic implications of experimental dream studies. Feinberg I, et al. **Behav Brain Res** 1995 Jul-Aug;69(1-2):97-108 (56 ref.)
One possible function of sleep: to produce dreams. Mancia M. **Behav Brain Res** 1995 Jul-Aug;69(1-2):203-6 (22 ref.)
Physical motion in dreams: one measure of three theories. Porte HS, et al. **J Abnorm Psychol** 1996 Aug;105(3):329-35 (45 ref.)

PSYCHOLOGY

The written dream: action, resistance and revelation. Stimmel B. **Psychoanal Q** 1995 Oct;64(4):658-71 (14 ref.)

DRESSINGS see **BANDAGES**

DRESSINGS, BIOLOGICAL see **BIOLOGICAL DRESSINGS**

DRESSINGS, OCCLUSIVE see **OCCLUSIVE DRESSINGS**

DRG see **DIAGNOSIS-RELATED GROUPS**

DRINKING

see related
ALCOHOL DRINKING

Appropriate fluid regimens to prevent bronchopulmonary dysplasia. Tammela OK. **Eur J Pediatr** 1995;154(8 Suppl 3):S15-8 (18 ref.)

PHYSIOLOGY

Neurobiology of central angiotensin III and dipsogenesis. Yang CC, et al. **Biol Signals** 1995 Mar-Apr;4(2):59-71 (70 ref.)

DRINKING, ALCOHOL see **ALCOHOL DRINKING**

DRINKING BEHAVIOR

The differential diagnosis of polyuria/polydipsia in dogs. Belshaw BE. **Vet Q** 1995 Apr;17 Suppl 1:S19-21 (0 ref.)

DRIP INFUSIONS see **INFUSIONS, INTRAVENOUS**

DRIVE

see related
MOTIVATION

DRONABINOL see **TETRAHYDROCANNABINOL**

DROOLING see **SIALORRHEA**

DROPERIDOL

ADVERSE EFFECTS

Neuroleptic malignant syndrome in a trauma patient [see comments] Burke C, et al. **J Trauma** 1995 Oct;39(4):796-8 (11 ref.) Comment in: J Trauma 1996 Apr;40(4):673.

DROPSY see **EDEMA**

DROSOPHILA

Speciation. Down the bottleneck? Charlesworth B. **Curr Biol** 1995 Sep 1;5(9):995-6 (10 ref.)

ANATOMY & HISTOLOGY

Dosage-dependent modification of position-effect variegation in Drosophila. Henikoff S. **Bioessays** 1996 May; 18(5):401-9 (53 ref.)
Wiring by fly: the neuromuscular system of the Drosophila embryo. Bate M, et al. **Neuron** 1995 Sep;15(3):513-25 (108 ref.)

CYTOLOGY

Cell-cell signaling, microtubules, and the loss of symmetry in the Drosophila oocyte. Lehmann R. **Cell** 1995 Nov 3; 83(3):353-6 (15 ref.)
Diversification of cell cycle controls in developing embryos. Edgar B. **Curr Opin Cell Biol** 1995 Dec;7(6):815-24 (77 ref.)
Fly division. Miller KG, et al. **J Cell Biol** 1995 Oct;131(1):1-5 (40 ref.)

EMBRYOLOGY

BMP signaling in Drosophila embryogenesis. Arora K, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:80-97 (68 ref.)
Drosophila gastrulation: from pattern formation to morphogenesis. Leptin M. **Ann Rev Cell Dev Biol** 1995; 11:189-212 (67 ref.)
Adherens junctions in the Drosophila embryo: the role of E-cadherin in their establishment and morphogenetic function. Knust E, et al. **Bioessays** 1996 Aug;18(8):609-12 (21 ref.)
Drosophila development pulls the strings of the cell cycle. Reed BH. **Bioessays** 1995 Jun;17(6):553-6 (23 ref.)
Tag team specification of a neural precursor in the Drosophila embryonic central nervous system. Skeath JB. **Bioessays** 1995 Oct;17(10):829-31 (18 ref.)
Spindle orientation and asymmetric localization in Drosophila: both inscuteable? Doe CQ. **Cell** 1996 Sep 6; 86(5):695-7 (16 ref.)
Morphogens, compartments, and pattern: lessons from drosophila? Lawrence PA, et al. **Cell** 1996 Jun 28; 85(7):951-61 (100 ref.)
Diversification of cell cycle controls in developing embryos. Edgar B. **Curr Opin Cell Biol** 1995 Dec;7(6):815-24 (77 ref.)
Early decisions in Drosophila eye morphogenesis. Bonini NM, et al. **Curr Opin Genet Dev** 1995 Aug;5(4):507-15 (73 ref.)
Signalling by hedgehog family proteins in Drosophila and vertebrate development. Ingham PW. **Curr Opin Genet Dev** 1995 Aug;5(4):492-8 (67 ref.)
Role of the actin cytoskeleton in early Drosophila development. Miller KG. **Curr Top Dev Biol** 1995; 31:167-96 (59 ref.)
Regulatory interactions during early neurogenesis in Drosophila. Hassan B, et al. **Dev Genet** 1996;18(1):18-27 (88 ref.)
Development and function of embryonic central nervous system glial cells in Drosophila. Klämbt C, et al. **Dev Genet** 1996;18(1):40-9 (87 ref.)
Growth factors in development: the role of TGF-beta related polypeptide signalling molecules in embryogenesis. Hogan BL, et al. **Dev Suppl** 1994;:53-60 (65 ref.)
Wiring by fly: the neuromuscular system of the Drosophila embryo. Bate M, et al. **Neuron** 1995 Sep;15(3):513-25 (108 ref.)
Long-range repression in the Drosophila embryo. Cai HN, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9309-14 (29 ref.)
A new turn (or two) for twist [comment] Michelson AM. **Science** 1996 Jun 7;272(5267):1449-50 (15 ref.) Comment on: Science 1996 Jun 7;272(5267):1476-80. Comment on: Science 1996 Jun 7;272(5267):1481-4.

GENETICS

Dosage-dependent modification of position-effect variegation in Drosophila. Henikoff S. **Bioessays** 1996 May; 18(5):401-9 (53 ref.)
The bond between sisters [comment] Sekelsky JJ, et al. **Cell** 1995 Oct 20;83(2):157-60 (23 ref.) Comment on: Cell 1995 Oct 20;83(2):247-56.
Quantitative genetics. Loci with large effects. Keightley PD. **Curr Biol** 1995 May 1;5(5):485-7 (7 ref.)
Muscle development. Making Drosophila muscle. Taylor MV. **Curr Biol** 1995 Jul 1;5(7):740-2 (14 ref.)
Heterochromatin and gene regulation in Drosophila. Elgin SC. **Curr Opin Genet Dev** 1996 Apr;6(2):193-202 (65 ref.)
Genomic regulation of transposable elements in Drosophila. Lozovskaya ER, et al. **Curr Opin Genet Dev** 1995 Dec; 5(6):768-73 (37 ref.)
Chromatin complexes regulating gene expression in Drosophila. Pirrotta V. **Curr Opin Genet Dev** 1995 Aug; 5(4):466-72 (57 ref.)
RNA localization and the cytoskeleton in Drosophila oocytes. Pokrywka NJ. **Curr Top Dev Biol** 1995;31:139-66 (49 ref.)
P elements in Drosophila. Engels WR. **Curr Top Microbiol Immunol** 1996;204:103-23 (134 ref.)
Gene silencing in Drosophila. Henikoff S. **Curr Top Microbiol Immunol** 1995;197:193-208 (77 ref.)
Regulatory interactions during early neurogenesis in Drosophila. Hassan B, et al. **Dev Genet** 1996;18(1):18-27 (88 ref.)
Flies, genes, learning, and memory. Greenspan RJ. **Neuron** 1995 Oct;15(4):747-50 (29 ref.)
The genetics of brain development: conserved programs in flies and mice. Thor S. **Neuron** 1995 Nov;15(5):975-7 (18 ref.)
Physiology and biochemistry of Drosophila learning mutants. Davis RL. **Physiol Rev** 1996 Apr;76(2):299-317 (97 ref.)
Genetic and molecular analysis of the gypsy chromatin insulator of Drosophila. Gdula DA, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9378-83 (43 ref.)
Meiosis in Drosophila: seeing is believing. Orr-Weaver TL. **Proc Natl Acad Sci U S A** 1995 Nov 7;92(23):10443-9 (59 ref.)
Medfly transformed—official! [comment] Ashburner M. **Science** 1995 Dec 22;270(5244):1941-2 (11 ref.) Comment on: Science 1995 Dec 22;270(5244):2002-5. Comment on: Science 1995 Dec 22;270(5244):2005-8.
Drosophila chromatin and transcription. Becker PB. **Semin Cell Biol** 1995 Aug;6(4):185-90 (50 ref.)
[Cloning, expression, and regulation of tissue-specific genes in Drosophila] Korochkin LI. **Genetika** 1995 Aug; 31(8):1029-42 (68 ref.) (Eng. Abstr.) **(Rus)**

GROWTH & DEVELOPMENT

Intercellular signaling and the polarization of body axes during Drosophila oogenesis. Ray RP, et al. **Genes Dev** 1996 Jul 15;10(14):1711-23 (80 ref.)
Metamorphosis in Drosophila: from molecular biology to mutants. Bender M. **Trends Genet** 1995 Sep;11(9):335-6 (21 ref.)

DROSOPHILA

METABOLISM

Co-assembly of potassium channel subunits in Drosophila: the combinatorial hypothesis revisited. Wu CF, et al. **Chin J Physiol** 1995;38(3):131–8 (50 ref.)
Dissection of the Torso signal transduction pathway in Drosophila. Perrimon N, et al. **Mol Reprod Dev** 1995 Dec; 42(4):515–22 (29 ref.)
Notch and Wingless signals collide [see comments] Blair SS. **Science** 1996 Mar 29;271(5257):1822–3 (16 ref.) Comment in: Science 1996 Mar 29;271(5257):1826–32.

PHYSIOLOGY

The specificity of homeotic gene function. Mann RS. **Bioessays** 1995 Oct;17(10):855–63 (74 ref.)
What the fly's glia tell the fly's brain. Pfrieger FW, et al. **Cell** 1995 Dec 1;83(5):671–4 (19 ref.)
Phosphoinositide-mediated phototransduction in Drosophila photoreceptors: the role of Ca2+ and trp. Hardie RC, et al. **Cell Calcium** 1995 Oct;18(4):256–74 (125 ref.)
The developmental consequences of alternate splicing in sex determination and differentiation in Drosophila. MacDougall C, et al. **Dev Biol** 1995 Dec;172(2):353–76 (144 ref.)
Cysteine string proteins and presynaptic function. Umbach JA, et al. **J Physiol Paris** 1995;89(2):95–101 (25 ref.)
Physiology and biochemistry of Drosophila learning mutants. Davis RL. **Physiol Rev** 1996 Apr;76(2):299–317 (97 ref.)
The biology of vision of Drosophila. Zuker CS. **Proc Natl Acad Sci U S A** 1996 Jan 23;93(2):571–6 (52 ref.)
A model for circadian oscillations in the Drosophila period protein (PER). Goldbeter A. **Proc R Soc Lond B Biol Sci** 1995 Sep 22;261(1362):319–24 (46 ref.)

DROSOPHILA MELANOGASTER

The accessory gland proteins in male Drosophila: structural, reproductive, and evolutionary aspects. Chen PS. **Experientia** 1996 Jun 15;52(6):503–10 (69 ref.)
The Drosophila Stock Centers and their implications for developmental biology. Rasmuson-Lestander A. **Int J Dev Biol** 1995 Oct;39(5):765–8 (29 ref.)

EMBRYOLOGY

The anterior-posterior and dorsal-ventral axes have a common origin in Drosophila melanogaster. Munn K, et al. **Bioessays** 1995 Nov;17(11):920–2 (22 ref.)
How many signals does it take? Venkatesh TV, et al. **Bioessays** 1995 Sep;17(9):754–7 (31 ref.)
Pattern formation. Gurken meets torpedo for the first time. Gavis ER. **Curr Biol** 1995 Nov 1;5(11):1252–4 (14 ref.)
Morphogenetic signalling. Responses to hedgehog. Kalderon D. **Curr Biol** 1995 Jun 1;5(6):580–2 (15 ref.)
mRNA localisation during development. Micklem DR. **Dev Biol** 1995 Dec;172(2):377–95 (165 ref.)
Cell proliferation and development of the Malpighian tubules in Drosophila melanogaster. Skaer H. **Exp Nephrol** 1996 Mar-Apr;4(2):119–26 (30 ref.)

ENZYMOLOGY

Analysis of biological function of poly(ADP-ribosyl)ation in Drosophila melanogaster. Miwa M, et al. **Biochimie** 1995; 77(6):466–71 (32 ref.)
The Wilhelmine E. Key 1992 Invitational lecture. Phenotypic analysis of the Dopa decarboxylase gene cluster mutants in Drosophila melanogaster. Wright TR. **J Hered** 1996 May-Jun;87(3):175–90 (99 ref.)

GENETICS

Chromosomal duplications in bacteria, fruit flies, and humans. Lupski JR, et al. **Am J Hum Genet** 1996 Jan;58(1):21–7 (79 ref.)
Transcriptional silencing of homeotic genes in Drosophila. Bienz M, et al. **Bioessays** 1995 Sep;17(9):775–84 (71 ref.)
Drosophila Sgs genes: stage and tissue specificity of hormone responsiveness. Lehmann M. **Bioessays** 1996 Jan; 18(1):47–54 (70 ref.)
The myosin superfamily in Drosophila melanogaster. Morgan NS. **J Exp Zool** 1995 Oct 1;273(2):104–17 (89 ref.)
Genetic mechanisms of early neurogenesis in Drosophila melanogaster. Campos-Ortega JA. **Mol Neurobiol** 1995 Apr-Jun;10(2-3):75–89 (97 ref.)
period and timeless tango: a dance of two clock genes. Reppert SM, et al. **Neuron** 1995 Nov;15(5):983–6 (23 ref.)
Gene disruptions using P transposable elements: an integral component of the Drosophila genome project. Spradling AC, et al. **Proc Natl Acad Sci U S A** 1995 Nov 21; 92(24):10824–30 (38 ref.)
Equality for X chromosomes [see comments] Kelley RL, et al. **Science** 1995 Dec 8;270(5242):1607–10 (49 ref.) Comment in: Science 1996 May 24;272(5265):1190–1.
The relationship between the flamenco gene and gypsy in Drosophila: how to tame a retrovirus. Bucheton A. **Trends Genet** 1995 Sep;11(9):349–53 (40 ref.)
The genetic basis of quantitative variation: numbers of sensory bristles of Drosophila melanogaster as a model system. Mackay TF. **Trends Genet** 1995 Dec;11(12):464–70 (35 ref.)

GROWTH & DEVELOPMENT

From embryogenesis to metamorphosis: the regulation and function of Drosophila nuclear receptor superfamily members. Thummel CS. **Cell** 1995 Dec 15;83(6):871–7 (56 ref.)

PHYSIOLOGY

The olfactory and visual systems are closely related in Drosophila. Gaines P, et al. **Braz J Med Biol Res** 1995 Feb;28(2):161–7 (27 ref.)
Serpentine proteins slither into the wingless and hedgehog fields. Perrimon N. **Cell** 1996 Aug 23;86(4):513–6 (19 ref.)
Memory mechanisms. Photographic memory in flies. Goda Y. **Curr Biol** 1995 Aug 1;5(8):852–3 (11 ref.)
Recent advances in understanding signal transduction pathways in worms and flies. Duffy JB, et al. **Curr Opin Cell Biol** 1996 Apr;8(2):231–8 (44 ref.)
Selection for increased longevity in Drosophila melanogaster: reflections on new data. Baret PV, et al. **Gerontology** 1996; 42(1):14–7 (10 ref.)
Biochemistry of insect learning: lessons from bees and flies. Meller VH, et al. **Insect Biochem Mol Biol** 1996 Apr; 26(4):327–35 (81 ref.)
Drosophila in vision research. The Friedenwald Lecture. Pak WL. **Invest Ophthalmol Vis Sci** 1995 Nov;36(12):2340–57 (137 ref.)
The biochemistry of learning and memory. Fagnou DD, et al. **Mol Cell Biochem** 1995 Aug-Sep;149-150:279–86 (84 ref.)
Molecular enhancement of memory formation. Carew TJ. **Neuron** 1996 Jan;16(1):5–8 (24 ref.)

VIROLOGY

The relationship between the flamenco gene and gypsy in Drosophila: how to tame a retrovirus. Bucheton A. **Trends Genet** 1995 Sep;11(9):349–53 (40 ref.)

DROUGHT see **NATURAL DISASTERS**

DROWNING

see related
NEAR DROWNING
RESUSCITATION

PHYSIOPATHOLOGY

[Clinical case of the month. Apropos a case of drowning] Moonen M, et al. **Rev Med Liege** 1996 Jul;51(7):453–60 (12 ref.) **(Fre)**

DROWSINESS see **SLEEP STAGES**

DRUG ABUSE see **SUBSTANCE ABUSE**

DRUG ABUSE, INTRAVENOUS see **SUBSTANCE ABUSE, INTRAVENOUS**

DRUG ABUSE, PARENTERAL see **SUBSTANCE ABUSE, INTRAVENOUS**

DRUG ABUSE, SPORTS see **DOPING IN SPORTS**

DRUG ABUSE TREATMENT CENTERS see **SUBSTANCE ABUSE TREATMENT CENTERS**

DRUG ADDICTION see **SUBSTANCE DEPENDENCE**

DRUG ADMINISTRATION, INHALATION see **ADMINISTRATION, INHALATION**

DRUG ADMINISTRATION, RESPIRATORY see **ADMINISTRATION, INHALATION**

DRUG ADMINISTRATION ROUTES

[Pharmacological routes of administration in circulatory collapse] Kristensen BB, et al. **Ugeskr Laeger** 1995 Dec 4;157(49):6864–8 (35 ref.) (Eng. Abstr.) **(Dan)**

DRUG ADMINISTRATION SCHEDULE

Adaptive control of drug dosage regimens using maximum a posteriori probability Bayesian fitting. Proost JH. **Int J Clin Pharmacol Ther** 1995 Oct;33(10):531–6 (43 ref.)

DRUG ADULTERATION see **DRUG CONTAMINATION**

DRUG AEROSOL THERAPY see **ADMINISTRATION, INHALATION**

DRUG AND NARCOTIC CONTROL

Pharmaceutical solids: a strategic approach to regulatory considerations. Byrn S, et al. **Pharm Res** 1995 Jul; 12(7):945–54 (22 ref.)

LEGISLATION & JURISPRUDENCE

Drug use and human rights: privacy, vulnerability, disability, and human rights infringements. Gilmore N. **J Contemp Health Law Policy** 1996 Spring;12(2):355–447 (348 ref.)
The North American Free Trade Agreement's effect on pharmaceutical patents: a bitter pill to swallow or a therapeutic solution? Silbermann JM. **J Contemp Health Law Policy** 1996 Spring;12(2):607–36 (176 ref.)

DRUG ANTAGONISM

see related
NARCOTIC ANTAGONISTS

DRUG APPROVAL

see related
DRUGS, INVESTIGATIONAL
Unapproved uses of approved drugs: the physician, the package insert, and the Food and Drug Administration: subject review. American Academy of Pediatrics Committee on Drugs [see comments] **Pediatrics** 1996 Jul; 98(1):143–5 (00 ref.) Comment in: Pediatrics 1996 Jul;98(1):118–23.

METHODS

Randomised trialomania? The multicentre liver transplant trials of tacrolimus [see comments] Starzl TE, et al. **Lancet** 1995 Nov 18;346(8986):1346–50 (28 ref.) Comment in: Lancet 1995 Nov 18;346(8986):1310–1.
[For new antimalarial drugs: the methods of fundamental research] Ambroise-Thomas P. **Med Trop (Mars)** 1995;55(4 Suppl):23–6 (11 ref.) (Eng. Abstr.) **(Fre)**

STATISTICS & NUMERICAL DATA

Defining, monitoring and combining safety information in clinical trials. Enas GG, et al. **Stat Med** 1995 May 15–30; 14(9–10):1099–111; discussion 1113–6 (24 ref.)

DRUG APPROVAL PROCESS see **DRUG APPROVAL**

DRUG BENEFIT PLANS see **INSURANCE, PHARMACEUTICAL SERVICES**

DRUG CARRIERS

Biodegradable polymers for protein and peptide drug delivery. Gombotz WR, et al. **Bioconjug Chem** 1995 Jul-Aug;6(4):332–51 (234 ref.)
Recent advances in liposomal drug-delivery systems. Chonn A, et al. **Curr Opin Biotechnol** 1995 Dec;6(6):698–708 (120 ref.)
Transporting therapeutics across the blood-brain barrier. Abbott NJ, et al. **Mol Med Today** 1996 Mar;2(3):106–13 (41 ref.)
Targeting of drugs to the liver. Meijer DK, et al. **Semin Liver Dis** 1995 Aug;15(3):202–56 (408 ref.)
[Kinetic analysis of hepatobiliary transport of drugs: importance of carrier-mediated transport] Yamazaki M, et al. **Yakugaku Zasshi** 1995 Dec;115(12):953–77 (101 ref.) (Eng. Abstr.) **(Jpn)**

DRUG COMBINATIONS, ANTIBIOTIC see **ANTIBIOTICS, COMBINED**

DRUG COMBINATIONS, ANTINEOPLASTIC see **ANTINEOPLASTIC AGENTS, COMBINED**

DRUG COMPOUNDING

[Mirror, mirror on the wall---stereoselectivity of drug effects] Fromm MF, et al. **Fortschr Med** 1995 Aug 30;113(24):343–5 (0 ref.) **(Ger)**

DRUG CONTAINERS AND CLOSURES see **DRUG PACKAGING**

DRUG CONTAMINATION

Viral iatrogenic contamination and safety of biologicals. Horaud F. **Blood Coagul Fibrinolysis** 1995 Jul;6 Suppl 2:S5–9 (21 ref.)
Determination of drug-related impurities by capillary electrophoresis. Altria KD. **J Chromatogr A** 1996 May 31; 735(1-2):43–56 (58 ref.)
Why prescribe highly purified factor VIII and IX concentrates? Berntorp E. **Vox Sang** 1996;70(2):61–8 (42 ref.)

DRUG COSTS

The cost of sedating and paralyzing the critically ill patient. Cheng EY. **Crit Care Clin** 1995 Oct;11(4):1005–19 (29 ref.)

DRUG DELIVERY SYSTEMS

see related
DRUG ADMINISTRATION ROUTES
DRUG CARRIERS
Emerging delivery systems for estrogen replacement: aspects of transdermal and oral delivery. Nachtigall LE. **Am J Obstet Gynecol** 1995 Sep;173(3 Pt 2):993–7 (15 ref.)
Optimizing inhaled drug delivery in patients with asthma. Jackson C, et al. **Br J Gen Pract** 1995 Dec;45(401):683–7

(35 ref.)
Novel delivery of antiarrhythmic agents. Labhasetwar V, et al. **Clin Pharmacokinet** 1995 Jul;29(1):1–5 (24 ref.)
Biodegradable microspheres in drug delivery. Okada H, et al. **Crit Rev Ther Drug Carrier Syst** 1995;12(1):1–99 (475 ref.)
Targeting HIV with liposome–encapsulated antivirals [editorial] Désormeaux A, et al. **Int J Med Microbiol Virol Parasitol Infect Dis** 1995 Apr; 282(3):225–31 (15 ref.)
Regional chemotherapy: revisited [editorial] Markman M. **J Cancer Res Clin Oncol** 1996;122(1):1–2 (11 ref.)
Receptor mediated glycotargeting. Wadhwa MS, et al. **J Drug Target** 1995;3(2):111–27 (179 ref.)
Delivery of protein antigen to the major histocompatibility complex class I–restricted antigen presentation pathway. Zhou F, et al. **J Drug Target** 1995;3(2):91–109 (177 ref.)
Transporting therapeutics across the blood–brain barrier. Abbott NJ, et al. **Mol Med Today** 1996 Mar;2(3):106–13 (41 ref.)
Identification of endothelial cell–surface proteins as targets for diagnosis and treatment of disease. Jacobson BS, et al. **Nat Med** 1996 Apr;2(4):482–4 (22 ref.)
Vector–mediated delivery of opioid peptides to the brain. Bickel U, et al. **NIDA Res Monogr** 1995;154:28–46 (39 ref.)
Retrometabolic approaches to drug targeting. Bodor N. **NIDA Res Monogr** 1995;154:1–27 (48 ref.)
Targeting drugs to the brain by sequential metabolism. Bodor N. **NIDA Res Monogr** 1995;147:1–32 (83 ref.)
Passive and facilitative transport of nucleobases, nucleosides, and oligonucleotides—application to antiviral and other therapies. Brewster ME, et al. **NIDA Res Monogr** 1995; 154:61–85 (62 ref.)
Oral peptide delivery: improving the systemic availability of small peptides and enkephalin analogs. Lee HJ, et al. **NIDA Res Monogr** 1995;154:86–106 (16 ref.)
Microtubule–based motor proteins: new targets for enhancing drug delivery? Hamm–Alvarez SF. **Pharm Res** 1996 Apr; 13(4):489–96 (48 ref.)
Aerosol delivery systems for bronchial asthma. Ariyananda PL, et al. **Postgrad Med J** 1996 Mar;72(845):151–6 (60 ref.)
Inhalers and nebulizers: which to choose and why. Pedersen S. **Respir Med** 1996 Feb;90(2):69–77 (65 ref.)
[Fundamentals of plasma chemistry and its application to drug engineering] Kuzuya M. **Yakugaku Zasshi** 1996 Apr; 116(4):266–85 (57 ref.) (Eng. Abstr.) **(Jpn)**
[Basic study and application of functional liposomes] Oku N. **Yakugaku Zasshi** 1995 Jul;115(7):483–98 (32 ref.) (Eng. Abstr.) **(Jpn)**

INSTRUMENTATION

Treatment of vascular disease with local drug delivery systems. Makkar RR, et al. **Cardiologia** 1995 Sep; 40(9):651–7 (47 ref.)
The use of polymers in the construction of controlled–release devices. Heller J. **NIDA Res Monogr** 1995;154:107–31 (33 ref.)
[Local drug administration systems, preclinical and clinical use: perspectives and limitations] Gonschior P, et al. **Z Kardiol** 1996 Mar;85(3):155–65 (59 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Protein engineering and design for drug delivery. Murphy JR. **Curr Opin Struct Biol** 1996 Aug;6(4):541–5 (25 ref.)
Chemotherapeutic tumour targeting using clostridial spores. Minton NP, et al. **FEMS Microbiol Rev** 1995 Oct; 17(3):357–64 (40 ref.)

TRENDS

Recent advances in liposomal drug–delivery systems. Chonn A, et al. **Curr Opin Biotechnol** 1995 Dec;6(6):698–708 (120 ref.)

DRUG DELIVERY SYSTEMS, IMPLANTABLE see **INFUSION PUMPS, IMPLANTABLE**

DRUG DEPENDENCE see **SUBSTANCE DEPENDENCE**

DRUG DESIGN

Design of orally active iron chelators. Hider RC, et al. **Acta Haematol** 1996;95(1):6–12 (23 ref.)
Protein crystallography in Australia. Parker MW. **Aust N Z J Med** 1995 Dec;25(6):876–82 (40 ref.)
Challenges in the development of orally bioavailable thrombin active site inhibitors. Kimball SD. **Blood Coagul Fibrinolysis** 1995 Sep;6(6):511–9 (98 ref.)
Update on computer–aided drug design. Jackson RC. **Curr Opin Biotechnol** 1995 Dec;6(6):646–51 (48 ref.)
Docking small–molecule ligands into active sites. Jones G, et al. **Curr Opin Biotechnol** 1995 Dec;6(6):652–6 (28 ref.)
The Rac and Rho pathways as a source of drug targets for Ras–mediated malignancies. Symons M. **Curr Opin Biotechnol** 1995 Dec;6(6):668–74 (63 ref.)
Modeling protein–ligand complexes. Bamborough P, et al. **Curr Opin Struct Biol** 1996 Apr;6(2):236–41 (54 ref.)
The Leon Golberg Memorial Lecture. Structural molecular biology and drug discovery. Blundell TL. **Food Chem Toxicol** 1995 Nov;33(11):979–85 (33 ref.)
Transcription factors as drug targets: opportunities for therapeutic selectivity. Butt TR, et al. **Gene Expr** 1995; 4(6):319–36 (137 ref.)
Translation–targeted therapeutics for viral diseases. Harford JB. **Gene Expr** 1995;4(6):357–67 (59 ref.)
Gene expression as a target for new drug discovery. Heguy A, et al. **Gene Expr** 1995;4(6):337–44 (33 ref.)
Signal transduction by Ras–like GTPases: a potential target for anticancer drugs. Spaargaren M, et al. **Gene Expr** 1995; 4(6):345–56 (122 ref.)
Designer contraceptive pills. Hsueh AJ. **Hum Reprod** 1995 Aug;10(8):1997–2000 (26 ref.)
Alternate antiestrogens and approaches to the prevention of breast cancer. Jordan VC. **J Cell Biochem Suppl** 1995; 22:51–7 (51 ref.)
Fostering chemopreventive agent development: how to proceed? Mulshine JL. **J Cell Biochem Suppl** 1995;22:254–9 (16 ref.)
The vitamin D Endocrine system: manipulation of structure–function relationships to provide opportunities for development of new cancer chemopreventive and immunosuppressive agents. Norman AW. **J Cell Biochem Suppl** 1995;22:218–25 (39 ref.)
Importance of stereospecific bioanalytical monitoring in drug development. Caldwell J. **J Chromatogr A** 1996 Jan 5; 719(1):3–13 (39 ref.)
New drug developments for opportunistic infections in immunosuppressed patients: Pneumocystis carinii. Queener SF. **J Med Chem** 1995 Nov 24;38(24):4739–59 (158 ref.)
Perspectives in pharmacokinetics. Physiologically based pharmacokinetic modeling as a tool for drug development [see comments] Charnick SB, et al. **J Pharmacokinet Biopharm** 1995 Apr;23(2):217–29 (70 ref.)
Comment in: J Pharmacokinet Biopharm 1995 Apr;23(2):231–5.
P450–dependent enzymes as targets for prostate cancer therapy. De Coster R, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1–6 Spec No):133–43 (101 ref.)
Discovery of novel intracellular receptor modulating drugs. Jones TK, et al. **J Steroid Biochem Mol Biol** 1996 Jan; 56(1–6 Spec No):61–6 (26 ref.)
Approaches to the development of novel inhibitors of hepatitis C virus replication. Clarke BE. **J Viral Hepat** 1995;2(1):1–8 (40 ref.)
The art and practice of structure–based drug design: a molecular modeling perspective. Bohacek RS, et al. **Med Res Rev** 1996 Jan;16(1):3–50 (120 ref.)
Design of drugs involving the concepts and theories of drug metabolism and pharmacokinetics. Smith DA, et al. **Med Res Rev** 1996 May;16(3):243–66 (54 ref.)
Prodrugs revisited: the "ad hoc" approach as a complement to ligand design. Testa B, et al. **Med Res Rev** 1996 May; 16(3):233–41 (17 ref.)
Drug development train gathering steam. Ito T, et al. **Nat Med** 1996 Apr;2(4):403–4 (12 ref.)
Complement–specific antibodies: designing novel anti–inflammatories. Matis LA, et al. **Nat Med** 1995 Aug; 1(8):839–42 (18 ref.)
Ion channels: too complex for rational drug design? Goldstein SA, et al. **Neuron** 1996 May;16(5):913–9 (50 ref.)
Thermodynamic strategies for rational protein and drug design. Murphy KP, et al. **Pharm Biotechnol** 1995;7:219–41 (57 ref.)
Lipophilicity in molecular modeling. Testa B, et al. **Pharm Res** 1996 Mar;13(3):335–43 (43 ref.)
Frontiers in the development of new medicines in relation to clinical pharmacology. Dollery CT. **Pharmacol Toxicol** 1995 May;76(5):334–8 (11 ref.)
Does the dopamine receptor subtype selectivity of antipsychotic agents provide useful leads for the development of novel therapeutic agents? Hacksell U, et al. **Pharmacol Toxicol** 1995 May;76(5):320–4 (21 ref.)
Generation of new–lead structures in computer–aided drug design. Cohen NC, et al. **Prog Drug Res** 1995;45:205–43 (139 ref.)
Immunospecific drug design—prospects for treatment of autoimmune diseases. Arnon R, et al. **Ther Immunol** 1994 Jan;1(1):65–70 (59 ref.)
Comparative pharmacology of site directed antithrombin agents. Implication in drug development. Callas D, et al. **Thromb Haemost** 1995 Jul;74(1):473–81 (54 ref.)
Application of combinatorial libraries and protein engineering to the discovery of novel anti–thrombotic drugs. Leung LL. **Thromb Haemost** 1995 Jul;74(1):373–6 (19 ref.)
Characterization of biochemical and functional effects of antiplatelet drugs as a key to their clinical development. Patrono C, et al. **Thromb Haemost** 1995 Jul;74(1):396–400 (45 ref.)
[Computer–designed site–specific drugs—myth or reality?] Taskinen J. **Duodecim** 1995;111(8):799–806 (25 ref.) **(Fin)**
[Design of antitumor 2'–deoxy–(2'–C–substituted) cytidines] Matsuda A. **Tanpakushitsu Kakusan Koso** 1994 Jul; 40(10):1232–41 (18 ref.) **(Jpn)**
[Molecular design of antisense oligonucleotide] Murakami A. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1364–70 (37 ref.) **(Jpn)**
[Design of S–adenosylhomocystein hydrolase (SHAase) inhibitors as potent anti–RNA viral agents] Shuto S. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1261–7 (27 ref.) **(Jpn)**

DRUG DETOXICATION, METABOLIC see **METABOLIC DETOXICATION, DRUG**

DRUG ERUPTIONS

Mechanisms of drug eruptions: Part I. Breathnach SM. **Australas J Dermatol** 1995 Aug;36(3):121–7 (100 ref.)

DIAGNOSIS

Management of drug eruptions: Part II. Diagnosis and treatment. Breathnach SM. **Australas J Dermatol** 1995 Nov; 36(4):187–91 (47 ref.)
Anticonvulsant hypersensitivity syndrome. Licata AL, et al. **Compr Ther** 1996 Mar;22(3):152–5 (22 ref.)

DRUG THERAPY

Systemic corticosteroids in the phenytoin hypersensitivity syndrome. Chopra S, et al. **Br J Dermatol** 1996 Jun; 134(6):1109–12 (19 ref.)

EPIDEMIOLOGY

Epidemiology of adverse cutaneous reactions to drugs. Stern RS, et al. **Dermatol Clin** 1995 Jul;13(3):681–8 (45 ref.)

ETIOLOGY

Report of three cases of cutaneous reactions to granulocyte macrophage–colony–stimulating factor and a review of the literature. Scott GA. **Am J Dermatopathol** 1995 Apr; 17(2):107–14 (25 ref.)
Cutaneous eruptions from suramin. A clinical and histopathologic study of 60 patients. Lowitt MH, et al. **Arch Dermatol** 1995 Oct;131(10):1147–53 (30 ref.)
Hydroxyurea–induced dermatomyositis–like eruption. Senet P, et al. **Br J Dermatol** 1995 Sep;133(3):455–9 (32 ref.)
Dilantin hypersensitivity reaction. Conger LA Jr, et al. **Cutis** 1996 Apr;57(4):223–6 (32 ref.)
Interleukin–3–induced urticaria–like eruption. Bridges AG, et al. **J Am Acad Dermatol** 1996 Jun;34(6):1076–8 (19 ref.)
[Cutaneous allergies and insulin therapy. Current aspects, management] Barbaud A, et al. **Ann Dermatol Venereol** 1996;123(3):214–8 (36 ref.) **(Fre)**
[Osteitis secondary to toxic dermatitis caused by hydroxyurea. Apropos ofa case, review of the literature (letter)] Mounier N, et al. **Ann Med Interne (Paris)** 1995; 146(8):590–1 (14 ref.) **(Fre)**
[Cotrimoxazole induced dermatitis and curative treatment of AIDS pneumocystosis] Caumes E. **Rev Mal Respir** 1996; 13(2):101–6 (45 ref.) (Eng. Abstr.) **(Fre)**
[Skin and hair] Briner VA. **Schweiz Med Wochenschr** 1996 Apr 6;126(14):549–58 (29 ref.) (Eng. Abstr.) **(Ger)**
[Cutaneous side–effects of nonsteroidal anti–inflammatory drugs (NSAID)] Gebhardt M, et al. **Z Rheumatol** 1995 Nov–Dec;54(6):405–12 (49 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Management of drug eruptions: Part II. Diagnosis and treatment. Breathnach SM. **Australas J Dermatol** 1995 Nov; 36(4):187–91 (47 ref.)
The management of adverse drug reactions. Mathelier–Fusade P, et al. **Clin Rev Allergy Immunol** 1995 Fall;13(3):281–90 (21 ref.)

DRUG EVALUATION

see related
CLINICAL TRIALS

ECONOMICS

Why is the pharmaceutical industry investing increasing amounts in health economic evaluations? Andersson F. **Int J Technol Assess Health Care** 1995 Fall;11(4):750–61 (40 ref.)
Pharmacoeconomic studies. Pitfalls and problems. De Graeve D, et al. **Int J Technol Assess Health Care** 1996 Winter; 12(1):22–30 (27 ref.)

METHODS

The use of toxicokinetics for the safety assessment of drugs acting in the brain. Campbell DB. **Mol Neurobiol** 1995 Aug–Dec;11(1–3):193–216 (125 ref.)
[Malaria vaccines: why, who and how?] Hommel M. **Med Trop (Mars)** 1995;55(4 Suppl):47–51 (15 ref.) (Eng. Abstr.) **(Fre)**

STANDARDS

Influences on the quality of published drug studies. Bero LA, et al. **Int J Technol Assess Health Care** 1996 Spring; 12(2):209–37 (146 ref.)

DRUG EVALUATION, FDA PHASE I see **CLINICAL TRIALS, PHASE I**

DRUG EVALUATION, FDA PHASE II see **CLINICAL TRIALS, PHASE II**

DRUG EVALUATION, FDA PHASE III see **CLINICAL TRIALS, PHASE III**

DRUG EVALUATION, PRECLINICAL see **DRUG**

DRUG EVALUATION, PRECLINICAL

SCREENING

DRUG-FOOD INTERACTIONS see FOOD-DRUG INTERACTIONS

DRUG HABITUATION see SUBSTANCE DEPENDENCE

DRUG HYPERSENSITIVITY

[Hypersensitivity syndrome caused by dapsone. Transient circulating clone T] Bocquet H, et al. **Ann Dermatol Venereol** 1995;122(8):514-6 (14 ref.) (Eng. Abstr.) **(Fre)**

[Drug allergy--especially on the induction of the oral tolerance and its specificity] Ikezawa Z. **Arerugi** 1996 Apr; 45(4):363-70 (19 ref.) **(Jpn)**

COMPLICATIONS

Phenomenology, pathogenesis, diagnosis and treatment of aspirin-sensitive rhinosinusitis. Schapowal AG, et al. **Acta Otorhinolaryngol Belg** 1995;49(3):235-50 (0 ref.)

[Delayed allergic reaction to Chlorambucil (Leukeran). Case report and literature review] Torricelli R, et al. **Schweiz Med Wochenschr** 1995 Oct 7;125(40):1870-3 (10 ref.) (Eng. Abstr.) **(Ger)**

DIAGNOSIS

Diagnosis of drug allergic reactions. Vervloet D, et al. **Clin Rev Allergy Immunol** 1995 Fall;13(3):265-80 (65 ref.)

Anticonvulsant hypersensitivity syndrome. Licata AL, et al. **Compr Ther** 1996 Mar;22(3):152-5 (22 ref.)

[Drug-induced hepatitis] Kawada N, et al. **Ryoikibetsu Shokogun Shiriza** 1995;(8):63-5 (4 ref.) **(Jpn)**

ETIOLOGY

Muscle relaxants and histamine release. Moss J. **Acta Anaesthesiol Scand Suppl** 1995;106:7-12 (30 ref.)

Pathogenesis and management of HIV-associated drug hypersensitivity. Carr A, et al. **AIDS Clin Rev** 1995-96; :65-97 (121 ref.)

Allergic reactions to penicillins. A changing world? Blanca M. **Allergy** 1995 Oct;50(10):777-82 (76 ref.)

Hypersensitivity reactions to etoposide. Hoetelmans RM, et al. **Ann Pharmacother** 1996 Apr;30(4):367-71 (25 ref.)

Serious adverse reactions induced by minocycline. Report of 13 patients and review of the literature. Knowles SR, et al. **Arch Dermatol** 1996 Aug;132(8):934-9 (38 ref.)

Azathioprine hypersensitivity-like reactions--a case report and a review of the literature. Knowles SR, et al. **Clin Exp Dermatol** 1995 Jul;20(4):353-6 (35 ref.)

Place of excipients in drug-related allergy. Barbaud A. **Clin Rev Allergy Immunol** 1995 Fall;13(3):253-63 (76 ref.)

Pleuropericarditis related to the use of mesalamine. Gujral N, et al. **Dig Dis Sci** 1996 Mar;41(3):624-6 (12 ref.)

Adverse reactions to antibiotics: is the patient really allergic? Boguniewicz M. **Drug Saf** 1995 Nov;13(5):273-80 (51 ref.)

Latex allergy precautions. A research-based protocol. Steelman VM. **Nurs Clin North Am** 1995 Sep;30(3):475-93 (85 ref.)

[Source and clinical significance of allergy for thiomersal, an organic mercury compound] van 't Veen AJ, et al. **Ned Tijdschr Geneeskd** 1996 Feb 10;140(6):297-300 (31 ref.) **(Dut)**

[Intolerance to trimethoprim-sulfamethoxazole in Pneumocystis carinii pneumonia in AIDS. Search for predictive factors] Pinzani V, et al. **Ann Med Interne (Paris)** 1995;146(7):505-9 (25 ref.) (Eng. Abstr.) **(Fre)**

[Importance of risk factors in drug allergies] Bircher AJ. **Rev Med Suisse Romande** 1996 Mar;116(3):215-20 (67 ref.) **(Fre)**

[Hypersensitivity to glucocorticoids: reflections on a published case report sample] Réveilleau-Richard S, et al. **Therapie** 1995 Sep-Oct;50(5):439-46 (24 ref.) (Eng. Abstr.) **(Fre)**

[Trimethoprim-sulfamethoxazole-induced cholestatic hepatitis. Clinico-immunological demonstration of its allergic origin] Cario E, et al. **Dtsch Med Wochenschr** 1996 Feb 2;121(5):129-32 (10 ref.) (Eng. Abstr.) **(Ger)**

[Anaphylactoid reactions to radiocontrast media] Confino-Cohen R, et al. **Harefuah** 1995 Jul;129(1-2):55-7 (17 ref.) **(Heb)**

[Iodinated contrast media: adverse reactions, prevention and treatment] Konen E, et al. **Harefuah** 1995 Jun 1; 128(11):719-23 (35 ref.) **(Heb)**

[Sensitivity to acetylsalicylic acid] Elverland HH. **Tidsskr Nor Laegeforen** 1996 Feb 28;116(6):754-6 (22 ref.) (Eng. Abstr.) **(Nor)**

[A possible hypersensitivity reaction to total parenteral nutrition] Vázquez Mora JR, et al. **Nutr Hosp** 1996 Mar-Apr;11(2):148-50 (13 ref.) (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

Allergy and intolerance to nonsteroidal anti-inflammatory agents. Arnaud A. **Clin Rev Allergy Immunol** 1995 Fall; 13(3):245-51 (26 ref.)

Drug-induced "allergic hepatitis". Podevin P, et al. **Clin Rev Allergy Immunol** 1995 Fall;13(3):223-44 (165 ref.)

Diagnosis of drug allergic reactions. Vervloet D, et al. **Clin Rev Allergy Immunol** 1995 Fall;13(3):265-80 (65 ref.)

Managing HIV. Part 3: Mechanisms of disease. 3.5 How HIV leads to hypersensitivity reactions. Carr A, et al. **Med J Aust** 1996 Feb 19;164(4):227-9 (9 ref.)

[Cutaneous reactions to external orthopedic materials] Vigan M, et al. **Ann Dermatol Venereol** 1995;122(8):548-50 (23 ref.) **(Fre)**

PHYSIOPATHOLOGY

Sensitisation to corticosteroids. Consequences for anti-inflammatory therapy. Dooms-Goossens A. **Drug Saf** 1995 Aug;13(2):123-9 (47 ref.)

[Cutaneous hypersensitivity at the site of injection of vitamin K1] Moreau-Cabarrot A, et al. **Ann Dermatol Venereol** 1996;123(3):177-9 (22 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

The management of adverse drug reactions. Mathelier-Fusade P, et al. **Clin Rev Allergy Immunol** 1995 Fall;13(3):281-90 (21 ref.)

Management of immediate allergic reactions. Becker DE. **Dent Clin North Am** 1995 Jul;39(3):577-86 (41 ref.)

Treatment of adverse reactions to radiographic contrast media in adults. Cohan RH, et al. **Radiol Clin North Am** 1996 Sep;34(5):1055-76 (105 ref.)

VIROLOGY

Managing HIV. Part 3: Mechanisms of disease. 3.5 How HIV leads to hypersensitivity reactions. Carr A, et al. **Med J Aust** 1996 Feb 19;164(4):227-9 (9 ref.)

DRUG IMPLANTS

Injectables in the treatment of female stress incontinence. Appell RA. **Curr Opin Obstet Gynecol** 1995 Oct;7(5):393-6 (32 ref.)

DRUG INCOMPATIBILITY

[Mixtures of infusion solutions and drugs. Compatibility and incompatibility] Pecar A, et al. **Anaesthesist** 1995 Nov; 44(11):793-803 (20 ref.) (Eng. Abstr.) **(Ger)**

DRUG INDUSTRY

see related
TECHNOLOGY, PHARMACEUTICAL

Ethical issues in the pharmaceutical industry. Wells FO. **Br J Urol** 1995 Nov;76 Suppl 2:41-7 (15 ref.)

Drug companies and continuing medical education. Bickell NA. **J Gen Intern Med** 1995 Jul;10(7):392-4 (9 ref.)

Pharmaceutical industry support for continuing medical education programs: a review of current ethical guidelines. Rosner F. **Mt Sinai J Med** 1995 Nov;62(6):427-30 (21 ref.)

Validation of computer-related systems.Parenteral Drug Association. **PDA J Pharm Sci Technol** 1995 Jan-Feb;49 Suppl 1:S1-17 (41 ref.)

Risk analysis in the manufacture of veterinary biologicals. Moreau Y. **Rev Sci Tech** 1995 Dec;14(4):937-50 (10 ref.)

[Drug surveillance within the pharmaceutical industry: present and future] Soto J, et al. **Med Clin (Barc)** 1996 May 4;106(17):665-9 (31 ref.) **(Spa)**

ECONOMICS

Why is the pharmaceutical industry investing increasing amounts in health economic evaluations? Andersson F. **Int J Technol Assess Health Care** 1995 Fall;11(4):750-61 (40 ref.)

The North American Free Trade Agreement's effect on pharmaceutical patents: a bitter pill to swallow or a therapeutic solution? Silbermann JM. **J Contemp Health Law Policy** 1996 Spring;12(2):607-36 (176 ref.)

INSTRUMENTATION

[Gas sterilization with gas hydrogen peroxide: a new technology in the pharmaceutical industry] Manzati C. **Boll Chim Farm** 1995 Sep;134(8):413-33 (23 ref.) (Eng. Abstr.) **(Ita)**

STANDARDS

Application of risk assessment to veterinary biologicals: the perspective of the animal health industry. Folkers C, et al. **Rev Sci Tech** 1995 Dec;14(4):1207-16 (5 ref.)

Risk analysis in the manufacture of veterinary biologicals. Moreau Y. **Rev Sci Tech** 1995 Dec;14(4):937-50 (10 ref.)

DRUG INFORMATION SERVICES

Pharmacists as agents of change for rational drug therapy. Lipton HL, et al. **Int J Technol Assess Health Care** 1995 Summer;11(3):485-508 (138 ref.)

DRUG INFUSION SYSTEMS see INFUSION PUMPS

DRUG INSURANCE see INSURANCE, PHARMACEUTICAL SERVICES

DRUG INTERACTIONS

Cigarette smoking and clinically significant drug interactions. Schein JR. **Ann Pharmacother** 1995 Nov;29(11):1139-48 (88 ref.)

Drug interactions and the cytochrome P450 system. The role of cytochrome P450 2C19. Flockhart DA. **Clin Pharmacokinet** 1995;29 Suppl 1:45-52 (51 ref.)

Managing selective serotonin reuptake inhibitor-drug interactions in clinical practice. Rosenbaum JR. **Clin Pharmacokinet** 1995;29 Suppl 1:53-9 (17 ref.)

Metabolism of drugs by cytochrome P450 3A isoforms. Implications for drug interactions in psychopharmacology. von Moltke LL, et al. **Clin Pharmacokinet** 1995;29 Suppl 1:33-43; discussion 43-4 (66 ref.)

Drug interactions between prescribed and over-the-counter medication. Honig PK, et al. **Drug Saf** 1995 Nov; 13(5):296-303 (73 ref.)

Slow-acting antirheumatic drugs. Drug interactions of clinical significance. Munro RA, et al. **Drug Saf** 1995 Jul; 13(1):25-30 (34 ref.)

Drug interactions of clinical importance. An updated guide. Quinn DI, et al. **Drug Saf** 1995 Jun;12(6):393-452 (14 ref.)

Managing HIV. Common drug interactions in HIV medicine. Carey DL, et al. **Med J Aust** 1996 May 20;164(10):605-6 (0 ref.)

Chemical mixtures: current risk assessment methodologies and future directions. Seed J, et al. **Regul Toxicol Pharmacol** 1995 Aug;22(1):76-94 (48 ref.)

A weight-of-evidence approach for assessing interactions in chemical mixtures. Mumtaz MM, et al. **Toxicol Ind Health** 1992 Nov-Dec;8(6):377-406 (14 ref.)

Analysis of competitive agonist-antagonist interactions by nonlinear regression. Lew MJ, et al. **Trends Pharmacol Sci** 1995 Oct;16(10):328-37 (12 ref.)

DRUG KINETICS see PHARMACOKINETICS

DRUG LABELING

Patient pack prescribing and the provision of patient information leaflets. **Drug Ther Bull** 1995 Nov;33(11):86-8 (12 ref.)

Unapproved uses of approved drugs: the physician, the package insert, and the Food and Drug Administration: subject review. American Academy of Pediatrics Committee on Drugs [see comments] **Pediatrics** 1996 Jul; 98(1):143-5 (00 ref.) Comment in: Pediatrics 1996 Jul;98(1):118-23.

DRUG LAWS see LEGISLATION, DRUG

DRUG MODELING see DRUG DESIGN

DRUG MONITORING

see related
ADVERSE DRUG REACTION REPORTING SYSTEMS

Titrating cardiovascular drugs. Marcus FI. **Clin Chem** 1996 Aug;42(8 Pt 2):1312-5 (17 ref.)

How important is therapeutic drug monitoring in the prediction and avoidance of adverse reactions? Gentry CA, et al. **Drug Saf** 1995 Jun;12(6):359-63 (43 ref.)

Adaptive control of drug dosage regimens using maximum a posteriori probability Bayesian fitting. Proost JH. **Int J Clin Pharmacol Ther** 1995 Oct;33(10):531-6 (43 ref.)

Perioperative monitoring of potentially toxic drugs. Stapp MD, et al. **J Am Podiatr Med Assoc** 1995 Nov;85(11):690-5 (23 ref.)

Therapeutic drug monitoring [editorial] Kshirsagar NA. **J Postgrad Med** 1994 Jan-Mar;40(1):1-2 (2 ref.)

Proceedings of the International Consensus Conference on Immunosuppressive Drugs. Lake Louise, Alberta, Canada, May 5-7, 1995. **Ther Drug Monit** 1995 Dec;17(6):559-703 (0 ref.)

Analysis of tacrolimus (FK 506) in relation to therapeutic drug monitoring. Jusko WJ. **Ther Drug Monit** 1995 Dec; 17(6):596-601 (42 ref.)

Consensus document: therapeutic monitoring of tacrolimus (FK-506). Jusko WJ, et al. **Ther Drug Monit** 1995 Dec; 17(6):606-14 (55 ref.)

Challenges in cyclosporine therapy: the role of therapeutic monitoring by area under the curve monitoring. Kahan BD, et al. **Ther Drug Monit** 1995 Dec;17(6):621-4 (15 ref.)

Potential applications of therapeutic drug monitoring of sirolimus immunosuppression in clinical renal transplantation. Kahan BD, et al. **Ther Drug Monit** 1995 Dec;17(6):672-5 (17 ref.)

Cyclosporine A: clinical experience and therapeutic drug monitoring. Lindholm A. **Ther Drug Monit** 1995 Dec; 17(6):631-7 (46 ref.)

Pharmacokinetics and therapeutic drug monitoring of immunosuppressants. Lindholm A, et al. **Ther Drug Monit** 1995 Dec;17(6):570-3 (13 ref.)

Therapeutic drug monitoring of tacrolimus in clinical transplantation. McMaster P, et al. **Ther Drug Monit** 1995 Dec;17(6):602-5 (8 ref.)

Lake Louise Consensus Conference on cyclosporin monitoring in organ transplantation: report of the consensus panel. Oellerich M, et al. **Ther Drug Monit** 1995 Dec; 17(6):642-54 (47 ref.)

Therapeutic drug monitoring of cyclosporin G. Yatscoff RW, et al. **Ther Drug Monit** 1995 Dec;17(6):655-9 (28 ref.)

Rapamycin: distribution, pharmacokinetics, and therapeutic

range investigations. Yatscoff RW, et al. **Ther Drug Monit** 1995 Dec;17(6):666–71 (32 ref.)

Consensus guidelines for therapeutic drug monitoring of rapamycin: report of the consensus panel. Yatscoff RW, et al. **Ther Drug Monit** 1995 Dec;17(6):676–80 (28 ref.)

[Phenytoin] Furuno K, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:924–7 (21 ref.) **(Jpn)**

[Primidone] Furuno K, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:928–30 (21 ref.) **(Jpn)**

[Lithium carbonate] Higuchi S, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:942–4 (9 ref.) **(Jpn)**

[Ethosuximide] Ichiba M, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:915–7 (8 ref.) **(Jpn)**

[Phenobarbital] Kawasaki H, et al. **Nippon Rinsho** 1995 Feb; 53 Su Pt 1:921–3 (12 ref.) **(Jpn)**

[Valproic acid] Kohda Y. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:918–20 (10 ref.) **(Jpn)**

[Digoxin] Kotaki H, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:950–3 (10 ref.) **(Jpn)**

[Aminoglycosides] Kubo H. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:998–1001 (11 ref.) **(Jpn)**

[Clinical evaluation of therapeutic drug monitoring] Kubo H, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:899–903 (14 ref.) **(Jpn)**

[Theophylline] Nishihara K. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:966–9 (9 ref.) **(Jpn)**

[Procainamide] Nishihara K. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:954–6 (8 ref.) **(Jpn)**

[Diuretics] Orita Y, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:960–5 (9 ref.) **(Jpn)**

[Haloperidol] Sakamoto N, et al. **Nippon Rinsho** 1995 Feb; 53 Su Pt 1:938–41 (14 ref.) **(Jpn)**

[Calcium antagonist] Sasaki S, et al. **Nippon Rinsho** 1995 Feb; 53 Su Pt 1:970–3 (9 ref.) **(Jpn)**

[Zonisamide] Shuto H, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:931–3 (6 ref.) **(Jpn)**

[Quinidine] Yamada K. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:957–9 (8 ref.) **(Jpn)**

[Digitoxin] Yamamoto K, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:945–9 (12 ref.) **(Jpn)**

[Tricyclic antidepressants (imipramine, desipramine, amitriptyline, nortriptyline)] Yasuda K. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:934–7 (20 ref.) **(Jpn)**

[Clonazepam, nitrazepam, diazepam] Yasuda K. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:911–4 (19 ref.) **(Jpn)**

ECONOMICS

The role of therapeutic drug monitoring in improving the cost effectiveness of anticonvulsant therapy. Eadie MJ. **Clin Pharmacokinet** 1995 Jul;29(1):29–35 (26 ref.)

METHODS

Methods for monitoring the level of sedation. Avramov MN, et al. **Crit Care Clin** 1995 Oct;11(4):803–26 (75 ref.)

Optimal intravenous dosing strategies for sedatives and analgesics in the intensive care unit. Barr J, et al. **Crit Care Clin** 1995 Oct;11(4):827–47 (64 ref.)

Pharmacokinetics of continuous renal replacement therapy. Schetz M, et al. **Intensive Care Med** 1995 Jul;21(7):612–20 (33 ref.)

International Normalized Ratio (INR): an improved way to monitor oral anticoagulant therapy. Oertel LB. **Nurse Pract** 1995 Sep;20(9):15–6, 21–2 (12 ref.)

Cyclosporin A: analytical methodology and factors affecting therapeutic drug monitoring. Holt DW, et al. **Ther Drug Monit** 1995 Dec;17(6):625–30 (29 ref.)

[Biological surveillance of hormone substitution: relying on the plasma levels of estradiol or the products used?] Jamin C. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(5):467–74 (34 ref.) (Eng. Abstr.) **(Fre)**

STANDARDS

A systematic review and critical comparison of internal standards for the routine liquid chromatographic assay of amiodarone and desethylamiodarone. Pollak PT. **Ther Drug Monit** 1996 Apr;18(2):168–78 (53 ref.)

DRUG PACKAGING

Patient pack prescribing and the provision of patient information leaflets. **Drug Ther Bull** 1995 Nov;33(11):86–8 (12 ref.)

DRUG POTENTIATION see **DRUG SYNERGISM**

DRUG PRECURSORS see **PRODRUGS**

DRUG REACTION REPORTING SYSTEMS, ADVERSE see **ADVERSE DRUG REACTION REPORTING SYSTEMS**

DRUG RECALL see **DRUG AND NARCOTIC CONTROL**

DRUG RECEPTORS see **RECEPTORS, DRUG**

DRUG REGULATIONS see **DRUG AND NARCOTIC CONTROL**

DRUG RESIDUES

see related
PESTICIDE RESIDUES

METABOLISM

Preclinical drug metabolism programs for food-producing animals. Clement RP. **Toxicol Pathol** 1995 Mar–Apr; 23(2):209–16 (7 ref.)

PHARMACOKINETICS

Narcosis due to environmental pollutants in aquatic organisms: residue-based toxicity, mechanisms, and membrane burdens. van Wezel AP, et al. **Crit Rev Toxicol** 1995;25(3):255–79 (94 ref.)

DRUG RESISTANCE

Glutathione and drug resistance. Schröder CP, et al. **Cancer Invest** 1996;14(2):158–68 (122 ref.)

Use of hydroxyurea to alter drug resistance of human tumor cells. Van den Berg C, et al. **Cancer Treat Res** 1995; 78:95–114 (123 ref.)

The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Hayes JD, et al. **Crit Rev Biochem Mol Biol** 1995;30(6):445–600 (779 ref.)

Drug resistance, illustration of the complexity of translational research. Steiner Award lecture 1995. Pinedo HM. **Int J Cancer** 1996 Mar 1;65(5):561–6 (62 ref.)

Insulin-like growth factor 1 resistance in chronic renal failure. Fouque D. **Miner Electrolyte Metab** 1996; 22(1–3):133–7 (55 ref.)

The prevalence of anthelmintic resistance in nematode parasites of sheep in southern Latin America: general overview. Waller PJ, et al. **Vet Parasitol** 1996 Apr; 62(3–4):181–7 (20 ref.)

[Role of modulators in Plasmodium falciparum resistance to antimalarials] Verdier F, et al. **Med Trop (Mars)** 1995;55(4 Suppl):27–32 (20 ref.) (Eng. Abstr.) **(Fre)**

[The concept and treatment of drug-resistant intractable epilepsy] Iváñez V. **Rev Neurol** 1995 Nov–Dec; 23(124):1214–9 (85 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

Resistance to activated protein C, the FV:Q506 allele, and venous thrombosis. Dahlbäck B, et al. **Ann Hematol** 1996 Apr;72(4):166–76 (152 ref.)

Causes and problems of nonresponse or poor response to drugs. Salvà Lacombe P, et al. **Drugs** 1996 Apr; 51(4):552–70 (162 ref.)

Molecular biology and evolution of resistance of toxicants. Taylor M, et al. **Mol Biol Evol** 1996 Jul;13(6):719–34 (141 ref.)

[Activated protein C resistance: role in venous and arterial thrombosis] Emmerich J, et al. **Arch Mal Coeur Vaiss** 1996 Jun;89(6):741–5 (31 ref.) (Eng. Abstr.) **(Fre)**

[Resistance to chemotherapy: current therapeutic approach] Ries F, et al. **Bull Soc Sci Med Grand Duche Luxemb** 1995; 132(3):19–26 (60 ref.) **(Fre)**

PHYSIOLOGY

P-glycoprotein: its role in drug resistance. Ling V. **Am J Med** 1995 Dec 29;99(6A):31S–34S (55 ref.)

New mechanisms of drug resistance in parasitic protozoa. Borst P, et al. **Annu Rev Microbiol** 1995;49:427–60 (196 ref.)

DRUG RESISTANCE, ANTINEOPLASTIC see **DRUG RESISTANCE, NEOPLASM**

DRUG RESISTANCE, MICROBIAL

see related
MICROBIAL SENSITIVITY TESTS
R FACTORS
SUPERINFECTION
TUBERCULOSIS, MULTIDRUG-RESISTANT

Pneumococcal infections in an era of multiple antibiotic resistance. Gray BM. **Adv Pediatr Infect Dis** 1996;11:55–99 (156 ref.)

Reasons for the emergence of antibiotic resistance. Tenover FC, et al. **Am J Med Sci** 1996 Jan;311(1):9–16 (82 ref.)

Emerging resistance to antibiotics: impact on respiratory infections in the outpatient setting. Green M, et al. **Ann Allergy Asthma Immunol** 1996 Sep;77(3):167–73; quiz 173–5 (21 ref.)

Erythromycin-resistant Staphylococcus aureus in Denmark. Westh H. **APMIS Suppl** 1996;57:1–37 (126 ref.)

Emerging antibiotic resistance: real and relative [editorial] Jones DB. **Arch Ophthalmol** 1996 Jan;114(1):91–2 (12 ref.)

Infections and antibiotic resistance in nursing homes. Nicolle LE, et al. **Clin Microbiol Rev** 1996 Jan;9(1):1–17 (188 ref.)

Quo vadis with bacterial resistance? Williams JD. **Drugs** 1995; 49 Suppl 2:1–9 (8 ref.)

Pathogens resistant to antimicrobial agents. Epidemiology, molecular mechanisms, and clinical management. Fraimow HS, et al. **Infect Dis Clin North Am** 1995 Sep;9(3):497–530 (113 ref.)

Development of drug resistance to HIV-1 protease inhibitors. Ridky T, et al. **J Biol Chem** 1995 Dec 15;270(50):29621–3 (28 ref.)

Strategies to Prevent and Control the Emergence and Spread of Antimicrobial-Resistant Microorganisms in Hospitals. A challenge to hospital leadership [see comments] Goldmann DA, et al. **JAMA** 1996 Jan 17;275(3):234–40 (81 ref.) Comment in: JAMA 1996 May 22–29;275(20):1544.

The challenges of emerging infectious diseases. Development and spread of multiply-resistant bacterial pathogens. Tenover FC, et al. **JAMA** 1996 Jan 24–31;275(4):300–4 (63 ref.)

Antibiotic resistance: relationship to persistence of group A streptococci in the upper respiratory tract. Gerber MA. **Pediatrics** 1996 Jun;97(6 Pt 2):971–5 (59 ref.)

The best of times, the worst of times. The global challenge of antimicrobial resistance. Tenover FC. **Pharm World Sci** 1995 Sep 22;17(5):149–51 (40 ref.)

Resistance to antibiotics in general practice. Hargreaves R. **Practitioner** 1995 Oct;239(1555):602–5 (10 ref.)

Biochemical mechanisms of resistance to non-cell wall antibacterial agents. Allen NE. **Prog Med Chem** 1995; 32:157–238 (539 ref.)

E test: a novel technique for antimicrobial susceptibility testing. Sader HS, et al. **Rev Paul Med** 1994 Oct–Dec; 112(4):635–8 (15 ref.)

Emerging resistance in clinically important gram-positive cocci. Thornsberry C. **West J Med** 1996 Jan;164(1):28–32 (18 ref.)

[Mechanism of antibiotic resistance in bacteria responsible for respiratory infections] Dye D, et al. **Rev Mal Respir** 1995;12(5):415–27 (67 ref.) (Eng. Abstr.) **(Fre)**

[Bacterial resistance—state and development in human and animal isolates] Schlatterer B. **DTW Dtsch Tierarztl Wochenschr** 1995 Jun;102(6):251–6 (6 ref.) **(Ger)**

[Resistance development of major pathogenic bacteria] Kristiansen BE, et al. **Tidsskr Nor Laegeforen** 1995 Sep 10;115(21):2663–8 (62 ref.) (Eng. Abstr.) **(Nor)**

[Microbial resistance. What to do?] Baquero Mochales F, et al. **Med Clin (Barc)** 1996 Feb 24;106(7):267–75 (4 ref.) **(Spa)**

[Increased resistance after administration of antibiotics to animals] Franklin A. **Lakartidningen** 1996 Apr 24; 93(17):1627–30 (21 ref.) **(Swe)**

[Clostridium difficile-associated diarrhea—an increasing problem. Reduce the administration of antibiotics and improve hygiene!] Svenungsson B. **Lakartidningen** 1996 Aug 28;93(35):2931–4 (67 ref.) **(Swe)**

PHYSIOLOGY

Ins and outs of antimicrobial resistance: era of the drug pumps. Jenkinson HF. **J Dent Res** 1996 Feb;75(2):736–42 (43 ref.)

DRUG RESISTANCE, MULTIPLE

see related
TUBERCULOSIS, MULTIDRUG-RESISTANT

P-glycoproteins and multidrug resistance. Bellamy WT. **Annu Rev Pharmacol Toxicol** 1996;36:161–83 (127 ref.)

Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Beck WT, et al. **Cancer Res** 1996 Jul 1;56(13):3010–20 (66 ref.)

The reversal of multidrug resistance. Fisher GA, et al. **Cancer Treat Res** 1995;78:45–70 (138 ref.)

Penicillin and multiply antibiotic-resistant Streptococcus pneumoniae. Estrada B, et al. **Compr Ther** 1995 Nov; 21(11):658–62 (32 ref.)

Clinical multidrug resistance in cancer: a multifactorial problem. Lehnert M. **Eur J Cancer** 1996 Jun;32A(6):912–20 (137 ref.)

MDR1/P-glycoprotein expression in colorectal cancer. Linn SC, et al. **Eur J Cancer** 1995 Jul–Aug;31A(7–8):1291–4 (30 ref.)

Multidrug resistance and the role of P-glycoprotein knockout mice. Schinkel AH, et al. **Eur J Cancer** 1995 Jul–Aug; 31A(7–8):1295–8 (30 ref.)

Multidrug drug resistance in pediatric sarcomas. Chan HS, et al. **Hematol Oncol Clin North Am** 1995 Aug;9(4):889–908 (118 ref.)

Locoregional immuno-chemotherapy transplenic and transtumoral in vivo immunostimulation. Lygidakis NJ, et al. **Hepatogastroenterology** 1996 Mar–Apr;43(8):440–7 (38 ref.)

Drug resistance, illustration of the complexity of translational research. Steiner Award lecture 1995. Pinedo HM. **Int J Cancer** 1996 Mar 1;65(5):561–6 (62 ref.)

Viral resistance and the selection of antiretroviral combinations. Larder BA. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995;10 Suppl 1:S28–33 (28 ref.)

Strategies to Prevent and Control the Emergence and Spread of Antimicrobial-Resistant Microorganisms in Hospitals. A challenge to hospital leadership [see comments] Goldmann DA, et al. **JAMA** 1996 Jan 17;275(3):234–40 (81 ref.) Comment in: JAMA 1996 May 22–29;275(20):1544.

The challenges of emerging infectious diseases. Development and spread of multiply-resistant bacterial pathogens.

Tenover FC, et al. **JAMA** 1996 Jan 24-31;275(4):300-4 (63 ref.)

The role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia. List AF. **Leukemia** 1996 Apr;10 Suppl 1:S36-8 (0 ref.)

Role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia. List AF. **Leukemia** 1996 Jun;10(6):937-42 (43 ref.)

Interaction of alpha-interferon with chemotherapeutic agents: effects on cytotoxic drug metabolism and multiple drug resistance. Sewell GJ. **Med Oncol** 1995 Mar;12(1):9-14 (43 ref.)

Chemoresistance and multiple myeloma: from biological to clinical aspects. Rossi JF. **Stem Cells (Dayt)** 1995 Aug;13 Suppl 2:64-71 (30 ref.)

[Exploration of clinical study of antileukemia cell drug-resistance by traditional Chinese medicine] Li D, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Oct; 15(10):636-7 (8 ref.) **(Chi)**

[Multidrug resistance and its reversal. General review of fundamental aspects] Robert J. **Ann Biol Clin (Paris)** 1996; 54(1):3-8 (50 ref.) (Eng. Abstr.) **(Fre)**

[Biology and clinical relevance of multidrug resistance associated antigen] Utsumi M, et al. **Nippon Rinsho** 1996 Jun;54(6):1690-7 (56 ref.) (Eng. Abstr.) **(Jpn)**

[The end of antibiotics? Increasing bacterial resistance in global and Norwegian perspective] Jensenius M, et al. **Tidsskr Nor Laegeforen** 1995 Nov 10;115(27):3382-6 (52 ref.) (Eng. Abstr.) **(Nor)**

[The molecular mechanisms of the multiple drug resistance of tumors] Leont'eva OV. **Antibiot Khimioter** 1995 May; 40(5):48-60 (84 ref.) **(Rus)**

[Thrombophilia characterized by resistance to anticoagulants with indirect action] Barkagan ZS, et al. **Ter Arkh** 1995; 67(7):50-2 (8 ref.) (Eng. Abstr.) **(Rus)**

[Diagnosis and treatment of drug-resistant epilepsy] Arroyo S. **Neurologia** 1996 Feb;11(2):56-68 (137 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

Modulation of multidrug resistance in multiple myeloma. Sonneveld P. **Baillieres Clin Haematol** 1995 Dec; 8(4):831-44 (107 ref.)

Multidrug resistance. Moscow JA, et al. **Cancer Chemother Biol Response Modif** 1996;16:111-31 (149 ref.)

kdr-Type resistance in insects with special reference to the German cockroach, Blattella germanica. Scott JG, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1994 Oct-Nov; 109(2-3):191-8 (68 ref.)

P-glycoprotein: clinical significance and methods of analysis. van der Heyden S, et al. **Crit Rev Clin Lab Sci** 1995; 32(3):221-64 (174 ref.)

Oligonucleotide modulation of multidrug resistance. Bouffard DY, et al. **Eur J Cancer** 1996 Jun;32A(6):1010-8 (111 ref.)

Multidrug resistance in breast cancer: mechanisms, strategies. Giaccone G, et al. **Eur J Cancer** 1995;31A Suppl 7:S15-7 (30 ref.)

Multidrug resistance in enteric and other gram-negative bacteria. George AM. **FEMS Microbiol Lett** 1996 May 15; 139(1):1-10 (42 ref.)

Clinical relevance of drug resistance genes in malignant disease. Filipits M, et al. **Leukemia** 1996 Jul;10 Suppl 3:S10-S17 (131 ref.)

MDR1 reversal: criteria for clinical trials designed to overcome the multidrug resistance phenotype. Hegewisch-Becker S. **Leukemia** 1996 Jul;10 Suppl 3:S32-S38 (53 ref.)

Immunophenotyping and cytogenetics in older adults with acute myeloid leukemia: significance of expression of the multidrug resistance gene-1 (MDR1). Willman CL. **Leukemia** 1996 Apr;10 Suppl 1:S33-5 (27 ref.)

Retroviral transfer of the multidrug resistance-1 gene into lineage-committed and primitive hemopoietic cells. Fruehauf S, et al. **Stem Cells** 1995 Dec;13 Suppl 3:93-9 (43 ref.)

[Multidrug resistance--genes and chemotherapy of ovarian cancer] Leng J, et al. **Chung Hua I Hsueh Tsa Chih** 1995 Sep;75(9):567-9 (7 ref.) **(Chi)**

[Modulation of chemoresistance: methodology of therapeutic trials] Rossi JF. **Ann Biol Clin (Paris)** 1996;54(1):25-9 (23 ref.) (Eng. Abstr.) **(Fre)**

[Expression of the MDR1 gene in five human cell lines of medullary thyroid cancer and reversion of the resistance to doxorubicine by ciclosporin A and verapamil] Massart C, et al. **Bull Cancer (Paris)** 1996 Jan;83(1):39-45 (32 ref.) (Eng. Abstr.) **(Fre)**

[In vivo drug-selectable markers in gene therapy] Sugimoto Y. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2635-44 (40 ref.) **(Jpn)**

[Mechanism of resistance to antitumor agents--its involvement in blood-brain barrier] Tsuruo T. **Yakugaku Zasshi** 1995 Jul;115(7):513-22 (36 ref.) (Eng. Abstr.) **(Jpn)**

[Overcoming tumor multiple drug resistance. MDR modulators] Dudnik IuV, et al. **Antibiot Khimioter** 1995 Oct;40(10):48-54 (81 ref.) **(Rus)**

PHYSIOLOGY

Regulation of multidrug resistance through the cAMP and EGF signalling pathways. Rohlff C, et al. **Cell Signal** 1995 Jul;7(5):431-43 (131 ref.)

Diagnosis and reversal of multidrug resistance in paediatric cancers. Chan HS, et al. **Eur J Cancer** 1996 Jun; 32A(6):1051-61 (153 ref.)

Pharmacological considerations in the modulation of multidrug resistance. Fisher GA, et al. **Eur J Cancer** 1996 Jun;32A(6):1082-8 (69 ref.)

Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitisers. Ford JM. **Eur J Cancer** 1996 Jun;32A(6):991-1001 (161 ref.)

P-glycoprotein--a mediator of multidrug resistance in tumour cells. Germann UA. **Eur J Cancer** 1996 Jun; 32A(6):927-44 (280 ref.)

Major vault protein LRP-related multidrug resistance. Izquierdo MA, et al. **Eur J Cancer** 1996 Jun;32A(6):979-84 (40 ref.)

Biology of the multidrug resistance-associated protein, MRP. Loe DW, et al. **Eur J Cancer** 1996 Jun;32A(6):945-57 (188 ref.)

Glutathione and related enzymes in multidrug resistance. O'Brien ML, et al. **Eur J Cancer** 1996 Jun;32A(6):967-78 (147 ref.)

Multidrug resistance reversal in childhood malignancies--potential for a real step forward? Pinkerton CR. **Eur J Cancer** 1996 Apr;32A(4):641-4 (37 ref.)

Reversal of multidrug resistance in acute myeloid leukaemia and other haematological malignancies. Sonneveld P. **Eur J Cancer** 1996 Jun;32A(6):1062-9 (97 ref.)

Experimental modulation of MRP (multidrug resistance-associated protein)-mediated resistance. Twentyman PR, et al. **Eur J Cancer** 1996 Jun; 32A(6):1002-9 (61 ref.)

The catalytic cycle of P-glycoprotein. Senior AE, et al. **FEBS Lett** 1995 Dec 27;377(3):285-9 (42 ref.)

Structure-activity-relationship studies on modulators of the multidrug transporter P-glycoprotein--an overview. Ecker G, et al. **Wien Klin Wochenschr** 1995;107(22):681-6 (51 ref.)

[The molecular basis and in vitro determination of multiple resistance to cytostatic agents] Krejsek J, et al. **Vnitr Lek** 1995 Aug;41(8):565-8 (34 ref.) (Eng. Abstr.) **(Cze)**

DRUG RESISTANCE, NEOPLASM

Resistance to cytotoxic therapy: a speculative overview. Preisler HD. **Ann Oncol** 1995 Sep;6(7):651-7 (83 ref.)

Human DNA topoisomerase II: biochemistry and role in chemotherapy resistance (review). Withoff S, et al. **Anticancer Res** 1996 Jul-Aug;16(4A):1867-80 (184 ref.)

DNA topoisomerase II mutations and resistance to anti-tumor drugs. Vassetzky YS, et al. **Bioessays** 1995 Sep; 17(9):767-74 (66 ref.)

Tumor chemosensitivity and chemoresistance assays. Brown E, et al. **Cancer** 1996 Mar 15;77(6):1020-5 (12 ref.)

Clinical multidrug resistance in cancer: a multifactorial problem. Lehnert M. **Eur J Cancer** 1996 Jun;32A(6):912-20 (137 ref.)

Multidrug resistance and the role of P-glycoprotein knockout mice. Schinkel AH, et al. **Eur J Cancer** 1995 Jul-Aug; 31A(7-8):1295-8 (30 ref.)

Multidrug drug resistance in pediatric sarcomas. Chan HS, et al. **Hematol Oncol Clin North Am** 1995 Aug;9(4):889-908 (118 ref.)

DNA repair: enzymatic mechanisms and relevance to drug response. Chaney SG, et al. **J Natl Cancer Inst** 1996 Oct 2;88(19):1346-60 (253 ref.)

Mechanisms of resistance of human tumours to anticancer drugs of the platinum family: a review. Ferguson PJ. **J Otolaryngol** 1995 Aug;24(4):242-52 (100 ref.)

Interaction of alpha-interferon with chemotherapeutic agents: effects on cytotoxic drug metabolism and multiple drug resistance. Sewell GJ. **Med Oncol** 1995 Mar;12(1):9-14 (43 ref.)

[Modulation of chemoresistance: methodology of therapeutic trials] Rossi JF. **Ann Biol Clin (Paris)** 1996;54(1):25-9 (23 ref.) (Eng. Abstr.) **(Fre)**

[Use of rhodamine 123 for the detection of multidrug resistance] Canitrot Y, et al. **Bull Cancer (Paris)** 1995 Sep; 82(9):687-97 (86 ref.) (Eng. Abstr.) **(Fre)**

[Cisplatin resistance in a murine leukemia cell line associated with defect of apoptosis] Segal-Bendirdjian E, et al. **Bull Cancer (Paris)** 1996 May;83(5):371-8 (37 ref.) (Eng. Abstr.) **(Fre)**

[Structure and function of P-glycoprotein in antitumor agent resistance; implication for clinical setting] Tsuruo T. **Nippon Rinsho** 1995 Oct;53(10):2604-11 (38 ref.) (Eng. Abstr.) **(Jpn)**

[Biology and clinical relevance of multidrug resistance associated antigen] Utsumi M, et al. **Nippon Rinsho** 1996 Jun;54(6):1690-7 (56 ref.) (Eng. Abstr.) **(Jpn)**

[Antineoplastic drug resistance] Sekiya M. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Aug; 47(8):872-84 (31 ref.) **(Jpn)**

GENETICS

Modulation of multidrug resistance in multiple myeloma. Sonneveld P. **Baillieres Clin Haematol** 1995 Dec; 8(4):831-44 (107 ref.)

P-glycoprotein: clinical significance and methods of analysis. van der Heyden S, et al. **Crit Rev Clin Lab Sci** 1995; 32(3):221-64 (174 ref.)

Genetic alterations associated with metastatic dissemination and chemoresistance in neuroblastoma. Bénard J. **Eur J Cancer** 1995;31A(4):560-4 (59 ref.)

Oligonucleotide modulation of multidrug resistance. Bouffard DY, et al. **Eur J Cancer** 1996 Jun;32A(6):1010-8 (111 ref.)

Multidrug resistance in breast cancer: mechanisms, strategies. Giaccone G, et al. **Eur J Cancer** 1995;31A Suppl 7:S15-7 (30 ref.)

Clinical relevance of drug resistance genes in malignant disease. Filipits M, et al. **Leukemia** 1996 Jul;10 Suppl 3:S10-S17 (131 ref.)

MDR1 reversal: criteria for clinical trials designed to overcome the multidrug resistance phenotype. Hegewisch-Becker S. **Leukemia** 1996 Jul;10 Suppl 3:S32-S38 (53 ref.)

Transfer of drug resistance genes into hematopoietic progenitors to improve chemotherapy tolerance. Koç ON, et al. **Semin Oncol** 1996 Feb;23(1):46-65 (196 ref.)

[Multidrug resistance--genes and chemotherapy of ovarian cancer] Leng J, et al. **Chung Hua I Hsueh Tsa Chih** 1995 Sep;75(9):567-9 (7 ref.) **(Chi)**

[Overcoming tumor multiple drug resistance. MDR modulators] Dudnik IuV, et al. **Antibiot Khimioter** 1995 Oct;40(10):48-54 (81 ref.) **(Rus)**

PHYSIOLOGY

Clinical drug resistance: the role of factors other than P-glycoprotein. Kaye SB. **Am J Med** 1995 Dec 29; 99(6A):40S-44S (37 ref.)

Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance. Reed JC. **Curr Opin Oncol** 1995 Nov;7(6):541-6 (57 ref.)

What have we learnt thus far from mice with disrupted P-glycoprotein genes? Borst P, et al. **Eur J Cancer** 1996 Jun;32A(6):985-90 (39 ref.)

Diagnosis and reversal of multidrug resistance in paediatric cancers. Chan HS, et al. **Eur J Cancer** 1996 Jun; 32A(6):1051-61 (153 ref.)

Clinical trials of P-glycoprotein reversal in solid tumours. Ferry DR, et al. **Eur J Cancer** 1996 Jun;32A(6):1070-81 (119 ref.)

Pharmacological considerations in the modulation of multidrug resistance. Fisher GA, et al. **Eur J Cancer** 1996 Jun;32A(6):1082-8 (69 ref.)

Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitisers. Ford JM. **Eur J Cancer** 1996 Jun;32A(6):991-1001 (161 ref.)

P-glycoprotein--a mediator of multidrug resistance in tumour cells. Germann UA. **Eur J Cancer** 1996 Jun; 32A(6):927-44 (280 ref.)

Apoptosis and chemotherapy resistance. Hickman JA. **Eur J Cancer** 1996 Jun;32A(6):921-6 (67 ref.)

Major vault protein LRP-related multidrug resistance. Izquierdo MA, et al. **Eur J Cancer** 1996 Jun;32A(6):979-84 (40 ref.)

Biology of the multidrug resistance-associated protein, MRP. Loe DW, et al. **Eur J Cancer** 1996 Jun;32A(6):945-57 (188 ref.)

Antitopoisomerase drug action and resistance. Nitiss JL, et al. **Eur J Cancer** 1996 Jun;32A(6):958-66 (115 ref.)

Glutathione and related enzymes in multidrug resistance. O'Brien ML, et al. **Eur J Cancer** 1996 Jun;32A(6):967-78 (147 ref.)

Thymidylate synthase and drug resistance. Peters GJ, et al. **Eur J Cancer** 1995 Jul-Aug;31A(7-8):1299-305 (41 ref.)

Multidrug resistance reversal in childhood malignancies--potential for a real step forward? Pinkerton CR. **Eur J Cancer** 1996 Apr;32A(4):641-4 (37 ref.)

Reversal of multidrug resistance in acute myeloid leukaemia and other haematological malignancies. Sonneveld P. **Eur J Cancer** 1996 Jun;32A(6):1062-9 (97 ref.)

Experimental modulation of MRP (multidrug resistance-associated protein)-mediated resistance. Twentyman PR, et al. **Eur J Cancer** 1996 Jun; 32A(6):1002-9 (61 ref.)

Resistance mechanisms in human lung cancer. Mattern J, et al. **Invasion Metastasis** 1995;15(3-4):81-94 (108 ref.)

Interaction between erbB-receptors and heregulin in breast cancer tumor progression and drug resistance. Lupu R, et al. **Semin Cancer Biol** 1995 Jun;6(3):135-45 (143 ref.)

[The molecular basis and in vitro determination of multiple resistance to cytostatic agents] Krejsek J, et al. **Vnitr Lek** 1995 Aug;41(8):565-8 (34 ref.) (Eng. Abstr.) **(Cze)**

[Selection of drugs for chemotherapy based on drug resistance marker] Fukumoto H, et al. **Nippon Rinsho** 1996 Jun;54(6):1680-4 (28 ref.) (Eng. Abstr.) **(Jpn)**

DRUG SCREENING

see related

TOXICITY TESTS

Evaluation of new iron chelators for clinical use. Porter JB. **Acta Haematol** 1996;95(1):13-25 (41 ref.)

METHODS

Human cell lines in pharmacotoxicology. An introduction to a panel discussion. Batt AM, et al. **Cell Biol Toxicol** 1995 Aug;11(3-4):179-85 (31 ref.)

Rapid screening of antiretroviral combinations. St Clair M, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995; 10 Suppl 1:S24-7 (15 ref.)

A strategy for validation of bioanalytical methods. Braggio S, et al. **J Pharm Biomed Anal** 1996 Feb;14(4):375–88 (20 ref.)
Antiemetic study methodology: recommendations for future studies. Olver IN. **Oncology** 1996 Jun;53 Suppl 1:96–101 (32 ref.)
Concomitant toxicokinetics: techniques for and interpretation of exposure data obtained during the conduct of toxicology studies. Dahlem AM, et al. **Toxicol Pathol** 1995 Mar–Apr; 23(2):170–8 (9 ref.)
[The assessment of drug effects on memory in animals] Hironaka N. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1995 Jun;15(3):211–22 (89 ref.) (Eng. Abstr.) **(Jpn)**
[Assessment of anxiolytics (3)—biochemical approach] Ito Y. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1995 Jun; 15(3):223–9 (11 ref.) (Eng. Abstr.) **(Jpn)**
[Strategies for studies on mechanism of action of antineoplastic agents] Kuśnierczyk H. **Postepy Hig Med Dosw** 1995;49(1):85–96 (20 ref.) (Eng. Abstr.) **(Pol)**

STANDARDS

Assessing bone quality—animal models in preclinical osteoporosis research. Mosekilde L. **Bone** 1995 Oct;17(4 Suppl):343S–352S (35 ref.)

DRUG SCREENING ASSAYS, ANTITUMOR

Tumor chemosensitivity and chemoresistance assays. Brown E, et al. **Cancer** 1996 Mar 15;77(6):1020–5 (12 ref.)
Are lifespan rodent carcinogenicity studies defensible for pharmaceutical agents? Monro A. **Exp Toxicol Pathol** 1996 Feb;48(2–3):155–66 (70 ref.)
In vitro drug response assays for entry into the rational era cancer chemotherapy. Hoffman RM. **Hum Cell** 1995 Dec; 8(4):131–48 (208 ref.)
[Cancer chemosensitivity test—from laboratory to clinic] Kubota T. **Hum Cell** 1995 Dec;8(4):189–94 (11 ref.) (Eng. Abstr.) **(Jpn)**

METHODS

Human cell lines in pharmacotoxicology. An introduction to a panel discussion. Batt AM, et al. **Cell Biol Toxicol** 1995 Aug;11(3–4):179–85 (31 ref.)
Medium-term liver and multi-organ carcinogenesis bioassays for carcinogens and chemopreventive agents. Ito N, et al. **Exp Toxicol Pathol** 1996 Feb;48(2–3):113–9 (40 ref.)
[Selection of drugs for chemotherapy based on drug resistance marker] Fukumoto H, et al. **Nippon Rinsho** 1996 Jun;54(6):1680–4 (28 ref.) (Eng. Abstr.) **(Jpn)**

DRUG SCREENING TESTS, TUMOR-SPECIFIC see **DRUG SCREENING ASSAYS, ANTITUMOR**

DRUG SENSITIVITY ASSAY, MICROBIAL see **MICROBIAL SENSITIVITY TESTS**

DRUG SURVEILLANCE, POSTMARKETING see **PRODUCT SURVEILLANCE, POSTMARKETING**

DRUG SYNERGISM

see related
COCARCINOGENESIS

The search for synergy: a critical review from a response surface perspective. Greco WR, et al. **Pharmacol Rev** 1995 Jun;47(2):331–85 (161 ref.)
[Methodology for statistical analysis of drug interactions] Luo F, et al. **Sheng Li Ko Hsueh Chin Chan** 1995 Jul; 26(3):276–80 (10 ref.) **(Chi)**

DRUG THERAPY

Advances in pediatric pharmacology and toxicology. Berlin CM Jr. **Adv Pediatr** 1995;42:593–629 (106 ref.)
Medication administration: how safe is your patient? **Am J Nurs** 1995 Oct;95(10):44–59; quiz 60 (35 ref.)
Targeting signal transduction for disease therapy. Levitzki A. **Curr Opin Cell Biol** 1996 Apr;8(2):239–44 (54 ref.)
Emergency drug therapy. Drugs and routes of administration. Bennett JD. **Dent Clin North Am** 1995 Jul;39(3):501–21 (27 ref.)
Risk:benefit analysis of drugs in practice. The doctor, the patient and the licensing authority. **Drug Ther Bull** 1995 May;33(5):33–5 (7 ref.)
Drugs for the doctor's bag [see comments] **Drug Ther Bull** 1995 Jan 19;33(1):3–5 (8 ref.) Comment in: Drug Ther Bull 1995 Jul;33(7):56.
Perioperative management of drug therapy, clinical considerations. Smith MS, et al. **Drugs** 1996 Feb; 51(2):238–59 (181 ref.)
Pharmacologic control of intracellular signaling pathways: from research to therapy. Hakim J. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S106–13 (64 ref.)
Systematic review of randomised trials of interventions to assist patients to follow prescriptions for medications. Haynes RB, et al. **Lancet** 1996 Aug 10;348(9024):383–6 (26 ref.)
Topical iontophoretic drug delivery: pathways, principles, factors, and skin irritation. Singh J, et al. **Med Res Rev** 1996 May;16(3):285–96 (88 ref.)
Stereochemical aspects of pharmacotherapy. Brocks DR, et al. **Pharmacotherapy** 1995 Sep–Oct;15(5):551–64 (72 ref.)
Drug delivery during pregnancy: evaluation in vitro of new drugs. Dancis J, et al. **Reprod Fertil Dev** 1995;7(6):1485–9 (33 ref.)
Medication decision-making and management: a client-centered model. Chewning B, et al. **Soc Sci Med** 1996 Feb;42(3):389–98 (110 ref.)
[Current therapeutic agents 1995–1996] Scheen AJ. **Rev Med Liege** 1996 Jun;51(6):399–405 (24 ref.) **(Fre)**
[Mirror, mirror on the wall—stereoselectivity of drug effects] Fromm MF, et al. **Fortschr Med** 1995 Aug 30;113(24):343–5 (0 ref.) **(Ger)**
[The physiopathology of acute spinal cord injury and a hope for a successful treatment] Harat M, et al. **Neurol Neurochir Pol** 1996 Jan–Feb;30(1):123–35 (22 ref.) (Eng. Abstr.) **(Pol)**
[Changes in patterns of medication as function of age of the aging patient (review of the literature) (editorial)] Rosario Burgos EN. **Bol Asoc Med P R** 1995 Jul–Sep;87(7–9):121–3 (8 ref.) **(Spa)**

ADVERSE EFFECTS

Adverse effects of potential agents for the treatment of Alzheimer's disease: a review. Domingo JL. **Adverse Drug React Toxicol Rev** 1995 Summer;14(2):101–15 (91 ref.)
Long-term effects of treatment of childhood malignancy. Malpas JS. **Clin Radiol** 1996 Jul;51(7):466–74 (65 ref.)
The poisoned patient. Toxicologic emergencies. Norris LH, et al. **Dent Clin North Am** 1995 Jul;39(3):595–619 (72 ref.)
Adverse effects of chemotherapeutic agents used in tropical medicine. Cook GC. **Drug Saf** 1995 Jul;13(1):31–45 (142 ref.)
How important is therapeutic drug monitoring in the prediction and avoidance of adverse reactions? Gentry CA, et al. **Drug Saf** 1995 Jun;12(6):359–63 (43 ref.)
Nonhormonal drugs and cancer. Stolley PD, et al. **Environ Health Perspect** 1995 Nov;103 Suppl 8:191–6 (114 ref.)
Perioperative monitoring of potentially toxic drugs. Stapp MD, et al. **J Am Podiatr Med Assoc** 1995 Nov;85(11):690–5 (23 ref.)
[Erection disorders and priapism due to drugs] Meinhardt W, et al. **Ned Tijdschr Geneeskd** 1995 Sep 16;139(37):1871–3 (24 ref.) **(Dut)**
[Drug treatment and exercise] Ylitalo P. **Duodecim** 1994; 110(12):1207–14 (41 ref.) **(Fin)**
[Pulmonary toxicity of drugs and thoracic irradiation in children] Fauroux B, et al. **Rev Mal Respir** 1996 Jul; 13(3):235–42 (58 ref.) (Eng. Abstr.) **(Fre)**
[Drug-induced neurological complications in a hospital cohort] Vuadens P, et al. **Schweiz Med Wochenschr** 1995 Sep 2;125(35):1625–33 (42 ref.) (Eng. Abstr.) **(Fre)**
[Psychiatrically relevant side effects of non-psychopharmacological pharmacotherapy] Kasper S, et al. **Nervenarzt** 1995 Sep;66(9):649–61 (95 ref.) (Eng. Abstr.) **(Ger)**
[Toxic lesions of the optic nerve] Mozherenkov VP, et al. **Vestn Oftalmol** 1996 Jan–Mar;112(1):54–5 (32 ref.) **(Rus)**

ECONOMICS

When drug treatment in the elderly is not cost effective. An ethical dilemma in an environment of healthcare rationing. Chadwick R, et al. **Drugs Aging** 1995 Dec;7(6):416–9 (25 ref.)
The cost benefit ratio of enantiomeric drugs. Pifferi G, et al. **Eur J Drug Metab Pharmacokinet** 1995 Jan–Mar; 20(1):15–25 (51 ref.)

METHODS

[Pharmacologic principles of drug prescribing in pregnancy] Estler CJ. **Z Arztl Fortbild (Jena)** 1995 Dec;89(7):743–8 (18 ref.) (Eng. Abstr.) **(Ger)**
[Age as a factor in dose-response relationship of drugs] Gundert-Remy U. **Z Gerontol Geriatr** 1995 Nov–Dec; 28(6):408–14 (68 ref.) (Eng. Abstr.) **(Ger)**
[How best to perform aerosol therapy. 2. Drugs] Battistini A. **Pediatr Med Chir** 1995 May–Jun;17(3):189–96 (46 ref.) (Eng. Abstr.) **(Ita)**

PSYCHOLOGY

Patient decision making. The missing ingredient in compliance research. Donovan JL. **Int J Technol Assess Health Care** 1995 Summer; 11(3):443–55 (46 ref.)

STANDARDS

Setting standards of prescribing performance in primary care: use of a consensus group of general practitioners and application of standards to practices in the north of England. Bateman DN, et al. **Br J Gen Pract** 1996 Jan; 46(402):20–5 (12 ref.)
Improving physician prescribing practices: bridge over troubled waters [editorial] MacLeod SM. **Can Med Assoc J** 1996 Mar 1;154(5):675–7 (10 ref.)
Causes and problems of nonresponse or poor response to drugs. Salvà Lacombe P, et al. **Drugs** 1996 Apr; 51(4):552–70 (162 ref.)
Pharmacists as agents of change for rational drug therapy. Lipton HL, et al. **Int J Technol Assess Health Care** 1995 Summer;11(3):485–508 (138 ref.)

TRENDS

The changing face of therapy for rheumatoid arthritis. Kremer JM. **Rheum Dis Clin North Am** 1995 Aug; 21(3):845–52 (34 ref.)

DRUG THERAPY, ADJUVANT see **CHEMOTHERAPY, ADJUVANT**

DRUG THERAPY, COMBINATION

see related
ANTIBIOTICS, COMBINED
ANTINEOPLASTIC AGENTS, COMBINED

Consensus symposium on combined antiviral therapy. Lisbon, Portugal, July 25–27. **Antiviral Res** 1996 Jan;29(1):3–122 (0 ref.)
Combined drug treatment of obesity. Atkinson RL, et al. **Obes Res** 1995 Nov;3 Suppl 4:497S–500S (32 ref.)

DRUG THERAPY, COMPUTER-ASSISTED

INSTRUMENTATION

Application of computers in diabetes care—a review. II. Computers for decision support and education. Lehmann ED, et al. **Med Inf (Lond)** 1995 Oct–Dec;20(4):303–29 (147 ref.)

DRUG TOLERANCE

Pediatric phase I drug tolerance: a review and comparison of recent adult and pediatric phase I trials. Carlson L, et al. **J Pediatr Hematol Oncol** 1996 Aug;18(3):250–6 (83 ref.)
Under siege: The brain on opiates. Nestler EJ. **Neuron** 1996 May;16(5):897–900 (26 ref.)
[Metabolic tolerance of isradipine. Evaluation after three months of therapy] Panuccio D, et al. **Clin Ter** 1995 Nov; 146(11):729–36 (82 ref.) (Eng. Abstr.) **(Ita)**

GENETICS

Causes and problems of nonresponse or poor response to drugs. Salvà Lacombe P, et al. **Drugs** 1996 Apr; 51(4):552–70 (162 ref.)

DRUG TREATMENT CENTERS see **SUBSTANCE ABUSE TREATMENT CENTERS**

DRUG USE DISORDERS see **SUBSTANCE USE DISORDERS**

DRUG UTILIZATION

Choosing the best medications. Chambliss ML. **Am Fam Physician** 1996 Jun;53(8):2565–70 (14 ref.)
Unapproved uses of approved drugs: the physician, the package insert, and the Food and Drug Administration: subject review. American Academy of Pediatrics Committee on Drugs [see comments] **Pediatrics** 1996 Jul; 98(1):143–5 (00 ref.) Comment in: Pediatrics 1996 Jul;98(1):118–23.
Avoiding problems prescribing to older patients. Beyth RJ, et al. **Tenn Med** 1996 Aug;89(8):296–8 (31 ref.)
[Medical prescription and consumption of psychotropic drugs: questions on the differences between men and women] Baumann M, et al. **Cah Sociol Demogr Med** 1996 Jan–Mar;36(1):63–78 (38 ref.) (Eng. Abstr.) **(Fre)**
[Proper use of antibiotics—what is that?] Jensenius M, et al. **Tidsskr Nor Laegeforen** 1995 Nov 20;115(28):3504–7 (23 ref.) (Eng. Abstr.) **(Nor)**
[Increased resistance after administration of antibiotics to animals] Franklin A. **Lakartidningen** 1996 Apr 24; 93(17):1627–30 (21 ref.) **(Swe)**

STATISTICS & NUMERICAL DATA

Comparison of dose standard units for drug utilisation studies. Merlo J, et al. **Eur J Clin Pharmacol** 1996;50(1–2):27–30 (33 ref.)
Comparing period prevalences with application to drug utilization. McFarland BH. **J Clin Epidemiol** 1996 Apr; 49(4):473–82 (21 ref.)

DRUG UTILIZATION REVIEW

Antihypertensive drug use in the long-term care facility: a pilot study and review of the literature. Fish JT, et al. **Pharmacotherapy** 1995 Nov–Dec;15(6):785–8 (11 ref.)
Cost-effective therapy for hypertension. Barrie W. **West J Med** 1996 Apr;164(4):303–9 (36 ref.)

METHODS

Improving the quality of antimicrobial drug use can result in cost containment. Gyssens IC, et al. **Pharm World Sci** 1995 Sep 22;17(5):163–7 (19 ref.)

DRUG WITHDRAWAL SYMPTOMS see **SUBSTANCE**

DRUG WITHDRAWAL SYMPTOMS

WITHDRAWAL SYNDROME

DRUGS

see related
PLANTS, MEDICINAL
RECEPTORS, DRUG

The human intestinal epithelial cell line Caco-2; pharmacological and pharmacokinetic applications. Meunier V, et al. **Cell Biol Toxicol** 1995 Aug; 11(3-4):187-94 (58 ref.)

Pharmacobezoar: an evolving new entity. Stack PE, et al. **Dig Dis** 1995 Nov-Dec;13(6):356-64 (38 ref.)

[Eating, nutrition and drugs] Noirfalise A. **J Pharm Belg** 1996 Mar-Apr;51(2):87-91 (23 ref.) **(Fre)**

[Disease states and changes in drug pharmacokinetics] Ventresca GP, et al. **Clin Ter** 1996 Mar;147(3):131-44 (25 ref.) (Eng. Abstr.) **(Ita)**

ADMINISTRATION & DOSAGE

Injectable medications for hemodialysis patients. Stivelman JC. **Am J Nephrol** 1996;16(1):73-8 (55 ref.)

Drug removal in continuous haemofiltration and haemodialysis. Davies JG, et al. **Br J Hosp Med** 1995 Nov 15-Dec 12;54(10):524-8 (30 ref.)

Comparison of dose standard units for drug utilisation studies. Merlo J, et al. **Eur J Clin Pharmacol** 1996;50(1-2):27-30 (33 ref.)

First-time-in-human dose selection: allometric thoughts and perspectives. Boxenbaum H, et al. **J Clin Pharmacol** 1995 Oct;35(10):957-66 (36 ref.)

Localized reactions to injected therapeutic materials. Part 1. Medical agents. Morgan AM. **J Cutan Pathol** 1995 Jun; 22(3):193-214 (90 ref.)

Drug administration in critically ill patients with acute renal failure. Kroh UF. **New Horiz** 1995 Nov;3(4):748-59 (42 ref.)

Drug delivery during pregnancy: evaluation in vitro of new drugs. Dancis J, et al. **Reprod Fertil Dev** 1995;7(6):1485-9 (33 ref.)

[Routes for drug administration during cardiopulmonary resuscitation] Kerz T, et al. **Anaesthesist** 1996 Jun; 45(6):550-65 (175 ref.) (Eng. Abstr.) **(Ger)**

[Changes in patterns of medication as function of age of the aging patient (review of the literature) (editorial)] Rosario Burgos EN. **Bol Asoc Med P R** 1995 Jul-Sep;87(7-9):121-3 (8 ref.) **(Spa)**

[Lipid vehicles for the parenteral administration of drugs (2): liposomes] Bermejo Vicedo T, et al. **Nutr Hosp** 1996 Mar-Apr;11(2):69-81 (80 ref.) (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Disturbances of thyroid function tests by drugs. Wenzel KW. **Acta Med Austriaca** 1996;23(1-2):57-60 (32 ref.)

Medication-related adverse reactions and the elderly: a literature review. Atkin PA, et al. **Adverse Drug React Toxicol Rev** 1995 Autumn;14(3):175-91 (125 ref.)

Medication administration: how safe is your patient? **Am J Nurs** 1995 Oct;95(10):44-59; quiz 60 (35 ref.)

All about drugs. Adverse effects to watch for. **Am J Nurs** 1995 Oct;95(10):32-42, quiz 43 (27 ref.)

Drugs and the elderly: do you know the risks? Lee M. **Am J Nurs** 1996 Jul;96(7):24-31; quiz 32 (9 ref.)

Clinical studies of drug effects in humans. Ray WA. **Clin Chem** 1996 Aug;42(8 Pt 2):1306-11 (25 ref.)

The management of adverse drug reactions. Mathelier-Fusade P, et al. **Clin Rev Allergy Immunol** 1995 Fall;13(3):281-90 (21 ref.)

Drug related hospital admissions in subspecialities of internal medicine. Hallas J. **Dan Med Bull** 1996 Apr;43(2):141-55 (178 ref.)

Drug-induced thyroid disorders. Gittoes NJ, et al. **Drug Saf** 1995 Jul;13(1):46-55 (63 ref.)

When a randomised controlled trial is needed to assess drug safety. The case of paediatric ibuprofen. Mitchell AA, et al. **Drug Saf** 1995 Jul;13(1):15-24 (21 ref.)

Drug-induced severe skin reactions. Incidence, management and prevention. Wolkenstein P, et al. **Drug Saf** 1995 Jul; 13(1):56-68 (82 ref.)

Gender as a risk factor for adverse events to medications. Kando JC, et al. **Drugs** 1995 Jul;50(1):1-6 (52 ref.)

Epidemiology of adverse drug events in the nursing home setting. Monette J, et al. **Drugs Aging** 1995 Sep;7(3):203-11 (57 ref.)

Drug related hepatic injuries. Sarin SK, et al. **J Assoc Physicians India** 1995 Oct;43(10):689-93 (20 ref.)

Localized reactions to injected therapeutic materials. Part 1. Medical agents. Morgan AM. **J Cutan Pathol** 1995 Jun; 22(3):193-214 (90 ref.)

Drug-induced hepatotoxicity [see comments] Lee WM. **N Engl J Med** 1995 Oct 26;333(17):1118-27 (101 ref.) Comment in: N Engl J Med 1996 Mar 28;334(13):863; discussion 864. Comment in: N Engl J Med 1996 Mar 28;334(13):863-4; discussion 864. Comment in: N Engl J Med 1996 Mar 28;334(13):864.

The role of cytochrome P450 enzymes in hepatic and extrahepatic human drug toxicity. Park BK, et al. **Pharmacol Ther** 1995;68(3):385-424 (369 ref.)

Epidemiological identification and evaluation of hepatic adverse drug reactions. Bruppacher R. **Semin Liver Dis** 1995 Aug;15(3):301-8 (40 ref.)

Molecular basis of drug-induced immunological liver injury. Van Pelt FN, et al. **Semin Liver Dis** 1995 Aug; 15(3):283-300 (133 ref.)

Defining, monitoring and combining safety information in clinical trials. Enas GG, et al. **Stat Med** 1995 May 15-30; 14(9-10):1099-111; discussion 1113-6 (24 ref.)

[The use of drugs in pregnant and nursing women with dermatologic diseases] Miteva L, et al. **Akush Ginekol (Sofiia)** 1995;34(2):42-6 (20 ref.) **(Bul)**

[Drug side-effects of the eye--a contribution to quality assurance in ophthalmology] Dangelmaier S, et al. **Klin Monatsbl Augenheilkd** 1996 May;208(5):385-8 (4 ref.) (Eng. Abstr.) **(Ger)**

[Decreased saliva secretion. A pharmacologic effect with sequelae for oral health] Foth H. **Med Monatsschr Pharm** 1995 Dec;18(12):350-7 (8 ref.) **(Ger)**

[Drug fever] Karban A, et al. **Harefuah** 1996 Jan 15; 130(2):113-6 (34 ref.) **(Heb)**

[The role of genetically determined acetylation of drugs and xenobiotics in pathogenesis of neoplastic diseases] Niewiński P, et al. **Postepy Hig Med Dosw** 1996; 50(2):131-43 (50 ref.) (Eng. Abstr.) **(Pol)**

ANALYSIS

Analysis of drugs of abuse in biological fluids by liquid chromatography. Binder SR. **Adv Chromatogr** 1996; 36:201-71 (413 ref.)

Forensic science. Brettell TA, et al. **Anal Chem** 1995 Jun 15;67(12):273R-294R (843 ref.)

Pharmaceuticals and related drugs. Gilpin RK, et al. **Anal Chem** 1995 Jun 15;67(12):295R-313R (429 ref.)

Determination of drug-related impurities by capillary electrophoresis. Altria KD. **J Chromatogr A** 1996 May 31; 735(1-2):43-56 (58 ref.)

Identification of chiral drug isomers by capillary electrophoresis. Fanali S. **J Chromatogr A** 1996 May 31; 735(1-2):77-121 (204 ref.)

Capillary electrophoretic analyses of drugs in body fluids: sample pretreatment and methods for direct injection of biofluids. Lloyd DK. **J Chromatogr A** 1996 May 31; 735(1-2):29-42 (69 ref.)

Application of capillary electrophoresis and related techniques to drug metabolism studies. Naylor S, et al. **J Chromatogr A** 1996 May 31;735(1-2):415-38 (139 ref.)

Micellar electrokinetic chromatography perspectives in drug analysis. Nishi H, et al. **J Chromatogr A** 1996 May 31; 735(1-2):3-27 (243 ref.)

Chemiluminescence in drug assay. Calokerinos AC, et al. **J Pharm Biomed Anal** 1995 Aug;13(9):1063-71 (122 ref.)

Sources, behaviour and fate of organic contaminants during sewage treatment and in sewage sludges. Rogers HR. **Sci Total Environ** 1996 Jun 21;185(1-3):3-26 (141 ref.)

[Measurement of drugs in neonatal hair--a window to fetal exposure] Koren G, et al. **Harefuah** 1995 Nov 1; 129(9):336-8 (15 ref.) **(Heb)**

[Stereoselective analysis of pharmaceutical compounds in biological fluids with capillary electrophoresis] Desiderio C, et al. **Boll Chim Farm** 1995 Nov;134(10):541-6 (14 ref.) (Eng. Abstr.) **(Ita)**

[Drug screening in clinical toxicology and analytical doping control in sports] Ueki M. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:904-6 (5 ref.) **(Jpn)**

CHEMISTRY

Radicals from one-electron reduction of nitro compounds, aromatic N-oxides and quinones: the kinetic basis for hypoxia-selective, bioreductive drugs. Wardman P, et al. **Biochem Soc Symp** 1995;61:171-94 (126 ref.)

Identification of chiral drug isomers by capillary electrophoresis. Fanali S. **J Chromatogr A** 1996 May 31; 735(1-2):77-121 (204 ref.)

Enantiomer separation of drugs by electrokinetic chromatography. Nishi H. **J Chromatogr A** 1996 May 31; 735(1-2):57-76 (151 ref.)

Pharmaceutical solids: a strategic approach to regulatory considerations. Byrn S, et al. **Pharm Res** 1995 Jul; 12(7):945-54 (22 ref.)

[Mirror, mirror on the wall--stereoselectivity of drug effects] Fromm MF, et al. **Fortschr Med** 1995 Aug 30;113(24):343-5 (0 ref.) **(Ger)**

[Synthetic enantiomers of drugs] Knabe J. **Pharm Unserer Zeit** 1995 Nov;24(6):324-30 (24 ref.) **(Ger)**

CLASSIFICATION

International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. IX. Recommendations on terms and symbols in quantitative pharmacology. Jenkinson DH, et al. **Pharmacol Rev** 1995 Jun;47(2):255-66 (14 ref.)

CONTRAINDICATIONS

Drugs to be used with caution in patients with asthma. Craig TJ. **Am Fam Physician** 1996 Sep 1;54(3):947-53, 957-8 (24 ref.)

ECONOMICS

Pharmacoepidemiology in practice. Current status and future trends. Alvarez-Requejo A, et al. **Drug Saf** 1995 Jul; 13(1):1-7 (39 ref.)

ISOLATION & PURIFICATION

Enantiomer separation of drugs by electrokinetic chromatography. Nishi H. **J Chromatogr A** 1996 May 31; 735(1-2):57-76 (151 ref.)

Marine fungi--a prolific resource of biologically active natural products? Liberra K, et al. **Pharmazie** 1995 Sep; 50(9):583-8 (35 ref.)

METABOLISM

Immunohistochemistry of drug-metabolizing enzymes. Murray GI, et al. **Biochem Pharmacol** 1995 Sep 28; 50(7):895-903 (73 ref.)

Myeloperoxidase as a generator of drug free radicals. Uetrecht JP. **Biochem Soc Symp** 1995;61:163-70 (44 ref.)

Molecular mechanisms of drug metabolism in the critically ill. Park GR. **Br J Anaesth** 1996 Jul;77(1):32-49 (160 ref.)

The genetic origin of responses to drugs. Waring RH, et al. **Br Med Bull** 1995 Apr;51(2):449-61 (30 ref.)

Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Bertilsson L. **Clin Pharmacokinet** 1995 Sep;29(3):192-209 (103 ref.)

Clinical importance of hepatic cytochrome P450 in drug metabolism. Spatzenegger M, et al. **Drug Metab Rev** 1995; 27(3):397-417 (146 ref.)

Racial, ethnic and gender differences in response to medicines. Matthews HW. **Drug Metabol Drug Interact** 1995;12(2):77-91 (38 ref.)

Application of capillary electrophoresis and related techniques to drug metabolism studies. Naylor S, et al. **J Chromatogr A** 1996 May 31;735(1-2):415-38 (139 ref.)

Membrane energization by proton pumps is important for compartmentalization of drugs and toxins: a new type of active transport. Moriyama Y. **J Exp Biol** 1996 Jul;199 (Pt 7):1447-54 (70 ref.)

Design of drugs involving the concepts and theories of drug metabolism and pharmacokinetics. Smith DA, et al. **Med Res Rev** 1996 May;16(3):243-66 (54 ref.)

Factors affecting drug metabolism in critically ill patients. Woodrooffe AJ, et al. **Middle East J Anesthesiol** 1995 Feb; 13(1):3-22 (71 ref.)

Models for studying the cellular processes and barriers to the incorporation of drugs into hair. Rollins DE, et al. **NIDA Res Monogr** 1995;154:235-44 (20 ref.)

Does fluid flow across the intestinal mucosa affect quantitative oral drug absorption? Is it time for a reevaluation? Lennernäs H. **Pharm Res** 1995 Nov; 12(11):1573-82 (71 ref.)

Progressive application of autoradiography in pharmacokinetic and metabolic studies for the development of new drugs. Shigematsu A, et al. **Regul Toxicol Pharmacol** 1995 Oct;22(2):122-42 (20 ref.)

Blood-brain interfaces: relevance to cerebral drug metabolism. Ghersi-Egea JF, et al. **Toxicol Lett** 1995 Dec; 82-83:645-53 (37 ref.)

Toxicokinetics/toxicodynamic correlations: goals, methods, and limitations. Batra VK. **Toxicol Pathol** 1995 Mar-Apr; 23(2):158-64 (15 ref.)

Basic principles of pharmacokinetics. Benet LZ, et al. **Toxicol Pathol** 1995 Mar-Apr;23(2):115-23 (15 ref.)

The role of drug metabolism in drug discovery: a case study in the selection of an oxytocin receptor antagonist for development. Chiu SH, et al. **Toxicol Pathol** 1995 Mar-Apr;23(2):124-30 (12 ref.)

Preclinical drug metabolism programs for food-producing animals. Clement RP. **Toxicol Pathol** 1995 Mar-Apr; 23(2):209-16 (7 ref.)

Goals, design, timing, and future opportunities for nonclinical drug metabolism studies. Miwa GT. **Toxicol Pathol** 1995 Mar-Apr;23(2):131-5 (12 ref.)

The use of in vitro metabolism techniques in the planning and interpretation of drug safety studies. Wrighton SA, et al. **Toxicol Pathol** 1995 Mar-Apr;23(2):199-208 (34 ref.)

[Cytochrome P-450 isoenzymes as predictors of drug interactions] Pelkonen O. **Duodecim** 1994;110(17):1575-9 (19 ref.) **(Fin)**

[Pharmacology in the elderly. Changes in the pharmacodynamic response to a given drug concentration and changes in mechanisms of regulation] Jolliet P, et al. **Ann Med Interne (Paris)** 1995;146(5):328-34 (71 ref.) **(Fre)**

[Hormones, growth factors, and drugs in metabolism and nutrition] García de Lorenzo A, et al. **Nutr Hosp** 1995 Sep-Oct;10(5):297-305 (91 ref.) (Eng. Abstr.) **(Spa)**

RADIATION EFFECTS

A review of the effects of gamma radiation on pharmaceutical materials. Jacobs GP. **J Biomater Appl** 1995 Jul;10(1):59-96 (213 ref.)

STANDARDS

A review of the effects of gamma radiation on pharmaceutical materials. Jacobs GP. **J Biomater Appl** 1995 Jul;10(1):59-96 (213 ref.)

TOXICITY

Predictive immunotoxicological test systems: suitability of

the popliteal lymph node assay in mice and rats. Bloksma N, et al. **Crit Rev Toxicol** 1995;25(5):369–96 (115 ref.)
Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer. Nebert DW, et al. **DNA Cell Biol** 1996 Apr;15(4):273–80 (96 ref.)
Role of rat strain in the differential sensitivity to pharmaceutical agents and naturally occurring substances. Kacew S, et al. **J Toxicol Environ Health** 1996 Jan; 47(1):1–30 (145 ref.)
Pregnancy, lactation, and menopause: how physiology and gender affect the toxicity of chemicals. Roberts JS, et al. **Mt Sinai J Med** 1995 Oct;62(5):343–55 (66 ref.)
Interactions of drugs with the developing kidney. Blowey DL, et al. **Pediatr Clin North Am** 1995 Dec;42(6):1415–31 (97 ref.)
Effects of myotoxins on skeletal muscle fibers. Khan MA. **Prog Neurobiol** 1995 Aug;46(5):541–60 (230 ref.)
Toxicokinetics/toxicodynamic correlations: goals, methods, and limitations. Batra VK. **Toxicol Pathol** 1995 Mar–Apr; 23(2):158–64 (15 ref.)
Considerations in the design of toxicokinetic programs. Cayen MN. **Toxicol Pathol** 1995 Mar–Apr;23(2):148–57 (48 ref.)
Concomitant toxicokinetics: techniques for and interpretation of exposure data obtained during the conduct of toxicology studies. Dahlem AM, et al. **Toxicol Pathol** 1995 Mar–Apr; 23(2):170–8 (9 ref.)
Differences between pharmacokinetics and toxicokinetics. Welling PG. **Toxicol Pathol** 1995 Mar–Apr;23(2):143–7 (23 ref.)
Kids are different: developmental variability in toxicology. Graeter LJ, et al. **Toxicology** 1996 Jul 17;111(1–3):15–20 (20 ref.)
[Basic in-vitro toxicity testing on cell cultures] Ioniță I. **Bacteriol Virusol Parazitol Epidemiol** 1995 Jul–Dec; 40(3–4):181–5 (27 ref.) **(Rum)**

DRUGS, CHINESE HERBAL

[Advances in the research of liuwei dihuang decoction] Li L. **Chung Kuo Chung Yao Tsa Chih** 1995 May;20(5):310–2 (36 ref.) **(Chi)**
[The status quo and prospect of experimental study on channel tropism of Chinese herbal drugs] Liang A, et al. **Chung Kuo Chung Yao Tsa Chih** 1996 Jan;21(1):58–60, inside back cover (15 ref.) (Eng. Abstr.) **(Chi)**
[Progress in the research of plant polysaccharides] Tian G, et al. **Chung Kuo Chung Yao Tsa Chih** 1995 Jul;20(7):441–4 (31 ref.) **(Chi)**
[Advances in the study on artificial cultivation of Cordyceps sinensis] Yin D, et al. **Chung Kuo Chung Yao Tsa Chih** 1995 Dec;20(12):707–9, inside back cover (29 ref.) **(Chi)**

ADVERSE EFFECTS

Acute hepatitis associated with the use of a Chinese herbal product, ma-huang. Nadir A, et al. **Am J Gastroenterol** 1996 Jul;91(7):1436–8 (20 ref.)
Usage and adverse effects of Chinese herbal medicines. Chan TY, et al. **Hum Exp Toxicol** 1996 Jan;15(1):5–12 (84 ref.)
Possible association of liver damage with the use of Chinese herbal medicine for skin disease. Perharic L, et al. **Vet Hum Toxicol** 1995 Dec;37(6):562–6 (30 ref.)
[A review of the adverse effects of Chinese herbal drugs as published in Chinese journals in 1993 and 1994] Gu Y, et al. **Chung Kuo Chung Yao Tsa Chih** 1995 Aug;20(8):502–7 (111 ref.) **(Chi)**

CHEMISTRY

[Advances in the study of the chemical constituents of gardenia] Wang G, et al. **Chung Kuo Chung Yao Tsa Chih** 1996 Feb;21(2):67–9, 72 (34 ref.) **(Chi)**
[Structure and pharmacological activity of pectic polysaccharides from the roots of Bupleurum falcatum L.] Yamada H. **Nippon Yakurigaku Zasshi** 1995 Sep; 106(3):229–37 (17 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSTIC USE

Novel therapeutic and diagnostic applications of hypocrellins and hypericins. Diwu Z. **Photochem Photobiol** 1995 Jun; 61(6):529–39 (118 ref.)

PHARMACOLOGY

Recent progress in the study of anticancer drugs originating from plants and traditional medicine in China. Han R. **Chin Med J (Engl)** 1995 Oct;108(10):729–31 (9 ref.)
Vascular effects of selected antihypertensive drugs derived from traditional medicinal herbs. Kwan CY. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S297–9 (12 ref.)
Immunopharmacological and biochemical bases of Chinese herbal medicine. Lien EJ, et al. **Prog Drug Res** 1996; 46:263–80 (29 ref.)
[Recent development in experimental research of single Chinese medicinal herb with positive inotropic action] Zhao W. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Jul;15(7):443–5 (25 ref.) **(Chi)**

THERAPEUTIC USE

Current treatment of vitiligo in China. Shao C, et al. **Chin Med J (Engl)** 1995 Sep;108(9):647–9 (10 ref.)
Taking the path of combining traditional Chinese medicine with Western medicine in cancer research and control. Yu R. **Chin Med J (Engl)** 1995 Oct;108(10):732–3 (0 ref.)
Usage and adverse effects of Chinese herbal medicines. Chan TY, et al. **Hum Exp Toxicol** 1996 Jan;15(1):5–12 (84 ref.)
Novel therapeutic and diagnostic applications of hypocrellins and hypericins. Diwu Z. **Photochem Photobiol** 1995 Jun; 61(6):529–39 (118 ref.)
[Recent developments of traditional Chinese medical therapy in treating aplastic anemia] Feng J, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Jun; 15(6):376–8 (21 ref.) **(Chi)**
[Progress on research of mechanism of Rheum palmatum in delaying the chronic renal failure] Huang CL, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Aug; 15(8):506–8 (22 ref.) **(Chi)**
[A survey on the treatment of acne] Huang ZM. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Jun; 15(6):379–81 (20 ref.) **(Chi)**
[Exploration of clinical study of antileukemia cell drug-resistance by traditional Chinese medicine] Li D, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Oct; 15(10):636–7 (8 ref.) **(Chi)**
[Progress on research in preventing and treating the myocardial ischemia/reperfussion injury with Chinese herb medicine] Yi HZ, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Aug; 15(8):509–11 (25 ref.) **(Chi)**

DRUGS, GENERIC

SUPPLY & DISTRIBUTION

[Generic drugs in developing countries] Trouiller P. **Sante** 1996 Jan–Feb;6(1):21–6 (24 ref.) (Eng. Abstr.) **(Fre)**

DRUGS, INVESTIGATIONAL

see related
CLINICAL TRIALS
DRUG EVALUATION

New antiepileptic drugs. Dichter MA, et al. **N Engl J Med** 1996 Jun 13;334(24):1583–90 (101 ref.)
[The investigational vaccine SPf66 against Plasmodium falciparum: myth or reality?] Robert F, et al. **Sante** 1996 Jan–Feb;6(1):56–7 (11 ref.) **(Fre)**

ECONOMICS

Review article: drug development in gastroenterology—the changing view of industry. Parsons ME, et al. **Aliment Pharmacol Ther** 1995 Oct;9(5):457–63 (14 ref.)

THERAPEUTIC USE

Present research trends in cancer chemotherapy. Eckhardt S. **Acta Med Hung** 1994;50(3–4):133–40 (14 ref.)
Status of antimalarial drugs under development. Olliaro PL, et al. **Bull World Health Organ** 1995;73(5):565–71 (35 ref.)
New anticancer agents. Weiss GR, et al. **Cancer Chemother Biol Response Modif** 1996;16:132–67 (205 ref.)
New promising anticancer agents in development: what comes next? Verweij J. **Cancer Chemother Pharmacol** 1996; 38 Suppl:S3–10 (69 ref.)
Ropinirole in the symptomatic treatment of Parkinson's disease. Brooks DJ, et al. **J Neural Transm Suppl** 1995; 45:231–8 (15 ref.)
Second generation of dopamine agonists: pros and cons. Rabey JM. **J Neural Transm Suppl** 1995;45:213–24 (63 ref.)
Investigational agents for rheumatoid arthritis. Merkel PA, et al. **Rheum Dis Clin North Am** 1995 Aug;21(3):779–96 (85 ref.)

DRUGS, NON-PRESCRIPTION

Drug interactions between prescribed and over-the-counter medication. Honig PK, et al. **Drug Saf** 1995 Nov; 13(5):296–303 (73 ref.)

ADMINISTRATION & DOSAGE

Over-the-counter hypnotics and chronic insomnia in the elderly [editorial] [see comments] Lasagna L. **J Clin Psychopharmacol** 1995 Dec;15(6):383–6 (14 ref.) Comment in: J Clin Psychopharmacol 1996 Apr;16(2):191.

ADVERSE EFFECTS

Switching drug availability from prescription only to over-the-counter status. Are elderly patients at increased risk? Benrimoj SI, et al. **Drugs Aging** 1995 Oct;7(4):255–65 (152 ref.)

CHEMISTRY

Characterization of drugs as antioxidant prophylactics. Aruoma OI. **Free Radic Biol Med** 1996;20(5):675–705 (473 ref.)

THERAPEUTIC USE

New OTC drugs and devices: a selected review. Newton GD, et al. **J Am Pharm Assoc (Wash)** 1996 Feb; NS36(2):108–116 (11 ref.)

TOXICITY

Series: current issues in mutagenesis and carcinogenesis, No. 65. The genotoxicity and carcinogenicity of paracetamol: a regulatory (re)view. Bergman K, et al. **Mutat Res** 1996 Feb 1;349(2):263–88 (103 ref.)

DRUGS, NONPROPRIETARY see **DRUGS, GENERIC**

DRUGS OF ABUSE see **STREET DRUGS**

DRY EYE SYNDROMES

[Dry eye syndrome: etiopathology and clinical forms] Pérez Domingo E, et al. **Aten Primaria** 1996 Jan;17(1):4p following 16 (21 ref.) **(Spa)**

CLASSIFICATION

Report of the National Eye Institute/Industry workshop on Clinical Trials in Dry Eyes. Lemp MA. **CLAO J** 1995 Oct; 21(4):221–32 (106 ref.)

ETIOLOGY

Report of the National Eye Institute/Industry workshop on Clinical Trials in Dry Eyes. Lemp MA. **CLAO J** 1995 Oct; 21(4):221–32 (106 ref.)

THERAPY

[Current medical treatment of dry eye] Roncin S, et al. **J Fr Ophtalmol** 1995;18(11):708–13, 715–30 (105 ref.) **(Fre)**

DRY SOCKET

see related
TOOTH EXTRACTION

DSIP see **DELTA SLEEP-INDUCING PEPTIDE**

DT DIAPHORASE see **NAD(P)H DEHYDROGENASE (QUINONE)**

DTP VACCINE see **DIPHTHERIA-TETANUS-PERTUSSIS VACCINE**

DTPA

ANALOGS & DERIVATIVES

Gadolinium-enhanced breast MRI. Kelcz F, et al. **Crit Rev Diagn Imaging** 1995;36(4):287–338 (41 ref.)
Liver. III: Gadolinium-based hepatobiliary contrast agents (Gd-EOB-DTPA and Gd-BOPTA/Dimeg). Giovagnoni A, et al. **Magn Reson Imaging Clin N Am** 1996 Feb; 4(1):61–72 (34 ref.)
Somatostatin-receptor imaging in lymphoma. Goldsmith SJ, et al. **Semin Nucl Med** 1995 Jul;25(3):262–71 (13 ref.)
Somatostatin receptor imaging of neuroendocrine tumors with indium-111 pentetreotide (Octreoscan). Olsen JO, et al. **Semin Nucl Med** 1995 Jul;25(3):251–61 (25 ref.)
[Gadolinium-DTPA (Magnevist) as contrast medium for galactography] Kaltenborn H, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1995 Nov;163(5):457–9 (14 ref.) **(Ger)**
[The magnetic resonance assessment of craniofacial fibrous dysplasia. The completion of the study with gadolinium administration and magnetic resonance angiography] Di Girolamo M, et al. **Radiol Med (Torino)** 1996 Mar; 91(3):313–6 (10 ref.) **(Ita)**

DUAL DIAGNOSIS, PSYCHIATRIC see **DIAGNOSIS, DUAL (PSYCHIATRY)**

DUAL PERSONALITY see **MULTIPLE-PERSONALITY DISORDER**

DUAL-PHOTON ABSORPTIOMETRY see **ABSORPTIOMETRY, PHOTON**

DUBIN-JOHNSON SYNDROME see **JAUNDICE, CHRONIC IDIOPATHIC**

DUCHENNE MUSCULAR DYSTROPHY see **MUSCULAR DYSTROPHY**

DUCK HEPATITIS B VIRUS see **HEPATITIS B VIRUS, DUCK**

DUCTUS ARTERIOSUS

EMBRYOLOGY

Prenatal ultrasonographic assessment of the ductus arteriosus: a review. Sherer DM, et al. **Obstet Gynecol** 1996 Apr; 87(4):630–7 (50 ref.)

ULTRASONOGRAPHY

Prenatal ultrasonographic assessment of the ductus arteriosus: a review. Sherer DM, et al. **Obstet Gynecol** 1996 Apr;

DUCTUS ARTERIOSUS

87(4):630–7 (50 ref.)
Fetal ductus arteriosus—how far may it bend? Brezinka C. **Ultrasound Obstet Gynecol** 1995 Jul;6(1):6–7 (19 ref.)

DUCTUS ARTERIOSUS, PATENT

see related
PERSISTENT FETAL CIRCULATION SYNDROME

COMPLICATIONS

[Five cases of ASD–PDA complex: a review of 38 cases reported in Japan] Iguchi T, et al. **Kyobu Geka** 1995 Aug; 48(9):732–4 (6 ref.) (Eng. Abstr.) **(Jpn)**

PREVENTION & CONTROL

Prophylactic indomethacin: systematic review and meta-analysis. Fowlie PW.
Arch Dis Child Fetal Neonatal Ed 1996 Mar;74(2):F81–7 (35 ref.)

SURGERY

Surgical correction of giant patent ductus arteriosus. Chen YF, et al. **J Cardiovasc Surg (Torino)** 1996 Jun;37(3):309–12 (5 ref.)

THERAPY

New developments in intracardiac and intravascular devices for congenital heart disease. Tabbutt S, et al.
Curr Opin Cardiol 1996 Jan;11(1):61–7 (49 ref.)
New closure devices for left-to-right shunt. Hijazi ZM.
Indian Heart J 1996 Mar–Apr;48(2):119–23 (22 ref.)
[Transvenous closure of persistent ductus arteriosus with an Ivalon plug] Fassbender D, et al.
Dtsch Med Wochenschr 1996 May 17;121(20):653–7 (36 ref.) (Eng. Abstr.) **(Ger)**

DUCTUS DEFERENS see **VAS DEFERENS**

DUE PROCESS see **JURISPRUDENCE**

DUFFY BLOOD-GROUP SYSTEM

The Duffy antigen receptor for chemokines: structural analysis and expression in the brain. Horuk R, et al.
J Leukoc Biol 1996 Jan;59(1):29–38 (28 ref.)

GENETICS

Molecular genetic basis of red cell markers and its forensic application. Ikemoto S, et al. **Forensic Sci Int** 1996 Jun 28;80(1–2):147–61 (42 ref.)

PHYSIOLOGY

Duffy and receptors for P. vivax and chemotactic peptides. Pogo AO, et al. **Transfus Clin Biol** 1995;2(4):269–76 (29 ref.)

DUHRING'S DISEASE see **DERMATITIS HERPETIFORMIS**

DUNCAN'S SYNDROME see **LYMPHOPROLIFERATIVE DISORDERS**

DUODENAL DISEASES

Spontaneous duodenal perforation in neonates: a case report and review of literature. Nazzal M, et al. **Am Surg** 1996 Sep;62(9):706–8 (16 ref.)
[Biliary ileus. Case report and therapeutic considerations] Ferranti F, et al. **Minerva Chir** 1995 Jul–Aug; 50(7–8):707–11 (28 ref.) (Eng. Abstr.) **(Ita)**
[A case of melanosis duodeni] Nishimura Y, et al.
Nippon Shokakibyo Gakkai Zasshi 1996 Mar;93(3):185–90 (15 ref.) **(Jpn)**
[Parapapillary choledochoduodenal fistula] Uetsuji S, et al.
Ryoikibetsu Shokogun Shirizu 1996;(9):528–9 (14 ref.) **(Jpn)**

COMPLICATIONS

Gastroduodenal dyspepsia: a personal view integrating clinical, endoscopic, histological and management criteria. The spiro syndrome. DeLuca VA Jr. **Dig Dis** 1996 Jan–Feb;14(1):27–42 (37 ref.)
Duodenal duplication cyst with massive gastrointestinal bleeding. Rubin RB, et al. **J Clin Gastroenterol** 1995 Jul; 21(1):72–4 (20 ref.)
[Lemmel's syndrome caused by a giant diverticulum in the third portion of the duodenum, report of a case] Hirano A, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Nov; 92(11):1863–70 (11 ref.) **(Jpn)**
[Digestive hemorrhage due to duodenal angiodysplasia in the periampullary area] Pamplona J, et al.
Gastroenterol Hepatol 1996 May;19(5):250–2 (22 ref.) (Eng. Abstr.) **(Spa)**

CONGENITAL

Gastroduodenal disorders associated with emesis in infants. Reyna TM, et al. **Semin Pediatr Surg** 1995 Aug;4(3):190–7 (38 ref.)

DIAGNOSIS

Primary aortoenteric fistula: two new case reports and a review of 44 previously reported cases. Tareen AH, et al. **Eur J Vasc Endovasc Surg** 1996 Jul;12(1):5–10 (34 ref.)
[Endoscopy of the upper gastrointestinal tract in HIV disease] Caca K, et al. **Bildgebung** 1995 Dec;62(4):244–51 (56 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Fistula between duodenum and portal vein caused by peptic ulcer disease and complicated by hemorrhage and portal vein thrombosis. Soares MA, et al. **Am J Gastroenterol** 1996 Jul;91(7):1462–3 (7 ref.)
Traumatic pyeloduodenal fistula: a case report and review of the literature. Ginsberg DA, et al. **Urology** 1996 Apr; 47(4):588–91 (20 ref.)
[A unusual cause of acute pancreatitis: obstruction of the afferent loop after gastrectomy according to Bilroth II. Apropos of a case and review of the literature] Moschopoulos C, et al. **Ann Radiol (Paris)** 1995; 38(7–8):426–9 (16 ref.) (Eng. Abstr.) **(Fre)**
[Chronic recurrent subileus due to Strongyloides stercoralis infection under immunosuppressive therapy] Birck R, et al. **Dtsch Med Wochenschr** 1996 May 31;121(22):723–6 (17 ref.) (Eng. Abstr.) **(Ger)**

PARASITOLOGY

Duodenal and hepatic toxoplasmosis in a patient with HIV infection: review of the literature. Bonacini M, et al.
Am J Gastroenterol 1996 Sep;91(9):1838–40 (13 ref.)

SURGERY

Duodenocaval fistula complicating peptic ulcer disease: case report and review of the literature. Miller CA, et al.
Surgery 1996 Jun;119(6):718–9 (14 ref.)

DUODENAL NEOPLASMS

Periampullary tumours: report of two cases. Kassa E.
East Afr Med J 1996 May;73(5):333–5 (17 ref.)

COMPLICATIONS

[Adenoma of Brunner's gland: a rare cause of duodenal obstruction] Rey P, et al. **J Chir (Paris)** 1996 Jun; 133(4):162–6 (41 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Small bowel carcinoid: review of a single institution experience and review of the literature. Box JC, et al.
Am Surg 1996 Apr;62(4):280–6 (40 ref.)
[Prospects of early immunocytochemical diagnosis in periampullary tumors (a review of foreign literature)] Kubyshkin VA, et al. **Khirurgiia (Mosk)** 1995;(6):50–2 (42 ref.) **(Rus)**

SECONDARY

Late presentation of a solitary metastasis of renal cell carcinoma as an obstructive duodenal mass. Toh SK, et al. **Postgrad Med J** 1996 Mar;72(845):178–9 (10 ref.)

SURGERY

Recent advances in the localization and surgical management of duodenal gastrinomas. Lawton GP, et al.
Curr Opin Gen Surg 1994;:131–7 (50 ref.)
Vater's papilla and periampullary area villous adenoma: personal experience about nine cases and review of the literature. Motton G, et al. **Hepatogastroenterology** 1996 Mar–Apr;43(8):448–55 (77 ref.)
[Primary adenocarcinoma of the duodenum. Study of three cases and review of the literature] Lachachi F, et al.
Ann Chir 1996;50(4):333–9 (30 ref.) (Eng. Abstr.) **(Fre)**

DUODENAL OBSTRUCTION

CONGENITAL

[Surgery of atresia of the gastrointestinal tract] Joppich I, et al. **Chirurg** 1996 Jun;67(6):576–83 (10 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Late presentation of a solitary metastasis of renal cell carcinoma as an obstructive duodenal mass. Toh SK, et al. **Postgrad Med J** 1996 Mar;72(845):178–9 (10 ref.)
[Adenoma of Brunner's gland: a rare cause of duodenal obstruction] Rey P, et al. **J Chir (Paris)** 1996 Jun; 133(4):162–6 (41 ref.) (Eng. Abstr.) **(Fre)**

DUODENAL PAPILLA, MAJOR see **VATER'S AMPULLA**

DUODENAL PAPILLA, MINOR see **PANCREATIC DUCTS**

DUODENAL ULCER

COMPLICATIONS

The role of acid in upper gastrointestinal haemorrhage due to ulcer and stress-related mucosal damage. Peterson WL.
Aliment Pharmacol Ther 1995;9 Suppl 1:43–6 (28 ref.)
Fistula between duodenum and portal vein caused by peptic ulcer disease and complicated by hemorrhage and portal vein thrombosis. Soares MA, et al. **Am J Gastroenterol** 1996 Jul;91(7):1462–3 (7 ref.)
Helicobacter pylori and complicated ulcer disease. Laine LA.
Am J Med 1996 May 20;100(5A):52S–57S; discussion 57S–59S (47 ref.)
What should be done when initial endoscopic therapy for bleeding peptic ulcer fails? [editorial] Swain P.
Endoscopy 1995 May;27(4):321–8 (69 ref.)
[When should Helicobacter pylori be eradicated?] Buckley M, et al. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S95–S102 (80 ref.) **(Fre)**
[Gastroduodenal hemorrhages of peptic origin and the outlook for using somatostatin (Stilamin)] Smakov GM.
Vestn Khir Im I I Grek 1995;154(3):120–3 (37 ref.) **(Rus)**

DRUG THERAPY

Eradication of Helicobacter pylori infection. Hunt RH.
Am J Med 1996 May 20;100(5A):42S–50S; discussion 50S–51S (72 ref.)
Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review. Hopkins RJ, et al. **Gastroenterology** 1996 Apr; 110(4):1244–52 (48 ref.)
H2-receptor antagonists an Helicobacter pylori eradication. Lamers CB. **Scand J Gastroenterol Suppl** 1995;212:126–7 (8 ref.)
The history of acid inhibition. Baron JH.
Yale J Biol Med 1994 May–Aug;67(3–4):97–106 (32 ref.)
[Therapeutic management of duodenal ulcer except in emergency: eradication of Helicobacter pylori] Lamouliatte H. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S58–S63 (63 ref.) **(Fre)**
[Therapeutic management of duodenal ulcer except in emergency cases: antisecretory treatment] Ruszniewski P. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S53–S57 (48 ref.) **(Fre)**

ECONOMICS

The economics of eradicating Helicobacter pylori infection in duodenal ulcer disease. Vakil N, et al. **Am J Med** 1996 May 20;100(5A):60S–63S; discussion 63S–64S (21 ref.)

EPIDEMIOLOGY

The relationship between gastric cancer frequency and the ratio of gastric to duodenal ulcer. Correa P, et al.
Aliment Pharmacol Ther 1995;9 Suppl 2:13–9 (26 ref.)
[Consensus conference: "Ulcer and gastritis at the time of Helicobacter pylori". Why and how? (editorial)] Bigard MA, et al. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S1–S4 (17 ref.) **(Fre)**
[Helicobacter pylori, gastric acid secretion, ulcer disease and HIV infection] Blondon H, et al.
Gastroenterol Clin Biol 1996;20(3):248–53 (49 ref.) **(Fre)**
[Gastroduodenal ulcer disease and gastritis: general epidemiology, natural history and progression] Bommelaer G. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S5–S8 (45 ref.) **(Fre)**
[Role of Helicobacter pylori in the pathogenesis of ulcer disease and gastritis] Dorval ED.
Gastroenterol Clin Biol 1996 Jan;20(1 Pt 2):S22–S26 (62 ref.) **(Fre)**

ETIOLOGY

Dragstedt, gastric acid and duodenal ulcer. Hobsley M.
Yale J Biol Med 1994 May–Aug;67(3–4):173–80 (42 ref.)
[Helicobacter pylori, nonsteroidal anti-inflammatory agents and gastroduodenal changes] Teixeira AV.
Acta Med Port 1995 Sep;8(9):517–21 (70 ref.) (Eng. Abstr.) **(Por)**
[Hypoxic factor and its significance in the onset of gastroduodenal diseases] Pogromov AP, et al.
Klin Med (Mosk) 1996;74(1):3–7 (117 ref.) **(Rus)**

METABOLISM

Inflammation, acid and ulcers. Muller MJ, et al.
Yale J Biol Med 1994 May–Aug;67(3–4):135–44 (93 ref.)

MICROBIOLOGY

No Helicobacter pylori, no Helicobacter pylori-associated peptic ulcer disease. Tytgat GN.
Aliment Pharmacol Ther 1995;9 Suppl 1:39–42 (15 ref.)
The economics of eradicating Helicobacter pylori infection in duodenal ulcer disease. Vakil N, et al. **Am J Med** 1996 May 20;100(5A):60S–63S; discussion 63S–64S (21 ref.)
Helicobacter pylori, duodenal ulcer, gastric cancer: tunnel vision or blinders? Graham DY, et al. **Ann Med** 1995 Oct; 27(5):589–94 (27 ref.)
Helicobacter pylori in duodenal and gastric ulcer disease. Rauws EJ, et al. **Baillieres Clin Gastroenterol** 1995 Sep; 9(3):529–47 (119 ref.)
Duodenal ulcer: the helicobacterization of a psychosomatic disease? Melmed RN, et al. **Isr J Med Sci** 1996 Mar–Apr; 32(3–4):211–6 (66 ref.)
Helicobacter pylori infection and peptic ulcer disease in children. Bourke B, et al. **Pediatr Infect Dis J** 1996 Jan;

15(1):1–13 (163 ref.)
[Role of Helicobacter infection in the causes and mechanisms of gastroduodenal ulcer and chronic gastritis] Chamouard P. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S103–S110 (120 ref.) **(Fre)**
[Helicobacter pylori and its role in gastric and duodenal ulcers] Mach T. **Przegl Lek** 1995;52(7):365–7 (24 ref.) **(Pol)**

PATHOLOGY

[Chronic gastritis and gastroduodenal ulcers: anatomopathological aspects, course and progression] Fléjou JF. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S9–S13 (41 ref.) **(Fre)**

PHYSIOPATHOLOGY

The somatostatin–gastrin link of Helicobacter pylori infection. Calam J. **Ann Med** 1995 Oct;27(5):569–73 (46 ref.)
[Role of acid secretion in the pathogenesis of duodenal ulcer] Mignon M, et al. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S14–S21 (105 ref.) **(Fre)**

PREVENTION & CONTROL

Diclofenac/misoprostol. A review of its pharmacology and therapeutic efficacy in painful inflammatory conditions. Davis R, et al. **Drugs Aging** 1995 Nov;7(5):372–93 (76 ref.)
[When to look for Helicobacter pylori?] Delchier JC. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S34–S37 (32 ref.) **(Fre)**

PSYCHOLOGY

Duodenal ulcer: the helicobacterization of a psychosomatic disease? Melmed RN, et al. **Isr J Med Sci** 1996 Mar–Apr; 32(3–4):211–6 (66 ref.)
Organic and psychosocial risk factors for duodenal ulcer. Lewin J, et al. **J Psychosom Res** 1995 Jul;39(5):531–48 (85 ref.)

SURGERY

Endoscopic vagotomy for duodenal ulcer disease: procedures and appraisal. Cuschieri A. **Adv Surg** 1996;29:291–302 (38 ref.)
[Management of duodenal ulcer except in emergency: surgical treatment] Michot F, et al. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S64–S72 (87 ref.) **(Fre)**
[Surgical hemostasis in recurrent peptic ulcer hemorrhage after endoscopic hemostasis—indications and results] Thon KP, et al. **Bildgebung** 1995 Oct;62 Suppl 2:22–8 (29 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Therapeutic applications of vagotomy. Olbe L. **Yale J Biol Med** 1994 May–Aug;67(3–4):153–7 (13 ref.)
[What is the right therapeutic management of duodenal ulcer except in emergency?] Bouhnik Y. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S131–S134 (40 ref.) **(Fre)**
[Possibilities and results of endoscopic hemostasis in peptic ulcer hemorrhage] Bode JC. **Bildgebung** 1995 Oct;62 Suppl 2:16–20 (29 ref.) **(Ger)**

DUODENOGASTRIC REFLUX

Duodenogastric reflux: an update. Girelli CM, et al. **Am J Gastroenterol** 1996 Apr;91(4):648–53 (85 ref.)

DUODENOPANCREATECTOMY see **PANCREATICODUODENECTOMY**

DUODENUM

ABNORMALITIES

Duodenal duplication cyst with massive gastrointestinal bleeding. Rubin RB, et al. **J Clin Gastroenterol** 1995 Jul; 21(1):72–4 (20 ref.)

BLOOD SUPPLY

Aneurysms of the pancreaticoduodenal artery associated with occlusion of the celiac artery. Uher P, et al. **Abdom Imaging** 1995 Sep–Oct;20(5):470–3 (22 ref.)
Aneurysms of the pancreaticoduodenal artery. Paty PS, et al. **J Vasc Surg** 1996 Apr;23(4):710–3 (12 ref.)
The arterial blood supply of the pancreas: a review. II. The posterior superior pancreaticoduodenal artery. An anatomical and radiological study. Bertelli E, et al. **Surg Radiol Anat** 1996;18(1):1–9 (51 ref.)

DRUG EFFECTS

[Helicobacter pylori, nonsteroidal anti-inflammatory agents and gastroduodenal changes] Teixeira AV. **Acta Med Port** 1995 Sep;8(9):517–21 (70 ref.) (Eng. Abstr.) **(Por)**

INJURIES

Evolution in the management of duodenal injuries. Carrillo EH, et al. **J Trauma** 1996 Jun;40(6):1037–45; discussion 1045–6 (55 ref.)
Complex duodenal injuries. Ivatury RR, et al. **Surg Clin North Am** 1996 Aug;76(4):797–812 (50 ref.)
[A report of 6 cases of traumatic ruptures of the duodenum] Bălan B, et al. **Chirurgia (Bucur)** 1995;44(1):8–14 (0 ref.) **(Rum)**

PATHOLOGY

[A case report of epithelioid smooth muscle tumor (leiomyoblastoma) of the stomach prolapsing into the duodenal bulbus] Takashima Y, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Nov; 92(11):1858–62 (16 ref.) **(Jpn)**

PHYSIOLOGY

[Messenger RNA of duodenal cholecystokinin: thanks to endoscopy... (editorial)] Chayvialle JA. **Gastroenterol Clin Biol** 1995 Aug–Sep;19(8–9):657–8 (13 ref.) **(Fre)**

SURGERY

Complex duodenal injuries. Ivatury RR, et al. **Surg Clin North Am** 1996 Aug;76(4):797–812 (50 ref.)

DUPUYTREN'S CONTRACTURE

EPIDEMIOLOGY

Dupuytren's disease in children. Urban M, et al. **J Hand Surg [Br]** 1996 Feb;21(1):112–6 (36 ref.)

ETIOLOGY

Can Dupuytren's contracture be work-related?: review of the evidence. Liss GM, et al. **Am J Ind Med** 1996 May; 29(5):521–32 (56 ref.)

DURA MATER

BLOOD SUPPLY

A cervical dural arteriovenous fistula in a patient presenting with radiculopathy. Case report. Kohno M, et al. **J Neurosurg** 1996 Jan;84(1):119–23 (26 ref.)
MR imaging and MR angiography in the diagnosis of dural arteriovenous fistulas. Panasci DJ, et al. **Magn Reson Imaging Clin N Am** 1995 Aug;3(3):493–508 (32 ref.)
Childhood dural arteriovenous fistulae of the posterior dural sinuses: three case reports and literature review. Morita A, et al. **Neurosurgery** 1995 Dec;37(6):1193–9; discussion 1199–200 (34 ref.)
Postsurgical development of dural arteriovenous malformations after transpetrosal and transtentorial operations: case report. Sasaki T, et al. **Neurosurgery** 1995 Oct;37(4):820–4; discussion 824–5 (14 ref.)
Dural arteriovenous fistulas of superior sagittal sinus: case report and review of literature. Kurl S, et al. **Surg Neurol** 1996 Mar;45(3):250–5 (23 ref.)
[A rare cause of neurologic bladder: arteriovenous dural fistula with venous epidural drainage] Punga-Maole ML, et al. **Prog Urol** 1995 Dec;5(6):1001–8 (32 ref.) (Eng. Abstr.) **(Fre)**
[Multiple dural arteriovenous shunts presenting as subarachnoid hemorrhage: a case report] Nimura K, et al. **No Shinkei Geka** 1995 Sep;23(9):819–24 (22 ref.) (Eng. Abstr.) **(Jpn)**

INJURIES

[Puncture of the dura mater, diagnosis and treatment in obstetrics] Villalpando Bravo J, et al. **Ginecol Obstet Mex** 1996 Feb;64:85–9 (35 ref.) (Eng. Abstr.) **(Spa)**

PATHOLOGY

Stage IE non-Hodgkin's lymphoma involving the dura: A clinicopathologic study of five cases. Miranda RN, et al. **Arch Pathol Lab Med** 1996 Mar;120(3):254–60 (20 ref.)
Diffuse bone marrow metastases from glioblastoma multiforme: the role of dural invasion. Kleinschmidt-Demasters BK. **Hum Pathol** 1996 Feb; 27(2):197–201 (22 ref.)

TRANSPLANTATION

[Dura-plasty in intracranial operations] Ernestus RI, et al. **Zentralbl Neurochir** 1995;56(3):106–10 (20 ref.) (Eng. Abstr.) **(Ger)**

DURABLE POWER OF ATTORNEY see **LIVING WILLS**

DURAPATITE

Crowned dens syndrome: a manifestation of hydroxy-apatite rheumatism. Malca SA, et al. **Acta Neurochir (Wien)** 1995; 135(3–4):126–30 (21 ref.)
Mastoidectomy reconstruction: management of the high facial ridge using hydroxylapatite implants. Black B, et al. **Am J Otol** 1994 Nov;15(6):785–92 (78 ref.)
Calcium pyrophosphate crystal deposition disease and other crystal deposition diseases. Fam AG. **Curr Opin Rheumatol** 1995 Jul;7(4):364–8 (32 ref.)
Evaluation of the clinical predictability of hydroxyapatite-coated endosseous dental implants: a review of the literature. Biesbrock AR, et al. **Int J Oral Maxillofac Implants** 1995 Nov–Dec;10(6):712–20 (63 ref.)

THERAPEUTIC USE

[The use of hydroxyapatite for the surgical preparation of the oral cavity for prosthesis] Zuev VP, et al. **Stomatologiia (Mosk)** 1996;75(1):71–4 (69 ref.) **(Rus)**

DURSBAN see **CHLORPYRIFOS**

DUST

see related
PNEUMOCONIOSIS

Introduction. House dust mite allergy. Guérin B. **Clin Rev Allergy Immunol** 1995 Summer;13(2):107–13 (57 ref.)
The biology of allergenic domestic mites. An update. Hart BJ. **Clin Rev Allergy Immunol** 1995 Summer;13(2):115–33 (134 ref.)
Dust mite allergens. Stewart GA. **Clin Rev Allergy Immunol** 1995 Summer;13(2):135–50 (65 ref.)
Occupational exposure to dusts containing asbestos and chronic airways disease. Zejda JE. **Int J Occup Med Environ Health** 1996;9(2):117–25 (50 ref.)

ADVERSE EFFECTS

Grain dust, endotoxin, and airflow obstruction. Schwartz DA. **Chest** 1996 Mar;109(3 Suppl):57S–63S (51 ref.)
Dermatophagoides siboney and Blomia tropicalis—dust mites of subtropical and tropical areas [editorial] van Hage-Hamsten M. **Clin Exp Allergy** 1995 Oct;25(10):905–7 (25 ref.)
Pulmonary reactions to organic dust exposures: development of an animal model. Castranova V, et al. **Environ Health Perspect** 1996 Mar;104 Suppl 1:41–53 (115 ref.)
Wood dust. **IARC Monogr Eval Carcinog Risks Hum** 1995; 62:35–215 (383 ref.)
Particulate pollution and health: a review of the Utah valley experience. Pope CA 3rd. **J Expo Anal Environ Epidemiol** 1996 Jan–Mar;6(1):23–34 (19 ref.)
A critical review of PM10-mortality time-series studies. Thurston GD. **J Expo Anal Environ Epidemiol** 1996 Jan–Mar;6(1):3–21 (33 ref.)
Exposure of children to pollutants in house dust and indoor air. Roberts JW, et al. **Rev Environ Contam Toxicol** 1995; 143:59–78 (74 ref.)
[Allergy to house dust mite: a public health problem] Maroli M, et al. **Ann Ist Super Sanita** 1995;31(3):343–50 (44 ref.) (Eng. Abstr.) **(Ita)**
[Allergy to house dust mites] Horak B. **Wiad Parazytol** 1995; 41(3):355–68 (47 ref.) (Eng. Abstr.) **(Pol)**

ANALYSIS

Immunochemical and molecular methods for defining and measuring indoor allergens: in dust and air. Chapman MD, et al. **Pediatr Allergy Immunol** 1995;6 Suppl 7:8–12 (32 ref.)
Allergen levels causing sensitisation, bronchial hyperreactivity and asthma. Dreborg S. **Pediatr Allergy Immunol** 1995;6 Suppl 7:22–6 (44 ref.)

DWARFISM

CLASSIFICATION

[Bird headed dwarfism in Seckel syndrome. Nosologic difficulties] Parent P, et al. **Arch Pediatr** 1996 Jan;3(1):55–62 (47 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

Anaesthetic management of the Kenny-Caffey syndrome using the laryngeal mask. Janke EL, et al. **Paediatr Anaesth** 1996;6(3):235–8 (16 ref.)

CONGENITAL

Progressive kyphosis and neurologic compromise complicating spondylothoracic dysplasia in infancy (Jarcho-Levin syndrome). Mooney JF 3rd, et al. **Spine** 1995 Sep 1;20(17):1938–42 (8 ref.)

DIAGNOSIS

How short is too short? Sherman L, et al. **Compr Ther** 1995 Oct;21(10):610–5 (9 ref.)
[Dwarfism with constrictive pericarditis. A case report] Alonso Falcón F, et al. **An Esp Pediatr** 1996 Mar; 44(3):279–81 (9 ref.) **(Spa)**

GENETICS

Microdontia with severe microcephaly and short stature in two brothers: osteodysplastic primordial dwarfism with dental findings. Lin HJ, et al. **Am J Med Genet** 1995 Aug

28;58(2):136–42 (4 ref.)
Juberg-Marsidi syndrome: report of an additional case. Tsukahara M, et al. **Am J Med Genet** 1995 Sep 25; 58(4):353–5 (7 ref.)
Autosomal recessive omodysplasia. Stoll C, et al. **Ann Genet** 1995;38(2):97–101 (8 ref.)
Floating-Harbor syndrome: description of a further patient, review of the literature, and suggestion of autosomal dominant inheritance. Lacombe D, et al. **Eur J Pediatr** 1995 Aug;154(8):658–61 (9 ref.)

THERAPY

[Growth hormone therapy in childhood. Growth hormone therapy in small children without growth hormone deficiency] Butenandt O. **Fortschr Med** 1996 Jun 10; 114(16):201–4 (42 ref.) (Eng. Abstr.) **(Ger)**

DWARFISM, CACHECTIC see **COCKAYNE SYNDROME**

DYE EXCLUSION ASSAYS, ANTITUMOR see **DRUG SCREENING ASSAYS, ANTITUMOR**

DYES

Colonic tattooing with India ink: benefits, risks, and alternatives. Nizam R, et al. **Am J Gastroenterol** 1996 Sep; 91(9):1804–8 (26 ref.)
Iontophoretic dye labeling of embryonic cells. Fraser SE. **Methods Cell Biol** 1996;51:147–60 (13 ref.)

ADVERSE EFFECTS

Methylene blue-induced phototoxicity: an unrecognized complication. Porat R, et al. **Pediatrics** 1996 May; 97(5):717–21 (19 ref.)

CHEMISTRY

Alcian blue. Now you see it, now you don't. Scott JE. **Eur J Oral Sci** 1996 Feb;104(1):2–9 (17 ref.)

DIAGNOSTIC USE

Indocyanine green angiography. Owens SL. **Br J Ophthalmol** 1996 Mar;80(3):263–6 (50 ref.)

DYNAMIC CARDIOMYOPLASTY see **CARDIOMYOPLASTY**

DYNEIN see **DYNEIN ATPASE**

DYNEIN ADENOSINETRIPHOSPHATASE see **DYNEIN ATPASE**

DYNEIN ATPASE

METABOLISM

Regulation of dynein-driven microtubule sliding by an axonemal kinase and phosphatase in Chlamydomonas flagella. Habermacher G, et al. **Cell Motil Cytoskeleton** 1995;32(2):106–9 (23 ref.)
Targeting of motor proteins. Vallee RB, et al. **Science** 1996 Mar 15;271(5255):1539–44 (108 ref.)

PHYSIOLOGY

The kinetic cycles of myosin, kinesin, and dynein. Hackney DD. **Annu Rev Physiol** 1996;58:731–50 (126 ref.)
Multi-dynein hypothesis. Asai DJ. **Cell Motil Cytoskeleton** 1995;32(2):129–32 (36 ref.)
Dynein family of motor proteins: present status and future questions. Gibbons IR. **Cell Motil Cytoskeleton** 1995; 32(2):136–44 (48 ref.)
Regulation of ciliary beat frequency by a dynein light chain. Hamasaki T, et al. **Cell Motil Cytoskeleton** 1995;32(2):121–4 (27 ref.)
Exploring the function of inner and outer dynein arms with Chlamydomonas mutants. Kamiya R. **Cell Motil Cytoskeleton** 1995;32(2):98–102 (34 ref.)

DYNORPHINS

see related
RECEPTORS, OPIOID, KAPPA

IMMUNOLOGY

Influence of dynorphin A antibodies on the formation of edema and cell changes in spinal cord trauma. Sharma HS, et al. **Prog Brain Res** 1995;104:401–16 (95 ref.)

PHARMACOLOGY

Dynorphin A: a rectifying peptide. Lee NM. **NIDA Res Monogr** 1995;147:161–9 (22 ref.)

DYSARTHRIA

PHYSIOPATHOLOGY

Transient cerebellar mutism after posterior fossa surgery in children. Van Calenbergh F, et al. **Neurosurgery** 1995 Nov; 37(5):894–8 (32 ref.)

DYSAUTONOMIA see **AUTONOMIC NERVOUS SYSTEM DISEASES**

DYSAUTONOMIA, FAMILIAL

SURGERY

Multiple and various anaesthetics, ketamine included, in a young patient with familial dysautonomia, Case report. Dell'oste C, et al. **Minerva Pediatr** 1996 Mar;48(3):113–6 (16 ref.)

DYSBETALIPOPROTEINEMIA see **HYPERLIPOPROTEINEMIA TYPE III**

DYSCHONDROPLASIAS see **OSTEOCHONDRODYSPLASIAS**

DYSEMBRYOMA see **TERATOMA**

DYSENTERY

The outpatient management of bloody diarrhea in young children. **Indian Pediatr** 1995 May;32(5):600–4 (7 ref.)

VETERINARY

Swine dysentery: more unknown than known. ter Huurne AA, et al. **Vet Microbiol** 1995 Oct;46(4):347–60 (96 ref.)

DYSENTERY, AMEBIC

DIAGNOSIS

Entamoeba histolytica and Giardia lamblia infections: current diagnostic strategies. Cook GC. **Parasite** 1995 Jun; 2(2):107–12 (31 ref.)

DYSENTERY, BACILLARY

MICROBIOLOGY

The cell biology of infection by intracellular bacterial pathogens. Theriot JA. **Ann Rev Cell Dev Biol** 1995; 11:213–39 (106 ref.)

PREVENTION & CONTROL

Live attenuated Shigella flexneri mutants as vaccine candidates against shigellosis and vectors for antigen delivery. Phalipon A, et al. **Biologicals** 1995 Jun; 23(2):125–34 (54 ref.)

DYSERYTHROPOIETIC ANEMIA, CONGENITAL see **ANEMIA, DYSERYTHROPOIETIC, CONGENITAL**

DYSGAMMAGLOBULINEMIA

COMPLICATIONS

[A case of selective IgM deficiency associated with systemic lupus erythematosus] Tanaka A, et al. **Nippon Jinzo Gakkai Shi** 1996 Apr;38(4):185–90 (21 ref.) (Eng. Abstr.) **(Jpn)**

DYSKINESIA see **MOVEMENT DISORDERS**

DYSKINESIA, DRUG-INDUCED

see related
AKATHISIA, DRUG-INDUCED

DIAGNOSIS

Symptomatic or secondary basal ganglia diseases and tardive dyskinesias. Berardelli A. **Curr Opin Neurol** 1995 Aug; 8(4):320–2 (16 ref.)
Tardive tourettism after exposure to neuroleptic therapy. Bharucha KJ, et al. **Mov Disord** 1995 Nov;10(6):791–3 (17 ref.)
[Schizophrenic deficit syndrome and neurologic tolerance] Verdoux H, et al. **Encephale** 1996 Jun;22 Spec No 2:45–7 (27 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

The treatment of tardive dyskinesia. Raja M. **Schweiz Arch Neurol Psychiatr** 1996;147(1):13–8 (99 ref.)

EPIDEMIOLOGY

Tardive dyskinesia in non-western countries: a review. Pandurangi AK, et al. **Eur Arch Psychiatry Clin Neurosci** 1995;246(1):47–52 (43 ref.)
The epidemiology of drug-induced akathisia: Part II. Chronic, tardive, and withdrawal akathisias. Sachdev P. **Schizophr Bull** 1995;21(3):451–61 (70 ref.)

ETIOLOGY

Tardive dyskinesia: a review. Latimer PR. **Can J Psychiatry** 1995 Sep;40(7 Suppl 2):S49–54 (44 ref.)
Tardive syndromes and other drug-induced movement disorders. Jankovic J. **Clin Neuropharmacol** 1995 Jun; 18(3):197–214 (124 ref.)
[Parkinson syndrome: iatrogenic causes, iatrogenic treatment results] Burgunder JM. **Schweiz Med Wochenschr** 1996 Mar 30;126(13):522–7 (22 ref.) (Eng. Abstr.) **(Ger)**

METABOLISM

D-1 receptors in neurology and psychiatry an overview. Bédard PJ. **Prog Neuropsychopharmacol Biol Psychiatry** 1995 Sep;19(5):713–26 (73 ref.)

PHYSIOPATHOLOGY

DOPA-induced "peak dose" dyskinesia: clues implicating D2 receptor-mediated mechanisms using dopaminergic agonists in MPTP monkeys. Blanchet PJ, et al. **J Neural Transm Suppl** 1995;45:103–12 (52 ref.)

DYSKINESIA, TARDIVE see **DYSKINESIA, DRUG-INDUCED**

DYSLEXIA

ETIOLOGY

Developmental dyslexia: a motor-articulatory feedback hypothesis. Heilman KM, et al. **Ann Neurol** 1996 Mar; 39(3):407–12 (35 ref.)

PHYSIOPATHOLOGY

Dyslexia. Reading between the laminae. Walsh V. **Curr Biol** 1995 Nov 1;5(11):1216–7 (10 ref.)
The magnocellular deficit hypothesis in dyslexia: a review of reported evidence. Greatrex JC, et al. **Ophthalmic Physiol Opt** 1995 Sep;15(5):501–6 (40 ref.)

PSYCHOLOGY

["Kukia poimi ja kukia kana, te sepele nistä ja omaiesi ana"--developmental dyslexia] Haapanen ML. **Duodecim** 1995;111(6):573–8 (27 ref.) **(Fin)**

DYSLEXIA, DEVELOPMENTAL see **DYSLEXIA**

DYSLIPIDEMIA see **HYPERLIPIDEMIA**

DYSMENORRHEA

DRUG THERAPY

Potential use of oxytocin and vasopressin V1a antagonists in the treatment of preterm labour and primary dysmenorrhoea. Akerlund M, et al. **Adv Exp Med Biol** 1995; 395:595–600 (32 ref.)

ETIOLOGY

[Dysmenorrhea] Ludwig H. **Ther Umsch** 1996 Jun; 53(6):431–41 (24 ref.) (Eng. Abstr.) **(Ger)**

DYSMYELOPOIETIC SYNDROMES see **MYELODYSPLASTIC SYNDROMES**

DYSOSTOSES

CLASSIFICATION

Oral-facial-skeletal syndromes [editorial; comment] Neri G, et al. **Am J Med Genet** 1995 Nov 20;59(3):365–8 (29 ref.) Comment on: Am J Med Genet 1995 Nov 20;59(3):359–64.

RADIOGRAPHY

Lumbar spine anomalies in a pycnodysostosis case. Beguiristain JL, et al. **Eur Spine J** 1995;4(5):320–1 (22 ref.)

DYSOSTOSIS, CLEIDOCRANIAL see **CLEIDOCRANIAL DYSPLASIA**

DYSOSTOSIS, CRANIOFACIAL see **CRANIOFACIAL DYSOSTOSIS**

DYSPEPSIA

Nonulcer dyspepsia. Scolapio JS, et al. **Gastroenterologist** 1996 Mar;4(1):13–23 (83 ref.)
Nonulcer dyspepsia: a look into the future. Camilleri M. **Mayo Clin Proc** 1996 Jun;71(6):614–22 (75 ref.)
Dyspepsia update. Colin-Jones DG. **Scand J Gastroenterol Suppl** 1995;210:32–5 (21 ref.)
[Current concepts concerning functional dyspepsia syndrome] Sheptulin AA. **Klin Med (Mosk)** 1995; 73(4):27–31 (31 ref.) **(Rus)**

DIAGNOSIS

Gastroduodenal dyspepsia: a personal view integrating clinical, endoscopic, histological and management criteria. The spiro syndrome. DeLuca VA Jr. **Dig Dis** 1996 Jan-Feb;14(1):27–42 (37 ref.)
Diagnosing dyspepsia: any controversies left? [editorial; comment] Bytzer P. **Gastroenterology** 1996 Jan; 110(1):302–6 (54 ref.) Comment on: Gastroenterology 1996 Jan;110(1):72–83.

DRUG THERAPY

Diagnosis and treatment of dyspepsia in the elderly. Pound SE, et al. **Drugs Aging** 1995 Nov;7(5):347–54 (32 ref.)

EPIDEMIOLOGY

[Helicobacter pylori infection: relationships between gastritis and clinical symptomatology] Bruley Des Varannes S, et al. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S84–S94 (92 ref.) **(Fre)**

ETIOLOGY

Nature of non-ulcer dyspepsia and related conditions. Porro GB, et al. **Baillieres Clin Gastroenterol** 1995 Sep;9(3):549–62 (68 ref.)

Diagnosis and treatment of dyspepsia in the elderly. Pound SE, et al. **Drugs Aging** 1995 Nov;7(5):347–54 (32 ref.)

Gastroparesis and dyspepsia in patients with diabetes mellitus. Mearin F, et al. **Eur J Gastroenterol Hepatol** 1995 Aug; 7(8):717–23 (42 ref.)

Helicobacter pylori and dyspepsia. O'Morain C, et al. **Scand J Gastroenterol Suppl** 1996;214:28–30; discussion 40–3 (16 ref.)

[Should Helicobacter pylori be eradicated in a patient with chronic gastritis?] Bouché O. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S143–S153 (127 ref.) **(Fre)**

[When should Helicobacter pylori be eradicated?] Buckley M, et al. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S95–S102 (80 ref.) **(Fre)**

MICROBIOLOGY

HP serology as a screening method prior to upper gastro-intestinal endoscopy in young dyspeptic patients: a different point of view. Denis P, et al. **Acta Gastroenterol Belg** 1995 Sep–Dec;58(5–6):378–81 (15 ref.)

Prevalence of Helicobacter pylori in non-ulcer dyspepsia. Buckley M, et al. **Aliment Pharmacol Ther** 1995;9 Suppl 2:53–8 (55 ref.)

Role of Helicobacter pylori in gastrointestinal disease: implications for primary care of a revolution in management of dyspepsia. Delaney BC. **Br J Gen Pract** 1995 Sep;45(398):489–94 (71 ref.)

PHYSIOPATHOLOGY

The effect of Helicobacter pylori infection on gastric emptying of digestible and indigestible solids in patients with nonulcer dyspepsia. Chang CS, et al. **Am J Gastroenterol** 1996 Mar;91(3):474–9 (49 ref.)

Functional dyspepsia. Insights on mechanisms and management strategies. Malagelada JR. **Gastroenterol Clin North Am** 1996 Mar;25(1):103–12 (24 ref.)

Nonulcer dyspepsia: pathophysiology update. Quigley EM. **Hosp Pract (Off Ed)** 1996 Feb 15;31(2):141–2, 145–6, 156 passim (16 ref.)

THERAPY

Modern management of dyspepsia. Talley NJ. **Aust Fam Physician** 1996 Jan;25(1):47–52 (6 ref.)

Gastroduodenal dyspepsia: a personal view integrating clinical, endoscopic, histological and management criteria. The spiro syndrome. DeLuca VA Jr. **Dig Dis** 1996 Jan–Feb;14(1):27–42 (37 ref.)

DYSPHAGIA see **DEGLUTITION DISORDERS**

DYSPHASIA see **APHASIA**

DYSPHONIA see **VOICE DISORDERS**

DYSPLASIA, ARTERIOHEPATIC see **ALAGILLE SYNDROME**

DYSPLASIA EPIPHYSIALIS PUNCTATA see **CHONDRODYSPLASIA PUNCTATA**

DYSPLASTIC NEVUS SYNDROME

GENETICS

Familial cutaneous melanoma. Lucchina LC, et al. **Melanoma Res** 1995 Dec;5(6):413–8 (29 ref.)

Uveal melanoma and familial atypical mole and melanoma (FAM-M) syndrome. Singh AD, et al. **Ophthalmic Genet** 1995 Jun;16(2):53–61 (32 ref.)

[Familial malignant melanoma] Takenouchi T, et al. **Nippon Rinsho** 1995 Nov;53(11):2754–8 (22 ref.) (Eng. Abstr.) **(Jpn)**

DYSPNEA

CHEMICALLY INDUCED

A case of acute dapsone poisoning: toxicological data and review of the literature. Tracqui A, et al. **J Anal Toxicol** 1995 Jul–Aug;19(4):229–35 (72 ref.)

DIAGNOSIS

Breathlessness. Strategies aimed at identifying and treating the cause of dyspnea. Seamens CM, et al. **Postgrad Med** 1995 Oct;98(4):215–6, 219–22, 225–7 (14 ref.)

ETIOLOGY

A 37-year-old woman with end-stage cirrhosis, progressive dyspnea, platypnea, and hypoxemia. Lange PA, et al. **Cleve Clin J Med** 1996 Jan–Feb;63(1):8–11 (6 ref.)

How does chronic heart failure cause dyspnoea? Nardini S. **Monaldi Arch Chest Dis** 1995 Aug;50(4):323–4 (6 ref.)

Breathlessness. Strategies aimed at identifying and treating the cause of dyspnea. Seamens CM, et al. **Postgrad Med** 1995 Oct;98(4):215–6, 219–22, 225–7 (14 ref.)

[Clinical approach to physiologic dispnea in pregnancy] García Río F, et al. **Aten Primaria** 1996 Jan;17(1):70–4 (23 ref.) **(Spa)**

[The pathogenetic mechanisms of dyspnea] García Río F, et al. **Rev Clin Esp** 1995 Sep;195(9):641–4 (46 ref.) **(Spa)**

NURSING

Dyspnoea: a study of measurement instruments for the assessment of dyspnoea and their application for patients with advanced cancer. van der Molen B. **J Adv Nurs** 1995 Nov;22(5):948–56 (49 ref.)

PHYSIOPATHOLOGY

The role of airway inflammation in the pathophysiology of nocturnal asthma. Oosterhoff Y, et al. **Clin Exp Allergy** 1995 Oct;25(10):915–21 (39 ref.)

Pathophysiology of dyspnea. Manning HL, et al. **N Engl J Med** 1995 Dec 7;333(23):1547–53 (58 ref.)

PREVENTION & CONTROL

Perception, personality, and respiratory control in life-threatening asthma. Gibson GJ. **Thorax** 1995 Sep;50 Suppl 1:S2–4 (15 ref.)

THERAPY

The therapeutics of dyspnoea. Davis CL. **Cancer Surv** 1994; 21:85–98 (78 ref.)

Laser-assisted removal of a foreign body in the bronchial system of an infant. Boelcskei PL, et al. **Lasers Surg Med** 1995;17(4):375–7 (20 ref.)

Orthodeoxia and platypnoea after acute organophosphorus poisoning reversed by CPAP: a newly described cause and review of the literature. Bouros D, et al. **Respir Med** 1995 Oct;89(9):625–8 (33 ref.)

VETERINARY

Dyspnea: how to solve the problem. Venker-van Haagen AJ. **Vet Q** 1995 Apr;17 Suppl 1:S7–8 (0 ref.)

DYSPNEA, PAROXYSMAL

ETIOLOGY

[Paroxysmal nocturnal dyspnea as a severe expression of the pacemaker syndrome] Minutiello L. **Minerva Cardioangiol** 1996 Mar;44(3):133–40 (9 ref.) (Eng. Abstr.) **(Ita)**

DYSSOCIAL BEHAVIOR see **ANTISOCIAL PERSONALITY DISORDER**

DYSTHYMIC DISORDER see **DEPRESSIVE DISORDER**

DYSTOCIA

COMPLICATIONS

Medico-legal aspects of brachial plexus injury: the obstetrician's point of view. Jakobovits A. **Med Law** 1996; 15(1):175–82 (30 ref.)

THERAPY

The Zavanelli maneuver for fetal shoulder dystocia. Three cases with poor outcomes. Spellacy WN. **J Reprod Med** 1995 Jul;40(7):543–4 (7 ref.)

DYSTONIA

DIAGNOSIS

[Dystonia] Chutorian A. **Rev Neurol** 1995;23 Suppl 3:S339–48 (100 ref.) **(Spa)**

DRUG THERAPY

Dopa-responsive dystonia. Nygaard TG. **Curr Opin Neurol** 1995 Aug;8(4):310–3 (24 ref.)

Dopa-responsive dystonia: a widening spectrum. Gordon N. **Dev Med Child Neurol** 1996 Jun;38(6):554–9 (39 ref.)

Clonazepam-sensitive intermittent dystonic tremor. Davis TL, et al. **South Med J** 1995 Oct;88(10):1069–71 (16 ref.)

GENETICS

Essential myoclonus and myoclonic dystonia. Quinn NP. **Mov Disord** 1996 Mar;11(2):119–24 (51 ref.)

[L-dopa-responsive dystonia: 2 familial cases of adult onset with sleep disorders] el Alaoui-Faris M, et al. **Rev Neurol (Paris)** 1995 May;151(5):347–9 (10 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Dystonia and the supplementary sensorimotor area. Hallett M, et al. **Adv Neurol** 1996;70:471–6 (31 ref.)

DYSTONIA MUSCULORUM DEFORMANS

PHYSIOPATHOLOGY

Cervical dystonia (spasmodic torticollis). Some aspects of the natural history. Van Zandijcke M. **Acta Neurol Belg** 1995 Dec;95(4):210–5 (39 ref.)

DYSTROPHIA MYOTONICA see **MYOTONIA ATROPHICA**

DYSTROPHIN

see related
MICE, INBRED MDX

[Dystrophin, dystrophin-associated protein and dystrophinopathy] **Ozawa E.** **Nihon Shinkei Seishin Yakurigaku Zasshi** 1995 Jun; 15(3):289–93 (15 ref.) (Eng. Abstr.) **(Jpn)**

ANALYSIS

[Histological and immunohistochemical analysis of dystrophin++ in muscular dystrophy of Duchenne and Becker type] Cabello A. **Rev Neurol** 1995;23 Suppl 3:S395–9 (31 ref.) **(Spa)**

CHEMISTRY

ZZ and TAZ: new putative zinc fingers in dystrophin and other proteins. Ponting CP, et al. **Trends Biochem Sci** 1996 Jan;21(1):11–13 (20 ref.)

DEFICIENCY

How does dystrophin deficiency lead to muscle degeneration?—evidence from the mdx mouse. McArdle A, et al. **Neuromuscul Disord** 1995 Nov;5(6):445–56 (78 ref.)

GENETICS

Dystrophin, its gene, and the dystrophinopathies. Roberts RG. **Adv Genet** 1995;33:177–231 (263 ref.)

The dystrophin gene and its product—a view. Manole E. **Rom J Neurol Psychiatry** 1995 Apr-Jun;33(2):109–19 (65 ref.)

Muscular dystrophies: diseases of the dystrophin-glycoprotein complex [comment] Worton R. **Science** 1995 Nov 3;270(5237):755–6 (15 ref.) Comment on: Science 1995 Nov 3;270(5237):819–22.

Duchenne muscular dystrophy. Matsuo M. **Southeast Asian J Trop Med Public Health** 1995;26 Suppl 1:166–71 (31 ref.)

METABOLISM

Dystrophin-glycoprotein complex: molecular organization and critical roles in skeletal muscle. Sunada Y, et al. **Curr Opin Neurol** 1995 Oct;8(5):379–84 (40 ref.)

Dystrophinopathies and related disorders. Cherin P. **Curr Opin Rheumatol** 1995 Nov;7(6):475–85 (85 ref.)

Dystrophin-associated proteins in muscular dystrophy. Ozawa E, et al. **Hum Mol Genet** 1995;4 Spec No:1711–6 (69 ref.)

PHYSIOLOGY

Dystrophin, its gene, and the dystrophinopathies. Roberts RG. **Adv Genet** 1995;33:177–231 (263 ref.)

Recent advances in muscular dystrophies and myopathies. Anderson JR. **J Clin Pathol** 1995 Jul;48(7):597–601 (33 ref.)

E ANTIGENS see **HEPATITIS B E ANTIGENS**

E-B VIRUS see **HERPESVIRUS 4, HUMAN**

E-CADHERINS see **CADHERINS**

E-MAIL see **COMPUTER COMMUNICATION NETWORKS**

E SELECTIN see **E-SELECTIN**

EAR

Biologic bases of noise-induced hearing loss. Henderson D, et al. Occup Med 1995 Jul–Aug;10(3):513–34 (27 ref.)

ABNORMALITIES

Treacher-Collins syndrome. Management of major and minor anomalies of the ear. Marres HA, et al. **Rev Laryngol Otol Rhinol (Bord)** 1995;116(2):105–8 (24 ref.)

INJURIES

Blast injury of the ear: an overview and guide to management. Garth RJ. **Injury** 1995 Jul;26(6):363–6 (14

ref.)

PATHOLOGY

Hearing loss and leukocytosis. Lossos IS, et al. **Postgrad Med J** 1996 Mar;72(845):183–5 (7 ref.)

PHYSIOLOGY

Endogenous factors related to susceptibility to damage from noise. Ward WD. **Occup Med** 1995 Jul–Aug;10(3):561–75 (138 ref.)

EAR CANAL

see related
CERUMEN

Pathologic conditions of the external ear and auditory canal. Ostrowski VB, et al. **Postgrad Med** 1996 Sep;100(3):223–8, 233–7 (14 ref.)

PATHOLOGY

Pleomorphic adenoma of the external auditory canal: a case report and review of the literature. Haraguchi H, et al. **J Laryngol Otol** 1996 Jan;110(1):52–6 (24 ref.)

Malignant melanoma of the external auditory canal. Langman A, et al. **Otolaryngol Head Neck Surg** 1996 Apr; 114(4):645–8 (19 ref.)

EAR DISEASES

Pathologic conditions of the external ear and auditory canal. Ostrowski VB, et al. **Postgrad Med** 1996 Sep;100(3):223–8, 233–7 (14 ref.)

ETIOLOGY

Fibrous dysplasia of the temporal bone: ten new cases demonstrating the spectrum of otologic sequelae. Megerian CA, et al. **Am J Otol** 1995 Jul;16(4):408–19 (49 ref.)

SURGERY

Advances in otology and neurotology. Fayad J, et al. **J Med Liban** 1994;42(4):203–7 (17 ref.)

EAR, EXTERNAL

Removal of superglue from the external ear using acetone: case report and literature review. Abadir WF, et al. **J Laryngol Otol** 1995 Dec;109(12):1219–21 (5 ref.)

Pathologic conditions of the external ear and auditory canal. Ostrowski VB, et al. **Postgrad Med** 1996 Sep;100(3):223–8, 233–7 (14 ref.)

[Using temporal bone artificial implantation for the fixation of external ear prosthesis] Chen X, et al. **Chung Hua Cheng Hsing Shao Shang Wai Ko Tsa Chih** 1995 Sep;11(5):379–81 (15 ref.) **(Chi)**

[Treatment of keloids of the earlobe (see comments)] Vegter F, et al. **Ned Tijdschr Geneeskd** 1995 Aug 19; 139(33):1678–80 (18 ref.) Comment in: Ned Tijdschr Geneeskd 1995 Oct 14;139(41):2110–1. Comment in: Ned Tijdschr Geneeskd 1995 Nov 25;139(47):2453. **(Dut)**

[Malignant infiltrating blue nevus of the plaque type. Case report and literature review] Wlotzke U, et al. **Hautarzt** 1995 Dec;46(12):860–4 (30 ref.) (Eng. Abstr.) **(Ger)**

ABNORMALITIES

Familial microtia with meatal atresia and conductive deafness in five generations. Gupta A, et al. **Am J Med Genet** 1995 Nov 6;59(2):238–41 (14 ref.)

Oculoauriculofrontonasal syndrome: report of another case and review of differential diagnosis. Toriello HV, et al. **Clin Dysmorphol** 1995 Oct;4(4):338–46 (25 ref.)

[Isotretinoin (RoAccutane) embryopathy. A case report] Pilorget H, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(5):511–5 (14 ref.) (Eng. Abstr.) **(Fre)**

[The Townes–Brocks syndrome] Arroyo Carrera I, et al. **An Esp Pediatr** 1996 Apr;44(4):364–6 (18 ref.) **(Spa)**

ANATOMY & HISTOLOGY

Comparative anatomy of the external and middle ear of palaeognathous birds. Starck JM. **Adv Anat Embryol Cell Biol** 1995;131:1–137 (225 ref.)

INJURIES

Initial management of auricular trauma. Lee D, et al. **Am Fam Physician** 1996 May 15;53(7):2339–44 (20 ref.)

INNERVATION

The clinical significance of the communicating branches of the somatic sensory supply of the middle and external ear. Grey P. **J Laryngol Otol** 1995 Dec;109(12):1141–5 (35 ref.)

MICROBIOLOGY

Necrotizing fasciitis originating from pinna perichondritis. Skorina J, et al. **Otolaryngol Head Neck Surg** 1995 Oct; 113(4):467–73 (33 ref.)

EAR, INTERNAL see **LABYRINTH**

EAR, MIDDLE

see related
TYMPANOPLASTY

Epitympanic compartment surgical considerations: reevaluation. Palva T, et al. **Am J Otol** 1995 Jul; 16(4):505–13 (24 ref.)

Mechanical and acoustic analysis of middle ear reconstruction. Rosowski JJ, et al. **Am J Otol** 1995 Jul; 16(4):486–97 (56 ref.)

ABNORMALITIES

[Congenital cholesteatoma and associated ossicular malformations] el Jerrari A, et al. **Ann Otolaryngol Chir Cervicofac** 1995;112(6):258–61 (22 ref.) (Eng. Abstr.) **(Fre)**

ANATOMY & HISTOLOGY

Comparative anatomy of the external and middle ear of palaeognathous birds. Starck JM. **Adv Anat Embryol Cell Biol** 1995;131:1–137 (225 ref.)

EMBRYOLOGY

Functional development of auditory sensitivity in the fetus and neonate. Sohmer H, et al. **J Basic Clin Physiol Pharmacol** 1995;6(2):95–108 (74 ref.)

INNERVATION

Tympanic neurectomy in the management of parotid sialectasis. Daud AS, et al. **J Laryngol Otol** 1995 Dec; 109(12):1155–8 (12 ref.)

The clinical significance of the communicating branches of the somatic sensory supply of the middle and external ear. Grey P. **J Laryngol Otol** 1995 Dec;109(12):1141–5 (35 ref.)

METABOLISM

Implications of middle ear hyperoxia induced by ventilation tubes in otitis media with effusion. Ovesen T. **APMIS Suppl** 1995;54:1–36 (233 ref.)

Collagen types in the middle ear mucosa. Nerlich AG. **Eur Arch Otorhinolaryngol** 1995;252(7):443–6; discussion 447–9 (25 ref.)

PATHOLOGY

Cartinoid tumor of the middle ear and mastoid. Himi T, et al. **Auris Nasus Larynx** 1995;22(2):128–33 (21 ref.)

Salivary gland choristoma of the middle ear: report of a case and review of the literature. Hinni ML, et al. **Ear Nose Throat J** 1996 Jul;75(7):422–4 (17 ref.)

PHYSIOLOGY

The lessons of middle-ear function in non-mammals: improving columellar prostheses [editorial] Manley GA. **J R Soc Med** 1995 Jul;88(7):367–8 (8 ref.)

[Importance of the eustachian tube in middle ear function] Sente M. **Med Pregl** 1995;48(11–12):405–6 (6 ref.) (Eng. Abstr.) **(Scr)**

PHYSIOPATHOLOGY

[Otitis media with effusion in children] Zielnik B. **Otolaryngol Pol** 1995;49(3):214–9 (53 ref.) (Eng. Abstr.) **(Pol)**

SURGERY

A surgical solution for the difficult chronic ear. Jackson CG, et al. **Am J Otol** 1996 Jan;17(1):7–14 (8 ref.)

EAR MOLDS see **HEARING AIDS**

EAR NEOPLASMS

Inflammatory meningiomas of the internal auditory canals. Doyle KJ, et al. **Otolaryngol Head Neck Surg** 1995 Nov; 113(5):617–20 (8 ref.)

DIAGNOSIS

Cartinoid tumor of the middle ear and mastoid. Himi T, et al. **Auris Nasus Larynx** 1995;22(2):128–33 (21 ref.)

[Malignant infiltrating blue nevus of the plaque type. Case report and literature review] Wlotzke U, et al. **Hautarzt** 1995 Dec;46(12):860–4 (30 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

Cartinoid tumor of the middle ear and mastoid. Himi T, et al. **Auris Nasus Larynx** 1995;22(2):128–33 (21 ref.)

Salivary gland choristoma of the middle ear: report of a case and review of the literature. Hinni ML, et al. **Ear Nose Throat J** 1996 Jul;75(7):422–4 (17 ref.)

Pleomorphic adenoma of the external auditory canal: a case report and review of the literature. Haraguchi H, et al. **J Laryngol Otol** 1996 Jan;110(1):52–6 (24 ref.)

Haemangiopericytoma of the middle ear: case report and literature review. Sutbeyaz Y, et al. **J Laryngol Otol** 1995 Oct;109(10):977–9 (26 ref.)

Malignant melanoma of the external auditory canal. Langman A, et al. **Otolaryngol Head Neck Surg** 1996 Apr; 114(4):645–8 (19 ref.)

RADIOGRAPHY

Osteoma of the internal auditory canal: case report. Coakley DJ, et al. **J Laryngol Otol** 1996 Feb;110(2):158–60 (10 ref.)

EAR OSSICLES

see related
STAPES SURGERY

EAR PROTECTIVE DEVICES

Technology advancements in hearing protection circa 1995: active noise reduction, frequency/amplitude-sensitivity, and uniform attenuation. Casali JG, et al. **Am Ind Hyg Assoc J** 1996 Feb;57(2):175–85 (31 ref.)

EARACHE

PATHOLOGY

Supertasting, earaches and head injury: genetics and pathology alter our taste worlds. Bartoshuk LM, et al. **Neurosci Biobehav Rev** 1996;20(1):79–87 (64 ref.)

EARLY GENE TRANSCRIPTION see **TRANSCRIPTION, GENETIC**

EARLY INTERVENTION (EDUCATION)

Prenatally drug-exposed children in out-of-home care: are we looking at the whole picture? Franck EJ. **Child Welfare** 1996 Jan–Feb;75(1):19–34 (30 ref.)

Brief report: early intervention in autism. Rogers SJ. **J Autism Dev Disord** 1996 Apr;26(2):243–6 (10 ref.)

EARLY PLACENTAL PHASE see **PREGNANCY TRIMESTER, FIRST**

EARLY PROMOTERS see **PROMOTER REGIONS (GENETICS)**

EARTHQUAKES see **NATURAL DISASTERS**

EARTHWORMS see **OLIGOCHAETA**

EAST COAST FEVER see **THEILERIASIS**

EATING

Geriatric oral health and its impact on eating. Ship JA, et al. **J Am Geriatr Soc** 1996 Apr;44(4):456–64 (105 ref.)

Effects of aging on energy requirements and the control of food intake in men. Roberts SB. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:101–6 (29 ref.)

Portion sizes in dietary assessment: issues and policy implications. Young LR, et al. **Nutr Rev** 1995 Jun; 53(6):149–58 (100 ref.)

Serotonin, eating behavior, and fat intake. Blundell JE, et al. **Obes Res** 1995 Nov;3 Suppl 4:471S–476S (61 ref.)

Control of voluntary intake of precision-chopped silages by ruminants: a review. Dulphy JP, et al. **Reprod Nutr Dev** 1996;36(2):113–35 (144 ref.)

[Orthostatic and postprandial hypotension] Koike Y, et al. **Nippon Naika Gakkai Zasshi** 1995 Sep 10;84(9):1429–34 (13 ref.) **(Jpn)**

[Regulation of food intake and appetite: overview] Aou S, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:13–8 (23 ref.) **(Jpn)**

[Rare forms of reflex epilepsy—the epilepsy of calculation and the epilepsy of eating] Karlov VA, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995;95(3):13–6 (18 ref.) (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

Neutral mediation of food aversions and anorexia induced by tumor necrosis factor and tumors. Bernstein IL. **Neurosci Biobehav Rev** 1996;20(1):177–81 (27 ref.)

Nutrient intake is modulated by peripheral peptide administration. Bray GA. **Obes Res** 1995 Nov;3 Suppl 4:569S–572S (31 ref.)

Biological actions of drugs affecting serotonin and eating. Garattini S. **Obes Res** 1995 Nov;3 Suppl 4:463S–470S (65 ref.)

Dopamine receptor subtype agonists and feeding behavior. Terry P, et al. **Obes Res** 1995 Nov;3 Suppl 4:515S–523S (57 ref.)

PHYSIOLOGY

Energy density and its role in the control of food intake: evidence from metabolic and community studies. Poppitt SD, et al. **Appetite** 1996 Apr;26(2):153–74 (102 ref.)

Post-prandial lipaemia. Kirchmair R, et al. **Baillieres Clin Endocrinol Metab** 1995 Oct;9(4):705–19 (115 ref.)

Postprandial state and atherosclerosis. Ebenbichler CF, et al. **Curr Opin Lipidol** 1995 Oct;6(5):286–90 (37 ref.)

Motor activity of the gallbladder and gastrointestinal tract as determinants of enterohepatic circulation. A scintigraphic and manometric study. Qvist N.

Dan Med Bull 1995 Nov;42(5):426–40 (196 ref.)
The cardiovascular responses to feeding in man. Kearney MT, et al. **Exp Physiol** 1995 Sep;80(5):683–700 (78 ref.)
Physiological regulation of macronutrient balance. Frayn KN. **Int J Obes Relat Metab Disord** 1995 Nov;19 Suppl 5:S4–10 (48 ref.)
Epidemiology of obesity in relation to nutrient intake. Gibney MJ. **Int J Obes Relat Metab Disord** 1995 Nov;19 Suppl 5:S1–3 (25 ref.)
Techniques for the experimental measurement of human eating behaviour and food intake: a practical guide. Hill AJ, et al. **Int J Obes Relat Metab Disord** 1995 Jun; 19(6):361–75 (91 ref.)
Exercise and the neurobiological control of food intake and energy expenditure. Richard D. **Int J Obes Relat Metab Disord** 1995 Oct;19 Suppl 4:S73–9 (78 ref.)
Macronutrient effects on appetite. Stubbs RJ. **Int J Obes Relat Metab Disord** 1995 Nov;19 Suppl 5:S11–9 (54 ref.)
Exercise, macronutrient preferences and food intake. Tremblay A, et al. **Int J Obes Relat Metab Disord** 1995 Oct;19 Suppl 4:S97–101 (32 ref.)
Does breakfast make a difference in school? Pollitt E. **J Am Diet Assoc** 1995 Oct;95(10):1134–9 (24 ref.)
Impact of changes in organic nutrient metabolism on feeding the transition dairy cow. Grummer RR. **J Anim Sci** 1995 Sep;73(9):2820–33 (81 ref.)
Characteristics of plant cell walls affecting intake and digestibility of forages by ruminants. Jung HG, et al. **J Anim Sci** 1995 Sep;73(9):2774–90 (147 ref.)
Endocrine regulation of food intake and body weight. Figlewicz DP, et al. **J Lab Clin Med** 1996 Apr; 127(4):328–32 (43 ref.)
Plant wax components: a new approach to estimating intake and diet composition in herbivores. Dove H, et al. **J Nutr** 1996 Jan;126(1):13–26 (62 ref.)
Post-prandial hypotension in the elderly. Aronow WS. **J R Soc Med** 1995 Sep;88(9):499–501 (12 ref.)
Impact of fat substitutes on fat intake. Miller GD, et al. **Lipids** 1996 Mar;31 Suppl:S293–6 (61 ref.)
Food reward: brain substrates of wanting and liking. Berridge KC. **Neurosci Biobehav Rev** 1996;20(1):1–25 (162 ref.)
How can eating behavior be regulated in the complex environments of free-living humans? De Castro JM. **Neurosci Biobehav Rev** 1996;20(1):119–31 (34 ref.)
Food selection: problems in understanding how we choose foods to eat. Galef BG Jr. **Neurosci Biobehav Rev** 1996; 20(1):67–73 (64 ref.)
Human eating: diagnosis and prognosis. Herman CP. **Neurosci Biobehav Rev** 1996;20(1):107–11 (4 ref.)
Mechanisms of sickness-induced decreases in food-motivated behavior. Kent S, et al. **Neurosci Biobehav Rev** 1996; 20(1):171–5 (36 ref.)
Role of the liver in the metabolic control of eating: what we know—and what we do not know. Langhans W. **Neurosci Biobehav Rev** 1996;20(1):145–53 (122 ref.)
Regulation of nutrient intake in humans: a theory based on taste and smell. Poothullil JM. **Neurosci Biobehav Rev** 1995 Fall;19(3):407–12 (61 ref.)
Sub-diaphragmatic vagal afferent integration of meal-related gastrointestinal signals. Schwartz GJ, et al. **Neurosci Biobehav Rev** 1996;20(1):47–56 (31 ref.)
The direct and indirect controls of meal size. Smith GP. **Neurosci Biobehav Rev** 1996;20(1):41–6 (23 ref.)
The importance of calcium in the control of salt intake. Tordoff MG. **Neurosci Biobehav Rev** 1996;20(1):89–99 (104 ref.)
Cytokines and food intake: the relevance of the immune system to the student of ingestive behavior. Weingarten HP. **Neurosci Biobehav Rev** 1996;20(1):163–70 (90 ref.)
The evaluation of insulin as a metabolic signal influencing behavior via the brain. Woods SC, et al. **Neurosci Biobehav Rev** 1996;20(1):139–44 (42 ref.)
Prevention of obesity in middle-aged monkeys: food intake during body weight clamp. Hansen BC, et al. **Obes Res** 1995 Sep;3 Suppl 2:199s–204s (26 ref.)
Does thermoregulatory feeding occur in newborn infants? A novel view of the role of brown adipose tissue thermogenesis in control of food intake. Himms-Hagen J. **Obes Res** 1995 Jul;3(4):361–9 (54 ref.)
The effect of infused nutrients and absorbed foods on daily food intake in rats. Koopmans HS. **Obes Res** 1995 Dec;3 Suppl 5:675S–684S (62 ref.)
Food intake and the menstrual cycle: a retrospective analysis, with implications for appetite research. Buffenstein R, et al. **Physiol Behav** 1995 Dec;58(6):1067–77 (142 ref.)
Feeding, fasting and starvation: factors affecting fuel utilization. MacDonald IA, et al. **Proc Nutr Soc** 1995 Mar; 54(1):267–74 (29 ref.)
Postprandial triacylglycerolaemia—nutritional implications. Roche HM, et al. **Prog Lipid Res** 1995;34(3):249–66 (110 ref.)
Commentary. The uncontrolled variable in risk assessment: ad libitum overfed rodents—fat, facts and fiction. Keenan KP. **Toxicol Pathol** 1996 May-Jun;24(3):376–83 (57 ref.)
[Regulation of food intake] Schusdziarra V. **Zentralbl Chir** 1996;121(5):354–7 (34 ref.) (Eng. Abstr.) **(Ger)**
[Role of miscellaneous substances (organic acids, lactone, etc) in regulation of food intake] Aou S, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:85–9 (19 ref.) **(Jpn)**
[Regulatory factors in food intake: glucoreceptor neuron and gluco-sensitive neuron] Aou S, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:26–32 (20 ref.) **(Jpn)**
[Regulatory factors in food intake: overview] Aou S, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:19–25 (20 ref.) **(Jpn)**
[Effect of brain peptides on feeding and body weight regulation] Inui A, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:49–57 (20 ref.) **(Jpn)**
[Effect of gut peptides on feeding and body weight regulation] Inui A, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:40–8 (15 ref.) **(Jpn)**
[Role of growth factors in regulation of food intake] Oomura Y, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:64–9 (15 ref.) **(Jpn)**
[Role of cytokines in regulation of food intake and appetite] Shimizu H. **Nippon Rinsho** 1995 Jun;53 Suppl:58–63 (39 ref.) **(Jpn)**
[Steroid hormone receptors in the CNS from animal models with fatty syndrome] Takeda R. **Nippon Rinsho** 1995 Jun; 53 Suppl:70–4 (13 ref.) **(Jpn)**
[Role of biogenic amines (catecholamines, histamine, serotonin, etc.) in food intake] Tsujii S. **Nippon Rinsho** 1995 Jun;53 Suppl:33–9 (20 ref.) **(Jpn)**

PSYCHOLOGY

Psychological consequences of food restriction. Polivy J. **J Am Diet Assoc** 1996 Jun;96(6):589–92; quiz 593–4 (48 ref.)

EATING BEHAVIOR see **FEEDING BEHAVIOR**

EATING DISORDERS

see related
ANOREXIA NERVOSA
OBESITY
THINNESS

Eating disorders in adolescents: a model for broadening our perspective. Rees JM. **J Am Diet Assoc** 1996 Jan;96(1):22–3 (4 ref.)
[Etiology and physiopathology of obesity: eating behaviors and their disorders] Fukudo S, et al. **Nippon Naika Gakkai Zasshi** 1995 Aug 10;84(8):1226–30 (11 ref.) **(Jpn)**

CLASSIFICATION

Views on classification and diagnosis of eating disorders [see comments] Garfinkel PE, et al. **Can J Psychiatry** 1995 Oct; 40(8):445–56 (112 ref.) Comment in: Can J Psychiatry 1995 Oct;40(8):435–6.

COMPLICATIONS

Binge eating among the overweight population: a serious and prevalent problem. Bruce B, et al. **J Am Diet Assoc** 1996 Jan;96(1):58–61 (30 ref.)

DIAGNOSIS

Eating disorders and disordered eating in different cultures. Weiss MG. **Psychiatr Clin North Am** 1995 Sep;18(3):537–53 (75 ref.)

DRUG THERAPY

Antidepressant treatment of binge-eating disorder: research findings and clinical guidelines. Hudson JI, et al. **J Clin Psychiatry** 1996;57 Suppl 8:73–9 (37 ref.)

EPIDEMIOLOGY

The spectrum of eating disturbances. Shisslak CM, et al. **Int J Eat Disord** 1995 Nov;18(3):209–19 (105 ref.)

ETIOLOGY

Opioid involvement in feeding behaviour and the pathogenesis of certain eating disorders. Johnson RD. **Med Hypotheses** 1995 Nov;45(5):491–7 (48 ref.)
Appetite in CAPD patients. Bergström J. **Perit Dial Int** 1996; 16 Suppl 1:S181–4 (29 ref.)
Is obesity an eating disorder? Jebb SA, et al. **Proc Nutr Soc** 1996 Nov;54(3):721–8 (22 ref.)

PHYSIOPATHOLOGY

Toward a unified theory of serotonin dysregulation in eating and related disorders. Brewerton TD. **Psychoneuroendocrinology** 1995;20(6):561–90 (160 ref.)

PREVENTION & CONTROL

Transition from tube feedings to feedings by mouth in children: preventing eating dysfunction. Schauster H, et al. **J Am Diet Assoc** 1996 Mar;96(3):277–81 (18 ref.)

PSYCHOLOGY

Views on classification and diagnosis of eating disorders [see comments] Garfinkel PE, et al. **Can J Psychiatry** 1995 Oct; 40(8):445–56 (112 ref.) Comment in: Can J Psychiatry 1995 Oct;40(8):435–6.
The dyslipophobias: a view of the psychopathologies involved and the hazards of construing anorexia nervosa and bulimia nervosa as 'eating disorders'. Crisp AH. **Proc Nutr Soc** 1996 Nov;54(3):701–9 (10 ref.)
[An update on merycism and early depression: a critical review of the literature and a psychopathological hypothesis] Guedeney A. **Psychiatr Enfant** 1995; 38(1):345–63 (69 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Practical management of eating disorders. Doyle MM. **Proc Nutr Soc** 1996 Nov;54(3):711–9 (29 ref.)
[Integrated psychotherapy for eating disorders] Tomizawa O. **Seishin Shinkeigaku Zasshi** 1995;97(5):326–56 (49 ref.) (Eng. Abstr.) **(Jpn)**

EATON AGENT see **MYCOPLASMA PNEUMONIAE**

EATON-LAMBERT SYNDROME see **LAMBERT-EATON MYASTHENIC SYNDROME**

EBOLA HEMORRHAGIC FEVER see **HEMORRHAGIC FEVER, EBOLA**

EBOLA VIRUS

Ebola virus transmission [editorial] Irving WL. **Int J Exp Pathol** 1995 Aug;76(4):225–6 (14 ref.)

PATHOGENICITY

Lessons learned from the hantaviruses and other hemorrhagic fever viruses. Butler JC, et al. **Am J Med Sci** 1996 Jan; 311(1):55–9 (39 ref.)

EBOLA VIRUS DISEASE see **HEMORRHAGIC FEVER, EBOLA**

EBSTEIN'S ANOMALY

COMPLICATIONS

Ebstein's anomaly with coarctation of the aorta—an unusual association. Salkar HR, et al. **Indian Heart J** 1996 May-Jun; 48(3):283–4 (7 ref.)

EBV see **HERPESVIRUS 4, HUMAN**

EC CELLS see **TUMOR STEM CELLS**

EC-IC ARTERIAL BYPASS see **CEREBRAL REVASCULARIZATION**

ECCENTRO-OSTEOCHONDRODYSPLASIA see **MUCOPOLYSACCHARIDOSIS IV**

ECCHYMOSIS

see related
PURPURA

ECDYSONE

PHYSIOLOGY

Metamorphosis in Drosophila: from molecular biology to mutants. Bender M. **Trends Genet** 1995 Sep;11(9):335–6 (21 ref.)

ECDYSTERONE

PHYSIOLOGY

Drosophila Sgs genes: stage and tissue specificity of hormone responsiveness. Lehmann M. **Bioessays** 1996 Jan; 18(1):47–54 (70 ref.)

ECG see **ELECTROCARDIOGRAPHY**

ECHINOCOCCOSIS

Recent developments in cestode research. Webbe G. **Trans R Soc Trop Med Hyg** 1995 Jul-Aug;89(4):345–6, 353 (35 ref.)
[Hydatidosis. A survey] Riber C, et al. **Ugeskr Laeger** 1995 Aug 7;157(32):4445–9 (28 ref.) (Eng. Abstr.) **(Dan)**
[Unusual locations of hydatid cysts] Khiari A, et al. **Ann Gastroenterol Hepatol (Paris)** 1995 Oct;31(5):295–305 (73 ref.) (Eng. Abstr.) **(Fre)**
[Multiple bilateral renal hydatidosis. A case report] Bennani S, et al. **Ann Urol (Paris)** 1995;29(3):150–3 (31 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

[Echinococcosis of the paravertebral space. Report of a case] Calderoni PP, et al. **Radiol Med (Torino)** 1995 Dec; 90(6):820–1 (11 ref.) (Eng. Abstr.) **(Ita)**

EPIDEMIOLOGY

Detection, screening and community epidemiology of taeniid cestode zoonoses: cystic echinococcosis, alveolar echinococcosis and neurocysticercosis. Craig PS, et al. **Adv Parasitol** 1996;38:169–250 (365 ref.)
Epidemiological studies on cystic echinococcosis in China—a review. Chai JJ. **Biomed Environ Sci** 1995 Jun;8(2):122–36 (73 ref.)

ECHINOCOCCOSIS

PREVENTION & CONTROL

Detection, screening and community epidemiology of taeniid cestode zoonoses: cystic echinococcosis, alveolar echinococcosis and neurocysticercosis. Craig PS, et al. **Adv Parasitol** 1996;38:169–250 (365 ref.)

VETERINARY

[Importance of epidemiology and control of the fox tapeworm, Echinococcus multilocularis, in Germany] Daugschies A. **DTW Dtsch Tierarztl Wochenschr** 1995 Aug; 102(8):306–10 (73 ref.) (Eng. Abstr.) **(Ger)**

ECHINOCOCCOSIS, HEPATIC

[Echinococcosis of the liver] Sato N, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):51–3 (10 ref.) **(Jpn)**

COMPLICATIONS

[Hepatic echinococcosis with gallstones of the echinococcal cavity] Kuntz C, et al. **Dtsch Med Wochenschr** 1995 Dec 8;120(49):1699–702 (13 ref.) (Eng. Abstr.) **(Ger)**

[Parasitic liver cirrhosis] Sekiya C. **Ryoikibetsu Shokogun Shirizu** 1995;(7):168–70 (12 ref.) **(Jpn)**

DIAGNOSIS

An imported case of hepatic unilocular hydatid disease. Chai JY, et al. **Korean J Parasitol** 1995 Jun;33(2):125–30 (26 ref.)

EPIDEMIOLOGY

[Epidemiological status of alveolar echinococcosis in China] Jiang CP. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1995 Aug;16(4):243–5 (16 ref.) **(Chi)**

PARASITOLOGY

[Hepatic hydatidosis in Madagascar: a case of autochthonous origin] Pécarrère JL, et al. **Arch Inst Pasteur Madagascar** 1994;61(2):103–4 (10 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

The scanning electron microscopy of scolices in a case of hydatid cyst from human liver. Warren BA, et al. **Pathology** 1995 Oct;27(4):318–23 (13 ref.)

Polycystic hydatid disease in Brazil. Report of five new human cases and a short review of other published observations. D'Alessandro A, et al. **Rev Soc Bras Med Trop** 1996 May–Jun;29(3):219–28 (30 ref.)

RADIOGRAPHY

[Icterus—sometimes something is wrong: the rupture of an echinococcal cyst into the biliary tract] Bücker A, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Jul;165(1):88–90 (10 ref.) **(Ger)**

SURGERY

The feasibility of safe laparoscopic treatment of hydatid cysts of the liver [letter; comment] Bickel A, et al. **Surg Endosc** 1995 Aug;9(8):934–5 (6 ref.) Comment on: Surg Endosc 1994 Sep;8(9):1103–4.

ECHINOCOCCOSIS, HEPATIC ALVEOLAR see **ECHINOCOCCOSIS, HEPATIC**

ECHINOCOCCUS

GENETICS

Genetic variability in parasites and host–parasite interactions. Thompson RC, et al. **Parasitology** 1996;112 Suppl:S7–22 (118 ref.)

PHYSIOLOGY

Detection, screening and community epidemiology of taeniid cestode zoonoses: cystic echinococcosis, alveolar echinococcosis and neurocysticercosis. Craig PS, et al. **Adv Parasitol** 1996;38:169–250 (365 ref.)

ULTRASTRUCTURE

The scanning electron microscopy of scolices in a case of hydatid cyst from human liver. Warren BA, et al. **Pathology** 1995 Oct;27(4):318–23 (13 ref.)

ECHINOSTOMA

PHYSIOLOGY

The Biology of the intestinal trematode Echinostoma caproni. Fried B, et al. **Adv Parasitol** 1996;38:311–68 (170 ref.)

ECHO-PLANAR IMAGING

Advances in vascular echoplanar imaging. Debatin JF, et al. **Cardiovasc Intervent Radiol** 1995 Sep–Oct;18(5):277–87 (41 ref.)

[Clinical application of functional mapping; the present state of the art and its future prospects: (series 1) functional MRI: signal mechanism of fMRI and quantification of brain function by echo planar imaging] Naruse S, et al. **No Shinkei Geka** 1996 Jan;24(1):7–17 (55 ref.) **(Jpn)**

INSTRUMENTATION

[Echo-planar imaging of the brain] Brüning R, et al. **Radiologe** 1995 Dec;35(12):902–10 (61 ref.) (Eng. Abstr.) **(Ger)**

[Fast and ultra-fast magnetic resonance tomography. Basic principles, pulse sequences and special properties] Stehling MK, et al. **Radiologe** 1995 Dec;35(12):879–93 (41 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Echo-planar magnetic resonance angiography. Cohen MS. **Magn Reson Imaging Clin N Am** 1993 Dec;1(2):359–65 (29 ref.)

ECHOCARDIOGRAPHY

Diagnosis of myocardial stunning: a new use for myocardial contrast and dobutamine echocardiography. Cheirif J. **Am J Card Imaging** 1995 Oct;9(4):261–8 (51 ref.)

Are there gender differences related to stress or pharmacological echocardiography? Crouse LJ, et al. **Am J Card Imaging** 1996 Jan;10(1):65–71 (29 ref.)

Perfusion imaging with contrast echocardiography: assessment of the no-reflow phenomenon. Winkelmann JW, et al. **Coron Artery Dis** 1995 Aug;6(8):619–24 (73 ref.)

Emergency medicine applications of echocardiography. Wellford AL, et al. **Emerg Med Clin North Am** 1995 Nov; 13(4):831–54 (72 ref.)

Identification of high-risk subgroups in infective endocarditis and the role of echocardiography. Erbel R, et al. **Eur Heart J** 1995 May;16(5):588–602 (86 ref.)

Analysis of left ventricular systolic function. Schiller NB, et al. **Heart** 1996 Jun;75(6 Suppl 2):17–26 (42 ref.)

How should we describe forward flow through replacement mitral valves using echocardiography? Chambers JB. **J Heart Valve Dis** 1995 Jul;4 Suppl 1:S55–8 (17 ref.)

Pediatric echocardiography: current role and a review of technical advances. Rice MJ, et al. **J Pediatr** 1996 Jan; 128(1):1–14 (66 ref.)

In vivo and in vitro studies on the mechanism and clinical significance of spontaneous echocardiographic contrast in patients with atrial dysrhythmias. Castello R, et al. **Prog Cardiovasc Dis** 1996 Jul–Aug;39(1):47–56 (65 ref.)

Atrial anatomy and function postcardioversion: insights from transthoracic and transesophageal echocardiography. Manning WJ, et al. **Prog Cardiovasc Dis** 1996 Jul–Aug; 39(1):33–46 (60 ref.)

Nuclear cardiology and echocardiography for the assessment of myocardial viability. Tarolo GL, et al. **Q J Nucl Med** 1996 Mar;40(1):91–107 (124 ref.)

[The role of echocardiography in the diagnosis of infectious endocarditis] Chlumský J. **Vnitr Lek** 1995 Nov;41(11):792–5 (12 ref.) (Eng. Abstr.) **(Cze)**

[Study of myocardial viability after recent infarction by echocardiography under dobutamine. Evidence of stunned myocardium] Guéret P, et al. **Arch Mal Coeur Vaiss** 1995 Aug;88 Spec No 3:13–7 (19 ref.) (Eng. Abstr.) **(Fre)**

[Traumatic tricuspid insufficiency] Vayre F, et al. **Arch Mal Coeur Vaiss** 1996 Apr;89(4):459–63 (30 ref.) (Eng. Abstr.) **(Fre)**

[Echocardiography and Jones criteria in the diagnosis of rheumatic heart diseases: 138 cases reviewed at the Cardiology Institute of Abidjan] Zabsonre P, et al. **Med Trop (Mars)** 1995;55(4):347–50 (17 ref.) (Eng. Abstr.) **(Fre)**

[Stress echocardiography versus myocardial scintigraphy: comparative value in coronary heart disease] Silber S. **Herz** 1996 Apr;21(2):136–41 (68 ref.) **(Ger)**

[A 63-year-old man with uncorrected tetralogy of Fallot] Hoffmann A, et al. **Z Kardiol** 1995 Dec;84(12):1039–42 (22 ref.) (Eng. Abstr.) **(Ger)**

[Prenatal diagnosis of left cardiac abnormality] Hajdú J, et al. **Orv Hetil** 1995 Oct 22;136(43):2333–7 (22 ref.) (Eng. Abstr.) **(Hun)**

[The utility of electrocardiography in the age of exercise echocardiography] Boccardi L, et al. **Cardiologia** 1995 Nov; 40(11):807–12 (20 ref.) **(Ita)**

[Echocardiographic and Doppler markers of heart valve prosthesis dysfunction] Faletra F, et al. **G Ital Cardiol** 1995 Nov;25(11):1513–32 (89 ref.) **(Ita)**

[The quantification of valvular regurgitation. What new does echocardiography offer?] Mele D. **G Ital Cardiol** 1995 Sep; 25(9):1195–203 (54 ref.) **(Ita)**

[Echocardiography with pharmacological stress: dobutamine or dipyridamole?] Salustri A, et al. **G Ital Cardiol** 1996 Apr;26(4):447–53 (45 ref.) **(Ita)**

[Echocardiographic examinations for mass-screening of cardiovascular abnormalities] Sato H, et al. **Rinsho Byori** 1995 Nov;43(11):1108–12 (11 ref.) (Eng. Abstr.) **(Jpn)**

[The prognostic importance of echocardiography in myocardial infarct] Gazarian GA, et al. **Ter Arkh** 1995; 67(9):83–6 (53 ref.) **(Rus)**

[Echocardiographic indicators of the surgical moment in chronic severe aortic insufficiency] Rosas Munive E. **Arch Inst Cardiol Mex** 1995 Jul–Aug;65(4):359–64 (22 ref.) **(Spa)**

[Diagnostic methods and the prognosis of the heart-hypertension interaction: cardiac echo-Doppler] Sánchez Domínguez J. **Rev Esp Cardiol** 1995;48 Suppl 4:49–56 (32 ref.) (Eng. Abstr.) **(Spa)**

DRUG EFFECTS

Pharmacological stress echocardiography—practical considerations. Schröder K. **Br J Clin Pract Symp Suppl** 1995 Nov;82:6–9 (6 ref.)

INSTRUMENTATION

Three-dimensional reconstruction of coronary arteries with intravascular ultrasound. von Birgelen C, et al. **Herz** 1995 Aug;20(4):277–89 (85 ref.)

-Practical implementation of stress echocardiography—what should be monitored?- Beckmann S, et al. **Herz** 1996 Feb; 21(1):65–70; discussion 64 (18 ref.) **(Ger)**

[Diagnosis of coronary heart disease using echocardiography 3D reconstructions. Diagnosis of global and regional left ventricular function] Buck T, et al. **Herz** 1995 Aug; 20(4):252–62 (57 ref.) (Eng. Abstr.) **(Ger)**

[Three-dimensional reconstruction of heart valves] Flachskampf FA, et al. **Herz** 1995 Aug;20(4):236–42 (21 ref.) (Eng. Abstr.) **(Ger)**

[Trans-thoracic 3D echocardiography reconstruction for left ventricular volume determination] Kupferwasser I, et al. **Herz** 1995 Aug;20(4):243–51 (53 ref.) (Eng. Abstr.) **(Ger)**

[3D echocardiography. Mathematical principles and technical realization] Wollschläger H. **Herz** 1995 Aug; 20(4):225–35 (15 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Three-dimensional echocardiography: methods and clinical application. Flachskampf FA. **Cardiologia** 1996 Jan; 41(1):35–40 (25 ref.)

Left heart catheterization by direct puncture with two-dimensional echocardiographic guidance: a case report. Havranek EP, et al. **Cathet Cardiovasc Diagn** 1995 Aug;35(4):358–61 (19 ref.)

Cardiac imaging techniques: which, when, and why. Thomas JD, et al. **Cleve Clin J Med** 1996 Jul–Aug;63(4):213–20 (35 ref.)

Contrast echocardiography. Nihoyannopoulos P. **Clin Radiol** 1996 Feb;51 Suppl 1:28–30 (12 ref.)

Assessment of myocardial viability by dobutamine echocardiography. Cheirif J, et al. **Coron Artery Dis** 1995 Aug;6(8):600–5 (30 ref.)

Acoustic quantification: a new tool for diagnostic echocardiography. Goens MB, et al. **Curr Opin Cardiol** 1996 Jan;11(1):52–60 (28 ref.)

Recent advances in stress echocardiography. Marwick TH. **Curr Opin Cardiol** 1995 Nov;10(6):619–25 (40 ref.)

Myocardial contrast echocardiography in acute myocardial infarction. Pathophysiological background and clinical applications. Iliceto S, et al. **Eur Heart J** 1996 Mar; 17(3):344–53 (68 ref.)

New technology in echocardiography II: imaging techniques. McDicken WN, et al. **Heart** 1996 Jun;75(6 Suppl 2):9–16 (59 ref.)

Ultrasonography characterization of heart morphology and blood flow of lower vertebrates. Coucelo J, et al. **J Exp Zool** 1996 Jun 1–15;275(2–3):73–82 (19 ref.)

Dobutamine stress echocardiography. Stănescu C. **Rom J Intern Med** 1995 Jan–Jun;33(1–2):3–11 (26 ref.)

[Correlation between transthoracic and transesophageal echocardiography and surgery in mitral stenosis] Khatouri A, et al. **Ann Cardiol Angeiol (Paris)** 1995 Nov;44(9):501–6 (18 ref.) (Eng. Abstr.) **(Fre)**

[Value of dobutamine echocardiography in the detection of coronary disease in heart transplant patient. Groupe de Recherche VACOMED] Derumeaux G, et al. **Arch Mal Coeur Vaiss** 1996 Jun;89(6):687–94 (30 ref.) (Eng. Abstr.) **(Fre)**

[Stress ultrasonography with dobutamine in the diagnosis of coronary disease] Brochet E, et al. **Presse Med** 1995 Dec 9;24(38):1800–5 (25 ref.) (Eng. Abstr.) **(Fre)**

[Provocation tests in echocardiography: stress—dipyridamole—dobutamine (editorial)] Dagianti A. **Cardiologia** 1995 Jul;40(7):451–9 (69 ref.) **(Ita)**

[Use of echocardiographic examination for infective endocarditis] Werner B. **Pediatr Pol** 1995 Aug;70(8):673–8 (29 ref.) (Eng. Abstr.) **(Pol)**

[Stress echocardiography. Rise of a new method] Mathias Júnior W. **Arq Bras Cardiol** 1995 Apr;64(4):401–8 (43 ref.) **(Por)**

[Use of contrast echocardiography in coronary insufficiency] Morcerf FA. **Arq Bras Cardiol** 1995 Apr;64(4):373–82 (66 ref.) **(Por)**

VETERINARY

Echocardiography in dogs. Tiemessen I. **Vet Q** 1995 Apr;17 Suppl 1:S34–5 (1 ref.)

ECHOCARDIOGRAPHY, COLOR DOPPLER see **ECHOCARDIOGRAPHY, DOPPLER, COLOR**

ECHOCARDIOGRAPHY, COLOR FLOW see **ECHOCARDIOGRAPHY, DOPPLER, COLOR**

ECHOCARDIOGRAPHY, CONTINUOUS DOPPLER see **ECHOCARDIOGRAPHY, DOPPLER**

ECHOCARDIOGRAPHY, CONTRAST see **ECHOCARDIOGRAPHY**

ECHOCARDIOGRAPHY, CROSS-SECTIONAL see **ECHOCARDIOGRAPHY**

ECHOCARDIOGRAPHY, DOPPLER

Newer Doppler measures of left ventricular diastolic function. Pai RG, et al. **Clin Cardiol** 1996 Apr;19(4):277–88 (68 ref.)

Assessing the physiologic significance of coronary artery disease: role of Doppler methodology. Schlaifer JD, et al. **Clin Cardiol** 1996 Mar;19(3):172–8 (38 ref.)

Stenotic lesions. Wranne B, et al. **Heart** 1996 Jun;75(6 Suppl 2):36–42 (42 ref.)

Analysis of left ventricular diastolic function. Yamamoto K, et al. **Heart** 1996 Jun;75(6 Suppl 2):27–35 (61 ref.)

A practical guide to assessment of ventricular diastolic function using Doppler echocardiography. Cohen GI, et al. **J Am Coll Cardiol** 1996 Jun;27(7):1753–60 (77 ref.)

Doppler echocardiography in normally functioning replacement heart valves: a literature review. Wang Z, et al. **J Heart Valve Dis** 1995 Nov;4(6):591–614 (70 ref.)

[The importance of measuring pulmonary venous flow using doppler echocardiography] Veselka J. **Vnitr Lek** 1995 Nov; 41(11):787–91 (32 ref.) (Eng. Abstr.) **(Cze)**

[Echocardiography in pulmonary embolism] Augusseau-Richard MP, et al. **Arch Mal Coeur Vaiss** 1995 Nov;88(11 Suppl):1715–22 (30 ref.) (Eng. Abstr.) **(Fre)**

[Pulmonary embolism and thrombi of the right heart] Chapoutot L, et al. **Arch Mal Coeur Vaiss** 1995 Nov;88(11 Suppl):1723–8 (35 ref.) (Eng. Abstr.) **(Fre)**

[Recording of pulmonary venous flow with Doppler echocardiography; normal and pathological aspects] Tribouilloy C, et al. **Arch Mal Coeur Vaiss** 1995 Sep; 88(9):1335–44 (26 ref.) (Eng. Abstr.) **(Fre)**

[Echocardiographic and Doppler markers of heart valve prosthesis dysfunction] Faletra F, et al. **G Ital Cardiol** 1995 Nov;25(11):1513–32 (89 ref.) **(Ita)**

[Hemodynamic evaluation of congenital heart defects by Doppler echocardiography] Martins TC, et al. **Arq Bras Cardiol** 1995 Apr;64(4):409–15 (41 ref.) **(Por)**

INSTRUMENTATION

Intracoronary Doppler flow velocity measurements for the evaluation and treatment of coronary artery disease. Bach RG, et al. **Curr Opin Cardiol** 1995 Jul;10(4):434–42 (35 ref.)

METHODS

Echocardiographic and other noninvasive measurements of cardiac hemodynamics and ventricular function. Pai RG, et al. **Curr Probl Cardiol** 1995 Oct;20(10):681–770 (241 ref.)

New technology in echocardiography I: Doppler techniques. McDicken WN, et al. **Heart** 1996 Jun;75(6 Suppl 2):2–8 (29 ref.)

[Left ventricular diastolic function assessment by transthoracic Doppler echocardiography] Poulsen SH, et al. **Ugeskr Laeger** 1996 Aug 12;158(33):4631–7 (33 ref.) (Eng. Abstr.) **(Dan)**

[Cardiac tissue Doppler. A new noninvasive technic for analysing myocardial wall function (see comments)] Azevedo J, et al. **Rev Port Cardiol** 1995 Sep;14(9):597–606 (34 ref.) Comment in: Rev Port Cardiol 1995 Sep;14(9):595. **(Por)**

[Tissue Doppler echocardiography: a new stage in the study of myocardial function (see comments)] Cardim N, et al. **Rev Port Cardiol** 1995 Sep;14(9):609–18 (57 ref.) (Eng. Abstr.) Comment in: Rev Port Cardiol 1995 Sep;14(9):595. **(Por)**

TRENDS

Recent progress in quantitative echocardiography. Flachskampf F. **Curr Opin Cardiol** 1995 Nov;10(6):634–9 (38 ref.)

Echocardiography in acute myocardial infarction: today and tomorrow. Firoozan S, et al. **Indian Heart J** 1996 Jan–Feb; 48(1):23–32 (63 ref.)

VETERINARY

[Doppler echocardiography of heart valve defects in the dog] Schneider M, et al. **Tierarztl Prax** 1996 Apr;24(2):177–89 (19 ref.) (Eng. Abstr.) **(Ger)**

ECHOCARDIOGRAPHY, DOPPLER, COLOR

Echocardiography assessment of left ventricular function in the critically ill. McLean AS. **Anaesth Intensive Care** 1996 Feb;24(1):60–5 (40 ref.)

Current status of flow convergence for clinical applications: is it a leaning tower of "PISA"? Simpson IA, et al. **J Am Coll Cardiol** 1996 Feb;27(2):504–9 (51 ref.)

METHODS

[Ultrasonic angiography: principles and clinical use] Skjoldbye B, et al. **Ugeskr Laeger** 1995 Oct 2; 157(40):5530–3 (8 ref.) (Eng. Abstr.) **(Dan)**

ECHOCARDIOGRAPHY, M-MODE see **ECHOCARDIOGRAPHY**

ECHOCARDIOGRAPHY, TRANSESOPHAGEAL

Transoesophageal echocardiography in congenital heart disease. Sutherland GR, et al. **Acta Paediatr Suppl** 1995 Aug;410:15–22 (39 ref.)

Role of echocardiography in perioperative management of patients undergoing open heart surgery. Joffe II, et al. **Am Heart J** 1996 Jan;131(1):162–76 (130 ref.)

Azygos vein aneurysm: contribution of transesophageal echography. Léna H, et al. **Ann Thorac Surg** 1996 Apr; 61(4):1253–5 (7 ref.)

Intraoperative transoesophageal echocardiography for implantation of a pulsatile left ventricular assist device. George SJ, et al. **Br J Anaesth** 1995 Dec;75(6):794–7 (9 ref.)

An introduction to transoesophageal echocardiography: I. Basic principles. Béique F, et al. **Can J Anaesth** 1996 Mar; 43(3):252–77 (73 ref.)

An introduction to transoesophageal echocardiography: II. Clinical applications. Oxorn D, et al. **Can J Anaesth** 1996 Mar;43(3):278–94 (122 ref.)

Serial changes of left atrial thrombus in mitral stenosis: transesophageal echocardiographic studies in candidates for balloon mitral commissurotomy. Hase M, et al. **Can J Cardiol** 1996 Mar;12(3):278–84 (28 ref.)

Transesophageal echocardiography in diagnosing cardioembolic stroke. Husain AM, et al. **Clin Cardiol** 1995 Dec;18(12):705–8 (14 ref.)

The role of prolonged thrombolytic infusions and transesophageal echocardiography in thrombosed prosthetic heart valves: case report and review of the literature. Puleo JA, et al. **Clin Cardiol** 1995 Nov; 18(11):679–84 (50 ref.)

A rare complication of aortic valve endocarditis: diagnosis with transesophageal echocardiography. Winslow TM, et al. **J Am Soc Echocardiogr** 1995 Jul–Aug;8(4):546–50 (25 ref.)

Intraoperative transesophageal echocardiographic evaluation of mitral regurgitation. Ammar T, et al. **J Cardiothorac Vasc Anesth** 1996 Apr;10(3):397–405 (44 ref.)

Transesophageal echocardiography in critical care units: Henry Ford Hospital experience and review of the literature. Alam M. **Prog Cardiovasc Dis** 1996 Jan–Feb; 38(4):315–28 (22 ref.)

Transesophageal echocardiography-guided approach to cardioversion of atrial fibrillation. Leung DY, et al. **Prog Cardiovasc Dis** 1996 Jul–Aug;39(1):21–32 (67 ref.)

[Correlation between transthoracic and transesophageal echocardiography and surgery in mitral stenosis] Khatouri A, et al. **Ann Cardiol Angeiol (Paris)** 1995 Nov;44(9):501–6 (18 ref.) (Eng. Abstr.) **(Fre)**

[Post-traumatic dissection of the aortic isthmus with favorable outcome without surgical treatment. Value of transesophageal echocardiography] Bourgeois M, et al. **Ann Fr Anesth Reanim** 1995;14(2):218–21 (16 ref.) (Eng. Abstr.) **(Fre)**

[Morphological study by transesophageal echocardiography and clinical aspects of ruptured chordae tendineae in the elderly] Benhalima B, et al. **Arch Mal Coeur Vaiss** 1995 Mar;88(3):345–52 (29 ref.) (Eng. Abstr.) **(Fre)**

[Spontaneous intracardiac contrast and embolic risk] Lardoux H, et al. **Arch Mal Coeur Vaiss** 1996 Apr;89(4):451–7 (33 ref.) (Eng. Abstr.) **(Fre)**

[Value of transesophageal echocardiography in post-infarction septal ruptures] Maillier B, et al. **Arch Mal Coeur Vaiss** 1996 Jun;89(6):695–702 (27 ref.) (Eng. Abstr.) **(Fre)**

[Intensive medical monitoring with transesophageal echocardiography in fulminant pulmonary embolism] Bruch C, et al. **Dtsch Med Wochenschr** 1996 Jun 21; 121(25–26):829–33 (23 ref.) (Eng. Abstr.) **(Ger)**

[Transesophageal echocardiography in the operating room: new applications] Gilon D, et al. **Harefuah** 1995 Dec 15; 129(12):575–9 (25 ref.) **(Heb)**

[The physiopathology of the left atrial appendage. The contribution of transesophageal echocardiography] Mele D. **Cardiologia** 1996 Jun;41(6):515–26 (62 ref.) **(Ita)**

[Transesophageal echocardiography. Indications and clinical impact] Campos Filho O. **Arq Bras Cardiol** 1995 Apr; 64(4):383–9 (47 ref.) **(Por)**

METHODS

Usefulness of multiplane transesophageal echocardiography in differentiating left atrial appendage thrombus from pectinate muscles. Orsinelli DA, et al. **Am Heart J** 1996 Mar;131(3):622–3 (8 ref.)

Pacemaker lead infection: detection by multiplane transesophageal echocardiography. Tighe DA, et al. **Am Heart J** 1996 Mar;131(3):616–8 (8 ref.)

[The main indications for transesophageal echocardiography] Lesbre JP. **Ann Cardiol Angeiol (Paris)** 1995 Dec; 44(10):547–51 (21 ref.) (Eng. Abstr.) **(Fre)**

ECHOCARDIOGRAPHY, TWO-DIMENSIONAL see **ECHOCARDIOGRAPHY**

ECHOCARDIOGRAPHY, TWO-DIMENSIONAL DOPPLER see **ECHOCARDIOGRAPHY, DOPPLER**

ECHOENCEPHALOGRAPHY

[Investigation of cerebrovascular reactivity using transcranial doppler ultrasonography] Sapieja W. **Neurol Neurochir Pol** 1995 Jul–Aug;29(4):591–5 (24 ref.) (Eng. Abstr.) **(Pol)**

ECHOGRAPHY see **ULTRASONOGRAPHY**

ECHOLOCATION

PHYSIOLOGY

Representation of perceptual dimensions of insect prey during terminal pursuit by echolocating bats. Simmons JA, et al. **Biol Bull** 1996 Aug;191(1):109–21 (56 ref.)

ECHOTOMOGRAPHY, COMPUTER see **ULTRASONOGRAPHY**

ECK FISTULA see **PORTACAVAL SHUNT, SURGICAL**

ECLAMPSIA

see related
PRE-ECLAMPSIA

Postpartum toxemia: hypertension, edema, proteinuria and unresponsiveness in an unknown female. Brady WJ, et al. **J Emerg Med** 1995 Sep–Oct;13(5):643–8 (27 ref.)

DIET THERAPY

Possible dietary measures in the prevention of pre-eclampsia and eclampsia. Baker PN. **Baillieres Clin Obstet Gynaecol** 1995 Sep;9(3):497–507 (73 ref.)

DRUG THERAPY

Magnesium sulphate: the time of reckoning [see comments] Robson SC. **Br J Obstet Gynaecol** 1996 Feb;103(2):99–102 (30 ref.) Comment in: Br J Obstet Gynaecol 1996 Feb;103(2):vii–viii.

ETIOLOGY

–Obstetric prognosis after pre-eclampsia, eclampsia or HELLP syndrome- Niesert S. **Geburtshilfe Frauenheilkd** 1996 Feb;56(2):93–6 (18 ref.) (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

Established role of magnesium sulfate as prophylactic anticonvulsive agent in preeclampsia/eclampsia. Skajaa K. **Acta Obstet Gynecol Scand** 1996 Apr;75(4):313–5 (18 ref.)

ECMO see **EXTRACORPOREAL MEMBRANE OXYGENATION**

ECOLOGICAL BIAS see **BIAS (EPIDEMIOLOGY)**

ECOLOGICAL MONITORING see **ENVIRONMENTAL MONITORING**

ECOLOGICAL SYSTEMS, CLOSED

see related
WASTE MANAGEMENT

ECOLOGY

Environmental paradigms: moving toward an ecocentric perspective. Kleffel D. **ANS Adv Nurs Sci** 1996 Jun; 18(4):1–10 (38 ref.)

Sexually transmitted diseases in animals: ecological and evolutionary implications. Lockhart AB, et al. **Biol Rev Camb Philos Soc** 1996 Aug;71(3):415–71 (302 ref.)

Heat-shock proteins as biomarkers of pollution. de Pomerai D. **Hum Exp Toxicol** 1996 Apr;15(4):279–85 (70 ref.)

Endectocidal drugs: ecological risks and counter-measures. Herd R. **Int J Parasitol** 1995 Aug;25(8):875–85 (82 ref.)

Symposium introductory remarks: "protistan molecular ecology and systematics". Caron DA. **J Eukaryot Microbiol** 1996 Mar–Apr;43(2):87–8 (22 ref.)

The planctomycetes: emerging models for microbial ecology, evolution and cell biology. Fuerst JA. **Microbiology** 1995 Jul;141 (Pt 7):1493–506 (94 ref.)

Introduction: ecological impact of parasitism on wildlife host populations. Grenfell BT, et al. **Parasitology** 1995;111 Suppl:S3–14 (185 ref.)

[Ecology and thermal parks in the context of the environment. Psychological and possible therapeutic aspects: trends in medicine] Grossi F, et al. **Clin Ter** 1995 Dec;146(12):781–92 (32 ref.) (Eng. Abstr.) **(Ita)**

[Biological monitoring with regard to parasites] Lonc E, et al. **Wiad Parazytol** 1996;42(1):29–35 (38 ref.) (Eng. Abstr.) **(Pol)**

[Ecology, adaptation and biorhythms] Agadzhanian NA, et al. **Aviakosm Ekolog Med** 1995;29(3):16–9 (17 ref.) (Eng. Abstr.) **(Rus)**

[The contribution of space biology and medicine to the solution of ecological problems] Grigor'ev AI, et al. **Aviakosm Ekolog Med** 1995;29(3):21–4 (14 ref.) (Eng. Abstr.) **(Rus)**

[The general concepts of development and the principle of sustainable development] Romanov IuA. **Aviakosm Ekolog Med** 1995;29(3):6–16 (44 ref.) (Eng. Abstr.) **(Rus)**

[The sequelae of the Kyshtym and Chernobyl accidents for hydrobionts] Polikarpov GG, et al. **Radiats Biol Radioecol** 1995 Jul–Aug;35(4):536–49 (79 ref.) (Eng. Abstr.) **(Rus)**

ECONOMETRIC MODELS see **MODELS, ECONOMETRIC**

ECONOMIC COMPETITION

see related
ANTITRUST LAWS

Implications of current procompetitive approaches on EDs. Weil TP. **Am J Emerg Med** 1996 Jan;14(1):74–8 (24 ref.)

National health expenditure limits: the case for a global budget process. Bishop CE, et al. **Milbank Q** 1996; 74(3):361–76 (17 ref.)

ORGANIZATION & ADMINISTRATION

Local markets and systems: hospital consolidations in metropolitan areas. Luke RD, et al. **Health Serv Res** 1995 Oct;30(4):555–75 (23 ref.)

ECONOMIC MODELS see **MODELS, ECONOMIC**

ECONOMIC VALUE OF LIFE

Health policy approaches to measuring and valuing human life: conceptual and ethical issues [see comments] Morrow RH, et al. **Am J Public Health** 1995 Oct;85(10):1356–60 (20 ref.) Comment in: Am J Public Health 1995 Oct;85(10):1345–6.

ECONOMICS

see related
EUROPEAN ECONOMIC COMMUNITY
MODELS, ECONOMIC
SOCIOECONOMIC FACTORS

Achieving and sustaining full employment. Rosen SM. **J Public Health Policy** 1995;16(3):286–303 (28 ref.)

The role of nutrition in economic development. Martorell R. **Nutr Rev** 1996 Apr;54(4 Pt 2):S66–71 (35 ref.)

ECONOMICS, HOSPITAL

see related
FINANCIAL MANAGEMENT, HOSPITAL

ECONOMICS, MEDICAL

Health economics as an aspect of health outcome: basic principles and application in rheumatoid arthritis [see comments] Lambert CM, et al. **Br J Rheumatol** 1995 Aug; 34(8):774–80 (49 ref.) Comment in: Br J Rheumatol 1996 May;35(5):494.

Introduction to clinical economics: assessment of cancer therapies. Schulman KA, et al. **Monogr Natl Cancer Inst** 1995;(19):1–9 (59 ref.)

STATISTICS & NUMERICAL DATA

Perspectives in health economics [editorial] Phelps CE. **Health Econ** 1995 Sep–Oct;4(5):335–53 (44 ref.)

ECONOMICS, PHARMACEUTICAL

see related
DRUG COSTS

Overview of pharmacoeconomics and pharmaceutical outcomes evaluations. Reeder CE. **Am J Health Syst Pharm** 1995 Oct 1;52(19 Suppl 4):S5–8 (4 ref.)

When drug treatment in the elderly is not cost effective. An ethical dilemma in an environment of healthcare rationing. Chadwick R, et al. **Drugs Aging** 1995 Dec;7(6):416–9 (25 ref.)

Pharmacoeconomic issues in the treatment of depression. Saklad SR. **Pharmacotherapy** 1995 Nov–Dec;15(6 Pt 2):76S–83S (24 ref.)

LEGISLATION & JURISPRUDENCE

Quo vademus? A review of the regulatory environment. Huss H, et al. **Qual Assur** 1995 Sep;4(3):181–6 (6 ref.)

ORGANIZATION & ADMINISTRATION

Why is the pharmaceutical industry investing increasing amounts in health economic evaluations? Andersson F. **Int J Technol Assess Health Care** 1995 Fall;11(4):750–61 (40 ref.)

TRENDS

Quo vademus? A review of the regulatory environment. Huss H, et al. **Qual Assur** 1995 Sep;4(3):181–6 (6 ref.)

ECOSYSTEM

Plants and animals as biomonitors of heavy metal level in the aquatic ecosystem of the river Danube. Oertel N. **Arch Toxicol Suppl** 1996;18:404–16 (23 ref.)

Biodiversity. Managing nature when there are no 'ill winds'. Curnutt JL, et al. **Curr Biol** 1995 Jul 1;5(7):713–5 (7 ref.)

Design and construction of model stream ecosystems. Rodgers JH Jr, et al. **Ecotoxicol Environ Saf** 1996 Feb; 33(1):30–7 (21 ref.)

Pesticides—how research has succeeded and failed to translate science into policy: endocrinological effects on wildlife. Colborn T. **Environ Health Perspect** 1995 Sep;103 Suppl 6:81–5 (55 ref.)

Commentary on effects of anthropogenic and natural organic chemicals on development, swimming behavior, and reproduction of Daphnia, a key member of aquatic ecosystems. Dodson SI, et al. **Environ Health Perspect** 1995 May;103 Suppl 4:7–11 (60 ref.)

The emergence of "emerging diseases": a lesson in holistic epidemiology. Kilbourne ED. **Mt Sinai J Med** 1996 May–Sep;63(3–4):159–66 (31 ref.)

Lymphocytes in a model ecosystem. Freitas AA. **Res Immunol** 1995 May–Jun;146(4–5):225–33 (54 ref.)

Toxicity testing with communities: microcosms, mesocosms, and whole-system manipulations. Cairns J Jr, et al. **Rev Environ Contam Toxicol** 1996;147:45–69 (97 ref.)

[Causes and consequences of an unbalanced vaginal ecosystem] Kunz J. **Schweiz Rundsch Med Prax** 1995 Nov 28;84(48):1405–15 (79 ref.) (Eng. Abstr.) **(Ger)**

ECT (PSYCHOTHERAPY) see **ELECTROCONVULSIVE THERAPY**

ECTO-5'-NUCLEOTIDASE see **5'-NUCLEOTIDASE**

ECTODERM

CYTOLOGY

Genetic mechanisms of early neurogenesis in Drosophila melanogaster. Campos-Ortega JA. **Mol Neurobiol** 1995 Apr–Jun;10(2–3):75–89 (97 ref.)

PHYSIOLOGY

How many signals does it take? Venkatesh TV, et al. **Bioessays** 1995 Sep;17(9):754–7 (31 ref.)

Regulatory interactions during early neurogenesis in Drosophila. Hassan B, et al. **Dev Genet** 1996;18(1):18–27 (88 ref.)

ECTODERMAL DEFECT, CONGENITAL see **ECTODERMAL DYSPLASIA**

ECTODERMAL DYSPLASIA

"New" ectodermal dysplasia with mental retardation and syndactyly. Ilyina HG, et al. **Am J Med Genet** 1995 Sep 25;58(4):345–7 (15 ref.)

The EEC syndrome: a literature study. Roelfsema NM, et al. **Clin Dysmorphol** 1996 Apr;5(2):115–27 (124 ref.)

CHEMICALLY INDUCED

Aplasia cutis congenita after exposure to methimazole: a causal relationship? Vogt T, et al. **Br J Dermatol** 1995 Dec; 133(6):994–6 (23 ref.)

DIAGNOSIS

Absent meibomian glands: a marker for EEC syndrome. Bonnar E, et al. **Eye** 1996;10 (Pt 3):355–61 (34 ref.)

[Epilepsy and psychomotor retardation in a child with aplasia cutis and brachydactyly (Adams-Oliver syndrome)] Verdú Pérez A, et al. **An Esp Pediatr** 1996 Mar;44(3):289–91 (15 ref.) **(Spa)**

GENETICS

Linkage of an American pedigree with palmoplantar keratoderma and malignancy (palmoplantar ectodermal dysplasia type III) to 17q24. Literature survey and proposed updated classification of the keratodermas. Stevens HP, et al. **Arch Dermatol** 1996 Jun;132(6):640–51 (143 ref.)

[Schimmelpenning-Feuerstein-Mims syndrome and its neurologic manifestations. 6 personal cases and review of the literature] Fritzsch C, et al. **Klin Padiatr** 1995 Sep–Oct; 207(5):288–97 (40 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

Odontotrichodysplasia: a case report with a review of conditions combining ectodermal dysplasia (subgroup 1–2) with skin manifestations. Yadav TP, et al. **J Dermatol** 1995 Aug;22(8):606–10 (14 ref.)

[The Hay-Wells syndrome, its incidence in Spain and a review of the literature] Martínez-Frías ML, et al. **An Esp Pediatr** 1996 Jul;45(1):101–4 (24 ref.) **(Spa)**

PHYSIOPATHOLOGY

[Physical exercise and increase in arterial pressure and temperature in a female heterozygote for anhidrotic ectodermal dysplasia] Bandinelli G, et al. **Ann Ital Med Int** 1996 Jan–Mar;11(1):59–61 (12 ref.) (Eng. Abstr.) **(Ita)**

ECTOHORMONES see **PHEROMONES**

ECTOPARASITIC INFESTATIONS

VETERINARY

Resistance and the control of sheep ectoparasites. Levot GW. **Int J Parasitol** 1995 Nov;25(11):1355–62 (35 ref.)

The cat, the flea, and pesticides. Logas DB. **Vet Clin North Am Small Anim Pract** 1995 Jul;25(4):801–11 (60 ref.)

ECTOPIA CORDIS see **HEART DEFECTS, CONGENITAL**

ECTOPIC ACTH SYNDROME see **ACTH SYNDROME, ECTOPIC**

ECTOPIC ATRIAL TACHYCARDIA see **TACHYCARDIA, ECTOPIC ATRIAL**

ECTOPIC HORMONE SYNDROMES see **NEOPLASTIC ENDOCRINE-LIKE SYNDROMES**

ECTOPIC JUNCTIONAL TACHYCARDIA see **TACHYCARDIA, ECTOPIC JUNCTIONAL**

ECTOPIC TISSUE see **CHORISTOMA**

ECTROMELIA

COMPLICATIONS

[Thrombocytopenia with absence of the radius in a 24-year-old woman] Fortuna AM, et al. **Sangre (Barc)** 1995 Jun;40(3):223–5 (13 ref.) (Eng. Abstr.) **(Spa)**

ECTROPION

THERAPY

Low-dose methotrexate as an adjunctive therapy with surgery for ectropion complicating dermatomyositis. Abernethy ML, et al. **Dermatology** 1996;192(2):153–5 (14 ref.)

ECZEMA

Eczematous dermatitis: a practical review. Zug KA, et al. **Am Fam Physician** 1996 Sep 15;54(4):1243–50, 1253–4 (20 ref.)

Neuropeptides, nerve growth factor and eczema. Giannetti A. **Australas J Dermatol** 1996 May;37 Suppl 1:S1–3 (47 ref.)

CLASSIFICATION

Development of childhood eczema and its classification. Oranje AP. **Pediatr Allergy Immunol** 1995;6 Suppl 7:31–5 (26 ref.)

DIAGNOSIS

Metastatic squamous cell carcinoma of the hand and review of the literature. Foley SJ, et al. **J R Army Med Corps** 1995 Jun;141(2):102–4 (8 ref.)

ETIOLOGY

Chronic finger dermatitis after trauma. Diagnosis: posttraumatic eczema with allergic contact dermatitis to neomycin, bacitracin, and topical corticosteroids. Sherertz EF. **Arch Dermatol** 1996 Apr;132(4):461, 464 (11 ref.)

[Contact dermatitis following cardiac pacemaker implantation] Moïni C, et al. **Arch Mal Coeur Vaiss** 1996 Feb;89(2):253–6 (12 ref.) (Eng. Abstr.) **(Fre)**

ECZEMA, ATOPIC see **DERMATITIS, ATOPIC**

ECZEMA, CONTACT see **DERMATITIS, CONTACT**

ECZEMA HERPETICUM see **KAPOSI'S VARICELLIFORM ERUPTION**

ECZEMA, INFANTILE see **DERMATITIS, ATOPIC**

ECZEMA VACCINATUM see **KAPOSI'S VARICELLIFORM ERUPTION**

EDATHAMIL see **EDETIC ACID**

EDEMA

see related
ANGIONEUROTIC EDEMA
BRAIN EDEMA
HYDROPS FETALIS
LYMPHEDEMA
PAPILLEDEMA
PULMONARY EDEMA

[Hydrops of the gallbladder] Kohno M, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):448–50 (12 ref.) **(Jpn)**

COMPLICATIONS

Massive edema of the ovary associated with androgenic manifestations. Siller BS, et al. **South Med J** 1995 Nov; 88(11):1153–5 (45 ref.)

DRUG THERAPY

The emerging roles of topical non-steroidal anti-inflammatory agents in ophthalmology. Koay P. **Br J Ophthalmol** 1996 May;80(5):480–5 (98 ref.)

Cellular basis of inflammation, edema and the activity of Daflon 500 mg. Friesenecker B, et al. **Int J Microcirc Clin Exp** 1995;15 Suppl 1:17–21 (44 ref.)

Does it make sense to administer albumin to the patient with nephrotic oedema? [editorial] Dorhout Mees EJ. **Nephrol Dial Transplant** 1996 Jul;11(7):1224–6 (17 ref.)

ETIOLOGY

Idiopathic edema. Pathogenesis, clinical features, and treatment. Streeten DH. **Endocrinol Metab Clin North Am** 1995 Sep;24(3):531–47 (22 ref.)

Perioperative fluid management for thoracic surgery: the puzzle of postpneumonectomy pulmonary edema. Slinger PD. **J Cardiothorac Vasc Anesth** 1995 Aug;9(4):442–51 (52 ref.)

Three edemas. Williams AV Jr, et al. **J S C Med Assoc** 1996 Jul;92(7):306–10 (25 ref.)

Purtscher's retinopathy associated with mandibular fracture: a case report. Peled M, et al. **J Trauma** 1996 Jan;40(1):141–3 (11 ref.)

Venous obstruction due to a distended urinary bladder. Evans JM, et al. **Mayo Clin Proc** 1995 Nov;70(11):1077–9 (17 ref.)

Facial edema and giant cell arteritis. Plantin P, et al. **Rev Rhum Engl Ed** 1996 Feb;63(2):145–7 (13 ref.)

IMMUNOLOGY

Influence of dynorphin A antibodies on the formation of edema and cell changes in spinal cord trauma. Sharma HS, et al. **Prog Brain Res** 1995;104:401–16 (95 ref.)

URINE

Renal sodium excretion and edematous disorders. Martin PY, et al. **Endocrinol Metab Clin North Am** 1995 Sep; 24(3):459–79 (114 ref.)

EDEMA, CARDIAC

PHYSIOPATHOLOGY

Effects of edema on systolic and diastolic function in vivo. Spotnitz HM. **J Card Surg** 1995 Jul;10(4 Suppl):454–9 (27 ref.)

EDEMA-PROTEINURIA-HYPERTENSION GESTOSIS see **GESTOSIS, EPH**

EDETATES see **EDETIC ACID**

EDETIC ACID

ANALOGS & DERIVATIVES

Mangafodipir trisodium injection (Mn-DPDP). A contrast agent for abdominal MR imaging. Rofsky NM, et al. **Magn Reson Imaging Clin N Am** 1996 Feb;4(1):73–85 (49 ref.)

THERAPEUTIC USE

[A wine pitcher, cause of lead poisoning] Jouglard J, et al. **Presse Med** 1996 Feb 17;25(6):243–6 (8 ref.) (Eng. Abstr.) **(Fre)**

EDTA see **EDETIC ACID**

EDUCATION

see related
LEARNING
RESEARCH SUPPORT
STUDENTS
TEACHING
TRAINING SUPPORT

Education, homeostasis, and longevity. Timiras PS. **Exp Gerontol** 1995 May-Aug;30(3–4):189–98 (41 ref.)

ORGANIZATION & ADMINISTRATION

Developing a workshop to address unresolved research issues. Brandt BF. **J Toxicol Environ Health** 1996 Aug 30; 48(6):ix–xii (6 ref.)

EDUCATION, COMPETENCY-BASED see **COMPETENCY-BASED EDUCATION**

EDUCATION, DENTAL

TRENDS

Global trends in oral and maxillofacial radiology education. Rohlin M, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1995 Nov;80(5):517–26 (52 ref.)

EDUCATION, DENTAL, GRADUATE

Accreditation of postdoctoral general dentistry programs. Glassman P. **J Am Coll Dent** 1995 Fall;62(3):27–30 (33 ref.)

EDUCATION, GRADUATE

STANDARDS

Consumer concerns about modern technology in agriculture: considerations for undergraduate and graduate teaching. Weber GM, et al. **J Anim Sci** 1995 Sep;73(9):2727–32 (16 ref.)

EDUCATION, HEALTH see **HEALTH EDUCATION**

EDUCATION, MEDICAL

Primary care of lesbian and gay patients: educating ourselves and our students [see comments] Harrison AE. **Fam Med** 1996 Jan;28(1):10–23 (86 ref.) Comment in: Fam Med 1996 Jan;28(1):57–8.

[Clinical ethics education in the United States of America] Asai A. **Nippon Naika Gakkai Zasshi** 1995 Aug 10; 84(8):1344–9 (11 ref.) **(Jpn)**

LEGISLATION & JURISPRUDENCE

Sexual harassment in medical education: a review of the literature with comments from the law. Nora LM. **Acad Med** 1996 Jan;71(1 Suppl):S113–8 (54 ref.)

METHODS

Medical education about alcohol: review of its role and effectiveness. Walsh RA. **Alcohol Alcohol** 1995 Nov; 30(6):689–702 (126 ref.)

Multidisciplinarity and multimedia in quality of care—education. Heyrman J. **Eur J Cancer** 1995;31A Suppl 6:S11–4 (6 ref.)

Educational challenges. Jaffe CC, et al. **Radiol Clin North Am** 1996 May;34(3):629–46 (13 ref.)

ORGANIZATION & ADMINISTRATION

Medical student education in managed care settings: beyond HMOs [see comments] Veloski J, et al. **JAMA** 1996 Sep 4;276(9):667–71 (58 ref.) Comment in: JAMA 1996 Sep 4;276(9):725–7.

The influence of surgical training on the practice of surgery. Are changes necessary? Stone MD, et al. **Surg Clin North Am** 1996 Feb;76(1):1–10 (33 ref.)

Controversies in community based education. Ogunbode O. **West Afr J Med** 1996 Jan-Mar;15(1):18–23 (15 ref.)

[On the need for analysis of the occupational health education system] Boczkowski A, et al. **Med Pr** 1995;46(4):415–26 (23 ref.) (Eng. Abstr.) **(Pol)**

STANDARDS

[Problem-oriented education, problem-based learning and activating teaching methods] Nikkarinen T, et al. **Duodecim** 1994;110(16):1548–55 (23 ref.) **(Fin)**

TRENDS

The future of gross anatomy teaching. Malamed S, et al. **Clin Anat** 1995;8(4):294–6 (13 ref.)

EDUCATION, MEDICAL, CONTINUING

Alcohol risk assessment and intervention for family physicians. Project of the College of Family Physicians of Canada. Peters C, et al. **Can Fam Physician** 1996 Apr; 42:681–9 (31 ref.)

Audit of continuing medical education for pathologists: strategies and implications. du Boulay C. **J Clin Pathol** 1996 Feb;49(2):100–1 (16 ref.)

On the need for evidence-based medicine. Sackett DL, et al. **J Public Health Med** 1995 Sep;17(3):330–4 (22 ref.)

[Does learning new knowledge and discarding old knowledge go too slowly?] Olesen F. **Nord Med** 1996 Apr; 111(4):119–22 (15 ref.) **(Dan)**

ECONOMICS

Pharmaceutical industry support for continuing medical education programs: a review of current ethical guidelines. Rosner F. **Mt Sinai J Med** 1995 Nov;62(6):427–30 (21 ref.)

METHODS

How should subspecialists be trained for clinical careers? McFadden D. **Am J Med** 1996 Jul;101(1):1–4 (12 ref.)

Self directed learning. Towle A, et al. **Arch Dis Child** 1996 Apr;74(4):357–9 (9 ref.)

Medical education by satellite: the EuroTransMed experience. Young HL. **J Audiov Media Med** 1995 Jun; 18(2):75–8 (0 ref.)

Satellite-delivered continuing medical education in Europe. Geraghty JG, et al. **Postgrad Med J** 1996 Apr; 72(846):218–20 (0 ref.)

STANDARDS

Drug companies and continuing medical education. Bickell NA. **J Gen Intern Med** 1995 Jul;10(7):392–4 (9 ref.)

Pharmaceutical industry support for continuing medical education programs: a review of current ethical guidelines. Rosner F. **Mt Sinai J Med** 1995 Nov;62(6):427–30 (21 ref.)

[Quality assessment of continuing medical education] Lipp M. **Anaesthesist** 1996 Apr;45(4):363–71 (27 ref.) (Eng. Abstr.) **(Ger)**

EDUCATION, MEDICAL, GRADUATE

Postgraduate training for rural family practice. Goals and opportunities. Rourke JT. **Can Fam Physician** 1996 Jun; 42:1133–8 (48 ref.)

Review your reading: how to prepare for the CRQ paper. Milne P. **Practitioner** 1996 Feb;240(1559):96–8 (5 ref.)

[Strategy for getting many experts in clinical pathology] Ohkubo A. **Rinsho Byori** 1995 Oct;43(10):1010–3 (0 ref.) (Eng. Abstr.) **(Jpn)**

[Learning clinical medicine] Lifshitz A. **Gac Med Mex** 1995 Sep-Dec;131(5–6):571–6 (15 ref.) (Eng. Abstr.) **(Spa)**

METHODS

Teaching and learning in ambulatory care settings: a thematic review of the literature. Irby DM. **Acad Med** 1995 Oct; 70(10):898–931 (152 ref.)

New rules for the game: interdisciplinary education for health professionals [see comments] Larson EL. **Nurs Outlook** 1995 Jul-Aug;43(4):180–5 (32 ref.) Comment in: Nurs Outlook 1996 Jan-Feb;44(1):41.

STANDARDS

Basic surgical training. 4: American and British scenes compared. Ger R. **Clin Anat** 1996;9(3):173–4 (2 ref.)

Basic surgical training. 1: Postgraduate surgical examinations in the UK and Ireland. Raftery AT. **Clin Anat** 1996; 9(3):163–6 (1 ref.)

TRENDS

The life so short, the craft so hard to learn: a model for post-basic education in palliative care. Sheldon F, et al. **Palliat Med** 1996 Apr;10(2):99–104 (21 ref.)

EDUCATION, MEDICAL, UNDERGRADUATE

Why literature and medicine? McLellan MF, et al. **Lancet** 1996 Jul 13;348(9020):109–11 (38 ref.)

HISTORY

Evolution of undergraduate education in ambulatory settings: historical models. Greenberg LW. **Pharos** 1995 Fall; 58(4):13–7 (20 ref.)

METHODS

Teaching and learning in ambulatory care settings: a thematic review of the literature. Irby DM. **Acad Med** 1995 Oct; 70(10):898–931 (152 ref.)

Narrowing the gap between rhetoric and the reality of medical ethics. Silverman DR. **Acad Med** 1996 Mar; 71(3):227–37 (109 ref.)

Basic surgical training. 2: Interactions with the undergraduate medical curriculum. Willan P. **Clin Anat** 1996;9(3):167–70 (1 ref.)

Teaching the social sciences to undergraduate medical students. Benbassat J. **Isr J Med Sci** 1996 Mar-Apr; 32(3–4):217–21 (40 ref.)

STANDARDS

Basic surgical training. 3: A view from Ireland. Monkhouse S. **Clin Anat** 1996;9(3):171–2 (0 ref.)

EDUCATION, NURSING

Moral competency. Cassidy VR. **Annu Rev Nurs Res** 1996; 14:181–204 (94 ref.)

The evolution and status of genetics education in nursing in the United States 1983–1995. Anderson GW. **Image J Nurs Sch** 1996 Summer;28(2):101–6 (40 ref.)

The role of the nurse in patient-focused care: models of competence and implications for education and training. Burchell H, et al. **Int J Nurs Stud** 1996 Feb;33(1):67–75 (42 ref.)

A critique of multiculturalism in heath care: the challenge for nurse education. Culley L. **J Adv Nurs** 1996 Mar; 23(3):564–70 (42 ref.)

The theory/practice 'gap': taking issue with the issue. Rafferty AM, et al. **J Adv Nurs** 1996 Apr;23(4):685–91 (44 ref.)

Past-present-future messages for nursing leadership. Kelley LS. **J Prof Nurs** 1996 Mar-Apr;12(2):76–85 (33 ref.)

EDUCATION, NURSING

Informing the nursing professions about IT. Barnett DE. **Medinfo** 1995;8 Pt 2:1316–20 (7 ref.)

HISTORY

A historical decline of educational perioperative clinical experiences. Wagner VD, et al. **AORN J** 1995 Nov; 62(5):771–2, 775–80, 782 (46 ref.)

METHODS

The impact of violence in the health care setting upon nursing education. Whitley GG, et al. **J Nurs Educ** 1996 May; 35(5):211–8 (46 ref.)

New rules for the game: interdisciplinary education for health professionals [see comments] Larson EL. **Nurs Outlook** 1995 Jul–Aug;43(4):180–5 (32 ref.) Comment in: Nurs Outlook 1996 Jan–Feb;44(1):41.

Focus on quantitative methods. Determining cut–off scores. Goodwin LD. **Res Nurs Health** 1996 Jun;19(3):249–56 (60 ref.)

ORGANIZATION & ADMINISTRATION

A sharing in critical thought by nursing faculty. Hendricks–Thomas J, et al. **J Adv Nurs** 1995 Sep; 22(3):594–9 (35 ref.)

Improving nursing practice, education, and research. Fagin CM. **J Nurs Adm** 1996 Mar;26(3):30–7 (12 ref.)

Heterosexism in nursing education. Gray DP, et al. **J Nurs Educ** 1996 May;35(5):204–10 (12 ref.)

Who is our consumer? Shaping nursing programs to meet emerging needs. Norbeck JS. **J Prof Nurs** 1995 Nov–Dec; 11(6):325–31 (9 ref.)

Transformation of the nursing workforce. Aiken LH. **Nurs Outlook** 1995 Sep–Oct;43(5):201–9 (36 ref.)

EDUCATION, NURSING, BACCALAUREATE

METHODS

Inquiry based learning, nursing student attitudes and the HIV patient. Cerny JE, et al. **J Nurs Educ** 1996 May; 35(5):219–22 (24 ref.)

Journal writing as a mode of thinking for RN–BSN students: a leveled approach to learning to listen to self and others. Hodges HF. **J Nurs Educ** 1996 Mar;35(3):137–41 (20 ref.)

ORGANIZATION & ADMINISTRATION

Oncology nursing education. Workman ML. **Annu Rev Nurs Res** 1996;14:167–78 (52 ref.)

The social body and the biomechanical body: can they coexist in nurse education? Brown C, et al. **J Adv Nurs** 1996 Apr; 23(4):651–6 (36 ref.)

A research development program for minority honors students. Inouye J. **J Nurs Educ** 1995 Sep;34(6):268–71 (35 ref.)

EDUCATION, NURSING, CONTINUING

ORGANIZATION & ADMINISTRATION

Oncology nursing education. Workman ML. **Annu Rev Nurs Res** 1996;14:167–78 (52 ref.)

STANDARDS

HIV infection. What nurses need to know. The consumer perspective. Schietinger H, et al. **Nurs Clin North Am** 1996 Mar;31(1):137–52 (21 ref.)

EDUCATION, NURSING, GRADUATE

METHODS

Empowerment of graduate nursing students: a dialogue toward change. Roberts SJ, et al. **J Prof Nurs** 1996 Jul–Aug;12(4):233–9 (25 ref.)

ORGANIZATION & ADMINISTRATION

Oncology nursing education. Workman ML. **Annu Rev Nurs Res** 1996;14:167–78 (52 ref.)

The future of graduate education in nursing: scholarship, the health of communities, and health care reform. Hall JM, et al. **J Prof Nurs** 1995 Nov–Dec;11(6):332–8 (22 ref.)

TRENDS

The preparation of advanced practice nurses. Current issues. O'Flynn AI. **Nurs Clin North Am** 1996 Sep;31(3):429–38 (20 ref.)

EDUCATION OF MENTALLY DEFECTIVE see **EDUCATION OF MENTALLY RETARDED**

EDUCATION OF MENTALLY RETARDED

Annotation: self–injurious behaviour in children with learning disabilities: recent advances in assessment and intervention. Oliver C. **J Child Psychol Psychiatry** 1995 Sep;36(6):909–27 (100 ref.)

[Pedagogic responsibilities in rehabilitation of brain damaged patients] Stadler H. **Rehabilitation (Stuttg)** 1996 May; 35(2):109–18 (25 ref.) (Eng. Abstr.) **(Ger)**

EDUCATION OF PATIENTS see **PATIENT EDUCATION**

EDUCATION, PREMEDICAL

STANDARDS

[Problem–oriented education, problem–based learning and activating teaching methods] Nikkarinen T, et al. **Duodecim** 1994;110(16):1548–55 (23 ref.) **(Fin)**

EDUCATION RESEARCH, NURSING see **NURSING EDUCATION RESEARCH**

EDUCATION, SEX see **SEX EDUCATION**

EDUCATION, SPECIAL

Effectiveness of special education: is placement the critical factor? Hocutt AM. **Future Child** 1996 Spring;6(1):77–102 (108 ref.)

Identification and assessment of students with disabilities. Reschly DJ. **Future Child** 1996 Spring;6(1):40–53 (51 ref.)

[Neuropedagogic aspects of children with acquired craniocerebral trauma—an overview] Vandermeulen JA, et al. **Rehabilitation (Stuttg)** 1995 Aug;34(3):139–47 (140 ref.) (Eng. Abstr.) **(Ger)**

ECONOMICS

Financing special education. Parrish TB, et al. **Future Child** 1996 Spring;6(1):121–38 (39 ref.)

LEGISLATION & JURISPRUDENCE

The school experience of children with arthritis. Coping in the 1990s and transition into adulthood. Spencer CH, et al. **Pediatr Clin North Am** 1995 Oct;42(5):1285–98 (25 ref.)

ORGANIZATION & ADMINISTRATION

Special education for students with disabilities: analysis and recommendations. Terman DL, et al. **Future Child** 1996 Spring;6(1):4–24 (60 ref.)

EDUCATIONAL ACHIEVEMENT see **EDUCATIONAL STATUS**

EDUCATIONAL MEASUREMENT

see related
APTITUDE TESTS

Audit of continuing medical education for pathologists: strategies and implications. du Boulay C. **J Clin Pathol** 1996 Feb;49(2):100–1 (16 ref.)

The MRCGP—the standard to set yourself. Dixon H. **Practitioner** 1995 Sep;239(1554):527–9 (3 ref.)

Review your reading: how to prepare for the CRQ paper. Milne P. **Practitioner** 1996 Feb;240(1559):96–8 (5 ref.)

A positive approach to preparation. Rawlinson G. **Practitioner** 1995 Oct;239(1555):596–8 (5 ref.)

STANDARDS

Basic surgical training. 1: Postgraduate surgical examinations in the UK and Ireland. Raftery AT. **Clin Anat** 1996; 9(3):163–6 (1 ref.)

STATISTICS & NUMERICAL DATA

Global rating scales in residency education. Gray JD. **Acad Med** 1996 Jan;71(1 Suppl):S55–63 (119 ref.)

EDUCATIONAL MODELS see **MODELS, EDUCATIONAL**

EDUCATIONAL STATUS

Improving patient education for patients with low literacy skills. Mayeaux EJ Jr, et al. **Am Fam Physician** 1996 Jan; 53(1):205–11 (34 ref.)

Readability of patient education materials: implications for clinical practice. Albright J, et al. **Appl Nurs Res** 1996 Aug; 9(3):139–43 (37 ref.)

Measurement of intelligence: misplaced trust and the lure of prophecy [see comments] Slack WV. **MD Comput** 1995 Sep–Oct;12(5):363–72 (127 ref.) Comment in: MD Comput 1995 Sep–Oct;12(5):325–6, 329.

Women's education and fertility: results from 26 Demographic and Health Surveys. Castro Martin T. **Stud Fam Plann** 1995 Jul–Aug;26(4):187–202 (50 ref.)

EDUCATIONAL TECHNOLOGY

see related
TEACHING MATERIALS

EEG see **ELECTROENCEPHALOGRAPHY**

EEL, CONGO see **URODELA**

EFFICIENCY, ADMINISTRATIVE see **EFFICIENCY, ORGANIZATIONAL**

EFFICIENCY, ORGANIZATIONAL

The economics of independent living: efficiency, equity and ethics. O'Shea E, et al. **Int J Rehabil Res** 1996 Mar; 19(1):13–26 (28 ref.)

Accepting the Galvin challenge: increasing efficiency and productivity in health professions education. Neuhauser D, et al. **Jt Comm J Qual Improv** 1996 Mar;22(3):223–27 (1 ref.)

How to increase efficiency in the operating room. Kanich DG, et al. **Surg Clin North Am** 1996 Feb;76(1):161–73 (23 ref.)

ECONOMICS

Economic evaluations in the critical care literature: do they help us improve the efficiency of our unit? Heyland DK, et al. **Crit Care Med** 1996 Sep;24(9):1591–8 (46 ref.)

EFFORT see **EXERTION**

EFFORT SYNDROME see **NEUROCIRCULATORY ASTHENIA**

EGF see **EPIDERMAL GROWTH FACTOR–UROGASTRONE**

EGF–RECEPTOR KINASE see **EPIDERMAL GROWTH FACTOR RECEPTOR PROTEIN–TYROSINE KINASE**

EGF–URO RECEPTORS see **RECEPTORS, EPIDERMAL GROWTH FACTOR–UROGASTRONE**

EGG see **OVUM**

EGG PROTEINS

ISOLATION & PURIFICATION

On hen egg fractionation: applications of liquid chromatography to the isolation and the purification of hen egg white and egg yolk proteins. Awade AC. **Z Lebensm Unters Forsch** 1996 Jan;202(1):1–14 (108 ref.)

METABOLISM

Sperm—egg recognition mechanisms in mammals. Wassarman PM, et al. **Curr Top Dev Biol** 1995;30:1–19 (70 ref.)

Sperm–binding proteins. Foltz KR. **Int Rev Cytol** 1995; 163:249–303 (310 ref.)

Egg proteins: what are their functions? Stevens L. **Sci Prog** 1996;79 (Pt 1):65–87 (25 ref.)

The beta–prism: a new folding motif. Shimizu T, et al. **Trends Biochem Sci** 1996 Jan;21(1):3–6 (28 ref.)

EGG SHELL PROTEINS see **EGG PROTEINS**

EGG WHITE

see related
OVALBUMIN

ANALYSIS

On hen egg fractionation: applications of liquid chromatography to the isolation and the purification of hen egg white and egg yolk proteins. Awade AC. **Z Lebensm Unters Forsch** 1996 Jan;202(1):1–14 (108 ref.)

EGG WHITE PROTEINS see **EGG PROTEINS**

EGG YOLK

CHEMISTRY

On hen egg fractionation: applications of liquid chromatography to the isolation and the purification of hen egg white and egg yolk proteins. Awade AC. **Z Lebensm Unters Forsch** 1996 Jan;202(1):1–14 (108 ref.)

EGG YOLK PROTEINS see **EGG PROTEINS**

EGO

Transformative narratives: from victimic to agentic life plots. Polkinghorne DE. **Am J Occup Ther** 1996 Apr; 50(4):299–305 (34 ref.)

A clinical concept of the self: the experiential being. De Waele M. **Br J Med Psychol** 1995 Sep;68 (Pt 3):223–42 (85 ref.)

Object relations units and the ego. Hamilton NG. **Bull Menninger Clin** 1995 Fall;59(4):416–26 (25 ref.)

Termination in group psychotherapy from the perspectives of contemporary object relations theory and self psychology. Schermer VL, et al. **Int J Group Psychother** 1996 Jan;46(1):99–115 (38 ref.)

An ego–psychological approach to the Rorschach. Frank G. **Psychol Rep** 1995 Dec;77(3 Pt 1):911–30 (110 ref.)

[Cognitive distortion in the affirmation of self. Various observations] Masson A, et al. **Rev Med Liege** 1995 Sep;

50(9):390–5 (21 ref.) **(Fre)**

EHDP see ETIDRONATE DISODIUM

EHLERS–DANLOS SYNDROME

BLOOD

Hemostasis in Ehlers–Danlos syndrome. Patient report and literature review. Nuss R, et al. **Clin Pediatr (Phila)** 1995 Oct;34(10):552–5 (10 ref.)

COMPLICATIONS

Cerebrovascular complications in Ehlers–Danlos syndrome type IV. North KN, et al. **Ann Neurol** 1995 Dec;38(6):960–4 (28 ref.)

Ehlers–Danlos type IV syndrome. A review from a vascular surgical point of view. Bergqvist D. **Eur J Surg** 1996 Mar; 162(3):163–70 (101 ref.)

[Spontaneous colonic perforations revealing Ehlers–Danlos syndrome type IV] Henry C, et al. **Arch Pediatr** 1995 Nov; 2(11):1067–72 (19 ref.) (Eng. Abstr.) **(Fre)**

[Ictus and cutaneous vascular syndromes] Trejo Gabriel y Galán JM. **Rev Neurol** 1995;23 Suppl 1:S99–105 (46 ref.) **(Spa)**

DIAGNOSIS

Presentation of Ehlers–Danlos syndrome: iliac artery pseudoaneurysm rupture. Meldon S, et al. **Ann Emerg Med** 1996 Aug;28(2):231–4 (14 ref.)

Hemostasis in Ehlers–Danlos syndrome. Patient report and literature review. Nuss R, et al. **Clin Pediatr (Phila)** 1995 Oct;34(10):552–5 (10 ref.)

[Ehlers–Danlos syndromes. Clinical, genetic and molecular aspects] Germain D. **Ann Dermatol Venereol** 1995; 122(4):187–204 (91 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

The Ehlers–Danlos syndrome: a heritable collagen disorder as cause of bleeding. de Paepe A. **Thromb Haemost** 1996 Mar;75(3):379–86 (75 ref.)

EHRLICHIA

GENETICS

Uncharacterized Ehrlichia spp. may contribute to clinical heartwater. Allsopp BA, et al. **Ann N Y Acad Sci** 1996 Jul 23;791:17–23 (24 ref.)

EHRLICHIOSIS

Ehrlichial infections. Mounzer KC, et al. **Clin Dermatol** 1996 May–Jun;14(3):289–93 (38 ref.)

Human ehrlichiosis: more trouble from ticks. Walker DH. **Hosp Pract (Off Ed)** 1996 Apr 15;31(4):47–57 (7 ref.)

DIAGNOSIS

The interface between research and the diagnosis of an emerging tick–borne disease, human ehrlichiosis due to Ehrlichia chaffeensis [see comments] Dawson JE, et al. **Arch Intern Med** 1996 Jan 22;156(2):137–42 (25 ref.) Comment in: Arch Intern Med 1996 Jan 22;156(2):124.

EPIDEMIOLOGY

The interface between research and the diagnosis of an emerging tick–borne disease, human ehrlichiosis due to Ehrlichia chaffeensis [see comments] Dawson JE, et al. **Arch Intern Med** 1996 Jan 22;156(2):137–42 (25 ref.) Comment in: Arch Intern Med 1996 Jan 22;156(2):124.

EHS TUMOR see SARCOMA, EXPERIMENTAL

EICOSANOIDS

BIOSYNTHESIS

[Biosynthesis and functions of eicosanoids. Recent data] Lagarde M. **C R Seances Soc Biol Fil** 1995;189(5):839–51 (52 ref.) (Eng. Abstr.) **(Fre)**

CHEMISTRY

Relationships between eicosanoids and cannabinoids. Are eicosanoids cannabimimetic agents?. Burstein SH, et al. **Biochem Pharmacol** 1995 Nov 27;50(11):1735–42 (44 ref.)

METABOLISM

Antagonistic effects of dietary arachidonic acid and n–3 polyunsaturated fatty acids. Whelan J. **J Nutr** 1996 Apr; 126(4 Suppl):1086S–91S (35 ref.)

PHARMACOLOGY

[Biosynthesis and functions of eicosanoids. Recent data] Lagarde M. **C R Seances Soc Biol Fil** 1995;189(5):839–51 (52 ref.) (Eng. Abstr.) **(Fre)**

[The modulation of cellular ion channel activity by arachidonic acid, its metabolic products and other fatty acids] Krutetskaia ZI, et al. **Tsitologiia** 1995;37(1–2):5–65 (241 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Eicosanoids and radiation. Milas L, et al. **Eur J Cancer** 1995 Sep;31A(10):1580–5 (57 ref.)

Activation of the HPA axis by immune insults: roles and interactions of cytokines, eicosanoids, glucocorticoids. Buckingham JC, et al. **Pharmacol Biochem Behav** 1996 May; 54(1):285–98 (138 ref.)

Eicosanoids, fatty acids and neutrophils: their relevance to the pathophysiology of disease. Bates EJ. **Prostaglandins Leukot Essent Fatty Acids** 1995 Aug; 53(2):75–86 (213 ref.)

Arachidonic acid and eicosanoids as targets and effectors in second messenger interactions. Di Marzo V. **Prostaglandins Leukot Essent Fatty Acids** 1995 Oct; 53(4):239–54 (183 ref.)

Role of fatty acids and eicosanoids in modulating proteoglycan metabolism in endothelial cells. Hennig B, et al. **Prostaglandins Leukot Essent Fatty Acids** 1995 Nov; 53(5):315–24 (114 ref.)

Eicosanoids in rheumatoid arthritis. Sperling RI. **Rheum Dis Clin North Am** 1995 Aug;21(3):741–58 (84 ref.)

5,8,11,14,17–EICOSAPENTAENOIC ACID

PHARMACOLOGY

[The experimental and clinical aspects of eicosapentaenoic amd docosahexaenoic acids (a review of the literature and the author's own data)] Serhiienko OO. **Lik Sprava** 1995 May–Jun;(5–6):61–6 (31 ref.) (Eng. Abstr.) **(Ukr)**

EICOSATETRAENOIC ACIDS see ARACHIDONIC ACIDS

8,11,14–EICOSATRIENOIC ACID

ANALOGS & DERIVATIVES

Mechanistic aspects of hepoxilin biosynthesis. Pace–Asciak CR, et al. **J Lipid Mediat Cell Signal** 1995 Oct; 12(2–3):307–11 (15 ref.)

EIGENMANNIA see ELECTRIC FISH

EIKENELLA CORRODENS

[Eikenella corrodens pleuro–pulmonary infection. Apropos of a case] Salem M, et al. **Rev Pneumol Clin** 1996; 52(3):192–5 (23 ref.) (Eng. Abstr.) **(Fre)**

[A case of secondary valve replacement caused by pulmonary bioprosthetic valve endocarditis] Fujii H, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Jul;43(7):1081–5 (18 ref.) (Eng. Abstr.) **(Jpn)**

EIMERIA

PHYSIOLOGY

Cytokines and immunological control of Eimeria spp. Ovington KS, et al. **Int J Parasitol** 1995 Nov; 25(11):1331–51 (114 ref.)

EISENMENGER COMPLEX

Severe pulmonary hypertension in congenital heart disease: a review of Eisenmenger syndrome. Hopkins WE. **Curr Opin Cardiol** 1995 Sep;10(5):517–23 (38 ref.)

EISENMENGER SYNDROME see EISENMENGER COMPLEX

EJACULATION

PHYSIOLOGY

On the epididymis and its role in the development of the fertile ejaculate. Turner TT. **J Androl** 1995 Jul–Aug; 16(4):292–8 (34 ref.)

EJACULATORY DUCTS

SURGERY

[Treatment of obstructive azoospermia] Hovatta O, et al. **Duodecim** 1994;110(8):802–7 (28 ref.) **(Fin)**

EJECTION SEATS see AIRCRAFT

EKBOM'S SYNDROME see RESTLESS LEGS

EKG see ELECTROCARDIOGRAPHY

ELAEOPHORIASIS see FILARIASIS

ELAM–1 see E–SELECTIN

ELAPIDAE

The emerging syndrome of envenoming by the New Guinea small–eyed snake Micropechis ikaheka. Warrell DA, et al. **QJM** 1996 Jul;89(7):523–30 (19 ref.)

ELASMOBRANCHII

PHYSIOLOGY

Cell–cell interactions in the testis of teleosts and elasmobranchs. Loir M, et al. **Microsc Res Tech** 1995 Dec 15;32(6):533–52 (93 ref.)

ELASMOBRANCHS see ELASMOBRANCHII

ELASTASE see PANCREATOPEPTIDASE

ELASTIC STOCKINGS see BANDAGES

ELASTIC TISSUE

ANATOMY & HISTOLOGY

The interstitium, the connective tissue environment of the lymphatic, and angiogenesis in human skin. Ryan TJ, et al. **Clin Dermatol** 1995 Sep–Oct;13(5):451–8 (54 ref.)

METABOLISM

Skin elastic fibres: regulation of human elastin promoter activity in transgenic mice. Uitto J, et al. **Ciba Found Symp** 1995;192:237–53; discussion 253–8 (49 ref.)

PATHOLOGY

Raimer's bands: case report with a review of solar elastosis. Stanford DG, et al. **Acta Derm Venereol** 1995 Sep; 75(5):372–4 (23 ref.)

Fibroelastolytic patterns of intrinsic skin aging: pseudoxanthoma–elasticum–like papillary dermal elastolysis and white fibrous papulosis of the neck. Rongioletti F, et al. **Dermatology** 1995;191(1):19–24 (32 ref.)

PHYSIOLOGY

Elastic fibers and their role in bladder extracellular matrix. Rosenbloom J, et al. **Adv Exp Med Biol** 1995;385:161–72; discussion 179–84 (52 ref.)

ELASTICA see RUBBER

ELASTICITY

An unusual case of mixed sclerosing bone dystrophy presenting with morning stiffness and joint swelling in childhood: a case report. Foeldvari I, et al. **Clin Exp Rheumatol** 1995 Jul–Aug;13(4):525–8 (19 ref.)

ELASTIN

BIOSYNTHESIS

Regulation of elastin synthesis in pathological states. Davidson JM, et al. **Ciba Found Symp** 1995;192:81–94; discussion 94–9 (62 ref.)

GENETICS

Structure of the elastin gene. Rosenbloom J, et al. **Ciba Found Symp** 1995;192:59–74; discussion 74–80 (48 ref.)

Skin elastic fibres: regulation of human elastin promoter activity in transgenic mice. Uitto J, et al. **Ciba Found Symp** 1995;192:237–53; discussion 253–8 (49 ref.)

METABOLISM

Elastin in systemic and pulmonary hypertension. Keeley FW, et al. **Ciba Found Symp** 1995;192:259–73; discussion 273–8 (65 ref.)

Elastin in lung development and disease. Pierce RA, et al. **Ciba Found Symp** 1995;192:199–212; discussion 212–4 (37 ref.)

Interaction of tumour cells with elastin and the metastatic phenotype. Timár J, et al. **Ciba Found Symp** 1995; 192:321–35; discussion 335–7 (44 ref.)

[Trabecular meshwork and elastin] Segawa K. **Nippon Ganka Gakkai Zasshi** 1995 Dec;99(12):1291–302 (51 ref.) (Eng. Abstr.) **(Jpn)**

[Metabolism of elastin and pulmonary emphysema] Marks J, et al. **Pneumonol Pol** 1990 Jul–Aug;58(7–8):403–9 (55 ref.) **(Pol)**

PHYSIOLOGY

Elastin in blood vessels. Robert L, et al. **Ciba Found Symp** 1995;192:286–99; discussion 299–303 (53 ref.)

Molecular biophysics of elastin structure, function and pathology. Urry DW, et al. **Ciba Found Symp** 1995; 192:4–22; discussion 22–30 (54 ref.)

ULTRASTRUCTURE

Elastin and mechanoreceptor mechanisms with special reference to the mammalian carotid sinus. Kimani JK. **Ciba Found Symp** 1995;192:215–30; discussion 230–6 (68 ref.)

Ultrastructure of elastin. Pasquali–Ronchetti I, et al. **Ciba Found Symp** 1995;192:31–42; discussion 42–50 (59 ref.)

ELASTOMERS

ELASTOMERS see **RUBBER**

ELASTOMERS, SILICONE see **SILICONE ELASTOMERS**

ELBOW

see related
TENNIS ELBOW

Magnetic resonance imaging of the musculoskeletal system: Part 3. The elbow. Fritz RC, et al. **Clin Orthop** 1996 Mar; (324):321–39 (88 ref.)

INJURIES

The immature athlete. Common injuries and overuse syndromes of the elbow and wrist. Gill TJ 4th, et al. **Clin Sports Med** 1996 Apr;15(2):401–23 (49 ref.)

Bony injuries of the wrist, forearm, and elbow. Griggs SM, et al. **Clin Sports Med** 1996 Apr;15(2):373–400 (114 ref.)

Unusual problems of the athlete's elbow, forearm, and wrist. Shaffer B, et al. **Clin Sports Med** 1996 Apr;15(2):425–38 (11 ref.)

INNERVATION

Intraepineurial constriction of nerve fascicles in pronator syndrome and anterior interosseous nerve syndrome. Haussmann P, et al. **Orthop Clin North Am** 1996 Apr; 27(2):339–44 (13 ref.)

ELBOW JOINT

ABNORMALITIES

Joint dislocation and cerebral anomalies are consistently associated with oral-facial-digital syndrome type IV. Digilio MC, et al. **Clin Genet** 1995 Sep;48(3):156–9 (11 ref.)

INJURIES

Common elbow fractures in children. Townsend DJ, et al. **Am Fam Physician** 1996 May 1;53(6):2031–41 (7 ref.)

Arthroscopy of the elbow. Baker CL, et al. **Clin Sports Med** 1996 Apr;15(2):261–81 (32 ref.)

The immature athlete. Common injuries and overuse syndromes of the elbow and wrist. Gill TJ 4th, et al. **Clin Sports Med** 1996 Apr;15(2):401–23 (49 ref.)

Bony injuries of the wrist, forearm, and elbow. Griggs SM, et al. **Clin Sports Med** 1996 Apr;15(2):373–400 (114 ref.)

Elbow injuries to the throwing athlete. Johnston J, et al. **Clin Sports Med** 1996 Apr;15(2):307–29 (33 ref.)

Compressive neuropathies and tendinopathies in the athletic elbow and wrist. Plancher KD, et al. **Clin Sports Med** 1996 Apr;15(2):331–71 (142 ref.)

Medial and lateral epicondylitis in the athlete. Plancher KD, et al. **Clin Sports Med** 1996 Apr;15(2):283–305 (52 ref.)

Unusual problems of the athlete's elbow, forearm, and wrist. Shaffer B, et al. **Clin Sports Med** 1996 Apr;15(2):425–38 (11 ref.)

Isolated dislocation of the radial head in an adult: case report and review of the literature. Deehan DJ, et al. **J R Coll Surg Edinb** 1995 Dec;40(6):421–3 (26 ref.)

[Fractures of the distal humerus and proximal forearm] Dorow C, et al. **Unfallchirurg** 1996 Jun;99(6):440–9 (10 ref.) **(Ger)**

SURGERY

[Elbow arthrodesis and its alternative] Hahn MP, et al. **Orthopade** 1996 Apr;25(2):112–20 (70 ref.) (Eng. Abstr.) **(Ger)**

[Infection following shoulder and elbow arthroplasty. Diagnosis and therapy] Schwyzer HK, et al. **Orthopade** 1995 Aug;24(4):367–75 (44 ref.) (Eng. Abstr.) **(Ger)**

ELDER ABUSE

DIAGNOSIS

Diagnosing and managing elder abuse. Jogerst G. **Iowa Med** 1996 Jan;86(1):29–31 (9 ref.)

[Violence against the elderly from the trauma surgery viewpoint] Witthohn A, et al. **Z Gerontol Geriatr** 1996 May-Jun;29(3):206–9 (22 ref.) (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

Diagnosing and managing elder abuse. Jogerst G. **Iowa Med** 1996 Jan;86(1):29–31 (9 ref.)

ELDERLY see **AGED**

ELDERLY, FRAIL see **FRAIL ELDERLY**

ELECTIVE SURGERY see **SURGERY, ELECTIVE**

ELECTRIC BURNS see **BURNS, ELECTRIC**

ELECTRIC COUNTERSHOCK

Anaesthesia for cardioversion. Stoneham MD. **Anaesthesia** 1996 Jun;51(6):565–70 (69 ref.)

Atrial fibrillation: restoration and maintenance of sinus rhythm and indications for anticoagulation therapy. Golzari H, et al. **Ann Intern Med** 1996 Aug 15;125(4):311–23 (205 ref.)

The revolution and evolution of prehospital cardiac care. Eisenberg MS, et al. **Arch Intern Med** 1996 Aug 12–26; 156(15):1611–9 (43 ref.)

ABC of atrial fibrillation. Cardioversion of atrial fibrillation [see comments] Lip GY, et al. **BMJ** 1996 Jan 13; 312(7023):112–5 (0 ref.) Comment in: BMJ 1996 May 18;312(7041):1300.

Nonpharmacologic approaches to the treatment of atrial fibrillation and atrial flutter. Baker BM, et al. **J Cardiovasc Electrophysiol** 1995 Oct;6(10 Pt 2):972–8 (66 ref.)

Transesophageal echocardiography-guided approach to cardioversion of atrial fibrillation. Leung DY, et al. **Prog Cardiovasc Dis** 1996 Jul-Aug;39(1):21–32 (67 ref.)

Atrial anatomy and function postcardioversion: insights from transthoracic and transesophageal echocardiography. Manning WJ, et al. **Prog Cardiovasc Dis** 1996 Jul-Aug; 39(1):33–46 (60 ref.)

[The treatment of chronic atrial fibrillation] Gosselink AT. **Tijdschr Gerontol Geriatr** 1995 Dec;26(6):259–63 (20 ref.) (Eng. Abstr.) **(Dut)**

[Semi-automatic external defibrillators] Silfvast T. **Duodecim** 1994;110(11):1049–53 (15 ref.) **(Fin)**

[Cardiac stimulation and atrial fibrillation] Kerr CR, et al. **Can J Cardiol** 1996 Feb;12 Suppl A:34A–37A (31 ref.) **(Fre)**

[Significance of initial defibrillation by paramedics] Mauer D, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Aug; 30(5):303–6 (30 ref.) **(Ger)**

[Sudden cardiac death and immediate defibrillation by trained lay persons] Theissen K. **Dtsch Med Wochenschr** 1996 Apr 12;121(15):463–4 (18 ref.) **(Ger)**

ADVERSE EFFECTS

Ventricular fibrillation, automatic external defibrillators, and the United States Food and Drug Administration: confrontation without comprehension. Cummins RO, et al. **Ann Emerg Med** 1995 Nov;26(5):621–31; discussion 632–4 (95 ref.)

INSTRUMENTATION

Ventricular fibrillation, automatic external defibrillators, and the United States Food and Drug Administration: confrontation without comprehension. Cummins RO, et al. **Ann Emerg Med** 1995 Nov;26(5):621–31; discussion 632–4 (95 ref.)

[Management of patients with sustained ventricular arrhythmia: anti-arrhythmia agents or defibrillator?] Cappato R, et al. **Cardiologia** 1996 Feb;41(2):95–105 (75 ref.) **(Ita)**

METHODS

Nonpharmacological therapy of atrial fibrillation. Klein GJ, et al. **Can J Cardiol** 1996 Jan;12 Suppl A:49A–50A (18 ref.)

Restoration of sinus rhythm in patients with atrial fibrillation. Talajic M, et al. **Can J Cardiol** 1996 Jan;12 Suppl A:29A–35A (83 ref.)

Impedance to defibrillation countershock: does an optimal impedance exist? KenKnight BH, et al. **Pacing Clin Electrophysiol** 1995 Nov;18(11):2068–87 (141 ref.)

Cardioversion of atrial fibrillation. Lip GY. **Postgrad Med J** 1995 Aug;71(838):457–65 (68 ref.)

[Restoration of the sinus rhythm in atrial fibrillation] Talajic M, et al. **Can J Cardiol** 1996 Feb;12 Suppl A:27A–34A (83 ref.) **(Fre)**

ELECTRIC FISH

PHYSIOLOGY

Convergent designs for electrogenesis and electroreception. Hopkins CD. **Curr Opin Neurobiol** 1995 Dec;5(6):769–77 (57 ref.)

ELECTRIC IMPEDANCE

Data processing techniques for serial EIT spectroscopy images: a review of some preliminary results. Smallwood RH, et al. **Physiol Meas** 1995 Aug;16(3 Suppl A):A129–42 (37 ref.)

[Bioelectric profiles and nutritional status in pregnancy: protocol of a multicentric project to measure bioimpedance in pregnancy] Mele MC, et al. **Minerva Ginecol** 1996 Jan-Feb;48(1-2):25–33 (23 ref.) (Eng. Abstr.) **(Ita)**

DIAGNOSTIC USE

Prediction of body composition in elderly men over 75 years of age. Fuller NJ, et al. **Ann Hum Biol** 1996 Mar-Apr; 23(2):127–47 (64 ref.)

ELECTRIC INJURIES

[Electrocution and lightning strikes--pathophysiology and treatment] Leibovici D, et al. **Harefuah** 1995 Jul; 129(1-2):62–8 (38 ref.) **(Heb)**

COMPLICATIONS

Rhabdomyolysis following electrical injury. Brumback RA, et al. **Semin Neurol** 1995 Dec;15(4):329–34 (22 ref.)

Central nervous system complications of lightning and electrical injuries. Cherington M. **Semin Neurol** 1995 Sep; 15(3):233–40 (107 ref.)

Autonomic nervous system disorders and reflex sympathetic dystrophy in lightning and electrical injuries. Cohen JA. **Semin Neurol** 1995 Dec;15(4):387–90 (23 ref.)

Involuntary movement disorders following lightning and electrical injuries. O'Brien CF. **Semin Neurol** 1995 Sep; 15(3):263–7 (18 ref.)

Peripheral nerve disorders in electrical and lightning injuries. Wilbourn AJ. **Semin Neurol** 1995 Sep;15(3):241–55 (95 ref.)

PATHOLOGY

Study on electrocution death by low-voltage. Zhang P, et al. **Forensic Sci Int** 1995 Dec 18;76(2):115–9 (4 ref.)

Forensic perspectives of electrical and lightning injuries. Jumbelic MI. **Semin Neurol** 1995 Dec;15(4):342–50 (31 ref.)

PHYSIOPATHOLOGY

Lightning and electrical injuries: neuro-ophthalmologic aspects. Grover S, et al. **Semin Neurol** 1995 Dec; 15(4):335–41 (37 ref.)

PSYCHOLOGY

Behavioral consequences of lightning and electrical injury. Primeau M, et al. **Semin Neurol** 1995 Sep;15(3):279–85 (31 ref.)

REHABILITATION

Neurorehabilitation of lightning and electrical injuries. Yarnell PR, et al. **Semin Neurol** 1995 Dec;15(4):391–6 (51 ref.)

THERAPY

Electrical injuries: current concepts. Leibovici D, et al. **Injury** 1995 Nov;26(9):623–7 (33 ref.)

Emergent care of lightning and electrical injuries. Cooper MA. **Semin Neurol** 1995 Sep;15(3):268–78 (114 ref.)

ELECTRIC ORGAN

INNERVATION

Convergent designs for electrogenesis and electroreception. Hopkins CD. **Curr Opin Neurobiol** 1995 Dec;5(6):769–77 (57 ref.)

PHYSIOLOGY

Convergent designs for electrogenesis and electroreception. Hopkins CD. **Curr Opin Neurobiol** 1995 Dec;5(6):769–77 (57 ref.)

ELECTRIC POWER PLANTS see **POWER PLANTS**

ELECTRIC RESISTANCE see **ELECTRIC IMPEDANCE**

ELECTRIC STIMULATION

see related
CARDIAC PACING, ARTIFICIAL
ELECTRIC COUNTERSHOCK
ELECTROSHOCK

Cortical electrical stimulation in humans. The negative motor areas. Lüders HO, et al. **Adv Neurol** 1995;67:115–29 (66 ref.)

No-go potential in the prefrontal cortex and electrical stimulation of its loci in monkeys. Sasaki K. **Adv Neurol** 1995;67:131–41 (20 ref.)

Conditioned healing with electroacupuncture. Ulett GA. **Altern Ther Health Med** 1996 Sep;2(5):56–60 (52 ref.)

Electrical stimulation of neural tissue to evoke behavioral responses. Tehovnik EJ. **J Neurosci Methods** 1996 Mar; 65(1):1–17 (144 ref.)

[Electrical tooth stimulation and somatosensory evoked potential] Umino M. **Kokubyo Gakkai Zasshi** 1996 Jun; 63(2):287–95 (36 ref.) **(Jpn)**

INSTRUMENTATION

Surface electrodes for physiological measurement and stimulation. Smith DC, et al. **Eur J Anaesthesiol** 1995 Sep; 12(5):451–69 (73 ref.)

ELECTRIC STIMULATION THERAPY

Second-line and 'alternative' treatments for alcohol withdrawal: alpha-agonists, beta-blockers, anticonvulsants, acupuncture and neuro-electric therapy. Brewer C. **Alcohol Alcohol** 1995 Nov;30(6):799–803 (25 ref.)

Clinical applications of functional electrical stimulation. Kumar VP, et al. **Ann Acad Med Singapore** 1995 May; 24(3):428–35 (68 ref.)

Epidural spinal cord stimulation in the treatment of limb threatening vasospasm--report of a case with a five-year follow-up. Lepantalo M, et al. **Eur J Vasc Endovasc Surg** 1996 Apr;11(3):368–70 (5 ref.)

[Epidural electrostimulation in the treatment of refractory

angina pectoris in elderly patients: preliminary results] Romanò M, et al. **Cardiologia** 1995 Jun;40(6):399–405 (32 ref.) (Eng. Abstr.) **(Ita)**

[Electric stimulation—hope for patients with urinary incontinence] Franek A, et al. **Pol Tyg Lek** 1996 Feb; 51(6–9):109–12 (40 ref.) **(Pol)**

[Therapy of epilepsy with stimulation of the vagus nerve] Tomović M. **Vojnosanit Pregl** 1994 Mar–Apr;51(2):143–6 (25 ref.) **(Scr)**

INSTRUMENTATION

Principles underlying functional electrical stimulation techniques. Jaeger RJ. **J Spinal Cord Med** 1996 Apr; 19(2):93–6 (38 ref.)

[Neurosurgical methods in Parkinson disease] Alesch F. **Wien Med Wochenschr** 1995;145(13):305–9 (23 ref.) (Eng. Abstr.) **(Ger)**

ELECTRIC STIMULATION, TRANSCUTANEOUS see **TRANSCUTANEOUS ELECTRIC NERVE STIMULATION**

ELECTRICITY

see related
LIGHTNING

ADVERSE EFFECTS

What occupations have been associated with brain cancer, and, more specifically, what is the connection between brain cancer and electric utility work?
J Occup Environ Med 1995 Sep;37(9):1067–9 (46 ref.)

ELECTROACUPUNCTURE

A concept in analgesic mechanisms of acupuncture. Lin JG. **Chin Med J (Engl)** 1996 Mar;109(3):185–8 (8 ref.)

ELECTROANALGESIA see **TRANSCUTANEOUS ELECTRIC NERVE STIMULATION**

ELECTROCARDIOGRAPHY

Reperfusion in acute inferior myocardial infarction: could tailored therapy be based on precordial ST depression? [editorial] Wong CK, et al. **Am Heart J** 1996 Jun; 131(6):1240–7 (61 ref.)

Solving nomenclature problems in cardiology. I. Updating terminology in electrocardiography. Constant J. **Cardiology** 1995;86(5):357–60 (9 ref.)

Wide complex tachycardia. Delbridge TR, et al. **Emerg Med Clin North Am** 1995 Nov;13(4):903–24 (64 ref.)

Right bundle branch block, persistent ST-segment elevation in V1–V3 and sudden cardiac death: always a distinct syndrome? D'Onofrio A, et al. **G Ital Cardiol** 1995 Sep; 25(9):1171–5 (12 ref.)

Role of electrophysiologic evaluation in patients with ventricular arrhythmias. Athill CA, et al. **Indian Heart J** 1996 Mar–Apr;48(2):179–85 (33 ref.)

Electrocardiographic and clinical precursors of ventricular fibrillation: chain of events. Bayés–Genís A, et al. **J Cardiovasc Electrophysiol** 1995 May;6(5):410–7 (47 ref.)

Benefits and lessons learned from stored electrogram information in implantable defibrillators. Marchlinski FE, et al. **J Cardiovasc Electrophysiol** 1995 Oct;6(10 Pt 1):832–51 (29 ref.)

Role of M cells in acquired long QT syndrome, U waves, and torsade de pointes. Antzelevitch C, et al. **J Electrocardiol** 1995;28 Suppl:131–8 (44 ref.)

Time-related perturbations of repolarization. Childers R. **J Electrocardiol** 1995;28 Suppl:124–30 (54 ref.)

Clinical aspects of cardiac memory revisited. Elizari MV, et al. **J Electrocardiol** 1995;28 Suppl:148–55 (25 ref.)

Nonlinear forecasting and the dynamics of cardiac rhythm. Lippman N, et al. **J Electrocardiol** 1995;28 Suppl:65–70 (15 ref.)

Repolarization gradients derived by subtraction of monophasic action potential recordings in the human heart. Studies incorporating altered mechanical loading and ischemia. Taggart P, et al. **J Electrocardiol** 1995;28 Suppl:156–61 (25 ref.)

Wide-complex tachycardias. The importance of identifying the mechanism. Janeira LF. **Postgrad Med** 1996 Sep; 100(3):259–62, 265–6, 269–72 passim (20 ref.)

Electrocardiographic predictors in the ESVEM trial: unsustained ventricular tachycardia, heart period variability, and the signal-averaged electrocardiogram. Anderson KP, et al. **Prog Cardiovasc Dis** 1996 May–Jun; 38(6):463–88 (89 ref.)

Electrocardiography in Chagas' heart disease. Garzon SA, et al. **Rev Paul Med** 1995 Mar–Apr;113(2):802–13 (17 ref.)

[Correlation between the persistence of ST elevation and left ventricular aneurysm in the post-infarction period] Hamani A, et al. **Ann Cardiol Angeiol (Paris)** 1995 Sep;44(7):361–4 (22 ref.) (Eng. Abstr.) **(Fre)**

[Radiofrequency ablation of the atrioventricular accessory pathways. Value of unipolar and bipolar recordings] Aliot E, et al. **Arch Mal Coeur Vaiss** 1996 Feb;89 Spec No 1:89–97 (35 ref.) (Eng. Abstr.) **(Fre)**

[The utility of electrocardiography in the age of exercise echocardiography] Boccardi L, et al. **Cardiologia** 1995 Nov; 40(11):807–12 (20 ref.) **(Ita)**

[Electrocardiogram in pre-excitation] Oreto G, et al. **G Ital Cardiol** 1996 Mar;26(3):303–22 (55 ref.) **(Ita)**

[Clinical usefulness of high-resolution electrocardiography] Arsénio A, et al. **Rev Port Cardiol** 1996 Apr;15(4):331–41 (87 ref.) **(Por)**

[Evaluation of a standard electrocardiogram in acute myocardial infarct and therapy with thrombolysis] Kuchárová L, et al. **Vnitr Lek** 1995 Dec;41(12):836–41 (43 ref.) (Eng. Abstr.) **(Slo)**

[Electrophysiological approach to the diagnosis of uncomplicated and complicated left ventricular blocks] de Micheli A, et al. **Arch Inst Cardiol Mex** 1996 Jan–Feb; 66(1):70–82 (27 ref.) **(Spa)**

[Electrophysiologic approach to the diagnosis of left ventricular hypertrophy] de Micheli A, et al. **Arch Inst Cardiol Mex** 1995 Jul–Aug;65(4):365–74 (12 ref.) **(Spa)**

[Complementary tests: conventional and Holter electrocardiography] Bayés de Luna A, et al. **Rev Esp Cardiol** 1995;48 Suppl 4:35–9 (23 ref.) (Eng. Abstr.) **(Spa)**

DRUG EFFECTS

Erythromycin-induced polymorphous ventricular tachycardia with normal QT interval. Chennareddy SB, et al. **Am Heart J** 1996 Sep;132(3):691–4 (11 ref.)

Pharmacological stress electrocardiography—when is it indicated? Davies J. **Br J Clin Pract Symp Suppl** 1995 Nov; 82:2–5 (3 ref.)

Tricyclic medication in children and the QT interval: case report and discussion. Alderton HR. **Can J Psychiatry** 1995 Aug;40(6):325–9 (30 ref.)

Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group. Jaillon P, et al. **J Antimicrob Chemother** 1996 May;37 Suppl A:161–7 (4 ref.)

[Calcium antagonists in treatment of ventricular tachycardia] Melichercik J, et al. **Z Kardiol** 1996 May;85(5):319–25 (31 ref.) (Eng. Abstr.) **(Ger)**

INSTRUMENTATION

Bedside diagnosis of wide QRS tachycardia [editorial; comment] Barold SS. **Pacing Clin Electrophysiol** 1995 Dec; 18(12 Pt 1):2109–15 (79 ref.) Comment on: Pacing Clin Electrophysiol 1995 Dec;18(12 Pt 1):2194–208.

–Practical implementation of stress echocardiography—what should be monitored?– Beckmann S, et al. **Herz** 1996 Feb; 21(1):65–70; discussion 64 (18 ref.) **(Ger)**

[In vivo registration of monophasic action potentials—new possible applications in clinical electrophysiology] Behrens S, et al. **Z Kardiol** 1996 May;85(5):326–33 (35 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Signal-averaged electrocardiography. **J Am Coll Cardiol** 1996 Jan;27(1):238–49 (138 ref.)

The P wave signal-averaged ECG. Ehlert FA, et al. **J Electrocardiol** 1995;28 Suppl:33–8 (12 ref.)

The signal-averaged high-resolution ECG. Selvester RH. **J Electrocardiol** 1995;28 Suppl:216–25 (74 ref.)

Signal-averaged electrocardiogram in chronic Chagas' heart disease. de Moraes AP, et al. **Rev Paul Med** 1995 Mar–Apr; 113(2):851–7 (26 ref.)

[Cardiointervalography in the practice of experimental and clinical pharmacology] Arushanian EB. **Eksp Klin Farmakol** 1995 Sep–Oct;58(5):74–8 (18 ref.) (Eng. Abstr.) **(Rus)**

[An analysis of heart rate variability. Spectrum analysis methods and complex signal demodulation] Burguera Pérez M, et al. **Rev Esp Cardiol** 1995 Oct;48(10):650–9 (49 ref.) (Eng. Abstr.) **(Spa)**

ELECTROCARDIOGRAPHY, AMBULATORY

Preoperative risk assessment: many studies, few solutions. Is a cardiac risk assessment paradigm possible? [editorial; comment] Mangano DT. **Anesthesiology** 1995 Nov; 83(5):897–901 (11 ref.) Comment on: Anesthesiology 1995 Nov;83(5):906–17.

[Ventricular extrasystole with R-on-T phenomenon in long-term ECG—prognostic relevance, subsequent diagnosis and therapeutic consequences?] Grimm W. **Internist (Berl)** 1995 Aug;36(8):847–50 (12 ref.) **(Ger)**

[Sinoatrial block caused by gastroesophageal reflux. The role of simultaneous 24 hr. esophageal pH-metry and Holter-ECG in the differential diagnosis of angina pectoris] Patai A, et al. **Orv Hetil** 1996 Mar 31;137(13):687–90 (38 ref.) (Eng. Abstr.) **(Hun)**

[Electrocardiographic Holter monitoring in patients with ventricular pre-excitation: possibilities of its uses and pitfalls] Jurkovičová O, et al. **Vnitr Lek** 1995 Sep; 41(9):629–36 (21 ref.) (Eng. Abstr.) **(Slo)**

[Complementary tests: conventional and Holter electrocardiography] Bayés de Luna A, et al. **Rev Esp Cardiol** 1995;48 Suppl 4:35–9 (23 ref.) (Eng. Abstr.) **(Spa)**

METHODS

Holter monitoring in Chagas' heart disease. Grupi CJ, et al. **Rev Paul Med** 1995 Mar–Apr;113(2):835–40 (40 ref.)

ELECTROCARDIOGRAPHY, DYNAMIC see **ELECTROCARDIOGRAPHY, AMBULATORY**

ELECTROCARDIOGRAPHY, HOLTER see **ELECTROCARDIOGRAPHY, AMBULATORY**

ELECTROCAUTERY see **ELECTROCOAGULATION**

ELECTROCHEMISTRY

[Biosensor models based on potentiometric and amperometric transducers for use in medicine, biotechnology, and environmental monitoring (review)] Reshetilov AN. **Prikl Biokhim Mikrobiol** 1996 Jan–Feb;32(1):78–93 (61 ref.) (Eng. Abstr.) **(Rus)**

INSTRUMENTATION

Dielectric relaxation spectroscopy and some applications in the pharmaceutical sciences. Smith G, et al. **J Pharm Sci** 1995 Sep;84(9):1029–44 (150 ref.)

METHODS

The potential of electroanalytical techniques in pharmaceutical analysis. Kauffmann JM, et al. **Acta Pharm Hung** 1996 Mar;66(2):57–64 (80 ref.)

Electrochemical detection of biomolecules in liquid chromatography and capillary electrophoresis. Chen JG, et al. **Adv Chromatogr** 1996;36:273–313 (60 ref.)

ELECTROCOAGULATION

Laparoscopic coagulation of myoma (myolysis). Goldfarb HA. **Obstet Gynecol Clin North Am** 1995 Dec;22(4):807–19 (32 ref.)

ADVERSE EFFECTS

Blindness due to electrocoagulation following functional endoscopic sinus surgery. Vanden Abeele D, et al. **J Laryngol Otol** 1996 Mar;110(3):261–4 (26 ref.)

Intraoperative fire with electrocautery. Brechtelsbauer PB, et al. **Otolaryngol Head Neck Surg** 1996 Feb;114(2):328–31 (17 ref.)

CONTRAINDICATIONS

[Electrocoagulation in patients with cardiac pacemakers: what should be considered?] Habicht JM, et al. **Chirurg** 1995 Aug;66(8):774–9 (22 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Pitfalls in polypectomy: from gene to cure. Waye JD. **Eur J Cancer** 1995 Jul–Aug;31A(7–8):1133–7 (15 ref.)

Colonoscopic biopsy and polypectomy. Pierzchajlo RP. **Prim Care** 1995 Sep;22(3):451–70 (78 ref.)

[Microwave coagulation therapy of hepatocellular carcinoma] Seki T, et al. **Nippon Naika Gakkai Zasshi** 1995 Dec 10;84(12):2024–7 (5 ref.) **(Jpn)**

ELECTROCONVULSIVE THERAPY

Electroconvulsive therapy: a guide for family physicians. Banazak DA. **Am Fam Physician** 1996 Jan;53(1):273–8, 281–2 (35 ref.)

Acute lymphocytic leukemia and psychosis: treatment with electroconvulsive therapy. Magen JG, et al. **Ann Clin Psychiatry** 1995 Sep;7(3):133–7 (27 ref.)

State of the art: nursing knowledge and electroconvulsive therapy. Froimson L, et al. **Convuls Ther** 1995 Sep; 11(3):205–11 (60 ref.)

Relapse and recurrence following a course of ECT: reasons for concern and strategies for further investigation. Grunhaus L, et al. **J Psychiatr Res** 1995 May–Jun; 29(3):165–72 (36 ref.)

Convulsive therapy in schizophrenia? Fink M, et al. **Schizophr Bull** 1996;22(1):27–39 (105 ref.)

Adjunctive treatments in schizophrenia: pharmacotherapies and electroconvulsive therapy. Johns CA, et al. **Schizophr Bull** 1995;21(4):607–19 (85 ref.)

[Development of electroconvulsive therapy] Brousil R. **Ceska Slov Psychiatr** 1995 Nov;91(5):299–304 (18 ref.) **(Cze)**

[Effect of adjuvant drug therapy following successful electroconvulsive therapy for therapy-resistant depression is still disappointing] Leentjens AF, et al. **Ned Tijdschr Geneeskd** 1996 Feb 3;140(5):241–3 (31 ref.) **(Dut)**

[Decisions regarding the technique of ECT] Bloch Y, et al. **Harefuah** 1995 Sep;129(5–6):206–11 (44 ref.) **(Heb)**

[Electro-convulsive therapy—review of law and literature] Tal I, et al. **Harefuah** 1996 Apr 1;130(7):470–4 (39 ref.) **(Heb)**

ADVERSE EFFECTS

ECT and non-memory cognition: a review. Calev A, et al. **Br J Clin Psychol** 1995 Nov;34 (Pt 4):505–15 (60 ref.)

Cognitive effects of electroconvulsive therapy: a clinical

review for nurses. Durr AL, et al. **Convuls Ther** 1995 Sep; 11(3):192–201 (33 ref.)
Does electroconvulsive therapy damage brain cells? Devanand DP. **Semin Neurol** 1995 Dec;15(4):351–7 (100 ref.)

METHODS

Fitting the treatment to the patient: recent advances in the practice of electroconvulsive therapy. Frukacz A, et al. **Aust N Z J Psychiatry** 1995 Sep;29(3):484–91 (24 ref.)
Prolongation of ECT-induced seizures with theophylline [letter] Stewart JT. **J Am Geriatr Soc** 1996 Apr;44(4):475 (9 ref.)

ELECTROCUTION, ACCIDENTAL see **ELECTRIC INJURIES**

ELECTRODES

Polyion-sensitive membrane electrodes for biomedical analysis. Meyerhoff ME, et al. **Anal Chem** 1996 Mar 1; 68(5):168A–175A (20 ref.)
Surface electrodes for physiological measurement and stimulation. Smith DC, et al. **Eur J Anaesthesiol** 1995 Sep; 12(5):451–69 (73 ref.)

UTILIZATION

Clinical and experimental evaluation of cranial TENS in the U.S.: a review. Taylor DN. **Acupunct Electrother Res** 1995 Apr–Jul;20(2):117–32 (45 ref.)

ELECTRODES, ENZYME see **BIOSENSORS**

ELECTRODES, MINIATURIZED see **MICROELECTRODES**

ELECTRODIAGNOSIS

Electrodiagnosis. Sheean GL, et al. **Curr Opin Neurol** 1995 Oct;8(5):339–44 (29 ref.)
Electrodiagnosis in the management of brachial plexus surgery. Deletis V, et al. **Hand Clin** 1995 Nov;11(4):555–61 (11 ref.)
General principles and use of electrodiagnostic studies in carpal and cubital tunnel syndromes. With special, attention to pitfalls and interpretation. Hilburn JW. **Hand Clin** 1996 May;12(2):205–21 (64 ref.)
Evoked potential testing. Vodušek DB. **Urol Clin North Am** 1996 Aug;23(3):427–46 (83 ref.)

INSTRUMENTATION

[Electrophysiologic diagnosis in erectile dysfunction] Jost WH, et al. **Urologe A** 1996 Mar;35(2):120–6 (32 ref.) (Eng. Abstr.) **(Ger)**

METHODS

New developments in EPG3 software. Jones W, et al. **Eur J Disord Commun** 1995;30(2):183–92 (22 ref.)
Diagnosis in neuromuscular diseases. Younger DS, et al. **Neurol Clin** 1996 Feb;14(1):135–68 (305 ref.)
Electrodiagnosis in compression neuropathies of the upper extremities. de Araujo MP. **Orthop Clin North Am** 1996 Apr;27(2):237–44 (50 ref.)
Differential diagnosis and pitfalls in electrodiagnostic studies and special tests for diagnosing compressive neuropathies. Kaufman MA. **Orthop Clin North Am** 1996 Apr; 27(2):245–52 (32 ref.)

ELECTROENCEPHALOGRAPHY

The possible role of a secondary pathogenetic factor in amyotrophic lateral sclerosis. Pinelli P, et al. **Adv Neurol** 1995;68:29–40 (25 ref.)
The EEG and neuroimaging in the management of the epilepsies. O'Donohoe NV. **Arch Dis Child** 1995 Dec; 73(6):552–7 (41 ref.)
The place of the EEG and imaging in the management of seizures. Verity CM. **Arch Dis Child** 1995 Dec;73(6):557–62 (34 ref.)
EEG slow waves and sleep spindles: windows on the sleeping brain. Dijk DJ. **Behav Brain Res** 1995 Jul–Aug; 69(1–2):109–16 (61 ref.)
Selected quantitative EEG (QEEG) and event-related potential (ERP) variables as discriminators for positive and negative schizophrenia. Gerez M, et al. **Biol Psychiatry** 1995 Jul 1;38(1):34–49 (152 ref.)
Exploring memory functions by means of brain electrical topography: a review. Rösler F, et al. **Brain Topogr** 1995 Summer;7(4):301–13 (45 ref.)
A review of the usefulness of the standard EEG in psychiatry. Hughes JR. **Clin Electroencephalogr** 1996 Jan; 27(1):35–9 (0 ref.)
Primary (idiopathic) generalized epilepsy and underlying mechanisms. Niedermeyer E. **Clin Electroencephalogr** 1996 Jan;27(1):1–21 (147 ref.)
Human EEG, behavioral stillness and biofeedback. Mulholland T. **Int J Psychophysiol** 1995 Apr;19(3):263–79 (107 ref.)
Brain electrical activity (quantitative EEG and bit-mapping neurocognitive CNV components), psychometrics and clinical findings in presenile subjects with initial mild cognitive decline or probable Alzheimer-type dementia. Zappoli R, et al. **Ital J Neurol Sci** 1995 Sep;16(6):341–76 (177 ref.)
The role of neuromonitoring in cardiovascular surgery. Edmonds HL Jr, et al. **J Cardiothorac Vasc Anesth** 1996 Jan;10(1):15–23 (51 ref.)
Electroclinical features of status epilepticus. Treiman DM. **J Clin Neurophysiol** 1995 Jul;12(4):343–62 (125 ref.)
Some considerations on estimating event-related brain signals. Krieger S, et al. **J Neural Transm Gen Sect** 1995; 99(1–3):103–29 (72 ref.)
Clinical correlations: MRI and EEG. Fish DR, et al. **Magn Reson Imaging** 1995;13(8):1113–7 (18 ref.)
Epileptiform electroencephalographic patterns. Westmoreland BF. **Mayo Clin Proc** 1996 May;71(5):501–11 (37 ref.)
Brain electrical activity in neurogerontology and psychogeriatric disorders. Franco-Maside A, et al. **Methods Find Exp Clin Pharmacol** 1995 Apr;17(3):207–24 (93 ref.)
Clinical evaluation and noninvasive electroencephalography. Preoperative evaluation. Cascino GD. **Neuroimaging Clin N Am** 1995 Nov;5(4):547–58 (58 ref.)
Diagnostic testing of seizure disorders. Gilliam F, et al. **Neurol Clin** 1996 Feb;14(1):61–84 (119 ref.)
Intraoperative electrocorticography in children with medically intractable epilepsy. Tanaka T, et al. **Neurol Med Chir (Tokyo)** 1996 Jul;36(7):440–6 (21 ref.)
Neuronal activities underlying the electroencephalogram and evoked potentials of sleeping and waking: implications for information processing. Coenen AM. **Neurosci Biobehav Rev** 1995 Fall;19(3):447–63 (75 ref.)
Electrophysiologic monitoring in head injury. Sloan TB. **New Horiz** 1995 Aug;3(3):431–8 (69 ref.)
Clinically relevant EEG studies and psychophysiological findings: possible neural mechanisms for multiple chemical sensitivity. Bell IR. **Toxicology** 1996 Jul 17;111(1–3):101–17 (122 ref.)
Mapping cognitive brain function with modern high-resolution electroencephalography. Gevins A, et al. **Trends Neurosci** 1995 Oct;18(10):429–36 (48 ref.)
[Sleep and intra-ictal epileptic electroencephalographic activities] Autret A. **Neurophysiol Clin** 1995;25(5):263–82 (111 ref.) (Eng. Abstr.) **(Fre)**
[The Quick Return Service of electroencephalogram] Shimazaki A, et al. **Rinsho Byori** 1995 Oct;43(10):1044–50 (4 ref.) (Eng. Abstr.) **(Jpn)**
[The development of electrocardiogram] Alfonso I, et al. **Rev Neurol** 1995;23 Suppl 3:S278–9 (12 ref.) **(Spa)**
[Neuroimaging techniques in the Gilles de la Tourette syndrome] Lampreave JL, et al. **Rev Neurol** 1996 Aug; 24(132):921–5 (39 ref.) (Eng. Abstr.) **(Spa)**

DRUG EFFECTS

Quantitative electroencephalography in aging brain and cerebrovascular disease: the effects of almitrine-raubasine. Sebban C. **Eur Neurol** 1995;35 Suppl 1:37–42 (16 ref.)
The EEG as a monitor of sedation: encouraging progress. Veselis RA. **J Clin Anesth** 1996 May;8(3 Suppl):81S–87S (69 ref.)
Design of clinical antiepileptic drug trials. Binnie CD. **Seizure** 1995 Sep;4(3):187–92 (14 ref.)
[Intraoperative awareness and auditory evoked potentials] Schwender D, et al. **Anaesthesist** 1996 Feb;45 Suppl 1:S46–51 (30 ref.) (Eng. Abstr.) **(Ger)**
[Clinical potency of nitrous oxide—is MAC the gold standard?] Schwilden H, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Oct; 30(6):337–40 (23 ref.) (Eng. Abstr.) **(Ger)**

INSTRUMENTATION

Neurophysiological monitoring of cranial nerves during posterior fossa surgery. Broggi G, et al. **Acta Neurochir Suppl (Wien)** 1995;64:35–9 (16 ref.)

METHODS

Invasive electroencephalography in the evaluation of supplementary motor area seizures. Van Ness PC. **Adv Neurol** 1996;70:319–40 (35 ref.)
Mapping function in the human brain with magnetoencephalography, anatomical magnetic resonance imaging, and functional magnetic resonance imaging. George JS, et al. **J Clin Neurophysiol** 1995 Sep;12(5):406–31 (90 ref.)
Intracranial electrophysiologic studies. Risinger MW, et al. **Neuroimaging Clin N Am** 1995 Nov;5(4):539–73 (60 ref.)
[Methods for analyzing brain evoked potentials clinically and in psychophysiology] Lytaev SA, et al. **Usp Fiziol Nauk** 1995 Jul–Sep;26(3):95–110 (106 ref.) (Eng. Abstr.) **(Rus)**

STANDARDS

Standard operating procedure (SOP) for the registration and computer-supported evaluation of pharmaco-EEG data. Working Team "EEG in Phase I" of CIPS. Versavel M, et al. **Pharmacopsychiatry** 1995 Nov;28(6):245–8 (8 ref.)

STATISTICS & NUMERICAL DATA

The analysis of the EEG. Gasser T, et al. **Stat Methods Med Res** 1996 Mar;5(1):67–99 (95 ref.)

TRENDS

Clinical neurophysiology of cortical sensorimotor function: yesterday, today, and tomorrow. Aminoff MJ. **J Clin Neurophysiol** 1996 May;13(3):219–26 (60 ref.)

VETERINARY

[Significance of electroencephalography for the diagnosis of seizures in dogs] Schütt-Mast I, et al. **Tierarztl Prax** 1996 Apr;24(2):129–36 (6 ref.) (Eng. Abstr.) **(Ger)**

ELECTROENCEPHALOGRAPHY, DELTA RHYTHM see **DELTA RHYTHM**

ELECTROFOCUSING see **ISOELECTRIC FOCUSING**

ELECTROHYDRAULIC SHOCKWAVE LITHOTRIPSY see **LITHOTRIPSY**

ELECTROIMMUNOBLOTTING see **IMMUNOBLOTTING**

ELECTROLYTES

see related
FLUID THERAPY
WATER-ELECTROLYTE BALANCE
WATER-ELECTROLYTE IMBALANCE

ADMINISTRATION & DOSAGE

Bowel preparation before colonoscopy. Choosing the best lavage regimen. Tooson JD, et al. **Postgrad Med** 1996 Aug; 100(2):203–4, 207–12, 214 (30 ref.)

ANALYSIS

Determination of inorganic ions of clinical interest: state-of-the-art and trends. Luque de Castro MD, et al. **J Pharm Biomed Anal** 1995 Jun;13(7):797–808 (235 ref.)

BLOOD

Colonoscopy preps: what's best? [editorial; comment] Keeffe EB. **Gastrointest Endosc** 1996 May;43(5):524–8 (30 ref.) Comment on: Gastrointest Endosc 1996 May;43(5):463–6. Comment on: Gastrointest Endosc 1996 May;43(5):467–9.

CHEMISTRY

Characterization of hydrogels using luminescence spectroscopy. Rangarajan B, et al. **Biomaterials** 1996 Apr; 17(7):649–61 (71 ref.)
The Dukhin–Deryaguin equation for the electrophoretic mobility in monovalent electrolytes with arbitrary ion mobilities. Egorova EM. **Electrophoresis** 1995 Jun; 16(6):905–10 (18 ref.)

METABOLISM

Electrolyte disturbances in chronic heart failure: metabolic and clinical aspects. Dei Cas L, et al. **Clin Cardiol** 1995 Jul;18(7):370–6 (103 ref.)
Renin–angiotensin–aldosterone system for blood pressure and electrolyte homeostasis and its involvement in hypertension, in congestive heart failure and in associated cardiovascular damage (myocardial infarction and stroke). Laragh JH. **J Hum Hypertens** 1995 Jun;9(6):385–90 (47 ref.)
[Electrolyte metabolism in renal tubules] Takahashi N, et al. **Nippon Rinsho** 1995 Aug;53(8):1868–72 (8 ref.) (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

Reducing arrhythmogenic effects in the isolated heart enriching roentgen contrast media with electrolytes. Survey and present state. Besjakov J, et al. **Acta Radiol Suppl** 1995;399:115–21 (53 ref.)

ELECTROMAGNETIC ENERGY see **RADIATION**

ELECTROMAGNETIC FIELDS

d'Arsonval Medal: address. some bioelectromagnetics research at the University of Utah: acceptance speech on the occasion of receiving the d'Arsonval Medal. Gandhi OP. **Bioelectromagnetics** 1996;17(1):3–9 (51 ref.)
Chronic relapsing multiple sclerosis: a case of rapid recovery by application of weak electromagnetic fields. Sandyk R. **Int J Neurosci** 1995 Jun;82(3–4):223–42 (160 ref.)
Effects of picotesla flux electromagnetic fields on dopaminergic transmission in Tourette's syndrome. Sandyk R. **Int J Neurosci** 1996 Feb;84(1–4):187–94 (95 ref.)
Speculations on the influence of electromagnetism on genomic and associated structures. Jacobson JI. **J Int Med Res** 1996 Jan–Feb;24(1):1–11 (49 ref.)
What occupations have been associated with brain cancer, and, more specifically, what is the connection between brain cancer and electric utility work? **J Occup Environ Med** 1995 Sep;37(9):1067–9 (46 ref.)
Cells, stress and EMFs. Smith O. **Nat Med** 1996 Jan;2(1):23–4 (13 ref.)
[Cardiac pacemaker dysfunction secondary to outside interference: a review] Grobéty M, et al. **Schweiz Med Wochenschr** 1996 Apr 27;126(17):723–33 (32

ref.) (Eng. Abstr.) **(Fre)**
[Safety aspects in MR imaging] Abart J, et al. **Aktuelle Radiol** 1995 Nov;5(6):376–84 (57 ref.) (Eng. Abstr.) **(Ger)**
[Electrocoagulation in patients with cardiac pacemakers: what should be considered?] Habicht JM, et al. **Chirurg** 1995 Aug;66(8):774–9 (22 ref.) (Eng. Abstr.) **(Ger)**
[Biotropic effects of electromagnetic fields: benefit or harm?] Agadzhanian NA, et al. **Aviakosm Ekolog Med** 1995; 29(4):9–12 (55 ref.) (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

Do power frequency magnetic fields cause leukemia in children? Levallois P. **Am J Prev Med** 1995 Jul–Aug; 11(4):263–70 (61 ref.)
Electromagnetic field exposure and cancer: a review of epidemiologic evidence. Heath CW Jr. **CA Cancer J Clin** 1996 Jan–Feb;46(1):29–44 (55 ref.)
The melatonin hypothesis: electric power and breast cancer. Stevens RG, et al. **Environ Health Perspect** 1996 Mar;104 Suppl 1:135–40 (66 ref.)
What can we infer from findings in subgroups? [editorial; comment] Hatch M. **Epidemiology** 1995 Sep;6(5):473–5 (4 ref.) Comment on: Epidemiology 1995 Sep;6(5):485–9.
Exposure to extremely low frequency electromagnetic fields and the risk of malignant diseases—an evaluation of epidemiological and experimental findings. Hardell L, et al. **Eur J Cancer Prev** 1995 Sep;4 Suppl 1:3–107 (314 ref.)
Free radical mechanism for the effects of environmental electromagnetic fields on biological systems. Brocklehurst B, et al. **Int J Radiat Biol** 1996 Jan;69(1):3–24 (45 ref.)
Reported biological consequences related to the suppression of melatonin by electric and magnetic field exposure. Reiter RJ. **Integr Physiol Behav Sci** 1995 Sep–Dec;30(4):314–30 (103 ref.)
Alleged health effects of electromagnetic fields: the misconceptions continue. Jauchem JR. **J Microw Power Electromagn Energy** 1995;30(3):165–77 (141 ref.)
Magnetic fields of video display terminals and pregnancy outcome. Lindbohm ML, et al. **J Occup Environ Med** 1995 Aug;37(8):952–6 (30 ref.)
Noise, impulse noise, and other physical factors: combined effects on hearing. Pekkarinen J. **Occup Med** 1995 Jul–Aug; 10(3):545–59 (152 ref.)
Nonionizing electromagnetic fields and cancer: a review. Salvatore JR, et al. **Oncology (Huntingt)** 1996 Apr; 10(4):563–70; discussion 573–4, 577–8 (71 ref.)
Low-frequency magnetic fields and cancer. What you should know and what to tell your patients. Salvatore JR. **Postgrad Med** 1996 Aug;100(2):183–8, 190 (21 ref.)
EMFs: cutting through the controversy. Wartenberg D. **Public Health Rep** 1996 May–Jun;111(3):204–17 (81 ref.)
Health risks of electric and magnetic fields caused by high-voltage systems in Finland. Valjus J. **Scand J Work Environ Health** 1996 Apr;22(2):85–93 (31 ref.)
Do electromagnetic fields cause brain tumors and other cancers? Deutsch S. **Semin Neurol** 1995 Sep;15(3):304–10 (13 ref.)
[Very low frequency electric and magnetic fields and the immune system] Petrini C, et al. **Ann Ist Super Sanita** 1995; 31(3):369–80 (64 ref.) (Eng. Abstr.) **(Ita)**
[Biological influences of electromagnetic fields] Kato M. **Hokkaido Igaku Zasshi** 1995 Jul;70(4):551–60 (21 ref.) (Eng. Abstr.) **(Jpn)**
[Biological effects of electromagnetic fields] Shimizu H, et al. **Nippon Eiseigaku Zasshi** 1995 Dec;50(5):919–31 (129 ref.) (Eng. Abstr.) **(Jpn)**
[Combined biological effect of electromagnetic fields and chemical substances (toxic)] Kamedula M, et al. **Med Pr** 1996;47(3):285–92 (20 ref.) (Eng. Abstr.) **(Pol)**

ELECTROMAGNETIC RADIATION see **RADIATION**

ELECTROMAGNETIC RADIATION, IONIZING see **RADIATION, IONIZING**

ELECTROMAGNETIC WAVES see **RADIATION**

ELECTROMAGNETICS

Therapeutic radiology: a potential unfolding through bioelectromagnetic sciences. Jacobson JI. **Altern Ther Health Med** 1996 Sep;2(5):49–55 (48 ref.)

ELECTROMYOGRAPHY

Mechanical and electromyographic stretch responses in spastic and healthy subjects. Toft E. **Acta Neurol Scand Suppl** 1995;163:1–24 (103 ref.)
Peripherally induced EMG silent periods. Normal physiology and disorders of motor control. Ford B, et al. **Adv Neurol** 1995;67:321–8 (47 ref.)
Technology assessment: the use of surface EMG in the diagnosis and treatment of nerve and muscle disorders. Haig AJ, et al. **Muscle Nerve** 1996 Mar;19(3):392–5 (21 ref.)
Technology assessment: dynamic electromyography in gait and motion analysis. Rechtien JJ, et al. **Muscle Nerve** 1996 Mar;19(3):396–402 (110 ref.)

INSTRUMENTATION

Neurophysiological monitoring of cranial nerves during posterior fossa surgery. Broggi G, et al. **Acta Neurochir Suppl (Wien)** 1995;64:35–9 (16 ref.)
[Current proctology—modern functional diagnosis] Feifel G, et al. **Chirurg** 1996 Mar;67(3):205–12 (33 ref.) (Eng. Abstr.) **(Ger)**
[Electrophysiologic diagnosis in erectile dysfunction] Jost WH, et al. **Urologe A** 1996 Mar;35(2):120–6 (32 ref.) (Eng. Abstr.) **(Ger)**

ELECTRON MICROSCOPY see **MICROSCOPY, ELECTRON**

ELECTRON MICROSCOPY, TRANSMISSION see **MICROSCOPY, ELECTRON**

ELECTRON NUCLEAR DOUBLE RESONANCE see **ELECTRON SPIN RESONANCE SPECTROSCOPY**

E' :RON PARAMAGNETIC RESONANCE see **.CTRON SPIN RESONANCE SPECTROSCOPY**

ELECTRON PROBE MICROANALYSIS

INSTRUMENTATION

[X-ray microscopy] Schmahl G, et al. **Naturwissenschaften** 1996 Feb;83(2):61–70 (43 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Ion localization and X-ray microanalysis. Hodson MJ. **Methods Cell Biol** 1995;49:21–31 (26 ref.)
[X-ray microscopy] Schmahl G, et al. **Naturwissenschaften** 1996 Feb;83(2):61–70 (43 ref.) (Eng. Abstr.) **(Ger)**

ELECTRON SPIN RESONANCE SPECTROSCOPY

[ESR-spectroscopy in medical practice and biomedical research] Maksina AG, et al. **Med Tekh** 1995 Sep–Oct; (5):32–4 (38 ref.) (Eng. Abstr.) **(Rus)**

ELECTRON TRANSPORT

Molecular recognition in protein complexes involved in electron transfer. Gómez-Moreno C, et al. **Biochem Soc Trans** 1996 Feb;24(1):111–6 (19 ref.)
Respiratory chains of archaea and extremophiles. Schäfer G, et al. **Biochim Biophys Acta** 1996 Jul 18;1275(1–2):16–20 (39 ref.)
Electron transfer and proton pumping in cytochrome oxidase. Brunori M, et al. **Biochimie** 1995;77(7–8):668–76 (58 ref.)
Biological electron transfer: structural and mechanistic studies. Canters GW, et al. **Biochimie** 1995;77(7–8):506–15 (87 ref.)
Flavocytochrome b2–cytochrome c interactions: the electron transfer reaction revisited. Capeillere-Blandin C. **Biochimie** 1995;77(7–8):516–30 (107 ref.)
Electron and proton transfer to the quinones in bacterial photosynthetic reaction centers: insight from combined approaches of molecular genetics and biophysics. Sebban P, et al. **Biochimie** 1995;77(7–8):677–94 (67 ref.)
Electron transfer in ruthenium-modified proteins. Bjerrum MJ, et al. **J Bioenerg Biomembr** 1995 Jun;27(3):295–302 (39 ref.)
Pathways, pathway tubes, pathway docking, and propagators in electron transfer proteins. Curry WB, et al. **J Bioenerg Biomembr** 1995 Jun;27(3):285–93 (65 ref.)
Biological electron transfer. Moser CC, et al. **J Bioenerg Biomembr** 1995 Jun;27(3):263–74 (70 ref.)
Respiratory-chain and pyruvate metabolism defects: Italian collaborative survey on 72 patients. Caruso U, et al. **J Inherit Metab Dis** 1996;19(2):143–8 (6 ref.)
The currents of life: the terminal electron-transfer complex of respiration [comment] Ramirez BE, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):11949–51 (27 ref.) Comment on: Proc Natl Acad Sci U S A 1995 Dec 19;92(26):11955–9.

GENETICS

Clinical presentations and laboratory investigations in respiratory chain deficiency. Munnich A, et al. **Eur J Pediatr** 1996 Apr;155(4):262–74 (28 ref.)

PHYSIOLOGY

Control of electron transfer in neuronal nitric oxide synthase by calmodulin, substrate, substrate analogs, and nitric oxide. Stuehr DJ, et al. **Adv Pharmacol** 1995;34:207–13 (15 ref.)
Enzymes and associated electron transport systems that catalyse the respiratory reduction of nitrogen oxides and oxyanions. Berks BC, et al. **Biochim Biophys Acta** 1995 Dec 12;1232(3):97–173 (625 ref.)

ELECTRONARCOSIS

see related
ELECTRIC STIMULATION THERAPY

ELECTRONIC DATA PROCESSING see **AUTOMATIC DATA PROCESSING**

ELECTRONIC MAIL see **COMPUTER COMMUNICATION NETWORKS**

ELECTRONICS, MEDICAL

Immobilization of enzymes/coenzymes for molecular electronics applications. Phadke RS. **Biosystems** 1995; 35(2–3):179–82 (14 ref.)
Principles of development and design of microsystems. Wagner B. **Endosc Surg Allied Technol** 1995 Aug;3(4):204–9 (26 ref.)

ELECTRONS

Electron beam treatment for cutaneous T-cell lymphoma. Jones GW, et al. **Hematol Oncol Clin North Am** 1995 Oct; 9(5):1057–76 (44 ref.)
[External electron irradiation in 2 cases of capillary hemangioma of the optic disk] Schlienger P, et al. **Bull Cancer Radiother** 1995;82(3):306–10 (29 ref.) (Eng. Abstr.) **(Fre)**

ELECTRONYSTAGMOGRAPHY

Comparison of assessment of caloric nystagmus by observation of duration and by electronystagmographic measurement of slow-phase velocity [see comments] Luxon L. **Br J Audiol** 1995 Apr;29(2):107–15 (29 ref.) Comment in: Br J Audiol 1995 Apr;29(2):83–6.
Assessment: electronystagmography. Report of the Therapeutics and Technology Assessment Subcommittee. **Neurology** 1996 Jun;46(6):1763–6 (9 ref.)

ELECTROPHORESIS

Theory and practice of gel electrophoresis of interacting macromolecules. Cann JR. **Anal Biochem** 1996 May 15; 237(1):1–16 (119 ref.)
Models of gel electrophoresis. Kozulić B. **Anal Biochem** 1995 Oct 10;231(1):1–12 (138 ref.)
Theory of the mobility-shift assay of nonspecific protein–DNA complexes governed by conditional probabilities: the HU:DNA complex. Cann JR, et al. **Electrophoresis** 1995 Jun;16(6):881–7 (29 ref.)
The Dukhin–Deryaguin equation for the electrophoretic mobility in monovalent electrolytes with arbitrary ion mobilities. Egorova EM. **Electrophoresis** 1995 Jun; 16(6):905–10 (18 ref.)
Indirect DNA/gene diagnoses via electrophoresis—an obsolete principle? Epplen JT, et al. **Electrophoresis** 1995 May;16(5):683–90 (53 ref.)
A computer model for time-based simulation of electrophoresis systems with freely defined initial and boundary conditions. Schafer-Nielsen C. **Electrophoresis** 1995 Aug;16(8):1369–76 (13 ref.)
Fluorophore-assisted carbohydrate electrophoresis in the separation, analysis, and sequencing of carbohydrates. Starr CM, et al. **J Chromatogr A** 1996 Jan 12;720(1–2):295–321 (42 ref.)
[Affinity electrophoresis—its application for studies on heterogeneity and functions of biomolecules] Nakamura K. **Seikagaku** 1996 Apr;68(4):265–81 (57 ref.) **(Jpn)**

METHODS

Benefits of advanced gel electrophoresis data analysis methods. Tietz D. **Appl Theor Electrophor** 1995;5(2):107–11 (24 ref.)
New types of separation matrices for electrophoresis. Chiari M, et al. **Electrophoresis** 1995 Oct;16(10):1815–29 (103 ref.)
Quantitative and automated electrophoresis in sieving media. Chrambach A. **Electrophoresis** 1996 Mar;17(3):454–64 (70 ref.)
Detection of mismatched bases in double stranded DNA by gel electrophoresis. Ganguly A, et al. **Electrophoresis** 1995 Oct;16(10):1830–5 (49 ref.)
Separation and detection of amino acids and their enantiomers by capillary electrophoresis: a review. Issaq HJ, et al. **Electrophoresis** 1995 Apr;16(4):467–80 (81 ref.)
Chiral separations by capillary electrophoresis. Rogan MM, et al. **Methods Mol Biol** 1996;52:171–96 (80 ref.)
Separation of plant proteins by electrophoresis. Shewry PR, et al. **Methods Mol Biol** 1995;49:399–422 (26 ref.)

ELECTROPHORESIS, AGAR GEL

[Agarose gel electrophoresis] Shimada M. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):477–9 (1 ref.) **(Jpn)**

INSTRUMENTATION

Commercial automated gel electrophoresis apparatus: application to DNA, band dispersion, nonlinear Ferguson curves, and isolation. Chrambach A, et al. **Electrophoresis** 1995 May;16(5):713–8 (26 ref.)

METHODS

The single cell gel electrophoresis/comet assay: a potential tool for detecting radiation-induced DNA damage in

humans. Tice RR, et al. **Stem Cells (Dayt)** 1995 May;13 Suppl 1:207–14 (12 ref.)
[Classical and pulsed gel electrophoresis of biopolymers. Theory and applications] Chebotarev VIu, et al. **Biofizika** 1992 Mar–Apr;37(2):243–89 (85 ref.) (Eng. Abstr.) **(Rus)**

ELECTROPHORESIS, AGAROSE GEL see **ELECTROPHORESIS, AGAR GEL**

ELECTROPHORESIS, CAPILLARY

Capillary electrophoresis with wavelength–resolved fluorescence detection. Timperman AT, et al. **Analyst** 1996 May;121(5):45R–52R (65 ref.)
Peptide chemistry: development of high performance liquid chromatography and capillary zone electrophoresis. Miller C, et al. **Biopolymers** 1996;40(3):265–317 (124 ref.)
Determination of drug–related impurities by capillary electrophoresis. Altria KD. **J Chromatogr A** 1996 May 31; 735(1–2):43–56 (58 ref.)
Capillary gel electrophoresis and antisense therapeutics. Analysis of DNA analogs. DeDionisio LA, et al. **J Chromatogr A** 1996 May 31;735(1–2):191–208 (32 ref.)
Identification of chiral drug isomers by capillary electrophoresis. Fanali S. **J Chromatogr A** 1996 May 31; 735(1–2):77–121 (204 ref.)
Separation of neutral carbohydrates by capillary electrophoresis. Honda S. **J Chromatogr A** 1996 Jan 12; 720(1–2):337–51 (44 ref.)
Analysis of glycoproteins, glycopeptides and glycoprotein–derived oligosaccharides by high–performance capillary electrophoresis. Kakehi K, et al. **J Chromatogr A** 1996 Jan 12;720(1–2):377–93 (48 ref.)
Separation of negatively charged carbohydrates by capillary electrophoresis. Linhardt RJ, et al. **J Chromatogr A** 1996 Jan 12;720(1–2):323–35 (67 ref.)
Application of capillary electrophoresis and related techniques to drug metabolism studies. Naylor S, et al. **J Chromatogr A** 1996 May 31;735(1–2):415–38 (139 ref.)
Capillary electrophoresis of cardiovascular drugs. Nguyen NT, et al. **J Chromatogr A** 1996 May 31;735(1–2):123–50 (95 ref.)
Detection of carbohydrates in capillary electrophoresis. Paulus A, et al. **J Chromatogr A** 1996 Jan 12; 720(1–2):353–76 (88 ref.)
Capillary electrophoresis of diuretics. Riekkola ML, et al. **J Chromatogr A** 1996 May 31;735(1–2):151–64 (23 ref.)

METHODS

Electrochemical detection of biomolecules in liquid chromatography and capillary electrophoresis. Chen JG, et al. **Adv Chromatogr** 1996;36:273–313 (60 ref.)
Microdialysis sampling for pharmacological studies: HPLC and CE analysis. Lunte SM, et al. **Adv Chromatogr** 1996; 36:383–432 (73 ref.)
Capillary electrophoresis. Xu Y. **Anal Chem** 1995 Jun 15; 67(12):463R–473R (162 ref.)
Monitoring of herbicide pollution in water by capillary electrophoresis. Dinelli G, et al. **J Chromatogr A** 1996 May 10;733(1–2):337–47 (60 ref.)
Capillary electrophoretic analyses of drugs in body fluids: sample pretreatment and methods for direct injection of biofluids. Lloyd DK. **J Chromatogr A** 1996 May 31; 735(1–2):29–42 (69 ref.)
Capillary electrophoresis of proteins. van de Goor TA. **Pharm Biotechnol** 1995;7:301–27 (103 ref.)

ELECTROPHORESIS, GEL, PULSED–FIELD

Analysis of bacterial genomes by pulsed field gel electrophoresis. Méndez–Alvarez S, et al. **Microbiologia** 1995 Sep;11(3):323–36 (93 ref.)

ELECTROPHORESIS, GEL, PULSED–FIELD GRADIENT see **ELECTROPHORESIS, GEL, PULSED–FIELD**

ELECTROPHORESIS, GEL, TWO–DIMENSIONAL

Two–dimensional DNA typing: A cost–effective way of analyzing complex mixtures of DNA fragments for sequence variations. Vijg J. **Mol Biotechnol** 1995 Dec; 4(3):275–95 (53 ref.)

METHODS

[High resolutional two–dimension electrophoresis of DNA: a refinement of RLGS method] Asakawa J. **Tanpakushitsu Kakusan Koso** 1996 Feb;41(2):170–7 (8 ref.) **(Jpn)**
[An ambient and low temperature two–dimensional electrophoresis: a convenient way to detect cold–dissociable proteins] Matsuo T. **Tanpakushitsu Kakusan Koso** 1995 Sep;40(12):1867–70 (7 ref.) **(Jpn)**

ELECTROPHORESIS, POLYACRYLAMIDE GEL

Mass spectrometric approaches for the identification of gel–separated proteins. Patterson SD, et al. **Electrophoresis** 1995 Oct;16(10):1791–814 (202 ref.)
[Polyacryl amide gel electrophoresis] Shimada M. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):480–2 (4 ref.) **(Jpn)**

METHODS

Molecular analysis of mutations in thyroid tumors with TGGE. Simon D, et al. **Exp Clin Endocrinol Diabetes** 1995; 103(5):275–9 (36 ref.)
[Classical and pulsed gel electrophoresis of biopolymers. Theory and applications] Chebotarev VIu, et al. **Biofizika** 1992 Mar–Apr;37(2):243–89 (85 ref.) (Eng. Abstr.) **(Rus)**

ELECTROPHYSIOLOGY

Mechanisms for electrical stimulation of excitable tissue. Roth BJ. **Crit Rev Biomed Eng** 1994;22(3–4):253–305 (194 ref.)
The resting membrane potential of cells are measures of electrical work, not of ionic currents. Veech RL, et al. **Integr Physiol Behav Sci** 1995 Sep–Dec;30(4):283–307 (46 ref.)
Electrophysiological monitoring and mild hypothermia. Kochs E. **J Neurosurg Anesthesiol** 1995 Jul;7(3):222–8 (56 ref.)
Electrophysiology of dopamine D–1 receptors in the basal ganglia: old facts and new perspectives. Stefani A, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1995 Sep; 19(5):779–93 (45 ref.)

INSTRUMENTATION

Surface electrodes for physiological measurement and stimulation. Smith DC, et al. **Eur J Anaesthesiol** 1995 Sep; 12(5):451–69 (73 ref.)
Electrical safety measures for physicians using electromedical equipment. Laks MM, et al. **Semin Neurol** 1995 Sep; 15(3):311–6 (24 ref.)

METHODS

Electrophysiological methods. Avery L, et al. **Methods Cell Biol** 1995;48:251–69 (20 ref.)
[A research tool for autonomic nervous function: methodology and application of microneurography] Mano T. **Masui** 1995;44 Suppl:S17–25 (41 ref.) **(Jpn)**

STANDARDS

Are intracardiac electrophysiological studies in healthy volunteers ethical? Time for multinational recommendations [editorial; comment] Funck–Brentano C. **J Cardiovasc Pharmacol** 1995 Oct;26(4):524–7 (18 ref.) Comment on: J Cardiovasc Pharmacol 1995 Oct;26(4):528–9. Comment on: J Cardiovasc Pharmacol 1995 Oct;26(4):530–40.

ELECTROPORATION

Electroporation theory. Concepts and mechanisms. Weaver JC. **Methods Mol Biol** 1995;47:1–26 (64 ref.)
Electroporation theory. Concepts and mechanisms. Weaver JC. **Methods Mol Biol** 1995;48:3–28 (64 ref.)
Electroporation theory. Concepts and mechanisms. Weaver JC. **Methods Mol Biol** 1995;55:3–28 (64 ref.)

INSTRUMENTATION

Instrumentation. Hofmann GA. **Methods Mol Biol** 1995; 47:27–45 (11 ref.)

METHODS

Effects of pulse length and strength on electroporation efficiency. Hui SW. **Methods Mol Biol** 1995;55:29–40 (20 ref.)

ELECTRORETINOGRAPHY

The relationship between visual field size and electroretinogram amplitude in retinitis pigmentosa. Sandberg MA, et al. **Invest Ophthalmol Vis Sci** 1996 Jul; 37(8):1693–8 (10 ref.)
Beta wave of the scotopic (rod) electroretinogram as a measure of the activity of human on–bipolar cells. Hood DC, et al. **J Opt Soc Am A** 1996 Mar;13(3):623–33 (54 ref.)
Electroretinogram flicker photometry and its applications. Jacobs GH, et al. **J Opt Soc Am A** 1996 Mar;13(3):641–8 (42 ref.)

STANDARDS

The ERG is alive and well [editorial; comment] Marmor MF. **Arch Ophthalmol** 1995 Nov;113(11):1371–2 (11 ref.) Comment on: Arch Ophthalmol 1995 Nov;113(11):1375–6.

ELECTROSHOCK

Biophysical mechanisms of cell membrane damage in electrical shock. Lee RC, et al. **Semin Neurol** 1995 Dec; 15(4):367–74 (28 ref.)

ELECTROSHOCK THERAPY see **ELECTROCONVULSIVE THERAPY**

ELECTROSURGERY

Treatment of arrhythmias by radiofrequency ablation. De Giovanni JV. **Arch Dis Child** 1995 Nov;73(5):385–7 (18 ref.)
Future therapeutic procedures. Edell ES. **Chest Surg Clin N Am** 1996 May;6(2):381–95 (93 ref.)

ADVERSE EFFECTS

Laparoscopic electrosurgical complications and their prevention. Tucker RD, et al. **AORN J** 1995 Jul;62(1):51–3, 55, 58–9 passim; quiz 74–7 (16 ref.)

METHODS

Electrosurgery: principles and safety issues. Odell RC. **Clin Obstet Gynecol** 1995 Sep;38(3):610–21 (15 ref.)
Large loop excision of the transformation zone. Prendiville W. **Clin Obstet Gynecol** 1995 Sep;38(3):622–39 (41 ref.)
Transanal electroresection of small rectal cancer: a sole treatment? Faivre J, et al. **Dis Colon Rectum** 1996 Mar; 39(3):270–8 (39 ref.)
[Electrosurgery. Principles and practical uses] Wery OM, et al. **Contracept Fertil Sex** 1995 Nov;23(11):651–4 (7 ref.) **(Fre)**

ELECTROTHERAPY see **ELECTRIC STIMULATION THERAPY**

ELECTROVERSION, CARDIAC see **ELECTRIC COUNTERSHOCK**

ELEMENTS

see related
ISOTOPES
RADIOISOTOPES

ELEPHANTIASIS, BANCROFTIAN see **ELEPHANTIASIS, FILARIAL**

ELEPHANTIASIS, FILARIAL

IMMUNOLOGY

Immunoregulation in human lymphatic filariasis: the role of interleukin 10. Mahanty S, et al. **Parasite Immunol** 1995 Aug;17(8):385–92 (51 ref.)

ELFIN FACIES SYNDROME see **WILLIAMS SYNDROME**

ELIGIBILITY DETERMINATION

see related
DISABILITY EVALUATION

ELISA see **ENZYME–LINKED IMMUNOSORBENT ASSAY**

ELLIPTOCYTOSIS, HEREDITARY

see related
ANEMIA, SIDEROBLASTIC

ELLIS–VAN CREVELD SYNDROME

RADIOGRAPHY

[The Ellis–van Creveld syndrome. A case report] Gambardella A, et al. **Radiol Med (Torino)** 1995 Sep; 90(3):311–3 (8 ref.) **(Ita)**

ELONGATION FACTOR TU see **PEPTIDE ELONGATION FACTOR TU**

EMBOLECTOMY

see related
THROMBECTOMY
Massive endobronchial hemorrhage after pulmonary embolectomy. Shimokawa S, et al. **Ann Thorac Surg** 1996 Apr;61(4):1241–2 (11 ref.)

INSTRUMENTATION

[Extensive acute pulmonary embolism: fragmentation treatment with a rotatable pigtail catheter] Schmitz–Rode T, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Feb;164(2):150–2 (12 ref.) (Eng. Abstr.) **(Ger)**

METHODS

[Unilateral pulmonary embolectomy without extracorporeal circulation. A report of a clinical case] Barboso G, et al. **Acta Biomed Ateneo Parmense** 1995;66(1–2):53–5 (10 ref.) (Eng. Abstr.) **(Ita)**

EMBOLIC TUMOR CELLS see **NEOPLASM CIRCULATING CELLS**

EMBOLISM

see related
EMBOLECTOMY

COMPLICATIONS

Fibrocartilaginous embolism of the spinal cord: a clinical and pathogenetic reconsideration. Tosi L, et al. **J Neurol Neurosurg Psychiatry** 1996 Jan;60(1):55–60 (44 ref.)

Myelopathy associated with fibrocartilaginous emboli (FE): review and two suspected cases. McLean JM, et al. **Surg Neurol** 1995 Sep;44(3):228–34; discussion 234–5 (46 ref.)

[Cardiogenic cerebral embolism] Rubio F, et al. **Rev Neurol** 1995;23 Suppl 1:S53–60 (98 ref.) **(Spa)**

DRUG THERAPY

[Thrombolytic therapy of renal artery embolism. An expanded case report with review of the literature] Gulba DC, et al. **Internist (Berl)** 1996 Jun;37(6):623–7 (51 ref.) **(Ger)**

ETIOLOGY

Paradoxical bullet embolism: case report and literature review. Schurr M, et al. **J Trauma** 1996 Jun;40(6):1034–6 (11 ref.)

PHYSIOPATHOLOGY

[Cardiogenic cerebral embolism] Rubio F, et al. **Rev Neurol** 1995;23 Suppl 1:S53–60 (98 ref.) **(Spa)**

RADIOGRAPHY

Carotid artery pseudoaneurysm and pellet embolism to the middle cerebral artery following a shotgun wound of the neck. Cogbill TH, et al. **J Trauma** 1995 Oct;39(4):763–7 (16 ref.)

THERAPY

[Medical treatment of arm embolisms] Boissier C, et al. **J Mal Vasc** 1996;21 Suppl A:68–71 (11 ref.) (Eng. Abstr.) **(Fre)**

[Atheromatous embolisms and cholesterol embolisms: medical treatment] Vayssairat M, et al. **J Mal Vasc** 1996; 21 Suppl A:97–9 (17 ref.) (Eng. Abstr.) **(Fre)**

ULTRASONOGRAPHY

Transesophageal echocardiography in diagnosing cardioembolic stroke. Husain AM, et al. **Clin Cardiol** 1995 Dec;18(12):705–8 (14 ref.)

[Detection of cardiac embolism by transcranial Doppler] Pettelot G, et al. **Ann Cardiol Angeiol (Paris)** 1996 Jan; 45(1):34–8 (19 ref.) (Eng. Abstr.) **(Fre)**

[Transesophageal echocardiography. Indications and clinical impact] Campos Filho O. **Arq Bras Cardiol** 1995 Apr; 64(4):383–9 (47 ref.) **(Por)**

EMBOLISM, AIR

see related
DECOMPRESSION SICKNESS

ETIOLOGY

Pneumatosis intestinalis and portal venous air associated with needle catheter jejunostomy. North JH Jr, et al. **Am Surg** 1995 Dec;61(12):1045–8 (25 ref.)

Hepatic-portal venous gas associated with ileus. Quirke TE. **Am Surg** 1995 Dec;61(12):1084–6 (12 ref.)

Gas embolism complicating obstetric or gynecologic procedures. Case reports and review of the literature. Mushkat Y, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Nov;63(1):97–103 (54 ref.)

Gas embolism in obstetrics and gynecology. A review. Weissman A, et al. **J Reprod Med** 1996 Feb;41(2):103–11 (89 ref.)

Venous gas embolism during cryosurgery for bone tumors. Schreuder HW, et al. **J Surg Oncol** 1995 Nov;60(3):196–200 (11 ref.)

Air embolism during cardiopulmonary bypass. Kurusz M, et al. **Perfusion** 1995 Nov;10(6):361–91 (389 ref.)

[Prognosis in iatrogenic gas embolism] Boussuges A, et al. **Minerva Med** 1995 Nov;86(11):453–7 (29 ref.) (Eng. Abstr.) **(Ita)**

[Arterial air embolism in explosive trauma to the lungs] Fomin NF, et al. **Vestn Khir Im I I Grek** 1995;154(2):120–3 (26 ref.) **(Rus)**

[Air embolism in neurosurgical interventions] Lubnin ALu, et al. **Zh Vopr Neirokhir Im N N Burdenko** 1995 Oct–Dec; (4):33–8 (80 ref.) **(Rus)**

PHYSIOPATHOLOGY

Air embolism during cardiopulmonary bypass. Kurusz M, et al. **Perfusion** 1995 Nov;10(6):361–91 (389 ref.)

EMBOLISM, AMNIOTIC FLUID

Amniotic fluid embolism. Martin RW. **Clin Obstet Gynecol** 1996 Mar;39(1):101–6 (26 ref.)

ETIOLOGY

Amniotic fluid embolism syndrome: case report and review. McDougall RJ, et al. **Anaesth Intensive Care** 1995 Dec; 23(6):735–40 (35 ref.)

EMBOLISM, CHOLESTEROL

see related
BLUE TOE SYNDROME

[Systemic cholesterol embolism] Ghannem M, et al. **Ann Cardiol Angeiol (Paris)** 1995 Oct;44(8):422–6 (24 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

Is cholesterol embolic disease an unrecognized cause of renal graft dysfunction? de Takats DL, et al. **Nephrol Dial Transplant** 1996 Jul;11(7):1325–7 (13 ref.)

ETIOLOGY

Atheroembolic disease. Robson MG, et al. **Br J Hosp Med** 1996 May 15–Jun 4;55(10):648–52 (22 ref.)

Cholesterol emboli presenting as acute allograft dysfunction after renal transplantation. Singh I, et al. **J Am Soc Nephrol** 1995 Aug;6(2):165–70 (25 ref.)

Thrombolytic-associated cholesterol emboli syndrome: case report and literature review. Geraets DR, et al. **Pharmacotherapy** 1995 Jul–Aug;15(4):441–50 (51 ref.)

[Multiple cholesterol emboli] Sidoti CP, et al. **Rev Med Suisse Romande** 1996 Jun;116(6):473–82 (22 ref.) **(Fre)**

PHYSIOPATHOLOGY

[Cholesterol emboli] Weisz G, et al. **Harefuah** 1996 Apr 15; 130(8):532–5 (38 ref.) **(Heb)**

SURGERY

[Emboligenic aortopathies. Cholesterol embolisms: surgical treatment] Fichelle JM, et al. **J Mal Vasc** 1996;21 Suppl A:100–12 (73 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

[Atheromatous embolisms and cholesterol embolisms: medical treatment] Vayssairat M, et al. **J Mal Vasc** 1996; 21 Suppl A:97–9 (17 ref.) (Eng. Abstr.) **(Fre)**

EMBOLISM, FAT

Fat embolism syndrome. Johnson MJ, et al. **Orthopedics** 1996 Jan;19(1):41–8; discussion 48–9 (131 ref.)

ETIOLOGY

[Systemic complications in intramedullary nailing] Wenda K, et al. **Orthopade** 1996 Jun;25(3):292–9 (28 ref.) (Eng. Abstr.) **(Ger)**

EMBOLISM, GAS see **EMBOLISM, AIR**

EMBOLISM, TUMOR see **NEOPLASM CIRCULATING CELLS**

EMBOLIZATION, THERAPEUTIC

Complications after multidisciplinary treatment of cerebral arteriovenous malformations. Deruty R, et al. **Acta Neurochir (Wien)** 1996;138(2):119–31 (46 ref.)

Interventional neuroradiology. Pelz DM. **Baillieres Clin Neurol** 1995 Aug;4(2):297–315 (60 ref.)

Interventional radiology in the treatment of blunt liver trauma: case report with review of literature. Harms J, et al. **Bildgebung** 1996 Mar;63(1):51–4 (22 ref.)

Case report: bleeding gastric varices secondary to splenic vein thrombosis successfully treated by splenic artery embolization. McDermott VG, et al. **Br J Radiol** 1995 Aug; 68(812):928–30 (14 ref.)

Posttraumatic high-flow priapism treated by N-butyl-cyanoacrylate embolization. Numan F, et al. **Cardiovasc Intervent Radiol** 1996 Jul–Aug;19(4):278–80 (22 ref.)

Combined malformation of the Vein of Galen and of spinal vessels: endovascular embolization. Hammen A, et al. **Clin Neuropathol** 1995 Jul–Aug;14(4):233–6 (15 ref.)

Endovascular therapy for surgical diseases of the cranial base. Chaloupka JC, et al. **Clin Plast Surg** 1995 Jul;22(3):417–50 (193 ref.)

Place of emergency arterial embolisation in obstetric haemorrhage about 16 personal cases. Merland JJ, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Mar;65(1):141–3 (20 ref.)

Cure, morbidity, and mortality associated with embolization of brain arteriovenous malformations: a review of 1246 patients in 32 series over a 35-year period. Frizzel RT, et al. **Neurosurgery** 1995 Dec;37(6):1031–9; discussion 1039–40 (56 ref.)

Childhood dural arteriovenous fistulae of the posterior dural sinuses: three case reports and literature review. Morita A, et al. **Neurosurgery** 1995 Dec;37(6):1193–9; discussion 1199–200 (34 ref.)

[Therapeutic risk in multidisciplinary approach of cerebral arteriovenous malformations] Deruty R, et al. **Neurochirurgie** 1996;42(1):35–43 (46 ref.) (Eng. Abstr.) **(Fre)**

[Failures and complications of bronchial artery embolization] Mesurolle B, et al. **Rev Mal Respir** 1996 Jul;13(3):217–25 (74 ref.) (Eng. Abstr.) **(Fre)**

[Pulmonary arteriovenous fistulae and brain abscesses: a report of 2 cases treated by embolization and a review of the literature] Ricci P, et al. **Radiol Med (Torino)** 1996 Apr; 91(4):497–501 (24 ref.) **(Ita)**

[TAE therapy of hepatocellular carcinoma] Kudo M. **Nippon Naika Gakkai Zasshi** 1995 Dec 10;84(12):2012–8 (7 ref.) **(Jpn)**

[A patient with Rendu-Osler-Weber disease and pulmonary arteriovenous malformations treated satisfactorily by embolization] Martin Diaz E, et al. **Arch Bronconeumol** 1996 Jun-Jul;32(6):307–9 (12 ref.) (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Deep venous thrombosis with pulmonary embolus after selective embolization of an internal iliac artery aneurysm. Su WT, et al. **J Vasc Surg** 1996 Jan;23(1):152–5 (13 ref.)

[Retroperitoneal abscess formation accompanied by intraabdominal free air, a rare complication of transcatheter arterial embolization of renal tumor: a case report] Koga F, et al. **Hinyokika Kiyo** 1996 Jun;42(6):443–6 (7 ref.) (Eng. Abstr.) **(Jpn)**

INSTRUMENTATION

New closure devices for left-to-right shunt. Hijazi ZM. **Indian Heart J** 1996 Mar–Apr;48(2):119–23 (22 ref.)

METHODS

Role of transarterial embolization in the management of cerebral arteriovenous malformations. Wikholm G. **Acta Radiol Suppl** 1996;404:1–25 (118 ref.)

A case of hemobilia after percutaneous liver biopsy treated by transcatheter arterial embolization with Histoacryl. Murata K, et al. **Am J Gastroenterol** 1996 Jan;91(1):160 (8 ref.)

[Postpartum hemorrhage. Current management] Bertault D, et al. **Presse Med** 1995 Oct 14;24(30):1397–9 (15 ref.) (Eng. Abstr.) **(Fre)**

[Experiences with the endovascular embolization therapy of aneurysms of the splanchnic arteries—a report on 13 cases] Kramann B, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1995 Nov;163(5):417–23 (35 ref.) (Eng. Abstr.) **(Ger)**

[Selective embolization with an adhesive fluid of complicated aneurysms of the hepatic artery: 3 cases] Cotroneo AR, et al. **Radiol Med (Torino)** 1996 Apr;91(4):492–6 (21 ref.) **(Ita)**

STANDARDS

Conservative management options for cervical pregnancy; case reports and literature review. Creinin MD, et al. **Int J Fertil Menopausal Stud** 1995 Jul–Aug;40(4):175–86 (67 ref.)

EMBOLUS see **EMBOLISM**

EMBRYO

see related
CELL DIFFERENTIATION
FETUS
GESTATIONAL AGE

Ethical and policy issues in human embryo twinning. Bonnicksen AL. **Camb Q Healthc Ethics** 1995 Summer; 4(3):268–84 (94 ref.)

Update in preimplantation genetic diagnosis: successes, advances, and problems. Grifo JA, et al. **Curr Opin Obstet Gynecol** 1996 Apr;8(2):135–8 (31 ref.)

The case of the switched embryos. Robertson JA. **Hastings Cent Rep** 1995 Nov–Dec;25(6):13–9 (24 ref.)

Strategies for the isolation and characterization of bovine embryonic stem cells. Cherny RA, et al. **Reprod Fertil Dev** 1994;6(5):569–75 (30 ref.)

Systems for production of calves from cultured bovine embryonic cells. First NL, et al. **Reprod Fertil Dev** 1994; 6(5):553–62 (35 ref.)

Studies of in vitro differentiation with embryonic stem cells. Pedersen RA. **Reprod Fertil Dev** 1994;6(5):543–52 (139 ref.)

Development and validation of swine embryonic stem cells: a review. Wheeler MB. **Reprod Fertil Dev** 1994;6(5):563–8 (59 ref.)

Embryonic stem cells in farm animals. Galli C, et al. **Zygote** 1994 Nov;2(4):385–9 (47 ref.)

[In vitro culture and transfer of mammalian early embryos] Toyoda Y. **Tanpakushitsu Kakusan Koso** 1995 Oct; 40(14):1995–2000 (11 ref.) **(Jpn)**

CYTOLOGY

In vitro differentiation of embryonic stem cells. Keller GM. **Curr Opin Cell Biol** 1995 Dec;7(6):862–9 (50 ref.)

Nuclear transplantation in mammalian eggs and embryos. Sun

FZ, et al. **Curr Top Dev Biol** 1995;30:147-76 (137 ref.)
Potential use of embryo coculture with human in vitro fertilization procedures. Thibodeaux JK, et al. **J Assist Reprod Genet** 1995 Nov;12(10):665-77 (146 ref.)
Iontophoretic dye labeling of embryonic cells. Fraser SE. **Methods Cell Biol** 1996;51:147-60 (13 ref.)
Co-culture of the early human embryo: factors affecting human blastocyst formation in vitro. Ménézo YJ, et al. **Microsc Res Tech** 1995 Sep 1;32(1):50-6 (52 ref.)
From uncommitted to committed embryonic cells: opportunities for their study and manipulation. Wales RG. **Reprod Fertil Dev** 1995;7(5):983-96 (203 ref.)
[Genetic screening for novel genes by insertional mutagenesis with gene trap method in ES cells] Araki K, et al. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2017-24 (17 ref.) **(Jpn)**
[Origin and Nature of the mammalian embryonic stem cell lines] Nakatsuji N. **Tanpakushitsu Kakusan Koso** 1995 Oct; 40(14):2008-12 (11 ref.) **(Jpn)**

DRUG EFFECTS

The road to embryologically based dose-response models. Kavlock RJ, et al. **Environ Health Perspect** 1996 Mar;104 Suppl 1:107-21 (88 ref.)

GROWTH & DEVELOPMENT

Embryonic development and pattern formation. Morriss-Kay GM, et al. **FASEB J** 1996 Jul;10(9):961-8 (55 ref.)

IMMUNOLOGY

[Early immunosuppression and implantation] Chaouat G. **Contracept Fertil Sex** 1995 Oct;23(10):617-21 (58 ref.) (Eng. Abstr.) **(Fre)**
[Expression and role of complement regulatory proteins on human gametes and pre-implantation embryos] Fénichel P, et al. **Contracept Fertil Sex** 1995 Sep;23(9):576-80 (50 ref.) (Eng. Abstr.) **(Fre)**
[Trophoblastic interferons and embryonal immune tolerance] Martal J, et al. **Contracept Fertil Sex** 1995 Sep;23(9):562-72 (163 ref.) (Eng. Abstr.) **(Fre)**
[The interleukin-1 system during human implantation] Simon C, et al. **Contracept Fertil Sex** 1995 Oct;23(10):626-30 (41 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Calcium and cell cycle control in early embryos. Wilding M. **Zygote** 1996 Feb;4(1):1-6 (69 ref.)

PHYSIOLOGY

Morphology and biochemistry of in-vitro produced bovine embryos: implications for their cryopreservation. Massip A, et al. **Hum Reprod** 1995 Nov;10(11):3004-11 (79 ref.)
Exploring the mechanism(s) of endometriosis-related infertility: an analysis of embryo development and implantation in assisted reproduction. Pellicer A, et al. **Hum Reprod** 1995 Dec;10 Suppl 2:91-7 (33 ref.)
Interleukin-1 system crosstalk between embryo and endometrium in implantation. Simón C, et al. **Hum Reprod** 1995 Dec;10 Suppl 2:43-54 (67 ref.)

ULTRASTRUCTURE

Morphology and biochemistry of in-vitro produced bovine embryos: implications for their cryopreservation. Massip A, et al. **Hum Reprod** 1995 Nov;10(11):3004-11 (79 ref.)
Progress in cloning embryos from domesticated livestock. Prather RS. **Proc Soc Exp Biol Med** 1996 May;212(1):38-43 (68 ref.)

EMBRYO, CHICK see **CHICK EMBRYO**

EMBRYO DEVELOPMENT see **FETAL DEVELOPMENT**

EMBRYO, NON-MAMMALIAN

Culture and microsurgical manipulation of the early avian embryo. Selleck MA. **Methods Cell Biol** 1996;51:1-21 (55 ref.)

GROWTH & DEVELOPMENT

Bone morphogenetic proteins: multifunctional regulators of vertebrate development. Hogan BL. **Genes Dev** 1996 Jul 1;10(13):1580-94 (160 ref.)
Neural induction and neurogenesis in amphibian embryos. Chitnis A, et al. **Perspect Dev Neurobiol** 1995;3(1):3-15 (63 ref.)

METABOLISM

Embryonic transcription and the control of developmental pathways. Wieschaus E. **Genetics** 1996 Jan;142(1):5-10 (53 ref.)

PHYSIOLOGY

BMP signaling in Drosophila embryogenesis. Arora K, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:80-97 (68 ref.)
Drosophila gastrulation: from pattern formation to morphogenesis. Leptin M. **Ann Rev Cell Dev Biol** 1995; 11:189-212 (67 ref.)
Drosophila development pulls the strings of the cell cycle. Reed BH. **Bioessays** 1995 Jun;17(6):553-6 (23 ref.)
GTP-binding proteins and early embryogenesis in Xenopus. Paquereau L, et al. **Cell Signal** 1995 May;7(4):295-302 (71 ref.)
Axis formation in zebrafish. Driever W. **Curr Opin Genet Dev** 1995 Oct;5(5):610-8 (81 ref.)
Cortical cytoskeleton of the Xenopus oocyte, egg, and early embryo. Larabell CA. **Curr Top Dev Biol** 1995;31:433-53 (72 ref.)
Extracellular matrix and its receptors during development. Gullberg D, et al. **Int J Dev Biol** 1995 Oct;39(5):845-54 (109 ref.)
The Drosophila Stock Centers and their implications for developmental biology. Rasmuson-Lestander A. **Int J Dev Biol** 1995 Oct;39(5):765-8 (29 ref.)
Signals that make you different: receptor-mediated signal transduction in early development. Saxe CL 3rd. **Zygote** 1994 Aug;2(3):179-83 (42 ref.)

EMBRYO, PLANT see **SEEDS**

EMBRYO, PREIMPLANTATION see **BLASTOCYST**

EMBRYO REDUCTION see **PREGNANCY REDUCTION, MULTIFETAL**

EMBRYO TRANSFER

Ethical and legal issues in human embryo donation [see comments] Robertson JA. **Fertil Steril** 1995 Nov; 64(5):885-94 (25 ref.) Comment in: Fertil Steril 1996 Jun;65(6):1262-3.
Hydrosalpinx affects the implantation of previously cryopreserved embryos. Akman MA, et al. **Hum Reprod** 1996 May;11(5):1013-4 (8 ref.)
Low- versus high-dose human menopausal gonadotropin in an in vitro fertilization-embryo transfer program. Levy T, et al. **J Assist Reprod Genet** 1995 Apr;12(4):235-8 (25 ref.)
[In vitro culture and transfer of mammalian early embryos] Toyoda Y. **Tanpakushitsu Kakusan Koso** 1995 Oct; 40(14):1995-2000 (11 ref.) **(Jpn)**

METHODS

Potential use of embryo coculture with human in vitro fertilization procedures. Thibodeaux JK, et al. **J Assist Reprod Genet** 1995 Nov;12(10):665-77 (146 ref.)

VETERINARY

[Reproductive medicine in transition: new developments in embryo transfer] Binder H, et al. **Schweiz Arch Tierheilkd** 1996;138(5):245-50 (18 ref.) (Eng. Abstr.) **(Ger)**

EMBRYOLOGIC GENE EXPRESSION REGULATION see **GENE EXPRESSION REGULATION, DEVELOPMENTAL**

EMBRYOLOGY

METHODS

In vitro differentiation of murine embryonic stem cells. New approaches to old problems. Weiss MJ, et al. **J Clin Invest** 1996 Feb 1;97(3):591-5 (59 ref.)

EMBRYONAL CARCINOMA CELLS see **TUMOR STEM CELLS**

EMBRYONIC INDUCTION

Signalling by hedgehog family proteins in Drosophila and vertebrate development. Ingham PW. **Curr Opin Genet Dev** 1995 Aug;5(4):492-8 (67 ref.)
Vertebrate limb development. Tickle C. **Curr Opin Genet Dev** 1995 Aug;5(4):478-84 (31 ref.)
Strategies for the generation of neuronal diversity in the developing central nervous system. McConnell SK. **J Neurosci** 1995 Nov;15(11):6987-98 (126 ref.)
Neural induction and neurogenesis in amphibian embryos. Chitnis A, et al. **Perspect Dev Neurobiol** 1995;3(1):3-15 (63 ref.)
An experimental system for analyzing response to a morphogen gradient. Gurdon JB, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9334-8 (24 ref.)
The genesis of avian neural crest cells: a classic embryonic induction. Selleck MA, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9352-7 (67 ref.)
Induction and patterning of the vertebrate nervous system. Kelly OG, et al. **Trends Genet** 1995 Jul;11(7):273-8 (62 ref.)
[Induction of an additional limb by FGF and duplication of digits by Sonic hedgehog] Ohuchi H, et al. **Seikagaku** 1995 Oct;67(10):1232-6 (16 ref.) **(Jpn)**
[Molecular mechanisms of the neural induction and morphogenesis] Okamoto H, et al. **Tanpakushitsu Kakusan Koso** 1996 May;41(6):746-57 (25 ref.) **(Jpn)**

GENETICS

Inductive signals. Revolving vertebrates. Jones CM, et al. **Curr Biol** 1995 Jun 1;5(6):574-6 (16 ref.)

PHYSIOLOGY

How many signals does it take? Venkatesh TV, et al. **Bioessays** 1995 Sep;17(9):754-7 (31 ref.)
Basic FGF as an inducer of anteroposterior neural pattern. Doniach T. **Cell** 1995 Dec 29;83(7):1067-70 (19 ref.)
Somite differentiation. Sonic signals somites. Bumcrot DA, et al. **Curr Biol** 1995 Jun 1;5(6):612-4 (13 ref.)
Limb development. The budding role of FGF. Tanaka EM, et al. **Curr Biol** 1995 Jun 1;5(6):594-7 (15 ref.)
Mesoderm-inducing factors and mesodermal patterning. Smith JC. **Curr Opin Cell Biol** 1995 Dec;7(6):856-61 (61 ref.)
The role of the notochord and floor plate in inductive interactions. Placzek M. **Curr Opin Genet Dev** 1995 Aug; 5(4):499-506 (74 ref.)
Specifying the dorsoanterior axis in frogs: 70 years since Spemann and Mangold. Elinson RP, et al. **Curr Top Dev Biol** 1995;30:253-85 (166 ref.)
Growth factors in development: the role of TGF-beta related polypeptide signalling molecules in embryogenesis. Hogan BL, et al. **Dev Suppl** 1994;:53-60 (65 ref.)

EMBRYOPATHIES see **FETAL DISEASES**

EMBRYOTOMY see **ABORTION, INDUCED**

EMBRYOTOXINS see **TERATOGENS**

EMERGENCIES

see related
CRISIS INTERVENTION
CRITICAL CARE
FIRST AID

Management of profound hypothermia. Antretter H, et al. **Br J Hosp Med** 1995 Sep 6-19;54(5):215-20 (26 ref.)
Acute cardiac care in dental practice. Assael LA. **Dent Clin North Am** 1995 Jul;39(3):555-65 (11 ref.)
Emergency management of hypoglycemia and hyperglycemia. Bavitz JB. **Dent Clin North Am** 1995 Jul; 39(3):587-94 (13 ref.)
Management of immediate allergic reactions. Becker DE. **Dent Clin North Am** 1995 Jul;39(3):577-86 (41 ref.)
Emergency drug therapy. Drugs and routes of administration. Bennett JD. **Dent Clin North Am** 1995 Jul;39(3):501-21 (27 ref.)
Occupational health and safety emergencies. Goupil MT. **Dent Clin North Am** 1995 Jul;39(3):637-47 (69 ref.)
The poisoned patient. Toxicologic emergencies. Norris LH, et al. **Dent Clin North Am** 1995 Jul;39(3):595-619 (72 ref.)
Emergency cardiac care. Moral, legal, and ethical considerations. Peskin RM, et al. **Dent Clin North Am** 1995 Jul;39(3):677-88 (35 ref.)
Neurologic emergencies. Piecuch JF, et al. **Dent Clin North Am** 1995 Jul;39(3):567-75 (13 ref.)
Resuscitation of the pediatric patient. Rosenberg MB, et al. **Dent Clin North Am** 1995 Jul;39(3):663-76 (26 ref.)
Assessment of the medical emergency. Saef SH. **Dent Clin North Am** 1995 Jul;39(3):487-99 (20 ref.)
Respiratory emergencies in the dental office. Shafer DM. **Dent Clin North Am** 1995 Jul;39(3):541-54 (12 ref.)
Medical emergencies in oncology. Advani SH, et al. **Natl Med J India** 1995 Nov-Dec;8(6):273-6 (0 ref.)
The emergency management of hyperglycemic-hyperosmolar nonketotic coma in the pediatric patient. Gottschalk ME, et al. **Pediatr Emerg Care** 1996 Feb;12(1):48-51 (26 ref.)
Expanding access to emergency contraception in developing countries. Ellertson C, et al. **Stud Fam Plann** 1995 Sep-Oct; 26(5):251-63 (70 ref.)
[Reflections and proposals on the organization for pre-hospitalization of emergencies] Pellerin D. **Bull Acad Natl Med** 1995 Dec;179(9):1823-33 (44 ref.) **(Fre)**
[Traumatic emergencies and hemostasis] Samama CM. **Cah Anesthesiol** 1995;43(5):479-82 (23 ref.) (Eng. Abstr.) **(Fre)**
[Diagnosis and treatment of hypertensive emergencies] Burnier M, et al. **Schweiz Med Wochenschr** 1995 Nov 25; 125(47):2261-6 (8 ref.) (Eng. Abstr.) **(Fre)**
[Hypercalcemic crisis. Exacerbation of an existing hypercalcemia syndrome] Hehrmann R. **Fortschr Med** 1996 Apr 10;114(10):118-22 (13 ref.) (Eng. Abstr.) **(Ger)**
[Thyrotoxic crisis. Pitfalls in diagnosis--intensive therapy] Hehrmann R. **Fortschr Med** 1996 Apr 10;114(10):114-7 (18 ref.) (Eng. Abstr.) **(Ger)**
[Hypocalcemic crisis. Hypoparathyroidism--non-parathyroid origin--the most frequent form: hyperventilation syndrome] Hehrmann R. **Fortschr Med** 1996 Jun 20;114(17):223-6 (11 ref.) (Eng. Abstr.) **(Ger)**
[Psychiatric emergencies and crises in gynecology] Gaebel W, et al. **Gynakologe** 1995 Dec;28(6):403-11 (19 ref.) **(Ger)**
[Airway occlusion as an emergency. Recognition and treatment] Lipp M, et al. **Internist (Berl)** 1995 Aug; 36(8):765-8 (15 ref.) **(Ger)**
[Severe life threatening asthma attack] Magnussen H, et al. **Internist (Berl)** 1995 Aug;36(8):779-84 (31 ref.) **(Ger)**
[Emergencies in obstetrics] Ludwig H. **Ther Umsch** 1996 Jun;

53(6):477–96 (54 ref.) (Eng. Abstr.) (Ger)
[Hemorrhage from the ORL area] Baerthold W. **Z Arztl Fortbild (Jena)** 1995 Dec;89(7):703–6 (0 ref.) (Eng. Abstr.) (Ger)
[Acute therapy and prevention of ischemic cerebral infarct] von Maravić M. **Z Arztl Fortbild (Jena)** 1995 Dec; 89(7):711–8 (0 ref.) (Eng. Abstr.) (Ger)
[Death or uncertain cause] Wilkens H, et al. **Z Arztl Fortbild (Jena)** 1995 Dec;89(7):719–23 (19 ref.) (Eng. Abstr.) (Ger)
[Injuries to the external male genitals] Zermann DH, et al. **Z Arztl Fortbild (Jena)** 1995 Dec;89(7):729–33 (31 ref.) (Eng. Abstr.) (Ger)
[Emergency situations in hypertension] Nagy V, et al. **Orv Hetil** 1996 Apr 28;137(17):913–21 (55 ref.) (Eng. Abstr.) (Hun)

VETERINARY

Client counseling in orthopedic emergencies. Brackenridge SS, et al. **Vet Clin North Am Small Anim Pract** 1995 Sep; 25(5):1047–58 (7 ref.)
[Sonographic possibilities in emergency medicine] Gerwing M, et al. **Berl Munch Tierarztl Wochenschr** 1996 Apr; 109(4):123–9 (37 ref.) (Eng. Abstr.) (Ger)

EMERGENCY CARE see **EMERGENCY MEDICAL SERVICES**

EMERGENCY CARE INFORMATION SYSTEMS see **INFORMATION SYSTEMS**

EMERGENCY HEALTH SERVICES see **EMERGENCY MEDICAL SERVICES**

EMERGENCY MEDICAL SERVICES

see related
AMBULANCES
FIRST AID

Out-of-hospital cardiac arrests: an 8-year New York City experience. Westal RE, et al. **Am J Emerg Med** 1996 Jul; 14(4):364–8 (60 ref.)
Acute-phase mental health consequences of disasters: implications for triage and emergency medical services [see comments] Burkle FM Jr. **Ann Emerg Med** 1996 Aug; 28(2):119–28 (78 ref.) Comment in: Ann Emerg Med 1996 Aug;28(2):220–2.
Immunization of the pediatric patient in the emergency department. Robinson PF, et al. **Ann Emerg Med** 1996 Sep; 28(3):334–41 (48 ref.)
Prehospital pain research. Yealy DM. **Ann Emerg Med** 1996 Apr;27(4):471–3 (14 ref.)
Recommended guidelines for uniform reporting of pediatric advanced life support: the pediatric Utstein style. American Academy of Pediatrics, American Heart Association and the European Resuscitation Council. Zaritsky A, et al. **Ann Emerg Med** 1995 Oct;26(4):487–503 (60 ref.)
Management of severe trauma. Part 2: Circulation and head injury. Pollard C. **Aust Fam Physician** 1995 Dec; 24(12):2230–3; quiz 2234–5 (0 ref.)
Prehospital monitoring of trauma patients: experience of a helicopter emergency medical service. Morley AP. **Br J Anaesth** 1996 May;76(5):726–30 (56 ref.)
Invisible victims: battered women in psychiatric and medical emergency rooms. Keller LE. **Bull Menninger Clin** 1996 Winter;60(1):1–21 (52 ref.)
Updates in pediatric emergency medicine for the office practitioner. Carlson DW, et al. **Curr Opin Pediatr** 1995 Oct;7(5):523–8 (37 ref.)
Prehospital interventions. McCallum AL, et al. **Emerg Med Clin North Am** 1996 Feb;14(1):1–12 (45 ref.)
Acute myocardial infarction: pre-hospital and in-hospital management. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. **Eur Heart J** 1996 Jan;17(1):43–63 (127 ref.)
Public relations in disaster management and planning for emergency physicians. Friedman FD. **J Emerg Med** 1995 Sep–Oct;13(5):661–8 (25 ref.)
Acute outpatient care and comprehensive management of acute myocardial ischemia in chest pain emergency departments. Bahr RD. **Md Med J** 1995 Sep;44(9):691–3 (9 ref.)
Neurocritical care for acute ischemic stroke. Hund E, et al. **Neurol Clin** 1995 Aug;13(3):511–27 (87 ref.)
The prehospital and emergency department management of penetrating head injuries. Eckstein M. **Neurosurg Clin N Am** 1995 Oct;6(4):741–51 (80 ref.)
Recommended guidelines for uniform reporting of pediatric advanced life support: the pediatric Utstein style. A statement for healthcare professionals from a task force of the American Academy of Pediatrics, the American Heart Association, and the European Resuscitation Council. Zaritsky A, et al. **Pediatrics** 1995 Oct;96(4 Pt 1):765–79 (60 ref.)
Preclinical management of thromboembolic disorders. Schreiber W, et al. **Semin Thromb Hemost** 1996;22(1):3–13 (96 ref.)
Management of acquired coagulation disorders in emergency and intensive-care medicine. Staudinger T, et al. **Semin Thromb Hemost** 1996;22(1):93–104 (192 ref.)
[Progresses in emergency medicine in China, 1995] Wang Z, et al. **Chung Hua I Hsueh Tsa Chih** 1995 Dec; 75(12):761–2 (0 ref.) (Eng. Abstr.) (Chi)
[Pre-hospital care for patients with multiple injuries] Kivioja A. **Duodecim** 1995;111(9):866–72 (23 ref.) (Fin)
[Semi-automatic external defibrillators] Silfvast T. **Duodecim** 1994;110(11):1049–53 (15 ref.) (Fin)
[Reflections and proposals on the organization for pre-hospitalization of emergencies] Pellerin D. **Bull Acad Natl Med** 1995 Dec;179(9):1823–33 (44 ref.) (Fre)
[Effectiveness of preclinical emergency management. Fiction or fact?] Dick WF. **Anaesthesist** 1996 Jan;45(1):75–87 (83 ref.) (Eng. Abstr.) (Ger)
[The value of preclinical thrombolysis in acute myocardial infarct] Arntz HR. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Aug; 30(5):299–302 (25 ref.) (Ger)
[Significance of initial defibrillation by paramedics] Mauer D, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Aug; 30(5):303–6 (30 ref.) (Ger)
[The treatment and teaching aspects in the computerized management of the surgical emergency (editorial)] Bonomo M, et al. **Recenti Prog Med** 1996 May;87(5):229–36 (24 ref.) (Ita)
[A cerebral accident: ictus is a medical emergency] Castillo J. **Rev Neurol** 1995 Mar–Apr;23(120):322–3 (22 ref.) (Spa)

LEGISLATION & JURISPRUDENCE

Unwinding the COBRA: new perspectives on EMTALA. Diekema DS. **Pediatr Emerg Care** 1995 Aug;11(4):243–8 (41 ref.)

METHODS

Initiation of mechanical ventilation in the emergency department. Orebaugh SL. **Am J Emerg Med** 1996 Jan; 14(1):59–69 (114 ref.)
[Severe preeclampsia. Principal management modalities before patient transfer] Aya AG, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(2):196–205 (78 ref.) (Eng. Abstr.) (Fre)

ORGANIZATION & ADMINISTRATION

The revolution and evolution of prehospital cardiac care. Eisenberg MS, et al. **Arch Intern Med** 1996 Aug 12–26; 156(15):1611–9 (43 ref.)
Health care personnel in disaster response. Reversible roles or territorial imperatives? Bissell RA, et al. **Emerg Med Clin North Am** 1996 May;14(2):267–88 (66 ref.)
Management of unique clinical entities in disaster medicine. Gans L, et al. **Emerg Med Clin North Am** 1996 May; 14(2):301–26 (104 ref.)
A medical disaster response to reduce immediate mortality after an earthquake [see comments] Schultz CH, et al. **N Engl J Med** 1996 Feb 15;334(7):438–44 (53 ref.) Comment in: N Engl J Med 1996 Jun 27;334(26):1746; discussion 1747. Comment in: N Engl J Med 1996 Jun 27;334(26):1746–7.

STANDARDS

Ventricular fibrillation, automatic external defibrillators, and the United States Food and Drug Administration: confrontation without comprehension. Cummins RO, et al. **Ann Emerg Med** 1995 Nov;26(5):621–31; discussion 632–4 (95 ref.)
Fluid resuscitation of the trauma patient: how much is enough? Hamiliton SM, et al. **Can J Surg** 1996 Feb; 39(1):11–6 (39 ref.)
Client counseling in orthopedic emergencies. Brackenridge SS, et al. **Vet Clin North Am Small Anim Pract** 1995 Sep; 25(5):1047–58 (7 ref.)

UTILIZATION

Preparing for pediatric emergencies. Seidel J. **Pediatr Rev** 1995 Dec;16(12):466–72 (16 ref.)

EMERGENCY MEDICAL TECHNICIANS

LEGISLATION & JURISPRUDENCE

A national consensus on guidelines for establishment of a post-exposure notification protocol for emergency responders. Laboratory Centre for Disease Control, Health Protection Branch, Health Canada. **Can Commun Dis Rep** 1995 Oct 15;21(19):169–80 (5 ref.) (Eng, Fre)

EMERGENCY MEDICINE

Disaster medicine: current assessment and blueprint for the future. SAEM Disaster Medicine White Paper Subcommittee. **Acad Emerg Med** 1995 Dec;2(12):1068–76 (91 ref.)
Research Directions Conference: Research directions in emergency medicine. January 20–21, 1995. **Acad Emerg Med** 1996 Mar;3(3):274–6 (0 ref.)
Sudden infant death syndrome—Part III: Emergency department approach. Lazoff M, et al. **Acad Emerg Med** 1995 Dec;2(12):1077–80 (24 ref.)
Accessing and using the Internet's World Wide Web for emergency physicians. Yamamoto LG, et al. **Am J Emerg Med** 1996 May;14(3):302–8 (10 ref.)
Research Directions Conference: Research directions in emergency medicine. January 20–21, 1995. **Ann Emerg Med** 1996 Mar;27(3):339–42 (0 ref.)
Pain–control research opportunities and future directions. Cordell WH. **Ann Emerg Med** 1996 Apr;27(4):474–8 (7 ref.)
Withholding and withdrawing medical treatment: an emergency medicine perspective. Iserson KV. **Ann Emerg Med** 1996 Jul;28(1):51–4 (14 ref.)
Sedation. Murphy MF. **Ann Emerg Med** 1996 Apr; 27(4):461–3 (20 ref.)
Studying emergency patients outside the emergency department. Sivilotti ML, et al. **Ann Emerg Med** 1996 Apr; 27(4):442–7 (24 ref.)
Local anesthetics. Sklar DP. **Ann Emerg Med** 1996 Apr; 27(4):464–5 (10 ref.)
Pediatric pain control. Terndrup TE. **Ann Emerg Med** 1996 Apr;27(4):466–70 (17 ref.)
Establishing pain policies in emergency medicine. Terndrup TE. **Ann Emerg Med** 1996 Apr;27(4):408–11 (31 ref.)
Guidelines for the emergency management of asthma in adults. CAEP/CTS Asthma Advisory Committee. Canadian Association of Emergency Physicians and the Canadian Thoracic Society. Beveridge RC, et al. **Can Med Assoc J** 1996 Jul 1;155(1):25–37 (167 ref.)
Radiation disasters and emergency department preparedness. Fong F, et al. **Emerg Med Clin North Am** 1996 May; 14(2):349–70 (18 ref.)
Medical support for mass gatherings. Leonard RB. **Emerg Med Clin North Am** 1996 May;14(2):383–97 (41 ref.)
Disaster planning, Part I. Overview of hospital and emergency department planning for internal and external disasters. Lewis CP, et al. **Emerg Med Clin North Am** 1996 May;14(2):439–52 (45 ref.)
Emergency medicine applications of echocardiography. Wellford AL, et al. **Emerg Med Clin North Am** 1995 Nov; 13(4):831–54 (72 ref.)
Training in the management of critical obstetric problems: trainee's view. Mikkelsen B, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Mar;65(1):149–51 (9 ref.)
Training in the management of critical problems: teacher's view. van Geijn HP, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Mar;65(1):145–8 (10 ref.)
Research directions in emergency medicine: 21–22 January 1995 [see comments] **J Emerg Med** 1996 Mar–Apr; 14(2):267–70 (0 ref.) Comment in: J Emerg Med 1996 Mar–Apr;14(2):242–3.
Cerebrospinal fluid shunt complications: an emergency medicine perspective. Key CB, et al. **Pediatr Emerg Care** 1995 Oct;11(5):265–73 (56 ref.)
Blood rheology in emergency medicine. Koppensteiner R. **Semin Thromb Hemost** 1996;22(1):89–91 (17 ref.)

ECONOMICS

Implications of current procompetitive approaches on EDs. Weil TP. **Am J Emerg Med** 1996 Jan;14(1):74–8 (24 ref.)

EDUCATION

Objectives to direct the training of emergency medicine residents on off-service rotations: Surgery, part 2. Rakowski RT, et al. **J Emerg Med** 1995 Nov–Dec; 13(6):823–9 (7 ref.)
Pediatric emergency medicine fellow clinical work requirements. Wiley JF 2nd, et al. **Pediatr Emerg Care** 1995 Dec;11(6):381–8 (13 ref.)
[Quality assessment of continuing medical education] Lipp M. **Anaesthesist** 1996 Apr;45(4):363–71 (27 ref.) (Eng. Abstr.) (Ger)
[The treatment and teaching aspects in the computerized management of the surgical emergency (editorial)] Bonomo M, et al. **Recenti Prog Med** 1996 May;87(5):229–36 (24 ref.) (Ita)

METHODS

Rapid-sequence intubation of the pediatric patient. Pediatric Emergency Medicine Committee of the American College of Emergency Physicians [see comments] Gerardi MJ, et al. **Ann Emerg Med** 1996 Jul;28(1):55–74 (200 ref.) Comment in: Ann Emerg Med 1996 Jul;28(1):79–81.

ORGANIZATION & ADMINISTRATION

Capitation for emergency physicians. Stapczynski JS. **Ann Emerg Med** 1996 Apr;27(4):501–5 (16 ref.)

TRENDS

[Sonographic possibilities in emergency medicine] Gerwing M, et al. **Berl Munch Tierarztl Wochenschr** 1996 Apr; 109(4):123–9 (37 ref.) (Eng. Abstr.) (Ger)

EMERGENCY MOBILE UNITS see **AMBULANCES**

EMERGENCY NURSING

Evolution of parental stress and coping processes: a framework for critical care practice. LaMontagne LL, et al. **J Pediatr Nurs** 1995 Aug;10(4):212–8 (13 ref.)

EMERGENCY OUTPATIENT UNIT see EMERGENCY SERVICE, HOSPITAL

EMERGENCY SERVICE, HOSPITAL

Immunization of the pediatric patient in the emergency department. Robinson PF, et al. **Ann Emerg Med** 1996 Sep; 28(3):334–41 (48 ref.)

'Emergency room' thoracotomy: is it ever justified? Roxburgh JC. **Ann R Coll Surg Engl** 1996 Jul;78(4):327–30 (14 ref.)

Management of asthma in the hospital emergency department. Beasley R, et al. **Br J Hosp Med** 1996 Mar 6–19;55(5):253–7 (18 ref.)

Epidemiology of illicit and abused drugs in the general population, emergency department drug-related episodes, and arrestees. Rouse BA. **Clin Chem** 1996 Aug;42(8 Pt 2):1330–6 (9 ref.)

Neuromuscular blocking agents in the emergency department. Rubin MA, et al. **J Emerg Med** 1996 Mar–Apr; 14(2):193–9 (67 ref.)

Security in pediatric emergency departments. Graham CJ, et al. **Pediatr Emerg Care** 1995 Aug;11(4):220–2 (9 ref.)

ECONOMICS

Using prediction models and cost-effectiveness analysis to improve clinical decisions: emergency department patients with acute chest pain. Goldman L. **Proc Assoc Am Physicians** 1995 Oct;107(3):329–33 (22 ref.)

LEGISLATION & JURISPRUDENCE

Interhospital transfers of obstetric patients under the Emergency Medical Treatment and Active Labor Act. Cardwell MS. **J Leg Med** 1995 Sep;16(3):357–72 (98 ref.)

An overview and analysis of the impact of the Emergency Medical Treatment and Active Labor Act. Furrow BR. **J Leg Med** 1995 Sep;16(3):325–55 (157 ref.)

Emergency room follow-up care and malpractice liability. Morgan D. **J Leg Med** 1995 Sep;16(3):373–406 (143 ref.)

[What can the hospital deliver? What must the hospital deliver?] Pannike A. **Unfallchirurgie** 1995 Aug;21(4):204–18 (68 ref.) **(Ger)**

MANPOWER

Implications of current procompetitive approaches on EDs. Weil TP. **Am J Emerg Med** 1996 Jan;14(1):74–8 (24 ref.)

ORGANIZATION & ADMINISTRATION

How safe is your ED? Keep NB, et al. **Am J Nurs** 1995 Sep;95(9):44–50; quiz 51 (5 ref.)

Disaster planning, Part I. Overview of hospital and emergency department planning for internal and external disasters. Lewis CP, et al. **Emerg Med Clin North Am** 1996 May;14(2):439–52 (45 ref.)

Advances in the use of ancillary diagnostic testing in the emergency department evaluation of chest pain. Stack LB, et al. **Emerg Med Clin North Am** 1995 Nov;13(4):713–33 (75 ref.)

Thrombolytic therapy. Young GP, et al. **Emerg Med Clin North Am** 1995 Nov;13(4):735–58 (124 ref.)

STANDARDS

Sudden infant death syndrome--Part III: Emergency department approach. Lazoff M, et al. **Acad Emerg Med** 1995 Dec;2(12):1077–80 (24 ref.)

UTILIZATION

Preparing for pediatric emergencies. Seidel J. **Pediatr Rev** 1995 Dec;16(12):466–72 (16 ref.)

EMERGENCY SERVICES, PSYCHIATRIC

Invisible victims: battered women in psychiatric and medical emergency rooms. Keller LE. **Bull Menninger Clin** 1996 Winter;60(1):1–21 (52 ref.)

Emergency pharmacotherapy: the evolving role of medications in the emergency department. Ellison JM, et al. **New Dir Ment Health Serv** 1995 Fall;(67):87–98 (64 ref.)

[The psychiatric emergency] Felber W. **Z Arztl Fortbild (Jena)** 1995 Dec;89(7):707–10 (2 ref.) (Eng. Abstr.) **(Ger)**

EMERGICENTERS see EMERGENCY MEDICAL SERVICES

EMEROGENES see GENES, SUPPRESSOR, TUMOR

EMIGRATION AND IMMIGRATION

Coronary artery disease among South Asians: identification of a high risk population [editorial] Jolly KS, et al. **Can J Cardiol** 1996 Jun;12(6):569–71 (32 ref.)

Immigrant children and their families: issues for research and policy. Board on Children and Families. **Future Child** 1995 Summer–Fall;5(2):72–89 (49 ref.)

Transculturation, psychosis and koro symptoms. Rosca-Rebaudengo P, et al. **Isr J Psychiatry Relat Sci** 1996; 33(1):54–62 (41 ref.)

Working effectively with interpreters in the primary care setting. Poss JE, et al. **Nurse Pract** 1995 Dec;20(12):43–7 (9 ref.)

[Reflections on international adoption] Laurent A, et al. **Ann Med Psychol (Paris)** 1995 Oct;153(8):528–30; discussion 531 (2 ref.) (Eng. Abstr.) **(Fre)**

[Transcultural symptomatology. Its expression in family practice] Ferron M. **Can Fam Physician** 1995 Oct; 41:1718–25 (20 ref.) (Eng. Abstr.) **(Fre)**

STATISTICS & NUMERICAL DATA

Immigrant children and pediatric dental practice. Waldman HB. **ASDC J Dent Child** 1995 Jul–Aug;62(4):288–94 (16 ref.)

TRENDS

[Public health in regard to the immigration phenomenon] Marceca M, et al. **Ann Ig** 1995 May–Jun;7(3):179–88 (67 ref.) (Eng. Abstr.) **(Ita)**

EMOTIONAL BONDS see OBJECT ATTACHMENT

EMOTIONAL DISTURBANCES see AFFECTIVE SYMPTOMS

EMOTIONAL STRESS see STRESS, PSYCHOLOGICAL

EMOTIONS

see related
AFFECTIVE SYMPTOMS

The primary care of patients who have bodily concerns. Blackwell B, et al. **Arch Fam Med** 1996 Sep;5(9):457–63 (65 ref.)

Expressed emotion and a hypothetical model of relapse in schizophrenia. Eva FJ, et al. **Med Hypotheses** 1995 Jul; 45(1):99–105 (65 ref.)

Imagery, concreteness, emotionality, meaningfulness, and pleasantness of words. Campos A. **Percept Mot Skills** 1995 Jun;80(3 Pt 1):867–80 (50 ref.)

Contingency detection and the contingent organization of behavior in interactions: implications for socioemotional development in infancy. Tarabulsy GM, et al. **Psychol Bull** 1996 Jul;120(1):25–41 (110 ref.)

The emotional Stroop task and psychopathology. Williams JM, et al. **Psychol Bull** 1996 Jul;120(1):3–24 (95 ref.)

Facial emotion recognition by persons with mental retardation: a review of the experimental literature. Rojahn J, et al. **Res Dev Disabil** 1995 Sep–Oct;16(5):393–414 (75 ref.)

[Emotion-focused couples therapy--treatment approach--evaluating effectiveness and process research] Heekerens HP. **Z Klin Psychol Psychopathol Psychother** 1995;43(4):308–24 (50 ref.) (Eng. Abstr.) **(Ger)**

[Pictures of the psyche. Imaging the highest functions of the brain: consciousness, language, emotions, is now possible] Ingvar DH. **Lakartidningen** 1995 Dec 20;92(51–52):4885–9 (20 ref.) **(Swe)**

PHYSIOLOGY

Personality, emotions and the temporolimbic system: a neuropsychological approach. Beeckmans K, et al. **Acta Neurol Belg** 1996 Mar;96(1):35–42 (51 ref.)

Social and emotional self-regulation. Tucker DM, et al. **Ann N Y Acad Sci** 1995 Dec 15;769:213–39 (120 ref.)

Emotion: systems, cells, synaptic plasticity. Rogan MT, et al. **Cell** 1996 May 17;85(4):469–75 (40 ref.)

Anatomic basis of cognitive-emotional interactions in the primate prefrontal cortex. Barbas H. **Neurosci Biobehav Rev** 1995 Fall;19(3):499–510 (155 ref.)

Amygdala role in conditioned associative learning. Ono T, et al. **Prog Neurobiol** 1995 Jul;46(4):401–22 (142 ref.)

Neurofunctional mechanisms in autism. Waterhouse L, et al. **Psychol Rev** 1996 Jul;103(3):457–89 (280 ref.)

EMPATHY

"Methodological notes on empathy": further considerations. Bennett JA. **ANS Adv Nurs Sci** 1995 Sep;18(1):36–50 (57 ref.)

"Becoming": a method for expanding systemic thinking and deepening empathic accuracy. Snyder M. **Fam Process** 1995 Jun;34(2):241–53 (40 ref.)

Professional caring: the moral dimension. Fealy GM. **J Adv Nurs** 1995 Dec;22(6):1135–40 (18 ref.)

Caring, curing, coping: towards an integrated model. Webb C. **J Adv Nurs** 1996 May;23(5):960–8 (44 ref.)

Breaking bad news. A review of the literature. Ptacek JT, et al. **JAMA** 1996 Aug 14;276(6):496–502 (83 ref.)

Using critical thinking to teach empathy. Greathouse GF, et al. **Radiol Technol** 1996 May–Jun;67(5):435–7 (2 ref.)

EMPHYSEMA

see related
PULMONARY EMPHYSEMA

Bilateral emphysematous pyelonephritis: a case report and review of the literature. Stein JP, et al. **Urology** 1996 Jan; 47(1):129–34 (14 ref.)

[Emphysematous cholecystitis] Nagami H, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):202–5 (16 ref.) **(Jpn)**

COMPLICATIONS

Emphysematous septic arthritis: case report and review of the literature. Roy R, et al. **J Rheumatol** 1995 Sep; 22(9):1776–8 (29 ref.)

DIAGNOSIS

Perforation in hypopharynx and deep cervical emphysema caused by blunt external trauma. Kiukaanniemi H, et al. **Mil Med** 1995 Sep;160(9):479–81 (5 ref.)

[Emphysematous pyelonephritis] Monllor Gisbert J, et al. **Arch Esp Urol** 1995 Nov;48(9):956–9 (8 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

Retroperitoneal and abdominal wall emphysema after transanal excision of a rectal carcinoma. Petros JG, et al. **Am Surg** 1996 Sep;62(9):759–61 (8 ref.)

The pathogenesis of emphysema: the elastase:antielastase hypothesis 30 years later. Shapiro SD. **Proc Assoc Am Physicians** 1995 Oct;107(3):346–52 (40 ref.)

IMMUNOLOGY

[Increased activity of phagocytes in cigarette smokers--supposed connection with lung emphysema] Zięba M, et al. **Pneumonol Pol** 1990 Nov–Dec; 58(11–12):651–4 (23 ref.) **(Pol)**

MICROBIOLOGY

Emphysematous cholecystitis. Lindsey I, et al. **Aust N Z J Surg** 1996 Apr;66(4):267–8 (14 ref.)

PATHOLOGY

Emphysema: concepts under change--a pathologist's perspective. Wright JL. **Mod Pathol** 1995 Oct;8(8):873–80 (51 ref.)

RADIOGRAPHY

[Computed tomographic demonstration of intraspinal air after an infection with peptostreptococci] Lorenzen J, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Feb;164(2):173–5 (10 ref.) **(Ger)**

EMPHYSEMA, PULMONARY see PULMONARY EMPHYSEMA

EMPHYSEMA, SUBCUTANEOUS see SUBCUTANEOUS EMPHYSEMA

EMPLOYEE ASSISTANCE PROGRAMS (HEALTH CARE) see OCCUPATIONAL HEALTH SERVICES

EMPLOYEE HEALTH see OCCUPATIONAL HEALTH

EMPLOYEE HEALTH BENEFIT PLANS see HEALTH BENEFIT PLANS, EMPLOYEE

EMPLOYEE HEALTH SERVICES see OCCUPATIONAL HEALTH SERVICES

EMPLOYEE ORIENTATION PROGRAMS see INSERVICE TRAINING

EMPLOYEE PERFORMANCE APPRAISAL

Evaluating teaching effectiveness. Kirschling JM, et al. **J Nurs Educ** 1995 Dec;34(9):401–10 (30 ref.)

EMPLOYEE WORKLOAD see WORKLOAD

EMPLOYMENT

see related
JOB SATISFACTION
UNEMPLOYMENT

Genetic testing: employability, insurability, and health reform. Rothstein MA. **J Natl Cancer Inst Monogr** 1995; (17):87–90 (14 ref.)

Achieving and sustaining full employment. Rosen SM. **J Public Health Policy** 1995;16(3):286–303 (28 ref.)

Careers and recruitment. Flexibility the key for neuroscientists. Horton B. **Nature** 1996 May 23; 381(6580):347–9 (0 ref.)

The view from Europe. Schermeier Q. **Nature** 1996 May 23;381(6580):349–50 (0 ref.)

Review of literature on heart transplant recipients' return to work: predictors and outcomes. Botsford AL. **Soc Work Health Care** 1995;21(2):19–39 (55 ref.)

[Atopy, asthma and the judgement of preemployment fitness] Innocenti A. **Med Lav** 1995 Jul–Aug;86(4):303–8 (36 ref.) (Eng. Abstr.) **(Ita)**

EMPLOYMENT, SUPPORTED

Employment supports for people with mental illness. Marrone J, et al. **Psychiatr Serv** 1995 Jul;46(7):707–11 (40

ref.)

EMPLOYMENT TERMINATION see **EMPLOYMENT**

EMPORIATRICS see **TRAVEL**

EMPYEMA

see related
ABSCESS

[Empyema of the gallbladder (empyema vesicae felleae)] Ise H, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):471–3 (13 ref.) **(Jpn)**

CHEMICALLY INDUCED

Silicone thorax: a complication of tube thoracostomy in the presence of mammary implants. Rice DC, et al. **Ann Thorac Surg** 1995 Nov;60(5):1417–9 (8 ref.)

EMPYEMA, GALLBLADDER see **CHOLECYSTITIS**

EMPYEMA, PLEURAL

Pleural empyema. Bryant RE, et al. **Clin Infect Dis** 1996 May; 22(5):747–62; quiz 763–4 (128 ref.)

[Pleural empyema] Krasnik M, et al. **Ugeskr Laeger** 1996 Apr 8;158(15):2109–12 (31 ref.) (Eng. Abstr.) **(Dan)**

MICROBIOLOGY

[A case of a patient with post-operative empyema due to Mycobacterium chelonae] Takemoto N, et al. **Kyobu Geka** 1996 Apr;49(4):301–5 (12 ref.) (Eng. Abstr.) **(Jpn)**

EMPYEMA, SUBDURAL

MICROBIOLOGY

[Acute lumbago: infectious traps] Bonny O, et al. **Rev Med Suisse Romande** 1996 May;116(5):399–403 (8 ref.) **(Fre)**

SURGERY

[Subdural empyema. Apropos of 17 cases] Ouahes O, et al. **Neurochirurgie** 1995;41(4):319–23 (22 ref.) (Eng. Abstr.) **(Fre)**

EMPYEMA, THORACIC see **EMPYEMA, PLEURAL**

EMPYEMA, TUBERCULOUS

ETIOLOGY

Primary Epstein-Barr virus-related non-Hodgkin's lymphoma of the pleural cavity following long-standing tuberculous empyema. Molinie V, et al. **Arch Pathol Lab Med** 1996 Mar;120(3):288–91 (18 ref.)

EMULSIFYING AGENTS see **EXCIPIENTS**

EMULSIONS

Lipid microemulsions for improving drug dissolution and oral absorption: physical and biopharmaceutical aspects. Constantinides PP. **Pharm Res** 1995 Nov;12(11):1561–72 (50 ref.)

CHEMISTRY

[Lipid vehicles for the parenteral administration of drugs (1): emulsions] Bermejo Vicedo T, et al. **Nutr Hosp** 1996 Jan–Feb;11(1):7–16 (49 ref.) (Eng. Abstr.) **(Spa)**

EN-1639A see **NALTREXONE**

ENABLING FACTORS see **CAUSALITY**

ENALAPRIL

ADVERSE EFFECTS

Delayed renal revascularisation after enalapril induced renal failure in renal artery stenosis. Khaira HS, et al. **Eur J Vasc Endovasc Surg** 1996 Apr;11(3):375–7 (17 ref.)

[Clinicopharmacological case report (3). Drug-induced angioedema] Kind B, et al. **Schweiz Rundsch Med Prax** 1996 Apr 23;85(17):567–9 (27 ref.) (Eng. Abstr.) **(Ger)**

THERAPEUTIC USE

Microvascular angina in systemic hypertension: diagnosis and treatment with enalapril. Iriarte MM, et al. **Am J Cardiol** 1995 Nov 2;76(13):31D–34D (18 ref.)

ENALAPRIL MALEATE see **ENALAPRIL**

ENALAPRILAT

ADVERSE EFFECTS

Perioperative angioedema in a patient on long-term angiotensin-converting enzyme (ACE)-inhibitor therapy. Ogbureke KU, et al. **J Oral Maxillofac Surg** 1996 Jul; 54(7):917–20 (18 ref.)

ENALAPRILIC ACID see **ENALAPRILAT**

ENAMEL see **DENTAL ENAMEL**

ENBUCRILATE

Posttraumatic high-flow priapism treated by N-butyl-cyanoacrylate embolization. Numan F, et al. **Cardiovasc Intervent Radiol** 1996 Jul–Aug;19(4):278–80 (22 ref.)

ADMINISTRATION & DOSAGE

A case of hemobilia after percutaneous liver biopsy treated by transcatheter arterial embolization with Histoacryl. Murata K, et al. **Am J Gastroenterol** 1996 Jan;91(1):160 (8 ref.)

[Selective embolization with an adhesive fluid of complicated aneurysms of the hepatic artery: 3 cases] Cotroneo AR, et al. **Radiol Med (Torino)** 1996 Apr;91(4):492–6 (21 ref.) **(Ita)**

ENCEPHALITIS

[Acute encephalitis in children] Bouguerra L. **Arch Pediatr** 1996 Mar;3(3):267–73 (17 ref.) (Eng. Abstr.) **(Fre)**

CEREBROSPINAL FLUID

[Cerebrospinal fluid diagnosis using polymerase chain reaction] van Manen SR, et al. **Ned Tijdschr Geneeskd** 1996 Jun 15;140(24):1259–63 (38 ref.) **(Dut)**

COMPLICATIONS

[Guillain-Barré syndrome associated with external ophthalmoplegia, consciousness disturbance, and extensor plantar responses: an overlap between Guillain-Barré syndrome and Bickerstaff's brainstem encephalitis] Kitazawa K, et al. **Rinsho Shinkeigaku** 1995 Jun; 35(6):626–32 (30 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Neurologic complications of Bartonella henselae infection. Marra CM. **Curr Opin Neurol** 1995 Jun;8(3):164–9 (65 ref.)

PREVENTION & CONTROL

Preventing toxoplasmic encephalitis in persons infected with human immunodeficiency virus. Richards FO Jr, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S49–56 (44 ref.)

VETERINARY

Neurobiology of simian and feline immunodeficiency virus infections. Gardner MB, et al. **Curr Top Microbiol Immunol** 1995;202:135–50 (62 ref.)

Feline immunodeficiency virus as a model for study of lentivirus infection of the central nervous system. Henriksen SJ, et al. **Curr Top Microbiol Immunol** 1995; 202:167–86 (88 ref.)

ENCEPHALITIS, CENTRAL EUROPEAN see **ENCEPHALITIS, TICK-BORNE**

ENCEPHALITIS, EPIDEMIC

EPIDEMIOLOGY

Australian X disease, Murray Valley encephalitis and the French connection. Mackenzie JS, et al. **Vet Microbiol** 1995 Sep;46(1–3):79–90 (49 ref.)

ETIOLOGY

The Gordon Wilson lecture: unique interactions between viruses, neurons and the immune system. Griffin DE. **Trans Am Clin Climatol Assoc** 1995;107:89–98 (36 ref.)

PREVENTION & CONTROL

[Japanese encephalitis--implications for travelers to the Far East] Shapira I, et al. **Harefuah** 1996 Mar 15;130(6):406–8 (36 ref.) **(Heb)**

VETERINARY

Australian X disease, Murray Valley encephalitis and the French connection. Mackenzie JS, et al. **Vet Microbiol** 1995 Sep;46(1–3):79–90 (49 ref.)

ENCEPHALITIS, POST-VACCINAL see **ENCEPHALOMYELITIS, ACUTE DISSEMINATED**

ENCEPHALITIS, TICK-BORNE

EPIDEMIOLOGY

[Tick-borne encephalitis in Central and Eastern Europe] Christmann D, et al. **Presse Med** 1996 Mar 2–9;25(8):420–3 (25 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

[After vaccination for tick-borne encephalitis must onset of neurologic disorders be expected?] Hofmann H. **Wien Klin Wochenschr** 1995;107(17):509–15 (17 ref.) (Eng. Abstr.) **(Ger)**

ENCEPHALITIS, VIRAL

Cytomegalovirus encephalitis. Arribas JR, et al. **Ann Intern Med** 1996 Oct 1;125(7):577–87 (133 ref.)

COMPLICATIONS

[Necrotizing herpes simplex encephalitis as the cause of a progressive dementia syndrome] Zachhuber C, et al. **Dtsch Med Wochenschr** 1995 Sep 22;120(38):1278–82 (19 ref.) (Eng. Abstr.) **(Ger)**

DIAGNOSIS

Neurologic opportunistic infections. Clifford DB. **Curr Opin Neurol** 1995 Jun;8(3):175–8 (32 ref.)

Acute viral infections. Jackson AC. **Curr Opin Neurol** 1995 Jun;8(3):170–4 (60 ref.)

[The clinico-microbiological diagnosis of encephalitis due to herpes zoster in an elderly patient: apropos a case] Muñoz García MD, et al. **An Med Interna** 1996 May; 13(5):243–4 (13 ref.) (Eng. Abstr.) **(Spa)**

[Applications of the polymerase chain reaction (PCR) to the diagnosis of central nervous system infections] Querol JM, et al. **An Med Interna** 1996 May;13(5):235–8 (20 ref.) (Eng. Abstr.) **(Spa)**

MICROBIOLOGY

Rotavirus encephalitis: detection of the virus genomic RNA in the cerebrospinal fluid of a child. Yoshida A, et al. **Pediatr Infect Dis J** 1995 Oct;14(10):914–6 (19 ref.)

PATHOLOGY

Quantitative neuropathologic assessment of HIV-1 encephalitis. Wiley CA. **Curr Top Microbiol Immunol** 1995; 202:55–61 (32 ref.)

SURGERY

[A case of herpes simplex encephalitis requiring surgical management] Kasó G, et al. **Orv Hetil** 1996 Feb 11; 137(6):299–302 (23 ref.) (Eng. Abstr.) **(Hun)**

TRANSMISSION

Neonatal herpes simplex virus-2 encephalitis. Irani MT, et al. **Indian Pediatr** 1995 Apr;32(4):476–80 (15 ref.)

VIROLOGY

Viral encephalitis in children. O'Meara M, et al. **Curr Opin Pediatr** 1996 Feb;8(1):11–5 (36 ref.)

ENCEPHALITIS VIRUS, CENTRAL EUROPEAN see **ENCEPHALITIS VIRUSES, TICK-BORNE**

ENCEPHALITIS VIRUS, MURRAY VALLEY

Australian X disease, Murray Valley encephalitis and the French connection. Mackenzie JS, et al. **Vet Microbiol** 1995 Sep;46(1–3):79–90 (49 ref.)

ENCEPHALITIS VIRUSES, JAPANESE

[Japanese encephalitis--implications for travelers to the Far East] Shapira I, et al. **Harefuah** 1996 Mar 15;130(6):406–8 (36 ref.) **(Heb)**

ENCEPHALITIS VIRUSES, TICK-BORNE

IMMUNOLOGY

[After vaccination for tick-borne encephalitis must onset of neurologic disorders be expected?] Hofmann H. **Wien Klin Wochenschr** 1995;107(17):509–15 (17 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Persistence and transmission of tick-borne viruses: Ixodes ricinus and louping-ill virus in red grouse populations. Hudson PJ, et al. **Parasitology** 1995;111 Suppl:S49–58 (27 ref.)

Viral envelope glycoproteins swing into action. Stuart D, et al. **Structure** 1995 Jul 15;3(7):645–8 (27 ref.)

ENCEPHALITOGENIC BASIC PROTEINS see **MYELIN BASIC PROTEINS**

ENCEPHALOCELE

COMPLICATIONS

Occipital encephalocele and MURCS association: case report and review of central nervous system anomalies in MURCS patients. Lin HJ, et al. **Am J Med Genet** 1996 Jan 2;

ENCEPHALOCELE

61(1):59–62 (23 ref.)
Basal encephaloceles with morning glory syndrome, and progressive hormonal and visual disturbances: case report and review of the literature. Morioka M, et al. **Brain Dev** 1995 May–Jun;17(3):196–201 (27 ref.)

ENCEPHALOMYELITIS

PATHOLOGY

[Pathologic anatomy of cytomegalovirus encephalomyelitis and varicella–zona virus encephalomyelitis] Henin D, et al. **J Neuroradiol** 1995 Sep;22(3):180–3 (14 ref.) (Eng. Abstr.) **(Fre)**

VIROLOGY

[Pathologic anatomy of cytomegalovirus encephalomyelitis and varicella–zona virus encephalomyelitis] Henin D, et al. **J Neuroradiol** 1995 Sep;22(3):180–3 (14 ref.) (Eng. Abstr.) **(Fre)**

ENCEPHALOMYELITIS, ACUTE DISSEMINATED

DIAGNOSIS

Mycoplasma pneumoniae infection associated with an acute brainstem syndrome. Pellegrini M, et al. **Acta Neurol Scand** 1996 Feb–Mar;93(2–3):203–6 (10 ref.)
Acute disseminated encephalomyelitis and isolated central nervous system demyelinative syndromes. Tselis AC, et al. **Curr Opin Neurol** 1995 Jun;8(3):227–9 (19 ref.)

ENCEPHALOMYELITIS, ALLERGIC

see related
MYELIN BASIC PROTEINS

Two models for multiple sclerosis: experimental allergic encephalomyelitis and Theiler's murine encephalomyelitis virus. Tsunoda I, et al. **J Neuropathol Exp Neurol** 1996 Jun;55(6):673–86 (136 ref.)

DRUG THERAPY

Multiple sclerosis: TNF revisited, with promise [comment] Raine CS. **Nat Med** 1995 Mar;1(3):211–4 (28 ref.) Comment on: Nat Med 1995 Mar;1(3):244–8.

ETIOLOGY

Transgenic mouse models of experimental autoimmune encephalomyelitis. Zaller DM, et al. **Curr Top Microbiol Immunol** 1996;206:15–31 (67 ref.)

IMMUNOLOGY

Oral tolerance in myasthenia gravis. Drachman DB, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:258–72 (58 ref.)
Oral tolerance in experimental autoimmune encephalomyelitis. Whitacre CC, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:217–27 (17 ref.)
Apoptosis in brain-specific autoimmune disease. Bauer J, et al. **Curr Opin Immunol** 1995 Dec;7(6):839–43 (48 ref.)
The role of macrophage subpopulations in autoimmune disease of the central nervous system. Bauer J, et al. **Histochem J** 1996 Feb;28(2):83–97 (104 ref.)
B7-mediated costimulation can either provoke or prevent clinical manifestations of experimental allergic encephalomyelitis. Perrin PJ, et al. **Immunol Res** 1995; 14(3):189–99 (47 ref.)
Evolution of the T-cell repertoire during the course of experimental immune-mediated demyelinating diseases. Miller SD, et al. **Immunol Rev** 1995 Apr;144:225–44 (66 ref.)
Critical influences of the cytokine orchestration on the outcome of myelin antigen-specific T-cell autoimmunity in experimental autoimmune encephalomyelitis and multiple sclerosis. Olsson T. **Immunol Rev** 1995 Apr; 144:245–68 (169 ref.)
Characteristics of the T lymphocytes involved in experimental allergic encephalomyelitis. Kalman B, et al. **J Neuroimmunol** 1995 Sep;61(2):107–16 (101 ref.)

METABOLISM

Glial fibrillary acidic protein mRNA and the development of gliosis in mice with chronic relapsing experimental allergic encephalomyelitis. Kothavale A, et al. **Prog Brain Res** 1995;105:305–10 (20 ref.)

PATHOLOGY

Two models of multiple sclerosis: experimental allergic encephalomyelitis (EAE) and Theiler's murine encephalomyelitis virus (TMEV) infection. A pathological and immunological comparison. Dal Canto MC, et al. **Microsc Res Tech** 1995 Oct 15;32(3):215–29 (74 ref.)

PHYSIOPATHOLOGY

Experimental autoimmune encephalomyelitis in rodents as a model for human demyelinating disease [see comments] Swanborg RH. **Clin Immunol Immunopathol** 1995 Oct; 77(1):4–13 (99 ref.) Comment in: Clin Immunol Immunopathol 1995 Oct;77(1):3.

THERAPY

Immune-based therapy of multiple sclerosis. Kaufman MD. **N C Med J** 1995 Aug;56(8):379–84 (24 ref.)

ENCEPHALOMYELITIS, AUTOIMMUNE see **ENCEPHALOMYELITIS, ALLERGIC**

ENCEPHALOMYELITIS, EXPERIMENTAL ALLERGIC see **ENCEPHALOMYELITIS, ALLERGIC**

ENCEPHALOMYELITIS, EXPERIMENTAL AUTOIMMUNE see **ENCEPHALOMYELITIS, ALLERGIC**

ENCEPHALOMYELITIS, MYALGIC see **FATIGUE SYNDROME, CHRONIC**

ENCEPHALOMYELITIS, OVINE see **VISNA**

ENCEPHALOMYELITIS VIRUS, PORCINE HEMAGGLUTINATING see **CORONAVIRUS**

ENCEPHALOMYOCARDITIS VIRUS

Immunomodulating agents for the management of heart failure with myocarditis and cardiomyopathy—lessons from animal experiments. Matsumori A, et al. **Eur Heart J** 1995 Dec;16 Suppl O:140–3 (10 ref.)

GENETICS

Translation of encephalomyocarditis virus RNA by internal ribosomal entry. Hellen CU, et al. **Curr Top Microbiol Immunol** 1995;203:31–63 (178 ref.)

ENCEPHALOPATHIES, SPONGIFORM see **PRION DISEASES**

ENCEPHALOPATHY, BOVINE SPONGIFORM

Bovine spongiform encephalopathy and the public health. Patterson WJ, et al. **J Public Health Med** 1995 Sep; 17(3):261–8 (70 ref.)
Origin and implications of bovine spongiform encephalopathy. Narang H. **Proc Soc Exp Biol Med** 1996 Apr;211(4):306–22 (105 ref.)

EPIDEMIOLOGY

[Bovine spongiform encephalopathy and Creutzfeldt–Jakob disease. Current questions] Brugère-Picoux J. **Bull Acad Natl Med** 1996 Feb;180(2):291–9; discussion 300–3 (38 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Bovine spongiform encephalopathy and Creutzfeldt–Jakob disease: implications for physicians [see comments] MacKnight C, et al. **Can Med Assoc J** 1996 Sep 1; 155(5):529–36 (107 ref.) Comment in: Can Med Assoc J 1996 Sep 1;155(5):549–51.

PHYSIOPATHOLOGY

[Bovine spongiform encephalopathy] **J Pharm Belg** 1996 Mar–Apr;51(2):97–8 (0 ref.) **(Fre)**

TRANSMISSION

Creutzfeldt–Jakob disease and bovine spongiform encephalopathy: any connection? [see comments] Almond JW, et al. **BMJ** 1995 Nov 25;311(7017):1415–21 (14 ref.) Comment in: BMJ 1996 Jan 20;312(7024):180. Comment in: BMJ 1996 Jan 20;312(7024):181. Comment in: BMJ 1996 Jul 20;313(7050):171–2.
Proposed link between transmissible spongiform encephalopathies of man and animals [see comments] Diringer H. **Lancet** 1995 Nov 4;346(8984):1208–10 (20 ref.) Comment in: Lancet 1996 Jan 6;347(8993):65–6.
[Spongiform encephalopathy in cattle and humans] Wientjens DP, et al. **Ned Tijdschr Geneeskd** 1996 Jun 15; 140(24):1252–4 (20 ref.) **(Dut)**
[Creutzfeldt–Jakob disease: in praise of madness (bovine)] Petrosillo N, et al. **Recenti Prog Med** 1996 May; 87(5):193–203 (103 ref.) **(Ita)**

ENCHONDROMA see **CHONDROMA**

ENCHONDROMA, MULTIPLE see **ENCHONDROMATOSIS**

ENCHONDROMATOSIS

DIAGNOSIS

[Cartilaginous tumors and other cutaneous lesions] Cribier B, et al. **Ann Dermatol Venereol** 1996;123(1):40–52 (80 ref.) **(Fre)**

ENCHONDROSIS, MULTIPLE see **ENCHONDROMATOSIS**

ENCLOMIFENE see **CLOMIPHENE**

ENCOPRESIS

Encopresis and soiling. Loening-Baucke V. **Pediatr Clin North Am** 1996 Feb;43(1):279–98 (71 ref.)

END-STAGE RENAL DISEASE see **KIDNEY FAILURE, CHRONIC**

ENDAMOEBA HISTOLYTICA see **ENTAMOEBA HISTOLYTICA**

ENDARTERECTOMY

see related
ANGIOPLASTY
ATHERECTOMY

[Current status of carotid surgery] Branchereau A, et al. **Chirurgie** 1994–95;120(10):572–81 (68 ref.) (Eng. Abstr.) **(Fre)**
[Arterial wall texture after uncomplicated endarterectomy] Bürrig KF, et al. **Pathologe** 1995 Sep;16(5):336–41 (49 ref.) (Eng. Abstr.) **(Ger)**
[Treatment of symptomatic carotid stenosis] von Segesser LK. **Schweiz Med Wochenschr** 1995 Oct 28;125(43):2033–9 (26 ref.) (Eng. Abstr.) **(Ger)**

INSTRUMENTATION

Current status of atherectomy for peripheral arterial occlusive disease. Ahn SS, et al. **World J Surg** 1996 Jul–Aug;20(6):635–43 (45 ref.)

METHODS

[Bilateral pulmonary thromboendarterectomy in chronic pulmonary thromboembolism. A case report and review of the literature] Ruyra Baliarda X, et al. **Rev Esp Cardiol** 1995 Oct;48(10):693–6 (9 ref.) (Eng. Abstr.) **(Spa)**

ENDARTERECTOMY, CAROTID

The dilemma of surgical treatment for patients with asymptomatic carotid disease [comment] Barnett HJ, et al. **Ann Intern Med** 1995 Nov 1;123(9):723–5 (22 ref.) Comment on: Ann Intern Med 1995 Nov 1;123(9):649–55. Comment on: Ann Intern Med 1995 Nov 1;123(9):729.
Surgical management of carotid stenosis. Halliday A. **Ann R Coll Surg Engl** 1995 Sep;77(5):323–4 (19 ref.)
Carotid endarterectomy: emerging indications. Meldrum HE, et al. **Baillieres Clin Neurol** 1995 Aug;4(2):339–55 (41 ref.)
Update on carotid endarterectomy. Barnett HJ, et al. **Curr Opin Cardiol** 1995 Sep;10(5):511–6 (28 ref.)
Vein patch rupture: early complication of carotid endarterectomy. Blok JG, et al. **Eur J Surg** 1995 Jul; 161(7):519–21 (17 ref.)
Who needs carotid endarterectomy? Fox A, et al. **Practitioner** 1996 Jan;240(1558):29–32 (4 ref.)
[Carotid thromboendarterectomy: personal experience and review of the literature] Tedesco M, et al. **Ann Ital Chir** 1995 May–Jun;66(3):313–8 (22 ref.) (Eng. Abstr.) **(Ita)**

ADVERSE EFFECTS

Complications associated with extracranial carotid artery interventions. Dorros G. **J Endovasc Surg** 1996 May; 3(2):166–70 (15 ref.)
Intracerebral hemorrhage after carotid endarterectomy associated with ipsilateral fibrinoid necrosis: a consequence of the hyperperfusion syndrome? Mansoor GA, et al. **J Vasc Surg** 1996 Jan;23(1):147–51 (20 ref.)
A systematic review of the risks of stroke and death due to endarterectomy for symptomatic carotid stenosis. Rothwell PM, et al. **Stroke** 1996 Feb;27(2):260–5 (68 ref.)
A systematic comparison of the risks of stroke and death due to carotid endarterectomy for symptomatic and asymptomatic stenosis. Rothwell PM, et al. **Stroke** 1996 Feb;27(2):266–9 (37 ref.)

METHODS

Carotid endarterectomy—when to do it, how to do it? Steiger HJ. **Acta Neurochir (Wien)** 1995;137(3–4):121–7 (65 ref.)
External carotid endarterectomy with internal carotid artery transposition flap angioplasty for symptomatic internal carotid artery occlusion. Harris LM, et al. **Cardiovasc Surg** 1995 Dec;3(6):625–9 (33 ref.)
Carotid Dacron patch angioplasty: immediate and long-term results of a prospective series. Perler BA, et al. **Cardiovasc Surg** 1995 Dec;3(6):631–6 (43 ref.)
Randomized clinical trial results define operative indications in symptomatic and asymptomatic carotid endarterectomy patients. Hobson RW 2nd. **Curr Opin Gen Surg** 1994; :265–71 (50 ref.)
Carotid angioplasty and stenting: is endovascular treatment for cerebrovascular disease justified [editorial] Bergeron P. **J Endovasc Surg** 1996 May;3(2):129–31 (12 ref.)
Indications for carotid artery stenting: a preview of the potential derived from early clinical experience [editorial] Diethrich EB. **J Endovasc Surg** 1996 May;3(2):132–9 (15 ref.)
Controversies in the management of carotid stenosis. Macdonald RL. **J Neurosci Nurs** 1996 Apr;28(2):93–8 (33 ref.)

MORTALITY

A systematic review of the risks of stroke and death due to endarterectomy for symptomatic carotid stenosis. Rothwell PM, et al. **Stroke** 1996 Feb;27(2):260–5 (68 ref.)
A systematic comparison of the risks of stroke and death due to carotid endarterectomy for symptomatic and asymptomatic stenosis. Rothwell PM, et al. **Stroke** 1996 Feb;27(2):266–9 (37 ref.)

UTILIZATION

Carotid endarterectomy: who should perform it? Cairols MA. **Eur J Vasc Endovasc Surg** 1995 Oct;10(3):263–4 (14 ref.)

ENDO-BETA-ACETYLGLUCOSAMINIDASE see **MANNOSYL-GLYCOPROTEIN ENDO-BETA-N-ACETYLGLUCOSAMINIDASE**

ENDO-1,4-BETA-GLUCANASE see **CELLULASE**

ENDOCARDIAL FIBROELASTOSIS

ULTRASONOGRAPHY

[Prenatal diagnosis of left cardiac abnormality] Hajdú J, et al. **Orv Hetil** 1995 Oct 22;136(43):2333–7 (22 ref.) (Eng. Abstr.) **(Hun)**

ENDOCARDITIS

COMPLICATIONS

[Cerebrovascular complications in patients with cancer] Casado JL, et al. **Rev Neurol** 1995;23 Suppl 1:S70–8 (75 ref.) **(Spa)**

ETIOLOGY

Deep tissue infections caused by Scopulariopsis brevicaulis: report of a case of prosthetic valve endocarditis and review. Migrino RQ, et al. **Clin Infect Dis** 1995 Sep;21(3):672–4 (16 ref.)

IMMUNOLOGY

Heart valve involvement (Libman–Sacks endocarditis) in the antiphospholipid syndrome. Hojnik M, et al. **Circulation** 1996 Apr 15;93(8):1579–87 (110 ref.)

PHYSIOPATHOLOGY

[Cerebrovascular complications in patients with cancer] Casado JL, et al. **Rev Neurol** 1995;23 Suppl 1:S70–8 (75 ref.) **(Spa)**

ULTRASONOGRAPHY

[Transesophageal echocardiography. Indications and clinical impact] Campos Filho O. **Arq Bras Cardiol** 1995 Apr; 64(4):383–9 (47 ref.) **(Por)**

ENDOCARDITIS, BACTERIAL

see related
ANEURYSM, INFECTED

Endocarditis in injection drug users. DeWitt DE, et al. **Am Fam Physician** 1996 May 1;53(6):2045–9 (24 ref.)
[Neisseria mucosa endocarditis: apropos of a case and review of the literature (letter)] Lechowski L, et al. **Ann Med Interne (Paris)** 1995;146(8):592–3 (17 ref.) **(Fre)**
[Brucella pancarditis with fatal outcome] Chevalier P, et al. **Presse Med** 1996 Apr 13;25(13):628–30 (12 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

Coronary artery obstruction caused by perivalvular abscess in aortic valve endocarditis. Schlaifer JD, et al. **Am Heart J** 1996 Feb;131(2):413–6 (8 ref.)
Infectious endocarditis due to non-typhi Salmonella in patients infected with human immunodeficiency virus: report of two cases and review. Fernández Guerrero ML, et al. **Clin Infect Dis** 1996 May;22(5):853–5 (10 ref.)
Recurrent Streptococcus pneumoniae endocarditis. Cunningham R, et al. **Eur J Clin Microbiol Infect Dis** 1995 Jun;14(6):526–8 (11 ref.)
A rare complication of aortic valve endocarditis: diagnosis with transesophageal echocardiography. Winslow TM, et al. **J Am Soc Echocardiogr** 1995 Jul–Aug;8(4):546–50 (25 ref.)
Fragmentation hemolysis: an unusual indication for valve replacement in native valve infective endocarditis. Gradon JD, et al. **South Med J** 1996 Aug;89(8):818–20 (7 ref.)
[Acute mitral valve insufficiency] Acar J. **Ann Cardiol Angeiol (Paris)** 1995 Dec;44(10):561–6 (22 ref.) (Eng. Abstr.) **(Fre)**
[Neurologic complications of infectious endocarditis] Gergaud JM, et al. **Ann Med Interne (Paris)** 1995; 146(6):413–8 (34 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Type b Haemophilus influenzae endocarditis in children: case report and review of the literature. Malik AS. **Ann Trop Paediatr** 1995 Sep;15(3):193–5 (16 ref.)
Nonfebrile mitral valve endocarditis due to Neisseria subflava. Amsel BJ, et al. **Chest** 1996 Jan;109(1):280–2 (16 ref.)
Misidentification of toxigenic Corynebacterium diphtheriae as a Corynebacterium species with low virulence in a child with endocarditis. Pennie RA, et al. **J Clin Microbiol** 1996 May;34(5):1275–6 (18 ref.)
Bacillus licheniformis prosthetic aortic valve endocarditis. Santini F, et al. **J Clin Microbiol** 1995 Nov;33(11):3070–3 (12 ref.)
[Diagnosis of infective endocarditis] Mansur AJ. **Arq Bras Cardiol** 1995 Aug;65(2):119–24 (73 ref.) **(Por)**
[Enterococcal neonatal endocarditis] Roca Comas A, et al. **An Esp Pediatr** 1996 Feb;44(2):159–60 (17 ref.) **(Spa)**

DRUG THERAPY

Outpatient treatment of endocarditis in a clinic-based program in Argentina. Stamboulian D. **Eur J Clin Microbiol Infect Dis** 1995 Jul;14(7):648–54 (31 ref.)
[Aminoglycosides in the treatment of infectious endocarditis] Malinverni R. **Schweiz Med Wochenschr Suppl** 1996; 76:14S–20S (41 ref.) (Eng. Abstr.) **(Ger)**
[Enterococcal endocarditis] Kizner V, et al. **Harefuah** 1996 Apr 15;130(8):548–50 (18 ref.) **(Heb)**
[Treatment of endocarditis and other severe infections caused by enterococci] Fernández-Guerrero ML. **Enferm Infecc Microbiol Clin** 1996 Mar;14(3):186–91 (74 ref.) **(Spa)**

EPIDEMIOLOGY

Epidemiologic aspects of infective endocarditis in an urban population. A 5-year prospective study. Hogevik H, et al. **Medicine (Baltimore)** 1995 Nov;74(6):324–39 (69 ref.)

ETIOLOGY

Clostridium innocuum endocarditis. Cutrona AF, et al. **Clin Infect Dis** 1995 Nov;21(5):1306–7 (17 ref.)
Tricuspid valve endocarditis with large vegetations in a non-drug addict without underlying cardiac disease. Iwama T, et al. **Intern Med** 1996 Mar;35(3):203–6 (20 ref.)
[Prognostic factors of prosthetic valve endocarditis. Apropos of 122 cases] Witchitz S, et al. **Arch Mal Coeur Vaiss** 1996 Jun;89(6):671–7 (30 ref.) (Eng. Abstr.) **(Fre)**

MICROBIOLOGY

Infectious endocarditis due to non-typhi Salmonella in patients infected with human immunodeficiency virus: report of two cases and review. Fernández Guerrero ML, et al. **Clin Infect Dis** 1996 May;22(5):853–5 (10 ref.)
Acinetobacter endocarditis in children: a case report and review of the literature. Malik AS. **Infection** 1995 Sep–Oct; 23(5):306–8 (18 ref.)
Misidentification of toxigenic Corynebacterium diphtheriae as a Corynebacterium species with low virulence in a child with endocarditis. Pennie RA, et al. **J Clin Microbiol** 1996 May;34(5):1275–6 (18 ref.)
Gonoccocal endocarditis. Thompson EC, et al. **J Natl Med Assoc** 1996 Jun;88(6):353–6 (44 ref.)
Salmonella prosthetic valve endocarditis. Fukushima N, et al. **J Thorac Cardiovasc Surg** 1996 Sep;112(3):840–2 (5 ref.)
[Septicemia and endocarditis related to transvenous pacing leads of pacemakers: surgical indications and results] Leprince P, et al. **Arch Mal Coeur Vaiss** 1995 Feb; 88(2):241–6 (20 ref.) (Eng. Abstr.) **(Fre)**

MORTALITY

[Prognostic factors of prosthetic valve endocarditis. Apropos of 122 cases] Witchitz S, et al. **Arch Mal Coeur Vaiss** 1996 Jun;89(6):671–7 (30 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Intracardiac thrombi: frequency, location, etiology, and complications: a morphologic review—Part IV. Waller BF, et al. **Clin Cardiol** 1995 Nov;18(11):669–74 (44 ref.)
[Pathogenetic aspects of infective endocarditis] Tomaszewski R. **Pol Arch Med Wewn** 1995 Dec;94(6):533–8 (40 ref.) **(Pol)**

PREVENTION & CONTROL

Prevention of infective endocarditis: enthusiasm tempered by realism. Prasad A, et al. **Br J Hosp Med** 1995 Oct 4–17; 54(7):341–7 (40 ref.)
Antibiotic prophylaxis for lower gastrointestinal endoscopy. Varma JR. **Prim Care** 1995 Sep;22(3):445–50 (6 ref.)
[Multifactor prevention of endocarditis and cardiac pacemakers. A prospective study apropos of 207 patients] Graux P, et al. **Ann Cardiol Angeiol (Paris)** 1996 Mar; 45(3):113–8 (34 ref.) (Eng. Abstr.) **(Fre)**
[Antibiotic prophylaxis and endoscopic retrograde cholangiopancreatography] Le Dreau G, et al. **Gastroenterol Clin Biol** 1996 Feb;20(1):55–63 (100 ref.) **(Fre)**

SURGERY

[A case of secondary valve replacement caused by pulmonary bioprosthetic valve endocarditis] Fujii H, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Jul;43(7):1081–5 (18 ref.) (Eng. Abstr.) **(Jpn)**

ULTRASONOGRAPHY

Identification of high-risk subgroups in infective endocarditis and the role of echocardiography. Erbel R, et al. **Eur Heart J** 1995 May;16(5):588–602 (86 ref.)
[The role of echocardiography in the diagnosis of infectious endocarditis] Chlumský J. **Vnitr Lek** 1995 Nov;41(11):792–5 (12 ref.) (Eng. Abstr.) **(Cze)**
[The main indications for transesophageal echocardiography] Lesbre JP. **Ann Cardiol Angeiol (Paris)** 1995 Dec; 44(10):547–51 (21 ref.) (Eng. Abstr.) **(Fre)**
[Use of echocardiographic examination for infective endocarditis] Werner B. **Pediatr Pol** 1995 Aug;70(8):673–8 (29 ref.) (Eng. Abstr.) **(Pol)**

ENDOCARDITIS LENTA see **ENDOCARDITIS, SUBACUTE BACTERIAL**

ENDOCARDITIS, LOEFFLER'S see **HYPEREOSINOPHILIC SYNDROME**

ENDOCARDITIS, SUBACUTE BACTERIAL

DRUG THERAPY

[Current approaches to the treatment and prevention of subacute infectious endocarditis] Belokrinitskaia OA, et al. **Klin Med (Mosk)** 1995;73(5):23–8 (50 ref.) **(Rus)**

ENDOCARDIUM

PATHOLOGY

Primary right atrial fibrosarcoma diagnosed by endocardial biopsy. Basso C, et al. **Am Heart J** 1996 Feb;131(2):399–402 (11 ref.)
Endomyocardial biopsy in Chagas' heart disease: pathogenetic contributions. Higuchi MD. **Rev Paul Med** 1995 Mar–Apr;113(2):821–5 (21 ref.)
[Endomyocardial biopsy in pediatric cardiovascular pathology (editorial)] Gallo P. **G Ital Cardiol** 1995 Nov; 25(11):1499–512 (97 ref.) **(Ita)**

PHYSIOLOGY

Mechanisms of endocardial endothelium modulation of myocardial performance. Mohan P, et al. **Adv Exp Med Biol** 1995;382:249–60 (57 ref.)

ENDOCAVITARY FULGURATION see **ELECTROCOAGULATION**

ENDOCRINE DISEASES

Molecular biology and its application in paediatric endocrinology. Mullis PE, et al. **Eur J Pediatr** 1995;154(9 Suppl 4):S30–9 (34 ref.)

BLOOD

African endocrine infertility: a review. Kuku SF. **Afr J Med Med Sci** 1995 Jun;24(2):111–23 (60 ref.)
[Pitfalls in hormone assays] Pelkonen R. **Duodecim** 1994; 110(10):959–67 (23 ref.) **(Fin)**

COMPLICATIONS

African endocrine infertility: a review. Kuku SF. **Afr J Med Med Sci** 1995 Jun;24(2):111–23 (60 ref.)
Endocrine disorders and orthopedic problems in children. Mann DC. **Curr Opin Pediatr** 1996 Feb;8(1):68–70 (12 ref.)
Metabolic and endocrine disease and arthritis. Matteucci BM. **Curr Opin Rheumatol** 1995 Jul;7(4):356–8 (8 ref.)
Endocrine-related gut dysfunction. Su AY, et al. **Semin Gastrointest Dis** 1995 Oct;6(4):217–27 (81 ref.)
[Diabetes secondary to endocrine diseases] Löffler J, et al. **Rev Med Suisse Romande** 1995 Sep;115(9):721–6 (38 ref.) **(Fre)**
[Diagnosis of endocrine-induced forms of hypertension] Vierhapper H. **Acta Med Austriaca** 1995;22(3):35–7 (20 ref.) (Eng. Abstr.) **(Ger)**
[Diabetes mellitus with endocrine diseases—the physiopathology , diagnosis and therapy] Okuda Y, et al. **Nippon Naika Gakkai Zasshi** 1996 Apr 10;85(4):530–5 (5 ref.) **(Jpn)**
[Endocrine abnormalities in active nephrolithiasis] Kuczera M, et al. **Pol Arch Med Wewn** 1995 Mar;93(3):243–9 (53 ref.) **(Pol)**

CONGENITAL

Endocrinology of the neonate. Ogilvy-Stuart AL. **Br J Hosp Med** 1995 Sep 6–19;54(5):207–11; quiz 212–3 (4 ref.)

DIAGNOSIS

Hormones and behaviour. Fahlbusch R, et al. **Acta Neurochir (Wien)** 1995;132(4):169–77 (75 ref.)
Endocrine disorders: new technology allows quick, accurate diagnosis. Miller M. **Geriatrics** 1996 Jan;51(1):52–4, 57–8 (11 ref.)
Diagnosis and management of endocrine disorders of erectile dysfunction. Zonszein J. **Urol Clin North Am** 1995 Nov;

ENDOCRINE DISEASES

22(4):789–802 (48 ref.)
[Quick Return Service in endocrinological tests] Hashimoto T. **Rinsho Byori** 1995 Oct;43(10):1034–7 (3 ref.) (Eng. Abstr.) **(Jpn)**

ETHNOLOGY

The Finnish disease heritage: a personal look. Perheentupa J. **Acta Paediatr** 1995 Oct;84(10):1094–9 (26 ref.)

ETIOLOGY

Growth and endocrine disturbances after bone marrow transplantation in childhood. Sklar C. **Acta Paediatr Suppl** 1995 Sep;411:57–61; discussion 62 (30 ref.)
Antigen presentation in the pathogenesis of autoimmune endocrine disease. Weetman AP. **J Autoimmun** 1995 Jun; 8(3):305–12 (38 ref.)
[Countermeasure for patients with endocrine disorders due to hemodialysis] Nihei H. **Nippon Naika Gakkai Zasshi** 1995 Oct 10;84(10):1691–5 (5 ref.) **(Jpn)**
[The current concepts of the etiology and pathogenesis of autoimmune endocrinopathies (editorial)] Luk'ianchikov VS, et al. **Ter Arkh** 1995;67(10):3–6 (22 ref.) **(Rus)**

GENETICS

Endocrine disorders associated with mutations in guanine nucleotide binding proteins. Milligan G. **Baillieres Clin Endocrinol Metab** 1996 Jan;10(1):177–87 (60 ref.)
Ligand-independent hormone secretion. Laue L. **Curr Opin Pediatr** 1995 Aug;7(4):434–9 (47 ref.)
Mutations in G proteins and G protein-coupled receptors in endocrine disease. Spiegel AM. **J Clin Endocrinol Metab** 1996 Jul;81(7):2434–42 (71 ref.)

IMMUNOLOGY

Leucocyte migration into autoimmune diseased endocrine tissues [comment] Delemarre FG, et al. **Eur J Endocrinol** 1996 Jan;134(1):9–11 (35 ref.) Comment on: Eur J Endocrinol 1996 Jan;134(1):51–60.
On the issue of inappropriate HLA class II expression on endocrine cells: an answer to a sceptic. Todd I, et al. **J Autoimmun** 1995 Jun;8(3):313–22 (48 ref.)

PATHOLOGY

Clinical review 74: Dermatological manifestations of endocrine disorders. Thiboutot DM. **J Clin Endocrinol Metab** 1995 Oct;80(10):3082–7 (27 ref.)

PHYSIOPATHOLOGY

Cytokines and the endocrine system. II. Roles in substrate metabolism, modulation of thyroidal and pancreatic endocrine cell functions and autoimmune endocrine diseases. Mandrup-Poulsen T, et al. **Eur J Endocrinol** 1996 Jan;134(1):21–30 (174 ref.)
Clinical review 74: Dermatological manifestations of endocrine disorders. Thiboutot DM. **J Clin Endocrinol Metab** 1995 Oct;80(10):3082–7 (27 ref.)
Peritoneal dialysis and endocrinology. Lim VS. **Perit Dial Int** 1996;16 Suppl 1:S257–9 (6 ref.)

VETERINARY

Systemic diseases with cutaneous manifestations. Merchant SR, et al. **Vet Clin North Am Small Anim Pract** 1995 Jul; 25(4):945–59 (56 ref.)
The skin in systemic disease. Rosser EJ Jr. **Vet Q** 1995 Apr; 17 Suppl 1:S38–9 (0 ref.)

ENDOCRINE GLAND NEOPLASMS

DIAGNOSIS

Cancer and male infertility. Meirow D, et al. **Hum Reprod** 1995 Aug;10(8):2017–22 (59 ref.)

THERAPY

Endocrine tumors. Lamberts SW. **Cancer Chemother Biol Response Modif** 1996;16:511–23 (107 ref.)

ENDOCRINE GLANDS

see related
HORMONES

Quantitative RT-PCR for neuroendocrine studies. A minireview. Zamorano PL, et al. **Neuroendocrinology** 1996 May;63(5):397–407 (39 ref.)

DRUG EFFECTS

Organization versus activation: the role of endocrine-disrupting contaminants (EDCs) during embryonic development in wildlife. Guillette LJ Jr, et al. **Environ Health Perspect** 1995 Oct;103 Suppl 7:157–64 (81 ref.)
Developmental effects of dioxins and related endocrine disrupting chemicals. Birnbaum LS. **Toxicol Lett** 1995 Dec; 82–83:743–50 (60 ref.)

GROWTH & DEVELOPMENT

[Evolution of the endocrine system] Leinonen P. **Duodecim** 1994;110(10):939–48 (28 ref.) **(Fin)**

INNERVATION

Endocrine glia: roles of glial cells in the brain actions of steroid and thyroid hormones and in the regulation of hormone secretion. Garcia-Segura LM, et al. **Front Neuroendocrinol** 1996 Apr;17(2):180–211 (253 ref.)

PATHOLOGY

The consequences of hypergastrinemia. Creutzfeldt W. **Yale J Biol Med** 1994 May-Aug;67(3–4):181–94 (63 ref.)

PHYSIOLOGY

Endocrine regulation of craniofacial growth. Pirinen S. **Acta Odontol Scand** 1995 Jun;53(3):179–85 (62 ref.)
Endocrine, paracrine and autocrine regulation of testicular steroidogenesis. Huhtaniemi I, et al. **Adv Exp Med Biol** 1995;377:33–54 (145 ref.)
Current aspects of autocrine and paracrine regulation of spermatogenesis. Jégou B, et al. **Adv Exp Med Biol** 1995; 377:67–86 (72 ref.)
Ovarian follicular growth, ovulation and atresia. Endocrine, paracrine and autocrine regulation. Moley KH, et al. **Adv Exp Med Biol** 1995;377:103–19 (105 ref.)
Role of endocrine cell microvesicles in intercellular chemical transduction. Moriyama Y, et al. **Biol Chem Hoppe Seyler** 1996 Mar;377(3):155–65 (108 ref.)
Anomalies in the endocrine axes of the guinea pig: relevance to human physiology and disease. Keightley MC, et al. **Endocr Rev** 1996 Feb;17(1):30–44 (182 ref.)
Cytokines and the endocrine system. II. Roles in substrate metabolism, modulation of thyroidal and pancreatic endocrine cell functions and autoimmune endocrine diseases. Mandrup-Poulsen T, et al. **Eur J Endocrinol** 1996 Jan;134(1):21–30 (174 ref.)
Cytokines and the endocrine system. I. The immunoendocrine network. Mandrup-Poulsen T, et al. **Eur J Endocrinol** 1995 Dec;133(6):660–71 (109 ref.)
The vitamin D Endocrine system: manipulation of structure-function relationships to provide opportunities for development of new cancer chemopreventive and immunosuppressive agents. Norman AW. **J Cell Biochem Suppl** 1995;22:218–25 (39 ref.)
Endocrine regulation of food intake and body weight. Figlewicz DP, et al. **J Lab Clin Med** 1996 Apr; 127(4):328–32 (43 ref.)
Antiaging action of caloric restriction: endocrine and metabolic aspects. Masoro EJ. **Obes Res** 1995 Sep;3 Suppl 2:241s–247s (30 ref.)
Gastric endocrine cells: gene expression, processing, and targeting of active products. Dockray GJ, et al. **Physiol Rev** 1996 Jul;76(3):767–98 (387 ref.)
[Growth factors and cytokines as messengers of hormonal effects] Ilvesmäki V, et al. **Duodecim** 1994;110(10):949–57 (53 ref.) **(Fin)**
[Immuno-endocrine interactions at the hypothalamo-hypophyseal level] Gaillard RC. **Ann Endocrinol (Paris)** 1995;56(6):561–6 (38 ref.) (Eng. Abstr.) **(Fre)**
[Current concepts of the interactions of regulating systems: nervous, endocrine and immune] Akmaev IG. **Usp Fiziol Nauk** 1996 Jan-Mar;27(1):3–20 (129 ref.) (Eng. Abstr.) **(Rus)**
[The genetics and endocrinology of homosexuality] Botella Llusiá J. **An R Acad Nac Med (Madr)** 1996;Spec No:19–29 (15 ref.) **(Spa)**
[The functional organization of the adaptive and compensatory reactions of the endocrine glands] Reznikov OH. **Fiziol Zh** 1994 Sep-Dec;40(5–6):121–7 (22 ref.) (Eng. Abstr.) **(Ukr)**

PHYSIOPATHOLOGY

[Clinical aspects of immunoneuroendocrine alterations in HIV infection] Rondanelli M, et al. **Minerva Endocrinol** 1995 Jun;20(2):113–26 (78 ref.) (Eng. Abstr.) **(Ita)**

SECRETION

Insulin-secreting cell lines: classification, characteristics and potential applications. Poitout V, et al. **Diabetes Metab** 1996 Feb;22(1):7–14 (54 ref.)
Endocrine glia: roles of glial cells in the brain actions of steroid and thyroid hormones and in the regulation of hormone secretion. Garcia-Segura LM, et al. **Front Neuroendocrinol** 1996 Apr;17(2):180–211 (253 ref.)

ENDOCRINE NEOPLASIA, MULTIPLE see **MULTIPLE ENDOCRINE NEOPLASIA**

ENDOCRINOLOGY

see related
ENDOCRINE DISEASES

[Endocrinology 1994–1995] Schreiber V. **Cas Lek Cesk** 1995 Sep 20;134(18):575–6 (15 ref.) (Eng. Abstr.) **(Cze)**
[Comment by a surgeon on Japan Endocrine Society, its past and future] Uozumi T. **Nippon Naibunpi Gakkai Zasshi** 1995 Nov 20;71(7):1047–52 (0 ref.) (Eng. Abstr.) **(Jpn)**

TRENDS

11 beta-Hydroxysteroid dehydrogenase: new answers, new questions [comment] Funder JW. **Eur J Endocrinol** 1996 Mar;134(3):267–8 (10 ref.) Comment on: Eur J Endocrinol 1996 Mar;134(3):301–7.
New insights into pancreatic beta-cell metabolic signaling in insulin secretion. Prenki M. **Eur J Endocrinol** 1996 Mar; 134(3):272–86 (134 ref.)
Advances in endocrinology and metabolism, 1990–1995. Kahn CB, et al. **Med Health R I** 1996 May;79(5):175–9 (7 ref.)
[Future aspects on endocrinology] Imura Y. **Nippon Naibunpi Gakkai Zasshi** 1995 Nov 20;71(7):1039–42 (0 ref.) **(Jpn)**
[A view of basic endocrinology] Matsumoto K. **Nippon Naibunpi Gakkai Zasshi** 1995 Nov 20;71(7):1043–6 (0 ref.) (Eng. Abstr.) **(Jpn)**
[The future of the Japan Endocrine Society] Yoshida S. **Nippon Naibunpi Gakkai Zasshi** 1995 Nov 20;71(7):1053–8 (11 ref.) (Eng. Abstr.) **(Jpn)**

ENDOCRINOLOGY AND METABOLISM (SPECIALTY) see **ENDOCRINOLOGY**

ENDOCYTOSIS

see related
ENDOSOMES

How MHC class II molecules acquire peptide cargo: biosynthesis and trafficking through the endocytic pathway. Wolf PR, et al. **Ann Rev Cell Dev Biol** 1995; 11:267–306 (169 ref.)
Membrane molecules and macrophage endocytosis: scavenger receptor and macrosialin as markers of plasma-membrane and vacuolar functions. da Silva RP, et al. **Biochem Soc Trans** 1996 Feb;24(1):220–4 (17 ref.)
Strategies to accomplish gene delivery via the receptor-mediated endocytosis pathway. Cristiano RJ, et al. **Cancer Gene Ther** 1996 Jan-Feb;3(1):49–57 (60 ref.)
Furin/PACE/SPC1: a convertase involved in exocytic and endocytic processing of precursor proteins. Denault JB, et al. **FEBS Lett** 1996 Jan 29;379(2):113–6 (46 ref.)
Strategies to achieve targeted gene delivery via the receptor-mediated endocytosis pathway. Michael SI, et al. **Gene Ther** 1994 Jul;1(4):223–32 (49 ref.)
Delivery of DNA into mammalian cells by receptor-mediated endocytosis and gene therapy. Guy J, et al. **Mol Biotechnol** 1995 Jun;3(3):237–48 (60 ref.)

PHYSIOLOGY

The role of microtubules in apical and basolateral endocytosis in epithelial Madin-Darby canine kidney (MDCK) cells. Prydz K, et al. **Biochem Soc Trans** 1995 Aug;23(3):535–8 (30 ref.)
Intracytoplasmic sequences involved in the biological properties of low-affinity receptors for IgG expressed by murine macrophages. Daëron M. **Braz J Med Biol Res** 1995 Mar;28(3):263–74 (50 ref.)
Membrane dynamics in endocytosis. Robinson MS, et al. **Cell** 1996 Jan 12;84(1):13–21 (22 ref.)
Membrane transport in the endocytic pathway. Gruenberg J, et al. **Curr Opin Cell Biol** 1995 Aug;7(4):552–63 (127 ref.)
Receptor signalling and the regulation of endocytic membrane transport. Seaman MN, et al. **Curr Opin Cell Biol** 1996 Aug;8(4):549–56 (67 ref.)
The function of dynamin in endocytosis. De Camilli P, et al. **Curr Opin Neurobiol** 1995 Oct;5(5):559–65 (73 ref.)
Dynamin and endocytosis. Liu JP, et al. **Endocr Rev** 1995 Oct;16(5):590–607 (172 ref.)
Dynamin and receptor-mediated endocytosis. Damke H. **FEBS Lett** 1996 Jun 24;389(1):48–51 (49 ref.)
Molecular mechanisms in synaptic vesicle endocytosis and recycling. De Camilli P, et al. **Neuron** 1996 Mar;16(3):481–6 (46 ref.)
Receptor cell biology: receptor-mediated endocytosis. Schwartz AL. **Pediatr Res** 1995 Dec;38(6):835–43 (133 ref.)
Cellular metabolism of triglyceride-rich lipoproteins: role of heparan sulfate, lipoprotein lipase and lipoprotein receptors. Schayek E, et al. **Z Gastroenterol** 1996 Jun;34 Suppl 3:110–2 (16 ref.)

ENDODEOXYRIBONUCLEASES

BIOSYNTHESIS

Mechanisms of intron mobility. Belfort M, et al. **J Biol Chem** 1995 Dec 22;270(51):30237–40 (55 ref.)

METABOLISM

DNA packaging and cutting by phage terminases: control in phage T4 by a synaptic mechanism. Black LW. **Bioessays** 1995 Dec;17(12):1025–30 (55 ref.)
The RuvABC proteins and Holliday junction processing in Escherichia coli. West SC. **J Bacteriol** 1996 Mar; 178(5):1237–41 (59 ref.)
Metallocene interactions with DNA and DNA-processing enzymes. Kuo LY, et al. **Met Ions Biol Syst** 1996;33:53–85 (113 ref.)

ENDODERMAL SINUS TUMOR

[Yolk sac tumor of the liver] Sasaki M.
Ryoikibetsu Shokogun Shirizu 1995;(7):306–9 (13 ref.) **(Jpn)**

GENETICS

Interphase cytogenetics on paraffin sections of paediatric extragonadal yolk sac tumours. Jenderny J, et al.
Virchows Arch 1996 Apr;428(1):53–7 (13 ref.)

PATHOLOGY

Interphase cytogenetics on paraffin sections of paediatric extragonadal yolk sac tumours. Jenderny J, et al.
Virchows Arch 1996 Apr;428(1):53–7 (13 ref.)

ENDODERMOPHYTON see **TRICHOPHYTON**

ENDODONTICS

see related
DENTAL PULP DISEASES

METHODS

Endodontics of dogs and cats: an alternative to extraction. Clarke DE. **Aust Vet J** 1995 Oct;72(10):383–9 (57 ref.)

ENDOGLYCOSIDASE F see
MANNOSYL-GLYCOPROTEIN
ENDO-BETA-N-ACETYLGLUCOSAMINIDASE

ENDOLYMPHATIC HYDROPS

see related
MENIERE'S DISEASE

ENDOLYMPHATIC SAC

Large vestibular aqueduct syndrome with massive endolymphatic sacs. Reussner LA, et al.
Otolaryngol Head Neck Surg 1995 Nov;113(5):606–10 (14 ref.)

ENDOMETRIAL CYCLE see **MENSTRUAL CYCLE**

ENDOMETRIAL HYPERPLASIA

DRUG THERAPY

[The role of gestagens in prevention and therapy of endometrial hyperplasia] Römer T. **Zentralbl Gynakol** 1995; 117 Suppl:14–8 (10 ref.) **(Ger)**

PATHOLOGY

The role of computerized morphometric and cytometric feature analysis in endometrial hyperplasia and cancer prognosis. Baak JP. **J Cell Biochem Suppl** 1995;23:137–46 (25 ref.)

THERAPY

[Conservative therapeutic possibilities in glandular or adenomatous endometrium hyperplasia] Schindler AE. **Zentralbl Gynakol** 1996;118(6):359–64 (29 ref.) (Eng. Abstr.) **(Ger)**

ULTRASONOGRAPHY

[Ultrasound endometrium diagnosis] Tercanli S, et al.
Ther Umsch 1996 Jun;53(6):455–66 (30 ref.) (Eng. Abstr.) **(Ger)**

ENDOMETRIAL NEOPLASMS

Endometrial carcinoma. Rose PG. **N Engl J Med** 1996 Aug 29;335(9):640–9 (100 ref.)
Endometrial cancer: risk factors and diagnosis. Clark K.
W V Med J 1996 Jan–Feb;92(1):28–30 (20 ref.)
[Serious papillary endometrial adenocarcinoma] Zhang G, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1996 Jan;31(1):48–51 (25 ref.) **(Chi)**

CHEMICALLY INDUCED

Organochlorine compounds in relation to breast cancer, endometrial cancer, and endometriosis: an assessment of the biological and epidemiological evidence. Ahlborg UG, et al. **Crit Rev Toxicol** 1995;25(6):463–531 (318 ref.)
The effects of tamoxifen treatment on the endometrium. Daniel Y, et al. **Fertil Steril** 1996 Jun;65(6):1083–9 (94 ref.)
Uterine neoplasms in patients treated with tamoxifen. Silva EG, et al. **J Cell Biochem Suppl** 1995;23:179–83 (22 ref.)
Postmenopausal estrogens and progestogens and the incidence of gynecologic cancer. Weiss NS, et al.
Maturitas 1996 Mar;23(2):235–9 (43 ref.)
The effect of tamoxifen on the endometrium. Barakat RR.
Oncology (Huntingt) 1995 Feb;9(2):129–34; discussion 139–40, 142 (27 ref.)
Tamoxifen and endometrial cancer: from experiment to patient. Assikis VJ, et al. **Recent Results Cancer Res** 1996; 140:61–71 (41 ref.)
–Tamoxifen and the endometrium: monitoring and evaluation of endometrial changes– Rageth JC, et al.
Arch Gynecol Obstet 1995;256 Suppl:S122–7 (24 ref.) **(Ger)**

DIAGNOSIS

Management of endometrial cancer. Homesley HD.
Am J Obstet Gynecol 1996 Feb;174(2):529–34 (26 ref.)
Hysteroscopy and adenocarcinoma. Mencaglia L.
Obstet Gynecol Clin North Am 1995 Sep;22(3):573–9 (30 ref.)
Endometrial cytology by direct sampling. Its value and limitations in the diagnosis of endometrial lesions. Nguyen GK, et al. **Pathol Annu** 1995;30 Pt 2:179–202 (42 ref.)
[Is it possible to screen for endometrial carcinoma? Incidence and risk factors] Broso PR, et al. **Minerva Ginecol** 1995 Dec;47(12):539–52 (70 ref.) (Eng. Abstr.) **(Ita)**
[Applications of tumor markers to the screening of endometrial and ovarian cancers] Nozawa S, et al.
Nippon Rinsho 1996 Jun;54(6):1665–73 (19 ref.) (Eng. Abstr.) **(Jpn)**
[Primary malignant neoplasms of the female genitalia] Saraiva J, et al. **Acta Med Port** 1995 Oct;8(10):585–8 (11 ref.) (Eng. Abstr.) **(Por)**

DRUG THERAPY

Primary squamous cell carcinoma of the endometrium: a first report of adjuvant chemoradiation. Kennedy AS, et al.
Gynecol Oncol 1995 Oct;59(1):117–23 (61 ref.)
Androgen receptor mediated growth control of breast cancer and endometrial cancer modulated by antiandrogen– and androgen–like steroids. Hackenberg R, et al.
J Steroid Biochem Mol Biol 1996 Jan;56(1–6 Spec No):113–7 (56 ref.)
The platinum compounds and paclitaxel in the management of carcinomas of the endometrium and uterine cervix. Thigpen T, et al. **Semin Oncol** 1995 Oct;22(5 Suppl 12):67–75 (25 ref.)
[Chemotherapy of metastatic endometrial carcinoma. Review of the literature] Pierga JY, et al. **Bull Cancer (Paris)** 1995 Dec;82(12):1005–18 (110 ref.) (Eng. Abstr.) **(Fre)**
[Hormone therapy of endometrial carcinoma] Kuramoto H, et al. **Gan To Kagaku Ryoho** 1996 May;23(6):673–7 (19 ref.) (Eng. Abstr.) **(Jpn)**

EPIDEMIOLOGY

Body weight: estimation of risk for breast and endometrial cancers. Ballard–Barbash R, et al. **Am J Clin Nutr** 1996 Mar;63(3 Suppl):437S–41S (38 ref.)
Epidemiology of endometrial neoplasia. Schottenfeld D.
J Cell Biochem Suppl 1995;23:151–9 (32 ref.)
[Obesity as a risk factor of endometrial cancer of the uterus] Hori S, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:290–5 (23 ref.) **(Jpn)**

ETIOLOGY

Organochlorine compounds and estrogen–related cancers in women. Adami HO, et al. **Cancer Causes Control** 1995 Nov; 6(6):551–66 (105 ref.)
Hormones and cancer in humans. Key TJ. **Mutat Res** 1995 Dec;333(1–2):59–67 (85 ref.)
[Etiology of endometrial cancer] Parslov M, et al.
Ugeskr Laeger 1996 Aug 5;158(32):4500–4 (40 ref.) (Eng. Abstr.) **(Dan)**

GENETICS

Pathways of chromosome alteration in human epithelial cancers. Dutrillaux B. **Adv Cancer Res** 1995;67:59–82 (80 ref.)
Molecular basis of endometrial cancer. Berchuck A, et al.
Cancer 1995 Nov 15;76(10 Suppl):2034–40 (63 ref.)
Biomarkers in the endometrium. Berchuck A.
J Cell Biochem Suppl 1995;23:174–8 (32 ref.)
Estrogen as a carcinogen: the genetics and molecular biology of human endometrial carcinoma. Boyd J.
Prog Clin Biol Res 1996;394:151–73 (162 ref.)

MORTALITY

[The prognostic factors in endometrial carcinoma (EC)] Gorchev G. **Akush Ginekol (Sofiia)** 1995;34(2):51–3 (32 ref.) **(Bul)**

PATHOLOGY

Treatment of vaginal recurrence in endometrial cancer. A review. Møller LA, et al. **Acta Obstet Gynecol Scand** 1996 Jan;75(1):1–7 (45 ref.)
Outpatient endometrial biopsy: the pipelle. Youssif SN, et al. **Br J Hosp Med** 1995 Sep 6–19;54(5):198–201 (23 ref.)
Advances in endometrial pathology. Sherman ME, et al.
Clin Lab Med 1995 Sep;15(3):517–43 (45 ref.)
Prognostic factors in endometrial neoplasia: old and new. Nogales FF. **Curr Opin Obstet Gynecol** 1996 Feb;8(1):74–8 (34 ref.)
Squamous cell carcinoma of the endometrium: a report of eight cases and a review of the literature. Goodman A, et al. **Gynecol Oncol** 1996 Apr;61(1):54–60 (55 ref.)
Recurrent endometrial adenocarcinoma presenting as a solitary humeral metastasis. Schöls WA, et al.
Gynecol Oncol 1995 Oct;59(1):148–50 (14 ref.)
Prognostic factors in endometrial cancer. Ludwig H.
Int J Gynaecol Obstet 1995 Jul;49 Suppl:S1–7 (35 ref.)
Metastatic endometrial carcinoma of the foot. A case report. Clarke SJ, et al. **J Am Podiatr Med Assoc** 1996 Jul; 86(7):331–3 (6 ref.)
The role of computerized morphometric and cytometric feature analysis in endometrial hyperplasia and cancer prognosis. Baak JP. **J Cell Biochem Suppl** 1995;23:137–46 (25 ref.)
Clinical aspects of risk in women with endometrial carcinoma. Burke TW, et al. **J Cell Biochem Suppl** 1995; 23:131–6 (32 ref.)
Quantitative cytopathology of endometrial lesions. Tezuka F, et al. **J Cell Biochem Suppl** 1995;23:147–50 (14 ref.)
Endometrial cytology by direct sampling. Its value and limitations in the diagnosis of endometrial lesions. Nguyen GK, et al. **Pathol Annu** 1995;30 Pt 2:179–202 (42 ref.)

PREVENTION & CONTROL

Hormones and breast and endometrial cancers: preventive strategies and future research. Hulka BS, et al.
Environ Health Perspect 1995 Nov;103 Suppl 8:185–9 (49 ref.)
Strategies for phase II cancer chemoprevention trials: cervix, endometrium, and ovary. Kelloff GJ, et al.
J Cell Biochem Suppl 1995;23:1–9 (51 ref.)
Endometrial cancer chemoprevention: implications of diverse pathways of carcinogenesis. Sherman ME, et al.
J Cell Biochem Suppl 1995;23:160–4 (27 ref.)

RADIOTHERAPY

Primary squamous cell carcinoma of the endometrium: a first report of adjuvant chemoradiation. Kennedy AS, et al.
Gynecol Oncol 1995 Oct;59(1):117–23 (61 ref.)
[Treatment of radiotherapy–induced gastroparesis with erythromycin] Sturm A, et al. **Dtsch Med Wochenschr** 1996 Mar 29;121(13):402–5 (16 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Laparoscopic lymphadenectomy. Melendez TD, et al.
Curr Opin Obstet Gynecol 1995 Aug;7(4):307–10 (20 ref.)
Primary squamous cell carcinoma of the endometrium. Aikins JK, et al. **Int J Gynaecol Obstet** 1995 Jul;50(1):55–60 (32 ref.)
[Stage I and II endometrial cancer: should lymphadenectomy still be done?] Descamps P, et al.
J Gynecol Obstet Biol Reprod (Paris) 1995;24(8):794–801 (48 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Management of endometrial cancer. Homesley HD.
Am J Obstet Gynecol 1996 Feb;174(2):529–34 (26 ref.)

ULTRASONOGRAPHY

Evaluating the endometrium of postmenopausal women with transvaginal ultrasonography. Bourne TH.
Ultrasound Obstet Gynecol 1995 Aug;6(2):75–80 (44 ref.)
[Ultrasound endometrium diagnosis] Tercanli S, et al.
Ther Umsch 1996 Jun;53(6):455–66 (30 ref.) (Eng. Abstr.) **(Ger)**

ENDOMETRIOSIS

Recurrent endometriosis: a review of biological and clinical aspects. Revelli A, et al. **Obstet Gynecol Surv** 1995 Oct; 50(10):747–54 (44 ref.)
[Advances in the research on the pathogenesis, diagnosis and treatment of uterine adenomyosis] Zhou YF, et al.
Chung Hua Fu Chan Ko Tsa Chih 1995 Aug;30(8):502–5 (32 ref.) **(Chi)**

COMPLICATIONS

Pain and infertility—a rationale for different treatment approaches. Martin DC. **Br J Obstet Gynaecol** 1995 Oct; 102 Suppl 12:2–3 (20 ref.)
Pain recurrence: a quality of life issue in endometriosis. Damario MA, et al. **Int J Gynaecol Obstet** 1995 Sep;50 Suppl 1:S27–42 (99 ref.)
Endometriosis as a cause of colonic obstruction. Valko GP, et al. **J Am Board Fam Pract** 1995 Nov–Dec;8(6):481–3 (8 ref.)
Ascites due to endometriosis. Spitzer M, et al.
Obstet Gynecol Surv 1995 Aug;50(8):628–31 (17 ref.)
[Obstetrical complications of adenomyosis. Literature review and two case reports] Bensaid F, et al.
J Gynecol Obstet Biol Reprod (Paris) 1996;25(4):416–8 (5 ref.) (Eng. Abstr.) **(Fre)**
[Cyclic sciatica and extrauterine endometriosis] Jelk W, et al. **Schweiz Rundsch Med Prax** 1995 Nov 14;84(46):1349–55 (29 ref.) (Eng. Abstr.) **(Ger)**
[Pulmonary endometriosis with recurrent catamenial hemoptysis] Ueno H, et al.
Nippon Kyobu Shikkan Gakkai Zasshi 1995 Aug; 33(8):888–93 (19 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

[Endometriosis of the diaphragm. Diagnostic aspects apropos of a case without pneumothorax] Witte A, et al.
Rev Med Interne 1995;16(7):527–32 (18 ref.) (Eng. Abstr.) **(Fre)**

ENDOMETRIOSIS

DRUG THERAPY

The biological basis of medical treatment of endometriosis. Venturini PL, et al. **Gynecol Endocrinol** 1995 Sep; 9(3):259–66 (43 ref.)

The impact of bone loss in women with endometriosis. Stevenson JC. **Int J Gynaecol Obstet** 1995 Sep;50 Suppl 1:S11–5 (26 ref.)

Treatment options in endometriosis. Cahill D, et al. **Practitioner** 1996 Apr;240(1561):250–4 (9 ref.)

[Endometriosis treatment] Ylikorkala O. **Duodecim** 1994; 110(9):903–8 (13 ref.) **(Fin)**

[Hormone therapy of endometriosis—principles and clinical aspects of gestagen treatment] Köhler G. **Zentralbl Gynakol** 1995;117 Suppl:6–13 (46 ref.) **(Ger)**

ETIOLOGY

[Endometriosis] Litschgi M. **Ther Umsch** 1996 Jun; 53(6):442–54 (41 ref.) (Eng. Abstr.) **(Ger)**

[Endometriosis of the abdominal wall. A report of a case secondary to cesarean section] Capanna A, et al. **G Chir** 1995 Aug–Sep;16(8–9):352–6 (19 ref.) (Eng. Abstr.) **(Ita)**

HISTORY

[The historical stages in the conservative treatment of endometriosis] Karag'ozov I, et al. **Akush Ginekol (Sofiia)** 1995;34(1):30–2 (12 ref.) **(Bul)**

IMMUNOLOGY

Immune dysfunction—a potential target for treatment in endometriosis. Gleicher N. **Br J Obstet Gynaecol** 1995 Oct; 102 Suppl 12:4–7 (25 ref.)

Immunological aspects of endometriosis. Dmowski WP. **Int J Gynaecol Obstet** 1995 Sep;50 Suppl 1:S3–10 (41 ref.)

PATHOLOGY

Malignant transformation in endometriosis of the urinary bladder: case report of clear cell adenocarcinoma. Balat O, et al. **Eur J Gynaecol Oncol** 1996;17(1):13–6 (14 ref.)

PHYSIOPATHOLOGY

Exploring the mechanism(s) of endometriosis-related infertility: an analysis of embryo development and implantation in assisted reproduction. Pellicer A, et al. **Hum Reprod** 1995 Dec;10 Suppl 2:91–7 (33 ref.)

SURGERY

Severe endometriosis and operative laparoscopy. Nezhat C, et al. **Curr Opin Obstet Gynecol** 1995 Aug;7(4):299–306 (55 ref.)

Conservative surgery for severe endometriosis: should laparotomy be abandoned definitively? Crosignani PG, et al. **Hum Reprod** 1995 Sep;10(9):2412–8 (63 ref.)

[Adenomyosis: role of hysteroscopic treatment] Mergui JL, et al. **Contracept Fertil Sex** 1995 Oct;23(10):590–4 (64 ref.) **(Fre)**

[Indications for hysterectomy—a time for re-evaluation] Lerner A, et al. **Harefuah** 1996 Mar 15;130(6):400–3 (25 ref.) **(Heb)**

[Neonatal ovarian endometriosis. Its conservative treatment] Díez García R, et al. **An Esp Pediatr** 1996 Apr;44(4):397–8 (16 ref.) **(Spa)**

THERAPY

[Current approaches to the treatment of endometriosis] Adamian LV, et al. **Akush Ginekol (Mosk)** 1995;(4):10–4 (68 ref.) **(Rus)**

ENDOMETRITIS

[Upper genital tract infections in women infected with HIV: epidemiologic, diagnostic and therapeutic aspects] Panel P, et al. **Contracept Fertil Sex** 1996 Jun;24(6):488–94 (22 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

[Antibiotics in gynecology. Treatment of acute infections] Judlin P. **Contracept Fertil Sex** 1996 May;24(5):353–8 (0 ref.) **(Fre)**

IMMUNOLOGY

[Tumor necrosis factor and underlying infection] Hazout A. **Contracept Fertil Sex** 1995 Oct;23(10):631–4 (9 ref.) (Eng. Abstr.) **(Fre)**

ENDOMETRIUM

BLOOD SUPPLY

Blood vessel growth in the endometrium. Goodger AM, et al. **Microcirculation** 1995 Dec;2(4):329–43 (102 ref.)

CYTOLOGY

[Participation of the cytoskeleton in the physiology of the endometrium] Durán Reyes G, et al. **Ginecol Obstet Mex** 1995 Nov;63:467–73 (30 ref.) (Eng. Abstr.) **(Spa)**

DRUG EFFECTS

Mifepristone: clinical application in general gynecology. Morales AJ, et al. **Clin Obstet Gynecol** 1996 Jun; 39(2):451–60 (33 ref.)

IMMUNOLOGY

[The interleukin-1 system during human implantation] Simon C, et al. **Contracept Fertil Sex** 1995 Oct;23(10):626–30 (41 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

MUC1, endometrium and embryo implantation. Aplin JD, et al. **Biochem Soc Trans** 1995 Nov;23(4):826–31 (49 ref.)

PATHOLOGY

Outpatient endometrial assessment. Read MD. **Br J Hosp Med** 1995 Aug 16–Sep 5;54(4):150–3 (45 ref.)

Outpatient endometrial biopsy: the pipelle. Youssif SN, et al. **Br J Hosp Med** 1995 Sep 6–19;54(5):198–201 (23 ref.)

Advances in endometrial pathology. Sherman ME, et al. **Clin Lab Med** 1995 Sep;15(3):517–43 (45 ref.)

Review of the endometrial safety during intravaginal treatment with estriol. Vooijs GP, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Sep;62(1):101–6 (50 ref.)

The effects of tamoxifen treatment on the endometrium. Daniel Y, et al. **Fertil Steril** 1996 Jun;65(6):1083–9 (94 ref.)

Endometrial morphology and bleeding patterns as a function of progestogen supplementation. Sturdee DW. **Int J Fertil Menopausal Stud** 1996 Jan–Feb;41(1):22–8 (31 ref.)

Quantitative cytopathology of endometrial lesions. Tezuka F, et al. **J Cell Biochem Suppl** 1995;23:147–50 (14 ref.)

PHYSIOLOGY

Endometrial responses to corpus luteum products in cycles with induced ovulation: theoretical and practical considerations. Seppälä M, et al. **Hum Reprod** 1995 Dec; 10 Suppl 2:67–76 (101 ref.)

Interleukin-1 system crosstalk between embryo and endometrium in implantation. Simón C, et al. **Hum Reprod** 1995 Dec;10 Suppl 2:43–54 (67 ref.)

The signals and molecular pathways involved in implantation, a symbiotic interaction between blastocyst and endometrium involving adhesion and tissue invasion. Tabibzadeh S, et al. **Hum Reprod** 1995 Jun;10(6):1579–602 (200 ref.)

Regulation of estrogen/progestogen receptors in the endometrium. Casper RF. **Int J Fertil Menopausal Stud** 1996 Jan–Feb;41(1):16–21 (35 ref.)

A biological model for the regulation of peri-implantational hemostasis and menstruation. Lockwood CJ, et al. **J Soc Gynecol Investig** 1996 Jul–Aug;3(4):159–65 (79 ref.)

Apoptosis in the human female reproductive tract. Spencer SJ, et al. **Obstet Gynecol Surv** 1996 May;51(5):314–23 (103 ref.)

The control of prostaglandin production by the endometrium in relation to luteolysis and menstruation. Poyser NL. **Prostaglandins Leukot Essent Fatty Acids** 1995 Sep; 53(3):147–95 (500 ref.)

The evolution of endometrial cycles and menstruation. Strassmann BI. **Q Rev Biol** 1996 Jun;71(2):181–220 (152 ref.)

[Hormonal regulation of differentiated endometrial functions and its derangement] Taketani Y. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Aug;47(8):803–8 (26 ref.) **(Jpn)**

[Participation of the cytoskeleton in the physiology of the endometrium] Durán Reyes G, et al. **Ginecol Obstet Mex** 1995 Nov;63:467–73 (30 ref.) (Eng. Abstr.) **(Spa)**

SURGERY

Endometrial resection. Holt EM, et al. **Baillieres Clin Obstet Gynaecol** 1995 Jun;9(2):279–97 (38 ref.)

Endometrial ablation: indications and preliminary diagnostic hysteroscopy. Taylor PJ, et al. **Baillieres Clin Obstet Gynaecol** 1995 Jun;9(2):251–60 (18 ref.)

Psychological aspects of heavy periods: does endometrial ablation provide the answer? Wright JB, et al. **Br J Hosp Med** 1996 Mar 6–19;55(5):289–94 (77 ref.)

Hysteroscopic endometrial ablation. Goldrath MH. **Obstet Gynecol Clin North Am** 1995 Sep;22(3):559–72 (44 ref.)

Postoperative uterine granulomata following endometrial resection. Smart PJ, et al. **Pathology** 1995 Apr;27(2):209–11 (14 ref.)

ULTRASONOGRAPHY

The application of transvaginal ultrasound for ovulation induction and in vitro fertilization. Nachtigall MJ, et al. **Clin Obstet Gynecol** 1996 Mar;39(1):231–47 (72 ref.)

Evaluating the endometrium of postmenopausal women with transvaginal ultrasonography. Bourne TH. **Ultrasound Obstet Gynecol** 1995 Aug;6(2):75–80 (44 ref.)

ENDOMYOCARDIAL FIBROSIS

Endomyocardial fibrosis, a case for the tropical doctor. Kartha CC. **Cardiovasc Res** 1995 Nov;30(5):636–43 (51 ref.)

BLOOD

Toward the biochemical assessment of myocardial fibrosis in hypertensive patients. Díez J, et al. **Am J Cardiol** 1995 Nov 2;76(13):14D–17D (36 ref.)

CHEMICALLY INDUCED

Steroids, hypertension and cardiac fibrosis. Funder JW. **Blood Press Suppl** 1995;2:39–42 (15 ref.)

PATHOLOGY

Structural remodelling of the heart by fibrous tissue: role of circulating hormones and locally produced peptides. Weber KT, et al. **Eur Heart J** 1995 Dec;16 Suppl N:12–8 (83 ref.)

PHYSIOPATHOLOGY

The renin-angiotensin-aldosterone system and myocardial collagen matrix remodelling in congestive heart failure. Brilla CG, et al. **Eur Heart J** 1995 Dec;16 Suppl O:107–9 (24 ref.)

ENDONEURIUM see **PERIPHERAL NERVES**

ENDONEXIN II see **ANNEXIN V**

ENDONUCLEASE MAPPING, RESTRICTION see **RESTRICTION MAPPING**

ENDONUCLEASES

METABOLISM

Survival factors, intracellular signal transduction, and the activation of endonucleases in apoptosis. Eastman A. **Semin Cancer Biol** 1995 Feb;6(1):45–52 (69 ref.)

ENDOPEPTIDASE-24.11 see **MEMBRANE METALLO-ENDOPEPTIDASE**

ENDOPEPTIDASES see **PEPTIDE PEPTIDOHYDROLASES**

ENDOPHTHALMITIS

Inflammatory glaucomas. Kwon YH, et al. **Int Ophthalmol Clin** 1996 Winter;36(1):81–9 (55 ref.)

COMPLICATIONS

Bilateral endogenous Escherichia coli endophthalmitis: a devastating complication in an insulin-dependent diabetic. Walmsley RS, et al. **Postgrad Med J** 1996 Jun;72(848):361–3 (10 ref.)

DIAGNOSIS

Intraocular retinoblastoma presenting as ocular and orbital inflammation. Foster BS, et al. **Int Ophthalmol Clin** 1996 Winter;36(1):153–60 (23 ref.)

Advances in rapid laboratory diagnosis of infectious endophthalmitis. Kinnear FB, et al. **J Hosp Infect** 1995 Jun;30 Suppl:253–61 (52 ref.)

[Endophthalmitis. 1: diagnosis] Bron A. **J Fr Ophtalmol** 1996; 19(3):225–40 (114 ref.) **(Fre)**

DRUG THERAPY

The role of nonsteroidal antiinflammatory drugs in ocular inflammation. Samiy N, et al. **Int Ophthalmol Clin** 1996 Winter;36(1):195–206 (38 ref.)

ETIOLOGY

Paediatric post-traumatic endophthalmitis. Alfaro DV, et al. **Br J Ophthalmol** 1995 Oct;79(10):888–91 (22 ref.)

Aqueous contamination during small incision cataract surgery: a lesson in study design [editorial; comment] Towler H. **Br J Ophthalmol** 1995 Oct;79(10):873 (12 ref.) Comment on: Br J Ophthalmol 1995 Oct;79(10):878–80.

MICROBIOLOGY

Endogenous Escherichia coli endophthalmitis. Wann SR, et al. **J Formos Med Assoc** 1996 Jan;95(1):56–60 (31 ref.)

Aspergillus endophthalmitis. An unrecognized endemic disease in orthotopic liver transplantation. Hunt KE, et al. **Ophthalmology** 1996 May;103(5):757–67 (65 ref.)

[Hematogenic bacterial endophthalmitis. A rare infection with very poor functional prognosis] Magadur-Joly G, et al. **Ann Med Interne (Paris)** 1996;147(3):212–7 (54 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

Controversies in endophthalmitis prevention. The risk for emerging resistance to vancomycin [editorial; comment] Alfonso EC, et al. **Arch Ophthalmol** 1995 Nov; 113(11):1369–70 (15 ref.) Comment on: Arch Ophthalmol 1995 Nov;113(11):1353–4.

THERAPY

The endophthalmitis vitrectomy study [editorial; comment] [see comments] Forster RK. **Arch Ophthalmol** 1995 Dec; 113(12):1555–7 (6 ref.) Comment on: Arch Ophthalmol 1995 Dec;113(12):1479–96. Comment in: Arch Ophthalmol 1996 Aug;114(8):1025; discussion 1026–7. Comment in: Arch Ophthalmol 1996 Aug;114(8):1029–30; discussion 1028–9.

A practical guideline for management of endophthalmitis. Peyman GA, et al. **Ophthalmic Surg** 1995 Jul–Aug; 26(4):294–303 (95 ref.)

[Endophthalmitis. 2: treatment] Bron A. **J Fr Ophtalmol** 1996; 19(4):294–314 (164 ref.) **(Fre)**

ENDOPLASMIC RETICULUM

[Calnexin is involved in the quality-control mechanism of the ER] Wada I. **Seikagaku** 1995 Sep;67(9):1133–7 (26 ref.) **(Jpn)**

METABOLISM

Ca2+ excitability of the ER membrane: an explanation for IP3-induced Ca2+ oscillations. Li YX, et al. **Am J Physiol** 1995 Nov;269(5 Pt 1):C1079–92 (103 ref.)

Capacitative calcium entry [see comments] Berridge MJ. **Biochem J** 1995 Nov 15;312 (Pt 1):1–11 (126 ref.) Comment in: Biochem J 1996 Mar 15;314 (Pt 3):1054–6.

Vesicle biogenesis: the coat connection [comment] Mallabiabarrena A, et al. **Cell** 1995 Dec 1;83(5):667–9 (21 ref.) Comment on: Cell 1995 Dec 1;83(5):703–13.

Sorting and retrieval between the endoplasmic reticulum and Golgi apparatus. Pelham HR. **Curr Opin Cell Biol** 1995 Aug;7(4):530–5 (47 ref.)

Approaching the mechanism of protein transport across the ER membrane. Rapoport TA, et al. **Curr Opin Cell Biol** 1996 Aug;8(4):499–504 (53 ref.)

Endoplasmic reticulum phosphate transport. Burchell A. **Kidney Int** 1996 Apr;49(4):953–8 (40 ref.)

InsP3-induced Ca2+ excitability of the endoplasmic reticulum. Keizer J, et al. **Mol Biol Cell** 1995 Aug; 6(8):945–51 (71 ref.)

PHYSIOLOGY

COPs regulating membrane traffic. Kreis TE, et al. **Ann Rev Cell Dev Biol** 1995;11:677–706 (165 ref.)

Roles for microtubules and kinesin in membrane traffic between the endoplasmic reticulum and the Golgi complex. Lippincott-Schwartz J, et al. **Biochem Soc Trans** 1995 Aug; 23(3):544–8 (24 ref.)

Structure and function of fusion pores in exocytosis and ectoplasmic membrane fusion. Lindau M, et al. **Curr Opin Cell Biol** 1995 Aug;7(4):509–17 (64 ref.)

ENDOPLASMIC RETICULUM, GRANULAR see **ENDOPLASMIC RETICULUM, ROUGH**

ENDOPLASMIC RETICULUM, ROUGH

METABOLISM

[Dolichol-coupled biosynthesis of an oligosaccharide precursor for N-glycosylated proteins in the rough endoplasmic reticulum] Shpakov AO. **Ukr Biokhim Zh** 1995 Mar–Apr;67(2):3–17 (87 ref.) (Eng. Abstr.) **(Rus)**

ENDOR see **ELECTRON SPIN RESONANCE SPECTROSCOPY**

ENDORIBONUCLEASE H see **RIBONUCLEASE H, CALF THYMUS**

ENDORIBONUCLEASE H (CALF THYMUS) see **RIBONUCLEASE H, CALF THYMUS**

ENDORIBONUCLEASES

GENETICS

RNase P—a 'Scarlet Pimpernel'. Kirsebom LA. **Mol Microbiol** 1995 Aug;17(3):411–20 (75 ref.)

METABOLISM

RNase P—a 'Scarlet Pimpernel'. Kirsebom LA. **Mol Microbiol** 1995 Aug;17(3):411–20 (75 ref.)

How many different RNA enzymes. Karwan R. **Nucleic Acids Symp Ser** 1995;(33):103–5 (22 ref.)

Eukaryotic nuclear RNase P: structures and functions. Chamberlain JR, et al. **Prog Nucleic Acid Res Mol Biol** 1996;55:87–119 (145 ref.)

ENDORPHIN, BETA see **BETA-ENDORPHIN**

ENDORPHIN RECEPTORS see **RECEPTORS, OPIOID**

ENDORPHINS

see related
RECEPTORS, OPIOID

GENETICS

Kainate-induced changes in gene expression in the rat hippocampus. Pennypacker KR, et al. **Prog Brain Res** 1995; 105:105–16 (64 ref.)

PHYSIOLOGY

Modulation of drug-induced sensitization processes by endogenous opioid systems. Spanagel R. **Behav Brain Res** 1995 Sep;70(1):37–49 (148 ref.)

Action of opioid drugs on the brain-reward system. Kornetsky C. **NIDA Res Monogr** 1995;147:33–52 (47 ref.)

A role for hippocampal opioids in long-term functional plasticity. Morris BJ, et al. **Trends Neurosci** 1995 Aug; 18(8):350–5 (59 ref.)

[Stress-protective role of the opioidergic system under conditions of military operations] Shanin VIu. **Fiziol Cheloveka** 1996 Mar–Apr;22(2):43–6 (11 ref.) **(Rus)**

ENDOSCOPIC HEMOSTASIS see **HEMOSTASIS, ENDOSCOPIC**

ENDOSCOPIC PAPILLOTOMY see **SPHINCTEROTOMY, ENDOSCOPIC**

ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY see **CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE**

ENDOSCOPIC SPHINCTEROTOMY see **SPHINCTEROTOMY, ENDOSCOPIC**

ENDOSCOPIC SURGERY see **SURGERY, ENDOSCOPIC**

ENDOSCOPY

Instrumentation and setup for endoscopic plastic surgery. Eaves FF 3rd, et al. **Clin Plast Surg** 1995 Oct;22(4):591–603 (27 ref.)

Endoscopic ultrasonography in pancreatobiliary disease using radial instruments. Buscail L. **Gastrointest Endosc Clin N Am** 1995 Oct;5(4):781–7 (25 ref.)

Pancreatic cancer. Influence of endoscopic ultrasonography on management and outcomes. Snady H. **Gastrointest Endosc Clin N Am** 1995 Oct;5(4):755–62 (20 ref.)

Laser treatment of lower airway stenosis. Coleman JA Jr, et al. **Otolaryngol Clin North Am** 1995 Aug;28(4):771–83 (8 ref.)

An overview of treatment options for lower airway obstruction. Wanamaker JR, et al. **Otolaryngol Clin North Am** 1995 Aug;28(4):751–70 (52 ref.)

[Modern neuroradiologic diagnosis and interventional strategies for the ENT physician] Hofmann E, et al. **HNO** 1995 Oct;43(10):584–9 (29 ref.) (Eng. Abstr.) **(Ger)**

[Progress of ductoscopy of the breast] Okazaki A, et al. **Nippon Geka Gakkai Zasshi** 1996 May;97(5):357–62 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Sedation in endoscopy] Pérez-Piqueras J, et al. **Rev Esp Enferm Dig** 1995 Oct;87(10):725–30 (95 ref.) **(Spa)**

ADVERSE EFFECTS

Complications in endoscopic plastic surgery. Howard PS, et al. **Clin Plast Surg** 1995 Oct;22(4):791–6 (13 ref.)

INSTRUMENTATION

High-level disinfection or "sterilization" of endoscopes? Muscarella LF. **Infect Control Hosp Epidemiol** 1996 Mar; 17(3):183–7 (61 ref.)

A retrospective comparison of endoscopic plantar fasciotomy to open plantar fasciotomy with heel spur resection for chronic plantar fasciitis/heel spur syndrome. Tomczak RL, et al. **J Foot Ankle Surg** 1995 May–Jun;34(3):305–11 (41 ref.)

Endoscopic treatment of septated chronic subdural hematoma. Hellwig D, et al. **Surg Neurol** 1996 Mar; 45(3):272–7 (15 ref.)

[Pancreaticoscopy: experiences, possibilities and limits] Wegerle W, et al. **Bildgebung** 1996 Mar;63(1):28–33 (34 ref.) (Eng. Abstr.) **(Ger)**

[Preventing transmission of infection in endoscopy: hygienic maintainance of flexible endoscopes and measures for personal protection] Leiss O, et al. **Leber Magen Darm** 1995 Dec;25(6):251–7 (25 ref.) (Eng. Abstr.) **(Ger)**

[Flexible ureterorenoscopy: a method for minimally invasive diagnosis and therapy in the upper urinary tract] Fuchs GJ. **Wien Med Wochenschr** 1995;145(11–12):267–73 (22 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Mammoscopy and endoscopic implant and breast tissue evaluation. Colon GA. **Clin Plast Surg** 1995 Oct; 22(4):697–706 (5 ref.)

Endoscopic abdominoplasty with repair of diastasis recti and abdominal wall hernia. Core GB, et al. **Clin Plast Surg** 1995 Oct;22(4):707–22 (14 ref.)

Endoscopic browlift. Core GB, et al. **Clin Plast Surg** 1995 Oct;22(4):619–31 (16 ref.)

Endoscopic forehead lift. Aesthetics and analysis. Daniel RK, et al. **Clin Plast Surg** 1995 Oct;22(4):605–18 (32 ref.)

Endoscopic techniques in aesthetic breast surgery. Augmentation, mastectomy, biopsy, capsulotomy, capsulorrhaphy, reduction, mastopexy, and reconstructive techniques. Eaves FF 3rd, et al. **Clin Plast Surg** 1995 Oct; 22(4):683–95 (32 ref.)

Endoscopic abdominoplasty, mastopexy, and breast reduction. Faria-Correa MA. **Clin Plast Surg** 1995 Oct; 22(4):723–45 (9 ref.)

Development of an instrument for endoscopic nasal surgery. Hochberg J, et al. **Clin Plast Surg** 1995 Oct;22(4):781–4 (4 ref.)

Endoscopic technique for free flap harvesting. Miller MJ, et al. **Clin Plast Surg** 1995 Oct;22(4):755–73 (20 ref.)

The biplanar endoscopically assisted forehead lift. Oslin B, et al. **Clin Plast Surg** 1995 Oct;22(4):633–8 (4 ref.)

Endoscopic harvest of the omental and jejunal free flaps. Saltz R. **Clin Plast Surg** 1995 Oct;22(4):747–54 (24 ref.)

Endoscopic carpal tunnel release. Sellers DS. **Clin Plast Surg** 1995 Oct;22(4):775–80 (27 ref.)

[Endoscopic treatment of vesicoureterorenal reflux in the child] Frey P. **Urologe A** 1996 Mar;35(2):97–103 (26 ref.) (Eng. Abstr.) **(Ger)**

[Neuroendoscopy] Prats A. **Rev Neurol** 1995;23 Suppl 3:S373–5 (16 ref.) **(Spa)**

VETERINARY

[Clinical use of rigid endoscopes in avian patients] Hochleithner M, et al. **Tierarztl Prax** 1995 Oct;23(5):469–74 (23 ref.) (Eng. Abstr.) **(Ger)**

ENDOSCOPY, DIGESTIVE SYSTEM

Endoscopic stenting of gallbladder for symptomatic cholelithiasis in patients with end-stage liver disease awaiting orthotopic liver transplantation. Shrestha R, et al. **Am J Gastroenterol** 1996 Mar;91(3):595–8 (21 ref.)

Mechanics of image manipulation. Swobodnik W. **Gastroenterologist** 1995 Dec;3(4):266–7 (0 ref.)

Technology assessment status evaluation: monitoring equipment for endoscopy. American Society for Gastrointestinal Endoscopy. Kimmey MB, et al. **Gastrointest Endosc** 1995 Dec;42(6):615–7 (13 ref.)

Endoscopic management of ulcer disease. Fleischer D. **Yale J Biol Med** 1994 May–Aug;67(3–4):167–72 (37 ref.)

[Clinical aspects and diagnosis of peptic ulcer hemorrhage—risk factors] Bosseckert H. **Bildgebung** 1995 Oct;62 Suppl 2:5–10 (11 ref.) **(Ger)**

[Endoscopy of the upper gastrointestinal tract in HIV disease] Caca K, et al. **Bildgebung** 1995 Dec;62(4):244–51 (56 ref.) (Eng. Abstr.) **(Ger)**

[Hepatobiliary stenting in malignant and benign stenosis—which approach is the best? Endoscopic approach] Jung M, et al. **Bildgebung** 1995 Oct;62 Suppl 2:47–52 (24 ref.) **(Ger)**

[Indications for endosonography in tumors of the pancreas and bile ducts] Nattermann C. **Bildgebung** 1995 Oct;62 Suppl 2:35–9 (37 ref.) **(Ger)**

[Endoscopic treatment of upper gastrointestinal diseases] Kaneko E. **Nippon Naika Gakkai Zasshi** 1995 Sep 10; 84(9):1528–31 (0 ref.) **(Jpn)**

ADVERSE EFFECTS

Endoscopic transmission of Helicobacter pylori. Tytgat GN. **Aliment Pharmacol Ther** 1995;9 Suppl 2:105–10 (31 ref.)

Complications of upper gastrointestinal endoscopy. Chan MF. **Gastrointest Endosc Clin N Am** 1996 Apr;6(2):287–303 (108 ref.)

Complications of pediatric endoscopy. Rothbaum RJ. **Gastrointest Endosc Clin N Am** 1996 Apr;6(2):445–59 (58 ref.)

[Digestive endoscopy and risk of transmission of hepatitis C virus: hygiene and discussion] René E, et al. **Gastroenterol Clin Biol** 1996 Feb;20(1):109–11 (8 ref.) **(Fre)**

CONTRAINDICATIONS

[Endoscopy for digestive system after acute myocardial infarction] Yi X. **Chung Hua Nei Ko Tsa Chih** 1995 Jul; 34(7):487–90 (20 ref.) **(Chi)**

INSTRUMENTATION

Image storage. Venables CW. **Gastroenterologist** 1995 Dec; 3(4):268–72 (7 ref.)

Technology assessment status evaluation: disposable endoscopic accessories. American Society for Gastrointestinal Endoscopy. Kimmey MB, et al. **Gastrointest Endosc** 1995 Dec;42(6):618–9 (5 ref.)

[Recent progress on digestive system endoscopies] Niwa F. **Nippon Naika Gakkai Zasshi** 1995 Aug 10;84(8):1334–7 (10 ref.) **(Jpn)**

METHODS

How effective is enteroscopy? Schmit A, et al. **Acta Gastroenterol Belg** 1995 Mar–Apr;58(2):201–7 (17 ref.)

Gastroesophageal reflux and Barrett's esophagus. Van Dam J. **Gastrointest Endosc Clin N Am** 1995 Jul;5(3):649–54 (9

ref.)
[An impassable iatrogenic lesion of the common bile duct at its junction: its recanalization via a combined percutaneous-endoscopic approach. A case] Ferro C, et al. **Radiol Med (Torino)** 1996 Apr;91(4):488–91 (16 ref.) **(Ita)**

ENDOSCOPY, GASTROINTESTINAL

Is endoscopic surveillance worthwhile in IBD? De Vos M, et al. **Acta Gastroenterol Belg** 1995 Sep–Dec;58(5–6):405–8 (28 ref.)
Intraoperative enteroscopy in the diagnosis of partial intestinal obstruction in infancy. Duggan C, et al. **Dig Dis Sci** 1995 Oct;40(10):2236–8 (12 ref.)
Technology assessment in laparoscopic general surgery and gastrointestinal endoscopy: science or convenience? Bouchard S, et al. **Gastroenterology** 1996 Mar;110(3):915–25 (110 ref.)
Technology Assessment status evaluation: endoscopic feeding tubes. American Society for Gastrointestinal Endoscopy. Kimmey MB, et al. **Gastrointest Endosc** 1995 Dec;42(6):612–4 (17 ref.)
Complications of conscious sedation. Benjamin SB. **Gastrointest Endosc Clin N Am** 1996 Apr;6(2):277–86 (18 ref.)
Management of patients before, during and after upper gastrointestinal endoscopy. Chuah SY. **Med J Malaysia** 1995 Jun;50(2):162–5 (31 ref.)
Endoscopic diagnosis and management of gastrointestinal malignancy. Kadish SL, et al. **Oncology (Huntingt)** 1995 Oct;9(10):967–83; discussion 984, 987 (46 ref.)
Antibiotic prophylaxis for lower gastrointestinal endoscopy. Varma JR. **Prim Care** 1995 Sep;22(3):445–50 (6 ref.)
Gastro-intestinal endoscopy in children. Mittal SK, et al. **Trop Gastroenterol** 1996 Apr–Jun;17(2):35–42 (25 ref.)
[What is the usefulness of enteroscopy?] Gay G, et al. **Gastroenterol Clin Biol** 1996;20(5 Pt 2):B127–33 (58 ref.) **(Fre)**
[Endoscopic diagnosis and treatment of flat colorectal neoplastic lesions] Saurin JC. **Gastroenterol Clin Biol** 1996; 20(5 Pt 2):B152–8 (44 ref.) **(Fre)**
[Possibilities and results of endoscopic hemostasis in peptic ulcer hemorrhage] Bode JC. **Bildgebung** 1995 Oct;62 Suppl 2:16–20 (29 ref.) **(Ger)**
[HIV infection and the lower gastrointestinal tract—characteristics of endoscopic diagnosis] Mauss S, et al. **Bildgebung** 1995 Dec;62(4):252–8 (46 ref.) (Eng. Abstr.) **(Ger)**
[Surgical hemostasis in recurrent peptic ulcer hemorrhage after endoscopic hemostasis—indications and results] Thon KP, et al. **Bildgebung** 1995 Oct;62 Suppl 2:22–8 (29 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Complications of upper gastrointestinal endoscopy. Chan MF. **Gastrointest Endosc Clin N Am** 1996 Apr;6(2):287–303 (108 ref.)
Complications of endoscopic gastrointestinal dilation techniques. Clouse RE. **Gastrointest Endosc Clin N Am** 1996 Apr;6(2):323–41 (113 ref.)
Complications of pediatric endoscopy. Rothbaum RJ. **Gastrointest Endosc Clin N Am** 1996 Apr;6(2):445–59 (58 ref.)
Negative outcomes related to gastrointestinal endoscopic procedures. Definitions, classification, and quality review process. Zuckerman GR. **Gastrointest Endosc Clin N Am** 1996 Apr;6(2):461–70 (15 ref.)
An ounce of prevention. Toward preventing gastrointestinal endoscopic complications. Zuckerman GR. **Gastrointest Endosc Clin N Am** 1996 Apr;6(2):265–75 (36 ref.)

INSTRUMENTATION

The endoscope and infection transmission: the problems and how to avoid them. Benjamin SB. **Cleve Clin J Med** 1995 Sep–Oct;62(5):279–80 (2 ref.)
[Risk of infection in endoscopy] Leiss O, et al. **Leber Magen Darm** 1995 Sep;25(5):198–202 (27 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Pediatric gastrointestinal endoscopy. Haight M, et al. **Gastroenterologist** 1995 Sep;3(3):181–6 (27 ref.)
A comparison of small-intestinal mucosal biopsies in children obtained by blind suction capsule with those obtained by endoscopy. Branski D, et al. **J Pediatr Gastroenterol Nutr** 1996 Feb;22(2):194–6 (17 ref.)
[Endoscopic ultrasonography—a new tool for gastroenterology] Färkkilä M, et al. **Duodecim** 1994; 110(20):1861–6 (24 ref.) **(Fin)**
[Current attitude to severe acute digestive hemorrhage caused by rupture of esophageal varices in cirrhotic patients] Castaing D, et al. **Ann Chir** 1995;49(6):463–8; discussion 468–70 (37 ref.) **(Fre)**
[Messenger RNA of duodenal cholecystokinin: thanks to endoscopy... (editorial)] Chayvialle JA. **Gastroenterol Clin Biol** 1995 Aug–Sep;19(8–9):657–8 (13 ref.) **(Fre)**
[Contribution of enteroscopy in the diagnosis of digestive hemorrhages of unknown origin] Schmit A, et al. **Rev Med Brux** 1996 Apr;17(2):62–6 (22 ref.) (Eng. Abstr.) **(Fre)**

TRENDS

[Endoscopy today (editorial)] Lehtola J. **Duodecim** 1994; 110(20):1833–6 (8 ref.) **(Fin)**

ENDOSCOPY, UTERINE see **HYSTEROSCOPY**

ENDOSOMES

see related
ENDOCYTOSIS

METABOLISM

Membrane transport in the endocytic pathway. Gruenberg J, et al. **Curr Opin Cell Biol** 1995 Aug;7(4):552–63 (127 ref.)
Endosomal proteolysis of internalized proteins. Authier F, et al. **FEBS Lett** 1996 Jun 24;389(1):55–60 (55 ref.)

PHYSIOLOGY

The endosomal-lysosomal system of neurons: new roles. Nixon RA, et al. **Trends Neurosci** 1995 Nov;18(11):489–96 (80 ref.)

ENDOSSEOUS IMPLANTATION see **DENTAL IMPLANTATION, ENDOSSEOUS**

ENDOTHELIAL CELL-DERIVED GROWTH FACTORS see **ENDOTHELIAL GROWTH FACTORS**

ENDOTHELIAL GROWTH FACTORS

[Involvement of the VEGF-Flt-receptor family in angiogenesis] Shibuya M. **Nippon Yakurigaku Zasshi** 1996 Mar;107(3):119–31 (44 ref.) (Eng. Abstr.) **(Jpn)**

BIOSYNTHESIS

Regulation of the expression of the VEGF/VPS and its receptors: role in tumor angiogenesis. Kolch W, et al. **Breast Cancer Res Treat** 1995;36(2):139–55 (156 ref.)

PHYSIOLOGY

Role of VEGF-flt receptor system in normal and tumor angiogenesis. Shibuya M. **Adv Cancer Res** 1995;67:281–316 (141 ref.)
Vasculogenesis. Risau W, et al. **Ann Rev Cell Dev Biol** 1995; 11:73–91 (122 ref.)
The role of vascular endothelial growth factor in pathological angiogenesis. Ferrara N. **Breast Cancer Res Treat** 1995; 36(2):127–37 (91 ref.)
VEGF-mediated tumour angiogenesis: a new target for cancer therapy. Martiny-Baron G, et al. **Curr Opin Biotechnol** 1995 Dec;6(6):675–80 (40 ref.)
Vascular endothelial growth factor and retinal neovascularisation: a new therapeutic approach for diabetic retinopathy. Favard C, et al. **Diabetes Metab** 1996 Jul; 22(4):268–73 (67 ref.)
Vascular endothelial growth factor, a potent and selective angiogenic agent. Thomas KA. **J Biol Chem** 1996 Jan 12; 271(2):603–6 (51 ref.)

ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE-1 see **E-SELECTIN**

ENDOTHELIN RECEPTORS see **RECEPTORS, ENDOTHELIN**

ENDOTHELIN-1 see **ENDOTHELINS**

ENDOTHELIN-2 see **ENDOTHELINS**

ENDOTHELIN-3 see **ENDOTHELINS**

ENDOTHELINS

see related
RECEPTORS, ENDOTHELIN
[Endothelin-1] Rozen B, et al. **Harefuah** 1996 Feb 1; 130(3):203–7 (44 ref.) **(Heb)**
[Histocytochemical and functional aspects on the "brain-vascular peptides"] Yamada H, et al. **Kaibogaku Zasshi** 1995 Oct;70(5):422–35 (108 ref.) (Eng. Abstr.) **(Jpn)**
[Endothelin—a vasoactive peptide and growth factor] Stjernquist M. **Lakartidningen** 1995 Dec 20; 92(51–52):4901–4 (60 ref.) **(Swe)**

ANALYSIS

[Endothelin] Shichiri M, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:749–51 (20 ref.) **(Jpn)**

ANTAGONISTS & INHIBITORS

Endothelin and endothelin antagonists: potential role in cardiovascular and renal disease. Noll G, et al. **Mol Cell Biochem** 1996 Apr 12–26;157(1–2):259–67 (105 ref.)

BIOSYNTHESIS

Molecular pharmacology of endothelin converting enzymes. Turner AJ, et al. **Biochem Pharmacol** 1996 Jan 26; 51(2):91–102 (127 ref.)
[Blood vessel endothelium as an endocrine organ] Viinikka L, et al. **Duodecim** 1994;110(10):983–9 (38 ref.) **(Fin)**
[Biosynthetic mechanism of endothelins with various physiological and physiopathological significance—structure and function of endothelin converting enzyme] Takayanagi R. **Fukuoka Igaku Zasshi** 1995 Sep;86(9):362–6 (3 ref.) **(Jpn)**

BLOOD

[Endothelin-1 and liver disease] Regev A, et al. **Harefuah** 1995 Jun 1;128(11):703–7 (40 ref.) **(Heb)**

IMMUNOLOGY

Endothelin in organ transplantation. Watschinger B, et al. **Am J Kidney Dis** 1996 Jan;27(1):151–61 (127 ref.)

METABOLISM

Endothelin receptors in normal and diseased kidneys. Nambi P. **Clin Exp Pharmacol Physiol** 1996 Apr;23(4):326–30 (86 ref.)

PHARMACOLOGY

Endothelin receptor antagonism. Opgenorth TJ. **Adv Pharmacol** 1995;33:1–65 (316 ref.)

PHYSIOLOGY

Effects of endothelin-1 and the ETA receptor antagonist BQ-123 on resistance arteries from normal pregnant and preeclamptic women. Wolff K, et al. **Acta Obstet Gynecol Scand** 1996 May;75(5):432–8 (34 ref.)
Endothelins as cardiovascular peptides. Levin ER. **Am J Nephrol** 1996;16(3):246–51 (64 ref.)
Endothelins and the lung. Michael JR, et al. **Am J Respir Crit Care Med** 1996 Sep;154(3 Pt 1):555–81 (446 ref.)
Endothelin in chronic heart failure: current position and future prospects. Love MP, et al. **Cardiovasc Res** 1996 May; 31(5):665–74 (99 ref.)
Endothelin receptor heterogeneity, G-proteins, and signaling via cAMP and cGMP cascades. Sokolovsky M. **Cell Mol Neurobiol** 1995 Oct;15(5):561–71 (40 ref.)
Is there a role for endothelin in the natural history of heart failure? [editorial; comment] Cohn JN. **Circulation** 1996 Aug 15;94(4):604–6 (39 ref.) Comment on: Circulation 1996 Aug 15;94(4):779–84.
Endothelins: renal tubule synthesis and actions. Kohan DE. **Clin Exp Pharmacol Physiol** 1996 Apr;23(4):337–44 (91 ref.)
Endothelin-1 and the regulation of vascular tone. La M, et al. **Clin Exp Pharmacol Physiol** 1995 May;22(5):315–23 (85 ref.)
Signalling pathways activated by endothelin stimulation of renal cells. Nord EP. **Clin Exp Pharmacol Physiol** 1996 Apr;23(4):331–6 (54 ref.)
The atherogenic potential of endothelin. Hasdai D, et al. **Coron Artery Dis** 1995 Nov;6(11):901–4 (60 ref.)
Neural crest development. Do developing enteric neurons need endothelins? Gershon MD. **Curr Biol** 1995 Jun 1; 5(6):601–4 (23 ref.)
Endothelin in hypertension. Schiffrin EL. **Curr Opin Cardiol** 1995 Sep;10(5):485–94 (110 ref.)
Defining the role of endothelins in renal pathophysiology on the basis of selective and unselective endothelin receptor antagonist studies. Benigni A. **Curr Opin Nephrol Hypertens** 1995 Jul;4(4):349–53 (51 ref.)
Local regulation of the coronary circulation in health and disease: role of nitric oxide and endothelin. Lüscher TF, et al. **Eur Heart J** 1995 May;16 Suppl C:51–8 (120 ref.)
Vasoactive peptides and uterine vessels. Stjernquist M, et al. **Gynecol Endocrinol** 1995 Jun;9(2):165–76 (77 ref.)
Endothelium-derived vasoactive factors in hypertension: nitric oxide and endothelin. Nava E, et al. **J Hypertens Suppl** 1995 Aug;13(2):S39–48 (97 ref.)
Endothelins in diabetic kidneys. Koide H, et al. **Kidney Int Suppl** 1995 Sep;51:S45–9 (68 ref.)
The role of endothelin in coronary atherosclerosis. Mathew V, et al. **Mayo Clin Proc** 1996 Aug;71(8):769–77 (76 ref.)
Endothelin in the progressive renal disease of glomerulopathies. Benigni A, et al. **Miner Electrolyte Metab** 1995;21(4–5):283–91 (83 ref.)
Role of intrarenal endothelin in the generation and maintenance of hypertension. Markewitz BA, et al. **Miner Electrolyte Metab** 1995;21(4–5):342–52 (115 ref.)
Endothelin and endothelin antagonists: potential role in cardiovascular and renal disease. Noll G, et al. **Mol Cell Biochem** 1996 Apr 12–26;157(1–2):259–67 (105 ref.)
Inositol lipid-mediated signalling in response to endothelin and ATP in the mammalian testis. Rudge SA, et al. **Mol Cell Biochem** 1995 Aug–Sep;149–150:161–74 (86 ref.)
Protein tyrosine phosphorylation in cardiovascular system. Srivastava AK. **Mol Cell Biochem** 1995 Aug–Sep; 149–150:87–94 (90 ref.)
Perspectives in endothelin research: tubulointerstitial actions of endothelins in the kidney: roles in health and disease.

Ong AC. **Nephrol Dial Transplant** 1996 Feb;11(2):251-7 (86 ref.)

The role of endothelin-1 in cardiovascular physiology and pathophysiology. Webb DJ, et al. **Scott Med J** 1995 Jun; 40(3):69-71 (26 ref.)

Potential roles for endothelins in systemic inflammatory response syndrome with a particular relationship to cytokines. Battistini B, et al. **Shock** 1996 Mar;5(3):167-83 (181 ref.)

[Endothelin--a cardiovascular regulatory peptide. I. Physiologic activity] Lisý O. **Cesk Fysiol** 1995 Sep; 44(3):147-51 (32 ref.) (Eng. Abstr.) **(Cze)**

[Endothelin--a cardiovascular regulatory peptide. II. Outline of its pathophysiologic activity] Lisý O. **Cesk Fysiol** 1995 Sep;44(3):152-7 (45 ref.) (Eng. Abstr.) **(Cze)**

[Neurohormonal factors in heart failure. II] Cosín Aguilar J, et al. **Rev Esp Cardiol** 1996 May;49(5):317-27 (47 ref.) (Eng. Abstr.) **(Spa)**

ENDOTHELIUM

CYTOLOGY

Tumor metastasis to brain: role of endothelial cells, neurotrophins, and paracrine growth factors. Nicolson GL, et al. **Crit Rev Oncog** 1994;5(5):451-71 (153 ref.)

[Computational fluid mechanical analyses of the mechanical environment: particularly the wall shear stress distribution and morphological responses of endothelial cells] Yamaguchi T. **Tanpakushitsu Kakusan Koso** 1996 Jan; 41(1):48-55 (11 ref.) **(Jpn)**

DRUG EFFECTS

In vitro activity of BaH1, the main hemorrhagic toxin of Bothrops asper snake venom on bovine endothelial cells. Borkow G, et al. **Toxicon** 1995 Oct;33(10):1387-91 (23 ref.)

PHYSIOLOGY

Tumor metastasis to brain: role of endothelial cells, neurotrophins, and paracrine growth factors. Nicolson GL, et al. **Crit Rev Oncog** 1994;5(5):451-71 (153 ref.)

[The endothelium] Parlapiano C, et al. **Riv Eur Sci Med Farmacol** 1995 Mar-Jun;17(2-3):91-101 (112 ref.) (Eng. Abstr.) **(Ita)**

[Computational fluid mechanical analyses of the mechanical environment: particularly the wall shear stress distribution and morphological responses of endothelial cells] Yamaguchi T. **Tanpakushitsu Kakusan Koso** 1996 Jan; 41(1):48-55 (11 ref.) **(Jpn)**

PHYSIOPATHOLOGY

The role of endothelial cells in the systemic inflammatory response syndrome and multiple system organ failure. Wang X, et al. **Eur J Surg** 1995 Oct;161(10):703-13 (141 ref.)

SECRETION

[The role of vascular nitric oxide (NO) in the pathomechanism of pre-eclampsia] Visontai ZZ, et al. **Orv Hetil** 1995 Nov 19;136(47):2547-51 (50 ref.) (Eng. Abstr.) **(Hun)**

ENDOTHELIUM, ANTERIOR CHAMBER see **ENDOTHELIUM, CORNEAL**

ENDOTHELIUM, CORNEAL

PATHOLOGY

Endothelial changes following refractive surgery. Frueh BE, et al. **J Cataract Refract Surg** 1996 May;22(4):490-6 (47 ref.)

ENDOTHELIUM-DERIVED RELAXING FACTOR

ADMINISTRATION & DOSAGE

Nitric oxide inhalation in infants and children: physiologic and clinical implications. Craig J, et al. **Am J Crit Care** 1995 Nov;4(6):443-50; quiz 451-2 (47 ref.)

BIOSYNTHESIS

Nitric oxide production and NO synthase gene expression contribute to vascular regulation during exercise. Shen W, et al. **Med Sci Sports Exerc** 1995 Aug;27(8):1125-34 (75 ref.)

PHYSIOLOGY

Atherosclerosis: risk factors and the vascular endothelium. Glasser SP, et al. **Am Heart J** 1996 Feb;131(2):379-84 (56 ref.)

Endothelium-derived relaxing factors and converting enzyme inhibition. Vanhoutte PM, et al. **Am J Cardiol** 1995 Nov 24;76(15):3E-12E (83 ref.)

Endothelium-dependent hyperpolarization. Beyond nitric oxide and cyclic GMP. Cohen RA, et al. **Circulation** 1995 Dec 1;92(11):3337-49 (211 ref.)

Endothelium-dependent responses in hypertension. Vanhoutte PM, et al. **Hypertens Res** 1995 Jun;18(2):87-98 (122 ref.)

Modulation of coronary autoregulatory responses by endothelium-derived nitric oxide. Canty JM Jr, et al. **Int J Cardiol** 1995 Jul;50(3):207-15 (27 ref.)

The influence of endothelium-derived nitric oxide on myocardial contractile function. Shah AM, et al. **Int J Cardiol** 1995 Jul;50(3):225-31 (39 ref.)

Homocysteine, EDRF, and endothelial function. Upchurch GR Jr, et al. **J Nutr** 1996 Apr;126(4 Suppl):1290S-4S (40 ref.)

The effect of NO/EDRF and monocytes/macrophages on LDL-oxidation. Leitinger N, et al. **J Physiol Pharmacol** 1995 Dec;46(4):385-408 (144 ref.)

Endothelium-mediated control of coronary vascular tone after chronic exercise training. Laughlin MH. **Med Sci Sports Exerc** 1995 Aug;27(8):1135-44 (34 ref.)

Contribution of endothelium-derived nitric oxide (EDNO) to the skeletal muscle blood flow response to exercise. McAllister RM, et al. **Med Sci Sports Exerc** 1995 Aug; 27(8):1145-51 (49 ref.)

Nitric oxide: a novel mediator of inflammation. Clancy RM, et al. **Proc Soc Exp Biol Med** 1995 Nov;210(2):93-101 (98 ref.)

Atherosclerosis, oxidative stress, and antioxidant protection in endothelium-derived relaxing factor action. Keaney JF Jr, et al. **Prog Cardiovasc Dis** 1995 Sep-Oct;38(2):129-54 (202 ref.)

[Nitric oxide in gastroenterology] Merino Ugarte C. **Rev Gastroenterol Peru** 1995;15 Suppl 1:S101-4 (21 ref.) (Eng. Abstr.) **(Spa)**

THERAPEUTIC USE

Nitric oxide: delivery, measurement, and clinical application. Body SC, et al. **J Cardiothorac Vasc Anesth** 1995 Dec; 9(6):748-63 (158 ref.)

ENDOTHELIUM-DERIVED VASOCONSTRICTOR FACTORS see **ENDOTHELINS**

ENDOTHELIUM, LYMPHATIC

IMMUNOLOGY

High endothelial venules (HEVs): specialized endothelium for lymphocyte migration. Girard JP, et al. **Immunol Today** 1995 Sep;16(9):449-57 (83 ref.)

ENDOTHELIUM, VASCULAR

Lymphocyte adhesion to endothelium. Dianzani U, et al. **Crit Rev Immunol** 1995;15(2):167-200 (258 ref.)

CHEMISTRY

[Measurement of biological parameters of endothelial origin: value in human pathology] Sampol J, et al. **Ann Biol Clin (Paris)** 1995;53(6):329-38 (108 ref.) (Eng. Abstr.) **(Fre)**

CYTOLOGY

Formation of the arterial media during vascular development. Thayer JM, et al. **Cell Mol Biol Res** 1995;41(4):251-62 (100 ref.)

Development of the embryonic vascular system. Wilting J, et al. **Cell Mol Biol Res** 1995;41(4):219-32 (152 ref.)

Endothelial cell transplantation. Williams SK. **Cell Transplant** 1995 Jul-Aug;4(4):401-10 (42 ref.)

Hypotheses regarding the role of pericytes in regulating movement of fluid, nutrients, and hormones across the microcirculatory endothelial barrier. Lonigro AJ, et al. **Diabetes** 1996 Jan;45 Suppl 1:S38-43 (21 ref.)

Endothelial cell seeding of native vascular surfaces. Walluscheck KP, et al. **Eur J Vasc Endovasc Surg** 1996 Apr;11(3):290-303 (177 ref.)

The dark side of nitric oxide: mediator of cell injury. Andreoli SP. **Pediatr Nephrol** 1995 Dec;9(6):779-82 (13 ref.)

Molecular organization and functional regulation of cell to cell junctions in the endothelium. Dejana E, et al. **Thromb Haemost** 1995 Jul;74(1):309-12 (35 ref.)

The molecular basis of platelet and endothelial cell interaction with neutrophils and monocytes: role of P-selectin and the P-selectin ligand, PSGL-1. Furie B, et al. **Thromb Haemost** 1995 Jul;74(1):224-7 (56 ref.)

Endothelial cell function, including tissue factor expression, under flow conditions. Grabowski EF, et al. **Thromb Haemost** 1995 Jul;74(1):123-8 (51 ref.)

Mechanisms involved in platelet vessel wall interaction. Hawiger J. **Thromb Haemost** 1995 Jul;74(1):369-72 (37 ref.)

Function and regulation of the beta 3 integrins in hemostasis and vascular biology. Shattil SJ. **Thromb Haemost** 1995 Jul;74(1):149-55 (98 ref.)

[Agents inducing cell death of the vascular wall] Munsch B, et al. **Ann Biol Clin (Paris)** 1995;53(9):473-80 (88 ref.) (Eng. Abstr.) **(Fre)**

DRUG EFFECTS

Effect of chronic angiotensin-converting enzyme inhibition on endothelial function in patients with chronic heart failure. Drexler H, et al. **Am J Cardiol** 1995 Nov 24; 76(15):13E-18E (35 ref.)

New insights into mechanisms underlying nitrate tolerance. Münzel T, et al. **Am J Cardiol** 1996 May 30;77(13):24C-30C (41 ref.)

Vascular endothelial cell activation and permeability responses to thrombin. Garcia JG, et al. **Blood Coagul Fibrinolysis** 1995 Oct;6(7):609-26 (129 ref.)

Mediators and vascular effects in response to endotoxin [see comments] Olson NC, et al. **Br Vet J** 1995 Sep-Oct; 151(5):489-522 (152 ref.) Comment in: Br Vet J 1995 Sep-Oct;151(5):469-71.

Homocysteine, EDRF, and endothelial function. Upchurch GR Jr, et al. **J Nutr** 1996 Apr;126(4 Suppl):1290S-4S (40 ref.)

Thrombolysis, flow, and vessel wall interactions. Grabowski EF. **J Vasc Interv Radiol** 1995 Nov-Dec;6(6 Pt 2 Su):25S-29S (37 ref.)

Antioxidants, lipoprotein oxidation, and arterial function. Bruckdorfer KR. **Lipids** 1996 Mar;31 Suppl:S83-5 (17 ref.)

Cellular effects of calcium channel blockers on vascular cells. Haller H. **Nephrol Dial Transplant** 1995 Oct;10 Suppl 9:3-8 (60 ref.)

In vitro activity of BaH1, the main hemorrhagic toxin of Bothrops asper snake venom on bovine endothelial cells. Borkow G, et al. **Toxicon** 1995 Oct;33(10):1387-91 (23 ref.)

[Arterial wall: a new pharmacological and therapeutic target?] Laurent S, et al. **Therapie** 1995 Jul-Aug; 50(4):387-98 (73 ref.) (Eng. Abstr.) **(Fre)**

EMBRYOLOGY

Formation of the coronary vasculature: a brief review. Tomanek RJ. **Cardiovasc Res** 1996 Feb;31 Spec No:E46-51 (53 ref.)

Development of the embryonic vascular system. Wilting J, et al. **Cell Mol Biol Res** 1995;41(4):219-32 (152 ref.)

Growth factor control of developing kidney endothelial cells. Loughna S, et al. **Exp Nephrol** 1996 Mar-Apr;4(2):112-8 (36 ref.)

Origin of the glomerular vasculature in the developing kidney. Hyink DP, et al. **Semin Nephrol** 1995 Jul; 15(4):300-14 (140 ref.)

ENZYMOLOGY

[Endothelial NO synthase] Boulanger CM. **C R Seances Soc Biol Fil** 1995;189(6):1069-79 (49 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Antibody-directed targeting of the vasculature of solid tumors. Thorpe PE, et al. **Breast Cancer Res Treat** 1995; 36(2):237-51 (55 ref.)

Heterogeneity of microfibrils: role of thrombospondin-microfibrils in the thrombogenicity of the subendothelium. Fauvel-Lafève F, et al. **C R Acad Sci III** 1996 Apr;319(4):333-41 (41 ref.)

Adhesion molecules in host defense. Etzioni A. **Clin Diagn Lab Immunol** 1994 Jan;1(1):1-4 (41 ref.)

Anti-endothelial cell antibodies: only for scientists or for clinicians too? Meroni PL, et al. **Clin Exp Immunol** 1996 May;104(2):199-202 (29 ref.)

Genetic engineering of endothelial cells to ameliorate xenograft rejection. Bach FH, et al. **Clin Transplant** 1996 Feb;10(1 Pt 2):124-7 (19 ref.)

T-lymphocyte interactions with endothelium and extracellular matrix. Hunt SW 3rd, et al. **Crit Rev Oral Biol Med** 1996;7(1):59-86 (199 ref.)

Role of vascular endothelial cells in the allograft response. Brindle NP. **Eye** 1995;9 (Pt 2):167-72 (63 ref.)

Anti-endothelial cell antibodies in sera from patients with inflammatory bowel disease. Aldebert D, et al. **Gastroenterol Clin Biol** 1995 Nov;19(11):867-70 (20 ref.)

Lymphocyte-endothelial cell interactions in hepatic inflammation. Adams DH. **Hepatogastroenterology** 1996 Jan-Feb;43(7):32-43 (82 ref.)

CD31 immunoreactivity in mesenchymal neoplasms of the skin and subcutis: report of 145 cases and review of putative immunohistologic markers of endothelial differentiation. DeYoung BR, et al. **J Cutan Pathol** 1995 Jun;22(3):215-22 (45 ref.)

Can graft endothelial cells initiate a host anti-graft immune response? Pober JS, et al. **Transplantation** 1996 Feb 15; 61(3):343-9 (72 ref.)

[Crohn disease, hemorrhagic rectocolitis: antibodies and humans (editorial)] Duclos B. **Gastroenterol Clin Biol** 1995 Nov;19(11):865-6 (21 ref.) **(Fre)**

[Anti-endothelial cell antibodies] Mayet WJ, et al. **Dtsch Med Wochenschr** 1996 May 24;121(21):702-9 (68 ref.) **(Ger)**

INJURIES

Flow-related platelet deposition on subendothelium. Weiss HJ. **Thromb Haemost** 1995 Jul;74(1):117-22 (78 ref.)

Gene therapy to restore prostacyclin presence to injured endothelium. Willerson JT, et al. **Trans Am Clin Climatol Assoc** 1994;106:100-7; discussion 107-8 (41 ref.)

METABOLISM

Control and consequences of endothelial nitric oxide formation. Fleming I, et al. **Adv Pharmacol** 1995;34:187-206 (118 ref.)

Regulation and functional consequences of endothelial nitric oxide formation. Busse R, et al. **Ann Med** 1995 Jun; 27(3):331–40 (128 ref.)

Interactions between endothelial secretogogues. Gryglewski RJ. **Ann Med** 1995 Jun;27(3):421–7 (80 ref.)

New concepts of regulation of retinal vessel tone. Brown SM, et al. **Arch Ophthalmol** 1996 Feb;114(2):199–204 (58 ref.)

Endothelial cells, nitric oxide and ischaemic preconditioning. Parratt JR, et al. **Basic Res Cardiol** 1996 Jan–Feb; 91(1):27–30 (14 ref.)

Sodium transport in endothelial cells—a brief review. Lau YT. **Chin J Physiol** 1995;38(3):139–45 (52 ref.)

Lu-ECAM-1 and DPP IV in lung metastasis. Eible RC, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 1):107–22 (77 ref.)

Involvement of tyrosine phosphorylation in endothelial adhesion molecule induction. Weber C. **Immunol Res** 1996; 15(1):30–7 (42 ref.)

Cytokines, fibrinolysis and vasculitis. Teofoli P, et al. **Int Angiol** 1995 Jun;14(2):125–9 (51 ref.)

Pentoxifylline: a potential treatment for thrombosis associated with abnormal tissue factor expression by monocytes and endothelial cells. de Prost D. **J Cardiovasc Pharmacol** 1995; 25 Suppl 2:S114–8 (41 ref.)

Cholesterol and the coronary endothelium. Knight CJ, et al. **J Cardiovasc Risk** 1995 Jun;2(3):180–8 (60 ref.)

Some aspects of IL-8 pathophysiology. III: Chemokine interaction with endothelial cells. Rot A, et al. **J Leukoc Biol** 1996 Jan;59(1):39–44 (34 ref.)

Reactive oxygen species and vascular signal transduction mechanisms. Wolin MS. **Microcirculation** 1996 Mar; 3(1):1–17 (131 ref.)

Identification of endothelial cell–surface proteins as targets for diagnosis and treatment of disease. Jacobson BS, et al. **Nat Med** 1996 Apr;2(4):482–4 (22 ref.)

Leukocyte—endothelial cell interactions in haemodialysis–induced neutropenia. Muñoz de Bustillo E, et al. **Nephrol Dial Transplant** 1996 Apr;11(4):572–4 (23 ref.)

Regulation of endothelial permeability by second messengers. Siflinger-Birnboim A, et al. **New Horiz** 1996 Feb;4(1):87–98 (86 ref.)

The role of nitric oxide and other endothelium–derived vasoactive substances in vascular disease. Cohen RA. **Prog Cardiovasc Dis** 1995 Sep–Oct;38(2):105–28 (294 ref.)

Role of fatty acids and eicosanoids in modulating proteoglycan metabolism in endothelial cells. Hennig B, et al. **Prostaglandins Leukot Essent Fatty Acids** 1995 Nov; 53(5):315–24 (114 ref.)

Hypoxia and modification of the endothelium: implications for regulation of vascular homeostatic properties. Pinsky DJ, et al. **Semin Cell Biol** 1995 Oct;6(5):283–94 (49 ref.)

Amino acid metabolism and the vascular endothelium: regulation and disease implications [editorial] Pan M, et al. **Shock** 1995 Aug;4(2):79–88 (96 ref.)

Gene therapy to restore prostacyclin presence to injured endothelium. Willerson JT, et al. **Trans Am Clin Climatol Assoc** 1994;106:100–7; discussion 107–8 (41 ref.)

[Blood vessel endothelium as an endocrine organ] Viinikka L, et al. **Duodecim** 1994;110(10):983–9 (38 ref.) **(Fin)**

[Biology of the endothelial cell and atherogenesis] Demuth K, et al. **Ann Biol Clin (Paris)** 1995;53(4):171–91 (211 ref.) (Eng. Abstr.) **(Fre)**

[New discoveries on atherosclerosis. LDL oxidation plays a central role] Nilsson J. **Lakartidningen** 1995 Oct 4; 92(40):3684–6, 3691 (19 ref.) **(Swe)**

PATHOLOGY

Role of plaque size and degree of stenosis in acute myocardial infarction. Little WC, et al. **Cardiol Clin** 1996 May; 14(2):221–8 (58 ref.)

Cellular and molecular mechanisms in the pathogenesis of severe pulmonary hypertension. Voelkel NF, et al. **Eur Respir J** 1995 Dec;8(12):2129–38 (77 ref.)

Selected histochemical and immunocytochemical markers of biological activity of brain blood vessels. Kałuża J. **Folia Neuropathol** 1995;33(4):195–200 (32 ref.)

Pathology of the vessels in cerebral amyloid angiopathy. Liberski PP, et al. **Folia Neuropathol** 1995;33(4):207–14 (68 ref.)

The central role of the endothelium in the pathogenesis of vasculitides. Lombardi A, et al. **Int Angiol** 1995 Jun; 14(2):175–82 (92 ref.)

Cardiac allograft vasculopathy: the central pathogenetic role of ischemia–induced endothelial cell injury. Day JD, et al. **J Heart Lung Transplant** 1995 Nov–Dec;14(6 Pt 2):S142–9 (84 ref.)

The pathogenesis of graft vascular disease: implications of vascular remodeling. Gibbons GH. **J Heart Lung Transplant** 1995 Nov–Dec;14(6 Pt 2):S149–58 (59 ref.)

[Biology of the endothelial cell and atherogenesis] Demuth K, et al. **Ann Biol Clin (Paris)** 1995;53(4):171–91 (211 ref.) (Eng. Abstr.) **(Fre)**

[Arterial wall texture after uncomplicated endarterectomy] Bürrig KF, et al. **Pathologe** 1995 Sep;16(5):336–41 (49 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Scatter factor and angiogenesis. Rosen EM, et al. **Adv Cancer Res** 1995;67:257–79 (93 ref.)

Control and consequences of endothelial nitric oxide formation. Fleming I, et al. **Adv Pharmacol** 1995;34:187–206 (118 ref.)

Endothelial cell function: biologic and physiologic functions in health and disease. Shireman PK, et al. **AJR Am J Roentgenol** 1996 Jan;166(1):7–13 (49 ref.)

Atherosclerosis: risk factors and the vascular endothelium. Glasser SP, et al. **Am Heart J** 1996 Feb;131(2):379–84 (56 ref.)

Vasculogenesis. Risau W, et al. **Ann Rev Cell Dev Biol** 1995; 11:73–91 (122 ref.)

Endothelial cell injury in cardiovascular surgery. Verrier ED, et al. **Ann Thorac Surg** 1996 Sep;62(3):915–22 (69 ref.)

Vascular endothelial cell activation and permeability responses to thrombin. Garcia JG, et al. **Blood Coagul Fibrinolysis** 1995 Oct;6(7):609–26 (129 ref.)

Disturbance of leucocyte circulation and adhesion to the endothelium as factors in circulatory pathology. Adams DH, et al. **Br J Anaesth** 1996 Jul;77(1):17–31 (114 ref.)

Paracrine modulation of heart cell function by endothelial cells. Shah AM. **Cardiovasc Res** 1996 Jun;31(6):847–67 (224 ref.)

Normal and pathological aspects of mass transport across the vascular wall. Kennedy JH, et al. **Cardiovasc Surg** 1995 Dec;3(6):611–5 (45 ref.)

Endothelium–dependent hyperpolarization. Beyond nitric oxide and cyclic GMP. Cohen RA, et al. **Circulation** 1995 Dec 1;92(11):3337–49 (211 ref.)

Glycosaminoglycans contribute to multiple functions of vascular endothelial cells. Cockwell P, et al. **Clin Exp Immunol** 1996 Apr;104(1):1–3 (30 ref.)

Modulation of vasoconstriction by endothelium–derived nitric oxide: the influence of vascular disease. Woodman OL. **Clin Exp Pharmacol Physiol** 1995 Sep;22(9):585–93 (97 ref.)

Mechanics of the arterial wall: review and directions. Humphrey JD. **Crit Rev Biomed Eng** 1995;23(1–2):1–162 (512 ref.)

Molecular responses of endothelial tissue to kinins. Busse R, et al. **Diabetes** 1996 Jan;45 Suppl 1:S8–13 (70 ref.)

The role of cell adhesion molecules in the development of IDDM: implications for pathogenesis and therapy. Yang XD, et al. **Diabetes** 1996 Jun;45(6):705–10 (61 ref.)

Age–related changes in vascular smooth muscle and endothelium. Dohi Y, et al. **Drugs Aging** 1995 Oct; 7(4):278–91 (141 ref.)

The role of the endothelium in hypoxic pulmonary vasoconstriction. Ward JP, et al. **Exp Physiol** 1995 Sep; 80(5):793–801 (24 ref.)

On the physiology of metazoa. Ameen AR. **Experientia** 1996 Mar 15;52(3):189–211 (205 ref.)

Endothelial control of the cardiovascular system: recent advances. Griendling KK, et al. **FASEB J** 1996 Feb; 10(2):283–92 (60 ref.)

Oxidant stress and endothelial membrane transport. Elliott SJ, et al. **Free Radic Biol Med** 1995 Nov;19(5):649–58 (98 ref.)

Superoxide anion and endothelial regulation of arterial tone. Katusic ZS. **Free Radic Biol Med** 1996;20(3):443–8 (52 ref.)

Endothelium–dependent regulation of the cardiovascular system. Shimokawa H, et al. **Intern Med** 1995 Oct; 34(10):939–46 (105 ref.)

Nitric oxide, oxygen–derived free radicals and vascular endothelium. Marin J, et al. **J Auton Pharmacol** 1995 Aug; 15(4):279–307 (223 ref.)

Vascular endothelial growth factor, a potent and selective angiogenic agent. Thomas KA. **J Biol Chem** 1996 Jan 12; 271(2):603–6 (51 ref.)

Neural and endothelial control of the peripheral circulation—implications for anesthesia: Part I. Neural control of the peripheral vasculature. Ebert TJ, et al. **J Cardiothorac Vasc Anesth** 1996 Jan;10(1):147–58 (124 ref.)

Neural and endothelial control of the peripheral circulation—implications for anesthesia: Part II, Endothelium–mediated effects in the normal and diseased circulation. Stowe DF, et al. **J Cardiothorac Vasc Anesth** 1996 Jan;10(1):159–71 (161 ref.)

New insights into the role of endothelial dysfunction in hypertension [editorial] van Zwieten PA, et al. **J Hypertens** 1995 Jul;13(7):713–6 (42 ref.)

Regulation and selectivity of leukocyte emigration. Schleiffenbaum B, et al. **J Lab Clin Med** 1996 Feb; 127(2):151–68 (251 ref.)

Flow–dependent regulation of gene expression in vascular endothelial cells. Ando J, et al. **Jpn Heart J** 1996 Jan; 37(1):19–32 (40 ref.)

PECAM-1: its expression and function as a cell adhesion molecule on hemopoietic and endothelial cells. Watt SM, et al. **Leuk Lymphoma** 1995 Apr;17(3–4):229–44 (85 ref.)

Endothelium, fibrinolysis, cardiac risk factors, and prostaglandins: a unified model of atherogenesis. Kadish J. **Med Hypotheses** 1995 Aug;45(2):205–13 (106 ref.)

Effects of exercise training on endothelium–dependent peripheral vascular responsiveness. Delp MD. **Med Sci Sports Exerc** 1995 Aug;27(8):1152–7 (38 ref.)

Endothelium–mediated control of coronary vascular tone after chronic exercise training. Laughlin MH. **Med Sci Sports Exerc** 1995 Aug;27(8):1135–44 (34 ref.)

Neo–endothelialisation of PTFE microvascular grafts: a five–year experience. Lanzetta M, et al. **Microsurgery** 1995; 16(6):404–11 (35 ref.)

Paracrine functions of the coronary vascular endothelium. Fleming I, et al. **Mol Cell Biochem** 1996 Apr 12–26; 157(1–2):137–45 (49 ref.)

Platelet–activating factor mediates procoagulant activity on the surface of endothelial cells by promoting leukocyte adhesion. Lorant DE, et al. **Semin Cell Biol** 1995 Oct; 6(5):295–303 (78 ref.)

Platelet–vessel wall interaction: from the bedside to molecules. Caen JP, et al. **Thromb Haemost** 1995 Jul; 74(1):18–24 (42 ref.)

[Vascular endothelium and vasomotor tonus] Vanhoutte PM. **Rev Med Liege** 1995 Oct;50(10):418–26 (72 ref.) **(Fre)**

[Endothelial cell function and angiogenesis] Kanayasu–Toyoda T, et al. **Nippon Yakurigaku Zasshi** 1996 Mar;107(3):99–107 (54 ref.) (Eng. Abstr.) **(Jpn)**

[Blood flow modulates vascular endothelial gene expressions] Ando J. **Tanpakushitsu Kakusan Koso** 1996 Jan;41(1):26–33 (23 ref.) **(Jpn)**

[Mechanisms for flow–induced responses of vascular endothelial cells] Masuda M, et al. **Tanpakushitsu Kakusan Koso** 1996 Jan;41(1):34–46 (82 ref.) **(Jpn)**

[Adhesion molecules in leukocyte and endothelium interactions] Horváthová M. **Bratisl Lek Listy** 1995 Apr; 96(4):217–22 (48 ref.) (Eng. Abstr.) **(Slo)**

[Lowered cholesterol beneficial for vascular endothelium] Strandberg T, et al. **Nord Med** 1996 Jan;111(1):10–2 (10 ref.) (Eng. Abstr.) **(Swe)**

[The participation of the arteriolar endothelium in regulating renin secretion] Rudychenko VM, et al. **Vrach Delo** 1995 Jan–Feb;(1–2):19–25 (42 ref.) **(Ukr)**

PHYSIOPATHOLOGY

The vascular biology of nitric oxide and its role in atherogenesis. Lloyd–Jones DM, et al. **Annu Rev Med** 1996; 47:365–75 (52 ref.)

Endothelial–dependent mechanisms in chronic inflammatory leukocyte recruitment. Luscinskas FW, et al. **Annu Rev Med** 1996;47:413–21 (31 ref.)

Role of endothelium in thrombosis and hemostasis. Wu KK, et al. **Annu Rev Med** 1996;47:315–31 (50 ref.)

Pathogenetic factors in hypertension. Endothelial factors. Taddei S, et al. **Clin Exp Hypertens** 1996 Apr–May; 18(3–4):323–35 (34 ref.)

Pathobiology of the endothelium in multiple organ dysfunction syndrome. Kirkpatrick CJ, et al. **Contrib Nephrol** 1995;116:1–9 (39 ref.)

Lung disease and pulmonary endothelial nitric oxide. Higenbottam T. **Exp Physiol** 1995 Sep;80(5):855–64 (29 ref.)

Tumor cell interactions with the vascular endothelium and their role in cancer metastasis. Nicolson GL. **EXS** 1995; 74:123–56 (189 ref.)

Significance of defective endothelial signal transduction in impaired endothelium–dependent relaxation in atherosclerosis. Shimokawa H, et al. **Gerontology** 1995;41 Suppl 1:28–33 (19 ref.)

Importance of endothelial function in chronic heart failure. Drexler H, et al. **J Cardiovasc Pharmacol** 1996;27 Suppl 2:S9–12 (49 ref.)

Endothelium–derived vasoactive factors in hypertension: nitric oxide and endothelin. Nava E, et al. **J Hypertens Suppl** 1995 Aug;13(2):S39–48 (97 ref.)

[Vascular complications in diabetes mellitus: role of endothelial dysfunction] Stehouwer CD. **Ned Tijdschr Geneeskd** 1996 Apr 20;140(16):870–4 (27 ref.) **(Dut)**

[Arterial wall: a new pharmacological and therapeutic target?] Laurent S, et al. **Therapie** 1995 Jul–Aug; 50(4):387–98 (73 ref.) (Eng. Abstr.) **(Fre)**

[The vascular bed of the skin. Integration site of endogenous and exogenous stimuli] Heckmann M. **Hautarzt** 1996 Jun; 47(6):417–21 (37 ref.) (Eng. Abstr.) **(Ger)**

[Nitric oxide: the endogenous nitrate in the cardiovascular system] Tschudi MR, et al. **Herz** 1996 Jun;21 Suppl 1:50–60 (104 ref.) (Eng. Abstr.) **(Ger)**

[Coronary endothelial dysfunction and graft atheromatosis following heart transplantation] Vassalli G. **Schweiz Med Wochenschr** 1995 Oct 14;125(41):1923–30 (51 ref.) (Eng. Abstr.) **(Ger)**

[Sympathetic nervous system and endothelial function in heart failure] Binggeli C, et al. **Schweiz Rundsch Med Prax** 1996 Feb 20;85(8):234–44 (104 ref.) (Eng. Abstr.) **(Ger)**

[Endothelial function and arterial hypertension] Taddei S, et al. **Ann Ital Med Int** 1995 Oct;10 Suppl:85S–90S (34 ref.) (Eng. Abstr.) **(Ita)**

[Endothelial function and coronary microcirculation in arterial hypertension] Salvetti A. **Cardiologia** 1996 Apr; 41(4):319–25 (41 ref.) **(Ita)**

[Impairment of endothelial function in hypertension and possible laboratory evaluation of its state] Krasnowski R, et al. **Postepy Hig Med Dosw** 1996;50(1):65–80 (93 ref.) (Eng. Abstr.) **(Pol)**

[Dyslipidemias and endothelial changes] Bertolami MC. **Arq Bras Cardiol** 1995 Sep;65(3):267–72 (59 ref.) **(Por)**

[The role of endothelial dysfunction in the genesis of hypertensive states in pregnant women] Supriaga OM. **Akush Ginekol (Mosk)** 1995;(6):5–9 (40 ref.) **(Rus)**

[Does a defective endothelial function influence blood pressure? Complex relation between endothelium and

hypertension] Lind L. **Lakartidningen** 1995 Nov 15; 92(46):4321–4 (54 ref.) **(Swe)**

RADIATION EFFECTS

Initiation of non-neoplastic late effects: the role of endothelium and connective tissue. Rezvani M, et al. **Stem Cells (Dayt)** 1995 May;13 Suppl 1:248–56 (72 ref.)

SECRETION

von Willebrand factor and its relevance to cardiovascular disorders. Lip GY, et al. **Br Heart J** 1995 Dec;74(6):580–3 (28 ref.)

TRANSPLANTATION

Endothelial cell seeding of native vascular surfaces. Walluscheck KP, et al. **Eur J Vasc Endovasc Surg** 1996 Apr;11(3):290–303 (177 ref.)

Can graft endothelial cells initiate a host anti-graft immune response? Pober JS, et al. **Transplantation** 1996 Feb 15; 61(3):343–9 (72 ref.)

ULTRASTRUCTURE

Advances in understanding permeability in fetal capillaries of the human placenta: a review of organization of the endothelial paracellular clefts and their junctional complexes. Leach L, et al. **Reprod Fertil Dev** 1995; 7(6):1451–6 (51 ref.)

Modelling the structural pathways for transcapillary exchange. Weinbaum S, et al. **Symp Soc Exp Biol** 1995; 49:323–45 (31 ref.)

VIROLOGY

Cytomegalovirus persistence in macrophages and endothelial cells. Fish KN, et al. **Scand J Infect Dis Suppl** 1995;99:34–40 (54 ref.)

ENDOTOXINS

BIOSYNTHESIS

How does Bacillus thuringiensis produce so much insecticidal crystal protein? Agaisse H, et al. **J Bacteriol** 1995 Nov; 177(21):6027–32 (59 ref.)

Regulation of insecticidal crystal protein production in Bacillus thuringiensis. Baum JA, et al. **Mol Microbiol** 1995 Oct;18(1):1–12 (50 ref.)

BLOOD

Alcohol and endotoxin: another path to alcoholic liver injury? Schenker S, et al. **Alcohol Clin Exp Res** 1995 Oct; 19(5):1364–6 (40 ref.)

Endotoxaemia: where do we go from here? [editorial; comment] Barton MH. **Br Vet J** 1995 Sep–Oct; 151(5):469–71 (4 ref.) Comment on: Br Vet J 1995 Sep–Oct;151(5):489–522.

Mediators and vascular effects in response to endotoxin [see comments] Olson NC, et al. **Br Vet J** 1995 Sep–Oct; 151(5):489–522 (152 ref.) Comment in: Br Vet J 1995 Sep–Oct;151(5):469–71.

Calcium: a regulator of the inflammatory response in endotoxemia and sepsis. Hotchkiss RS, et al. **New Horiz** 1996 Feb;4(1):58–71 (70 ref.)

Role of the gut in multiple organ failure: bacterial translocation and permeability changes. Swank GM, et al. **World J Surg** 1996 May;20(4):411–7 (65 ref.)

[Endotoxemia and carbonhydrate metabolism] Zhai Z, et al. **Chung Hua Cheng Hsing Shao Shang Wai Ko Tsa Chih** 1996 Jan;12(1):62–5 (21 ref.) **(Chi)**

IMMUNOLOGY

Is sepsis a mediator-inhibitor mismatch? Lamy M, et al. **Intensive Care Med** 1995 Nov;21 Suppl 2:S250–7 (55 ref.)

Antibodies to lipopolysaccharide. Poxton IR. **J Immunol Methods** 1995 Oct 12;186(1):1–15 (85 ref.)

Endogenous endotoxin-core antibody (EndoCAb) as a marker of endotoxin exposure and a prognostic indicator: a review. Barclay GR. **Prog Clin Biol Res** 1995;392:263–72 (20 ref.)

The nonspecific nature of endotoxin tolerance. Cavaillon JM. **Trends Microbiol** 1995 Aug;3(8):320–4 (64 ref.)

METABOLISM

Trauma and bacterial translocation [see comments] Saadia R. **Br J Surg** 1995 Sep;82(9):1243–4 (18 ref.) Comment in: Br J Surg 1996 Feb;83(2):282–3. Comment in: Br J Surg 1996 Feb;83(2):283.

The beta-prism: a new folding motif. Shimizu T, et al. **Trends Biochem Sci** 1996 Jan;21(1):3–6 (28 ref.)

PHARMACOLOGY

Endotoxin signal transduction in macrophages. Sweet MJ, et al. **J Leukoc Biol** 1996 Jul;60(1):8–26 (304 ref.)

PHYSIOLOGY

Bacterial modulins: a novel class of virulence factors which cause host tissue pathology by inducing cytokine synthesis. Henderson B, et al. **Microbiol Rev** 1996 Jun;60(2):316–41 (260 ref.)

TOXICITY

Molecular mechanisms of endotoxin activity. Schletter J, et al. **Arch Microbiol** 1995 Dec;164(6):383–9 (48 ref.)

Effects of endotoxin on lipid metabolism. Hardardóttir I, et al. **Biochem Soc Trans** 1995 Nov;23(4):1013–8 (62 ref.)

Involvement of bacteria/endotoxin translocation in the development of multiple organ failure. Bahrami S, et al. **Curr Top Microbiol Immunol** 1996;216:239–58 (111 ref.)

Bacterial endotoxin: Chemical constitution, biological recognition, host response, and immunological detoxification. Rietschel ET, et al. **Curr Top Microbiol Immunol** 1996;216:39–81 (265 ref.)

Pathogenic effects of endotoxin. Zivot JB, et al. **New Horiz** 1995 May;3(2):267–75 (86 ref.)

Endotoxins in the environment. Rylander R. **Prog Clin Biol Res** 1995;392:79–90 (63 ref.)

ENDOWMENTS see **FINANCIAL MANAGEMENT**

ENEMA

ADVERSE EFFECTS

Oral sodium phosphate catharsis and acute renal failure. Ahmed M, et al. **Am J Gastroenterol** 1996 Jun;91(6):1261–2 (9 ref.)

[Ano-rectal and colonic complications of suppositories and enemas] de Parades V, et al. **Gastroenterol Clin Biol** 1996; 20(5):446–52 (118 ref.) **(Fre)**

ENERGY EXPENDITURE see **ENERGY METABOLISM**

ENERGY-GENERATING RESOURCES

see related
POWER PLANTS
POWER SOURCES

ENERGY METABOLISM

Is lead toxicosis a reflection of altered energy metabolism in brain synaptosomes? Rafałowska U, et al. **Acta Neurobiol Exp (Warsz)** 1996;56(2):611–7 (30 ref.)

Mechanisms of human muscle fatigue. Quantitating the contribution of metabolic factors and activation impairment. Miller RG, et al. **Adv Exp Med Biol** 1995; 384:195–210 (38 ref.)

Contribution of fiber and resistant starch to metabolizable energy. Behall KM, et al. **Am J Clin Nutr** 1995 Nov;62(5 Suppl):1158S–1160S (35 ref.)

Methods available to estimate the energy values of sugar alcohols. Ellwood KC. **Am J Clin Nutr** 1995 Nov;62(5 Suppl):1169S–1174S (38 ref.)

Body composition, respiratory quotient, and weight maintenance. Flatt JP. **Am J Clin Nutr** 1995 Nov;62(5 Suppl):1107S–1117S (72 ref.)

Control of energy intake by energy metabolism. Friedman MI. **Am J Clin Nutr** 1995 Nov;62(5 Suppl):1096S–1100S (45 ref.)

The calorie: myth, measurement, and reality. Heymsfield SB, et al. **Am J Clin Nutr** 1995 Nov;62(5 Suppl):1034S–1041S (78 ref.)

New model for the regulation of energy balance and adiposity by the central nervous system. Kaiyala KJ, et al. **Am J Clin Nutr** 1995 Nov;62(5 Suppl):1123S–1134S (130 ref.)

Metabolizable energy of macronutrients. Livesey G. **Am J Clin Nutr** 1995 Nov;62(5 Suppl):1135S–1142S (35 ref.)

Sympathetic nervous system response to intake. Welle S. **Am J Clin Nutr** 1995 Nov;62(5 Suppl):1118S–1122S (46 ref.)

The neural network that regulates energy balance is responsive to glucocorticoids and insulin and also regulates HPA axis responsivity at a site proximal to CRF neurons. Dallman MF, et al. **Ann N Y Acad Sci** 1995 Dec 29; 771:730–42 (43 ref.)

Energetic problems of extremely alkaliphilic aerobes. Krulwich TA, et al. **Biochim Biophys Acta** 1996 Jul 18; 1275(1–2):21–6 (49 ref.)

Cardiac efficiency. Gibbs CL, et al. **Cardiovasc Res** 1995 Nov; 30(5):627–34 (67 ref.)

Doubly labelled water measurement of total energy expenditure. Ritz P, et al. **Diabete Metab** 1995 Oct; 21(4):241–51 (68 ref.)

Mitochondria and diabetes. Genetic, biochemical, and clinical implications of the cellular energy circuit. Gerbitz KD, et al. **Diabetes** 1996 Feb;45(2):113–26 (152 ref.)

Banting Lecture 1995. A lesson in metabolic regulation inspired by the glucokinase glucose sensor paradigm. Matschinsky FM. **Diabetes** 1996 Feb;45(2):223–41 (86 ref.)

Energy requirements of infants. Butte NF. **Eur J Clin Nutr** 1996 Feb;50 Suppl 1:S24–36 (54 ref.)

Protein requirements of infants and children. Dewey KG, et al. **Eur J Clin Nutr** 1996 Feb;50 Suppl 1:S119–47; discussion S147–50 (140 ref.)

Energy requirements: general principles. Durnin JV. **Eur J Clin Nutr** 1996 Feb;50 Suppl 1:S2–9; discussion 9–10 (26 ref.)

The impact of complex carbohydrates on energy balance. Livesey G. **Eur J Clin Nutr** 1995 Oct;49 Suppl 3:S89–96 (30 ref.)

Energy requirements of pregnant and lactating women. Prentice AM, et al. **Eur J Clin Nutr** 1996 Feb;50 Suppl 1:S82–110; discussion S10–1 (114 ref.)

Energy requirements of older individuals. Roberts SB. **Eur J Clin Nutr** 1996 Feb;50 Suppl 1:S112–7; discussion S117–8 (20 ref.)

Energy requirements of adults: an update on basal metabolic rates (BMRs) and physical activity levels (PALs). Shetty PS, et al. **Eur J Clin Nutr** 1996 Feb;50 Suppl 1:S11–23 (77 ref.)

Energy requirements and dietary energy recommendations for children and adolescents 1 to 18 years old. Torun B, et al. **Eur J Clin Nutr** 1996 Feb;50 Suppl 1:S37–80; discussion S80–1 (164 ref.)

Magnetic resonance imaging and spectroscopy in studying exercise in children. Cooper DM, et al. **Exerc Sport Sci Rev** 1996;24:475–99 (78 ref.)

Control of adenine nucleotide metabolism and glycolysis in vertebrate skeletal muscle during exercise. Krause U, et al. **Experientia** 1996 May 15;52(5):396–403 (51 ref.)

The Pasteur effect in facultative anaerobic metazoa. Schmidt H, et al. **Experientia** 1996 May 15;52(5):440–8 (89 ref.)

Is there a critical tissue oxygen tension for bioenergetic status and cellular pH regulation in solid tumors? Vaupel P. **Experientia** 1996 May 15;52(5):464–8 (33 ref.)

Flying insects: model systems in exercise physiology. Wegener G. **Experientia** 1996 May 15;52(5):404–12 (41 ref.)

Allosteric enzymes as models for chemomechanical energy transducing assemblies. Goldsmith EJ. **FASEB J** 1996 May; 10(7):702–8 (50 ref.)

Impact of continuous renal replacement therapies on metabolism. Druml W. **Int J Artif Organs** 1996 Feb; 19(2):118–20 (1 ref.)

Role of the endocrine pancreas in control of fuel metabolism by the liver during exercise. Wasserman DH, et al. **Int J Obes Relat Metab Disord** 1995 Oct;19 Suppl 4:S22–30 (83 ref.)

Indirect calorimetry in critically ill patients: role of the clinical dietitian in interpreting results. Porter C, et al. **J Am Diet Assoc** 1996 Jan;96(1):49–57 (38 ref.)

Exercise for weight loss: what are the facts? Zelasko CJ. **J Am Diet Assoc** 1995 Dec;95(12):1414–7 (22 ref.)

The contribution of mitochondria to energetic metabolism in photosynthetic cells. Gardeström P, et al. **J Bioenerg Biomembr** 1995 Aug;27(4):415–21 (53 ref.)

Role of scalar protons in metabolic energy generation in lactic acid bacteria. Lolkema JS, et al. **J Bioenerg Biomembr** 1995 Aug;27(4):467–73 (13 ref.)

Membrane energization by proton pumps is important for compartmentalization of drugs and toxins: a new type of active transport. Moriyama Y. **J Exp Biol** 1996 Jul;199 (Pt 7):1447–54 (70 ref.)

Bioenergetic and oxidative stress in neurodegenerative diseases. Bowling AC, et al. **Life Sci** 1995;56(14):1151–71 (257 ref.)

Calcium, energy metabolism and the development of selective neuronal loss following short-term cerebral ischemia. Sims NR. **Metab Brain Dis** 1995 Sep; 10(3):191–217 (168 ref.)

Fuel metabolism in growth hormone-deficient adults. Jørgensen JO, et al. **Metabolism** 1995 Oct;44(10 Suppl 4):103–7 (33 ref.)

Homeostatic maintenance regulated by hypothalamic neuronal histamine. Sakata T, et al. **Methods Find Exp Clin Pharmacol** 1995 Nov;17 Suppl C:51–6 (39 ref.)

Effects of exercise on daily energy expenditure. Toth MJ, et al. **Nutr Rev** 1996 Apr;54(4 Pt 2):S140–8 (51 ref.)

Histamine receptor and its regulation of energy metabolism. Sakata T. **Obes Res** 1995 Nov;3 Suppl 4:541S–548S (62 ref.)

Energy homeostasis, autonomic activity and obesity. Scheurink AJ, et al. **Obes Res** 1995 Dec;3 Suppl 5:721S–727S (54 ref.)

Fuel metabolism in pregnancy and in gestational diabetes mellitus. Boden G. **Obstet Gynecol Clin North Am** 1996 Mar;23(1):1–10 (53 ref.)

Fuel metabolism in deviant fetal growth in offspring of diabetic women. Hod M, et al. **Obstet Gynecol Clin North Am** 1996 Mar;23(1):259–77 (105 ref.)

Insights into cellular energy metabolism from transgenic mice. Koretsky AP. **Physiol Rev** 1995 Oct;75(4):667–88 (130 ref.)

Postexercise recovery period: carbohydrate and protein metabolism. Viru A. **Scand J Med Sci Sports** 1996 Feb; 6(1):2–14 (125 ref.)

Exercise performance of lower-extremity amputees. Ward KH, et al. **Sports Med** 1995 Oct;20(4):207–14 (50 ref.)

[Nervous regulation of metabolism] Niijima A. **Nippon Rinsho** 1995 Jun;53 Suppl:3–10 (10 ref.) **(Jpn)**

[Metabolic and ventilatory thresholds during exercise. Physiological and methodological aspects] Ribeiro JP. **Arq Bras Cardiol** 1995 Feb;64(2):171–81 (178 ref.) **(Por)**

DRUG EFFECTS

Beta-blockers and their effects on protein metabolism and resting energy expenditure. Lamont LS. **J Cardpulm Rehabil** 1995 May-Jun;15(3):183–5 (21 ref.)

ENERGY METABOLISM

GENETICS

Ethnicity and energy stores. Conway JM.
Am J Clin Nutr 1995 Nov;62(5 Suppl):1067S–1071S (35 ref.)

PHYSIOLOGY

Disturbances of acetyl-CoA, energy and acetylcholine metabolism in some encephalopathies. Szutowicz A, et al. **Acta Neurobiol Exp (Warsz)** 1996;56(1):323–39 (110 ref.)

On the principles underlying the diagnosis of brain tumours--a survey article. Go KG, et al.
Acta Neurochir (Wien) 1995;135(1–2):1–11 (31 ref.)

Energetics of fish larvae, the smallest vertebrates. Wieser W. **Acta Physiol Scand** 1995 Jul;154(3):279–90 (62 ref.)

Bioenergetics and muscle cell types. Kushmerick MJ.
Adv Exp Med Biol 1995;384:175–84 (55 ref.)

Clinical applications of proton MR spectroscopy. Castillo M, et al. **AJNR Am J Neuroradiol** 1996 Jan;17(1):1–15 (64 ref.)

Neuroprotective effects of free radical scavengers and energy repletion in animal models of neurodegenerative disease. Schulz JB, et al. **Ann N Y Acad Sci** 1995 Sep 15;765:100–10; discussion 116–8 (56 ref.)

Energy partitioning and modeling in animal nutrition. Baldwin RL, et al. **Annu Rev Nutr** 1995;15:191–211 (56 ref.)

Whole-body protein turnover in humans--past, present, and future. Waterlow JC. **Annu Rev Nutr** 1995;15:57–92 (171 ref.)

Energy density and its role in the control of food intake: evidence from metabolic and community studies. Poppitt SD, et al. **Appetite** 1996 Apr;26(2):153–74 (102 ref.)

Energy conservation and sleep. Berger RJ, et al.
Behav Brain Res 1995 Jul–Aug;69(1–2):65–73 (77 ref.)

Electron transfer and proton pumping in cytochrome oxidase. Brunori M, et al. **Biochimie** 1995;77(7–8):668–76 (58 ref.)

Aspects of oxidative metabolism in schizophrenia [editorial] Marchbanks RM, et al. **Br J Psychiatry** 1995 Sep; 167(3):293–8 (24 ref.)

Metabolic responses of the critically ill patient. Kinney JM. **Crit Care Clin** 1995 Jul;11(3):569–85 (66 ref.)

Theories and assumptions on energy expenditure. Determinations in the clinical setting. Molina P, et al.
Crit Care Clin 1995 Jul;11(3):587–601 (53 ref.)

Physical activity assessment: a review of methods. Melanson EL Jr, et al. **Crit Rev Food Sci Nutr** 1996 May;36(5):385–96 (91 ref.)

Regulation of adipose maturation and energy homeostasis. Yeh WC, et al. **Curr Opin Cell Biol** 1995 Dec;7(6):885–90 (57 ref.)

Management of nutrition in the critically ill patient. Kudsk KA, et al. **Curr Opin Gen Surg** 1994;:24–9 (15 ref.)

Regulation of protein metabolism during stress. Matthews DE, et al. **Curr Opin Gen Surg** 1993;:72–7 (45 ref.)

Energy requirements of pregnancy for healthy Dutch women. van Raaij JM.
Eur J Obstet Gynecol Reprod Biol 1995 Jul;61(1):7–13 (12 ref.)

Integration of the overall response to exercise. Flatt JP.
Int J Obes Relat Metab Disord 1995 Oct;19 Suppl 4:S31–40 (23 ref.)

Physiological regulation of macronutrient balance. Frayn KN. **Int J Obes Relat Metab Disord** 1995 Nov;19 Suppl 5:S4–10 (48 ref.)

Epidemiology of obesity in relation to nutrient intake. Gibney MJ. **Int J Obes Relat Metab Disord** 1995 Nov;19 Suppl 5:S1–3 (25 ref.)

Exercise and macronutrient balance. Hill JO, et al.
Int J Obes Relat Metab Disord 1995 Oct;19 Suppl 4:S88–92 (39 ref.)

Exercise, substrate utilization and energy requirements in the elderly. Poehlman ET, et al.
Int J Obes Relat Metab Disord 1995 Oct;19 Suppl 4:S93–6 (20 ref.)

Energy density of diets and obesity. Poppitt SD.
Int J Obes Relat Metab Disord 1995 Nov;19 Suppl 5:S20–6 (55 ref.)

Importance of energy density and macronutrients in the regulation of energy intake. Prentice AM, et al.
Int J Obes Relat Metab Disord 1996 Mar;20 Suppl 2:S18–23 (27 ref.)

Manipulating carbohydrate content and sources in obesity prone subjects: effect on energy expenditure and macronutrient balance. Raben A, et al.
Int J Obes Relat Metab Disord 1996 Mar;20 Suppl 2:S24–30 (81 ref.)

Exercise and the neurobiological control of food intake and energy expenditure. Richard D.
Int J Obes Relat Metab Disord 1995 Oct;19 Suppl 4:S73–9 (78 ref.)

Macronutrient effects on appetite. Stubbs RJ.
Int J Obes Relat Metab Disord 1995 Nov;19 Suppl 5:S11–9 (54 ref.)

Variability in metabolic rate: biological sites of regulation. Tataranni PA, et al. **Int J Obes Relat Metab Disord** 1995 Oct;19 Suppl 4:S102–6 (27 ref.)

Energy requirements of the fat sand rat (Psammomys obesus) when consuming the saltbush, Atriplex halimus: a review. Degen AA. **J Basic Clin Physiol Pharmacol** 1993 Apr–Jun; 4(1–2):13–28 (37 ref.)

Application of spectroscopic imaging in epilepsy. Garcia PA, et al. **Magn Reson Imaging** 1995;13(8):1181–5 (28 ref.)

Application of high field spectroscopic imaging in the evaluation of temporal lobe epilepsy. Hetherington HP, et al. **Magn Reson Imaging** 1995;13(8):1175–80 (14 ref.)

Overview--the role of NMR spectroscopy in epilepsy. Novotny EJ Jr. **Magn Reson Imaging** 1995;13(8):1171–3 (17 ref.)

NMR studies of brain 13C-glucose uptake and metabolism: present status. van Zijl PC, et al. **Magn Reson Imaging** 1995;13(8):1213–21 (44 ref.)

Influence of altered body weight on energy expenditure. Kinney JM. **Nutr Rev** 1995 Sep;53(9):265–8 (14 ref.)

The role of energy expenditure in energy regulation: findings from a decade of research. Saltzman E, et al. **Nutr Rev** 1995 Aug;53(8):209–20 (64 ref.)

Abnormalities of energy expenditure and the development of obesity. Roberts SB. **Obes Res** 1995 Sep;3 Suppl 2:155s–163s (50 ref.)

Abnormalities of fuel utilization as predisposing to the development of obesity in humans. Schutz Y. **Obes Res** 1995 Sep;3 Suppl 2:173S–178S (27 ref.)

New strategies in clinical nutrition. Fürst P.
Perit Dial Int 1996;16 Suppl 1:S28–35 (25 ref.)

Nuclear magnetic resonance spectroscopy of living systems: applications in comparative physiology. Van Den Thillart G, et al. **Physiol Rev** 1996 Jul;76(3):799–837 (277 ref.)

Organ fuel selection: brain. Amiel SA. **Proc Nutr Soc** 1995 Mar;54(1):151–5 (20 ref.)

Comparative studies on programmes for management of energy supply: torpor, pre-winter fattening and migration. Andrews JF. **Proc Nutr Soc** 1995 Mar;54(1):301–15 (33 ref.)

Fuel selection by the kidney: adaptation to starvation. Baverel G, et al. **Proc Nutr Soc** 1995 Mar;54(1):197–212 (116 ref.)

Fuel utilization by cells of the immune system. Calder PC. **Proc Nutr Soc** 1995 Mar;54(1):65–82 (79 ref.)

Fuel selection at the level of mitochondria in mammalian tissues. Denton RM, et al. **Proc Nutr Soc** 1995 Mar; 54(1):11–22 (39 ref.)

Metabolic fuel selection by intestinal epithelium. Desjeux JF. **Proc Nutr Soc** 1995 Mar;54(1):157–63 (36 ref.)

Fuel selection in intestinal cells. Duée PH, et al.
Proc Nutr Soc 1995 Mar;54(1):83–94 (59 ref.)

General integration and regulation of metabolism at the organ level. Elia M. **Proc Nutr Soc** 1995 Mar;54(1):213–32 (84 ref.)

Fuel selection in white adipose tissue. Frayn KN, et al.
Proc Nutr Soc 1995 Mar;54(1):177–89 (50 ref.)

Muscle fuel selection: effect of exercise and training. Henriksson J. **Proc Nutr Soc** 1995 Mar;54(1):125–38 (100 ref.)

Fuel selection, muscle fibre. Hultman E. **Proc Nutr Soc** 1995 Mar;54(1):107–21 (51 ref.)

Nutrient effects: post-absorptive interactions. Jéquier E.
Proc Nutr Soc 1995 Mar;54(1):253–65 (57 ref.)

Cellular aspects of fuel mobilization and selection in white adipocytes. Lafontan M, et al. **Proc Nutr Soc** 1995 Mar; 54(1):49–63 (81 ref.)

What determines fuel selection in relation to exercise? Lindholm A. **Proc Nutr Soc** 1995 Mar;54(1):275–82 (23 ref.)

Feeding, fasting and starvation: factors affecting fuel utilization. MacDonald IA, et al. **Proc Nutr Soc** 1995 Mar; 54(1):267–74 (29 ref.)

Hepatic fuel selection. Müller MJ. **Proc Nutr Soc** 1995 Mar; 54(1):139–50 (67 ref.)

Whole-body fuel selection in ruminants: nutrient supply and utilization by major tissues. Ortigues I, et al.
Proc Nutr Soc 1995 Mar;54(1):235–51 (55 ref.)

Metabolic fuel selection: general integration at the whole-body level. Randle PJ. **Proc Nutr Soc** 1995 Mar; 54(1):317–27 (24 ref.)

Energy substrates for the rumen epithelium. Rémond D, et al. **Proc Nutr Soc** 1995 Mar;54(1):95–105 (53 ref.)

Whole-body fuel selection: 'reproduction'. Robinson JJ, et al. **Proc Nutr Soc** 1995 Mar;54(1):283–99 (108 ref.)

The human epidermis. Schallreuter KU, et al.
Proc Nutr Soc 1995 Mar;54(1):191–5 (18 ref.)

Fuel selection in brown adipose tissue. Trayhurn P.
Proc Nutr Soc 1995 Mar;54(1):39–47 (46 ref.)

Thyroid status and exercise tolerance. Cardiovascular and metabolic considerations. McAllister RM, et al.
Sports Med 1995 Sep;20(3):189–98 (64 ref.)

Thyroid hormone control of thermogenesis and energy balance. Silva JE. **Thyroid** 1995 Dec;5(6):481–92 (99 ref.)

Metabolism of sepsis and multiple organ failure. Michie HR. **World J Surg** 1996 May;20(4):460–4 (31 ref.)

Metabolic aspects of hibernating myocardium. Pantely GA, et al. **Z Kardiol** 1995;84 Suppl 4:101–5 (25 ref.)

[Liver metabolism and acid-base balance] Zander R.
Anasthesiol Intensivmed Notfallmed Schmerzther 1995 Oct; 30 Suppl 1:S48–51 (26 ref.) **(Ger)**

[Pathophysiology of the "hibernating" myocardium] Schulz R, et al. **Z Kardiol** 1995;84 Suppl 4:91–100 (40 ref.) (Eng. Abstr.) **(Ger)**

-Myocardial protection by preconditioning. Experimental and clinical significance- Strasser R, et al. **Z Kardiol** 1996 Feb;85(2):79–89 (108 ref.) (Eng. Abstr.) **(Ger)**

ENGELMANN'S DISEASE see **DIAPHYSEAL DYSPLASIA, PROGRESSIVE**

ENGINE EXHAUST see **VEHICLE EMISSIONS**

ENGINEERING, CLINICAL see **BIOMEDICAL ENGINEERING**

ENGINEERING, HOSPITAL see **MAINTENANCE AND ENGINEERING, HOSPITAL**

ENGINEERING PSYCHOLOGY see **HUMAN ENGINEERING**

ENHANCER ELEMENTS (GENETICS)

Interleukin-5 receptor alpha subunit gene regulation in human eosinophil development: identification of a unique cis-element that acts lie an enhancer in regulating activity of the IL-5R alpha promoter. Sun Z, et al.
Curr Top Microbiol Immunol 1996;211:173–87 (64 ref.)

Hepatocarcinogenesis in transgenic mice. Sandgren EP, et al. **Prog Clin Biol Res** 1995;391:213–22 (35 ref.)

[Transcriptional machinery and its regulatory elements of HBV genome] Nishizono A, et al. **Nippon Rinsho** 1995 Oct; 53 Suppl:28–34 (30 ref.) **(Jpn)**

[Promoter and enhancer of the ornithine transcarbamylase gene] Nishiyori A, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2606–12 (26 ref.) **(Jpn)**

GENETICS

A unique role for enhancers is revealed during early mouse development. Majumder S, et al. **Bioessays** 1995 Oct; 17(10):879–89 (77 ref.)

Nucleoprotein architecture of the albumin transcriptional enhancer. Zaret KS. **Semin Cell Biol** 1995 Aug;6(4):209–18 (56 ref.)

ENHANCING ANTIBODIES see **ANTIBODIES, BLOCKING**

ENKEPHALIN DIPEPTIDYL CARBOXYPEPTIDASE see **MEMBRANE METALLO-ENDOPEPTIDASE**

ENKEPHALIN RECEPTORS see **RECEPTORS, OPIOID**

ENKEPHALINASE see **MEMBRANE METALLO-ENDOPEPTIDASE**

ENKEPHALINS

see related
RECEPTORS, OPIOID

BLOOD

[Enkephalin] Kato Y. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:329–32 (18 ref.) **(Jpn)**

GENETICS

Proenkephalin gene regulation in the neuroendocrine hypothalamus: a model of gene regulation in the CNS. Borsook D, et al. **Am J Physiol** 1995 Sep;269(3 Pt 1):E393–408 (203 ref.)

METABOLISM

Proenkephalin-processing enzymes in chromaffin granules: model for neuropeptide biosynthesis. Hook VY, et al.
Ann N Y Acad Sci 1996 Mar 22;780:121–33 (22 ref.)

Dual inhibitors of enkephalin-degrading enzymes (neutral endopeptidase 24.11 and aminopeptidase N) as potential new medications in the management of pain and opioid addiction. Roques BP, et al. **NIDA Res Monogr** 1995; 147:104–45 (149 ref.)

PHARMACOKINETICS

Oral peptide delivery: improving the systemic availability of small peptides and enkephalin analogs. Lee HJ, et al. **NIDA Res Monogr** 1995;154:86–106 (16 ref.)

PHYSIOLOGY

Transgenic mice: preproenkephalin and the mu opiate receptor. Donovan DM, et al. **Ann N Y Acad Sci** 1996 Mar 22;780:19–28 (28 ref.)

SECRETION

Release of catecholamines and enkephalin peptides induced by reversal of the Na(+)-Ca2+ exchanger in chromaffin cells. Duarte EP, et al. **Ann N Y Acad Sci** 1996 Apr 15; 779:391–4 (6 ref.)

ENOXAPARIN

THERAPEUTIC USE

The role of low-molecular-weight heparins in the prevention of venous thrombosis in surgery with special reference to enoxaparin. Haas S. **Haemostasis** 1996;26 Suppl 2:39–48 (21 ref.)

ENOXOLONE see **GLYCYRRHETINIC ACID**

ENOYL COA REDUCTASES see **FATTY ACID DESATURASES**

ENRICHED FOOD see FOOD, FORTIFIED

ENTAMOEBA HISTOLYTICA

Amebiasis. Ravdin JI. **Clin Infect Dis** 1995 Jun;20(6):1453–64; quiz 1465–6 (46 ref.)

GENETICS

Amebiasis and the Entamoeba histolytica Gal/GalNAc lectin: from lab bench to bedside. Petri Wa Jr. **J Investig Med** 1996 Feb;44(2):24–36 (84 ref.)

PATHOGENICITY

New concepts regarding the pathogenesis of amebiasis. Reed SL. **Clin Infect Dis** 1995 Oct;21 Suppl 2:S182–5 (39 ref.)
Role of signalling and cytoskeletal rearrangements in the pathogenesis of Entamoeba histolytica. Guillén N. **Trends Microbiol** 1996 May;4(5):191–7 (47 ref.)

ENTAMOEBIASIS

Amebiasis. Ravdin JI. **Clin Infect Dis** 1995 Jun;20(6):1453–64; quiz 1465–6 (46 ref.)

PARASITOLOGY

New concepts regarding the pathogenesis of amebiasis. Reed SL. **Clin Infect Dis** 1995 Oct;21 Suppl 2:S182–5 (39 ref.)
Amebiasis and the Entamoeba histolytica Gal/GalNAc lectin: from lab bench to bedside. Petri Wa Jr. **J Investig Med** 1996 Feb;44(2):24–36 (84 ref.)

ENTAMOEBIASIS, HEPATIC see LIVER ABSCESS, AMEBIC

ENTAMOEBIASIS, INTESTINAL see DYSENTERY, AMEBIC

ENTERAL FEEDING see ENTERAL NUTRITION

ENTERAL NUTRITION

see related
FOOD, FORMULATED
GASTROSTOMY
INTUBATION, GASTROINTESTINAL

Optimizing enteral nutrition. Rodman DP, et al. **Am Fam Physician** 1996 Jun;53(8):2535–42 (35 ref.)
Barriers to forgoing nutrition and hydration in nursing homes. Meisel A. **Am J Law Med** 1995;21(4):335–82 (274 ref.)
Malnutrition, injury, and the host immune response: nutrient substitution. Gallagher HJ, et al. **Curr Opin Gen Surg** 1993; :92–104 (116 ref.)
Enteral nutrition. Payne-James JJ. **Eur J Gastroenterol Hepatol** 1995 Jun;7(6):501–6 (28 ref.)
Enteral nutrition in patients with respiratory disease. Pingleton SK. **Eur Respir J** 1996 Feb;9(2):364–70 (58 ref.)
Transition from tube feedings to feedings by mouth in children: preventing eating dysfunction. Schauster H, et al. **J Am Diet Assoc** 1996 Mar;96(3):277–81 (18 ref.)
The necessity of selenium substitution in total parenteral nutrition and artificial alimentation. Gramm HJ, et al. **J Trace Elem Med Biol** 1995 Mar;9(1):1–12 (75 ref.)
Nutrition support in hospitalized patients with diabetes mellitus. McMahon MM, et al. **Mayo Clin Proc** 1996 Jun; 71(6):587–94 (9 ref.)
Nutrition in the head-injured patient. Roberts PR. **New Horiz** 1995 Aug;3(3):506–17 (96 ref.)
Neonatal enteral and parenteral nutrition. Pittard WB 3rd, et al. **Pediatr Ann** 1995 Nov;24(11):592–8 (62 ref.)
Nutritional support to prevent and treat multiple organ failure. Bengmark S, et al. **World J Surg** 1996 May; 20(4):474–81 (90 ref.)
[Parenteral and enteral nutrition in patients with diseases of the gastrointestinal tract] Bureš J. **Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove** 1995;38(1 Suppl):21–35 (207 ref.) (Eng. Abstr.) **(Cze)**
[Enteral vs parenteral nutrition?] Nuutinen L, et al. **Duodecim** 1994;110(20):1935–43 (42 ref.) **(Fin)**
[Artificial (parenteral and enteral) nutrition in postoperative rehabilitation] Vantini I, et al. **Chir Ital** 1994;46(6):54–67 (112 ref.) (Eng. Abstr.) **(Ita)**

ADVERSE EFFECTS

Colocutaneous fistula as a complication of PEG tube placement. Kilmartin C, et al. **J Fam Pract** 1996 Jul; 43(1):76–8 (10 ref.)
Intestinal responses induced by enteral feeding. Bowling TE, et al. **Nutrition** 1995 May-Jun;11(3):304–7 (67 ref.)
The Sir David Cuthbertson Medal Lecture. Enteral-feeding-related diarrhoea: proposed causes and possible solutions. Bowling TE. **Proc Nutr Soc** 1995 Jul; 54(2):579–90 (64 ref.)

INSTRUMENTATION

Technology Assessment status evaluation: endoscopic feeding tubes. American Society for Gastrointestinal Endoscopy. Kimmey MB, et al. **Gastrointest Endosc** 1995 Dec;42(6):612–4 (17 ref.)
Colocutaneous fistula as a complication of PEG tube placement. Kilmartin C, et al. **J Fam Pract** 1996 Jul; 43(1):76–8 (10 ref.)

METHODS

Fluoroscopically guided percutaneous gastrostomy: current status. McLoughlin RF, et al. **Can Assoc Radiol J** 1996 Feb;47(1):10–5 (54 ref.)
Management of nutrition in the critically ill patient. Kudsk KA, et al. **Curr Opin Gen Surg** 1994;:24–9 (15 ref.)
Nasogastric tube feeding in infants on peritoneal dialysis. Warady BA, et al. **Perit Dial Int** 1996;16 Suppl 1:S521–5 (32 ref.)
[Cyclic enteral nutrition] Hébuterne X, et al. **Presse Med** 1996 Feb 10;25(5):202–6 (30 ref.) (Eng. Abstr.) **(Fre)**

ENTERIC FEVER see TYPHOID

ENTERIC HORMONES see GASTROINTESTINAL HORMONES

ENTERIC NERVOUS SYSTEM

CYTOLOGY

Neurons and glial cells of the enteric nervous system: studies in tissue culture. Hanani M. **J Basic Clin Physiol Pharmacol** 1993 Jul-Sep;4(3):157–79 (72 ref.)

EMBRYOLOGY

Neural crest development. Do developing enteric neurons need endothelins? Gershon MD. **Curr Biol** 1995 Jun 1; 5(6):601–4 (23 ref.)

PHYSIOLOGY

[The participation of enteral mechanisms in the sympathetic-adrenal inhibition of gastric secretion] Trefilov AB. **Usp Fiziol Nauk** 1995 Jan-Mar;26(1):76–92 (79 ref.) (Eng. Abstr.) **(Rus)**

ENTERICALLY-TRANSMITTED NON-A, NON-B HEPATITIS see HEPATITIS E

ENTERITIS

see related
ENTEROCOLITIS

CHEMICALLY INDUCED

Nonsteroidal antiinflammatory drug-induced enteropathy and severe chronic anemia in a patient with rheumatoid arthritis. Davies NM, et al. **Arthritis Rheum** 1996 Feb; 39(2):321–4 (15 ref.)

DRUG THERAPY

Antimicrobial-resistant Campylobacter species--a new threat to travelers to Thailand [editorial] DuPont HL. **Clin Infect Dis** 1995 Sep;21(3):542–3 (18 ref.)
Fluoroquinolones and bacterial enteritis, when and for whom? Wiström J, et al. **J Antimicrob Chemother** 1995 Jul; 36(1):23–39 (84 ref.)

EPIDEMIOLOGY

Bacterial enteric infections in persons infected with human immunodeficiency virus. Angulo FJ, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S84–93 (96 ref.)

ETIOLOGY

Multifocal stenosing ulcerations of the small intestine revealing vasculitis associated with C2 deficiency. Perlemuter G, et al. **Gastroenterology** 1996 May; 110(5):1628–32 (23 ref.)
[Radiation injury of the small intestine. Radiobiological, radiopathological aspects; risk factors and prevention] Touboul E, et al. **Ann Chir** 1996;50(1):58–71 (95 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

The prevention of radiation-induced small bowel complications. Letschert JG. **Eur J Cancer** 1995 Jul-Aug; 31A(7-8):1361–5 (26 ref.)

THERAPY

[Medical treatment of chronic radiation induced enteritis] Cosnes J. **Ann Chir** 1996;50(1):36–9 (23 ref.) (Eng. Abstr.) **(Fre)**

ENTERITIS, GRANULOMATOUS see CROHN DISEASE

ENTERITIS, PSEUDOMEMBRANOUS see ENTEROCOLITIS, PSEUDOMEMBRANOUS

ENTERITIS, REGIONAL see CROHN DISEASE

ENTEROBACTER

Indications and complications of medicinal leech therapy. Haycox CL, et al. **J Am Acad Dermatol** 1995 Dec; 33(6):1053–5 (10 ref.)

ENTEROBACTERIACEAE

DRUG EFFECTS

In vitro activity of fourth generation cephalosporins against enterobacteriaceae producing extended-spectrum beta-lactamases. Sanders CC. **J Chemother** 1996 Feb;8 Suppl 2:57–62 (26 ref.)

ENZYMOLOGY

Novel plasmid-mediated beta-lactamases in enterobacteriaceae: emerging problems for new beta-lactam antibiotics. Thomson KS, et al. **Curr Clin Top Infect Dis** 1996;16:151–63 (46 ref.)

GENETICS

Genome evolution in enteric bacteria. Ochman H, et al. **Curr Opin Genet Dev** 1995 Dec;5(6):734–8 (40 ref.)
Multidrug resistance in enteric and other gram-negative bacteria. George AM. **FEMS Microbiol Lett** 1996 May 15; 139(1):1–10 (42 ref.)
The catabolite repressor/activator (Cra) protein of enteric bacteria. Saier MH Jr, et al. **J Bacteriol** 1996 Jun; 178(12):3411–7 (46 ref.)
The role of anti-sigma factors in gene regulation. Brown KL, et al. **Mol Microbiol** 1995 May;16(3):397–404 (49 ref.)

METABOLISM

Microcins. Moreno F, et al. **Biotechnology** 1995;28:307–21 (58 ref.)

PHYSIOLOGY

How bacteria sense and swim. Blair DF. **Annu Rev Microbiol** 1995;49:489–522 (197 ref.)

ENTEROBACTERIACEAE INFECTIONS

DRUG THERAPY

Novel plasmid-mediated beta-lactamases in enterobacteriaceae: emerging problems for new beta-lactam antibiotics. Thomson KS, et al. **Curr Clin Top Infect Dis** 1996;16:151–63 (46 ref.)

ETIOLOGY

Indications and complications of medicinal leech therapy. Haycox CL, et al. **J Am Acad Dermatol** 1995 Dec; 33(6):1053–5 (10 ref.)

ENTEROBIASIS

DIAGNOSIS

Pinworms in pregnancy. Hamblin J, et al. **J Am Board Fam Pract** 1995 Jul-Aug;8(4):321–4 (15 ref.)

ENTEROCELE see HERNIA

ENTEROCHROMAFFIN CELLS

PATHOLOGY

The consequences of hypergastrinemia. Creutzfeldt W. **Yale J Biol Med** 1994 May-Aug;67(3-4):181–94 (63 ref.)

PHYSIOLOGY

Neuroendocrine insights from the laboratory to the clinic. Ahlman H, et al. **Am J Surg** 1996 Jul;172(1):61–7 (40 ref.)
The biology and physiology of the ECL cell. Håkanson R, et al. **Yale J Biol Med** 1994 May-Aug;67(3-4):123–34 (50 ref.)

ENTEROCOCCUS

[Enterococci; increase in infection rate and antibiotic resistance] Thompson J. **Ned Tijdschr Geneeskd** 1996 Jan 20;140(3):130–3 (23 ref.) (Eng. Abstr.) **(Dut)**
[Enterococcal endocarditis] Kizner V, et al. **Harefuah** 1996 Apr 15;130(8):548–50 (18 ref.) **(Heb)**
[Enterococcal neonatal endocarditis] Roca Comas A, et al. **An Esp Pediatr** 1996 Feb;44(2):159–60 (17 ref.) **(Spa)**
[Treatment of endocarditis and other severe infections caused by enterococci] Fernández-Guerrero ML. **Enferm Infecc Microbiol Clin** 1996 Mar;14(3):186–91 (74 ref.) **(Spa)**

DRUG EFFECTS

Antibiotic-resistant enterococci and the changing face of surgical infections. de Vera ME, et al. **Arch Surg** 1996 Mar; 131(3):338–42 (59 ref.)
Antibiotic resistance in Enterococcus species: an update. Eliopoulos GM. **Curr Clin Top Infect Dis** 1996;16:21–51 (231 ref.)
Emerging resistance in Enterococcus spp. Heath CH, et al. **Med J Aust** 1996 Jan 15;164(2):116–20 (44 ref.)

ENZYMOLOGY

Beta-lactamase-producing enterococci. Rice LB, et al.

ENTEROCOCCUS

Dev Biol Stand 1995;85:107–14 (33 ref.)

GENETICS

Molecular analysis of enterococcal loci involved in novel catabolic pathways. Claiborne A, et al. **Dev Biol Stand** 1995;85:129–33 (23 ref.)

METABOLISM

Molecular analysis of enterococcal loci involved in novel catabolic pathways. Claiborne A, et al. **Dev Biol Stand** 1995;85:129–33 (23 ref.)

ENTEROCOCCUS FAECALIS

Enterococcal arthritis: case report and review. Raymond NJ, et al. **Clin Infect Dis** 1995 Sep;21(3):516–22 (54 ref.)

DRUG EFFECTS

Antimicrobial-resistant pathogens in the 1990s. Jacoby GA. **Annu Rev Med** 1996;47:169–79 (62 ref.)

GENETICS

The conjugative transposon Tn916 of Enterococcus faecalis: structural analysis and some key factors involved in movement. Clewell DB, et al. **Dev Biol Stand** 1995;85:11–7 (28 ref.)

ISOLATION & PURIFICATION

Enterococcal arthritis with avascular necrosis in a lupus patient. Markov G, et al. **Br J Rheumatol** 1996 Jun; 35(6):595–7 (11 ref.)

Pyogenic liver abscess: warning indicator of silent colonic cancer. Report of a case and review of the literature. Teitz S, et al. **Dis Colon Rectum** 1995 Nov;38(11):1220–3 (18 ref.)

ENTEROCOCCUS FAECIUM

DRUG EFFECTS

Antimicrobial-resistant pathogens in the 1990s. Jacoby GA. **Annu Rev Med** 1996;47:169–79 (62 ref.)

ENTEROCOLITIS

ETIOLOGY

[2 cases of neutropenic enteropathy and bone marrow hypoplasia. An association not reported in Mexico] Gamboa-Dominguez A, et al. **Rev Invest Clin** 1995 Jul-Aug;47(4):303–9 (25 ref.) (Eng. Abstr.) **(Spa)**

ENTEROCOLITIS, NECROTIZING see **ENTEROCOLITIS, PSEUDOMEMBRANOUS**

ENTEROCOLITIS, PSEUDOMEMBRANOUS

Clostridium difficile colitis in the critically ill. Grundfest-Broniatowski S, et al. **Dis Colon Rectum** 1996 Jun;39(6):619–23 (35 ref.)

Pseudomembranous colitis. Ros PR, et al. **Radiology** 1996 Jan;198(1):1–9 (32 ref.)

Necrotizing enterocolitis. Albanese CT, et al. **Semin Pediatr Surg** 1995 Nov;4(4):200–6 (62 ref.)

Antibiotic-induced colitis. Devenyi AG. **Semin Pediatr Surg** 1995 Nov;4(4):215–20 (39 ref.)

CHEMICALLY INDUCED

Albendazole-induced pseudomembranous colitis. Shah V, et al. **Am J Gastroenterol** 1996 Jul;91(7):1453–4 (11 ref.)

COMPLICATIONS

[Pseudomembranous colitis complicated with toxic megacolon. Report of a case] Fernández-Guisasola J, et al. **Rev Esp Anestesiol Reanim** 1995 Nov;42(9):389–91 (44 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Update on diagnosis of Clostridium difficile-associated diarrhea. DeMaio J, et al. **Curr Clin Top Infect Dis** 1995; 15:97–114 (139 ref.)

[Septic abortion in Campylobacter jejuni infection] Abderhalden R, et al. **Geburtshilfe Frauenheilkd** 1995 Oct; 55(10):599–601 (14 ref.) (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

[Epidemiology of Clostridium difficile nosocomial infections] Barbut F, et al. **Presse Med** 1996 Mar 2–9;25(8):385–92 (33 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Increased substance P receptor expression by blood vessels and lymphoid aggregates in Clostridium difficile-induced pseudomembranous colitis. Mantyh CR, et al. **Dig Dis Sci** 1996 Mar;41(3):614–20 (22 ref.)

MICROBIOLOGY

Necrotizing enterocolitis: the search for a unifying pathogenic theory leading to prevention. Neu J. **Pediatr Clin North Am** 1996 Apr;43(2):409–32 (132 ref.)

[Clostridium difficile-associated diarrhea—an increasing problem. Reduce the administration of antibiotics and improve hygiene!] Svenungsson B. **Lakartidningen** 1996 Aug 28;93(35):2931–4 (67 ref.) **(Swe)**

PATHOLOGY

Enterocolitis in infantile common variable immunodeficiency. A case report and review of the literature. John HA, et al. **Dig Dis Sci** 1996 Mar;41(3):621–3 (9 ref.)

PREVENTION & CONTROL

Necrotizing enterocolitis: the search for a unifying pathogenic theory leading to prevention. Neu J. **Pediatr Clin North Am** 1996 Apr;43(2):409–32 (132 ref.)

ENTEROGLUCAGON

see related
GASTROINTESTINAL AGENTS

BLOOD

[Enteroglucagon] Nakano I, et al. **Nippon Rinsho** 1995 Mar; 53 Su Pt 2:656–8 (20 ref.) **(Jpn)**

ENTEROHEPATIC CIRCULATION

PHYSIOLOGY

Motor activity of the gallbladder and gastrointestinal tract as determinants of enterohepatic circulation. A scintigraphic and manometric study. Qvist N. **Dan Med Bull** 1995 Nov;42(5):426–40 (196 ref.)

ENTEROPATHY, EXUDATIVE see **PROTEIN-LOSING ENTEROPATHIES**

ENTEROPATHY, HIV see **HIV ENTEROPATHY**

ENTEROSORPTION

[Enterosorption as a method for prolonging life] Mamal AV, et al. **Fiziol Cheloveka** 1996 May-Jun;22(3):131–5 (32 ref.) **(Rus)**

ENTEROSTOMY

ADVERSE EFFECTS

Parastomal hernia. Martin L, et al. **Ann R Coll Surg Engl** 1996 Mar;78(2):81–4 (31 ref.)

ENTEROTOXINS

BIOSYNTHESIS

[Infections with verocytotoxin-producing Escherichia coli and hemolytic-uremic syndrome] van de Kar NC, et al. **Ned Tijdschr Geneeskd** 1996 Jan 20;140(3):134–7 (22 ref.) (Eng. Abstr.) **(Dut)**

IMMUNOLOGY

Immunoregulatory mechanisms of T-cell-dependent shock induced by a bacterial superantigen in mice. Florquin S, et al. **Infect Immun** 1996 Sep;64(9):3443–5 (31 ref.)

METABOLISM

Role of verotoxin receptors in pathogenesis. Lingwood CA. **Trends Microbiol** 1996 Apr;4(4):147–53 (89 ref.)

PHYSIOLOGY

Enterotoxigenic Bacteroides fragilis. Sears CL, et al. **Clin Infect Dis** 1995 Jun;20 Suppl 2:S142–8 (33 ref.)

ENTEROVIRUS INFECTIONS

Nonpolio enteroviruses and the febrile young infant: epidemiologic, clinical and diagnostic aspects. Dagan R. **Pediatr Infect Dis J** 1996 Jan;15(1):67–71 (41 ref.)

DIAGNOSIS

Fatal enterovirus type 71 infection: rapid detection and diagnostic pitfalls. Landry ML, et al. **Pediatr Infect Dis J** 1995 Dec;14(12):1095–100 (16 ref.)

ENTHESOPATHY see **RHEUMATIC DISEASES**

ENTORHINAL AREA see **ENTORHINAL CORTEX**

ENTORHINAL CORTEX

ANATOMY & HISTOLOGY

Perirhinal and postrhinal cortices of the rat: a review of the neuroanatomical literature and comparison with findings from the monkey brain. Burwell RD, et al. **Hippocampus** 1995;5(5):390–408 (85 ref.)

ENTRAPMENT NEUROPATHY see **NERVE COMPRESSION SYNDROMES**

ENURESIS

Enuresis. Husmann DA. **Urology** 1996 Aug;48(2):184–93 (77 ref.)

DRUG THERAPY

Desmopressin tablet treatment in nocturnal enuresis. Stenberg A, et al. **Scand J Urol Nephrol Suppl** 1995;173:95–9 (9 ref.)

ETIOLOGY

Nocturnal enuresis: a guide to evaluation and treatment. Tietjen DN, et al. **Mayo Clin Proc** 1996 Sep;71(9):857–62 (30 ref.)

THERAPY

Nocturnal enuresis: a guide to evaluation and treatment. Tietjen DN, et al. **Mayo Clin Proc** 1996 Sep;71(9):857–62 (30 ref.)

Behavioural treatment for enuresis. Houts AC. **Scand J Urol Nephrol Suppl** 1995;173:83–6; discussion 87 (14 ref.)

Predicting treatment outcome with conditioning alarms. Moffatt ME, et al. **Scand J Urol Nephrol Suppl** 1995; 173:119–22 (12 ref.)

ENV GENE PRODUCTS see **GENE PRODUCTS, ENV**

ENV-ONC FUSION PROTEIN see **ONCOGENE PROTEINS, FUSION**

ENV POLYPROTEINS see **GENE PRODUCTS, ENV**

ENV PROTEIN see **GENE PRODUCTS, ENV**

ENV PROTEIN GP120, HIV see **HIV ENVELOPE PROTEIN GP120**

ENVELOPE GLYCOPROTEIN GP120, HIV see **HIV ENVELOPE PROTEIN GP120**

ENVELOPE PROTEINS, VIRAL see **VIRAL ENVELOPE PROTEINS**

ENVIRONMENT

see related
SOCIAL ENVIRONMENT

Gene-environment interaction in parkinson's disease. The case of CYP2D6 gene polymorphism. Landi MT, et al. **Adv Neurol** 1996;69:61–72 (80 ref.)

Environmental paradigms: moving toward an ecocentric perspective. Kleffel D. **ANS Adv Nurs Sci** 1996 Jun; 18(4):1–10 (38 ref.)

Smoking and other health related behaviour in the social and environmental context. Logan S, et al. **Arch Dis Child** 1996 Feb;74(2):176–9 (46 ref.)

Alzheimer's disease: genetics or environment? Mera SL. **Br J Biomed Sci** 1996 Jun;53(2):91–2 (8 ref.)

Environmentally-regulated genes of hypertension. Hamet P. **Clin Exp Hypertens** 1996 Apr-May;18(3-4):267–78 (35 ref.)

Etiology, environmental relationships, epidemiology, and genetics of systemic lupus erythematosus. Hess EV, et al. **Curr Opin Rheumatol** 1995 Sep;7(5):371–5 (39 ref.)

Role of environmental signals and transcriptional regulators in neural crest development. Groves AK, et al. **Dev Genet** 1996;18(1):64–72 (82 ref.)

Hereditary and environmental risk factors; clinical and laboratory risk matters for head and neck, especially oral, cancer and precancer. Johnson NW, et al. **Eur J Cancer Prev** 1996 Feb;5(1):5–17 (139 ref.)

Environmental policy and children's health. Landrigan PJ, et al. **Future Child** 1995 Summer-Fall;5(2):34–52 (33 ref.)

Fluid needs in hot and cold environments. Murray R. **Int J Sport Nutr** 1995 Jun;5 Suppl:S62–73 (51 ref.)

Environmental considerations of livestock producers. Morse D. **J Anim Sci** 1995 Sep;73(9):2733–40 (35 ref.)

Evolutionary and environmental influences on human lactation. Prentice AM, et al. **Proc Nutr Soc** 1995 Jul; 54(2):391–400 (25 ref.)

Gene-environment interaction in schizophrenia: season-of-birth effect reveals etiologically different subgroups. Franzek E, et al. **Psychopathology** 1996; 29(1):14–26 (129 ref.)

Environmental considerations of disinfectants used in agriculture. Bruins G, et al. **Rev Sci Tech** 1995 Mar; 14(1):81–94 (15 ref.)

Cloud-to-ground lightning: mechanisms of damage and methods of protection. Krider EP, et al. **Semin Neurol** 1995 Sep;15(3):227–32 (17 ref.)

Aggressive behavior in childhood and early adolescence: an ecological-developmental perspective on youth violence. Fraser MW. **Soc Work** 1996 Jul;41(4):347–61 (120 ref.)

[Infectious diseases from the hygienic viewpoint with special reference to environmental infections—a retrospective and prospective view] Exner M. **Zentralbl Hyg Umweltmed** 1995 Apr;197(1-3):134–61 (79 ref.) (Eng. Abstr.) **(Ger)**

[Mycotic pollution prevention in the indoor environments] Petyx M, et al. **Ann Ig** 1996 Mar-Apr;8(2):305-15 (53 ref.) (Eng. Abstr.) **(Ita)**

[Ecology and thermal parks in the context of the environment. Psychological and possible therapeutic aspects: trends in medicine] Grossi F, et al. **Clin Ter** 1995 Dec;146(12):781-92 (32 ref.) (Eng. Abstr.) **(Ita)**

[Occupational health services in Sweden. II. Internal control of the working environment] Zielińska-Jankiewicz K, et al. **Med Pr** 1996;47(2):189-93 (3 ref.) (Eng. Abstr.) **(Pol)**

[The general concepts of development and the principle of sustainable development] Romanov IuA. **Aviakosm Ekolog Med** 1995;29(3):6-16 (44 ref.) (Eng. Abstr.) **(Rus)**

ENVIRONMENT, CONTROLLED

The potential for use of steam at atmospheric pressure to decontaminate or sterilize parenteral filling lines incorporating barrier isolation technology. Lysfjord JP, et al. **PDA J Pharm Sci Technol** 1995 Sep-Oct;49(5):212-9 (17 ref.)

[Function of the bio-clean room for bone marrow transplantation] Yamayoshi T. **Rinsho Byori** 1995 Jul;Suppl 99:74-83 (22 ref.) **(Jpn)**

ENVIRONMENTAL AIR POLLUTANTS see **AIR POLLUTANTS, ENVIRONMENTAL**

ENVIRONMENTAL EXPOSURE

see related
AIR POLLUTANTS, ENVIRONMENTAL
ENVIRONMENTAL ILLNESS
ENVIRONMENTAL MONITORING
MULTIPLE CHEMICAL SENSITIVITY
OCCUPATIONAL EXPOSURE
PERSIAN GULF SYNDROME

Aerobiologic and clinical aspects of mould allergy in Europe. D'Amato G, et al. **Allergy** 1995 Nov;50(11):870-7 (62 ref.)

Human response to environmental noise. Psychological research and public policy. Staples SL. **Am Psychol** 1996 Feb;51(2):143-50 (95 ref.)

Breast cancer and environmental risk factors: epidemiological and experimental findings. Wolff MS, et al. **Annu Rev Pharmacol Toxicol** 1996;36:573-96 (116 ref.)

Hypothyroidism and spontaneous abortions among Hanford, Washington, downwinders. Grossman CM, et al. **Arch Environ Health** 1996 May-Jun;51(3):175-6 (8 ref.)

Persistent organic pollutants--the state of contamination of ambient air in central Europe. Possible sources and effects. Holoubek I. **Arch Toxicol Suppl** 1996;18:381-90 (10 ref.)

The effects on mammals of pre- and postnatal environmental exposure to PCBS. The Dutch Collaborative PCB/Dioxin Study. Smits-van Prooije AE, et al. **Arch Toxicol Suppl** 1996;18:97-102 (22 ref.)

The neurobehavioural toxicology and teratology of lead. Winneke G, et al. **Arch Toxicol Suppl** 1996;18:57-70 (60 ref.)

Potential role of environmental genotoxic agents in diabetes mellitus and neurodegenerative diseases. Eizirik DL, et al. **Biochem Pharmacol** 1996 Jun 28;51(12):1585-91 (92 ref.)

Consensus statement regarding the HIV "window period". **Can Commun Dis Rep** 1995 Dec 30;21(24):213-5 (4 ref.) **(Eng, Fre)**

Use of biomarkers to investigate occupational and environmental lung disorders. Schulte PA. **Chest** 1996 Mar; 109(3 Suppl):9S-12S (26 ref.)

Evaluating the impact of exposure to environmental contaminants on human health. Silkworth JB, et al. **Clin Chem** 1996 Aug;42(8 Pt 2):1345-9 (34 ref.)

Biochemical principles of metabolic depression. Guppy M, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1994 Oct-Nov;109(2-3):175-89 (108 ref.)

Improving the science and art of risk assessment. Doull J. **Drug Metab Rev** 1996 Feb-May;28(1-2):1-7 (6 ref.)

Hazard evaluation in risk assessment: whatever happened to sound scientific judgment and weight of evidence? Doull J, et al. **Drug Metab Rev** 1996 Feb-May;28(1-2):285-99 (9 ref.)

Biological markers and risk assessment. Goldstein BD. **Drug Metab Rev** 1996 Feb-May;28(1-2):225-33 (12 ref.)

Reducing uncertainty in risk assessment by using specific knowledge to replace default options. McClellan RO. **Drug Metab Rev** 1996 Feb-May;28(1-2):149-79 (64 ref.)

Noncancer risk assessment: reproductive toxicology. Schwetz BA. **Drug Metab Rev** 1996 Feb-May; 28(1-2):77-84 (11 ref.)

Reality versus extrapolation: an academic perspective of cancer risk regulation. Waddell WJ. **Drug Metab Rev** 1996 Feb-May;28(1-2):181-95 (32 ref.)

Design and construction of model stream ecosystems. Rodgers JH Jr, et al. **Ecotoxicol Environ Saf** 1996 Feb; 33(1):30-7 (21 ref.)

Radionuclides in the Great Lakes basin. Ahier BA, et al. **Environ Health Perspect** 1995 Dec;103 Suppl 9:89-101 (41 ref.)

Pulmonary reactions to organic dust exposures: development of an animal model. Castranova V, et al. **Environ Health Perspect** 1996 Mar;104 Suppl 1:41-53 (115 ref.)

Organic halogens in the environment: studies of environmental biodegradability and human exposure. Salkinoja-Salonen M, et al. **Environ Health Perspect** 1995 Jun;103 Suppl 5:63-9 (40 ref.)

Environmental health hazards: how children are different from adults. Bearer CF. **Future Child** 1995 Summer-Fall; 5(2):11-26 (61 ref.)

Case studies of environmental risks to children. Goldman LR. **Future Child** 1995 Summer-Fall;5(2):27-33 (15 ref.)

Quantitative risk assessment and the limitations of the linearized multistage model. Lovell DP, et al. **Hum Exp Toxicol** 1996 Feb;15(2):87-104 (50 ref.)

Is there a dose-response relationship between exposure to indoor allergens and symptoms of asthma? [editorial] Platts-Mills TA, et al. **J Allergy Clin Immunol** 1995 Oct; 96(4):435-40 (44 ref.)

Estimating long-term exposures from short-term measurements. Buck RJ, et al. **J Expo Anal Environ Epidemiol** 1995 Jul-Sep;5(3):359-73 (20 ref.)

Overview of important design issues for a National Human Exposure Assessment Survey. Callahan MA, et al. **J Expo Anal Environ Epidemiol** 1995 Jul-Sep;5(3):257-82 (36 ref.)

Conceptual framework for designing a national survey of human exposure. Lioy PJ, et al. **J Expo Anal Environ Epidemiol** 1995 Jul-Sep;5(3):425-44 (31 ref.)

Informed decisions about protecting and promoting public health: rationale for a National Human Exposure Assessment Survey. Sexton K, et al. **J Expo Anal Environ Epidemiol** 1995 Jul-Sep;5(3):233-56 (52 ref.)

An introduction to the National Human Exposure Assessment Survey (NHEXAS) and related phase I field studies. Sexton K, et al. **J Expo Anal Environ Epidemiol** 1995 Jul-Sep;5(3):229-32 (9 ref.)

Brain tumor and exposure to pesticides in humans: a review of the epidemiologic data. Bohnen NI, et al. **J Neurol Sci** 1995 Oct;132(2):110-21 (93 ref.)

Aluminum toxicokinetics. Exley C, et al. **J Toxicol Environ Health** 1996 Aug 30;48(6):569-84 (64 ref.)

Status and future concerns of clinical and environmental aluminum toxicology. Flaten TP, et al. **J Toxicol Environ Health** 1996 Aug 30;48(6):527-41 (97 ref.)

The ozone hole. Lehmann P. **Med J Aust** 1995 Dec 4-18; 163(11-12):576-8 (7 ref.)

Health risk implications of magnetic field exposures. Wartenberg D. **Mt Sinai J Med** 1995 Oct;62(5):356-9 (12 ref.)

Mutation and mutagenesis in inherited and acquired human disease. The first EEMS Frits Sobels Prize Lecture, Noordwijkerhout, The Netherlands, June 1995. Evans HJ. **Mutat Res** 1996 Apr 13;351(2):89-103 (120 ref.)

Assessment of exposure to environmental pollutants. Coggon D. **Occup Environ Med** 1995 Sep;52(9):562-4 (5 ref.)

Direct and indirect exposure to air pollution. Thron RW. **Otolaryngol Head Neck Surg** 1996 Feb;114(2):281-5 (24 ref.)

Pesticides and children. Reigart JR. **Pediatr Ann** 1995 Dec; 24(12):663-8 (18 ref.)

Hormonal and environmental factors affecting cell proliferation and neoplasia in the mammary gland. Snedeker SM, et al. **Prog Clin Biol Res** 1996;394:211-53 (315 ref.)

EMFs: cutting through the controversy. Wartenberg D. **Public Health Rep** 1996 May-Jun;111(3):204-17 (81 ref.)

Environmental hazards of aluminum to plants, invertebrates, fish, and wildlife. Sparling DW, et al. **Rev Environ Contam Toxicol** 1996;145:1-127 (242 ref.)

Methodology for assessment of exposure to environmental factors in application to epidemiological studies: assessment of exposure to natural ionizing radiation. Akerblom G. **Sci Total Environ** 1995 Jun 16;168(2):155-68 (69 ref.)

Questionnaire based exposure assessment methods. Coggon D. **Sci Total Environ** 1995 Jun 16;168(2):175-8 (8 ref.)

An overview of exposure to, and effects of, petroleum oil and organochlorine pollution in grey seals (Halichoerus grypus). Jenssen BM. **Sci Total Environ** 1996 Jul 16; 186(1-2):109-18 (54 ref.)

Exposure assessment strategies in epidemiological studies of health effects of electric and magnetic fields. Savitz DA. **Sci Total Environ** 1995 Jun 16;168(2):143-53 (41 ref.)

Uncertainty in estimated half-lives of PCBS in humans: impact on exposure assessment. Shirai JH, et al. **Sci Total Environ** 1996 Sep 9;187(3):199-210 (30 ref.)

Environmental effects on human reproduction: the basis for new efforts in eastern Europe. Kulin HE, et al. **Soc Sci Med** 1995 Dec;41(11):1479-86 (36 ref.)

ATSDR evaluation of health effects of chemicals. II. Mirex and chlordecone: health effects, toxicokinetics, human exposure, and environmental fate. Faroon O, et al. **Toxicol Ind Health** 1995;11(6):1-203 (681 ref.)

Environmental factors and respiratory hypersensitivity: experiences from studies in Eastern and Western Europe. Björkstén B. **Toxicol Lett** 1996 Aug;86(2-3):93-8 (17 ref.)

Strategies for use of biological markers of exposure. Henderson RF. **Toxicol Lett** 1995 Dec;82-83:379-83 (9 ref.)

Case studies of the use of biomarkers to assess exposures. Needham LL, et al. **Toxicol Lett** 1995 Dec;82-83:373-8 (14 ref.)

Interaction of environmental chemicals with respiratory sensitization. Van Loveren H, et al. **Toxicol Lett** 1996 Aug; 86(2-3):163-7 (12 ref.)

[Principles of evaluation of public health risk for environmental exposures] Bard D. **Rev Epidemiol Sante Publique** 1995;43(5):423-31 (11 ref.) (Eng. Abstr.) **(Fre)**

[Variations in the degree of protection conferred by BCG: role and implications for heterologous immunity] Moren A. **Rev Epidemiol Sante Publique** 1996 Jun;44(3):290-2 (4 ref.) **(Fre)**

[Biological effects of electromagnetic fields] Shimizu H, et al. **Nippon Eiseigaku Zasshi** 1995 Dec;50(5):919-31 (129 ref.) (Eng. Abstr.) **(Jpn)**

[Combined biological effect of electromagnetic fields and chemical substances (toxic)] Kamedula M, et al. **Med Pr** 1996;47(3):285-92 (20 ref.) (Eng. Abstr.) **(Pol)**

[Glutathione S-transferase as a metabolic biomarker for predisposition to lung neoplasms induced by chemical carcinogens] Lutz W, et al. **Med Pr** 1995;46(5):497-503 (14 ref.) (Eng. Abstr.) **(Pol)**

[Biosensor models based on potentiometric and amperometric transducers for use in medicine, biotechnology, and environmental monitoring (review)] Reshetilov AN. **Prikl Biokhim Mikrobiol** 1996 Jan-Feb;32(1):78-93 (61 ref.) (Eng. Abstr.) **(Rus)**

[Distribution of polycyclic aromatic hydrocarbons in the environment and personal exposure] Šišović A. **Arh Hig Rada Toksikol** 1995 Jun;46(2):243-58 (71 ref.) (Eng. Abstr.) **(Scr)**

ADVERSE EFFECTS

Exposure to domestic cats: risk factor for Pasteurella multocida peritonitis in liver cirrhosis? Koch CA, et al. **Am J Gastroenterol** 1996 Jul;91(7):1447-9 (29 ref.)

Sentinel screening for human immunotoxicity. Descotes J, et al. **Arch Toxicol Suppl** 1996;18:29-33 (13 ref.)

Developmental neurotoxicology in the neonate--effects of pesticides and polychlorinated organic substances. Eriksson P. **Arch Toxicol Suppl** 1996;18:81-8 (26 ref.)

Human health perspectives on environmental exposure to benzidine: a review. Choudhary G. **Chemosphere** 1996 Jan; 32(2):267-91 (80 ref.)

Environmental lung disease: exposures and mechanisms. Brain JD. **Chest** 1996 Mar;109(3 Suppl):74S-78S (14 ref.)

Molecular mechanisms of lung cancer. Interaction of environmental and genetic factors. Giles F. Filley Lecture. Devereux TR, et al. **Chest** 1996 Mar;109(3 Suppl):14S-19S (80 ref.)

Biomarkers in epidemiology. Grandjean P. **Clin Chem** 1995 Dec;41(12 Pt 2):1800-3 (13 ref.)

Biomarkers as tools in human health risk assessment. Greim H, et al. **Clin Chem** 1995 Dec;41(12 Pt 2):1804-8 (13 ref.)

Do environmental estrogens contribute to the decline in male reproductive health? Jensen TK, et al. **Clin Chem** 1995 Dec; 41(12 Pt 2):1896-901 (68 ref.)

Some thoughts about the use and communication of toxicology information. Kennedy GL Jr, et al. **Drug Metab Rev** 1996 Feb-May;28(1-2):235-43 (10 ref.)

Exposure to extremely low frequency electromagnetic fields and the risk of malignant diseases--an evaluation of epidemiological and experimental findings. Hardell L, et al. **Eur J Cancer Prev** 1995 Sep;4 Suppl 1:3-107 (314 ref.)

Occupation- and exposure-related studies on human sperm. Lähdetie J. **J Occup Environ Med** 1995 Aug;37(8):922-30 (92 ref.)

Induction of cytochrome P-450 in the Norway rat, Rattus norvegicus, following exposure to potential environmental contaminants. Nims RW, et al. **J Toxicol Environ Health** 1995 Nov;46(3):271-92 (133 ref.)

Modifiers of non-specific symptoms in occupational and environmental syndromes. Spurgeon A, et al. **Occup Environ Med** 1996 Jun;53(6):361-6 (61 ref.)

Epidemiological studies of sunlight and cataract: the critical factor of ultraviolet exposure geometry [see comments] Sliney DH. **Ophthalmic Epidemiol** 1994 Jun;1(2):107-19 (33 ref.) Comment in: Int J Food Sci Nutr 1994 Jun;1(2):63-5.

Environmental factors influencing the levels of indoor allergens. Munir AK. **Pediatr Allergy Immunol** 1995;6 Suppl 7:13-21 (91 ref.)

Tumor suppressor genes: at the crossroads of molecular carcinogenesis, molecular epidemiology, and human risk assessment. Harris CC. **Prev Med** 1996 Jan-Feb;25(1):10-2 (33 ref.)

Scientific challenges in environmental carcinogenesis. Hoffmann D, et al. **Prev Med** 1996 Jan-Feb;25(1):14-22 (85 ref.)

Can environmental estrogens cause breast cancer? Davis DL, et al. **Sci Am** 1995 Oct;273(4):167-72 (5 ref.)

Trichloroethylene--a review of the literature from a health effects perspective. Gist GL, et al. **Toxicol Ind Health** 1995 May-Jun;11(3):253-307 (470 ref.)

Environmental chemicals relevant for respiratory hypersensitivity: the indoor environment. Becher R, et al. **Toxicol Lett** 1996 Aug;86(2-3):155-62 (47 ref.)

[Biological influences of electromagnetic fields] Kato M. **Hokkaido Igaku Zasshi** 1995 Jul;70(4):551-60 (21 ref.) (Eng. Abstr.) **(Jpn)**

[Subclinical neuro-psychobehavioral effects in occupational, environmental and community health: methodology and

recent findings] Araki S, et al. **Nippon Eiseigaku Zasshi** 1995 Aug;50(3):713–29 (122 ref.) (Eng. Abstr.) **(Jpn)**

[Exposure to mercury and population health. I. Immunotoxicity of mercury] Moszczyński P, et al. **Med Pr** 1995;46(4):385–93 (91 ref.) (Eng. Abstr.) **(Pol)**

ANALYSIS

Biomarkers for Great Lakes priority contaminants: halogenated aromatic hydrocarbons. Feeley MM. **Environ Health Perspect** 1995 Dec;103 Suppl 9:7–16 (106 ref.)

Dermal exposure to environmental contaminants in the Great Lakes. Moody RP, et al. **Environ Health Perspect** 1995 Dec;103 Suppl 9:103–14 (88 ref.)

LEGISLATION & JURISPRUDENCE

Risk proposals of the 103rd Congress. Paxman D. **Drug Metab Rev** 1996 Feb–May;28(1–2):245–67 (18 ref.)

STANDARDS

Stimulating effects of ionizing radiation: new issue for regulatory policy. Jaworowski Z. **Regul Toxicol Pharmacol** 1995 Oct;22(2):172–9 (40 ref.)

STATISTICS & NUMERICAL DATA

Do power frequency magnetic fields cause leukemia in children? Levallois P. **Am J Prev Med** 1995 Jul–Aug; 11(4):263–70 (61 ref.)

The use of geographical information systems in studies on environment and health. Briggs DJ, et al. **World Health Stat Q** 1995;48(2):85–94 (31 ref.)

Health and environment analysis for decision making. Corvalán C, et al. **World Health Stat Q** 1995;48(2):71–7 (16 ref.)

Linkage failures in ecological studies. Nurminen M. **World Health Stat Q** 1995;48(2):78–84 (20 ref.)

ENVIRONMENTAL HEALTH

Surveillance in environmental public health: issues, systems, and sources [see comments] Thacker SB, et al. **Am J Public Health** 1996 May;86(5):633–8 (51 ref.) Comment in: Am J Public Health 1996 May;86(5):624–5. Comment in: Am J Public Health 1996 May;86(5):638–41.

Health effects of outdoor air pollution. Committee of the Environmental and Occupational Health Assembly of the American Thoracic Society. **Am J Respir Crit Care Med** 1996 Jan;153(1):3–50 (578 ref.)

A review of articles published in Aviation, Space, and Environmental Medicine, 1975–94. Rudge FW. **Aviat Space Environ Med** 1995 Oct;66(10):1005–9 (4 ref.)

Environmental change and disease. Tickell C. **Br J Rheumatol** 1995 Dec;34(12):1105–11 (15 ref.)

Ethylenebisdithiocarbamates and ethylenethiourea: possible human health hazards. Houeto P, et al. **Environ Health Perspect** 1995 Jun;103(6):568–73 (102 ref.)

Environmental health and Hispanic children. Metzger R, et al. **Environ Health Perspect** 1995 Sep;103 Suppl 6:25–32 (49 ref.)

Health effects associated with global climate changes: a role for environmental mutagens? Rosenkranz HS. **Environ Mol Mutagen** 1996;27(2):81–3 (39 ref.)

Race, class, and environmental health: a review and systematization of the literature. Brown P. **Environ Res** 1995 Apr;69(1):15–30 (53 ref.)

Environmental health science research and human risk assessment. Olden K, et al. **Mol Carcinog** 1995 Sep;14(1):2–9 (25 ref.)

Hispanic environmental health: ambient and indoor air pollution. National Coalition of Hispanic Health and Human Services Organizations (COSSMHO). **Otolaryngol Head Neck Surg** 1996 Feb;114(2):256–64 (27 ref.)

Environmental health during childhood: pediatrician advocacy. Carlson JE, et al. **Pediatr Ann** 1995 Dec; 24(12):624, 626–8 (19 ref.)

Epidemiological analysis of persistent organochlorine contaminants in cetaceans. Colborn T, et al. **Rev Environ Contam Toxicol** 1996;146:91–172 (247 ref.)

Chlorophenols in the terrestrial environment. Jensen J. **Rev Environ Contam Toxicol** 1996;146:25–51 (95 ref.)

Uranium in the environment: occurrence, transfer, and biological effects. Ribera D, et al. **Rev Environ Contam Toxicol** 1996;146:53–89 (130 ref.)

Gender differences in risk perception: effects differ in stressed vs. non-stressed environments. Greenberg MR, et al. **Risk Anal** 1995 Aug;15(4):503–11 (29 ref.)

NIEHS perspectives on collaboration among government, academia, and industry. Olden K. **Toxicol Lett** 1995 Sep; 79(1–3):287–9 (0 ref.)

Research to strengthen the scientific basis for health risk assessment: a survey of the context and rationale for mechanistically based methods and models. Sexton K, et al. **Toxicology** 1995 Sep 1;102(1–2):3–20 (62 ref.)

[Principles of evaluation of public health risk for environmental exposures] Bard D. **Rev Epidemiol Sante Publique** 1995;43(5):423–31 (11 ref.) (Eng. Abstr.) **(Fre)**

[Epidemiologic research on the environment and health: some methodologic aspects] Hémon D. **Rev Epidemiol Sante Publique** 1995;43(5):395–411 (55 ref.) (Eng. Abstr.) **(Fre)**

[Public health surveillance and the environment] Quénel P. **Rev Epidemiol Sante Publique** 1995;43(5):412–22 (38 ref.) (Eng. Abstr.) **(Fre)**

[Regional and local problems of chemical environmental pollution and health of the population (review of the literature)] Revich BA, et al. **Med Tr Prom Ekol** 1995; (9):23–9 (12 ref.) **(Rus)**

LEGISLATION & JURISPRUDENCE

Risk proposals of the 103rd Congress. Paxman D. **Drug Metab Rev** 1996 Feb–May;28(1–2):245–67 (18 ref.)

Regulatory reform proposals and the public health. Buffler PA, et al. **Environ Health Perspect** 1996 Apr;104(4):356–61 (55 ref.)

STANDARDS

Environmental health issues in prisoner of war camps. Korte DV, et al. **Mil Med** 1995 Oct;160(10):483–6 (24 ref.)

Toxicity testing with communities: microcosms, mesocosms, and whole-system manipulations. Cairns J Jr, et al. **Rev Environ Contam Toxicol** 1996;147:45–69 (97 ref.)

TRENDS

Significance of individual sensitivity to chemicals: elucidation of host susceptibility by use of biomarkers in environmental health research. Cullen MR, et al. **Clin Chem** 1995 Dec; 41(12 Pt 2):1809–13 (21 ref.)

Sensitizing nurses for a changing environmental health role. Tiedje LB, et al. **Public Health Nurs** 1995 Dec;12(6):359–65 (34 ref.)

ENVIRONMENTAL HYPERSENSITIVITY see **ENVIRONMENTAL ILLNESS**

ENVIRONMENTAL ILLNESS

Environmental change and disease. Tickell C. **Br J Rheumatol** 1995 Dec;34(12):1105–11 (15 ref.)

CHEMICALLY INDUCED

Impact of environmental pollution on respiratory sensitization and asthma. Kimber I. **Arch Toxicol Suppl** 1996;18:34–48 (85 ref.)

Evaluating human variability in chemical risk assessment: hazard identification and dose–response assessment for noncancer oral toxicity of trichloroethylene. Barton HA, et al. **Toxicology** 1996 Jul 17;111(1–3):271–87 (83 ref.)

Exposure–response functions in Air Force toxic risk modeling. Philipson LL, et al. **Toxicology** 1996 Jul 17; 111(1–3):239–49 (22 ref.)

Interindividual variations in susceptibility and sensitivity: linking risk assessment and risk management. Preston RJ. **Toxicology** 1996 Jul 17;111(1–3):331–41 (42 ref.)

EPIDEMIOLOGY

Nontraditional epidemiologic approaches in the analysis of gene–environment interaction: case–control studies with no controls! Khoury MJ, et al. **Am J Epidemiol** 1996 Aug 1; 144(3):207–13 (41 ref.)

Obtaining information about susceptibility from the epidemiological literature. Grassman JA. **Toxicology** 1996 Jul 17;111(1–3):253–70 (104 ref.)

ETIOLOGY

Unexplained illness: the mind versus the environment [see comments] Radcliffe MJ, et al. **J R Soc Med** 1995 Dec; 88(12):678–9 (12 ref.) Comment in: J R Soc Med 1996 Mar;89(3):180. Comment in: J R Soc Med 1996 Apr;89(4):238.

GENETICS

Interindividual variations in susceptibility and sensitivity: linking risk assessment and risk management. Preston RJ. **Toxicology** 1996 Jul 17;111(1–3):331–41 (42 ref.)

ENVIRONMENTAL MICROBIOLOGY

Microbial biofilms. Costerton JW, et al. **Annu Rev Microbiol** 1995;49:711–45 (127 ref.)

Environmental virology: from detection of virus in sewage and water by isolation to identification by molecular biology—a trip of over 50 years. Metcalf TG, et al. **Annu Rev Microbiol** 1995;49:461–87 (146 ref.)

Epidemiology of mycobacterial diseases. Portaels F. **Clin Dermatol** 1995 May–Jun;13(3):207–22 (117 ref.)

Luminescence-based systems for detection of bacteria in the environment. Prosser JI, et al. **Crit Rev Biotechnol** 1996; 16(2):157–83 (90 ref.)

Nucleic acids in the environment. Trevors JT. **Curr Opin Biotechnol** 1996 Jun;7(3):331–6 (33 ref.)

Fluorescent probes and flow cytometry: new insights into environmental bacteriology. Porter J, et al. **Cytometry** 1996 Feb 1;23(2):91–6 (74 ref.)

[Allergy to house dust mite: a public health problem] Maroli M, et al. **Ann Ist Super Sanita** 1995;31(3):343–50 (44 ref.) (Eng. Abstr.) **(Ita)**

[Function of the bio-clean room for bone marrow transplantation] Yamayoshi T. **Rinsho Byori** 1995 Jul;Suppl 99:74–83 (22 ref.) **(Jpn)**

ENVIRONMENTAL MONITORING

Applications of electrochemical immunosensors to environmental monitoring. Sadik OA, et al. **Biosens Bioelectron** 1996;11(8):i–xi (32 ref.)

Improving exposure assessment by monitoring human tissues for toxic chemicals. Pirkle JL, et al. **J Expo Anal Environ Epidemiol** 1995 Jul–Sep;5(3):405–24 (33 ref.)

Particulate pollution and health: a review of the Utah valley experience. Pope CA 3rd. **J Expo Anal Environ Epidemiol** 1996 Jan–Mar;6(1):23–34 (19 ref.)

Hemoglobin adducts for in vivo dose monitoring and cancer risk estimation. Törnqvist M, et al. **J Occup Environ Med** 1995 Sep;37(9):1077–85 (41 ref.)

The implications for risk assessment of measuring the relative contribution to exposure from occupation, environment and lifestyle: hemoglobin adducts from amino- and nitro-arenes. Neumann HG, et al. **Toxicol Lett** 1995 Dec; 82–83:771–8 (20 ref.)

[Exposure to mercury and population health. I. Immunotoxicity of mercury] Moszczyński P, et al. **Med Pr** 1995;46(4):385–93 (91 ref.) (Eng. Abstr.) **(Pol)**

[Biological monitoring with regard to parasites] Lonc E, et al. **Wiad Parazytol** 1996;42(1):29–35 (38 ref.) (Eng. Abstr.) **(Pol)**

METHODS

Review: methods of monitoring for process micro-organisms in biotechnology. Crook B. **Ann Occup Hyg** 1996 Jun; 40(3):245–60 (23 ref.)

Plants and animals as biomonitors of heavy metal level in the aquatic ecosystem of the river Danube. Oertel N. **Arch Toxicol Suppl** 1996;18:404–16 (23 ref.)

Molecular techniques and their potential application in monitoring the microbiological quality of indoor air. MacNeil L, et al. **Can J Microbiol** 1995 Aug;41(8):657–65 (69 ref.)

Biomarkers as tools in human health risk assessment. Greim H, et al. **Clin Chem** 1995 Dec;41(12 Pt 2):1804–8 (13 ref.)

Strategy of biological monitoring and setting of biological threshold limits (BAT values) in Germany [see comments] Lehnert G, et al. **Isr J Med Sci** 1995 Sep;31(9):549–57 (23 ref.) Comment in: Isr J Med Sci 1995 Sep;31(9):563–4.

Application of biological monitoring to the diagnosis of poisoning. Ikeda M. **J Toxicol Clin Toxicol** 1995; 33(6):617–23 (32 ref.)

Monitoring of occupational exposure to cytostatic anticancer agents. Sorsa M, et al. **Mutat Res** 1996 Aug 17; 355(1–2):253–61 (58 ref.)

The methodological problems of multinational epidemiological studies with particular reference to carbon black studies. Gardiner K. **Occup Med (Oxf)** 1995 Oct; 45(5):247–55 (39 ref.)

Questionnaire based exposure assessment methods. Coggon D. **Sci Total Environ** 1995 Jun 16;168(2):175–8 (8 ref.)

Validation of a methodology for modelling PCDD and PCDF intake via the foodchain. Eduljee GH, et al. **Sci Total Environ** 1996 Sep 9;187(3):211–29 (36 ref.)

Uncertainty in estimated half-lives of PCBS in humans: impact on exposure assessment. Shirai JH, et al. **Sci Total Environ** 1996 Sep 9;187(3):199–210 (30 ref.)

Monitoring of exposure to air pollution. Williams ML. **Sci Total Environ** 1995 Jun 16;168(2):169–74 (6 ref.)

Exposure to environmental chemicals relevant for respiratory hypersensitivity: European aspects. Sivertsen B, et al. **Toxicol Lett** 1996 Aug;86(2–3):143–53 (23 ref.)

Development and application of non-invasive biomarkers for carcinogen–DNA adduct analysis in occupationally exposed populations. Talaska G, et al. **Toxicology** 1996 Jul 17;111(1–3):207–12 (17 ref.)

[Potential and limitations of neutron activation analysis methods for measuring elements of toxicological and environmental interest] Gallorini M. **Ann Ist Super Sanita** 1995;31(2):239–44 (10 ref.) (Eng. Abstr.) **(Ita)**

STANDARDS

[Quality control for trace elements in occupational and environmental medicine] Morisi G, et al. **Ann Ist Super Sanita** 1995;31(2):245–54 (8 ref.) (Eng. Abstr.) **(Ita)**

[Reference values in biological monitoring of occupational exposure to mutagens and carcinogens] Clonfero E, et al. **G Ital Med Lav** 1994 Jan–Nov;16(1–6):25–9 (43 ref.) (Eng. Abstr.) **(Ita)**

STATISTICS & NUMERICAL DATA

Environmental sampling: a brief review. Anderson-Sprecher R, et al. **J Expo Anal Environ Epidemiol** 1994 Apr–Jun; 4(2):115–31 (49 ref.)

The use of geographical information systems in studies on environment and health. Briggs DJ, et al. **World Health Stat Q** 1995;48(2):85–94 (31 ref.)

Health and environment analysis for decision making. Corvalán C, et al. **World Health Stat Q** 1995;48(2):71–7 (16 ref.)

Linkage failures in ecological studies. Nurminen M. **World Health Stat Q** 1995;48(2):78–84 (20 ref.)

ENVIRONMENTAL POLLUTANTS

see related

CARCINOGENS, ENVIRONMENTAL

Selected new developments in computational chemistry. Darden TA, et al. **Environ Health Perspect** 1996 Mar;104 Suppl 1:69–74 (56 ref.)

Assessment of exposure to environmental pollutants. Coggon D. **Occup Environ Med** 1995 Sep;52(9):562–4 (5 ref.)

Measurements of environmental lead contamination and human exposure. Flegal AR, et al. **Rev Environ Contam Toxicol** 1995;143:1–45 (231 ref.)

Fate and effects of acrolein. Ghilarducci DP, et al. **Rev Environ Contam Toxicol** 1995;144:95–146 (222 ref.)

ADVERSE EFFECTS

Pollutants in breast milk. Rogan WJ. **Arch Pediatr Adolesc Med** 1996 Sep;150(9):981–90 (102 ref.)

Impact of environmental pollution on respiratory sensitization and asthma. Kimber I. **Arch Toxicol Suppl** 1996;18:34–48 (85 ref.)

Human health perspectives on environmental exposure to benzidine: a review. Choudhary G. **Chemosphere** 1996 Jan; 32(2):267–91 (80 ref.)

Organochlorine compounds in relation to breast cancer, endometrial cancer, and endometriosis: an assessment of the biological and epidemiological evidence. Ahlborg UG, et al. **Crit Rev Toxicol** 1995;25(6):463–531 (318 ref.)

Some thoughts about the use and communication of toxicology information. Kennedy GL Jr, et al. **Drug Metab Rev** 1996 Feb–May;28(1–2):235–43 (10 ref.)

Developmental toxicity risk assessment: consensus building, hypothesis formulation, and focused research. Kimmel CA. **Drug Metab Rev** 1996 Feb–May;28(1–2):85–103 (51 ref.)

Possible interrelations among environmental toxicants, amphibian development, and decline of amphibian populations. Carey C, et al. **Environ Health Perspect** 1995 May;103 Suppl 4:13–7 (39 ref.)

Biomarker research in neurotoxicology: the role of mechanistic studies to bridge the gap between the laboratory and epidemiological investigations. Costa LG. **Environ Health Perspect** 1996 Mar;104 Suppl 1:55–67 (187 ref.)

Possible mechanisms of action of environmental contaminants on St. Lawrence beluga whales (Delphinapterus leucas). De Guise S, et al. **Environ Health Perspect** 1995 May;103 Suppl 4:73–7 (78 ref.)

Reproductive effects in birds exposed to pesticides and industrial chemicals. Fry DM. **Environ Health Perspect** 1995 Oct;103 Suppl 7:165–71 (85 ref.)

Organization versus activation: the role of endocrine-disrupting contaminants (EDCs) during embryonic development in wildlife. Guillette LJ Jr, et al. **Environ Health Perspect** 1995 Oct;103 Suppl 7:157–64 (81 ref.)

Green turtle fibropapillomatosis: challenges to assessing the role of environmental cofactors. Herbst LH, et al. **Environ Health Perspect** 1995 May;103 Suppl 4:27–30 (37 ref.)

Pesticides: an important but underused model for the environmental health sciences. Hodgson E, et al. **Environ Health Perspect** 1996 Mar;104 Suppl 1:97–106 (105 ref.)

Defining the role of pollutants in the disruption of reproduction in wildlife. Hose JE, et al. **Environ Health Perspect** 1995 May;103 Suppl 4:87–91 (44 ref.)

Unraveling the chronic toxicity of lead: an essential priority for environmental health. Todd AC, et al. **Environ Health Perspect** 1996 Mar;104 Suppl 1:141–6 (68 ref.)

Neuropsychopathological changes by organophosphorus compounds—a review. Eyer P. **Hum Exp Toxicol** 1995 Nov;14(11):857–64 (76 ref.)

Status and future concerns of clinical and environmental aluminum toxicology. Flaten TP, et al. **J Toxicol Environ Health** 1996 Aug 30;48(6):527–41 (97 ref.)

Cardiovascular effects of environmental chemicals. Taylor AE. **Otolaryngol Head Neck Surg** 1996 Feb;114(2):209–11 (26 ref.)

Vermiculite: a review of the mineralogy and health effects of vermiculite exploitation. Addison J. **Regul Toxicol Pharmacol** 1995 Jun;21(3):397–405 (74 ref.)

Chemistry, toxicology, and human health risk of cyanide compounds in soils at former manufactured gas plant sites. Shifrin NS, et al. **Regul Toxicol Pharmacol** 1996 Apr; 23(2):106–16 (50 ref.)

A case study in avoiding a deadly legacy in developing countries. Lemen RA, et al. **Toxicol Ind Health** 1994 Jan–Apr;10(1–2):59–87 (210 ref.)

Chemicals and proteins as allergens and adjuvants. Kapsenberg ML. **Toxicol Lett** 1996 Aug;86(2–3):79–83 (30 ref.)

The role of the skin in the development of chemical respiratory hypersensitivity. Kimber I. **Toxicol Lett** 1996 Aug;86(2–3):89–92 (29 ref.)

Environmental chemicals and respiratory hypersensitization: a synopsis. Løvik M, et al. **Toxicol Lett** 1996 Aug; 86(2–3):211–22 (20 ref.)

Risk assessment policy for evaluating reproductive system toxicants and the impact of responses on sensitive populations. Briggs GB. **Toxicology** 1996 Jul 17; 111(1–3):305–13 (106 ref.)

Obtaining information about susceptibility from the epidemiological literature. Grassman JA. **Toxicology** 1996 Jul 17;111(1–3):253–70 (104 ref.)

[Environment and reproduction] Gerhard I. **Arch Gynecol Obstet** 1995;257(1–4):239–46 (21 ref.) **(Ger)**

[Environmental pollutants in ovarian cysts] Rixner-Koschade R. **Arch Gynecol Obstet** 1995;257(1–4):117–21 (11 ref.) **(Ger)**

[Relationship between exposure to environmental toxins and motor neuron disease: a case report] Vanacore N, et al. **Med Lav** 1995 Nov–Dec;86(6):522–33 (50 ref.) (Eng. Abstr.) **(Ita)**

[An outline of chloro-organic compound toxicology] Starek A. **Rocz Panstw Zakl Hig** 1996;47(1):1–12 (72 ref.) (Eng. Abstr.) **(Pol)**

[Formaldehyde in the environment and its effect on health] Kalinić N. **Arh Hig Rada Toksikol** 1995 Jun;46(2):259–73 (35 ref.) (Eng. Abstr.) **(Scr)**

ANALYSIS

Environmental analysis. Clement RE, et al. **Anal Chem** 1995 Jun 15;67(12):221R–255R (1269 ref.)

Pollutants in breast milk. Rogan WJ. **Arch Pediatr Adolesc Med** 1996 Sep;150(9):981–90 (102 ref.)

Interdisciplinary "case studies" and training experts for primary prevention of environmentally-born health hazard. Dobrowolski JW. **Arch Toxicol Suppl** 1996;18:391–403 (16 ref.)

Sources of PCDD/PCDF and impact on the environment. Fiedler H. **Chemosphere** 1996 Jan;32(1):55–64 (17 ref.)

Chemical contaminants in human milk: an overview. Sonawane BR. **Environ Health Perspect** 1995 Sep;103 Suppl 6:197–205 (80 ref.)

Childhood cancer: overview of incidence trends and environmental carcinogens. Zahm SH, et al. **Environ Health Perspect** 1995 Sep;103 Suppl 6:177–84 (143 ref.)

Reliability of the determinations of polychlorinated contaminants (biphenyls, dioxins, furans). Horwitz W, et al. **J AOAC Int** 1996 May-Jun;79(3):589–621 (55 ref.)

Derivatization reactions for the determination of amines by gas chromatography and their applications in environmental analysis. Kataoka H. **J Chromatogr A** 1996 May 10;733(1–2):19–34 (178 ref.)

Persistent pesticides in Mexico. Albert LA. **Rev Environ Contam Toxicol** 1996;147:1–44 (85 ref.)

Environmental pollutants in marine mammals from the Norwegian coast and Arctic. Skaare JU. **Sci Total Environ** 1996 Jul 16;186(1–2):25–7 (12 ref.)

Radical intermediates during degradation of lignin-model compounds and environmental pollutants: an electron spin resonance study. Kalyanaraman B. **Xenobiotica** 1995 Jul; 25(7):667–75 (18 ref.)

[Abiotic and biotic transformation of persistent organochlorine compounds in the environment] Struciński P, et al. **Rocz Panstw Zakl Hig** 1995;46(3):279–92 (51 ref.) (Eng. Abstr.) **(Pol)**

[Formaldehyde in the environment and its effect on health] Kalinić N. **Arh Hig Rada Toksikol** 1995 Jun;46(2):259–73 (35 ref.) (Eng. Abstr.) **(Scr)**

[Distribution of polycyclic aromatic hydrocarbons in the environment and personal exposure] Sišović A. **Arh Hig Rada Toksikol** 1995 Jun;46(2):243–58 (71 ref.) (Eng. Abstr.) **(Scr)**

BLOOD

Improving exposure assessment by monitoring human tissues for toxic chemicals. Pirkle JL, et al. **J Expo Anal Environ Epidemiol** 1995 Jul–Sep;5(3):405–24 (33 ref.)

ISOLATION & PURIFICATION

Microbial mobilization and immobilization of heavy metals. Unz RF, et al. **Curr Opin Biotechnol** 1996 Jun;7(3):307–10 (35 ref.)

METABOLISM

Metallothionein research in terrestrial invertebrates: synopsis and perspectives. Dallinger R. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1996 Feb;113(2):125–33 (48 ref.)

Environmental processes mediated by iron-reducing bacteria. Fredrickson JK, et al. **Curr Opin Biotechnol** 1996 Jun; 7(3):287–94 (48 ref.)

Anaerobic biodegradation of hydrocarbons. Holliger C, et al. **Curr Opin Biotechnol** 1996 Jun;7(3):326–30 (40 ref.)

Intrinsic bioremediation: an environmental restoration technology. Hooker BS, et al. **Curr Opin Biotechnol** 1996 Jun;7(3):317–20 (26 ref.)

Biodegradation of chlorinated aliphatic compounds. Leisinger T. **Curr Opin Biotechnol** 1996 Jun;7(3):295–300 (51 ref.)

Aerobic and anaerobic PCB biodegradation in the environment. Abramowicz DA. **Environ Health Perspect** 1995 Jun;103 Suppl 5:97–9 (27 ref.)

Organic halogens in the environment: studies of environmental biodegradability and human exposure. Salkinoja-Salonen M, et al. **Environ Health Perspect** 1995 Jun;103 Suppl 5:63–9 (40 ref.)

Recruitment of co-metabolic enzymes for environmental detoxification of organohalides. Wackett LP. **Environ Health Perspect** 1995 Jun;103 Suppl 5:45–8 (20 ref.)

A mechanistic approach to deriving quantitative structure-activity relationship models for microbial degradation of organic compounds. Damborský J. **SAR QSAR Environ Res** 1996;5(1):27–36 (57 ref.)

PHARMACOKINETICS

Microbial mobilization and immobilization of heavy metals. Unz RF, et al. **Curr Opin Biotechnol** 1996 Jun;7(3):307–10 (35 ref.)

Pharmacokinetics and molecular detoxication. Cashman JR, et al. **Environ Health Perspect** 1996 Mar;104 Suppl 1:23–40 (143 ref.)

Plant genetic engineering may help with environmental cleanup. Raskin I. **Proc Natl Acad Sci U S A** 1996 Apr 16;93(8):3164–6 (32 ref.)

Use of physiologically based pharmacokinetic modeling to investigate individual versus population risk. Clewell HJ 3rd, et al. **Toxicology** 1996 Jul 17;111(1–3):315–29 (107 ref.)

Phenotypic variation in xenobiotic metabolism and adverse environmental response: focus on sulfur-dependent detoxification pathways. McFadden SA. **Toxicology** 1996 Jul 17;111(1–3):43–65 (145 ref.)

POISONING

Biomarkers and pediatric environmental health. Lubin B, et al. **Environ Health Perspect** 1995 Sep;103 Suppl 6:99–104 (25 ref.)

Behavioral toxicology. Needleman HL. **Environ Health Perspect** 1995 Sep;103 Suppl 6:77–9 (15 ref.)

Environmental poisoning of children—lessons from the past. Rogan WJ. **Environ Health Perspect** 1995 Sep;103 Suppl 6:19–23 (29 ref.)

The concern for developmental neurotoxicology: is it justified and what is being done about it? Tilson HA. **Environ Health Perspect** 1995 Sep;103 Suppl 6:147–51 (31 ref.)

Comparison of four human studies of perinatal exposure to methylmercury for use in risk assessment. Cicmanec JL. **Toxicology** 1996 Jul 17;111(1–3):157–62 (11 ref.)

TOXICITY

Noncancer risk assessment: reproductive toxicology. Schwetz BA. **Drug Metab Rev** 1996 Feb–May; 28(1–2):77–84 (11 ref.)

How are children different from adults? Bearer CF. **Environ Health Perspect** 1995 Sep;103 Suppl 6:7–12 (76 ref.)

The role of nutrition in mitigating environmental insults: policy and ethical issues. Hu H, et al. **Environ Health Perspect** 1995 Sep;103 Suppl 6:185–90 (56 ref.)

Looking for causes of neural tube defects: where does the environment fit in? Sever LE. **Environ Health Perspect** 1995 Sep;103 Suppl 6:165–71 (57 ref.)

Toxicity of endogenous and environmental estrogens: what is the role of elemental interactions? Stancel GM, et al. **Environ Health Perspect** 1995 Oct;103 Suppl 7:29–33 (48 ref.)

Application of biologic markers to studies of environmental risks in children and the developing fetus. Whyatt RM, et al. **Environ Health Perspect** 1995 Sep;103 Suppl 6:105–10 (66 ref.)

Inorganic mercury. Von Burg R. **J Appl Toxicol** 1995 Nov-Dec;15(6):483–93 (135 ref.)

Endotoxins in the environment. Rylander R. **Prog Clin Biol Res** 1995;392:79–90 (63 ref.)

Holistic risk assessment: an emerging process for environmental decisions. Harvey T, et al. **Regul Toxicol Pharmacol** 1995 Oct;22(2):110–7 (62 ref.)

Ectoxicology of chlorpyrifos. Barron MG, et al. **Rev Environ Contam Toxicol** 1995;144:1–93 (337 ref.)

U.S. EPA regulatory perspectives on the use of QSAR for new and existing chemical evaluations. Zeeman M, et al. **SAR QSAR Environ Res** 1995;3(3):179–201 (48 ref.)

Review of the multiple chemical exposure factors which may disturb human behavioral development. Liu G, et al. **Soz Praventivmed** 1995;40(4):209–17 (69 ref.)

Predictive testing for respiratory sensitisation. Pauluhn J. **Toxicol Lett** 1996 Aug;86(2–3):177–85 (17 ref.)

Use of physiologically based pharmacokinetic modeling to investigate individual versus population risk. Clewell HJ 3rd, et al. **Toxicology** 1996 Jul 17;111(1–3):315–29 (107 ref.)

Human interindividual variability in susceptibility to toxic effects: from annoying detail to a central determinant of risk. Hattis D. **Toxicology** 1996 Jul 17;111(1–3):5–14 (37 ref.)

ENVIRONMENTAL POLLUTION

Tinkering with the tinkerer: pollution versus evolution. Fox GA. **Environ Health Perspect** 1995 May;103 Suppl 4:93–100 (84 ref.)

ENVIRONMENTAL POLLUTION

An introduction to the National Human Exposure Assessment Survey (NHEXAS) and related phase I field studies. Sexton K, et al.
J Expo Anal Environ Epidemiol 1995 Jul–Sep;5(3):229–32 (9 ref.)

Hospitals and plastics. Dioxin prevention and medical waste incinerators. Thornton J, et al. **Public Health Rep** 1996 Jul–Aug;111(4):299–313 (121 ref.)

Risk assessment and research: an essential link. Vandenberg JJ. **Toxicol Lett** 1995 Sep;79(1–3):17–22 (11 ref.)

[Is the risk of leukemia increased for children near nuclear installations?] Auvinen A. **Duodecim** 1994;110(5):479–86 (39 ref.) **(Fin)**

[Regional and local problems of chemical environmental pollution and health of the population (review of the literature)] Revich BA, et al. **Med Tr Prom Ekol** 1995; (9):23–9 (12 ref.) **(Rus)**

ADVERSE EFFECTS

Environmentally Induced Alterations in Development: a Focus on Wildlife. Proceedings of a meeting. Racine, Wisconsin, December 10–12, 1993.
Environ Health Perspect 1995 May;103 Suppl 4:1–100 (0 ref.)

Environment and the genitourinary tract. Droller MJ.
Otolaryngol Head Neck Surg 1996 Feb;114(2):248–52 (37 ref.)

Environmental factors and respiratory hypersensitivity: the Americas. Bascom R. **Toxicol Lett** 1996 Aug; 86(2–3):115–30 (28 ref.)

ANALYSIS

[Biological monitoring with regard to parasites] Lonc E, et al. **Wiad Parazytol** 1996;42(1):29–35 (38 ref.) (Eng. Abstr.) **(Pol)**

LEGISLATION & JURISPRUDENCE

Holistic risk assessment: an emerging process for environmental decisions. Harvey T, et al.
Regul Toxicol Pharmacol 1995 Oct;22(2):110–7 (62 ref.)

U.S. EPA regulatory perspectives on the use of QSAR for new and existing chemical evaluations. Zeeman M, et al. **SAR QSAR Environ Res** 1995;3(3):179–201 (48 ref.)

STATISTICS & NUMERICAL DATA

Health and environment analysis for decision making. Corvalán C, et al. **World Health Stat Q** 1995;48(2):71–7 (16 ref.)

ENVIRONMENTAL POLLUTION, TOBACCO SMOKE see **TOBACCO SMOKE POLLUTION**

ENVIRONMENTAL PROTECTION AGENCY (U.S.) see **UNITED STATES ENVIRONMENTAL PROTECTION AGENCY**

ENZOOTIC BOVINE LEUKOSIS

IMMUNOLOGY

Role of cell–mediated immunity in bovine leukemia virus (BLV) infection in ruminants: its implication for the vaccination strategy against retroviruses. Sugimoto M, et al. **Ther Immunol** 1994 Oct;1(5):297–301 (30 ref.)

ENZOOTIC ENCEPHALOMYELITIS VIRUS see **BORNA DISEASE VIRUS**

ENZYME ACTIVATION

DRUG EFFECTS

Stimulation of enzyme activity by oxovanadium complexes. Stankiewicz PJ, et al. **Met Ions Biol Syst** 1995;31:249–85 (158 ref.)

ENZYME IMMUNOASSAY see **IMMUNOENZYME TECHNIQUES**

ENZYME INDUCTION

DRUG EFFECTS

Chemoprotection against cancer by phase 2 enzyme induction. Talalay P, et al. **Toxicol Lett** 1995 Dec; 82–83:173–9 (36 ref.)

ENZYME INHIBITORS

Finasteride: a clinical review. Gormley GJ.
Biomed Pharmacother 1995;49(7–8):319–24 (36 ref.)

Regulation of sex–specific formation of oestrogen in brain development: endogenous inhibitors of aromatase. Hutchison JB, et al. **J Steroid Biochem Mol Biol** 1996 Jan; 56(1–6 Spec No):201–7 (37 ref.)

Mycophenolate mofetil: a report of the consensus panel. Shaw LM, et al. **Ther Drug Monit** 1995 Dec;17(6):690–9 (27 ref.)

[Advances in the research on tyrosine protein kinase inhibitors] Pang SH, et al. **Yao Hsueh Hsueh Pao** 1996; 31(1):75–80 (43 ref.) **(Chi)**

[Regulation of the cell cycle--involvement of protein inhibitors of cyclin–dependent kinases]
Grzelakowska–Sztabert B. **Postepy Biochem** 1995; 41(2):80–93 (161 ref.) **(Pol)**

ADVERSE EFFECTS

Vigabatrin–associated reversible acute psychosis in a child. Cánovas Martínez A, et al. **Ann Pharmacother** 1995 Nov; 29(11):1115–7 (10 ref.)

Therapy–related acute leukemia associated with t(11q23) after primary acute myeloid leukemia with t(8;21): a report of two cases [letter] Roulston D, et al. **Blood** 1995 Nov 1;86(9):3613–4 (7 ref.)

Contact dermatitis due to imidazole antimycotics. Guidetti MS, et al. **Contact Dermatitis** 1995 Oct;33(4):282 (5 ref.)

[Osteitis secondary to toxic dermatitis caused by hydroxyurea. Apropos ofa case, review of the literature (letter)] Mounier N, et al. **Ann Med Interne (Paris)** 1995; 146(8):590–1 (14 ref.) **(Fre)**

CHEMISTRY

Recent advances in Annonaceous acetogenins. Zeng L, et al. **Nat Prod Rep** 1996 Aug;13(4):275–306 (177 ref.)

IMMUNOLOGY

[Digoxin–like immunoreactive factors. Review of the literature] Ozzola G, et al. **Minerva Med** 1995 Nov; 86(11):475–80 (42 ref.) (Eng. Abstr.) **(Ita)**

ISOLATION & PURIFICATION

Isolation and biological activities of signal transduction inhibitors from microorganisms and plants. Umezawa K. **Adv Enzyme Regul** 1995;35:43–53 (35 ref.)

METABOLISM

Genetic alterations of cyclins, cyclin–dependent kinases, and Cdk inhibitors in human cancer. Hall M, et al.
Adv Cancer Res 1996;68:67–108 (219 ref.)

Protein phosphatase regulation by endogenous inhibitors. Shenolikar S. **Semin Cancer Biol** 1995 Aug;6(4):219–27 (60 ref.)

Ornithine decarboxylase antizyme: a novel type of regulatory protein. Hayashi S, et al. **Trends Biochem Sci** 1996 Jan; 21(1):27–30 (47 ref.)

[Endogenous digitalis–like substance. I. Basic characteristics] Martinka E. **Vnitr Lek** 1995 Sep;41(9):637–43 (31 ref.) (Eng. Abstr.) **(Slo)**

PHARMACOKINETICS

Application of saliva for drug monitoring. An in vivo model for transmembrane transport. Haeckel R, et al.
Eur J Clin Chem Clin Biochem 1996 Mar;34(3):171–91 (179 ref.)

PHARMACOLOGY

Isolation and biological activities of signal transduction inhibitors from microorganisms and plants. Umezawa K. **Adv Enzyme Regul** 1995;35:43–53 (35 ref.)

Proton pump inhibitors: new drugs and indications. Mears JM, et al. **Am Fam Physician** 1996 Jan;53(1):285–92 (38 ref.)

Regulation and inhibition of steroid sulfatase activity in breast cancer. Purohit A, et al. **Ann N Y Acad Sci** 1996 Apr 30; 784:40–9 (28 ref.)

Folate–based thymidylate synthase inhibitors as anticancer drugs. Jackman AL, et al. **Ann Oncol** 1995 Nov;6(9):871–81 (84 ref.)

Discovery, biosynthesis, and mechanism of action of the zaragozic acids: potent inhibitors of squalene synthase. Bergstrom JD, et al. **Annu Rev Microbiol** 1995;49:607–39 (80 ref.)

SRC as a target for anti–cancer drugs. Levitzki A.
Anticancer Drug Des 1996 Apr;11(3):175–82 (45 ref.)

Human DNA topoisomerase II: biochemistry and role in chemotherapy resistance (review). Withoff S, et al.
Anticancer Res 1996 Jul–Aug;16(4A):1867–80 (184 ref.)

Topical beta–adrenergic antagonists and quinidine. A risky interaction [editorial] Higginbotham EJ.
Arch Ophthalmol 1996 Jun;114(6):745–6 (7 ref.)

Selective pharmacological inhibition of distinct nitric oxide synthase isoforms. Southan GJ, et al.
Biochem Pharmacol 1996 Feb 23;51(4):383–94 (131 ref.)

Do telomerase antagonists represent a novel anti–cancer strategy? [editorial] Parkinson EK. **Br J Cancer** 1996 Jan; 73(1):1–4 (47 ref.)

DNA topoisomerase inhibitors. Capranico G, et al.
Cancer Chemother Biol Response Modif 1996;16:68–87 (94 ref.)

The mechanism of alpha–glucosidase inhibition in the management of diabetes. Bischoff H. **Clin Invest Med** 1995 Aug;18(4):303–11 (31 ref.)

Ribonucleotide reductase inhibitors: new strategies for cancer chemotherapy. Nocentini G. **Crit Rev Oncol Hematol** 1996 Mar;22(2):89–126 (335 ref.)

Inhibitors of protein tyrosine kinases. Fry DW, et al.
Curr Opin Biotechnol 1995 Dec;6(6):662–7 (37 ref.)

Inhibitors of serine/threonine kinases. Lee JC, et al.
Curr Opin Biotechnol 1995 Dec;6(6):657–61 (35 ref.)

Glycosylation inhibitors in biology and medicine. Jacob GS.
Curr Opin Struct Biol 1995 Oct;5(5):605–11 (44 ref.)

Heterocyclic betaines containing pi–deficient and pi–excessive moieties. Synthetic and biological aspects. Alcalde E, et al. **Farmaco** 1996 Jun;51(6):381–93 (51 ref.)

Mechanisms of resistance to topoisomerases poisons. Prost S. **Gen Pharmacol** 1995 Dec;26(8):1673–84 (88 ref.)

Newer penicillins and beta–lactamase inhibitors. Bush LM, et al. **Infect Dis Clin North Am** 1995 Sep;9(3):653–86 (154 ref.)

Beta–lactam/beta–lactamase inhibitor combinations: development, antibacterial activity and clinical applications. Sutherland R. **Infection** 1995 Jul–Aug; 23(4):191–200 (49 ref.)

Regulation of blood pressure by nitroxidergic nerve. Toda N. **J Diabetes Complications** 1995 Oct–Dec;9(4):200–2 (21 ref.)

Inhibition of phosphate–metabolizing enzymes by oxovanadium(V) complexes. Stankiewicz PJ, et al.
Met Ions Biol Syst 1995;31:287–324 (169 ref.)

Nitric oxide synthase, immunophilins and poly(ADP–ribose) synthetase: novel targets for the development of neuroprotective drugs. Zhang J, et al. **Neurol Res** 1995 Aug;17(4):285–8 (37 ref.)

NO honey, I don't remember. Hawkins RD. **Neuron** 1996 Mar;16(3):465–7 (18 ref.)

The effects of NMDA receptor antagonists and nitric oxide synthase inhibitors on opioid tolerance and withdrawal. Medication development issues for opiate addiction. Herman BH, et al. **Neuropsychopharmacology** 1995 Dec; 13(4):269–93 (165 ref.)

Perspectives on the N–methyl–D–aspartate/nitric oxide cascade and opioid tolerance. Pasternak GW, et al.
Neuropsychopharmacology 1995 Dec;13(4):309–13 (24 ref.)

Nitric oxide synthase inhibitors. Preclinical studies of potential use for treatment of opioid withdrawal. Vaupel DB, et al. **Neuropsychopharmacology** 1995 Dec; 13(4):315–22 (27 ref.)

P450 inhibitors of use in medical treatment: focus on mechanisms of action. Vanden Bossche H, et al.
Pharmacol Ther 1995;67(1):79–100 (155 ref.)

Endogenous sodium pump inhibition: current status and therapeutic opportunities. Hollenberg NK, et al.
Prog Drug Res 1996;46:9–42 (116 ref.)

Diabetes complications: why is glucose potentially toxic? [see comments] Porte D Jr, et al. **Science** 1996 May 3; 272(5262):699–700 (12 ref.) Comment in: Science 1996 May 3;272(5262):728–31.

Preclinical evaluation of CPT–11 and its active metabolite SN–38. Lavelle F, et al. **Semin Oncol** 1996 Feb;23(1 Suppl 3):11–20 (44 ref.)

Mechanism of action of mycophenolate mofetil. Ransom JT.
Ther Drug Monit 1995 Dec;17(6):681–4 (14 ref.)

Inositol monophosphatase--a putative target for Li+ in the treatment of bipolar disorder. Atack JR, et al.
Trends Neurosci 1995 Aug;18(8):343–9 (97 ref.)

[Inhibitors of protein–tyrosine kinases: pharmacological perspectives? (editorial)] Jacquemin–Sablon A, et al.
Pathol Biol (Paris) 1995 May;43(5):389–94 (66 ref.) **(Fre)**

[The ribonucleotide reductase enzyme as a target for enzyme–directed chemotherapy effects of trimidox (3,4,5–trihydroxybenzohydroxamidoxim), a new inhibitor of ribonucleotide reductases] Findenig G, et al.
Wien Klin Wochenschr 1995;107(22):694–7 (28 ref.) (Eng. Abstr.) **(Ger)**

THERAPEUTIC USE

Review article: the continuing development of proton pump inhibitors with particular reference to pantoprazole. Huber R, et al. **Aliment Pharmacol Ther** 1995 Aug;9(4):363–78 (59 ref.)

Aromatase inhibitors: current status. Ibrahim NK, et al.
Am J Clin Oncol 1995 Oct;18(5):407–17 (142 ref.)

Interactions with hydroxymethylglutaryl–coenzyme A reductase inhibitors. Garnett WR.
Am J Health Syst Pharm 1995 Aug 1;52(15):1639–45 (44 ref.)

Signal transduction interception as a novel approach to disease management. Levitzki A. **Ann N Y Acad Sci** 1995 Sep 7;766:363–8 (22 ref.)

Comparative evaluation of the safety and efficacy of HMG–CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia [see comments] Hsu I, et al. **Ann Pharmacother** 1995 Jul–Aug; 29(7–8):743–59 (114 ref.) Comment in: Ann Pharmacother 1995 Dec;29(12):1304.

Comparative role of omeprazole in the treatment of gastroesophageal reflux disease. Skoutakis VA, et al.
Ann Pharmacother 1995 Dec;29(12):1252–62 (64 ref.)

Human DNA topoisomerase II: biochemistry and role in chemotherapy resistance (review). Withoff S, et al.
Anticancer Res 1996 Jul–Aug;16(4A):1867–80 (184 ref.)

The role of inhibitors of poly(ADP–ribose) polymerase as resistance–modifying agents in cancer therapy. Griffin RJ, et al. **Biochimie** 1995;77(6):408–22 (84 ref.)

Potential for protein kinase C inhibitors in cancer therapy. Philip PA, et al. **Cancer Treat Res** 1995;78:3–27 (156 ref.)

Clinical experience with acarbose as first line therapy in NIDDM. Fölsch UR. **Clin Invest Med** 1995 Aug; 18(4):312–7 (28 ref.)

Statin therapy in clinical practice: new developments. Shepherd J. **Curr Opin Lipidol** 1995 Oct;6(5):254–5 (13 ref.)

Benign prostatic hyperplasia: pathophysiology and

pharmacological treatment. Madsen FA, et al. **Curr Opin Nephrol Hypertens** 1995 Sep;4(5):455–9 (23 ref.)
Treatment of Gaucher disease with an enzyme inhibitor. Radin NS. **Glycoconj J** 1996 Apr;13(2):153–7 (22 ref.)
Development of inhibitors of protein farnesylation as potential chemotherapeutic agents. Kohl NE, et al. **J Cell Biochem Suppl** 1995;22:145–50 (29 ref.)
Ornithine decarboxylase as a target for chemoprevention. Pegg AE, et al. **J Cell Biochem Suppl** 1995;22:132–8 (41 ref.)
Cancer prevention with dehydroepiandrosterone and non-androgenic structural analogs. Schwartz AG, et al. **J Cell Biochem Suppl** 1995;22:210–7 (58 ref.)
Inhibitors of cyclin-dependent kinase and cancer. Biggs JR, et al. **J Mol Med** 1995 Oct;73(10):509–14 (58 ref.)
P450-dependent enzymes as targets for prostate cancer therapy. De Coster R, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1–6 Spec No):133–43 (101 ref.)
The control and biological importance of intratumoural aromatase in breast cancer. Dowsett M, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1–6 Spec No):145–50 (22 ref.)
The effect of finasteride on prostate specific antigen: review of available data. Guess HA, et al. **J Urol** 1996 Jan; 155(1):3–9 (33 ref.)
Dual inhibitors of enkephalin-degrading enzymes (neutral endopeptidase 24.11 and aminopeptidase N) as potential new medications in the management of pain and opioid addiction. Roques BP, et al. **NIDA Res Monogr** 1995; 147:104–45 (149 ref.)
First clinical studies with orlistat: a short review. Drent ML, et al. **Obes Res** 1995 Nov;3 Suppl 4:623S–625S (6 ref.)
Role of xanthine oxidase and its inhibitor in hypoxia: reoxygenation injury. Saugstad OD. **Pediatrics** 1996 Jul; 98(1):103–7 (83 ref.)
5alpha-reductase inhibitors/finasteride. Stoner E. **Prostate Suppl** 1996;6:82–7 (28 ref.)
CPT-11: clinical experience in phase I studies. Armand JP. **Semin Oncol** 1996 Feb;23(1 Suppl 3):27–33 (22 ref.)
CPT-11: an original spectrum of clinical activity. Rothenberg ML. **Semin Oncol** 1996 Feb;23(1 Suppl 3):21–6 (38 ref.)
CPT-11 in the treatment of colorectal cancer: clinical efficacy and safety profile. Rougier P, et al. **Semin Oncol** 1996 Feb;23(1 Suppl 3):34–41 (35 ref.)
Inositol monophosphatase--a putative target for Li+ in the treatment of bipolar disorder. Atack JR, et al. **Trends Neurosci** 1995 Aug;18(8):343–9 (97 ref.)
[Medical treatment of benign hypertrophy of the prostate] Bensadoun H. **Presse Med** 1995 Oct 28;24(32):1485–9 (16 ref.) (Eng. Abstr.) **(Fre)**
[The effect of 5-alpha-reductase inhibitors on benign prostatic hyperplasia] Djavan B, et al. **Wien Med Wochenschr** 1996;146(8):165–8 (21 ref.) (Eng. Abstr.) **(Ger)**

ENZYME-LABELED ANTIBODY TECHNIQUE see **IMMUNOENZYME TECHNIQUES**

ENZYME-LINKED IMMUNOSORBENT ASSAY

[Application of enzyme-linked immunosorbent assay (ELISA) to the medico-legal identification] Komuro T, et al. **Nippon Rinsho** 1995 Sep;53(9):2322–9 (13 ref.) (Eng. Abstr.) **(Jpn)**
[ELISA for diagnosis of infections by viruses] Yoshihara N. **Nippon Rinsho** 1995 Sep;53(9):2277–82 (12 ref.) (Eng. Abstr.) **(Jpn)**

METHODS

[Detection of bacterial protein toxins by a bead-ELISA] Kurazono H, et al. **Nippon Rinsho** 1995 Sep;53(9):2296–300 (11 ref.) (Eng. Abstr.) **(Jpn)**

ENZYME MAPPING, RESTRICTION see **RESTRICTION MAPPING**

ENZYME PRECURSORS

CHEMISTRY

The bifunctional cytochrome c reductase/processing peptidase complex from plant mitochondria. Braun HP, et al. **J Bioenerg Biomembr** 1995 Aug;27(4):423–36 (110 ref.)

DEFICIENCY

Syk deficiency--a knockout for B-cell development. Harnett M. **Immunol Today** 1996 Jan;17(1):4 (6 ref.)

METABOLISM

Regulation of utero-placental prorenin. Poisner AM. **Adv Exp Med Biol** 1995;377:411–26 (96 ref.)
[A new serine protease zymogen activated by components of the fungal cell wall] Muta T. **Seikagaku** 1995 Aug; 67(8):1032–6 (15 ref.) **(Jpn)**

PHYSIOLOGY

The pathophysiology of ovarian hyperstimulation syndrome (OHSS). A proposal role of the ovarian derived prorenin to angiotensin cascade (ODPAC). Morris RS, et al. **Adv Exp Med Biol** 1995;377:391–8 (37 ref.)
Relevance of the tissue prorenin-renin-angiotensin system to male reproductive physiology. Mukhopadhyay AK, et al. **Adv Exp Med Biol** 1995;377:269–77 (47 ref.)
Evidence for cardiovascular effects of prorenin. Sealey JE. **J Hum Hypertens** 1995 Jun;9(6):381–4 (32 ref.)
The Syk/ZAP-70 protein tyrosine kinase connection to antigen receptor signalling processes. van Oers NS, et al. **Semin Immunol** 1995 Aug;7(4):227–36 (71 ref.)

ENZYME STABILITY

Engineering thermostability: lessons from thermophilic proteins. Russell RJ, et al. **Curr Opin Biotechnol** 1995 Aug; 6(4):370–4 (22 ref.)
Engineering enzymes for stability. Shaw A, et al. **Curr Opin Struct Biol** 1996 Aug;6(4):546–50 (45 ref.)

ENZYME TESTS

[Use of urinary enzymes in diagnostic follow-up in kidney transplantation] Jovanović SD. **Med Pregl** 1995; 48(5–6):163–6 (21 ref.) (Eng. Abstr.) **(Scr)**

ENZYMES

[Molecular pharmacological and toxicological studies of drug-metabolizing enzymes] Kato R. **Yakugaku Zasshi** 1995 Sep;115(9):661–80 (94 ref.) (Eng. Abstr.) **(Jpn)**

ADMINISTRATION & DOSAGE

[Enzyme tableting--questions on administration and stability] Schulz B, et al. **Pharmazie** 1995 Aug;50(8):519–24 (78 ref.) **(Ger)**

ADVERSE EFFECTS

Fibrosing colonopathy: recent advances. Dodge JA. **J R Soc Med** 1996;89 Suppl 27:19–23 (18 ref.)

BIOSYNTHESIS

Bioproduction of human enzymes in transgenic tobacco. Cramer CL, et al. **Ann N Y Acad Sci** 1996 May 25; 792:62–71 (50 ref.)

CHEMISTRY

The denaturation and degradation of stable enzymes at high temperatures. Daniel RM, et al. **Biochem J** 1996 Jul 1;317 (Pt 1):1–11 (109 ref.)
Simulations of enzymic reactions. Mulholland AJ, et al. **Biochem Soc Trans** 1996 Feb;24(1):247–54 (56 ref.)
Brownian dynamics simulations of enzyme-substrate encounter. Wade RC. **Biochem Soc Trans** 1996 Feb; 24(1):254–9 (29 ref.)
Inactivation precedes overall molecular conformation changes during enzyme denaturation. Tsou CL. **Biochim Biophys Acta** 1995 Dec 6;1253(2):151–62 (107 ref.)
Micro-osmosis in gels, cells and enzymes. Wiggins PM. **Cell Biochem Funct** 1995 Sep;13(3):165–72 (54 ref.)
Interfacial metal-binding site design. Matthews DJ. **Curr Opin Biotechnol** 1995 Aug;6(4):419–24 (49 ref.)
Engineering thermostability: lessons from thermophilic proteins. Russell RJ, et al. **Curr Opin Biotechnol** 1995 Aug; 6(4):370–4 (22 ref.)
Stability and folding of ultrastable proteins: eye lens crystallins and enzymes from thermophiles. Jaenicke R. **FASEB J** 1996 Jan;10(1):84–92 (50 ref.)

DEFICIENCY

Clinical presentations and laboratory investigations in respiratory chain deficiency. Munnich A, et al. **Eur J Pediatr** 1996 Apr;155(4):262–74 (28 ref.)

GENETICS

Genetic delivery of enzymes for cancer therapy. Deonarain MP, et al. **Gene Ther** 1995 Jun;2(4):235–44 (76 ref.)

IMMUNOLOGY

Autoantibodies to specific enzymes: a review. Kiechle FL, et al. **Ann Clin Lab Sci** 1996 May-Jun;26(3):195–207 (70 ref.)

METABOLISM

Kinetic models in reverse micelles. Bru R, et al. **Biochem J** 1995 Sep 15;310 (Pt 3):721–39 (161 ref.)
Physiological control of metabolic flux: the requirement for multisite modulation. Fell DA, et al. **Biochem J** 1995 Oct 1;311 (Pt 1):35–9 (48 ref.)
Immunohistochemistry of drug-metabolizing enzymes. Murray GI, et al. **Biochem Pharmacol** 1995 Sep 28; 50(7):895–903 (73 ref.)
Simulations of enzymic reactions. Mulholland AJ, et al. **Biochem Soc Trans** 1996 Feb;24(1):247–54 (56 ref.)
Enzymes of nucleotide biosynthesis: differences between intact and lysed cells as well as between species and tissues can be important. Simmonds HA. **Biochem Soc Trans** 1995 Nov;23(4):877–9 (11 ref.)
Brownian dynamics simulations of enzyme-substrate encounter. Wade RC. **Biochem Soc Trans** 1996 Feb; 24(1):254–9 (29 ref.)
Detecting enzymatic activity in cells using fluorogenic substrates. Haugland RP. **Biotech Histochem** 1995 Sep; 70(5):243–51 (17 ref.)
Mechanisms for controlling enzymatic reactions in foods. Ashie IN, et al. **Crit Rev Food Sci Nutr** 1996 Jan; 36(1–2):1–30 (203 ref.)
Co-metabolism: is the emperor wearing any clothes? Wackett LP. **Curr Opin Biotechnol** 1996 Jun;7(3):321–5 (32 ref.)
Enzymes: chemistry and biochemistry. Jeffery J. **EXS** 1995; 73:79–104 (181 ref.)
Stereochemical constraint in the evolution of pyridoxal-5'-phosphate-dependent enzymes. A hypothesis. Christen P, et al. **FEBS Lett** 1996 Jun 24;389(1):12–4 (21 ref.)
Enzymatic synthesis of hydrophobic penicillins. Luengo JM. **J Antibiot (Tokyo)** 1995 Nov;48(11):1195–212 (96 ref.)
Pyridoxal enzymes: mechanistic diversity and uniformity. Hayashi H. **J Biochem (Tokyo)** 1995 Sep;118(3):463–73 (54 ref.)
Catalytic antibodies. Structure and possible applications. Amital H, et al. **Methods Mol Biol** 1995;51:203–10 (29 ref.)
Biochemistry meets genetics in the holoenzyme. Berk AJ. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):11952–4 (45 ref.)
[Systemic enzyme therapy: problems of resorption of enzyme macromolecules] Nouza K, et al. **Cas Lek Cesk** 1995 Oct 4;134(19):615–9 (56 ref.) (Eng. Abstr.) **(Cze)**
[Enzyme-linked immunoglobulin] Sugita O. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:432–4 (20 ref.) **(Jpn)**
[Dysfunctions of the cellular enzyme apparatus of organs and tissues in surgical diseases] Karelin AA, et al. **Vopr Med Khim** 1995 Nov-Dec;41(6):2–8 (43 ref.) **(Rus)**

PHYSIOLOGY

Antidepressants and drug-metabolizing enzymes--expert group report. Meyer UA, et al. **Acta Psychiatr Scand** 1996 Feb;93(2):71–9 (45 ref.)
Application of enzymes in food processing. James J, et al. **Crit Rev Food Sci Nutr** 1996 May;36(5):437–63 (48 ref.)

STANDARDS

[1995: a decisive progress for the interlaboratory transferability of results by using enzyme and protein reference materials (editorial)] Férard G, et al. **Ann Biol Clin (Paris)** 1995;53(9):469–71 (14 ref.) (Eng. Abstr.) **(Fre)**

THERAPEUTIC USE

[Systemic enzyme therapy: problems of resorption of enzyme macromolecules] Nouza K, et al. **Cas Lek Cesk** 1995 Oct 4;134(19):615–9 (56 ref.) (Eng. Abstr.) **(Cze)**

URINE

[Use of urinary enzymes in diagnostic follow-up in kidney transplantation] Jovanović SD. **Med Pregl** 1995; 48(5–6):163–6 (21 ref.) (Eng. Abstr.) **(Scr)**

ENZYMES, IMMOBILIZED

see related
ENZYME STABILITY

New designs of macroporous polymers and supports: from separation to biocatalysis. Svec F, et al. **Science** 1996 Jul 12;273(5272):205–11 (48 ref.)
[Immobilization in alginate gels] Jankovský M, et al. **Vet Med (Praha)** 1996 May;41(5):159–64 (60 ref.) (Eng. Abstr.) **(Cze)**

ISOLATION & PURIFICATION

Immobilization of enzymes/coenzymes for molecular electronics applications. Phadke RS. **Biosystems** 1995; 35(2–3):179–82 (14 ref.)

ENZYMOLOGIC GENE EXPRESSION REGULATION see **GENE EXPRESSION REGULATION, ENZYMOLOGIC**

EOSINOPHIL CHEMOTACTIC FACTORS see **CHEMOTACTIC FACTORS, EOSINOPHIL**

EOSINOPHIL CHEMOTAXINS see **CHEMOTACTIC FACTORS, EOSINOPHIL**

EOSINOPHIL DIFFERENTIATION FACTOR see **INTERLEUKIN-5**

EOSINOPHILIA

see related
ANGIOLYMPHOID HYPERPLASIA WITH EOSINOPHILIA

Eosinophilic ulcer of the oral mucosa. Mezei MM, et al. **J Am Acad Dermatol** 1995 Nov;33(5 Pt 1):734–40 (47 ref.)
Eosinophilic granulomatous cystitis in children. Ladocsi LT, et al. **Urology** 1995 Nov;46(5):732–5 (22 ref.)

EOSINOPHILIA

CHEMICALLY INDUCED

Hepatitis, rash and eosinophilia following trichloroethylene exposure: a case report and speculation on mechanistic similarity to halothane induced hepatitis. Bond GR. **J Toxicol Clin Toxicol** 1996;34(4):461–6 (11 ref.)

Intravesical thiotepa–induced eosinophilic cystitis. Choe JM, et al. **Urology** 1995 Nov;46(5):729–31 (15 ref.)

CLASSIFICATION

[Eosinophilic cystitis: a single anatomopathologic entity and three different presentation forms. Proposed classification] Server Pastor G, et al. **Actas Urol Esp** 1996 Feb; 20(2):155–61 (37 ref.) (Eng. Abstr.) **(Spa)**

COMPLICATIONS

Eosinophilia–myalgia syndrome, toxic–oil syndrome, and diffuse fasciitis with eosinophilia. Kaufman LD, et al. **Curr Opin Rheumatol** 1995 Nov;7(6):560–7 (89 ref.)

Eosinophilic gastro–enteritis associated with protein–losing enteropathy and protein C deficiency. Wing–Harkins DL, et al. **J Int Med Res** 1996 Jan–Feb;24(1):155–63 (44 ref.)

Idiopathic eosinophilic synovitis. Case report and review of the literature. Atanes A, et al. **Scand J Rheumatol** 1996; 25(3):183–5 (13 ref.)

[Fasciitis with eosinophilia and bronchial cancer (letter)] Blanche P, et al. **Ann Med Interne (Paris)** 1996;147(1):62–4 (19 ref.) **(Fre)**

[Eosinophilic cholangitis] Tazawa J. **Ryoikibetsu Shokogun Shirizu** 1996;(9):17–9 (18 ref.) **(Jpn)**

DIAGNOSIS

Eosinophilic panniculitis: diagnostic considerations and evaluation. Adame J, et al. **J Am Acad Dermatol** 1996 Feb; 34(2 Pt 1):229–34 (37 ref.)

Wells' syndrome in childhood: case report and review of the literature. Anderson CR, et al. **J Am Acad Dermatol** 1995 Nov;33(5 Pt 2):857–64 (19 ref.)

ETIOLOGY

Visceral larva migrans induced eosinophilic cardiac pseudotumor: a cause of sudden death in a child. Boschetti A, et al. **J Forensic Sci** 1995 Nov;40(6):1097–9 (12 ref.)

GENETICS

Myelodysplastic syndrome with t(5;12)(q31;p12–p13) and eosinophilia: a pediatric case with review of literature. Pellier I, et al. **J Pediatr Hematol Oncol** 1996 Aug; 18(3):285–8 (19 ref.)

METABOLISM

Deposits of eosinophil granule proteins in eosinophilic cholecystitis and eosinophilic colitis associated with hypereosinophilic syndrome. Tajima K, et al. **Dig Dis Sci** 1996 Feb;41(2):282–8 (25 ref.)

PATHOLOGY

HIV–associated eosinophilic folliculitis: case report and review of the literature. Bosarab T, et al. **Br J Dermatol** 1996 Mar;134(3):499–503 (16 ref.)

RADIOGRAPHY

Radiographic manifestations of eosinophilic gastroenteritis. Vitellas KM, et al. **Abdom Imaging** 1995 Sep–Oct; 20(5):406–13 (34 ref.)

VETERINARY

Eosinophilic colitis and hepatitis in a horse with colonic intramucosal ciliated protozoa. French RA, et al. **Vet Pathol** 1996 Mar;33(2):235–8 (10 ref.)

EOSINOPHILIA–MYALGIA SYNDROME

CHEMICALLY INDUCED

Epidemiology of potential association between L–tryptophan ingestion and eosinophilia–myalgia syndrome. Daniels SR, et al. **J Clin Epidemiol** 1995 Dec;48(12):1413–27; discussion 1429–40 (64 ref.)

EPIDEMIOLOGY

Epidemiology of potential association between L–tryptophan ingestion and eosinophilia–myalgia syndrome. Daniels SR, et al. **J Clin Epidemiol** 1995 Dec;48(12):1413–27; discussion 1429–40 (64 ref.)

ETIOLOGY

Eosinophilia–myalgia syndrome, toxic–oil syndrome, and diffuse fasciitis with eosinophilia. Kaufman LD, et al. **Curr Opin Rheumatol** 1995 Nov;7(6):560–7 (89 ref.)

EOSINOPHILIA, PULMONARY see **PULMONARY EOSINOPHILIA**

EOSINOPHILIA, TROPICAL see **PULMONARY EOSINOPHILIA**

EOSINOPHILIC GRANULOMA

[Eosinophilic granuloma of the liver] Nakabayashi S, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):349–51 (16 ref.) **(Jpn)**

COMPLICATIONS

Spinal cord compression by eosinophilic granuloma of the cervical spine. Case report and review of the literature. Scarpinati M, et al. **Neurosurg Rev** 1995;18(3):209–12 (34 ref.)

PATHOLOGY

Ulcerative eosinophilic granuloma: a report of five new cases. Movassaghi K, et al. **Br J Oral Maxillofac Surg** 1996 Feb; 34(1):115–7 (12 ref.)

Eosinophilic granuloma of soft tissue: a case report and literature review. Kim YG, et al. **J Oral Maxillofac Surg** 1996 Mar;54(3):353–7 (12 ref.)

Recurrent multifocal Langerhans cell eosinophilic granuloma of the jaws: report of a case. Uckan S, et al. **J Oral Maxillofac Surg** 1996 Jul;54(7):906–9 (15 ref.)

[Eosinophilic granuloma of bones in children] Leblan I, et al. **Ann Radiol (Paris)** 1995;38(3):125–38 (37 ref.) (Eng. Abstr.) **(Fre)**

VETERINARY

Selected feline eosinophilic skin diseases. Power HT, et al. **Vet Clin North Am Small Anim Pract** 1995 Jul;25(4):833–50 (30 ref.)

EOSINOPHILIC PNEUMONIA see **PULMONARY EOSINOPHILIA**

EOSINOPHILS

IMMUNOLOGY

Eosinophils in allergy: role in disease, degranulation, and cytokines. Martin LB, et al. **Int Arch Allergy Immunol** 1996 Mar;109(3):207–15 (147 ref.)

Interleukin–5, eosinophils and the control of helminth infections in man and laboratory animals. Tagboto SK. **J Helminthol** 1995 Dec;69(4):271–8 (80 ref.)

METABOLISM

The eosinophil: a cytokine–producing cell? [editorial] Kita H. **J Allergy Clin Immunol** 1996 Apr;97(4):889–92 (20 ref.)

PATHOLOGY

Eosinophils and asthma. What do measurements tell us? [editorial; comment] Robinson DS. **Clin Exp Allergy** 1995 Sep;25(9):795–8 (55 ref.) Comment on: Clin Exp Allergy 1995 Sep;25(9):820–7.

Macroscopic versus microscopic diagnosis of reflux esophagitis: erosions or eosinophils? Hassall E. **J Pediatr Gastroenterol Nutr** 1996 Apr;22(3):321–5 (60 ref.)

PHYSIOLOGY

Eosinophils: biology and role in disease. Wardlaw AJ, et al. **Adv Immunol** 1995;60:151–266 (760 ref.)

Calcium signalling during chemotaxis. Fay FS, et al. **Ciba Found Symp** 1995;188:121–35; discussion 136–40 (34 ref.)

Interleukin–5 receptor alpha subunit gene regulation in human eosinophil development: identification of a unique cis–element that acts lie an enhancer in regulating activity of the IL–5R alpha promoter. Sun Z, et al. **Curr Top Microbiol Immunol** 1996;211:173–87 (64 ref.)

Chemokines active on eosinophils: potential roles in allergic inflammation [comment] Kita H, et al. **J Exp Med** 1996 Jun 1;183(6):2421–6 (60 ref.) Comment on: J Exp Med 1996 Jun 1;183(6):2437–48.

Role of eosinophil–chemotactic C–C chemokines in cutaneous inflammation. Schröder JM, et al. **J Leukoc Biol** 1996 Jan;59(1):1–5 (24 ref.)

Alpha 4 integrin–induced cytokine production and eosinophil function. Broide DH. **Springer Semin Immunopathol** 1995; 16(4):405–15 (85 ref.)

Mechanisms and pharmacological manipulation of eosinophil accumulation in vivo. Teixeira MM, et al. **Trends Pharmacol Sci** 1995 Dec;16(12):418–23 (69 ref.)

EPENDYMOMA

DIAGNOSIS

Ependymoblastoma: MR presentation. A case report and review of the literature. Dorsay TA, et al. **Pediatr Radiol** 1995;25(6):433–5 (13 ref.)

PATHOLOGY

Multiple neuroepithelial tumors of different cell types—case report. Akai T, et al. **Neurol Med Chir (Tokyo)** 1995 Dec; 35(12):901–4 (9 ref.)

SURGERY

Intra–operative monitoring is not essential. Malis LI. **Clin Neurosurg** 1995;42:203–13 (8 ref.)

EPENDYMOMA, MYXOPAPILLARY see **GLIOMA**

EPH GESTOSIS see **GESTOSIS, EPH**

EPHEDRINE

ADVERSE EFFECTS

Acute hepatitis associated with the use of a Chinese herbal product, ma–huang. Nadir A, et al. **Am J Gastroenterol** 1996 Jul;91(7):1436–8 (20 ref.)

PHARMACOLOGY

Pharmacological and clinical studies of ephedrine and other thermogenic agonists. Astrup A, et al. **Obes Res** 1995 Nov; 3 Suppl 4:537S–540S (12 ref.)

THERAPEUTIC USE

Pharmacological and clinical studies of ephedrine and other thermogenic agonists. Astrup A, et al. **Obes Res** 1995 Nov; 3 Suppl 4:537S–540S (12 ref.)

EPICONDYLITIS, LATERAL HUMERAL see **TENNIS ELBOW**

EPIDEMIC NON–A, NON–B HEPATITIS see **HEPATITIS E**

EPIDEMICS see **DISEASE OUTBREAKS**

EPIDEMIOLOGIC DETERMINANTS see **EPIDEMIOLOGIC FACTORS**

EPIDEMIOLOGIC FACTORS

Study design for epidemiologic studies with measurement error. Holford TR, et al. **Stat Methods Med Res** 1995 Dec; 4(4):339–58 (43 ref.)

EPIDEMIOLOGIC METHODS

Capture–recapture and multiple–record systems estimation I: History and theoretical development. International Working Group for Disease Monitoring and Forecasting. **Am J Epidemiol** 1995 Nov 15;142(10):1047–58 (47 ref.)

Capture–recapture and multiple–record systems estimation II: Applications in human diseases. International Working Group for Disease Monitoring and Forecasting. **Am J Epidemiol** 1995 Nov 15;142(10):1059–68 (87 ref.)

A critical look at methods for handling missing covariates in epidemiologic regression analyses. Greenland S, et al. **Am J Epidemiol** 1995 Dec 15;142(12):1255–64 (26 ref.)

The Bell Curve: on race, social class, and epidemiologic research. Muntaner C, et al. **Am J Epidemiol** 1996 Sep 15; 144(6):531–6 (76 ref.)

The role of medical examiners and coroners in public health surveillance and epidemiologic research. Hanzlick R, et al. **Annu Rev Public Health** 1996;17:383–409 (85 ref.)

Epidemiologic and clinical challenges in reviving the necropsy. Feinstein AR. **Arch Pathol Lab Med** 1996 Aug; 120(8):749–52 (11 ref.)

Capture–recapture methods in epidemiology: methods and limitations. Hook EB, et al. **Epidemiol Rev** 1995; 17(2):243–64 (140 ref.)

Clinical epidemiology: what, why and how? Nath R, et al. **Indian J Ophthalmol** 1995 Jun;43(2):83–7 (13 ref.)

Epidemiology for prevention. Wall S. **Int J Epidemiol** 1995 Aug;24(4):655–64 (55 ref.)

Air pollution and mortality: issues and uncertainties. Lipfert FW, et al. **J Air Waste Manag Assoc** 1995 Dec; 45(12):949–66 (54 ref.)

The impact of surveys on hospital infection. Emmerson AM. **J Hosp Infect** 1995 Jun;30 Suppl:421–40 (68 ref.)

Mathematical and computer models in epidemiology. Massad E. **MD Comput** 1996 Mar–Apr;13(2):147–54 (31 ref.)

An introduction to neuroepidemiology. Kurtzke JF. **Neurol Clin** 1996 May;14(2):255–72 (26 ref.)

An overview of pharmacoepidemiology. Wertheimer AL, et al. **Pharm World Sci** 1995 May 26;17(3):61–6 (13 ref.)

Methodology for assessment of exposure to environmental factors in application to epidemiological studies: assessment of exposure to natural ionizing radiation. Akerblom G. **Sci Total Environ** 1995 Jun 16;168(2):155–68 (69 ref.)

Exposure assessment strategies in epidemiological studies of health effects of electric and magnetic fields. Savitz DA. **Sci Total Environ** 1995 Jun 16;168(2):143–53 (41 ref.)

Spatial statistical methods in environmental epidemiology: a critique. Elliott P, et al. **Stat Methods Med Res** 1995 Jun;4(2):137–59 (114 ref.)

[Epidemiologic research on the environment and health: some methodologic aspects] Hémon D. **Rev Epidemiol Sante Publique** 1995;43(5):395–411 (55 ref.) (Eng. Abstr.) **(Fre)**

EPIDEMIOLOGICAL MONITORING see **ENVIRONMENTAL MONITORING**

EPIDEMIOLOGY

Contraception, unintended pregnancies, and sexually transmitted diseases: why isn't a simple solution possible? Cates W Jr. **Am J Epidemiol** 1996 Feb 15;143(4):311–8 (30

ref.)
Disaster epidemiology. Noji EK.
Emerg Med Clin North Am 1996 May;14(2):289–300 (60 ref.)
Epidemiology of minority health. Flack JM, et al.
Health Psychol 1995 Dec;14(7):592–600 (50 ref.)
Biomechanical epidemiology: a new approach to injury control research. Winston FK, et al. **J Trauma** 1996 May; 40(5):820–4 (32 ref.)
Environmental health science research and human risk assessment. Olden K, et al. **Mol Carcinog** 1995 Sep;14(1):2–9 (25 ref.)
Assigning causation in disease: beyond Koch's postulates. Sutter MC. **Perspect Biol Med** 1996 Summer;39(4):581–92 (24 ref.)
[Advantages and disadvantages of induced labor without medical indication: the viewpoint of the epidemiologist] Goffinet F. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24 Suppl 1:108–15 (21 ref.) **(Fre)**
[The epidemiologists' point of view on medical indications for induced labor] Subtil D.
J Gynecol Obstet Biol Reprod (Paris) 1995;24 Suppl 1:62–6 (29 ref.) **(Fre)**

EDUCATION

A guide to clinical epidemiology for radiologists: Part I study design and research methods. Goldin J, et al.
Clin Radiol 1996 May;51(5):313–6 (30 ref.)
A guide to clinical epidemiology for radiologists: Part II statistical analysis. Goldin J, et al. **Clin Radiol** 1996 May; 51(5):317–24 (68 ref.)
On the need for ethics curricula in epidemiology. Coughlin SS, et al. **Epidemiology** 1995 Sep;6(5):566–7 (31 ref.)

STANDARDS

Biomarkers in epidemiology. Grandjean P. **Clin Chem** 1995 Dec;41(12 Pt 2):1800–3 (13 ref.)

TRENDS

Traditional epidemiology, modern epidemiology, and public health [see comments] Pearce N. **Am J Public Health** 1996 May;86(5):678–83 (64 ref.) Comment in: Am J Public Health 1996 May;86(5):621–2.

EPIDEMIOLOGY, MOLECULAR

Molecular epidemiology: issues in study design and statistical analysis. Chia KS, et al. **Ann Acad Med Singapore** 1996 Jan;25(1):55–63 (46 ref.)
Subtypes, genotypes and molecular epidemiology of the hepatitis B virus as reflected by sequence variability of the S-gene. Magnius LO, et al. **Intervirology** 1995; 38(1–2):24–34 (57 ref.)
[The mode of infection of tuberculosis—analysis using molecular epidemiologic methods] Abe C. **Kekkaku** 1995 Nov;70(11):645–50 (32 ref.) (Eng. Abstr.) **(Jpn)**
[Molecular cancer epidemiology—the present status and future possibilities] Sakai T. **Nippon Eiseigaku Zasshi** 1996 Feb;50(6):1036–46 (46 ref.) (Eng. Abstr.) **(Jpn)**
[Trends in molecular epidemiology of hepatitis B virus] Hijikata M. **Nippon Rinsho** 1995 Oct;53 Suppl:40–6 (17 ref.) **(Jpn)**
[Genotypic classification and molecular epidemiology of hepatitis A virus] Sata M, et al. **Nippon Rinsho** 1995 Oct; 53 Suppl:791–5 (17 ref.) **(Jpn)**

CLASSIFICATION

[The applications of molecular biology in taxonomy and epidemiology] Otelea D, et al.
Bacteriol Virusol Parazitol Epidemiol 1995 Jul–Dec; 40(3–4):171–80 (61 ref.) **(Rum)**

METHODS

[Role of genetic epidemiology in the study of infectious diseases. The example of malaria] Garcia A, et al.
Med Trop (Mars) 1995;55(4 Suppl):14–8 (39 ref.) (Eng. Abstr.) **(Fre)**
[Use of molecular biology in epidemiology in rabies] Sadkowska M. **Przegl Epidemiol** 1995;49(3):215–25 (14 ref.) (Eng. Abstr.) **(Pol)**

TRENDS

Biomarkers: a molecular approach to cancer epidemiology. Shi CY, et al. **Ann Acad Med Singapore** 1996 Jan; 25(1):49–54 (41 ref.)

EPIDEMIOLOGY, PHARMACEUTICAL see **PHARMACOEPIDEMIOLOGY**

EPIDERMAL CYST

DIAGNOSIS

[A case of intrapancreatic accessory spleen with epidermoid cyst] Kanemaki N, et al.
Nippon Shokakibyo Gakkai Zasshi 1995 Aug;92(8):1212–6 (12 ref.) **(Jpn)**

ETIOLOGY

[Iatrogenic spinal epidermoid tumors. A late complication of spinal puncture] Reina MA, et al.
Rev Esp Anestesiol Reanim 1996 Apr;43(4):142–6 (84 ref.) (Eng. Abstr.) **(Spa)**

PATHOLOGY

Multiple milia localized to the vulva. Kanekura T, et al.
J Dermatol 1996 Jun;23(6):427–8 (18 ref.)
Lymphoepithelial cyst of the pancreas: a preoperatively diagnosed case based on an aspiration biopsy. Rino Y, et al. **Surg Today** 1995;25(12):1043–6 (11 ref.)

EPIDERMAL GROWTH FACTOR see **EPIDERMAL GROWTH FACTOR-UROGASTRONE**

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE see **EPIDERMAL GROWTH FACTOR RECEPTOR PROTEIN-TYROSINE KINASE**

EPIDERMAL GROWTH FACTOR RECEPTOR PROTEIN-TYROSINE KINASE

METABOLISM

Pattern formation. Gurken meets torpedo for the first time. Gavis ER. **Curr Biol** 1995 Nov 1;5(11):1252–4 (14 ref.)
LET-23-mediated signal transduction during Caenorhabditis elegans development. Sternberg PW, et al.
Mol Reprod Dev 1995 Dec;42(4):523–8 (35 ref.)

PHYSIOLOGY

Neuregulins and their receptors. Carraway KL 3rd, et al. **Curr Opin Neurobiol** 1995 Oct;5(5):606–12 (54 ref.)
Interaction between erbB-receptors and heregulin in breast cancer tumor progression and drug resistance. Lupu R, et al. **Semin Cancer Biol** 1995 Jun;6(3):135–45 (143 ref.)

EPIDERMAL GROWTH FACTOR RECEPTORS see **RECEPTORS, EPIDERMAL GROWTH FACTOR-UROGASTRONE**

EPIDERMAL GROWTH FACTOR-RELATED TRANSFORMING GROWTH FACTOR see **TRANSFORMING GROWTH FACTOR ALPHA**

EPIDERMAL GROWTH FACTOR-UROGASTRONE

see related
ANTI-ULCER AGENTS
GASTROINTESTINAL AGENTS
RECEPTORS, EPIDERMAL GROWTH FACTOR-UROGASTRONE

ANALYSIS

[Fibroblast growth factor (FGF)] Ito H. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:815–8 (22 ref.) **(Jpn)**
[Epidermal growth factor (EGF)] Kojima T, et al.
Nippon Rinsho 1995 Mar;53 Su Pt 2:810–4 (15 ref.) **(Jpn)**

ANTAGONISTS & INHIBITORS

Role of growth factors, steroid and peptide hormones in the regulation of human prostatic tumor growth. Motta M, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1–6 Spec No):107–11 (36 ref.)

DRUG EFFECTS

[New approaches to antitumor therapy: the use of preparations acting on processes regulated by epidermal and/or alpha-transforming growth factors] Kushlinskii NE, et al. **Eksp Klin Farmakol** 1996 Jan–Feb;59(1):74–80 (64 ref.) **(Rus)**

METABOLISM

Interaction of signaling and trafficking proteins with the carboxyterminus of the epidermal growth factor receptor. Carpenter G, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:44–51 (28 ref.)
Role of heterotrimeric G-proteins in epidermal growth factor signalling. Ramírez I, et al. **Cell Signal** 1995 May; 7(4):303–11 (123 ref.)
Regulation of multidrug resistance through the cAMP and EGF signalling pathways. Rohlff C, et al. **Cell Signal** 1995 Jul;7(5):431–43 (131 ref.)
Dual regulation of the epidermal growth factor family of growth factors in breast cancer by sex steroids and protein kinase C. Martinez-Lacaci I, et al.
J Steroid Biochem Mol Biol 1996 Jan;57(1–2):1–11 (145 ref.)

PHARMACOLOGY

Mouse lactoferrin gene: a marker for estrogen and epidermal growth factor. Teng C. **Environ Health Perspect** 1995 Oct; 103 Suppl 7:17–20 (37 ref.)
Endocrine and paracrine negative regulators of adipose differentiation. Serrero G, et al.
Int J Obes Relat Metab Disord 1996 Mar;20 Suppl 3:S58–64 (33 ref.)

PHYSIOLOGY

Epidermal growth factor (EGF). Goodlad RA, et al.
Baillieres Clin Gastroenterol 1996 Mar;10(1):33–47 (92 ref.)
Peptide growth factors in the prostate as mediators of stromal epithelial interaction. Byrne RL, et al. **Br J Urol** 1996 May; 77(5):627–33 (65 ref.)
New concepts in tissue repair: skin as an example. Meddahi A, et al. **Diabetes Metab** 1996 Jul;22(4):274–8 (28 ref.)
Role of epidermal growth factor in peptic ulcer healing. Calabrò A, et al. **Dig Dis Sci** 1995 Nov;40(11):2497–504 (63 ref.)
The epidermal growth factor/transforming growth factor-alpha family and their receptors. Brown KD.
Eur J Gastroenterol Hepatol 1995 Oct;7(10):914–22 (58 ref.)
Epidermal growth factor and transforming growth factor-alpha actions on the gut. Goodlad RA, et al.
Eur J Gastroenterol Hepatol 1995 Oct;7(10):928–32 (29 ref.)
Epidermal growth factor and transforming growth factor-alpha: role in protection and healing of gastric mucosal lesions. Konturek PC, et al.
Eur J Gastroenterol Hepatol 1995 Oct;7(10):933–7 (26 ref.)
Role of epidermal growth factor (EGF) and its receptor in the development of the human placenta. Maruo T, et al.
Reprod Fertil Dev 1995;7(6):1465–70 (15 ref.)
Epidermal growth factor-related peptides and the epidermal growth factor receptor in normal and malignant prostate. Sherwood ER, et al. **World J Urol** 1995;13(5):290–6 (65 ref.)
[Growth factors in tubular cells] Okuda S. **Nippon Rinsho** 1995 Aug;53(8):1879–85 (18 ref.) (Eng. Abstr.) **(Jpn)**

THERAPEUTIC USE

Clinical applications of epidermal growth factor. Guglietta A, et al. **Eur J Gastroenterol Hepatol** 1995 Oct;7(10):945–50 (35 ref.)
Growth factors: new 'endogenous drugs' for ulcer healing. Szabo S, et al. **Scand J Gastroenterol Suppl** 1995;210:15–8 (33 ref.)

EPIDERMAL NECROLYSIS, TOXIC

COMPLICATIONS

[Eruptive nevus in the course of Lyell syndrome] Jullien D, et al. **Ann Dermatol Venereol** 1995;122(8):540–2 (14 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

[Toxic epidermal necrolysis: a report of 2 pediatric cases] Muñoz Romero F, et al. **An Esp Pediatr** 1996 Jul;45(1):71–5 (26 ref.) **(Spa)**

ETIOLOGY

[Stevens-Johnson syndrome and toxic epidermal necrolysis; therapy policy in these life-threatening illnesses. Netherlands Work Group Toxic Epidermal Necrolysis] van der Meer JB. **Ned Tijdschr Geneeskd** 1996 Jul 27; 140(30):1538–43 (29 ref.) **(Dut)**
[Cutaneous side-effects of nonsteroidal anti-inflammatory drugs (NSAID)] Gebhardt M, et al. **Z Rheumatol** 1995 Nov-Dec;54(6):405–12 (49 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Toxic epidermal necrolysis: a review and report of the successful use of Biobrane for early wound coverage. Bradley T, et al. **Ann Plast Surg** 1995 Aug;35(2):124–32 (45 ref.)

EPIDERMIS

Pemphigus: autoimmunity to epidermal cell adhesion molecules. Amagai M. **Adv Dermatol** 1996;11:319–52; discussion 353 (166 ref.)

METABOLISM

Spontaneous disappearance of intraepidermal type VII collagen in a patient with dystrophic epidermolysis bullosa. Hatta N, et al. **Br J Dermatol** 1995 Oct;133(4):619–24 (17 ref.)
What is the epidermal intercellular cement and why is it important? Stanley JR. **J Dermatol** 1995 Nov;22(11):836–8 (9 ref.)
The significance of polyunsaturated fatty acids in cutaneous biology. Ziboh VA. **Lipids** 1996 Mar;31 Suppl:S249–53 (29 ref.)
Hypothesis: spermine may be an important epidermal antioxidant. Løsvaas E. **Med Hypotheses** 1995 Jul; 45(1):59–67 (125 ref.)
The human epidermis. Schallreuter KU, et al.
Proc Nutr Soc 1995 Mar;54(1):191–5 (18 ref.)

PHYSIOPATHOLOGY

Defective cell-cell adhesion in the epidermis. Stanley JR. **Ciba Found Symp** 1995;189:107–20; discussion 120–3, 174–6 (64 ref.)

EPIDERMIS

RADIATION EFFECTS

UVB-dependent modulation of epidermal cytokine network: roles in UVB-induced depletion of Langerhans cells and dendritic epidermal T cells. Takashima A. **J Dermatol** 1995 Nov;22(11):876–87 (100 ref.)

EPIDERMODYSPLASIA VERRUCIFORMIS

Epidermodysplasia verruciformis as a model of human papillomavirus–induced genetic cancer of the skin. Majewski S, et al. **Arch Dermatol** 1995 Nov;131(11):1312–8 (62 ref.)

EPIDERMOID CYST see **EPIDERMAL CYST**

EPIDERMOLYSINS see **EXFOLIATINS**

EPIDERMOLYSIS BULLOSA

DIAGNOSIS

[Transient bullous epidermolysis of the newborn infant. A benign clinical form of dystrophic bullous epidermolysis or an autonomous entity?] D'Incan M, et al. **Ann Dermatol Venereol** 1996;123(2):100–02 (10 ref.) (Eng. Abstr.) **(Fre)**

EPIDEMIOLOGY

Epidermolysis bullosa. Application of epidemiologic principles to the study of a group of rare diseases via a disease registry. Fine JD. **Dermatol Clin** 1995 Jul; 13(3):659–70 (82 ref.)

GENETICS

Lessons from skin blistering: molecular mechanisms and unusual patterns of inheritance? [comment] Paller AS. **Am J Pathol** 1996 Jun;148(6):1727–31 (38 ref.) Comment on: Am J Pathol 1996 Jun;148(6):1787–96.

Premature termination codon mutations in the type VII collagen gene (COL7A1) underlie severe recessive dystrophic epidermolysis bullosa. Uitto J, et al. **Proc Assoc Am Physicians** 1995 Jul;107(2):245–52 (30 ref.)

[Incidence of structural disorders of teeth in hereditary epidermolysis bullosa] Gábris K, et al. **Fogorv Sz** 1996 Jan; 89(1):7–10 (25 ref.) (Eng. Abstr.) **(Hun)**

METABOLISM

Molecular complexity of the cutaneous basement membrane zone. Revelations from the paradigms of epidermolysis bullosa. Christiano AM, et al. **Exp Dermatol** 1996 Feb; 5(1):1–11 (97 ref.)

THERAPY

Management of patients with epidermolysis bullosa. Lin AN. **Dermatol Clin** 1996 Apr;14(2):381–7 (57 ref.)

EPIDERMOLYSIS BULLOSA, ACQUIRED see **EPIDERMOLYSIS BULLOSA ACQUISITA**

EPIDERMOLYSIS BULLOSA ACQUISITA

COMPLICATIONS

Localized epidermolysis bullosa acquisita of the esophagus in a patient with Crohn's disease. Schattenkirchner S, et al. **Am J Gastroenterol** 1996 Aug;91(8):1657–9 (15 ref.)

EPIDERMOLYSIS BULLOSA, DYSTROPHIC see **EPIDERMOLYSIS BULLOSA DYSTROPHICA**

EPIDERMOLYSIS BULLOSA DYSTROPHICA

DIAGNOSIS

Molecular diagnosis of inherited skin diseases: the paradigm of dystrophic epidermolysis bullosa. Christiano AM, et al. **Adv Dermatol** 1996;11:199–213; discussion 214 (45 ref.)

GENETICS

Molecular diagnosis of inherited skin diseases: the paradigm of dystrophic epidermolysis bullosa. Christiano AM, et al. **Adv Dermatol** 1996;11:199–213; discussion 214 (45 ref.)

METABOLISM

Spontaneous disappearance of intraepidermal type VII collagen in a patient with dystrophic epidermolysis bullosa. Hatta N, et al. **Br J Dermatol** 1995 Oct;133(4):619–24 (17 ref.)

PHYSIOPATHOLOGY

Twelve hour anaesthesia in a patient with epidermolysis bullosa. Yonker-Sell AE, et al. **Can J Anaesth** 1995 Aug; 42(8):735–9 (25 ref.)

EPIDERMOLYSIS BULLOSA, JUNCTIONAL

Generalized gravis junctional epidermolysis bullosa: case report, laboratory evaluation, and review of recent advances. Lim KK, et al. **Mayo Clin Proc** 1996 Sep; 71(9):863–8 (34 ref.)

EPIDERMOLYSIS BULLOSA LETALIS see **EPIDERMOLYSIS BULLOSA, JUNCTIONAL**

EPIDERMOLYSIS BULLOSA PROGRESSIVA see **EPIDERMOLYSIS BULLOSA, JUNCTIONAL**

EPIDERMOLYTIC TOXINS see **EXFOLIATINS**

EPIDERMOPHYTOSIS see **TINEA**

EPIDIDYMIS

Malacoplakia of the epididymis. Report of a case and review of the literature. Dieckmann KP, et al. **Urol Int** 1995; 55(4):222–5 (23 ref.)

Epididymocutaneous fistula in a patient with the acquired immunodeficiency syndrome and Marfan's syndrome. Weiner DM, et al. **Urology** 1996 May;47(5):766–8 (14 ref.)

[Epididymal malacoplakia in a heart transplant recipient: clinico-pathologic study of a case] Soria Corón MR, et al. **Arch Esp Urol** 1996 Mar;49(2):172–6 (15 ref.) (Eng. Abstr.) **(Spa)**

CYTOLOGY

The apical mitochondria-rich cells of the mammalian epididymis. Martínez-García F, et al. **Andrologia** 1995 Jul–Aug;27(4):195–206 (83 ref.)

METABOLISM

Sperm, a source of estrogen. Hess RA, et al. **Environ Health Perspect** 1995 Oct;103 Suppl 7:59–62 (41 ref.)

Specialized gene expression in the epididymis. Cornwall GA, et al. **J Androl** 1995 Sep–Oct;16(5):379–83 (27 ref.)

Homeobox genes and male reproductive development. Lindsey S, et al. **J Assist Reprod Genet** 1996 Feb; 13(2):182–92 (49 ref.)

MICROBIOLOGY

Epididymal histoplasmosis diagnosed by isolation of Histoplasma capsulatum from semen. Randhawa HS, et al. **Mycopathologia** 1995 Sep;131(3):173–7 (20 ref.)

PATHOLOGY

[Fibrous pseudotumor of the epididymis] Pérez Herms S, et al. **Actas Urol Esp** 1995 Apr;19(4):322–4 (14 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

Role of the epididymis in mediating changes in the male gamete during maturation. Cooper TG. **Adv Exp Med Biol** 1995;377:87–101 (133 ref.)

On the epididymis and its role in the development of the fertile ejaculate. Turner TT. **J Androl** 1995 Jul–Aug; 16(4):292–8 (34 ref.)

The epididymis as protector of maturing spermatozoa. Hinton BT, et al. **Reprod Fertil Dev** 1995;7(4):731–45 (149 ref.)

EPIDURAL ANALGESIA see **ANALGESIA, EPIDURAL**

EPIDURAL ANESTHESIA see **ANESTHESIA, EPIDURAL**

EPIDURAL INJECTIONS see **INJECTIONS, EPIDURAL**

EPIDURAL SPACE

The risk of extradural abscess [editorial] Carson D, et al. **Br J Anaesth** 1995 Nov;75(5):520–1 (13 ref.)

Cauda equina compression by epidural lipomatosis in obesity. Effectiveness of weight reduction. Pouchot J, et al. **J Rheumatol** 1995 Sep;22(9):1771–5 (20 ref.)

BLOOD SUPPLY

[A rare cause of neurologic bladder: arteriovenous dural fistula with venous epidural drainage] Punga-Maole ML, et al. **Prog Urol** 1995 Dec;5(6):1001–8 (32 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Neurogenic claudication by epidural lipomatosis: a case report and review of literature. Kurt E, et al. **Clin Neurol Neurosurg** 1995 Nov;97(4):354–7 (14 ref.)

RADIOGRAPHY

[Vertebral vacuum phenomena] Hamzé B, et al. **Ann Radiol (Paris)** 1995;38(4):186–91 (17 ref.) (Eng. Abstr.) **(Fre)**

EPIGASTRIC ARTERIES

SURGERY

[Reconstructive surgery using the flaps pedicled by rectus abdominis muscle or deep inferior epigastric artery] Hyakusoku H. **Nippon Ika Daigaku Zasshi** 1995 Dec; 62(6):567–73 (22 ref.) **(Jpn)**

EPIGLOTTIS

ABNORMALITIES

Bifid epiglottis. Goldenberg JD, et al. **Ann Otol Rhinol Laryngol** 1996 Feb;105(2):155–7 (15 ref.)

Bifid epiglottis syndrome. Sturgis EM, et al. **Int J Pediatr Otorhinolaryngol** 1995 Oct;33(2):149–57 (16 ref.)

EPIGLOTTITIS

DIAGNOSIS

Epiglottitis in adults. Carey MJ. **Am J Emerg Med** 1996 Jul; 14(4):421–4 (77 ref.)

MICROBIOLOGY

Isolated candidal epiglottitis: report of a fatal case. Alba D, et al. **Clin Infect Dis** 1996 Apr;22(4):732–3 (10 ref.)

[Review of epiglottitis] Acuña García M, et al. **Acta Otorrinolaringol Esp** 1996 Mar–Apr;47(2):144–8 (27 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

Epiglottitis in adults. Carey MJ. **Am J Emerg Med** 1996 Jul; 14(4):421–4 (77 ref.)

EPILEPSY

see related
KINDLING (NEUROLOGY)
LANDAU-KLEFFNER SYNDROME

Update on epilepsy in pediatric patients. Zupanc ML. **Mayo Clin Proc** 1996 Sep;71(9):899–916 (102 ref.)

[Drug-resistant epilepsy in adults] Loiseau P, et al. **Rev Neurol (Paris)** 1995 May;151(5):295–306 (96 ref.) (Eng. Abstr.) **(Fre)**

[Epilepsy and quality of life] Forcadas I. **Rev Neurol** 1995 Nov–Dec;23(124):1212–3 (10 ref.) **(Spa)**

[Advances in the diagnostic and treatment of infantile epilepsy] Legido A. **Rev Neurol** 1996 Jun;24(130):688–93 (25 ref.) **(Spa)**

[Neonatal seizures: diagnostic and therapeutic controversies] Legido A. **Rev Neurol** 1996 Jun;24(130):694–700 (40 ref.) **(Spa)**

[Infantile epilepsy and sleep] Prats Viñas JM. **Rev Neurol** 1995 Nov–Dec;23(124):1284–6 (32 ref.) **(Spa)**

BLOOD

Pharmacokinetic and pharmacodynamic drug interactions during treatment with vigabatrin. Richens A. **Acta Neurol Scand Suppl** 1995;162:43–6 (16 ref.)

CLASSIFICATION

Negative motor phenomena in generalized epilepsies. A study of atonic seizures. Andermann F, et al. **Adv Neurol** 1995; 67:9–28 (117 ref.)

Inhibitory mechanisms of epileptic seizure generation. Engel J Jr. **Adv Neurol** 1995;67:157–71 (52 ref.)

Drop attacks. Lee MS, et al. **Adv Neurol** 1995;67:41–52 (99 ref.)

A clinical approach to the classification of seizures and epileptic syndromes. Mosewich RK, et al. **Mayo Clin Proc** 1996 Apr;71(4):405–14 (36 ref.)

Classifications and epidemiologic considerations of epileptic seizures and epilepsy. So EL. **Neuroimaging Clin N Am** 1995 Nov;5(4):513–26 (38 ref.)

[Classification of epileptic seizures. Comparison of two systems] Benbadis S, et al. **Neurophysiol Clin** 1995; 25(5):297–302 (12 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

The development of psychosis in epilepsy: a re-examination of the kindling hypothesis. Smith PF, et al. **Behav Brain Res** 1996 Feb;75(1–2):59–66 (94 ref.)

[Migraine and epilepsy] Hernández Gallego J. **Rev Neurol** 1995;23 Suppl 2:S240–2 (27 ref.) **(Spa)**

DIAGNOSIS

Negative motor phenomena in generalized epilepsies. A study of atonic seizures. Andermann F, et al. **Adv Neurol** 1995; 67:9–28 (117 ref.)

Drop attacks. Lee MS, et al. **Adv Neurol** 1995;67:41–52 (99 ref.)

The EEG and neuroimaging in the management of the epilepsies. O'Donohoe NV. **Arch Dis Child** 1995 Dec; 73(6):552–7 (41 ref.)

Convulsive syncope in the aviation environment. Voge VM, et al. **Aviat Space Environ Med** 1995 Dec;66(12):1198–204 (45 ref.)

Update in the treatment of epilepsy. Schachter SC. **Compr Ther** 1995 Sep;21(9):473–9 (7 ref.)
Pediatric epilepsy syndromes: an update and critical review. Duchowny M, et al. **Epilepsia** 1996;37 Suppl 1:S26–40 (154 ref.)
Magnetic resonance spectroscopy. Duncan JS. **Epilepsia** 1996 Jul;37(7):598–605 (37 ref.)
Neuroimaging in pediatric epilepsy. Kuzniecky RI. **Epilepsia** 1996;37 Suppl 1:S10–21 (77 ref.)
Acquired epileptiform opercular syndrome: a second case report, review of the literature, and comparison to the Landau–Kleffner syndrome. Shafrir Y, et al. **Epilepsia** 1995 Oct;36(10):1050–7 (32 ref.)
The case for a dissociative interpretation of pseudoepileptic seizures. Kuyk J, et al. **J Nerv Ment Dis** 1996 Aug; 184(8):468–74 (83 ref.)
The diagnosis of epilepsies. Grünewald RA, et al. **J R Coll Physicians Lond** 1996 Mar–Apr;30(2):122–7 (27 ref.)
Clinical correlations: MRI and EEG. Fish DR, et al. **Magn Reson Imaging** 1995;13(8):1113–7 (18 ref.)
New technical developments in magnetic resonance imaging of epilepsy. Riederer SJ, et al. **Magn Reson Imaging** 1995; 13(8):1095–8 (18 ref.)
Clinical applications: MRI, SPECT, and PET. Spencer SS, et al. **Magn Reson Imaging** 1995;13(8):1119–24 (34 ref.)
Novel MR image contrast mechanisms in epilepsy. Tofts PS. **Magn Reson Imaging** 1995;13(8):1099–106 (67 ref.)
Epileptiform electroencephalographic patterns. Westmoreland BF. **Mayo Clin Proc** 1996 May;71(5):501–11 (37 ref.)
Clinical evaluation and noninvasive electroencephalography. Preoperative evaluation. Cascino GD. **Neuroimaging Clin N Am** 1995 Nov;5(4):547–58 (58 ref.)
Transcranial magnetic stimulation. Gates JR. **Neuroimaging Clin N Am** 1995 Nov;5(4):711–20 (51 ref.)
Magnetic resonance imaging. Neuroimaging and anatomy. Jack CR Jr. **Neuroimaging Clin N Am** 1995 Nov; 5(4):597–622 (94 ref.)
Functional MR imaging in the evaluation of the patient with epilepsy. Functional localization. Latchaw RE, et al. **Neuroimaging Clin N Am** 1995 Nov;5(4):683–93 (20 ref.)
Spike and slow wave localization by magnetoencephalography. Lewine JD, et al. **Neuroimaging Clin N Am** 1995 Nov;5(4):575–96 (45 ref.)
Intracranial electrophysiologic studies. Risinger MW, et al. **Neuroimaging Clin N Am** 1995 Nov;5(4):559–73 (60 ref.)
Functional localization by magnetoencephalography. Rowley HA, et al. **Neuroimaging Clin N Am** 1995 Nov; 5(4):695–710 (92 ref.)
Status epilepticus. Chang CW, et al. **Neurol Clin** 1995 Aug; 13(3):529–48 (58 ref.)
Diagnostic testing of seizure disorders. Gilliam F, et al. **Neurol Clin** 1996 Feb;14(1):61–84 (119 ref.)
Intraoperative electrocorticography in children with medically intractable epilepsy. Tanaka T, et al. **Neurol Med Chir (Tokyo)** 1996 Jul;36(7):440–6 (21 ref.)
[Status epilepticus in the elderly] Cid MA. **Rev Neurol** 1995 Nov–Dec;23(124):1310–3 (27 ref.) **(Spa)**

DRUG THERAPY

Vigabatrin: effect on brain GABA levels measured by nuclear magnetic resonance spectroscopy. Mattson RH, et al. **Acta Neurol Scand Suppl** 1995;162:27–30 (16 ref.)
Pharmacological principles as a basis for polytherapy. Perucca E. **Acta Neurol Scand Suppl** 1995;162:31–4 (16 ref.)
Behavioural abnormalities and retention rates of anti-epilepsy drugs during long-term treatment of epilepsy: a clinical perspective. Schmidt D. **Acta Neurol Scand Suppl** 1995; 162:7–10 (28 ref.)
Acetazolamide in the treatment of seizures. Reiss WG, et al. **Ann Pharmacother** 1996 May;30(5):514–9 (68 ref.)
New drugs for the treatment of epilepsy. Fraser AD. **Clin Biochem** 1996 Apr;29(2):97–110 (114 ref.)
Interactions of valproic acid with carbamazepine and its metabolites' concentrations, concentrations ratios, and level/dose ratios in epileptic children. Liu H, et al. **Clin Neuropharmacol** 1995 Feb;18(1):1–12 (34 ref.)
The role of therapeutic drug monitoring in improving the cost effectiveness of anticonvulsant therapy. Eadie MJ. **Clin Pharmacokinet** 1995 Jul;29(1):29–35 (26 ref.)
Anticonvulsant hypersensitivity syndrome. Licata AL, et al. **Compr Ther** 1996 Mar;22(3):152–5 (22 ref.)
Update in the treatment of epilepsy. Schachter SC. **Compr Ther** 1995 Sep;21(9):473–9 (7 ref.)
Lamotrigine. An update of its pharmacology and therapeutic use in epilepsy. Fitton A, et al. **Drugs** 1995 Oct; 50(4):691–713 (175 ref.)
Vigabatrin. Ben-Menachem E. **Epilepsia** 1995;36 Suppl 2:S95–104 (70 ref.)
Antiepileptic drugs in pediatric practice. Bourgeois BF. **Epilepsia** 1995;36 Suppl 2:S34–45 (100 ref.)
Drug interaction profile of topiramate. Bourgeois BF. **Epilepsia** 1996;37 Suppl 2:S14–S17 (23 ref.)
Antiepileptic drug therapy: when is epilepsy truly intractable? Camfield PR, et al. **Epilepsia** 1996;37 Suppl 1:S60–5 (18 ref.)
Cognitive and behavioral effects of antiepileptic drugs. Devinsky O. **Epilepsia** 1995;36 Suppl 2:S46–65 (106 ref.)
Rational polypharmacy. Ferrendelli JA. **Epilepsia** 1995;36 Suppl 2:S115–8 (11 ref.)
Clobazam, oxcarbazepine, tiagabine, topiramate, and other new antiepileptic drugs. Fisher R, et al. **Epilepsia** 1995;36 Suppl 2:S105–14 (113 ref.)
Neuropharmacology and drug interactions in clinical practice. Graves NM. **Epilepsia** 1995;36 Suppl 2:S27–33 (20 ref.)
Felbamate. Leppik IE. **Epilepsia** 1995;36 Suppl 2:S66–72 (55 ref.)
Gabapentin. McLean MJ. **Epilepsia** 1995;36 Suppl 2:S73–86 (70 ref.)
Efficacy and adverse effects of established and new antiepileptic drugs. Mattson RH. **Epilepsia** 1995;36 Suppl 2:S13–26 (108 ref.)
Lamotrigine. Messenheimer JA. **Epilepsia** 1995;36 Suppl 2:S87–94 (64 ref.)
Utilization of new antiepileptic drugs in children. Pellock JM. **Epilepsia** 1996;37 Suppl 1:S66–73 (40 ref.)
The epidemiology and treatment of chronic and refractory epilepsy. Shorvon SD. **Epilepsia** 1996;37 Suppl 2:S1–S3 (6 ref.)
The effect of age on pharmacokinetics of antiepileptic drugs. Willmore LJ. **Epilepsia** 1995;36 Suppl 5:S14–21 (72 ref.)
Cognitive side-effects of chronic antiepileptic drug treatment: a review of 25 years of research. Vermeulen J, et al. **Epilepsy Res** 1995 Oct;22(2):65–95 (130 ref.)
Antiepileptic drugs and mechanisms of epileptogenesis. A review. Mutani R, et al. **Ital J Neurol Sci** 1995 May; 16(4):217–22 (51 ref.)
Managing patients who have seizure disorders: dental and medical issues. Sanders BJ, et al. **J Am Dent Assoc** 1995 Dec;126(12):1641–7 (18 ref.)
Does early anti-epileptic drug treatment alter the prognosis for remission of the epilepsies? O'Donoghue M, et al. **J R Soc Med** 1996 May;89(5):245–8 (38 ref.)
Neurochemical correlates of antiepileptic drugs in the genetically epilepsy-prone rat (GEPR). Dailey JW, et al. **Life Sci** 1995;58(4):259–66 (49 ref.)
Selection of antiepileptic drugs: a practical approach. Britton JW, et al. **Mayo Clin Proc** 1996 Aug;71(8):778–86 (76 ref.)
Antiepileptic drugs [published erratum appears in N Engl J Med 1996 Feb 15;334(7):479] Brodie MJ, et al. **N Engl J Med** 1996 Jan 18;334(3):168–75 (83 ref.)
Parenteral antiepileptic/anticonvulsant drugs. Mattson RH. **Neurology** 1996 Jun;46(6 Suppl 1):S8–13 (42 ref.)
Cognitive effects of vigabatrin: a review. Monaco F. **Neurology** 1996 Jul;47(1 Suppl 1):S6–11 (71 ref.)
Fosphenytoin use in children. Pellock JM. **Neurology** 1996 Jun;46(6 Suppl 1):S14–6 (8 ref.)
Intravenous administration of fosphenytoin: options for the management of seizures. Ramsay RE, et al. **Neurology** 1996 Jun;46(6 Suppl 1):S17–9 (12 ref.)
Emergency treatment of status epilepticus. Runge JW, et al. **Neurology** 1996 Jun;46(6 Suppl 1):S20–3 (25 ref.)
Intramuscular use of fosphenytoin: an overview. Uthman BM, et al. **Neurology** 1996 Jun;46(6 Suppl 1):S24–8 (28 ref.)
NMDA antagonists: antiepileptic–neuroprotective drugs with diversified neuropharmacological profiles. Sagratella S. **Pharmacol Res** 1995 Jul–Aug;32(1–2):1–13 (124 ref.)
Treatment of childhood epilepsy. Appleton RE. **Pharmacol Ther** 1995;67(3):419–31 (72 ref.)
Interactions involving new antiepileptic drugs. Mawer GE, et al. **Pharmacol Ther** 1995;68(2):209–31 (110 ref.)
Adverse effects of established and new antiepileptic drugs: an attempted comparison. Rogvi-Hansen B, et al. **Pharmacol Ther** 1995;68(3):425–34 (98 ref.)
Clinical pharmacokinetics of new antiepileptic drugs. Walker MC, et al. **Pharmacol Ther** 1995;67(3):351–84 (164 ref.)
Design of clinical antiepileptic drug trials. Binnie CD. **Seizure** 1995 Sep;4(3):187–92 (14 ref.)
Management issues in severe childhood epilepsies. Wallace SJ. **Seizure** 1995 Sep;4(3):215–20 (46 ref.)
[Withdrawal of antiepileptic treatment] Balslev T. **Ugeskr Laeger** 1996 Apr 1;158(14):1961–4 (24 ref.) (Eng. Abstr.) **(Dan)**
[Current anti-epilepsy drugs] Iivanainen M, et al. **Duodecim** 1995;111(8):751–8 (30 ref.) **(Fin)**
[Discontinuation of epilepsy drug therapy] Keränen T. **Duodecim** 1994;110(18):1725–9 (26 ref.) **(Fin)**
[Current viewpoints in the treatment of epilepsies: role of new antiepileptics?] Despland PA. **Schweiz Rundsch Med Prax** 1995 Sep 19;84(38):1036–41 (51 ref.) (Eng. Abstr.) **(Fre)**
[Therapy of epilepsy: trends and effectiveness of new anticonvulsants] Scollo-Lavizzari G, et al. **Schweiz Arch Neurol Psychiatr** 1995;146(4):168–73 (27 ref.) (Eng. Abstr.) **(Ger)**
[Treatment of epilepsy: where are we today?] Wieser HG. **Schweiz Rundsch Med Prax** 1996 Jan 23;85(4):74–9 (29 ref.) (Eng. Abstr.) **(Ger)**
[Drug treatment after a first unprovoked epileptic seizure] Gilad R, et al. **Harefuah** 1995 Jun 15;128(12):806–8 (19 ref.) **(Heb)**
[Molecular mechanisms in epilepsy and possibilities of their therapeutic correction] Jovičić A, et al. **Vojnosanit Pregl** 1994 Jan–Feb;51(1):40–6 (24 ref.) **(Scr)**
[Diagnosis and treatment of drug-resistant epilepsy] Arroyo S. **Neurologia** 1996 Feb;11(2):56–68 (137 ref.) (Eng. Abstr.) **(Spa)**
[Refractory epilepsy in adults and the new antiepileptic drugs: the role of gabapentin] Galdames D, et al. **Rev Med Chil** 1995 Apr;123(4):500–8 (34 ref.) (Eng. Abstr.) **(Spa)**
[The concept and treatment of drug-resistant intractable epilepsy] Iváñez V. **Rev Neurol** 1995 Nov–Dec; 23(124):1214–9 (85 ref.) (Eng. Abstr.) **(Spa)**
[Felbamate: perspectives for new antiepileptic treatment] Pérez-Miranda J, et al. **Rev Neurol** 1995 Nov–Dec; 23(124):1220–5 (46 ref.) (Eng. Abstr.) **(Spa)**
[Interaction of sleep, epilepsy and antiepileptic drugs in an adult] Salas Puig J. **Rev Neurol** 1995 Nov–Dec; 23(124):1287–9 (10 ref.) **(Spa)**
[Epilepsy is difficult to treat during an attack of porphyria] Bylesjö EI, et al. **Lakartidningen** 1996 Jun 26; 93(26–27):2506–8 (15 ref.) **(Swe)**

EPIDEMIOLOGY

Recent developments in the epidemiology of epilepsy. Hauser WA. **Acta Neurol Scand Suppl** 1995;162:17–21 (31 ref.)
The epidemiology and treatment of chronic and refractory epilepsy. Shorvon SD. **Epilepsia** 1996;37 Suppl 2:S1–S3 (6 ref.)
Descriptive epidemiology of epilepsy: contributions of population-based studies from Rochester, Minnesota. Hauser WA, et al. **Mayo Clin Proc** 1996 Jun;71(6):576–86 (15 ref.)
Classifications and epidemiologic considerations of epileptic seizures and epilepsy. So EL. **Neuroimaging Clin N Am** 1995 Nov;5(4):513–26 (38 ref.)
The epidemiology of epilepsy. Past, present, and future. Berg AT, et al. **Neurol Clin** 1996 May;14(2):383–98 (116 ref.)
Clinical profile of patients with epileptic and nonepileptic seizures. Devinsky O, et al. **Neurology** 1996 Jun; 46(6):1530–3 (29 ref.)

ETIOLOGY

Drop attacks. Lee MS, et al. **Adv Neurol** 1995;67:41–52 (99 ref.)
The understanding of epilepsy across three millennia. Eadie MJ. **Clin Exp Neurol** 1994;31:1–12 (16 ref.)
Causes of epilepsy: contributions of the Rochester epidemiology project. Annegers JF, et al. **Mayo Clin Proc** 1996 Jun;71(6):570–5 (37 ref.)
Magnetic resonance imaging in epilepsy. Jack CR Jr. **Mayo Clin Proc** 1996 Jul;71(7):695–711 (70 ref.)
Arachnoid cysts: does surgery improve epileptic seizures and headaches? Koch CA, et al. **Neurosurg Rev** 1995; 18(3):173–81 (37 ref.)
Post-traumatic epilepsy: mechanisms and prevention. Willmore LJ. **Psychiatry Clin Neurosci** 1995 Jun; 49(3):S171–3 (11 ref.)
The aetiologies of epilepsy in tropical Africa. Adamolekun B. **Trop Geogr Med** 1995;47(3):115–7 (29 ref.)
[Clinical aspects of vascular epilepsy in aging] Carod FJ, et al. **Rev Neurol** 1995 Nov–Dec;23(124):1314–7 (11 ref.) **(Spa)**
[Epileptogenesis. Epilepsy and aging] Olaskoaga J, et al. **Rev Neurol** 1995 Nov–Dec;23(124):1297–306 (87 ref.) **(Spa)**

GENETICS

The first gene for an idiopathic epilepsy: a fruitful collaboration of Australian clinical research and molecular genetics [editorial] Berkovic SF, et al. **Aust N Z J Med** 1996 Apr;26(2):154–6 (13 ref.)
Neurochemical correlates of antiepileptic drugs in the genetically epilepsy-prone rat (GEPR). Dailey JW, et al. **Life Sci** 1995;58(4):259–66 (49 ref.)
MRI in cerebral developmental malformations and epilepsy. Kuzniecky RI. **Magn Reson Imaging** 1995;13(8):1137–45 (31 ref.)
Clinical genetics of epilepsy. Iida N, et al. **Psychiatry Clin Neurosci** 1995 Jun;49(3):S207–8 (7 ref.)
Epilepsy and genetics. Kaneko S, et al. **Psychiatry Clin Neurosci** 1995 Jun;49(3):S199–200 (3 ref.)

METABOLISM

Neurochemical and morphological changes associated with human epilepsy. Glass M, et al. **Brain Res Brain Res Rev** 1995 Jul;21(1):29–41 (158 ref.)
Carnitine deficiency in epilepsy: Risk factors and treatment. Coulter DL. **J Child Neurol** 1995 Nov;10 Suppl 2:S32–9 (90 ref.)
Glutamate, GABA and epilepsy. Bradford HF. **Prog Neurobiol** 1995 Dec;47(6):477–511 (185 ref.)
The role of dopamine in epilepsy. Starr MS. **Synapse** 1996 Feb;22(2):159–94 (462 ref.)
[Molecular mechanisms in epilepsy and possibilities of their therapeutic correction] Jovičić A, et al. **Vojnosanit Pregl** 1994 Jan–Feb;51(1):40–6 (24 ref.) **(Scr)**

NURSING

A model of family adaptation to new-onset childhood epilepsy. Austin JK. **J Neurosci Nurs** 1996 Apr;28(2):82–92 (55 ref.)

PATHOLOGY

Magnetic resonance imaging and supplementary motor area epilepsy. Fish DR. **Adv Neurol** 1996;70:341–51 (25 ref.)
Neurochemical and morphological changes associated with human epilepsy. Glass M, et al. **Brain Res Brain Res Rev** 1995 Jul;21(1):29–41 (158 ref.)

EPILEPSY

PHYSIOPATHOLOGY

Negative motor phenomena in generalized epilepsies. A study of atonic seizures. Andermann F, et al. **Adv Neurol** 1995; 67:9–28 (117 ref.)
Supplementary sensorimotor area epilepsy in adults. Bleasel AF, et al. **Adv Neurol** 1996;70:271–84 (54 ref.)
Inhibitory mechanisms of epileptic seizure generation. Engel J Jr. **Adv Neurol** 1995;67:157–71 (52 ref.)
Supplementary sensorimotor area epilepsy in adults. King DW, et al. **Adv Neurol** 1996;70:285–91 (31 ref.)
Unusual features of supplementary sensorimotor area epilepsy: cyclic pattern, unusual sensory aura, startle sensitivity, anoxic encephalopathy, and spontaneous remission. Reutens DC, et al. **Adv Neurol** 1996;70:293–300 (22 ref.)
Hemifacial seizures and cerebellar ganglioglioma: an epilepsy syndrome of infancy with seizures of cerebellar origin. Harvey AS, et al. **Ann Neurol** 1996 Jul;40(1):91–8 (7 ref.)
The understanding of epilepsy across three millennia. Eadie MJ. **Clin Exp Neurol** 1994;31:1–12 (16 ref.)
Management of low-grade gliomas: results of resections without electrocorticography. Fried I. **Clin Neurosurg** 1995;42:453–63 (41 ref.)
Developmental aspects of epileptogenesis. Johnston MV. **Epilepsia** 1996;37 Suppl 1:S2–9 (64 ref.)
Application of spectroscopic imaging in epilepsy. Garcia PA, et al. **Magn Reson Imaging** 1995;13(8):1181–5 (28 ref.)
Diffusion-weighted imaging in epilepsy. Helpern JA, et al. **Magn Reson Imaging** 1995;13(8):1227–31 (32 ref.)
Overview--the role of NMR spectroscopy in epilepsy. Novotny EJ Jr. **Magn Reson Imaging** 1995;13(8):1171–3 (17 ref.)
NMR studies of brain 13C-glucose uptake and metabolism: present status. van Zijl PC, et al. **Magn Reson Imaging** 1995;13(8):1213–21 (44 ref.)
Functional MR imaging in the evaluation of the patient with epilepsy. Functional localization. Latchaw RE, et al. **Neuroimaging Clin N Am** 1995 Nov;5(4):683–93 (20 ref.)
Functional localization by magnetoencephalography. Rowley HA, et al. **Neuroimaging Clin N Am** 1995 Nov; 5(4):695–710 (92 ref.)
Endogenous control of epilepsy: the nigral inhibitory system. Depaulis A, et al. **Prog Neurobiol** 1994 Jan;42(1):33–52 (186 ref.)
Analyses of the molecular basis of kindling development. McNamara JO. **Psychiatry Clin Neurosci** 1995 Jun; 49(3):S175–8 (33 ref.)
Lennox-Gastaut syndrome: a new vista. Ohtahara S, et al. **Psychiatry Clin Neurosci** 1995 Jun;49(3):S179–83 (19 ref.)
Post-traumatic epilepsy: mechanisms and prevention. Willmore LJ. **Psychiatry Clin Neurosci** 1995 Jun; 49(3):S171–3 (11 ref.)
Autonomic epilepsy. Freeman R, et al. **Semin Neurol** 1995 Jun;15(2):158–66 (134 ref.)
[Sleep and intra-ictal epileptic electroencephalographic activities] Autret A. **Neurophysiol Clin** 1995;25(5):263–82 (111 ref.) (Eng. Abstr.) **(Fre)**
[Interaction of epileptic seizures and biological rhythms] Bülau P, et al. **Wien Med Wochenschr** 1995; 145(17–18):448–51 (37 ref.) (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

Does antiepileptic drug therapy prevent the development of "chronic" epilepsy? Shinnar S, et al. **Epilepsia** 1996 Aug; 37(8):701–8 (92 ref.)

PSYCHOLOGY

The development of psychosis in epilepsy: a re-examination of the kindling hypothesis. Smith PF, et al. **Behav Brain Res** 1996 Feb;75(1–2):59–66 (94 ref.)
A model of family adaptation to new-onset childhood epilepsy. Austin JK. **J Neurosci Nurs** 1996 Apr;28(2):82–92 (55 ref.)
Sexuality and related issues in the preadolescent and adolescent female with epilepsy. Mims J. **J Neurosci Nurs** 1996 Apr;28(2):102–6 (34 ref.)
[Depression and epilepsy] Sirota P, et al. **Harefuah** 1995 Nov 15;129(10):423–6 (44 ref.) **(Heb)**
[Epilepsy and delinquent behavior] Arias Horcajadas F, et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1995 Sep–Oct;23(5):235–40 (33 ref.) (Eng. Abstr.) **(Spa)**

RADIONUCLIDE IMAGING

Single photon emission computed tomography. Mullan BP, et al. **Neuroimaging Clin N Am** 1995 Nov;5(4):647–73 (154 ref.)

SURGERY

Latest advances in epilepsy surgery. Silfvenius H. **Acta Neurol Scand Suppl** 1995;162:11–6 (32 ref.)
Surgical ablations of the mesial frontal lobe in humans. Bleasel A, et al. **Adv Neurol** 1996;70:217–35 (57 ref.)
Intractable epilepsy in children. Holmes GL. **Epilepsia** 1996; 37 Suppl 3:14–27 (129 ref.)
Long-term outcome after epilepsy surgery. Spencer SS. **Epilepsia** 1996 Sep;37(9):807–13 (56 ref.)
Surgery for catastrophic localization-related epilepsy in infants. Wyllie E. **Epilepsia** 1996;37 Suppl 1:S22–5 (36 ref.)
Hemispherectomy: a hemidecortication approach and review of 52 cases. Carson BS, et al. **J Neurosurg** 1996 Jun; 84(6):903–11 (59 ref.)
Magnetic resonance imaging and epilepsy: neurosurgical decision making. Fried I. **Magn Reson Imaging** 1995; 13(8):1163–70 (47 ref.)
Surgery for seizures. Engel J Jr. **N Engl J Med** 1996 Mar 7;334(10):647–52 (47 ref.)
Clinical evaluation and noninvasive electroencephalography. Preoperative evaluation. Cascino GD. **Neuroimaging Clin N Am** 1995 Nov;5(4):547–58 (58 ref.)
Epilepsy surgery. Marsh WR. **Neuroimaging Clin N Am** 1995 Nov;5(4):729–38 (7 ref.)
Image-guided surgery of epilepsy. Olivier A, et al. **Neurosurg Clin N Am** 1996 Apr;7(2):229–43 (23 ref.)
The evaluation and image-guided surgical treatment of the patient with a medically intractable seizure disorder. Roberts DW, et al. **Neurosurg Clin N Am** 1996 Apr; 7(2):215–27 (46 ref.)
[Surgical treatment of epilepsy] Dam M. **Ugeskr Laeger** 1996 Apr 1;158(14):1965–8 (21 ref.) (Eng. Abstr.) **(Dan)**
[Problems related to neurosurgical treatment of epilepsy in children] Dulac O, et al. **Arch Pediatr** 1996 Apr;3(4):369–77 (49 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Management of epilepsy in Hungary. Halász P. **Acta Neurol Scand Suppl** 1995;162:24–6 (2 ref.)
Care of patients with epilepsy in the community: will new initiatives address old problems? [see comments] Thapar AK. **Br J Gen Pract** 1996 Jan;46(402):37–42 (69 ref.) Comment in: Br J Gen Pract 1996 Jan;46(402):3–4.
Structured management in primary care of patients with epilepsy [editorial; comment] White P. **Br J Gen Pract** 1996 Jan;46(402):3–4 (14 ref.) Comment on: Br J Gen Pract 1996 Jan;46(402):37–42.
Intravenous immune globulin in the treatment of intractable childhood epilepsy. Duse M, et al. **Clin Exp Immunol** 1996 May;104 Suppl 1:71–6 (68 ref.)
Alternative epilepsy therapies: the ketogenic diet, immunoglobulins, and steroids. Prasad AN, et al. **Epilepsia** 1996;37 Suppl 1:S81–95 (106 ref.)
[Therapy of epilepsy with stimulation of the vagus nerve] Tomović M. **Vojnosanit Pregl** 1994 Mar–Apr;51(2):143–6 (25 ref.) **(Scr)**

VETERINARY

[Seizure disorders in the dog. 1. Clinical features and differential diagnosis] Fischer A. **Tierarztl Prax** 1995 Dec; 23(6):596–602 (30 ref.) (Eng. Abstr.) **(Ger)**
[Significance of electroencephalography for the diagnosis of seizures in dogs] Schütt-Mast I, et al. **Tierarztl Prax** 1996 Apr;24(2):129–36 (6 ref.) (Eng. Abstr.) **(Ger)**

EPILEPSY, ABDOMINAL see **EPILEPSY, TEMPORAL LOBE**

EPILEPSY, ABSENCE

RADIONUCLIDE IMAGING

[Positron-emission tomography in akinetic rigidity syndrome] Goldman S. **Rev Med Brux** 1995 Dec; 16(6):399–403 (35 ref.) (Eng. Abstr.) **(Fre)**

EPILEPSY, ATONIC see **EPILEPSY, GENERALIZED**

EPILEPSY, COMPLEX PARTIAL

PHYSIOPATHOLOGY

Sleep and the temporal lobe. Van Sweden B. **Acta Neurol Belg** 1996 Mar;96(1):19–30 (20 ref.)

EPILEPSY, CRYPTOGENIC see **EPILEPSY**

EPILEPSY, FOCAL see **EPILEPSY, PARTIAL**

EPILEPSY, GENERALIZED

CLASSIFICATION

Atonic phenomena and partial seizures. A reappraisal. So NK. **Adv Neurol** 1995;67:29–39 (33 ref.)

DIAGNOSIS

Drop attacks. Lee MS, et al. **Adv Neurol** 1995;67:41–52 (99 ref.)
Atonic phenomena and partial seizures. A reappraisal. So NK. **Adv Neurol** 1995;67:29–39 (33 ref.)

DRUG THERAPY

Clinical use of drugs useful in the treatment of atonic seizures. Bourgeois B. **Adv Neurol** 1995;67:361–7 (42 ref.)

ETIOLOGY

Preliminary molecular neurobiology study on the pathogenesis of primary epilepsy. Wu XR, et al. **Prog Brain Res** 1995;105:283–8 (17 ref.)
[Rare forms of reflex epilepsy--the epilepsy of calculation and the epilepsy of eating] Karlov VA, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995;95(3):13–6 (18 ref.) (Eng. Abstr.) **(Rus)**

GENETICS

The genetics of idiopathic generalized epilepsy: implications for the understanding of its aetiology. Sander T. **Mol Med Today** 1996 Apr;2(4):173–80 (35 ref.)

PHYSIOPATHOLOGY

Physiology of atonic seizures. Blume WT. **Adv Neurol** 1995; 67:173–9 (38 ref.)
Primary (idiopathic) generalized epilepsy and underlying mechanisms. Niedermeyer E. **Clin Electroencephalogr** 1996 Jan;27(1):1–21 (147 ref.)

EPILEPSY, GENERALIZED PRIMARY see **EPILEPSY, GENERALIZED**

EPILEPSY, GENERALIZED SECONDARY see **EPILEPSY, PARTIAL**

EPILEPSY, GRAND MAL see **EPILEPSY, TONIC-CLONIC**

EPILEPSY, LOCALIZATION-RELATED see **EPILEPSY, PARTIAL**

EPILEPSY, MYOCLONIC

[Progressive myoclonic epilepsy] Sørensen TT, et al. **Ugeskr Laeger** 1996 Jan 8;158(2):153–7 (32 ref.) (Eng. Abstr.) **(Dan)**

DIAGNOSIS

Negative motor phenomena in generalized epilepsies. A study of atonic seizures. Andermann F, et al. **Adv Neurol** 1995; 67:9–28 (117 ref.)
Epileptic negative myoclonus. Tassinari CA, et al. **Adv Neurol** 1995;67:181–97 (40 ref.)
[Epileptogenesis in the elderly. Part II. Spike-wave confusional states. Myoclonic seizure in Alzheimer's disease] Urcola J, et al. **Rev Neurol** 1995 Nov–Dec; 23(124):1307–9 (18 ref.) **(Spa)**

DRUG THERAPY

Mechanism of action of antiepileptic and antimyoclonic drugs. Pranzatelli MR, et al. **Adv Neurol** 1995;67:329–60 (251 ref.)

ETIOLOGY

[Activated mechanisms of epilepsy during sleep and wakefulness] Arroyo Serrano S. **Rev Neurol** 1995 Nov–Dec;23(124):1280–3 (39 ref.) **(Spa)**

GENETICS

Shaking down new epilepsy genes. Allen KM, et al. **Nat Med** 1996 May;2(5):516–8 (19 ref.)

PHYSIOPATHOLOGY

Negative motor phenomena in generalized epilepsies. A study of atonic seizures. Andermann F, et al. **Adv Neurol** 1995; 67:9–28 (117 ref.)
Epileptic negative myoclonus. Tassinari CA, et al. **Adv Neurol** 1995;67:181–97 (40 ref.)
Myoclonus. Shibasaki H. **Curr Opin Neurol** 1995 Aug; 8(4):331–4 (24 ref.)

EPILEPSY, MYOCLONUS see **EPILEPSY, MYOCLONIC**

EPILEPSY, PARTIAL

DIAGNOSIS

Atonic phenomena and partial seizures. A reappraisal. So NK. **Adv Neurol** 1995;67:29–39 (33 ref.)
Magnetic resonance spectroscopy. Garcia PA, et al. **Neuroimaging Clin N Am** 1995 Nov;5(4):675–82 (40 ref.)
Evaluation for surgical treatment of partial epilepsy: an overview. Benbadis SR. **Wis Med J** 1995;94(9):500–4 (27 ref.)
[Rolandic epilepsy] Mukhin KIu, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995;95(3):78–84 (43 ref.) **(Rus)**

DRUG THERAPY

Rationalized polytherapy for epilepsy. Goldsmith P, et al. **Acta Neurol Scand Suppl** 1995;162:35–9 (27 ref.)
[Gabapentin (Neurontin): a new possibility in the add-on therapy of partial epilepsies] Krämer G. **Schweiz Rundsch Med Prax** 1996 Jan 23;85(4):84–93 (106 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

[Rare forms of reflex epilepsy--the epilepsy of calculation and the epilepsy of eating] Karlov VA, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995;95(3):13–6 (18 ref.) (Eng. Abstr.) **(Rus)**

PATHOLOGY

Clinical correlations with hippocampal atrophy. Cascino GD. **Magn Reson Imaging** 1995;13(8):1133–6 (18 ref.)

PHYSIOPATHOLOGY

Wiring, dysmorphogenesis and epilepsy: a hypothesis. Sisodiya SM. **Seizure** 1995 Sep;4(3):169–85 (89 ref.)

RADIOGRAPHY

Early onset bilateral calcifications and epilepsy. Nunes ML, et al. **Pediatr Neurol** 1995 Jul;13(1):80–2 (11 ref.)

RADIONUCLIDE IMAGING

Use of positron emission tomography for the evaluation of epilepsy. DeCarli C, et al. **Neuroimaging Clin N Am** 1995 Nov;5(4):623–45 (134 ref.)

Single photon emission computed tomography studies of partial epilepsies. Jibiki I. **Psychiatry Clin Neurosci** 1995 Jun;49(3):S191–3 (3 ref.)

SURGERY

[Temporal lobectomy: indications and role in the surgery of epilepsy] Benbadis S, et al. **Rev Med Interne** 1995; 16(8):626–35 (40 ref.) (Eng. Abstr.) **(Fre)**

EPILEPSY, PARTIAL COMPLEX see **EPILEPSY, COMPLEX PARTIAL**

EPILEPSY, PETIT MAL see **EPILEPSY, ABSENCE**

EPILEPSY, POST-TRAUMATIC

Causes, prevention, and treatment of post-traumatic epilepsy. Temkin NR, et al. **New Horiz** 1995 Aug;3(3):518–22 (46 ref.)

ETIOLOGY

Penetrating injuries in the Vietnam war. Traumatic unconsciousness, epilepsy, and psychosocial outcome. Salazar AM, et al. **Neurosurg Clin N Am** 1995 Oct; 6(4):715–26 (34 ref.)

PHYSIOPATHOLOGY

Post-traumatic epilepsy and recovery of function from experimental brain damage: a review. Droogan J. **Seizure** 1995 Sep;4(3):163–7 (31 ref.)

EPILEPSY, PSYCHIC EQUIVALENT see **EPILEPSY, COMPLEX PARTIAL**

EPILEPSY, PSYCHOMOTOR see **EPILEPSY, COMPLEX PARTIAL**

EPILEPSY, SIMPLE PARTIAL see **EPILEPSY, PARTIAL**

EPILEPSY, TEMPORAL LOBE

DIAGNOSIS

The diagnosis of hippocampal sclerosis: other techniques. Jackson GD. **Magn Reson Imaging** 1995;13(8):1081–93 (21 ref.)

ETIOLOGY

Photosensitive temporal lobe epilepsy. Benbadis SR, et al. **Neurology** 1996 Jun;46(6):1540–2 (10 ref.)

[Sleep and deprivation in the epilepsy diagnostic] Madoz P. **Rev Neurol** 1995 Nov–Dec;23(124):1271–9 (84 ref.) **(Spa)**

METABOLISM

[N-acetyl-aspartate abnormalities in internal-temporal epileptic foci using proton magnetic resonance spectroscopy] Giroud M, et al. **Rev Neurol (Paris)** 1995 Jun–Jul;151(6–7):404–9 (28 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Clinical correlations with hippocampal atrophy. Cascino GD. **Magn Reson Imaging** 1995;13(8):1133–6 (18 ref.)

PHYSIOPATHOLOGY

Application of high field spectroscopic imaging in the evaluation of temporal lobe epilepsy. Hetherington HP, et al. **Magn Reson Imaging** 1995;13(8):1175–80 (14 ref.)

PSYCHOLOGY

Anatomic correlates of psychological events related to temporolimbic epilepsy. Tackenberg JN, et al. **J Neurosci Nurs** 1996 Apr;28(2):73–81 (51 ref.)

SURGERY

MRI hippocampal volume and neuropsychology in epilepsy surgery. Trenerry MR, et al. **Magn Reson Imaging** 1995; 13(8):1125–32 (47 ref.)

Intracarotid amobarbital procedure. The Wada test. Trenerry MR, et al. **Neuroimaging Clin N Am** 1995 Nov;5(4):721–8 (41 ref.)

[Temporal lobectomy: indications and role in the surgery of epilepsy] Benbadis S, et al. **Rev Med Interne** 1995; 16(8):626–35 (40 ref.) (Eng. Abstr.) **(Fre)**

EPILEPSY, TONIC see **EPILEPSY, GENERALIZED**

EPILEPSY, TONIC-CLONIC

DIAGNOSIS

[Rolandic epilepsy] Mukhin KIu, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995;95(3):78–84 (43 ref.) **(Rus)**

[Epilepsy and psychomotor retardation in a child with aplasia cutis and brachydactyly (Adams–Oliver syndrome)] Verdú Pérez A, et al. **An Esp Pediatr** 1996 Mar;44(3):289–91 (15 ref.) **(Spa)**

PHYSIOPATHOLOGY

Breath-holding spells. Breningstall GN. **Pediatr Neurol** 1996 Feb;14(2):91–7 (35 ref.)

EPILEPSY, TRAUMATIC see **EPILEPSY, POST-TRAUMATIC**

EPILEPSY, UNCINATE see **EPILEPSY, TEMPORAL LOBE**

EPINEPHRINE

see related
RECEPTORS, ADRENERGIC

ADMINISTRATION & DOSAGE

[Self-administration of adrenaline aerosol in anaphylactic reactions after insect stings] Ackermann RW, et al. **Ugeskr Laeger** 1996 Aug 5;158(32):4497–9 (27 ref.) **(Eng. Abstr.)** **(Dan)**

ADVERSE EFFECTS

Ambulatory phlebectomy. A rare complication of local anesthetic: case report and literature review. Olivencia JA. **Dermatol Surg** 1996 Jan;22(1):53–5 (15 ref.)

METABOLISM

Clinical assessment of sympathetic responses to stress. Goldstein DS. **Ann N Y Acad Sci** 1995 Dec 29;771:570–93 (144 ref.)

Adrenaline and its receptors: one hundred years of research. García-Sáinz JA. **Arch Med Res** 1995 Autumn;26(3):205–12 (70 ref.)

EPINEURIUM see **PERIPHERAL NERVES**

EPIPHYSEAL CARTILAGE see **GROWTH PLATE**

EPIPHYSEAL PLATE see **GROWTH PLATE**

EPIPHYSES

GROWTH & DEVELOPMENT

Traumatic ulnar physeal arrest after distal forearm fractures in children. Ray TD, et al. **J Pediatr Orthop** 1996 Mar–Apr; 16(2):195–200 (15 ref.)

INJURIES

Dorsally displaced epiphyseal fracture of the phalangeal base. Hashizume H, et al. **J Hand Surg [Br]** 1996 Feb;21(1):136–8 (10 ref.)

EPIPHYSES, SLIPPED

DIAGNOSIS

The adolescent with slipped capital femoral epiphysis. Benchot R. **J Pediatr Nurs** 1996 Jun;11(3):175–82 (18 ref.)

ETIOLOGY

[Orthopaedic disorders and problems related to obesity] Koshino T. **Nippon Rinsho** 1995 Jun;53 Suppl:382–7 (20 ref.) **(Jpn)**

RADIOGRAPHY

[Slipped capital femoral epiphyses] Kallio P, et al. **Duodecim** 1994;110(19):1802–9 (28 ref.) **(Fin)**

SURGERY

Treatment of the unstable (acute) slipped capital femoral epiphysis. Aronsson DD, et al. **Clin Orthop** 1996 Jan; (322):99–110 (50 ref.)

The adolescent with slipped capital femoral epiphysis. Benchot R. **J Pediatr Nurs** 1996 Jun;11(3):175–82 (18 ref.)

EPIPHYSES, STIPPLED see **CHONDRODYSPLASIA PUNCTATA**

EPIPHYSIOLYSIS see **EPIPHYSES, SLIPPED**

EPIPHYSIS CEREBRI see **PINEAL BODY**

EPIPODOPHYLLOTOXIN see **PODOPHYLLOTOXIN**

EPISCLERITIS see **SCLERITIS**

EPISIOTOMY

The relationship of episiotomy to third and fourth degree lacerations. Golden WE, et al. **J Ark Med Soc** 1996 Feb; 92(9):447–8 (15 ref.)

Benefits and risks of episiotomy: a review of the English-language literature since 1980. Part I. Woolley RJ. **Obstet Gynecol Surv** 1995 Nov;50(11):806–20 (189 ref.)

Benefits and risks of episiotomy: a review of the English-language literature since 1980. Part II. Woolley RJ. **Obstet Gynecol Surv** 1995 Nov;50(11):821–35 (189 ref.)

EPISOMES see **PLASMIDS**

EPISPADIAS

Male epispadias. Diamond DA, et al. **J Urol** 1995 Dec; 154(6):2150–5 (40 ref.)

EPISTASIS, GENETIC

Co-suppression of beta-1,3-glucanase genes in Nicotiana tabacum. de Carvalho Niebel F, et al. **Curr Top Microbiol Immunol** 1995;197:91–103 (39 ref.)

Suppression of flavonoid flower pigmentation genes in Petunia hybrida by the introduction of antisense and sense genes. de Lange P, et al. **Curr Top Microbiol Immunol** 1995; 197:57–75 (88 ref.)

Developmental regulation of co-suppression in Petunia hybrida. Flavell RB, et al. **Curr Top Microbiol Immunol** 1995;197:43–56 (63 ref.)

Sense and antisense inactivation of fruit ripening genes in tomato. Hamilton AJ, et al. **Curr Top Microbiol Immunol** 1995;197:77–89 (70 ref.)

trans-inactivation of homologous sequences in Nicotiana tabacum. Matzke AJ, et al. **Curr Top Microbiol Immunol** 1995;197:1–14 (30 ref.)

DNA methylation and transgene silencing in Petunia hybrida. Meyer P. **Curr Top Microbiol Immunol** 1995;197:15–28 (61 ref.)

Paramutation in maize and related allelic interactions. Patterson GI, et al. **Curr Top Microbiol Immunol** 1995; 197:121–41 (94 ref.)

MIP: an epigenetic gene silencing process in Ascobolus immersus. Rossignol JL, et al. **Curr Top Microbiol Immunol** 1995;197:179–91 (32 ref.)

Transgene inactivation in Arabidopsis thaliana. Scheid OM. **Curr Top Microbiol Immunol** 1995;197:29–42 (57 ref.)

EPISTATIC DEVIATION see **EPISTASIS, GENETIC**

EPISTAXIS

ETIOLOGY

Acute epistaxis. How to spot the source and stop the flow. Alvi A, et al. **Postgrad Med** 1996 May;99(5):83–90, 94–6 (11 ref.)

THERAPY

Interventional neuroradiology of the head and neck. Hurst RW. **Neuroimaging Clin N Am** 1996 May;6(2):473–95 (38 ref.)

Acute epistaxis. How to spot the source and stop the flow. Alvi A, et al. **Postgrad Med** 1996 May;99(5):83–90, 94–6 (11 ref.)

EPITHELIAL NEOPLASMS, MALIGNANT see **CARCINOMA**

EPITHELIOID CELLS

see related
GIANT CELLS

Purely epithelioid schwannoma. Two case reports and a review of the literature. Artico M, et al. **Neurochirurgie** 1996;42(1):61–5 (20 ref.)

EPITHELIOMA see **CARCINOMA**

EPITHELIOMA, BASAL CELL see **CARCINOMA, BASAL CELL**

EPITHELIUM

CHEMISTRY

The leucocyte protein L1 (calprotectin): a putative nonspecific defence factor at epithelial surfaces. Brandtzaeg P, et al. **Adv Exp Med Biol** 1995;371A:201–6 (30 ref.)

CYTOLOGY

Transformations between epithelium and mesenchyme: normal, pathological, and experimentally induced. Hay ED, et al. **Am J Kidney Dis** 1995 Oct;26(4):678–90 (103 ref.)

Factors controlling growth, motility, and morphogenesis of normal and malignant epithelial cells. Birchmeier C, et al. **Int Rev Cytol** 1995;160:221–66 (280 ref.)

EPITHELIUM

Reversal of malignancy by the adenovirus E1a gene. Frisch SM. **Mutat Res** 1996 Feb 19;350(1):261–6 (31 ref.)
[A model of the spatial organization of double-row (pseudostratified) epithelium (a topical article)] Savost'anov GA. **Zh Evol Biokhim Fiziol** 1994 Sep–Oct; 30(5):625–31 (23 ref.) **(Rus)**

EMBRYOLOGY

Epithelium–mesenchyme transition during neural crest development. Duband JL, et al. **Acta Anat (Basel)** 1995; 154(1):63–78 (107 ref.)
An overview of epithelio–mesenchymal transformation. Hay ED. **Acta Anat (Basel)** 1995;154(1):8–20 (101 ref.)
Cell–cell adhesion molecules in epithelial–mesenchymal transformations. Prieto AL, et al. **Acta Anat (Basel)** 1995; 154(1):21–33 (176 ref.)
Epithelio–mesenchymal transformation during formation of the mesoderm in the mammalian embryo. Viebahn C. **Acta Anat (Basel)** 1995;154(1):79–97 (170 ref.)

PHYSIOLOGY

An overview of epithelio–mesenchymal transformation. Hay ED. **Acta Anat (Basel)** 1995;154(1):8–20 (101 ref.)
Cell–cell adhesion molecules in epithelial–mesenchymal transformations. Prieto AL, et al. **Acta Anat (Basel)** 1995; 154(1):21–33 (176 ref.)
Tight junctions and the molecular basis for regulation of paracellular permeability. Anderson JM, et al. **Am J Physiol** 1995 Oct;269(4 Pt 1):G467–75 (63 ref.)
Epithelial integrins. Sheppard D. **Bioessays** 1996 Aug; 18(8):655–60 (65 ref.)
Synovium and epithelia: barriers between self and non–self? Berthelot JM, et al. **Clin Exp Rheumatol** 1995 Jul–Aug; 13(4):517–9 (40 ref.)

VIROLOGY

Virus entry and release in polarized epithelial cells. Compans RW. **Curr Top Microbiol Immunol** 1995;202:209–19 (54 ref.)

EPITHELIUM, ANTERIOR CHAMBER see **ENDOTHELIUM, CORNEAL**

EPITHELIUM, RETINAL PIGMENT see **PIGMENT EPITHELIUM OF EYE**

EPITOPE MAPPING

Malaria transmission–blocking immunity. Identification of epitopes and evaluation of immunogenicity. Kumar N, et al. **Adv Exp Med Biol** 1995;383:65–72 (18 ref.)

EPITOPES

see related
ANTIBODIES, ANTI–IDIOTYPIC
ANTIBODY AFFINITY
EPITOPE MAPPING
MOLECULAR MIMICRY

Use of plant viruses for delivery of vaccine epitopes. Beachy RN, et al. **Ann N Y Acad Sci** 1996 May 25;792:43–9 (16 ref.)
Neutralising epitopes of simian immunodeficiency virus envelope glycoprotein. Kent KA. **J Med Primatol** 1995 May;24(3):145–9 (41 ref.)
Sperm antigens and immunocontraception. Kerr LE. **Reprod Fertil Dev** 1995;7(4):825–30 (74 ref.)
Antigen–specific therapies for the treatment of autoimmune diseases. Hafler DA, et al. **Springer Semin Immunopathol** 1995;17(1):61–76 (78 ref.)
[Epitopes of the target proteins of anti–SS–A/Ro and anti–SS–B/La autoantibodies] Kato T. **Nippon Rinsho** 1995 Oct;53(10):2434–9 (26 ref.) (Eng. Abstr.) **(Jpn)**

ANALYSIS

The enigmatic specificity of gamma delta T cells. Weintraub BC, et al. **Immunol Res** 1995;14(3):163–75 (92 ref.)
[C8–2 (NS5) antibody and epitope analysis] Nozaki C, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:230–5 (11 ref.) **(Jpn)**

CHEMISTRY

Elucidation of T–cell epitopes: a synthetic approach with random peptide libraries. Walden P, et al. **Biochem Soc Trans** 1995 Aug;23(3):678–81 (16 ref.)
Use of macromolecular assemblies as expression systems for peptides and synthetic vaccines. Lomonossoff GP, et al. **Curr Opin Struct Biol** 1996 Apr;6(2):176–82 (66 ref.)

IMMUNOLOGY

The alpha–galactosyl epitope: a sugar coating that makes viruses and cells unpalatable. Rother RP, et al. **Cell** 1996 Jul 26;86(2):185–8 (20 ref.)
New methods to predict MHC–binding sequences within protein antigens. Hammer J. **Curr Opin Immunol** 1995 Apr; 7(2):263–9 (60 ref.)
Autoepitopes in lupus. Harley JB, et al. **J Lab Clin Med** 1995 Dec;126(6):509–16 (75 ref.)
New treatment options for patients with melanoma: review of melanoma–derived T–cell epitope–based peptide vaccines. Maeurer MJ, et al. **Melanoma Res** 1996 Feb; 6(1):11–24 (102 ref.)
Mutant ras epitopes as targets for cancer vaccines. Abrams SI, et al. **Semin Oncol** 1996 Feb;23(1):118–34 (79 ref.)
[Role of antigen specific T–cell in collagen diseases] Yamamoto K. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Feb;18(1):1–13 (40 ref.) **(Jpn)**
[Epitopes of hepatitis B virus nucleocapsid protein] Ehata T, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:148–54 (17 ref.) **(Jpn)**
[HCV core specific CTL and epitope] Kita H, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:156–62 (19 ref.) **(Jpn)**
[Linear B cell epitopes located on core and NS3 regions of HCV] Ueda S. **Nippon Rinsho** 1995 Sep;53 Suppl:123–8 (21 ref.) **(Jpn)**

METABOLISM

A family of murine NK cell receptors specific for target cell MHC class I molecules. Yokoyama WM, et al. **Semin Immunol** 1995 Apr;7(2):89–101 (93 ref.)

THERAPEUTIC USE

From epitopes to peptides to immunotherapy. Hoyne G, et al. **Clin Immunol Immunopathol** 1996 Sep;80(3 Pt 2):S23–30 (90 ref.)
T–cell immunotherapy of tumors by adoptive transfer of cytotoxic T lymphocytes and by vaccination with minimal essential epitopes. Melief CJ, et al. **Immunol Rev** 1995 Jun; 145:167–77 (42 ref.)

EPOPROSTENOL

ADMINISTRATION & DOSAGE

Prostacyclin in primary pulmonary hypertension. Magnani B, et al. **Eur Heart J** 1996 Jan;17(1):18–24 (36 ref.)

AGONISTS

[Prostacyclin mimetics with non–prostanoid structures] Kondo K, et al. **Nippon Yakurigaku Zasshi** 1995 Sep; 106(3):181–91 (21 ref.) (Eng. Abstr.) **(Jpn)**

ANALYSIS

[Prostacyclin and metabolites] Suzuki H, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:709–12 (13 ref.) **(Jpn)**

METABOLISM

Gene therapy to restore prostacyclin presence to injured endothelium. Willerson JT, et al. **Trans Am Clin Climatol Assoc** 1994;106:100–7; discussion 107–8 (41 ref.)
[Prostacyclin and metabolites] Suzuki H, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:709–12 (13 ref.) **(Jpn)**

PHARMACOLOGY

Focus on prostacyclin and its novel mimetics. Wise H, et al. **Trends Pharmacol Sci** 1996 Jan;17(1):17–21 (51 ref.)

PHYSIOLOGY

Interactions between endothelial secretogogues. Gryglewski RJ. **Ann Med** 1995 Jun;27(3):421–7 (80 ref.)
Focus on prostacyclin and its novel mimetics. Wise H, et al. **Trends Pharmacol Sci** 1996 Jan;17(1):17–21 (51 ref.)

THERAPEUTIC USE

Prostacyclin in primary pulmonary hypertension. Magnani B, et al. **Eur Heart J** 1996 Jan;17(1):18–24 (36 ref.)

EPOXIDE HYDRASES see **EPOXIDE HYDROLASES**

EPOXIDE HYDRATASES see **EPOXIDE HYDROLASES**

EPOXIDE HYDROLASES

METABOLISM

Leukotriene A4 hydrolase and leukotriene B4 metabolism. Yokomizo T, et al. **J Lipid Mediat Cell Signal** 1995 Oct; 12(2–3):321–32 (77 ref.)

EPOXIDES see **EPOXY COMPOUNDS**

EPOXY COMPOUNDS

PHARMACOLOGY

Influence of etomoxir on the expression of several genes in liver, testis and heart. Hegardt FG, et al. **Gen Pharmacol** 1995 Sep;26(5):897–904 (33 ref.)

EPOXYTRICHOTHECENES see **TRICHOTHECENES**

EPSILON FC RECEPTORS see **RECEPTORS, IGE**

EPSTEIN–BARR VIRUS see **HERPESVIRUS 4, HUMAN**

EPSTEIN–BARR VIRUS SYNDROME, CHRONIC see **FATIGUE SYNDROME, CHRONIC**

EPTASTATIN see **PRAVASTATIN**

EPULIS, GIANT CELL see **GRANULOMA, GIANT CELL**

EQUIDAE

GENETICS

[DNA fingerprinting in wild equid and Poitou ass breeding] Werner P, et al. **Schweiz Arch Tierheilkd** 1995;137(8):395–7 (10 ref.) **(Ger)**

EQUILIBRIUM

Investigations of disorders of balance. Rudge P, et al. **J Neurol Neurosurg Psychiatry** 1995 Dec;59(6):568–78 (70 ref.)
Mobility and balance in the elderly: a guide to bedside assessment. MacKnight C, et al. **Postgrad Med** 1996 Mar; 99(3):269–71, 275–6 (19 ref.)

PHYSIOLOGY

New diagnostic tests for the function of utricles, saccules and somatic graviceptors. Mittelstaedt H. **Acta Otolaryngol Suppl (Stockh)** 1995;520 Pt 1:188–93 (5 ref.)
Balance and equilibrium, I: The vestibule and semicircular canals. Swartz JD, et al. **AJNR Am J Neuroradiol** 1996 Jan;17(1):17–21 (12 ref.)
Neurodevelopmental treatment: application to nursing and effects on the hemiplegic stroke patient. Hafsteinsdóttir TB. **J Neurosci Nurs** 1996 Feb;28(1):36–47 (45 ref.)

EQUINE INFLUENZA VIRUS see **ORTHOMYXOVIRUSES TYPE A**

EQUIPMENT AND SUPPLIES

STANDARDS

Analytical instruments for stable isotopic tracers in mineral metabolism. Yergey AL. **J Nutr** 1996 Jan;126(1):355S–361S (59 ref.)

EQUIPMENT CONTAMINATION

Intravascular device–related infections in cancer patients. Raad II, et al. **Cancer Treat Res** 1995;79:211–31 (149 ref.)
Dental unit water contamination. Peters E, et al. **J Can Dent Assoc** 1996 Jun;62(6):492–5 (41 ref.)
The environmental risk factors associated with medical and dental equipment in the transmission of Burkholderia (Pseudomonas) cepacia in cystic fibrosis patients. Pankhurst CL, et al. **J Hosp Infect** 1996 Apr;32(4):249–55 (32 ref.)
[What are the non transfusional modes of transmission of hepatitis C virus?] Serfaty L, et al. **Gastroenterol Clin Biol** 1995 May;19(5):525–33 (110 ref.) **(Fre)**
[Transmission of infection in oral medicine. Evaluation of the risk of transmission in the office surgery] Vacher C, et al. **Rev Stomatol Chir Maxillofac** 1996;97(2):121–4 (7 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

The endoscope and infection transmission: the problems and how to avoid them. Benjamin SB. **Cleve Clin J Med** 1995 Sep–Oct;62(5):279–80 (2 ref.)

EQUIPMENT DESIGN

see related
DENTURE DESIGN

Integrating instruments and the laboratory information system. Chou D. **Am J Clin Pathol** 1996 Apr;105(4 Suppl 1):S60–4 (10 ref.)
Intravenous drug delivery systems: toward an intravenous "vaporizer". Egan TD. **J Clin Anesth** 1996 May;8(3 Suppl):8S–14S (38 ref.)
The need for ergonomics considerations for the design and development of agricultural machinery in Thailand. Mamansari DU, et al. **J Hum Ergol (Tokyo)** 1995 Jun; 24(1):61–72 (11 ref.)

EQUIPMENT, DISPOSABLE see **DISPOSABLE EQUIPMENT**

EQUIPMENT REUSE

Sterilization and reprocessing of materials and medical devices—reusability. Jayabalan M. **J Biomater Appl** 1995 Jul;10(1):97–112 (39 ref.)
[Questions about re–sterilization and reuse of sterile disposable devices] Petrás G, et al. **Orv Hetil** 1995 Oct 22;136(43):2339–42 (39 ref.) (Eng. Abstr.) **(Hun)**

ECONOMICS

Reuse of coronary angioplasty equipment: technical and clinical issues [editorial] Mak K–H, et al. **Am Heart J** 1996 Mar;131(3):624–30 (49 ref.)

EQUIPMENT SAFETY

[European regulations concerning medical devices] Savarino L, et al. **Minerva Med** 1995 Nov;86(11):481–93 (26 ref.) (Eng. Abstr.) **(Ita)**

STANDARDS

Electrical safety measures for physicians using electromedical equipment. Laks MM, et al. **Semin Neurol** 1995 Sep; 15(3):311–6 (24 ref.)

ERBA ONCOGENE PROTEINS see **ONCOGENE PROTEINS V-ERBA**

ERBA PROTO-ONCOGENE PRODUCTS see **RECEPTORS, THYROID HORMONE**

ERBB-2 GENES see **GENES, ERBB-2**

ERBB-1 PROTO-ONCOGENE PRODUCTS see **RECEPTORS, EPIDERMAL GROWTH FACTOR-UROGASTRONE**

ERBB-2 PROTO-ONCOGENE PROTEINS see **PROTO-ONCOGENE PROTEINS C-ERBB-2**

ERCP see **CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE**

ERECTILE DYSFUNCTION see **IMPOTENCE**

ERGASTOPLASM see **ENDOPLASMIC RETICULUM**

ERGOLINES

THERAPEUTIC USE

New drugs for hyperprolactinaemia. **Drug Ther Bull** 1995 Sep;33(9):65–7 (24 ref.)

Cabergoline: a new drug for the treatment of hyperprolactinaemia. Ferrari C, et al. **Hum Reprod** 1995 Jul;10(7):1647–52 (46 ref.)

ERGOLOID MESYLATES

THERAPEUTIC USE

Drug treatment of Alzheimer's disease. Effects on caregiver burden and patient quality of life. Hollister L, et al. **Drugs Aging** 1996 Jan;8(1):47–55 (58 ref.)

ERGOMETRY

see related
EXERTION

The utility of isokinetic dynamometry in the assessment of human muscle function. Gleeson NP, et al. **Sports Med** 1996 Jan;21(1):18–34 (86 ref.)

METHODS

An ultrasonic time-of-flight system for hand movement measurement. Berners AC, et al. **Physiol Meas** 1995 Nov; 16(4):203–11 (13 ref.)

ERGONOMICS see **HUMAN ENGINEERING**

ERGOT ALKALOIDS

ADVERSE EFFECTS

Accidental administration of an ergot alkaloid to a neonate. Baum CR, et al. **Pediatrics** 1996 Sep;98(3 Pt 1):457–8 (8 ref.)

Teratogen update: ergot and ergotamine. Raymond GV. **Teratology** 1995 May;51(5):344–7 (19 ref.)

ERGOT ALKALOIDS, HYDROGENATED see **ERGOLOID MESYLATES**

ERGOTAMINE

ADVERSE EFFECTS

Aortic and mitral valve disease induced by ergotamine therapy for migraine: a case report and review of the literature. Hendrikx M, et al. **J Heart Valve Dis** 1996 Mar; 5(2):235–7 (14 ref.)

Teratogen update: ergot and ergotamine. Raymond GV. **Teratology** 1995 May;51(5):344–7 (19 ref.)

THERAPEUTIC USE

Pharmacologic treatment of recurrent pediatric headache. Graf WD, et al. **Pediatr Ann** 1995 Sep;24(9):477–84 (27 ref.)

[Prophylactic treatment of chronic cluster headache] Alberca R. **Rev Neurol** 1995;23 Suppl 4:S530–4 (55 ref.) **(Spa)**

[Prophylactic treatment of episodic forms of cluster headache] Liaño H, et al. **Rev Neurol** 1995;23 Suppl 4:S525–9 (29 ref.) **(Spa)**

[Symptomatic treatment of cluster headache] Titus F. **Rev Neurol** 1995;23 Suppl 4:S519–24 (46 ref.) **(Spa)**

[Treatment of the acute migraine attack] Titus F. **Rev Neurol** 1995;23 Suppl 2:S203–7 (49 ref.) **(Spa)**

ERGOTAMINE DERIVATIVES

CLASSIFICATION

[Ergotamine derivatives] Balcells M. **Rev Neurol** 1995;23 Suppl 2:S162–5 (25 ref.) **(Spa)**

PHARMACOLOGY

[Ergotamine derivatives] Balcells M. **Rev Neurol** 1995;23 Suppl 2:S162–5 (25 ref.) **(Spa)**

ERGOTAMINE TARTRATE see **ERGOTAMINE**

ERUCIC ACIDS

THERAPEUTIC USE

Adrenoleukodystrophy: molecular genetics, pathology, and Lorenzo's oil. Moser HW, et al. **Brain Pathol** 1995 Jul; 5(3):259–66 (72 ref.)

Komrower Lecture. Adrenoleukodystrophy: natural history, treatment and outcome. Moser HW. **J Inherit Metab Dis** 1995;18(4):435–47 (47 ref.)

ERWINIA

METABOLISM

[Carotenoid biosynthetic pathway elucidated at the gene level] Misawa N. **Tanpakushitsu Kakusan Koso** 1996 Apr; 41(4):337–46 (47 ref.) **(Jpn)**

ERYSIPELAS

PREVENTION & CONTROL

[Adjuvant therapy in lymphedema] Brenke R, et al. **Z Lymphol** 1996 Jun;20(1):31–5 (10 ref.) (Eng. Abstr.) **(Ger)**

ERYTHEMA

CONGENITAL

[Darier's erythema annulare centrifugum of neonatal onset with a 15 years' follow-up. Efficacy of interferon and role of cytokines] Guillet MH, et al. **Ann Dermatol Venereol** 1995;122(6–7):422–6 (31 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

[Cutaneous granulomatous lesions in congenital immune deficiencies. 5 cases] Paul C, et al. **Ann Dermatol Venereol** 1995;122(8):501–6 (34 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Erythema gyratum repens unassociated with underlying malignancy. Kawakami T, et al. **J Dermatol** 1995 Aug; 22(8):587–9 (16 ref.)

Erythematous papules in a patient with cardiac myxoma: a case report and review of the literature. Misago N, et al. **J Dermatol** 1995 Aug;22(8):600–5 (22 ref.)

ERYTHEMA CHRONICUM MIGRANS

DIAGNOSIS

Misdiagnosis of erythema migrans. Feder HM Jr, et al. **Am J Med** 1995 Oct;99(4):412–9 (31 ref.)

[Erythema (chronicum) migrans. The clinical variability of the earliest manifestation of Lyme borreliosis] Mrowietz U. **Dtsch Med Wochenschr** 1996 Aug 2;121(31–32):988–93 (24 ref.) **(Ger)**

ERYTHEMA INFECTIOSUM

Parvovirus B19: an expanding spectrum of disease. Cohen B. **BMJ** 1995 Dec 9;311(7019):1549–52 (45 ref.)

Human parvovirus B19 in pregnancy. Finch CM. **J Obstet Gynecol Neonatal Nurs** 1995 Jul–Aug;24(6):495–8 (20 ref.)

Parvovirus B19 infection. Associated diseases, common and uncommon. Qari M, et al. **Postgrad Med** 1996 Jul; 100(1):239–43, 246, 252 (10 ref.)

[Parvovirus B19 infection. Current status] Karmochkine M, et al. **Ann Dermatol Venereol** 1996;123(3):208–13 (61 ref.) **(Fre)**

[Human parvovirus B19 infection. Update] Karmochkine M. **Rev Med Interne** 1995;16(12):905–12 (67 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

Parvovirus B19 infection. Kerr JR. **Eur J Clin Microbiol Infect Dis** 1996 Jan;15(1):10–29 (222 ref.)

[Cardiac involvement in fetal parvovirus B19 infection] Soulié JC. **Pathol Biol (Paris)** 1995 May;43(5):416–9 (22 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Viral arthritis: the lessons of parvovirus B19. Mangi RJ. **Hosp Pract (Off Ed)** 1995 Nov 15;30(11):65–72 (7 ref.)

[[Human parvovirus B19 and its clinical significance] Schwarz TF, et al. **Hautarzt** 1995 Dec;46(12):831–5 (44 ref.) (Eng. Abstr.) **(Ger)**

[Juvenile chronic arthritis (JCA) or chronic arthropathy due to parvovirus B19?] Andreu Alapont E, et al. **An Esp Pediatr** 1996 Feb;44(2):157–8 (14 ref.) **(Spa)**

ETIOLOGY

[Parvovirus B19 (PV-B19) and the human diseases it causes] Iavorkovskiĭ LI. **Ter Arkh** 1995;67(11):56–8 (30 ref.) (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

Leukophagocytosis in human parvovirus B19-induced transient bicytopenia in a healthy child. Wakamoto H, et al. **Acta Paediatr Jpn** 1996 Jun;38(3):278–81 (19 ref.)

PHYSIOPATHOLOGY

Parvovirus B19 infection and hematopoiesis. Brown KE, et al. **Blood Rev** 1995 Sep;9(3):176–82 (30 ref.)

[Parvovirus B19 infection. New physiopathological approaches] Labau E, et al. **Presse Med** 1996 Feb 3; 25(4):162–6 (26 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Parvovirus infection and its treatment. Young NS. **Clin Exp Immunol** 1996 May;104 Suppl 1:26–30 (31 ref.)

VIROLOGY

Viral arthritis: the lessons of parvovirus B19. Mangi RJ. **Hosp Pract (Off Ed)** 1995 Nov 15;30(11):65–72 (7 ref.)

New pathogens, and diseases old and new. I) Afipia felis and Rochalimaea. II) Parvovirus B 19. III) herpesvirus 6. Zannolli R, et al. **Panminerva Med** 1995 Dec;37(4):238–47 (111 ref.)

ERYTHEMA MULTIFORME

see related
REITER'S DISEASE

ERYTHEMA NODOSUM

Erythema nodosum leprosum. Meyerson MS. **Int J Dermatol** 1996 Jun;35(6):389–92 (65 ref.)

ETIOLOGY

Erythema nodosum: prospective study of 32 cases. Fernandes NC, et al. **Rev Inst Med Trop Sao Paulo** 1994 Nov–Dec; 36(6):507–13 (47 ref.)

[Rheumatic involvement in Hansen's disease] Cossermelli-Messina W, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1995 Mar–Apr; 50(2):107–10 (50 ref.) (Eng. Abstr.) **(Por)**

ERYTHREMIA see **POLYCYTHEMIA VERA**

ERYTHREMIC MYELOSIS see **LEUKEMIA, ERYTHROBLASTIC, ACUTE**

ERYTHROBLASTIC LEUKEMIA, ACUTE see **LEUKEMIA, ERYTHROBLASTIC, ACUTE**

ERYTHROBLASTOSIS, FETAL

see related
JAUNDICE, NEONATAL

Management of neonatal Rh disease. Peterec SM. **Clin Perinatol** 1995 Sep;22(3):561–92 (192 ref.)

In vitro assays to predict the severity of hemolytic disease of the newborn. Hadley AG. **Transfus Med Rev** 1995 Oct; 9(4):302–13 (68 ref.)

COMPLICATIONS

[Inspissated bile syndrome] Isobe K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):578–81 (18 ref.) **(Jpn)**

GENETICS

Rh haemolytic disease of the newborn and Rh genotyping by RFLP—and allele-specific—PCR. Le Van Kim C, et al. **Transfus Clin Biol** 1995;2(4):317–24 (16 ref.)

PREVENTION & CONTROL

The introduction of human monoclonal anti-D for therapeutic use. Fletcher A, et al. **Transfus Med Rev** 1995 Oct;9(4):314–26 (87 ref.)

THERAPY

Fetal transfusion for red blood cell alloimmunization in pregnancy. Schumacher B, et al. **Obstet Gynecol** 1996 Jul; 88(1):137–50 (161 ref.)

ERYTHROCYTE ANION TRANSPORT PROTEIN see

ERYTHROCYTE ANION TRANSPORT PROTEIN

BAND 3 PROTEIN

ERYTHROCYTE APLASIA see **RED-CELL APLASIA, PURE**

ERYTHROCYTE BURST-PROMOTING FACTOR see **INTERLEUKIN-3**

ERYTHROCYTE DEFORMABILITY

see related
HEMORHEOLOGY

Osmotic scan ektacytometry in clinical diagnosis. Johnson RM, et al. **J Pediatr Hematol Oncol** 1996 May;18(2):122–9 (33 ref.)

ERYTHROCYTE FILTERABILITY see **ERYTHROCYTE DEFORMABILITY**

ERYTHROCYTE GHOST see **ERYTHROCYTE MEMBRANE**

ERYTHROCYTE HEMOGLOBIN, MEAN CELL see **ERYTHROCYTE INDICES**

ERYTHROCYTE INDICES

[Old and new red blood cell indices (editorial)] Seppä K, et al. **Duodecim** 1994;110(5):467–9 (17 ref.) **(Fin)**

ERYTHROCYTE MEMBRANE

CHEMISTRY

Biochemical approaches to the detection and characterization of membrane proteins carrying blood group determinants. Blanchard D. **Transfus Clin Biol** 1995;2(4):217–22 (19 ref.)

Red cell membrane polypeptides under normal conditions and in genetic disorders. Delaunay J. **Transfus Clin Biol** 1995;2(4):207–16 (29 ref.)

Glycosyl phosphatidylinositol-linked blood group antigens and paroxysmal nocturnal hemoglobinuria. Telen MJ. **Transfus Clin Biol** 1995;2(4):277–90 (73 ref.)

IMMUNOLOGY

ABH and Colton blood group antigens on aquaporin-1, the human red cell water channel protein. Agre P, et al. **Transfus Clin Biol** 1995;2(4):303–8 (21 ref.)

METABOLISM

Urea transport and Kidd blood groups. Cartron JP, et al. **Transfus Clin Biol** 1995;2(4):309–15 (24 ref.)

MNSs and major glycophorins of human erythrocytes. Cartron JP, et al. **Transfus Clin Biol** 1995;2(4):251–8 (12 ref.)

Gerbich blood groups and minor glycophorins of human erythrocytes. Colin Y. **Transfus Clin Biol** 1995;2(4):259–68 (47 ref.)

ERYTHROCYTE MEMBRANE BAND 3 PROTEIN see **BAND 3 PROTEIN**

ERYTHROCYTE SIALOGLYCOPROTEIN see **GLYCOPHORIN**

ERYTHROCYTE SIZE DETERMINATION see **ERYTHROCYTE INDICES**

ERYTHROCYTE SUBSTITUTES see **BLOOD SUBSTITUTES**

ERYTHROCYTE TRANSFUSION

Red blood cell transfusion practices in the neonate. Strauss RG. **Clin Perinatol** 1995 Sep;22(3):641–55 (48 ref.)

Small volume red blood cell transfusions for neonatal patients. Hume H, et al. **Transfus Med Rev** 1995 Jul; 9(3):187–99 (65 ref.)

[Use of red blood cells to compensate for surgical blood loss in adults. Consensus development conference. Paris, 17 December 1993] **Ann Fr Anesth Reanim** 1995;14 Suppl 1:1–117 (0 ref.) **(Fre)**

UTILIZATION

Epidemiology of red blood cell utilization. Vamvakas EC. **Transfus Med Rev** 1996 Jan;10(1):44–61 (65 ref.)

ERYTHROCYTE VOLUME

PHYSIOLOGY

From low hematocrit physiology to isovolemic hemodilution. Oriani G, et al. **Int J Artif Organs** 1995 Mar;18(3):143–9 (19 ref.)

ERYTHROCYTE VOLUME, MEAN CELL see **ERYTHROCYTE INDICES**

ERYTHROCYTES

Erythrocyte complement receptors. Birmingham DJ. **Crit Rev Immunol** 1995;15(2):133–54 (155 ref.)

Myelodysplastic syndrome associated with erythrophagocytosis by blasts and myeloid cells. Kuyama J, et al. **Int J Hematol** 1995 Dec;62(4):243–6 (14 ref.)

[Current data on the counting of weak leukocyte concentrations in labile blood products] Masse M. **Transfus Clin Biol** 1995;2(5):365–72 (19 ref.) (Eng. Abstr.) **(Fre)**

CHEMISTRY

Molecular genetic basis of red cell markers and its forensic application. Ikemoto S, et al. **Forensic Sci Int** 1996 Jun 28;80(1–2):147–61 (42 ref.)

CYTOLOGY

Isolating fetal nucleated red blood cells from maternal blood: the Baylor experience--1995. Simpson JL, et al. **Prenat Diagn** 1995 Oct;15(10):907–12 (19 ref.)

Red blood cells, phase contrast, interference contrast microscopy and microspectrophotometry. Marsden NV. **Ups J Med Sci** 1995;100(1):33–40 (12 ref.)

DRUG EFFECTS

Erythrocytes as target cells for testing bacterial adhesins. Goldhar J. **Methods Enzymol** 1995;253:43–50 (32 ref.)

ENZYMOLOGY

Molecular basis of erythroenzymopathies associated with hereditary hemolytic anemia: tabulation of mutant enzymes. Miwa S, et al. **Am J Hematol** 1996 Feb;51(2):122–32 (105 ref.)

Hereditary red cell enzymopathies. Arya R, et al. **Blood Rev** 1995 Sep;9(3):165–75 (155 ref.)

Cholinesterase inhibition: complexities in interpretation. Lotti M. **Clin Chem** 1995 Dec;41(12 Pt 2):1814–8 (22 ref.)

Molecular defects of erythroid 5-aminolevulinate synthase in X-linked sideroblastic anemia. Bottomley SS, et al. **J Bioenerg Biomembr** 1995 Apr;27(2):161–8 (50 ref.)

[Red cell enzyme activities] Miwa S. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:254–7 (7 ref.) **(Jpn)**

[Erythrocyte transketolase] Yasuda K, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:258–61 (10 ref.) **(Jpn)**

[Erythrocyte glutathione reductase (EGR)] Yasuda K, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:218–20 (12 ref.) **(Jpn)**

IMMUNOLOGY

Hemolytic disorders associated with cancer. Rytting M, et al. **Hematol Oncol Clin North Am** 1996 Apr;10(2):365–76 (87 ref.)

METABOLISM

Three cases of hereditary nonspherocytic hemolytic anemia associated with red blood cell glutathione deficiency. Hirono A, et al. **Blood** 1996 Mar 1;87(5):2071–4 (28 ref.)

Diffusional water permeability of mammalian red blood cells. Benga G, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1995 Dec; 112(4):653–9 (54 ref.)

[Dynamics of photosensitizer in the cell] Aizawa K, et al. **Gan To Kagaku Ryoho** 1996 Jan;23(1):22–6 (5 ref.) (Eng. Abstr.) **(Jpn)**

PARASITOLOGY

[Physiopathology of symptoms of malaria. Role of cytokines, cytoadherence and premunition] Hommel M. **Presse Med** 1996 Jan 20;25(2):70–6 (54 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Haemoglobin function in intact lamprey erythrocytes: interactions with membrane function in the regulation of gas transport and acid–base balance. Nikinmaa M, et al. **J Exp Biol** 1995 Dec;198 (Pt 12):2423–30 (42 ref.)

Red cell polymorphisms in nonhuman primates: a review. Socha WW, et al. **J Med Primatol** 1995 Dec;24(4):282–305 (115 ref.)

Plasma skimming in vascular trees: numerical estimates of symmetry recovery lengths. Carr RT, et al. **Microcirculation** 1995 Dec;2(4):345–53 (25 ref.)

Mechanics of blood flow in the microcirculation. Secomb TW. **Symp Soc Exp Biol** 1995;49:305–21 (41 ref.)

[The rheological properties of the erythrocytes. Current study methods] Katiukhin LN. **Fiziol Zh Im I M Sechenova** 1995 Jun;81(6):122–9 (24 ref.) (Eng. Abstr.) **(Rus)**

ULTRASTRUCTURE

Can nucleated erythrocytes found in maternal venous blood be used in the noninvasive prenatal diagnosis of fetal chromosome abnormalities? Slunga-Tallberg A, et al. **Eur J Hum Genet** 1995;3(4):264–70 (46 ref.)

ERYTHROCYTOSIS see **POLYCYTHEMIA**

ERYTHRODERMA see **DERMATITIS, EXFOLIATIVE**

ERYTHRODERMA, SEZARY see **SEZARY SYNDROME**

ERYTHROID PRECURSOR CELLS see **ERYTHROID PROGENITOR CELLS**

ERYTHROID PROGENITOR CELLS

DRUG EFFECTS

Enhancement of erythroid colony growth by triiodothyronine in cell cultures from bone marrow of normal and anemic rats with chronic renal failure. Malgor LA, et al. **Acta Physiol Pharmacol Ther Latinoam** 1995; 45(2):79–86 (40 ref.)

Cellular mechanism of resistance to erythropoietin. Casadevall N. **Nephrol Dial Transplant** 1995;10 Suppl 6:27–30 (34 ref.)

ERYTHROLEUKEMIA see **LEUKEMIA, ERYTHROBLASTIC, ACUTE**

ERYTHROMYCIN

ADVERSE EFFECTS

Erythromycin-induced polymorphous ventricular tachycardia with normal QT interval. Chennareddy SB, et al. **Am Heart J** 1996 Sep;132(3):691–4 (11 ref.)

Erythromycin-induced acute pancreatitis. Fang CC, et al. **J Toxicol Clin Toxicol** 1996;34(1):93–5 (13 ref.)

CHEMISTRY

[Effect of the molecular structure of azithromycin on pharmacokinetics and the antimicrobial activity] Pechère JC. **Pathol Biol (Paris)** 1995 Jun;43(6):483–7 (8 ref.) (Eng. Abstr.) **(Fre)**

PHARMACOLOGY

Erythromycin-resistant Staphylococcus aureus in Denmark. Westh H. **APMIS Suppl** 1996;57:1–37 (126 ref.)

[Azithromycin: critical points] Philippon A, et al. **Pathol Biol (Paris)** 1995 Jun;43(6):488–97 (55 ref.) (Eng. Abstr.) **(Fre)**

THERAPEUTIC USE

Benzamycin gel for acne. **Drug Ther Bull** 1995 Aug; 33(8):62–4 (13 ref.)

Treatment of infection caused by toxigenic and non-toxigenic strains of Corynebacterium diphtheriae. Wilson AP. **J Antimicrob Chemother** 1995 Jun;35(6):717–20 (33 ref.)

Antibiotic resistance: relationship to persistence of group A streptococci in the upper respiratory tract. Gerber MA. **Pediatrics** 1996 Jun;97(6 Pt 2):971–5 (59 ref.)

[Azithromycin, pharmacodynamic evaluation in animal models] Lagrange PH. **Pathol Biol (Paris)** 1995 Jun; 43(6):515–23 (37 ref.) (Eng. Abstr.) **(Fre)**

[Treatment of radiotherapy-induced gastroparesis with erythromycin] Sturm A, et al. **Dtsch Med Wochenschr** 1996 Mar 29;121(13):402–5 (16 ref.) (Eng. Abstr.) **(Ger)**

ERYTHROPOIESIS

Interaction of inflammatory cytokines and erythropoeitin in iron metabolism and erythropoiesis in anaemia of chronic disease. Jongen-Lavrencic M, et al. **Clin Rheumatol** 1995 Sep;14(5):519–25 (93 ref.)

[Erythropoiesis and use of hematopoietic growth factors in children] Illum NO. **Ugeskr Laeger** 1996 Jul 15; 158(29):4171–4 (10 ref.) **(Dan)**

DRUG EFFECTS

Enhancement of erythroid colony growth by triiodothyronine in cell cultures from bone marrow of normal and anemic rats with chronic renal failure. Malgor LA, et al. **Acta Physiol Pharmacol Ther Latinoam** 1995; 45(2):79–86 (40 ref.)

PHYSIOLOGY

Myelodysplastic syndrome associated with erythrophagocytosis by blasts and myeloid cells. Kuyama J, et al. **Int J Hematol** 1995 Dec;62(4):243–6 (14 ref.)

Molecular control of erythroid differentiation. Migliaccio AR, et al. **Int J Hematol** 1996 Jul;64(1):1–29 (270 ref.)

Erythropoietin and erythropoiesis in renal transplantation. Kessler M. **Nephrol Dial Transplant** 1995;10 Suppl 6:114–6 (26 ref.)

[The role of erythropoietin in erythropoiesis regulation in fetuses and newborn infants] Ulman I. **Ginekol Pol** 1996 Apr;67(4):205–9 (29 ref.) (Eng. Abstr.) **(Pol)**

ERYTHROPOIETIC PROGENITOR CELLS see **ERYTHROID PROGENITOR CELLS**

ERYTHROPOIETIC PROTOPORPHYRIA see **PORPHYRIA, ERYTHROHEPATIC**

ERYTHROPOIETIC STEM CELLS see **ERYTHROID PROGENITOR CELLS**

ERYTHROPOIETIN

Erythropoietin. Fried W. **Annu Rev Nutr** 1995;15:353–77 (127 ref.)

Erythropoietin. Mehta BC. **J Assoc Physicians India** 1995; Suppl 3:52–7 (59 ref.)

ADVERSE EFFECTS

Is there a link between erythropoietin therapy and adynamic bone disease? Smans KA, et al. **Nephrol Dial Transplant** 1996 Jul;11(7):1248–9 (13 ref.)

Peliosis of the spleen: possible association with chronic renal failure and erythropoietin therapy. Lam KY, et al. **Postgrad Med J** 1995 Aug;71(838):493–6 (30 ref.)

[Arterial hypertension induced by erythropoietin] Lietz K, et al. **Pol Arch Med Wewn** 1996 Feb;95(2):153–9 (60 ref.) **(Pol)**

BIOSYNTHESIS

Biology of erythropoietin production. Eckardt KU. **Nephrol Dial Transplant** 1995;10(9):1572–4 (13 ref.)

Erythropoietin and erythropoiesis in renal transplantation. Kessler M. **Nephrol Dial Transplant** 1995;10 Suppl 6:114–6 (26 ref.)

BLOOD

[Erythropoietin] Mizoguchi H. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:741–4 (4 ref.) **(Jpn)**

PHARMACOLOGY

Epoetin beta. A review of its pharmacological properties and clinical use in the management of anaemia associated with chronic renal failure. Dunn CJ, et al. **Drugs** 1996 Feb; 51(2):299–318 (91 ref.)

Cellular mechanism of resistance to erythropoietin. Casadevall N. **Nephrol Dial Transplant** 1995;10 Suppl 6:27–30 (34 ref.)

PHYSIOLOGY

Interaction of inflammatory cytokines and erythropoeitin in iron metabolism and erythropoiesis in anaemia of chronic disease. Jongen-Lavrencic M, et al. **Clin Rheumatol** 1995 Sep;14(5):519–25 (93 ref.)

Erythropoiesis and erythropoietin in multiple myeloma. Beguin Y. **Leuk Lymphoma** 1995 Aug;18(5–6):413–21 (135 ref.)

[The role of erythropoietin in erythropoiesis regulation in fetuses and newborn infants] Ulman I. **Ginekol Pol** 1996 Apr;67(4):205–9 (29 ref.) (Eng. Abstr.) **(Pol)**

[Erythropoietin—physiology and therapeutic use] Balint B, et al. **Vojnosanit Pregl** 1994 Mar–Apr;51(2):136–42 (24 ref.) **(Scr)**

SECRETION

[Erythropoietin and delayed taking of autologous blood: from physiologic secretion to the rationale for exogenous supplementation] Casadevall N. **Nouv Rev Fr Hematol** 1995;37 Suppl 1:S11–5 (35 ref.) **(Fre)**

THERAPEUTIC USE

Erythropoietin and the anemia of cancer. Beguin Y. **Acta Clin Belg** 1996;51(1):36–52 (104 ref.)

Recombinant human erythropoietin therapy in children on dialysis. Jabs K, et al. **Adv Ren Replace Ther** 1996 Jan; 3(1):24–36 (98 ref.)

Haematopoietic growth factors as supportive therapy in HIV-infected patients. Hermans P. **AIDS** 1995 Dec;9 Suppl 2:S9–S14 (35 ref.)

Treatment of anemia of nephrotic syndrome with recombinant erythropoietin. Gansevoort RT, et al. **Am J Kidney Dis** 1996 Aug;28(2):274–7 (14 ref.)

Recombinant erythropoietin for zidovudine-induced anemia in AIDS. Kuehl AK, et al. **Ann Pharmacother** 1995 Jul–Aug;29(7–8):778–9 (15 ref.)

The role of biotherapies (interleukins, interferons and erythropoietin) in multiple myeloma. Avvisati G, et al. **Baillieres Clin Haematol** 1995 Dec;8(4):815–29 (76 ref.)

Recombinant human erythropoietin in chemotherapy-associated anemia. Cascinu S, et al. **Cancer Treat Rev** 1996 Nov;21(6):553–64 (61 ref.)

Treatment of renal anemia by erythropoietin substitution. The effects on the cardiovascular system. Radermacher J, et al. **Clin Nephrol** 1995 Nov;44 Suppl 1:S56–60 (51 ref.)

Recombinant human erythropoietin in neonatal anemia. Shannon K. **Clin Perinatol** 1995 Sep;22(3):627–40 (26 ref.)

Management of chemotherapy-induced anemia. Eguchi K. **Curr Opin Oncol** 1995 Jul;7(4):316–9 (33 ref.)

Epoetin beta. A review of its pharmacological properties and clinical use in the management of anaemia associated with chronic renal failure. Dunn CJ, et al. **Drugs** 1996 Feb; 51(2):299–318 (91 ref.)

Epoetin alfa. A review of its clinical efficacy in the management of anaemia associated with renal failure and chronic disease and its use in surgical patients. Dunn CJ, et al. **Drugs Aging** 1995 Aug;7(2):131–56 (186 ref.)

Aplastic anaemia with a trilineage response to erythropoietin therapy. Bernell P. **J Intern Med** 1996 Jan;239(1):79–81 (11 ref.)

Successful treatment of pure red cell aplasia in systemic lupus erythematosus with erythropoietin. Orbach H, et al. **J Rheumatol** 1995 Nov;22(11):2166–9 (27 ref.)

Myelodysplastic syndromes in the elderly: the role of growth factors in management. Saba HI. **Leuk Res** 1996 Mar; 20(3):203–19 (136 ref.)

How to diagnose and correct iron deficiency during r-huEPO therapy--a consensus report. Hörl WH, et al. **Nephrol Dial Transplant** 1996 Feb;11(2):246–50 (38 ref.)

rHuEpo before dialysis and in dialysed patients. López-Gómez JM, et al. **Nephrol Dial Transplant** 1995;10 Suppl 6:31–5 (39 ref.)

Poor response to erythropoietin: practical guidelines on investigation and management. Macdougall IC. **Nephrol Dial Transplant** 1995;10(5):607–14 (62 ref.)

Arterial hypertension in uraemic patients treated with erythropoietin [editorial] Kokot F, et al. **Nephron** 1995; 71(2):127–32 (52 ref.)

The potential use of human recombinant erythropoietin in orthopedic surgery. Bose WJ. **Orthopedics** 1996 Apr; 19(4):325–8 (24 ref.)

New hormones in the therapeutic arsenal of chronic renal failure. Growth hormone and erythropoietin. Warady BA, et al. **Pediatr Clin North Am** 1995 Dec;42(6):1551–77 (124 ref.)

Endocrinology and PD: optimal treatment of anemia in peritoneal dialysis patients. Bárány P. **Perit Dial Int** 1996; 16 Suppl 1:S260–6 (65 ref.)

[Erythropoietin in oncology. II. Evaluation of the effectiveness of erythropoietin in hematologic and oncologic diseases] Adam Z, et al. **Vnitr Lek** 1996 May; 42(5):351–8 (82 ref.) (Eng. Abstr.) **(Cze)**

[Erythropoietin in hematology and oncology. I. Chronic anemia in malignant disease and the pharmacology of erythropoietin] Adam Z, et al. **Vnitr Lek** 1996 Apr; 42(4):285–9 (39 ref.) (Eng. Abstr.) **(Cze)**

[Delayed autologous transfusion and erythropoietin] Baron JF. **Nouv Rev Fr Hematol** 1995;37 Suppl 1:S17–25 (41 ref.) **(Fre)**

[Erythropoietin and delayed taking of autologous blood: from physiologic secretion to the rationale for exogenous supplementation] Casadevall N. **Nouv Rev Fr Hematol** 1995;37 Suppl 1:S11–5 (35 ref.) **(Fre)**

[Eprex and daily autologous transfusion] Chassaigne M, et al. **Nouv Rev Fr Hematol** 1995;37 Suppl 1:S37–40 (21 ref.) **(Fre)**

[Erythropoietin, a milestone in the history of nephrology] Uehlinger DE, et al. **Ther Umsch** 1995 Oct;52(10):672–7 (16 ref.) (Eng. Abstr.) **(Ger)**

[Erythropoietin—physiology and therapeutic use] Balint B, et al. **Vojnosanit Pregl** 1994 Mar–Apr;51(2):136–42 (24 ref.) **(Scr)**

ESCHERICHIA COLI

Escherichia coli O157:H7 infection in humans. Su C, et al. **Ann Intern Med** 1995 Nov 1;123(9):698–714 (217 ref.)

Production of antibody fragments in Escherichia coli. Harrison JS, et al. **Ann N Y Acad Sci** 1996 May 15; 782:143–58 (81 ref.)

Enterohaemorrhagic Escherichia coli: a new problem, an old group of organisms. Bettelheim KA. **Aust Vet J** 1996 Jan; 73(1):20–6 (97 ref.)

CLASSIFICATION

Enteropathogenic and enteroaggregative strains of Escherichia coli: clinical features of infection, epidemiology, and pathogenesis. Wanke CA. **Curr Clin Top Infect Dis** 1995;15:230–52 (116 ref.)

CYTOLOGY

Cell shape and chromosome partition in prokaryotes or, why E. coli is rod-shaped and haploid. Donachie WD, et al. **Bioessays** 1995 Jun;17(6):569–76 (32 ref.)

Regulation of chromosomal replication in E. coli: sequestration and beyond. Crooke E. **Cell** 1995 Sep 22; 82(6):877–80 (18 ref.)

GASPing for life in stationary phase. Zambrano MM, et al. **Cell** 1996 Jul 26;86(2):181–4 (17 ref.)

ENZYMOLOGY

From growth to autolysis: the murein hydrolases in Escherichia coli. Höltje JV. **Arch Microbiol** 1995 Oct; 164(4):243–54 (94 ref.)

Genetics of pentose-phosphate pathway enzymes of Escherichia coli K-12. Sprenger GA. **Arch Microbiol** 1995 Nov;164(5):324–30 (47 ref.)

Escherichia coli chorismate synthase. Bornemann S, et al. **Biochem Soc Trans** 1996 Feb;24(1):84–8 (36 ref.)

DNA polymerase III: running rings around the fork. Herendeen DR, et al. **Cell** 1996 Jan 12;84(1):5–8 (18 ref.)

Lytic transglycosylases. Höltje JV. **EXS** 1996;75:425–9 (20 ref.)

Mechanism and structure of thioredoxin reductase from Escherichia coli. Williams CH Jr. **FASEB J** 1995 Oct; 9(13):1267–76 (47 ref.)

The Escherichia coli trigger factor. Hesterkamp T, et al. **FEBS Lett** 1996 Jun 24;389(1):32–4 (21 ref.)

Regulation of hydroperoxidase (catalase) expression in Escherichia coli. Schellhorn HE. **FEMS Microbiol Lett** 1995 Sep 1;131(2):113–9 (25 ref.)

A hypothetical holoenzyme involved in the replication of the murein sacculus of Escherichia coli. Höltje JV. **Microbiology** 1996 Aug;142 (Pt 8):1911–8 (45 ref.)

Open complex formation by Escherichia coli RNA polymerase: the mechanism of polymerase-induced strand separation of double helical DNA. deHaseth PL, et al. **Mol Microbiol** 1995 Jun;16(5):817–24 (72 ref.)

GENETICS

Mutational analysis of 16S ribosomal RNA structure and function in Escherichia coli. Triman KL. **Adv Genet** 1995; 33:1–39 (144 ref.)

Leucine-responsive regulatory protein: a global regulator of gene expression in E. coli. Newman EB, et al. **Annu Rev Microbiol** 1995;49:747–75 (122 ref.)

Cell shape and chromosome partition in prokaryotes or, why E. coli is rod-shaped and haploid. Donachie WD, et al. **Bioessays** 1995 Jun;17(6):569–76 (32 ref.)

Does replication-induced transcription regulate synthesis of the myriad low copy number proteins of Escherichia coli? Guptasarma P. **Bioessays** 1995 Nov;17(11):987–97 (57 ref.)

Expression of correctly folded proteins in Escherichia coli. Georgiou G, et al. **Curr Opin Biotechnol** 1996 Apr; 7(2):190–7 (40 ref.)

Effects of rare codon clusters on high-level expression of heterologous proteins in Escherichia coli. Kane JF. **Curr Opin Biotechnol** 1995 Oct;6(5):494–500 (26 ref.)

Gene fusion expression systems in Escherichia coli. LaVallie ER, et al. **Curr Opin Biotechnol** 1995 Oct;6(5):501–6 (47 ref.)

Effects of overexpressing folding modulators on the in vivo folding of heterologous proteins in Escherichia coli. Wall JG, et al. **Curr Opin Biotechnol** 1995 Oct;6(5):507–16 (77 ref.)

Assembly of macromolecular complexes in bacterial and baculovirus expression systems. Roy P, et al. **Curr Opin Struct Biol** 1996 Apr;6(2):157–61 (53 ref.)

Regulation of hydroperoxidase (catalase) expression in Escherichia coli. Schellhorn HE. **FEMS Microbiol Lett** 1995 Sep 1;131(2):113–9 (25 ref.)

The RuvABC proteins and Holliday junction processing in Escherichia coli. West SC. **J Bacteriol** 1996 Mar; 178(5):1237–41 (59 ref.)

Old and new concepts for the role of chi in bacterial recombination. Stahl F, et al. **J Hered** 1995 Sep–Oct; 86(5):327–9 (48 ref.)

Over-production of proteins in Escherichia coli: mutant hosts that allow synthesis of some membrane proteins and globular proteins at high levels. Miroux B, et al. **J Mol Biol** 1996 Jul 19;260(3):289–98 (27 ref.)

Signal transduction in the control of phosphate-regulated genes of Escherichia coli. Wanner BL. **Kidney Int** 1996 Apr;49(4):964–7 (24 ref.)

Control of rRNA transcription in Escherichia coli. Condon C, et al. **Microbiol Rev** 1995 Dec;59(4):623–45 (369 ref.)

Collapse and repair of replication forks in Escherichia coli. Kuzminov A. **Mol Microbiol** 1995 May;16(3):373–84 (102 ref.)

Hypothesis: chromosome separation in Escherichia coli involves autocatalytic gene expression, transertion and membrane-domain formation. Norris V. **Mol Microbiol** 1995 Jun;16(6):1051–7 (71 ref.)

Molecular handles on adaptive mutation. Rosenberg SM, et al. **Mol Microbiol** 1995 Oct;18(2):185–9 (33 ref.)

Experimental analysis of global gene regulation in Escherichia coli. Blumenthal RM, et al. **Prog Nucleic Acid Res Mol Biol** 1996;55:1–86 (304 ref.)

Genetically engineered bacterial cells and applications. Waterman MR, et al. **Toxicol Lett** 1995 Dec;82–83:807–13 (27 ref.)

[tRNA identify--a view of Escherichia coli system] Hasegawa T. **Tanpakushitsu Kakusan Koso** 1994 Jul; 40(10):1474–84 (87 ref.) **(Jpn)**

GROWTH & DEVELOPMENT

Overview of controls in the Escherichia coli cell cycle. Vinella D, et al. **Bioessays** 1995 Jun;17(6):527–36 (87 ref.)

GASPing for life in stationary phase. Zambrano MM, et al. **Cell** 1996 Jul 26;86(2):181–4 (17 ref.)

Adaptation to life at micromolar nutrient levels: the regulation of Escherichia coli glucose transport by endoinduction and cAMP. Ferenci T. **FEMS Microbiol Rev** 1996 Jul;18(4):301–17 (92 ref.)

High pressure influences on gene and protein expression. Bartlett DH, et al. **Res Microbiol** 1995 Oct;146(8):697–706 (63 ref.)

IMMUNOLOGY

A hypothetical holoenzyme involved in the replication of the murein sacculus of Escherichia coli. Höltje JV. **Microbiology** 1996 Aug;142 (Pt 8):1911–8 (45 ref.)

ISOLATION & PURIFICATION

[Enterohaemorrhagic Escherichia coli O157:H7 infection] Michałowicz-Wojczyńska E, et al. **Pediatr Pol** 1996 May; 71(5):453–8 (40 ref.) (Eng. Abstr.) **(Pol)**

METABOLISM

Ribosome recycling by ribosome recycling factor (RRF)--an important but overlooked step of protein biosynthesis. Janosi L, et al. **Adv Biophys** 1996;32:121–201 (188 ref.)

ESCHERICHIA COLI

Membrane permeation and intracellular trafficking of long chain fatty acids: insights from Escherichia coli and 3T3-L1 adipocytes. Mangroo D, et al. **Biochem Cell Biol** 1995 May-Jun;73(5-6):223-34 (98 ref.)

Escherichia coli as a model for the regulation of dissociable (type II) fatty acid biosynthesis. Rock CO, et al. **Biochim Biophys Acta** 1996 Jul 12;1302(1):1-16 (143 ref.)

Molecular biology of the lactose carrier of Escherichia coli. Varela MF, et al. **Biochim Biophys Acta** 1996 Aug 7; 1276(1):21-34 (120 ref.)

Does replication-induced transcription regulate synthesis of the myriad low copy number proteins of Escherichia coli? Guptasarma P. **Bioessays** 1995 Nov;17(11):987-97 (37 ref.)

Isoprenoid antibiotics. Cane DE. **Biotechnology** 1995; 28:633-55 (99 ref.)

Bacteriocin release proteins: mode of action, structure, and biotechnological application. van der Wal FJ, et al. **FEMS Microbiol Rev** 1995 Dec;17(4):381-99 (174 ref.)

Structural organization of transcription termination factor Rho. Richardson JP. **J Biol Chem** 1996 Jan 19; 271(3):1251-4 (50 ref.)

Colicin import and pore formation: a system for studying protein transport across membranes? Lazdunski CJ. **Mol Microbiol** 1995 Jun;16(6):1059-66 (84 ref.)

Why does Escherichia coli recycle its cell wall peptides? Park JT. **Mol Microbiol** 1995 Aug;17(3):421-6 (41 ref.)

The biosynthesis of pyridoxine. Spenser ID, et al. **Nat Prod Rep** 1995 Dec;12(6):555-65 (51 ref.)

[Infections with verocytotoxin-producing Escherichia coli and hemolytic-uremic syndrome] van de Kar NC, et al. **Ned Tijdschr Geneeskd** 1996 Jan 20;140(3):134-7 (22 ref.) (Eng. Abstr.) **(Dut)**

[Polyamine transport in Escherichia coli and Eukaryotic cells] Kashiwagi K. **Yakugaku Zasshi** 1996 Mar; 116(3):175-91 (40 ref.) (Eng. Abstr.) **(Jpn)**

PATHOGENICITY

Adherence & colonization properties of Vibrio cholerae & diarrhoeagenic Escherichia coli. Ghose AC. **Indian J Med Res** 1996 Jul;104:38-51 (160 ref.)

Triggering bacterial virulence [comment] Cotter PA, et al. **Science** 1996 Aug 30;273(5279):1183-4 (15 ref.) Comment on: Science 1996 Aug 30;273(5279):1231-3. Comment on: Science 1996 Aug 30;273(5279):1234-6.

Role of verotoxin receptors in pathogenesis. Lingwood CA. **Trends Microbiol** 1996 Apr;4(4):147-53 (89 ref.)

PHYSIOLOGY

Global physiological controls. Doull JL, et al. **Biotechnology** 1995;28:9-63 (257 ref.)

Regulation of interaction between signaling protein CheY and flagellar motor during bacterial chemotaxis. Barak R, et al. **Curr Top Cell Regul** 1996;34:137-58 (156 ref.)

[Regulation of Escherichia coli heat shock response] Liberek K. **Postepy Biochem** 1995;41(2):94-102 (110 ref.) **(Pol)**

ESCHERICHIA COLI ADHESINS see **ADHESINS, ESCHERICHIA COLI**

ESCHERICHIA COLI INFECTIONS

Escherichia coli O157:H7 infection in humans. Su C, et al. **Ann Intern Med** 1995 Nov 1;123(9):698-714 (217 ref.)

Enteropathogenic and enteroaggregative strains of Escherichia coli: clinical features of infection, epidemiology, and pathogenesis. Wanke CA. **Curr Clin Top Infect Dis** 1995;15:230-52 (116 ref.)

Endogenous Escherichia coli endophthalmitis. Wann SR, et al. **J Formos Med Assoc** 1996 Jan;95(1):56-60 (31 ref.)

[A case of psoas abscess associated in the elderly] Yamamoto T, et al. **Kansenshogaku Zasshi** 1996 Apr;70(4):371-6 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Falciform ligament abscess] Kaneko K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):61-2 (14 ref.) **(Jpn)**

COMPLICATIONS

Escherichia coli O157:H7 infections: a frequent cause of bloody diarrhea and the hemolytic-uremic syndrome. Cohen MB. **Adv Pediatr** 1996;43:171-207 (187 ref.)

Mechanism and treatment of diarrhoea due to Vibrio cholerae and Escherichia coli: roles of drugs and prostaglandins. Rabbani GH. **Dan Med Bull** 1996 Apr;43(2):173-85 (169 ref.)

Emphysematous septic arthritis: case report and review of the literature. Roy R, et al. **J Rheumatol** 1995 Sep; 22(9):1776-8 (29 ref.)

Bilateral endogenous Escherichia coli endophthalmitis: a devastating complication in an insulin-dependent diabetic. Walmsley RS, et al. **Postgrad Med J** 1996 Jun;72(848):361-3 (10 ref.)

[Enterohaemorrhagic Escherichia coli O157:H7 infection] Michalowicz-Wojczyńska E, et al. **Pediatr Pol** 1996 May; 71(5):453-8 (40 ref.) (Eng. Abstr.) **(Pol)**

[Spontaneous bladder perforation secondary to bacterial cystitis. Cause of acute abdomen in diabetic elderly] Rodríguez Rodríguez A, et al. **Actas Urol Esp** 1995 May; 19(5):393-7 (14 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

Escherichia coli infection of an abdominal aortic aneurysm. Khaira HS, et al. **J Infect** 1996 Mar;32(2):161-3 (14 ref.)

[Retroperitoneal abscess formation accompanied by intraabdominal free air, a rare complication of transcatheter arterial embolization of renal tumor: a case report] Koga F, et al. **Hinyokika Kiyo** 1996 Jun;42(6):443-6 (7 ref.) (Eng. Abstr.) **(Jpn)**

MICROBIOLOGY

Enterohaemorrhagic Escherichia coli: a new problem, an old group of organisms. Bettelheim KA. **Aust Vet J** 1996 Jan; 73(1):20-6 (97 ref.)

[Treatment of cystitis in women] Lobel B. **Presse Med** 1995 Oct 28;24(32):1527-9 (9 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

Oral vaccines against cholera and enterotoxigenic Escherichia coli diarrhea. Svennerholm AM, et al. **Adv Exp Med Biol** 1995;371B:1623-8 (19 ref.)

TRANSMISSION

Nosocomial acquisition of Escherichia coli by infants delivered in hospitals. Fujita K, et al. **J Hosp Infect** 1996 Apr;32(4):277-81 (23 ref.)

ESOPHAGEAL ACHALASIA

Achalasia. Achkar E. **Gastroenterologist** 1995 Dec; 3(4):273-88 (141 ref.)

COMPLICATIONS

Achalasia. A possible late cause of postpolio dysphagia. Benini L, et al. **Dig Dis Sci** 1996 Mar;41(3):516-8 (20 ref.)

DIAGNOSIS

Gastric cancer and pernicious anemia appearing as pseudoachalasia. el-Newihi HM, et al. **South Med J** 1996 Sep;89(9):906-10 (30 ref.)

SURGERY

Laparoscopic management of achalasia. Oddsdóttir M. **Surg Clin North Am** 1996 Jun;76(3):451-8 (38 ref.)

ULTRASONOGRAPHY

Primary achalasia: analysis of endoscopic ultrasonography features with different instruments. Devière J. **Gastrointest Endosc Clin N Am** 1995 Jul;5(3):631-4 (13 ref.)

The use of high frequency endoscopic ultrasonography probes in the evaluation of achalasia. Miller LS, et al. **Gastrointest Endosc Clin N Am** 1995 Jul;5(3):635-47 (22 ref.)

ESOPHAGEAL AND GASTRIC VARICES

CLASSIFICATION

Classification of gastric lesions associated with portal hypertension. Hashizume M, et al. **J Gastroenterol Hepatol** 1995 May-Jun;10(3):339-43 (20 ref.)

COMPLICATIONS

Variceal bleeding. Can it be prevented? Korula J. **Postgrad Med** 1995 Dec;98(6):131-4, 137-8 (30 ref.)

Variceal bleeding. What are the treatment options? Stein C, et al. **Postgrad Med** 1995 Dec;98(6):143-6, 149-52 (15 ref.)

[Current attitude to severe acute digestive hemorrhage caused by rupture of esophageal varices in cirrhotic patients] Castaing D, et al. **Ann Chir** 1995;49(6):463-8; discussion 468-70 (37 ref.) **(Fre)**

[Intrahepatic portasystemic shunt and hemorrhagic emergencies in the cirrhotic patient] Perarnau JM, et al. **Ann Chir** 1995;49(7):580-6; discussion 587-8 (17 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

Pharmacological therapy for portal hypertension: rationale and results. Burroughs AK, et al. **Semin Gastrointest Dis** 1995 Jul;6(3):148-64 (148 ref.)

ETIOLOGY

Alcohol and oesophageal varices. Sutton R, et al. **Alcohol Alcohol** 1995 Sep;30(5):581-9 (60 ref.)

Portal hypertensive hemorrhage: pathogenesis and risk factors. Boyer TD. **Semin Gastrointest Dis** 1995 Jul; 6(3):125-33 (75 ref.)

SURGERY

Transjugular intrahepatic portasystemic stent-shunt in the treatment of variceal haemorrhage. Jalan R, et al. **Br J Surg** 1995 Sep;82(9):1158-64 (46 ref.)

Portal hypertension. Rhee P, et al. **Curr Opin Gen Surg** 1993; :249-56 (36 ref.)

Transjugular intrahepatic portosystemic shunt: a medical perspective. Sanyal AJ, et al. **Dig Dis** 1995 May-Jun; 13(3):153-62 (47 ref.)

[Portal hypertension and splenic circulation] Romero Torres R. **Rev Gastroenterol Peru** 1995;15 Suppl 1:S110-7 (31 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

Nonsurgical treatment of variceal bleeding: new modalities. Binmoeller KF, et al. **Am J Gastroenterol** 1995 Nov; 90(11):1923-31 (95 ref.)

Current management of oesophageal varices. Sandford NL, et al. **Aust N Z J Med** 1995 Oct;25(5):528-34 (68 ref.)

Emergency and long-term management of bleeding oesophageal varices. Parks RW, et al. **Br J Hosp Med** 1995 Aug 16-Sep 5;54(4):161-8 (10 ref.)

Case report: bleeding gastric varices secondary to splenic vein thrombosis successfully treated by splenic artery embolization. McDermott VG, et al. **Br J Radiol** 1995 Aug; 68(812):928-30 (14 ref.)

Drug treatment of esophageal variceal bleeding: alternative or supplement to endoscopic therapy? Zoller WG, et al. **Endoscopy** 1995 Oct;27(8):616-21 (65 ref.)

New approaches to endoscopic therapy for hemostasis of upper GI bleed. Rauws EA, et al. **Scand J Gastroenterol Suppl** 1995;212:90-5 (66 ref.)

[Hemorrhage caused by rupture of gastroesophageal varices: should we dilate the liver or strangulate the varices? (editorial)- Calès P. **Gastroenterol Clin Biol** 1995 Nov; 19(11):899-902 (34 ref.) **(Fre)**

[Techniques and indications of endoscopic treatment of esophago-gastric varices in 1995] Ramond MJ. **Gastroenterol Clin Biol** 1995 Nov;19(11):921-34 (130 ref.) **(Fre)**

[Therapy of bleeding varicosities] Gerbes AL, et al. **Dtsch Med Wochenschr** 1996 Mar 29;121(13):416-23 (75 ref.) **(Ger)**

[Endoscopic treatment of upper gastrointestinal diseases] Kaneko E. **Nippon Naika Gakkai Zasshi** 1995 Sep 10; 84(9):1528-31 (0 ref.) **(Jpn)**

[Endoscopic sclerotherapy of esophageal and gastric varicose veins in liver cirrhosis with portal hypertension] Bulanov KI, et al. **Klin Khir** 1995;(4):38-40 (49 ref.) **(Rus)**

ESOPHAGEAL ATRESIA

SURGERY

Oesophageal atresia--need for life-long follow-up? Lindahl H. **Ann Chir Gynaecol** 1995;84(2):235-9 (27 ref.)

[Surgery of atresia of the gastrointestinal tract] Joppich I, et al. **Chirurg** 1996 Jun;67(6):576-83 (10 ref.) (Eng. Abstr.) **(Ger)**

ESOPHAGEAL CYST

COMPLICATIONS

Severe dysphagia, dysmotility, and unusual saccular dilation (diverticulum) of the esophagus following excision of an asymptomatic congenital cyst. Mahajan RJ, et al. **Am J Gastroenterol** 1996 Jun;91(6):1254-8 (23 ref.)

CONGENITAL

Severe dysphagia, dysmotility, and unusual saccular dilation (diverticulum) of the esophagus following excision of an asymptomatic congenital cyst. Mahajan RJ, et al. **Am J Gastroenterol** 1996 Jun;91(6):1254-8 (23 ref.)

PATHOLOGY

Isolated intra-abdominal esophageal cyst. Case report and review of the literature. Harvell JD, et al. **Am J Surg Pathol** 1996 Apr;20(4):476-9 (17 ref.)

ESOPHAGEAL DISEASES

see related

ESOPHAGEAL ATRESIA

Esophageal emergencies. Swann LA, et al. **Emerg Med Clin North Am** 1996 Aug;14(3):557-70 (53 ref.)

CHEMICALLY INDUCED

A case of esophageal perforation due to a pill-induced ulcer successfully treated with conservative measures. Yamaoka K, et al. **Am J Gastroenterol** 1996 May;91(5):1044-5 (9 ref.)

COMPLICATIONS

Boerhaave's syndrome presenting with abdominal pain and right hydropneumothorax. Jagminas L, et al. **Am J Emerg Med** 1996 Jan;14(1):53-6 (46 ref.)

Localized epidermolysis bullosa acquisita of the esophagus in a patient with Crohn's disease. Schattenkirchner S, et al. **Am J Gastroenterol** 1996 Aug;91(8):1657-9 (15 ref.)

Esophageal disorders associated with emesis in infants and children. Myers NA. **Semin Pediatr Surg** 1995 Aug; 4(3):166-75 (25 ref.)

DIAGNOSIS

Diagnostic imaging in the evaluation of dysphagia. Barloon TJ, et al. **Am Fam Physician** 1996 Feb 1;53(2):535-46 (22 ref.)

Primary esophageal tuberculosis: a case report and 1996

update [letter] Trehan AK. **Am J Gastroenterol** 1996 Jun; 91(6):1286–7 (10 ref.)
[Endoscopy of the upper gastrointestinal tract in HIV disease] Caca K, et al. **Bildgebung** 1995 Dec;62(4):244–51 (56 ref.) (Eng. Abstr.) **(Ger)**
[Noncardiac chest pain--a disease of the esophagus?] Lux G, et al. **Dtsch Med Wochenschr** 1995 Dec 15; 120(50):1748–55 (71 ref.) **(Ger)**

ETIOLOGY

Gastroesophageal reflux disease. Kahrilas PJ. **JAMA** 1996 Sep 25;276(12):983–8 (66 ref.)
Double-lumen esophagus: formation of a new lumen or septation of the existing one? Choudhry U, et al. **South Med J** 1996 May;89(5):538–41 (10 ref.)

MICROBIOLOGY

Esophageal tuberculosis [letter] Jiménez FJ, et al. **Am J Gastroenterol** 1996 Apr;91(4):826–7 (10 ref.)

RADIOGRAPHY

[Esophageal duplications: role of computed tomography. Apropos of 2 cases] Jouini S, et al. **Ann Radiol (Paris)** 1995; 38(7–8):418–25 (22 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Pharyngoesophageal swallowing disorders. Jamieson JR. **Curr Opin Gen Surg** 1993;:189–94 (33 ref.)
The role of minimal-access surgery in esophageal disease. Pellegrini CA. **Curr Opin Gen Surg** 1994;:117–9 (22 ref.)

ULTRASONOGRAPHY

[Endosonography of the esophagus and mediastinum] Schüder G, et al. **Bildgebung** 1995 Oct;62 Suppl 2:29–34 (21 ref.) (Eng. Abstr.) **(Ger)**

ESOPHAGEAL DIVERTICULUM

ETIOLOGY

Severe dysphagia, dysmotility, and unusual saccular dilation (diverticulum) of the esophagus following excision of an asymptomatic congenital cyst. Mahajan RJ, et al. **Am J Gastroenterol** 1996 Jun;91(6):1254–8 (23 ref.)

SURGERY

Oesophageal epiphrenic diverticulum: an unusual presentation and review. Clark SC, et al. **Ann R Coll Surg Engl** 1995 Sep;77(5):342–5 (9 ref.)

ESOPHAGEAL DYSMOTILITY see **ESOPHAGEAL MOTILITY DISORDERS**

ESOPHAGEAL FISTULA

CHEMICALLY INDUCED

Bronchoesophagopleural fistula after photodynamic therapy for malignant mesothelioma. Luketich JD, et al. **Ann Thorac Surg** 1996 Jul;62(1):283–4 (7 ref.)

DIAGNOSIS

Survival after aberrant right subclavian artery–esophageal fistula: case report and literature review. Miller RG, et al. **J Vasc Surg** 1996 Aug;24(2):271–5 (45 ref.)

ETIOLOGY

Primary aortoesophageal fistula caused by an atherosclerotic thoracoabdominal aortic aneurysm: a case report and review of the literature. Hageman JH, et al. **Cardiovasc Surg** 1995 Oct;3(5):495–9 (17 ref.)
Oesophago-vascular fistulae secondary to benign peptic ulcer disease: a rare cause of fatal haemorrhage. Kenny PJ, et al. **Eur J Vasc Endovasc Surg** 1995 Oct;10(3):370–1 (6 ref.)

ESOPHAGEAL MOTILITY DISORDERS

DIAGNOSIS

Reversible esophageal motility disorder in a patient with sarcoidosis. Geissinger BW, et al. **Am J Gastroenterol** 1996 Jul;91(7):1423–6 (21 ref.)
Ambulatory esophageal manometry in the evaluation of unexplained chest pain. Leite LP, et al. **Dig Dis** 1995 May-Jun;13(3):145–52 (15 ref.)
Esophageal motility and reflux testing. State-of-the-art and clinical role in the twenty-first century. Dent J, et al. **Gastroenterol Clin North Am** 1996 Mar;25(1):51–73 (85 ref.)

ETIOLOGY

Severe dysphagia, dysmotility, and unusual saccular dilation (diverticulum) of the esophagus following excision of an asymptomatic congenital cyst. Mahajan RJ, et al. **Am J Gastroenterol** 1996 Jun;91(6):1254–8 (23 ref.)

RADIOGRAPHY

[Functional disorders of the esophagus. Radiologic diagnosis] Schima W, et al. **Radiologe** 1995 Oct;35(10):693–702 (64 ref.) (Eng. Abstr.) **(Ger)**
[Radiologic differential diagnosis of neurologically-induced deglutition disorders] Wuttge-Hanning A, et al. **Radiologe** 1995 Oct;35(10):733–40 (16 ref.) (Eng. Abstr.) **(Ger)**

RADIONUCLIDE IMAGING

Esophageal transit scintigraphy. Klein HA. **Semin Nucl Med** 1995 Oct;25(4):306–17 (77 ref.)

SURGERY

Oropharyngeal dysphagia and disorders of the upper esopharyngeal sphincter. Duranceau A. **Ann Chir Gynaecol** 1995;84(2):225–33 (15 ref.)
Laparoscopic antireflux repair and myotomy. Peters JH, et al. **Curr Opin Gen Surg** 1993;:170–9 (36 ref.)
Endoscopic surgical treatment of primary oesophageal motility disorders. Patti MG, et al. **J R Coll Surg Edinb** 1996 Jun;41(3):137–42 (27 ref.)

ESOPHAGEAL NEOPLASMS

Esophageal cancer. Flood WA, et al. **Curr Opin Oncol** 1995 Jul;7(4):381–6 (61 ref.)
Diagnosis and treatment of esophageal neoplasms. Kato H. **Jpn J Cancer Res** 1995 Nov;86(11):993–1009 (116 ref.)
Early detection and treatment of oesophageal and gastric cancer. The Rotterdam Oesophageal Tumour Study Group. Siersema PD, et al. **Neth J Med** 1995 Aug; 47(2):76–86 (69 ref.)

COMPLICATIONS

Barrett's esophagus: a review. Sawyer DR, et al. **Mo Med** 1995 Oct;92(10):645–7 (13 ref.)
Laser therapy in the palliation of dysphagia in oesophageal malignancy. Lewis-Jones CM, et al. **Palliat Med** 1995 Oct; 9(4):327–30 (15 ref.)

DIAGNOSIS

Early detection of neoplasia of the esophagus and gastroesophageal junction. Riddell RH. **Am J Gastroenterol** 1996 May;91(5):853–63 (167 ref.)
What is the earliest malignant lesion in the esophagus? Kitamura K, et al. **Cancer** 1996 Apr 15;77(8 Suppl):1614–9 (32 ref.)
[Cerebral metastasis as the form of presentation of a basaloid carcinoma of the esophagus] Carvalho IR, et al. **Acta Med Port** 1995 Sep;8(9):505–9 (9 ref.) (Eng. Abstr.) **(Por)**

DRUG THERAPY

Neoadjuvant treatment in oesophageal cancer: the needs for future trials. The Rotterdam Esophageal Tumor Study Group. Kok TC, et al. **Eur J Surg Oncol** 1996 Aug; 22(4):323–5 (30 ref.)
Preoperative concomitant radiochemotherapy in squamous cell carcinoma of the esophagus: results of a study of 56 patients. Malhaire JP, et al. **Int J Radiat Oncol Biol Phys** 1996 Jan 15;34(2):429–37 (52 ref.)
[Percutaneous and intraluminal radiotherapy and radiochemotherapy in esophageal carcinoma] Staar S, et al. **Schweiz Rundsch Med Prax** 1996 Mar 5;85(10):307–12 (41 ref.) (Eng. Abstr.) **(Ger)**
[Photodynamic therapy for esophageal cancer] Shimao H, et al. **Gan To Kagaku Ryoho** 1996 Jan;23(1):36–40 (13 ref.) (Eng. Abstr.) **(Jpn)**

ETIOLOGY

Barrett's esophagus: a model of human neoplastic progression. Neshat K, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:577–83 (58 ref.)
Risk factors for neoplastic progression in Barrett's mucosa. Menke-Pluymers MB. **Eur J Surg Oncol** 1996 Aug; 22(4):311–6 (65 ref.)
Malignant tumor developed in colon–esophagus. Altorjay A, et al. **Hepatogastroenterology** 1995 Nov-Dec;42(6):797–9 (19 ref.)
[From Barrett esophagus to adenocarcinoma: can the dangers of natural history be overcome?] Robaszkiewicz M. **Gastroenterol Clin Biol** 1996;20(5 Pt 2):B89–97 (111 ref.) **(Fre)**

GENETICS

Mutations in Alport syndrome associated with diffuse esophageal leiomyomatosis. Antignac C, et al. **Contrib Nephrol** 1996;117:172–82 (37 ref.)
Genetic alterations in esophageal cancer and their relevance to etiology and pathogenesis: a review. Montesano R, et al. **Int J Cancer** 1996 Jun 21;69(3):225–35 (120 ref.)
Nutritional intervention to prevent hereditary cancer. Taylor PR, et al. **J Natl Cancer Inst Monogr** 1995;(17):43–7 (19 ref.)
[Prognostic factors for esophageal cancer--from the viewpoint of molecular biology] Shimada Y, et al. **Gan To Kagaku Ryoho** 1996 Jul;23(8):972–81 (98 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Barrett's esophagus and esophageal adenocarcinoma: the scope of the problem. Levine MS, et al. **Abdom Imaging** 1995 Jul-Aug;20(4):291–8 (69 ref.)
Primary esophageal lymphoma in AIDS presenting as a nonhealing esophageal ulcer. Chow DC, et al. **Am J Gastroenterol** 1996 Mar;91(3):602–3 (13 ref.)
Primary malignant melanoma of the esophagus. Ribeiro U Jr, et al. **Am J Gastroenterol** 1996 May;91(5):1048–9 (9 ref.)
What is the earliest malignant lesion in the esophagus? Kitamura K, et al. **Cancer** 1996 Apr 15;77(8 Suppl):1614–9 (32 ref.)
[Advances in pathology of several common seen tumors in China] Liu F, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1995 Aug;24(4):207–9 (20 ref.) **(Chi)**
[Value of surgical treatment in patients with gastrointestinal metastatic tumors] Wang Z, et al. **Chung Hua Wai Ko Tsa Chih** 1995 Sep;33(9):551–3 (6 ref.) (Eng. Abstr.) **(Chi)**
[Place of celioscopy in the diagnosis of invasiveness of digestive cancers] Chambon JP, et al. **Ann Chir** 1995; 49(6):513–8 (25 ref.) (Eng. Abstr.) **(Fre)**
[A case of breast metastasis of esophageal squamous cell carcinoma] Meloni GB, et al. **Radiol Med (Torino)** 1996 Jun;91(6):812–4 (7 ref.) **(Ita)**
[Reevaluation of precancerous lesion of squamous cell carcinoma] Sumiyoshi K, et al. **Gan To Kagaku Ryoho** 1995 Dec;22(14):2038–42 (16 ref.) (Eng. Abstr.) **(Jpn)**
[Pathogenesis and progression of esophageal cancer] Sugimachi K. **Nippon Geka Gakkai Zasshi** 1995 Aug; 96(8):518–24 (6 ref.) **(Jpn)**

PREVENTION & CONTROL

Nutritional intervention to prevent hereditary cancer. Taylor PR, et al. **J Natl Cancer Inst Monogr** 1995;(17):43–7 (19 ref.)

RADIOGRAPHY

Imaging of small cell carcinoma of the oesophagus. Fenlon HM, et al. **Clin Radiol** 1995 Sep;50(9):634–8 (33 ref.)
Small-cell carcinoma of the esophagus: radiographic findings. Levine MS, et al. **Radiology** 1996 Jun;199(3):703–5 (18 ref.)
[Radiological criteria for laryngeal tumors and cervical metastases] Melchor Díaz MA, et al. **Acta Otorrinolaringol Esp** 1996 Jan-Feb;47(1):1–7 (17 ref.) (Eng. Abstr.) **(Spa)**

RADIOTHERAPY

Preoperative concomitant radiochemotherapy in squamous cell carcinoma of the esophagus: results of a study of 56 patients. Malhaire JP, et al. **Int J Radiat Oncol Biol Phys** 1996 Jan 15;34(2):429–37 (52 ref.)
Endoluminal high-dose-rate brachytherapy with a palliative aim in esophageal cancer: preliminary results at the Institut Gustave Roussy. Rovirosa A, et al. **Tumori** 1995 Sep-Oct; 81(5):359–63 (37 ref.)
[Percutaneous and intraluminal radiotherapy and radiochemotherapy in esophageal carcinoma] Staar S, et al. **Schweiz Rundsch Med Prax** 1996 Mar 5;85(10):307–12 (41 ref.) (Eng. Abstr.) **(Ger)**

SECONDARY

[Radiological criteria for laryngeal tumors and cervical metastases] Melchor Díaz MA, et al. **Acta Otorrinolaringol Esp** 1996 Jan-Feb;47(1):1–7 (17 ref.) (Eng. Abstr.) **(Spa)**

SURGERY

Surgical treatment of esophageal and gastric cancer. Kiss J. **Acta Med Hung** 1994;50(3–4):205–19 (51 ref.)
Long-term survival in a patient with verrucous carcinoma of the esophagus. Malik AB, et al. **Am J Gastroenterol** 1996 May;91(5):1031–3 (29 ref.)
Surgical management of Barrett's esophagus. Clark GW, et al. **Ann Chir Gynaecol** 1995;84(2):139–44 (30 ref.)
Oesophageal substitution. Isolauri J. **Ann Chir Gynaecol** 1995; 84(2):241–6 (30 ref.)
Extended resections in the management of esophageal carcinoma. Altorki NK. **Curr Opin Gen Surg** 1994;:113–6 (24 ref.)
The role of minimal-access surgery in esophageal disease. Pellegrini CA. **Curr Opin Gen Surg** 1994;:117–9 (22 ref.)
Transhiatal oesophagectomy compared with transthoracic resection and systematic lymphadenectomy for the treatment of oesophageal cancer. Horstmann O, et al. **Eur J Surg** 1995 Aug;161(8):557–67 (62 ref.)
Oesophageal carcinoma--past and present studies. Lerut T. **Eur J Surg Oncol** 1996 Aug;22(4):317–23 (88 ref.)
Detection of anastomotic recurrence by endoscopic ultrasonography. Lightdale CJ. **Gastrointest Endosc Clin N Am** 1995 Jul;5(3):595–600 (20 ref.)
Cancer of the oesophagus. Hennessy TP. **Postgrad Med J** 1996 Aug;72(850):458–63 (26 ref.)
Can the morbidity of esophagectomy be reduced by the thoracoscopic approach? Gossot D, et al. **Surg Endosc** 1995

ESOPHAGEAL NEOPLASMS

Oct;9(10):1113-5 (14 ref.)
Radical (en bloc) esophagectomy. Kapoor VK. **Trop Gastroenterol** 1996 Apr-Jun;17(2):6-11 (24 ref.)
[Lymph node excision in cancer of the esophagus] Collard JM. **Ann Chir** 1996;50(2):121-9 (79 ref.) (Eng. Abstr.) **(Fre)**
[Current technique of gastric plasties in esophageal surgery] Ségol P, et al. **Ann Chir** 1996;50(1):13-22 (24 ref.) **(Fre)**
[Surgical treatment of esophageal cancer in patients over 70 years of age] Thomas P, et al. **Chirurgie** 1996;121(2):101-7 (22 ref.) (Eng. Abstr.) **(Fre)**
[Biliary and esophageal self-expandable stents] Dumas R, et al. **Gastroenterol Clin Biol** 1996;20(5 Pt 2):B145-51 (84 ref.) **(Fre)**
[Resection of the posterior mediastinal gastric tube used in reconstruction after radical surgery for esophageal cancer--case reports] Hashimoto M, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Jul;43(7):1016-22 (19 ref.) (Eng. Abstr.) **(Jpn)**
[A simultaneous operation for esophageal and cholangiocellular carcinomas--a case of report] Kudo T, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Oct; 92(10):1789-93 (12 ref.) **(Jpn)**

THERAPY

Multimodal treatment of oesophageal carcinoma. Iizuka T. **Ann Chir Gynaecol** 1995;84(2):216-21 (16 ref.)
Palliation of malignant dysphagia from oesophageal cancer. Ellul JP, et al. **Br J Hosp Med** 1996 Mar 6-19;55(5):272-4 (15 ref.)
Upper gastrointestinal tumors. Ogawa M, et al. **Cancer Chemother Biol Response Modif** 1996;16:487-94 (22 ref.)
Endoscopic intubation of oesophagogastric malignancy. Hill J, et al. **Eur J Gastroenterol Hepatol** 1995 Sep;7(9):815-6 (8 ref.)
Metal stents in the oesophagus. Sturgess RP, et al. **Gut** 1995 Nov;37(5):593-4 (8 ref.)
Concurrent radiation therapy and chemotherapy followed by esophagectomy for localized esophageal carcinoma. Bates BA, et al. **J Clin Oncol** 1996 Jan;14(1):156-63 (48 ref.)
Changing patterns in the treatment of carcinoma of the esophagus. Tilanus HW. **Scand J Gastroenterol Suppl** 1995; 212:38-42 (67 ref.)
Adjuvant therapy of upper gastrointestinal tract cancers. Kelsen DP. **Semin Oncol** 1995 Dec;22(6):582-99 (78 ref.)
Comparison of different treatments for unresectable esophageal cancer. Reed CE. **World J Surg** 1995 Nov-Dec; 19(6):828-35 (99 ref.)
[Cancers of the esophagus. Combined modality therapy by radiotherapy, chemotherapy with or without surgery] Calais G, et al. **Bull Cancer Radiother** 1995;82(2):137-46 (67 ref.) **(Fre)**
[Current perspectives in the treatment of epidermoid cancer of the esophagus (editorial)] Lozach P. **Presse Med** 1995 Jun 24;24(23):1059-61 (10 ref.) (Eng. Abstr.) **(Fre)**
[Perioperative therapy in esophageal and stomach carcinoma] Stahl M, et al. **Med Klin** 1996 Apr 12;91 Suppl 3:85-92 (38 ref.) **(Ger)**
[Neoadjuvant chemotherapy and chemoradiotherapy in the treatment of esophageal cancer] Ando N, et al. **Gan To Kagaku Ryoho** 1995 Nov;22(13):1878-85 (26 ref.) (Eng. Abstr.) **(Jpn)**

ULTRASONOGRAPHY

Endosonographic staging of esophageal cancer: a review of literature results. Rösch T. **Gastrointest Endosc Clin N Am** 1995 Jul;5(3):537-47 (50 ref.)
[Endosonography of the esophagus and mediastinum] Schüder G, et al. **Bildgebung** 1995 Oct;62 Suppl 2:29-34 (21 ref.) (Eng. Abstr.) **(Ger)**

ESOPHAGEAL PERFORATION

CHEMICALLY INDUCED

A case of esophageal perforation due to a pill-induced ulcer successfully treated with conservative measures. Yamaoka K, et al. **Am J Gastroenterol** 1996 May;91(5):1044-5 (9 ref.)

COMPLICATIONS

Invasive candidiasis complicating spontaneous esophageal perforation (Boerhaave syndrome). Bauer TM, et al. **Am J Gastroenterol** 1996 Jun;91(6):1248-50 (11 ref.)

ETIOLOGY

Pharyngo-esophageal perforation due to blunt trauma. Polsky S, et al. **Am Surg** 1995 Nov;61(11):994-6 (11 ref.)

SURGERY

Emergency transhiatal oesophagectomy for instrumental perforation of an obstructed thoracic oesophagus. Gupta NM. **Br J Surg** 1996 Jul;83(7):1007-9 (29 ref.)

ESOPHAGEAL REFLUX see **GASTROESOPHAGEAL REFLUX**

ESOPHAGEAL SPASM, DIFFUSE

COMPLICATIONS

Low-amplitude distal esophageal spasm as a cause of severe dysphagia for solid food. Breumelhof R, et al. **Am J Gastroenterol** 1996 Jan;91(1):143-6 (14 ref.)

ESOPHAGEAL SPHINCTER see **ESOPHAGOGASTRIC JUNCTION**

ESOPHAGEAL STENOSIS

COMPLICATIONS

Esophageal disorders associated with emesis in infants and children. Myers NA. **Semin Pediatr Surg** 1995 Aug; 4(3):166-75 (25 ref.)

CONGENITAL

Isolated congenital esophageal stenosis. Murphy SG, et al. **J Pediatr Surg** 1995 Aug;30(8):1238-41 (25 ref.)

DIAGNOSIS

[Esophageal stenosis in children. Etiology, pathogenesis, and diagnosis (part I)] de la Rionda Gallardo LM, et al. **Acta Gastroenterol Latinoam** 1995;25(2):103-12 (62 ref.) **(Spa)**

ETIOLOGY

Esophageal involvement in chronic granulomatous disease. Case report and review [see comments] Hiller N, et al. **Pediatr Radiol** 1995;25(4):308-9 (8 ref.) Comment in: Pediatr Radiol 1996;26(2):169.
[Esophageal stenosis in children. Etiology, pathogenesis, and diagnosis (part I)] de la Rionda Gallardo LM, et al. **Acta Gastroenterol Latinoam** 1995;25(2):103-12 (62 ref.) **(Spa)**

SURGERY

Corrosive injuries of the oesophagus and stomach: experience in management at a regional paediatric centre. Stiff G, et al. **Ann R Coll Surg Engl** 1996 Mar;78(2):119-23 (68 ref.)
Emergency transhiatal oesophagectomy for instrumental perforation of an obstructed thoracic oesophagus. Gupta NM. **Br J Surg** 1996 Jul;83(7):1007-9 (29 ref.)

THERAPY

Palliation of malignant dysphagia from oesophageal cancer. Ellul JP, et al. **Br J Hosp Med** 1996 Mar 6-19;55(5):272-4 (15 ref.)
Esophageal dilatation. Nostrant TT. **Dig Dis** 1995 Nov-Dec; 13(6):337-55 (93 ref.)

ESOPHAGEAL STRICTURE see **ESOPHAGEAL STENOSIS**

ESOPHAGEAL VARICES see **ESOPHAGEAL AND GASTRIC VARICES**

ESOPHAGECTOMY

Can the morbidity of esophagectomy be reduced by the thoracoscopic approach? Gossot D, et al. **Surg Endosc** 1995 Oct;9(10):1113-5 (14 ref.)
Radical (en bloc) esophagectomy. Kapoor VK. **Trop Gastroenterol** 1996 Apr-Jun;17(2):6-11 (24 ref.)

ADVERSE EFFECTS

Emergency transhiatal oesophagectomy for instrumental perforation of an obstructed thoracic oesophagus. Gupta NM. **Br J Surg** 1996 Jul;83(7):1007-9 (29 ref.)
[Surgical treatment of esophageal cancer in patients over 70 years of age] Thomas P, et al. **Chirurgie** 1996;121(2):101-7 (22 ref.) (Eng. Abstr.) **(Fre)**

METHODS

Oesophageal substitution. Isolauri J. **Ann Chir Gynaecol** 1995; 84(2):241-6 (30 ref.)
Extended resections in the management of esophageal carcinoma. Altorki NK. **Curr Opin Gen Surg** 1994;:113-6 (24 ref.)
Transhiatal oesophagectomy compared with transthoracic resection and systematic lymphadenectomy for the treatment of oesophageal cancer. Horstmann O, et al. **Eur J Surg** 1995 Aug;161(8):557-67 (62 ref.)

ESOPHAGITIS

CHEMICALLY INDUCED

Esophagitis associated with the use of alendronate [see comments] de Groen PC, et al. **N Engl J Med** 1996 Oct 3;335(14):1016-21 (17 ref.) Comment in: N Engl J Med 1996 Oct 3;335(14):1058-9. Comment in: N Engl J Med 1996 Oct 3;335(14):1069-70.

DRUG THERAPY

Medical management of esophageal reflux. Hirschowitz BI. **Yale J Biol Med** 1994 May-Aug;67(3-4):223-31 (35 ref.)

PATHOLOGY

[Inflammatory esophageal diseases caused by herpes simplex virus infections--overview and report of 15 personal cases] Becker K, et al. **Z Gastroenterol** 1996 May;34(5):286-95 (73 ref.) (Eng. Abstr.) **(Ger)**

ESOPHAGITIS, PEPTIC

Reflux esophagitis: overview. Orlando RC. **Scand J Gastroenterol Suppl** 1995;210:36-7 (14 ref.)
[Current views on pathogenesis, diagnosis and treatment of reflux esophagitis] Sheptulin AA, et al. **Klin Med (Mosk)** 1995;73(6):11-4 (50 ref.) **(Rus)**

DIAGNOSIS

Macroscopic versus microscopic diagnosis of reflux esophagitis: erosions or eosinophils? Hassall E. **J Pediatr Gastroenterol Nutr** 1996 Apr;22(3):321-5 (60 ref.)

DRUG THERAPY

Why is the high grade inhibition of gastric acid secretion afforded by proton pump inhibitors often required for healing of reflux esophagitis? An epithelial perspective. Orlando RC. **Am J Gastroenterol** 1996 Sep;91(9):1692-6 (22 ref.)

ECONOMICS

Quality of life and cost of therapy in reflux disease. Glise H. **Scand J Gastroenterol Suppl** 1995;210:38-42 (33 ref.)

PATHOLOGY

Reflux esophagitis: biopsy or not? Vandenplas Y. **J Pediatr Gastroenterol Nutr** 1996 Apr;22(3):326-7 (10 ref.)

THERAPY

Current management of gastroesophageal reflux disease. DeVault KR. **Gastroenterologist** 1996 Mar;4(1):24-32 (92 ref.)
[Current review of the treatment of reflux esophagitis and its complications] Ayala Espinoza L. **Rev Gastroenterol Peru** 1995;15 Suppl 1:S1-5 (9 ref.) (Eng. Abstr.) **(Spa)**

ESOPHAGITIS, REFLUX see **ESOPHAGITIS, PEPTIC**

ESOPHAGOGASTRIC JUNCTION

Early detection of neoplasia of the esophagus and gastroesophageal junction. Riddell RH. **Am J Gastroenterol** 1996 May;91(5):853-63 (167 ref.)

DRUG EFFECTS

[Effects of anesthesia on the lower sphincter of the esophagus] Chassard D, et al. **Ann Fr Anesth Reanim** 1996; 15(3):277-83 (61 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Airway protective mechanisms: current concepts. Shaker R. **Dysphagia** 1995 Fall;10(4):216-27 (112 ref.)

PHYSIOPATHOLOGY

[Esophageal reflux disease] Pikkarainen P, et al. **Duodecim** 1994;110(20):1845-51 (31 ref.) **(Fin)**

ESOPHAGOGASTRODUODENOSCOPY see **ENDOSCOPY, DIGESTIVE SYSTEM**

ESOPHAGOPHARYNGEAL DIVERTICULUM see **ZENKER'S DIVERTICULUM**

ESOPHAGOPLASTY

INSTRUMENTATION

Laparoscopic antireflux repair and myotomy. Peters JH, et al. **Curr Opin Gen Surg** 1993;:170-9 (36 ref.)

METHODS

[Current technique of gastric plasties in esophageal surgery] Ségol P, et al. **Ann Chir** 1996;50(1):13-22 (24 ref.) **(Fre)**

ESOPHAGOSCOPY

[Endosonography of the esophagus and mediastinum] Schüder G, et al. **Bildgebung** 1995 Oct;62 Suppl 2:29-34 (21 ref.) (Eng. Abstr.) **(Ger)**

ESOPHAGOTRACHEAL FISTULA see **TRACHEOESOPHAGEAL FISTULA**

ESOPHAGUS

see related
ESOPHAGECTOMY
ESOPHAGOPLASTY
ESOPHAGOSCOPY

Endoscopic intubation of oesophagogastric malignancy. Hill J, et al. **Eur J Gastroenterol Hepatol** 1995 Sep;7(9):815–6 (8 ref.)

ABNORMALITIES

Multiple rings of the esophagus associated with gastroesophageal reflux [case report] McKinley MJ, et al. **Am J Gastroenterol** 1996 Mar;91(3):574–6 (16 ref.)

Duplication of the cervical esophagus in children. Billmire DF, et al. **J Pediatr Surg** 1995 Oct;30(10):1498–9 (6 ref.)

[Esophageal duplications: role of computed tomography. Apropos of 2 cases] Jouini S, et al. **Ann Radiol (Paris)** 1995; 38(7–8):418–25 (22 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Structure and role of Langerhans' cells in the human oesophageal epithelium. Terris B, et al. **Digestion** 1995;56 Suppl 1:9–14 (47 ref.)

INJURIES

Acute thermal injury of the esophagus. Javors BR, et al. **Dysphagia** 1996 Winter;11(1):72–4 (6 ref.)

METABOLISM

Statement of the North American Society for Pediatric Gastroenterology and Nutrition (NASPGN). Indications for pediatric esophageal pH monitoring. Colletti RB, et al. **J Pediatr Gastroenterol Nutr** 1995 Oct;21(3):253–62 (126 ref.)

PATHOLOGY

The columnar-lined esophagus, intestinal metaplasia, and Norman Barrett [see comments] Spechler SJ, et al. **Gastroenterology** 1996 Feb;110(2):614–21 (63 ref.) Comment in: Gastroenterology 1996 Aug;111(2):565–6.

Macroscopic versus microscopic diagnosis of reflux esophagitis: erosions or eosinophils? Hassall E. **J Pediatr Gastroenterol Nutr** 1996 Apr;22(3):321–5 (60 ref.)

Double-lumen esophagus: formation of a new lumen or septation of the existing one? Choudhry U, et al. **South Med J** 1996 May;89(5):538–41 (10 ref.)

PHYSIOLOGY

Clinical applications of esophageal manometry and pH monitoring. Ergun GA, et al. **Am J Gastroenterol** 1996 Jun;91(6):1077–89 (92 ref.)

Transmucosal potential difference as an index of esophageal mucosal integrity. Scarpignato C, et al. **Digestion** 1995;56 Suppl 1:51–60 (41 ref.)

Esophago/pharyngo/laryngeal interrelationships: airway protection mechanisms. Kidder TM. **Dysphagia** 1995 Fall; 10(4):228–31 (21 ref.)

Twenty-four hour esophageal pH monitoring: technique and application. Trimble KC, et al. **Gastroenterologist** 1995 Sep; 3(3):187–98 (97 ref.)

[Esophagus sensoriality (editorial)] López Gastón L. **Acta Gastroenterol Latinoam** 1995;25(3):185–9 (30 ref.) **(Spa)**

PHYSIOPATHOLOGY

Swallowing and esophageal function in Parkinson's disease. Johnston BT, et al. **Am J Gastroenterol** 1995 Oct; 90(10):1741–6 (54 ref.)

How does the esophageal epithelium maintain its integrity? Tobey NA. **Digestion** 1995;56 Suppl 1:45–50 (23 ref.)

Pathological pharyngo-esophageal interactions. Massey BT. **Dysphagia** 1995 Fall;10(4):232–4 (21 ref.)

Esophageal motility and reflux testing. State-of-the-art and clinical role in the twenty-first century. Dent J, et al. **Gastroenterol Clin North Am** 1996 Mar;25(1):51–73 (85 ref.)

[The pharyngoesophageal segment] Ekberg O, et al. **Radiologe** 1995 Oct;35(10):689–92 (22 ref.) (Eng. Abstr.) **(Ger)**

RADIONUCLIDE IMAGING

Esophageal transit scintigraphy. Klein HA. **Semin Nucl Med** 1995 Oct;25(4):306–17 (77 ref.)

SURGERY

Esophageal tissue band transected with hot biopsy forceps. Su AY, et al. **Dig Dis Sci** 1995 Oct;40(10):2197–9 (7 ref.)

ESOPHAGUS, BARRETT see **BARRETT ESOPHAGUS**

ESOTROPIA

COMPLICATIONS

On infantile esotropia with nystagmus in abduction. Ciancia AO. **J Pediatr Ophthalmol Strabismus** 1995 Sep–Oct; 32(5):280–8 (62 ref.)

PHYSIOPATHOLOGY

[Neural mechanisms in infantile esotropia--what is not functioning? (news)] Tychsen L, et al. **Klin Monatsbl Augenheilkd** 1996 Mar;208(3):aA4–12 (0 ref.) **(Ger)**

ESRD see **KIDNEY FAILURE, CHRONIC**

ESSENTIAL AMINO ACIDS see **AMINO ACIDS, ESSENTIAL**

ESSENTIAL POLYARTERITIS see **POLYARTERITIS NODOSA**

ESTERASES

BLOOD

Catalytic properties and distribution profiles of paraoxonase and cholinesterase phenotypes in human sera. Reiner E, et al. **Toxicol Lett** 1995 Dec;82–83:447–52 (24 ref.)

CHEMISTRY

Molecular aspects of carboxylesterase isoforms in comparison with other esterases. Satoh T, et al. **Toxicol Lett** 1995 Dec; 82–83:439–45 (17 ref.)

GENETICS

[Cloning, expression, and regulation of tissue-specific genes in Drosophila] Korochkin LI. **Genetika** 1995 Aug; 31(8):1029–42 (68 ref.) (Eng. Abstr.) **(Rus)**

ESTERS

PHARMACOLOGY

The esters of carboxylic nutrients as insulinotropic tools in non-insulin-dependent diabetes mellitus. Malaisse WJ. **Gen Pharmacol** 1995 Oct;26(6):1133–41 (40 ref.)

ESTETROL

ANALYSIS

[Estetrol (E4)] Sakamoto H, et al. **Nippon Rinsho** 1995 Mar; 53 Su Pt 2:566–8 (9 ref.) **(Jpn)**

ESTHESIONEUROBLASTOMA

SECONDARY

Central nervous system metastases from esthesioneuroblastoma. Shaari CM, et al. **Otolaryngol Head Neck Surg** 1996 Jun;114(6):808–12 (20 ref.)

SURGERY

Treatment of olfactory neuroblastoma. A report of 11 cases. Jekunen AP, et al. **Am J Clin Oncol** 1996 Aug;19(4):375–8 (21 ref.)

ESTHETIC SURGERY see **SURGERY, PLASTIC**

ESTHETICS

Perspective of facial esthetics in dental treatment planning. Mack MR. **J Prosthet Dent** 1996 Feb;75(2):169–76 (48 ref.)

ESTHETICS, DENTAL

Complete-denture esthetics. Engelmeier RL. **Dent Clin North Am** 1996 Jan;40(1):71–84 (26 ref.)

Perspective of facial esthetics in dental treatment planning. Mack MR. **J Prosthet Dent** 1996 Feb;75(2):169–76 (48 ref.)

[Impressions and esthetic rehabilitation. The preparatory work, clinical procedures and materials] Magne P, et al. **Schweiz Monatsschr Zahnmed** 1995;105(10):1302–16 (33 ref.) **(Fre, Ger)**

ESTRADIOL

see related
RECEPTORS, ESTRADIOL

ADMINISTRATION & DOSAGE

Menorest: technical development and pharmacokinetic profile. Marty JP. **Eur J Obstet Gynecol Reprod Biol** 1996 Apr;64 Suppl:S29–33 (12 ref.)

ADVERSE EFFECTS

Accumulated knowledge of Kliogest safety aspects. Ulrich LG. **Br J Obstet Gynaecol** 1996 May;103 Suppl 13:99–102; discussion 102–3 (14 ref.)

ANALOGS & DERIVATIVES

The effects of estradiol valerate plus medroxyprogesterone acetate and conjugated estrogens plus medrogestone on climacteric symptoms and metabolic variables in perimenopausal women. Egarter C, et al. **Acta Obstet Gynecol Scand** 1996 Apr;75(4):386–93 (40 ref.)

[Intramuscular depot estrogens (Estradurin) in treatment of patients with prostate carcinoma. Historical aspects, mechanism of action, results and current clinical status] Stege R, et al. **Urologe A** 1995 Sep;34(5):398–403 (52 ref.) (Eng. Abstr.) **(Ger)**

BIOSYNTHESIS

Are estradiol-producing cells incompletely endowed? A chronicle of the emergence of certitude from conjecture. Lieberman S. **Gynecol Obstet Invest** 1996;41(3):147–72 (152 ref.)

Role of 17 beta-hydroxysteroid dehydrogenase type 1 in endocrine and intracrine estradiol biosynthesis. Poutanen M, et al. **J Steroid Biochem Mol Biol** 1995 Dec; 55(5–6):525–32 (52 ref.)

BLOOD

An ovarian tumor of probable Wolffian origin with hormonal function. Inoue H, et al. **Gynecol Oncol** 1995 Nov; 59(2):304–8 (11 ref.)

[Biological surveillance of hormone substitution: relying on the plasma levels of estradiol or the products used?] Jamin C. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(5):467–74 (34 ref.) (Eng. Abstr.) **(Fre)**

PHARMACOKINETICS

Menorest: technical development and pharmacokinetic profile. Marty JP. **Eur J Obstet Gynecol Reprod Biol** 1996 Apr;64 Suppl:S29–33 (12 ref.)

PHARMACOLOGY

Protein tyrosine phosphorylation and estradiol action. Auricchio F, et al. **Ann N Y Acad Sci** 1996 Apr 30; 784:149–72 (41 ref.)

Oestradiol inhibition of vascular myointimal proliferation following immune, chemical and mechanical injury. Foegh ML, et al. **Ciba Found Symp** 1995;191:139–45; discussion 145–9 (19 ref.)

Oviduct during early pregnancy: hormonal regulation and interactions with the fertilized ovum. Murray MK, et al. **Microsc Res Tech** 1995 Aug 15;31(6):497–506 (49 ref.)

TOXICITY

Estrogen-induced hypothalamic beta-endorphin neuron loss: a possible model of hypothalamic aging. Desjardins GC, et al. **Exp Gerontol** 1995 May–Aug;30(3–4):253–67 (143 ref.)

ESTRADIOL-17 BETA see **ESTRADIOL**

ESTRADIOL RECEPTORS see **RECEPTORS, ESTRADIOL**

ESTRAMUSTINE

THERAPEUTIC USE

Estramustine revisited. Kreis W. **Cancer Treat Res** 1995; 78:163–84 (90 ref.)

Estramustine phosphate sodium. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer. Perry CM, et al. **Drugs Aging** 1995 Jul;7(1):49–74 (124 ref.)

ESTRAMUSTINPHOSPHATE see **ESTRAMUSTINE**

ESTRENOLONE see **NANDROLONE**

ESTRIOL

ADVERSE EFFECTS

Accumulated knowledge of Kliogest safety aspects. Ulrich LG. **Br J Obstet Gynaecol** 1996 May;103 Suppl 13:99–102; discussion 102–3 (14 ref.)

Review of the endometrial safety during intravaginal treatment with estriol. Vooijs GP, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Sep;62(1):101–6 (50 ref.)

BLOOD

Differential diagnosis and management of very low second trimester maternal serum unconjugated estriol levels, with special emphasis on the diagnosis of X-linked ichthyosis. Zalel Y, et al. **Obstet Gynecol Surv** 1996 Mar;51(3):200–3 (24 ref.)

[Maternal serum screening for detection of fetal chromosome abnormalities] Holzgreve W, et al. **Gynakologe** 1995 Oct; 28(5):280–8 (44 ref.) **(Ger)**

ESTROGEN ANALOGS see **ESTROGENS, SYNTHETIC**

ESTROGEN ANTAGONISTS

ADVERSE EFFECTS

The effects of tamoxifen on the uterus. Ismail SM. **Curr Opin Obstet Gynecol** 1996 Feb;8(1):27–31 (22 ref.)

Tamoxifen-associated eye disease. A review. Nayfield SG, et al. **J Clin Oncol** 1996 Mar;14(3):1018–26 (58 ref.)

The beneficial effect of the estrogen antagonist tamoxifen on experimental systemic lupus erythematosus [letter; comment] Thylan S. **J Rheumatol** 1995 Aug;22(8):1606–7 (11 ref.) Comment on: J Rheumatol 1994 Dec;21(12):2231–8.

[Expansive uterine myoma during tamoxifen therapy. 11 cases] Le Bouëdec G, et al. **Presse Med** 1995 Nov 25;

24(36):1694–6 (18 ref.) (Eng. Abstr.) **(Fre)**
[Surveillance of patients treated with tamoxifen] Sananes S, et al. **Presse Med** 1996 Mar 23;25(10):499–502 (25 ref.) (Eng. Abstr.) **(Fre)**

PHARMACOLOGY

Gynaecologic effects of tamoxifen. Kuo DY, et al. **Med Oncol** 1995 Jun;12(2):87–94 (79 ref.)
Tissue-specific actions of antioestrogens. Wakeling AE. **Mutat Res** 1995 Dec;333(1–2):45–9 (28 ref.)
Chemoprevention of breast cancer by tamoxifen: risks and opportunities. Smith LL, et al. **Toxicol Lett** 1995 Dec; 82–83:181–6 (18 ref.)
[Anti-estrogens and bone tissue] Ribot C, et al. **Ann Endocrinol (Paris)** 1995;56(6):603–8 (40 ref.) (Eng. Abstr.) **(Fre)**

THERAPEUTIC USE

Tamoxifen therapy—long-term results and complications. Moore MP, et al. **Adv Surg** 1996;29:263–9 (29 ref.)
Aromatase inhibitors: current status. Ibrahim NK, et al. **Am J Clin Oncol** 1995 Oct;18(5):407–17 (142 ref.)
Pure antiestrogens. The most important advance in the endocrine therapy of breast cancer since 1896. Nicholson RI, et al. **Ann N Y Acad Sci** 1996 Apr 30;784:325–35 (60 ref.)
Third annual William L. McGuire Memorial Lecture. "Studies on the estrogen receptor in breast cancer"—20 years as a target for the treatment and prevention of cancer. Jordan VC. **Breast Cancer Res Treat** 1995;36(3):267–85 (123 ref.)
The endocrine prevention of breast cancer. Spicer DV, et al. **Cancer Invest** 1995;13(5):495–504 (72 ref.)
The future of antihormone therapy: innovations based on an established principle. Parczyk K, et al. **J Cancer Res Clin Oncol** 1996;122(7):383–96 (82 ref.)
Alternate antiestrogens and approaches to the prevention of breast cancer. Jordan VC. **J Cell Biochem Suppl** 1995; 22:51–7 (51 ref.)
Hormonally induced differentiation: a novel approach to breast cancer prevention. Russo J, et al. **J Cell Biochem Suppl** 1995;22:58–64 (40 ref.)
Androgen receptor mediated growth control of breast cancer and endometrial cancer modulated by antiandrogen- and androgen-like steroids. Hackenberg R, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1–6 Spec No):113–7 (56 ref.)
Targeted anti-estrogens to treat and prevent diseases in women. Tonetti DA, et al. **Mol Med Today** 1996 May; 2(5):218–23 (35 ref.)
Tamoxifen: teaching an old drug new tricks? Grainger DJ, et al. **Nat Med** 1996 Apr;2(4):381–5 (23 ref.)
Clinical uses of antiestrogens. Baker VL, et al. **Obstet Gynecol Surv** 1996 Jan;51(1):45–59 (153 ref.)
Current and future roles of adjuvant endocrine therapy in the management of early carcinoma of the breast. Baum M, et al. **Recent Results Cancer Res** 1996;140:215–26 (30 ref.)
[Estrogen agonists, especially raloxifene, in the treatment of osteoporosis] Lips P, et al. **Ned Tijdschr Geneeskd** 1996 Jun 8;140(23):1215–7 (31 ref.) **(Dut)**
[Surveillance of patients treated with tamoxifen] Sananes S, et al. **Presse Med** 1996 Mar 23;25(10):499–502 (25 ref.) (Eng. Abstr.) **(Fre)**
[Agonists-antagonists of estrogens, their potential use in prophylaxis and treatment of osteoporosis] Hoszowski K. **Pol Tyg Lek** 1995 Nov;50(44–47):41–2 (16 ref.) (Eng. Abstr.) **(Pol)**
[Treatment of idiopathic thrombocytopenic purpura with danazol] Ruberto E, et al. **Sangre (Barc)** 1995 Aug; 40(4):307–10 (18 ref.) (Eng. Abstr.) **(Spa)**

TOXICITY

Chlorinated hydrocarbons: estrogens and antiestrogens. Safe S, et al. **Toxicol Lett** 1995 Dec;82–83:731–6 (30 ref.)

ESTROGEN RECEPTORS see **RECEPTORS, ESTROGEN**

ESTROGEN REPLACEMENT THERAPY

Alternatives to hormone replacement for menopause. Soffa VM. **Altern Ther Health Med** 1996 Mar;2(2):34–9 (46 ref.)
Hormone replacement therapy and breast cancer risk. Gambrell RD Jr. **Arch Fam Med** 1996 Jun;5(6):341–8 (82 ref.)
HRT, a general practice approach: how to reach the most vulnerable. Coope JK, et al. **Br J Clin Pract** 1996 Jan–Feb; 50(1):38–43 (67 ref.)
Benefits of exogenous oestrogen in inhibiting stress-related coronary artery atherosclerosis. Clarkson TB, et al. **Br J Obstet Gynaecol** 1996 May;103 Suppl 13:73–8; discussion 78–9 (40 ref.)
Hormone replacement therapy and syndrome X. Collins P. **Br J Obstet Gynaecol** 1996 May;103 Suppl 13:68–71; discussion 71–2 (45 ref.)
What do women want? Mattsson LA, et al. **Br J Obstet Gynaecol** 1996 May;103 Suppl 13:104–6; discussion 106–7 (11 ref.)
Oestrogen replacement therapy and Alzheimer's disease. Paganini-Hill A. **Br J Obstet Gynaecol** 1996 May;103 Suppl 13:80–6 (49 ref.)
Decision factors influencing hormone replacement therapy. Rozenberg S, et al. **Br J Obstet Gynaecol** 1996 May;103 Suppl 13:92–7; discussion 97–8 (45 ref.)
Are changes in lipoproteins during HRT important? Stevenson JC. **Br J Obstet Gynaecol** 1996 May;103 Suppl 13:39–43; discussion 43–4 (37 ref.)
Hormone replacement therapy and cardiovascular disease: the human model. Sullivan JM. **Br J Obstet Gynaecol** 1996 May;103 Suppl 13:59–65; discussion 66–7 (34 ref.)
Direction, misdirection and misconception in menopause research and management. Utian WH. **Br J Obstet Gynaecol** 1996 Aug;103(8):736–9 (11 ref.)
Postmenopausal oestrogens and arteries. Vyas S, et al. **Br J Obstet Gynaecol** 1995 Dec;102(12):942–6 (30 ref.)
Psychological and sexual symptoms associated with the menopause and the effects of hormone replacement therapy. Pearce J, et al. **Br J Psychiatry** 1995 Aug; 167(2):163–73 (60 ref.)
Women, hormones and blood pressure. Khaw KT. **Can J Cardiol** 1996 Jun;12 Suppl D:9D–12D (16 ref.)
The risks and benefits of hormone replacement therapy [see comments] Boyd ME. **Can J Surg** 1995 Oct;38(5):415–9 (45 ref.) Comment in: Can J Surg 1995 Oct;38(5):396–7.
Hormone replacement therapy: boon or bane? [see comments] Shibata HR. **Can J Surg** 1995 Oct;38(5):409–14 (42 ref.) Comment in: Can J Surg 1995 Oct;38(5):396–7.
Hormone replacement therapy and cardiovascular disease: the case for a randomized controlled trial. Vickers MR, et al. **Ciba Found Symp** 1995;191:150–60; discussion 160–4 (31 ref.)
Health consequences of short- and long-term postmenopausal hormone therapy. Weiss NS. **Clin Chem** 1996 Aug;42(8 Pt 2):1342–4 (17 ref.)
Hormone replacement therapy and diabetes mellitus. Dunne FP, et al. **Clin Endocrinol (Oxf)** 1996 Jun;44(6):615–20 (48 ref.)
Hormone replacement therapy for breast cancer survivors: facts versus fears. DiSaia PJ. **Clin Oncol (R Coll Radiol)** 1995;7(4):241–5 (24 ref.)
Osteoporosis prevention and treatment with sex hormone replacement therapy. Rozenberg S, et al. **Clin Rheumatol** 1995 Sep;14 Suppl 3:14–7 (28 ref.)
Continuous combined estrogen/progestin hormone replacement therapy. Andrews WC. **Clin Ther** 1995 Sep–Oct;17(5):812–26; discussion 811 (70 ref.)
Managing osteoporosis. **Drug Ther Bull** 1996 Jun;34(6):45–8 (34 ref.)
Estrogen replacement therapy in survivors of breast cancer: a risk-benefit assessment. Eden JA. **Drugs Aging** 1996 Feb; 8(2):127–33 (34 ref.)
Hormone replacement therapy in the aged. A state of the art review. Jacobs S, et al. **Drugs Aging** 1996 Mar; 8(3):193–213 (202 ref.)
The climacteric in The Netherlands: a review of Dutch studies on epidemiology, attitudes and use of hormone replacement therapy. Barentsen R. **Eur J Obstet Gynecol Reprod Biol** 1996 Apr;64 Suppl:S7–11 (22 ref.)
HRT management: the American experience. Carr BR. **Eur J Obstet Gynecol Reprod Biol** 1996 Apr;64 Suppl:S17–20 (12 ref.)
Management of hormone replacement therapy: the Italian experience. Crosignani PG. **Eur J Obstet Gynecol Reprod Biol** 1996 Apr;64 Suppl:S13–5 (11 ref.)
Does hormone replacement therapy increase the risk of breast cancer? Lécuru F, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Oct;62(2):159–66 (62 ref.)
Advantages and disadvantages of estrogen treatment by transdermal or oral administration. Rozenbaum H. **Eur J Obstet Gynecol Reprod Biol** 1996 Mar;65(1):33–7 (28 ref.)
Mechanisms whereby oestrogens influence arterial health. Stevenson JC. **Eur J Obstet Gynecol Reprod Biol** 1996 Mar; 65(1):39–42 (30 ref.)
The case for postmenopausal hormone therapy. Speroff L. **Hosp Pract (Off Ed)** 1996 Feb 15;31(2):75–89 (13 ref.)
European consensus development conference on menopause. European Menopause Society. **Hum Reprod** 1996 May; 11(5):975–9 (0 ref.)
A practical guide to prescribing estrogen replacement therapy. Corson SL. **Int J Fertil Menopausal Stud** 1995 Sep–Oct;40(5):229–47 (140 ref.)
The risks and benefits of estrogen replacement therapy: Leisure World. Paganini-Hill A. **Int J Fertil Menopausal Stud** 1995;40 Suppl 1:54–62 (37 ref.)
Compliance to hormone replacement therapy. Rozenberg S, et al. **Int J Fertil Menopausal Stud** 1995;40 Suppl 1:23–32 (51 ref.)
Is HRT indicated for the prevention of cardiovascular disease? Samsioe G. **Int J Fertil Menopausal Stud** 1995;40 Suppl 1:33–9 (17 ref.)
Medical and surgical strategies for treating urogynecological disorders. Samsioe G. **Int J Fertil Menopausal Stud** 1996 Mar–Apr;41(2):136–41 (22 ref.)
Cardiovascular disease in women: implications of hormone replacement therapy. Sarrel PM. **Int J Fertil Menopausal Stud** 1996 Mar–Apr;41(2):90–3 (20 ref.)
Does HRT modify risk of gynecological cancers? Schneider HP, et al. **Int J Fertil Menopausal Stud** 1995;40 Suppl 1:40–53 (86 ref.)
The women's health agenda: evolution of hormone replacement therapy as treatment and prophylaxis for coronary artery disease. King KM, et al. **J Adv Nurs** 1996 May;23(5):984–91 (39 ref.)
Is there a role for estrogen replacement therapy in the prevention and treatment of dementia? [see comments] Birge SJ. **J Am Geriatr Soc** 1996 Jul;44(7):865–70 (79 ref.) Comment in: J Am Geriatr Soc 1996 Jul;44(7):878–80.
Benefit/risk of estrogen therapy in cardiovascular disease: current knowledge and future challenges. Chow MS. **J Clin Pharmacol** 1995 Sep;35(9 Suppl):11S–17S (14 ref.)
Estrogen therapy for postmenopausal symptoms and prevention of osteoporosis. Sagraves R. **J Clin Pharmacol** 1995 Sep;35(9 Suppl):2S–10S (46 ref.)
Current concepts in postmenopausal hormone replacement therapy. Mayeaux EJ Jr, et al. **J Fam Pract** 1996 Jul; 43(1):69–75 (44 ref.)
Hormone replacement therapy and cardiovascular risk: the cardiovascular physicians' viewpoint. Lip GY, et al. **J Intern Med** 1995 Nov;238(5):389–99 (88 ref.)
Rationale for estrogen with interrupted progestin as a new low-dose hormonal replacement therapy. Casper RF, et al. **J Soc Gynecol Investig** 1996 Sep–Oct;3(5):225–34 (79 ref.)
Postmenopausal estrogens and breast cancer. Colditz GA. **J Soc Gynecol Investig** 1996 Mar–Apr;3(2):50–6 (48 ref.)
Estrogen replacement therapy for the breast cancer survivor. DiSaia PJ. **J Soc Gynecol Investig** 1996 Mar–Apr;3(2):57–9 (10 ref.)
The menopause, hormone replacement, and cardiovascular disease: the epidemiologic evidence. Barrett-Connor E. **Maturitas** 1996 Mar;23(2):227–34 (57 ref.)
Hormonal and non-hormonal interventions for menopausal symptoms. Coope J. **Maturitas** 1996 Mar;23(2):159–68 (73 ref.)
Hormone therapy in the menopause and breast cancer risk—a review. Ewertz M. **Maturitas** 1996 Mar;23(2):241–6 (32 ref.)
Office gynecology for the primary care physician, part I: vaginitis, the Papanicolaou smear, contraception, and postmenopausal estrogen replacement. Reife CM. **Med Clin North Am** 1996 Mar;80(2):299–319 (63 ref.)
Review article: taking estrogens. Abrams J. **N J Med** 1995 Sep;92(9):580–2 (18 ref.)
Menopause and hormone replacement therapy: an overview. Hammond CB. **Obstet Gynecol** 1996 Feb;87(2 Suppl):2S–15S (97 ref.)
The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. Grodstein F, et al. **Prog Cardiovasc Dis** 1995 Nov–Dec;38(3):199–210 (86 ref.)
Estrogen replacement therapy and stroke. Paganini-Hill A. **Prog Cardiovasc Dis** 1995 Nov–Dec;38(3):223–42 (85 ref.)
Coronary arteriography in estrogen-treated postmenopausal women. Sullivan JM. **Prog Cardiovasc Dis** 1995 Nov–Dec; 38(3):211–22 (34 ref.)
Practical aspects of hormone replacement therapy. Thorneycroft IH. **Prog Cardiovasc Dis** 1995 Nov–Dec; 38(3):243–54 (83 ref.)
Sex hormones and breast cancer: the issue of hormone replacement. Pritchard KI, et al. **Recent Results Cancer Res** 1996;140:285–93 (33 ref.)
Estrogen replacement therapy in the elderly. Paganini-Hill A. **Zentralbl Gynakol** 1996;118(5):255–61 (41 ref.)
Hormone replacement therapy and vaginal bleeds. Theoretical aspects and clinical management. Samsioe G. **Zentralbl Gynakol** 1996;118(4):181–7 (28 ref.)
[Current trends in hormone therapy during menopause and postmenopause] Suhonen S. **Duodecim** 1994;110(10):1011–8 (35 ref.) **(Fin)**
[Biological surveillance of hormone substitution: relying on the plasma levels of estradiol or the products used?] Jamin C. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(5):467–74 (34 ref.) (Eng. Abstr.) **(Fre)**
[Progestins and osteoporosis. Does progestin contribute to the effectiveness of estrogen replacement therapy in menopause?] Lopes P. **Rev Fr Gynecol Obstet** 1995 May–Jun;90(5–6):307–8 (17 ref.) **(Fre)**
[Hormone replacement treatment and skin aging] Vaillant L, et al. **Therapie** 1996 Jan–Feb;51(1):67–70 (20 ref.) (Eng. Abstr.) **(Fre)**
–Hormone substitution in postmenopause– Keller PJ. **Arch Gynecol Obstet** 1995;256 Suppl:S193–7 (6 ref.) **(Ger)**
[Estrogen–gestagen substitution in geriatric gynecology. Long-term prevention for the third segment of life after menopause] Lauritzen C. **Fortschr Med** 1996 May 30; 114(15):187–90 (0 ref.) (Eng. Abstr.) **(Ger)**
[Estrogens in menopause—therapy and prevention. II. Estrogens and osteoporosis] Hüfner M. **Internist (Berl)** 1996 Apr;37(4):405–9 (50 ref.) **(Ger)**
[Estrogens in menopause—therapy and prevention. III. Estrogen replacement in menopause: uses and risks in prevention and therapy of cardiovascular diseases] Reincke M, et al. **Internist (Berl)** 1996 Apr;37(4):410–5; discussion 415 (20 ref.) **(Ger)**
[Sex hormone replacement following menopause—for all women? A plea for prevention using estrogens and gestagens] Nocke W. **Ther Umsch** 1995 Oct;52(10):693–704

(14 ref.) (Eng. Abstr.) **(Ger)**

[Gestagens and hormone substitution] Klinger G. **Zentralbl Gynakol** 1995;117 Suppl:25–9 (0 ref.) **(Ger)**

[Prevention of cardiovascular diseases by hormone replacement in postmenopause] Windler E. **Zentralbl Gynakol** 1996;118(4):188–97 (77 ref.) (Eng. Abstr.) **(Ger)**

[Estrogen–progesterone "add–back" for long–term GNRH analogue therapy] Levy T, et al. **Harefuah** 1995 Jun 15; 128(12):789–92 (42 ref.) **(Heb)**

[Postmenopausal estrogen replacement therapy—does it reduce morbidity and mortality from ischemic heart disease?] Zyssman I, et al. **Harefuah** 1996 Feb 1; 130(3):200–3 (34 ref.) **(Heb)**

[Sex hormones, glycolipid metabolism, and atherogenesis] Sarubbi B, et al. **Minerva Med** 1995 Jun;86(6):265–73 (67 ref.) (Eng. Abstr.) **(Ita)**

[Contemporary views on estrogen replacement therapy. II. Hormonal therapy in women with imminent ischemic heart disease] Krasomski G. **Ginekol Pol** 1995 Feb;66(2):93–6 (27 ref.) (Eng. Abstr.) **(Pol)**

[Cardiovascular disease and hormone replacement therapy] Aldrighi JM, et al. **Arq Bras Cardiol** 1995 Sep;65(3):249–54 (72 ref.) **(Por)**

ADVERSE EFFECTS

Benefits and risks of estrogen replacement therapy. Lobo RA. **Am J Obstet Gynecol** 1995 Sep;173(3 Pt 2):982–9 (33 ref.)

Hormone replacement therapy and breast cancer: an overview. Theriault RL. **Br J Obstet Gynaecol** 1996 May; 103 Suppl 13:87–90; discussion 90–1 (17 ref.)

Hormones and breast cancer. Helzlsouer KJ, et al. **Cancer** 1995 Nov 15;76(10 Suppl):2059–63 (34 ref.)

Hormone replacement therapy: aspects of bleeding problems and compliance. Samsioe G. **Int J Fertil Menopausal Stud** 1996 Jan–Feb;41(1):11–5 (20 ref.)

Hormone replacement therapy in women with breast cancer. Do the risks outweigh the benefits? Roy JA, et al. **J Clin Oncol** 1996 Mar;14(3):997–1006 (85 ref.)

Vascular aspects of oestrogen. Collins P. **Maturitas** 1996 Mar; 23(2):217–26 (97 ref.)

The menopause and hormone replacement therapy: lipids, lipoproteins, coagulation and fibrinolytic factors. Tikkanen MJ. **Maturitas** 1996 Mar;23(2):209–16 (66 ref.)

Postmenopausal estrogens and progestogens and the incidence of gynecologic cancer. Weiss NS, et al. **Maturitas** 1996 Mar;23(2):235–9 (43 ref.)

Postmenopausal hormone therapy and breast cancer. Speroff L. **Obstet Gynecol** 1996 Feb;87(2 Suppl):44S–54S (81 ref.)

[Hormone replacement therapy in menopause and cancers] Cappelaere P. **Rev Med Interne** 1995;16(12):945–59 (76 ref.) (Eng. Abstr.) **(Fre)**

[Long–term hormone replacement and risk of breast carcinoma: current status. On behalf of the German Menopause Society and the Professional Society of Gynecologic Endocrinology and Reproductive Medicine of the German Society of Gynecology and Obstetrics] Kuhl H, et al. **Zentralbl Gynakol** 1995;117(10):549–53 (35 ref.) **(Ger)**

[Estrogen replacement therapy and malignant tumors of the female genital tract] Piura B, et al. **Harefuah** 1996 Feb 15; 130(4):263–7 (35 ref.) **(Heb)**

[Menopause, hormonal replacement therapy, and coronary disease] Gebara OC, et al. **Arq Bras Cardiol** 1995 Apr; 64(4):355–8 (40 ref.) **(Por)**

CONTRAINDICATIONS

Hormonal therapy and genital tract cancer. Wren B. **Curr Opin Obstet Gynecol** 1996 Feb;8(1):38–41 (31 ref.)

Postmenopausal estrogen replacement therapy in the patient with breast carcinoma. Cyr MG. **R I Med** 1995 Sep; 78(9):261–3 (23 ref.)

METHODS

The effects of estradiol valerate plus medroxyprogesterone acetate and conjugated estrogens plus medrogestone on climacteric symptoms and metabolic variables in perimenopausal women. Egarter C, et al. **Acta Obstet Gynecol Scand** 1996 Apr;75(4):386–93 (40 ref.)

Menorest: technical development and pharmacokinetic profile. Marty JP. **Eur J Obstet Gynecol Reprod Biol** 1996 Apr;64 Suppl:S29–33 (12 ref.)

Handling hormone replacement therapy: key issues for the prescriber. Stevenson JC. **Eur J Obstet Gynecol Reprod Biol** 1996 Apr;64 Suppl:S25–7 (10 ref.)

Perimenopausal and postmenopausal hormone replacement therapy. Part 2. Hormonal regimens and complementary and alternative therapies. Lichtman R. **J Nurse Midwifery** 1996 May–Jun;41(3):195–210 (109 ref.)

A nurse's guide to hormone replacement therapy. Moore AA, et al. **J Obstet Gynecol Neonatal Nurs** 1996 Jan;25(1):24–31 (43 ref.)

[Hormonal replacement treatment: therapeutic protocols] Jamin C. **Contracept Fertil Sex** 1996 Feb;24(2):147–52 (39 ref.) (Eng. Abstr.) **(Fre)**

[Hormone replacement therapy: practical management] Tamborini A. **Contracept Fertil Sex** 1996 Jun;24(6):444–51 (22 ref.) **(Fre)**

[Hormone replacement therapy in menopausal women previously treated for breast cancer (editorial)] This P. **Presse Med** 1996 Feb 3;25(4):141–4 (25 ref.) (Eng. Abstr.) **(Fre)**

[Estrogens in menopause—therapy and prevention. I. Hormone substitution in climacteric and postmenopause] Wuttke W. **Internist (Berl)** 1996 Apr;37(4):402–5 (50 ref.) **(Ger)**

[Value of transdermal hormone substitution for postmenopausal osteoporosis] Felsenberg D. **Zentralbl Gynakol** 1995;117(10):516–23 (47 ref.) (Eng. Abstr.) **(Ger)**

[Transdermal and oral hormone substitution with estrogens: a comparison] Schindler AE. **Zentralbl Gynakol** 1995; 117(10):504–7 (27 ref.) (Eng. Abstr.) **(Ger)**

[Hormone replacement therapy and the cardiovascular system: on the role of hemostasis] Winkler UH. **Zentralbl Gynakol** 1995;117(10):510–5 (34 ref.) (Eng. Abstr.) **(Ger)**

PSYCHOLOGY

[Reflections on compliance in menopause hormone replacement therapy] Berthet J, et al. **Rev Fr Gynecol Obstet** 1995 Dec;90(12):548–51 (0 ref.) (Eng. Abstr.) **(Fre)**

STANDARDS

Benefits and risks of estrogen replacement therapy. Lobo RA. **Am J Obstet Gynecol** 1995 Sep;173(3 Pt 2):982–9 (33 ref.)

Emerging delivery systems for estrogen replacement: aspects of transdermal and oral delivery. Nachtigall LE. **Am J Obstet Gynecol** 1995 Sep;173(3 Pt 2):993–7 (15 ref.)

Progestogens in estrogen–replacement therapy. Gambrell RD Jr. **Clin Obstet Gynecol** 1995 Dec;38(4):890–901 (43 ref.)

The rational use of androgens in hormone replacement therapy. Peterson CM. **Clin Obstet Gynecol** 1995 Dec; 38(4):915–20 (20 ref.)

The impact of different HRT regimens on compliance. Dören M, et al. **Int J Fertil Menopausal Stud** 1996 Jan–Feb; 41(1):29–39 (49 ref.)

UTILIZATION

Estrogen replacement therapy in practice: trends and issues. Thompson W. **Am J Obstet Gynecol** 1995 Sep;173(3 Pt 2):990–3 (21 ref.)

ESTROGENIC HORMONES, CONJUGATED see **ESTROGENS, CONJUGATED**

ESTROGENIC SUBSTANCES, CONJUGATED see **ESTROGENS, CONJUGATED**

ESTROGENS

see related
ESTROGEN ANTAGONISTS
RECEPTORS, ESTROGEN

Organochlorine compounds and estrogen–related cancers in women. Adami HO, et al. **Cancer Causes Control** 1995 Nov; 6(6):551–66 (105 ref.)

Phytoestrogens, body composition, and breast cancer. Horn–Ross PL. **Cancer Causes Control** 1995 Nov; 6(6):567–73 (59 ref.)

The control and biological importance of intratumoural aromatase in breast cancer. Dowsett M, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1–6 Spec No):145–50 (22 ref.)

Alternative splicing of the estrogen receptor primary transcript normally occurs in estrogen receptor positive tissues and cell lines. Pfeffer U, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1–6 Spec No):99–105 (37 ref.)

[35 years of estrogen–progestagen pills: where is the vascular risk?] Gaspard U. **Rev Med Liege** 1996 Jan;51(1):133–8 (15 ref.) **(Fre)**

[Biosynthesis and microbial transformation of griseofulvin and carcinogenesis and prevention of cancer by estrogens] Sato Y. **Yakugaku Zasshi** 1995 Nov;115(11):892–908 (80 ref.) (Eng. Abstr.) **(Jpn)**

ADMINISTRATION & DOSAGE

Emerging delivery systems for estrogen replacement: aspects of transdermal and oral delivery. Nachtigall LE. **Am J Obstet Gynecol** 1995 Sep;173(3 Pt 2):993–7 (15 ref.)

Hormones and breast and endometrial cancers: preventive strategies and future research. Hulka BS, et al. **Environ Health Perspect** 1995 Nov;103 Suppl 8:185–9 (49 ref.)

Rationale for estrogen with interrupted progestin as a new low–dose hormonal replacement therapy. Casper RF, et al. **J Soc Gynecol Investig** 1996 Sep–Oct;3(5):225–34 (79 ref.)

Practical aspects of hormone replacement therapy. Thorneycroft IH. **Prog Cardiovasc Dis** 1995 Nov–Dec; 38(3):243–54 (83 ref.)

ADVERSE EFFECTS

Molecular mechanisms of estrogen carcinogenesis. Yager JD, et al. **Annu Rev Pharmacol Toxicol** 1996;36:203–32 (226 ref.)

Blood supply, blood flow and autoregulation in the adenohypophysis, and altered patterns in oestrogen–induced adenomatous hyperplasia. Jakubowski J. **Br J Neurosurg** 1995;9(3):331–46 (103 ref.)

Hormone replacement therapy and breast cancer: an overview. Theriault RL. **Br J Obstet Gynaecol** 1996 May; 103 Suppl 13:87–90; discussion 90–1 (17 ref.)

Vitellogenesis as a biomarker for estrogenic contamination of the aquatic environment. Sumpter JP, et al. **Environ Health Perspect** 1995 Oct;103 Suppl 7:173–8 (39 ref.)

Endometrial cancer chemoprevention: implications of diverse pathways of carcinogenesis. Sherman ME, et al. **J Cell Biochem Suppl** 1995;23:160–4 (27 ref.)

Hormone replacement therapy in women with breast cancer. Do the risks outweigh the benefits? Roy JA, et al. **J Clin Oncol** 1996 Mar;14(3):997–1006 (85 ref.)

Vascular aspects of oestrogen. Collins P. **Maturitas** 1996 Mar; 23(2):217–26 (97 ref.)

Postmenopausal estrogens and progestogens and the incidence of gynecologic cancer. Weiss NS, et al. **Maturitas** 1996 Mar;23(2):235–9 (43 ref.)

Estrogen as a carcinogen: the genetics and molecular biology of human endometrial carcinoma. Boyd J. **Prog Clin Biol Res** 1996;394:151–73 (162 ref.)

Can environmental estrogens cause breast cancer? Davis DL, et al. **Sci Am** 1995 Oct;273(4):167–72 (5 ref.)

[Steroid–induced liver tumor] Nishizawa Y, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):449–52 (21 ref.) **(Jpn)**

ANALYSIS

[Estrogen: estrone (E1), estradiol (E2) and estriol (E3)] Shimizu Y, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:553–65 (21 ref.) **(Jpn)**

BIOSYNTHESIS

DHEA and peripheral androgen and estrogen formation: intracinology. Labrie F, et al. **Ann N Y Acad Sci** 1995 Dec 29;774:16–28 (70 ref.)

Estrogen biosynthesis in adipose. Significance in breast cancer development. Simpson ER, et al. **Ann N Y Acad Sci** 1996 Apr 30;784:18–26 (60 ref.)

Sperm, a source of estrogen. Hess RA, et al. **Environ Health Perspect** 1995 Oct;103 Suppl 7:59–62 (41 ref.)

Estrogen biosynthesis—regulation, action, remote effects, and value of monitoring in ovarian stimulation cycles. Shoham Z, et al. **Fertil Steril** 1996 Apr;65(4):687–701 (161 ref.)

Regulation of sex–specific formation of oestrogen in brain development: endogenous inhibitors of aromatase. Hutchison JB, et al. **J Steroid Biochem Mol Biol** 1996 Jan; 56(1–6 Spec No):201–7 (37 ref.)

BLOOD

Regulation of oestrogen action: role of 17 beta–hydroxysteroid dehydrogenases. Poutanen M, et al. **Ann Med** 1995 Dec;27(6):675–82 (44 ref.)

[Biological surveillance of hormone substitution: relying on the plasma levels of estradiol or the products used?] Jamin C. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(5):467–74 (34 ref.) (Eng. Abstr.) **(Fre)**

CONTRAINDICATIONS

Hormonal therapy and genital tract cancer. Wren B. **Curr Opin Obstet Gynecol** 1996 Feb;8(1):38–41 (31 ref.)

DEFICIENCY

Osteoporosis prevention and treatment with sex hormone replacement therapy. Rozenberg S, et al. **Clin Rheumatol** 1995 Sep;14 Suppl 3:14–7 (28 ref.)

DIAGNOSTIC USE

[Urinary incontinence in castrated female dogs. 2. Therapy] Blendinger C, et al. **Tierarztl Prax** 1995 Aug;23(4):402–6 (30 ref.) (Eng. Abstr.) **(Ger)**

GENETICS

Oestrogen– and anti–oestrogen–regulated genes in human breast cancer. Rochefort H. **Ciba Found Symp** 1995; 191:254–65; discussion 265–8 (40 ref.)

METABOLISM

Estrogen content and metabolism in human breast tumor tissues and cells. Castagnetta LA, et al. **Ann N Y Acad Sci** 1996 Apr 30;784:314–24 (47 ref.)

Estrogen regulated messenger RNAs in human breast cancer cells. May FE, et al. **Biomed Pharmacother** 1995; 49(9):400–14 (85 ref.)

Phytoestrogens: epidemiology and a possible role in cancer protection. Adlercreutz H. **Environ Health Perspect** 1995 Oct;103 Suppl 7:103–12 (133 ref.)

Interrelationships of neurochemicals, estrogen, and recurring headache. Marcus DA. **Pain** 1995 Aug;62(2):129–39 (136 ref.)

[Estrogens and breast cancer: from action mechanisms to clinical applications] Garcia M, et al. **Ann Endocrinol (Paris)** 1995;56(5):543–5 (10 ref.) (Eng. Abstr.) **(Fre)**

ESTROGENS

PHARMACOKINETICS

Pharmacokinetic and pharmacologic variation between different estrogen products. O'Connell MB. **J Clin Pharmacol** 1995 Sep;35(9 Suppl):18S-24S (45 ref.)

PHARMACOLOGY

Non-genomic effects of estrogen and the vessel wall. Farhat MY, et al. **Biochem Pharmacol** 1996 Mar 8;51(5):571-6 (78 ref.)

Cardiovascular effects of estrogen and lipid-lowering therapies in postmenopausal women. Guetta V, et al. **Circulation** 1996 May 15;93(10):1928-37 (153 ref.)

Mouse lactoferrin gene: a marker for estrogen and epidermal growth factor. Teng C. **Environ Health Perspect** 1995 Oct; 103 Suppl 7:17-20 (37 ref.)

The vascular protective effects of estrogen. Farhat MY, et al. **FASEB J** 1996 Apr;10(5):615-24 (123 ref.)

Spatial cognition in humans: possible modulation by androgens and estrogens. Hampson E. **J Psychiatry Neurosci** 1995 Nov;20(5):397-404 (66 ref.)

A morphologist's approach to the vagina--age-related changes and estrogen sensitivity. Forsberg JG. **Maturitas** 1995 Dec;22 Suppl:S7-S15 (82 ref.)

PHYSIOLOGY

Estrogen modulation of oxytocin and its relation to behavior. McCarthy MM. **Adv Exp Med Biol** 1995;395:235-45 (67 ref.)

Cardiovascular protection by oestrogen is partly mediated through modulation of autonomic nervous function. Du XJ, et al. **Cardiovasc Res** 1995 Aug;30(2):161-5 (57 ref.)

Human prostate cancer: a direct role for oestrogens. Castagnetta LA, et al. **Ciba Found Symp** 1995;191:269-86; discussion 286-9 (55 ref.)

Oestrogens and the structural and functional plasticity of neurons: implications for memory, ageing and neurodegenerative processes. McEwen BS, et al. **Ciba Found Symp** 1995;191:52-66; discussion 66-73 (43 ref.)

Oestrogens and calcium regulatory hormones: potential implications for bone. Naveh-Many T, et al. **Curr Opin Nephrol Hypertens** 1995 Jul;4(4):319-23 (50 ref.)

Estrogen, progesterone, and vascular reactivity: potential cellular mechanisms. White MM, et al. **Endocr Rev** 1995 Dec;16(6):739-51 (172 ref.)

The role of estrogen in turtle sex determination and the effect of PCBs. Crews D, et al. **Environ Health Perspect** 1995 Oct;103 Suppl 7:73-7 (19 ref.)

Oestrogen and colonic epithelial cell growth. Singh S, et al. **Gut** 1995 Dec;37(6):737-9 (42 ref.)

Role of growth hormone and sex steroids in achieving and maintaining normal bone mass. Holmes SJ, et al. **Horm Res** 1996;45(1-2):86-93 (96 ref.)

Medical and surgical strategies for treating urogynecological disorders. Samsioe G. **Int J Fertil Menopausal Stud** 1996 Mar-Apr;41(2):136-41 (22 ref.)

Estrogen and cardiovascular function after menopause. Samaan SA, et al. **J Am Coll Cardiol** 1995 Nov 15; 26(6):1403-10 (77 ref.)

Is there a role for estrogen replacement therapy in the prevention and treatment of dementia? [see comments] Birge SJ. **J Am Geriatr Soc** 1996 Jul;44(7):865-70 (79 ref.) Comment in: J Am Geriatr Soc 1996 Jul;44(7):878-80.

Mechanisms of estrogen action during neural development: mediation by interactions with the neurotrophins and their receptors? Toran-Allerand CD. **J Steroid Biochem Mol Biol** 1996 Jan;56(1-6 Spec No):169-78 (77 ref.)

The estrogen connection: the etiological relationship between diabetes, cancer, rheumatoid arthritis and psychiatric disorders. Holden RJ. **Med Hypotheses** 1995 Aug; 45(2):169-89 (162 ref.)

Estrogen: effects on the cardiovascular tree. Wild RA. **Obstet Gynecol** 1996 Feb;87(2 Suppl):27S-35S (70 ref.)

Roles of estrogen and SHBG in prostate physiology. Farnsworth WE. **Prostate** 1996 Jan;28(1):17-23 (49 ref.)

[Natural estrogens and the cardiovascular system] Bader A, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(3):233-7 (38 ref.) (Eng. Abstr.) **(Fre)**

[Hormonal regulation of differentiated endometrial functions and its derangement] Taketani Y. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Aug;47(8):803-8 (26 ref.) **(Jpn)**

[The effects of androgens and other sex hormones on serum lipoproteins] Reiner Z. **Lijec Vjesn** 1996 Mar;118 Suppl 1:33-7 (55 ref.) (Eng. Abstr.) **(Ser)**

[Ischemic cardiopathy in women: the role of estrogens in the coronary vascular wall and in syndrome X] Gaxiola E, et al. **Arch Inst Cardiol Mex** 1995 Sep-Oct;65(5):461-7 (61 ref.) **(Spa)**

THERAPEUTIC USE

Present and future of osteoporosis therapy. Seeman E, et al. **Bone** 1995 Aug;17(2 Suppl):23S-29S (47 ref.)

Hormone replacement therapy and syndrome X. Collins P. **Br J Obstet Gynaecol** 1996 May;103 Suppl 13:68-71; discussion 71-2 (45 ref.)

Oestrogen replacement therapy and Alzheimer's disease. Paganini-Hill A. **Br J Obstet Gynaecol** 1996 May;103 Suppl 13:80-6 (49 ref.)

The case for postmenopausal hormone therapy. Speroff L. **Hosp Pract (Off Ed)** 1996 Feb 15;31(2):75-89 (13 ref.)

Current concepts in postmenopausal hormone replacement therapy. Mayeaux EJ Jr, et al. **J Fam Pract** 1996 Jul; 43(1):69-75 (44 ref.)

Estrogens in the treatment of prostate cancer. Cox RL, et al. **J Urol** 1995 Dec;154(6):1991-8 (96 ref.)

The menopause, hormone replacement, and cardiovascular disease: the epidemiologic evidence. Barrett-Connor E. **Maturitas** 1996 Mar;23(2):227-34 (57 ref.)

Vascular aspects of oestrogen. Collins P. **Maturitas** 1996 Mar; 23(2):217-26 (97 ref.)

Hormone therapy in the menopause and breast cancer risk--a review. Ewertz M. **Maturitas** 1996 Mar;23(2):241-6 (32 ref.)

Coronary arteriography in estrogen-treated postmenopausal women. Sullivan JM. **Prog Cardiovasc Dis** 1995 Nov-Dec; 38(3):211-22 (34 ref.)

[Inducing feminization in Turner syndrome (editorial)] Bost M. **Arch Pediatr** 1995 Nov;2(11):1035-7 (12 ref.) **(Fre)**

TOXICITY

Effects of estrogenic chemicals on development. Jones LA, et al. **Environ Health Perspect** 1995 Oct;103 Suppl 7:63-7 (27 ref.)

Toxicity of endogenous and environmental estrogens: what is the role of elemental interactions? Stancel GM, et al. **Environ Health Perspect** 1995 Oct;103 Suppl 7:29-33 (48 ref.)

Mechanisms of estrogen-associated carcinogenesis. Barrett JC, et al. **Prog Clin Biol Res** 1996;394:105-11 (38 ref.)

Estrogen carcinogenesis in the hamster kidney: a hormone-driven multistep process. Li JJ, et al. **Prog Clin Biol Res** 1996;394:255-67 (57 ref.)

Feminized responses in fish to environmental estrogens. Sumpter JP. **Toxicol Lett** 1995 Dec;82-83:737-42 (18 ref.)

ESTROGENS, CATECHOL

ANALYSIS

[Catechol estrogen] Takami M, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:611-5 (19 ref.) **(Jpn)**

ESTROGENS, CONJUGATED

PHARMACOLOGY

The effects of estradiol valerate plus medroxyprogesterone acetate and conjugated estrogens plus medrogestone on climacteric symptoms and metabolic variables in perimenopausal women. Egarter C, et al. **Acta Obstet Gynecol Scand** 1996 Apr;75(4):386-93 (40 ref.)

ESTROGENS, NON-STEROIDAL

A review of the clinical effects of phytoestrogens. Knight DC, et al. **Obstet Gynecol** 1996 May;87(5 Pt 2):897-904 (90 ref.)

ADMINISTRATION & DOSAGE

Phytoestrogens--a short review. Knight DC, et al. **Maturitas** 1995 Nov;22(3):167-75 (89 ref.)

ADVERSE EFFECTS

Phytoestrogens, body composition, and breast cancer. Horn-Ross PL. **Cancer Causes Control** 1995 Nov; 6(6):567-73 (59 ref.)

Do environmental estrogens contribute to the decline in male reproductive health? Jensen TK, et al. **Clin Chem** 1995 Dec; 41(12 Pt 2):1896-901 (68 ref.)

Transplacental hormonal carcinogenesis: diethylstilbestrol as an example. Newbold RR, et al. **Prog Clin Biol Res** 1996; 394:131-47 (37 ref.)

TOXICITY

Directly toxic effects of plant chemicals which may occur in human and animal foods. Seawright AA. **Nat Toxins** 1995;3(4):227-32; discussion 242 (54 ref.)

ESTROGENS, SYNTHETIC

ADMINISTRATION & DOSAGE

[Renaissance of estrogen therapy in advanced prostate carcinoma?] Smith PH, et al. **Urologe A** 1995 Sep; 34(5):393-7 (17 ref.) (Eng. Abstr.) **(Ger)**

[Intramuscular depot estrogens (Estradurin) in treatment of patients with prostate carcinoma. Historical aspects, mechanism of action, results and current clinical status] Stege R, et al. **Urologe A** 1995 Sep;34(5):398-403 (52 ref.) (Eng. Abstr.) **(Ger)**

BLOOD

[Synthetic steroids] Miyazaki S. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:1036-9 (19 ref.) **(Jpn)**

PHARMACOLOGY

Tissue-selective actions of estrogen analogs. Evans GL, et al. **Bone** 1995 Oct;17(4 Suppl):181S-190S (61 ref.)

THERAPEUTIC USE

Hormone replacement therapy in the aged. A state of the art review. Jacobs S, et al. **Drugs Aging** 1996 Mar; 8(3):193-213 (202 ref.)

[Treatment of metastatic cancer of the prostate] Fournier G, et al. **Presse Med** 1995 Oct 28;24(32):1465-70 (10 ref.) (Eng. Abstr.) **(Fre)**

ESTROUS CYCLE see **ESTRUS**

ESTRUS

PHYSIOLOGY

Synchronization of ovarian follicular waves with a gonadotropin-releasing hormone agonist to increase the precision of estrus in cattle: a review. Twagiramungu H, et al. **J Anim Sci** 1995 Oct;73(10):3141-51 (87 ref.)

Ultrastructure and histochemistry of acid mucus glycoproteins in the estrous mammal oviduct. Jansen RP. **Microsc Res Tech** 1995 Sep 1;32(1):24-49 (80 ref.)

ESWL (EXTRACORPOREAL SHOCKWAVE LITHOTRIPSY) see **LITHOTRIPSY**

ETCHING, DENTAL see **ACID ETCHING, DENTAL**

ETHAMBUTOL

PHARMACOLOGY

Glycosyltransferases as targets for inhibition of cell wall synthesis in M. tuberculosis and M. avium. Maddry JA, et al. **Res Microbiol** 1996 Jan-Feb;147(1-2):106-12 (25 ref.)

ETHANEHYDROXYDIPHOSPHONATE see **ETIDRONATE DISODIUM**

ETHANOL see **ALCOHOL, ETHYL**

ETHANOLAMINE PHOSPHOGLYCERIDES see **PHOSPHATIDYLETHANOLAMINES**

ETHANOLAMINES

METABOLISM

The N-acylation-phosphodiesterase pathway and cell signalling. Schmid HH, et al. **Chem Phys Lipids** 1996 May 24;80(1-2):133-42 (64 ref.)

PHARMACOLOGY

Pharmacological basis for duration of effect: formoterol and salmeterol versus short-acting beta 2-adrenoceptor agonists. Lindén A, et al. **Lung** 1996;174(1):1-22 (52 ref.)

ETHERS

Which inhalation anaesthetic agent is best for pediatric use? Lindahl SG. **Acta Anaesthesiol Belg** 1996;47(1):23-7 (14 ref.)

Adult clinical experience with sevoflurane and pharmaco-economic aspects. Young CJ, et al. **Acta Anaesthesiol Belg** 1996;47(1):29-42 (180 ref.)

Sevoflurane in pediatric anesthesia. Lerman J. **Anesth Analg** 1995 Dec;81(6 Suppl):S4-10 (47 ref.)

Sevoflurane--a long-awaited volatile anaesthetic. Smith I, et al. **Br J Anaesth** 1996 Mar;76(3):435-45 (92 ref.)

Sevoflurane. A review of its pharmacodynamic and pharmacokinetic properties and its clinical use in general anaesthesia. Patel SS, et al. **Drugs** 1996 Apr;51(4):658-700 (471 ref.)

Inhalational anesthetics: desflurane and sevoflurane. Young CJ, et al. **J Clin Anesth** 1995 Nov;7(7):564-77 (198 ref.)

[Sevoflurane] Murat I, et al. **Ann Fr Anesth Reanim** 1995; 14(6):489-501 (149 ref.) (Eng. Abstr.) **(Fre)**

[Intraoperative awareness and auditory evoked potentials] Schwender D, et al. **Anaesthesist** 1996 Feb;45 Suppl 1:S46-51 (30 ref.) (Eng. Abstr.) **(Ger)**

ADMINISTRATION & DOSAGE

The role of sevoflurane in outpatient anesthesia. Smith I, et al. **Anesth Analg** 1995 Dec;81(6 Suppl):S67-72 (24 ref.)

METABOLISM

Polyethers. Birch AW, et al. **Biotechnology** 1995;28:443-76 (100 ref.)

PHARMACOKINETICS

Biotransformation of sevoflurane. Kharasch ED. **Anesth Analg** 1995 Dec;81(6 Suppl):S27-38 (68 ref.)

[Sevoflurane in pediatric anesthesia] Hobbhahn J, et al. **Anaesthesist** 1996 Feb;45 Suppl 1:S22-7 (35 ref.) (Eng. Abstr.) **(Ger)**

PHARMACOLOGY

Cardiovascular and autonomic effects of sevoflurane. Ebert TJ. **Acta Anaesthesiol Belg** 1996;47(1):15-21 (22 ref.)

Cardiovascular responses to sevoflurane: a review. Ebert TJ, et al. **Anesth Analg** 1995 Dec;81(6 Suppl):S11-22 (43 ref.)

The hepatic effects of sevoflurane. Frink EJ Jr. **Anesth Analg** 1995 Dec;81(6 Suppl):S46–50 (29 ref.)
The ventilatory effects of sevoflurane. Green WB Jr. **Anesth Analg** 1995 Dec;81(6 Suppl):S23–6 (19 ref.)
Sevoflurane and renal function. Malan TP Jr. **Anesth Analg** 1995 Dec;81(6 Suppl):S39–45 (34 ref.)
[Effects of sevoflurane on the area of the liver and spleen] Schindler E, et al. **Anaesthesist** 1996 Feb;45 Suppl 1:S29–31 (30 ref.) (Eng. Abstr.) **(Ger)**

TOXICITY

Methyl tertiary butyl ether (MTBE)--evaluation of MTBE carcinogenicity studies. Rudo KM. **Toxicol Ind Health** 1995 Mar–Apr;11(2):167–73 (14 ref.)
[Nephrotoxicity and fluoride from the viewpoint of the nephrologist] Bosch T. **Anaesthesist** 1996 Feb;45 Suppl 1:S41–5 (28 ref.) (Eng. Abstr.) **(Ger)**
[Fluoride-induced nephrotoxicity: factor fiction?] Nuscheler M, et al. **Anaesthesist** 1996 Feb;45 Suppl 1:S32–40 (54 ref.) (Eng. Abstr.) **(Ger)**

ETHERS, CYCLIC

TOXICITY

Protein serine/threonine phosphatases as binding proteins for okadaic acid. Nagao M, et al. **Mutat Res** 1995 Dec; 333(1–2):173–9 (33 ref.)

ETHICS

see related
CONFIDENTIALITY
HUMAN RIGHTS

Benefits and burdens: legal and ethical issues raised by veterinary specialization. Tannenbaum J. **Adv Vet Sci Comp Med** 1995;39:253–96 (31 ref.)
Judging the other. Responding to traditional female genital surgeries. Lane SD, et al. **Hastings Cent Rep** 1996 May–Jun; 26(3):31–40 (61 ref.)
At the bedside. Influencing a patient's religious beliefs: mandate or no-man's land? Howe EG. **J Clin Ethics** 1995 Fall;6(3):194–201 (29 ref.)
[Alternative methods to animal experimentation. Scientific and ethical problems] Adolphe M. **Bull Acad Natl Med** 1995 Jun;179(6):1009–16; discussion 1116–9 (16 ref.) (Eng. Abstr.) **(Fre)**

ETHICS, DENTAL

Emergency cardiac care. Moral, legal, and ethical considerations. Peskin RM, et al. **Dent Clin North Am** 1995 Jul;39(3):677–88 (35 ref.)
The role of the AADR in promoting research integrity: perspectives and consensus statements. Bebeau MJ, et al. **J Dent Res** 1996 Feb;75(2):856–60 (9 ref.)

ETHICS, INSTITUTIONAL

Ethical and legal issues in nursing home care. Hayley DC, et al. **Arch Intern Med** 1996 Feb 12;156(3):249–56 (65 ref.)

ETHICS, MEDICAL

see related
HUMAN EXPERIMENTATION

Narrowing the gap between rhetoric and the reality of medical ethics. Silverman DR. **Acad Med** 1996 Mar; 71(3):227–37 (109 ref.)
Working with noncompliant and abusive dialysis patients: practical strategies based on ethics and the law. Johnson CC, et al. **Adv Ren Replace Ther** 1996 Jan;3(1):77–86 (40 ref.)
Care at the twilight: ethics and end-of-life care. Doukas DJ, et al. **Am Fam Physician** 1995 Oct;52(5):1294–6, 1299 (12 ref.)
Foregoing renal dialysis: a case study and review of ethical issues. The End-Stage Renal Disease Group. Tobe SW, et al. **Am J Kidney Dis** 1996 Jul;28(1):147–53 (33 ref.)
Legal & ethical safeguards: protection of society's most vulnerable participants in a commercialized organ transplantation system. Banks GJ. **Am J Law Med** 1995; 21(1):45–110 (505 ref.)
Ethically justified clinically comprehensive guidelines for the management of the depressed pregnant patient. Coverdale JH, et al. **Am J Obstet Gynecol** 1996 Jan;174(1 Pt 1):169–73 (25 ref.)
A consideration of ethical issues in the design of clinical trials. Weymuller EA Jr. **Am J Otolaryngol** 1996 Jan–Feb; 17(1):2–11 (26 ref.)
Ethical considerations of ensuring an informed and autonomous consent in research involving critically ill patients. Silverman HJ. **Am J Respir Crit Care Med** 1996 Sep;154(3 Pt 1):582–6 (34 ref.)
Withholding and withdrawing medical treatment: an emergency medicine perspective. Iserson KV. **Ann Emerg Med** 1996 Jul;28(1):51–4 (14 ref.)
Ethical issues of fertility and reproduction. Baird PA. **Annu Rev Med** 1996;47:107–16 (30 ref.)
The autopsy. Some ethical reflections on the obligations of pathologists, hospitals, families, and society. Pellegrino ED. **Arch Pathol Lab Med** 1996 Aug;120(8):739–42 (0 ref.)
Consent to neuroleptic medication for schizophrenia: clinical, ethical and legal issues. Brabbins C, et al. **Br J Psychiatry** 1996 May;168(5):540–4 (23 ref.)
Ethical issues in assisted reproductive medicine: a pragmatic approach. Appleton T. **Br J Urol** 1995 Nov;76 Suppl 2:85–92 (26 ref.)
Ethical issues in healthcare prioritization: a medical viewpoint. Asplund K. **Br J Urol** 1995 Nov;76 Suppl 2:49–54 (12 ref.)
Ethical issues in clinical trials. Claessens MT, et al. **Br J Urol** 1995 Nov;76 Suppl 2:29–36 (39 ref.)
Ethical issues in children with genital ambiguity. Grant DB. **Br J Urol** 1995 Nov;76 Suppl 2:75–8 (13 ref.)
Ethical issues in the developing world. Harrison NW, et al. **Br J Urol** 1995 Nov;76 Suppl 2:93–6 (13 ref.)
Ethical issues in healthcare prioritization: a political viewpoint. McColl. **Br J Urol** 1995 Nov;76 Suppl 2:55–7 (4 ref.)
Ethical issues in the economics of rationing healthcare. Maynard A. **Br J Urol** 1995 Nov;76 Suppl 2:59–64 (25 ref.)
Ethical issues in renal transplantation in developing countries. Naqvi SA, et al. **Br J Urol** 1995 Nov;76 Suppl 2:97–101 (16 ref.)
Ethical issues and molecular biology in urology. Neal DE. **Br J Urol** 1995 Nov;76 Suppl 2:65–70 (15 ref.)
Ethical and regulatory issues in gene therapy. Nicholson S, et al. **Br J Urol** 1995 Nov;76 Suppl 2:71–4 (16 ref.)
Ethical issues in cancer treatment. Penson RT, et al. **Br J Urol** 1995 Nov;76 Suppl 2:37–40 (18 ref.)
Ethical issues of diagnosis in utero. Perrotti M, et al. **Br J Urol** 1995 Nov;76 Suppl 2:79–83 (37 ref.)
Ethical issues in male sterilization in developing countries. Rizvi SA, et al. **Br J Urol** 1995 Nov;76 Suppl 2:103–5 (18 ref.)
Ethical issues in urology: the patient's perspective. Wilkie P. **Br J Urol** 1995 Nov;76 Suppl 2:5–7 (6 ref.)
The doctor's dilemma. Irvine DH, et al. **Br Med Bull** 1995 Oct;51(4):842–53 (28 ref.)
The ethics of rationing. Weale A. **Br Med Bull** 1995 Oct; 51(4):831–41 (23 ref.)
Ethical and policy issues in human embryo twinning. Bonnicksen AL. **Camb Q Healthc Ethics** 1995 Summer; 4(3):268–84 (94 ref.)
How important is consent for controlled clinical trials? MacKinnon B. **Camb Q Healthc Ethics** 1996 Spring; 5(2):221–7 (6 ref.)
Germ-line therapy to cure mitochondrial disease: protocol and ethics of in vitro ovum nuclear transplantation. Rubenstein DS, et al. **Camb Q Healthc Ethics** 1995 Summer; 4(3):316–39 (101 ref.)
Measurement of moral development in medicine. Self DJ, et al. **Camb Q Healthc Ethics** 1996 Spring;5(2):269–77 (70 ref.)
Intimacy in the patient-physician relationship. Committee on Ethics of the College of Family Physicians of Canada. Yeo M, et al. **Can Fam Physician** 1996 Aug;42:1505–8 (4 ref.)
Bioethics for clinicians: 1. Consent [see comments] Etchells E, et al. **Can Med Assoc J** 1996 Jul 15;155(2):177–80 (31 ref.) Comment in: Can Med Assoc J 1996 Jul 15;155(2):189–90.
Prevention. How much harm? How much benefit? 4. The ethics of informed consent for preventive screening programs. Marshall KG. **Can Med Assoc J** 1996 Aug 15; 155(4):377–83 (57 ref.)
A closer look at reproductive technology and postmenopausal motherhood [comment] Parks JA. **Can Med Assoc J** 1996 Apr 15;154(8):1189–91 (10 ref.) Comment on: Can Med Assoc J 1994 Aug 1;151(3):353, 355.
Ethical and policy issues in human fetal tissue transplants. Vawter DE, et al. **Cell Transplant** 1995 Sep–Oct; 4(5):479–82 (4 ref.)
Ethical issues in the case of surgical repair of cleft palate. Berkowitz S. **Cleft Palate Craniofac J** 1995 Jul;32(4):271–6; discussion 277–81 (66 ref.)
Common ethical dilemmas encountered in the management of HIV-infected women and newborns. Chervenak FA, et al. **Clin Obstet Gynecol** 1996 Jun;39(2):411–9 (16 ref.)
Ethics, genomics, and information retrieval. Goodman KW. **Comput Biol Med** 1996 May;26(3):223–9 (23 ref.)
The third age, the Third World and the third millennium. Diczfalusy E. **Contraception** 1996 Jan;53(1):1–7 (23 ref.)
Futile care or caregiver frustration? A practical approach. Civetta JM. **Crit Care Med** 1996 Feb;24(2):346–51 (13 ref.)
Advances in molecular diagnosis. Korf BR. **Curr Opin Obstet Gynecol** 1996 Apr;8(2):130–4 (24 ref.)
When drug treatment in the elderly is not cost effective. An ethical dilemma in an environment of healthcare rationing. Chadwick R, et al. **Drugs Aging** 1995 Dec;7(6):416–9 (25 ref.)
Logic, hermeneutics, and informed consent. Little JM, et al. **Eur J Surg** 1996 Jan;162(1):3–10 (31 ref.)
Ethics and research. Carriero A, et al. **Eur Radiol** 1996; 6(2):S11–5 (21 ref.)
Ethical and legal issues in human embryo donation [see comments] Robertson JA. **Fertil Steril** 1995 Nov; 64(5):885–94 (25 ref.) Comment in: Fertil Steril 1996 Jun;65(6):1262–3.
Terminating life-sustaining treatment of the demented. Callahan D. **Hastings Cent Rep** 1995 Nov–Dec;25(6):25–31 (11 ref.)
The run on Ritalin. Attention deficit disorder and stimulant treatment in the 1990s. Diller LH. **Hastings Cent Rep** 1996 Mar–Apr;26(2):12–8 (45 ref.)
Dworkin on dementia. Elegant theory, questionable policy. Dresser R. **Hastings Cent Rep** 1995 Nov–Dec;25(6):32–8 (17 ref.)
The case of the switched embryos. Robertson JA. **Hastings Cent Rep** 1995 Nov–Dec;25(6):13–9 (24 ref.)
Managed care in mental health: the ethical issues. Boyle PJ, et al. **Health Aff (Millwood)** 1995 Fall;14(3):7–22; discussion 23–33 (40 ref.)
Social work and end-of-life decisions: self-determination and the common good. Wesley CA. **Health Soc Work** 1996 May;21(2):115–21 (52 ref.)
Acute renal failure and membranes. Some medical and ethical questions [editorial] Schaefer K, et al. **Int J Artif Organs** 1996 Mar;19(3):145–6 (4 ref.)
Medical ethics under managed care. Schwartz P. **Int J Fertil Menopausal Stud** 1996 Mar–Apr;41(2):124–8 (16 ref.)
Competing or complementary? Ethical considerations and the quality of randomized trials. Lumley J, et al. **Int J Technol Assess Health Care** 1996 Spring;12(2):247–63 (103 ref.)
Deception/trust. Sobel R. **Isr J Med Sci** 1996 Mar–Apr; 32(3–4):256–9 (15 ref.)
The 1994 Multi-Society Task Force consensus statement on the Persistent Vegetative State: a critical analysis. Howsepian AA. **Issues Law Med** 1996 Summer;12(1):3–29 (87 ref.)
Are intracardiac electrophysiological studies in healthy volunteers ethical? Time for multinational recommendations [editorial; comment] Funck-Brentano C. **J Cardiovasc Pharmacol** 1995 Oct;26(4):524–7 (18 ref.) Comment on: J Cardiovasc Pharmacol 1995 Oct;26(4):528–9. Comment on: J Cardiovasc Pharmacol 1995 Oct;26(4):530–40.
Ethical reasoning in clinical genetics: a survey of cases and methods. Callahan TC, et al. **J Clin Ethics** 1995 Fall; 6(3):248–53 (23 ref.)
Managed care: "new moves, moral uncertainty, and a radical attitude. Howe EG. **J Clin Ethics** 1995 Winter;6(4):290–305 (57 ref.)
Jewish medical ethics [see comments] Rosner F. **J Clin Ethics** 1995 Fall;6(3):202–17 (48 ref.) Comment in: J Clin Ethics 1995 Fall;6(3):218–21. Comment in: J Clin Ethics 1995 Fall;6(3):232–6.
Face to face, not eye to eye: further conversations on Jewish medical ethics. Zoloth-Dorfman L. **J Clin Ethics** 1995 Fall; 6(3):222–31 (34 ref.)
The patient as commodity: managed care and the question of ethics. Zoloth-Dorfman L, et al. **J Clin Ethics** 1995 Winter;6(4):339–57 (70 ref.)
Questing for grails: duplicity, betrayal and self-deception in postmodern medical research. Annas GJ. **J Contemp Health Law Policy** 1996 Spring;12(2):297–324 (101 ref.)
Chinese Confucian culture and the medical ethical tradition. Guo Z. **J Med Ethics** 1995 Aug;21(4):239–46 (13 ref.)
What is obstetric ethics? Chervenak FA, et al. **J Perinat Med** 1995;23(5):331–41 (52 ref.)
Informed consent for genetic research on stored tissue samples [see comments] Clayton EW, et al. **JAMA** 1995 Dec 13;274(22):1786–92 (31 ref.) Comment in: JAMA 1995 Dec 13;274(22):1806–7. Comment in: JAMA 1996 Apr 10;275(14):1085; discussion 1086. Comment in: JAMA 1996 Apr 10;275(14):1085–6.
Breaking bad news. A review of the literature. Ptacek JT, et al. **JAMA** 1996 Aug 14;276(6):496–502 (83 ref.)
The clinical and ethical implications of hepatitis C for organ transplantation in Australia. Kerridge IH, et al. **Med J Aust** 1996 Sep 2;165(5):282–5 (49 ref.)
The evolution of the intensivist: from health care provider to economic rationalist and ethicist [see comments] Scheinkestel CD. **Med J Aust** 1996 Mar 4;164(5):310–2 (14 ref.) Comment in: Med J Aust 1996 Jun 17;164(12):758–9.
Deception in medical and behavioral research: is it ever acceptable? Wendler D. **Milbank Q** 1996;74(1):87–114 (18 ref.)
Ethical and legal barriers to futility policies. King NM. **N C Med J** 1995 Sep;56(9):444–8 (35 ref.)
Ethical decision making in managing trauma. Ratzan SC. **Neurosurg Clin N Am** 1995 Oct;6(4):809–16 (12 ref.)
Ethical and legal issues in social network research: the real and the ideal. Woodhouse DE, et al. **NIDA Res Monogr** 1995;151:131–43 (11 ref.)
HIV infection. Clinical research. Considerations for prospective participants. Hutchins SA, et al. **Nurs Clin North Am** 1996 Mar;31(1):125–35 (17 ref.)
Ethics and the care of critically ill infants and children. American Academy of Pediatrics Committee on Bioethics. **Pediatrics** 1996 Jul;98(1):149–52 (58 ref.)
Discussing cardiopulmonary resuscitation with patients and relatives. Stewart K. **Postgrad Med J** 1995 Oct; 71(840):585–9 (30 ref.)
The procurement of vital organs: a synopsis of policy from various nations and the ethical implications of policy options. Chelminski PR. **Ren Fail** 1996 Mar;18(2):151–72 (178 ref.)
Ethical aspects of prevention. Tomatis L. **Scand J Work Environ Health** 1995 Aug;21(4):245–51 (44 ref.)
A personal view of some controversies in allocating treatment

to patients in clinical trials [see comments] Senn S. **Stat Med** 1995 Dec 30;14(24):2661–74 (41 ref.) Comment in: Stat Med 1996 Jan 15;15(1):113–6.
Medical ethics in relation to transfusion medicine. Young IF. **Transfus Med Rev** 1996 Jan;10(1):23–30 (43 ref.)
Ethical issues in living related donor liver transplantation. Strong RW, et al. **Transplant Proc** 1996 Aug;28(4):2366–9 (21 ref.)
Ethical concerns in the research and treatment of complex disease. Parker LS. **Trends Genet** 1995 Dec;11(12):520–3 (40 ref.)
Current ethical issues in organ transplantation. McGeown MG. **Ulster Med J** 1994 Apr;63(1):32–43 (21 ref.)
Regulating assisted reproductive technologies: an ethical framework. Steinbock B. **Womens Health Issues** 1996 May–Jun;6(3):167–74 (12 ref.)
[Epidemiology and prevention of cancer: reflections on the ethics of public health measures] Sasco AJ. **Bull Acad Natl Med** 1995 May;179(5):987–1004; discussion 1005–7 (23 ref.) (Eng. Abstr.) **(Fre)**
[Research in psychiatry and legislative restrictions] Bougerol T. **Encephale** 1996 May;22 Spec No 1:63–8 (5 ref.) (Eng. Abstr.) **(Fre)**
[Ambivalence to prolonging life from the medical ethics viewpoint] Fritsche P. **Anaesthesist** 1996 Jan;45(1):99–109 (48 ref.) **(Ger)**
[Help or hinderniss? The effect of legal norms on the physician–patient relationship] Ulsenheimer K. **Geburtshilfe Frauenheilkd** 1995 Sep;55(9):M110–9 (113 ref.) **(Ger)**
[Ethical evaluation of somatic gene therapy] Honnefelder L. **Internist (Berl)** 1996 Apr;37(4):382–6 (6 ref.) **(Ger)**
[Clinical phase I studies in oncology and hematology. Concepts, implementation and ethical considerations] Hanauske AR. **Med Klin** 1996 Apr 12;91 Suppl 3:68–70 (28 ref.) **(Ger)**
[Ethical decisions in medical treatment] Jorke D. **Med Klin** 1996 Apr 10;91(4):238–42 (45 ref.) **(Ger)**
[Recommendations for patient education in poor prognosis. Australian Consensus Document] Bornkessel B. **Med Monatsschr Pharm** 1996 May;19(5):143–5 (0 ref.) **(Ger)**
[What is our approach to patients in persistent vegetative state? (editorial)] Roth F. **Schweiz Med Wochenschr** 1996 Jul 9;126(27–28):1187–90 (20 ref.) **(Ger)**
[Assisted dying—death on demand: borderline between medicine and law] Oehmichen M. **Z Gerontol Geriatr** 1995 Jul–Aug;28(4):273–8 (21 ref.) (Eng. Abstr.) **(Ger)**
[Psychological aspects of neurotransplantation] Ellgring H. **Zentralbl Neurochir** 1995;56(4):168–72 (11 ref.) (Eng. Abstr.) **(Ger)**
[Open questions in neurotransplantation. Attempted at an unbiased ethical analysis] Reiter–Theil S. **Zentralbl Neurochir** 1995;56(4):173–9 (8 ref.) (Eng. Abstr.) **(Ger)**
[Why bioethics today?] Figueroa G. **Rev Med Chil** 1995 Jun; 123(6):777–84 (26 ref.) (Eng. Abstr.) **(Spa)**

EDUCATION

[Clinical ethics education in the United States of America] Asai A. **Nippon Naika Gakkai Zasshi** 1995 Aug 10; 84(8):1344–9 (11 ref.) **(Jpn)**

ETHICS, NURSING

Moral competency. Cassidy VR. **Annu Rev Nurs Res** 1996; 14:181–204 (94 ref.)
Advocacy and empowerment: dichotomous or synchronous concepts? Rafael AR. **ANS Adv Nurs Sci** 1995 Dec; 18(2):25–32 (56 ref.)
Medical futility and nursing. Taylor C. **Image J Nurs Sch** 1995 Winter;27(4):301–6 (37 ref.)
Is the professional code still the cornerstone of clinical nursing practice? Esterhuizen P. **J Adv Nurs** 1996 Jan; 23(1):25–31 (39 ref.)
Professional caring: the moral dimension. Fealy GM. **J Adv Nurs** 1995 Dec;22(6):1135–40 (18 ref.)
Control and restraint in contemporary psychiatric nursing: some ethical considerations. Hopton J. **J Adv Nurs** 1995 Jul;22(1):110–5 (48 ref.)
Role, role enactment and the health care practitioner. Scott PA. **J Adv Nurs** 1995 Aug;22(2):323–8 (15 ref.)

EDUCATION

Critical reflections about professional ethical stances: have we lost sight of the major objectives? McAlpine H. **J Nurs Educ** 1996 Mar;35(3):119–26 (110 ref.)

ETHICS, PROFESSIONAL

Psychosocial and ethical implications of defining genetic risk for cancers. Kash KM. **Ann N Y Acad Sci** 1995 Sep 30; 768:41–52 (26 ref.)
Ethical issues in the pharmaceutical industry. Wells FO. **Br J Urol** 1995 Nov;76 Suppl 2:41–7 (15 ref.)
Ethical, social and counselling issues in hereditary cancer susceptibility. Garber JE, et al. **Cancer Surv** 1995;25:381–97 (54 ref.)
Bad ethics, good ethics and the genetic engineering of animals in agriculture. Rollin BE. **J Anim Sci** 1996 Mar; 74(3):535–41 (10 ref.)
Drug companies and continuing medical education. Bickell NA. **J Gen Intern Med** 1995 Jul;10(7):392–4 (9 ref.)
1994 Le Tourneau Award. An insurer's right to settle versus its duty to defend nonmeritorious medical malpractice claims. Thomas SS. **J Leg Med** 1995 Dec;16(4):545–83 (204 ref.)
Pharmaceutical industry support for continuing medical education programs: a review of current ethical guidelines. Rosner F. **Mt Sinai J Med** 1995 Nov;62(6):427–30 (21 ref.)
Responsible dissemination of scholarly work in radiology. Dowd SB, et al. **Radiol Technol** 1996 May–Jun;67(5):407–14 (22 ref.)

EDUCATION

On the need for ethics curricula in epidemiology. Coughlin SS, et al. **Epidemiology** 1995 Sep;6(5):566–7 (31 ref.)
Design elements of professional ethics courses. Spafford MM, et al. **Optom Vis Sci** 1995 Oct;72(10):741–52 (59 ref.)

ETHINYL ESTRADIOL

ADMINISTRATION & DOSAGE

The effectiveness of the Yuzpe regimen of emergency contraception. Trussell J, et al. **Fam Plann Perspect** 1996 Mar–Apr;28(2):58–64, 87 (30 ref.)

ADVERSE EFFECTS

Lactotroph hyperplasia in an estrogen treated male-to-female transsexual patient. Serri O, et al. **J Clin Endocrinol Metab** 1996 Sep;81(9):3177–9 (12 ref.)

BLOOD

[Synthetic steroids] Miyazaki S. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:1036–9 (19 ref.) **(Jpn)**

ETHINYL TRICHLORIDE see **TRICHLOROETHYLENE**

ETHINYLNORTESTOSTERONE see **NORETHINDRONE**

ETHIOFOS see **AMIFOSTINE**

ETHMOID BONE

SURGERY

[Endonasal ethmoidectomy in naso–sinusal polyposis. Results in 110 surgically treated patients] Simon D, et al. **Ann Otolaryngol Chir Cervicofac** 1995;112(8):359–66 (35 ref.) (Eng. Abstr.) **(Fre)**
[Decompressive neurovascular nose and skull–base surgery in primary headache with a rhinogenic trigger] Bonaccorsi P. **Ital J Neurol Sci** 1995 Nov;16(8 Suppl):69–100 (104 ref.) (Eng. Abstr.) **(Ita)**

ETHMOID SINUS

Breast carcinoma metastatic to paranasal sinuses. Austin JR, et al. **Head Neck** 1995 Mar–Apr;17(2):161–5 (20 ref.)
Neuralgia–like symptoms in a patient with an airgun pellet in the ethmoid sinus: a case report. Donald PJ, et al. **J Laryngol Otol** 1995 Jul;109(7):646–9 (19 ref.)
Blindness due to electrocoagulation following functional endoscopic sinus surgery. Vanden Abeele D, et al. **J Laryngol Otol** 1996 Mar;110(3):261–4 (26 ref.)
Magnetic resonance imaging of massive intracranial invasion by an ethmoidal adenoid cystic carcinoma (cylindroma). Veillon BJ, et al. **South Med J** 1996 Mar;89(3):321–3 (10 ref.)

PATHOLOGY

Ethmoidal myofibroblastoma. Samuel D, et al. **J Otolaryngol** 1995 Oct;24(5):313–6 (18 ref.)

SURGERY

Tension pneumocephalus following craniofacial resection. Wanamaker JR, et al. **Head Neck** 1995 Mar–Apr; 17(2):152–6 (22 ref.)

ETHNIC GROUPS

Meeting the needs of minority ethnic communities. Webb E. **Arch Dis Child** 1996 Mar;74(3):264–7 (49 ref.)
Cervical cancer screening: meeting the needs of minority ethnic women. Luke K. **Br J Cancer** 1996 Sep;74 Suppl 29:S47–50 (11 ref.)
Epidemiology of cancer in ethnic groups. Muir CS. **Br J Cancer** 1996 Sep;74 Suppl 29:S12–6 (32 ref.)
Ethnicity and health beliefs with respect to cancer: a critical review of methodology. Pfeffer N, et al. **Br J Cancer** 1996 Sep;74 Suppl 29:S66–72 (112 ref.)
Assessing the health needs for cancer services for people from ethnic groups. Rawaf S. **Br J Cancer** 1996 Sep;74 Suppl 29:S35–7 (28 ref.)
Smoking cessation programmes targeted at black and minority ethnic communities. Farren C, et al. **Br J Cancer Suppl** 1996 Sep;29:S78–80 (17 ref.)
Epidemiology of cancer in ethnic groups. Muir CS. **Br J Cancer Suppl** 1996 Sep;29:S12–6 (32 ref.)
Ethnicity and health beliefs with respect to cancer: a critical review of methodology. Pfeffer N, et al. **Br J Cancer Suppl** 1996 Sep;29:S66–72 (112 ref.)
HIV/AIDS in the context of culture: selection of ethnocultural communities for study in Canada. Cappon P, et al. **Can J Public Health** 1996 May–Jun;87 Suppl 1:S11–4, S11–5 (50 ref.) **(Eng, Fre)**
Phenytoin disposition and toxicity: role of pharmacogenetic and interethnic factors. Edeki TI, et al. **Drug Metab Rev** 1995;27(3):449–69 (89 ref.)
Racial, ethnic and gender differences in response to medicines. Matthews HW. **Drug Metabol Drug Interact** 1995;12(2):77–91 (38 ref.)
Epidemiology of minority health. Flack JM, et al. **Health Psychol** 1995 Dec;14(7):592–600 (50 ref.)
Behavioral risk factors related to chronic diseases in ethnic minorities. Myers HF, et al. **Health Psychol** 1995 Dec; 14(7):613–21 (65 ref.)
Ethnic minorities, health care systems, and behavior. Penn NE, et al. **Health Psychol** 1995 Dec;14(7):641–6 (40 ref.)
Risk–taking and abusive behaviors among ethnic minorities. Yee BW, et al. **Health Psychol** 1995 Dec;14(7):622–31 (100 ref.)
Challenging old notions of professionalism: how can nurses work with paraprofessional ethnic health workers? Fuller J. **J Adv Nurs** 1995 Sep;22(3):465–72 (44 ref.)

PSYCHOLOGY

Cultural challenges to the psychiatric enterprise. Fabrega H Jr. **Compr Psychiatry** 1995 Sep–Oct;36(5):377–83 (48 ref.)
Eating disturbances among American minority groups: a review. Crago M, et al. **Int J Eat Disord** 1996 Apr; 19(3):239–48 (59 ref.)
Ethnicity and psychotherapy. A component in the treatment of cocaine addiction in African Americans. Foulks EF, et al. **Psychiatr Clin North Am** 1995 Sep;18(3):607–20 (59 ref.)
Ethnicity and psychopharmacology. Bridging the gap. Lin KM, et al. **Psychiatr Clin North Am** 1995 Sep;18(3):635–47 (56 ref.)

STATISTICS & NUMERICAL DATA

Cancer and ethnic minorities—the Department of Health's perspective. Bahl V. **Br J Cancer** 1996 Sep;74 Suppl 29:S2–10 (28 ref.)
Cancer in minority ethnic populations: priorities from epidemiological data. Bhopal RS, et al. **Br J Cancer** 1996 Sep;74 Suppl 29:S22–32 (15 ref.)
Cancer in minority ethnic populations: priorities from epidemiological data. Bhopal RS, et al. **Br J Cancer Suppl** 1996 Sep;29:S22–32 (15 ref.)

ETHNOGRAPHY see **ANTHROPOLOGY, CULTURAL**

ETHNOLOGY

METHODS

Ethnicity and health beliefs with respect to cancer: a critical review of methodology. Pfeffer N, et al. **Br J Cancer** 1996 Sep;74 Suppl 29:S66–72 (112 ref.)
Ethnicity and health beliefs with respect to cancer: a critical review of methodology. Pfeffer N, et al. **Br J Cancer Suppl** 1996 Sep;29:S66–72 (112 ref.)

ETHNOMEDICINE see **MEDICINE, TRADITIONAL**

ETHNOPSYCHOLOGY

[The mental health of ethnic minorities in the United Kingdom] Picarda V, et al. **Cah Sociol Demogr Med** 1995 Jan–Mar;35(1):5–19 (59 ref.) (Eng. Abstr.) **(Fre)**

ETHOLOGY

see related
BEHAVIOR, ANIMAL

The neuroethological development of food–storing memory: a case of use it, or lose it! Clayton NS. **Behav Brain Res** 1995 Sep;70(1):95–102 (54 ref.)
[Some theoretical aspects of behavior research in domestic animals] Puppe B. **Berl Munch Tierarztl Wochenschr** 1995 Apr;108(4):133–7 (60 ref.) (Eng. Abstr.) **(Ger)**
[Developmental trends in farm animal husbandry from an ethological point of view] Graf B. **Schweiz Arch Tierheilkd** 1995;137(9):423–31 (12 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Homologizing primate facial displays: a critical review of methods. Preuschoft S, et al. **Folia Primatol (Basel)** 1995; 65(3):121–37 (71 ref.)

ETHOSUCCIMID see **ETHOSUXIMIDE**

ETHOSUXIMIDE

BLOOD

[Ethosuximide] Ichiba M, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:915–7 (8 ref.) **(Jpn)**

ETHYL CARBAMATE see **URETHANE**

TOXICITY

Quantification of endogenous carcinogens. The ethylene oxide paradox. Bolt HM. **Biochem Pharmacol** 1996 Jul 12; 52(1):1–5 (51 ref.)

ETHYLENE POLYMERS see POLYETHYLENES

ETHYLENEBIS (DITHIOCARBAMATES)

ADVERSE EFFECTS

Ethylenebisdithiocarbamates and ethylenethiourea: possible human health hazards. Houeto P, et al. **Environ Health Perspect** 1995 Jun;103(6):568–73 (102 ref.)

ETHYLENEDIAMINETETRAACETIC ACID see EDETIC ACID

ETHYLENEIMINES see AZIRIDINES

ETHYLENES

see related
POLYETHYLENES

METABOLISM

Plant hormones: more than one way to detect ethylene. Theologis A. **Curr Biol** 1996 Feb 1;6(2):144–5 (14 ref.)
Ethylene sensors: how perceptive! [comment] Theologis A. **Science** 1995 Dec 15;270(5243):1774 (10 ref.) Comment on: Science 1995 Dec 15;270(5243):1804. Comment on: Science 1995 Dec 15;270(5243):1807–9. Comment on: Science 1995 Dec 15;270(5243):1809–11.
[Ethylene—its role in fruit ripening and senescence of blossoms. Biotechnologic aspects] Jakubowicz M. **Postepy Biochem** 1996;42(1):65–72 (70 ref.) **(Pol)**

PHARMACOLOGY

Genetic analysis of a seedling stress response to ethylene in Arabidopsis. Roman G, et al. **Philos Trans R Soc Lond B Biol Sci** 1995 Oct 30; 350(1331):75–81 (48 ref.)
The ethylene signal transduction pathway in Arabidopsis: an emerging paradigm? Chang C. **Trends Biochem Sci** 1996 Apr;21(4):129–33 (35 ref.)

ETHYLENETHIOUREA

ADVERSE EFFECTS

Ethylenebisdithiocarbamates and ethylenethiourea: possible human health hazards. Houeto P, et al. **Environ Health Perspect** 1995 Jun;103(6):568–73 (102 ref.)

TOXICITY

International safety assessment of pesticides: dithiocarbamate pesticides, ETU, and PTU—a review and update. Vettorazzi G, et al. **Teratog Carcinog Mutagen** 1995–96; 15(6):313–37 (88 ref.)

ETHYNYL ESTRADIOL see ETHINYL ESTRADIOL

ETIDRONATE see ETIDRONATE DISODIUM

ETIDRONATE DISODIUM

THERAPEUTIC USE

Critical drug appraisal: etidronate intermittent cyclic therapy for postmenopausal osteoporosis. Miller PD. **Br J Clin Pract** 1996 Jan–Feb;50(1):23–31 (71 ref.)

ETIDRONIC ACID see ETIDRONATE DISODIUM

ETOPOSIDE

ADMINISTRATION & DOSAGE

Review of current clinical experience with prolonged (oral) etoposide in cancer treatment. de Jong RS, et al. **Anticancer Res** 1995 Sep–Oct;15(5B):2319–30 (120 ref.)
[Etoposide: specificity of prolonged oral administration] Munck JN. **Bull Cancer (Paris)** 1996 May;83(5):352–60 (66 ref.) (Eng. Abstr.) **(Fre)**
[An elderly case of squamous cell lung cancer showing partial response by daily administration of oral etoposide] Fukabori T, et al. **Gan To Kagaku Ryoho** 1996 Aug; 23(9):1187–90 (12 ref.) (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Hypersensitivity reactions to etoposide. Hoetelmans RM, et al. **Ann Pharmacother** 1996 Apr;30(4):367–71 (25 ref.)
Therapy-related acute leukemia associated with t(11q23) after primary acute myeloid leukemia with t(8;21): a report of two cases [letter] Roulston D, et al. **Blood** 1995 Nov 1;86(9):3613–4 (7 ref.)

THERAPEUTIC USE

Phase II study of oral etoposide for patients with advanced breast cancer. Atienza DM, et al. **Cancer** 1995 Dec 15; 76(12):2485–90 (39 ref.)

ETORPHINE

PHARMACOLOGY

Etorphine elicits unique inhibitory–agonist and excitatory–antagonist actions at opioid receptors on sensory neurons: new rationale for improved clinical analgesia and treatment of opiate addiction. Crain SM, et al. **NIDA Res Monogr** 1995;147:234–68 (67 ref.)

ETRETIN see ACITRETIN

ETRETINATE

ADVERSE EFFECTS

Prolonged treatment with oral retinoids in adults: no influence on the frequency and severity of spinal abnormalities. Van Dooren-Greebe RJ, et al. **Br J Dermatol** 1996 Jan;134(1):71–6 (30 ref.)
Oral retinoids and pregnancy. Chan A, et al. **Med J Aust** 1996 Aug 5;165(3):164–7 (20 ref.)

PHARMACOKINETICS

[Trans–acitretin is metabolized back to etretinate. Importance for oral retinoid therapy] Almond-Roesler B, et al. **Hautarzt** 1996 Mar;47(3):173–7 (29 ref.) (Eng. Abstr.) **(Ger)**

EUCOCCIDIIDA

ISOLATION & PURIFICATION

A 'new' parasite: human infection with Cyclospora cayetanensis. Chiodini PL. **Trans R Soc Trop Med Hyg** 1994 Jul–Aug;88(4):369–71 (18 ref.)

PATHOGENICITY

Cyclospora in patients with traveller's diarrhea. Gascon J, et al. **Scand J Infect Dis** 1995;27(5):511–4 (18 ref.)

EUGENIC ABORTION see ABORTION, EUGENIC

EUGENICS

see related
GENETIC COUNSELING

EUGLYCEMIC CLAMPING see GLUCOSE CLAMP TECHNIQUE

EUKARYOTIC CELLS

The end in sight: terminating translation in eukaryotes. Stansfield I, et al. **Trends Biochem Sci** 1995 Dec; 20(12):489–91 (17 ref.)

CYTOLOGY

Mutations in fibroblast growth factor receptors: phenotypic consequences during eukaryotic development [editorial] Park WJ, et al. **Am J Hum Genet** 1995 Oct;57(4):748–54 (45 ref.)
[Evolution of cells] Maier UG, et al. **Naturwissenschaften** 1996 Mar;83(3):103–12 (54 ref.) (Eng. Abstr.) **(Ger)**

ENZYMOLOGY

NADPH–P-450 reductase: structural and functional comparisons of the eukaryotic and prokaryotic isoforms. Sevrioukova IF, et al. **Biochimie** 1995;77(7–8):562–72 (59 ref.)

METABOLISM

Analysis and modeling of substrate uptake and product release by prokaryotic and eukaryotic cells. Krämer R. **Adv Biochem Eng Biotechnol** 1996;54:31–74 (147 ref.)
Eukaryotic phospholipid biosynthesis. Kent C. **Annu Rev Biochem** 1995;64:315–43 (221 ref.)
Common themes in assembly and function of eukaryotic transcription complexes. Zawel L, et al. **Annu Rev Biochem** 1995;64:533–61 (230 ref.)
Protein synthesis in eukaryotic organisms: new insights into the function of translation initiation factor eIF–3. Hannig EM. **Bioessays** 1995 Nov;17(11):915–9 (49 ref.)
Eukaryotic polypeptide elongation system and its sensitivity to the inhibitory substances of plant origin. Gałasiński W. **Proc Soc Exp Biol Med** 1996 May;212(1):24–37 (189 ref.)
[Translation termination in eukaryotes] Kiselev LL, et al. **Mol Biol (Mosk)** 1995 Nov–Dec;29(6):1286–93 (39 ref.) **(Rus)**

PHYSIOLOGY

Ras target proteins in eukaryotic cells. Marshall MS. **FASEB J** 1995 Oct;9(13):1311–8 (78 ref.)
Biochemistry and genetics of eukaryotic mismatch repair. Kolodner R. **Genes Dev** 1996 Jun 15;10(12):1433–42 (85 ref.)

ULTRASTRUCTURE

Structural and functional hierarchy of eukaryotic cilia and flagella. Omoto CK. **Eur J Histochem** 1995;39(2):85–90 (53 ref.)
[Mycoplasma infections as a possible factor in genetic changes in the cells of higher eukaryotes] Chernov VM, et al. **Tsitologiia** 1996;38(2):107–14 (59 ref.) (Eng. Abstr.) **(Rus)**

EUPHAUSIA see CRUSTACEA

EUROPEAN COMMON MARKET see EUROPEAN ECONOMIC COMMUNITY

EUROPEAN COMMUNITY see EUROPEAN ECONOMIC COMMUNITY

EUROPEAN ECONOMIC COMMUNITY

Obtaining marketing authorization for nucleic acid vaccines in the European Union. Cichutek K. **Ann N Y Acad Sci** 1995 Nov 27;772:178–85 (15 ref.)
A European project assessing the appropriateness of hospital utilization: background, objectives and preliminary results. The Project Steering Group and the Coordinating Center. Liberati A, et al. **Int J Qual Health Care** 1995 Sep; 7(3):187–99 (111 ref.)
Regulation of Agrobacterium gene manipulation. Dewhurst F. **Methods Mol Biol** 1995;44:369–91 (33 ref.)

EUROPEAN VIPER see VIPERIDAE

EUSTACHIAN TUBE

PHYSIOLOGY

[Importance of the eustachian tube in middle ear function] Sente M. **Med Pregl** 1995;48(11–12):405–6 (6 ref.) (Eng. Abstr.) **(Scr)**

PHYSIOPATHOLOGY

Role of allergy in eustachian tube blockage and otitis media with effusion: a review. Bernstein JM. **Otolaryngol Head Neck Surg** 1996 Apr;114(4):562–8 (28 ref.)

EUTELEGENESIS see INSEMINATION, ARTIFICIAL

EUTHANASIA

Euthanasia and the good life. Lemmens T. **Perspect Biol Med** 1995 Autumn;39(1):15–27 (25 ref.)
[When a patient wants to die (editorial)] Linkola A. **Duodecim** 1995;111(7):589–91 (14 ref.) **(Fin)**
[Euthanasia: compulsory reflection] Kraus A. **Rev Invest Clin** 1995 May–Jun;47(3):217–29 (40 ref.) (Eng. Abstr.) **(Spa)**

LEGISLATION & JURISPRUDENCE

The euthanasia debate: attitudes, practices and psychiatric considerations. Chochinov HM, et al. **Can J Psychiatry** 1995 Dec;40(10):593–602 (69 ref.)
The Good Samaritan and the "Good Death": Catholic reflections on euthanasia. Doerflinger RM. **Issues Law Med** 1995 Fall;11(2):149–58 (31 ref.)
The 1994 Multi–Society Task Force consensus statement on the Persistent Vegetative State: a critical analysis. Howsepian AA. **Issues Law Med** 1996 Summer;12(1):3–29 (87 ref.)
Physician–assisted suicide and euthanasia in the United States. Legal and ethical observations. Stone TH, et al. **J Leg Med** 1995 Dec;16(4):481–507 (194 ref.)

PSYCHOLOGY

Patient requests for euthanasia and assisted suicide in terminal illness. The role of the psychiatrist. Block SD, et al. **Psychosomatics** 1995 Sep–Oct;36(5):445–57 (75 ref.)

EUTHANASIA, PASSIVE

see related
RESUSCITATION ORDERS

Withholding and withdrawing medical treatment: an emergency medicine perspective. Iserson KV. **Ann Emerg Med** 1996 Jul;28(1):51–4 (14 ref.)
[When a patient wants to die (editorial)] Linkola A. **Duodecim** 1995;111(7):589–91 (14 ref.) **(Fin)**

EUTHYROID SICK SYNDROMES

see related
THYROID HORMONE RESISTANCE SYNDROME

GENETICS

Diagnosis of thyroid hormone transport protein anomalies: an overview. Langsteger W. **Acta Med Austriaca** 1996; 23(1–2):31–40 (140 ref.)

EVALUATION, PROGRAM

EVALUATION, PROGRAM see **PROGRAM EVALUATION**

EVALUATION RESEARCH, NURSING see **NURSING EVALUATION RESEARCH**

EVALUATION STUDIES

see related
PROGRAM EVALUATION

EVALUATION STUDIES, DRUG see **DRUG EVALUATION**

EVALUATION STUDIES, DRUG, PRE-CLINICAL see **DRUG SCREENING**

EVALUATION STUDIES, FDA PHASE I see **CLINICAL TRIALS, PHASE I**

EVALUATION STUDIES, FDA PHASE II see **CLINICAL TRIALS, PHASE II**

EVALUATION STUDIES, FDA PHASE III see **CLINICAL TRIALS, PHASE III**

EVALUATION STUDIES, POSTMARKETING see **PRODUCT SURVEILLANCE, POSTMARKETING**

EVENT-RELATED POTENTIALS see **EVOKED POTENTIALS**

EVENT-RELATED POTENTIALS, P300

The P300 and vascular dementia: not quite ready for prime time [editorial; comment] Bergethon PR, et al. **J Am Geriatr Soc** 1995 Nov;43(11):1311-3 (14 ref.) Comment on: J Am Geriatr Soc 1995 Nov;43(11):1228-36.

EVOKED POTENTIALS

Use of evoked potentials in preterm neonates. Taylor MJ, et al. **Arch Dis Child Fetal Neonatal Ed** 1996 Jan; 74(1):F70-6 (74 ref.)

Selected quantitative EEG (QEEG) and event-related potential (ERP) variables as discriminators for positive and negative schizophrenia. Gerez M, et al. **Biol Psychiatry** 1995 Jul 1;38(1):34-49 (152 ref.)

Some considerations on estimating event-related brain signals. Krieger S, et al. **J Neural Transm Gen Sect** 1995; 99(1-3):103-29 (72 ref.)

Electrophysiologic monitoring in head injury. Sloan TB. **New Horiz** 1995 Aug;3(3):431-8 (69 ref.)

[Development of late potentials in ventricular activation in myocardial infarction (1)] Gobin E, et al. **Rev Med Liege** 1996 Mar;51(3):230-40 (64 ref.) **(Fre)**

PHYSIOLOGY

Variable-frequency stimulation patterns for the optimization of force during muscle fatigue. Muscle wisdom and the catch-like property. Binder-Macleod SA. **Adv Exp Med Biol** 1995;384:227-40 (67 ref.)

Transcranial magnetic stimulation. Negative effects. Hallett M. **Adv Neurol** 1995;67:107-13 (40 ref.)

No-go potential in the prefrontal cortex and electrical stimulation of its loci in monkeys. Sasaki K. **Adv Neurol** 1995;67:131-41 (20 ref.)

Neurometrics, dynamic brain imaging and attention deficit hyperactivity disorder. Levy F, et al. **J Paediatr Child Health** 1995 Aug;31(4):279-83 (49 ref.)

Words and sentences: event-related brain potential measures. van Petten C. **Psychophysiology** 1995 Nov;32(6):511-25 (141 ref.)

[Evoked potentials: their spatial physiological characteristics and the problem of their functional assessment] Khasabov GA. **Usp Fiziol Nauk** 1996 Jan-Mar;27(1):61-86 (216 ref.) (Eng. Abstr.) **(Rus)**

[Methods for analyzing brain evoked potentials clinically and in psychophysiology] Lytaev SA, et al. **Usp Fiziol Nauk** 1995 Jul-Sep;26(3):95-110 (106 ref.) (Eng. Abstr.) **(Rus)**

EVOKED POTENTIALS, AUDITORY

DRUG EFFECTS

[Intraoperative awareness and auditory evoked potentials] Schwender D, et al. **Anaesthesist** 1996 Feb;45 Suppl 1:S46-51 (30 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Generators of electrical and magnetic mismatch responses in humans. Näätänen R, et al. **Brain Topogr** 1995 Summer; 7(4):315-20 (63 ref.)

Gating and habituation deficits in the schizophrenia disorders. Braff DL, et al. **Clin Neurosci** 1995;3(2):131-9 (48 ref.)

The pedunculopontine nucleus--auditory input, arousal and pathophysiology. Reese NB, et al. **Prog Neurobiol** 1995 Oct;47(2):105-33 (365 ref.)

The temporal relationship between the brainstem and primary cortical auditory evoked potentials. Shaw NA. **Prog Neurobiol** 1995 Oct;47(2):95-103 (66 ref.)

EVOKED POTENTIALS, AUDITORY, BRAIN STEM

Bilateral evoked otoacoustic emissions in a child with bilateral profound hearing loss. Laccourreye L, et al. **Ann Otol Rhinol Laryngol** 1996 Apr;105(4):286-8 (15 ref.)

[Establishment of the criteria to evaluate intraoperative changes of brainstem auditory evoked potentials during microvascular decompression and acoustic neurinoma excision] Sekiya T, et al. **No Shinkei Geka** 1996 May; 24(5):431-6 (55 ref.) (Eng. Abstr.) **(Jpn)**

EVOKED POTENTIALS, P300 COMPONENT see **EVENT-RELATED POTENTIALS, P300**

EVOKED POTENTIALS, SOMATOSENSORY

Localization of functional regions of human mesial cortex by somatosensory evoked potential recording and by cortical stimulation. Allison T, et al. **Electroencephalogr Clin Neurophysiol** 1996 Mar; 100(2):126-40 (62 ref.)

[Electrical tooth stimulation and somatosensory evoked potential] Umino M. **Kokubyo Gakkai Zasshi** 1996 Jun; 63(2):287-95 (36 ref.) **(Jpn)**

[Methods of studying somatosensory evoked responses and long-latency reflexes] Jovičić A, et al. **Vojnosanit Pregl** 1994 Nov-Dec;51(6):527-33 (38 ref.) **(Scr)**

PHYSIOLOGY

Generation of movement-related potentials and fields in the supplementary sensorimotor area and the primary motor area. Deecke L, et al. **Adv Neurol** 1996;70:127-46 (50 ref.)

Generation of movement-related potentials in the supplementary sensorimotor area. Hallett M, et al. **Adv Neurol** 1996;70:147-52 (20 ref.)

Generation of movement-related potentials in the supplementary sensorimotor area. Shibasaki H, et al. **Adv Neurol** 1996;70:117-25 (45 ref.)

Comparative assessment of sensorimotor function using functional magnetic resonance imaging and electrophysiological methods. Puce A. **J Clin Neurophysiol** 1995 Sep;12(5):450-9 (55 ref.)

Somatosensory evoked potentials in acute neurological decompression illness. Murrison A, et al. **J Neurol** 1995 Oct;242(10):669-76 (22 ref.)

EVOKED POTENTIALS, VISUAL

Intra-operative monitoring is not essential. Malis LI. **Clin Neurosurg** 1995;42:203-13 (8 ref.)

[Origin of the visual evoked potentials in the light of the conducted research] Sobieszczańska-Lampika M, et al. **Neurol Neurochir Pol** 1995 May-Jun;29(3):419-25 (17 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOLOGY

[Influence of pattern stimulus modality on visual evoked potentials] Sobieszczańska M, et al. **Klin Oczna** 1995 Nov-Dec;97(11-12):353-5 (17 ref.) (Eng. Abstr.) **(Pol)**

EVOKED RESPONSES, AUDITORY, BRAIN STEM see **EVOKED POTENTIALS, AUDITORY, BRAIN STEM**

EVOLUTION

Evolutionary aspects, and taxonomic definition of viruses together with mobile extrachromosomal elements of relative autonomy into a special highest rank taxon (a review). Berencsi G, et al. **Acta Microbiol Immunol Hung** 1995;42(2):141-53 (154 ref.)

Evolutionary ancient roles of serotonin: long-lasting regulation of activity and development. Turlejski K. **Acta Neurobiol Exp (Warsz)** 1996;56(2):619-36 (138 ref.)

Evolutionary and comparative neurobiology of the supplementary sensorimotor area. Wise SP. **Adv Neurol** 1996;70:71-83 (133 ref.)

Evolution in tooth developmental biology: of morphology and molecules. Slavkin HC, et al. **Anat Rec** 1996 Jun; 245(2):131-50 (166 ref.)

Evolution of ticks. Klompen JS, et al. **Annu Rev Entomol** 1996;41:141-61 (62 ref.)

Genetics, physiology, and evolutionary relationships of the genus Buchnera: intracellular symbionts of aphids. Baumann P, et al. **Annu Rev Microbiol** 1995;49:55-94 (179 ref.)

Mechanism and evolution of RNA editing in kinetoplastida. Arts GJ, et al. **Biochim Biophys Acta** 1996 Jun 3; 1307(1):39-54 (150 ref.)

Recombination, mutation and the origin of species. Cox EC. **Bioessays** 1995 Sep;17(9):747-9 (23 ref.)

Simple sequences and the expanding genome. Hancock JM. **Bioessays** 1996 May;18(5):421-5 (50 ref.)

Sexually transmitted diseases in animals: ecological and evolutionary implications. Lockhart AB, et al. **Biol Rev Camb Philos Soc** 1996 Aug;71(3):415-71 (302 ref.)

The evolution of soldiers in aphids. Stern DL, et al. **Biol Rev Camb Philos Soc** 1996 Feb;71(1):27-79 (166 ref.)

A Darwinian approach to the origins of psychosis [published erratum appears in Br J Psychiatry 1995 Sep;167(3):414] Crow TJ. **Br J Psychiatry** 1995 Jul;167(1):12-25 (77 ref.)

The dorsal thalamus of jawed vertebrates: a comparative viewpoint. Butler AB. **Brain Behav Evol** 1995; 46(4-5):209-23 (115 ref.)

The evolution of isocortex. Kaas JH. **Brain Behav Evol** 1995; 46(4-5):187-96 (52 ref.)

Neurotransmitter organization and connectivity of the basal ganglia in vertebrates: implications for the evolution of basal ganglia. Medina L, et al. **Brain Behav Evol** 1995; 46(4-5):235-58 (214 ref.)

The forebrain of gnathostomes: in search of a morphotype. Northcutt RG. **Brain Behav Evol** 1995;46(4-5):275-318 (256 ref.)

The thalamus of reptiles and mammals: similarities and differences. Pritz MB. **Brain Behav Evol** 1995; 46(4-5):197-208 (54 ref.)

A segmental morphological paradigm for understanding vertebrate forebrains. Puelles L. **Brain Behav Evol** 1995; 46(4-5):319-37 (145 ref.)

The origin and early evolution of life: prebiotic chemistry, the pre-RNA world, and time. Lazcano A, et al. **Cell** 1996 Jun 14;85(6):793-8 (53 ref.)

Human evolution. Y-chromosome clues to human ancestry. Brookfield JF. **Curr Biol** 1995 Oct 1;5(10):1114-5 (9 ref.)

The evolution of chromosomal sex determination and dosage compensation. Charlesworth B. **Curr Biol** 1996 Feb 1; 6(2):149-62 (113 ref.)

Speciation. Down the bottleneck? Charlesworth B. **Curr Biol** 1995 Sep 1;5(9):995-6 (10 ref.)

Hybrid speciation. Evolution under the microscope. Charlesworth D. **Curr Biol** 1995 Aug 1;5(8):835-6 (9 ref.)

Evolutionary genetics. The silence of the genes. Hurst LD. **Curr Biol** 1995 May 1;5(5):459-61 (13 ref.)

Inductive signals. Revolving vertebrates. Jones CM, et al. **Curr Biol** 1995 Jun 1;5(6):574-6 (16 ref.)

Evolutionary immunology. A boost to immunity from nurse sharks. Parham P. **Curr Biol** 1995 Jul 1;5(7):696-9 (16 ref.)

Evolution of ATP-binding cassette transporter genes. Dean M, et al. **Curr Opin Genet Dev** 1995 Dec;5(6):779-85 (42 ref.)

The natural history and evolution of human and simian T cell leukemia/lymphotropic viruses. Dekaban GA, et al. **Curr Opin Genet Dev** 1995 Dec;5(6):807-13 (42 ref.)

Comparative maps: the mammalian jigsaw puzzle. Eppig JT, et al. **Curr Opin Genet Dev** 1995 Dec;5(6):709-16 (52 ref.)

New perspectives on eye evolution. Halder G, et al. **Curr Opin Genet Dev** 1995 Oct;5(5):602-9 (68 ref.)

Evolution of the intron-exon structure of eukaryotic genes. Long M, et al. **Curr Opin Genet Dev** 1995 Dec;5(6):774-8 (58 ref.)

Cereal genome evolution: pastoral pursuits with 'Lego' genomes. Moore G. **Curr Opin Genet Dev** 1995 Dec; 5(6):717-24 (65 ref.)

Genome evolution in enteric bacteria. Ochman H, et al. **Curr Opin Genet Dev** 1995 Dec;5(6):734-8 (40 ref.)

DNA excision repair and transcription: implications for genome evolution. Sullivan DT. **Curr Opin Genet Dev** 1995 Dec;5(6):786-91 (55 ref.)

LTR-retrotransposons and MITEs: important players in the evolution of plant genomes. Wessler SR, et al. **Curr Opin Genet Dev** 1995 Dec;5(6):814-21 (65 ref.)

Bovine genome mapping: evolutionary inference and the power of comparative genomics. Womack JE, et al. **Curr Opin Genet Dev** 1995 Dec;5(6):725-33 (35 ref.)

Development and evolution of an egg cytoskeletal domain in ascidians. Jeffery WR. **Curr Top Dev Biol** 1995;31:243-76 (77 ref.)

Resynthesizing evolutionary and developmental biology. Gilbert SF, et al. **Dev Biol** 1996 Feb 1;173(2):357-72 (169 ref.)

Hox genes and chordate evolution. Holland PW, et al. **Dev Biol** 1996 Feb 1;173(2):382-95 (75 ref.)

Evolution of nematode vulval fate patterning. Sommer RJ, et al. **Dev Biol** 1996 Feb 1;173(2):396-407 (62 ref.)

Developmental evolution of metazoan bodyplans: the fossil evidence. Valentine JW, et al. **Dev Biol** 1996 Feb 1; 173(2):373-81 (88 ref.)

Epigenetic programming of differential gene expression in development and evolution. Monk M. **Dev Genet** 1995; 17(3):188-97 (58 ref.)

Genetic conflict and evolution of mammalian X-chromosome inactivation. Moore T, et al. **Dev Genet** 1995;17(3):206-11 (44 ref.)

On the importance of evolution to developmental psychobiology. Hill WL. **Dev Psychobiol** 1995 Mar; 28(2):117-29 (70 ref.)

The evolving role of Hox genes in arthropods. Akam M, et al. **Dev Suppl** 1994;:209-15 (62 ref.)

The origin of vertebrate limbs. Coates MI. **Dev Suppl** 1994; :169-80 (116 ref.)

Evolutionary developmental biology of the tetrapod limb. Hinchliffe JR. **Dev Suppl** 1994;:163-8 (115 ref.)

A class act: conservation of homeodomain protein functions. Manak JR, et al. **Dev Suppl** 1994;:61-77 (230 ref.)

The evolution of arthropod segmentation: insights from comparisons of gene expression patterns. Patel NH. **Dev Suppl** 1994;:201-7 (34 ref.)

Tinkering with the tinkerer: pollution versus evolution. Fox GA. **Environ Health Perspect** 1995 May;103 Suppl 4:93-100 (84 ref.)

Prohibitin: potential role in senescence, development, and tumor suppression. McClung JK, et al. **Exp Gerontol** 1995

Mar-Apr;30(2):99-124 (90 ref.)
The accessory gland proteins in male Drosophila: structural, reproductive, and evolutionary aspects. Chen PS. **Experientia** 1996 Jun 15;52(6):503-10 (69 ref.)
Conservation, evolution, and specificity in cellular control by protein phosphorylation. Hofer HW. **Experientia** 1996 May 15;52(5):449-54 (27 ref.)
Towards prediction of cognate complexes between the WW domain and proline-rich ligands. Einbond A, et al. **FEBS Lett** 1996 Apr 8;384(1):1-8 (53 ref.)
The role of antibiotics in the evolution of microorganisms. Cavallo G. G **Batteriol Virol Immunol** 1992 Jan-1993 Dec; 85(1-12):3-11 (9 ref.)
The relevance of cell microenvironments for the appearance of lympho-haemopoietic tissues in primitive vertebrates. Zapata AG, et al. **Histol Histopathol** 1995 Jul;10(3):761-78 (82 ref.)
Evolution of Mhc class II polymorphism: the rise and fall of class II gene function in primates. Bergström T, et al. **Immunol Rev** 1995 Feb;143:13-31 (45 ref.)
Evolution of major histocompatibility complex polymorphisms and T-cell receptor diversity in primates. Bontrop RE, et al. **Immunol Rev** 1995 Feb;143:33-62 (96 ref.)
Class II B Mhc motifs in an evolutionary perspective. Klein J, et al. **Immunol Rev** 1995 Feb;143:89-111 (53 ref.)
Evolution of MHC class II allelic diversity. McDevitt H. **Immunol Rev** 1995 Feb;143:113-22 (25 ref.)
Exonic MHC-DRB polymorphisms and intronic simple repeat sequences: Janus faces of DNA sequence evolution. Schwaiger FW, et al. **Immunol Rev** 1995 Feb;143:199-224 (55 ref.)
Evolution of class I promoter sequences: relationship to function and diversity. Vallejo AN, et al. **Immunol Rev** 1995 Feb;143:249-62 (54 ref.)
IgY: clues to the origins of modern antibodies. Warr GW, et al. **Immunol Today** 1995 Aug;16(8):392-8 (42 ref.)
Pathogenicity islands and the evolution of bacterial pathogens. Lee CA. **Infect Agents Dis** 1996 Jan;5(1):1-7 (46 ref.)
Evolutionary recruitment of biochemically specialized subdivisions of Family I within the protein superfamily of aminotransferases. Jensen RA, et al. **J Bacteriol** 1996 Apr; 178(8):2161-71 (68 ref.)
Homology in the evolution of the cerebral hemispheres. The case of reptilian dorsal ventricular ridge and its possible correspondence with mammalian neocortex. Aboitiz F. **J Hirnforsch** 1995;36(4):461-72 (84 ref.)
Evolution of myosin filament arrangements in vertebrate skeletal muscle. Luther PK, et al. **J Morphol** 1996 Sep; 229(3):325-35 (28 ref.)
An evolutionary perspective enhances understanding of human nutritional requirements. Eaton SB, et al. **J Nutr** 1996 Jun;126(6):1732-40 (92 ref.)
The evolution of virulence: a unifying link between parasitology and ecology. Ewald PW. **J Parasitol** 1995 Oct; 81(5):659-69 (71 ref.)
What is the ultimate cause of socio-economic inequalities in health? An explanation in terms of evolutionary psychology. Charlton BG. **J R Soc Med** 1996 Jan;89(1):3-8 (47 ref.)
Evolution of longevity in mammals. Smith DW. **Mech Ageing Dev** 1995 Jun 30;81(1):51-60 (50 ref.)
Hair growth and the fluid factor. Foote SI. **Med Hypotheses** 1995 Jun;44(6):475-8 (18 ref.)
Gene competition and the possible evolutionary role of tumours. Kozlov AP. **Med Hypotheses** 1996 Feb;46(2):81-4 (33 ref.)
Can evolutionary principles help resolve the acquired immune deficiency syndrome crisis? Powell PD. **Med Hypotheses** 1996 Feb;46(2):130-4 (40 ref.)
The planctomycetes: emerging models for microbial ecology, evolution and cell biology. Fuerst JA. **Microbiology** 1995 Jul;141 (Pt 7):1493-506 (94 ref.)
Genetic analysis of ageing: role of oxidative damage and environmental stresses. Martin GM, et al. **Nat Genet** 1996 May;13(1):25-34 (151 ref.)
An evolutionary perspective on signaling in behavior and immunology. McKean KA, et al. **Naturwissenschaften** 1995 Nov;82(11):509-16 (74 ref.)
The neurobiology of human consciousness: an evolutionary approach. Donald M. **Neuropsychologia** 1995 Sep; 33(9):1087-102 (74 ref.)
The search for missing links between self-replicating nucleic acids and the RNA world. James KD, et al. **Orig Life Evol Biosph** 1995 Dec;25(6):515-30 (76 ref.)
Evolutionary pressures in the spread and persistence of infectious agents in vertebrate populations. Anderson RM. **Parasitology** 1995;111 Suppl:S15-31 (69 ref.)
Hox genes and the evolution of diverse body plans. Akam M. **Philos Trans R Soc Lond B Biol Sci** 1995 Sep 29; 349(1329):313-9 (52 ref.)
Myth, metaphor and hypothesis: how anthropomorphism defeats science. Sullivan LG. **Philos Trans R Soc Lond B Biol Sci** 1995 Aug 29; 349(1328):215-8; discussion 219-24 (9 ref.)
The gene for pyruvate, orthophosphate dikinase in C4 plants: structure, regulation and evolution. Matsuoka M. **Plant Cell Physiol** 1995 Sep;36(6):937-43 (55 ref.)
Evolution and expression of C4 photosynthesis genes. Ku MS, et al. **Plant Physiol** 1996 Aug;111(4):949-57 (48 ref.)
Uniparental inheritance of mitochondrial and chloroplast genes: mechanisms and evolution. Birky CW Jr. **Proc Natl Acad Sci U S A** 1995 Dec 5;92(25):11331-8 (96 ref.)
The histone fold: evolutionary questions. Ramakrishnan V. **Proc Natl Acad Sci U S A** 1995 Dec 5;92(25):11328-30 (30 ref.)
Evolutionary and environmental influences on human lactation. Prentice AM, et al. **Proc Nutr Soc** 1995 Jul; 54(2):391-400 (25 ref.)
Peptidergic neurons in the vertebrate spinal cord: evolutionary trends. Brodin L, et al. **Prog Brain Res** 1995; 104:61-74 (119 ref.)
Alu: structure, origin, evolution, significance and function of one-tenth of human DNA. Schmid CW. **Prog Nucleic Acid Res Mol Biol** 1996;53:283-319 (180 ref.)
Concerted evolution of repetitive DNA sequences in eukaryotes. Elder JF Jr, et al. **Q Rev Biol** 1995 Sep; 70(3):297-320 (146 ref.)
The evolution of endometrial cycles and menstruation. Strassmann BI. **Q Rev Biol** 1996 Jun;71(2):181-220 (152 ref.)
Sex chromatin in lepidoptera. Traut W, et al. **Q Rev Biol** 1996 Jun;71(2):239-56 (71 ref.)
Infection, evolution and autoimmunity: a hypothesis. Jones DE, et al. **QJM** 1995 Dec;88(12):919-25 (56 ref.)
Evolution of neuropeptide Y, peptide YY and pancreatic polypeptide. Larhammar D. **Regul Pept** 1996 Apr 9; 62(1):1-11 (104 ref.)
Sperm competition: evolutionary causes and consequences. Birkhead TR. **Reprod Fertil Dev** 1995;7(4):755-75 (216 ref.)
The origin of programmed cell death. Ameisen JC. **Science** 1996 May 31;272(5266):1278-9 (11 ref.)
Mechanisms and evolution of aging. Lithgow GJ, et al. **Science** 1996 Jul 5;273(5271):80 (14 ref.)
Evolution of the major histocompatibility complex: a current overview. Kasahara M, et al. **Transpl Immunol** 1995 Mar; 3(1):1-20 (224 ref.)
The function and evolution of Msx genes: pointers and paradoxes. Davidson D. **Trends Genet** 1995 Oct; 11(10):405-11 (64 ref.)
Fathers and sons: the Y chromosome and human evolution. Jobling MA, et al. **Trends Genet** 1995 Nov;11(11):449-56 (33 ref.)
Chasing tails in ascidians: developmental insights into the origin and evolution of chordates. Satoh N, et al. **Trends Genet** 1995 Sep;11(9):354-9 (44 ref.)
The scope for virulence management: a comment on Ewald's view on the evolution of virulence. van Baalen M, et al. **Trends Microbiol** 1995 Nov;3(11):414-6; discussion 416-7 (11 ref.)
Numbers, time and neocortical neuronogenesis: a general developmental and evolutionary model. Caviness VS Jr, et al. **Trends Neurosci** 1995 Sep;18(9):379-83 (24 ref.)
Exuberant development of connections, and its possible permissive role in cortical evolution. Innocenti GM. **Trends Neurosci** 1995 Sep;18(9):397-402 (57 ref.)
The emergence and evolution of mammalian neocortex. Northcutt RG, et al. **Trends Neurosci** 1995 Sep;18(9):373-9 (51 ref.)
Theory of mind: evolutionary history of a cognitive specialization. Povinelli DJ, et al. **Trends Neurosci** 1995 Sep;18(9):418-24 (58 ref.)
A small step for the cell, a giant leap for mankind: a hypothesis of neocortical expansion during evolution. Rakic P. **Trends Neurosci** 1995 Sep;18(9):383-8 (59 ref.)
Vasopressin and oxytocin: molecular biology and evolution of the peptide hormones and their receptors. Mohr E, et al. **Vitam Horm** 1995;51:235-66 (137 ref.)
[Evolution of cells] Maier UG, et al. **Naturwissenschaften** 1996 Mar;83(3):103-12 (54 ref.) (Eng. Abstr.) **(Ger)**
[Lipoprotein(a)—atherogenic waste product of evolution?] Kronenberg F, et al. **Wien Med Wochenschr** 1994; 144(12-13):324-30 (68 ref.) (Eng. Abstr.) **(Ger)**
[Molecular evolutionary classification of hepatitis B virus] Ohba K, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:299-304 (5 ref.) **(Jpn)**
[Intraspecific genetic diversity: monitoring and principles of conservation] Altukhov IuP. **Genetika** 1995 Oct; 31(10):1333-57 (110 ref.) (Eng. Abstr.) **(Rus)**
[Comparative genetics of representatives of the genus Yersinia and evolution of their pathogenicity] Anisimov PI, et al. **Genetika** 1996 Mar;32(3):325-30 (36 ref.) (Eng. Abstr.) **(Rus)**
[Mitochondrial introns of fungi and their role in evolution] Shnyreva AV. **Genetika** 1995 Jul;31(7):869-76 (46 ref.) (Eng. Abstr.) **(Rus)**
[The problem of systemic mutation] Stegnil VN. **Genetika** 1996 Jan;32(1):14-22 (43 ref.) (Eng. Abstr.) **(Rus)**
[Regulatory selection as an alternative to the neutrality theory] Sukhodolets VV. **Genetika** 1995 Dec; 31(12):1589-97 (41 ref.) (Eng. Abstr.) **(Rus)**
[The evolution of the synapses in the vertebrate central nervous system (a topical paper)] Motorina MV. **Zh Evol Biokhim Fiziol** 1995 Jan-Feb;31(1):3-13 (68 ref.) (Eng. Abstr.) **(Rus)**
[Stress in the evolution of societies: a means for survival] Sudakov KV. **Zh Evol Biokhim Fiziol** 1995 Jul-Aug; 31(4):489-99 (51 ref.) **(Rus)**

EVOLUTION, MOLECULAR

see related
DIRECTED MOLECULAR EVOLUTION

Origin and early evolution of eukaryotes inferred from the amino acid sequences of translation elongation factors 1alpha/Tu and 2/G. Hashimoto T, et al. **Adv Biophys** 1996; 32:73-120 (138 ref.)
Man and the chimaera. Selective versus neutral oxytocin evolution. Acher R, et al. **Adv Exp Med Biol** 1995; 395:615-27 (59 ref.)
Molecular evolution in bacteria. Trevors JT. **Antonie Van Leeuwenhoek** 1995;67(4):315-24 (76 ref.)
Unusual evolution of 11beta- and 17beta-hydroxysteroid and retinol dehydrogenases. Baker ME. **Bioessays** 1996 Jan; 18(1):63-70 (47 ref.)
Rubisco rules fall; gene transfer triumphs. Palmer JD. **Bioessays** 1995 Dec;17(12):1005-8 (31 ref.)
Evolution of chlorophyll biosynthesis--the challenge to survive photooxidation. Reinbothe S, et al. **Cell** 1996 Sep 6;86(5):703-5 (14 ref.)
Evolution and developmental regulation of the major histocompatibility complex. Salter-Cid L, et al. **Crit Rev Immunol** 1995;15(1):31-75 (389 ref.)
The evolution of major histocompatibility class I genes in primates. Watkins DI. **Crit Rev Immunol** 1995;15(1):1-29 (135 ref.)
Protein families in the metazoan genome. Chothia C. **Dev Suppl** 1994;:27-33 (41 ref.)
Molecular evolution of ruminant lysozymes. Irwin DM. **EXS** 1996;75:347-61 (42 ref.)
Adaptive evolution of lysozyme: changes in amino acid sequence, regulation of expression and gene number. Prager EM. **EXS** 1996;75:323-45 (75 ref.)
Polyclonal antisera elicited by lysozymes: insights into antigenic structure and evolution. Prager EM. **EXS** 1996; 75:261-76 (57 ref.)
Basic concepts in RNA virus evolution. Domingo E, et al. **FASEB J** 1996 Jun;10(8):859-64 (48 ref.)
Stereochemical constraint in the evolution of pyridoxal-5'-phosphate-dependent enzymes. A hypothesis. Christen P, et al. **FEBS Lett** 1996 Jun 24;389(1):12-4 (21 ref.)
The emergence of major cellular processes in evolution. Ouzounis C, et al. **FEBS Lett** 1996 Jul 22;390(2):119-23 (35 ref.)
The unique structures of protozoan myoglobin and yeast hemoglobin: an evolutionary diversity. Shikama K, et al. **Int J Biochem Cell Biol** 1995 Nov;27(11):1107-15 (35 ref.)
Phosphate load as the evolutionary driving force for the development of a high filtration rate based excretory organ: a hypothesis. Ilani A. **J Basic Clin Physiol Pharmacol** 1993 Apr-Jun;4(1-2):123-38 (32 ref.)
Studies of DNA methylation in animals. Bird A, et al. **J Cell Sci Suppl** 1995;19:37-9 (23 ref.)
Structural aspects of the p53 protein in relation to gene evolution: a second look. Soussi T, et al. **J Mol Biol** 1996 Aug 2;260(5):623-37 (143 ref.)
Molecular biology and evolution of resistance of toxicants. Taylor M, et al. **Mol Biol Evol** 1996 Jul;13(6):719-34 (141 ref.)
Support for interordinal eutherian relationships with an emphasis on primates and their archontan relatives. Allard MW, et al. **Mol Phylogenet Evol** 1996 Feb;5(1):78-88 (74 ref.)
Cases of ancient mobile element DNA insertions that now affect gene regulation. Britten RJ. **Mol Phylogenet Evol** 1996 Feb;5(1):13-7 (32 ref.)
The variety of human virus evolution. Fitch WM. **Mol Phylogenet Evol** 1996 Feb;5(1):247-58 (15 ref.)
Evolutionary strategies for the elucidation of cis and trans factors that regulate the developmental switching programs of the beta-like globin genes. Gumucio DL, et al. **Mol Phylogenet Evol** 1996 Feb;5(1):18-32 (78 ref.)
The evolutionary conservation of the splicing apparatus between fission yeast and man. Wentz-Hunter K, et al. **Nucleic Acids Symp Ser** 1995;(33):226-8 (17 ref.)
GTPases: a family of molecular switches and clocks. Bourne HR. **Philos Trans R Soc Lond B Biol Sci** 1995 Sep 29; 349(1329):283-9 (32 ref.)
Evolution of a dynamic cytoskeleton. Mitchison TJ. **Philos Trans R Soc Lond B Biol Sci** 1995 Sep 29; 349(1329):299-304 (18 ref.)
DNA sequence evolution: the sounds of silence. Sharp PM, et al. **Philos Trans R Soc Lond B Biol Sci** 1995 Sep 29; 349(1329):241-7 (54 ref.)
DNA sequence insertion and evolutionary variation in gene regulation. Britten RJ. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9374-7 (41 ref.)
Mapping the protein universe. Holm L, et al. **Science** 1996 Aug 2;273(5275):595-603 (36 ref.)
Human and rodent DNA sequence comparisons: a mosaic model of genomic evolution. Koop BF. **Trends Genet** 1995 Sep;11(9):367-71 (25 ref.)
[The origin and early development of biological catalysts] Masinovský Z. **Cas Lek Cesk** 1995 Oct 4;134(19):607-10 (26 ref.) (Eng. Abstr.) **(Cze)**
[Molecular evolutionary analyses of organisms] Ohba K, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:35-9 (13 ref.) **(Jpn)**
[Molecular evolution of voltage-gated ion channels] Iwabe N, et al. **Tanpakushitsu Kakusan Koso** 1995 Nov;

EVOLUTION, MOLECULAR

40(15):2311–8 (31 ref.) **(Jpn)**
[Beta-lactamase and its molecular evolution] Sawai T, et al. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(13):1887–99 (34 ref.) **(Jpn)**
[Directed molecular evolution of oligonucleotides] Terabe M. **Tanpakushitsu Kakusan Koso** 1996 Feb;41(2):166–9 (16 ref.) **(Jpn)**
[Molecular biological research on the origin of the angiosperms] Bobrova VK, et al. **Zh Obshch Biol** 1995 Nov–Dec;56(6):645–61 (51 ref.) (Eng. Abstr.) **(Rus)**

EVOLUTION, MOLECULAR, DIRECTED see **DIRECTED MOLECULAR EVOLUTION**

EWING'S TUMOR see **SARCOMA, EWING'S**

EXANTHEMA

Childhood exanthems. Frieden IJ. **Curr Opin Pediatr** 1995 Aug;7(4):411–4 (42 ref.)

ETIOLOGY

[Exanthema in children] Winterberg DH.
Ned Tijdschr Geneeskd 1996 Jul 20;140(29):1494–9 (14 ref.) **(Dut)**

VIROLOGY

Viral exanthems in childhood. Hogan PA.
Australas J Dermatol 1996 May;37 Suppl 1:S14–6 (8 ref.)

EXANTHEMA SUBITUM

VIROLOGY

New pathogens, and diseases old and new. I) Afipia felis and Rochalimaea. II) Parvovirus B 19. III) herpesvirus 6. Zannolli R, et al. **Panminerva Med** 1995 Dec;37(4):238–47 (111 ref.)
[Human herpes viruses type 6 and 7; causative agents of, among others, exanthema subitum] Galama JM.
Ned Tijdschr Geneeskd 1996 Jan 20;140(3):124–8 (20 ref.) (Eng. Abstr.) **(Dut)**
[Human herpesviruses 6 and 7. Basic principles and possible significance for dermatology] Lasch JA, et al. **Hautarzt** 1996 May;47(5):341–50 (85 ref.) (Eng. Abstr.) **(Ger)**

EXCIPIENTS

A compendium of vaccine adjuvants and excipients. Vogel FR, et al. **Pharm Biotechnol** 1995;6:141–228 (284 ref.)

ADVERSE EFFECTS

Place of excipients in drug-related allergy. Barbaud A.
Clin Rev Allergy Immunol 1995 Fall;13(3):253–63 (76 ref.)

EXCITATORY AMINO ACID AGONISTS

PHARMACOLOGY

NMDA antagonists: antiepileptic-neuroprotective drugs with diversified neuropharmacological profiles. Sagratella S. **Pharmacol Res** 1995 Jul–Aug;32(1–2):1–13 (124 ref.)

EXCITATORY AMINO ACID ANTAGONISTS

ADVERSE EFFECTS

A review of NMDA receptors and the phencyclidine model of schizophrenia. Thornberg SA, et al. **Pharmacotherapy** 1996 Jan–Feb;16(1):82–93 (122 ref.)
[Glutamatergic hypothesis of schizophrenia: psychoses induced by phencyclidine and cortical-subcortical imbalance] Krebs MO. **Encephale** 1995 Sep–Oct; 21(5):581–8 (52 ref.) (Eng. Abstr.) **(Fre)**

PHARMACOLOGY

The phencyclidine-glutamate model of schizophrenia. Halberstadt AL. **Clin Neuropharmacol** 1995 Jun; 18(3):237–49 (108 ref.)
Histogranin, a modified histone H4 fragment endowed with N-methyl-D-aspartate antagonist and immunostimulatory activities. Lemaire S, et al. **Life Sci** 1995 Mar 3; 56(15):1233–41 (34 ref.)
Pharmacological tools for the investigation of metabotropic glutamate receptors (mGluRs): phenylglycine derivatives and other selective antagonists—an update. Roberts PJ. **Neuropharmacology** 1995 Aug;34(8):813–9 (38 ref.)
N-methyl-D-aspartate (NMDA) receptors, mu and kappa opioid tolerance, and perspectives on new analgesic drug development. Elliott K, et al. **Neuropsychopharmacology** 1995 Dec;13(4):347–56 (58 ref.)
The effects of NMDA receptor antagonists and nitric oxide synthase inhibitors on opioid tolerance and withdrawal. Medication development issues for opiate addiction. Herman BH, et al. **Neuropsychopharmacology** 1995 Dec; 13(4):269–93 (165 ref.)
NMDA antagonists as neurotherapeutic drugs, psychotogens, neurotoxins, and research tools for studying schizophrenia. Olney JW, et al. **Neuropsychopharmacology** 1995 Dec; 13(4):335–45 (75 ref.)
Perspectives on the N-methyl-D-aspartate/nitric oxide cascade and opioid tolerance. Pasternak GW, et al. **Neuropsychopharmacology** 1995 Dec;13(4):309–13 (24 ref.)
Effects of noncompetitive N-methyl-D-aspartate receptor antagonists on opiate tolerance and physical dependence. Trujillo KA. **Neuropsychopharmacology** 1995 Dec; 13(4):301–7 (38 ref.)
Etorphine elicits unique inhibitory-agonist and excitatory-antagonist actions at opioid receptors on sensory neurons: new rationale for improved clinical analgesia and treatment of opiate addiction. Crain SM, et al.
NIDA Res Monogr 1995;147:234–68 (67 ref.)
NMDA antagonists: antiepileptic-neuroprotective drugs with diversified neuropharmacological profiles. Sagratella S. **Pharmacol Res** 1995 Jul–Aug;32(1–2):1–13 (124 ref.)
Excitatory amino acid antagonists and the anticonvulsive activity of conventional antiepileptic drugs. Kleinrok Z, et al. **Pol J Pharmacol** 1995 May–Jun;47(3):247–52 (47 ref.)

THERAPEUTIC USE

Clinical applications of excitatory amino acid antagonists in pain management. Wong CS, et al.
Acta Anaesthesiol Sin 1995 Dec;33(4):227–32 (48 ref.)
Strategies for neuroprotection with glutamate antagonists. Extrapolating from evidence taken from the first stroke and head injury studies. Bullock R. **Ann N Y Acad Sci** 1995 Sep 15;765:272–8; discussion 298 (11 ref.)
The rationale for glutamate antagonists in the treatment of traumatic brain injury. Myseros JS, et al.
Ann N Y Acad Sci 1995 Sep 15;765:262–71; discussion 298 (44 ref.)
Ischemic stroke: treatment on the horizon. Giroux C, et al. **Eur Neurol** 1996;36(2):61–4 (12 ref.)
The role of excitatory amino acids in severe brain trauma: opportunities for therapy: a review. Zauner A, et al.
J Neurotrauma 1995 Aug;12(4):547–54 (51 ref.)
Development of HU-211 as a neuroprotectant for ischemic brain damage. Biegon A, et al. **Neurol Res** 1995 Aug; 17(4):275–80 (27 ref.)
[Glutamate antagonists—a new stage in the development of cerebral protection?] Vasilev D, et al.
Khirurgiia (Sofiia) 1995;48(5):63–5 (10 ref.) (Eng. Abstr.) **(Bul)**
[New therapeutic possibilities with low-affinity NMDA receptor antagonists] Kornhuber J, et al. **Nervenarzt** 1996 Jan;67(1):77–82 (22 ref.) (Eng. Abstr.) **(Ger)**

TOXICITY

NMDA antagonists as neurotherapeutic drugs, psychotogens, neurotoxins, and research tools for studying schizophrenia. Olney JW, et al. **Neuropsychopharmacology** 1995 Dec; 13(4):335–45 (75 ref.)

EXCITATORY AMINO ACID RECEPTORS see **RECEPTORS, GLUTAMATE**

EXCITATORY AMINO ACIDS

see related
RECEPTORS, GLUTAMATE

METABOLISM

Excitatory amino acids and MPTP toxicity. Fornai F, et al. **Adv Neurol** 1996;69:167–76 (52 ref.)
Molecular mechanisms for neurodegeneration. Synergism between reactive oxygen species, calcium, and excitotoxic amino acids. Gerlach M, et al. **Adv Neurol** 1996;69:177–94 (119 ref.)
Excitatory amino acid receptors in glia: different subtypes for distinct functions? Gallo V, et al. **J Neurosci Res** 1995 Sep 1;42(1):1–8 (69 ref.)
Interaction of neuropeptides and excitatory amino acids in the rat superficial spinal dorsal horn. Randić M, et al.
Prog Brain Res 1995;104:225–53 (306 ref.)
[Cerebral hypoxic and ischemic damage in newborn infants: cellular mechanisms and role of excitatory amino acids] Cortey A. **Arch Pediatr** 1995 Dec;2(12):1192–9 (44 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Glutamate excitotoxicity in transient global cerebral ischemia. Paschen W. **Acta Neurobiol Exp (Warsz)** 1996; 56(1):313–22 (68 ref.)
Physiological release of excitatory amino acids. Fillenz M. **Behav Brain Res** 1995 Nov;71(1–2):51–67 (159 ref.)
Excitatory amino acids in health and disease. Thomas RJ. **J Am Geriatr Soc** 1995 Nov;43(11):1279–89 (132 ref.)
The role of excitatory amino acids in severe brain trauma: opportunities for therapy: a review. Zauner A, et al.
J Neurotrauma 1995 Aug;12(4):547–54 (51 ref.)
Excitatory amino acid receptor-mediated neuronal signal transduction: modulation by polyamines and calcium. Iqbal Z. **Mol Cell Biochem** 1995 Aug–Sep;149–150:233–40 (61 ref.)

TOXICITY

NMDA receptor-dependent excitotoxicity: the role of intracellular Ca2+ release. Mody I, et al.
Trends Pharmacol Sci 1995 Oct;16(10):356–9 (68 ref.)
[Neurotoxicity of excitatory amino acids and the central nervous system] Martos JM, et al. **Rev Clin Esp** 1996 Feb; 196(2):113–8 (102 ref.) **(Spa)**

EXCITEMENT, PSYCHOMOTOR see **PSYCHOMOTOR AGITATION**

EXCITOTOXINS see **NEUROTOXINS**

EXERCISE

see related
EXERTION
PHYSICAL FITNESS
The athlete with type I diabetes: managing insulin, diet and exercise. Fahey PJ, et al. **Am Fam Physician** 1996 Apr; 53(5):1611–24 (22 ref.)
Exercised-induced hematuria. Gambrell RC, et al.
Am Fam Physician 1996 Feb 15;53(3):905–11 (28 ref.)
Prescribing exercise for health: a simple framework for primary care [see comments] Will PM, et al.
Am Fam Physician 1996 Feb 1;53(2):579–85 (16 ref.)
Comment in: Am Fam Physician 1996 Feb 1;53(2):484–6.
Increasing physical activity: alterations in body mass and composition. Wilmore JH. **Am J Clin Nutr** 1996 Mar;63(3 Suppl):456S–460S (27 ref.)
The role of adjunctive therapy in the management of chronic nonmalignant pain. Allegrante JP. **Am J Med** 1996 Jul 31; 101(1A):33S–39S (69 ref.)
The benefits of physical activity in childhood. Harsha DW. **Am J Med Sci** 1995 Dec;310 Suppl 1:S109–13 (22 ref.)
The importance of diet and physical activity in the treatment of conditions managed in general practice. Little P, et al. **Br J Gen Pract** 1996 Mar;46(404):187–92 (122 ref.)
Physical exertion as a trigger of myocardial infarction and sudden cardiac death. Mittleman MA, et al.
Cardiol Clin 1996 May;14(2):263–70 (47 ref.)
Physical inactivity and coronary heart disease in elderly patients. Wenger NK. **Clin Geriatr Med** 1996 Feb; 12(1):79–88 (88 ref.)
The young athlete with chronic disease. Small E, et al.
Clin Sports Med 1995 Jul;14(3):709–26 (144 ref.)
Physical activity: breast and reproductive cancer. Francis K. **Compr Ther** 1996 Feb;22(2):94–9 (49 ref.)
Physical activity in the treatment and prevention of diabetes. Spelsberg A, et al. **Compr Ther** 1995 Oct;21(10):559–62 (59 ref.)
Exercise and cancer: linkages with obesity? Shephard RJ. **Crit Rev Food Sci Nutr** 1996 Apr;36(4):321–39 (108 ref.)
Do physical activity and physical fitness avert premature mortality? Lee IM, et al. **Exerc Sport Sci Rev** 1996; 24:135–71 (113 ref.)
Influence of exercise on human sleep. O'Connor PJ, et al. **Exerc Sport Sci Rev** 1995;23:105–34 (187 ref.)
Physical activity and health-related quality of life. Rejeski WJ, et al. **Exerc Sport Sci Rev** 1996;24:71–108 (102 ref.)
Effects of diving and hyperbaria on responses to exercise. Shiraki K, et al. **Exerc Sport Sci Rev** 1995;23:459–85 (76 ref.)
Role of exercise in the cause and prevention of cardiac dysfunction. Starnes JW, et al. **Exerc Sport Sci Rev** 1995; 23:349–73 (107 ref.)
Exercise and the prevention of dyslipidemia and coronary heart disease. Després JP, et al.
Int J Obes Relat Metab Disord 1995 Oct;19 Suppl 4:S45–51 (72 ref.)
Exercise in the treatment of childhood obesity. Epstein LH. **Int J Obes Relat Metab Disord** 1995 Oct;19 Suppl 4:S117–21 (32 ref.)
Exercise in the treatment of obesity: a marginal contribution. Garrow JS. **Int J Obes Relat Metab Disord** 1995 Oct;19 Suppl 4:S126–9 (36 ref.)
Exercise in the management of non-insulin-dependent (type 2) diabetes mellitus. Gautier JF, et al.
Int J Obes Relat Metab Disord 1995 Oct;19 Suppl 4:S58–61 (29 ref.)
Exercise with or without dietary restriction and obesity treatment. Saris WH. **Int J Obes Relat Metab Disord** 1995 Oct;19 Suppl 4:S113–6 (31 ref.)
The role of progressive resistance training and nutrition in the preservation of lean body mass in the elderly. Fielding RA. **J Am Coll Nutr** 1995 Dec;14(6):587–94 (51 ref.)
Exercise and postprandial lipaemia. Föger B, et al.
J Cardiovasc Risk 1995 Aug;2(4):316–22 (59 ref.)
Physical activity and cardiovascular risk. Hardman A.
J Cardiovasc Risk 1995 Aug;2(4):285–8 (17 ref.)
Influence of exercise on insulin sensitivity. Henriksson J.
J Cardiovasc Risk 1995 Aug;2(4):303–9 (62 ref.)
Exercise and haemostatic function. Meade TW.
J Cardiovasc Risk 1995 Aug;2(4):323–9 (28 ref.)
Exercise and lipoprotein metabolism. Superko HR.
J Cardiovasc Risk 1995 Aug;2(4):310–5 (70 ref.)
Epidemiology of physical activity, physical fitness and coronary heart disease. Whaley MH, et al.
J Cardiovasc Risk 1995 Aug;2(4):289–95 (38 ref.)
The role of lipid management by diet and exercise in the progression, stabilization, and regression of coronary artery atherosclerosis. LaFontaine T. **J Cardpulm Rehabil** 1995 Jul–Aug;15(4):262–8 (26 ref.)
Randomised controlled trials of physical activity promotion in free living populations: a review. Hillsdon M, et al.

J Epidemiol Community Health 1995 Oct;49(5):448–53 (23 ref.)

Physical activity, the compression of morbidity, and the health of the elderly. Fries JF. **J R Soc Med** 1996 Feb; 89(2):64–8 (36 ref.)

Physical activity and psychological well-being: knowledge base, current issues, and caveats. Gauvin L, et al. **Nutr Rev** 1996 Apr;54(4 Pt 2):S53–65 (154 ref.)

Habitual physical activity, psychomotor performance, and older workers. Ilmarinen J, et al. **Nutr Rev** 1996 Apr;54(4 Pt 2):S44–52 (39 ref.)

Is increased dietary protein necessary or beneficial for individuals with a physically active lifestyle? Lemon PW. **Nutr Rev** 1996 Apr;54(4 Pt 2):S169–75 (79 ref.)

Measuring nutrition status, physical activity, and fitness, with special emphasis on populations at nutritional risk. Rodrigues Matsudo VK. **Nutr Rev** 1996 Apr;54(4 Pt 2):S79–96 (171 ref.)

Physical inactivity and metabolic factors as predictors of weight gain. Saris WH. **Nutr Rev** 1996 Apr;54(4 Pt 2):S110–3 (28 ref.)

Habitual physical activity and academic performance. Shephard RJ. **Nutr Rev** 1996 Apr;54(4 Pt 2):S32–6 (42 ref.)

Peak bone mass and physical activity: a short review. Vuori I. **Nutr Rev** 1996 Apr;54(4 Pt 2):S11–4 (54 ref.)

Dietary intake and physical activity as "predictors" of weight gain in observational, prospective studies of adults. Williamson DF. **Nutr Rev** 1996 Apr;54(4 Pt 2):S101–9 (15 ref.)

Clinical applications of diet and physical activity in weight loss. Wood PD. **Nutr Rev** 1996 Apr;54(4 Pt 2):S131–5 (29 ref.)

Physical activity in the prevention of cardiovascular disease. Francis K. **Phys Ther** 1996 May;76(5):456–68 (106 ref.)

Cardiovascular risk–factor reduction in elderly patients with cardiac disease. Williams MA. **Phys Ther** 1996 May; 76(5):469–80 (103 ref.)

Infectious and lymphocytic myocarditis: epidemiology and factors relevant to sports medicine. Friman G, et al. **Scand J Med Sci Sports** 1995 Oct;5(5):269–78 (97 ref.)

Sudden death and physical activity in athletes and nonathletes. Jensen–Urstad M. **Scand J Med Sci Sports** 1995 Oct;5(5):279–84 (46 ref.)

Carbohydrate ingestion/supplementation or resistance exercise and training. Conley MS, et al. **Sports Med** 1996 Jan;21(1):7–17 (104 ref.)

Sleep disturbances and exercise. Driver S, et al. **Sports Med** 1996 Jan;21(1):1–6 (36 ref.)

Aging, physical activity and sports injuries. An overview of common sports injuries in the elderly. Kallinen M, et al. **Sports Med** 1995 Jul;20(1):41–52 (76 ref.)

Benefits of aerobic exercise after stroke. Potempa K, et al. **Sports Med** 1996 May;21(5):337–46 (57 ref.)

Gastro–oesophageal reflux and exercise. Important pathology to consider in the athletic population. Shawdon A. **Sports Med** 1995 Aug;20(2):109–16 (32 ref.)

[Physical activity and bone mineral content in postmenopausal women] Eiken PA. **Ugeskr Laeger** 1995 Sep 11;157(37):5086–91 (47 ref.) (Eng. Abstr.) **(Dan)**

[Contraindications for physical training (editorial)] Näveri H. **Duodecim** 1994;110(12):1181–3 (16 ref.) **(Fin)**

[Physical activity and health: minimum, optimum and maximum] Vuori I. **Duodecim** 1994;110(12):1184–90 (54 ref.) **(Fin)**

[Exercise, health and health services (editorial)] Vuori I. **Duodecim** 1994;110(12):1175–7 (16 ref.) **(Fin)**

[Physical exercise and its effects on the cardiovascular system in elderly subjects] Arroyo JF, et al. **Schweiz Rundsch Med Prax** 1996 Feb 6;85(6):172–5 (29 ref.) (Eng. Abstr.) **(Fre)**

[Benefits and risks of physical activity in patient with coronary heart disease] Gohlke H. **Wien Klin Wochenschr** 1995;107(24):760–5 (29 ref.) (Eng. Abstr.) **(Ger)**

[Intense physical exercise—excessive strain on the immune system?] Eliakim A, et al. **Harefuah** 1995 Dec 1; 129(11):498–502 (44 ref.) **(Heb)**

[The role of physical activity in the prevention of certain internal diseases] Jákó P. **Orv Hetil** 1995 Oct 29; 136(44):2379–83 (44 ref.) (Eng. Abstr.) **(Hun)**

[Gynecologic problems in female athletes] Broso R, et al. **Minerva Ginecol** 1996 Mar;48(3):99–106 (33 ref.) (Eng. Abstr.) **(Ita)**

[Effect of physical exercise in fibromyalgia] Mengshoel AM. **Tidsskr Nor Laegeforen** 1996 Feb 28;116(6):746–8 (31 ref.) (Eng. Abstr.) **(Nor)**

[Effects of aerobic physical conditioning on blood pressure control] Waib PH, et al. **Arq Bras Cardiol** 1995 Mar; 64(3):243–6 (80 ref.) **(Por)**

[Old principles for th treatment of obesity are still valid. Diet and exercise are still the most important factors] Rössner S. **Lakartidningen** 1996 Mar 20;93(12):1117–20 (12 ref.) **(Swe)**

[TV and sedentary life result in more overweight people] Sjöström L. **Lakartidningen** 1996 Jan 17;93(3):167–70 (37 ref.) **(Swe)**

PHYSIOLOGY

K+ balance in humans during exercise. Hallén J. **Acta Physiol Scand** 1996 Mar;156(3):279–86 (38 ref.)

Effects of training on potassium, calcium and hydrogen ion regulation in skeletal muscle and blood during exercise. McKenna MJ, et al. **Acta Physiol Scand** 1996 Mar; 156(3):335–46 (68 ref.)

Role of potassium in the regulation of systemic physiological function during exercise. Paterson DJ. **Acta Physiol Scand** 1996 Mar;156(3):287–94 (77 ref.)

Muscular function, metabolism and electrolyte shifts during prolonged repetitive exercise in humans. Vøllestad NK, et al. **Acta Physiol Scand** 1996 Mar;156(3):271–8 (38 ref.)

Task-dependent factors in fatigue of human voluntary contractions. Bigland-Ritchie B, et al. **Adv Exp Med Biol** 1995;384:361–80 (92 ref.)

Associations between muscle soreness, damage, and fatigue. Clarkson PM, et al. **Adv Exp Med Biol** 1995;384:457–69 (63 ref.)

An integrative view of limitations to muscular performance. Dempsey JA, et al. **Adv Exp Med Biol** 1995;384:393–9 (17 ref.)

Exercise hyperpnea. Chairman's introduction. Dempsey JA. **Adv Exp Med Biol** 1995;393:133–6 (4 ref.)

Central fatigue. Critical issues, quantification and practical implications. Gandevia SC, et al. **Adv Exp Med Biol** 1995; 384:281–94 (79 ref.)

Tryptophan, 5-hydroxytryptamine and a possible explanation for central fatigue. Newsholme EA, et al. **Adv Exp Med Biol** 1995;384:315–20 (16 ref.)

Metabolic correlates of fatigue from different types of exercise in man. Vøllestad NK. **Adv Exp Med Biol** 1995; 384:185–94 (37 ref.)

Is the slow component of exercise VO2 a respiratory adaptation to anaerobiosis? Wasserman K, et al. **Adv Exp Med Biol** 1995;393:187–94 (11 ref.)

Post-exercise lactate metabolism: a comparative review of sites, pathways, and regulation. Gleeson TT. **Annu Rev Physiol** 1996;58:565–81 (105 ref.)

Exercise-induced muscle damage and inflammation: a review. Pyne DB. **Aust J Sci Med Sport** 1994 Sep–Dec; 26(3–4):49–58 (133 ref.)

Using functional loading to influence bone mass and architecture: objectives, mechanisms, and relationship with estrogen of the mechanically adaptive process in bone. Lanyon LE. **Bone** 1996 Jan;18(1 Suppl):37S–43S (74 ref.)

Osteoporosis and exercise. Mosekilde L. **Bone** 1995 Sep; 17(3):193–5 (42 ref.)

Dose–response relationship between physical loading and mechanical competence of bone. Smith EL, et al. **Bone** 1996 Jan;18(1 Suppl):45S–50S (66 ref.)

Exercise and bone mass in young and premenopausal women. Snow CM. **Bone** 1996 Jan;18(1 Suppl):51S–55S (30 ref.)

Benefits of exercise for type II diabetics: convergence of epidemiologic, physiologic, and molecular evidence. Bonen A. **Can J Appl Physiol** 1995 Sep;20(3):261–79 (80 ref.)

Contribution of acid–base changes to control of breathing during exercise. Forster HV, et al. **Can J Appl Physiol** 1995 Sep;20(3):380–94 (97 ref.)

Acid–base balance: origin of plasma [H+] during exercise. Kowalchuk JM, et al. **Can J Appl Physiol** 1995 Sep; 20(3):341–56 (33 ref.)

Origins of [H+] changes in exercising skeletal muscle. Lindinger MI. **Can J Appl Physiol** 1995 Sep;20(3):357–68 (38 ref.)

Adrenergic control of the force–frequency relation. Ross J Jr, et al. **Circulation** 1995 Oct 15;92(8):2327–32 (48 ref.)

Mechanisms for reduction of cardiovascular risk by regular exercise. Jennings GL. **Clin Exp Pharmacol Physiol** 1995 Mar;22(3):209–11 (24 ref.)

Exercise, nutrition, and aging. Evans WJ. **Clin Geriatr Med** 1995 Nov;11(4):725–34 (49 ref.)

Getting rid of carbon dioxide during exercise [editorial] Jones NL, et al. **Clin Sci (Colch)** 1996 May;90(5):323–35 (92 ref.)

Physical activity assessment: a review of methods. Melanson EL Jr, et al. **Crit Rev Food Sci Nutr** 1996 May;36(5):385–96 (91 ref.)

Growth, physical activity, and bone mineral acquisition. Bailey DA, et al. **Exerc Sport Sci Rev** 1996;24:233–66 (146 ref.)

Magnetic resonance imaging and spectroscopy in studying exercise in children. Cooper DM, et al. **Exerc Sport Sci Rev** 1996;24:475–99 (78 ref.)

Integration of the physiological factors determining endurance performance ability. Coyle EF. **Exerc Sport Sci Rev** 1995;23:25–63 (67 ref.)

Physical activity, body weight, and adiposity: an epidemiologic perspective. DiPietro L. **Exerc Sport Sci Rev** 1995;23:275–303 (146 ref.)

Muscle mechanics: adaptations with exercise–training. Fitts RH, et al. **Exerc Sport Sci Rev** 1996;24:427–73 (139 ref.)

The slow component of oxygen uptake kinetics in humans. Gaesser GA, et al. **Exerc Sport Sci Rev** 1996;24:35–71 (130 ref.)

Exercise and oxidative stress: role of the cellular antioxidant systems. Ji LL. **Exerc Sport Sci Rev** 1995;23:135–66 (140 ref.)

Free radicals and exercise: effects of nutritional antioxidant supplementation. Kanter M. **Exerc Sport Sci Rev** 1995; 23:375–97 (142 ref.)

Strength and power training: physiological mechanisms of adaptation. Kraemer WJ, et al. **Exerc Sport Sci Rev** 1996; 24:363–97 (158 ref.)

Effects of acute and chronic exercise on fat metabolism. Martin WH 3rd. **Exerc Sport Sci Rev** 1996;24:203–31 (84 ref.)

The impact of exercise on the immune system: NK cells, interleukins 1 and 2, and related responses. Shephard RJ, et al. **Exerc Sport Sci Rev** 1995;23:215–41 (233 ref.)

Exercise training and the cross–stressor adaptation hypothesis. Sothmann MS, et al. **Exerc Sport Sci Rev** 1996; 24:267–87 (89 ref.)

Impact of exercise on adipose tissue metabolism in humans. Arner P. **Int J Obes Relat Metab Disord** 1995 Oct;19 Suppl 4:S18–21 (25 ref.)

Evolution of the understanding of the role of exercise in obesity and its complications. Björntorp P. **Int J Obes Relat Metab Disord** 1995 Oct;19 Suppl 4:S1–4 (15 ref.)

Individual differences in the response to regular exercise. Bouchard C. **Int J Obes Relat Metab Disord** 1995 Oct;19 Suppl 4:S5–8 (21 ref.)

Integration of the overall response to exercise. Flatt JP. **Int J Obes Relat Metab Disord** 1995 Oct;19 Suppl 4:S31–40 (23 ref.)

Exercise and macronutrient balance. Hill JO, et al. **Int J Obes Relat Metab Disord** 1995 Oct;19 Suppl 4:S88–92 (39 ref.)

The regulation of glucose uptake and oxidation during exercise. Kelley DE. **Int J Obes Relat Metab Disord** 1995 Oct;19 Suppl 4:S14–7 (12 ref.)

Exercise, substrate utilization and energy requirements in the elderly. Poehlman ET, et al. **Int J Obes Relat Metab Disord** 1995 Oct;19 Suppl 4:S93–6 (20 ref.)

Exercise and the neurobiological control of food intake and energy expenditure. Richard D. **Int J Obes Relat Metab Disord** 1995 Oct;19 Suppl 4:S73–9 (78 ref.)

The effects of endurance and resistance training on blood pressure. Schwartz RS, et al. **Int J Obes Relat Metab Disord** 1995 Oct;19 Suppl 4:S52–7 (38 ref.)

Exercise and thermogenesis in obesity. Segal KR. **Int J Obes Relat Metab Disord** 1995 Oct;19 Suppl 4:S80–7 (25 ref.)

Exercise and cancer: linkages with obesity? Shephard RJ. **Int J Obes Relat Metab Disord** 1995 Oct;19 Suppl 4:S62–8 (107 ref.)

Adaptation of human skeletal muscle to exercise–training. Simoneau JA. **Int J Obes Relat Metab Disord** 1995 Oct; 19 Suppl 4:S9–13 (47 ref.)

Exercise, macronutrient preferences and food intake. Tremblay A, et al. **Int J Obes Relat Metab Disord** 1995 Oct;19 Suppl 4:S97–101 (32 ref.)

Role of the endocrine pancreas in control of fuel metabolism by the liver during exercise. Wasserman DH, et al. **Int J Obes Relat Metab Disord** 1995 Oct;19 Suppl 4:S22–30 (83 ref.)

Variations in physical activity habits and body composition. Wilmore JH. **Int J Obes Relat Metab Disord** 1995 Oct;19 Suppl 4:S107–12 (30 ref.)

Fat loading: the next magic bullet? Sherman WM, et al. **Int J Sport Nutr** 1995 Jun;5 Suppl:S1–12 (29 ref.)

Exercise for weight loss: what are the facts? Zelasko CJ. **J Am Diet Assoc** 1995 Dec;95(12):1414–7 (22 ref.)

Scaling, normalizing, and per ratio standards: an allometric modeling approach. Nevill AM, et al. **J Appl Physiol** 1995 Sep;79(3):1027–31 (28 ref.)

Oxidants and antioxidants in exercise. Sen CK. **J Appl Physiol** 1995 Sep;79(3):675–86 (100 ref.)

A review of heart rate and blood pressure responses in the cold in healthy subjects and coronary artery disease patients. Emmett JD. **J Cardpulm Rehabil** 1995 Jan–Feb; 15(1):19–24 (47 ref.)

Effects of exercise on body composition and functional capacity of the elderly. Evans WJ. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:147–50 (23 ref.)

Strength and aerobic training attenuate muscle wasting and improve resistance to the development of disability with aging. Tseng BS, et al. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:113–9 (49 ref.)

Potassium regulation during exercise and recovery in humans: implications for skeletal and cardiac muscle. Lindinger MI. **J Mol Cell Cardiol** 1995 Apr;27(4):1011–22 (83 ref.)

Effects of training on potassium homeostasis during exercise. McKenna MJ. **J Mol Cell Cardiol** 1995 Apr;27(4):941–9 (52 ref.)

The measurement and interpretation of aerobic fitness in children: current issues. Welsman JR, et al. **J R Soc Med** 1996 May;89(5):281P–5P (57 ref.)

The therapeutic role of exercise in patients with orthotopic heart transplant. Badenhop DT. **Med Sci Sports Exerc** 1995 Jul;27(7):975–85 (38 ref.)

Criteria for maximal oxygen uptake: review and commentary. Howley ET, et al. **Med Sci Sports Exerc** 1995 Sep; 27(9):1292–301 (61 ref.)

Behaviour of zinc in physical exercise: a special reference to immunity and fatigue. Cordova A, et al. **Neurosci Biobehav Rev** 1995 Fall;19(3):439–45 (101 ref.)

Vitamin and mineral supplements as nutritional aids to exercise performance and health. Armstrong LE, et al. **Nutr Rev** 1996 Apr;54(4 Pt 2):S149–58 (126 ref.)

Fluid balance for optimal performance. Gisolfi CV. **Nutr Rev** 1996 Apr;54(4 Pt 2):S159–68 (86 ref.)

Carbohydrates and exercise performance. Hargreaves M. **Nutr Rev** 1996 Apr;54(4 Pt 2):S136–9 (40 ref.)

Exercise, physical activity, nutrition, and the brain. Hollmann

W, et al. **Nutr Rev** 1996 Apr;54(4 Pt 2):S37–43 (42 ref.)
Effects of exercise on daily energy expenditure. Toth MJ, et al. **Nutr Rev** 1996 Apr;54(4 Pt 2):S140–8 (51 ref.)
Changing diet and exercise behaviors in individuals at risk for weight gain. Wing RR. **Obes Res** 1995 Sep;3 Suppl 2:277s–282s (28 ref.)
The cardiopulmonary system and movement dysfunction. Peel C. **Phys Ther** 1996 May;76(5):448–55 (34 ref.)
Effects of exercise training in the elderly: impact of progressive- resistance training on skeletal muscle and whole-body protein metabolism. Fielding RA. **Proc Nutr Soc** 1996 Nov;54(3):665–75 (58 ref.)
Muscle fuel selection: effect of exercise and training. Henriksson J. **Proc Nutr Soc** 1995 Mar;54(1):125–38 (100 ref.)
What determines fuel selection in relation to exercise? Lindholm A. **Proc Nutr Soc** 1995 Mar;54(1):275–82 (23 ref.)
Postexercise recovery period: carbohydrate and protein metabolism. Viru A. **Scand J Med Sci Sports** 1996 Feb; 6(1):2–14 (125 ref.)
The interrelationships of body fat, exercise, and hormonal status and their impact on reproduction and bone health. Ramos RH, et al. **Semin Perinatol** 1995 Jun;19(3):163–70 (53 ref.)
The effects of exercise on growth. Borer KT. **Sports Med** 1995 Dec;20(6):375–97 (347 ref.)
Physiological monitoring of elite cyclists. Practical methods. Boulay MR. **Sports Med** 1995 Jul;20(1):1–11 (22 ref.)
Flow cytometry. Principles and applications in exercise immunology. Gabriel H, et al. **Sports Med** 1995 Nov; 20(5):302–20 (121 ref.)
Factors limiting adenosine triphosphatase function during high intensity exercise. Thermodynamic and regulatory considerations. Korge P. **Sports Med** 1995 Oct;20(4):215–25 (31 ref.)
Exercise and brain neurotransmission. Meeusen R, et al. **Sports Med** 1995 Sep;20(3):160–88 (117 ref.)
Vitamin E status and response to exercise training. Tiidus PM, et al. **Sports Med** 1995 Jul;20(1):12–23 (101 ref.)
Blood hormones as markers of training stress and overtraining. Urhausen A, et al. **Sports Med** 1995 Oct; 20(4):251–76 (233 ref.)
Age, altitude, and arrhythmia. Alexander JK. **Tex Heart Inst J** 1995;22(4):308–16 (69 ref.)
[Physical exercise and the skeleton] Barlet JP, et al. **Arch Physiol Biochem** 1995 Dec;103(6):681–98 (214 ref.) (Eng. Abstr.) **(Fre)**
[Exercise capacity after heart transplantation] Cohen-Solal A, et al. **Presse Med** 1995 Dec 9;24(38):1806–8 (29 ref.) (Eng. Abstr.) **(Fre)**
[Heart patient and sports] Niederhauser HU. **Schweiz Rundsch Med Prax** 1995 Aug 29;84(35):933–8 (33 ref.) (Eng. Abstr.) **(Ger)**
[Physical exercise and increase in arterial pressure and temperature in a female heterozygote for anhidrotic ectodermal dysplasia] Bandinelli G, et al. **Ann Ital Med Int** 1996 Jan–Mar;11(1):59–61 (12 ref.) (Eng. Abstr.) **(Ita)**
[Cardiovascular response to physical exercise] Iacono A, et al. **Cardiologia** 1996 Mar;41(3):241–50 (82 ref.) **(Ita)**
[Metabolic and ventilatory thresholds during exercise. Physiological and methodological aspects] Ribeiro JP. **Arq Bras Cardiol** 1995 Feb;64(2):171–81 (178 ref.) **(Por)**
[Glutathione homeostasis: the cardinal physiological defense against oxygen toxicity induced by physical exercise] Sen CK, et al. **Fiziol Zh Im I M Sechenova** 1995 Nov; 81(11):143–50 (15 ref.) **(Rus)**
[Exercise physiology and the rehabilitation of the heart transplant patient] Martínez Martínez A, et al. **Rev Esp Cardiol** 1995;48 Suppl 7:135–9 (27 ref.) (Eng. Abstr.) **(Spa)**
[Physical exercise and chronic renal insufficiency] Bolaños L, et al. **Rev Med Univ Navarra** 1993 Jan–Mar;38(1):38–41 (25 ref.) **(Spa)**

PSYCHOLOGY

Exercise and obesity treatment: psychological aspects. Brownell KD. **Int J Obes Relat Metab Disord** 1995 Oct; 19 Suppl 4:S122–5 (24 ref.)
Does exercise help in the treatment of psychiatric disorders? Plante TG. **J Psychosoc Nurs Ment Health Serv** 1996 Mar; 34(3):38–43 (46 ref.)
The acute effects of exercise on mood state. Yeung RR. **J Psychosom Res** 1996 Feb;40(2):123–41 (108 ref.)
Exercise and mental health: a review. Glenister D. **J R Soc Health** 1996 Feb;116(1):7–13 (63 ref.)
Pain sensitivity, exercise and stoicism. Janal MN. **J R Soc Med** 1996 Jul;89(7):376–81 (38 ref.)
Influence of time of day on psychological responses to exercise. A review. Trine MR, et al. **Sports Med** 1995 Nov; 20(5):328–37 (69 ref.)

EXERCISE, AEROBIC see **EXERCISE**

EXERCISE-INDUCED ASTHMA see **ASTHMA, EXERCISE-INDUCED**

EXERCISE-INDUCED BRONCHOSPASM see **ASTHMA, EXERCISE-INDUCED**

EXERCISE, ISOMETRIC see **EXERCISE**

EXERCISE, PHYSICAL see **EXERCISE**

EXERCISE TEST

Stress testing for coronary artery disease in the elderly. Schulman SP, et al. **Clin Geriatr Med** 1996 Feb; 12(1):101–19 (98 ref.)
Cardiovascular stress testing: a description of the various types of stress tests and indications for their use. Mayo Clinic Cardiovascular Working Group on Stress Testing. **Mayo Clin Proc** 1996 Jan;71(1):43–52 (31 ref.)
Clinical exercise testing in chronic airflow limitation. Marciniuk DD, et al. **Med Clin North Am** 1996 May; 80(3):565–87 (105 ref.)
Role of exercise in the assessment and management of neuromuscular disease in children. Bar-Or O. **Med Sci Sports Exerc** 1996 Apr;28(4):421–7 (63 ref.)
Role of exercise in the evaluation and management of pulmonary disease in children and youth. Nixon PA. **Med Sci Sports Exerc** 1996 Apr;28(4):414–20 (86 ref.)
Role of exercise in the management of cardiovascular disease in children and youth. Tomassoni TL. **Med Sci Sports Exerc** 1996 Apr;28(4):406–13 (66 ref.)
A system for non-invasively measuring blood pressure on a treadmill. Chong-pong Au T, et al. **Physiol Meas** 1995 Nov;16(4):273–85 (7 ref.)
[Detection of multivessel lesions after myocardial infarction. Improvement of the predictive value of early exercise stress test by discriminant analysis] Leroy F, et al. **Arch Mal Coeur Vaiss** 1996 Feb;89(2):193–200 (31 ref.) (Eng. Abstr.) **(Fre)**
[Stress echocardiography versus myocardial scintigraphy: comparative value in coronary heart disease] Silber S. **Herz** 1996 Apr;21(2):136–41 (68 ref.) **(Ger)**
[The utility of electrocardiography in the age of exercise echocardiography] Boccardi L, et al. **Cardiologia** 1995 Nov; 40(11):807–12 (20 ref.) **(Ita)**
[Exercise testing in cardiac patients] Koike A, et al. **Rinsho Byori** 1995 Aug;43(8):820–7 (19 ref.) (Eng. Abstr.) **(Jpn)**
[Exercise test in respiratory system] Miyazato I, et al. **Rinsho Byori** 1995 Aug;43(8):813–9 (9 ref.) (Eng. Abstr.) **(Jpn)**
[National Consensus on Ergometry. Department of Ergometry and Cardiovascular Rehabilitation of the Brazilian Cardiology Society] **Arq Bras Cardiol** 1995 Aug; 65(2):189–211 (48 ref.) **(Por)**
[Stress echocardiography. Rise of a new method] Mathias Júnior W. **Arq Bras Cardiol** 1995 Apr;64(4):401–8 (43 ref.) **(Por)**
[Ergometry in the diagnosis and prognosis of arterial hypertension] Grima Serrano A. **Rev Esp Cardiol** 1995;48 Suppl 4:40–4 (23 ref.) (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Acute stent thrombosis associated with exercise testing after successful percutaneous transluminal coronary angioplasty. Samuels B, et al. **Am Heart J** 1995 Nov;130(5):1120–2 (15 ref.)

DRUG EFFECTS

What is the ideal study design for evaluation of treatment for heart failure? Insights from trials assessing the effect of ACE inhibitors on exercise capacity. Narang R, et al. **Eur Heart J** 1996 Jan;17(1):120–34 (45 ref.)

INSTRUMENTATION

–Practical implementation of stress echocardiography—what should be monitored?– Beckmann S, et al. **Herz** 1996 Feb; 21(1):65–70; discussion 64 (18 ref.) **(Ger)**

METHODS

Selecting training workloads using treadmill test heart rate/oxygen uptake regressions. McConnell TR. **J Cardpulm Rehabil** 1996 May–Jun;16(3):160–2 (8 ref.)
Stress echocardiography. Burn S, et al. **QJM** 1995 Nov; 88(11):755–61 (68 ref.)
Dobutamine stress echocardiography. Stănescu C. **Rom J Intern Med** 1995 Jan–Jun;33(1–2):3–11 (26 ref.)
[Provocation tests in echocardiography: stress—dipyridamole—dobutamine (editorial)] Dagianti A. **Cardiologia** 1995 Jul;40(7):451–9 (69 ref.) **(Ita)**

NURSING

Diagnostic and functional exercise testing: test selection and interpretation. Franklin BA. **J Cardiovasc Nurs** 1995 Oct; 10(1):8–29 (57 ref.)

EXERCISE THERAPY

Exercise training for coronary artery disease in the elderly. Brechue WF, et al. **Clin Geriatr Med** 1996 Feb;12(1):207–29 (91 ref.)
The conservative management of the unstable shoulder including rehabilitation. Dines DM, et al. **Clin Sports Med** 1995 Oct;14(4):797–816 (76 ref.)
Exercise rehabilitation for patients with peripheral arterial disease. Regensteiner JG, et al. **Exerc Sport Sci Rev** 1995; 23:1–24 (95 ref.)
Does exercise training play a role in the treatment of essential hypertension? Hagberg JM, et al. **J Cardiovasc Risk** 1995 Aug;2(4):296–302 (40 ref.)
Cardiac rehabilitation based on group light exercise and discussion. An Australian hospital model. Hare DL, et al. **J Cardpulm Rehabil** 1995 May–Jun;15(3):186–92 (27 ref.)
The therapeutic role of exercise in patients with orthotopic heart transplant. Badenhop DT. **Med Sci Sports Exerc** 1995 Jul;27(7):975–85 (38 ref.)
Role of exercise in the assessment and management of neuromuscular disease in children. Bar-Or O. **Med Sci Sports Exerc** 1996 Apr;28(4):421–7 (63 ref.)
Exercise in treating obesity in children and adolescents. Epstein LH, et al. **Med Sci Sports Exerc** 1996 Apr; 28(4):428–35 (52 ref.)
Role of exercise in the evaluation and management of pulmonary disease in children and youth. Nixon PA. **Med Sci Sports Exerc** 1996 Apr;28(4):414–20 (86 ref.)
Role of exercise in the management of cardiovascular disease in children and youth. Tomassoni TL. **Med Sci Sports Exerc** 1996 Apr;28(4):406–13 (66 ref.)
The role of quadriceps exercise in the treatment of patellofemoral pain syndrome. Callaghan MJ, et al. **Sports Med** 1996 May;21(5):384–91 (55 ref.)
Applied physiology of water-skiing. Leggett SH, et al. **Sports Med** 1996 Apr;21(4):262–76 (30 ref.)
Use of exercise for treatment of chronic fatigue syndrome. McCully KK, et al. **Sports Med** 1996 Jan;21(1):35–48 (78 ref.)
Spinal cord injury, exercise and quality of life. Noreau L, et al. **Sports Med** 1995 Oct;20(4):226–50 (171 ref.)
Benefits of aerobic exercise after stroke. Potempa K, et al. **Sports Med** 1996 May;21(5):337–46 (57 ref.)
[Exercise therapy of obesity] Abe R. **Nippon Naika Gakkai Zasshi** 1995 Aug 10;84(8):1279–83 (3 ref.) **(Jpn)**
[Effects of one-week inpatient weight reduction program for obese persons] Ogawa K, et al. **Nippon Rinsho** 1995 Jun; 53 Suppl:501–8 (11 ref.) **(Jpn)**
[Physical exercise and obesity] Sato Y, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:455–9 (20 ref.) **(Jpn)**
[Childhood obesity: treatment and prognosis] Yamazaki K, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:529–33 (12 ref.) **(Jpn)**

METHODS

Assessment and exercise in low back pain. With special reference to the management of pain and disability following first time lumbar disc surgery. Manniche C. **Dan Med Bull** 1995 Sep;42(4):301–13 (155 ref.)
Reversing sarcopenia: how weight training can build strength and vitality. Evans WJ. **Geriatrics** 1996 May;51(5):46–7, 51–3; quiz 54 (18 ref.)
Exercise intensity prescription in cardiovascular disease. Theoretical basis for anaerobic threshold determination. Gordon NF, et al. **J Cardpulm Rehabil** 1995 May–Jun; 15(3):193–6 (20 ref.)
Selecting training workloads using treadmill test heart rate/oxygen uptake regressions. McConnell TR. **J Cardpulm Rehabil** 1996 May–Jun;16(3):160–2 (8 ref.)
Physical therapy as an effective change agent in the treatment of patients with urinary incontinence. McCandless S, et al. **J Miss State Med Assoc** 1995 Sep;36(9):271–4 (18 ref.)
Resistive exercise training in cardiac rehabilitation. An update. Verrill DE, et al. **Sports Med** 1996 May; 21(5):347–83 (246 ref.)
[Effects of aerobic physical conditioning on blood pressure control] Waib PH, et al. **Arq Bras Cardiol** 1995 Mar; 64(3):243–6 (80 ref.) **(Por)**

EXERCISE TOLERANCE

Impaired exercise tolerance in hypertensive patients. Lim PO, et al. **Ann Intern Med** 1996 Jan 1;124(1 Pt 1):41–55 (170 ref.)
Thyroid status and exercise tolerance. Cardiovascular and metabolic considerations. McAllister RM, et al. **Sports Med** 1995 Sep;20(3):189–98 (64 ref.)

EXERTION

see related
EXERCISE
FATIGUE
SPORTS
WORK

Exertional collapse and sudden death associated with sickle cell trait. Kerle KK, et al. **Am Fam Physician** 1996 Jul; 54(1):237–40 (18 ref.)
Nuclear magnetic resonance studies of muscle and applications to exercise and diabetes. Shulman RG, et al. **Diabetes** 1996 Jan;45 Suppl 1:S93–8 (20 ref.)
A review of the control of breathing during exercise. Mateika JH, et al. **Eur J Appl Physiol** 1995;71(1):1–27 (277 ref.)
Energy requirements of adults: an update on basal metabolic rates (BMRs) and physical activity levels (PALs). Shetty PS, et al. **Eur J Clin Nutr** 1996 Feb;50 Suppl 1:S11–23 (77 ref.)
Control of adenine nucleotide metabolism and glycolysis in vertebrate skeletal muscle during exercise. Krause U, et al. **Experientia** 1996 May 15;52(5):396–403 (51 ref.)
The plasma level of some amino acids and physical and mental fatigue. Newsholme EA, et al. **Experientia** 1996

May 15;52(5):413-5 (14 ref.)
Flying insects: model systems in exercise physiology. Wegener G. **Experientia** 1996 May 15;52(5):404-12 (41 ref.)
Employment-related physical activity and pregnancy outcome. Berkowitz GS. **J Am Med Wom Assoc** 1995 Sep-Oct;50(5):167-9, 174 (33 ref.)
Early nutrition and later physical work capacity. Haas JD, et al. **Nutr Rev** 1996 Feb;54(2 Pt 2):S41-8 (22 ref.)
Exercise-induced lower leg pain. Rochcongar P. **Rev Rhum Engl Ed** 1995 Nov;62(10):627-31 (35 ref.)
[Physical activity and musculoskeletal functioning] Alaranta H, et al. **Duodecim** 1994;110(12):1200-5 (38 ref.) **(Fin)**
[Physical activity and prevention and treatment of metabolic syndrome] Eriksson J, et al. **Duodecim** 1994;110(12):1193-9 (46 ref.) **(Fin)**
[The role of physical activity in the prevention of certain internal diseases] Jákó P. **Orv Hetil** 1995 Oct 29; 136(44):2379-83 (44 ref.) (Eng. Abstr.) **(Hun)**

DRUG EFFECTS

Creatine and its application as an ergogenic aid. Greenhaff PL. **Int J Sport Nutr** 1995 Jun;5 Suppl:S100-10 (33 ref.)
Antioxidants, carnitine, and choline as putative ergogenic aids. Kanter MM, et al. **Int J Sport Nutr** 1995 Jun;5 Suppl:S120-31 (73 ref.)
[Drug treatment and exercise] Ylitalo P. **Duodecim** 1994; 110(12):1207-14 (41 ref.) **(Fin)**

PHYSIOLOGY

Role of potassium in the regulation of systemic physiological function during exercise. Paterson DJ. **Acta Physiol Scand** 1996 Mar;156(3):287-94 (77 ref.)
Post-exercise lactate metabolism: a comparative review of sites, pathways, and regulation. Gleeson TT. **Annu Rev Physiol** 1996;58:565-81 (105 ref.)
Extreme derangements of acid-base balance in exercise: advantages and limitations of the Stewart analysis. Fedde MR, et al. **Can J Appl Physiol** 1995 Sep;20(3):369-79 (10 ref.)
Dietary carbohydrate as an ergogenic aid for prolonged and brief competitions in sport. Walberg-Rankin J. **Int J Sport Nutr** 1995 Jun;5 Suppl:S13-28 (67 ref.)
Inhibition of citrate lyase may aid aerobic endurance. McCarty MF. **Med Hypotheses** 1995 Sep;45(3):247-54 (77 ref.)
Nitric oxide production and NO synthase gene expression contribute to vascular regulation during exercise. Shen W, et al. **Med Sci Sports Exerc** 1995 Aug;27(8):1125-34 (75 ref.)
Hemiatrophy, juvenile-onset exertional alternating leg paresis, hypotonia, and hemidystonia and adult-onset hemiparkinsonism: the spectrum of hemiparkinsonism-hemiatrophy syndrome. Lang AE. **Mov Disord** 1995 Jul;10(4):489-95 (32 ref.)
Cough, exertional, and sexual headaches: an analysis of 72 benign and symptomatic cases. Pascual J, et al. **Neurology** 1996 Jun;46(6):1520-4 (19 ref.)
Behaviour of zinc in physical exercise: a special reference to immunity and fatigue. Cordova A, et al. **Neurosci Biobehav Rev** 1995 Fall;19(3):439-45 (101 ref.)
Exercise loading of tendons and the development of overuse injuries. A review of current literature. Archambault JM, et al. **Sports Med** 1995 Aug;20(2):77-89 (71 ref.)
Methodological and statistical considerations for exercise-related hormone evaluations. Tremblay MS, et al. **Sports Med** 1995 Aug;20(2):90-108 (129 ref.)
[Is heavy physical work a risk factor for ischemic heart disease?] Makowiec-Dąbrowska T. **Med Pr** 1995; 46(3):263-74 (42 ref.) (Eng. Abstr.) **(Pol)**

EXFOLIATINS

BIOSYNTHESIS

Staphylococcal scalded skin syndrome. Gemmell CG. **J Med Microbiol** 1995 Nov;43(5):318-27 (77 ref.)

TOXICITY

The epidermolytic (exfoliative) toxins of Staphylococcus aureus. Bailey CJ, et al. **Med Microbiol Immunol (Berl)** 1995 Aug;184(2):53-61 (67 ref.)

EXFOLIATION SYNDROME

see related
GLAUCOMA, OPEN-ANGLE

EXFOLIATIVE TOXINS see **EXFOLIATINS**

EXISTENTIAL PSYCHOLOGY see **EXISTENTIALISM**

EXISTENTIALISM

Constructivism in psychotherapy. Truth and consequences. Held BS. **Ann N Y Acad Sci** 1996 Jun 24;775:198-206 (43 ref.)
Antiscience trends in the rise of the "alternative medicine" movement. Sampson W. **Ann N Y Acad Sci** 1996 Jun 24; 775:188-97 (34 ref.)
Hermeneutic phenomenology: philosophical perspectives and current use in nursing research. Annells M. **J Adv Nurs** 1996 Apr;23(4):705-13 (52 ref.)
Transcultural nursing: a perspective derived from Jean-Paul Sartre. Rajan MF. **J Adv Nurs** 1995 Sep;22(3):450-5 (20 ref.)

EXO-1,4-ALPHA-GLUCOSIDASE see **GLUCAN 1,4-ALPHA-GLUCOSIDASE**

EXOCYTOSIS

Exocytosis: proteins and perturbations. Augustine GJ, et al. **Annu Rev Pharmacol Toxicol** 1996;36:659-701 (273 ref.)
Furin/PACE/SPC1: a convertase involved in exocytic and endocytic processing of precursor proteins. Denault JB, et al. **FEBS Lett** 1996 Jan 29;379(2):113-6 (46 ref.)
A unifying hypothesis for acetylcholine release. Israël M, et al. **Neurochem Int** 1996 Jan;28(1):1-9 (88 ref.)
The neuronal exocytotic fusion machine: some new developments. Chapman ER, et al. **Neuropharmacology** 1995 Nov;34(11):1343-9 (64 ref.)
v- and t-SNAREs in neuronal exocytosis: a need for additional components to define sites of release. Galli T, et al. **Neuropharmacology** 1995 Nov;34(11):1351-60 (63 ref.)

PHYSIOLOGY

Structure and function of fusion pores in exocytosis and ectoplasmic membrane fusion. Lindau M, et al. **Curr Opin Cell Biol** 1995 Aug;7(4):509-17 (64 ref.)
Neuroexocytosis. Benfenati F, et al. **Curr Top Microbiol Immunol** 1995;195:195-219 (132 ref.)
Molecular mechanisms in exocytosis. Edwardson JM, et al. **J Membr Biol** 1995 Jul;146(2):113-22 (138 ref.)
Synaptic like microvesicles: do they participate in regulated exocytosis? Llona I. **Neurochem Int** 1995 Sep;27(3):219-26 (82 ref.)
Synaptic vesicle proteins and regulated exocytosis. Elferink LA, et al. **Prog Brain Res** 1995;105:79-85 (42 ref.)

EXODONTICS see **TOOTH EXTRACTION**

EXOMPHALOS see **HERNIA, UMBILICAL**

EXOMPHALOS-MACROGLOSSIA-GIGANTISM SYNDROME see **BECKWITH-WIEDEMANN SYNDROME**

EXONS

Identification of a new exon of the brain microtubule-associated protein 2. Guilleminot J, et al. **C R Acad Sci III** 1995 Sep;318(9):959-64 (21 ref.)
Evolution of the intron-exon structure of eukaryotic genes. Long M, et al. **Curr Opin Genet Dev** 1995 Dec;5(6):774-8 (58 ref.)

GENETICS

Analysis of MAOA mutations in humans. Hsu YP, et al. **Prog Brain Res** 1995;106:67-75 (54 ref.)

EXONUCLEASES

[Gamma exonuclease method] Ishida S, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):531-3 (7 ref.) **(Jpn)**

EXOPHIALA

Catheter-associated fungemia due to Wangiella (Exophiala) dermatitidis. Nachman S, et al. **J Clin Microbiol** 1996 Apr; 34(4):1011-3 (10 ref.)

EXOPHTHALMIC GOITER see **GRAVES' DISEASE**

EXOPHTHALMOS

DIAGNOSIS

Six signs in children with life-threatening implications. Tien DR. **R I Med** 1995 Dec;78(12):342-5 (6 ref.)

EXOSTOSES

DIAGNOSIS

Tori mandibularis: a case report and review of the literature. Pynn BR, et al. **J Can Dent Assoc** 1995 Dec;61(12):1057-8, 1063-6 (29 ref.)

ETIOLOGY

Torus palatinus and torus mandibularis: a review of the literature. Seah YH. **Aust Dent J** 1995 Oct;40(5):318-21 (31 ref.)

EXOSTOSES, FAMILIAL see **EXOSTOSES, MULTIPLE HEREDITARY**

EXOSTOSES, HEREDITARY MULTIPLE see **EXOSTOSES, MULTIPLE HEREDITARY**

EXOSTOSES, MULTIPLE see **EXOSTOSES, MULTIPLE HEREDITARY**

EXOSTOSES, MULTIPLE CARTILAGINOUS see **EXOSTOSES, MULTIPLE HEREDITARY**

EXOSTOSES, MULTIPLE HEREDITARY

COMPLICATIONS

Diaphyseal aclasis with spinal cord compression. Report of two cases and review of the literature. Labram EK, et al. **J Neurosurg** 1996 Mar;84(3):518-21 (18 ref.)

GENETICS

[Positional cloning of the putative gene responsible for transient abnormal myelopoiesis and that for multiple cartilaginous exostoses] Niikawa N. **Rinsho Byori** 1996 Jan; 44(1):13-8 (6 ref.) (Eng. Abstr.) **(Jpn)**

EXOSTOSIS, CARTILAGINOUS see **OSTEOCHONDROMA**

EXOSTOSIS, OSTEOCARTILAGINOUS see **OSTEOCHONDROMA**

EXOTOXINS

BIOSYNTHESIS

[Cytolysins and homologous proteins produced by gram-negative bacteria. I. Hemolysis and leukotoxins of Escherichia coli, Bordetella pertussis, Pasteurella haemolytica and Actinobacillus sp] Różalski A. **Postepy Hig Med Dosw** 1996;50(2):173-90 (103 ref.) (Eng. Abstr.) **(Pol)**

IMMUNOLOGY

Bacterial pyrogenic exotoxins as superantigens. Kotb M. **Clin Microbiol Rev** 1995 Jul;8(3):411-26 (292 ref.)

PHARMACOLOGY

Single-chain fusion toxins for the treatment of breast cancer: antitumor activity of BR96 sFv-PE40 and heregulin-PE40. Siegall CB. **Recent Results Cancer Res** 1996;140:51-60 (21 ref.)

THERAPEUTIC USE

Targeting Pseudomonas exotoxin to hematologic malignancies. Kreitman RJ, et al. **Semin Cancer Biol** 1995 Oct;6(5):297-306 (54 ref.)
Targeted therapy of carcinomas using BR96 sFv-PE40, a single-chain immunotoxin that binds to the Le(y) antigen. Siegall CB. **Semin Cancer Biol** 1995 Oct;6(5):289-95 (44 ref.)

TOXICITY

Biological effects of RTX toxins: the possible role of lipopolysaccharide. Czuprynski CJ, et al. **Trends Microbiol** 1995 Dec;3(12):480-3 (48 ref.)

EXPECTORANTS

see related
ANTITUSSIVE AGENTS

THERAPEUTIC USE

Aerosolized dornase alpha (rhDNase) in cystic fibrosis. Bates RD, et al. **J Clin Pharm Ther** 1995 Dec;20(6):313-5 (19 ref.)
The role of N-acetylcysteine in the treatment of chronic obstructive pulmonary disease [editorial] van Herwaarden CL, et al. **Neth J Med** 1995 Aug;47(2):45-8 (21 ref.)
Dornase alfa: a new option in the management of cystic fibrosis. Witt DM, et al. **Pharmacotherapy** 1996 Jan-Feb; 16(1):40-8 (24 ref.)
[Bronchial mucolytic agents] Leuenberger P. **Rev Med Suisse Romande** 1996 May;116(5):335-9 (16 ref.) **(Fre)**
[New pharmacological approaches: rhDNase] Tournier G, et al. **Rev Pneumol Clin** 1995;51(3):193-200 (40 ref.) (Eng. Abstr.) **(Fre)**

EXPENDITURES, HEALTH see **HEALTH EXPENDITURES**

EXPERIENTIAL LEARNING see **PROBLEM-BASED LEARNING**

EXPERIMENTAL DESIGN see **RESEARCH DESIGN**

EXPERT SYSTEMS

The NST-EXPERT project: the need to evolve. Alonso-Betanzos A, et al. **Artif Intell Med** 1995 Aug; 7(4):297-313 (40 ref.)
Computer systems in dysmorphology. Evans CD. **Clin Dysmorphol** 1995 Jul;4(3):185-201 (34 ref.)
Knowledge-based systems, artificial neural networks and pattern recognition: applications to biotechnological processes. Kamimura R, et al. **Curr Opin Biotechnol** 1996

EXPERT SYSTEMS

Apr;7(2):231–4 (18 ref.)
Intelligent fetal heart rate computer systems in intrapartum surveillance. Greene KR. **Curr Opin Obstet Gynecol** 1996 Apr;8(2):123–7 (19 ref.)
Programs, databases, and expert systems for human geneticists—a survey. Fischer C, et al. **Hum Genet** 1996 Feb;97(2):129–37 (103 ref.)
Problems of knowledge acquisition automation in medical expert systems. Stempczyńska J, et al. **Medinfo** 1995;8 Pt 1:857–60 (9 ref.)
Methods for combining experts' probability assessments. Jacobs RA. **Neural Comput** 1995 Sep;7(5):867–88 (51 ref.)
Development of structure–activity relationship rules for predicting carcinogenic potential of chemicals. Woo YT, et al. **Toxicol Lett** 1995 Sep;79(1–3):219–28 (18 ref.)
[Development and use of expert systems in medicine] Božović Z, et al. **Vojnosanit Pregl** 1994 Sep–Oct;51(5):423–8 (42 ref.) **(Ser)**

EXPERT TESTIMONY

LEGISLATION & JURISPRUDENCE

Adversarial medical and scientific testimony and lay jurors: a proposal for medical malpractice reform. Menon JW. **Am J Law Med** 1995;21(2–3):281–300 (141 ref.)
Accident neurosis revisited [editorial] Mayou R. **Br J Psychiatry** 1996 Apr;168(4):399–403 (26 ref.)
Neurolaw: towards a new medical jurisprudence. Taylor JS. **Brain Inj** 1995 Oct;9(7):745–51 (44 ref.)
Cult membership as a source of self-cohesion: forensic implications. Feldmann TB, et al. **Bull Am Acad Psychiatry Law** 1995;23(2):239–48 (46 ref.)
'Functional overlay', and illness behaviour in chronic pain: distress or malingering? Conceptual difficulties in medico-legal assessment of personal injury claims. Main CJ, et al. **J Psychosom Res** 1995 Aug;39(6):737–53 (58 ref.)
[Clinical aspects and neurologic expert assessment in sequelae of whiplash injury to the cervical spine] Jenzer G. **Nervenarzt** 1995 Oct;66(10):730–5 (30 ref.) (Eng. Abstr.) **(Ger)**
[Compliance with psychiatric legal ordinance section 63 STGB. Legal principles—current status—treatment concepts—perspectives] Nedopil N, et al. **Nervenarzt** 1995 Nov;66(11):793–801 (38 ref.) (Eng. Abstr.) **(Ger)**
[Occupational asthma: definition—epidemiology—etiologic substances—prognosis—prevention—diagnosis—expert assessment aspects] Merget R, et al. **Pneumologie** 1996 May; 50(5):356–63 (83 ref.) **(Ger)**
[Forensic practice between commonality, the law and psychiatry. 2] Hoffmann-Richter U, et al. **Psychiatr Prax** 1996 May;23(3):150–4 (16 ref.) **(Ger)**

STANDARDS

Credibility: the key to the successful physician witness. Marshall JC. **Surv Ophthalmol** 1995 Jul–Aug;40(1):69–72 (14 ref.)

EXPIRATORY PEAK FLOW RATE see **PEAK EXPIRATORY FLOW RATE**

EXPLORATORY BEHAVIOR

The value of curiosity and naiveté for the cross-cultural psychotherapist. Dyche L, et al. **Fam Process** 1995 Dec; 34(4):389–99 (33 ref.)
Behavioral and neuroimaging studies on schizophrenia in Japan. Shimazono Y, et al. **Psychiatry Clin Neurosci** 1995 Mar;49(1):3–11 (72 ref.)

PHYSIOLOGY

Exploration and predation models of anxiety: evidence from laboratory and wild species. Hendrie CA, et al. **Pharmacol Biochem Behav** 1996 May;54(1):13–20 (56 ref.)

EXPLOSIONS

see related
BLAST INJURIES

EXPOSURE NOTIFICATION see **DISEASE NOTIFICATION**

EXTENDED CARE FACILITIES see **SKILLED NURSING FACILITIES**

EXTERNAL DEGREE PROGRAMS, NURSING see **EDUCATION, NURSING, BACCALAUREATE**

EXTERNAL FISTULA see **CUTANEOUS FISTULA**

EXTERNAL FIXATORS

Intramedullary nailing after external fixation of the tibia. Tornetta P 3rd, et al. **Bull Hosp Jt Dis** 1995;54(1):5–13 (31 ref.)
External fixation of the wrist. Pennig D, et al. **Injury** 1996 Jan;27(1):1–15 (108 ref.)
[External fixation of bones (fixateur externe) in fracture treatment] Höntzsch D, et al. **Versicherungsmedizin** 1996 Jun 1;48(3):96–100 (18 ref.) (Eng. Abstr.) **(Ger)**

VETERINARY

Treatment of fractures of the tibia and radius–ulna by external coaptation. Adams SB, et al. **Vet Clin North Am Food Anim Pract** 1996 Mar;12(1):181–98 (15 ref.)
External skeletal fixation in ruminants. Anderson DE, et al. **Vet Clin North Am Food Anim Pract** 1996 Mar;12(1):117–52 (139 ref.)

EXTRACELLULAR FLUID see **EXTRACELLULAR SPACE**

EXTRACELLULAR MATRIX

[Structure and function of extracellular matrix with special references to proteoglycan] Takeuchi J. **Rinsho Byori** 1995 Oct;43(10):979–87 (32 ref.) (Eng. Abstr.) **(Jpn)**

CHEMISTRY

Extracellular matrix. 1: fibril-forming collagens. Kadler K. **Protein Profile** 1994;1(5):519–638 (3411 ref.)
Organization of the provisional fibronectin matrix: control by products of blood coagulation. Mosher DF. **Thromb Haemost** 1995 Jul;74(1):529–33 (62 ref.)

ENZYMOLOGY

Cytokine regulation of matrix metalloproteinase activity and its regulatory dysfunction in disease. Ries C, et al. **Biol Chem Hoppe Seyler** 1995 Jun;376(6):345–55 (100 ref.)
Matrix metalloproteinases and cardiovascular disease. Dollery CM, et al. **Circ Res** 1995 Nov;77(5):863–8 (49 ref.)
Proteolytic remodeling of extracellular matrix. Birkedal-Hansen H. **Curr Opin Cell Biol** 1995 Oct; 7(5):728–35 (61 ref.)
Chronic renal disease: do metalloproteinase inhibitors have a demonstrable role in extracellular matrix accumulation? Baricos WH. **Curr Opin Nephrol Hypertens** 1995 Jul; 4(4):365–8 (24 ref.)
Interplay of T cells and cytokines in the context of enzymatically modified extracellular matrix. Gilat D, et al. **Immunol Today** 1996 Jan;17(1):16–20 (40 ref.)
Matrix metalloproteinases in immunity. Goetzl EJ, et al. **J Immunol** 1996 Jan 1;156(1):1–4 (32 ref.)
Hyaluronidases—a group of neglected enzymes. Kreil G. **Protein Sci** 1995 Sep;4(9):1666–9 (52 ref.)

IMMUNOLOGY

T-lymphocyte interactions with endothelium and extracellular matrix. Hunt SW 3rd, et al. **Crit Rev Oral Biol Med** 1996;7(1):59–86 (199 ref.)
Interplay of T cells and cytokines in the context of enzymatically modified extracellular matrix. Gilat D, et al. **Immunol Today** 1996 Jan;17(1):16–20 (40 ref.)
Matrix metalloproteinases in immunity. Goetzl EJ, et al. **J Immunol** 1996 Jan 1;156(1):1–4 (32 ref.)

METABOLISM

Regulation of matrix metalloproteinases during extracellular matrix turnover. Corcoran ML, et al. **Adv Exp Med Biol** 1995;385:151–9; discussion 179–84 (53 ref.)
Dynamics of matrix turnover during pathologic remodeling of the extracellular matrix [comment] Stetler-Stevenson WG. **Am J Pathol** 1996 May;148(5):1345–50 (34 ref.) Comment on: Am J Pathol 1996 May;148(5):1639–48.
Cell–matrix adhesion: structure and regulation. Hemmings L, et al. **Biochem Soc Trans** 1995 Aug;23(3):619–26 (75 ref.)
Utilization of transgenic mice in the study of matrix degrading proteinases and their inhibitors. Khokha R, et al. **Cancer Metastasis Rev** 1995 Jun;14(2):97–111 (109 ref.)
New insights into the function of collagens from genetic analysis. Olsen BR. **Curr Opin Cell Biol** 1995 Oct;7(5):720–7 (59 ref.)
Matrix turnover in fibrogenesis. Iredale JP. **Hepatogastroenterology** 1996 Jan–Feb;43(7):56–71 (136 ref.)
Matrilysin: an epithelial matrix metalloproteinase with potentially novel functions. Wilson CL, et al. **Int J Biochem Cell Biol** 1996 Feb;28(2):123–36 (64 ref.)
Extracellular matrix, supramolecular organisation and shape. Scott JE. **J Anat** 1995 Oct;187 (Pt 2):259–69 (21 ref.)
Role of transforming growth factor-beta in diabetic glomerulosclerosis and renal hypertrophy. Ziyadeh FN, et al. **Kidney Int Suppl** 1995 Sep;51:S34–6 (34 ref.)
Integrin signaling and matrix assembly. Ruoslahti E. **Tumour Biol** 1996;17(2):117–24 (44 ref.)
[Role of glycosoaminoglycans in venous disease. Mode of action of some flavonoid drugs] Drubaix I, et al. **Pathol Biol (Paris)** 1995 May;43(5):461–70 (37 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Extracellular matrix. Rennard SI. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 2):S14–5 (24 ref.)
Biology of tumor cell invasion: interplay of cell adhesion and matrix degradation. Heino J. **Int J Cancer** 1996 Mar 15;65(6):717–22 (66 ref.)
Extracellular matrix and the kidney. Furness PN. **J Clin Pathol** 1996 May;49(5):355–9 (70 ref.)
Interactions of glioma cells and extracellular matrix. Paulus W, et al. **J Neurooncol** 1995;24(1):87–91 (25 ref.)
[Liver fibrosis] Chevallier M, et al. **Ann Pathol** 1995; 15(5):372–9 (50 ref.) **(Fre)**
[Interstitial collagen matrix and its relationship with expansion of acute myocardial infarction] Matsubara BB, et al. **Arq Bras Cardiol** 1995 Jun;64(6):559–63 (39 ref.) **(Por)**

PHYSIOLOGY

Molecular interactions in the submembrane plaque of cell–cell and cell–matrix adhesions. Geiger B, et al. **Acta Anat (Basel)** 1995;154(1):46–62 (181 ref.)
Angiotensin II in cell growth and matrix production. Hsueh WA, et al. **Adv Exp Med Biol** 1995;377:217–23 (49 ref.)
Elastic fibers and their role in bladder extracellular matrix. Rosenbloom J, et al. **Adv Exp Med Biol** 1995;385:161–72; discussion 179–84 (52 ref.)
Matrix changes in the bladder associated with normal aging. Shapiro E, et al. **Adv Exp Med Biol** 1995;385:187–90; discussion 223–8 (23 ref.)
Between molecules and morphology. Extracellular matrix and creation of vascular form. Vernon RB, et al. **Am J Pathol** 1995 Oct;147(4):873–83 (77 ref.)
Regulation of APP expression, biogenesis and metabolism by extracellular matrix and cytokines. Beyreuther K, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:74–6 (17 ref.)
Signalling in extracellular-matrix-mediated control of epithelial cell phenotype. Edwards G, et al. **Biochem Soc Trans** 1995 Aug;23(3):464–8 (39 ref.)
Interactions of connective tissue cells with the extracellular matrix. Horton MA. **Bone** 1995 Aug;17(2 Suppl):51S–53S (20 ref.)
The thymic nurse cell complex: an in vitro model for extracellular matrix–mediated intrathymic T cell migration. Villa-Verde DM, et al. **Braz J Med Biol Res** 1995 Aug; 28(8):907–12 (35 ref.)
A hierarchy of ECM-mediated signalling regulates tissue-specific gene expression. Roskelley CD, et al. **Curr Opin Cell Biol** 1995 Oct;7(5):736–47 (117 ref.)
SPARC and the extracellular matrix: implications for cancer and wound repair. Reed MJ, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 1):81–94 (66 ref.)
Extracellular matrix and cell adhesion molecules in nephrogenesis. Ekblom P. **Exp Nephrol** 1996 Mar–Apr; 4(2):92–6 (30 ref.)
Role of laminin–nidogen complexes in basement membrane formation during embryonic development. Dziadek M. **Experientia** 1995 Sep 29;51(9–10):901–13 (136 ref.)
Extracellular matrix in animal development. Role of extracellular matrix in animal development—an introduction. Ekblom P. **Experientia** 1995 Sep 29; 51(9–10):851–2 (14 ref.)
The extracellular matrix of the hematopoietic microenvironment. Klein G. **Experientia** 1995 Sep 29; 51(9–10):914–26 (123 ref.)
The extracellular matrix during heart development. Little CD, et al. **Experientia** 1995 Sep 29;51(9–10):873–82 (133 ref.)
Extracellular matrix components in intestinal development. Simon-Assmann P, et al. **Experientia** 1995 Sep 29; 51(9–10):883–900 (160 ref.)
The extracellular matrix of the Dictyostelium discoideum slug. Wilkins MR, et al. **Experientia** 1995 Dec 18; 51(12):1189–96 (80 ref.)
The extracellular matrix in hepatic regeneration. Martinez-Hernandez A, et al. **FASEB J** 1995 Nov; 9(14):1401–10 (60 ref.)
Dynamic interactions of the extracellular matrix. Slater M. **Histol Histopathol** 1996 Jan;11(1):175–80 (72 ref.)
Extracellular matrix and its receptors during development. Gullberg D, et al. **Int J Dev Biol** 1995 Oct;39(5):845–54 (109 ref.)
ADAM, a novel family of membrane proteins containing A Disintegrin And Metalloprotease domain: multipotential functions in cell–cell and cell–matrix interactions. Wolfsberg TG, et al. **J Cell Biol** 1995 Oct;131(2):275–8 (22 ref.)
The osteoclast clear zone is a specialized cell–extracellular matrix adhesion structure. Väänänen HK, et al. **J Cell Sci** 1995 Aug;108 (Pt 8):2729–32 (39 ref.)
Extracellular matrix and its interactions in the diabetic kidney: a molecular biological approach. Gilbert RE, et al. **J Diabetes Complications** 1995 Oct–Dec;9(4):252–4 (27 ref.)
Migration and adhesion assays. Lallier T. **Methods Cell Biol** 1996;51:285–99 (3 ref.)
Extracellular matrix signaling from the cellular membrane skeleton to the nuclear skeleton: a model of gene regulation. Lelièvre S, et al. **Recent Prog Horm Res** 1996;51:417–32 (54 ref.)
Involvement of extracellular matrix constituents in breast cancer. Lochter A, et al. **Semin Cancer Biol** 1995 Jun; 6(3):165–73 (106 ref.)
The extracellular matrix and its modulation in the trabecular meshwork. Yue BY. **Surv Ophthalmol** 1996 Mar–Apr; 40(5):379–90 (146 ref.)
Extracellular matrix and pattern in plant embryos: on the lookout for developmental information. Brownlee C, et al. **Trends Genet** 1995 Sep;11(9):344–8 (52 ref.)
[Extracellular matrix components and angiogenesis] Imamura M. **Nippon Yakurigaku Zasshi** 1996 Mar;107(3):153–60 (30

ref.) (Eng. Abstr.) **(Jpn)**

ULTRASTRUCTURE

Structural relationship between the primary crystal formations and the matrix macromolecules in different hard tissues. Discussion of a general principle. Höhling HJ, et al. **Connect Tissue Res** 1995;33(1-3):171-8 (59 ref.)

Ultrastructure of dentin matrix in heritable dentin defects. Waltimo J, et al. **Scanning Microsc** 1995 Mar;9(1):185-97; discussion 197-8 (89 ref.)

EXTRACELLULAR MATRIX PROTEINS

ANALYSIS

Fibrillin-containing microfibrils: structure and function in health and disease. Kielty CM, et al. **Int J Biochem Cell Biol** 1995 Aug;27(8):747-60 (70 ref.)

BIOSYNTHESIS

Glomerular hypertension and progressive renal disease: the interplay of mesangial cell stretch, cytokine formation and extracellular matrix synthesis. Cortes P, et al. **Contrib Nephrol** 1996;118:229-33 (14 ref.)

GENETICS

Reelin: a novel extracellular matrix protein involved in brain lamination. Rugarli EI, et al. **Bioessays** 1995 Oct; 17(10):832-4 (32 ref.)

IMMUNOLOGY

Extracellular matrix proteins, regulators of T-cell functions in healthy and diseased individuals. Gorski A, et al. **Clin Diagn Lab Immunol** 1995 Nov;2(6):646-51 (69 ref.)

[Extracellular matrix proteins as regulators of the immune response] Matysiak W, et al. **Pol Arch Med Wewn** 1995 Aug;94(2):173-7 (33 ref.) **(Pol)**

METABOLISM

Integrins: emerging paradigms of signal transduction. Schwartz MA, et al. **Ann Rev Cell Dev Biol** 1995;11:549-99 (402 ref.)

Complex roles of matrix metalloproteinases in tumor progression. Powell WC, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 1):1-21 (46 ref.)

Membrane type-matrix metalloproteinase and tumor invasion. Seiki M. **Curr Top Microbiol Immunol** 1996;213 (Pt 1):23-32 (44 ref.)

Role of Ito cells in the degradation of matrix in liver. Arthur MJ. **J Gastroenterol Hepatol** 1995;10 Suppl 1:S57-62 (61 ref.)

Alterations in extracellular matrix protein expression in neonatal pulmonary hypertension: implications for vascular function. Durmowicz AG, et al. **J Perinatol** 1996 Mar-Apr; 16(2 Pt 2 Su):S11-8 (39 ref.)

Binding of extracellular matrix proteins by microbes. Ljungh A, et al. **Methods Enzymol** 1995;253:501-14 (50 ref.)

Mediators of hyperglycemia and the pathogenesis of matrix accumulation in diabetic renal disease. Ziyadeh FN. **Miner Electrolyte Metab** 1995;21(4-5):292-302 (157 ref.)

Calcification of elastic fibers in pseudoxanthoma elasticum. Truter S, et al. **Mt Sinai J Med** 1996 May-Sep; 63(3-4):210-5 (53 ref.)

PHYSIOLOGY

Dentin matrix proteins and dentinogenesis. Butler WT. **Connect Tissue Res** 1995;33(1-3):59-65 (48 ref.)

Extracellular matrix in animal development. Role of extracellular matrix in animal development--an introduction. Ekblom P. **Experientia** 1995 Sep 29; 51(9-10):851-2 (14 ref.)

The extracellular matrix during heart development. Little CD, et al. **Experientia** 1995 Sep 29;51(9-10):873-82 (133 ref.)

The extracellular matrix in hepatic regeneration. Martinez-Hernandez A, et al. **FASEB J** 1995 Nov; 9(14):1401-10 (60 ref.)

Extracellular matrix proteins and hepatic fibrosis. Johnson SJ. **Hepatogastroenterology** 1996 Jan-Feb;43(7):44-55 (149 ref.)

[VLA and alpha6, beta4 integrins. Expression in normal and neoplastic human tissues] Hofman P, et al. **Arch Anat Cytol Pathol** 1995;43(5-6):309-24 (112 ref.) (Eng. Abstr.) **(Fre)**

[Adhesion and migration of epidermal dendritic cells] Staquet MJ. **Pathol Biol (Paris)** 1995 Dec;43(10):858-62 (41 ref.) (Eng. Abstr.) **(Fre)**

[Morphology of basement membrane and associated matrix proteins in normal and pathological tissues] Nerlich A. **Veroff Pathol** 1995;145:1-139 (336 ref.) (Eng. Abstr.) **(Ger)**

[Mosaic proteins] Zak I. **Postepy Biochem** 1995;41(2):120-30 (81 ref.) **(Pol)**

EXTRACELLULAR SIGNAL-REGULATED KINASES see CALMODULIN-DEPENDENT PROTEIN KINASES

EXTRACELLULAR SPACE

METABOLISM

In vivo stationary flux analysis by 13C labeling experiments. Wiechert W, et al. **Adv Biochem Eng Biotechnol** 1996; 54:109-54 (144 ref.)

On the significance of brain extracellular uric acid detected with in-vivo monitoring techniques: a review. O Neill RD, et al. **Behav Brain Res** 1995 Nov;71(1-2):33-49 (254 ref.)

Hypertensive heart disease: cardioreparation by reversal of interstitial collagen in patients. Motz W, et al. **Eur Heart J** 1995 May;16 Suppl C:69-73 (45 ref.)

A cloned extracellular Ca(2+)-sensing receptor: molecular mediator of the actions of extracellular Ca2+ on parathyroid and kidney cells? Brown EM, et al. **Kidney Int** 1996 Apr;49(4):1042-6 (37 ref.)

Hypertension in African Americans: the role of sodium chloride and extracellular fluid volume. Weinberger MH. **Semin Nephrol** 1996 Mar;16(2):110-6 (49 ref.)

EXTRACHROMOSOMAL INHERITANCE

Uniparental inheritance of mitochondrial and chloroplast genes: mechanisms and evolution. Birky CW Jr. **Proc Natl Acad Sci U S A** 1995 Dec 5;92(25):11331-8 (96 ref.)

[The analysis of maternal inheritance of mitochondrial DNA in mammal] Kaneda H, et al. **Seikagaku** 1996 Apr; 68(4):282-5 (14 ref.) **(Jpn)**

EXTRACORPOREAL CIRCULATION

[Unilateral pulmonary embolectomy without extracorporeal circulation. A report of a clinical case] Barboso G, et al. **Acta Biomed Ateneo Parmense** 1995;66(1-2):53-5 (10 ref.) (Eng. Abstr.) **(Ita)**

[Biocompatibility and extracorporeal circulation] Camici M. **Clin Ter** 1995 Nov;146(11):713-9 (30 ref.) (Eng. Abstr.) **(Ita)**

[Removal of infected pacemaker leads in the elderly under extracorporeal circulation: two case reports and review of Japanese literature] Sato M, et al. **Kyobu Geka** 1995 Nov; 48(12):1009-12 (11 ref.) (Eng. Abstr.) **(Jpn)**

INSTRUMENTATION

[Pulmonary (side)effects of extracorporeal therapy procedures] Kolb G. **Wien Klin Wochenschr Suppl** 1996; 1:15-20 (42 ref.) **(Ger)**

[Activation of blood coagulation in extracorporeal circulation] Nowak G. **Wien Klin Wochenschr Suppl** 1996; 1:9-14 (28 ref.) **(Ger)**

[Clinical aspects of biocompatibility] Schiffl H, et al. **Wien Klin Wochenschr Suppl** 1996;1:4-8 (27 ref.) **(Ger)**

METHODS

Extracorporeal treatment of acute renal failure: methods, indications, quantified and personalized therapeutic approach. Canaud B, et al. **Adv Nephrol Necker Hosp** 1995; 24:271-313 (109 ref.)

Maintaining blood flow in the extracorporeal circuit: haemostasis and anticoagulation. Webb AR, et al. **Intensive Care Med** 1995 Jan;21(1):84-93 (77 ref.)

STANDARDS

Practical aspects of renal replacement therapy. Kox WJ, et al. **Int J Artif Organs** 1996 Feb;19(2):100-5 (17 ref.)

TRENDS

The next generation extracorporeal method for the management of atherosclerosis [editorial] Matsuda Y, et al. **Artif Organs** 1995 Sep;19(9):877-9 (22 ref.)

EXTRACORPOREAL DIALYSIS see HEMODIALYSIS

EXTRACORPOREAL MEMBRANE OXYGENATION

Commentary on neonatal ECMO: a North American and Scandinavian perspective. Milerad J, et al. **Acta Paediatr** 1995 Aug;84(8):841-7 (69 ref.)

Heparin-bonded surfaces in extracorporeal membrane oxygenation for cardiac support. von Segesser LK. **Ann Thorac Surg** 1996 Jan;61(1):330-5; discussion 340-1 (28 ref.)

Extracorporeal life support (ECLS) for adult respiratory failure: the North American Experience. Bartlett RH, et al. **Int J Artif Organs** 1995 Oct;18(10):620-3 (10 ref.)

Extracorporeal membrane oxygenation (ECMO) for cardiorespiratory failure in children: the Leicester experience. Firmin RK, et al. **Int J Artif Organs** 1995 Oct; 18(10):603-6 (23 ref.)

Congenital diaphragmatic hernia. Frenckner B. **Int J Artif Organs** 1995 Oct;18(10):579-83 (24 ref.)

Clinical application of novel ventilation techniques. Müller E. **Int J Artif Organs** 1995 Oct;18(10):656-69 (140 ref.)

Treatment of ARDS with nitric oxide and ECMO. Pappert D, et al. **Int J Artif Organs** 1995 Oct;18(10):611-9 (40 ref.)

Neonatal ECMO: are indications changing? Short BL. **Int J Artif Organs** 1995 Oct;18(10):562-4 (20 ref.)

Severity and outcome of ARDS: the present place of extracorporeal lung assist (ECLA). Steltzer H, et al. **Int J Artif Organs** 1995 Oct;18(10):607-10 (11 ref.)

Benefits of extracorporeal membrane oxygenation for hydrocarbon pneumonitis. Chyka PA. **J Toxicol Clin Toxicol** 1996;34(4):357-63 (34 ref.)

Alveolar capillary dysplasia--a cause of persistent pulmonary hypertension unresponsive to a second course of extracorporeal membrane oxygenation. Chelliah BP, et al. **Pediatrics** 1995 Dec;96(6):1159-61 (13 ref.)

METHODS

Risks of extracorporeal membrane oxygenation: is there a role for use in the management of the acutely poisoned patient? Banner W Jr. **J Toxicol Clin Toxicol** 1996; 34(4):365-71 (18 ref.)

STANDARDS

Current status of extracorporeal membrane oxygenation for severe respiratory failure. Ichiba S, et al. **Artif Organs** 1996 Feb;20(2):120-3 (12 ref.)

EXTRACORPOREAL PHOTOCHEMOTHERAPY see PHOTOPHERESIS

EXTRACORPOREAL PHOTOPHERESIS see PHOTOPHERESIS

EXTRACORPOREAL SHOCKWAVE LITHOTRIPSY see LITHOTRIPSY

EXTRACRANIAL-INTRACRANIAL ARTERIAL BYPASS see CEREBRAL REVASCULARIZATION

EXTRACTION, OBSTETRICAL

see related
OBSTETRICAL FORCEPS

EXTRADURAL INJECTIONS see INJECTIONS, EPIDURAL

EXTRAHEPATIC BILIARY SYSTEM see BILE DUCTS, EXTRAHEPATIC

EXTRAORAL TRACTION APPLIANCES

ADVERSE EFFECTS

A review of orthodontic face-bow injuries and safety equipment. Samuels RH. **Am J Orthod Dentofacial Orthop** 1996 Sep;110(3):269-72 (13 ref.)

EXTRAORDINARY TREATMENT see LIFE SUPPORT CARE

EXTRAPYRAMIDAL DISORDERS see BASAL GANGLIA DISEASES

EXTRASENSORY PERCEPTION see PARAPSYCHOLOGY

EXTRASYSTOLE see CARDIAC COMPLEXES, PREMATURE

EXTRASYSTOLE, ATRIAL see ATRIAL PREMATURE COMPLEXES

EXTRASYSTOLE, VENTRICULAR see VENTRICULAR PREMATURE COMPLEXES

EXTRATERRESTRIAL ENVIRONMENT

see related
MOON

[The problem of the effect of cosmogeophysical factors on the formation of the properties of developing organisms during early ontogeny] Semenenia IN. **Aviakosm Ekolog Med** 1995;29(3):19-21 (27 ref.) (Eng. Abstr.) **(Rus)**

EXTRAVASATION OF CONTRAST MEDIA see EXTRAVASATION OF DIAGNOSTIC AND THERAPEUTIC MATERIALS

EXTRAVASATION OF DIAGNOSTIC AND THERAPEUTIC MATERIALS

DIAGNOSIS

Extravasation of radiographic contrast material: recognition, prevention, and treatment. Cohan RH, et al. **Radiology** 1996 Sep;200(3):593-604 (91 ref.)

THERAPY

[The treatment of extravasation of drugs] Takx-Köhlen BC,

et al. **Ned Tijdschr Geneeskd** 1996 Feb 24;140(8):418–22 (21 ref.) **(Dut)**

EXTREMITIES

Limb–sparing therapy for soft tissue sarcomas. Pollock RE. **Curr Opin Gen Surg** 1994;:224–9 (13 ref.)
The origin of vertebrate limbs. Coates MI. **Dev Suppl** 1994; :169–80 (116 ref.)
Tumor size and prognosis in aggressively treated osteosarcoma. Bieling P, et al. **J Clin Oncol** 1996 Mar; 14(3):848–58 (38 ref.)

ABNORMALITIES

Rehabilitation in limb deficiency. 2. The pediatric amputee. Jain S. **Arch Phys Med Rehabil** 1996 Mar;77(3 Suppl):S9–13 (42 ref.)
The CHILD nevus: a distinct skin disorder. Happle R, et al. **Dermatology** 1995;191(3):210–6 (64 ref.)
Limb length discrepancy. Dahl MT. **Pediatr Clin North Am** 1996 Aug;43(4):849–65 (11 ref.)
Orthopedic conditions of small ruminants. Llama, sheep, goat, and deer. Kaneps AJ. **Vet Clin North Am Food Anim Pract** 1996 Mar;12(1):211–31 (51 ref.)

BLOOD SUPPLY

Peripheral thrombolysis: state of the art. Earnshaw JJ, et al. **Cardiovasc Surg** 1995 Aug;3(4):357–67 (28 ref.)
Venography of the extremities and pelvis. Spritzer CE. **Magn Reson Imaging Clin N Am** 1993 Dec;1(2):239–51 (28 ref.)
[Do we still need a blood–free field?] Sarkar MR. **Unfallchirurg** 1996 May;99(5):374–8 (40 ref.) **(Ger)**

EMBRYOLOGY

Growth factor interactions in limb development. Niswander L. **Ann N Y Acad Sci** 1996 Jun 8;785:23–6 (15 ref.)
Retinoid signaling in vertebrate limb development. Thaller C, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:1–11 (58 ref.)
Limb development. The budding role of FGF. Tanaka EM, et al. **Curr Biol** 1995 Jun 1;5(6):594–7 (15 ref.)
Evolutionary developmental biology of the tetrapod limb. Hinchliffe JR. **Dev Suppl** 1994;:163–8 (115 ref.)
Micromass cultures of limb and other mesenchyme. Daniels K, et al. **Methods Cell Biol** 1996;51:237–47 (24 ref.)
Operations on limb buds of avian embryos. Saunders JW Jr. **Methods Cell Biol** 1996;51:125–45 (30 ref.)
Cell death in the embryonic developing limb. Hurle JM, et al. **Scanning Microsc** 1995 Jun;9(2):319–33; discussion 333–4 (118 ref.)
[Induction of an additional limb by FGF and duplication of digits by Sonic hedgehog] Ohuchi H, et al. **Seikagaku** 1995 Oct;67(10):1232–6 (16 ref.) **(Jpn)**

GROWTH & DEVELOPMENT

Vertebrate limb development. Tickle C. **Curr Opin Genet Dev** 1995 Aug;5(4):478–84 (31 ref.)
Significance of programmed cell death (apoptosis) in mammalian limb and palate development. Mori C. **Kaibogaku Zasshi** 1995 Dec;70(6):503–8 (12 ref.)

INJURIES

The epidemiology of peripheral fractures. Baron JA, et al. **Bone** 1996 Mar;18(3 Suppl):209S–213S (29 ref.)

INNERVATION

Perspectives on the role of afferent signals in control of motor neuroprostheses. Johnson KO, et al. **Med Eng Phys** 1995 Oct;17(7):481–96 (99 ref.)

PHYSIOLOGY

Field analysis of a tape helix with embedded bio–media for microwave hyperthermia. Pathak SK, et al. **J Med Eng Technol** 1996 Jan–Feb;20(1):24–33 (23 ref.)
Transdifferentiation as a basis for amphibian limb regeneration. Tsonis PA, et al. **Semin Cell Biol** 1995 Jun; 6(3):127–35 (58 ref.)

SURGERY

Soft–tissue sarcoma of the extremities. MR appearance of post–treatment changes and local recurrences. Varma DG, et al. **Magn Reson Imaging Clin N Am** 1995 Nov; 3(4):695–712 (59 ref.)
Operations on limb buds of avian embryos. Saunders JW Jr. **Methods Cell Biol** 1996;51:125–45 (30 ref.)
[Surgical therapy of soft tissue sarcomas II. Sarcomas of the extremities and their surgical resection] Karakousis CP. **Chirurg** 1995 Oct;66(10):1006–15 (9 ref.) (Eng. Abstr.) **(Ger)**

TRANSPLANTATION

[Homologous transplantation of a limb (compound tissue): perspective for the future] Ferreira LM, et al. **Rev Assoc Med Bras** 1995 Mar–Apr;41(2):151–7 (73 ref.) **(Por)**

EXTREMITIES, ARTIFICIAL see **ARTIFICIAL LIMBS**

EXTREMITY, LOWER see **LEG**

EXTREMITY, UPPER see **ARM**

EXUDATES AND TRANSUDATES

see related
ASCITIC FLUID
PERICARDIAL EFFUSION
PLEURAL EFFUSION

Seromas in the breast: imaging findings. Soo MS, et al. **Crit Rev Diagn Imaging** 1995;36(5):385–440 (34 ref.)

CHEMISTRY

[Coagulation and fibrinolysis parameters in neoplastic pleural exudates] Talalaj J. **Pneumonol Alergol Pol** 1995; 63(5–6):339–43 (15 ref.) **(Pol)**

METABOLISM

Presence and distribution of growth factors in breast cyst fluid. Zanardi S, et al. **Ann N Y Acad Sci** 1996 Apr 30; 784:542–9 (27 ref.)

EYE

see related
INTRAOCULAR PRESSURE
REFRACTION, OCULAR
VISION

ANATOMY & HISTOLOGY

New perspectives on eye evolution. Halder G, et al. **Curr Opin Genet Dev** 1995 Oct;5(5):602–9 (68 ref.)
Normal values of ocular protrusion in Saudi Arabian male children. Osuobeni EP, et al. **Optom Vis Sci** 1995 Aug; 72(8):557–64 (18 ref.)

BLOOD SUPPLY

Color Doppler ultrasound imaging of the eye and orbit. Williamson TH, et al. **Surv Ophthalmol** 1996 Jan–Feb; 40(4):255–67 (69 ref.)

CHEMISTRY

Histological study of oxalosis in the eye and adnexa of AIDS patients. Pecorella I, et al. **Histopathology** 1995 Nov; 27(5):431–8 (22 ref.)

DRUG EFFECTS

Determination of the intra– and interlaboratory reproducibility of the low volume eye test and its statistical relationship to the Draize eye test. Cormier EM, et al. **Regul Toxicol Pharmacol** 1996 Apr;23(2):156–61 (23 ref.)
[Drug side–effects of the eye—a contribution to quality assurance in ophthalmology] Dangelmaier S, et al. **Klin Monatsbl Augenheilkd** 1996 May;208(5):385–8 (4 ref.) (Eng. Abstr.) **(Ger)**

EMBRYOLOGY

Genetic aspects of embryonic eye development in vertebrates. Graw J. **Dev Genet** 1996;18(3):181–97 (146 ref.)

GROWTH & DEVELOPMENT

Retinal–image mediated ocular growth as a mechanism for juvenile onset myopia and for emmetropization. A literature review. Goss DA, et al. **Doc Ophthalmol** 1995; 90(4):341–75 (182 ref.)
Early refractive development in humans. Saunders KJ. **Surv Ophthalmol** 1995 Nov–Dec;40(3):207–16 (72 ref.)

IMMUNOLOGY

Immunological non–responsiveness and acquisition of tolerance in relation to immune privilege in the eye. Streilein JW. **Eye** 1995;9 (Pt 2):236–40 (28 ref.)
Ocular immune privilege and the Faustian dilemma. The Proctor lecture. Streilein JW. **Invest Ophthalmol Vis Sci** 1996 Sep;37(10):1940–50 (36 ref.)

INNERVATION

The sympathetic innervation of the eyes and face: a clinicoanatomic review. Watson C, et al. **Clin Anat** 1995; 8(4):262–72 (44 ref.)

METABOLISM

Clinical pharmacokinetics of various topical ophthalmic delivery systems. Frangie JP. **Clin Pharmacokinet** 1995 Aug;29(2):130–8 (37 ref.)

MICROBIOLOGY

Paediatric post–traumatic endophthalmitis. Alfaro DV, et al. **Br J Ophthalmol** 1995 Oct;79(10):888–91 (22 ref.)
Analysis of ocular microbial adhesion. Hazlett LD. **Methods Enzymol** 1995;253:53–66 (29 ref.)

PATHOLOGY

Apoptosis and oncosis in ocular disease. Heathcote JG. **Can J Ophthalmol** 1995 Oct;30(6):298–300 (14 ref.)
[Treatment with silicone oil in complicated retinal detachment. Anatomopathological test of 2 enucleated eyes] Bacin F, et al. **J Fr Ophtalmol** 1996;19(1):13–8 (25 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Oculocentric spatial representation in parietal cortex. Colby CL, et al. **Cereb Cortex** 1995 Sep–Oct;5(5):470–81 (38 ref.)
New perspectives on eye evolution. Halder G, et al. **Curr Opin Genet Dev** 1995 Oct;5(5):602–9 (68 ref.)
Age–related changes in visual function and visual organs of rats. Kiyosawa I. **Exp Anim** 1996 Apr;45(2):103–14 (34 ref.)
The integrin superfamily and the eye. Elner SG, et al. **Invest Ophthalmol Vis Sci** 1996 Apr;37(5):696–701 (12 ref.)
Animal models of emmetropization: matching axial length to the focal plane. Norton TT, et al. **J Am Optom Assoc** 1995 Jul;66(7):405–14 (87 ref.)
Theory meets experiment: correlated neural activity helps determine ocular dominance column periodicity. Goodhill GJ, et al. **Trends Neurosci** 1995 Oct;18(10):437–9 (38 ref.)
[Morphologic adaptation of the vertebrate eye to the environment] Puzzolo D. **Arch Ital Anat Embriol** 1994 Oct–Dec;99(4):17–100 (250 ref.) **(Ita)**

PHYSIOPATHOLOGY

[Nystagmus and other anomalous movements of the eye] Prats Viñas JM. **Rev Neurol** 1995;23 Suppl 3:S359–62 (25 ref.) **(Spa)**

RADIATION EFFECTS

Light damage revisited: converging evidence, diverging views? Remé C, et al. **Graefes Arch Clin Exp Ophthalmol** 1996 Jan;234(1):2–11 (88 ref.)
Bactericidal UV–C lamp misuse [letter] [corrected] [published erratum appears in Isr J Med Sci 1995 Nov;31(11):701] Zamir E. **Isr J Med Sci** 1995 Sep;31(9):578 (5 ref.)
Solar ultraviolet radiation and ocular disease: a review of the epidemiological and experimental evidence. Dolin PJ, et al. **Ophthalmic Epidemiol** 1994 Dec;1(3):155–64 (79 ref.)
Methodological considerations for future epidemiological studies of solar ultraviolet radiation and eye disease. Dolin PJ. **Ophthalmic Epidemiol** 1994 Dec;1(3):165–70 (16 ref.)

SURGERY

Perfluorocarbon heavy liquids. Bourke RD, et al. **Aust N Z J Ophthalmol** 1995 Aug;23(3):165–71 (40 ref.)
Laser–tissue interactions. Carr LW 3rd, et al. **Optom Clin** 1995;4(4):17–31 (31 ref.)

ULTRASONOGRAPHY

Color Doppler ultrasound imaging of the eye and orbit. Williamson TH, et al. **Surv Ophthalmol** 1996 Jan–Feb; 40(4):255–67 (69 ref.)

EYE ABNORMALITIES

COMPLICATIONS

Ophthalmologic abnormalities in encephalocraniocutaneous lipomatosis. MacLaren MJ, et al. **Doc Ophthalmol** 1995; 90(1):87–98 (31 ref.)
Fraser syndrome (cryptophthalmos [hidden eye]–syndactyly syndrome). Sarman G, et al. **J Perinatol** 1995 Nov–Dec; 15(6):503–6 (12 ref.)

EMBRYOLOGY

Ocular anomalies: embryological implications. Miller MT. **Acta Ophthalmol Scand** 1995;73 Suppl 214:4–9; discussion 9–11 (30 ref.)
Ocular anomalies: embryological implications. Miller MT. **Acta Ophthalmol Scand Suppl** 1995;(214):4–9; discussion 9–11 (30 ref.)

ETIOLOGY

[Williams–Beuren syndrome: diagnosis and ocular manifestations] Offret H, et al. **J Fr Ophtalmol** 1995; 18(11):699–702 (13 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Kaufman oculocerebrofacial syndrome in a girl of 15 years. Briscioli V, et al. **Am J Med Genet** 1995 Jul 31;58(1):21–3 (6 ref.)
Happenstance, circumstance or enemy action: cyclin D1 in breast, eye and brain. Schmidt EV. **Bioessays** 1996 Jan; 18(1):6–8 (29 ref.)
The frequency of genetic eye diseases in a genetic counseling center. Elçioğlu N, et al. **Genet Couns** 1995;6(4):329–42 (31 ref.)
Transgenic models for eye malformations. Götz W. **Ophthalmic Genet** 1995 Sep;16(3):85–104 (160 ref.)
Pax6: more than meets the eye. Hanson I, et al. **Trends Genet** 1995 Jul;11(7):268–72 (41 ref.)
[Schimmelpenning–Feuerstein–Mims syndrome and its neurologic manifestations. 6 personal cases and review of the literature] Fritzsch C, et al. **Klin Padiatr** 1995 Sep–Oct; 207(5):288–97 (40 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Rehabilitation of a child with partial unilateral cryptophthalmos and multiple congenital anomalies. Konrad H, et al. **Trans Am Ophthalmol Soc** 1995;93:219–40; discussion 241–4 (121 ref.)

EYE DISEASES

Vitreoretinal emergencies. Reichel E. **Am Fam Physician** 1995 Oct;52(5):1415–9 (16 ref.)
Infections of the eye. Baum J. **Clin Infect Dis** 1995 Sep; 21(3):479–86; quiz 487–8 (10 ref.)
Cicatricial pemphigoid: diagnosis and treatment. Nguyen QD, et al. **Int Ophthalmol Clin** 1996 Winter;36(1):41–60 (52 ref.)
Primary care for women. Management of common problems of the head and neck. Phillips LP, et al. **J Nurse Midwifery** 1996 Mar–Apr;41(2):101–16 (55 ref.)

CHEMICALLY INDUCED

Tamoxifen–associated eye disease. A review. Nayfield SG, et al. **J Clin Oncol** 1996 Mar;14(3):1018–26 (58 ref.)
Medications used to prevent migraine headaches and their potential ocular adverse effects. Doughty MJ, et al. **Optom Vis Sci** 1995 Dec;72(12):879–91 (176 ref.)
[Drug side–effects of the eye—a contribution to quality assurance in ophthalmology] Dangelmaier S, et al. **Klin Monatsbl Augenheilkd** 1996 May;208(5):385–8 (4 ref.) (Eng. Abstr.) **(Ger)**

CLASSIFICATION

Evolution of classification systems for Graves' ophthalmopathy. Bartley GB. **Ophthal Plast Reconstr Surg** 1995 Dec;11(4):229–37 (48 ref.)

COMPLICATIONS

Ocular complication in HIV infected individuals. Harrison TJ. **Alaska Med** 1995 Jul–Sep;37(3):91–100 (78 ref.)
Preventing blindness in Americans: the need for eye health education. Javitt JC. **Surv Ophthalmol** 1995 Jul–Aug; 40(1):41–4 (25 ref.)

DIAGNOSIS

Ocular and orbital imaging. Mafee MF, et al. **Neuroimaging Clin N Am** 1996 May;6(2):291–318 (84 ref.)
[Neuroradiology in ophthalmology. 2] Müller–Forell W, et al. **Ophthalmologe** 1995 Oct;92(5):757–84 (26 ref.) **(Ger)**
[Neuroradiology in ophthalmology. 1] Müller–Forell W, et al. **Ophthalmologe** 1995 Aug;92(4):595–614 (0 ref.) **(Ger)**
[Retinal antigens in eye diseases—clinical value of diagnostic tests] Misiuk–Hojlo M, et al. **Klin Oczna** 1995 Mar–Apr; 97(3–4):86–9 (26 ref.) (Eng. Abstr.) **(Pol)**

DRUG THERAPY

Corticosteroid therapy of eye disease. Fifty years later [editorial; comment] Raizman M. **Arch Ophthalmol** 1996 Aug;114(8):1000–1 (25 ref.) Comment on: Arch Ophthalmol 1996 Aug;114(8):933–7.
The emerging roles of topical non–steroidal anti–inflammatory agents in ophthalmology. Koay P. **Br J Ophthalmol** 1996 May;80(5):480–5 (98 ref.)
Cytokine antagonists: new ideas for the management of Graves' ophthalmopathy [editorial; comment] Bartalena L, et al. **J Clin Endocrinol Metab** 1996 Feb;81(2):446–8 (15 ref.) Comment on: J Clin Endocrinol Metab 1996 Feb;81(2):449–52.
Botulinum neurotoxin A in ophthalmology. Bentley C. **Ophthalmic Physiol Opt** 1996 Mar;16 Suppl 1:S9–14 (43 ref.)

EPIDEMIOLOGY

Clinical epidemiology: what, why and how? Nath R, et al. **Indian J Ophthalmol** 1995 Jun;43(2):83–7 (13 ref.)
Methodological considerations for future epidemiological studies of solar ultraviolet radiation and eye disease. Dolin PJ. **Ophthalmic Epidemiol** 1994 Dec;1(3):165–70 (16 ref.)
Solar ultraviolet radiation and ocular disease: a review of the epidemiological and experimental evidence. Dolin PJ, et al. **Ophthalmic Epidemiol** 1994 Dec;1(3):155–64 (79 ref.)
Methods for a population–based study of eye disease: the Melbourne Visual Impairment Project. Livingston PM, et al. **Ophthalmic Epidemiol** 1994 Dec;1(3):139–48 (32 ref.)
Epidemiology of blindness and eye disease. Krumpaszky HG, et al. **Ophthalmologica** 1996;210(1):1–84 (293 ref.)

ETHNOLOGY

The prevalence of eye disease in elderly Bengalis in Tower Hamlets. Gray PJ. **J R Soc Med** 1996 Jan;89(1):23–6 (17 ref.)

ETIOLOGY

AIDS and the eye. A 10–year experience. Maclean H, et al. **Aust N Z J Ophthalmol** 1996 Feb;24(1):61–7 (18 ref.)
The eye in systemic disease. Stanbury RM, et al. **Br J Hosp Med** 1996 Jan 17–Feb 6;55(1–2):19–26 (16 ref.)
Sarcoidosis and its ocular manifestations. Smith JA, et al. **Int Ophthalmol Clin** 1996 Winter;36(1):109–25 (77 ref.)
Neuro–ophthalmology and systemic disease—Part II. An annual review (1994). Newman NJ. **J Neuroophthalmol** 1995 Dec;15(4):241–53 (134 ref.)
Neuro–ophthalmology and systemic disease—Part I. An annual review (1994). Newman NJ. **J Neuroophthalmol** 1995 Jun;15(2):109–21 (136 ref.)
AIDS and the eyes. Sarraf D, et al. **Lancet** 1996 Aug 24; 348(9026):525–8 (30 ref.)
Nutrition and metabolic eye disease. Haddad HM. **Metab Pediatr Syst Ophthalmol** 1994;17(1–4):41–4 (11 ref.)
Solar ultraviolet radiation and ocular disease: a review of the epidemiological and experimental evidence. Dolin PJ, et al. **Ophthalmic Epidemiol** 1994 Dec;1(3):155–64 (79 ref.)
Complications of anterior segment laser procedures. Carr LW 3rd, et al. **Optom Clin** 1995;4(4):33–49 (50 ref.)
Ocular disorders in women. Figueroa FX, et al. **R I Med** 1995 Dec;78(12):352–5 (5 ref.)
Diabetic eye disease: a primary care perspective. Frank KJ, et al. **South Med J** 1996 May;89(5):463–70 (25 ref.)
Involvement of the orbital fibroblast and TSH receptor in the pathogenesis of Graves' ophthalmopathy. Heufelder AE. **Thyroid** 1995 Aug;5(4):331–40 (84 ref.)
[Ocular involvement in Basedow disease. Therapeutic strategy] Le Jeunne C, et al. **Ann Med Interne (Paris)** 1996; 147(2):93–8 (38 ref.) **(Fre)**
[The ocular manifestations in systemic lupus erythematosus] Gheorghiu M. **Oftalmologia** 1996 Apr–Jun;40(2):100–4 (22 ref.) (Eng. Abstr.) **(Rum)**

GENETICS

The frequency of genetic eye diseases in a genetic counseling center. Elçioğlu N, et al. **Genet Couns** 1995;6(4):329–42 (31 ref.)
Transgenic models for eye malformations. Götz W. **Ophthalmic Genet** 1995 Sep;16(3):85–104 (160 ref.)
Ophthalmic manifestations of Smith–Magenis syndrome. Chen RM, et al. **Ophthalmology** 1996 Jul;103(7):1084–91 (29 ref.)

IMMUNOLOGY

Allergic and immunologic pediatric disorders of the eye. Bielory L, et al. **J Investig Allergol Clin Immunol** 1995 Nov–Dec;5(6):309–17 (33 ref.)

METABOLISM

The emerging roles of topical non–steroidal anti–inflammatory agents in ophthalmology. Koay P. **Br J Ophthalmol** 1996 May;80(5):480–5 (98 ref.)

PATHOLOGY

Apoptosis and oncosis in ocular disease. Heathcote JG. **Can J Ophthalmol** 1995 Oct;30(6):298–300 (14 ref.)

PREVENTION & CONTROL

Immunotolerance and prevention of ocular autoimmune disease. Rizzo LV, et al. **Curr Eye Res** 1995 Sep; 14(9):857–64 (99 ref.)
The risk intraocular juvenile xanthogranuloma: survey of current practices and assessment of risk. Chang MW, et al. **J Am Acad Dermatol** 1996 Mar;34(3):445–9 (26 ref.)
Epidemiological aspects, development and management of prevention in ophthalmology in relation to different ages. Nuzzi R, et al. **Panminerva Med** 1995 Mar;37(1):28–37 (19 ref.)

SURGERY

Lasers in ophthalmology. Krauss JM, et al. **Lasers Surg Med** 1995;17(2):102–59 (536 ref.)
Laser photocoagulation using binocular indirect ophthalmoscope laser delivery systems. Friberg TR. **Ophthalmic Surg Lasers** 1995 Nov–Dec;26(6):549–59 (18 ref.)
Laser–tissue interactions. Carr LW 3rd, et al. **Optom Clin** 1995;4(4):17–31 (31 ref.)

THERAPY

Management of ocular emergencies and urgent eye problems. Garcia GE. **Am Fam Physician** 1996 Feb 1;53(2):565–74 (07 ref.)
Towards cytokine insight in sight. Rosenbaum JT. **Br J Ophthalmol** 1995 Nov;79(11):970–1 (15 ref.)

ULTRASONOGRAPHY

Ocular ultrasound. Fielding JA. **Clin Radiol** 1996 Aug; 51(8):533–44 (35 ref.)
Orbital sonography in children. Ramji FG, et al. **Pediatr Radiol** 1996;26(4):245–58 (70 ref.)

EYE DISEASES, HEREDITARY

PATHOLOGY

Ocular amyloidosis, with special reference to the hereditary forms with vitreous involvement. Sandgren O. **Surv Ophthalmol** 1995 Nov–Dec;40(3):173–96 (261 ref.)

EYE ENUCLEATION

Metastatic choroidal melanoma to the contralateral orbit 40 years after enucleation. Coupland SE, et al. **Arch Ophthalmol** 1996 Jun;114(6):751–6 (27 ref.)

EYE EVISCERATION

see related
EYE ENUCLEATION

EYE FOREIGN BODIES

SURGERY

An unusual intraocular foreign body. Gupta AK, et al. **Acta Ophthalmol Scand** 1996 Apr;74(2):200–1 (3 ref.)

VETERINARY

Ocular and orbital porcupine quills in the dog: a review and case series. Grahn BH, et al. **Can Vet J** 1995 Aug; 36(8):488–93 (24 ref.)

EYE HEMORRHAGE

DRUG THERAPY

[Intraocular hemorrhage of diabetic etiology: current notions on pathogenesis and enzyme therapy] Evgrafov VIu, et al. **Vestn Oftalmol** 1995 Oct–Dec;111(4):35–7 (43 ref.) **(Rus)**

ETIOLOGY

Clinical syndrome of endocapsular hematoma: presentation of a collected series and review of the literature. Hagan JC 3rd, et al. **J Cataract Refract Surg** 1996 Apr;22(3):379–84 (18 ref.)
[Intraocular hemorrhage of diabetic etiology: current notions on pathogenesis and enzyme therapy] Evgrafov VIu, et al. **Vestn Oftalmol** 1995 Oct–Dec;111(4):35–7 (43 ref.) **(Rus)**

EYE INFECTIONS

COMPLICATIONS

Acquired immunodeficiency syndrome (AIDS) and the eye. Armstrong RA. **Ophthalmic Physiol Opt** 1995 Sep;15 Suppl 2:S42–8 (25 ref.)

THERAPY

A practical guideline for management of endophthalmitis. Peyman GA, et al. **Ophthalmic Surg** 1995 Jul–Aug; 26(4):294–303 (95 ref.)

EYE INFECTIONS, BACTERIAL

DRUG THERAPY

Antibacterial agents in infections of the central nervous system and eye. Papastamelos AG, et al. **Infect Dis Clin North Am** 1995 Sep;9(3):615–37 (81 ref.)

ETIOLOGY

Chronic blepharitis: a review. Smith RE, et al. **CLAO J** 1995 Jul;21(3):200–7 (81 ref.)

PREVENTION & CONTROL

Controversies in endophthalmitis prevention. The risk for emerging resistance to vancomycin [editorial; comment] Alfonso EC, et al. **Arch Ophthalmol** 1995 Nov; 113(11):1369–70 (15 ref.) Comment on: Arch Ophthalmol 1995 Nov;113(11):1353–4.

THERAPY

The endophthalmitis vitrectomy study [editorial; comment] [see comments] Forster RK. **Arch Ophthalmol** 1995 Dec; 113(12):1555–7 (6 ref.) Comment on: Arch Ophthalmol 1995 Dec;113(12):1479–96. Comment in: Arch Ophthalmol 1996 Aug;114(8):1025; discussion 1026–7. Comment in: Arch Ophthalmol 1996 Aug;114(8):1029–30; discussion 1028–9.

VETERINARY

Antimicrobial agents for treatment of infectious keratitis in horses. Moore CP, et al. **J Am Vet Med Assoc** 1995 Oct 1;207(7):855–62 (29 ref.)

EYE INFECTIONS, FUNGAL

ETIOLOGY

Corneal phaeohyphomycosis due to Exserohilum rostratum. A case report and brief review. Kanungo R, et al. **Acta Ophthalmol Scand** 1996 Apr;74(2):197–9 (21 ref.)
Aspergillus endophthalmitis. An unrecognized endemic disease in orthotopic liver transplantation. Hunt KE, et al. **Ophthalmology** 1996 May;103(5):757–67 (65 ref.)

VETERINARY

Antimicrobial agents for treatment of infectious keratitis in horses. Moore CP, et al. **J Am Vet Med Assoc** 1995 Oct 1;207(7):855–62 (29 ref.)

EYE INFECTIONS, PARASITIC

[Human external ophthalmomyiasis: a bibliographic review apropos of cases in the Republic of Djibouti] Dorchies P, et al. **Bull Soc Pathol Exot** 1995;88(3):86-9 (40 ref.) (Eng. Abstr.) **(Fre)**

PARASITOLOGY

[2 cases of ocular infestation by Oestrus ovis (letter)] Boquet E, et al. **Enferm Infecc Microbiol Clin** 1995 Aug-Sep; 13(7):442-4 (9 ref.) **(Spa)**

EYE INFECTIONS, VIRAL

TRANSMISSION

AIDS and the contact lens practice. Slonim CB. **CLAO J** 1995 Oct;21(4):233-5 (19 ref.)

EYE INJURIES

COMPLICATIONS

Ruptured globes following radial and hexagonal keratotomy surgery [see comments] Vinger PF, et al. **Arch Ophthalmol** 1996 Feb;114(2):129-34 (51 ref.) Comment in: Arch Ophthalmol 1996 Feb;114(2):211-2.

Paediatric post-traumatic endophthalmitis. Alfaro DV, et al. **Br J Ophthalmol** 1995 Oct;79(10):888-91 (22 ref.)

DIAGNOSIS

Corneal abrasions: diagnosis and management. Torok PG, et al. **Am Fam Physician** 1996 Jun;53(8):2521-9, 2532 (26 ref.)

ETIOLOGY

Ocular injury from a rooster attack. Kronwith SD, et al. **Clin Pediatr (Phila)** 1996 Apr;35(4):219-20 (10 ref.)

PATHOLOGY

[Bilateral ocular blast injury after refractive surgery by 2 current techniques. Comparative anatomo-clinical analysis of a case] Schmitt-Bernard CF, et al. **J Fr Ophtalmol** 1996; 19(4):287-91 (19 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Lightning and electrical injuries: neuro-ophthalmologic aspects. Grover S, et al. **Semin Neurol** 1995 Dec; 15(4):335-41 (37 ref.)

THERAPY

Management of ocular emergencies and urgent eye problems. Garcia GE. **Am Fam Physician** 1996 Feb 1;53(2):565-74 (07 ref.)

Corneal abrasions: diagnosis and management. Torok PG, et al. **Am Fam Physician** 1996 Jun;53(8):2521-9, 2532 (26 ref.)

EYE INJURIES, PENETRATING

SURGERY

An unusual intraocular foreign body. Gupta AK, et al. **Acta Ophthalmol Scand** 1996 Apr;74(2):200-1 (3 ref.)

EYE MOTILITY DISORDERS see OCULAR MOTILITY DISORDERS

EYE MOVEMENT DISORDERS see OCULAR MOTILITY DISORDERS

EYE MOVEMENTS

see related
NYSTAGMUS
SLEEP, REM

The empirical status of the clinical application of eye movement desensitization and reprocessing. Lohr JM, et al. **J Behav Ther Exp Psychiatry** 1995 Dec;26(4):285-302 (67 ref.)

Eye movements as a window into real-time spoken language comprehension in natural contexts. Eberhard KM, et al. **J Psycholinguist Res** 1995 Nov;24(6):409-36 (44 ref.)

Behavioral and neuroimaging studies on schizophrenia in Japan. Shimazono Y, et al. **Psychiatry Clin Neurosci** 1995 Mar;49(1):3-11 (72 ref.)

[Special ocular movements in the neonate and Bell's phenomenon] Kuperman AA, et al. **Harefuah** 1996 Mar 1;130(5):333-6 (33 ref.) **(Heb)**

PHYSIOLOGY

A review of the role of efference copy in sensory and oculomotor control systems. Bridgeman B. **Ann Biomed Eng** 1995 Jul-Aug;23(4):409-22 (82 ref.)

Ocular motor systems. Part 2: Nuclear and supranuclear systems. Skarf B. **J Neuroophthalmol** 1995 Sep; 15(3):191-201 (74 ref.)

Evolution of control system models of ocular accommodation, vergence and their interaction. Eadie AS, et al. **Med Biol Eng Comput** 1995 Jul;33(4):517-24 (84 ref.)

Binocular eye movements and the perception of depth. Collewijn H, et al. **Rev Oculomot Res** 1990;4:213-61 (169 ref.)

The role of visual and cognitive processes in the control of eye movement. Kowler E. **Rev Oculomot Res** 1990; 4:1-70 (255 ref.)

Eye movements and reading. O'Regan JK. **Rev Oculomot Res** 1990;4:395-453 (204 ref.)

Predictive control of eye movement. Pavel M. **Rev Oculomot Res** 1990;4:71-114 (84 ref.)

Eye movement and visual localization of objects in space. Skavenski AA. **Rev Oculomot Res** 1990;4:263-87 (110 ref.)

Comparison of perception in the moving and stationary eye. Sperling G. **Rev Oculomot Res** 1990;4:307-51 (120 ref.)

The role of eye movement in the detection of contrast and spatial detail. Steinman RM, et al. **Rev Oculomot Res** 1990; 4:115-212 (176 ref.)

Eye-movement models for arithmetic and reading performance. Suppes P. **Rev Oculomot Res** 1990;4:455-77 (53 ref.)

Eye movements in visual search: cognitive, perceptual and motor control aspects. Viviani P. **Rev Oculomot Res** 1990; 4:353-93 (235 ref.)

The role of eye movements in the perception of motion and shape. Wallach H. **Rev Oculomot Res** 1990;4:289-305 (24 ref.)

EYE NEOPLASMS

Tumors in the posterior pole. Edwards MG, et al. **Int Ophthalmol Clin** 1995 Fall;35(4):123-35 (48 ref.)

DIAGNOSIS

Intraocular retinoblastoma presenting as ocular and orbital inflammation. Foster BS, et al. **Int Ophthalmol Clin** 1996 Winter;36(1):153-60 (23 ref.)

[Retinoblastoma: clinical and molecular diagnostic aspects] Thonney F, et al. **Schweiz Rundsch Med Prax** 1996 Aug 27;85(35):1058-62 (17 ref.) (Eng. Abstr.) **(Fre)**

[A case of uncomplicated retinal astrocytoma] Ikeda T, et al. **Nippon Ganka Gakkai Zasshi** 1995 Sep;99(9):1052-5 (21 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Genetics of embryonal tumours of childhood: retinoblastoma, Wilms' tumour and neuroblastoma. Brodeur GM. **Cancer Surv** 1995;25:67-99 (209 ref.)

Role of transgenic mice in identification and characterization of tumour suppressor genes. Sharan SK, et al. **Cancer Surv** 1995;25:143-59 (103 ref.)

Genetics of retinoblastoma: implications for other human cancers. Yandell DW, et al. **Med Pediatr Oncol Suppl** 1996; 1:25-8 (17 ref.)

[Primary leiomyosarcoma of the liver 37 years after successful treatment of hereditary retinoblastoma] Abdelli N, et al. **Gastroenterol Clin Biol** 1996;20(5):502-5 (31 ref.) (Eng. Abstr.) **(Fre)**

[Genetics of retinoblastoma] Minoda K. **Nippon Rinsho** 1995 Nov;53(11):2774-8 (12 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Pathology of ocular melanomas. McCartney AC. **Br Med Bull** 1995 Jul;51(3):678-93 (56 ref.)

[Neurocutaneous syndromes with predominant vascular anomalies] Rodríguez-Barrionuevo AC. **Rev Neurol** 1996 Sep;24(133):1072-84 (121 ref.) **(Spa)**

PHYSIOPATHOLOGY

[Regressive bilateral retinoblastoma. Clinical and genetic study. Apropos of a case] Marrakchi S, et al. **J Fr Ophtalmol** 1995;18(5):390-5 (17 ref.) (Eng. Abstr.) **(Fre)**

RADIOTHERAPY

[External electron irradiation in 2 cases of capillary hemangioma of the optic disk] Schlienger P, et al. **Bull Cancer Radiother** 1995;82(3):306-10 (29 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Management of ocular melanoma. Hungerford JL. **Br Med Bull** 1995 Jul;51(3):694-716 (67 ref.)

ULTRASONOGRAPHY

Practical application of ultrasound biomicroscopy. Pavlin CJ. **Can J Ophthalmol** 1995 Jun;30(4):225-9 (44 ref.)

EYE PROTEINS

ADMINISTRATION & DOSAGE

Intraocular inflammatory disease (uveitis) and the use of oral tolerance: a status report. Nussenblatt RB, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:325-37 (23 ref.)

PHYSIOLOGY

The intermediate filament cytoskeleton of the lens: an ever changing network through development and differentiation. A minireview. Prescott AR, et al. **Ophthalmic Res** 1996;28 Suppl 1:58-61 (33 ref.)

Regulation of G protein-coupled receptors by receptor kinases and arrestins. Sterne-Marr R, et al. **Vitam Horm** 1995;51:193-234 (121 ref.)

EYEBROWS

SURGERY

Endoscopic browlift. Core GB, et al. **Clin Plast Surg** 1995 Oct;22(4):619-31 (16 ref.)

EYEDROPS see OPHTHALMIC SOLUTIONS

EYELASHES

An unusual intraocular foreign body. Gupta AK, et al. **Acta Ophthalmol Scand** 1996 Apr;74(2):200-1 (3 ref.)

EYELID CONDITIONING see CONDITIONING, EYELID

EYELID DISEASES

[Floppy eyelid syndrome. Apropos of 4 cases and review of the literature] Mortemousque B, et al. **J Fr Ophtalmol** 1995;18(8-9):542-7 (17 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

Meibomian gland dysfunction. Driver PJ, et al. **Surv Ophthalmol** 1996 Mar-Apr;40(5):343-67 (224 ref.)

DIAGNOSIS

Streptococcal gangrene of the eyelids and orbit. Shayegani A, et al. **Am J Ophthalmol** 1995 Dec;120(6):784-92 (49 ref.)

Dermatologic diagnosis and treatment of itchy red eyelids. Zug KA, et al. **Surv Ophthalmol** 1996 Jan-Feb; 40(4):293-306 (89 ref.)

PATHOLOGY

Multiple subepidermal calcified nodules on the eyelids [letter] Butt KI, et al. **Br J Dermatol** 1995 Oct;133(4):664-5 (8 ref.)

Infections of the eyelid, lacrimal system, conjunctiva, and cornea. Durand M, et al. **Curr Clin Top Infect Dis** 1996; 16:125-50 (150 ref.)

Lichen planus of the eyelids. Itin PH, et al. **Dermatology** 1995;191(4):350-1 (8 ref.)

[Xanthelasma palpebrarum] Kemler MA, et al. **Ned Tijdschr Geneeskd** 1996 May 11;140(19):1014-7 (38 ref.) **(Dut)**

EYELID NEOPLASMS

ETIOLOGY

[A case of Sjögren's syndrome with an eyelid tumor, a so-termed pseudolymphoma of the lacrimal gland] Takeshita S, et al. **Ryumachi** 1996 Feb;36(1):43-9 (17 ref.) (Eng. Abstr.) **(Jpn)**

RADIOGRAPHY

[Primary orbital lymphoma within the context of Sjögren's syndrome secondary to rheumatoid arthritis] Rasquin F, et al. **Bull Soc Belge Ophtalmol** 1994;254:125-32 (40 ref.) (Eng. Abstr.) **(Fre)**

EYELIDS

ABNORMALITIES

Blepharophimosis-ptosis-epicanthus inversus syndrome (BPES). Strømme P, et al. **Acta Ophthalmol Scand** 1996 Feb;74(1):45-7 (24 ref.)

Oculoauriculofrontonasal syndrome: report of another case and review of differential diagnosis. Toriello HV, et al. **Clin Dysmorphol** 1995 Oct;4(4):338-46 (25 ref.)

Rehabilitation of a child with partial unilateral cryptophthalmos and multiple congenital anomalies. Konrad H, et al. **Trans Am Ophthalmol Soc** 1995;93:219-40; discussion 241-4 (121 ref.)

[Cerebro-oculofacial dysplasia associated with vertebral changes] Munteanu G, et al. **Oftalmologia** 1995 Oct-Dec; 39(4):316-21 (10 ref.) (Eng. Abstr.) **(Rum)**

[The Hay-Wells syndrome, its incidence in Spain and a review of the literature] Martínez-Frías ML, et al. **An Esp Pediatr** 1996 Jul;45(1):101-4 (24 ref.) **(Spa)**

PHYSIOLOGY

Blepharospasm: report of a workshop. Hallett M, et al. **Neurology** 1996 May;46(5):1213-8 (43 ref.)

A line imaging system for measurement of eyelid movements. Gittins J, et al. **Physiol Meas** 1995 Nov;16(4):303-11 (6 ref.)

SURGERY

A new concept in blepharoplasty. de la Plaza R, et al. **Aesthetic Plast Surg** 1996 May-Jun;20(3):221-33 (30 ref.)

Ptosis repair and blepharoplasty in the adult. Older JJ. **Ophthalmic Surg** 1995 Jul-Aug;26(4):304-8 (1 ref.)

Rehabilitation of a child with partial unilateral cryptophthalmos and multiple congenital anomalies. Konrad H, et al. **Trans Am Ophthalmol Soc** 1995;93:219–40; discussion 241–4 (121 ref.)

F1 ATPASE see **H(+)-TRANSPORTING ATP SYNTHASE**

F(1)F(0)-ATPASE see **H(+)-TRANSPORTING ATP SYNTHASE**

F-ACTIN see **ACTINS**

FAB FRAGMENTS see **IMMUNOGLOBULINS, FAB**

FAB IMMUNOGLOBULINS see **IMMUNOGLOBULINS, FAB**

FABRY'S DISEASE

[Lysosomal storage diseases with angiokeratoma corporis diffusum] Kanzaki T. **Nippon Rinsho** 1995 Dec; 53(12):3062–7 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Fabry disease (alpha-galactosidase deficiency)] Okumiya T, et al. **Nippon Rinsho** 1995 Dec;53(12):2952–9 (21 ref.) (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

[Ictus and cutaneous vascular syndromes] Trejo Gabriel y Galán JM. **Rev Neurol** 1995;23 Suppl 1:S99–105 (46 ref.) **(Spa)**

FACE

Orofacial manifestations of child abuse and neglect. Jessee SA. **Am Fam Physician** 1995 Nov 1;52(6):1829–34 (38 ref.)

Is face recognition 'special'? Evidence from neuropsychology. Farah MJ. **Behav Brain Res** 1996 Apr; 76(1–2):181–9 (18 ref.)

The difficulty with recalling people's names: the plausible phonology hypothesis. Brennen T. **Memory** 1993 Dec; 1(4):409–31 (45 ref.)

Naming faces and naming names: exploring an interactive activation model of person recognition. Burton AM, et al. **Memory** 1993 Dec;1(4):457–80 (26 ref.)

Proper names and how they are learned. La Palme Reyes M, et al. **Memory** 1993 Dec;1(4):433–55 (32 ref.)

Epidemiologic review of pediatric and adult maxillofacial infections in hospitalized patients. Scutari P Jr, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Mar;81(3):270–4 (11 ref.)

Facial edema and giant cell arteritis. Plantin P, et al. **Rev Rhum Engl Ed** 1996 Feb;63(2):145–7 (13 ref.)

ABNORMALITIES

Abnormal craniofacial growth. Friede H. **Acta Odontol Scand** 1995 Jun;53(3):203–9 (53 ref.)

Inversion duplication of the short arm of chromosome 8: clinical data on seven patients and review of the literature. de Die-Smulders CE, et al. **Am J Med Genet** 1995 Nov 20;59(3):369–74 (16 ref.)

Kabuki make-up (Niikawa-Kuroki) syndrome in five Spanish children. Galán-Gómez E, et al. **Am J Med Genet** 1995 Nov 20;59(3):276–82 (30 ref.)

Prenatal exposure to phenytoin, facial development, and a possible role for vitamin K. Howe AM, et al. **Am J Med Genet** 1995 Sep 11;58(3):238–44 (52 ref.)

Fryns syndrome survivors and neurologic outcome. Van Hove JL, et al. **Am J Med Genet** 1995 Nov 20;59(3):334–40 (39 ref.)

Schinzel-Giedion syndrome: further delineation of the phenotype. Elliott AM, et al. **Clin Dysmorphol** 1996 Apr; 5(2):135–42 (18 ref.)

Serpentine fibula syndrome: expansion of the phenotype with three affected siblings. Rosser EM, et al. **Clin Dysmorphol** 1996 Apr;5(2):105–13 (12 ref.)

Molecular biology experimental strategies for craniofacial-oral-dental dysmorphology. Slavkin HC. **Connect Tissue Res** 1995;32(1–4):233–9 (62 ref.)

Microcephaly, characteristic facies, joint abnormalities, and deficient leucocyte chemotaxis: a further case of the syndrome of Say et al. Perandones C, et al. **J Med Genet** 1996 Mar;33(3):227–9 (7 ref.)

What's in a face? [see comments] Winter RM. **Nat Genet** 1996 Feb;12(2):124–9 (40 ref.) Comment in: Nat Genet 1996 Feb;12(2):130–6.

[Striato-pallido-dentate calcifications and acquired facial atrophy] Derex L, et al. **Rev Neurol (Paris)** 1995 Oct; 151(10):559–62 (13 ref.) (Eng. Abstr.) **(Fre)**

[Congenital developmental defects of the face and jaws: their morbidity, mortality and risk factors] Beliakov SV, et al. **Stomatologiia (Mosk)** 1995;74(5):72–5 (66 ref.) **(Rus)**

ANATOMY & HISTOLOGY

Cephalometric analysis of Deutero-Malay Indonesians. Munandar S, et al. **Aust Dent J** 1995 Dec;40(6):381–8 (38 ref.)

Superimposition and reconstruction in forensic facial identification: a survey. Aulsebrook WA, et al. **Forensic Sci Int** 1995 Oct 30;75(2–3):101–20 (230 ref.)

Perspective of facial esthetics in dental treatment planning. Mack MR. **J Prosthet Dent** 1996 Feb;75(2):169–76 (48 ref.)

EMBRYOLOGY

Human prenatal craniofacial development related to brain development under normal and pathologic conditions. Kjaer I. **Acta Odontol Scand** 1995 Jun;53(3):135–43 (69 ref.)

Prenatal craniofacial development: new insights on normal and abnormal mechanisms [corrected and republished article originally printed in Crit Rev Oral Biol Med 1995;6(1):25–79] Johnston MC, et al. **Crit Rev Oral Biol Med** 1995;6(4):368–422 (405 ref.)

INNERVATION

The sympathetic innervation of the eyes and face: a clinicoanatomic review. Watson C, et al. **Clin Anat** 1995; 8(4):262–72 (44 ref.)

PATHOLOGY

Cervicofacial Actinomyces viscosus infection in a Brazilian fila: a case report and literature review. Donohue DE, et al. **J Am Anim Hosp Assoc** 1995 Nov-Dec;31(6):501–5 (20 ref.)

[Radiotherapy of cutaneous cervical-facial carcinomas] Tordiglione M, et al. **Acta Otorhinolaryngol Ital** 1995 Jun; 15(3):168–78; discussion 179 (18 ref.) (Eng. Abstr.) **(Ita)**

PHYSIOLOGY

Face recognition. What are faces for? Tovée MJ. **Curr Biol** 1995 May 1;5(5):480–2 (23 ref.)

SURGERY

Some aspects of bone formation and remodeling pertinent to craniofacial development and reconstructive treatment. Vargervik K. **Acta Odontol Scand** 1995 Jun;53(3):167–73 (16 ref.)

Injectable silicone: cause of facial nodules, cellulitis, ulceration, and migration. Rapaport MJ, et al. **Aesthetic Plast Surg** 1996 May-Jun;20(3):267–76 (34 ref.)

Soft tissue reconstructive choices for craniofacial reconstruction. Mustoe TA, et al. **Clin Plast Surg** 1995 Jul; 22(3):543–54 (41 ref.)

Dermabrasion, chemabrasion, and laserabrasion. Historical perspectives, modern dermabrasion techniques, and future trends. Fulton JE Jr. **Dermatol Surg** 1996 Jul;22(7):619–28 (52 ref.)

The current status of expanded polytetrafluoroethylene (Gore-Tex) in facial plastic surgery. Levine B, et al. **Ear Nose Throat J** 1995 Oct;74(10):681–2, 684 (17 ref.)

Recent advances in facial plastic and reconstructive surgery. Haddad NM. **J Med Liban** 1994;42(4):240–1 (14 ref.)

Economic analysis and its application to oral and maxillofacial surgery. Sandler NA, et al. **J Oral Maxillofac Surg** 1996 May;54(5):622–6 (12 ref.)

[Philosophy in reconstruction of the face] Faga A. **Acta Otorhinolaryngol Ital** 1995 Jun;15(3):164–6; discussion 167 (13 ref.) **(Ita)**

ULTRASONOGRAPHY

[The ultrasonic diagnosis of soft-tissue diseases of the maxillofacial area] Vorob'ev Iul. **Stomatologiia (Mosk)** 1995;74(2):74–7 (29 ref.) **(Rus)**

FACE BOW, ORTHODONTIC see **EXTRAORAL TRACTION APPLIANCES**

FACE LIFT see **RHYTIDOPLASTY**

FACIAL ASYMMETRY

EPIDEMIOLOGY

Picture of the month. Congenital hypoplasia of the depressor anguli oris muscle. Franco SM, et al. **Arch Pediatr Adolesc Med** 1996 Mar;150(3):325–6 (9 ref.)

ETIOLOGY

Perspectives on craniofacial asymmetry. V. The craniosynostoses. Cohen MM Jr. **Int J Oral Maxillofac Surg** 1995 Jun;24(3):191–4 (24 ref.)

Perspectives on craniofacial asymmetry. VI. The hamartoses. Cohen MM Jr. **Int J Oral Maxillofac Surg** 1995 Jun; 24(3):195–200 (14 ref.)

FACIAL BONES

ABNORMALITIES

Midline craniofacial defects and morning glory disc anomaly. A distinct clinical entity. Leitch RJ, et al. **Acta Ophthalmol Scand Suppl** 1996;(219):16–9 (13 ref.)

Kaufman oculocerebrofacial syndrome in a girl of 15 years. Briscioli V, et al. **Am J Med Genet** 1995 Jul 31;58(1):21–3 (6 ref.)

Oculoauriculofrontonasal syndrome: report of another case and review of differential diagnosis. Toriello HV, et al. **Clin Dysmorphol** 1995 Oct;4(4):338–46 (25 ref.)

Variability of clinical and immunological phenotype in immunodeficiency-centromeric instability-facial anomalies syndrome. Report of two new patients and review of the literature. Franceschini P, et al. **Eur J Pediatr** 1995 Oct; 154(10):840–6 (21 ref.)

Floating-Harbor syndrome: description of a further patient, review of the literature, and suggestion of autosomal dominant inheritance. Lacombe D, et al. **Eur J Pediatr** 1995 Aug;154(8):658–61 (9 ref.)

Frontonasal dysplasia: analysis of 21 cases and literature review. Guion-Almeida ML, et al. **Int J Oral Maxillofac Surg** 1996 Apr;25(2):91–7 (62 ref.)

Anaesthesia and craniofacial surgery. Karapurkar SA, et al. **J Postgrad Med** 1994 Jan-Mar;40(1):3–6 (6 ref.)

[Use of porous plyethylene (Medpor) in maxillofacial surgery] Cenzi R, et al. **Minerva Stomatol** 1995 Dec; 44(12):559–82 (17 ref.) (Eng. Abstr.) **(Ita)**

EMBRYOLOGY

Programmed cell death and cell transformation in craniofacial development. Shuler CF. **Crit Rev Oral Biol Med** 1995;6(3):202–17 (124 ref.)

INJURIES

Removal of asymptomatic bone plates used for orthognathic surgery and facial fractures. Alpert B, et al. **J Oral Maxillofac Surg** 1996 May;54(5):618–21 (41 ref.)

Retention of asymptomatic bone plates used for orthognathic surgery and facial fractures. Haug RH. **J Oral Maxillofac Surg** 1996 May;54(5):611–7 (90 ref.)

PATHOLOGY

[The magnetic resonance assessment of craniofacial fibrous dysplasia. The completion of the study with gadolinium administration and magnetic resonance angiography] Di Girolamo M, et al. **Radiol Med (Torino)** 1996 Mar; 91(3):313–6 (10 ref.) **(Ita)**

SURGERY

Anaesthesia and craniofacial surgery. Karapurkar SA, et al. **J Postgrad Med** 1994 Jan-Mar;40(1):3–6 (6 ref.)

Use of demineralized bone implants in orbital and craniofacial reconstruction and a review of the literature. Neigel JM, et al. **Ophthal Plast Reconstr Surg** 1996 Jun;12(2):108–20 (63 ref.)

Facial bone wound healing. An overview. Szachowicz EH. **Otolaryngol Clin North Am** 1995 Oct;28(5):865–80 (35 ref.)

[Craniofacial surgery] Lyberg T. **Tidsskr Nor Laegeforen** 1996 Jan 20;116(2):230–4 (22 ref.) (Eng. Abstr.) **(Nor)**

FACIAL DERMATOSES

COMPLICATIONS

Mucocutaneous histoplasmosis in AIDS. Souza Filho FJ, et al. **Br J Dermatol** 1995 Sep;133(3):472–4 (26 ref.)

Atopic retinal detachment. Report of four cases and a review of the literature. Yoneda K, et al. **Br J Dermatol** 1995 Oct; 133(4):586–91 (78 ref.)

DIAGNOSIS

Dermatologic diagnosis and treatment of itchy red eyelids. Zug KA, et al. **Surv Ophthalmol** 1996 Jan-Feb; 40(4):293–306 (89 ref.)

DRUG THERAPY

Clinical management of oral and perioral candidosis. Fotos PG, et al. **Dermatol Clin** 1996 Apr;14(2):273–80 (70 ref.)

ETIOLOGY

Perioral dermatitis. Hogan DJ. **Curr Probl Dermatol** 1995; 22:98–104 (51 ref.)

Bactericidal UV-C lamp misuse [letter] [corrected] [published erratum appears in Isr J Med Sci 1995 Nov;31(11):701] Zamir E. **Isr J Med Sci** 1995 Sep;31(9):578 (5 ref.)

[Necrotic purpura of the head disclosing Churg-Strauss syndrome] Ly S, et al. **Ann Dermatol Venereol** 1995; 122(3):94–6 (17 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Primary lipogranuloma of the forehead. Lang S, et al. **Am J Otolaryngol** 1995 Sep-Oct;16(5):354–6 (19 ref.)

Destructive facial porokeratosis. Rahbari H, et al. **J Am Acad Dermatol** 1995 Dec;33(6):1049–50 (7 ref.)

RADIOTHERAPY

Ignition potential of the 585-nm pulsed-dye laser. Review of the literature and safety recommendations. Fretzin S, et al. **Dermatol Surg** 1996 Aug;22(8):699–702 (13 ref.)

VETERINARY

Facial, pedal, and other regional dermatoses. Foil CS. **Vet Clin North Am Small Anim Pract** 1995 Jul;25(4):923–44 (64 ref.)

FACIAL EXPRESSION

Homologizing primate facial displays: a critical review of methods. Preuschoft S, et al. **Folia Primatol (Basel)** 1995; 65(3):121–37 (71 ref.)

Facial emotion recognition by persons with mental retardation: a review of the experimental literature. Rojahn

FACIAL EXPRESSION

J, et al. **Res Dev Disabil** 1995 Sep-Oct;16(5):393-414 (75 ref.)

Facial processing in schizophrenia and delusional misidentification: cognitive neuropsychiatric approaches. Phillips ML, et al. **Schizophr Res** 1995 Sep;17(1):109-14 (45 ref.)

FACIAL HEMIATROPHY

PATHOLOGY

[Magnetic resonance of brain involvement in progressive facial hemiatrophy (Romberg's disease). Reconsideration of a syndrome] Terstegge K, et al. **Arq Neuropsiquiatr** 1995 Mar;53(1):98-113 (54 ref.) (Eng. Abstr.) **(Por)**

FACIAL INJURIES

COMPLICATIONS

Treatment of post-traumatic lower lip ptosis: report of case. Motamedi MH. **J Oral Maxillofac Surg** 1996 Feb; 54(2):230-3 (8 ref.)

Hypopituitarism secondary to transfacial gunshot wound. D'Angelica M, et al. **J Trauma** 1995 Oct;39(4):768-71 (12 ref.)

ETIOLOGY

A review of orthodontic face-bow injuries and safety equipment. Samuels RH.
Am J Orthod Dentofacial Orthop 1996 Sep;110(3):269-72 (13 ref.)

SURGERY

Burns and wound management. Ahrenholz DH, et al.
Otolaryngol Clin North Am 1995 Oct;28(5):1039-55 (45 ref.)

Facial bone wound healing. An overview. Szachowicz EH.
Otolaryngol Clin North Am 1995 Oct;28(5):865-80 (35 ref.)

[Craniofacial surgery] Lyberg T. **Tidsskr Nor Laegeforen** 1996 Jan 20;116(2):230-4 (22 ref.) (Eng. Abstr.) **(Nor)**

THERAPY

Planning for pediatric laceration repairs. Brokaw A, et al. **Nurse Pract** 1996 Mar;21(3):42, 45, 49 (3 ref.)

FACIAL MUSCLES

ABNORMALITIES

Picture of the month. Congenital hypoplasia of the depressor anguli oris muscle. Franco SM, et al.
Arch Pediatr Adolesc Med 1996 Mar;150(3):325-6 (9 ref.)

INNERVATION

Recurrence of hemifacial spasm after microvascular decompression. Payner TD, et al. **Neurosurgery** 1996 Apr; 38(4):686-90; discussion 690-1 (28 ref.)

PHYSIOPATHOLOGY

Hemifacial seizures and cerebellar ganglioglioma: an epilepsy syndrome of infancy with seizures of cerebellar origin. Harvey AS, et al. **Ann Neurol** 1996 Jul;40(1):91-8 (7 ref.)

SURGERY

[Antebrachial free flap with radial pedicle. II. Surgical technique] Iriarte Ortabe JI, et al. **Acta Stomatol Belg** 1995 Sep;92(3):105-23 (195 ref.) (Eng. Abstr.) **(Fre)**

[Microsurgical vascular decompression in the treatment of facial hemispasm. A retrospective study of a series of 65 cases and review of the literature] Sindou M, et al.
Neurochirurgie 1996;42(1):17-28 (40 ref.) (Eng. Abstr.) **(Fre)**

FACIAL NEOPLASMS

DIAGNOSIS

[Malignant histiocytofibroma. Apropos of 3 cases of cervicofacial localization] Bonnin P, et al.
Ann Otolaryngol Chir Cervicofac 1995;112(7):336-44 (29 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

[Extemporaneous histologic examination of cutaneous carcinoma of the face] Barrellier P, et al.
Rev Stomatol Chir Maxillofac 1995;96(5):329-34 (20 ref.) (Eng. Abstr.) **(Fre)**

[Microcystic adnexal carcinoma of the skin. An underestimated tumor] Rank C, et al. **Hautarzt** 1996 Apr; 47(4):284-8 (31 ref.) (Eng. Abstr.) **(Ger)**

[Desmoplastic malignant melanoma. Clinical and histopathologic results of a study in 34 patients] Rütten A, et al. **Hautarzt** 1996 Jun;47(6):447-53 (41 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

[The role of microsurgery in the reconstruction of loss of substance of soft tissue in the maxillofacial region] Iriarte Ortabe JI, et al. **Acta Stomatol Belg** 1995 Mar;92(1):17-29 (142 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

[The current therapeutic trends in rhabdomyosarcoma of the cervicofacial area. A review of the topic] Colella G, et al. **Minerva Stomatol** 1995 Jul-Aug;44(7-8):335-44 (37 ref.) (Eng. Abstr.) **(Ita)**

FACIAL NERVE

Simultaneous, multiple cranial neuropathies in diabetes mellitus. Eshbaugh CG, et al. **J Neuroophthalmol** 1995 Dec; 15(4):219-24 (23 ref.)

Intratemporal facial nerve perineurioma. Li D, et al.
Laryngoscope 1996 Mar;106(3 Pt 1):328-33 (39 ref.)

Pineal germinoma with cranial nerve metastasis. Incesu L, et al. **Radiol Med (Torino)** 1996 Apr;91(4):471-2 (11 ref.)

INJURIES

[Iatrogenic lesions of the facial nerve during parotid surgery for pleomorphic adenoma] Colella G, et al.
Minerva Stomatol 1995 Dec;44(12):591-6 (40 ref.) (Eng. Abstr.) **(Ita)**

SURGERY

Total facial nerve decompression: technique to avoid complications. Pulec JL. **Ear Nose Throat J** 1996 Jul; 75(7):410-5 (12 ref.)

Cross-face facial nerve anastomosis: historical notes. Scaramella LF. **Ear Nose Throat J** 1996 Jun;75(6):343, 347-52, 354 (11 ref.)

FACIAL NERVE DISEASES

ETIOLOGY

Pineal germinoma with cranial nerve metastasis. Incesu L, et al. **Radiol Med (Torino)** 1996 Apr;91(4):471-2 (11 ref.)

SURGERY

Recurrence of hemifacial spasm after microvascular decompression. Payner TD, et al. **Neurosurgery** 1996 Apr; 38(4):686-90; discussion 690-1 (28 ref.)

FACIAL PAIN

see related
TEMPOROMANDIBULAR JOINT SYNDROME
TRIGEMINAL NEURALGIA

Orofacial phantom pain: theory and phenomenology. Marbach JJ. **J Am Dent Assoc** 1996 Feb;127(2):221-9 (48 ref.)

DIAGNOSIS

Trigeminal neuralgia versus atypical facial pain. A review of the literature and case report. Türp JC, et al.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996 Apr;81(4):424-32 (73 ref.)

[Neurovascular facial pain] Sadzot B, et al.
Rev Med Liege 1995 Nov;50(11):472-6 (19 ref.) **(Fre)**

DRUG THERAPY

Identifying a neurobiologic basis for drug therapy in TMDs. Denucci DJ, et al. **J Am Dent Assoc** 1996 May; 127(5):581-93 (80 ref.)

ETIOLOGY

Facial pain as a symptom of nonmetastatic lung cancer. Capobianco DJ. **Headache** 1995 Nov-Dec;35(10):581-5 (18 ref.)

Differential diagnosis of jaw pain in the elderly. Sandler NA, et al. **J Am Dent Assoc** 1995 Sep;126(9):1263-72 (40 ref.)

Pterygoid hamulus bursitis: one cause of craniofacial pain. Shankland WE 2nd. **J Prosthet Dent** 1996 Feb;75(2):205-10 (26 ref.)

Occipital neuralgia manifesting as orofacial pain. Sulfaro MA, et al.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995 Dec;80(6):751-5 (22 ref.)

PHYSIOPATHOLOGY

Identifying a neurobiologic basis for drug therapy in TMDs. Denucci DJ, et al. **J Am Dent Assoc** 1996 May; 127(5):581-93 (80 ref.)

SURGERY

The surgical management of idiopathic facial pain produces intractable iatrogenic pain? [editorial] Harris M.
Br J Oral Maxillofac Surg 1996 Feb;34(1):1-3 (32 ref.)

FACIAL PARALYSIS

[Recurrent or familial facial palsy. Apropos of 6 cases and review of the literature] Benlyazid A, et al.
Ann Otolaryngol Chir Cervicofac 1995;112(8):374-80 (23 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Traumatic pseudoaneurysm of the superficial temporal artery associated with facial nerve palsy. Lalak NJ, et al.
J Cardiovasc Surg (Torino) 1996 Apr;37(2):119-23 (54 ref.)

Simultaneous, multiple cranial neuropathies in diabetes mellitus. Eshbaugh CG, et al. **J Neuroophthalmol** 1995 Dec; 15(4):219-24 (23 ref.)

All that palsies is not Bell's. James DG. **J R Soc Med** 1996 Apr;89(4):184-7 (22 ref.)

[Isolated peripheral facial paralysis and HIV infection: 7 cases] Kohler A, et al. **Rev Neurol (Paris)** 1995 May; 151(5):332-7 (48 ref.) (Eng. Abstr.) **(Fre)**

[Iatrogenic lesions of the facial nerve during parotid surgery for pleomorphic adenoma] Colella G, et al.
Minerva Stomatol 1995 Dec;44(12):591-6 (40 ref.) (Eng. Abstr.) **(Ita)**

PHYSIOPATHOLOGY

[Special ocular movements in the neonate and Bell's phenomenon] Kuperman AA, et al. **Harefuah** 1996 Mar 1;130(5):333-6 (33 ref.) **(Heb)**

[Simultaneous bilateral facial paralysis] Morales Angulo C, et al. **Acta Otorrinolaringol Esp** 1995 Jul-Aug;46(4):305-9 (71 ref.) (Eng. Abstr.) **(Spa)**

[Facial paralysis] Peña J, et al. **Rev Neurol** 1995;23 Suppl 3:S318-21 (36 ref.) **(Spa)**

SURGERY

Total facial nerve decompression: technique to avoid complications. Pulec JL. **Ear Nose Throat J** 1996 Jul; 75(7):410-5 (12 ref.)

Hemifacial spasm: a prospective long-term follow up of 83 cases treated by microvascular decompression at two neurosurgical centres in the United Kingdom. Illingworth RD, et al. **J Neurol Neurosurg Psychiatry** 1996 Jan; 60(1):72-7 (45 ref.)

FACIES

Floating-Harbor syndrome: description of a further patient, review of the literature, and suggestion of autosomal dominant inheritance. Lacombe D, et al. **Eur J Pediatr** 1995 Aug;154(8):658-61 (9 ref.)

FACILITY DESIGN AND CONSTRUCTION

see related
BUILDING CODES

FACILITY REGULATION AND CONTROL

Nursing homes: what you need to know for quality patient care. Cefalu CA. **Geriatrics** 1995 Dec;50(12):37-40, 49-50 (22 ref.)

National health expenditure limits: the case for a global budget process. Bishop CE, et al. **Milbank Q** 1996; 74(3):361-76 (17 ref.)

LEGISLATION & JURISPRUDENCE

Public health and regulatory considerations of the Safe Drinking Water Act. Raucher RS.
Annu Rev Public Health 1996;17:179-202 (20 ref.)

Omnibus Budget Reconciliation Act of 1987 and its implications for the medical director. Elon RD.
Clin Geriatr Med 1995 Aug;11(3):419-32 (5 ref.)

FACTITIOUS DISORDERS

DIAGNOSIS

Factitious gastrointestinal bleeding: a case of autophlebotomy and ingestion. Rose MI, et al. **Am J Gastroenterol** 1996 Jul;91(7):1457-9 (11 ref.)

Factitious disorder presenting as bacteremia. Case report and literature review. Catalano G, et al. **J Fla Med Assoc** 1995 Aug;82(8):535-9 (29 ref.)

PSYCHOLOGY

[Self-injury behavior] Rechenberger I. **Gynakologe** 1995 Dec; 28(6):446-51 (13 ref.) **(Ger)**

FACTOR CONSTRUCT RATING SCALES (FCRS) see **PSYCHIATRIC STATUS RATING SCALES**

FACTOR I see **FIBRINOGEN**

FACTOR II see **PROTHROMBIN**

FACTOR III see **THROMBOPLASTIN**

FACTOR IV see **CALCIUM**

FACTOR V

ANALYSIS

[Factor V] Fukutake K, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:68-70 (11 ref.) **(Jpn)**

GENETICS

Resistance to activated protein C, the FV:Q506 allele, and venous thrombosis. Dahlbäck B, et al. **Ann Hematol** 1996 Apr;72(4):166–76 (152 ref.)
Resistance to activated protein C due to mutated factor V as a novel cause of inherited thrombophilia. De Stefano V, et al. **Haematologica** 1995 Jul–Aug;80(4):344–56 (99 ref.)
Resistance to activated protein C and factor V Leiden as risk factors for venous thrombosis. Bertina RM, et al. **Thromb Haemost** 1995 Jul;74(1):449–53 (53 ref.)
New molecular insights into the genetics of thrombophilia. Resistance to activated protein C caused by Arg506 to Gln mutation in factor V as a pathogenic risk factor for venous thrombosis. Dahlbäck B. **Thromb Haemost** 1995 Jul; 74(1):139–48 (112 ref.)
Resistance to activate protein C, the Arg506 to Gln mutation in the factor V gene, and venous thrombosis. Functional tests and DNA–based assays, pros and cons [see comments] Dahlbäck B. **Thromb Haemost** 1995 May;73(5):739–42 (33 ref.) Comment in: Thromb Haemost 1995 Nov;74(5):1380–1.
[Point mutation G—>A nucleotide 1691 factor V gene as a cause of developing thrombotic complications in a family with plasma resistance to activated protein C] Lew Andowski KL, et al. **Pol Arch Med Wewn** 1996 May; 95(5):464–70 (11 ref.) (Eng. Abstr.) **(Pol)**

FACTOR V DEFICIENCY

COMPLICATIONS

Resistance to activated protein C and factor V Leiden as risk factors for venous thrombosis. Bertina RM, et al. **Thromb Haemost** 1995 Jul;74(1):449–53 (53 ref.)
New molecular insights into the genetics of thrombophilia. Resistance to activated protein C caused by Arg506 to Gln mutation in factor V as a pathogenic risk factor for venous thrombosis. Dahlbäck B. **Thromb Haemost** 1995 Jul; 74(1):139–48 (112 ref.)
Resistance to activate protein C, the Arg506 to Gln mutation in the factor V gene, and venous thrombosis. Functional tests and DNA–based assays, pros and cons [see comments] Dahlbäck B. **Thromb Haemost** 1995 May;73(5):739–42 (33 ref.) Comment in: Thromb Haemost 1995 Nov;74(5):1380–1.
Activated protein C resistance: molecular mechanisms. Griffin JH, et al. **Thromb Haemost** 1995 Jul;74(1):444–8 (35 ref.)

GENETICS

Resistance to activated protein C due to mutated factor V as a novel cause of inherited thrombophilia. De Stefano V, et al. **Haematologica** 1995 Jul–Aug;80(4):344–56 (99 ref.)

FACTOR VII

ANALYSIS

[Factor VII] Fukutake K, et al. **Nippon Rinsho** 1995 Mar; 53 Su Pt 2:71–3 (9 ref.) **(Jpn)**
[Activated factor VII as a new cardiovascular risk factor of atherothrombotic disease] Kario K, et al. **Rinsho Byori** 1995 Dec;43(12):1201–8 (28 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Inherited factor VII deficiency: genetics and molecular pathology. Tuddenham EG, et al. **Thromb Haemost** 1995 Jul;74(1):313–21 (63 ref.)

FACTOR VII, ACTIVATED see **FACTOR VIIA**

FACTOR VII DEFICIENCY

GENETICS

Inherited factor VII deficiency: genetics and molecular pathology. Tuddenham EG, et al. **Thromb Haemost** 1995 Jul;74(1):313–21 (63 ref.)

FACTOR VIIA

ADMINISTRATION & DOSAGE

Review of pumps for continuous infusion of coagulation factor concentrates: what are the options? Martinowitz U, et al. **Blood Coagul Fibrinolysis** 1996 Mar;7 Suppl 1:S27–33 (10 ref.)

CHEMISTRY

Initiation of blood coagulation: the tissue factor/factor VIIa complex. Kirchhofer D, et al. **Curr Opin Biotechnol** 1996 Aug;7(4):386–91 (46 ref.)

METABOLISM

Tissue factor modulation of factor VIIa activity: use in measuring trace levels of factor VIIa in plasma. Morrissey JH. **Thromb Haemost** 1995 Jul;74(1):185–8 (64 ref.)

PHYSIOLOGY

Initiation of blood coagulation: the tissue factor/factor VIIa complex. Kirchhofer D, et al. **Curr Opin Biotechnol** 1996 Aug;7(4):386–91 (46 ref.)
Regulation of the extrinsic pathway system in health and disease: the role of factor VIIa and tissue factor pathway inhibitor. Petersen LC, et al. **Thromb Res** 1995 Jul 1; 79(1):1–47 (256 ref.)

FACTOR VIII

ADMINISTRATION & DOSAGE

Prophylaxis and continuous infusion for hemophilia: can we afford it? Aledort LM, et al. **Blood Coagul Fibrinolysis** 1996 Mar;7 Suppl 1:S35–7 (5 ref.)
Rationale and indications for continuous infusion of antihemophilic factor (factor VIII). Goldsmith JC. **Blood Coagul Fibrinolysis** 1996 Mar;7 Suppl 1:S3–6 (9 ref.)
Family issues in continuous infusion therapy with factor VIII. Manco–Johnson MJ. **Blood Coagul Fibrinolysis** 1996 Mar; 7 Suppl 1:S21–5 (13 ref.)
Review of pumps for continuous infusion of coagulation factor concentrates: what are the options? Martinowitz U, et al. **Blood Coagul Fibrinolysis** 1996 Mar;7 Suppl 1:S27–33 (10 ref.)
Factor VIII pharmacokinetics: intermittent infusion versus continuous infusion. Morfini M, et al. **Blood Coagul Fibrinolysis** 1996 Mar;7 Suppl 1:S11–4 (16 ref.)
Design and assessment of clinical trials on continuous infusion. Schulman S, et al. **Blood Coagul Fibrinolysis** 1996 Mar;7 Suppl 1:S7–9 (8 ref.)
Spinal extradural hematoma in an infant with hemophilia A: an unusual presentation of a rare complication. Hutt PJ, et al. **J Pediatr** 1996 May;128(5 Pt 1):704–6 (8 ref.)
Nonoperative management of a splenic tear in a Jehovah's Witness with hemophilia. Zieg PM, et al. **J Trauma** 1996 Feb;40(2):299–301 (21 ref.)

ADVERSE EFFECTS

Factor VIII concentrates and the immune system—laboratory investigations. Wadhwa M, et al. **Blood Coagul Fibrinolysis** 1995 Jul;6 Suppl 2:S65–79 (73 ref.)

ANALYSIS

In vivo recovery of factor VIII following transfusion: a survey of recent data and publications to assess the influence of standards used for potency assignment. On behalf of the Subcommittee on Factor VIII and IX of the Scientific and Standardization Committee of the ISTH. Prowse CV. **Thromb Haemost** 1995 Oct;74(4):1191–6 (43 ref.)
[Factor VIII] Ueda M, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:74–6 (15 ref.) **(Jpn)**

ANTAGONISTS & INHIBITORS

[The diagnosis and therapy of acquired factor–VIII inhibitors in combination with lupus anticoagulants] Grossmann R, et al. **Dtsch Med Wochenschr** 1996 Jul 12;121(28–29):906–10 (14 ref.) (Eng. Abstr.) **(Ger)**

GENETICS

Molecular genetics of coagulation factor VIII gene and hemophilia A. Antonarakis SE. **Thromb Haemost** 1995 Jul; 74(1):322–8 (66 ref.)

IMMUNOLOGY

Diagnostic methodologies for circulating anticoagulants. Exner T. **Thromb Haemost** 1995 Jul;74(1):338–44 (59 ref.)
[Acquired factor VIII inhibitor and chronic lymphoid leukemia: apropos of a case] Ceballos P, et al. **Rev Med Interne** 1996;17(2):150–3 (15 ref.) (Eng. Abstr.) **(Fre)**
[Factor VIII inhibitors] Takamatsu J. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:94–7 (11 ref.) **(Jpn)**

ISOLATION & PURIFICATION

Improved safety from plasma derivatives: purification and viral elimination characteristics of mononine. Feldman F, et al. **Acta Haematol** 1995;94 Suppl 1:25–32; discussion 33–4 (13 ref.)
Why prescribe highly purified factor VIII and IX concentrates? Berntorp E. **Vox Sang** 1996;70(2):61–8 (42 ref.)

PHARMACOKINETICS

Factor VIII pharmacokinetics: intermittent infusion versus continuous infusion. Morfini M, et al. **Blood Coagul Fibrinolysis** 1996 Mar;7 Suppl 1:S11–4 (16 ref.)

PHARMACOLOGY

Effects of factor VIII concentrates on the immune system of patients with hemophilia. Mannucci PM. **Thromb Haemost** 1995 Jul;74(1):437–9 (19 ref.)

PHYSIOLOGY

[Structural–functional features of factor VIII (FVIII) and its role in the cascade system of blood coagulation] Gutsalo AE. **Ukr Biokhim Zh** 1995 Jul–Aug;67(4):12–23 (62 ref.) (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

[Anti–hemophilia drugs: from cryoprecipitate to factor VIII concentrates of high purity] Gutsalo AE, et al. **Ukr Biokhim Zh** 1995 Jan–Feb;67(1):3–13 (62 ref.) (Eng. Abstr.) **(Rus)**

FACTOR VIII CLOTTING ANTIGEN see **FACTOR VIII**

FACTOR VIII COAGULANT ANTIGEN see **FACTOR VIII**

FACTOR VIII DEFICIENCY see **HEMOPHILIA**

FACTOR VIII PROCOAGULANT ACTIVITY see **FACTOR VIII**

FACTOR VIII–RELATED ANTIGEN see **VON WILLEBRAND FACTOR**

FACTOR IX

ANALYSIS

[Factor IX] Higasa S, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:77–9 (13 ref.) **(Jpn)**

BIOSYNTHESIS

Biosynthesis of factor IX: implications for gene therapy. Furie BC, et al. **Thromb Haemost** 1995 Jul;74(1):274–7 (60 ref.)

IMMUNOLOGY

[Factor IX inhibitor] Higasa S, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:98–9 (6 ref.) **(Jpn)**

ISOLATION & PURIFICATION

Improved safety from plasma derivatives: purification and viral elimination characteristics of mononine. Feldman F, et al. **Acta Haematol** 1995;94 Suppl 1:25–32; discussion 33–4 (13 ref.)
Why prescribe highly purified factor VIII and IX concentrates? Berntorp E. **Vox Sang** 1996;70(2):61–8 (42 ref.)

FACTOR IX DEFICIENCY see **CHRISTMAS DISEASE**

FACTOR XI

ANALYSIS

[Factor XI] Saito H. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:84–6 (11 ref.) **(Jpn)**

FACTOR XII

ANALYSIS

[Factor XII (Hageman factor)] Saito H. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:87–9 (11 ref.) **(Jpn)**

FACTOR XIII

ANALYSIS

[Factor XIII] Yorifuji H, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:90–3 (7 ref.) **(Jpn)**

FACULTY, MEDICAL

Professional networks: the influence of colleagues on the academic success of faculty. Hitchcock MA, et al. **Acad Med** 1995 Dec;70(12):1108–16 (47 ref.)

FACULTY, NURSING

A sharing in critical thought by nursing faculty. Hendricks–Thomas J, et al. **J Adv Nurs** 1995 Sep; 22(3):594–9 (35 ref.)

STANDARDS

Evaluating teaching effectiveness. Kirschling JM, et al. **J Nurs Educ** 1995 Dec;34(9):401–10 (30 ref.)

FACULTY PRACTICE, NURSING see **NURSING FACULTY PRACTICE**

FAGINE see **CHOLINE**

FAIDS see **FELINE ACQUIRED IMMUNODEFICIENCY SYNDROME**

FAILURE TO THRIVE

DIAGNOSIS

Failure to thrive in the elderly. Verdery RB. **Clin Geriatr Med** 1995 Nov;11(4):653–9 (17 ref.)

ETIOLOGY

Congenital vallecular cyst: a cause of failure to thrive. Oluwole M. **Br J Clin Pract** 1996 Apr–May;50(3):170 (9 ref.)

NURSING

Failure to thrive: an ambulatory approach. Schwartz R, et al. **Nurse Pract** 1996 May;21(5):19–20, 26–8, 31–2 passim (45 ref.)

FAINTING see **SYNCOPE**

FAITH HEALING see **MENTAL HEALING**

FALLOPIAN TUBE DISEASES

DIAGNOSIS

[Peritoneal and tubal Schistosoma haematobium bilharziasis. Two case reports] Ekoukou D, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(8):819–24 (20 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Hydrosalpinx affects the implantation of previously cryopreserved embryos. Akman MA, et al. **Hum Reprod** 1996 May;11(5):1013–4 (8 ref.)

SURGERY

Is there ever a role for tubal surgery? Penzias AS, et al. **Am J Obstet Gynecol** 1996 Apr;174(4):1218–21; discussion 1221–3 (17 ref.)

Primary therapy for tubal disease: surgery versus IVF. Gocial B. **Int J Fertil Menopausal Stud** 1995 Nov–Dec; 40(6):297–302 (20 ref.)

Tubal surgery of IVF—making the best choice in the 1990s. Novy MJ. **Int J Fertil Menopausal Stud** 1995 Nov–Dec; 40(6):292–7 (35 ref.)

[Hydrosalpinx and sterility: indications for salpingectomy] Aubriot FX, et al. **Contracept Fertil Sex** 1995 Nov; 23(11):670–3 (36 ref.) **(Fre)**

[Pro and contra: pelviscopy and microsurgery of the fallopian tube] Semm K. **Arch Gynecol Obstet** 1995;257(1–4):302–10 (14 ref.) **(Ger)**

[Possibilities and limits of endoscopic fallopian tube surgery] Korell M, et al. **Zentralbl Gynakol** 1995;117(12):663–9 (21 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Tubal cannulation. Valle RF. **Obstet Gynecol Clin North Am** 1995 Sep;22(3):519–40 (48 ref.)

ULTRASONOGRAPHY

[Vaginal ultrasound diagnosis of tubal diseases] Degenhardt F. **Gynakologe** 1995 Aug;28(4):247–53 (20 ref.) **(Ger)**

FALLOPIAN TUBE NEOPLASMS

DIAGNOSIS

Diagnosis and clinical management in malignant Müllerian tumors of the fallopian tube. A report of four cases and review of recent literature. Horn LC, et al. **Arch Gynecol Obstet** 1996;258(1):47–53 (23 ref.)

EPIDEMIOLOGY

Primary cancer of the fallopian tube. Report of 26 patients. Jereczek B, et al. **Acta Obstet Gynecol Scand** 1996 Mar; 75(3):281–6 (33 ref.)

THERAPY

Diagnosis and clinical management in malignant Müllerian tumors of the fallopian tube. A report of four cases and review of recent literature. Horn LC, et al. **Arch Gynecol Obstet** 1996;258(1):47–53 (23 ref.)

ULTRASONOGRAPHY

Transvaginal color Doppler and pelvic tumor vascularity: lessons learned and future challenges. Kurjak A, et al. **Ultrasound Obstet Gynecol** 1995 Aug;6(2):145–59 (38 ref.)

FALLOPIAN TUBES

see related
HYSTEROSALPINGOGRAPHY
SALPINGOSTOMY
STERILIZATION, TUBAL

ABNORMALITIES

Hernia uteri (correction of: uterus) inguinale associated with unilateral renal agenesis. Keating JP, et al. **Aust N Z J Surg** 1995 Sep;65(9):688–90 (10 ref.)

CHEMISTRY

Ultrastructure and histochemistry of acid mucus glycoproteins in the estrous mammal oviduct. Jansen RP. **Microsc Res Tech** 1995 Sep 1;32(1):24–49 (80 ref.)

CYTOLOGY

Functions of proteins secreted by oviduct epithelial cells. Gandolfi F. **Microsc Res Tech** 1995 Sep 1;32(1):1–12 (133 ref.)

METABOLISM

Oviduct during early pregnancy: hormonal regulation and interactions with the fertilized ovum. Murray MK, et al. **Microsc Res Tech** 1995 Aug 15;31(6):497–506 (49 ref.)

PHYSIOLOGY

Human sperm reservoirs and Fallopian tube function: a rôle for the intra-mural portion? Hunter RH. **Acta Obstet Gynecol Scand** 1995 Oct;74(9):677–81 (32 ref.)

Oviductal function is critical for very early human life. Pulkkinen MO. **Ann Med** 1995 Jun;27(3):307–10 (12 ref.)

Ovarian regulation of sperm progression in the fallopian tubes. Hunter RH. **Zygote** 1994 Nov;2(4):363–6 (22 ref.)

[Neurohumoral regulation of Fallopian tube motility] Janković SM, et al. **Med Pregl** 1995;48(11–12):395–8 (34 ref.) (Eng. Abstr.) **(Scr)**

SECRETION

Functions of proteins secreted by oviduct epithelial cells. Gandolfi F. **Microsc Res Tech** 1995 Sep 1;32(1):1–12 (133 ref.)

SURGERY

Is there ever a role for tubal surgery? Penzias AS, et al. **Am J Obstet Gynecol** 1996 Apr;174(4):1218–21; discussion 1221–3 (17 ref.)

Ectopic pregnancy and laparoscopy: review of 1197 patients treated by salpingectomy or salpingotomy. Maymon R, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Sep;62(1):61–7 (62 ref.)

In vitro fertilization versus tubal surgery: is pelvic reconstructive surgery obsolete? Benadiva CA, et al. **Fertil Steril** 1995 Dec;64(6):1051–61 (85 ref.)

FALLOT'S TETRALOGY see **TETRALOGY OF FALLOT**

FALLS, ACCIDENTAL see **ACCIDENTAL FALLS**

FAMILIAL AMYLOID POLYNEUROPATHIES see **AMYLOID NEUROPATHIES**

FAMILIAL ATYPICAL MULTIPLE MOLE-MELANOMA see **DYSPLASTIC NEVUS SYNDROME**

FAMILIAL MEDITERRANEAN FEVER see **PERIODIC DISEASE**

FAMILY

Chemically dependent patients in recovery: roles for the family physician. Del Toro IM, et al. **Am Fam Physician** 1996 Apr;53(5):1667–81 (19 ref.)

Who are the donors in organ donation? The family's perspective in mandated choice. Klassen AC, et al. **Ann Intern Med** 1996 Jul 1;125(1):70–3 (14 ref.)

Mandated choice for organ donation: time to give it a try. Spital A. **Ann Intern Med** 1996 Jul 1;125(1):66–9 (33 ref.)

Women, work, and family: mental health issues. Denmark F, et al. **Ann N Y Acad Sci** 1996 Jun 18;789:101–17 (46 ref.)

Stepfamilies and children's adjustment. Dunn J. **Arch Dis Child** 1995 Dec;73(6):487–9 (23 ref.)

Risk and resilience among children and youth with disabilities. Patterson J, et al. **Arch Pediatr Adolesc Med** 1996 Jul;150(7):692–8 (115 ref.)

Family issues in continuous infusion therapy with factor VIII. Manco-Johnson MJ. **Blood Coagul Fibrinolysis** 1996 Mar; 7 Suppl 1:S21–5 (13 ref.)

Immigrant children and their families: issues for research and policy. Board on Children and Families. **Future Child** 1995 Summer–Fall;5(2):72–89 (49 ref.)

The effects of family structure and family relations on adolescent marijuana use. Hoffmann JP. **Int J Addict** 1995 Aug;30(10):1207–41 (106 ref.)

Processes in the creation and diffusion of nursing knowledge: an examination of the developing concept of family-centred care. Bradley SF. **J Adv Nurs** 1996 Apr; 23(4):722–7 (33 ref.)

A review of the historical and social processes contributing to care and caregiving in Chinese families. Holroyd EA, et al. **J Adv Nurs** 1995 Sep;22(3):473–9 (39 ref.)

Epilogue: psychology, law, and the family. Roesch R. **Nebr Symp Motiv** 1995;42:173–86 (24 ref.)

Community, family, and the social good: the psychological dynamics of procedural justice and social identification. Tyler TR, et al. **Nebr Symp Motiv** 1995;42:53–91 (100 ref.)

Family support for persons with dual disorders. Clark RE. **New Dir Ment Health Serv** 1996 Summer;(70):65–78 (54 ref.)

Radiation protection issues associated with nuclear medicine out-patients [see comments] Thomson WH, et al. **Nucl Med Commun** 1995 Nov;16(11):879–92 (43 ref.) Comment in: Nucl Med Commun 1995 Nov;16(11):877–8.

Family response to the low birth weight infant. Gennaro S. **Nurs Clin North Am** 1996 Jun;31(2):341–50 (34 ref.)

Integrating family-centered developmental assessment and intervention into routine care in the neonatal intensive care unit. McGrath JM, et al. **Nurs Clin North Am** 1996 Jun; 31(2):367–86 (104 ref.)

Looking toward the twenty-first century. The role of nursing research in care of children and families affected by HIV. Sherwen LN, et al. **Nurs Clin North Am** 1996 Mar; 31(1):165–78 (35 ref.)

Discussing cardiopulmonary resuscitation with patients and relatives. Stewart K. **Postgrad Med J** 1995 Oct; 71(840):585–9 (30 ref.)

Ethical issues in living related donor liver transplantation. Strong RW, et al. **Transplant Proc** 1996 Aug;28(4):2366–9 (21 ref.)

[Renal transplantation from related live donors. Results and survival] Hajri M, et al. **Ann Urol (Paris)** 1995;29(3):186–92 (17 ref.) (Eng. Abstr.) **(Fre)**

[Family counseling in primary health care: a systemic approach] Jarabo Crespo Y, et al. **Aten Primaria** 1995 Nov 30;16(9):557–62 (27 ref.) **(Spa)**

PSYCHOLOGY

Quality of life and caregiving in technological home care. Smith CE. **Annu Rev Nurs Res** 1996;14:95–118 (141 ref.)

Family relationships of adults with borderline personality disorder. Allen DM, et al. **Compr Psychiatry** 1996 Jan–Feb; 37(1):43–51 (43 ref.)

Illness and family functioning: theoretical and practical considerations from the primary care point of view. Tansella CZ. **Fam Pract** 1995 Jun;12(2):214–20 (14 ref.)

Gay men with AIDS and their families of origin: an analysis of social support. Kadushin G. **Health Soc Work** 1996 May; 21(2):141–9 (100 ref.)

The effects of family structure and family relations on adolescent marijuana use. Hoffmann JP. **Int J Addict** 1995 Aug;30(10):1207–41 (106 ref.)

Helping the vulnerable or condoning control within the family: where is nursing? Cody A. **J Adv Nurs** 1996 May; 23(5):882–6 (51 ref.)

Relationship between elderly carers and the older adult with learning disabilities: an overview of the literature. Maggs C, et al. **J Adv Nurs** 1996 Feb;23(2):243–51 (56 ref.)

Chronic illness and the family life-cycle. Newby NM. **J Adv Nurs** 1996 Apr;23(4):786–91 (29 ref.)

Somatisation in children. Garralda ME. **J Child Psychol Psychiatry** 1996 Jan;37(1):13–33 (125 ref.)

Family and parental functioning in cystic fibrosis. Ievers CE, et al. **J Dev Behav Pediatr** 1996 Feb;17(1):48–55 (45 ref.)

A model of family adaptation to new-onset childhood epilepsy. Austin JK. **J Neurosci Nurs** 1996 Apr;28(2):82–92 (55 ref.)

Hardiness and stress: a critical review. Huang C. **Matern Child Nurs J** 1995 Jul–Sep;23(3):82–9 (36 ref.)

African American families, religion, and disability: a conceptual framework. Rogers-Dulan J, et al. **Ment Retard** 1995 Aug;33(4):226–38 (65 ref.)

Familial and ecological correlates of self-esteem in African American children. Walker K, et al. **Nurs Dir Child Dev** 1995 Summer;(68):23–34 (70 ref.)

Pediatric and family HIV. Psychosocial concerns across the continuum of disease. Lewis SL, et al. **Nurs Clin North Am** 1996 Mar;31(1):221–30 (29 ref.)

A cultural perspective on family theory and therapy. Kaslow NJ, et al. **Psychiatr Clin North Am** 1995 Sep;18(3):621–33 (34 ref.)

A model for the classification and diagnosis of relational disorders. Committee on the Family, Group for the Advancement of Psychiatry. **Psychiatr Serv** 1995 Sep; 46(9):926–31 (61 ref.)

Family caregiver role acquisition: role-making through situated interaction. Schumacher KL. **Sch Inq Nurs Pract** 1995 Fall;9(3):211–26; discussion 227–9 (76 ref.)

Social influences on bipolar affective disorders. Ramana R, et al. **Soc Psychiatry Psychiatr Epidemiol** 1995 Jul; 30(4):152–60 (55 ref.)

Risk factors for adolescent suicide and suicidal behavior: mental and substance abuse disorders, family environmental factors, and life stress. Brent DA. **Suicide Life Threat Behav** 1995;25 Suppl:52–63 (44 ref.)

[Depressed patients and their family] Väisänen L, et al. **Duodecim** 1994;110(3):333–8 (11 ref.) **(Fin)**

[Systemic approach to families dealing with cancer diagnosis, its treatment and its prognosis] Bodart A, et al. **Acta Psychiatr Belg** 1996 Jan–Feb;96(1):30–57 (73 ref.) (Eng. Abstr.) **(Fre)**

FAMILY CAREGIVERS see **CAREGIVERS**

FAMILY CHARACTERISTICS

Women's education and fertility: results from 26 Demographic and Health Surveys. Castro Martin T.

Stud Fam Plann 1995 Jul-Aug;26(4):187-202 (50 ref.)

FAMILY HEALTH

Children and smoking: the family circle. Charlton A. **Br Med Bull** 1996 Jan;52(1):90-107 (83 ref.)

Helping the relatives of patients with cancer [editorial; comment] Fallowfield L. **Eur J Cancer** 1995 Oct; 31A(11):1731-2 (13 ref.) Comment on: Eur J Cancer 1995 Oct;31A(11):1736-40.

Pediatric HIV infection: recent advances [editorial] Sen S. **Indian Pediatr** 1995 May;32(5):519-27 (41 ref.)

The use of discordant sibling pairs for finding genetic loci linked to obesity: practical considerations. Allison DB. **Int J Obes Relat Metab Disord** 1996 Jun;20(6):553-60 (54 ref.)

Familial trends of obesity through three generations: the Belgian-Luxembourg child study. Guillaume M, et al. **Int J Obes Relat Metab Disord** 1995 Sep;19 Suppl 3:S5-9 (31 ref.)

The changing profile of acute childhood illness: a need for the development of family nursing knowledge. Rennick JE. **J Adv Nurs** 1995 Aug;22(2):258-66 (57 ref.)

FAMILY LIFE CYCLES see **FAMILY**

FAMILY-PATIENT LODGING see **HOUSING**

FAMILY PLANNING

see related
CONTRACEPTION

Contraceptive methods: do Hispanic adolescents and their family planning care providers think about contraceptive methods the same way? Erickson PI. **Med Anthropol** 1996 May;17(1):65-82 (53 ref.)

Preconception counseling for the primary care physician. Leuzzi RA, et al. **Med Clin North Am** 1996 Mar; 80(2):337-74 (113 ref.)

A fertility diet for planning pregnancy. Wynn M, et al. **Nutr Health** 1995;10(3):219-38 (50 ref.)

Women's education and fertility: results from 26 Demographic and Health Surveys. Castro Martin T. **Stud Fam Plann** 1995 Jul-Aug;26(4):187-202 (50 ref.)

[Progresses in family planning in China, 1995] Wu Y. **Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):749-51 (0 ref.) **(Chi)**

[Depot gestagens] Zahradnik HP. **Arch Gynecol Obstet** 1995; 257(1-4):536-41 (9 ref.) **(Ger)**

[Tumor therapy and family planning] Theile U, et al. **Med Klin** 1996 Jun 15;91(6):402-9 (43 ref.) **(Ger)**

METHODS

Directive counseling on long-acting contraception. Moskowitz E, et al. **Am J Public Health** 1996 Jun; 86(6):787-90 (24 ref.)

Abortion and fertility regulation [see comments] Kulczycki A, et al. **Lancet** 1996 Jun 15;347(9016):1663-8 (41 ref.) Comment in: Lancet 1996 Aug 17;348(9025):478; discussion 478-9.

[Lactational amenorrhea as a method of family planning] Canto-de Cetina T, et al. **Salud Publica Mex** 1996 Jan-Feb; 38(1):58-63 (38 ref.) (Eng. Abstr.) **(Spa)**

ORGANIZATION & ADMINISTRATION

Family planning: an essential component of prenatal care. Klerman LV, et al. **J Am Med Wom Assoc** 1995 Sep-Oct; 50(5):147-51 (31 ref.)

Public policy and adolescent pregnancy: a reexamination of the issues. Montessoro AC, et al. **Nurs Outlook** 1996 Jan-Feb;44(1):31-6 (18 ref.)

STATISTICS & NUMERICAL DATA

[Natural family planning] Freundl G. **Arch Gynecol Obstet** 1995;257(1-4):525-32 (11 ref.) **(Ger)**

TRENDS

Hormonal male contraception: progress and prospects for the 21st century. Handelsman DJ. **Aust N Z J Med** 1995 Dec;25(6):808-16 (54 ref.)

FAMILY PRACTICE

see related
COMPREHENSIVE HEALTH CARE
PHYSICIANS, FAMILY

Incorporating gun safety into clinical practice. Camosy PA. **Am Fam Physician** 1996 Sep 1;54(3):971-5, 977-8 (16 ref.)

Preventive dentistry and the family physician. Clark MM, et al. **Am Fam Physician** 1996 Feb 1;53(2):619-26, 631-2 (30 ref.)

Prevention, diagnosis, and management of viral hepatitis. A guide for primary care physicians. AMA Advisory Group on Prevention, Diagnosis, and Management of Viral Hepatitis. Noskin GA. **Arch Fam Med** 1995 Nov; 4(11):923-34 (28 ref.)

ABC of atrial fibrillation. Atrial fibrillation in general and hospital practice [see comments] Lip GY, et al. **BMJ** 1996 Jan 20;312(7024):175-8 (5 ref.) Comment in: BMJ 1996 Apr 27;312(7028):1101.

ABC of medical computing. Computers in general practice--I. Millman A, et al. **BMJ** 1995 Sep 23; 311(7008):800-2 (0 ref.)

Domestic violence: a hidden problem for general practice. Richardson J, et al. **Br J Gen Pract** 1996 Apr; 46(405):239-42 (43 ref.)

Interventional radiology. Application to family practice. Asch M, et al. **Can Fam Physician** 1996 Aug;42:1511-8, 1521-3 (24 ref.)

Exercise-induced asthma. What family physicians should do. D'Urzo A. **Can Fam Physician** 1995 Nov;41:1900-6 (50 ref.)

Identifying and managing problem drinkers. Kahan M. **Can Fam Physician** 1996 Apr;42:661-71 (59 ref.)

Preventing children from smoking. How family physicians and pediatricians can help. Thomas RE, et al. **Can Fam Physician** 1995 Sep;41:1517-23 (50 ref.)

Primary care of lesbian and gay patients: educating ourselves and our students [see comments] Harrison AE. **Fam Med** 1996 Jan;28(1):10-23 (86 ref.) Comment in: Fam Med 1996 Jan;28(1):57-8.

Using focus groups in general practice research. Barbour RS. **Fam Pract** 1995 Sep;12(3):328-34 (31 ref.)

Situational disease. Gannik DE. **Fam Pract** 1995 Jun; 12(2):202-6 (14 ref.)

Teenage pregnancy in the United Kingdom in the 1990s: the implications for primary care. Jacobson LD, et al. **Fam Pract** 1995 Jun;12(2):232-6 (60 ref.)

Illness and family functioning: theoretical and practical considerations from the primary care point of view. Tansella CZ. **Fam Pract** 1995 Jun;12(2):214-20 (14 ref.)

Obsessive-compulsive spectrum disorders in primary care: the possibilities and the pitfalls. Higgins ES. **J Clin Psychiatry** 1996;57 Suppl 8:7-9; discussion 9-10 (14 ref.)

Compliance issues in primary care. Lieberman JA 3rd. **J Clin Psychiatry** 1996;57 Suppl 7:76-82; discussion 83-5 (20 ref.)

Hope or experience? Clinical practice guidelines in family practice [editorial] Worrall G, et al. **J Fam Pract** 1996 Apr; 42(4):353-6 (33 ref.)

Managing hypertension in general practice: can we do better? Hosie J, et al. **J Hum Hypertens** 1995 Jul;9 Suppl 2:S15-8 (7 ref.)

Primary care: specialists or generalists. Gabriel SE. **Mayo Clin Proc** 1996 Apr;71(4):415-9 (62 ref.)

Preventing complications in diabetes mellitus: the role of the primary care physician. Laine C, et al. **Med Clin North Am** 1996 Mar;80(2):457-74 (96 ref.)

Psychosocial support, treatment of metastatic disease and palliative care [see comments] Ashby MA, et al. **Med J Aust** 1996 Jan 1;164(1):43-9 (23 ref.) Comment in: Med J Aust 1996 Jun 17;164(12):759-60.

The Role of General Practice in Maternity Care. Royal College of General Practitioners. Report of the RCGP Maternity Care Group. **Occas Pap R Coll Gen Pract** 1995 Nov;(72):1-14 (24 ref.)

Rural general practice: international perspectives. Evans PR. **Occas Pap R Coll Gen Pract** 1995 Sep;(71):46-9 (20 ref.)

Clues to depression in primary care practice. el-Mallakh RS, et al. **Postgrad Med** 1996 Jul;100(1):85-8, 93-6 (20 ref.)

Screening for disease, cost-effectiveness, and guidelines. Meyer DL. **Prim Care** 1995 Dec;22(4):591-9 (18 ref.)

The primary care physician as a sports medicine and exercise advocate and activist. Rouzier PA. **Prim Care** 1995 Dec; 22(4):785-804 (43 ref.)

Prevention of colorectal cancer by screening flexible sigmoidoscopy: possible role of the primary care physician. Abbas Z, et al. **Scott Med J** 1995 Jun;40(3):67-9 (41 ref.)

[Diagnosis of bronchial asthma and chronic obstructive lung disease by the family physician. Ad hoc consensus group 'Diagnosis of asthma/chronic obstructive lung disease by the family physician' (see comments)] van Schayck CP. **Ned Tijdschr Geneeskd** 1995 Sep 30;139(39):1966-71 (22 ref.) Comment in: Ned Tijdschr Geneeskd 1995 Dec 2;139(48):2512-3. **(Dut)**

[When should a child be suspected of having a malignancy?] Saarinen U. **Duodecim** 1995;111(5):466-70 (5 ref.) **(Fin)**

[Transcultural symptomatology. Its expression in family practice] Ferron M. **Can Fam Physician** 1995 Oct; 41:1718-25 (20 ref.) (Eng. Abstr.) **(Fre)**

[[Wallonian general physicians. Which prescriptions should be given to elderly persons over 75 years?] Franck J, et al. **Rev Med Liege** 1996 Feb;51(2):163-74 (47 ref.) **(Fre)**

[Role of the general practitioner in screening for and diagnosis of breast cancer] van der Kaa F, et al. **Rev Med Liege** 1995 Nov;50(11):458-68 (23 ref.) **(Fre)**

ECONOMICS

General practitioner fundholding: weighing the evidence [see comments] Petchey R. **Lancet** 1995 Oct 28; 346(8983):1139-42 (42 ref.) Comment in: Lancet 1995 Dec 23-30;346(8991-8992):1710-1.

EDUCATION

Alcohol risk assessment and intervention for family physicians. Project of the College of Family Physicians of Canada. Peters C, et al. **Can Fam Physician** 1996 Apr; 42:681-9 (31 ref.)

Postgraduate training for rural family practice. Goals and opportunities. Rourke JT. **Can Fam Physician** 1996 Jun; 42:1133-8 (48 ref.)

Women's health and enhancing generalism in internal medicine. Hoffman E, et al. **J Gen Intern Med** 1995 Aug; 10(8):451-4 (59 ref.)

The MRCGP--the standard to set yourself. Dixon H. **Practitioner** 1995 Sep;239(1554):527-9 (3 ref.)

Review your reading: how to prepare for the CRQ paper. Milne P. **Practitioner** 1996 Feb;240(1559):96-8 (5 ref.)

A positive approach to preparation. Rawlinson G. **Practitioner** 1995 Oct;239(1555):596-8 (5 ref.)

METHODS

Clinical applications of genetic testing: implications for the family physician [see comments] Whittaker L. **Am Fam Physician** 1996 May 1;53(6):2077-84 (37 ref.) Comment in: Am Fam Physician 1996 May 1;53(6):1976, 1978.

A dying child. Dawson SA. **Can Fam Physician** 1995 Sep; 41:1534-40 (27 ref.)

Managing early presentation of rheumatoid arthritis. Systematic overview. Glazier R. **Can Fam Physician** 1996 May;42:913-22 (85 ref.)

Alcohol risk assessment and intervention for family physicians. Project of the College of Family Physicians of Canada. Peters C, et al. **Can Fam Physician** 1996 Apr; 42:681-9 (31 ref.)

[Hypertension. A new way to approach an old problem] Aubin M. **Can Fam Physician** 1996 Apr;42:702-8 (30 ref.) (Eng. Abstr.) **(Fre)**

ORGANIZATION & ADMINISTRATION

ABC of medical computing. Computers in general practice--III. Millman A, et al. **BMJ** 1995 Oct 7; 311(7010):938-41 (0 ref.)

ABC of medical computing. Computers in general practice--II [see comments] Millman A, et al. **BMJ** 1995 Sep 30;311(7009):864-7 (0 ref.) Comment in: BMJ 1996 Jan 27;312(7025):254.

Has general practitioner computing made a difference to patient care? A systematic review of published reports. Sullivan F, et al. **BMJ** 1995 Sep 30;311(7009):848-52 (56 ref.)

Privileges, credentialing, and liability. Musallam LS. **Prim Care** 1995 Sep;22(3):491-8 (12 ref.)

STANDARDS

ABC of medical computing. Using computers in clinical audit. Kinn S, et al. **BMJ** 1995 Sep 16;311(7007):739-42 (0 ref.)

Setting standards of prescribing performance in primary care: use of a consensus group of general practitioners and application of standards to practices in the north of England. Bateman DN, et al. **Br J Gen Pract** 1996 Jan; 46(402):20-5 (12 ref.)

Guidelines for general practitioners administering thrombolytics. Rawles J. **Drugs** 1995 Oct;50(4):615-25 (45 ref.)

TRENDS

Recent advances: ambulatory care and family medicine. Gums JG. **Ann Pharmacother** 1995 Jul-Aug;29(7-8):716-8 (10 ref.)

GP 2000: a general practitioner for the new millennium [editorial] Wright AF. **Br J Gen Pract** 1996 Jan;46(402):4-5 (15 ref.)

Office gynecology for the primary care physician, part II: pelvic pain, vulvar disease, disorders of menstruation, premenstrual syndrome, and breast disease. Klein TA. **Med Clin North Am** 1996 Mar;80(2):321-36 (68 ref.)

Preconception counseling for the primary care physician. Leuzzi RA, et al. **Med Clin North Am** 1996 Mar; 80(2):337-74 (113 ref.)

Office gynecology for the primary care physician, part I: vaginitis, the Papanicolaou smear, contraception, and postmenopausal estrogen replacement. Reife CM. **Med Clin North Am** 1996 Mar;80(2):299-319 (63 ref.)

The modernisation of general practice in the UK: 1980 to 1995 and beyond. Part I [see comments] Iliffe S. **Postgrad Med J** 1996 Apr;72(846):201-6 (56 ref.) Comment in: Postgrad Med J 1996 Apr;72(846):195.

FAMILY, RECONSTITUTED see **FAMILY**

FAMILY RELATIONSHIP see **FAMILY**

FAMILY, SINGLE-PARENT see **SINGLE PARENT**

FAMILY SIZE see **FAMILY CHARACTERISTICS**

FAMILY THERAPY

Research update on the psychosocial treatment of schizophrenia. Penn DL, et al. **Am J Psychiatry** 1996 May; 153(5):607-17 (89 ref.)

Preserving families at risk of child abuse and neglect: the role of the helping alliance [see comments] Dore MM, et al. **Child Abuse Negl** 1996 Apr;20(4):349-61 (80 ref.) Comment in: Child Abuse Negl 1996 Apr;20(4):345-7.

An infertility primer for family therapists: I. Medical, social, and psychological dimensions. Meyers M, et al.

FAMILY THERAPY

Fam Process 1995 Jun;34(2):219–29 (53 ref.)
Family-based treatment for adolescent drug use: state of the science. Liddle HA, et al. **NIDA Res Monogr** 1995; 156:218–54 (153 ref.)
A cultural perspective on family theory and therapy. Kaslow NJ, et al. **Psychiatr Clin North Am** 1995 Sep;18(3):621–33 (34 ref.)
Maintenance treatment of schizophrenia: a review of dose reduction and family treatment strategies. Schooler NR, et al. **Psychiatr Q** 1995 Winter;66(4):279–92 (41 ref.)
Psychoeducation in first-episode psychosis: a therapeutic process. McGorry PD. **Psychiatry** 1995 Nov;58(4):313–28 (41 ref.)
Family interventions for schizophrenia. Dixon LB, et al. **Schizophr Bull** 1995;21(4):631–43 (45 ref.)
Counseling laryngectomees and families. Renner MJ. **Semin Speech Lang** 1995 Aug;16(3):215–20 (5 ref.)
Research in adolescent suicide: implications for training, service delivery, and public policy. Brent DA, et al. **Suicide Life Threat Behav** 1995 Summer;25(2):222–30 (40 ref.)

EDUCATION

Training to think culturally: a multidimensional comparative framework. Falicov CJ. **Fam Process** 1995 Dec; 34(4):373–88 (56 ref.)

METHODS

Training to think culturally: a multidimensional comparative framework. Falicov CJ. **Fam Process** 1995 Dec; 34(4):373–88 (56 ref.)
An infertility primer for family therapists: II. Working with couples who struggle with infertility. Meyers M, et al. **Fam Process** 1995 Jun;34(2):231–40 (14 ref.)
Integrating qualitative and quantitative research methods: a research model. Sells SP, et al. **Fam Process** 1995 Jun; 34(2):199–218 (95 ref.)
"Becoming": a method for expanding systemic thinking and deepening empathic accuracy. Snyder M. **Fam Process** 1995 Jun;34(2):241–53 (40 ref.)
Current status of family-based outcome and process research. Diamond GS, et al.
J Am Acad Child Adolesc Psychiatry 1996 Jan;35(1):6–16 (120 ref.)
[Counseling male adolescents with homosexual orientation and their parents] Rauchfleisch U.
Prax Kinderpsychol Kinderpsychiatr 1996 May–Jun; 45(5):166–70 (35 ref.) (Eng. Abstr.) **(Ger)**

FAMILY VIOLENCE see **DOMESTIC VIOLENCE**

FAMOTIDINE

ADVERSE EFFECTS

Thrombotic thrombo-cytopenic purpura associated with histamine H2-receptor antagonist therapy. Kallal SM, et al. **West J Med** 1996 May;164(5):446–8 (25 ref.)

THERAPEUTIC USE

Drug therapy of peptic ulcer disease. Ching CK, et al. **Br J Hosp Med** 1995 Jul 12–Aug 15;54(2–3):101–6 (39 ref.)
[Clinical aspects of Kvamatel (famotidine) administration] Golochevskaia VS. **Klin Med (Mosk)** 1996;74(1):45–7 (10 ref.) **(Rus)**

FANCONI SYNDROME

COMPLICATIONS

Osteomalacia associated with adult Fanconi's syndrome: clinical and diagnostic features. Clarke BL, et al. **Clin Endocrinol (Oxf)** 1995 Oct;43(4):479–90 (62 ref.)

FANCONI'S ANEMIA

[Chromosome breakage syndrome and fragile X syndrome] Shiraishi Y. **Nippon Rinsho** 1995 Nov;53(11):2807–14 (16 ref.) (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

Successful allogeneic bone marrow transplantation in a case with myelodysplastic syndrome which developed following Fanconi anemia. Ikushima S, et al. **Bone Marrow Transplant** 1995 Oct;16(4):621–4 (21 ref.)
Diamond-Blackfan anemia and malignancy. A case report and a review of the literature [see comments] van Dijken PJ, et al. **Cancer** 1995 Aug 1;76(3):517–20 (22 ref.) Comment in: Cancer 1996 May 1;77(9):1961–2.
Osteogenic sarcoma in a child with transfusion-dependent Diamond-Blackfan anemia. Aquino VM, et al. **J Pediatr Hematol Oncol** 1996 May;18(2):230–2 (17 ref.)
Squamous cell carcinoma of the tongue in a child with Fanconi anemia: a case report and review of the literature. Somers GR, et al. **Pediatr Pathol Lab Med** 1995 Jul–Aug; 15(4):597–607 (62 ref.)

DIAGNOSIS

Prenatal diagnosis of Blackfan-Diamond syndrome: case report and review of the literature. McLennan AC, et al. **Prenat Diagn** 1996 Apr;16(4):349–53 (15 ref.)

THERAPY

Osteogenic sarcoma in a child with transfusion-dependent Diamond-Blackfan anemia. Aquino VM, et al. **J Pediatr Hematol Oncol** 1996 May;18(2):230–2 (17 ref.)

FANTASY

Cultural psychopathology and the "false memory syndrome" debates: a view from psychoanalysis. Berger LS. **Am J Psychother** 1996 Spring;50(2):167–77 (41 ref.)
Unconscious fantasy in psychotherapy. Levin K. **Am J Psychother** 1996 Spring;50(2):137–53 (54 ref.)

FAR EASTERN RUSSIAN ENCEPHALITIS see **ENCEPHALITIS, TICK-BORNE**

FARM ANIMALS see **ANIMALS, DOMESTIC**

FARMER'S LUNG

EPIDEMIOLOGY

[Extrinsic allergic alveolitis of occupational origin] Toubas D, et al. **Presse Med** 1995 Oct 14;24(30):1391–6 (42 ref.) (Eng. Abstr.) **(Fre)**

FARNESYLATION see **PROTEIN ISOPRENYLATION**

FARSIGHTEDNESS see **HYPEROPIA**

FAS ANTIGENS see **ANTIGENS, CD95**

FASCIA

RADIOGRAPHY

[Imaging of connective tissue formations of the sub-umbilical anterior abdominal wall] Roy C, et al.
Ann Radiol (Paris) 1995;38(7–8):389–95 (20 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

The use of the temporoparietal fascial flap in temporal bone reconstruction. Cheney ML, et al. **Am J Otol** 1996 Jan; 17(1):137–42 (11 ref.)

FASCIA LATA

INJURIES

Biomechanics of iliotibial band friction syndrome in runners. Orchard JW, et al. **Am J Sports Med** 1996 May–Jun; 24(3):375–9 (26 ref.)

FASCICULAR BLOCK see **BUNDLE-BRANCH BLOCK**

FASCICULATION

Clues to the diagnosis of amyotrophic lateral sclerosis. Cambier J, et al. **Adv Neurol** 1995;68:161–2 (12 ref.)
The diagnosis of amyotrophic lateral sclerosis. A discussion. Swash M. **Adv Neurol** 1995;68:157–60 (21 ref.)

FASCIITIS

Idiopathic palmar fasciitis. Laszlo KS, et al. **Int J Dermatol** 1995 Sep;34(9):658–60 (13 ref.)
[Fournier's gangrene. A special form of necrotizing fasciitis] Gerdes B, et al. **Dtsch Med Wochenschr** 1996 Aug 16; 121(33):1021–4 (37 ref.) **(Ger)**

COMPLICATIONS

Eosinophilia-myalgia syndrome, toxic-oil syndrome, and diffuse fasciitis with eosinophilia. Kaufman LD, et al. **Curr Opin Rheumatol** 1995 Nov;7(6):560–7 (89 ref.)
[Fasciitis with eosinophilia and bronchial cancer (letter)] Blanche P, et al. **Ann Med Interne (Paris)** 1996;147(1):62–4 (19 ref.) **(Fre)**

DIAGNOSIS

Magnetic resonance imaging of plantar fasciitis and other causes of heel pain. Kier R.
Magn Reson Imaging Clin N Am 1994 Feb;2(1):97–107 (35 ref.)
The fasciitis-panniculitis syndromes. Clinical and pathologic features. Naschitz JE, et al. **Medicine (Baltimore)** 1996 Jan; 75(1):6–16 (59 ref.)

ETIOLOGY

[Panniculitis-fasciitis syndrome disclosing systemic erythematous lupus] Carsuzaa F, et al.
Ann Dermatol Venereol 1996;123(4):259–61 (23 ref.) (Eng. Abstr.) **(Fre)**

MICROBIOLOGY

Polymerase chain reaction of Borrelia burgdorferi flagellin gene in Shulman syndrome. Hashimoto Y, et al.
Dermatology 1996;192(2):136–9 (26 ref.)

NURSING

The diagnosis and management of plantar fasciitis. Quaschnick MS. **Nurse Pract** 1996 Apr;21(4):50–4, 60–3, quiz 64–5 (33 ref.)

PATHOLOGY

Oral fasciitis [letter; comment] Mighell A.
Eur J Cancer B Oral Oncol 1995 May;31B(3):207–8 (39 ref.) Comment on: Eur J Cancer B Oral Oncol 1994 May;30B(3):221–2.

SURGERY

A retrospective comparison of endoscopic plantar fasciotomy to open plantar fasciotomy with heel spur resection for chronic plantar fasciitis/heel spur syndrome. Tomczak RL, et al. **J Foot Ankle Surg** 1995 May–Jun;34(3):305–11 (41 ref.)

FASCIITIS, NECROTIZING

Necrotizing fasciitis. Kotrappa KS, et al.
Am Fam Physician 1996 Apr;53(5):1691–7 (18 ref.)
Necrotizing fasciitis in children: report of two cases and review of the literature. Barton LL, et al.
Arch Pediatr Adolesc Med 1996 Jan;150(1):105–8 (50 ref.)
Necrotizing fasciitis. Green RJ, et al. **Chest** 1996 Jul; 110(1):219–29 (105 ref.)

DIAGNOSIS

Streptococcal gangrene of the eyelids and orbit. Shayegani A, et al. **Am J Ophthalmol** 1995 Dec;120(6):784–92 (49 ref.)
Rapid identification of group A streptococcus as the cause of necrotizing fasciitis. Ault MJ, et al. **Ann Emerg Med** 1996 Aug;28(2):227–30 (16 ref.)
Necrotising soft tissue infections as a complication of chickenpox. Nathan S, et al. **Singapore Med J** 1995 Dec; 36(6):656–60 (11 ref.)

ETIOLOGY

Necrotizing fasciitis originating from pinna perichondritis. Skorina J, et al. **Otolaryngol Head Neck Surg** 1995 Oct; 113(4):467–73 (33 ref.)

PATHOLOGY

Cervical necrotizing fasciitis: a distinct clinicopathological entity? Banerjee AR, et al. **J Laryngol Otol** 1996 Jan; 110(1):81–6 (67 ref.)

RADIOGRAPHY

CT evaluation of soft tissue and muscle infection and inflammation: a systematic compartmental approach. Beauchamp NJ Jr, et al. **Skeletal Radiol** 1995 Jul; 24(5):317–24 (8 ref.)

SURGERY

Necrotizing fasciitis following laparoscopic surgery. Case report and review of the literature. Golshani S, et al. **Surg Endosc** 1996 Jul;10(7):751–4 (20 ref.)

FASCIOLA HEPATICA

IMMUNOLOGY

Comparison of purified 12 kDa and recombinant 15 kDa Fasciola hepatica antigens related to a Schistosoma mansoni fatty acid binding protein. Hillyer GV.
Mem Inst Oswaldo Cruz 1995 Mar–Apr;90(2):249–53 (17 ref.)

FASCIOLIASIS

[Fascioliasis] Suou T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):90–2 (10 ref.) **(Jpn)**

FASCIOLOPSIASIS see **TREMATODE INFECTIONS**

FAST ATOM BOMBARDMENT MASS SPECTROMETRY see **SPECTROMETRY, MASS, FAST ATOM BOMBARDMENT**

FAST ATOM BOMBARDMENT MASS SPECTROSCOPY see **SPECTROMETRY, MASS, FAST ATOM BOMBARDMENT**

FAST ELECTRONS see **ELECTRONS**

FASTING

see related
STARVATION
Inpatient management of adults with diabetes. Hirsch IB, et al. **Diabetes Care** 1995 Jun;18(6):870–8 (82 ref.)
Pediatric ambulatory anesthesia: NPO—before or after surgery? Schreiner MS, et al. **J Clin Anesth** 1995 Nov; 7(7):589–96 (41 ref.)
[Perioperative fasting in children: current data] Paut O, et al. **Arch Pediatr** 1995 Aug;2(8):774–82 (52 ref.) (Eng. Abstr.) **(Fre)**
[The child with minor trauma. Does observation of fasting

times reduce the risk of aspiration?] Kraus GB, et al. **Anaesthesist** 1996 May;45(5):420–7 (71 ref.) (Eng. Abstr.) **(Ger)**

[Is traditional preoperative fasting still applicable?] Wrenger K, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May; 31(4):250–4 (36 ref.) **(Ger)**

[The recent trend in preoperative fasting] Kawasaki J, et al. **Masui** 1995 Aug;44(8):1154–8 (31 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

The effect of fasting and fructose and glucose infusion on gluconeogenesis and triose phosphate flux in rats in vivo. Wolf G. **Nutr Rev** 1995 Oct;53(10):299–301 (2 ref.)

Feeding, fasting and starvation: factors affecting fuel utilization. MacDonald IA, et al. **Proc Nutr Soc** 1995 Mar; 54(1):267–74 (29 ref.)

FAT CELLS see **ADIPOCYTES**

FAT EMULSIONS, INTRAVENOUS

THERAPEUTIC USE

[The use of lipids in total parenteral nutrition] Motton G, et al. **Chir Ital** 1994;46(6):31–5 (49 ref.) (Eng. Abstr.) **(Ita)**

FAT NECROSIS

DIAGNOSIS

[Fat necrosis in the newborn] Beneggi A, et al. **Pediatr Med Chir** 1995 May–Jun;17(3):281–2 (10 ref.) (Eng. Abstr.) **(Ita)**

RADIOGRAPHY

The mammographic spectrum of fat necrosis of the breast. Hogge JP, et al. **Radiographics** 1995 Nov;15(6):1347–56 (25 ref.)

FAT-RESTRICTED DIET see **DIET, FAT-RESTRICTED**

FATHER–CHILD RELATIONS

Parents as partners: including mothers and fathers in the treatment of children who stutter. Kelly EM. **J Commun Disord** 1995 Jun;28(2):93–105 (50 ref.)

FATHERS

PSYCHOLOGY

The role of the father in parental postnatal mental health. Marks M, et al. **Br J Med Psychol** 1995 Jun;68 (Pt 2):157–68 (75 ref.)

Mendacious moms or devious dads? Some perplexing issues in child custody/sexual abuse allegation disputes. Penfold PS. **Can J Psychiatry** 1995 Aug;40(6):337–41 (38 ref.)

FATIGUE

The plasma level of some amino acids and physical and mental fatigue. Newsholme EA, et al. **Experientia** 1996 May 15;52(5):413–5 (14 ref.)

Fatigue and weakness in cancer patients: the symptoms experience. Nail LM, et al. **Semin Oncol Nurs** 1995 Nov; 11(4):272–8 (42 ref.)

EPIDEMIOLOGY

The epidemiology of fatigue and depression: a French primary-care study. Fuhrer R, et al. **Psychol Med** 1995 Sep;25(5):895–905 (51 ref.)

ETIOLOGY

Postoperative fatigue. Christensen T. **Dan Med Bull** 1995 Sep; 42(4):314–22 (132 ref.)

Carbohydrates, branched-chain amino acids, and endurance: the central fatigue hypothesis. Davis JM. **Int J Sport Nutr** 1995 Jun;5 Suppl:S29–38 (42 ref.)

PHYSIOPATHOLOGY

Explaining fatigue in congestive heart failure. Drexler H, et al. **Annu Rev Med** 1996;47:241–56 (83 ref.)

FATIGUE FRACTURES see **FRACTURES, STRESS**

FATIGUE, MENTAL see **MENTAL FATIGUE**

FATIGUE, MUSCLE see **MUSCLE FATIGUE**

FATIGUE SYNDROME, CHRONIC

New developments: diagnosis and management of chronic fatigue in children and adolescents. Carter BD, et al. **Curr Probl Pediatr** 1995 Oct;25(9):281–93 (103 ref.)

+hronic fatigue syndrome: current perspectives on evaluation and management [see comments] Hickie IB, et al. **Med J Aust** 1995 Sep 18;163(6):314–8 (48 ref.) Comment in: Med J Aust 1996 Mar 18;164(6):384.

Use of exercise for treatment of chronic fatigue syndrome. McCully KK, et al. **Sports Med** 1996 Jan;21(1):35–48 (78 ref.)

[Chronic fatigue syndrome—a review of the literature] Hamre HJ. **Tidsskr Nor Laegeforen** 1995 Oct 10; 115(24):3042–5 (85 ref.) (Eng. Abstr.) **(Nor)**

[Postviral fatigue syndrome] Haukenes G, et al. **Tidsskr Nor Laegeforen** 1995 Oct 10;115(24):3017–22 (36 ref.) (Eng. Abstr.) **(Nor)**

DIAGNOSIS

Can the chronic fatigue syndrome be defined by distinct clinical features? Hickie I, et al. **Psychol Med** 1995 Sep; 25(5):925–35 (60 ref.)

DRUG THERAPY

[Therapeutic guidelines in chronic fatigue syndrome] Bertolín Guillén JM, et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1994 May–Jun;22(3):127–30 (46 ref.) (Eng. Abstr.) **(Spa)**

EPIDEMIOLOGY

Fibromyalgia, chronic fatigue syndrome, and myofascial pain. Goldenberg DL. **Curr Opin Rheumatol** 1996 Mar; 8(2):113–23 (95 ref.)

The epidemiology of chronic fatigue syndrome. Wessely S. **Epidemiol Rev** 1995;17(1):139–51 (138 ref.)

ETIOLOGY

Chronic fatigue syndrome. 1: Etiology and pathogenesis. Farrar DJ, et al. **Behav Med** 1995 Spring;21(1):5–16 (133 ref.)

The rise and fall of the chronic fatigue syndrome as defined by Holmes et al. van Waveren EK. **Med Hypotheses** 1996 Feb;46(2):63–6 (14 ref.)

Chronic fatigue syndrome (myalgic encephalopathy). Plioplys S, et al. **South Med J** 1995 Oct;88(10):993–1000 (81 ref.)

PSYCHOLOGY

Chronic fatigue syndrome. 1: Etiology and pathogenesis. Farrar DJ, et al. **Behav Med** 1995 Spring;21(1):5–16 (133 ref.)

[Chronic fatigue syndrome—psychiatric aspects] Lemke MR. **Fortschr Neurol Psychiatr** 1996 Apr;64(4):132–41 (77 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Chronic fatigue syndrome. 2: Treatment and future research. Kantrowitz FG, et al. **Behav Med** 1995 Spring;21(1):17–24 (32 ref.)

[Differential therapy of chronic fatigue syndrome] Pankow W, et al. **Internist (Berl)** 1995 Dec;36(12):1156–61 (25 ref.) **(Ger)**

[Therapeutic guidelines in chronic fatigue syndrome] Bertolín Guillén JM, et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1994 May–Jun;22(3):127–30 (46 ref.) (Eng. Abstr.) **(Spa)**

FATIGUE SYNDROME, POSTVIRAL see **FATIGUE SYNDROME, CHRONIC**

FATTY ACID CYCLO-OXYGENASE see **PROSTAGLANDIN-ENDOPEROXIDE SYNTHASE**

FATTY ACID DESATURASES

DEFICIENCY

[Glutaric aciduria type 2 (multiple acyl-CoA dehydrogenase deficiency)] Yamaguchi S. **Ryoikibetsu Shokogun Shirizu** 1995;(8):325–8 (20 ref.) **(Jpn)**

FATTY ACID SYNTHETASE COMPLEX

BIOSYNTHESIS

Nutritional and hormonal regulation of fatty acid synthase. Wolf G. **Nutr Rev** 1996 Apr;54(4 Pt 1):122–3 (9 ref.)

METABOLISM

[Fatty acid synthases—strategic functions of multienzymes] Schweizer E. **Naturwissenschaften** 1996 Aug;83(8):347–58 (52 ref.) (Eng. Abstr.) **(Ger)**

FATTY ACIDS

ADVERSE EFFECTS

Trans fatty acids and cancer. Ip C, et al. **Nutr Rev** 1996 May; 54(5):138–45 (35 ref.)

ANALYSIS

Influence of dietary fatty acid composition and vitamin E on fatty acids and alpha-tocopherol in carp (Cyprinus carpio L.). Schwarz FJ. **Arch Tierernahr** 1996;49(1):63–71 (37 ref.)

Fatty acid profiles of lipid samples. Gutnikov G. **J Chromatogr B Biomed Appl** 1995 Sep 15;671(1–2):71–89 (218 ref.)

Fatty acid composition of adipose tissue in humans. Implications for the dietary fat-serum cholesterol-CHD issue. Seidelin KN. **Prog Lipid Res** 1995;34(3):199–217 (158 ref.)

BIOSYNTHESIS

Recent advances in the biosynthesis of plant fatty acids. Harwood JL. **Biochim Biophys Acta** 1996 May 31; 1301(1–2):7–56 (588 ref.)

Escherichia coli as a model for the regulation of dissociable (type II) fatty acid biosynthesis. Rock CO, et al. **Biochim Biophys Acta** 1996 Jul 12;1302(1):1–16 (143 ref.)

CHEMISTRY

Position paper on trans fatty acids. ASCN/AIN Task Force on Trans Fatty Acids. American Society for Clinical Nutrition and American Institute of Nutrition. **Am J Clin Nutr** 1996 May;63(5):663–70 (32 ref.)

Gas chromatographic analysis of fatty acid methyl esters. Eder K. **J Chromatogr B Biomed Appl** 1995 Sep 15; 671(1–2):113–31 (140 ref.)

The role of stereospecific saturated fatty acid positions on lipid nutrition. Decker EA. **Nutr Rev** 1996 Apr;54(4 Pt 1):108–10 (18 ref.)

IMMUNOLOGY

Comparison of purified 12 kDa and recombinant 15 kDa Fasciola hepatica antigens related to a Schistosoma mansoni fatty acid binding protein. Hillyer GV. **Mem Inst Oswaldo Cruz** 1995 Mar–Apr;90(2):249–53 (17 ref.)

Nutrition and immunity with emphasis on infection and autoimmune disease. Harbige LS. **Nutr Health** 1996; 10(4):285–312 (136 ref.)

METABOLISM

Membrane permeation and intracellular trafficking of long chain fatty acids: insights from Escherichia coli and 3T3-L1 adipocytes. Mangroo D, et al. **Biochem Cell Biol** 1995 May–Jun;73(5–6):223–34 (98 ref.)

Role of insulin in hepatic fatty acid partitioning: emerging concepts. Zammit VA. **Biochem J** 1996 Feb 15;314 (Pt 1):1–14 (186 ref.)

Hormonal and nutritional control of liver fatty acid oxidation and ketogenesis during development. Prip-Buus C, et al. **Biochem Soc Trans** 1995 Aug;23(3):500–6 (47 ref.)

Insulin and the partitioning of hepatic fatty acid metabolism. Zammit VA. **Biochem Soc Trans** 1995 Aug;23(3):506–11 (43 ref.)

Potential pathogenic roles of aberrant lipoprotein and fatty acid metabolism in pre-eclampsia. Sattar N, et al. **Br J Obstet Gynaecol** 1996 Jul;103(7):614–20 (57 ref.)

The role of insulin in the control of hepatic fatty acid and glycerolipid metabolism assessed by studies in vivo. Zammit VA. **Braz J Med Biol Res** 1995 Oct;28(10):1027–31 (24 ref.)

Effects of acute and chronic exercise on fat metabolism. Martin WH 3rd. **Exerc Sport Sci Rev** 1996;24:203–31 (84 ref.)

Metabolic disruptions in the adipocyte-hepatocyte fatty acid axis as causes of HyperapoB. Sniderman AD, et al. **Int J Obes Relat Metab Disord** 1995 May;19 Suppl 1:S27–33 (68 ref.)

Regulation of organic nutrient metabolism during transition from late pregnancy to early lactation. Bell AW. **J Anim Sci** 1995 Sep;73(9):2804–19 (117 ref.)

Design of the oxygen and substrate pathways. VII. Different structural limits for oxygen and substrate supply to muscle mitochondria. Weibel ER, et al. **J Exp Biol** 1996 Aug;199 (Pt 8):1699–709 (18 ref.)

Lipid status and fatty acid metabolism in phenylketonuria. Giovannini M, et al. **J Inherit Metab Dis** 1995;18(3):265–72 (28 ref.)

Disorders of mitochondrial long-chain fatty acid oxidation. Pollitt RJ. **J Inherit Metab Dis** 1995;18(4):473–90 (78 ref.)

In vivo 13C nuclear magnetic resonance: applications and current limitations for noninvasive assessment of fatty acid status. Cunnane SC, et al. **Lipids** 1996 Mar;31 Suppl:S127–30 (15 ref.)

Very long-chain fatty acids in diagnosis, pathogenesis, and therapy of peroxisomal disorders. Moser HW, et al. **Lipids** 1996 Mar;31 Suppl:S141–4 (18 ref.)

Branched-chain fatty acids: the case for a novel form of cell-cell signalling during Myxococcus xanthus development. Downard J, et al. **Mol Microbiol** 1995 Apr; 16(2):171–5 (18 ref.)

Trans fatty acids: implications for health, analytical methods, incidence in edible fats and intake (a review). Precht D, et al. **Nahrung** 1995;39(5–6):343–74 (195 ref.)

Protein-mediated facilitated uptake processes for fatty acids, bilirubin, and other amphipathic compounds [see comments] Fitscher BA, et al. **Proc Soc Exp Biol Med** 1996 May;212(1):15–23 (99 ref.) Comment in: Proc Soc Exp Biol Med 1996 May;212(1):1–4.

Fatty acids enter cells by simple diffusion [see comments] Zakim D. **Proc Soc Exp Biol Med** 1996 May;212(1):5–14 (53 ref.) Comment in: Proc Soc Exp Biol Med 1996 May;212(1):1–4.

beta-oxidation of fatty acids in mitochondria, peroxisomes, and bacteria: a century of continued progress. Kunau WH, et al. **Prog Lipid Res** 1995;34(4):267-342 (951 ref.)
[Hepatic mitochondrial fatty acid oxidation disorders] Matsubara Y. **Ryoikibetsu Shokogun Shirizu** 1995;(8):312-6 (21 ref.) **(Jpn)**

PHARMACOKINETICS

Fatty acid transport and fatty acid-binding proteins. Veerkamp JH. **Proc Nutr Soc** 1995 Mar;54(1):23-37 (75 ref.)

PHARMACOLOGY

Trans fatty acids and their effects on lipoproteins in humans. Katan MB, et al. **Annu Rev Nutr** 1995;15:473-93 (53 ref.)
Influence of dietary fatty acid composition and vitamin E on fatty acids and alpha-tocopherol in carp (Cyprinus carpio L.). Schwarz FJ. **Arch Tierernahr** 1996;49(1):63-71 (37 ref.)
Effect of royal jelly on serum lipids in experimental animals and humans with atherosclerosis. Vittek J. **Experientia** 1995 Sep 29;51(9-10):927-35 (68 ref.)
Botanical lipids: effects on inflammation, immune responses, and rheumatoid arthritis. Rothman D, et al. **Semin Arthritis Rheum** 1995 Oct;25(2):87-96 (75 ref.)
[The modulation of cellular ion channel activity by arachidonic acid, its metabolic products and other fatty acids] Krutetskaia ZI, et al. **Tsitologiia** 1995;37(1-2):5-65 (241 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Fatty acid-related functions. Dupont J, et al. **Am J Clin Nutr** 1996 Jun;63(6):991S-993S (10 ref.)
Fatty acid binding protein in locust and mammalian muscle. Comparison of structure, function and regulation. Haunerland NH. **Comp Biochem Physiol B Biochem Mol Biol** 1994 Oct-Nov; 109(2-3):199-208 (49 ref.)
Adipocyte differentiation. When precursors are also regulators. MacDougald OA, et al. **Curr Biol** 1995 Jun 1; 5(6):618-21 (16 ref.)
Role of glucocorticoids and fatty acids in the impairment of lipid metabolism observed in the metabolic syndrome. Brindley DN. **Int J Obes Relat Metab Disord** 1995 May; 19 Suppl 1:S69-75 (61 ref.)
Eicosanoids, fatty acids and neutrophils: their relevance to the pathophysiology of disease. Bates EJ. **Prostaglandins Leukot Essent Fatty Acids** 1995 Aug; 53(2):75-86 (213 ref.)
Role of fatty acids and eicosanoids in modulating proteoglycan metabolism in endothelial cells. Hennig B, et al. **Prostaglandins Leukot Essent Fatty Acids** 1995 Nov; 53(5):315-24 (114 ref.)
[Role of miscellaneous substances (organic acids, lactone, etc) in regulation of food intake] Aou S, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:85-9 (19 ref.) **(Jpn)**

FATTY ACIDS, ESSENTIAL

ADMINISTRATION & DOSAGE

Essential fatty acid requirements in carp. Takeuchi T. **Arch Tierernahr** 1996;49(1):23-32 (29 ref.)
Nutritional pharmacology and malignant disease: a therapeutic modality in patients with cancer. Heys SD, et al. **Br J Surg** 1996 May;83(5):608-19 (135 ref.)

PHYSIOLOGY

Essentiality of omega-3 and omega-6 fatty acids for efficient liver sterol metabolism. Levy E. **Can J Cardiol** 1995 Oct; 11 Suppl G:29G-35G (79 ref.)
Essential fatty acids in pregnancy and early human development. Hornstra G, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Jul;61(1):57-62 (35 ref.)
Role of essential fatty acids in the function of the developing nervous system. Uauy R, et al. **Lipids** 1996 Mar;31 Suppl:S167-76 (84 ref.)

FATTY ACIDS, FREE see **FATTY ACIDS, NONESTERIFIED**

FATTY ACIDS, MONOUNSATURATED

PHARMACOKINETICS

Development and pharmacology of fluvastatin. Jokubaitis LA. **Br J Clin Pract Symp Suppl** 1996 Jan;77A:11-5 (4 ref.)

PHARMACOLOGY

[The pharmacology of the statins: the evidence of a direct antiatherosclerotic action] Raiteri M, et al. **Ann Ital Med Int** 1995 Oct;10 Suppl:35S-42S (74 ref.) (Eng. Abstr.) **(Ita)**

THERAPEUTIC USE

Fluvastatin for the prevention of restenosis after coronary balloon angioplasty: angiographic and methodological background of the fluvastatin angioplasty restenosis trial. Foley DP, et al. **Br J Clin Pract Symp Suppl** 1996 Jan; 77A:40-53 (53 ref.)
Fluvastatin in combination with other lipid-lowering agents. Jokubaitis LA. **Br J Clin Pract Symp Suppl** 1996 Jan; 77A:28-32 (4 ref.)
Treatment of dyslipidaemias with fluvastatin. Peters TK. **Br J Clin Pract Symp Suppl** 1996 Jan;77A:16-9 (7 ref.)
[An update on the use of fluvastatin in primary hypercholesterolemia] Baggio G. **Ann Ital Med Int** 1995 Oct;10 Suppl:43S (5 ref.) **(Ita)**

N-3 FATTY ACIDS see **FATTY ACIDS, OMEGA-3**

FATTY ACIDS, NONESTERIFIED

BLOOD

Are increased plasma non-esterified fatty acid concentrations a risk marker for coronary heart disease and other chronic diseases? [editorial] Frayn KN, et al. **Clin Sci (Colch)** 1996 Apr;90(4):243-53 (129 ref.)
Fatty acids and insulin resistance. Boden G. **Diabetes Care** 1996 Apr;19(4):394-5 (14 ref.)
[Free fatty acids and its species] Uji Y, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:611-4 (12 ref.) **(Jpn)**

METABOLISM

Metformin and free fatty acid metabolism. Del Prato S, et al. **Diabetes Metab Rev** 1995 Sep;11 Suppl 1:S33-41 (56 ref.)
How do long-chain free fatty acids cross cell membranes? [comment] Berk PD. **Proc Soc Exp Biol Med** 1996 May; 212(1):1-4 (33 ref.) Comment on: Proc Soc Exp Biol Med 1996 May;212(1):5-14. Comment on: Proc Soc Exp Biol Med 1996 May;212(1):15-23.

FATTY ACIDS, OMEGA-3

IMMUNOLOGY

Can n-3 polyunsaturated fatty acids be used as immunomodulatory agents? Calder PC. **Biochem Soc Trans** 1996 Feb;24(1):211-20 (83 ref.)

METABOLISM

Omega-3 fatty acids--nutritional aspects. Drevon CA, et al. **Can J Cardiol** 1995 Oct;11 Suppl G:47G-54G (47 ref.)
n-3 polyunsaturated fatty acids and human cytokine synthesis. Endres S. **Lipids** 1996 Mar;31 Suppl:S239-42 (19 ref.)

PHARMACOLOGY

Prevention of cardiac sudden death by N-3 fatty acids: a review of the evidence. Leaf A, et al. **J Intern Med** 1996 Jul;240(1):5-12 (32 ref.)
Modulation of inflammation and cytokine production by dietary (n-3) fatty acids. Blok WL, et al. **J Nutr** 1996 Jun; 126(6):1515-33 (131 ref.)
Antagonistic effects of dietary arachidonic acid and n-3 polyunsaturated fatty acids. Whelan J. **J Nutr** 1996 Apr; 126(4 Suppl):1086S-91S (35 ref.)
Polyunsaturated fatty acid regulation of hepatic gene transcription. Clarke SD, et al. **Lipids** 1996 Mar;31 Suppl:S7-11 (50 ref.)
Effects of modulation of inflammatory and immune parameters in patients with rheumatic and inflammatory disease receiving dietary supplementation of n-3 and n-6 fatty acids. Kremer JM. **Lipids** 1996 Mar;31 Suppl:S243-7 (50 ref.)

PHYSIOLOGY

Can n-3 polyunsaturated fatty acids be used as immunomodulatory agents? Calder PC. **Biochem Soc Trans** 1996 Feb;24(1):211-20 (83 ref.)
Essentiality of omega-3 and omega-6 fatty acids for efficient liver sterol metabolism. Levy E. **Can J Cardiol** 1995 Oct; 11 Suppl G:29G-35G (79 ref.)

THERAPEUTIC USE

Therapeutic use of n-3 fatty acids for vascular disease and thrombosis. Goodnight SH, et al. **Chest** 1995 Oct;108(4 Suppl):302S-304S (36 ref.)
n-3 polyunsaturated fatty acids: update 1995. Endres S, et al. **Eur J Clin Invest** 1995 Sep;25(9):629-38 (72 ref.)

FATTY ACIDS, POLYUNSATURATED see **FATTY ACIDS, UNSATURATED**

FATTY ACIDS, SHORT-CHAIN see **FATTY ACIDS, VOLATILE**

FATTY ACIDS, UNSATURATED

BIOSYNTHESIS

Reevaluation of the pathways for the biosynthesis of polyunsaturated fatty acids. Sprecher H, et al. **J Lipid Res** 1995 Dec;36(12):2471-7 (48 ref.)

METABOLISM

Microbial oxidation of unsaturated fatty acids. Hou CT. **Adv Appl Microbiol** 1995;41:1-23 (37 ref.)
Fatty acid metabolism in freshwater fish with particular reference to polyunsaturated fatty acids. Henderson RJ. **Arch Tierernahr** 1996;49(1):5-22 (69 ref.)
The significance of polyunsaturated fatty acids in cutaneous biology. Ziboh VA. **Lipids** 1996 Mar;31 Suppl:S249-53 (29 ref.)
Eicosanoids in rheumatoid arthritis. Sperling RI. **Rheum Dis Clin North Am** 1995 Aug;21(3):741-58 (84 ref.)
[Cell damage as reason for the formation of unsaturated fatty acid hydroperoxides] Hölzel C, et al. **Naturwissenschaften** 1995 Oct;82(10):452-60 (74 ref.) (Eng. Abstr.) **(Ger)**
[Polyunsaturated fatty acids and their metabolites in chronic inflammatory bowel disease] Cabré i Gelada E, et al. **Gastroenterol Hepatol** 1995 Dec;18(10):515-25 (90 ref.) **(Spa)**

PHARMACOLOGY

Polyunsaturated fatty acid regulation of hepatic gene transcription. Clarke SD, et al. **J Nutr** 1996 Apr;126(4 Suppl):1105S-9S (52 ref.)
Polyunsaturated fatty acid regulation of hepatic gene transcription. Clarke SD, et al. **Lipids** 1996 Mar;31 Suppl:S7-11 (50 ref.)
Effects of modulation of inflammatory and immune parameters in patients with rheumatic and inflammatory disease receiving dietary supplementation of n-3 and n-6 fatty acids. Kremer JM. **Lipids** 1996 Mar;31 Suppl:S243-7 (50 ref.)
[Polyunsaturated fatty acids and cerebral-sensory development in infants (editorial)] Ghisolfi J. **Arch Pediatr** 1995 Sep;2(9):825-30 (15 ref.) **(Fre)**

PHYSIOLOGY

Essentiality of omega-3 and omega-6 fatty acids for efficient liver sterol metabolism. Levy E. **Can J Cardiol** 1995 Oct; 11 Suppl G:29G-35G (79 ref.)

THERAPEUTIC USE

[Polyunsaturated fatty acids and their metabolites in chronic inflammatory bowel disease] Cabré i Gelada E, et al. **Gastroenterol Hepatol** 1995 Dec;18(10):515-25 (90 ref.) **(Spa)**

FATTY ACIDS, VOLATILE

ANALYSIS

Prediction of ruminal volatile fatty acids and pH within the net carbohydrate and protein system. Pitt RE, et al. **J Anim Sci** 1996 Jan;74(1):226-44 (126 ref.)

METABOLISM

The role of glutamine, short-chain fatty acids, and nucleotides in intestinal adaptation to gastrointestinal disease. LeLeiko NS, et al. **Pediatr Clin North Am** 1996 Apr;43(2):451-70 (98 ref.)
Fuel selection in intestinal cells. Duée PH, et al. **Proc Nutr Soc** 1995 Mar;54(1):83-94 (59 ref.)

PHYSIOLOGY

Role of short-chain fatty acids in the prevention of colorectal cancer. Scheppach W, et al. **Eur J Cancer** 1995 Jul-Aug; 31A(7-8):1077-80 (29 ref.)
Short-chain fatty acids and colorectal cancer. Vernia P, et al. **Eur J Clin Nutr** 1995 Oct;49 Suppl 3:S18-21 (20 ref.)

FATTY ACYL COA see **ACYL COENZYME A**

FATTY LIVER

[Idiopathic acute fatty liver of pregnancy: IAFLP] Ibe T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):24-7 (23 ref.) **(Jpn)**
[Mottled fatty infiltration of the liver] Oda T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):35-7 (4 ref.) **(Jpn)**
[Fatty liver] Tanaka N. **Ryoikibetsu Shokogun Shirizu** 1995; (8):18-20 (11 ref.) **(Jpn)**

CHEMICALLY INDUCED

[Drug induced steatosis] Yamamoto K. **Ryoikibetsu Shokogun Shirizu** 1995;(8):38-41 (15 ref.) **(Jpn)**
[Chemical substance induced steatosis] Yamamoto K. **Ryoikibetsu Shokogun Shirizu** 1995;(8):7-10 (10 ref.) **(Jpn)**

COMPLICATIONS

Disseminated intravascular coagulation and antithrombin III depression in acute fatty liver of pregnancy. Castro MA, et al. **Am J Obstet Gynecol** 1996 Jan;174(1 Pt 1):211-6 (13 ref.)
[A case of cholangiocarcinoma with temporary subsegmental fatty liver and intrahepatic portal aneurysm] Miyanaga O, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Sep; 92(9):1297-303 (9 ref.) **(Jpn)**

[Hepatocarcinoma associated to fatty liver degeneration. Report of a clinical case] Pacheco R, et al. **G E N** 1995 Jul-Sep;49(3):234-7 (16 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Nonalcoholic steatohepatitis. Neuschwander-Tetri BA, et al. **Med Clin North Am** 1996 Sep;80(5):1147-66 (98 ref.)

ETIOLOGY

Hepatic steatosis revealing celiac disease: a case complicated by transitory liver failure [letter] Cassagnou M, et al. **Am J Gastroenterol** 1996 Jun;91(6):1291-2 (8 ref.)

Liver disturbances in obesity and diabetes mellitus. Van Steenbergen W, et al. **Int J Obes Relat Metab Disord** 1995 Sep;19 Suppl 3:S27-36 (80 ref.)

[Liver injuries in obese patients] Toshima K, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:354-8 (30 ref.) **(Jpn)**

[Total parenteral nutrition] Hosoda S, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):309-11 (16 ref.) **(Jpn)**

[Nonalcoholic steatohepatitis (NASH)] Ishii H, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):28-31 (22 ref.) **(Jpn)**

[Fatty liver in obesity] Ishii M, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):32-4 (18 ref.) **(Jpn)**

[Fatty liver and diabetes mellitus] Kobayashi K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):21-3 (12 ref.) **(Jpn)**

[Obesity] Saito Y. **Ryoikibetsu Shokogun Shirizu** 1995;(8):407-9 (6 ref.) **(Jpn)**

PATHOLOGY

[Focal fatty change of the liver] Bamba T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):14-7 (12 ref.) **(Jpn)**

FATTY STREAK, ARTERIAL see **ATHEROSCLEROSIS**

FATTY TISSUE see **ADIPOSE TISSUE**

FATTY TUMOR see **LIPOMA**

FAVISM

DIAGNOSIS

Favism in a female newborn infant whose mother ingested fava beans before delivery. Corchia C, et al. **J Pediatr** 1995 Nov;127(5):807-8 (8 ref.)

FAVRE-RACOUCHOT SYNDROME

[Heliodermatitis or photo-induced skin aging] Leccia MT, et al. **Ann Dermatol Venereol** 1995;122(10):720-8 (89 ref.) **(Fre)**

ETIOLOGY

[Heliodermatitis or photo-induced skin aging] Leccia MT, et al. **Ann Dermatol Venereol** 1995;122(10):720-8 (89 ref.) **(Fre)**

FC EPSILON RECEPTORS see **RECEPTORS, IGE**

FC GAMMA RECEPTORS see **RECEPTORS, IGG**

FC RECEPTORS see **RECEPTORS, FC**

FC RECEPTORS, EPSILON see **RECEPTORS, IGE**

FC RECEPTORS, GAMMA see **RECEPTORS, IGG**

FEAR

see related
PHOBIC DISORDERS

Fear of AIDS and suicide in Finland: a review. Aro AR, et al. **AIDS Care** 1995;7 Suppl 2:5187-97 (60 ref.)

Heterosexism in nursing education. Gray DP, et al. **J Nurs Educ** 1996 May;35(5):204-10 (12 ref.)

Fear of AIDS and homophobia: implications for direct practice and advocacy. O'Hare T, et al. **Soc Work** 1996 Jan;41(1):51-8 (22 ref.)

PHYSIOLOGY

[Fear as a risk factor in perinatology] Zdziennicki A. **Wiad Lek** 1994 Sep;47(17-18):698-9 (21 ref.) (Eng. Abstr.) **(Pol)**

FEAR, DENTAL see **DENTAL ANXIETY**

FECAL INCONTINENCE

see related
ENCOPRESIS

Constipation and fecal incontinence in the elderly population. Romero Y, et al. **Mayo Clin Proc** 1996 Jan;71(1):81-92 (73 ref.)

Encopresis and soiling. Loening-Baucke V. **Pediatr Clin North Am** 1996 Feb;43(1):279-98 (71 ref.)

Functional colonic and anorectal disorders. Detecting and overcoming causes of constipation and fecal incontinence. Rao SS. **Postgrad Med** 1995 Nov;98(5):115-9, 124-6 (40 ref.)

ETIOLOGY

Incontinence and anorectal dysfunction in patients with diabetes mellitus. Wald A. **Eur J Gastroenterol Hepatol** 1995 Aug;7(8):737-9 (16 ref.)

Systemic diseases causing disorders of defecation and continence. Wald A. **Semin Gastrointest Dis** 1995 Oct;6(4):194-202 (55 ref.)

[Current proctology--modern functional diagnosis] Feifel G, et al. **Chirurg** 1996 Mar;67(3):205-12 (33 ref.) (Eng. Abstr.) **(Ger)**

[Fecal incontinence. Etiology and therapeutic possibilities] Staude G. **Med Monatsschr Pharm** 1996 Apr;19(4):99-105 (18 ref.) **(Ger)**

PATHOLOGY

[Results and conclusions from 328 radical operations of rectal carcinoma by one surgeon. Comparative anatomic studies with Brachydanio rerio and Latimeria chalumnae] Stelzner F. **Chirurg** 1995 Dec;66(12):1230-8 (22 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Anorectal and pelvic floor function. Relevance of continence, incontinence, and constipation. Sagar PM, et al. **Gastroenterol Clin North Am** 1996 Mar;25(1):163-82 (102 ref.)

Clinical and physiological aspects of ileal pouch-anal anastomosis. Salemans JM, et al. **Scand J Gastroenterol Suppl** 1995;212:3-12 (98 ref.)

PREVENTION & CONTROL

Continence-preserving procedures for benign and malignant disease. Lewis WG, et al. **Curr Opin Gen Surg** 1993;:157-63 (53 ref.)

Protecting the pelvic floor: obstetric management to prevent incontinence and pelvic organ prolapse. Handa VL, et al. **Obstet Gynecol** 1996 Sep;88(3):470-8 (46 ref.)

SURGERY

Continence disorders. Grotz RL, et al. **Curr Opin Gen Surg** 1993;:147-56 (54 ref.)

[Surgery of primary sphincter incontinence] Athanasiadis S. **Chirurg** 1996 May;67(5):483-90 (37 ref.) (Eng. Abstr.) **(Ger)**

[Reinterventions in secondary incontinence] Buchmann P, et al. **Chirurg** 1996 May;67(5):491-7 (18 ref.) (Eng. Abstr.) **(Ger)**

[Pelvic floor insufficiency as an interdisciplinary responsibility] Hansen H. **Chirurg** 1996 May;67(5):498-504 (14 ref.) (Eng. Abstr.) **(Ger)**

[Surgery is efficient in anal incontinence] Hultén L, et al. **Lakartidningen** 1996 Sep 11;93(37):3141-4, 3147-8 (4 ref.) **(Swe)**

ULTRASONOGRAPHY

Anal endosonography in faecal incontinence [editorial] Bartram C. **Endoscopy** 1996 Feb;28(2):259-60 (26 ref.)

[The role of ultrasonic endoscopy in the examination of post-obstetrical anal incontinence] Roseau G. **Contracept Fertil Sex** 1995 Dec;23(12):752-7 (28 ref.) (Eng. Abstr.) **(Fre)**

FECES

see related
MANURE

[Determination of the activated proto-oncogene (Ki-ras) in feces. A new laboratory analysis for early diagnosis of colorectal cancer] Koornstra JJ, et al. **Tidsskr Nor Laegeforen** 1995 Oct 30;115(26):3266-70 (42 ref.) (Eng. Abstr.) **(Nor)**

MICROBIOLOGY

Transmission of Helicobacter pylori: faecal-oral versus oral-oral route. Mégraud F. **Aliment Pharmacol Ther** 1995; 9 Suppl 2:85-91 (54 ref.)

[Adenoviruses from stool samples in hospital units. Comparison with main pathogens in gastroenteritis (rotavirus, Campylobacter, Salmonella)] Durepaire N, et al. **Pathol Biol (Paris)** 1995 Sep;43(7):601-10 (22 ref.) (Eng. Abstr.) **(Fre)**

PARASITOLOGY

Enteric parasitology. Interpreting laboratory reports. MacPherson DW. **Can Fam Physician** 1995 Oct;41:1729-31 (9 ref.)

VIROLOGY

[Fecal-oral transmission of viral hepatitis] Buisson Y, et al. **Med Trop (Mars)** 1995;55(4):305-11 (0 ref.) **(Fre)**

FECUNDITY see **FERTILITY**

FEE, CAPITATION see **CAPITATION FEE**

FEE-FOR-SERVICE, MEDICAL see **FEE-FOR-SERVICE PLANS**

FEE-FOR-SERVICE PLANS

Physician remuneration methods: the need for change and flexibility [editorial] Wright CJ. **Can Med Assoc J** 1996 Mar 1;154(5):678-80 (12 ref.)

FEEDBACK

see related
BIOFEEDBACK (PSYCHOLOGY)

The promise of computerized feedback systems for diabetes care. McDonald CJ, et al. **Ann Intern Med** 1996 Jan 1;124(1 Pt 2):170-4 (37 ref.)

Developmental dyslexia: a motor-articulatory feedback hypothesis. Heilman KM, et al. **Ann Neurol** 1996 Mar; 39(3):407-12 (35 ref.)

Fluent speech, fast articulatory rate, and delayed auditory feedback: creating a crisis for a scientific revolution? Stuart A, et al. **Percept Mot Skills** 1996 Feb;82(1):211-8 (42 ref.)

PHYSIOLOGY

Homeostatic control of plasma calcium concentration. Hurwitz S. **Crit Rev Biochem Mol Biol** 1996 Feb; 31(1):41-100 (500 ref.)

FEEDBACK, PSYCHOPHYSIOLOGIC see **BIOFEEDBACK (PSYCHOLOGY)**

FEEDING BEHAVIOR

Why do insects bite? A review of blood sucking behaviour. Dodd CS, et al. **J R Army Med Corps** 1995 Oct; 141(3):151-6 (52 ref.)

Pharmacology of ingestive behaviour. Samanin R, et al. **Therapie** 1996 Mar-Apr;51(2):107-15 (85 ref.)

[Etiology and physiopathology of obesity: eating behaviors and their disorders] Fukudo S, et al. **Nippon Naika Gakkai Zasshi** 1995 Aug 10;84(8):1226-30 (11 ref.) **(Jpn)**

[Feeding behavior: its deviation in obese subjects] Kurokawa M. **Nippon Rinsho** 1995 Jun;53 Suppl:398-404 (12 ref.) **(Jpn)**

[Behavioural modification for therapy of obesity] Ohno M, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:460-7 (15 ref.) **(Jpn)**

[Features of eating behaviour and their psychological background in simple obesity patients] Takeda N, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:407-11 (8 ref.) **(Jpn)**

PHYSIOLOGY

Establishing behavioral and physiological functions of central oxytocin: insights from studies of oxytocin and ingestive behaviors. Verbalis JG, et al. **Adv Exp Med Biol** 1995; 395:209-25 (61 ref.)

Control of energy intake by energy metabolism. Friedman MI. **Am J Clin Nutr** 1995 Nov;62(5 Suppl):1096S-1100S (45 ref.)

Cholecystokinin modulation of serotonergic control of feeding behavior. Cooper SJ. **Ann N Y Acad Sci** 1996 Mar 22;780:213-22 (49 ref.)

The neuroethological development of food-storing memory: a case of use it, or lose it! Clayton NS. **Behav Brain Res** 1995 Sep;70(1):95-102 (54 ref.)

New perspectives on dietary and behavioural treatments for obesity. Fairburn CG, et al. **Int J Obes Relat Metab Disord** 1996 Feb;20 Suppl 1:S9-13 (63 ref.)

Behaviour change in practice: group approaches. Hayaki J, et al. **Int J Obes Relat Metab Disord** 1996 Feb;20 Suppl 1:S27-30 (18 ref.)

Techniques for the experimental measurement of human eating behaviour and food intake: a practical guide. Hill AJ, et al. **Int J Obes Relat Metab Disord** 1995 Jun; 19(6):361-75 (91 ref.)

Behaviour change in practice: targeting individuals. Rollnick S. **Int J Obes Relat Metab Disord** 1996 Feb;20 Suppl 1:S22-6 (19 ref.)

Obesity and behaviour change: matching problems to practice. Wardle J. **Int J Obes Relat Metab Disord** 1996 Feb;20 Suppl 1:S1-8 (90 ref.)

Behaviour change in practice: population strategies. Wiseman MJ. **Int J Obes Relat Metab Disord** 1996 Feb;20 Suppl 1:S31-3 (14 ref.)

Feeding behavior and management factors during the transition period in dairy cattle. Grant RJ, et al. **J Anim Sci** 1995 Sep;73(9):2791-803 (86 ref.)

Opioid involvement in feeding behaviour and the pathogenesis of certain eating disorders. Johnson RD. **Med Hypotheses** 1995 Nov;45(5):491-7 (48 ref.)

How can eating behavior be regulated in the complex environments of free-living humans? De Castro JM. **Neurosci Biobehav Rev** 1996;20(1):119-31 (34 ref.)

Human eating: diagnosis and prognosis. Herman CP. **Neurosci Biobehav Rev** 1996;20(1):107-11 (4 ref.)

Mechanisms of sickness-induced decreases in food-motivated behavior. Kent S, et al. **Neurosci Biobehav Rev** 1996;

FEEDING BEHAVIOR

20(1):171–5 (36 ref.)
Probing the causes of high-fat diet hyperphagia: a mechanistic and behavioral dissection. Warwick ZS. **Neurosci Biobehav Rev** 1996;20(1):155–61 (33 ref.)
Unrealistic optimism about diet-related risks: implications for interventions. Raats MM, et al. **Proc Nutr Soc** 1996 Nov; 54(3):737–45 (36 ref.)
[Progress in research on the central mechanism of feeding behavior—neuronal network] Oomura Y, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:585–96 (20 ref.) **(Jpn)**
[Food regulation of exocrine pancreatic secretion and bile secretion in swine] Corring T. **Fiziol Zh Im I M Sechenova** 1995 Nov;81(11):70–81 (55 ref.) **(Rus)**
[The development of I. P. Pavlov's concepts of the food center] Kassil' VG. **Fiziol Zh Im I M Sechenova** 1995 Nov; 81(11):18–29 (49 ref.) **(Rus)**
[The regulation of food consumption (the ontogenetic aspects)] Kassil' VG. **Usp Fiziol Nauk** 1995 Jan–Mar; 26(1):46–75 (253 ref.) (Eng. Abstr.) **(Rus)**
[Food-acquisition and avoidance behaviors: the role of immunomodulators in their systemic organization] Zhuravlev BV, et al. **Usp Fiziol Nauk** 1996 Apr–Jun; 27(2):90–106 (107 ref.) (Eng. Abstr.) **(Rus)**

PSYCHOLOGY

Psychological consequences of food restriction. Polivy J. **J Am Diet Assoc** 1996 Jun;96(6):589–92; quiz 593–4 (48 ref.)

FEEDING PATTERNS see **FEEDING BEHAVIOR**

FEELINGS see **EMOTIONS**

FEES, MEDICAL

LEGISLATION & JURISPRUDENCE

Re-minding our Ps and Qs: medical cost controls in Canada. Barer ML, et al. **Health Aff (Millwood)** 1996 Summer; 15(2):216–34 (34 ref.)

FELDSHERS see **PHYSICIAN ASSISTANTS**

FELINE ACQUIRED IMMUNODEFICIENCY SYNDROME

Feline immunodeficiency virus as a model for study of lentivirus infection of the central nervous system. Henriksen SJ, et al. **Curr Top Microbiol Immunol** 1995; 202:167–86 (88 ref.)

COMPLICATIONS

Neurobiology of simian and feline immunodeficiency virus infections. Gardner MB, et al. **Curr Top Microbiol Immunol** 1995;202:135–50 (62 ref.)

PREVENTION & CONTROL

[Vaccination against feline retrovirus infections] Horzinek MC. **Tierarztl Prax** 1996 Apr;24(2):197–202 (16 ref.) (Eng. Abstr.) **(Ger)**

VIROLOGY

[Dendritic cells in dogs and cats: models of study in human pathology] Marchal T, et al. **Pathol Biol (Paris)** 1995 Dec; 43(10):910–20 (68 ref.) (Eng. Abstr.) **(Fre)**

FELINE AIDS see **FELINE ACQUIRED IMMUNODEFICIENCY SYNDROME**

FELINE IMMUNODEFICIENCY VIRUS see **IMMUNODEFICIENCY VIRUS, FELINE**

FELINE LEUKEMIA VIRUS see **LEUKEMIA VIRUS, FELINE**

FELINE LYMPHOMA VIRUS see **LEUKEMIA VIRUS, FELINE**

FELINE T-LYMPHOTROPIC LENTIVIRUS see **IMMUNODEFICIENCY VIRUS, FELINE**

FELINE SYNCYTIUM-FORMING VIRUS see **SPUMAVIRUS**

FELLOWSHIPS AND SCHOLARSHIPS

ORGANIZATION & ADMINISTRATION

Pediatric emergency medicine fellow clinical work requirements. Wiley JF 2nd, et al. **Pediatr Emerg Care** 1995 Dec;11(6):381–8 (13 ref.)

FELODIPINE

THERAPEUTIC USE

Vascular selective calcium entry blockers in the treatment of cardiovascular disorders: focus on felodipine. Little WC, et al. **Cardiovasc Drugs Ther** 1995 Oct;9(5):657–63 (49 ref.)
A felodipine-metoprolol extended-release tablet: its properties and clinical development. Dahlöf B, et al. **J Hum Hypertens** 1995 Jul;9 Suppl 2:S43–7 (17 ref.)
Improving the therapeutic balance between efficacy and tolerability in antihypertensive drugs—the rationale and benefits of combining felodipine and metoprolol. Trenkwalder P, et al. **J Hum Hypertens** 1995 Jul;9 Suppl 2:S37–42 (17 ref.)

FELTY'S SYNDROME

DIAGNOSIS

[Rheumatoid arthritis, neutropenia and splenomegaly: the Felty syndrome] Hofbauer LC, et al. **Dtsch Med Wochenschr** 1995 Dec 8;120(49):1689–94 (21 ref.) (Eng. Abstr.) **(Ger)**
[The ocular manifestations in Felty's syndrome] Giuri S. **Oftalmologia** 1996 Jan–Mar;40(1):51–7 (28 ref.) (Eng. Abstr.) **(Rum)**

DRUG THERAPY

Resolution of the neutropenia of Felty's syndrome by longterm administration of recombinant granulocyte colony stimulating factor. Krishnaswamy G, et al. **J Rheumatol** 1996 Apr;23(4):763–5 (18 ref.)
[Felty syndrome: a therapy-resistant variant of chronic rheumatoid arthritis? 2 case reports and literature review] Brücker R, et al. **Schweiz Rundsch Med Prax** 1996 Apr 16;85(16):534–40 (38 ref.) (Eng. Abstr.) **(Ger)**

FEMALE CIRCUMCISION see **CIRCUMCISION, FEMALE**

FEMINISM see **WOMEN'S RIGHTS**

FEMINIZATION

CHEMICALLY INDUCED

[Feminization: a paradoxical effect of stimulation with hCG/hMG in the infertile male] Arango Toro O, et al. **Actas Urol Esp** 1995 May;19(5):376–82 (48 ref.) (Eng. Abstr.) **(Spa)**

FEMORAL ARTERY

Assessing patient comfort: local infiltration of lidocaine during femoral sheath removal. Bowden SM, et al. **Am J Crit Care** 1995 Sep;4(5):368–9 (4 ref.)
Fourth-degree burn induced thrombosis of the femoral artery and vein. De Santis F, et al. **Eur J Vasc Endovasc Surg** 1996 Apr;11(3):378–80 (9 ref.)
Rupture of true profunda femoris artery aneurysms. Two new cases. Levi N, et al. **J Cardiovasc Surg (Torino)** 1996 Apr;37(2):117–8 (9 ref.)
Isolated true atherosclerotic aneurysms of the deep femoral artery. Case report and literature review. Yahel J, et al. **J Cardiovasc Surg (Torino)** 1996 Feb;37(1):17–20 (23 ref.)
Ureteroarterial fistula: case report and review of the literature. Batter SJ, et al. **Urology** 1996 Sep;48(3):481–9 (35 ref.)
[Contiguity spondylodiscitis following percutaneous femoral artery catheterization. A case report] Mascalchi M, et al. **Radiol Med (Torino)** 1996 Mar;91(3):325–6 (9 ref.) **(Ita)**

INJURIES

Motor-scooter handlebar syndrome: blunt traumatic injury of the femoral artery. Baker WE, et al. **J Trauma** 1996 Jun;40(6):1017–20 (18 ref.)
Major vascular injury from high-pressure water jet. Harvey RL, et al. **J Trauma** 1996 Jan;40(1):165–7 (15 ref.)

SURGERY

Late rupture of femoropopliteal Dacron grafts: a rare complication. Vrancken Peeters MT, et al. **Eur J Vasc Endovasc Surg** 1996 Feb;11(2):243–6 (5 ref.)

FEMORAL FRACTURES

COMPLICATIONS

Subcapital fracture of a congenitally dislocated hip: revival of Girdlestone resection arthroplasty. Taha AM. **Bull Hosp Jt Dis** 1995;54(1):35–42 (100 ref.)
[Systemic complications in intramedullary nailing] Wenda K, et al. **Orthopade** 1996 Jun;25(3):292–9 (28 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

The rationales of interlocking nailing of the femur, tibia, and humerus. Brumback RJ. **Clin Orthop** 1996 Mar; (324):292–320 (142 ref.)
[Intramedullary osteosynthesis: elastic or rigid?] Gillet P, et al. **Acta Orthop Belg** 1995;61 Suppl 1:144–9 (32 ref.) **(Fre)**
[Secondary internal osteosynthesis after external fixation for recent or old open fracture of the lower limb] Bernat M, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1996; 82(2):137–44 (18 ref.) (Eng. Abstr.) **(Fre)**
[Local complications of intramedullary nailing] Strecker W, et al. **Orthopade** 1996 Jun;25(3):274–91 (59 ref.) (Eng. Abstr.) **(Ger)**
[Borderline indications for locked intramedullary nailing of femur and tibia] Vécsei V, et al. **Orthopade** 1996 Jun; 25(3):234–46 (66 ref.) (Eng. Abstr.) **(Ger)**
[Management of ipsilateral fractures of the femur shaft and proximal femur—therapy overview and current management] Haas NP, et al. **Zentralbl Chir** 1995; 120(11):856–61 (19 ref.) (Eng. Abstr.) **(Ger)**

VETERINARY

Fractures and luxations of the pelvis and proximal femur. Hull BL. **Vet Clin North Am Food Anim Pract** 1996 Mar; 12(1):47–58 (25 ref.)
Fractures of the femur. Trostle SS, et al. **Vet Clin North Am Food Anim Pract** 1996 Mar;12(1):169–80 (16 ref.)

FEMORAL HEAD PROSTHESIS see **HIP PROSTHESIS**

FEMORAL HERNIA see **HERNIA, FEMORAL**

FEMORAL NECK FRACTURES

ETIOLOGY

Are the etiologies of cervical and trochanteric hip fractures different? Mautalen CA, et al. **Bone** 1996 Mar;18(3 Suppl):133S–137S (39 ref.)

SURGERY

Total hip arthroplasty after acute displaced femoral neck fractures. Papandrea RF, et al. **Am J Orthop** 1996 Feb; 25(2):85–8 (21 ref.)
[Medial femoral neck fracture—femur head preserving therapeutic concepts] Dávid A, et al. **Zentralbl Chir** 1995; 120(11):841–9 (45 ref.) (Eng. Abstr.) **(Ger)**
[Management of ipsilateral fractures of the femur shaft and proximal femur—therapy overview and current management] Haas NP, et al. **Zentralbl Chir** 1995; 120(11):856–61 (19 ref.) (Eng. Abstr.) **(Ger)**
[Classification, therapy and complications of pediatric femoral neck fractures] Hahn MP, et al. **Zentralbl Chir** 1995;120(11):832–40 (56 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Femoral neck stress fractures in children and adolescents. St Pierre P, et al. **J Pediatr Orthop** 1995 Jul–Aug; 15(4):470–3 (12 ref.)

FEMORAL NEOPLASMS

DIAGNOSIS

Intracortical low grade osteosarcoma. A unique case and review of the literature on intracortical osteosarcoma. Blasius S, et al. **Gen Diagn Pathol** 1996 Mar;141(3–4):273–8 (22 ref.)

DRUG THERAPY

Can amputation be avoided in local recurrence after limb salvage for high grade osteosarcoma? A case report and a review of the literature. Babin SR, et al. **Int Orthop** 1995; 19(6):374–6 (10 ref.)

GENETICS

[Osteosarcoma in 2 siblings. A case report] Danckwerth F, et al. **Klin Padiatr** 1995 Sep–Oct;207(5):298–301 (41 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Can amputation be avoided in local recurrence after limb salvage for high grade osteosarcoma? A case report and a review of the literature. Babin SR, et al. **Int Orthop** 1995; 19(6):374–6 (10 ref.)
Multifocal osteolysis following limb-sparing procedures: imaging findings and a review of the literature. Kaste SC, et al. **Pediatr Radiol** 1996;26(2):158–61 (17 ref.)

FEMORAL NERVE

[Meralgia paresthetica. A rare differential diagnosis of circumscribed alopecia] Nabavi DG, et al. **Dtsch Med Wochenschr** 1996 Jun 21;121(25–26):834–8 (25 ref.) (Eng. Abstr.) **(Ger)**
[Femoral neuropathy due to a spontaneous hematoma of the iliopsoas muscle during therapy with heparin-calcium] Casoni P, et al. **Acta Biomed Ateneo Parmense** 1994; 65(5–6):289–96 (5 ref.) (Eng. Abstr.) **(Ita)**

FEMORAL VEIN

Assessing patient comfort: local infiltration of lidocaine during femoral sheath removal. Bowden SM, et al. **Am J Crit Care** 1995 Sep;4(5):368–9 (4 ref.)
Fourth-degree burn induced thrombosis of the femoral artery and vein. De Santis F, et al. **Eur J Vasc Endovasc Surg** 1996 Apr;11(3):378–80 (9 ref.)

INJURIES

Major vascular injury from high-pressure water jet. Harvey RL, et al. **J Trauma** 1996 Jan;40(1):165-7 (15 ref.)

FEMUR

Primary embryonal rhabdomyosarcoma of long bone. Case report and review of the literature. Lucas DR, et al. **Am J Surg Pathol** 1996 Feb;20(2):239-44 (32 ref.)

ABNORMALITIES

Autosomal recessive omodysplasia. Stoll C, et al. **Ann Genet** 1995;38(2):97-101 (8 ref.)

GROWTH & DEVELOPMENT

[Anatomy and development of the hip joint during growth. II. Anatomy and development of the proximal femur] Wierusz-Kozlowska M. **Chir Narzadow Ruchu Ortop Pol** 1996;61(1):59-62 (26 ref.) (Eng. Abstr.) **(Pol)**

PATHOLOGY

MR imaging of the patellofemoral compartment. Quinn SF, et al. **Magn Reson Imaging Clin N Am** 1994 Aug;2(3):425-40 (53 ref.)

Giant bone island of femur. Case report, literature review, and its distinction from low grade osteosarcoma. Brien EW, et al. **Skeletal Radiol** 1995 Oct;24(7):546-50 (15 ref.)

PHYSIOLOGY

Epidemiology of hip fractures: implications of the exponential increase with age. Melton LJ 3rd. **Bone** 1996 Mar;18(3 Suppl):121S-125S (53 ref.)

PHYSIOPATHOLOGY

The role of quadriceps exercise in the treatment of patellofemoral pain syndrome. Callaghan MJ, et al. **Sports Med** 1996 May;21(5):384-91 (55 ref.)

[Biomechanical changes in the hip, femur and knee joint after removal of a tensor fasciae latae flap] Lattermann C, et al. **Handchir Mikrochir Plast Chir** 1996 Mar;28(2):76-82 (33 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Desmoplastic fibroma of the bone. A report of two patients, review of the literature, and therapeutic implications. Böhm P, et al. **Cancer** 1996 Sep 1;78(5):1011-23 (97 ref.)

Radiographic course after acetabuloplasty and femoral osteotomy in hip dysplasia. Fritsch EW, et al. **Clin Orthop** 1996 Feb;(323):215-25 (52 ref.)

Endoprosthetic bone reconstruction following malignant tumor resection in skeletally immature patients. Ward WG, et al. **Orthop Clin North Am** 1996 Jul;27(3):493-502 (43 ref.)

FEMUR HEAD

Treatment of the unstable (acute) slipped capital femoral epiphysis. Aronsson DD, et al. **Clin Orthop** 1996 Jan; (322):99-110 (50 ref.)

The adolescent with slipped capital femoral epiphysis. Benchot R. **J Pediatr Nurs** 1996 Jun;11(3):175-82 (18 ref.)

[Slipped capital femoral epiphyses] Kallio P, et al. **Duodecim** 1994;110(19):1802-9 (28 ref.) **(Fin)**

[Transient osteoporosis of the hip. Presentation of a case and literature review] Leyes Vence M, et al. **Acta Orthop Belg** 1996 Mar;62(1):56-9 (6 ref.) (Eng. Abstr.) **(Fre)**

INJURIES

Slipped capital femoral epiphysis associated with hyperparathyroidism. A case report. Kinoshita J, et al. **Int Orthop** 1995;19(4):245-7 (14 ref.)

PHYSIOPATHOLOGY

Slipped capital femoral epiphysis associated with hyperparathyroidism. A case report. Kinoshita J, et al. **Int Orthop** 1995;19(4):245-7 (14 ref.)

FEMUR HEAD NECROSIS

COMPLICATIONS

Rapidly progressive destruction of the hip. Case report and review of the literature. Puylaert D, et al. **Acta Orthop Belg** 1995;61(4):312-4 (5 ref.)

PHYSIOPATHOLOGY

Avascular necrosis of the proximal femur in developmental dislocation of the hip. Incidence, risk factors, sequelae and MR imaging for diagnosis and prognosis. Kruczynski J. **Acta Orthop Scand Suppl** 1996 Apr;268:1-48 (167 ref.)

THERAPY

Core decompression versus nonoperative management for osteonecrosis of the hip. Mont MA, et al. **Clin Orthop** 1996 Mar;(324):169-78 (67 ref.)

FEMUR NECK

[Transient osteoporosis of the hip. Presentation of a case and literature review] Leyes Vence M, et al. **Acta Orthop Belg** 1996 Mar;62(1):56-9 (6 ref.) (Eng. Abstr.) **(Fre)**

RADIOGRAPHY

[Spontaneous disappearance of herniation pit on the femoral neck] Lerais JM, et al. **J Radiol** 1995 Sep;76(9):593-5 (7 ref.) (Eng. Abstr.) **(Fre)**

FENESTRATION

ADVERSE EFFECTS

Anomalous internal carotid artery-anterior cerebral artery anastomosis associated with fenestration and cerebral aneurysm. Fujimura M, et al. **Neurol Med Chir (Tokyo)** 1996 Apr;36(4):229-33 (26 ref.)

FENFLURAMINE

THERAPEUTIC USE

Clinical studies with dexfenfluramine: from past to future. Guy-Grand B. **Obes Res** 1995 Nov;3 Suppl 4:491S-496S (34 ref.)

FENILBUTAZON see **PHENYLBUTAZONE**

FENITOIN see **PHENYTOIN**

FENOFIBRATE see **PROCETOFEN**

FENRETINIDE

PHARMACOLOGY

4-Hydroxyphenylretinamide in the chemoprevention of cancer. Naik HR, et al. **Adv Pharmacol** 1995;33:315-47 (98 ref.)

Bioactivities of N-(4-hydroxyphenyl) retinamide and retinoyl beta-glucuronide. Formelli F, et al. **FASEB J** 1996 Jul;10(9):1014-24 (109 ref.)

THERAPEUTIC USE

4-Hydroxyphenylretinamide in the chemoprevention of cancer. Naik HR, et al. **Adv Pharmacol** 1995;33:315-47 (98 ref.)

Retinoids in cancer chemoprevention. Clinical trials with the synthetic analogue fenretinide. Costa A, et al. **Ann N Y Acad Sci** 1995 Sep 30;768:148-62 (49 ref.)

Controlled clinical trials with fenretinide in breast cancer, basal cell carcinoma and oral leukoplakia. De Palo G, et al. **J Cell Biochem Suppl** 1995;22:11-7 (16 ref.)

-Results of ongoing breast cancer prevention studies- Jungi WF. **Arch Gynecol Obstet** 1995;256 Suppl:S116-21 (18 ref.) **(Ger)**

FENTOLAMIN see **PHENTOLAMINE**

FEP see **POLYTETRAFLUOROETHYLENE**

FERMENTATION

Bacterial fermentation of complex carbohydrate in the human colon. Hill MJ. **Eur J Cancer Prev** 1995 Oct;4(5):353-8 (23 ref.)

PHYSIOLOGY

Interactions between large intestine fermentation and dietary calcium. Demigné C, et al. **Eur J Clin Nutr** 1995 Oct;49 Suppl 3:S235-8 (13 ref.)

FERREDOXIN-NADP REDUCTASE

CHEMISTRY

Molecular recognition in protein complexes involved in electron transfer. Gómez-Moreno C, et al. **Biochem Soc Trans** 1996 Feb;24(1):111-6 (19 ref.)

METABOLISM

Molecular recognition in protein complexes involved in electron transfer. Gómez-Moreno C, et al. **Biochem Soc Trans** 1996 Feb;24(1):111-6 (19 ref.)

FERREDOXINS

CHEMISTRY

Molecular recognition in protein complexes involved in electron transfer. Gómez-Moreno C, et al. **Biochem Soc Trans** 1996 Feb;24(1):111-6 (19 ref.)

METABOLISM

Molecular recognition in protein complexes involved in electron transfer. Gómez-Moreno C, et al. **Biochem Soc Trans** 1996 Feb;24(1):111-6 (19 ref.)

FERRICYTOCHROME C see **CYTOCHROME C**

FERRIHEMOPROTEIN P-450 REDUCTASE see **NADPH-FERRIHEMOPROTEIN REDUCTASE**

FERRITIN

BIOSYNTHESIS

Effects of the ferritin open reading frame on translational induction by iron. Mascotti DP, et al. **Prog Nucleic Acid Res Mol Biol** 1996;55:121-34 (82 ref.)

BLOOD

[Ferritin] Fujioka S. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:248-50 (14 ref.) **(Jpn)**

METABOLISM

Placental isoferritin: a new biomarker from conception to delivery. Maymon R, et al. **Br J Obstet Gynaecol** 1996 Apr;103(4):301-5 (29 ref.)

PHARMACOLOGY

Ferritin as a source of iron and protection from iron-induced toxicities. Aust SD. **Toxicol Lett** 1995 Dec;82-83:941-4 (25 ref.)

PHYSIOLOGY

The ferritins: molecular properties, iron storage function and cellular regulation. Harrison PM, et al. **Biochim Biophys Acta** 1996 Jul 31;1275(3):161-203 (477 ref.)

A role for ferritin in hematopoiesis and the immune system. Morikawa K, et al. **Leuk Lymphoma** 1995 Aug; 18(5-6):429-33 (27 ref.)

FERROCHELATASE

[Discovery of heme O and heme A synthases] Saiki K. **Seikagaku** 1995 Aug;67(8):1048-53 (15 ref.) **(Jpn)**

CHEMISTRY

Structure and function of ferrochelatase. Ferreira GC, et al. **J Bioenerg Biomembr** 1995 Apr;27(2):221-9 (74 ref.)

GENETICS

The ferrochelatase gene structure and molecular defects associated with erythropoietic protoporphyria. Taketani S, et al. **J Bioenerg Biomembr** 1995 Apr;27(2):231-8 (57 ref.)

PHYSIOLOGY

Structure and function of ferrochelatase. Ferreira GC, et al. **J Bioenerg Biomembr** 1995 Apr;27(2):221-9 (74 ref.)

FERROCYTOCHROME C see **CYTOCHROME C**

FERROPROTOPORPHYRIN see **HEME**

FERROUS COMPOUNDS

CHEMISTRY

Fenton chemistry: an introduction. Wardman P, et al. **Radiat Res** 1996 May;145(5):523-31 (73 ref.)

METABOLISM

Molecular aspects of the electron transfer system which participates in the oxidation of ferrous ion by Thiobacillus ferrooxidans. Yamanaka T, et al. **FEMS Microbiol Rev** 1995 Dec;17(4):401-13 (50 ref.)

FERROXIDASE see **CERULOPLASMIN**

FERTILITY

see related
INFERTILITY

Conservative versus radical surgery for tubal pregnancy. A review. Clausen I. **Acta Obstet Gynecol Scand** 1996 Jan; 75(1):8-12 (44 ref.)

Growth hormone and fertility--clinical studies. Homburg R. **Horm Res** 1996;45(1-2):81-5 (27 ref.)

Abortion and fertility regulation [see comments] Kulczycki A, et al. **Lancet** 1996 Jun 15;347(9016):1663-8 (41 ref.) Comment in: Lancet 1996 Aug 17;348(9025):478; discussion 478-9.

A fertility diet for planning pregnancy. Wynn M, et al. **Nutr Health** 1995;10(3):219-38 (50 ref.)

Population growth in the 21st century: cause for crisis or celebration? Cleland J. **Trop Med Int Health** 1996 Feb; 1(1):15-26 (22 ref.)

Fertility of mammalian spermatozoa: its development and relativity. Yanagimachi R. **Zygote** 1994 Nov;2(4):371-2 (13 ref.)

[Fertility] Tica V. **Contracept Fertil Sex** 1996 Mar; 24(3):173-83 (110 ref.) **(Fre)**

[Role of essential trace elements on sexual function and its disorder] Shinohara A, et al. **Nippon Rinsho** 1996 Jan; 54(1):155-61 (20 ref.) (Eng. Abstr.) **(Jpn)**

FERTILITY

DRUG EFFECTS

Gonadal damage and effects on fertility in adult patients with haematological malignancy undergoing stem cell transplantation. Chatterjee R, et al. **Bone Marrow Transplant** 1996 Jan;17(1):5–11 (79 ref.)

The effects of sulphasalazine on male fertility. Marmor D. **Reprod Toxicol** 1995 May–Jun;9(3):219–23 (58 ref.)

IMMUNOLOGY

Synthetic hormone/growth factor subunit vaccine with application to antifertility and cancer. Snyder LL, et al. **Pharm Biotechnol** 1995;6:907–30 (145 ref.)

PHYSIOLOGY

Selenium and fertility in animals and man—a review. Hansen JC, et al. **Acta Vet Scand** 1996;37(1):19–30 (81 ref.)

The effects of lactation on the fertility of dairy cows. Macmillan KL, et al. **Aust Vet J** 1996 Apr;73(4):141–7 (56 ref.)

On the epididymis and its role in the development of the fertile ejaculate. Turner TT. **J Androl** 1995 Jul–Aug; 16(4):292–8 (34 ref.)

The sperm centrosome during fertilization in mammals: implications for fertility and reproduction. Navara CS, et al. **Reprod Fertil Dev** 1995;7(4):747–54 (30 ref.)

FERTILITY AGENTS, FEMALE

ADVERSE EFFECTS

The risk of ovarian cancer after treatment for infertility. Bristow RE, et al. **Curr Opin Obstet Gynecol** 1996 Feb; 8(1):32–7 (35 ref.)

FERTILITY AGENTS, FEMALE, HORMONAL see **FERTILITY AGENTS, FEMALE**

FERTILITY AGENTS, FEMALE, SYNTHETIC see **FERTILITY AGENTS, FEMALE**

FERTILIZATION

see related
GAMETE INTRAFALLOPIAN TRANSFER

Mammalian fertilization: egg and sperm (glyco)proteins that support gamete adhesion. Wassarman PM. **Am J Reprod Immunol** 1995 Mar;33(3):253–8 (48 ref.)

Carbohydrate-and heparin-binding proteins in mammalian fertilization. Töpfer-Petersen E, et al. **Andrologia** 1995 Nov–Dec;27(6):303–24 (226 ref.)

Genetic control of the secondary sex ratio. Bernstein ME. **Hum Reprod** 1995 Oct;10(10):2531–3 (26 ref.)

Follicular phase length, cycle day of conception and sex ratio of offspring. James WH. **Hum Reprod** 1995 Oct; 10(10):2529–31 (39 ref.)

Strategies in frozen donor semen procreation. Le Lannou D, et al. **Hum Reprod** 1995 Jul;10(7):1765–74 (90 ref.)

Functional motion changes during sperm transit to the site of fertilization and in-vitro applications: a review. Mbizvo MT. **Int J Androl** 1995 Jun;18 Suppl 1:1–6 (59 ref.)

Interactions between gametes leading to fertilization: the sperm's eye view. Storey BT. **Reprod Fertil Dev** 1995; 7(4):927–42 (144 ref.)

Oocyte activation in invertebrates and humans. Dale B. **Zygote** 1994 Nov;2(4):373–7 (38 ref.)

Beakers versus breakers: how fertilisation in the laboratory differs from fertilisation in nature. Mead KS, et al. **Zygote** 1995 May;3(2):95–9 (62 ref.)

PHYSIOLOGY

Human sperm reservoirs and Fallopian tube function: a rôle for the intra-mural portion? Hunter RH. **Acta Obstet Gynecol Scand** 1995 Oct;74(9):677–81 (32 ref.)

The molecules of mammalian fertilization. Snell WJ, et al. **Cell** 1996 May 31;85(5):629–37 (70 ref.)

Calcium signalling during mammalian fertilization. Miyazaki S. **Ciba Found Symp** 1995;188:235–47; discussion 247–51 (42 ref.)

Towards molecular mechanisms for gamete adhesion and fusion during mammalian fertilization. Wassarman PM. **Curr Opin Cell Biol** 1995 Oct;7(5):658–64 (76 ref.)

Actin-membrane cytoskeletal dynamics in early sea urchin development. Bonder EM, et al. **Curr Top Dev Biol** 1995; 31:101–37 (131 ref.)

Cytoskeleton in teleost eggs and early embryos: contributions to cytoarchitecture and motile events. Hart NH, et al. **Curr Top Dev Biol** 1995;31:343–81 (144 ref.)

Mammalian model systems for exploring cytoskeletal dynamics during fertilization. Navara CS, et al. **Curr Top Dev Biol** 1995;31:321–42 (54 ref.)

Mechanisms of calcium regulation in sea urchin eggs and their activities during fertilization. Shen SS. **Curr Top Dev Biol** 1995;30:63–101 (270 ref.)

Cytogenetics of human spermatozoa: what about the reproductive relevance of structural chromosome aberrations? Rosenbusch BE. **J Assist Reprod Genet** 1995 Jul;12(6):375–83 (53 ref.)

Evidence that mammalian sex ratios at birth are partially controlled by parental hormone levels at the time of conception. James WH. **J Theor Biol** 1996 Jun 21; 180(4):271–86 (164 ref.)

Oviduct during early pregnancy: hormonal regulation and interactions with the fertilized ovum. Murray MK, et al. **Microsc Res Tech** 1995 Aug 15;31(6):497–506 (49 ref.)

The sperm centrosome during fertilization in mammals: implications for fertility and reproduction. Navara CS, et al. **Reprod Fertil Dev** 1995;7(4):747–54 (30 ref.)

FERTILIZATION, DELAYED see **FERTILIZATION**

FERTILIZATION IN VITRO

see related
EMBRYO TRANSFER
OVARIAN HYPERSTIMULATION SYNDROME

Ovarian hyperstimulation syndrome may be more likely if multiple pregnancy occurs following assisted conception. Mathur RS, et al. **Acta Genet Med Gemellol (Roma)** 1995; 44(3–4):233–5 (15 ref.)

In vitro fertilization, gamete intrafallopian transfer, and superovulation with intrauterine insemination: efficacy and potential health hazards on babies delivered. Dawood MY. **Am J Obstet Gynecol** 1996 Apr;174(4):1208–17 (26 ref.)

The application of transvaginal ultrasound for ovulation induction and in vitro fertilization. Nachtigall MJ, et al. **Clin Obstet Gynecol** 1996 Mar;39(1):231–47 (72 ref.)

In vitro fertilization versus tubal surgery: is pelvic reconstructive surgery obsolete? Benadiva CA, et al. **Fertil Steril** 1995 Dec;64(6):1051–61 (85 ref.)

Polycystic ovary syndrome: pathophysiology and outcome with in vitro fertilization. Buyalos RP, et al. **Fertil Steril** 1996 Jan;65(1):1–10 (63 ref.)

Clinical approaches to increasing uterine receptivity during human implantation. Edwards RG. **Hum Reprod** 1995 Dec; 10 Suppl 2:60–6 (26 ref.)

An argument for the past and continued use of pentoxifylline in assisted reproductive technology. Matson PL, et al. **Hum Reprod** 1995 Oct;10 Suppl 1:67–71 (38 ref.)

Exploring the mechanism(s) of endometriosis-related infertility: an analysis of embryo development and implantation in assisted reproduction. Pellicer A, et al. **Hum Reprod** 1995 Dec;10 Suppl 2:91–7 (33 ref.)

Functional motion changes during sperm transit to the site of fertilization and in-vitro applications: a review. Mbizvo MT. **Int J Androl** 1995 Jun;18 Suppl 1:1–6 (59 ref.)

Primary therapy for tubal disease: surgery versus IVF. Gocial B. **Int J Fertil Menopausal Stud** 1995 Nov–Dec; 40(6):297–302 (20 ref.)

Tubal surgery of IVF—making the best choice in the 1990s. Novy MJ. **Int J Fertil Menopausal Stud** 1995 Nov–Dec; 40(6):292–7 (35 ref.)

Low- versus high-dose human menopausal gonadotropin in an in vitro fertilization–embryo transfer program. Levy T, et al. **J Assist Reprod Genet** 1995 Apr;12(4):235–8 (25 ref.)

The human menopausal gonadotropin (hMG) dose in in vitro fertilization (IVF): what is the optimal dose? van Hooff MH. **J Assist Reprod Genet** 1995 Apr;12(4):233–5 (13 ref.)

Micro-assisted fertilization. Payne D. **Reprod Fertil Dev** 1995; 7(4):831–9 (55 ref.)

Sperm activation in species with external fertilisation. Tosti E. **Zygote** 1994 Nov;2(4):359–61 (23 ref.)

[Diagnosis of sterility and IVF] Deutinger J. **Gynakologe** 1995 Aug;28(4):240–6 (52 ref.) **(Ger)**

ADVERSE EFFECTS

Micromanipulative assisted fertilization – still clinical research. Bui TH, et al. **Hum Reprod** 1996 May;11(5):925–6 (21 ref.)

Genetic anomaly and ICSI. Chandley AC, et al. **Hum Reprod** 1996 May;11(5):930–2 (26 ref.)

The risk of chromosomal abnormalities following ICSI. Martin RH. **Hum Reprod** 1996 May;11(5):924–5 (12 ref.)

Is ICSI associated with risks of genetic disease? Implications for counselling, practice and research. Persson JW, et al. **Hum Reprod** 1996 May;11(5):921–4 (30 ref.)

Micro-assisted fertilization and sperm chromosome abnormalities. Rosenbusch B, et al. **Hum Reprod** 1996 May; 11(5):928–30 (29 ref.)

[Questions about the future of the child] David G. **Bull Acad Natl Med** 1995 Nov;179(8):1751–7 (21 ref.) **(Eng. Abstr.)** **(Fre)**

METHODS

Intracytoplasmic sperm injection: a powerful tool to overcome fertilization failure. Palermo GD, et al. **Fertil Steril** 1996 May;65(5):899–908 (80 ref.)

Debate. Assisted reproductive techniques – are we avoiding the genetic issues? Baschat AA, et al. **Hum Reprod** 1996 May;11(5):926–8 (10 ref.)

Micromanipulative assisted fertilization – still clinical research. Bui TH, et al. **Hum Reprod** 1996 May;11(5):925–6 (21 ref.)

Genetic anomaly and ICSI. Chandley AC, et al. **Hum Reprod** 1996 May;11(5):930–2 (26 ref.)

Intracytoplasmic sperm injection—what kind of reproduction is being assisted? De Jonge CJ, et al. **Hum Reprod** 1995 Oct;10(10):2518–20 (11 ref.)

The risk of chromosomal abnormalities following ICSI. Martin RH. **Hum Reprod** 1996 May;11(5):924–5 (12 ref.)

Intracytoplasmic sperm injection—is there a need for an animal model, especially in assessing the genetic risks involved? Ng SC, et al. **Hum Reprod** 1995 Oct; 10(10):2523–5 (26 ref.)

Intracytoplasmic sperm injection (ICSI): potential genetic concerns. Patrizio P. **Hum Reprod** 1995 Oct;10(10):2520–3 (26 ref.)

Is ICSI associated with risks of genetic disease? Implications for counselling, practice and research. Persson JW, et al. **Hum Reprod** 1996 May;11(5):921–4 (30 ref.)

Micro-assisted fertilization and sperm chromosome abnormalities. Rosenbusch B, et al. **Hum Reprod** 1996 May; 11(5):928–30 (29 ref.)

Use of pentoxifylline in assisted reproductive technology. Tournaye H, et al. **Hum Reprod** 1995 Oct;10 Suppl 1:72–9 (48 ref.)

Intracytoplasmic sperm injection three years after the birth of the first ICSI child. Van Steirteghem A, et al. **Hum Reprod** 1995 Oct;10(10):2527–8 (16 ref.)

Is an animal model needed for intracytoplasmic sperm injection (ICSI) and other assisted reproduction technologies? Yanagimachi R. **Hum Reprod** 1995 Oct; 10(10):2525–6 (11 ref.)

Micromanipulation of gametes—new horizons in the treatment of male infertility. Simon A, et al. **Isr J Med Sci** 1995 Nov;31(11):652–6 (35 ref.)

The potential of intracytoplasmic sperm injection (ICSI) to transmit genetic defects causing male infertility. de Kretser DM. **Reprod Fertil Dev** 1995;7(2):137–41; discussion 141–2 (36 ref.)

Cell cycle factors in the human oocyte and the intracytoplasmic injection of spermatozoa. Edwards RG. **Reprod Fertil Dev** 1995;7(2):143–53 (86 ref.)

Spermatids as male gametes. Ogura A, et al. **Reprod Fertil Dev** 1995;7(2):155–8; discussion 158–9 (16 ref.)

Intracytoplasmic sperm injection: instrumentation and injection technique. Payne D. **Reprod Fertil Dev** 1995; 7(2):185–96 (22 ref.)

[Intracytoplasmic injection of spermatozoa (ICSI). Ethical requirements and assessment] Moutel G, et al. **Presse Med** 1996 Jun 15;25(21):989–93 (37 ref.) **(Eng. Abstr.)** **(Fre)**

[In vitro fertilization] Hoshi K. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Aug; 47(8):833–44 (60 ref.) **(Jpn)**

PSYCHOLOGY

[Pregnancy, labor and partnership in a family with an IVF child] Pastor VS, et al. **Geburtshilfe Frauenheilkd** 1995 Aug; 55(8):M83–7 (45 ref.) **(Ger)**

VETERINARY

Morphology and biochemistry of in-vitro produced bovine embryos: implications for their cryopreservation. Massip A, et al. **Hum Reprod** 1995 Nov;10(11):3004–11 (79 ref.)

FERTILIZATION, POLYSPERMIC see **FERTILIZATION**

FERTILIZED OVUM see **ZYGOTE**

FETAL ALCOHOL SYNDROME

Present state of the fetal alcohol syndrome. Strömland K. **Acta Ophthalmol Scand Suppl** 1996;(219):10–2 (25 ref.)

Fetal alcohol syndrome: diagnosis, management, and prevention. Appelbaum MG. **Nurse Pract** 1995 Oct; 20(10):24, 27–8, 31–3 passim (28 ref.)

COMPLICATIONS

[Fetal alcohol syndrome: an unrecognized cause of intellectual handicap and problem behavior in The Netherlands] van Balkom ID, et al. **Ned Tijdschr Geneeskd** 1996 Mar 16;140(11):592–5 (37 ref.) **(Dut)**

EPIDEMIOLOGY

An update on incidence of FAS: FAS is not an equal opportunity birth defect. Abel EL. **Neurotoxicol Teratol** 1995 Jul–Aug;17(4):437–43 (80 ref.)

Maternal risk factors in fetal alcohol syndrome: provocative and permissive influences. Abel EL, et al. **Neurotoxicol Teratol** 1995 Jul–Aug;17(4):445–62 (327 ref.)

PHYSIOPATHOLOGY

Ethanol neurobehavioural teratogenesis and the role of L-glutamate in the fetal hippocampus. Reynolds JD, et al. **Can J Physiol Pharmacol** 1995 Sep;73(9):1209–23 (175 ref.)

Fetal alcohol syndrome from infancy through childhood: a review of the literature. Wekselman K, et al. **J Pediatr Nurs** 1995 Oct;10(5):296–303 (36 ref.)

PREVENTION & CONTROL

Interpretations of risk: the use of scientific information in the development of the alcohol warning label policy. Kaskutas LA. **Int J Addict** 1995;30(12):1519–48 (70 ref.)

A multiple-level, comprehensive approach to the prevention of fetal alcohol syndrome (FAS) and other alcohol-related birth defects (ARBD). May PA. **Int J Addict** 1995; 30(12):1549–602 (160 ref.)

Fetal alcohol syndrome. How you can help prevent it.

Bratton RL. **Postgrad Med** 1995 Nov;98(5):197–200 (8 ref.)

PSYCHOLOGY

Children of alcoholic parents. A review. Steinhausen HC. **Eur Child Adolesc Psychiatry** 1995 Jul;4(3):143–52 (55 ref.)

FETAL ANOXIA

see related

ASPHYXIA NEONATORUM

The brain of the asphyxiated fetus—basic research. Jensen A. **Eur J Obstet Gynecol Reprod Biol** 1996 Mar;65(1):19–24 (57 ref.)

COMPLICATIONS

Neuronal damage in the developing brain following intrauterine asphyxia. Mallard EC, et al. **Reprod Fertil Dev** 1995;7(3):647–53 (100 ref.)

DIAGNOSIS

–Diagnosis of fetal hypoxia by monitoring during labor– Béguin F. **Arch Gynecol Obstet** 1995;256 Suppl:S50–60 (39 ref.) **(Fre)**

[Significance of intrapartum hypoxia for cerebral long–term morbidity] Schneider H. **Z Geburtshilfe Neonatol** 1996 Mar–Apr;200(2):43–9 (47 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Asphyxia. Mac Donald D. **Baillieres Clin Obstet Gynaecol** 1995 Sep;9(3):579–94 (65 ref.)

Birth under water—to breathe or not to breathe. Johnson P. **Br J Obstet Gynaecol** 1996 Mar;103(3):202–8 (37 ref.)

The Zavanelli maneuver for fetal shoulder dystocia. Three cases with poor outcomes. Spellacy WN. **J Reprod Med** 1995 Jul;40(7):543–4 (7 ref.)

METABOLISM

Fetal metabolic responses to hypoxia. Hooper SB. **Reprod Fertil Dev** 1995;7(3):527–38 (75 ref.)

PREVENTION & CONTROL

Asphyxia. Mac Donald D. **Baillieres Clin Obstet Gynaecol** 1995 Sep;9(3):579–94 (65 ref.)

[Characteristics of delivery of the small premature infant] Schneider H, et al. **Arch Gynecol Obstet** 1995; 257(1–4):462–71 (51 ref.) **(Ger)**

ULTRASONOGRAPHY

[Diagnostic and clinical value of Doppler ultrasound in obstetrics] Gonser M, et al. **Geburtshilfe Frauenheilkd** 1995 Nov;55(11):605–15 (127 ref.) (Eng. Abstr.) **(Ger)**

FETAL BLOOD

Umbilical cord blood as a new and promising source of unrelated–donor hematopoietic stem cells for transplantation. Newburger PE, et al. **Curr Opin Pediatr** 1996 Feb;8(1):29–32 (24 ref.)

CD34+ progenitor cell selection: clinical transplantation, tumor cell purging, gene therapy, ex vivo expansion, and cord blood processing. Colter M, et al. **J Hematother** 1996 Apr;5(2):179–84 (22 ref.)

Clinical challenges and cord blood transplantation: are we asking the right questions? Lowry PA. **J Hematother** 1996 Apr;5(2):99–104 (37 ref.)

Methods of isolation and cryopreservation of stem cells from cord blood. Quillen K, et al. **J Hematother** 1996 Apr; 5(2):153–5 (12 ref.)

Immune functions of cord blood cells before and after transplantation. Roncarolo MG, et al. **J Hematother** 1996 Apr;5(2):157–60 (13 ref.)

Umbilical cord blood for use in transplantation. Varadi G, et al. **Obstet Gynecol Surv** 1995 Aug;50(8):611–7 (30 ref.)

The fetus as a recipient and donor of blood components. Roberts GT, et al. **Transfus Med Rev** 1995 Jul;9(3):260–70 (59 ref.)

[Clinical use of placental blood cells] Gluckman E. **C R Seances Soc Biol Fil** 1995;189(4):597–600 (8 ref.) (Eng. Abstr.) **(Fre)**

CHEMISTRY

Follow–up of children born with an umbilical arterial blood pH < 7 [see comments] Nagel HT, et al. **Am J Obstet Gynecol** 1995 Dec;173(6):1758–64 (26 ref.) Comment in: Am J Obstet Gynecol 1996 Jul;175(1):229.

Fetal monitoring by combined CTG and FBA. Goeschen K. **J Perinat Med** 1996;24(1):37–41 (8 ref.)

Continuous fetal monitoring of HbO2 with pulse oximetry. Knitza R, et al. **J Perinat Med** 1996;24(1):55–9 (5 ref.)

CYTOLOGY

Stem cells from bone marrow, umbilical cord blood and peripheral blood for clinical application: current status and future application. Lu L, et al. **Crit Rev Oncol Hematol** 1996 Mar;22(2):61–78 (243 ref.)

Umbilical cord blood as a source of hematopoietic stem cells: from research to clinical application. Almici C, et al. **Haematologica** 1995 Sep–Oct;80(5):473–9 (53 ref.)

Human umbilical cord blood for hematopoietic progenitor cells transplantation. Varadi G, et al. **Leuk Lymphoma** 1995 Dec;20(1–2):51–8 (54 ref.)

Isolating fetal nucleated red blood cells from maternal blood: the Baylor experience—1995. Simpson JL, et al. **Prenat Diagn** 1995 Oct;15(10):907–12 (19 ref.)

The use of umbilical cord blood as a cellular source for correction of genetic diseases affecting the hematopoietic system. Clapp DW, et al. **Stem Cells (Dayt)** 1995 Nov; 13(6):613–21 (87 ref.)

[Noninvasive prenatal diagnosis of fetal cells in maternal blood] Tutschek B, et al. **Gynakologe** 1995 Oct; 28(5):289–301 (74 ref.) **(Ger)**

[Human umbilical cord blood as a source of hematopoietic progenitor cells for transplantations] Elchalal U, et al. **Harefuah** 1995 Jun 15;128(12):776–80 (38 ref.) **(Heb)**

FETAL CIRCULATION, PERSISTENT see PERSISTENT FETAL CIRCULATION SYNDROME

FETAL DEATH

EPIDEMIOLOGY

Cytogenetic evaluation of cystic hygroma associated with hydrops fetalis, oligohydramnios or intrauterine fetal death: the roles of amniocentesis, postmortem chorionic villus sampling and cystic hygroma paracentesis. Chen CP, et al. **Acta Obstet Gynecol Scand** 1996 May;75(5):454–8 (29 ref.)

Incidence of congenital heart disease: II. Prenatal incidence. Hoffman JI. **Pediatr Cardiol** 1995 Jul–Aug;16(4):155–65 (79 ref.)

ETIOLOGY

Uterine rupture with fetal death following blunt trauma. Harrison SD, et al. **AJR Am J Roentgenol** 1995 Dec; 165(6):1452 (9 ref.)

FETAL DEVELOPMENT

Evolutionary ancient roles of serotonin: long–lasting regulation of activity and development. Turlejski K. **Acta Neurobiol Exp (Warsz)** 1996;56(2):619–36 (138 ref.)

Pax genes and skeletal development. Balling R, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:27–33 (29 ref.)

Signaling pathways in skeletal formation: a role for BMP receptors. Rosen V, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:59–69 (45 ref.)

Effects of folate deficiency on embryonic development. Christensen B, et al. **Baillieres Clin Haematol** 1995 Sep; 8(3):617–37 (133 ref.)

Galectins in mouse embryogenesis. Colnot C, et al. **Biochem Soc Trans** 1996 Feb;24(1):141–6 (41 ref.)

Ultrasound features of normal early pregnancy development. Jurkovic D, et al. **Curr Opin Obstet Gynecol** 1995 Dec; 7(6):493–504 (55 ref.)

Heterochrony and the phylotypic period. Richardson MK. **Dev Biol** 1995 Dec;172(2):412–21 (86 ref.)

Pre–conception care of diabetes, congenital malformations, and spontaneous abortions. Kitzmiller JL, et al. **Diabetes Care** 1996 May;19(5):514–41 (324 ref.)

Parathyroid hormone–related protein: a polyhormone involved in growth, development and gestation [comment] Rizzoli R, et al. **Eur J Endocrinol** 1995 Sep;133(3):272–4 (35 ref.) Comment on: Eur J Endocrinol 1995 Sep;133(3):278–83.

Bone morphogenetic proteins: multifunctional regulators of vertebrate development. Hogan BL. **Genes Dev** 1996 Jul 1;10(13):1580–94 (160 ref.)

The ontogeny of growth hormone, insulin–like growth factors and sex steroids: molecular aspects. Han VK. **Horm Res** 1996;45(1–2):61–6 (45 ref.)

Role of platelet–derived growth factors in mouse development. Betsholtz C. **Int J Dev Biol** 1995 Oct; 39(5):817–25 (76 ref.)

What can be learned from intermediate filament gene regulation in the mouse embryo. Duprey P, et al. **Int J Dev Biol** 1995 Jun;39(3):443–57 (150 ref.)

Extracellular matrix and its receptors during development. Gullberg D, et al. **Int J Dev Biol** 1995 Oct;39(5):845–54 (109 ref.)

DNA methylation and polyamines in embryonic development and cancer. Heby O. **Int J Dev Biol** 1995 Oct;39(5):737–57 (169 ref.)

Notch–related genes in animal development. Lardelli M, et al. **Int J Dev Biol** 1995 Oct;39(5):769–80 (106 ref.)

Sex differentiation — gonadogenesis and novel genes. Nordqvist K. **Int J Dev Biol** 1995 Oct;39(5):727–36 (76 ref.)

Developmental failure in preimplantation human conceptuses. Winston NJ. **Int Rev Cytol** 1996;164:139–88 (282 ref.)

Embryonic angiogenesis: a review. Wilting J, et al. **Naturwissenschaften** 1996 Apr;83(4):153–64 (168 ref.)

Fuel metabolism in deviant fetal growth in offspring of diabetic women. Hod M, et al. **Obstet Gynecol Clin North Am** 1996 Mar;23(1):259–77 (105 ref.)

Systems for production of calves from cultured bovine embryonic cells. First NL, et al. **Reprod Fertil Dev** 1994; 6(5):553–62 (35 ref.)

Nutrition and fetal growth. Harding JE, et al. **Reprod Fertil Dev** 1995;7(3):539–47 (54 ref.)

Development and validation of swine embryonic stem cells: a review. Wheeler MB. **Reprod Fertil Dev** 1994;6(5):563–8 (59 ref.)

The length of human pregnancy as calculated by ultrasonographic measurement of the fetal biparietal diameter. Kieler H, et al. **Ultrasound Obstet Gynecol** 1995 Nov;6(5):353–7 (26 ref.)

Gap junction communication and cell adhesion in development. DeHaan RL. **Zygote** 1994 Aug;2(3):183–8 (71 ref.)

[Polyunsaturated fatty acids and cerebral–sensory development in infants (editorial)] Ghisolfi J. **Arch Pediatr** 1995 Sep;2(9):825–30 (15 ref.) **(Fre)**

DRUG EFFECTS

Immunoteratology: I. MHC involvement in the embryo response to teratogens in mice. Torchinsky A, et al. **Am J Reprod Immunol** 1995 Nov;34(5):288–98 (27 ref.)

Examination of developmental neurotoxicity by the use of tissue culture model systems. Heller A, et al. **Clin Exp Pharmacol Physiol** 1995 May;22(5):375–8 (29 ref.)

Developmental toxicity risk assessment: consensus building, hypothesis formulation, and focused research. Kimmel CA. **Drug Metab Rev** 1996 Feb–May;28(1–2):85–103 (51 ref.)

What we know and what we need to know about developmental aluminum toxicity. Golub MS, et al. **J Toxicol Environ Health** 1996 Aug 30;48(6):585–97 (74 ref.)

Vanadium: a review of the reproductive and developmental toxicity. Domingo JL. **Reprod Toxicol** 1996 May–Jun; 10(3):175–82 (61 ref.)

Kids are different: developmental variability in toxicology. Graeter LJ, et al. **Toxicology** 1996 Jul 17;111(1–3):15–20 (20 ref.)

GENETICS

Antigen presentation by class I major histocompatibility complex molecules: a context for thinking about HLA–G. Parham P. **Am J Reprod Immunol** 1995 Jul;34(1):10–9 (48 ref.)

Transformations in null mutants of Hox genes: do they represent intercalary regenerates? Crawford M. **Bioessays** 1995 Dec;17(12):1065–73 (48 ref.)

A unique role for enhancers is revealed during early mouse development. Majumder S, et al. **Bioessays** 1995 Oct; 17(10):879–89 (77 ref.)

Towards unravelling the Igf2/H19 imprinted domain. Viville S, et al. **Bioessays** 1995 Oct;17(10):835–8 (23 ref.)

DNA methylation in early development. Razin A, et al. **Hum Mol Genet** 1995;4 Spec No:1751–5 (39 ref.)

Mutations, malformations and mortality. Suthers G. **J Paediatr Child Health** 1996 Feb;32(1):10–5 (67 ref.)

The Gorlin syndrome gene: a tumor suppressor active in basal cell carcinogenesis and embryonic development. Bale AE, et al. **Proc Assoc Am Physicians** 1995 Jul;107(2):253–7 (35 ref.)

Gametic imprinting in mammals. Barlow DP. **Science** 1995 Dec 8;270(5242):1610–3 (31 ref.)

Winner of the Theodore E. Woodward Award: c–Myb and the coordinate regulation of thymic genes. Hutton JJ, et al. **Trans Am Clin Climatol Assoc** 1995;107:115–24 (39 ref.)

[The roles of Wnt genes during mouse development] Takada S. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2162–74 (66 ref.) **(Jpn)**

IMMUNOLOGY

Antigen presentation by class I major histocompatibility complex molecules: a context for thinking about HLA–G. Parham P. **Am J Reprod Immunol** 1995 Jul;34(1):10–9 (48 ref.)

Immunoteratology: I. MHC involvement in the embryo response to teratogens in mice. Torchinsky A, et al. **Am J Reprod Immunol** 1995 Nov;34(5):288–98 (27 ref.)

A role for glycoconjugates in human development: the human feto–embryonic defence system hypothesis. Clark GF, et al. **Hum Reprod** 1996 Mar;11(3):467–73 (62 ref.)

B–lymphoid potential in pre–liver mouse embryo. Godin I, et al. **Semin Immunol** 1995 Jun;7(3):131–41 (70 ref.)

In–vitro models of B–lineage commitment. Kee BL, et al. **Semin Immunol** 1995 Jun;7(3):143–54 (115 ref.)

Lymphohematopoietic development from embryonic stem cells in vitro. Nakano T. **Semin Immunol** 1995 Jun; 7(3):197–203 (26 ref.)

PHYSIOLOGY

Nitric oxide in the developing lung. Shaul PW. **Adv Pediatr** 1995;42:367–414 (182 ref.)

The roles of retinoids in vertebrate development. Means AL, et al. **Annu Rev Biochem** 1995;64:201–33 (213 ref.)

Epidermal growth factor receptor function in early mammalian development. Wiley LM, et al. **Bioessays** 1995 Oct;17(10):839–46 (65 ref.)

The CD44 proteins in embryonic development and in cancer. Sherman L, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 1):249–69 (123 ref.)

The equine embryonic capsule: practical implications of

recent research. Oriol JG. **Equine Vet J** 1994 May; 26(3):184–6 (34 ref.)

Early human nutrition. Exalto N.
Eur J Obstet Gynecol Reprod Biol 1995 Jul;61(1):3–6 (15 ref.)

Maternal nutrition in relation to fetal and placental growth. Godfrey KM, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Jul;61(1):15–22 (62 ref.)

Apoptosis: programmed cell death in fetal development. Haanen C, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Jan;64(1):129–33 (58 ref.)

Essential fatty acids in pregnancy and early human development. Hornstra G, et al.
Eur J Obstet Gynecol Reprod Biol 1995 Jul;61(1):57–62 (35 ref.)

A role for glycoconjugates in human development: the human feto–embryonic defence system hypothesis. Clark GF, et al. **Hum Reprod** 1996 Mar;11(3):467–73 (62 ref.)

Role of yolk sac endodermal cells with special reference to the fetal macrophage differentiation. Yamashita A.
J Leukoc Biol 1996 Feb;59(2):139–44 (26 ref.)

Co–culture of the early human embryo: factors affecting human blastocyst formation in vitro. Ménézo YJ, et al.
Microsc Res Tech 1995 Sep 1;32(1):50–6 (52 ref.)

Molecular approach to intrauterine growth retardation: an overview of recent data. Alsat E, et al.
Reprod Fertil Dev 1995;7(6):1457–64 (73 ref.)

Endocrine regulation of fetal growth. Fowden AL.
Reprod Fertil Dev 1995;7(3):351–63 (68 ref.)

Implication of inhibin and related proteins in fetal development. Jenkin G, et al. **Reprod Fertil Dev** 1995; 7(3):323–31 (71 ref.)

Placental control of fetal growth. Robinson J, et al.
Reprod Fertil Dev 1995;7(3):333–44 (133 ref.)

Cell death in normo– and teratogenesis. I. Cell death in normogenesis. Sandor S, et al. **Rom J Morphol Embryol** 1994 Jul–Dec;40(3–4):69–81 (79 ref.)

Cell death in normo– and teratogenesis. II. Cell death in teratogenesis. Sandor S, et al. **Rom J Morphol Embryol** 1994 Jul–Dec;40(3–4):83–91 (67 ref.)

[Prenatal auditory perception—on the relevance of new concepts of perception] Schmidt HU, et al.
Geburtshilfe Frauenheilkd 1995 Oct;55(10):M125–8 (13 ref.) **(Ger)**

[Effect of fetal and neonatal growth on the occurrence of some diseases in adults] Jendryczko A, et al.
Ginekol Pol 1996 Jan;67(1):34–6 (11 ref.) (Eng. Abstr.) **(Pol)**

[The participation of retinoic acid in embryonic and postembryonic development] Maden M. **Ontogenez** 1995 Nov–Dec;26(6):419–29 (57 ref.) (Eng. Abstr.) **(Rus)**

[Pattern formation in the early embryogenesis of the clawed toad] Mglinets VA. **Ontogenez** 1995 Jul–Aug;26(4):282–92 (72 ref.) (Eng. Abstr.) **(Rus)**

FETAL DISEASES

see related

ABNORMALITIES

CHORIONIC VILLI SAMPLING

The foetal pituitary, postmaturity and breech presentation [comment] de Zegher F, et al. **Acta Paediatr** 1995 Oct; 84(10):1100–2 (32 ref.) Comment on: Acta Paediatr 1995 Oct;84(10):1201–3.

Asphyxia. Mac Donald D.
Baillieres Clin Obstet Gynaecol 1995 Sep;9(3):579–94 (65 ref.)

Fetal porencephaly: a review of etiology, diagnosis, and prognosis. Eller KM, et al. **Obstet Gynecol Surv** 1995 Sep; 50(9):684–7 (14 ref.)

[Prenatal alloimmune thrombocytopenia] Peled Y, et al.
Harefuah 1995 Jun 15;128(12):781–4 (47 ref.) **(Heb)**

[Clinical aspects, diagnosis and treatment of intrauterine infections] Simakova MG, et al. **Akush Ginekol (Mosk)** 1995;(4):7–10 (54 ref.) **(Rus)**

BLOOD

Fetal and neonatal thrombocytopenia. Udom–Rice I, et al.
Blood Rev 1995 Jun;9(2):57–64 (60 ref.)

Fetal neonatal thrombocytopenia. Bussel JB.
Thromb Haemost 1995 Jul;74(1):426–8 (11 ref.)

CHEMICALLY INDUCED

Hand anomalies in fetal–hydantoin syndrome: from nail/phalangeal hypoplasia to unilateral acheiria [letter] Sabry MA, et al. **Am J Med Genet** 1996 Apr 24;62(4):410–2 (34 ref.)

Cocaine during pregnancy: a critical review of the literature. Offidani C, et al. **Minerva Ginecol** 1995 Sep;47(9):381–90 (40 ref.)

Antenatal drugs affecting vitamin K status of the fetus and the newborn. Astedt B. **Semin Thromb Hemost** 1995; 21(4):364–70 (84 ref.)

DIAGNOSIS

Comprehensive ultrasound examination in a private perinatal practice. Ott WJ, et al. **Am J Perinatol** 1995 Nov; 12(6):385–91 (14 ref.)

Fluorescent PCR: a new technique for PGD of sex and single–gene defects. Findlay I, et al.
J Assist Reprod Genet 1996 Feb;13(2):96–103 (28 ref.)

Use of ultrasonography in the home care of high–risk childbearing women. Stringer M. **Nurs Clin North Am** 1996 Jun;31(2):305–12 (17 ref.)

What are the present possibilities for the prenatal diagnosis of primary hyperoxaluria? Danpure CJ. **Pediatr Nephrol** 1996 Apr;10(2):190 (7 ref.)

The current approach to the assessment of fetal renal function: fact or fiction? Spitzer A. **Pediatr Nephrol** 1996 Apr;10(2):230–5 (27 ref.)

Non– or minimally invasive prenatal diagnostic tests on maternal blood samples or transcervical cells. Adinolfi M. **Prenat Diagn** 1995 Oct;15(10):889–96 (79 ref.)

Prenatal screening for haemoglobin disorders [see comments] Petrou M, et al. **Prenat Diagn** 1995 Dec;15(13):1275–95 (60 ref.) Comment in: Prenat Diagn 1995 Dec;15(13):1209–13.

[Congenital varicella. Problems with prenatal diagnosis after an early, primary maternal infection] Lécuru F, et al.
J Gynecol Obstet Biol Reprod (Paris) 1995;24(6):618–21 (24 ref.) (Eng. Abstr.) **(Fre)**

[Fetal and neonatal immune thrombocytopenias] Neuhart D, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996; 25(2):206–11 (30 ref.) (Eng. Abstr.) **(Fre)**

[Prenatal diagnosis of fetal varicella in the second trimester of pregnancy] Pons JC, et al.
J Gynecol Obstet Biol Reprod (Paris) 1995;24(8):829–38 (59 ref.) (Eng. Abstr.) **(Fre)**

[Magnetic resonance imaging of the fetus. Contribution to antenatal diagnosis] Garel C, et al. **Presse Med** 1996 Mar 16;25(9):452–6 (23 ref.) (Eng. Abstr.) **(Fre)**

[Amniocentesis and single choroid plexus cyst. Current status] Morales–Roselló J, et al. **Rev Fr Gynecol Obstet** 1995 Oct;90(10):412–6 (30 ref.) (Eng. Abstr.) **(Fre)**

[Prenatal diagnosis of lysosomal diseases] Owada M, et al.
Nippon Rinsho 1995 Dec;53(12):2926–32 (22 ref.) **(Jpn)**

EPIDEMIOLOGY

Prevalence of fetal facial cleft at different stages of pregnancy. Snijders RJ, et al.
Ultrasound Obstet Gynecol 1995 Nov;6(5):327–9 (11 ref.)

[Varicella in pregnancy] Lécuru F, et al. **Presse Med** 1995 Oct 7;24(29):1352–7 (23 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Zonary placenta. Steemers NY, et al.
Int J Gynaecol Obstet 1995 Dec;51(3):251–3 (3 ref.)

[The etiology and pathogenesis of intrauterine infection] Durova AA, et al. **Akush Ginekol (Mosk)** 1995;(6):9–12 (59 ref.) **(Rus)**

GENETICS

Risk of fetal mosaicism when placental mosaicism is diagnosed by chorionic villus sampling. Phillips OP, et al.
Am J Obstet Gynecol 1996 Mar;174(3):850–5 (24 ref.)

[Prenatal diagnosis of cutaneous genetic diseases by the study of fetal DNA] Hovnanian A, et al.
Ann Dermatol Venereol 1995;122(4):173–85 (151 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Placental pathology casebook. Liveborn twin of an extramembranous pregnancy. Baergen RN, et al.
J Perinatol 1995 Nov–Dec;15(6):510–3 (7 ref.)

Bilateral agenesis/aplasia of the lungs: report of a second case in the offspring of one woman. Podlech J, et al.
Pediatr Pathol Lab Med 1995 Sep–Oct;15(5):781–90 (26 ref.)

PHYSIOPATHOLOGY

Observations on vitamin K deficiency in the fetus and newborn: has nature made a mistake? Israels LG, et al.
Semin Thromb Hemost 1995;21(4):357–63 (36 ref.)

PREVENTION & CONTROL

Multifetal pregnancies. Smith–Levitin M, et al.
Curr Opin Obstet Gynecol 1995 Dec;7(6):465–71 (52 ref.)

SURGERY

Fetal surgery. Harrison MR. **Am J Obstet Gynecol** 1996 Apr; 174(4):1255–64 (53 ref.)

Antenatal diagnosis and management of meconium peritonitis: a case report and review of the literature. Konje JC, et al. **Ultrasound Obstet Gynecol** 1995 Jul;6(1):66–9 (13 ref.)

THERAPY

Fetal medicine: treating the unborn patient. Camosy P.
Am Fam Physician 1995 Oct;52(5):1385–92 (27 ref.)

Medical fetal therapy. Yankowitz J, et al.
Baillieres Clin Obstet Gynaecol 1995 Sep;9(3):553–70 (130 ref.)

The maternal–fetal rights dilemma: honoring a woman's choice of medical care during pregnancy. Arch RR.
J Contemp Health Law Policy 1996 Spring;12(2):637–73 (255 ref.)

"State–of–the–art" management strategies for the fetus and neonate with congenital diaphragmatic hernia.
Karamanoukian HL, et al. **J Perinatol** 1996 Mar–Apr;16(2 Pt 2 Su):S40–7 (76 ref.)

The challenge of fetal gene therapy. Coutelle C, et al.
Nat Med 1995 Sep;1(9):864–6 (14 ref.)

Fetal transfusion therapy. Skupski DW, et al.
Obstet Gynecol Surv 1996 Mar;51(3):181–92 (73 ref.)

Prenatal gene therapy: prospects and issues [see comments] Pergament E, et al. **Prenat Diagn** 1995 Dec;15(13):1303–11 (63 ref.) Comment in: Prenat Diagn 1995 Dec;15(13):1209–13.

The fetus as a recipient and donor of blood components. Roberts GT, et al. **Transfus Med Rev** 1995 Jul;9(3):260–70 (59 ref.)

[Fetal and neonatal immune thrombocytopenias] Neuhart D, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996; 25(2):206–11 (30 ref.) (Eng. Abstr.) **(Fre)**

[Therapy of fetal diseases] Chiba Y.
Nippon Sanka Fujinka Gakkai Zasshi 1995 Aug; 47(8):845–51 (35 ref.) **(Jpn)**

ULTRASONOGRAPHY

Prenatal sonographic diagnosis of Treacher Collins syndrome: a case and review of the literature. Cohen J, et al. **Am J Perinatol** 1995 Nov;12(6):416–9 (23 ref.)

Ethical issues of diagnosis in utero. Perrotti M, et al.
Br J Urol 1995 Nov;76 Suppl 2:79–83 (37 ref.)

Extra–lobar pulmonary sequestration with prenatal diagnosis. A report of 5 cases and review of the literature. Plattner V, et al. **Eur J Pediatr Surg** 1995 Aug;5(4):235–7 (16 ref.)

Prenatally diagnosed choledochal cysts: observation or early surgery? Lugo–Vicente HL. **J Pediatr Surg** 1995 Sep; 30(9):1288–90 (24 ref.)

Ultrasound screening for fetal abnormalities [see comments] Chitty LS. **Prenat Diagn** 1995 Dec;15(13):1241–57 (74 ref.) Comment in: Prenat Diagn 1995 Dec;15(13):1209–13.

Non–immunological hydrops fetalis and intrapericardial teratoma: case report and review. Perez–Aytes A, et al.
Prenat Diagn 1995 Sep;15(9):859–63 (20 ref.)

The fetal heart: a practical sonographic approach. Sohaey R, et al. **Semin Ultrasound CT MR** 1996 Feb;17(1):15–33 (36 ref.)

First–trimester ultrasound: the essentials. Sohaey R, et al.
Semin Ultrasound CT MR 1996 Feb;17(1):2–14 (64 ref.)

The fetal thorax: noncardiac chest anomalies. Sohaey R, et al. **Semin Ultrasound CT MR** 1996 Feb;17(1):34–50 (64 ref.)

Fetal gastrointestinal anomalies. Sohaey R, et al.
Semin Ultrasound CT MR 1996 Feb;17(1):51–65 (64 ref.)

Antenatal diagnosis and treatment of fetal goitrous hypothyroidism: case report and review of the literature. Abuhamad AZ, et al. **Ultrasound Obstet Gynecol** 1995 Nov; 6(5):368–71 (27 ref.)

The art of ultrasound in obstetrics: from abstraction to hyper–realism [editorial] Achiron R.
Ultrasound Obstet Gynecol 1995 Jul;6(1):1–3 (9 ref.)

The significance of echogenic areas in the fetal abdomen. Carroll SG, et al. **Ultrasound Obstet Gynecol** 1996 Apr; 7(4):293–8 (58 ref.)

Fetal structural disorders—the large series are emerging [comment] Eik–Nes SH. **Ultrasound Obstet Gynecol** 1995 Jun;5(6):364–5 (10 ref.) Comment on: Ultrasound Obstet Gynecol 1995 Jun;5(6):366–71. Comment on: Ultrasound Obstet Gynecol 1995 Jun;5(6):372–80.

Antenatal diagnosis and management of meconium peritonitis: a case report and review of the literature. Konje JC, et al. **Ultrasound Obstet Gynecol** 1995 Jul;6(1):66–9 (13 ref.)

IRONFAN—a sonographic window into the natural history of fetal anomalies. International Registry of the Onset of Fetal Anomalies [editorial] Rottem S.
Ultrasound Obstet Gynecol 1995 Jun;5(6):361–3 (6 ref.)

Resolving fetal hyperechogenic lung lesions: an unresolved issue [see comments] Sepulveda W, et al.
Ultrasound Obstet Gynecol 1995 Jul;6(1):4–5 (26 ref.) Comment in: Ultrasound Obstet Gynecol 1995 Nov;6(5):372–3.

Prenatal diagnosis of cerebral arteriovenous malformation using color Doppler ultrasonography: case report and review of the literature. Sepulveda W, et al.
Ultrasound Obstet Gynecol 1995 Oct;6(4):282–6 (30 ref.)

First–trimester ultrasound screening for chromosomal defects. Snijders RJ, et al. **Ultrasound Obstet Gynecol** 1996 Mar;7(3):216–26 (58 ref.)

[The antenatal diagnosis of sacrococcygeal teratoma] Dukovski A. **Akush Ginekol (Sofiia)** 1995;34(2):53–5 (6 ref.) (Eng. Abstr.) **(Bul)**

[Ultrasonic signs of fetal toxoplasmosis. Review of the literature] Abboud P, et al.
J Gynecol Obstet Biol Reprod (Paris) 1995;24(7):733–8 (17 ref.) (Eng. Abstr.) **(Fre)**

VETERINARY

Pathogenesis of intrauterine infections with bovine viral diarrhea virus. Moennig V, et al.
Vet Clin North Am Food Anim Pract 1995 Nov;11(3):477–87 (51 ref.)

FETAL DISTRESS

DIAGNOSIS

The diagnosis of foetal distress: a challenge to midwives. Mead M. **J Adv Nurs** 1996 May;23(5):975–83 (73 ref.)

Use of cordocentesis in the management of preterm or growth–restricted fetuses with abnormal monitoring.

Shalev E, et al. **Obstet Gynecol Surv** 1995 Dec; 50(12):839–44 (55 ref.)
[Fetal admission test and fetal heart rate response to vibratory stimuli test] Wu L. **Chung Hua Fu Chan Ko Tsa Chih** 1995 Oct;30(10):633–5 (18 ref.) **(Chi)**

FETAL GLOBULINS see **FETAL PROTEINS**

FETAL GROWTH RETARDATION

see related
INFANT, SMALL FOR GESTATIONAL AGE

Use of cordocentesis in the management of preterm or growth-restricted fetuses with abnormal monitoring. Shalev E, et al. **Obstet Gynecol Surv** 1995 Dec; 50(12):839–44 (55 ref.)
Postnatal consequences of chronic intrauterine compromise. Henderson-Smart DJ. **Reprod Fertil Dev** 1995;7(3):559–65 (44 ref.)
[Blood circulation in retarded and normal offspring of hypertonic pregnant women] Jakobovits A, et al. **Orv Hetil** 1996 Apr 14;137(15):793–7 (46 ref.) (Eng. Abstr.) **(Hun)**

COMPLICATIONS

Growth in utero and coronary heart disease. Barker DJ. **Nutr Rev** 1996 Feb;54(2 Pt 2):S1–7 (40 ref.)
[Treatment with growth hormone of children with short stature, borne with intrauterine growth retardation] Czernichow P. **Arch Pediatr** 1996;3 Suppl 1:194s–196s (5 ref.) **(Fre)**

DIET THERAPY

[Nutrition in the neonatal period] Lapillonne A, et al. **Arch Pediatr** 1996;3 Suppl 1:189s–190s (8 ref.) **(Fre)**

DRUG THERAPY

[Indication of corticotherapy for fetal pulmonary maturation] Tchobroutsky C. **Contracept Fertil Sex** 1996 May; 24(5):413–6 (11 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Apparent mineralocorticoid excess due to 11 beta-hydroxysteroid dehydrogenase deficiency: a possible cause of intrauterine growth retardation. Kitanaka S, et al. **Clin Endocrinol (Oxf)** 1996 Mar;44(3):353–9 (33 ref.)
Intra-uterine growth retardation. Holmes RP, et al. **Curr Opin Obstet Gynecol** 1996 Apr;8(2):148–54 (51 ref.)
Molecular approach to intrauterine growth retardation: an overview of recent data. Alsat E, et al. **Reprod Fertil Dev** 1995;7(6):1457–64 (73 ref.)
[Smoking and pregnancy] Wenderlein JM. **Z Arztl Fortbild (Jena)** 1995 Oct;89(5):467–71 (15 ref.) (Eng. Abstr.) **(Ger)**

GENETICS

Partial deletion 11q: report of a case with a large terminal deletion 11q21–qter without loss of telomeric sequences, and review of the literature. Hertz JM, et al. **Clin Genet** 1995 May;47(5):231–5 (19 ref.)
Prenatal and postnatal growth failure associated with maternal heterodisomy for chromosome 7. Langlois S, et al. **J Med Genet** 1995 Nov;32(11):871–5 (25 ref.)
[Genetic and cytogenetic aspects] Delozier-Blanchet C, et al. **Arch Pediatr** 1996;3 Suppl 1:179s–181s (18 ref.) **(Fre)**

PHYSIOPATHOLOGY

Relationship of anxiety, stress, and psychosocial development to reproductive health [see comments] Lederman RP. **Behav Med** 1995 Fall;21(3):101–12 (110 ref.) Comment in: Behav Med 1995 Fall;21(3):123–9.
[Effect of fetal and neonatal growth on the occurrence of some diseases in adults] Jendryczko A, et al. **Ginekol Pol** 1996 Jan;67(1):34–6 (11 ref.) (Eng. Abstr.) **(Pol)**

PREVENTION & CONTROL

[Uterine velocimetry and vascular pregnancy pathologies prevented with low-dose aspirin] Haddad B, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(4):396–404 (51 ref.) (Eng. Abstr.) **(Fre)**
[Aspirin during pregnancy. Indications and modalities of prescription after the publication of the later trials] Uzan S, et al. **Presse Med** 1996 Jan 6–13;25(1):31–6 (30 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

[Indications for pregnancy termination in cases of pre-eclampsia, hypertension, intrauterine growth retardation, liver and heart disease] Uzan S, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24 Suppl 1:33–40 (54 ref.) **(Fre)**

ULTRASONOGRAPHY

[Uterine velocimetry and vascular pregnancy pathologies prevented with low-dose aspirin] Haddad B, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(4):396–404 (51 ref.) (Eng. Abstr.) **(Fre)**

[Diagnostic and clinical value of Doppler ultrasound in obstetrics] Gonser M, et al. **Geburtshilfe Frauenheilkd** 1995 Nov;55(11):605–15 (127 ref.) (Eng. Abstr.) **(Ger)**

FETAL HEART

Fetal cardiology. Allan LD. **Curr Opin Obstet Gynecol** 1996 Apr;8(2):142–7 (28 ref.)

PHYSIOLOGY

[Developmental aspects of electrophysiology in cardiac muscle] Satoh H, et al. **Nippon Yakurigaku Zasshi** 1996 May;107(5):213–23 (38 ref.) (Eng. Abstr.) **(Jpn)**
[Developmental changes in the pacemaker current and membrane currents of the guinea pig myocardium] Shigenobu K, et al. **Nippon Yakurigaku Zasshi** 1996 Jun; 107(6):259–72 (48 ref.) (Eng. Abstr.) **(Jpn)**

ULTRASONOGRAPHY

The fetal heart: a practical sonographic approach. Sohaey R, et al. **Semin Ultrasound CT MR** 1996 Feb;17(1):15–33 (36 ref.)

FETAL HEART RATE see **HEART RATE, FETAL**

FETAL HEMOGLOBIN

ANALYSIS

Alloimmunization during pregnancy treated with high dose intravenous immunoglobulin. Effects on fetal hemoglobin concentration and anti-D concentrations in the mother and fetus. Gottvall T, et al. **Acta Obstet Gynecol Scand** 1995 Nov;74(10):777–83 (30 ref.)

BIOSYNTHESIS

Reactivation of fetal hemoglobin in patients with beta-thalassemia. Olivieri NF. **Semin Hematol** 1996 Jan; 33(1):24–42 (121 ref.)
[Stimulation of fetal hemoglobin production in children with sickle cell anemia (editorial)] de Montalembert M. **Arch Pediatr** 1996 Mar;3(3):207–9 (27 ref.) **(Fre)**

DRUG EFFECTS

Pharmacologic manipulation of fetal hemoglobin levels in sickle cell diseases and thalassemia: promise and reality. Pearson HA. **Adv Pediatr** 1996;43:309–34 (57 ref.)

GENETICS

Hemoglobin switching and fetal hemoglobin reactivation. Cunningham JM, et al. **Semin Hematol** 1996 Jan;33(1):9–23 (142 ref.)

FETAL HYDROPS see **HYDROPS FETALIS**

FETAL IMMUNITY, MATERNALLY-ACQUIRED see **IMMUNITY, MATERNALLY-ACQUIRED**

FETAL MACROSOMIA

Critical management of the very low birth weight infant and macrosomic fetus. Mastrogiannis DS, et al. **Clin Perinatol** 1996 Mar;23(1):51–89 (158 ref.)
[Labor and delivery in a pregnancy involving fetal macrosomia] Rech F, et al. **Minerva Ginecol** 1995 Oct; 47(10):431–8 (36 ref.) (Eng. Abstr.) **(Ita)**

DIAGNOSIS

The evaluation of accelerated fetal growth. Lurie S, et al. **Curr Opin Obstet Gynecol** 1995 Dec;7(6):477–81 (30 ref.)

PREVENTION & CONTROL

Diabetes. Oats JN. **Baillieres Clin Obstet Gynaecol** 1995 Sep; 9(3):481–95 (67 ref.)

THERAPY

[Is induced labor justified in diabetes, macrosomia and prolonged pregnancy?] Treisser A, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24 Suppl 1:41–7 (38 ref.) **(Fre)**

ULTRASONOGRAPHY

Guessing the weight of the baby [comment] Hall MH. **Br J Obstet Gynaecol** 1996 Aug;103(8):734–6 (24 ref.) Comment on: Br J Obstet Gynaecol 1996 Aug;103(8):747–54.

FETAL MATURITY, CHRONOLOGIC see **GESTATIONAL AGE**

FETAL MATURITY, FUNCTIONAL see **FETAL ORGAN MATURITY**

FETAL MEMBRANES

PHYSIOLOGY

Peptide signaling in human placenta and membranes: autocrine, paracrine, and endocrine mechanisms. Petraglia F, et al. **Endocr Rev** 1996 Apr;17(2):156–86 (431 ref.)
Angiotensin II and its different receptor subtypes in placenta and fetal membranes. **Kalenga MK, et al. Placenta** 1996 Mar-Apr;17(2-3):103–110 (50 ref.)

FETAL MEMBRANES, PREMATURE RUPTURE

Premature rupture of membranes. Poma PA. **J Natl Med Assoc** 1996 Jan;88(1):27–32 (54 ref.)

SURGERY

[Are there still indications for cerclage in 1995?] Dufour P, et al. **Rev Fr Gynecol Obstet** 1995 Oct;90(10):423–30 (26 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Antimicrobial therapy in expectant management of preterm premature rupture of the membranes [see comments] [published erratum appears in Lancet 1996 Feb 10;347(8998):410] Mercer BM, et al. **Lancet** 1995 Nov 11; 346(8985):1271–9 (46 ref.) Comment in: Lancet 1996 Jan 20;347(8995):203. Comment in: Lancet 1996 Jan 20;347(8995):203–4. Comment in: Lancet 1996 Jan 20;347(8995):204. Comment in: Lancet 1996 Mar 23;347(9004):837–8.

FETAL MONITORING

see related
SIGNAL PROCESSING, COMPUTER-ASSISTED

Review: perinatal monitoring. Huch R. **Acta Anaesthesiol Scand Suppl** 1995;107:91–4 (11 ref.)
On intrapartum fetal monitoring. Cibils LA. **Am J Obstet Gynecol** 1996 Apr;174(4):1382–9 (71 ref.)
Intrapartum fetal pulse oximetry: past, present, and future. Dildy GA, et al. **Am J Obstet Gynecol** 1996 Jul;175(1):1–9 (57 ref.)
Intrapartum use of fetal heart rate monitoring, contraction monitoring, and amnioinfusion. Cusick W, et al. **Clin Perinatol** 1995 Dec;22(4):875–906 (130 ref.)
Intelligent fetal heart rate computer systems in intrapartum surveillance. Greene KR. **Curr Opin Obstet Gynecol** 1996 Apr;8(2):123–7 (19 ref.)
Fetal assessment in low-risk pregnancy. Manning FA. **Curr Opin Obstet Gynecol** 1995 Dec;7(6):461–4 (14 ref.)
Use of cordocentesis in the management of preterm or growth-restricted fetuses with abnormal monitoring. Shalev E, et al. **Obstet Gynecol Surv** 1995 Dec; 50(12):839–44 (55 ref.)
-Diagnosis of fetal hypoxia by monitoring during labor- Béguin F. **Arch Gynecol Obstet** 1995;256 Suppl:S50–60 (39 ref.) **(Fre)**

METHODS

Medicolegal ramifications of electronic fetal monitoring during labor. Schifrin BS. **Clin Perinatol** 1995 Dec; 22(4):837–54 (42 ref.)
Intrapartum fetal pulse oximetry: present and future. Elchalal U, et al. **Int J Gynaecol Obstet** 1995 Aug;50(2):131–7 (33 ref.)
Continuous fetal monitoring of HbO2 with pulse oximetry. Knitza R, et al. **J Perinat Med** 1996;24(1):55–9 (5 ref.)
[Fetal admission test and fetal heart rate response to vibratory stimuli test] Wu L. **Chung Hua Fu Chan Ko Tsa Chih** 1995 Oct;30(10):633–5 (18 ref.) **(Chi)**
[Intensive monitoring of the fetus sub partu--value and false interpretation] Saling E. **Geburtshilfe Frauenheilkd** 1995 Nov;55(11):628–33 (18 ref.) (Eng. Abstr.) **(Ger)**

FETAL MOVEMENT

PHYSIOLOGY

Hypoxic inhibition of breathing and motor activity in the foetus and newborn. Walker DW. **Clin Exp Pharmacol Physiol** 1995 Aug;22(8):533–6 (30 ref.)
The placenta and the control of fetal breathing movements. Thorburn GD. **Reprod Fertil Dev** 1995;7(3):577–94 (107 ref.)

FETAL ORGAN MATURITY

Thyrotrophin-releasing hormone (TRH) and lung maturation. Liggins GC. **Reprod Fertil Dev** 1995; 7(3):443–50 (54 ref.)

DRUG EFFECTS

Use of antenatal corticosteroids for fetal maturation. Gardner MO, et al. **Curr Opin Obstet Gynecol** 1996 Apr;8(2):106–9 (37 ref.)

FETAL PRESENTATION, BREECH see **BREECH PRESENTATION**

FETAL PROTEINS

PHYSIOLOGY

The CD44 proteins in embryonic development and in cancer.

FETAL PROTEINS

Sherman L, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 1):249–69 (123 ref.)

FETAL REDUCTION see **PREGNANCY REDUCTION, MULTIFETAL**

FETAL TERMINATION, SELECTIVE see **PREGNANCY REDUCTION, MULTIFETAL**

FETAL TISSUE TRANSPLANTATION

Development of the human striatum: implications for fetal striatal transplantation in the treatment of Huntington's disease. Freeman TB, et al. **Cell Transplant** 1995 Nov–Dec; 4(6):539–45 (61 ref.)

Neural transplantation. Lindvall O. **Cell Transplant** 1995 Jul–Aug;4(4):393–400 (35 ref.)

The mechanism of clinical effectiveness of human fetal liver cell transfusion. Wu Z. **Chin Med J (Engl)** 1995 Sep; 108(9):650–2 (8 ref.)

HIV–1–associated pathology in hemato–lymphoid organs and the experimental evaluation in the SCID–hu mouse. Kaneshima H. **Int J Hematol** 1996 Jun;63(4):253–64 (89 ref.)

Quo vadis? Fetal tissue transplantation. Michejda M. **J Hematother** 1996 Apr;5(2):185–8 (31 ref.)

In utero transplantation of fetal liver stem cells into human fetuses. Touraine JL. **J Hematother** 1996 Apr;5(2):195–9 (15 ref.)

Maintaining the neuronal phenotype after injury in the adult CNS. Neurotrophic factors, axonal growth substrates, and gene therapy. Tuszynski MH, et al. **Mol Neurobiol** 1995 Apr–Jun;10(2–3):151–67 (107 ref.)

Core Assessment Program for Intracerebral Transplantation in Huntington's Disease (CAPIT–HD). Quinn N, et al. **Mov Disord** 1996 Mar;11(2):143–50 (44 ref.)

Tempting fate and commitment in the developing forebrain. Barbe MF. **Neuron** 1996 Jan;16(1):1–4 (16 ref.)

[Cell and gene transfers for therapeutic use into the central nervous system] Peschanski M. **Ann Endocrinol (Paris)** 1995;56(6):575–7 (17 ref.) (Eng. Abstr.) **(Fre)**

[Neurotransplantation in Parkinson disease: experimental and clinical results of functional reconstruction of the dopaminergic system] Nikkhah G, et al. **Zentralbl Neurochir** 1995;56(4):153–60 (29 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

[Neuronal transplantation in animal models of Parkinson disease: in vivo voltammetry, tissue cryopreservation and immunology] Sautter J, et al. **Zentralbl Neurochir** 1995; 56(4):161–7 (28 ref.) (Eng. Abstr.) **(Ger)**

LEGISLATION & JURISPRUDENCE

Ethical and policy issues in human fetal tissue transplants. Vawter DE, et al. **Cell Transplant** 1995 Sep–Oct; 4(5):479–82 (4 ref.)

[Legal aspects of neurotransplantation] Wolfslast G. **Zentralbl Neurochir** 1995;56(4):210–4 (35 ref.) (Eng. Abstr.) **(Ger)**

PSYCHOLOGY

[Identity of the personality and personal identity: philosophical questions in relation to transplantation of brain tissue] Birnbacher D. **Zentralbl Neurochir** 1995; 56(4):180–5 (6 ref.) (Eng. Abstr.) **(Ger)**

[Psychological aspects of neurotransplantation] Ellgring H. **Zentralbl Neurochir** 1995;56(4):168–72 (11 ref.) (Eng. Abstr.) **(Ger)**

[Open questions in neurotransplantation. Attempted at an unbiased ethical analysis] Reiter–Theil S. **Zentralbl Neurochir** 1995;56(4):173–9 (8 ref.) (Eng. Abstr.) **(Ger)**

STANDARDS

Fetal tissue banking: standards and regulatory issues. Newman–Gage H. **J Hematother** 1996 Apr;5(2):189–93 (16 ref.)

STATISTICS & NUMERICAL DATA

[Clinical use of placental blood cells] Gluckman E. **C R Seances Soc Biol Fil** 1995;189(4):597–600 (8 ref.) (Eng. Abstr.) **(Fre)**

FETAL TRANSFUSION see **BLOOD TRANSFUSION, INTRAUTERINE**

FETAL ULTRASONOGRAPHY see **ULTRASONOGRAPHY, PRENATAL**

FETAL VIABILITY

Fetal viability as a threshold to personhood. A legal analysis. Peterfy A. **J Leg Med** 1995 Dec;16(4):607–36 (344 ref.)

FETOFETAL TRANSFUSION

Twin–to–twin transfusion syndrome: new perspectives. Lopriore E, et al. **J Pediatr** 1995 Nov;127(5):675–80 (72 ref.)

PATHOLOGY

Mechanism of visceral damage in fetofetal transfusion syndrome. Rehan VK, et al. **Arch Dis Child Fetal Neonatal Ed** 1995 Jul;73(1):F48–50 (32 ref.)

FETOMATERNAL TRANSFUSION

COMPLICATIONS

[Fetal cerebral accident due to massive fetomaternal hemorrhage. A case report] Lionnet C, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(5):553–6 (18 ref.) (Eng. Abstr.) **(Fre)**

[Hepatitis C virus infection. Epidemiology] Bastie A, et al. **Pathol Biol (Paris)** 1995 Oct;43(8):674–80 (78 ref.) (Eng. Abstr.) **(Fre)**

FETOTOXINS see **TERATOGENS**

FETUINS see **ALPHA–FETOPROTEINS**

FETUS

see related
GESTATIONAL AGE
MATERNAL–FETAL EXCHANGE

The fetus as a passive smoker. Koren G. **Can Fam Physician** 1996 Jul;42:1301–3 (15 ref.)

The fetal and infant origins of disease. Barker DJ. **Eur J Clin Invest** 1995 Jul;25(7):457–63 (51 ref.)

The maternal–fetal rights dilemma: honoring a woman's choice of medical care during pregnancy. Arch RR. **J Contemp Health Law Policy** 1996 Spring;12(2):637–73 (255 ref.)

Role of fetal surveillance in diabetic pregnancies. Fuentes A, et al. **J Matern Fetal Med** 1996 Mar–Apr;5(2):85–8 (12 ref.)

ANATOMY & HISTOLOGY

[Magnetic resonance imaging of the fetus. Contribution to antenatal diagnosis] Garel C, et al. **Presse Med** 1996 Mar 16;25(9):452–6 (23 ref.) (Eng. Abstr.) **(Fre)**

BLOOD SUPPLY

Parturition and fetal adaptation. Lowe NK, et al. **J Obstet Gynecol Neonatal Nurs** 1996 May;25(4):339–49 (71 ref.)

Not trophoblast alone: a review of the contribution of the fetal microvasculature to transplacental exchange. Firth JA, et al. **Placenta** 1996 Mar–Apr;17(2–3):89–96 (64 ref.)

Current topic: in vivo investigation of the placental circulations by Doppler echography [see comments] Jauniaux E, et al. **Placenta** 1995 Jun;16(4):323–31 (52 ref.) Comment in: Placenta 1995 Jun;16(4):333–4.

Regulation of human placental fetal vessel tone: role of nitric oxide. King RG, et al. **Reprod Fertil Dev** 1995;7(6):1407–11 (56 ref.)

Advances in understanding permeability in fetal capillaries of the human placenta: a review of organization of the endothelial paracellular clefts and their junctional complexes. Leach L, et al. **Reprod Fertil Dev** 1995; 7(6):1451–6 (51 ref.)

CHEMISTRY

Ontogeny of angiotensin II receptors. Shanmugam S, et al. **Cell Biol Int** 1996 Mar;20(3):169–76 (42 ref.)

CYTOLOGY

The fetal macrophage: a review. Brighton VW, et al. **J Am Coll Surg** 1996 Mar;182(3):270–6 (50 ref.)

Role of yolk sac endodermal cells with special reference to the fetal macrophage differentiation. Yamashita A. **J Leukoc Biol** 1996 Feb;59(2):139–44 (26 ref.)

DRUG EFFECTS

Neurobehavioral effects of developmental methylmercury exposure. Gilbert SG, et al. **Environ Health Perspect** 1995 Sep;103 Suppl 6:135–42 (107 ref.)

Growth abnormalities in the population exposed in utero and early postnatally to polychlorinated biphenyls and dibenzofurans. Guo YL, et al. **Environ Health Perspect** 1995 Sep;103 Suppl 6:117–22 (53 ref.)

Behavioral toxicology. Needleman HL. **Environ Health Perspect** 1995 Sep;103 Suppl 6:77–9 (15 ref.)

The concern for developmental neurotoxicology: is it justified and what is being done about it? Tilson HA. **Environ Health Perspect** 1995 Sep;103 Suppl 6:147–51 (31 ref.)

Application of biologic markers to studies of environmental risks in children and the developing fetus. Whyatt RM, et al. **Environ Health Perspect** 1995 Sep;103 Suppl 6:105–10 (66 ref.)

Influence of epidural analgesia on fetal and neonatal well–being. Scherer R, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 May;59 Suppl:S17–29 (118 ref.)

Extrapulmonary effects of antenatally administered steroids. Padbury JF, et al. **J Pediatr** 1996 Feb;128(2):167–72 (61 ref.)

Effects of cocaine on fetal brain metabolism and behavioral state in the sheep model. Burchfield DJ. **NIDA Res Monogr** 1995;158:58–66 (30 ref.)

Fetal cerebral vascular effects of cocaine exposure. Schreiber MD. **NIDA Res Monogr** 1995;158:67–87 (50 ref.)

Pharmacologic treatment of psychiatric disease in pregnancy and lactation: fetal and neonatal effects. Kuller JA, et al. **Obstet Gynecol** 1996 May;87(5 Pt 1):789–94 (38 ref.)

[Maternal corticotherapy . Pharmacology and effect on the fetus] Guillonneau M, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(2):160–7 (53 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Fetal versus adult PreB or B cells: the human VH repertoire. Tonnelle C, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:231–41 (38 ref.)

[Immunologic tolerance of fetal allograft] Deneys V, et al. **Presse Med** 1995 Nov 18;24(35):1651–7 (31 ref.) (Eng. Abstr.) **(Fre)**

INJURIES

Fetal complications related to minor maternal trauma. Huzel PS, et al. **J Obstet Gynecol Neonatal Nurs** 1996 Feb; 25(2):121–4 (9 ref.)

[Trauma in the last trimester of pregnancy] Prokop A, et al. **Unfallchirurg** 1996 Jun;99(6):450–3 (11 ref.) (Eng. Abstr.) **(Ger)**

METABOLISM

Actions of placental and fetal adrenal steroid hormones in primate pregnancy. Pepe GJ, et al. **Endocr Rev** 1995 Oct; 16(5):608–48 (617 ref.)

Pharmacokinetics and pharmacodynamics of maternal–fetal transport of drugs of abuse: a critical review. Melethil S. **NIDA Res Monogr** 1995;154:132–51 (48 ref.)

Pharmacodynamics in the maternal–fetal–placental unit. Rudolph AM. **NIDA Res Monogr** 1995;154:163–74 (15 ref.)

Maternal–fetal pharmacokinetics: summary and future directions. Szeto HH. **NIDA Res Monogr** 1995;154:203–17 (36 ref.)

New approaches for drug and kinetic analysis in the maternal–fetal unit. Tonn GR, et al. **NIDA Res Monogr** 1995;154:175–202 (43 ref.)

Fuel metabolism in deviant fetal growth in offspring of diabetic women. Hod M, et al. **Obstet Gynecol Clin North Am** 1996 Mar;23(1):259–77 (105 ref.)

Fetal metabolic responses to hypoxia. Hooper SB. **Reprod Fertil Dev** 1995;7(3):527–38 (75 ref.)

Observations on vitamin K deficiency in the fetus and newborn: has nature made a mistake? Israels LG, et al. **Semin Thromb Hemost** 1995;21(4):357–63 (36 ref.)

Unique organ specific characteristics of amino acid metabolism in early development. Battaglia FC, et al. **Trans Am Clin Climatol Assoc** 1994;106:141–9; discussion 149–50 (22 ref.)

PHYSIOLOGY

The function of fetal/neonatal rapid eye movement sleep. Mirmiran M. **Behav Brain Res** 1995 Jul–Aug;69(1–2):13–22 (64 ref.)

Perinatal thermogenesis. Gunn TR, et al. **Early Hum Dev** 1995 Aug 18;42(3):169–83 (60 ref.)

Parturition and fetal adaptation. Lowe NK, et al. **J Obstet Gynecol Neonatal Nurs** 1996 May;25(4):339–49 (71 ref.)

Scar formation: the spectral nature of fetal and adult wound repair. Ferguson MW, et al. **Plast Reconstr Surg** 1996 Apr; 97(4):854–60 (42 ref.)

Baroreflex and chemoreflex control of fetal hormone secretion. Wood CE. **Reprod Fertil Dev** 1995;7(3):479–89 (94 ref.)

[The role of erythropoietin in erythropoiesis regulation in fetuses and newborn infants] Ulman I. **Ginekol Pol** 1996 Apr;67(4):205–9 (29 ref.) (Eng. Abstr.) **(Pol)**

RADIATION EFFECTS

Mantle irradiation for Hodgkin's disease during pregnancy: safe and practical? [editorial; comment] Byram D. **Australas Radiol** 1996 May;40(2):101–3 (30 ref.) Comment on: Australas Radiol 1996 May;40(2):146–8.

SURGERY

Fetal surgery. Harrison MR. **Am J Obstet Gynecol** 1996 Apr; 174(4):1255–64 (53 ref.)

TRANSPLANTATION

Neural transplantation for Huntington's disease: experimental rationale and recommendations for clinical trials. Shannon KM, et al. **Cell Transplant** 1996 Mar–Apr;5(2):339–52 (107 ref.)

FEVER

see related
ANTI–INFLAMMATORY AGENTS
ANTI–INFLAMMATORY AGENTS,

NON-STEROIDAL
HEAT-SHOCK PROTEINS
HYPERTHERMIA, INDUCED
PYROGENS

Hyperthermia and birth defects. Edwards MJ, et al. **Reprod Toxicol** 1995 Sep-Oct;9(5):411-25 (109 ref.)

CHEMICALLY INDUCED

Acute febrile toxic reaction in patients with refractory rheumatoid arthritis who are receiving combined therapy with methotrexate and azathioprine. Blanco R, et al. **Arthritis Rheum** 1996 Jun;39(6):1016-20 (19 ref.)

Drug fever. Johnson DH, et al. **Infect Dis Clin North Am** 1996 Mar;10(1):85-91 (23 ref.)

[Drug fever] Karban A, et al. **Harefuah** 1996 Jan 15; 130(2):113-6 (34 ref.) **(Heb)**

CLASSIFICATION

The clinical significance of fever patterns. Cunha BA. **Infect Dis Clin North Am** 1996 Mar;10(1):33-44 (12 ref.)

DIAGNOSIS

Fever, convulsions and coma in scleromyxedema: a "dermato-neuro syndrome". River Y, et al. **Neurology** 1996 Jun;46(6):1778-9 (7 ref.)

Assessment of fever in HIV-infected patients. Gleckman R, et al. **Postgrad Med** 1996 Mar;99(3):78-80, 87-9, 93-4 passim (37 ref.)

DRUG THERAPY

An approach to the design and implementation of clinical trials of empirical antibiotic therapy in febrile and neutropenic cancer patients. Viscoli C, et al. **Eur J Cancer** 1995 Nov;31A(12):2013-22 (60 ref.)

[Rational use of antibiotics in the neutropenic patient with fever] de Pauw BE, et al. **Ned Tijdschr Geneeskd** 1995 Aug 26;139(34):1725-9 (26 ref.) **(Dut)**

[Amidazophen. Yes or no?] Jákó J, et al. **Orv Hetil** 1995 Sep 24;136(39):2121-4 (50 ref.) (Eng. Abstr.) **(Hun)**

EPIDEMIOLOGY

Epidemiology and pathoetiology of neurological syndromes with hyperthermia. Di Rosa AE, et al. **Funct Neurol** 1995 May-Jun;10(3):111-9 (49 ref.)

ETIOLOGY

Selective causes of fever in adult human immunodeficiency virus-infected patients relative to CD4+ cell counts. Czachor JS, et al. **Arch Fam Med** 1995 Oct;4(10):879-84 (77 ref.)

Evaluating fever in travellers returning from tropical countries. Humar A, et al. **BMJ** 1996 Apr 13; 312(7036):953-6 (25 ref.)

An approach to acute fever and rash (AFR) in the adult. Levin S, et al. **Curr Clin Top Infect Dis** 1995;15:19-75 (234 ref.)

Epidemiology and pathoetiology of neurological syndromes with hyperthermia. Di Rosa AE, et al. **Funct Neurol** 1995 May-Jun;10(3):111-9 (49 ref.)

Fever in rheumatic and autoimmune disease. Carsons SE. **Infect Dis Clin North Am** 1996 Mar;10(1):67-84 (49 ref.)

Fever in the intensive care unit. Cunha BA, et al. **Infect Dis Clin North Am** 1996 Mar;10(1):185-209 (45 ref.)

Fever in the compromised host. Donowitz GR. **Infect Dis Clin North Am** 1996 Mar;10(1):129-48 (50 ref.)

Fever in the solid organ transplant patient. Fischer SA, et al. **Infect Dis Clin North Am** 1996 Mar;10(1):167-84 (115 ref.)

Fever in the elderly. Norman DC, et al. **Infect Dis Clin North Am** 1996 Mar;10(1):93-9 (38 ref.)

Fever in neurologic diseases. Powers JH, et al. **Infect Dis Clin North Am** 1996 Mar;10(1):45-66 (57 ref.)

Fever and rash. Schlossberg D. **Infect Dis Clin North Am** 1996 Mar;10(1):101-10 (9 ref.)

Cytokines and fever. Luheshi G, et al. **Int Arch Allergy Immunol** 1996 Apr;109(4):301-7 (30 ref.)

Assessment of fever in HIV-infected patients. Gleckman R, et al. **Postgrad Med** 1996 Mar;99(3):78-80, 87-9, 93-4 passim (37 ref.)

Differential diagnosis of fever and pulmonary densities in mechanically ventilated patients. Louthan FB, et al. **Semin Respir Infect** 1996 Jun;11(2):77-95 (136 ref.)

[Giant hemangioma of the liver disclosed by fever and an inflammatory syndrome. Apropos of 3 cases] Taillandier J, et al. **Ann Med Interne (Paris)** 1995;146(5):319-21 (9 ref.) (Eng. Abstr.) **(Fre)**

[Hyperimmunoglobulin D syndrome] Drenth JP, et al. **Presse Med** 1995 Sep 16;24(26):1211-3 (21 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

The neurological basis of fever. Samii A. **Surg Neurol** 1996 Apr;45(4):392-3 (11 ref.)

METABOLISM

The pharmacologic consequences of fever. Sarwari AR, et al. **Infect Dis Clin North Am** 1996 Mar;10(1):21-32 (62 ref.)

PHYSIOPATHOLOGY

The adaptive value of fever. Kluger MJ, et al. **Infect Dis Clin North Am** 1996 Mar;10(1):1-20 (96 ref.)

The use of conditioning to probe for CNS pathways that regulate fever and NK cell activity. Hiramoto R, et al. **Int J Neurosci** 1996 Feb;84(1-4):229-45 (55 ref.)

The neurological basis of fever. Samii A. **Surg Neurol** 1996 Apr;45(4):392-3 (11 ref.)

[Drug fever] Karban A, et al. **Harefuah** 1996 Jan 15; 130(2):113-6 (34 ref.) **(Heb)**

[Theoretical and clinical aspects of the problem of low-grade fever] Semenenia IN, et al. **Fiziol Cheloveka** 1995 Nov-Dec;21(6):127-36 (30 ref.) **(Rus)**

THERAPY

Treatment of fever. Klein NC, et al. **Infect Dis Clin North Am** 1996 Mar;10(1):211-6 (45 ref.)

Fever in patients with HIV infection. Sullivan M, et al. **Infect Dis Clin North Am** 1996 Mar;10(1):149-65 (94 ref.)

Approach to fever and infection in the nursing home. Yoshikawa TT, et al. **J Am Geriatr Soc** 1996 Jan; 44(1):74-82 (87 ref.)

FEVER OF UNKNOWN ORIGIN

Fever without apparent source on clinical examination, lower respiratory infections in children, other infectious diseases, and acute gastroenteritis and diarrhea of infancy and early childhood. McCarthy PL, et al. **Curr Opin Pediatr** 1996 Feb;8(1):75-93 (134 ref.)

DIAGNOSIS

[Fever of unknown origin in HIV infection. New facets of an old problem (editorial)] Barbado Hernández FJ, et al. **Med Clin (Barc)** 1995 Nov 11;105(16):615-6 (24 ref.) **(Spa)**

ETIOLOGY

Fever of unknown origin. Cunha BA. **Infect Dis Clin North Am** 1996 Mar;10(1):111-27 (64 ref.)

Fever of unknown origin. Miller ML, et al. **Pediatr Clin North Am** 1995 Oct;42(5):999-1015 (107 ref.)

[The Schnitzler syndrome as a cause of recurrent fever of unknown origin] Winckelmann G, et al. **Dtsch Med Wochenschr** 1996 Jul 5;121(27):860-4 (14 ref.) (Eng. Abstr.) **(Ger)**

FEVER THERAPY see **HYPERTHERMIA, INDUCED**

FGF RECEPTORS see **RECEPTORS, FIBROBLAST GROWTH FACTOR**

FIBER OPTICS

[Fiber optic chemical gas sensors based on environmental chromism] Sadaoka Y. **Tanpakushitsu Kakusan Koso** 1995 Nov;40(15):2355-60 (14 ref.) **(Jpn)**

FIBERGLASS CASTS see **CASTS, SURGICAL**

FIBRIN

METABOLISM

Fibrin-selective thrombolytic therapy for acute myocardial infarction. Collen D. **Circulation** 1996 Mar 1;93(5):857-65 (90 ref.)

PHYSIOLOGY

Lipoprotein(a), plasmin modulation, and atherogenesis. Harpel PC, et al. **Thromb Haemost** 1995 Jul;74(1):382-6 (83 ref.)

FIBRIN ADHESIVE see **FIBRIN TISSUE ADHESIVE**

FIBRIN DEGRADATION PRODUCTS see **FIBRIN FIBRINOGEN DEGRADATION PRODUCTS**

FIBRIN FIBRINOGEN DEGRADATION PRODUCTS

ANALYSIS

D-dimer testing and acute venous thromboembolism. A shortcut to accurate diagnosis? Becker DM, et al. **Arch Intern Med** 1996 May 13;156(9):939-46 (46 ref.)

[Contribution of laboratory tests and venous investigations in the diagnosis of pulmonary embolism] Perrier A, et al. **Arch Mal Coeur Vaiss** 1995 Nov;88(11 Suppl):1699-707 (48 ref.) (Eng. Abstr.) **(Fre)**

[Soluble fibrin monomer complex (SFMC)] Kazama M, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:22-5 (10 ref.) **(Jpn)**

[FDP-E fraction] Kazama M. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:30-3 (11 ref.) **(Jpn)**

[D dimer] Kurokawa I, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:34-8 (8 ref.) **(Jpn)**

[Fibrinopeptide A (FPA) and fibrinopeptide B beta 15-42 (FPB beta 15-42)] Tatsumi N, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:39-42 (15 ref.) **(Jpn)**

[Coagulation and fibrinolysis parameters in neoplastic pleural exudates] Talałaj J. **Pneumonol Alergol Pol** 1995; 63(5-6):339-43 (15 ref.) **(Pol)**

METABOLISM

Fibrin D-dimer: a useful clinical marker of thrombogenesis? [editorial] Lip GY, et al. **Clin Sci (Colch)** 1995 Sep; 89(3):205-14 (115 ref.)

URINE

[Fibrin/fibrinogen degradation products (FDP)] Miyajima Y, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:26-9 (11 ref.) **(Jpn)**

FIBRIN FIBRINOGEN SPLIT PRODUCTS see **FIBRIN FIBRINOGEN DEGRADATION PRODUCTS**

FIBRIN GLUE see **FIBRIN TISSUE ADHESIVE**

FIBRIN SEALANT SYSTEM see **FIBRIN TISSUE ADHESIVE**

FIBRIN STABILIZING FACTOR see **FACTOR XIII**

FIBRIN TISSUE ADHESIVE

Preparation and use of fibrin glue in surgery. Silver FH, et al. **Biomaterials** 1995 Aug;16(12):891-903 (124 ref.)

[Fibrin glue (editorial)] Viljanto J. **Duodecim** 1995; 111(6):495-7 (14 ref.) **(Fin)**

[Fibrin glue--an effective hemostatic-adhesive system] Balint B, et al. **Vojnosanit Pregl** 1995 Sep-Oct;52(5):477-82 (33 ref.) **(Scr)**

ADMINISTRATION & DOSAGE

[Fibrin sealing, a concept for early elective endoscopic therapy] Friedrichs O. **Wien Med Wochenschr** 1995; 145(14):313-8 (42 ref.) (Eng. Abstr.) **(Ger)**

[The treatment of a bronchopleural fistula with fibrin adhesive in a premature infant] Galiana Ferré C, et al. **An Esp Pediatr** 1996 Jun;44(6):596-8 (11 ref.) **(Spa)**

THERAPEUTIC USE

Role of fibrin sealants in surgical procedures on patients with hemostatic disorders. Martinowitz U, et al. **Clin Orthop** 1996 Jul;(328):65-75 (76 ref.)

Fibrin sealant in surgery of patients with a hemorrhagic diathesis. Martinowitz U, et al. **Thromb Haemost** 1995 Jul; 74(1):486-92 (81 ref.)

Fibrin sealant in the United States: clinical use at the University of Virginia. Spotnitz WD. **Thromb Haemost** 1995 Jul;74(1):482-5 (54 ref.)

FIBRINASE see **FACTOR XIII**

FIBRINOGEN

see related
HEMOSTATICS

ANALYSIS

[Fibrinogen as a cardiovascular risk factor] Giannasi G, et al. **Minerva Cardioangiol** 1995 May;43(5):169-75 (100 ref.) (Eng. Abstr.) **(Ita)**

[Fibrinogen (factor I)] Samori T. **Nippon Rinsho** 1995 Mar; 53 Su Pt 2:18-21 (5 ref.) **(Jpn)**

GENETICS

[Association of dysfibrinogenemia and thrombosis. Apropos of a family (Fibrinogen Melun) and review of the literature] Bentolila S, et al. **Ann Med Interne (Paris)** 1995; 146(8):575-80 (32 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Haemorheological consequences of chronic cigarette smoking. Ernst E. **J Cardiovasc Risk** 1995 Oct;2(5):435-9 (70 ref.)

Fibrinogen and cardiovascular risk. Heinrich J, et al. **J Cardiovasc Risk** 1995 Jun;2(3):197-205 (88 ref.)

Drugs affecting plasma fibrinogen levels. Implications for new antithrombotic strategies. Margaglione M, et al. **Prog Drug Res** 1996;46:169-81 (89 ref.)

Mechanisms involved in platelet vessel wall interaction. Hawiger J. **Thromb Haemost** 1995 Jul;74(1):369-72 (37 ref.)

PHYSIOLOGY

The role of von Willebrand factor and fibrinogen in the initiation of platelet adhesion to thrombogenic surfaces. Ruggeri ZM. **Thromb Haemost** 1995 Jul;74(1):460-3 (45 ref.)

FIBRINOGEN ADHESIVE see **FIBRIN TISSUE ADHESIVE**

FIBRINOGEN DEFICIENCY see **AFIBRINOGENEMIA**

FIBRINOGEN RECEPTORS see **PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX**

FIBRINOGENS, ABNORMAL

ANALYSIS

[Abnormal fibrinogen] Matsuda M. **Nippon Rinsho** 1995 Mar; 53 Su Pt 2:150–3 (14 ref.) **(Jpn)**

FIBRINOLYSIN see **PLASMIN**

FIBRINOLYSIS

Fibrinolysis and atherosclerosis. Hamsten A, et al. **Baillieres Clin Haematol** 1995 Jun;8(2):345–63 (119 ref.)

Pathophysiology of fibrinolysis. Juhan-Vague I, et al. **Baillieres Clin Haematol** 1995 Jun;8(2):329–43 (109 ref.)

Risk factors for cerebrovascular disease and the role of coagulation and fibrinolysis. Catto AJ, et al. **Blood Coagul Fibrinolysis** 1995 Sep;6(6):497–510 (173 ref.)

Endothelium, fibrinolysis, cardiac risk factors, and prostaglandins: a unified model of atherogenesis. Kadish J. **Med Hypotheses** 1995 Aug;45(2):205–13 (106 ref.)

[Blood coagulation and fibrinolysis in patients with acute coronary syndrome] Ogawa H, et al. **Nippon Naika Gakkai Zasshi** 1995 Oct 10;84(10):1755–9 (12 ref.) **(Jpn)**

DRUG EFFECTS

Roentgen contrast media and fibrinolysis. Brosstad F, et al. **Acta Radiol Suppl** 1995;399:185–7 (7 ref.)

The effects of metformin on cardiovascular risk factors. Grant PJ. **Diabetes Metab Rev** 1995 Sep;11 Suppl 1:S43–50 (56 ref.)

Fibrinolytic mechanism, biochemistry, and preclinical pharmacology of recombinant prourokinase. Credo RB, et al. **J Vasc Interv Radiol** 1995 Nov–Dec;6(6 Pt 2 Su):8S–18S (59 ref.)

Standards in fibrinolysis--current status and future challenges. Gaffney PJ. **Thromb Haemost** 1995 Dec; 74(6):1389–97 (59 ref.)

GENETICS

Physiological consequences of over- or under-expression of fibrinolytic system components in transgenic mice. Carmeliet PF. **Baillieres Clin Haematol** 1995 Jun; 8(2):391–401 (49 ref.)

Gene targeting and gene transfer studies of the biological role of the plasminogen/plasmin system. Carmeliet P, et al. **Thromb Haemost** 1995 Jul;74(1):429–36 (66 ref.)

PHYSIOLOGY

Mechanisms of physiological fibrinolysis. Lijnen HR, et al. **Baillieres Clin Haematol** 1995 Jun;8(2):277–90 (83 ref.)

Profibrinolytic and antifibrinolytic effects of platelets. Devine DV, et al. **Coron Artery Dis** 1995 Dec;6(12):915–22 (62 ref.)

Diet, blood coagulation and fibrinolysis. Marckmann P. **Dan Med Bull** 1995 Nov;42(5):410–25 (275 ref.)

Fibrinolytic system and reproductive process with special reference to fibrinolytic failure in pre-eclampsia. Gilabert J, et al. **Hum Reprod** 1995 Dec;10 Suppl 2:121–31 (83 ref.)

Cytokines, fibrinolysis and vasculitis. Teofoli P, et al. **Int Angiol** 1995 Jun;14(2):125–9 (51 ref.)

Hypofibrinolysis and the insulin resistance syndrome. Vague P, et al. **Int J Obes Relat Metab Disord** 1995 May;19 Suppl 1:S11–5 (59 ref.)

Lipoprotein (a): a prothrombotic risk factor for coronary artery disease. Seed M, et al. **J Cardiovasc Risk** 1995 Jun; 2(3):206–15 (67 ref.)

Platelets in fibrinolytic system. Korbut R, et al. **J Physiol Pharmacol** 1995 Dec;46(4):409–18 (42 ref.)

Molecular basis of fibrinolysis, as relevant for thrombolytic therapy. Collen D, et al. **Thromb Haemost** 1995 Jul; 74(1):167–71 (40 ref.)

The fibrinolytic system: from Petri dishes to genetic engineering. Verstraete M. **Thromb Haemost** 1995 Jul; 74(1):25–35 (108 ref.)

[Coagulation and fibrinolysis parameters in neoplastic pleural exudates] Talalaj J. **Pneumonol Alergol Pol** 1995; 63(5–6):339–43 (15 ref.) **(Pol)**

[Fibrinolysis process in prostatic carcinoma] Ziętek Z, et al. **Pol Tyg Lek** 1996 Feb;51(6–9):107–8 (26 ref.) **(Pol)**

FIBRINOLYTIC AGENTS

New thrombolytic agents and strategies. Collen D, et al. **Baillieres Clin Haematol** 1995 Jun;8(2):425–35 (50 ref.)

Antithrombotic agents: from RGD to peptide mimetics. Ojima I, et al. **Bioorg Med Chem** 1995 Apr;3(4):337–60 (142 ref.)

4th American College of Chest Physicians Consensus Conference on Antithrombotic Therapy. Tucson, Arizona, April 1995. Proceedings. **Chest** 1995 Oct;108(4 Suppl):225S–522S (0 ref.)

[Selective type III phosphodiesterase inhibitor as an antithrombotic agent] Kimura Y. **Nippon Yakurigaku Zasshi** 1995 Sep;106(3):205–16 (39 ref.) (Eng. Abstr.) **(Jpn)**

ADMINISTRATION & DOSAGE

Antithrombotic therapy in atrial fibrillation. Laupacis A, et al. **Chest** 1995 Oct;108(4 Suppl):352S–359S (52 ref.)

Antithrombotic therapy in children. Michelson AD, et al. **Chest** 1995 Oct;108(4 Suppl):506S–522S (205 ref.)

Antithrombotic therapy in patients with saphenous vein and internal mammary artery bypass grafts. Stein PD, et al. **Chest** 1995 Oct;108(4 Suppl):424S–430S (30 ref.)

Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Stein PD, et al. **Chest** 1995 Oct;108(4 Suppl):371S–379S (59 ref.)

Technical determinants of success in catheter-directed thrombolysis for peripheral arterial occlusions. Kandarpa K. **J Vasc Interv Radiol** 1995 Nov–Dec;6(6 Pt 2 Su):55S–61S (54 ref.)

Heparin dosing. Farnsworth TL. **S D J Med** 1995 Nov; 48(11):386–7 (13 ref.)

[Thrombolysis of an extensive venous thrombosis of the lower body in an anomaly of the vena cava inferior] Rühlmann C, et al. **Dtsch Med Wochenschr** 1996 Feb 2; 121(5):124–8 (29 ref.) (Eng. Abstr.) **(Ger)**

[Thrombolysis in stroke] Diener HC, et al. **Internist (Berl)** 1996 Jun;37(6):613–8 (26 ref.) **(Ger)**

[Postoperative thrombolytic therapy] Kolben M, et al. **Internist (Berl)** 1996 Jun;37(6):619–22 (27 ref.) **(Ger)**

[Thrombolytic therapy of acute pulmonary embolism] Pilger E, et al. **Internist (Berl)** 1996 Jun;37(6):574–84 (56 ref.) **(Ger)**

[Percutaneous local thrombolytic therapy and thrombectomy in occlusion of extremity arteries] Schneider E, et al. **Internist (Berl)** 1996 Jun;37(6):607–12 (23 ref.) **(Ger)**

[Recommendations for prevention of thromboembolism in heart valve diseases. Working Group on Valvular Heart Disease, European Society of Cardiology] Gohlke-Bärwolf C, et al. **Z Kardiol** 1995 Dec;84(12):1018–32 (168 ref.) (Eng. Abstr.) **(Ger)**

[Local drug administration systems, preclinical and clinical use: perspectives and limitations] Gonschior P, et al. **Z Kardiol** 1996 Mar;85(3):155–65 (59 ref.) (Eng. Abstr.) **(Ger)**

[Antithrombotic treatment in connection with PTCA. New substances and regimes are coming] Scherstén F, et al. **Lakartidningen** 1996 Jun 26;93(26–27):2499–502 (29 ref.) **(Swe)**

ADVERSE EFFECTS

Hemorrhagic complications of thrombolytic therapy in the treatment of myocardial infarction and venous thromboembolism. Levine MN, et al. **Chest** 1995 Oct;108(4 Suppl):291S–301S (86 ref.)

How safe is the readministration of streptokinase? Lee HS. **Drug Saf** 1995 Aug;13(2):76–80 (27 ref.)

Does the potential for development of streptokinase antibodies change the risk-benefit ratio in older patients? Brügemann J, et al. **Drugs Aging** 1995 Aug;7(2):110–6 (32 ref.)

Thrombolytic-associated cholesterol emboli syndrome: case report and literature review. Geraets DR, et al. **Pharmacotherapy** 1995 Jul–Aug;15(4):441–50 (51 ref.)

[Femoral neuropathy due to a spontaneous hematoma of the iliopsoas muscle during therapy with heparin-calcium] Casoni P, et al. **Acta Biomed Ateneo Parmense** 1994; 65(5–6):289–96 (5 ref.) (Eng. Abstr.) **(Ita)**

ANALYSIS

[Enzyme immunoassay of blood coagulation and fibrinolysis factors] Koike K, et al. **Nippon Rinsho** 1995 Sep; 53(9):2269–76 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Tissue factor pathway inhibitor (TFPI)] Matsuo T, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:157–61 (10 ref.) **(Jpn)**

CHEMISTRY

Structure-activity relationship of antithrombotic polysaccharide derivatives. Franz G, et al. **Int J Biol Macromol** 1995 Dec;17(6):311–4 (16 ref.)

Application of combinatorial libraries and protein engineering to the discovery of novel anti-thrombotic drugs. Leung LL. **Thromb Haemost** 1995 Jul;74(1):373–6 (19 ref.)

CLASSIFICATION

[Current and future antithrombotic therapies] Uzan A. **Ann Pharm Fr** 1996;54(1):8–20 (21 ref.) (Eng. Abstr.) **(Fre)**

[New antithrombotic agents] Kereveur A, et al. **Presse Med** 1995 Dec 9;24(38):1777–87 (60 ref.) (Eng. Abstr.) **(Fre)**

ECONOMICS

Clinical and economic lessons from studies of coronary thrombolysis. Mark DB. **J Vasc Interv Radiol** 1995 Nov–Dec;6(6 Pt 2 Su):94S–101S (27 ref.)

IMMUNOLOGY

Does the potential for development of streptokinase antibodies change the risk-benefit ratio in older patients? Brügemann J, et al. **Drugs Aging** 1995 Aug;7(2):110–6 (32 ref.)

PHARMACOLOGY

Thrombosis and the pharmacology of antithrombotic agents. Haines ST, et al. **Ann Pharmacother** 1995 Sep;29(9):892–905 (105 ref.)

Antiplatelet effects of fibrinolytic agents: a potential contributor to the hemostatic defect after thrombolysis. Kamat SG, et al. **Coron Artery Dis** 1995 Dec;6(12):930–5 (55 ref.)

Platelet activation by fibrinolytic agents: a potential mechanism for resistance to thrombolysis and reocclusion after successful thrombolysis. Leopold JA, et al. **Coron Artery Dis** 1995 Dec;6(12):923–9 (60 ref.)

Thrombolytic agents in development. Verstraete M, et al. **Drugs** 1995 Jul;50(1):29–42 (90 ref.)

Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans. Frydman A. **Haemostasis** 1996;26 Suppl 2:24–38 (77 ref.)

New thrombin inhibiting strategies for coronary artery disease. Shah PK, et al. **Indian Heart J** 1995 Jul–Aug; 47(4):381–6 (41 ref.)

From the experimental myocardial infarction to the clinical acute myocardial infarction: limitations of thrombolytic therapy. Marzilli M. **Int J Cardiol** 1995 Aug;49 Suppl:S71–5 (30 ref.)

Fibrinolytic mechanism, biochemistry, and preclinical pharmacology of recombinant prourokinase. Credo RB, et al. **J Vasc Interv Radiol** 1995 Nov–Dec;6(6 Pt 2 Su):8S–18S (59 ref.)

Thrombolysis, flow, and vessel wall interactions. Grabowski EF. **J Vasc Interv Radiol** 1995 Nov–Dec;6(6 Pt 2 Su):25S–29S (37 ref.)

Interactions between endothelial mediators. Gryglewski RJ. **Pharmacol Toxicol** 1995 Jul;77(1):1–9 (120 ref.)

Drugs affecting plasma fibrinogen levels. Implications for new antithrombotic strategies. Margaglione M, et al. **Prog Drug Res** 1996;46:169–81 (89 ref.)

Molecular basis of fibrinolysis, as relevant for thrombolytic therapy. Collen D, et al. **Thromb Haemost** 1995 Jul; 74(1):167–71 (40 ref.)

Fibrinolytic agents: mechanisms of activity and pharmacology. Lijnen HR, et al. **Thromb Haemost** 1995 Jul;74(1):387–90 (33 ref.)

Staphylokinase: fibrinolytic properties and current experience in patients with occlusive arterial thrombosis. Collen D, et al. **Verh K Acad Geneeskd Belg** 1995;57(3):183–96; discussion 196–8 (40 ref.)

Mechanism of action and thrombolytic potential of staphylokinase. Lijnen HR. **Verh K Acad Geneeskd Belg** 1995;57(4):303–14 (32 ref.)

[Anti-adhesive and anti-thrombotic effects of integrin-inhibiting tripeptides (Arg-Gly-Asp)] Udvardy M. **Orv Hetil** 1995 Oct 1;136(40):2155–9 (42 ref.) (Eng. Abstr.) **(Hun)**

THERAPEUTIC USE

Thrombolysis of primary angioplasty? An ongoing controversy in the management of acute myocardial infarction. Futterman LG, et al. **Am J Crit Care** 1996 Mar; 5(2):160–66 (20 ref.)

The results of arterial thrombolysis. Kroese AJ, et al. **Ann Chir Gynaecol** 1995;84(4):350–3 (17 ref.)

Thrombolysis in extremital arteries--indications and methods. Wellander E, et al. **Ann Chir Gynaecol** 1995; 84(4):341–8 (74 ref.)

Clinical applications of new antithrombotic agents. Beijering RJ, et al. **Ann Hematol** 1996 Apr;72(4):177–83 (52 ref.)

Safety profile of thrombolytic drugs. Maggioni AP, et al. **Arq Bras Cardiol** 1995 Jul;65(1):87–90 (11 ref.)

ABC of atrial fibrillation. Antithrombotic treatment for atrial fibrillation. Lip GY, et al. **BMJ** 1996 Jan 6;312(7022):45–9 (0 ref.)

Acute care of myocardial infarction [see comments] Gutman MB, et al. **Can Fam Physician** 1996 Jul;42:1330–9 (30 ref.) Comment in: Can Fam Physician 1996 Jul;42:1269–70, 1278–9.

Interpreting results from thrombolytic megatrials: distinguishing fact from fiction. Brophy JM. **Can J Cardiol** 1996 Jan;12(1):89–92 (22 ref.)

Antithrombotic therapy in atrial fibrillation. Connolly SJ, et al. **Can J Cardiol** 1996 Jan;12 Suppl A:17A–20A (13 ref.)

Risk-benefit of thrombolysis. Simoons ML. **Cardiol Clin** 1995 Aug;13(3):339–45 (28 ref.)

Selecting a thrombolytic agent. White HD. **Cardiol Clin** 1995 Aug;13(3):347–54 (54 ref.)

Coronary thrombolysis. Cairns JA, et al. **Chest** 1995 Oct; 108(4 Suppl):401S–423S (141 ref.)

Antithrombotic agents in coronary artery disease. Cairns JA, et al. **Chest** 1995 Oct;108(4 Suppl):380S–400S (155 ref.)

Antithrombotic therapy in peripheral arterial occlusive disease. Clagett GP, et al. **Chest** 1995 Oct;108(4 Suppl):431S–443S (193 ref.)

Making decisions about antithrombotic therapy in heart disease. Decision analytic and cost-effectiveness issues. Eckman MH, et al. **Chest** 1995 Oct;108(4 Suppl):457S–470S (64 ref.)

Use of antithrombotic agents during pregnancy. Ginsberg JS, et al. **Chest** 1995 Oct;108(4 Suppl):305S–311S (53 ref.)

Antithrombotic therapy for venous thromboembolic disease. Hyers TM, et al. **Chest** 1995 Oct;108(4 Suppl):335S–351S (232 ref.)

Antithrombotic therapy in valvular heart disease. Levine HJ, et al. **Chest** 1995 Oct;108(4 Suppl):360S–370S (137 ref.)

Antithrombotic therapy in patients undergoing coronary angioplasty [published erratum appears in Chest 1996 Jan;109(1):295–6] Popma JJ, et al. **Chest** 1995 Oct;108(4 Suppl):486S–501S (133 ref.)
Antithrombotic therapy for cerebrovascular disorders. An update. Sherman DG, et al. **Chest** 1995 Oct;108(4 Suppl):444S–456S (203 ref.)
New antithrombotics. Weitz JI, et al. **Chest** 1995 Oct;108(4 Suppl):471S–485S (142 ref.)
Augmentation of thrombolysis with antiplatelet drugs. Coller BS. **Coron Artery Dis** 1995 Dec;6(12):911–4 (14 ref.)
Aspirin augmentation of the efficacy of thrombolysis. O'Donnell CJ, et al. **Coron Artery Dis** 1995 Dec;6(12):936–9 (23 ref.)
Antiplatelet, antithrombotic, and lytic therapy for unstable angina, and the appropriate role of revascularization. de Feyter PJ, et al. **Curr Opin Cardiol** 1995 Jul;10(4):389–98 (36 ref.)
Alteplase. A reappraisal of its pharmacological properties and therapeutic use in acute myocardial infarction. Gillis JC, et al. **Drugs** 1995 Jul;50(1):102–36 (154 ref.)
Thrombolytic therapy. Young GP, et al. **Emerg Med Clin North Am** 1995 Nov;13(4):735–58 (124 ref.)
Atrial fibrillation: steering a management course between thromboembolism and proarrhythmic risk. Campbell RW. **Eur Heart J** 1995 Aug;16 Suppl G:28–31 (56 ref.)
Current and future perspectives on antithrombotic therapy of acute myocardial infarction. Hennekens CH, et al. **Eur Heart J** 1995 Jul;16 Suppl D:2–9 (42 ref.)
Advances in antithrombotic drug therapy for coronary artery disease. Rihal CS, et al. **Eur Heart J** 1995 Jul;16 Suppl D:10–21 (107 ref.)
Low-molecular-weight heparins and new strategies for the treatment of patients with established venous thrombosis. Baglin TP. **Haemostasis** 1996;26 Suppl 2:10–5 (19 ref.)
The role of low-molecular-weight heparins in the prevention of venous thrombosis in surgery with special reference to enoxaparin. Haas S. **Haemostasis** 1996;26 Suppl 2:39–48 (21 ref.)
Thrombolytic and antithrombotic treatment in myocardial infarction: main achievements and future perspectives. Agnelli G. **Int J Cardiol** 1995 Aug;49 Suppl:S77–87 (60 ref.)
Third generation plasminogen activators in the treatment of acute myocardial infarction. Talley JD. **J Ark Med Soc** 1996 Apr;92(11):587–8 (6 ref.)
Modification of coronary artery disease using antithrombotic therapy. Drake-Holland AJ. **J Cardiovasc Risk** 1995 Jun; 2(3):229–33 (47 ref.)
Rationalizing antithrombotic management for patients with prosthetic heart valves [editorial] Butchart EG. **J Heart Valve Dis** 1995 Mar;4(2):106–13 (62 ref.)
Thrombolytic therapy in 1995. Mahanonda N. **J Med Assoc Thai** 1995 Jun;78(6):314–21 (56 ref.)
The promise of new genetically engineered plasminogen activators. Cutler D, et al. **J Vasc Interv Radiol** 1995 Nov–Dec;6(6 Pt 2 Su):3S–7S (16 ref.)
Drug variables in thrombolytic therapy. Meyerovitz MF. **J Vasc Interv Radiol** 1995 Nov–Dec;6(6 Pt 2 Su):62S–65S (34 ref.)
Surgery versus thrombolytic therapy in the management of peripheral arterial occlusions. Ouriel K. **J Vasc Interv Radiol** 1995 Nov–Dec;6(6 Pt 2 Su):48S–54S (42 ref.)
Acute myocardial infarction: enhancing the results of reperfusion therapy. Reeder GS. **Mayo Clin Proc** 1995 Dec; 70(12):1185–90 (31 ref.)
Use of thrombolytics for the treatment of thromboembolic disease during pregnancy. Turrentine MA, et al. **Obstet Gynecol Surv** 1995 Jul;50(7):534–41 (52 ref.)
Heparin therapy: current regimens and principles of monitoring. Berry BR, et al. **Postgrad Med** 1996 Jun; 99(6):64–6, 69–76 (19 ref.)
New developments in acute anticoagulation therapy: what improvements over traditional heparin are on the horizon? Carter CJ. **Postgrad Med** 1996 Jun;99(6):129–36 (22 ref.)
A practical guide to thrombolysis. Gordon I. **Practitioner** 1995 Nov;239(1556):676–8 (10 ref.)
Antithrombotic therapy in atrial fibrillation: a review of randomized trials with special reference to the Stroke Prevention in Atrial Fibrillation II (SPAF II) Trial. Shivkumar K, et al. **Prog Cardiovasc Dis** 1996 Jan–Feb; 38(4):337–42 (25 ref.)
Thromboembolism in chronic Chagas' heart disease. Braga JC, et al. **Rev Paul Med** 1995 Mar–Apr;113(2):862–6 (29 ref.)
The role of thrombolysis in the management of acute arterial occlusions of the lower limb. Browning NG, et al. **S Afr J Surg** 1995 Dec;33(4):170–4 (52 ref.)
Thrombolytic therapy: overview of results in major vascular occlusions. Marder VJ. **Thromb Haemost** 1995 Jul; 74(1):101–5 (60 ref.)
Thrombin generation in myocardial infarction and hypercholesterolemia: effects of aspirin. Szczeklik A. **Thromb Haemost** 1995 Jul;74(1):77–80 (34 ref.)
Advances in antithrombotic therapy: novel agents. Turpie AG, et al. **Thromb Haemost** 1995 Jul;74(1):565–71 (63 ref.)
The fibrinolytic system: from Petri dishes to genetic engineering. Verstraete M. **Thromb Haemost** 1995 Jul; 74(1):25–35 (108 ref.)
[Antithrombotic treatment of atrial fibrillation] Connelly SJ, et al. **Can J Cardiol** 1996 Feb;12 Suppl A:14A–18A (13 ref.) **(Fre)**
[Unstable angina. Physiopathology, clinical course and therapeutic principles] Aubry P, et al. **Presse Med** 1995 Dec 9;24(38):1788–94 (30 ref.) (Eng. Abstr.) **(Fre)**
[Therapeutic role of coagulation in small cell lung cancers] LeBeau B. **Rev Mal Respir** 1996;13(1):21–6 (41 ref.) (Eng. Abstr.) **(Fre)**
[Fibrinolytics. Development and current application] David JL. **Rev Med Liege** 1996 Jan;51(1):35–43 (19 ref.) **(Fre)**
[Thrombolytic therapy in ischemic cerebrovascular accidents] Hommel M, et al. **Schweiz Rundsch Med Prax** 1995 Sep 19;84(38):1025–31 (59 ref.) (Eng. Abstr.) **(Fre)**
[Ginkgo biloba in treatment of intermittent claudication. A systematic research based on controlled studies in the literature] Ernst E. **Fortschr Med** 1996 Mar 20;114(8):85–7 (14 ref.) (Eng. Abstr.) **(Ger)**
–Differential antithrombotic therapy in patients with low and high PTCA risk– Silber S, et al. **Herz** 1996 Feb;21(1):44–59 (213 ref.) (Eng. Abstr.) **(Ger)**
[Biochemical, pharmacologic and clinical properties of new thrombolytic agents] Gulba DC. **Internist (Berl)** 1996 Jun; 37(6):552–66 (21 ref.) **(Ger)**
[Thrombolysis in acute myocardial infarct] Heintzen MP, et al. **Internist (Berl)** 1996 Jun;37(6):585–96 (80 ref.) **(Ger)**
[Thrombolytic therapy of venous thromboses] Heinz M, et al. **Internist (Berl)** 1996 Jun;37(6):567–73 (38 ref.) **(Ger)**
[Symptomatic therapy refractory myocardial ischemia in coronary heart disease. Chronic intermittent urokinase therapy and invasive therapeutic measures] Leschke M, et al. **Internist (Berl)** 1996 Jun;37(6):597–606 (50 ref.) **(Ger)**
[Fibrinolytic agents—who benefits when?] Weichert W, et al. **Ther Umsch** 1995 Oct;52(10):652–60 (35 ref.) (Eng. Abstr.) **(Ger)**
[Magnesium sulfate in acute myocardial infarction] Balli E, et al. **G Ital Cardiol** 1995 Nov;25(11):1425–32 (33 ref.) (Eng. Abstr.) **(Ita)**
[The new frontier of antithrombotic therapy: ASA + warfarin, the ideal solution?] Cimminiello C, et al. **G Ital Cardiol** 1995 Sep;25(9):1187–93 (36 ref.) (Eng. Abstr.) **(Ita)**
[Thrombolysis (Consensus about post-myocardial infarction treatment)] **Arq Bras Cardiol** 1995 Mar;64(3):271–80 (65 ref.) **(Por)**
[Non-rheumatic atrial fibrillation and antithrombotic treatment: current status] Gayán Laviña R, et al. **Rev Clin Esp** 1995 Aug;195(8):559–64 (28 ref.) **(Spa)**

FIBRINOLYTIC THERAPY see **THROMBOLYTIC THERAPY**

FIBRINOPEPTIDES A

ANALYSIS

[Fibrinopeptide A (FPA) and fibrinopeptide B beta 15–42 (FPB beta 15–42)] Tatsumi N, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:39–42 (15 ref.) **(Jpn)**

FIBROADENOMA

DIAGNOSIS

[Giant fibroadenoma of the breast. Its clinical picture and differential diagnosis. A report of a clinical case] Magnoni P, et al. **Minerva Chir** 1996 Jan–Feb;51(1–2):71–5 (16 ref.) (Eng. Abstr.) **(Ita)**

THERAPY

Conservative management of fibroadenoma of the breast. Alle KM, et al. **Br J Surg** 1996 Jul;83(7):992–3 (10 ref.)

FIBROBLAST GROWTH FACTOR

see related
RECEPTORS, FIBROBLAST GROWTH FACTOR

PHARMACOLOGY

How neurotrophic factors protect brain against excitotoxicity. Cuevas Sanchez P. **Surg Neurol** 1996 Aug; 46(2):152–3 (15 ref.)

PHYSIOLOGY

Vasculogenesis. Risau W, et al. **Ann Rev Cell Dev Biol** 1995; 11:73–91 (122 ref.)
Signals for mesoderm induction. Roles of fibroblast growth factor (FGF)/mitogen-activated protein kinase (MAPK) pathway. Gotoh Y, et al. **Biochim Biophys Acta** 1996 Aug 8;1288(1):F1–7 (121 ref.)
Peptide growth factors in the prostate as mediators of stromal epithelial interaction. Byrne RL, et al. **Br J Urol** 1996 May; 77(5):627–33 (65 ref.)
Limb development. The budding role of FGF. Tanaka EM, et al. **Curr Biol** 1995 Jun 1;5(6):594–7 (15 ref.)
Functions of fibroblast growth factors and their receptors. Wilkie AO, et al. **Curr Biol** 1995 May 1;5(5):500–7 (56 ref.)
Fibroblast growth factors in mammalian development. Yamaguchi TP, et al. **Curr Opin Genet Dev** 1995 Aug; 5(4):485–91 (49 ref.)
Correlation between proto-oncogene, fibroblast growth factor and adaptive response in brain infarct. Liu HM. **Prog Brain Res** 1995;105:239–44 (44 ref.)
Fibroblast growth factor signalling and myogenic development. Swain JL. **Trans Am Clin Climatol Assoc** 1994;106:109–12; discussion 112–3 (0 ref.)
Regulation of prostate growth by fibroblast growth factors. Story MT. **World J Urol** 1995;13(5):297–305 (96 ref.)
[Role of growth factors in regulation of food intake] Oomura Y, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:64–9 (15 ref.) **(Jpn)**
[Induction of an additional limb by FGF and duplication of digits by Sonic hedgehog] Ohuchi H, et al. **Seikagaku** 1995 Oct;67(10):1232–6 (16 ref.) **(Jpn)**

THERAPEUTIC USE

Growth factors: new 'endogenous drugs' for ulcer healing. Szabo S, et al. **Scand J Gastroenterol Suppl** 1995;210:15–8 (33 ref.)
How neurotrophic factors protect brain against excitotoxicity. Cuevas Sanchez P. **Surg Neurol** 1996 Aug; 46(2):152–3 (15 ref.)

FIBROBLAST GROWTH FACTOR, ACIDIC

METABOLISM

Expression of heparin-binding growth factors and their receptors in neural development. Wanaka A. **Kaibogaku Zasshi** 1995 Dec;70(6):512–20 (17 ref.)

PHYSIOLOGY

Vascular endothelial growth factor and retinal neovascularisation: a new therapeutic approach for diabetic retinopathy. Favard C, et al. **Diabetes Metab** 1996 Jul; 22(4):268–73 (67 ref.)
Molecular mechanisms of fibroblast growth factor-1 traffick, signaling and release. Maciag T, et al. **Thromb Haemost** 1995 Jul;74(1):411–4 (56 ref.)

FIBROBLAST GROWTH FACTOR, BASIC

PHARMACOLOGY

Basic fibroblast growth factor for stimulation of bone formation in osteoinductive or conductive implants. Wang JS. **Acta Orthop Scand Suppl** 1996 Apr;269:1–33 (204 ref.)

PHYSIOLOGY

Growth factors and the glomerulus: relationships between development and injury. Alpers CE, et al. **Adv Nephrol Necker Hosp** 1995;24:33–52 (85 ref.)
Basic fibroblast growth factor and PDGF in GI diseases. Szabo S, et al. **Baillieres Clin Gastroenterol** 1996 Mar; 10(1):97–112 (68 ref.)
Basic FGF as an inducer of anteroposterior neural pattern. Doniach T. **Cell** 1995 Dec 29;83(7):1067–70 (19 ref.)
Vascular endothelial growth factor and retinal neovascularisation: a new therapeutic approach for diabetic retinopathy. Favard C, et al. **Diabetes Metab** 1996 Jul; 22(4):268–73 (67 ref.)
Control of cell proliferation by heparan sulfate and heparin-binding growth factors. Vlodavsky I, et al. **Thromb Haemost** 1995 Jul;74(1):534–40 (33 ref.)
[Nephritis and cytokines—special reference to the role of basic fibroblast growth factor in etiological mechanism of irreversible sclerosing glomerulonephritis] Osawa G. **Nippon Naika Gakkai Zasshi** 1995 Sep 10;84(9):1583–7 (10 ref.) **(Jpn)**

FIBROBLAST GROWTH FACTOR RECEPTORS see **RECEPTORS, FIBROBLAST GROWTH FACTOR**

FIBROBLAST INTERMEDIATE FILAMENT PROTEINS see **INTERMEDIATE FILAMENT PROTEINS**

FIBROBLASTS

CYTOLOGY

Expression and role of epidermal growth factor receptors during differentiation of cementoblasts, osteoblasts, and periodontal ligament fibroblasts in the rat. Cho MI, et al. **Anat Rec** 1996 Jun;245(2):342–60 (69 ref.)
Moving membrane up to the front of migrating cells. Bretscher MS. **Cell** 1996 May 17;85(4):465–7 (18 ref.)
The last mitoses of the human fibroblast proliferative life span, physiopathologic implications. Macieira-Coelho A. **Mech Ageing Dev** 1995 Aug 8;82(2-3):91–104 (22 ref.)
The fibroblast—a (trans-) differentiated cell? [editorial] Strutz F. **Nephrol Dial Transplant** 1995;10(9):1504–6 (13 ref.)
[Agents inducing cell death of the vascular wall] Munsch B, et al. **Ann Biol Clin (Paris)** 1995;53(9):473–80 (88 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Role of angiotensin II and prostaglandin E2 in regulating cardiac fibroblast collagen turnover. Brilla CG, et al.

FIBROBLASTS

Am J Cardiol 1995 Nov 2;76(13):8D–13D (42 ref.)

PHYSIOLOGY

Periodontal ligament cell population: the central role of fibroblasts in creating a unique tissue. Lekic P, et al. **Anat Rec** 1996 Jun;245(2):327–41 (190 ref.)

Phenotype modulation of human adult fibroblasts by oncogenes. Kopelovich L, et al. **Mol Carcinog** 1996 Mar; 15(3):163–6 (60 ref.)

Involvement of the orbital fibroblast and TSH receptor in the pathogenesis of Graves' ophthalmopathy. Heufelder AE. **Thyroid** 1995 Aug;5(4):331–40 (84 ref.)

RADIATION EFFECTS

Radiation therapy tolerance limits. For one or for all?—Janeway Lecture. Peters LJ. **Cancer** 1996 Jun 1; 77(11):2379–85 (39 ref.)

TRANSPLANTATION

Grafting of genetically manipulated cells into adult brain: toward graft-gene therapy. Uchida K, et al. **Keio J Med** 1996 Jun;45(2):81–9 (40 ref.)

[Use of cultured fibroblasts for restoration of skin in severe burns] Sarkisov DS, et al. **Biull Eksp Biol Med** 1995 Jun; 119(6):566–70 (28 ref.) **(Rus)**

FIBROCYSTIC DISEASE OF BREAST

METABOLISM

Presence and distribution of growth factors in breast cyst fluid. Zanardi S, et al. **Ann N Y Acad Sci** 1996 Apr 30; 784:542–9 (27 ref.)

FIBROCYSTIC DISEASE OF PANCREAS see **CYSTIC FIBROSIS**

FIBROCYSTIC MASTOPATHY see **FIBROCYSTIC DISEASE OF BREAST**

FIBRODYSPLASIA OSSIFICANS PROGRESSIVA see **MYOSITIS OSSIFICANS**

FIBROID see **FIBROMA**

FIBROID TUMOR see **LEIOMYOMA**

FIBROID UTERUS see **LEIOMYOMA**

FIBROIDS, UTERINE see **LEIOMYOMA**

FIBROMA

see related
TUBEROUS SCLEROSIS

[Multiple perifollicular fibroma] Yamamoto T, et al. **Nippon Rinsho** 1995 Nov;53(11):2759–63 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Fibroma and fibrosarcoma of the extra hepatic bile ducts] Shiga J. **Ryoikibetsu Shokogun Shirizu** 1996;(9):40–2 (20 ref.) **(Jpn)**

[Primary fibroma of the liver, primary fibrosarcoma of the liver] Tameda Y, et al. **Ryoikibetsu Shokogun Shirizu** 1995; (7):384–6 (19 ref.) **(Jpn)**

DIAGNOSIS

Don't confuse dental soft tissues with odontogenic tumors. Suarez PA, et al. **Ann Otol Rhinol Laryngol** 1996 Jun; 105(6):490–4 (9 ref.)

Solitary intestinal fibromatosis mimicking malabsorption syndromes. Türken A, et al. **J Pediatr Surg** 1995 Sep; 30(9):1387–9 (9 ref.)

[Elastofibroma dorsi. A report of a case diagnosed with magnetic resonance] Bianchi M, et al. **Radiol Med (Torino)** 1996 Jan–Feb;91(1–2):128–30 (16 ref.) **(Ita)**

[Pseudosarcoma botryoides during pregnancy] Lasso de la Vega J, et al. **Rev Med Panama** 1995 Jan–May;20(1–2):45–9 (8 ref.) (Eng. Abstr.) **(Spa)**

PATHOLOGY

Pseudosarcomatous myofibroblastic tumor of the urinary bladder in children: a study of 11 cases with review of the literature. An Intergroup Rhabdomyosarcoma Study. Hojo H, et al. **Am J Surg Pathol** 1995 Nov;19(11):1224–36 (43 ref.)

An update on pachydermodactyly and a report of three additional cases. Kopera D, et al. **Br J Dermatol** 1995 Sep; 133(3):433–7 (26 ref.)

Recurring digital fibroma of childhood. Burgert S, et al. **J Hand Surg [Br]** 1996 Jun;21(3):400–2 (15 ref.)

Papillary carcinoma of the thyroid gland with fibromatosis-like stroma: a case report and review of the literature. Mizukami Y, et al. **Mod Pathol** 1995 May; 8(4):366–70 (4 ref.)

SURGERY

Excision of papillary fibroelastoma arising from the septal leaflet of the tricuspid valve. Lee CC, et al. **J Card Surg** 1995 Sep;10(5):589–91 (11 ref.)

Papillary fibroelastoma of the mitral valve. A rare cause of embolic events. Colucci V, et al. **Tex Heart Inst J** 1995; 22(4):327–31 (31 ref.)

FIBROMA, DESMOPLASTIC

SURGERY

Desmoplastic fibroma of the bone. A report of two patients, review of the literature, and therapeutic implications. Böhm P, et al. **Cancer** 1996 Sep 1;78(5):1011–23 (97 ref.)

Desmoplastic fibroma. Aggressive curettage as a surgical alternative for treatment. Nishida J, et al. **Clin Orthop** 1995 Nov;(320):142–8 (27 ref.)

FIBROMA, SHOPE see **TUMOR VIRUS INFECTIONS**

FIBROMA, UTERINE see **LEIOMYOMA**

FIBROMATOSIS, ABDOMINAL

DIAGNOSIS

[Intra-abdominal fibromatosis] Brătucu E, et al. **Chirurgia (Bucur)** 1995;44(2):45–53 (12 ref.) (Eng. Abstr.) **(Rum)**

GENETICS

[Familial abdominal fibromatosis] Constantinoiu S, et al. **Chirurgia (Bucur)** 1995;44(2):68–78 (10 ref.) (Eng. Abstr.) **(Rum)**

FIBROMATOSIS, AGGRESSIVE

Extraabdominal desmoid tumor. Pereyo NG, et al. **J Am Acad Dermatol** 1996 Feb;34(2 Pt 2):352–6 (37 ref.)

Desmoid tumors. Anthony T, et al. **J Am Coll Surg** 1996 Apr;182(4):369–77 (71 ref.)

DRUG THERAPY

Chemotherapy for desmoid tumours in association with familial adenomatous polyposis: a report of three cases. Hamilton L, et al. **Can J Surg** 1996 Jun;39(3):247–52 (21 ref.)

ETIOLOGY

Thoracic desmoid tumors: a rare evolution of rib fracture. Etiopathogenesis and therapeutic considerations. Wiel Marin A, et al. **G Chir** 1995 Aug–Sep;16(8–9):341–3 (12 ref.)

GENETICS

Trisomy 8 and 20 in desmoid tumors and breast cancer: more than a casual coincidence? [letter; comment] Rohen G, et al. **Cancer Genet Cytogenet** 1996 Jan;86(1):92 (9 ref.) Comment on: Cancer Genet Cytogenet 1995 Feb;79(2):139–43.

THERAPY

Sequential treatment of recurrent mesenteric desmoid tumor. Bauernhofer T, et al. **Cancer** 1996 Mar 15;77(6):1061–5 (44 ref.)

FIBROMATOSIS GINGIVAE

GENETICS

Zimmermann–Laband syndrome in a patient with severe mental retardation. Van Buggenhout GJ, et al. **Genet Couns** 1995;6(4):321–7 (15 ref.)

[Hereditary gingival fibromatosis] Shinozaki F, et al. **Nippon Rinsho** 1995 Nov;53(11):2786–9 (23 ref.) (Eng. Abstr.) **(Jpn)**

FIBROMUSCULAR DYSPLASIA

COMPLICATIONS

[The moyamoya syndrome secondary to fibromuscular dysplasia of the middle cerebral artery] Verdú Pérez A, et al. **An Esp Pediatr** 1996 Jul;45(1):99–100 (12 ref.) **(Spa)**

[Cephalic fibromuscular dysplasia and stroke in infancy: a case report] and review of literature] Romera-López J, et al. **Rev Neurol** 1996 Jun;24(130):650–2 (11 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Unusual appearance of intracranial fibromuscular dysplasia. A case report. Belen D, et al. **Angiology** 1996 Jun; 47(6):627–32 (21 ref.)

DRUG THERAPY

[Angiotensin II receptor antagonists. Clinical relevance] Scholze J. **Internist (Berl)** 1996 Jun;37(6):636–42 (47 ref.) **(Ger)**

PATHOLOGY

Carotid-cavernous sinus fistula and aneurysmal rupture associated with fibromuscular dysplasia. A case report. Hirai T, et al. **Acta Radiol** 1996 Jan;37(1):49–51 (8 ref.)

Fibromuscular dysplasia of coronary arteries as a rare cause of death. Zack F, et al. **Int J Legal Med** 1996;108(4):215–8 (18 ref.)

PHYSIOPATHOLOGY

The heart and vascular changes in hypertension. Leonetti G, et al. **J Hypertens Suppl** 1995 Aug;13(2):S29–34 (54 ref.)

Large artery function and alterations in hypertension. London GM. **J Hypertens Suppl** 1995 Aug;13(2):S35–8 (23 ref.)

Structural cardiovascular alterations and blood pressure variability in human hypertension. Mancia G, et al. **J Hypertens Suppl** 1995 Aug;13(2):S7–14 (39 ref.)

FIBROMYALGIA

see related
FATIGUE SYNDROME, CHRONIC

Fibromyalgia syndrome: a review. Reiffenberger DH, et al. **Am Fam Physician** 1996 Apr;53(5):1698–712 (34 ref.)

Fibromyalgia. Raspe H, et al. **Baillieres Clin Rheumatol** 1995 Aug;9(3):599–614 (80 ref.)

The fibromyalgia syndrome. Nasr FW. **J Med Liban** 1995; 43(1):23–5 (14 ref.)

Fibromyalgia. Parziale JR, et al. **Med Health R I** 1996 May; 79(5):188–92 (8 ref.)

Fibromyalgia. Recognizing and addressing the multiple interrelated factors. Wilke WS. **Postgrad Med** 1996 Jul; 100(1):153–6, 159, 163–6 passim (29 ref.)

DIAGNOSIS

Tender points/fibromyalgia vs. trigger points/myofascial pain syndrome: a need for clarity in terminology and differential diagnosis. Schneider MJ. **J Manipulative Physiol Ther** 1995 Jul–Aug;18(6):398–406 (43 ref.)

Problems with myofascial pain syndrome and fibromyalgia syndrome [editorial] Bohr T. **Neurology** 1996 Mar; 46(3):593–7 (46 ref.)

[Fibromyalgia] Siegmeth W, et al. **Wien Med Wochenschr** 1995;145(14):320–5 (7 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

A guide to the understanding and use of tricyclic antidepressants in the overall management of fibromyalgia and other chronic pain syndromes. Godfrey RG. **Arch Intern Med** 1996 May 27;156(10):1047–52 (44 ref.)

An analytical review of 24 controlled clinical trials for fibromyalgia syndrome (FMS). White KP, et al. **Pain** 1996 Feb;64(2):211–9 (65 ref.)

EPIDEMIOLOGY

Fibromyalgia, chronic fatigue syndrome, and myofascial pain. Goldenberg DL. **Curr Opin Rheumatol** 1996 Mar; 8(2):113–23 (95 ref.)

ETIOLOGY

[Causes of fibromyalgia are both peripheral and central] Bengtsson A, et al. **Lakartidningen** 1996 Jan 17;93(3):161–3 (26 ref.) **(Swe)**

PHYSIOPATHOLOGY

Studies of sleep in fibromyalgia; techniques, clinical significance, and future directions [editorial] Smythe HA. **Br J Rheumatol** 1995 Oct;34(10):897–9 (13 ref.)

The pathogenesis of chronic pain and fatigue syndromes, with special reference to fibromyalgia. Clauw DJ. **Med Hypotheses** 1995 May;44(5):369–78 (83 ref.)

PSYCHOLOGY

Fibromyalgia syndrome and psychiatric disorder. Dunne FJ, et al. **Br J Hosp Med** 1995 Sep 6–19;54(5):194–7 (23 ref.)

REHABILITATION

[Effect of physical exercise in fibromyalgia] Mengshoel AM. **Tidsskr Nor Laegeforen** 1996 Feb 28;116(6):746–8 (31 ref.) (Eng. Abstr.) **(Nor)**

FIBROMYOMA see **LEIOMYOMA**

FIBROMYXOMA see **FIBROMA**

FIBRONECTIN RECEPTORS see **RECEPTORS, FIBRONECTIN**

FIBRONECTINS

see related
RECEPTORS, FIBRONECTIN

ANALYSIS

High levels of fibronectin in the stroma of aural cholesteatoma. Schilling V, et al. **Am J Otolaryngol** 1995 Jul–Aug;16(4):232–5 (28 ref.)

[Fibronectin] Usui N, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:162–6 (22 ref.) **(Jpn)**

BIOSYNTHESIS

Fibronectin expression during physiological and pathological cardiac growth. Farhadian F, et al. **J Mol Cell Cardiol** 1995 Apr;27(4):981–90 (57 ref.)

BLOOD

[Diagnostic aspects of IgA–fibronectin in serum of patients with IgA nephropathy] Sela BA, et al. **Harefuah** 1995 Aug; 129(3–4):127–30 (20 ref.) **(Heb)**

CHEMISTRY

Organization of the provisional fibronectin matrix: control by products of blood coagulation. Mosher DF. **Thromb Haemost** 1995 Jul;74(1):529–33 (62 ref.)

GENETICS

Alternative splicing of fibronectin—many different proteins but few different functions. french–Constant C. **Exp Cell Res** 1995 Dec;221(2):261–71 (111 ref.)

The fibronectin gene as a model for splicing and transcription studies. Kornblihtt AR, et al. **FASEB J** 1996 Feb; 10(2):248–57 (76 ref.)

IMMUNOLOGY

[Adhesion molecules and trophoblastic invasion] Loke YW, et al. **Contracept Fertil Sex** 1995 Sep;23(9):573–5 (40 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Fibronectin and cell adhesion: specificity of integrin–ligand interaction. Aota S, et al. **Adv Enzymol Relat Areas Mol Biol** 1995;70:1–21 (81 ref.)

Mechanisms of VCAM–1 and fibronectin binding to integrin alpha 4 beta 1: implications for integrin function and rational drug design. Humphries MJ, et al. **Ciba Found Symp** 1995;189:177–91; discussion 191–9 (43 ref.)

PHYSIOLOGY

Fibronectin and integrins in invasion and metastasis. Akiyama SK, et al. **Cancer Metastasis Rev** 1995 Sep;14(3):173–89 (117 ref.)

Role of platelets, thrombin, integrin IIb–IIIa, fibronectin and von Willebrand factor on tumor adhesion in vitro and metastasis in vivo. Nierodzik ML, et al. **Thromb Haemost** 1995 Jul;74(1):282–90 (67 ref.)

FIBRO–ODONTOMA, AMELOBLASTIC see **ODONTOMA**

FIBROSARCOMA

[Fibroma and fibrosarcoma of the extra hepatic bile ducts] Shiga J. **Ryoikibetsu Shokogun Shirizu** 1996;(9):40–2 (20 ref.) **(Jpn)**

[Primary fibroma of the liver, primary fibrosarcoma of the liver] Tameda Y, et al. **Ryoikibetsu Shokogun Shirizu** 1995; (7):384–6 (19 ref.) **(Jpn)**

CONGENITAL

Congenital–infantile fibrosarcoma: magnetic resonance imaging findings. Lee MJ, et al. **Can Assoc Radiol J** 1996 Apr;47(2):121–5 (27 ref.)

[The current controversy in the treatment of congenital fibrosarcoma. A case report] Ramos Díaz JC, et al. **An Esp Pediatr** 1996 Apr;44(4):367–8 (13 ref.) **(Spa)**

DIAGNOSIS

Congenital–infantile fibrosarcoma: magnetic resonance imaging findings. Lee MJ, et al. **Can Assoc Radiol J** 1996 Apr;47(2):121–5 (27 ref.)

Fibrosarcoma of the thigh. Case report and literature review. Testini M, et al. **Panminerva Med** 1996 Mar;38(1):51–5 (14 ref.)

[Metastatic pulmonary fibrosarcoma: apropos a case and a review of the literature] Quintana González JI, et al. **Arch Bronconeumol** 1996 May;32(5):256–8 (17 ref.) (Eng. Abstr.) **(Spa)**

METABOLISM

Is there a critical tissue oxygen tension for bioenergetic status and cellular pH regulation in solid tumors? Vaupel P. **Experientia** 1996 May 15;52(5):464–8 (33 ref.)

PATHOLOGY

Primary right atrial fibrosarcoma diagnosed by endocardial biopsy. Basso C, et al. **Am Heart J** 1996 Feb;131(2):399–402 (11 ref.)

[Low malignancy myxofibrosarcoma versus low malignancy fibromyxoid sarcoma. Distinct entities with similar names but different clinical course] Mentzel T, et al. **Pathologe** 1996 Mar;17(2):116–21 (19 ref.) (Eng. Abstr.) **(Ger)**

SECONDARY

Fibrosarcomatous metastasis the central nervous system with overt hemorrhage: case report and review of the literature. Jeffery DR, et al. **J Neurol Sci** 1995 Dec;134(1–2):207–9 (8 ref.)

[Metastatic pulmonary fibrosarcoma: apropos a case and a review of the literature] Quintana González JI, et al. **Arch Bronconeumol** 1996 May;32(5):256–8 (17 ref.) (Eng. Abstr.) **(Spa)**

SURGERY

Fibrosarcoma of the thigh. Case report and literature review. Testini M, et al. **Panminerva Med** 1996 Mar;38(1):51–5 (14 ref.)

[Finger fibrosarcoma. A case report] Ouarab M, et al. **Ann Chir Main Memb Super** 1995;14(4–5):235–8 (9 ref.) (Eng. Abstr.) **(Fre)**

[The current controversy in the treatment of congenital fibrosarcoma. A case report] Ramos Díaz JC, et al. **An Esp Pediatr** 1996 Apr;44(4):367–8 (13 ref.) **(Spa)**

VETERINARY

Feline cutaneous and subcutaneous neoplasms. Fox LE. **Vet Clin North Am Small Anim Pract** 1995 Jul;25(4):961–79 (138 ref.)

FIBROSIS

ETIOLOGY

[Late complications of radiotherapy. Radiofibrosis is reversible] Baillet F. **Bull Cancer Radiother** 1995; 82(2):113–9 (37 ref.) **(Fre)**

FIBROSIS, BONE MARROW see **MYELOFIBROSIS**

FIBROSIS, LIVER see **LIVER CIRRHOSIS**

FIBROSITIS see **FIBROMYALGIA**

FIBROUS DYSPLASIA, MONOSTOTIC

DIAGNOSIS

Monostotic fibrous dysplasia of the thoracic spine. A case report. Przybylski GJ, et al. **Spine** 1996 Apr 1;21(7):860–5 (28 ref.)

PATHOLOGY

[Fibrous dysplasia of bone and osteofibrous dysplasia. Focusing] Laredo JD, et al. **Ann Radiol (Paris)** 1995; 38(5):225–36 (24 ref.) (Eng. Abstr.) **(Fre)**

RADIOGRAPHY

[A mediastinal mass in a young man. Monostotic fibrous dysplasia] Sáez–Royuela A, et al. **Rev Clin Esp** 1995 Dec; 195(12):841–2 (8 ref.) **(Spa)**

SURGERY

Monostotic fibrous dysplasia of the thoracic spine. A case report. Przybylski GJ, et al. **Spine** 1996 Apr 1;21(7):860–5 (28 ref.)

FIBROUS DYSPLASIA OF BONE

Neonatal osteofibrous dysplasia: report of two cases. Hindman BW, et al. **Pediatr Radiol** 1996;26(4):303–6 (14 ref.)

COMPLICATIONS

Fibrous dysplasia of the temporal bone: ten new cases demonstrating the spectrum of otologic sequelae. Megerian CA, et al. **Am J Otol** 1995 Jul;16(4):408–19 (49 ref.)

Caso quiz. Tibia vara caused by focal fibrocartilaginous dysplasia. Marchiodi L, et al. **Chir Organi Mov** 1995 Oct–Dec;80(4):453–6 (9 ref.) **(Eng, Ita)**

An unusual case of mixed sclerosing bone dystrophy presenting with morning stiffness and joint swelling in childhood: a case report. Foeldvari I, et al. **Clin Exp Rheumatol** 1995 Jul–Aug;13(4):525–8 (19 ref.)

PHYSIOPATHOLOGY

An unusual case of mixed sclerosing bone dystrophy presenting with morning stiffness and joint swelling in childhood: a case report. Foeldvari I, et al. **Clin Exp Rheumatol** 1995 Jul–Aug;13(4):525–8 (19 ref.)

FIBROUS DYSPLASIA, POLYOSTOTIC

DIAGNOSIS

[The magnetic resonance assessment of craniofacial fibrous dysplasia. The completion of the study with gadolinium administration and magnetic resonance angiography] Di Girolamo M, et al. **Radiol Med (Torino)** 1996 Mar; 91(3):313–6 (10 ref.) **(Ita)**

METABOLISM

Clinical implications of genetic defects in G proteins. The molecular basis of McCune–Albright syndrome and Albright hereditary osteodystrophy. Ringel MD, et al. **Medicine (Baltimore)** 1996 Jul;75(4):171–84 (174 ref.)

PATHOLOGY

[Fibrous dysplasia of bone and osteofibrous dysplasia. Focusing] Laredo JD, et al. **Ann Radiol (Paris)** 1995; 38(5):225–36 (24 ref.) (Eng. Abstr.) **(Fre)**

FIBULA

Neonatal osteofibrous dysplasia: report of two cases. Hindman BW, et al. **Pediatr Radiol** 1996;26(4):303–6 (14 ref.)

[Osteosarcoma in 2 siblings. A case report] Danckwerth F, et al. **Klin Padiatr** 1995 Sep–Oct;207(5):298–301 (41 ref.) (Eng. Abstr.) **(Ger)**

ABNORMALITIES

Serpentine fibula syndrome: expansion of the phenotype with three affected siblings. Rosser EM, et al. **Clin Dysmorphol** 1996 Apr;5(2):105–13 (12 ref.)

INJURIES

[Acute isolated ventral dislocation of the head of the fibula] Kohler G, et al. **Unfallchirurg** 1996 Mar;99(3):221–2 (10 ref.) (Eng. Abstr.) **(Ger)**

RADIOGRAPHY

Intraosseous neurilemmoma of the lower third of the fibula [letter] Chevalier X, et al. **AJR Am J Roentgenol** 1995 Dec; 165(6):1555–6 (4 ref.)

SURGERY

Transfibular osteotomy in the correction of ankle joint incongruity. Davis JL, et al. **J Foot Ankle Surg** 1995 Jul–Aug;34(4):389–99 (23 ref.)

Tibiofibular arthrodesis for malunion of the talocrural joint. Loder BG, et al. **J Foot Ankle Surg** 1995 May–Jun; 34(3):283–8 (8 ref.)

TRANSPLANTATION

Clawtoe deformity following vascularized fibula graft. Bohay DR, et al. **Foot Ankle Int** 1995 Oct;16(10):607–9 (10 ref.)

FIFTH DISEASE see **ERYTHEMA INFECTIOSUM**

FIGLU see **FORMIMINOGLUTAMIC ACID**

FIGURAL AFTEREFFECT

Inverse–intensity effect in duration of visible persistence. Di Lollo V, et al. **Psychol Bull** 1995 Sep;118(2):223–37 (100 ref.)

FIJIVIRUS see **REOVIRIDAE**

FILARIA BANCROFTI see **WUCHERERIA BANCROFTI**

FILARIA SANGUINIS HOMINIS see **WUCHERERIA BANCROFTI**

FILARIAL ELEPHANTIASIS see **ELEPHANTIASIS, FILARIAL**

FILARIASIS

DRUG THERAPY

[Role of ivermectin in the prophylaxis of lymphatic filariasis] Cartel JL, et al. **Med Trop (Mars)** 1995;55(3 Suppl):30–3 (26 ref.) **(Fre)**

PREVENTION & CONTROL

Control of parasitic diseases in China. Current status and prospects. Yu S. **Chin Med J (Engl)** 1996 Apr;109(4):259–65 (16 ref.)

Vaccine research and development for the prevention of filarial nematode infections. Grieve RB, et al. **Pharm Biotechnol** 1995;6:737–68 (250 ref.)

FILARIASIS, LYMPHATIC see **ELEPHANTIASIS, FILARIAL**

FILARICIDES

THERAPEUTIC USE

[Role of ivermectin in the prophylaxis of lymphatic filariasis] Cartel JL, et al. **Med Trop (Mars)** 1995;55(3 Suppl):30–3 (26 ref.) **(Fre)**

FILARIOIDEA INFECTIONS see **FILARIASIS**

FILOVIRUS INFECTIONS

EPIDEMIOLOGY

Emerging and reemerging of filoviruses. Feldmann H, et al. **Arch Virol Suppl** 1996;11:77–100 (93 ref.)

TRANSMISSION

Emerging and reemerging of filoviruses. Feldmann H, et al.

FILOVIRUS INFECTIONS

Arch Virol Suppl 1996;11:77–100 (93 ref.)

FILUM TERMINALE see **CAUDA EQUINA**

FIMBRIAE, BACTERIAL

see related
ADHESINS, BACTERIAL

METABOLISM

Prepilin-like molecules in type 4 pilus biogenesis: minor subunits, chaperones or mediators of organelle translocation? Koomey M. **Trends Microbiol** 1995 Nov; 3(11):409–10; discussion 411–3 (49 ref.)

PHYSIOLOGY

Salmonella fimbriae: novel antigens in the detection and control of salmonella infections. Thorns CJ. **Br Vet J** 1995 Nov-Dec;151(6):643–58 (82 ref.)

Interaction of pathogenic neisseriae with nonphagocytic cells. Nassif X, et al. **Clin Microbiol Rev** 1995 Jul; 8(3):376–88 (148 ref.)

FIMBRIAL ADHESINS see **ADHESINS, BACTERIAL**

FINANCIAL MANAGEMENT

ORGANIZATION & ADMINISTRATION

Breakeven under capitation: pure and simple? Boles KE, et al. **Health Care Manage Rev** 1996 Winter;21(1):38–47 (15 ref.)

STANDARDS

Measuring financial performance: an overview of financial statements. Dalsted NL.
Vet Clin North Am Food Anim Pract 1995 Jul;11(2):293–311 (2 ref.)

SPA: marketing and financial performance measures for the cow-calf enterprise. Gutierrez PH.
Vet Clin North Am Food Anim Pract 1995 Jul;11(2):313–60 (3 ref.)

Farm Financial Standards. McGrann JM.
Vet Clin North Am Food Anim Pract 1995 Jul;11(2):279–91 (3 ref.)

STATISTICS & NUMERICAL DATA

Hints. Abu-Mostafa YS. **Neural Comput** 1995 Jul;7(4):639–71 (34 ref.)

FINANCIAL MANAGEMENT, HOSPITAL

You are in charge of cost. Loop FD. **Ann Thorac Surg** 1995 Nov;60(5):1509–12 (3 ref.)

STATISTICS & NUMERICAL DATA

The effects of hospital-physician integration strategies on hospital financial performance. Goes JB, et al.
Health Serv Res 1995 Oct;30(4):507–30 (40 ref.)

FINANCING, GOVERNMENT

Federal reimbursement to laboratories. Logue J.
Clin Chem 1996 May;42(5):817–21 (7 ref.)

ORGANIZATION & ADMINISTRATION

Financing special education. Parrish TB, et al.
Future Child 1996 Spring;6(1):121–38 (39 ref.)

FINANCING, ORGANIZED

METHODS

Funding the clinical autopsy [editorial] Start RD, et al.
J Pathol 1995 Sep;177(1):5–9 (17 ref.)

FINANCING, PERSONAL

ORGANIZATION & ADMINISTRATION

The role of employee flexible spending accounts in health care financing. Schweitzer M, et al.
Am J Public Health 1996 Aug;86(8 Pt 1):1079–81 (15 ref.)

FINANCING, PUBLIC see **FINANCING, GOVERNMENT**

FINASTERIDE

Finasteride: a clinical review. Gormley GJ.
Biomed Pharmacother 1995;49(7–8):319–24 (36 ref.)

PHARMACOKINETICS

Clinical pharmacokinetics and pharmacodynamics of finasteride. Steiner JF. **Clin Pharmacokinet** 1996 Jan; 30(1):16–27 (50 ref.)

PHARMACOLOGY

Clinical pharmacokinetics and pharmacodynamics of finasteride. Steiner JF. **Clin Pharmacokinet** 1996 Jan; 30(1):16–27 (50 ref.)

THERAPEUTIC USE

The potential application of finasteride for chemoprevention of prostate cancer. Gormley GJ, et al.
Ann N Y Acad Sci 1995 Sep 30;768:163–9 (22 ref.)

Benign prostatic hyperplasia: pathophysiology and pharmacological treatment. Madsen FA, et al.
Curr Opin Nephrol Hypertens 1995 Sep;4(5):455–9 (23 ref.)

Finasteride and benign prostatic hyperplasia.
Drug Ther Bull 1995 Mar;33(3):19–21 (24 ref.)

The effect of finasteride on prostate specific antigen: review of available data. Guess HA, et al. **J Urol** 1996 Jan; 155(1):3–9 (33 ref.)

[alpha-reductase inhibitors/finasteride. Stoner E.
Prostate Suppl 1996;6:82–7 (28 ref.)

[The effect of 5-alpha-reductase inhibitors on benign prostatic hyperplasia] Djavan B, et al.
Wien Med Wochenschr 1996;146(8):165–8 (21 ref.) (Eng. Abstr.) **(Ger)**

FINGER INJURIES

COMPLICATIONS

Chronic finger dermatitis after trauma. Diagnosis: posttraumatic eczema with allergic contact dermatitis to neomycin, bacitracin, and topical corticosteroids. Sherertz EF. **Arch Dermatol** 1996 Apr;132(4):461, 464 (11 ref.)

DIAGNOSIS

MR imaging of the metacarpophalangeal joints. Masson JA, et al. **Magn Reson Imaging Clin N Am** 1995 May; 3(2):313–25 (54 ref.)

EPIDEMIOLOGY

Dorsally displaced epiphyseal fracture of the phalangeal base. Hashizume H, et al. **J Hand Surg [Br]** 1996 Feb;21(1):136–8 (10 ref.)

ETIOLOGY

[A syndrome caused by separating rags in textile industry: a new clinical entity?] Fioravanti A, et al.
Minerva Med 1995 Nov;86(11):467–4 (25 ref.) (Eng. Abstr.) **(Ita)**

PATHOLOGY

Boutonniere deformity. Coons MS, et al. **Hand Clin** 1995 Aug;11(3):387–402 (30 ref.)

RADIOGRAPHY

Dislocation of the distal interphalangeal and the metacarpophalangeal joints in the same finger: a case report. Andersen MB, et al. **J Hand Surg [Am]** 1995 Jul; 20(4):574–5 (4 ref.)

REHABILITATION

Early motion after extensor tendon surgery. Crosby CA, et al. **Hand Clin** 1996 Feb;12(1):57–64 (37 ref.)

SURGERY

Flap reconstruction in the upper limb. Ikuta Y, et al.
Ann Acad Med Singapore 1995 Jul;24(4 Suppl):124–30 (10 ref.)

The role of microsurgery and free tissue transfer in the reconstruction of the paediatric upper extremity. Kay S, et al. **Ann Acad Med Singapore** 1995 Jul;24(4 Suppl):113–23 (50 ref.)

Current concepts of replantation. Raskin KB, et al.
Ann Acad Med Singapore 1995 Jul;24(4 Suppl):131–4 (29 ref.)

Leech therapy in digital replantation. Golden MA, et al.
AORN J 1995 Sep;62(3):364–6, 369, 371–2, passim (0 ref.)

Toe-to-hand transfer. Current concepts, techniques, and research. Wei FC, et al. **Clin Plast Surg** 1996 Jan; 23(1):103–16 (64 ref.)

THERAPY

Extensor tendon injuries at the distal interphalangeal joint. Brzezienski MA, et al. **Hand Clin** 1995 Aug;11(3):373–86 (47 ref.)

[Results of orthopedic and surgical treatment of mallet finger by subcutaneous rupture of the extensor tendon. Apropos of a series of 216 cases] Foucher G, et al.
Rev Chir Orthop Reparatrice Appar Mot 1995;81(6):491–6 (43 ref.) (Eng. Abstr.) **(Fre)**

FINGER JOINT

Extensor tendon injuries at the distal interphalangeal joint. Brzezienski MA, et al. **Hand Clin** 1995 Aug;11(3):373–86 (47 ref.)

PATHOLOGY

Etiologic factors in finger osteoarthritis [see comments] Verrouil E, et al. **Rev Rhum Engl Ed** 1995 Jun;62(6 Suppl 1):9S–13S (39 ref.) Comment in: Rev Rhum Engl Ed 1995 Jun;62(6 Suppl 1):1S–2S.

PHYSIOLOGY

Thumb movements, motions, and moments. Hollister A, et al. **J Hand Ther** 1995 Apr-Jun;8(2):106–14 (8 ref.)

RADIOGRAPHY

Dislocation of the distal interphalangeal and the metacarpophalangeal joints in the same finger: a case report. Andersen MB, et al. **J Hand Surg [Am]** 1995 Jul; 20(4):574–5 (4 ref.)

SURGERY

Surgical treatment for osteoarthritis at the base of the thumb. Kuschner SH, et al. **Am J Orthop** 1996 Feb;25(2):91–100 (73 ref.)

Early motion after arthroplasty. Kirkpatrick WH, et al.
Hand Clin 1996 Feb;12(1):73–86 (45 ref.)

Salvage of extensor tendon function with tenolysis and joint release. Uhl RL. **Hand Clin** 1995 Aug;11(3):461–70 (19 ref.)

FINGERPRINTS, DNA see **DNA FINGERPRINTING**

FINGERPRINTS, PEPTIDE see **PEPTIDE MAPPING**

FINGERS

Leech therapy in digital replantation. Golden MA, et al.
AORN J 1995 Sep;62(3):364–6, 369, 371–2, passim (0 ref.)

Nodular lesions on fingertips. Diagnosis: cutaneous sarcoidosis. Di Landro A, et al. **Arch Dermatol** 1996 Apr; 132(4):460, 463 (9 ref.)

Violaceous rash of dorsal fingers in a woman. Diagnosis: chilblain lupus erythematosus (perniosis). Fisher DA, et al. **Arch Dermatol** 1996 Apr;132(4):459, 462 (8 ref.)

An angiomyoma with t(X;10)(q22;q23.2). Sonobe H, et al.
Cancer Genet Cytogenet 1996 Aug;90(1):54–6 (17 ref.)

[Finger fibrosarcoma. A case report] Ouarab M, et al.
Ann Chir Main Memb Super 1995;14(4–5):235–8 (9 ref.) (Eng. Abstr.) **(Fre)**

ABNORMALITIES

The EEC syndrome: a literature study. Roelfsema NM, et al. **Clin Dysmorphol** 1996 Apr;5(2):115–27 (124 ref.)

Zimmermann-Laband syndrome in a patient with severe mental retardation. Van Buggenhout GJ, et al.
Genet Couns 1995;6(4):321–7 (15 ref.)

[The Townes-Brocks syndrome] Arroyo Carrera I, et al.
An Esp Pediatr 1996 Apr;44(4):364–6 (18 ref.) **(Spa)**

[The MMT syndrome (microcephaly, mesobrachyphalangy and tracheoesophageal fistula). The first case described in Spain and a review of the literature] Martínez-Frías ML, et al. **An Esp Pediatr** 1996 Jul;45(1):87–9 (7 ref.) **(Spa)**

BLOOD SUPPLY

Hypothenar hammer syndrome caused by playing tennis. Nakamura T, et al. **Eur J Vasc Endovasc Surg** 1996 Feb; 11(2):240–2 (8 ref.)

Ovarian cancer and gangrene of the digits: case report and review of the literature. Chow SF, et al.
Mayo Clin Proc 1996 Mar;71(3):253–8 (45 ref.)

Aneurysms of the digital artery: a review and report of three cases. Yajima H, et al. **Microsurgery** 1995;16(8):566–70 (19 ref.)

PATHOLOGY

Recurring digital fibroma of childhood. Burgert S, et al.
J Hand Surg [Br] 1996 Jun;21(3):400–2 (15 ref.)

Ovarian cancer and gangrene of the digits: case report and review of the literature. Chow SF, et al.
Mayo Clin Proc 1996 Mar;71(3):253–8 (45 ref.)

[Digital necrosis associated with fenoxazoline poisoning. Apropos of a case and review of the literature] Hauet T, et al. **Rev Med Interne** 1996;17(1):66–9 (19 ref.) (Eng. Abstr.) **(Fre)**

RADIOGRAPHY

Acute calcific periarthritis of the fingers. Gálvez J, et al.
Rev Rhum Engl Ed 1995 Oct;62(9):602–4 (11 ref.)

FIREARMS

see related
WOUNDS, GUNSHOT

Firearm violence among youth: public health strategies for prevention. Powell EC, et al. **Ann Emerg Med** 1996 Aug; 28(2):204–12 (83 ref.)

Dementia and guns [see comments] Mendez MF.
J Am Geriatr Soc 1996 Apr;44(4):409–10 (10 ref.) Comment in: J Am Geriatr Soc 1996 Apr;44(4):467–9.

Venous injuries: military versus civilian experience. Ierardi RP, et al. **Mil Med** 1995 Aug;160(8):396–8 (25 ref.)

FIREFLIES see **BEETLES**

FIRES

see related
BURNS, INHALATION

Toxicity of combustion products of polymeric materials. Cempel M. **Bull Inst Marit Trop Med Gdynia** 1993-94; 44-45(1-4):75-81 (21 ref.)
Ignition potential of the 585-nm pulsed-dye laser. Review of the literature and safety recommendations. Fretzin S, et al. **Dermatol Surg** 1996 Aug;22(8):699-702 (13 ref.)
Occupational mortality among firefighters: assessing the association. Guidotti TL. **J Occup Environ Med** 1995 Dec; 37(12):1348-56 (35 ref.)
Intraoperative fire with electrocautery. Brechtelsbauer PB, et al. **Otolaryngol Head Neck Surg** 1996 Feb;114(2):328-31 (17 ref.)

FIRST AID

Trauma systems, shock, and resuscitation. Fallon WF. **Curr Opin Gen Surg** 1993;:40-5 (24 ref.)
[Pre-hospital care for patients with multiple injuries] Kivioja A. **Duodecim** 1995;111(9):866-72 (23 ref.) **(Fin)**

METHODS

Psychological first-aid: a practical aide-memoire. Leach J. **Aviat Space Environ Med** 1995 Jul;66(7):668-74 (22 ref.)

FISH DISEASES

Immune response to synthetic peptides representing antigenic sites on the glycoprotein of infectious hematopoietic necrosis virus. Emmenegger E, et al. **Vet Res** 1995; 26(5-6):374-8 (21 ref.)
Viruses associated with the epizootic ulcerative syndrome (EUS) of fish in South-East Asia. Frerichs GN. **Vet Res** 1995;26(5-6):449-54 (26 ref.)

PARASITOLOGY

Parasitisms of catfish and other farm-raised food fish [see comments] Klesius P, et al. **J Am Vet Med Assoc** 1995 Dec 1;207(11):1473-8 (40 ref.) Comment in: J Am Vet Med Assoc 1996 Feb 1;208(3):338.

PHYSIOPATHOLOGY

Lipid nutritional pathology in farmed fish. Tacon AG. **Arch Tierernahr** 1996;49(1):33-9 (71 ref.)

PREVENTION & CONTROL

Disinfection in aquaculture. Torgersen Y, et al. **Rev Sci Tech** 1995 Jun;14(2):419-34 (39 ref.)

FISH LIVER OILS see FISH OILS

FISH OILS

ADMINISTRATION & DOSAGE

Fish oil and antioxidants after heart transplantation: future strategies or eye of newt and wing of bat revisited? Young JB. **J Heart Lung Transplant** 1995 Nov-Dec;14(6 Pt 2):S250-4 (29 ref.)
Dietary fish oil and airways obstruction. Britton J. **Thorax** 1995 Sep;50 Suppl 1:S11-5 (28 ref.)

PHARMACOLOGY

Fish oil, lipid peroxidation and mammary tumor growth. Gonzalez MJ. **J Am Coll Nutr** 1995 Aug;14(4):325-35 (159 ref.)
Fish oil may impede tumour angiogenesis and invasiveness by down-regulating protein kinase C and modulating eicosanoid production. McCarty MF. **Med Hypotheses** 1996 Feb;46(2):107-15 (120 ref.)

THERAPEUTIC USE

Can we recommend fish oil for hypertension? Howe PR. **Clin Exp Pharmacol Physiol** 1995 Mar;22(3):199-203 (33 ref.)
Pharmacologic prevention of colonic neoplasms. Effects of calcium, vitamins, omega fatty acids, and nonsteroidal anti-inflammatory drugs. Eastwood GL. **Dig Dis** 1996 Mar-Apr;14(2):119-28 (124 ref.)
Marine and botanical lipids as immunomodulatory and therapeutic agents in the treatment of rheumatoid arthritis. DeLuca P, et al. **Rheum Dis Clin North Am** 1995 Aug; 21(3):759-77 (91 ref.)
[Is a fish oil enriched diet therapeutically beneficial?] Machura E, et al. **Pediatr Pol** 1995 Jul;70(7):597-602 (23 ref.) (Eng. Abstr.) **(Pol)**

FISH PRODUCTS

STANDARDS

Value-added products from underutilized fish species. Venugopal V, et al. **Crit Rev Food Sci Nutr** 1995 Sep; 35(5):431-53 (160 ref.)
Fish and heart disease: what is the real story? Katan MB. **Nutr Rev** 1995 Aug;53(8):228-30 (16 ref.)

FISHERIES

Parasitisms of catfish and other farm-raised food fish [see comments] Klesius P, et al. **J Am Vet Med Assoc** 1995 Dec 1;207(11):1473-8 (40 ref.) Comment in: J Am Vet Med Assoc 1996 Feb 1;208(3):338.

FISHES

Biogenic amines in fish and shellfish. Rawles DD, et al. **Adv Food Nutr Res** 1996;39:329-65 (147 ref.)
Spoilage and shelf-life extension of fresh fish and shellfish. Ashie IN, et al. **Crit Rev Food Sci Nutr** 1996 Jan; 36(1-2):87-121 (246 ref.)
Fish flavor. Kawai T. **Crit Rev Food Sci Nutr** 1996 Feb; 36(3):257-98 (127 ref.)
Regulation of oocyte growth and maturation in fish. Nagahama Y, et al. **Curr Top Dev Biol** 1995;30:103-45 (134 ref.)
Skin hazards of the marine aquarium industry. Tong DW. **Int J Dermatol** 1996 Mar;35(3):153-8 (43 ref.)
[Transgenesis and ES cell lines in Medaka] Ozato K, et al. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2249-56 (19 ref.) **(Jpn)**

ANATOMY & HISTOLOGY

Structural diversity in the inner ear of teleost fishes: implications for connections to the Mauthner cell. Popper AN, et al. **Brain Behav Evol** 1995;46(3):131-40 (70 ref.)
[Results and conclusions from 328 radical operations of rectal carcinoma by one surgeon. Comparative anatomic studies with Brachydanio rerio and Latimeria chalumnae] Stelzner F. **Chirurg** 1995 Dec;66(12):1230-8 (22 ref.) (Eng. Abstr.) **(Ger)**

EMBRYOLOGY

Cytoskeleton in teleost eggs and early embryos: contributions to cytoarchitecture and motile events. Hart NH, et al. **Curr Top Dev Biol** 1995;31:343-81 (144 ref.)

GENETICS

Structure and organization of the isotocin and vasotocin genes from teleosts. Venkatesh B, et al. **Adv Exp Med Biol** 1995;395:629-38 (24 ref.)
Transgenic fish in aquaculture and developmental biology. Gong Z, et al. **Curr Top Dev Biol** 1995;30:177-214 (174 ref.)
Fish major histocompatibility complex genes: an expansion. Dixon B, et al. **Dev Comp Immunol** 1995 Mar-Apr; 19(2):109-33 (77 ref.)
Regulation and expression of transgenes in fish — a review. Iyengar A, et al. **Transgenic Res** 1996 May;5(3):147-66 (101 ref.)
[Transgene expression and integration in the zebrafish, Danio rerio] Amanuma K, et al. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2257-64 (19 ref.) **(Jpn)**
[The results of multiyear research on fish populations from reservoirs falling within the area of the Kyshtym accident (a review)] Fetisov AN. **Radiats Biol Radioecol** 1995 Sep-Oct;35(5):751-8 (19 ref.) (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

Bacterial antigen priming of marine fish larvae. Olafsen JA. **Adv Exp Med Biol** 1995;371A:349-52 (36 ref.)

METABOLISM

Energetics of fish larvae, the smallest vertebrates. Wieser W. **Acta Physiol Scand** 1995 Jul;154(3):279-90 (62 ref.)
Fatty acid metabolism in freshwater fish with particular reference to polyunsaturated fatty acids. Henderson RJ. **Arch Tierernahr** 1996;49(1):5-22 (69 ref.)

MICROBIOLOGY

[Contaminated fish and pork] Perret JL, et al. **Med Trop (Mars)** 1996;56(1):25-7 (0 ref.) **(Fre)**

PARASITOLOGY

[Contaminated fish and pork] Perret JL, et al. **Med Trop (Mars)** 1996;56(1):25-7 (0 ref.) **(Fre)**

PHYSIOLOGY

The octavolateralis system and Mauthner cell: interactions and questions. Eaton RC, et al. **Brain Behav Evol** 1995; 46(3):124-30 (60 ref.)
Comparative studies on the Mauthner cell of teleost fish in relation to sensory input. Zottoli SJ, et al. **Brain Behav Evol** 1995;46(3):151-64 (115 ref.)
Vitellogenesis as a biomarker for estrogenic contamination of the aquatic environment. Sumpter JP, et al. **Environ Health Perspect** 1995 Oct;103 Suppl 7:173-8 (39 ref.)
Care of fish in biological research. Klontz GW. **J Anim Sci** 1995 Nov;73(11):3485-92 (24 ref.)
Distribution and molecular forms of urotensin II and its role in cardiovascular regulation in vertebrates. Coulon JM, et al. **J Exp Zool** 1996 Jun 1-15;275(2-3):226-38 (92 ref.)
Cell-cell interactions in the testis of teleosts and elasmobranchs. Loir M, et al. **Microsc Res Tech** 1995 Dec 15;32(6):533-52 (93 ref.)
The nutritional requirements of ornamental fish. Earle KE. **Vet Q** 1995 Apr;17 Suppl 1:S53-5 (5 ref.)

VIROLOGY

Molecular biology of fish viruses: a review. Bernard J, et al. **Vet Res** 1995;26(5-6):341-51 (65 ref.)
Viruses associated with the epizootic ulcerative syndrome (EUS) of fish in South-East Asia. Frerichs GN. **Vet Res** 1995;26(5-6):449-54 (26 ref.)

FISSION YEAST see SCHIZOSACCHAROMYCES

FISSURE IN ANO

SURGERY

[Fistula, fissure, abscess] Girona J, et al. **Chirurg** 1996 Mar; 67(3):222-8 (28 ref.) (Eng. Abstr.) **(Ger)**

FISSURES, DENTAL see DENTAL FISSURES

FISTULA

[Biliary ileus. Case report and therapeutic considerations] Ferranti F, et al. **Minerva Chir** 1995 Jul-Aug; 50(7-8):707-11 (28 ref.) (Eng. Abstr.) **(Ita)**
[Intrahepatic portal-hepatic venous fistula] Iwahashi K. **Ryoikibetsu Shokogun Shirizu** 1995;(8):214-7 (19 ref.) **(Jpn)**
[Cholecystogastric fistula, cholecystoenteric fistula] Souda S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):436-8 (8 ref.) **(Jpn)**

CHEMICALLY INDUCED

Bronchoesophagopleural fistula after photodynamic therapy for malignant mesothelioma. Luketich JD, et al. **Ann Thorac Surg** 1996 Jul;62(1):283-4 (7 ref.)

COMPLICATIONS

Epididymocutaneous fistula in a patient with the acquired immunodeficiency syndrome and Marfan's syndrome. Weiner DM, et al. **Urology** 1996 May;47(5):766-8 (14 ref.)

CONGENITAL

[Clinical and surgical aspects of cysts and fistulae of the nose in children. Apropos of 37 cases] Ducroz V, et al. **Ann Otolaryngol Chir Cervicofac** 1995;112(5):218-24 (33 ref.) (Eng. Abstr.) **(Fre)**
[Late manifestation of congenital intrahepatic portacaval shunt in a healthy liver] Kerleau JM, et al. **Rev Med Interne** 1995;16(8):616-8 (7 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Primary aortoenteric fistula: two new case reports and a review of 44 previously reported cases. Tareen AH, et al. **Eur J Vasc Endovasc Surg** 1996 Jul;12(1):5-10 (34 ref.)
Survival after aberrant right subclavian artery-esophageal fistula: case report and literature review. Miller RG, et al. **J Vasc Surg** 1996 Aug;24(2):271-5 (45 ref.)
[Apical hypertrophic myocardiopathy and multiple fistulae between the coronary vessels and the left ventricle] Monmeneu JV, et al. **Rev Esp Cardiol** 1995 Nov; 48(11):768-70 (10 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

Labyrinthine fistulae. Vantrappen G, et al. **Acta Otorhinolaryngol Belg** 1996;50(1):63-8 (13 ref.)
Persistent dizziness following head trauma and perilymphatic fistula. Fitzgerald DC. **Arch Phys Med Rehabil** 1995 Nov; 76(11):1017-20 (26 ref.)
Traumatic fistula between the left anterior descending coronary artery and a left ventricular pseudoaneurysm. Haapanen YT, et al. **Cardiovasc Intervent Radiol** 1996 Jul-Aug;19(4):272-4 (11 ref.)
Primary aortoesophageal fistula caused by an atherosclerotic thoracoabdominal aortic aneurysm: a case report and review of the literature. Hageman JH, et al. **Cardiovasc Surg** 1995 Oct;3(5):495-9 (17 ref.)
Oesophago-vascular fistulae secondary to benign peptic ulcer disease: a rare cause of fatal haemorrhage. Kenny PJ, et al. **Eur J Vasc Endovasc Surg** 1995 Oct;10(3):370-1 (6 ref.)
Coronary ventricular fistula as a complication of PTCA: a case report and literature review. el-Omar MM, et al. **Int J Cardiol** 1995 Sep;51(2):113-6 (10 ref.)
Traumatic pyeloduodenal fistula: a case report and review of the literature. Ginsberg DA, et al. **Urology** 1996 Apr; 47(4):588-91 (20 ref.)
[Postoperative lymphoceles and lymphatic fistula in gynecologic and breast neoplasms] Brun JL. **Bull Cancer (Paris)** 1995 Sep;82(9):711-6 (37 ref.) (Eng. Abstr.) **(Fre)**
[Traumatic spinothoracic cerebrospinal fluid fistula] Löw R, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1995 Nov;163(5):454-6 (9 ref.) **(Ger)**
[Porto-systemic shunt] Hamazaki K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):243-7 (21 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Embryological basis of some aspects of cerebral vascular

fistulas and malformations. Mullan S, et al. **J Neurosurg** 1996 Jul;85(1):1–8 (20 ref.)

RADIOGRAPHY

[Coronary fistula in adults. Review with reference to personal experience] Zanchin L, et al. **Schweiz Med Wochenschr** 1996 Feb 24;126(8):299–307 (77 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Primary aortoenteric fistula: report of eight new cases and review of the literature. Voorhoeve R, et al. **Ann Vasc Surg** 1996 Jan;10(1):40–8 (76 ref.)

Palatal mucoperiosteal expansion as an adjunct to palatal fistula repair: case report and review of the literature. Van Damme PA, et al. **Cleft Palate Craniofac J** 1996 May; 33(3):255–7 (10 ref.)

THERAPY

[The treatment of a bronchopleural fistula with fibrin adhesive in a premature infant] Galiana Ferré C, et al. **An Esp Pediatr** 1996 Jun;44(6):596–8 (11 ref.) **(Spa)**

VETERINARY

Diagnosis and treatment of porto-systemic shunts. Bellenger CR, et al. **Vet Q** 1995 Apr;17 Suppl 1:S4–5 (6 ref.)

FIV see IMMUNODEFICIENCY VIRUS, FELINE

FIXATION DEVICES, EXTERNAL see EXTERNAL FIXATORS

FIXATION DEVICES, INTERNAL see INTERNAL FIXATORS

FIXATION, OCULAR

PHYSIOLOGY

Comparison of perception in the moving and stationary eye. Sperling G. **Rev Oculomot Res** 1990;4:307–51 (120 ref.)

FIXATION, TISSUE see TISSUE FIXATION

FK-506 see TACROLIMUS

FLACCIDITY, MUSCLE see MUSCLE HYPOTONIA

FLAGELLA

CHEMISTRY

Flagellar assembly in two hundred and fifty easy-to-follow steps. Dutcher SK. **Trends Genet** 1995 Oct;11(10):398–404 (62 ref.)

PHYSIOLOGY

How bacteria sense and swim. Blair DF. **Annu Rev Microbiol** 1995;49:489–522 (197 ref.)

Flagellar kinesins: new moves with an old beat. Bernstein M. **Cell Motil Cytoskeleton** 1995;32(2):125–8 (27 ref.)

Regulation of dynein-driven microtubule sliding by an axonemal kinase and phosphatase in Chlamydomonas flagella. Habermacher G, et al. **Cell Motil Cytoskeleton** 1995;32(2):106–9 (23 ref.)

Regulation of ciliary beat frequency by a dynein light chain. Hamasaki T, et al. **Cell Motil Cytoskeleton** 1995;32(2):121–4 (27 ref.)

Exploring the function of inner and outer dynein arms with Chlamydomonas mutants. Kamiya R. **Cell Motil Cytoskeleton** 1995;32(2):98–102 (34 ref.)

Regulation of interaction between signaling protein CheY and flagellar motor during bacterial chemotaxis. Barak R, et al. **Curr Top Cell Regul** 1996;34:137–58 (156 ref.)

Structural and functional hierarchy of eukaryotic cilia and flagella. Omoto CK. **Eur J Histochem** 1995;39(2):85–90 (53 ref.)

Regulation of sperm motility at the axonemal level. Gagnon C. **Reprod Fertil Dev** 1995;7(4):847–55 (73 ref.)

ULTRASTRUCTURE

Structural and functional hierarchy of eukaryotic cilia and flagella. Omoto CK. **Eur J Histochem** 1995;39(2):85–90 (53 ref.)

FLAPS see SURGICAL FLAPS

FLATFOOT

PHYSIOPATHOLOGY

Flexible flatfoot and skewfoot. Mosca VS. **Instr Course Lect** 1996;45:347–54 (73 ref.)

FLATULENCE

ETIOLOGY

Gastrointestinal gas formation and infantile colic. Sferra TJ, et al. **Pediatr Clin North Am** 1996 Apr;43(2):489–510 (116 ref.)

FLATUS see FLATULENCE

FLATWORMS see PLATYHELMINTHS

FLAVINS

CHEMISTRY

Radical thoughts about the life of MAO. Silverman RB. **Prog Brain Res** 1995;106:23–31 (25 ref.)

The colorful past and bright future of monoamine oxidase research. Singer TP. **Prog Brain Res** 1995;106:1–22 (86 ref.)

METABOLISM

Unifying concepts in flavin-dependent catalysis. Vervoort J, et al. **Biochem Soc Trans** 1996 Feb;24(1):127–30 (14 ref.)

Riboflavin binding proteins and flavin assimilation in insects. Miller SG, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1995 Mar; 110(3):467–75 (48 ref.)

FLAVOBACTERIUM

IMMUNOLOGY

[Hypersensitivity pneumonitis caused by a home humidifier] Hagiwara S, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Sep; 33(9):1024–9 (10 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Microbial oxidation of unsaturated fatty acids. Hou CT. **Adv Appl Microbiol** 1995;41:1–23 (37 ref.)

PATHOGENICITY

Pyomyositis in intravenous drug abusers: report of a unique case and review of the literature. Hsueh PR, et al. **Clin Infect Dis** 1996 May;22(5):858–60 (10 ref.)

FLAVOBACTERIUM MENINGOSEPTICUM see FLAVOBACTERIUM

FLAVONES

CHEMISTRY

Protein tyrosine kinase inhibitors. Groundwater PW, et al. **Prog Med Chem** 1996;33:233–329 (277 ref.)

ISOLATION & PURIFICATION

[Advances in the study of the chemical constituents of gardenia] Wang G, et al. **Chung Kuo Chung Yao Tsa Chih** 1996 Feb;21(2):67–9, 72 (34 ref.) **(Chi)**

FLAVOPROTEINS

CHEMISTRY

A glutathione reductase-like flavoenzyme of the malaria parasite Plasmodium falciparum: structural considerations based on the DNA sequence. Becker K, et al. **Biochem Soc Trans** 1996 Feb;24(1):67–72 (37 ref.)

Recent studies on xanthine oxidase and related enzymes. Bray RC, et al. **Biochem Soc Trans** 1996 Feb;24(1):99–105 (41 ref.)

Glutamate synthase: a complex iron-sulphur flavoprotein. Curti B, et al. **Biochem Soc Trans** 1996 Feb;24(1):95–9 (20 ref.)

The chemical mechanism of flavoprotein-catalysed alpha-hydroxy acid dehydrogenation: a mutational analysis. Lederer F, et al. **Biochem Soc Trans** 1996 Feb; 24(1):77–83 (50 ref.)

Protein engineering of domains in flavoprotein disulphide oxidoreductases: contributions to folding and assembly. Perham RN, et al. **Biochem Soc Trans** 1996 Feb;24(1):61–6 (45 ref.)

METABOLISM

Recent studies on xanthine oxidase and related enzymes. Bray RC, et al. **Biochem Soc Trans** 1996 Feb;24(1):99–105 (41 ref.)

Glutamate synthase: a complex iron-sulphur flavoprotein. Curti B, et al. **Biochem Soc Trans** 1996 Feb;24(1):95–9 (20 ref.)

The chemical mechanism of flavoprotein-catalysed alpha-hydroxy acid dehydrogenation: a mutational analysis. Lederer F, et al. **Biochem Soc Trans** 1996 Feb; 24(1):77–83 (50 ref.)

Unifying concepts in flavin-dependent catalysis. Vervoort J, et al. **Biochem Soc Trans** 1996 Feb;24(1):127–30 (14 ref.)

Mechanism and structure of thioredoxin reductase from Escherichia coli. Williams CH Jr. **FASEB J** 1995 Oct; 9(13):1267–76 (47 ref.)

FLAVORING AGENTS

STANDARDS

Risk assessment of carcinogens in food with special consideration of non-genotoxic carcinogens. Scientific arguments for use of risk assessment and for changing the Delaney Clause specifically. Williams GM, et al. **Exp Toxicol Pathol** 1996 Feb;48(2-3):209–15 (21 ref.)

FEMA GRAS--a GRAS assessment program for flavor ingredients. Flavor and Extract Manufacturers Association. Hallagan JB, et al. **Regul Toxicol Pharmacol** 1995 Jun; 21(3):422–30 (12 ref.)

FLEAS

The cat, the flea, and pesticides. Logas DB. **Vet Clin North Am Small Anim Pract** 1995 Jul;25(4):801–11 (60 ref.)

FLECAINIDE

PHARMACOLOGY

[Flecainide acetate] Bordier P, et al. **Ann Cardiol Angeiol (Paris)** 1996 May;45(5):263–79 (135 ref.) (Eng. Abstr.) **(Fre)**

FLECAINIDE ACETATE see FLECAINIDE

FLEROXACIN

ADMINISTRATION & DOSAGE

Oral fleroxacin prophylaxis in transurethral surgery. Gasser TC, et al. **J Urol** 1996 Jul;156(1):146–8 (27 ref.)

FLESH-EATING BACTERIA see STREPTOCOCCUS PYOGENES

FLETCHER FACTOR see PREKALLIKREIN

FLIES, TRUE see DIPTERA

FLIGHT, ANIMAL

PHYSIOLOGY

Unsteady aerodynamics of insect flight. Ellington CP. **Symp Soc Exp Biol** 1995;49:109–29 (74 ref.)

Dynamics of the vortex wakes of flying and swimming vertebrates. Rayner JM. **Symp Soc Exp Biol** 1995;49:131–55 (103 ref.)

FLOODS see NATURAL DISASTERS

FLOOR OF MOUTH see MOUTH FLOOR

FLOPPY MITRAL VALVE see MITRAL VALVE PROLAPSE

FLORAFUR see TEGAFUR

FLOUR

[Food fortification with emphasis on the addition of micronutrients to wheat flour] Arroyave G. **Arch Latinoam Nutr** 1993 Sep;43(3):186–90 (16 ref.) (Eng. Abstr.) **(Spa)**

ANALYSIS

Cowpea flour: a potential ingredient in food products. Prinyawiwatkul W, et al. **Crit Rev Food Sci Nutr** 1996 May; 36(5):413–36 (130 ref.)

FLOW CYTOMETRY

B-lineage differentiation stages resolved by multiparameter flow cytometry. Hardy RR, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:19–24 (26 ref.)

Flow cytometry: a clinical test of platelet function. Michelson AD. **Blood** 1996 Jun 15;87(12):4925–36 (145 ref.)

Histologic, flow cytometric, and genetic criteria in endocrine surgery. Flynn SD, et al. **Curr Opin Gen Surg** 1993;:115–20 (45 ref.)

Flow cytometric and clinicopathologic study of 197 hydatidiform moles with special reference to the significance of cytometric aneuploidy and literature review. Fukunaga M, et al. **Cytometry** 1995 Jun 15;22(2):135–8 (21 ref.)

Quantitative determination of antibody binding capacity (ABC) by flow cytometry. Schwartz A, et al. **Eur J Histochem** 1994;38 Suppl 1:13–20 (14 ref.)

Flow cytometry applications in physiological study and detection of foodborne microorganisms. Ueckert J, et al. **Int J Food Microbiol** 1995 Dec;28(2):317–26 (30 ref.)

Clinical application of flow cytometry to urological malignancies. Tachibana M. **Keio J Med** 1996 Jun; 45(2):73–80 (54 ref.)

Sex preselection by flow cytometric separation of X and Y chromosome-bearing sperm based on DNA difference: a review. Johnson LA. **Reprod Fertil Dev** 1995;7(4):893–903 (47 ref.)

Flow cytometry. Principles and applications in exercise immunology. Gabriel H, et al. **Sports Med** 1995 Nov; 20(5):302–20 (121 ref.)

[Use of morphometry and DNA flow cytometry in the differential diagnosis, prognosis and treatment of primary

tumors of the liver (review of the literature)] Pimenova EL, et al. **Klin Lab Diagn** 1996 Mar-Apr;(2):7-11 (47 ref.) **(Rus)**

INSTRUMENTATION

Use of flow chamber devices and image analysis methods to study microbial adhesion. Busscher HJ, et al. **Methods Enzymol** 1995;253:455-77 (43 ref.)

[Instruments used for measurement of intracellular calcium ions] Miyakawa A. **Nippon Seirigaku Zasshi** 1995; 57(10):401-17 (18 ref.) **(Jpn)**

METHODS

Detection and isolation of rare cells. Radbruch A, et al. **Curr Opin Immunol** 1995 Apr;7(2):270-3 (22 ref.)

Measurement of apoptotic cells in peripheral blood. Carbonari M, et al. **Cytometry** 1995 Sep 15;22(3):161-7 (52 ref.)

Applications of flow cytometric DNA analysis to diagnostic cytology. Cibas ES. **Diagn Cytopathol** 1995 Aug; 13(2):166-71 (50 ref.)

A standardized flow cytometry protocol for mobilized peripheral CD34+ cells estimation and collection for autotransplantation in cancer patients. Brando B, et al. **Eur J Histochem** 1994;38 Suppl 1:21-6 (12 ref.)

Isolating fetal nucleated red blood cells from maternal blood: the Baylor experience--1995. Simpson JL, et al. **Prenat Diagn** 1995 Oct;15(10):907-12 (19 ref.)

[Detection of hematopoietic stem cells using automated blood cell counter and flow cytometry] Takekawa K, et al. **Rinsho Byori** 1995 Jul;Suppl 99:117-22 (20 ref.) **(Jpn)**

TRENDS

Fluorescent probes and flow cytometry: new insights into environmental bacteriology. Porter J, et al. **Cytometry** 1996 Feb 1;23(2):91-6 (74 ref.)

Recent advances in cytometry, cytogenetics and molecular genetics of thyroid tumours and tumour-like lesions. Soares P, et al. **Pathol Res Pract** 1995 May;191(4):304-17 (141 ref.)

FLOW MICROFLUORIMETRY see **FLOW CYTOMETRY**

FLOW, PULSATING see **PULSATILE FLOW**

FLOWMETRY see **RHEOLOGY**

FLOWMETRY, LASER-DOPPLER see **LASER-DOPPLER FLOWMETRY**

FLOXACILLIN

ADVERSE EFFECTS

Flucloxacillin associated cholestatic hepatitis. An Australian and Swedish epidemic? Devereaux BM, et al. **Eur J Clin Pharmacol** 1995;49(1-2):81-5 (30 ref.)

FLOXURIDINE

METABOLISM

Fluoropyrimidine catabolism. Diasio RB, et al. **Cancer Treat Res** 1995;78:71-93 (103 ref.)

PHARMACOLOGY

Current status of radiation sensitization by fluoropyrimidines. Pu AT, et al. **Oncology (Huntingt)** 1995 Aug;9(8):707-14; discussion 714, 717-8, 721 (42 ref.)

THERAPEUTIC USE

Biochemical modulation of fluoropyrimidines: is there an optimal (6R,S) leucovorin dose and schedule? [editorial; comment] Doroshow JH. **J Natl Cancer Inst** 1996 Apr 3; 88(7):393-5 (24 ref.) Comment on: J Natl Cancer Inst 1996 Apr 3;88(7):430-6.

Clinical development of new fluoropyrimidines: a major improvement in colorectal cancer treatment? Colleoni M, et al. **Tumori** 1995 Sep-Oct;81(5):303-7 (44 ref.)

[Survival and changes of clinical laboratory data in phase II study with 5'-DFUR] Taguchi T. **Gan To Kagaku Ryoho** 1996 Jul;23(8):1019-29 (31 ref.) (Eng. Abstr.) **(Jpn)**

FLUCLOXACILLIN see **FLOXACILLIN**

FLUCONAZOLE

ADMINISTRATION & DOSAGE

Oral fluconazole for vaginal candidiasis. Desai PC, et al. **Am Fam Physician** 1996 Sep 15;54(4):1337-40, 1345-6 (11 ref.)

ADVERSE EFFECTS

Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration. Guillaume MP, et al. **Am J Gastroenterol** 1996 Jan;91(1):165-8 (14 ref.)

PHARMACOKINETICS

Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients. Goa KL, et al. **Drugs** 1995 Oct;50(4):658-90 (204 ref.)

PHARMACOLOGY

Is antifungal susceptibility testing useful in guiding fluconazole therapy? Ghannoum MA. **Clin Infect Dis** 1996 May;22 Suppl 2:S161-5 (25 ref.)

Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients. Goa KL, et al. **Drugs** 1995 Oct;50(4):658-90 (204 ref.)

THERAPEUTIC USE

Role of azoles in antifungal therapy. Kauffman CA. **Clin Infect Dis** 1996 May;22 Suppl 2:S148-53 (72 ref.)

Fluconazole: its properties and efficacy in vaginal candidiasis. Troke PF. **Curr Probl Dermatol** 1996;24:203-8 (19 ref.)

Central venous catheter infection with Rhodotorula minuta in a patient with AIDS taking suppressive doses of fluconazole. Goldani LZ, et al. **J Med Vet Mycol** 1995 Jul-Aug;33(4):267-70 (22 ref.)

FLUID BALANCE see **WATER-ELECTROLYTE BALANCE**

FLUID THERAPY

see related
REHYDRATION SOLUTIONS

Barriers to forgoing nutrition and hydration in nursing homes. Meisel A. **Am J Law Med** 1995;21(4):335-82 (274 ref.)

Appropriate fluid regimens to prevent bronchopulmonary dysplasia. Tammela OK. **Eur J Pediatr** 1995;154(8 Suppl 3):S15-8 (18 ref.)

Fluid resuscitation in traumatic haemorrhage. Cutress R. **J Accid Emerg Med** 1995 Sep;12(3):165-72 (29 ref.)

Perioperative fluid management for thoracic surgery: the puzzle of postpneumonectomy pulmonary edema. Slinger PD. **J Cardiothorac Vasc Anesth** 1995 Aug;9(4):442-51 (52 ref.)

Rehydration in palliative and terminal care: if not--why not? Dunphy K, et al. **Palliat Med** 1995 Jul;9(3):221-8 (32 ref.)

Electrolyte fluxes in the gut and oral rehydration solutions. Acra SA, et al. **Pediatr Clin North Am** 1996 Apr; 43(2):433-49 (64 ref.)

Emergency fluid management for hypovolemia. Pflederer TA. **Postgrad Med** 1996 Sep;100(3):243-4, 247-8, 251-4 (17 ref.)

Gastrointestinal symptoms during exercise. The effect of fluid supplementation. Peters HP, et al. **Sports Med** 1995 Aug; 20(2):65-76 (76 ref.)

METHODS

The use of colloids in clinical practice. Cone A. **Br J Hosp Med** 1995 Aug 16-Sep 5;54(4):155-9 (20 ref.)

Influence of different volume therapies and pentoxifylline infusion on circulating soluble adhesion molecules in critically ill patients. Boldt J, et al. **Crit Care Med** 1996 Mar;24(3):385-91 (39 ref.)

Practical guidelines for the treatment of cholera. Seas C, et al. **Drugs** 1996 Jun;51(6):966-73 (24 ref.)

Utility of clysis for hydration in nursing home residents. Hussain NA, et al. **J Am Geriatr Soc** 1996 Aug;44(8):969-73 (20 ref.)

Oral rehydration therapy programme in India: standard case management of acute watery diarrhoea. Manchanda VK. **J Indian Med Assoc** 1995 Jun;93(6):220-6 (17 ref.)

Fluid management in patients with traumatic brain injury. Zornow MH, et al. **New Horiz** 1995 Aug;3(3):488-98 (55 ref.)

VETERINARY

General management considerations for the trauma patient. Payne JT. **Vet Clin North Am Small Anim Pract** 1995 Sep; 25(5):1015-29 (6 ref.)

FLUKES see **TREMATODA**

FLUMAZENIL

[Flumazenil] Shapira Y, et al. **Harefuah** 1995 Jun 15; 128(12):812-7 (45 ref.) **(Heb)**

ADMINISTRATION & DOSAGE

Flumazenil and midazolam in anaesthesia. Whitwam JG. **Acta Anaesthesiol Scand Suppl** 1995;108:15-22 (67 ref.)

ADVERSE EFFECTS

Antidotes: benefits and risks. Proudfoot AT. **Toxicol Lett** 1995 Dec;82-83:779-83 (20 ref.)

PHARMACOLOGY

Reversal of conscious sedation by flumazenil: current status and future prospects. McCloy RF. **Acta Anaesthesiol Scand Suppl** 1995;108:35-42 (51 ref.)

Pharmacology of flumazenil. Whitwam JG, et al. **Acta Anaesthesiol Scand Suppl** 1995;108:3-14 (97 ref.)

The effects of flumazenil in neuropsychiatric disorders. Malizia AL, et al. **Clin Neuropharmacol** 1995 Jun; 18(3):215-32 (134 ref.)

GABAergic deafferentation hypothesis of brain aging and Alzheimer's disease; pharmacologic profile of the benzodiazepine antagonist, flumazenil. Marczynski TJ. **Rev Neurosci** 1995 Jul-Sep;6(3):221-58 (164 ref.)

THERAPEUTIC USE

The role of flumazenil in the critically ill. Park GR, et al. **Acta Anaesthesiol Scand Suppl** 1995;108:23-34 (120 ref.)

FLUMAZEPIL see **FLUMAZENIL**

FLUON see **POLYTETRAFLUOROETHYLENE**

FLUOREN-2-YLACETAMIDE see **2-ACETYLAMINOFLUORENE**

FLUORESCEIN ANGIOGRAPHY

Indocyanine green angiography. Can it help preserve the vision of our patients? [editorial; comment] Bressler NM, et al. **Arch Ophthalmol** 1996 Jun;114(6):747-9 (30 ref.) Comment on: Arch Ophthalmol 1996 Jun;114(6):693-7.

Indocyanine green angiography. Lim JI, et al. **Int Ophthalmol Clin** 1995 Fall;35(4):59-70 (49 ref.)

FLUORESCENCE-ACTIVATED CELL SORTING see **FLOW CYTOMETRY**

FLUORESCENCE ANGIOGRAPHY see **FLUORESCEIN ANGIOGRAPHY**

FLUORESCENCE MICROSCOPY see **MICROSCOPY, FLUORESCENCE**

FLUORESCENCE SPECTROPHOTOMETRY see **SPECTROMETRY, FLUORESCENCE**

FLUORESCENCE SPECTROSCOPY see **SPECTROMETRY, FLUORESCENCE**

FLUORESCENT ANTINUCLEAR ANTIBODIES see **ANTIBODIES, ANTINUCLEAR**

FLUORESCENT DYES

Slow fluorescent indicators of membrane potential: a survey of different approaches to probe response analysis. Plášek J, et al. **J Photochem Photobiol B** 1996 Apr;33(2):101-24 (206 ref.)

Effect of metal ions on the fluorescence of dyes bound to DNA. Bregadze VG, et al. **Met Ions Biol Syst** 1996; 33:253-67 (20 ref.)

CHEMICAL SYNTHESIS

[New fluorogenic dienophile: synthesis, reaction with vitamin D, vitamin A and microcystins, and application to fluorometric assays] Shimizu M, et al. **Yakugaku Zasshi** 1995 Aug;115(8):584-602 (67 ref.) (Eng. Abstr.) **(Jpn)**

CHEMISTRY

DAPI: a DNA-specific fluorescent probe. Kapuscinski J. **Biotech Histochem** 1995 Sep;70(5):220-33 (184 ref.)

Fluorophore-assisted carbohydrate electrophoresis in the separation, analysis, and sequencing of carbohydrates. Starr CM, et al. **J Chromatogr A** 1996 Jan 12;720(1-2):295-321 (42 ref.)

DIAGNOSTIC USE

Use of voltage-sensitive dyes and optical recordings in the central nervous system. Ebner TJ, et al. **Prog Neurobiol** 1995 Aug;46(5):463-506 (242 ref.)

METABOLISM

Detecting enzymatic activity in cells using fluorogenic substrates. Haugland RP. **Biotech Histochem** 1995 Sep; 70(5):243-51 (17 ref.)

FLUORESCENT IN SITU HYBRIDIZATION see **IN SITU HYBRIDIZATION, FLUORESCENCE**

FLUORESCENT PROBES see **FLUORESCENT DYES**

FLUORIDATION

Water fluoridation, bone density and hip fractures: a review of recent literature. Raheb J. **Community Dent Oral Epidemiol** 1995 Oct;23(5):309-16 (49 ref.)

METHODS

Should we use milk fluoridation? A review. Mariño R. **Bull Pan Am Health Organ** 1995 Dec;29(4):287-98 (71 ref.)

FLUORIDE POISONING

[Progresses in endemiology in China, 1995] Wang Z, et al. **Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):764–5 (0 ref.) **(Chi)**

PATHOLOGY

[Advances in pathology of 5 endemic diseases in China] Wang F, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1995 Aug;24(4):252–4 (20 ref.) **(Chi)**

PREVENTION & CONTROL

[The fluorosis problem in Senegal: data evaluation and presentation of a new method for defluoridating the water supply] Pontié M, et al. **Sante** 1996 Jan–Feb;6(1):27–36 (44 ref.) (Eng. Abstr.) **(Fre)**

FLUORIDES

[The formulation of glass ionomers and their degree of fluoride] De Moor R. **Rev Belge Med Dent** 1996;51(3):9–21 (33 ref.) (Eng. Abstr.) **(Fre)**

[Cariostatic mechanisms of fluoride and its effects on human beings] Sato T, et al. **Nippon Rinsho** 1996 Jan;54(1):67–72 (11 ref.) (Eng. Abstr.) **(Jpn)**

ADMINISTRATION & DOSAGE

What is the effective concentration of fluoride? Ismail AI. **Community Dent Oral Epidemiol** 1995 Aug;23(4):246–51 (51 ref.)

The role of fluoride toothpastes in the prevention of dental caries. Bowen WH. **J R Soc Med** 1995 Sep;88(9):505–7 (16 ref.)

CHEMISTRY

[Evaluation of long–term release of fluoride by type II glass ionomer cements with a conventional hardening reaction] De Moor R, et al. **Rev Belge Med Dent** 1996;51(3):22–35 (38 ref.) (Eng. Abstr.) **(Fre)**

PHARMACOLOGY

Antimicrobial actions of fluoride for oral bacteria. Marquis RE. **Can J Microbiol** 1995 Nov;41(11):955–64 (92 ref.)

Fluoride and the skeleton. Kleerekoper M. **Crit Rev Clin Lab Sci** 1996 Apr;33(2):139–61 (81 ref.)

TOXICITY

[Nephrotoxicity and fluoride from the viewpoint of the nephrologist] Bosch T. **Anaesthesist** 1996 Feb;45 Suppl 1:S41–5 (28 ref.) (Eng. Abstr.) **(Ger)**

[Fluoride–induced nephrotoxicity: factor fiction?] Nuscheler M, et al. **Anaesthesist** 1996 Feb;45 Suppl 1:S32–40 (54 ref.) (Eng. Abstr.) **(Ger)**

FLUORIMETRY see **FLUOROMETRY**

FLUORINATED HYDROCARBONS see **HYDROCARBONS, FLUORINATED**

FLUORINE RADIOISOTOPES

DIAGNOSTIC USE

FDG uptake within regionally stunned myocardium. McFalls EO, et al. **Am J Card Imaging** 1995 Oct;9(4):269–74 (30 ref.)

Fluorine–18–fluorodeoxyglucose PET to determine regional cerebral glucose utilization: a re–examination. Schmidt KC, et al. **J Nucl Med** 1996 Feb;37(2):394–9 (42 ref.)

Iodine–123–labeled glucose analogs: prospects for a single–photon–emitting analog of fluorine–18–labeled deoxyglucose [editorial; comment] Gatley SJ. **Nucl Med Biol** 1995 Oct;22(7):829–35 (49 ref.) Comment on: Nucl Med Biol 1995 Oct;22(7):875–85.

FLUOROCARBON AEROSOLS see **FREONS**

FLUOROCARBON EMULSIONS see **FLUOROCARBONS**

FLUOROCARBON PROPELLANTS see **FREONS**

FLUOROCARBONS

see related

BLOOD SUBSTITUTES

Perfluorocarbon heavy liquids. Bourke RD, et al. **Aust N Z J Ophthalmol** 1995 Aug;23(3):165–71 (40 ref.)

[Organization of mobile structures in the blood stream—basis for the function of perfluorocarbon "artificial blood"] Ivanitskii GR, et al. **Biofizika** 1996 Jan–Feb;41(1):178–90 (47 ref.) (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

Several methods utilized for the assessment of biocompatibility of perfluorochemicals. Lutz J, et al. **Artif Cells Blood Substit Immobil Biotechnol** 1995; 23(3):407–15 (30 ref.)

PHARMACOLOGY

Perfluorocarbon emulsions and cardiopulmonary bypass: a technique for the future. Spiess BD, et al. **J Cardiothorac Vasc Anesth** 1996 Jan;10(1):83–89; quiz 89–90 (65 ref.)

THERAPEUTIC USE

Use of Oxygent, a perfluorochemical–based oxygen carrier, as an alternative to intraoperative blood transfusion. Keipert PE. **Artif Cells Blood Substit Immobil Biotechnol** 1995; 23(3):381–94 (29 ref.)

Perfluorocarbons in the twenty–first century: clinical applications as transfusion alternatives. Spence RK. **Artif Cells Blood Substit Immobil Biotechnol** 1995; 23(3):367–80 (35 ref.)

Perfluorochemical liquid ventilation: from the animal laboratory to the intensive care unit. Degraeuwe PL, et al. **Int J Artif Organs** 1995 Oct;18(10):674–83 (92 ref.)

TOXICITY

Toxicology of chlorofluorocarbon replacements. Dekant W. **Environ Health Perspect** 1996 Mar;104 Suppl 1:75–83 (78 ref.)

FLUOROCHLOROXACILLIN see **FLOXACILLIN**

FLUOROCHROMES see **FLUORESCENT DYES**

FLUORODEOXYURIDINE see **FLOXURIDINE**

FLUOROFUR see **TEGAFUR**

FLUOROMETRY

[The assay of enzyme activity in EIA—colorimetric, fluorometric and luminometric method] Maeda M. **Nippon Rinsho** 1995 Sep;53(9):2198–202 (16 ref.) (Eng. Abstr.) **(Jpn)**

[New fluorogenic dienophile: synthesis, reaction with vitamin D, vitamin A and microcystins, and application to fluorometric assays] Shimizu M, et al. **Yakugaku Zasshi** 1995 Aug;115(8):584–602 (67 ref.) (Eng. Abstr.) **(Jpn)**

P-FLUOROPHENYLALANINE

PHARMACOLOGY

Identification of new drug targets in Mycobacterium avium and Mycobacterium tuberculosis. Rastogi N, et al. **Res Microbiol** 1996 Jan–Feb;147(1–2):97–105 (36 ref.)

FLUOROQUINOLONE ANTI-INFECTIVE AGENTS see **ANTI-INFECTIVE AGENTS, FLUOROQUINOLONE**

FLUOROSCOPY

INSTRUMENTATION

[Videocinematography of swallowing. Indications, methodology and findings] Pokieser P, et al. **Radiologe** 1995 Oct;35(10):703–11 (9 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Fluoroscopically guided percutaneous gastrostomy: current status. McLoughlin RF, et al. **Can Assoc Radiol J** 1996 Feb;47(1):10–5 (54 ref.)

FLUOROSIS, DENTAL see **MOTTLED ENAMEL**

FLUOROURACIL

ADMINISTRATION & DOSAGE

Locoregional chemotherapy for adjuvant treatment of colorectal adenocarcinoma. Penna C, et al. **Eur J Cancer** 1996 Jun;32A(7):1117–22 (47 ref.)

Bolus mitomycin C and 5–FU with sequential radiation for poor–prognosis locally advanced cervical cancer. Denehy TR, et al. **Gynecol Oncol** 1996 Jan;60(1):64–71 (21 ref.)

Preoperative chemoradiation for adenocarcinoma of the pancreas: excessive toxicity of prophylactic hepatic irradiation [see comments] Evans DB, et al. **Int J Radiat Oncol Biol Phys** 1995 Nov 1;33(4):913–8 (35 ref.) Comment in: Int J Radiat Oncol Biol Phys 1995 Nov 1;33(4):969–70.

ADVERSE EFFECTS

Punctal and canalicular stenosis associated with systemic fluorouracil therapy. Report of five cases and review of the literature. Brink HM, et al. **Doc Ophthalmol** 1995; 90(1):1–6 (23 ref.)

[Severe 5–fluorouracil toxicity in a woman treated for breast cancer with concurrent osteogenesis imperfecta and dehydrogenase deficiency] Beuzeboc P, et al. **Bull Cancer (Paris)** 1996 Apr;83(4):324–7 (24 ref.) (Eng. Abstr.) **(Fre)**

ANALOGS & DERIVATIVES

Synthesis and antitumor activity of 5–fluorouracil derivatives. Ozaki S. **Med Res Rev** 1996 Jan;16(1):51–86 (55 ref.)

METABOLISM

Fluoropyrimidine catabolism. Diasio RB, et al. **Cancer Treat Res** 1995;78:71–93 (103 ref.)

PHARMACOLOGY

Aspects of one–carbon folate cycling related to fluoropyrimidine and antifolate therapy. Spears CP, et al. **Cancer Treat Res** 1995;78:115–34 (128 ref.)

The role of interferon–alpha as a modulator of fluorouracil and leucovorin. Grem JL, et al. **Eur J Cancer** 1995 Jul–Aug;31A(7–8):1316–20 (29 ref.)

Role of leucovorin dosing and administration schedule. Jolivet J. **Eur J Cancer** 1995 Jul–Aug;31A(7–8):1311–5 (52 ref.)

Thymidylate synthase and drug resistance. Peters GJ, et al. **Eur J Cancer** 1995 Jul–Aug;31A(7–8):1299–305 (41 ref.)

Modulation of 5–fluorouracil by interferon: a review of potential cellular targets. Horowitz R, et al. **Med Oncol** 1995 Mar;12(1):3–8 (48 ref.)

Synthesis and antitumor activity of 5–fluorouracil derivatives. Ozaki S. **Med Res Rev** 1996 Jan;16(1):51–86 (55 ref.)

Current status of radiation sensitization by fluoropyrimidines. Pu AT, et al. **Oncology (Huntingt)** 1995 Aug;9(8):707–14; discussion 714, 717–8, 721 (42 ref.)

THERAPEUTIC USE

Cancers of the large bowel and hepatobiliary tract. Vaughn DJ, et al. **Cancer Chemother Biol Response Modif** 1996; 16:495–510 (63 ref.)

Adjuvant radiation therapy for colon cancer. Minsky BD. **Cancer Treat Rev** 1995 Sep;21(5):407–14 (18 ref.)

5–fluorouracil plus radiation for head and neck cancer. Stupp R, et al. **J Infus Chemother** 1995 Spring;5(2):55–60 (65 ref.)

Biochemical modulation of fluoropyrimidines: is there an optimal (6R,S) leucovorin dose and schedule? [editorial; comment] Doroshow JH. **J Natl Cancer Inst** 1996 Apr 3; 88(7):393–5 (24 ref.) Comment on: J Natl Cancer Inst 1996 Apr 3;88(7):430–6.

Prognostic variable in patients with advanced colorectal cancer treated with fluorouracil and leucovorin–based chemotherapy. Fountzilas G, et al. **Med Pediatr Oncol** 1996 May;26(5):305–17 (45 ref.)

Trabeculectomy with intraoperative sponge 5–fluorouracil. Mora JS, et al. **Ophthalmology** 1996 Jun;103(6):963–70 (28 ref.)

[Use of 5–fluorouracil in digestive cancer] Setiz JF, et al. **Gastroenterol Clin Biol** 1996;20(5 Pt 2):B80–88 (68 ref.) **(Fre)**

[Factors of the therapeutic effectiveness of 5–fluorouracil] Manziuk LV, et al. **Vopr Onkol** 1996;42(2):31–6 (33 ref.) **(Rus)**

TOXICITY

Biological modeling of 5–fluorouracil developmental toxicity. Shuey DL, et al. **Toxicology** 1995 Sep 1;102(1–2):207–13 (23 ref.)

FLUOXETINE

THERAPEUTIC USE

Does intolerance or lack of response with fluoxetine predict the same will happen with sertraline? Zarate CA, et al. **J Clin Psychiatry** 1996 Feb;57(2):67–71 (23 ref.)

FLUSHING

CHEMICALLY INDUCED

[Hot flashes and hormonal treatment of prostate cancer] Lanfrey P, et al. **Prog Urol** 1996 Feb;6(1):17–22 (31 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

[Hot flushes in men after surgical or pharmacologic castration] Aubert J, et al. **Prog Urol** 1995 Sep;5(4):507–9 (13 ref.) (Eng. Abstr.) **(Fre)**

FLUVOXAMINE

PHARMACOKINETICS

Overview of the pharmacokinetics of fluvoxamine. van Harten J. **Clin Pharmacokinet** 1995;29 Suppl 1:1–9 (49 ref.)

PHARMACOLOGY

Drug interactions and the cytochrome P450 system. The role of cytochrome P450 1A2. Brøsen K. **Clin Pharmacokinet** 1995;29 Suppl 1:20–5 (20 ref.)

Fluvoxamine. A review of global drug–drug interaction data. Wagner W, et al. **Clin Pharmacokinet** 1995;29 Suppl 1:26–31; discussion 31–2 (23 ref.)

THERAPEUTIC USE

New antidepressants. Kupecz D. **Nurse Pract** 1995 Sep; 20(9):64–7 (18 ref.)

FOAM CELLS

METABOLISM

Targeting lipoproteins to Fc gamma receptors with bispecific antibodies. Morganelli PM. **J Hematother** 1995 Oct; 4(5):457–61 (19 ref.)

PATHOLOGY

LDL-platelet interaction under oxidative stress induces macrophage foam cell formation. Aviram M. **Thromb Haemost** 1995 Jul;74(1):560–4 (41 ref.)

FOAMY VIRUS see **SPUMAVIRUS**

FOCAL INFECTION

ETIOLOGY

Catheter sepsis: the central venous line Achilles' heel. Wiener ES. **Semin Pediatr Surg** 1995 Nov;4(4):207–14 (56 ref.)

FOCAL INFECTION, DENTAL

COMPLICATIONS

Cerebral abscess complicating dental treatment. Case report and review of the literature. Renton TF, et al. **Aust Dent J** 1996 Feb;41(1):12–5 (32 ref.)

[Odontogenic sinusitis with cutaneous fistulization. A case report] Garbarino R, et al. **Minerva Stomatol** 1995 Jun; 44(6):319–23 (18 ref.) (Eng. Abstr.) **(Ita)**

FOCUS GROUPS

Using focus groups in general practice research. Barbour RS. **Fam Pract** 1995 Sep;12(3):328–34 (31 ref.)

Using focus groups in drug abuse and HIV/AIDS research. Shedlin MG, et al. **NIDA Res Monogr** 1995;157:136–55 (13 ref.)

FOGARTY BALLOON CATHETERIZATION see **BALLOON DILATATION**

FOLEY BALLOON CATHETERIZATION see **BALLOON DILATATION**

FOLIC ACID

Folate requirements for health in different population groups. McNulty H. **Br J Biomed Sci** 1995 Jun;52(2):110–9 (75 ref.)

Vitamin B12 deficiency and the fortification of food with folic acid. Bower C, et al. **Eur J Clin Nutr** 1995 Nov; 49(11):787–93 (34 ref.)

ADMINISTRATION & DOSAGE

What practitioners need to know about folic acid. Hine RJ. **J Am Diet Assoc** 1996 May;96(5):451–2 (15 ref.)

Fortification of the food supply with folic acid to prevent neural tube defects is not yet warranted. Gaull GE, et al. **J Nutr** 1996 Mar;126(3):773S–780S (48 ref.)

More folic acid for everyone, now. Oakley GP Jr, et al. **J Nutr** 1996 Mar;126(3):751S–755S (18 ref.)

A food industry perspective on folic acid fortification. Schaller DR, et al. **J Nutr** 1996 Mar;126(3):761S–764S (9 ref.)

The challenge of regulating health claims and food fortification. Yetley EA, et al. **J Nutr** 1996 Mar; 126(3):765S–772S (19 ref.)

Folate and neural tube defects. Bower C. **Nutr Rev** 1995 Sep;53(9 Pt 2):S33–8 (39 ref.)

Periconceptional folic acid supplementation as a social intervention. Rose NC, et al. **Semin Perinatol** 1995 Aug; 19(4):243–54 (61 ref.)

[Prevention of neural tube defects by preconception administration of folic acid. Presentation of the current status of research] Hages M, et al. **Geburtshilfe Frauenheilkd** 1996 May;56(5):M59–65 (57 ref.) **(Ger)**

ADVERSE EFFECTS

How safe are folic acid supplements? Campbell NR. **Arch Intern Med** 1996 Aug 12–26;156(15):1638–44 (108 ref.)

BLOOD

Blood folic acid and vitamin B12 in relation to neural tube defects. Wald NJ, et al. **Br J Obstet Gynaecol** 1996 Apr; 103(4):319–24 (16 ref.)

Molecular genetic aspects of hyperhomocysteinemia and its relation to folic acid. Rozen R. **Clin Invest Med** 1996 Jun; 19(3):171–8 (18 ref.)

[Folic acid] Wada Y. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:726–30 (12 ref.) **(Jpn)**

METABOLISM

Nutritional ecogenetics: homocysteine-related arteriosclerotic vascular disease, neural tube defects, and folic acid [editorial; comment] Motulsky AG. **Am J Hum Genet** 1996 Jan;58(1):17–20 (28 ref.) Comment on: Am J Hum Genet 1996 Jan;58(1):35–41.

Congenital errors of folate metabolism. Zittoun J. **Baillieres Clin Haematol** 1995 Sep;8(3):603–16 (51 ref.)

Folate metabolism and neural tube defects. Gordon N. **Brain Dev** 1995 Sep–Oct;17(5):307–11 (44 ref.)

Aspects of one-carbon folate cycling related to fluoropyrimidine and antifolate therapy. Spears CP, et al. **Cancer Treat Res** 1995;78:115–34 (128 ref.)

Folate metabolism and neural tube defects: a review. Steegers-Theunissen RP. **Eur J Obstet Gynecol Reprod Biol** 1995 Jul;61(1):39–48 (65 ref.)

Symposium on the subcellular compartmentation of folate metabolism. Wagner C. **J Nutr** 1996 Apr;126(4 Suppl):1228S–34S (30 ref.)

[The folic acid requirement and metabolism] Müller HE. **Dtsch Med Wochenschr** 1995 Sep 22;120(38):1285–9 (21 ref.) **(Ger)**

PHARMACOLOGY

Phenytoin–folic acid interaction [see comments] Lewis DP, et al. **Ann Pharmacother** 1995 Jul–Aug;29(7–8):726–35 (65 ref.) Comment in: Ann Pharmacother 1995 Dec;29(12):1303–4.

PHYSIOLOGY

Folate metabolism and neural tube defects: a review. Steegers-Theunissen RP. **Eur J Obstet Gynecol Reprod Biol** 1995 Jul;61(1):39–48 (65 ref.)

THERAPEUTIC USE

Nutritional ecogenetics: homocysteine-related arteriosclerotic vascular disease, neural tube defects, and folic acid [editorial; comment] Motulsky AG. **Am J Hum Genet** 1996 Jan;58(1):17–20 (28 ref.) Comment on: Am J Hum Genet 1996 Jan;58(1):35–41.

Folic acid and the prevention of neural tube defects: the need for public health action. Wald NJ. **Bibl Nutr Dieta** 1995; (52):56–65 (14 ref.)

Folate supplementation and methotrexate. Dijkmans BA. **Br J Rheumatol** 1995 Dec;34(12):1172–4 (22 ref.)

Periconceptional folic acid and neural tube defects: public health issues. Pérez-Escamilla R. **Bull Pan Am Health Organ** 1995 Sep;29(3):250–63 (70 ref.)

Periconceptional folate intake and neural tube defects. Rayburn WF, et al. **J Am Coll Nutr** 1996 Apr;15(2):121–5 (32 ref.)

Congenital defects, folic-acid, and homoeobox genes. Milunsky A. **Lancet** 1996 Aug 17;348(9025):419–20 (8 ref.)

Folic acid as a cancer-preventing agent. Jennings E. **Med Hypotheses** 1995 Sep;45(3):297–303 (60 ref.)

[Folic acid in the prevention of neural tube defects] Tönz O, et al. **Schweiz Med Wochenschr** 1996 Feb 3;126(5):177–87 (60 ref.) (Eng. Abstr.) **(Ger)**

FOLIC ACID ANTAGONISTS

see related
ANTIMETABOLITES
ANTIMETABOLITES, ANTINEOPLASTIC

PHARMACOLOGY

Folate-based thymidylate synthase inhibitors as anticancer drugs. Jackman AL, et al. **Ann Oncol** 1995 Nov;6(9):871–81 (84 ref.)

Aspects of one-carbon folate cycling related to fluoropyrimidine and antifolate therapy. Spears CP, et al. **Cancer Treat Res** 1995;78:115–34 (128 ref.)

Brodimoprim, a new bacterial dihydrofolate reductase inhibitor: a minireview. Periti P. **J Chemother** 1995 Jun; 7(3):221–3 (22 ref.)

THERAPEUTIC USE

Medical management should be routinely used as primary therapy for ectopic pregnancy. Stovall TG. **Clin Obstet Gynecol** 1995 Jun;38(2):346–52 (28 ref.)

Methotrexate for nonsurgical treatment of ectopic pregnancy: nursing implications. Maiolatesi CR, et al. **J Obstet Gynecol Neonatal Nurs** 1996 Mar–Apr;25(3):205–8 (16 ref.)

[Role of conservative therapy and medical treatment in ectopic pregnancy: literature review and clinical trial comparing medical treatment and conservative laparoscopic treatment] Fernandez H, et al. **Contracept Fertil Sex** 1996 Apr;24(4):297–302 (36 ref.) (Eng. Abstr.) **(Fre)**

[Current indications for medical treatment of ectopic pregnancy] Darai E, et al. **Rev Fr Gynecol Obstet** 1995 Dec;90(12):552–7 (41 ref.) (Eng. Abstr.) **(Fre)**

[Use of methotrexate in spondylarthropathies. Review of the literature] Toussirot E, et al. **Rev Med Interne** 1996; 17(4):333–9 (40 ref.) (Eng. Abstr.) **(Fre)**

TOXICITY

Inhibitors of thymine nucleotide biosynthesis: antimetabolites that provoke genetic change via primary non-DNA targets. Kunz BA. **Mutat Res** 1996 Aug 17;355(1–2):129–40 (135 ref.)

Toxicity prediction from metabolic pathway modelling. Jackson RC. **Toxicology** 1995 Sep 1;102(1–2):197–205 (23 ref.)

FOLIC ACID DEFICIENCY

see related
ANEMIA, SIDEROBLASTIC

COMPLICATIONS

[Folate deficiency, cancer and congenital abnormalities. Is there a connection?] Christensen B. **Tidsskr Nor Laegeforen** 1996 Jan 20;116(2):250–4 (45 ref.) (Eng. Abstr.) **(Nor)**

EMBRYOLOGY

Effects of folate deficiency on embryonic development. Christensen B, et al. **Baillieres Clin Haematol** 1995 Sep; 8(3):617–37 (133 ref.)

GENETICS

DNA damage in folate deficiency. Blount BC, et al. **Baillieres Clin Haematol** 1995 Sep;8(3):461–78 (75 ref.)

METABOLISM

Metabolite assays in cobalamin and folate deficiency. Green R. **Baillieres Clin Haematol** 1995 Sep;8(3):533–66 (161 ref.)

PATHOLOGY

Morphology, biology and biochemistry of cobalamin- and folate-deficient bone marrow cells. Wickramasinghe SN. **Baillieres Clin Haematol** 1995 Sep;8(3):441–59 (70 ref.)

PHYSIOPATHOLOGY

Cobalamin and folate deficiency in the elderly. Matthews JH. **Baillieres Clin Haematol** 1995 Sep;8(3):679–97 (96 ref.)

Folate, epithelial dysplasia and colon cancer. Kim Y, et al. **Proc Assoc Am Physicians** 1995 Jul;107(2):218–27 (81 ref.)

FOLIC ACID REDUCTASE see **TETRAHYDROFOLATE DEHYDROGENASE**

FOLIE A DEUX see **SHARED PARANOID DISORDER**

FOLINIC ACID see **LEUCOVORIN**

FOLK MEDICINE see **MEDICINE, TRADITIONAL**

FOLK REMEDIES see **MEDICINE, TRADITIONAL**

FOLLICLE-STIMULATING HORMONE see **FSH**

FOLLICLE-STIMULATING HORMONE, ALPHA SUBUNIT see **GLYCOPROTEIN HORMONES, ALPHA SUBUNIT**

FOLLICLE-STIMULATING HORMONE RECEPTORS see **RECEPTORS, FSH**

FOLLICULAR ATRESIA

PHYSIOLOGY

Ovarian follicular growth, ovulation and atresia. Endocrine, paracrine and autocrine regulation. Moley KH, et al. **Adv Exp Med Biol** 1995;377:103–19 (105 ref.)

Ovulation as a tissue remodelling process. Proteolysis and cumulus expansion. Tsafriri A. **Adv Exp Med Biol** 1995; 377:121–40 (191 ref.)

Follicular atresia in pigs: measurement and physiology. Guthrie HD, et al. **J Anim Sci** 1995 Sep;73(9):2834–44 (47 ref.)

FOLLICULAR PHASE

Follicular phase length, cycle day of conception and sex ratio of offspring. James WH. **Hum Reprod** 1995 Oct; 10(10):2529–31 (39 ref.)

DRUG EFFECTS

Gonadotrophin surge-inhibiting/attenuating factor governs luteinizing hormone secretion during the ovarian cycle: physiology and pathology. de Koning J. **Hum Reprod** 1995 Nov;10(11):2854–61 (86 ref.)

PHYSIOLOGY

Gonadotrophin surge-inhibiting/attenuating factor governs luteinizing hormone secretion during the ovarian cycle: physiology and pathology. de Koning J. **Hum Reprod** 1995 Nov;10(11):2854–61 (86 ref.)

FOLLICULITIS

PATHOLOGY

HIV-associated eosinophilic folliculitis: case report and review of the literature. Basarab T, et al. **Br J Dermatol** 1996 Mar;134(3):499–503 (16 ref.)

FOLLICULOSTATIN see **INHIBIN**

FONTAN OPERATION

FONTAN OPERATION see **FONTAN PROCEDURE**

FONTAN PROCEDURE

Late conduit occlusion after modified Fontan procedure with classic Glenn shunt. Koutlas TC, et al.
Ann Thorac Surg 1996 Jul;62(1):258–61; discussion 261–2 (8 ref.)

[Normal pregnancy duration after maternal Fontan operation of univentricular heart] Osmers R, et al.
Z Geburtshilfe Neonatol 1995 Sep–Oct;199(5):195–8 (15 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

[Right atrial thrombosis; an unusual late complication of the Fontan procedure. Apropos of a case] Soyer R, et al.
Arch Mal Coeur Vaiss 1995 Mar;88(3):391–5 (14 ref.) (Eng. Abstr.) **(Fre)**

FOOD

see related
DIET
PLANTS, EDIBLE

The rheology of semiliquid foods. Barbosa-Cánovas GV, et al. **Adv Food Nutr Res** 1996;39:1–69 (143 ref.)

Interaction between nutrients, pro-inflammatory cytokines and inflammation [editorial] Grimble RF.
Clin Sci (Colch) 1996 Aug;91(2):121–30 (102 ref.)

Mechanisms for controlling enzymatic reactions in foods. Ashie IN, et al. **Crit Rev Food Sci Nutr** 1996 Jan; 36(1–2):1–30 (203 ref.)

Fish flavor. Kawai T. **Crit Rev Food Sci Nutr** 1996 Feb; 36(3):257–98 (127 ref.)

On modeling changes in food and biosolids at and around their glass transition temperature range. Peleg M.
Crit Rev Food Sci Nutr 1996 Jan;36(1–2):49–67 (37 ref.)

Nonenzymatic deamidation of food proteins. Riha WE 3rd, et al. **Crit Rev Food Sci Nutr** 1996 Feb;36(3):225–55 (102 ref.)

Lipid oxidation on foods. St Angelo AJ.
Crit Rev Food Sci Nutr 1996 Feb;36(3):175–224 (324 ref.)

Dietary modifiers of carcinogenesis. Kohlmeier L, et al.
Environ Health Perspect 1995 Nov;103 Suppl 8:177–84 (78 ref.)

A fertility diet for planning pregnancy. Wynn M, et al.
Nutr Health 1995;10(3):219–38 (50 ref.)

[Food-dependent Cushing syndrome: a new entity of organic hypercorticism] Matejka G, et al. **Rev Med Interne** 1996; 17(6):461–6 (23 ref.) (Eng. Abstr.) **(Fre)**

ADVERSE EFFECTS

Allergenic cross-reactivity of foods and characterization of food allergens and extracts. Bernhisel-Broadbent J.
Ann Allergy Asthma Immunol 1995 Oct;75(4):295–303; quiz 304–7 (80 ref.)

IgE-mediated (and food-induced) intestinal disease. Strobel S. **Clin Exp Allergy** 1995 Jul;25 Suppl 1:3–6 (61 ref.)

Food intolerance and asthma. Warner JO.
Clin Exp Allergy 1995 Jul;25 Suppl 1:29–30 (10 ref.)

Food intolerance and allergy. Pace V. **Panminerva Med** 1995 Jun;37(2):84–91 (11 ref.)

The food-derived heterocyclic amines and breast cancer: a 1995 perspective. Synderwine EG.
Recent Results Cancer Res 1996;140:17–25 (54 ref.)

Assessment of novel foods: a call for a new and broader GRAS concept. Knudsen I, et al.
Regul Toxicol Pharmacol 1995 Jun;21(3):365–9 (18 ref.)

CLASSIFICATION

International tables of glycemic index. Foster-Powell K, et al. **Am J Clin Nutr** 1995 Oct;62(4):871S–890S (79 ref.)

STANDARDS

Position of the American Dietetic Association: food irradiation. **J Am Diet Assoc** 1996 Jan;96(1):69–72 (27 ref.)

STATISTICS & NUMERICAL DATA

Food sampling strategies for energy intake estimates. Holden JM. **Am J Clin Nutr** 1995 Nov;62(5 Suppl):1151S–1157S (31 ref.)

TOXICITY

Assessment of novel foods: a call for a new and broader GRAS concept. Knudsen I, et al.
Regul Toxicol Pharmacol 1995 Jun;21(3):365–9 (18 ref.)

FOOD ADDITIVES

Nutrition labeling: energy values of foods and fat substitutes. Wiesenfeld PL. **Am J Clin Nutr** 1995 Nov;62(5 Suppl):1143S–1146S (21 ref.)

Making regulatory decisions across the food ingredient spectrum. Rulis AM. **Drug Metab Rev** 1996 Feb–May; 28(1–2):197–208 (8 ref.)

Evaluation of the safety of sodium pectate as a food ingredient. Borzelleca JF, et al. **Food Chem Toxicol** 1996 Jan;34(1):21–5 (18 ref.)

Threshold of estimated toxicity for regulation of indirect food additives. Matthews EJ, et al. **Toxicol Lett** 1995 Sep; 79(1–3):123–9 (26 ref.)

ADMINISTRATION & DOSAGE

Chemoprevention of colon cancer by minor dietary constituents and their synthetic analogues. Reddy BS.
Prev Med 1996 Jan–Feb;25(1):48–50 (13 ref.)

ADVERSE EFFECTS

Reactions to food additives. Lessof MH.
Clin Exp Allergy 1995 Jul;25 Suppl 1:27–8 (19 ref.)

Capsaicin in hot chili pepper: carcinogen, co-carcinogen or anticarcinogen? Surh YJ, et al. **Food Chem Toxicol** 1996 Mar;34(3):313–6 (48 ref.)

Information needed to support hazard identification and risk assessment of toxic substances. Scheuplein RJ.
Toxicol Lett 1995 Sep;79(1–3):23–8 (0 ref.)

ANALYSIS

[Detection of food additives by enzyme immunoassay] Yoshida A, et al. **Nippon Rinsho** 1995 Sep;53(9):2316–21 (13 ref.) (Eng. Abstr.) **(Jpn)**

STANDARDS

Risk assessment of carcinogens in food with special consideration of non-genotoxic carcinogens. Scientific arguments for use of risk assessment and for changing the Delaney Clause specifically. Williams GM, et al.
Exp Toxicol Pathol 1996 Feb;48(2–3):209–15 (21 ref.)

FEMA GRAS—a GRAS assessment program for flavor ingredients. Flavor and Extract Manufacturers Association. Hallagan JB, et al. **Regul Toxicol Pharmacol** 1995 Jun; 21(3):422–30 (12 ref.)

TOXICITY

Safety evaluation of beta-glucanase derived from Trichoderma reesei: summary of toxicological data. Coenen TM, et al. **Food Chem Toxicol** 1995 Oct;33(10):859–66 (24 ref.)

Limonene. Von Burg R. **J Appl Toxicol** 1995 Nov–Dec; 15(6):495–9 (65 ref.)

Variable responses of species and strains to white mineral oils and paraffin waxes. Miller MJ, et al.
Regul Toxicol Pharmacol 1996 Feb;23(1 Pt 1):55–68 (78 ref.)

FOOD ADULTERATION see **FOOD CONTAMINATION**

FOOD ALLERGY see **FOOD HYPERSENSITIVITY**

FOOD ANALYSIS

Antioxidant agents in raw materials and processed foods. Eriksson CE, et al. **Biochem Soc Symp** 1995;61:221–34 (106 ref.)

Trace element food toxicology: an old and ever-growing discipline. Ybañez N, et al. **Crit Rev Food Sci Nutr** 1996 Apr;36(4):299–320 (87 ref.)

Accreditation in the UK for pesticide residue analysis in foods. Thorpe SA, et al. **J Chromatogr A** 1996 Jun 14; 737(1):3–7 (4 ref.)

BCR- and M&T-activities in the area of mycotoxin analysis in food and feedstuffs. Boenke A. **Nat Toxins** 1995; 3(4):243–7; discussion 280 (10 ref.)

Keeping the mycotoxins out: experience gathered by an international food company. Pittet A. **Nat Toxins** 1995; 3(4):281–7; discussion 317 (26 ref.)

[Biogenic amines in food] Crahay F, et al.
Rev Med Liege 1996 Jul;51(7):479–84 (23 ref.) **(Fre)**

METHODS

Dietary fibre analysis--an overview. Asp NG.
Eur J Clin Nutr 1995 Oct;49 Suppl 3:S42–7 (32 ref.)

In vitro studies to predict physiological effects of dietary fibre. Brighenti F, et al. **Eur J Clin Nutr** 1995 Oct;49 Suppl 3:S81–8 (38 ref.)

Definition and measurement of dietary fibre. Englyst HN, et al. **Eur J Clin Nutr** 1995 Oct;49 Suppl 3:S48–62 (38 ref.)

Dietary fibre analysis: methodological error sources. Mañas E, et al. **Eur J Clin Nutr** 1995 Oct;49 Suppl 3:S158–62 (22 ref.)

[Enzyme immunoassay of pesticide residues in foods] Nishijima M. **Nippon Rinsho** 1995 Sep;53(9):2310–5 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Detection of food additives by enzyme immunoassay] Yoshida A, et al. **Nippon Rinsho** 1995 Sep;53(9):2316–21 (13 ref.) (Eng. Abstr.) **(Jpn)**

STANDARDS

Making regulatory decisions across the food ingredient spectrum. Rulis AM. **Drug Metab Rev** 1996 Feb–May; 28(1–2):197–208 (8 ref.)

Swedish pesticide risk reduction 1981–1995: food residues, health hazard, and reported poisonings. Ekström G, et al.
Rev Environ Contam Toxicol 1996;147:119–47 (67 ref.)

FOOD AND DRUG ADMINISTRATION (U.S.) see **UNITED STATES FOOD AND DRUG ADMINISTRATION**

FOOD, CANNED see **FOOD PRESERVATION**

FOOD CONTAINERS see **FOOD PACKAGING**

FOOD CONTAMINATION

Foodborne and waterborne illness in children. Rivera-Matos IR, et al. **Adv Pediatr Infect Dis** 1996;11:101–34 (112 ref.)

Evaluating the impact of exposure to environmental contaminants on human health. Silkworth JB, et al.
Clin Chem 1996 Aug;42(8 Pt 2):1345–9 (34 ref.)

Cyanide detoxification in cassava for food and feed uses. Padmaja G. **Crit Rev Food Sci Nutr** 1995 Jul;35(4):299–339 (133 ref.)

Age-specific carcinogenesis: environmental exposure and susceptibility. Thomas RD. **Environ Health Perspect** 1995 Sep;103 Suppl 6:45–8 (47 ref.)

Biogenic amines: their importance in foods. Silla Santos MH. **Int J Food Microbiol** 1996 Apr;29(2–3):213–31 (140 ref.)

Anti-nutritional factors of Datura in feedstuffs. Piva G, et al. **Nat Toxins** 1995;3(4):238–41; discussion 242 (24 ref.)

Validation of a methodology for modelling PCDD and PCDF intake via the foodchain. Eduljee GH, et al.
Sci Total Environ 1996 Sep 9;187(3):211–29 (36 ref.)

Health implications for Faroe islanders of heavy metals and PCBs from pilot whales. Weihe P, et al.
Sci Total Environ 1996 Jul 16;186(1–2):141–8 (37 ref.)

Information needed to support hazard identification and risk assessment of toxic substances. Scheuplein RJ.
Toxicol Lett 1995 Sep;79(1–3):23–8 (0 ref.)

Comparison of four human studies of perinatal exposure to methylmercury for use in risk assessment. Cicmanec JL.
Toxicology 1996 Jul 17;111(1–3):157–62 (11 ref.)

ANALYSIS

[Enzyme immunoassay of pesticide residues in foods] Nishijima M. **Nippon Rinsho** 1995 Sep;53(9):2310–5 (16 ref.) (Eng. Abstr.) **(Jpn)**

LEGISLATION & JURISPRUDENCE

[Adulteration of food and luxuries and the origins of uniform state food legislation in Germany] Teuteberg HJ.
Z Ernahrungswiss 1995 Jun;34(2):95–112 (192 ref.) (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

Evaluation of food safety. Urbanek-Karlowska B, et al.
Rocz Panstw Zakl Hig 1995;46(3):217–22 (8 ref.)

FOOD DEPRIVATION

see related
FASTING
STARVATION

Possible dietary measures in the prevention of pre-eclampsia and eclampsia. Baker PN.
Baillieres Clin Obstet Gynaecol 1995 Sep;9(3):497–507 (73 ref.)

The effects of overfeeding and moderate dietary restriction on Sprague-Dawley rat survival, pathology, carcinogenicity, and the toxicity of pharmaceutical agents. Keenan KP, et al. **Exp Toxicol Pathol** 1996 Feb; 48(2–3):139–44 (24 ref.)

PHYSIOLOGY

The effects of dietary restriction on drug testing and toxicity. Hart RW, et al. **Exp Toxicol Pathol** 1996 Feb;48(2–3):121–7 (33 ref.)

Psychological consequences of food restriction. Polivy J.
J Am Diet Assoc 1996 Jun;96(6):589–92; quiz 593–4 (48 ref.)

FOOD DIARIES see **DIET RECORDS**

FOOD, DRIED see **FOOD PRESERVATION**

FOOD, DRUG AND COSMETIC ACT see **LEGISLATION, DRUG**

FOOD-DRUG INTERACTIONS

Nutrient-drug interactions. D'Arcy PF.
Adverse Drug React Toxicol Rev 1995 Winter;14(4):233–54 (182 ref.)

Phenytoin-folic acid interaction [see comments] Lewis DP, et al. **Ann Pharmacother** 1995 Jul–Aug;29(7–8):726–35 (65 ref.) Comment in: Ann Pharmacother 1995 Dec;29(12):1303–4.

Dietary fibre: effect of processing and nutrient interactions. Carnovale E, et al. **Eur J Clin Nutr** 1995 Oct;49 Suppl 3:S307–11 (42 ref.)

Dietary fibre and drug interactions. Chiesara E, et al.
Eur J Clin Nutr 1995 Oct;49 Suppl 3:S123–8 (47 ref.)

The making of a user friendly MAOI diet. Gardner DM, et al. **J Clin Psychiatry** 1996 Mar;57(3):99–104 (53 ref.)

Drug-nutrient interactions. Thomas JA. **Nutr Rev** 1995 Oct; 53(10):271–82 (54 ref.)

[Monoamine oxidase inhibitors and food precautions. A comparison of utilization in Belgian psychiatric education institutes and current findings in the literature] Mallet L, et al. **Acta Psychiatr Belg** 1996 Mar–Apr;96(2):74–100 (52

ref.) (Eng. Abstr.) **(Fre)**
[Eating, nutrition and drugs] Noirfalise A. **J Pharm Belg** 1996 Mar-Apr;51(2):87-91 (23 ref.) **(Fre)**
[Interactions between drugs and food in pediatric age] Paci A, et al. **Pediatr Med Chir** 1996 Jan-Feb;18(1):47-52 (25 ref.) (Eng. Abstr.) **(Ita)**

FOOD, FORMULATED

Nutrient substitutes and their energy values in fat substitutes and replacers. Miraglio AM. **Am J Clin Nutr** 1995 Nov; 62(5 Suppl):1175S-1179S (22 ref.)
Nutritional support in Crohn's disease: current status and future directions. O'Morain C, et al. **J Gastroenterol** 1995 Nov;30 Suppl 8:102-7 (32 ref.)
Impact of fat substitutes on fat intake. Miller GD, et al. **Lipids** 1996 Mar;31 Suppl:S293-6 (61 ref.)
[Infant formula follow-up: an update] Szajewska H, et al. **Pediatr Pol** 1995 Apr;70(4):291-301 (41 ref.) (Eng. Abstr.) **(Pol)**

STANDARDS

Nutrition evaluation of dietary fat substitutes. Gershoff SN. **Nutr Rev** 1995 Nov;53(11):305-13 (63 ref.)

FOOD, FORTIFIED

Possible dietary measures in the prevention of pre-eclampsia and eclampsia. Baker PN. **Baillieres Clin Obstet Gynaecol** 1995 Sep;9(3):497-507 (73 ref.)
Should we use milk fluoridation? A review. Mariño R. **Bull Pan Am Health Organ** 1995 Dec;29(4):287-98 (71 ref.)
Vitamin B12 deficiency and the fortification of food with folic acid. Bower C, et al. **Eur J Clin Nutr** 1995 Nov; 49(11):787-93 (34 ref.)
Clinical effects of a dietary fibre supplement. A review. Gatti E. **Eur J Clin Nutr** 1995 Oct;49 Suppl 3:S199-200 (12 ref.)
What practitioners need to know about folic acid. Hine RJ. **J Am Diet Assoc** 1996 May;96(5):451-2 (15 ref.)
Seven deadly sins in confronting endemic iodine deficiency, and how to avoid them. Dunn JT. **J Clin Endocrinol Metab** 1996 Apr;81(4):1332-5 (22 ref.)
Fortification of the food supply with folic acid to prevent neural tube defects is not yet warranted. Gaull GE, et al. **J Nutr** 1996 Mar;126(3):773S-780S (48 ref.)
More folic acid for everyone, now. Oakley GP Jr, et al. **J Nutr** 1996 Mar;126(3):751S-755S (18 ref.)
A food industry perspective on folic acid fortification. Schaller DR, et al. **J Nutr** 1996 Mar;126(3):761S-764S (9 ref.)
The challenge of regulating health claims and food fortification. Yetley EA, et al. **J Nutr** 1996 Mar; 126(3):765S-772S (19 ref.)
Calcium supplementation prevents pregnancy-induced hypertension by increasing the production of vascular nitric oxide. López-Jaramillo P, et al. **Med Hypotheses** 1995 Jul; 45(1):68-72 (73 ref.)
Surgically significant nutritional supplements. Petry JJ. **Plast Reconstr Surg** 1996 Jan;97(1):233-40 (70 ref.)
[Food supplements] Van Peteghem C. **J Pharm Belg** 1996 Mar-Apr;51(2):92-6 (8 ref.) **(Fre)**
[Food fortification with emphasis on the addition of micronutrients to wheat flour] Arroyave G. **Arch Latinoam Nutr** 1993 Sep;43(3):186-90 (16 ref.) (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

A prediction of chromium(III) accumulation in humans from chromium dietary supplements. Stearns DM, et al. **FASEB J** 1995 Dec;9(15):1650-7 (49 ref.)

FOOD HABITS

Phytoestrogens--a short review. Knight DC, et al. **Maturitas** 1995 Nov;22(3):167-75 (89 ref.)
Chemoprevention of colon cancer by minor dietary constituents and their synthetic analogues. Reddy BS. **Prev Med** 1996 Jan-Feb;25(1):48-50 (13 ref.)
The mechanistic rationale in support of dietary cancer prevention. Rose DP. **Prev Med** 1996 Jan-Feb;25(1):34-7 (36 ref.)
Looking for 'fresh' food: diet and lone parents. Dowler E, et al. **Proc Nutr Soc** 1996 Nov;54(3):759-69 (22 ref.)
[Nutrition and metabolic syndrome] Hauner H. **Internist (Berl)** 1995 Nov;36(11):1040-5 (37 ref.) **(Ger)**
[Nutrition behavior in Germany] Pudel V, et al. **Internist (Berl)** 1995 Nov;36(11):1032-9 (22 ref.) **(Ger)**
[Nutrition and cancer] Schusdziarra V. **Internist (Berl)** 1995 Nov;36(11):1046-51 (74 ref.) **(Ger)**
[Prevention and therapy of nutrition-induced diseases and disease-induced nutrition disorders by internists. Deficiencies and future developments] Ollenschläger G. **Med Klin** 1995 Aug 15;90(8):486-9 (16 ref.) **(Ger)**
[Nutrition in prevention of coronary heart disease] Hrboticky N, et al. **Z Arztl Fortbild (Jena)** 1996 Feb;90(1):11-8 (27 ref.) (Eng. Abstr.) **(Ger)**
[Nutrition-related prevention studies in children and adolescents on a population level--concepts, methods, outcome] Kersting M, et al. **Z Arztl Fortbild (Jena)** 1996 Feb;90(1):25-31 (34 ref.) (Eng. Abstr.) **(Ger)**
[Old principles for th treatment of obesity are still valid. Diet and exercise are still the most important factors] Rössner S. **Lakartidningen** 1996 Mar 20;93(12):1117-20 (12 ref.) **(Swe)**

PSYCHOLOGY

Food and behaviour. Warner JO. **Clin Exp Allergy** 1995 Jul; 25 Suppl 1:23-6 (23 ref.)
Social influences on food choice and dietary change: a sociological attitude. Murcott A. **Proc Nutr Soc** 1996 Nov; 54(3):729-35 (13 ref.)
Parental influences on children's diets. Wardle J. **Proc Nutr Soc** 1996 Nov;54(3):747-58 (63 ref.)

FOOD HANDLING

Antioxidant agents in raw materials and processed foods. Eriksson CE, et al. **Biochem Soc Symp** 1995;61:221-34 (106 ref.)

METHODS

Application of enzymes in food processing. James J, et al. **Crit Rev Food Sci Nutr** 1996 May;36(5):437-63 (48 ref.)
Cyanide detoxification in cassava for food and feed uses. Padmaja G. **Crit Rev Food Sci Nutr** 1995 Jul;35(4):299-339 (133 ref.)
Cowpea flour: a potential ingredient in food products. Prinyawiwatkul W, et al. **Crit Rev Food Sci Nutr** 1996 May; 36(5):413-36 (130 ref.)
Dietary fibre: effect of processing and nutrient interactions. Carnovale E, et al. **Eur J Clin Nutr** 1995 Oct;49 Suppl 3:S307-11 (42 ref.)
Effects of processing on dietary fibre in vegetables. Nyman M. **Eur J Clin Nutr** 1995 Oct;49 Suppl 3:S215-8 (22 ref.)
Vitamin retention in cook/chill and cook/hot-hold hospital food-services. Williams PG. **J Am Diet Assoc** 1996 May; 96(5):490-8; quiz 499-500 (78 ref.)
[Contaminated fish and pork] Perret JL, et al. **Med Trop (Mars)** 1996;56(1):25-7 (0 ref.) **(Fre)**

STANDARDS

Food safety: review and implications for dietitians and dietetic technicians [see comments] Ollinger-Snyder P, et al. **J Am Diet Assoc** 1996 Feb;96(2):163-8, 171; quiz 169-70 (82 ref.) Comment in: J Am Diet Assoc 1996 Aug;96(8):751.
Evaluation of food safety. Urbanek-Karłowska B, et al. **Rocz Panstw Zakl Hig** 1995;46(3):217-22 (8 ref.)

FOOD HYPERSENSITIVITY

Active immunity or tolerance to foods in patients with celiac disease or inflammatory bowel disease. Ferguson A, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:202-16 (25 ref.)
Biochemical features of grain legume allergens in humans and animals. Lallès JP, et al. **Nutr Rev** 1996 Apr;54(4 Pt 1):101-7 (65 ref.)

COMPLICATIONS

Food-allergic disease. Edwards AM. **Clin Exp Allergy** 1995 Jul;25 Suppl 1:16-9 (30 ref.)
Food reactions in pollen and latex allergic patients [editorial] Frankland AW. **Clin Exp Allergy** 1995 Jul;25(7):580-1 (22 ref.)
Emesis in infants as a consequence of feedings. Marshall CM, et al. **Semin Pediatr Surg** 1995 Aug;4(3):147-51 (31 ref.)
The role of the gastrointestinal tract in the development of respiratory hypersensitivities. Björkstén B. **Toxicol Lett** 1996 Aug;86(2-3):85-8 (15 ref.)
[Type I hypersensitivity reactions and etiopathogenesis of hemorrhagic rectocolitis] Leprince E, et al. **Presse Med** 1995 Dec 16-23;24(39):1902-6 (58 ref.) (Eng. Abstr.) **(Fre)**
[Diet and migraine] Leira R, et al. **Rev Neurol** 1996 May; 24(129):534-8 (46 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

The diagnosis of food intolerance. Lessof MH. **Clin Exp Allergy** 1995 Jul;25 Suppl 1:14-5 (5 ref.)
Diagnostic criteria for gastrointestinal food allergy in childhood. Walker-Smith JA. **Clin Exp Allergy** 1995 Jul; 25 Suppl 1:20-2 (15 ref.)
Clinical features of food allergy in infants. Brigino E, et al. **Clin Rev Allergy Immunol** 1995 Winter;13(4):329-45 (89 ref.)
Food allergy in children. Watson WT. **Clin Rev Allergy Immunol** 1995 Winter;13(4):347-59 (50 ref.)
Diagnosis of food hypersensitivity. Terho EO, et al. **Eur J Clin Nutr** 1996 Jan;50(1):1-5 (18 ref.)
[Assessment of adverse reactions to food] Terho EO. **Duodecim** 1994;110(9):909-14 (6 ref.) **(Fin)**
[Food allergy] Vandenplas Y. **Gastroenterol Clin Biol** 1996; 20(5 Pt 2):B36-41 (56 ref.) **(Fre)**
[New aspects of food allergy] Pfau A, et al. **Dtsch Med Wochenschr** 1996 Mar 15;121(11):346-50 (29 ref.) **(Ger)**
[Food allergy: definition, diagnosis, epidemiology, clinical aspects] Wüthrich B. **Schweiz Med Wochenschr** 1996 May 4;126(18):770-6 (37 ref.) (Eng. Abstr.) **(Ger)**

DIET THERAPY

Dietary treatment of food allergy and intolerance. Carter C. **Clin Exp Allergy** 1995 Jul;25 Suppl 1:34-42 (36 ref.)
The effect of hypo-allergenic formulas in infants at risk of allergic disease. Halken S, et al. **Eur J Clin Nutr** 1995 Sep; 49 Suppl 1:S77-83 (35 ref.)
Product development horizons--a view from industry. Hudson MJ. **Eur J Clin Nutr** 1995 Sep;49 Suppl 1:S64-70 (9 ref.)
'Prevention programmes'--a dietetic minefield. Wolfe SP. **Eur J Clin Nutr** 1995 Sep;49 Suppl 1:S92-9 (65 ref.)

DRUG THERAPY

Oral sodium cromoglycate: its use in the management of food allergy. Edwards AM. **Clin Exp Allergy** 1995 Jul;25 Suppl 1:31-3 (30 ref.)

ETIOLOGY

Reactions to food additives. Lessof MH. **Clin Exp Allergy** 1995 Jul;25 Suppl 1:27-8 (19 ref.)
IgE-mediated (and food-induced) intestinal disease. Strobel S. **Clin Exp Allergy** 1995 Jul;25 Suppl 1:3-6 (61 ref.)
Food intolerance and asthma. Warner JO. **Clin Exp Allergy** 1995 Jul;25 Suppl 1:29-30 (10 ref.)
Food allergy and atopic disease. Chandra RK, et al. **Clin Rev Allergy Immunol** 1995 Winter;13(4):293-314 (57 ref.)
"Hidden" allergens in foods. Steinman HA. **J Allergy Clin Immunol** 1996 Aug;98(2):241-50 (93 ref.)
Sulfite sensitivity: significance in human health. Lester MR. **J Am Coll Nutr** 1995 Jun;14(3):229-32 (9 ref.)
Food intolerance and allergy. Pace V. **Panminerva Med** 1995 Jun;37(2):84-91 (11 ref.)
[The scientific basis for food allergy] Bischoff SC, et al. **Med Klin** 1996 Jun 15;91(6):389-95 (32 ref.) **(Ger)**
[Reactions to food] Halvorsen R, et al. **Tidsskr Nor Laegeforen** 1995 Dec 10;115(30):3730-3 (24 ref.) (Eng. Abstr.) **(Nor)**

IMMUNOLOGY

Allergenic cross-reactivity of foods and characterization of food allergens and extracts. Bernhisel-Broadbent J. **Ann Allergy Asthma Immunol** 1995 Oct;75(4):295-303; quiz 304-7 (80 ref.)
IgG and IgA antibodies to dietary antigens in food allergy and intolerance. Barnes RM. **Clin Exp Allergy** 1995 Jul;25 Suppl 1:7-9 (39 ref.)
Evidence for cell-mediated hypersensitivity as an important pathogenetic mechanism in food intolerance. MacDonald TT. **Clin Exp Allergy** 1995 Jul;25 Suppl 1:10-3 (41 ref.)
Regulation of IgE production and other immunopathogenetic mechanisms. Chowdhury BA. **Clin Rev Allergy Immunol** 1995 Winter;13(4):315-28 (74 ref.)
Type 1 allergic reactions to plant-derived food: a consequence of primary sensitization to pollen allergens. Valenta R, et al. **J Allergy Clin Immunol** 1996 Apr; 97(4):893-5 (29 ref.)
[Relationship between intestinal permeability and antibodies against food antigens in IgA nephropathy] Kovács T, et al. **Orv Hetil** 1996 Jan 14;137(2):65-9 (35 ref.) (Eng. Abstr.) **(Hun)**
[Sick of food? Knowledge and hypothesis on food intolerance] Jacobsen MB, et al. **Nord Med** 1996 Apr; 111(4):109-12, 118 (15 ref.) (Eng. Abstr.) **(Nor)**

PREVENTION & CONTROL

Allergy prevention--an attainable objective? Hide DW. **Eur J Clin Nutr** 1995 Sep;49 Suppl 1:S71-6 (23 ref.)
Product development horizons--a view from industry. Hudson MJ. **Eur J Clin Nutr** 1995 Sep;49 Suppl 1:S64-70 (9 ref.)
'Prevention programmes'--a dietetic minefield. Wolfe SP. **Eur J Clin Nutr** 1995 Sep;49 Suppl 1:S92-9 (65 ref.)

FOOD, INFANT see **INFANT FOOD**

FOOD INTAKE see **EATING**

FOOD INTAKE REGULATION see **APPETITE REGULATION**

FOOD INTERACTIONS see **FOOD-DRUG INTERACTIONS**

FOOD, IRRADIATED see **FOOD IRRADIATION**

FOOD IRRADIATION

Free radicals and food irradiation. Dodd NJ. **Biochem Soc Symp** 1995;61:247-58 (49 ref.)
Position of the American Dietetic Association: food irradiation. J **Am Diet Assoc** 1996 Jan;96(1):69-72 (27 ref.)

STANDARDS

[Food irradiation] Migdal W. **Rocz Panstw Zakl Hig** 1995; 46(4):323-8 (14 ref.) (Eng. Abstr.) **(Pol)**

FOOD LABELING

Complex carbohydrates: the science and the label. **Nutr Rev** 1995 Jul;53(7):186–93 (8 ref.)

LEGISLATION & JURISPRUDENCE

Nutrition labeling: energy values of foods and fat substitutes. Wiesenfeld PL. **Am J Clin Nutr** 1995 Nov;62(5 Suppl):1143S–1146S (21 ref.)

Interpretations of risk: the use of scientific information in the development of the alcohol warning label policy. Kaskutas LA. **Int J Addict** 1995;30(12):1519–48 (70 ref.)

Putting things in perspective: building on our experience. Shank FR, et al. **J Nutr** 1996 Mar;126(3):781S–787S (18 ref.)

FOOD LAWS see **LEGISLATION, FOOD**

FOOD MICROBIOLOGY

Foodborne and waterborne illness in children. Rivera-Matos IR, et al. **Adv Pediatr Infect Dis** 1996;11:101–34 (112 ref.)

The changing epidemiology of foodborne diseases. Altekruse SF, et al. **Am J Med Sci** 1996 Jan;311(1):23–9 (50 ref.)

The polymerase chain reaction: applications for the detection of foodborne pathogens. Hill WE. **Crit Rev Food Sci Nutr** 1996 Jan;36(1–2):123–73 (294 ref.)

Microbial modeling in foods. Whiting RC. **Crit Rev Food Sci Nutr** 1995 Nov;35(6):464–94 (217 ref.)

Salmonellae and food safety. Tietjen M, et al. **Crit Rev Microbiol** 1995;21(1):53–83 (104 ref.)

Bacteriocins: modes of action and potentials in food preservation and control of food poisoning. Abee T, et al. **Int J Food Microbiol** 1995 Dec;28(2):169–85 (56 ref.)

Probes and polymerase chain reaction for detection of food-borne bacterial pathogens. Olsen JE, et al. **Int J Food Microbiol** 1995 Nov;28(1):1–78 (331 ref.)

The significance of bacteria in stationary phase to food microbiology. Rees CE, et al. **Int J Food Microbiol** 1995 Dec;28(2):263–75 (74 ref.)

Flow cytometry applications in physiological study and detection of foodborne microorganisms. Ueckert J, et al. **Int J Food Microbiol** 1995 Dec;28(2):317–26 (30 ref.)

Food safety: review and implications for dietitians and dietetic technicians [see comments] Ollinger-Snyder P, et al. **J Am Diet Assoc** 1996 Feb;96(2):163–8, 171; quiz 169–70 (82 ref.) Comment in: J Am Diet Assoc 1996 Aug;96(8):751.

Wiley Award Address. Evolution of methods for the detection of Salmonella in foods. Andrews WH. **J AOAC Int** 1996 Jan-Feb;79(1):4–12 (58 ref.)

BCR- and M&T-activities in the area of mycotoxin analysis in food and feedstuffs. Boenke A. **Nat Toxins** 1995; 3(4):243–7; discussion 280 (10 ref.)

Economic losses and decontamination. Charmley LL, et al. **Nat Toxins** 1995;3(4):199–203; discussion 221 (36 ref.)

Keeping the mycotoxins out: experience gathered by an international food company. Pittet A. **Nat Toxins** 1995; 3(4):281–7; discussion 317 (26 ref.)

The proteolytic pathway of Lactococcus lactis. Poolman B, et al. **Soc Appl Bacteriol Symp Ser** 1995;24:65S–75S (46 ref.)

[Risk assessment of microorganisms relevant to food hygiene] Untermann F. **Zentralbl Hyg Umweltmed** 1995 Apr; 197(1–3):222–31 (44 ref.) (Eng. Abstr.) **(Ger)**

STANDARDS

Water activity, water glass dynamics, and the control of microbiological growth in foods. Chirife J, et al. **Crit Rev Food Sci Nutr** 1996 May;36(5):465–513 (151 ref.)

The real story about food safety. Kastner CL. **J Anim Sci** 1995 Sep;73(9):2741–3 (2 ref.)

FOOD PACKAGING

Antioxidants in food packaging: a risk factor? Scott G. **Biochem Soc Symp** 1995;61:225–46 (28 ref.)

Functional properties and applications of edible films made of milk proteins. Chen H. **J Dairy Sci** 1995 Nov; 78(11):2563–83 (94 ref.)

FOOD PARASITOLOGY

Foodborne and waterborne illness in children. Rivera-Matos IR, et al. **Adv Pediatr Infect Dis** 1996;11:101–34 (112 ref.)

The polymerase chain reaction: applications for the detection of foodborne pathogens. Hill WE. **Crit Rev Food Sci Nutr** 1996 Jan;36(1–2):123–73 (294 ref.)

FOOD PLANTS see **PLANTS, EDIBLE**

FOOD POISONING

Foodborne disease and other hygiene issues in the home. Scott E. **J Appl Bacteriol** 1996 Jan;80(1):5–9 (37 ref.)

[Recent food poisoning and molecular biology] Yo M, et al. **Nippon Naika Gakkai Zasshi** 1995 Nov 10; 84(11):1917–25 (14 ref.) **(Jpn)**

COMPLICATIONS

[Acute life-threatening bradycardia: food poisoning by Turkish wild honey] von Malottki K, et al. **Dtsch Med Wochenschr** 1996 Jul 26;121(30):936–8 (8 ref.) (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

The changing epidemiology of foodborne diseases. Altekruse SF, et al. **Am J Med Sci** 1996 Jan;311(1):23–9 (50 ref.)

ETIOLOGY

[Causes and mechanisms of nitrate and nitrite poisoning (review of the literature)] Gozhenko AI, et al. **Med Tr Prom Ekol** 1996;(4):15–21 (42 ref.) **(Rus)**

PREVENTION & CONTROL

Food safety: review and implications for dietitians and dietetic technicians [see comments] Ollinger-Snyder P, et al. **J Am Diet Assoc** 1996 Feb;96(2):163–8, 171; quiz 169–70 (82 ref.) Comment in: J Am Diet Assoc 1996 Aug;96(8):751.

FOOD POLICY see **NUTRITION POLICY**

FOOD PREFERENCES

Energy intake and sensory properties of food. Drewnowski A. **Am J Clin Nutr** 1995 Nov;62(5 Suppl):1081S–1085S (38 ref.)

Food selection: problems in understanding how we choose foods to eat. Galef BG Jr. **Neurosci Biobehav Rev** 1996; 20(1):67–73 (64 ref.)

Brain serotonin, carbohydrate-craving, obesity and depression. Wurtman RJ, et al. **Obes Res** 1995 Nov;3 Suppl 4:477S–480S (34 ref.)

Food preferences in farm animals: why don't they always choose wisely? Forbes JM, et al. **Proc Nutr Soc** 1995 Jul; 54(2):429–40 (45 ref.)

An effective procedure for changing food preferences in 5–7-year-old children. Horne PJ, et al. **Proc Nutr Soc** 1995 Jul;54(2):441–52 (61 ref.)

Understanding fat preference and consumption: applications of behavioural sciences to a nutritional problem. Mela DJ. **Proc Nutr Soc** 1995 Jul;54(2):453–64 (77 ref.)

How food preferences are learned: laboratory animal models. Sclafani A. **Proc Nutr Soc** 1995 Jul;54(2):419–27 (63 ref.)

PHYSIOLOGY

Exercise, macronutrient preferences and food intake. Tremblay A, et al. **Int J Obes Relat Metab Disord** 1995 Oct;19 Suppl 4:S97–101 (32 ref.)

FOOD PRESERVATION

Spoilage and shelf-life extension of fresh fish and shellfish. Ashie IN, et al. **Crit Rev Food Sci Nutr** 1996 Jan; 36(1–2):87–121 (246 ref.)

METHODS

Use of edible coatings to preserve quality of lightly (and slightly) processed products. Baldwin EA, et al. **Crit Rev Food Sci Nutr** 1995 Nov;35(6):509–24 (128 ref.)

Bacteriocins: modes of action and potentials in food preservation and control of food poisoning. Abee T, et al. **Int J Food Microbiol** 1995 Dec;28(2):169–85 (56 ref.)

Understanding physical inactivation processes: combined preservation opportunities using heat, ultrasound and pressure. Earnshaw RG, et al. **Int J Food Microbiol** 1995 Dec;28(2):197–219 (122 ref.)

Vitamin retention in cook/chill and cook/hot-hold hospital food-services. Williams PG. **J Am Diet Assoc** 1996 May; 96(5):490–8; quiz 499–500 (78 ref.)

FOOD PRESERVATIVES

see related
ANTIOXIDANTS

Use of edible coatings to preserve quality of lightly (and slightly) processed products. Baldwin EA, et al. **Crit Rev Food Sci Nutr** 1995 Nov;35(6):509–24 (128 ref.)

FOOD, PRESERVED see **FOOD PRESERVATION**

FOOD PROCESSING see **FOOD HANDLING**

FOOD-PROCESSING INDUSTRY

A food industry perspective on folic acid fortification. Schaller DR, et al. **J Nutr** 1996 Mar;126(3):761S–764S (9 ref.)

STANDARDS

The real story about food safety. Kastner CL. **J Anim Sci** 1995 Sep;73(9):2741–3 (2 ref.)

Disinfection of food production areas. Holah JT. **Rev Sci Tech** 1995 Jun;14(2):343–63 (55 ref.)

Cleaning and disinfection practice in the meat industries of Europe. Salvat G, et al. **Rev Sci Tech** 1995 Jun;14(2):313–41 (19 ref.) **(Eng, Fre)**

FOOD SELECTION see **FOOD PREFERENCES**

FOOD SERVICE, HOSPITAL

ORGANIZATION & ADMINISTRATION

The feeding of patients in hospital: a review. McGlone PC, et al. **J R Soc Health** 1995 Oct;115(5):282–8 (49 ref.)

STANDARDS

Vitamin retention in cook/chill and cook/hot-hold hospital food-services. Williams PG. **J Am Diet Assoc** 1996 May; 96(5):490–8; quiz 499–500 (78 ref.)

FOOD SERVICES

ORGANIZATION & ADMINISTRATION

Improving workplace environments and working conditions at worksites providing school lunch service in Japan. Koda S, et al. **J Hum Ergol (Tokyo)** 1995 Jun;24(1):93–101 (26 ref.)

STANDARDS

Food safety: review and implications for dietitians and dietetic technicians [see comments] Ollinger-Snyder P, et al. **J Am Diet Assoc** 1996 Feb;96(2):163–8, 171; quiz 169–70 (82 ref.) Comment in: J Am Diet Assoc 1996 Aug;96(8):751.

Does breakfast make a difference in school? Pollitt E. **J Am Diet Assoc** 1995 Oct;95(10):1134–9 (24 ref.)

FOOD, SUPPLEMENTED see **FOOD, FORTIFIED**

FOOD SUPPLY

ECONOMICS

The international political economy of food: a global crisis. Friedmann H. **Int J Health Serv** 1995;25(3):511–38 (55 ref.)

STANDARDS

Enrichment of food staples through plant breeding: a new strategy for fighting micronutrient malnutrition. Bouis H. **Nutr Rev** 1996 May;54(5):131–7 (31 ref.)

FOOD TECHNOLOGY

Immunolocalization and microstructure of milk proteins and fat mimetics in reduced fat cheese. Armbruster BL, et al. **Adv Exp Med Biol** 1995;367:277–94 (47 ref.)

Contribution of milk-clotting enzymes and plasmin to cheese ripening. Farkye NY. **Adv Exp Med Biol** 1995;367:195–207 (64 ref.)

Methods for assessing proteolysis in cheese during maturation. Fox PF, et al. **Adv Exp Med Biol** 1995; 367:161–94 (244 ref.)

Overview: cheese chemistry and rheology. Holsinger VH, et al. **Adv Exp Med Biol** 1995;367:1–6 (15 ref.)

Practical aspects of electron microscopy in cheese research. Kaláb M. **Adv Exp Med Biol** 1995;367:247–76 (136 ref.)

Contribution of lactic acid bacteria to cheese ripening. Steele JL. **Adv Exp Med Biol** 1995;367:209–20 (43 ref.)

Spoilage and shelf-life extension of fresh fish and shellfish. Ashie IN, et al. **Crit Rev Food Sci Nutr** 1996 Jan; 36(1–2):87–121 (246 ref.)

Mechanisms for controlling enzymatic reactions in foods. Ashie IN, et al. **Crit Rev Food Sci Nutr** 1996 Jan; 36(1–2):1–30 (203 ref.)

Applications of magnetic resonance imaging in food science. Schmidt SJ, et al. **Crit Rev Food Sci Nutr** 1996 Apr; 36(4):357–85 (114 ref.)

Carrageenans and their use in meat products. Trius A, et al. **Crit Rev Food Sci Nutr** 1996 Jan;36(1–2):69–85 (71 ref.)

Product development horizons--a view from industry. Hudson MJ. **Eur J Clin Nutr** 1995 Sep;49 Suppl 1:S64–70 (9 ref.)

Position of the American Dietetic Association: biotechnology and the future of food. **J Am Diet Assoc** 1995 Dec; 95(12):1429–32 (29 ref.)

Functional properties and applications of edible films made of milk proteins. Chen H. **J Dairy Sci** 1995 Nov; 78(11):2563–83 (94 ref.)

Novel products and new technologies for use of a familiar carbohydrate, milk lactose. Yang ST, et al. **J Dairy Sci** 1995 Nov;78(11):2541–62 (128 ref.)

A review of protein engineering for the food industry. Goodenough PW. **Mol Biotechnol** 1995 Oct;4(2):151–66 (55 ref.)

On-line food and nutrition information resources. Institute of Food Science and Technology. **Nutr Rev** 1996 May; 54(5):158 (0 ref.)

HISTORY

The 37 year history of the Delaney Clause. Weisburger JH. **Exp Toxicol Pathol** 1996 Feb;48(2–3):183–8 (21 ref.)

LEGISLATION & JURISPRUDENCE

The 37 year history of the Delaney Clause. Weisburger JH. **Exp Toxicol Pathol** 1996 Feb;48(2–3):183–8 (21 ref.)

Human protection against non-genotoxic carcinogens in the US without the Delaney Clause. Weisburger JH.

Exp Toxicol Pathol 1996 Feb;48(2-3):201-8 (41 ref.)
Risk assessment of carcinogens in food with special consideration of non-genotoxic carcinogens. Scientific arguments for use of risk assessment and for changing the Delaney Clause specifically. Williams GM, et al. **Exp Toxicol Pathol** 1996 Feb;48(2-3):209-15 (21 ref.)
FEMA GRAS—a GRAS assessment program for flavor ingredients. Flavor and Extract Manufacturers Association. Hallagan JB, et al. **Regul Toxicol Pharmacol** 1995 Jun; 21(3):422-30 (12 ref.)

METHODS

Improving the sensory characteristics of reduced-fat cheese. Mistry VV. **Adv Exp Med Biol** 1995;367:371-82 (19 ref.)
Time-temperature effects on microbial, chemical and sensory changes during cooling and aging of cheddar cheese. Torres JA, et al. **Adv Exp Med Biol** 1995;367:123-59 (95 ref.)
Value-added products from underutilized fish species. Venugopal V, et al. **Crit Rev Food Sci Nutr** 1995 Sep; 35(5):431-53 (160 ref.)

TRENDS

Issues and advances in the use of transgenic organisms for the production of thaumatin, the intensely sweet protein from Thaumatococcus danielli. Zemanek EC, et al. **Crit Rev Food Sci Nutr** 1995 Sep;35(5):455-66 (44 ref.)

FOOT

Gorham's disease: a literature review and case reports. Green HD, et al. **J Foot Ankle Surg** 1995 Sep-Oct;34(5):435-41 (17 ref.)

ANATOMY & HISTOLOGY

Normal magnetic resonance imaging anatomy of the ankle and foot. Kirsch MD, et al. **Magn Reson Imaging Clin N Am** 1994 Feb;2(1):1-21 (24 ref.)
Technical considerations for magnetic resonance imaging of the ankle and foot. Kneeland JB. **Magn Reson Imaging Clin N Am** 1994 Feb;2(1):23-8 (7 ref.)

BLOOD SUPPLY

[The ischemic diabetic foot] Telić D. **Med Pregl** 1995; 48(7-8):235-40 (29 ref.) (Eng. Abstr.) **(Scr)**

PATHOLOGY

Clinical significance of magnetic resonance imaging of the ankle and foot. Jahss MH. **Magn Reson Imaging Clin N Am** 1994 Feb;2(1):29-38 (10 ref.)
[Progress on diagnosis and therapy of diabetic gangrene] Saito N, et al. **Nippon Naika Gakkai Zasshi** 1996 Apr 10; 85(4):556-61 (8 ref.) **(Jpn)**

PHYSIOLOGY

Role of surgery of nerves in leprosy in the restoration of sensibility in hands and feet of leprosy patients. Kazen R. **Indian J Lepr** 1996 Jan-Mar;68(1):55-65 (44 ref.)
Transducers for foot pressure measurement: survey of recent developments. Cobb J, et al. **Med Biol Eng Comput** 1995 Jul;33(4):525-32 (44 ref.)

PHYSIOPATHOLOGY

The role of diabetic neuropathy and high plantar pressures in the pathogenesis of foot ulceration. Katoulis EC, et al. **Horm Metab Res** 1996 Apr;28(4):159-64 (62 ref.)

SURGERY

Metallic implants used in foot surgery. Chang TJ, et al. **Clin Podiatr Med Surg** 1995 Jul;12(3):457-74 (57 ref.)
Future materials for foot surgery. Latour RA Jr. **Clin Podiatr Med Surg** 1995 Jul;12(3):519-44 (76 ref.)
Musculoskeletal applications of hyaluronan and hylan. Potential uses in the foot and ankle. Weiss C, et al. **Clin Podiatr Med Surg** 1995 Jul;12(3):497-517 (44 ref.)
Appropriate methods for bone fixation [editorial] Reinherz RP. **J Foot Ankle Surg** 1996 Mar-Apr;35(2):93 (29 ref.)

FOOT-AND-MOUTH DISEASE

EPIDEMIOLOGY

Overview of foot and mouth disease in southern Africa. Thomson GR. **Rev Sci Tech** 1995 Sep;14(3):503-20 (50 ref.)

IMMUNOLOGY

[Mechanisms involved in the prolonged humoral immune response: behavior of aphthous fever virus] Wigdorovitz A, et al. **Rev Argent Microbiol** 1996 Jan-Mar;28(1):45-54 (45 ref.) (Eng. Abstr.) **(Spa)**

PREVENTION & CONTROL

The interference by maternally-derived antibody with active immunization of farm animals against foot-and-mouth disease. Kitching RP, et al. **Br Vet J** 1995 Jul-Aug; 151(4):379-89 (40 ref.)
Risk of introducing exotic disease through importation of animals and animal products. Metcalf HE, et al. **Rev Sci Tech** 1995 Dec;14(4):951-6 (12 ref.)

FOOT-AND-MOUTH DISEASE VIRUS see **APHTHOVIRUS**

FOOT DEFORMITIES

DIAGNOSIS

Magnetic resonance imaging of pediatric disorders of the ankle and foot. Schoenberg NY, et al. **Magn Reson Imaging Clin N Am** 1994 Feb;2(1):109-22 (51 ref.)

SURGERY

Cuneiform and cuboid wedge osteotomies for correction of residual metatarsus adductus: a surgical review. Brink DS, et al. **J Foot Ankle Surg** 1995 Jul-Aug;34(4):371-8 (26 ref.)
Complications of distal first metatarsal osteotomies. Laughlin TJ. **J Foot Ankle Surg** 1995 Nov-Dec;34(6):524-31; discussion 593-4 (46 ref.)

VETERINARY

Orthopedic conditions of small ruminants. Llama, sheep, goat, and deer. Kaneps AJ. **Vet Clin North Am Food Anim Pract** 1996 Mar;12(1):211-31 (51 ref.)

FOOT DEFORMITIES, ACQUIRED

Volkmann's ischemic contracture of the foot and ankle: evaluation and treatment of established deformity. Santi MD, et al. **Foot Ankle Int** 1995 Jun;16(6):368-77 (72 ref.)

ETIOLOGY

Clawtoe deformity following vascularized fibula graft. Bohay DR, et al. **Foot Ankle Int** 1995 Oct;16(10):607-9 (10 ref.)

RADIOGRAPHY

Melorheostosis of the foot: a case report and review of the literature. Mudge I, et al. **Nebr Med J** 1996 Jan;81(1):18-21 (6 ref.)

SURGERY

Bunions and deformities of the toes in children and adolescents. Thompson GH. **Instr Course Lect** 1996; 45:355-67 (79 ref.)

FOOT DEFORMITIES, CONGENITAL

Evaluation of pediatric foot problems: Part II. The hindfoot and the ankle. Manusov EG, et al. **Am Fam Physician** 1996 Sep 1;54(3):1012-26, 1031 (21 ref.)

DIAGNOSIS

[The Tel Hashomer camptodactyly syndrome] Rogovina EG, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995; 95(4):83-6 (6 ref.) (Eng. Abstr.) **(Rus)**

ETIOLOGY

Symmetrical terminal transverse limb defects: report of a twenty-week fetus. Harmon JV Jr, et al. **Teratology** 1995 Apr;51(4):237-42 (18 ref.)

GENETICS

Kaufman oculocerebrofacial syndrome in a girl of 15 years. Briscioli V, et al. **Am J Med Genet** 1995 Jul 31;58(1):21-3 (6 ref.)
Mirror image duplication of the hands and feet: report of a sporadic case with multiple congenital anomalies. Hersh JH, et al. **Am J Med Genet** 1995 Nov 20;59(3):341-5 (14 ref.)
Congenital hand and forearm anomalies. Louis DS, et al. **Curr Opin Pediatr** 1996 Feb;8(1):61-4 (12 ref.)

PATHOLOGY

Tarsal coalition. Kulik SA Jr, et al. **Foot Ankle Int** 1996 May; 17(5):286-96 (63 ref.)
Congenital constriction band syndrome. Perdue PS, et al. **J South Orthop Assoc** 1996 Spring;5(1):71-5 (12 ref.)

PHYSIOPATHOLOGY

Flexible flatfoot and skewfoot. Mosca VS. **Instr Course Lect** 1996;45:347-54 (73 ref.)

RADIOGRAPHY

Congenital vertical talus. Drennan JC. **Instr Course Lect** 1996;45:315-22 (34 ref.)

SURGERY

Tarsal coalitions. Drennan JC. **Instr Course Lect** 1996; 45:323-9 (42 ref.)
Bunions and deformities of the toes in children and adolescents. Thompson GH. **Instr Course Lect** 1996; 45:355-67 (79 ref.)

FOOT DERMATOSES

Papular-purpuric 'gloves and socks' syndrome [letter] Veraldi S, et al. **Arch Dermatol** 1996 Aug;132(8):975-7 (17 ref.)

ETIOLOGY

Milia-like idiopathic calcinosis cutis: an unusual dermatosis associated with Down syndrome. Schepis C, et al. **Br J Dermatol** 1996 Jan;134(1):143-6 (17 ref.)

MICROBIOLOGY

Pseudallescheria boydii in an immunocompromised host. Successful treatment with debridement and itraconazole. Ruxin TA, et al. **Arch Dermatol** 1996 Apr;132(4):382-4 (23 ref.)

PATHOLOGY

The scleroatrophic syndrome of Huriez: a cancer-prone genodermatosis. Hamm H, et al. **Br J Dermatol** 1996 Mar; 134(3):512-8 (24 ref.)
Problem sites: scalp, palm and sole, and nail. Larko O. **Dermatol Clin** 1995 Oct;13(4):771-7 (91 ref.)

VETERINARY

Facial, pedal, and other regional dermatoses. Foil CS. **Vet Clin North Am Small Anim Pract** 1995 Jul;25(4):923-44 (64 ref.)

FOOT DISEASES

Tibialis posterior tendon dysfunction and peroneal tendon subluxation. Hutchinson BL, et al. **Clin Podiatr Med Surg** 1995 Oct;12(4):703-23 (92 ref.)
Sinus tarsi syndrome. Beltran J. **Magn Reson Imaging Clin N Am** 1994 Feb;2(1):59-65 (18 ref.)
Chronic rupture of the posterior tibial tendon. Rosenberg ZS. **Magn Reson Imaging Clin N Am** 1994 Feb;2(1):79-87 (36 ref.)
Mesenchymal chondrosarcoma of the foot, an unusual location: case report and review of the literature. Sans M, et al. **Med Pediatr Oncol** 1996 Feb;26(2):139-42 (12 ref.)

COMPLICATIONS

Hypophosphatemic osteomalacia with plantar neurilemoma. A review of the literature (100 cases). Crouzet J, et al. **Rev Rhum Engl Ed** 1995 Jun;62(6):463-6 (34 ref.)

DIAGNOSIS

Lower extremity manifestations of Vibrio vulnificus infection. Laughlin TJ, et al. **J Foot Ankle Surg** 1995 Jul-Aug;34(4):354-7 (19 ref.)
Imaging of pedal soft tissue neoplasms. Levey DS, et al. **J Foot Ankle Surg** 1995 Jul-Aug;34(4):411-8 (23 ref.)
Magnetic resonance imaging manifestations of synovial lesions of the ankle and foot. Bergman AG. **Magn Reson Imaging Clin N Am** 1994 Feb;2(1):131-8 (33 ref.)
Achilles tendon and miscellaneous tendon lesions. Chandnani VP, et al. **Magn Reson Imaging Clin N Am** 1994 Feb; 2(1):89-96 (21 ref.)
Magnetic resonance imaging of pediatric disorders of the ankle and foot. Schoenberg NY, et al. **Magn Reson Imaging Clin N Am** 1994 Feb;2(1):109-22 (51 ref.)
Tumors of the ankle and foot. Shankman S, et al. **Magn Reson Imaging Clin N Am** 1994 Feb;2(1):139-53 (57 ref.)

DRUG THERAPY

Considerations of prescription medications for the pregnant podiatric patient. Haverstock BD, et al. **J Am Podiatr Med Assoc** 1996 Jul;86(7):334-46 (108 ref.)

GENETICS

Piezogenic pedal papules in two family members. Gibney MD, et al. **Cutis** 1996 Apr;57(4):260-2 (12 ref.)

MICROBIOLOGY

Motile Aeromonas as agent of infections of the foot. Wakabongo M. **J Am Podiatr Med Assoc** 1995 Sep; 85(9):505-8 (53 ref.)

NURSING

The diagnosis and management of plantar fasciitis. Quaschnick MS. **Nurse Pract** 1996 Apr;21(4):50-4, 60-3, quiz 64-5 (33 ref.)

PATHOLOGY

Clear cell dermatofibroma. Case report of an unusual fibrohistiocytic lesion. Zelger BW, et al. **Am J Surg Pathol** 1996 Apr;20(4):483-91 (23 ref.)
Magnetic resonance imaging and histopathologic appearances of benign soft-tissue masses of the foot. Logan PM, et al. **Can Assoc Radiol J** 1996 Feb;47(1):36-43 (9 ref.)
Subcutaneous and superficial granuloma pyogenicum. Park YH, et al. **Int J Dermatol** 1996 Mar;35(3):205-6 (9 ref.)

FOOT DISEASES

Lipoblastoma of the foot. Gilbert TJ, et al. **Skeletal Radiol** 1996 Apr;25(3):283–6 (25 ref.)

SURGERY

Surgical hemostasis by pneumatic ankle tourniquet during 3027 podiatric operations. Derner R, et al. **J Foot Ankle Surg** 1995 May–Jun;34(3):236–46 (87 ref.)
Appropriate methods for bone fixation [editorial] Reinherz RP. **J Foot Ankle Surg** 1996 Mar–Apr;35(2):93 (29 ref.)
Morton's interdigital neuroma: a clinical review of its etiology, treatment, and results. Wu KK. **J Foot Ankle Surg** 1996 Mar–Apr;35(2):112–9; discussion 187–8 (41 ref.)

THERAPY

The dose effect of continuous passive motion in postoperative rehabilitation of the first metatarsophalangeal joint. Lawrence BR. **J Foot Ankle Surg** 1996 Mar–Apr; 35(2):155–61; discussion 190–1 (73 ref.)

VETERINARY

Calcinosis circumscripta in the footpad of a dog. Joffe DJ. **Can Vet J** 1996 Mar;37(3):161–2 (11 ref.)
Orthopedic conditions of small ruminants. Llama, sheep, goat, and deer. Kaneps AJ. **Vet Clin North Am Food Anim Pract** 1996 Mar;12(1):211–31 (51 ref.)

FOOT INJURIES

Tibialis posterior tendon dysfunction and peroneal tendon subluxation. Hutchinson BL, et al. **Clin Podiatr Med Surg** 1995 Oct;12(4):703–23 (92 ref.)
Gunshot wounds to the foot and ankle. Sergi AR, et al. **Clin Podiatr Med Surg** 1995 Oct;12(4):689–702 (41 ref.)

COMPLICATIONS

[Post-traumatic psoriatic arthritis. 2 cases] Thomachot B, et al. **Presse Med** 1996 Jan 6–13;25(1):21–4 (13 ref.) (Eng. Abstr.) **(Fre)**

NURSING

The diagnosis and management of plantar fasciitis. Quaschnick MS. **Nurse Pract** 1996 Apr;21(4):50–4, 60–3, quiz 64–5 (33 ref.)

SURGERY

Treatment of open fractures of the foot and ankle: a preliminary report. Acello AN, et al. **J Foot Ankle Surg** 1995 Jul–Aug;34(4):329–46 (92 ref.)

THERAPY

Subtalar joint dislocations. Bohay DR, et al. **Foot Ankle Int** 1995 Dec;16(12):803–8 (16 ref.)

FOOT JOINT see **TARSAL JOINT**

FOOT ULCER

DIAGNOSIS

[Recurrent ulcers associated with Hodgkin's lymphoma] Lara Fernández A, et al. **Rev Clin Esp** 1996 May;196(5):337, 340–1 (15 ref.) **(Spa)**

PATHOLOGY

The role of diabetic neuropathy and high plantar pressures in the pathogenesis of foot ulceration. Katoulis EC, et al. **Horm Metab Res** 1996 Apr;28(4):159–64 (62 ref.)

THERAPY

A healed ulcer: what now? Walsh CH. **Diabet Med** 1996;13 Suppl 1:S58–60 (16 ref.)

FOOT ULCER, DIABETIC see **DIABETIC FOOT**

FOOTBALL

INJURIES

Injury data collection in the rugby codes. Lower T. **Aust J Sci Med Sport** 1995 Jun;27(2):38–42 (49 ref.)
Cervical spinal stenosis with cord neurapraxia and transient quadriplegia. Torg JS. **Sports Med** 1995 Dec;20(6):429–34 (10 ref.)

FOOTPRINTS, DNA see **DNA FOOTPRINTING**

FORAMEN MAGNUM

SURGERY

Surgical indication and results of foramen magnum decompression versus syringosubarachnoid shunting for syringomyelia associated with Chiari I malformation. Hida K, et al. **Neurosurgery** 1995 Oct;37(4):673–8; discussion 678–9 (33 ref.)

FORAMEN OF MONRO see **CEREBRAL VENTRICLES**

FORAMEN OVALE see **HEART SEPTUM**

FORAMEN OVALE, PATENT see **HEART SEPTAL DEFECTS, ATRIAL**

FOREARM

Desmoplastic melanoma of the hand: case reports and review of the literature. Chung KC, et al. **J Hand Surg [Am]** 1995 Sep;20(5):873–6 (10 ref.)

ABNORMALITIES

Congenital hand and forearm anomalies. Louis DS, et al. **Curr Opin Pediatr** 1996 Feb;8(1):61–4 (12 ref.)

ANATOMY & HISTOLOGY

A walk through the anatomy of the hand and forearm. Riordan DC. **J Hand Ther** 1995 Apr–Jun;8(2):68–78 (9 ref.)

INNERVATION

Anatomic considerations of the peripheral nerve in compressive neuropathies of the upper extremity. George V, et al. **Orthop Clin North Am** 1996 Apr;27(2):211–8 (22 ref.)
Intraepineurial constriction of nerve fascicles in pronator syndrome and anterior interosseous nerve syndrome. Haussmann P, et al. **Orthop Clin North Am** 1996 Apr; 27(2):339–44 (13 ref.)

PATHOLOGY

Chronic disorders of the forearm. Richards RR. **J Bone Joint Surg Am** 1996 Jun;78(6):916–30 (143 ref.)

SURGERY

Extradigital glomus tumour. Takei TR, et al. **J Hand Surg [Br]** 1995 Jun;20(3):409–12 (26 ref.)

FOREARM INJURIES

DIAGNOSIS

Bony injuries of the wrist, forearm, and elbow. Griggs SM, et al. **Clin Sports Med** 1996 Apr;15(2):373–400 (114 ref.)
Unusual problems of the athlete's elbow, forearm, and wrist. Shaffer B, et al. **Clin Sports Med** 1996 Apr;15(2):425–38 (11 ref.)

SURGERY

Flap reconstruction in the upper limb. Ikuta Y, et al. **Ann Acad Med Singapore** 1995 Jul;24(4 Suppl):124–30 (10 ref.)
Current concepts of replantation. Raskin KB, et al. **Ann Acad Med Singapore** 1995 Jul;24(4 Suppl):131–4 (29 ref.)

FOREBRAIN see **PROSENCEPHALON**

FORECASTING

Prenatal care: an update and future trends. Groutz A, et al. **Curr Opin Obstet Gynecol** 1995 Dec;7(6):452–60 (83 ref.)
Future directions in clinical research in Wilms tumor. Green DM, et al. **Hematol Oncol Clin North Am** 1995 Dec; 9(6):1329–39 (57 ref.)
Reading the changes: new frontiers in dialysis [editorial] Bonomini V. **Int J Artif Organs** 1995 Feb;18(2):59–63 (15 ref.)
Molecular conjugates: a targeted gene delivery vector for molecular medicine. Cristiano RJ, et al. **J Mol Med** 1995 Oct;73(10):479–86 (45 ref.)
How predictable are the results of excimer laser photorefractive keratectomy? A review. Grosvenor T. **Optom Vis Sci** 1995 Oct;72(10):698–712 (55 ref.)
[Digestive surgery using the celioscopic route. Prospects for the future] Périssat J. **Bull Acad Natl Med** 1996 Mar; 180(3):679–91; discussion 691–6 (30 ref.) (Eng. Abstr.) **(Fre)**
[The future and forseeable of intravascular echographic technics] Balbarini A. **Cardiologia** 1996 Jun;41(6):501–4 (42 ref.) **(Ita)**
[Assessing the basic stages of the phagocytic process: current approaches to and prospects for research development] Khaitov RM, et al. **Patol Fiziol Eksp Ter** 1995 Jul–Sep; (3):3–10 (59 ref.) (Eng. Abstr.) **(Rus)**

METHODS

Definitions of attributable risk—revisited. Gefeller O. **Public Health Rev** 1995;23(4):343–55 (47 ref.)

FOREFOOT, HUMAN

SURGERY

Long-term results of forefoot arthroplasty in patients with rheumatoid arthritis. Patsalis T, et al. **Orthopedics** 1996 May;19(5):439–47 (48 ref.)

ULTRASONOGRAPHY

[Form and structure of the metatarsal head arch in adults. Ultrasonographic and podometric studies] Hermann B. **Z Orthop Ihre Grenzgeb** 1995 Jul–Aug;133(4):335–40 (55 ref.) (Eng. Abstr.) **(Ger)**

FOREHEAD

PATHOLOGY

Primary lipogranuloma of the forehead. Lang S, et al. **Am J Otolaryngol** 1995 Sep–Oct;16(5):354–6 (19 ref.)

SURGERY

Endoscopic forehead lift. Aesthetics and analysis. Daniel RK, et al. **Clin Plast Surg** 1995 Oct;22(4):605–18 (32 ref.)
The biplanar endoscopically assisted forehead lift. Oslin B, et al. **Clin Plast Surg** 1995 Oct;22(4):633–8 (4 ref.)

FOREIGN AID see **INTERNATIONAL COOPERATION**

FOREIGN BODIES

Foreign bodies in the gastrointestinal tract. Stack LB, et al. **Emerg Med Clin North Am** 1996 Aug;14(3):493–521 (88 ref.)
Foreign body aspiration in dentistry: a review. Cameron SM, et al. **J Am Dent Assoc** 1996 Aug;127(8):1224–9 (30 ref.)
Shotgun wounds and pellet emboli: case reports and review of the literature. Yoshioka H, et al. **J Trauma** 1995 Sep; 39(3):596–601 (33 ref.)
Retained intraaortic balloon. Case report and review of the literature. Grande AM, et al. **Tex Heart Inst J** 1995; 22(4):332–4 (19 ref.)
[Foreign body in the liver] Tanimura H. **Ryoikibetsu Shokogun Shirizu** 1995;(8):496–8 (17 ref.) **(Jpn)**

COMPLICATIONS

Neuralgia-like symptoms in a patient with an airgun pellet in the ethmoid sinus: a case report. Donald PJ, et al. **J Laryngol Otol** 1995 Jul;109(7):646–9 (19 ref.)

DIAGNOSIS

Airway foreign bodies. Kelly SM, et al. **Chest Surg Clin N Am** 1996 May;6(2):253–76 (42 ref.)

EPIDEMIOLOGY

Airway foreign bodies in children. Somanath BP, et al. **Indian Pediatr** 1995 Aug;32(8):890–7 (26 ref.)

ETIOLOGY

[Intravesical foreign body caused arising from ureterostomy protective resin-gum] Oliver Llinares FJ, et al. **Arch Esp Urol** 1995 Oct;48(8):847–8 (6 ref.) (Eng. Abstr.) **(Spa)**

SURGERY

Foreign bodies of dental origin in the appendix. Mellor TK, et al. **J R Army Med Corps** 1995 Oct;141(3):174–6 (25 ref.)

THERAPY

Use of cardiopulmonary bypass during bronchoscopy following sand aspiration. A case report. Mellema JD, et al. **Chest** 1995 Oct;108(4):1176–7 (6 ref.)
Airway foreign bodies. Kelly SM, et al. **Chest Surg Clin N Am** 1996 May;6(2):253–76 (42 ref.)
Removal of superglue from the external ear using acetone: case report and literature review. Abadir WF, et al. **J Laryngol Otol** 1995 Dec;109(12):1219–21 (5 ref.)
Laser-assisted removal of a foreign body in the bronchial system of an infant. Boelcskei PL, et al. **Lasers Surg Med** 1995;17(4):375–7 (20 ref.)

FOREIGN-BODY GRANULOMA see **GRANULOMA, FOREIGN-BODY**

FOREIGN-BODY MIGRATION

Paradoxical bullet embolism: case report and literature review. Schurr M, et al. **J Trauma** 1996 Jun;40(6):1034–6 (11 ref.)
[Uterine perforation and localization of an IUD in the bladder associated with bladder calculosis. Report of a case and review of the literature] Reyes-Acevedo J, et al. **Ginecol Obstet Mex** 1995 Oct;63:407–9 (13 ref.) (Eng. Abstr.) **(Spa)**

CHEMICALLY INDUCED

Injectable silicone: cause of facial nodules, cellulitis, ulceration, and migration. Rapaport MJ, et al. **Aesthetic Plast Surg** 1996 May–Jun;20(3):267–76 (34 ref.)

COMPLICATIONS

Buckshot colic: case report and review of the literature [see comments] Fildes JJ, et al. **J Trauma** 1995 Dec;39(6):1181–4 (27 ref.) Comment in: J Trauma 1996 Jun;40(6):1054.
Tricuspid insufficiency after intracardiac migration of a Greenfield filter: case report and review of the literature. James KV, et al. **J Vasc Surg** 1996 Sep;24(3):494–8 (21 ref.)

Migration of jugular or subclavian venous catheters into inferior tributaries of the brachiocephalic veins or into the azygos vein, with possible complications. Currarino G. **Pediatr Radiol** 1996 Jul;26(7):439–49 (52 ref.)

ETIOLOGY

[Anal migration of ventriculo-peritoneal shunt catheter. Apropos of 3 cases] Sami A, et al. **Neurochirurgie** 1995; 41(4):315–8 (25 ref.) (Eng. Abstr.) **(Fre)**

RADIOGRAPHY

Radiological case of the month. Shunt migration into the thorax. Huang PP, et al. **Arch Pediatr Adolesc Med** 1996 Mar;150(3):323–4 (13 ref.)

Carotid artery pseudoaneurysm and pellet embolism to the middle cerebral artery following a shotgun wound of the neck. Cogbill TH, et al. **J Trauma** 1995 Oct;39(4):763–7 (16 ref.)

CT of a peripatetic intracranial foreign body. Bearcroft PW, et al. **Neuroradiology** 1995 Oct;37(7):542–4 (16 ref.)

FOREIGN-BODY REACTION

[Destructive paraffinoma of the breast and thoracic wall caused by paraffin injection for mammary increase. Apropos of 3 cases with review of the literature] Zekri A, et al. **Ann Chir Plast Esthet** 1996 Feb;41(1):90–3 (7 ref.) (Eng. Abstr.) **(Fre)**

CHEMICALLY INDUCED

Injectable silicone: cause of facial nodules, cellulitis, ulceration, and migration. Rapaport MJ, et al. **Aesthetic Plast Surg** 1996 May–Jun;20(3):267–76 (34 ref.)

PHYSIOPATHOLOGY

Periprosthetic osteolysis in total hip arthroplasty: the role of particulate wear debris. Maloney WJ, et al. **Instr Course Lect** 1996;45:171–82 (85 ref.)

PREVENTION & CONTROL

Biocompatibility and immunology in the encapsulation of islets of Langerhans (bioartificial pancreas). Zekorn TD, et al. **Int J Artif Organs** 1996 Apr;19(4):251–7 (34 ref.)

FORELIMB

PHYSIOLOGY

Monosynaptic Ia pathways and motor behaviour of the cat distal forelimb. Illert M. **Acta Neurobiol Exp (Warsz)** 1996; 56(1):423–34 (29 ref.)

FORENSIC ANTHROPOLOGY

METHODS

Superimposition and reconstruction in forensic facial identification: a survey. Aulsebrook WA, et al. **Forensic Sci Int** 1995 Oct 30;75(2–3):101–20 (230 ref.)

FORENSIC DENTISTRY

Molecular biological studies on teeth, and inquests. Yamamoto K. **Forensic Sci Int** 1996 Jun 28;80(1–2):79–87 (21 ref.)

METHODS

Use of orthopantomography in forensic identification. Doychinov I, et al. **Folia Med (Plovdiv)** 1994;36(3):57–61 (6 ref.)

FORENSIC MEDICINE

Forensic science. Brettell TA, et al. **Anal Chem** 1995 Jun 15;67(12):273R–294R (843 ref.)

Role of the clinical toxicologist in court. Chamberlain RT. **Clin Chem** 1996 Aug;42(8 Pt 2):1337–41 (29 ref.)

Molecular genetic basis of red cell markers and its forensic application. Ikemoto S, et al. **Forensic Sci Int** 1996 Jun 28;80(1–2):147–61 (42 ref.)

Current research and case work activities of criminalistics in Japan. Seta S. **Forensic Sci Int** 1996 Jun 28; 80(1–2):109–35 (83 ref.)

Penetrating gunshots to the head and lack of immediate incapacitation. I. Wound ballistics and mechanisms of incapacitation. Karger B. **Int J Legal Med** 1995; 108(2):53–61 (90 ref.)

Nursing interventions in Münchausen syndrome by proxy. Volz AG. **J Psychosoc Nurs Ment Health Serv** 1995 Sep; 33(9):51–8 (13 ref.)

Handwriting in health and disease. Ficarra BJ. **Leg Med** 1995; :261–78 (22 ref.)

Death registration and cause-of-death statements. Hanzlick R. **Leg Med** 1995;:117–45 (50 ref.)

DNA technology in forensic applications. Hochmeister MN. **Mol Aspects Med** 1995;16(4):315–437 (345 ref.)

Forensic perspectives of electrical and lightning injuries. Jumbelic MI. **Semin Neurol** 1995 Dec;15(4):342–50 (31 ref.)

Sleep-related violence: a medical and forensic challenge. Broughton RJ, et al. **Sleep** 1995 Nov;18(9):727–30 (42 ref.)

Forensic sleep medicine and nocturnal wandering. Guilleminault C, et al. **Sleep** 1995 Nov;18(9):721–3 (15 ref.)

Complex motor behavior arising during the sleep period: forensic science implications. Mahowald MW, et al. **Sleep** 1995 Nov;18(9):724–7 (26 ref.)

Neurobehavioral assessment in toxic injury evaluations. Lees-Haley PR. **Toxicol Lett** 1995 Dec;82–83:197–202 (58 ref.)

[Searching for genetic markers—in the fields of forensic medicine and human genetics] Ikemoto S. **Nippon Hoigaku Zasshi** 1995 Dec;49(6):419–31 (36 ref.) (Eng. Abstr.) **(Jpn)**

[Relationship among "kenshi" (inquest), "kenshi" (postmortem examination) and "ken-an" (postmortem inspection) in Japan] Mikami H, et al. **Nippon Hoigaku Zasshi** 1995 Dec; 49(6):488–97 (74 ref.) (Eng. Abstr.) **(Jpn)**

[Sudden unexpected natural death from a viewpoint of forensic pathology] Takatsu A. **Nippon Hoigaku Zasshi** 1995 Dec;49(6):432–46 (37 ref.) (Eng. Abstr.) **(Jpn)**

[Application of enzyme-linked immunosorbent assay (ELISA) to the medico-legal identification] Komuro T, et al. **Nippon Rinsho** 1995 Sep;53(9):2322–9 (13 ref.) (Eng. Abstr.) **(Jpn)**

[PCR amplification on forensic science] Kasai K. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):738–43 (20 ref.) **(Jpn)**

LEGISLATION & JURISPRUDENCE

Medicolegal investigative system and sudden death in Scandinavia. Saukko P. **Nippon Hoigaku Zasshi** 1995 Dec; 49(6):458–65 (7 ref.)

METHODS

Mutation processes at human minisatellites. Jeffreys AJ, et al. **Electrophoresis** 1995 Sep;16(9):1577–85 (49 ref.)

Forensic applications of genetic polymorphisms detected in human body fluids (urine, semen and blood). Kishi K, et al. **Forensic Sci Int** 1996 Jun 28;80(1–2):89–97 (55 ref.)

DNA markers in forensic medicine. Mayr WR. **Transfus Clin Biol** 1995;2(4):325–8 (4 ref.)

STANDARDS

On the need for more expertise in death investigation (and a National Office of Death Investigation Affairs?) [editorial] Hanzlick R. **Arch Pathol Lab Med** 1996 Apr; 120(4):329–32 (26 ref.)

Statistical and genetic aspects of quality control for DNA identification. Morton NE, et al. **Electrophoresis** 1995 Sep; 16(9):1670–7 (30 ref.)

Crime laboratory proficiency testing results, 1978–1991, II: Resolving questions of common origin. Peterson JL, et al. **J Forensic Sci** 1995 Nov;40(6):1009–29 (4 ref.)

Crime laboratory proficiency testing results, 1978–1991, I: Identification and classification of physical evidence. Peterson JL, et al. **J Forensic Sci** 1995 Nov;40(6):994–1008 (52 ref.)

FORENSIC PSYCHIATRY

Psychoactive substance use in forensic psychiatry. Kermani EJ, et al. **Am J Drug Alcohol Abuse** 1996 Feb;22(1):1–27 (173 ref.)

The False Memory Syndrome debate—will the victim please stand up? Choiniere M. **J Contemp Health Law Policy** 1996 Spring;12(2):675–700 (201 ref.)

Malingering a challenge for the forensic examiner. Palermo GB, et al. **Med Law** 1996;15(1):143–60 (25 ref.)

LEGISLATION & JURISPRUDENCE

[Some medico-psychological perspectives on sexual homicides. Three cases] Bénézech M. **Ann Med Psychol (Paris)** 1995 Oct;153(8):501–11 (22 ref.) (Eng. Abstr.) **(Fre)**

FORESTIER-CERTONCINY SYNDROME see **POLYMYALGIA RHEUMATICA**

FORESTIER DISEASE see **HYPEROSTOSIS, DIFFUSE IDIOPATHIC SKELETAL**

FORESTRY

Effects of smog on absenteeism in forestry workers. Moll Van Charante AW, et al. **Arch Environ Health** 1996 Jan–Feb;51(1):34–41 (39 ref.)

[Arachnids as risk factors in occupational exposure] Dutkiewicz J. **Wiad Parazytol** 1995;41(3):253–66 (48 ref.) (Eng. Abstr.) **(Pol)**

FORM PERCEPTION

Origins and early development of perception, action, and representation. Bertenthal BI. **Annu Rev Psychol** 1996; 47:431–59 (150 ref.)

PHYSIOLOGY

Eye movement and visual localization of objects in space. Skavenski AA. **Rev Oculomot Res** 1990;4:263–87 (110 ref.)

The role of eye movements in the perception of motion and shape. Wallach H. **Rev Oculomot Res** 1990;4:289–305 (24 ref.)

FORMALDEHYDE

Formaldehyde disinfection in laboratories: limitations and hazards. Cheney JE, et al. **Br J Biomed Sci** 1995 Sep; 52(3):195–201 (53 ref.)

ADVERSE EFFECTS

Formaldehyde. **IARC Monogr Eval Carcinog Risks Hum** 1995;62:217–375 (479 ref.)

[Formaldehyde in the environment and its effect on health] Kalinić N. **Arh Hig Rada Toksikol** 1995 Jun;46(2):259–73 (35 ref.) (Eng. Abstr.) **(Scr)**

ANALYSIS

[Formaldehyde in the environment and its effect on health] Kalinić N. **Arh Hig Rada Toksikol** 1995 Jun;46(2):259–73 (35 ref.) (Eng. Abstr.) **(Scr)**

FORMALIN see **FORMALDEHYDE**

FORMALIN TEST see **PAIN MEASUREMENT**

FORMICOIDEA VENOMS see **ANT VENOMS**

N-FORMIMIDOYLTHIENAMYCIN see **IMIPENEM**

FORMIMINOGLUTAMIC ACID

URINE

[Formiminoglutamic acid (FIGLU)] Owada M. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:518–22 (14 ref.) **(Jpn)**

FORMS AND RECORDS CONTROL

see related
MEDICAL RECORDS SYSTEMS, COMPUTERIZED

METHODS

Research practice and data management. van Es GA. **Neth J Med** 1996 Jan;48(1):38–44 (7 ref.)

STANDARDS

In pursuit of excellence: quality assurance, documentation, and peer review by home birth CNMs. Morales ME, et al. **J Nurse Midwifery** 1995 Nov–Dec;40(6):555–69 (56 ref.)

Death registration and cause-of-death statements. Hanzlick R. **Leg Med** 1995;:117–45 (50 ref.)

FORMULARIES

see related
PHARMACOPOEIAS

FORMULARY, NATIONAL see **PHARMACOPOEIAS**

N(5)-FORMYLTETRAHYDROFOLATE see **LEUCOVORIN**

FOS-ASSOCIATED PROTEIN P39 see **PROTO-ONCOGENE PROTEINS C-JUN**

FOS B PROTEIN see **PROTO-ONCOGENE PROTEINS C-FOS**

FOS GENES see **GENES, FOS**

FOS ONCOGENE PROTEINS see **ONCOGENE PROTEINS V-FOS**

FOS PROTO-ONCOGENE PROTEINS see **PROTO-ONCOGENE PROTEINS C-FOS**

FOS-RELATED ANTIGENS see **PROTO-ONCOGENE PROTEINS C-FOS**

FOSCARNET

ADVERSE EFFECTS

Nephrogenic diabetes insipidus and renal tubular acidosis secondary to foscarnet therapy. Navarro JF, et al. **Am J Kidney Dis** 1996 Mar;27(3):431–4 (16 ref.)

THERAPEUTIC USE

Current management of cytomegalovirus retinitis in AIDS update on ganciclovir and foscarnet for CMV infections. Jacobson MA. **Adv Exp Med Biol** 1996;394:85–92 (28 ref.)

Controversies in the treatment of cytomegalovirus retinitis: foscarnet versus ganciclovir. Jabs DA. **Infect Agents Dis** 1995 Sep;4(3):131–42 (63 ref.)

Management of cytomegalovirus infection. The Jefferiss Wing Therapeutics and Protocols Group. Fisher M, et al. **Int J STD AIDS** 1995 Sep–Oct;6(5):313–9 (28 ref.)

FOSSIL FUELS

Fossil fuel biodegradation: laboratory studies. Chapman PJ, et al. **Environ Health Perspect** 1995 Jun;103 Suppl 5:79–83 (14 ref.)

FOSSILS

Developmental evolution of metazoan bodyplans: the fossil evidence. Valentine JW, et al. **Dev Biol** 1996 Feb 1; 173(2):373–81 (88 ref.)

FOSTER HOME CARE

Prenatally drug-exposed children in out-of-home care: are we looking at the whole picture? Franck EJ. **Child Welfare** 1996 Jan-Feb;75(1):19–34 (30 ref.)

Infants and young children in orphanages: one view from pediatrics and child psychiatry. Frank DA, et al. **Pediatrics** 1996 Apr;97(4):569–78 (173 ref.)

Psychopathology among children placed in family foster care. Pilowsky D. **Psychiatr Serv** 1995 Sep;46(9):906–10 (32 ref.)

PSYCHOLOGY

A closer look at self-image in male foster care adolescents. Lyman SB, et al. **Soc Work** 1996 Jan;41(1):85–96 (70 ref.)

FOUNDATIONS

Foundations' impact on policy making: results from a pilot study. Weissert CS, et al. **Health Aff (Millwood)** 1995 Winter;14(4):275–86 (31 ref.)

FOUR CORNERS VIRUS see **HANTAVIRUS**

FOURIER ANALYSIS

Spectral analysis of clinical signals: an interface between medical statisticians and medical engineers. Campbell MJ. **Stat Methods Med Res** 1996 Mar;5(1):51–66 (54 ref.)

FOURIER SERIES see **FOURIER ANALYSIS**

FOURIER TRANSFORM see **FOURIER ANALYSIS**

FOURIER TRANSFORM INFRARED SPECTROSCOPY see **SPECTROSCOPY, FOURIER TRANSFORM INFRARED**

FOURNIER'S DISEASE see **FOURNIER'S GANGRENE**

FOURNIER'S GANGRENE

Fournier's gangrene: a urologic emergency. Anzai AK. **Am Fam Physician** 1995 Nov 1;52(6):1821–5 (06 ref.)

Gangrene of the perineum. Benizri E, et al. **Urology** 1996 Jun;47(6):935–9 (36 ref.)

[Fournier's gangrene. A special form of necrotizing fasciitis] Gerdes B, et al. **Dtsch Med Wochenschr** 1996 Aug 16; 121(33):1021–4 (37 ref.) **(Ger)**

DIAGNOSIS

[Fournier's gangrene. Experiences and changes in the disease picture since its initial description] Thum P, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Aug; 30(5):315–9 (43 ref.) (Eng. Abstr.) **(Ger)**

RADIOGRAPHY

[Fournier's gangrene in a woman in computed tomography] Lehmann KJ, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1995 Nov;163(5):446–8 (15 ref.) **(Ger)**

FOVEA CENTRALIS

PATHOLOGY

A foveal-sparing pattern of cytomegalovirus retinitis in the acquired immunodeficiency syndrome. Luckie AP, et al. **Aust N Z J Ophthalmol** 1996 Feb;24(1):53–9 (23 ref.)

FOWL PARALYSIS see **MAREK'S DISEASE**

FOWL PEST see **FOWL PLAGUE**

FOWL PLAGUE

TRANSMISSION

Interspecies transmission of influenza viruses. Webster RG, et al. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 2):S25–30 (27 ref.)

FOWL PLAGUE VIRUS see **ORTHOMYXOVIRUS TYPE A, AVIAN**

FOWLS, DOMESTIC see **POULTRY**

FOXES

METABOLISM

Environmental pollutants in marine mammals from the Norwegian coast and Arctic. Skaare JU. **Sci Total Environ** 1996 Jul 16;186(1-2):25–7 (12 ref.)

PARASITOLOGY

[Importance of epidemiology and control of the fox tapeworm, Echinococcus multilocularis, in Germany] Daugschies A. **DTW Dtsch Tierarztl Wochenschr** 1995 Aug; 102(8):306–10 (73 ref.) (Eng. Abstr.) **(Ger)**

FRACTALS

see related
NONLINEAR DYNAMICS

Self-similarity and fractal irregularity in pathologic tissues. Losa GA, et al. **Mod Pathol** 1996 Mar;9(3):174–82 (79 ref.)

Fractals in pathology: are they really useful? Losa GA. **Pathologica** 1995 Jun;87(3):310–7 (74 ref.)

FRACTURE FIXATION

see related
EXTERNAL FIXATORS
ORTHOPEDIC FIXATION DEVICES

Orthopedic treatment of hip fracture. Obrant K. **Bone** 1996 Mar;18(3 Suppl):145S–148S (31 ref.)

METHODS

Indications and techniques for external fixation of the pelvis. Poka A, et al. **Clin Orthop** 1996 Aug;(329):54–9 (18 ref.)

Treatment of comminuted mandibular fractures by closed reduction. Finn RA. **J Oral Maxillofac Surg** 1996 Mar; 54(3):320–7 (85 ref.)

FRACTURE FIXATION, INTERNAL

see related
INTERNAL FIXATORS

Treatment of comminuted mandibular fractures by open reduction and rigid internal fixation. Smith BR, et al. **J Oral Maxillofac Surg** 1996 Mar;54(3):328–31 (54 ref.)

Volar transscaphoid perilunate fracture dislocation: case report and review. Hayeems EB, et al. **J Trauma** 1996 Jun; 40(6):1031–3 (14 ref.)

[Diagnosis and therapy of local infections after surgical management of proximal femoral fractures] Dávid A, et al. **Zentralbl Chir** 1995;120(11):887–92 (29 ref.) (Eng. Abstr.) **(Ger)**

[Classification, therapy and complications of pediatric femoral neck fractures] Hahn MP, et al. **Zentralbl Chir** 1995;120(11):832–40 (56 ref.) (Eng. Abstr.) **(Ger)**

INSTRUMENTATION

[Current status of therapy of subtrochanteric femoral fractures] Hoffmann R, et al. **Unfallchirurg** 1996 Apr; 99(4):240–8 (44 ref.) (Eng. Abstr.) **(Ger)**

METHODS

The rationales of interlocking nailing of the femur, tibia, and humerus. Brumback RJ. **Clin Orthop** 1996 Mar; (324):292–320 (142 ref.)

The internal fixation of ankle fracture repair. Savage TJ, et al. **Clin Podiatr Med Surg** 1995 Oct;12(4):603–31 (82 ref.)

Transfibular osteotomy in the correction of ankle joint incongruity. Davis JL, et al. **J Foot Ankle Surg** 1995 Jul-Aug;34(4):389–99 (23 ref.)

Talar fracture/dislocation in the adolescent patient. Valentine BC 2nd, et al. **J Foot Ankle Surg** 1995 Jul-Aug;34(4):379–83 (11 ref.)

[Secondary internal osteosynthesis after external fixation for recent or old open fracture of the lower limb] Bernat M, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1996; 82(2):137–44 (18 ref.) (Eng. Abstr.) **(Fre)**

[Plate osteosynthesis in humerus shaft fracture] Kuner EH, et al. **Chirurg** 1995 Nov;66(11):1085–91 (14 ref.) (Eng. Abstr.) **(Ger)**

[Fractures of the distal humerus and proximal forearm] Dorow C, et al. **Unfallchirurg** 1996 Jun;99(6):440–9 (10 ref.) **(Ger)**

[Medial femoral neck fracture—femur head preserving therapeutic concepts] Dávid A, et al. **Zentralbl Chir** 1995; 120(11):841–9 (45 ref.) (Eng. Abstr.) **(Ger)**

[Pertrochanteric fractures] Stürmer KM, et al. **Zentralbl Chir** 1995;120(11):862–72 (25 ref.) (Eng. Abstr.) **(Ger)**

VETERINARY

Fracture biology, biomechanics, and internal fixation. Trostle SS, et al. **Vet Clin North Am Food Anim Pract** 1996 Mar; 12(1):19–46 (52 ref.)

FRACTURE FIXATION, INTRAMEDULLARY

see related
INTERNAL FIXATORS

[Local complications of intramedullary nailing] Strecker W, et al. **Orthopade** 1996 Jun;25(3):274–91 (59 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

[Systemic complications in intramedullary nailing] Wenda K, et al. **Orthopade** 1996 Jun;25(3):292–9 (28 ref.) (Eng. Abstr.) **(Ger)**

INSTRUMENTATION

[Borderline indications for locked intramedullary nailing of femur and tibia] Vécsei V, et al. **Orthopade** 1996 Jun; 25(3):234–46 (66 ref.) (Eng. Abstr.) **(Ger)**

[Management of ipsilateral fractures of the femur shaft and proximal femur—therapy overview and current management] Haas NP, et al. **Zentralbl Chir** 1995; 120(11):856–61 (19 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Intramedullary nailing after external fixation of the tibia. Tornetta P 3rd, et al. **Bull Hosp Jt Dis** 1995;54(1):5–13 (31 ref.)

[Intramedullary osteosynthesis: elastic or rigid?] Gillet P, et al. **Acta Orthop Belg** 1995;61 Suppl 1:144–9 (32 ref.) **(Fre)**

[Intramedullary nailing of the humerus as an alternative to conservative therapy and to plate osteosynthesis] Kessler SB, et al. **Orthopade** 1996 Jun;25(3):216–22 (57 ref.) (Eng. Abstr.) **(Ger)**

[Intramedullary nailing of open fractures] Krettek C, et al. **Orthopade** 1996 Jun;25(3):223–33 (63 ref.) (Eng. Abstr.) **(Ger)**

[Intramedullary nailing in multiple trauma] Nast-Kolb D, et al. **Orthopade** 1996 Jun;25(3):266–73 (32 ref.) (Eng. Abstr.) **(Ger)**

[Intramedullary nailing of lower leg fractures with minimal soft tissue injuries] Ruchholtz S, et al. **Orthopade** 1996 Jun; 25(3):197–206 (49 ref.) (Eng. Abstr.) **(Ger)**

[Pertrochanteric fractures] Stürmer KM, et al. **Zentralbl Chir** 1995;120(11):862–72 (25 ref.) (Eng. Abstr.) **(Ger)**

FRACTURE HEALING

PHYSIOLOGY

Enhancement of fracture healing. Einhorn TA. **Instr Course Lect** 1996;45:401–16 (140 ref.)

FRACTURES

The scapula: coracoid, acromial, and avulsion fractures. Goss TP. **Am J Orthop** 1996 Feb;25(2):106–15 (39 ref.)

Fractures of the lateral process of the talus: a clinical review. "Snowboarder's ankle". McCrory P, et al. **Clin J Sport Med** 1996 Apr;6(2):124–8 (13 ref.)

Transchondral fractures of the talar dome. Cox HA, et al. **Clin Podiatr Med Surg** 1995 Oct;12(4):667–87 (64 ref.)

Lisfranc's fracture-dislocation. A literature review and case presentations of tarsometatarsal joint injuries. Felder-Johnson KL, et al. **Clin Podiatr Med Surg** 1995 Oct;12(4):565–602 (61 ref.)

First metatarsal fractures. Saraiya MJ. **Clin Podiatr Med Surg** 1995 Oct;12(4):749–58 (20 ref.)

Intra-articular calcaneal fractures. Current concepts. Stone ML. **Clin Podiatr Med Surg** 1995 Oct;12(4):551–64 (19 ref.)

Fractures of the central metatarsals. Urteaga AJ, et al. **Clin Podiatr Med Surg** 1995 Oct;12(4):759–72 (51 ref.)

Midfoot fractures. Valkosky GJ, et al. **Clin Podiatr Med Surg** 1995 Oct;12(4):773–89 (44 ref.)

Fifth metatarsal fractures. Biomechanics, classification, and treatment. Vogler HW, et al. **Clin Podiatr Med Surg** 1995 Oct;12(4):725–47 (33 ref.)

Fractures of the calcaneus. Part I: Anatomy, injury mechanism, and classification. Lowery RB, et al. **Foot Ankle Int** 1996 Apr;17(4):230–5 (67 ref.)

Occult fracture of the calcaneus in toddlers. Schindler A, et al. **J Pediatr Orthop** 1996 Mar-Apr;16(2):201–5 (28 ref.)

COMPLICATIONS

Fracture blisters. Wallace GF, et al. **Clin Podiatr Med Surg** 1995 Oct;12(4):801–12 (19 ref.)

DIAGNOSIS

Magnetic resonance imaging of bone marrow and osteochondral injury. Vellet D. **Magn Reson Imaging Clin N Am** 1994 Aug;2(3):413–23 (22 ref.)

DRUG THERAPY

Comparison of intravenous and oral antibiotic therapy in the treatment of fractures caused by low-velocity gunshots. A prospective, randomized study of infection rates. Knapp TP, et al. **J Bone Joint Surg Am** 1996 Aug;78(8):1167–71 (35 ref.)

EPIDEMIOLOGY

Fractures in the elderly. Thorngren KG. **Acta Orthop Scand Suppl** 1995 Oct;266:208–10 (5 ref.)

The epidemiology of peripheral fractures. Baron JA, et al. **Bone** 1996 Mar;18(3 Suppl):209S–213S (29 ref.)
Dorsally displaced epiphyseal fracture of the phalangeal base. Hashizume H, et al. **J Hand Surg [Br]** 1996 Feb;21(1):136–8 (10 ref.)

ETIOLOGY

Fracturing osteoporosis after kidney transplantation--what are the options? Coen G. **Nephrol Dial Transplant** 1996 Apr;11(4):567–9 (17 ref.)
[Fracture of an ossified Achilles tendon] Krause K, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Feb;164(2):171–2 (9 ref.) **(Ger)**

GENETICS

Genetic influences on bone turnover, bone density and fracture. Kelly PJ, et al. **Eur J Endocrinol** 1995 Sep; 133(3):265–71 (42 ref.)

MORTALITY

[The characteristics of bone injuries in childhood] Kuznetsov LE, et al. **Sud Med Ekspert** 1996 Apr-Jun;39(2):7–9 (36 ref.) (Eng. Abstr.) **(Rus)**

NURSING

Meeting the challenge of the older trauma patient [published erratum appears in Am J Nurs 1996 Jun;96(6):17] Stamatos CA, et al. **Am J Nurs** 1996 May;96(5):40–7; quiz 48 (7 ref.)

PATHOLOGY

Avulsion fracture of the tuberosity of the calcaneus in children. A report of four cases and review of the literature. Cole RJ, et al. **J Bone Joint Surg Am** 1995 Oct; 77(10):1568–71 (14 ref.)

PHYSIOPATHOLOGY

The issue of vascularity in fractures and non-union of the scaphoid. Büchler U, et al. **J Hand Surg [Br]** 1995 Dec; 20(6):726–35 (86 ref.)
Complex carpal dislocation. Irwin LR, et al. **J Hand Surg [Br]** 1995 Dec;20(6):746–9 (15 ref.)

PREVENTION & CONTROL

Osteoporotic fractures: background and prevention strategies. Wark JD. **Maturitas** 1996 Mar;23(2):193–207 (140 ref.)

RADIOGRAPHY

Dislocation of the distal radioulnar joint associated with a transstyloid radiocarpal fracture dislocation. A case report and review of the literature. Stoffelen D, et al. **Acta Orthop Belg** 1996 Mar;62(1):52–5 (7 ref.)
Common elbow fractures in children. Townsend DJ, et al. **Am Fam Physician** 1996 May 1;53(6):2031–41 (7 ref.)
Unusual capitate fracture: a case report. Volk AG, et al. **J Hand Surg [Am]** 1995 Jul;20(4):581–2 (5 ref.)
[Views necessary for the traumatic wrist] Zeitoun F, et al. **Ann Radiol (Paris)** 1995;38(5):255–65 (25 ref.) (Eng. Abstr.) **(Fre)**
[clinical application of multiplanar and 3D reconstruction of spiral CT in diagnosis of acetabulum fractures] Stroszczynski C, et al. **Aktuelle Radiol** 1996 Mar;6(2):91–5 (23 ref.) (Eng. Abstr.) **(Ger)**
[Fracture of the lunatotriquetrum bone in the triquetral part. Case report and review of the literature] Höcker K, et al. **Handchir Mikrochir Plast Chir** 1995 Sep;27(5):254–7 (45 ref.) (Eng. Abstr.) **(Ger)**
[Pseudarthrosis of the atlas after Jefferson's fracture] Wichmann HU, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1995 Nov;163(5):452–3 (11 ref.) **(Ger)**

SURGERY

Advances in the management of musculoskeletal trauma. Lazarus MD, et al. **Curr Opin Gen Surg** 1993;:46–54 (26 ref.)
Talar fracture/dislocation in the adolescent patient. Valentine BC 2nd, et al. **J Foot Ankle Surg** 1995 Jul-Aug;34(4):379–83 (11 ref.)
Volar transscaphoid perilunate fracture dislocation: case report and review. Hayeems EB, et al. **J Trauma** 1996 Jun; 40(6):1031–3 (14 ref.)
[Intramedullary nailing in multiple trauma] Nast-Kolb D, et al. **Orthopade** 1996 Jun;25(3):266–73 (32 ref.) (Eng. Abstr.) **(Ger)**
[External fixation of bones (fixateur externe) in fracture treatment] Höntzsch D, et al. **Versicherungsmedizin** 1996 Jun 1;48(3):96–100 (18 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Common elbow fractures in children. Townsend DJ, et al. **Am Fam Physician** 1996 May 1;53(6):2031–41 (7 ref.)
History of rest and motion and the scientific basis for early continuous passive motion. Salter RB. **Hand Clin** 1996 Feb; 12(1):1–11 (66 ref.)
The management of complex orthopedic injuries. Alonso JE, et al. **Surg Clin North Am** 1996 Aug;76(4):879–903 (82 ref.)
[Treatment principles in hand fractures] Schuind F, et al. **Rev Med Brux** 1996 Jun;17(3):120–6 (40 ref.) (Eng. Abstr.) **(Fre)**

VETERINARY

Surgical management of digit disorders in cattle. Desrochers A, et al. **Vet Clin North Am Food Anim Pract** 1996 Mar; 12(1):277–98 (45 ref.)
Fractures and luxations of the pelvis and proximal femur. Hull BL. **Vet Clin North Am Food Anim Pract** 1996 Mar; 12(1):47–58 (25 ref.)
Orthopedic conditions of small ruminants. Llama, sheep, goat, and deer. Kaneps AJ. **Vet Clin North Am Food Anim Pract** 1996 Mar;12(1):211–31 (51 ref.)
Fracture biology, biomechanics, and internal fixation. Trostle SS, et al. **Vet Clin North Am Food Anim Pract** 1996 Mar; 12(1):19–46 (52 ref.)
Metacarpal and metatarsal fractures in cattle. Tulleners EP. **Vet Clin North Am Food Anim Pract** 1996 Mar; 12(1):199–209 (13 ref.)
Management of fracture-associated thoracic trauma. Cockshutt JR. **Vet Clin North Am Small Anim Pract** 1995 Sep;25(5):1031–46 (53 ref.)
Fracture management decisions. Roush JK. **Vet Clin North Am Small Anim Pract** 1995 Sep; 25(5):1059–72 (19 ref.)

FRACTURES, BLOW-OUT see **ORBITAL FRACTURES**

FRACTURES, CLOSED

COMPLICATIONS

Surgical management of soft tissue lesions associated with pelvic ring injury. Kottmeier SA, et al. **Clin Orthop** 1996 Aug;(329):46–53 (43 ref.)
Thromboembolic complications in patients with pelvic trauma. Montgomery KD, et al. **Clin Orthop** 1996 Aug; (329):68–87 (94 ref.)
Neurologic injuries in pelvic ring fractures. Reilly MC, et al. **Clin Orthop** 1996 Aug;(329):28–36 (32 ref.)
Urologic injuries in pelvic ring disruptions. Watnik NF, et al. **Clin Orthop** 1996 Aug;(329):37–45 (38 ref.)

SURGERY

Assessment of pelvic ring stability after injury. Indications for surgical stabilization. Olson SA, et al. **Clin Orthop** 1996 Aug;(329):15–27 (26 ref.)
Indications and techniques for external fixation of the pelvis. Poka A, et al. **Clin Orthop** 1996 Aug;(329):54–9 (18 ref.)
Irreducible fracture of the calcaneus due to flexor hallucis longus tendon interposition. Anglen JO, et al. **J Orthop Trauma** 1996;10(4):285–8 (4 ref.)
[Intramedullary nailing of lower leg fractures with minimal soft tissue injuries] Ruchholtz S, et al. **Orthopade** 1996 Jun; 25(3):197–206 (49 ref.) (Eng. Abstr.) **(Ger)**

FRACTURES, COMMINUTED

SURGERY

Treatment of comminuted mandibular fractures by open reduction and rigid internal fixation. Smith BR, et al. **J Oral Maxillofac Surg** 1996 Mar;54(3):328–31 (34 ref.)

THERAPY

Treatment of comminuted mandibular fractures by closed reduction. Finn RA. **J Oral Maxillofac Surg** 1996 Mar; 54(3):320–7 (85 ref.)

FRACTURES, COMPOUND see **FRACTURES, OPEN**

FRACTURES, FATIGUE see **FRACTURES, STRESS**

FRACTURES, MALUNITED

SURGERY

Tibiofibular arthrodesis for malunion of the talocrural joint. Loder BG, et al. **J Foot Ankle Surg** 1995 May-Jun; 34(3):283–8 (8 ref.)

FRACTURES, MARCH see **FRACTURES, STRESS**

FRACTURES, OPEN

A review of open tibia fractures in children. Kreder HJ, et al. **J Pediatr Orthop** 1995 Jul-Aug;15(4):482–8 (19 ref.)

NURSING

Surgical treatment of patients with open tibial fractures. Brown C, et al. **AORN J** 1996 May;63(5):875–81, 885–96; quiz 899–906 (31 ref.)

SURGERY

Surgical treatment of patients with open tibial fractures. Brown C, et al. **AORN J** 1996 May;63(5):875–81, 885–96; quiz 899–906 (31 ref.)
Treatment of open fractures of the foot and ankle: a preliminary report. Acello AN, et al. **J Foot Ankle Surg** 1995 Jul-Aug;34(4):329–46 (92 ref.)
Lower limb salvage: microvascular reconstruction of post-traumatic soft tissue and skeletal defects. Tomaino MM. **Orthopedics** 1995 Jul;18(7):665–72 (68 ref.)
[Secondary internal osteosynthesis after external fixation for recent or old open fracture of the lower limb] Bernat M, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1996; 82(2):137–44 (18 ref.) (Eng. Abstr.) **(Fre)**
[Intramedullary nailing of open fractures] Krettek C, et al. **Orthopade** 1996 Jun;25(3):223–33 (63 ref.) (Eng. Abstr.) **(Ger)**
[Concept for the management of combined bone-soft tissue defects of the lower extremity] Amgwerd MG, et al. **Swiss Surg** 1995;(2):90–5 (30 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Treatment of open fractures. Healey KM, et al. **Clin Podiatr Med Surg** 1995 Oct;12(4):791–800 (17 ref.)

VETERINARY

Open fracture management. Tillson DM. **Vet Clin North Am Small Anim Pract** 1995 Sep; 25(5):1093–110 (55 ref.)

FRACTURES, PATHOLOGICAL see **FRACTURES, SPONTANEOUS**

FRACTURES, SPONTANEOUS

ETIOLOGY

Pathogenesis of osteoporosis. Johnston CC Jr, et al. **Bone** 1995 Aug;17(2 Suppl):19S–22S (30 ref.)
Insufficiency fractures of the sacrum and os pubis. Peh WC, et al. **Br J Hosp Med** 1995 Jun 21-Jul 11;54(1):15–9 (20 ref.)
Fracture of the iliac crest following bone grafting: a case report and literature review. Friend KD, et al. **Bull Hosp Jt Dis** 1995;54(1):49–51 (8 ref.)
Spontaneous intrauterine linear skull fracture: a rare complication of spontaneous vaginal delivery. Heise RH, et al. **Obstet Gynecol** 1996 May;87(5 Pt 2):851–4 (15 ref.)

PREVENTION & CONTROL

Present and future of osteoporosis therapy. Seeman E, et al. **Bone** 1995 Aug;17(2 Suppl):23S–29S (47 ref.)
Screening and treatment in the elderly to reduce osteoporotic fracture risk. Black DM. **Br J Obstet Gynaecol** 1996 May; 103 Suppl 13:2–7; discussion 7–8 (49 ref.)

SURGERY

Osteoporosis--a modifying factor of surgical treatment. Perlaky G, et al. **Acta Med Hung** 1994;50(3–4):245–56 (8 ref.)

ULTRASONOGRAPHY

On measuring bone to predict osteoporotic fracture: moving beyond statistical inference [editorial; comment] Beck TJ. **Radiology** 1996 Jun;199(3):612–4 (25 ref.) Comment on: Radiology 1996 Jun;199(3):725–32.

FRACTURES, STRESS

Stress fractures. Anderson MW, et al. **Radiology** 1996 Apr; 199(1):1–12 (105 ref.)

ETIOLOGY

Stress fractures of the sacrum and lower extremity. Fanciullo JJ, et al. **Curr Opin Rheumatol** 1996 Mar;8(2):158–62 (26 ref.)

PHYSIOPATHOLOGY

[Stress fractures] Taimela S, et al. **Duodecim** 1994; 110(4):432–42 (45 ref.) **(Fin)**
[Stress fractures in athletes and military recruits. An overview] Orava S, et al. **Orthopade** 1995 Sep;24(5):457–66 (51 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Femoral neck stress fractures in children and adolescents. St Pierre P, et al. **J Pediatr Orthop** 1995 Jul-Aug; 15(4):470–3 (12 ref.)

FRACTURES, UNUNITED

SURGERY

Arteriovenous fistulae complicating orthopaedic procedures. Ward AS, et al. **Aust N Z J Surg** 1995 Dec;65(12):905–7 (20 ref.)
[Percutaneous autologus bone marrow grafting in the treatment of ununited fractures and bone defects] Zhu J, et al. **Chung Hua Wai Ko Tsa Chih** 1995 Sep;33(9):574–6 (18 ref.) **(Chi)**

FRAGILE SITES, CHROMOSOME see **CHROMOSOME FRAGILE SITES**

FRAGILE X SYNDROME

[Chromosome breakage syndrome and fragile X syndrome] Shiraishi Y. **Nippon Rinsho** 1995 Nov;53(11):2807–14 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Fragile X syndrome and mental disorders] Arinami T. **Seishin Shinkeigaku Zasshi** 1995;97(8):599–604 (41 ref.) **(Jpn)**

DIAGNOSIS

Molecular diagnosis of fragile X syndrome. Naber SP. **Diagn Mol Pathol** 1995 Sep;4(3):158–61 (16 ref.)

Single-cell analysis of unstable genes. Daniels R, et al. **J Assist Reprod Genet** 1996 Feb;13(2):163–9 (28 ref.)

GENETICS

A fragile gene. Oostra BA, et al. **Bioessays** 1995 Nov; 17(11):941–7 (70 ref.)

Molecular diagnosis of fragile X syndrome. Naber SP. **Diagn Mol Pathol** 1995 Sep;4(3):158–61 (16 ref.)

Fragile X syndrome—a review. Keenan E, et al. **Ir Med J** 1993 May;86(3):92, 95–6 (28 ref.)

Complex behavior of simple repeats: the fragile X syndrome. Oostra BA, et al. **Pediatr Res** 1995 Nov;38(5):629–37 (117 ref.)

Fragile X syndrome and other dynamic mutation diseases. Sutherland GR, et al. **Southeast Asian J Trop Med Public Health** 1995;26 Suppl 1:77–85 (41 ref.)

FRAGILITAS OSSIUM see **OSTEOGENESIS IMPERFECTA**

FRAIL ELDERLY

see related
HEALTH SERVICES FOR THE AGED

[Violence against the elderly from the trauma surgery viewpoint] Witthohn A, et al. **Z Gerontol Geriatr** 1996 May-Jun;29(3):206–9 (22 ref.) (Eng. Abstr.) **(Ger)**

PSYCHOLOGY

"Failure to thrive" in older adults. Sarkisian CA, et al. **Ann Intern Med** 1996 Jun 15;124(12):1072–8 (68 ref.)

FRAIL OLDER ADULTS see **FRAIL ELDERLY**

FRAMESHIFT MUTATION

Molecular handles on adaptive mutation. Rosenberg SM, et al. **Mol Microbiol** 1995 Oct;18(2):185–9 (33 ref.)

FRAMESHIFTING, RIBOSOMAL

see related
FRAMESHIFT MUTATION

Ribosomal frameshifting in yeast viruses. Dinman JD. **Yeast** 1995 Sep 30;11(12):1115–27 (60 ref.)

FRAMESHIFTING, TRANSLATIONAL see **FRAMESHIFTING, RIBOSOMAL**

FRAMYCETIN

ADVERSE EFFECTS

Ototoxicity of ear drops: a clinical perspective. Linder TE, et al. **Am J Otol** 1995 Sep;16(5):653–7 (23 ref.)

FRANCISELLA TULARENSIS

PATHOGENICITY

[Francisella tularensis persistence in the body of highly sensitive animals] Shlygina KN. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Mar-Apr; (2):110–2 (34 ref.) **(Rus)**

FRANKLIN'S DISEASE see **HEAVY CHAIN DISEASE**

FRECKLES see **MELANOSIS**

FREE FATTY ACIDS see **FATTY ACIDS, NONESTERIFIED**

FREE RADICAL SCAVENGERS

Functional aspects of the pineal hormone melatonin in combating cell and tissue damage induced by free radicals. Reiter RJ. **Eur J Endocrinol** 1996 Apr;134(4):412–20 (89 ref.)

The role of the neurohormone melatonin as a buffer against macromolecular oxidative damage. Reiter RJ. **Neurochem Int** 1995 Dec;27(6):453–60 (54 ref.)

[Physiological roles of metallothionein as possible scavenger and promoter for active oxygen species] Sakurai H. **Nippon Rinsho** 1996 Jan;54(1):2–4 (5 ref.) **(Jpn)**

CHEMISTRY

Plant polyphenols: free radical scavengers or chain-breaking antioxidants? Rice-Evans C. **Biochem Soc Symp** 1995; 61:103–16 (53 ref.)

Commentary: mannitol: molecule magnifique or a case of radical misinterpretation? Gillbe CE, et al. **Free Radic Res** 1996 Jan;24(1):1–7 (38 ref.)

METABOLISM

Scavenging of reactive oxygen species as the mechanism of drug action. Robak J, et al. **Pol J Pharmacol** 1995 Mar-Apr; 47(2):89–98 (134 ref.)

PHARMACOLOGY

Neuroprotective effects of free radical scavengers and energy repletion in animal models of neurodegenerative disease. Schulz JB, et al. **Ann N Y Acad Sci** 1995 Sep 15;765:100–10; discussion 116–8 (56 ref.)

Radioprotective and antioxidant action of caffeine: mechanistic considerations. Devasagayam TP, et al. **Indian J Exp Biol** 1996 Apr;34(4):291–7 (69 ref.)

The neuroprotective properties of the Ginkgo biloba leaf: a review of the possible relationship to platelet-activating factor (PAF). Smith PF, et al. **J Ethnopharmacol** 1996 Mar; 50(3):131–9 (62 ref.)

THERAPEUTIC USE

Ischemic stroke: treatment on the horizon. Giroux C, et al. **Eur Neurol** 1996;36(2):61–4 (12 ref.)

beta-carotene and cancer chemoprevention. Buring JE, et al. **J Cell Biochem Suppl** 1995;22:226–30 (37 ref.)

Possibilities of brain protection with tirilazad after cardiac arrest. Sterz F, et al. **Semin Thromb Hemost** 1996; 22(1):105–12 (37 ref.)

FREE RADICALS

Free radicals in health and disease. Hollán S. **Haematologia (Budap)** 1995;26(4):177–89 (73 ref.)

Free radical damage, iron, and Alzheimer's disease. Smith MA, et al. **J Neurol Sci** 1995 Dec;134 Suppl:92–4 (21 ref.)

Catalytic metals, ascorbate and free radicals: combinations to avoid. Buettner GR, et al. **Radiat Res** 1996 May; 145(5):532–41 (79 ref.)

Free radicals, lipid peroxidation and sperm function. Aitken RJ. **Reprod Fertil Dev** 1995;7(4):659–68 (62 ref.)

[Free oxygen radicals during transplantation surgery] Bolbjerg ML, et al. **Ugeskr Laeger** 1995 Oct 16; 157(42):5841–5 (40 ref.) (Eng. Abstr.) **(Dan)**

[New findings on reactive oxidative materials and their role in biological systems] Jovičić A, et al. **Vojnosanit Pregl** 1995 Nov-Dec;52(6):579–84 (24 ref.) **(Scr)**

[Free oxygen radicals in the pathogenesis of ischemic-reperfusion heart damage and possibilities of its pharmacologic control] Jadroňová O, et al. **Ceska Slov Farm** 1995 Oct;44(5):268–72 (28 ref.) (Eng. Abstr.) **(Slo)**

ADVERSE EFFECTS

Oxyradical pathophysiology. Zimmerman JJ. **Adv Pediatr** 1995;42:243–302 (274 ref.)

[Oxygen radicals and asthma] Kinnula V. **Duodecim** 1994; 110(9):863–9 (29 ref.) **(Fin)**

[Free radicals and their importance in medicine] Andrzejak R, et al. **Postepy Hig Med Dosw** 1995;49(4):531–49 (89 ref.) (Eng. Abstr.) **(Pol)**

ANALYSIS

Free radicals (nitric oxide). Kostka P. **Anal Chem** 1995 Jun 15;67(12):411R–416R (118 ref.)

CHEMISTRY

Fragmentation reactions of aromatic cation radicals: a tool for the detection of electron transfer mechanisms in biomimetic and enzymatic oxidations. Baciocchi E. **Xenobiotica** 1995 Jul;25(7):653–66 (37 ref.)

Radical intermediates during degradation of lignin-model compounds and environmental pollutants: an electron spin resonance study. Kalyanaraman B. **Xenobiotica** 1995 Jul; 25(7):667–75 (18 ref.)

IMMUNOLOGY

[The role of free radicals in pathogenesis of insulin dependent diabetes mellitus] Komosińska K, et al. **Postepy Hig Med Dosw** 1995;49(6):733–46 (64 ref.) (Eng. Abstr.) **(Pol)**

METABOLISM

Generation of free radicals and messenger function. Carlson JC, et al. **Can J Appl Physiol** 1995 Sep;20(3):280–8 (47 ref.)

Free radicals and intracellular events associated with cerebrovascular spasm. Cook DA, et al. **Cardiovasc Res** 1995 Oct;30(4):493–500 (112 ref.)

White mineral and substance P. Weber KT. **Cardiovasc Res** 1996 May;31(5):675–82 (51 ref.)

Free radical mechanism for the effects of environmental electromagnetic fields on biological systems. Brocklehurst B, et al. **Int J Radiat Biol** 1996 Jan;69(1):3–24 (45 ref.)

Free radical activity of melanins and related substances: biochemical and pathobiochemical aspects. Borovanský J. **Sb Lek** 1996;97(1):49–70 (146 ref.)

Central role of radical cations in metabolic activation of polycyclic aromatic hydrocarbons. Cavalieri EL, et al. **Xenobiotica** 1995 Jul;25(7):677–88 (49 ref.)

Aminium cation radical mechanism proposed for monoamine oxidase B catalysis: are there alternatives? Edmondson DE. **Xenobiotica** 1995 Jul;25(7):735–53 (53 ref.)

Cation radicals of organosulphur compounds. Glass RS. **Xenobiotica** 1995 Jul;25(7):637–51 (64 ref.)

Radical cation intermediates in N-dealkylation reactions. Guengerich FP, et al. **Xenobiotica** 1995 Jul;25(7):689–709 (138 ref.)

[The role of oxygen radicals in the pathogenesis of glomerulonephritis] Zima T, et al. **Cas Lek Cesk** 1995 Nov 15;134(22):716–9 (32 ref.) (Eng. Abstr.) **(Cze)**

[Free radicals in the central nervous system] Rokyta R, et al. **Cesk Fysiol** 1996 Mar;45(1):4–12 (34 ref.) (Eng. Abstr.) **(Cze)**

[Interaction of free radicals with proteins] Skrzydlewska E, et al. **Postepy Hig Med Dosw** 1995;49(6):747–66 (92 ref.) (Eng. Abstr.) **(Pol)**

PHARMACOLOGY

Antioxidants, oxidants and free radical stress in cardiovascular disease. Singh RB, et al. **J Assoc Physicians India** 1996 Jan;44(1):43–8 (55 ref.)

[Free radicals as second messengers] Raes M, et al. **C R Seances Soc Biol Fil** 1995;189(3):355–66 (46 ref.) (Eng. Abstr.) **(Fre)**

FREEDOM

"Freedom's just another word": aboriginal youth and mental health. Hunter E. **Aust N Z J Psychiatry** 1995 Sep; 29(3):374–84 (64 ref.)

A contextual approach for understanding individual autonomy in managed community long-term care. Capitman J, et al. **Gerontologist** 1995 Aug;35(4):533–40 (55 ref.)

The contrary ideals of individualism and nursing value of care. Katims I. **Sch Inq Nurs Pract** 1995 Fall;9(3):231–40; discussion 241–4 (30 ref.)

FREEZE DRYING

[The way to long-term ambient temperature stabilization of biologicals—freeze-drying and evaporative-drying with vitrification] Franks F, et al. **Tanpakushitsu Kakusan Koso** 1996 May;41(6):810–6 (13 ref.) **(Jpn)**

FREEZE ETCHING

Freeze-fracture, deep-etch, and freeze-substitution studies of olfactory epithelia, with special emphasis on immunocytochemical variables. Menco BP. **Microsc Res Tech** 1995 Nov 1;32(4):337–56 (132 ref.)

METHODS

Freeze-fracture deep-etch methods. Hawes C, et al. **Methods Cell Biol** 1995;49:33–43 (21 ref.)

FREEZE FRACTURING

Freeze-fracture, deep-etch, and freeze-substitution studies of olfactory epithelia, with special emphasis on immunocytochemical variables. Menco BP. **Microsc Res Tech** 1995 Nov 1;32(4):337–56 (132 ref.)

METHODS

Freeze-fracture deep-etch methods. Hawes C, et al. **Methods Cell Biol** 1995;49:33–43 (21 ref.)

Gap junctions revealed by freeze-fracture electron microscopy. Shivers RR, et al. **Microsc Res Tech** 1995 Aug 1;31(5):437–45 (44 ref.)

FREEZE SUBSTITUTION

METHODS

Freeze-substitution. Parthasarathy MV. **Methods Cell Biol** 1995;49:57–69 (25 ref.)

FREEZING

see related
CRYOPRESERVATION
CRYOSURGERY

The freezing phenomenon in parkinsonism. Fahn S. **Adv Neurol** 1995;67:53–63 (49 ref.)

FRENUM, LINGUAL see **LINGUAL FRENUM**

FREONS

POISONING

Occupational phosgene poisoning: a case report and review. Wyatt JP, et al. **J Accid Emerg Med** 1995 Sep;12(3):212–3 (11 ref.)

FRESH FROZEN PLASMA see **PLASMA**

FRESH WATER

Fatty acid metabolism in freshwater fish with particular reference to polyunsaturated fatty acids. Henderson RJ. **Arch Tierernahr** 1996;49(1):5–22 (69 ref.)

Plants and animals as biomonitors of heavy metal level in the aquatic ecosystem of the river Danube. Oertel N. **Arch Toxicol Suppl** 1996;18:404–16 (23 ref.)

The influence of salinity on the toxicity of various classes of chemicals to aquatic biota. Hall LW Jr, et al. **Crit Rev Toxicol** 1995;25(4):281–346 (100 ref.)

Commentary on effects of anthropogenic and natural organic chemicals on development, swimming behavior, and reproduction of Daphnia, a key member of aquatic ecosystems. Dodson SI, et al. **Environ Health Perspect** 1995 May;103 Suppl 4:7–11 (60 ref.)

Dermal exposure to environmental contaminants in the Great Lakes. Moody RP, et al. **Environ Health Perspect** 1995 Dec;103 Suppl 9:103–14 (88 ref.)

CHEMISTRY

The Dead Sea is alive. Sukenik S, et al. **Isr J Med Sci** 1996 Jul;32 Suppl:S1–3 (9 ref.)

The medical and scientific aspects of spa therapy. Tishler M, et al. **Isr J Med Sci** 1996 Jul;32 Suppl:S8–10 (10 ref.)

Monitoring of herbicide pollution in water by capillary electrophoresis. Dinelli G, et al. **J Chromatogr A** 1996 May 10;733(1–2):337–47 (60 ref.)

FREUDIAN THEORY

The third step: Freud, the feminists, and postmodernism. Dimen M. **Am J Psychoanal** 1995 Dec;55(4):303–19; discussion 321–30 (31 ref.)

Freudian suspicion versus suspicion of Freud. Crews F. **Ann N Y Acad Sci** 1996 Jun 24;775:470–82 (58 ref.)

Freud's psychology. Can it survive? Yorke C. **Psychoanal Study Child** 1995;50:3–31 (105 ref.)

[Anna, Irma and Dora—the key to the mothers in the creation of psychoanalysis] King V. **Psyche (Stuttg)** 1995 Sep–Oct; 49(9–10):838–66 (60 ref.) (Eng. Abstr.) **(Ger)**

FREUND'S ADJUVANT

IMMUNOLOGY

Establishment of a mouse model of myasthenia gravis which mimics human myasthenia gravis pathogenesis for immune intervention. Christadoss P, et al. **Adv Exp Med Biol** 1995; 383:195–9 (16 ref.)

FREY'S SYNDROME see **SWEATING, GUSTATORY**

FRIEDREICH'S ATAXIA

GENETICS

The expanding world of trinucleotide repeats [comment] Warren ST. **Science** 1996 Mar 8;271(5254):1374–5 (7 ref.) Comment on: Science 1996 Mar 8;271(5254):1423–7.

FRIEND VIRUS

Operating under a Gag order: a block against incoming virus by the Fv1 gene. Goff SP. **Cell** 1996 Sep 6;86(5):691–3 (20 ref.)

FRIENDSHIP see **INTERPERSONAL RELATIONS**

FRINGE BENEFITS see **SALARIES AND FRINGE BENEFITS**

FROEHLICH'S SYNDROME see **HYPOTHALAMIC DISEASES**

FROG, GREEN see **RANA ESCULENTA**

FROGS AND TOADS see **ANURA**

FRONTAL BONE

[En-plaque meningioma as a rare cause of an osteosclerotic bone tumor of the frontal bone] Steidle B, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1995 Oct;163(4):350–2 (10 ref.) **(Ger)**

SURGERY

Dermoid cyst of the frontal bone away from the anterior fontanel. Fujimaki T, et al. **Childs Nerv Syst** 1995 Jul; 11(7):424–7 (19 ref.)

FRONTAL LOBE

Neuropsychological aspects of frontotemporal degeneration. Neary D. **Ann N Y Acad Sci** 1995 Dec 15;769:15–22 (31 ref.)

[Frontal cerebral abscess, a rare complication of nasosinusal polyposis. Apropos of a case] Abgrall S, et al. **Neurochirurgie** 1995;41(5):367–71 (13 ref.) (Eng. Abstr.) **(Fre)**

[Subcortical dementia] Sellal F. **Rev Med Interne** 1996; 17(5):419–24 (26 ref.) (Eng. Abstr.) **(Fre)**

[Frontal type dementia and amyotrophic lateral sclerosis. 3 cases with (HmPAO Tc99m) single-photon emission tomography study] Vercelletto M, et al. **Rev Neurol (Paris)** 1995 Nov;151(11):640–7 (43 ref.) (Eng. Abstr.) **(Fre)**

[Oligodendroglioma in childhood: a case report (letter)] del Val Río MR, et al. **An Esp Pediatr** 1996 Jan;44(1):80–2 (10 ref.) **(Spa)**

ANATOMY & HISTOLOGY

Anatomic and behavioral aspects of frontal-subcortical circuits. Cummings JL. **Ann N Y Acad Sci** 1995 Dec 15; 769:1–13 (69 ref.)

Functional organization of the human frontal cortex for mnemonic processing. Evidence from neuroimaging studies. Petrides M. **Ann N Y Acad Sci** 1995 Dec 15; 769:85–96 (25 ref.)

BLOOD SUPPLY

Frontal abnormalities in a patient with obsessive-compulsive disorder: the role of structural lesions in obsessive-compulsive behavior. Swoboda KJ, et al. **Neurology** 1995 Dec;45(12):2130–4 (25 ref.)

INJURIES

Unilateral spatial neglect due to a haemorrhagic contusion in the right frontal lobe. Maeshima S, et al. **J Neurol** 1995 Oct;242(10):613–7 (15 ref.)

PATHOLOGY

The new neuropathology of degenerative frontotemporal dementias. Jackson M, et al. **Acta Neuropathol (Berl)** 1996; 91(2):127–34 (38 ref.)

Stage IE non-Hodgkin's lymphoma involving the dura: A clinicopathologic study of five cases. Miranda RN, et al. **Arch Pathol Lab Med** 1996 Mar;120(3):254–60 (20 ref.)

Frontotemporal dementia: a clinicopathological review of four postmortem studies. Hooten WM, et al. **J Neuropsychiatry Clin Neurosci** 1996 Winter;8(1):10–9 (65 ref.)

Primary Ki-1-positive T-cell lymphoma of the brain—an aggressive subtype of lymphoma: case report and review of the literature. Goldbrunner R, et al. **Surg Neurol** 1996 Jul;46(1):37–41 (24 ref.)

PHYSIOLOGY

Surgical ablations of the mesial frontal lobe in humans. Bleasel A, et al. **Adv Neurol** 1996;70:217–35 (57 ref.)

Human rehearsal processes and the frontal lobes: PET evidence. Awh E, et al. **Ann N Y Acad Sci** 1995 Dec 15; 769:97–117 (37 ref.)

Anatomic and behavioral aspects of frontal-subcortical circuits. Cummings JL. **Ann N Y Acad Sci** 1995 Dec 15; 769:1–13 (69 ref.)

Analogical transfer in sequence learning. Human and neural-network models of frontostriatal function. Dominey PF, et al. **Ann N Y Acad Sci** 1995 Dec 15;769:369–73 (5 ref.)

Frontal lobes, memory, and aging. Moscovitch M, et al. **Ann N Y Acad Sci** 1995 Dec 15;769:119–50 (228 ref.)

Functional organization of the human frontal cortex for mnemonic processing. Evidence from neuroimaging studies. Petrides M. **Ann N Y Acad Sci** 1995 Dec 15; 769:85–96 (25 ref.)

A multidisciplinary approach to anterior attentional functions. Stuss DT, et al. **Ann N Y Acad Sci** 1995 Dec 15;769:191–211 (87 ref.)

Social and emotional self-regulation. Tucker DM, et al. **Ann N Y Acad Sci** 1995 Dec 15;769:213–39 (120 ref.)

Frontal lobe mechanisms subserving vision-for-action versus vision-for-perception. Boussaoud D, et al. **Behav Brain Res** 1995 Dec 14;72(1–2):1–15 (145 ref.)

The sources of visual information to the primate frontal lobe: a novel role for the superior parietal lobule. Caminiti R, et al. **Cereb Cortex** 1996 May-Jun;6(3):319–28 (102 ref.)

PHYSIOPATHOLOGY

Toward a cognitive account of frontal lobe function: simulating frontal lobe deficits in normal subjects. Dunbar K, et al. **Ann N Y Acad Sci** 1995 Dec 15;769:289–304 (34 ref.)

Re-examining the role of executive functions in routine action production. Schwartz MF. **Ann N Y Acad Sci** 1995 Dec 15;769:321–35 (51 ref.)

The anatomy of melancholia: does frontal-subcortical pathophysiology underpin its psychomotor and cognitive manifestations? [editorial] Austin MP, et al. **Psychol Med** 1995 Jul;25(4):665–72 (90 ref.)

Neuropsychological and olfactory dysfunction in schizophrenia: relationship of frontal syndromes to syndromes of schizophrenia. Pantelis C, et al. **Schizophr Res** 1995 Sep;17(1):35–45 (75 ref.)

RADIOGRAPHY

Early onset bilateral calcifications and epilepsy. Nunes ML, et al. **Pediatr Neurol** 1995 Jul;13(1):80–2 (11 ref.)

SURGERY

Surgical ablations of the mesial frontal lobe in humans. Bleasel A, et al. **Adv Neurol** 1996;70:217–35 (57 ref.)

FRONTAL SINUS

[Pneumocephalus complicating osteoma of the frontal sinus] Attane F, et al. **Rev Neurol (Paris)** 1996 Apr;152(4):279–82 (13 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Management of the frontal sinus with inverted papilloma. Shohet JA, et al. **Otolaryngol Head Neck Surg** 1996 Apr; 114(4):649–52 (14 ref.)

FROZEN SECTIONS

Discordant CD3 expression in lymphomas when studied on frozen and paraffin sections. Chan JK, et al. **Hum Pathol** 1995 Oct;26(10):1139–43 (48 ref.)

FROZEN SEMEN see **SEMEN PRESERVATION**

FRUCTOSE

ANALOGS & DERIVATIVES

Drug interaction profile of topiramate. Bourgeois BF. **Epilepsia** 1996;37 Suppl 2:S14–S17 (23 ref.)

Pharmacokinetic profile of topiramate in comparison with other new antiepileptic drugs. Perucca E. **Epilepsia** 1996; 37 Suppl 2:S8–S13 (55 ref.)

The epidemiology and treatment of chronic and refractory epilepsy. Shorvon SD. **Epilepsia** 1996;37 Suppl 2:S1–S3 (6 ref.)

ANALYSIS

On the presence of inulin and oligofructose as natural ingredients in the western diet. van Loo J, et al. **Crit Rev Food Sci Nutr** 1995 Nov;35(6):525–52 (102 ref.)

BLOOD

[Fructose] Kizaki Z, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:536–9 (17 ref.) **(Jpn)**

PHARMACOLOGY

The effect of fasting and fructose and glucose infusion on gluconeogenesis and triose phosphate flux in rats in vivo. Wolf G. **Nutr Rev** 1995 Oct;53(10):299–301 (2 ref.)

FRUCTOSE-BIPHOSPHATASE DEFICIENCY see **FRUCTOSE-1,6-DIPHOSPHATASE DEFICIENCY**

FRUCTOSE-1,6-BISPHOSPHATASE DEFICIENCY see **FRUCTOSE-1,6-DIPHOSPHATASE DEFICIENCY**

FRUCTOSE-1,6-DIPHOSPHATASE DEFICIENCY

METABOLISM

[Disorders of fructose and galactose metabolism] Abukawa D, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):371–4 (12 ref.) **(Jpn)**

FRUCTOSE INTOLERANCE

[Disorders of fructose and galactose metabolism] Abukawa D, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):371–4 (12 ref.) **(Jpn)**

GENETICS

Molecular basis of hereditary fructose intolerance: mutations and polymorphisms in the human aldolase B gene. Tolan DR. **Hum Mutat** 1995;6(3):210–8 (67 ref.)

FRUCTOSEDIPHOSPHATE ALDOLASE

ANALYSIS

Aldolase C/zebrin II and the regionalization of the cerebellum. Hawkes R, et al. **J Mol Neurosci** 1995; 6(3):147–58 (75 ref.)

BLOOD

[Aldolase] Ida M. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:284–7 (12 ref.) **(Jpn)**

GENETICS

Molecular basis of hereditary fructose intolerance: mutations and polymorphisms in the human aldolase B gene. Tolan DR. **Hum Mutat** 1995;6(3):210–8 (67 ref.)

FRUCTOSEDIPHOSPHATES

METABOLISM

Covalent control of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase: insights into autoregulation of a bifunctional enzyme.

Kurland IJ, et al. **Protein Sci** 1995 Jun;4(6):1023–37 (70 ref.)

FRUIT

What accounts for the association of vegetables and fruits with lower incidence of cancers and coronary heart disease? [editorial; comment] Omenn GS. **Ann Epidemiol** 1995 Jul;5(4):333–5 (12 ref.) Comment on: Ann Epidemiol 1995 Jul;5(4):255–60. Comment on: Ann Epidemiol 1995 Jul;5(4):261–9.

CHEMISTRY

Anthocyanins in grapes and grape products. Mazza G. **Crit Rev Food Sci Nutr** 1995 Jul;35(4):341–71 (167 ref.)

METABOLISM

[Ethylene—its role in fruit ripening and senescence of blossoms. Biotechnologic aspects] Jakubowicz M. **Postepy Biochem** 1996;42(1):65–72 (70 ref.) **(Pol)**

STANDARDS

Diet, nutrition & cancer—the Indian scenario. Krishnaswamy K, et al. **Indian J Med Res** 1995 Nov;102:200–9 (70 ref.)

FRUIT FLIES see **DROSOPHILA**

FRUSEMIDE see **FUROSEMIDE**

FSH

see related
RECEPTORS, FSH

CHEMISTRY

Follicle-stimulating isohormones: characterization and physiological relevance. Ulloa-Aguirre A, et al. **Endocr Rev** 1995 Dec;16(6):765–87 (210 ref.)

GENETICS

Gonadotropin gene modulation by steroids and gonadotropin-releasing hormone. Shupnik MA. **Biol Reprod** 1996 Feb;54(2):279–86 (60 ref.)

The gonadotropin genes: evolution of distinct mechanisms for hormonal control. Albanese C, et al. **Recent Prog Horm Res** 1996;51:23–58; discussion 59–61 (140 ref.)

PHYSIOLOGY

The role of follicle-stimulating hormone in the selection of follicles in human ovaries: a survey of the literature and a proposed model. Scheele F, et al. **Gynecol Endocrinol** 1996 Feb;10(1):55–66 (108 ref.)

The human menopausal gonadotropin (hMG) dose in in vitro fertilization (IVF): what is the optimal dose? van Hooff MH. **J Assist Reprod Genet** 1995 Apr;12(4):233–5 (13 ref.)

The endocrine regulation of spermatogenesis: independent roles for testosterone and FSH. McLachlan RI, et al. **J Endocrinol** 1996 Jan;148(1):1–9 (62 ref.)

[Recombinant FSH. Characteristics and therapeutical values] De Chambine S, et al. **Ann Endocrinol (Paris)** 1995; 56(4):233–44 (55 ref.) (Eng. Abstr.) **(Fre)**

SECRETION

Increased follicle stimulating hormone in infertile men. Is increased plasma FSH always due to damaged germinal epithelium? Martin-du-Pan RC, et al. **Hum Reprod** 1995 Aug;10(8):1940–5 (82 ref.)

Whither the investigation of male infertility? Is FSH measurement redundant and should all azoospermic patients have testicular biopsy? Wu FC. **Hum Reprod** 1995 Aug;10(8):1945–7 (25 ref.)

THERAPEUTIC USE

[Recombinant FSH. Characteristics and therapeutical values] De Chambine S, et al. **Ann Endocrinol (Paris)** 1995; 56(4):233–44 (55 ref.) (Eng. Abstr.) **(Fre)**

FSH, ALPHA SUBUNIT see **GLYCOPROTEIN HORMONES, ALPHA SUBUNIT**

FSH RECEPTORS see **RECEPTORS, FSH**

FSH-RELEASING HORMONE see **GONADORELIN**

FTIR see **SPECTROSCOPY, FOURIER TRANSFORM INFRARED**

FTLV see **IMMUNODEFICIENCY VIRUS, FELINE**

FTORAFUR see **TEGAFUR**

FUCOSIDASE

see related
FUCOSIDOSIS

GENETICS

Mutations in fucosidosis gene: a review. Tiberio G, et al. **Acta Genet Med Gemellol (Roma)** 1995;44(3–4):223–32 (24 ref.)

FUCOSIDOSIS

GENETICS

Mutations in fucosidosis gene: a review. Tiberio G, et al. **Acta Genet Med Gemellol (Roma)** 1995;44(3–4):223–32 (24 ref.)

FUCOSYL SSEA-1 see **ANTIGENS, CD15**

FUCOSYLTRANSFERASES

GENETICS

The genetic regulation of sialyl-Lewisx expression in haemopoietic cells. Watkins WM, et al. **Adv Exp Med Biol** 1995;376:83–93 (64 ref.)

Molecular genetics of H, Se, Lewis and other fucosyltransferase genes. Mollicone R, et al. **Transfus Clin Biol** 1995;2(4):235–42 (60 ref.)

Lewis histo-blood group system and associated secretory phenotypes. Henry S, et al. **Vox Sang** 1995;69(3):166–82 (158 ref.)

FUDR see **FLOXURIDINE**

FUGUE see **DISSOCIATIVE DISORDERS**

FUKUHARA DISEASE see **MERRF SYNDROME**

FUNCTIONALLY-IMPAIRED ELDERLY see **FRAIL ELDERLY**

FUNDOPLICATION

Open Nissen fundoplication. Ferguson MK. **Chest Surg Clin N Am** 1995 Aug;5(3):379–94 (24 ref.)

Laparoscopic antireflux surgery. Richardson WS, et al. **Surg Clin North Am** 1996 Jun;76(3):437–50 (48 ref.)

ECONOMICS

Results of Nissen fundoplication. A cost analysis. Hinder RA, et al. **Surg Endosc** 1995 Dec;9(12):1328–32 (20 ref.)

INSTRUMENTATION

[Differential concept on use of laparoscopic anti-reflux operations] Fuchs KH, et al. **Zentralbl Chir** 1996; 121(4):294–9; discussion 300–2 (32 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Nissen fundoplication for gastro-oesophageal reflux disease: long-term results. Luostarinen M. **Ann Chir Gynaecol** 1995; 84(2):115–20 (29 ref.)

[Antireflux surgery: from Nissen to mini-invasive technics] Rossetti M. **Minerva Chir** 1995 Sep;50(9 Suppl):104–8 (16 ref.) **(Ita)**

FUNDUS FLUORESCENCE PHOTOGRAPHY see **FLUORESCEIN ANGIOGRAPHY**

FUNDUS OCULI

see related
OPHTHALMOSCOPY

Indirect fundus biomicroscopy. Flanagan JG, et al. **Ophthalmic Physiol Opt** 1995 Sep;15 Suppl 2:S38–41 (3 ref.)

Fundus manifestations of orbital disease and treatment of orbital disease. De La Paz MA, et al. **Surv Ophthalmol** 1995 Jul–Aug;40(1):3–21 (271 ref.)

FUNGAL ANTIBODIES see **ANTIBODIES, FUNGAL**

FUNGAL ANTIGENS see **ANTIGENS, FUNGAL**

FUNGAL DNA see **DNA, FUNGAL**

FUNGAL GENE EXPRESSION REGULATION see **GENE EXPRESSION REGULATION, FUNGAL**

FUNGAL GENE PRODUCTS see **FUNGAL PROTEINS**

FUNGAL GENE PROTEINS see **FUNGAL PROTEINS**

FUNGAL GENES see **GENES, FUNGAL**

FUNGAL GENOME see **GENOME, FUNGAL**

FUNGAL PEPTIDES see **FUNGAL PROTEINS**

FUNGAL PROTEINS

Prions of yeast and heat-shock protein 104: 'coprion' and cure. Wickner RB. **Trends Microbiol** 1995 Oct;3(10):367–9 (21 ref.)

[Prion-like cytoplasmic genetic determinants of the budding yeast: conformations and biological functions of protein] Ono B. **Tanpakushitsu Kakusan Koso** 1995 Nov; 40(15):2320–8 (49 ref.) **(Jpa)**

BIOSYNTHESIS

Molecular basis of cell integrity and morphogenesis in Saccharomyces cerevisiae. Cid VJ, et al. **Microbiol Rev** 1995 Sep;59(3):345–86 (463 ref.)

CHEMISTRY

A heterodimeric transcriptional repressor becomes crystal clear [comment] Andrews BJ, et al. **Science** 1995 Oct 13; 270(5234):251–3 (18 ref.) Comment on: Science 1995 Oct 13;270(5234):262–9. Comment on: Science 1995 Oct 13;270(5234):262–9. Comment on: Science 1995 Oct 13;270(5234):290–3.

[Structure and functional similarity of yeast Sup35p and Ure2p proteins to mammalian prions] Kushnirov VV, et al. **Mol Biol (Mosk)** 1995 Jul–Aug;29(4):750–5 (27 ref.) (Eng. Abstr.) **(Rus)**

GENETICS

The molecular control mechanisms of meiosis in fission yeast. Yamamoto M. **Trends Biochem Sci** 1996 Jan;21(1):18–22 (48 ref.)

Cf9 and Avr9, two major players in the gene-for-gene game. de Wit PJ. **Trends Microbiol** 1995 Jul;3(7):251–2 (15 ref.)

[PSI] and [URE3] as yeast prions. Wickner RB, et al. **Yeast** 1995 Dec;11(16):1671–85 (79 ref.)

METABOLISM

Receptor-mediated protein sorting to the vacuole in yeast: roles for a protein kinase, a lipid kinase and GTP-binding proteins. Stack JH, et al. **Ann Rev Cell Dev Biol** 1995; 11:1–33 (146 ref.)

The TOR signalling pathway and growth control in yeast. Hall MN. **Biochem Soc Trans** 1996 Feb;24(1):234–9 (42 ref.)

Transcriptional regulation. Flipping the Myc switch. Bernards R. **Curr Biol** 1995 Aug 1;5(8):859–61 (13 ref.)

Cell division. Bud-site selection is only skin deep. Sanders SL, et al. **Curr Biol** 1995 Nov 1;5(11):1213–5 (25 ref.)

Protein transport to the yeast vacuole. Horazdovsky BF, et al. **Curr Opin Cell Biol** 1995 Aug;7(4):544–51 (71 ref.)

Start-specific transcription in yeast. Breeden L. **Curr Top Microbiol Immunol** 1996;208:95–127 (112 ref.)

The role of PRP8 protein in nuclear pre-mRNA splicing in yeast. Beggs JD, et al. **J Cell Sci Suppl** 1995;19:101–5 (47 ref.)

Vanadium-dependent haloperoxidases. Vilter H. **Met Ions Biol Syst** 1995;31:325–62 (192 ref.)

Post-translational protein translocation: not all hsc70s are created equal. Brodsky JL. **Trends Biochem Sci** 1996 Apr; 21(4):122–6 (40 ref.)

PHYSIOLOGY

Septin scaffolds and cleavage planes in Saccharomyces. Chant J. **Cell** 1996 Jan 26;84(2):187–90 (22 ref.)

Vacuolar biogenesis in yeast: sorting out the sorting proteins. Conibear E, et al. **Cell** 1995 Nov 17;83(4):513–6 (17 ref.)

The GAL4 system as a tool for unravelling the mysteries of the Drosophila nervous system. Brand AH, et al. **Curr Opin Neurobiol** 1995 Oct;5(5):572–8 (60 ref.)

Flavoprotein structure and mechanism. 8. Structure-function relations for old yellow enzyme. Karplus PA, et al. **FASEB J** 1995 Dec;9(15):1518–26 (39 ref.)

Yeast motor proteins. Streiblová E, et al. **Folia Microbiol (Praha)** 1995;40(6):571–82 (59 ref.)

Fungal lipopeptide mating pheromones: a model system for the study of protein prenylation. Caldwell GA, et al. **Microbiol Rev** 1995 Sep;59(3):406–22 (181 ref.)

Cyclins of the fission yeast Schizosaccharomyces pombe. Fisher D, et al. **Semin Cell Biol** 1995 Apr;6(2):73–8 (38 ref.)

Control of signal transduction and morphogenesis by Ras. Hughes DA. **Semin Cell Biol** 1995 Apr;6(2):89–94 (49 ref.)

An overview of membrane transport proteins in Saccharomyces cerevisiae. Andre B. **Yeast** 1995 Dec; 11(16):1575–611 (258 ref.)

FUNGAL RNA see **RNA, FUNGAL**

FUNGAL STRUCTURAL GENES see **GENES, STRUCTURAL, FUNGAL**

FUNGAL TOXINS see **MYCOTOXINS**

FUNGAL TYPING TECHNIQUES see **MYCOLOGICAL TYPING TECHNIQUES**

FUNGAL VACCINES

THERAPEUTIC USE

T helper cell dichotomy to Candida albicans: implications for pathology, therapy, and vaccine design. Romani L, et al. **Immunol Res** 1995;14(2):148–62 (105 ref.)

FUNGEMIA

COMPLICATIONS

Contained rupture of infected abdominal aortic aneurysm due to systemic candidiasis. Ikeda M, et al. **Cardiovasc Surg** 1995 Dec;3(6):711–4 (30 ref.)

DRUG THERAPY

Problems and controversies in the management of hematogenous candidiasis. Uzun O, et al. **Clin Infect Dis** 1996 May;22 Suppl 2:S95–101 (62 ref.)

ETIOLOGY

The role of the gastrointestinal tract in hematogenous candidiasis: from the laboratory to the bedside. Cole GT, et al. **Clin Infect Dis** 1996 May;22 Suppl 2:S73–88 (114 ref.)

Catheter-associated fungemia due to Wangiella (Exophiala) dermatitidis. Nachman S, et al. **J Clin Microbiol** 1996 Apr; 34(4):1011–3 (10 ref.)

Central venous catheter infection with Rhodotorula minuta in a patient with AIDS taking suppressive doses of fluconazole. Goldani LZ, et al. **J Med Vet Mycol** 1995 Jul–Aug;33(4):267–70 (22 ref.)

Peracute disseminated fatal Aspergillus fumigatus sepsis as a complication of corticoid-treated systemic lupus erythematosus. Nenoff P, et al. **Mycoses** 1995 Nov–Dec; 38(11–12):467–71 (21 ref.)

MICROBIOLOGY

[Disseminated Histoplasma capsulatum histoplasmosis in African AIDS patients (3 cases)] Imbert P, et al. **Med Trop (Mars)** 1995;55(2):151–3 (12 ref.) (Eng. Abstr.) **(Fre)**

FUNGI

see related
ANTIFUNGAL AGENTS
FUNGICIDES, INDUSTRIAL

Aerobiologic and clinical aspects of mould allergy in Europe. D'Amato G, et al. **Allergy** 1995 Nov;50(11):870–7 (62 ref.)

Condensation and mould: the Canadian experience. Rayner KF. **J R Soc Health** 1996 Apr;116(2):83–6 (19 ref.)

Marine natural products research: current directions and future potential. König GM, et al. **Planta Med** 1996 Jun; 62(3):193–211 (160 ref.)

[A new serine protease zymogen activated by components of the fungal cell wall] Muta T. **Seikagaku** 1995 Aug; 67(8):1032–6 (15 ref.) **(Jpn)**

CHEMISTRY

Isolation and biological activities of signal transduction inhibitors from microorganisms and plants. Umezawa K. **Adv Enzyme Regul** 1995;35:43–53 (35 ref.)

Marine fungi—a prolific resource of biologically active natural products? Liberra K, et al. **Pharmazie** 1995 Sep; 50(9):583–8 (35 ref.)

CLASSIFICATION

Use of molecular biological techniques in the diagnostic laboratory for detecting and differentiating fungi. Hopfer RL. **Arch Med Res** 1995 Autumn;26(3):287–92 (22 ref.)

Molecular Phylogenetic classification of fungi. Taylor JW. **Arch Med Res** 1995 Autumn;26(3):307–14 (72 ref.)

Current status of the plasmodiophorids. Braselton JP. **Crit Rev Microbiol** 1995;21(4):263–75 (50 ref.)

Nomenclature of fungal diseases. Odds FC, et al. **Curr Top Med Mycol** 1995;6:33–46 (12 ref.)

DRUG EFFECTS

Use of amphotericin B with azole antifungal drugs: what are we doing? Sugar AM. **Antimicrob Agents Chemother** 1995 Sep;39(9):1907–12 (46 ref.)

Microbial interactions with aluminium. Piña RG, et al. **Biometals** 1996 Jul;9(3):311–6 (63 ref.)

Is antifungal susceptibility testing useful in guiding fluconazole therapy? Ghannoum MA. **Clin Infect Dis** 1996 May;22 Suppl 2:S161–5 (25 ref.)

Mechanisms of fungicide resistance in phytopathogenic fungi. Steffens JJ, et al. **Curr Opin Biotechnol** 1996 Jun; 7(3):348–55 (77 ref.)

Modes of action of disinfectants. Maris P. **Rev Sci Tech** 1995 Mar;14(1):47–55 (24 ref.)

Biocides: mechanisms of antifungal action and fungal resistance. Russell AD, et al. **Sci Prog** 1996;79 (Pt 1):27–48 (102 ref.)

ENZYMOLOGY

Vanadium-dependent haloperoxidases. Vilter H. **Met Ions Biol Syst** 1995;31:325–62 (192 ref.)

GENETICS

Peptides. von Döhren H. **Biotechnology** 1995;28:129–71 (256 ref.)

Self/nonself recognition in fungi: old mysteries and simple solutions. Kahmann R, et al. **Cell** 1996 Apr 19;85(2):145–8 (20 ref.)

Tetrapolar fungal mating types: sexes by the thousands. Kothe E. **FEMS Microbiol Rev** 1996 Mar;18(1):65–87 (210 ref.)

Chromosome-length polymorphism in fungi. Zolan ME. **Microbiol Rev** 1995 Dec;59(4):686–98 (145 ref.)

A brief history of hemoglobins: plant, animal, protist, and bacteria. Hardison RC. **Proc Natl Acad Sci U S A** 1996 Jun 11;93(12):5675–9 (33 ref.)

Eukaryotic gene expression: metabolite control by amino acids. Laine RO, et al. **Prog Nucleic Acid Res Mol Biol** 1996;53:219–48 (110 ref.)

[Mitochondrial introns of fungi and their role in evolution] Shnyreva AV. **Genetika** 1995 Jul;31(7):869–76 (46 ref.) (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

Activation of the complement system by pathogenic fungi. Kozel TR. **Clin Microbiol Rev** 1996 Jan;9(1):34–46 (109 ref.)

Direct antimicrobial activity of T cells. Levitz SM, et al. **Immunol Today** 1995 Aug;16(8):387–91 (36 ref.)

ISOLATION & PURIFICATION

Generation of DNA probes for detection of microorganisms by polymerase chain reaction fingerprinting [editorial] Giesendorf BA, et al. **Zentralbl Bakteriol** 1996 Apr; 283(4):417–30 (47 ref.)

METABOLISM

Breakdown of plastics and polymers by microorganisms. Kawai F. **Adv Biochem Eng Biotechnol** 1995;52:151–94 (190 ref.)

Cellulose hydrolysis by bacteria and fungi. Tomme P, et al. **Adv Microb Physiol** 1995;37:1–81 (367 ref.)

Biodegradation of nitroaromatic compounds. Spain JC. **Annu Rev Microbiol** 1995;49:523–55 (136 ref.)

Molecular and genetic control of chitin biosynthesis in fungi. Ruiz-Herrera J, et al. **Arch Med Res** 1995 Autumn; 26(3):315–21 (23 ref.)

Peptidolactones. Keller U. **Biotechnology** 1995;28:173–96 (74 ref.)

Peptides. von Döhren H. **Biotechnology** 1995;28:129–71 (256 ref.)

Mechanisms for polycyclic aromatic hydrocarbon degradation by ligninolytic fungi. Hammel KE. **Environ Health Perspect** 1995 Jun;103 Suppl 5:41–3 (14 ref.)

PATHOGENICITY

Mechanisms of fungicide resistance in phytopathogenic fungi. Steffens JJ, et al. **Curr Opin Biotechnol** 1996 Jun; 7(3):348–55 (77 ref.)

Cell surface hydrophobicity and medically important fungi. Hazen KC, et al. **Curr Top Med Mycol** 1995;6:1–31 (157 ref.)

Molecular genetic approaches for the study of virulence in both pathogenic bacteria and fungi. Hensel M, et al. **Microbiology** 1996 May;142 (Pt 5):1049–58 (52 ref.)

New insights into the mechanisms of fungal pathogenesis in insects. Clarkson JM, et al. **Trends Microbiol** 1996 May; 4(5):197–203 (68 ref.)

PHYSIOLOGY

Cell surface hydrophobicity and medically important fungi. Hazen KC, et al. **Curr Top Med Mycol** 1995;6:1–31 (157 ref.)

Fungal lipopeptide mating pheromones: a model system for the study of protein prenylation. Caldwell GA, et al. **Microbiol Rev** 1995 Sep;59(3):406–22 (181 ref.)

FUNGICIDES, INDUSTRIAL

PHARMACOLOGY

Mechanisms of fungicide resistance in phytopathogenic fungi. Steffens JJ, et al. **Curr Opin Biotechnol** 1996 Jun; 7(3):348–55 (77 ref.)

Biocides: mechanisms of antifungal action and fungal resistance. Russell AD, et al. **Sci Prog** 1996;79 (Pt 1):27–48 (102 ref.)

TOXICITY

Biotransformation and renal processing of nephrotoxic agents. Dekant W. **Arch Toxicol Suppl** 1996;18:163–72 (63 ref.)

FUNGICIDES, THERAPEUTIC see **ANTIFUNGAL AGENTS**

FUNGUS DISEASES see **MYCOSES**

FUNGUS POISONING see **MYCOTOXICOSIS**

FURANS

[Role of miscellaneous substances (organic acids, lactone, etc) in regulation of food intake] Aou S, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:85–9 (19 ref.) **(Jpn)**

CHEMICAL SYNTHESIS

[Synthesis of lactone ring-containing bioactive natural products. Cardiotonic steroids, naphthoquinone antibiotics, and tetronic acid ionophore antibiotics] Yoshii E. **Yakugaku Zasshi** 1996 Jan;116(1):1–20 (45 ref.) (Eng. Abstr.) **(Jpn)**

CHEMISTRY

Recent advances in Annonaceous acetogenins. Zeng L, et al. **Nat Prod Rep** 1996 Aug;13(4):275–306 (177 ref.)

FURAZOSIN see **PRAZOSIN**

FURCATION DEFECTS

SURGERY

Platelet-derived growth factor-modulated guided tissue regenerative therapy. Cho MI, et al. **J Periodontol** 1995 Jun;66(6):522–30 (43 ref.)

FUROCOUMARINS see **PSORALENS**

FUROSEMIDE

Loop diuretics: comparison of torsemide, furosemide, and bumetanide. Chen BP. **Conn Med** 1996 Jun;60(6):343–5 (6 ref.)

ADVERSE EFFECTS

Recurrent and chronic leg ulcers secondary to furosemide-induced bullous pemphigoid [letter] Siddiqui MA, et al. **J Am Geriatr Soc** 1995 Oct;43(10):1183–4 (7 ref.)

THERAPEUTIC USE

[Clinico-pharmacological approaches to the use of lasix] Kukes VG, et al. **Anesteziol Reanimatol** 1995 Sep–Oct; (5):40–4 (17 ref.) **(Rus)**

FURSEMIDE see **FUROSEMIDE**

FUSARIUM

Opportunistic fusarial infections in humans. Guarro J, et al. **Eur J Clin Microbiol Infect Dis** 1995 Sep;14(9):741–54 (131 ref.)

Fusarium peritonitis in a child on peritoneal dialysis: case report and review of the literature. Flynn JT, et al. **Perit Dial Int** 1996 Jan–Feb;16(1):52–7 (45 ref.)

ISOLATION & PURIFICATION

Mixed intranasal infection caused by Fusarium solani and a zygomycete in a leukaemic patient. Lopes JO, et al. **Mycoses** 1995 Jul–Aug;38(7–8):281–4 (26 ref.)

FUSION PROTEINS, BCR-ABL

see related
PHILADELPHIA CHROMOSOME

GENETICS

Acute leukemias expressing p210-and p 190-type bcr/abl mRNAs: report of two cases and review of the literature. Yamashita S, et al. **Acta Haematol** 1996;96(2):99–104 (23 ref.)

Genetic approaches to defining signaling by the CML-associated tyrosine kinase BCR-ABL. Afar DE, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:589–94 (49 ref.)

BCR/ABL and leukemia. Butturini A, et al. **Leuk Res** 1996 Jun;20(6):523–9 (87 ref.)

The molecular biology of chronic myeloid leukaemia. Melo JV. **Leukemia** 1996 May;10(5):751–6 (58 ref.)

PHYSIOLOGY

The repression of apoptosis by activated abl oncogenes in chronic myelogenous leukaemia. Fernandes RS, et al. **Leukemia** 1996 Jun;10 Suppl 2:s17–21 (39 ref.)

FUSION PROTEINS, ENV-ONC see **ONCOGENE PROTEINS, FUSION**

FUSION PROTEINS, GAG-FOS-FOX see **ONCOGENE PROTEINS V-FOS**

FUSION PROTEINS, GAG-JUN see **ONCOGENE PROTEIN P65(GAG-JUN)**

FUSION PROTEINS, RECOMBINANT see **RECOMBINANT FUSION PROTEINS**

FUSION PROTEINS, VIRAL see **VIRAL FUSION PROTEINS**

FUSOBACTERIUM INFECTIONS

Lemierre syndrome: postanginal sepsis. Leugers CM, et al. **J Am Board Fam Pract** 1995 Sep–Oct;8(5):384–91 (40 ref.)

FUSOBACTERIUM INFECTIONS

DIAGNOSIS

Otogenic Fusobacterium necrophorum meningitis in children. Figueras G, et al. **Pediatr Infect Dis J** 1995 Jul; 14(7):627–8 (10 ref.)

MICROBIOLOGY

Taxonomy, biology, and periodontal aspects of Fusobacterium nucleatum. Bolstad AI, et al. **Clin Microbiol Rev** 1996 Jan;9(1):55–71 (319 ref.)

VETERINARY

Fusobacterium necrophorum infections: virulence factors, pathogenic mechanism and control measures. Tan ZL, et al. **Vet Res Commun** 1996;20(2):113–40 (156 ref.)

FUSOBACTERIUM NECROPHORUM

Lemierre syndrome: postanginal sepsis. Leugers CM, et al. **J Am Board Fam Pract** 1995 Sep–Oct;8(5):384–91 (40 ref.)

ISOLATION & PURIFICATION

Otogenic Fusobacterium necrophorum meningitis in children. Figueras G, et al. **Pediatr Infect Dis J** 1995 Jul; 14(7):627–8 (10 ref.)

PATHOGENICITY

Fusobacterium necrophorum infections: virulence factors, pathogenic mechanism and control measures. Tan ZL, et al. **Vet Res Commun** 1996;20(2):113–40 (156 ref.)

FUSOBACTERIUM NUCLEATUM

PATHOGENICITY

Taxonomy, biology, and periodontal aspects of Fusobacterium nucleatum. Bolstad AI, et al. **Clin Microbiol Rev** 1996 Jan;9(1):55–71 (319 ref.)

FUTILE TREATMENT see **MEDICAL FUTILITY**

FUTUROLOGY see **FORECASTING**

FUZZY LOGIC

Symbiosis of nurse and machine through fuzzy logic: improved specificity of a neonatal pulse oximeter alarm. Bosque EM. **ANS Adv Nurs Sci** 1995 Dec;18(2):67–75 (60 ref.)

[Use of fuzzy set theory in diagnostics] Bogdanik T. **Pol Arch Med Wewn** 1995 Feb;93(2):143–8 (27 ref.) **(Pol)**

[Use of fuzzy set theory in therapy] Bogdanik T. **Pol Arch Med Wewn** 1995 Feb;93(2):149–54 (13 ref.) **(Pol)**

G1 PHASE

Origins of G1 arrest in senescent human fibroblasts. Stein GH, et al. **Bioessays** 1995 Jun;17(6):537–43 (66 ref.)

G1 regulation and checkpoints operating around START in fission yeast. Woollard A, et al. **Bioessays** 1995 Jun; 17(6):481–90 (65 ref.)

PHYSIOLOGY

Happenstance, circumstance or enemy action: cyclin D1 in breast, eye and brain. Schmidt EV. **Bioessays** 1996 Jan; 18(1):6–8 (29 ref.)

D-type cyclins and their cyclin-dependent kinases: G1 phase integrators of the mitogenic response. Sherr CJ, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:11–9 (86 ref.)

What is the restriction point? Zetterberg A, et al. **Curr Opin Cell Biol** 1995 Dec;7(6):835–42 (30 ref.)

Mammalian G1 cyclins and cell cycle progression. Sherr CJ. **Proc Assoc Am Physicians** 1995 Jul;107(2):181–6 (57 ref.)

RADIATION EFFECTS

Role of poly(ADP-ribose) polymerase in cell-cycle checkpoint mechanisms following gamma-irradiation. Masutani M, et al. **Biochimie** 1995;77(6):462–5 (24 ref.)

G2 PHASE

PHYSIOLOGY

The role of protein phosphatase type-2A in the Xenopus cell cycle: initiation of the G2/M transition. Lee TH. **Semin Cancer Biol** 1995 Aug;6(4):203–9 (39 ref.)

RADIATION EFFECTS

Role of poly(ADP-ribose) polymerase in cell-cycle checkpoint mechanisms following gamma-irradiation. Masutani M, et al. **Biochimie** 1995;77(6):462–5 (24 ref.)

G-ACTIN see **ACTINS**

G-CSF see **GRANULOCYTE COLONY-STIMULATING FACTOR**

G-CSF RECEPTORS see **RECEPTORS, GRANULOCYTE COLONY-STIMULATING FACTOR**

G FORCE see **GRAVITATION**

G PERIODS see **INTERPHASE**

G PHASES see **INTERPHASE**

G-PROTEINS

G-protein-coupled receptors in insect cells. Vanden Broeck JJ. **Int Rev Cytol** 1996;164:189–268 (319 ref.)

GTP-binding proteins. I: heterotrimeric G proteins. Pennington SR. **Protein Profile** 1994;1(3):169–342 (2704 ref.)

[COP-coated vesicles in intracellular protein transport] Kuge O, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec; 40(16):2427–35 (39 ref.) **(Jpn)**

ANALYSIS

[Analysis of GTP-binding protein function with a photoaffinity GTP analog] Hatta S, et al. **Nippon Yakurigaku Zasshi** 1995 Jun;105(6):431–6 (18 ref.) (Eng. Abstr.) **(Jpn)**

CHEMISTRY

A new point of view on the problem of G-protein aggregation. Assembly-disassembly of tubulin as an oscillation process. Tulub AA, et al. **Biochem Mol Biol Int** 1995 Jul;36(3):475–82 (20 ref.)

G-protein palmitoylation: regulation and functional significance. Milligan G, et al. **Biochem Soc Trans** 1995 Aug;23(3):583–7 (36 ref.)

G protein heterodimers: new structures propel new questions. Neer EJ, et al. **Cell** 1996 Jan 26;84(2):175–8 (15 ref.)

Ras-catalyzed hydrolysis of GTP: a new perspective from model studies. Maegley KA, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8160–6 (93 ref.)

How Ras works: structure of a Rap-Raf complex. Sprang SR. **Structure** 1995 Jul 15;3(7):641–3 (17 ref.)

[Structure and function of beta gamma subunits of heterotrimeric G proteins] Touhara K. **Seikagaku** 1996 Mar;68(3):210–4 (16 ref.) **(Jpn)**

[Structure and functional properties of GTP-binding proteins of plasma membranes] Usatiuk SA, et al. **Ukr Biokhim Zh** 1995 Jan–Feb;67(1):14–25 (25 ref.) (Eng. Abstr.) **(Ukr)**

GENETICS

Endocrine disorders associated with mutations in guanine nucleotide binding proteins. Milligan G. **Baillieres Clin Endocrinol Metab** 1996 Jan;10(1):177–87 (60 ref.)

G protein-coupled receptor structure and function: the impact of disease-causing mutations. Shenker A. **Baillieres Clin Endocrinol Metab** 1995 Jul;9(3):427–51 (114 ref.)

Mutations in G proteins and G protein-coupled receptors in endocrine disease. Spiegel AM. **J Clin Endocrinol Metab** 1996 Jul;81(7):2434–42 (71 ref.)

Clinical implications of genetic defects in G proteins. The molecular basis of McCune-Albright syndrome and Albright hereditary osteodystrophy. Ringel MD, et al. **Medicine (Baltimore)** 1996 Jul;75(4):171–84 (174 ref.)

[Mutation of G proteins] Trüeb RM. **Hautarzt** 1995 Sep; 46(9):603–6 (15 ref.) (Eng. Abstr.) **(Ger)**

METABOLISM

Compartmentalization of cyclic AMP phosphodiesterases, signalling 'crosstalk', desensitization and the phosphorylation of Gi-2 add cell specific personalization to the control of the levels of the second messenger cyclic AMP. Houslay MD. **Adv Enzyme Regul** 1995;35:303–38 (68 ref.)

The G protein-coupled receptor family and one of its members, the TSH receptor. Vassart G, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:23–30 (43 ref.)

COPs regulating membrane traffic. Kreis TE, et al. **Ann Rev Cell Dev Biol** 1995;11:677–706 (165 ref.)

Receptor-mediated protein sorting to the vacuole in yeast: roles for a protein kinase, a lipid kinase and GTP-binding proteins. Stack JH, et al. **Ann Rev Cell Dev Biol** 1995; 11:1–33 (146 ref.)

Regulation of phosphoinositide phospholipases by hormones, neurotransmitters, and other agonists linked to G proteins. Exton JH. **Annu Rev Pharmacol Toxicol** 1996;36:481–509 (170 ref.)

Diversity and selectivity of receptor-G protein interaction. Gudermann T, et al. **Annu Rev Pharmacol Toxicol** 1996; 36:429–59 (216 ref.)

Complexity and diversity of mammalian adenylyl cyclases. Sunahara RK, et al. **Annu Rev Pharmacol Toxicol** 1996; 36:461–80 (95 ref.)

Regulation of ionotropic receptors by protein phosphorylation. Pasqualotto BA, et al. **Biochem Pharmacol** 1996 Jun 14;51(11):1417–25 (77 ref.)

Dynamic regulation of G-protein coupled receptor palmitoylation: potential role in receptor function. Bouvier M, et al. **Biochem Soc Trans** 1995 Aug;23(3):577–81 (35 ref.)

G-protein palmitoylation: regulation and functional significance. Milligan G, et al. **Biochem Soc Trans** 1995 Aug;23(3):583–7 (36 ref.)

Multiple affinity and guanine nucleotide sensitive forms of the calcitonin gene related peptide (CGRP) receptor. Chatterjee TK, et al. **Can J Physiol Pharmacol** 1995 Jul; 73(7):968–73 (34 ref.)

Galanin—a neuropeptide with inhibitory actions. Kask K, et al. **Cell Mol Neurobiol** 1995 Dec;15(6):653–73 (146 ref.)

GTP-binding proteins and early embryogenesis in Xenopus. Paquereau L, et al. **Cell Signal** 1995 May;7(4):295–302 (71 ref.)

Somatostatin modulates voltage-dependent Ca2+ channels in GH3 cells via a specific G(o) splice variant. Kleuss C. **Ciba Found Symp** 1995;190:171–82; discussion 182–6 (38 ref.)

Interaction of somatostatin receptors with G proteins and cellular effector systems. Reisine T, et al. **Ciba Found Symp** 1995;190:160–7; discussion 167–70 (40 ref.)

Protein-protein interactions. Putting the pieces together. Bax B, et al. **Curr Biol** 1995 Oct 1;5(10):1119–21 (21 ref.)

Intracellular regulation. Rac and Bcr regulate phagocytic phoxes. Ridley AJ. **Curr Biol** 1995 Jul 1;5(7):710–2 (19 ref.)

Heterotrimeric G proteins. Hamm HE, et al. **Curr Opin Cell Biol** 1996 Apr;8(2):189–96 (108 ref.)

Integrin-mediated signalling: regulation by protein tyrosine kinases and small GTP-binding proteins. Parsons JT. **Curr Opin Cell Biol** 1996 Apr;8(2):146–52 (47 ref.)

Regulation of vesicular transport by GTP-binding proteins. Stow JL. **Curr Opin Nephrol Hypertens** 1995 Sep;4(5):421–5 (42 ref.)

Direct and indirect receptor-independent G-protein activation by cationic-amphiphilic substances. Studies with mast cells, HL-60 human leukemic cells and purified G-proteins. Klinker JF, et al. **Exp Dermatol** 1995 Aug;4(4 Pt 2):231–9 (53 ref.)

G protein-coupled receptors and signaling pathways regulating growth responses. Post GR, et al. **FASEB J** 1996 May;10(7):741–9 (137 ref.)

Receptor regulation: why should an anesthesiologist care? Smiley RM. **J Clin Anesth** 1996 May;8(3 Suppl):42S–47S (40 ref.)

Molecular characterization of a common binding site for small molecules within the transmembrane domain of G-protein coupled receptors. Cascieri MA, et al. **J Pharmacol Toxicol Methods** 1995 Aug;33(4):179–85 (32 ref.)

Alterations of beta-adrenoceptor-G-protein-regulated adenylyl cyclase in heart failure. Böhm M. **Mol Cell Biochem** 1995 Jun 7–21;147(1–2):147–60 (84 ref.)

Polyunsaturated fatty acids and signalling via phospholipase C-beta and A2 in myocardium. de Jonge HW, et al. **Mol Cell Biochem** 1996 Apr 12–26;157(1–2):199–210 (79 ref.)

Regulation of G protein function: implications for heart disease. Meij JT. **Mol Cell Biochem** 1996 Apr 12–26; 157(1–2):31–8 (43 ref.)

Phosphotransfer reactions as a means of G protein activation. Piacentini L, et al. **Mol Cell Biochem** 1996 Apr 12–26; 157(1–2):59–63 (45 ref.)

Endothelin receptor subtypes and their role in transmembrane signaling mechanisms. Sokolovsky M. **Pharmacol Ther** 1995;68(3):435–71 (208 ref.)

Ionotropic glutamate receptors—focus on non-NMDA receptors. Jørgensen M, et al. **Pharmacol Toxicol** 1995 May; 76(5):312–9 (48 ref.)

Agonist-specific coupling of G-protein-coupled receptors to second-messenger systems. Evans PD, et al. **Prog Brain Res** 1995;106:259–68 (35 ref.)

Desensitization of G protein-coupled receptors. Freedman NJ, et al. **Recent Prog Horm Res** 1996;51:319–51; discussion 352–3 (109 ref.)

Cell shape determination: a pivotal role for Rho [comment] Bussey H. **Science** 1996 Apr 12;272(5259):224–5 (12 ref.) Comment on: Science 1996 Apr 12;272(5259):277–9. Comment on: Science 1996 Apr 12;272(5259):279–81.

How Ras works: structure of a Rap-Raf complex. Sprang SR. **Structure** 1995 Jul 15;3(7):641–3 (17 ref.)

An evolutionary view of drug-receptor interaction: the bioamine receptor family. Vernier P, et al. **Trends Pharmacol Sci** 1995 Nov;16(11):375–81 (56 ref.)

Signals that make you different: receptor-mediated signal transduction in early development. Saxe CL 3rd. **Zygote** 1994 Aug;2(3):179–83 (42 ref.)

PHYSIOLOGY

G protein regulation of cardiac muscarinic potassium channel. Kurachi Y. **Am J Physiol** 1995 Oct;269(4 Pt 1):C821–30 (80 ref.)

Molecular mechanisms of opiate receptor coupling to G proteins and effector systems. Reisine T, et al. **Ann N Y Acad Sci** 1996 Mar 22;780:168–75 (34 ref.)

Defects in G protein-coupled signal transduction in human disease. Spiegel AM. **Annu Rev Physiol** 1996;58:143–70 (90 ref.)

Small G proteins and the neutrophil NADPH oxidase. Dagher MC, et al. **Biochimie** 1995;77(7–8):651–60 (94 ref.)

Nobel Lecture. G proteins and regulation of adenylyl cyclase. Gilman AG. **Biosci Rep** 1995 Apr;15(2):65–97 (154 ref.)

Endothelin receptor heterogeneity, G-proteins, and signaling

via cAMP and cGMP cascades. Sokolovsky M. **Cell Mol Neurobiol** 1995 Oct;15(5):561–71 (40 ref.)
Role of heterotrimeric G–proteins in epidermal growth factor signalling. Ramírez I, et al. **Cell Signal** 1995 May; 7(4):303–11 (123 ref.)
Pancreastatin action in the liver: dual coupling to different G proteins. Sánchez–Margalet V, et al. **Cell Signal** 1996 Jan;8(1):9–12 (53 ref.)
ARF–regulated phospholipase D: a potential role in membrane traffic. Cockcroft S. **Chem Phys Lipids** 1996 May 24;80(1–2):59–80 (165 ref.)
Transgenic manipulation of myocardial G protein–coupled receptors and receptor kinases. Koch WJ, et al. **Circ Res** 1996 Apr;78(4):511–6 (29 ref.)
The Rac and Rho pathways as a source of drug targets for Ras–mediated malignancies. Symons M. **Curr Opin Biotechnol** 1995 Dec;6(6):668–74 (63 ref.)
G–protein regulation of ion channels. Wickman KD, et al. **Curr Opin Neurobiol** 1995 Jun;5(3):278–85 (77 ref.)
Ligand–independent hormone secretion. Laue L. **Curr Opin Pediatr** 1995 Aug;7(4):434–9 (47 ref.)
Regulation of cellular calcium through signaling cross–talk involves an intricate interplay between the actions of receptors, G–proteins, and second messengers. Bygrave FL, et al. **FASEB J** 1995 Oct;9(13):1297–303 (62 ref.)
Potential roles of heterotrimeric G proteins of the endomembrane system. Nürnberg B, et al. **FEBS Lett** 1996 Jun 24;389(1):61–5 (66 ref.)
G–protein–coupled receptors in HL–60 human leukemia cells. Klinker JF, et al. **Gen Pharmacol** 1996 Jan;27(1):33–54 (247 ref.)
Beta–adrenergic receptors and G–proteins in the ob/ob mouse. Bégin–Heick N. **Int J Obes Relat Metab Disord** 1996 Mar;20 Suppl 3:S32–5 (21 ref.)
The Gs alpha/Gi alpha 2 axis controls adipogenesis independently of adenylylcyclase. Wang HY, et al. **Int J Obes Relat Metab Disord** 1996 Mar;20 Suppl 3:S26–31 (62 ref.)
G–protein–coupled receptor kinases. Lohse MJ, et al. **Kidney Int** 1996 Apr;49(4):1047–52 (65 ref.)
Interleukin–1 signal transduction. Bankers–Fulbright JL, et al. **Life Sci** 1996;59(2):61–83 (237 ref.)
In vitro analysis of G–protein functions. Ma H, et al. **Methods Cell Biol** 1995;49:471–85 (65 ref.)
Tyrosine kinase–mediated signal transduction pathways and the actions of polypeptide growth factors and G–protein–coupled agonists in smooth muscle. Hollenberg MD. **Mol Cell Biochem** 1995 Aug–Sep;149–150:77–85 (77 ref.)
Seminars in medicine of the Beth Israel Hospital, Boston. Adrenergic receptors—evolving concepts and clinical implications. Insel PA. **N Engl J Med** 1996 Feb 29; 334(9):580–5 (47 ref.)
GTPases: a family of molecular switches and clocks. Bourne HR. **Philos Trans R Soc Lond B Biol Sci** 1995 Sep 29; 349(1329):283–9 (32 ref.)
Ion channel regulation by G proteins. Wickman K, et al. **Physiol Rev** 1995 Oct;75(4):865–85 (261 ref.)
Control of signal transduction and morphogenesis by Ras. Hughes DA. **Semin Cell Biol** 1995 Apr;6(2):89–94 (49 ref.)
Switching to Rac and Rho. Block C, et al. **Structure** 1995 Dec 15;3(12):1281–4 (30 ref.)
Regulation of G protein–coupled receptors by receptor kinases and arrestins. Sterne–Marr R, et al. **Vitam Horm** 1995;51:193–234 (121 ref.)
[Receptor independent activation of G proteins] Klinker JF, et al. **Pharm Unserer Zeit** 1995 Sep;24(5):250–63 (73 ref.) **(Ger)**
[Hormone signal transduction and G protein] Okajima F. **Nippon Naika Gakkai Zasshi** 1995 Nov 10;84(11):1926–33 (10 ref.) **(Jpn)**
[Structure and function of beta gamma subunits of heterotrimeric G proteins] Touhara K. **Seikagaku** 1996 Mar;68(3):210–4 (16 ref.) **(Jpn)**
[Molecular mechanism of the G protein regulation of inwardly rectifying potassium channels] Yamada M, et al. **Tanpakushitsu Kakusan Koso** 1995 Nov;40(15):2297–306 (36 ref.) **(Jpn)**
[Structure and functional properties of GTP–binding proteins of plasma membranes] Usatiuk SA, et al. **Ukr Biokhim Zh** 1995 Jan–Feb;67(1):14–25 (25 ref.) (Eng. Abstr.) **(Ukr)**

GABA

see related
RECEPTORS, GABA

ANALOGS & DERIVATIVES

Rationalized polytherapy for epilepsy. Goldsmith P, et al. **Acta Neurol Scand Suppl** 1995;162:35–9 (27 ref.)
Vigabatrin: effect on brain GABA levels measured by nuclear magnetic resonance spectroscopy. Mattson RH, et al. **Acta Neurol Scand Suppl** 1995;162:27–30 (16 ref.)
Pharmacokinetic and pharmacodynamic drug interactions during treatment with vigabatrin. Richens A. **Acta Neurol Scand Suppl** 1995;162:43–6 (16 ref.)
Behavioural abnormalities and retention rates of anti–epilepsy drugs during long–term treatment of epilepsy: a clinical perspective. Schmidt D. **Acta Neurol Scand Suppl** 1995; 162:7–10 (28 ref.)
Vigabatrin–associated reversible acute psychosis in a child. Cánovas Martínez A, et al. **Ann Pharmacother** 1995 Nov; 29(11):1115–7 (10 ref.)
Vigabatrin. Ben–Menachem E. **Epilepsia** 1995;36 Suppl 2:S95–104 (70 ref.)
Cognitive effects of vigabatrin: a review. Monaco F. **Neurology** 1996 Jul;47(1 Suppl 1):S6–11 (71 ref.)
[Advances in the diagnostic and treatment of infantile epilepsy] Legido A. **Rev Neurol** 1996 Jun;24(130):688–93 (25 ref.) **(Spa)**

DEFICIENCY

GABA and mood disorders: a brief review and hypothesis. Petty F. **J Affect Disord** 1995 Aug 18;34(4):275–81 (60 ref.)

METABOLISM

Vigabatrin: effect on brain GABA levels measured by nuclear magnetic resonance spectroscopy. Mattson RH, et al. **Acta Neurol Scand Suppl** 1995;162:27–30 (16 ref.)
gamma–Aminobutyric acid (GABA) metabolism in mammalian neural and nonneural tissues. Tillakaratne NJ, et al. **Comp Biochem Physiol A Physiol** 1995 Oct; 112(2):247–63 (162 ref.)
Recent advances in the GABA–A–benzodiazepine receptor pharmacology. Kostowski W. **Pol J Pharmacol** 1995 May–Jun;47(3):237–46 (57 ref.)
Glutamate, GABA and epilepsy. Bradford HF. **Prog Neurobiol** 1995 Dec;47(6):477–511 (185 ref.)

PHARMACOLOGY

Tiagabine pharmacology in profile. Brodie MJ. **Epilepsia** 1995;36 Suppl 6:S7–S9 (18 ref.)
A review of the preclinical pharmacology of tiagabine: a potent and selective anticonvulsant GABA uptake inhibitor. Suzdak PD, et al. **Epilepsia** 1995 Jun;36(6):612–26 (81 ref.)
Structure and pharmacology of vertebrate GABAA receptor subtypes. Whiting PJ, et al. **Int Rev Neurobiol** 1995; 38:95–138 (476 ref.)

PHYSIOLOGY

Molecular genetic analysis of the role of GABAergic systems in the behavioral and cellular actions of alcohol. Buck KJ. **Behav Genet** 1996 May;26(3):313–23 (72 ref.)
Central auditory aging: GABA changes in the inferior colliculus. Caspary DM, et al. **Exp Gerontol** 1995 May–Aug;30(3–4):349–60 (85 ref.)
Frank A. Beach Award. Functional significance of steroid modulation of GABAergic neurotransmission: analysis at the behavioral, cellular, and molecular levels. McCarthy MM. **Horm Behav** 1995 Jun;29(2):131–40 (48 ref.)
Involvement of endogenous benzodiazepine receptor ligands in brain disorders: therapeutic potential for benzodiazepine antagonists? Polc P. **Med Hypotheses** 1995 Jun;44(6):439–46 (51 ref.)
The usual suspects: GABA and glutamate may regulate proliferation in the neocortex. LaMantia AS. **Neuron** 1995 Dec;15(6):1223–5 (25 ref.)

GABA–A RECEPTORS see **RECEPTORS, GABA–A**

GABA AGONISTS

PHARMACOLOGY

Structure and pharmacology of gamma–aminobutyric acidA receptor subtypes. Sieghart W. **Pharmacol Rev** 1995 Jun; 47(2):181–234 (504 ref.)
GABAB receptors. Kerr DI, et al. **Pharmacol Ther** 1995; 67(2):187–246 (584 ref.)
Recent advances in the GABA–A–benzodiazepine receptor pharmacology. Kostowski W. **Pol J Pharmacol** 1995 May–Jun;47(3):237–46 (57 ref.)

GABA ANTAGONISTS

PHARMACOLOGY

Structure and pharmacology of gamma–aminobutyric acidA receptor subtypes. Sieghart W. **Pharmacol Rev** 1995 Jun; 47(2):181–234 (504 ref.)
GABAB receptors. Kerr DI, et al. **Pharmacol Ther** 1995; 67(2):187–246 (584 ref.)
GABAergic deafferentation hypothesis of brain aging and Alzheimer's disease; pharmacologic profile of the benzodiazepine antagonist, flumazenil. Marczynski TJ. **Rev Neurosci** 1995 Jul–Sep;6(3):221–58 (164 ref.)

GABA–B RECEPTORS see **RECEPTORS, GABA–B**

GABA MODULATORS

see related
ANESTHETICS, GENERAL
ANTI–ANXIETY AGENTS, BENZODIAZEPINE
SEDATIVES, BARBITURATE
[Flumazenil] Shapira Y, et al. **Harefuah** 1995 Jun 15; 128(12):812–7 (45 ref.) **(Heb)**

ADMINISTRATION & DOSAGE

Flumazenil and midazolam in anaesthesia. Whitwam JG. **Acta Anaesthesiol Scand Suppl** 1995;108:15–22 (67 ref.)

PHARMACOLOGY

Reversal of conscious sedation by flumazenil: current status and future prospects. McCloy RF. **Acta Anaesthesiol Scand Suppl** 1995;108:35–42 (51 ref.)
Pharmacology of flumazenil. Whitwam JG, et al. **Acta Anaesthesiol Scand Suppl** 1995;108:3–14 (97 ref.)
The effects of flumazenil in neuropsychiatric disorders. Malizia AL, et al. **Clin Neuropharmacol** 1995 Jun; 18(3):215–32 (134 ref.)

THERAPEUTIC USE

The role of flumazenil in the critically ill. Park GR, et al. **Acta Anaesthesiol Scand Suppl** 1995;108:23–34 (120 ref.)
The management of alcohol withdrawal using chlormethiazole. Morgan MY. **Alcohol Alcohol** 1995 Nov; 30(6):771–4 (21 ref.)

GABA RECEPTORS see **RECEPTORS, GABA**

GABA TRANSAMINASE see **AMINOBUTYRATE AMINOTRANSFERASE**

GABOON VIPER see **VIPERIDAE**

GADOLINIUM

DIAGNOSTIC USE

Liver. III: Gadolinium–based hepatobiliary contrast agents (Gd–EOB–DTPA and Gd–BOPTA/Dimeg). Giovagnoni A, et al. **Magn Reson Imaging Clin N Am** 1996 Feb; 4(1):61–72 (34 ref.)
Liver I: Currently available gadolinium chelates. Mitchell DG. **Magn Reson Imaging Clin N Am** 1996 Feb;4(1):37–51 (15 ref.)
Body MR angiography with gadolinium contrast agents. Prince MR. **Magn Reson Imaging Clin N Am** 1996 Feb; 4(1):11–24 (28 ref.)
[Gadolinium–DTPA (Magnevist) as contrast medium for galactography] Kaltenborn H, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1995 Nov;163(5):457–9 (14 ref.) **(Ger)**
[The magnetic resonance assessment of craniofacial fibrous dysplasia. The completion of the study with gadolinium administration and magnetic resonance angiography] Di Girolamo M, et al. **Radiol Med (Torino)** 1996 Mar; 91(3):313–6 (10 ref.) **(Ita)**

GAFFKYA ANAEROBIA see **PEPTOSTREPTOCOCCUS**

GAG GENE PRODUCTS see **GENE PRODUCTS, GAG**

GAG POLYPROTEINS see **GENE PRODUCTS, GAG**

GAG PROTEIN see **GENE PRODUCTS, GAG**

GAG VIRAL PROTEINS see **GENE PRODUCTS, GAG**

GAIT

Rehabilitation in limb deficiency. 1. Gait and motion analysis. Czerniecki JM. **Arch Phys Med Rehabil** 1996 Mar;77(3 Suppl):S3–8 (41 ref.)
Gait disorders in older adults. Alexander NB. **J Am Geriatr Soc** 1996 Apr;44(4):434–51 (311 ref.)
The child who has a limp. Renshaw TS. **Pediatr Rev** 1995 Dec;16(12):458–65 (15 ref.)

PHYSIOLOGY

The use of artificial intelligence in the analysis of sports performance: a review of applications in human gait analysis and future directions for sports biomechanics. Lapham AC, et al. **J Sports Sci** 1995 Jun;13(3):229–37 (38 ref.)
Technology assessment: dynamic electromyography in gait and motion analysis. Rechtien JJ, et al. **Muscle Nerve** 1996 Mar;19(3):396–402 (110 ref.)

GALACTOCEREBROSIDASE see **GALACTOSYLCERAMIDASE**

GALACTOKINASE

see related
GALACTOSEMIA

PHYSIOLOGY

The Leloir pathway: a mechanistic imperative for three enzymes to change the stereochemical configuration of a single carbon in galactose. Frey PA. **FASEB J** 1996 Mar; 10(4):461–70 (40 ref.)

GALACTOSAMINIDASE

DEFICIENCY

[Schindler disease/Kanzaki disease] Kanzaki T. **Nippon Rinsho** 1995 Dec;53(12):2982–7 (18 ref.) (Eng. Abstr.) **(Jpn)**

GALACTOSAMINIDASE

METABOLISM

Enzymatic release of oligosaccharides from glycoproteins for chromatographic and electrophoretic analysis. O'Neill RA. **J Chromatogr A** 1996 Jan 12;720(1-2):201-15 (101 ref.)

GALACTOSE

see related
GALACTOSEMIA

ANALYSIS

Galactofuranose-containing glycoconjugates in trypanosomatids. de Lederkremer RM, et al. **Glycobiology** 1995 Sep;5(6):547-52 (42 ref.)

[Galactose] Ohya N, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:532-5 (18 ref.) **(Jpn)**

CHEMISTRY

The Leloir pathway: a mechanistic imperative for three enzymes to change the stereochemical configuration of a single carbon in galactose. Frey PA. **FASEB J** 1996 Mar; 10(4):461-70 (40 ref.)

IMMUNOLOGY

The alpha-galactosyl epitope: a sugar coating that makes viruses and cells unpalatable. Rother RP, et al. **Cell** 1996 Jul 26;86(2):185-8 (20 ref.)

METABOLISM

Significance and molecular basis for IgG glycosylation changes in rheumatoid arthritis. Rademacher TW, et al. **Adv Exp Med Biol** 1995;376:193-204 (52 ref.)

The Leloir pathway: a mechanistic imperative for three enzymes to change the stereochemical configuration of a single carbon in galactose. Frey PA. **FASEB J** 1996 Mar; 10(4):461-70 (40 ref.)

GALACTOSEMIA

GENETICS

Galactosaemia: pathogenesis and treatment. Holton JB. **J Inherit Metab Dis** 1996;19(1):3-7 (32 ref.)

METABOLISM

[Disorders of fructose and galactose metabolism] Abukawa D, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):371-4 (12 ref.) **(Jpn)**

THERAPY

Galactosaemia: pathogenesis and treatment. Holton JB. **J Inherit Metab Dis** 1996;19(1):3-7 (32 ref.)

GALACTOSEPHOSPHATE URIDYLYLTRANSFERASE

PHYSIOLOGY

The Leloir pathway: a mechanistic imperative for three enzymes to change the stereochemical configuration of a single carbon in galactose. Frey PA. **FASEB J** 1996 Mar; 10(4):461-70 (40 ref.)

GALACTOSYLCERAMIDASE

GENETICS

The twitcher mouse: a model for Krabbe disease and for experimental therapies. Suzuki K, et al. **Brain Pathol** 1995 Jul;5(3):249-58 (63 ref.)

GALACTOSYLTRANSFERASES

BLOOD

[Galactosyltransferase] Taki T. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:423-7 (8 ref.) **(Jpn)**

METABOLISM

[beta 1,4-Galactosyltransferase] Ichikawa T, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:405-8 (5 ref.) **(Jpn)**

GALANIN

METABOLISM

Minireview. Galanin-acetylcholine interactions: relevance to memory and Alzheimer's disease. Crawley JN. **Life Sci** 1996;58(24):2185-99 (112 ref.)

PHARMACOLOGY

Galanin--a neuropeptide with inhibitory actions. Kask K, et al. **Cell Mol Neurobiol** 1995 Dec;15(6):653-73 (146 ref.)

PHYSIOLOGY

Galanin and 5-HT1A receptor interactions as an integrative mechanism in 5-HT neurotransmission in the brain. Hedlund PB, et al. **Ann N Y Acad Sci** 1996 Mar 22; 780:193-212 (82 ref.)

Galanin--a neuropeptide with inhibitory actions. Kask K, et al. **Cell Mol Neurobiol** 1995 Dec;15(6):653-73 (146 ref.)

Brain peptides and obesity: pharmacologic treatment. Leibowitz SF. **Obes Res** 1995 Nov;3 Suppl 4:573S-589S (196 ref.)

GALANTAMIN see **GALANTHAMINE**

GALANTHAMINE

PHARMACOLOGY

The pharmacology of galanthamine and its analogues. Harvey AL. **Pharmacol Ther** 1995;68(1):113-28 (100 ref.)

GALLBLADDER

see related
CHOLECYSTECTOMY

[Anomalous positions of the gallbladder] Higashi S. **Ryoikibetsu Shokogun Shirizu** 1996;(9):363-6 (13 ref.) **(Jpn)**

[Heterotopic bone formation] Kiyomatsu K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):462-3 (9 ref.) **(Jpn)**

ABNORMALITIES

[A rare case of gallbladder interposition in the extrahepatic bile ducts] Nikolov K, et al. **Khirurgiia (Sofiia)** 1994; 47(6):52-3 (2 ref.) (Eng. Abstr.) **(Bul)**

[Anatomical variations of the gallbladder] Higashi S. **Ryoikibetsu Shokogun Shirizu** 1996;(9):379-84 (15 ref.) **(Jpn)**

[Formal abnormalities of the gallbladder] Honma T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):367-70 (17 ref.) **(Jpn)**

[Intrahepatic gallbladder] Matsuzaki M, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):154-5 (20 ref.) **(Jpn)**

[Gallbladder anomalies--multiple gallbladders] Nakagawara G, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):371-4 (16 ref.) **(Jpn)**

[Congenital agenesis of the gallbladder, hypoplastic gallbladder, gallbladder atresia] Sato K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):356-9 (24 ref.) **(Jpn)**

BLOOD SUPPLY

[Variations in the arterial supply of the gallbladder] Higashi S. **Ryoikibetsu Shokogun Shirizu** 1996;(9):375-8 (9 ref.) **(Jpn)**

[Ischemic cholecystitis] Takahashi M, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):210-2 (22 ref.) **(Jpn)**

[Isolated periarteritis nodosa of the gallbladder] Tsugu Y, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):222-4 (21 ref.) **(Jpn)**

INJURIES

Gunshot cholecystitis. Petersen JM, et al. **J Clin Gastroenterol** 1995 Dec;21(4):320-2 (17 ref.)

Blunt gallbladder injuries: presentation of twenty-two cases with review of the literature. Sharma O. **J Trauma** 1995 Sep;39(3):576-80 (51 ref.)

[Gallbladder injury, injury of the gallbladder, traumatic rupture of the gallbladder] Ishizaka K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):451-5 (20 ref.) **(Jpn)**

PATHOLOGY

[Reactive lymphoid hyperplasia (RLH) of the gallbladder] Hayasaka T, et al. **Ryoikibetsu Shokogun Shirizu** 1996; (9):326-8 (14 ref.) **(Jpn)**

[Small polypoid lesions of the gallbladder] Itoi T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):287-9 (5 ref.) **(Jpn)**

[Pseudotumors of the gallbladder] Iwase H, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):329-32 (20 ref.) **(Jpn)**

[Pseudostone of the gallbladder] Kubota Y, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):415-7 (3 ref.) **(Jpn)**

[Metaplastic cholecystitis] Ozeki Y, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):199-201 (12 ref.) **(Jpn)**

[Thickening of the GB wall] Sato K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):385-7 (9 ref.) **(Jpn)**

[Hyperplastic polyp, metaplastic polyp] Taira A, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):256-8 (22 ref.) **(Jpn)**

PHYSIOLOGY

Effects of sphincterotomy on gallbladder physiology: a review. Targarona EM, et al. **Endoscopy** 1995 Jun; 27(5):388-91 (29 ref.)

[Neurohormonal control of gallbladder motility by intra-ileal and intracolonic nutrients--a review] Niebergall-Roth E, et al. **Berl Munch Tierarztl Wochenschr** 1996 Mar; 109(3):87-94 (110 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Gallbladder motility, gallstones, and the surgeon. Patankar R, et al. **Dig Dis Sci** 1995 Nov;40(11):2323-35 (188 ref.)

GALLBLADDER DISEASES

[Biliary ileus. Case report and therapeutic considerations] Ferranti F, et al. **Minerva Chir** 1995 Jul-Aug; 50(7-8):707-11 (28 ref.) (Eng. Abstr.) **(Ita)**

[Torsion of the gallbladder] Fujii K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):468-70 (20 ref.) **(Jpn)**

[Tuberculosis of the gallbladder] Ikai M, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):219-21 (10 ref.) **(Jpn)**

[Empyema of the gallbladder (empyema vesicae felleae)] Ise H, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):471-3 (13 ref.) **(Jpn)**

[Spontaneous (idiopathic) perforation of the gallbladder] Ishizaka K, et al. **Ryoikibetsu Shokogun Shirizu** 1996; (9):477-81 (30 ref.) **(Jpn)**

[Heterotopic tissues in the gallbladder (heterotopic gastric mucosa, heterotopic intestinal epithelium, heterotopic pancreatic tissue and ectopic liver in the gallbladder] Kodama T, et al. **Ryoikibetsu Shokogun Shirizu** 1996; (9):360-2 (17 ref.) **(Jpn)**

[Pericholecystic abscess] Kogure K. **Ryoikibetsu Shokogun Shirizu** 1996;(9):225-7 (6 ref.) **(Jpn)**

[Hydrops of the gallbladder] Kohno M, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):448-50 (12 ref.) **(Jpn)**

[Herniation of the gallbladder through the foramen of Winslow] Nagahori J. **Ryoikibetsu Shokogun Shirizu** 1996; (9):432-5 (7 ref.) **(Jpn)**

[Intragallbladder ascariasis] Nakazawa O, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):464-7 (11 ref.) **(Jpn)**

[Cholesterosis (cholesterolosis) of the gallbladder] Noda A, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):444-7 (10 ref.) **(Jpn)**

[Porcelain gallbladder] Oyama H, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):474-6 (13 ref.) **(Jpn)**

[Ulcer formation of gallbladder] Seki T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):439-40 (5 ref.) **(Jpn)**

[Morgagni's hernia of gallbladder] Suto T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):428-31 (10 ref.) **(Jpn)**

[Retention cyst of the gallbladder] Yamada M, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):456-8 (15 ref.) **(Jpn)**

COMPLICATIONS

[Diseases of the gallbladder and biliary tract in patients with AIDS] Regev A, et al. **Harefuah** 1996 Mar 1;130(5):330-2 (15 ref.) **(Heb)**

DIAGNOSIS

[1995 literature review: ultrasound and roentgen diagnosis of gallbladder, bile ducts and pancreas] Brambs HJ, et al. **Rontgenpraxis** 1996 Apr;49(4):94-9 (31 ref.) **(Ger)**

ECONOMICS

Managing gallbladder disease in a cost-effective manner. Orlando R 3rd, et al. **Surg Clin North Am** 1996 Feb; 76(1):117-28 (36 ref.)

RADIOGRAPHY

[A case of intramural cyst in the gallbladder] Fujisawa T, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Sep; 92(9):1309-14 (14 ref.) **(Jpn)**

SURGERY

Managing gallbladder disease in a cost-effective manner. Orlando R 3rd, et al. **Surg Clin North Am** 1996 Feb; 76(1):117-28 (36 ref.)

Laparoscopic cholecystectomy for gallbladder torsion. Schroder DM, et al. **Surg Laparosc Endosc** 1995 Aug; 5(4):330-4 (39 ref.)

GALLBLADDER EMPTYING

PHYSIOLOGY

Motor activity of the gallbladder and gastrointestinal tract as determinants of enterohepatic circulation. A scintigraphic and manometric study. Qvist N. **Dan Med Bull** 1995 Nov;42(5):426-40 (196 ref.)

Cholesterol gallstone formation in man and potential treatments of the gallbladder motility defect. Portincasa P, et al. **Scand J Gastroenterol Suppl** 1995;212:63-78 (294 ref.)

[Impaired gallbladder motility--an underestimated pathogenetic factor of gallstones] Jonderko K. **Przegl Lek** 1995;52(7):358-64 (102 ref.) **(Pol)**

GALLBLADDER NEOPLASMS

[Mucin producing gallbladder cancer] Araida T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):352–5 (15 ref.) **(Jpn)**

[Leiomyoma, lipoma, myxoma, and fibroma of the gallbladder] Furukawa H. **Ryoikibetsu Shokogun Shirizu** 1996;(9):333–4 (8 ref.) **(Jpn)**

[Leiomyosarcoma of the gallbladder] Ikuno N, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):335–7 (18 ref.) **(Jpn)**

[Carcinoma in adenoma of the gallbladder] Itoi T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):311–3 (6 ref.) **(Jpn)**

[Polyp and polypoid lesions of the gallbladder] Itoi T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):348–51 (12 ref.) **(Jpn)**

[Pseudotumors of the gallbladder] Iwase H, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):329–32 (20 ref.) **(Jpn)**

[Carcinoid of the gallbladder] Kawaguchi M, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):261–4 (12 ref.) **(Jpn)**

[Undifferentiated carcinoma] Kinami Y, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):341–4 (20 ref.) **(Jpn)**

[Granular cell tumor] Kitamra T. **Ryoikibetsu Shokogun Shirizu** 1996;(9):259–60 (5 ref.) **(Jpn)**

[Granulation polyp of the gallbladder, inflammation of the Rokitansky–Aschoff sinus] Liao CM, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):321–3 (6 ref.) **(Jpn)**

[Malignant fibrous histiocytoma of the gallbladder] Miyakawa R, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):243–4 (18 ref.) **(Jpn)**

[Malignant lymphoma of the gallbladder] Murakami H, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):245–7 (16 ref.) **(Jpn)**

[Gallbladder tumors (benign and malignant)] Nakamura S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):283–6 (11 ref.) **(Jpn)**

[Adenocarcinoma of the gallbladder] Nakamura S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):299–302 (16 ref.) **(Jpn)**

[Clear cell carcinoma of the gallbladder] Nomura S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):345–7 (8 ref.) **(Jpn)**

[Gallbladder papilloma] Ono T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):324–5 (17 ref.) **(Jpn)**

[Malignant melanoma of the gallbladder] Saoshiro T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):240–2 (12 ref.) **(Jpn)**

[Pleomorphic giant cell adenocarcinoma (PGCA–Ca)] Seki S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):318–20 (20 ref.) **(Jpn)**

[Adenosquamous cell carcinoma of the gallbladder] Shimoi K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):314–7 (21 ref.) **(Jpn)**

[Squamous cell carcinoma of the gallbladder] Shimoi K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):338–40 (16 ref.) **(Jpn)**

[Hyperplastic polyp, metaplastic polyp] Taira A, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):256–8 (22 ref.) **(Jpn)**

[Inflammatory polyp] Taira A, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):248–50 (22 ref.) **(Jpn)**

[Lipoma of the gallbladder] Takagi I, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):514–5 (5 ref.) **(Jpn)**

[Gallbladder neck cancer] Takeda Y. **Ryoikibetsu Shokogun Shirizu** 1996;(9):275–9 (10 ref.) **(Jpn)**

[Oat cell carcinoma of the gallbladder] Todoroki T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):251–5 (11 ref.) **(Jpn)**

[Fibroepithelial polyp of the gallbladder] Tokoi S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):292–4 (8 ref.) **(Jpn)**

[Adenomyomatosis of the gallbladder] Yamaguchi T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):305–7 (18 ref.) **(Jpn)**

CHEMISTRY

[Gallbladder carcinoma producing CEA, AFP, CA19–9, sialyl SSEA and CSF] Tanigawa N. **Ryoikibetsu Shokogun Shirizu** 1996;(9):237–9 (7 ref.) **(Jpn)**

CLASSIFICATION

[Gallbladder adenoma (pyloric gland type, intestinal type, proper epithelial type, papillary type, mucinous cystic type] Ono T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):308–10 (16 ref.) **(Jpn)**

EPIDEMIOLOGY

Small cell carcinoma of gallbladder: report of two cases. Muraina OI, et al. **Am J Gastroenterol** 1996 Apr;91(4):792–4 (9 ref.)

PATHOLOGY

Malignant melanoma of the gallbladder: report of a case and review of the literature. Velez AF, et al. **Am Surg** 1995 Dec;61(12):1095–8 (17 ref.)

Carcinoma of the gall–bladder: an experience and review of the literature. Wilkinson DS. **Aust N Z J Surg** 1995 Oct;65(10):724–7 (40 ref.)

Gallbladder adenocarcinoma, acalculous chronic lymphoplasmacytic cholecystitis, ulcerative colitis. Herzog K, et al. **Mod Pathol** 1996 Mar;9(3):194–8 (26 ref.)

[Implantation metastases following laparoscopic cholecystectomy in gallbladder carcinoma] Buhr J, et al. **Dtsch Med Wochenschr** 1996 Jan 19;121(3):57–61; discussion 61–2 (36 ref.) (Eng. Abstr.) **(Ger)**

[Small polypoid lesions of the gallbladder] Itoi T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):287–9 (5 ref.) **(Jpn)**

[Cholesterol polyp] Taira A, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):280–2 (8 ref.) **(Jpn)**

[Pseudopolyp of the gallbladder] Watanabe H, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):273–4 (5 ref.) **(Jpn)**

SURGERY

Biliary neoplasms. Puntis MC. **Curr Opin Gen Surg** 1993; :277–81 (24 ref.)

Carcinoid tumor of the gallbladder: report of a case. Khetan N, et al. **Surg Today** 1995;25(12):1047–9 (25 ref.)

ULTRASONOGRAPHY

Intraportal tumor thrombus of gallbladder carcinoma: detection with intravascular ultrasonography. Kaneko T, et al. **Am J Gastroenterol** 1996 Jun;91(6):1268–9 (8 ref.)

[A case of early carcinoma of the gall–bladder arising in adenomyomatosis detected by endoscopic ultrasonography] Sakurai T, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Sep;92(9):1304–8 (18 ref.) **(Jpn)**

GALLIUM RADIOISOTOPES

DIAGNOSTIC USE

Role of 67Ga scintigraphy in localization of lymphoma. van Amsterdam JA, et al. **Ann Hematol** 1996 Apr;72(4):202–7 (56 ref.)

The uptake mechanisms of inflammation– and infection–localizing agents. Oyen WJ, et al. **Eur J Nucl Med** 1996 Apr;23(4):459–65 (62 ref.)

PHARMACOKINETICS

The uptake mechanisms of inflammation– and infection–localizing agents. Oyen WJ, et al. **Eur J Nucl Med** 1996 Apr;23(4):459–65 (62 ref.)

GALLODESOXYCHOLIC ACID see **CHENODEOXYCHOLIC ACID**

GALLSTONES see **CHOLELITHIASIS**

GALLSTONES, COMMON BILE DUCT see **COMMON BILE DUCT CALCULI**

GAMASOIDIASIS see **MITE INFESTATIONS**

GAMBLING

[Pathologic gambling] Nešpor K. **Cas Lek Cesk** 1996 Jan 31;135(3):67–70 (20 ref.) (Eng. Abstr.) **(Cze)**

PSYCHOLOGY

Diagnosis, neurobiology, and treatment of pathological gambling. DeCaria CM, et al. **J Clin Psychiatry** 1996;57 Suppl 8:80–3; discussion 83–4 (36 ref.)

GAMBUSIA see **CYPRINODONTIFORMES**

GAMETE INTRAFALLOPIAN TRANSFER

In vitro fertilization, gamete intrafallopian transfer, and superovulation with intrauterine insemination: efficacy and potential health hazards on babies delivered. Dawood MY. **Am J Obstet Gynecol** 1996 Apr;174(4):1208–17 (26 ref.)

GAMETOGENESIS

IMMUNOLOGY

[Expression and role of complement regulatory proteins on human gametes and pre–implantation embryos] Fénichel P, et al. **Contracept Fertil Sex** 1995 Sep;23(9):576–80 (50 ref.) (Eng. Abstr.) **(Fre)**

GAMMA–AMINOBUTYRIC ACID see **GABA**

GAMMA–AMINOBUTYRIC ACID AGONISTS see **GABA AGONISTS**

GAMMA–AMINOBUTYRIC ACID ANTAGONISTS see **GABA ANTAGONISTS**

GAMMA–AMINOBUTYRIC ACID MODULATORS see **GABA MODULATORS**

GAMMA–AMINOBUTYRIC ACID RECEPTORS see **RECEPTORS, GABA**

GAMMA–AMYLASE see **GLUCAN 1,4–ALPHA–GLUCOSIDASE**

GAMMA–BENZENE HEXACHLORIDE see **LINDANE**

GAMMA–BUTYROLACTONE see **4–BUTYROLACTONE**

GAMMA CAMERA IMAGING see **RADIONUCLIDE IMAGING**

GAMMA–CARBOXYGLUTAMATE see **1–CARBOXYGLUTAMIC ACID**

GAMMA–CARBOXYGLUTAMIC ACID see **1–CARBOXYGLUTAMIC ACID**

GAMMA–CHAIN DISEASE see **HEAVY CHAIN DISEASE**

GAMMA FC RECEPTORS see **RECEPTORS, IGG**

GAMMA–GLOBIN see **GLOBIN**

GAMMA GLOBULIN, 7S see **IGG**

GAMMA GLOBULIN, 19S see **IGM**

GAMMA–GLOBULINS

ADMINISTRATION & DOSAGE

Treatment of inflammatory myopathy with intravenous gamma globulin. Sussman GL, et al. **Curr Opin Rheumatol** 1995 Nov;7(6):510–5 (57 ref.)

[Vaccination against hepatitis A gives protection fast. Combination with gamma–globulin is probably unnecessary] Iwarson S. **Lakartidningen** 1996 May 22; 93(21):2045–6 (9 ref.) **(Swe)**

GAMMA–GLUTAMYL–CYSTEINE SYNTHETASE

DEFICIENCY

Three cases of hereditary nonspherocytic hemolytic anemia associated with red blood cell glutathione deficiency. Hirono A, et al. **Blood** 1996 Mar 1;87(5):2071–4 (28 ref.)

GAMMA–GLUTAMYLTRANSFERASE

ANALYSIS

[Isoenzyme] Ohta H, et al. **Nippon Rinsho** 1996 Jun; 54(6):1505–9 (16 ref.) (Eng. Abstr.) **(Jpn)**

[gamma–Glutamyl transpeptidase (gamma GTP)] Sakai T. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:280–3 (8 ref.) **(Jpn)**

BLOOD

Gamma–glutamyltranspeptidase and carbohydrate deficient transferrin: alternative measures of excessive alcohol consumption. Litten RZ, et al. **Alcohol Clin Exp Res** 1995 Dec;19(6):1541–6 (37 ref.)

GENETICS

gamma–Glutamyl transpeptidase. What does the organization and expression of a multipromoter gene tell us about its functions? Lieberman MW, et al. **Am J Pathol** 1995 Nov; 147(5):1175–85 (91 ref.)

PHYSIOLOGY

gamma–Glutamyl transpeptidase. What does the organization and expression of a multipromoter gene tell us about its functions? Lieberman MW, et al. **Am J Pathol** 1995 Nov; 147(5):1175–85 (91 ref.)

GAMMA–INTERFERON see **INTERFERON TYPE II**

GAMMA–INTERFERON, RECOMBINANT see **INTERFERON–GAMMA, RECOMBINANT**

GAMMA KNIFE RADIOSURGERY see **RADIOSURGERY**

GAMMA–LINOLENIC ACID

PHARMACOLOGY

Botanical lipids: effects on inflammation, immune responses, and rheumatoid arthritis. Rothman D, et al. **Semin Arthritis Rheum** 1995 Oct;25(2):87–96 (75 ref.)

GAMMA RAYS

A review of the effects of gamma radiation on pharmaceutical materials. Jacobs GP. **J Biomater Appl** 1995 Jul;10(1):59–96

GAMMA RAYS

(213 ref.)

GAMMA-SEMINOPROTEIN see **PROSTATE-SPECIFIC ANTIGEN**

GAMMAPHOS see **AMIFOSTINE**

GANCICLOVIR

ADMINISTRATION & DOSAGE

[A case of Guillain-Barré syndrome associated with anti-GM2 antibody due to cytomegalovirus infection--special reference to the effect of ganciclovir] Niwa K, et al. **Rinsho Shinkeigaku** 1995 Jun;35(6):652-6 (18 ref.) (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

Molecular detection of human cytomegalovirus and determination of genotypic ganciclovir resistance in clinical specimens. Spector SA, et al. **Clin Infect Dis** 1995 Oct;21 Suppl 2:S170-3 (22 ref.)

THERAPEUTIC USE

Oral ganciclovir for cytomegalovirus infections. Follansbee SE, et al. **Adv Exp Med Biol** 1996;394:93-103 (10 ref.)

Current management of cytomegalovirus retinitis in AIDS update on ganciclovir and foscarnet for CMV infections. Jacobson MA. **Adv Exp Med Biol** 1996;394:85-92 (28 ref.)

Controversies in the treatment of cytomegalovirus retinitis: foscarnet versus ganciclovir. Jabs DA. **Infect Agents Dis** 1995 Sep;4(3):131-42 (63 ref.)

Management of cytomegalovirus infection. The Jefferiss Wing Therapeutics and Protocols Group. Fisher M, et al. **Int J STD AIDS** 1995 Sep-Oct;6(5):313-9 (28 ref.)

Oral ganciclovir: a new option for patients with CMV retinitis [editorial] Fisher M, et al. **Int J STD AIDS** 1996 Jan-Feb;7(1):1-3 (19 ref.)

Ganciclovir. Crumpacker CS. **N Engl J Med** 1996 Sep 5; 335(10):721-9 (86 ref.)

GANGLIA

ANATOMY & HISTOLOGY

Identifiable Achatina giant neurones: their localizations in ganglia, axonal pathways and pharmacological features. Takeuchi H, et al. **Gen Pharmacol** 1996 Jan;27(1):3-32 (220 ref.)

GANGLIA, AUTONOMIC

T-cell-mediated ganglionitis associated with acute sensory neuronopathy. Hainfellner JA, et al. **Ann Neurol** 1996 Apr; 39(4):543-7 (20 ref.)

GANGLIA, BASAL see **BASAL GANGLIA**

GANGLIA, INTRAOSSEOUS see **BONE CYSTS**

GANGLIA, INVERTEBRATE

ANATOMY & HISTOLOGY

Neuroanatomy: mushrooming mushroom bodies. Davis RL, et al. **Curr Biol** 1996 Feb 1;6(2):146-8 (24 ref.)

GANGLIA, SENSORY

T-cell-mediated ganglionitis associated with acute sensory neuronopathy. Hainfellner JA, et al. **Ann Neurol** 1996 Apr; 39(4):543-7 (20 ref.)

PHYSIOLOGY

The role of neurotrophins in development of neural-crest cells that become sensory ganglia. Kalcheim C. **Philos Trans R Soc Lond B Biol Sci** 1996 Mar 29; 351(1338):375-81 (45 ref.)

PHYSIOPATHOLOGY

Atypical amyotrophic lateral sclerosis. Ben Hamida M, et al. **Adv Neurol** 1995;68:153-5 (9 ref.)

GANGLIA, SPINAL

CHEMISTRY

Effects of ankle joint inflammation on the proportion of calcitonin gene-related peptide (CGRP)-immunopositive perikarya in dorsal root ganglia. Hanesch U, et al. **Prog Brain Res** 1995;104:339-47 (72 ref.)

GROWTH & DEVELOPMENT

Expression of the trk family of neurotrophin receptors in developing and adult dorsal root ganglion neurons. Phillips HS, et al. **Philos Trans R Soc Lond B Biol Sci** 1996 Mar 29;351(1338):413-6 (30 ref.)

Dorsal root ganglion neurons require functional neurotrophin receptors for survival during development. Snider WD, et al. **Philos Trans R Soc Lond B Biol Sci** 1996 Mar 29; 351(1338):395-403 (56 ref.)

INJURIES

Identifying a neurobiologic basis for drug therapy in TMDs. Denucci DJ, et al. **J Am Dent Assoc** 1996 May; 127(5):581-93 (80 ref.)

PHYSIOLOGY

Neuropeptides in morphologically and functionally identified primary afferent neurons in dorsal root ganglia: substance P, CGRP and somatostatin. Lawson SN. **Prog Brain Res** 1995;104:161-73 (56 ref.)

RADIOGRAPHY

Calcification of cervical ganglia: case report. Casolin AL, et al. **Neuroradiology** 1995 Aug;37(6):468-70 (19 ref.)

GANGLIA, SYMPATHETIC

Neuroblastoma and brain tumors in childhood. Ater JL. **Pediatr Dent** 1995 Jul-Aug;17(4):268-72 (19 ref.)

Does sympathetic ganglionic block prevent postherpetic neuralgia? Literature review. Ali NM. **Reg Anesth** 1995 May-Jun;20(3):227-33 (44 ref.)

SURGERY

Thoracoscopic sympathectomy. Daniel TM. **Chest Surg Clin N Am** 1996 Feb;6(1):69-83 (10 ref.)

GANGLIOCYTOMA see **GANGLIONEUROMA**

GANGLIOGLIOMA

PATHOLOGY

Rapid growth of an optic nerve ganglioglioma in a patient with neurofibromatosis 1. Sadun F, et al. **Ophthalmology** 1996 May;103(5):794-9 (41 ref.)

PHYSIOPATHOLOGY

Hemifacial seizures and cerebellar ganglioglioma: an epilepsy syndrome of infancy with seizures of cerebellar origin. Harvey AS, et al. **Ann Neurol** 1996 Jul;40(1):91-8 (7 ref.)

GANGLIONEUROBLASTOMA

DIAGNOSIS

[Imaging diagnosis in a case of adrenal cystic ganglioneuroblastoma in a child] Miele V, et al. **Radiol Med (Torino)** 1996 Apr;91(4):485-8 (11 ref.) **(Ita)**

GANGLIONEUROMA

DIAGNOSIS

Gangliocytomas of the sellar region--a review. Puchner MJ, et al. **Exp Clin Endocrinol Diabetes** 1995;103(3):129-49 (115 ref.)

Diffuse ganglioneuromatosis with plexiform neurofibromas limited to the gastrointestinal tract involving a large segment of small intestine. Hirata K, et al. **J Gastroenterol** 1996 Apr;31(2):263-7 (15 ref.)

[Lhermitte-Duclos disease: is MRI diagnosis feasible?] Lemercier-Bertout C, et al. **Rev Neurol (Paris)** 1995 May; 151(5):327-31 (13 ref.) **(Fre)**

METABOLISM

Neuropeptides in neuroblastomas and ganglioneuromas. Kogner P. **Prog Brain Res** 1995;104:325-38 (99 ref.)

PATHOLOGY

Ganglion cell-containing tumors of the pituitary gland. Towfighi J, et al. **Arch Pathol Lab Med** 1996 Apr; 120(4):369-77 (44 ref.)

Cutaneous ganglioneuromas: a case report and review of the literature. Hammond RR, et al. **Hum Pathol** 1996 Jul; 27(7):735-8 (13 ref.)

THERAPY

Gangliocytomas of the sellar region--a review. Puchner MJ, et al. **Exp Clin Endocrinol Diabetes** 1995;103(3):129-49 (115 ref.)

GANGLIONIC BLOCKERS

see related
NICOTINIC ANTAGONISTS
RECEPTORS, NICOTINIC

GANGLIONIC STIMULANTS

see related
RECEPTORS, NICOTINIC

ADVERSE EFFECTS

Pharmacology of nicotine: addiction and therapeutics. Benowitz NL. **Annu Rev Pharmacol Toxicol** 1996; 36:597-613 (93 ref.)

GANGLIOSIDES

ANALYSIS

High-resolution thin-layer chromatography of gangliosides. Müthing J. **J Chromatogr A** 1996 Jan 12;720(1-2):3-25 (234 ref.)

[Clinical value of carbohydrate antigens, sialyl Lewis-x and sialyl Lewis-a in gastrointestinal cancer] Nakamori S, et al. **Nippon Geka Gakkai Zasshi** 1996 Feb;97(2):165-71 (27 ref.) (Eng. Abstr.) **(Jpn)**

BIOSYNTHESIS

A reappraisal of ganglioside GD3 expression in the CNS. Goldman JE, et al. **Glia** 1996 Apr;16(4):291-5 (39 ref.)

BLOOD

Serum gangliosides as endogenous immunomodulators. Bergelson LD. **Immunol Today** 1995 Oct;16(10):483-6 (46 ref.)

CHEMISTRY

The basic pharmacology of gangliosides. Toffano G. **Rev Neurol** 1995 Jul-Aug;23(122):880-4 (51 ref.)

IMMUNOLOGY

Generation of human monoclonal antibodies against ganglioside antigens and their applications in the diagnosis and therapy of cancer. Alfonso M, et al. **Acta Oncol** 1996; 35(3):287-95 (67 ref.)

Approaches to augmenting the immunogenicity of melanoma gangliosides: from whole melanoma cells to ganglioside-KLH conjugate vaccines. Livingston PO. **Immunol Rev** 1995 Jun;145:147-66 (68 ref.)

Serum gangliosides as endogenous immunomodulators. Bergelson LD. **Immunol Today** 1995 Oct;16(10):483-6 (46 ref.)

Cholinergic-specific glycoconjugates. Whittaker VP, et al. **Neurochem Res** 1995 Nov;20(11):1377-87 (47 ref.)

[Neuropathy and anti-ganglioside antibodies] Kusunoki S. **Nippon Naika Gakkai Zasshi** 1996 Apr 10;85(4):629-34 (13 ref.) **(Jpn)**

[Anti-gangliosides antibodies in neuromuscular's pathology] Illa I. **Rev Neurol** 1995 Jul-Aug;23(122):885-8 (48 ref.) **(Spa)**

METABOLISM

Evidence that molecules on the surface of one cell can adhere to the oligosaccharide portion of gangliosides on the surface of another cell. Schengrund CL. **Biol Signals** 1995 Jan-Feb;4(1):1-13 (85 ref.)

Role of gangliosides in tumour progression: a molecular target for cancer therapy? Fish RG. **Med Hypotheses** 1996 Feb;46(2):140-4 (45 ref.)

[Prognosis of colorectal cancer and sialyl-lea antigen] Watanabe M, et al. **Nippon Geka Gakkai Zasshi** 1996 Feb; 97(2):177-81 (13 ref.) **(Jpn)**

PHARMACOKINETICS

[Clinical trials on ganglioside effectiveness] Horga JF, et al. **Rev Neurol** 1995 Jul-Aug;23(122):889-95 (90 ref.) **(Spa)**

PHYSIOLOGY

Ganglioside modulation of the PDGF receptor. A model for ganglioside functions. Yates AJ, et al. **J Neurooncol** 1995;24(1):65-73 (66 ref.)

THERAPEUTIC USE

[Clinical trials on ganglioside effectiveness] Horga JF, et al. **Rev Neurol** 1995 Jul-Aug;23(122):889-95 (90 ref.) **(Spa)**

GANGLIOSIDOSIS G(M1)

[beta-galactosidosis--GM1 gangliosidosis and Morquio B disease] Yoshida K, et al. **Nippon Rinsho** 1995 Dec; 53(12):2960-6 (23 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

[The metabolism of radiolabelled GM1-ganglioside in cultured skin fibroblasts from controls and patients with GM1-gangliosidosis] Inui K. **Nippon Rinsho** 1995 Dec; 53(12):3102-4 (4 ref.) (Eng. Abstr.) **(Jpn)**

GANGLIOSIDOSIS G(M2), TYPE I see **TAY-SACHS DISEASE**

GANGLIOSIDOSIS G(M2), TYPE II see **SANDHOFF DISEASE**

GANGRENE

ETIOLOGY

[Multiple gangrenous lesions of the scalp in a case of cranial arteritis] Tomasina C, et al. **Minerva Med** 1995 May; 86(5):233-5 (12 ref.) (Eng. Abstr.) **(Ita)**

PREVENTION & CONTROL

[The treatment of distal neuropathy--an important means for preventing the development of diabetic gangrene] Datsun IH, et al. **Vrach Delo** 1995 Jan-Feb;(1-2):25-9 (29 ref.) **(Ukr)**

GANJA see CANNABIS

GANSER SYNDROME see FACTITIOUS DISORDERS

GAP JUNCTION PROTEINS see CONNEXINS

GAP JUNCTIONS

see related
CONNEXINS

CHEMISTRY

New insights into myocardial arrhythmogenesis: distribution of gap-junctional coupling in normal, ischaemic and hypertrophied human hearts. Peters NS. **Clin Sci (Colch)** 1996 Jun;90(6):447-52 (56 ref.)

Structure of gap junction intercellular channels. Yeager M, et al. **Curr Opin Struct Biol** 1996 Apr;6(2):183-92 (78 ref.)

DRUG EFFECTS

Modulation of gap junctional intercellular communication by phosphorylation: effects of growth factors, kinase activators and phosphatase inhibitors. Mikalsen SO, et al. **Prog Clin Biol Res** 1995;391:425-38 (72 ref.)

METABOLISM

Gap junctions in the vertebrate retina. Cook JE, et al. **Microsc Res Tech** 1995 Aug 1;31(5):408-19 (123 ref.)

Spatial organization of cardiac gap junctions can affect access resistance. Hall JE, et al. **Microsc Res Tech** 1995 Aug 1; 31(5):446-51 (30 ref.)

Structural and molecular determinants of intercellular coupling in cardiac myocytes. Kanter HL, et al. **Microsc Res Tech** 1995 Aug 1;31(5):357-63 (32 ref.)

Myocardial gap junction organization in ischemia and infarction. Peters NS. **Microsc Res Tech** 1995 Aug 1; 31(5):375-86 (95 ref.)

PATHOLOGY

X-linked dominant Charcot-Marie-Tooth disease and other potential gap-junction diseases of the nervous system [see comments] Spray DC, et al. **Trends Neurosci** 1995 Jun; 18(6):256-62 (92 ref.) Comment in: Trends Neurosci 1995 Dec;18(12):520-1.

PHYSIOLOGY

Possible role of coupling between glomus cells in carotid body chemoreception. Eyzaguirre C, et al. **Biol Signals** 1995 Sep-Oct;4(5):263-70 (30 ref.)

Cardiac intercellular communication: consequences of connexin distribution and diversity. Beyer EC, et al. **Braz J Med Biol Res** 1995 Apr;28(4):415-25 (62 ref.)

The gap junction communication channel. Kumar NM, et al. **Cell** 1996 Feb 9;84(3):381-8 (61 ref.)

New functions for gap junctions. Paul DL. **Curr Opin Cell Biol** 1995 Oct;7(5):665-72 (36 ref.)

Physiology of Bergmann glial cells. Müller T, et al. **Int Rev Neurobiol** 1995;38:341-59 (76 ref.)

The molecular basis of anisotropy: role of gap junctions. Saffitz JE, et al. **J Cardiovasc Electrophysiol** 1995 Jun; 6(6):498-510 (69 ref.)

Role of gap junctions in the development of the preimplantation mouse embryo. Becker DL, et al. **Microsc Res Tech** 1995 Aug 1;31(5):364-74 (31 ref.)

Nonsynaptic modulation of neuronal activity in the brain: electric currents and extracellular ions. Jefferys JG. **Physiol Rev** 1995 Oct;75(4):689-723 (404 ref.)

Role of blocked gap junctional intercellular communication in non-genotoxic carcinogenesis. Mesnil M, et al. **Toxicol Lett** 1995 Dec;82-83:701-6 (27 ref.)

Gap junction communication and cell adhesion in development. DeHaan RL. **Zygote** 1994 Aug;2(3):183-8 (71 ref.)

ULTRASTRUCTURE

Ocular lens gap junctions: protein expression, assembly, and structure-function analysis. Kistler J, et al. **Microsc Res Tech** 1995 Aug 1;31(5):347-56 (60 ref.)

Gap junctions in blood forming tissues. Rosendaal M. **Microsc Res Tech** 1995 Aug 1;31(5):396-407 (70 ref.)

Gap junctions revealed by freeze-fracture electron microscopy. Shivers RR, et al. **Microsc Res Tech** 1995 Aug 1;31(5):437-45 (44 ref.)

GARDNER SYNDROME

Adrenal carcinoma in a patient with Gardner's syndrome: imaging findings. Traill Z, et al. **AJR Am J Roentgenol** 1995 Dec;165(6):1460-1 (8 ref.)

[Gardner syndrome: diagnostic, clinical and genetic questions in the light of 2 case reports] Messinetti S, et al. **Ann Ital Chir** 1995 Jul-Aug;66(4):497-512 (85 ref.) (Eng. Abstr.) **(Ita)**

GARGOYLISM see MUCOPOLYSACCHARIDOSIS I

GARLIC

[Garlic (Allium sativum)--a potent medicinal plant] Resch KL, et al. **Fortschr Med** 1995 Jul 20;113(20-21):311-5 (43 ref.) (Eng. Abstr.) **(Ger)**

CHEMISTRY

Therapeutic actions of garlic constituents. Agarwal KC. **Med Res Rev** 1996 Jan;16(1):111-24 (132 ref.)

GARTNER'S DUCTS see WOLFFIAN DUCT

GAS GANGRENE

[Gas-containing liver abscess, hepatic gas gangrene] Takesue Y, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):36-8 (7 ref.) **(Jpn)**

COMPLICATIONS

Emphysematous cholecystitis. Lindsey I, et al. **Aust N Z J Surg** 1996 Apr;66(4):267-8 (14 ref.)

[Gangrenous cholecystitis] Kano N, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):193-5 (18 ref.) **(Jpn)**

EPIDEMIOLOGY

Malignancy, mortality, and medicosurgical management of Clostridium septicum infection. Larson CM, et al. **Surgery** 1995 Oct;118(4):592-7; discussion 597-8 (13 ref.)

RADIOGRAPHY

Clostridial infection of the abdomen: CT findings in two successfully treated patients. Spencer JA, et al. **AJR Am J Roentgenol** 1996 May;166(5):1094-6 (8 ref.)

GAS, NATURAL see FOSSIL FUELS

GASES

[Hepatic portal venous gas] Kudo M, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):595-7 (18 ref.) **(Jpn)**

[Gas-containing gallstones] Kurosaki A, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):394-6 (11 ref.) **(Jpn)**

[Pneumobilia] Watanabe F, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):512-3 (2 ref.) **(Jpn)**

ANALYSIS

The novel selected-ion flow tube approach to trace gas analysis of air and breath. Smith D, et al. **Rapid Commun Mass Spectrom** 1996;10(10):1183-98 (37 ref.)

[Fiber optic chemical gas sensors based on environmental chromism] Sadaoka Y. **Tanpakushitsu Kakusan Koso** 1995 Nov;40(15):2355-60 (14 ref.) **(Jpn)**

BLOOD

Clinical and economic performance criteria for intraarterial and extraarterial blood gas monitors, with comparison with in vitro testing. Shapiro BA. **Am J Clin Pathol** 1995 Oct; 104(4 Suppl 1):S100-6 (39 ref.)

GASOLINE

ADVERSE EFFECTS

Disposition, metabolism, and toxicity of methyl tertiary butyl ether, an oxygenate for reformulated gasoline. Hutcheon DE, et al. **J Toxicol Environ Health** 1996 Apr 5; 47(5):453-64 (40 ref.)

Review of the Wisconsin DHSS report on health concerns attributed to reformulated gasoline use in southeastern Wisconsin [editorial] Rudo K. **Toxicol Ind Health** 1995 Sep-Oct;11(5):463-6 (3 ref.)

GASSERIAN GANGLION see TRIGEMINAL GANGLION

GASSER'S SYNDROME see HEMOLYTIC-UREMIC SYNDROME

GASTRECTOMY

see related
GASTRIC STUMP
POSTGASTRECTOMY SYNDROMES

Should the 1996 citation for Zollinger-Ellison syndrome read: "Acid-reducing surgery in, aggressive resection out"? [editorial; comment] Jensen RT. **Am J Gastroenterol** 1996 Jun;91(6):1067-70 (43 ref.) Comment on: Am J Gastroenterol 1996 Jun;91(6):1104-11.

Effect of some abdominal surgical operations on small bowel motility in humans: our experience. Bassotti G, et al. **J Clin Gastroenterol** 1995 Oct;21(3):211-6 (86 ref.)

Primary non-Hodgkin lymphoma of the gastric stump. Vanbockrijck M, et al. **Pathol Res Pract** 1995 Jul; 191(6):525-9 (18 ref.)

Arterial vasculature of the stomach and oncologic gastrectomies. Guadagni S, et al. **Surg Radiol Anat** 1995; 17(3):269-76 (40 ref.)

ADVERSE EFFECTS

Carcinogenesis after remote peptic ulcer surgery: the long-term prognosis of partial gastrectomy. Tersmette AC, et al. **Scand J Gastroenterol Suppl** 1995;212:96-9 (49 ref.)

[A unusual cause of acute pancreatitis: obstruction of the afferent loop after gastrectomy according to Bilroth II. Apropos of a case and review of the literature] Moschopoulos C, et al. **Ann Radiol (Paris)** 1995; 38(7-8):426-9 (16 ref.) (Eng. Abstr.) **(Fre)**

[Cholelithiasis following gastrectomy] Miyazaki I, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):388-90 (26 ref.) **(Jpn)**

METHODS

Oesophageal substitution. Isolauri J. **Ann Chir Gynaecol** 1995; 84(2):241-6 (30 ref.)

[Prognostic value of extensive lymph node excision in curative resections of stomach cancers. Apropos of a series of 100 patients] Berthet B, et al. **Chirurgie** 1996; 121(2):108-12 (21 ref.) (Eng. Abstr.) **(Fre)**

[Management of stomach ulcer except in emergency: surgical treatment] Lacaine F. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S81-S83 (16 ref.) **(Fre)**

[Differential surgical procedure in curative therapy of stomach carcinoma] Hermanek P. **Leber Magen Darm** 1996 Mar;26(2):64, 67-72 (41 ref.) (Eng. Abstr.) **(Ger)**

[Pylorus-preserving gastrectomy for early gastric cancer] Sasaki I, et al. **Nippon Geka Gakkai Zasshi** 1996 Apr; 97(4):291-6 (22 ref.) (Eng. Abstr.) **(Jpn)**

[Modified surgery for early gastric cancer] Yoshino K, et al. **Nippon Geka Gakkai Zasshi** 1996 Apr;97(4):269-72 (9 ref.) (Eng. Abstr.) **(Jpn)**

[Resection of the posterior mediastinal gastric tube used in reconstruction after radical surgery for esophageal cancer--case reports] Hashimoto M, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Jul;43(7):1016-22 (19 ref.) (Eng. Abstr.) **(Jpn)**

GASTRIC ACID

see related
ACHLORHYDRIA

METABOLISM

Helicobacter pylori and gastric acid: biological and therapeutic implications [see comments] McGowan CC, et al. **Gastroenterology** 1996 Mar;110(3):926-38 (140 ref.) Comment in: Gastroenterology 1996 Mar;110(3):947-50.

The history of acid inhibition. Baron JH. **Yale J Biol Med** 1994 May-Aug;67(3-4):97-106 (32 ref.)

PHYSIOLOGY

Healing of experimental gastric ulcers. Interference by gastric acid. Halter F, et al. **Dig Dis Sci** 1995 Nov;40(11):2481-6 (23 ref.)

SECRETION

The relationship between the control of pH and healing and symptom relief in gastro-oesophageal reflux disease. Hunt RH. **Aliment Pharmacol Ther** 1995;9 Suppl 1:3-7 (38 ref.)

The role of acid in upper gastrointestinal haemorrhage due to ulcer and stress-related mucosal damage. Peterson WL. **Aliment Pharmacol Ther** 1995;9 Suppl 1:43-6 (28 ref.)

An update on histamine H3 receptors and gastrointestinal functions. Bertaccini G, et al. **Dig Dis Sci** 1995 Sep; 40(9):2052-63 (90 ref.)

Histamine, histamine H2-receptor antagonists, gastric acid secretion and ulcers: an overview. Pattichis K, et al. **Drug Metabol Drug Interact** 1995;12(1):1-36 (43 ref.)

Gastric secretion and the pathogenesis of peptic ulcer in the Helicobacter pylori infection. Konturek PC, et al. **J Physiol Pharmacol** 1996 Mar;47(1):5-19 (80 ref.)

The pathways regulating acid secretion: the view from the isolated cell. Chuang CN, et al. **Yale J Biol Med** 1994 May-Aug;67(3-4):107-12 (17 ref.)

Vagal regulation of acid secretion and gastrin release. Debas HT, et al. **Yale J Biol Med** 1994 May-Aug;67(3-4):145-51 (25 ref.)

Dragstedt, gastric acid and duodenal ulcer. Hobsley M. **Yale J Biol Med** 1994 May-Aug;67(3-4):173-80 (42 ref.)

Inflammation, acid and ulcers. Muller MJ, et al. **Yale J Biol Med** 1994 May-Aug;67(3-4):135-44 (93 ref.)

Gastric acid secretion: activation and inhibition. Sachs G, et al. **Yale J Biol Med** 1994 May-Aug;67(3-4):81-95 (68 ref.)

[Reinstatement of calcium-containing antacids] Tytgat GN. **Ned Tijdschr Geneeskd** 1995 Nov 25;139(47):2405-7 (14 ref.) **(Dut)**

[Effects of long-term treatment with gastric acid antisecretory agents on the fundic mucosa] Cadiot G, et al. **Ann Pathol** 1996;16(2):81-90 (111 ref.) **(Fre)**

[Role of acid secretion in the pathogenesis of duodenal ulcer] Mignon M, et al. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S14-S21 (105 ref.) **(Fre)**

[Losek (omeprazole), a new therapeutic agent in the treatment of peptic ulcer and hyperacidity states] Bulgakov

GASTRIC ACID

SA. **Klin Med (Mosk)** 1995;73(5):11–6 (77 ref.) **(Rus)**
[Regulation of gastric acid secretion] Valenzuela M, et al. **Rev Esp Enferm Dig** 1995 Dec;87(12):874–82 (92 ref.) **(Spa)**

GASTRIC ACIDITY DETERMINATION

Assessment of gastric acidity in intensive care patients: intermittent pH registration cannot replace continuous pH monitoring. Bonten MJ, et al. **Intensive Care Med** 1996 Mar;22(3):220–5 (26 ref.)

GASTRIC ANTRUM see **PYLORIC ANTRUM**

GASTRIC BYPASS

[Surgical treatment of obesity] Kawamura I. **Nippon Naika Gakkai Zasshi** 1995 Aug 10;84(8):1295–9 (5 ref.) **(Jpn)**

GASTRIC EMPTYING

The effect of Helicobacter pylori infection on gastric emptying of digestible and indigestible solids in patients with nonulcer dyspepsia. Chang CS, et al. **Am J Gastroenterol** 1996 Mar;91(3):474–9 (49 ref.)
Recent advances in gastric emptying scintigraphy. Urbain JL, et al. **Semin Nucl Med** 1995 Oct;25(4):318–25 (38 ref.)

PHYSIOLOGY

Gastric emptying in diabetes. Kong MF, et al. **Diabet Med** 1996 Feb;13(2):112–9 (65 ref.)
Gastric and small intestinal motility in health and disease. Quigley EM. **Gastroenterol Clin North Am** 1996 Mar; 25(1):113–45 (164 ref.)
Helicobacter pylori infection and gastric motor dysfunction. Wingate DL. **J Physiol Pharmacol** 1996 Mar;47(1):21–9 (0 ref.)

GASTRIC FISTULA

see related
GASTROSTOMY

DRUG THERAPY

[Gastrointestinal fistulas. Treatment with a somatostatin analogue (SMS 201–995)] Gerardo Pérez D, et al. G E N 1994 Oct–Dec;48(4):209–18 (51 ref.) (Eng. Abstr.) **(Spa)**

GASTRIC FUNDUS

see related
FUNDOPLICATION

DRUG EFFECTS

[Effects of long-term treatment with gastric acid antisecretory agents on the fundic mucosa] Cadiot G, et al. **Ann Pathol** 1996;16(2):81–90 (111 ref.) **(Fre)**
[Mucosa of the gastric fundus and antisecretory agents (editorial)] Diébold MD, et al. **Ann Pathol** 1996;16(2):75–7 (17 ref.) **(Fre)**

SURGERY

Laparoscopic antireflux repair and myotomy. Peters JH, et al. **Curr Opin Gen Surg** 1993;:170–9 (36 ref.)

GASTRIC GLANDS see **GASTRIC MUCOSA**

GASTRIC HYPOTHERMIA see **HYPOTHERMIA, INDUCED**

GASTRIC INHIBITORY POLYPEPTIDE

see related
GASTROINTESTINAL AGENTS

BLOOD

[Gastric inhibitory polypeptide (GIP)] Shimosegawa T, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:651–5 (60 ref.) **(Jpn)**

GASTRIC JUICE

see related
ACHLORHYDRIA
PEPSINOGEN

CHEMISTRY

Assessment of gastric acidity in intensive care patients: intermittent pH registration cannot replace continuous pH monitoring. Bonten MJ, et al. **Intensive Care Med** 1996 Mar;22(3):220–5 (26 ref.)
[Extraction of DNA from pancreatic and/or duodenal juice] Fukayama N, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr; 41(5):466–8 (3 ref.) **(Jpn)**

DRUG EFFECTS

[Helicobacter pylori and azithromycin] Mégraud F, et al. **Pathol Biol (Paris)** 1995 Jun;43(6):555–60 (15 ref.) (Eng. Abstr.) **(Fre)**
[Ranitidine: consequences on secretory function and gastric mucosa] Vallot T, et al. **Rev Med Suisse Romande** 1995 Oct;115(10):773–80 (23 ref.) **(Fre)**

GASTRIC LAVAGE

[Break in the trend of treatment of acute poisoning. Ventricular lavage may be substituted by active carbon] Kulling P, et al. **Lakartidningen** 1995 Oct 4;92(40):3676, 3683 (33 ref.) **(Swe)**

GASTRIC MUCOSA

[Choristoma of the gastric mucosa: report of a case] Fernandes M, et al. **Rev Laryngol Otol Rhinol (Bord)** 1995; 116(5):347–9 (09 ref.) (Eng. Abstr.) **(Fre)**
[Heterotopic tissues in the gallbladder (heterotopic gastric mucosa, heterotopic intestinal epithelium, heterotopic pancreatic tissue and ectopic liver in the gallbladder] Kodama T, et al. **Ryoikibetsu Shokogun Shirizu** 1996; (9):360–2 (17 ref.) **(Jpn)**

ABNORMALITIES

Gastric gland heterotopia with extensive lymphoid stroma: a gastric lymphoepithelial cyst. Delvaux S, et al. **Am J Gastroenterol** 1996 Mar;91(3):599–601 (17 ref.)

BLOOD SUPPLY

Chemosensitive afferent nerves in the regulation of gastric blood flow and protection. Holzer P. **Adv Exp Med Biol** 1995;371B:891–5 (21 ref.)
Diverse interactions of calcitonin gene related peptide and nitric oxide in the gastric and cutaneous microcirculation. Holzer P, et al. **Can J Physiol Pharmacol** 1995 Jul; 73(7):991–4 (37 ref.)

CYTOLOGY

Present views on restitution of gastrointestinal epithelium. Paimela H, et al. **Dig Dis Sci** 1995 Nov;40(11):2495–6 (25 ref.)
Indomethacin inhibits cell proliferation and increases cell losses in rat gastrointestinal epithelium. Uribe A, et al. **Dig Dis Sci** 1995 Nov;40(11):2490–4 (25 ref.)
New insights into the stem cells and the precursors of the gastric epithelium. Karam SM. **Nutrition** 1995 Sep–Oct; 11(5 Suppl):607–13 (27 ref.)

DRUG EFFECTS

Pharmacological regulation of gastric mucous glycoprotein secretion. Heim HK, et al. **Eur J Gastroenterol Hepatol** 1995 Nov;7(11):1105–22 (364 ref.)
NSAID-associated upper gastrointestinal damage in patients with rheumatoid arthritis. Dijkmans BA, et al. **Scand J Gastroenterol Suppl** 1995;212:105–8 (26 ref.)
[Effects of long-term treatment with gastric acid antisecretory agents on the fundic mucosa] Cadiot G, et al. **Ann Pathol** 1996;16(2):81–90 (111 ref.) **(Fre)**
[Mucosa of the gastric fundus and antisecretory agents (editorial)] Diébold MD, et al. **Ann Pathol** 1996;16(2):75–7 (17 ref.) **(Fre)**
[Helicobacter pylori and azithromycin] Mégraud F, et al. **Pathol Biol (Paris)** 1995 Jun;43(6):555–60 (15 ref.) (Eng. Abstr.) **(Fre)**
[Morphology of gastric mucosa lesions induced by nonsteroidal anti-inflammatory agents] Valenzuela M, et al. **Rev Esp Enferm Dig** 1996 May;88(5):351–8 (55 ref.) **(Spa)**

IMMUNOLOGY

Neonatal gastrointestinal mucosal immunity. Mannick E, et al. **Clin Perinatol** 1996 Jun;23(2):287–304 (111 ref.)
Impact of aging on gastrointestinal mucosal immunity. Schmucker DL, et al. **Dig Dis Sci** 1996 Jun;41(6):1183–93 (76 ref.)
The cellular and molecular basis of gastric mucosal defense. Wallace JL, et al. **FASEB J** 1996 May;10(7):731–40 (74 ref.)

INNERVATION

Chemosensitive afferent nerves in the regulation of gastric blood flow and protection. Holzer P. **Adv Exp Med Biol** 1995;371B:891–5 (21 ref.)

METABOLISM

The gastric tonometer. A valuable monitor of splanchnic perfusion? Trinder TJ, et al. **Anaesthesia** 1996 Feb; 51(2):161–70 (142 ref.)
An update on histamine receptors and gastroprotection. Bertaccini G, et al. **Ital J Gastroenterol** 1995 Jun; 27(5):259–64 (54 ref.)
Gastric alkalinization, pneumonia, and systemic infections: the controversy. Tryba M, et al. **Scand J Gastroenterol Suppl** 1995;210:53–9 (69 ref.)
The pathways regulating acid secretion: the view from the isolated cell. Chuang CN, et al. **Yale J Biol Med** 1994 May–Aug;67(3–4):107–12 (17 ref.)
Gastric acid secretion: activation and inhibition. Sachs G, et al. **Yale J Biol Med** 1994 May–Aug;67(3–4):81–95 (68 ref.)

PATHOLOGY

The role of acid in upper gastrointestinal haemorrhage due to ulcer and stress-related mucosal damage. Peterson WL. **Aliment Pharmacol Ther** 1995;9 Suppl 1:43–6 (28 ref.)
Recognizing atrophy: another step toward a classification of gastritis. Genta RM. **Am J Surg Pathol** 1996;20 Suppl 1:S23–30 (38 ref.)
The columnar-lined esophagus, intestinal metaplasia, and Norman Barrett [see comments] Spechler SJ, et al. **Gastroenterology** 1996 Feb;110(2):614–21 (63 ref.) Comment in: Gastroenterology 1996 Aug;111(2):565–6.
Classification of gastric lesions associated with portal hypertension. Hashizume M, et al. **J Gastroenterol Hepatol** 1995 May–Jun;10(3):339–43 (20 ref.)
Cellular and molecular mechanisms of gastric ulcer healing. Is the quality of mucosal scar affected by treatment? Tarnawski A, et al. **Scand J Gastroenterol Suppl** 1995; 210:9–14 (30 ref.)
Gastric carcinoma arising from a hyperplasiogenic polyp with a diameter of less than 2 centimeters. Gschwantler M, et al. **Z Gastroenterol** 1995 Oct;33(10):610–2 (15 ref.)
[Portal hypertensive gastropathy] Brinch K, et al. **Ugeskr Laeger** 1995 Nov 13;157(46):6421–5 (31 ref.) (Eng. Abstr.) **(Dan)**
[Gastric mucosal lesion and free radicals] Hiraishi H, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Nov; 92(11):1817–24 (39 ref.) **(Jpn)**

PHYSIOLOGY

An update on histamine H3 receptors and gastrointestinal functions. Bertaccini G, et al. **Dig Dis Sci** 1995 Sep; 40(9):2052–63 (90 ref.)
Peptides and gastrointestinal mucosal integrity. Playford RJ. **Gut** 1995 Nov;37(5):595–7 (24 ref.)
Gastric endocrine cells: gene expression, processing, and targeting of active products. Dockray GJ, et al. **Physiol Rev** 1996 Jul;76(3):767–98 (387 ref.)
Gastric mucosal protection against penetration of carcinogens into the mucosa. Sørbye H, et al. **Scand J Gastroenterol** 1995 Oct;30(10):929–34 (91 ref.)
Rapid epithelial restitution in the stomach: an updated perspective. Lacy ER. **Scand J Gastroenterol Suppl** 1995; 210:6–8 (18 ref.)
The role of prostaglandins in gastric mucosal protection. Wilson DE. **Trans Am Clin Climatol Assoc** 1995;107:99–113; discussion 113–4 (78 ref.)

PHYSIOPATHOLOGY

Epidermal growth factor and transforming growth factor-alpha: role in protection and healing of gastric mucosal lesions. Konturek PC, et al. **Eur J Gastroenterol Hepatol** 1995 Oct;7(10):933–7 (26 ref.)

SECRETION

Gastric secretion and the pathogenesis of peptic ulcer in the Helicobacter pylori infection. Konturek PC, et al. **J Physiol Pharmacol** 1996 Mar;47(1):5–19 (80 ref.)
[The participation of enteral mechanisms in the sympathetic-adrenal inhibition of gastric secretion] Trefilov AB. **Usp Fiziol Nauk** 1995 Jan–Mar;26(1):76–92 (79 ref.) (Eng. Abstr.) **(Rus)**

SURGERY

[Endoscopic mucosal resection (EMR) for early gastric cancer] Hiki Y. **Nippon Geka Gakkai Zasshi** 1996 Apr; 97(4):273–8 (11 ref.) (Eng. Abstr.) **(Jpn)**

ULTRASONOGRAPHY

[High frequency ultrasonography of the gastrointestinal wall] Odegaard S, et al. **Tidsskr Nor Laegeforen** 1996 May 10; 116(12):1455–9 (32 ref.) (Eng. Abstr.) **(Nor)**

GASTRIC OUTLET OBSTRUCTION

THERAPY

[The use of self-expanding stents in the recanalization of gastric antrum neoplastic obstructions. The experience of a case] Profili S, et al. **Radiol Med (Torino)** 1995 Sep; 90(3):330–3 (23 ref.) **(Ita)**

GASTRIC PARIETAL CELLS see **PARIETAL CELLS, GASTRIC**

GASTRIC STASIS see **GASTROPARESIS**

GASTRIC STUMP

Carcinogenesis after remote peptic ulcer surgery: the long-term prognosis of partial gastrectomy. Tersmette AC, et al. **Scand J Gastroenterol Suppl** 1995;212:96–9 (49 ref.)
[Cancer of the gastric stump] Pinatel Lopasso F. **Rev Gastroenterol Peru** 1996 Jan–Apr;16(1):57–63 (69 ref.) (Eng. Abstr.) **(Spa)**

PATHOLOGY

Primary non-Hodgkin lymphoma of the gastric stump. Vanbockrijck M, et al. **Pathol Res Pract** 1995 Jul; 191(6):525-9 (18 ref.)

GASTRIC VARICES see **ESOPHAGEAL AND GASTRIC VARICES**

GASTRIN-PRODUCING TUMOR see **GASTRINOMA**

GASTRIN RECEPTORS see **RECEPTORS, CHOLECYSTOKININ**

GASTRIN-RELEASING PEPTIDE RECEPTORS see **RECEPTORS, BOMBESIN**

GASTRINOMA

see related
MULTIPLE ENDOCRINE NEOPLASIA TYPE 1
ZOLLINGER-ELLISON SYNDROME

COMPLICATIONS

Pancreatic duct stricture caused by islet cell tumors. Heller SJ, et al. **Am J Gastroenterol** 1996 Jan;91(1):147-9 (15 ref.)

DIAGNOSIS

Endocrine tumors of the gastrointestinal tract. Perry RR, et al. **Annu Rev Med** 1996;47:57-68 (33 ref.)
Localization of gastrinomas. Prinz RA. **Int J Pancreatol** 1996 Apr;19(2):79-91 (53 ref.)
[Imaging of endocrine tumors of the pancreas] Thérasse E, et al. **Ann Endocrinol (Paris)** 1995;56(5):509-10 (4 ref.) **(Fre)**

SURGERY

The place for curative surgical procedures in the treatment of sporadic and familial Zollinger-Ellison syndrome. Delcore R, et al. **Curr Opin Gen Surg** 1994;:69-76 (119 ref.)
Recent advances in the localization and surgical management of duodenal gastrinomas. Lawton GP, et al. **Curr Opin Gen Surg** 1994;:131-7 (50 ref.)

GASTRINS

see related
GASTROINTESTINAL AGENTS

BLOOD

The consequences of hypergastrinemia. Creutzfeldt W. **Yale J Biol Med** 1994 May-Aug;67(3-4):181-94 (63 ref.)
[Gastrin] Sakai Y, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:622-5 (7 ref.) **(Jpn)**

METABOLISM

Review article: gastrin releasing peptide and its value in assessing gastric secretory function. McColl KE, et al. **Aliment Pharmacol Ther** 1995 Aug;9(4):341-7 (52 ref.)

PHYSIOLOGY

Review article: gastrin releasing peptide and its value in assessing gastric secretory function. McColl KE, et al. **Aliment Pharmacol Ther** 1995 Aug;9(4):341-7 (52 ref.)

SECRETION

The somatostatin-gastrin link of Helicobacter pylori infection. Calam J. **Ann Med** 1995 Oct;27(5):569-73 (46 ref.)
Antral G-cell hyperplasia: a vanishing disease? Kwan CP, et al. **Eur J Gastroenterol Hepatol** 1995 Nov; 7(11):1099-1103 (44 ref.)
Primary carcinoid tumor of the liver: report of four resected cases including one with gastrin production. Krishnamurthy SC, et al. **J Surg Oncol** 1996 Jul; 62(3):218-21 (19 ref.)
Vagal regulation of acid secretion and gastrin release. Debas HT, et al. **Yale J Biol Med** 1994 May-Aug;67(3-4):145-51 (25 ref.)
[Role of acid secretion in the pathogenesis of duodenal ulcer] Mignon M, et al. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S14-S21 (105 ref.) **(Fre)**

GASTRITIS

Helicobacter pylori in children. Sullivan PB. **Baillieres Clin Gastroenterol** 1995 Sep;9(3):519-28 (71 ref.)
[Gastric erosion, erosive gastritis: their forms and approaches to treatment] Ryss ES, et al. **Klin Med (Mosk)** 1995; 73(4):31-4 (5 ref.) **(Rus)**

COMPLICATIONS

[When should Helicobacter pylori be eradicated?] Buckley M, et al. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S95-S102 (80 ref.) **(Fre)**

DRUG THERAPY

[Treatment of peptic ulcer and gastritis associated with Helicobacter pylori] López-Brea M, et al. **Enferm Infecc Microbiol Clin** 1995 Aug-Sep;13(7):422-8 (75 ref.) **(Spa)**

ETIOLOGY

[Portal hypertension-induced stomach disease] Hermann R, et al. **Schweiz Med Wochenschr** 1996 Jun 15; 126(24):1066-73 (46 ref.) (Eng. Abstr.) **(Ger)**

METABOLISM

Inflammation, acid and ulcers. Muller MJ, et al. **Yale J Biol Med** 1994 May-Aug;67(3-4):135-44 (93 ref.)

MICROBIOLOGY

The role of Helicobacter pylori in gastritis and its progression to peptic ulcer disease. Blaser MJ. **Aliment Pharmacol Ther** 1995;9 Suppl 1:27-30 (27 ref.)
Testing for Helicobacter pylori in clinical practice. Cutler AF. **Am J Med** 1996 May 20;100(5A):35S-39S; discussion 39S-41S (44 ref.)
H. pylori infection: its role in chronic gastritis, carcinoma and peptic ulcer. Pajares JM. **Hepatogastroenterology** 1995 Nov-Dec;42(6):827-41 (141 ref.)
Helicobacter pylori and the evolution of gastritis. Stolte M, et al. **Scand J Gastroenterol Suppl** 1996;214:13-6; discussion 21-3 (31 ref.)
The significance of Helicobacter pylori colonization of the stomach. Cilley RE, et al. **Semin Pediatr Surg** 1995 Nov; 4(4):221-7 (68 ref.)
[Peptic ulcer and gastritis in the time of Helicobacter pylori] **Ann Gastroenterol Hepatol (Paris)** 1996 Jan-Feb; 32(1):25-34 (0 ref.) **(Fre)**
[Helicobacter pylori infection in peptic ulcer and gastric cancer diseases] Matsukura N, et al. **Nippon Ika Daigaku Zasshi** 1995 Aug;62(4):313-9 (22 ref.) **(Jpn)**

PATHOLOGY

The biopsy diagnosis of gastroesophageal reflux disease, "carditis," and Barrett's esophagus, and sequelae of therapy. Riddell RH. **Am J Surg Pathol** 1996;20 Suppl 1:S31-50 (82 ref.)
Histological responses to Helicobacter pylori infection: gastritis, atrophy and preneoplasia. Dixon MF. **Baillieres Clin Gastroenterol** 1995 Sep;9(3):467-86 (75 ref.)

PHYSIOPATHOLOGY

Chronic gastritis: its clinical and physiopathological meaning. Cheli R, et al. **J Clin Gastroenterol** 1995 Oct;21(3):193-7 (56 ref.)

THERAPY

Helicobacter pylori in infants and children. Czinn SJ, et al. **Adv Pediatr Infect Dis** 1996;11:389-401 (54 ref.)
Animal models and vaccine development. Lee A. **Baillieres Clin Gastroenterol** 1995 Sep;9(3):615-32 (74 ref.)

GASTRITIS, ATROPHIC

COMPLICATIONS

Bacteria in the aetio-pathogenesis of gastric cancer: a review. Houben GM, et al. **Scand J Gastroenterol Suppl** 1995; 212:13-8 (61 ref.)
[Should Helicobacter pylori be eradicated in a patient with chronic gastritis?] Bouché O. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S143-S153 (127 ref.) **(Fre)**
[Stomach cancer: what's new? (editorial)] Faivre J, et al. **Gastroenterol Clin Biol** 1995 Oct;19(10):793-6 (22 ref.) **(Fre)**
[Neuropsychiatric symptoms in vitamin B12 deficiency and microcarcinoidosis. The complications of chronic atrophic gastritis] Ossege LM, et al. **Dtsch Med Wochenschr** 1996 Jun 7;121(23):758-62 (25 ref.) (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

Review article: the development of atrophic gastritis--Helicobacter pylori and the effects of acid suppressive therapy. Kuipers EJ, et al. **Aliment Pharmacol Ther** 1995 Aug;9(4):331-40 (97 ref.)
[Consensus conference: "Ulcer and gastritis at the time of Helicobacter pylori". Why and how? (editorial)] Bigard MA, et al. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S1-S4 (17 ref.) **(Fre)**
[Gastroduodenal ulcer disease and gastritis: general epidemiology, natural history and progression] Bommelaer G. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S5-S8 (45 ref.) **(Fre)**
[Helicobacter pylori infection: relationships between gastritis and clinical symptomatology] Bruley Des Varannes S, et al. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S84-S94 (92 ref.) **(Fre)**
[Role of Helicobacter pylori in the pathogenesis of ulcer disease and gastritis] Dorval ED. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S22-S26 (62 ref.) **(Fre)**

ETIOLOGY

Review article: the development of atrophic gastritis--Helicobacter pylori and the effects of acid suppressive therapy. Kuipers EJ, et al. **Aliment Pharmacol Ther** 1995 Aug;9(4):331-40 (97 ref.)
[Atrophic gastritis in Sjögren's syndrome] Sugaya T, et al. **Nippon Rinsho** 1995 Oct;53(10):2540-4 (11 ref.) (Eng. Abstr.) **(Jpn)**

MICROBIOLOGY

The relationships between chronic gastritis and gastric acid secretion. Sipponen P, et al. **Aliment Pharmacol Ther** 1996 Apr;10 Suppl 1:103-18 (147 ref.)
[Role of Helicobacter infection in the causes and mechanisms of gastroduodenal ulcer and chronic gastritis] Chamouard P. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S103-S110 (120 ref.) **(Fre)**

PATHOLOGY

Recognizing atrophy: another step toward a classification of gastritis. Genta RM. **Am J Surg Pathol** 1996;20 Suppl 1:S23-30 (38 ref.)
[Chronic gastritis and gastroduodenal ulcers: anatomopathological aspects, course and progression] Fléjou JF. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S9-S13 (41 ref.) **(Fre)**

PREVENTION & CONTROL

[When to look for Helicobacter pylori?] Delchier JC. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S34-S37 (32 ref.) **(Fre)**

GASTROCNEMIUS MUSCLE see **MUSCLE, SKELETAL**

GASTROCOELE see **GASTRULA**

GASTRODUODENAL ULCER see **PEPTIC ULCER**

GASTROENTERITIS

Fever without apparent source on clinical examination, lower respiratory infections in children, other infectious diseases, and acute gastroenteritis and diarrhea of infancy and early childhood. McCarthy PL, et al. **Curr Opin Pediatr** 1996 Feb;8(1):75-93 (134 ref.)

COMPLICATIONS

Eosinophilic gastro-enteritis associated with protein-losing enteropathy and protein C deficiency. Wing-Harkins DL, et al. **J Int Med Res** 1996 Jan-Feb;24(1):155-63 (44 ref.)
Rotavirus encephalitis: detection of the virus genomic RNA in the cerebrospinal fluid of a child. Yoshida A, et al. **Pediatr Infect Dis J** 1995 Oct;14(10):914-6 (19 ref.)
[Lactose intolerance after gastroenteritis. Not the serious clinical problem as supposed earlier] Gothefors L, et al. **Lakartidningen** 1995 Oct 4;92(40):3694, 3698-9 (16 ref.) **(Swe)**

DIAGNOSIS

[Belching, flatus, breath. Measurements of airborne nitric oxide in the non-invasive diagnosis of inflammation] Lundberg J, et al. **Lakartidningen** 1996 May 15; 93(20):1945-8 (22 ref.) (Eng. Abstr.) **(Swe)**

EPIDEMIOLOGY

[Adenoviruses from stool samples in hospital units. Comparison with main pathogens in gastroenteritis (rotavirus, Campylobacter, Salmonella)] Durepaire N, et al. **Pathol Biol (Paris)** 1995 Sep;43(7):601-10 (22 ref.) (Eng. Abstr.) **(Fre)**
[Risk assessment of microorganisms relevant to food hygiene] Untermann F. **Zentralbl Hyg Umweltmed** 1995 Apr; 197(1-3):222-31 (44 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Role of mast cells and basophils in gastrointestinal inflammation. Wershil BK. **Chem Immunol** 1995;62:187-203 (83 ref.)
Astrovirus gastroenteritis. Blacklow NR, et al. **Trans Am Clin Climatol Assoc** 1994;106:58-66; discussion 66-8 (31 ref.)

MICROBIOLOGY

Infectious gastroenterocolitides in children: an update on emerging pathogens. Sherman PM, et al. **Pediatr Clin North Am** 1996 Apr;43(2):391-407 (114 ref.)

PREVENTION & CONTROL

Review of rotavirus vaccine trials in Finland. Vesikari T, et al. **J Infect Dis** 1996 Sep;174 Suppl 1:S81-7 (46 ref.)

RADIOGRAPHY

Radiographic manifestations of eosinophilic gastroenteritis. Vitellas KM, et al. **Abdom Imaging** 1995 Sep-Oct; 20(5):406-13 (34 ref.)

VIROLOGY

[Adenoviruses as causative agents in gastroenteritis] de Jong JC. **Ned Tijdschr Geneeskd** 1996 Mar 9;140(10):536-41 (48

GASTROENTERITIS

ref.) **(Dut)**

[Does vaccination prevent Rotavirus gastroenteritis? (editorial)] Vesikari T. **Duodecim** 1994;110(2):121–3 (15 ref.) **(Fin)**

[A vaccine against diarrhea. Soon a reality in the fight against viral gastroenteritis in both developed and developing countries] Svensson L. **Lakartidningen** 1996 Jan 31; 93(5):353–8 (26 ref.) **(Swe)**

GASTROENTERITIS VIRUS, MURINE

GENETICS

Regulation of transcription of coronaviruses. van Marle G, et al. **Adv Exp Med Biol** 1995;380:507–10 (23 ref.)

METABOLISM

Site directed mutagenesis of the murine coronavirus spike protein. Effects on fusion. Bos EC, et al. **Adv Exp Med Biol** 1995;380:283–6 (14 ref.)

PATHOGENICITY

MHVR–independent cell–cell spread of mouse hepatitis virus infection requires neutral pH fusion. Nash TC, et al. **Adv Exp Med Biol** 1995;380:351–7 (8 ref.)

Spread of MHV–JHM from nasal cavity to white matter of spinal cord. Transneuronal movement and involvement of astrocytes. Perlman S, et al. **Adv Exp Med Biol** 1995; 380:73–8 (21 ref.)

PHYSIOLOGY

Characterization of a new gene that encodes a functional MHV receptor and progress in the identification of the virus–binding site(s). Dveksler G, et al. **Adv Exp Med Biol** 1995;380:345–50 (18 ref.)

MHVR–independent cell–cell spread of mouse hepatitis virus infection requires neutral pH fusion. Nash TC, et al. **Adv Exp Med Biol** 1995;380:351–7 (8 ref.)

Spread of MHV–JHM from nasal cavity to white matter of spinal cord. Transneuronal movement and involvement of astrocytes. Perlman S, et al. **Adv Exp Med Biol** 1995; 380:73–8 (21 ref.)

[Mouse hepatitis virus] Homberger FR. **Schweiz Arch Tierheilkd** 1996;138(4):183–8 (10 ref.) (Eng. Abstr.) **(Ger)**

GASTROENTEROLOGY

see related

GASTROINTESTINAL DISEASES

Gastrodontology: a clinical perspective worth consideration [editorial] Siegel MA. **Am J Gastroenterol** 1996 Jan; 91(1):1–2 (35 ref.)

The clinical challenge of nuclear medicine in gastroenterology. Notghi A, et al. **Br J Hosp Med** 1995 Jul 12–Aug 15;54(2–3):80–6 (23 ref.)

ORGANIZATION & ADMINISTRATION

Nutrition support teams: an integral part of developing a gastroenterology service. Reynolds N, et al. **Gut** 1995 Dec; 37(6):740–2 (19 ref.)

TRENDS

Review article: drug development in gastroenterology—the changing view of industry. Parsons ME, et al. **Aliment Pharmacol Ther** 1995 Oct;9(5):457–63 (14 ref.)

Hepatology. McNair AN, et al. **BMJ** 1995 Nov 18; 311(7016):1351–5 (48 ref.)

Cirrhosis: ascites and hepatorenal syndrome. Recent advances in pathogenesis. Henriksen JH. **J Hepatol** 1995; 23 Suppl 1:25–30 (74 ref.)

GASTROESOPHAGEAL REFLUX

see related

FUNDOPLICATION

Critical issues in the management of gastroesophageal reflux disease. Freston JW, et al. **Eur J Gastroenterol Hepatol** 1995 Jun;7(6):577–86 (77 ref.)

The diagnosis and management of gastroesophageal reflux disease. Weinberg DS, et al. **Med Clin North Am** 1996 Mar; 80(2):411–29 (58 ref.)

Gastroesophageal reflux in children. Vandenplas Y. **Scand J Gastroenterol Suppl** 1995;213:31–8 (56 ref.)

Gastrointestinal motility disorders in pregnancy. Torbey CF, et al. **Semin Gastrointest Dis** 1995 Oct;6(4):203–16 (138 ref.)

COMPLICATIONS

Gastroesophageal reflux and sinusitis in asthma. Hamilos DL. **Clin Chest Med** 1995 Dec;16(4):683–97 (61 ref.)

Pathological pharyngo–esophageal interactions. Massey BT. **Dysphagia** 1995 Fall;10(4):232–4 (21 ref.)

Sialorrhea and gastroesophageal reflux [see comments] Mandel L, et al. **J Am Dent Assoc** 1995 Nov; 126(11):1537–41 (40 ref.) Comment in: J Am Dent Assoc 1996 Jan;127(1):18, 20.

Excluding gastroesophageal reflux disease as the cause of chronic cough [editorial] Johnston BT, et al. **J Clin Gastroenterol** 1996 Apr;22(3):168–9 (13 ref.)

The relationship between gastro–oesophageal reflux disease and dental erosion. Bartlett DW, et al. **J Oral Rehabil** 1996 May;23(5):289–97 (48 ref.)

Gastroesophageal reflux disease. Kahrilas PJ. **JAMA** 1996 Sep 25;276(12):983–8 (66 ref.)

Gastroesophageal reflux disease as a cause for emesis in infants. Jolley SG. **Semin Pediatr Surg** 1995 Aug; 4(3):176–89 (48 ref.)

[Reflux associated respiratory tract diseases] Jaspersen D. **Dtsch Med Wochenschr** 1996 Apr 5;121(14):449–52 (56 ref.) **(Ger)**

[Sinoatrial block caused by gastroesophageal reflux. The role of simultaneous 24 hr. esophageal pH–metry and Holter–ECG in the differential diagnosis of angina pectoris] Patai A, et al. **Orv Hetil** 1996 Mar 31;137(13):687–90 (38 ref.) (Eng. Abstr.) **(Hun)**

[The infrequent complications of gastroesophageal reflux in children] Espín Jaime B, et al. **An Esp Pediatr** 1996 Apr; 44(4):361–3 (21 ref.) **(Spa)**

DIAGNOSIS

The diagnosis and treatment of gastroesophageal reflux disease in a managed care environment. Suggested disease management guidelines. Fennerty MB, et al. **Arch Intern Med** 1996 Mar 11;156(5):477–84 (59 ref.)

Gastroesophageal reflux in the preterm infant. Novak DA. **Clin Perinatol** 1996 Jun;23(2):305–20 (131 ref.)

Gastroesophageal reflux in childhood. Fonkalsrud EW, et al. **Curr Probl Surg** 1996 Jan;33(1):1–70 (275 ref.)

Esophageal motility and reflux testing. State–of–the–art and clinical role in the twenty–first century. Dent J, et al. **Gastroenterol Clin North Am** 1996 Mar;25(1):51–73 (85 ref.)

Typical and atypical presentations of gastroesophageal reflux disease. The role of esophageal testing in diagnosis and management. Richter JE. **Gastroenterol Clin North Am** 1996 Mar;25(1):75–102 (119 ref.)

Statement of the North American Society for Pediatric Gastroenterology and Nutrition (NASPGN). Indications for pediatric esophageal pH monitoring. Colletti RB, et al. **J Pediatr Gastroenterol Nutr** 1995 Oct;21(3):253–62 (126 ref.)

Gastroesophageal reflux. Diagnostic and therapeutic approaches. Hillemeier AC. **Pediatr Clin North Am** 1996 Feb;43(1):197–212 (74 ref.)

[Evaluation of complaints and diagnostic methods, considered to be objective, in gastroesophageal reflux] Szendrényi V, et al. **Orv Hetil** 1996 Jan 7;137(1):9–14 (32 ref.) (Eng. Abstr.) **(Hun)**

DRUG THERAPY

The role of proton pump inhibitors in the treatment of gastro–oesophageal reflux disease. Bardhan KD. **Aliment Pharmacol Ther** 1995;9 Suppl 1:15–25 (73 ref.)

The role and limitations of H2–receptor antagonists in the treatment of gastro–oesophageal reflux disease. Colin–Jones DG. **Aliment Pharmacol Ther** 1995;9 Suppl 1:9–14 (29 ref.)

Comparative role of omeprazole in the treatment of gastroesophageal reflux disease. Skoutakis VA, et al. **Ann Pharmacother** 1995 Dec;29(12):1252–62 (64 ref.)

The medical management of gastro–oesophageal reflux. **Drug Ther Bull** 1996 Jan;34(1):1–4 (38 ref.)

Individualized acute treatment strategies for gastroesophageal reflux disease. Reynolds JC. **Scand J Gastroenterol Suppl** 1995;213:17–24 (51 ref.)

Medical management of esophageal reflux. Hirschowitz BI. **Yale J Biol Med** 1994 May–Aug;67(3–4):223–31 (35 ref.)

[Gastroesophageal reflux and bronchial asthma (letter)] Müller–Lissner S. **Dtsch Med Wochenschr** 1996 Aug 2; 121(31–32):1000–1 (11 ref.) **(Ger)**

[Gastroesophageal reflux: current status of therapy] Seifert E. **Leber Magen Darm** 1995 Jul;25(4):156–60, 163 (55 ref.) (Eng. Abstr.) **(Ger)**

ECONOMICS

Quality of life and cost of therapy in reflux disease. Glise H. **Scand J Gastroenterol Suppl** 1995;210:38–42 (33 ref.)

EPIDEMIOLOGY

[Position and sudden death of the infant (editorial)] Faure C. **Presse Med** 1995 Dec 16–23;24(39):1879–81 (14 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Multiple rings of the esophagus associated with gastroesophageal reflux [case report] McKinley MJ, et al. **Am J Gastroenterol** 1996 Mar;91(3):574–6 (16 ref.)

Gastro–oesophageal reflux and exercise. Important pathology to consider in the athletic population. Shawdon A. **Sports Med** 1995 Aug;20(2):109–16 (32 ref.)

METABOLISM

The relationship between the control of pH and healing and symptom relief in gastro–oesophageal reflux disease. Hunt RH. **Aliment Pharmacol Ther** 1995;9 Suppl 1:3–7 (38 ref.)

PATHOLOGY

The biopsy diagnosis of gastroesophageal reflux disease, "carditis," and Barrett's esophagus, and sequelae of therapy. Riddell RH. **Am J Surg Pathol** 1996;20 Suppl 1:S31–50 (82 ref.)

PHYSIOPATHOLOGY

Physiological studies of gastro–oesophageal reflux and airway protective responses in the young animal and human infant. Jeffery HE, et al. **Clin Exp Pharmacol Physiol** 1995 Aug;22(8):544–9 (51 ref.)

Do salivary organic components play a protective role in health and disease of the esophageal mucosa? Sarosiek J, et al. **Digestion** 1995;56 Suppl 1:32–7 (34 ref.)

How does the esophageal epithelium maintain its integrity? Tobey NA. **Digestion** 1995;56 Suppl 1:45–50 (23 ref.)

Airway protective mechanisms: current concepts. Shaker R. **Dysphagia** 1995 Fall;10(4):216–27 (112 ref.)

The pathophysiology of gastro–oesophageal reflux disease: an overview. Galmiche JP, et al. **Scand J Gastroenterol Suppl** 1995;211:7–18 (97 ref.)

[Esophageal reflux disease] Pikkarainen P, et al. **Duodecim** 1994;110(20):1845–51 (31 ref.) **(Fin)**

SURGERY

Nissen fundoplication for gastro–oesophageal reflux disease: long–term results. Luostarinen M. **Ann Chir Gynaecol** 1995; 84(2):115–20 (29 ref.)

Laparoscopic and thoracoscopic antireflux surgery. Roberts PJ, et al. **Ann Chir Gynaecol** 1995;84(2):130–7 (30 ref.)

Reoperations after failed antireflux procedures. Siewert JR, et al. **Ann Chir Gynaecol** 1995;84(2):122–8 (29 ref.)

Open Nissen fundoplication. Ferguson MK. **Chest Surg Clin N Am** 1995 Aug;5(3):379–94 (24 ref.)

Laparoscopic antireflux repair and myotomy. Peters JH, et al. **Curr Opin Gen Surg** 1993;:170–9 (36 ref.)

Laparoscopic antireflux surgery. Richardson WS, et al. **Surg Clin North Am** 1996 Jun;76(3):437–50 (48 ref.)

[Differential concept on use of laparoscopic anti–reflux operations] Fuchs KH, et al. **Zentralbl Chir** 1996; 121(4):294–9; discussion 300–2 (32 ref.) (Eng. Abstr.) **(Ger)**

[Antireflux surgery: from Nissen to mini–invasive technics] Rossetti M. **Minerva Chir** 1995 Sep;50(9 Suppl):104–8 (16 ref.) **(Ita)**

THERAPY

Gastroesophageal reflux in childhood. Fonkalsrud EW, et al. **Curr Probl Surg** 1996 Jan;33(1):1–70 (275 ref.)

Current management of gastroesophageal reflux disease. DeVault KR. **Gastroenterologist** 1996 Mar;4(1):24–32 (92 ref.)

Gastroesophageal reflux in children. Yaseen M, et al. **J Ark Med Soc** 1996 Jan;92(8):390–6 (10 ref.)

Gastroesophageal reflux disease. Kahrilas PJ. **JAMA** 1996 Sep 25;276(12):983–8 (66 ref.)

Gastroesophageal reflux. Diagnostic and therapeutic approaches. Hillemeier AC. **Pediatr Clin North Am** 1996 Feb;43(1):197–212 (74 ref.)

Long–term management of gastroesophageal reflux disease. Heading RC. **Scand J Gastroenterol Suppl** 1995;213:25–30 (27 ref.)

The knife or the pill in the long–term treatment of gastroesophageal reflux disease? Lundell LR. **Yale J Biol Med** 1994 May–Aug;67(3–4):233–46 (100 ref.)

[Therapeutic principles in gastroesophageal reflux] Chassany O, et al. **Rev Med Interne** 1995;16(12):960–70 (68 ref.) (Eng. Abstr.) **(Fre)**

ULTRASONOGRAPHY

Gastroesophageal reflux and Barrett's esophagus. Van Dam J. **Gastrointest Endosc Clin N Am** 1995 Jul;5(3):649–54 (9 ref.)

GASTROILEAL BYPASS see **GASTRIC BYPASS**

GASTROINTESTINAL AGENTS

PHARMACOLOGY

Clinical pharmacology forum: motility agents and the gastrointestinal tract. McCallum RW. **Am J Med Sci** 1996 Jul;312(1):19–26 (58 ref.)

Gastrointestinal prokinetic benzamides: the pharmacology underlying stimulation of motility. Briejer MR, et al. **Pharmacol Rev** 1995 Dec;47(4):631–51 (203 ref.)

THERAPEUTIC USE

Cisapride for the treatment of chronic idiopathic constipation. Gardner VY, et al. **Ann Pharmacother** 1995 Nov;29(11):1161–3 (12 ref.)

Octreotide. Lamberts SW, et al. **N Engl J Med** 1996 Jan 25;334(4):246–54 (76 ref.)

Prevention of gastrointestinal damage induced by nonsalicylate nonsteroidal antiinflammatory drugs. Florent C, et al. **Rev Rhum Engl Ed** 1996 Feb;63(2):131–4 (15 ref.)

Individualized acute treatment strategies for gastroesophageal reflux disease. Reynolds JC. **Scand J Gastroenterol Suppl** 1995;213:17–24 (51 ref.)

[The potentials for using sandostatin in gastroenterology (a review)] Lopatkina TN. **Ter Arkh** 1995;67(7):66–8 (62 ref.) **(Rus)**

[Gastrointestinal fistulas. Treatment with a somatostatin analogue (SMS 201–995)] Gerardo Pérez D, et al. **G E N** 1994 Oct–Dec;48(4):209–18 (51 ref.) (Eng. Abstr.) **(Spa)**

[Somatostatin and its analogs in the treatment of gastrointestinal and liver diseases] Feu F, et al. **Gastroenterol Hepatol** 1996 Feb;19(2):68–77 (102 ref.) **(Spa)**

GASTROINTESTINAL CANCER ANTIGEN see **CA–19–9 ANTIGEN**

GASTROINTESTINAL DISEASES

Spondylarthropathies: from gut to target organs. Veys EM, et al. **Baillieres Clin Rheumatol** 1996 Feb;10(1):123–46 (157 ref.)

Gastrointestinal manifestations of HIV infection. Sharpstone D, et al. **Lancet** 1996 Aug 10;348(9024):379–83 (50 ref.)

Gastrointestinal motility disorders in pregnancy. Torbey CF, et al. **Semin Gastrointest Dis** 1995 Oct;6(4):203–16 (138 ref.)

Endoscopic management of ulcer disease. Fleischer D. **Yale J Biol Med** 1994 May–Aug;67(3–4):167–72 (37 ref.)

[The most common gastrointestinal problems in pediatric practice] Zoppi G. **Pediatr Med Chir** 1996 Mar–Apr; 18(2):131–9 (59 ref.) (Eng. Abstr.) **(Ita)**

CHEMICALLY INDUCED

Nonsteroidal anti–inflammatory drug–induced gastrointestinal injury. Bjorkman DJ. **Am J Med** 1996 Jul 31;101(1A):25S–32S (88 ref.)

A unifying hypothesis for the mechanism of NSAID related gastrointestinal toxicity. Mahmud T, et al. **Ann Rheum Dis** 1996 Apr;55(4):211–3 (31 ref.)

NSAIDs and the gut—where are we now? Shield M. **Eur J Rheumatol Inflamm** 1994;14(3 Suppl):13–23 (62 ref.)

Hydrogen peroxide 3% exposures. Henry MC, et al. **J Toxicol Clin Toxicol** 1996;34(3):323–7 (21 ref.)

A reader's guide to the evaluation of causation. Podrebarac T, et al. **Postgrad Med J** 1996 Mar;72(845):131–6 (19 ref.)

Nonsteroidal anti–inflammatory drugs and the gut. Hirschowitz BI. **South Med J** 1996 Mar;89(3):259–63 (20 ref.)

[Extramedullary toxicity in bone marrow transplantation using busulfan and cyclophosphamide conditioning] Pascual MJ, et al. **Sangre (Barc)** 1995 Jun;40(3):191–7 (31 ref.) (Eng. Abstr.) **(Spa)**

COMPLICATIONS

Rheumatological complications of GI disorders. Fomberstein B, et al. **Am J Gastroenterol** 1996 Jun;91(6):1090–103 (200 ref.)

Gastrointestinal manifestations of acquired immunodeficiency syndrome: radiologic–pathologic correlation. Pantongrag–Brown L, et al. **Radiographics** 1995 Sep; 15(5):1155–78 (105 ref.)

[Kidney transplantation in patients with diseases of the gastrointestinal tract and the liver] Kliem V, et al. **Dtsch Med Wochenschr** 1995 Dec 1;120(48):1673–7 (43 ref.) **(Ger)**

DIAGNOSIS

Screening for gastrointestinal diseases—therapeutic impact [editorial] Fiasse R. **Acta Gastroenterol Belg** 1995 Sep–Dec; 58(5–6):343–7 (18 ref.)

Gastrointestinal motility disorders. Abell TL, et al. **Am Fam Physician** 1996 Feb 15;53(3):895–902 (46 ref.)

Adolescent chest pain. Anzai AK, et al. **Am Fam Physician** 1996 Apr;53(5):1682–90 (16 ref.)

Diagnosing and treating patients with refractory functional gastrointestinal disorders. Drossman DA. **Ann Intern Med** 1995 Nov 1;123(9):688–97 (98 ref.)

Diagnostic criteria for gastrointestinal food allergy in childhood. Walker–Smith JA. **Clin Exp Allergy** 1995 Jul; 25 Suppl 1:20–2 (15 ref.)

Neonatal gastrointestinal imaging. Cumming WA, et al. **Clin Perinatol** 1996 Jun;23(2):387–407 (31 ref.)

Diagnosis and treatment of dyspepsia in the elderly. Pound SE, et al. **Drugs Aging** 1995 Nov;7(5):347–54 (32 ref.)

Gastrointestinal motility testing—a personal perspective. Quigley EM. **Ir Med J** 1995 Nov–Dec;88(6):210–2 (23 ref.)

Gastrointestinal contrast agents for MR imaging. Brown JJ. **Magn Reson Imaging Clin N Am** 1996 Feb;4(1):25–35 (43 ref.)

[The gastrointestinal manifestations of amyloidosis] Neef B, et al. **Dtsch Med Wochenschr** 1995 Nov 17; 120(46):1597–602 (50 ref.) **(Ger)**

[Indication for gastroscopy is not the problem. It may prevent medication without previous diagnosis!] Järhult J. **Lakartidningen** 1996 Jun 26;93(26–27):2518–20 (22 ref.) **(Swe)**

DRUG THERAPY

Review article: drug development in gastroenterology—the changing view of industry. Parsons ME, et al. **Aliment Pharmacol Ther** 1995 Oct;9(5):457–63 (14 ref.)

A risk–benefit assessment of cisapride in the treatment of gastrointestinal disorders. Tack J, et al. **Drug Saf** 1995 Jun; 12(6):384–92 (103 ref.)

Cisapride therapy for gastrointestinal disease. Cucchiara S. **J Pediatr Gastroenterol Nutr** 1996 Apr;22(3):259–69 (90 ref.)

Octreotide. Lamberts SW, et al. **N Engl J Med** 1996 Jan 25;334(4):246–54 (76 ref.)

Antioxidants in pediatric gastrointestinal disease. Sokol RJ, et al. **Pediatr Clin North Am** 1996 Apr;43(2):471–88 (102 ref.)

[Proton pump blockers and their significance in gastroenterology] Dítě P, et al. **Vnitr Lek** 1995 Aug; 41(8):549–54 (23 ref.) (Eng. Abstr.) **(Cze)**

[The potentials for using sandostatin in gastroenterology (a review)] Lopatkina TN. **Ter Arkh** 1995;67(7):66–8 (62 ref.) **(Rus)**

[Somatostatin and its analogs in the treatment of gastrointestinal and liver diseases] Feu F, et al. **Gastroenterol Hepatol** 1996 Feb;19(2):68–77 (102 ref.) **(Spa)**

EPIDEMIOLOGY

The epidemiology of functional gastrointestinal disorders in North America. Locke GR 3rd. **Gastroenterol Clin North Am** 1996 Mar;25(1):1–19 (166 ref.)

ETIOLOGY

Acute gastrointestinal complications after cardiac surgery. Halm MA. **Am J Crit Care** 1996 Mar;5(2):109–18; quiz 119–20 (34 ref.)

Gastrointestinal problems in a child with dyskeratosis congenita. Berezin S, et al. **Am J Gastroenterol** 1996 Jun; 91(6):1271–2 (6 ref.)

Sexual and physical abuse and gastrointestinal illness. Review and recommendations [see comments] Drossman DA, et al. **Ann Intern Med** 1995 Nov 15;123(10):782–94 (99 ref.) Comment in: Ann Intern Med 1995 Nov 15;123(10):774–81. Comment in: Ann Intern Med 1996 Sep 1;125(5):426; discussion 426–7.

Symptomatic management of HIV associated gastrointestinal disease. McGowan I, et al. **Cancer Surv** 1994;21:157–77 (113 ref.)

Epidemiology of gastrointestinal complications of diabetes mellitus. Locke GR 3rd. **Eur J Gastroenterol Hepatol** 1995 Aug;7(8):711–6 (31 ref.)

Managing HIV. Part 5: Treating secondary outcomes. 5.3 HIV, gastrointestinal and hepatobiliary disease. Sievert W, et al. **Med J Aust** 1996 Mar 18;164(6):360–5 (25 ref.)

Gastrointestinal and nutritional problems in children with immunodeficiency and AIDS. Winter H, et al. **Pediatr Clin North Am** 1996 Apr;43(2):573–90 (40 ref.)

Gastrointestinal manifestations of collagen–vascular diseases. Bassel K, et al. **Semin Gastrointest Dis** 1995 Oct;6(4):228–40 (124 ref.)

Endocrine–related gut dysfunction. Su AY, et al. **Semin Gastrointest Dis** 1995 Oct;6(4):217–27 (81 ref.)

[Schonlein–Henoch syndrome with severe abdominal involvement in an adult] Vogt M, et al. **Dtsch Med Wochenschr** 1996 Jul 5;121(27):871–5 (49 ref.) **(Ger)**

[Acute gastrointestinal side effects of radiotherapy. What is certain in the treatment?] Paulsen F, et al. **Strahlenther Onkol** 1996 Feb;172(2):53–63 (77 ref.) (Eng. Abstr.) **(Ger)**

[A case of lupus cystitis successfully treated with corticosteroid accompanied by gastrointestinal symptoms] Sato M, et al. **Ryumachi** 1995 Oct;35(5):814–20 (38 ref.) (Eng. Abstr.) **(Jpn)**

[Role of Helicobacter pylori (HP) in digestive pathology] Garrido Klinge G. **Rev Gastroenterol Peru** 1995;15 Suppl 1:S29–35 (20 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

Cystic fibrosis. Gastrointestinal complications and gene therapy. Shalon LB, et al. **Pediatr Clin North Am** 1996 Feb;43(1):157–96 (147 ref.)

IMMUNOLOGY

Development of immune function in the intestine and its role in neonatal diseases. Insoft RM, et al. **Pediatr Clin North Am** 1996 Apr;43(2):551–71 (83 ref.)

Antioxidants in pediatric gastrointestinal disease. Sokol RJ, et al. **Pediatr Clin North Am** 1996 Apr;43(2):471–88 (102 ref.)

METABOLISM

Cytokines and gastrointestinal disease mechanisms. Przemioslo RT, et al. **Baillieres Clin Gastroenterol** 1996 Mar;10(1):17–32 (73 ref.)

The role of glutamine, short–chain fatty acids, and nucleotides in intestinal adaptation to gastrointestinal disease. LeLeiko NS, et al. **Pediatr Clin North Am** 1996 Apr;43(2):451–70 (98 ref.)

MICROBIOLOGY

Helicobacter pylori and gastrointestinal disease. Pezzi JS, et al. **Am Fam Physician** 1995 Nov 1;52(6):1717–24, 1729 (41 ref.)

Clostridial disease of the gut. Borriello SP. **Clin Infect Dis** 1995 Jun;20 Suppl 2:S242–50 (135 ref.)

Sea monsters. Sodeman WA Jr. **Compr Ther** 1995 Nov; 21(11):668–72 (18 ref.)

Clostridium difficile—associated diarrhoeal diseases: an overview. Niyogi SK. **J Indian Med Assoc** 1995 Mar; 93(3):105–7 (29 ref.)

PATHOLOGY

Cell death by apoptosis: basic concepts and disease relevance for the gastroenterologist [see comments] Que FG, et al. **Gastroenterology** 1996 Apr;110(4):1238–43 (21 ref.) Comment in: Gastroenterology 1996 Aug;111(2):567–8.

Pigments of the gastrointestinal tract: a comparison of light microscopic and electron microscopic findings. Ghadially FN, et al. **Ultrastruct Pathol** 1995 Jul–Aug;19(4):213–9 (36 ref.)

PHYSIOPATHOLOGY

Gastrointestinal motility disorders. Abell TL, et al. **Am Fam Physician** 1996 Feb 15;53(3):895–902 (46 ref.)

Gastrointestinal sensation. Mechanisms and relation to functional gastrointestinal disorders. Camilleri M, et al. **Gastroenterol Clin North Am** 1996 Mar;25(1):247–58 (41 ref.)

Mast cells in the gastrointestinal tract. Barczyk M, et al. **Rocz Akad Med Bialymst** 1995;40(1):36–57 (108 ref.)

Overview of functional gut disorders: a challenge. Diamant NE. **Scand J Gastroenterol Suppl** 1995;213:1–6 (49 ref.)

Neuroendocrine disorders of the gut [see comments] Yee LF, et al. **West J Med** 1995 Nov;163(5):454–62 (45 ref.) Comment in: West J Med 1995 Nov;163(5):485–6.

[Gastrointestinal motility disorders in intensive care patients] Grote R, et al. **Anaesthesist** 1995 Aug;44(8):595–609 (36 ref.) **(Ger)**

PREVENTION & CONTROL

Prevention of Helicobacter pylori infection. Feldman RA. **Baillieres Clin Gastroenterol** 1995 Sep;9(3):447–65 (132 ref.)

Gastrointestinal symptoms during exercise. The effect of fluid supplementation. Peters HP, et al. **Sports Med** 1995 Aug; 20(2):65–76 (76 ref.)

PSYCHOLOGY

Psychosocial aspects of functional gastrointestinal disorders. Whitehead WE. **Gastroenterol Clin North Am** 1996 Mar; 25(1):21–34 (95 ref.)

RADIOGRAPHY

The gastrointestinal manifestations of pediatric AIDS. Stoane JM, et al. **Radiol Clin North Am** 1996 Jul;34(4):779–90 (44 ref.)

[What can be expected from x–ray computed tomography in gastrointestinal diseases?] Bruel JM, et al. **Gastroenterol Clin Biol** 1996;20(5 Pt 2):B140–4 (27 ref.) **(Fre)**

RADIONUCLIDE IMAGING

Role of nuclear medicine in evaluating patients with suspected gastrointestinal motility disorders. Parkman HP, et al. **Semin Nucl Med** 1995 Oct;25(4):289–305 (114 ref.)

SURGERY

Recent developments in upper gastrointestinal surgery. Jamieson GG. **Aust N Z J Surg** 1996 Jan;66(1):46–9 (36 ref.)

Laparoscopic interventions in the gut: yesterday, today, and tomorrow. McMahon AJ, et al. **Dig Dis** 1996 Jan–Feb; 14(1):14–26 (164 ref.)

What's new in gastrointestinal and hepatobiliary surgery. Meyers WC. **J Am Coll Surg** 1996 Feb;182(2):100–6 (52 ref.)

[Laparoscopy in gastroenterology] Ovaska J, et al. **Duodecim** 1994;110(20):1875–80 (16 ref.) **(Fin)**

[Artificial (parenteral and enteral) nutrition in postoperative rehabilitation] Vantini I, et al. **Chir Ital** 1994;46(6):54–67 (112 ref.) (Eng. Abstr.) **(Ita)**

THERAPY

Basic fibroblast growth factor and PDGF in GI diseases. Szabo S, et al. **Baillieres Clin Gastroenterol** 1996 Mar; 10(1):97–112 (68 ref.)

Symptomatic management of HIV associated gastrointestinal disease. McGowan I, et al. **Cancer Surv** 1994;21:157–77 (113 ref.)

Clinical applications of epidermal growth factor. Guglietta A, et al. **Eur J Gastroenterol Hepatol** 1995 Oct;7(10):945–50 (35 ref.)

Therapeutic strategies for motility disorders. Medications, nutrition, biofeedback, and hypnotherapy. Farrugia G, et al. **Gastroenterol Clin North Am** 1996 Mar;25(1):225–46 (129 ref.)

Primary care for women. Management and treatment of gastrointestinal disorders. Shaw B. **J Nurse Midwifery** 1996 Mar–Apr;41(2):155–72 (20 ref.)

The role of glutamine, short–chain fatty acids, and nucleotides in intestinal adaptation to gastrointestinal disease. LeLeiko NS, et al. **Pediatr Clin North Am** 1996 Apr;43(2):451–70 (98 ref.)

[Parenteral and enteral nutrition in patients with diseases of the gastrointestinal tract] Bureš J. **Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove** 1995;38(1 Suppl):21–35 (207 ref.) (Eng. Abstr.) **(Cze)**

[Update gastroenterology 1995—I] Layer P, et al. **Med Klin** 1995 Dec 15;90(12):701–8 (85 ref.) **(Ger)**

[Gastroenterology update] Layer P, et al. **Med Klin** 1996 Apr 1;91 Suppl 1:65–71 (77 ref.) **(Ger)**

GASTROINTESTINAL DISEASES

[1995 gastroenterology update--I] Layer P, et al. **Med Klin** 1996 Apr 1;91 Suppl 1:73–80 (85 ref.) **(Ger)**
[1995 gastroenterology update--II] Layer P, et al. **Med Klin** 1996 Apr 1;91 Suppl 1:81–8 (88 ref.) **(Ger)**

ULTRASONOGRAPHY

Ultrasonography of the gastrointestinal tract in infants and children. Hayden CK Jr. **Abdom Imaging** 1996 Jan–Feb; 21(1):9–20 (86 ref.)
Gastrointestinal tract sonography. Wilson SR. **Abdom Imaging** 1996 Jan–Feb;21(1):1–8 (23 ref.)
[Endoscopic ultrasonography--a new tool for gastroenterology] Färkkilä M, et al. **Duodecim** 1994; 110(20):1861–6 (24 ref.) **(Fin)**

VETERINARY

Gastrointestinal motility and disease in large animals. Navarre CB, et al. **J Vet Intern Med** 1996 Mar–Apr;10(2):51–9 (119 ref.)

VIROLOGY

Enteric adenoviruses. Mautner V, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 3):229–82 (189 ref.)

GASTROINTESTINAL HEMORRHAGE

see related
HEMOSTASIS, ENDOSCOPIC

Upper gastrointestinal tract bleeding. McGuirk TD, et al. **Emerg Med Clin North Am** 1996 Aug;14(3):523–45 (141 ref.)
[Upper gastrointestinal bleeding] Chahud Isee A. **Rev Gastroenterol Peru** 1995;15 Suppl 1:S37–44 (43 ref.) (Eng. Abstr.) **(Spa)**

CHEMICALLY INDUCED

Nonsteroidal antiinflammatory drug-induced enteropathy and severe chronic anemia in a patient with rheumatoid arthritis. Davies NM, et al. **Arthritis Rheum** 1996 Feb; 39(2):321–4 (15 ref.)
Gastrointestinal bleeding during low-dose aspirin administration for prevention of arterial occlusive events. A critical analysis. Stalnikowicz-Darvasi R. **J Clin Gastroenterol** 1995 Jul;21(1):13–6 (20 ref.)

DIAGNOSIS

Factitious gastrointestinal bleeding: a case of autophlebotomy and ingestion. Rose MI, et al. **Am J Gastroenterol** 1996 Jul;91(7):1457–9 (11 ref.)
Management of gastrointestinal hemorrhage. Hilsden RJ, et al. **Can Fam Physician** 1995 Nov;41:1931–6, 1939–41 (49 ref.)
Management of upper gastrointestinal bleeding in the patient with chronic liver disease. Jutabha R, et al. **Med Clin North Am** 1996 Sep;80(5):1035–68 (261 ref.)
[Endoscopy for digestive system after acute myocardial infarction] Yi X. **Chung Hua Nei Ko Tsa Chih** 1995 Jul; 34(7):487–90 (20 ref.) **(Chi)**
[Contribution of enteroscopy in the diagnosis of digestive hemorrhages of unknown origin] Schmit A, et al. **Rev Med Brux** 1996 Apr;17(2):62–6 (22 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

Drugs for pH control in upper gastrointestinal bleeding. Brunner G, et al. **Aliment Pharmacol Ther** 1995;9 Suppl 1:47–50 (26 ref.)
Watermelon stomach. An unusual cause of recurrent upper GI tract bleeding in the uraemic patient: efficient treatment with oestrogen-progesterone therapy. Hermans C, et al. **Nephrol Dial Transplant** 1996 May;11(5):871–4 (29 ref.)
Pharmacological therapy for portal hypertension: rationale and results. Burroughs AK, et al. **Semin Gastrointest Dis** 1995 Jul;6(3):148–64 (148 ref.)
[Prevention and treatment of upper gastrointestinal bleeding by nonsteroidal anti-inflammatory drugs] Bar-Dayan Y, et al. **Harefuah** 1996 Apr 15;130(8):535–7 (34 ref.) **(Heb)**

ETIOLOGY

Alcohol and oesophageal varices. Sutton R, et al. **Alcohol Alcohol** 1995 Sep;30(5):581–9 (60 ref.)
The role of acid in upper gastrointestinal haemorrhage due to ulcer and stress-related mucosal damage. Peterson WL. **Aliment Pharmacol Ther** 1995;9 Suppl 1:43–6 (28 ref.)
Bleeding from polypoid colonic arteriovenous malformations. Koziara FJ, et al. **Am J Gastroenterol** 1996 Mar;91(3):584–6 (6 ref.)
Massive rectal bleeding from colonic tuberculosis. Monkemuller KE, et al. **Am J Gastroenterol** 1996 Jul; 91(7):1439–41 (22 ref.)
Hemosuccus pancreaticus as a source of obscure upper gastrointestinal bleeding: three cases and literature review. Risti B, et al. **Am J Gastroenterol** 1995 Oct;90(10):1878–80 (14 ref.)
Pancreatitis secondary to percutaneous liver biopsy-associated hemobilia. Van Os EC, et al. **Am J Gastroenterol** 1996 Mar;91(3):577–80 (18 ref.)
Pheocromocytoma and gastrointestinal bleeding. Vázquez-Quintana E, et al. **Am Surg** 1995 Nov; 61(11):937–9 (12 ref.)
Angiodysplasia as the cause of massive lower gastrointestinal hemorrhage in a young adult. Report of a case. Greason KL, et al. **Dis Colon Rectum** 1996 Jun;39(6):702–4 (12 ref.)
Life-threatening lower intestinal bleeding leading to discovery of a colonic paraganglioma [letter] Velitchkov NG, et al. **Dis Colon Rectum** 1996 Aug;39(8):943–5 (4 ref.)
Lower gastrointestinal tract bleeding. Bono MJ. **Emerg Med Clin North Am** 1996 Aug;14(3):547–56 (32 ref.)
Oesophago-vascular fistulae secondary to benign peptic ulcer disease: a rare cause of fatal haemorrhage. Kenny PJ, et al. **Eur J Vasc Endovasc Surg** 1995 Oct;10(3):370–1 (6 ref.)
Jejunal phlebectasia presenting with massive gastrointestinal hemorrhage. Mejia EM, et al. **J Clin Gastroenterol** 1996 Apr;22(3):215–7 (7 ref.)
Duodenal duplication cyst with massive gastrointestinal bleeding. Rubin RB, et al. **J Clin Gastroenterol** 1995 Jul; 21(1):72–4 (20 ref.)
Massive lower gastrointestinal bleeding due to 'Dieulafoy's vascular malformation' of the jejunum: case report. Goins WA, et al. **J Natl Med Assoc** 1995 Oct;87(10):766–70 (27 ref.)
Watermelon stomach. An unusual cause of recurrent upper GI tract bleeding in the uraemic patient: efficient treatment with oestrogen-progesterone therapy. Hermans C, et al. **Nephrol Dial Transplant** 1996 May;11(5):871–4 (29 ref.)
Pulmonary acremonium abscesses and gastrointestinal tuberculosis manifested as massive upper gastrointestinal bleeding. Miró O, et al. **Nephrol Dial Transplant** 1995; 10(8):1444–6 (17 ref.)
Rectal bleeding: when is it right to refer? Thompson M, et al. **Practitioner** 1996 Mar;240(1560):198–200 (9 ref.)
Portal hypertensive hemorrhage: pathogenesis and risk factors. Boyer TD. **Semin Gastrointest Dis** 1995 Jul; 6(3):125–33 (75 ref.)
[Current attitude to severe acute digestive hemorrhage caused by rupture of esophageal varices in cirrhotic patients] Castaing D, et al. **Ann Chir** 1995;49(6):463–8; discussion 468–70 (37 ref.) **(Fre)**
[Butyrate and hemorrhagic rectocolitis] Flourié B, et al. **Gastroenterol Clin Biol** 1995 Jun–Jul;19(6–7):619–24 (51 ref.) **(Fre)**
[Portal hypertension-induced stomach disease] Hermann R, et al. **Schweiz Med Wochenschr** 1996 Jun 15; 126(24):1066–73 (46 ref.) (Eng. Abstr.) **(Ger)**
[Digestive hemorrhage in a patient with multiple neurofibromatosis] Vagni V, et al. **G Chir** 1995 Aug–Sep; 16(8–9):357–9 (14 ref.) (Eng. Abstr.) **(Ita)**
[Watermelon stomach and gastric carcinoid tumor in a cirrhotic patient] Oliveira CV, et al. **Arq Gastroenterol** 1995 Apr–Jun;32(2):66–70 (34 ref.) (Eng. Abstr.) **(Por)**
[Digestive hemorrhage due to duodenal angiodysplasia in the periampullary area] Pamplona J, et al. **Gastroenterol Hepatol** 1996 May;19(5):250–2 (22 ref.) (Eng. Abstr.) **(Spa)**

PREVENTION & CONTROL

Prophylaxis for stress-related gastrointestinal hemorrhage: a cost effectiveness analysis. Ben-Menachem T, et al. **Crit Care Med** 1996 Feb;24(2):338–45 (59 ref.)
Variceal bleeding. Can it be prevented? Korula J. **Postgrad Med** 1995 Dec;98(6):131–4, 137–8 (30 ref.)
Variceal bleeding. What are the treatment options? Stein C, et al. **Postgrad Med** 1995 Dec;98(6):143–6, 149–52 (15 ref.)
[Techniques and indications of endoscopic treatment of esophago-gastric varices in 1995] Ramond MJ. **Gastroenterol Clin Biol** 1995 Nov;19(11):921–34 (130 ref.) **(Fre)**
[Prevention and treatment of upper gastrointestinal bleeding by nonsteroidal anti-inflammatory drugs] Bar-Dayan Y, et al. **Harefuah** 1996 Apr 15;130(8):535–7 (34 ref.) **(Heb)**

SURGERY

Transjugular intrahepatic portasystemic stent-shunt in the treatment of variceal haemorrhage. Jalan R, et al. **Br J Surg** 1995 Sep;82(9):1158–64 (46 ref.)
Gastrointestinal vascular and ischemic syndromes. Brophy CM. **Curr Opin Gen Surg** 1993;:225–31 (26 ref.)
Portal hypertension. Rhee P, et al. **Curr Opin Gen Surg** 1993; :249–56 (36 ref.)
Transjugular intrahepatic portosystemic shunt: a medical perspective. Sanyal AJ, et al. **Dig Dis** 1995 May–Jun; 13(3):153–62 (47 ref.)
Laparoscopic treatment of Meckel's diverticulum. Obstruction and bleeding managed with minimal morbidity. Sanders LE. **Surg Endosc** 1995 Jun;9(6):724–7 (14 ref.)
[Intrahepatic portasystemic shunt and hemorrhagic emergencies in the cirrhotic patient] Perarnau JM, et al. **Ann Chir** 1995;49(7):580–6; discussion 587–8 (17 ref.) (Eng. Abstr.) **(Fre)**
[Recurrent bleeding from colonic varices in portal hypertension. The successful prevention of recurrence by the implantation of a transjugular intrahepatic stent-shunt (TIPS)] Allgaier HP, et al. **Dtsch Med Wochenschr** 1995 Dec 22;120(51–52):1773–6 (29 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Nonsurgical treatment of variceal bleeding: new modalities. Binmoeller KF, et al. **Am J Gastroenterol** 1995 Nov; 90(11):1923–31 (95 ref.)
Current management of oesophageal varices. Sandford NL, et al. **Aust N Z J Med** 1995 Oct;25(5):528–34 (68 ref.)
Emergency and long-term management of bleeding oesophageal varices. Parks RW, et al. **Br J Hosp Med** 1995 Aug 16–Sep 5;54(4):161–8 (10 ref.)
Case report: bleeding gastric varices secondary to splenic vein thrombosis successfully treated by splenic artery embolization. McDermott VG, et al. **Br J Radiol** 1995 Aug; 68(812):928–30 (14 ref.)
Gastrointestinal bleeding. Talbot-Stern JK. **Emerg Med Clin North Am** 1996 Feb;14(1):173–84 (31 ref.)
Drug treatment of esophageal variceal bleeding: alternative or supplement to endoscopic therapy? Zoller WG, et al. **Endoscopy** 1995 Oct;27(8):616–21 (65 ref.)
Therapeutic intervention for nonvariceal gastrointestinal hemorrhage. Wyllie R, et al. **J Pediatr Gastroenterol Nutr** 1996 Feb;22(2):123–33 (61 ref.)
New approaches to endoscopic therapy for hemostasis of upper GI bleed. Rauws EA, et al. **Scand J Gastroenterol Suppl** 1995;212:90–5 (66 ref.)
[Hemorrhage caused by rupture of gastroesophageal varices: should we dilate the liver or strangulate the varices? (editorial)- Calès P. **Gastroenterol Clin Biol** 1995 Nov; 19(11):899–902 (34 ref.) **(Fre)**
[Emergency medical treatment of portal hypertension] Heresbach D, et al. **Presse Med** 1995 Sep 30;24(28):1311–4 (26 ref.) (Eng. Abstr.) **(Fre)**
[Therapy of bleeding varicosities] Gerbes AL, et al. **Dtsch Med Wochenschr** 1996 Mar 29;121(13):416–23 (75 ref.) **(Ger)**
[A case of arteriovenous malformation of the ileum complicated with decompensated liver cirrhosis: effective case of home parenteral nutrition for intestinal bleeding] Fukushima M, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Nov;92(11):1871–5 (15 ref.) **(Jpn)**

GASTROINTESTINAL HORMONE RECEPTORS see **RECEPTORS, GASTROINTESTINAL HORMONE**

GASTROINTESTINAL HORMONES

see related
GASTROINTESTINAL AGENTS
RECEPTORS, GASTROINTESTINAL HORMONE

GENETICS

Evolution of neuropeptide Y, peptide YY and pancreatic polypeptide. Larhammar D. **Regul Pept** 1996 Apr 9; 62(1):1–11 (104 ref.)

PHYSIOLOGY

[Neurohormonal control of gallbladder motility by intra-ileal and intracolonic nutrients--a review] Niebergall-Roth E, et al. **Berl Munch Tierarztl Wochenschr** 1996 Mar; 109(3):87–94 (110 ref.) (Eng. Abstr.) **(Ger)**
[Effect of gut peptides on feeding and body weight regulation] Inui A, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:40–8 (15 ref.) **(Jpn)**

SECRETION

Secretory diarrhea in children: newly recognized toxins and hormone-secreting tumors. Udall JN Jr. **Pediatr Clin North Am** 1996 Apr;43(2):333–53 (78 ref.)

THERAPEUTIC USE

The clinical use of gastrointestinal hormones for alimentary tract disease. Townsend CM Jr, et al. **Adv Surg** 1996; 29:79–92 (50 ref.)
Progress toward hormonal therapy of gastrointestinal cancer [see comments] Bold RJ, et al. **Ann Surg** 1996 Jan; 223(1):4–11 (36 ref.) Comment in: Ann Surg 1996 Jan;223(1):12–3.

GASTROINTESTINAL MOTILITY

Gastrointestinal motility disorders. Abell TL, et al. **Am Fam Physician** 1996 Feb 15;53(3):895–902 (46 ref.)
Clinical significance of gastric myoelectrical dysrhythmias. Chen JD, et al. **Dig Dis** 1995 Sep–Oct;13(5):275–90 (103 ref.)
Therapeutic strategies for motility disorders. Medications, nutrition, biofeedback, and hypnotherapy. Farrugia G, et al. **Gastroenterol Clin North Am** 1996 Mar;25(1):225–46 (129 ref.)
The epidemiology of functional gastrointestinal disorders in North America. Locke GR 3rd. **Gastroenterol Clin North Am** 1996 Mar;25(1):1–19 (166 ref.)
Psychosocial aspects of functional gastrointestinal disorders. Whitehead WE. **Gastroenterol Clin North Am** 1996 Mar; 25(1):21–34 (95 ref.)
Human colonic motility: physiological aspects. Bassotti G, et al. **Int J Colorectal Dis** 1995;10(3):173–80 (138 ref.)
Gastrointestinal motility testing--a personal perspective. Quigley EM. **Ir Med J** 1995 Nov–Dec;88(6):210–2 (23 ref.)
Effect of some abdominal surgical operations on small bowel motility in humans: our experience. Bassotti G, et al. **J Clin Gastroenterol** 1995 Oct;21(3):211–6 (86 ref.)
Gastrointestinal motility and disease in large animals. Navarre CB, et al. **J Vet Intern Med** 1996 Mar–Apr;10(2):51–9 (119 ref.)

Chronic nonspecific diarrhea of childhood: pathophysiology and management. Kneepkens CM, et al. **Pediatr Clin North Am** 1996 Apr;43(2):375–90 (103 ref.)

Ambulatory manometry of the small bowel: indications and analysis. Wilmer A, et al. **Rev Esp Enferm Dig** 1996 Feb; 88(2):118–32 (45 ref.) **(Eng, Spa)**

Gastrointestinal motility disorders in pregnancy. Torbey CF, et al. **Semin Gastrointest Dis** 1995 Oct;6(4):203–16 (138 ref.)

Pediatric gastrointestinal motility studies. Heyman S. **Semin Nucl Med** 1995 Oct;25(4):339–47 (59 ref.)

Role of nuclear medicine in evaluating patients with suspected gastrointestinal motility disorders. Parkman HP, et al. **Semin Nucl Med** 1995 Oct;25(4):289–305 (114 ref.)

DRUG EFFECTS

Clinical pharmacology forum: motility agents and the gastrointestinal tract. McCallum RW. **Am J Med Sci** 1996 Jul;312(1):19–26 (58 ref.)

Beta 3-adrenoceptors and intestinal motility. Manara L, et al. **Fundam Clin Pharmacol** 1995;9(4):332–42 (70 ref.)

Cisapride [see comments] Washabau RJ, et al. **J Am Vet Med Assoc** 1995 Nov 15;207(10):1285–8 (33 ref.) Comment in: J Am Vet Med Assoc 1996 Jan 15;208(2):184.

Gastrointestinal prokinetic benzamides: the pharmacology underlying stimulation of motility. Briejer MR, et al. **Pharmacol Rev** 1995 Dec;47(4):631–51 (203 ref.)

Cisapride toxicosis in dogs. Volmer PA. **Vet Hum Toxicol** 1996 Apr;38(2):118–20 (20 ref.)

PHYSIOLOGY

Gastrointestinal motility in the neonate. Berseth CL. **Clin Perinatol** 1996 Jun;23(2):179–90 (38 ref.)

Motor activity of the gallbladder and gastrointestinal tract as determinants of enterohepatic circulation. A scintigraphic and manometric study. Qvist N. **Dan Med Bull** 1995 Nov;42(5):426–40 (196 ref.)

An update on histamine H3 receptors and gastrointestinal functions. Bertaccini G, et al. **Dig Dis Sci** 1995 Sep; 40(9):2052–63 (90 ref.)

Role of gastrointestinal motility in the delay of absorption by dietary fibre. Cherbut C. **Eur J Clin Nutr** 1995 Oct;49 Suppl 3:S74–80 (61 ref.)

Gastrointestinal motility in neonatal and pediatric practice. DiLorenzo C, et al. **Gastroenterol Clin North Am** 1996 Mar; 25(1):203–24 (95 ref.)

Colonic motility in health and disease. O'Brien MD, et al. **Gastroenterol Clin North Am** 1996 Mar;25(1):147–62 (62 ref.)

Gastric and small intestinal motility in health and disease. Quigley EM. **Gastroenterol Clin North Am** 1996 Mar; 25(1):113–45 (164 ref.)

A case for interstitial cells of Cajal as pacemakers and mediators of neurotransmission in the gastrointestinal tract. Sanders KM. **Gastroenterology** 1996 Aug;111(2):492–515 (154 ref.)

The enteric nervous system. Goyal RK, et al. **N Engl J Med** 1996 Apr 25;334(17):1106–15 (82 ref.)

Control of motor and secretory functions of the stomach by a portal glucose signal. Sakaguchi T. **Neurosci Biobehav Rev** 1995 Fall;19(3):469–78 (134 ref.)

Intestinal motility during ontogeny and intestinal pseudo-obstruction in children. Milla PJ. **Pediatr Clin North Am** 1996 Apr;43(2):511–32 (72 ref.)

[Esophageal reflux disease] Pikkarainen P, et al. **Duodecim** 1994;110(20):1845–51 (31 ref.) **(Fin)**

[Nitric oxide, the non-adrenergic non-cholinergic system and digestive motility] de Laet MH, et al. **Arch Pediatr** 1996; 3 Suppl 1:287s–291s (32 ref.) **(Fre)**

[Gastrointestinal motility disorders in intensive care patients] Grote R, et al. **Anaesthesist** 1995 Aug;44(8):595–609 (36 ref.) **(Ger)**

GASTROINTESTINAL NEOPLASMS

Premalignant and early malignant lesions in the gastrointestinal tract: definitions, terminology, and problems. Riddell RH. **Am J Gastroenterol** 1996 May; 91(5):864–72 (69 ref.)

Mucosa-associated lymphoid tissue lymphomas. Thieblemont C, et al. **Curr Opin Oncol** 1995 Sep;7(5):415–20 (61 ref.)

Primary gastrointestinal lymphomas. Cooper DL, et al. **Gastroenterologist** 1996 Mar;4(1):54–64 (94 ref.)

[New findings on the classification, diagnosis and therapy of primary gastrointestinal lymphomas] Krč I, et al. **Vnitr Lek** 1995 Jul;41(7):498–503 (29 ref.) (Eng. Abstr.) **(Cze)**

BLOOD

[State of the hemostatic system in complicated cancer of the gastrointestinal tract] Kirichuk VF, et al. **Vopr Onkol** 1996; 42(3):15–21 (70 ref.) **(Rus)**

CHEMISTRY

CA 50: a tumor marker for gastrointestinal malignancies. Bunworasate U, et al. **J Med Assoc Thai** 1995 May; 78(5):255–70 (155 ref.)

Adhesion receptors in malignant transformation and dissemination of gastrointestinal tumors. Streit M, et al. **J Mol Med** 1996 May;74(5):253–68 (140 ref.)

COMPLICATIONS

Gastrointestinal manifestations of acquired immunodeficiency syndrome: radiologic-pathologic correlation. Pantongrag-Brown L, et al. **Radiographics** 1995 Sep; 15(5):1155–78 (105 ref.)

[State of the hemostatic system in complicated cancer of the gastrointestinal tract] Kirichuk VF, et al. **Vopr Onkol** 1996; 42(3):15–21 (70 ref.) **(Rus)**

DIAGNOSIS

Endocrine tumors of the gastrointestinal tract. Perry RR, et al. **Annu Rev Med** 1996;47:57–68 (33 ref.)

The use of serologic tumor markers in gastrointestinal malignancies. Posner MR, et al. **Hematol Oncol Clin North Am** 1994 Jun;8(3):533–53 (87 ref.)

Endoscopic diagnosis and management of gastrointestinal malignancy. Kadish SL, et al. **Oncology (Huntingt)** 1995 Oct;9(10):967–83; discussion 984, 987 (46 ref.)

Imaging of gastrointestinal malignancy in childhood. Davey MS, et al. **Radiol Clin North Am** 1996 Jul;34(4):717–42 (96 ref.)

Gastrointestinal stromal tumors--a recently defined entity. Literature data and personal case report. Laky D, et al. **Rom J Morphol Embryol** 1995 Jan-Jun;41(1-2):73–8 (20 ref.)

Imaging of gastrointestinal neuroendocrine tumors. Gorman B, et al. **Semin Ultrasound CT MR** 1995 Aug;16(4):331–41 (46 ref.)

DRUG THERAPY

Docetaxel delivers new management opportunities for gastrointestinal carcinomas. Rougier P. **Anticancer Drugs** 1995 Jul;6 Suppl 4:25–9 (16 ref.)

Is there a role for intraperitoneal therapy in the management of gastrointestinal malignancies? Markman M. **Cancer Invest** 1995;13(6):625–8 (27 ref.)

Cancer chemotherapy in the elderly. Conti JA, et al. **J Clin Gastroenterol** 1995 Jul;21(1):65–71 (63 ref.)

[Chemotherapy of gastrointestinal carcinomas and non-small-cell pulmonary carcinoma: a controversy] Fey MF, et al. **Schweiz Med Wochenschr** 1996 May 18; 126(20):872–8 (26 ref.) (Eng. Abstr.) **(Ger)**

[Cancer chemosensitivity test--from laboratory to clinic] Kubota T. **Hum Cell** 1995 Dec;8(4):189–94 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Can lymphoma be cured by antibiotics?] Gunvén P, et al. **Lakartidningen** 1996 Feb 28;93(9):767–8 (7 ref.) **(Swe)**

EPIDEMIOLOGY

Gastrointestinal cancer: epidemiological data and premalignant lesions. Hertan HI, et al. **Gastroenterologist** 1995 Sep;3(3):199–219 (189 ref.)

ETIOLOGY

Review article: the risks of malignancy from either immunosuppression or diagnostic radiation in inflammatory bowel disease. Forbes A, et al. **Aliment Pharmacol Ther** 1995 Oct;9(5):465–70 (31 ref.)

Malignancy in Crohn's disease. Bernstein D, et al. **Am J Gastroenterol** 1996 Mar;91(3):434–40 (107 ref.)

Angioimmunoblastic lymphadenopathy: an etiology for gastrointestinal lymphomatous polyposis. Goenka MK, et al. **Am J Gastroenterol** 1996 Jun;91(6):1236–8 (16 ref.)

GENETICS

Genetic markers and premalignancy. Grandjouan S. **Am J Gastroenterol** 1996 May;91(5):844–6 (31 ref.)

Phenotype and cancer risk of various polyposis syndromes. Giardiello FM, et al. **Eur J Cancer** 1995 Jul-Aug; 31A(7-8):1085–7 (26 ref.)

Type-1 growth factor receptors in pancreatic and gastrointestinal neoplasia. Lemoine NR, et al. **Eur J Gastroenterol Hepatol** 1995 Oct;7(10):939–44 (74 ref.)

IMMUNOLOGY

[Clinical value of carbohydrate antigens, sialyl Lewis-x and sialyl Lewis-a in gastrointestinal cancer] Nakamori S, et al. **Nippon Geka Gakkai Zasshi** 1996 Feb;97(2):165–71 (27 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

[Functions of mucin molecules in gastrointestinal cancer] Imai K, et al. **Nippon Geka Gakkai Zasshi** 1996 Feb; 97(2):152–9 (34 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Transforming growth factor-beta in GI neoplasia, wound healing and immune response. Pignatelli M, et al. **Baillieres Clin Gastroenterol** 1996 Mar;10(1):65–81 (110 ref.)

Secondary tumors of the gastrointestinal tract: surgical pathologic findings and comparison with autopsy survey. Washington K, et al. **Mod Pathol** 1995 May;8(4):427–33 (24 ref.)

Gastrointestinal adenomatous polyps. Itzkowitz SH. **Semin Gastrointest Dis** 1996 Apr;7(2):105–16 (85 ref.)

Laparoscopy for staging and palliation of gastrointestinal malignancy. Bogen GL, et al. **Surg Clin North Am** 1996 Jun;76(3):557–69 (56 ref.)

[Gastrointestinal lymphomas] Baroni CD. **Riv Eur Sci Med Farmacol** 1994 Sep-Dec;16 Suppl 1:15–23 (20 ref.) (Eng. Abstr.) **(Ita)**

[Primary lymphomas of the gastrointestinal tract: clinical picture] Grieco A, et al. **Riv Eur Sci Med Farmacol** 1994 Sep-Dec;16 Suppl 1:25–9 (9 ref.) (Eng. Abstr.) **(Ita)**

[Procedures for staging primary gastrointestinal lymphoma] Tedeschi L. **Riv Eur Sci Med Farmacol** 1994 Sep-Dec;16 Suppl 1:69–74 (17 ref.) (Eng. Abstr.) **(Ita)**

[Cancer chemosensitivity test--from laboratory to clinic] Kubota T. **Hum Cell** 1995 Dec;8(4):189–94 (11 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

Neuroendocrine disorders of the gut [see comments] Yee LF, et al. **West J Med** 1995 Nov;163(5):454–62 (45 ref.) Comment in: West J Med 1995 Nov;163(5):485–6.

PREVENTION & CONTROL

Screening for gastrointestinal cancer. Miller AB. **Curr Opin Oncol** 1995 Jul;7(4):373–6 (26 ref.)

Ascorbic acid and gastrointestinal cancer. Cohen M, et al. **J Am Coll Nutr** 1995 Dec;14(6):565–78 (136 ref.)

Prevention of gastrointestinal cancer--the potential role of NSAIDs in colorectal cancer. Luk GD. **Schweiz Med Wochenschr** 1996 May 11;126(19):801–12 (125 ref.)

RADIOTHERAPY

[Intraoperative radiotherapy in gastrointestinal tumors] Frommhold H, et al. **Schweiz Rundsch Med Prax** 1996 Mar 5;85(10):295–8 (25 ref.) (Eng. Abstr.) **(Ger)**

SECONDARY

Secondary tumors of the gastrointestinal tract: surgical pathologic findings and comparison with autopsy survey. Washington K, et al. **Mod Pathol** 1995 May;8(4):427–33 (24 ref.)

SURGERY

Lymphadenectomy in gastrointestinal cancer surgery. Horváth OP. **Acta Med Hung** 1994;50(3–4):221–8 (21 ref.)

Surgical therapy of gastrointestinal non-Hodgkin's lymphomas. Ernst M, et al. **Eur J Surg Oncol** 1996 Apr; 22(2):177–81 (30 ref.)

Assessment of resectability of gastrointestinal cancers by endoscopic ultrasonography. Dittler HJ. **Gastrointest Endosc Clin N Am** 1995 Jul;5(3):569–75 (10 ref.)

Role of extended lymph node dissection in the treatment of gastrointestinal tumours: a review of the literature. Taat CW, et al. **Scand J Gastroenterol Suppl** 1995;212:109–16 (63 ref.)

Laparoscopy for staging and palliation of gastrointestinal malignancy. Bogen GL, et al. **Surg Clin North Am** 1996 Jun;76(3):557–69 (56 ref.)

[Seed metastases following laparoscopic surgery for gastrointestinal malignancies] Nieveen van Dijkum EJ, et al. **Ned Tijdschr Geneeskd** 1996 Jul 6;140(27):1391–4 (50 ref.) **(Dut)**

[Role of surgery in gastrointestinal lymphomas] Tissot E. **Schweiz Med Wochenschr** 1996 May 11;126(19):836–40 (26 ref.) (Eng. Abstr.) **(Fre)**

[Tumor of the gastrointestinal autonomic nervous system (GAN-tumor or plexus sarcoma)] Flückiger R, et al. **Chirurg** 1996 Apr;67(4):371–9 (20 ref.) (Eng. Abstr.) **(Ger)**

[Intraoperative radiotherapy in gastrointestinal tumors] Frommhold H, et al. **Schweiz Rundsch Med Prax** 1996 Mar 5;85(10):295–8 (25 ref.) (Eng. Abstr.) **(Ger)**

[Abdominal carcinoid: various locations and clinical course] Rossi V, et al. **G Chir** 1995 Oct;16(10):429–36 (32 ref.) (Eng. Abstr.) **(Ita)**

[Endoscopic treatment of gastrointestinal cancers--indication and limitation] Suzuki H, et al. **Nippon Rinsho** 1996 Jun; 54(6):1699–704 (12 ref.) (Eng. Abstr.) **(Jpn)**

THERAPY

Current options in the management of gastrointestinal cancer. Middleton G, et al. **Ann Oncol** 1995;6 Suppl 1:17–25; discussion 25–6 (68 ref.)

Progress toward hormonal therapy of gastrointestinal cancer [see comments] Bold RJ, et al. **Ann Surg** 1996 Jan; 223(1):4–11 (36 ref.) Comment in: Ann Surg 1996 Jan;223(1):12–3.

Endoscopic diagnosis and management of gastrointestinal malignancy. Kadish SL, et al. **Oncology (Huntingt)** 1995 Oct;9(10):967–83; discussion 984, 987 (46 ref.)

[Update gastroenterology 1995--I] Layer P, et al. **Med Klin** 1995 Dec 15;90(12):701–8 (85 ref.) **(Ger)**

[Gastroenterology update] Layer P, et al. **Med Klin** 1996 Apr 1;91 Suppl 1:65–71 (77 ref.) **(Ger)**

[1995 gastroenterology update--I] Layer P, et al. **Med Klin** 1996 Apr 1;91 Suppl 1:73–80 (85 ref.) **(Ger)**

[1995 gastroenterology update--II] Layer P, et al. **Med Klin** 1996 Apr 1;91 Suppl 1:81–8 (88 ref.) **(Ger)**

[Treatment of gastrointestinal non-Hodgkin's lymphoma] Barone C, et al. **Riv Eur Sci Med Farmacol** 1994 Sep-Dec;

GASTROINTESTINAL NEOPLASMS

16 Suppl 1:89-100 (29 ref.) (Eng. Abstr.) **(Ita)**

ULTRASONOGRAPHY

Staging concepts for gastrointestinal malignancies: the importance of preoperative locoregional T- and N-staging. Hölscher AH, et al. **Gastrointest Endosc Clin N Am** 1995 Jul;5(3):529-36 (24 ref.)

Restaging after radiotherapy and chemotherapy: value of endoscopic ultrasonography. Hordijk ML. **Gastrointest Endosc Clin N Am** 1995 Jul;5(3):601-8 (30 ref.)

Interobserver variation in tumor staging. Palazzo L, et al. **Gastrointest Endosc Clin N Am** 1995 Jul;5(3):559-67 (28 ref.)

Endoscopic ultrasonography in upper gastrointestinal submucosal tumors: a literature review. Rösch T. **Gastrointest Endosc Clin N Am** 1995 Jul;5(3):609-14 (29 ref.)

Puncture of submucosal and extrinsic tumors: is there a clinical need? Puncture techniques and their accuracy. Wegener M, et al. **Gastrointest Endosc Clin N Am** 1995 Jul;5(3):615-23 (24 ref.)

[Gastrointestinal lymphomas: ultrasonic aspects] Stuckmann G, et al. **Schweiz Med Wochenschr** 1996 May 11; 126(19):813-8 (20 ref.) (Eng. Abstr.) **(Ger)**

[The role of ultrasonography in the diagnosis and staging of gastroenteric lymphoma] Rapaccini GL, et al. **Riv Eur Sci Med Farmacol** 1994 Sep-Dec;16 Suppl 1:75-81 (17 ref.) (Eng. Abstr.) **(Ita)**

GASTROINTESTINAL SYSTEM

Foreign bodies in the gastrointestinal tract. Stack LB, et al. **Emerg Med Clin North Am** 1996 Aug;14(3):493-521 (88 ref.)

[Ciliated hepatic foregut cyst and hepatic foregut cyst] Kakita A, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):128-31 (19 ref.) **(Jpn)**

ABNORMALITIES

Fetal gastrointestinal anomalies. Sohaey R, et al. **Semin Ultrasound CT MR** 1996 Feb;17(1):51-65 (64 ref.)

ANATOMY & HISTOLOGY

Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals. Kararli TT. **Biopharm Drug Dispos** 1995 Jul; 16(5):351-80 (79 ref.)

CHEMISTRY

Pigments of the gastrointestinal tract: a comparison of light microscopic and electron microscopic findings. Ghadially FN, et al. **Ultrastruct Pathol** 1995 Jul-Aug;19(4):213-9 (36 ref.)

[Distribution and localization of nitric oxide containing neural elements in the digestive tract] Altdorfer K, et al. **Orv Hetil** 1996 Apr 21;137(16):857-60 (32 ref.) (Eng. Abstr.) **(Hun)**

CYTOLOGY

Gastrointestinal intra-epithelial lymphocytes in man: the saga continues. Trejdosiewicz LK, et al. **Eur J Gastroenterol Hepatol** 1995 Jun;7(6):537-40 (55 ref.)

A case for interstitial cells of Cajal as pacemakers and mediators of neurotransmission in the gastrointestinal tract. Sanders KM. **Gastroenterology** 1996 Aug;111(2):492-515 (154 ref.)

DRUG EFFECTS

Clinical pharmacology forum: motility agents and the gastrointestinal tract. McCallum RW. **Am J Med Sci** 1996 Jul;312(1):19-26 (58 ref.)

Riboflavin-iron interactions with particular emphasis on the gastrointestinal tract. Powers HJ. **Proc Nutr Soc** 1995 Jul; 54(2):509-17 (45 ref.)

IMMUNOLOGY

Neuroimmunophysiology of the gastrointestinal mucosa: implications for inflammatory diseases. Powell DW. **Trans Am Clin Climatol Assoc** 1994;106:124-38; discussion 138-40 (34 ref.)

INNERVATION

Histopathology of the enteric neuropathies. From silver staining to immunohistochemistry. Singaram C, et al. **Gastroenterol Clin North Am** 1996 Mar;25(1):183-201 (87 ref.)

The central control of vomiting. Meadows N. **J Pediatr Gastroenterol Nutr** 1995;21 Suppl 1:S20-1 (8 ref.)

The enteric nervous system. Goyal RK, et al. **N Engl J Med** 1996 Apr 25;334(17):1106-15 (82 ref.)

[Tumor of the gastrointestinal autonomic nervous system (GAN-tumor or plexus sarcoma)] Flückiger R, et al. **Chirurg** 1996 Apr;67(4):371-9 (20 ref.) (Eng. Abstr.) **(Ger)**

[Distribution and localization of nitric oxide containing neural elements in the digestive tract] Altdorfer K, et al. **Orv Hetil** 1996 Apr 21;137(16):857-60 (32 ref.) (Eng. Abstr.) **(Hun)**

METABOLISM

Impaired absorption of magnesium in the aetiology of grass tetany. Dua K, et al. **Br Vet J** 1995 Jul-Aug;151(4):413-26 (98 ref.)

Implications of altering the rate of carbohydrate absorption from the gastrointestinal tract. Jenkins DJ, et al. **Clin Invest Med** 1995 Aug;18(4):296-302 (57 ref.)

The nifedipine gastrointestinal therapeutic system (GITS). Evaluation of pharmaceutical, pharmacokinetic and pharmacological properties. Grundy JS, et al. **Clin Pharmacokinet** 1996 Jan;30(1):28-51 (131 ref.)

Uptake of foreign DNA by mammalian cells via the gastrointestinal tract in mice: methylation of foreign DNA--a cellular defense mechanism. Doerfler W. **Curr Top Microbiol Immunol** 1995;197:209-24 (73 ref.)

Dietary purine nucleotides and the gastrointestinal tract. Leleiko NS, et al. **Nutrition** 1995 Nov-Dec;11(6):725-30 (44 ref.)

MICROBIOLOGY

The role of the gastrointestinal tract in hematogenous candidiasis: from the laboratory to the bedside. Cole GT, et al. **Clin Infect Dis** 1996 May;22 Suppl 2:S73-88 (114 ref.)

Infection, the gut and the development of the multiple organ dysfunction syndrome. Nieuwenhuijzen GA, et al. **Eur J Surg** 1996 Apr;162(4):259-73 (185 ref.)

Prevention of bacterial infection in the transplant recipient. The role of selective bowel decontamination. Arnow PM. **Infect Dis Clin North Am** 1995 Dec;9(4):849-62 (63 ref.)

Selective decontamination of the digestive tract: indications and problems [editorial] Lode H, et al. **Infection** 1995 May-Jun;23(3):129-32 (31 ref.)

PARASITOLOGY

Patterns in the evenness of gastrointestinal helminth communities. Poulin R. **Int J Parasitol** 1996 Feb; 26(2):181-6 (13 ref.)

PATHOLOGY

Technology assessment status evaluation: balloon dilation of gastrointestinal tract strictures. American Society for Gastrointestinal Endoscopy. Kimmey MB, et al. **Gastrointest Endosc** 1995 Dec;42(6):608-11 (18 ref.)

PHYSIOLOGY

Enkephalinase (EC 3.4.24.11)--neutral endopeptidase (NEP)--characterization, distribution and role in the human gastrointestinal tract. Skrzydło-Radomańska B. **Ann Univ Mariae Curie Sklodowska [Med]** 1993;48:115-20 (37 ref.)

The nutritional significance of endogenous N-losses along the gastro-intestinal tract of farm animals. Tamminga S, et al. **Arch Tierernahr** 1995;48(1-2):9-22 (44 ref.)

Epidermal growth factor (EGF). Goodlad RA, et al. **Baillieres Clin Gastroenterol** 1996 Mar;10(1):33-47 (92 ref.)

Trophic factors for the gastrointestinal tract. Carver JD, et al. **Clin Perinatol** 1996 Jun;23(2):265-85 (174 ref.)

An update on histamine H3 receptors and gastrointestinal functions. Bertaccini G, et al. **Dig Dis Sci** 1995 Sep; 40(9):2052-63 (90 ref.)

Epidermal growth factor and transforming growth factor-alpha actions on the gut. Goodlad RA, et al. **Eur J Gastroenterol Hepatol** 1995 Oct;7(10):928-32 (29 ref.)

Gastrointestinal sensation. Mechanisms and relation to functional gastrointestinal disorders. Camilleri M, et al. **Gastroenterol Clin North Am** 1996 Mar;25(1):247-58 (41 ref.)

Gastrointestinal surface protection and mucosa reconditioning. Bengmark S, et al. **JPEN J Parenter Enteral Nutr** 1995 Sep-Oct;19(5):410-5 (57 ref.)

Nitric oxide in the gut. Salzman AL. **New Horiz** 1995 May; 3(2):352-64 (145 ref.)

Carbonic anhydrase in the alimentary tract. Roles of the different isozymes and salivary factors in the maintenance of optimal conditions in the gastrointestinal canal. Parkkila S, et al. **Scand J Gastroenterol** 1996 Apr;31(4):305-17 (171 ref.)

Neuroimmunophysiology of the gastrointestinal mucosa: implications for inflammatory diseases. Powell DW. **Trans Am Clin Climatol Assoc** 1994;106:124-38; discussion 138-40 (34 ref.)

[Physiological and pathophysiological role of histamine in the gastrointestinal tract] Dyduch A, et al. **Pediatr Pol** 1996 May;71(5):391-5 (36 ref.) (Eng. Abstr.) **(Pol)**

[Vagovagal regulation of the gastrointestinal tract: from signal conduction to performance response] Grundy D, et al. **Fiziol Zh Im I M Sechenova** 1995 Nov;81(11):104-11 (36 ref.) **(Rus)**

PHYSIOPATHOLOGY

Gastrointestinal dysfunction in liver disease and portal hypertension. Gut-liver interactions revisited [editorial] Quigley EM. **Dig Dis Sci** 1996 Mar;41(3):557-61 (48 ref.)

Gastrointestinal function in chronic renal failure. Ravelli AM. **Pediatr Nephrol** 1995 Dec;9(6):756-62 (90 ref.)

[Physiological and pathophysiological role of histamine in the gastrointestinal tract] Dyduch A, et al. **Pediatr Pol** 1996 May;71(5):391-5 (36 ref.) (Eng. Abstr.) **(Pol)**

RADIOGRAPHY

CT of the pediatric gastrointestinal tract. Auringer ST, et al. **Radiol Clin North Am** 1996 Jul;34(4):701-15 (38 ref.)

Interventional procedures in the gastrointestinal tract in children. Kaye RD, et al. **Radiol Clin North Am** 1996 Jul; 34(4):903-17 (87 ref.)

Emergency gastrointestinal radiology of the newborn. McAlister WH, et al. **Radiol Clin North Am** 1996 Jul; 34(4):819-44 (31 ref.)

RADIONUCLIDE IMAGING

Pediatric gastrointestinal nuclear imaging. O'Hara SM. **Radiol Clin North Am** 1996 Jul;34(4):845-62 (64 ref.)

Pediatric gastrointestinal motility studies. Heyman S. **Semin Nucl Med** 1995 Oct;25(4):339-47 (59 ref.)

SURGERY

New applications of laparoscopy in gastrointestinal surgery. Sackier JM. **Am Fam Physician** 1996 Jan;53(1):237-42 (18 ref.)

Experience with augmentation cystoplasty. A review. Mast P, et al. **Paraplegia** 1995 Oct;33(10):560-4 (25 ref.)

[Progresses in general surgery in China, 1995] Huang Y. **Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):731-2 (0 ref.) **(Chi)**

ULTRASONOGRAPHY

Ultrasonography of the gastrointestinal tract in infants and children. Hayden CK Jr. **Abdom Imaging** 1996 Jan-Feb; 21(1):9-20 (86 ref.)

Gastrointestinal tract sonography. Wilson SR. **Abdom Imaging** 1996 Jan-Feb;21(1):1-8 (23 ref.)

Normal structures on endoscopic ultrasonography: visualization measurement data and interobserver variation. Catalano MF. **Gastrointest Endosc Clin N Am** 1995 Jul; 5(3):475-86 (29 ref.)

In vitro studies of lymph node analysis. Heintz A, et al. **Gastrointest Endosc Clin N Am** 1995 Jul;5(3):577-86 (21 ref.)

Emergency gastrointestinal radiology of the newborn. McAlister WH, et al. **Radiol Clin North Am** 1996 Jul; 34(4):819-44 (31 ref.)

ULTRASTRUCTURE

Pigments of the gastrointestinal tract: a comparison of light microscopic and electron microscopic findings. Ghadially FN, et al. **Ultrastruct Pathol** 1995 Jul-Aug;19(4):213-9 (36 ref.)

GASTROINTESTINAL TRANSIT

Results of colectomy for severe slow transit constipation. Lubowski DZ, et al. **Dis Colon Rectum** 1996 Jan;39(1):23-9 (23 ref.)

An overview of the effects of dietary fiber on gastrointestinal transit. Hillemeier C. **Pediatrics** 1995 Nov;96(5 Pt 2):997-9 (13 ref.)

GASTROPARESIS

Gastroparesis: diagnosis and management. Horowitz M, et al. **Scand J Gastroenterol Suppl** 1995;213:7-16 (65 ref.)

DRUG THERAPY

[Treatment of radiotherapy-induced gastroparesis with erythromycin] Sturm A, et al. **Dtsch Med Wochenschr** 1996 Mar 29;121(13):402-5 (16 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Diabetic gastroparesis. Farrell FJ, et al. **Dig Dis** 1995 Sep-Oct;13(5):291-300 (83 ref.)

Gastroparesis and dyspepsia in patients with diabetes mellitus. Mearin F, et al. **Eur J Gastroenterol Hepatol** 1995 Aug; 7(8):717-23 (42 ref.)

Diabetic gastroparesis: a review. Nilsson PH. **J Diabetes Complications** 1996 Mar-Apr;10(2):113-22 (96 ref.)

Diabetic gastroparesis. Malagelada JR. **Semin Gastrointest Dis** 1995 Oct;6(4):181-6 (69 ref.)

[Treatment of radiotherapy-induced gastroparesis with erythromycin] Sturm A, et al. **Dtsch Med Wochenschr** 1996 Mar 29;121(13):402-5 (16 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Gastric and small intestinal motility in health and disease. Quigley EM. **Gastroenterol Clin North Am** 1996 Mar; 25(1):113-45 (164 ref.)

GASTROSCOPY

Endoscopic ultrasonography. Pollack BJ, et al. **Semin Oncol** 1996 Jun;23(3):336-46 (83 ref.)

[Fibrin sealing, a concept for early elective endoscopic therapy] Friedrichs O. **Wien Med Wochenschr** 1995; 145(14):313-8 (42 ref.) (Eng. Abstr.) **(Ger)**

[Indication for gastroscopy is not the problem. It may prevent medication without previous diagnosis!] Järhult J.

Lakartidningen 1996 Jun 26;93(26-27):2518-20 (22 ref.) **(Swe)**

ADVERSE EFFECTS

Colocutaneous fistula: a rare and silent complication of percutaneous endoscopic gastrostomy. Siddique I, et al. **Dig Dis Sci** 1996 Feb;41(2):301-4 (14 ref.)
Complications of percutaneous endoscopic gastrostomy. Schapiro GD, et al. **Gastrointest Endosc Clin N Am** 1996 Apr;6(2):409-22 (52 ref.)

GASTROSTOMY

ADVERSE EFFECTS

Colocutaneous fistula: a rare and silent complication of percutaneous endoscopic gastrostomy. Siddique I, et al. **Dig Dis Sci** 1996 Feb;41(2):301-4 (14 ref.)
Complications of percutaneous endoscopic gastrostomy. Schapiro GD, et al. **Gastrointest Endosc Clin N Am** 1996 Apr;6(2):409-22 (52 ref.)
Abdominal wall metastasis following percutaneous endoscopic gastrostomy. Becker G, et al. **Support Care Cancer** 1995 Sep;3(5):313-6 (18 ref.)

METHODS

Fluoroscopically guided percutaneous gastrostomy: current status. McLoughlin RF, et al. **Can Assoc Radiol J** 1996 Feb;47(1):10-5 (54 ref.)
Gasless laparoscopic gastrostomy. Viani MP, et al. **J Laparoendosc Surg** 1995 Aug;5(4):245-9 (9 ref.)

GASTRULA

Primitive-streak origin and state of commitment of cells of the cardiovascular system in avian and mammalian embryos. Schoenwolf GC, et al. **Cell Mol Biol Res** 1995; 41(4):233-40 (54 ref.)

CYTOLOGY

Vertebrate gastrulation and axial patterning: editorial overview, Part 1. Magnuson T, et al. **Dev Genet** 1995; 17(1):1-5 (49 ref.)

PHYSIOLOGY

Drosophila gastrulation: from pattern formation to morphogenesis. Leptin M. **Ann Rev Cell Dev Biol** 1995; 11:189-212 (67 ref.)
Homeobox genes in vertebrate gastrulation. Boncinelli E, et al. **Curr Opin Genet Dev** 1995 Oct;5(5):619-27 (58 ref.)
Cytoskeleton in teleost eggs and early embryos: contributions to cytoarchitecture and motile events. Hart NH, et al. **Curr Top Dev Biol** 1995;31:343-81 (144 ref.)
Vertebrate gastrulation and axial patterning: editorial overview, Part 2. Magnuson T, et al. **Dev Genet** 1995; 17(2):103-6 (43 ref.)
Growth factors in development: the role of TGF-beta related polypeptide signalling molecules in embryogenesis. Hogan BL, et al. **Dev Suppl** 1994;:53-60 (65 ref.)

GATEKEEPERS, HEALTH SERVICE see **REFERRAL AND CONSULTATION**

GATING, ION CHANNEL see **ION CHANNEL GATING**

GAUCHER'S DISEASE

Gaucher's disease: a review. Morales LE. **Ann Pharmacother** 1996 Apr;30(4):381-8 (39 ref.)
[Gaucher disease] Kaminsky P, et al. **Presse Med** 1996 Jan 27;25(3):108-12 (34 ref.) (Eng. Abstr.) **(Fre)**
[Gaucher disease] Ohashi T. **Nippon Rinsho** 1995 Dec; 53(12):2943-6 (12 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Gaucher disease. Current issues in diagnosis and treatment. NIH Technology Assessment Panel on Gaucher Disease. **JAMA** 1996 Feb 21;275(7):548-53 (0 ref.)

DRUG THERAPY

Treatment of Gaucher disease with an enzyme inhibitor. Radin NS. **Glycoconj J** 1996 Apr;13(2):153-7 (22 ref.)
[The treatment of Gaucher's disease in The Netherlands using enzyme substitution therapy] Hollak CE, et al. **Ned Tijdschr Geneeskd** 1996 May 11;140(19):1011-3 (17 ref.) **(Dut)**

GENETICS

Gaucher disease. Balicki D, et al. **Medicine (Baltimore)** 1995 Nov;74(6):305-23 (148 ref.)
[Molecular studies of Gaucher disease] Eto Y, et al. **Rinsho Byori** 1996 Apr;44(4):327-34 (17 ref.) (Eng. Abstr.) **(Jpn)**

THERAPY

Bone marrow transplantation for metabolic diseases. Parkman R, et al. **Cancer Treat Res** 1995;76:87-96 (33 ref.)
Gaucher disease. Current issues in diagnosis and treatment. NIH Technology Assessment Panel on Gaucher Disease. **JAMA** 1996 Feb 21;275(7):548-53 (0 ref.)
[Gene therapy for Gaucher disease] Ohashi T. **Nippon Rinsho** 1995 Dec;53(12):3089-94 (13 ref.) (Eng. Abstr.) **(Jpn)**

GAUSSIAN DISTRIBUTION see **NORMAL DISTRIBUTION**

GAYS see **HOMOSEXUALITY, MALE**

GBGASE see **PROPERDIN FACTOR D**

GC PROTEIN see **VITAMIN D-BINDING PROTEIN**

GEHRIG'S DISEASE see **AMYOTROPHIC LATERAL SCLEROSIS**

GEIGER-MUELLER COUNTERS see **RADIOMETRY**

GEL ELECTROPHORESIS, PULSED-FIELD see **ELECTROPHORESIS, GEL, PULSED-FIELD**

GEL ELECTROPHORESIS, TWO-DIMENSIONAL see **ELECTROPHORESIS, GEL, TWO-DIMENSIONAL**

GELS

CHEMISTRY

Characterization of hydrogels using luminescence spectroscopy. Rangarajan B, et al. **Biomaterials** 1996 Apr; 17(7):649-61 (71 ref.)
Micro-osmosis in gels, cells and enzymes. Wiggins PM. **Cell Biochem Funct** 1995 Sep;13(3):165-72 (54 ref.)

GELSOLIN

GENETICS

[Finnish hereditary amyloidosis: a mutation in the gelsolin gene] Maury P. **Duodecim** 1994;110(7):675-80 (27 ref.) **(Fin)**

GEMFIBROZIL

PHARMACOLOGY

Gemfibrozil. A reappraisal of its pharmacological properties and place in the management of dyslipidaemia. Spencer CM, et al. **Drugs** 1996 Jun;51(6):982-1018 (234 ref.)

THERAPEUTIC USE

Gemfibrozil. A reappraisal of its pharmacological properties and place in the management of dyslipidaemia. Spencer CM, et al. **Drugs** 1996 Jun;51(6):982-1018 (234 ref.)

GEMINIVIRUS

GENETICS

Agrobacterium-mediated transfer of geminiviruses to plant tissues. Boulton MI. **Methods Mol Biol** 1995;49:77-93 (47 ref.)

GENDER see **SEX**

GENDER IDENTITY

Women and AIDS in Zambia: a review of the psychosocial factors implicated in the transmission of HIV. Campbell T, et al. **AIDS Care** 1995;7(3):365-73 (26 ref.)
The third step: Freud, the feminists, and postmodernism. Dimen M. **Am J Psychoanal** 1995 Dec;55(4):303-19; discussion 321-30 (31 ref.)
Reinventing the mother-daughter relationship. van Mens-Verhulst J. **Am J Psychother** 1995 Fall;49(4):526-39 (49 ref.)
Influence of sex on pain assessment and management. Nevin K. **Ann Emerg Med** 1996 Apr;27(4):424-6 (26 ref.)
The role of the father in parental postnatal mental health. Marks M, et al. **Br J Med Psychol** 1995 Jun;68 (Pt 2):157-68 (75 ref.)
Preventing suicide in women and men. Lester D. **Crisis** 1995; 16(2):79-84 (33 ref.)
Work conditions as explanations for the relation between socioeconomic status, gender, and psychological disorders. Lennon MC. **Epidemiol Rev** 1995;17(1):120-7 (118 ref.)
Mental health, work, and gender. Dennerstein L. **Int J Health Serv** 1995;25(3):503-9 (27 ref.)
Abortion: the antithesis of womanhood? Timpson J. **J Adv Nurs** 1996 Apr;23(4):776-85 (121 ref.)
Case study: sexual abuse of boys by females. Peluso E, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Jan;35(1):51-4 (31 ref.)
Psychological characteristics of Turner syndrome. el Abd S, et al. **J Child Psychol Psychiatry** 1995 Oct;36(7):1109-25 (60 ref.)
The biology of homosexuality: sexual orientation or sexual preference? De Cecco JP, et al. **J Homosex** 1995; 28(1-2):1-27 (55 ref.)
Wilson's Panchreston: the inclusive fitness hypothesis of sociobiology re-examined. Dickemann M. **J Homosex** 1995; 28(1-2):147-83 (65 ref.)
Identity formation for lesbian, bisexual, and gay persons: beyond a "minoritizing" view. Eliason MJ. **J Homosex** 1996; 30(3):31-58 (40 ref.)
Homosexuality, biology, and ideology. Haumann G. **J Homosex** 1995;28(1-2):57-77 (90 ref.)
Female or male: the classification of homosexuality and gender. Oudshoorn N. **J Homosex** 1995;28(1-2):79-86 (15 ref.)
Male gender assignment in penile agenesis: a case report and review of the literature. Ciftci AO, et al. **J Pediatr Surg** 1995 Sep;30(9):1358-60 (13 ref.)
A multifactorial approach to the study of gender characteristics. Koestner R, et al. **J Pers** 1995 Sep; 63(3):681-710 (80 ref.)
The menstrual cycle and the well being of women. Bancroft J. **Soc Sci Med** 1995 Sep;41(6):785-91 (29 ref.)
The social life of bonding theory. Crouch M, et al. **Soc Sci Med** 1995 Sep;41(6):837-44 (88 ref.)
The menstrual cycle, science and femininity: assumptions underlying menstrual cycle research. Nicolson P. **Soc Sci Med** 1995 Sep;41(6):779-84 (64 ref.)
Theory and methodology in premenstrual syndrome research. Walker A. **Soc Sci Med** 1995 Sep;41(6):793-800 (56 ref.)
The household context for women's health care decisions: impacts of U.K. policy changes. Young R. **Soc Sci Med** 1996 Mar;42(6):949-63 (92 ref.)
Models of development: understanding risk in adolescence. Graber JA, et al. **Suicide Life Threat Behav** 1995;25 Suppl:18-25 (35 ref.)
Adolescent development and the emergence of sexuality. Petersen AC, et al. **Suicide Life Threat Behav** 1995;25 Suppl:4-17 (95 ref.)
Sexual orientation and developmental challenges experienced by gay and lesbian youths. Rotheram-Borus MJ, et al. **Suicide Life Threat Behav** 1995;25 Suppl:26-34; discussion 35-9 (60 ref.)
Constructing the symbolic complainant: police subculture and the nonenforcement of protection orders for battered women. Rigakos GS. **Violence Vict** 1995 Fall;10(3):227-47 (50 ref.)
Male and female sexual victimization in dating relationships: gender differences in coercion techniques and outcomes. Waldner-Haugrud LK, et al. **Violence Vict** 1995 Fall; 10(3):203-15 (23 ref.)
[Schizophrenia and quality of life--sex-specific aspects] Röder-Wanner UU, et al. **Fortschr Neurol Psychiatr** 1995 Oct;63(10):393-401 (115 ref.) (Eng. Abstr.) **(Ger)**
[Between idealization and devaluation--problems and perspectives of theoretical analyses of female homo- and heterosexuality] Flaake K. **Psyche (Stuttg)** 1995 Sep-Oct; 49(9-10):867-85 (70 ref.) (Eng. Abstr.) **(Ger)**
[Difficulties in becoming a woman and staying a woman. On the problems of female identity in menopause] Hettlage-Varjas A, et al. **Psyche (Stuttg)** 1995 Sep-Oct; 49(9-10):903-37 (40 ref.) (Eng. Abstr.) **(Ger)**
[Anna, Irma and Dora--the key to the mothers in the creation of psychoanalysis] King V. **Psyche (Stuttg)** 1995 Sep-Oct; 49(9-10):838-66 (60 ref.) (Eng. Abstr.) **(Ger)**
[Transsexual wish and and cis-sexual defense] Sigusch V. **Psyche** (Stuttg) 1995 Sep-Oct;49(9-10):811-37 (75 ref.) (Eng. Abstr.) **(Ger)**
[Education and women's health: reflections from a gender perspective] Campero-Cuenca L. **Salud Publica Mex** 1996 May-Jun;38(3):217-22 (48 ref.) (Eng. Abstr.) **(Spa)**

GENDER RELATIONS see **INTERPERSONAL RELATIONS**

GENDER ROLE see **GENDER IDENTITY**

GENE ACTION REGULATION see **GENE EXPRESSION REGULATION**

GENE ACTIVATION see **GENE EXPRESSION REGULATION**

GENE AMPLIFICATION

see related
GENE DOSAGE

DNA amplification assays: a new standard for diagnosis of Chlamydia trachomatis infections. Quinn TC. **Ann Acad Med Singapore** 1995 Jul;24(4):627-33 (52 ref.)
Nucleic acid amplification and related techniques in microbiological diagnostics and epidemiology. Van Belkum A, et al. **Cell Mol Biol (Noisy-le-grand)** 1995 Jul; 41(5):615-23 (48 ref.)
Minireview: the herpes simplex virus amplicon--a versatile defective virus vector. Frenkel N, et al. **Gene Ther** 1994; 1 Suppl 1:S40-6 (44 ref.)
Gene amplification in human gliomas. Collins VP. **Glia** 1995 Nov;15(3):289-96 (81 ref.)
Gene amplification as a cause for inherited thyroxine-binding globulin excess? [editorial; comment] Robbins J. **J Clin Endocrinol Metab** 1995 Dec;80(12):3425-6 (23 ref.) Comment on: J Clin Endocrinol Metab 1995 Dec;80(12):3758-62.
The discrepancy in discrepant analysis. Hadgu A. **Lancet** 1996 Aug 31;348(9027):592-3 (7 ref.)
Somatic recombination, gene amplification and cancer.

GENE AMPLIFICATION

Ramel C, et al. **Mutat Res** 1996 Jun 12;353(1-2):85-107 (34 ref.)
Genetic clinical markers of human neuroblastoma with special reference to N-myc oncogene: amplified or not amplified?—An overview. Tsuchida Y, et al. **Tumour Biol** 1996;17(2):65-74 (78 ref.)

METHODS

Strategies to accelerate the applicability of gene amplification protocols for pathogen detection in meat and meat products. Pillai SD, et al. **Crit Rev Microbiol** 1995; 21(4):239-61 (121 ref.)
RT-PCR and alternative methods to PCR for in vitro amplification of nucleic acids. Hagen-Mann K, et al. **Exp Clin Endocrinol Diabetes** 1995;103(3):150-5 (22 ref.)

GENE BANK see **GENE LIBRARY**

GENE CLUSTERS see **GENES, REITERATED**

GENE CONVERSION

Gene conversion and homologous recombination in murine B cells. Selsing E, et al. **Semin Immunol** 1996 Jun;8(3):151-8 (39 ref.)

GENE COPY NUMBER see **GENE DOSAGE**

GENE DELETION

The deleted in colorectal cancer (DCC) gene: a candidate tumour suppressor gene encoding a cell surface protein with similarity to neural cell adhesion molecules. Fearon ER, et al. **Cancer Surv** 1995;24:3-17 (58 ref.)
The influence of gene deletions and duplications within the IGHC locus on serum immunoglobulin subclass levels. Rabbani H, et al. **Clin Immunol Immunopathol** 1995 Sep; 76(3 Pt 2):S214-8 (24 ref.)
Preimplantation genetic diagnosis of cystic fibrosis (delta F508). Ao A, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Mar;65(1):7-10 (23 ref.)
[Molecular genetic diagnosis and deletion analysis in Type I-III spinal muscular atrophy] Spiegel R, et al. **Schweiz Med Wochenschr** 1996 May 25;126(21):907-14 (30 ref.) (Eng. Abstr.) **(Ger)**
[Detection of DNA aberrations in human cancers by AP-PCR-SSCP analysis] Okano A, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):633-7 (12 ref.) **(Jpn)**
[Morphological analysis of NCAM-180 deficient mouse brain—polysialic acid moiety and neuronal migration] Ono K. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2188-96 (44 ref.) **(Jpn)**

GENE DOSAGE

Dosage-dependent modification of position-effect variegation in Drosophila. Henikoff S. **Bioessays** 1996 May; 18(5):401-9 (53 ref.)
Xp duplications and sex reversal. Zanaria E, et al. **Philos Trans R Soc Lond B Biol Sci** 1995 Nov 29; 350(1333):291-6 (28 ref.)
Transgenic models for chromosome 21 gene dosage effects. Groner Y. **Prog Clin Biol Res** 1995;393:193-212 (40 ref.)

GENE DUPLICATION see **GENES, REITERATED**

GENE EXPRESSION

see related
PHENOTYPE

Possible genomic mechanism involved in control systems responses to hypoxia. Cherniack NS, et al. **Adv Exp Med Biol** 1995;393:89-94 (26 ref.)
Differential display RT-PCR for identifying novel gene expression in the lung. Sunday ME. **Am J Physiol** 1995 Sep;269(3 Pt 1):L273-84 (72 ref.)
Mucin gene structure and expression: protection vs. adhesion. Van Klinken BJ, et al. **Am J Physiol** 1995 Nov;269(5 Pt 1):G613-27 (125 ref.)
Physiological consequences of over- or under-expression of fibrinolytic system components in transgenic mice. Carmeliet PF. **Baillieres Clin Haematol** 1995 Jun; 8(2):391-401 (49 ref.)
Genome analysis with gene expression microarrays. Schena M. **Bioessays** 1996 May;18(5):427-31 (24 ref.)
c-fos expression as a marker of central cardiovascular neurons. Dun NJ, et al. **Biol Signals** 1995 May-Jun; 4(3):117-23 (25 ref.)
Gene expression and vascular smooth muscle cell phenotype. Weissberg PL, et al. **Blood Press Suppl** 1995;2:68-73 (19 ref.)
Photosynthesis. Regulation by redox signalling. Allen JF, et al. **Curr Biol** 1995 Aug 1;5(8):869-72 (14 ref.)
Terminal myeloid gene expression and differentiation requires the transcription factor PU.1. Simon MC, et al. **Curr Top Microbiol Immunol** 1996;211:113-9 (26 ref.)
Cadherin expression in the developing vertebrate CNS: from neuromeres to brain nuclei and neural circuits. Redies C. **Exp Cell Res** 1995 Oct;220(2):243-56 (187 ref.)
Expression of apoptosis-related molecules in acute renal injury. Yoshimura A, et al. **Exp Nephrol** 1996 Jan-Feb; 4(1):15-8 (18 ref.)
The Met-HGF/SF autocrine signaling mechanism is involved in sarcomagenesis. Cortner J, et al. **EXS** 1995; 74:89-121 (101 ref.)
Regulation of scatter factor (hepatocyte growth factor) production by tumor-stroma interaction. Rosen EM, et al. **EXS** 1995;74:17-31 (51 ref.)
Lysozyme gene expression and regulation. Short ML, et al. **EXS** 1996;75:243-57 (52 ref.)
The ontogeny of growth hormone, insulin-like growth factors and sex steroids: molecular aspects. Han VK. **Horm Res** 1996;45(1-2):61-6 (45 ref.)
Molecular and cellular events in spermatogenesis. Grootegoed JA, et al. **Hum Reprod** 1995 Oct;10 Suppl 1:10-4 (26 ref.)
Specialized gene expression in the epididymis. Cornwall GA, et al. **J Androl** 1995 Sep-Oct;16(5):379-83 (27 ref.)
Gene analysis of human skin and skin diseases. Yamanishi K. **J Dermatol Sci** 1996 Mar;11(3):169-76 (40 ref.)
Molecular mechanism in tolerance to lipopolysaccharide. Ziegler-Heitbrock HW. **J Inflamm** 1995;45(1):13-26 (131 ref.)
Over-production of proteins in Escherichia coli: mutant hosts that allow synthesis of some membrane proteins and globular proteins at high levels. Miroux B, et al. **J Mol Biol** 1996 Jul 19;260(3):289-98 (27 ref.)
CD44: physiological expression of distinct isoforms as evidence for organ-specific metastasis formation. Zöller M. **J Mol Med** 1995 Sep;73(9):425-38 (265 ref.)
Expression of the CD44 adhesion molecule in tumours of the central and peripheral nervous system. Baltuch GH, et al. **J Neurooncol** 1995 Dec;26(3):191-8 (62 ref.)
Mediators of injury in neurotrauma: intracellular signal transduction and gene expression. Bazan NG, et al. **J Neurotrauma** 1995 Oct;12(5):791-814 (249 ref.)
Changes in gene expression following traumatic brain injury in the rat. Hayes RL, et al. **J Neurotrauma** 1995 Oct; 12(5):779-90 (59 ref.)
Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells. Drexler HG. **Leukemia** 1996 Apr; 10(4):588-99 (118 ref.)
Manipulating gene expression with replication-competent retroviruses. Morgan BA, et al. **Methods Cell Biol** 1996; 51:185-218 (25 ref.)
In situ hybridization analysis of chick embryos in whole mount and tissue sections. Nieto MA, et al. **Methods Cell Biol** 1996;51:219-35 (9 ref.)
The potential exploitation of plant viral translational enhancers in biotechnology for increased gene expression. Turner R, et al. **Mol Biotechnol** 1995 Jun;3(3):225-36 (40 ref.)
p55 and p75 tumor necrosis factor receptor expression on human glioblastoma cells. Kato T, et al. **Neurol Med Chir (Tokyo)** 1995 Aug;35(8):567-74 (30 ref.)
The site of expression of NMDA receptor-dependent LTP: new fuel for an old fire. Kullmann DM, et al. **Neuron** 1995 Nov;15(5):997-1002 (22 ref.)
Expression of stress genes during development. Arrigo AP. **Neuropathol Appl Neurobiol** 1995 Dec;21(6):488-91 (45 ref.)
Chromosomal position effects and the modulation of transgene expression. Clark AJ, et al. **Reprod Fertil Dev** 1994;6(5):589-98 (49 ref.)
Replicative senescence: implications for in vivo aging and tumor suppression. Smith JR, et al. **Science** 1996 Jul 5; 273(5271):63-7 (52 ref.)
Use of intragraft gene expression in the diagnosis of kidney allograft rejection. Pavlakis M, et al. **Transplant Proc** 1996 Aug;28(4):2019-21 (24 ref.)
[Correlation between p-53 expression and clinical resistance in testicular cancer] Hanna E, et al. **Orv Hetil** 1996 Jan 14;137(2):59-64 (26 ref.) (Eng. Abstr.) **(Hun)**
[Mechanism of gene expression—basic transcription factor and starting mechanism of genetic transcription] Kitajima S. **Fukuoka Igaku Zasshi** 1995 Dec;86(12):432-6 (2 ref.) **(Jpn)**
[Heterogenity of diacylglycerol Kinase—Structure, biochemical characteristics and gene expression in the brain] Goto K. **Kaibogaku Zasshi** 1995 Dec;70(6):509-11 (4 ref.) **(Jpn)**
[Clinicopathological study on primary lung cancer—immunohistochemical expression of p53 suppressor gene and bcl-2 oncogene in relation to prognosis] Irie K, et al. **Rinsho Byori** 1996 Jan;44(1):32-41 (23 ref.) (Eng. Abstr.) **(Jpn)**
[Type IV collagen: gene expression, supramolecular aggregates, and role in human diseases] Ninomiya Y. **Seikagaku** 1995 Nov;67(11):1301-7 (15 ref.) **(Jpn)**
[Blood flow modulates vascular endothelial gene expressions] Ando J. **Tanpakushitsu Kakusan Koso** 1996 Jan;41(1):26-33 (23 ref.) **(Jpn)**
[Gene expression analysis by random cDNA sequencing] Fujimoto N, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr; 41(5):708-14 (15 ref.) **(Jpn)**
[Overview: gene expression and gene therapy] Fujinaga K. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2588-91 (8 ref.) **(Jpn)**
[Gene expression in hematopoietic cells] Ozawa K. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2592-7 (11 ref.) **(Jpn)**

DRUG EFFECTS

Oligonucleotide-mediated modulation of mammalian gene expression. Scanlon KJ, et al. **FASEB J** 1995 Oct; 9(13):1288-96 (68 ref.)
Influence of etomoxir on the expression of several genes in liver, testis and heart. Hegardt FG, et al. **Gen Pharmacol** 1995 Sep;26(5):897-904 (33 ref.)
Gene expression as a target for new drug discovery. Heguy A, et al. **Gene Expr** 1995;4(6):337-44 (33 ref.)

GENETICS

Molecular physiology, biochemistry, and pharmacology of Alzheimer's amyloid precursor protein (APP). Suh YH, et al. **Ann N Y Acad Sci** 1996 Jun 15;786:169-83 (59 ref.)
A hierarchy of ECM-mediated signalling regulates tissue-specific gene expression. Roskelley CD, et al. **Curr Opin Cell Biol** 1995 Oct;7(5):736-47 (117 ref.)
Protein phosphorylation in neuronal plasticity and gene expression. Schulman H. **Curr Opin Neurobiol** 1995 Jun; 5(3):375-81 (47 ref.)
Underexpression of the apolipoprotein E2 and E4 alleles in the Greek Cypriot population of Cyprus. Cariolou MA, et al. **Genet Epidemiol** 1995;12(5):489-97 (29 ref.)
Regulation of GABAA receptor function and gene expression in the central nervous system. Morrow AL. **Int Rev Neurobiol** 1995;38:1-41 (275 ref.)
Insulin receptor gene expression and insulin resistance. Brunetti A, et al. **J Endocrinol Invest** 1995 May; 18(5):398-405 (44 ref.)
Genetic and epigenetic mechanisms in the pathogenesis of neurofibromatosis type I. Metheny LJ, et al. **J Neuropathol Exp Neurol** 1995 Nov;54(6):753-60 (58 ref.)
Expression of human monoamine oxidase (MAO) A gene controlled by transcription factor Sp1. Shih JC, et al. **Prog Brain Res** 1995;106:49-56 (36 ref.)

IMMUNOLOGY

Simple developmental programs of gene expression and cellular composition of lymphoid organs at the origin of natural tolerance. Coutinho A. **Res Immunol** 1995 May-Jun;146(4-5):321-32 (0 ref.)

PHYSIOLOGY

Hormonal and neurotransmitter regulation of GnRH gene expression and related reproductive behaviors. Sagrillo CA, et al. **Behav Genet** 1996 May;26(3):241-77 (360 ref.)
Putting the bits and pieces of the RET proto-oncogene puzzle together. Gagel RF. **Bone** 1995 Aug;17(2 Suppl):13S-16S (30 ref.)
The olfactory system as a model for the analysis of the contribution of gene expression to programmed cell death. Hayward MD, et al. **Chem Senses** 1995 Apr;20(2):261-9 (100 ref.)
Stretch-induced parathyroid hormone-related peptide gene expression: implication in the regulation of myogenic tone. Noda M, et al. **Curr Opin Nephrol Hypertens** 1995 Sep; 4(5):383-7 (23 ref.)
The GAL4 system as a tool for unravelling the mysteries of the Drosophila nervous system. Brand AH, et al. **Curr Opin Neurobiol** 1995 Oct;5(5):572-8 (60 ref.)
Insulin receptor gene expression and insulin resistance. Brunetti A, et al. **J Endocrinol Invest** 1995 May; 18(5):398-405 (44 ref.)
Selective neuronal vulnerability in the hippocampus—a role for gene expression? Schreiber SS, et al. **Trends Neurosci** 1995 Oct;18(10):446-51 (93 ref.)
[Control of gene expression. Cell specialization and adaptation of gene expression to current need] Neye H. **Med Monatsschr Pharm** 1996 Apr;19(4):94-8 (29 ref.) **(Ger)**

GENE EXPRESSION REGULATION

see related
CELL DIFFERENTIATION
CHROMOSOMAL PROTEINS, NON-HISTONE
TRANS-ACTIVATORS
TRANSCRIPTION FACTORS

The regulation of cell- and tissue-specific expression of glycans by glycosyltransferases. Dinter A, et al. **Adv Exp Med Biol** 1995;376:53-82 (187 ref.)
The genetic regulation of sialyl-Lewisx expression in haemopoietic cells. Watkins WM, et al. **Adv Exp Med Biol** 1995;376:83-93 (64 ref.)
The mammary gland as a bioreactor: factors regulating the efficient expression of milk protein-based transgenes. Rosen JM, et al. **Am J Clin Nutr** 1996 Apr;63(4):627S-32S (53 ref.)
Proenkephalin gene regulation in the neuroendocrine hypothalamus: a model of gene regulation in the CNS. Borsook D, et al. **Am J Physiol** 1995 Sep;269(3 Pt 1):E393-408 (203 ref.)
Molecular regulation of the Na(+)-Ca2+ exchanger. Philipson KD, et al. **Ann N Y Acad Sci** 1996 Apr 15; 779:20-8 (15 ref.)
Transcription factors responsive to cAMP. Sassone-Corsi P. **Ann Rev Cell Dev Biol** 1995;11:355-77 (73 ref.)
Transcriptional regulation of gene expression during adipocyte differentiation. MacDougald OA, et al. **Annu Rev Biochem** 1995;64:345-73 (164 ref.)
Multiple steps in the regulation of transcription-factor level and activity. Calkhoven CF, et al. **Biochem J** 1996 Jul 15; 317 (Pt 2):329-42 (269 ref.)

Genomic mechanisms involved in the pleiotropic actions of 1,25-dihydroxyvitamin D3. Christakos S, et al. **Biochem J** 1996 Jun 1;316 (Pt 2):361-71 (169 ref.)

Transcriptional regulation of genes for ornithine cycle enzymes. Takiguchi M, et al. **Biochem J** 1995 Dec 15;312 (Pt 3):649-59 (272 ref.)

p53 and translational control. Ewen ME, et al. **Biochim Biophys Acta** 1996 Mar 18;1242(3):181-4 (48 ref.)

Cooperation between transcription factors regulates liver development. Aran A, et al. **Biol Neonate** 1995;67(6):387-96 (46 ref.)

The transcriptional control of hematopoiesis. Shivdasani RA, et al. **Blood** 1996 May 15;87(10):4025-39 (175 ref.)

Alterations in neurokinin 1 receptor gene expression in models of pain and inflammation. Krause JE, et al. **Can J Physiol Pharmacol** 1995 Jul;73(7):854-9 (49 ref.)

Transcriptional control of neuropeptide gene expression in sensory neurons, using the preprotachykinin-A gene as a model. Quinn JP, et al. **Can J Physiol Pharmacol** 1995 Jul; 73(7):957-62 (59 ref.)

The role of the genome project in determining gene function: insights from model organisms. Miklos GL, et al. **Cell** 1996 Aug 23;86(4):521-9 (92 ref.)

Skin elastic fibres: regulation of human elastin promoter activity in transgenic mice. Uitto J, et al. **Ciba Found Symp** 1995;192:237-53; discussion 253-8 (49 ref.)

Transcription factors. Barnes PJ, et al. **Clin Exp Allergy** 1995 Nov;25 Suppl 2:46-9 (27 ref.)

Progesterone receptors: expression and regulation in the mammalian ovary. Pinter JH, et al. **Clin Obstet Gynecol** 1996 Jun;39(2):424-35 (85 ref.)

The Ets family of proteins: weak modulators of gene expression in quest for transcriptional partners. Crepieux P, et al. **Crit Rev Oncog** 1994;5(6):615-38 (192 ref.)

Evolutionary genetics. The silence of the genes. Hurst LD. **Curr Biol** 1995 May 1;5(5):459-61 (13 ref.)

Regulation of transcription by MAP kinase cascades. Treisman R. **Curr Opin Cell Biol** 1996 Apr;8(2):205-15 (95 ref.)

C/EBP alpha: a critical regulator of genes governing integrative metabolic processes. Darlington GJ, et al. **Curr Opin Genet Dev** 1995 Oct;5(5):565-70 (37 ref.)

Prolactin-mediated gene activation in mammary epithelial cells. Groner B, et al. **Curr Opin Genet Dev** 1995 Oct; 5(5):587-94 (73 ref.)

Genomic regulation of transposable elements in Drosophila. Lozovskaya ER, et al. **Curr Opin Genet Dev** 1995 Dec; 5(6):768-73 (37 ref.)

Complementation cloning of mammalian transcriptional regulators: the example of MHC class II gene regulators. Steimle V, et al. **Curr Opin Genet Dev** 1995 Oct;5(5):646-51 (53 ref.)

Regulation of adipocyte gene expression and differentiation by peroxisome proliferator activated receptor gamma. Tontonoz P, et al. **Curr Opin Genet Dev** 1995 Oct; 5(5):571-6 (51 ref.)

Silencing is golden: negative regulation in the control of neuronal gene transcription. Schoenherr CJ, et al. **Curr Opin Neurobiol** 1995 Oct;5(5):566-71 (48 ref.)

Regulation of viral and cellular gene expression by E1A proteins encoded by the oncogenic adenovirus type 12. Brockmann D, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 3):81-112 (221 ref.)

Gene silencing in Drosophila. Henikoff S. **Curr Top Microbiol Immunol** 1995;197:193-208 (77 ref.)

Transcriptional regulation by the t(8;21) fusion protein, AML-1/ETO. Hiebert SW, et al. **Curr Top Microbiol Immunol** 1996;211:253-8 (19 ref.)

Coordinate regulation of neutrophil secondary granule protein gene expression. Khanna-Gupta A, et al. **Curr Top Microbiol Immunol** 1996;211:165-71 (20 ref.)

Interleukin-5 receptor alpha subunit gene regulation in human eosinophil development: identification of a unique cis-element that acts lie an enhancer in regulating activity of the IL-5R alpha promoter. Sun Z, et al. **Curr Top Microbiol Immunol** 1996;211:173-87 (64 ref.)

Role of environmental signals and transcriptional regulators in neural crest development. Groves AK, et al. **Dev Genet** 1996;18(1):64-72 (82 ref.)

Regulatory interactions during early neurogenesis in Drosophila. Hassan B, et al. **Dev Genet** 1996;18(1):18-27 (88 ref.)

Journey to the surface of the cell: Fos regulation and the SRE. Treisman R. **EMBO J** 1995 Oct 16;14(20):4905-13 (100 ref.)

T3 or not T3--the slings and arrows of outrageous TR function [editorial; comment] Chin WW, et al. **Endocrinology** 1996 Feb;137(2):387-8 (23 ref.) Comment on: Endocrinology 1996 Feb;137(2):390-9.

Translational control of eukaryotic gene expression. Role of the guanine nucleotide exchange factor and chain initiation factor-2. Singh LP, et al. **Enzyme Protein** 1994-95; 48(2):61-80 (101 ref.)

Initiation of protein synthesis in eukaryotic cells. Pain VM. **Eur J Biochem** 1996 Mar 15;236(3):747-71 (372 ref.)

Co-activators and co-repressors: mediators of gene activation by nuclear hormone receptors. Meier CA. **Eur J Endocrinol** 1996 Feb;134(2):158-9 (5 ref.)

PSF and CMF, autocrine factors that regulate gene expression during growth and early development of Dictyostelium. Clarke M, et al. **Experientia** 1995 Dec 18; 51(12):1124-34 (60 ref.)

Regulation of HGF and HGFR gene expression. Zarnegar R. **EXS** 1995;74:33-49 (59 ref.)

How are class II MHC genes turned on and off? Abdulkadir SA, et al. **FASEB J** 1995 Nov;9(14):1429-35 (68 ref.)

Regulation of gene expression by alternative promoters. Ayoubi TA, et al. **FASEB J** 1996 Mar;10(4):453-60 (41 ref.)

TNF-alpha- and IFN-gamma-mediated signal transduction pathways: effects on glial cell gene expression and function. Benveniste EN, et al. **FASEB J** 1995 Dec;9(15):1577-84 (68 ref.)

A decade of molecular biology of retinoic acid receptors. Chambon P. **FASEB J** 1996 Jul;10(9):940-54 (120 ref.)

Molecular mechanisms of retinoid actions in skin. Fisher GJ, et al. **FASEB J** 1996 Jul;10(9):1002-13 (87 ref.)

Constitutive expression of hepatic cytochrome P450 genes. Gonzalez FJ, et al. **FASEB J** 1996 Aug;10(10):1112-7 (49 ref.)

Posttranscriptional regulation of gene expression in liver regeneration: role of mRNA stability. Kren BT, et al. **FASEB J** 1996 Apr;10(5):559-73 (93 ref.)

Retinoids and Hox genes. Marshall H, et al. **FASEB J** 1996 Jul;10(9):969-78 (62 ref.)

Iron-sulphur clusters as genetic regulatory switches: the bifunctional iron regulatory protein-1. Paraskeva E, et al. **FEBS Lett** 1996 Jun 24;389(1):40-3 (50 ref.)

The regulation of expression of histocompatibility antigens on the cell surface; molecular genetic basis. Petrányi GG. **Folia Biol (Praha)** 1995;41(3-4):163-77 (57 ref.)

Repression and activation by multiprotein complexes that alter chromatin structure. Kingston RE, et al. **Genes Dev** 1996 Apr 15;10(8):905-20 (145 ref.)

Regulation of the c-fos promoter. Janknecht R. **Immunobiology** 1995 Jul;193(2-4):137-42 (14 ref.)

The regulation of IGF-I receptor gene expression. Werner H, et al. **Int J Biochem Cell Biol** 1995 Oct;27(10):987-94 (46 ref.)

What can be learned from intermediate filament gene regulation in the mouse embryo. Duprey P, et al. **Int J Dev Biol** 1995 Jun;39(3):443-57 (150 ref.)

Control of cell cycle regulated histone genes during proliferation and differentiation. Stein JL, et al. **Int J Obes Relat Metab Disord** 1996 Mar;20 Suppl 3:S84-90 (67 ref.)

Regulation of human IgE synthesis. Vercelli D, et al. **Int Rev Immunol** 1989;5(2):111-5 (35 ref.)

Metabolic regulation of gene transcription in mammals. Towle HC. **J Biol Chem** 1995 Oct 6;270(40):23235-8 (59 ref.)

Intracellular receptors and signal transducers and activators of transcription superfamilies: novel targets for small-molecule drug discovery. Rosen J, et al. **J Med Chem** 1995 Dec 8;38(25):4855-74 (124 ref.)

The role of transcription factors in the pituitary expression of the glycoprotein hormone alpha-subunit gene. Aylwin SJ, et al. **J Mol Endocrinol** 1995 Dec;15(3):221-31 (82 ref.)

Chicken ovalbumin upstream promoter-transcription factors and their regulation. Qiu Y, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1-6 Spec No):81-5 (30 ref.)

Flow-dependent regulation of gene expression in vascular endothelial cells. Ando J, et al. **Jpn Heart J** 1996 Jan; 37(1):19-32 (40 ref.)

Role of iron-sulfur proteins in gene regulation. Kennedy MC. **Met Ions Biol Syst** 1996;32:579-602 (121 ref.)

Regulation of neuropeptide expression in the brain by neurotrophins. Potential role in vivo. Carnahan J, et al. **Mol Neurobiol** 1995 Apr-Jun;10(2-3):135-49 (107 ref.)

Neuropeptide messenger plasticity in the CNS neurons following axotomy. Palkovits M. **Mol Neurobiol** 1995 Apr-Jun;10(2-3):91-103 (48 ref.)

Transgenic targeting of neuroendocrine peptide genes in the hypothalamic-pituitary axis. Waschek JA. **Mol Neurobiol** 1995 Apr-Jun;10(2-3):205-17 (50 ref.)

Cases of ancient mobile element DNA insertions that now affect gene regulation. Britten RJ. **Mol Phylogenet Evol** 1996 Feb;5(1):13-7 (32 ref.)

The role of receptors in multistage carcinogenesis. Pitot HC. **Mutat Res** 1995 Dec;333(1-2):3-14 (87 ref.)

Epigenetics and human disease. Issa JP, et al. **Nat Med** 1996 Mar;2(3):281-2 (18 ref.)

Positive and negative regulators of neural fate. Simpson P. **Neuron** 1995 Oct;15(4):739-42 (20 ref.)

Regulatory mechanism of stress response in mammalian nervous system during cerebral ischaemia or after heat shock. Higashi T, et al. **Neuropathol Appl Neurobiol** 1995 Dec;21(6):480-3 (19 ref.)

Molecular diversity of myofibrillar proteins: gene regulation and functional significance. Schiaffino S, et al. **Physiol Rev** 1996 Apr;76(2):371-423 (585 ref.)

Human surfactant protein B: structure, function, regulation, and genetic disease. Whitsett JA, et al. **Physiol Rev** 1995 Oct;75(4):749-57 (66 ref.)

Molecular control of vertebrate iron metabolism: mRNA-based regulatory circuits operated by iron, nitric oxide, and oxidative stress. Hentze MW, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8175-82 (151 ref.)

The large ribosomal subunit stalk as a regulatory element of the eukaryotic translational machinery. Ballesta JP, et al. **Prog Nucleic Acid Res Mol Biol** 1996;55:157-93 (119 ref.)

Effects of the ferritin open reading frame on translational induction by iron. Mascotti DP, et al. **Prog Nucleic Acid Res Mol Biol** 1996;55:121-34 (82 ref.)

S1-nuclease-sensitive DNA structures contribute to transcriptional regulation of the human PDGF A-chain. Wang ZY, et al. **Prog Nucleic Acid Res Mol Biol** 1996; 55:227-44 (110 ref.)

The JAK-STAT pathway: summary of initial studies and recent advances. Darnell JE Jr. **Recent Prog Horm Res** 1996;51:391-403; discussion 403-4 (75 ref.)

Extracellular matrix signaling from the cellular membrane skeleton to the nuclear skeleton: a model of gene regulation. Lelièvre S, et al. **Recent Prog Horm Res** 1996;51:417-32 (54 ref.)

Melanogenic factors: regulation of gene expression. Vachtenheim J, et al. **Sb Lek** 1996;97(1):41-7 (39 ref.)

Histone deacetylase: a regulator of transcription [comment] Wolffe AP. **Science** 1996 Apr 19;272(5260):371-2 (16 ref.) Comment on: Science 1996 Apr 19;272(5260):408-11.

Genes of intracellular calcium metabolism and blood pressure control in primary hypertension. Orlov SN, et al. **Semin Nephrol** 1995 Nov;15(6):569-92 (240 ref.)

Regulation of gene transcription during the differentiation of megakaryocytes. Uzan G, et al. **Thromb Haemost** 1995 Jul;74(1):210-2 (20 ref.)

Regulation and expression of transgenes in fish -- a review. Iyengar A, et al. **Transgenic Res** 1996 May;5(3):147-66 (101 ref.)

Porcine TNF: a review. Pauli U. **Vet Immunol Immunopathol** 1995 Aug;47(3-4):187-201 (63 ref.)

Transcriptional regulation of the genes encoding the cytochrome P-450 steroid hydroxylases. Parker KL, et al. **Vitam Horm** 1995;51:339-70 (121 ref.)

[Cytoskeleton and differentiation. Genetic regulation of intermediate filaments in the neuromuscular system] Li Z, et al. **Arch Inst Pasteur Tunis** 1994 Jul-Oct;71(3-4):419-30 (48 ref.) **(Fre)**

[Role of trace elements on metallothionein gene expression] Ohta H. **Nippon Rinsho** 1996 Jan;54(1):40-5 (23 ref.) (Eng. Abstr.) **(Jpn)**

[Regulation of gene expression through phosphorylation of transcription factors] Hagiwara M. **Seikagaku** 1995 Dec; 67(12):1288-91 (11 ref.) **(Jpn)**

[YAC-modification system for analyzing gene regulation] Koide T. **Seikagaku** 1996 Feb;68(2):137-42 (15 ref.) **(Jpn)**

[Regulation of gene expression by antisense molecule] Matsukura M. **Tanpakushitsu Kakusan Koso** 1994 Jul; 40(10):1378-82 (20 ref.) **(Jpn)**

[Regulatory mechanisms of globin genes--erythroid specific expression and gene therapy] Shirohzu H, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2598-605 (45 ref.) **(Jpn)**

[Regulatory pathways of the c-fos proto-oncogene] Terent'ev AA. **Biokhimiia** 1995 Dec;60(12):1923-52 (179 ref.) (Eng. Abstr.) **(Rus)**

[Genetic regulation of plasmid transfer] Pekhov AP, et al. **Biull Eksp Biol Med** 1995 Jul;120(7):6-12 (37 ref.) **(Rus)**

[Cloning, expression, and regulation of tissue-specific genes in Drosophila] Korochkin LI. **Genetika** 1995 Aug; 31(8):1029-42 (68 ref.) (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

Regulation of expression of sodium-calcium exchanger and plasma membrane calcium ATPase by protein kinases, glucocorticoids, and growth factors. Smith JB, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:258-71 (36 ref.)

Progress in antisense oligonucleotide therapeutics. Crooke ST, et al. **Annu Rev Pharmacol Toxicol** 1996;36:107-29 (185 ref.)

The therapeutic potential of antisense oligonucleotides. Sharma HW, et al. **Bioessays** 1995 Dec;17(12):1055-63 (72 ref.)

Gonadotropin gene modulation by steroids and gonadotropin-releasing hormone. Shupnik MA. **Biol Reprod** 1996 Feb;54(2):279-86 (60 ref.)

Expression of genes coding for growth factors in experimental pneumoconiosis. Morris GF, et al. **Chest** 1996 Mar;109(3 Suppl):45S-49S (55 ref.)

Mouse lactoferrin gene: a marker for estrogen and epidermal growth factor. Teng C. **Environ Health Perspect** 1995 Oct; 103 Suppl 7:17-20 (37 ref.)

Regulation of transforming growth factor beta by sex steroids. Hering S, et al. **Horm Metab Res** 1995 Aug; 27(8):345-51 (87 ref.)

Positive regulation of the nuclear activator CREM by the mitogen-induced p70 S6 kinase. de Groot RP, et al. **Immunobiology** 1995 Jul;193(2-4):155-60 (9 ref.)

Regulation of HLA class I loci by interferons. Girdlestone J. **Immunobiology** 1995 Jul;193(2-4):229-37 (37 ref.)

Control of cytokeratin 17 expression by interferon gamma. Vogel U, et al. **Immunobiology** 1995 Jul;193(2-4):322-7 (16 ref.)

Polyunsaturated fatty acid regulation of hepatic gene transcription. Clarke SD, et al. **J Nutr** 1996 Apr;126(4 Suppl):1105S-9S (52 ref.)

Metal-responsive gene regulation and the zinc metalloregulatory model. Suhy DA, et al. **Met Ions Biol Syst** 1996;32:557-78 (49 ref.)

Brief overview of control of genetic expression by antisense

oligonucleotides and in vivo applications. Prospects for neurobiology. Zon G. **Mol Neurobiol** 1995 Apr-Jun; 10(2-3):219-29 (69 ref.)

Diverse strategies for tetracycline-regulated inducible gene expression [see comments] Shockett PE, et al. **Proc Natl Acad Sci U S A** 1996 May 28;93(11):5173-6 (38 ref.) Comment in: Proc Natl Acad Sci U S A 1996 May 28;93(11):5185-90.

Kainate-induced changes in gene expression in the rat hippocampus. Pennypacker KR, et al. **Prog Brain Res** 1995; 105:105-16 (64 ref.)

Androgen regulation of gene expression. Perry JE, et al. **Prostate Suppl** 1996;6:79-81 (22 ref.)

In vivo antisense approaches to the role of immediate early gene expression in the brain. Cirelli C, et al. **Regul Pept** 1995 Oct 20;59(2):151-62 (48 ref.)

Antisense oligonucleotides in in vivo regulatory peptide research [editorial] Phillips MI. **Regul Pept** 1995 Oct 20; 59(2):iii-v (13 ref.)

In vivo applications of antisense oligonucleotides for peptide research. [editorial] Phillips MI, et al. **Regul Pept** 1995 Oct 20;59(2):131-41 (56 ref.)

Mode of action of tacrolimus (FK506): molecular and cellular mechanisms. Thomson AW, et al. **Ther Drug Monit** 1995 Dec;17(6):584-91 (79 ref.)

Immunoregulatory and fibrogenic activities of cyclosporine: a unifying hypothesis based on transforming growth factor-beta expression. Khanna A, et al. **Transplant Proc** 1996 Aug;28(4):2015-8 (38 ref.)

cAMP-dependent regulation of gene transcription by cAMP response element-binding protein and cAMP response element modulator. Habener JF, et al. **Vitam Horm** 1995; 51:1-57 (196 ref.)

[Progress in the study of inhibin subunit gene expression and regulation in mammalian ovary] Kong DJ, et al. **Sheng Li Ko Hsueh Chin Chan** 1995 Jul;26(3):204-8 (17 ref.) (Eng. Abstr.) **(Chi)**

GENETICS

New understanding of the molecular mechanism of receptor-mediated genomic actions of the vitamin D hormone. Haussler MR, et al. **Bone** 1995 Aug;17(2 Suppl):33S-38S (30 ref.)

Syndromal mental retardation due to mutations in a regulator of gene expression. Gibbons RJ, et al. **Hum Mol Genet** 1995;4 Spec No:1705-9 (24 ref.)

Epigenetic regulation of gene expression: the effect of altered chromatin structure from yeast to mammals. Hendrich BD, et al. **Hum Mol Genet** 1995;4 Spec No:1765-77 (188 ref.)

Glucose transporter gene expression: regulation of transcription and mRNA stability. McGowan KM, et al. **Pharmacol Ther** 1995 Jun;66(3):465-505 (287 ref.)

IMMUNOLOGY

The interplay between lymphoid-specific and ubiquitous transcription factors controls the expression of interleukin 2 gene in T lymphocytes. Avots A, et al. **Immunobiology** 1995 Jul;193(2-4):254-8 (20 ref.)

Regulation of IL-1 beta expression by cyclic AMP in myeloid cells. Hurme M. **Immunobiology** 1995 Jul; 193(2-4):224-8 (18 ref.)

Transcriptional regulation of the tumor necrosis factor alpha gene. Jongeneel CV. **Immunobiology** 1995 Jul; 193(2-4):210-6 (23 ref.)

NF-Y, IRF-2, and C/EBP proteins are involved in regulation of human IL-4 gene expression. Li-Weber M, et al. **Immunobiology** 1995 Jul;193(2-4):263-7 (9 ref.)

The cis-acting elements controlling mouse IL-2R alpha transcription. Nabholz M, et al. **Immunobiology** 1995 Jul; 193(2-4):259-62 (4 ref.)

Transcriptional regulation of the human T cell receptor delta gene. Redondo JM, et al. **Immunobiology** 1995 Jul; 193(2-4):288-92 (14 ref.)

Regulation of MHC class II gene expression. Reith W, et al. **Immunobiology** 1995 Jul;193(2-4):248-53 (23 ref.)

Multi-step activation of NF-kappa B/Rel transcription factors. Schmitz ML, et al. **Immunobiology** 1995 Jul; 193(2-4):116-27 (72 ref.)

The inducible transcription factor NF-AT plays an important role in the activation of the murine interleukin-4 promoter. Schneider G, et al. **Immunobiology** 1995 Jul; 193(2-4):268-72 (14 ref.)

Transcriptional regulation of the human intercellular adhesion molecule-1 gene: a short overview. Stratowa C, et al. **Immunobiology** 1995 Jul;193(2-4):293-304 (37 ref.)

Molecular principles of Oct2-mediated gene activation in B cells. Wirth T, et al. **Immunobiology** 1995 Jul; 193(2-4):161-70 (45 ref.)

Molecular defects in the bare lymphocyte syndrome and regulation of MHC class II genes. Reith W, et al. **Immunol Today** 1995 Nov;16(11):539-46 (61 ref.)

PHYSIOLOGY

gamma-Glutamyl transpeptidase. What does the organization and expression of a multipromoter gene tell us about its functions? Lieberman MW, et al. **Am J Pathol** 1995 Nov; 147(5):1175-85 (91 ref.)

Overexpression of human keratin 16 produces a distinct skin phenotype in transgenic mouse skin. Coulombe PA, et al. **Biochem Cell Biol** 1995 Sep-Oct;73(9-10):611-8 (42 ref.)

Functional mapping of odor-activated neurons in the olfactory bulb. Guthrie KM, et al. **Chem Senses** 1995 Apr; 20(2):271-82 (44 ref.)

Dopamine regulation of transcription factor-target interactions in rat striatum. Hyman SE, et al. **Chem Senses** 1995 Apr;20(2):257-60 (24 ref.)

The glucocorticoid receptor synergizes with Jun homodimers to activate AP-1-regulated promoters lacking GR binding sites. Teurich S, et al. **Chem Senses** 1995 Apr;20(2):251-3 (17 ref.)

Overexpression of genes in health and sickness. A bird's eye view. Shastry BS. **Comp Biochem Physiol B Biochem Mol Biol** 1995 Sep; 112(1):1-13 (146 ref.)

Special HATs for special occasions: linking histone acetylation to chromatin assembly and gene activation. Brownell JE, et al. **Curr Opin Genet Dev** 1996 Apr; 6(2):176-84 (83 ref.)

Heterochromatin and gene regulation in Drosophila. Elgin SC. **Curr Opin Genet Dev** 1996 Apr;6(2):193-202 (65 ref.)

Boundary and insulator elements in chromosomes. Gerasimova TI, et al. **Curr Opin Genet Dev** 1996 Apr; 6(2):185-92 (42 ref.)

Regulation of gene expression by nucleosomes. Svaren J, et al. **Curr Opin Genet Dev** 1996 Apr;6(2):164-70 (63 ref.)

Insulin gene: organisation, expression and regulation. Dumonteil E, et al. **Diabetes Metab** 1996 Jun;22(3):164-73 (82 ref.)

Signal transduction and activation of gene transcription by interferons. Gilmour KC, et al. **Gene Expr** 1995;5(1):1-18 (145 ref.)

Regulation of cytokine gene expression by reactive oxygen and reactive nitrogen intermediates. Remick DG, et al. **J Leukoc Biol** 1996 Apr;59(4):471-5 (34 ref.)

Calcium transport proteins in the nonfailing and failing heart: gene expression and function. Wankerl M, et al. **J Mol Med** 1995 Oct;73(10):487-96 (92 ref.)

The regulation of neuron-specific gene expression in the mammalian nervous system. Twyman RM, et al. **J Neurogenet** 1995 Nov;10(2):67-101 (190 ref.)

Interaction of steroid hormone receptors with transcription factors involves chromatin remodelling. Beato M, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1-6 Spec No):47-59 (144 ref.)

Ribosome regulation by the nascent peptide. Lovett PS, et al. **Microbiol Rev** 1996 Jun;60(2):366-85 (148 ref.)

Dysmyelination in class I MHC transgenic mice. Turnley AM, et al. **Microsc Res Tech** 1995 Nov 1;32(4):286-94 (64 ref.)

Platelet-activating factor is a synapse messenger and a modulator of gene expression in the nervous system. Bazan NG, et al. **Neurochem Int** 1995 May;26(5):435-41 (72 ref.)

A RT-PCR study of gene expression in a mechanical injury model. Eng LF, et al. **Prog Brain Res** 1995;105:219-29 (29 ref.)

Regulation of spinal neuropeptide genes in a rat model of peripheral inflammation and hyperalgesia. Ruda MA, et al. **Prog Brain Res** 1995;104:349-65 (121 ref.)

The molecular organization of voltage-dependent K+ channels in vivo. Sheng M, et al. **Prog Brain Res** 1995; 105:87-93 (30 ref.)

Gene expression in astrocytes during and after ischemia. Yu AC, et al. **Prog Brain Res** 1995;105:245-53 (50 ref.)

Eukaryotic gene expression: metabolite control by amino acids. Laine RO, et al. **Prog Nucleic Acid Res Mol Biol** 1996;53:219-48 (110 ref.)

Hypoxia-inducible gene expression. Fandrey J. **Respir Physiol** 1995 Jul;101(1):1-10 (47 ref.)

Mechanisms of gene activation [comment] Buratowski S. **Science** 1995 Dec 15;270(5243):1773-4 (7 ref.) Comment on: Science 1995 Dec 15;270(5243):1825-8.

Induction of genes during apoptosis: examples from the immune system. Osborne BA. **Semin Cancer Biol** 1995 Feb; 6(1):27-33 (61 ref.)

Implications of prolonged expression of Fos-related antigens. Pennypacker KR, et al. **Trends Pharmacol Sci** 1995 Sep; 16(9):317-21 (44 ref.)

Epidermal growth factor-related peptides and the epidermal growth factor receptor in normal and malignant prostate. Sherwood ER, et al. **World J Urol** 1995;13(5):290-6 (65 ref.)

[Reactive oxygen species and gene expression regulation] Jurgowiak M, et al. **Postepy Biochem** 1996;42(1):6-13 (75 ref.) **(Pol)**

[Cell sources, regulatory factors and gene expression in the regeneration of the crystalline lens and retina in vertebrate animals] Mitashov VI. **Izv Akad Nauk Ser Biol** 1996 May-Jun;(3):298-318 (183 ref.) (Eng. Abstr.) **(Rus)**

[The mechanisms of synaptic plasticity: the role of synaptic protein phosphorylation and gene expression] Godukhin OV, et al. **Usp Fiziol Nauk** 1995 Jul-Sep;26(3):41-56 (98 ref.) (Eng. Abstr.) **(Rus)**

GENE EXPRESSION REGULATION, BACTERIAL

Exopolysaccharide alginate synthesis in Pseudomonas aeruginosa: enzymology and regulation of gene expression. Shankar S, et al. **Adv Enzymol Relat Areas Mol Biol** 1995; 70:221-55 (84 ref.)

Molecular responses of microbes to environmental pH stress. Hall HK, et al. **Adv Microb Physiol** 1995;37:229-72 (240 ref.)

Leucine-responsive regulatory protein: a global regulator of gene expression in E. coli. Newman EB, et al. **Annu Rev Microbiol** 1995;49:747-75 (122 ref.)

Expression of correctly folded proteins in Escherichia coli. Georgiou G, et al. **Curr Opin Biotechnol** 1996 Apr; 7(2):190-7 (40 ref.)

Genetic analysis of exoenzyme S expression by Pseudomonas aeruginosa. Goranson J, et al. **FEMS Microbiol Lett** 1996 Jan 15;135(2-3):149-55 (39 ref.)

Expression of heat shock genes in Clostridium acetobutylicum. Bahl H, et al. **FEMS Microbiol Rev** 1995 Oct;17(3):341-8 (38 ref.)

The catabolite repressor/activator (Cra) protein of enteric bacteria. Saier MH Jr, et al. **J Bacteriol** 1996 Jun; 178(12):3411-7 (46 ref.)

Control of rRNA transcription in Escherichia coli. Condon C, et al. **Microbiol Rev** 1995 Dec;59(4):623-45 (369 ref.)

Nitrogen control in bacteria. Merrick MJ, et al. **Microbiol Rev** 1995 Dec;59(4):604-22 (275 ref.)

Regulation of insecticidal crystal protein production in Bacillus thuringiensis. Baum JA, et al. **Mol Microbiol** 1995 Oct;18(1):1-12 (50 ref.)

Heat-shock and general stress response in Bacillus subtilis. Hecker M, et al. **Mol Microbiol** 1996 Feb;19(3):417-28 (49 ref.)

The signal-transduction network for Pho regulation in Bacillus subtilis. Hulett FM. **Mol Microbiol** 1996 Mar; 19(5):933-9 (27 ref.)

Signal sensing by sigma 54-dependent regulators: derepression as a control mechanism. Shingler V. **Mol Microbiol** 1996 Feb;19(3):409-16 (51 ref.)

Transcriptional regulation of bioluminescence genes from Vibrio fischeri. Sitnikov DM, et al. **Mol Microbiol** 1995 Sep;17(5):801-12 (84 ref.)

Gene regulation of siderophore-mediated iron acquisition in Pseudomonas: not only the Fur repressor. Venturi V, et al. **Mol Microbiol** 1995 Aug;17(4):603-10 (40 ref.)

Experimental analysis of global gene regulation in Escherichia coli. Blumenthal RM, et al. **Prog Nucleic Acid Res Mol Biol** 1996;55:1-86 (304 ref.)

Growth-phase regulation of plasmid virulence genes in Salmonella. Guiney DG, et al. **Trends Microbiol** 1995 Jul; 3(7):275-9 (29 ref.)

Environmental modulation of gene expression and pathogenesis in Yersinia. Straley SC, et al. **Trends Microbiol** 1995 Aug;3(8):310-7 (56 ref.)

GENETICS

Hypothesis: chromosome separation in Escherichia coli involves autocatalytic gene expression, transertion and membrane-domain formation. Norris V. **Mol Microbiol** 1995 Jun;16(6):1051-7 (71 ref.)

PHYSIOLOGY

O2-sensing and O2-dependent gene regulation in facultatively anaerobic bacteria. Unden G, et al. **Arch Microbiol** 1995 Aug;164(2):81-90 (112 ref.)

Solventogenic enzymes of Clostridium acetobutylicum: catalytic properties, genetic organization, and transcriptional regulation. Dürre P, et al. **FEMS Microbiol Rev** 1995 Oct;17(3):251-62 (90 ref.)

Regulation of nitrogen metabolism, starch utilisation and the beta-hbd-adh1 gene cluster in Clostridium acetobutylicum. Woods DR, et al. **FEMS Microbiol Rev** 1995 Oct; 17(3):299-306 (29 ref.)

The significance of bacteria in stationary phase to food microbiology. Rees CE, et al. **Int J Food Microbiol** 1995 Dec;28(2):263-75 (74 ref.)

The role of anti-sigma factors in gene regulation. Brown KL, et al. **Mol Microbiol** 1995 May;16(3):397-404 (49 ref.)

GENE EXPRESSION REGULATION, DEVELOPMENTAL

An overview of epithelio-mesenchymal transformation. Hay ED. **Acta Anat (Basel)** 1995;154(1):8-20 (101 ref.)

Cell-cell adhesion molecules in epithelial-mesenchymal transformations. Prieto AL, et al. **Acta Anat (Basel)** 1995; 154(1):21-33 (176 ref.)

Molecular mechanisms of cell and tissue interactions during early tooth development. Thesleff I, et al. **Anat Rec** 1996 Jun;245(2):151-61 (68 ref.)

Developmental regulation of the human antibody repertoire. Schroeder HW Jr, et al. **Ann N Y Acad Sci** 1995 Sep 29; 764:242-60 (60 ref.)

The expressed heavy chain V gene repertoire of circulating B cells in normal adults. Stollar BD. **Ann N Y Acad Sci** 1995 Sep 29;764:265-74 (82 ref.)

Identification of genes specifically expressed at discrete stages of B-cell development. Zhang Y, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:25-6 (3 ref.)

Cosmic influences on the expression of a specific gene in the Colorado potato beetle: the diapause protein 1 gene. de Kort CA. **Arch Insect Biochem Physiol** 1996; 32(3-4):567-73 (15 ref.)

Transcriptional silencing of homeotic genes in Drosophila. Bienz M, et al. **Bioessays** 1995 Sep;17(9):775-84 (71 ref.)

MHox and vertebrate skeletogenesis: the long and the short of it. Brickell PM. **Bioessays** 1995 Sep;17(9):750-3 (31 ref.)

Lens development and crystallin gene expression: many roles for Pax-6. Cvekl A, et al. **Bioessays** 1996 Aug;18(8):621-30

(72 ref.)
Drosophila Sgs genes: stage and tissue specificity of hormone responsiveness. Lehmann M. **Bioessays** 1996 Jan; 18(1):47–54 (70 ref.)
How many signals does it take? Venkatesh TV, et al. **Bioessays** 1995 Sep;17(9):754–7 (31 ref.)
Regulation of cardiac gene expression during development. Robbins J. **Cardiovasc Res** 1996 Feb;31 Spec No:E2–16 (168 ref.)
Transcription and masking of mRNA in germ cells: involvement of Y-box proteins. Sommerville J, et al. **Chromosoma** 1996 Apr;104(7):469–78 (66 ref.)
The hepatocyte nuclear factor-3/forkhead transcription regulatory family in development, inflammation, and neoplasia. Hromas R, et al. **Crit Rev Oncol Hematol** 1995 Aug;20(1–2):129–40 (64 ref.)
Neural development. A 'LIM code' for motor neurons? Lumsden A. **Curr Biol** 1995 May 1;5(5):491–5 (26 ref.)
Developmental roles for chromatin and chromosomal structure. Patterton D, et al. **Dev Biol** 1996 Jan 10; 173(1):2–13 (140 ref.)
Epigenetic programming of differential gene expression in development and evolution. Monk M. **Dev Genet** 1995; 17(3):188–97 (58 ref.)
The genetic background of craniosynostosis syndromes. Heutink P, et al. **Eur J Hum Genet** 1995;3(5):312–23 (70 ref.)
Transcription factor families: muscling in on the myogenic program. Ludolph DC, et al. **FASEB J** 1995 Dec; 9(15):1595–604 (65 ref.)
Embryonic transcription and the control of developmental pathways. Wieschaus E. **Genetics** 1996 Jan;142(1):5–10 (53 ref.)
PAX genes: what's new in developmental biology and cancer? Stuart ET, et al. **Hum Mol Genet** 1995;4 Spec No:1717–20 (52 ref.)
Role of platelet-derived growth factors in mouse development. Betsholtz C. **Int J Dev Biol** 1995 Oct; 39(5):817–25 (76 ref.)
Sonic hedgehog: a common signal for ventral patterning along the rostrocaudal axis of the neural tube. Ericson J, et al. **Int J Dev Biol** 1995 Oct;39(5):809–16 (45 ref.)
Neurotrophins and their receptors in chicken neuronal development. Hallböök F, et al. **Int J Dev Biol** 1995 Oct; 39(5):855–68 (115 ref.)
DNA methylation and polyamines in embryonic development and cancer. Heby O. **Int J Dev Biol** 1995 Oct;39(5):737–57 (169 ref.)
Homeobox genes and male reproductive development. Lindsey S, et al. **J Assist Reprod Genet** 1996 Feb; 13(2):182–92 (49 ref.)
Autoinduction of nuclear receptor genes and its significance. Tata JR, et al. **J Steroid Biochem Mol Biol** 1993 Aug; 46(2):105–19 (54 ref.)
Genetic dissection of developmental pathways. Huang LS, et al. **Methods Cell Biol** 1995;48:97–122 (34 ref.)
Genetic mechanisms of early neurogenesis in Drosophila melanogaster. Campos-Ortega JA. **Mol Neurobiol** 1995 Apr–Jun;10(2–3):75–89 (97 ref.)
Retinoic acid and retinoic acid receptors in development. Sucov HM, et al. **Mol Neurobiol** 1995 Apr–Jun; 10(2–3):169–84 (113 ref.)
Genetic control of segmentation in the vertebrate hindbrain. Wilkinson DG. **Perspect Dev Neurobiol** 1995;3(1):29–38 (54 ref.)
Developmental control of N-CAM expression by Hox and Pax gene products. Edelman GM, et al. **Philos Trans R Soc Lond B Biol Sci** 1995 Sep 29; 349(1329):305–12 (33 ref.)
DNA sequence insertion and evolutionary variation in gene regulation. Britten RJ. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9374–7 (41 ref.)
Long-range repression in the Drosophila embryo. Cai HN, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9309–14 (29 ref.)
Chromatin structure and gene expression. Felsenfeld G, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9384–8 (19 ref.)
Genetic and molecular analysis of the gypsy chromatin insulator of Drosophila. Gdula DA, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9378–83 (43 ref.)
Modular cis-regulatory organization of developmentally expressed genes: two genes transcribed territorially in the sea urchin embryo, and additional examples. Kirchhamer CV, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3; 93(18):9322–8 (67 ref.)
Combinatorial control of muscle development by basic helix-loop-helix and MADS-box transcription factors. Molkentin JD, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9366–73 (108 ref.)
A dynamic assembly of diverse transcription factors integrates activation and cell-type information for interleukin 2 gene regulation. Rothenberg EV, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9358–65 (87 ref.)
An intrinsic genetic program for autonomous differentiation of muscle cells in the ascidian embryo. Satoh N, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9315–21 (48 ref.)
The genesis of avian neural crest cells: a classic embryonic induction. Selleck MA, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9352–7 (67 ref.)
Molecular pathways controlling heart development. Olson EN, et al. **Science** 1996 May 3;272(5262):671–6 (57 ref.)
Metamorphosis in Drosophila: from molecular biology to mutants. Bender M. **Trends Genet** 1995 Sep;11(9):335–6 (21 ref.)
Extracellular matrix and pattern in plant embryos: on the lookout for developmental information. Brownlee C, et al. **Trends Genet** 1995 Sep;11(9):344–8 (52 ref.)
[Genetics of sexual development and its disorders] Osipova GR. **Genetika** 1996 Feb;32(2):184–91 (84 ref.) (Eng. Abstr.) **(Rus)**

GENETICS

Gene expression in the intestine: the effect of dietary nucleotides. LeLeiko NS, et al. **Adv Pediatr** 1995;42:145–69 (65 ref.)
Mechanistic and developmental aspects of genetic imprinting in mammals. Latham KE, et al. **Int Rev Cytol** 1995; 160:53–98 (185 ref.)
Genes involved in testicular development and function. Lamb DJ. **World J Urol** 1995;13(5):277–84 (118 ref.)

IMMUNOLOGY

[Expression and role of complement regulatory proteins on human gametes and pre-implantation embryos] Fénichel P, et al. **Contracept Fertil Sex** 1995 Sep;23(9):576–80 (50 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Class I and class IV alcohol dehydrogenase (retinol dehydrogenase) gene expression in mouse embryos. Duester G, et al. **Adv Exp Med Biol** 1995;372:301–13 (42 ref.)
Mechanisms of gene expression and cell fate determination in the developing pulmonary epithelium. Hackett BP, et al. **Annu Rev Physiol** 1996;58:51–71 (90 ref.)
GTP-binding proteins and early embryogenesis in Xenopus. Paquereau L, et al. **Cell Signal** 1995 May;7(4):295–302 (71 ref.)
Early decisions in Drosophila eye morphogenesis. Bonini NM, et al. **Curr Opin Genet Dev** 1995 Aug;5(4):507–15 (73 ref.)
Chromatin complexes regulating gene expression in Drosophila. Pirrotta V. **Curr Opin Genet Dev** 1995 Aug; 5(4):466–72 (57 ref.)
Transgenic systems in studying myelin gene expression. Ikenaka K, et al. **Dev Neurosci** 1995;17(3):127–36 (76 ref.)
Ovine 11 beta-hydroxysteroid dehydrogenase: from gene to function. Yang K. **Endocr Res** 1995 Feb–May; 21(1–2):367–77 (49 ref.)
Materno-fetal immunobiology in normal pregnancy and its possible failure in recurrent spontaneous abortion? Vince GS, et al. **Hum Reprod** 1995 Dec;10 Suppl 2:107–13 (50 ref.)
An experimental system for analyzing response to a morphogen gradient. Gurdon JB, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9334–8 (24 ref.)
Gene expression of serotonergic neurons in the central nervous system: molecular and developmental analysis. Joh TH, et al. **Prog Brain Res** 1995;105:43–52 (31 ref.)
'Chauvinist genes' of male germ cells: gene expression during mouse spermatogenesis. Eddy EM. **Reprod Fertil Dev** 1995; 7(4):695–704 (80 ref.)
A model for understanding gene regulation during spermatogenesis: the mouse testis Pdha-2 promoter. Iannello RC, et al. **Reprod Fertil Dev** 1995;7(4):705–12 (51 ref.)
The molecular biology of SRY and its role in sex determination in mammals. Koopman P. **Reprod Fertil Dev** 1995;7(4):713–22 (63 ref.)
Hemoglobin switching and fetal hemoglobin reactivation. Cunningham JM, et al. **Semin Hematol** 1996 Jan;33(1):9–23 (142 ref.)
[Genetics of sexual development and its disorders] Osipova GR. **Genetika** 1996 Feb;32(2):184–91 (84 ref.) (Eng. Abstr.) **(Rus)**

GENE EXPRESSION REGULATION, EMBRYOLOGIC
see **GENE EXPRESSION REGULATION, DEVELOPMENTAL**

GENE EXPRESSION REGULATION, ENZYMOLOGIC

Regulation of mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase gene expression in liver and intestine from the rat. Hegardt FG. **Biochem Soc Trans** 1995 Aug;23(3):486–90 (23 ref.)
Adaptive evolution of lysozyme: changes in amino acid sequence, regulation of expression and gene number. Prager EM. **EXS** 1996;75:323–45 (75 ref.)
Lysozyme gene expression and regulation. Short ML, et al. **EXS** 1996;75:243–57 (52 ref.)
Activation of nitric oxide synthase gene for inhibition of cancer metastasis. Xie K, et al. **J Leukoc Biol** 1996 Jun; 59(6):797–803 (107 ref.)
Necessary but not sufficient: the role of glucocorticoids in the acidosis-induced increase in levels of mRNAs encoding proteins of the ATP-dependent proteolytic pathway in rat muscle. Price SR, et al. **Miner Electrolyte Metab** 1996; 22(1–3):72–5 (14 ref.)
Regulation of expression of cardiac sarcoplasmic reticulum proteins under pathophysiological conditions. Dillmann WH. **Mol Cell Biochem** 1996 Apr 12–26;157(1–2):125–8 (14 ref.)
Nitric oxide synthase: expression and expressional control of the three isoforms. Förstermann U, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Oct; 352(4):351–64 (166 ref.)
The gene for pyruvate, orthophosphate dikinase in C4 plants: structure, regulation and evolution. Matsuoka M. **Plant Cell Physiol** 1995 Sep;36(6):937–43 (55 ref.)
Evolution and expression of C4 photosynthesis genes. Ku MS, et al. **Plant Physiol** 1996 Aug;111(4):949–57 (48 ref.)
In vivo regulation of muscle glycogen synthase and the control of glycogen synthesis. Shulman RG, et al. **Proc Natl Acad Sci U S A** 1995 Sep 12;92(19):8535–42 (64 ref.)
Regulation of the hypoxanthine phosphoribosyltransferase gene: in vitro and in vivo approaches. Jiralerspong S, et al. **Proc Soc Exp Biol Med** 1996 Jun;212(2):116–27 (144 ref.)
The regulation of stearoyl-CoA desaturase (SCD). Ntambi JM. **Prog Lipid Res** 1995;34(2):139–50 (130 ref.)
Covalent control of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase: insights into autoregulation of a bifunctional enzyme. Kurland IJ, et al. **Protein Sci** 1995 Jun;4(6):1023–37 (70 ref.)
[Expression and purification of hepatitis C virus serine proteinase] Shoji I, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:30–5 (18 ref.) **(Jpn)**

DRUG EFFECTS

Induced gene transcription: implications for biomarkers. Sewall CH, et al. **Clin Chem** 1995 Dec;41(12 Pt 2):1829–34 (59 ref.)
Modulation of gene expression and endocrine response pathways by 2,3,7,8-tetrachlorodibenzo-p-dioxin and related compounds. Safe SH. **Pharmacol Ther** 1995; 67(2):247–81 (369 ref.)
Studies on glucocorticoid hormone actions in the regulation of human amnion PGHS. Zakar T, et al. **Reprod Fertil Dev** 1995;7(3):517–20 (12 ref.)

GENETICS

Nitric oxide synthases: gene structure and regulation. Wang Y, et al. **Adv Pharmacol** 1995;34:71–90 (99 ref.)
Specific factors leading to interindividual variability in response to occupational toxicants. Goergens HW. **Arch Toxicol Suppl** 1996;18:357–61 (28 ref.)
Mammalian deoxyribonucleoside kinases. Arnér ES, et al. **Pharmacol Ther** 1995;67(2):155–86 (241 ref.)
Engineering of human cholinesterases explains and predicts diverse consequences of administration of various drugs and poisons. Schwarz M, et al. **Pharmacol Ther** 1995; 67(2):283–322 (198 ref.)

PHYSIOLOGY

Class I and class IV alcohol dehydrogenase (retinol dehydrogenase) gene expression in mouse embryos. Duester G, et al. **Adv Exp Med Biol** 1995;372:301–13 (42 ref.)
Class 3 aldehyde dehydrogenase. A northern perspective in the land down under. Feimer J, et al. **Adv Exp Med Biol** 1995;372:137–41 (12 ref.)
Control and consequences of endothelial nitric oxide formation. Fleming I, et al. **Adv Pharmacol** 1995;34:187–206 (118 ref.)
Expression and expressional control of nitric oxide synthases in various cell types. Förstermann U, et al. **Adv Pharmacol** 1995;34:171–86 (102 ref.)
Regulation of the expression of the inducible isoform of nitric oxide synthase. Szabó C, et al. **Adv Pharmacol** 1995; 34:113–53 (265 ref.)
Regulation and function of inducible nitric oxide synthase during sepsis and acute inflammation. Wong JM, et al. **Adv Pharmacol** 1995;34:155–70 (68 ref.)
Ovine 11 beta-hydroxysteroid dehydrogenase: from gene to function. Yang K. **Endocr Res** 1995 Feb–May; 21(1–2):367–77 (49 ref.)
Regulation of gene expression by serine/threonine protein phosphatases. Schönthal AH. **Semin Cancer Biol** 1995 Aug; 6(4):239–48 (102 ref.)
Mutations affecting human lipoprotein lipase gene. Antikainen M, et al. **Z Gastroenterol** 1996 Jun;34 Suppl 3:59–61 (20 ref.)

GENE EXPRESSION REGULATION, FUNGAL

Silencing and heritable domains of gene expression. Loo S, et al. **Ann Rev Cell Dev Biol** 1995;11:519–48 (113 ref.)
Control of glycolytic gene expression in the budding yeast (Saccharomyces cerevisiae). Chambers A, et al. **Curr Genet** 1995 Dec;29(1):1–9 (100 ref.)
Molecular mechanisms of cell-type determination in budding

yeast. Johnson AD. **Curr Opin Genet Dev** 1995 Oct; 5(5):552–8 (52 ref.)
MIP: an epigenetic gene silencing process in Ascobolus immersus. Rossignol JL, et al. **Curr Top Microbiol Immunol** 1995;197:179–91 (32 ref.)
Genetic and epigenetic inactivation of repetitive sequences in Neurospora crassa: RIP, DNA methylation, and quelling. Singer MJ, et al. **Curr Top Microbiol Immunol** 1995; 197:165–77 (54 ref.)

GENETICS

The regulation of euchromatin and heterochromatin by histones in yeast. Grunstein M, et al. **J Cell Sci Suppl** 1995; 19:29–36 (65 ref.)

GENE EXPRESSION REGULATION, LEUKEMIC

DCC (deleted in colorectal cancer) inactivation in hematological malignancies. Porfiri E. **Leuk Lymphoma** 1995 Jun;18(1–2):69–72 (49 ref.)
The molecular biology of chronic myeloid leukaemia. Melo JV. **Leukemia** 1996 May;10(5):751–6 (58 ref.)

GENE EXPRESSION REGULATION, NEOPLASTIC

Expression and regulation of cyclin genes in breast cancer. Sutherland RL, et al. **Acta Oncol** 1995;34(5):651–6 (25 ref.)
Oncogenic role of "master" transcription factors in human leukemias and sarcomas: a developmental model. Look AT. **Adv Cancer Res** 1995;67:25–57 (162 ref.)
Alterations in DNA methylation may play a variety of roles in carcinogenesis. Counts JL, et al. **Cell** 1995 Oct 6; 83(1):13–5 (18 ref.)
The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Hayes JD, et al. **Crit Rev Biochem Mol Biol** 1995;30(6):445–600 (779 ref.)
Oncogenic activation of the ret protooncogene in thyroid cancer. Takahashi M. **Crit Rev Oncog** 1995;6(1):35–46 (96 ref.)
Alterations in gene expression and signal transductions in human melanocytes and melanoma cells. Yamanishi DT, et al. **Crit Rev Oncog** 1994;5(5):429–50 (143 ref.)
Von Hippel–Lindau tumor suppressor protein and transcription elongation: new insights into regulation of gene expression. Bertherat J. **Eur J Endocrinol** 1996 Feb; 134(2):157, 159 (2 ref.)
PAX genes: what's new in developmental biology and cancer? Stuart ET, et al. **Hum Mol Genet** 1995;4 Spec No:1717–20 (52 ref.)
Gene regulation by NF-M and Myb during differentiation and leukemic transformation. Kowenz-Leutz E, et al. **Immunobiology** 1995 Jul;193(2–4):356–62 (15 ref.)
Human tumor rejection antigens MAGE. Itoh K, et al. **J Biochem (Tokyo)** 1996 Mar;119(3):385–90 (33 ref.)
Progress against cancer. Broder S, et al. **J Cancer Res Clin Oncol** 1995;121(11):633–47 (134 ref.)
Stage-specific gene expression during hepatocarcinogenesis in the rat. Pitot HC. **J Cancer Res Clin Oncol** 1996; 122(5):257–65 (98 ref.)
Intrinsic expression of the multidrug transporter, P-glycoprotein 170, in multiple myeloma: implications for treatment. Pilarski LM, et al. **Leuk Lymphoma** 1995 May; 17(5–6):367–74 (70 ref.)
Oncogene activation and oncogene cooperation in MMTV-induced mouse mammary cancer. van Leeuwen F, et al. **Semin Cancer Biol** 1995 Jun;6(3):127–33 (91 ref.)
Characteristics of invasive bladder cancers: histological and molecular markers. Liebert M, et al. **Semin Urol Oncol** 1996 May;14(2):62–72 (136 ref.)
[Mechanisms for inactivation of tumor suppressor genes] Ishizaki K. **Nippon Rinsho** 1995 Nov;53(11):2660–5 (16 ref.) (Eng. Abstr.) **(Jpn)**
[Regulation of tumor marker gene expression] Sakai M, et al. **Nippon Rinsho** 1996 Jun;54(6):1560–7 (26 ref.) (Eng. Abstr.) **(Jpn)**

DRUG EFFECTS

P-glycoproteins and multidrug resistance. Bellamy WT. **Annu Rev Pharmacol Toxicol** 1996;36:161–83 (127 ref.)
Cisplatin. Dabholkar M, et al. **Cancer Chemother Biol Response Modif** 1996;16:88–110 (101 ref.)
Effect of antisense inhibition of Urokinase receptor on malignancy. Ossowski L. **Curr Top Microbiol Immunol** 1996;213 (Pt 3):101–12 (71 ref.)
Effects of sex hormones on oncogene expression in the vagina and on development of sexual dimorphism of the pelvis and anococcygeus muscle in the mouse. Iguchi T, et al. **Environ Health Perspect** 1995 Oct;103 Suppl 7:79–82 (34 ref.)
Gene expression and neuroblastoma cell differentiation in response to retinoic acid: differential effects of 9-cis and all-trans retinoic acid. Redfern CP, et al. **Eur J Cancer** 1995;31A(4):486–94 (73 ref.)
Effects of oltipraz and related chemoprevention compounds on gene expression in rat liver. Anderson L, et al. **J Cell Biochem Suppl** 1995;22:108–16 (20 ref.)
Modulation of gene expression and endocrine response pathways by 2,3,7,8-tetrachlorodibenzo-p-dioxin and related compounds. Safe SH. **Pharmacol Ther** 1995; 67(2):247–81 (369 ref.)
Hypomethylation of DNA: a possible epigenetic mechanism involved in tumor promotion. Counts JL, et al. **Prog Clin Biol Res** 1995;391:81–101 (112 ref.)
A transgenic mouse model (TG.AC) for skin carcinogenesis: inducible transgene expression as a second critical event. Hansen LA, et al. **Prog Clin Biol Res** 1995;391:223–35 (34 ref.)
Mechanistic considerations in risk assessment for epigenetic tumor-promoting carcinogens. Williams GM, et al. **Prog Clin Biol Res** 1995;391:369–83 (69 ref.)
Negative selection in hepatic tumor promotion in relation to cancer risk assessment. Andersen ME, et al. **Toxicology** 1995 Sep 1;102(1–2):223–37 (82 ref.)

GENETICS

Variability in gene expression and tumor formation within genetically homogeneous animal populations in bioassays. Wolff GL. **Fundam Appl Toxicol** 1996 Feb;29(2):176–84 (30 ref.)
The cyclin D1/PRAD1 oncogene in human neoplasia. Arnold A. **J Investig Med** 1995 Dec;43(6):543–9 (44 ref.)
[Biology of solid cancers: breast cancer as an example. Second part: gene disregulation in breast cancer] Bièche I, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996; 25(2):142–52 (65 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Multidrug resistance. Moscow JA, et al. **Cancer Chemother Biol Response Modif** 1996;16:111–31 (149 ref.)
Oestrogen- and anti-oestrogen-regulated genes in human breast cancer. Rochefort H. **Ciba Found Symp** 1995; 191:254–65; discussion 265–8 (40 ref.)
Parathyroid hormone-related protein gene expression and human T cell leukemia virus-1 infection. Ejima E, et al. **Miner Electrolyte Metab** 1995;21(1–3):143–7 (53 ref.)
[Antisense strategies in studies on the role of sugar chains in phenotype expression of neoplasms] Ugorski M. **Postepy Hig Med Dosw** 1995;49(1):77–84 (22 ref.) (Eng. Abstr.) **(Pol)**

GENE EXPRESSION REGULATION, PLANT

Co-suppression of beta-1,3-glucanase genes in Nicotiana tabacum. de Carvalho Niebel F, et al. **Curr Top Microbiol Immunol** 1995;197:91–103 (39 ref.)
Suppression of flavonoid flower pigmentation genes in Petunia hybrida by the introduction of antisense and sense genes. de Lange P, et al. **Curr Top Microbiol Immunol** 1995; 197:57–75 (88 ref.)
DNA methylation and activity of the maize Spm transposable element. Fedoroff NV. **Curr Top Microbiol Immunol** 1995; 197:143–64 (54 ref.)
Developmental regulation of co-suppression in Petunia hybrida. Flavell RB, et al. **Curr Top Microbiol Immunol** 1995;197:43–56 (63 ref.)
Sense and antisense inactivation of fruit ripening genes in tomato. Hamilton AJ, et al. **Curr Top Microbiol Immunol** 1995;197:77–89 (70 ref.)
trans-inactivation of homologous sequences in Nicotiana tabacum. Matzke AJ, et al. **Curr Top Microbiol Immunol** 1995;197:1–14 (30 ref.)
Gene silencing in transgenic plants: a heuristic autoregulation model. Meins F Jr, et al. **Curr Top Microbiol Immunol** 1995; 197:105–20 (55 ref.)
DNA methylation and transgene silencing in Petunia hybrida. Meyer P. **Curr Top Microbiol Immunol** 1995;197:15–28 (61 ref.)
Paramutation in maize and related allelic interactions. Patterson GI, et al. **Curr Top Microbiol Immunol** 1995; 197:121–41 (94 ref.)
Transgene inactivation in Arabidopsis thaliana. Scheid OM. **Curr Top Microbiol Immunol** 1995;197:29–42 (57 ref.)
The gene for pyruvate, orthophosphate dikinase in C4 plants: structure, regulation and evolution. Matsuoka M. **Plant Cell Physiol** 1995 Sep;36(6):937–43 (55 ref.)
Evolution and expression of C4 photosynthesis genes. Ku MS, et al. **Plant Physiol** 1996 Aug;111(4):949–57 (48 ref.)
Extracellular matrix and pattern in plant embryos: on the lookout for developmental information. Brownlee C, et al. **Trends Genet** 1995 Sep;11(9):344–8 (52 ref.)

DRUG EFFECTS

DNA elements responsive to auxin. Abel S, et al. **Bioessays** 1996 Aug;18(8):647–54 (62 ref.)

RADIATION EFFECTS

Gene expression in plant cell cultures under continuous blue light irradiation of high intensity. Kaldenhoff R. **J Photochem Photobiol B** 1995 Dec;31(3):97–100 (35 ref.)

GENE EXPRESSION REGULATION, VIRAL

Regulation of transcription of coronaviruses. van Marle G, et al. **Adv Exp Med Biol** 1995;380:507–10 (23 ref.)
Interactions of human immunodeficiency virus type 1 transactivator of transcription protein with signal transduction pathways. Garza HH Jr, et al. **Adv Neuroimmunol** 1995;5(3):321–5 (27 ref.)
Subversion of intracellular signal transduction by herpes simplex virus type 1. Halford WP, et al. **Adv Neuroimmunol** 1995;5(3):327–34 (46 ref.)
Internal transcriptional regulatory elements in HIV-1 and other retroviruses. Verdin E, et al. **Cell Mol Biol (Noisy-le-grand)** 1995 May;41(3):365–9 (26 ref.)
Nucleic acid vaccines. Vogel FR, et al. **Clin Microbiol Rev** 1995 Jul;8(3):406–10 (32 ref.)
Enhancing expression of recombinant proteins in mammalian cells using the herpesvirus VP16 transactivator. Hippenmeyer PJ, et al. **Curr Opin Biotechnol** 1995 Oct; 6(5):548–52 (15 ref.)
Regulation of viral and cellular gene expression by E1A proteins encoded by the oncogenic adenovirus type 12. Brockmann D, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 3):81–112 (221 ref.)
Post-transcriptional control of adenovirus gene expression. Imperiale MJ, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 2):139–71 (143 ref.)
Transcriptional modulation by the adenovirus E1A gene. Jones N. **Curr Top Microbiol Immunol** 1995;199 (Pt 3):59–80 (118 ref.)
Adenovirus E1A: transcription regulation and alteration of cell growth control. Nevins JR. **Curr Top Microbiol Immunol** 1995;199 (Pt 3):25–32 (39 ref.)
Regulation of adenovirus E2 transcription unit. Swaminathan S, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 3):177–94 (46 ref.)
Transcriptional regulation of the adenovirus E1A gene. Yoshida K, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 3):113–30 (107 ref.)
Modulation of gene expression by adenovirus transformation. Zantema A, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 3):1–23 (158 ref.)
Transcription antitermination: the lambda paradigm updated. Friedman DI, et al. **Mol Microbiol** 1995 Oct;18(2):191–200 (70 ref.)
Varicella-zoster virus gene regulation. Piette J, et al. **Neurology** 1995 Dec;45(12 Suppl 8):S23–7 (37 ref.)
Oncogene activation and oncogene cooperation in MMTV-induced mouse mammary cancer. van Leeuwen F, et al. **Semin Cancer Biol** 1995 Jun;6(3):127–33 (91 ref.)
Transcriptional regulation: lessons from the human neurotropic polyomavirus, JCV. Raj GV, et al. **Virology** 1995 Nov 10;213(2):283–91 (79 ref.)
[Expression of HCV genes using adenovirus vector with CAG promoter] Makimura M, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:91–4 (9 ref.) **(Jpn)**

DRUG EFFECTS

[Inhibition of HBx gene expression by antisense oligonucleotide] Moriya K, et al. **Nippon Rinsho** 1995 Oct; 53 Suppl:111–4 (9 ref.) **(Jpn)**

IMMUNOLOGY

Cytokine gene regulation by viral gene products. Geist LJ, et al. **J Lab Clin Med** 1995 Dec;126(6):517–20 (40 ref.)

PHYSIOLOGY

Parathyroid hormone-related protein gene expression and human T cell leukemia virus-1 infection. Ejima E, et al. **Miner Electrolyte Metab** 1995;21(1–3):143–7 (53 ref.)

GENE FREQUENCY

GENETICS

The frequency of genetic eye diseases in a genetic counseling center. Elçioğlu N, et al. **Genet Couns** 1995;6(4):329–42 (31 ref.)
Underexpression of the apolipoprotein E2 and E4 alleles in the Greek Cypriot population of Cyprus. Cariolou MA, et al. **Genet Epidemiol** 1995;12(5):489–97 (29 ref.)
[Role of genetic epidemiology in the study of infectious diseases. The example of malaria] Garcia A, et al. **Med Trop (Mars)** 1995;55(4 Suppl):14–8 (39 ref.) (Eng. Abstr.) **(Fre)**

GENE FUSION see **CLONING, MOLECULAR**

GENE LIBRARY

see related
DNA, RECOMBINANT

Construction and application of human chromosomal specific DNA probe pools. Li L. **Chin Med J (Engl)** 1996 Feb; 109(2):112–3 (4 ref.)
Selection of ligands for polyclonal antibodies from random peptide libraries: potential identification of (auto)antigens that may trigger B and T cell responses in autoimmune diseases. Sioud M, et al. **Clin Immunol Immunopathol** 1996 May;79(2):105–14 (65 ref.)
Ethics, genomics, and information retrieval. Goodman KW. **Comput Biol Med** 1996 May;26(3):223–9 (23 ref.)
High-density gridding: techniques and applications. Southern

EM. **Curr Opin Biotechnol** 1996 Feb;7(1):85–8 (21 ref.)
Chaperonins in phage display of antibody fragments. Söderlind E, et al. **Methods Mol Biol** 1995;51:343–53 (28 ref.)
Finding prospective partners in the library: the two-hybrid system and phage display find a match. Allen JB, et al. **Trends Biochem Sci** 1995 Dec;20(12):511–6 (50 ref.)

GENE MAPPING see **CHROMOSOME MAPPING**

GENE PROBES, DNA see **DNA PROBES**

GENE PROBES, RNA see **RNA PROBES**

GENE PRODUCTS see **PROTEINS**

GENE PRODUCTS, BACTERIAL see **BACTERIAL PROTEINS**

GENE PRODUCTS, ENV

IMMUNOLOGY

Retroviral vectors for HIV immunotherapy. Warner JF, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:105–16 (36 ref.)
Envelope glycoproteins of human immunodeficiency virus type 1: profound influences on immune functions. Chirmule N, et al. **Microbiol Rev** 1996 Jun;60(2):386–406 (435 ref.)

PHYSIOLOGY

The role of human immunodeficiency virus type 1 envelope glycoproteins in virus infection. Freed EO, et al. **J Biol Chem** 1995 Oct 13;270(41):23883–6 (153 ref.)

GENE PRODUCTS, FUNGAL see **FUNGAL PROTEINS**

GENE PRODUCTS, GAG

GENETICS

Ribozyme mimics as catalytic antisense reagents. Bashkin JK, et al. **Appl Biochem Biotechnol** 1995 Jul–Sep;54(1–3):43–56 (21 ref.)

METABOLISM

Cyclophilin and gag in HIV-1 replication and pathogenesis. Franke EK, et al. **Adv Exp Med Biol** 1995;374:217–28 (122 ref.)

PHYSIOLOGY

HIV-1 virology. Simply Marvelous nuclear transport. Goldfarb DS. **Curr Biol** 1995 Jun 1;5(6):570–3 (19 ref.)

GENE PRODUCTS, POL

see related
ENDONUCLEASES
PEPTIDE HYDROLASES
RNA-DIRECTED DNA POLYMERASE

GENE PRODUCTS, RAS see **RAS PROTEINS**

GENE PRODUCTS, REV

IMMUNOLOGY

Retroviral vectors for HIV immunotherapy. Warner JF, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:105–16 (36 ref.)

METABOLISM

[RNA ligands for HIV proteins] Iwai S. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1430–7 (64 ref.) **(Jpn)**

GENE PRODUCTS, TAT

IMMUNOLOGY

HIV-1 Tat protein as a potential AIDS vaccine. Goldstein G. **Nat Med** 1996 Sep;2(9):960–4 (34 ref.)

METABOLISM

[RNA ligands for HIV proteins] Iwai S. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1430–7 (64 ref.) **(Jpn)**

PHYSIOLOGY

Interactions of human immunodeficiency virus type 1 transactivator of transcription protein with signal transduction pathways. Garza HH Jr, et al. **Adv Neuroimmunol** 1995;5(3):321–5 (27 ref.)

GENE PRODUCTS, TAX

GENETICS

[Gene structure and transformation mechanism of HTLV-I] Matsumoto K. **Nippon Rinsho** 1995 Nov;53(11):2837–45 (21 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Molecular interactions between HTLV-1 Tax protein and the NF-kappa B/kappa B transcription complex. Hiscott J, et al. **Virology** 1995 Dec 1;214(1):3–11 (77 ref.)

PHYSIOLOGY

Activation of NF-kappa B by the Tax protein of HTLV-1. Munoz E, et al. **Immunobiology** 1995 Jul;193(2–4):128–36 (54 ref.)

GENE PRODUCTS, VIRAL see **VIRAL PROTEINS**

GENE PROTEINS see **PROTEINS**

GENE REARRANGEMENT

see related
ANTIBODY DIVERSITY
GENES, IMMUNOGLOBULIN
IMMUNOGLOBULIN VARIABLE REGION

Gene rearrangements in Ewing's sarcoma. Denny CT. **Cancer Invest** 1996;14(1):83–8 (47 ref.)
Immunoglobulin diversity: rearranging by cutting and repairing. Lieber M. **Curr Biol** 1996 Feb 1;6(2):134–6 (30 ref.)
HRX gene rearrangement in secondary acute lymphoblastic leukemia. Kobayashi Y, et al. **Leuk Lymphoma** 1995 May; 17(5–6):391–9 (71 ref.)
11q23 rearrangements in acute leukemia. Rubnitz JE, et al. **Leukemia** 1996 Jan;10(1):74–82 (75 ref.)
Genetic balancers. Edgley ML, et al. **Methods Cell Biol** 1995; 48:147–84 (62 ref.)
Clinical applications of genetic rearrangements in cancer. Sheer D, et al. **Semin Cancer Biol** 1996 Feb;7(1):25–32 (34 ref.)
DNA double-strand break repair and V(D)J recombination: involvement of DNA-PK. Jackson SP, et al. **Trends Biochem Sci** 1995 Oct;20(10):412–5 (41 ref.)
[Lymphoproliferative disorders in patients with Sjögren's syndrome--Vg gene rearrangement and expression of bcl-2 protein] Sugai S, et al. **Nippon Rinsho** 1995 Oct; 53(10):2580–6 (15 ref.) (Eng. Abstr.) **(Jpn)**
[Analysis of regulatory mechanism for humoral immunity using transgenic mice of rearranged immunoglobulin genes] Shimizu A. **Tanpakushitsu Kakusan Koso** 1995 Oct; 40(14):2107–17 (21 ref.) **(Jpn)**

GENETICS

Molecular genetics of the glycophorin gene family, the antigens for MNSs blood groups: multiple gene rearrangements and modulation of splice site usage result in extensive diversification. Blumenfeld OO, et al. **Hum Mutat** 1995;6(3):199–209 (52 ref.)

IMMUNOLOGY

Potential targets for autosomal SCID mutations. Taccioli GE, et al. **Curr Opin Immunol** 1995 Aug;7(4):436–40 (50 ref.)

GENE REARRANGEMENT, DELTA-CHAIN T-CELL ANTIGEN RECEPTOR

TCR delta gene rearrangements in acute myeloid leukemia with T-lymphoid antigen expression. Schmidt CA, et al. **Leuk Lymphoma** 1995 Dec;20(1–2):45–9 (57 ref.)

GENE REARRANGEMENT, B-LYMPHOCYTE

In vivo switching: identification of germline transcripts for human IgA. Smith CI, et al. **Adv Exp Med Biol** 1995; 371A:9–13 (15 ref.)
Human B-cell development. Billips LG, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:1–8 (31 ref.)
Developmental regulation of the human antibody repertoire. Schroeder HW Jr, et al. **Ann N Y Acad Sci** 1995 Sep 29; 764:242–60 (60 ref.)
Development of the immunoglobulin repertoire. Fanning LJ, et al. **Clin Immunol Immunopathol** 1996 Apr;79(1):1–14 (129 ref.)
Analysis of immunoglobulin gene rearrangements in single B cells. Ehlich A, et al. **Curr Opin Immunol** 1995 Apr; 7(2):281–4 (18 ref.)
B-cell superantigens: implications for selection of the human antibody repertoire. Zouali M. **Immunol Today** 1995 Aug; 16(8):399–405 (73 ref.)

GENETICS

Cutting apart V(D)J recombination. Oettinger MA. **Curr Opin Genet Dev** 1996 Apr;6(2):141–5 (43 ref.)
New insights into V(D)J recombination and its role in the evolution of the immune system. Thompson CB. **Immunity** 1995 Nov;3(5):531–9 (104 ref.)

PHYSIOLOGY

Somatic hypermutation: how many mechanisms diversify V region sequences? Maizels N. **Cell** 1995 Oct 6;83(1):9–12 (26 ref.)

GENE REARRANGEMENT, B-LYMPHOCYTE, HEAVY CHAIN

Development of the antibody repertoire in rabbits. Knight KL, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:198–206 (23 ref.)
The expressed heavy chain V gene repertoire of circulating B cells in normal adults. Stollar BD. **Ann N Y Acad Sci** 1995 Sep 29;764:265–74 (82 ref.)
Molecular analysis of VH regions expressed in the adult B-cell repertoire. van der Stoep N, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:275–84 (19 ref.)
Multiple myeloma: new evidence and insights from the immunoglobulin heavy chain gene and phenotypes. Takishita M, et al. **Leuk Lymphoma** 1995 Nov; 19(5–6):395–400 (36 ref.)

PHYSIOLOGY

[Repertoire of rearranged immunoglobulin genes of human peripheral lymphocytes] Kraj P. **Postepy Hig Med Dosw** 1995;49(1):9–22 (79 ref.) (Eng. Abstr.) **(Pol)**

GENE REARRANGEMENT, B-LYMPHOCYTE, LIGHT CHAIN

Regulation of human lambda light chain gene expression. Blomberg BB, et al. **Ann N Y Acad Sci** 1995 Sep 29; 764:84–98 (58 ref.)

GENE REARRANGEMENT, T-LYMPHOCYTE

Immunoglobulin gene rearrangement in T-cell-rich reactive pleural effusion of a patient with B-cell chronic lymphocytic leukemia. Miyahara M, et al. **Acta Haematol** 1996;96(1):41–4 (24 ref.)

GENETICS

Cutting apart V(D)J recombination. Oettinger MA. **Curr Opin Genet Dev** 1996 Apr;6(2):141–5 (43 ref.)
New insights into V(D)J recombination and its role in the evolution of the immune system. Thompson CB. **Immunity** 1995 Nov;3(5):531–9 (104 ref.)

IMMUNOLOGY

Lymphocyte development and function in T-cell receptor and RAG-1 mutant mice. Mombaerts P. **Int Rev Immunol** 1995;13(1):43–63 (23 ref.)
B-cell lymphoproliferative disorder complicated by a natural killer cell lymphoproliferative disorder of granular lymphocytes associated with T-cell gene rearrangement: case report and review of the literature. Dunphy CH, et al. **Mod Pathol** 1995 Oct;8(8):803–10 (30 ref.)

PHYSIOLOGY

DNA-dependent protein kinase defects are linked to deficiencies in DNA repair and V(D)J recombination. Finnie NJ, et al. **Philos Trans R Soc Lond B Biol Sci** 1996 Feb 29;351(1336):173–9 (50 ref.)

GENE REARRANGEMENT, T-CELL ANTIGEN RECEPTOR see **GENE REARRANGEMENT, T-LYMPHOCYTE**

GENE TARGETING

Gene-targeting and transgenic approaches to IGF and IGF binding protein function. Wood TL. **Am J Physiol** 1995 Oct;269(4 Pt 1):E613–22 (101 ref.)
Pathology of the thymus: changes induced by xenobiotics and gene targeting. Schuurman HJ, et al. **APMIS** 1995 Jul–Aug;103(7–8):481–500 (110 ref.)
Targeting the mouse genome: a compendium of knockouts (Part II). Brandon EP, et al. **Curr Biol** 1995 Jul 1; 5(7):758–65 (189 ref.)
Transgenetics and gene targeting in studies of prion diseases. Scott MR, et al. **Curr Top Microbiol Immunol** 1996; 207:95–123 (134 ref.)
Conditional gene targeting. Rajewsky K, et al. **J Clin Invest** 1996 Aug 1;98(3):600–3 (30 ref.)
Gaining insights into the ontogeny and activation of T cells through the use of gene-targeted mutant mice. Mak TW. **J Inflamm** 1995;45(2):79–84 (22 ref.)
Molecular conjugates: a targeted gene delivery vector for molecular medicine. Cristiano RJ, et al. **J Mol Med** 1995 Oct;73(10):479–86 (45 ref.)
Transgenic targeting of neuroendocrine peptide genes in the hypothalamic-pituitary axis. Waschek JA. **Mol Neurobiol** 1995 Apr–Jun;10(2–3):205–17 (50 ref.)
[Preparation and application of knock-out mice] Noguchi S. **Nippon Rinsho** 1995 Aug;53(8):2079–85 (22 ref.) (Eng. Abstr.) **(Jpn)**
[Overview: application of gene targeting technologies and its problems] Ikawa Y. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2631–4 (3 ref.) **(Jpn)**
[Mouse model for familial adenomatous polyposis coli and APC gene] Ito M, et al. **Tanpakushitsu Kakusan Koso** 1995

GENE TARGETING

Oct;40(14):2035–44 (22 ref.) **(Jpn)**

[Gene targeting: mechanism and efficiency] Kobayashi I. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2645–53 (25 ref.) **(Jpn)**

[Targeted ablation of transcription factor genes] Kondoh H. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2126–33 (30 ref.) **(Jpn)**

[Mice with targeted DNA repair genes] Tanaka K. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2214–22 (10 ref.) **(Jpn)**

[Molecular mechanism of learning and memory with genetics] Yagi T. **Tanpakushitsu Kakusan Koso** 1995 Oct; 40(14):2175–80 (31 ref.) **(Jpn)**

METHODS

Transgenic insertional mutagenesis. Applications to inner-ear genetics. Friedman RA.
Arch Otolaryngol Head Neck Surg 1996 Mar;122(3):252–7 (55 ref.)

Gene targeting and its application to basic hypertension research [editorial] Clark AF, et al. **Clin Sci (Colch)** 1996 Jun;90(6):435–46 (71 ref.)

Strategies to achieve targeted gene delivery via the receptor-mediated endocytosis pathway. Michael SI, et al. **Gene Ther** 1994 Jul;1(4):223–32 (49 ref.)

Gene modification via "plug and socket" gene targeting. Lewis J, et al. **J Clin Invest** 1996 Jan 1;97(1):3–5 (7 ref.)

Facilitating oligonucleotide delivery: helping antisense deliver on its promise. Gewirtz AM, et al.
Proc Natl Acad Sci U S A 1996 Apr 16;93(8):3161–3 (33 ref.)

[Homologous recombination for gene targeting] Aizawa S. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2013–6 (3 ref.) **(Jpn)**

GENE THERAPY

Gene therapy for ornithine transcarbamylase deficiency. Kiwaki K, et al. **Acta Paediatr Jpn** 1996 Apr;38(2):189–92 (31 ref.)

Gene therapy for skin diseases. Vogel JC, et al.
Adv Dermatol 1996;11:383–98; discussion 399 (38 ref.)

Vascular gene therapy. Flugelman MY.
Adv Exp Med Biol 1995;382:269–77 (25 ref.)

Gene therapy for HIV-1 infection. Kohn DB, et al.
Adv Exp Med Biol 1996;394:421–8 (23 ref.)

Alternative approaches for the application of ribozymes as gene therapies for retroviral infections. Campbell TB, et al. **Adv Pharmacol** 1995;33:143–78 (146 ref.)

Genetic therapies for HIV infections: promise for the future [editorial] Pomerantz RJ, et al. **AIDS** 1995 Sep;9(9):985–93 (64 ref.)

Gene therapy and HIV disease. Poeschla EM, et al.
AIDS Clin Rev 1995–96;:1–45 (255 ref.)

Recent advances in the application of gene therapy to human disease. Hanania EG, et al. **Am J Med** 1995 Nov; 99(5):537–52 (73 ref.)

Gene therapy approaches for inherited and acquired lung diseases. Curiel DT, et al. **Am J Respir Cell Mol Biol** 1996 Jan;14(1):1–18 (211 ref.)

Immunotherapy of human cancers. Hui KM, et al.
Ann Acad Med Singapore 1996 Jan;25(1):113–9 (19 ref.)

The multidrug-resistance gene in gene therapy of cancer and hematopoietic disorders. Licht T, et al. **Ann Hematol** 1996 Apr;72(4):184–93 (118 ref.)

Adenovirus and adeno-associated virus as vectors for gene therapy. Berns KI, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:95–104 (48 ref.)

Strategies for efficient gene transfer into hematopoietic cells. The use of adeno-associated virus vectors in gene therapy. Chatterjee S, et al. **Ann N Y Acad Sci** 1995 Dec 29; 770:79–90 (40 ref.)

Improved cationic lipid formulations for in vivo gene therapy. Felgner PL, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:126–39 (51 ref.)

Retroviral vectors for HIV immunotherapy. Warner JF, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:105–16 (36 ref.)

Gene therapy for lung cancer. Lee CT, et al. **Ann Oncol** 1995;6 Suppl 3:S61–3 (16 ref.)

Gene therapy for lung cancer. Woll PJ, et al. **Ann Oncol** 1995;6 Suppl 1:73–7 (35 ref.)

Immunologic consequences of nucleic acid therapy. Pisetsky DS. **Antisense Res Dev** 1995 Fall;5(3):219–25 (53 ref.)

Human gene therapy [editorial] Wicks I.
Aust N Z J Med 1995 Aug;25(4):280–3 (23 ref.)

Gene therapy for cystic fibrosis: current issues. Southern KW. **Br J Hosp Med** 1996 Apr 17–30;55(8):495–9 (19 ref.)

The twitcher mouse: a model for Krabbe disease and for experimental therapies. Suzuki K, et al. **Brain Pathol** 1995 Jul;5(3):249–58 (63 ref.)

Germ-line therapy to cure mitochondrial disease: protocol and ethics of in vitro ovum nuclear transplantation. Rubenstein DS, et al. **Camb Q Healthc Ethics** 1995 Summer; 4(3):316–39 (101 ref.)

Gene therapy of cancer. Mullen CA, et al.
Cancer Chemother Biol Response Modif 1996;16:285–94 (74 ref.)

Vectors in cancer therapy: how will they deliver? Blaese M, et al. **Cancer Gene Ther** 1995 Dec;2(4):291–7 (33 ref.)

Application of ribozymes to cancer gene therapy. Kashani-Sabet M, et al. **Cancer Gene Ther** 1995 Sep; 2(3):213–23 (102 ref.)

Tumor cells engineered to produce cytokines or cofactors as cellular vaccines: do animal studies really support clinical trials? Colombo MP, et al. **Cancer Immunol Immunother** 1995 Nov;41(5):265–70 (66 ref.)

The potential applications of gene transfer in the treatment of patients with cancer: a concise review. Hussein AM. **Cancer Invest** 1996;14(4):343–52 (150 ref.)

Gene therapy for cystic fibrosis. Rosenfeld MA, et al.
Chest 1996 Jan;109(1):241–52 (103 ref.)

Gene therapy of familial hypercholesterolemia. Cai H.
Chin Med J (Engl) 1996 Feb;109(2):104–6 (9 ref.)

Applications of bio-techniques on treatment of cardiovascular diseases. Tang J, et al.
Chin Med J (Engl) 1996 Feb;109(2):108–10 (0 ref.)

Gene therapy for plastic and reconstructive surgery. Shenaq SM, et al. **Clin Plast Surg** 1996 Jan;23(1):157–71 (119 ref.)

Novel strategy of gene therapy in cardiovascular disease with HVJ-liposome method. Morishita R, et al.
Contrib Nephrol 1996;118:254–64 (26 ref.)

Curing metastases? Gene and peptide therapy. Eisenbach L.
Curr Top Microbiol Immunol 1996;213 (Pt 3):85–100 (150 ref.)

Gene therapy using adenovirus vectors. Haddada H, et al.
Curr Top Microbiol Immunol 1995;199 (Pt 3):297–306 (35 ref.)

Transcriptionally targeted gene therapy. Hart IR.
Curr Top Microbiol Immunol 1996;213 (Pt 3):19–25 (28 ref.)

Gene therapy. Clinical potential and relationship to drug treatment. Whartenby KA, et al. **Drugs** 1995 Dec; 50(6):951–8 (91 ref.)

Gene therapy for cardiovascular diseases. Bauters C.
Eur Heart J 1995 Sep;16(9):1166–8 (17 ref.)

The use of DNA viruses as vectors for gene therapy. Ali M, et al. **Gene Ther** 1994 Nov;1(6):367–84 (179 ref.)

Gene therapy for cystic fibrosis in humans by liposome-mediated DNA transfer: the production of resources and the regulatory process. Caplen NJ, et al.
Gene Ther 1994 Mar;1(2):139–47 (21 ref.)

The role of IL-2 in gene therapy. Dalgleish AG.
Gene Ther 1994 Mar;1(2):83–7 (51 ref.)

Genetic delivery of enzymes for cancer therapy. Deonarain MP, et al. **Gene Ther** 1995 Jun;2(4):235–44 (76 ref.)

Skeletal muscle as a target for gene therapy [editorial] Partridge T. **Gene Ther** 1994 Mar;1(2):77–9 (31 ref.)

Genetic approaches to cancer therapy [editorial] Sikora K.
Gene Ther 1994 May;1(3):149–51 (15 ref.)

Gene delivery systems for use in gene therapy: an overview of quality assurance and safety issues. Smith KT, et al.
Gene Ther 1996 Mar;3(3):190–200 (52 ref.)

Liver-directed gene therapy: prospects and problems. Strauss M. **Gene Ther** 1994 May;1(3):156–64 (66 ref.)

Progress towards gene therapy for HIV infection. Yu M, et al. **Gene Ther** 1994 Jan;1(1):13–26 (159 ref.)

Gene therapy for head and neck cancer. Clayman GL.
Head Neck 1995 Nov-Dec;17(6):535–41 (39 ref.)

Steps toward gene therapy: 2. Cancer and AIDS. Blaese RM.
Hosp Pract (Off Ed) 1995 Dec 15;30(12):37–45 (6 ref.)

The impact of gene therapy on T cell function in cancer. Zier KS, et al. **Hum Gene Ther** 1995 Oct;6(10):1259–64 (45 ref.)

Preventing abnormalities in signal transduction of T cells in cancer: the promise of cytokine gene therapy. Zier K, et al. **Immunol Today** 1996 Jan;17(1):39–45 (62 ref.)

Gene replacement strategies for cancer. Roth JA.
Isr J Med Sci 1996 Feb;32(2):89–94 (12 ref.)

Porphyrias: animal models and prospects for cellular and gene therapy. de Verneuil H, et al.
J Bioenerg Biomembr 1995 Apr;27(2):239–48 (55 ref.)

Getting human gene therapy to work. Stewart FM.
J Cell Biochem 1995 Aug;58(4):416–23 (77 ref.)

Targeted mutagenesis: analysis of phenotype without germ line transmission. Nagy A, et al. **J Clin Invest** 1996 Mar 15;97(6):1360–5 (38 ref.)

CD34+ progenitor cell selection: clinical transplantation, tumor cell purging, gene therapy, ex vivo expansion, and cord blood processing. Colter M, et al. **J Hematother** 1996 Apr;5(2):179–84 (22 ref.)

Bone marrow and clinical gene therapy. Schmidt-Wolf GD, et al. **J Hematother** 1995 Dec;4(6):551–61 (90 ref.)

Liver-directed gene therapy: molecular tools and current preclinical and clinical studies. Alt M, et al. **J Hepatol** 1995 Dec;23(6):746–58 (96 ref.)

Gene therapy for cystic fibrosis. Alton EW.
J Inherit Metab Dis 1995;18(4):501–7 (17 ref.)

Designing trials for gene therapy. Geddes D.
J Inherit Metab Dis 1995;18(4):517–24 (7 ref.)

Framework for the selection of subjects in human gene therapy and diagnostic trials. Modell SM.
J Investig Med 1996 Jun;44(5):228–37 (59 ref.)

IL-2 gene therapy of solid tumors: an approach for the prevention of signal transduction defects in T cells. Zier KS, et al. **J Mol Med** 1996 Mar;74(3):127–34 (78 ref.)

Gene therapy in the central nervous system: direct versus indirect gene delivery. Ridet JL, et al. **J Neurosci Res** 1995 Oct 15;42(3):287–93 (64 ref.)

Perspectives on investigational chemotherapy and biologic therapy for childhood brain tumors. Kadota RP.
J Pediatr Hematol Oncol 1996 Feb;18(1):13–22 (110 ref.)

Towards gene therapy for cystic fibrosis. Alton EW.
J Pharm Pharmacol 1995 May;47(5):351–4 (18 ref.)

Post-natal somatic cell gene therapy. Culver KW.
J Postgrad Med 1994 Jan-Mar;40(1):23–30 (27 ref.)

Grafting of genetically manipulated cells into adult brain: toward graft-gene therapy. Uchida K, et al.
Keio J Med 1996 Jun;45(2):81–9 (40 ref.)

Gene therapy against retroviral diseases. Essex M, et al.
Leukemia 1995 Oct;9 Suppl 1:S71–4 (13 ref.)

P53 and induction of apoptosis as a target for anticancer therapy. Neubauer A, et al. **Leukemia** 1996 Jul;10 Suppl 3:S2–S4 (46 ref.)

Can virus therapy of human cancer be improved by apoptosis induction? [published erratum appears in Med Hypotheses 1995 Sep;45(3):316] Sinkovics JG, et al.
Med Hypotheses 1995 May;44(5):359–68 (72 ref.)

Somatic gene therapy of human melanoma: preclinical studies and early clinical trials. Parmiani G, et al.
Melanoma Res 1995 Oct;5(5):295–301 (59 ref.)

Delivery of DNA into mammalian cells by receptor-mediated endocytosis and gene therapy. Guy J, et al. **Mol Biotechnol** 1995 Jun;3(3):237–48 (60 ref.)

Measuring success in clinical gene therapy research. Culver KW. **Mol Med Today** 1996 Jun;2(6):234–6 (11 ref.)

Maintaining the neuronal phenotype after injury in the adult CNS. Neurotrophic factors, axonal growth substrates, and gene therapy. Tuszynski MH, et al. **Mol Neurobiol** 1995 Apr-Jun;10(2-3):151–67 (107 ref.)

Gene therapy—a novel form of drug delivery. Blau HM, et al. **N Engl J Med** 1995 Nov 2;333(18):1204–7 (0 ref.)

Adenoviruses as gene-delivery vehicles. Wilson JM.
N Engl J Med 1996 May 2;334(18):1185–7 (0 ref.)

The challenge of fetal gene therapy. Coutelle C, et al.
Nat Med 1995 Sep;1(9):864–6 (14 ref.)

New pharmaceutical approaches to the treatment of cystic fibrosis [comment] Delaney SJ, et al. **Nat Med** 1996 Apr; 2(4):392–3 (14 ref.) Comment on: Nat Med 1996 Apr;2(4):467–9.

Gene therapy. Kumar VL, et al. **Natl Med J India** 1995 Nov-Dec;8(6):263–8 (44 ref.)

Gene therapy for cancer (present status). Altaner C.
Neoplasma 1995;42(5):209–13 (43 ref.)

DNA-mediated gene transfer into mammalian cells and cancer. Sláviková K, et al. **Neoplasma** 1995;42(6):293–7 (33 ref.)

Advances in the enzymology and molecular genetics of primary hyperoxaluria type 1. Prospects for gene therapy. Danpure CJ. **Nephrol Dial Transplant** 1995;10 Suppl 8:24–9 (29 ref.)

Novel biologic therapies for malignant gliomas. Antiangiogenesis, immunotherapy, and gene therapy. Fine HA. **Neurol Clin** 1995 Nov;13(4):827–46 (128 ref.)

Gene therapy in acute critical illness. Brigham KL, et al.
New Horiz 1995 May;3(2):321–9 (34 ref.)

Cystic fibrosis. Gastrointestinal complications and gene therapy. Shalon LB, et al. **Pediatr Clin North Am** 1996 Feb;43(1):157–96 (147 ref.)

Therapeutic applications of ribozymes. Kijima H, et al.
Pharmacol Ther 1995;68(2):247–67 (200 ref.)

Prenatal gene therapy: prospects and issues [see comments] Pergament ☐, et al. **Prenat Diagn** 1995 Dec;15(13):1303–11 (63 ref.) Comment in: Prenat Diagn 1995 Dec;15(13):1209–13.

New molecular targets for cancer therapy. Oliff A, et al.
Sci Am 1996 Sep;275(3):144–9 (0 ref.)

Transfer of genes to humans: early lessons and obstacles to success. Crystal RG. **Science** 1995 Oct 20;270(5235):404–10 (69 ref.)

Towards gene therapy of hemoglobinopathies. Beuzard Y.
Semin Hematol 1996 Jan;33(1):43–52 (61 ref.)

Prospects of therapy of liver diseases with foreign genes. Kormis KK, et al. **Semin Liver Dis** 1995 Aug;15(3):257–67 (184 ref.)

Gene therapy for human cancer: an essay for clinicians. Mastrangelo MJ, et al. **Semin Oncol** 1996 Feb;23(1):4–21 (104 ref.)

Blood stem cell transplantation and gene therapy of cancer. Körbling M. **Stem Cells** 1995 Dec;13 Suppl 3:106–13 (55 ref.)

The contribution of marker gene studies to hemopoietic stem cell therapies. Brenner MK. **Stem Cells (Dayt)** 1995 Sep; 13(5):453–61 (44 ref.)

Basic principles associated with gene therapy of cancer. Geraghty PJ, et al. **Surg Oncol** 1995 Jun;4(3):125–37 (90 ref.)

State and prospects of gene therapy for the hemophilias. Fallaux FJ, et al. **Thromb Haemost** 1995 Jul;74(1):266–73 (64 ref.)

Inhibition of intravascular thrombosis and vascular smooth muscle cell proliferation by gene therapy. Flugelman MY.
Thromb Haemost 1995 Jul;74(1):406–10 (35 ref.)

Biosynthesis of factor IX: implications for gene therapy. Furie BC, et al. **Thromb Haemost** 1995 Jul;74(1):274–7 (60 ref.)

Progress towards gene therapy for the hemophilias. Thompson AR. **Thromb Haemost** 1995 Jul;74(1):45–51 (58 ref.)

Gene therapy on renal-cell carcinoma: magic bullet or tragic insanity? Mickisch GH. **World J Urol** 1995;13(3):178–85 (37 ref.)

Apolipoprotein B mRNA editing protein: a tool for dissecting lipoprotein metabolism and a potential therapeutic gene for hypercholesterolemia. Chan L, et al.
Z Gastroenterol 1996 Jun;34 Suppl 3:31–2 (16 ref.)

Reconstitution of apoB mRNA editing in liver by

gene-transfer as a potential approach for the treatment of severe forms of polygenic hypercholesterolemia--an outline of the rationale. Greeve J, et al. **Z Gastroenterol** 1996 Jun;34 Suppl 3:27–30 (70 ref.)

[Progresses in medical genetics in China, 1995] Wu M, et al. **Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):780 (0 ref.) **(Chi)**

[Gene therapy of adrenoleukodystrophy] Cartier N, et al. **Arch Pediatr** 1996;3 Suppl 1:77s–81s (18 ref.) **(Fre)**

[Gene therapy of mucoviscidosis with liposomes] Lehn P, et al. **Arch Pediatr** 1996;3 Suppl 1:88s–92s (20 ref.) **(Fre)**

[Vectors of gene transfer. Applications in pneumology] Demoly P, et al. **Rev Mal Respir** 1996 Jul;13(3):251–7 (43 ref.) (Eng. Abstr.) **(Fre)**

[Gene therapy: technics, strategy and application (see comments)] Hallez S. **Rev Mal Respir** 1995;12(6):567–83 (105 ref.) (Eng. Abstr.) Comment in: Rev Mal Respir 1995;12(6):515–6. **(Fre)**

[Gene therapy in mucoviscidosis] Schatz C, et al. **Rev Pneumol Clin** 1995;51(3):201–6 (33 ref.) (Eng. Abstr.) **(Fre)**

[Somatic gene therapy. Initial clinical applications and current research approach (see comments)] Runge DM, et al. **Fortschr Med** 1995 Aug 30;113(24):337–40 (20 ref.) (Eng. Abstr.) Comment in: Fortschr Med 1995 Aug 30;113(24):341. **(Ger)**

[Ethical evaluation of somatic gene therapy] Honnefelder L. **Internist (Berl)** 1996 Apr;37(4):382–6 (6 ref.) **(Ger)**

[First steps in clinical gene therapy] Körbling M. **Med Klin** 1996 Apr 10;91(4):218–25 (46 ref.) **(Ger)**

[Molecular medicine and gene therapy as exemplified with arteriosclerosis and restenosis] Lüscher TF, et al. **Schweiz Med Wochenschr** 1995 Nov 4;125(44):2107–21 (112 ref.) (Eng. Abstr.) **(Ger)**

[Experimental approaches for gene therapy modification of vascular remodeling] von der Leyen HE, et al. **Z Kardiol** 1995 Oct;84(10):791–7 (62 ref.) (Eng. Abstr.) **(Ger)**

[Safer trials of vaccine and gene therapy against HIV] Ikuta K. **Hokkaido Igaku Zasshi** 1996 Jan;71(1):21–6 (31 ref.) (Eng. Abstr.) **(Jpn)**

[Gene therapy for cancer] Sakamaki S, et al. **Hokkaido Igaku Zasshi** 1996 Jan;71(1):15–20 (8 ref.) (Eng. Abstr.) **(Jpn)**

[Gene therapy for adenosine deaminase deficiency] Sakiyama Y. **Hokkaido Igaku Zasshi** 1996 Jan;71(1):27–32 (9 ref.) (Eng. Abstr.) **(Jpn)**

[Present status of gene therapy in cancer] Yoshida T. **Nippon Naika Gakkai Zasshi** 1996 Mar 10;85(3):351–5 (6 ref.) **(Jpn)**

[Gene therapy for Gaucher disease] Ohashi T. **Nippon Rinsho** 1995 Dec;53(12):3089–94 (13 ref.) (Eng. Abstr.) **(Jpn)**

[Gene therapy of glioma using cytokine] Ikeda H, et al. **No To Shinkei** 1995 Sep;47(9):835–43 (47 ref.) **(Jpn)**

[Therapy of malignant brain tumors by using apoptosis] Kuchino Y. **No To Shinkei** 1995 Sep;47(9):829–34 (34 ref.) **(Jpn)**

[Human gene therapy] Shimada T. **Ryumachi** 1996 Feb;36(1):62–8 (10 ref.) **(Jpn)**

[An experimental model for gene therapy of murine retroviral leukemias] Aizaki K, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2679–85 (19 ref.) **(Jpn)**

[Gene therapy for ADA deficiency] Ariga T, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2772–80 (13 ref.) **(Jpn)**

[Overview: animal models of human diseases] Asano S. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2661–2 (3 ref.) **(Jpn)**

[Overview: gene expression and gene therapy] Fujinaga K. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2588–91 (8 ref.) **(Jpn)**

[Gene delivery by immunogene and its application to cancer gene therapy] Gamou S, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2562–9 (22 ref.) **(Jpn)**

[Gene therapy of AIDS by a Rev mutant without nucleolar dysfunction] Hatanaka M. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2753–8 (8 ref.) **(Jpn)**

[The model mouse for gene therapy] Katsuki M. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2663–7 (2 ref.) **(Jpn)**

[Gene targeting: mechanism and efficiency] Kobayashi I. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2645–53 (25 ref.) **(Jpn)**

[Homologous recombination and triple helix DNA] Kotani H. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2654–60 (22 ref.) **(Jpn)**

[Application of myc family genes to therapy of malignant brain tumors] Kuchino Y, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2713–9 (24 ref.) **(Jpn)**

[Gene therapy for ornithine transcarbamylase deficiency] Matsuda I, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2759–64 (19 ref.) **(Jpn)**

[Usefulness of myelin basic protein gene promoter for the gene therapy of malignant glioma] Miyao Y, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2618–23 (13 ref.) **(Jpn)**

[Cytokine gene therapy for malignant brain tumors] Mizuno M, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2709–12 (13 ref.) **(Jpn)**

[Gene therapy for cardiovascular disease] Morishita R, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2739–45 (26 ref.) **(Jpn)**

[Gene therapy for diabetes: various approaches including adoptive transfer of cytokine gene-transduced lymphocytes] Moritani M, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2746–52 (23 ref.) **(Jpn)**

[Overview: basic research for gene therapy in Japan] Niitsu Y. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2686–7 (0 ref.) **(Jpn)**

[Diseases relevant to gene therapy] Niitsu Y. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2496–7 (4 ref.) **(Jpn)**

[Bovine papillomavirus vector] Ohe Y. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2539–44 (16 ref.) **(Jpn)**

[Inducible regulatable promoter--ionizing radiation-inducible promoter EGR-1] Ohno T. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2624–30 (25 ref.) **(Jpn)**

[Gene transfer into hematopoietic stem cells] Ozawa K. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2732–8 (24 ref.) **(Jpn)**

[Gene therapy for ornithine transcarbamylase (OTC) deficient mice] Shimada T, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2674–8 (24 ref.) **(Jpn)**

[In vivo drug-selectable markers in gene therapy] Sugimoto Y. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2635–44 (40 ref.) **(Jpn)**

[Suicide genes for gene therapy] Suzuki S, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2720–6 (24 ref.) **(Jpn)**

[Guide line for gene therapy] Takaku F. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2498–502 (4 ref.) **(Jpn)**

[Gene therapy in muscular dystrophy] Takeda S, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2765–71 (32 ref.) **(Jpn)**

[Human alpha-fetoprotein transcriptional regulatory regions: application to gene therapy] Tamaoki T, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2613–7 (25 ref.) **(Jpn)**

[Cancer gene therapy by IFN gene transfer] Watanabe Y. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2700–8 (46 ref.) **(Jpn)**

[Gene therapy for pancreatic cancer] Yoshida T, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2727–31 (12 ref.) **(Jpn)**

[Human gene therapy: trends and current problems] Lazo PA. **Med Clin (Barc)** 1996 Mar 30;106(12):469–76 (52 ref.) **(Spa)**

[Duchenne muscular dystrophy: clinical analysis and prospects of genetic therapy] Mateos F. **Rev Neurol** 1995; 23 Suppl 3:S404–7 (32 ref.) **(Spa)**

[Gene therapy. Expectations and realization] Smith E. **Lakartidningen** 1996 Jan 31;93(5):349–50 (16 ref.) **(Swe)**

ADVERSE EFFECTS

Risk potential of the chromosomal insertion of foreign DNA. Kurth R. **Ann N Y Acad Sci** 1995 Nov 27;772:140–51 (25 ref.)

[Somatic gene therapy--is it safe?] Huminiecki L. **Postepy Biochem** 1996;42(1):14–21 (51 ref.) **(Pol)**

METHODS

Gene therapy in pediatric medicine. Ledley FD. **Adv Pediatr** 1996;43:1–25 (90 ref.)

Prospects for gene therapy with direct injection of polynucleotides. Kass-Eisler A, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:232–40 (33 ref.)

Gene transfer to hematopoietic stem cells: implications for gene therapy of human disease. Dunbar CE. **Annu Rev Med** 1996;47:11–20 (43 ref.)

Development and application of herpes simplex virus vectors for human gene therapy. Glorioso JC, et al. **Annu Rev Microbiol** 1995;49:675–710 (176 ref.)

Viral vectors in gene therapy. Smith AE. **Annu Rev Microbiol** 1995;49:807–38 (150 ref.)

Gene therapy of rheumatoid arthritis via cytokine regulation: future perspectives. Chernajovsky Y, et al. **Br Med Bull** 1995 Apr;51(2):503–16 (41 ref.)

Targeted gene therapy. Hart IR, et al. **Br Med Bull** 1995 Jul;51(3):647–55 (26 ref.)

Strategies to accomplish gene delivery via the receptor-mediated endocytosis pathway. Cristiano RJ, et al. **Cancer Gene Ther** 1996 Jan-Feb;3(1):49–57 (60 ref.)

Genetic therapy using bone marrow transplantation. Giles RE, et al. **Cancer Treat Res** 1995;76:271–80 (20 ref.)

The use of adenoviral vectors for gene therapy and gene transfer in vivo. Bramson JL, et al. **Curr Opin Biotechnol** 1995 Oct;6(5):590–5 (49 ref.)

European School of Oncology position paper. Gene therapy for the medical oncologist. Blaese M, et al. **Eur J Cancer** 1995;31A(9):1531–7 (17 ref.)

Adeno-associated virus vectors for gene therapy. Flotte TR, et al. **Gene Ther** 1995 Aug;2(6):357–62 (59 ref.)

Mammalian artificial chromosomes: a new tool for gene therapy. Huxley C. **Gene Ther** 1994 Jan;1(1):7–12 (56 ref.)

Gene transfer technologies for the gene therapy of cancer. Vile R, et al. **Gene Ther** 1994 Mar;1(2):88–98 (88 ref.)

Steps toward gene therapy: 1. The initial trials. Blaese RM. **Hosp Pract (Off Ed)** 1995 Nov 15;30(11):33–40 (7 ref.)

Nonviral gene therapy: the promise of genes as pharmaceutical products. Ledley FD. **Hum Gene Ther** 1995 Sep;6(9):1129–44 (179 ref.)

Strategies for cancer gene therapy using adenoviral vectors. Descamps V, et al. **J Mol Med** 1996 Apr;74(4):183–9 (80 ref.)

Development of retroviral vectors as safe, targeted gene delivery systems. Günzburg WH, et al. **J Mol Med** 1996 Apr;74(4):171–82 (92 ref.)

Clinical application of gene transfer. Herrmann F. **J Mol Med** 1996 Apr;74(4):213–21 (120 ref.)

Liver-directed gene transfer and application to therapy. Sandig V, et al. **J Mol Med** 1996 Apr;74(4):205–12 (89 ref.)

Antisense oncogene and tumor suppressor gene therapy of cancer. Zhang WW. **J Mol Med** 1996 Apr;74(4):191–204 (137 ref.)

Gene transfer into the kidney: promise for unravelling disease mechanisms, limitations for human gene therapy [editorial] Fine LG. **Kidney Int** 1996 Mar;49(3):612–9 (61 ref.)

Construction of retroviral vectors for targeted delivery and expression of therapeutic genes. Salmons B, et al. **Leukemia** 1995 Oct;9 Suppl 1:S53–60 (44 ref.)

Liver-directed gene therapy. Nunes FA, et al. **Med Clin North Am** 1996 Sep;80(5):1201–13 (74 ref.)

Gene therapy against cancer and HIV infection using the gene encoding herpes simplex virus thymidine kinase. Caruso M. **Mol Med Today** 1996 May;2(5):212–7 (37 ref.)

Site-specific delivery of cytokines in cancer. Klingemann HG, et al. **Mol Med Today** 1996 Apr;2(4):154–9 (38 ref.)

Muscle-based gene therapy: realistic possibilities for the future. Svensson EC, et al. **Mol Med Today** 1996 Apr; 2(4):166–72 (40 ref.)

Muscle-mediated gene therapy. Blau HM, et al. **N Engl J Med** 1995 Dec 7;333(23):1554–6 (0 ref.)

Pseudotyped retroviral vectors for studies of human gene therapy. Friedmann T, et al. **Nat Med** 1995 Mar;1(3):275–7 (29 ref.)

Radiotherapy for genes that cause cancer. McBride WH, et al. Nat Med 1995 Nov;1(11):1215–7 (29 ref.)

Ribozymes in gene therapy. Thompson JD, et al. **Nat Med** 1995 Mar;1(3):277–8 (11 ref.)

p53 gene therapy in vivo of herpatocellular and liver metastatic colorectal cancer. Bookstein R, et al. **Semin Oncol** 1996 Feb;23(1):66–77 (109 ref.)

Polynucleotide-mediated immunization therapy of cancer. Conry RM, et al. **Semin Oncol** 1996 Feb;23(1):135–47 (79 ref.)

Noninfectious gene transfer and expression systems for cancer gene therapy. Cooper MJ. **Semin Oncol** 1996 Feb; 23(1):172–87 (176 ref.)

In situ use of suicide genes for cancer therapy. Freeman SM, et al. **Semin Oncol** 1996 Feb;23(1):31–45 (120 ref.)

Tissue specific promoters in targeting systemically delivered gene therapy. Hart IR. **Semin Oncol** 1996 Feb;23(1):154–8 (33 ref.)

Genomic targeting and genetic conversion in cancer therapy. Kmiec EB. **Semin Oncol** 1996 Feb;23(1):188–93 (17 ref.)

Transfer of drug resistance genes into hematopoietic progenitors to improve chemotherapy tolerance. Koç ON, et al. **Semin Oncol** 1996 Feb;23(1):46–65 (196 ref.)

Parvoviral vectors for the gene therapy of cancer. Shaughnessy E, et al. **Semin Oncol** 1996 Feb;23(1):159–71 (116 ref.)

The Gordon Wilson Lecture. In vivo gene therapy: a strategy to use human genes as therapeutics. Crystal RG. **Trans Am Clin Climatol Assoc** 1994;106:87–99 (72 ref.)

Gene therapy to restore prostacyclin presence to injured endothelium. Willerson JT, et al. **Trans Am Clin Climatol Assoc** 1994;106:100–7; discussion 107–8 (41 ref.)

Gene therapy. Saksena S, et al. **Trop Gastroenterol** 1996 Jan-Mar;17(1):6–17 (119 ref.)

[Gene therapy for alpha 1-antitrypsin deficiency. Hopes, realities and perspectives] LeMarchand P. **Rev Mal Respir** 1996;13(1):7–12 (24 ref.) (Eng. Abstr.) **(Fre)**

[Gene therapy approaches in metabolic diseases] Ameis D, et al. **Internist (Berl)** 1996 Apr;37(4):360–8 (88 ref.) **(Ger)**

[Principles and strategies of gene therapy] Brach MA, et al. **Internist (Berl)** 1996 Apr;37(4):343–9 (35 ref.) **(Ger)**

[Gene therapy concepts in coronary stenoses] Schott E, et al. **Internist (Berl)** 1996 Apr;37(4):350–9 (69 ref.) **(Ger)**

[Immunotherapy with genetically modified tumor cells] Topf N, et al. **Internist (Berl)** 1996 Apr;37(4):374–81 (55 ref.) **(Ger)**

[Using the thymidine kinase gene in therapy of solid tumors] Wicke I, et al. **Internist (Berl)** 1996 Apr;37(4):369–73 (15 ref.) **(Ger)**

[Somatic gene therapy: perspectives in the use of hematopoietic stem cells (editorial)] Wodnar-Filipowicz A. **Schweiz Rundsch Med Prax** 1996 Apr 9;85(15):469–72 (13 ref.) **(Ger)**

[Overview: application of gene targeting technologies and its problems] Ikawa Y. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2631–4 (3 ref.) **(Jpn)**

GENE THERAPY

NURSING

Gene therapy of cancer. Robinson KD, et al. **Semin Oncol Nurs** 1996 May;12(2):142–51 (52 ref.)

STANDARDS

Ethical and regulatory issues in gene therapy. Nicholson S, et al. **Br J Urol** 1995 Nov;76 Suppl 2:71–4 (16 ref.)

TRENDS

Current status and future prospects of human gene therapy. Shimada T. **Acta Paediatr Jpn** 1996 Apr;38(2):176–81 (27 ref.)

Innovative approaches to gene therapy. Cunliffe V, et al. **Curr Opin Biotechnol** 1995 Dec;6(6):709–13 (41 ref.)

Molecular conjugates: a targeted gene delivery vector for molecular medicine. Cristiano RJ, et al. **J Mol Med** 1995 Oct;73(10):479–86 (45 ref.)

Human gene therapy—an immature genie, but certainly out of the bottle. Friedmann T. **Nat Med** 1996 Feb;2(2):144–7 (15 ref.)

Gene therapy: prospects for treatment of liver disease. Sandig V, et al. **Z Gastroenterol** 1996 Jun;34 Suppl 3:25–6 (32 ref.)

[Gene therapy for AIDS: current trends] Takatsuki K, et al. **Nippon Rinsho** 1996 Jan;54(1):233–41 (9 ref.) (Eng. Abstr.) **(Jpn)**

[History and current status of human gene therapy] Asano S. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2491–5 (30 ref.) **(Jpn)**

GENE TRANSFER

Prospects for genetic manipulation of cardiac excitability. Lawrence JH, et al. **Adv Exp Med Biol** 1995;382:41–8 (44 ref.)

Genetic modification of milk proteins. Clark AJ. **Am J Clin Nutr** 1996 Apr;63(4):633S–8S (48 ref.)

Evaluation of phenotypic alteration by microcell-mediated chromosome transfer. Hunt JD. **Anal Biochem** 1996 Jul 1;238(2):107–16 (92 ref.)

Immunotherapy of human cancers. Hui KM, et al. **Ann Acad Med Singapore** 1996 Jan;25(1):113–9 (19 ref.)

Strategies for efficient gene transfer into hematopoietic cells. The use of adeno-associated virus vectors in gene therapy. Chatterjee S, et al. **Ann N Y Acad Sci** 1995 Dec 29; 770:79–90 (40 ref.)

Direct gene transfer for treatment of human cancer. Nabel GJ, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:227–31 (40 ref.)

Gene transfer. Slama J, et al. **Ann Plast Surg** 1995 Oct; 35(4):429–39 (101 ref.)

Gene transfer to hematopoietic stem cells: implications for gene therapy of human disease. Dunbar CE. **Annu Rev Med** 1996;47:11–20 (43 ref.)

Transgenic approaches to salivary gland research. Samuelson LC. **Annu Rev Physiol** 1996;58:209–29 (106 ref.)

The effects of cytokine gene transfer into tumors on host cell infiltration and regression. McBride WH, et al. **Anticancer Res** 1996 May-Jun;16(3A):1139–43 (32 ref.)

Introducing genes into zebrafish. Gaiano N, et al. **Biochim Biophys Acta** 1996 Aug 8;1288(1):O11–4 (43 ref.)

Gene therapy of cancer. Mullen CA, et al. **Cancer Chemother Biol Response Modif** 1996;16:285–94 (74 ref.)

Strategies to accomplish gene delivery via the receptor-mediated endocytosis pathway. Cristiano RJ, et al. **Cancer Gene Ther** 1996 Jan-Feb;3(1):49–57 (60 ref.)

The potential applications of gene transfer in the treatment of patients with cancer: a concise review. Hussein AM. **Cancer Invest** 1996;14(4):343–52 (150 ref.)

Nucleic acid vaccines. Vogel FR, et al. **Clin Microbiol Rev** 1995 Jul;8(3):406–10 (32 ref.)

The use of adenoviral vectors for gene therapy and gene transfer in vivo. Bramson JL, et al. **Curr Opin Biotechnol** 1995 Oct;6(5):590–5 (49 ref.)

Use of somatic gene transfer to study lipoprotein metabolism in experimental animals in vivo. Chan L. **Curr Opin Lipidol** 1995 Oct;6(5):335–40 (56 ref.)

Transfer of the MDR1 gene into haematopoietic cells. Baudard M, et al. **Eur J Cancer** 1996 Jun;32A(6):1019–23 (52 ref.)

Strategies to achieve targeted gene delivery via the receptor-mediated endocytosis pathway. Michael SI, et al. **Gene Ther** 1994 Jul;1(4):223–32 (49 ref.)

Gene transfer technologies for the gene therapy of cancer. Vile R, et al. **Gene Ther** 1994 Mar;1(2):88–98 (88 ref.)

In vivo gene transfer: a potential approach for immunotherapy. Schmid RM. **Hybridoma** 1995 Apr; 14(2):135–7 (27 ref.)

In the driver's seat: the Bacteroides conjugative transposons and the elements they mobilize. Salyers AA, et al. **J Bacteriol** 1995 Oct;177(20):5727–31 (22 ref.)

Getting human gene therapy to work. Stewart FM. **J Cell Biochem** 1995 Aug;58(4):416–23 (77 ref.)

Development of retroviral vectors as safe, targeted gene delivery systems. Günzburg WH, et al. **J Mol Med** 1996 Apr;74(4):171–82 (92 ref.)

Increased expression of DNA cointroduced with nuclear protein in adult rat liver. Kaneda Y, et al. **J Mol Med** 1995 Jun;73(6):289–97 (14 ref.)

Retrovirus-mediated transfer of MHC class II cDNA into swine bone marrow cells. LeGuern C, et al. **J Mol Med** 1995 Jun;73(6):269–78 (86 ref.)

A defective HIV-1 vector for gene transfer to human lymphocytes. Parolin C, et al. **J Mol Med** 1995 Jun; 73(6):279–88 (176 ref.)

Liver-directed gene transfer and application to therapy. Sandig V, et al. **J Mol Med** 1996 Apr;74(4):205–12 (89 ref.)

Gene transfer into the kidney: promise for unravelling disease mechanisms, limitations for human gene therapy [editorial] Fine LG. **Kidney Int** 1996 Mar;49(3):612–9 (61 ref.)

Construction of retroviral vectors for targeted delivery and expression of therapeutic genes. Salmons B, et al. **Leukemia** 1995 Oct;9 Suppl 1:S53–60 (44 ref.)

Gene transfer using replication-defective retroviral and adenoviral vectors. Leber SM, et al. **Methods Cell Biol** 1996;51:161–83 (42 ref.)

Conjugative transposons: an unusual and diverse set of integrated gene transfer elements. Salyers AA, et al. **Microbiol Rev** 1995 Dec;59(4):579–90 (86 ref.)

HSV as a gene transfer vector for the nervous system. Glorioso JC, et al. **Mol Biotechnol** 1995 Aug;4(1):87–99 (61 ref.)

Delivery of DNA into mammalian cells by receptor-mediated endocytosis and gene therapy. Guy J, et al. **Mol Biotechnol** 1995 Jun;3(3):237–48 (60 ref.)

The potential exploitation of plant viral translational enhancers in biotechnology for increased gene expression. Turner R, et al. **Mol Biotechnol** 1995 Jun;3(3):225–36 (40 ref.)

Gene transfer to hematopoietic cells. Brenner MK. **N Engl J Med** 1996 Aug 1;335(5):337–9 (0 ref.)

Pseudotyped retroviral vectors for studies of human gene therapy. Friedmann T, et al. **Nat Med** 1995 Mar;1(3):275–7 (29 ref.)

DNA-mediated gene transfer into mammalian cells and cancer. Slávíková K, et al. **Neoplasma** 1995;42(6):293–7 (33 ref.)

In vivo gene transfer: focus on the kidney. Wagner J, et al. **Nephrol Dial Transplant** 1995 Oct;10(10):1801–7 (53 ref.)

Germ line transmission of yeast artificial chromosomes in transgenic mice. Montoliu L, et al. **Reprod Fertil Dev** 1994; 6(5):577–84 (44 ref.)

Site-specific transgene insertion: an approach. Wigley P, et al. **Reprod Fertil Dev** 1994;6(5):585–8 (21 ref.)

Transfer of genes to humans: early lessons and obstacles to success. Crystal RG. **Science** 1995 Oct 20;270(5235):404–10 (69 ref.)

Noninfectious gene transfer and expression systems for cancer gene therapy. Cooper MJ. **Semin Oncol** 1996 Feb; 23(1):172–87 (176 ref.)

The contribution of marker gene studies to hemopoietic stem cell therapies. Brenner MK. **Stem Cells (Dayt)** 1995 Sep; 13(5):453–61 (44 ref.)

Gene targeting and gene transfer studies of the biological role of the plasminogen/plasmin system. Carmeliet P, et al. **Thromb Haemost** 1995 Jul;74(1):429–36 (66 ref.)

Immunotherapy and gene transfer in the treatment of the oncology patient: role of transfusion medicine. Hillyer CD, et al. **Transfus Med Rev** 1996 Jan;10(1):1–14 (111 ref.)

Reconstitution of apoB mRNA editing in liver by gene-transfer as a potential approach for the treatment of severe forms of polygenic hypercholesterolemia—an outline of the rationale. Greeve J, et al. **Z Gastroenterol** 1996 Jun;34 Suppl 3:27–30 (70 ref.)

[Cell and gene transfers for therapeutic use into the central nervous system] Peschanski M. **Ann Endocrinol (Paris)** 1995;56(6):575–7 (17 ref.) (Eng. Abstr.) **(Fre)**

[Gene transfer and radiotherapy] Bourhis J, et al. **Bull Cancer (Paris)** 1996 Feb;83(2):107–13 (43 ref.) (Eng. Abstr.) **(Fre)**

[Vectors of gene transfer. Applications in pneumology] Demoly P, et al. **Rev Mal Respir** 1996 Jul;13(3):251–7 (43 ref.) (Eng. Abstr.) **(Fre)**

[Experimental approaches for gene therapy modification of vascular remodeling] von der Leyen HE, et al. **Z Kardiol** 1995 Oct;84(10):791–7 (62 ref.) (Eng. Abstr.) **(Ger)**

[Studies on tumor suppressor genes by gene/chromosome transfer] Horikawa I, et al. **Nippon Rinsho** 1995 Nov; 53(11):2647–52 (25 ref.) (Eng. Abstr.) **(Jpn)**

[Inhibition of HBx gene expression by antisense oligonucleotide] Moriya K, et al. **Nippon Rinsho** 1995 Oct; 53 Suppl:111–4 (9 ref.) **(Jpn)**

[Establishment of in vitro model for HBV infection via asialoglycoprotein receptor] Neda H, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:121–4 (15 ref.) **(Jpn)**

[Cationic liposome-mediated expression of hepatitis C virus genome in adult rat liver] Takehara T, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:102–6 (13 ref.) **(Jpn)**

[YAC-modification system for analyzing gene regulation] Koide T. **Seikagaku** 1996 Feb;68(2):137–42 (15 ref.) **(Jpn)**

[Safety issues of retrovirus vectors] Amanuma H. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2583–7 (21 ref.) **(Jpn)**

[Transgene expression and integration in the zebrafish, Danio rerio] Amanuma K, et al. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2257–64 (19 ref.) **(Jpn)**

[Hybrid biomaterial] Emi N. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2514–8 (14 ref.) **(Jpn)**

[Gene delivery by immunogene and its application to cancer gene therapy] Gamou S, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2562–9 (22 ref.) **(Jpn)**

[Herpes virus vector] Hidaka Y. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2545–9 (11 ref.) **(Jpn)**

[Chronic rheumatoid arthritis model mice transgenic for the HTLV-I tax gene] Iwakura Y. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2074–82 (33 ref.) **(Jpn)**

[Gene gun] Kagawa Y. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2570–6 (20 ref.) **(Jpn)**

[Gene expression using adenovirus vector] Kanegae Y, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2525–31 (11 ref.) **(Jpn)**

[Gene transfer using recombinant HIV vectors] Miyake K, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec; 40(17):2519–24 (15 ref.) **(Jpn)**

[Gene therapy for diabetes: various approaches including adoptive transfer of cytokine gene-transduced lymphocytes] Moritani M, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2746–52 (23 ref.) **(Jpn)**

[The mouse embryogenesis of jumonji mutant obtained by gene-trap method] Motoyama J, et al. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2152–61 (24 ref.) **(Jpn)**

[Chick embryo culture and manipulation of early avian embryo] Naito M. **Tanpakushitsu Kakusan Koso** 1995 Oct; 40(14):2025–34 (51 ref.) **(Jpn)**

[Fusogenic liposomes: a new system for gene transfer] Nakanishi M. **Tanpakushitsu Kakusan Koso** 1995 Dec; 40(17):2550–5 (16 ref.) **(Jpn)**

[Receptor-mediated targeted gene delivery by ligand-receptor system] Neda H, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2556–61 (15 ref.) **(Jpn)**

[Abnormal T-cell differentiation and development of T-cell lymphomas in TL-transgenic mice] Obata Y, et al. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2054–61 (34 ref.) **(Jpn)**

[Bovine papillomavirus vector] Ohe Y. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2539–44 (16 ref.) **(Jpn)**

[Gene transfer into hematopoietic stem cells] Ozawa K. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2732–8 (24 ref.) **(Jpn)**

[Overview: gene transfer techniques] Shimada T. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2503–7 (21 ref.) **(Jpn)**

[Adeno-associated virus (AAV) vectors] Tamayose K, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2532–8 (24 ref.) **(Jpn)**

[Retrovirus vector] Wakimoto H, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2508–13 (19 ref.) **(Jpn)**

[Cancer gene therapy by IFN gene transfer] Watanabe Y. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2700–8 (46 ref.) **(Jpn)**

[Cationic liposomes] Yagi K. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2577–82 (6 ref.) **(Jpn)**

[Genetic regulation of plasmid transfer] Pekhov AP, et al. **Biull Eksp Biol Med** 1995 Jul;120(7):6–12 (37 ref.) **(Rus)**

GENERAL ADAPTATION SYNDROME

PHYSIOPATHOLOGY

Regulation of protein metabolism during stress. Matthews DE, et al. **Curr Opin Gen Surg** 1993;:72–7 (45 ref.)

Lipid fuel metabolism in health and disease. Miles JM. **Curr Opin Gen Surg** 1993;:78–84 (34 ref.)

GENERAL ANESTHETICS see **ANESTHETICS, GENERAL**

GENERAL PRACTICE see **FAMILY PRACTICE**

GENERAL PRACTICE, DENTAL

EDUCATION

Accreditation of postdoctoral general dentistry programs. Glassman P. **J Am Coll Dent** 1995 Fall;62(3):27–30 (33 ref.)

GENERAL PRACTITIONERS see **PHYSICIANS, FAMILY**

GENERAL SYSTEMS THEORY see **SYSTEMS THEORY**

GENERALISTS see **PHYSICIANS, FAMILY**

GENERALIZED GLYCOGENOSIS see **GLYCOGEN STORAGE DISEASE TYPE II**

GENERALIZED THYROID HORMONE RESISTANCE see **THYROID HORMONE RESISTANCE SYNDROME**

GENES

see related
BASE SEQUENCE
GENOMIC LIBRARY

The first gene for an idiopathic epilepsy: a fruitful

collaboration of Australian clinical research and molecular genetics [editorial] Berkovic SF, et al. **Aust N Z J Med** 1996 Apr;26(2):154–6 (13 ref.)
Operating under a Gag order: a block against incoming virus by the Fv1 gene. Goff SP. **Cell** 1996 Sep 6;86(5):691–3 (20 ref.)
CpG islands and genes. Cross SH, et al. **Curr Opin Genet Dev** 1995 Jun;5(3):309–14 (55 ref.)
Identification of mismatch repair genes and their role in the development of cancer. Fishel R, et al. **Curr Opin Genet Dev** 1995 Jun;5(3):382–95 (158 ref.)
Invertebrate versus vertebrate neurogenesis: variations on the same theme? Salzberg A, et al. **Dev Genet** 1996;18(1):1–10 (128 ref.)
SA gene and hypertension. Samani NJ, et al. **J Hum Hypertens** 1995 Jun;9(6):501–3 (16 ref.)
Genes for ischaemic stroke: strategies for their detection. Sharma P. **J Hypertens** 1996 Mar;14(3):277–85 (62 ref.)
Variation in synonymous substitution rates among mammalian genes and the correlation between synonymous and nonsynonymous divergences. Ohta T, et al. **J Mol Evol** 1995 Dec;41(6):717–20 (20 ref.)
The molecular genetics of human sex determination. Wolf U. **J Mol Med** 1995 Jul;73(7):325–31 (55 ref.)
A molecular switch for the neuron–glia developmental decision. Anderson DJ. **Neuron** 1995 Dec;15(6):1219–22 (25 ref.)
Searching for complex disease genes: can it be made any easier? Baron M. **Psychiatr Genet** 1995 Summer;5(2):89–91 (26 ref.)
A continuum of psychosis, one human gene, and not much else—the case for homogeneity. Crow TJ. **Schizophr Res** 1995 Oct;17(2):135–45 (85 ref.)
[The new perspectives in gene diagnostics] Palotie L, et al. **Duodecim** 1994;110(7):647–53 (21 ref.) **(Fin)**
[Genetic aspects of hypertension—etiology of essential hypertension] Ogihara T. **Nippon Naika Gakkai Zasshi** 1995 Jul 10;84(7):1172–7 (16 ref.) **(Jpn)**
[Molecular biology in medicine. I. Molecular structure of the gene] Moreno G, et al. **Rev Invest Clin** 1996 Jan–Feb; 48(1):81–4 (5 ref.) **(Spa)**

GENETICS

Candidate genes in alcoholism. Goldman D. **Clin Neurosci** 1995;3(3):174–81 (76 ref.)
The inward rectifier potassium channel family. Doupnik CA, et al. **Curr Opin Neurobiol** 1995 Jun;5(3):268–77 (86 ref.)
Recent progress in human molecular biology and expression profiling of active genes in the body. Matsubara K, et al. **Jpn J Pharmacol** 1995 Nov;69(3):181–5 (3 ref.)
The dystrophin gene and its product—a view. Manole E. **Rom J Neurol Psychiatry** 1995 Apr–Jun;33(2):109–19 (65 ref.)
[Susceptibility to multiple sclerosis and T-lymphocyte receptor genes. A synthetic review] Bongioanni P, et al. **Minerva Med** 1995 Dec;86(12):543–9 (57 ref.) (Eng. Abstr.) **(Ita)**

IMMUNOLOGY

Primary immunodeficiencies: a flurry of new genes. Conley ME. **Immunol Today** 1995 Jul;16(7):313–5 (14 ref.)

PHYSIOLOGY

Networks of neurons, networks of genes. Berkowitz A. **Neuron** 1996 Aug;17(2):199–202 (25 ref.)

RADIATION EFFECTS

Genomic instability induced by ionizing radiation. Morgan WF, et al. **Radiat Res** 1996 Sep;146(3):247–58 (175 ref.)

GENES, ABL

see related
FUSION PROTEINS, BCR-ABL
PROTO-ONCOGENE PROTEINS C-ABL

BCR-ABL: an anti-apoptosis gene in chronic myelogenous leukemia. Cotter TG. **Leuk Lymphoma** 1995 Jul; 18(3–4):231–6 (32 ref.)

GENES, APC

The genetic background of familial adenomatous polyposis. Linkage analysis, the APC gene identification and mutation screening. Kartheuser A, et al. **Acta Gastroenterol Belg** 1995 Sep–Dec;58(5–6):433–51 (112 ref.)
In vitro models for studying colorectal carcinogenesis: cellular and molecular events including APC and Rb cleavage in the control of proliferation, differentiation and apoptosis. Williams AC, et al. **Biochim Biophys Acta** 1996 Aug 8;1288(1):F9–19 (91 ref.)
Emergent issues in the genetics of intestinal neoplasia. Dove WF, et al. **Cancer Surv** 1995;25:335–55 (98 ref.)
The adenomatous polyposis coli gene of the mouse in development and neoplasia. Dove WF, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:501–8 (43 ref.)
ApcMin: a mouse model for intestinal and mammary tumorigenesis. Moser AR, et al. **Eur J Cancer** 1995 Jul–Aug;31A(7–8):1061–4 (30 ref.)
The adenomatous polyposis coli gene and human cancers. Nakamura Y. **J Cancer Res Clin Oncol** 1995; 121(9–10):529–34 (63 ref.)
Multistep carcinogenesis in colorectal cancers. Takami K, et al. **Southeast Asian J Trop Med Public Health** 1995;26 Suppl 1:190–6 (28 ref.)

GENETICS

A tale of four syndromes: familial adenomatous polyposis, Gardner syndrome, attenuated APC and Turcot syndrome. Foulkes WD. **QJM** 1995 Dec;88(12):853–63 (58 ref.)

GENES, BACTERIAL

Molecular responses of microbes to environmental pH stress. Hall HK, et al. **Adv Microb Physiol** 1995;37:229–72 (240 ref.)
Transport mutants and transport genes of Corynebacterium glutamicum. Eggeling L, et al. **Ann N Y Acad Sci** 1996 May 15;782:191–201 (32 ref.)
Polyethers. Birch AW, et al. **Biotechnology** 1995;28:443–76 (100 ref.)
Agrocins. Clare BG. **Biotechnology** 1995;28:619–32 (53 ref.)
Genetics of antibiotic production in Streptomyces coelicolor A3(2), a model streptomycete. Hopwood DA, et al. **Biotechnology** 1995;28:65–102 (132 ref.)
Aminoglycosides and aminocyclitols (other than streptomycin). Hotta K, et al. **Biotechnology** 1995;28:571–95 (82 ref.)
Anthracyclines. Hutchinson CR. **Biotechnology** 1995; 28:331–57 (118 ref.)
Beta-lactams. Jensen SE, et al. **Biotechnology** 1995;28:239–68 (208 ref.)
Macrolides. Katz L, et al. **Biotechnology** 1995;28:385–420 (136 ref.)
Microcins. Moreno F, et al. **Biotechnology** 1995;28:307–21 (58 ref.)
Streptomycin and related aminoglycosides. Piepersberg W. **Biotechnology** 1995;28:531–70 (179 ref.)
Thiopeptides. Strohl WR, et al. **Biotechnology** 1995;28:223–38 (50 ref.)
Bialaphos. Thompson CJ, et al. **Biotechnology** 1995; 28:197–222 (68 ref.)
Peptides. von Döhren H. **Biotechnology** 1995;28:129–71 (256 ref.)
Evolution of ATP-binding cassette transporter genes. Dean M, et al. **Curr Opin Genet Dev** 1995 Dec;5(6):779–85 (42 ref.)
Polymerase chain reaction of Borrelia burgdorferi flagellin gene in Shulman syndrome. Hashimoto Y, et al. **Dermatology** 1996;192(2):136–9 (26 ref.)
Physical and genetic maps of the chromosome of the Lactococcus lactis subsp. lactis strain IL1403 and Lactococcus lactis subsp. cremoris strain MG1363. Le Bourgeois P, et al. **Dev Biol Stand** 1995;85:597–603 (33 ref.)
The streptokinase gene: allelic variation, genomic environment and expression control. Malke H, et al. **Dev Biol Stand** 1995;85:183–93 (36 ref.)
Characterization of the capsular polysaccharide genes of group B streptococci. Rubens CE, et al. **Dev Biol Stand** 1995;85:237–44 (31 ref.)
Regulation and organization of the groE and dnaK operons in Eubacteria. Segal R, et al. **FEMS Microbiol Lett** 1996 Apr 15;138(1):1–10 (32 ref.)
Regulation of oxidative phosphorylation: the flexible respiratory network of Paracoccus denitrificans. Van Spanning RJ, et al. **J Bioenerg Biomembr** 1995 Oct; 27(5):499–512 (93 ref.)
Gene cassettes: a new class of mobile element. Recchia GD, et al. **Microbiology** 1995 Dec;141 (Pt 12):3015–27 (43 ref.)
High pressure influences on gene and protein expression. Bartlett DH, et al. **Res Microbiol** 1995 Oct;146(8):697–706 (63 ref.)
[Regulation of the toxin production in Clostridium perfringens] Shimizu T. **Nippon Saikingaku Zasshi** 1995 Jul; 50(3):737–44 (27 ref.) **(Jpn)**
[Study on Pseudomonas transposons and molecular genetic analysis of Pseudomonas by use of transposons] Tsuda M. **Nippon Saikingaku Zasshi** 1995 Oct;50(4):947–59 (58 ref.) **(Jpn)**
[Rapid detection and identification of mycobacteria by the PCR assay based on the co-amplification of the gene IS6110 and groEL] Fusegawa H, et al. **Rinsho Byori** 1995 Oct;43(10):1051–6 (18 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Antimicrobial agent resistance in mycobacteria: molecular genetic insights. Musser JM. **Clin Microbiol Rev** 1995 Oct; 8(4):496–514 (181 ref.)
Signal transduction in the control of phosphate-regulated genes of Escherichia coli. Wanner BL. **Kidney Int** 1996 Apr;49(4):964–7 (24 ref.)
The genetics of multiple drug resistance in Mycobacterium tuberculosis and the Mycobacterium avium complex. Morris SL, et al. **Res Microbiol** 1996 Jan–Feb; 147(1–2):68–73 (40 ref.)

PHYSIOLOGY

Manipulations of catabolic genes for the degradation and detoxification of xenobiotics. Lal R, et al. **Adv Appl Microbiol** 1995;41:55–95 (181 ref.)
Genetics of gliding motility and development in Myxococcus xanthus. Hartzell PL, et al. **Arch Microbiol** 1995 Nov; 164(5):309–23 (117 ref.)
Molecular genetics and the initiation of solventogenesis in Clostridium beijerinckii (formerly Clostridium acetobutylicum) NCIMB 8052. Wilkinson SR, et al. **FEMS Microbiol Rev** 1995 Oct;17(3):275–85 (69 ref.)
Pseudomonas aeruginosa, mucoidy and the chronic infection phenotype in cystic fibrosis. Deretic V, et al. **Trends Microbiol** 1995 Sep;3(9):351–6 (59 ref.)

GENES, CDC

see related
CELL CYCLE PROTEINS

[Gas6: a ligand for receptor tyrosine kinase containing gamma-carboxyglutamic acids] Nakano T. **Seikagaku** 1996 Apr;68(4):299–302 (11 ref.) **(Jpn)**

GENETICS

Regulation of cellular proliferation effects on alteration of normal signaling pathways. Malkin D. **Med Pediatr Oncol Suppl** 1996;1:20–4 (25 ref.)

GENES, CELL DIVISION CYCLE see **GENES, CDC**

GENES, CLASS I see **GENES, MHC CLASS I**

GENES, CLASS II see **GENES, MHC CLASS II**

GENES, DCC

The deleted in colorectal cancer (DCC) gene: a candidate tumour suppressor gene encoding a cell surface protein with similarity to neural cell adhesion molecules. Fearon ER, et al. **Cancer Surv** 1995;24:3–17 (58 ref.)
DCC (deleted in colorectal cancer) inactivation in hematological malignancies. Porfiri E. **Leuk Lymphoma** 1995 Jun;18(1–2):69–72 (49 ref.)

PHYSIOLOGY

DCC: linking tumour suppressor genes and altered cell surface interactions in cancer? Cho KR, et al. **Eur J Cancer** 1995 Jul–Aug;31A(7–8):1055–60 (47 ref.)

GENES, DEVELOPMENTAL see **GENES, STRUCTURAL**

GENES, DIFFERENTIATED see **GENES, STRUCTURAL**

GENES, DOMINANT

Chromosome 12-linked autosomal dominant scapuloperoneal muscular dystrophy. Wilhelmsen KC, et al. **Ann Neurol** 1996 Apr;39(4):507–20 (75 ref.)
Dominant oncogenes, tumor suppressors, and radiosensitivity. Chiarugi V, et al. **Cell Mol Biol Res** 1995; 41(3):161–6 (63 ref.)
The myotubular myopathies: differential diagnosis of the X linked recessive, autosomal dominant, and autosomal recessive forms and present state of DNA studies. Wallgren-Pettersson C, et al. **J Med Genet** 1995 Sep; 32(9):673–9 (56 ref.)
[Hereditary nonpolyposis colorectal cancers] Caplin S, et al. **Schweiz Rundsch Med Prax** 1996 Aug 27;85(35):1041–5 (68 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Floating-Harbor syndrome: description of a further patient, review of the literature, and suggestion of autosomal dominant inheritance. Lacombe D, et al. **Eur J Pediatr** 1995 Aug;154(8):658–61 (9 ref.)
Zimmermann-Laband syndrome in a patient with severe mental retardation. Van Buggenhout GJ, et al. **Genet Couns** 1995;6(4):321–7 (15 ref.)
Review: the dominant flocculation genes of Saccharomyces cerevisiae constitute a new subtelomeric gene family. Teunissen AW, et al. **Yeast** 1995 Sep 15;11(11):1001–13 (57 ref.)

GENES, EPISTATIC see **EPISTASIS, GENETIC**

GENES, ERBA

see related
ONCOGENE PROTEINS V-ERBA
RECEPTORS, THYROID HORMONE

GENES, ERBB-1

see related
RECEPTORS, EPIDERMAL GROWTH FACTOR-UROGASTRONE

GENES, ERBB-2

see related
PROTO-ONCOGENE PROTEINS C-ERBB-2
RECEPTORS, EPIDERMAL GROWTH FACTOR-UROGASTRONE

GENETICS

[Advances in the study of proto-oncogene c-erbB-2] Jiang K, et al. **Chung Hua I Hsueh Tsa Chih** 1996 Feb;

76(2):158–60 (18 ref.) **(Chi)**

GENES, FOS

see related
ONCOGENE PROTEINS V-FOS
PROTO-ONCOGENE PROTEINS C-FOS

c-Fos expression as a tool to search for the neurobiological base of the sexual behaviour of males. Bialy M, et al. **Acta Neurobiol Exp (Warsz)** 1996;56(2):567–77 (52 ref.)

c-fos expression as a marker of central cardiovascular neurons. Dun NJ, et al. **Biol Signals** 1995 May–Jun; 4(3):117–23 (25 ref.)

Regulation of the c-fos promoter. Janknecht R. **Immunobiology** 1995 Jul;193(2–4):137–42 (14 ref.)

Fos and bone cell development: lessons from a nuclear oncogene. Grigoriadis AE, et al. **Trends Genet** 1995 Nov; 11(11):436–41 (57 ref.)

Implications of prolonged expression of Fos-related antigens. Pennypacker KR, et al. **Trends Pharmacol Sci** 1995 Sep; 16(9):317–21 (44 ref.)

[Regulatory pathways of the c-fos proto-oncogene] Terent'ev AA. **Biokhimiia** 1995 Dec;60(12):1923–52 (179 ref.) (Eng. Abstr.) **(Rus)**

GENETICS

Journey to the surface of the cell: Fos regulation and the SRE. Treisman R. **EMBO J** 1995 Oct 16;14(20):4905–13 (100 ref.)

PHYSIOLOGY

[A role of AP-1 in proliferation and differentiation of lymphocytes] Tokuhisa T, et al. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2045–53 (16 ref.) **(Jpn)**

GENES, FUNGAL

Silencing and heritable domains of gene expression. Loo S, et al. **Ann Rev Cell Dev Biol** 1995;11:519–48 (113 ref.)

Beta-lactams. Jensen SE, et al. **Biotechnology** 1995;28:239–68 (208 ref.)

Molecular mechanisms of cell-type determination in budding yeast. Johnson AD. **Curr Opin Genet Dev** 1995 Oct; 5(5):552–8 (52 ref.)

Control of mating and development in Ustilago maydis. Kahmann R, et al. **Curr Opin Genet Dev** 1995 Oct; 5(5):559–64 (31 ref.)

DNA structure checkpoints in fission yeast. Carr AM. **Semin Cell Biol** 1995 Apr;6(2):65–72 (33 ref.)

Cf9 and Avr9, two major players in the gene-for-gene game. de Wit PJ. **Trends Microbiol** 1995 Jul;3(7):251–2 (15 ref.)

GENETICS

Interplay between nucleosomes and transcription factors at the yeast PHO5 promoter. Svaren J, et al. **Semin Cell Biol** 1995 Aug;6(4):177–83 (52 ref.)

Review: the dominant flocculation genes of Saccharomyces cerevisiae constitute a new subtelomeric gene family. Teunissen AW, et al. **Yeast** 1995 Sep 15;11(11):1001–13 (57 ref.)

GENES, H-2 CLASS I see **GENES, MHC CLASS I**

GENES, HELMINTH

Molecular genetics of proto-oncogenes and candidate tumor suppressors in Caenorhabditis elegans. Sternberg PW, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:155–63 (49 ref.)

The nematode Caenorhabditis elegans and its genome. Hodgkin J, et al. **Science** 1995 Oct 20;270(5235):410–4 (25 ref.)

Mechanisms and evolution of aging. Lithgow GJ, et al. **Science** 1996 Jul 5;273(5271):80 (14 ref.)

GENES, HER-2 see **GENES, ERBB-2**

GENES, HLA CLASS I see **GENES, MHC CLASS I**

GENES, HLA CLASS II see **GENES, MHC CLASS II**

GENES, HOMEOBOX

see related
HOMEODOMAIN PROTEINS

PAX and HOX in neoplasia. Stuart ET, et al. **Adv Genet** 1995;33:255–74 (92 ref.)

Function of homeobox genes in skeletal development. Capecchi MR. **Ann N Y Acad Sci** 1996 Jun 8;785:34–7 (11 ref.)

Transcriptional silencing of homeotic genes in Drosophila. Bienz M, et al. **Bioessays** 1995 Sep;17(9):775–84 (71 ref.)

MHox and vertebrate skeletogenesis: the long and the short of it. Brickell PM. **Bioessays** 1995 Sep;17(9):750–3 (31 ref.)

Transformations in null mutants of Hox genes: do they represent intercalary regenerates? Crawford M. **Bioessays** 1995 Dec;17(12):1065–73 (48 ref.)

Inductive signals. Revolving vertebrates. Jones CM, et al. **Curr Biol** 1995 Jun 1;5(6):574–6 (16 ref.)

Neural development. A 'LIM code' for motor neurons? Lumsden A. **Curr Biol** 1995 May 1;5(5):491–5 (26 ref.)

Homeobox genes in vertebrate gastrulation. Boncinelli E, et al. **Curr Opin Genet Dev** 1995 Oct;5(5):619–27 (58 ref.)

Hox genes and chordate evolution. Holland PW, et al. **Dev Biol** 1996 Feb 1;173(2):382–95 (75 ref.)

The origin of vertebrate limbs. Coates MI. **Dev Suppl** 1994; :169–80 (116 ref.)

A class act: conservation of homeodomain protein functions. Manak JR, et al. **Dev Suppl** 1994;:61–77 (230 ref.)

Longitudinal organization of the anterior neural plate and neural tube. Shimamura K, et al. **Development** 1995 Dec; 121(12):3923–33 (66 ref.)

Retinoids and Hox genes. Marshall H, et al. **FASEB J** 1996 Jul;10(9):969–78 (62 ref.)

Homeobox genes and male reproductive development. Lindsey S, et al. **J Assist Reprod Genet** 1996 Feb; 13(2):182–92 (49 ref.)

Genetic control of segmentation in the vertebrate hindbrain. Wilkinson DG. **Perspect Dev Neurobiol** 1995;3(1):29–38 (54 ref.)

GENETICS

Homeobox genes and growth factors in regulation of craniofacial and tooth morphogenesis. Thesleff I. **Acta Odontol Scand** 1995 Jun;53(3):129–34 (38 ref.)

Homeobox genes and orofacial development. Sharpe PT. **Connect Tissue Res** 1995;32(1–4):17–25 (64 ref.)

MADS-box genes in plant ontogeny and phylogeny: Haeckel's 'biogenetic law' revisited. Theissen G, et al. **Curr Opin Genet Dev** 1995 Oct;5(5):628–39 (97 ref.)

[Mice carrying null mutations of the homeotic genes Hoxa10 and Msx1] Satokata I, et al. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2134–43 (50 ref.) **(Jpn)**

[Homeotic genes and the origin of syntax] Greenhood W. **Zh Evol Biokhim Fiziol** 1994 Nov–Dec;30(6):798–808 (3131 ref.) **(Rus)**

PHYSIOLOGY

Hox genes in the lung. Kappen C. **Am J Respir Cell Mol Biol** 1996 Aug;15(2):156–62 (91 ref.)

Vertebrate Hox genes and proliferation: an alternative pathway to homeosis? Duboule D. **Curr Opin Genet Dev** 1995 Aug;5(4):525–8 (17 ref.)

Homeotic genes and diversification of the insect body plan. Warren R, et al. **Curr Opin Genet Dev** 1995 Aug;5(4):459–65 (48 ref.)

The evolving role of Hox genes in arthropods. Akam M, et al. **Dev Suppl** 1994;:209–15 (62 ref.)

Homeobox genes in the functioning of plant meristems. Hake S, et al. **Philos Trans R Soc Lond B Biol Sci** 1995 Oct 30;350(1331):45–51 (32 ref.)

The function and evolution of Msx genes: pointers and paradoxes. Davidson D. **Trends Genet** 1995 Oct; 11(10):405–11 (64 ref.)

[Function of Hox genes in formation of skeletons] Suemori H. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2144–51 (31 ref.) **(Jpn)**

GENES, HOMEOTIC see **GENES, HOMEOBOX**

GENES, HYPOSTATIC see **EPISTASIS, GENETIC**

GENES, IG see **GENES, IMMUNOGLOBULIN**

GENES, IMMEDIATE-EARLY

Activation of immediate early genes by vestibular stimulation. Kaufman GD. **Ann N Y Acad Sci** 1996 Jun 19;781:437–442 (12 ref.)

Immediate early genes (IEGs) encoding for inducible transcription factors (ITFs) and neuropeptides in the nervous system: functional network for long-term plasticity and pain. Herdegen T, et al. **Prog Brain Res** 1995; 104:299–321 (184 ref.)

Proto-oncogenes: basic concepts and stimulation induced changes in the spinal cord. Munglani R, et al. **Prog Brain Res** 1995;104:283–98 (114 ref.)

In vivo antisense approaches to the role of immediate early gene expression in the brain. Cirelli C, et al. **Regul Pept** 1995 Oct 20;59(2):151–62 (48 ref.)

[Genes and the modulation of learning and memory] Xiong Y, et al. **Sheng Li Ko Hsueh Chin Chan** 1995 Oct; 26(4):293–8 (19 ref.) (Eng. Abstr.) **(Chi)**

GENETICS

A role for immediate-early transcription factors in learning and memory. Dragunow M. **Behav Genet** 1996 May; 26(3):293–9 (55 ref.)

Light, immediate-early genes, and circadian rhythms. Kornhauser JM, et al. **Behav Genet** 1996 May;26(3):221–40 (120 ref.)

Immediate-early genes induced by antigen receptor stimulation. Kelly K, et al. **Curr Opin Immunol** 1995 Jun; 7(3):327–32 (45 ref.)

Changes in gene expression following traumatic brain injury in the rat. Hayes RL, et al. **J Neurotrauma** 1995 Oct; 12(5):779–90 (59 ref.)

GENES, IMMUNE RESPONSE see **GENES, MHC CLASS II**

GENES, IMMUNOGLOBULIN

see related
IMMUNOGLOBULIN FRAGMENTS

Immunoglobulin gene rearrangement in T-cell-rich reactive pleural effusion of a patient with B-cell chronic lymphocytic leukemia. Miyahara M, et al. **Acta Haematol** 1996;96(1):41–4 (24 ref.)

In vivo switching: identification of germline transcripts for human IgA. Smith CI, et al. **Adv Exp Med Biol** 1995; 371A:9–13 (15 ref.)

Regulation of human lambda light chain gene expression. Blomberg BB, et al. **Ann N Y Acad Sci** 1995 Sep 29; 764:84–98 (58 ref.)

Somatic mutation of human immunoglobulin V genes: bias, rate, and regulation. Insel RA, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:158–69 (46 ref.)

B-1 cellular origin and VH segment structure of IgG, IgA, and IgM anti-DNA autoantibodies in patients with systemic lupus erythematosus. Kasaian MT, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:410–23 (52 ref.)

Expression and hypermutation of human immunoglobulin kappa genes. Klein R, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:74–83 (16 ref.)

Development of the antibody repertoire in rabbits. Knight KL, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:198–206 (23 ref.)

Polymorphism and utilization of human VH Genes. Milner EC, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:50–61 (23 ref.)

Origins of anti-DNA antibodies and their implications for B-cell tolerance. Radic MZ, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:384–96 (13 ref.)

Developmental regulation of the human antibody repertoire. Schroeder HW Jr, et al. **Ann N Y Acad Sci** 1995 Sep 29; 764:242–60 (60 ref.)

Unconventional B-cell antigens and human immune repertoires. Silverman GJ. **Ann N Y Acad Sci** 1995 Sep 29;764:342–55 (42 ref.)

A genetic approach to idiotypic vaccination for B cell lymphoma. Stevenson FK, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:212–26 (23 ref.)

The expressed heavy chain V gene repertoire of circulating B cells in normal adults. Stollar BD. **Ann N Y Acad Sci** 1995 Sep 29;764:265–74 (82 ref.)

A complete map of the human immunoglobulin VH locus. Tomlinson IM, et al. **Ann N Y Acad Sci** 1995 Sep 29; 764:43–6 (12 ref.)

Fetal versus adult PreB or B cells: the human VH repertoire. Tonnelle C, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:231–41 (38 ref.)

Molecular analysis of VH regions expressed in the adult B-cell repertoire. van der Stoep N, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:275–84 (19 ref.)

Rheumatoid factors, B cells and immunoglobulin genes. Jefferis R. **Br Med Bull** 1995 Apr;51(2):312–31 (46 ref.)

Development of the immunoglobulin repertoire. Fanning LJ, et al. **Clin Immunol Immunopathol** 1996 Apr;79(1):1–14 (129 ref.)

Analysis of immunoglobulin gene rearrangements in single B cells. Ehlich A, et al. **Curr Opin Immunol** 1995 Apr; 7(2):281–4 (18 ref.)

Somatic hypermutation. Neuberger MS, et al. **Curr Opin Immunol** 1995 Apr;7(2):248–54 (69 ref.)

Advances in human immunoglobulin allotypes. Grubb R. **Exp Clin Immunogenet** 1995;12(3):191–7 (30 ref.)

Immunoglobulin allotypes and RFLPs in disease association. Propert D. **Exp Clin Immunogenet** 1995;12(3):198–205 (42 ref.)

Human antibody variable region gene usage in HIV-1 infection. Wisnewski A, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Jan 1;11(1):31–8 (57 ref.)

Multiple myeloma: new evidence and insights from the immunoglobulin heavy chain gene and phenotypes. Takishita M, et al. **Leuk Lymphoma** 1995 Nov; 19(5–6):395–400 (36 ref.)

Phage libraries—a new route to clinically useful antibodies. Marks C, et al. **N Engl J Med** 1996 Sep 5;335(10):730–3 (0 ref.)

The targeting of somatic hypermutation. Jolly CJ, et al. **Semin Immunol** 1996 Jun;8(3):159–68 (53 ref.)

Gene conversion and homologous recombination in murine B cells. Selsing E, et al. **Semin Immunol** 1996 Jun;8(3):151–8 (39 ref.)

Characterization of the cis-acting elements required for somatic hypermutation of murine antibody V genes using conventional transgenic and transgene homologous recombination approaches. Tumas-Brundage K, et al. **Semin Immunol** 1996 Jun;8(3):141–50 (68 ref.)

GENETICS

The influence of gene deletions and duplications within the IGHC locus on serum immunoglobulin subclass levels. Rabbani H, et al. **Clin Immunol Immunopathol** 1995 Sep; 76(3 Pt 2):S214–8 (24 ref.)

IMMUNOLOGY

Immunoglobulin gene usage in the human anti-pathogen response. Newkirk MM, et al. **Infect Agents Dis** 1995 Sep; 4(3):153–60 (59 ref.)

GENES, IMMUNOGLOBULIN HEAVY CHAIN see **GENES, IMMUNOGLOBULIN**

GENES, IMMUNOGLOBULIN LIGHT CHAIN see **GENES, IMMUNOGLOBULIN**

GENES, IMMUNOGLOBULIN VH GERM LINE see **GENES, IMMUNOGLOBULIN**

GENES, INSECT

Cosmic influences on the expression of a specific gene in the Colorado potato beetle: the diapause protein 1 gene. de Kort CA. **Arch Insect Biochem Physiol** 1996; 32(3–4):567–73 (15 ref.)

Overview of the regulation of metamorphosis-associated genes in Trichoplusia ni. Jones G, et al. **Arch Insect Biochem Physiol** 1996;32(3–4):429–37 (18 ref.)

Analysis of biological function of poly(ADP-ribosyl)ation in Drosophila melanogaster. Miwa M, et al. **Biochimie** 1995; 77(6):466–71 (32 ref.)

Dosage-dependent modification of position-effect variegation in Drosophila. Henikoff S. **Bioessays** 1996 May; 18(5):401–9 (53 ref.)

The bond between sisters [comment] Sekelsky JJ, et al. **Cell** 1995 Oct 20;83(2):157–60 (23 ref.) Comment on: Cell 1995 Oct 20;83(2):247–56.

How is pheromone specificity encoded in proteins? Prestwich GD, et al. **Chem Senses** 1995 Aug;20(4):461–9 (36 ref.)

Early decisions in Drosophila eye morphogenesis. Bonini NM, et al. **Curr Opin Genet Dev** 1995 Aug;5(4):507–15 (73 ref.)

Chromatin complexes regulating gene expression in Drosophila. Pirrotta V. **Curr Opin Genet Dev** 1995 Aug; 5(4):466–72 (57 ref.)

Gene silencing in Drosophila. Henikoff S. **Curr Top Microbiol Immunol** 1995;197:193–208 (77 ref.)

Regulatory interactions during early neurogenesis in Drosophila. Hassan B, et al. **Dev Genet** 1996;18(1):18–27 (88 ref.)

The genetic basis of quantitative variation: numbers of sensory bristles of Drosophila melanogaster as a model system. Mackay TF. **Trends Genet** 1995 Dec;11(12):464–70 (35 ref.)

Propagating memory of transcriptional states. Paro R. **Trends Genet** 1995 Aug;11(8):295–7 (17 ref.)

GENES, JUN

see related
ONCOGENE PROTEIN P65(GAG-JUN)
PROTO-ONCOGENE PROTEINS C-JUN

GENES, LETHAL

PHYSIOLOGY

Programmed cell death in bacteria: proteic plasmid stabilization systems. Jensen RB, et al. **Mol Microbiol** 1995 Jul;17(2):205–10 (48 ref.)

GENES, MATING TYPE see **GENES, FUNGAL**

GENES, MCC

see related
GENES, DCC

GENES, MHC CLASS I

HLA class I antigens in human tumors. Garrido F, et al. **Adv Cancer Res** 1995;67:155–95 (287 ref.)

Immunotherapy of human cancers. Hui KM, et al. **Ann Acad Med Singapore** 1996 Jan;25(1):113–9 (19 ref.)

Direct gene transfer for treatment of human cancer. Nabel GJ, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:227–31 (40 ref.)

The regulation of expression of histocompatibility antigens on the cell surface; molecular genetic basis. Petrányi GG. **Folia Biol (Praha)** 1995;41(3–4):163–77 (57 ref.)

Materno-fetal immunobiology in normal pregnancy and its possible failure in recurrent spontaneous abortion? Vince GS, et al. **Hum Reprod** 1995 Dec;10 Suppl 2:107–13 (50 ref.)

Dysmyelination in class I MHC transgenic mice. Turnley AM, et al. **Microsc Res Tech** 1995 Nov 1;32(4):286–94 (64 ref.)

Population biology of antigen presentation by MHC class I molecules [see comments] Parham P, et al. **Science** 1996 Apr 5;272(5258):67–74 (71 ref.) Comment in: Science 1996 Aug 9;273(5276):723–5.

DRUG EFFECTS

Regulation of HLA class I loci by interferons. Girdlestone J. **Immunobiology** 1995 Jul;193(2–4):229–37 (37 ref.)

GENETICS

Evolution of class I promoter sequences: relationship to function and diversity. Vallejo AN, et al. **Immunol Rev** 1995 Feb;143:249–62 (54 ref.)

[Regulation of the expression of HLA class I genes in human trophoblasts] Le Bouteiller P. **Pathol Biol (Paris)** 1995 Sep; 43(7):628–35 (53 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Antigen presentation by class I major histocompatibility complex molecules: a context for thinking about HLA-G. Parham P. **Am J Reprod Immunol** 1995 Jul;34(1):10–9 (48 ref.)

Structure and function of the CD1 family of MHC-like cell surface proteins. Blumberg RS, et al. **Immunol Rev** 1995 Oct;147:5–29 (86 ref.)

NK cell recognition of major histocompatibility complex class I molecules. Lanier LL, et al. **Semin Immunol** 1995 Apr;7(2):75–82 (67 ref.)

A family of murine NK cell receptors specific for target cell MHC class I molecules. Yokoyama WM, et al. **Semin Immunol** 1995 Apr;7(2):89–101 (93 ref.)

[Structure and function of major tissue histocompatibility complex (MHC) class I antigens] Falkiewicz B, et al. **Postepy Biochem** 1996;42(1):41–8 (64 ref.) **(Pol)**

PHYSIOLOGY

MHC class I-selected CD4-CD8-TCR alpha beta+ T cells: an important source of IL-4. Leite-de-Moraes MC, et al. **Braz J Med Biol Res** 1995 Aug;28(8):903–5 (28 ref.)

GENES, MHC CLASS II

Complementation cloning of mammalian transcriptional regulators: the example of MHC class II gene regulators. Steimle V, et al. **Curr Opin Genet Dev** 1995 Oct;5(5):646–51 (53 ref.)

How are class II MHC genes turned on and off? Abdulkadir SA, et al. **FASEB J** 1995 Nov;9(14):1429–35 (68 ref.)

The regulation of expression of histocompatibility antigens on the cell surface; molecular genetic basis. Petrányi GG. **Folia Biol (Praha)** 1995;41(3–4):163–77 (57 ref.)

[Progress in the study on immunogenetics of systemic lupus erythematosus] Lu Y, et al. **Chung Hua Nei Ko Tsa Chih** 1995 Jul;34(7):491–4 (17 ref.) **(Chi)**

[Use of DNA analysis for determining HLA class II antigens] Brojer E. **Acta Haematol Pol** 1995;26(3):247–56 (30 ref.) (Eng. Abstr.) **(Pol)**

GENETICS

Generation of MHC class II diversity by intra- and intergenic recombination. Andersson L, et al. **Immunol Rev** 1995 Feb; 143:5–12 (19 ref.)

Evolution of major histocompatibility complex polymorphisms and T-cell receptor diversity in primates. Bontrop RE, et al. **Immunol Rev** 1995 Feb;143:33–62 (96 ref.)

Class II B Mhc motifs in an evolutionary perspective. Klein J, et al. **Immunol Rev** 1995 Feb;143:89–111 (53 ref.)

Evolution of MHC class II allelic diversity. McDevitt H. **Immunol Rev** 1995 Feb;143:113–22 (25 ref.)

Quantifying the degree of convergence in primate Mhc-DRB genes. O hUigin C. **Immunol Rev** 1995 Feb;143:123–40 (24 ref.)

Exonic MHC-DRB polymorphisms and intronic simple repeat sequences: Janus' faces of DNA sequence evolution. Schwaiger FW, et al. **Immunol Rev** 1995 Feb;143:199–224 (55 ref.)

HLA genetics and allergic disease [editorial] Howell WM, et al. **Thorax** 1995 Aug;50(8):815–8 (32 ref.)

IMMUNOLOGY

Regulation of MHC class II gene expression. Reith W, et al. **Immunobiology** 1995 Jul;193(2–4):248–53 (23 ref.)

Molecular defects in the bare lymphocyte syndrome and regulation of MHC class II genes. Reith W, et al. **Immunol Today** 1995 Nov;16(11):539–46 (61 ref.)

PHYSIOLOGY

Evolution of Mhc class II polymorphism: the rise and fall of class II gene function in primates. Bergström T, et al. **Immunol Rev** 1995 Feb;143:13–31 (45 ref.)

Trauma-induced suppression of antigen presentation and expression of major histocompatibility class II antigen complex in leukocytes [editorial] Ayala A, et al. **Shock** 1996 Feb;5(2):79–90 (140 ref.)

GENES, MYC

see related
PROTO-ONCOGENE PROTEINS C-MYC

Proteins of the Myc network: essential regulators of cell growth and differentiation. Henriksson M, et al. **Adv Cancer Res** 1996;68:109–82 (267 ref.)

Myc oncogenes: the enigmatic family. Ryan KM, et al. **Biochem J** 1996 Mar 15;314 (Pt 3):713–21 (113 ref.)

Insight into atherosclerosis: a review of c-myc and the vascular smooth muscle cell. Golja AM, et al. **Cell Mol Biol Res** 1995;41(6):487–99 (74 ref.)

Transcriptional regulation. Flipping the Myc switch. Bernards R. **Curr Biol** 1995 Aug 1;5(8):859–61 (13 ref.)

Antitumor effects of antisense phosphorothioate c-myc oligodeoxynucleotides: a question of mechanism [editorial; comment] Stein C.A.. **J Natl Cancer Inst** 1996 Apr 3; 88(7):391–3 (9 ref.) Comment on: J Natl Cancer Inst 1996 Apr 3;88(7):419–29.

MYC family ties [news; comment] Schmidt EV. **Nat Genet** 1996 Sep;14(1):8–10 (25 ref.) Comment on: Nat Genet 1996 Sep;14(1):69–77.

[Negative repressor THZif-1 of protooncogene c-myc] Yokoyama K, et al. **Nippon Rinsho** 1995 Nov; 53(11):2827–36 (13 ref.) (Eng. Abstr.) **(Jpn)**

[Application of myc family genes to therapy of malignant brain tumors] Kuchino Y, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2713–9 (24 ref.) **(Jpn)**

GENETICS

A nuclear matrix acceptor site for the progesterone receptor in the avian c-myc gene promoter. Spelsberg TC, et al. **Recent Prog Horm Res** 1996;51:63–96 (121 ref.)

Genetic clinical markers of human neuroblastoma with special reference to N-myc oncogene: amplified or not amplified?--An overview. Tsuchida Y, et al. **Tumour Biol** 1996;17(2):65–74 (78 ref.)

PHYSIOLOGY

Role of three cancer "master genes" p53, bcl2 and c-myc on the apoptotic process. Chiarugi V, et al. **Tumori** 1996 May-Jun;82(3):205–9 (57 ref.)

GENES, NEU see **GENES, ERBB-2**

GENES, NEUROFIBROMATOSIS 1

The neurofibromatosis type 1 (NF1) tumor suppressor gene and myeloid leukemia. Largaespada DA, et al. **Curr Top Microbiol Immunol** 1996;211:233–9 (29 ref.)

GENES, NEUROFIBROMATOSIS 2

Schwannomin: new insights into this member of the band 4.1 superfamily. Belliveau MJ, et al. **Biochem Cell Biol** 1995 Sep-Oct;73(9–10):733–7 (44 ref.)

The neurofibromatosis 2 (NF2) tumour suppressor gene: implications beyond the hereditary tumour syndrome? Kley N, et al. **Cancer Surv** 1995;25:207–18 (45 ref.)

Neurofibromatosis type 2 and von Hippel-Lindau disease: from gene cloning to function. Kley N, et al. **Glia** 1995 Nov;15(3):297–307 (75 ref.)

GENETICS

CNS Young Investigator Award Lecture: molecular analysis of the neurofibromatosis 2 tumor suppressor. MacCollin M. **Brain Dev** 1995 Jul-Aug;17(4):231–8 (64 ref.)

Neurofibromatosis type 2 and von Hippel-Lindau disease: from gene cloning to function. Kley N, et al. **Glia** 1995 Nov;15(3):297–307 (75 ref.)

[A new tumor suppressor gene responsible for type 2 neurofibromatosis is inactivated in neurinoma and meningioma] Sanson M. **Rev Neurol (Paris)** 1996 Jan; 152(1):1–10 (74 ref.) (Eng. Abstr.) **(Fre)**

GENES, NF1 see **GENES, NEUROFIBROMATOSIS 1**

GENES, NF2 see **GENES, NEUROFIBROMATOSIS 2**

GENES, P53

see related
PROTEIN P53

Tumour suppressor p53 and Rb genes in human hepatocellular carcinoma. Lin Y, et al. **Ann Acad Med Singapore** 1996 Jan;25(1):22–30 (72 ref.)

Immunochemical and genetic analysis of the p53 gene in liver preneoplastic nodules from aflatoxin-induced rats in one year. Liu YP, et al. **Ann Acad Med Singapore** 1996 Jan; 25(1):31–6 (51 ref.)

p53 and prognosis in colorectal cancer. Smith DR, et al. **Ann Acad Med Singapore** 1996 Jan;25(1):107–12 (97 ref.)

The spectrum of mutations at the p53 locus. Evidence for tissue-specific mutagenesis, selection of mutant alleles, and a "gain of function" phenotype. Levine AJ, et al. **Ann N Y Acad Sci** 1995 Sep 30;768:111–28 (55 ref.)

Effects of p53 mutation on tumor progression: recent insights from mouse tumor models. Donehower LA. **Biochim Biophys Acta** 1996 Mar 18;1242(3):171–6 (66 ref.)

The 1995 Walter Hubert Lecture--molecular epidemiology of human cancer: insights from the mutational analysis of the p53 tumour-suppressor gene. Harris CC. **Br J Cancer** 1996 Feb;73(3):261–9 (89 ref.)

Cisplatin. Dabholkar M, et al. **Cancer Chemother Biol Response Modif** 1996;16:88–110 (101 ref.)

Murine models of neoplasia: functional analysis of the tumour suppressor genes Rb-1 and p53. Clarke AR. **Cancer Metastasis Rev** 1995 Jun;14(2):125–48 (107 ref.)

Apoptosis, cancer and the p53 tumour suppressor gene. Lee JM, et al. **Cancer Metastasis Rev** 1995 Jun;14(2):149–61 (113 ref.)

Germline mutations in the TP53 gene. Eeles RA. **Cancer Surv** 1995;25:101–24 (106 ref.)

Dominant oncogenes, tumor suppressors, and radiosensitivity. Chiarugi V, et al. **Cell Mol Biol Res** 1995; 41(3):161–6 (63 ref.)

Biological and clinical importance of the p53 tumor

suppressor gene. Velculescu VE, et al. **Clin Chem** 1996 Jun;42(6 Pt 1):858–68 (169 ref.)
DNA damage responses: p53 induction, cell cycle perturbations, and apoptosis. Canman CE, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:277–86 (53 ref.)
Transgenic approaches to the analysis of ras and p53 function in multistage carcinogenesis. Kemp CJ, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:427–34 (50 ref.)
The significance of alterations in p53 expression in gynaecological neoplasms. Manek S, et al. **Curr Opin Obstet Gynecol** 1996 Feb;8(1):52–5 (33 ref.)
Cancer therapy and p53. Lowe SW. **Curr Opin Oncol** 1995 Nov;7(6):547–53 (61 ref.)
The p53 gene and its role in human brain tumors. Bögler O, et al. **Glia** 1995 Nov;15(3):308–27 (191 ref.)
p53 proteins and aflatoxin b1: the good, the bad, and the ugly [editorial] Liang TJ. **Hepatology** 1995 Oct;22(4 Pt 1):1330–2 (21 ref.)
Lessons from the p53 mutant mouse. Jacks T. **J Cancer Res Clin Oncol** 1996;122(6):319–27 (79 ref.)
Structural aspects of the p53 protein in relation to gene evolution: a second look. Soussi T, et al. **J Mol Biol** 1996 Aug 2;260(5):623–37 (143 ref.)
The p53 tumour suppressor gene and tumour prognosis: is there a relationship? [editorial] Dowell SP, et al. **J Pathol** 1995 Nov;177(3):221–4 (40 ref.)
Chromosome 17 abnormalities and inactivation of the p53 gene in chronic myeloid leukemia and their prognostic significance. Nakai H, et al. **Leuk Lymphoma** 1995 Oct; 19(3–4):213–21 (58 ref.)
p53 gene therapy in vivo of herpatocellular and liver metastatic colorectal cancer. Bookstein R, et al. **Semin Oncol** 1996 Feb;23(1):66–77 (109 ref.)
Role of p53 in leukemogenesis of chronic myeloid leukemia. Lanza F, et al. **Stem Cells (Dayt)** 1995 Jul;13(4):445–52 (54 ref.)
1995 Deichmann Lecture—p53 tumor suppressor gene: at the crossroads of molecular carcinogenesis, molecular epidemiology and cancer risk assessment. Harris CC. **Toxicol Lett** 1995 Dec;82–83:1–7 (43 ref.)
The role of p53 in regulating genomic stability when DNA and RNA synthesis are inhibited. Chernova OB, et al. **Trends Biochem Sci** 1995 Oct;20(10):431–4 (49 ref.)
Cellular responses to DNA damage: cell-cycle checkpoints, apoptosis and the roles of p53 and ATM. Enoch T, et al. **Trends Biochem Sci** 1995 Oct;20(10):426–30 (45 ref.)
[Some new advances in the study on p53] Zhou Q, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1995 Aug;24(4):267–8 (16 ref.) **(Chi)**
[Correlation between p-53 expression and clinical resistance in testicular cancer] Hanna E, et al. **Orv Hetil** 1996 Jan 14;137(2):59–64 (26 ref.) (Eng. Abstr.) **(Hun)**
[Prognostic factors of colon cancer from a molecular biology standpoint] Mori M, et al. **Gan To Kagaku Ryoho** 1996 Jul;23(8):982–9 (51 ref.) (Eng. Abstr.) **(Jpn)**
[Human papillomavirus type 16–gene functions relevant to molecular human carcinogenesis] Yasumoto S. **Nippon Rinsho** 1995 Nov;53(11):2858–67 (20 ref.) (Eng. Abstr.) **(Jpn)**
[Clinicopathological study on primary lung cancer—immunohistochemical expression of p53 suppressor gene and bcl-2 oncogene in relation to prognosis] Irie K, et al. **Rinsho Byori** 1996 Jan;44(1):32–41 (23 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

P53-mediated radioresistance does not correlate with metastatic potential in tumorigenic rat embryo cell lines following oncogene transfection. Bristow RG, et al. **Int J Radiat Oncol Biol Phys** 1996 Jan 15;34(2):341–55 (81 ref.)
P53 gene mutations in lymphoid diseases and their possible relevance to drug resistance. Newcomb EW. **Leuk Lymphoma** 1995 Apr;17(3–4):211–21 (86 ref.)
P53 and induction of apoptosis as a target for anticancer therapy. Neubauer A, et al. **Leukemia** 1996 Jul;10 Suppl 3:S2–S4 (46 ref.)
p53 tumor suppressor gene: implications for iatrogenic cancer and cancer therapy. De Benedetti V, et al. **Med Pediatr Oncol Suppl** 1996;1:2–11 (129 ref.)
A unique spectrum of p53 mutations in B-cell chronic lymphocytic leukemia distinct from that of other lymphoid malignancies. Newcomb EW, et al. **Mol Carcinog** 1995 Dec; 14(4):227–32 (64 ref.)
Genetic alterations associated with the evolution and progression of astrocytic brain tumours. Ohgaki H, et al. **Virchows Arch** 1995;427(2):113–8 (44 ref.)
[Hereditary mutations in the p53 tumor suppressor gene; significance for clinical practice. National Work Group Hereditary Mamma Carcinoma] Menko FH, et al. **Ned Tijdschr Geneeskd** 1996 Jun 29;140(26):1347–50 (21 ref.) **(Dut)**
[P53 protein: a new tool for the clinician? (editorial)] Laurent-Puig P. **Gastroenterol Clin Biol** 1995 May; 19(5):463–4 (8 ref.) **(Fre)**
[Transactivation function of HBV X protein and tumor suppressor gene p53] Takada S. **Nippon Rinsho** 1995 Oct; 53 Suppl:82–8 (33 ref.) **(Jpn)**
[p53 gene mutations in brain tumors] Koga H, et al. **No To Shinkei** 1995 Sep;47(9):845–55 (108 ref.) **(Jpn)**
[P53 protein gene. Review of the literature and assessment of the prognostic impact of its mutations in bladder tumors] Marchal Escalona C, et al. **Actas Urol Esp** 1996 Feb; 20(2):93–102 (42 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

Life and death by p53. Elledge RM, et al. **Bioessays** 1995 Nov;17(11):923–30 (95 ref.)
Molecular mechanisms of lung cancer. Interaction of environmental and genetic factors. Giles F. Filley Lecture. Devereux TR, et al. **Chest** 1996 Mar;109(3 Suppl):14S–19S (80 ref.)
Apoptosis and chemotherapy resistance. Hickman JA. **Eur J Cancer** 1996 Jun;32A(6):921–6 (67 ref.)
Cancer progression and p53. Carson DA, et al. **Lancet** 1995 Oct 14;346(8981):1009–11 (23 ref.)
Role of three cancer "master genes" p53, bcl2 and c-myc on the apoptotic process. Chiarugi V, et al. **Tumori** 1996 May-Jun;82(3):205–9 (57 ref.)

RADIATION EFFECTS

p53 gene mutations and photocarcinogenesis. Nataraj AJ, et al. **Photochem Photobiol** 1995 Aug;62(2):218–30 (140 ref.)
Marker genes for cytotoxic exposure: p53. Montenarh M. **Stem Cells (Dayt)** 1995 May;13 Suppl 1:136–41 (68 ref.)

GENES, PLANT

MADS-box genes in plant ontogeny and phylogeny: Haeckel's 'biogenetic law' revisited. Theissen G, et al. **Curr Opin Genet Dev** 1995 Oct;5(5):628–39 (97 ref.)
Suppression of flavonoid flower pigmentation genes in Petunia hybrida by the introduction of antisense and sense genes. de Lange P, et al. **Curr Top Microbiol Immunol** 1995; 197:57–75 (88 ref.)
Developmental regulation of co-suppression in Petunia hybrida. Flavell RB, et al. **Curr Top Microbiol Immunol** 1995;197:43–56 (63 ref.)
Sense and antisense inactivation of fruit ripening genes in tomato. Hamilton AJ, et al. **Curr Top Microbiol Immunol** 1995;197:77–89 (70 ref.)
trans-inactivation of homologous sequences in Nicotiana tabacum. Matzke AJ, et al. **Curr Top Microbiol Immunol** 1995;197:1–14 (30 ref.)
Paramutation in maize and related allelic interactions. Patterson GI, et al. **Curr Top Microbiol Immunol** 1995; 197:121–41 (94 ref.)
Transgene inactivation in Arabidopsis thaliana. Scheid OM. **Curr Top Microbiol Immunol** 1995;197:29–42 (57 ref.)
URF13, a ligand-gated, pore-forming receptor for T-toxin in the inner membrane of cms-T mitochondria. Rhoads DM, et al. **J Bioenerg Biomembr** 1995 Aug;27(4):437–45 (52 ref.)
Gene characterization by southern analysis. Sabelli PA, et al. **Methods Mol Biol** 1995;49:161–80 (39 ref.)
Xenopus oocytes as a heterologous expression system. Theodoulou FL, et al. **Methods Mol Biol** 1995;49:317–40 (48 ref.)
Heterologous expression in yeast. Trueman LJ. **Methods Mol Biol** 1995;49:341–54 (18 ref.)
Compilation and classification of higher plant mitochondrial tRNA genes. Veronico P, et al. **Nucleic Acids Res** 1996 Jun 15;24(12):2199–203 (27 ref.)
Arabidopsis in Madison: genes and phenotypes spread like weeds. Chasan R. **Plant Cell** 1995 Nov;7(11):1737–48 (34 ref.)
Infertility treatment: a nuclear restorer gene in maize [comment] Levings CS 3rd. **Science** 1996 May 31; 272(5266):1279–80 (16 ref.) Comment on: Science 1996 May 31;272(5266):1334–6.
Green light for steroid hormones [comment] Russell DW. **Science** 1996 Apr 19;272(5260):370–1 (7 ref.) Comment on: Science 1996 Apr 19;272(5260):398–401.
The ethylene signal transduction pathway in Arabidopsis: an emerging paradigm? Chang C. **Trends Biochem Sci** 1996 Apr;21(4):129–33 (35 ref.)
Extracellular matrix and pattern in plant embryos: on the lookout for developmental information. Brownlee C, et al. **Trends Genet** 1995 Sep;11(9):344–8 (52 ref.)
Shoot development in plants: time for a change. Lawson EJ, et al. **Trends Genet** 1995 Jul;11(7):263–8 (32 ref.)
Cf9 and Avr9, two major players in the gene-for-gene game. de Wit PJ. **Trends Microbiol** 1995 Jul;3(7):251–2 (15 ref.)
[Molecular cloning of differentially expressed genes during plant somatic embryogenesis] Kayano T, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):721–6 (32 ref.) **(Jpn)**

PHYSIOLOGY

Homeobox genes in the functioning of plant meristems. Hake S, et al. **Philos Trans R Soc Lond B Biol Sci** 1995 Oct 30;350(1331):45–51 (32 ref.)
Genetic and environmental control of flowering time in Arabidopsis. Coupland G. **Trends Genet** 1995 Oct; 11(10):393–7 (38 ref.)

GENES, PROTOZOAN

Molecular identification of nanoplanktonic protists based on small subunit ribosomal RNA gene sequences for ecological studies. Lim EL. **J Eukaryot Microbiol** 1996 Mar-Apr; 43(2):101–6 (47 ref.)

GENES, PX

[Chronic rheumatoid arthritis model mice transgenic for the HTLV-I tax gene] Iwakura Y. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2074–82 (33 ref.) **(Jpn)**

GENETICS

Role of kinases in HTLV-I transformation. Xu X, et al. **J Investig Med** 1996 Apr;44(4):113–23 (169 ref.)

GENES, RAS

see related
ONCOGENE PROTEIN P21(RAS)
PROTO-ONCOGENE PROTEIN P21(RAS)
RAS PROTEINS

Glycerophosphoinositols as potential markers of ras-induced transformation and novel second messengers. Corda D, et al. **Anticancer Res** 1996 May-Jun;16(3B):1341–50 (86 ref.)
Altered adhesions in ras-transformed breast epithelial cells. Kinch MS, et al. **Biochem Soc Trans** 1995 Aug;23(3):446–50 (43 ref.)
Transgenic approaches to the analysis of ras and p53 function in multistage carcinogenesis. Kemp CJ, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:427–34 (50 ref.)
Genetic markers: the key to early diagnosis and improved survival in pancreatic cancer? [editorial; comment] [see comments] Urrutia R, et al. **Gastroenterology** 1996 Jan; 110(1):306–10 (57 ref.) Comment on: Gastroenterology 1996 Jan;110(1):221–6. Comment on: Gastroenterology 1996 Jan;110(1):227–31. Comment in: Gastroenterology 1996 Aug;111(2):566–7.
K-ras mutation and pancreatic adenocarcinoma. Caldas C, et al. **Int J Pancreatol** 1995 Aug;18(1):1–6 (66 ref.)
Diagnostic detection of mutant ras genes in minor cell populations. Kahn SM, et al. **Methods Enzymol** 1995; 255:452–64 (47 ref.)
Control of signal transduction and morphogenesis by Ras. Hughes DA. **Semin Cell Biol** 1995 Apr;6(2):89–94 (49 ref.)
[Genetic abnormalities in lung cancer and their prognostic implications] Mitsudomi T, et al. **Gan To Kagaku Ryoho** 1996 Jul;23(8):990–6 (54 ref.) (Eng. Abstr.) **(Jpn)**
[Heterogeneity of GTPase-activating proteins for Ras in the regulation of Ras signal transduction pathway] Hattori S, et al. **Yakugaku Zasshi** 1996 Jan;116(1):21–38 (58 ref.) (Eng. Abstr.) **(Jpn)**
[Determination of the activated proto-oncogene (Ki-ras) in feces. A new laboratory analysis for early diagnosis of colorectal cancer] Koornstra JJ, et al. **Tidsskr Nor Laegeforen** 1995 Oct 30;115(26):3266–70 (42 ref.) (Eng. Abstr.) **(Nor)**

DRUG EFFECTS

Opportunities for pharmacological intervention in the ras pathway. Marshall CJ. **Ann Oncol** 1995;6 Suppl 1:63–7 (34 ref.)
The Rac and Rho pathways as a source of drug targets for Ras-mediated malignancies. Symons M. **Curr Opin Biotechnol** 1995 Dec;6(6):668–74 (63 ref.)

GENETICS

K-ras mutation in a tubular adenoma originating at an ileostomy in a familial adenomatous polyposis patient. Herring JA, et al. **Am J Gastroenterol** 1996 Mar; 91(3):587–91 (38 ref.)
P53-mediated radioresistance does not correlate with metastatic potential in tumorigenic rat embryo cell lines following oncogene transfection. Bristow RG, et al. **Int J Radiat Oncol Biol Phys** 1996 Jan 15;34(2):341–55 (81 ref.)

PHYSIOLOGY

Activated ras. Yet another player in melanoma? [comment] Herlyn M, et al. **Am J Pathol** 1996 Sep;149(3):739–44 (47 ref.) Comment on: Am J Pathol 1996 Sep;149(3):883–93.
Isoprenoids and Ras: potential role in chronic rejection. O'Donnell MP, et al. **Kidney Int Suppl** 1995 Dec;52:S29–33 (49 ref.)

GENES, RB see **GENES, RETINOBLASTOMA**

GENES, RECESSIVE

Autosomal recessive omodysplasia. Stoll C, et al. **Ann Genet** 1995;38(2):97–101 (8 ref.)
Bloom syndrome: is the gene mapped to the point? Bamezai R. **Indian J Exp Biol** 1996 Apr;34(4):298–301 (38 ref.)
Absence/hypoplasia of tibia, polydactyly, retrocerebellar arachnoid cyst, and other anomalies: an autosomal recessive disorder. Holmes LB, et al. **J Med Genet** 1995 Nov; 32(11):896–900 (29 ref.)
The myotubular myopathies: differential diagnosis of the X linked recessive, autosomal dominant, and autosomal recessive forms and present state of DNA studies. Wallgren-Pettersson C, et al. **J Med Genet** 1995 Sep; 32(9):673–9 (56 ref.)
X-linked recessive bulbospinal neuronopathy (SBMA). Sobue G. **Nagoya J Med Sci** 1995 Dec;58(3–4):95–106 (41 ref.)

Association of infantile neuroaxonal dystrophy and osteopetrosis: a rare autosomal recessive disorder. Rees H, et al. **Pediatr Neurosurg** 1995;22(6):321–7 (36 ref.)
[Autosomal recessive limb-girdle muscular dystrophy probably linked to chromosome 15] Noguera Moya A, et al. **An Esp Pediatr** 1996 Mar;44(3):267–9 (17 ref.) **(Spa)**

GENETICS

Chondrodysplasia punctata: case report and literature review of patients with heart lesions. Fourie DT. **Pediatr Cardiol** 1995 Sep–Oct;16(5):247–50 (33 ref.)

GENES, REGULATOR

see related
REGULON
TRANS-ACTIVATION (GENETICS)

Internal transcriptional regulatory elements in HIV-1 and other retroviruses. Verdin E, et al. **Cell Mol Biol (Noisy-le-grand)** 1995 May;41(3):365–9 (26 ref.)
Transcriptional regulation of the genes involved in lipoprotein transport. The role of proximal promoters and long-range regulatory elements and factors in apolipoprotein gene regulation. Kardassis D, et al. **Hypertension** 1996 Apr;27(4):980–1008 (116 ref.)
Mechanisms of transcriptional synergism of eukaryotic genes. The interferon-beta paradigm. Thanos D. **Hypertension** 1996 Apr;27(4):1025–9 (25 ref.)
[Brakes of the cell cycle—new inhibitor genes? (editorial)] Laiho M. **Duodecim** 1994;110(16):1502–4 (12 ref.) **(Fin)**

GENES, REITERATED

see related
REPETITIVE SEQUENCES, NUCLEIC ACID

The alcohol dehydrogenase system. Jörnvall H, et al. **Adv Exp Med Biol** 1995;372:281–94 (51 ref.)
Short-chain dehydrogenases/reductases. Persson B, et al. **Adv Exp Med Biol** 1995;372:383–95 (38 ref.)
Rat and human bile acid binders are members of the monomeric reductase gene family. Stolz A, et al. **Adv Exp Med Biol** 1995;372:269–80 (56 ref.)
The proteolipid protein gene: double, double, ... and trouble [editorial] Hodes ME, et al. **Am J Hum Genet** 1996 Jul; 59(1):12–5 (27 ref.)
Clinical dysmorphology beyond developmental genetics: recent advances in some human developmental genes. Lacombe D. **Ann Genet** 1995;38(3):137–44 (59 ref.)
Pax genes and skeletal development. Balling R, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:27–33 (29 ref.)
Schwannomin: new insights into this member of the band 4.1 superfamily. Belliveau MJ, et al. **Biochem Cell Biol** 1995 Sep–Oct;73(9–10):733–7 (44 ref.)
Myc oncogenes: the enigmatic family. Ryan KM, et al. **Biochem J** 1996 Mar 15;314 (Pt 3):713–21 (113 ref.)
The pleckstrin homology domain: an intriguing multifunctional protein module. Shaw G. **Bioessays** 1996 Jan;18(1):35–46 (69 ref.)
Membrane adhesion and other functions for the myelin basic proteins. Staugaitis SM, et al. **Bioessays** 1996 Jan;18(1):13–8 (45 ref.)
Src and the control of cell division. Taylor SJ, et al. **Bioessays** 1996 Jan;18(1):9–11 (40 ref.)
Molecular cytogenetic studies of duplication 9q32—>q34.3 inserted into 9q13. Hou JW, et al. **Clin Genet** 1995 Sep; 48(3):148–50 (9 ref.)
Bcl-2 gene family and the regulation of programmed cell death. Yin XM, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:387–93 (46 ref.)
Evolution of ATP-binding cassette transporter genes. Dean M, et al. **Curr Opin Genet Dev** 1995 Dec;5(6):779–85 (42 ref.)
Regulation of nitrogen metabolism, starch utilisation and the beta-hbd-adh1 gene cluster in Clostridium acetobutylicum. Woods DR, et al. **FEMS Microbiol Rev** 1995 Oct; 17(3):299–306 (29 ref.)
The C/EBP family of transcription factors. Wedel A, et al. **Immunobiology** 1995 Jul;193(2–4):171–85 (100 ref.)
Notch-related genes in animal development. Lardelli M, et al. **Int J Dev Biol** 1995 Oct;39(5):769–80 (106 ref.)
The Wilhelmine E. Key 1992 Invitational lecture. Phenotypic analysis of the Dopa decarboxylase gene cluster mutants in Drosophila melanogaster. Wright TR. **J Hered** 1996 May–Jun;87(3):175–90 (99 ref.)
The CYP2A gene subfamily: species differences, regulation, catalytic activities and role in chemical carcinogenesis. Fernandez-Salguero P, et al. **Pharmacogenetics** 1995;5 Spec No:S123–8 (56 ref.)
Seeing double: appreciating genetic redundancy. Pickett FB, et al. **Plant Cell** 1995 Sep;7(9):1347–56 (53 ref.)
'Chauvinist genes' of male germ cells: gene expression during mouse spermatogenesis. Eddy EM. **Reprod Fertil Dev** 1995; 7(4):695–704 (80 ref.)

IMMUNOLOGY

The influence of gene deletions and duplications within the IGHC locus on serum immunoglobulin subclass levels. Rabbani H, et al. **Clin Immunol Immunopathol** 1995 Sep; 76(3 Pt 2):S214–8 (24 ref.)

GENES, REPORTER

The beta-glucuronidase (gus) reporter gene system. Gene fusions; spectrophotometric, fluorometric, and histochemical detection. Hull GA, et al. **Methods Mol Biol** 1995;49:125–41 (35 ref.)

GENETICS

Inactivation in vivo of metabotropic glutamate receptor 1 by specific chromosomal insertion of reporter gene lacZ. Conquet F. **Neuropharmacology** 1995 Aug;34(8):865–70 (14 ref.)

GENES, RETINOBLASTOMA

Tumour suppressor p53 and Rb genes in human hepatocellular carcinoma. Lin Y, et al. **Ann Acad Med Singapore** 1996 Jan;25(1):22–30 (72 ref.)
E2F and the molecular mechanisms of early cell-cycle control. La Thangue NB. **Biochem Soc Trans** 1996 Feb; 24(1):54–9 (29 ref.)
In vitro models for studying colorectal carcinogenesis: cellular and molecular events including APC and Rb cleavage in the control of proliferation, differentiation and apoptosis. Williams AC, et al. **Biochim Biophys Acta** 1996 Aug 8;1288(1):F9–19 (91 ref.)
Murine models of neoplasia: functional analysis of the tumour suppressor genes Rb-1 and p53. Clarke AR. **Cancer Metastasis Rev** 1995 Jun;14(2):125–48 (107 ref.)
The retinoblastoma protein as a fundamental mediator of growth and differentiation signals. Chen PL, et al. **Crit Rev Eukaryot Gene Expr** 1995;5(1):79–95 (114 ref.)
Retinoblastoma gene in mouse neural development. Slack RS, et al. **Dev Genet** 1996;18(1):81–91 (155 ref.)
Alterations of the retinoblastoma a susceptibility gene in chronic lymphocytic leukemia. Neubauer A, et al. **Leuk Lymphoma** 1995 Aug;18(5–6):399–404 (44 ref.)
Abnormalities of retinoblastoma gene expression in hematological malignancies. Zhu YM, et al. **Leuk Lymphoma** 1995 Jun;18(1–2):61–7 (80 ref.)

GENES, REV

[Gene therapy of AIDS by a Rev mutant without nucleolar dysfunction] Hatanaka M. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2753–8 (8 ref.) **(Jpn)**

GENES, REX see **GENES, PX**

GENES, SPLICED see **DNA, RECOMBINANT**

GENES, SPLIT see **GENES**

GENES, SRC

see related
SRC HOMOLOGY DOMAINS

Regulation, substrates and functions of src. Brown MT, et al. **Biochim Biophys Acta** 1996 Jun 7;1287(2–3):121–49 (393 ref.)
Src and the control of cell division. Taylor SJ, et al. **Bioessays** 1996 Jan;18(1):9–11 (40 ref.)

GENES, STRUCTURAL

The Ca2+(-)binding proteins parvalbumin and oncomodulin and their genes: new structural and functional findings. Pauls TL, et al. **Biochim Biophys Acta** 1996 Apr 10; 1306(1):39–54 (168 ref.)
Single-cell analysis of unstable genes. Daniels R, et al. **J Assist Reprod Genet** 1996 Feb;13(2):163–9 (28 ref.)

GENETICS

T-cell receptor gene analysis in cutaneous T-cell lymphomas. Whittaker S. **Clin Exp Dermatol** 1996 Mar;21(2):81–7 (67 ref.)
[Lipoprotein lipase: a multifunctional enzyme in lipoprotein metabolism] Foubert L, et al. **Presse Med** 1996 Feb 10; 25(5):207–10 (25 ref.) (Eng. Abstr.) **(Fre)**
[The mouse embryogenesis of jumonji mutant obtained by gene-trap method] Motoyama J, et al. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2152–61 (24 ref.) **(Jpn)**
[Mice carrying null mutations of the homeotic genes Hoxa10 and Msx1] Satokata I, et al. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2134–43 (50 ref.) **(Jpn)**
[Looking for a needle in a haystack. Identification of differentially expressed genes] Dąbrowski M. **Postepy Biochem** 1995;41(2):110–5 (36 ref.) **(Pol)**

PHYSIOLOGY

[Function of Hox genes in formation of skeletons] Suemori H. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2144–51 (31 ref.) **(Jpn)**
[The roles of Wnt genes during mouse development] Takada S. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2162–74 (66 ref.) **(Jpn)**

GENES, STRUCTURAL, BACTERIAL

The genetics of lantibiotic biosynthesis. Jack R, et al. **Bioessays** 1995 Sep;17(9):793–802 (69 ref.)
The role of the genome project in determining gene function: insights from model organisms. Miklos GL, et al. **Cell** 1996 Aug 23;86(4):521–9 (92 ref.)

GENETICS

Genetics of pentose-phosphate pathway enzymes of Escherichia coli K-12. Sprenger GA. **Arch Microbiol** 1995 Nov;164(5):324–30 (47 ref.)

GENES, STRUCTURAL, FUNGAL

Secondary structure conservation of the U3 small nucleolar RNA introns in Saccharomyces. Brulé F, et al. **C R Acad Sci III** 1995 Dec;318(12):1197–206 (48 ref.)
The role of the genome project in determining gene function: insights from model organisms. Miklos GL, et al. **Cell** 1996 Aug 23;86(4):521–9 (92 ref.)

GENES, STRUCTURAL, INSECT

Transcriptional silencing of homeotic genes in Drosophila. Bienz M, et al. **Bioessays** 1995 Sep;17(9):775–84 (71 ref.)
Drosophila Sgs genes: stage and tissue specificity of hormone responsiveness. Lehmann M. **Bioessays** 1996 Jan; 18(1):47–54 (70 ref.)
Genetic mechanisms of early neurogenesis in Drosophila melanogaster. Campos-Ortega JA. **Mol Neurobiol** 1995 Apr–Jun;10(2–3):75–89 (97 ref.)
Gene disruptions using P transposable elements: an integral component of the Drosophila genome project. Spradling AC, et al. **Proc Natl Acad Sci U S A** 1995 Nov 21; 92(24):10824–30 (38 ref.)
Metamorphosis in Drosophila: from molecular biology to mutants. Bender M. **Trends Genet** 1995 Sep;11(9):335–6 (21 ref.)
The relationship between the flamenco gene and gypsy in Drosophila: how to tame a retrovirus. Bucheton A. **Trends Genet** 1995 Sep;11(9):349–53 (40 ref.)

GENES, STRUCTURAL, NEOPLASM

Fusion genes and their hybrid proteins in human leukemias and lymphomas. Look AT. **Proc Assoc Am Physicians** 1995 Jul;107(2):175–80 (76 ref.)

GENES, STRUCTURAL, PLANT

Co-suppression of beta-1,3-glucanase genes in Nicotiana tabacum. de Carvalho Niebel F, et al. **Curr Top Microbiol Immunol** 1995;197:91–103 (39 ref.)

GENES, STRUCTURAL, PROTOZOAN

[Advances in the study of molecular biology in Cryptosporidium] Ma L, et al. **Chung Kuo Chi Sheng Chung Hsueh Yu Chi Sheng Chung Ping Tsa Chih** 1995;13(2):145–9 (20 ref.) **(Chi)**

GENES, STRUCTURAL, VIRAL

DNA immunization with bovine herpesvirus-1 genes. Babiuk LA, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:47–63 (56 ref.)
[Gene structure and transformation mechanism of HTLV-I] Matsumoto K. **Nippon Rinsho** 1995 Nov;53(11):2837–45 (21 ref.) (Eng. Abstr.) **(Jpn)**

GENES, SUPPRESSOR

see related
SUPPRESSION, GENETIC

GENETICS

Transcription factors in renal development: the WT1 and Pax-2 story. Dressler GR. **Semin Nephrol** 1995 Jul; 15(4):263–71 (86 ref.)
[Oncogenes and suppressor genes: apoptosis mechanisms] Mezquita C. **Med Clin (Barc)** 1995 Sep 30;105(10):389–95 (53 ref.) **(Spa)**

GENES, SUPPRESSOR, TUMOR

Mutation and cancer: a personal odyssey. Knudson AG Jr. **Adv Cancer Res** 1995;67:1–23 (144 ref.)
The two faces of tumor suppressor p53. Smith ML, et al. **Am J Pathol** 1996 Apr;148(4):1019–22 (39 ref.)
Molecular cloning of the von Hippel-Lindau tumor suppressor gene and its role in renal carcinoma. Gnarra JR, et al. **Biochim Biophys Acta** 1996 Mar 18;1242(3):201–10 (60 ref.)
p16INK4A as a human tumor suppressor. Shapiro GI, et al. **Biochim Biophys Acta** 1996 Mar 18;1242(3):165–9 (59 ref.)
Genetic characteristics of prostate cancer. Huncharek M, et al. **Cancer Epidemiol Biomarkers Prev** 1995 Sep;4(6):681–7 (65 ref.)
Recent advances in the molecular genetics of malignant melanoma. Haluska FG, et al. **Cancer Surv** 1995;25:277–92

(72 ref.)
The neurofibromatosis 2 (NF2) tumour suppressor gene: implications beyond the hereditary tumour syndrome? Kley N, et al. **Cancer Surv** 1995;25:207–18 (45 ref.)
Role of transgenic mice in identification and characterization of tumour suppressor genes. Sharan SK, et al. **Cancer Surv** 1995;25:143–59 (103 ref.)
Prospects for cancer genetics. Weinberg RA. **Cancer Surv** 1995;25:3–12 (20 ref.)
Von Hippel–Lindau disease and sporadic renal cell carcinoma. Zbar B. **Cancer Surv** 1995;25:219–32 (32 ref.)
Molecular genetics of proto–oncogenes and candidate tumor suppressors in Caenorhabditis elegans. Sternberg PW, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:155–63 (49 ref.)
Biological characteristics of micrometastatic carcinoma cells in bone marrow. Braun S, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 1):163–77 (55 ref.)
Molecular control of development in normal and leukemic myeloid cells by cytokines, tumor suppressor and oncogenes. Sachs L. **Curr Top Microbiol Immunol** 1996; 211:3–5 (18 ref.)
1p36: every subband a suppressor? Versteeg R, et al. **Eur J Cancer** 1995;31A(4):538–41 (27 ref.)
Prohibitin: potential role in senescence, development, and tumor suppression. McClung JK, et al. **Exp Gerontol** 1995 Mar–Apr;30(2):99–124 (90 ref.)
Cell cycle regulation and human leukemias: the role of p16INK4 gene inactivation in the development of human acute lymphoblastic leukemia. Della Ragione F, et al. **Haematologica** 1995 Nov–Dec;80(6):557–68 (87 ref.)
Molecular pathogenesis of non–Hodgkin lymphoma: a clinical perspective. Gaidano G, et al. **Haematologica** 1995 Sep–Oct;80(5):454–72 (151 ref.)
Gene replacement strategies for cancer. Roth JA. **Isr J Med Sci** 1996 Feb;32(2):89–94 (12 ref.)
Progress against cancer. Broder S, et al. **J Cancer Res Clin Oncol** 1995;121(11):633–47 (134 ref.)
Biomarkers in the endometrium. Berchuck A. **J Cell Biochem Suppl** 1995;23:174–8 (32 ref.)
Molecular biology of testicular germ cell tumors: current status. Schmidt B, et al. **J Mol Med** 1995 Jul;73(7):355–67 (189 ref.)
Antisense oncogene and tumor suppressor gene therapy of cancer. Zhang WW. **J Mol Med** 1996 Apr;74(4):191–204 (137 ref.)
Tumor suppressor genes and clonal evolution in B–CLL. Kay NE, et al. **Leuk Lymphoma** 1995 Jun;18(1–2):41–9 (103 ref.)
Biology of small cell lung cancer. Johnson BE, et al. **Lung Cancer** 1995 Jun;12 Suppl 3:S5–16 (88 ref.)
Molecular events in lung cancer. Roth JA. **Lung Cancer** 1995 Jun;12 Suppl 2:S3–15 (51 ref.)
Tumor suppresaor genes in the TGF–beta signaling pathway? Serra R, et al. **Nat Med** 1996 Apr;2(4):390–1 (15 ref.)
The Gorlin syndrome gene: a tumor suppressor active in basal cell carcinogenesis and embryonic development. Bale AE, et al. **Proc Assoc Am Physicians** 1995 Jul;107(2):253–7 (35 ref.)
Replicative senescence: implications for in vivo aging and tumor suppression. Smith JR, et al. **Science** 1996 Jul 5; 273(5271):63–7 (52 ref.)
Tumor suppressor genes and their alterations in breast cancer. Lee EY. **Semin Cancer Biol** 1995 Jun;6(3):119–25 (46 ref.)
Mutations of the BRCA1 gene in human cancer. Xu CF, et al. **Semin Cancer Biol** 1996 Feb;7(1):33–40 (63 ref.)
Multistep carcinogenesis in colorectal cancers. Takami K, et al. **Southeast Asian J Trop Med Public Health** 1995;26 Suppl 1:190–6 (28 ref.)
[Viruses and cancer: molecular pathologic mechanisms of viral carcinogenesis] Butz K, et al. **Immun Infekt** 1995 Oct; 23(5):179–84 (65 ref.) (Eng. Abstr.) **(Ger)**
[Molecular prognostic markers for urogenital cancers] Kubota Y. **Gan To Kagaku Ryoho** 1996 Jul;23(8):997–1003 (32 ref.) (Eng. Abstr.) **(Jpn)**
[Evaluation of prognostic factors in gynecological cancer examined by molecular biological study] Nagai N. **Gan To Kagaku Ryoho** 1996 Jul;23(8):1004–9 (27 ref.) (Eng. Abstr.) **(Jpn)**
[Familial cancer and oncogenic factors] Ohmori M, et al. **Gan To Kagaku Ryoho** 1996 Mar;23(4):395–400 (31 ref.) (Eng. Abstr.) **(Jpn)**
[Progress of research on tumor suppressor genes] Kuzumaki N. **Hokkaido Igaku Zasshi** 1996 Mar;71(2):133–7 (20 ref.) (Eng. Abstr.) **(Jpn)**
[Molecular cancer epidemiology—the present status and future possibilities] Sakai T. **Nippon Eiseigaku Zasshi** 1996 Feb;50(6):1036–46 (46 ref.) (Eng. Abstr.) **(Jpn)**
[Study of cancers as genetic diseases] Kuroki T. **Nippon Naika Gakkai Zasshi** 1996 Mar 10;85(3):318–21 (2 ref.) **(Jpn)**
[Structure and function of tumor suppressor genes] Akiyama T. **Nippon Rinsho** 1995 Nov;53(11):2654–9 (10 ref.) (Eng. Abstr.) **(Jpn)**
[Role of tumor marker in the presymptomatic diagnosis of hereditary malignant tumors] Baba S, et al. **Nippon Rinsho** 1996 Jun;54(6):1597–603 (13 ref.) (Eng. Abstr.) **(Jpn)**
[Studies on tumor suppressor genes by gene/chromosome transfer] Horikawa I, et al. **Nippon Rinsho** 1995 Nov; 53(11):2647–52 (25 ref.) (Eng. Abstr.) **(Jpn)**
[Mechanisms for inactivation of tumor suppressor genes] Ishizaki K. **Nippon Rinsho** 1995 Nov;53(11):2660–5 (16 ref.) (Eng. Abstr.) **(Jpn)**
[Clinical application of oncogene and antioncogene as a tumor marker] Kondo H, et al. **Nippon Rinsho** 1996 Jun; 54(6):1494–8 (7 ref.) (Eng. Abstr.) **(Jpn)**
[Strategies for the detection and the identification of tumor suppressor genes] Takimoto M, et al. **Nippon Rinsho** 1995 Nov;53(11):2666–71 (22 ref.) (Eng. Abstr.) **(Jpn)**
[Negative repressor THZif–1 of protooncogene c–myc] Yokoyama K, et al. **Nippon Rinsho** 1995 Nov; 53(11):2827–36 (13 ref.) (Eng. Abstr.) **(Jpn)**
[Tumor suppressor genes in hematopoietic tumors] Hirai H. **Rinsho Ketsueki** 1996 May;37(5):398–403 (22 ref.) **(Jpn)**
[Tumor suppressor genes] Varshaver NB. **Mol Gen Mikrobiol Virusol** 1996 Jan–Mar;(1):3–10 (140 ref.) (Eng. Abstr.) **(Rus)**

GENETICS

Molecular and genetic events in schistosomiasis–associated human bladder cancer: role of oncogenes and tumor suppressor genes. Badawi AF. **Cancer Lett** 1996 Aug 2; 105(2):123–38 (111 ref.)
Oncogenes and antioncogenes in lung tumorigenesis. Giaccone G. **Chest** 1996 May;109(5 Suppl):130S–134S (46 ref.)
Tumor suppressor genes: at the crossroads of molecular carcinogenesis, molecular epidemiology, and human risk assessment. Harris CC. **Prev Med** 1996 Jan–Feb;25(1):10–2 (33 ref.)
[Biology of solid cancers: breast cancer as an example. First part: genetic systems implicated in carcinogenesis] Bièche I, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996; 25(2):131–41 (37 ref.) (Eng. Abstr.) **(Fre)**
[Correlation between p–53 expression and clinical resistance in testicular cancer] Hanna E, et al. **Orv Hetil** 1996 Jan 14;137(2):59–64 (26 ref.) (Eng. Abstr.) **(Hun)**

PHYSIOLOGY

Control of apoptosis in hematopoiesis and leukemia by cytokines, tumor suppressor and oncogenes. Lotem J, et al. **Leukemia** 1996 Jun;10(6):925–31 (131 ref.)
Cytogenetic, molecular and functional evidence for novel tumor suppressor genes on the long arm of human chromosome 7. Zenklusen JC, et al. **Mol Carcinog** 1996 Mar;15(3):167–75 (142 ref.)
Induction of apoptosis by tumor suppressor genes and oncogenes. Canman CE, et al. **Semin Cancer Biol** 1995 Feb; 6(1):17–25 (90 ref.)
[The cell cycle and the tumor suppressor genes] Kobayashi H. **Rinsho Byori** 1996 Jan;44(1):3–11 (35 ref.) (Eng. Abstr.) **(Jpn)**
[The significance of tumor suppressor genes and viral oncoproteins in the onset of malignant cell transformation] Bojić I, et al. **Vojnosanit Pregl** 1995 Jul–Aug;52(4):371–6 (42 ref.) **(Scr)**

GENES, SWITCH

Evolutionary strategies for the elucidation of cis and trans factors that regulate the developmental switching programs of the beta–like globin genes. Gumucio DL, et al. **Mol Phylogenet Evol** 1996 Feb;5(1):18–32 (78 ref.)
Hemoglobin switching and fetal hemoglobin reactivation. Cunningham JM, et al. **Semin Hematol** 1996 Jan;33(1):9–23 (142 ref.)

GENES, TAX see **GENES, PX**

GENES, TP53 see **GENES, P53**

GENES, VIRAL

see related
DNA, VIRAL
RNA, VIRAL
VIRAL PROTEINS

Transcription, replication, recombination, and engineering of coronavirus genes. Lai MM. **Adv Exp Med Biol** 1995; 380:463–71 (29 ref.)
Modulation of gene expression by adenovirus transformation. Zantema A, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 3):1–23 (158 ref.)
Molecular biology of the feline immunodeficiency virus auxiliary genes. Tomonaga K, et al. **J Gen Virol** 1996 Aug; 77 (Pt 8):1611–21 (137 ref.)
Can virus therapy of human cancer be improved by apoptosis induction? [published erratum appears in Med Hypotheses 1995 Sep;45(3):316] Sinkovics JG, et al. **Med Hypotheses** 1995 May;44(5):359–68 (72 ref.)
A role for bacteriophages in the evolution and transfer of bacterial virulence determinants. Cheetham BF, et al. **Mol Microbiol** 1995 Oct;18(2):201–8 (85 ref.)
Transcription antitermination: the lambda paradigm updated. Friedman DI, et al. **Mol Microbiol** 1995 Oct;18(2):191–200 (70 ref.)
Reversal of malignancy by the adenovirus E1a gene. Frisch SM. **Mutat Res** 1996 Feb 19;350(1):261–6 (31 ref.)
[Current status of the study on hepatitis C virus envelope region gene and its vaccine] Li Q, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1995 Nov; 29(6):363–5 (18 ref.) **(Chi)**
[Expression of sequences homologous to HTLV–I pXIV gene in the labial salivary glands of Japanese patients with Sjögren's syndrome and pathogenesis] Yonaha–Nagato F, et al. **Nippon Rinsho** 1995 Oct;53(10):2473–8 (13 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

P53–mediated radioresistance does not correlate with metastatic potential in tumorigenic rat embryo cell lines following oncogene transfection. Bristow RG, et al. **Int J Radiat Oncol Biol Phys** 1996 Jan 15;34(2):341–55 (81 ref.)

PHYSIOLOGY

Hepatitis B virus and hepatocellular carcinoma. Ren EC. **Ann Acad Med Singapore** 1996 Jan;25(1):17–21 (52 ref.)
Cytomegalovirus genes: their structure and function. Stenberg RM, et al. **Scand J Infect Dis Suppl** 1995;99:3–6 (42 ref.)
[Human papillomavirus type 16–gene functions relevant to molecular human carcinogenesis] Yasumoto S. **Nippon Rinsho** 1995 Nov;53(11):2858–67 (20 ref.) (Eng. Abstr.) **(Jpn)**

GENES, WILMS' TUMOR

The WT1 Wilms' tumor suppressor gene: how much do we really know? Reddy JC, et al. **Biochim Biophys Acta** 1996 May 16;1287(1):1–28 (201 ref.)
RNA processing. Wilms' tumour—the splicing connection? Lamond AI. **Curr Biol** 1995 Aug 1;5(8):862–5 (10 ref.)
Molecular genetics of Wilms' tumour. Tay JS. **J Paediatr Child Health** 1995 Oct;31(5):379–83 (64 ref.)

PHYSIOLOGY

Does the Wilms' tumour suppressor gene, WT1, play roles in both splicing and transcription? Charlieu JP, et al. **J Cell Sci Suppl** 1995;19:95–9 (20 ref.)

GENETIC CARRIERS see **HETEROZYGOTE**

GENETIC CARRIERS, DETECTION see **HETEROZYGOTE DETECTION**

GENETIC CODE

Partition of aminoacyl–tRNA synthetases in two different structural classes dating back to early metabolism: implications for the origin of the genetic code and the nature of protein sequences. Delarue M. **J Mol Evol** 1995 Dec;41(6):703–11 (52 ref.)
On the origin and evolution of the genetic code. Jiménez–Sánchez A. **J Mol Evol** 1995 Dec;41(6):712–6 (18 ref.)
Genetic origins of protein shape and interaction rules [comment] [see comments] Blalock JE. **Nat Med** 1995 Sep; 1(9):876–8 (20 ref.) Comment on: Nat Med 1995 Sep;1(9):894–901. Comment in: Nat Med 1995 Dec;1(12):1222. Comment in: Nat Med 1995 Dec;1(12):1222–3.
Origin of genetic code: A needle in the haystack of tRNA sequences. Schimmel P. **Proc Natl Acad Sci U S A** 1996 May 14;93(10):4521–2 (17 ref.)

GENETIC COUNSELING

see related
GENETIC TECHNIQUES
PRECONCEPTION CARE

Retinal dystrophies and genetic counselling. Jay M, et al. **Acta Ophthalmol Scand Suppl** 1996;(219):5–7 (31 ref.)
Genetic counselling and testing for susceptibility to breast, ovarian and colon cancer: where are we today? Cole DE, et al. **Can Med Assoc J** 1996 Jan 15;154(2):149–55 (56 ref.)
Ethical, social and counselling issues in hereditary cancer susceptibility. Garber JE, et al. **Cancer Surv** 1995;25:381–97 (54 ref.)
Ethical issues and genetic counselling. Grantham JJ. **Contrib Nephrol** 1995;115:39–43 (6 ref.)
The frequency of genetic eye diseases in a genetic counseling center. Elçioğlu N, et al. **Genet Couns** 1995;6(4):329–42 (31 ref.)
Genetic counseling for familial cancer risk. Weitzel JN. **Hosp Pract (Off Ed)** 1996 Feb 15;31(2):57–69 (17 ref.)
Genetic counseling and predictive testing for colorectal cancer risk. Petersen GM. **Int J Cancer** 1996 Feb 20; 69(1):53–4 (12 ref.)
Genetic testing for cancer predisposition: behavioral science issues. Lerman C, et al. **J Natl Cancer Inst Monogr** 1995; (17):63–6 (27 ref.)
Family care related to alpha–fetoprotein screening. Covington C, et al. **J Obstet Gynecol Neonatal Nurs** 1996 Feb;25(2):125–30 (28 ref.)
Genetic counselling: communication and psychosocial aspects. Borreani C, et al. **Tumori** 1996 Mar–Apr; 82(2):147–50 (37 ref.)
Genetic counseling in hereditary non–polyposis colorectal cancer. Heouaine A, et al. **Tumori** 1996 Mar–Apr; 82(2):136–42 (31 ref.)
[From the DNA laboratory to the clinical practice] Kääriäinen H. **Duodecim** 1994;110(7):757–61 (7 ref.) **(Fin)**

[Genetic counseling in psychiatric diseases] Körner J, et al. **Nervenarzt** 1996 Jan;67(1):3–14 (58 ref.) (Eng. Abstr.) **(Ger)**

ORGANIZATION & ADMINISTRATION

The emerging role of the physician in genetic counselling and testing for heritable breast, ovarian and colon cancer. Taylor KM, et al. **Can Med Assoc J** 1996 Apr 15; 154(8):1155–8 (23 ref.)

GENETIC DIVERSITY see **VARIATION (GENETICS)**

GENETIC DRIFT see **GENE FREQUENCY**

GENETIC ENGINEERING

see related
ANIMALS, TRANSGENIC
DNA, RECOMBINANT
MICE, KNOCKOUT
MICE, TRANSGENIC
PLANTS, TRANSGENIC
PROTEIN ENGINEERING

Genetic modification of plants: significant issues and hurdles to success. Day PR. **Am J Clin Nutr** 1996 Apr; 63(4):651S–6S (34 ref.)

Anticipating public reaction to the use of genetic engineering in infant nutrition. Hoban TJ 4th. **Am J Clin Nutr** 1996 Apr;63(4):657S–62S (8 ref.)

Recombinant human milk proteins – an opportunity and a challenge. Lönnerdal B. **Am J Clin Nutr** 1996 Apr; 63(4):622S–6S (63 ref.)

Antigen-presenting cell engineering. The molecular toolbox. Tykocinski ML, et al. **Am J Pathol** 1996 Jan;148(1):1–16 (180 ref.)

Polyketide synthase gene manipulation: a structure-function approach in engineering novel antibiotics. Hutchinson CR, et al. **Annu Rev Microbiol** 1995;49:201–38 (144 ref.)

Techniques for genetic engineering in mycobacteria. Alternative host strains, DNA-transfer systems and vectors. Hermans J, et al. **Antonie Van Leeuwenhoek** 1996 Apr;69(3):243–56 (100 ref.)

Engineering recombinant antibodies for immunotherapy. Neri D, et al. **Cell Biophys** 1995 Aug;27(1):47–61 (62 ref.)

Genetic engineering of endothelial cells to ameliorate xenograft rejection. Bach FH, et al. **Clin Transplant** 1996 Feb;10(1 Pt 2):124–7 (19 ref.)

Genetically engineered mice: tools to understand craniofacial development. Ignelzi MA Jr, et al. **Crit Rev Oral Biol Med** 1995;6(3):181–201 (118 ref.)

Haemoglobin engineering. For fun and money. Brunori M, et al. **Curr Biol** 1995 May 1;5(5):462–5 (18 ref.)

The promise of new genetically engineered plasminogen activators. Cutler D, et al. **J Vasc Interv Radiol** 1995 Nov–Dec;6(6 Pt 2 Su):3S–7S (16 ref.)

Genetic elements of plant viruses as tools for genetic engineering. Mushegian AR, et al. **Microbiol Rev** 1995 Dec; 59(4):548–78 (375 ref.)

Genome engineering: the new mouse genetics. Rossant J, et al. **Nat Med** 1995 Jun;1(6):592–4 (11 ref.)

Genetically engineered animal models of human neurodegenerative diseases. Higgins LS, et al. **Neurodegeneration** 1995 Jun;4(2):117–29 (49 ref.)

Plant genetic engineering may help with environmental cleanup. Raskin I. **Proc Natl Acad Sci U S A** 1996 Apr 16;93(8):3164–6 (32 ref.)

Environmental safety assessment of vaccines derived from biotechnology. Pastoret PP, et al. **Rev Sci Tech** 1995 Dec; 14(4):963–77 (40 ref.)

ADVERSE EFFECTS

Safety evaluation of biological and biotechnology-derived medicines. Dayan AD. **Toxicology** 1995 Dec 20; 105(1):59–68 (18 ref.)

LEGISLATION & JURISPRUDENCE

Regulation of Agrobacterium gene manipulation. Dewhurst F. **Methods Mol Biol** 1995;44:369–91 (33 ref.)

METHODS

Manipulations of catabolic genes for the degradation and detoxification of xenobiotics. Lal R, et al. **Adv Appl Microbiol** 1995;41:55–95 (181 ref.)

A review of attenuation of influenza viruses by genetic manipulation. Belshe RB. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 2):S72–5 (26 ref.)

Rifamycins: strain improvement program. Lal R, et al. **Crit Rev Microbiol** 1995;21(1):19–30 (42 ref.)

The design and engineering of nucleic acid nanoscale assemblies. Seeman NC. **Curr Opin Struct Biol** 1996 Aug; 6(4):519–26 (52 ref.)

Hammerhead ribozyme engineering. Usman N, et al. **Curr Opin Struct Biol** 1996 Aug;6(4):527–33 (61 ref.)

The zebrafish: heritable disorders in transparent embryos. Driever W, et al. **J Clin Invest** 1996 Apr 15;97(8):1788–94 (67 ref.)

Genome engineering: the new mouse genetics. Rossant J, et al. **Nat Med** 1995 Jun;1(6):592–4 (11 ref.)

TRENDS

Issues and advances in the use of transgenic organisms for the production of thaumatin, the intensely sweet protein from Thaumatococcus danielli. Zemanek EC, et al. **Crit Rev Food Sci Nutr** 1995 Sep;35(5):455–66 (44 ref.)

[New horizons for medicine on the basis of genetic technology] Werner RG. **Arzneimittelforschung** 1995 Sep; 45(9):1040–7 (30 ref.) (Eng. Abstr.) **(Ger)**

VETERINARY

Bad ethics, good ethics and the genetic engineering of animals in agriculture. Rollin BE. **J Anim Sci** 1996 Mar; 74(3):535–41 (10 ref.)

GENETIC ENGINEERING OF PROTEINS see **PROTEIN ENGINEERING**

GENETIC HETEROGENEITY

The clinical and genetic heterogeneity of autosomal dominant cataract. Ionides A, et al. **Acta Ophthalmol Scand Suppl** 1996;(219):40–1 (14 ref.)

Genetic and phenotypic heterogeneity of human malignancies: finding order in chaos. Shackney SE, et al. **Cytometry** 1995 Sep 1;21(1):2–5 (21 ref.)

Genetic determinants of Alzheimer disease. St George-Hyslop P. **Prog Clin Biol Res** 1995;393:139–45 (23 ref.)

Genetic heterogeneity of schizophrenia. Tsuang MT, et al. **Seishin Shinkeigaku Zasshi** 1995;97(7):485–501 (145 ref.)

[Genetic heterogeneity and variability of hepatitis C virus and hypervariable regions] Kato N, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:64–70 (17 ref.) **(Jpn)**

GENETIC HYPOSTASIS see **EPISTASIS, GENETIC**

GENETIC IMPRINTING see **GENOMIC IMPRINTING**

GENETIC INDUCTION see **GENE EXPRESSION REGULATION**

GENETIC INTERVENTION see **GENETIC ENGINEERING**

GENETIC MARKERS

see related
CHROMOSOME MAPPING

Can molecular markers now be used for early diagnosis of malignancy? Duffy MJ. **Clin Chem** 1995 Oct;41(10):1410–3 (38 ref.)

Linkage homology for bronchial hyperresponsiveness between DNA markers on human chromosome 5q31–q33 and mouse chromosome 13. Levitt RC, et al. **Clin Exp Allergy** 1995 Nov;25 Suppl 2:61–3 (21 ref.)

Linkage and association to genetic markers. Elston RC. **Exp Clin Immunogenet** 1995;12(3):129–40 (39 ref.)

Analysis of liver development, regeneration, and carcinogenesis by genetic marking studies. Ponder KP. **FASEB J** 1996 May;10(7):673–82 (59 ref.)

Markers of risk for human malignancies. Garber JE. **Hematol Oncol Clin North Am** 1994 Jun;8(3):471–83 (59 ref.)

Microsatellites and PCR genomic analysis. Koreth J, et al. **J Pathol** 1996 Mar;178(3):239–48 (152 ref.)

Transcriptional activation of thymidine kinase, a marker for cell cycle control. Dou QP, et al. **Prog Nucleic Acid Res Mol Biol** 1996;53:197–217 (92 ref.)

The contribution of marker gene studies to hemopoietic stem cell therapies. Brenner MK. **Stem Cells (Dayt)** 1995 Sep; 13(5):453–61 (44 ref.)

Marker genes for cytotoxic exposure: p53. Montenarh M. **Stem Cells (Dayt)** 1995 May;13 Suppl 1:136–41 (68 ref.)

DNA markers in forensic medicine. Mayr WR. **Transfus Clin Biol** 1995;2(4):325–8 (4 ref.)

The future of blood groups and other markers in reference laboratories. Rouger P, et al. **Transfus Clin Biol** 1995; 2(4):329–34 (8 ref.)

[Searching for genetic markers--in the fields of forensic medicine and human genetics] Ikemoto S. **Nippon Hoigaku Zasshi** 1995 Dec;49(6):419–31 (36 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Genes and psychosis: old wine in new bottles? Baron M. **Acta Psychiatr Scand** 1995 Aug;92(2):81–6 (74 ref.)

Strategies for mapping and identifying quantitative trait loci specifying behavioral responses to alcohol. Buck KJ. **Alcohol Clin Exp Res** 1995 Aug;19(4):795–801 (57 ref.)

German population data on the loci low-density-lipoprotein receptor, glycophorin A, hemoglobin gamma G, D7S8 and group-specific component. Huckenbeck W, et al. **Anthropol Anz** 1995 Sep;53(3):193–8 (14 ref.)

Progress in Alzheimer's disease genetics. Schellenberg GD. **Curr Opin Neurol** 1995 Aug;8(4):262–7 (68 ref.)

GENETIC RECOMBINATION see **RECOMBINATION, GENETIC**

GENETIC SCREENING

see related
HETEROZYGOTE DETECTION

Use of molecular methods in the early diagnosis of familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer. Khine K, et al. **Ann Acad Med Singapore** 1996 Jan;25(1):64–70 (88 ref.)

Should patients with recent onset rheumatoid arthritis be offered genetic screening? Symmons DP, et al. **Ann Rheum Dis** 1996 Jul;55(7):407–10 (25 ref.)

Genetic counselling and testing for susceptibility to breast, ovarian and colon cancer: where are we today? Cole DE, et al. **Can Med Assoc J** 1996 Jan 15;154(2):149–55 (56 ref.)

Screening for cancer in high risk families. Narod SA. **Clin Biochem** 1995 Aug;28(4):367–72 (30 ref.)

Colorectal cancer: future population screening for early colorectal cancer. Blum HE. **Eur J Cancer** 1995 Jul–Aug; 31A(7–8):1369–72 (35 ref.)

Screening for clonal genetic alterations. Sidransky D. **Eur J Cancer** 1995 Jul–Aug;31A(7–8):1127–9 (23 ref.)

Genetic screening for colorectal cancer and intervention. Alberts DS, et al. **Int J Cancer** 1996 Feb 20;69(1):62–3 (10 ref.)

Current issues of personnel and laboratory practices in genetic testing. Mark HF, et al. **J Med Genet** 1995 Oct; 32(10):780–6 (13 ref.)

National Cancer Institute Workshop on Genetic Screening for Colorectal Cancer. Rossi SC, et al. **J Natl Cancer Inst** 1996 Mar 20;88(6):331–9 (49 ref.)

[Management of a family with genetic hemochromatosis] Moirand R, et al. **Gastroenterol Clin Biol** 1996;20(5 Pt 2):B9–14 (17 ref.) **(Fre)**

[The direct gene test in familial medullary thyroid gland carcinoma and in MEN syndromes. Detection of mutations in the ret proto-oncogene saves screening studies] Stuhrmann M. **Fortschr Med** 1995 Dec 20;113(35–36):503–6 (23 ref.) (Eng. Abstr.) **(Ger)**

[Biochemical, molecular and social aspects of carrier screening for Tay-Sachs disease] Peleg L, et al. **Harefuah** 1995 Dec 1;129(11):475–80 (43 ref.) **(Heb)**

ADVERSE EFFECTS

Genetic testing for cancer predisposition: behavioral science issues. Lerman C, et al. **J Natl Cancer Inst Monogr** 1995; (17):63–6 (27 ref.)

Genetic testing: employability, insurability, and health reform. Rothstein MA. **J Natl Cancer Inst Monogr** 1995; (17):87–90 (14 ref.)

ECONOMICS

Use of gene tests to detect hereditary predisposition to cancer: what do we know about cost effectiveness? Brown ML, et al. **Int J Cancer** 1996 Feb 20;69(1):55–7 (17 ref.)

Justifying prenatal screening and genetic amniocentesis programs by cost-effectiveness analyses: a re-evaluation. Ganiats TG. **Med Decis Making** 1996 Jan–Mar;16(1):45–50 (61 ref.)

METHODS

Clinical applications of genetic testing: implications for the family physician [see comments] Whittaker L. **Am Fam Physician** 1996 May 1;53(6):2077–84 (37 ref.) Comment in: Am Fam Physician 1996 May 1;53(6):1976, 1978.

Prenatal diagnosis of hematologic disorders. Phillips OP, et al. **Clin Obstet Gynecol** 1995 Sep;38(3):558–72 (30 ref.)

Applications of heteroduplex analysis for mutation detection in disease genes. Glavac D, et al. **Hum Mutat** 1995; 6(4):281–7 (75 ref.)

Molecular markers in cancer diagnosis. Sidransky D. **J Natl Cancer Inst Monogr** 1995;(17):27–9 (26 ref.)

Antenatal screening for Down syndrome. Wald NJ. **Prog Clin Biol Res** 1995;393:27–42 (25 ref.)

[Detection of fetal cells in maternal blood: towards a noninvasive prenatal diagnosis] Simpson JL, et al. **Contracept Fertil Sex** 1995 Jul–Aug;23(7–8):445–50 (64 ref.) (Eng. Abstr.) **(Fre)**

[Genetic screening for novel genes by insertional mutagenesis with gene trap method in ES cells] Araki K, et al. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2017–24 (17 ref.) **(Jpn)**

NURSING

Family care related to alpha-fetoprotein screening. Covington C, et al. **J Obstet Gynecol Neonatal Nurs** 1996 Feb;25(2):125–30 (28 ref.)

PSYCHOLOGY

Genetic testing of children. Fryer A. **Arch Dis Child** 1995 Aug;73(2):97–9 (9 ref.)

VETERINARY

Estimating disease prevalence with health surveys and genetic screening. Dodds WJ. **Adv Vet Sci Comp Med** 1995; 39:29–96 (125 ref.)

GENETIC TECHNIQUES

see related
CHROMOSOMES, YEAST ARTIFICIAL

Genome analysis with gene expression microarrays. Schena M. **Bioessays** 1996 May;18(5):427–31 (24 ref.)

Genetic and environmental control of antibiotic production. Vining LC. **Biotechnology** 1995;28:1–7 (26 ref.)

New technology in the diagnosis of tuberculosis. Marshall BG, et al. **Br J Hosp Med** 1996 Apr 17–30;55(8):491–34 (25 ref.)

Nucleic acid amplification and related techniques in microbiological diagnostics and epidemiology. Van Belkum A, et al. **Cell Mol Biol (Noisy-le-grand)** 1995 Jul; 41(5):615–23 (48 ref.)

Tutorial. Molecular biology for the clinician. Part II. Tools of molecular biology. Shore EM, et al. **Clin Orthop** 1995 Nov;(320):247–78 (7 ref.)

High-density gridding: techniques and applications. Southern EM. **Curr Opin Biotechnol** 1996 Feb;7(1):85–8 (21 ref.)

Advances in molecular diagnosis. Korf BR. **Curr Opin Obstet Gynecol** 1996 Apr;8(2):130–4 (24 ref.)

Major gene analysis for diseases and disorders of complex etiology. Amos CI, et al. **Exp Clin Immunogenet** 1995; 12(3):141–55 (32 ref.)

Genetic knockouts in mice: an update. Shastry BS. **Experientia** 1995 Nov 15;51(11):1028–39 (159 ref.)

Current techniques in cell and molecular biology. Downey GP, et al. **J Crit Care** 1995 Sep;10(3):136–49 (22 ref.)

Genetic tagging of cells and cell layers for studies of plant development. Spena A, et al. **Methods Cell Biol** 1995; 49:331–54 (110 ref.)

Diagnostic detection of mutant ras genes in minor cell populations. Kahn SM, et al. **Methods Enzymol** 1995; 255:452–64 (47 ref.)

Molecular genetic approaches for the study of virulence in both pathogenic bacteria and fungi. Hensel M, et al. **Microbiology** 1996 May;142 (Pt 5):1049–58 (52 ref.)

DNA technology in forensic applications. Hochmeister MN. **Mol Aspects Med** 1995;16(4):315–437 (345 ref.)

Nucleic acid fingerprinting by PCR-based methods: applications to problems in aging and mutagenesis. Welsh J, et al. **Mutat Res** 1995 Oct;338(1–6):215–29 (72 ref.)

DNA markers in forensic medicine. Mayr WR. **Transfus Clin Biol** 1995;2(4):325–8 (4 ref.)

Finding prospective partners in the library: the two-hybrid system and phage display find a match. Allen JB, et al. **Trends Biochem Sci** 1995 Dec;20(12):511–6 (50 ref.)

Representational difference analysis: finding the differences between genomes. Lisitsyn NA. **Trends Genet** 1995 Aug; 11(8):303–7 (20 ref.)

[The new perspectives in gene diagnostics] Palotie L, et al. **Duodecim** 1994;110(7):647–53 (21 ref.) **(Fin)**

[Application of genetic principles to the causal assessment of atherosclerosis] Miserez AR, et al. **Ther Umsch** 1995 Dec;52(12):835–43 (48 ref.) (Eng. Abstr.) **(Ger)**

[Gene technology to overproduce the enzymes useful as diagnostic reagents] Sugiyama M, et al. **Rinsho Byori** 1995 Aug;43(8):765–71 (8 ref.) (Eng. Abstr.) **(Jpn)**

[Revolution in diagnostic microbiology. Needs, driving forces and consequences] Bukholm G, et al. **Tidsskr Nor Laegeforen** 1995 Nov 10;115(27):3387–9 (3 ref.) (Eng. Abstr.) **(Nor)**

TRENDS

[Medical genetics. Between consultation and molecular genetic research—an analysis of the current status] Schroeder-Kurth T. **Fortschr Med** 1995 Dec 20; 113(35–36):499–502 (11 ref.) (Eng. Abstr.) **(Ger)**

[Application of molecular biological techniques for obstetric and gynecologic field] Suganuma N. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Aug; 47(8):785–90 (19 ref.) **(Jpn)**

GENETIC TOXICITY TESTS see **MUTAGENICITY TESTS**

GENETIC TRANSLATION see **TRANSLATION, GENETIC**

GENETIC VECTORS

see related
DNA, RECOMBINANT

Use of plant viruses for delivery of vaccine epitopes. Beachy RN, et al. **Ann N Y Acad Sci** 1996 May 25;792:43–9 (16 ref.)

Adenovirus and adeno-associated virus as vectors for gene therapy. Berns KI, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:95–104 (48 ref.)

Strategies for efficient gene transfer into hematopoietic cells. The use of adeno-associated virus vectors in gene therapy. Chatterjee S, et al. **Ann N Y Acad Sci** 1995 Dec 29; 770:79–90 (40 ref.)

Improved cationic lipid formulations for in vivo gene therapy. Felgner PL, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:126–39 (51 ref.)

DNA vectors. Precedents and safety. Hilleman MR. **Ann N Y Acad Sci** 1995 Nov 27;772:1–14 (52 ref.)

Prospects for gene therapy with direct injection of polynucleotides. Kass-Eisler A, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:232–40 (33 ref.)

Retroviral vectors for HIV immunotherapy. Warner JF, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:105–16 (36 ref.)

Development and application of herpes simplex virus vectors for human gene therapy. Glorioso JC, et al. **Annu Rev Microbiol** 1995;49:675–710 (176 ref.)

Viral vectors in gene therapy. Smith AE. **Annu Rev Microbiol** 1995;49:807–38 (150 ref.)

Influenza virus vectors. García-Sastre A, et al. **Biologicals** 1995 Jun;23(2):171–8 (40 ref.)

BCG as a vector for the construction of multivalent recombinant vaccines. Gicquel B. **Biologicals** 1995 Jun; 23(2):113–8 (34 ref.)

The use of picornaviruses as vectors for the engineering of live recombinant vaccines. Girard M, et al. **Biologicals** 1995 Jun;23(2):165–9 (32 ref.)

Poxvirus-based vectors as vaccine candidates. Pincus S, et al. **Biologicals** 1995 Jun;23(2):159–64 (31 ref.)

Recombinant adenoviruses as vaccines. Randrianarison-Jewtoukoff V, et al. **Biologicals** 1995 Jun; 23(2):145–57 (82 ref.)

The twitcher mouse: a model for Krabbe disease and for experimental therapies. Suzuki K, et al. **Brain Pathol** 1995 Jul;5(3):249–58 (63 ref.)

Vectors in cancer therapy: how will they deliver? Blaese M, et al. **Cancer Gene Ther** 1995 Dec;2(4):291–7 (33 ref.)

The use of adenoviral vectors for gene therapy and gene transfer in vivo. Bramson JL, et al. **Curr Opin Biotechnol** 1995 Oct;6(5):590–5 (49 ref.)

Gene therapy using adenovirus vectors. Haddada H, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 3):297–306 (35 ref.)

The use of DNA viruses as vectors for gene therapy. Ali M, et al. **Gene Ther** 1994 Nov;1(6):367–84 (179 ref.)

Adeno-associated virus vectors for gene therapy. Flotte TR, et al. **Gene Ther** 1995 Aug;2(6):357–62 (59 ref.)

Minireview: the herpes simplex virus amplicon—a versatile defective virus vector. Frenkel N, et al. **Gene Ther** 1994; 1 Suppl 1:S40–6 (44 ref.)

Gene delivery systems for use in gene therapy: an overview of quality assurance and safety issues. Smith KT, et al. **Gene Ther** 1996 Mar;3(3):190–200 (52 ref.)

Molecular conjugates: a targeted gene delivery vector for molecular medicine. Cristiano RJ, et al. **J Mol Med** 1995 Oct;73(10):479–86 (45 ref.)

Strategies for cancer gene therapy using adenoviral vectors. Descamps V, et al. **J Mol Med** 1996 Apr;74(4):183–9 (80 ref.)

Development of retroviral vectors as safe, targeted gene delivery systems. Günzburg WH, et al. **J Mol Med** 1996 Apr;74(4):171–82 (92 ref.)

Retrovirus-mediated transfer of MHC class II cDNA into swine bone marrow cells. LeGuern C, et al. **J Mol Med** 1995 Jun;73(6):269–78 (86 ref.)

A defective HIV-1 vector for gene transfer to human lymphocytes. Parolin C, et al. **J Mol Med** 1995 Jun; 73(6):279–88 (176 ref.)

Construction of retroviral vectors for targeted delivery and expression of therapeutic genes. Salmons B, et al. **Leukemia** 1995 Oct;9 Suppl 1:S53–60 (44 ref.)

Gene transfer using replication-defective retroviral and adenoviral vectors. Leber SM, et al. **Methods Cell Biol** 1996;51:161–83 (42 ref.)

Manipulating gene expression with replication-competent retroviruses. Morgan BA, et al. **Methods Cell Biol** 1996; 51:185–218 (25 ref.)

Agrobacterium-mediated transfer of geminiviruses to plant tissues. Boulton MI. **Methods Mol Biol** 1995;49:77–93 (47 ref.)

HSV as a gene transfer vector for the nervous system. Glorioso JC, et al. **Mol Biotechnol** 1995 Aug;4(1):87–99 (61 ref.)

Adenoviruses as gene-delivery vehicles. Wilson JM. **N Engl J Med** 1996 May 2;334(18):1185–7 (0 ref.)

Virus-vectored immunocontraception for control of wild rabbits: identification of target antigens and construction of recombinant viruses. Holland MK, et al. **Reprod Fertil Dev** 1994;6(5):631–42 (61 ref.)

Baculovirus bounty. Volkman LE. **Science** 1995 Sep 29; 269(5232):1834 (12 ref.)

In situ cytokine gene transfection using vaccinia virus vectors. Lattime EC, et al. **Semin Oncol** 1996 Feb; 23(1):88–100 (98 ref.)

Parvoviral vectors for the gene therapy of cancer. Shaughnessy E, et al. **Semin Oncol** 1996 Feb;23(1):159–71 (116 ref.)

Adenovirus vectors as recombinant viral vaccines. Imler JL. **Vaccine** 1995 Sep;13(13):1143–51 (72 ref.)

[Vectors of gene transfer. Applications in pneumology] Demoly P, et al. **Rev Mal Respir** 1996 Jul;13(3):251–7 (43 ref.) (Eng. Abstr.) **(Fre)**

[Expression of HCV proteins by using recombinant baculoviruses] Aizaki H, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:80–4 (16 ref.) **(Jpn)**

[Expression of HCV genes using adenovirus vector with CAG promoter] Makimura M, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:91–4 (9 ref.) **(Jpn)**

[Safety issues of retrovirus vectors] Amanuma H. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2583–7 (21 ref.) **(Jpn)**

[Herpes virus vector] Hidaka Y. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2545–9 (11 ref.) **(Jpn)**

[Gene expression using adenovirus vector] Kanegae Y, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2525–31 (11 ref.) **(Jpn)**

[Gene transfer using recombinant HIV vectors] Miyake K, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec; 40(17):2519–24 (15 ref.) **(Jpn)**

[The mouse embryogenesis of jumonji mutant obtained by gene-trap method] Motoyama J, et al. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2152–61 (24 ref.) **(Jpn)**

[Bovine papillomavirus vector] Ohe Y. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2539–44 (16 ref.) **(Jpn)**

[Retrovirus vector] Wakimoto H, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2508–13 (19 ref.) **(Jpn)**

ADVERSE EFFECTS

Risk potential of the chromosomal insertion of foreign DNA. Kurth R. **Ann N Y Acad Sci** 1995 Nov 27;772:140–51 (25 ref.)

CHEMISTRY

Second-generation adenovirus vectors. Wang Q, et al. **Nat Med** 1996 Jun;2(6):714–6 (36 ref.)

GENETICS

Second-generation adenovirus vectors. Wang Q, et al. **Nat Med** 1996 Jun;2(6):714–6 (36 ref.)

GENETICS

see related
HISTOCOMPATIBILITY TESTING

Genetic control of the secondary sex ratio. Bernstein ME. **Hum Reprod** 1995 Oct;10(10):2531–3 (26 ref.)

Genetic and non-genetic determinants of the human sex ratio at birth [editorial] James WH. **Hum Reprod** 1996 May; 11(5):939–40 (24 ref.)

Genetics and the organization of the basal ganglia. Hitzemann R, et al. **Int Rev Neurobiol** 1995;38:43–94 (356 ref.)

[Searching for genetic markers—in the fields of forensic medicine and human genetics] Ikemoto S. **Nippon Hoigaku Zasshi** 1995 Dec;49(6):419–31 (36 ref.) (Eng. Abstr.) **(Jpn)**

EDUCATION

The evolution and status of genetics education in nursing in the United States 1983–1995. Anderson GW. **Image J Nurs Sch** 1996 Summer;28(2):101–6 (40 ref.)

GENETICS, BEHAVIORAL

Application of antisense DNA method for the study of molecular bases of brain function and behavior. Ogawa S, et al. **Behav Genet** 1996 May;26(3):279–92 (85 ref.)

Behavioral genetics: concepts for research and practice in language development and disorders. Gilger JW. **J Speech Hear Res** 1995 Oct;38(5):1126–42 (119 ref.)

[Genetic aspects of learning mechanisms] Ponomarenko VV, et al. **Fiziol Zh Im I M Sechenova** 1995 Aug;81(8):57–62 (20 ref.) (Eng. Abstr.) **(Rus)**

GENETICS, BIOCHEMICAL

see related
NUCLEIC ACIDS

Molecular genetics of early liver development. Zaret KS. **Annu Rev Physiol** 1996;58:231–51 (132 ref.)

The first gene for an idiopathic epilepsy: a fruitful collaboration of Australian clinical research and molecular genetics [editorial] Berkovic SF, et al. **Aust N Z J Med** 1996 Apr;26(2):154–6 (13 ref.)

Recent advances in the molecular genetics of hypertension. Shimkets RA, et al. **Curr Opin Nephrol Hypertens** 1996 Mar;5(2):162–5 (31 ref.)

Molecular genetic analysis of circadian rhythms in vertebrates and invertebrates. Sehgal A. **Curr Opin Neurobiol** 1995 Dec;5(6):824–31 (73 ref.)

Programs, databases, and expert systems for human geneticists—a survey. Fischer C, et al. **Hum Genet** 1996 Feb;97(2):129–37 (103 ref.)

Linear genetics, non-linear epigenetics: complementary approaches to understanding complex diseases. Strohman RC. **Integr Physiol Behav Sci** 1995 Sep–Dec;30(4):273–82 (24 ref.)

Molecular genetics and craniofacial surgery. Mulliken JB, et al. **Plast Reconstr Surg** 1996 Mar;97(3):666–75 (71 ref.)

[Ehlers-Danlos syndromes. Clinical, genetic and molecular aspects] Germain D. **Ann Dermatol Venereol** 1995; 122(4):187–204 (91 ref.) (Eng. Abstr.) **(Fre)**

[Reflexions apropos of recent progresses in molecular genetics of myopathies (editorial)] Kaplan JC. **Arch Pediatr** 1995 Aug;2(8):715–8 (13 ref.) **(Fre)**

["Miguel F. Jiménez lecture. The paradigm of modern medicine: molecular genetics] Benítez-Bribiesca L. **Gac Med Mex** 1995 Mar-Apr;131(2):197–203 (33 ref.) **(Spa)**

EDUCATION

[Essays on current molecular genetics for lecture courses for

students of the Biology Department at Moscow State University] Sverdlov ED. **Mol Gen Mikrobiol Virusol** 1995 Oct-Dec;(4):3-19 (28 ref.) **(Rus)**

METHODS

Sequence-based identification of microbial pathogens: a reconsideration of Koch's postulates. Fredericks DN, et al. **Clin Microbiol Rev** 1996 Jan;9(1):18-33 (119 ref.)

In vitro folding of inclusion body proteins. Rudolph R, et al. **FASEB J** 1996 Jan;10(1):49-56 (80 ref.)

New molecular endpoints and methods for routine toxicity testing. MacGregor JT, et al. **Fundam Appl Toxicol** 1995 Jul;26(2):156-73 (76 ref.)

Biochemistry meets genetics in the holoenzyme. Berk AJ. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):11952-4 (45 ref.)

[Molecular genetic analysis--a new stage in the study of hereditary diseases of the central nervous system] Ivanova-Smolenskaia IA, et al. **Vestn Ross Akad Med Nauk** 1996;(4):6-10 (45 ref.) (Eng. Abstr.) **(Rus)**

TRENDS

Recent advances in cytometry, cytogenetics and molecular genetics of thyroid tumours and tumour-like lesions. Soares P, et al. **Pathol Res Pract** 1995 May;191(4):304-17 (141 ref.)

[Molecular biological methods in the mycobacteriological laboratory--was 1995 a year of progress, problems or both?] Böttger EC, et al. **Pneumologie** 1995 Dec; 49(12):664-6 (19 ref.) **(Ger)**

GENETICS, HUMAN see **GENETICS, MEDICAL**

GENETICS, MEDICAL

see related
CHROMOSOME ABNORMALITIES
DISEASES IN TWINS
HEREDITARY DISEASES

Chromosome 22: a model with implications for diagnostic imaging. Starshak RJ. **AJR Am J Roentgenol** 1996 Aug; 167(2):315-24 (62 ref.)

Medical genetics in Israel. Zlotogora J, et al. **Eur J Hum Genet** 1995;3(3):147-54 (31 ref.)

Programs, databases, and expert systems for human geneticists--a survey. Fischer C, et al. **Hum Genet** 1996 Feb;97(2):129-37 (103 ref.)

Ethical reasoning in clinical genetics: a survey of cases and methods. Callahan TC, et al. **J Clin Ethics** 1995 Fall; 6(3):248-53 (23 ref.)

Informed consent for genetic research on stored tissue samples [see comments] Clayton EW, et al. **JAMA** 1995 Dec 13;274(22):1786-92 (31 ref.) Comment in: JAMA 1995 Dec 13;274(22):1806-7. Comment in: JAMA 1996 Apr 10;275(14):1085; discussion 1086. Comment in: JAMA 1996 Apr 10;275(14):1085-6.

The impact of molecular medicine on health services. Jones R. **Nat Med** 1996 Sep;2(9):959-60 (11 ref.)

Medical genetics in Thailand. Sirinavin C. **Southeast Asian J Trop Med Public Health** 1995;26 Suppl 1:26-33 (41 ref.)

Medical genetics in Singapore. Tay JS. **Southeast Asian J Trop Med Public Health** 1995;26 Suppl 1:19-25 (32 ref.)

[Current trends in medical genetics] Galjaard H. **Cas Lek Cesk** 1995 Jun 14;134(12):366-70 (27 ref.) (Eng. Abstr.) **(Cze)**

TRENDS

Recent advances. Medical genetics. Yate JR. **BMJ** 1996 Apr 20;312(7037):1021-5 (66 ref.)

[Medical genetics. Between consultation and molecular genetic research--an analysis of the current status] Schroeder-Kurth T. **Fortschr Med** 1995 Dec 20; 113(35-36):499-502 (11 ref.) (Eng. Abstr.) **(Ger)**

GENETICS, MICROBIAL

see related
CHROMOSOMES, BACTERIAL
CHROMOSOMES, FUNGAL

GENETICS, MOLECULAR see **GENETICS, BIOCHEMICAL**

GENETICS, POPULATION

Mouse-parasite interactions: from gene to population. Moulia C, et al. **Adv Parasitol** 1996;38:119-67 (195 ref.)

Population biology of antigen presentation by MHC class I molecules [see comments] Parham P, et al. **Science** 1996 Apr 5;272(5258):67-74 (71 ref.) Comment in: Science 1996 Aug 9;273(5276):723-5.

[From identification of mutation to population screening] Aula P, et al. **Duodecim** 1994;110(7):749-56 (20 ref.) **(Fin)**

DRUG EFFECTS

Use of physiologically based pharmacokinetic modeling to investigate individual versus population risk. Clewell HJ 3rd, et al. **Toxicology** 1996 Jul 17;111(1-3):315-29 (107 ref.)

GENICULATE BODIES

BLOOD SUPPLY

Stereotactic radiosurgery for postgeniculate visual pathway arteriovenous malformations. Pollock BE, et al. **J Neurosurg** 1996 Mar;84(3):437-41 (29 ref.)

PHYSIOLOGY

Dyslexia. Reading between the laminae. Walsh V. **Curr Biol** 1995 Nov 1;5(11):1216-7 (10 ref.)

Emergence of order in visual system development. Shatz CJ. **Proc Natl Acad Sci U S A** 1996 Jan 23;93(2):602-8 (61 ref.)

GENITAL DISEASES, FEMALE

Office gynecology for the primary care physician, part II: pelvic pain, vulvar disease, disorders of menstruation, premenstrual syndrome, and breast disease. Klein TA. **Med Clin North Am** 1996 Mar;80(2):321-36 (68 ref.)

CHEMICALLY INDUCED

[Gynecologic monitoring of tamoxifen treatment of breast cancer] Le Bouedec G, et al. **Rev Fr Gynecol Obstet** 1995 Jul-Sep;90(7-9):379-82 (30 ref.) **(Fre)**

COMPLICATIONS

Preterm labor: emerging role of genital tract infections. Andrews WW, et al. **Infect Agents Dis** 1995 Dec; 4(4):196-211 (185 ref.)

[Genital infections as a cause of abortion in the first trimester of pregnancy. Review of the literature] Capuzzo E, et al. **Minerva Ginecol** 1995 Dec;47(12):557-60 (15 ref.) (Eng. Abstr.) **(Ita)**

DIAGNOSIS

Clinical aspects of genito-anal papillomavirus infection with a focus on when and how to investigate. von Krogh G. **Curr Probl Dermatol** 1996;24:140-50 (42 ref.)

Contrast-enhanced MR imaging of gynecologic disorders. Outwater EK. **Magn Reson Imaging Clin N Am** 1996 Feb; 4(1):133-51 (84 ref.)

Laparoscopic appendectomy and the management of gynecologic pathologic conditions found at laparoscopy for presumed appendicitis. Apelgren KN, et al. **Surg Clin North Am** 1996 Jun;76(3):469-82 (47 ref.)

[Current trends in the diagnosis and treatment of genital discharge] Borisov I. **Akush Ginekol (Sofiia)** 1995; 34(3):53-7 (11 ref.) **(Bul)**

[Magnetic resonance imaging in gynecology] Martin B, et al. **Contracept Fertil Sex** 1996 Feb;24(2):123-6 (0 ref.) **(Fre)**

DRUG THERAPY

Mifepristone: clinical application in general gynecology. Morales AJ, et al. **Clin Obstet Gynecol** 1996 Jun; 39(2):451-60 (33 ref.)

Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in benign gynaecological disorders. Perry CM, et al. **Drugs** 1996 Feb; 51(2):319-46 (113 ref.)

[LHRH analogs in gynecology] Rachev E, et al. **Akush Ginekol (Sofiia)** 1994;33(2):36-9 (12 ref.) **(Bul)**

[Nitric oxide: new horizons in gynecology and obstetrics] Ohl J, et al. **Contracept Fertil Sex** 1995 Nov;23(11):645-50 (51 ref.) **(Fre)**

[Azithromycin and genital infections] Micoud M, et al. **Pathol Biol (Paris)** 1995 Jun;43(6):542-6 (19 ref.) (Eng. Abstr.) **(Fre)**

EPIDEMIOLOGY

Human papillomavirus infection and associated disease in persons infected with human immunodeficiency virus. Vernon SD, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S121-4 (27 ref.)

ETIOLOGY

Genital oncogenic human papillomavirus infection: a short review on the mode of transmission. Tay SK. **Ann Acad Med Singapore** 1995 Jul;24(4):598-601 (39 ref.)

Gas embolism in obstetrics and gynecology. A review. Weissman A, et al. **J Reprod Med** 1996 Feb;41(2):103-11 (89 ref.)

[Human papilloma virus infection and renal transplantation. Two personally observed cases and a review of the literature] Lefebvre G, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(6):600-3 (20 ref.) (Eng. Abstr.) **(Fre)**

MICROBIOLOGY

Modern diagnosis and management of genital Chlamydia trachomatis infection [see comments] Robinson AJ, et al. **Br J Hosp Med** 1996 Apr 3-16;55(7):388-93 (31 ref.) Comment in: Br J Hosp Med 1996 Apr 3-16;55(7):386-7.

Genital tract infections in women. Anderson JR. **Med Clin North Am** 1995 Nov;79(6):1271-98 (147 ref.)

[Chlamydia trachomatis infection in women] Suchet JH. **Rev Med Interne** 1996;17 Suppl 1:36S-38S (18 ref.) **(Fre)**

PSYCHOLOGY

Psychosexual gynecology. Bachmann GA, et al. **Med Clin North Am** 1995 Nov;79(6):1299-317 (45 ref.)

[Psychiatric emergencies and crises in gynecology] Gaebel W, et al. **Gynakologe** 1995 Dec;28(6):403-11 (19 ref.) **(Ger)**

[Self-injury behavior] Rechenberger I. **Gynakologe** 1995 Dec; 28(6):446-51 (13 ref.) **(Ger)**

REHABILITATION

[Oncologic after-care and rehabilitation--physician-patient interaction in gynecologic oncology] Schünemann H, et al. **Arch Gynecol Obstet** 1995;257(1-4):277-83 (14 ref.) **(Ger)**

SURGERY

Laparoscopic surgery: a real step forward, or tempting simply because possible and new? [editorial] Bruhat MA, et al. **Curr Opin Obstet Gynecol** 1995 Aug;7(4):239-42 (48 ref.)

Advances in gynaecology. Baird G. **Practitioner** 1996 Feb; 240(1559):90-5 (12 ref.)

-Gynecologic endoscopic surgery. What are the limits?- Janecek P. **Arch Gynecol Obstet** 1995;256 Suppl:S6-11 (17 ref.) **(Fre)**

[Bowel complications in gynecologic laparoscopic surgery and their immediate repair without laparotomy. Four cases] Renault B, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996; 25(4):360-4 (16 ref.) (Eng. Abstr.) **(Fre)**

[Cardiovascular function during laparoscopic interventions in surgery and gynecology] Berg K, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Nov; 30(7):446-50 (28 ref.) **(Ger)**

[Endoscopic surgery and malpractice] Ulsenheimer K. **Arch Gynecol Obstet** 1995;257(1-4):29-36 (29 ref.) **(Ger)**

-Complications. Surgical endoscopy versus gynecologic minimal invasive surgery- Wallwiener D, et al. **Arch Gynecol Obstet** 1995;256 Suppl:S21-31 (18 ref.) **(Ger)**

[The "Vienna School" of surgical gynecology as an important component of modern therapeutic concepts] Kölbl H. **Gynakol Geburtshilfliche Rundsch** 1995;35(3):139-41 (18 ref.) (Eng. Abstr.) **(Ger)**

[Surgical management of psychiatrically ill patients. Particular aspects of perioperative monitoring] Diefenbacher A, et al. **Gynakologe** 1995 Dec;28(6):412-9 (33 ref.) **(Ger)**

[Vaginal ultrasound of surgical gynecologic complications] Klug PW. **Gynakologe** 1995 Aug;28(4):262-9 (25 ref.) **(Ger)**

[Conservative hemotherapy. Blood component therapy instead of whole blood transfusion and homologous blood saving methods (editorial)] Reiff K, et al. **Gynakologe** 1995 Dec;28(6):393-400 (55 ref.) **(Ger)**

[Gynecologic endoscopic surgery] Yoshida H, et al. **Hokkaido Igaku Zasshi** 1995 May;70(3):397-400 (8 ref.) (Eng. Abstr.) **(Jpn)**

[The prevention of adhesion formation in surgical gynecology (the role of suture materials and barriers)] Mynbaev OA, et al. **Akush Ginekol (Mosk)** 1995;(5):37-40 (38 ref.) **(Rus)**

ULTRASONOGRAPHY

Transvaginal ultrasonography in nonpregnant and postmenopausal women. Weissman AM, et al. **Am Fam Physician** 1996 May 1;53(6):2065-72 (23 ref.)

[Basic principles of vaginal ultrasound] Bernaschek G. **Gynakologe** 1995 Aug;28(4):220-4 (11 ref.) **(Ger)**

[Transvaginal 3 D ultrasound in gynecology] Merz E, et al. **Gynakologe** 1995 Aug;28(4):270-5 (9 ref.) **(Ger)**

[Transvaginal Doppler/color Doppler in gynecologic diagnosis] Voigt HJ. **Gynakologe** 1995 Aug;28(4):254-61 (45 ref.) **(Ger)**

VIROLOGY

Pathobiology of human papillomavirus. Prasad CJ. **Clin Lab Med** 1995 Sep;15(3):685-704 (81 ref.)

GENITAL DISEASES, MALE

Gangrene of the perineum. Benizri E, et al. **Urology** 1996 Jun;47(6):935-9 (36 ref.)

Hemospermia: diagnosis and management. Mulhall JP, et al. **Urology** 1995 Oct;46(4):463-7 (51 ref.)

DIAGNOSIS

Diagnostic imaging of patients with acute scrotal pain. Barloon TJ, et al. **Am Fam Physician** 1996 Apr; 53(5):1734-50 (17 ref.)

[Hemospermia associated with a urogenital sinus cyst: diagnostic contribution of MRI. Report a case] Cinque T, et al. **Radiol Med (Torino)** 1995 Dec;90(6):840-2 (8 ref.) **(Ita)**

GENITAL DISEASES, MALE

DRUG THERAPY

[Azithromycin and genital infections] Micoud M, et al. **Pathol Biol (Paris)** 1995 Jun;43(6):542–6 (19 ref.) (Eng. Abstr.) **(Fre)**

EPIDEMIOLOGY

Human papillomavirus infection and associated disease in persons infected with human immunodeficiency virus. Vernon SD, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S121–4 (27 ref.)

ETIOLOGY

Crohn's disease complicating male genitourinary tract without overlying cutaneous involvement. Minocha A, et al. **Am J Gastroenterol** 1996 Jul;91(7):1463–4 (9 ref.)

Pneumoscrotum: an unusual complication of pulmonary resection. Raudat CW, et al. **J Am Osteopath Assoc** 1996 Jun;96(6):362–3 (16 ref.)

Cystic dysplasia of the testis: an unusual cause of a pediatric scrotal mass. Zaragoza MR, et al. **Urology** 1996 Feb; 47(2):244–7 (12 ref.)

MICROBIOLOGY

Modern diagnosis and management of genital Chlamydia trachomatis infection [see comments] Robinson AJ, et al. **Br J Hosp Med** 1996 Apr 3–16;55(7):388–93 (31 ref.) Comment in: Br J Hosp Med 1996 Apr 3–16;55(7):386–7.

PARASITOLOGY

Protozoan infections in the male genital tract. Martínez-García F, et al. **J Urol** 1996 Aug;156(2 Pt 1):340–9 (171 ref.)

PATHOLOGY

[Gangrene of the external genitalia] Hubert J, et al. **Prog Urol** 1995 Dec;5(6):911–24 (99 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

ABC of general surgery in children. Acute problems of the scrotum [see comments] Davenport M. **BMJ** 1996 Feb 17; 312(7028):435–7 (0 ref.) Comment in: BMJ 1996 May 25;312(7042):1358–9.

ULTRASONOGRAPHY

[Potential of ultrasonography in urologic diagnostic algorithms] Mayayo Dehesa T, et al. **Arch Esp Urol** 1995 Sep;48(7):665–77; discussion 678 (35 ref.) (Eng. Abstr.) **(Spa)**

GENITAL NEOPLASMS, FEMALE

Does HRT modify risk of gynecological cancers? Schneider HP, et al. **Int J Fertil Menopausal Stud** 1995;40 Suppl 1:40–53 (86 ref.)

The female pelvic mass. Diagnosis and management. Russell DJ. **Med Clin North Am** 1995 Nov;79(6):1481–93 (19 ref.)

[Molecular biology of human papilloma virus infection of the female genital tract] Davidson B, et al. **Harefuah** 1995 Nov 15;129(10):417–20 (37 ref.) **(Heb)**

BLOOD

[Tumor markers in gynecology] Alekseeva ML, et al. **Akush Ginekol (Mosk)** 1995;(5):35–7 (30 ref.) **(Rus)**

BLOOD SUPPLY

[Angiogenesis of gynecologic tumors studied with color Doppler] Kurjak A, et al. **Lijec Vjesn** 1995 May–Jun; 117(5–6):139–45 (88 ref.) (Eng. Abstr.) **(Scr)**

CHEMICALLY INDUCED

Hormonal therapy and genital tract cancer. Wren B. **Curr Opin Obstet Gynecol** 1996 Feb;8(1):38–41 (31 ref.)

Depot medroxyprogesterone acetate contraception and the risk of breast and gynecologic cancer. Kaunitz AM. **J Reprod Med** 1996 May;41(5 Suppl):419–27 (38 ref.)

[Estrogen replacement therapy and malignant tumors of the female genital tract] Piura B, et al. **Harefuah** 1996 Feb 15; 130(4):263–7 (35 ref.) **(Heb)**

COMPLICATIONS

Special needs related to the pain and discomfort of patients with gynecologic cancer. Miaskowski C. **J Obstet Gynecol Neonatal Nurs** 1996 Feb;25(2):181–8 (26 ref.)

DIAGNOSIS

Clinical applications of urinary gonadotropin peptides (UGP) in gynecologic oncology. Schwartz PE, et al. **Anticancer Res** 1996 Jul–Aug;16(4B):2135–9 (35 ref.)

Immunohistochemical approaches to diagnosis in gynecologic pathology. Beckstead JH. **Clin Lab Med** 1995 Sep;15(3):727–42 (80 ref.)

Beta-core fragment (beta-core/UGF/UGP), a tumor marker: a 7-year report. Cole LA, et al. **Gynecol Oncol** 1996 Feb;60(2):264–70 (38 ref.)

MR in the evaluation of gynecologic tumor. Barentsz J. **J Belge Radiol** 1995 Oct;78(5):305–7 (31 ref.)

Contrast-enhanced MR imaging of gynecologic disorders. Outwater EK. **Magn Reson Imaging Clin N Am** 1996 Feb; 4(1):133–51 (84 ref.)

[Gynecologic malignancies] Kato H. **Nippon Rinsho** 1996 Jun;54(6):1637–41 (12 ref.) (Eng. Abstr.) **(Jpn)**

DRUG THERAPY

Chemotherapy for gynecologic malignancies. Vermorken JB, et al. **Curr Opin Oncol** 1995 Sep;7(5):457–65 (79 ref.)

[Chemotherapy for gynecologic tumors] Machover D. **Contracept Fertil Sex** 1996 Apr;24(4):264–7 (0 ref.) **(Fre)**

[Neoadjuvant chemotherapy in advanced gynecologic cancer] Hirabayashi K. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Aug; 47(8):797–802 (7 ref.) **(Jpn)**

GENETICS

[Hereditary gynecological cancers] Delaloye JF. **Schweiz Rundsch Med Prax** 1996 Aug 27;85(35):1032–4 (43 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

[Current developments in psychoneuroimmunology and psycho-oncology] Müller N. **Geburtshilfe Frauenheilkd** 1996 Jun;56(6):M82–6 (34 ref.) **(Ger)**

METABOLISM

The significance of alterations in p53 expression in gynaecological neoplasms. Manek S, et al. **Curr Opin Obstet Gynecol** 1996 Feb;8(1):52–5 (33 ref.)

NURSING

Special needs related to the pain and discomfort of patients with gynecologic cancer. Miaskowski C. **J Obstet Gynecol Neonatal Nurs** 1996 Feb;25(2):181–8 (26 ref.)

PATHOLOGY

Malignant mixed müllerian tumor of the extraovarian secondary müllerian system. Report of two cases and review of the English literature. Mira JL, et al. **Arch Pathol Lab Med** 1995 Nov;119(11):1044–9 (31 ref.)

Alveolar soft-part sarcoma of the female genital tract: a report of nine cases and review of the literature. Nielsen GP, et al. **Int J Gynecol Pathol** 1995 Oct;14(4):283–92 (30 ref.)

[The value of MRI in staging gynecologic tumors] Lorenzen M. **Aktuelle Radiol** 1996 Mar;6(2):63–8 (39 ref.) (Eng. Abstr.) **(Ger)**

[Recent problems on the endocrine and chemotherapy] Nishiya I, et al. **Hum Cell** 1995 Sep;8(3):107–14 (39 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

Oncogenes and other growth factors in gynaecological neoplasms. Cheung AN. **Curr Opin Obstet Gynecol** 1996 Feb;8(1):46–51 (47 ref.)

PREVENTION & CONTROL

Physical activity: breast and reproductive cancer. Francis K. **Compr Ther** 1996 Feb;22(2):94–9 (49 ref.)

Screening and early diagnosis of gynecologic cancers. Warner EA, et al. **Med Clin North Am** 1996 Jan;80(1):45–61 (80 ref.)

PSYCHOLOGY

After treatment. Psychosocial issues in gynecologic cancer survivorship. Auchincloss SS. **Cancer** 1995 Nov 15;76(10 Suppl):2117–24 (21 ref.)

[Psycho-oncology in gynecology] **Arch Gynecol Obstet** 1995; 257(1–4):270–7 (28 ref.) **(Ger)**

[Quality of life--attempt at a definition of the concept] Schnürch HG. **Arch Gynecol Obstet** 1995;257(1–4):257–64 (8 ref.) **(Ger)**

RADIOTHERAPY

Innovations in brachytherapy in gynecologic oncology. Brady LW, et al. **Cancer** 1995 Nov 15;76(10 Suppl):2143–51 (62 ref.)

Intestinal complications of radiotherapy in gynecologic malignancy--clinical presentation and management. Kao MS. **Int J Gynaecol Obstet** 1995 Jul;49 Suppl:S69–75 (35 ref.)

Addressing sexual dysfunction following radiation therapy for a gynecologic malignancy [published erratum appears in Oncol Nurs Forum 1995 Nov-Dec;22(10):1476] Cartwright-Alcarese F. **Oncol Nurs Forum** 1995 Sep; 22(8):1227–32 (27 ref.)

SURGERY

New trends in the surgery of gynaecological tumours. Szánthó A, et al. **Acta Med Hung** 1994;50(3–4):195–203 (21 ref.)

Operative laparoscopy and the gynecologic oncologist. Commentary and review. Edraki B, et al. **Cancer** 1995 Nov 15;76(10 Suppl):1987–91 (29 ref.)

The role of laparoscopy in gynecologic oncology. Hatch KD, et al. **Cancer** 1995 Nov 15;76(10 Suppl):2113–6 (15 ref.)

The current role of laparoscopic surgery in gynecological oncology. Donato DM, et al. **Cancer Invest** 1996; 14(5):482–90 (66 ref.)

Laparoscopic surgery: does it have a role in the management of gynecologic malignancies? Montz FJ, et al. **Clin Obstet Gynecol** 1995 Jun;38(2):426–35 (34 ref.)

Advances in surgery for gynecologic malignancies. Benjamin I, et al. **Curr Opin Oncol** 1995 Sep;7(5):473–7 (20 ref.)

Lymph node dissection in gynaecologic malignancy: the role of laparoscopy. Montz FJ. **Endosc Surg Allied Technol** 1995 Apr–Jun;3(2–3):96–100 (33 ref.)

Laser surgery in gynecologic oncology. Schellhas HF. **Semin Surg Oncol** 1995 Jul–Aug;11(4):299–306 (53 ref.)

-Gynecologic endoscopic surgery. What are the limits?- Janecek P. **Arch Gynecol Obstet** 1995;256 Suppl:S6–11 (17 ref.) **(Fre)**

[Postoperative lymphoceles and lymphatic fistula in gynecologic and breast neoplasms] Brun JL. **Bull Cancer (Paris)** 1995 Sep;82(9):711–6 (37 ref.) (Eng. Abstr.) **(Fre)**

-Complications. Surgical endoscopy versus gynecologic minimal invasive surgery- Wallwiener D, et al. **Arch Gynecol Obstet** 1995;256 Suppl:S21–31 (18 ref.) **(Ger)**

[The "Vienna School" of surgical gynecology as an important component of modern therapeutic concepts] Kölbl H. **Gynakol Geburtshilfliche Rundsch** 1995;35(3):139–41 (18 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Gynecological malignancies. Schaebler DL, et al. **Cancer Chemother Biol Response Modif** 1996;16:564–91 (83 ref.)

New therapeutic approaches in gynecologic oncology. Kucera PR. **Clin Lab Med** 1995 Sep;15(3):743–70 (76 ref.)

Combined modality therapy for gynecologic cancer. Ackerman I, et al. **Curr Opin Oncol** 1995 Sep;7(5):466–72 (48 ref.)

Biologic therapies for gynecologic cancer. Bookman MA. **Curr Opin Oncol** 1995 Sep;7(5):478–84 (73 ref.)

[Uses of interventional arteriographic technics in gynecologic neoplasms] Yue D, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1995 Jul;30(7):435–7 (14 ref.) **(Chi)**

[The cancer patient between academic medicine and alternative medicine--therapeutic concepts] Nagel GA. **Arch Gynecol Obstet** 1995;257(1–4):283–94 (13 ref.) **(Ger)**

[Immunotherapy in gynecologic oncology] Mallmann P. **Geburtshilfe Frauenheilkd** 1994 Nov;54(11):M137–9 (13 ref.) **(Ger)**

[Recent problems on the endocrine and chemotherapy] Nishiya I, et al. **Hum Cell** 1995 Sep;8(3):107–14 (39 ref.) (Eng. Abstr.) **(Jpn)**

ULTRASONOGRAPHY

[Angiogenesis of gynecologic tumors studied with color Doppler] Kurjak A, et al. **Lijec Vjesn** 1995 May–Jun; 117(5–6):139–45 (88 ref.) (Eng. Abstr.) **(Scr)**

URINE

Beta-core fragment (beta-core/UGF/UGP), a tumor marker: a 7-year report. Cole LA, et al. **Gynecol Oncol** 1996 Feb;60(2):264–70 (38 ref.)

VIROLOGY

Human papillomaviruses in gynecological cancer. Duggan MA. **Curr Opin Obstet Gynecol** 1996 Feb;8(1):56–62 (41 ref.)

[Current concepts on human papillomavirus infection] Garfias Cano R, et al. **Ginecol Obstet Mex** 1995 Dec; 63:509–13 (36 ref.) (Eng. Abstr.) **(Spa)**

GENITAL NEOPLASMS, MALE

Malignant fibrous histiocytoma of the spermatic cord. Glazier DB, et al. **J Urol** 1996 Mar;155(3):955–7 (26 ref.)

DIAGNOSIS

[Cystadenoma of the seminal vesicles. A case report] D'Erme M, et al. **Radiol Med (Torino)** 1996 Mar;91(3):322–4 (8 ref.) **(Ita)**

PATHOLOGY

Massive primary lipoma of the scrotum. Greeley DJ Jr, et al. **Am Surg** 1995 Nov;61(11):954–5 (10 ref.)

VIROLOGY

[Current concepts on human papillomavirus infection] Garfias Cano R, et al. **Ginecol Obstet Mex** 1995 Dec; 63:509–13 (36 ref.) (Eng. Abstr.) **(Spa)**

GENITAL WARTS see **CONDYLOMATA ACUMINATA**

GENITALIA

EMBRYOLOGY

The development of the genital peritoneum in domestic mammals. An analysis of the literature and nomenclature. Martin E. **Anat Histol Embryol** 1995 Dec;24(4):285–7 (18 ref.)

PHYSIOLOGY

Structural remodelling of reproductive tissues. Luck MR, et al. **J Endocrinol** 1995 Aug;146(2):191–5 (61 ref.)

GENITALIA, FEMALE

see related
HYSTEROSALPINGOGRAPHY

ABNORMALITIES

Transsphincteric anorectal reconstruction of ambiguous genitalia: an innovative approach to neovaginoplasty, pioneer in Brazil. Braz A, et al. **Rev Paul Med** 1995 Nov–Dec;113(6):1022–32 (25 ref.)

Ambiguous genitalia in an elderly woman with a mosaic 45,X/46,X,dic(Y)(Q11.2) karyotype. Smith YR, et al. **Urology** 1996 Feb;47(2):259–62 (13 ref.)

[Gynecological malformations. Classification and contribution of different imaging methods] Maubon A, et al. **J Radiol** 1996 Jul;77(7):465–75 (32 ref.) **(Fre)**

BLOOD SUPPLY

Angiogenesis in the human female reproductive tract. Gordon JD, et al. **Obstet Gynecol Surv** 1995 Sep; 50(9):688–97 (126 ref.)

DRUG EFFECTS

Gynaecologic effects of tamoxifen. Kuo DY, et al. **Med Oncol** 1995 Jun;12(2):87–94 (79 ref.)

[Inducing feminization in Turner syndrome (editorial)] Bost M. **Arch Pediatr** 1995 Nov;2(11):1035–7 (12 ref.) **(Fre)**

[Medical adverse effects of chemoprevention: the example of tamoxifen] Sasco AJ, et al. **Bull Cancer (Paris)** 1995 Jul; 82 Suppl 3:186s–206s (116 ref.) (Eng. Abstr.) **(Fre)**

[Gynecologic monitoring of tamoxifen treatment of breast cancer] Le Bouedec G, et al. **Rev Fr Gynecol Obstet** 1995 Jul–Sep;90(7–9):379–82 (30 ref.) **(Fre)**

PATHOLOGY

Contrast-enhanced MR imaging of gynecologic disorders. Outwater EK. **Magn Reson Imaging Clin N Am** 1996 Feb; 4(1):133–51 (84 ref.)

PHYSIOLOGY

The tissue renin-angiotensin system in the female reproductive tissues. A review. Nielsen AH, et al. **Adv Exp Med Biol** 1995;377:253–68 (145 ref.)

Prolactin release after mating and genitosensory stimulation in females. Erskine MS. **Endocr Rev** 1995 Aug;16(4):508–28 (222 ref.)

SURGERY

Lasers in gynecology: why pragmatic surgeons have not abandoned this valuable technology. Reid R, et al. **Lasers Surg Med** 1995;17(3):201–301 (209 ref.)

Transsphincteric anorectal reconstruction of ambiguous genitalia: an innovative approach to neovaginoplasty, pioneer in Brazil. Braz A, et al. **Rev Paul Med** 1995 Nov–Dec;113(6):1022–32 (25 ref.)

[Use of suture materials in gynecologic surgery] Durdević S, et al. **Med Pregl** 1995;48(3–4):91–4 (12 ref.) (Eng. Abstr.) **(Scr)**

GENITALIA, MALE

ABNORMALITIES

Declining semen quality and increasing incidence of abnormalities in male reproductive organs--fact or fiction? Giwercman A. **Hum Reprod** 1995 Oct;10 Suppl 1:158–64 (44 ref.)

INJURIES

[Injuries to the external male genitals] Zermann DH, et al. **Z Arztl Fortbild (Jena)** 1995 Dec;89(7):729–33 (31 ref.) (Eng. Abstr.) **(Ger)**

[Massive avulsion of the genital skin in a man. Apropos a case and a review of treatment] Cavadas Rodriguez P. **Arch Esp Urol** 1995 Nov;48(9):952–4 (3 ref.) (Eng. Abstr.) **(Spa)**

METABOLISM

Expression of renin in coagulating glands. Kon Y, et al. **Histol Histopathol** 1996 Jan;11(1):257–66 (104 ref.)

PHYSIOLOGY

Relevance of the tissue prorenin-renin-angiotensin system to male reproductive physiology. Mukhopadhyay AK, et al. **Adv Exp Med Biol** 1995;377:269–77 (47 ref.)

GENITOURINARY DISEASES see **UROGENITAL DISEASES**

GENITOURINARY NEOPLASMS see **UROGENITAL NEOPLASMS**

GENITOURINARY SYSTEM see **UROGENITAL SYSTEM**

GENOME

Mapping of mammalian genomes with radiation (Goss and Harris) hybrids. Leach RJ, et al. **Adv Genet** 1995;33:63–99 (82 ref.)

Simple sequences and the expanding genome. Hancock JM. **Bioessays** 1996 May;18(5):421–5 (50 ref.)

Genome analysis with gene expression microarrays. Schena M. **Bioessays** 1996 May;18(5):427–31 (24 ref.)

Knockouts. Targeting the mouse genome: a compendium of knockouts (Part I). Brandon EP, et al. **Curr Biol** 1995 Jun 1;5(6):625–34 (207 ref.)

Comparative maps: the mammalian jigsaw puzzle. Eppig JT, et al. **Curr Opin Genet Dev** 1995 Dec;5(6):709–16 (52 ref.)

An update and lessons from whole-genome sequencing projects. Jones SJ. **Curr Opin Genet Dev** 1995 Jun; 5(3):349–53 (35 ref.)

DNA excision repair and transcription: implications for genome evolution. Sullivan DT. **Curr Opin Genet Dev** 1995 Dec;5(6):786–91 (55 ref.)

Chromosome painting in mammals as an approach to comparative genomics. Wienberg J, et al. **Curr Opin Genet Dev** 1995 Dec;5(6):792–7 (36 ref.)

Bovine genome mapping: evolutionary inference and the power of comparative genomics. Womack JE, et al. **Curr Opin Genet Dev** 1995 Dec;5(6):725–33 (35 ref.)

Simple repetitive sequences in the genome: structure and functional significance. Brahmachari SK, et al. **Electrophoresis** 1995 Sep;16(9):1705–14 (92 ref.)

Repetitive sequence fingerprinting in the long range mapping of mammalian genomes. Hamvas RM, et al. **Electrophoresis** 1995 Sep;16(9):1602–6 (64 ref.)

Genomes with distinct function composition. Tamames J, et al. **FEBS Lett** 1996 Jun 24;389(1):96–101 (13 ref.)

Optical mapping: a novel, single-molecule approach to genomic analysis. Samad A, et al. **Genome Res** 1995 Aug; 5(1):1–4 (12 ref.)

Human/mouse homology relationships. DeBry RW, et al. **Genomics** 1996 May 1;33(3):337–51 (46 ref.)

The nuclear matrix: a structural milieu for genomic function. Berezney R, et al. **Int Rev Cytol** 1995;162A:1–65 (270 ref.)

Speculations on the influence of electromagnetism on genomic and associated structures. Jacobson JI. **J Int Med Res** 1996 Jan–Feb;24(1):1–11 (49 ref.)

Creation of genomic methylation patterns. Bestor TH, et al. **Nat Genet** 1996 Apr;12(4):363–7 (51 ref.)

Genome engineering: the new mouse genetics. Rossant J, et al. **Nat Med** 1995 Jun;1(6):592–4 (11 ref.)

Genome sequencing projects. Schlessinger D. **Nat Med** 1995 Sep;1(9):866–8 (15 ref.)

Genomic instability induced by ionizing radiation. Morgan WF, et al. **Radiat Res** 1996 Sep;146(3):247–58 (175 ref.)

The nematode Caenorhabditis elegans and its genome. Hodgkin J, et al. **Science** 1995 Oct 20;270(5235):410–4 (25 ref.)

From ion currents to genomic analysis: recent advances in GABAA receptor research. Rabow LE, et al. **Synapse** 1995 Nov;21(3):189–274 (675 ref.)

Dinucleotide relative abundance extremes: a genomic signature. Karlin S, et al. **Trends Genet** 1995 Jul; 11(7):283–90 (27 ref.)

Representational difference analysis: finding the differences between genomes. Lisitsyn NA. **Trends Genet** 1995 Aug; 11(8):303–7 (20 ref.)

[The problem of systemic mutation] Stegnii VN. **Genetika** 1996 Jan;32(1):14–22 (43 ref.) (Eng. Abstr.) **(Rus)**

GENOME, BACTERIAL

Genome evolution in enteric bacteria. Ochman H, et al. **Curr Opin Genet Dev** 1995 Dec;5(6):734–8 (40 ref.)

The Sulfolobus solfataricus P2 genome project. Charlebois RL, et al. **FEBS Lett** 1996 Jun 24;389(1):88–91 (21 ref.)

Sequencing and functional analysis of the genome of Bacillus subtilis strain 168. Harwood CR, et al. **FEBS Lett** 1996 Jun 24;389(1):84–7 (39 ref.)

Analysis of bacterial genomes by pulsed field gel electrophoresis. Méndez-Alvarez S, et al. **Microbiologia** 1995 Sep;11(3):323–36 (93 ref.)

Bacterial genomes: a TIGR in the tank. Devine KM, et al. **Trends Genet** 1995 Nov;11(11):429–31 (13 ref.)

[Information from complete bacterial genome sequences] Ogasawara N. **Tanpakushitsu Kakusan Koso** 1996 Apr; 41(4):366–70 (12 ref.) **(Jpn)**

GENOME, FUNGAL

Phylogenesis of fission yeasts. Contradictions surrounding the origin of a century old genus. Sipiczki M. **Antonie Van Leeuwenhoek** 1995 Aug;68(2):119–49 (300 ref.)

GENOME, HUMAN

Mapping of mammalian genomes with radiation (Goss and Harris) hybrids. Leach RJ, et al. **Adv Genet** 1995;33:63–99 (82 ref.)

Cell cycle checkpoints, genomic integrity, and cancer. Hartwell L, et al. **Cold Spring Harb Symp Quant Biol** 1994; 59:259–63 (30 ref.)

Genomic integrity and the genetics of cancer. Tlsty TD, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:265–75 (53 ref.)

Human genome organization. Gardiner K. **Curr Opin Genet Dev** 1995 Jun;5(3):315–22 (53 ref.)

Positional cloning reaches maturity. Nelson DL. **Curr Opin Genet Dev** 1995 Jun;5(3):298–303 (32 ref.)

Simple repetitive sequences in the genome: structure and functional significance. Brahmachari SK, et al. **Electrophoresis** 1995 Sep;16(9):1705–14 (92 ref.)

Human/mouse homology relationships. DeBry RW, et al. **Genomics** 1996 May 1;33(3):337–51 (46 ref.)

Pressing ahead with human genome sequencing. Gibbs RA. **Nat Genet** 1995 Oct;11(2):121–5 (35 ref.)

The viruses in all of us: characteristics and biological significance of human endogenous retrovirus sequences. Löwer R, et al. **Proc Natl Acad Sci U S A** 1996 May 28; 93(11):5177–84 (80 ref.)

A graphical interface for searching the human genome. Adler D. **Trends Genet** 1995 Oct;11(10):416–7 (0 ref.)

[The high fork of genome programs (editorial)] Weissenbach J. **C R Acad Sci III** 1996 Apr;319(4):247–8 (11 ref.) **(Fre)**

[Positional cloning of the genes for progeroid syndromes] Miki T, et al. **Tanpakushitsu Kakusan Koso** 1996 Mar; 41(3):245–54 (41 ref.) **(Jpn)**

GENOME, PLANT

Cereal genome evolution. Grasses, line up and form a circle. Moore G, et al. **Curr Biol** 1995 Jul 1;5(7):737–9 (13 ref.)

Cereal genome evolution: pastoral pursuits with 'Lego' genomes. Moore G. **Curr Opin Genet Dev** 1995 Dec; 5(6):717–24 (65 ref.)

LTR-retrotransposons and MITEs: important players in the evolution of plant genomes. Wessler SR, et al. **Curr Opin Genet Dev** 1995 Dec;5(6):814–21 (65 ref.)

How do alterations in plant mitochondrial genomes disrupt pollen development? Conley CA, et al. **J Bioenerg Biomembr** 1995 Aug;27(4):447–57 (78 ref.)

Isolation and characterization of plant genomic DNA sequences via (inverse) PCR amplification. Offringa R, et al. **Methods Mol Biol** 1995;49:181–95 (38 ref.)

GENOME PROJECT, HUMAN see **HUMAN GENOME PROJECT**

GENOME, VIRAL

Transcription, replication, recombination, and engineering of coronavirus genes. Lai MM. **Adv Exp Med Biol** 1995; 380:463–71 (29 ref.)

Coronaviruses use discontinuous extension for synthesis of subgenome-length negative strands. Sawicki SG, et al. **Adv Exp Med Biol** 1995;380:499–506 (21 ref.)

Rhinoviruses and cells: molecular aspects. Rowlands DJ. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 2):S31–5 (41 ref.)

The complete nucleotide sequence of the DNA of human adenovirus type 12. Sprengel J, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 2):189–274 (45 ref.)

Viral arthritis: the lessons of parvovirus B19. Mangi RJ. **Hosp Pract (Off Ed)** 1995 Nov 15;30(11):65–72 (7 ref.)

Heterogeneity of HBV genome. Raimondo G, et al. **Ital J Gastroenterol** 1995 Mar;27(2):88–90 (22 ref.)

Hepatitis C virus : prevalence in Lebanese blood donors and brief overview of the disease. Araj GF, et al. **J Med Liban** 1995;43(1):11–6 (44 ref.)

Substitution rates in hepatitis delta virus. Krushkal J, et al. **J Mol Evol** 1995 Dec;41(6):721–6 (31 ref.)

Minute virus of mice cis-acting sequences required for genome replication and the role of the trans-acting viral protein, NS-1. Astell CR, et al. **Prog Nucleic Acid Res Mol Biol** 1996;55:245–85 (116 ref.)

Molecular recognition in the assembly of the segmented reovirus genome. Joklik WK, et al. **Prog Nucleic Acid Res Mol Biol** 1996;53:249–81 (188 ref.)

Genome organization in the caliciviridae. Lambden PR, et al. **Trends Microbiol** 1995 Jul;3(7):261–5 (44 ref.)

Functional organization of variola major and vaccinia virus genomes. Shchelkunov SN. **Virus Genes** 1995;10(1):53–71 (261 ref.)

[Hepatitis B virus replication and fulminant hepatitis: special reference to genomic variants] Kamimura T. **Nippon Rinsho** 1995 Oct;53 Suppl:473–6 (8 ref.) **(Jpn)**

[Structure and function of hepatitis A virus RNA] Kuwabara Y. **Nippon Rinsho** 1995 Oct;53 Suppl:785–90 (16 ref.) **(Jpn)**

[Expression of the proteins encoded by the hepatitis C viral genome by vaccinia virus expression system] Tanaka T, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:85–90 (16 ref.) **(Jpn)**

[HCV genome in type C hepatocellular carcinoma] Yamada G. **Nippon Rinsho** 1995 Sep;53 Suppl:777–81 (13 ref.) **(Jpn)**

[Detection of HBV genomes in liver tissue by in situ hybridization] Yamada S, et al. **Nippon Rinsho** 1995 Oct;

53 Suppl:325–30 (19 ref.) **(Jpn)**
[Detection and analysis of human herpesvirus genomes by polymerase chain reaction] Aono T, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):669–75 (24 ref.) **(Jpn)**
[Hepatitis C virus] Kato N, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):676–80 (19 ref.) **(Jpn)**
[Detection of Borna disease virus RNA by RT-PCR in PBMC] Nakaya T, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):700–4 (20 ref.) **(Jpn)**
[Analysis of HTLV-1 expression in vivo] Saito M, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):681–5 (13 ref.) **(Jpn)**
[Detection and typing of HPV genome: consensus PCR method] Yamashita T, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):664–8 (21 ref.) **(Jpn)**
[Structure and function of RNA from closterovirus genomes] Agranovskaĭ AA. **Mol Biol (Mosk)** 1995 Nov–Dec; 29(6):1265–85 (121 ref.) **(Rus)**

GENOMIC IMPRINTING

Do imprinted genes have few and small introns? Haig D. **Bioessays** 1996 May;18(5):351–3 (21 ref.)
Towards unravelling the Igf2/H19 imprinted domain. Viville S, et al. **Bioessays** 1995 Oct;17(10):835–8 (23 ref.)
Genomic imprinting in mice: its function and mechanism. Leighton PA, et al. **Biol Reprod** 1996 Feb;54(2):273–8 (56 ref.)
Genomic imprinting and cancer. Brenton JD, et al. **Cancer Surv** 1995;25:161–71 (68 ref.)
Genome imprinting: an overview. Sapienza C. **Dev Genet** 1995;17(3):185–7 (10 ref.)
The Wellcome Prize Lecture. Genetic imprinting: the battle of the sexes rages on. Reik W. **Exp Physiol** 1996 Mar; 81(2):161–72 (8 ref.)
Uniparental disomy in humans: development of an imprinting map and its implications for prenatal diagnosis. Ledbetter DH, et al. **Hum Mol Genet** 1995;4 Spec No:1757–64 (100 ref.)
Normal development and neoplasia: the imprinting connection. Ohlsson R, et al. **Int J Dev Biol** 1995 Oct; 39(5):869–76 (54 ref.)
Prenatal and postnatal growth failure associated with maternal heterodisomy for chromosome 7. Langlois S, et al. **J Med Genet** 1995 Nov;32(11):871–5 (25 ref.)
Genomic imprinting, DNA methylation, and cancer. Feinberg AP, et al. **J Natl Cancer Inst Monogr** 1995; (17):21–6 (83 ref.)
Epigenetics and human disease. Issa JP, et al. **Nat Med** 1996 Mar;2(3):281–2 (18 ref.)
Genomic imprinting and mammalian development. Franklin GC, et al. **Placenta** 1996 Jan;17(1):3–14 (107 ref.)
Gametic imprinting in mammals. Barlow DP. **Science** 1995 Dec 8;270(5242):1610–3 (31 ref.)
Genomic imprinting in tumours. Squire J, et al. **Semin Cancer Biol** 1996 Feb;7(1):41–7 (52 ref.)
[Genomic imprinting and human pathology. 2.] Cirillo Silengo M, et al. **Pediatr Med Chir** 1995 Sep–Oct; 17(5):389–94 (41 ref.) (Eng. Abstr.) **(Ita)**
[Genomic imprinting and human pathology. I. General Part] Guala A, et al. **Pediatr Med Chir** 1995 Jul–Aug; 17(4):311–21 (46 ref.) (Eng. Abstr.) **(Ita)**

GENETICS

Mechanistic and developmental aspects of genetic imprinting in mammals. Latham KE, et al. **Int Rev Cytol** 1995; 160:53–98 (185 ref.)

PHYSIOLOGY

Multiple roles for DNA methylation in gametic imprinting. Neumann B, et al. **Curr Opin Genet Dev** 1996 Apr; 6(2):159–63 (45 ref.)
Parental genomic imprinting. Deal CL. **Curr Opin Pediatr** 1995 Aug;7(4):445–58 (146 ref.)

GENOMIC LIBRARY

see related
CHROMOSOMES, YEAST ARTIFICIAL
DNA, RECOMBINANT
HUMAN GENOME PROJECT

Filamentous phage display of oligopeptide libraries. Burritt JB, et al. **Anal Biochem** 1996 Jun 15;238(1):1–13 (102 ref.)

GENOTYPE

Antisocial personality disorder: a biopsychosocial model. Paris J. **Can J Psychiatry** 1996 Mar;41(2):75–80 (70 ref.)
Discordance between phenotype and genotype in malignant hyperthermia. MacLennan DH. **Curr Opin Neurol** 1995 Oct;8(5):397–401 (33 ref.)
Relationship between genotype and phenotype in monogenic diseases: relevance to polygenic diseases. Summers KM. **Hum Mutat** 1996;7(4):283–93 (98 ref.)
In defence of the right shift theory. Annett M. **Percept Mot Skills** 1996 Feb;82(1):115–37 (62 ref.)

GENTAMICINS

ADMINISTRATION & DOSAGE

†Hematogenous osteomyelitis of the calcaneus in children: surgical treatment and use of implanted antibiotic beads. Kelsey R, et al. **J Foot Ankle Surg** 1995 Nov–Dec; 34(6):547–55; discussion 594 (26 ref.)

ADVERSE EFFECTS

Gentamicin nephrotoxicity in humans and animals: some recent research. Ali BH. **Gen Pharmacol** 1995 Nov; 26(7):1477–87 (119 ref.)

PHARMACOLOGY

Antibiotic resistance in Enterococcus species: an update. Eliopoulos GM. **Curr Clin Top Infect Dis** 1996;16:21–51 (231 ref.)

THERAPEUTIC USE

[Use of mini-septopal in trauma surgery of the hand. Experimental and clinical studies] Zimmer K. **Polim Med** 1996;26(1–2):3–57 (136 ref.) (Eng. Abstr.) **(Pol)**

GENTAMYCIN see **GENTAMICINS**

GENTIAN see **PLANTS, MEDICINAL**

GEOGRAPHIC TONGUE see **GLOSSITIS, BENIGN MIGRATORY**

GEOGRAPHY

The development of Ontario's Home Care Program: a critical geographical analysis. Williams AM. **Soc Sci Med** 1996 Mar;42(6):937–48 (52 ref.)

GEOLOGIC SEDIMENTS

ANALYSIS

Persistent pesticides in Mexico. Albert LA. **Rev Environ Contam Toxicol** 1996;147:1–44 (85 ref.)

GERANYLGERANYLATION see **PROTEIN ISOPRENYLATION**

GERBILLINAE

METABOLISM

Energy requirements of the fat sand rat (Psammomys obesus) when consuming the saltbush, Atriplex halimus: a review. Degen AA. **J Basic Clin Physiol Pharmacol** 1993 Apr–Jun; 4(1–2):13–28 (37 ref.)

PARASITOLOGY

Discovery and study of Leishmania turanica for the first time in China. Guan LR, et al. **Bull World Health Organ** 1995; 73(5):667–72 (35 ref.)

PHYSIOLOGY

The fat sand rat: a quintessential desert rodent. Pinshow B. **J Basic Clin Physiol Pharmacol** 1993 Apr–Jun;4(1–2):5–12 (56 ref.)
Psammomys obesus of the Jerusalem colony: a model for nutritionally induced, non-insulin-dependent diabetes. Shafrir E, et al. **J Basic Clin Physiol Pharmacol** 1993 Apr–Jun;4(1–2):83–99 (54 ref.)

GERBILS see **GERBILLINAE**

GERIATRIC ASSESSMENT

Review: cobalamin deficiency and mental impairment in elderly people. van Goor L, et al. **Age Ageing** 1995 Nov; 24(6):536–42 (80 ref.)
Computerized geriatric assessment for geriatric care management. De Vore PA. **Aging (Milano)** 1995 Jun; 7(3):194–6 (22 ref.)
A proposal for an integrated multidisciplinary assessment battery in elderly stroke patients. Kalra L. **Aging (Milano)** 1995 Jun;7(3):197–201 (57 ref.)
Elderly people who fall: identifying and managing the causes. Campbell AJ, et al. **Br J Hosp Med** 1995 Nov 15–Dec 12;54(10):520–3 (21 ref.)
Assessing appropriateness of treatment: a case study of transplantation in older patients with congestive heart failure. Montague T, et al. **Can J Cardiol** 1996 Jan; 12(1):47–52 (33 ref.)
Preventing falls: how to identify risk factors, reduce complications. Tideiksaar R. **Geriatrics** 1996 Feb; 51(2):43–6, 49–50, 53, quiz 54–5 (5 ref.)
Picture imperfect: hidden problems among Asian Pacific islander elderly. Tanjasiri SP, et al. **Gerontologist** 1995 Dec; 35(6):753–60 (65 ref.)
Antidepressants in geriatric depression: what difference have they made? Baldwin RC. **Int Psychogeriatr** 1995;7 Suppl:55–68 (65 ref.)
Treatment-resistant depression in the elderly. Bonner D, et al. **Int Psychogeriatr** 1995;7 Suppl:83–94 (70 ref.)
Late-life delusional depression: acute and long-term treatment. Meyers BS. **Int Psychogeriatr** 1995;7 Suppl:113–24 (73 ref.)
The difficult elderly patient: curable hostile depression or personality disorder? Monfort JC. **Int Psychogeriatr** 1995; 7 Suppl:95–111 (50 ref.)
Maintenance therapies for late-life recurrent major depression: research and review circa 1995. Reynolds CF 3rd, et al. **Int Psychogeriatr** 1995;7 Suppl:27–39 (27 ref.)
Efficacy of acute treatment for geriatric depression. Schneider LS, et al. **Int Psychogeriatr** 1995;7 Suppl:7–25 (75 ref.)
Diagnosing and managing elder abuse. Jogerst G. **Iowa Med** 1996 Jan;86(1):29–31 (9 ref.)
Benign aging or Alzheimer disease? Gorman WF. **J Okla State Med Assoc** 1995 Sep;88(9):383–91 (51 ref.)
Geriatric health maintenance. Scheitel SM, et al. **Mayo Clin Proc** 1996 Mar;71(3):289–302 (144 ref.)
Mobility and balance in the elderly: a guide to bedside assessment. MacKnight C, et al. **Postgrad Med** 1996 Mar; 99(3):269–71, 275–6 (19 ref.)
Prevention and screening in the nursing home. Gershman K, et al. **Prim Care** 1995 Dec;22(4):731–53 (106 ref.)
Health maintenance and prevention in the elderly. Gleich GS. **Prim Care** 1995 Dec;22(4):697–711 (50 ref.)
Longitudinal studies of dependence in daily life activities among elderly persons. Sonn U. **Scand J Rehabil Med Suppl** 1996;34:1–35 (168 ref.)
Elderly mental health in the developing world. Levkoff SE, et al. **Soc Sci Med** 1995 Oct;41(7):983–1003 (178 ref.)
[Anxiety disorders in the elderly—diagnostic problems and therapeutic prospects] Boerner RJ. **Z Gerontol Geriatr** 1995 Nov–Dec;28(6):435–43 (48 ref.) (Eng. Abstr.) **(Ger)**

GERIATRIC DENTISTRY

see related
DENTAL CARE FOR AGED

GERIATRIC HEALTH SERVICES see **HEALTH SERVICES FOR THE AGED**

GERIATRIC NURSING

METHODS

Obtaining "informed" consent from the elderly. Alt-White AC. **West J Nurs Res** 1995 Dec;17(6):700–5 (12 ref.)

STANDARDS

Development of a functional capacity model for the elderly. Song M, et al. **Res Nurs Health** 1996 Jun;19(3):173–81 (631 ref.)

GERIATRIC PSYCHIATRY

[Treatment of chronic insomnia. A recommendation with special emphasis on problems of the elderly] Neckelmann D. **Tidsskr Nor Laegeforen** 1996 Mar 10;116(7):854–9 (40 ref.) (Eng. Abstr.) **(Nor)**

GERIATRICS

see related
AGED

Computerized geriatric assessment for geriatric care management. De Vore PA. **Aging (Milano)** 1995 Jun; 7(3):194–6 (22 ref.)
Inhalation anaesthesia at the extremes of age: geriatric anaesthesia. Conzen P, et al. **Anaesthesia** 1995 Oct;50 Suppl:29–33 (33 ref.)
Update in geriatrics. Hall WJ. **Ann Intern Med** 1996 Sep 1;125(5):390–7 (2 ref.)
Geriatric medicine. Elon RD. **BMJ** 1996 Mar 2; 312(7030):561–3 (19 ref.)
Reminiscence: a continuity theory framework. Parker RG. **Gerontologist** 1995 Aug;35(4):515–25 (81 ref.)
Geriatric health maintenance. Scheitel SM, et al. **Mayo Clin Proc** 1996 Mar;71(3):289–302 (144 ref.)
General medicine and geriatrics, where is the difference? The example of infective disease. Evans JG. **Schweiz Med Wochenschr** 1995 Oct 7;125(40):1847–54 (34 ref.)
Avoiding problems prescribing to older patients. Beyth RJ, et al. **Tenn Med** 1996 Aug;89(8):296–8 (31 ref.)
[Nursing home medicine, a new medical specialism] de Pijper NF, et al. **Ned Tijdschr Geneeskd** 1995 Sep 9;139(36):1820–3 (41 ref.) **(Dut)**

EDUCATION

Academics and the nursing home. Katz PR, et al. **Clin Geriatr Med** 1995 Aug;11(3):503–16 (36 ref.)

METHODS

Rehabilitation of geriatric patients. Weber DC, et al. **Mayo Clin Proc** 1995 Dec;70(12):1198–204 (18 ref.)

ORGANIZATION & ADMINISTRATION

The medical director in the multi-level long-term care facility. Applebaum GE. **Clin Geriatr Med** 1995 Aug;

11(3):359–72 (4 ref.)
Nursing homes: what you need to know for quality patient care. Cefalu CA. **Geriatrics** 1995 Dec;50(12):37–40, 49–50 (22 ref.)

TRENDS

[Progresses in geriatrics in China, 1995] Wang S, et al. **Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):768–70 (0 ref.) **(Chi)**

GERM CELL TUMOR see **GERMINOMA**

GERM CELLS

Germ-line therapy to cure mitochondrial disease: protocol and ethics of in vitro ovum nuclear transplantation. Rubenstein DS, et al. **Camb Q Healthc Ethics** 1995 Summer; 4(3):316–39 (101 ref.)
Targeted mutagenesis: analysis of phenotype without germ line transmission. Nagy A, et al. **J Clin Invest** 1996 Mar 15;97(6):1360–5 (38 ref.)
Gamete microsurgery for assisted fertilization. Sparks AE. **Microsurgery** 1995;16(5):345–8 (25 ref.)
Germ line transmission of yeast artificial chromosomes in transgenic mice. Montoliu L, et al. **Reprod Fertil Dev** 1994; 6(5):577–84 (44 ref.)

CYTOLOGY

E2F and cell proliferation: a world turned upside down. Weinberg RA. **Cell** 1996 May 17;85(4):457–9 (10 ref.)

DRUG EFFECTS

Synthesis report of the step project detection of germ cell mutagens. Adler ID, et al. **Mutat Res** 1996 Jun 12; 353(1–2):65–84 (76 ref.)

METABOLISM

Transcription and masking of mRNA in germ cells: involvement of Y-box proteins. Sommerville J, et al. **Chromosoma** 1996 Apr;104(7):469–78 (66 ref.)

PATHOLOGY

So-called intracranial germ cell tumours: are they really of germ cell origin? Sano K. **Br J Neurosurg** 1995;9(3):391–401 (26 ref.)

GERM-FREE LIFE

PHYSIOLOGY

Nutritional and physiological characteristics in germ-free chickens. Furuse M, et al. **Comp Biochem Physiol A Physiol** 1994 Nov;109(3):547–56 (68 ref.)

GERM-LINE CELLS see **GERM CELLS**

GERM-LINE MUTATION

CDKN2A (p16INK4A) somatic and germline mutations. Smith-Sørensen B, et al. **Hum Mutat** 1996;7(4):294–303 (81 ref.)
[Hereditary mutations in the p53 tumor suppressor gene; significance for clinical practice. National Work Group Hereditary Mamma Carcinoma] Menko FH, et al. **Ned Tijdschr Geneeskd** 1996 Jun 29;140(26):1347–50 (21 ref.) **(Dut)**

GERM LINE THEORY see **ANTIBODY DIVERSITY**

GERMINAL CENTER

see related
APOPTOSIS

IMMUNOLOGY

Follicular dendritic cells: origin and function. Heinen E, et al. **Curr Top Microbiol Immunol** 1995;201:15–47 (200 ref.)
Follicular dendritic cells: antigen retention, B cell activation, and cytokine production. Kosco-Vilbois MH, et al. **Curr Top Microbiol Immunol** 1995;201:69–82 (30 ref.)
Life and death in germinal centers (redux). Kelsoe G. **Immunity** 1996 Feb;4(2):107–11 (102 ref.)
The germinal center reaction. Kelsoe G. **Immunol Today** 1995 Jul;16(7):324–6 (24 ref.)

PHYSIOLOGY

The germinal center: a crucible for lymphocyte selection. Kelsoe G. **Semin Immunol** 1996 Jun;8(3):179–84 (52 ref.)
Sequential triggering of apoptosis, somatic mutation and isotype switch during germinal center development. Liu YJ, et al. **Semin Immunol** 1996 Jun;8(3):169–77 (51 ref.)

VIROLOGY

Follicular dendritic cells initiate and maintain infection of the germinal centers by human immunodeficiency virus. Tenner-Racz K, et al. **Curr Top Microbiol Immunol** 1995; 201:141–59 (110 ref.)

GERMINOBLASTOMA see **LYMPHOMA**

GERMINOMA

[Malignant germ cell tumor of the liver] Sasaki M. **Ryoikibetsu Shokogun Shirizu** 1995;(7):310–3 (7 ref.) **(Jpn)**

BLOOD

Primary mediastinal malignant germ cell tumour. Single institution experience in Chinese patients and correlation with specific alpha-fetoprotein bends. Chan AT, et al. **Acta Oncol** 1996;35(2):221–7 (29 ref.)

CLASSIFICATION

[Classification of ovarian tumors based on embryogenesis] Minh HN, et al. **Arch Anat Cytol Pathol** 1995;43(3):126–39 (17 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

Sudden death caused by testicular germ cell tumour. Dada MA, et al. **Med Sci Law** 1995 Oct;35(4):357–9 (12 ref.)

DIAGNOSIS

Pineal germinoma with cranial nerve metastasis. Incesu L, et al. **Radiol Med (Torino)** 1996 Apr;91(4):471–2 (11 ref.)
[Double localization of intracranial germinoma. Apropos of a case] Alifdal M, et al. **Neurochirurgie** 1995;41(6):424–8 (23 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

Ifosfamide in the treatment of germ cell tumors. Nichols CR. **Semin Oncol** 1996 Jun;23(3 Suppl 6):65–73 (55 ref.)
[Treatment of stage I non-seminomatous germ cell tumors of the testis] Droz JP. **Presse Med** 1995 Oct 28; 24(32):1501–3 (10 ref.) (Eng. Abstr.) **(Fre)**
[Germ cell tumors in children and adolescents] Göbel U, et al. **Schweiz Rundsch Med Prax** 1995 Sep 26;84(39):1063–7 (9 ref.) (Eng. Abstr.) **(Ger)**
[Chemotherapy with combined treatment of malignant germ cell tumors in children] Zaleska-Czepko E. **Pediatr Pol** 1995 Nov;70(11):955–8 (33 ref.) (Eng. Abstr.) **(Pol)**

EPIDEMIOLOGY

Extragonadal germ cell tumor: a clinical study. Bassetto MA, et al. **Anticancer Res** 1995 Nov-Dec;15(6B):2751–4 (17 ref.)
A Scottish national audit of current patterns of management for patients with testicular non-seminomatous germ-cell tumours. The Scottish Radiological Society and the Scottish Committee of the Royal College of Radiologists. Howard GC, et al. **Br J Cancer** 1995 Nov;72(5):1303–6 (17 ref.)
Intramedullary spinal cord germinoma. Matsuyama Y, et al. **Spine** 1995 Nov 1;20(21):2338–40 (8 ref.)

GENETICS

Molecular biology of testicular germ cell tumors: current status. Schmidt B, et al. **J Mol Med** 1995 Jul;73(7):355–67 (189 ref.)
[Correlation between p-53 expression and clinical resistance in testicular cancer] Hanna E, et al. **Orv Hetil** 1996 Jan 14;137(2):59–64 (26 ref.) (Eng. Abstr.) **(Hun)**

MORTALITY

A Scottish national mortality study assessing cause of death, quality of and variation in management of patients with testicular non-seminomatous germ-cell tumours. The Scottish Radiological Society and the Scottish Standing Committee of the Royal College of Radiologists. Howard GC, et al. **Br J Cancer** 1995 Nov;72(5):1307–11 (14 ref.)

PATHOLOGY

Malignant sacrococcygeal germ cell tumour in an adult. Smithers BM, et al. **Aust N Z J Surg** 1996 Mar;66(3):185–9 (25 ref.)
So-called intracranial germ cell tumours: are they really of germ cell origin? Sano K. **Br J Neurosurg** 1995;9(3):391–401 (26 ref.)

SECONDARY

[Intracardiac metastases of germ cell tumors. Apropos of a case (letter)] Hauteville D, et al. **Ann Med Interne (Paris)** 1996;147(3):218–21 (26 ref.) **(Fre)**

SURGERY

Intramedullary spinal cord germinoma: case report and review of the literature. Itoh Y, et al. **Neurosurgery** 1996 Jan;38(1):187–90; discussion 190–1 (17 ref.)

THERAPY

Primary mediastinal malignant germ cell tumour. Single institution experience in Chinese patients and correlation with specific alpha-fetoprotein bends. Chan AT, et al. **Acta Oncol** 1996;35(2):221–7 (29 ref.)
The role of adjuvant treatment in low-stage germ cell testicular tumors. Pizzocaro G, et al. **Eur Urol** 1995; 28(4):267–72 (28 ref.)
[Germ cell tumor] Kasai M, et al. **Gan To Kagaku Ryoho** 1995 Oct;22(12):1749–55 (19 ref.) (Eng. Abstr.) **(Jpn)**
[Treatment of hypothalamic-pituitary tumors—experiences at Hiroshima University School of Medicine] Uozumi T. **Nippon Naibunpi Gakkai Zasshi** 1995 Nov 20;71(7):1019–36 (43 ref.) (Eng. Abstr.) **(Jpn)**
[Current procedure for treating testicular germ-cell tumors] Tiuliandin SA, et al. **Urol Nefrol (Mosk)** 1995 Nov-Dec; (6):40–4 (15 ref.) (Eng. Abstr.) **(Rus)**

GERONTOLOGY see **GERIATRICS**

GERSTMANN-STRAUSSLER-SCHEINKER DISEASE see **GERSTMANN-STRAUSSLER SYNDROME**

GERSTMANN-STRAUSSLER SYNDROME

GENETICS

[A case of variant Gerstmann-Sträussler-Scheinker disease with the mutation of codon P105L] Kubo M, et al. **Rinsho Shinkeigaku** 1995 Aug;35(8):873–7 (9 ref.) (Eng. Abstr.) **(Jpn)**

GESTATIONAL AGE

see related
INFANT, PREMATURE

Fetal exomphalos and chromosomal defects: relationship to maternal age and gestation. Snijders RJ, et al. **Ultrasound Obstet Gynecol** 1995 Oct;6(4):250–5 (30 ref.)

GESTATIONAL DIABETES see **DIABETES, GESTATIONAL**

GESTOSIS, EPH

ETIOLOGY

[The clinico-biochemical aspects of the pathogenesis of gestoses] Kulakov VI, et al. **Akush Ginekol (Mosk)** 1995; (6):3–5 (51 ref.) **(Rus)**

METABOLISM

[The clinico-biochemical aspects of the pathogenesis of gestoses] Kulakov VI, et al. **Akush Ginekol (Mosk)** 1995; (6):3–5 (51 ref.) **(Rus)**

GESTURES

[Characterization of gestural disorders in primary progressive apraxia: diagnostic and nosographic contribution] Habib M, et al. **Rev Neurol (Paris)** 1995 Oct;151(10):541–51 (29 ref.) (Eng. Abstr.) **(Fre)**

GETAH VIRUS see **ALPHAVIRUS**

GHETTOS see **POVERTY AREAS**

GIANT CELL ARTERITIS see **TEMPORAL ARTERITIS**

GIANT CELL GRANULOMA see **GRANULOMA, GIANT CELL**

GIANT CELL TUMOR OF BONE

METABOLISM

[Study of the reactivity of giant cell tumors of bones to different lectins] Illés T, et al. **Arch Anat Cytol Pathol** 1995; 43(5–6):331–7 (23 ref.) (Eng. Abstr.) **(Fre)**

SECONDARY

Giant cell tumour of metacarpal with pulmonary and skeletal metastases. Sanjay BK, et al. **J Hand Surg [Br]** 1996 Feb; 21(1):126–32 (22 ref.)

GIANT CELL TUMORS

[Osteoclast-like giant cell tumor of the liver] Horie Y, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):429–31 (8 ref.) **(Jpn)**

GENETICS

A new cytogenetic subgroup in tenosynovial giant cell tumors (nodular tenosynovitis) is characterized by involvement of 16q24. Dal Cin P, et al. **Cancer Genet Cytogenet** 1996 Mar;87(1):85–7 (5 ref.)

ULTRASONOGRAPHY

[Giant-cell tumor of the carpal tunnel, a color Doppler echographic study. A case report] Chiodi E, et al. **Radiol Med (Torino)** 1996 Jan-Feb;91(1-2):126–7 (9 ref.) **(Ita)**

GIANT CELLS

PATHOLOGY

[Giant cell hepatitis with virus associated hemophagocytic syndrome] Onuki M, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):520-2 (18 ref.) **(Jpn)**

[Giant cell hepatitis] Onuki M, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):517-9 (22 ref.) **(Jpn)**

GIANT CELLS, MULTINUCLEATED see **GIANT CELLS**

GIANT LYMPH NODE HYPERPLASIA

Angiofollicular lymph node hyperplasia (Castleman's disease). McCarty MJ, et al. **Cancer Treat Rev** 1995 Jul; 21(4):291-310 (109 ref.)

Castleman's disease. Shahidi H, et al. **Mayo Clin Proc** 1995 Oct;70(10):969-77 (60 ref.)

[Multicentric Castleman's disease. Current aspects of pathogenesis and treatment] Ribas A, et al. **Sangre (Barc)** 1995 Oct;40(5):401-6 (61 ref.) **(Spa)**

COMPLICATIONS

Coexistence of Hodgkin's disease and giant lymph node hyperplasia of the plasma-cell type (Castleman's disease). Abdel-Reheim FA, et al. **Arch Pathol Lab Med** 1996 Jan; 120(1):91-6 (27 ref.)

DIAGNOSIS

[Castleman's disease: a histological concept for a wide clinical spectrum] Vallina E, et al. **An Med Interna** 1996 May; 13(5):232-4 (19 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

A plasma cell variant of Castleman's disease treated successfully with cimetidine. Case report and review of the literature. Barbounis V, et al. **Anticancer Res** 1996 Jan-Feb;16(1):545-7 (21 ref.)

PATHOLOGY

A plasma cell variant of Castleman's disease treated successfully with cimetidine. Case report and review of the literature. Barbounis V, et al. **Anticancer Res** 1996 Jan-Feb;16(1):545-7 (21 ref.)

Castleman's disease of the abdomen and pelvis: report of three cases and a review of the literature. Kiguchi H, et al. **J Gastroenterol** 1995 Oct;30(5):661-6 (32 ref.)

RADIOGRAPHY

Castleman's disease of the lung: radiographic, high-resolution CT, and pathologic findings. Barrie JR, et al. **AJR Am J Roentgenol** 1996 May;166(5):1055-6 (8 ref.)

GIANT PLATELET SYNDROME see **BERNARD-SOULIER SYNDROME**

GIARDIA

GENETICS

Genetic variability in parasites and host-parasite interactions. Thompson RC, et al. **Parasitology** 1996;112 Suppl:S7-22 (118 ref.)

METABOLISM

Carbohydrate and amino acid metabolism in Giardia: a review. Jarroll EL, et al. **Folia Parasitol (Praha)** 1995; 42(2):81-9 (49 ref.)

GIARDIA INTESTINALIS see **GIARDIA LAMBLIA**

GIARDIA LAMBLIA

METABOLISM

Carbohydrate and amino acid metabolism in Giardia: a review. Jarroll EL, et al. **Folia Parasitol (Praha)** 1995; 42(2):81-9 (49 ref.)

PHYSIOLOGY

Specialized surface adaptations of Giardia lamblia. Aley SB, et al. **Infect Agents Dis** 1995 Sep;4(3):161-6 (32 ref.)

GIARDIASIS

DIAGNOSIS

Entamoeba histolytica and Giardia lamblia infections: current diagnostic strategies. Cook GC. **Parasite** 1995 Jun; 2(2):107-12 (31 ref.)

[Giardiasis: a brief review. The diagnostic prospects in the clinical laboratory (editorial)] Diaz Carbonell JV, et al. **An Esp Pediatr** 1996 Feb;44(2):87-91 (62 ref.) **(Spa)**

GIEMSA STAIN see **AZURE STAINS**

GIFT see **GAMETE INTRAFALLOPIAN TRANSFER**

GIGANTISM

see related
BECKWITH-WIEDEMANN SYNDROME

ETIOLOGY

Syringomyelia as a cause of body hypertrophy. Sudo K, et al. **Lancet** 1996 Jun 8;347(9015):1593-5 (30 ref.)

GILBERT'S DISEASE

[Gilbert's syndrome] Tazuma S, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):434-6 (23 ref.) **(Jpn)**

GILLES DE LA TOURETTE'S DISEASE see **TOURETTE SYNDROME**

GINGER see **SPICES**

GINGIVA

see related
GINGIVOPLASTY

BLOOD SUPPLY

Reflex parasympathetic vasodilatation in facial skin. Izumi H. **Gen Pharmacol** 1995 Mar;26(2):237-44 (74 ref.)

MICROBIOLOGY

Aspects of adherence of oral spirochetes. Thomas DD. **Crit Rev Oral Biol Med** 1996;7(1):4-11 (48 ref.)

GINGIVAL DISEASES

PATHOLOGY

Verruciform xanthoma. Case report and literature review. Huang JS, et al. **J Periodontol** 1996 Feb;67(2):162-5 (13 ref.)

GINGIVAL HYPERPLASIA

CHEMICALLY INDUCED

The pathogenesis of drug-induced gingival overgrowth. Seymour RA, et al. **J Clin Periodontol** 1996 Mar;23(3 Pt 1):165-75 (120 ref.)

Pathogenesis of drug-induced gingival overgrowth. A review of studies in the rat model. Nishikawa S, et al. **J Periodontol** 1996 May;67(5):463-71 (94 ref.)

DIAGNOSIS

Common and less common gingival overgrowth conditions. Moghadam BK, et al. **Cutis** 1995 Jul;56(1):46-8 (31 ref.)

GENETICS

Zimmermann-Laband syndrome in a patient with severe mental retardation. Van Buggenhout GJ, et al. **Genet Couns** 1995;6(4):321-7 (15 ref.)

GINGIVAL INDEX see **PERIODONTAL INDEX**

GINGIVAL NEOPLASMS

PATHOLOGY

Primary intraoral epithelioid hemangioendothelioma presenting in childhood: review of the literature and case report. Flaitz CM, et al. **Ultrastruct Pathol** 1995 Jul-Aug; 19(4):275-9 (8 ref.)

[False Merkel cell tumor of the gingival mucosa disclosed by small cell bronchial carcinoma] Paume P, et al. **Rev Stomatol Chir Maxillofac** 1995;96(6):352-5 (14 ref.) (Eng. Abstr.) **(Fre)**

GINGIVAL RECESSION

SURGERY

A critical evaluation of methods for root coverage. Goldstein M, et al. **Crit Rev Oral Biol Med** 1996;7(1):87-98 (93 ref.)

GINGIVITIS

PSYCHOLOGY

Psychosocial factors in inflammatory periodontal diseases. A review. da Silva AM, et al. **J Clin Periodontol** 1995 Jul; 22(7):516-26 (103 ref.)

GINGIVITIS, NECROTIZING ULCERATIVE

IMMUNOLOGY

Chronic ulcerative stomatitis with stratified epithelium-specific antinuclear antibodies. Lewis JE, et al. **Int J Dermatol** 1996 Apr;35(4):272-5 (7 ref.)

GINGIVOPLASTY

METHODS

A critical evaluation of methods for root coverage. Goldstein M, et al. **Crit Rev Oral Biol Med** 1996;7(1):87-98 (93 ref.)

GINGIVOSIS see **GINGIVAL DISEASES**

GINGIVOSTOMATITIS, HERPETIC see **STOMATITIS, HERPETIC**

GLA-PROTEIN see **OSTEOCALCIN**

GLANDULAR FEVER see **INFECTIOUS MONONUCLEOSIS**

GLASGOW COMA SCALE

Patients with Glasgow Coma Scale scores 3, 4, 5 after gunshot wounds to the brain. Kaufman HH, et al. **Neurosurg Clin N Am** 1995 Oct;6(4):701-14 (63 ref.)

GLASGOW OUTCOME SCALE see **GLASGOW COMA SCALE**

GLASS

Water activity, water glass dynamics, and the control of microbiological growth in foods. Chirife J, et al. **Crit Rev Food Sci Nutr** 1996 May;36(5):465-513 (151 ref.)

CHEMISTRY

Nuclear magnetic resonance investigation of the structures of phosphate and phosphate-containing glasses: a review. Kirkpatrick RJ, et al. **Solid State Nucl Magn Reson** 1995 Oct;5(1):9-21 (51 ref.)

GLASS IONOMER CEMENTS

CHEMICAL SYNTHESIS

[The formulation of glass ionomers and their degree of fluoride] De Moor R. **Rev Belge Med Dent** 1996;51(3):9-21 (33 ref.) (Eng. Abstr.) **(Fre)**

CHEMISTRY

Some physical and biological properties of glass ionomer cement. Mount GJ. **Int Dent J** 1995 Apr;45(2):135-40 (43 ref.)

[Evaluation of long-term release of fluoride by type II glass ionomer cements with a conventional hardening reaction] De Moor R, et al. **Rev Belge Med Dent** 1996;51(3):22-35 (38 ref.) (Eng. Abstr.) **(Fre)**

GLAUCOMA

see related
SCLEROSTOMY
TRABECULECTOMY

Inflammatory glaucomas. Kwon YH, et al. **Int Ophthalmol Clin** 1996 Winter;36(1):81-9 (55 ref.)

Glaucoma: changing concepts and future directions. Liesegang TJ. **Mayo Clin Proc** 1996 Jul;71(7):689-94 (14 ref.)

COMPLICATIONS

Glaucoma and findings simulating glaucoma in the Rubinstein-Taybi syndrome. Brei TJ, et al. **J Pediatr Ophthalmol Strabismus** 1995 Jul-Aug; 32(4):248-52 (56 ref.)

Surgical management of coexisting cataract and glaucoma. Schuman JS. **Ophthalmic Surg Lasers** 1996 Jan;27(1):45-59 (27 ref.)

The Glenn A. Fry Award Lecture. Early losses of visual function in glaucoma. Johnson CA. **Optom Vis Sci** 1995 Jun;72(6):359-70 (67 ref.)

DIAGNOSIS

Recognizing glaucoma. A guide for the primary care physician. . Chaudhry I, et al. **Postgrad Med** 1996 May; 99(5):247-8, 251-2, 257-9, Pass;M (12 ref.)

DRUG THERAPY

Comparison of the ocular beta-blockers. Sorensen SJ, et al. **Ann Pharmacother** 1996 Jan;30(1):43-54 (85 ref.)

Beta blockers and the elderly with glaucoma: are we adding insult to injury? O'Donoghue E. **Br J Ophthalmol** 1995 Sep;79(9):794-6 (48 ref.)

[Topical carbonic anhydrase inhibitors in the treatment of glaucoma] Bayer A, et al. **J Fr Ophtalmol** 1996;19(5):357-62 (30 ref.) (Eng. Abstr.) **(Fre)**

ETHNOLOGY

Number of people with glaucoma worldwide [see comments] Quigley HA. **Br J Ophthalmol** 1996 May;80(5):389-93 (54 ref.) Comment in: Br J Ophthalmol 1996 May;80(5):385-7.

ETIOLOGY

[Neovascular glaucoma in the diabetic patient] Detry-Morel

M. **Bull Soc Belge Ophtalmol** 1995;256:133–41 (27 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

[A family with glaucomatous excavation but without glaucoma] Radian AB, et al. **Oftalmologia** 1996 Jan–Mar; 40(1):16–7 (6 ref.) (Eng. Abstr.) **(Rum)**

PATHOLOGY

Ganglion cell death in glaucoma: pathology recapitulates ontogeny. Quigley HA. **Aust N Z J Ophthalmol** 1995 May; 23(2):85–91 (42 ref.)

[Ophthalmoscopic study of the retinal nerve fiber layer] Jonas JB, et al. **Klin Monatsbl Augenheilkd** 1996 Feb;208(2):aA3–9 (0 ref.) **(Ger)**

[Accuracy in the measurements of the glaucomatous papilla] Radian AB, et al. **Oftalmologia** 1996 Jan–Mar;40(1):48–50 (6 ref.) (Eng. Abstr.) **(Rum)**

PHYSIOPATHOLOGY

Glaucoma: current thinking. Hitchings RA. **Br J Hosp Med** 1996 Mar 20–Apr 2;55(6):312–4 (21 ref.)

[The excito-toxicity theory of glaucomatous neuropathy. General review] Bonne C, et al. **J Fr Ophtalmol** 1996; 19(1):69–74 (46 ref.) **(Fre)**

SURGERY

Is laser sclerostomy surgery ready for 'prime time'? [editorial] Higginbotham EJ. **Arch Ophthalmol** 1995 Oct; 113(10):1243–4 (22 ref.)

Surgical management of coexisting cataract and glaucoma. Schuman JS. **Ophthalmic Surg Lasers** 1996 Jan;27(1):45–59 (27 ref.)

[Is trabeculectomy without danger in case of threatened fixation?] Grunewald F, et al. **J Fr Ophtalmol** 1996; 19(4):253–8 (18 ref.) (Eng. Abstr.) **(Fre)**

[Treatment of refractory glaucoma by diode semiconductor laser cyclophotocoagulation] Hamard P, et al. **J Fr Ophtalmol** 1995;18(6–7):447–54 (26 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Medical treatment of glaucoma—a reappraisal of the risks. Diggory P, et al. **Br J Ophthalmol** 1996 Jan;80(1):85–9 (38 ref.)

Trabeculectomy with intraoperative sponge 5-fluorouracil. Mora JS, et al. **Ophthalmology** 1996 Jun;103(6):963–70 (28 ref.)

[New trends in conservative treatment of glaucoma] Nesterov AP. **Vestn Oftalmol** 1995 Oct–Dec;111(4):3–5 (23 ref.) (Eng. Abstr.) **(Rus)**

ULTRASONOGRAPHY

Practical application of ultrasound biomicroscopy. Pavlin CJ. **Can J Ophthalmol** 1995 Jun;30(4):225–9 (44 ref.)

VETERINARY

The role of tonometry in the clinical management of the glaucomas in companion animals. Gelatt KN. **Vet Q** 1995 Apr;17 Suppl 1:S45 (0 ref.)

GLAUCOMA, ANGLE-CLOSURE

[Progresses in ophthalmology in China, 1995] Zhang S. **Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):755–7 (0 ref.) **(Chi)**

SURGERY

Laser therapy and angle-closure glaucoma. Fleming JB. **Optom Clin** 1995;4(4):97–111 (39 ref.)

GLAUCOMA, CLOSED-ANGLE see **GLAUCOMA, ANGLE-CLOSURE**

GLAUCOMA, OPEN-ANGLE

CONGENITAL

[Late congenital glaucoma and pigmentary retinopathy] Ghenoiu R, et al. **Oftalmologia** 1995 Oct–Dec;39(4):333–7 (12 ref.) (Eng. Abstr.) **(Rum)**

DIAGNOSIS

Retinal nerve fiber layer [editorial; comment] Sommer A. **Am J Ophthalmol** 1995 Nov;120(5):665–7 (20 ref.) Comment on: Am J Ophthalmol 1995 Nov;120(5):577–86.

Clinical alternative for reducing the time needed to perform automated threshold perimetry. Fingeret M. **J Am Optom Assoc** 1995 Nov;66(11):699–705 (14 ref.)

Newer visual function tests in the evaluation of glaucoma. Stewart WC, et al. **Surv Ophthalmol** 1995 Sep–Oct; 40(2):119–35 (186 ref.)

DRUG THERAPY

Will latanoprost be the 'wonder' drug of the '90s for the treatment of glaucoma? [editorial; comment] Higginbotham EJ. **Arch Ophthalmol** 1996 Aug;114(8):998–9 (16 ref.) Comment on: Arch Ophthalmol 1996 Aug;114(8):929–32.

EPIDEMIOLOGY

The epidemiology and control of open angle glaucoma: a population-based perspective. Tielsch JM. **Annu Rev Public Health** 1996;17:121–36 (85 ref.)

ETIOLOGY

Doyne Lecture. Glaucoma: facts and fancies. Sommer A. **Eye** 1996;10 (Pt 3):295–301 (57 ref.)

PREVENTION & CONTROL

The epidemiology and control of open angle glaucoma: a population-based perspective. Tielsch JM. **Annu Rev Public Health** 1996;17:121–36 (85 ref.)

Screening for primary open-angle glaucoma: a review. Harper R, et al. **Ophthalmic Physiol Opt** 1995 Sep;15 Suppl 2:S27–34 (49 ref.)

SURGERY

Laser therapy for open-angle glaucoma. Talley DK. **Optom Clin** 1995;4(4):85–96 (22 ref.)

[Long-term reduction of intraocular pressure by goniotrepanation or laser trabeculoplasty] Funk J, et al. **Klin Monatsbl Augenheilkd** 1995 Oct;207(4):215–23 (38 ref.) (Eng. Abstr.) **(Ger)**

GLAUCOMA, PIGMENTARY see **GLAUCOMA, OPEN-ANGLE**

GLAUCOMA, SIMPLE see **GLAUCOMA, OPEN-ANGLE**

GLAUCOMA SIMPLEX see **GLAUCOMA, OPEN-ANGLE**

GLAUCOMA, SUSPECT see **OCULAR HYPERTENSION**

GLIA see **NEUROGLIA**

GLIADIN

ADVERSE EFFECTS

The precipitating factor in coeliac disease. Wieser H. **Baillieres Clin Gastroenterol** 1995 Jun;9(2):191–207 (63 ref.)

IMMUNOLOGY

Serology of coeliac disease: early diagnosis and therapeutic impact. Mascart-Lemone F, et al. **Acta Gastroenterol Belg** 1995 Sep–Dec;58(5–6):388–96 (40 ref.)

GLIAL FIBRILLARY ACIDIC PROTEIN

GENETICS

Glial fibrillary acidic protein mRNA and the development of gliosis in mice with chronic relapsing experimental allergic encephalomyelitis. Kothavale A, et al. **Prog Brain Res** 1995;105:305–10 (20 ref.)

GLIAL INTERMEDIATE FILAMENT PROTEIN see **GLIAL FIBRILLARY ACIDIC PROTEIN**

GLIBENCLAMIDE see **GLYBURIDE**

GLIOBLASTOMA

BLOOD SUPPLY

Vascular morphology and angiogenesis in glial tumors. Plate KH, et al. **Exp Toxicol Pathol** 1995 May;47(2–3):89–94 (62 ref.)

DRUG THERAPY

p55 and p75 tumor necrosis factor receptor expression on human glioblastoma cells. Kato T, et al. **Neurol Med Chir (Tokyo)** 1995 Aug;35(8):567–74 (30 ref.)

EPIDEMIOLOGY

Triple primary malignant neoplasms including a malignant brain tumor: report of two cases and review of the literature. Nagane M, et al. **Surg Neurol** 1996 Mar; 45(3):219–29 (44 ref.)

GENETICS

p55 and p75 tumor necrosis factor receptor expression on human glioblastoma cells. Kato T, et al. **Neurol Med Chir (Tokyo)** 1995 Aug;35(8):567–74 (30 ref.)

PATHOLOGY

Vascular morphology and angiogenesis in glial tumors. Plate KH, et al. **Exp Toxicol Pathol** 1995 May;47(2–3):89–94 (62 ref.)

From rodent glial precursor cell to human glial neoplasia in the oligodendrocyte-type-2 astrocyte lineage. Noble M, et al. **Glia** 1995 Nov;15(3):222–30 (63 ref.)

[Extracerebral metastases of a glioblastoma, in the absence of surgery] Chretien F, et al. **Arch Anat Cytol Pathol** 1995; 43(5–6):342–9 (16 ref.) (Eng. Abstr.) **(Fre)**

RADIOTHERAPY

Operation and permanent low activity 125I brachytheraphy for recurrent high-grade astrocytomas. Halligan JB, et al. **Int J Radiat Oncol Biol Phys** 1996 Jun 1;35(3):541–7 (24 ref.)

SECONDARY

Diffuse bone marrow metastases from glioblastoma multiforme: the role of dural invasion. Kleinschmidt-Demasters BK. **Hum Pathol** 1996 Feb; 27(2):197–201 (22 ref.)

SURGERY

Operation and permanent low activity 125I brachytheraphy for recurrent high-grade astrocytomas. Halligan JB, et al. **Int J Radiat Oncol Biol Phys** 1996 Jun 1;35(3):541–7 (24 ref.)

THERAPY

Thermoradiotherapy for brain tumors. Three cases of recurrent malignant astrocytoma and review of clinical experience. Seegenschmiedt MH, et al. **Am J Clin Oncol** 1995 Dec;18(6):510–8 (53 ref.)

Acute promyelocytic leukemia after treatment of malignant glioma in a patient with von Recklinghausen's disease: case report and review of the literature. Wiernik PH, et al. **Leukemia** 1996 Jan;10(1):178–82 (49 ref.)

High-grade astrocytomas. Wen PY, et al. **Neurol Clin** 1995 Nov;13(4):875–900 (164 ref.)

GLIOBLASTOMA-DERIVED T-CELL SUPPRESSOR FACTOR see **TRANSFORMING GROWTH FACTOR BETA**

GLIOBLASTOMA MULTIFORME see **GLIOBLASTOMA**

GLIOCLADIUM see **HYPHOMYCETES**

GLIOMA

Glial neoplasms: classification, treatment, and pathways for the future. Armstrong TS, et al. **Oncol Nurs Forum** 1996 May;23(4):615–25; quiz 626–7 (69 ref.)

BLOOD SUPPLY

Angiogenesis in malignant gliomas. Plate KH, et al. **Glia** 1995 Nov;15(3):339–47 (78 ref.)

CLASSIFICATION

[Classification and grading of glial tumors] Kros JM. **Ned Tijdschr Geneeskd** 1996 Feb 10;140(6):292–7 (33 ref.) **(Dut)**

COMPLICATIONS

[Neurofibromatosis type I (NF1): peculiarities and complications] Pascual-Castroviejo I. **Rev Neurol** 1996 Sep; 24(133):1051–5 (22 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Intratumoral chemotherapy. Walter KA, et al. **Neurosurgery** 1995 Dec;37(6):1128–45 (131 ref.)

GENETICS

Genetics and malignant progression of human brain tumours. Furnari FB, et al. **Cancer Surv** 1995;25:233–75 (312 ref.)

The p53 gene and its role in human brain tumors. Bögler O, et al. **Glia** 1995 Nov;15(3):308–27 (191 ref.)

Gene amplification in human gliomas. Collins VP. **Glia** 1995 Nov;15(3):289–96 (81 ref.)

Genetic alterations in gliomas. Collins VP. **J Neurooncol** 1995;24(1):37–8 (10 ref.)

Molecular cytogenetic quantitation of gains and losses of genetic material from human gliomas. Feuerstein BG, et al. **J Neurooncol** 1995;24(1):47–55 (23 ref.)

A tiger behind many doors: multiple genetic pathways to malignant glioma. Louis DN, et al. **Trends Genet** 1995 Oct; 11(10):412–5 (38 ref.)

[Molecular biology in cerebral gliomas: recent advances] Hoang-Xuan K, et al. **Rev Neurol (Paris)** 1995 Nov; 151(11):608–18 (107 ref.) (Eng. Abstr.) **(Fre)**

[Malignant glioma] Okamura K. **Nippon Rinsho** 1995 Nov; 53(11):2678–83 (18 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Tumor antigens in astrocytic gliomas. Kurpad SN, et al. **Glia** 1995 Nov;15(3):244–56 (105 ref.)

METABOLISM

Protein kinase C and growth regulation of malignant gliomas. Baltuch GH, et al. **Can J Neurol Sci** 1995 Nov;22(4):264–71 (98 ref.)

Platelet-derived growth factor in human glioma. Westermark B, et al. **Glia** 1995 Nov;15(3):257–63 (60 ref.)

PATHOLOGY

Cavernous angioma associated with oligo-astrocytoma-like proliferation. Report of two cases and review of the

GLIOMA

literature with a reappraisal of the term "angioglioma". Palma L, et al. **Acta Neurochir (Wien)** 1995;133(3-4):169-73 (36 ref.)

Genetics and malignant progression of human brain tumours. Furnari FB, et al. **Cancer Surv** 1995;25:233-75 (312 ref.)

Histopathology, classification, and grading of gliomas. Kleihues P, et al. **Glia** 1995 Nov;15(3):211-21 (62 ref.)

Molecular pathways in the formation of gliomas. von Deimling A, et al. **Glia** 1995 Nov;15(3):328-38 (58 ref.)

Interactions of glioma cells and extracellular matrix. Paulus W, et al. **J Neurooncol** 1995;24(1):87-91 (25 ref.)

PHYSIOPATHOLOGY

Physiology of transformed glial cells. Brismar T. **Glia** 1995 Nov;15(3):231-43 (136 ref.)

[Prognosis of gliomas] Loiseau H. **Rev Neurol (Paris)** 1996 Feb;152(2):84-102 (223 ref.) (Eng. Abstr.) **(Fre)**

RADIONUCLIDE IMAGING

[The use of SPECT with 201Tl in the evaluation of brain tumors] Prat-Acín R, et al. **Rev Neurol** 1996 Aug; 24(132):909-13 (34 ref.) (Eng. Abstr.) **(Spa)**

RADIOTHERAPY

Management of low-grade gliomas: radiation therapy at time of recurrence. Piepmeier JM, et al. **Clin Neurosurg** 1995; 42:495-507 (53 ref.)

The low-grade glioma debate: evidence defending the position of early radiation therapy. Shaw EG. **Clin Neurosurg** 1995;42:488-94 (10 ref.)

Advances in radiation therapy for brain tumors. Shrieve DC, et al. **Neurol Clin** 1995 Nov;13(4):773-93 (89 ref.)

SURGERY

Surgery for gliomas and other mass lesions of the brainstem. Bricolo A, et al. **Adv Tech Stand Neurosurg** 1995;22:261-341 (209 ref.)

Functional mapping-guided resection of low-grade gliomas. Berger MS. **Clin Neurosurg** 1995;42:437-52 (44 ref.)

Low-grade glioma: the case for delayed surgery. Cairncross JG. **Clin Neurosurg** 1995;42:391-8 (18 ref.)

Management of low-grade gliomas: results of resections without electrocorticography. Fried I. **Clin Neurosurg** 1995;42:453-63 (41 ref.)

Surgical issues in the management of supratentorial low-grade gliomas. Kelly PJ. **Clin Neurosurg** 1995; 42:399-436 (39 ref.)

Radical resection for the treatment of glioma. Laws ER Jr. **Clin Neurosurg** 1995;42:480-7 (11 ref.)

Surgery for low-grade glioma: rationale for early intervention. Wilson CB, et al. **Clin Neurosurg** 1995; 42:383-90 (11 ref.)

Low-grade gliomas. Recht LD, et al. **Neurol Clin** 1995 Nov; 13(4):847-59 (75 ref.)

A technique for interactive image-guided neurosurgical intervention in primary brain tumors. Maciunas RJ, et al. **Neurosurg Clin N Am** 1996 Apr;7(2):245-66 (111 ref.)

THERAPY

Brain tumor gene therapy in mice with a novel "suicide" gene: the cyclophosphamide-activating CYP2B1 gene. Chiocca EA. **Clin Neurosurg** 1995;42:370-82 (49 ref.)

Treatment of malignant glioma in adults. Forsyth PA, et al. **Curr Opin Neurol** 1995 Dec;8(6):414-8 (56 ref.)

Steps toward gene therapy: 2. Cancer and AIDS. Blaese RM. **Hosp Pract (Off Ed)** 1995 Dec 15;30(12):37-45 (6 ref.)

Novel biologic therapies for malignant gliomas. Antiangiogenesis, immunotherapy, and gene therapy. Fine HA. **Neurol Clin** 1995 Nov;13(4):827-46 (128 ref.)

[Prognostic factors in malignant gliomas] Ushio Y, et al. **Gan To Kagaku Ryoho** 1996 Apr;23(5):643-8 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Gene therapy of glioma using cytokine] Ikeda H, et al. **No To Shinkei** 1995 Sep;47(9):835-43 (47 ref.) **(Jpn)**

[Approach to human glioma cells using antisense molecules] Yoshida S, et al. **No To Shinkei** 1995 Sep;47(9):823-8 (24 ref.) **(Jpn)**

[Application of myc family genes to therapy of malignant brain tumors] Kuchino Y, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2713-9 (24 ref.) **(Jpn)**

[Usefulness of myelin basic protein gene promoter for the gene therapy of malignant glioma] Miyao Y, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2618-23 (13 ref.) **(Jpn)**

GLIOSIS

METABOLISM

Glial fibrillary acidic protein mRNA and the development of gliosis in mice with chronic relapsing experimental allergic encephalomyelitis. Kothavale A, et al. **Prog Brain Res** 1995;105:305-10 (20 ref.)

PATHOLOGY

Role for astrocytosis in HIV-1-associated dementia. Vitkovic L, et al. **Curr Top Microbiol Immunol** 1995;202:105-16 (49 ref.)

GLNH see GIANT LYMPH NODE HYPERPLASIA

GLOBAL WARMING see GREENHOUSE EFFECT

GLOBIN

Novel treatment options in the severe beta-globin disorders. Rodgers GP, et al. **Br J Haematol** 1995 Oct;91(2):263-8 (63 ref.)

GENETICS

Evolutionary strategies for the elucidation of cis and trans factors that regulate the developmental switching programs of the beta-like globin genes. Gumucio DL, et al. **Mol Phylogenet Evol** 1996 Feb;5(1):18-32 (78 ref.)

Prevention of beta-thalassemia major and Hb Bart's hydrops fetalis syndrome. Beris P, et al. **Semin Hematol** 1995 Oct; 32(4):244-61 (86 ref.)

Hemoglobin switching and fetal hemoglobin reactivation. Cunningham JM, et al. **Semin Hematol** 1996 Jan;33(1):9-23 (142 ref.)

[Regulatory mechanisms of globin genes--erythroid specific expression and gene therapy] Shirohzu H, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2598-605 (45 ref.) **(Jpn)**

GLOBULINS, IMMUNE see IMMUNOGLOBULINS

GLOBUS HYSTERICUS see CONVERSION DISORDER

GLOBUS PALLIDUS

PATHOLOGY

[Clinical picture of DRPLA] Naito H. **No To Shinkei** 1995 Oct;47(10):931-8 (35 ref.) **(Jpn)**

[Neuropathology of dentatorubral-pallidoluysian atrophy and Machado-Joseph disease] Takahashi H, et al. **No To Shinkei** 1995 Oct;47(10):947-53 (34 ref.) **(Jpn)**

[How was the gene for dentatorubral-pallidoluysian atrophy discovered?] Tsuji S, et al. **No To Shinkei** 1996 Apr; 48(4):323-8 (27 ref.) **(Jpn)**

SURGERY

There is a renaissance of interest in pallidotomy for Parkinson's disease. Goetz CG, et al. **Nat Med** 1996 May; 2(5):510-4 (21 ref.)

GLOMANGIOMA see GLOMUS TUMOR

GLOMERULAR FILTRATION RATE

Iothalamate clearance and its use in large-scale clinical trials. Hall PM, et al. **Curr Opin Nephrol Hypertens** 1995 Nov; 4(6):510-3 (22 ref.)

Nitric oxide in the regulation of renal blood flow. Ito S, et al. **New Horiz** 1995 Nov;3(4):615-23 (68 ref.)

Renal functional reserve in children. Anastasio P, et al. **Semin Nephrol** 1995 Sep;15(5):454-62 (38 ref.)

Renal reserve: a functional view of glomerular filtration rate. Bosch JP. **Semin Nephrol** 1995 Sep;15(5):381-5 (10 ref.)

Tubule effects of glomerular hyperfiltration: an integrated view. Capasso G, et al. **Semin Nephrol** 1995 Sep; 15(5):419-25 (52 ref.)

Renal reserve in patients with high blood pressure. Gabbai FB. **Semin Nephrol** 1995 Sep;15(5):482-7 (35 ref.)

Intrarenal mechanisms of renal reserve. Woods LL. **Semin Nephrol** 1995 Sep;15(5):386-95 (68 ref.)

[Inulin] Iino Y. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:1071-3 (13 ref.) **(Jpn)**

[Renal alterations in obesity] Kato A, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:359-64 (20 ref.) **(Jpn)**

[Sodium thiosulfate clearance] Nagase S, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:1078-81 (9 ref.) **(Jpn)**

DRUG EFFECTS

Vasoactive drugs and the importance of renal perfusion pressure. Bersten AD, et al. **New Horiz** 1995 Nov; 3(4):650-61 (94 ref.)

PHYSIOLOGY

A re-evaluation of the determinants of glomerular filtration rate. Karlsen FM, et al. **Acta Physiol Scand** 1995 Dec; 155(4):335-50 (61 ref.)

The renal toxicity of sustained glomerular protein traffic. Benigni A, et al. **Lab Invest** 1995 Oct;73(4):461-8 (78 ref.)

[The prostaglandin system in the kidney] Stošić Z. **Med Pregl** 1996;49(1-2):32-6 (38 ref.) (Eng. Abstr.) **(Ser)**

GLOMERULAR MESANGIUM

ENZYMOLOGY

Effect of high glucose concentration on phospholipase A2 activity in mesangial cells. Choi K. **Kidney Int Suppl** 1995 Sep;51:S22-7 (48 ref.)

IMMUNOLOGY

Pan-nephritis (glomerulonephritis, arteriolitis, and tubulointerstitial nephritis) associated with predominant mesangial C1q deposition and hypocomplementemia: a variant type of C1q nephropathy? Imai H, et al. **Am J Kidney Dis** 1996 Apr;27(4):583-7 (15 ref.)

METABOLISM

Advanced glycosylation end products modulate transcriptional regulations on mesangial cells. Iehara N, et al. **Contrib Nephrol** 1996;118:141-6 (13 ref.)

Role of protein kinase C and cyclic AMP/protein kinase A in high glucose-stimulated transcriptional activation of collagen alpha 1 (IV) in glomerular mesangial cells. Ziyadeh FN, et al. **J Diabetes Complications** 1995 Oct-Dec; 9(4):255-61 (35 ref.)

Role of growth factors in mesangial cell ion channel regulation. Ling BN, et al. **Kidney Int** 1995 Oct; 48(4):1158-66 (39 ref.)

PHYSIOLOGY

Glomerular hypertension and progressive renal disease: the interplay of mesangial cell stretch, cytokine formation and extracellular matrix synthesis. Cortes P, et al. **Contrib Nephrol** 1996;118:229-33 (14 ref.)

GLOMERULONEPHRITIS

see related
KIDNEY FAILURE, CHRONIC

The primary glomerulopathies. Glassock RJ, et al. **Dis Mon** 1996 Jun;42(6):329-83 (182 ref.)

BLOOD

Role of platelets in progressive glomerular diseases. Zoja C, et al. **Pediatr Nephrol** 1995 Aug;9(4):495-502 (86 ref.)

COMPLICATIONS

Hepatitis C virus infection in dialysis and clinical nephrology [editorial] Fabrizi F, et al. **Int J Artif Organs** 1995 May; 18(5):235-44 (138 ref.)

Recurrence of the original disease. Does this influence renal graft failure? Michielsen P. **Kidney Int Suppl** 1995 Dec; 52:S79-84 (68 ref.)

The pathogenesis of tubulointerstitial disease associated with glomerulonephritis: the glomerular cytokine theory. Pichler R, et al. **Miner Electrolyte Metab** 1995; 21(4-5):317-27 (140 ref.)

[The role of tubulointerstitial changes in progression of kidney function failure in patients with chronic glomerulonephritis (GN)] Idasiak-Piechocka I, et al. **Przegl Lek** 1996;53(5):443-53 (72 ref.) (Eng. Abstr.) **(Pol)**

DIAGNOSIS

Chronic glomerulonephritis in childhood. Membranoproliferative glomerulonephritis, Henoch-Schönlein purpura nephritis, and IgA nephropathy. Andreoli SP. **Pediatr Clin North Am** 1995 Dec;42(6):1487-503 (60 ref.)

[Early diagnosis of rapidly progressive glomerulonephritis] Maggiore U, et al. **Ann Ital Med Int** 1995 Oct-Dec; 10(4):227-32 (22 ref.) (Eng. Abstr.) **(Ita)**

DRUG THERAPY

Lipoxygenases as therapeutic targets in the acute and subacute phases of glomerular immune injury. Badr KF. **Contrib Nephrol** 1996;118:113-25 (75 ref.)

Application of antisense oligodeoxynucleotides (ODNs) for the intervention of kidney disease. Antisense ODNs for transforming growth factor-beta-suppressed glomerulosclerosis in experimental glomerulonephritis. Imai E, et al. **Contrib Nephrol** 1996;118:86-93 (17 ref.)

Innovative strategies for pharmacological intervention in immune damage to the kidney. Abbate M, et al. **Nephrol Dial Transplant** 1995;10(7):1131-6 (66 ref.)

EPIDEMIOLOGY

[Glomerulonephritis in the elderly] Piccoli G, et al. **Minerva Urol Nefrol** 1996 Mar;48(1):7-12 (22 ref.) (Eng. Abstr.) **(Ita)**

ETIOLOGY

Leukotrienes and 15-lipoxygenase products in glomerulonephritis. Badr KF. **Adv Nephrol Necker Hosp** 1995;24:19-31 (58 ref.)

Involvement of tumor necrosis factor-alpha in the pathogenesis of experimental and human glomerulonephritis. Ortiz A, et al. **Adv Nephrol Necker Hosp** 1995;24:53-77 (139 ref.)

Glomerulonephritis associated with acute hepatitis B. Safadi R, et al. **Am J Gastroenterol** 1996 Jan;91(1):138-9 (21 ref.)

Role of apoptosis in the progression of glomerulosclerosis. Makino H, et al. **Contrib Nephrol** 1996;118:41-7 (30 ref.)

Kidney-limited recurrence in a patient with microscopic polyarteritis [see comments] Sato Y, et al. **Intern Med** 1995 Oct;34(10):1000-4 (18 ref.) Comment in: Intern Med 1995 Oct;34(10):936-7.

Angiotensin II and glomerulonephritis. Jardine AG. **J Hypertens** 1995 May;13(5):487–93 (73 ref.)
Interleukin-1 in crescentic glomerulonephritis. Atkins RC. **Kidney Int** 1995 Aug;48(2):576–86 (95 ref.)
Pathogenesis of nonimmune glomerulosclerosis: studies in animals and potential applications to humans. Striker GE, et al. **Lab Invest** 1995 Nov;73(5):596–605 (93 ref.)
Tumor necrosis factor in renal injury. Baud L, et al. **Miner Electrolyte Metab** 1995;21(4–5):336–41 (55 ref.)
Endothelin in the progressive renal disease of glomerulopathies. Benigni A, et al. **Miner Electrolyte Metab** 1995;21(4–5):283–91 (83 ref.)
The role of cytokines in inflammatory glomerular injury. Lakkis FG, et al. **Miner Electrolyte Metab** 1995; 21(4–5):250–61 (116 ref.)
Role of leukotrienes and lipoxygenases in glomerular injury. Nassar GM, et al. **Miner Electrolyte Metab** 1995; 21(4–5):262–70 (76 ref.)
Coexistent membranous nephropathy and ANCA-positive crescentic glomerulonephritis in association with penicillamine. Mathieson PW, et al. **Nephrol Dial Transplant** 1996 May;11(5):863–6 (26 ref.)
Glomerulonephritis associated with malignant diseases of non-renal origin. A report of three cases and a review of the literature. Wągrowska-Danilewicz M, et al. **Pol J Pathol** 1995;46(3):195–8 (20 ref.)
[Ki-1 positive non-Hodgkin's lymphoma disclosed by mucocutaneous ulcerations and glomerulonephritis] Bellou A, et al. **Rev Med Interne** 1995;16(12):913–8 (26 ref.) (Eng. Abstr.) **(Fre)**
[Renal involvement in Sjögren's syndrome—interstitial nephritis and glomerulonephritis] Fujimoto T, et al. **Nippon Rinsho** 1995 Oct;53(10):2495–502 (29 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Molecular analysis of the pathological autoimmune antigens of Heymann nephritis [comment] Farquhar MG. **Am J Pathol** 1996 May;148(5):1331–7 (46 ref.) Comment on: Am J Pathol 1996 May;148(5):1613–24.
Glomerulonephritis: from new knowledge on the mechanisms of tissue damage to novel therapies. Abbate M, et al. **Curr Opin Nephrol Hypertens** 1995 Jul;4(4):374–82 (90 ref.)
The Heymann nephritis antigenic complex: megalin (gp330) and RAP [editorial] Farquhar MG, et al. **J Am Soc Nephrol** 1995 Jul;6(1):35–47 (70 ref.)
[Immunopathogenic mechanisms in glomerulonephritis] Amoroso A, et al. **Riv Eur Sci Med Farmacol** 1995 Jul–Aug; 17(4):133–40 (30 ref.) (Eng. Abstr.) **(Ita)**

METABOLISM

The nitric oxide pathway in glomerulonephritis. Cattell V, et al. **Curr Opin Nephrol Hypertens** 1995 Jul;4(4):359–64 (52 ref.)
Regulation and expression of chemokines: potential role in glomerulonephritis. Brown Z, et al. **J Leukoc Biol** 1996 Jan;59(1):75–80 (43 ref.)

PATHOLOGY

Local macrophage proliferation in progressive renal injury. Lan HY, et al. **Contrib Nephrol** 1996;118:100–8 (22 ref.)
The Banff classification of renal allograft pathology: where do we go from here? Racusen L, et al. **Transplant Proc** 1996 Feb;28(1):486–8 (22 ref.)
[Retrospect and prospect in renal pathology] Wei M, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1995 Aug;24(4):225–7 (22 ref.) **(Chi)**
[Immunopathogenic mechanisms in glomerulonephritis] Amoroso A, et al. **Riv Eur Sci Med Farmacol** 1995 Jul–Aug; 17(4):133–40 (30 ref.) (Eng. Abstr.) **(Ita)**

PHYSIOPATHOLOGY

[The role of oxygen radicals in the pathogenesis of glomerulonephritis] Zima T, et al. **Cas Lek Cesk** 1995 Nov 15;134(22):716–9 (32 ref.) (Eng. Abstr.) **(Cze)**
[The role of cytokines and growth factors in pathogenesis and progression of glomerulonephritis] Wągrowska-Danilewicz M, et al. **Pol Arch Med Wewn** 1996 May;95(5):493–6 (74 ref.) **(Pol)**

PREVENTION & CONTROL

Effects of lipids on the pathogenesis of progressive renal failure: role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in the prevention of glomerulosclerosis. Guijarro C, et al. **Miner Electrolyte Metab** 1996; 22(1–3):147–52 (45 ref.)

THERAPY

Suppression of experimental glomerulonephritis by interference with T- or B-cell activation signals or adhesion molecules. Andres G, et al. **Adv Nephrol Necker Hosp** 1995;24:91–105 (51 ref.)
Glomerulonephritis: from new knowledge on the mechanisms of tissue damage to novel therapies. Abbate M, et al. **Curr Opin Nephrol Hypertens** 1995 Jul;4(4):374–82 (90 ref.)
Treatment of systemic and renal-limited vasculitic disorders with pooled human intravenous immune globulin. Jordan SC. **J Clin Immunol** 1995 Nov;15(6 Suppl):76S–85S (40 ref.)
Limitations of therapeutic approaches to glomerular diseases. Schlöndorff D, et al. **Kidney Int Suppl** 1995 Aug;50:S19–25 (103 ref.)

GLOMERULONEPHRITIS, FOCAL SCLEROSING see **GLOMERULOSCLEROSIS, FOCAL**

GLOMERULONEPHRITIS, IGA

Clinical guidelines of IgA nephropathy. Sakai H, et al. **Nippon Jinzo Gakkai Shi** 1995 Aug;37(8):417–21 (0 ref.)
[Progresses in nephrology in China, 1995] Lin S. **Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):719–20 (0 ref.) **(Chi)**

COMPLICATIONS

Rheumatoid arthritis associated with membranous nephropathy and IgA nephritis with necrotizing lesions. Irie F, et al. **Nephrol Dial Transplant** 1996 Jul;11(7):1338–41 (28 ref.)

DIAGNOSIS

Crescentic nodular glomerulosclerosis secondary to truncated immunoglobulin alpha heavy chain deposition. Cheng IK, et al. **Am J Kidney Dis** 1996 Aug;28(2):283–8 (13 ref.)
[Diagnostic aspects of IgA-fibronectin in serum of patients with IgA nephropathy] Sela BA, et al. **Harefuah** 1995 Aug; 129(3–4):127–30 (20 ref.) **(Heb)**

DRUG THERAPY

Use of cyclosporin in membranous and mesangioproliferative (IgA) nephropathy. Cattran DC. **Contrib Nephrol** 1995; 114:49–58 (47 ref.)

ETIOLOGY

Abnormal glycosylation of IgA: is it related to the pathogenesis of IgA nephropathy? [editorial] Allen AC. **Nephrol Dial Transplant** 1995;10(7):1121–4 (11 ref.)
[Hepatic IgA nephropathy] Abe H, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):471–3 (15 ref.) **(Jpn)**

GENETICS

Immunogenetic aspects of primary IgA nephropathy. Schena FP. **Kidney Int** 1995 Dec;48(6):1998–2013 (129 ref.)

IMMUNOLOGY

IgA glycosylation and disease. Dueymes M, et al. **Adv Exp Med Biol** 1995;376:217–20 (18 ref.)
[Relationship between intestinal permeability and antibodies against food antigens in IgA nephropathy] Kovács T, et al. **Orv Hetil** 1996 Jan 14;137(2):65–9 (35 ref.) (Eng. Abstr.) **(Hun)**

PATHOLOGY

IgA-associated renal diseases. Fogazzi GB, et al. **Curr Opin Nephrol Hypertens** 1996 Mar;5(2):134–40 (43 ref.)

THERAPY

Treatment of IgA nephropathy [editorial; comment] Peh CA, et al. **Nephrol Dial Transplant** 1995;10(7):1119–21 (15 ref.) Comment on: Nephrol Dial Transplant 1995;10(7):1173–81.
[Physiopathology and therapy of IgA nephropathy] Dohi K. **Nippon Naika Gakkai Zasshi** 1996 Mar 10;85(3):468–73 (6 ref.) **(Jpn)**

GLOMERULONEPHRITIS, LUPUS see **LUPUS NEPHRITIS**

GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE

DIAGNOSIS

Pan-nephritis (glomerulonephritis, arteriolitis, and tubulointerstitial nephritis) associated with predominant mesangial C1q deposition and hypocomplementemia: a variant type of C1q nephropathy? Imai H, et al. **Am J Kidney Dis** 1996 Apr;27(4):583–7 (15 ref.)

ETIOLOGY

Hepatitis C virus infection, cryoglobulinemia, and glomerulonephritis. Schifferli JA, et al. **Adv Nephrol Necker Hosp** 1995;24:107–29 (88 ref.)

PHYSIOPATHOLOGY

[The importance of interleukin 6 (IL-6) in pathogenesis and diagnosis of renal glomerular diseases] Kacprzyk F. **Postepy Hig Med Dosw** 1995;49(4):513–22 (50 ref.) (Eng. Abstr.) **(Pol)**

VIROLOGY

Glomerulonephritis, thrombocytopenia, and autoimmune neutropenia probably induced by a virus-like illness: case report and review of the literature. Mackey JR, et al. **Nephron** 1995;71(4):454–8 (33 ref.)

GLOMERULONEPHRITIS, MEMBRANOUS

COMPLICATIONS

Membranous glomerulonephritis associated with inflammatory demyelinating peripheral neuropathies. Panjwani M, et al. **Am J Kidney Dis** 1996 Feb;27(2):279–83 (20 ref.)
Rheumatoid arthritis associated with membranous nephropathy and IgA nephritis with necrotizing lesions. Irie F, et al. **Nephrol Dial Transplant** 1996 Jul;11(7):1338–41 (28 ref.)

DRUG THERAPY

Use of cyclosporin in membranous and mesangioproliferative (IgA) nephropathy. Cattran DC. **Contrib Nephrol** 1995; 114:49–58 (47 ref.)

ETIOLOGY

Coexistent membranous nephropathy and ANCA-positive crescentic glomerulonephritis in association with penicillamine. Mathieson PW, et al. **Nephrol Dial Transplant** 1996 May;11(5):863–6 (26 ref.)

PATHOLOGY

Progression from Goodpasture's disease to membranous glomerulonephritis. Elder G, et al. **Pathology** 1995 Jul; 27(3):233–6 (32 ref.)

THERAPY

What is the actual management of a child with membranous glomerulopathy associated with chronic hepatitis B? Chiu MC. **Pediatr Nephrol** 1996 Apr;10(2):146 (18 ref.)
[Therapeutic prospects in primary extramembranous glomerulonephritis in adults] Rostoker G, et al. **Ann Med Interne (Paris)** 1996;147(1):49–60 (112 ref.) **(Fre)**

GLOMERULONEPHRITIS, MESANGIOCAPILLARY see **GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE**

GLOMERULONEPHRITIS, MINIMAL CHANGE see **NEPHROSIS, LIPOID**

GLOMERULOSCLEROSIS, DIABETIC see **DIABETIC NEPHROPATHIES**

GLOMERULOSCLEROSIS, FOCAL

Human immunodeficiency virus-associated glomerulosclerosis. Humphreys MH. **Kidney Int** 1995 Aug; 48(2):311–20 (96 ref.)

ETIOLOGY

Pathogenesis of nonimmune glomerulosclerosis: studies in animals and potential applications to humans. Striker GE, et al. **Lab Invest** 1995 Nov;73(5):596–605 (93 ref.)
Glomerulosclerosis: intrinsic and extrinsic pathways. El Nahas AM. **Nephrol Dial Transplant** 1996 May;11(5):773–7 (51 ref.)
[Nephritis and cytokines—special reference to the role of basic fibroblast growth factor in etiological mechanism of irreversible sclerosing glomerulonephritis] Osawa G. **Nippon Naika Gakkai Zasshi** 1995 Sep 10;84(9):1583–7 (10 ref.) **(Jpn)**

IMMUNOLOGY

A reappraisal of immune-mediated glomerulosclerosis. Bergijk EC, et al. **Kidney Int** 1996 Mar;49(3):605–11 (75 ref.)

PATHOLOGY

Mechanisms and implications of heterogeneity of human glomerulosclerosis. Fogo A. **Contrib Nephrol** 1996;118:6–11 (27 ref.)

PHYSIOPATHOLOGY

Glomerulosclerosis: the final pathway is clarified, but can we deal with the triggers? [editorial] Wardle N. **Nephron** 1996;73(1):1–7 (110 ref.)

PREVENTION & CONTROL

Effects of ACE inhibitors and calcium channel blockers on the development of glomerular sclerosis in models of renal damage. Raij L. **Nephrol Dial Transplant** 1995 Oct;10 Suppl 9:23–7 (55 ref.)

THERAPY

Living-related donor transplants should be performed with caution in patients with focal segmental glomerulosclerosis. First MR. **Pediatr Nephrol** 1995;9 Suppl:S40–2 (35 ref.)

GLOMUS AORTICUM see **AORTIC BODIES**

GLOMUS CAROTICUM see **CAROTID BODY**

GLOMUS TUMOR

Congenital glomangioma: case report and review of the world literature. Glick SA, et al. **Pediatr Dermatol** 1995 Sep;12(3):242–4 (11 ref.)

GENETICS

Hereditary multiple glomus tumors involving the glans penis. A case report and review of the literature. Kiyosawa T, et al. **Dermatol Surg** 1995 Oct;21(10):895–9 (36 ref.)

PATHOLOGY

Glomus tumor of the penis. Khoudary KP, et al. **J Urol** 1996 Feb;155(2):707 (3 ref.)

SURGERY

Extradigital glomus tumour. Takei TR, et al. **J Hand Surg [Br]** 1995 Jun;20(3):409–12 (26 ref.)

GLOMUS VAGALE see **AORTIC BODIES**

GLOSSINA see **TSETSE FLIES**

GLOSSITIS AREATA EXFOLIATIVA see **GLOSSITIS, BENIGN MIGRATORY**

GLOSSITIS, BENIGN MIGRATORY

[Benign migratory glossitis: an enigmatic lesion] Beaudoin N, et al. **J Can Dent Assoc** 1995 Sep;61(9):802–3, 806–8 (30 ref.) (Eng. Abstr.) **(Fre)**

GLOTTIS

Management of carcinoma of the supraglottic larynx: evolution, current concepts, and future trends. Myers EN, et al. **Laryngoscope** 1996 May;106(5 Pt 1):559–67 (46 ref.)

PHYSIOPATHOLOGY

Subglottic air pressure: a key component of swallowing efficiency. Eibling DE, et al. **Ann Otol Rhinol Laryngol** 1996 Apr;105(4):253–8 (19 ref.)

GLOVES, PROTECTIVE

Hand protection. Gerberding JL, et al. **Surg Clin North Am** 1995 Dec;75(6):1133–9 (15 ref.)

GLOVES, SURGICAL

Glove safety: summary of recent findings and recommendations from health care regulators. Heller ET, et al. **South Med J** 1995 Nov;88(11):1093–8 (25 ref.)

[Perforations and porosity of surgical gloves. Frequency, mechanism, risk] Johanet H, et al. **Ann Chir** 1996; 50(4):352–5 (35 ref.) (Eng. Abstr.) **(Fre)**

[Latex allergy] Schürer NY, et al. **Hautarzt** 1995 Oct; 46(10):742–53 (10 ref.) **(Ger)**

ADVERSE EFFECTS

Issues of latex safety in dentistry. Field EA, et al. **Br Dent J** 1995 Oct 7;179(7):247–53 (51 ref.)

Hypoallergenic gloves. Field EA. **Int Dent J** 1995 Dec; 45(6):339–46 (36 ref.)

GLUCAGON

see related
RECEPTORS, GLUCAGON

BLOOD

[Pancreatic glucagon (IRG)] Sako Y, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:662–5 (9 ref.) **(Jpn)**

PHYSIOLOGY

Glucagon-like peptide-1 and control of insulin secretion. Thorens B. **Diabete Metab** 1995 Dec;21(5):311–8 (83 ref.)

Glucagon and its family revisited. Lefebvre PJ. **Diabetes Care** 1995 May;18(5):715–30 (186 ref.)

[Role of peptide hormones in adipocyte metabolism] Kaneko T, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:100–5 (20 ref.) **(Jpn)**

SECRETION

Chromium and other insulin sensitizers may enhance glucagon secretion: implications for hypoglycemia and weight control. McCarty MF. **Med Hypotheses** 1996 Feb; 46(2):77–80 (35 ref.)

GLUCAGON RECEPTORS see **RECEPTORS, GLUCAGON**

GLUCAN 1,4-ALPHA-GLUCOSIDASE

see related
GLYCOGEN STORAGE DISEASE TYPE II

DEFICIENCY

[Glycogenosis type II; acid alpha-glucosidase deficiency] Hirayasu T, et al. **Nippon Rinsho** 1995 Dec;53(12):2938–42 (22 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Amylolytic enzymes and products derived from starch: a review. Guzmán-Maldonado H, et al. **Crit Rev Food Sci Nutr** 1995 Sep;35(5):373–403 (190 ref.)

GLUCAN PHOSPHORYLASE see **GLYCOGEN PHOSPHORYLASE**

GLUCANS

PHARMACOKINETICS

Optimal use of glucose polymer (icodextrin) in peritoneal dialysis. Mistry CD, et al. **Perit Dial Int** 1996;16 Suppl 1:S104–8 (23 ref.)

GLUCITOL see **SORBITOL**

GLUCOAMYLASE see **GLUCAN 1,4-ALPHA-GLUCOSIDASE**

GLUCOCEREBROSIDASE see **GLUCOSYLCERAMIDASE**

GLUCOCORTICOID ANALOGS see **GLUCOCORTICOIDS, SYNTHETIC**

GLUCOCORTICOID RECEPTORS see **RECEPTORS, GLUCOCORTICOID**

GLUCOCORTICOIDS

see related
RECEPTORS, GLUCOCORTICOID

Oral candidiasis, HIV, and saliva glucocorticoids. Enwonwu CO, et al. **Am J Pathol** 1996 Apr;148(4):1313–8 (68 ref.)

ADMINISTRATION & DOSAGE

Glucocorticoid-remediable aldosteronism. Litchfield WR, et al. **Compr Ther** 1995 Oct;21(10):553–8 (21 ref.)

Low-dose glucocorticoid therapy in rheumatoid arthritis. Trèves R. **Rev Rhum Engl Ed** 1995 Nov;62(10):611–7 (40 ref.)

[Safety and side effects of inhalant steroid therapy in children with bronchial asthma] Schöni MH. **Schweiz Rundsch Med Prax** 1995 Oct 3;84(40):1108–13 (37 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Minimizing complications from systemic glucocorticosteroid use. Nesbitt LT Jr. **Dermatol Clin** 1995 Oct;13(4):925–39 (56 ref.)

[Present status of cortisone myopathy] Bielefeld P. **Rev Med Interne** 1996;17(3):255–61 (29 ref.) (Eng. Abstr.) **(Fre)**

ANTAGONISTS & INHIBITORS

Mifepristone: treatment of Cushing's syndrome. Sartor O, et al. **Clin Obstet Gynecol** 1996 Jun;39(2):506–10 (12 ref.)

BLOOD

The nature of the ponderostat: Hervey's hypothesis revived. Cabanac M, et al. **Appetite** 1996 Feb;26(1):45–54 (77 ref.)

METABOLISM

Pathophysiological basis of vulnerability to drug abuse: role of an interaction between stress, glucocorticoids, and dopaminergic neurons. Piazza PV, et al. **Annu Rev Pharmacol Toxicol** 1996;36:359–78 (117 ref.)

Mechanisms for inducible control of angiotensinogen gene transcription. Brasier AR, et al. **Hypertension** 1996 Mar; 27(3 Pt 2):465–75 (108 ref.)

PHARMACOKINETICS

Pharmacodynamics and pharmacokinetics of inhaled glucocorticoids. Johnson M. **J Allergy Clin Immunol** 1996 Jan;97(1 Pt 2):169–76 (26 ref.)

PHARMACOLOGY

Glucocorticoids and growth problems. Robinson IC, et al. **Acta Paediatr Suppl** 1995 Sep;411:81–6 (45 ref.)

Regulation of expression of sodium-calcium exchanger and plasma membrane calcium ATPase by protein kinases, glucocorticoids, and growth factors. Smith JB, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:258–71 (36 ref.)

Anti-inflammatory mechanisms of glucocorticoids. Barnes PJ. **Biochem Soc Trans** 1995 Nov;23(4):940–5 (50 ref.)

Molecular mechanisms of steroid action in asthma. Barnes PJ. **J Allergy Clin Immunol** 1996 Jan;97(1 Pt 2):159–68 (74 ref.)

Pharmacodynamics and pharmacokinetics of inhaled glucocorticoids. Johnson M. **J Allergy Clin Immunol** 1996 Jan;97(1 Pt 2):169–76 (26 ref.)

Glucocorticosteroid inhibition of cytokine production: relevance to antiallergic actions. Schwiebert LA, et al. **J Allergy Clin Immunol** 1996 Jan;97(1 Pt 2):143–52 (105 ref.)

The biochemistry and molecular biology of glucocorticoid-induced apoptosis in the immune system. Cidlowski JA, et al. **Recent Prog Horm Res** 1996;51:457–90; discussion 490–1 (161 ref.)

Studies on glucocorticoid hormone actions in the regulation of human amnion PGHS. Zakar T, et al. **Reprod Fertil Dev** 1995;7(3):517–20 (12 ref.)

[Mechanisms of action of high-dosage glucocorticoid therapy] Buttgereit F, et al. **Dtsch Med Wochenschr** 1996 Feb 23;121(8):248–52 (32 ref.) **(Ger)**

[Molecular mechanism of glucocorticoid action] Grzanka A, et al. **Pol Arch Med Wewn** 1996 Apr;95(4):375–82 (30 ref.) **(Pol)**

PHYSIOLOGY

The neural network that regulates energy balance is responsive to glucocorticoids and insulin and also regulates HPA axis responsivity at a site proximal to CRF neurons. Dallman MF, et al. **Ann N Y Acad Sci** 1995 Dec 29; 771:730–42 (43 ref.)

Molecular mechanisms of anti-inflammatory action of glucocorticoids. Cato AC, et al. **Bioessays** 1996 May; 18(5):371–8 (67 ref.)

Fifteenth Gaddum Memorial Lecture December 1994. Stress and the neuroendocrine-immune axis: the pivotal role of glucocorticoids and lipocortin 1. Buckingham JC. **Br J Pharmacol** 1996 May;118(1):1–19 (138 ref.)

Mechanism of glucocorticoid-induced hypertension. Saruta T. **Hypertens Res** 1996 Mar;19(1):1–8 (11 ref.)

Role of glucocorticoids and fatty acids in the impairment of lipid metabolism observed in the metabolic syndrome. Brindley DN. **Int J Obes Relat Metab Disord** 1995 May; 19 Suppl 1:S69–75 (61 ref.)

Hypothalamic-pituitary-adrenal-glucocorticoid axis function in rheumatoid arthritis [editorial; comment] Masi AT, et al. **J Rheumatol** 1996 Apr;23(4):577–81 (19 ref.) Comment on: J Rheumatol 1996 Apr;23(4):596–602.

Lymphoid cell resistance to glucocorticoids in HIV infection. Kawa SK, et al. **J Steroid Biochem Mol Biol** 1996 Mar; 57(5–6):259–63 (68 ref.)

SLE and osteoporosis: dependence and/or independence on glucocorticoids. Sels F, et al. **Lupus** 1996 Apr;5(2):89–92 (23 ref.)

Acidosis and glucocorticoids induce branched-chain amino acid catabolism. England BK, et al. **Miner Electrolyte Metab** 1996;22(1–3):69–71 (26 ref.)

Necessary but not sufficient: the role of glucocorticoids in the acidosis-induced increase in levels of mRNAs encoding proteins of the ATP-dependent proteolytic pathway in rat muscle. Price SR, et al. **Miner Electrolyte Metab** 1996; 22(1–3):72–5 (14 ref.)

Activation of the HPA axis by immune insults: roles and interactions of cytokines, eicosanoids, glucocorticoids. Buckingham JC, et al. **Pharmacol Biochem Behav** 1996 May; 54(1):285–98 (138 ref.)

Why stress is bad for your brain. Sapolsky RM. **Science** 1996 Aug 9;273(5276):749–50 (11 ref.)

Cell-adhesion molecules, glucocorticoids and long-term-memory formation. Rose SP. **Trends Neurosci** 1995 Nov;18(11):502–6 (46 ref.)

[Role of steroid hormone in adipocyte metabolism] Nagasaka Y, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:111–4 (9 ref.) **(Jpn)**

THERAPEUTIC USE

Glucocorticoid resistance in asthma. Barnes PJ, et al. **Am J Respir Crit Care Med** 1995 Dec;152(6 Pt 2):S125–40 (231 ref.)

Glucocorticoid-remediable aldosteronism. Dluhy RG, et al. **Cardiovasc Res** 1996 Jun;31(6):870–2 (16 ref.)

Remodeling of asthmatic airways by glucocorticosteroids. Laitinen LA, et al. **J Allergy Clin Immunol** 1996 Jan;97(1 Pt 2):153–8 (22 ref.)

Clinical use of inhaled corticosteroids in asthma. Wasserfallen JB, et al. **J Allergy Clin Immunol** 1996 Jan;97(1 Pt 2):177–82 (41 ref.)

Do topical corticosteroids have a role following excimer laser photorefractive keratectomy? [see comments] Corbett MC, et al. **J Refract Surg** 1995 Sep–Oct;11(5):380–7 (64 ref.) Comment in: J Refract Surg 1995 Sep–Oct;11(5):339–40.

Methotrexate in the treatment of systemic glucocorticoid-dependent severe persistent asthma: a word of caution. Fabbri L, et al. **Monaldi Arch Chest Dis** 1996 Apr;51(2):130–7 (118 ref.)

[Mechanisms of action of high-dosage glucocorticoid therapy] Buttgereit F, et al. **Dtsch Med Wochenschr** 1996 Feb 23;121(8):248–52 (32 ref.) **(Ger)**

[Approach to the diagnosis and therapy of vascular neuropathy] Hernández MA, et al. **Rev Neurol** 1995 Sep–Oct;23(123):1008–12 (40 ref.) (Eng. Abstr.) **(Spa)**

TOXICITY

Methodologic issues in studying glucocorticoid-induced damage to neurons. Sapolsky R, et al. **J Neurosci Methods** 1995 May;58(1–2):1–15 (73 ref.)

Review of the interaction between TCDD and glucocorticoids in embryonic palate. Abbott BD. **Toxicology** 1995 Dec 28;105(2–3):365–73 (86 ref.)

GLUCOCORTICOIDS, SYNTHETIC

see related
ANTI-INFLAMMATORY AGENTS, STEROIDAL
ANTI-INFLAMMATORY AGENTS, TOPICAL

[Hypersensitivity to glucocorticoids: reflections on a published case report sample] Réveilleau-Richard S, et al. **Therapie** 1995 Sep-Oct;50(5):439-46 (24 ref.) (Eng. Abstr.) **(Fre)**

ADMINISTRATION & DOSAGE

Glucocorticosteroid treatment of asthma. Bai TR. **Can Fam Physician** 1995 Nov;41:1921-7 (25 ref.)

Low dose corticosteroids in early rheumatoid arthritis. Can these drugs slow disease progression? Kirwan JR, et al. **Drugs Aging** 1996 Mar;8(3):157-61 (16 ref.)

ADVERSE EFFECTS

Prevention and management of glucocorticoid-induced osteoporosis. Lane NE, et al. **Bull Rheum Dis** 1995 Aug; 44(5):1-4 (23 ref.)

Steroids in head injury. Kelly DF. **New Horiz** 1995 Aug; 3(3):453-5 (15 ref.)

[Hypertrophic cardiomyopathy in a low-birth-weight newborn treated with dexamethasone] Villa Alcázar M, et al. **An Esp Pediatr** 1996 Apr;44(4):393-4 (20 ref.) **(Spa)**

BLOOD

[Synthetic steroids] Miyazaki S. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:1036-9 (19 ref.) **(Jpn)**

PHARMACOLOGY

How do steroids work? Schleimer RP. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 2):S28-30 (34 ref.)

THERAPEUTIC USE

Can steroids cause asthma to remit? Pedersen S. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 2):S31-2 (16 ref.)

The role of anti-inflammatory drugs in the prevention and treatment of Alzheimer's disease. Breitner JC. **Annu Rev Med** 1996;47:401-11 (81 ref.)

Cyclosporin in steroid-resistant idiopathic nephrotic syndrome. Tejani A, et al. **Contrib Nephrol** 1995;114:73-7 (32 ref.)

Long-term effect of interferon alpha alone or after prednisone withdrawal in chronic hepatitis B. Interim report and review of the literature. Gonzalez-Mateos F, et al. **Hepatogastroenterology** 1995 Nov-Dec;42(6):893-9 (25 ref.)

Therapeutic uses of methyl prednisolone. Mondal T, et al. **Indian Pediatr** 1995 Jul;32(7):787-93 (26 ref.)

Bilateral inguinal scrofuloderma during steroid therapy in a patient with bullous pemphigoid. Kawabata E, et al. **J Dermatol** 1995 Aug;22(8):582-6 (22 ref.)

Adjunctive dexamethasone therapy for pediatric bacterial meningitis. Bonadio WA. **J Emerg Med** 1996 Mar-Apr; 14(2):165-72 (40 ref.)

[Glucocorticoid treatment] Kauppinen-Mäkelin R. **Duodecim** 1995;111(8):725-31 (28 ref.) **(Fin)**

[Specific respiratory manifestations associated with hemorrhagic rectocolitis. Analysis of a case and review of the literature] Lagier E, et al. **Gastroenterol Clin Biol** 1996;20(4):397-400 (28 ref.) (Eng. Abstr.) **(Fre)**

[[Therapeutic perspectives in multiple sclerosis (editorial)] Lubetzki C, et al. **Presse Med** 1996 Jun 15;25(21):964-6 (10 ref.) (Eng. Abstr.) **(Fre)**

TOXICITY

Review of the toxicology of beclomethasone dipropionate. Libretto SE. **Arch Toxicol** 1995;69(8):509-25 (68 ref.)

GLUCOCORTICOIDS, TOPICAL

ADMINISTRATION & DOSAGE

Issues in the use of inhaled glucocorticoids. The Asthma Clinical Research Network. Kamada AK, et al. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 1):1739-48 (86 ref.)

Once-a-day topical corticosteroids. **Drug Ther Bull** 1995 Mar;33(3):21-2 (15 ref.)

Inhaled glucocorticoids: new developments relevant to updating of the asthma management guidelines. Barnes PJ. **Respir Med** 1996 Aug;90(7):379-84 (44 ref.)

[Inhalation treatment: glucocorticoids] Aubert JD. **Rev Med Suisse Romande** 1996 May;116(5):329-33 (20 ref.) **(Fre)**

[Inhaled corticotherapy in asthma: when should it be started and how to stop?] Aubier M. **Rev Pneumol Clin** 1996; 52(2):145-9 (19 ref.) (Eng. Abstr.) **(Fre)**

ADVERSE EFFECTS

Contact allergy to topical corticosteroids and systemic contact dermatitis from prednisolone with tolerance of triamcinolone. Bircher AJ, et al. **Acta Derm Venereol** 1995 Nov;75(6):490-3 (38 ref.)

Issues in the use of inhaled glucocorticoids. The Asthma Clinical Research Network. Kamada AK, et al. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 1):1739-48 (86 ref.)

Fluticasone propionate: safety profile. Johnson M. **Cutis** 1996 Feb;57(2 Suppl):10-2 (15 ref.)

[Primum non nocere: inhaled corticoids] Lacronique J. **Rev Pneumol Clin** 1996;52(2):137-43 (81 ref.) (Eng. Abstr.) **(Fre)**

THERAPEUTIC USE

Topical corticosteroids in clinical practice: focus on fluticasone propionate. Piacquadio DJ. **Cutis** 1996 Feb;57(2 Suppl):4-9 (19 ref.)

Topical corticosteroids. Katz HI. **Dermatol Clin** 1995 Oct; 13(4):805-15 (91 ref.)

[Pharma-clinics. How I treat... rosacea] Piérard-Franchimont C, et al. **Rev Med Liege** 1996 Jun; 51(6):393-5 (25 ref.) **(Fre)**

[Topical corticosteroids] Duchesneau J, et al. **Union Med Can** 1995 Mar;124(1):15-9 (15 ref.) **(Fre)**

[Advances in the topical steroid treatment of inflammatory bowel diseases] Díaz Blasco J, et al. **Rev Esp Enferm Dig** 1995 Nov;87(11):802-7 (62 ref.) **(Spa)**

GLUCOKINASE

GENETICS

Glucokinase mutations, insulin secretion, and diabetes mellitus. Bell GI, et al. **Annu Rev Physiol** 1996;58:171-86 (63 ref.)

[Glucokinase: the first hit in the hunt for a gene in late-onset diabetes (editorial)] Laakso M. **Duodecim** 1994;110(1):13-5 (18 ref.) **(Fin)**

METABOLISM

Banting Lecture 1995. A lesson in metabolic regulation inspired by the glucokinase glucose sensor paradigm. Matschinsky FM. **Diabetes** 1996 Feb;45(2):223-41 (86 ref.)

GLUCONEOGENESIS

The role of intracellular Ca2+ in the regulation of gluconeogenesis. Krauss-Friedmann N, et al. **Metabolism** 1996 Mar;45(3):389-403 (208 ref.)

DRUG EFFECTS

Rationale and hurdles of inhibitors of hepatic gluconeogenesis in treatment of diabetes mellitus. Kashiwagi A. **Diabetes Res Clin Pract** 1995 Aug;28 Suppl:S195-200 (30 ref.)

Inhibition of citrate lyase may aid aerobic endurance. McCarty MF. **Med Hypotheses** 1995 Sep;45(3):247-54 (77 ref.)

The effect of fasting and fructose and glucose infusion on gluconeogenesis and triose phosphate flux in rats in vivo. Wolf G. **Nutr Rev** 1995 Oct;53(10):299-301 (2 ref.)

GLUCOSE

see related
BLOOD GLUCOSE
GLYCOSURIA
HYPERGLYCEMIA
HYPOGLYCEMIA

International tables of glycemic index. Foster-Powell K, et al. **Am J Clin Nutr** 1995 Oct;62(4):871S-890S (79 ref.)

ADMINISTRATION & DOSAGE

Pro: glucose priming solutions should be used for cardiopulmonary bypass. Metz S. **J Cardiothorac Vasc Anesth** 1995 Oct;9(5):603-4 (25 ref.)

ANALOGS & DERIVATIVES

Iodine-123-labeled glucose analogs: prospects for a single-photon-emitting analog of fluorine-18-labeled deoxyglucose [editorial; comment] Gatley SJ. **Nucl Med Biol** 1995 Oct;22(7):829-35 (49 ref.) Comment on: Nucl Med Biol 1995 Oct;22(7):875-85.

CHEMISTRY

Heat sterilization of glucose-containing fluids for peritoneal dialysis: biological consequences of chemical alterations. Wieslander AP, et al. **Perit Dial Int** 1995;15(7 Suppl):S52-9; discussion S59-60 (32 ref.)

CONTRAINDICATIONS

Con: glucose priming solutions should not be used for cardiopulmonary bypass. Hindman B. **J Cardiothorac Vasc Anesth** 1995 Oct;9(5):605-7 (39 ref.)

METABOLISM

In vitro studies of human skeletal muscle: hormonal and metabolic regulation of glucose transport. Zierath JR. **Acta Physiol Scand Suppl** 1995;626:1-96 (435 ref.)

Biocatalytic syntheses of aromatics from D-glucose: renewable microbial sources of aromatic compounds. Frost JW, et al. **Annu Rev Microbiol** 1995;49:557-79 (81 ref.)

Role of glucose regulatory mechanisms in diabetic retinopathy. Knott RM, et al. **Br J Ophthalmol** 1995 Nov; 79(11):1046-9 (43 ref.)

Glucose metabolism assessment in pregnancy. Garner PR. **Clin Biochem** 1995 Oct;28(5):499-502 (18 ref.)

Positron emission tomography studies of abnormal glucose metabolism in schizophrenic illness. Buchsbaum MS. **Clin Neurosci** 1995;3(2):122-30 (77 ref.)

Glycation, oxidation, and glycoxidation reactions in the development of diabetic complications. Lyons TJ. **Contrib Nephrol** 1995;112:1-10 (42 ref.)

Facilitative glucose transport proteins and sodium-glucose co-transporters in the kidney. Hoffman BB, et al. **Curr Opin Nephrol Hypertens** 1995 Sep;4(5):406-11 (52 ref.)

Regulation of hepatic glucose production in healthy subjects and patients with non-insulin-dependent diabetes mellitus. Tappy L. **Diabete Metab** 1995 Oct;21(4):233-40 (71 ref.)

The coupling of glucose metabolism and perfusion in human skeletal muscle. The potential role of endothelium-derived nitric oxide. Baron AD. **Diabetes** 1996 Jan;45 Suppl 1:S105-9 (43 ref.)

Significance of insulin for glucose metabolism in skeletal muscle during contractions. Hespel P, et al. **Diabetes** 1996 Jan;45 Suppl 1:S99-104 (61 ref.)

Banting Lecture 1995. A lesson in metabolic regulation inspired by the glucokinase glucose sensor paradigm. Matschinsky FM. **Diabetes** 1996 Feb;45(2):223-41 (86 ref.)

Insulin-induced redistribution of GLUT4 glucose carriers in the muscle fiber. In search of GLUT4 trafficking pathways. Zorzano A, et al. **Diabetes** 1996 Jan;45 Suppl 1:S70-81 (120 ref.)

Fatty acids and insulin resistance. Boden G. **Diabetes Care** 1996 Apr;19(4):394-5 (14 ref.)

Determinants of glucose turnover in the pathophysiology of diabetes: an in vivo analysis in diabetic dogs. Fisher SJ, et al. **Diabetes Metab** 1996 Apr;22(2):111-21 (78 ref.)

Metformin and intestinal glucose handling. Bailey CJ. **Diabetes Metab Rev** 1995 Sep;11 Suppl 1:S23-32 (47 ref.)

Insulin regulation of muscle glucose metabolism: role of pre-receptorial mechanisms. Capaldo B, et al. **Diabetes Metab Rev** 1995 Dec;11(4):365-82 (141 ref.)

Can hypoglycaemia be predicted before its onset? Lönnroth P. **Diabetologia** 1996 May;39(5):613-4 (17 ref.)

Can hypoglycaemia be predicted before its onset? (Comment). Maggs D. **Diabetologia** 1996 May;39(5):615-7 (16 ref.)

Does fall in tissue glucose precede fall in blood glucose? Sternberg F, et al. **Diabetologia** 1996 May;39(5):609-12 (22 ref.)

Methods to assess glucose metabolism in humans in relation to carbohydrate and fibre in the diet. Bornet FR, et al. **Eur J Clin Nutr** 1995 Oct;49 Suppl 3:S97-104 (60 ref.)

In vitro studies to predict physiological effects of dietary fibre. Brighenti F, et al. **Eur J Clin Nutr** 1995 Oct;49 Suppl 3:S81-8 (38 ref.)

Glucose metabolism and liver cirrhosis. Nolte W, et al. **Exp Clin Endocrinol Diabetes** 1995;103(2):63-74 (99 ref.)

The Leloir pathway: a mechanistic imperative for three enzymes to change the stereochemical configuration of a single carbon in galactose. Frey PA. **FASEB J** 1996 Mar; 10(4):461-70 (40 ref.)

Reoxidation of the NADPH produced by the pentose phosphate pathway is necessary for the utilization of glucose by Kluyveromyces lactis rag2 mutants. González Siso MI, et al. **FEBS Lett** 1996 May 27;387(1):7-10 (27 ref.)

Adaptation to life at micromolar nutrient levels: the regulation of Escherichia coli glucose transport by endoinduction and cAMP. Ferenci T. **FEMS Microbiol Rev** 1996 Jul;18(4):301-17 (92 ref.)

Glucose metabolism in obese subjects: lessons from OGTT, IVGTT and clamp studies. Scheen AJ, et al. **Int J Obes Relat Metab Disord** 1995 Sep;19 Suppl 3:S14-20 (45 ref.)

Role of the endocrine pancreas in control of fuel metabolism by the liver during exercise. Wasserman DH, et al. **Int J Obes Relat Metab Disord** 1995 Oct;19 Suppl 4:S22-30 (83 ref.)

Regulation of organic nutrient metabolism during transition from late pregnancy to early lactation. Bell AW. **J Anim Sci** 1995 Sep;73(9):2804-19 (117 ref.)

Fluorine-18-fluorodeoxyglucose PET to determine regional cerebral glucose utilization: a re-examination. Schmidt KC, et al. **J Nucl Med** 1996 Feb;37(2):394-9 (42 ref.)

Stable isotopic tracers for studies of glucose metabolism. Kalhan SC. **J Nutr** 1996 Jan;126(1):362S-369S (56 ref.)

Glucose modulation of ischemic brain injury: review and clinical recommendations. Wass CT, et al. **Mayo Clin Proc** 1996 Aug;71(8):801-12 (108 ref.)

Inhibition of citrate lyase may aid aerobic endurance. McCarty MF. **Med Hypotheses** 1995 Sep;45(3):247-54 (77 ref.)

'Toxicity of glucose: is AGE the answer?' Makita Z. **Nephrol Dial Transplant** 1995;10 Suppl 7:33-7 (32 ref.)

Substrate selection and oxygen uptake by the lactating mammary gland. Williamson DH, et al. **Proc Nutr Soc** 1995 Mar;54(1):165-75 (62 ref.)

Regulation of placental metabolism by glucose supply. Hay WW Jr. **Reprod Fertil Dev** 1995;7(3):365-75 (45 ref.)

Localized and lateralized cerebral glucose metabolism

associated with eye movements during REM sleep and wakefulness: a positron emission tomography (PET) study. Hong CC, et al. **Sleep** 1995 Sep;18(7):570–80 (71 ref.)
[Susceptibility to infections in diabetes—effects on metabolism] Perschel WT, et al. **Immun Infekt** 1995 Dec; 23(6):196–200 (34 ref.) (Eng. Abstr.) **(Ger)**
[Abnormal glucose metabolism and insulin resistance in obesity] Inoue Y, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:299–303 (22 ref.) **(Jpn)**
[Cerebral glucose metabolism in craniocerebral trauma: an evaluation] Schelp AO, et al. **Arq Neuropsiquiatr** 1995 Sep; 53(3–B):698–705 (44 ref.) (Eng. Abstr.) **(Por)**

PHARMACOKINETICS

Molecular actions of insulin on glucose transport. Czech MP. **Annu Rev Nutr** 1995;15:441–71 (214 ref.)
The regulation of glucose uptake and oxidation during exercise. Kelley DE. **Int J Obes Relat Metab Disord** 1995 Oct;19 Suppl 4:S14–7 (12 ref.)

PHARMACOLOGY

Role of protein kinase C and cyclic AMP/protein kinase A in high glucose–stimulated transcriptional activation of collagen alpha 1 (IV) in glomerular mesangial cells. Ziyadeh FN, et al. **J Diabetes Complications** 1995 Oct–Dec; 9(4):255–61 (35 ref.)
Effect of high glucose concentration on phospholipase A2 activity in mesangial cells. Choi K. **Kidney Int Suppl** 1995 Sep;51:S22–7 (48 ref.)
The effect of fasting and fructose and glucose infusion on gluconeogenesis and triose phosphate flux in rats in vivo. Wolf G. **Nutr Rev** 1995 Oct;53(10):299–301 (2 ref.)
The role of TGF-beta in growth inhibition of peritoneal mesothelial cells in high-glucose dialysate. Kumano K, et al. **Perit Dial Int** 1995;15(7 Suppl):S93–5 (18 ref.)

PHYSIOLOGY

Glucose regulation and cognitive functions: relation to Alzheimer's disease and diabetes. Messier C, et al. **Behav Brain Res** 1996 Feb;75(1–2):1–11 (127 ref.)
Hypoglycemia–induced autonomic failure in insulin–dependent diabetes mellitus. Cryer PE. **Proc Assoc Am Physicians** 1995 Apr;107(1):67–70 (30 ref.)

TOXICITY

Glucose toxicity: the implications of hyperglycemia in the pathophysiology of diabetes mellitus. Rossetti L. **Clin Invest Med** 1995 Aug;18(4):255–60 (22 ref.)
Glucose–induced vascular smooth muscle dysfunction: the role of protein kinase C. Williams B. **J Hypertens** 1995 May;13(5):477–86 (96 ref.)
[Glucose toxicity—pros and cons. Useful adaptation and common cause of insulin resistance in diabetic patients] Yki-Järvinen H. **Nord Med** 1996 Mar;111(3):80–3 (15 ref.) (Eng. Abstr.) **(Swe)**

GLUCOSE, BLOOD see **BLOOD GLUCOSE**

GLUCOSE CLAMP TECHNIQUE

In praise of the hyperglycemic clamp. A method for assessment of beta-cell sensitivity and insulin resistance. Elahi D. **Diabetes Care** 1996 Mar;19(3):278–86 (26 ref.)

GLUCOSE CLAMPING see **GLUCOSE CLAMP TECHNIQUE**

GLUCOSE–DEPENDENT INSULINOTROPIC PEPTIDE see **GASTRIC INHIBITORY POLYPEPTIDE**

GLUCOSE INTOLERANCE

see related
DIABETES MELLITUS
GLUCOSE TOLERANCE TEST

BLOOD

Insulin resistance: a multifaceted metabolic syndrome. Insights gained using a low–dose insulin infusion technique. Krentz AJ, et al. **Diabet Med** 1996 Jan;13(1):30–9 (54 ref.)

CHEMICALLY INDUCED

Carbohydrate tolerance in patients with tropical ataxic neuropathy—A human model of chronic cyanide intoxication. Famuyiwa OO, et al. **Afr J Med Med Sci** 1995 Jun;24(2):151–7 (28 ref.)

CLASSIFICATION

Impaired glucose tolerance—fact or fiction. Alberti KG. **Diabet Med** 1996;13(3 Suppl 2):S6–8 (14 ref.)

DRUG THERAPY

Effects of metformin in obese patients with impaired glucose tolerance. Scheen AJ, et al. **Diabetes Metab Rev** 1995 Sep; 11 Suppl 1:S69–80 (75 ref.)

EPIDEMIOLOGY

Impaired glucose tolerance—prevalence and conversion to NIDDM. Harris MI. **Diabet Med** 1996;13(3 Suppl 2):S9–11 (14 ref.)

ETIOLOGY

Loss of skeletal muscle mass with aging: effect on glucose tolerance. Kohrt WM, et al. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:68–72 (43 ref.)

GENETICS

Hyperproinsulinemia in a three–generation Caucasian family due to mutant proinsulin (Arg65–His) not associated with imparied glucose tolerance: the contribution of mutant proinsulin to insulin bioactivity. Röder ME, et al. **J Clin Endocrinol Metab** 1996 Apr;81(4):1634–40 (29 ref.)

PHYSIOPATHOLOGY

The cardiovascular risk associated with impaired glucose tolerance. Jarrett RJ. **Diabet Med** 1996;13(3 Suppl 2):S15–9 (25 ref.)
Review of previous impaired glucose tolerance intervention studies. Melander A. **Diabet Med** 1996;13(3 Suppl 2):S20–2 (5 ref.)

THERAPY

Review of previous impaired glucose tolerance intervention studies. Melander A. **Diabet Med** 1996;13(3 Suppl 2):S20–2 (5 ref.)

GLUCOSE–6–PHOSPHATASE

PHYSIOLOGY

The glucose–6–phosphatase system in human development. Burchell A, et al. **Histol Histopathol** 1995 Oct;10(4):979–93 (97 ref.)

GLUCOSE–6–PHOSPHATASE DEFICIENCY see **GLYCOGEN STORAGE DISEASE TYPE I**

GLUCOSE–6–PHOSPHATE DEHYDROGENASE see **GLUCOSEPHOSPHATE DEHYDROGENASE**

GLUCOSE PHOSPHOMUTASE see **PHOSPHOGLUCOMUTASE**

GLUCOSE–SODIUM TRANSPORT SYSTEM see **MONOSACCHARIDE TRANSPORT PROTEINS**

GLUCOSE TOLERANCE TEST

Impaired glucose tolerance—fact or fiction. Alberti KG. **Diabet Med** 1996;13(3 Suppl 2):S6–8 (14 ref.)
Why use the oral glucose tolerance test? Stolk RP, et al. **Diabetes Care** 1995 Jul;18(7):1045–9 (40 ref.)
Glucose metabolism in obese subjects: lessons from OGTT, IVGTT and clamp studies. Scheen AJ, et al. **Int J Obes Relat Metab Disord** 1995 Sep;19 Suppl 3:S14–20 (45 ref.)

METHODS

An alternative approach to the diagnosis of diabetes with a review of the literature. Davidson MB, et al. **Diabetes Care** 1995 Jul;18(7):1065–71 (49 ref.)

GLUCOSE TRANSPORT PROTEIN see **MONOSACCHARIDE TRANSPORT PROTEINS**

GLUCOSEPHOSPHATASE see **GLUCOSE–6–PHOSPHATASE**

GLUCOSEPHOSPHATASE DEFICIENCY see **GLYCOGEN STORAGE DISEASE TYPE I**

GLUCOSEPHOSPHATE DEHYDROGENASE

BLOOD

[Glucose–6–phosphate dehydrogenase (G6PD)] Hirota K, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:206–9 (15 ref.) **(Jpn)**

GENETICS

Asthma and oxidant stress: nutritional, environmental, and genetic risk factors. Greene LS. **J Am Coll Nutr** 1995 Aug; 14(4):317–24 (80 ref.)

METABOLISM

Mechanism of cancer preventive action of DHEA. Role of glucose–6–phosphate dehydrogenase. Schwartz AG, et al. **Ann N Y Acad Sci** 1995 Dec 29;774:180–6 (57 ref.)

PHYSIOLOGY

A new lease of life for an old enzyme. Martini G, et al. **Bioessays** 1996 Aug;18(8):631–7 (65 ref.)

GLUCOSEPHOSPHATE DEHYDROGENASE DEFICIENCY

BLOOD

Disorders of neutrophil function. Bogomolski–Yahalom V, et al. **Blood Rev** 1995 Sep;9(3):183–90 (71 ref.)

COMPLICATIONS

Severe hyperbilirubinemia due to acute hepatitis A superimposed on a chronic hepatitis B carrier with glucose–6–phosphate dehydrogenase deficiency. Huo TI, et al. **Am J Gastroenterol** 1996 Jan;91(1):158–9 (10 ref.)

DIAGNOSIS

Hematologic disorders in children from southeast Asia. Glader BE, et al. **Pediatr Clin North Am** 1996 Jun; 43(3):665–81 (48 ref.)

ENZYMOLOGY

A new lease of life for an old enzyme. Martini G, et al. **Bioessays** 1996 Aug;18(8):631–7 (65 ref.)

EPIDEMIOLOGY

Glucose–6–phosphate dehydrogenase deficiency in Singapore. Quak SH, et al. **Ann Acad Med Singapore** 1996 Jan;25(1):45–8 (38 ref.)

GENETICS

Molecular basis of erythroenzymopathies associated with hereditary hemolytic anemia: tabulation of mutant enzymes. Miwa S, et al. **Am J Hematol** 1996 Feb;51(2):122–32 (105 ref.)
Glucose–6–phosphate dehydrogenase deficiency. Chang JG, et al. **Crit Rev Oncol Hematol** 1995 Aug;20(1–2):1–7 (63 ref.)
Red cell enzymopathies as a model of inborn errors of metabolism. Miwa S, et al. **Southeast Asian J Trop Med Public Health** 1995;26 Suppl 1:112–9 (39 ref.)

PHYSIOPATHOLOGY

Hereditary red cell enzymopathies. Arya R, et al. **Blood Rev** 1995 Sep;9(3):165–75 (155 ref.)

GLUCOSEPHOSPHATE ISOMERASE

METABOLISM

Reoxidation of the NADPH produced by the pentose phosphate pathway is necessary for the utilization of glucose by Kluyveromyces lactis rag2 mutants. González Siso MI, et al. **FEBS Lett** 1996 May 27;387(1):7–10 (27 ref.)

GLUCOSIDASES

CHEMISTRY

Saposin–like proteins (SAPLIP) carry out diverse functions on a common backbone structure. Munford RS, et al. **J Lipid Res** 1995 Aug;36(8):1653–63 (83 ref.)

GLUCOSINOLATES

PHARMACOLOGY

Natural toxins and protective factors in brassica species, including rapeseed. Heaney RK, et al. **Nat Toxins** 1995; 3(4):233–7; discussion 242 (16 ref.)

TOXICITY

Natural toxins and protective factors in brassica species, including rapeseed. Heaney RK, et al. **Nat Toxins** 1995; 3(4):233–7; discussion 242 (16 ref.)

GLUCOSYLCERAMIDASE

ADMINISTRATION & DOSAGE

Gaucher's disease: a review. Morales LE. **Ann Pharmacother** 1996 Apr;30(4):381–8 (39 ref.)
[Enzyme replacement therapy of patients with lysosomal storage disease] Takada G, et al. **Nippon Rinsho** 1995 Dec; 53(12):3077–82 (22 ref.) (Eng. Abstr.) **(Jpn)**

ANTAGONISTS & INHIBITORS

Treatment of Gaucher disease with an enzyme inhibitor. Radin NS. **Glycoconj J** 1996 Apr;13(2):153–7 (22 ref.)

THERAPEUTIC USE

[The treatment of Gaucher's disease in The Netherlands using enzyme substitution therapy] Hollak CE, et al. **Ned Tijdschr Geneeskd** 1996 May 11;140(19):1011–3 (17 ref.) **(Dut)**

GLUCOSYLTRANSFERASES

ANTAGONISTS & INHIBITORS

Antifungal drug targets: Candida secreted aspartyl protease and fungal wall beta-glucan synthesis. Goldman RC, et al. **Infect Agents Dis** 1995 Dec;4(4):228-47 (120 ref.)

GLUCURONIDASE

BLOOD

[beta-Glucuronidase] Kambegawa A. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:354-7 (12 ref.) **(Jpn)**

GENETICS

The beta-glucuronidase (gus) reporter gene system. Gene fusions; spectrophotometric, fluorometric, and histochemical detection. Hull GA, et al. **Methods Mol Biol** 1995;49:125-41 (35 ref.)

D-GLUCURONOLACTONE DEHYDROGENASE see **ALDEHYDE DEHYDROGENASE**

GLUCURONOSYLTRANSFERASE

METABOLISM

Specificity of human UDP-glucuronosyltransferases and xenobiotic glucuronidation. Burchell B, et al. **Life Sci** 1995; 57(20):1819-31 (64 ref.)

GLUCURONYLTRANSFERASE see **GLUCURONOSYLTRANSFERASE**

GLUE SNIFFING see **SUBSTANCE USE DISORDERS**

GLUES see **ADHESIVES**

GLUTAMATE see **GLUTAMIC ACID**

GLUTAMATE AGONISTS see **EXCITATORY AMINO ACID AGONISTS**

GLUTAMATE ANTAGONISTS see **EXCITATORY AMINO ACID ANTAGONISTS**

GLUTAMATE CARBOXY-LYASE see **GLUTAMATE DECARBOXYLASE**

GLUTAMATE DECARBOXYLASE

IMMUNOLOGY

Glutamic acid decarboxylase and other autoantigens in IDDM. Nepom GT. **Curr Opin Immunol** 1995 Dec; 7(6):825-30 (63 ref.)

HLA and glutamic acid decarboxylase in human insulin-dependent diabetes mellitus. Sanjeevi CB, et al. **Diabet Med** 1996 Mar;13(3):209-17 (68 ref.)

Stiff-person syndrome with anti-glutamic acid decarboxylase autoantibodies: complete remission of symptoms after intrathecal baclofen administration. Seitz RJ, et al. **J Neurol** 1995 Oct;242(10):618-22 (32 ref.)

The clinical significance of an autoimmune response against glutamic acid decarboxylase. Ellis TM, et al. **Nat Med** 1996 Feb;2(2):148-53 (30 ref.)

[Autoimmunity and glutamate decarboxylase antibodies in the pathogenesis of type I diabetes mellitus in experimental and clinical practice] Kučera P, et al. **Vnitr Lek** 1996 May; 42(5):359-67 (65 ref.) (Eng. Abstr.) **(Cze)**

[Cytoplasmic islet cell antibodies and GAD antibodies in diagnosis of diabetes] Bieg S, et al. **Med Klin** 1995 Oct 15;90(10):594-8 (48 ref.) **(Ger)**

[Marked clinical improvement by plasmapheresis in a patient with stiff-man syndrome: a case with a negative anti-GAD antibody] Nakamagoe K, et al. **Rinsho Shinkeigaku** 1995 Aug;35(8):897-900 (12 ref.) (Eng. Abstr.) **(Jpn)**

GLUTAMATE DEHYDROGENASE

BLOOD

[Glutamate dehydrogenase] Imai T. **Nippon Rinsho** 1995 Feb; 53 Su Pt 1:342-5 (20 ref.) **(Jpn)**

CHEMISTRY

Insights into the molecular basis of thermal stability from the structure determination of Pyrococcus furiosus glutamate dehydrogenase. Rice DW, et al. **FEMS Microbiol Rev** 1996 May;18(2-3):105-17 (43 ref.)

GLUTAMATE RECEPTORS see **RECEPTORS, GLUTAMATE**

GLUTAMATE RECEPTORS, METABOTROPIC see **RECEPTORS, METABOTROPIC GLUTAMATE**

GLUTAMATE SYNTHASE

CHEMISTRY

Glutamate synthase: a complex iron-sulphur flavoprotein. Curti B, et al. **Biochem Soc Trans** 1996 Feb;24(1):95-9 (20 ref.)

METABOLISM

Glutamate synthase: a complex iron-sulphur flavoprotein. Curti B, et al. **Biochem Soc Trans** 1996 Feb;24(1):95-9 (20 ref.)

GLUTAMATES

see related
RECEPTORS, GLUTAMATE

ANTAGONISTS & INHIBITORS

Strategies for neuroprotection with glutamate antagonists. Extrapolating from evidence taken from the first stroke and head injury studies. Bullock R. **Ann N Y Acad Sci** 1995 Sep 15;765:272-8; discussion 298 (11 ref.)

GLUTAMIC ACID

see related
RECEPTORS, GLUTAMATE

Studies on the active-site structure of C3-like exoenzymes: involvement of glutamic acid in catalysis of ADP-ribosylation. Aktories K, et al. **Biochimie** 1995; 77(5):326-32 (62 ref.)

METABOLISM

Amyotrophic lateral sclerosis. A multifactorial disease. Eisen AA. **Adv Neurol** 1995;68:121-34 (108 ref.)

The possible role of a secondary pathogenetic factor in amyotrophic lateral sclerosis. Pinelli P, et al. **Adv Neurol** 1995;68:29-40 (25 ref.)

Excitotoxic mechanisms in the pathogenesis of amyotrophic lateral sclerosis. Rothstein JD. **Adv Neurol** 1995;68:7-20; discussion 21-7 (80 ref.)

Cognitive enhancement. New strategies for stimulating cholinergic, glutamatergic, and nitric oxide systems. Ingram DK, et al. **Ann N Y Acad Sci** 1996 Jun 15; 786:348-61 (80 ref.)

Neurotransmitters. NMDA receptors: do glia hold the key? Cull-Candy S. **Curr Biol** 1995 Aug 1;5(8):841-3 (25 ref.)

Metabolic trafficking between neurons and astrocytes: the glutamate/glutamine cycle revisited. Westergaard N, et al. **Dev Neurosci** 1995;17(4):203-11 (97 ref.)

Glutamate, GABA and epilepsy. Bradford HF. **Prog Neurobiol** 1995 Dec;47(6):477-511 (185 ref.)

PHARMACOLOGY

The sodium-calcium exchanger and glutamate-induced calcium loads in aged hippocampal neurons in vitro. Mills LR. **Ann N Y Acad Sci** 1996 Apr 15;779:379-90 (39 ref.)

Get receptive to metabotropic glutamate receptors. Pin JP, et al. **Curr Opin Neurobiol** 1995 Jun;5(3):342-9 (60 ref.)

Excitotoxicity and neurodegenerative diseases. Ikonomidou C, et al. **Curr Opin Neurol** 1995 Dec;8(6):487-97 (182 ref.)

Co-agonism in drug-receptor interaction: illustrated by the NMDA receptors. Corsi M, et al. **Trends Pharmacol Sci** 1996 Jun;17(6):220-2 (14 ref.)

PHYSIOLOGY

Glutamate excitotoxicity in transient global cerebral ischemia. Paschen W. **Acta Neurobiol Exp (Warsz)** 1996; 56(1):313-22 (68 ref.)

Contribution of dopaminergic and glutamatergic mechanisms to the pathogenesis of motor response complications in Parkinson's disease. Chase TN, et al. **Adv Neurol** 1996; 69:497-501 (30 ref.)

Ethanol neurobehavioural teratogenesis and the role of L-glutamate in the fetal hippocampus. Reynolds JD, et al. **Can J Physiol Pharmacol** 1995 Sep;73(9):1209-23 (175 ref.)

The phencyclidine-glutamate model of schizophrenia. Halberstadt AL. **Clin Neuropharmacol** 1995 Jun; 18(3):237-49 (108 ref.)

Glutamate and Parkinson's disease. Blandini F, et al. **Mol Neurobiol** 1996 Feb;12(1):73-94 (165 ref.)

The usual suspects: GABA and glutamate may regulate proliferation in the neocortex. LaMantia AS. **Neuron** 1995 Dec;15(6):1223-5 (25 ref.)

[The excito-toxicity theory of glaucomatous neuropathy. General review] Bonne C, et al. **J Fr Ophtalmol** 1996; 19(1):69-74 (46 ref.) **(Fre)**

[Role of glutamate and excitotoxicity in neurologic diseases] Hugon J, et al. **Rev Neurol (Paris)** 1996 Apr;152(4):239-48 (115 ref.) (Eng. Abstr.) **(Fre)**

SECRETION

Neuroprotective use-dependent blockers of Na+ and Ca2+ channels controlling presynaptic release of glutamate. Goldin SM, et al. **Ann N Y Acad Sci** 1995 Sep 15;765:210-29 (59 ref.)

GLUTAMIC ACID-SPECIFIC TRNA see **RNA, TRANSFER, GLU**

GLUTAMIC-OXALOACETIC TRANSAMINASE see **ASPARTATE AMINOTRANSFERASE**

GLUTAMIC-PYRUVIC TRANSAMINASE see **ALANINE AMINOTRANSFERASE**

GLUTAMINASE

PHYSIOLOGY

Regulation of glutaminase activity and glutamine metabolism. Curthoys NP, et al. **Annu Rev Nutr** 1995;15:133-59 (140 ref.)

GLUTAMINE

Glutamine. Hall JC, et al. **Br J Surg** 1996 Mar;83(3):305-12 (102 ref.)

ADMINISTRATION & DOSAGE

Glutamine--a conditionally essential amino acid in cirrhosis? Teran JC, et al. **Am J Clin Nutr** 1995 Nov;62(5):897-900 (40 ref.)

Nutritional pharmacology and malignant disease: a therapeutic modality in patients with cancer. Heys SD, et al. **Br J Surg** 1996 May;83(5):608-19 (135 ref.)

GENETICS

When more is less: pathogenesis of glutamine repeat neurodegenerative diseases. Ross CA. **Neuron** 1995 Sep; 15(3):493-6 (35 ref.)

METABOLISM

Regulation of glutaminase activity and glutamine metabolism. Curthoys NP, et al. **Annu Rev Nutr** 1995;15:133-59 (140 ref.)

Metabolic trafficking between neurons and astrocytes: the glutamate/glutamine cycle revisited. Westergaard N, et al. **Dev Neurosci** 1995;17(4):203-11 (97 ref.)

Glutamine nutrition and metabolism: where do we go from here ? Neu J, et al. **FASEB J** 1996 Jun;10(8):829-37 (43 ref.)

Glutamine metabolism and transport in skeletal muscle and heart and their clinical relevance. Rennie MJ, et al. **J Nutr** 1996 Apr;126(4 Suppl):1142S-9S (33 ref.)

The role of glutamine, short-chain fatty acids, and nucleotides in intestinal adaptation to gastrointestinal disease. LeLeiko NS, et al. **Pediatr Clin North Am** 1996 Apr;43(2):451-70 (98 ref.)

Regulation of gut glutamine metabolism: role of hormones and cytokines. Abumrad NN, et al. **Proc Nutr Soc** 1995 Jul;54(2):525-33 (33 ref.)

[The metabolic role of glutamine] Balzola FA, et al. **Minerva Gastroenterol Dietol** 1996 Mar;42(1):17-26 (96 ref.) (Eng. Abstr.) **(Ita)**

PHYSIOLOGY

The possible role of glutamine in some cells of the immune system and the possible consequence for the whole animal. Newsholme EA. **Experientia** 1996 May 15;52(5):455-9 (20 ref.)

TOXICITY

Amplification of glutamate-induced oxidative stress. Savolainen KM, et al. **Toxicol Lett** 1995 Dec;82-83:399-405 (46 ref.)

GLUTAMINE KETOGLUTARATE AMIDOTRANSFERASE see **GLUTAMATE SYNTHASE**

GLUTAMYL TRANSPEPTIDASE see **GAMMA-GLUTAMYLTRANSFERASE**

GLUTARAL

ADVERSE EFFECTS

Disinfectant colitis. Rinse as well as you wash [editorial] Ryan CK, et al. **J Clin Gastroenterol** 1995 Jul;21(1):6-9 (23 ref.)

GLUTARALDEHYDE see **GLUTARAL**

GLUTARALDEHYDE-STABILIZED GRAFTS see **BIOPROSTHESIS**

GLUTARATES

BLOOD

[Glutaric aciduria type 2 (multiple acyl-CoA dehydrogenase deficiency)] Yamaguchi S. **Ryoikibetsu Shokogun Shirizu** 1995;(8):325-8 (20 ref.) **(Jpn)**

GLUTATHIONE

Glutathione in health and disease: pharmacotherapeutic issues. Lomaestro BM, et al. **Ann Pharmacother** 1995 Dec; 29(12):1263-73 (80 ref.)

GLUTATHIONE

ANALOGS & DERIVATIVES

Advances in glyoxalase research. Glyoxalase expression in malignancy, anti-proliferative effects of methylglyoxal, glyoxalase I inhibitor diesters and S-D-lactoylglutathione, and methylglyoxal-modified protein binding and endocytosis by the advanced glycation endproduct receptor. Thornalley PJ. **Crit Rev Oncol Hematol** 1995 Aug;20(1-2):99-128 (225 ref.)

BLOOD

[Measurement of glutathione] Fujii H. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:215-7 (3 ref.) **(Jpn)**

DRUG EFFECTS

Three cases of hereditary nonspherocytic hemolytic anemia associated with red blood cell glutathione deficiency. Hirono A, et al. **Blood** 1996 Mar 1;87(5):2071-4 (28 ref.)

METABOLISM

Nutritional and hormonal regulation of glutathione homeostasis. Taylor CG, et al. **Curr Top Cell Regul** 1996; 34:189-208 (129 ref.)

Enzymes and transport systems involved in the formation and disposition of glutathione S-conjugates. Role in bioactivation and detoxication mechanisms of xenobiotics. Commandeur JN, et al. **Pharmacol Rev** 1995 Jun; 47(2):271-330 (596 ref.)

Variability in glutathione-dependent detoxication in vivo and its relevance to detoxication of chemical mixtures. Jones DP, et al. **Toxicology** 1995 Dec 28;105(2-3):267-74 (40 ref.)

PHARMACOLOGY

Antioxidants and immune response in aged persons: overview of present evidence. Meydani SN, et al. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1462S-1476S (146 ref.)

PHYSIOLOGY

Glutathione and drug resistance. Schröder CP, et al. **Cancer Invest** 1996;14(2):158-68 (122 ref.)

Glutathione and related enzymes in multidrug resistance. O'Brien ML, et al. **Eur J Cancer** 1996 Jun;32A(6):967-78 (147 ref.)

[Glutathione homeostasis: the cardinal physiological defense against oxygen toxicity induced by physical exercise] Sen CK, et al. **Fiziol Zh Im I M Sechenova** 1995 Nov; 81(11):143-50 (15 ref.) **(Rus)**

THERAPEUTIC USE

N-acetylcysteine (NAC) and glutathione (GSH): antioxidant and chemopreventive properties, with special reference to lung cancer. van Zandwijk N. **J Cell Biochem Suppl** 1995; 22:24-32 (48 ref.)

GLUTATHIONE S-ALKYLTRANSFERASE see **GLUTATHIONE TRANSFERASES**

GLUTATHIONE S-ARYLTRANSFERASE see **GLUTATHIONE TRANSFERASES**

GLUTATHIONE S-EPOXIDETRANSFERASE see **GLUTATHIONE TRANSFERASES**

GLUTATHIONE PEROXIDASE

BLOOD

[Glutathione peroxidase] Imura T, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:428-31 (13 ref.) **(Jpn)**

GLUTATHIONE REDUCTASE

BLOOD

[Erythrocyte glutathione reductase (EGR)] Yasuda K, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:218-20 (12 ref.) **(Jpn)**

CHEMISTRY

A glutathione reductase-like flavoenzyme of the malaria parasite Plasmodium falciparum: structural considerations based on the DNA sequence. Becker K, et al. **Biochem Soc Trans** 1996 Feb;24(1):67-72 (37 ref.)

GLUTATHIONE SYNTHETASE

DEFICIENCY

Three cases of hereditary nonspherocytic hemolytic anemia associated with red blood cell glutathione deficiency. Hirono A, et al. **Blood** 1996 Mar 1;87(5):2071-4 (28 ref.)

GLUTATHIONE TRANSFERASES

ANALYSIS

[Glutathione S-transferase as a metabolic biomarker for predisposition to lung neoplasms induced by chemical carcinogens] Lutz W, et al. **Med Pr** 1995;46(5):497-503 (14 ref.) (Eng. Abstr.) **(Pol)**

GENETICS

Specific factors leading to interindividual variability in response to occupational toxicants. Goergens HW. **Arch Toxicol Suppl** 1996;18:357-61 (28 ref.)

Metabolic polymorphisms and cancer susceptibility. Smith G, et al. **Cancer Surv** 1995;25:27-65 (249 ref.)

The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Hayes JD, et al. **Crit Rev Biochem Mol Biol** 1995;30(6):445-600 (779 ref.)

Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer. Nebert DW, et al. **DNA Cell Biol** 1996 Apr;15(4):273-80 (96 ref.)

Genetic polymorphisms of drug-metabolizing enzymes and lung cancer susceptibility. Kawajiri K, et al. **Pharmacogenetics** 1995;5 Spec No:S70-3 (17 ref.)

METABOLISM

Lens crystallins of invertebrates--diversity and recruitment from detoxification enzymes and novel proteins. Tomarev SI, et al. **Eur J Biochem** 1996 Feb 1;235(3):449-65 (225 ref.)

Leukotriene C4 synthase. Lam BK, et al. **J Lipid Mediat Cell Signal** 1995 Oct;12(2-3):333-41 (52 ref.)

PHYSIOLOGY

The role of glutathione S-transferases in head and neck squamous cell carcinogenesis. Bongers V, et al. **Eur J Cancer B Oral Oncol** 1995 Nov;31B(6):349-54 (63 ref.)

GLUTEAL REGION see **BUTTOCKS**

GLUTEN

ADVERSE EFFECTS

Coeliac disease in adults. Corazza GR, et al. **Baillieres Clin Gastroenterol** 1995 Jun;9(2):329-50 (105 ref.)

Coeliac disease research and clinical practice: maintaining momentum into the twenty-first century. Ferguson A. **Baillieres Clin Gastroenterol** 1995 Jun;9(2):395-412 (41 ref.)

Dermatitis herpetiformis. Fry L. **Baillieres Clin Gastroenterol** 1995 Jun;9(2):371-93 (65 ref.)

Coeliac disease in childhood. Littlewood JM. **Baillieres Clin Gastroenterol** 1995 Jun;9(2):295-327 (125 ref.)

Morphology of the mucosal lesion in gluten sensitivity. Marsh MN, et al. **Baillieres Clin Gastroenterol** 1995 Jun; 9(2):273-93 (60 ref.)

The precipitating factor in coeliac disease. Wieser H. **Baillieres Clin Gastroenterol** 1995 Jun;9(2):191-207 (63 ref.)

The major complications of coeliac disease. Wright DH. **Baillieres Clin Gastroenterol** 1995 Jun;9(2):351-69 (65 ref.)

IMMUNOLOGY

The humoral immune system in coeliac disease. Mäki M. **Baillieres Clin Gastroenterol** 1995 Jun;9(2):231-49 (115 ref.)

The gluten-host interaction. Tighe MR, et al. **Baillieres Clin Gastroenterol** 1995 Jun;9(2):211-30 (42 ref.)

T-cell responses and cellular immunity in coeliac disease. Trejdosiewicz LK, et al. **Baillieres Clin Gastroenterol** 1995 Jun;9(2):251-72 (160 ref.)

GLUTEN ENTEROPATHY see **CELIAC DISEASE**

GLYBURIDE

ADVERSE EFFECTS

Granulomatous hepatitis associated with glyburide. Saw D, et al. **Dig Dis Sci** 1996 Feb;41(2):322-5 (11 ref.)

GLYCANS see **POLYSACCHARIDES**

GLYCATION END PRODUCTS, ADVANCED see **GLYCOSYLATION END PRODUCTS, ADVANCED**

GLYCERALDEHYDEPHOSPHATE DEHYDROGENASE

CHEMISTRY

Glyceraldehyde-3-phosphate dehydrogenase from Thermotoga maritima: strategies of protein stabilization. Jaenicke R. **FEMS Microbiol Rev** 1996 May;18(2-3):215-24 (33 ref.)

METABOLISM

Glyceraldehyde-3-phosphate dehydrogenase: a target for nitric oxide signaling. Brüne B, et al. **Adv Pharmacol** 1995; 34:351-60 (30 ref.)

PHYSIOLOGY

Minireview. Emerging new functions of the glycolytic protein, glyceraldehyde-3-phosphate dehydrogenase, in mammalian cells. Sirover MA. **Life Sci** 1996;58(25):2271-7 (28 ref.)

GLYCERIDES

CHEMISTRY

The different conformations of the glycerol region of crystalline acylglycerols. Pascher I. **Curr Opin Struct Biol** 1996 Aug;6(4):439-48 (59 ref.)

GLYCERIN

ADMINISTRATION & DOSAGE

[Treatment of ischemic cerebral infarct with glycerine] Winter R, et al. **Nervenarzt** 1995 Aug;66(8):596-602 (63 ref.) (Eng. Abstr.) **(Ger)**

GLYCEROL see **GLYCERIN**

GLYCERYL TRINITRATE see **NITROGLYCERIN**

GLYCINE

see related
RECEPTORS, GLYCINE

ANALOGS & DERIVATIVES

Pharmacological tools for the investigation of metabotropic glutamate receptors (mGluRs): phenylglycine derivatives and other selective antagonists--an update. Roberts PJ. **Neuropharmacology** 1995 Aug;34(8):813-9 (38 ref.)

BLOOD

[Hyperglycinemia without ketosis and NMDA receptor dysfunction] Ponsot G. **Arch Pediatr** 1996;3 Suppl 1:172s-175s (27 ref.) **(Fre)**

PHARMACOLOGY

Pharmacological tools for the investigation of metabotropic glutamate receptors (mGluRs): phenylglycine derivatives and other selective antagonists--an update. Roberts PJ. **Neuropharmacology** 1995 Aug;34(8):813-9 (38 ref.)

Co-agonism in drug-receptor interaction: illustrated by the NMDA receptors. Corsi M, et al. **Trends Pharmacol Sci** 1996 Jun;17(6):220-2 (14 ref.)

GLYCINE MAX see **SOYBEANS**

GLYCINE RECEPTORS see **RECEPTORS, GLYCINE**

GLYCOCONJUGATES

ADMINISTRATION & DOSAGE

Receptor mediated glycotargeting. Wadhwa MS, et al. **J Drug Target** 1995;3(2):111-27 (179 ref.)

ANALYSIS

Alterations in glycoconjugates related to the transformation grade of human uroepithelial cell lines. Ugorski M, et al. **Arch Immunol Ther Exp (Warsz)** 1995;43(3-4):161-6 (42 ref.)

ANTAGONISTS & INHIBITORS

The surface glycoconjugates of parasitic protozoa: potential targets for new drugs. McConville MJ. **Aust N Z J Med** 1995 Dec;25(6):768-76 (40 ref.)

BIOSYNTHESIS

Glycobiology of the cell surface: the emergence of sugars as an important feature of the cell periphery. Cook GM. **Glycobiology** 1995 Jul;5(5):449-58 (74 ref.)

CHEMICAL SYNTHESIS

Glycosylation reactions--present status future directions. Whitfield DM, et al. **Glycoconj J** 1996 Feb;13(1):5-17 (82 ref.)

CHEMISTRY

Neoglycoconjugates and their applications in glycobiology. Wong SY. **Curr Opin Struct Biol** 1995 Oct;5(5):599-604 (53 ref.)

Glycosylation reactions--present status future directions. Whitfield DM, et al. **Glycoconj J** 1996 Feb;13(1):5-17 (82 ref.)

IMMUNOLOGY

A role for glycoconjugates in human development: the human feto-embryonic defence system hypothesis. Clark GF, et al. **Hum Reprod** 1996 Mar;11(3):467-73 (62 ref.)

Cholinergic-specific glycoconjugates. Whittaker VP, et al. **Neurochem Res** 1995 Nov;20(11):1377-87 (47 ref.)

METABOLISM

Microbial recognition of target-cell glycoconjugates. Karlsson KA. **Curr Opin Struct Biol** 1995 Oct;5(5):622-35 (74 ref.)

Glycobiology of schistosomiasis. Cummings RD, et al. **FASEB J** 1996 Jun;10(8):838–48 (91 ref.)
Galactofuranose-containing glycoconjugates in trypanosomatids. de Lederkremer RM, et al. **Glycobiology** 1995 Sep;5(6):547–52 (42 ref.)

PHYSIOLOGY

A role for glycoconjugates in human development: the human feto-embryonic defence system hypothesis. Clark GF, et al. **Hum Reprod** 1996 Mar;11(3):467–73 (62 ref.)
[Protein-carbohydrate recognition. Foundation and medical application with illustrations of tumor lectin studies] Gabius HJ, et al. **Naturwissenschaften** 1995 Dec;82(12):533–43 (162 ref.) (Eng. Abstr.) **(Ger)**

GLYCOGEN

ANALYSIS

Glycogen levels and obesity. Flatt JP. **Int J Obes Relat Metab Disord** 1996 Mar;20 Suppl 2:S1–11 (48 ref.)

BIOSYNTHESIS

In vivo regulation of muscle glycogen synthase and the control of glycogen synthesis. Shulman RG, et al. **Proc Natl Acad Sci U S A** 1995 Sep 12;92(19):8535–42 (64 ref.)

METABOLISM

From glycogen to amylopectin: a model for the biogenesis of the plant starch granule. Ball S, et al. **Cell** 1996 Aug 9;86(3):349–52 (18 ref.)
Nuclear magnetic resonance studies of muscle and applications to exercise and diabetes. Shulman RG, et al. **Diabetes** 1996 Jan;45 Suppl 1:S93–8 (20 ref.)
Inhibition of citrate lyase may aid aerobic endurance. McCarty MF. **Med Hypotheses** 1995 Sep;45(3):247–54 (77 ref.)
Glycosomes--the organelles of glycogen metabolism. Rybicka KK. **Tissue Cell** 1996 Jun;28(3):253–65 (63 ref.)

GLYCOGEN PHOSPHORYLASE

DEFICIENCY

Genetic deficiencies of the glycogen phosphorylase system. Hendrickx J, et al. **Hum Genet** 1996 May;97(5):551–6 (51 ref.)

GENETICS

Genetic deficiencies of the glycogen phosphorylase system. Hendrickx J, et al. **Hum Genet** 1996 May;97(5):551–6 (51 ref.)

GLYCOGEN STORAGE DISEASE

[Lysosomal glycogen storage disease without acid maltase deficiency] Usuki F, et al. **Nippon Rinsho** 1995 Dec; 53(12):3050–4 (15 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Genetic deficiencies of the glycogen phosphorylase system. Hendrickx J, et al. **Hum Genet** 1996 May;97(5):551–6 (51 ref.)

PHYSIOPATHOLOGY

The hepatic glycogen storage diseases--problems beyond childhood. Lee PJ, et al. **J Inherit Metab Dis** 1995; 18(4):462–72 (42 ref.)

GLYCOGEN STORAGE DISEASE TYPE I

COMPLICATIONS

Renal involvement in type I glycogen storage disease. Chen YT, et al. **Adv Nephrol Necker Hosp** 1995;24:357–65 (52 ref.)

PATHOLOGY

Type Ia glycogen storage disease with focal nodular hyperplasia in siblings. Takamura M, et al. **Acta Paediatr Jpn** 1995 Aug;37(4):510–3 (20 ref.)

GLYCOGEN STORAGE DISEASE TYPE II

[Glycogenosis type II; acid alpha-glucosidase deficiency] Hirayasu T, et al. **Nippon Rinsho** 1995 Dec;53(12):2938–42 (22 ref.) (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

Surgical treatment of myogenic blepharoptosis. De Wilde F, et al. **Bull Soc Belge Ophtalmol** 1995;255:139–46 (9 ref.)

GLYCOGEN STORAGE DISEASE TYPE VII

GENETICS

Mutations in muscle phosphofructokinase gene. Raben N, et al. **Hum Mutat** 1995;6(1):1–6 (37 ref.)

GLYCOGEN SYNTHASE

METABOLISM

Regulation of glycogen synthase activation in isolated hepatocytes. Pugazhenthi S, et al. **Mol Cell Biochem** 1995 Aug–Sep;149–150:95–101 (66 ref.)
In vivo regulation of muscle glycogen synthase and the control of glycogen synthesis. Shulman RG, et al. **Proc Natl Acad Sci U S A** 1995 Sep 12;92(19):8535–42 (64 ref.)

GLYCOGEN SYNTHASE KINASES see **CALMODULIN-DEPENDENT PROTEIN KINASES**

GLYCOGEN SYNTHETASE see **GLYCOGEN SYNTHASE**

GLYCOGENOSIS see **GLYCOGEN STORAGE DISEASE**

GLYCOGENOSIS 1 see **GLYCOGEN STORAGE DISEASE TYPE I**

GLYCOGENOSIS 2 see **GLYCOGEN STORAGE DISEASE TYPE II**

GLYCOGENOSIS 7 see **GLYCOGEN STORAGE DISEASE TYPE VII**

GLYCOHEMOGLOBIN A see **HEMOGLOBIN A, GLYCOSYLATED**

GLYCOLATES

see related
POLYGLYCOLIC ACID

GLYCOLIPIDS

ANALYSIS

[Glycolipid analysis by confocal laser scanning microscopic system] Itoh K. **Nippon Rinsho** 1995 Dec;53(12):3095–101 (11 ref.) (Eng. Abstr.) **(Jpn)**
[Glycolipids] Semba U, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:674–7 (20 ref.) **(Jpn)**
[Importance of taxonomic and immunologic lipid markers of actinomycetes and similar bacteria] Szponar B. **Postepy Hig Med Dosw** 1995;49(1):161–70 (25 ref.) (Eng. Abstr.) **(Pol)**

BIOSYNTHESIS

Production of rhamnolipid biosurfactants. Ochsner UA, et al. **Adv Biochem Eng Biotechnol** 1996;53:89–118 (70 ref.)

CHEMISTRY

The variable surface glycolipids of mycobacteria: structures, synthesis of epitopes, and biological properties. Aspinall GO, et al. **Adv Carbohydr Chem Biochem** 1995;51:169–242 (226 ref.)
Neoglycoconjugates and their applications in glycobiology. Wong SY. **Curr Opin Struct Biol** 1995 Oct;5(5):599–604 (53 ref.)

METABOLISM

[Metabolic pathway of the degradation of macromolecules by lysosomal enzymes] Arai K, et al. **Nippon Rinsho** 1995 Dec;53(12):2904–10 (12 ref.) (Eng. Abstr.) **(Jpn)**

GLYCOLS

CHEMISTRY

What is the basis of sequence-directed curvature in DNAs containing A tracts? Harvey SC, et al. **J Biomol Struct Dyn** 1995 Oct;13(2):301–7 (55 ref.)

GLYCOLYSIS

Conservation, evolution, and specificity in cellular control by protein phosphorylation. Hofer HW. **Experientia** 1996 May 15;52(5):449–54 (27 ref.)
Control of adenine nucleotide metabolism and glycolysis in vertebrate skeletal muscle during exercise. Krause U, et al. **Experientia** 1996 May 15;52(5):396–403 (51 ref.)
The Pasteur effect in facultative anaerobic metazoa. Schmidt H, et al. **Experientia** 1996 May 15;52(5):440–8 (89 ref.)
Regulation and control of compartmentalized glycolysis in bloodstream form Trypanosoma brucei. Bakker BM, et al. **J Bioenerg Biomembr** 1995 Oct;27(5):513–25 (63 ref.)

GENETICS

Control of glycolytic gene expression in the budding yeast (Saccharomyces cerevisiae). Chambers A, et al. **Curr Genet** 1995 Dec;29(1):1–9 (100 ref.)

PHYSIOLOGY

Ageing, oscillations and efficiency. Gilbert DA. **Biosystems** 1995;36(1):1–5 (30 ref.)
Hereditary red cell enzymopathies. Arya R, et al. **Blood Rev** 1995 Sep;9(3):165–75 (155 ref.)

GLYCOPEPTIDES

ANALYSIS

Analysis of glycoproteins, glycopeptides and glycoprotein-derived oligosaccharides by high-performance capillary electrophoresis. Kakehi K, et al. **J Chromatogr A** 1996 Jan 12;720(1–2):377–93 (48 ref.)

BIOSYNTHESIS

Glycopeptides. Zmijewski MJ Jr, et al. **Biotechnology** 1995; 28:269–81 (49 ref.)
Chemical and enzymatic synthesis of glycopeptides. Schultz M, et al. **EXS** 1995;73:201–28 (80 ref.)

CHEMICAL SYNTHESIS

Glycopeptides. Zmijewski MJ Jr, et al. **Biotechnology** 1995; 28:269–81 (49 ref.)
Chemical and enzymatic synthesis of glycopeptides. Schultz M, et al. **EXS** 1995;73:201–28 (80 ref.)

GLYCOPHORIN

GENETICS

German population data on the loci low-density-lipoprotein receptor, glycophorin A, hemoglobin gamma G, D7S8 and group-specific component. Huckenbeck W, et al. **Anthropol Anz** 1995 Sep;53(3):193–8 (14 ref.)
Molecular genetics of the glycophorin gene family, the antigens for MNSs blood groups: multiple gene rearrangements and modulation of splice site usage result in extensive diversification. Blumenfeld OO, et al. **Hum Mutat** 1995;6(3):199–209 (52 ref.)
MNSs and major glycophorins of human erythrocytes. Cartron JP, et al. **Transfus Clin Biol** 1995;2(4):251–8 (12 ref.)
Gerbich blood groups and minor glycophorins of human erythrocytes. Colin Y. **Transfus Clin Biol** 1995;2(4):259–68 (47 ref.)

IMMUNOLOGY

[Studies on diversification and restriction of immune response against glycopeptide antigens] Czerwiński M. **Postepy Hig Med Dosw** 1995;49(1):23–31 (47 ref.) (Eng. Abstr.) **(Pol)**

GLYCOPROTEIN HORMONES, ALPHA SUBUNIT

BIOSYNTHESIS

The role of transcription factors in the pituitary expression of the glycoprotein hormone alpha-subunit gene. Aylwin SJ, et al. **J Mol Endocrinol** 1995 Dec;15(3):221–31 (82 ref.)

GLYCOPROTEIN SIALYLTRANSFERASES see **SIALYLTRANSFERASES**

GLYCOPROTEIN SYNDROME, CARBOHYDRATE-DEFICIENT see **CARBOHYDRATE-DEFICIENT GLYCOPROTEIN SYNDROME**

GLYCOPROTEINS

ADVERSE EFFECTS

Specific immunotherapy in house dust mite allergy. Bousquet J, et al. **Clin Rev Allergy Immunol** 1995 Summer;13(2):151–9 (57 ref.)
Atopic dermatitis and delayed hypersensitivity to dust mites. Castelain M. **Clin Rev Allergy Immunol** 1995 Summer; 13(2):161–72 (53 ref.)

ANALYSIS

Differential release of molecular markers in joint disease. Saxne T. **Acta Orthop Scand Suppl** 1995 Oct;266:80–3 (29 ref.)
TAG-72 expression and its role in the biological evaluation of human colorectal cancer. Guadagni F, et al. **Anticancer Res** 1996 Jul–Aug;16(4B):2141–8 (71 ref.)
Matrix-assisted laser desorption/ionisation mass spectrometry of oligosaccharides and glycoconjugates. Harvey DJ. **J Chromatogr A** 1996 Jan 12;720(1–2):429–46 (64 ref.)
Analysis of glycoproteins, glycopeptides and glycoprotein-derived oligosaccharides by high-performance capillary electrophoresis. Kakehi K, et al. **J Chromatogr A** 1996 Jan 12;720(1–2):377–93 (48 ref.)
Enzymatic release of oligosaccharides from glycoproteins for chromatographic and electrophoretic analysis. O'Neill RA.

GLYCOPROTEINS

J Chromatogr A 1996 Jan 12;720(1-2):201-15 (101 ref.)
Ultrastructure and histochemistry of acid mucus glycoproteins in the estrous mammal oviduct. Jansen RP. Microsc Res Tech 1995 Sep 1;32(1):24-49 (80 ref.)
Radioimmunoguided Surgery system improves survival for patients with recurrent colorectal cancer. Bertsch DJ, et al. Surgery 1995 Oct;118(4):634-8; discussion 638-9 (9 ref.)

BIOSYNTHESIS

Characterization of a new gene that encodes a functional MHV receptor and progress in the identification of the virus-binding site(s). Dveksler G, et al. Adv Exp Med Biol 1995;380:345-50 (18 ref.)
Recombinant glycoprotein production in the slime mould Dictyostelium discoideum. Williams KL, et al. Curr Opin Biotechnol 1995 Oct;6(5):538-42 (43 ref.)

BLOOD

The role of beta 2-glycoprotein I in the antiphospholipid syndrome. Krilis SA, et al. Lupus 1996 Apr;5(2):150-2 (16 ref.)
[Alpha 1-T glycoprotein] Itoh Y. Nippon Rinsho 1995 Feb; 53 Su Pt 1:171-4 (4 ref.) (Jpn)

CHEMISTRY

A review of the biological significance of carbohydrates on glycoproteins and methods for their analysis. Dennis RP. Adv Exp Med Biol 1995;376:1-11 (30 ref.)
Characterization of protein glycosylation by mass spectrometry. Burlingame AL. Curr Opin Biotechnol 1996 Feb;7(1):4-10 (78 ref.)
The structural role of sugars in glycoproteins. Wyss DF, et al. Curr Opin Biotechnol 1996 Aug;7(4):409-16 (44 ref.)
Neoglycoconjugates and their applications in glycobiology. Wong SY. Curr Opin Struct Biol 1995 Oct;5(5):599-604 (53 ref.)
O-linked protein glycosylation structure and function. Hounsell EF, et al. Glycoconj J 1996 Feb;13(1):19-26 (102 ref.)
EP-GP and the lipocalin VEGh, two different human salivary 20-kDa proteins. Schenkels LC, et al. J Dent Res 1995 Sep;74(9):1543-50 (80 ref.)
Structure and function of peripheral nerve myelin proteins. Uyemura K, et al. Prog Brain Res 1995;105:311-8 (27 ref.)

DEFICIENCY

[Niemann-Pick disease types A and B] Ohno K. Nippon Rinsho 1995 Dec;53(12):3014-8 (7 ref.) (Eng. Abstr.) (Jpn)

DRUG EFFECTS

Pharmacological regulation of gastric mucous glycoprotein secretion. Heim HK, et al. Eur J Gastroenterol Hepatol 1995 Nov;7(11):1105-22 (364 ref.)

GENETICS

Characterization of a new gene that encodes a functional MHV receptor and progress in the identification of the virus-binding site(s). Dveksler G, et al. Adv Exp Med Biol 1995;380:345-50 (18 ref.)
[Disorders of sphingolipid activator proteins] Suzuki Y. Nippon Rinsho 1995 Dec;53(12):3025-7 (14 ref.) (Eng. Abstr.) (Jpn)

IMMUNOLOGY

Dust mite allergens. Stewart GA. Clin Rev Allergy Immunol 1995 Summer;13(2):135-50 (65 ref.)
Anticardiolipin antibodies and beta 2-glycoprotein I. Koike T, et al. Lupus 1996 Apr;5(2):156-7 (13 ref.)

ISOLATION & PURIFICATION

Cholesterol nucleation in bile. Holzbach RT. Ital J Gastroenterol 1995 Mar;27(2):101-5 (38 ref.)
Fractionation of glycoprotein-derived oligosaccharides by affinity chromatography using immobilized lectin columns. Endo T. J Chromatogr A 1996 Jan 12;720(1-2):251-61 (66 ref.)

METABOLISM

The tartrate-resistant purple acid phosphatase of bone osteoclasts--a protein phosphatase with multivalent substrate specificity and regulation. Andersaon G, et al. Acta Orthop Scand Suppl 1995 Oct;266:189-94 (28 ref.)
Matrix metalloproteinases and their inhibitors. Murphy G. Acta Orthop Scand Suppl 1995 Oct;266:55-60 (53 ref.)
Carbohydrate-protein interactions in vascular biology. Nelson RM, et al. Ann Rev Cell Dev Biol 1995;11:601-31 (185 ref.)
Proteolytic remodeling of extracellular matrix. Birkedal-Hansen H. Curr Opin Cell Biol 1995 Oct; 7(5):728-35 (61 ref.)
O-linked protein glycosylation structure and function. Hounsell EF, et al. Glycoconj J 1996 Feb;13(1):19-26 (102 ref.)
N-glycosylation/deglycosylation as a mechanism for the post-translational modification/remodification of proteins. Suzuki T, et al. Glycoconj J 1995 Jun;12(3):183-93 (141 ref.)
Molecular role of sulfated glycoprotein-1 (SGP-1/prosaposin) in Sertoli cells. Morales CR, et al. Histol Histopathol 1995 Oct;10(4):1023-34 (11 ref.)
Surfactant protein-D modulates interaction of Pneumocystis carinii with alveolar macrophages [see comments] Limper AH, et al. J Lab Clin Med 1995 Nov;126(5):416-22 (37 ref.) Comment in: J Lab Clin Med 1995 Nov;126(5):414-5.
Are there biological functions for bacterial endo-N-acetyl-beta-D-glucosaminidases? Karamanos Y, et al. Res Microbiol 1995 Jul-Aug;146(6):437-43 (42 ref.)
[Metabolic pathway of the degradation of macromolecules by lysosomal enzymes] Arai K, et al. Nippon Rinsho 1995 Dec;53(12):2904-10 (12 ref.) (Eng. Abstr.) (Jpn)
[Disorders of glycoprotein degradation] Yoshida K, et al. Nippon Rinsho 1995 Dec;53(12):2973-81 (23 ref.) (Eng. Abstr.) (Jpn)

PHARMACOLOGY

Single-chain fusion toxins for the treatment of breast cancer: antitumor activity of BR96 sFv-PE40 and heregulin-PE40. Siegall CB. Recent Results Cancer Res 1996;140:51-60 (21 ref.)

PHYSIOLOGY

A review of the biological significance of carbohydrates on glycoproteins and methods for their analysis. Dennis RP. Adv Exp Med Biol 1995;376:1-11 (30 ref.)
Neuregulins and their receptors. Carraway KL 3rd, et al. Curr Opin Neurobiol 1995 Oct;5(5):606-12 (54 ref.)
Stimulation and regulation of tumor cell motility in invasion and metastasis. Levine MD, et al. EXS 1995;74:157-79 (135 ref.)
The roles of tissue inhibitors of metalloproteinases in tissue remodelling and cell growth. Edwards DR, et al. Int J Obes Relat Metab Disord 1996 Mar;20 Suppl 3:S9-15 (59 ref.)
Implication of inhibin and related proteins in fetal development. Jenkin G, et al. Reprod Fertil Dev 1995; 7(3):323-31 (71 ref.)
[Lysosomal enzymes, sphingolipid activator proteins, and protective protein] Suzuki Y. Nippon Rinsho 1995 Dec; 53(12):2887-91 (7 ref.) (Eng. Abstr.) (Jpn)

GLYCOSAMINOGLYCANS

[A new avenue of proteoglycan studies: reconstruction of glycosaminoglycan chains using endo-type glycosidases] Endo M, et al. Seikagaku 1995 Nov;67(11):1269-82 (84 ref.) (Jpn)

ANALYSIS

Cartilage matrix molecules in serum and synovial fluid. Simkin PA, et al. Curr Opin Rheumatol 1995 Jul;7(4):346-51 (28 ref.)
High-performance liquid chromatographic analysis of glycosaminoglycan-derived oligosaccharides. Imanari T, et al. J Chromatogr A 1996 Jan 12;720(1-2):275-93 (134 ref.)
[Glycosaminoglycans] Murata K. Nippon Rinsho 1995 Feb; 53 Su Pt 1:561-5 (22 ref.) (Jpn)

CHEMISTRY

[Glycosaminoglycans--structure and function] Głowacki A, et al. Postepy Biochem 1995;41(2):139-48 (98 ref.) (Pol)

METABOLISM

Carbohydrate-protein interactions in vascular biology. Nelson RM, et al. Ann Rev Cell Dev Biol 1995;11:601-31 (185 ref.)
Enzymatic degradation of glycosaminoglycans. Ernst S, et al. Crit Rev Biochem Mol Biol 1995;30(5):387-444 (267 ref.)
[Role of glycosoaminoglycans in venous disease. Mode of action of some flavonoid drugs] Drubaix I, et al. Pathol Biol (Paris) 1995 May;43(5):461-70 (37 ref.) (Eng. Abstr.) (Fre)

PHYSIOLOGY

Glycosaminoglycans contribute to multiple functions of vascular endothelial cells. Cockwell P, et al. Clin Exp Immunol 1996 Apr;104(1):1-3 (30 ref.)
[Role of glycosaminoglycans relating to formation of urolithiasis] Nishio S. Nippon Hinyokika Gakkai Zasshi 1995 Nov;86(11):1597-609 (99 ref.) (Jpn)
[Glycosaminoglycans--structure and function] Głowacki A, et al. Postepy Biochem 1995;41(2):139-48 (98 ref.) (Pol)

THERAPEUTIC USE

Glycosaminoglycans: a new paradigm in the prevention of proteinuria and progression of glomerular disease [editorial] Gambaro G, et al. Nephrol Dial Transplant 1996 May; 11(5):762-4 (17 ref.)

GLYCOSIDASES see **GLYCOSIDE HYDROLASES**

GLYCOSIDE ANTIBIOTICS see **ANTIBIOTICS, AMINOGLYCOSIDE**

GLYCOSIDE HYDROLASES

Specific beta glucanases as tools for polysaccharide structure determination. Mishra C, et al. Glycobiology 1995 Oct; 5(7):645-54 (84 ref.)
[A new avenue of proteoglycan studies: reconstruction of glycosaminoglycan chains using endo-type glycosidases] Endo M, et al. Seikagaku 1995 Nov;67(11):1269-82 (84 ref.) (Jpn)

ANTAGONISTS & INHIBITORS

Glycosylation inhibitors in biology and medicine. Jacob GS. Curr Opin Struct Biol 1995 Oct;5(5):605-11 (44 ref.)

CHEMISTRY

Biochemical properties and function of poly(ADP-ribose) glycohydrolase. Desnoyers S, et al. Biochimie 1995; 77(6):433-8 (44 ref.)
Intestinal brush border glycohydrolases: structure, function, and development. Van Beers EH, et al. Crit Rev Biochem Mol Biol 1995;30(3):197-262 (295 ref.)
Chitinases, chitosanases, and lysozymes can be divided into procaryotic and eucaryotic families sharing a conserved core. Monzingo AF, et al. Nat Struct Biol 1996 Feb; 3(2):133-40 (27 ref.)
Structures and mechanisms of glycosyl hydrolases. Davies G, et al. Structure 1995 Sep 15;3(9):853-9 (49 ref.)

METABOLISM

Mechanisms in the glucansucrase synthesis of polysaccharides and oligosaccharides from sucrose. Robyt JF. Adv Carbohydr Chem Biochem 1995;51:133-68 (146 ref.)
Thermolabile folding intermediates: inclusion body precursors and chaperonin substrates. King J, et al. FASEB J 1996 Jan;10(1):57-66 (63 ref.)
Enzymatic release of oligosaccharides from glycoproteins for chromatographic and electrophoretic analysis. O'Neill RA. J Chromatogr A 1996 Jan 12;720(1-2):201-15 (101 ref.)
Oligosaccharide sequencing based on exo- and endoglycosidase digestion and liquid chromatographic analysis of the products. Prime S, et al. J Chromatogr A 1996 Jan 12;720(1-2):263-74 (92 ref.)
Structures and mechanisms of glycosyl hydrolases. Davies G, et al. Structure 1995 Sep 15;3(9):853-9 (49 ref.)

PHYSIOLOGY

Intestinal brush border glycohydrolases: structure, function, and development. Van Beers EH, et al. Crit Rev Biochem Mol Biol 1995;30(3):197-262 (295 ref.)

GLYCOSPHINGOLIPIDS

BLOOD

Biochemical characterization of blood group-active glycosphingolipids. Bouhours JF, et al. Transfus Clin Biol 1995;2(4):223-33 (50 ref.)

IMMUNOLOGY

Parasite escape mechanisms: the role of Leishmania lipophosphoglycan on the human phagocyte functions. A review. Panaro MA, et al. Immunopharmacol Immunotoxicol 1995 Aug;17(3):595-605 (50 ref.)

METABOLISM

[Cancer-associated alterations of glycoconjugates--special reference to glycosphingolipids] Taki T. Nippon Geka Gakkai Zasshi 1996 Feb;97(2):123-30 (44 ref.) (Eng. Abstr.) (Jpn)

PHARMACOKINETICS

[Clinical trials on ganglioside effectiveness] Horga JF, et al. Rev Neurol 1995 Jul-Aug;23(122):889-95 (90 ref.) (Spa)

PHYSIOLOGY

A reflection on the early history of glycosphingolipids. Yamakawa T. Glycoconj J 1996 Apr;13(2):123-6 (43 ref.)
Functional role of glycosphingolipids in cell recognition and signaling. Hakomori S, et al. J Biochem (Tokyo) 1995 Dec; 118(6):1091-103 (123 ref.)

THERAPEUTIC USE

[Clinical trials on ganglioside effectiveness] Horga JF, et al. Rev Neurol 1995 Jul-Aug;23(122):889-95 (90 ref.) (Spa)

GLYCOSURIA

Screening for NIDDM in nonpregnant adults. A review of principles, screening tests, and recommendations. Engelgau MM, et al. Diabetes Care 1995 Dec;18(12):1606-18 (118 ref.)
Tests of glycemia in diabetes. Goldstein DE, et al. Diabetes Care 1995 Jun;18(6):896-909 (144 ref.)

URINE

[Urine sugar] Goto Y. Nippon Rinsho 1995 Feb;53 Su Pt 1:133-7 (4 ref.) (Jpn)

GLYCOSYLATED HEMOGLOBIN A see HEMOGLOBIN A, GLYCOSYLATED

GLYCOSYLATION

see related
GLYCOSYLATION END PRODUCTS, ADVANCED
PROTEIN PROCESSING, POST-TRANSLATIONAL

Glycosylation reactions--present status future directions. Whitfield DM, et al. **Glycoconj J** 1996 Feb;13(1):5–17 (82 ref.)

GLYCOSYLATION END PRODUCTS, ADVANCED

ADVERSE EFFECTS

[Long-term complications in diabetes mellitus: role of irreversible glycosylation products] Treskes M, et al. **Ned Tijdschr Geneeskd** 1996 Jun 22;140(25):1299–303 (52 ref.) **(Dut)**

BIOSYNTHESIS

The pathological implications of protein glycation. Brownlee M. **Clin Invest Med** 1995 Aug;18(4):275–81 (22 ref.)

BLOOD

Advanced glycation end products in peritoneal dialysis. Dawnay A. **Perit Dial Int** 1996;16 Suppl 1:S50–3 (39 ref.)

METABOLISM

Beta 2-microglobulin modified with the AGE products of the Maillard reaction in dialysis-related amyloidosis. Miyata T, et al. **Contrib Nephrol** 1995;112:52–64 (52 ref.)

Formation of methylglyoxal-modified proteins in vitro and in vivo and their involvement in AGE-related processes. Thornalley PJ, et al. **Contrib Nephrol** 1995;112:24–31 (31 ref.)

Advances in glyoxalase research. Glyoxalase expression in malignancy, anti-proliferative effects of methylglyoxal, glyoxalase I inhibitor diesters and S-D-lactoylglutathione, and methylglyoxal-modified protein binding and endocytosis by the advanced glycation endproduct receptor. Thornalley PJ. **Crit Rev Oncol Hematol** 1995 Aug;20(1–2):99–128 (225 ref.)

RAGE: a novel cellular receptor for advanced glycation end products. Schmidt AM, et al. **Diabetes** 1996 Jul;45 Suppl 3:S77–80 (14 ref.)

Recent progress in advanced glycation and diabetic vascular disease: role of advanced glycation end product receptors. Vlassara H, et al. **Diabetes** 1996 Jul;45 Suppl 3:S65–6 (17 ref.)

New aspects in the pathogenesis of dialysis-related amyloidosis: pathophysiology of advanced glycation end products in renal failure. Miyata T. **Nippon Jinzo Gakkai Shi** 1996 May;38(5):191–7 (51 ref.)

PHYSIOLOGY

Advanced glycosylation end products in diabetic renal and vascular disease. Bucala R, et al. **Am J Kidney Dis** 1995 Dec;26(6):875–88 (114 ref.)

Advanced glycosylation end products modulate transcriptional regulations on mesangial cells. Iehara N, et al. **Contrib Nephrol** 1996;118:141–6 (13 ref.)

Crosslines, fluorophores in the AGE-related cross-linked proteins. Ienaga K, et al. **Contrib Nephrol** 1995;112:42–51 (14 ref.)

Role of Amadori-modified nonenzymatically glycated serum proteins in the pathogenesis of diabetic nephropathy [editorial] Cohen MP, et al. **J Am Soc Nephrol** 1996 Feb; 7(2):183–90 (127 ref.)

Advanced glycation endproducts and diabetic nephropathy. Makita Z, et al. **J Diabetes Complications** 1995 Oct-Dec; 9(4):265–8 (26 ref.)

GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORS see GLYCOSYLPHOSPHATIDYLINOSITOLS

GLYCOSYLPHOSPHATIDYLINOSITOLS

ANALYSIS

Glycosylphosphatidylinositol (GPI)-anchored membrane proteins in clinical pathophysiology of paroxysmal nocturnal hemoglobinuria (PNH). Shichishima T. **Fukushima J Med Sci** 1995 Jun;41(1):1–13 (45 ref.)

BIOSYNTHESIS

Defective glycosyl phosphatidylinositol anchor synthesis and paroxysmal nocturnal hemoglobinuria. Kinoshita T, et al. **Adv Immunol** 1995;60:57–103 (275 ref.)

GPI-anchor biosynthesis. Takeda J, et al. **Trends Biochem Sci** 1995 Sep;20(9):367–71 (32 ref.)

DEFICIENCY

The molecular basis of paroxysmal nocturnal hemoglobinuria. Rosse WF, et al. **Blood** 1995 Nov 1;86(9):3277–86 (123 ref.)

[Characteristics and diagnostics of blood cell defects in paroxysmal nocturnal haemoglobinuria (NNH)] Bogdanik I. **Acta Haematol Pol** 1995;26(4):353–60 (36 ref.) (Eng. Abstr.) **(Pol)**

[Etiology and pathogenesis of glycosylphosphatidylinositol anchor-linked membrane protein deficiency] Bogdanik I. **Acta Haematol Pol** 1995;26(3):239–46 (30 ref.) (Eng. Abstr.) **(Pol)**

GENETICS

Defective glycosyl phosphatidylinositol anchor synthesis and paroxysmal nocturnal hemoglobinuria. Xinoshita T, et al. **Adv Immunol** 1995;60:57–103 (275 ref.)

Cell-surface engineering with GPI-anchored proteins. Medof ME, et al. **FASEB J** 1996 Apr;10(5):574–86 (82 ref.)

METABOLISM

How glycosylphosphatidylinositol-anchored membrane proteins are made. Udenfriend S, et al. **Annu Rev Biochem** 1995;64:563–91 (129 ref.)

PHYSIOLOGY

Structural and functional roles of glycosylphosphoinositides. Saltiel AR. **Subcell Biochem** 1996;26:165–85 (152 ref.)

Glycosyl phosphatidylinositol-linked blood group antigens and paroxysmal nocturnal hemoglobinuria. Telen MJ. **Transfus Clin Biol** 1995;2(4):277–90 (73 ref.)

GLYCOSYLTRANSFERASES

CHEMISTRY

Molecular cloning of eukaryotic glycoprotein and glycolipid glycosyltransferases: a survey. Field MC, et al. **Glycobiology** 1995 Jul;5(5):463–72 (142 ref.)

DRUG EFFECTS

Glycosyltransferases as targets for inhibition of cell wall synthesis in M. tuberculosis and M. avium. Maddry JA, et al. **Res Microbiol** 1996 Jan-Feb;147(1–2):106–12 (25 ref.)

GENETICS

The regulation of cell- and tissue-specific expression of glycans by glycosyltransferases. Dinter A, et al. **Adv Exp Med Biol** 1995;376:53–82 (187 ref.)

Molecular genetics of the ABO histo-blood group system. Yamamoto F. **Vox Sang** 1995;69(1):1–7 (38 ref.)

METABOLISM

Lytic transglycosylases. Höltje JV. **EXS** 1996;75:425–9 (20 ref.)

Glycosyltransferase mutants: key to new insights in glycobiology. Stanley P, et al. **FASEB J** 1995 Nov; 9(14):1436–44 (48 ref.)

GLYCYRRHETIC ACID see GLYCYRRHETINIC ACID

GLYCYRRHETINIC ACID

ADVERSE EFFECTS

[Licorice, aldosterone and blood pressure] Sane T. **Duodecim** 1994;110(10):974–80 (27 ref.) **(Fin)**

GLYCYRRHIZA

[Licorice, aldosterone and blood pressure] Sane T. **Duodecim** 1994;110(10):974–80 (27 ref.) **(Fin)**

GLYOXALASE I see LACTOYL GLUTATHIONE LYASE

GLYOXALINYLACRYLIC ACID see UROCANIC ACID

GM ALLOTYPES see IMMUNOGLOBULIN GM ALLOTYPES

GM-CSF see GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR

G(M1) GANGLIOSIDE

see related
GANGLIOSIDOSIS G(M1)

DIAGNOSTIC USE

[The metabolism of radiolabelled GM1-ganglioside in cultured skin fibroblasts from controls and patients with GM1-gangliosidosis] Inui K. **Nippon Rinsho** 1995 Dec; 53(12):3102–4 (4 ref.) (Eng. Abstr.) **(Jpn)**

ISOLATION & PURIFICATION

[Asialo GM1] Nakahara K. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:195–7 (7 ref.) **(Jpn)**

G(M2) GANGLIOSIDE

see related
SANDHOFF DISEASE
TAY-SACHS DISEASE

METABOLISM

GM2 ganglioside and pyramidal neuron dendritogenesis. Walkley SU, et al. **Neurochem Res** 1995 Nov; 20(11):1287–99 (115 ref.)

G(M1) GANGLIOSIDOSIS see GANGLIOSIDOSIS G(M1)

G(M2) GANGLIOSIDOSIS, TYPE I see TAY-SACHS DISEASE

G(M2) GANGLIOSIDOSIS, TYPE II see SANDHOFF DISEASE

GMP-140 see P-SELECTIN

GNOTOBIOTICS see GERM-FREE LIFE

GNRH see GONADORELIN

GNRH RECEPTORS see RECEPTORS, LHRH

GOALS, ORGANIZATIONAL see ORGANIZATIONAL OBJECTIVES

GOAT DISEASES

Selected models of HIV-induced neurological disease. Narayan O, et al. **Curr Top Microbiol Immunol** 1995; 202:151–66 (61 ref.)

EPIDEMIOLOGY

Ruminant pestivirus infections in animals other than cattle and sheep. Løken T. **Vet Clin North Am Food Anim Pract** 1995 Nov; 11(3):597–614 (97 ref.)

VIROLOGY

Characteristics of ovine and caprine lentivirus infections. Perk K. **Leukemia** 1995 Oct;9 Suppl 1:S98–100 (25 ref.)

GOATS

GROWTH & DEVELOPMENT

Status and prospects of the dairy goat industry in the United States. Haenlein GF. **J Anim Sci** 1996 May;74(5):1173–81 (29 ref.)

Prospects for expanded mohair and cashmere production and processing in the United States of America. Lupton CJ. **J Anim Sci** 1996 May;74(5):1164–72 (18 ref.)

GOITER

BLOOD

[Secretion of thyrotropin during states of wakefulness and sleep. Physiological data and clinical applications] Goichot B, et al. **Presse Med** 1996 Jun 15;25(21):980–4 (25 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Optimal laboratory testing for diagnosis and monitoring of thyroid nodules, goiter, and thyroid cancer. Ladenson PW. **Clin Chem** 1996 Jan;42(1):183–7 (27 ref.)

ETIOLOGY

Role of goitrogens in iodine deficiency disorders & brain development. Rao PS, et al. **Indian J Med Res** 1995 Nov; 102:223–6 (16 ref.)

GENETICS

Molecular genetics of hereditary thyroid diseases due to a defect in the thyroglobulin or thyroperoxidase synthesis. Targovnik HM, et al. **Braz J Med Biol Res** 1994 Dec; 27(12):2745–57 (31 ref.)

GOITER, ENDEMIC

EPIDEMIOLOGY

[Endemic iodine deficiency in Hungary and possibilities of iodine substitution] Bogye G, et al. **Orv Hetil** 1996 Feb 11;137(6):287–90 (25 ref.) (Eng. Abstr.) **(Hun)**

PREVENTION & CONTROL

Seven deadly sins in confronting endemic iodine deficiency, and how to avoid them. Dunn JT. **J Clin Endocrinol Metab** 1996 Apr;81(4):1332–5 (22 ref.)

GOITER, EXOPHTHALMIC see GRAVES' DISEASE

GOITER, INTRATHORACIC see GOITER, SUBSTERNAL

GOITER, NODULAR

DIAGNOSIS

A primary care approach to the adult patient with nodular thyroid disease. Petrone LR. **Arch Fam Med** 1996 Feb; 5(2):92–100 (98 ref.)

GOITER, NODULAR

PATHOLOGY

Mechanisms of nonneoplastic endocrine hyperplasia--a changing concept: a review focused on the thyroid gland. Studer H, et al. **Endocr Rev** 1995 Aug;16(4):411-26 (212 ref.)

RADIOTHERAPY

131I treatment of nodular non-toxic goitre. Nygaard B, et al. **Eur J Endocrinol** 1996 Jan;134(1):15-20 (60 ref.)

THERAPY

A primary care approach to the adult patient with nodular thyroid disease. Petrone LR. **Arch Fam Med** 1996 Feb; 5(2):92-100 (98 ref.)

GOITER, SUBSTERNAL

COMPLICATIONS

Partial unilateral phrenic nerve paralysis caused by a large intrathoracic goitre. van Doorn LG, et al. **Neth J Med** 1996 Jun;48(6):216-9 (3 ref.)

DIAGNOSIS

Substernal goiter. Newman E, et al. **J Surg Oncol** 1995 Nov; 60(3):207-12 (37 ref.)

RADIOGRAPHY

A lump in the chest. A common problem in an unusual setting [clinical conference] Patel V, et al. **BMJ** 1995 Dec 2; 311(7018):1491-4 (38 ref.)

GOITROGENS see **ANTITHYROID AGENTS**

GOLD RADIOISOTOPES

THERAPEUTIC USE

Gold, electron microscopy, and cancer therapy. Hainfeld JF. **Scanning Microsc** 1995 Mar;9(1):239-54; discussion 254-6 (28 ref.)

GOLD SODIUM THIOMALATE

ADMINISTRATION & DOSAGE

[Towards more individualized parenteral gold therapy (editorial)] Kaarela K, et al. **Duodecim** 1994;110(11):1046-7 (14 ref.) **(Fin)**

GOLD THIOMALATE see **GOLD SODIUM THIOMALATE**

GOLDENHAR SYNDROME

[Goldenhar syndrome: apropos of a case] D'Khissy M, et al. **Rev Laryngol Otol Rhinol (Bord)** 1996;117(1):61-3 (13 ref.) (Eng. Abstr.) **(Fre)**

GOLDFISH

PHYSIOLOGY

Physiology of primary saccular afferents of goldfish: implications for Mauthner cell response. Fay RR. **Brain Behav Evol** 1995;46(3):141-50 (54 ref.)

GOLGI APPARATUS

CHEMISTRY

A comparison of the transmembrane domains of Golgi and plasma membrane proteins. Munro S. **Biochem Soc Trans** 1995 Aug;23(3):527-30 (28 ref.)

METABOLISM

Vesicle biogenesis: the coat connection [comment] Mallabiabarrena A, et al. **Cell** 1995 Dec 1;83(5):667-9 (21 ref.) Comment on: Cell 1995 Dec 1;83(5):703-13.

Membrane traffic. Is the Golgi complex? Armstrong J. **Curr Biol** 1995 Sep 1;5(9):980-1 (10 ref.)

Sorting and retrieval between the endoplasmic reticulum and Golgi apparatus. Pelham HR. **Curr Opin Cell Biol** 1995 Aug;7(4):530-5 (47 ref.)

PATHOLOGY

The Golgi apparatus and the pathogenesis of Alzheimer's disease [comment] Dal Canto MC. **Am J Pathol** 1996 Feb; 148(2):355-60 (40 ref.) Comment on: Am J Pathol 1996 Feb;148(2):415-26.

PHYSIOLOGY

COPs regulating membrane traffic. Kreis TE, et al. **Ann Rev Cell Dev Biol** 1995;11:677-706 (165 ref.)

Roles for microtubules and kinesin in membrane traffic between the endoplasmic reticulum and the Golgi complex. Lippincott-Schwartz J, et al. **Biochem Soc Trans** 1995 Aug; 23(3):544-8 (24 ref.)

Molecular mechanisms in the disassembly and reassembly of the mammalian Golgi apparatus during M-phase. Misteli T. **FEBS Lett** 1996 Jun 24;389(1):66-9 (44 ref.)

ULTRASTRUCTURE

Trans-Golgi network (TGN) of different cell types: three-dimensional structural characteristics and variability. Clermont Y, et al. **Anat Rec** 1995 Jul;242(3):289-301 (79 ref.)

Keeping Golgi membranes intact in the pericentriolar region of mammalian cells. Acharya U, et al. **Biochem Soc Trans** 1995 Aug;23(3):538-41 (20 ref.)

GONADAL DYSGENESIS, 45,X see **TURNER'S SYNDROME**

GONADAL DYSGENESIS, XO see **TURNER'S SYNDROME**

GONADAL DYSGENESIS, MIXED

GENETICS

Ambiguous genitalia in an elderly woman with a mosaic 45,X/46,X,dic(Y)(Q11.2) karyotype. Smith YR, et al. **Urology** 1996 Feb;47(2):259-62 (13 ref.)

GONADOLIBERIN see **GONADORELIN**

GONADOLIBERIN RECEPTORS see **RECEPTORS, LHRH**

GONADORELIN

see related
RECEPTORS, LHRH

ADMINISTRATION & DOSAGE

From physiology to clinics--20 years of experience with pulsatile GnRH. Leyendecker G, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Apr;65 Suppl:S3-12 (107 ref.)

The role of the GnRH dose and the route of administration on treatment outcome and complications. Schoemaker J. **Eur J Obstet Gynecol Reprod Biol** 1996 Apr;65 Suppl:S13-6 (13 ref.)

ADVERSE EFFECTS

The impact of bone loss in women with endometriosis. Stevenson JC. **Int J Gynaecol Obstet** 1995 Sep;50 Suppl 1:S11-5 (26 ref.)

AGONISTS

Gn-RH agonists in the treatment of prostatic carcinoma. Vacher P. **Biomed Pharmacother** 1995;49(7-8):325-31 (60 ref.)

Combined androgen blockade. Crawford ED. **Eur Urol** 1996; 29 Suppl 2:54-61 (28 ref.)

Ovarian hyperstimulation: effects of GnRH analogues. Triggering the final stage of ovulation using gonadotrophin-releasing hormone analogues: effective dose, prevention of ovarian hyperstimulation syndrome and the luteal phase. Ben-Arie A, et al. **Hum Reprod** 1996 Jun; 11(6):1146-8 (31 ref.)

Ovarian hyperstimulation: effects of GnRH analogues. Does triggering ovulation with gonadotrophin-releasing hormone analogue prevent severe ovarian hyperstimulation syndrome? Casper RF. **Hum Reprod** 1996 Jun;11(6):1144-6 (12 ref.)

Ovarian hyperstimulation: effects of GnRH analogues. Ovarian hyperstimulation syndrome after using gonadotrophin-releasing hormone analogue as a trigger of ovulation: causes and implications. Kol S, et al. **Hum Reprod** 1996 Jun;11(6):1143-4 (15 ref.)

Synchronization of ovarian follicular waves with a gonadotropin-releasing hormone agonist to increase the precision of estrus in cattle: a review. Twagiramungu H, et al. **J Anim Sci** 1995 Oct;73(10):3141-51 (87 ref.)

Role of growth factors, steroid and peptide hormones in the regulation of human prostatic tumor growth. Motta M, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1-6 Spec No):107-11 (36 ref.)

Long-term gonadotropin-releasing hormone agonist therapy: the evolving issue of steroidal "add-back" paradigms. Adashi EY. **Keio J Med** 1995 Dec;44(4):124-32 (120 ref.)

[Estrogen-progesterone "add-back" for long-term GNRH analogue therapy] Levy T, et al. **Harefuah** 1995 Jun 15; 128(12):789-92 (42 ref.) **(Heb)**

ANALOGS & DERIVATIVES

Ovulation induction in the era of recombinant gonadotropins and GnRH analogues. Insler V, et al. **Isr J Med Sci** 1996 Feb;32(2):79-89 (68 ref.)

Clinical review 81: Gonadotropin-releasing hormone analogs in ovulation induction: current status and perspectives. Filicori M. **J Clin Endocrinol Metab** 1996 Jul;81(7):2413-6 (23 ref.)

Current status of neoadjuvant therapy in localized prostate cancer. Witjes WP, et al. **Prostate** 1995 Dec;27(6):297-303 (69 ref.)

[LHRH analogs in gynecology] Rachev E, et al. **Akush Ginekol (Sofiia)** 1994;33(2):36-9 (12 ref.) **(Bul)**

[Treatment of uterine fibromas] Amiel C, et al. **Ann Chir** 1996;50(1):40-50 (79 ref.) (Eng. Abstr.) **(Fre)**

[Pituitary gonadotropin releasing hormone (GnRH) and breast cancer] Vargas Hernández VM, et al. **Ginecol Obstet Mex** 1995 Dec;63:493-6 (12 ref.) (Eng. Abstr.) **(Spa)**

ANTAGONISTS & INHIBITORS

Development and applications of luteinizing hormone-releasing hormone antagonists in the treatment of infertility: an overview. Reissmann T, et al. **Hum Reprod** 1995 Aug;10(8):1974-81 (62 ref.)

GENETICS

Hormonal and neurotransmitter regulation of GnRH gene expression and related reproductive behaviors. Sagrillo CA, et al. **Behav Genet** 1996 May;26(3):241-77 (360 ref.)

METABOLISM

Behavioral regulation of gonadotropin-releasing hormone. Rissman EF. **Biol Reprod** 1996 Feb;54(2):413-9 (89 ref.)

PHARMACOLOGY

Gonadotropin gene modulation by steroids and gonadotropin-releasing hormone. Shupnik MA. **Biol Reprod** 1996 Feb;54(2):279-86 (60 ref.)

Gonadotrophin surge-inhibiting/attenuating factor governs luteinizing hormone secretion during the ovarian cycle: physiology and pathology. de Koning J. **Hum Reprod** 1995 Nov;10(11):2854-61 (86 ref.)

Novel aspects of GnRH-induced intracellular signaling and secretion in pituitary gonadotrophs. Stojilkovic SS, et al. **J Neuroendocrinol** 1995 Oct;7(10):739-57 (110 ref.)

PHYSIOLOGY

Signal transduction of the gonadotropin releasing hormone (GnRH) receptor: cross-talk of calcium, protein kinase C (PKC), and arachidonic acid. Naor Z, et al. **Cell Mol Neurobiol** 1995 Oct;15(5):527-44 (142 ref.)

The LHRH pulse generator: a mediobasal hypothalamic location. Maeda K, et al. **Neurosci Biobehav Rev** 1995 Fall; 19(3):427-37 (55 ref.)

[Gonadotropin releasing hormone (GnRH)] Isurugi K. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:337-41 (17 ref.) **(Jpn)**

SECRETION

[Ethanol mechanism(s) of action on LHRH secretion] Canteros MG, et al. **Acta Physiol Pharmacol Ther Latinoam** 1995;45(1):55-63 (18 ref.) **(Spa)**

THERAPEUTIC USE

Gn-RH agonists in the treatment of prostatic carcinoma. Vacher P. **Biomed Pharmacother** 1995;49(7-8):325-31 (60 ref.)

Compliance with hormonal treatment for prostate cancer. Kaisary AV. **Br J Hosp Med** 1996 Mar 20-Apr 2; 55(6):359-66 (59 ref.)

Growth hormone and fertility---clinical studies. Homburg R. **Horm Res** 1996;45(1-2):81-5 (27 ref.)

Current status of neoadjuvant therapy in localized prostate cancer. Witjes WP, et al. **Prostate** 1995 Dec;27(6):297-303 (69 ref.)

[Acceleration of pubertal development] Antoniazzi F, et al. **Pediatr Med Chir** 1996 Jan-Feb;18(1):19-25 (30 ref.) (Eng. Abstr.) **(Ita)**

GONADORELIN RECEPTORS see **RECEPTORS, LHRH**

GONADOTROPIN RECEPTORS see **RECEPTORS, GONADOTROPIN**

GONADOTROPIN-RELEASING HORMONE see **GONADORELIN**

GONADOTROPIN RELEASING-HORMONE RECEPTORS see **RECEPTORS, LHRH**

GONADOTROPIN-RESISTANT OVARY SYNDROME see **OVARIAN FAILURE, PREMATURE**

GONADOTROPINS

see related
RECEPTORS, GONADOTROPIN

ADVERSE EFFECTS

The effects of ovulation induction with gonadotrophins on the ovary and uterus and implications for assisted reproduction. Balen A. **Hum Reprod** 1995 Sep;10(9):2233-7 (55 ref.)

BIOSYNTHESIS

Recombinant technique and gonadotropins production: new era in reproductive medicine. Shoham Z, et al. **Fertil Steril** 1996 Aug;66(2):187-201 (137 ref.)

[Acceleration of pubertal development] Antoniazzi F, et al. **Pediatr Med Chir** 1996 Jan–Feb;18(1):19–25 (30 ref.) (Eng. Abstr.) **(Ita)**

BLOOD

[Delayed constitutional puberty or hypogonadotrophic hypogonadism?] Beas F. **Rev Med Chil** 1995 Feb; 123(2):233–40 (30 ref.) (Eng. Abstr.) **(Spa)**

DEFICIENCY

The role of the GnRH dose and the route of administration on treatment outcome and complications. Schoemaker J. **Eur J Obstet Gynecol Reprod Biol** 1996 Apr;65 Suppl:S13–6 (13 ref.)

PHARMACOLOGY

Pharmacological interventions for the induction of ovulation. Collins JA, et al. **Drugs** 1995 Sep;50(3):480–94 (91 ref.)

PHYSIOLOGY

Gonadotrophin control of testicular germ cell development. Weinbauer GF, et al. **Adv Exp Med Biol** 1995;377:55–65 (59 ref.)

Gonadotropin control of follicle and oocyte maturation: implications for ovulation induction. Brannian JD, et al. **S D J Med** 1995 Oct;48(10):335–9 (20 ref.)

Transduction mechanisms for gonadotrophin-induced oocyte maturation in mammals. Mattioli M. **Zygote** 1994 Nov; 2(4):347–9 (10 ref.)

[Current concepts concerning the role of sex hormones and gonadotropins in the development of laryngeal cancer] Shadyev KhD, et al. **Vestn Ross Akad Med Nauk** 1995; (10):22–4 (30 ref.) **(Rus)**

THERAPEUTIC USE

Ovulation induction in the era of recombinant gonadotropins and GnRH analogues. Insler V, et al. **Isr J Med Sci** 1996 Feb;32(2):79–89 (68 ref.)

GONADOTROPINS, CHORIONIC

see related
RECEPTORS, GONADOTROPIN

ADVERSE EFFECTS

Ovulation induction. Effects of ovulation induction with gonadotrophins on the ovary and uterus and their implications for assisted reproduction. Rojas FJ. **Hum Reprod** 1995 Sep;10(9):2219–24 (47 ref.)

[Feminization: a paradoxical effect of stimulation with hCG/hMG in the infertile male] Arango Toro O, et al. **Actas Urol Esp** 1995 May;19(5):376–82 (48 ref.) (Eng. Abstr.) **(Spa)**

ANALYSIS

[Human chorionic gonadotropin (hCG) and subunits] Ibuki Y, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:593–9 (11 ref.) **(Jpn)**

BLOOD

Why is there a peak of human chorionic gonadotrophin (HCG) in early pregnancy? Chard T, et al. **Hum Reprod** 1995 Jul;10(7):1837–40 (61 ref.)

[Maternal serum screening for detection of fetal chromosome abnormalities] Holzgreve W, et al. **Gynakologe** 1995 Oct; 28(5):280–8 (44 ref.) **(Ger)**

GENETICS

The gonadotropin genes: evolution of distinct mechanisms for hormonal control. Albanese C, et al. **Recent Prog Horm Res** 1996;51:23–58; discussion 59–61 (140 ref.)

PHARMACOLOGY

Thyrotropic action of human chorionic gonadotropin. Yoshimura M, et al. **Thyroid** 1995 Oct;5(5):425–34 (62 ref.)

SECRETION

[Large-cell lung carcinoma producing chorionic gonadotropin hormone: the difficulty in its differential diagnosis from choriocarcinoma] Cremades Romero MJ, et al. **Arch Bronconeumol** 1996 May;32(5):253–5 (10 ref.) (Eng. Abstr.) **(Spa)**

GONADOTROPINS, CHORIONIC, HUMAN see **GONADOTROPINS, CHORIONIC**

GONADOTROPINS, CHORIONIC, HUMAN BETA SUBUNIT see **CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN**

GONADOTROPINS, HUMAN MENOPAUSAL see **MENOTROPINS**

GONADOTROPINS, PITUITARY

see related
RECEPTORS, GONADOTROPIN

BLOOD

[Evaluation of ovarian sensitivity to gonadotrophins: role of ovarian reserve tests] Hugues JN, et al. **Contracept Fertil Sex** 1996 Apr;24(4):303–6 (23 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSTIC USE

[Evaluation of ovarian sensitivity to gonadotrophins: role of ovarian reserve tests] Hugues JN, et al. **Contracept Fertil Sex** 1996 Apr;24(4):303–6 (23 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Molecular biology in reproductive endocrinology. Layman LC. **Curr Opin Obstet Gynecol** 1995 Oct;7(5):328–39 (104 ref.)

PHYSIOLOGY

[Physiopathologic anomalies in ovarian response] Christin-Maitre S, et al. **Contracept Fertil Sex** 1996 Feb; 24(2):105–10 (27 ref.) **(Fre)**

SECRETION

Gonadotropin secretion during aging in women: review article. Rossmanith WG. **Exp Gerontol** 1995 May–Aug; 30(3–4):369–81 (38 ref.)

GONADS

see related
CASTRATION
SEX REVERSAL, GONADAL

ABNORMALITIES

Intersexuality in pigs: clinical, physiological and practical considerations. Hunter RH, et al. **Acta Vet Scand** 1996; 37(1):1–12 (29 ref.)

CYTOLOGY

Molecular basis of neuronal plasticity to gonadal steroids. Matsumoto A, et al. **Funct Neurol** 1995 Mar–Apr; 10(2):59–76 (137 ref.)

DRUG EFFECTS

Mechanism and management of treatment-related gonadal failure in recipients of high dose chemoradiotherapy. Apperley JF, et al. **Blood Rev** 1995 Jun;9(2):93–116 (158 ref.)

Gonadal damage and effects on fertility in adult patients with haematological malignancy undergoing stem cell transplantation. Chatterjee R, et al. **Bone Marrow Transplant** 1996 Jan;17(1):5–11 (79 ref.)

Risk assessment policy for evaluating reproductive system toxicants and the impact of responses on sensitive populations. Briggs GB. **Toxicology** 1996 Jul 17; 111(1–3):305–13 (106 ref.)

PHYSIOLOGY

Molecular basis of neuronal plasticity to gonadal steroids. Matsumoto A, et al. **Funct Neurol** 1995 Mar–Apr; 10(2):59–76 (137 ref.)

Growth hormone, growth factors and the gonad. Albanese A, et al. **Horm Res** 1995;44 Suppl 3:15–17 (25 ref.)

Endocrine–immunological homeostasis: the interrelationship between the immune system and sex steroids involves the hypothalamo–pituitary–gonadal axis. Drača SR. **Panminerva Med** 1995 Jun;37(2):71–6 (45 ref.)

RADIATION EFFECTS

Mechanism and management of treatment-related gonadal failure in recipients of high dose chemoradiotherapy. Apperley JF, et al. **Blood Rev** 1995 Jun;9(2):93–116 (158 ref.)

GONIOTOMY see **TRABECULECTOMY**

GONOCOCCUS see **NEISSERIA GONORRHOEAE**

GONORRHEA

Syphilis and gonorrhea. Siegel MA. **Dent Clin North Am** 1996 Apr;40(2):369–83 (34 ref.)

COMPLICATIONS

Pyomyositis as the sole manifestation of disseminated gonococcal infection: case report and review. Haugh PJ, et al. **Clin Infect Dis** 1996 May;22(5):861–3 (7 ref.)

Gonococcal endocarditis. Thompson EC, et al. **J Natl Med Assoc** 1996 Jun;88(6):353–6 (44 ref.)

[Perihepatitis] Iwata N, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):463–5 (20 ref.) **(Jpn)**

[Fitz-Hugh–Curtis syndrome] Sakai H, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):430–3 (7 ref.) **(Jpn)**

DIAGNOSIS

Modern diagnosis and management of gonorrhoea [see comments] Sherrard J. **Br J Hosp Med** 1996 Apr 3–16; 55(7):394–8 (22 ref.) Comment in: Br J Hosp Med 1996 Apr 3–16;55(7):386–7.

Pyomyositis as the sole manifestation of disseminated gonococcal infection: case report and review. Haugh PJ, et al. **Clin Infect Dis** 1996 May;22(5):861–3 (7 ref.)

Gonorrhoea. Lind I. **Curr Probl Dermatol** 1996;24:12–9 (22 ref.)

DRUG THERAPY

Gonorrhoea: single-dose oral treatment. Kohl PK, et al. **Curr Probl Dermatol** 1996;24:82–9 (29 ref.)

Surveillance of antibiotic resistance in Neisseria gonorrhoeae and implications for the therapy of gonorrhoea [editorial] Tapsall JW. **Int J STD AIDS** 1995 Jul–Aug;6(4):233–6 (24 ref.)

Azithromycin in gonorrhoea. Waugh MA. **Int J STD AIDS** 1996;7 Suppl 1:2–4 (11 ref.)

MICROBIOLOGY

Uses and limitations of gonococcal serotyping [editorial] Ross JD. **Int J STD AIDS** 1996 Jan–Feb;7(1):14–8 (68 ref.)

Surveillance of antibiotic resistance in Neisseria gonorrhoeae and implications for the therapy of gonorrhoea [editorial] Tapsall JW. **Int J STD AIDS** 1995 Jul–Aug;6(4):233–6 (24 ref.)

PREVENTION & CONTROL

Vaccines for gonorrhea: where are we on the curve? Blake MS, et al. **Trends Microbiol** 1995 Dec;3(12):469–74 (63 ref.)

GONOSOMES see **SEX CHROMOSOMES**

GONYAULAX see **DINOFLAGELLIDA**

GOODPASTURE'S SYNDROME

DIAGNOSIS

Recurrent Goodpasture's disease. Levy JB, et al. **Am J Kidney Dis** 1996 Apr;27(4):573–8 (22 ref.)

Goodpasture's disease and Alport's syndromes. Turner AN, et al. **Annu Rev Med** 1996;47:377–86 (34 ref.)

[Goodpasture's syndrome—a case report] Stoicescu P, et al. **Pneumoftiziologia** 1995 Jan–Jun;44(1–2):67–70 (8 ref.) (Eng. Abstr.) **(Rum)**

EPIDEMIOLOGY

[Goodpasture syndrome: role of an epidemiological factor? Apropos of two cases] Molinier S, et al. **Rev Med Interne** 1995;16(8):589–94 (37 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Identification of the alpha 3 chain of type IV collagen as the common autoantigen in antibasement membrane disease and Goodpasture syndrome. Kalluri R, et al. **J Am Soc Nephrol** 1995 Oct;6(4):1178–85 (64 ref.)

PATHOLOGY

Progression from Goodpasture's disease to membranous glomerulonephritis. Elder G, et al. **Pathology** 1995 Jul; 27(3):233–6 (32 ref.)

GORDIUS see **HELMINTHS**

GORHAM DISEASE see **OSTEOLYSIS, ESSENTIAL**

GORLIN-PSAUME SYNDROME see **OROFACIODIGITAL SYNDROMES**

GORLIN SYNDROME see **BASAL CELL NEVUS SYNDROME**

GOSERELIN

PHARMACOLOGY

Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in benign gynaecological disorders. Perry CM, et al. **Drugs** 1996 Feb; 51(2):319–46 (113 ref.)

THERAPEUTIC USE

Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in benign gynaecological disorders. Perry CM, et al. **Drugs** 1996 Feb; 51(2):319–46 (113 ref.)

GOUT

see related
GOUT SUPPRESSANTS

GOUT

COMPLICATIONS

Rheumatoid arthritis preceding the onset of polyarticular tophaceous gout [letter] Zonana-Nacach A, et al. **Ann Rheum Dis** 1996 Jul;55(7):489-90 (25 ref.)

DIAGNOSIS

Gout as a source of sesamoid pain. Mair SD, et al. **Foot Ankle Int** 1995 Oct;16(10):613-6 (17 ref.)

Unusual presentations of gout. Tips for accurate diagnosis. Uy JP, et al. **Postgrad Med** 1996 Jul;100(1):253-4, 257-60, 266 passim (21 ref.)

DIET THERAPY

[Diet in hyperlipidemia, hypertension and gout] Wolfram G. **Internist (Berl)** 1995 Nov;36(11):1070-6 (35 ref.) **(Ger)**

DRUG THERAPY

Individualizing the treatment of gout. George TM, et al. **Cleve Clin J Med** 1996 May-Jun;63(3):150-5 (16 ref.)

An evidence based appraisal of the management of nontophaceous interval gout [editorial] [see comments] Ferraz MB. **J Rheumatol** 1995 Sep;22(9):1618-9 (26 ref.) Comment in: J Rheumatol 1995 Sep;22(9):1621-3.

ETIOLOGY

[Hyperuricemia] Gröbner W, et al. **Internist (Berl)** 1995 Dec; 36(12):1207-21 (13 ref.) **(Ger)**

[Hyperuricemia] Gröbner W, et al. **Urologe A** 1996 May; 35(3):263-77 (13 ref.) **(Ger)**

[Obesity and the related diseases: gout] Akaoka Y, et al. **Nippon Naika Gakkai Zasshi** 1995 Aug 10;84(8):1262-6 (6 ref.) **(Jpn)**

[Lead gout] Lebedeva MV, et al. **Klin Med (Mosk)** 1995; 73(3):103-4 (8 ref.) **(Rus)**

METABOLISM

Gout, uric acid metabolism, and crystal-induced inflammation. Weinberger A. **Curr Opin Rheumatol** 1995 Jul;7(4):359-63 (49 ref.)

RADIOGRAPHY

Radiologic features of gout. Buckley TJ. **Am Fam Physician** 1996 Sep 15;54(4):1232-8 (17 ref.)

THERAPY

The management of gout [see comments] Emmerson BT. **N Engl J Med** 1996 Feb 15;334(7):445-51 (85 ref.) Comment in: N Engl J Med 1996 Jun 6;334(23):1543; discussion 1543-4.

GOUT SUPPRESSANTS

[Colchicine] Le Hello C. **Ann Med Interne (Paris)** 1996; 147(3):185-211 (329 ref.) **(Fre)**

THERAPEUTIC USE

An evidence based appraisal of the management of nontophaceous interval gout [editorial] [see comments] Ferraz MB. **J Rheumatol** 1995 Sep;22(9):1618-9 (26 ref.) Comment in: J Rheumatol 1995 Sep;22(9):1621-3.

The management of gout [see comments] Emmerson BT. **N Engl J Med** 1996 Feb 15;334(7):445-51 (85 ref.) Comment in: N Engl J Med 1996 Jun 6;334(23):1543; discussion 1543-4.

GOUTY ARTHRITIS see **ARTHRITIS, GOUTY**

GOVERNING BOARD

STATISTICS & NUMERICAL DATA

The effects of hospital-physician integration strategies on hospital financial performance. Goes JB, et al. **Health Serv Res** 1995 Oct;30(4):507-30 (40 ref.)

GOVERNMENT

Becoming knowledgeable in the legislative process can help nurses shape their own future. Porter J, et al. **AORN J** 1996 Mar;63(3):618-21; quiz 622-4 (0 ref.)

Risk proposals of the 103rd Congress. Paxman D. **Drug Metab Rev** 1996 Feb-May;28(1-2):245-67 (18 ref.)

GOVERNMENT AGENCIES

A limited bibliography of the Federal Government-funded human radiation experiments. Samei E, et al. **Health Phys** 1995 Dec;69(6):885-91 (55 ref.)

Economic and quality of life outcomes in oncology: the regulatory perspective. Turner S. **Oncology (Huntingt)** 1995 Nov;9(11 Suppl):121-5 (0 ref.)

LEGISLATION & JURISPRUDENCE

Historical perspective on risk assessment in the federal government. Graham JD. **Toxicology** 1995 Sep 1; 102(1-2):29-52 (169 ref.)

GP120(HIV) see **HIV ENVELOPE PROTEIN GP120**

GPI MEMBRANE ANCHORS see **GLYCOSYLPHOSPHATIDYLINOSITOLS**

GPIIB-IIIA RECEPTORS see **PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX**

GRAAFIAN FOLLICLE

see related
GRANULOSA CELLS
OVUM

DRUG EFFECTS

Assessment of follicle destruction in chemical-induced ovarian toxicity. Hoyer PB, et al. **Annu Rev Pharmacol Toxicol** 1996;36:307-31 (122 ref.)

GROWTH & DEVELOPMENT

Regulation of ovarian follicular development in primates: facts and hypotheses. Gougeon A. **Endocr Rev** 1996 Apr; 17(2):121-55 (371 ref.)

METABOLISM

Regulation of angiotensin II receptor expression in ovarian follicles. A review. Nielsen AH, et al. **Adv Exp Med Biol** 1995;377:407-10 (19 ref.)

PHYSIOLOGY

Ovarian follicular growth, ovulation and atresia. Endocrine, paracrine and autocrine regulation. Moley KH, et al. **Adv Exp Med Biol** 1995;377:103-19 (105 ref.)

Ovulation as a tissue remodelling process. Proteolysis and cumulus expansion. Tsafriri A. **Adv Exp Med Biol** 1995; 377:121-40 (191 ref.)

The regulation of follicle growth: some clinical implications in reproductive endocrinology. Taymor ML. **Fertil Steril** 1996 Feb;65(2):235-47 (91 ref.)

The role of follicle-stimulating hormone in the selection of follicles in human ovaries: a survey of the literature and a proposed model. Scheele F, et al. **Gynecol Endocrinol** 1996 Feb;10(1):55-66 (108 ref.)

Synchronization of ovarian follicular waves with a gonadotropin-releasing hormone agonist to increase the precision of estrus in cattle: a review. Twagiramungu H, et al. **J Anim Sci** 1995 Oct;73(10):3141-51 (87 ref.)

[Human folliculogenesis and local regulation] Fukaya T. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Aug; 47(8):726-37 (7 ref.) (Eng. Abstr.) **(Jpn)**

ULTRASONOGRAPHY

The application of transvaginal ultrasound for ovulation induction and in vitro fertilization. Nachtigall MJ, et al. **Clin Obstet Gynecol** 1996 Mar;39(1):231-47 (72 ref.)

GRADUATE RECORDS EXAMINATION see **EDUCATIONAL MEASUREMENT**

GRAFFI VIRUS see **LEUKEMIA VIRUSES, MURINE**

GRAFFI'S CHLOROLEUKEMIC STRAIN see **LEUKEMIA VIRUSES, MURINE**

GRAFT ENHANCEMENT, IMMUNOLOGIC

METHODS

Complement inhibitory therapeutics and xenotransplantation. Ryan US. **Nat Med** 1995 Sep;1(9):967-8 (19 ref.)

GRAFT OCCLUSION, VASCULAR

BLOOD

Hemodialysis vascular access: effect on urea kinetics and the dialysis prescription. Butterly DW, et al. **Am J Nephrol** 1996;16(1):45-51 (32 ref.)

DRUG THERAPY

Lower limb intraarterial thrombolysis as an adjunct to the management of arterial and graft occlusions. Braithwaite BD, et al. **World J Surg** 1996 Jul-Aug;20(6):649-54 (38 ref.)

GENETICS

Molecular biology of graft occlusion. Callow AD. **Curr Opin Cardiol** 1995 Nov;10(6):569-76 (56 ref.)

PATHOLOGY

Vascular access stenosis: prospects for prevention and therapy. Sukhatme VP. **Kidney Int** 1996 Apr;49(4):1161-74 (101 ref.)

PREVENTION & CONTROL

The role of surveillance after infrainguinal bypass grafting. Giannoukas AD, et al. **Eur J Vasc Endovasc Surg** 1996 Apr;11(3):279-89 (107 ref.)

Interposition vein cuffs. Harris P, et al. **J Mal Vasc** 1996; 21 Suppl A:178-80 (11 ref.)

RADIOGRAPHY

[Coronary arteries and coronary artery bypass in CT: options, limitations and perspectives] Steiner P. **Aktuelle Radiol** 1995 Sep;5(5):283-9 (28 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Late conduit occlusion after modified Fontan procedure with classic Glenn shunt. Koutlas TC, et al. **Ann Thorac Surg** 1996 Jul;62(1):258-61; discussion 261-2 (8 ref.)

THERAPY

Intravascular stents: current applications. Bailey SR, et al. **Curr Probl Cardiol** 1995 Sep;20(9):614-78 (191 ref.)

GRAFT REJECTION

An interesting case of failed renal transplant complicated by a lymphocele infected with Pasteurella multocida and a review of the literature. Mayo RR, et al. **Am J Nephrol** 1996;16(4):361-6 (38 ref.)

Xenograft rejection--molecular mechanisms and therapeutic implications. Magee JC, et al. **Ther Immunol** 1994 Jan; 1(1):45-58 (123 ref.)

Comparative study of the role of professional versus semiprofessional or nonprofessional antigen presenting cells in the rejection of vascularized organ allografts. Sundstrom JB, et al. **Transpl Immunol** 1995 Dec;3(4):273-89 (147 ref.)

Graft-versus-host reaction and rejection after experimental small-bowel transplantation. Minireview based on a doctoral thesis. Johnsson C. **Ups J Med Sci** 1995; 100(2):53-92 (178 ref.)

CHEMICALLY INDUCED

Does interferon precipitate rejection of liver allografts? [editorial] Min AD, et al. **Hepatology** 1995 Oct;22(4 Pt 1):1333-5 (22 ref.)

CLASSIFICATION

Liver allograft rejection: current status of classification and grading. Batts K. **Transplant Proc** 1996 Feb;28(1):453-6 (17 ref.)

Diagnosis and grading of liver allograft rejection: a European perspective. Hübscher S. **Transplant Proc** 1996 Feb; 28(1):504-7 (23 ref.)

The Banff classification of renal allograft pathology: where do we go from here? Racusen L, et al. **Transplant Proc** 1996 Feb;28(1):486-8 (22 ref.)

COMPLICATIONS

Spontaneous bacterial peritonitis in a patient with nephrogenic ascites during an episode of acute renal transplant rejection. Horn S, et al. **Am J Kidney Dis** 1996 Mar;27(3):441-3 (22 ref.)

Clinical correlation between renal allograft failure and hyperlipidemia. Guijarro C, et al. **Kidney Int Suppl** 1995 Dec;52:S56-9 (22 ref.)

Recurrence of the original disease. Does this influence renal graft failure? Michielsen P. **Kidney Int Suppl** 1995 Dec; 52:S79-84 (68 ref.)

Post-transplant hypertension and chronic renal allograft failure. Paul LC, et al. **Kidney Int Suppl** 1995 Dec;52:S34-7 (25 ref.)

Chronic rejection and hypertension: a chicken-and-egg problem [editorial; comment] Bock HA. **Nephrol Dial Transplant** 1995;10(7):1126-8 (13 ref.) Comment on: Nephrol Dial Transplant 1995;10(7):1206-11.

[Cholangiopathy after orthotopic liver transplantation: Rejection cholangiopathy] Hashimoto E, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):550-2 (20 ref.) **(Jpn)**

DIAGNOSIS

Liver allograft rejection--current concepts on diagnosis and treatment. Neuberger J. **J Hepatol** 1995;23 Suppl 1:54-61 (52 ref.)

The differential diagnosis between rejection and cyclosporine toxicity. Mihatsch MJ, et al. **Kidney Int Suppl** 1995 Dec; 52:S63-9 (9 ref.)

The Banff classification of renal allograft pathology: where do we go from here? Racusen LC, et al. **Transplant Proc** 1995 Oct;27(5):2561-3 (22 ref.)

[Chronic transplant damages: unsatisfactory long-term results of organ transplantation] Tullius SG, et al. **Dtsch Med Wochenschr** 1995 Dec 22;120(51-52):1791-6 (60 ref.) **(Ger)**

[Corticoid-resistant rejection and humoral rejection. The diagnostic criteria and therapeutic management] Crespo Leiro MG, et al. **Rev Esp Cardiol** 1995;48 Suppl 7:77-85 (29 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Overview of immunosuppressive therapy in organ transplantation. MacGregor MS, et al. **Br J Hosp Med** 1995 Sep 20-Oct 3;54(6):276-84 (32 ref.)

Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in

renal transplantation. Fulton B, et al. **Drugs** 1996 Feb; 51(2):278–98 (78 ref.)
Dual roles of HMG–CoA reductase inhibitors in solid organ transplantation: lipid lowering and immunosuppression. Katznelson S, et al. **Kidney Int Suppl** 1995 Dec;52:S112–5 (30 ref.)
Deoxyspergualin: clinical experience. Gores PF. **Transplant Proc** 1996 Apr;28(2):871–2 (12 ref.)
15–Deoxyspergualin in experimental transplant models: a review. Kaufman DB. **Transplant Proc** 1996 Apr; 28(2):868–70 (31 ref.)
Cyclosporine pharmacology. Lee JI, et al. **Transplant Proc** 1996 Aug;28(4):2156–8 (20 ref.)

ETIOLOGY

Primary corneal graft failure. A national reporting system [editorial; comment] Brightbill FS. **Arch Ophthalmol** 1995 Dec;113(12):1554–5 (9 ref.) Comment on: Arch Ophthalmol 1995 Dec;113(12):1497–502.
Long–term failure of renal transplants: adding insult to injury. Carpenter CB. **Kidney Int Suppl** 1995 Aug;50:S40–4 (43 ref.)
Chronic renal allograft failure: clinical overview. The Leuven Collaborative Group for Transplantation. Peeters J, et al. **Kidney Int Suppl** 1995 Dec;52:S97–101 (50 ref.)
Role of hypertension in chronic renal allograft dysfunction. Sanders CE Jr, et al. **Kidney Int Suppl** 1995 Dec;52:S43–7 (97 ref.)
Chronic rejection and late renal allograft dysfunction. Laine J, et al. **Pediatr Nephrol** 1996 Apr;10(2):221–9 (83 ref.)
Chronic rejection: pathogenesis and treatment. Lee HM. **Transplant Proc** 1996 Jun;28(3):1146–7 (14 ref.)

GENETICS

Hybrid resistance: 'negative' and 'positive' signaling of murine natural killer cells. Bennett M, et al. **Semin Immunol** 1995 Apr;7(2):121–7 (24 ref.)

IMMUNOLOGY

The immune response in small bowel transplantation. Clark CL. **Ann R Coll Surg Engl** 1996 Mar;78(2):97–102 (22 ref.)
The role of cellular adhesion molecules in surgery. Breidahl AF, et al. **Aust N Z J Surg** 1995 Dec;65(12):838–47 (54 ref.)
Role of vascular endothelial cells in the allograft response. Brindle NP. **Eye** 1995;9 (Pt 2):167–72 (63 ref.)
The role of human minor histocompatibility antigens in graft failure: a mini–review. Goulmy E, et al. **Eye** 1995;9 (Pt 2):180–4 (33 ref.)
The mechanisms of corneal graft failure in the rat. Katami M. **Eye** 1995;9 (Pt 2):197–207 (38 ref.)
Histocompatibility antigens. Taylor CJ, et al. **Eye** 1995;9 (Pt 2):173–9 (81 ref.)
Immunobiology and immunopharmacology of organ allograft rejection. Suthanthiran M, et al. **J Clin Immunol** 1995 Jul; 15(4):161–71 (87 ref.)
Immune and nonimmune mechanisms of chronic rejection of kidney allografts. Azuma H, et al. **J Heart Lung Transplant** 1995 Nov–Dec;14(6 Pt 2):S136–42 (50 ref.)
The role of histoincompatibility in cardiac allograft vasculopathy. Costanzo MR. **J Heart Lung Transplant** 1995 Nov–Dec;14(6 Pt 2):S180–4 (19 ref.)
Acute rejection: culprit or coincidence in the pathogenesis of cardiac graft vascular disease? Hauptman PJ, et al. **J Heart Lung Transplant** 1995 Nov–Dec;14(6 Pt 2):S173–80 (55 ref.)
Role of heat shock proteins in heart transplant rejection. Liu K, et al. **J Heart Lung Transplant** 1996 Mar;15(3):222–8 (71 ref.)
Macrophages and transplant arteriosclerosis: known and novel molecules. Russell ME. **J Heart Lung Transplant** 1995 Nov–Dec;14(6 Pt 2):S111–5 (31 ref.)
Alloantigen processing and presentation. Tambur AR, et al. **J Heart Lung Transplant** 1995 Nov–Dec;14(6 Pt 1):1031–7 (49 ref.)
Role of the type I interferons in allograft rejection. Tovey MG, et al. **J Leukoc Biol** 1996 Apr;59(4):512–7 (39 ref.)
Tissue antigens in tubulointerstitial and vascular rejection. van der Woude FJ, et al. **Kidney Int Suppl** 1995 Dec; 52:S11–3 (17 ref.)
Contribution of class I HLA–A2 antigen in immune reactions. Komlos L, et al. **Med Hypotheses** 1995 Jul;45(1):54–8 (41 ref.)
Effector mechanisms in renal allograft rejection. Tax WJ, et al. **Nephrol Dial Transplant** 1995;10(9):1569–71 (15 ref.)
Eicosanoids and renal allograft rejection. Wardle EN. **Nephron** 1995;70(2):151–4 (48 ref.)
Xenobiotics, chimerism and the induction of tolerance following organ transplantation. Delaney CP, et al. **Ther Immunol** 1994 Jun;1(3):153–64 (118 ref.)
Insights into acute and chronic rejection. Azuma H, et al. **Transplant Proc** 1996 Aug;28(4):2081–4 (34 ref.)
[Xenotransplantation] White DJ, et al. **Chirurg** 1996 Apr; 67(4):324–30 (44 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

Pathogenesis and mechanisms of graft rejection in concordant xenotransplantation with special reference to hamster–to–rat cardiac transplantation. Steinbrüchel DA. **APMIS Suppl** 1996;58:5–45 (281 ref.)
Liver allograft rejection: current status of classification and grading. Batts K. **Transplant Proc** 1996 Feb;28(1):453–6 (17 ref.)
Chronic cyclosporine nephropathy in renal transplantation. Bennett WM, et al. **Transplant Proc** 1996 Aug;28(4):2100–3 (29 ref.)
Diagnosis and grading of liver allograft rejection: a European perspective. Hübscher S. **Transplant Proc** 1996 Feb; 28(1):504–7 (23 ref.)
Use of intragraft gene expression in the diagnosis of kidney allograft rejection. Pavlakis M, et al. **Transplant Proc** 1996 Aug;28(4):2019–21 (24 ref.)
The Banff classification of renal allograft pathology: where do we go from here? Racusen L, et al. **Transplant Proc** 1996 Feb;28(1):486–8 (22 ref.)
Clinical and immunological aspects of liver allograft rejection. Schlitt HJ. **Transplant Proc** 1996 Feb;28(1):514–6 (13 ref.)
Report of the Third Banff Conference on Allograft Pathology (July 20–24, 1995) on classification and lesion scoring in renal allograft pathology. Solez K, et al. **Transplant Proc** 1996 Feb;28(1):441–4 (51 ref.)
Adhesion molecules as markers of acute cellular rejection of renal allografts. Truong L, et al. **Transplant Proc** 1996 Feb;28(1):519–22 (31 ref.)
Protocol core biopsy as intermediate efficacy end–point in chronic kidney allograft rejection. Yilmaz S, et al. **Transplant Proc** 1996 Feb;28(1):491–3 (15 ref.)

PHYSIOPATHOLOGY

Endogenous nitric oxide in cardiovascular disease and transplantation. Dusting GJ, et al. **Ann Med** 1995 Jun; 27(3):395–406 (123 ref.)
Ischemia, injury, and renal allograft rejection. Lu CY. **Curr Opin Nephrol Hypertens** 1996 Mar;5(2):107–10 (52 ref.)
Molecular mechanisms of chronic renal allograft rejection. Lemström K, et al. **Kidney Int Suppl** 1995 Dec;52:S2–10 (88 ref.)
Isoprenoids and Ras: potential role in chronic rejection. O'Donnell MP, et al. **Kidney Int Suppl** 1995 Dec;52:S29–33 (49 ref.)
Chronic rejection and late renal allograft dysfunction. Laine J, et al. **Pediatr Nephrol** 1996 Apr;10(2):221–9 (83 ref.)
Chronic allograft rejection. Häyry P, et al. **Transplant Proc** 1996 Aug;28(4):2337–8 (20 ref.)
Clinical and immunological aspects of liver allograft rejection. Schlitt HJ. **Transplant Proc** 1996 Feb;28(1):514–6 (13 ref.)

PREVENTION & CONTROL

The dichotomous functions of passenger leukocytes in solid–organ transplantation. Demetris AJ, et al. **Adv Nephrol Necker Hosp** 1995;24:341–54 (66 ref.)
Optimizing the use of cyclosporine in renal transplantation. Sketris I, et al. **Clin Biochem** 1995 Jun;28(3):195–211 (182 ref.)
Genetic engineering of endothelial cells to ameliorate xenograft rejection. Bach FH, et al. **Clin Transplant** 1996 Feb;10(1 Pt 2):124–7 (19 ref.)
Mycophenolate mofetil (MMF) in heart transplantation: rejection prevention and treatment. Renlund DG, et al. **Clin Transplant** 1996 Feb;10(1 Pt 2):136–9 (29 ref.)
New concepts in tolerance. Wood KJ. **Clin Transplant** 1996 Feb;10(1 Pt 2):93–9 (47 ref.)
The pharmacology of immunosuppressant drugs in skin transplant rejection in mice and other rodents. Gardner CR. **Gen Pharmacol** 1995 Mar;26(2):245–71 (217 ref.)
Adhesion molecules and liver transplantation: new strategies for therapeutic intervention. Adams DH. **J Hepatol** 1995 Aug;23(2):225–31 (58 ref.)
Mycophenolate mofetil in renal transplantation: results from the U.S. randomized trials. Danovitch GM. **Kidney Int Suppl** 1995 Dec;52:S93–6 (19 ref.)
Long–term use of cyclosporine A does not adversely impact on clinical outcomes following renal transplantation. Lewis RM. **Kidney Int Suppl** 1995 Dec;52:S75–8 (35 ref.)
Cyclosporine–induced renal dysfunction in experimental animals and humans. Remuzzi G, et al. **Kidney Int Suppl** 1995 Dec;52:S70–4 (49 ref.)
Mycophenolate mofetil. Sollinger HW. **Kidney Int Suppl** 1995 Dec;52:S14–7 (23 ref.)
Randomised trialomania? The multicentre liver transplant trials of tacrolimus [see comments] Starzl TE, et al. **Lancet** 1995 Nov 18;346(8986):1346–50 (28 ref.) Comment in: Lancet 1995 Nov 18;346(8986):1310–1.
The generation of transgenic pigs as potential organ donors for humans. Cozzi E, et al. **Nat Med** 1995 Sep;1(9):964–6 (30 ref.)
Complement inhibitory therapeutics and xenotransplantation. Ryan US. **Nat Med** 1995 Sep;1(9):967–8 (19 ref.)
The role of calcium–channel antagonists in solid organ transplantation. Huntress JD, et al. **New Horiz** 1996 Feb; 4(1):129–33 (30 ref.)
Brequinar sodium. Cramer DV. **Pediatr Nephrol** 1995;9 Suppl:S52–5 (29 ref.)
Clinical use of tacrolimus (FK–506) in infants and children with renal transplants. Ellis D. **Pediatr Nephrol** 1995 Aug; 9(4):487–94 (45 ref.)
Xenotransplantation: a possible solution to the shortage of donor organs. Bach FH, et al. **Transplant Proc** 1996 Feb; 28(1):416–7 (9 ref.)
Brequinar sodium. Cramer DV. **Transplant Proc** 1996 Apr; 28(2):960–3 (20 ref.)
The potential role of therapeutic antibodies in the regulation of rejection. Ettenger RB, et al. **Transplant Proc** 1995 Oct; 27(5 Suppl 1):13–7 (28 ref.)
Deoxyspergualin: clinical experience. Gores PF. **Transplant Proc** 1996 Apr;28(2):871–2 (12 ref.)
Pharmacokinetics of rapamycin. Yatscoff RW. **Transplant Proc** 1996 Apr;28(2):970–3 (28 ref.)
[Dynamic control of acute crisis of rejection of the transplanted heart based on echocardiography] Kuznetsova LM, et al. **Khirurgiia (Mosk)** 1995;(5):69–72 (47 ref.) **(Rus)**

THERAPY

Liver allograft rejection—current concepts on diagnosis and treatment. Neuberger J. **J Hepatol** 1995;23 Suppl 1:54–61 (52 ref.)
Chronic renal allograft rejection and clinical trial design. Kasiske BL, et al. **Kidney Int Suppl** 1995 Dec;52:S116–9 (12 ref.)
Clinical utility of antilipidemic therapies in chronic renal allograft failure. Wanner C, et al. **Kidney Int Suppl** 1995 Dec;52:S60–2 (38 ref.)
Chronic rejection: pathogenesis and treatment. Lee HM. **Transplant Proc** 1996 Jun;28(3):1146–7 (14 ref.)

GRAFT SURVIVAL

15–Deoxyspergualin in experimental transplant models: a review. Kaufman DB. **Transplant Proc** 1996 Apr; 28(2):868–70 (31 ref.)
[Renal transplantation from related live donors. Results and survival] Hajri M, et al. **Ann Urol (Paris)** 1995;29(3):186–92 (17 ref.) (Eng. Abstr.) **(Fre)**

DRUG EFFECTS

Long–term use of cyclosporine A does not adversely impact on clinical outcomes following renal transplantation. Lewis RM. **Kidney Int Suppl** 1995 Dec;52:S75–8 (35 ref.)
Cyclosporine–induced renal dysfunction in experimental animals and humans. Remuzzi G, et al. **Kidney Int Suppl** 1995 Dec;52:S70–4 (49 ref.)
Immunosuppression with the vitamin D analogue MC 1288 in experimental transplantation. Johnsson C, et al. **Transplant Proc** 1996 Apr;28(2):888–91 (35 ref.)

IMMUNOLOGY

IL–10 immunosuppression in transplantation. Bromberg JS. **Curr Opin Immunol** 1995 Oct;7(5):639–43 (51 ref.)
Immunological non–responsiveness and acquisition of tolerance in relation to immune privilege in the eye. Streilein JW. **Eye** 1995;9 (Pt 2):236–40 (28 ref.)
The changing immunology of organ transplantation. Starzl TE, et al. **Hosp Pract (Off Ed)** 1995 Oct 15;30(10):31–4, 37–42 (11 ref.)
Tolerance and xenograft survival. Sachs DH, et al. **Nat Med** 1995 Sep;1(9):969 (6 ref.)
Liver transplants contribute to their own success [comment] Starzl TE, et al. **Nat Med** 1996 Feb;2(2):163–5 (22 ref.) Comment on: Nat Med 1996 Feb;2(2):198–203.
Antiviral antibodies in transplantation. Snydman DR. **Transplant Proc** 1995 Oct;27(5 Suppl 1):10–2 (22 ref.)

PHYSIOLOGY

[Dynamic bone marrow take and lymphohematopoietic chimerism following allogeneic bone marrow transplantation] Demidova IA, et al. **Ter Arkh** 1995; 67(8):74–80 (90 ref.) **(Rus)**

GRAFT–VERSUS–HOST DISEASE see **GRAFT VS HOST DISEASE**

GRAFT VS HOST DISEASE

[Graft–versus–host disease] Hashimoto E, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):453–6 (20 ref.) **(Jpn)**

CLASSIFICATION

1994 Consensus Conference on Acute GVHD Grading. Przepiorka D, et al. **Bone Marrow Transplant** 1995 Jun; 15(6):825–8 (11 ref.)

COMPLICATIONS

Unexplained effusions: association with allogeneic bone marrow transplantation and acute or chronic graft–versus–host disease. Seber A, et al. **Bone Marrow Transplant** 1996 Feb;17(2):207–11 (28 ref.)

DIAGNOSIS

[Clinical and histologic diagnosis of graft–versus–host disease] Takahashi S, et al. **Rinsho Byori** 1995 Jul;Suppl 99:111–6 (12 ref.) **(Jpn)**

DRUG THERAPY

Targeting T cells for GVHD therapy. Vallera DA.

GRAFT VS HOST DISEASE

Semin Cancer Biol 1996 Apr;7(2):57–64 (57 ref.)

ETIOLOGY

T cells, graft–versus–host disease and graft–versus–leukemia: innovative approaches for blood and marrow transplantation. Champlin R, et al. **Acta Haematol** 1996; 95(3–4):157–63 (67 ref.)

Bone marrow transplantation for chronic myeloid leukemia with volunteer unrelated donors using ex vivo or in vivo T-cell depletion: major prognostic impact of HLA class I identity between donor and recipient. Spencer A, et al. **Blood** 1995 Nov 1;86(9):3590–7 (40 ref.)

Immunomodulation in allogeneic marrow transplantation: use of intravenous immune globulin to suppress acute graft–versus–host disease. Sullivan KM. **Clin Exp Immunol** 1996 May;104 Suppl 1:43–8 (68 ref.)

Graft–versus–host disease and the Th1/Th2 paradigm. Krenger W, et al. **Immunol Res** 1996;15(1):50–73 (172 ref.)

Posttransfusion graft–versus–host disease in Japanese newborns [see comments] Ohto H, et al. **Transfusion** 1996 Feb;36(2):117–23 (60 ref.) Comment in: Transfusion 1996 Feb;36(2):101–3.

IMMUNOLOGY

Strategies to enhance the graft–versus–malignancy effect in allogeneic transplants. Barrett JA. **Ann N Y Acad Sci** 1995 Dec 29;770:203–12 (45 ref.)

Antitumor activity of syngeneic/autologous graft–versus–host disease. Hess AD, et al. **Ann N Y Acad Sci** 1995 Dec 29;770:189–202 (59 ref.)

The immune response in small bowel transplantation. Clark CL. **Ann R Coll Surg Engl** 1996 Mar;78(2):97–102 (22 ref.)

Predicting graft–versus–host disease. Theobald M. **Curr Opin Immunol** 1995 Oct;7(5):649–55 (57 ref.)

Graft–versus–host disease and the Th1/Th2 paradigm. Krenger W, et al. **Immunol Res** 1996;15(1):50–73 (172 ref.)

Does graft–versus–host disease attack epithelial stem cells? Sale GE. **Mol Med Today** 1996 Mar;2(3):114–9 (32 ref.)

Survey of transfusion–associated graft–versus–host disease in immunocompetent recipients. Ohto H, et al. **Transfus Med Rev** 1996 Jan;10(1):31–43 (132 ref.)

[Skin manifestations of graft–versus–host reaction following bone marrow transplantation] Itin PH, et al. **Schweiz Med Wochenschr** 1996 Mar 2;126(9):339–47 (41 ref.) (Eng. Abstr.) **(Ger)**

METABOLISM

Cytokines, adhesion molecules (E–selectin and VCAM–1) and graft–versus–host disease. Lange A, et al. **Arch Immunol Ther Exp (Warsz)** 1995;43(2):99–105 (23 ref.)

PHYSIOPATHOLOGY

Dysregulation of cytokines during graft–versus–host disease. Krenger W, et al. **J Hematother** 1996 Feb;5(1):3–14 (136 ref.)

PREVENTION & CONTROL

Use of irradiated blood components: practice parameter. Przepiorka D, et al. **Am J Clin Pathol** 1996 Jul;106(1):6–11 (55 ref.)

Prevention and treatment of graft–versus–host disease. Chao NJ, et al. **Ann N Y Acad Sci** 1995 Dec 29;770:130–40 (13 ref.)

Cytokine inhibitors and graft–versus–host disease. Ferrara JL. **Ann N Y Acad Sci** 1995 Dec 29;770:227–36 (38 ref.)

Prevention of graft–versus–host disease. Studies in a canine model. Storb R, et al. **Ann N Y Acad Sci** 1995 Dec 29; 770:149–64 (27 ref.)

Irradiation in the prevention of transfusion associated graft–versus–host disease. Webb DK. **Arch Dis Child** 1995 Nov;73(5):388–9 (38 ref.)

Immunomodulation in allogeneic marrow transplantation: use of intravenous immune globulin to suppress acute graft–versus–host disease. Sullivan KM. **Clin Exp Immunol** 1996 May;104 Suppl 1:43–8 (68 ref.)

Separation of graft–vs.–host disease and graft–vs.–leukemia effect against chronic myelogenous leukemia [editorial; comment] Champlin R. **Exp Hematol** 1995 Oct; 23(11):1148–51 (48 ref.) Comment on: Exp Hematol 1995 Oct;23(11):1167–72.

Posttransfusion graft–versus–host disease in Japanese newborns [see comments] Ohto H, et al. **Transfusion** 1996 Feb;36(2):117–23 (60 ref.) Comment in: Transfusion 1996 Feb;36(2):101–3.

Prevention of graft–versus–host disease after bone marrow transplantation. Storb R. **Transplant Proc** 1995 Oct; 27(5):2653–6 (20 ref.)

THERAPY

Prevention and treatment of graft–versus–host disease. Chao NJ, et al. **Ann N Y Acad Sci** 1995 Dec 29;770:130–40 (13 ref.)

New and experimental therapies for treating graft–versus–host disease. Lazarus HM, et al. **Blood Rev** 1995 Jun;9(2):117–33 (271 ref.)

GRAFT VS HOST REACTION

see related
GRAFT VS HOST DISEASE

Graft–versus–leukemia and graft–versus–lymphoma effects of allogeneic bone marrow transplantation and of allogeneic donor leukocyte transfusions. Vandenberghe P, et al. **Ann Hematol** 1995 Nov;71(5):209–17 (65 ref.)

Graft–versus–host reaction and rejection after experimental small–bowel transplantation. Minireview based on a doctoral thesis. Johnsson C. **Ups J Med Sci** 1995; 100(2):53–92 (178 ref.)

[Bone marrow transplantation and GVH reaction] Imamura M. **Nippon Naika Gakkai Zasshi** 1995 Sep 10;84(9):1489–93 (22 ref.) **(Jpn)**

GRAFTING, BONE see **BONE TRANSPLANTATION**

GRAFTING, BONE MARROW see **BONE MARROW TRANSPLANTATION**

GRAFTING, BRAIN TISSUE see **BRAIN TISSUE TRANSPLANTATION**

GRAFTING, CORNEAL see **CORNEAL TRANSPLANTATION**

GRAFTING, FETAL TISSUE see **FETAL TISSUE TRANSPLANTATION**

GRAFTING, HEART see **HEART TRANSPLANTATION**

GRAFTING, HEART–LUNG see **HEART–LUNG TRANSPLANTATION**

GRAFTING, ISLETS OF LANGERHANS see **ISLETS OF LANGERHANS TRANSPLANTATION**

GRAFTING, KIDNEY see **KIDNEY TRANSPLANTATION**

GRAFTING, LIVER see **LIVER TRANSPLANTATION**

GRAFTING, LUNG see **LUNG TRANSPLANTATION**

GRAFTING, ORGAN see **ORGAN TRANSPLANTATION**

GRAFTING, PANCREAS see **PANCREAS TRANSPLANTATION**

GRAFTING, SKIN see **SKIN TRANSPLANTATION**

GRAFTING, TISSUE see **TISSUE TRANSPLANTATION**

GRAIN see **CEREALS**

GRAM–NEGATIVE AEROBIC BACTERIA

DRUG EFFECTS

Antimicrobial activity of cefotaxime tested against infrequently isolated pathogenic species (unusual pathogens). Cormican MG, et al. **Diagn Microbiol Infect Dis** 1995 May–Jun;22(1–2):43–8 (46 ref.)

Prevention of bacterial infection in the transplant recipient. The role of selective bowel decontamination. Arnow PM. **Infect Dis Clin North Am** 1995 Dec;9(4):849–62 (63 ref.)

METABOLISM

Methanotrophic bacteria. Hanson RS, et al. **Microbiol Rev** 1996 Jun;60(2):439–71 (436 ref.)

PHYSIOLOGY

The genus Sphingomonas: physiology and ecology. White DC, et al. **Curr Opin Biotechnol** 1996 Jun;7(3):301–6 (32 ref.)

GRAM–NEGATIVE ANAEROBIC BACTERIA

CLASSIFICATION

Update on the taxonomy and the clinical and laboratory characteristics of pigmented anaerobic gram–negative rods. Jousimies–Somer HR. **Clin Infect Dis** 1995 Jun;20 Suppl 2:S187–91 (24 ref.)

ISOLATION & PURIFICATION

Bilophila wadsworthia isolates from clinical specimens. Summanen PH, et al. **Clin Infect Dis** 1995 Jun;20 Suppl 2:S210–1 (7 ref.)

PATHOGENICITY

Clinical correlates of anaerobic bacteriology in peritonitis. Wilson SE, et al. **Clin Infect Dis** 1995 Jun;20 Suppl 2:S251–6 (38 ref.)

GRAM–NEGATIVE BACTERIA

CHEMISTRY

Phylogenetic analyses of the ATP–binding constituents of bacterial extracytoplasmic receptor–dependent ABC–type nutrient uptake permeases. Kuan G, et al. **Res Microbiol** 1995 May;146(4):271–8 (16 ref.)

CLASSIFICATION

Fastidious gram–negative bacteria: meeting the diagnostic challenge with nucleic acid analysis. Tønjum T, et al. **APMIS** 1995 Sep;103(9):609–27 (100 ref.)

DRUG EFFECTS

Antimicrobial resistance patterns in long term geriatric care. Implications for drug therapy. Mao CA, et al. **Drugs Aging** 1996 Mar;8(3):162–70 (66 ref.)

[Specificities of antibacterial activity of zwitterionic 7–methoxyimino cephems (cephalosporins of fourth generation] Pechère JC. **Pathol Biol (Paris)** 1996 Feb; 44(2):99–105 (26 ref.) (Eng. Abstr.) **(Fre)**

[Azithromycin: critical points] Philippon A, et al. **Pathol Biol (Paris)** 1995 Jun;43(6):488–97 (55 ref.) (Eng. Abstr.) **(Fre)**

ENZYMOLOGY

beta–Lactamases in laboratory and clinical resistance. Livermore DM. **Clin Microbiol Rev** 1995 Oct;8(4):557–84 (283 ref.)

GENETICS

Multidrug resistance in enteric and other gram–negative bacteria. George AM. **FEMS Microbiol Lett** 1996 May 15; 139(1):1–10 (42 ref.)

IMMUNOLOGY

Role of O–antigen variation in the immune response. Reeves P. **Trends Microbiol** 1995 Oct;3(10):381–6 (49 ref.)

METABOLISM

Enzymes and associated electron transport systems that catalyse the respiratory reduction of nitrogen oxides and oxyanions. Berks BC, et al. **Biochim Biophys Acta** 1995 Dec 12;1232(3):97–173 (625 ref.)

HPr: heteromorphous protein. Vadeboncoeur C. **Res Microbiol** 1995 Sep;146(7):525–30 (41 ref.)

[Cytolysins and homologous proteins produced by gram–negative bacteria. I. Hemolysis and leukotoxins of Escherichia coli, Bordetella pertussis, Pasteurella haemolytica and Actinobacillus sp] Różalski A. **Postepy Hig Med Dosw** 1996;50(2):173–90 (103 ref.) (Eng. Abstr.) **(Pol)**

PATHOGENICITY

Molecular aspects of bacterial colonization. Bisno AL. **Infect Control Hosp Epidemiol** 1995 Nov;16(11):648–57 (83 ref.)

PHYSIOLOGY

[Role of gram–negative bacterial endotoxins in infectious and non–infectious diseases] Likhoded VG, et al. **Arkh Patol** 1996 Mar–Apr;58(2):8–13 (43 ref.) (Eng. Abstr.) **(Rus)**

GRAM–NEGATIVE BACTERIAL INFECTIONS

Motile Aeromonas as agent of infections of the foot. Wakabongo M. **J Am Podiatr Med Assoc** 1995 Sep; 85(9):505–8 (53 ref.)

COMPLICATIONS

Rahnella aquatilis bacteremia in an HIV–infected intravenous drug abuser. Funke G, et al. **Diagn Microbiol Infect Dis** 1995 Jul;22(3):293–6 (8 ref.)

[Neurologic complications of infectious endocarditis] Gergaud JM, et al. **Ann Med Interne (Paris)** 1995; 146(6):413–8 (34 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Fastidious gram–negative bacteria: meeting the diagnostic challenge with nucleic acid analysis. Tønjum T, et al. **APMIS** 1995 Sep;103(9):609–27 (100 ref.)

Capnocytophaga canimorsus septicemia: fifth report of a cat–associated infection and five other cases. Valtonen M, et al. **Eur J Clin Microbiol Infect Dis** 1995 Jun;14(6):520–3 (25 ref.)

Alcaligenes xylosoxidans subsp xylosoxidans in children with chronic otorrhea. Wintermeyer SM, et al. **Otolaryngol Head Neck Surg** 1996 Feb;114(2):332–4 (15 ref.)

Plesiomonas shigelloides septicemia: case report and literature review. Lee AC, et al. **Pediatr Hematol Oncol** 1996 May–Jun;13(3):265–9 (23 ref.)

DRUG THERAPY

Neutropenic infections: strategies for empirical therapy. Kibbler CC. **J Antimicrob Chemother** 1995 Oct;36 Suppl B:107–17 (65 ref.)

[Aminoglycosides in pediatrics] Schaad UB. **Schweiz Med Wochenschr Suppl** 1996;76:34S–38S (23 ref.) (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

[Soft-tissue infection caused by Aeromonas hydrophila] Ramos JM, et al. **Enferm Infecc Microbiol Clin** 1995 Oct; 13(8):469–72 (27 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

Pyomyositis in intravenous drug abusers: report of a unique case and review of the literature. Hsueh PR, et al. **Clin Infect Dis** 1996 May;22(5):858–60 (10 ref.)

Indications and complications of medicinal leech therapy. Haycox CL, et al. **J Am Acad Dermatol** 1995 Dec; 33(6):1053–5 (10 ref.)

[Eikenella corrodens pleuro-pulmonary infection. Apropos of a case] Salem M, et al. **Rev Pneumol Clin** 1996; 52(3):192–5 (23 ref.) (Eng. Abstr.) **(Fre)**

MICROBIOLOGY

Stenotrophomonas maltophilia: an unusual cause of biliary sepsis. Papadakis KA, et al. **Clin Infect Dis** 1995 Oct; 21(4):1032–4 (9 ref.)

Bilophila wadsworthia isolates from clinical specimens. Summanen PH, et al. **Clin Infect Dis** 1995 Jun;20 Suppl 2:S210–1 (7 ref.)

Clinical correlates of anaerobic bacteriology in peritonitis. Wilson SE, et al. **Clin Infect Dis** 1995 Jun;20 Suppl 2:S251–6 (38 ref.)

Resistant nosocomial gram-negative bacillary pathogens: Acinetobacter baumannii, Xanthomonas maltophilia, and Pseudomonas cepacia. Fang FC, et al. **Curr Clin Top Infect Dis** 1996;16:52–83 (363 ref.)

Veillonella infections in children. Brook I. **J Clin Microbiol** 1996 May;34(5):1283–5 (21 ref.)

The emergence of epidemic, multiple-antibiotic-resistant Stenotrophomonas (Xanthomonas) maltophilia and Burkholderia (Pseudomonas) cepacia. Spencer RC. **J Hosp Infect** 1995 Jun;30 Suppl:453–64 (105 ref.)

PREVENTION & CONTROL

[Antibiotic prophylaxis in biliary surgery] Gondret R, et al. **Ann Chir** 1995;49(6):493–9 (52 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

[A case of secondary valve replacement caused by pulmonary bioprosthetic valve endocarditis] Fujii H, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Jul;43(7):1081–5 (18 ref.) (Eng. Abstr.) **(Jpn)**

THERAPY

Endotoxin-based molecular strategies for the prevention and treatment of gram-negative sepsis and septic shock. Pollack M, et al. **Curr Top Microbiol Immunol** 1996;216:275–97 (185 ref.)

New immunotherapies for sepsis. Young LS, et al. **Proc Assoc Am Physicians** 1995 Oct;107(3):361–4 (19 ref.)

GRAM-NEGATIVE FACULTATIVELY ANAEROBIC RODS

GENETICS

O2-sensing and O2-dependent gene regulation in facultatively anaerobic bacteria. Unden G, et al. **Arch Microbiol** 1995 Aug;164(2):81–90 (112 ref.)

GRAM-POSITIVE BACTERIA

CHEMISTRY

Phylogenetic analyses of the ATP-binding constituents of bacterial extracytoplasmic receptor-dependent ABC-type nutrient uptake permeases. Kuan G, et al. **Res Microbiol** 1995 May;146(4):271–8 (16 ref.)

DRUG EFFECTS

Antimicrobial activity of cefotaxime tested against infrequently isolated pathogenic species (unusual pathogens). Cormican MG, et al. **Diagn Microbiol Infect Dis** 1995 May-Jun;22(1-2):43–8 (46 ref.)

In vitro activity of fluoroquinolones against gram-positive bacteria. Eliopoulos GM. **Drugs** 1995;49 Suppl 2:48–57 (37 ref.)

Bacteriocins: modes of action and potentials in food preservation and control of food poisoning. Abee T, et al. **Int J Food Microbiol** 1995 Dec;28(2):169–85 (56 ref.)

[Specificities of antibacterial activity of zwitterionic 7-methoxyimino cephems (cephalosporins of fourth generation] Pechère JC. **Pathol Biol (Paris)** 1996 Feb; 44(2):99–105 (26 ref.) (Eng. Abstr.) **(Fre)**

[Azithromycin: critical points] Philippon A, et al. **Pathol Biol (Paris)** 1995 Jun;43(6):488–97 (55 ref.) (Eng. Abstr.) **(Fre)**

ENZYMOLOGY

beta-Lactamases in laboratory and clinical resistance. Livermore DM. **Clin Microbiol Rev** 1995 Oct;8(4):557–84 (283 ref.)

GENETICS

The genetics of lantibiotic biosynthesis. Jack R, et al. **Bioessays** 1995 Sep;17(9):793–802 (69 ref.)

Site-specific recombination in gram-positive theta-replicating plasmids. Alonso JC, et al. **FEMS Microbiol Lett** 1996 Aug 15;142(1):1–10 (28 ref.)

ISOLATION & PURIFICATION

Microbiological monitoring of aortic aneurysm sac contents during abdominal aneurysmectomy: results in 176 patients and review of the literature. Fourneau I, et al. **Acta Chir Belg** 1996 Jun;96(3):119–22 (14 ref.)

Recovery of uncommon bacteria from blood: association with neoplastic disease. Beebe JL, et al. **Clin Microbiol Rev** 1995 Jul;8(3):336–56 (332 ref.)

METABOLISM

Lantibiotics. Gasson MJ. **Biotechnology** 1995;28:283–306 (78 ref.)

Maturation pathway of nisin and other lantibiotics: post-translationally modified antimicrobial peptides exported by gram-positive bacteria. de Vos WM, et al. **Mol Microbiol** 1995 Aug;17(3):427–37 (73 ref.)

HPr: heteromorphous protein. Vadeboncoeur C. **Res Microbiol** 1995 Sep;146(7):525–30 (41 ref.)

PATHOGENICITY

The new threats of Gram positive pathogens: re-emergence of things past. Howe RA, et al. **J Clin Pathol** 1996 Jun; 49(6):444–9 (69 ref.)

PHYSIOLOGY

Anchorage and release of Gram-positive bacterial cell-surface polypeptides. Jenkinson HF. **Trends Microbiol** 1995 Sep;3(9):333–5 (15 ref.)

GRAM-POSITIVE BACTERIAL INFECTIONS

COMPLICATIONS

Identification, classification, and clinical relevance of catalase-negative, gram-positive cocci, excluding the streptococci and enterococci. Facklam R, et al. **Clin Microbiol Rev** 1995 Oct;8(4):479–95 (162 ref.)

DIAGNOSIS

[Enterococcal neonatal endocarditis] Roca Comas A, et al. **An Esp Pediatr** 1996 Feb;44(2):159–60 (17 ref.) **(Spa)**

DRUG THERAPY

Injectable medications for hemodialysis patients. Stivelman JC. **Am J Nephrol** 1996;16(1):73–8 (55 ref.)

Current perspectives on glycopeptide resistance. Woodford N, et al. **Clin Microbiol Rev** 1995 Oct;8(4):585–615 (429 ref.)

Bacteria and antimicrobial agents in the treatment of acne. Parry EJ, et al. **Int J Dermatol** 1996 Apr;35(4):249–51 (15 ref.)

Neutropenic infections: strategies for empirical therapy. Kibbler CC. **J Antimicrob Chemother** 1995 Oct;36 Suppl B:107–17 (65 ref.)

[Enterococcal endocarditis] Kizner V, et al. **Harefuah** 1996 Apr 15;130(8):548–50 (18 ref.) **(Heb)**

[Treatment of endocarditis and other severe infections caused by enterococci] Fernández-Guerrero ML. **Enferm Infecc Microbiol Clin** 1996 Mar;14(3):186–91 (74 ref.) **(Spa)**

EPIDEMIOLOGY

Current perspectives on glycopeptide resistance. Woodford N, et al. **Clin Microbiol Rev** 1995 Oct;8(4):585–615 (429 ref.)

[Enterococci; increase in infection rate and antibiotic resistance] Thompson J. **Ned Tijdschr Geneeskd** 1996 Jan 20;140(3):130–3 (23 ref.) (Eng. Abstr.) **(Dut)**

ETIOLOGY

Propionibacterium acnes vertebral osteomyelitis following lumbar puncture: case report and review [letter] Abolnik IZ, et al. **Clin Infect Dis** 1995 Sep;21(3):694–5 (10 ref.)

Enterococcal arthritis: case report and review. Raymond NJ, et al. **Clin Infect Dis** 1995 Sep;21(3):516–22 (54 ref.)

Pyogenic liver abscess: warning indicator of silent colonic cancer. Report of a case and review of the literature. Teitz S, et al. **Dis Colon Rectum** 1995 Nov;38(11):1220–3 (18 ref.)

MICROBIOLOGY

Enterococcal arthritis with avascular necrosis in a lupus patient. Markov G, et al. **Br J Rheumatol** 1996 Jun; 35(6):595–7 (11 ref.)

[Enterococci; increase in infection rate and antibiotic resistance] Thompson J. **Ned Tijdschr Geneeskd** 1996 Jan 20;140(3):130–3 (23 ref.) (Eng. Abstr.) **(Dut)**

PREVENTION & CONTROL

Controversies in endophthalmitis prevention. The risk for emerging resistance to vancomycin [editorial; comment] Alfonso EC, et al. **Arch Ophthalmol** 1995 Nov; 113(11):1369–70 (15 ref.) Comment on: Arch Ophthalmol 1995 Nov;113(11):1353–4.

RADIOGRAPHY

[Computed tomographic demonstration of intraspinal air after an infection with peptostreptococci] Lorenzen J, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Feb;164(2):173–5 (10 ref.) **(Ger)**

GRAM-POSITIVE COCCI

CLASSIFICATION

Identification, classification, and clinical relevance of catalase-negative, gram-positive cocci, excluding the streptococci and enterococci. Facklam R, et al. **Clin Microbiol Rev** 1995 Oct;8(4):479–95 (162 ref.)

DRUG EFFECTS

Activity of quinolones against gram-positive cocci: clinical features. Giamarellou H. **Drugs** 1995;49 Suppl 2:58–66 (60 ref.)

Emerging resistance in clinically important gram-positive cocci. Thornsberry C. **West J Med** 1996 Jan;164(1):28–32 (18 ref.)

GENETICS

Current perspectives on glycopeptide resistance. Woodford N, et al. **Clin Microbiol Rev** 1995 Oct;8(4):585–615 (429 ref.)

IMMUNOLOGY

Superantigens and pseudosuperantigens of gram-positive cocci. Fleischer B, et al. **Med Microbiol Immunol (Berl)** 1995 May;184(1):1–8 (85 ref.)

ISOLATION & PURIFICATION

Identification, classification, and clinical relevance of catalase-negative, gram-positive cocci, excluding the streptococci and enterococci. Facklam R, et al. **Clin Microbiol Rev** 1995 Oct;8(4):479–95 (162 ref.)

RADIATION EFFECTS

Repair of ionizing-radiation damage in the radiation resistant bacterium Deinococcus radiodurans. Minton KW. **Mutat Res** 1996 May 15;363(1):1–7 (34 ref.)

GRAMICIDIN

CHEMISTRY

Molecular structure and mechanisms of action of cyclic and linear ion transport antibiotics. Duax WL, et al. **Biopolymers** 1996;40(1):141–55 (44 ref.)

GRAMINEA see **GRASSES**

GRANA see **CHLOROPLASTS**

GRANISETRON

Granisetron: the second serotonin-receptor antagonist. Adams VR, et al. **Ann Pharmacother** 1995 Dec; 29(12):1240–51 (72 ref.)

PHARMACOLOGY

A pharmacologic profile of oral granisetron (Kytril tablets). Blower P. **Semin Oncol** 1995 Aug;22(4 Suppl 10):3–5 (13 ref.)

THERAPEUTIC USE

Prophylaxis with oral granisetron for acute emesis induced by moderately emetogenic chemotherapy. Hesketh P. **Semin Oncol** 1995 Aug;22(4 Suppl 10):19–23 (23 ref.)

GRANTS AND SUBSIDIES, EDUCATIONAL see **TRAINING SUPPORT**

GRANTS AND SUBSIDIES, GOVERNMENT see **FINANCING, GOVERNMENT**

GRANTS AND SUBSIDIES, RESEARCH see **RESEARCH SUPPORT**

GRANTS, PEER REVIEW see **PEER REVIEW, RESEARCH**

GRANULAR CELL MYOBLASTOMA see **GRANULAR CELL TUMOR**

GRANULAR CELL TUMOR

[Granular-cell tumor: review of the literature apropos of a case of bronchial site] Hocqueloux L, et al. **Rev Med Interne** 1996;17(5):415–8 (16 ref.) (Eng. Abstr.) **(Fre)**

[Granular cell tumor of the male breast. Case report and review of the literature] Reale D, et al. **Minerva Chir** 1995 Jul–Aug;50(7–8):717–20 (18 ref.) (Eng. Abstr.) **(Ita)**

[Granular cell tumor] Kitamra T. **Ryoikibetsu Shokogun Shirizu** 1996;(9):259–60 (5 ref.) **(Jpn)**

PATHOLOGY

Granular cell change in astrocytic tumors. Geddes JF, et al. **Am J Surg Pathol** 1996 Jan;20(1):55–63 (50 ref.)

Stump the experts. Case. Granular-cell tumor [see comments] Skidmore RA, et al. **Dermatol Surg** 1995 Nov;21(11):925, 997–8 (17 ref.) Comment in: Dermatol Surg 1996 May;22(5):484.

Tumoral fibrosis and lack of circumscription in granular cell tumor of the breast. Kragel PJ, et al. **South Med J** 1995 Nov;88(11):1146–8 (26 ref.)

[Granular-cell tumor of the oral cavity (a case report and statistical notes)] Sica GS, et al. **Minerva Stomatol** 1995 May;44(5):257–61 (18 ref.) (Eng. Abstr.) **(Ita)**

GRANULOCYTE COLONY-STIMULATING FACTOR

see related
RECEPTORS, GRANULOCYTE COLONY-STIMULATING FACTOR

Filgrastim (r-metHuG-CSF): the first 10 years. Welte K, et al. **Blood** 1996 Sep 15;88(6):1907–29 (176 ref.)

[Biologic aspects and clinical use of granulocyte growth factor] Rupoli S, et al. **Recenti Prog Med** 1995 Dec; 86(12):510–7 (30 ref.) (Eng. Abstr.) **(Ita)**

ADMINISTRATION & DOSAGE

European School of Oncology European consensus on the use of granulocyte colony-stimulating factor: the example of breast cancer. Antoine EC, et al. **Cancer Chemother Pharmacol** 1996;38 Suppl:S103–9 (71 ref.)

Resolution of the neutropenia of Felty's syndrome by longterm administration of recombinant granulocyte colony stimulating factor. Krishnaswamy G, et al. **J Rheumatol** 1996 Apr;23(4):763–5 (18 ref.)

ADVERSE EFFECTS

Safety of AlloPBPCT donors: biometrical considerations on monitoring long term risks. Hasenclever D, et al. **Bone Marrow Transplant** 1996 Mar;17 Suppl 2:S28–30 (14 ref.)

Sweet's syndrome associated with granulocyte colony-stimulating factor. Jain KK. **Cutis** 1996 Feb; 57(2):107–10 (26 ref.)

BLOOD

[Granulocyte colony-stimulating factor (G-CSF)] Wakimoto N, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:800–2 (8 ref.) **(Jpn)**

PHARMACOLOGY

The place of blood stem cells in allogeneic transplantation. Russel N, et al. **Br J Haematol** 1996 Jun 2;93(4):747–53 (55 ref.)

G-CSF-stimulated PMN in immunotherapy of breast cancer with a bispecific antibody to Fc gamma RI and to HER-2/neu (MDX-210). Repp R, et al. **J Hematother** 1995 Oct;4(5):415–21 (26 ref.)

Rising serum lactate dehydrogenase often caused by granulocyte-or Granulocyte-macrophage colony stimulating factor and not tumor progression in patients with lymphoma or myeloma. Sarris AH, et al. **Leuk Lymphoma** 1995 May;17(5–6):473–7 (25 ref.)

Cytokine-mobilized peripheral blood progenitor cells. Nemunaitis J. **Semin Oncol** 1996 Apr;23(2 Suppl 4):9–14 (18 ref.)

PHYSIOLOGY

Review: granulocyte colony-stimulating factor--role and relationships in infectious diseases. Dale DC, et al. **J Infect Dis** 1995 Oct;172(4):1061–75 (204 ref.)

G-CSF in the biology and treatment of acute myeloid leukemias. Visani G, et al. **Leuk Lymphoma** 1995 Aug; 18(5–6):423–8 (62 ref.)

THERAPEUTIC USE

Haematopoietic growth factors as supportive therapy in HIV-infected patients. Hermans P. **AIDS** 1995 Dec;9 Suppl 2:S9–S14 (35 ref.)

Rationale for high-dose chemotherapy and application of haematopoietic growth factors in acute myeloid leukaemia. Hiddemann W, et al. **Ann Oncol** 1995;6 Suppl 4:27–31 (33 ref.)

Haematological support of high-dose sequential chemotherapy: clinical evidence for reduction of toxicity and high response rates in poor risk lymphomas. Tarella C, et al. **Ann Oncol** 1995;6 Suppl 4:3–8 (30 ref.)

Hematopoietic growth factors in cancer chemotherapy. Morstyn G, et al. **Cancer Chemother Biol Response Modif** 1996;16:295–314 (99 ref.)

Biology and clinical potential of stem-cell factor. Glaspy J, et al. **Cancer Chemother Pharmacol** 1996;38 Suppl:S53–7 (33 ref.)

Should hematopoietic growth factors routinely be given concurrently with cytotoxic chemotherapy? Croockewit AJ, et al. **Clin Pharmacol Ther** 1996 Jan;59(1):1–6 (31 ref.)

Haemopoietic growth factors and childhood cancer. Hann IM. **Eur J Cancer** 1995;31A(9):1476–8 (27 ref.)

Adjuncts to antibacterial therapy. Frank MO, et al. **Infect Dis Clin North Am** 1995 Sep;9(3):769–81 (63 ref.)

Successful hematopoietic reconstitution with granulocyte colony-stimulating factor in a patient with hypoplastic acute myelogenous leukemia. Lee M, et al. **Intern Med** 1995 Jul;34(7):692–4 (15 ref.)

Use of cytokines in the treatment of acute myelocytic leukemia: a critical review. Geller RB. **J Clin Oncol** 1996 Apr;14(4):1371–82 (65 ref.)

Review: granulocyte colony-stimulating factor--role and relationships in infectious diseases. Dale DC, et al. **J Infect Dis** 1995 Oct;172(4):1061–75 (204 ref.)

The use of GM-CSF and G-CSF in the treatment of acute leukemias. Harousseau JL, et al. **Leuk Lymphoma** 1995 Aug;18(5–6):405–12 (70 ref.)

G-CSF in the biology and treatment of acute myeloid leukemias. Visani G, et al. **Leuk Lymphoma** 1995 Aug; 18(5–6):423–8 (62 ref.)

Myelodysplastic syndromes in the elderly: the role of growth factors in management. Saba HI. **Leuk Res** 1996 Mar; 20(3):203–19 (136 ref.)

Do G-CSF and GM-CSF contribute to the management of acute lymphoblastic leukemia? [editorial] Ottmann OG, et al. **Leukemia** 1996 Jul;10(7):1111–6 (33 ref.)

[Agranulocytosis caused by clozapine: the importance of leukocyte monitoring and efficacy of hematopoietic growth factors] van Melick EJ, et al. **Ned Tijdschr Geneeskd** 1995 Nov 25;139(47):2437–40 (18 ref.) (Eng. Abstr.) **(Dut)**

GRANULOCYTE-COLONY-STIMULATING FACTOR RECEPTORS see **RECEPTORS, GRANULOCYTE COLONY-STIMULATING FACTOR**

GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR

BLOOD

[Granulocyte-macrophage colony stimulating factor (GM-CSF)] Kimura F, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:806–9 (19 ref.) **(Jpn)**

PHARMACOLOGY

The place of blood stem cells in allogeneic transplantation. Russel N, et al. **Br J Haematol** 1996 Jun 2;93(4):747–53 (55 ref.)

[Recent data and current studies of epidermal Langerhans cells] Dezutter-Dambuyant C. **Pathol Biol (Paris)** 1995 Dec;43(10):841–7 (78 ref.) (Eng. Abstr.) **(Fre)**

[In vitro differenciation and functions of dendritic cells obtained from CD34+ hematopoietic progenitors] Dubois B, et al. **Pathol Biol (Paris)** 1995 Dec;43(10):829–40 (88 ref.) (Eng. Abstr.) **(Fre)**

THERAPEUTIC USE

Haematopoietic growth factors as supportive therapy in HIV-infected patients. Hermans P. **AIDS** 1995 Dec;9 Suppl 2:S9–S14 (35 ref.)

Rationale for high-dose chemotherapy and application of haematopoietic growth factors in acute myeloid leukaemia. Hiddemann W, et al. **Ann Oncol** 1995;6 Suppl 4:27–31 (33 ref.)

Hematopoietic growth factors in cancer chemotherapy. Morstyn G, et al. **Cancer Chemother Biol Response Modif** 1996;16:295–314 (99 ref.)

Use of cytokines in the treatment of acute myelocytic leukemia: a critical review. Geller RB. **J Clin Oncol** 1996 Apr;14(4):1371–82 (65 ref.)

Do G-CSF and GM-CSF contribute to the management of acute lymphoblastic leukemia? [editorial] Ottmann OG, et al. **Leukemia** 1996 Jul;10(7):1111–6 (33 ref.)

GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR

ADMINISTRATION & DOSAGE

Vaccine adjuvancy: a new potential area of development for GM-CSF. Taglietti M. **Adv Exp Med Biol** 1995;378:565–9 (22 ref.)

ADVERSE EFFECTS

Report of three cases of cutaneous reactions to granulocyte macrophage-colony-stimulating factor and a review of the literature. Scott GA. **Am J Dermatopathol** 1995 Apr; 17(2):107–14 (25 ref.)

BIOSYNTHESIS

Inhibition of GM-CSF production by recombinant human interleukin-4: negative regulator of hematopoiesis. Sawada K, et al. **Leuk Lymphoma** 1995 Sep;19(1–2):33–42 (1661 ref.)

GENETICS

Regulation of granulocyte-macrophage colony-stimulating factor and interleukin 3 expression. Nimer SD, et al. **Stem Cells (Dayt)** 1995 Jul;13(4):324–35 (95 ref.)

PHARMACOLOGY

The effect of granulocyte-macrophage colony-stimulating factor on myeloid cells and its clinical applications. Hill AD, et al. **J Leukoc Biol** 1995 Dec;58(6):634–42 (103 ref.)

Rising serum lactate dehydrogenase often caused by granulocyte-or Granulocyte-macrophage colony stimulating factor and not tumor progression in patients with lymphoma or myeloma. Sarris AH, et al. **Leuk Lymphoma** 1995 May;17(5–6):473–7 (25 ref.)

Cytokine-mobilized peripheral blood progenitor cells. Nemunaitis J. **Semin Oncol** 1996 Apr;23(2 Suppl 4):9–14 (18 ref.)

PHYSIOLOGY

Gene transfer for cytokine functional studies in the lung: the multifunctional role of GM-CSF in pulmonary inflammation. Xing Z, et al. **J Leukoc Biol** 1996 Apr; 59(4):481–8 (55 ref.)

THERAPEUTIC USE

Should hematopoietic growth factors routinely be given concurrently with cytotoxic chemotherapy? Croockewit AJ, et al. **Clin Pharmacol Ther** 1996 Jan;59(1):1–6 (31 ref.)

Haemopoietic growth factors and childhood cancer. Hann IM. **Eur J Cancer** 1995;31A(9):1476–8 (27 ref.)

Adjuncts to antibacterial therapy. Frank MO, et al. **Infect Dis Clin North Am** 1995 Sep;9(3):769–81 (63 ref.)

The use of GM-CSF and G-CSF in the treatment of acute leukemias. Harousseau JL, et al. **Leuk Lymphoma** 1995 Aug;18(5–6):405–12 (70 ref.)

Myelodysplastic syndromes in the elderly: the role of growth factors in management. Saba HI. **Leuk Res** 1996 Mar; 20(3):203–19 (136 ref.)

Use of growth factors during induction therapy for acute myeloid leukemia. Rowe JM. **Leukemia** 1996 Apr;10 Suppl 1:S40–3 (10 ref.)

Perspective of rhGM-CSF in the treatment of neutropenic infections and aggressive lymphomas. Gerhartz HH. **Stem Cells (Dayt)** 1995 Sep;13(5):472–6 (27 ref.)

GRANULOCYTES

CYTOLOGY

Expansion of myeloid stem cells in culture. Moore MA. **Semin Hematol** 1995 Jul;32(3):183–200 (131 ref.)

PHYSIOLOGY

[Clinical significance of reactive oxygen species] Bruchelt G. **Immun Infekt** 1995 Oct;23(5):174–8 (40 ref.) (Eng. Abstr.) **(Ger)**

ULTRASTRUCTURE

[Granulocyte abnormal chromatin clumping syndrome: report of a new case and review of the literature] Esteve J, et al. **Sangre (Barc)** 1995 Aug;40(4):327–30 (22 ref.) (Eng. Abstr.) **(Spa)**

GRANULOCYTIC LEUKEMIA see **LEUKEMIA, MYELOID**

GRANULOCYTIC LEUKEMIA, CHRONIC see **LEUKEMIA, MYELOID, CHRONIC**

GRANULOCYTIC LEUKEMIA, CHRONIC, STABLE-PHASE see **LEUKEMIA, MYELOID, CHRONIC-PHASE**

GRANULOCYTOPENIA see **AGRANULOCYTOSIS**

GRANULOMA

Eosinophilic granulomatous cystitis in children. Ladocsi LT, et al. **Urology** 1995 Nov;46(5):732–5 (22 ref.)

[Granulomatous mastitis] Lafont A, et al. **Rev Fr Gynecol Obstet** 1995 Dec;90(12):530–3 (11 ref.) (Eng. Abstr.) **(Fre)**

[Xanthogranulomatous cholecystitis] Iwamoto S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):196–8 (10 ref.) **(Jpn)**

CHEMICALLY INDUCED

Granulomatous hepatitis associated with glyburide. Saw D, et al. **Dig Dis Sci** 1996 Feb;41(2):322–5 (11 ref.)

DIAGNOSIS

Granulomatous vasculitis. Hammar SP.
Semin Respir Infect 1995 Jun;10(2):107–20 (47 ref.)
Hypersensitivity pneumonitis: a noninfectious granulomatosis. Sharma OP, et al. **Semin Respir Infect** 1995 Jun;10(2):96–106 (32 ref.)
Differential diagnoses of bone marrow granuloma. Eid A, et al. **West J Med** 1996 Jun;164(6):510–5 (49 ref.)
[Fibroxanthogranulomatous inflammation] Kitamra T.
Ryoikibetsu Shokogun Shirizu 1996;(9):290–1 (8 ref.) **(Jpn)**

ETIOLOGY

Cutaneous reactions following herpes zoster infections: report of three cases and a review of the literature. Gibney MD, et al. **Br J Dermatol** 1996 Mar;134(3):504–9 (22 ref.)
Cytokine regulation of granuloma formation in schistosomiasis. Wynn TA, et al. **Curr Opin Immunol** 1995 Aug;7(4):505–11 (61 ref.)
Non-sarcoid granulomatous disease with involvement of the lungs. Müns G, et al. **Sarcoidosis** 1995 Sep;12(2):99–110 (91 ref.)
[Granulomatous peritonitis after laparoscopic surgery of an ovarian dermoid cyst. Diagnosis, management, prevention, a case report] Huss M, et al.
J Gynecol Obstet Biol Reprod (Paris) 1996;25(4):365–72 (54 ref.) (Eng. Abstr.) **(Fre)**
[Hepatic granuloma] Shiga J, et al.
Ryoikibetsu Shokogun Shirizu 1995;(7):420–2 (6 ref.) **(Jpn)**

IMMUNOLOGY

The hamster cheek pouch: an immunologically privileged site suitable to the study of granulomatous infections. de Arruda MS, et al. **Rev Inst Med Trop Sao Paulo** 1995 Jul-Aug;37(4):303–9 (46 ref.)

METABOLISM

Calcium oxalate crystal deposition in epithelioid histiocytes of granulomatous lymphadenitis: analysis by light and electronmicroscopy. Symmans PJ, et al. **Histopathology** 1995 Nov;27(5):423–9 (11 ref.)

MICROBIOLOGY

Localized soft-tissue infections with Mycobacterium avium/Mycobacterium intracellulare complex in immunocompetent patients: granulomatous tenosynovitis of the hand or wrist. Hellinger WC, et al. **Clin Infect Dis** 1995 Jul;21(1):65–9 (25 ref.)

PATHOLOGY

Granulomatous slack skin. Report of a case and review of the literature. Balus L, et al. **Am J Dermatopathol** 1996 Apr;18(2):199–206 (28 ref.)
Primary lipogranuloma of the forehead. Lang S, et al.
Am J Otolaryngol 1995 Sep-Oct;16(5):354–6 (19 ref.)
Necrobiotic xanthogranuloma with cardiac involvement. Umbert I, et al. **Br J Dermatol** 1995 Sep;133(3):438–43 (37 ref.)
Calcium oxalate crystal deposition in epithelioid histiocytes of granulomatous lymphadenitis: analysis by light and electronmicroscopy. Symmans PJ, et al. **Histopathology** 1995 Nov;27(5):423–9 (11 ref.)
Vulvitis granulomatosa: a cryptogenic chronic inflammatory hypertrophy of vulvar labia related to cheilitis granulomatosa and Crohn's disease. Guerrieri C, et al.
Int J Gynecol Pathol 1995 Oct;14(4):352–9 (62 ref.)
Postoperative uterine granulomata following endometrial resection. Smart PJ, et al. **Pathology** 1995 Apr;27(2):209–11 (14 ref.)
The experimental granuloma. A hypothesis to explain the persistence of the lesion. Mariano M.
Rev Inst Med Trop Sao Paulo 1995 Mar-Apr;37(2):161–76 (115 ref.)
Granulomatous disorders of the oral mucosa. Eveson JW. **Semin Diagn Pathol** 1996 May;13(2):118–27 (46 ref.)

PHYSIOPATHOLOGY

The leprosy granuloma in nerve: summary of recent work. Ridley MJ. **Indian J Lepr** 1996 Jan-Mar;68(1):93–4 (5 ref.)

SURGERY

An overview of treatment options for lower airway obstruction. Wanamaker JR, et al.
Otolaryngol Clin North Am 1995 Aug;28(4):751–70 (52 ref.)

GRANULOMA, EOSINOPHILIC see **EOSINOPHILIC GRANULOMA**

GRANULOMA, FOREIGN-BODY

CHEMICALLY INDUCED

Adverse effects of bone wax in surgery of the orbit. Katz SE, et al. **Ophthal Plast Reconstr Surg** 1996 Jun;12(2):121–6 (15 ref.)

ETIOLOGY

Sea urchin granuloma of the nail apparatus: report of 2 cases. Haneke E, et al. **Dermatology** 1996;192(2):140–2 (9 ref.)
Elemental mercury-induced skin granuloma: a case report and review of the literature. Bradberry SM, et al.
J Toxicol Clin Toxicol 1996;34(2):209–16 (38 ref.)

PATHOLOGY

Pathological case of the month. Synthetic fiber granuloma (Teddy Bear Granuloma). Lueder GT, et al.
Arch Pediatr Adolesc Med 1996 Mar;150(3):327–8 (5 ref.)
Sea urchin granuloma of the nail apparatus: report of 2 cases. Haneke E, et al. **Dermatology** 1996;192(2):140–2 (9 ref.)

GRANULOMA GANGRAENESCENS see **GRANULOMA, LETHAL MIDLINE**

GRANULOMA, GIANT CELL

CHEMICALLY INDUCED

Adverse effects of bone wax in surgery of the orbit. Katz SE, et al. **Ophthal Plast Reconstr Surg** 1996 Jun;12(2):121–6 (15 ref.)

PATHOLOGY

Synchronous central giant cell lesions of the jaws: report of a case and review of the literature. Miloro M, et al.
J Oral Maxillofac Surg 1995 Nov;53(11):1350–5 (32 ref.)

GRANULOMA, GIANT CELL REPARATIVE see **GRANULOMA, GIANT CELL**

GRANULOMA, HODGKIN'S see **HODGKIN'S DISEASE**

GRANULOMA, LETHAL MIDLINE

PATHOLOGY

Nasal T-cell lymphoma and the lethal midline granuloma syndrome. Hartig G, et al.
Otolaryngol Head Neck Surg 1996 Apr;114(4):653–6 (16 ref.)

GRANULOMA, MALIGNANT see **HODGKIN'S DISEASE**

GRANULOMA, PLASMA CELL

Inflammatory pseudotumor of the uterus: a case report. Kargi HA, et al. **Tumori** 1995 Nov-Dec;81(6):454–6 (8 ref.)
[Inflammatory pseudotumor of the liver] Iwamoto S, et al.
Ryoikibetsu Shokogun Shirizu 1995;(7):321–2 (9 ref.) **(Jpn)**

DIAGNOSIS

Inflammatory pseudotumor of the spleen: a rare entity that may mimic hematopoietic malignancy. McHenry CR, et al. **Am Surg** 1995 Dec;61(12):1067–71 (23 ref.)
Inflammatory pseudotumor of the liver in children. A case report and review of the literature. Passalides A, et al.
Eur J Pediatr Surg 1996 Feb;6(1):35–7 (14 ref.)
[Inflammatory pseudotumor of the liver. Case report of a rare differential diagnosis of hepatocellular carcinoma] Strohm WD, et al. **Z Gastroenterol** 1996 Feb;34(2):132–7 (45 ref.) (Eng. Abstr.) **(Ger)**
[The imaging diagnosis of a rare case of inflammatory pseudotumor of the spleen] Meduri S, et al.
Radiol Med (Torino) 1996 Jan-Feb;91(1-2):143–5 (7 ref.) **(Ita)**
[Abdominal pseudotumor and Whipple's disease] Guilera M, et al. **Gastroenterol Hepatol** 1996 May;19(5):247–9 (16 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

Visceral larva migrans induced eosinophilic cardiac pseudotumor: a cause of sudden death in a child. Boschetti A, et al. **J Forensic Sci** 1995 Nov;40(6):1097–9 (12 ref.)
[Inflammatory pseudotumor of the intestine caused by necrotizing vasculitis in the course of Horton disease] Fontaney F, et al. **Gastroenterol Clin Biol** 1995 Nov; 19(11):940–3 (25 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Inflammatory pseudotumor (plasma cell granuloma) of the heart. Report of two cases and literature review. Rose AG, et al. **Arch Pathol Lab Med** 1996 Jun;120(6):549–54 (43 ref.)
Chronic cholecystitis with features of diffuse inflammatory pseudotumour: a clinico-pathological case study and review of the literature. Corsi A, et al.
Ital J Gastroenterol 1995 Jun;27(5):252–5 (30 ref.)
Inflammatory pseudotumour of the mouth and maxilla. Shek AW, et al. **J Clin Pathol** 1996 Feb;49(2):164–7 (23 ref.)
[Inflammatory pseudotumor of the breast. Report of a case and review of the literature] Bisceglia M, et al.
Pathologica 1995 Feb;87(1):59–64 (36 ref.) (Eng. Abstr.) **(Ita)**

RADIOGRAPHY

Inflammatory pseudotumours in children: CT and ultrasound appearances with histopathological correlation. Brown G, et al. **Clin Radiol** 1995 Nov;50(11):782–6 (16 ref.)

ULTRASONOGRAPHY

Inflammatory pseudotumours in children: CT and ultrasound appearances with histopathological correlation. Brown G, et al. **Clin Radiol** 1995 Nov;50(11):782–6 (16 ref.)

GRANULOMA, PLASMA CELL, ORBITAL

DIAGNOSIS

Pediatric orbital pseudotumor: case report and review of the literature. Berger JW, et al. **Int Ophthalmol Clin** 1996 Winter;36(1):161–77 (31 ref.)

ETIOLOGY

Orbital pseudotumor: report of a case after treatment for temporomandibular joint dysfunction. Oliver AJ, et al.
J Oral Maxillofac Surg 1995 Dec;53(12):1465–9 (20 ref.)

GRANULOMA, PSEUDOPYOGENIC see **ANGIOLYMPHOID HYPERPLASIA WITH EOSINOPHILIA**

GRANULOMA, PYOGENIC

PATHOLOGY

Pyogenic granuloma of the cornea: report of a case and review of the literature. Mietz H, et al.
Graefes Arch Clin Exp Ophthalmol 1996 Feb;234(2):131–6 (22 ref.)
Subcutaneous and superficial granuloma pyogenicum. Park YH, et al. **Int J Dermatol** 1996 Mar;35(3):205–6 (9 ref.)

THERAPY

Eruptive pyogenic granulomas: a successfully treated patient and review of the literature. Shah M, et al.
Br J Dermatol 1995 Nov;133(5):795–6 (27 ref.)

GRANULOMA TELANGIECTICUM see **GRANULOMA, PYOGENIC**

GRANULOMATOSIS, LYMPHOMATOID see **LYMPHOMATOID GRANULOMATOSIS**

GRANULOMATOSIS, WEGENER'S see **WEGENER'S GRANULOMATOSIS**

GRANULOMATOUS CHEILITIS see **MELKERSSON-ROSENTHAL SYNDROME**

GRANULOMATOUS DISEASE, CHRONIC

BLOOD

Disorders of neutrophil function. Bogomolski-Yahalom V, et al. **Blood Rev** 1995 Sep;9(3):183–90 (71 ref.)

COMPLICATIONS

Esophageal involvement in chronic granulomatous disease. Case report and review [see comments] Hiller N, et al.
Pediatr Radiol 1995;25(4):308–9 (8 ref.) Comment in: Pediatr Radiol 1996;26(2):169.

DIAGNOSIS

Unusual clinical manifestation of a disfiguring necrobiotic granulomatous disease. Willemsen M, et al.
J Am Acad Dermatol 1995 Nov;33(5 Pt 2):887–90 (13 ref.)

ENZYMOLOGY

Phagocytic NADPH oxidase and its role in chronic granulomatous disease. Pallister CJ, et al.
Br J Biomed Sci 1995 Jun;52(2):149–56 (91 ref.)
The NADPH oxidase and chronic granulomatous disease. Segal AW. **Mol Med Today** 1996 Mar;2(3):129–35 (31 ref.)

ETIOLOGY

[Cutaneous granulomatous lesions in congenital immune deficiencies. 5 cases] Paul C, et al.
Ann Dermatol Venereol 1995;122(8):501–6 (34 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Mutations in the X-linked and autosomal recessive forms of chronic granulomatous disease. Roos D, et al. **Blood** 1996 Mar 1;87(5):1663–81 (151 ref.)

GRANULOSA CELL TUMOR

RADIOGRAPHY

Hepatic metastases from granulosa cell tumor of the ovary: CT and sonographic findings. Neste MG, et al.
AJR Am J Roentgenol 1996 May;166(5):1122–4 (8 ref.)

GRANULOSA CELL TUMOR

SECONDARY

Hepatic metastases from granulosa cell tumor of the ovary: CT and sonographic findings. Neste MG, et al. **AJR Am J Roentgenol** 1996 May;166(5):1122–4 (8 ref.)

ULTRASONOGRAPHY

Hepatic metastases from granulosa cell tumor of the ovary: CT and sonographic findings. Neste MG, et al. **AJR Am J Roentgenol** 1996 May;166(5):1122–4 (8 ref.)

GRANULOSA CELLS

PHYSIOLOGY

Cell–cell interactions and oocyte growth. Canipari R. **Zygote** 1994 Nov;2(4):343–5 (31 ref.)

SECRETION

Oxytocin in bovine and porcine granulosa cells. Regulation of secretion and biological effects. Sirotkin AV, et al. **Adv Exp Med Biol** 1995;395:541–2 (11 ref.)

GRANULOSIS VIRUSES see **BACULOVIRIDAE**

GRAPES see **FRUIT**

GRASSES

see related
POLLEN

The potential of pasture to supply the nutritional requirements of grazing horses. Gallagher JR. **Aust Vet J** 1996 Feb;73(2):67–8 (19 ref.)

GENETICS

Cereal genome evolution. Grasses, line up and form a circle. Moore G, et al. **Curr Biol** 1995 Jul 1;5(7):737–9 (13 ref.)

GRASSHOPPERS

PHYSIOLOGY

Fatty acid binding protein in locust and mammalian muscle. Comparison of structure, function and regulation. Haunerland NH. **Comp Biochem Physiol B Biochem Mol Biol** 1994 Oct–Nov; 109(2–3):199–208 (49 ref.)

GRAVES' DISEASE

CLASSIFICATION

Evolution of classification systems for Graves' ophthalmopathy. Bartley GB. **Ophthal Plast Reconstr Surg** 1995 Dec;11(4):229–37 (48 ref.)

COMPLICATIONS

Cytokine antagonists: new ideas for the management of Graves' ophthalmopathy [editorial; comment] Bartalena L, et al. **J Clin Endocrinol Metab** 1996 Feb;81(2):446–8 (15 ref.) Comment on: J Clin Endocrinol Metab 1996 Feb;81(2):449–52.

Involvement of the orbital fibroblast and TSH receptor in the pathogenesis of Graves' ophthalmopathy. Heufelder AE. **Thyroid** 1995 Aug;5(4):331–40 (84 ref.)

[Ocular involvement in Basedow disease. Therapeutic strategy] Le Jeunne C, et al. **Ann Med Interne (Paris)** 1996; 147(2):93–8 (38 ref.) **(Fre)**

DIAGNOSIS

[Endocrine exophthalmos] Apostol S, et al. **Oftalmologia** 1996 Jan–Mar;40(1):4–10 (5 ref.) (Eng. Abstr.) **(Rum)**

ETIOLOGY

[Basedow disease following metastatic thyroid cancer] Le Pommelet C, et al. **Presse Med** 1996 Apr 20;25(14):671–3 (20 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

[Pathophysiology and clinical aspects of myxedema] Reisert PM. **Z Lymphol** 1996 Jun;20(1):6–10, 12–4 (27 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Management of thyroid optic neuropathy. Lucarelli MJ, et al. **Int Ophthalmol Clin** 1996 Winter;36(1):179–93 (56 ref.)

Medical management of Graves' ophthalmopathy. Prummel MF, et al. **Thyroid** 1995 Jun;5(3):231–4 (25 ref.)

[Current trends in the treatment of Graves' disease] Nicolosi A, et al. **Minerva Chir** 1995 Jul–Aug;50(7–8):659–65 (17 ref.) (Eng. Abstr.) **(Ita)**

GRAVISTIMULATION see **GRAVITATION**

GRAVITATION

Evidence of somatic graviception from new and classical investigations. Mittelstaedt H. **Acta Otolaryngol Suppl (Stockh)** 1995;520 Pt 1:186–7 (5 ref.)

New diagnostic tests for the function of utricles, saccules and somatic graviceptors. Mittelstaedt H. **Acta Otolaryngol Suppl (Stockh)** 1995;520 Pt 1:188–93 (5 ref.)

Gravitational effects of the period of high tides and the new moon on lunacy. Myers DE. **J Emerg Med** 1995 Jul–Aug; 13(4):529–32 (24 ref.)

[Methods of gravitational surgery on the blood in obstetrics and gynecology] Abubakirova AM, et al. **Akush Ginekol (Mosk)** 1995;(5):40–3 (45 ref.) **(Rus)**

GRAVITY see **GRAVITATION**

GRAVITY PERCEPTION

PHYSIOLOGY

[The general principles of cellular gravisensing] Tairbekov MG. **Izv Akad Nauk Ser Biol** 1996 Mar–Apr;(2):133–40 (41 ref.) (Eng. Abstr.) **(Rus)**

GRAVITY SENSING see **GRAVITY PERCEPTION**

GRAWITZ TUMOR see **CARCINOMA, RENAL CELL**

GREEK WORLD

A classical view of the theory–practice gap in nursing. Allmark P. **J Adv Nurs** 1995 Jul;22(1):18–23 (23 ref.)

GREEN FROG see **RANA ESCULENTA**

GREENHOUSE EFFECT

Health effects associated with global climate changes: a role for environmental mutagens? Rosenkranz HS. **Environ Mol Mutagen** 1996;27(2):81–3 (39 ref.)

Climate change and global infectious disease threats. Jackson EK. **Med J Aust** 1995 Dec 4–18;163(11–12):570–4 (67 ref.)

The potential health impacts of climate change: an overview. Kovats S, et al. **Med War** 1995 Oct–Dec;11(4):168–78 (28 ref.)

Climate change and human health: possible communicable disease consequences in the United Kingdom. Rowland MG. **Med War** 1995 Oct–Dec;11(4):188–94 (19 ref.)

GRIEF

Anticipatory grief and AIDS: strategies for intervening with caregivers. Walker RJ, et al. **Health Soc Work** 1996 Feb; 21(1):49–57 (43 ref.)

GRIPPE see **INFLUENZA**

GRISEOFULVIN

BIOSYNTHESIS

[Biosynthesis and microbial transformation of griseofulvin and carcinogenesis and prevention of cancer by estrogens] Sato Y. **Yakugaku Zasshi** 1995 Nov;115(11):892–908 (80 ref.) (Eng. Abstr.) **(Jpn)**

THERAPEUTIC USE

Management of scalp ringworm. **Drug Ther Bull** 1996 Jan; 34(1):5–6 (15 ref.)

GRNA see **RNA, GUIDE**

GROEL PROTEIN

METABOLISM

[The transport function of GroEL family chaperonins] Poglazov BF. **Dokl Akad Nauk** 1995 Jul;343(3):400–2 (13 ref.) **(Rus)**

GROMMET INSERTION see **MIDDLE EAR VENTILATION**

GRONBLAD–STRANDBERG SYNDROME see **PSEUDOXANTHOMA ELASTICUM**

GROOMING

Grooming. McDonough S. **Vet Clin North Am Small Anim Pract** 1995 Jul;25(4):767–78 (9 ref.)

GROUP HEALTH INSURANCE see **INSURANCE, HEALTH**

GROUP HEALTH ORGANIZATIONS, PREPAID see **HEALTH MAINTENANCE ORGANIZATIONS**

GROUP IDENTIFICATION see **SOCIAL IDENTIFICATION**

GROUP PRACTICE

ORGANIZATION & ADMINISTRATION

The problematic fit of diagnosis and strategy for medical group stakeholders—including IDS/Ns. Blair JD, et al. **Health Care Manage Rev** 1996 Winter;21(1):7–28 (21 ref.)

GROUP PROCESSES

see related
SOCIAL CHANGE

The use of the Nominal Group Technique in research with community nurses. Carney O, et al. **J Adv Nurs** 1996 May; 23(5):1024–9 (13 ref.)

Group decision making. Palazzolo C. **J Am Vet Med Assoc** 1996 Aug 1;209(3):566–9 (11 ref.)

GROUP-SPECIFIC COMPONENT see **VITAMIN D-BINDING PROTEIN**

GROUP THERAPY see **PSYCHOTHERAPY, GROUP**

GROWTH

see related
CHILD DEVELOPMENT
PERSONALITY DEVELOPMENT

Parathyroid hormone–related protein: a polyhormone involved in growth, development and gestation [comment] Rizzoli R, et al. **Eur J Endocrinol** 1995 Sep;133(3):272–4 (35 ref.) Comment on: Eur J Endocrinol 1995 Sep;133(3):278–83.

Growth, growth hormone and cognitive functions. Sartorio A, et al. **Horm Res** 1996;45(1–2):23–9 (61 ref.)

Growth in children with moderate renal insufficiency: measurement, evaluation, and treatment. Abitbol c, et al. **J Pediatr** 1996 Aug;129(2):s3–8 (25 ref.)

State-dependent life histories. McNamara JM, et al. **Nature** 1996 Mar 21;380(6571):215–21 (73 ref.)

Assessment of large and small for gestational age newborn infants using growth curves. Georgieff MK. **Pediatr Ann** 1995 Nov;24(11):599–607 (23 ref.)

Genetic analysis of thyroid hormone receptors in development and disease. Forrest D, et al. **Recent Prog Horm Res** 1996;51:1–22 (78 ref.)

Transgenic models to study the roles of inhibins and activins in reproduction, oncogenesis, and development. Matzuk MM, et al. **Recent Prog Horm Res** 1996;51:123–54; discussion 155–7 (107 ref.)

Thyroid hormone metabolism during development. Polk DH. **Reprod Fertil Dev** 1995;7(3):469–77 (44 ref.)

Is the lesser growth of African schoolchildren essentially prejudicial to their present and future health? Walker AR, et al. **Trop Geogr Med** 1995;47(4):145–50 (53 ref.)

DRUG EFFECTS

Effect of chemotherapy on growth. Ogilvy-Stuart AL, et al. **Acta Paediatr Suppl** 1995 Sep;411:52–6 (46 ref.)

Glucocorticoids and growth problems. Robinson IC, et al. **Acta Paediatr Suppl** 1995 Sep;411:81–6 (45 ref.)

[Human insulin-like growth factor I and treatment in diabetes] Koivisto VA. **Duodecim** 1994; 110(23–24):2197–201 (25 ref.) **(Fin)**

GENETICS

Genomic imprinting and mammalian development. Franklin GC, et al. **Placenta** 1996 Jan;17(1):3–14 (107 ref.)

PHYSIOLOGY

Growth and its assessment. Pomerance HH. **Adv Pediatr** 1995;42:545–74 (42 ref.)

Euclidean distance matrix analysis: confidence intervals for form and growth differences. Lele S, et al. **Am J Phys Anthropol** 1995 Sep;98(1):73–86 (28 ref.)

Calcium waves and development. Jaffe LF. **Ciba Found Symp** 1995;188:4–12; discussion 12–7 (53 ref.)

Physiology of growth and development. Its relationship to performance in the young athlete. Roemmich JN, et al. **Clin Sports Med** 1995 Jul;14(3):483–502 (79 ref.)

Dietary fat content and energy density during infancy and childhood; the effect on energy intake and growth. Michaelsen KF, et al. **Eur J Clin Nutr** 1995 Jul;49(7):467–83 (75 ref.)

The glucose-6-phosphatase system in human development. Burchell A, et al. **Histol Histopathol** 1995 Oct;10(4):979–93 (97 ref.)

The effects of exercise on growth. Borer KT. **Sports Med** 1995 Dec;20(6):375–97 (347 ref.)

[The problem of the effect of cosmogeophysical factors on the formation of the properties of developing organisms during early ontogeny] Semenenia IN. **Aviakosm Ekolog Med** 1995;29(3):19–21 (27 ref.) (Eng. Abstr.) **(Rus)**

[A shift in types of nutrition and digestion in ontogeny] Arshavskiĭ IA, et al. **Usp Fiziol Nauk** 1996 Jan–Mar; 27(1):109–29 (95 ref.) (Eng. Abstr.) **(Rus)**

GROWTH DISORDERS

see related
BONE DISEASES, DEVELOPMENTAL
DWARFISM
GIGANTISM

CHEMICALLY INDUCED

Growth abnormalities in the population exposed in utero and early postnatally to polychlorinated biphenyls and dibenzofurans. Guo YL, et al. **Environ Health Perspect** 1995 Sep;103 Suppl 6:117-22 (53 ref.)

DIAGNOSIS

Growth and its assessment. Pomerance HH. **Adv Pediatr** 1995;42:545-74 (42 ref.)

Identification and assessment of the slowly growing child. Duck SC. **Am Fam Physician** 1996 May 15;53(7):2305-12 (18 ref.)

Short stature and growth hormone deficiency. Hindmarsh PC, et al. **Clin Endocrinol (Oxf)** 1995 Aug;43(2):133-42 (35 ref.)

[Current status of diagnosis and treatment of growth retardation] Okuno A. **Hokkaido Igaku Zasshi** 1996 Mar; 71(2):145-50 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Leprechaunism (Donohue's syndrome)] Morooka K. **Ryoikibetsu Shokogun Shirizu** 1995;(8):262-4 (12 ref.) **(Jpn)**

[The diagnostic-therapeutic fundamentals of growth-hormone secretagogues (editorial)] Argente Oliver J, et al. **An Esp Pediatr** 1996 Jul;45(1):2-5 (36 ref.) **(Spa)**

DRUG THERAPY

Growth hormone and dysmorphic syndromes. Galasso C, et al. **Horm Res** 1995;44 Suppl 3:42-8 (73 ref.)

Guidelines for the use of growth hormone in children with short stature. A report by the Drug and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society. **J Pediatr** 1995 Dec;127(6):857-67 (72 ref.)

Carbohydrate metabolism in primary growth hormone resistance (Laron syndrome) before and during insulin-like growth factor-I treatment. Laron Z, et al. **Metabolism** 1995 Oct;44(10 Suppl 4):113-8 (41 ref.)

[Growth hormone therapy] Sipilä I. **Duodecim** 1994; 110(10):991-9 (28 ref.) **(Fin)**

[Treatment with growth hormone of children with short stature, borne with intrauterine growth retardation] Czernichow P. **Arch Pediatr** 1996;3 Suppl 1:194s-196s (5 ref.) **(Fre)**

[Growth hormone: who can benefit from it?] Schwarz HP. **Ther Umsch** 1995 Oct;52(10):678-81 (16 ref.) (Eng. Abstr.) **(Ger)**

[The diagnostic-therapeutic fundamentals of growth-hormone secretagogues (editorial)] Argente Oliver J, et al. **An Esp Pediatr** 1996 Jul;45(1):2-5 (36 ref.) **(Spa)**

EPIDEMIOLOGY

Common causes of short stature detectable by a height surveillance programme. Hyer W, et al. **J Med Screen** 1995; 2(3):150-3 (47 ref.)

ETIOLOGY

Growth and endocrine disturbances after bone marrow transplantation in childhood. Sklar C. **Acta Paediatr Suppl** 1995 Sep;411:57-61; discussion 62 (30 ref.)

Growth following therapy for childhood cancer. Sklar CA. **Cancer Invest** 1995;13(5):511-6 (40 ref.)

Common causes of short stature detectable by a height surveillance programme. Hyer W, et al. **J Med Screen** 1995; 2(3):150-3 (47 ref.)

Effects of uremia on growth in children. Hanna JD, et al. **Semin Nephrol** 1996 May;16(3):230-41 (79 ref.)

[Treatment with growth hormone of children with short stature, borne with intrauterine growth retardation] Czernichow P. **Arch Pediatr** 1996;3 Suppl 1:194s-196s (5 ref.) **(Fre)**

GENETICS

Monozygotic twins discordant for the Russell-Silver syndrome. Bailey W, et al. **Am J Med Genet** 1995 Aug 28;58(2):101-5 (3 ref.)

Detection of a subtle rearrangement of chromosome 22 using molecular techniques. Biesecker LG, et al. **Am J Med Genet** 1995 Sep 25;58(4):389-94 (15 ref.)

GAPO syndrome: a new case. Sandgren G. **Am J Med Genet** 1995 Jul 31;58(1):87-90 (16 ref.)

Prenatal and postnatal growth failure associated with maternal heterodisomy for chromosome 7. Langlois S, et al. **J Med Genet** 1995 Nov;32(11):871-5 (25 ref.)

METABOLISM

Metabolic effects of GH: a rationale for continued GH treatment of GH-deficient adults after cessation of linear growth. Juul A, et al. **Horm Res** 1995;44 Suppl 3:64-72 (90 ref.)

Carbohydrate metabolism in primary growth hormone resistance (Laron syndrome) before and during insulin-like growth factor-I treatment. Laron Z, et al. **Metabolism** 1995 Oct;44(10 Suppl 4):113-8 (41 ref.)

PSYCHOLOGY

Short stature: does it matter? A review of the evidence. Voss LD. **J Med Screen** 1995;2(3):130-2 (35 ref.)

THERAPY

[Current status of diagnosis and treatment of growth retardation] Okuno A. **Hokkaido Igaku Zasshi** 1996 Mar; 71(2):145-50 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Skeletal dysplasia. Medical interdisciplinary care is necessary for optimal treatment] Gustavson KH, et al. **Lakartidningen** 1995 Sep 20;92(38):3425-30 (12 ref.) **(Swe)**

VETERINARY

Growth hormone: its clinical relevance. Rijnberk A. **Vet Q** 1995 Apr;17 Suppl 1:S17-9 (11 ref.)

GROWTH FACTOR RECEPTORS see **RECEPTORS, GROWTH FACTOR**

GROWTH FACTORS see **GROWTH SUBSTANCES**

GROWTH HORMONE, PITUITARY see **SOMATOTROPIN**

GROWTH HORMONE RECEPTORS see **RECEPTORS, SOMATOTROPIN**

GROWTH HORMONE-RELEASING FACTOR see **SOMATOTROPIN-RELEASING HORMONE**

GROWTH HORMONE-RELEASING FACTOR 44 see **SOMATOTROPIN-RELEASING HORMONE**

GROWTH HORMONE-RELEASING HORMONE see **SOMATOTROPIN-RELEASING HORMONE**

GROWTH INHIBITORS

Molecular targets in the National Cancer Institute drug screen. Bates SE, et al. **J Cancer Res Clin Oncol** 1995; 121(9-10):495-500 (20 ref.)

GENETICS

Mammalian DNA damage-inducible genes associated with growth arrest and apoptosis. Smith ML, et al. **Mutat Res** 1996 Jun;340(2-3):109-24 (143 ref.)

METABOLISM

Cell cycle regulation by the retinoblastoma family of growth inhibitory proteins. Beijersbergen RL, et al. **Biochim Biophys Acta** 1996 Jun 7;1287(2-3):103-20 (223 ref.)

Growth suppression by members of the retinoblastoma protein family. Zhu L, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:75-84 (67 ref.)

PHARMACOLOGY

[Modulation of integrin alpha-v-beta-1 expression on human tumor cells by leukemia inhibitory factor (LIF) and oncostatin M (OSM)] Heymann D, et al. **Bull Cancer (Paris)** 1996 Jan;83(1):13-21 (41 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Immuno-endocrine interactions in early pregnancy. Chaouat G, et al. **Hum Reprod** 1995 Dec;10 Suppl 2:55-9 (45 ref.)

Role of embryonic factors in human implantation. Polan ML, et al. **Hum Reprod** 1995 Dec;10 Suppl 2:22-9 (32 ref.)

Feedback inhibitors in normal and tumor tissues. Marshall E, et al. **Int Rev Cytol** 1996;167:185-261 (299 ref.)

Ceramide: an intracellular mediator of apoptosis and growth suppression. Saba JD, et al. **Philos Trans R Soc Lond B Biol Sci** 1996 Feb 29; 351(1336):233-40; discussion 240-1 (40 ref.)

[Anti-Mullerian hormone. Structure and role in sexual differentiation] Jarmińska-Jackowiak T, et al. **Ginekol Pol** 1995 Jan;66(1):51-8 (35 ref.) (Eng. Abstr.) **(Pol)**

THERAPEUTIC USE

Potential of antineoplastons in diseases of old age. Burzynski SR. **Drugs Aging** 1995 Sep;7(3):157-67 (175 ref.)

Novel biologic therapies for malignant gliomas. Antiangiogenesis, immunotherapy, and gene therapy. Fine HA. **Neurol Clin** 1995 Nov;13(4):827-46 (128 ref.)

GROWTH PLATE

see related
BONE DEVELOPMENT

INJURIES

[Lesions of the growth plate caused by sports stress] Segesser B, et al. **Orthopade** 1995 Sep;24(5):446-56 (60 ref.) (Eng. Abstr.) **(Ger)**

GROWTH RETARDATION, INTRAUTERINE see **FETAL GROWTH RETARDATION**

GROWTH SUBSTANCES

see related
RECEPTORS, GROWTH FACTOR

ADVERSE EFFECTS

Prebiopsy neo-adjuvant endocrine therapy for breast cancer to prevent post-surgery trauma-induced growth factor and immune-suppression mediated tumour progression. Oliver RT, et al. **Eur J Cancer** 1996 Mar;32A(3):396-7 (20 ref.)

ANALYSIS

Growth factors: potential for the management of solid epithelial tumours. Jankowski JA. **Baillieres Clin Gastroenterol** 1996 Mar;10(1):165-79 (64 ref.)

BIOSYNTHESIS

Saliva and growth factors: the fountain of youth resides in us all. Zelles T, et al. **J Dent Res** 1995 Dec;74(12):1826-32 (90 ref.)

CHEMISTRY

Cystine knots. Isaacs NW. **Curr Opin Struct Biol** 1995 Jun; 5(3):391-5 (22 ref.)

GENETICS

Genes involved in testicular development and function. Lamb DJ. **World J Urol** 1995;13(5):277-84 (118 ref.)

[Cardiac gene expression after brief coronary occlusion] Zimmermann R, et al. **Z Kardiol** 1995;84 Suppl 4:159-65 (23 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Synthetic hormone/growth factor subunit vaccine with application to antifertility and cancer. Snyder LL, et al. **Pharm Biotechnol** 1995;6:907-30 (145 ref.)

METABOLISM

Presence and distribution of growth factors in breast cyst fluid. Zanardi S, et al. **Ann N Y Acad Sci** 1996 Apr 30; 784:542-9 (27 ref.)

Poly(alpha-hydroxy acids): carriers for bone morphogenetic proteins. Hollinger JO, et al. **Biomaterials** 1996 Jan; 17(2):187-94 (101 ref.)

Growth factors and their receptors in neoplastic mammary glands. Rudland PS, et al. **Biomed Pharmacother** 1995; 49(9):389-99 (95 ref.)

Autoregulators. Horinouchi S, et al. **Biotechnology** 1995; 28:103-19 (47 ref.)

Mediators, cytokines, and growth factors in liver-lung interactions. Panos RJ, et al. **Clin Chest Med** 1996 Mar; 17(1):151-69 (220 ref.)

Role of growth factors in mesangial cell ion channel regulation. Ling BN, et al. **Kidney Int** 1995 Oct; 48(4):1158-66 (39 ref.)

Intervention in diabetic vascular disease by modulation of growth factors. Serri O, et al. **Metabolism** 1995 Oct;44(10 Suppl 4):83-90 (106 ref.)

Activation of the androgen receptor by polypeptide growth factors and cellular regulators. Culig Z, et al. **World J Urol** 1995;13(5):285-9 (43 ref.)

[Fundamental aspects of osteoinductive activity of bone tissue and potential clinical application] Aldinger G, et al. **Z Orthop Ihre Grenzgeb** 1996 May-Jun;134(3):205-9 (22 ref.) (Eng. Abstr.) **(Ger)**

PHARMACOLOGY

Growth factors: possible new clinical tools. A review. Lind M. **Acta Orthop Scand** 1996 Aug;67(4):407-17 (111 ref.)

Regulation of expression of sodium-calcium exchanger and plasma membrane calcium ATPase by protein kinases, glucocorticoids, and growth factors. Smith JB, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:258-71 (36 ref.)

Autocrine feedback death and the regulation of mature T lymphocyte antigen responses. Lenardo MJ, et al. **Int Rev Immunol** 1995;13(2):115-34 (76 ref.)

Modulation of gap junctional intercellular communication by phosphorylation: effects of growth factors, kinase activators and phosphatase inhibitors. Mikalsen SO, et al. **Prog Clin Biol Res** 1995;391:425-38 (72 ref.)

[Pathogenesis of tumor metastases] Ruiter DJ, et al. **Ned Tijdschr Geneeskd** 1995 Nov 4;139(44):2240-6 (53 ref.) **(Dut)**

[Inhibin and activin] Toppari J, et al. **Duodecim** 1994; 110(10):1029-34 (31 ref.) **(Fin)**

PHYSIOLOGY

Growth factors in colorectal tumorigenesis. Van Laethem JL, et al. **Acta Gastroenterol Belg** 1995 May-Aug; 58(3-4):274-9 (22 ref.)

Homeobox genes and growth factors in regulation of craniofacial and tooth morphogenesis. Thesleff I. **Acta Odontol Scand** 1995 Jun;53(3):129-34 (38 ref.)

Cartilage-derived morphogenetic proteins. Key regulators in chondrocyte differentiation? Luyten FP. **Acta Orthop Scand Suppl** 1995 Oct;266:51-4 (22 ref.)

Angiotensin as a renal growth promoting factor. Wolf G. **Adv Exp Med Biol** 1995;377:225-36 (99 ref.)

Relative contributions of marrow microenvironment, growth factors, and stem cells to hematopoiesis in vivo in man. Review of results from autologous stem cell transplant trials and laboratory studies at the Moffitt Cancer Center. Elfenbein GJ, et al. **Ann N Y Acad Sci** 1995 Dec 29; 770:315–38 (21 ref.)

Growth factor interactions in limb development. Niswander L. **Ann N Y Acad Sci** 1996 Jun 8;785:23–6 (15 ref.)

The trefoil peptide family. Sands BE, et al. **Annu Rev Physiol** 1996;58:253–73 (87 ref.)

Trefoil peptides. Poulsom R. **Baillieres Clin Gastroenterol** 1996 Mar;10(1):113–34 (110 ref.)

BMP-1 and the astacin family of metalloproteinases: a potential link between the extracellular matrix, growth factors and pattern formation. Sarras MP Jr. **Bioessays** 1996 Jun;18(6):439–42 (26 ref.)

Vascular remodeling in hypertension: role of autocrine–paracrine factors. Gibbons GH. **Blood Press Suppl** 1995;2:49–54 (56 ref.)

The effects of cytokines and growth factors on osteoblastic cells. Mundy GR, et al. **Bone** 1995 Aug;17(2 Suppl):71S–75S (41 ref.)

Growth factor regulation of integrin–mediated cell motility. Matsumoto K, et al. **Cancer Metastasis Rev** 1995 Sep; 14(3):205–17 (89 ref.)

Regulation of growth factor activation by proteoglycans: what is the role of the low affinity receptors? Schlessinger J, et al. **Cell** 1995 Nov 3;83(3):357–60 (20 ref.)

Roles of protein–tyrosine phosphatases in growth factor signalling. Matozaki T, et al. **Cell Signal** 1996 Jan;8(1):13–9 (67 ref.)

Osteogenic protein–1: biology and applications. Cook SD, et al. **Clin Orthop** 1996 Mar;(324):29–38 (45 ref.)

Regulation of bone formation by bone morphogenetic proteins and other growth factors. Mundy GR. **Clin Orthop** 1996 Mar;(324):24–8 (25 ref.)

Targeting the alveolar epithelium in acute lung injury: keratinocyte growth factor and regulation of the alveolar epithelial barrier [editorial; comment] Matuschak GM, et al. **Crit Care Med** 1996 Jun;24(6):905–7 (18 ref.) Comment on: Crit Care Med 1996 Jun;24(6):925–31.

Tumor metastasis to brain: role of endothelial cells, neurotrophins, and paracrine growth factors. Nicolson GL, et al. **Crit Rev Oncog** 1994;5(5):451–71 (153 ref.)

The biology of growth regulation in normal and malignant breast epithelium: from bench to clinic. Nguyen B, et al. **Crit Rev Oncol Hematol** 1995 Oct;20(3):223–36 (170 ref.)

Influence of growth factors on neuronal differentiation. Birling MC, et al. **Curr Opin Cell Biol** 1995 Dec;7(6):878–84 (66 ref.)

Mesoderm–inducing factors and mesodermal patterning. Smith JC. **Curr Opin Cell Biol** 1995 Dec;7(6):856–61 (61 ref.)

Growth factors and comprehensive surgical care of diabetic wounds. Knighton DR, et al. **Curr Opin Gen Surg** 1993; :32–9 (42 ref.)

Oncogenes and other growth factors in gynaecological neoplasms. Cheung AN. **Curr Opin Obstet Gynecol** 1996 Feb;8(1):46–51 (47 ref.)

Growth factors in development: the role of TGF–beta related polypeptide signalling molecules in embryogenesis. Hogan BL, et al. **Dev Suppl** 1994;:53–60 (65 ref.)

Reg protein: a potential beta–cell–specific growth factor? Baeza N, et al. **Diabetes Metab** 1996 Jul;22(4):229–34 (40 ref.)

New concepts in tissue repair: skin as an example. Meddahi A, et al. **Diabetes Metab** 1996 Jul;22(4):274–8 (28 ref.)

Growth factors in breast cancer. Dickson RB, et al. **Endocr Rev** 1995 Oct;16(5):559–89 (508 ref.)

Cross talk between peptide growth factor and estrogen receptor signaling systems. Ignar–Trowbridge DM, et al. **Environ Health Perspect** 1995 Oct;103 Suppl 7:35–8 (34 ref.)

p21ras: an oncoprotein functioning in growth factor–induced signal transduction. Bos JL. **Eur J Cancer** 1995 Jul–Aug; 31A(7–8):1051–4 (29 ref.)

Differentiation and survival influences of growth factors in human neuroblastoma. Påhlman S, et al. **Eur J Cancer** 1995; 31A(4):453–8 (49 ref.)

Molecular mechanisms for organ–specific colon carcinoma metastasis. Radinsky R. **Eur J Cancer** 1995 Jul–Aug; 31A(7–8):1091–5 (28 ref.)

Growth factors in skin wound healing. Moulin V. **Eur J Cell Biol** 1995 Sep;68(1):1–7 (89 ref.)

Paracrine mechanism of ovarian regulation. Dor J, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Mar;65(1):25–8 (26 ref.)

Growth factor control of developing kidney endothelial cells. Loughna S, et al. **Exp Nephrol** 1996 Mar–Apr;4(2):112–8 (36 ref.)

Growth factors and metanephrogenesis. Schofield PN, et al. **Exp Nephrol** 1996 Mar–Apr;4(2):97–104 (49 ref.)

Stimulation and regulation of tumor cell motility in invasion and metastasis. Levine MD, et al. **EXS** 1995;74:157–79 (135 ref.)

Keratinocyte growth factor as a cytokine that mediates mesenchymal–epithelial interaction. Rubin JS, et al. **EXS** 1995;74:191–214 (90 ref.)

Liver regeneration. 2. Role of growth factors and cytokines in hepatic regeneration. Fausto N, et al. **FASEB J** 1995 Dec;9(15):1527–36 (68 ref.)

Growth hormone, growth factors and the gonad. Albanese A, et al. **Horm Res** 1995;44 Suppl 3:15–17 (25 ref.)

Growth hormone, growth factors and hematopoiesis. Kelley KW, et al. **Horm Res** 1996;45(1–2):38–45 (91 ref.)

Growth factors in pregnancy. Cooper JC, et al. **Indian J Physiol Pharmacol** 1995 Jul;39(3):197–203 (22 ref.)

Factors controlling growth, motility, and morphogenesis of normal and malignant epithelial cells. Birchmeier C, et al. **Int Rev Cytol** 1995;160:221–66 (280 ref.)

The role of growth factors in vascular cell development and differentiation. Moses MA, et al. **Int Rev Cytol** 1995; 161:1–48 (315 ref.)

The potential role of growth and differentiation factors in periodontal regeneration. **J Periodontol** 1996 May; 67(5):545–53 (128 ref.)

The role of growth factors in wound healing. Greenhalgh DG. **J Trauma** 1996 Jul;41(1):159–67 (133 ref.)

The insulin–like growth factor system in vascular smooth muscle: interaction with insulin and growth factors. Arnqvist HJ, et al. **Metabolism** 1995 Oct;44(10 Suppl 4):58–66 (102 ref.)

Intracellular signaling by growth factors. Seedorf K. **Metabolism** 1995 Oct;44(10 Suppl 4):24–32 (89 ref.)

The role of growth factors in the development of diabetic retinopathy. Sharp PS. **Metabolism** 1995 Oct;44(10 Suppl 4):72–5 (58 ref.)

Tyrosine kinase–mediated signal transduction pathways and the actions of polypeptide growth factors and G–protein–coupled agonists in smooth muscle. Hollenberg MD. **Mol Cell Biochem** 1995 Aug–Sep;149–150:77–85 (77 ref.)

Cytokines and growth factors in renal disease. Noronha IL, et al. **Nephrol Dial Transplant** 1995;10(6):775–86 (156 ref.)

Growth factors in wound healing. Hom DB. **Otolaryngol Clin North Am** 1995 Oct;28(5):933–53 (96 ref.)

Hepatocarcinogenesis in transgenic mice. Sandgren EP, et al. **Prog Clin Biol Res** 1995;391:213–22 (35 ref.)

The role of growth factors in mouse skin tumor promotion and premalignant progression. Yuspa SH, et al. **Prog Clin Biol Res** 1995;391:39–48 (43 ref.)

Regulation of prostatic growth and function by peptide growth factors. Culig Z, et al. **Prostate** 1996 Jun; 28(6):392–405 (142 ref.)

Growth factors as mediators of androgen action during male urogenital development. Cunha GR. **Prostate Suppl** 1996; 6:22–5 (33 ref.)

Cellular biology of prostatic growth factors. Peehl DM. **Prostate Suppl** 1996;6:74–8 (55 ref.)

Peptide growth factors and breast cancer treatment: recent translational research. Pollak M. **Recent Results Cancer Res** 1996;140:43–9 (17 ref.)

Survival factors, intracellular signal transduction, and the activation of endonucleases in apoptosis. Eastman A. **Semin Cancer Biol** 1995 Feb;6(1):45–52 (69 ref.)

Growth factor requirements for normal and leukemic cells. Minden M. **Semin Hematol** 1995 Jul;32(3):162–82 (242 ref.)

Growth factors in renal development. Hammerman MR. **Semin Nephrol** 1995 Jul;15(4):291–9 (56 ref.)

Growth factors as mediators of androgen action during the development of the male urogenital tract. Cunha GR, et al. **World J Urol** 1995;13(5):264–76 (124 ref.)

Keratinocyte growth factor: an androgen–regulated mediator of stromal–epithelial interactions in the prostate. Peehl DM, et al. **World J Urol** 1995;13(5):312–7 (43 ref.)

[Growth factors. From the laboratory to the clinic (editorial; comment)] Carré P. **Rev Mal Respir** 1996;13(2):93–4 (3 ref.) Comment on: Rev Mal Respir 1996;13(2):117–21. Comment on: Rev Mal Respir 1996;13(2):123–6. **(Fre)**

[Cellular growth factors (see comments)] Chettab A, et al. **Rev Mal Respir** 1996;13(2):117–21 (50 ref.) Comment in: Rev Mal Respir 1996;13(2):93–4. **(Fre)**

[Cellular growth factors and cancer (see comments)] Martinet Y, et al. **Rev Mal Respir** 1996;13(2):123–6 (12 ref.) Comment in: Rev Mal Respir 1996;13(2):93–4. **(Fre)**

[Growth factors in liver regeneration and hepatocarcinogenesis] Schirmacher P, et al. **Verh Dtsch Ges Pathol** 1995;79:55–60 (47 ref.) (Eng. Abstr.) **(Ger)**

[Hypertrophy and hyperplasia of renal tubular interstitial cells—regulatory factors] Kanetake H, et al. **Nippon Rinsho** 1995 Aug;53(8):1894–9 (22 ref.) (Eng. Abstr.) **(Jpn)**

[The role of cytokines and growth factors in pathogenesis and progression of glomerulonephritis] Wagrowska–Danilewicz M, et al. **Pol Arch Med Wewn** 1996 May;95(5):493–6 (74 ref.) **(Pol)**

[Hormones, growth factors, and drugs in metabolism and nutrition] García de Lorenzo A, et al. **Nutr Hosp** 1995 Sep–Oct;10(5):297–305 (91 ref.) (Eng. Abstr.) **(Spa)**

THERAPEUTIC USE

Platelet–derived growth factor–modulated guided tissue regenerative therapy. Cho MI, et al. **J Periodontol** 1995 Jun;66(6):522–30 (43 ref.)

Periodontal regenerative potential of space–providing expanded polytetrafluoroethylene membranes and recombinant human bone morphogenetic proteins. Sigurdsson TJ, et al. **J Periodontol** 1995 Jun;66(6):511–21 (37 ref.)

The potential role of bone morphogenetic proteins in periodontal reconstruction. Wozney JM. **J Periodontol** 1995 Jun;66(6):506–10 (34 ref.)

Molecular and cell biology of acute renal failure: new therapeutic strategies. Wagener OE, et al. **New Horiz** 1995 Nov;3(4):634–49 (164 ref.)

Growth factors in surgery. Rudkin GH, et al. **Plast Reconstr Surg** 1996 Feb;97(2):469–76 (90 ref.)

Recombinant bone morphogenetic proteins: novel substances for enhancing bone healing. Kirker–Head CA. **Vet Surg** 1995 Sep–Oct;24(5):408–19 (80 ref.)

[Prospects of clinical uses of peptide growth factors] Zhao G, et al. **Chung Hua I Hsueh Tsa Chih** 1995 Jun;75(6):375–7 (11 ref.) **(Chi)**

[Growth factors. From the laboratory to the clinic (editorial; comment)] Carré P. **Rev Mal Respir** 1996;13(2):93–4 (3 ref.) Comment on: Rev Mal Respir 1996;13(2):117–21. Comment on: Rev Mal Respir 1996;13(2):123–6. **(Fre)**

[Cellular growth factors (see comments)] Chettab A, et al. **Rev Mal Respir** 1996;13(2):117–21 (50 ref.) Comment in: Rev Mal Respir 1996;13(2):93–4. **(Fre)**

[Treatment with growth factors and cytokines in hematologic diseases] Waage A, et al. **Tidsskr Nor Laegeforen** 1996 May 10;116(12):1465–9 (33 ref.) (Eng. Abstr.) **(Nor)**

GTP see **GUANOSINE TRIPHOSPHATE**

GTP–BINDING PROTEINS see **G–PROTEINS**

GTP PHOSPHOHYDROLASE

CHEMISTRY

GTPases: a family of molecular switches and clocks. Bourne HR. **Philos Trans R Soc Lond B Biol Sci** 1995 Sep 29; 349(1329):283–9 (32 ref.)

Ras–catalyzed hydrolysis of GTP: a new perspective from model studies. Maegley KA, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8160–6 (93 ref.)

DRUG EFFECTS

Signal transduction by Ras–like GTPases: a potential target for anticancer drugs. Spaargaren M, et al. **Gene Expr** 1995; 4(6):345–56 (122 ref.)

METABOLISM

Cell polarity. The importance of being polar. Glotzer M, et al. **Curr Biol** 1995 Oct 1;5(10):1102–5 (21 ref.)

Biochemical and functional diversity of microtubule motors in the nervous system. Brady ST, et al. **Curr Opin Neurobiol** 1995 Oct;5(5):551–8 (65 ref.)

Cell shape determination: a pivotal role for Rho [comment] Bussey H. **Science** 1996 Apr 12;272(5259):224–5 (12 ref.) Comment on: Science 1996 Apr 12;272(5259):277–9. Comment on: Science 1996 Apr 12;272(5259):279–81.

PHYSIOLOGY

Rho, rac and cdc42 GTPases: regulators of actin structures, cell adhesion and motility. Nobes CD, et al. **Biochem Soc Trans** 1995 Aug;23(3):456–9 (16 ref.)

The function of dynamin in endocytosis. De Camilli P, et al. **Curr Opin Neurobiol** 1995 Oct;5(5):559–65 (73 ref.)

Dynamin and endocytosis. Liu JP, et al. **Endocr Rev** 1995 Oct;16(5):590–607 (172 ref.)

The Ras superfamily of GTPases. Macara IG, et al. **FASEB J** 1996 Apr;10(5):625–30 (45 ref.)

Dynamin and receptor–mediated endocytosis. Damke H. **FEBS Lett** 1996 Jun 24;389(1):48–51 (49 ref.)

GTPases: a family of molecular switches and clocks. Bourne HR. **Philos Trans R Soc Lond B Biol Sci** 1995 Sep 29; 349(1329):283–9 (32 ref.)

A heterotrimeric GTPase–regulated isoform of PI3K and the regulation of its potential effectors. Stephens L, et al. **Philos Trans R Soc Lond B Biol Sci** 1996 Feb 29; 351(1336):211–5 (40 ref.)

Switching to Rac and Rho. Block C, et al. **Structure** 1995 Dec 15;3(12):1281–4 (30 ref.)

The Rho's progress: a potential role during neuritogenesis for the Rho family of GTPases. Mackay DJ, et al. **Trends Neurosci** 1995 Nov;18(11):496–501 (43 ref.)

GTP–REGULATORY PROTEINS see **G–PROTEINS**

GTPASE see **GTP PHOSPHOHYDROLASE**

GUAMA GROUP VIRUSES see **BUNYAVIRUS**

GUAMA VIRUS see **BUNYAVIRUS**

GUANASE see **GUANINE DEAMINASE**

GUANIDINES

ADVERSE EFFECTS

Mechanisms of hyperkalemia caused by nafamostat mesilate. Muto S, et al. **Gen Pharmacol** 1995 Dec;26(8):1627–32 (34 ref.)

METABOLISM

Some aspects of guanidine secondary metabolites. Gomes de Souza Berlinck R. **Fortschr Chem Org Naturst** 1995; 66:119–295 (901 ref.)

PHARMACOKINETICS

Deoxyspergualin: mechanism of action and pharmacokinetics. Ramos EL, et al. **Transplant Proc** 1996 Apr;28(2):873–5 (49 ref.)

PHARMACOLOGY

Neuroprotective use-dependent blockers of Na+ and Ca2+ channels controlling presynaptic release of glutamate. Goldin SM, et al. **Ann N Y Acad Sci** 1995 Sep 15;765:210–29 (59 ref.)

Deoxyspergualin: mechanism of action and pharmacokinetics. Ramos EL, et al. **Transplant Proc** 1996 Apr;28(2):873–5 (49 ref.)

THERAPEUTIC USE

Deoxyspergualin: a new immunosuppressive drug for the treatment of auto-immune disease [editorial] Nikolic-Paterson DJ, et al. **Nephron** 1995;70(4):391–6 (63 ref.)

Deoxyspergualin: clinical experience. Gores PF. **Transplant Proc** 1996 Apr;28(2):871–2 (12 ref.)

15-Deoxyspergualin in experimental transplant models: a review. Kaufman DB. **Transplant Proc** 1996 Apr; 28(2):868–70 (31 ref.)

URINE

[Guanidino compound derivation] Oishi N, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:496–500 (13 ref.) **(Jpn)**

GUANINE

Nickel complexes as probes of guanine sites in nucleic acid folding. Burrows CJ, et al. **Met Ions Biol Syst** 1996; 33:537–60 (41 ref.)

ANALOGS & DERIVATIVES

[8-Oxoguanine repair system and its role in mitochondria] Kang D, et al. **Seikagaku** 1996 Apr;68(4):289–95 (22 ref.) **(Jpn)**

CHEMISTRY

[Oxidative reactions of the base moiety in purine nucleosides and their applications] Maki Y, et al. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1211–8 (30 ref.) **(Jpn)**

GUANINE AMINASE see **GUANINE DEAMINASE**

GUANINE AMINOHYDROLASE see **GUANINE DEAMINASE**

GUANINE DEAMINASE

BLOOD

[Guanase] Ito S. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:296–8 (14 ref.) **(Jpn)**

GUANINE NUCLEOTIDE REGULATORY PROTEINS see **G-PROTEINS**

GUANINE NUCLEOTIDES

METABOLISM

Guanine nucleotide-dependent carboxymethylation: a pathway for aldosterone modulation of apical Na+ permeability in epithelia. Sariban-Sohraby S, et al. **Kidney Int** 1995 Oct;48(4):965–9 (66 ref.)

GUANINE PHOSPHORIBOSYLTRANSFERASE see **HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE**

GUANOSINE

ANALOGS & DERIVATIVES

A new approach to vaccine adjuvants. Immunopotentiation by intracellular T-helper-like signals transmitted by loxoribine. Goodman MG. **Pharm Biotechnol** 1995; 6:581–609 (73 ref.)

GUANOSINE CYCLIC MONOPHOSPHATE-DEPENDENT PROTEIN KINASES see **CYCLIC GMP-DEPENDENT PROTEIN KINASES**

GUANOSINE CYCLIC 3',5'-MONOPHOSPHATE see **CYCLIC GMP**

GUANOSINE PHOSPHATES see **GUANINE NUCLEOTIDES**

GUANOSINE TRIPHOSPHATE

ANALOGS & DERIVATIVES

[Analysis of GTP-binding protein function with a photoaffinity GTP analog] Hatta S, et al. **Nippon Yakurigaku Zasshi** 1995 Jun;105(6):431–6 (18 ref.) (Eng. Abstr.) **(Jpn)**

CHEMISTRY

Ras-catalyzed hydrolysis of GTP: a new perspective from model studies. Maegley KA, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8160–6 (93 ref.)

METABOLISM

Role of guanosine triphosphate in ferric ion-linked Fenton chemistry. Biaglow JE, et al. **Radiat Res** 1996 May; 145(5):554–62 (69 ref.)

GUANOSINE TRIPHOSPHATE PHOSPHOHYDROLASE see **GTP PHOSPHOHYDROLASE**

GUANOSINETRIPHOSPHATASE see **GTP PHOSPHOHYDROLASE**

GUANYLORIBONUCLEASE see **RIBONUCLEASE T1**

GUERIN-STERN SYNDROME see **ARTHROGRYPOSIS**

GUEST RELATIONS see **HOSPITAL-PATIENT RELATIONS**

GUIDE RNA see **RNA, GUIDE**

GUIDED IMAGERY see **IMAGERY (PSYCHOTHERAPY)**

GUIDED TISSUE REGENERATION

Platelet-derived growth factor-modulated guided tissue regenerative therapy. Cho MI, et al. **J Periodontol** 1995 Jun;66(6):522–30 (43 ref.)

Periodontal regenerative potential of space-providing expanded polytetrafluoroethylene membranes and recombinant human bone morphogenetic proteins. Sigurdsson TJ, et al. **J Periodontol** 1995 Jun;66(6):511–21 (37 ref.)

Regenerative therapy. The future of periodontics. Breault MR, et al. **N Y State Dent J** 1995 Dec;61(10):34–7 (0 ref.)

[The GTR technic within the framework of combined periodontal-orthodontic treatments. A case report] Stelzel M, et al. **Fortschr Kieferorthop** 1995 Nov;56(6):347–52 (28 ref.) (Eng. Abstr.) **(Ger)**

GUIDELINES

Controversy in the pharmacologic treatment of hypertension in African Americans [see comments] Lockette W. **J Assoc Acad Minor Phys** 1995;6(4):125–9 (32 ref.) Comment in: J Assoc Acad Minor Phys 1995;6(4):124.

Management guidelines for hypertension: is anyone taking notice? Swales JD. **J Hum Hypertens** 1995 Jul;9 Suppl 2:S9–13 (13 ref.)

A reader's guide to the evaluation of prognostic studies. van Walraven C, et al. **Postgrad Med J** 1996 Jan;72(843):6–11 (7 ref.)

[The guideline for clinical trials proposed by Japan Society for Cancer Therapy (JSCT)] Kurihara M. **Gan To Kagaku Ryoho** 1996 Jan;23(2):156–65 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Guide line for gene therapy] Takaku F. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2498–502 (4 ref.) **(Jpn)**

STANDARDS

Risk assessment: the default conservatism controversy. Barnard RC. **Regul Toxicol Pharmacol** 1995 Jun;21(3):431–8 (14 ref.)

Copper regulatory level in drinking-water as proposed by Sidhu et al. Fitzgerald DJ. **Regul Toxicol Pharmacol** 1996 Apr;23(2):173–5 (9 ref.)

Writing guidelines to require disinfection. Grow AG. **Rev Sci Tech** 1995 Jun;14(2):469–77 (6 ref.)

GUIDELINES FOR HEALTH PLANNING see **HEALTH PLANNING GUIDELINES**

GUILLAIN-BARRE SYNDROME see **POLYRADICULONEURITIS**

GULF WAR SYNDROME see **PERSIAN GULF SYNDROME**

GUMS see **GINGIVA**

GUNS see **FIREARMS**

GUT GLUCAGON see **ENTEROGLUCAGON**

GYMNASTICS

Health concerns of artistic women gymnasts. O'Connor PJ, et al. **Sports Med** 1996 May;21(5):321–5 (37 ref.)

GYMNODINIUM see **DINOFLAGELLIDA**

GYMNOTID see **ELECTRIC FISH**

GYNECOLOGIC DISEASES see **GENITAL DISEASES, FEMALE**

GYNECOLOGIC NEOPLASMS see **GENITAL NEOPLASMS, FEMALE**

GYNECOLOGY

see related
GENITAL DISEASES, FEMALE
REPRODUCTIVE MEDICINE

Complications of gynecologic laparoscopic surgery. Querleu D, et al. **Curr Opin Obstet Gynecol** 1995 Aug;7(4):257–61 (18 ref.)

Office gynecology for the primary care physician, part II: pelvic pain, vulvar disease, disorders of menstruation, premenstrual syndrome, and breast disease. Klein TA. **Med Clin North Am** 1996 Mar;80(2):321–36 (68 ref.)

Office gynecology for the primary care physician, part I: vaginitis, the Papanicolaou smear, contraception, and postmenopausal estrogen replacement. Reife CM. **Med Clin North Am** 1996 Mar;80(2):299–319 (63 ref.)

Epidemiology of injuries by needles and other sharp instruments. Minimizing sharp injuries in gynecologic and obstetric operations. Lewis FR Jr, et al. **Surg Clin North Am** 1995 Dec;75(6):1105–21 (34 ref.)

[Pregnancy after breast cancer] Mignot L, et al. **Contracept Fertil Sex** 1996 Apr;24(4):319–21 (16 ref.) (Eng. Abstr.) **(Fre)**

[Application of molecular biological techniques for obstetric and gynecologic field] Suganuma N. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Aug; 47(8):785–90 (19 ref.) **(Jpn)**

EDUCATION

Materials, methods and results of the Norplant training program. Bromham DR, et al. **Adv Contracept** 1995 Sep; 11(3):255–62 (4 ref.)

TRENDS

What's new in gynecology and obstetrics. Kammerer-Doak DN, et al. **J Am Coll Surg** 1996 Feb;182(2):107–14 (52 ref.)

Advances in gynaecology. Baird G. **Practitioner** 1996 Feb; 240(1559):90–5 (12 ref.)

GYNECOMASTIA

ETIOLOGY

[Diseases of the male breast] Krause W, et al. **Hautarzt** 1996 Jun;47(6):422–6 (16 ref.) (Eng. Abstr.) **(Ger)**

GENETICS

The expanded trinucleotide repeat in Kennedy's disease. Fischbeck KH. **Proc Assoc Am Physicians** 1995 Jul; 107(2):228–30 (9 ref.)

GYRATE ATROPHY

GENETICS

[Hyperornithinemia and gyrate atrophy: ornithine aminotransferase gene error causing a Finnish disease] Sipilä I, et al. **Duodecim** 1994;110(7):681–6 (18 ref.) **(Fin)**

GYRECTOMY see **PSYCHOSURGERY**

GYRUS CINGULI

PHYSIOLOGY

Role for the mesocortical dopamine system in the motivating effects of cocaine. Koob GF, et al. **NIDA Res Monogr** 1994;145:1–18 (44 ref.)

GYRUS DENTATUS see **DENTATE GYRUS**

H-2 ANTIGENS

IMMUNOLOGY

MHC class I-like, class II-like and CD1 molecules: distinct roles in immunity. Beckman EM, et al. **Immunol Today** 1995 Jul;16(7):349–52 (38 ref.)

PHYSIOLOGY

Inhibitory effects of class I molecules on murine NK cells: speculations on function, specificity and self-tolerance. Raulet DH, et al. **Semin Immunol** 1995 Apr;7(2):103–7 (24 ref.)

H 93-26 see **METOPROLOL**

H(+)ATPASE COMPLEX see **H(+)-TRANSPORTING ATP SYNTHASE**

H(+)-K(+)-EXCHANGING ATPASE

ANTAGONISTS & INHIBITORS

Proton pump inhibitors: new drugs and indications. Mears JM, et al. **Am Fam Physician** 1996 Jan;53(1):285–92 (38 ref.)

Why is the high grade inhibition of gastric acid secretion afforded by proton pump inhibitors often required for healing of reflux esophagitis? An epithelial perspective. Orlando RC. **Am J Gastroenterol** 1996 Sep;91(9):1692–6 (22 ref.)

Lansoprazole--another proton pump inhibitor. **Drug Ther Bull** 1995 May;33(5):36–7 (14 ref.)

Gastric acid secretion: activation and inhibition. Sachs G, et al. **Yale J Biol Med** 1994 May–Aug;67(3–4):81–95 (68 ref.)

METABOLISM

Gastric acid secretion: activation and inhibition. Sachs G, et al. **Yale J Biol Med** 1994 May–Aug;67(3–4):81–95 (68 ref.)

PHYSIOLOGY

Proton and potassium transport by H+/K(+)-ATPases. van Driel IR, et al. **Clin Exp Pharmacol Physiol** 1995 Dec; 22(12):952–60 (91 ref.)

H(+)-K(+)-TRANSPORTING ATPASE see **H(+)-K(+)-EXCHANGING ATPASE**

H(+) PUMP see **PROTON PUMP**

H(+)-TRANSPORTING ATP SYNTHASE

CHEMISTRY

ATP hydrolysis by membrane-bound Escherichia coli F0F1 causes rotation of the gamma subunit relative to the beta subunits. Zhou Y, et al. **Biochim Biophys Acta** 1996 Jul 18;1275(1–2):96–100 (23 ref.)

Membrane sectors of F- and V-type H+-transporting ATPases. Fillingame RH. **Curr Opin Struct Biol** 1996 Aug; 6(4):491–8 (58 ref.)

New insight into lysosomal protein storage disease: delayed catabolism of ATP synthase subunit c in Batten disease. Kominami E, et al. **Neurochem Res** 1995 Nov;20(11):1305–9 (26 ref.)

METABOLISM

Plasticity in epithelial polarity of renal intercalated cells: targeting of the H(+)-ATPase and band 3. Al-Awqati Q. **Am J Physiol** 1996 Jun;270(6 Pt 1):C1571–80 (67 ref.)

Physiology and biochemistry of the kidney vacuolar H+-ATPase. Gluck SL, et al. **Annu Rev Physiol** 1996; 58:427–45 (129 ref.)

Thioredoxin and control of F0F1: function and distribution. Mills JD, et al. **Biochem Soc Trans** 1995 Nov;23(4):775–80 (35 ref.)

F1F0-ATP synthase: development of direct optical probes of the catalytic mechanism. Weber J, et al. **Biochim Biophys Acta** 1996 Jul 18;1275(1–2):101–4 (26 ref.)

Allosteric enzymes as models for chemomechanical energy transducing assemblies. Goldsmith EJ. **FASEB J** 1996 May; 10(7):702–8 (50 ref.)

ATPase activity, IF1 content, and proton conductivity of ESMP from control and ischemic slow and fast heart-rate hearts. Roualin W, et al. **J Bioenerg Biomembr** 1995 Aug; 27(4):459–66 (30 ref.)

Mechanisms of active transport in the F0F1 ATP synthase. Nakamoto RK. **J Membr Biol** 1996 May;151(2):101–11 (123 ref.)

The role of H(+)-ATPases in urinary acidification. Constantinescu A. **Pediatr Nephrol** 1995 Aug;9(4):510–3 (24 ref.)

H(+)-TRANSPORTING ATPASE see **H(+)-TRANSPORTING ATP SYNTHASE**

H-D ANTIGENS see **ANTIGENS, HETEROPHILE**

H-Y ANTIGEN

H-Y antigens. Müller U. **Hum Genet** 1996 Jun;97(6):701–4 (50 ref.)

HA-RAS GENES see **GENES, RAS**

HABILITATION see **REHABILITATION**

HABIT DISTURBANCES see **HABITS**

HABITS

Habits affecting dental and maxillofacial growth and development. Josell SD. **Dent Clin North Am** 1995 Oct; 39(4):851–60 (32 ref.)

Variations in physical activity habits and body composition. Wilmore JH. **Int J Obes Relat Metab Disord** 1995 Oct;19 Suppl 4:S107–12 (30 ref.)

Habit reversal: a review of applications and variations. Woods DW, et al. **J Behav Ther Exp Psychiatry** 1995 Jun; 26(2):123–31 (55 ref.)

HABITUATION (PSYCHOPHYSIOLOGY)

Neurophysiological approach to tinnitus patients. Jastreboff PJ, et al. **Am J Otol** 1996 Mar;17(2):236–40 (38 ref.)

Deficient habituation of evoked cortical potentials in migraine: a link between brain biology, behavior and trigeminovascular activation? Schoenen J. **Biomed Pharmacother** 1996;50(2):71–8 (78 ref.)

PHYSIOLOGY

Stimulus specific adaptation in inferior temporal and medial temporal cortex of the monkey. Ringo JL. **Behav Brain Res** 1996 Apr;76(1–2):191–7 (39 ref.)

Gating and habituation deficits in the schizophrenia disorders. Braff DL, et al. **Clin Neurosci** 1995;3(2):131–9 (48 ref.)

HABRONEMIASIS see **SPIRURIDA INFECTIONS**

HAEM OXYGENASE see **HEME OXYGENASE**

HAEMONCHIASIS

PREVENTION & CONTROL

Progress on vaccination against Haemonchus contortus. Newton SE. **Int J Parasitol** 1995 Nov;25(11):1281–9 (35 ref.)

HAEMONCHUS

IMMUNOLOGY

Progress on vaccination against Haemonchus contortus. Newton SE. **Int J Parasitol** 1995 Nov;25(11):1281–9 (35 ref.)

HAEMOPHILUS DUCREYI

see related

CHANCROID

Chancroid: new developments in an old disease. Marrazzo JM, et al. **Curr Clin Top Infect Dis** 1995;15:129–52 (83 ref.)

CLASSIFICATION

Chancroid and Haemophilus ducreyi: an update. Trees DL, et al. **Clin Microbiol Rev** 1995 Jul;8(3):357–75 (170 ref.)

PATHOGENICITY

Chancroid and Haemophilus ducreyi: an update. Trees DL, et al. **Clin Microbiol Rev** 1995 Jul;8(3):357–75 (170 ref.)

HAEMOPHILUS INFECTIONS

Remediable recurrent meningitis. Rajeshwari K, et al. **Indian Pediatr** 1995 Apr;32(4):491–6 (28 ref.)

DIAGNOSIS

Type b Haemophilus influenzae endocarditis in children: case report and review of the literature. Malik AS. **Ann Trop Paediatr** 1995 Sep;15(3):193–5 (16 ref.)

DRUG THERAPY

Lower respiratory tract infection therapy--the role of ciprofloxacin. Ball AP, et al. **J Int Med Res** 1995 Sep–Oct; 23(5):315–27 (55 ref.)

[Azithromycin and bronchopulmonary infections] Leophonte P. **Pathol Biol (Paris)** 1995 Jun;43(6):534–41 (38 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Acute on chronic bronchitis: A model of mucosal immunology. Clancy R, et al. **Immunol Cell Biol** 1995 Oct; 73(5):414–7 (26 ref.)

MICROBIOLOGY

Phenotypic variation of carbohydrate surface antigens and the pathogenesis of Haemophilus influenzae infections. Roche RJ, et al. **Trends Microbiol** 1995 Aug;3(8):304–9 (60 ref.)

PREVENTION & CONTROL

Preventing bacterial respiratory tract infections among persons infected with human immunodeficiency virus. Keller DW, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S77–83 (66 ref.)

Impact of immunization on Haemophilus influenzae type b disease. Madore DV. **Infect Agents Dis** 1996 Jan;5(1):8–20 (129 ref.)

Haemophilus influenzae: capsule vaccine and capsulation genetics. Kroll JS, et al. **Mol Med Today** 1996 Apr; 2(4):160–5 (37 ref.)

VETERINARY

[Infectious coryza: review of diagnostic methods and vaccines] Blackall PJ, et al. **Rev Argent Microbiol** 1995 Jul–Sep;27(3):156–74 (62 ref.) **(Spa)**

HAEMOPHILUS INFLUENZAE

Type b Haemophilus influenzae endocarditis in children: case report and review of the literature. Malik AS. **Ann Trop Paediatr** 1995 Sep;15(3):193–5 (16 ref.)

Acute on chronic bronchitis: A model of mucosal immunology. Clancy R, et al. **Immunol Cell Biol** 1995 Oct; 73(5):414–7 (26 ref.)

Impact of immunization on Haemophilus influenzae type b disease. Madore DV. **Infect Agents Dis** 1996 Jan;5(1):8–20 (129 ref.)

Lower respiratory tract infection therapy--the role of ciprofloxacin. Ball AP, et al. **J Int Med Res** 1995 Sep–Oct; 23(5):315–27 (55 ref.)

CLASSIFICATION

[Purulent meningitis with nonserotypable Haemophilus influenzae in infants and adults] Mihancea N, et al. **Bacteriol Virusol Parazitol Epidemiol** 1995 Apr–Jun; 40(2):149–51 (17 ref.) **(Rum)**

ENZYMOLOGY

Antigenic and genetic heterogeneity among Haemophilus influenzae and Neisseria IgA1 proteases. Lomholt H, et al. **Adv Exp Med Biol** 1995;371A:599–603 (18 ref.)

GENETICS

Novel PTS proteins revealed by bacterial genome sequencing: a unique fructose-specific phosphoryl transfer protein with two HPr-like domains in Haemophilus influenzae. Reizer J, et al. **Res Microbiol** 1996 May; 147(4):209–15 (29 ref.)

Bacterial genomes: a TIGR in the tank. Devine KM, et al. **Trends Genet** 1995 Nov;11(11):429–31 (13 ref.)

[Information from complete bacterial genome sequences] Ogasawara N. **Tanpakushitsu Kakusan Koso** 1996 Apr; 41(4):366–70 (12 ref.) **(Jpn)**

IMMUNOLOGY

Preventing bacterial respiratory tract infections among persons infected with human immunodeficiency virus. Keller DW, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S77–83 (66 ref.)

Haemophilus influenzae type b conjugate vaccines. Kniskern PJ, et al. **Pharm Biotechnol** 1995;6:673–94 (63 ref.)

Phenotypic variation of carbohydrate surface antigens and the pathogenesis of Haemophilus influenzae infections. Roche RJ, et al. **Trends Microbiol** 1995 Aug;3(8):304–9 (60 ref.)

ISOLATION & PURIFICATION

[Influenza-bacillus: who discovered the organism?] Taguchi F, et al. **Nippon Saikingaku Zasshi** 1995 Jul;50(3):787–91 (8 ref.) **(Jpn)**

[Review of epiglottitis] Acuña García M, et al. **Acta Otorrinolaringol Esp** 1996 Mar–Apr;47(2):144–8 (27 ref.) (Eng. Abstr.) **(Spa)**

HAEMOPHILUS PERTUSSIS see **BORDETELLA PERTUSSIS**

HAEMOPHILUS PLEUROPNEUMONIAE see **ACTINOBACILLUS PLEUROPNEUMONIAE**

HAEMOPHILUS VACCINES

Haemophilus influenzae: capsule vaccine and capsulation genetics. Kroll JS, et al. **Mol Med Today** 1996 Apr; 2(4):160–5 (37 ref.)

[Infectious coryza: review of diagnostic methods and vaccines] Blackall PJ, et al. **Rev Argent Microbiol** 1995 Jul–Sep;27(3):156–74 (62 ref.) **(Spa)**

ADMINISTRATION & DOSAGE

The contribution of the case-control approach to vaccine evaluation: Pneumococcal and Haemophilus influenzae type B PRP vaccines. Mills OF, et al. **J Clin Epidemiol** 1996 Jun;49(6):631–6 (34 ref.)

HAGEMAN FACTOR see **FACTOR XII**

HAGFISH

ANATOMY & HISTOLOGY

[The brain of the Agnatha] Kusunoki T, et al. **Kaibogaku Zasshi** 1995 Oct;70(5):436–47 (57 ref.) (Eng. Abstr.) **(Jpn)**

HAIR

Prospects for expanded mohair and cashmere production and processing in the United States of America. Lupton CJ. **J Anim Sci** 1996 May;74(5):1164–72 (18 ref.)

ABNORMALITIES

Hair shaft abnormalities: Part I. Rogers M. **Australas J Dermatol** 1995 Nov;36(4):179–84; quiz 185–6 (23 ref.)
Nucleotide excision repair and the link with transcription. Lehmann AR. **Trends Biochem Sci** 1995 Oct;20(10):402–5 (29 ref.)
[Abnormal hair, anthology of pilary dysplasias] Piérard-Franchimont C, et al. **Rev Med Liege** 1996 Apr; 51(4):280–90 (14 ref.) **(Fre)**

CHEMISTRY

Technical issues concerning hair analysis for drugs of abuse. Harkey MR. **NIDA Res Monogr** 1995;154:218–34 (34 ref.)
[Measurement of drugs in neonatal hair—a window to fetal exposure] Koren G, et al. **Harefuah** 1995 Nov 1; 129(9):336–8 (15 ref.) **(Heb)**

METABOLISM

Models for studying the cellular processes and barriers to the incorporation of drugs into hair. Rollins DE, et al. **NIDA Res Monogr** 1995;154:235–44 (20 ref.)

PHYSIOLOGY

Hair growth and the fluid factor. Foote SI. **Med Hypotheses** 1995 Jun;44(6):475–8 (18 ref.)

ULTRASTRUCTURE

Hair shaft abnormalities: Part I. Rogers M. **Australas J Dermatol** 1995 Nov;36(4):179–84; quiz 185–6 (23 ref.)

HAIR BALLS see **BEZOARS**

HAIR CELLS

PHYSIOLOGY

Ionic conductances and hair cell tuning in the turtle cochlea. Art JJ, et al. **Ann N Y Acad Sci** 1996 Jun 19;781:103–22 (27 ref.)
Routes of calcium entry and extrusion in turtle hair cells. Tucker T, et al. **Ann N Y Acad Sci** 1996 Jun 19;781:123–37 (44 ref.)
Molecular machinery of auditory and vestibular transduction. Gillespie PG. **Curr Opin Neurobiol** 1995 Aug;5(4):449–55 (62 ref.)
Deaf and dizzy mice with mutated myosin motors. Gillespie PG. **Nat Med** 1996 Jan;2(1):27–9 (13 ref.)
Signal transduction in hair cells and its regulation by calcium. Jaramillo F. **Neuron** 1995 Dec;15(6):1227–30 (19 ref.)

HAIR CELLS, OUTER

PHYSIOLOGY

Cholinergic and purinergic signalling in outer hair cells of mammalian cochlea. Heilbronn E, et al. **Neurochem Int** 1995 Oct-Nov;27(4–5):301–11 (79 ref.)

HAIR CELLS, VESTIBULAR

EMBRYOLOGY

Hair cell generation in vestibular sensory receptor epithelia. Oesterle EC, et al. **Ann N Y Acad Sci** 1996 Jun 19;781:34–46 (80 ref.)

PHYSIOLOGY

Filtering properties of vestibular hair cells: an update. Correia MJ, et al. **Ann N Y Acad Sci** 1996 Jun 19;781:138–49 (24 ref.)
[Mechano-electrical transduction in hair cells in the inner ear] Sugihara I. **Tanpakushitsu Kakusan Koso** 1996 Jan; 41(1):19–25 (31 ref.) **(Jpn)**

HAIR DISEASES

CHEMICALLY INDUCED

[Hair-like hyperkeratoses in patients with kidney transplants. A new cyclosporin side-effect] Izakovic J, et al. **Hautarzt** 1995 Dec;46(12):841–6 (45 ref.) (Eng. Abstr.) **(Ger)**

CLASSIFICATION

Another patient with an unusual syndrome of mental retardation and sparse hair? [letter] Krajewska-Walasek M, et al. **Clin Dysmorphol** 1996 Apr;5(2):183–6 (1 ref.)
[Abnormal hair, anthology of pilary dysplasias] Piérard-Franchimont C, et al. **Rev Med Liege** 1996 Apr; 51(4):280–90 (14 ref.) **(Fre)**

PATHOLOGY

Hair shaft abnormalities: Part I. Rogers M. **Australas J Dermatol** 1995 Nov;36(4):179–84; quiz 185–6 (23 ref.)
Perforating pilomatricoma. Alli N, et al. **J Am Acad Dermatol** 1996 Jul;35(1):116–8 (11 ref.)

HAIR FOLLICLE

see related
FOLLICULITIS

PATHOLOGY

The 'mantle hair of Pinkus'. A review on the occasion of its centennial. de Viragh PA. **Dermatology** 1995;191(2):82–7 (47 ref.)
Multiple tumors of the follicular infundibulum. Kolenik SA 3rd, et al. **Int J Dermatol** 1996 Apr;35(4):282–4 (11 ref.)

PHYSIOLOGY

Mast cells as modulators of hair follicle cycling. Maurer M, et al. **Exp Dermatol** 1995 Aug;4(4 Pt 2):266–71 (99 ref.)

HAIR PREPARATIONS

ADVERSE EFFECTS

Reproductive disorders due to chemical exposure among hairdressers. Kersemaekers WM, et al. **Scand J Work Environ Health** 1995 Oct;21(5):325–34 (85 ref.)

HAIRY CELL LEUKEMIA see **LEUKEMIA, HAIRY CELL**

HAJDU-CHENEY SYNDROME see **OSTEOLYSIS, ESSENTIAL**

HALITOSIS

DIAGNOSIS

Clinical assessment of bad breath: current concepts. Rosenberg M. **J Am Dent Assoc** 1996 Apr;127(4):475–82 (33 ref.)

ETIOLOGY

Halitosis. Replogle WH, et al. **Am Fam Physician** 1996 Mar; 53(4):1215–8, 1223 (16 ref.)

HALLERVORDEN-SPATZ SYNDROME

CLASSIFICATION

The nosology of Hallervorden-spatz disease. Halliday W. **J Neurol Sci** 1995 Dec;134 Suppl:84–91 (36 ref.)

DIAGNOSIS

In vivo diagnosis of Hallervorden-Spatz disease [see comments] Ostergaard JR, et al. **Dev Med Child Neurol** 1995 Sep;37(9):827–33 (22 ref.) Comment in: Dev Med Child Neurol 1996 Apr;38(4):372–3.
Hallervorden-Spatz disease. Kaushik A, et al. **Indian Pediatr** 1995 Apr;32(4):483–5 (4 ref.)

HALLOPEAU-SIEMENS DISEASE see **EPIDERMOLYSIS BULLOSA DYSTROPHICA**

HALLUCINATIONS

see related
HALLUCINOGENS

CHEMICALLY INDUCED

Acetylcholine and hallucinations: disease-related compared to drug-induced alterations in human consciousness. Perry EK, et al. **Brain Cogn** 1995 Aug;28(3):240–58 (65 ref.)
[An anticholinergic syndrome with hallucinatory psychosis after diphenhydramine poisoning] Lang K, et al. **Dtsch Med Wochenschr** 1995 Dec 8;120(49):1695–8 (17 ref.) (Eng. Abstr.) **(Ger)**

COMPLICATIONS

Acetylcholine and hallucinations: disease-related compared to drug-induced alterations in human consciousness. Perry EK, et al. **Brain Cogn** 1995 Aug;28(3):240–58 (65 ref.)
Charles Bonnet syndrome: an early marker for dementia? [see comments] Pliskin NH, et al. **J Am Geriatr Soc** 1996 Sep;44(9):1055–61 (43 ref.) Comment in: J Am Geriatr Soc 1996 Sep;44(9):1128–9.

DIAGNOSIS

[Stability of positive/negative symptoms in schizophrenia] Ribeyre JM, et al. **Encephale** 1996 Jun;22 Spec No 2:29–31 (11 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Anatomic correlates of psychological events related to temporolimbic epilepsy. Tackenberg JN, et al. **J Neurosci Nurs** 1996 Apr;28(2):73–81 (51 ref.)

PSYCHOLOGY

True auditory hallucinations as a conversion symptom. Nakaya M. **Psychopathology** 1995;28(4):214–9 (14 ref.)
[Delusions and imagination] Schmidt-Degenhard M. **Fortschr Neurol Psychiatr** 1995 Sep;63(9):350–7 (57 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

The management of drug-resistant, persistent and unpleasant auditory hallucinations. Lecompte D. **Acta Psychiatr Belg** 1996 Jan-Feb;96(1):21–9 (21 ref.)

HALLUCINOGENS

[MDMA—"ecstasy"] Keup W. **Med Monatsschr Pharm** 1996 Jan;19(1):2–5 (27 ref.) **(Ger)**

METABOLISM

Some ethnopharmacological notes on African hallucinogens. De Smet PA. **J Ethnopharmacol** 1996 Mar;50(3):141–6 (50 ref.)

PHARMACOLOGY

100 years of ibogaine: neurochemical and pharmacological actions of a putative anti-addictive drug. Popik P, et al. **Pharmacol Rev** 1995 Jun;47(2):235–53 (224 ref.)

POISONING

Ecstasy intoxication: an overlap between serotonin syndrome and neuroleptic malignant syndrome. Demirkiran M, et al. **Clin Neuropharmacol** 1996 Apr;19(2):157–64 (43 ref.)

HALLUCINOSIS, ORGANIC see **ORGANIC MENTAL DISORDERS, PSYCHOTIC**

HALLUX

Gout as a source of sesamoid pain. Mair SD, et al. **Foot Ankle Int** 1995 Oct;16(10):613–6 (17 ref.)
Mesenchymal chondrosarcoma of the foot, an unusual location: case report and review of the literature. Sans M, et al. **Med Pediatr Oncol** 1996 Feb;26(2):139–42 (12 ref.)

SURGERY

Avascular necrosis of the hallucial sesamoids. Fleischli J, et al. **J Foot Ankle Surg** 1995 Jul-Aug;34(4):358–65 (34 ref.)
[Arthrodesis of the metatarsophalangeal joint of the large toe] Wülker N. **Orthopade** 1996 Apr;25(2):187–93 (28 ref.) (Eng. Abstr.) **(Ger)**

HALLUX ABDUCTOVALGUS see **HALLUX VALGUS**

HALLUX VALGUS

Hallux valgus. Coughlin MJ. **J Bone Joint Surg Am** 1996 Jun;78(6):932–66 (151 ref.)

COMPLICATIONS

Ochronosis and alkaptonuria. Case report and literature review. Kneebone TS, et al. **J Am Podiatr Med Assoc** 1995 Oct;85(10):554–5 (7 ref.)

ETIOLOGY

[Pathogenesis and treatments for hallux valgus] Takakura Y. **Nippon Seikeigeka Gakkai Zasshi** 1996 Apr;70(4):146–58 (25 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Bunions and deformities of the toes in children and adolescents. Thompson GH. **Instr Course Lect** 1996; 45:355–67 (79 ref.)

SURGERY

Prognostic factors in bunion surgery. Scranton PE Jr, et al. **Foot Ankle Int** 1995 Nov;16(11):698–704 (26 ref.)
[Pathogenesis and treatments for hallux valgus] Takakura Y. **Nippon Seikeigeka Gakkai Zasshi** 1996 Apr;70(4):146–58 (25 ref.) **(Jpn)**

HALOBACTERIUM

PHYSIOLOGY

Shuttling between two protein conformations: the common mechanism for sensory transduction and ion transport. Spudich JL, et al. **Curr Opin Cell Biol** 1996 Aug;8(4):452–7 (47 ref.)

HALOBACTERIUM MARISMORTUI see **HALOBACTERIUM**

HALOGENATED HYDROCARBONS see **HYDROCARBONS, HALOGENATED**

HALOGENS

[A variety of halogenating enzymes and their roles in organisms] Itoh N. **Tanpakushitsu Kakusan Koso** 1996 Mar; 41(3):256–66 (49 ref.) **(Jpn)**

HALOPERIDOL

ADVERSE EFFECTS

Neuroleptic malignant syndrome in a trauma patient [see comments] Burke C, et al. **J Trauma** 1995 Oct;39(4):796–8 (11 ref.) Comment in: J Trauma 1996 Apr;40(4):673.

The association between intravenous haloperidol and Torsades de Pointes. Three cases and a literature review. Hunt N, et al. **Psychosomatics** 1995 Nov–Dec;36(6):541–9 (55 ref.)

ANALOGS & DERIVATIVES

[The neuroleptic malignant syndrome (NMS). A report of a clinical case with a protracted and recurrent course. A review of the literature] Marelli A, et al. **Minerva Med** 1996 Jan–Feb;87(1–2):45–51 (30 ref.) (Eng. Abstr.) **(Ita)**

BLOOD

[Haloperidol] Sakamoto N, et al. **Nippon Rinsho** 1995 Feb; 53 Su Pt 1:938–41 (14 ref.) **(Jpn)**

HALOTHANE

ADVERSE EFFECTS

[Chemical hepatitis (halothane, toluene)] Shiomi S, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):49–51 (17 ref.) **(Jpn)**

HALSTED MASTECTOMY see MASTECTOMY, RADICAL

HAMARTOMA

[Mesenchymal hamartoma of the liver] Fukuhara K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):327–8 (14 ref.) **(Jpn)**

[von Meyenburg's complex (biliary microhamartoma)] Tetsuka I, et al. **Ryoikibetsu Shokogun Shirizu** 1995; (7):277–8 (5 ref.) **(Jpn)**

COMPLICATIONS

The clinical spectrum of naevus anaemicus and its association with port wine stains: report of 15 cases and a review of the literature. Katugampola GA, et al. **Br J Dermatol** 1996 Feb;134(2):292–5 (19 ref.)

[Clinical analysis of lung cancer in patients with chondromatous hamartoma] Umemori Y, et al. **Kyobu Geka** 1995 Nov;48(12):1061–4 (11 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

[A case of huge renal hamartoma] Yanaihara H, et al. **Nippon Hinyokika Gakkai Zasshi** 1995 Aug;86(8):1394–7 (11 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Polysyndactyly and asymptomatic hypothalamic hamartoma in mother and son: a variant of Pallister–Hall syndrome. Löw M, et al. **Clin Genet** 1995 Oct;48(4):209–12 (15 ref.)

PATHOLOGY

Ophthalmologic abnormalities in encephalocraniocutaneous lipomatosis. MacLaren MJ, et al. **Doc Ophthalmol** 1995; 90(1):87–98 (31 ref.)

Isolated collagenoma: a case report with a review of connective tissue nevi of the collagen type. Gautam RK, et al. **J Dermatol** 1996 Jul;23(7):476–8 (22 ref.)

Giant hamartoma of the oropharynx. Santana–Hernandez DJ, et al. **J Laryngol Otol** 1996 May;110(5):480–2 (20 ref.)

Multiple pulmonary chondrohamartomas in trachea, bronchi and lung parenchyma. Review of the literature. Domínguez H, et al. **Respir Med** 1996 Feb;90(2):111–4 (17 ref.)

RADIOTHERAPY

Ignition potential of the 585–nm pulsed–dye laser. Review of the literature and safety recommendations. Fretzin S, et al. **Dermatol Surg** 1996 Aug;22(8):699–702 (13 ref.)

HAMARTOMA SYNDROME, MULTIPLE

PATHOLOGY

Perspectives on craniofacial asymmetry. VI. The hamartoses. Cohen MM Jr. **Int J Oral Maxillofac Surg** 1995 Jun; 24(3):195–200 (14 ref.)

HAMMAN–RICH SYNDROME see PULMONARY FIBROSIS

HAMSTER SPUMAVIRUS see SPUMAVIRUS

HAMSTERS

The hamster cheek pouch: an immunologically privileged site suitable to the study of granulomatous infections. de Arruda MS, et al. **Rev Inst Med Trop Sao Paulo** 1995 Jul–Aug;37(4):303–9 (46 ref.)

HAND

Salvage of extensor tendon function with tenolysis and joint release. Uhl RL. **Hand Clin** 1995 Aug;11(3):461–70 (19 ref.)

Extensor tendon ruptures in rheumatoid arthritis. Williamson SC, et al. **Hand Clin** 1995 Aug;11(3):449–59 (21 ref.)

Idiopathic palmar fasciitis. Laszlo KS, et al. **Int J Dermatol** 1995 Sep;34(9):658–60 (13 ref.)

Infantile haemangiopericytoma of the hand. Templeton PA, et al. **J Hand Surg [Br]** 1996 Feb;21(1):121–3 (8 ref.)

Guidelines for evaluating assessment instruments. Fess EE. **J Hand Ther** 1995 Apr–Jun;8(2):144–8 (17 ref.)

Metastatic squamous cell carcinoma of the hand and review of the literature. Foley SJ, et al. **J R Army Med Corps** 1995 Jun;141(2):102–4 (8 ref.)

MR imaging of musculoskeletal tumors of the hand and wrist. Kransdorf MJ, et al. **Magn Reson Imaging Clin N Am** 1995 May;3(2):327–44 (105 ref.)

Hand protection. Gerberding JL, et al. **Surg Clin North Am** 1995 Dec;75(6):1133–9 (15 ref.)

ANATOMY & HISTOLOGY

The hand as a concept: digital differences and their importance. Ranney D. **Clin Anat** 1995;8(4):281–7 (29 ref.)

Anatomy of the extensor mechanism of the hand and wrist. Wehbé MA. **Hand Clin** 1995 Aug;11(3):361–6 (13 ref.)

A walk through the anatomy of the hand and forearm. Riordan DC. **J Hand Ther** 1995 Apr–Jun;8(2):68–78 (9 ref.)

Normal anatomy of the hand and wrist. Prendergast N, et al. **Magn Reson Imaging Clin N Am** 1995 May;3(2):197–212 (33 ref.)

BLOOD SUPPLY

MR angiography of the hand and wrist. Rofsky NM. **Magn Reson Imaging Clin N Am** 1995 May;3(2):345–59 (31 ref.)

Aneurysms of the digital artery: a review and report of three cases. Yajima H, et al. **Microsurgery** 1995;16(8):566–70 (19 ref.)

Arteriography and interventional therapy for diseases of the hand. Loring LA, et al. **Radiographics** 1995 Nov; 15(6):1299–310 (25 ref.)

PATHOLOGY

Multinucleate cell angiohistiocytoma. A review and report of four cases. Cribier B, et al. **Acta Derm Venereol** 1995 Sep;75(5):337–9 (5 ref.)

Rhabdomyosarcoma of the hand. Two case reports and a review of the literature. Xarchas K, et al. **J Hand Surg [Br]** 1996 Jun;21(3):325–9 (11 ref.)

Synovial lesions of the hand and wrist. Bergman AG. **Magn Reson Imaging Clin N Am** 1995 May;3(2):265–79 (31 ref.)

The epidemiology of osteoarthritis of the hand [see comments] Cicuttini FM, et al. **Rev Rhum Engl Ed** 1995 Jun;62(6 Suppl 1):3S–8S (45 ref.) Comment in: Rev Rhum Engl Ed 1995 Jun;62(6 Suppl 1):1S–2S.

Methodology of clinical trials in hand osteoarthritis. Issues and proposals. Maheu E, et al. **Rev Rhum Engl Ed** 1995 Jun;62(6 Suppl 1):55S–62S (22 ref.)

PHYSIOLOGY

Extensor physiology in the hand and wrist. Thompson ST, et al. **Hand Clin** 1995 Aug;11(3):367–71 (16 ref.)

Role of surgery of nerves in leprosy in the restoration of sensibility in hands and feet of leprosy patients. Kazen R. **Indian J Lepr** 1996 Jan–Mar;68(1):55–65 (44 ref.)

An ultrasonic time–of–flight system for hand movement measurement. Berners AC, et al. **Physiol Meas** 1995 Nov; 16(4):203–11 (13 ref.)

Grasping objects: the cortical mechanisms of visuomotor transformation. Jeannerod M, et al. **Trends Neurosci** 1995 Jul;18(7):314–20 (43 ref.)

PHYSIOPATHOLOGY

Application of biomechanics to tendon transfers. Hoard AS, et al. **J Hand Ther** 1995 Apr–Jun;8(2):115–23 (44 ref.)

[Most frequent causes for hand tremor in clinical practice] Málly J. **Orv Hetil** 1995 Oct 8;136(41):2211–6 (53 ref.) (Eng. Abstr.) **(Hun)**

SURGERY

Functional hand surgery following tetraplegia. Waters RL, et al. **Arch Phys Med Rehabil** 1996 Jan;77(1):86–94 (48 ref.)

Microsurgical reconstruction of the extensor system. Desai SS, et al. **Hand Clin** 1995 Aug;11(3):471–82 (43 ref.)

Clinical applications of MR imaging in hand and wrist surgery. Rettig ME, et al. **Magn Reson Imaging Clin N Am** 1995 May;3(2):361–8 (18 ref.)

HAND DEFORMITIES

DIAGNOSIS

Joint failure in erosive osteoarthritis of the hands. Rovetta G, et al. **Int J Tissue React** 1995;17(1):33–42 (36 ref.)

HAND DEFORMITIES, ACQUIRED

PATHOLOGY

Boutonniere deformity. Coons MS, et al. **Hand Clin** 1995 Aug;11(3):387–402 (30 ref.)

REHABILITATION

Rehabilitation of the burned hand: questionnaire results. Torres–Gray D, et al. **J Burn Care Rehabil** 1996 Mar–Apr; 17(2):161–8 (38 ref.)

HAND DEFORMITIES, CONGENITAL

CHEMICALLY INDUCED

Hand anomalies in fetal–hydantoin syndrome: from nail/phalangeal hypoplasia to unilateral acheiria [letter] Sabry MA, et al. **Am J Med Genet** 1996 Apr 24;62(4):410–2 (34 ref.)

CLASSIFICATION

Another patient with an unusual syndrome of mental retardation and sparse hair? [letter] Krajewska–Walasek M, et al. **Clin Dysmorphol** 1996 Apr;5(2):183–6 (1 ref.)

DIAGNOSIS

Anomalous flexor digitorum superficialis presenting as a painful palmar mass: a case report. Grant SD, et al. **Clin Anat** 1995;8(6):432–3 (6 ref.)

[The Tel Hashomer camptodactyly syndrome] Rogovina EG, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995; 95(4):83–6 (6 ref.) (Eng. Abstr.) **(Rus)**

ETIOLOGY

Symmetrical terminal transverse limb defects: report of a twenty–week fetus. Harmon JV Jr, et al. **Teratology** 1995 Apr;51(4):237–42 (18 ref.)

GENETICS

Kaufman oculocerebrofacial syndrome in a girl of 15 years. Briscioli V, et al. **Am J Med Genet** 1995 Jul 31;58(1):21–3 (6 ref.)

Kabuki make–up (Niikawa–Kuroki) syndrome in five Spanish children. Galán–Gómez E, et al. **Am J Med Genet** 1995 Nov 20;59(3):276–82 (30 ref.)

Mirror image duplication of the hands and feet: report of a sporadic case with multiple congenital anomalies. Hersh JH, et al. **Am J Med Genet** 1995 Nov 20;59(3):341–5 (14 ref.)

Interstitial deletion of the long arm of chromosome 6 associated with unusual limb anomalies: report of two new patients and review of the literature. Pandya A, et al. **Am J Med Genet** 1995 Oct 23;59(1):38–43 (22 ref.)

Polysyndactyly and asymptomatic hypothalamic hamartoma in mother and son: a variant of Pallister–Hall syndrome. Löw M, et al. **Clin Genet** 1995 Oct;48(4):209–12 (15 ref.)

Congenital hand and forearm anomalies. Louis DS, et al. **Curr Opin Pediatr** 1996 Feb;8(1):61–4 (12 ref.)

SURGERY

The role of microsurgery and free tissue transfer in the reconstruction of the paediatric upper extremity. Kay S, et al. **Ann Acad Med Singapore** 1995 Jul;24(4 Suppl):113–23 (50 ref.)

HAND DERMATOSES

Papular–purpuric 'gloves and socks' syndrome [letter] Veraldi S, et al. **Arch Dermatol** 1996 Aug;132(8):975–7 (17 ref.)

Knuckle pads—a forgotten skin condition: report of a case and review of the literature. Guberman D, et al. **Cutis** 1996 Apr;57(4):241–2 (20 ref.)

CHEMICALLY INDUCED

Adverse contact reactions to sculptured acrylic nails: 4 case reports and a literature review. Freeman S, et al. **Contact Dermatitis** 1995 Dec;33(6):381–5 (48 ref.)

ETIOLOGY

Chronic finger dermatitis after trauma. Diagnosis: posttraumatic eczema with allergic contact dermatitis to neomycin, bacitracin, and topical corticosteroids. Sherertz EF. **Arch Dermatol** 1996 Apr;132(4):461, 464 (11 ref.)

Milia–like idiopathic calcinosis cutis: an unusual dermatosis associated with Down syndrome. Schepis C, et al. **Br J Dermatol** 1996 Jan;134(1):143–6 (17 ref.)

Hypoallergenic gloves. Field EA. **Int Dent J** 1995 Dec; 45(6):339–46 (36 ref.)

[Cryptococcal whitlow in a HIV positive patient] Verneuil L, et al. **Ann Dermatol Venereol** 1995;122(10):688–91 (29 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

The scleroatrophic syndrome of Huriez: a cancer–prone genodermatosis. Hamm H, et al. **Br J Dermatol** 1996 Mar; 134(3):512–8 (24 ref.)

An update on pachydermodactyly and a report of three

additional cases. Kopera D, et al. **Br J Dermatol** 1995 Sep; 133(3):433–7 (26 ref.)
Problem sites: scalp, palm and sole, and nail. Larko O. **Dermatol Clin** 1995 Oct;13(4):771–7 (91 ref.)
Isolated collagenoma: a case report with a review of connective tissue nevi of the collagen type. Gautam RK, et al. **J Dermatol** 1996 Jul;23(7):476–8 (22 ref.)

HAND INJURIES

see related
WRIST INJURIES
Upper extremity disorders: a literature review to determine work-relatedness. Vender MI, et al. **J Hand Surg [Am]** 1995 Jul;20(4):534–41 (79 ref.)

DIAGNOSIS

Bartender's hand an unusual form of occupational cumulative trauma disorder. David AM, et al. **West J Med** 1996 Apr; 164(4):353–4 (6 ref.)

ETIOLOGY

Human bites to the hand. Carr MM. **J Can Dent Assoc** 1995 Sep;61(9):782–4 (32 ref.)
[A syndrome caused by separating rags in textile industry: a new clinical entity?] Fioravanti A, et al. **Minerva Med** 1995 Nov;86(11):467–4 (25 ref.) (Eng. Abstr.) **(Ita)**

REHABILITATION

Posttraumatic stiffness in the hand. Putnam MD. **Clin Orthop** 1996 Jun;(327):182–90 (47 ref.)
Continuous passive motion use in hand therapy. Adams KM, et al. **Hand Clin** 1996 Feb;12(1):109–27 (22 ref.)
Early motion after flexor tendon surgery. Wang AW, et al. **Hand Clin** 1996 Feb;12(1):43–55 (47 ref.)
Silicone rubber splinting for athletic hand and wrist injuries. Canelón MF. **J Hand Ther** 1995 Oct–Dec;8(4):252–7 (43 ref.)

SURGERY

Microsurgical reconstruction of sensory skin. Brunelli GA, et al. **Ann Acad Med Singapore** 1995 Jul;24(4 Suppl):108–12 (14 ref.)
Flap reconstruction in the upper limb. Ikuta Y, et al. **Ann Acad Med Singapore** 1995 Jul;24(4 Suppl):124–30 (10 ref.)
The role of microsurgery and free tissue transfer in the reconstruction of the paediatric upper extremity. Kay S, et al. **Ann Acad Med Singapore** 1995 Jul;24(4 Suppl):113–23 (50 ref.)
Current concepts of replantation. Raskin KB, et al. **Ann Acad Med Singapore** 1995 Jul;24(4 Suppl):131–4 (29 ref.)
[Therapy of osteomyelitis in the metacarpal region with local pedicle m. interosseus dorsalis II and III–flap–plasty. Anatomic principles and case report] Giunta R, et al. **Handchir Mikrochir Plast Chir** 1996 Mar;28(2):64–9 (28 ref.) (Eng. Abstr.) **(Ger)**
[Use of mini-septopal in trauma surgery of the hand. Experimental and clinical studies] Zimmer K. **Polim Med** 1996;26(1–2):3–57 (136 ref.) (Eng. Abstr.) **(Pol)**

THERAPY

[Treatment principles in hand fractures] Schuind F, et al. **Rev Med Brux** 1996 Jun;17(3):120–6 (40 ref.) (Eng. Abstr.) **(Fre)**

HANDEDNESS see **LATERALITY**

HANDICAPPED see **DISABLED**

HANDWASHING

Compliance with handwashing and barrier precautions. Larson E, et al. **J Hosp Infect** 1995 Jun;30 Suppl:88–106 (81 ref.)

METHODS

APIC guideline for handwashing and hand antisepsis in health care settings. Larson EL. **Am J Infect Control** 1995 Aug;23(4):251–69 (239 ref.)

HANDWRITING

Handwriting in health and disease. Ficarra BJ. **Leg Med** 1995; :261–78 (22 ref.)

HANGANUTZIU–DEICHER ANTIGENS see **ANTIGENS, HETEROPHILE**

HANSEN'S DISEASE see **LEPROSY**

HANTAVIRUS

Hantaviruses: clinical, microbiologic, and epidemiologic aspects. Hjelle B, et al. **Crit Rev Clin Lab Sci** 1995; 32(5–6):469–508 (164 ref.)

ISOLATION & PURIFICATION

Hantavirus pulmonary syndrome: clinical, diagnostic, and virologic aspects. Jenison S, et al. **Semin Respir Infect** 1995 Dec;10(4):259–269 (65 ref.)

PATHOGENICITY

Lessons learned from the hantaviruses and other hemorrhagic fever viruses. Butler JC, et al. **Am J Med Sci** 1996 Jan; 311(1):55–9 (39 ref.)
Hantaviruses are likely threat to NATO forces in Bosnia and Herzegovina and Croatia. Markotić A, et al. **Nat Med** 1996 Mar;2(3):269–70 (18 ref.)

HANTAVIRUS INFECTIONS

Hantavirus infection: a rare disease which you should be aware. Rodríguez Rodríguez J, et al. **Bol Asoc Med P R** 1995 Mar–Apr;87(3–4):64–6 (21 ref.)
Hantavirus illness in humans: review and update. Warner GS. **South Med J** 1996 Mar;89(3):264–71 (26 ref.)
[The hantaviruses—clinical syndromes] George J, et al. **Harefuah** 1995 Nov 15;129(10):421–3 (21 ref.) **(Heb)**

DIAGNOSIS

Hantaviruses: clinical, microbiologic, and epidemiologic aspects. Hjelle B, et al. **Crit Rev Clin Lab Sci** 1995; 32(5–6):469–508 (164 ref.)
Production of recombinant hantavirus nucleocapsid protein expressed in silkworm larvae and its use as a diagnostic antigen in detecting antibodies in serum from infected rats. Yoshimatsu K, et al. **Lab Anim Sci** 1995 Dec;45(6):641–6 (8 ref.)

DRUG THERAPY

Hantavirus infections in the United States: diagnosis and treatment. Mertz G, et al. **Adv Exp Med Biol** 1996; 394:153–62 (28 ref.)

EPIDEMIOLOGY

Lessons learned from the hantaviruses and other hemorrhagic fever viruses. Butler JC, et al. **Am J Med Sci** 1996 Jan; 311(1):55–9 (39 ref.)
Hantaviruses: clinical, microbiologic, and epidemiologic aspects. Hjelle B, et al. **Crit Rev Clin Lab Sci** 1995; 32(5–6):469–508 (164 ref.)
Patterns and predictability in emerging infections. Morse SS. **Hosp Pract (Off Ed)** 1996 Apr 15;31(4):85–91, 96–101, 104 passim (11 ref.)

THERAPY

Hantavirus infections in the United States: diagnosis and treatment. Mertz G, et al. **Adv Exp Med Biol** 1996; 394:153–62 (28 ref.)

HANTAVIRUS PULMONARY SYNDROME

Hantavirus pulmonary syndrome. Khan AS, et al. **Lancet** 1996 Mar 16;347(9003):739–41 (28 ref.)
The role of molecular techniques in the understanding of emerging infections. Sable CA, et al. **Mol Med Today** 1996 Mar;2(3):120–8 (43 ref.)

DIAGNOSIS

Hantavirus pulmonary syndrome in Canada: update. **Can Med Assoc J** 1995 Nov 1;153(9):1303–4, 1308–9; discussion 1304–5, (10 ref.)
Hantavirus pulmonary syndrome: clinical, diagnostic, and virologic aspects. Jenison S, et al. **Semin Respir Infect** 1995 Dec;10(4):259–269 (65 ref.)
Retrospective diagnosis of a fatal case of the hantavirus pulmonary syndrome, 1980. Schwarcz SK, et al. **West J Med** 1996 Apr;164(4):348–50 (21 ref.)

VIROLOGY

[New pulmonary symptoms by killer Hantavirus (editorial)] Vapalahti O, et al. **Duodecim** 1994;110(4):372–4 (18 ref.) **(Fin)**

HAPALE see **CALLITHRIX**

HAPLORHINI

Simian bites and bacterial infection. Goldstein EJ, et al. **Clin Infect Dis** 1995 Jun;20(6):1551–2 (14 ref.)

ANATOMY & HISTOLOGY

Genetic and morphological records of the Hominoidea and hominid origins: a synthesis. Pilbeam D. **Mol Phylogenet Evol** 1996 Feb;5(1):155–68 (121 ref.)

GENETICS

Genetic and morphological records of the Hominoidea and hominid origins: a synthesis. Pilbeam D. **Mol Phylogenet Evol** 1996 Feb;5(1):155–68 (121 ref.)

PHYSIOLOGY

Cognitive functions of the basal forebrain cholinergic system in monkeys: memory or attention? Voytko ML. **Behav Brain Res** 1996 Feb;75(1–2):13–25 (123 ref.)

HAPLOTYPES

GENETICS

[Allelic and haplotypic polymorphism of HLA–DR] Kuśnierczyk P. **Postepy Hig Med Dosw** 1996;50(1):1–8 (11 ref.) (Eng. Abstr.) **(Pol)**

HAPPY PUPPET SYNDROME see **ANGELMAN SYNDROME**

HAPTENS

CHEMISTRY

Antibody catalysis via strategic use of haptenic charge. Kikuchi K, et al. **Acta Chem Scand** 1996 Apr;50(4):333–6 (34 ref.)

IMMUNOLOGY

T cell immune responses to haptens. Structural models for allergic and autoimmune reactions. Weltzien HU, et al. **Toxicology** 1996 Feb 22;107(2):141–51 (54 ref.)
[Adhesion and migration of epidermal dendritic cells] Staquet MJ. **Pathol Biol (Paris)** 1995 Dec;43(10):858–62 (41 ref.) (Eng. Abstr.) **(Fre)**

HAPTOGLOBINS

ANALYSIS

[Haptoglobin] Terano Y. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:213–9 (10 ref.) **(Jpn)**

CHEMISTRY

Glycosylation of alpha–1–proteinase inhibitor and haptoglobin in ovarian cancer: evidence for two different mechanisms. Turner GA, et al. **Glycoconj J** 1995 Jun; 12(3):211–8 (62 ref.)

METABOLISM

Haptoglobin. A potential reporter molecule for glycosylation changes in disease. Turner GA. **Adv Exp Med Biol** 1995; 376:231–8 (26 ref.)

HARASSMENT, NON-SEXUAL see **SOCIAL BEHAVIOR**

HARASSMENT, SEXUAL see **SEXUAL HARASSMENT**

HARDERIAN GLAND

ANATOMY & HISTOLOGY

The harderian gland: a tercentennial review. Payne AP. **J Anat** 1994 Aug;185 (Pt 1):1–49 (263 ref.)

PHYSIOLOGY

The harderian gland: a tercentennial review. Payne AP. **J Anat** 1994 Aug;185 (Pt 1):1–49 (263 ref.)

HARDWARE, COMPUTER see **COMPUTERS**

HARELIP see **CLEFT LIP**

HARRINGTONINES

PHARMACOLOGY

Homoharringtonine: an effective new natural product in cancer chemotherapy. Zhou DC, et al. **Bull Cancer (Paris)** 1995 Dec;82(12):987–95 (83 ref.)

HASHIMOTO'S DISEASE see **THYROIDITIS, AUTOIMMUNE**

HASHISH see **CANNABIS**

HASHISH SMOKING see **MARIJUANA SMOKING**

HAY FEVER

Allergic rhinitis. Baroody FM. **J Med Liban** 1994; 42(4):171–83 (105 ref.)
[Diagnosis of allergic rhinitis] Olivé-Pérez A. **Allergol Immunopathol (Madr)** 1995 Mar–Apr;23(2):85–90 (44 ref.) **(Spa)**

COMPLICATIONS

Food reactions in pollen and latex allergic patients [editorial] Frankland AW. **Clin Exp Allergy** 1995 Jul;25(7):580–1 (22 ref.)

DRUG THERAPY

Seasonal allergic rhinitis—a review of current therapy. Lund VJ. **Allergy** 1996;51(28 Suppl):5–7 (7 ref.)

HAY FEVER

Effectiveness and safety of beclomethasone dipropionate, an intranasal corticosteroid, in the treatment of patients with allergic rhinitis. Edwards TB. **Clin Ther** 1995 Nov-Dec; 17(6):1032-41 (31 ref.)

Levocabastine. An update of its pharmacology, clinical efficacy and tolerability in the topical treatment of allergic rhinitis and conjunctivitis. Noble S, et al. **Drugs** 1995 Dec; 50(6):1032-49 (60 ref.)

Allergic rhinoconjunctivitis: current therapy. Hollingsworth HM. **Hosp Pract (Off Ed)** 1996 Jun 15;31(6):61-2, 65-7, 71-3 (12 ref.)

Counseling patients about allergic rhinitis. Swanson KA. **J Am Pharm Assoc (Wash)** 1996 May;NS36(5):300-7 (40 ref.)

ETIOLOGY

Role of mast cells and basophils in rhinitis. Peebles RS Jr, et al. **Chem Immunol** 1995;62:60-83 (113 ref.)

PHYSIOPATHOLOGY

Role of microcirculation in seasonal allergic rhinitis [editorial] Rajakulasingam K. **Clin Exp Allergy** 1995 Oct; 25(10):910-1 (12 ref.)

Pathophysiology of allergic rhinitis. Bousquet J, et al. **Int Arch Allergy Immunol** 1996 Jul;110(3):207-18 (165 ref.)

THERAPY

The role of immunotherapy in allergic rhinitis/allergic asthma. Creticos PS. **Allergy Proc** 1995 Nov-Dec; 16(6):297-302 (78 ref.)

HAZARD MANAGEMENT see **SAFETY MANAGEMENT**

HAZARDOUS CHEMICALS see **HAZARDOUS SUBSTANCES**

HAZARDOUS MATERIALS see **HAZARDOUS SUBSTANCES**

HAZARDOUS SUBSTANCES

see related

HAZARDOUS WASTE

Hazardous materials. Disaster medical planning and response. Levitin HW, et al. **Emerg Med Clin North Am** 1996 May; 14(2):327-48 (56 ref.)

A basic framework of working environment control for occupational health in Japan. Koshi S. **Ind Health** 1996; 34(3):149-65 (5 ref.)

Toxicity testing with communities: microcosms, mesocosms, and whole-system manipulations. Cairns J Jr, et al. **Rev Environ Contam Toxicol** 1996;147:45-69 (97 ref.)

Perspectives on collaboration and infrastructure development: industry perspectives. Knaak JB. **Toxicol Lett** 1995 Sep;79(1-3):305-12 (32 ref.)

Extrapolating the future: research trends in modeling. Menzel DB. **Toxicol Lett** 1995 Sep;79(1-3):299-303 (8 ref.)

[Regional and local problems of chemical environmental pollution and health of the population (review of the literature)] Revich BA, et al. **Med Tr Prom Ekol** 1995; (9):23-9 (12 ref.) **(Rus)**

ADMINISTRATION & DOSAGE

Ingestion of sludge applied organic chemicals by animals. Fries GF. **Sci Total Environ** 1996 Jun 21;185(1-3):93-108 (112 ref.)

ADVERSE EFFECTS

Ethylenebisdithiocarbamates and ethylenethiourea: possible human health hazards. Houeto P, et al. **Environ Health Perspect** 1995 Jun;103(6):568-73 (102 ref.)

Induction of cytochrome P-450 in the Norway rat, Rattus norvegicus, following exposure to potential environmental contaminants. Nims RW, et al. **J Toxicol Environ Health** 1995 Nov;46(3):271-92 (133 ref.)

Modifiers of non-specific symptoms in occupational and environmental syndromes. Spurgeon A, et al. **Occup Environ Med** 1996 Jun;53(6):361-6 (61 ref.)

Effects of industrial solvents on hearing. Johnson AC, et al. **Occup Med** 1995 Jul-Aug;10(3):623-40 (87 ref.)

Epidemiologic considerations in the evaluation of occupational hearing loss. Morata TC, et al. **Occup Med** 1995 Jul-Aug;10(3):641-56 (67 ref.)

Hazard to man and the environment posed by the use of urban waste compost: a review. Déportes I, et al. **Sci Total Environ** 1995 Nov 30;172(2-3):197-22 (182 ref.)

Environmental chemicals relevant for respiratory hypersensitivity: the indoor environment. Becher R, et al. **Toxicol Lett** 1996 Aug;86(2-3):155-62 (47 ref.)

ATSDR's information databases to support human health risk assessment of hazardous substances. Agency for Toxic Substances and Disease Registry. Johnson BL. **Toxicol Lett** 1995 Sep;79(1-3):11-6 (0 ref.)

Toxicological consequences of multiple chemical interactions: a primer. Calabrese EJ. **Toxicology** 1995 Dec 28;105(2-3):121-35 (81 ref.)

Isobolographic analysis of interactions: an update on applications and utility. Gessner PK. **Toxicology** 1995 Dec 28;105(2-3):161-79 (33 ref.)

Risk assessment: toxicity from chemical exposure resulting from enhanced expression of CYP2E1. Raucy JL. **Toxicology** 1995 Dec 28;105(2-3):217-24 (48 ref.)

[Occupational medicine aspects related to carcinogenic hazardous substances] Letzel S. **Dtsch Med Wochenschr** 1996 Jan 26;121(4):104-9 (11 ref.) **(Ger)**

[Biomarkers of neurotoxic effects induced by environmental chemicals] Indulski JA, et al. **Med Pr** 1996;47(4):383-91 (32 ref.) (Eng. Abstr.) **(Pol)**

[Combined biological effect of electromagnetic fields and chemical substances (toxic)] Kamedula M, et al. **Med Pr** 1996;47(3):285-92 (20 ref.) (Eng. Abstr.) **(Pol)**

ANALYSIS

Interdisciplinary "case studies" and training experts for primary prevention of environmentally-born health hazard. Dobrowolski JW. **Arch Toxicol Suppl** 1996;18:391-403 (16 ref.)

Evaluating human variability in chemical risk assessment: hazard identification and dose-response assessment for noncancer oral toxicity of trichloroethylene. Barton HA, et al. **Toxicology** 1996 Jul 17;111(1-3):271-87 (83 ref.)

CLASSIFICATION

Fundamentals and possibilities of classification of occupational substances as developmental toxicants. Hofmann A. **Int Arch Occup Environ Health** 1995; 67(3):139-45 (45 ref.)

[A new method for evaluating acute toxicity intragastrically for classification of chemical substances] Rydzyński K, et al. **Med Pr** 1995;46(4):369-83 (29 ref.) (Eng. Abstr.) **(Pol)**

IMMUNOLOGY

[Immunotoxicity of chemicals] Sawada J. **Eisei Shikenjo Hokoku** 1995;(113):1-18 (145 ref.) (Eng. Abstr.) **(Jpn)**

PHARMACOKINETICS

Ingestion of sludge applied organic chemicals by animals. Fries GF. **Sci Total Environ** 1996 Jun 21;185(1-3):93-108 (112 ref.)

The application of physiologically based pharmacokinetic modeling in human health risk assessment of hazardous substances. Clewell HJ 3rd. **Toxicol Lett** 1995 Sep; 79(1-3):207-17 (79 ref.)

Summary of panel discussion on the 'advantages/limitations/uncertainties in the use of physiologically based pharmacokinetic and pharmacodynamic models in hazard identification and risk assessment of toxic substances'. Frederick CB. **Toxicol Lett** 1995 Sep;79(1-3):201-6 (4 ref.)

The application of dosimetry models to identify key processes and parameters for default dose-response assessment approaches. Jarabek AM. **Toxicol Lett** 1995 Sep; 79(1-3):171-84 (26 ref.)

Physiologically based pharmacokinetic and pharmacodynamic modeling in health risk assessment and characterization of hazardous substances. Leung HW, et al. **Toxicol Lett** 1995 Sep;79(1-3):55-65 (121 ref.)

The application of physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) modeling to understanding the mechanism of action of hazardous substances. Medinsky MA. **Toxicol Lett** 1995 Sep; 79(1-3):185-91 (16 ref.)

The application of physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) modeling for exploring risk assessment approaches of chemical mixtures. Yang RS, et al. **Toxicol Lett** 1995 Sep; 79(1-3):193-200 (37 ref.)

Variability in glutathione-dependent detoxication in vivo and its relevance to detoxication of chemical mixtures. Jones DP, et al. **Toxicology** 1995 Dec 28;105(2-3):267-74 (40 ref.)

TOXICITY

Approaches to the evaluation of chemical-induced immunotoxicity. Krzystyniak K, et al. **Environ Health Perspect** 1995 Dec;103 Suppl 9:17-22 (75 ref.)

Combined effects of noise and chemicals. Fechter LD. **Occup Med** 1995 Jul-Aug;10(3):609-21 (51 ref.)

Utilizing uncertainty factors in minimal risk levels derivation. Pohl HR, et al. **Regul Toxicol Pharmacol** 1995 Oct; 22(2):180-8 (52 ref.)

A weight-of-evidence approach for assessing interactions in chemical mixtures. Mumtaz MM, et al. **Toxicol Ind Health** 1992 Nov-Dec;8(6):377-406 (14 ref.)

Development of physiologically based pharmacokinetic and physiologically based pharmacodynamic models for applications in toxicology and risk assessment. Andersen ME. **Toxicol Lett** 1995 Sep;79(1-3):35-44 (38 ref.)

Use of graph theoretic parameters in risk assessment of chemicals. Basak SC, et al. **Toxicol Lett** 1995 Sep; 79(1-3):239-50 (55 ref.)

Summary and recommendations for session B: activity classification and structure-activity relationship modeling for human health risk assessment of toxic substances. Bristol DW. **Toxicol Lett** 1995 Sep;79(1-3):265-80 (10 ref.)

Decision support methodologies for human health assessment of toxic substances: Agency for Toxic Substances and Disease Registry's perspectives on collaboration and infrastructure development among government, academia, and industry. DeRosa CT. **Toxicol Lett** 1995 Sep; 79(1-3):283-5 (0 ref.)

Summary of panel discussion on the 'advantages/limitations/uncertainties in the use of physiologically based pharmacokinetic and pharmacodynamic models in hazard identification and risk assessment of toxic substances'. Frederick CB. **Toxicol Lett** 1995 Sep;79(1-3):201-6 (4 ref.)

The application of dosimetry models to identify key processes and parameters for default dose-response assessment approaches. Jarabek AM. **Toxicol Lett** 1995 Sep; 79(1-3):171-84 (26 ref.)

Toxicity estimation by chemical substructure analysis: the TOX II program. Klopman G, et al. **Toxicol Lett** 1995 Sep;79(1-3):145-55 (14 ref.)

Physiologically based pharmacokinetic and pharmacodynamic modeling in health risk assessment and characterization of hazardous substances. Leung HW, et al. **Toxicol Lett** 1995 Sep;79(1-3):55-65 (121 ref.)

The application of physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) modeling to understanding the mechanism of action of hazardous substances. Medinsky MA. **Toxicol Lett** 1995 Sep; 79(1-3):185-91 (16 ref.)

Role of computational chemistry in support of hazard identification (ID): mechanism-based SARs. Richard AM. **Toxicol Lett** 1995 Sep;79(1-3):115-22 (31 ref.)

Use of mechanistic and pharmacokinetic data for risk assessment at the National Institute of Environmental Health Sciences (NIEHS). Schwetz BA. **Toxicol Lett** 1995 Sep;79(1-3):29-32 (0 ref.)

The new chemicals process at the Environmental Protection Agency (EPA): structure-activity relationships for hazard identification and risk assessment. Wagner PM, et al. **Toxicol Lett** 1995 Sep;79(1-3):67-73 (3 ref.)

The application of physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) modeling for exploring risk assessment approaches of chemical mixtures. Yang RS, et al. **Toxicol Lett** 1995 Sep; 79(1-3):193-200 (37 ref.)

Toxicological consequences of multiple chemical interactions: a primer. Calabrese EJ. **Toxicology** 1995 Dec 28;105(2-3):121-35 (81 ref.)

Toxicodynamics of low level toxicant interactions of biological significance: inhibition of tissue repair. Mehendale HM. **Toxicology** 1995 Dec 28;105(2-3):251-66 (95 ref.)

[Immunotoxicity of chemicals] Sawada J. **Eisei Shikenjo Hokoku** 1995;(113):1-18 (145 ref.) (Eng. Abstr.) **(Jpn)**

[Prospects of the use of a quantitative functional-morphological method in the evaluation of toxicity of chemical substances] Popuchiyev VV. **Med Tr Prom Ekol** 1995;(12):24-7 (10 ref.) (Eng. Abstr.) **(Rus)**

HAZARDOUS WASTE

ANALYSIS

Interdisciplinary "case studies" and training experts for primary prevention of environmentally-born health hazard. Dobrowolski JW. **Arch Toxicol Suppl** 1996;18:391-403 (16 ref.)

HAZARDOUS WASTE, RADIOACTIVE see **RADIOACTIVE WASTE**

HAZARDOUS WASTE SITES see **HAZARDOUS WASTE**

HAZARDS, EQUIPMENT see **EQUIPMENT SAFETY**

HB A1C see **HEMOGLOBIN A, GLYCOSYLATED**

HBA1 see **HEMOGLOBIN A, GLYCOSYLATED**

HBAG see **HEPATITIS B ANTIGENS**

HBCAG see **HEPATITIS B CORE ANTIGENS**

HBEAG see **HEPATITIS B E ANTIGENS**

HBGF-1 see **FIBROBLAST GROWTH FACTOR, ACIDIC**

HBGF-2 see **FIBROBLAST GROWTH FACTOR, BASIC**

HBLV see **HERPESVIRUS 6, HUMAN**

HBSAG see **HEPATITIS B SURFACE ANTIGENS**

HCG see **GONADOTROPINS, CHORIONIC**

HCG, ALPHA SUBUNIT see **GLYCOPROTEIN HORMONES, ALPHA SUBUNIT**

HCG-BETA see **CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN**

HCG RECEPTORS see **RECEPTORS, LH**

HCV ANTIBODIES see **HEPATITIS C ANTIBODIES**

HDL CHOLESTEROL see **LIPOPROTEINS, HDL CHOLESTEROL**

HEAD

see related
FACIAL BONES
SKULL

PATHOLOGY

Molecular alterations in head and neck squamous cell carcinoma. Bron L, et al. **Clin Otolaryngol** 1995 Aug; 20(4):291–8 (86 ref.)

PHYSIOLOGY

Deciphering the hippocampal polyglot: the hippocampus as a path integration system. McNaughton BL, et al. **J Exp Biol** 1996 Jan;199 (Pt 1):173–85 (56 ref.)

[Jaw position, head position, body posture: development of an integrated system of examination, Part I] Takigawa T, et al. **Kokubyo Gakkai Zasshi** 1995 Sep;62(3):441–50 (23 ref.) (Eng. Abstr.) **(Jpn)**

SURGERY

Lasers in otorhinolaryngology–head and neck surgery. Rebeiz EE. **J Med Liban** 1994;42(4):242–9 (21 ref.)

Head and neck reconstruction. Deschler DG, et al. **Neuroimaging Clin N Am** 1996 May;6(2):505–14 (38 ref.)

HEAD AND NECK NEOPLASMS

Second primary malignancies in the head and neck cancer patient. Sturgis EM, et al. **Ann Otol Rhinol Laryngol** 1995 Dec;104(12):946–54 (97 ref.)

Head and neck liposarcoma. Golledge J, et al. **Cancer** 1995 Sep 15;76(6):1051–8 (53 ref.)

Aggressive basal cell carcinoma of head and neck areas. Vico P, et al. **Eur J Surg Oncol** 1995 Oct;21(5):490–7 (25 ref.)

Inclusion of comorbidity in a staging system for head and neck cancer. Piccirillo JF. **Oncology (Huntingt)** 1995 Sep; 9(9):831–6; discussion 841, 845–8 (47 ref.)

[Prognostic factors in squamous cell carcinoma of the head and neck] Horiuchi M, et al. **Gan To Kagaku Ryoho** 1996 Jun;23(7):949–56 (42 ref.) (Eng. Abstr.) **(Jpn)**

CLASSIFICATION

Developmental lesions of the head and neck: terminology and biologic behavior. Ferlito A, et al. **Ann Otol Rhinol Laryngol** 1995 Nov;104(11):913–8 (39 ref.)

DIAGNOSIS

Advanced imaging of head and neck tumors [see comments] Vogl T, et al. **Acta Radiol** 1995 Nov;36(6):566–80 (44 ref.) Comment in: Acta Radiol 1995 Nov;36(6):565.

Squamous cell carcinoma–associated antigens used in novel strategies for the detection and treatment of minimal residual head and neck cancer. van Dongen GA, et al. **Anticancer Res** 1996 Jul–Aug;16(4C):2409–13 (41 ref.)

ABC of general surgery in children. Lumps and swellings of the head and neck. Davenport M. **BMJ** 1996 Feb 10; 312(7027):368–71 (0 ref.)

Merkel cell carcinoma. O'Connor WJ, et al. **Dermatol Surg** 1996 Mar;22(3):262–7 (21 ref.)

Multimodality imaging of cervical adenopathies. Giron J, et al. **Eur J Radiol** 1996 Feb;21(3):159–66 (21 ref.)

Diagnosis of head and neck cancer. Hilal EY. **J Med Liban** 1994;42(4):212–5 (12 ref.)

Imaging of cervical lymphadenopathy. van den Brekel MW, et al. **Neuroimaging Clin N Am** 1996 May;6(2):417–34 (137 ref.)

Soft tissue chondroma of the neck: a case report and review of the literature. Kamysz JW, et al. **Pediatr Radiol** 1996; 26(2):145–7 (14 ref.)

Malignant melanoma of soft parts involving the head and neck region: review of literature and case report. Hicks MJ, et al. **Ultrastruct Pathol** 1995 Sep–Oct;19(5):395–400 (28 ref.)

[Prognostic factors of stage I melanoma: non histological factors] Delaunay M. **Ann Dermatol Venereol** 1995; 122(5):267–75 (114 ref.) **(Fre)**

[Malignant histiocytofibroma. Apropos of 3 cases of cervicofacial localization] Bonnin P, et al. **Ann Otolaryngol Chir Cervicofac** 1995;112(7):336–44 (29 ref.) (Eng. Abstr.) **(Fre)**

[Clinico–pathological predictive indicators in squamous cell carcinoma of the head and neck] Horiuchi M. **Gan To Kagaku Ryoho** 1996 Feb;23(3):257–64 (28 ref.) (Eng. Abstr.) **(Jpn)**

[Facial and cervical manifestations of AIDS] Gebrim EM, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1995 Jul–Aug; 50(4):222–6 (22 ref.) (Eng. Abstr.) **(Por)**

DIET THERAPY

[Prevention of second primary cancer with vitamin supplementation in patients treated for head and neck cancers] Bairati I, et al. **Bull Cancer Radiother** 1996; 83(1):12–6 (37 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

Chemotherapy of head and neck cancer. LaFollette S, et al. **Cancer Chemother Biol Response Modif** 1996;16:462–73 (50 ref.)

Chemotherapy in locally advanced head and neck cancer: a critical reappraisal. Jassem J, et al. **Cancer Treat Rev** 1995 Sep;21(5):447–62 (106 ref.)

Taxol plus radiation for head and neck cancer. Rosenthal DI, et al. **J Infus Chemother** 1995 Spring;5(2):46–54 (99 ref.)

5–fluorouracil plus radiation for head and neck cancer. Stupp R, et al. **J Infus Chemother** 1995 Spring;5(2):55–60 (65 ref.)

Cisplatin plus radiation therapy. Wheeler RH, et al. **J Infus Chemother** 1995 Spring;5(2):61–6 (46 ref.)

Mechanisms of resistance of human tumours to anticancer drugs of the platinum family: a review. Ferguson PJ. **J Otolaryngol** 1995 Aug;24(4):242–52 (100 ref.)

Chemotherapeutic treatment of malignant chordoma in children. Scimeca PG, et al. **J Pediatr Hematol Oncol** 1996 May;18(2):237–40 (10 ref.)

Adjuvant and neoadjuvant treatment of head and neck cancers: the next chapter. Jacobs C, et al. **Semin Oncol** 1995 Dec;22(6):540–52 (66 ref.)

The role of paclitaxel in the treatment of head and neck cancer. Vokes EE, et al. **Semin Oncol** 1995 Oct;22(5 Suppl 12):8–12 (27 ref.)

Radiation and concurrent carboplatin administration in locally advanced head and neck cancer. A Hellenic Cooperative Oncology Group Study. Fountzilas G, et al. **Tumori** 1995 Sep–Oct;81(5):354–8 (19 ref.)

[Current knowledge on the action of retinoids in carcinoma of the head and neck] Dolivet G, et al. **Rev Laryngol Otol Rhinol (Bord)** 1996;117(1):19–26 (34 ref.) (Eng. Abstr.) **(Fre)**

[The radiochemotherapy of advanced head–neck tumors—what is certain?] Wendt TG. **Strahlenther Onkol** 1996 Aug;172(8):409–16 (73 ref.) (Eng. Abstr.) **(Ger)**

[Head and neck cancer] Inuyama Y, et al. **Gan To Kagaku Ryoho** 1996 Aug;23(9):1136–42 (19 ref.) (Eng. Abstr.) **(Jpn)**

[Chemotherapy of head and neck cancer] Kohno N, et al. **Gan To Kagaku Ryoho** 1996 Feb;23(3):277–82 (33 ref.) (Eng. Abstr.) **(Jpn)**

ENZYMOLOGY

The role of glutathione S–transferases in head and neck squamous cell carcinogenesis. Bongers V, et al. **Eur J Cancer B Oral Oncol** 1995 Nov;31B(6):349–54 (63 ref.)

EPIDEMIOLOGY

Hereditary and environmental risk factors; clinical and laboratory risk matters for head and neck, especially oral, cancer and precancer. Johnson NW, et al. **Eur J Cancer Prev** 1996 Feb;5(1):5–17 (139 ref.)

ETIOLOGY

Alcohol as a cause of cancer. Thomas DB. **Environ Health Perspect** 1995 Nov;103 Suppl 8:153–60 (65 ref.)

Head and neck sarcomas: a review. Odell PF. **J Otolaryngol** 1996 Feb;25(1):7–13 (56 ref.)

GENETICS

Genomic instability in squamous cell carcinoma of the head and neck. Field JK. **Anticancer Res** 1996 Jul–Aug; 16(4C):2421–31 (122 ref.)

Molecular alterations in head and neck squamous cell carcinoma. Bron L, et al. **Clin Otolaryngol** 1995 Aug; 20(4):291–8 (86 ref.)

Hereditary and environmental risk factors; clinical and laboratory risk matters for head and neck, especially oral, cancer and precancer. Johnson NW, et al. **Eur J Cancer Prev** 1996 Feb;5(1):5–17 (139 ref.)

IMMUNOLOGY

Causes of immunosuppression in squamous cell carcinoma of the head and neck. Wustrow TP, et al. **Anticancer Res** 1996 Jul–Aug;16(4C):2433–68 (714 ref.)

METABOLISM

p53 overexpression in head and neck squamous cell carcinoma: review of the literature. Raybaud–Diogène H, et al. **Eur J Cancer B Oral Oncol** 1996 May;32B(3):143–9 (66 ref.)

PATHOLOGY

Retropharyngeal liposarcoma. Yueh B, et al. **Am J Otolaryngol** 1995 Sep–Oct;16(5):331–40 (65 ref.)

Basaloid squamous cell carcinoma of the head and neck: clinicopathological features and differential diagnosis. Barnes L, et al. **Ann Otol Rhinol Laryngol** 1996 Jan; 105(1):75–82 (40 ref.)

Malignant fibrous histiocytoma of the head and neck. Case report. Zapater E, et al. **Bull Group Int Rech Sci Stomatol Odontol** 1995 Sep–Oct; 38(3–4):121–4 (17 ref.)

Orofacial biopsies: a survey of 1,723 cases seen over a 10 year period. Chidzonga MM, et al. **Cent Afr J Med** 1996 Apr;42(4):102–8 (17 ref.)

Molecular alterations in head and neck squamous cell carcinoma. Bron L, et al. **Clin Otolaryngol** 1995 Aug; 20(4):291–8 (86 ref.)

Cell adhesion and regulatory molecules involved in tumor formation, hemostasis, and wound healing. Van Waes C. **Head Neck** 1995 Mar–Apr;17(2):140–7 (18 ref.)

Basal cell adenocarcinoma of minor salivary and seromucous glands of the head and neck region. Fonseca I, et al. **Semin Diagn Pathol** 1996 May;13(2):128–37 (30 ref.)

Primary intraoral epithelioid hemangioendothelioma presenting in childhood: review of the literature and case report. Flaitz CM, et al. **Ultrastruct Pathol** 1995 Jul–Aug; 19(4):275–9 (8 ref.)

[Lymph node problem in cutaneous head and neck carcinomas] Spriano G, et al. **Acta Otorhinolaryngol Ital** 1995 Jun;15(3):159–62; discussion 163 (32 ref.) (Eng. Abstr.) **(Ita)**

[A neck tumor in a 2–year–old girl] Fortún J, et al. **Rev Clin Esp** 1996 May;196(5):331–2 (9 ref.) **(Spa)**

PREVENTION & CONTROL

Retinoids and their receptors in modulation of differentiation, development, and prevention of head and neck cancers. Lotan R. **Anticancer Res** 1996 Jul–Aug;16(4C):2415–9 (45 ref.)

Chemoprevention of head and neck cancer. Voravud N. **J Med Assoc Thai** 1996 Mar;79(3):185–93 (65 ref.)

RADIOGRAPHY

Infected third branchial cleft cyst: retropharyngeal extension to the superior mediastinum. Hewel K, et al. **Can Assoc Radiol J** 1996 Apr;47(2):111–3 (8 ref.)

[Radiological criteria for laryngeal tumors and cervical metastases] Melchor Díaz MA, et al. **Acta Otorrinolaringol Esp** 1996 Jan–Feb;47(1):1–7 (17 ref.) (Eng. Abstr.) **(Spa)**

RADIONUCLIDE IMAGING

Preliminary experience with thallous chloride T1 201–labeled single–photon emission computed tomography scanning in head and neck cancer. Gregor RT, et al. **Arch Otolaryngol Head Neck Surg** 1996 May;122(5):509–14 (25 ref.)

RADIOTHERAPY

Adult soft tissue sarcomas of the head and neck treated by radiation and surgery or radiation alone: patterns of failure and prognostic factors. Willers H, et al. **Int J Radiat Oncol Biol Phys** 1995 Oct 15;33(3):585–93 (26 ref.)

Taxol plus radiation for head and neck cancer. Rosenthal DI, et al. **J Infus Chemother** 1995 Spring;5(2):46–54 (99 ref.)

5–fluorouracil plus radiation for head and neck cancer. Stupp R, et al. **J Infus Chemother** 1995 Spring;5(2):55–60 (65 ref.)

Cisplatin plus radiation therapy. Wheeler RH, et al. **J Infus Chemother** 1995 Spring;5(2):61–6 (46 ref.)

Diagnostic imaging aids to head and neck radiation oncology. Tamler BJ, et al. **Neuroimaging Clin N Am** 1996 May; 6(2):515–30 (61 ref.)

Irradiated bone and its management. Costantino PD, et al. **Otolaryngol Clin North Am** 1995 Oct;28(5):1021–38 (29 ref.)

Irradiated soft tissue and its management. Hom DB, et al. **Otolaryngol Clin North Am** 1995 Oct;28(5):1003–19 (47 ref.)

Adjuvant and neoadjuvant treatment of head and neck cancers: the next chapter. Jacobs C, et al. **Semin Oncol** 1995 Dec;22(6):540–52 (66 ref.)

Radiation and concurrent carboplatin administration in locally advanced head and neck cancer. A Hellenic Cooperative Oncology Group Study. Fountzilas G, et al. **Tumori** 1995 Sep–Oct;81(5):354–8 (19 ref.)

[Contribution of curietherapy in the treatment of ENT tumors] Beauvois S. **Rev Med Brux** 1996 Apr;17(2):86–90 (23 ref.) (Eng. Abstr.) **(Fre)**

[The radiochemotherapy of advanced head–neck tumors—what is certain?] Wendt TG. **Strahlenther Onkol** 1996 Aug;172(8):409–16 (73 ref.) (Eng. Abstr.) **(Ger)**

[Treatment of head and neck cancer: radiation therapy] Chatani M, et al. **Gan To Kagaku Ryoho** 1996 Feb; 23(3):271–6 (21 ref.) (Eng. Abstr.) **(Jpn)**

REHABILITATION

Evolution of quality of life assessment in head and neck cancer. Morton RP. **J Laryngol Otol** 1995 Nov; 109(11):1029–35 (63 ref.)

SECONDARY

[Incidence and risk factors of second primary cancers in patients treated for primary pharyngeal cancer] Brochet F, et al. **Bull Cancer Radiother** 1996;83(1):8–11 (34 ref.) (Eng. Abstr.) **(Fre)**

[Management of N–O neck] Tovi F, et al. **Harefuah** 1995 Jun 15;128(12):801–2 (18 ref.) **(Heb)**

SURGERY

The maxillofacial surgeon and cranial base surgery. Vaughan

ED. **Br J Oral Maxillofac Surg** 1996 Feb;34(1):4–17 (18 ref.)
Adult soft tissue sarcomas of the head and neck treated by radiation and surgery or radiation alone: patterns of failure and prognostic factors. Willers H, et al. **Int J Radiat Oncol Biol Phys** 1995 Oct 15;33(3):585–93 (26 ref.)
[Cervical paraganglioma. Results apropos of a series of 33 patients] Guerrier B, et al. **J Chir (Paris)** 1995 Jun–Jul; 132(6–7):287–94 (34 ref.) (Eng. Abstr.) **(Fre)**
[Philosophy in reconstruction of the face] Faga A. **Acta Otorhinolaryngol Ital** 1995 Jun;15(3):164–6; discussion 167 (13 ref.) **(Ita)**
[Recent advance in head and neck cancer surgery] Kamata S. **Gan To Kagaku Ryoho** 1996 Feb;23(3):265–70 (8 ref.) (Eng. Abstr.) **(Jpn)**

THERAPY

Rationale and development of a quality-of-life instrument for head-and-neck cancer patients. Morton RP, et al. **Am J Otolaryngol** 1995 Sep–Oct;16(5):284–93 (69 ref.)
Radiotherapy-chemotherapy combinations in head and neck squamous cell carcinoma: overview of randomized trials. Bourhis J, et al. **Anticancer Res** 1996 Jul–Aug; 16(4C):2397–402 (78 ref.)
Predicting response to therapy of squamous cell carcinoma of the head and neck (review). Wennerberg J. **Anticancer Res** 1996 Jul–Aug;16(4C):2389–96 (90 ref.)
Treatment of cancer of the head and neck. Shah JP, et al. **CA Cancer J Clin** 1995 Nov–Dec;45(6):352–68 (53 ref.)
Gene therapy for head and neck cancer. Clayman GL. **Head Neck** 1995 Nov–Dec;17(6):535–41 (39 ref.)
Unknown primary of the head and neck. Talmi YP, et al. **J Laryngol Otol** 1996 Apr;110(4):353–6 (12 ref.)
Head and neck cancer: state of the art. Atiyah RA. **J Med Liban** 1994;42(4):216–20 (22 ref.)
Interferons and other cytokines in head and neck cancer. Hamasaki VK, et al. **Med Oncol** 1995 Mar;12(1):23–33 (64 ref.)
Interventional neuroradiology of the head and neck. Hurst RW. **Neuroimaging Clin N Am** 1996 May;6(2):473–95 (38 ref.)
Interventional magnetic resonance imaging of the head and neck and new imaging techniques. Lambre H, et al. **Neuroimaging Clin N Am** 1996 May;6(2):461–72 (51 ref.)
Management of congenital vascular lesions of the head and neck. Waner M, et al. **Oncology (Huntingt)** 1995 Oct; 9(10):989–94, 997; discussion 998 passim (16 ref.)
[Comparison of concomitant radiotherapy and chemotherapy with radiotherapy alone in advanced cancers of the head and neck: results of a randomized trial] Haddad E, et al. **Bull Cancer Radiother** 1996;83(2):97–103 (35 ref.) (Eng. Abstr.) **(Fre)**
[The current therapeutic trends in rhabdomyosarcoma of the cervicofacial area. A review of the topic] Colella G, et al. **Minerva Stomatol** 1995 Jul–Aug;44(7–8):335–44 (37 ref.) (Eng. Abstr.) **(Ita)**
[Neo-adjuvant chemotherapy in patients with head and neck cancer] Tsukuda M. **Gan To Kagaku Ryoho** 1995 Nov; 22(13):1905–11 (15 ref.) (Eng. Abstr.) **(Jpn)**
[Immunotherapy of patients with head and neck carcinomas] Tsukuda M. **Gan To Kagaku Ryoho** 1996 Feb;23(3):283–90 (32 ref.) (Eng. Abstr.) **(Jpn)**

VETERINARY

Aggressive, undifferentiated sarcoma with widespread metastasis in a six-month-old Neopolitan mastiff. Sanders NA, et al. **J Am Anim Hosp Assoc** 1996 Mar–Apr; 32(2):97–101 (18 ref.)
Radiation therapy for head and neck cancers. Gillette SM, et al. **Semin Vet Med Surg (Small Anim)** 1995 Aug; 10(3):168–72 (28 ref.)

HEAD BANGING see **STEREOTYPED BEHAVIOR**

HEAD-DOWN TILT

see related
TILT-TABLE TEST

HEAD INJURIES

see related
BRAIN INJURIES

Gunshot wounds to the head in an urban setting. Krieger MD, et al. **Neurosurg Clin N Am** 1995 Oct;6(4):605–10 (28 ref.)
Characteristics of cerebral gunshot injuries in the rural setting. Pikus HJ, et al. **Neurosurg Clin N Am** 1995 Oct; 6(4):611–20 (39 ref.)
Intracranial pressure monitoring techniques. Ghajar J. **New Horiz** 1995 Aug;3(3):395–9 (42 ref.)

COMPLICATIONS

Persistent dizziness following head trauma and perilymphatic fistula. Fitzgerald DC. **Arch Phys Med Rehabil** 1995 Nov; 76(11):1017–20 (26 ref.)
A new application for near-infrared spectroscopy: detection of delayed intracranial hematomas after head injury. Robertson CS, et al. **J Neurotrauma** 1995 Aug; 12(4):591–600 (64 ref.)
Head trauma: hearing loss and dizziness. Fitzgerald DC. **J Trauma** 1996 Mar;40(3):488–96 (83 ref.)
Clostridial meningitis as a result of craniocerebral arrow injury. Neal G, et al. **J Trauma** 1996 Mar;40(3):476–80 (23 ref.)
Secondary brain insults after head injury: clinical perspectives. Chesnut RM. **New Horiz** 1995 Aug; 3(3):366–75 (44 ref.)
Medical complications in severe head injury. Piek J. **New Horiz** 1995 Aug;3(3):534–8 (39 ref.)
Causes, prevention, and treatment of post-traumatic epilepsy. Temkin NR, et al. **New Horiz** 1995 Aug;3(3):518–22 (46 ref.)

DRUG THERAPY

Steroids in head injury. Kelly DF. **New Horiz** 1995 Aug; 3(3):453–5 (15 ref.)
Sedative and neuromuscular blocking drug use in critically ill patients with head injuries. Prielipp RC, et al. **New Horiz** 1995 Aug;3(3):456–68 (102 ref.)
High-dose barbiturates for intracranial pressure control. Wilberger JE, et al. **New Horiz** 1995 Aug;3(3):469–73 (27 ref.)
[Analgesia and sedation in patients with head-brain trauma] Gremmelt A, et al. **Anaesthesist** 1995 Dec;44 Suppl 3:S559–65 (71 ref.) (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

Epidemiology of head injury. Jennett B. **J Neurol Neurosurg Psychiatry** 1996 Apr;60(4):362–9 (64 ref.)

METABOLISM

Amyloid beta-protein, APOE genotype and head injury. Nicoll JA, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:271–5 (9 ref.)
Nutrition in the head-injured patient. Roberts PR. **New Horiz** 1995 Aug;3(3):506–17 (96 ref.)
Cerebral metabolic management. Robertson CS, et al. **New Horiz** 1995 Aug;3(3):410–22 (97 ref.)

NURSING

Surgical management of patients with severe head injuries. Pieper DR, et al. **AORN J** 1996 May;63(5):854–64, 867 (29 ref.)

PHYSIOPATHOLOGY

Strategies for neuroprotection with glutamate antagonists. Extrapolating from evidence taken from the first stroke and head injury studies. Bullock R. **Ann N Y Acad Sci** 1995 Sep 15;765:272–8; discussion 298 (11 ref.)
The rationale for glutamate antagonists in the treatment of traumatic brain injury. Myseros JS, et al. **Ann N Y Acad Sci** 1995 Sep 15;765:262–71; discussion 298 (44 ref.)
Alcohol and head injury: an issue revisited. Kelly DF. **J Neurotrauma** 1995 Oct;12(5):883–90 (62 ref.)
Neurobehavioral outcome of closed head injury: implications for clinical trials. Levin HS. **J Neurotrauma** 1995 Aug; 12(4):601–10 (60 ref.)
Head injury mechanisms and the concept of preventive management: a review and critical synthesis. Ommaya AK. **J Neurotrauma** 1995 Aug;12(4):527–46 (101 ref.)
Cerebral blood flow in severe clinical head injury. Bouma GJ, et al. **New Horiz** 1995 Aug;3(3):384–94 (52 ref.)
Electrophysiologic monitoring in head injury. Sloan TB. **New Horiz** 1995 Aug;3(3):431–8 (69 ref.)
[Severe head injuries in neonates and infants: physiopathological and therapeutic aspects] Giroux JD, et al. **Arch Pediatr** 1996 May;3(5):473–9 (54 ref.) (Eng. Abstr.) **(Fre)**

PSYCHOLOGY

Neurobehavioral outcome of closed head injury: implications for clinical trials. Levin HS. **J Neurotrauma** 1995 Aug; 12(4):601–10 (60 ref.)

REHABILITATION

[Clinico-instrumental assessment of swallowing in head injury rehabilitation] Zanardi L, et al. **Minerva Anestesiol** 1995 Nov;61(11):463–70 (26 ref.) (Eng. Abstr.) **(Ita)**

SURGERY

Surgical management of patients with severe head injuries. Pieper DR, et al. **AORN J** 1996 May;63(5):854–64, 867 (29 ref.)
Anesthesia and head trauma. McGrath BJ, et al. **New Horiz** 1995 Aug;3(3):523–33 (103 ref.)

THERAPY

Management of severe trauma. Part 2: Circulation and head injury. Pollard C. **Aust Fam Physician** 1995 Dec; 24(12):2230–3; quiz 2234–5 (0 ref.)
Head injury mechanisms and the concept of preventive management: a review and critical synthesis. Ommaya AK. **J Neurotrauma** 1995 Aug;12(4):527–46 (101 ref.)
Medical management of severe head injury: present and future. Chesnut RM. **New Horiz** 1995 Aug;3(3):581–93 (45 ref.)
Hypothermia and hyperbaric oxygen as treatment modalities for severe head injury. Clifton GL. **New Horiz** 1995 Aug; 3(3):474–8 (42 ref.)
Intracranial pressure and cerebral perfusion pressure in severe head injury. Lang EW, et al. **New Horiz** 1995 Aug; 3(3):400–9 (98 ref.)
Pharmacologic therapy: promising clinical investigations. Marshall LF, et al. **New Horiz** 1995 Aug;3(3):573–80 (30 ref.)
Nutrition in the head-injured patient. Roberts PR. **New Horiz** 1995 Aug;3(3):506–17 (96 ref.)
[Severe head injuries in neonates and infants: physiopathological and therapeutic aspects] Giroux JD, et al. **Arch Pediatr** 1996 May;3(5):473–9 (54 ref.) (Eng. Abstr.) **(Fre)**

HEAD INJURIES, CLOSED

see related
BRAIN INJURIES

Head and spine injuries in youth sports. Cantu RC. **Clin Sports Med** 1995 Jul;14(3):517–32 (31 ref.)

COMPLICATIONS

Obsessive-compulsive disorder after closed head injury: review of literature and report of four cases. Kant R, et al. **Brain Inj** 1996 Jan;10(1):55–63 (37 ref.)

DIAGNOSIS

Minor head injury: attempts at clarifying the confusion. Kibby MY, et al. **Brain Inj** 1996 Mar;10(3):159–86 (71 ref.)
The neuropsychiatric aspects of boxing. Mendez MF. **Int J Psychiatry Med** 1995;25(3):249–62 (74 ref.)

DRUG THERAPY

Advances in neurotrauma. Wilberger J. **Curr Opin Gen Surg** 1993;:55–61 (40 ref.)

PATHOLOGY

Neuroimaging in head injury. Gean AD, et al. **New Horiz** 1995 Aug;3(3):549–61 (43 ref.)

THERAPY

Fluid resuscitation of the trauma patient: how much is enough? Hamiliton SM, et al. **Can J Surg** 1996 Feb; 39(1):11–6 (39 ref.)
Airway management and mechanical ventilation. Abrams KJ. **New Horiz** 1995 Aug;3(3):479–87 (65 ref.)

ULTRASONOGRAPHY

Transcranial Doppler measurements. Newell DW. **New Horiz** 1995 Aug;3(3):423–30 (69 ref.)

HEAD NURSES see **NURSING, SUPERVISORY**

HEADACHE

Evaluation of patients with chronic headache. Ryan CW. **Am Fam Physician** 1996 Sep 1;54(3):1051–7 (14 ref.)
Headaches in women, including women who are pregnant. Paulson GW. **Am J Obstet Gynecol** 1995 Dec; 173(6):1734–41 (53 ref.)
Primary care for women. Assessment and management of headache. Barrett E. **J Nurse Midwifery** 1996 Mar–Apr; 41(2):117–24 (23 ref.)
Headache. Agrawal R, et al. **Natl Med J India** 1996 May–Jun; 9(3):127–9 (9 ref.)
[Headache as a health problem: past, present and future] Lozano Sánchez M, et al. **Rev Clin Esp** 1995 Sep;195(2 Spec No):3–7 (23 ref.) **(Spa)**

CHEMICALLY INDUCED

Analgesic rebound headache. How great is the problem and what can be done? Silberstein SD, et al. **Drug Saf** 1995 Sep;13(3):133–44 (62 ref.)
Wine and headache. Jarisch R, et al. **Int Arch Allergy Immunol** 1996 May;110(1):7–12 (45 ref.)

CLASSIFICATION

Classification of primary headaches. Olesen J, et al. **Biomed Pharmacother** 1995;49(10):446–51 (24 ref.)
The management of migraine and cluster headaches. Diamond S. **Compr Ther** 1995 Sep;21(9):492–8 (27 ref.)
[Classification of primary headache and International Headache Society diagnostic criteria 1988: critical review] Manzoni GC. **Ital J Neurol Sci** 1995 Nov;16(8 Suppl):9–14 (16 ref.) (Eng. Abstr.) **(Ita)**
[Chronic headache--approach from the view of new international classification] Sakai F. **Nippon Naika Gakkai Zasshi** 1995 Sep 10;84(9):1545–8 (2 ref.) **(Jpn)**

DIAGNOSIS

The management of migraine and cluster headaches. Diamond S. **Compr Ther** 1995 Sep;21(9):492–8 (27 ref.)
Comprehensive evaluation and treatment of recurrent

pediatric headache. Smith MS. **Pediatr Ann** 1995 Sep; 24(9):450, 453–7 (14 ref.)
[Diagnosis and treatment of headache in childhood] Hämäläinen M, et al. **Duodecim** 1994;110(11):1096–101 (10 ref.) **(Fin)**
[The chronic daily headache] Láinez Andrés JM, et al. **Rev Clin Esp** 1995 Sep;195(2 Spec No):41–7 (64 ref.) **(Spa)**

DRUG THERAPY

[Therapeutic guidelines for headache] Nappi G, et al. **Ital J Neurol Sci** 1995 Nov;16(8 Suppl):29–34 (14 ref.) (Eng. Abstr.) **(Ita)**

ETIOLOGY

Recurrent headaches: what every allergist should know. Schuller DE, et al. **Ann Allergy Asthma Immunol** 1996 Mar; 76(3):219–26; quiz 226–30 (71 ref.)
Migraine and other causes of headache. Spence J. **Ann Emerg Med** 1996 Apr;27(4):448–50 (25 ref.)
Cervicogenic headache: a personal view. Pearce JM. **Cephalalgia** 1995 Dec;15(6):463–9 (39 ref.)
Headache as a symptom of organic diseases. Edmeads JG. **Curr Opin Neurol** 1995 Jun;8(3):233–6 (32 ref.)
Oculocephalic sympathetic dysfunction in posttraumatic headaches. Khurana RK. **Headache** 1995 Nov–Dec; 35(10):614–20 (32 ref.)
Characteristics of patients successfully treated for cervicogenic headache by surgical decompression of the second cervical root. Pikus HJ, et al. **Headache** 1995 Nov–Dec;35(10):621–9 (39 ref.)
Symptomatic headaches. Bono G, et al. **Ital J Neurol Sci** 1995 Nov;16(8 Suppl):21–8 (43 ref.)
Diagnostic testing for the evaluation of headaches. Evans RW. **Neurol Clin** 1996 Feb;14(1):1–26 (159 ref.)
Cough, exertional, and sexual headaches: an analysis of 72 benign and symptomatic cases. Pascual J, et al. **Neurology** 1996 Jun;46(6):1520–4 (19 ref.)
Arachnoid cysts: does surgery improve epileptic seizures and headaches? Koch CA, et al. **Neurosurg Rev** 1995; 18(3):173–81 (37 ref.)
Postmyelography headache: a review. Peterman SB. **Radiology** 1996 Sep;200(3):765–70 (39 ref.)
[Postmyelographic headache] Fries J. **Ugeskr Laeger** 1995 Nov 6;157(45):6249–52 (35 ref.) (Eng. Abstr.) **(Dan)**
[Centro–peripheral etiopathogenesis of primary headache triggered nasally] Ottaviani F. **Ital J Neurol Sci** 1995 Nov; 16(8 Suppl):35–9 (18 ref.) (Eng. Abstr.) **(Ita)**

PATHOLOGY

Anatomy and physiology of headache. Bogduk N. **Biomed Pharmacother** 1995;49(10):435–45 (47 ref.)

PHYSIOPATHOLOGY

Anatomy and physiology of headache. Bogduk N. **Biomed Pharmacother** 1995;49(10):435–45 (47 ref.)
Yes, but do they still get headaches? DeWitt D, et al. **Cell** 1995 Nov 3;83(3):345–8 (16 ref.)
Oculocephalic sympathetic dysfunction in posttraumatic headaches. Khurana RK. **Headache** 1995 Nov–Dec; 35(10):614–20 (32 ref.)
Pathophysiology of recurrent headaches in children and adolescents. Rothner AD. **Pediatr Ann** 1995 Sep;24(9):458, 461–6 (34 ref.)
[Trigemino–vegetative physiopathology in the central dysnociceptive biorhythms in primary headache] Passàli D, et al. **Ital J Neurol Sci** 1995 Nov;16(8 Suppl):41–5 (14 ref.) (Eng. Abstr.) **(Ita)**
[Evoked potentials and headache] Giubelli D, et al. **Minerva Med** 1995 Sep;86(9):367–78 (39 ref.) (Eng. Abstr.) **(Ita)**
[Chronic paroxysmal hemicrania] Morales–Asín F. **Rev Neurol** 1995;23 Suppl 4:S535–9 (27 ref.) **(Spa)**

PSYCHOLOGY

Association between psychopathology and headache syndromes. Merikangas KR. **Curr Opin Neurol** 1995 Jun; 8(3):248–51 (19 ref.)
A frequent attender. Crossley N, et al. **Practitioner** 1995 Nov; 239(1556):631–2, 635–8 (3 ref.)

SURGERY

Characteristics of patients successfully treated for cervicogenic headache by surgical decompression of the second cervical root. Pikus HJ, et al. **Headache** 1995 Nov–Dec;35(10):621–9 (39 ref.)

THERAPY

The management of migraine and cluster headaches. Diamond S. **Compr Ther** 1995 Sep;21(9):492–8 (27 ref.)

HEADGEAR, ORTHODONTIC see **EXTRAORAL TRACTION APPLIANCES**

HEALTH

Sugar substitutes: their energy values, bulk characteristics, and potential health benefits. Levin GV, et al. **Am J Clin Nutr** 1995 Nov;62(5 Suppl):1161S–1168S (38 ref.)
Overexpression of genes in health and sickness. A bird's eye view. Shastry BS. **Comp Biochem Physiol B Biochem Mol Biol** 1995 Sep; 112(1):1–13 (146 ref.)
The sense of coherence: an historical and future perspective. McCubbin HI, et al. **Isr J Med Sci** 1996 Mar–Apr; 32(3–4):170–8 (19 ref.)
Postmodernism, health and illness. Mitchell DP. **J Adv Nurs** 1996 Jan;23(1):201–5 (28 ref.)
Expanding the horizon of reflection on health and disease. Khushf G. **J Med Philos** 1995 Oct;20(5):461–73 (31 ref.)
Health as an analogical concept. Mordacci R. **J Med Philos** 1995 Oct;20(5):475–97 (46 ref.)
[Exercise, health and health services (editorial)] Vuori I. **Duodecim** 1994;110(12):1175–7 (16 ref.) **(Fin)**
[Traditional medicine: its influence on the concepts of health and disease] Ahmed AM, et al. **Ann Ig** 1995 May–Jun; 7(3):201–8 (34 ref.) (Eng. Abstr.) **(Ita)**

HEALTH AND WELFARE PLANNING see **HEALTH PLANNING**

HEALTH BEHAVIOR

Evaluation of the Interaction Model of Client Health Behavior through the first decade of research. Carter KF, et al. **ANS Adv Nurs Sci** 1995 Sep;18(1):62–73 (47 ref.)
Smoking and other health related behaviour in the social and environmental context. Logan S, et al. **Arch Dis Child** 1996 Feb;74(2):176–9 (46 ref.)
Food and behaviour. Warner JO. **Clin Exp Allergy** 1995 Jul; 25 Suppl 1:23–6 (23 ref.)
Preventing skin cancer through behavior change. Implications for interventions. Rossi JS, et al. **Dermatol Clin** 1995 Jul;13(3):613–22 (103 ref.)
Do physical activity and physical fitness avert premature mortality? Lee IM, et al. **Exerc Sport Sci Rev** 1996; 24:135–71 (113 ref.)
Lifestyles of the risky and infamous. From managed care to managed lives. Morreim EH. **Hastings Cent Rep** 1995 Nov–Dec;25(6):5–12 (43 ref.)
Behavioral risk factors related to chronic diseases in ethnic minorities. Myers HF, et al. **Health Psychol** 1995 Dec; 14(7):613–21 (65 ref.)
Schema model of the self–concept. Stein KF. **Image J Nurs Sch** 1995 Fall;27(3):187–93 (60 ref.)
Adolescent condom use, the health belief model, and the prevention of sexually transmitted disease. Hiltabiddle SJ. **J Obstet Gynecol Neonatal Nurs** 1996 Jan;25(1):61–6 (36 ref.)
Reduction of tobacco health hazards in continuing users: individual behavioral and public health approaches. Kozlowski LT. **J Subst Abuse** 1989;1(3):345–57 (50 ref.)
Physical activity and cardiovascular health. NIH Consensus Development Panel on Physical Activity and Cardiovascular Health. **JAMA** 1996 Jul 17;276(3):241–6 (0 ref.)
Lifestyle change for coronary artery disease. What to tell patients. O'Keefe JH Jr, et al. **Postgrad Med** 1996 Feb; 99(2):89–92, 95–6, 102–6 (34 ref.)
Motivating change in health behavior. Implications for health promotion and disease prevention. Botelho RJ, et al. **Prim Care** 1995 Dec;22(4):565–89 (52 ref.)
Applying cognitive-social theory to health-protective behavior: breast self–examination in cancer screening. Miller SM, et al. **Psychol Bull** 1996 Jan;119(1):70–94 (263 ref.)
Anabolic steroid use and associated health risk behaviours. Middleman AB, et al. **Sports Med** 1996 Apr;21(4):251–5 (26 ref.)
[Old principles for th treatment of obesity are still valid. Diet and exercise are still the most important factors] Rössner S. **Lakartidningen** 1996 Mar 20;93(12):1117–20 (12 ref.) **(Swe)**

ETHNOLOGY

Health risk behaviors for Hispanic women. Torres S, et al. **Annu Rev Nurs Res** 1995;13:293–319 (94 ref.)

HEALTH BENEFIT PLANS, EMPLOYEE

ECONOMICS

The role of employee flexible spending accounts in health care financing. Schweitzer M, et al. **Am J Public Health** 1996 Aug;86(8 Pt 1):1079–81 (15 ref.)

LEGISLATION & JURISPRUDENCE

Liability for managed care decisions: the Employee Retirement Income Security Act (ERISA) and the uneven playing field. Mariner WK. **Am J Public Health** 1996 Jun; 86(6):863–9 (66 ref.)

HEALTH CAMPAIGNS see **HEALTH PROMOTION**

HEALTH CARE COSTS

see related
HEALTH EXPENDITURES

Social and economic effects of body weight in the United States. Wolf AM, et al. **Am J Clin Nutr** 1996 Mar;63(3 Suppl):466S–469S (19 ref.)
Economic considerations of point–of–care testing. Keffer JH. **Am J Clin Pathol** 1995 Oct;104(4 Suppl 1):S107–10 (14 ref.)
Cost–effectiveness analysis: what is it and how will it influence neurology. Holloway RG. **Ann Neurol** 1996 Jun; 39(6):818–23 (32 ref.)
The winds of change. Roski RA. **Clin Neurosurg** 1995;42:1–14 (8 ref.)
Behavioral medicine, clinical health psychology, and cost offset. Friedman R, et al. **Health Psychol** 1995 Nov; 14(6):509–18 (52 ref.)
Economic strategies in modern male subfertility treatment. Comhaire F. **Hum Reprod** 1995 Oct;10 Suppl 1:103–6 (16 ref.)
The impact of obesity on health status: some implications for health care costs. Seidell JC. **Int J Obes Relat Metab Disord** 1995 Nov;19 Suppl 6:S13–6 (9 ref.)
Performance measurement: integrating quality management and activity–based cost management. McKeon T. **J Nurs Adm** 1996 Apr;26(4):45–51 (8 ref.)
The economics of cardiac failure. Kleber FX. **J R Soc Med** 1996 Jan;89(1):9–12 (28 ref.)
Neurologic intensive care unit management and economic issues. Sundrani S. **Neurol Clin** 1995 Aug;13(3):679–93 (57 ref.)
Economic and quality of life outcomes in oncology: the regulatory perspective. Turner S. **Oncology (Huntingt)** 1995 Nov;9(11 Suppl):121–5 (0 ref.)
Health care costs: market forces and reform. Vincenzino JV. **Oncology (Huntingt)** 1995 May;9(5):367–8, 371, 374 (6 ref.)
The cost of the illness that defies [editorial] Howlett M, et al. **Postgrad Med J** 1995 Dec;71(842):705–6 (15 ref.)
Investing in nutrition at the national level: an African perspective. Kavishe FP. **Proc Nutr Soc** 1995 Jul; 54(2):367–78 (19 ref.)
Estimated societal costs of assertive community mental health care. Wolff N, et al. **Psychiatr Serv** 1995 Sep;46(9):898–906 (29 ref.)
Profit–managed health care. Clements R. **Radiol Technol** 1996 May–Jun;67(5):377–8 (13 ref.)
Diabetes in minorities: reflections on the medical dilemma and the healthcare crisis. Gavin JR 3rd. **Trans Am Clin Climatol Assoc** 1995;107:213–23; discussion 223–5 (20 ref.)
[Economic evaluation of health. Principles—example of laparoscopic cholecystectomy] de Pouvourville G. **Ann Chir** 1995;49(10):881–8 (11 ref.) (Eng. Abstr.) **(Fre)**
[Economic assessment in health care: contribution and limits (editorial)] Lanoë JL. **Gastroenterol Clin Biol** 1996 Feb; 20(1):33–5 (7 ref.) **(Fre)**
[Impact of HMOs on costs and quality of care] Perneger TV, et al. **Rev Med Suisse Romande** 1995 Dec; 115(12):971–6 (42 ref.) **(Fre)**

LEGISLATION & JURISPRUDENCE

Strains in the fiduciary metaphor: divided physician loyalties and obligations in a changing health care system. Rodwin MA. **Am J Law Med** 1995;21(2–3):241–57 (108 ref.)
Current challenges to the principles of medical law and their new interpretation. Paaso I. **Med Law** 1995;14(7–8):611–21 (15 ref.)

STATISTICS & NUMERICAL DATA

The medical costs attributable to meat consumption [see comments] Barnard ND, et al. **Prev Med** 1995 Nov; 24(6):646–55 (105 ref.) Comment in: Prev Med 1995 Nov;24(6):565–7.

TRENDS

The costs of cancer care in the United States: implications for action. Schuette HL, et al. **Oncology (Huntingt)** 1995 Nov;9(11 Suppl):19–22 (18 ref.)
Health–care economics and peritoneal dialysis. Nissenson AR. **Perit Dial Int** 1996;16 Suppl 1:S373–7 (17 ref.)

HEALTH CARE DELIVERY see **DELIVERY OF HEALTH CARE**

HEALTH CARE PROVIDERS see **HEALTH PERSONNEL**

HEALTH CARE RATIONING

see related
PATIENT SELECTION

Ethical issues in healthcare prioritization: a medical viewpoint. Asplund K. **Br J Urol** 1995 Nov;76 Suppl 2:49–54 (12 ref.)
Ethical issues in the economics of rationing healthcare. Maynard A. **Br J Urol** 1995 Nov;76 Suppl 2:59–64 (25 ref.)
Sweden: no easy choices. Calltorp J. **Br Med Bull** 1995 Oct; 51(4):791–8 (7 ref.)
Core services and the New Zealand health reforms. Cooper MH. **Br Med Bull** 1995 Oct;51(4):799–807 (10 ref.)
Clinical practice guidelines—do they enhance value for money in health care? Grimshaw JM, et al. **Br Med Bull** 1995 Oct;51(4):927–40 (33 ref.)
Synthesis: what can we learn from international experience? Ham C. **Br Med Bull** 1995 Oct;51(4):819–30 (18 ref.)

Rationing in the NHS: the dance of the seven veils–in reverse. Klein R, et al. **Br Med Bull** 1995 Oct;51(4):769–80 (24 ref.)
Information for public choice. McIver S. **Br Med Bull** 1995 Oct;51(4):900–13 (29 ref.)
Can we do better? Maxwell RJ. **Br Med Bull** 1995 Oct; 51(4):941–8 (4 ref.)
Why rationing is on the agenda. Maxwell RJ. **Br Med Bull** 1995 Oct;51(4):761–8 (14 ref.)
Choices in health care: a contribution from The Netherlands. van de Ven WP. **Br Med Bull** 1995 Oct;51(4):781–90 (7 ref.)
Healthcare resources should be targeted to chemoprevention in prostate cancer: the argument for. Denis LJ. **Eur Urol** 1996;29 Suppl 2:13–6 (13 ref.)
Healthcare resources should be targeted to chemoprevention: the argument against. Trachtenberg J. **Eur Urol** 1996;29 Suppl 2:17–8 (1 ref.)
Pharmacoeconomic studies. Pitfalls and problems. De Graeve D, et al. **Int J Technol Assess Health Care** 1996 Winter; 12(1):22–30 (27 ref.)
Health status index models for use in resource allocation decisions. A critical review in the light of observed preferences for social choice. Nord E. **Int J Technol Assess Health Care** 1996 Winter;12(1):31–44 (47 ref.)
Health care rationing: nursing perspectives. Wells JS. **J Adv Nurs** 1995 Oct;22(4):738–44 (39 ref.)
Using cluster analysis for medical resource decision making. Dilts D, et al. **Med Decis Making** 1995 Oct–Dec; 15(4):333–47 (72 ref.)
Ethics and the care of critically ill infants and children. American Academy of Pediatrics Committee on Bioethics. **Pediatrics** 1996 Jul;98(1):149–52 (58 ref.)

ECONOMICS

Rationing health care and the need for credible scarcity: why Americans can't say no. Mariner WK. **Am J Public Health** 1995 Oct;85(10):1439–45 (50 ref.)
Contracting and choice. Carruthers I. **Br Med Bull** 1995 Oct; 51(4):914–26 (0 ref.)
On the Oregon trail. Kitzhaber J, et al. **Br Med Bull** 1995 Oct;51(4):808–18 (0 ref.)
Help or hindrance? The role of economics in rationing health care. Maynard A, et al. **Br Med Bull** 1995 Oct;51(4):854–68 (31 ref.)
When drug treatment in the elderly is not cost effective. An ethical dilemma in an environment of healthcare rationing. Chadwick R, et al. **Drugs Aging** 1995 Dec;7(6):416–9 (25 ref.)
An exercise on the feasibility of carrying out secondary economic analyses. Jefferson T, et al. **Health Econ** 1996 Mar–Apr;5(2):155–65 (50 ref.)

LEGISLATION & JURISPRUDENCE

Medical futility and implications for physician autonomy. Daar JF. **Am J Law Med** 1995;21(2–3):221–40 (117 ref.)
Rationing health care: the political perspective. Hunter DJ. **Br Med Bull** 1995 Oct;51(4):876–84 (14 ref.)
Allocating health care: cost–utility analysis, informed democratic decision making, or the veil of ignorance? Goold SD. **J Health Polit Policy Law** 1996 Spring; 21(1):69–98 (41 ref.)

ORGANIZATION & ADMINISTRATION

A policy agenda for health care rationing. Harrison S. **Br Med Bull** 1995 Oct;51(4):885–99 (36 ref.)
Simulation modelling for resource allocation and planning in the health sector. Lehaney B, et al. **J R Soc Health** 1995 Dec;115(6):382–5 (47 ref.)

STANDARDS

Health policy approaches to measuring and valuing human life: conceptual and ethical issues [see comments] Morrow RH, et al. **Am J Public Health** 1995 Oct;85(10):1356–60 (20 ref.) Comment in: Am J Public Health 1995 Oct;85(10):1345–6.
The doctor's dilemma. Irvine DH, et al. **Br Med Bull** 1995 Oct;51(4):842–53 (28 ref.)
Involving the public: practical and ethical issues. Jacobson B, et al. **Br Med Bull** 1995 Oct;51(4):869–75 (16 ref.)
The ethics of rationing. Weale A. **Br Med Bull** 1995 Oct; 51(4):831–41 (23 ref.)
Managed care in mental health: the ethical issues. Boyle PJ, et al. **Health Aff (Millwood)** 1995 Fall;14(3):7–22; discussion 23–33 (40 ref.)
What is the ultimate cause of socio-economic inequalities in health? An explanation in terms of evolutionary psychology. Charlton BG. **J R Soc Med** 1996 Jan;89(1):3–8 (47 ref.)

HEALTH CARE REFORM

The current state of health care in the former Soviet Union: implications for health care policy and reform [see comments] Barr DA, et al. **Am J Public Health** 1996 Mar; 86(3):307–12 (61 ref.) Comment in: Am J Public Health 1996 Mar;86(3):321–3.
Addressing the epidemiologic transition in the former Soviet Union: strategies for health system and public health reform in Russia [see comments] Tulchinsky TH, et al. **Am J Public Health** 1996 Mar;86(3):313–20 (46 ref.) Comment in: Am J Public Health 1996 Mar;86(3):321–3.
Think before you prep: defining the terms of change in American healthcare. Tanenbaum SJ. **Ann Thorac Surg** 1995 Nov;60(5):1530–3 (12 ref.)
Alcohol treatment and health care system reform. McCrady BS, et al. **Arch Gen Psychiatry** 1996 Aug;53(8):737–46 (109 ref.)
College of American Pathologists Conference XXIX on restructuring autopsy practice for health care reform. Let's make this autopsy conference matter. Lundberg GD. **Arch Pathol Lab Med** 1996 Aug;120(8):736–8 (11 ref.)
Primary care and the maelstrom of health care reform in the United States of America. Curtis P. **Br J Gen Pract** 1995 Aug;45(397):433–7 (36 ref.)
GP 2000: a general practitioner for the new millennium [editorial] Wright AF. **Br J Gen Pract** 1996 Jan;46(402):4–5 (15 ref.)
Core services and the New Zealand health reforms. Cooper MH. **Br Med Bull** 1995 Oct;51(4):799–807 (10 ref.)
On the Oregon trail. Kitzhaber J, et al. **Br Med Bull** 1995 Oct;51(4):808–18 (0 ref.)
The effect of health care reform on academic medicine in Canada. Editorial Committee of the Canadian Institute for Academic Medicine. Hollenberg CH. **Can Med Assoc J** 1996 May 15;154(10):1483–9 (0 ref.)
Impact of cost cutting on laboratories: new business strategies for laboratories. Ash KO. **Clin Chem** 1996 May;42(5):822–6 (6 ref.)
The politics of health care reform. Desmarais H. **Clin Neurosurg** 1995;42:15–22 (0 ref.)
Health reform: past, present, and future. Smits HL. **Clin Neurosurg** 1995;42:30–6 (0 ref.)
Medicine in transition: strategies for change. Vogel DE. **Clin Neurosurg** 1995;42:23–9 (0 ref.)
Critical issues in reforming rural mental health service delivery. Blank MB, et al. **Community Ment Health J** 1995 Dec;31(6):511–24 (46 ref.)
Local knowledge and rural mental health reform. Hill CE, et al. **Community Ment Health J** 1995 Dec;31(6):553–68 (48 ref.)
Securing health care quality for Medicare. Palmer RH. **Health Aff (Millwood)** 1995 Winter;14(4):89–100 (31 ref.)
Joint nursing appointments: a vehicle for influencing health care change. Tamlyn D, et al. **J Adv Nurs** 1995 Sep; 22(3):490–3 (18 ref.)
Health, illness, and healing in an uncertain era: challenges from and for medical sociology. Pescosolido BA, et al. **J Health Soc Behav** 1995;Spec No:5–33 (155 ref.)
Genetic testing: employability, insurability, and health reform. Rothstein MA. **J Natl Cancer Inst Monogr** 1995; (17):87–90 (14 ref.)
Care at home and quality of life: an overview of the issues. Henwood M. **J R Soc Health** 1995 Oct;115(5):323–5 (6 ref.)
Understanding American health-care and health-care reform [see comments] Johnson D. **J R Soc Med** 1995 Nov; 88(11):652P–656P (8 ref.) Comment in: J R Soc Med 1996 Mar;89(3):179.
Population-centered and patient-focused purchasing: the U.K. experience. Ham C. **Milbank Q** 1996;74(2):191–214 (58 ref.)
Economic and quality of life outcomes: managed care perspectives. Glandon GL, et al. **Oncology (Huntingt)** 1995 Nov;9(11 Suppl):111–9 (31 ref.)
[The Italian situation in psychiatry after fifteen years of the psychiatric reform: the mental health service in north Italy] Mizuno M. **Seishin Shinkeigaku Zasshi** 1996;98(1):27–40 (27 ref.) **(Jpn)**

ECONOMICS

Quality, cost-effective psychiatric treatment: A CNS--MD collaborative practice model. Saur CD, et al. **Arch Psychiatr Nurs** 1995 Dec;9(6):332–7 (15 ref.)
Rural mental health coverage under health care reform. Shelton DA, et al. **Community Ment Health J** 1995 Dec; 31(6):539–52 (33 ref.)
Allocating health care: cost–utility analysis, informed democratic decision making, or the veil of ignorance? Goold SD. **J Health Polit Policy Law** 1996 Spring; 21(1):69–98 (41 ref.)
National health expenditure limits: the case for a global budget process. Bishop CE, et al. **Milbank Q** 1996; 74(3):361–76 (17 ref.)
Health care costs: market forces and reform. Vincenzino JV. **Oncology (Huntingt)** 1995 May;9(5):367–8, 371, 374 (6 ref.)

LEGISLATION & JURISPRUDENCE

Adversarial medical and scientific testimony and lay jurors: a proposal for medical malpractice reform. Menon JW. **Am J Law Med** 1995;21(2–3):281–300 (141 ref.)
Strains in the fiduciary metaphor: divided physician loyalties and obligations in a changing health care system. Rodwin MA. **Am J Law Med** 1995;21(2–3):241–57 (108 ref.)
Omnibus Budget Reconciliation Act of 1987 and its implications for the medical director. Elon RD. **Clin Geriatr Med** 1995 Aug;11(3):419–32 (5 ref.)
Well-healed: inside lobbying for health care reform, Part II. Center for Public Integrity. **Int J Health Serv** 1995; 25(4):593–632 (76 ref.)
Publicity-stunt participation and sound bites polemics: the health care debate 1993–94. Disch L. **J Health Polit Policy Law** 1996 Spring;21(1):3–33 (78 ref.)
Harry and Louise go to Washington: political advertising and health care reform. West DM, et al. **J Health Polit Policy Law** 1996 Spring;21(1):35–68 (57 ref.)
Alternative dispute resolution for medical malpractice actions: an efficient approach to the law and health care. White WF. **Leg Med** 1995;:227–39 (47 ref.)
View from across the Atlantic. America struggles with health care reform. Friedman EA. **Nephrol Dial Transplant** 1996 Jan;11(1):203–7 (37 ref.)

ORGANIZATION & ADMINISTRATION

Prevention and the reforming U.S. health care system: changing roles and responsibilities for public health. Gordon RL, et al. **Annu Rev Public Health** 1996;17:489–509 (86 ref.)
The need for a national autopsy policy. Setlow VP. **Arch Pathol Lab Med** 1996 Aug;120(8):773–7 (6 ref.)
How cardiac rehabilitation is being influenced by changes in health-care delivery. Froelicher VF, et al. **J Cardpulm Rehabil** 1996 May–Jun;16(3):151–9 (24 ref.)
The future of graduate education in nursing: scholarship, the health of communities, and health care reform. Hall JM, et al. **J Prof Nurs** 1995 Nov–Dec;11(6):332–8 (22 ref.)
The Dutch health care system: lessons for reform in the United States. Jackson JL. **South Med J** 1996 Jun; 89(6):567–72 (31 ref.)
The influence of surgical training on the practice of surgery. Are changes necessary? Stone MD, et al. **Surg Clin North Am** 1996 Feb;76(1):1–10 (33 ref.)

TRENDS

Welfare reform and children's health. Geltman PL, et al. **Arch Pediatr Adolesc Med** 1996 Apr;150(4):384–9 (64 ref.)
What will be the outcome of the outcomes movement? Braithwaite J, et al. **Aust N Z J Med** 1995 Dec;25(6):731–5 (49 ref.)

HEALTH CARE RESEARCH see **HEALTH SERVICES RESEARCH**

HEALTH CARE SEEKING BEHAVIOR see **PATIENT ACCEPTANCE OF HEALTH CARE**

HEALTH CARE SYSTEMS see **DELIVERY OF HEALTH CARE**

HEALTH CARE TEAM see **PATIENT CARE TEAM**

HEALTH CENTERS, AMBULATORY see **AMBULATORY CARE FACILITIES**

HEALTH DIARIES see **MEDICAL RECORDS**

HEALTH EDUCATION

see related
HEALTH PROMOTION

AIDS education for college students: review and proposal for a research-based curriculum. Mulvihill CK. **AIDS Educ Prev** 1996 Feb;8(1):11–25 (72 ref.)
Caring for the lay caregiver. Ruppert RA. **Am J Nurs** 1996 Mar;96(3):40–5; quiz 46 (6 ref.)
Reducing demand for physician visits through public education: a look at the pilot cold-and-flu campaign in London, Ontario. Brown EM, et al. **Can Med Assoc J** 1996 Mar 15;154(6):835–40 (21 ref.)
Assessment of nutrition and physical activity education programmes in children. Burke V, et al. **Clin Exp Pharmacol Physiol** 1995 Mar;22(3):212–6 (33 ref.)
A work-systems analysis of compliance with universal precautions among health care workers. DeJoy DM, et al. **Health Educ Q** 1996 May;23(2):159–74 (80 ref.)
Worksite health programs: working together to advance employee health. Heaney CA, et al. **Health Educ Q** 1996 May;23(2):133–6 (18 ref.)
The ecology of work and health: research and policy directions for the promotion of employee health. Stokols D, et al. **Health Educ Q** 1996 May;23(2):137–58 (162 ref.)
A multiple-level, comprehensive approach to the prevention of fetal alcohol syndrome (FAS) and other alcohol-related birth defects (ARBD). May PA. **Int J Addict** 1995; 30(12):1549–602 (160 ref.)
STDs: Screening, therapy, and long-term implications for the adolescent patient. Bishop-Townsend V. **Int J Fertil Menopausal Stud** 1996 Mar–Apr;41(2):109–14 (41 ref.)
The use of poison prevention and education strategies to enhance the awareness of the poison information center and to prevent accidental pediatric poisonings. Krenzelok EP. **J Toxicol Clin Toxicol** 1995;33(6):663–7 (7 ref.)
Transferring research findings on persuasion to improve drug abuse prevention programs. McGuire WJ. **NIDA Res Monogr** 1995;155:225–45 (8 ref.)
Network models for HIV outreach and prevention programs for drug users. Trotter RT II, et al. **NIDA Res Monogr** 1995;151:144–80 (31 ref.)
Educating African-Americans about cancer prevention and detection: a review of the literature. Lowe JI, et al. **Soc Work Health Care** 1995;21(4):17–36 (36 ref.)

Preventing blindness in Americans: the need for eye health education. Javitt JC. **Surv Ophthalmol** 1995 Jul-Aug; 40(1):41-4 (25 ref.)
Potential interventions for preventing pneumonia among young children in developing countries: promoting maternal education. van Ginneken JK, et al. **Trop Med Int Health** 1996 Jun;1(3):283-94 (34 ref.)
[Education and women's health: reflections from a gender perspective] Campero-Cuenca L. **Salud Publica Mex** 1996 May-Jun;38(3):217-22 (48 ref.) (Eng. Abstr.) **(Spa)**

METHODS

Effectiveness in adolescent health. Macfarlane A. **Acta Paediatr** 1995 Oct;84(10):1089-93 (19 ref.)
AIDS prevention with adolescents. Rotheram-Borus MJ, et al. **AIDS Educ Prev** 1995 Aug;7(4):320-36 (125 ref.)
A research agenda for health education among underserved populations. Marin G, et al. **Health Educ Q** 1995 Aug; 22(3):346-63 (86 ref.)
At risk, infected, and invisible: older gay men and HIV/AIDS. Grossman AH. **J Assoc Nurses AIDS Care** 1995 Nov-Dec;6(6):13-9 (14 ref.)
Creating strong attitudes: two routes to persuasion. Petty RE. **NIDA Res Monogr** 1995;155:209-24 (33 ref.)
Incorporating effective smoking prevention and cessation counseling into practice. Klein JD. **Pediatr Ann** 1995 Dec; 24(12):646-52 (31 ref.)

ORGANIZATION & ADMINISTRATION

Reducing impediments to technology transfer in drug abuse programming. Brown BS. **NIDA Res Monogr** 1995; 155:169-85 (38 ref.)
Diffusion of drug abuse prevention programs: spontaneous diffusion, agenda setting, and reinvention. Rogers EM. **NIDA Res Monogr** 1995;155:90-105 (10 ref.)
Are our information, education and communication-based interventions too superficial? Clarke I. **Trop Doct** 1995 Oct; 25(4):167-70 (7 ref.)

TRENDS

Evaluation of health education programs: current assessment and future directions. Israel BA, et al. **Health Educ Q** 1995 Aug;22(3):364-89 (114 ref.)
Settings as an important dimension in health education/promotion policy, programs, and research. Mullen PD, et al. **Health Educ Q** 1995 Aug;22(3):329-45 (101 ref.)
Health education intervention strategies: recommendations for future research. Steckler A, et al. **Health Educ Q** 1995 Aug;22(3):307-28 (121 ref.)

HEALTH EXPENDITURES

see related
HEALTH CARE COSTS

The Lyme disease controversy. Social and financial costs of misdiagnosis and mismanagement. Sigal LH. **Arch Intern Med** 1996 Jul 22;156(14):1493-500 (30 ref.)
The doctor's dilemma. Irvine DH, et al. **Br Med Bull** 1995 Oct;51(4):842-53 (28 ref.)
On the Oregon trail. Kitzhaber J, et al. **Br Med Bull** 1995 Oct;51(4):808-18 (0 ref.)
Rationing in the NHS: the dance of the seven veils-in reverse. Klein R, et al. **Br Med Bull** 1995 Oct;51(4):769-80 (24 ref.)
Help or hindrance? The role of economics in rationing health care. Maynard A, et al. **Br Med Bull** 1995 Oct;51(4):854-68 (31 ref.)
Investing in health wisely. The role of needs-based technology assessment. Jamison DT, et al. **Int J Technol Assess Health Care** 1995 Fall;11(4):673-84 (6 ref.)

LEGISLATION & JURISPRUDENCE

National health expenditure limits: the case for a global budget process. Bishop CE, et al. **Milbank Q** 1996; 74(3):361-76 (17 ref.)

STATISTICS & NUMERICAL DATA

Health care expenditure and life expectancy in Australia: how well do we perform? Taylor R, et al. **Aust N Z J Public Health** 1996 Jun;20(3):233-40 (12 ref.)

HEALTH FACILITIES

ORGANIZATION & ADMINISTRATION

Implementing TQM in the health care sector. Motwani J, et al. **Health Care Manage Rev** 1996 Winter;21(1):73-82 (44 ref.)
[Computer systems in medical practice. I. The aims, difficulties and implementation of computerization in health care organizations] Michalak J. **Med Pr** 1995;46(5):509-16 (12 ref.) (Eng. Abstr.) **(Pol)**

HEALTH FACILITY ACQUISITION see **HEALTH FACILITY MERGER**

HEALTH FACILITY ENVIRONMENT

Burnout. Why do we blame the nurse? Cullen A. **Am J Nurs** 1995 Nov;95(11):22-7; quiz 28 (11 ref.)

HEALTH FACILITY MERGER

Owned vertical integration and health care: promise and performance. Walston SL, et al. **Health Care Manage Rev** 1996 Winter;21(1):83-92 (59 ref.)

ORGANIZATION & ADMINISTRATION

The impact of multiskilling on quality of care. Holzemer WL. **Int Nurs Rev** 1996 Jan-Feb;43(1):21-5 (32 ref.)

TRENDS

Mergers, networking, and vertical integration: managed care and investor-owned hospitals. Brown M. **Health Care Manage Rev** 1996 Winter;21(1):29-37 (7 ref.)

HEALTH INSURANCE see **INSURANCE, HEALTH**

HEALTH INSURANCE FOR AGED AND DISABLED, TITLE 18 see **MEDICARE**

HEALTH INSURANCE, VOLUNTARY see **INSURANCE, HEALTH**

HEALTH LEGISLATION see **LEGISLATION**

HEALTH MAINTENANCE ORGANIZATIONS

ECONOMICS

[Impact of HMOs on costs and quality of care] Perneger TV, et al. **Rev Med Suisse Romande** 1995 Dec; 115(12):971-6 (42 ref.) **(Fre)**

ORGANIZATION & ADMINISTRATION

Managed care contracting/capitation. Reardon TM. **Ann Thorac Surg** 1995 Nov;60(5):1500-8 (0 ref.)

HEALTH MANPOWER

UTILIZATION

Spain: an explanatory model of supply and utilization of human resources of the health care system. Alfonso Sanchez JL, et al. **Cah Sociol Demogr Med** 1995 Oct-Dec; 35(3-4):227-61 (79 ref.)

HEALTH OCCUPATIONS

[Hepatitis B virus infection in health care settings] Sodeyama T. **Nippon Rinsho** 1995 Oct;53 Suppl:362-70 (15 ref.) **(Jpn)**

EDUCATION

Can educational accreditation drive interdisciplinary learning in the health professions? Gelmon SB. **Jt Comm J Qual Improv** 1996 Mar;22(3):213-22 (27 ref.)
Accepting the Galvin challenge: increasing efficiency and productivity in health professions education. Neuhauser D, et al. **Jt Comm J Qual Improv** 1996 Mar;22(3):223-27 (1 ref.)

HEALTH OCCUPATIONS MANPOWER see **HEALTH MANPOWER**

HEALTH PERSONNEL

Prophylaxis for occupational exposure to HIV. Gerberding JL. **Ann Intern Med** 1996 Sep 15;125(6):497-501 (31 ref.)
Violence in the health care environment. Gregg CM, et al. **Arch Otolaryngol Head Neck Surg** 1996 Jan;122(1):11-6 (19 ref.)
Health care personnel in disaster response. Reversible roles or territorial imperatives? Bissell RA, et al. **Emerg Med Clin North Am** 1996 May;14(2):267-88 (66 ref.)
Monitoring of occupational exposure to cytostatic anticancer agents. Sorsa M, et al. **Mutat Res** 1996 Aug 17; 355(1-2):253-61 (58 ref.)
Use of back belts in occupational settings. Minor SD. **Phys Ther** 1996 Apr;76(4):403-8 (21 ref.)
Management of occupational exposure to HIV. Critchley SE, et al. **Semin Dermatol** 1995 Sep;14(3):235-9 (36 ref.)
Preventing bloodborne pathogen transmission from health-care workers to patients. The CDC perspective. Bell DM, et al. **Surg Clin North Am** 1995 Dec;75(6):1189-203 (80 ref.)
Occupational risk of infection with hepatitis B and hepatitis C virus. Shapiro CN. **Surg Clin North Am** 1995 Dec; 75(6):1047-56 (51 ref.)

EDUCATION

A work-systems analysis of compliance with universal precautions among health care workers. DeJoy DM, et al. **Health Educ Q** 1996 May;23(2):159-74 (80 ref.)
Role, role enactment and the health care practitioner. Scott PA. **J Adv Nurs** 1995 Aug;22(2):323-8 (15 ref.)

LEGISLATION & JURISPRUDENCE

Bloodborne pathogen transmission from healthcare worker to patients. Legal issues and provider perspectives. Rhodes RS, et al. **Surg Clin North Am** 1995 Dec;75(6):1205-17 (29 ref.)

PSYCHOLOGY

Contraceptive methods: do Hispanic adolescents and their family planning care providers think about contraceptive methods the same way? Erickson PI. **Med Anthropol** 1996 May;17(1):65-82 (53 ref.)
College health providers' knowledge, attitudes, and management practices of genital HPV infection. Linnehan MJ, et al. **Nurse Pract** 1996 May;21(5):122-4, 127-9 (55 ref.)
Health care workers and HIV/AIDS: a critical review of the literature. Horsman JM, et al. **Soc Sci Med** 1995 Dec; 41(11):1535-67 (164 ref.)
[Therapists' coping with his own abilities] Joss R. **Schweiz Rundsch Med Prax** 1996 Jul 16;85(29-30):904-10 (25 ref.) (Eng. Abstr.) **(Ger)**

HEALTH PHYSICS

see related
RADIATION MONITORING
RADIATION PROTECTION
RADIOMETRY

Radiation physics and radiobiology. Rossi HH. **Health Phys** 1996 Jun;70(6):828-31 (7 ref.)

HEALTH PLAN IMPLEMENTATION

ORGANIZATION & ADMINISTRATION

Secondary prevention of excessive alcohol use: assessing the prospects of implementation. Botelho RJ, et al. **Fam Pract** 1996 Apr;13(2):182-93 (139 ref.)
Health transition and needs-based technology planning and implementation. Sitthi-Amorn C. **Int J Technol Assess Health Care** 1995 Fall;11(4):663-72 (44 ref.)

HEALTH PLANNING

Cancer in minority ethnic populations: priorities from epidemiological data. Bhopal RS, et al. **Br J Cancer** 1996 Sep;74 Suppl 29:S22-32 (15 ref.)

HEALTH PLANNING COUNCILS

The future of preventive medicine. Council on Long Range Planning and Development. **Prev Med** 1996 Jan-Feb; 25(1):73-81 (65 ref.)

HEALTH PLANNING GUIDELINES

Issues in health policy for indigenous peoples in Canada. O'Neil JD. **Aust J Public Health** 1995 Dec;19(6):559-66 (50 ref.)

HEALTH PLANS, PREPAID see **PREPAID HEALTH PLANS**

HEALTH POLICY

Policy and healthy weight. Dwyer J. **Am J Clin Nutr** 1996 Mar;63(3 Suppl):415S-418S (27 ref.)
Policy evaluation: better living through research. Boden LI. **Am J Ind Med** 1996 Apr;29(4):346-52 (40 ref.)
The risk of domestic violence and women with HIV infection: implications for partner notification, public policy, and the law. Rothenberg KH, et al. **Am J Public Health** 1995 Nov;85(11):1569-76 (98 ref.)
Vaccination policies and practices [see comments] Henderson DA. **Aust J Public Health** 1995 Dec;19(6):634-8 (5 ref.) Comment in: Aust J Public Health 1995 Dec;19(6):545-6.
Issues in health policy for indigenous peoples in Canada. O'Neil JD. **Aust J Public Health** 1995 Dec;19(6):559-66 (50 ref.)
A policy agenda for health care rationing. Harrison S. **Br Med Bull** 1995 Oct;51(4):885-99 (36 ref.)
Historical and analytical overview of policy issues affecting women living with AIDS: a blueprint for learning from our past. Cooper EB. **Bull N Y Acad Med** 1995 Summer; 72(1 Suppl):283-99 (59 ref.)
Health policy planning: a look at consumer involvement in Nova Scotia. Sullivan MJ, et al. **Can J Public Health** 1995 Sep-Oct;86(5):317-20 (26 ref.)
The politics of health care reform. Desmarais H. **Clin Neurosurg** 1995;42:15-22 (0 ref.)
Health reform: past, present, and future. Smits HL. **Clin Neurosurg** 1995;42:30-6 (0 ref.)
Reproductive health: a rendezvous with human dignity. Diczfalusy E. **Contraception** 1995 Jul;52(1):1-12 (69 ref.)
Oral health policies and programs affecting the preschool child. Casamassimo PS. **Dent Clin North Am** 1995 Oct; 39(4):877-85 (23 ref.)
Prevention of cardiovascular disease: from biomedical research to health policy. Muntoni S. **Eur J Epidemiol** 1995 Oct;11(5):485-94 (74 ref.)
The regionalization of perinatal care in France--description

of a missing policy. Papiernik E, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Aug;61(2):99–103 (40 ref.)

Dworkin on dementia. Elegant theory, questionable policy. Dresser R. **Hastings Cent Rep** 1995 Nov–Dec;25(6):32–8 (17 ref.)

Foundations' impact on policy making: results from a pilot study. Weissert CS, et al. **Health Aff (Millwood)** 1995 Winter;14(4):275–86 (31 ref.)

The ecology of work and health: research and policy directions for the promotion of employee health. Stokols D, et al. **Health Educ Q** 1996 May;23(2):137–58 (162 ref.)

Professional dynamics and the changing nature of medical work. Hafferty FW, et al. **J Health Soc Behav** 1995;Spec No:132–53 (130 ref.)

Alcohol–problem prevention research policy: the need for a phases research model. Holder H, et al. **J Public Health Policy** 1995;16(3):324–46 (43 ref.)

The Department of Health Cardiovascular Review Group and public health policy: an alternative view [see comments] Gurr MI, et al. **J R Soc Health** 1995 Oct; 115(5):279–81 (20 ref.) Comment in: J R Soc Health 1996 Apr;116(2):121–2.

Good care of the dying patient. Council on Scientific Affairs, American Medical Association. **JAMA** 1996 Feb 14; 275(6):474–8 (96 ref.)

Benefits from specialised cancer care. Selby P, et al. **Lancet** 1996 Aug 3;348(9023):313–8 (52 ref.)

Crime, disorder and legal pressure as a result of addiction problems in The Netherlands. Wolters RD. **Med Law** 1995; 14(7–8):521–9 (28 ref.)

Economic and quality of life outcomes in oncology: the regulatory perspective. Turner S. **Oncology (Huntingt)** 1995 Nov;9(11 Suppl):121–5 (0 ref.)

Health promotion, health protection, and preventive services. Cooke BE. **Prim Care** 1995 Dec;22(4):555–64 (36 ref.)

The procurement of vital organs: a synopsis of policy from various nations and the ethical implications of policy options. Chelminski PR. **Ren Fail** 1996 Mar;18(2):151–72 (178 ref.)

Treatment outcomes in schizophrenia: implications for practice, policy, and research. Lehman AF, et al. **Schizophr Bull** 1995;21(4):669–75 (15 ref.)

Do-not-resuscitate orders: towards a policy in Singapore [see comments] Sahadevan S, et al. **Singapore Med J** 1995 Jun; 36(3):267–70 (28 ref.) Comment in: Singapore Med J 1995 Jun;36(3):258–9.

Risk assessment policy for evaluating reproductive system toxicants and the impact of responses on sensitive populations. Briggs GB. **Toxicology** 1996 Jul 17; 111(1–3):305–13 (106 ref.)

[Decision making policies on the utilization of antimalarials in response to a modification of chloroquine efficacy. Applications to Africa] Baudon D. **Med Trop (Mars)** 1995; 55(4 Suppl):37–40 (5 ref.) (Eng. Abstr.) **(Fre)**

ECONOMICS

Health policy approaches to measuring and valuing human life: conceptual and ethical issues [see comments] Morrow RH, et al. **Am J Public Health** 1995 Oct;85(10):1356–60 (20 ref.) Comment in: Am J Public Health 1995 Oct;85(10):1345–6.

LEGISLATION & JURISPRUDENCE

Measurement of moral development in medicine. Self DJ, et al. **Camb Q Healthc Ethics** 1996 Spring;5(2):269–77 (70 ref.)

TRENDS

The need for a national autopsy policy. Setlow VP. **Arch Pathol Lab Med** 1996 Aug;120(8):773–7 (6 ref.)

The household context for women's health care decisions: impacts of U.K. policy changes. Young R. **Soc Sci Med** 1996 Mar;42(6):949–63 (92 ref.)

HEALTH PRIORITIES

Women's health as a priority. **Am Pharm** 1995 Sep;NS35(9 Suppl):S1–11; quiz S12–3 (47 ref.)

Ethical issues in healthcare prioritization: a medical viewpoint. Asplund K. **Br J Urol** 1995 Nov;76 Suppl 2:49–54 (12 ref.)

Ethical issues in healthcare prioritization: a political viewpoint. McColl. **Br J Urol** 1995 Nov;76 Suppl 2:55–7 (4 ref.)

Synthesis: what can we learn from international experience? Ham C. **Br Med Bull** 1995 Oct;51(4):819–30 (18 ref.)

Opportunistic coccidioidomycosis in patients infected with human immunodeficiency virus: prevention issues and priorities. McNeil MM, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S111–3 (19 ref.)

Opportunistic candidal infections in patients infected with human immunodeficiency virus: prevention issues and priorities. Reef SE, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S99–102 (24 ref.)

Autism research: prospects and priorities. Rutter M. **J Autism Dev Disord** 1996 Apr;26(2):257–75 (50 ref.)

Priorities for nutrition interventions in reproductive health: a bilateral agency perspective. Davidson FR. **Proc Nutr Soc** 1995 Jul;54(2):361–6 (19 ref.)

ECONOMICS

An exercise on the feasibility of carrying out secondary economic analyses. Jefferson T, et al. **Health Econ** 1996 Mar–Apr;5(2):155–65 (50 ref.)

HEALTH PROFESSIONS see **HEALTH OCCUPATIONS**

HEALTH PROMOTION

see related
HEALTH BEHAVIOR

Diet and psychological health. Miller M. **Altern Ther Health Med** 1996 Sep;2(5):40–8 (73 ref.)

The role of the pediatrician in the promotion of cardiovascular health. Bronfin DR, et al. **Am J Med Sci** 1995 Dec;310 Suppl 1:S42–7 (43 ref.)

Roles of nurses and health workers in cardiovascular health promotion. Hill MN, et al. **Am J Med Sci** 1995 Dec;310 Suppl 1:S123–6 (16 ref.)

Health enhancement and companion animal ownership. Beck AM, et al. **Annu Rev Public Health** 1996;17:247–57 (60 ref.)

The importance of diet and physical activity in the treatment of conditions managed in general practice. Little P, et al. **Br J Gen Pract** 1996 Mar;46(404):187–92 (122 ref.)

The integrated model: implications for worksite health promotion and occupational health and safety practice. Baker E, et al. **Health Educ Q** 1996 May;23(2):175–90 (61 ref.)

Worksite health programs: working together to advance employee health. Heaney CA, et al. **Health Educ Q** 1996 May;23(2):133–6 (18 ref.)

The ecology of work and health: research and policy directions for the promotion of employee health. Stokols D, et al. **Health Educ Q** 1996 May;23(2):137–58 (162 ref.)

Ethnic minorities, health care systems, and behavior. Penn NE, et al. **Health Psychol** 1995 Dec;14(7):641–6 (40 ref.)

Effects of ageism on individual and health care providers' responses to healthy aging. Grant LD. **Health Soc Work** 1996 Feb;21(1):9–15 (46 ref.)

Social support: some pragmatic implications for health care professionals. Keeling DI, et al. **J Adv Nurs** 1996 Jan; 23(1):76–81 (36 ref.)

Health-promoting nursing practice: the demise of the nursing process? Lindsey E, et al. **J Adv Nurs** 1996 Jan;23(1):106–12 (24 ref.)

Health promotion activities in Japan. Takeshita T, et al. **J Epidemiol** 1996 Aug;6(3 Suppl):S165–8 (30 ref.)

Social theory, social action, and intervention research: implications for cancer prevention among Latinos. Flores ET, et al. **J Natl Cancer Inst Monogr** 1995;(18):101–8 (53 ref.)

Market testing specialist health promotion services—a test case for an imaginative public health presence in purchasing. Whitelaw S, et al. **J Public Health Med** 1995 Jun;17(2):211–6 (22 ref.)

A critique of Geoffrey Rose's 'population strategy' for preventive medicine [see comments] Charlton BG. **J R Soc Med** 1995 Nov;88(11):607–10 (18 ref.) Comment in: J R Soc Med 1995 Nov;88(11):605–6. Comment in: J R Soc Med 1996 Mar;89(3):179.

Ought low alcohol intake to be promoted for health reasons? Holman CD, et al. **J R Soc Med** 1996 Mar;89(3):123–9 (36 ref.)

Vitamin and mineral supplements as nutritional aids to exercise performance and health. Armstrong LE, et al. **Nutr Rev** 1996 Apr;54(4 Pt 2):S149–58 (126 ref.)

Screening, health promotion, and prevention in men. Horst T, et al. **Prim Care** 1995 Dec;22(4):679–95 (72 ref.)

Prevention in adults. Molberg P. **Prim Care** 1995 Dec; 22(4):653–60 (21 ref.)

The primary care physician as a sports medicine and exercise advocate and activist. Rouzier PA. **Prim Care** 1995 Dec; 22(4):785–804 (43 ref.)

Building community capacity for health promotion: a challenge for public health nurses. Kang R. **Public Health Nurs** 1995 Oct;12(5):312–8 (24 ref.)

Health promotion and the "ideology of choice". Lowenberg JS. **Public Health Nurs** 1995 Oct;12(5):319–23 (37 ref.)

Using multiple indicators to test the dimensionality of concepts in the health promotion model. Ratner PA, et al. **Res Nurs Health** 1996 Jun;19(3):237–47 (44 ref.)

ECONOMICS

Cost-effectiveness of alternative interventions for the prevention and treatment of coronary heart disease. Crowley S, et al. **Aust J Public Health** 1995 Aug; 19(4):336–46 (77 ref.)

METHODS

Multinational approaches to cervical cancer screening: a review. Lovejoy NC. **Cancer Nurs** 1996 Apr;19(2):126–34 (42 ref.)

Randomised controlled trials of physical activity promotion in free living populations: a review. Hillsdon M, et al. **J Epidemiol Community Health** 1995 Oct;49(5):448–53 (23 ref.)

Motivating change in health behavior. Implications for health promotion and disease prevention. Botelho RJ, et al. **Prim Care** 1995 Dec;22(4):565–89 (52 ref.)

Media strategies for community health advocacy. Woodruff K. **Prim Care** 1995 Dec;22(4):805–15 (29 ref.)

ORGANIZATION & ADMINISTRATION

Healthy Cities: toward worldwide health promotion. Flynn BC. **Annu Rev Public Health** 1996;17:299–309 (59 ref.)

Sustaining interventions in community systems: on the relationship between researchers and communities. Altman DG. **Health Psychol** 1995 Nov;14(6):526–36 (72 ref.)

Health promotion, health protection, and preventive services. Cooke BE. **Prim Care** 1995 Dec;22(4):555–64 (36 ref.)

Problems with public health outreach. Azzarto J. **Soc Work Health Care** 1995;22(1):57–67 (20 ref.)

[Health promotion in the heart of Quebec and Canada: the ever present influence of the North Karelia model] Paradis G, et al. **Union Med Can** 1995 Sep;124(2):1–6 (19 ref.) **(Fre)**

STANDARDS

[Quality in preventive and health promotion activities] Blomberg I. **Nord Med** 1995;110(10):246–9 (15 ref.) (Eng. Abstr.) **(Swe)**

TRENDS

Strengthening individual and community capacity to prevent disease and promote health: in search of relevant theories and principles. Freudenberg N, et al. **Health Educ Q** 1995 Aug;22(3):290–306 (83 ref.)

Settings as an important dimension in health education/promotion policy, programs, and research. Mullen PD, et al. **Health Educ Q** 1995 Aug;22(3):329–45 (101 ref.)

HEALTH RECORDS, PERSONAL see **MEDICAL RECORDS**

HEALTH RESORTS

Dermatology at the Dead Sea spas. Even-Paz Z. **Isr J Med Sci** 1996 Jul;32 Suppl:S11–5 (23 ref.)

[Dermatologic climate therapy--definition, indications and public health necessity] Vocks E, et al. **Rehabilitation (Stuttg)** 1995 Aug;34(3):148–53 (21 ref.) (Eng. Abstr.) **(Ger)**

HEALTH RESOURCES

see related
HEALTH CARE RATIONING

Healthcare resources should be targeted to chemoprevention in prostate cancer: the argument for. Denis LJ. **Eur Urol** 1996;29 Suppl 2:13–6 (13 ref.)

Healthcare resources should be targeted to chemoprevention: the argument against. Trachtenberg J. **Eur Urol** 1996;29 Suppl 2:17–8 (1 ref.)

[Social networks and social support as health resources] Vahtera J, et al. **Duodecim** 1994;110(11):1054–60 (40 ref.) **(Fin)**

ECONOMICS

An exercise on the feasibility of carrying out secondary economic analyses. Jefferson T, et al. **Health Econ** 1996 Mar–Apr;5(2):155–65 (50 ref.)

SUPPLY & DISTRIBUTION

Rationing health care and the need for credible scarcity: why Americans can't say no. Mariner WK. **Am J Public Health** 1995 Oct;85(10):1439–45 (50 ref.)

TRENDS

Workforce deployment: reconciling demands and resources. Andrews G. **Aust N Z J Psychiatry** 1995 Sep;29(3):394–402 (20 ref.)

The health crisis in the former Soviet Union: a report from the 'post-war' zone. Field MG. **Soc Sci Med** 1995 Dec; 41(11):1469–78 (37 ref.)

HEALTH RISK APPRAISAL see **HEALTH STATUS INDICATORS**

HEALTH SERVICES

[Exercise, health and health services (editorial)] Vuori I. **Duodecim** 1994;110(12):1175–7 (16 ref.) **(Fin)**

ORGANIZATION & ADMINISTRATION

The role for regional autopsy centers in the evaluation of covered deaths. Survey of opinions of US and Canadian chairs of pathology and major health insurers in the United States. Trelstad RL, et al. **Arch Pathol Lab Med** 1996 Aug; 120(8):753–8 (48 ref.)

The research basis of health care decision making. Ingram N. **J Adv Nurs** 1996 Apr;23(4):692–6 (18 ref.)

Defence Costs Study 15 [editorial] Macmillan AH. **J R Army Med Corps** 1996 Feb;142(1):3–8 (10 ref.)

The development of healthcare services for diabetic prisoners. MacFarlane IA. **Postgrad Med J** 1996 Apr; 72(846):214–7 (15 ref.)

STANDARDS

Health care in correctional facilities. Thorburn KM. **West J Med** 1995 Dec;163(6):560–4 (47 ref.)

[Quality assurance] Kaste M, et al. **Duodecim** 1995; 111(1):56–62 (37 ref.) **(Fin)**

TRENDS

An overview of health-related industrial biotechnology in Latin America and the Caribbean. Marques MB. **Bull Pan Am Health Organ** 1996 Jun;30(2):95–105 (36 ref.)

UTILIZATION

Generalized anxiety and mixed anxiety–depression: association with disability and health care utilization. Roy-Byrne PP. **J Clin Psychiatry** 1996;57 Suppl 7:86–91 (33 ref.)

Appropriateness in patient care: a new conceptual framework. Sharpe VA, et al. **Milbank Q** 1996;74(1):115–38 (80 ref.)

HEALTH SERVICES ACCESSIBILITY

An ecological view of the rural environment: levels of influence on access to health care. Shreffler MJ. **ANS Adv Nurs Sci** 1996 Jun;18(4):48–59 (50 ref.)

A closer look at reproductive technology and postmenopausal motherhood [comment] Parks JA. **Can Med Assoc J** 1996 Apr 15;154(8):1189–91 (10 ref.) Comment on: Can Med Assoc J 1994 Aug 1;151(3):353, 355.

Condom availability and prevention issues for adolescents. Spingarn RW. **Curr Opin Pediatr** 1995 Aug;7(4):360–5 (53 ref.)

Assisted conception techniques. On what basis do health technologies become routinely available when they have been assessed as effective? Freemantle N, et al. **Int J Technol Assess Health Care** 1995 Fall;11(4):786–94 (35 ref.)

Access to substance abuse treatment for homeless women of reproductive age. Wenzel SL, et al. **J Psychoactive Drugs** 1996 Jan–Mar;28(1):17–30 (110 ref.)

Key ingredients to effective addictions treatment. Waltman D. **J Subst Abuse Treat** 1995 Nov–Dec;12(6):429–39 (50 ref.)

Access to and patterns of use of oral health care among elderly veterans. Gilbert GH. **Med Care** 1995 Nov;33(11 Suppl):NS78–89 (58 ref.)

Barriers to cancer screening. Womeodu RJ, et al. **Med Clin North Am** 1996 Jan;80(1):115–33 (81 ref.)

A review of problems of universal access to prenatal care. York R, et al. **Nurs Clin North Am** 1996 Jun;31(2):279–92 (40 ref.)

Dental problems in the offshore oil and gas industry: a review. Duffy B. **Occup Med (Oxf)** 1996 Feb;46(1):79–83 (8 ref.)

Reaching out to the African American community through innovative strategies. Robinson KD, et al. **Oncol Nurs Forum** 1995 Oct;22(9):1383–91 (28 ref.)

STATISTICS & NUMERICAL DATA

Who cares? Pathways to psychiatric care for young people experiencing a first episode of psychosis. Lincoln CV, et al. **Psychiatr Serv** 1995 Nov;46(11):1166–71 (89 ref.)

[Epidemiology of rheumatologic health care in Germany] Zink A. **Z Rheumatol** 1995 Jul–Aug;54(4):184–91 (7 ref.) (Eng. Abstr.) **(Ger)**

TRENDS

Expanding access to emergency contraception in developing countries. Ellertson C, et al. **Stud Fam Plann** 1995 Sep–Oct; 26(5):251–63 (70 ref.)

HEALTH SERVICES, ADOLESCENT see **ADOLESCENT HEALTH SERVICES**

HEALTH SERVICES FOR THE AGED

Caring for Older People. Public transport. Roper TA, et al. **BMJ** 1996 Aug 17;313(7054):415–8 (0 ref.)

Caring for older people. Carers. Travers AF. **BMJ** 1996 Aug 24;313(7055):482–6 (6 ref.)

Rehabilitation and older people. Young J. **BMJ** 1996 Sep 14;313(7058):677–81 (2 ref.)

LEGISLATION & JURISPRUDENCE

[Legal aspects of treatment and care of elderly patients] Kaatsch HJ, et al. **Z Gerontol Geriatr** 1996 May–Jun; 29(3):176–9 (11 ref.) (Eng. Abstr.) **(Ger)**

ORGANIZATION & ADMINISTRATION

Effects of ageism on individual and health care providers' responses to healthy aging. Grant LD. **Health Soc Work** 1996 Feb;21(1):9–15 (46 ref.)

Rethinking the organization of children's programs: lessons from the elderly. Grason H, et al. **Milbank Q** 1995; 73(4):565–97 (37 ref.)

TRENDS

Elderly mental health in the developing world. Levkoff SE, et al. **Soc Sci Med** 1995 Oct;41(7):983–1003 (178 ref.)

HEALTH SERVICES, INDIGENOUS

ORGANIZATION & ADMINISTRATION

Issues in health policy for indigenous peoples in Canada. O'Neil JD. **Aust J Public Health** 1995 Dec;19(6):559–66 (50 ref.)

STANDARDS

Evaluating government health and substance abuse programs for indigenous peoples: a comparative review. Gray D, et al. **Aust J Public Health** 1995 Dec;19(6):567–72 (62 ref.)

HEALTH SERVICES MARKETING see **MARKETING OF HEALTH SERVICES**

HEALTH SERVICES MISUSE

ACE inhibitors for the prevention and treatment of heart failure: why are they 'under-used'? Cleland JG. **J Hum Hypertens** 1995 Jun;9(6):435–42 (47 ref.)

Appropriateness in patient care: a new conceptual framework. Sharpe VA, et al. **Milbank Q** 1996;74(1):115–38 (80 ref.)

Limiting excessive postoperative blood transfusion after cardiac procedures. A review. Ferraris VA, et al. **Tex Heart Inst J** 1995;22(3):216–30 (167 ref.)

HEALTH SERVICES NEEDS AND DEMAND

Addressing the epidemiologic transition in the former Soviet Union: strategies for health system and public health reform in Russia [see comments] Tulchinsky TH, et al. **Am J Public Health** 1996 Mar;86(3):313–20 (46 ref.) Comment in: Am J Public Health 1996 Mar;86(3):321–3.

Heterologous antisera and antivenins are essential biologicals: perspectives on a worldwide crisis. Wilde H, et al. **Ann Intern Med** 1996 Aug 1;125(3):233–6 (22 ref.)

Meeting the needs of minority ethnic communities. Webb E. **Arch Dis Child** 1996 Mar;74(3):264–7 (49 ref.)

Exploring the medical need for alternate site testing. A clinician's perspective. Becker RC. **Arch Pathol Lab Med** 1995 Oct;119(10):894–7 (47 ref.)

Cervical cancer screening: meeting the needs of minority ethnic women. Luke K. **Br J Cancer** 1996 Sep;74 Suppl 29:S47–50 (11 ref.)

Assessing the health needs for cancer services for people from ethnic groups. Rawaf S. **Br J Cancer** 1996 Sep;74 Suppl 29:S35–7 (28 ref.)

Review of teenage health: time for a new direction. Jacobson LD, et al. **Br J Gen Pract** 1994 Sep;44(386):420–4 (64 ref.)

Perspectives on treatment needs in schizophrenia. Meise U, et al. **Br J Psychiatry Suppl** 1996 May;(29):9–16 (110 ref.)

Reducing demand for physician visits through public education: a look at the pilot cold-and-flu campaign in London, Ontario. Brown EM, et al. **Can Med Assoc J** 1996 Mar 15;154(6):835–40 (21 ref.)

Monitoring cardiovascular disease in Zimbabwe: a review of needs and options. Razum O. **Cent Afr J Med** 1996 Apr; 42(4):120–4 (23 ref.)

Investing in health wisely. The role of needs-based technology assessment. Jamison DT, et al. **Int J Technol Assess Health Care** 1995 Fall;11(4):673–84 (6 ref.)

Health transition and needs-based technology planning and implementation. Sitthi-Amorn C. **Int J Technol Assess Health Care** 1995 Fall;11(4):663–72 (44 ref.)

Technology assessment. Old, new, and needs-based. Tugwell P, et al. **Int J Technol Assess Health Care** 1995 Fall; 11(4):650–62 (39 ref.)

Approaches to community needs assessment: a literature review. Billings JR, et al. **J Adv Nurs** 1995 Oct;22(4):721–30 (100 ref.)

A critical analysis of nursing: meeting the spiritual needs of patients. Oldnall A. **J Adv Nurs** 1996 Jan;23(1):138–44 (43 ref.)

Managed care: will the healthcare needs of rural citizens be met? Pierce SF, et al. **J Nurs Adm** 1996 Apr;26(4):28–32 (10 ref.)

Transforming prenatal care: reflections on the past and present with implications for the future. Maloni JA, et al. **J Obstet Gynecol Neonatal Nurs** 1996 Jan;25(1):17–23 (51 ref.)

Health care needs of gay men and lesbians in the United States. Council on Scientific Affairs, American Medical Association. **JAMA** 1996 May 1;275(17):1354–9 (126 ref.)

HIV infection. What nurses need to know. The consumer perspective. Schietinger H, et al. **Nurs Clin North Am** 1996 Mar;31(1):137–52 (21 ref.)

Health needs of rural residents. Watt IS. **Occas Pap R Coll Gen Pract** 1995 Sep;(71):5–9 (75 ref.)

Prevention of traumatic deaths to children in the United States: how far have we come and where do we need to go? Rivara FP, et al. **Pediatrics** 1996 Jun;97(6 Pt 1):791–7 (58 ref.)

Meeting the needs of young adults. McCauley AP, et al. **Popul Rep J** 1995 Oct;(41):1–43 (595 ref.)

The impact of HIV-1 infection on child health in sub-Saharan Africa: the burden on the health services. Walraven G, et al. **Trop Med Int Health** 1996 Feb;1(1):3–14 (87 ref.)

The development and state of health and safety in the workplace in west Africa: perspectives from Nigeria. Asuzu MC. **West Afr J Med** 1996 Jan–Mar;15(1):36–44 (19 ref.)

ECONOMICS

An exercise on the feasibility of carrying out secondary economic analyses. Jefferson T, et al. **Health Econ** 1996 Mar–Apr;5(2):155–65 (50 ref.)

TRENDS

Workforce deployment: reconciling demands and resources. Andrews G. **Aust N Z J Psychiatry** 1995 Sep;29(3):394–402 (20 ref.)

Population laboratories and health needs assessment. Clarke M. **Int J Epidemiol** 1995;24 Suppl 1:S65–8 (26 ref.)

Who is our consumer? Shaping nursing programs to meet emerging needs. Norbeck JS. **J Prof Nurs** 1995 Nov–Dec; 11(6):325–31 (9 ref.)

Vaccinations in the Third World: a consideration of community demand. Nichter M. **Soc Sci Med** 1995 Sep; 41(5):617–32 (96 ref.)

The development of Ontario's Home Care Program: a critical geographical analysis. Williams AM. **Soc Sci Med** 1996 Mar;42(6):937–48 (52 ref.)

HEALTH SERVICES RESEARCH

Case management. Lamb GS. **Annu Rev Nurs Res** 1995; 13:117–36 (46 ref.)

Health services research and policy studies. Prashker MJ. **Curr Opin Rheumatol** 1996 Mar;8(2):106–9 (8 ref.)

Dermatologic health services research. Chren MM. **Dermatol Clin** 1995 Jul;13(3):689–95 (40 ref.)

Strategic planning in hospitals: a review and proposal. Bruton GD, et al. **Health Care Manage Rev** 1995 Summer; 20(3):16–25 (45 ref.)

A research agenda for health education among underserved populations. Marin G, et al. **Health Educ Q** 1995 Aug; 22(3):346–63 (86 ref.)

Appropriateness of hospital use: an overview of Italian studies. Fellin G, et al. **Int J Qual Health Care** 1995 Sep; 7(3):219–25 (12 ref.)

An overview of Spanish studies on appropriateness of hospital use. Lorenzo S, et al. **Int J Qual Health Care** 1995 Sep;7(3):213–8 (28 ref.)

Appropriateness of hospital use in the United Kingdom: a review of activity in the field. O'Neill D, et al. **Int J Qual Health Care** 1995 Sep;7(3):239–44 (22 ref.)

Improving the use of information in medical effectiveness research. Phillips KA, et al. **Int J Qual Health Care** 1996 Feb;8(1):21–30 (96 ref.)

Medical appropriateness of hospital utilization: an overview of the Swiss experience. Santos-Eggimann B, et al. **Int J Qual Health Care** 1995 Sep;7(3):227–32 (24 ref.)

The research basis of health care decision making. Ingram N. **J Adv Nurs** 1996 Apr;23(4):692–6 (18 ref.)

Inner-city hospitals: a call for research. Gautam K, et al. **J Health Care Poor Underserved** 1995;6(4):387–402 (49 ref.)

CLASSIFICATION

Making sense of action research through the use of a typology. Hart E, et al. **J Adv Nurs** 1996 Jan;23(1):152–9 (14 ref.)

METHODS

Nationally speaking. Life history and narrative research: generating a humanistic knowledge base for occupational therapy. Larson EA, et al. **Am J Occup Ther** 1996 Apr; 50(4):247–50 (27 ref.)

Benefit-cost analysis in public health. Lave LB, et al. **Annu Rev Public Health** 1996;17:203–19 (28 ref.)

Ethnography: a stepwise approach for primary care researchers. Ventres WB, et al. **Fam Med** 1996 Jan; 28(1):52–6 (25 ref.)

The use of condition specific outcome measures in economic appraisal. Brazier J, et al. **Health Econ** 1995 Jul–Aug; 4(4):255–64 (35 ref.)

Sensitivity analysis in economic evaluation: a review of published studies. Briggs A, et al. **Health Econ** 1995 Sep–Oct;4(5):355–71 (109 ref.)

Perspectives in health economics [editorial] Phelps CE. **Health Econ** 1995 Sep–Oct;4(5):335–53 (44 ref.)

The design and analysis of hospital utilization studies. Ash A. **Int J Qual Health Care** 1995 Sep;7(3):245–52 (18 ref.)

The evolution of hospital utilization review methods in the United States. Restuccia JD. **Int J Qual Health Care** 1995 Sep;7(3):253–60 (19 ref.)

The use of different research methodologies to evaluate the effectiveness of programmes to improve the care of patients in postoperative pain. Allcock N. **J Adv Nurs** 1996 Jan; 23(1):32–8 (34 ref.)

Alcohol-problem prevention research policy: the need for a phases research model. Holder H, et al. **J Public Health Policy** 1995;16(3):324–46 (43 ref.)

The challenge of health outcomes. Hall J. **J Qual Clin Pract** 1996 Mar;16(1):5–15; discussion 17–8 (43 ref.)

Quality and effectiveness issues related to oral health.

Antczak-Bouckoms A. **Med Care** 1995 Nov;33(11 Suppl):NS123-42 (60 ref.)
Environmental and health-related quality of life: conceptual and methodological similarities. Rogerson RJ. **Soc Sci Med** 1995 Nov;41(10):1373-82 (80 ref.)

ORGANIZATION & ADMINISTRATION

Sustaining interventions in community systems: on the relationship between researchers and communities. Altman DG. **Health Psychol** 1995 Nov;14(6):526-36 (72 ref.)
Making sense of action research through the use of a typology. Hart E, et al. **J Adv Nurs** 1996 Jan;23(1):152-9 (14 ref.)

TRENDS

Strengthening individual and community capacity to prevent disease and promote health: in search of relevant theories and principles. Freudenberg N, et al. **Health Educ Q** 1995 Aug;22(3):290-306 (83 ref.)
Evaluation of health education programs: current assessment and future directions. Israel BA, et al. **Health Educ Q** 1995 Aug;22(3):364-89 (114 ref.)
Settings as an important dimension in health education/promotion policy, programs, and research. Mullen PD, et al. **Health Educ Q** 1995 Aug;22(3):329-45 (101 ref.)
Health education intervention strategies: recommendations for future research. Steckler A, et al. **Health Educ Q** 1995 Aug;22(3):307-28 (121 ref.)

HEALTH SERVICES, WOMEN'S see **WOMEN'S HEALTH SERVICES**

HEALTH STATUS

American Health Foundation Roundtable on Healthy Weight. Proceedings of an expert panel discussion. New York, New York, September 20, 1994. **Am J Clin Nutr** 1996 Mar;63(3 Suppl):409S-477S (0 ref.)
Policy and healthy weight. Dwyer J. **Am J Clin Nutr** 1996 Mar;63(3 Suppl):415S-418S (27 ref.)
Fractionating healthy weight. Garn SM. **Am J Clin Nutr** 1996 Mar;63(3 Suppl):412S-414S (13 ref.)
Does weight cycling present a health risk? Jeffery RW. **Am J Clin Nutr** 1996 Mar;63(3 Suppl):452S-455S (16 ref.)
Summary and recommendations from the American Health Foundation's Expert Panel on Healthy Weight. Meisler JG, et al. **Am J Clin Nutr** 1996 Mar;63(3 Suppl):474S-477S (13 ref.)
Overweight and health: communications challenges and opportunities. Rippe JM. **Am J Clin Nutr** 1996 Mar;63(3 Suppl):470S-473S (32 ref.)
Physical health of homeless adults. Lindsey AM. **Annu Rev Nurs Res** 1995;13:31-61 (112 ref.)
Health and unemployment. Dooley D, et al. **Annu Rev Public Health** 1996;17:449-65 (112 ref.)
Racial differences in health: not just black and white, but shades of gray. Lillie-Blanton M, et al. **Annu Rev Public Health** 1996;17:411-48 (52 ref.)
Out-of-home day care and health. Roberts I. **Arch Dis Child** 1996 Jan;74(1):73-6 (16 ref.)
Health and development in the Hudson Bay/James Bay region. Stieb D, et al. **Arctic Med Res** 1995 Oct; 54(4):170-83 (101 ref.)
Review of teenage health: time for a new direction. Jacobson LD, et al. **Br J Gen Pract** 1994 Sep;44(386):420-4 (64 ref.)
Acknowledging the weather-health link. Bart JL, et al. **Can Med Assoc J** 1995 Oct 1;153(7):941-4 (30 ref.)
Picture imperfect: hidden problems among Asian Pacific islander elderly. Tanjasiri SP, et al. **Gerontologist** 1995 Dec; 35(6):753-60 (65 ref.)
Macrosocial and environmental influences on minority health. Johnson KW, et al. **Health Psychol** 1995 Dec; 14(7):601-12 (115 ref.)
The impact of obesity on health status: some implications for health care costs. Seidell JC. **Int J Obes Relat Metab Disord** 1995 Nov;19 Suppl 6:S13-6 (9 ref.)
Vitamin C and human health--a review of recent data relevant to human requirements. Weber P, et al. **Int J Vitam Nutr Res** 1996;66(1):19-30 (107 ref.)
How nursing research makes a difference. Holzemer W, et al. **Int Nurs Rev** 1996 Mar-Apr;43(2):49-52, 58 (38 ref.)
Deprivation indices: their interpretation and use in relation to health. Carstairs V. **J Epidemiol Community Health** 1995 Dec;49 Suppl 2:S3-8 (27 ref.)
The influence of social class on health status: American and British research on health inequalities. Fein O. **J Gen Intern Med** 1995 Oct;10(10):577-86 (69 ref.)
Self-ratings of health: do they also predict change in functional ability? Idler EL, et al. **J Gerontol B Psychol Sci Soc Sci** 1995 Nov;50(6):S344-53 (49 ref.)
What is the ultimate cause of socio-economic inequalities in health? An explanation in terms of evolutionary psychology. Charlton BG. **J R Soc Med** 1996 Jan;89(1):3-8 (47 ref.)
Physical activity, the compression of morbidity, and the health of the elderly. Fries JF. **J R Soc Med** 1996 Feb; 89(2):64-8 (36 ref.)
Handwriting in health and disease. Ficarra BJ. **Leg Med** 1995; :261-78 (22 ref.)
Well-being, symptoms and the menopausal transition. Dennerstein L. **Maturitas** 1996 Mar;23(2):147-57 (51 ref.)
The person-trade-off approach to valuing health care programs [see comments] Nord E. **Med Decis Making** 1995 Jul-Sep;15(3):201-8 (32 ref.) Comment in: Med Decis Making 1995 Jul-Sep;15(3):287-8.
Managing HIV. Part 3: Mechanisms of disease. 3.8 How psychosocial aspects of HIV infection can affect health. Ross MW. **Med J Aust** 1996 Feb 19;164(4):235-7 (5 ref.)
An eastern perspective on nutrition and performance. Chen JD. **Nutr Rev** 1996 Apr;54(4 Pt 2):S176-81 (28 ref.)
Effect of degree of weight loss on health benefits. Blackburn G. **Obes Res** 1995 Sep;3 Suppl 2:211s-216s (48 ref.)
Clinical and public health perspectives and applications of health-related quality of life measurement. Ebrahim S. **Soc Sci Med** 1995 Nov;41(10):1383-94 (68 ref.)
Evaluating the efficacy of medical treatment: possibilities and limitations. Jenkinson C. **Soc Sci Med** 1995 Nov; 41(10):1395-401 (49 ref.)
Is the lesser growth of African schoolchildren essentially prejudicial to their present and future health? Walker AR, et al. **Trop Geogr Med** 1995;47(4):145-50 (53 ref.)
[Who is ill and what are the diseases in Finland?] Huttunen JK, et al. **Duodecim** 1995;111(1):17-25 (27 ref.) **(Fin)**
[Physical activity and health: minimum, optimum and maximum] Vuori I. **Duodecim** 1994;110(12):1184-90 (54 ref.) **(Fin)**
[Effects of lifestyle on health status] Takeshita T, et al. **Rinsho Byori** 1995 Nov;43(11):1087-94 (15 ref.) (Eng. Abstr.) **(Jpn)**
[Health effects of unemployment] Korzeniewska M. **Med Pr** 1995;46(4):407-14 (34 ref.) (Eng. Abstr.) **(Pol)**
[The concept of risk factors and flight certificate examination] Vlasov VV. **Aviakosm Ekolog Med** 1995;29(5):4-9 (60 ref.) (Eng. Abstr.) **(Rus)**
[The problem in assessing the health status of children and adolescents in hygienic research] Antonova LT, et al. **Gig Sanit** 1995 Nov-Dec;(6):22-8 (47 ref.) **(Rus)**

HEALTH STATUS INDEX see **HEALTH STATUS INDICATORS**

HEALTH STATUS INDICATORS

Child health statistical review, 1995. Platt MJ, et al. **Arch Dis Child** 1995 Dec;73(6):541-8 (12 ref.)
Evaluative laboratory testing. Assessing tests that assess disease activity. Ward MM. **Arthritis Rheum** 1995 Nov; 38(11):1555-63 (63 ref.)
An overview of disability. Fitzpatrick F, et al. **Br J Rheumatol** 1996 Feb;35(2):184-7 (36 ref.)
Measurement properties of the AUA symptom score: a methodological clarification. Lawrence K. **Br J Urol** 1996 Feb;77(2):175-80 (25 ref.)
Coronary artery disease among South Asians: identification of a high risk population [editorial] Jolly KS, et al. **Can J Cardiol** 1996 Jun;12(6):569-71 (32 ref.)
The tooth wear index: a flawed epidemiological tool in an ageing population group. Donachie MA, et al. **Community Dent Oral Epidemiol** 1996 Apr;24(2):152-8 (28 ref.)
Using quality of life assessment methods in patients with advanced cancer: a clinical perspective. Kaasa S. **Eur J Cancer** 1995;31A Suppl 6:S15-7 (16 ref.)
Functional status instruments: outcome measure in the evaluation of patients with chronic obstructive pulmonary disease. Lareau SC, et al. **Heart Lung** 1996 May-Jun; 25(3):212-24 (63 ref.)
Measuring oral health: an historical view and details of a contemporary oral health index (OHX). Burke FJ, et al. **Int Dent J** 1995 Dec;45(6):358-70 (53 ref.)
Health status index models for use in resource allocation decisions. A critical review in the light of observed preferences for social choice. Nord E. **Int J Technol Assess Health Care** 1996 Winter;12(1):31-44 (47 ref.)
Evolution of quality of life assessment in head and neck cancer. Morton RP. **J Laryngol Otol** 1995 Nov; 109(11):1029-35 (63 ref.)
Oral health, health, and health-related quality of life. Gift HC, et al. **Med Care** 1995 Nov;33(11 Suppl):NS57-77 (95 ref.)
Identifying high-risk youth: prevalence and patterns of adolescent drug abuse. Newcomb MD. **NIDA Res Monogr** 1995;156:7-38 (68 ref.)
Assessment of long-term outcomes of rheumatoid arthritis. How choices of measures and study designs may lead to apparently different conclusions. Pincus T. **Rheum Dis Clin North Am** 1995 Aug;21(3):619-54 (112 ref.)
The health crisis in the former Soviet Union: a report from the 'post-war' zone. Field MG. **Soc Sci Med** 1995 Dec; 41(11):1469-78 (37 ref.)
Explaining urban-rural variations in health: a review of interactions between individual and environment. Verheij RA. **Soc Sci Med** 1996 Mar;42(6):923-35 (73 ref.)
[Principles of evaluation of public health risk for environmental exposures] Bard D. **Rev Epidemiol Sante Publique** 1995;43(5):423-31 (11 ref.) (Eng. Abstr.) **(Fre)**

HEALTH SURVEYS

Animal health monitoring and surveillance in Switzerland. Stärk KD. **Aust Vet J** 1996 Mar;73(3):96-7 (14 ref.)
Advances in strategies for minimizing and adjusting for survey nonresponse. Kessler RC, et al. **Epidemiol Rev** 1995; 17(1):192-204 (67 ref.)
Factors influencing the immediate and late outcome of Cushing's disease treated by transsphenoidal surgery: a retrospective study by the European Cushing's Disease Survey Group [see comments] Bochicchio D, et al. **J Clin Endocrinol Metab** 1995 Nov;80(11):3114-20 (43 ref.) Comment in: J Clin Endocrinol Metab 1995 Nov;80(11):3111-3.
[A practical approach to health information in Spain] Mirón Canelo JA, et al. **Rev Clin Esp** 1996 Mar;196(3):174-8 (57 ref.) **(Spa)**

HEALTH VISITORS see **COMMUNITY HEALTH NURSING**

HEARING

see related
ACOUSTIC STIMULATION
AUDITORY PERCEPTION

Hearing preservation in bilateral acoustic neurinomas. Samii M. **Br J Neurosurg** 1995;9(3):413-24 (16 ref.)

DRUG EFFECTS

Auditory and vestibular functions after single or combined exposure to toluene: a review. Morata TC, et al. **Arch Toxicol** 1995;69(7):431-43 (106 ref.)

PHYSIOLOGY

Ionic conductances and hair cell tuning in the turtle cochlea. Art JJ, et al. **Ann N Y Acad Sci** 1996 Jun 19;781:103-22 (27 ref.)
The octavolateralis system and Mauthner cell: interactions and questions. Eaton RC, et al. **Brain Behav Evol** 1995; 46(3):124-30 (60 ref.)
Physiology of primary saccular afferents of goldfish: implications for Mauthner cell response. Fay RR. **Brain Behav Evol** 1995;46(3):141-50 (54 ref.)
Structural diversity in the inner ear of teleost fishes: implications for connections to the Mauthner cell. Popper AN, et al. **Brain Behav Evol** 1995;46(3):131-40 (70 ref.)
Comparative studies on the Mauthner cell of teleost fish in relation to sensory input. Zottoli SJ, et al. **Brain Behav Evol** 1995;46(3):151-64 (115 ref.)
Effects of noise and age on the auditory system. Boettcher FA, et al. **Occup Med** 1995 Jul-Aug;10(3):577-91 (41 ref.)

HEARING AIDS

Hearing aids. II. Implantable hearing aids. Gulya AJ, et al. **Arch Otolaryngol Head Neck Surg** 1996 Apr;122(4):363-7 (22 ref.)
Hearing aids. I. Conventional hearing devices. Stach BA, et al. **Arch Otolaryngol Head Neck Surg** 1996 Mar; 122(3):227-31 (19 ref.)
Perceptual consequences of cochlear hearing loss and their implications for the design of hearing aids. Moore BC. **Ear Hear** 1996 Apr;17(2):133-61 (200 ref.)
[The implantable middle ear hearing aid] Niehaus HH. **HNO** 1995 Dec;43(12):697-701 (27 ref.) **(Ger)**
[Sensible utilization of modern hearing aid technique. II: Multiple channel compression] Steffens T. **HNO** 1996 May; 44(5):273-85 (24 ref.) **(Ger)**

HEARING DISORDERS

ABC of work related disorders. Occupational hearing loss and vibration induced disorders. Jones CM. **BMJ** 1996 Jul 27;313(7051):223-6 (0 ref.)

CHEMICALLY INDUCED

Monitoring chemotherapy-induced hearing loss in children. Bellman SC. **Eur J Cancer** 1996 Jun;32A(7):1185-8 (25 ref.)

DIAGNOSIS

Screening infants for hearing impairment. Vohr BR, et al. **J Pediatr** 1996 May;128(5 Pt 1):710-4 (46 ref.)
Hearing loss. Weissman JL. **Radiology** 1996 Jun; 199(3):593-611 (82 ref.)

ETIOLOGY

Recent changes in the etiology of hearing disorders: perinatal drug exposure. Gerber SE, et al. **J Am Acad Audiol** 1995 Sep;6(5):371-7 (50 ref.)
Factors causing hearing impairment: some perspectives from Europe. Parving A. **J Am Acad Audiol** 1995 Sep; 6(5):387-95 (70 ref.)
Head trauma: hearing loss and dizziness. Fitzgerald DC. **J Trauma** 1996 Mar;40(3):488-96 (83 ref.)
Combined effects of noise and chemicals. Fechter LD. **Occup Med** 1995 Jul-Aug;10(3):609-21 (51 ref.)
[Hearing loss following bacterial meningitis] Hefer T, et al. **Harefuah** 1995 Aug;129(3-4):138-42 (38 ref.) **(Heb)**

HEARING LOSS, CONDUCTIVE

COMPLICATIONS

Osteogenesis imperfecta and hearing loss. Verstreken M, et al. **Acta Otorhinolaryngol Belg** 1996;50(2):91–8 (47 ref.)

ETIOLOGY

Long-term hearing results following stapedotomy. Dornhoffer JL, et al. **Am J Otol** 1994 Sep;15(5):674–8 (14 ref.)

Fibrous dysplasia of the temporal bone: ten new cases demonstrating the spectrum of otologic sequelae. Megerian CA, et al. **Am J Otol** 1995 Jul;16(4):408–19 (49 ref.)

Human immunodeficiency virus and acquired immune deficiency syndrome AIDS-related hearing disorders. Madriz JJ, et al. **J Am Acad Audiol** 1995 Sep;6(5):358–64 (48 ref.)

GENETICS

Familial microtia with meatal atresia and conductive deafness in five generations. Gupta A, et al. **Am J Med Genet** 1995 Nov 6;59(2):238–41 (14 ref.)

PHYSIOPATHOLOGY

Preservation of cochlear function after extensive labyrinthine destruction. Ars B, et al. **Am J Otol** 1996 Jan;17(1):40–5 (49 ref.)

SURGERY

Tympanic membrane wound healing. An overview. Gladstone HB, et al. **Otolaryngol Clin North Am** 1995 Oct; 28(5):913–32 (111 ref.)

Treacher-Collins syndrome. Management of major and minor anomalies of the ear. Marres HA, et al. **Rev Laryngol Otol Rhinol (Bord)** 1995;116(2):105–8 (24 ref.)

HEARING LOSS, EXTREME see **DEAFNESS**

HEARING LOSS, FUNCTIONAL

Effects of industrial solvents on hearing. Johnson AC, et al. **Occup Med** 1995 Jul–Aug;10(3):623–40 (87 ref.)

DIAGNOSIS

Two new otolaryngologic findings in child abuse. Drake AF, et al. **Arch Otolaryngol Head Neck Surg** 1995 Dec; 121(12):1417–20 (11 ref.)

HEARING LOSS, NOISE-INDUCED

Potential risk of hearing damage associated with exposure to highly amplified music. Hétu R, et al. **J Am Acad Audiol** 1995 Sep;6(5):378–86 (43 ref.)

Biologic bases of noise-induced hearing loss. Henderson D, et al. **Occup Med** 1995 Jul–Aug;10(3):513–34 (27 ref.)

Impact of occupational hearing loss on the lives of workers. Hétu R, et al. **Occup Med** 1995 Jul–Aug;10(3):495–512 (55 ref.)

Effects of industrial solvents on hearing. Johnson AC, et al. **Occup Med** 1995 Jul–Aug;10(3):623–40 (87 ref.)

Noise, impulse noise, and other physical factors: combined effects on hearing. Pekkarinen J. **Occup Med** 1995 Jul–Aug; 10(3):545–59 (152 ref.)

Presbycusis and occupational hearing loss. Rosenhall U, et al. **Occup Med** 1995 Jul–Aug;10(3):593–607 (73 ref.)

ECONOMICS

Economic compensation for hearing loss. Dobie RA. **Occup Med** 1995 Jul–Aug;10(3):663–8 (22 ref.)

EPIDEMIOLOGY

Epidemiologic considerations in the evaluation of occupational hearing loss. Morata TC, et al. **Occup Med** 1995 Jul–Aug;10(3):641–56 (67 ref.)

ETIOLOGY

Noise induced hearing loss in military helicopter aircrew—a review of the evidence. Owen JP. **J R Army Med Corps** 1995 Jun;141(2):98–101 (19 ref.)

Endogenous factors related to susceptibility to damage from noise. Ward WD. **Occup Med** 1995 Jul–Aug;10(3):561–75 (138 ref.)

PHYSIOPATHOLOGY

Use of animal models in the study of the effects of noise on hearing. Dancer AL. **Occup Med** 1995 Jul–Aug; 10(3):535–44 (28 ref.)

PREVENTION & CONTROL

Hearing conservation programs for nonserved occupations and populations. Axelsson A, et al. **Occup Med** 1995 Jul–Aug;10(3):657–62 (11 ref.)

Historical assessment and future directions in the prevention of occupational hearing loss. Merry CJ, et al. **Occup Med** 1995 Jul–Aug;10(3):669–81 (39 ref.)

HEARING LOSS, NONORGANIC see **HEARING LOSS, FUNCTIONAL**

HEARING LOSS, PARTIAL

Vestibular schwannoma and the only hearing ear. Bhatia S, et al. **J Laryngol Otol** 1996 Apr;110(4):366–9 (18 ref.)

DIAGNOSIS

Hearing loss. A plan for individualized management. Ruckenstein MJ. **Postgrad Med** 1995 Oct;98(4):197–200, 203, 206 passim (1 ref.)

ETIOLOGY

Preservation of auditory and vestibular function after surgical removal of bilateral vestibular schwannomas in a patient with neurofibromatosis type 2. Black FO, et al. **Am J Otol** 1995 Jul;16(4):431–43 (51 ref.)

Hearing loss and leukocytosis. Lossos IS, et al. **Postgrad Med J** 1996 Mar;72(845):183–5 (7 ref.)

THERAPY

Hearing loss. A plan for individualized management. Ruckenstein MJ. **Postgrad Med** 1995 Oct;98(4):197–200, 203, 206 passim (1 ref.)

HEARING LOSS, SENSORINEURAL

Sudden sensorineural hearing loss: an otologic emergency. Gulya AJ. **Compr Ther** 1996 Apr;22(4):217–21 (14 ref.)

Effects of noise and age on the auditory system. Boettcher FA, et al. **Occup Med** 1995 Jul–Aug;10(3):577–91 (41 ref.)

CHEMICALLY INDUCED

Experimental evidence of ototoxicity of ear drops. A review of the literature. Kuhweide R. **Acta Otorhinolaryngol Belg** 1995;49(3):293–8 (28 ref.)

Carbohydrate tolerance in patients with tropical ataxic neuropathy—A human model of chronic cyanide intoxication. Famuyiwa OO, et al. **Afr J Med Med Sci** 1995 Jun;24(2):151–7 (28 ref.)

Ototoxicity of ear drops: a clinical perspective. Linder TE, et al. **Am J Otol** 1995 Sep;16(5):653–7 (23 ref.)

COMPLICATIONS

Hearing impairment in Engelmann disease. Higashi K, et al. **Am J Otol** 1996 Jan;17(1):26–9 (23 ref.)

Cogan's syndrome: ophthalmic, audiovestibular, and systemic manifestations and therapy. Chynn EW, et al. **Int Ophthalmol Clin** 1996 Winter;36(1):61–72 (46 ref.)

DIAGNOSIS

Neurotology. Baloh RW, et al. **Neurol Clin** 1996 Feb; 14(1):85–101 (22 ref.)

ETIOLOGY

The etiology of idiopathic sudden sensorineural hearing loss. A review of the literature. Stokroos RJ, et al. **Acta Otorhinolaryngol Belg** 1996;50(1):69–76 (51 ref.)

Fibrous dysplasia of the temporal bone: ten new cases demonstrating the spectrum of otologic sequelae. Megerian CA, et al. **Am J Otol** 1995 Jul;16(4):408–19 (49 ref.)

Audiovestibular complications of non-otological surgery. Mahoney CF, et al. **Clin Otolaryngol** 1995 Dec;20(6):510–6 (53 ref.)

Human immunodeficiency virus and acquired immune deficiency syndrome AIDS-related hearing disorders. Madriz JJ, et al. **J Am Acad Audiol** 1995 Sep;6(5):358–64 (48 ref.)

[Two cases of sensory neural hearing loss as a manifestation of HIV infection] Ohashi S, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1995 Sep;98(9):1399–406 (25 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

Perceptual consequences of cochlear hearing loss and their implications for the design of hearing aids. Moore BC. **Ear Hear** 1996 Apr;17(2):133–61 (200 ref.)

REHABILITATION

Perceptual consequences of cochlear hearing loss and their implications for the design of hearing aids. Moore BC. **Ear Hear** 1996 Apr;17(2):133–61 (200 ref.)

[Sensible utilization of modern hearing aid technique. II: Multiple channel compression] Steffens T. **HNO** 1996 May; 44(5):273–85 (24 ref.) **(Ger)**

THERAPY

Therapy of idiopathic sudden sensorineural hearing loss. A review of the literature. Stokroos RJ, et al. **Acta Otorhinolaryngol Belg** 1996;50(1):77–84 (34 ref.)

HEARING PROTECTIVE DEVICES see **EAR PROTECTIVE DEVICES**

HEARING TESTS

METHODS

Monitoring chemotherapy-induced hearing loss in children. Bellman SC. **Eur J Cancer** 1996 Jun;32A(7):1185–8 (25 ref.)

HEART

see related
ANTI-ARRHYTHMIA AGENTS
CARDIOTONIC AGENTS
ELECTROCARDIOGRAPHY
MYOCARDIUM

Optimal myocardial preservation: cooling, cardioplegia, and conditioning. Cleveland JC Jr, et al. **Ann Thorac Surg** 1996 Feb;61(2):760–8 (75 ref.)

Evaluation of cardiac 31P magnetic resonance spectroscopy: reviewing NMR principles. Hoffenberg EF, et al. **J Surg Res** 1996 Apr;62(1):135–43 (38 ref.)

[New frontiers in myocardial preservation] Juffe Stein A. **Rev Esp Cardiol** 1995;48 Suppl 7:24–8 (29 ref.) (Eng. Abstr.) **(Spa)**

ANATOMY & HISTOLOGY

Left and right ventricular volumes determined by magnetic resonance imaging. Møgelvang J. **Dan Med Bull** 1996 Apr; 43(2):156–72 (168 ref.)

Ultrasonography characterization of heart morphology and blood flow of lower vertebrates. Coucelo J, et al. **J Exp Zool** 1996 Jun 1–15;275(2–3):73–82 (19 ref.)

MRI of myocardial function: motion tracking techniques. McVeigh ER. **Magn Reson Imaging** 1996;14(2):137–50 (65 ref.)

Quantitative MR imaging of the heart. Peshock RM, et al. **Magn Reson Imaging Clin N Am** 1996 May;4(2):287–305 (130 ref.)

Very fast cardiac imaging. Schwitter J, et al. **Magn Reson Imaging Clin N Am** 1996 May;4(2):419–32 (56 ref.)

Registration of multi-modal biomedical images of the heart. Gilardi MC, et al. **Q J Nucl Med** 1996 Mar;40(1):142–50 (43 ref.)

[The current problems of cardiac morphology] Sokolov VV. **Morfologiia** 1994 Jul–Dec;107(7–12):163–73 (141 ref.) **(Rus)**

DRUG EFFECTS

Cardiac electrophysiology, arrhythmogenic mechanisms and roentgen contrast media. Jacobsen EA, et al. **Acta Radiol Suppl** 1995;399:105–14 (60 ref.)

Sodium-calcium relationships and cardiac function during coronary bolus perfusion. Jynge P, et al. **Acta Radiol Suppl** 1995;399:122–34 (74 ref.)

Tamoxifen as an antioxidant and cardioprotectant. Wiseman H. **Biochem Soc Symp** 1995;61:209–19 (65 ref.)

Role of bradykinin in the antihypertensive and cardioprotective actions of converting enzyme inhibitors. Zhu YC, et al. **Can J Physiol Pharmacol** 1995 Jul; 73(7):827–31 (39 ref.)

Novel delivery of antiarrhythmic agents. Labhasetwar V, et al. **Clin Pharmacokinet** 1995 Jul;29(1):1–5 (24 ref.)

Cardiotoxicity and cardioprotection during chemotherapy. Hochster H, et al. **Curr Opin Oncol** 1995 Jul;7(4):304–9 (37 ref.)

Cardiotoxic drugs. Derlet RW, et al. **Emerg Med Clin North Am** 1995 Nov;13(4):771–91 (93 ref.)

Cardiac adrenergic receptor effects of carvedilol. Yoshikawa T, et al. **Eur Heart J** 1996 Apr;17 Suppl B:8–16 (37 ref.)

Effects of ACE inhibition on the heart. Gavras I, et al. **J Hum Hypertens** 1995 Jun;9(6):455–8 (61 ref.)

Prevention of cardiac sudden death by N-3 fatty acids: a review of the evidence. Leaf A, et al. **J Intern Med** 1996 Jul;240(1):5–12 (32 ref.)

Possibilities for the pharmacological exploitation of ischaemic preconditioning. Parratt JR. **J Mol Cell Cardiol** 1995 Apr; 27(4):991–1000 (81 ref.)

Does acetaminophen damage the heart? [see comments] Lip GY, et al. **J Toxicol Clin Toxicol** 1996;34(2):145–7 (23 ref.) Comment in: J Toxicol Clin Toxicol 1996;34(2):149–53. Comment in: J Toxicol Clin Toxicol 1996;34(2):155–6.

Angiopeptin: experimental and clinical studies of inhibition of myointimal proliferation. Foegh ML, et al. **Kidney Int Suppl** 1995 Dec;52:S18–22 (47 ref.)

Structural and biochemical remodelling in catecholamine-induced cardiomyopathy: comparative and ontogenetic aspects. Oštádal B, et al. **Mol Cell Biochem** 1995 Jun 7–21;147(1–2):83–8 (49 ref.)

Cytoprotective agents for anthracyclines. Dorr RT. **Semin Oncol** 1996 Aug;23(4 Suppl 8):23–34 (122 ref.)

[Cardiotoxicity and cardioprotection in chemo- and radiotherapy for malignant diseases (editorial)] Wagdi P, et al. **Schweiz Rundsch Med Prax** 1995 Oct 24;84(43):1216–9 (46 ref.) **(Ger)**

[Late effects of organophosphate poisoning on the heart] Lev E, et al. **Harefuah** 1995 Dec 1;129(11):507–11 (40 ref.) **(Heb)**

[Main cardiotoxic drugs] Pettirossi G, et al. **Clin Ter** 1996 Jan–Feb;147(1–2):67–77 (34 ref.) (Eng. Abstr.) **(Ita)**

HEART

EMBRYOLOGY

Regulation of ribosomal DNA transcription during neonatal cardiomyocyte hypertrophy. Hannan RD, et al. **Cardiovasc Res** 1995 Oct;30(4):501–10 (135 ref.)

Regulation of intracellular calcium concentration in the developing heart. Mahony L. **Cardiovasc Res** 1996 Feb;31 Spec No:E61–7 (83 ref.)

Contractile protein phenotypic variation during development. Murphy AM. **Cardiovasc Res** 1996 Feb;31 Spec No:E25–33 (106 ref.)

Regulation of cardiac gene expression during development. Robbins J. **Cardiovasc Res** 1996 Feb;31 Spec No:E2–16 (168 ref.)

Developmental cardiac electrophysiology recent advances in cellular physiology. Wetzel GT, et al. **Cardiovasc Res** 1996 Feb;31 Spec No:E52–60 (76 ref.)

Visual understanding of cardiac development: the neural crest's contribution. Leatherbury L, et al. **Cell Mol Biol Res** 1995;41(4):279–91 (27 ref.)

The cardiac mutant gene c in axolotls: cellular, developmental, and molecular studies. Lemanski LF, et al. **Cell Mol Biol Res** 1995;41(4):293–305 (28 ref.)

Mouse mutants and cardiac development: new molecular insights into cardiogenesis. Rossant J. **Circ Res** 1996 Mar; 78(3):349–53 (60 ref.)

The extracellular matrix during heart development. Little CD, et al. **Experientia** 1995 Sep 29;51(9–10):873–82 (133 ref.)

Developmental biology of the vertebrate heart. Icardo JM. **J Exp Zool** 1996 Jun 1–15;275(2–3):144–61 (175 ref.)

Fibronectin expression during physiological and pathological cardiac growth. Farhadian F, et al. **J Mol Cell Cardiol** 1995 Apr;27(4):981–90 (57 ref.)

Molecular pathways controlling heart development. Olson EN, et al. **Science** 1996 May 3;272(5262):671–6 (57 ref.)

GROWTH & DEVELOPMENT

Developmental regulation of cation pumps in skeletal and cardiac muscle. Dauncey MJ, et al. **Acta Physiol Scand** 1996 Mar;156(3):313–23 (75 ref.)

Autonomic receptor—effector coupling during post-natal development. Robinson RB. **Cardiovasc Res** 1996 Feb;31 Spec No:E68–76 (68 ref.)

Postnatal growth of the heart and its blood vessels. Hudlicka O, et al. **J Vasc Res** 1996 Jul–Aug;33(4):266–87 (265 ref.)

Ultrastructural and functional features of the developing mammalian heart: a brief overview. Smolich JJ. **Reprod Fertil Dev** 1995;7(3):451–61 (73 ref.)

INNERVATION

Lesions of mediastinal paraganglia in chronic chagasic cardiomyopathy: cause of sudden death? [editorial] Ramos SG, et al. **Am Heart J** 1996 Feb;131(2):417–20 (32 ref.)

Role of peripheral autonomic neurones in maintaining adequate cardiac function. Horackova M, et al. **Cardiovasc Res** 1995 Sep;30(3):326–35 (88 ref.)

The hibernator heart—nature's model of resistance to ventricular fibrillation. Johansson BW. **Cardiovasc Res** 1996 May;31(5):826–32 (39 ref.)

The autonomic nervous system and the regulation of arterial tone in migraine. Thomsen LL, et al. **Clin Auton Res** 1995 Oct;5(5):243–50 (111 ref.)

Myocardial imaging of sympathetic nervous function by radiolabelled metaiodobenzylguanidine [editorial; comment] Nakagawa M. **Intern Med** 1996 Feb;35(2):85–6 (7 ref.) Comment on: Intern Med 1996 Feb;35(2):94–9.

In vivo assessment of neurotransmitter system in cardiovascular diseases. Clinical issues. Merlet P, et al. **Q J Nucl Med** 1996 Mar;40(1):108–20 (108 ref.)

[Nervous mechanisms and ischemic cardiopathy (editorial)] Malliani A. **Cardiologia** 1996 Jan;41(1):9–17 (54 ref.) **(Ita)**

[Acute Chagas cardiopathy. A systematic study of the intracardiac excitatory-conduction and autonomic nervous systems in an autochthonous case in Acre] Rocha A, et al. **Rev Soc Bras Med Trop** 1996 Jul–Aug;29(4):367–71 (12 ref.) (Eng. Abstr.) **(Por)**

PHYSIOLOGY

Na+, K(+)-ATPase and heart excitability. Lichtstein D. **Adv Exp Med Biol** 1995;382:23–30 (51 ref.)

Mechanisms of endocardial endothelium modulation of myocardial performance. Mohan P, et al. **Adv Exp Med Biol** 1995;382:249–60 (57 ref.)

Role of the cardiac renin-angiotensin system in human heart failure. Paul M, et al. **Adv Exp Med Biol** 1995;377:279–83 (17 ref.)

Mechanoperception and mechanotransduction in cardiac adaptation: mechanical and molecular aspects. Reneman RS, et al. **Adv Exp Med Biol** 1995;382:185–94 (37 ref.)

Chymase-dependent angiotensin II forming systems in humans. Urata H, et al. **Am J Hypertens** 1996 Mar; 9(3):277–84 (63 ref.)

The roles of the sodium and calcium current in triggering calcium release from the sarcoplasmic reticulum. Cannell MB, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:443–50 (21 ref.)

Action potential duration modulates calcium influx, Na(+)-Ca2+ exchange, and intracellular calcium release in rat ventricular myocytes. Clark RB, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:417–29 (51 ref.)

Mechanism of XIP in cardiac sarcolemmal vesicles. Hale CC. **Ann N Y Acad Sci** 1996 Apr 15;779:171–81 (7 ref.)

The molecular biology of the Na(+)-Ca2+ exchanger and its functional roles in heart, smooth muscle cells, neurons, glia, lymphocytes, and nonexcitable cells. Lederer WJ, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:7–17 (60 ref.)

Cardiac surgical implications of calcium dyshomeostasis in the heart. Meldrum DR, et al. **Ann Thorac Surg** 1996 Apr; 61(4):1273–80 (61 ref.)

Myocardial potassium channels: electrophysiological and molecular diversity. Barry DM, et al. **Annu Rev Physiol** 1996;58:363–94 (211 ref.)

Signal transduction in the cardiac k-receptor. Wong TM, et al. **Biol Signals** 1995 May–Jun;4(3):174–8 (18 ref.)

Molecular signalling mechanisms controlling growth and function of cardiac fibroblasts. Booz GW, et al. **Cardiovasc Res** 1995 Oct;30(4):537–43 (57 ref.)

Cell cycle control mechanisms and their role in cardiac growth. McGill CJ, et al. **Cardiovasc Res** 1995 Oct; 30(4):557–69 (182 ref.)

Paracrine modulation of heart cell function by endothelial cells. Shah AM. **Cardiovasc Res** 1996 Jun;31(6):847–67 (224 ref.)

Mechano-electric feedback in the human heart. Taggart P. **Cardiovasc Res** 1996 Jul;32(1):38–43 (41 ref.)

Nitric oxide and cardiac function. Kelly RA, et al. **Circ Res** 1996 Sep;79(3):363–80 (232 ref.)

Inward rectification and implications for cardiac excitability. Nichols CG, et al. **Circ Res** 1996 Jan;78(1):1–7 (52 ref.)

The mathematical basis for imaging cardia electrical function. Greensite F. **Crit Rev Biomed Eng** 1994;22(5–6):347–99 (81 ref.)

Hormonal regulation of cardiac fibroblast function. Brilla CG, et al. **Eur Heart J** 1995 May;16 Suppl C:45–50 (42 ref.)

Determination of impulse conduction characteristics at a microscopic scale in patterned growth heart cell cultures using multiple site optical recording of transmembrane voltage. Rohr S. **J Cardiovasc Electrophysiol** 1995 Jul; 6(7):551–68 (84 ref.)

Are intracardiac electrophysiological studies in healthy volunteers ethical? Time for multinational recommendations [editorial; comment] Funck-Brentano C. **J Cardiovasc Pharmacol** 1995 Oct;26(4):524–7 (18 ref.) Comment on: J Cardiovasc Pharmacol 1995 Oct;26(4):528–9. Comment on: J Cardiovasc Pharmacol 1995 Oct;26(4):530–40.

The third beta is not the charm. [editorial; comment] Bond RA, et al. **J Clin Invest** 1996 Jul 15;98(2):241 (8 ref.) Comment on: J Clin Invest 1996 Jul 15;98(2):556–62.

Repolarization gradients derived by subtraction of monophasic action potential recordings in the human heart. Studies incorporating altered mechanical loading and ischemia. Taggart P, et al. **J Electrocardiol** 1995;28 Suppl:156–61 (25 ref.)

Crossbridge dynamics under various inotropic states in cardiac muscle: evaluation by perturbation analyses. Saeki Y. **Jpn J Physiol** 1995;45(5):687–705 (101 ref.)

Spatial organization of cardiac gap junctions can affect access resistance. Hall JE, et al. **Microsc Res Tech** 1995 Aug 1; 31(5):446–51 (30 ref.)

Polyunsaturated fatty acids and signalling via phospholipase C-beta and A2 in myocardium. de Jonge HW, et al. **Mol Cell Biochem** 1996 Apr 12–26;157(1–2):199–210 (79 ref.)

Angiotensin II signalling pathways in cardiac fibroblasts: conventional versus novel mechanisms in mediating cardiac growth and function. Dostal DE, et al. **Mol Cell Biochem** 1996 Apr 12–26;157(1–2):15–21 (66 ref.)

Regulation and functional significance of phospholipase D in myocardium. Eskildsen-Helmond YE, et al. **Mol Cell Biochem** 1996 Apr 12–26;157(1–2):39–48 (72 ref.)

Regulation of G protein function: implications for heart disease. Meij JT. **Mol Cell Biochem** 1996 Apr 12–26; 157(1–2):31–8 (43 ref.)

Mitogen-activated protein kinase (MAPK) in cardiac tissues. Page C, et al. **Mol Cell Biochem** 1996 Apr 12–26; 157(1–2):49–57 (39 ref.)

Signalling by protein kinase C isoforms in the heart. Pucéat M, et al. **Mol Cell Biochem** 1996 Apr 12–26;157(1–2):65–72 (72 ref.)

Phosphoinositide-generated messengers in cardiac signal transduction. van Heugten HA, et al. **Mol Cell Biochem** 1996 Apr 12–26;157(1–2):5–14 (88 ref.)

Cardiac performance: growth hormone enters the race. Saccà L, et al. **Nat Med** 1996 Jan;2(1):29–31 (16 ref.)

Basic concepts in cellular cardiac electrophysiology: Part II: Block of ion channels by antiarrhythmic drugs. Whalley DW, et al. **Pacing Clin Electrophysiol** 1995 Sep;18(9 Pt 1):1686–704 (119 ref.)

Basic concepts in cellular cardiac electrophysiology: Part I: Ion channels, membrane currents, and the action potential. Whalley DW, et al. **Pacing Clin Electrophysiol** 1995 Aug; 18(8):1556–74 (72 ref.)

Role of nitric oxide in the regulation of myocardial function. Hare JM, et al. **Prog Cardiovasc Dis** 1995 Sep–Oct; 38(2):155–66 (70 ref.)

Ultrastructural and functional features of the developing mammalian heart: a brief overview. Smolich JJ. **Reprod Fertil Dev** 1995;7(3):451–61 (73 ref.)

[Growth hormone—a pathogenetic factor in chronic congestive heart insufficiency?] Dreifuss PM. **Dtsch Med Wochenschr** 1996 Apr 12;121(15):492–6 (35 ref.) **(Ger)**

[Hypertrophic responses to mechanical stretch in cardiac myocytes] Yamazaki T, et al. **Tanpakushitsu Kakusan Koso** 1996 Jan;41(1):14–8 (8 ref.) **(Jpn)**

[Tissue Doppler echocardiography: a new stage in the study of myocardial function (see comments)] Cardim N, et al. **Rev Port Cardiol** 1995 Sep;14(9):609–18 (57 ref.) (Eng. Abstr.) Comment in: Rev Port Cardiol 1995 Sep;14(9):595. **(Por)**

[Polyploidy in the myocardium. Compensatory reserve of the heart] Brodskiĭ VIa. **Biull Eksp Biol Med** 1995 May; 119(5):454–9 (49 ref.) **(Rus)**

PHYSIOPATHOLOGY

Cardiac coherence: a new, noninvasive measure of autonomic nervous system order. Tiller WA, et al. **Altern Ther Health Med** 1996 Jan;2(1):52–65 (65 ref.)

Electrophysiologic characteristics of human atrial muscle in paroxysmal atrial fibrillation. Hashiba K, et al. **Am Heart J** 1996 Apr;131(4):778–89 (77 ref.)

Arterial and cardiac changes in hypertension in the elderly. Asmar R, et al. **Blood Press** 1995;Suppl 3:31–7 (48 ref.)

On the mechanism and possible therapeutic application of delayed cardiac adaptation to stress. Szekeres L. **Can J Cardiol** 1996 Feb;12(2):177–85 (49 ref.)

The autonomic nervous system and the regulation of arterial tone in migraine. Thomsen LL, et al. **Clin Auton Res** 1995 Oct;5(5):243–50 (111 ref.)

New strategies for intraoperative myocardial protection. Flameng W. **Curr Opin Cardiol** 1995 Nov;10(6):577–83 (37 ref.)

The inflammatory response to cardiopulmonary bypass and its impact on postoperative myocardial function. Menasché P. **Curr Opin Cardiol** 1995 Nov;10(6):597–604 (59 ref.)

Biological adaptation of the myocardium to chronic mechanical overload. Molecular determinants of the autonomic nervous system. Mondry A, et al. **Eur Heart J** 1995 Aug;16 Suppl I:64–73 (96 ref.)

Hypertensive heart disease: cardioreparation by reversal of interstitial collagen in patients. Motz W, et al. **Eur Heart J** 1995 May;16 Suppl C:69–73 (45 ref.)

Genes and physiology: molecular physiology in genetically engineered animals. Chien KR. **J Clin Invest** 1996 Feb 15; 97(4):901–9 (66 ref.)

Age-related changes before and after imposition of hemodynamic stress in the mammalian heart. Isoyama S. **Life Sci** 1996;58(19):1601–14 (112 ref.)

MR imaging of pulmonary hypertension and right ventricular dysfunction. Boxt LM. **Magn Reson Imaging Clin N Am** 1996 May;4(2):307–25 (94 ref.)

Regulation of expression of cardiac sarcoplasmic reticulum proteins under pathophysiological conditions. Dillmann WH. **Mol Cell Biochem** 1996 Apr 12–26;157(1–2):125–8 (14 ref.)

Impedance to defibrillation countershock: does an optimal impedance exist? KenKnight BH, et al. **Pacing Clin Electrophysiol** 1995 Nov;18(11):2068–87 (141 ref.)

Delayed protection of the heart against ischaemia. Parratt JR, et al. **Trends Pharmacol Sci** 1995 Oct;16(10):351–5 (52 ref.)

[Diastolic dysfunction of the heart. A frequently overlooked cause of chronic heart failure] Sitzler G, et al. **Dtsch Med Wochenschr** 1996 Jan 19;121(3):70–6 (46 ref.) **(Ger)**

[The physiopathology of the left atrial appendage. The contribution of transesophageal echocardiography] Mele D. **Cardiologia** 1996 Jun;41(6):515–26 (62 ref.) **(Ita)**

[Diagnostic methods and the prognosis of the heart-hypertension interaction: cardiac echo-Doppler] Sánchez Domínguez J. **Rev Esp Cardiol** 1995;48 Suppl 4:49–56 (32 ref.) (Eng. Abstr.) **(Spa)**

[Cerebrovascular complications in patients with cancer] Casado JL, et al. **Rev Neurol** 1995;23 Suppl 1:S70–8 (75 ref.) **(Spa)**

[Non-valvular atrial fibrillation and cerebral infarction] Martín R. **Rev Neurol** 1995 Mar–Apr;23(120):370–6 (81 ref.) (Eng. Abstr.) **(Spa)**

[Cardiogenic cerebral embolism] Rubio F, et al. **Rev Neurol** 1995;23 Suppl 1:S53–60 (98 ref.) **(Spa)**

RADIATION EFFECTS

[Cardiotoxicity and cardioprotection in chemo- and radiotherapy for malignant diseases (editorial)] Wagdi P, et al. **Schweiz Rundsch Med Prax** 1995 Oct 24;84(43):1216–9 (46 ref.) **(Ger)**

RADIONUCLIDE IMAGING

The role of scintigraphic perfusion imaging for predicting ischemic cardiac events in noncardiac surgery. Gojer B, et al. **Am J Card Imaging** 1995 Jul;9(3):213–25 (78 ref.)

Gender-related imaging issues in assessment of coronary artery disease by nuclear techniques. Grover-McKay M. **Am J Card Imaging** 1996 Jan;10(1):54–64 (67 ref.)

What is the current status of quantification and nuclear medicine in cardiology? Hör G. **Eur J Nucl Med** 1996 Jul; 23(7):815–51 (483 ref.)

Myocardial imaging of sympathetic nervous function by radiolabelled metaiodobenzylguanidine [editorial; comment] Nakagawa M. **Intern Med** 1996 Feb;35(2):85–6 (7 ref.) Comment on: Intern Med 1996 Feb;35(2):94–9.
Attenuation compensation for cardiac single-photon emission computed tomographic imaging: Part 2. Attenuation compensation algorithms. King MA, et al. **J Nucl Cardiol** 1996 Jan–Feb;3(1):55–64 (66 ref.)
Cardiac studies with metaiodobenzylguanidine: a critique of methods and interpretation of results. Glowniak JV. **J Nucl Med** 1995 Nov;36(11):2133–7 (41 ref.)
Detection of myocardial viability with 99mTc-labelled myocardial perfusion agents. Bisi G, et al. **Q J Nucl Med** 1996 Mar;40(1):68–75 (60 ref.)
Nuclear medicine techniques and magnetic resonance imaging in coronary artery disease. Pauwels E, et al. **Q J Nucl Med** 1996 Mar;40(1):132–41 (63 ref.)
[Continuous ambulatory measurement of left ventricular function by an isotopic method] Millaire A. **Arch Mal Coeur Vaiss** 1995 Oct;88(10):1453–63 (30 ref.) (Eng. Abstr.) **(Fre)**
[Image diagnosis of heart diseases using new radioisotope compounds] Nishimural T. **Nippon Naika Gakkai Zasshi** 1995 Sep 10;84(9):1564–8 (8 ref.) **(Jpn)**
[Diagnostic methods and the prognosis of the heart-hypertension interaction. Isotopes] del Río Ligorit A, et al. **Rev Esp Cardiol** 1995;48 Suppl 4:45–8 (22 ref.) (Eng. Abstr.) **(Spa)**

HEART ABNORMALITIES see **HEART DEFECTS, CONGENITAL**

HEART ANEURYSM

[Aneurysms of the left ventricle without atheromatous coronary artery disease. Apropos of 2 cases] Obadia JF, et al. **Arch Mal Coeur Vaiss** 1996 Jun;89(6):755–9 (10 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

Association between stroke and atrial septal aneurysm assessed by transesophageal echocardiography in a cardiologic population. Ossemann M, et al. **Acta Neurol Belg** 1995;95(3):170–7 (49 ref.)

DIAGNOSIS

[Supraventricular cardiac arrhythmia and fenestrated aneurysm of the interatrial septum in a newborn infant] Armengol Rofes AJ, et al. **An Esp Pediatr** 1996 Jan; 44(1):63–4 (7 ref.) **(Spa)**

ETIOLOGY

Traumatic fistula between the left anterior descending coronary artery and a left ventricular pseudoaneurysm. Haapanen YT, et al. **Cardiovasc Intervent Radiol** 1996 Jul–Aug;19(4):272–4 (11 ref.)
Postinfarction ventricular aneurysms. Friedman BM, et al. **Clin Cardiol** 1995 Sep;18(9):505–11 (80 ref.)
[Mitral subvalvular aneurysm of probable chagasic etiology] García Hernández N, et al. **Arch Inst Cardiol Mex** 1995 May–Jun;65(3):265–9 (20 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

[Correlation between the persistence of ST elevation and left ventricular aneurysm in the post-infarction period] Hamani A, et al. **Ann Cardiol Angeiol (Paris)** 1995 Sep;44(7):361–4 (22 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Surgical management of left ventricular aneurysms. Mickleborough LL. **Semin Thorac Cardiovasc Surg** 1995 Oct;7(4):233–9 (63 ref.)
[Surgical treatment of aneurysms of the left ventricle. Immediate and long-term results. Apropos of a consecutive series of 121 cases] Valla J, et al. **Ann Chir** 1995; 49(9):816–23 (52 ref.) (Eng. Abstr.) **(Fre)**
[Auricular flutter associated with an interatrial septal aneurysm submitted to radiofrequency ablation] Araya Gómez V, et al. **Arch Inst Cardiol Mex** 1995 May–Jun; 65(3):245–54 (17 ref.) (Eng. Abstr.) **(Spa)**

ULTRASONOGRAPHY

[Atrial septal aneurysm. Report of two clinical cases and review of the literature] Perrotta S, et al. **Minerva Cardioangiol** 1995 Jul–Aug;43(7–8):339–43 (23 ref.) (Eng. Abstr.) **(Ita)**

HEART ARREST

see related
RESUSCITATION

CHEMICALLY INDUCED

Cardiac arrest in cocaine users. Karch SB. **Am J Emerg Med** 1996 Jan;14(1):79–81 (30 ref.)
Use of suxamethonium in children [editorial] [see comments] Hopkins PM. **Br J Anaesth** 1995 Dec;75(6):675–7 (23 ref.) Comment in: Br J Anaesth 1996 Jun;76(6):883; discussion 884. Comment in: Br J Anaesth 1996 Jun;76(6):883–4; discussion 884.
[Heart arrest in children after intravenous injection of succinylcholine in the ENT operating room (see comments)] Schulte-Sasse U. **HNO** 1995 Nov;43(11):676–9 (29 ref.) (Eng. Abstr.) Comment in: Hosp Formul 1995 Nov;43(11):640–1. **(Ger)**

COMPLICATIONS

The mystery of bradyasystole during cardiac arrest. Ornato JP, et al. **Ann Emerg Med** 1996 May;27(5):576–87 (233 ref.)
Global brain ischemia and reperfusion. White BC, et al. **Ann Emerg Med** 1996 May;27(5):588–94 (48 ref.)
Cerebral resuscitation from cardiac arrest: treatment potentials. Gisvold SE, et al. **Crit Care Med** 1996 Feb;24(2 Suppl):S69–80 (79 ref.)
Cerebral resuscitation from cardiac arrest: pathophysiologic mechanisms. Vaagenes P, et al. **Crit Care Med** 1996 Feb; 24(2 Suppl):S57–68 (103 ref.)
Possibilities of brain protection with tirilazad after cardiac arrest. Sterz F, et al. **Semin Thromb Hemost** 1996; 22(1):105–12 (37 ref.)

ETIOLOGY

The mystery of bradyasystole during cardiac arrest. Ornato JP, et al. **Ann Emerg Med** 1996 May;27(5):576–87 (233 ref.)
[What are the complications likely to lead to medicolegal problems? How to manage them?] Samii K, et al. **Cah Anesthesiol** 1995;43(6):521–4 (20 ref.) **(Fre)**

PHYSIOPATHOLOGY

Newer methods of improving blood flow during CPR. Halperin HR, et al. **Ann Emerg Med** 1996 May;27(5):553–62 (69 ref.)
Kidney transplantation from asystolic donors. Nicholson M. **Br J Hosp Med** 1996 Jan 17–Feb 6;55(1–2):51–6 (19 ref.)
[Cerebral resuscitation: pathophysiological limitations and therapeutic possibilities (editorial)] Strebel S. **Schweiz Rundsch Med Prax** 1996 Jan 16;85(3):35–8 (33 ref.) **(Ger)**

PSYCHOLOGY

Impact of aborted sudden cardiac death on survivors and their spouses: the phenomenon of different reference points. Doolittle ND, et al. **Am J Crit Care** 1995 Sep;4(5):389–96 (24 ref.)

REHABILITATION

Impact of aborted sudden cardiac death on survivors and their spouses: the phenomenon of different reference points. Doolittle ND, et al. **Am J Crit Care** 1995 Sep;4(5):389–96 (24 ref.)

THERAPY

Out-of-hospital cardiac arrests: an 8-year New York City experience. Westal RE, et al. **Am J Emerg Med** 1996 Jul; 14(4):364–8 (60 ref.)
Newer methods of improving blood flow during CPR. Halperin HR, et al. **Ann Emerg Med** 1996 May;27(5):553–62 (69 ref.)
Reassessing the need for ventilation during CPR. Idris AH. **Ann Emerg Med** 1996 May;27(5):569–75 (52 ref.)
Aortic-based therapy for cardiac arrest. Paradis NA. **Ann Emerg Med** 1996 May;27(5):563–8 (42 ref.)
The revolution and evolution of prehospital cardiac care. Eisenberg MS, et al. **Arch Intern Med** 1996 Aug 12–26; 156(15):1611–9 (43 ref.)
Advanced cardiac life support: update on recent guidelines and a look at the future. Tucker KJ, et al. **Clin Cardiol** 1995 Sep;18(9):497–504 (64 ref.)
Resuscitative hypothermia. Marion DW, et al. **Crit Care Med** 1996 Feb;24(2 Suppl):S81–9 (75 ref.)
Selective brain cooling after cardiac arrest [editorial; comment] Safar P, et al. **Crit Care Med** 1996 Jun; 24(6):911–4 (47 ref.) Comment on: Crit Care Med 1996 Jun;24(6):1009–17.
Emergency cardiac care. Moral, legal, and ethical considerations. Peskin RM, et al. **Dent Clin North Am** 1995 Jul;39(3):677–88 (35 ref.)
Cardiopulmonary resuscitation. Barton CW, et al. **Emerg Med Clin North Am** 1995 Nov;13(4):811–29 (101 ref.)
Cardiac arrest. DeBehnke DJ, et al. **Emerg Med Clin North Am** 1996 Feb;14(1):57–81 (112 ref.)
Resuscitating the pediatric patient. Wright JL, et al. **Emerg Med Clin North Am** 1996 Feb;14(1):219–31 (36 ref.)
Management of cardiac arrest survivors: drugs or devices. Madan N, et al. **Indian Heart J** 1995 Jul–Aug;47(4):387–93 (38 ref.)
[Consensus 'Basic Resuscitation' from the Nederlandse Reanimatie Raad] van Vliet J. **Ned Tijdschr Geneeskd** 1996 Mar 16;140(11):596–9 (13 ref.) **(Dut)**
[Semi-automatic external defibrillators] Silfvast T. **Duodecim** 1994;110(11):1049–53 (15 ref.) **(Fin)**
[To treat a cardiac arrest or to count ventricular arrhythmias? (editorial)] Toivonen L, et al. **Duodecim** 1994;110(9):857–9 (15 ref.) **(Fin)**
[Resuscitation in multiple trauma] Berger K, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Apr; 31(3):187–90 (23 ref.) (Eng. Abstr.) **(Ger)**
[Resuscitation by active compression and decompression] Dirks B. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Aug; 30(5):309–12 (10 ref.) **(Ger)**
[Significance of initial defibrillation by paramedics] Mauer D, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Aug; 30(5):303–6 (30 ref.) **(Ger)**
[Treatment strategies in mechanical and electrical cardiovascular failure] Oechslin E. **Ther Umsch** 1996 Aug; 53(8):646–57 (21 ref.) (Eng. Abstr.) **(Ger)**

HEART ARREST, INDUCED

see related
CARDIOPLEGIC SOLUTIONS

Physiological and cellular mechanisms of myocardial protection. Krukenkamp IB, et al. **Am J Surg** 1996 Jul; 172(1):79–84 (21 ref.)
The electrophysiology of ischemia and cardioplegia: implications for myocardial protection. Damiano RJ Jr. **J Card Surg** 1995 Jul;10(4 Suppl):445–53 (61 ref.)
Preconditioning and its potential role in myocardial protection during cardiac surgery. Lasley RD, et al. **J Card Surg** 1995 Jul;10(4 Pt 1):349–53 (33 ref.)
The management of temperature during cardiopulmonary bypass: effect on neuropsychological outcome. Nathan HJ, et al. **J Card Surg** 1995 Jul;10(4 Suppl):481–7 (50 ref.)
Cerebral perfusion and hypothermic circulatory arrest. Chanyi S. **J Cardiothorac Vasc Anesth** 1996 Jan;10(1):75–81; quiz 81–2 (47 ref.)
Is aprotinin safe when used in the context of profound hypothermia and circulatory arrest? A literary review [comment] Hornick P, et al. **J Heart Valve Dis** 1995 Nov; 4(6):669–73 (60 ref.) Comment on: J Heart Valve Dis 1995 Nov;4(6):674–7.
Metabolic aspects of hibernating myocardium. Pantely GA, et al. **Z Kardiol** 1995;84 Suppl 4:101–5 (25 ref.)
[Pathophysiology of the "hibernating" myocardium] Schulz R, et al. **Z Kardiol** 1995;84 Suppl 4:91–100 (40 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Hypothermia, circulatory arrest, and the pediatric brain. Jonas RA. **J Cardiothorac Vasc Anesth** 1996 Jan;10(1):66–74 (34 ref.)

METHODS

Circulatory arrest in a reoperation for brachiocephalic arterial occlusive disease. Bastounis EA, et al. **Ann Thorac Surg** 1996 Apr;61(4):1259–61 (7 ref.)
Normothermic techniques during open heart operations. Birdi I, et al. **Ann Thorac Surg** 1996 May;61(5):1573–80 (75 ref.)
The scientific basis for hypocalcemic cardioplegia and reperfusion in cardiac surgery. Chen RH. **Ann Thorac Surg** 1996 Sep;62(3):910–4 (57 ref.)
Suspended animation for delayed resuscitation. Bellamy R, et al. **Crit Care Med** 1996 Feb;24(2 Suppl):S24–47 (137 ref.)
Neurological outcomes and cardiopulmonary temperature: a clinical review. Christakis GT, et al. **J Card Surg** 1995 Jul;10(4 Suppl):475–80 (33 ref.)
[Profound hypothermia and circulatory arrest in cerebral aneurysm surgery] Nagao S. **No Shinkei Geka** 1996 Jun; 24(6):507–15 (70 ref.) **(Jpn)**

HEART, ARTIFICIAL

Marine propellers: the latest topics. Kubo H. **Artif Organs** 1996 Feb;20(2):109–13 (9 ref.)
The artificial heart: device and concept evolution. Donato L, et al. **Technol Health Care** 1996 Apr;4(1):37–41 (9 ref.)
Cardiac devices. Frazier OH. **Transplant Proc** 1996 Aug; 28(4):2039–41 (7 ref.)

HISTORY

From womb to tomb: the Brno TAH story. Dostál M. **Artif Organs** 1995 Jun;19(6):551–6 (25 ref.)

STANDARDS

Constructional and functional characteristics of recent total artificial heart models TNS Brno VII, VIII, and IX. Vašku J, et al. **Artif Organs** 1995 Jun;19(6):535–43 (15 ref.)

HEART-ASSIST DEVICES

Intraoperative transoesophageal echocardiography for implantation of a pulsatile left ventricular assist device. George SJ, et al. **Br J Anaesth** 1995 Dec;75(6):734–7 (9 ref.)
Long term, implantable ventricular assist devices: what are they and who needs them? Oz MC, et al. **Compr Ther** 1995 Jul;21(7):351–4 (10 ref.)
Long-term blood pumping: an overview. McCarthy T, et al. **Perfusion** 1995 May;10(3):143–51 (20 ref.)
[Wearable mechanical ventricular support] Loisance D, et al. **Bull Acad Natl Med** 1996 Feb;180(2):381–94; discussion 394–5 (10 ref.) (Eng. Abstr.) **(Fre)**
[Circulatory assistance in cardiac decompensation: when and how] Gavazzi A, et al. **G Ital Cardiol** 1995 Dec; 25(12):1627–33 (20 ref.) **(Ita)**

HEART-ASSIST DEVICES

STANDARDS

Long-term ventricular wall actuation: can and should it be systematically explored? Melvin DB, et al. **Artif Organs** 1996 Jan;20(1):63–8 (13 ref.)

Biomaterials for rotary blood pumps. van Oeveren W. **Artif Organs** 1995 Jul;19(7):603–7 (25 ref.)

TRENDS

Can we treat dilated cardiomyopathy using a left ventricular assist device? [editorial] Tayama E, et al. **Artif Organs** 1996 Mar;20(3):197–201 (57 ref.)

HEART ATRIUM

[Heart rupture at the right atrial level as the first manifestation of malignant lymphoma] Menotti A, et al. **Cardiologia** 1996 Jan;41(1):65–7 (10 ref.) (Eng. Abstr.) **(Ita)**

[Renal adenocarcinoma with venous tumor extension to the right atrium: diagnostic and therapeutic considerations] Herranz Amo F, et al. **Arch Esp Urol** 1996 Jan–Feb; 49(1):17–25 (61 ref.) (Eng. Abstr.) **(Spa)**

MICROBIOLOGY

Candida albicans septic thrombosis of the right atrium is associated with a central venous catheter. Kentos A, et al. **Clin Infect Dis** 1995 Aug;21(2):440–2 (18 ref.)

PATHOLOGY

Serial changes of left atrial thrombus in mitral stenosis: transesophageal echocardiographic studies in candidates for balloon mitral commissurotomy. Hase M, et al. **Can J Cardiol** 1996 Mar;12(3):278–84 (28 ref.)

PHYSIOPATHOLOGY

Left atrial enlargement in healthy obese: prevalence and relation to left ventricular mass and diastolic function. Sasson Z, et al. **Can J Cardiol** 1996 Mar;12(3):257–63 (39 ref.)

SURGERY

Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation [see comments] Blackshear JL, et al. **Ann Thorac Surg** 1996 Feb;61(2):755–9 (59 ref.) Comment in: Ann Thorac Surg 1996 Feb;61(2):515.

[Mediastinal malignant tumor resection and superior vena cava revascularization. Resection of invasive thymoma with growth into the superior vena cava and right atrium using cardiopulmonary bypass] **Nippon Kyobu Geka Gakkai Zasshi** 1995 May;43(5):717–9 (4 ref.) **(Jpn)**

ULTRASONOGRAPHY

Atrial anatomy and function postcardioversion: insights from transthoracic and transesophageal echocardiography. Manning WJ, et al. **Prog Cardiovasc Dis** 1996 Jul–Aug; 39(1):33–46 (60 ref.)

[Spontaneous intracardiac contrast and embolic risk] Lardoux H, et al. **Arch Mal Coeur Vaiss** 1996 Apr;89(4):451–7 (33 ref.) (Eng. Abstr.) **(Fre)**

HEART AUSCULTATION

ECONOMICS

Cardiac auscultation: a cost–effective diagnostic skill. Shaver JA. **Curr Probl Cardiol** 1995 Jul;20(7):441–530 (183 ref.)

HEART BLOCK

CHEMICALLY INDUCED

Sarcoidosis after interferon therapy for chronic active hepatitis C. Teragawa H, et al. **Intern Med** 1996 Jan; 35(1):19–23 (20 ref.)

COMPLICATIONS

Infants with long–QT syndrome and 2:1 atrioventricular block. Trippel DL, et al. **Am Heart J** 1995 Nov; 130(5):1130–4 (21 ref.)

CONGENITAL

[A complete congenital heart block in twins] Barquero Genovés IM, et al. **An Esp Pediatr** 1996 Feb;44(2):164–6 (37 ref.) **(Spa)**

DIAGNOSIS

[Total atrioventricular block as the primary clinical manifestation of undiagnosed aortic dissection] Lorenzoni R, et al. **G Ital Cardiol** 1995 Aug;25(8):1031–5 (12 ref.) (Eng. Abstr.) **(Ita)**

ETIOLOGY

Complete heart block and severe tricuspid regurgitation after radiotherapy. Case report and review of the literature [see comments] Knight CJ, et al. **Chest** 1995 Dec;108(6):1748–51 (26 ref.) Comment in: Chest 1996 Aug;110(2):580–1.

Atrioventricular block occurring late after heart transplantation: presentation of three cases and literature review. Cataldo R, et al. **Pacing Clin Electrophysiol** 1996 Mar;19(3):325–30 (15 ref.)

Delayed effects of radiofrequency energy: mechanisms and clinical implications. Fenelon G, et al. **Pacing Clin Electrophysiol** 1996 Apr;19(4 Pt 1):484–9 (31 ref.)

The complete heart–block—an extraintestinal manifestation of ulcerative colitis. Maeder HU. **Z Gastroenterol** 1996 Jan; 34(1):27–9 (9 ref.)

[Cardiac sarcoidosis with myopathy and advanced A–V nodal block in a woman with a previous diagnosis of sarcoidosis] Sugo A, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Oct; 33(10):1111–8 (33 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

[Electrophysiological approach to the diagnosis of uncomplicated and complicated left ventricular blocks] de Micheli A, et al. **Arch Inst Cardiol Mex** 1996 Jan–Feb; 66(1):70–82 (27 ref.) **(Spa)**

THERAPY

Advances in pacing. Skehan JD. **Br J Hosp Med** 1996 Jan 17–Feb 6;55(1–2):41–3 (6 ref.)

Cost benefit analysis of single and dual chamber pacing for sick sinus syndrome and atrioventricular block. An economic sensitivity analysis of the literature [see comments] Sutton R, et al. **Eur Heart J** 1996 Apr; 17(4):574–82 (46 ref.) Comment in: Eur Heart J 1996 Apr;17(4):495–6.

HEART CATHETERIZATION

see related
PULMONARY WEDGE PRESSURE

ADVERSE EFFECTS

[Multiple cholesterol emboli] Sidoti CP, et al. **Rev Med Suisse Romande** 1996 Jun;116(6):473–82 (22 ref.) **(Fre)**

[Risks in diagnostic and therapeutic invasive cardiological procedures] Seiler C, et al. **Schweiz Med Wochenschr** 1996 Apr 6;126(14):559–65 (25 ref.) (Eng. Abstr.) **(Ger)**

INSTRUMENTATION

Intracoronary Doppler flow velocity measurements for the evaluation and treatment of coronary artery disease. Bach RG, et al. **Curr Opin Cardiol** 1995 Jul;10(4):434–42 (35 ref.)

Interventional catheterization in paediatric cardiology. Gatzoulis MA, et al. **Eur Heart J** 1995 Dec;16(12):1767–72 (75 ref.)

[Pulmonary artery catheter. Theory and practice] Versprille A. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May;31(1 Suppl):S9–16 (22 ref.) **(Ger)**

METHODS

Left heart catheterization by direct puncture with two–dimensional echocardiographic guidance: a case report. Havranek EP, et al. **Cathet Cardiovasc Diagn** 1995 Aug;35(4):358–61 (19 ref.)

New developments in intracardiac and intravascular devices for congenital heart disease. Tabbutt S, et al. **Curr Opin Cardiol** 1996 Jan;11(1):61–7 (49 ref.)

Building a pediatric cardiac catheterization laboratory and conference room: design considerations and filmless imaging. Mathewson JW. **Pediatr Cardiol** 1996 Sep–Oct; 17(5):279–94 (30 ref.)

HEART CONDUCTION SYSTEM

see related
ARRHYTHMIA

DRUG EFFECTS

The cardiac ion channels: relevance to management of arrhythmias. Roden DM, et al. **Annu Rev Med** 1996; 47:135–48 (66 ref.)

Is there a need for new antiarrhythmic drugs? Roden DM. **Arch Mal Coeur Vaiss** 1996 Feb;89 Spec No 1:13–8 (36 ref.)

Interactions between antiarrhythmic drugs and implantable cardioverter–defibrillators. Dougherty AH. **Curr Opin Cardiol** 1996 Jan;11(1):2–8 (25 ref.)

PATHOLOGY

[Acute Chagas cardiopathy. A systematic study of the intracardiac excitatory–conduction and autonomic nervous systems in an autochthonous case in Acre] Rocha A, et al. **Rev Soc Bras Med Trop** 1996 Jul–Aug;29(4):367–71 (12 ref.) (Eng. Abstr.) **(Por)**

PHYSIOLOGY

Mechanisms for electrical stimulation of excitable tissue. Roth BJ. **Crit Rev Biomed Eng** 1994;22(3–4):253–305 (194 ref.)

Determination of impulse conduction characteristics at a microscopic scale in patterned growth heart cell cultures using multiple site optical recording of transmembrane voltage. Rohr S. **J Cardiovasc Electrophysiol** 1995 Jul; 6(7):551–68 (84 ref.)

The molecular basis of anisotropy: role of gap junctions. Saffitz JE, et al. **J Cardiovasc Electrophysiol** 1995 Jun; 6(6):498–510 (69 ref.)

PHYSIOPATHOLOGY

Mechanisms and management of congenital and acquired long QT syndromes. Lazzara R. **Arch Mal Coeur Vaiss** 1996 Feb;89 Spec No 1:51–5 (34 ref.)

Delayed effects of radiofrequency energy: mechanisms and clinical implications. Fenelon G, et al. **Pacing Clin Electrophysiol** 1996 Apr;19(4 Pt 1):484–9 (31 ref.)

["Malignant Kent" arrhythmia, clinical case and literature review] Baroud I, et al. **Rev Med Brux** 1996 Apr;17(2):51–6 (10 ref.) (Eng. Abstr.) **(Fre)**

[Development of late potentials in ventricular activation in myocardial infarction (1)] Gobin E, et al. **Rev Med Liege** 1996 Mar;51(3):230–40 (64 ref.) **(Fre)**

SURGERY

[Radiofrequency ablation of the atrioventricular accessory pathways. Value of unipolar and bipolar recordings] Aliot E, et al. **Arch Mal Coeur Vaiss** 1996 Feb;89 Spec No 1:89–97 (35 ref.) (Eng. Abstr.) **(Fre)**

[Surgery for WPW syndrome with concomitant CABG: a case report] Ueda T, et al. **Kyobu Geka** 1996 Apr; 49(4):331–3 (5 ref.) (Eng. Abstr.) **(Jpn)**

HEART CONTRACTILITY see **MYOCARDIAL CONTRACTION**

HEART DEFECTS, CONGENITAL

Coronary sinus ostial atresia with persistent left superior vena cava. Santoscoy R, et al. **Ann Thorac Surg** 1996 Mar; 61(3):879–82 (20 ref.)

Standardizing care delivery for infants and children with common congenital cardiac lesions. Allen HD, et al. **Curr Opin Pediatr** 1995 Oct;7(5):601–5 (33 ref.)

[Double outlet left ventricle: a rare and unusual cardiopathy. Apropos of 7 new cases] Gouton M, et al. **Arch Mal Coeur Vaiss** 1996 May;89(5):553–9 (10 ref.) (Eng. Abstr.) **(Fre)**

[Pulmonary vein stenosis. Report of 2 cases and review of the literature] Zamorano M de M. **Arq Bras Cardiol** 1995 Jul;65(1):47–53 (22 ref.) (Eng. Abstr.) **(Por)**

CHEMICALLY INDUCED

[Isotretinoin (RoAccutane) embryopathy. A case report] Pilorget H, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(5):511–5 (14 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

Atrial fibrillation and flutter in children and in young adults with congenital heart disease. Gow RM. **Can J Cardiol** 1996 Jan;12 Suppl A:45A–48A (40 ref.)

Respiratory syncytial virus infection in children with congenital heart disease: a review. Fixler DE. **Pediatr Cardiol** 1996 May–Jun;17(3):163–8 (40 ref.)

Neuroblastoma and congenital cardiovascular malformations. Rosti L, et al. **Pediatrics** 1996 Feb;97(2):258–61 (24 ref.)

[Atrial fibrillation and flutter in children and young adults with congenital cardiopathies] Gow RM. **Can J Cardiol** 1996 Feb;12 Suppl A:43A–48A (40 ref.) **(Fre)**

DIAGNOSIS

Atrioventricular canal and 3C (cranio–cerebello–cardiac) syndrome [letter; comment] Digilio MC, et al. **Am J Med Genet** 1995 Jul 31;58(1):97–8 (15 ref.) Comment on: Am J Med Genet 1994 Aug 1;52(1):66–9.

Advances in cardiac imaging in congenital heart disease. Marx GR. **Curr Opin Pediatr** 1995 Oct;7(5):580–6 (26 ref.)

MR imaging of congenital heart disease. Boxt LM. **Magn Reson Imaging Clin N Am** 1996 May;4(2):327–59 (62 ref.)

Building a pediatric cardiac catheterization laboratory and conference room: design considerations and filmless imaging. Mathewson JW. **Pediatr Cardiol** 1996 Sep–Oct; 17(5):279–94 (30 ref.)

MR angiography of congenital heart disease in adults. Hartnell GG, et al. **Radiographics** 1995 Jul;15(4):781–94 (24 ref.)

Magnetic resonance imaging of congenital heart disease. Gutierrez FR. **Top Magn Reson Imaging** 1995 Fall; 7(4):246–57 (36 ref.)

Cardiac MR imaging: principles and techniques. Haacke EM, et al. **Top Magn Reson Imaging** 1995 Fall;7(4):200–17 (59 ref.)

Congenital heart disease in adults. Foster E. **West J Med** 1995 Nov;163(5):492–8 (33 ref.)

DRUG THERAPY

Inhaled nitric oxide in the management of congenital heart disease. Kulik TJ. **Curr Opin Cardiol** 1996 Jan;11(1):75–80 (29 ref.)

EPIDEMIOLOGY

Incidence of congenital heart disease: II. Prenatal incidence.

Hoffman JI. **Pediatr Cardiol** 1995 Jul-Aug;16(4):155-65 (79 ref.)

ETIOLOGY

Aspects of the aetiology of congenital heart disease. Buskens E, et al. **Eur Heart J** 1995 May;16(5):584-7 (17 ref.)

GENETICS

Kabuki make-up (Niikawa-Kuroki) syndrome in five Spanish children. Galán-Gómez E, et al. **Am J Med Genet** 1995 Nov 20;59(3):276-82 (30 ref.)

The genetic basis of paediatric heart disease. Johnson MC, et al. **Ann Med** 1995 Jun;27(3):289-300 (126 ref.)

The search for genetic mechanisms of congenital heart disease. Bristow J. **Cell Mol Biol Res** 1995;41(4):307-19 (54 ref.)

Mouse mutants and cardiac development: new molecular insights into cardiogenesis. Rossant J. **Circ Res** 1996 Mar; 78(3):349-53 (60 ref.)

Evaluation of relatives for congenital heart defects. Thurmon TF. **J La State Med Soc** 1996 Jan;148(1):31-7 (59 ref.)

Molecular pathways controlling heart development. Olson EN, et al. **Science** 1996 May 3;272(5262):671-6 (57 ref.)

[Congenital cardiopathies and reproductive risk] Lalatta F, et al. **Cardiologia** 1996 Jun;41(6):563-70 (16 ref.) **(Ita)**

PATHOLOGY

Interruption of aortic arch and hypoplastic left heart syndrome. Devloo-Blancquaert A, et al. **Pediatr Cardiol** 1995 Nov-Dec;16(6):304-8 (10 ref.)

PHYSIOPATHOLOGY

Unusual form of total anomalous pulmonary venous connection with double drainage. Lee ML, et al. **Pediatr Cardiol** 1995 Nov-Dec;16(6):301-3 (6 ref.)

[Pregnancy in patients with congenital heart defect] Schlemmer M. **Wien Klin Wochenschr** 1995;107(20):608-12 (20 ref.) (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

Fetal cardiology. Allan LD. **Curr Opin Obstet Gynecol** 1996 Apr;8(2):142-7 (28 ref.)

SURGERY

Advances in surgical care of infants and children with congenital heart disease. Jonas RA. **Curr Opin Pediatr** 1995 Oct;7(5):572-9 (39 ref.)

[Normal pregnancy duration after maternal Fontan operation of univentricular heart] Osmers R, et al. **Z Geburtshilfe Neonatol** 1995 Sep-Oct;199(5):195-8 (15 ref.) (Eng. Abstr.) **(Ger)**

[The heart transplant in congenital cardiopathies. The surgical considerations] Ugarte J, et al. **Rev Esp Cardiol** 1995;48 Suppl 7:33-6 (14 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

New developments in intracardiac and intravascular devices for congenital heart disease. Tabbutt S, et al. **Curr Opin Cardiol** 1996 Jan;11(1):61-7 (49 ref.)

Interventional catheterization in paediatric cardiology. Gatzoulis MA, et al. **Eur Heart J** 1995 Dec;16(12):1767-72 (75 ref.)

ULTRASONOGRAPHY

Transoesophageal echocardiography in congenital heart disease. Sutherland GR, et al. **Acta Paediatr Suppl** 1995 Aug;410:15-22 (39 ref.)

The levoatriocardinal vein: morphology and echocardiographic identification of the pulmonary-systemic connection. Bernstein HS, et al. **J Am Coll Cardiol** 1995 Oct;26(4):995-1001 (15 ref.)

The fetal heart: a practical sonographic approach. Sohaey R, et al. **Semin Ultrasound CT MR** 1996 Feb;17(1):15-33 (36 ref.)

[Prenatal diagnosis of Bourneville-Pringle disease (cerebral tuberous sclerosis)] Stümpflen-Mauser I, et al. **Ultraschall Med** 1996 Feb;17(1):34-7 (16 ref.) (Eng. Abstr.) **(Ger)**

[Hemodynamic evaluation of congenital heart defects by Doppler echocardiography] Martins TC, et al. **Arq Bras Cardiol** 1995 Apr;64(4):409-15 (41 ref.) **(Por)**

VETERINARY

[Heart diseases in foals. A literature review exemplified by 2 case reports] de Groot J, et al. **Tijdschr Diergeneeskd** 1996 Jul 1;121(13):382-7 (18 ref.) (Eng. Abstr.) **(Dut)**

HEART DISEASE, ISCHEMIC see **MYOCARDIAL ISCHEMIA**

HEART DISEASES

see related
NEUROCIRCULATORY ASTHENIA

Update in cardiology. Alpert JS, et al. **Ann Intern Med** 1996 Jul 1;125(1):40-6 (1 ref.)

Pregnancy and heart disease. Oakley CM. **Br J Hosp Med** 1996 Apr 3-16;55(7):423-6 (15 ref.)

Intracardiac thrombi: frequency, location, etiology, and complications: a morphologic review--Part I. Waller BF, et al. **Clin Cardiol** 1995 Aug;18(8):477-9 (13 ref.)

LEOPARD syndrome (cardiocutaneous lentiginosis syndrome). Józwiak S, et al. **Cutis** 1996 Apr;57(4):208-14 (129 ref.)

Impact of anesthetic management on the outcome of cardiac patients for non-cardiac surgery. Gabriel FS. **Middle East J Anesthesiol** 1996 Feb;13(4):385-93 (20 ref.)

BLOOD

Cardiac surgery and cold-reactive proteins. Agarwal SK, et al. **Ann Thorac Surg** 1995 Oct;60(4):1143-50 (47 ref.)

CHEMICALLY INDUCED

Prevention of anthracycline cardiotoxicity by iron chelation. Hershko C, et al. **Acta Haematol** 1996;95(1):87-92 (68 ref.)

Anthracycline-induced cardiotoxicity. Shan K, et al. **Ann Intern Med** 1996 Jul 1;125(1):47-58 (146 ref.)

Does acetaminophen damage the heart? [see comments] Lip GY, et al. **J Toxicol Clin Toxicol** 1996;34(2):145-7 (23 ref.) Comment in: J Toxicol Clin Toxicol 1996;34(2):149-53. Comment in: J Toxicol Clin Toxicol 1996;34(2):155-6.

Cardiovascular effects of androgenic-anabolic steroids. Melchert RB, et al. **Med Sci Sports Exerc** 1995 Sep; 27(9):1252-62 (114 ref.)

[Late effects of organophosphate poisoning on the heart] Lev E, et al. **Harefuah** 1995 Dec 1;129(11):507-11 (40 ref.) **(Heb)**

[Main cardiotoxic drugs] Pettirossi G, et al. **Clin Ter** 1996 Jan-Feb;147(1-2):67-77 (34 ref.) (Eng. Abstr.) **(Ita)**

COMPLICATIONS

Cardioembolic stroke. Brickner ME. **Am J Med** 1996 Apr; 100(4):465-74 (92 ref.)

Cardioembolism as a source of cerebrovascular events. Hennerici MG. **J Heart Valve Dis** 1995 Mar;4(2):121-6 (23 ref.)

Structural and non-structural disease underlying high-risk cardiac arrhythmias relevant to sports medicine. Rossi L. **J Sports Med Phys Fitness** 1995 Jun;35(2):79-86 (29 ref.)

Sudden death from cardiac causes in children and young adults. Liberthson RR. **N Engl J Med** 1996 Apr 18; 334(16):1039-44 (52 ref.)

Clinical neuromythology XV. Feinting science: Neurocardiogenic syncope and collateral vasovagal confusion. Landau WM, et al. **Neurology** 1996 Mar; 46(3):609-18 (77 ref.)

[Heart-related chest pain without manifest coronary disease] Hartikainen J, et al. **Nord Med** 1995;110(8-9):216-20 (12 ref.) (Eng. Abstr.) **(Swe)**

DIAGNOSIS

MR flow quantification with cardiovascular applications: a short overview. Ståhlberg F, et al. **Acta Paediatr Suppl** 1995 Aug;410:49-56 (56 ref.)

Preoperative risk assessment: many studies, few solutions. Is a cardiac risk assessment paradigm possible? [editorial; comment] Mangano DT. **Anesthesiology** 1995 Nov; 83(5):897-901 (11 ref.) Comment on: Anesthesiology 1995 Nov;83(5):906-17.

Trends in the utilization of noninvasive cardiac diagnostic tests in Ontario from fiscal year 1989/90 to 1992/93. Chan B, et al. **Can J Cardiol** 1996 Mar;12(3):237-48 (67 ref.)

Cardiac imaging techniques: which, when, and why. Thomas JD, et al. **Cleve Clin J Med** 1996 Jul-Aug;63(4):213-20 (35 ref.)

Cardiovascular magnetic resonance imaging goes beyond anatomy. Ganz W, et al. **Crit Rev Diagn Imaging** 1995; 36(6):479-503 (34 ref.)

Preoperative assessment of the patient with cardiac disease. Mangano DT. **Curr Opin Cardiol** 1995 Sep;10(5):530-42 (121 ref.)

Magnetic resonance imaging of the heart and its role in current cardiology. Sayad DE, et al. **Curr Opin Cardiol** 1995 Nov;10(6):640-9 (53 ref.)

Echocardiographic and other noninvasive measurements of cardiac hemodynamics and ventricular function. Pai RG, et al. **Curr Probl Cardiol** 1995 Oct;20(10):681-770 (241 ref.)

Signal-averaged electrocardiography. **J Am Coll Cardiol** 1996 Jan;27(1):238-49 (138 ref.)

MRI of myocardial function: motion tracking techniques. McVeigh ER. **Magn Reson Imaging** 1996;14(2):137-50 (65 ref.)

MR evaluation of the pericardium and cardiac malignancies. White CS. **Magn Reson Imaging Clin N Am** 1996 May; 4(2):237-51 (48 ref.)

Cardiovascular disease in elderly patients. Duncan AK, et al. **Mayo Clin Proc** 1996 Feb;71(2):184-96 (156 ref.)

Preoperative cardiac evaluation. Assessing risk before noncardiac surgery. Almany SL, et al. **Postgrad Med** 1995 Oct;98(4):171-4, 180-2 (12 ref.)

Heart disease: functional evaluation with MR imaging. Higgins CB, et al. **Radiology** 1996 May;199(2):307-15 (85 ref.)

[Left atrial free floating thrombus without mitral valve disease. Review of the literature apropos of a case] Trémeau G, et al. **Arch Mal Coeur Vaiss** 1996 Jan;89(1):99-102 (10 ref.) (Eng. Abstr.) **(Fre)**

[Fast and ultra-fast MRI imaging of the heart] von Schulthess GK, et al. **Radiologe** 1995 Dec;35(12):952-63 (69 ref.) (Eng. Abstr.) **(Ger)**

[A comparison between magnetic resonance and other imaging technics in the study of cardiac pathology] Pirolli FM, et al. **Clin Ter** 1996 Apr;147(4):205-10 (20 ref.) (Eng. Abstr.) **(Ita)**

[Apical hypertrophic myocardiopathy and multiple fistulae between the coronary vessels and the left ventricle] Monmeneu JV, et al. **Rev Esp Cardiol** 1995 Nov; 48(11):768-70 (10 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Digoxin in clinical practice: sorting out the facts. Doi SA, et al. **Br J Clin Pract** 1995 Sep-Oct;49(5):257-61 (73 ref.)

Making decisions about antithrombotic therapy in heart disease. Decision analytic and cost-effectiveness issues. Eckman MH, et al. **Chest** 1995 Oct;108(4 Suppl):457S-470S (64 ref.)

The role of prolonged thrombolytic infusions and transesophageal echocardiography in thrombosed prosthetic heart valves: case report and review of the literature. Puleo JA, et al. **Clin Cardiol** 1995 Nov; 18(11):679-84 (50 ref.)

[Urokinase in a premature infant: its use in a case of right atrial thrombosis secondary to catheterization of the umbilical vein] Colnaghi C, et al. **Pediatr Med Chir** 1995 May-Jun;17(3):275-7 (10 ref.) (Eng. Abstr.) **(Ita)**

ENZYMOLOGY

Signalling by protein kinase C isoforms in the heart. Pucéat M, et al. **Mol Cell Biochem** 1996 Apr 12-26;157(1-2):65-72 (72 ref.)

EPIDEMIOLOGY

Passive and active smoking. A problem for adults [editorial; comment] Glantz SA, et al. **Circulation** 1996 Aug 15; 94(4):596-8 (38 ref.) Comment on: Circulation 1996 Aug 15;94(4):614-21. Comment on: Circulation 1996 Aug 15;94(4):622-8.

Preoperative strategies to assess cardiac risk before noncardiac surgery. Younis LT, et al. **Clin Cardiol** 1995 Aug;18(8):447-54 (53 ref.)

Is insulin really a heart disease risk factor. Wingard DL, et al. **Diabetes Care** 1995 Sep;18(9):1299-304 (45 ref.)

Heart disease in Africa: what is known? [editorial] Anabwani GM. **East Afr Med J** 1996 Apr;73(4):213-4 (18 ref.)

Why are lipids not predictive of cardiovascular death in the dialysis patient? Ritz E. **Miner Electrolyte Metab** 1996; 22(1-3):9-12 (25 ref.)

ETHNOLOGY

[Anthropology and cardiology in Niamey (Niger)] Jaffré Y, et al. **Bull Soc Pathol Exot** 1996;89(1):68-75 (24 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Prosthetic valve thrombosis: a case report and review of the literature. Goh PP, et al. **Ann Acad Med Singapore** 1996 Jan;25(1):147-51 (28 ref.)

Diabetic and hypertensive heart disease. Grossman E, et al. **Ann Intern Med** 1996 Aug 15;125(4):304-10 (100 ref.)

Defibrillator patch electrode constriction: an underrecognized entity [see comments] Barrington WW, et al. **Ann Thorac Surg** 1995 Oct;60(4):1112-5; discussion 1115-6 (11 ref.) Comment in: Ann Thorac Surg 1996 Mar;61(3):1042.

Exposure to moderate altitude and cardiorespiratory diseases. Gong H Jr. **Cardiologia** 1995 Jul;40(7):477-88 (98 ref.)

Intracardiac thrombi: frequency, location, etiology, and complications: a morphologic review--Part V. Waller BF, et al. **Clin Cardiol** 1995 Dec;18(12):731-4 (17 ref.)

Hypertensive heart disease and the diabetic patient. Grossman E, et al. **Curr Opin Cardiol** 1995 Sep;10(5):458-65 (92 ref.)

Cardiovascular effects of environmental chemicals. Taylor AE. **Otolaryngol Head Neck Surg** 1996 Feb;114(2):209-11 (26 ref.)

The heart in uremia. Massry SG, et al. **Semin Nephrol** 1996 May;16(3):214-21 (65 ref.)

[Cardiac manifestations of Behçet disease. A propos of 3 cases (letter)] Bennis A, et al. **Ann Med Interne (Paris)** 1996; 147(2):126-9 (23 ref.) **(Fre)**

[Pericarditis and other cardiac disorders, late consequences of radiotherapy] Chappuis MA, et al. **Rev Med Suisse Romande** 1996 Jun;116(6):429-39 (25 ref.) **(Fre)**

[Intraoperative cardiac risk and preoperative examinations from the anesthetic viewpoint] Rolf N, et al. **Dtsch Med Wochenschr** 1996 Apr 5;121(14):453-8 (47 ref.) **(Ger)**

[A case report of a left atrial ball thrombus at 16 years after mitral valve replacement] Iida M, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Apr;44(4):539-44 (28 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

The genetic basis of paediatric heart disease. Johnson MC, et al. **Ann Med** 1995 Jun;27(3):289-300 (126 ref.)

Molecular genetics: cardiac disease and risk-related genes.

Roberts R. **Clin Cardiol** 1995 Sep;18(9 Suppl 4):IV13–9 (54 ref.)

Heart disease: daddies and timebombs. Soutar AK. **Trends Genet** 1995 Nov;11(11):425–8 (24 ref.)

[Genetics of hereditary cardiopathies] Debrus S, et al. **Arch Mal Coeur Vaiss** 1996 May;89(5):619–27 (56 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

[The heart and antiphospholipid antibodies. Personal experience and review of the literature] Laraki R, et al. **Rev Med Interne** 1996;17(1):46–57 (78 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

[Nuclear cardiology: techniques of metabolic evaluation] Parodi O, et al. **G Ital Cardiol** 1995 Dec;25(12):1675–8 (10 ref.) **(Ita)**

MORTALITY

Trends in heart disease in the United States. Feinleib M. **Am J Med Sci** 1995 Dec;310 Suppl 1:S8–14 (9 ref.)

PATHOLOGY

Inflammatory pseudotumor (plasma cell granuloma) of the heart. Report of two cases and literature review. Rose AG, et al. **Arch Pathol Lab Med** 1996 Jun;120(6):549–54 (43 ref.)

Intracardiac thrombi: frequency, location, etiology, and complications: a morphologic review—Part II. Waller BF, et al. **Clin Cardiol** 1995 Sep;18(9):530–4 (29 ref.)

Intracardiac thrombi: frequency, location, etiology, and complications: a morphologic review—Part IV. Waller BF, et al. **Clin Cardiol** 1995 Nov;18(11):669–74 (44 ref.)

The role of MR imaging in the evaluation of acquired cardiovascular disease. Carotti L, et al. **Radiol Med (Torino)** 1996 Jun;91(6):677–86 (87 ref.)

[Endomyocardial biopsy in pediatric cardiovascular pathology (editorial)] Gallo P. **G Ital Cardiol** 1995 Nov; 25(11):1499–512 (97 ref.) **(Ita)**

[Cardiac thrombosis in myocardial infarct] Perdigão C. **Rev Port Cardiol** 1996 Mar;15(3):233–51 (93 ref.) **(Por)**

[Basic forms of acute injury to cardiomyocytes determined by polarized microscopy of myofibrils] Nepomniashchikh LM. **Biull Eksp Biol Med** 1996 Jan;121(1):4–13 (49 ref.) **(Rus)**

PHYSIOPATHOLOGY

The patient with heart disease. Ramsay J. **Can J Anaesth** 1996 May;43(5 Pt 2):R99–107 (28 ref.) **(Eng, Fre)**

New concepts regarding events that lead to end-stage heart disease. Cohn JN. **Cardiovasc Drugs Ther** 1995 Aug;9 Suppl 3:489–92 (32 ref.)

Paracrine modulation of heart cell function by endothelial cells. Shah AM. **Cardiovasc Res** 1996 Jun;31(6):847–67 (224 ref.)

Evaluation and recommendations for participation in athletics for children with heart disease. Kaminer SJ, et al. **Curr Opin Pediatr** 1995 Oct;7(5):595–600 (15 ref.)

Endothelium, fibrinolysis, cardiac risk factors, and prostaglandins: a unified model of atherogenesis. Kadish J. **Med Hypotheses** 1995 Aug;45(2):205–13 (106 ref.)

Regulation of G protein function: implications for heart disease. Meij JT. **Mol Cell Biochem** 1996 Apr 12–26; 157(1–2):31–8 (43 ref.)

[Recording of pulmonary venous flow with Doppler echocardiography; normal and pathological aspects] Tribouilloy C, et al. **Arch Mal Coeur Vaiss** 1995 Sep; 88(9):1335–44 (26 ref.) (Eng. Abstr.) **(Fre)**

[Heart patient and sports] Niederhauser HU. **Schweiz Rundsch Med Prax** 1995 Aug 29;84(35):933–8 (33 ref.) (Eng. Abstr.) **(Ger)**

[Cardiac diseases and sleep related breathing disorders] Shpirer I, et al. **Harefuah** 1996 Apr 15;130(8):551–4 (44 ref.) **(Heb)**

[Recent morphofunctional findings on the left atrium: their relations to thromboembolic risk] Zeppellini R, et al. **G Ital Cardiol** 1995 Aug;25(8):1055–65 (57 ref.) (Eng. Abstr.) **(Ita)**

PREVENTION & CONTROL

Prevention of anthracycline cardiotoxicity by iron chelation. Hershko C, et al. **Acta Haematol** 1996;95(1):87–92 (68 ref.)

Preventive cardiology and its potential influence on the early natural history of adult heart diseases: the Bogalusa Heart Study and the Heart Smart Program. Berenson GS, et al. **Am J Med Sci** 1995 Dec;310 Suppl 1:S133–8 (37 ref.)

Minimising cardiac anaesthetic risk: the tortoise or the hare? Juste RN, et al. **Anaesthesia** 1996 Mar;51(3):255–62 (63 ref.)

Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation [see comments] Blackshear JL, et al. **Ann Thorac Surg** 1996 Feb;61(2):755–9 (59 ref.) Comment in: Ann Thorac Surg 1996 Feb;61(2):515.

Statin therapy in clinical practice: new developments. Shepherd J. **Curr Opin Lipidol** 1995 Oct;6(5):254–5 (13 ref.)

Fetal cardiology. Allan LD. **Curr Opin Obstet Gynecol** 1996 Apr;8(2):142–7 (28 ref.)

Cardiotoxicity and cardioprotection during chemotherapy. Hochster H, et al. **Curr Opin Oncol** 1995 Jul;7(4):304–9 (37 ref.)

Cardioprotection: definition, classification, and fundamental principles. Kübler W, et al. **Heart** 1996 Apr;75(4):330–3 (29 ref.)

Fish and heart disease: what is the real story? Katan MB. **Nutr Rev** 1995 Aug;53(8):228–30 (16 ref.)

Preoperative cardiac evaluation. Assessing risk before noncardiac surgery. Almany SL, et al. **Postgrad Med** 1995 Oct;98(4):171–4, 180–2 (12 ref.)

Cytoprotective agents for anthracyclines. Dorr RT. **Semin Oncol** 1996 Aug;23(4 Suppl 8):23–34 (122 ref.)

RADIONUCLIDE IMAGING

Preoperative risk assessment: many studies, few solutions. Is a cardiac risk assessment paradigm possible? [editorial; comment] Mangano DT. **Anesthesiology** 1995 Nov; 83(5):897–901 (11 ref.) Comment on: Anesthesiology 1995 Nov;83(5):906–17.

New agents and new techniques in nuclear cardiology. Itchhaporia D, et al. **Curr Opin Cardiol** 1995 Nov; 10(6):650–5 (20 ref.)

Does positron emission tomography contribute to the management of clinical cardiac problems? Camici PG, et al. **Eur Heart J** 1996 Feb;17(2):174–81 (70 ref.)

The impact of myocardial blood flow quantitation with PET on the understanding of cardiac diseases. Camici PG, et al. **Eur Heart J** 1996 Jan;17(1):25–34 (95 ref.)

What is the current status of quantification and nuclear medicine in cardiology? Hör G. **Eur J Nucl Med** 1996 Jul; 23(7):815–51 (483 ref.)

In vivo assessment of neurotransmitter system in cardiovascular diseases. Clinical issues. Merlet P, et al. **Q J Nucl Med** 1996 Mar;40(1):108–20 (108 ref.)

[Nuclear cardiology: techniques of metabolic evaluation] Parodi O, et al. **G Ital Cardiol** 1995 Dec;25(12):1675–8 (10 ref.) **(Ita)**

REHABILITATION

Cardiovascular, pulmonary, and cancer rehabilitation. 1. Cardiac rehabilitation. Hertanu JS, et al. **Arch Phys Med Rehabil** 1996 Mar;77(3 Suppl):S38–44 (92 ref.)

How cardiac rehabilitation is being influenced by changes in health-care delivery. Froelicher VF, et al. **J Cardpulm Rehabil** 1996 May–Jun;16(3):151–9 (24 ref.)

Selecting training workloads using treadmill test heart rate/oxygen uptake regressions. McConnell TR. **J Cardpulm Rehabil** 1996 May–Jun;16(3):160–2 (8 ref.)

Outcomes in cardiopulmonary rehabilitation. Pashkow P. **Phys Ther** 1996 Jun;76(6):643–56 (164 ref.)

Resistive exercise training in cardiac rehabilitation. An update. Verrill DE, et al. **Sports Med** 1996 May; 21(5):347–83 (246 ref.)

[Rehabilitation of cardiac patients] Hämäläinen H, et al. **Duodecim** 1994;110(15):1403–9 (35 ref.) **(Fin)**

SURGERY

Cardiopulmonary bypass during pregnancy. Parry AJ, et al. **Ann Thorac Surg** 1996 Jun;61(6):1865–9 (47 ref.)

Selection and treatment of candidates for heart transplantation. A statement for health professionals from the Committee on Heart Failure and Cardiac Transplantation of the Council on Clinical Cardiology, American Heart Association. Costanzo MR, et al. **Circulation** 1995 Dec 15;92(12):3593–612 (139 ref.)

Antifibrinolytic therapy in cardiac surgery. Chen RH, et al. **Tex Heart Inst J** 1995;22(3):211–5 (73 ref.)

Limiting excessive postoperative blood transfusion after cardiac procedures. A review. Ferraris VA, et al. **Tex Heart Inst J** 1995;22(3):216–30 (167 ref.)

[Does heart disease recur following heart transplantation?] Gallino A. **Ther Umsch** 1995 Sep;52(9):581–4 (24 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Acute cardiac care in dental practice. Assael LA. **Dent Clin North Am** 1995 Jul;39(3):555–65 (11 ref.)

Interventional cardiology in pregnancy. Presbitero P, et al. **Eur Heart J** 1996 Feb;17(2):182–8 (104 ref.)

Extracorporeal membrane oxygenation (ECMO) for cardiorespiratory failure in children: the Leicester experience. Firmin RK, et al. **Int J Artif Organs** 1995 Oct; 18(10):603–6 (23 ref.)

Cardiovascular disease in elderly patients. Duncan AK, et al. **Mayo Clin Proc** 1996 Feb;71(2):184–96 (156 ref.)

Cardiac pacing [see comments] Kusumoto FM, et al. **N Engl J Med** 1996 Jan 11;334(2):89–97 (53 ref.) Comment in: N Engl J Med 1996 May 30;334(22):1476–7.

[Indications for pregnancy termination in cases of pre-eclampsia, hypertension, intrauterine growth retardation, liver and heart disease] Uzan S, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24 Suppl 1:33–40 (54 ref.) **(Fre)**

ULTRASONOGRAPHY

Usefulness of multiplane transesophageal echocardiography in differentiating left atrial appendage thrombus from pectinate muscles. Orsinelli DA, et al. **Am Heart J** 1996 Mar;131(3):622–3 (8 ref.)

Transesophageal echocardiography in diagnosing cardioembolic stroke. Husain AM, et al. **Clin Cardiol** 1995 Dec;18(12):705–8 (14 ref.)

The role of prolonged thrombolytic infusions and transesophageal echocardiography in thrombosed prosthetic heart valves: case report and review of the literature. Puleo JA, et al. **Clin Cardiol** 1995 Nov; 18(11):679–84 (50 ref.)

New technology in echocardiography I: Doppler techniques. McDicken WN, et al. **Heart** 1996 Jun;75(6 Suppl 2):2–8 (29 ref.)

[Detection of cardiac embolism by transcranial Doppler] Pettelot G, et al. **Ann Cardiol Angeiol (Paris)** 1996 Jan; 45(1):34–8 (19 ref.) (Eng. Abstr.) **(Fre)**

[Pulmonary embolism and thrombi of the right heart] Chapoutot L, et al. **Arch Mal Coeur Vaiss** 1995 Nov;88(11 Suppl):1723–8 (35 ref.) (Eng. Abstr.) **(Fre)**

[Clinical usefulness of high-resolution electrocardiography] Arsénio A, et al. **Rev Port Cardiol** 1996 Apr;15(4):331–41 (87 ref.) **(Por)**

VETERINARY

Diagnosis of cardiac disease. Overduin LM. **Vet Q** 1995 Apr; 17 Suppl 1:S27–8 (2 ref.)

Echocardiography in dogs. Tiemessen I. **Vet Q** 1995 Apr;17 Suppl 1:S34–5 (1 ref.)

[Heart diseases in foals. A literature review exemplified by 2 case reports] de Groot J, et al. **Tijdschr Diergeneeskd** 1996 Jul 1;121(13):382–7 (18 ref.) (Eng. Abstr.) **(Dut)**

HEART ENLARGEMENT see **HEART HYPERTROPHY**

HEART FAILURE, CONGESTIVE

Congestive heart failure with normal left ventricular systolic function. Clinical approaches to the diagnosis and treatment of diastolic heart failure. Vasan RS, et al. **Arch Intern Med** 1996 Jan 22;156(2):146–57 (184 ref.)

Heart failure in the elderly patient [see comments] Valacio R, et al. **Br J Clin Pract** 1995 Jul–Aug;49(4):200–4 (36 ref.) Comment in: Br J Clin Pract 1995 Jul–Aug;49(4):171.

Heart failure: an old problem. Nolan J, et al. **Br J Hosp Med** 1995 Jun 21–Jul 11;54(1):43–6 (23 ref.)

Heart failure in women. Kimmelstiel CD, et al. **Cardiology** 1995;86(4):304–9 (37 ref.)

Identification, diagnosis and treatment of heart failure: could we do better? Struthers AD. **Cardiology** 1996;87 Suppl 1:29–32 (11 ref.)

Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective. Vasan RS, et al. **J Am Coll Cardiol** 1995 Dec;26(7):1565–74 (86 ref.)

Heart failure. Cahalin LP. **Phys Ther** 1996 May;76(5):516–33 (84 ref.)

Congestive heart failure. Considerations for primary care physicians. Seager LH. **Postgrad Med** 1995 Nov; 98(5):127–30, 132–4, 136–7 (18 ref.)

BLOOD

Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure. Struthers AD. **J Card Fail** 1996 Mar;2(1):47–54 (56 ref.)

[Atrial natriuretic factor and brain natriuretic peptide. Variations in elderly subjects with heart failure] Tissandier O, et al. **Presse Med** 1995 Dec 9;24(38):1837–41 (27 ref.) (Eng. Abstr.) **(Fre)**

CHEMICALLY INDUCED

Exacerbation of congestive heart failure after administration of polyethylene glycol-electrolyte lavage solution. Granberry MC, et al. **Ann Pharmacother** 1995 Dec; 29(12):1232–35 (12 ref.)

COMPLICATIONS

Mitral valve repair in lupus valvulitis—report of a case and review of the literature. Kalangos A, et al. **J Heart Valve Dis** 1995 Mar;4(2):202–7 (29 ref.)

Three edemas. Williams AV Jr, et al. **J S C Med Assoc** 1996 Jul;92(7):306–10 (25 ref.)

Systemic amyloidosis following ankylosing spondylitis associated with congestive heart failure. A case report. Fujito T, et al. **Jpn Heart J** 1995 Sep;36(5):681–8 (17 ref.)

How does chronic heart failure cause dyspnoea? Nardini S. **Monaldi Arch Chest Dis** 1995 Aug;50(4):323–4 (6 ref.)

[Arteriovenous fistula with cardiac insufficiency disclosing kidney cancer] Jan N, et al. **Rev Med Interne** 1996; 17(4):329–32 (30 ref.) (Eng. Abstr.) **(Fre)**

[The liver in shock and acute heart failure] Sekiyama T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):341–4 (9 ref.) **(Jpn)**

[The liver in congestive heart failure] Yanagisawa N, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):294–6 (9 ref.) **(Jpn)**

[Cardiac cirrhosis] Yanagisawa N, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):188–90 (9 ref.) **(Jpn)**

DIAGNOSIS

Assessment and diagnosis of heart failure. Cleland JG, et al. **J Intern Med** 1996 Apr;239(4):317–25 (20 ref.)

Diagnosis and outpatient management of congestive heart failure. Karon BL. **Mayo Clin Proc** 1995 Nov;70(11):1080–5 (00 ref.)

Aspects of tricuspid valve disease, heart failure and the "restriction–dilatation syndrome". Barlow JB. **Rev Port Cardiol** 1995 Dec;14(12):991–1004 (43 ref.)

DRUG THERAPY

Direct selective blockade of the vascular angiotensin II receptors in therapy for hypertension and severe congestive heart failure. Awan NA, et al. **Am Heart J** 1996 Jan; 131(1):177–85 (81 ref.)

Successful heart failure therapy is effective antiarrhythmia therapy [editorial] Khosla S, et al. **Am Heart J** 1996 May; 131(5):1048–50 (23 ref.)

Is there a role for thiamine supplementation in the management of heart failure? [editorial] Leslie D, et al. **Am Heart J** 1996 Jun;131(6):1248–50 (18 ref.)

Renin inhibition: a novel therapy for cardiovascular disease. Lin C, et al. **Am Heart J** 1996 May;131(5):1024–34 (115 ref.)

Effect of chronic angiotensin–converting enzyme inhibition on endothelial function in patients with chronic heart failure. Drexler H, et al. **Am J Cardiol** 1995 Nov 24; 76(15):13E–18E (35 ref.)

Nitrates in the treatment of congestive heart failure. Elkayam U. **Am J Cardiol** 1996 May 30;77(13):41C–51C (56 ref.)

Nitric oxide and nitrovasodilators: similarities, differences, and interactions. Kelly RA, et al. **Am J Cardiol** 1996 May 30;77(13):2C–7C (70 ref.)

Milrinone: basic and clinical pharmacology and acute and chronic management. Shipley JB, et al. **Am J Med Sci** 1996 Jun;311(6):286–91 (36 ref.)

Is aspirin safe for patients with heart failure? Cleland JG, et al. **Br Heart J** 1995 Sep;74(3):215–9 (53 ref.)

Can we improve diuretic response in heart failure? Trelawny JM. **Br J Hosp Med** 1996 May 15–Jun 4;55(10):616–9 (24 ref.)

Treatment of refractory heart failure. Dei Cas L, et al. **Cardiologia** 1992 Jul;37(7):501–5 (32 ref.)

Interruption of the progression of heart failure: are ACE inhibitors the solution? Coats A. **Cardiology** 1996;87 Suppl 1:11–5 (7 ref.)

Current controversies with ACE inhibitor treatment in heart failure. Visser FC, et al. **Cardiology** 1996;87 Suppl 1:23–8 (21 ref.)

ACE inhibitors and calcium antagonists in the treatment of congestive heart failure. Hansen JF. **Cardiovasc Drugs Ther** 1995 Aug;9 Suppl 3:503–7 (30 ref.)

Pharmacologic treatment of congestive heart failure. Carson P. **Clin Cardiol** 1996 Apr;19(4):271–7 (25 ref.)

Strategies for pharmacologic modulation of the heart failure phenotype. Feldman AM, et al. **Clin Cardiol** 1995 Sep;18(9 Suppl 4):IV28–35 (94 ref.)

Inotropic therapy for the failing myocardium [see comments] Shipley JB, et al. **Clin Cardiol** 1995 Nov;18(11):615–9 (18 ref.) Comment in: Clin Cardiol 1996 Mar;19(3):162.

Management of congestive heart failure in the elderly patient. Aronow WS. **Compr Ther** 1995 Jul;21(7):329–38 (36 ref.)

Inotropic therapy for systolic heart failure. Wagoner LE, et al. **Compr Ther** 1995 Jul;21(7):367–77 (57 ref.)

Quality of life in older patients with congestive heart failure. Effects of ACE inhibitors. Fergus I, et al. **Drugs Aging** 1996 Jan;8(1):23–8 (45 ref.)

Digoxin in the treatment of patients with chronic heart failure. Its place in therapy. Uretsky BF. **Drugs Aging** 1995 Jul;7(1):1–9 (44 ref.)

Improvement in cardiac myocyte function by biological effects of medical therapy: a new concept in the treatment of heart failure. Bristow MR, et al. **Eur Heart J** 1995 Jul; 16 Suppl F:20–31 (93 ref.)

ACE inhibitors in non–ischaemic heart failure: results from the MEGA trials. Cohn JN. **Eur Heart J** 1995 Dec;16 Suppl O:133–6 (31 ref.)

Digitalis—friend or foe? Erdmann E. **Eur Heart J** 1995 Jul; 16 Suppl F:16–9 (18 ref.)

Beta–blockers in heart failure—the evidence from clinical trials. Hampton JR. **Eur Heart J** 1996 Apr;17 Suppl B:17–20 (23 ref.)

Angiotensin converting enzyme inhibition in asymptomatic left ventricular systolic dysfunction and early heart failure. Konstam MA. **Eur Heart J** 1995 Dec;16 Suppl N:59–64 (44 ref.)

What is the ideal study design for evaluation of treatment for heart failure? Insights from trials assessing the effect of ACE inhibitors on exercise capacity. Narang R, et al. **Eur Heart J** 1996 Jan;17(1):120–34 (45 ref.)

Beta–blockade in the management of chronic heart failure. Another step in the conceptual evolution of a neurohormonal model of the disease. Packer M. **Eur Heart J** 1996 Apr;17 Suppl B:21–3 (23 ref.)

Effects of angiotensin receptor antagonists in heart failure: clinical and experimental aspects. Regitz–Zagrosek V, et al. **Eur Heart J** 1995 Dec;16 Suppl N:86–91 (19 ref.)

Neurohormonal modulation in heart failure: ACE inhibition and beyond. Remme WJ. **Eur Heart J** 1995 Dec;16 Suppl N:73–8 (36 ref.)

Beta–blockers in heart failure. Future directions. Sharpe N. **Eur Heart J** 1996 Apr;17 Suppl B:39–42 (23 ref.)

Neurohormonal activation and congestive heart failure: today's experience with ACE inhibitors and rationale for their use. Sigurdsson A, et al. **Eur Heart J** 1995 Dec;16 Suppl N:65–72 (53 ref.)

Aldosterone escape during ACE inhibitor therapy in chronic heart failure. Struthers AD. **Eur Heart J** 1995 Dec;16 Suppl N:103–6 (26 ref.)

Refocus on diuretics in the treatment of heart failure. Taylor SH. **Eur Heart J** 1995 Jul;16 Suppl F:7–15 (86 ref.)

Congestive heart failure. Towards a comprehensive treatment. Taylor SH. **Eur Heart J** 1996 Apr;17 Suppl B:43–56 (105 ref.)

Adrenergic beta–blocking agents in congestive heart failure due to idiopathic dilated cardiomyopathy. Waagstein F. **Eur Heart J** 1995 Dec;16 Suppl O:128–32 (37 ref.)

Modern management of heart failure. Stevenson LW. **Hosp Pract (Off Ed)** 1996 Mar 15;31(3):103–6,109–10 (9 ref.)

Impact of advances in therapy for heart failure on secular trends in mortality [editorial] Rector TS. **J Card Fail** 1996 Mar;2(1):31–2 (7 ref.)

Quality of life with ACE inhibitors in chronic heart failure. Bulpitt CJ. **J Cardiovasc Pharmacol** 1996;27 Suppl 2:S31–5 (35 ref.)

Prevention of congestive heart failure by ACE inhibition in patients with acute myocardial infarction. Sigurdsson A, et al. **J Cardiovasc Risk** 1995 Oct;2(5):406–12 (44 ref.)

Treatment of heart failure. Kjekshus J, et al. **J Intern Med** 1996 Apr;239(4):335–43 (53 ref.)

What have we learned from clinical trials in congestive heart failure? Swedberg K. **J Intern Med** 1996 Apr;239(4):307–8 (13 ref.)

Significance of sodium pump isoforms in digitalis therapy. McDonough AA, et al. **J Mol Cell Cardiol** 1995 Apr; 27(4):1001–9 (65 ref.)

Rationale for treatment of patients with chronic heart failure with adrenergic blockade. Sackner–Bernstein JD, et al. **JAMA** 1995 Nov 8;274(18):1462–7 (71 ref.)

Phosphodiesterase inhibition and Ca2+ sensitization. Ravens U, et al. **Mol Cell Biochem** 1996 Apr 12–26;157(1–2):245–9 (21 ref.)

Adrenergic and muscarinic receptor regulation and therapeutic implications in heart failure. Schmitz W, et al. **Mol Cell Biochem** 1996 Apr 12–26;157(1–2):251–8 (91 ref.)

Cardiac performance: growth hormone enters the race. Saccà L, et al. **Nat Med** 1996 Jan;2(1):29–31 (16 ref.)

Angiotensin II receptor blockers: novel therapy for heart failure? Munger MA, et al. **Pharmacotherapy** 1996 Mar–Apr;16(2 Pt 2):59S–68S (86 ref.)

Evolving role of calcium channel blockers in heart failure. Pieper JA. **Pharmacotherapy** 1996 Mar–Apr;16(2 Pt 2):43S–49S (26 ref.)

Evolving concepts in the treatment of heart failure: should new inotropic agents carry promise or paranoia? Young JB. **Pharmacotherapy** 1996 Mar–Apr;16(2 Pt 2):78S–84S (25 ref.)

Current trends in cardiovascular pharmacology. Ciccone CD. **Phys Ther** 1996 May;76(5):481–97 (184 ref.)

[Should beta–adrenergic blockade be part of drug therapy for heart failure? (editorial)] Leinonen H. **Duodecim** 1995; 111(3):209–13 (18 ref.) **(Fin)**

[Calcium sensitizers] Nieminen MS, et al. **Duodecim** 1995; 111(8):779–87 (56 ref.) **(Fin)**

[Classic treatment of chronic heart insufficiency. What if new?] Aumont MC, et al. **Arch Mal Coeur Vaiss** 1995 Apr; 88(4 Suppl):599–602 (11 ref.) (Eng. Abstr.) **(Fre)**

[Anti–arrhythmic therapy and cardiac failure] Cosnay P, et al. **Arch Mal Coeur Vaiss** 1995 Dec;88 Spec No 5:35–41 (44 ref.) (Eng. Abstr.) **(Fre)**

[Treatment of chronic heart failure: current views] Komajda M. **Arch Mal Coeur Vaiss** 1995 Apr;88(4 Suppl):603–6 (12 ref.) (Eng. Abstr.) **(Fre)**

[Calcium antagonists and treatment of chronic heart failure] Lanfranchi J. **Arch Mal Coeur Vaiss** 1995 Apr;88(4 Suppl):623–31 (49 ref.) (Eng. Abstr.) **(Fre)**

[Current status of treatment of chronic cardiac insufficiency] Théry C, et al. **Rev Med Interne** 1996;17(2):135–43 (80 ref.) (Eng. Abstr.) **(Fre)**

[Chronic cardiac insufficiency: current treatment and future outlook] Reuge L, et al. **Rev Med Suisse Romande** 1996 Jun;116(6):441–50 (34 ref.) **(Fre)**

[Cardiac insufficiency: therapeutic aspects in the elderly person] Perrenoud JJ. **Schweiz Rundsch Med Prax** 1996 Feb 6;85(6):164–7 (19 ref.) (Eng. Abstr.) **(Fre)**

[The role of nitrates in therapy of heart failure] Strasser RH. **Herz** 1996 Jun;21 Suppl 1:35–7 (36 ref.) (Eng. Abstr.) **(Ger)**

[Therapy of heart failure. Digitalis, diuretic plus ACE inhibitor or more?] Becker H, et al. **Internist (Berl)** 1995 Dec;36(12):1117–23 (43 ref.) **(Ger)**

[Beta–blockers in cardiac insufficiency. Time to reconsider? (editorial)] Follath F. **Schweiz Med Wochenschr** 1996 May 4;126(18):747–9 (12 ref.) **(Ger)**

[Drug therapy of cardiac insufficiency: status 1995] Rickenbacher P, et al. **Schweiz Med Wochenschr** 1996 May 25;126(21):933–45 (161 ref.) (Eng. Abstr.) **(Ger)**

[Beta receptor blockers in chronic heart failure] Sigmund M, et al. **Z Kardiol** 1995 Oct;84(10):820–6 (74 ref.) (Eng. Abstr.) **(Ger)**

[Beta–blockers in congestive heart failure—a therapeutic paradox] Jonas M, et al. **Harefuah** 1995 Sep;129(5–6):192–7 (44 ref.) **(Heb)**

[Efficacy and problems of cardiotonic agents viewed from physiopathology of chronic congestive heart failure] Asanoi H, et al. **Nippon Naika Gakkai Zasshi** 1995 Sep 10;84(9):1465–9 (19 ref.) **(Jpn)**

[Emergency drug therapy of acute heart failure and cardiogenic shock] Inishi Y, et al. **Nippon Naika Gakkai Zasshi** 1995 Nov 10;84(11):1810–4 (5 ref.) **(Jpn)**

[Clinical evaluation of ACE inhibitors for therapy of chronic congestive heart failure] Matsuo H. **Nippon Naika Gakkai Zasshi** 1995 Sep 10;84(9):1470–4 (17 ref.) **(Jpn)**

[Use of beta–blockers in the treatment of chronic heart failure] Sutka J, et al. **Vnitr Lek** 1996 Jan;42(1):37–42 (30 ref.) (Eng. Abstr.) **(Slo)**

[The lessons from clinical trials in congestive heart failure] Anguita Sánchez M. **Rev Esp Cardiol** 1995 Nov; 48(11):699–709 (85 ref.) (Eng. Abstr.) **(Spa)**

ECONOMICS

The cost–effective way forward for the management of the patient with heart failure. Giles T. **Cardiology** 1996;87 Suppl 1:33–9 (15 ref.)

Cost–effectiveness in clinical cardiology. Part 1: Coronary artery disease and congestive heart failure. Willens HJ, et al. **Chest** 1996 May;109(5):1359–69 (60 ref.)

Epidemiologic and economic impact of advanced heart failure. Funk M, et al. **J Cardiovasc Nurs** 1996 Jan; 10(2):1–10 (33 ref.)

The economics of cardiac failure. Kleber FX. **J R Soc Med** 1996 Jan;89(1):9–12 (28 ref.)

EPIDEMIOLOGY

Epidemiologic and economic impact of advanced heart failure. Funk M, et al. **J Cardiovasc Nurs** 1996 Jan; 10(2):1–10 (33 ref.)

Heart failure—implications of the true size of the problem. Dargie HJ, et al. **J Intern Med** 1996 Apr;239(4):309–15 (30 ref.)

Pathophysiology of heart failure: changing perceptions. Patterson JH, et al. **Pharmacotherapy** 1996 Mar–Apr;16(2 Pt 2):27S–36S (26 ref.)

[The epidemiology of heart failure: its incidence, prevalence and mortality. The data and uncertainties] Dolara A. **Cardiologia** 1992 Jul;37(7):497–9 (15 ref.) **(Ita)**

[The epidemiology of heart failure: a growing public health problem] Sinagra G, et al. **G Ital Cardiol** 1995 Aug; 25(8):1043–53 (32 ref.) **(Ita)**

ETIOLOGY

Congestive heart failure due to hypertensive ventricular diastolic dysfunction. Iriarte MM, et al. **Am J Cardiol** 1995 Nov 2;76(13):43D–47D (20 ref.)

Systolic ventricular dysfunction and heart failure due to coronary microangiopathy in hypertensive heart disease. Vogt M, et al. **Am J Cardiol** 1995 Nov 2;76(13):48D–53D (34 ref.)

Cardiac manifestations of Lyme disease: a review. Nagi KS, et al. **Can J Cardiol** 1996 May;12(5):503–6 (38 ref.)

Endothelin in chronic heart failure: current position and future prospects. Love MP, et al. **Cardiovasc Res** 1996 May; 31(5):665–74 (99 ref.)

'Til death do us part: a case of failed affection. Weber KT, et al. **Cardiovasc Res** 1995 Jul;30(1):26–30 (32 ref.)

Left ventricular dysfunction and heart failure. Mechanistic and therapeutic distinctions. Cohn JN. **Clin Exp Hypertens** 1996 Apr–May;18(3–4):559–68 (29 ref.)

Cardiac hypertrophy and failure in hypertension. Johnson DB, et al. **Curr Opin Nephrol Hypertens** 1996 Mar; 5(2):186–91 (44 ref.)

Diabetic cardiomyopathy. A unique entity or a complication of coronary artery disease? Bell DS. **Diabetes Care** 1995 May;18(5):708–14 (79 ref.)

Haemodynamic basis for the development of left ventricular failure in systolic hypertension and for its logical therapy [editorial] Westerhof N, et al. **J Hypertens** 1995 Sep; 13(9):943–52 (55 ref.)

Congestive heart failure due to rapid right ventricular obliteration by metastatic malignant melanoma. Rusconi C, et al. **Minerva Cardioangiol** 1996 Mar;44(3):123–5 (8 ref.)

Pathophysiology of heart failure: changing perceptions. Patterson JH, et al. **Pharmacotherapy** 1996 Mar–Apr;16(2 Pt 2):27S–36S (26 ref.)

Management of cardiac complications in patients with thalassemia major. Vecchio C, et al. **Semin Hematol** 1995 Oct;32(4):288–96 (41 ref.)

[Growth hormone—a pathogenetic factor in chronic congestive heart insufficiency?] Dreifuss PM. **Dtsch Med Wochenschr** 1996 Apr 12;121(15):492–6 (35 ref.) **(Ger)**

[Diastolic dysfunction of the heart. A frequently overlooked cause of chronic heart failure] Sitzler G, et al. **Dtsch Med Wochenschr** 1996 Jan 19;121(3):70–6 (46 ref.) **(Ger)**

[Left–ventricular hypertrophy as a cardiac risk factor: role of the renin–angiotensin–aldosterone system] Erne P. **Schweiz Rundsch Med Prax** 1996 Feb 20;85(8):227–33 (34 ref.) (Eng. Abstr.) **(Ger)**

[Etiological significance of humoral nerve factors in congestive heart failure] Kinoshita M, et al. **Nippon Naika Gakkai Zasshi** 1995 Sep 10;84(9):1454–8 (14 ref.) **(Jpn)**

[Role of cytokines in etiological mechanism of congestive heart failure] Sasayama S, et al. **Nippon Naika Gakkai Zasshi** 1995 Sep 10;84(9):1459–64 (25 ref.) **(Jpn)**

[Congestive heart failure associated with ischemic

cardiopathy] da Silva MA. **Arq Bras Cardiol** 1995 Apr; 64(4):347–54 (42 ref.) **(Por)**

GENETICS

Molecular biology of myocardial hypertrophy and failure: gene expression and trophic signaling. Parker TG. **New Horiz** 1995 May;3(2):288–300 (113 ref.)

IMMUNOLOGY

Tumor necrosis factor–alpha and the failing human heart. Oral H, et al. **Clin Cardiol** 1995 Sep;18(9 Suppl 4):IV20–7 (71 ref.)

METABOLISM

Electrolyte disturbances in chronic heart failure: metabolic and clinical aspects. Dei Cas L, et al. **Clin Cardiol** 1995 Jul;18(7):370–6 (103 ref.)

Nitric oxide, myocardial failure and septic shock. Brady AJ. **Int J Cardiol** 1995 Jul;50(3):269–72 (32 ref.)

Alterations of beta–adrenoceptor–G–protein–regulated adenylyl cyclase in heart failure. Böhm M. **Mol Cell Biochem** 1995 Jun 7–21;147(1–2):147–60 (84 ref.)

Regulation of expression of cardiac sarcoplasmic reticulum proteins under pathophysiological conditions. Dillmann WH. **Mol Cell Biochem** 1996 Apr 12–26;157(1–2):125–8 (14 ref.)

Oxidative stress and heart failure. Singh N, et al. **Mol Cell Biochem** 1995 Jun 7–21;147(1–2):77–81 (36 ref.)

[Ca2+]i in human heart failure: a review and discussion of current areas of controversy. Liao R, et al. **Yale J Biol Med** 1994 Sep–Dec;67(5–6):247–64 (44 ref.)

[Therapy–oriented assessment of heart failure in the hospital and clinical practice] Mohacsi P, et al. **Schweiz Rundsch Med Prax** 1996 Feb 20;85(8):245–55 (110 ref.) (Eng. Abstr.) **(Ger)**

MORTALITY

Impact of advances in therapy for heart failure on secular trends in mortality [editorial] Rector TS. **J Card Fail** 1996 Mar;2(1):31–2 (7 ref.)

PATHOLOGY

Does ACE inhibition limit structural changes in the heart following myocardial infarction? Smits JF, et al. **Eur Heart J** 1995 Dec;16 Suppl N:46–51 (48 ref.)

Structural remodelling of the heart by fibrous tissue: role of circulating hormones and locally produced peptides. Weber KT, et al. **Eur Heart J** 1995 Dec;16 Suppl N:12–8 (83 ref.)

PHYSIOPATHOLOGY

Role of the cardiac renin–angiotensin system in human heart failure. Paul M, et al. **Adv Exp Med Biol** 1995;377:279–83 (17 ref.)

Significance of magnesium in congestive heart failure. Douban S, et al. **Am Heart J** 1996 Sep;132(3):664–71 (103 ref.)

The role of neurohormonal activation in chronic heart failure and postmyocardial infarction. Sigurdsson A, et al. **Am Heart J** 1996 Jul;132(1 Pt 2 Su):229–34 (50 ref.)

Phosphodiesterase activity as a mediator of renal resistance to ANP in pathological salt retention. Lee EY, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):F3–6 (27 ref.)

Explaining fatigue in congestive heart failure. Drexler H, et al. **Annu Rev Med** 1996;47:241–56 (83 ref.)

The role of hypertension in the pathogenesis of heart failure. A clinical mechanistic overview. Vasan RS, et al. **Arch Intern Med** 1996 Sep 9;156(16):1789–96 (159 ref.)

Diastolic dysfunction. Tardif JC, et al. **Can J Cardiol** 1996 Apr;12(4):389–98 (73 ref.)

Is contractility depressed in the failing human heart? Gwathmey JK, et al. **Cardiovasc Drugs Ther** 1995 Aug; 9(4):581–7 (40 ref.)

Signal transduction mechanisms controlling cardiac contractility and their alterations in chronic heart failure. Brodde OE, et al. **Cardiovasc Res** 1995 Oct;30(4):570–84 (214 ref.)

Effects of mechano–electrical feedback: potential arrhythmogenic influence in patients with congestive heart failure. Reiter MJ. **Cardiovasc Res** 1996 Jul;32(1):44–51 (44 ref.)

Is there a role for endothelin in the natural history of heart failure? [editorial; comment] Cohn JN. **Circulation** 1996 Aug 15;94(4):604–6 (39 ref.) Comment on: Circulation 1996 Aug 15;94(4):779–84.

Critical review of heart failure: the role of left ventricular remodeling in the therapeutic response. Cohn JN. **Clin Cardiol** 1995 Sep;18(9 Suppl 4):IV4–12 (21 ref.)

Neuroendocrine changes in heart failure and their clinical relevance. Parmley WW. **Clin Cardiol** 1995 Aug; 18(8):440–5 (27 ref.)

Hypertensive heart disease and heart failure. Cody RJ. **Curr Opin Cardiol** 1995 Sep;10(5):450–7 (13 ref.)

The ageing spontaneously hypertensive rat as a model of the transition from stable compensated hypertrophy to heart failure. Boluyt MO, et al. **Eur Heart J** 1995 Dec;16 Suppl N:19–30 (49 ref.)

The renin–angiotensin–aldosterone system and myocardial collagen matrix remodelling in congestive heart failure. Brilla CG, et al. **Eur Heart J** 1995 Dec;16 Suppl O:107–9 (24 ref.)

The lungs in chronic heart failure. Chua TP, et al. **Eur Heart J** 1995 Jul;16(7):882–7 (75 ref.)

Changes in neurohumoral systems during the development of congestive heart failure: impact on cardiovascular and renal function. Elsner D. **Eur Heart J** 1995 Dec;16 Suppl N:52–8 (37 ref.)

Post–infarction myocardial remodelling: why does it happen? Francis GS, et al. **Eur Heart J** 1995 Dec;16 Suppl N:31–6 (41 ref.)

The cardiomyopathy of overload: an unnatural growth response. Katz AM. **Eur Heart J** 1995 Dec;16 Suppl O:110–4 (73 ref.)

Evolution of the neurohormonal hypothesis to explain the progression of chronic heart failure. Packer M. **Eur Heart J** 1995 Jul;16 Suppl F:4–6 (40 ref.)

Beta–blockade in the management of chronic heart failure. Another step in the conceptual evolution of a neurohormonal model of the disease. Packer M. **Eur Heart J** 1996 Apr;17 Suppl B:21–3 (23 ref.)

Mechanisms of angiotensin II formation in humans. Urata H, et al. **Eur Heart J** 1995 Dec;16 Suppl N:79–85 (63 ref.)

Aldosterone and heart failure. Zannad F. **Eur Heart J** 1995 Dec;16 Suppl N:98–102 (33 ref.)

Spirals, paradigms, and the progression of heart failure [editorial] Poole–Wilson PA. **J Card Fail** 1996 Mar;2(1):1–4 (22 ref.)

Physiologic changes in heart failure–"What's new". Oka RK. **J Cardiovasc Nurs** 1996 Jan;10(2):11–28 (93 ref.)

Importance of endothelial function in chronic heart failure. Drexler H, et al. **J Cardiovasc Pharmacol** 1996;27 Suppl 2:S9–12 (49 ref.)

Neurohumoral mechanisms in heart failure: a central role for the renin–angiotensin system. Teerlink JR. **J Cardiovasc Pharmacol** 1996;27 Suppl 2:S1–8 (70 ref.)

Two new culprits in cardiovascular disease: QT dispersion and aldosterone. Struthers AD. **J Hum Hypertens** 1995 Aug;9(8):659–61 (19 ref.)

New concepts in the pathophysiology of heart failure: beneficial and deleterious interaction of endogenous haemodynamic and neurohormonal mechanisms. Packer M. **J Intern Med** 1996 Apr;239(4):327–33 (28 ref.)

Local renin–angiotensin systems. Danser AH. **Mol Cell Biochem** 1996 Apr 12–26;157(1–2):211–6 (25 ref.)

[Diastolic dysfunction of the left ventricle as a cause of heart failure: a clinical problem] Muntinga HJ, et al. **Ned Tijdschr Geneeskd** 1995 Oct 7;139(40):2023–8 (30 ref.) **(Dut)**

[The sympathetic–adrenergic system in heart failure] Ungerer M, et al. **Dtsch Med Wochenschr** 1996 Feb 2;121(5):141–5 (60 ref.) **(Ger)**

[Cardiac structure–function relationship and the renin–angiotensin–aldosterone system in hypertensive heart disease] Funck RC, et al. **Herz** 1995 Oct;20(5):330–9 (56 ref.) (Eng. Abstr.) **(Ger)**

[Sympathetic nervous system and endothelial function in heart failure] Binggeli C, et al. **Schweiz Rundsch Med Prax** 1996 Feb 20;85(8):234–44 (104 ref.) (Eng. Abstr.) **(Ger)**

[Heart failure in elderly patients] Hunziker P, et al. **Schweiz Rundsch Med Prax** 1995 Oct 31;84(44):1272–6 (34 ref.) (Eng. Abstr.) **(Ger)**

[Efficacy and problems of cardiotonic agents viewed from physiopathology of chronic congestive heart failure] Asanoi H, et al. **Nippon Naika Gakkai Zasshi** 1995 Sep 10;84(9):1465–9 (19 ref.) **(Jpn)**

[Basic and clinical study of left ventricular remodeling] Sasayama S. **Nippon Naika Gakkai Zasshi** 1995 Jul 10; 84(7):1178–85 (20 ref.) **(Jpn)**

[Physiopathology of heart failure and new approach to the therapy] Yazaki Y. **Nippon Naika Gakkai Zasshi** 1995 Sep 10;84(9):1449–53 (10 ref.) **(Jpn)**

[Neurohormonal factors in heart failure. I] Cosín Aguilar J, et al. **Rev Esp Cardiol** 1996 Apr;49(4):239–52 (112 ref.) (Eng. Abstr.) **(Spa)**

[Neurohormonal factors in heart failure. II] Cosín Aguilar J, et al. **Rev Esp Cardiol** 1996 May;49(5):317–27 (47 ref.) (Eng. Abstr.) **(Spa)**

PREVENTION & CONTROL

ACE inhibitors: myocardial infarction and congestive heart failure. Cody RJ. **Am Fam Physician** 1995 Nov 1; 52(6):1801–6 (18 ref.)

Improving outcome after acute myocardial infarction: what is the role of ACE inhibitors? [see comments] Purcell H, et al. **Br J Clin Pract** 1995 Jul–Aug;49(4):195–9 (59 ref.) Comment in: Br J Clin Pract 1995 Jul–Aug;49(4):171.

[The high risk cardiac patient in anesthesia] Francke A. **Anaesthesiol Reanim** 1996;21(2):32–42 (89 ref.) (Eng. Abstr.) **(Ger)**

PSYCHOLOGY

Quality of life with ACE inhibitors in chronic heart failure. Bulpitt CJ. **J Cardiovasc Pharmacol** 1996;27 Suppl 2:S31–5 (35 ref.)

RADIOGRAPHY

Congestive heart failure and adult respiratory distress syndrome. New insights using computed tomography. Goodman LR. **Radiol Clin North Am** 1996 Jan;34(1):33–46 (30 ref.)

REHABILITATION

Health–related quality of life as an outcome for patients with heart failure. Shively M, et al. **J Cardiovasc Nurs** 1996 Jan; 10(2):89–96 (14 ref.)

Cardiac rehabilitation: how can it be improved? [editorial] Thompson DR. **J Psychosom Res** 1995 Jul;39(5):519–23 (20 ref.)

[Therapeutic effectiveness of Crataegus] Weihmayr T, et al. **Fortschr Med** 1996 Jan 20;114(1–2):27–9 (30 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Skeletal muscle ventricles: frontiers in 1995. Isoda S, et al. **Artif Organs** 1996 Feb;20(2):114–9 (33 ref.)

Assessing appropriateness of treatment: a case study of transplantation in older patients with congestive heart failure. Montague T, et al. **Can J Cardiol** 1996 Jan; 12(1):47–52 (33 ref.)

Cardiomyoplasty—the beginning of a new era. Bolotin G, et al. **Isr J Med Sci** 1996 May;32(5):321–6 (40 ref.)

When to transplant: Recipient selection for heart transplantation. Grady KL. **J Cardiovasc Nurs** 1996 Jan; 10(2):58–70 (55 ref.)

Selection and treatment of candidates for heart transplantation. Costanzo MR. **Semin Thorac Cardiovasc Surg** 1996 Apr;8(2):113–25 (88 ref.)

[When should the family physician contact the cardiological transplantation team?] Mohacsi P, et al. **Ther Umsch** 1995 Sep;52(9):617–25 (31 ref.) (Eng. Abstr.) **(Ger)**

[Biomechanical heart and cardiovascular support] Lange R, et al. **Zentralbl Chir** 1996;121(4):263–77 (121 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Bi–level positive airway pressure support system use in acute congestive heart failure: preliminary case series. Sacchetti AD, et al. **Acad Emerg Med** 1995 Aug;2(8):714–8 (21 ref.)

Refractory congestive heart failure: overview and application of extracorporeal ultrafiltration. Blake P, et al. **Adv Ren Replace Ther** 1996 Apr;3(2):166–73 (50 ref.)

Long–term ventricular wall actuation: can and should it be systematically explored? Melvin DB, et al. **Artif Organs** 1996 Jan;20(1):63–8 (13 ref.)

Cost–effectiveness in clinical cardiology. Part 1: Coronary artery disease and congestive heart failure. Willens HJ, et al. **Chest** 1996 May;109(5):1359–69 (60 ref.)

Acute myocardial infarction and congestive heart failure. Howell JM. **Emerg Med Clin North Am** 1996 Feb; 14(1):83–91 (36 ref.)

Immunomodulating agents for the management of heart failure with myocarditis and cardiomyopathy—lessons from animal experiments. Matsumori A, et al. **Eur Heart J** 1995 Dec;16 Suppl O:140–3 (10 ref.)

Shifting the paradigm for the treatment of dilated cardiomyopathy. Sole MJ. **Eur Heart J** 1995 Dec;16 Suppl O:176–9 (25 ref.)

Optimal management of heart failure. Hsu I. **J Am Pharm Assoc (Wash)** 1996 Feb;NS36(2):92–107 (45 ref.)

Maximizing therapy in the advanced heart failure patient. Moser DK. **J Cardiovasc Nurs** 1996 Jan;10(2):29–46 (62 ref.)

Nonpharmacologic interventions in the treatment of heart failure. Sullivan MJ, et al. **J Cardiovasc Nurs** 1996 Jan; 10(2):47–57 (44 ref.)

Diagnosis and outpatient management of congestive heart failure. Karon BL. **Mayo Clin Proc** 1995 Nov;70(11):1080–5 (00 ref.)

The management of chronic heart failure. Cohn JN. **N Engl J Med** 1996 Aug 15;335(7):490–8 (89 ref.)

Continuous hemofiltration for the failing heart. Coraim FI, et al. **New Horiz** 1995 Nov;3(4):725–31 (44 ref.)

[Ambulatory treatment of chronic cardiac insufficiency] Guérot C, et al. **Ann Cardiol Angeiol (Paris)** 1995 Oct; 44(8):465–8 (13 ref.) (Eng. Abstr.) **(Fre)**

[Value of cardiac pacing in hypertrophic obstructive cardiomyopathy refractory to medical treatment] Gras D, et al. **Arch Mal Coeur Vaiss** 1995 Apr;88(4 Suppl):577–83 (20 ref.) (Eng. Abstr.) **(Fre)**

[Treatment of heart failure] Bounhoure JP, et al. **Presse Med** 1996 Jun 29;25(23):1076–82 (22 ref.) (Eng. Abstr.) **(Fre)**

[Treatment of chronic congestive heart failure to improve their quality of life—clinical study of thermal vasodilation therapy] Tei C, et al. **Nippon Naika Gakkai Zasshi** 1995 Sep 10;84(9):1475–82 (35 ref.) **(Jpn)**

[Physiopathology of heart failure and new approach to the therapy] Yazaki Y. **Nippon Naika Gakkai Zasshi** 1995 Sep 10;84(9):1449–53 (10 ref.) **(Jpn)**

HEART FUNCTION TESTS

[Intraoperative cardiac risk and preoperative examinations from the anesthetic viewpoint] Rolf N, et al. **Dtsch Med Wochenschr** 1996 Apr 5;121(14):453–8 (47 ref.) **(Ger)**

[Diagnostic electrophysiological studies] Fuhrer J. **Schweiz Rundsch Med Prax** 1996 Apr 30;85(18):584–94 (20

ref.) (Eng. Abstr.) **(Ger)**

METHODS

Glossary: methods for the measurement of coronary blood flow and myocardial perfusion. Sakka SG, et al. **Basic Res Cardiol** 1996 Mar-Apr;91(2):155-78 (197 ref.)
Noninvasive measurement of cardiac output. Wilson AF. **Cardiologia** 1995 Aug;40(8):551-9 (77 ref.)

HEART HYPERTROPHY

COMPLICATIONS

[Myocardial hypertrophy and arterial hypertension] Trevi G, et al. **G Ital Cardiol** 1995 Oct;25(10):1331-8 (37 ref.) (Eng. Abstr.) **(Ita)**

DRUG THERAPY

Neurohormonal modulation in heart failure: ACE inhibition and beyond. Remme WJ. **Eur Heart J** 1995 Dec;16 Suppl N:73-8 (36 ref.)

ENZYMOLOGY

The role of protein kinases in adaptational growth of the heart. Bogoyevitch MA, et al. **Int J Biochem Cell Biol** 1996 Jan;28(1):1-12 (101 ref.)

ETIOLOGY

Evidence in vivo for induction of cardiovascular growth processes by vasoconstrictor systems. Adams MA, et al. **Blood Press Suppl** 1995;2:61-7 (64 ref.)
Stretching the evidence in the case of cardiac growth. Weber KT. **Cardiovasc Res** 1996 Apr;31(4):492-8 (45 ref.)
Cardiac hypertrophy and failure in hypertension. Johnson DB, et al. **Curr Opin Nephrol Hypertens** 1996 Mar; 5(2):186-91 (44 ref.)
[Cardiac hypertrophy and ischemic heart disease in obesity] Ohta M, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:332-7 (20 ref.) **(Jpn)**

GENETICS

Mechanoperception and mechanotransduction in cardiac adaptation: mechanical and molecular aspects. Reneman RS, et al. **Adv Exp Med Biol** 1995;382:185-94 (37 ref.)
The biological cascade leading to cardiac hypertrophy. Neyses L, et al. **Eur Heart J** 1995 Dec;16 Suppl N:8-11 (27 ref.)
Familial hypertrophic cardiomyopathy: a genetic model of cardiac hypertrophy. Watkins H, et al. **Hum Mol Genet** 1995;4 Spec No:1721-7 (59 ref.)
Molecular biology of myocardial hypertrophy and failure: gene expression and trophic signaling. Parker TG. **New Horiz** 1995 May;3(2):288-300 (113 ref.)
[Molecular adaptation of the heart to hypertension] Neyses L, et al. **Z Kardiol** 1995;84 Suppl 4:71-6 (21 ref.) (Eng. Abstr.) **(Ger)**
[Genetics and molecular biology of cardiac hypertrophy] Rossi G, et al. **G Ital Cardiol** 1995 Dec;25(12):1643-8 (20 ref.) **(Ita)**

METABOLISM

Collagen turnover and its regulation in the normal and hypertrophying heart. Bishop JE, et al. **Eur Heart J** 1995 May;16 Suppl C:38-44 (43 ref.)
Fibronectin expression during physiological and pathological cardiac growth. Farhadian F, et al. **J Mol Cell Cardiol** 1995 Apr;27(4):981-90 (57 ref.)
Calcium transport proteins in the nonfailing and failing heart: gene expression and function. Wankerl M, et al. **J Mol Med** 1995 Oct;73(10):487-96 (92 ref.)
Oxidative stress and heart failure. Singh N, et al. **Mol Cell Biochem** 1995 Jun 7-21;147(1-2):77-81 (36 ref.)

PATHOLOGY

Molecular and cellular biology of the senescent hypertrophied and failing heart. Swynghedauw B, et al. **Am J Cardiol** 1995 Nov 2;76(13):2D-7D (21 ref.)
The athlete's heart: is big beautiful? Shephard RJ. **Br J Sports Med** 1996 Mar;30(1):5-10 (75 ref.)
Ventricular remodeling in global ischemia. Anversa P, et al. **Cardioscience** 1995 Jun;6(2):89-100 (59 ref.)
Does ACE inhibition limit structural changes in the heart following myocardial infarction? Smits JF, et al. **Eur Heart J** 1995 Dec;16 Suppl N:46-51 (48 ref.)

PHYSIOPATHOLOGY

The cardiac renin-angiotensin-aldosterone system and hypertensive cardiac hypertrophy. Raman VK, et al. **Am J Cardiol** 1995 Nov 2;76(13):18D-23D (44 ref.)
The exchanger and cardiac hypertrophy. Menick DR, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:489-501 (18 ref.)
Cardiac hypertrophy and related growth processes: the role of insulin-like growth factor-I. Friberg P, et al. **Blood Press Suppl** 1995;2:22-9 (57 ref.)
Left atrial enlargement in healthy obese: prevalence and relation to left ventricular mass and diastolic function. Sasson Z, et al. **Can J Cardiol** 1996 Mar;12(3):257-63 (39 ref.)
Left ventricular hypertrophy regression as a process with variable biological implications. Simko F. **Can J Cardiol** 1996 May;12(5):507-13 (89 ref.)
The ageing spontaneously hypertensive rat as a model of the transition from stable compensated hypertrophy to heart failure. Boluyt MO, et al. **Eur Heart J** 1995 Dec;16 Suppl N:19-30 (49 ref.)
Post-infarction myocardial remodelling: why does it happen? Francis GS, et al. **Eur Heart J** 1995 Dec;16 Suppl N:31-6 (41 ref.)
Coronary reserve in experimental myocardial hypertrophy. Gosse P, et al. **Eur Heart J** 1995 Aug;16 Suppl I:22-5 (28 ref.)
Biological adaptation of the myocardium to chronic mechanical overload. Molecular determinants of the autonomic nervous system. Mondry A, et al. **Eur Heart J** 1995 Aug;16 Suppl I:64-73 (96 ref.)
Cardiovascular hypertrophy: role of angiotensin II and bradykinin. Waeber B, et al. **J Cardiovasc Pharmacol** 1996; 27 Suppl 2:S36-40 (37 ref.)
Biological characteristics of the myocardium during the regression of cardiac hypertrophy due to mechanical overload. Swynghedauw B, et al. **J Heart Valve Dis** 1995 Oct;4 Suppl 2:S154-9 (13 ref.)
[Genetics and molecular biology of cardiac hypertrophy] Rossi G, et al. **G Ital Cardiol** 1995 Dec;25(12):1643-8 (20 ref.) **(Ita)**

PREVENTION & CONTROL

Prevention of remodeling of the heart after myocardial infarction. Gorlin R. **Mt Sinai J Med** 1995 Sep;62(4):287-92 (32 ref.)

HEART INJURIES

Blunt myocardial injury [see comments] Feghali NT, et al. **Chest** 1995 Dec;108(6):1673-7 (35 ref.) Comment in: Chest 1996 May;109(5):1413-4.

COMPLICATIONS

Traumatic fistula between the left anterior descending coronary artery and a left ventricular pseudoaneurysm. Haapanen YT, et al. **Cardiovasc Intervent Radiol** 1996 Jul-Aug;19(4):272-4 (11 ref.)
[A case report of mitral valve plasty for traumatic mitral regurgitation] Shimokawa T, et al. **Kyobu Geka** 1996 Mar; 49(3):228-30 (9 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Cardiac and mediastinal trauma. Rosenthal MA, et al. **Emerg Med Clin North Am** 1995 Nov;13(4):887-902 (78 ref.)

EPIDEMIOLOGY

Traumatic rupture of the pericardium. Case report and literature review. Galindo Gallego M, et al. **J Cardiovasc Surg (Torino)** 1996 Apr;37(2):187-91 (32 ref.)

ETIOLOGY

Traumatic tricuspid insufficiency: a case followed for 32 years, with a note on early sources. FitzGibbon GM, et al. **Can J Cardiol** 1996 Mar;12(3):289-94 (19 ref.)

SURGERY

'Emergency room' thoracotomy: is it ever justified? Roxburgh JC. **Ann R Coll Surg Engl** 1996 Jul;78(4):327-30 (14 ref.)
Cardiopulmonary bypass for resuscitation after penetrating cardiac trauma. Karmy-Jones R, et al. **Ann Thorac Surg** 1996 Apr;61(4):1244-5 (5 ref.)
Penetrating cardiac injuries. Asensio JA, et al. **Surg Clin North Am** 1996 Aug;76(4):685-724 (119 ref.)
Successful repair of left ventricular rupture caused by blunt trauma: a case report. Aida H, et al. **Surgery** 1995 Nov; 118(5):907-8 (11 ref.)

HEART-LUNG BYPASS see **CARDIOPULMONARY BYPASS**

HEART-LUNG TRANSPLANTATION

[Pulmonary and cardiopulmonary transplantation in mucoviscidosis] Haloun A, et al. **Rev Pneumol Clin** 1995; 51(3):207-14 (47 ref.) (Eng. Abstr.) **(Fre)**

ADVERSE EFFECTS

Obliterative bronchiolitis after lung and heart-lung transplantation. Reichenspurner H, et al. **Ann Thorac Surg** 1995 Dec;60(6):1845-53 (86 ref.)

PHYSIOLOGY

[Respiratory insufficiency. Role of lung and heart/lung transplantation. Indications and results] Wagner TO. **Internist (Berl)** 1995 Aug;36(8):818-27 (37 ref.) **(Ger)**

HEART MASSAGE

METHODS

[Resuscitation by active compression and decompression] Dirks B. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Aug; 30(5):309-12 (10 ref.) **(Ger)**

HEART MITOCHONDRIA see **MITOCHONDRIA, HEART**

HEART MURMURS

see related
HEART AUSCULTATION

DIAGNOSIS

Innocent heart murmurs in children. Taking a diagnostic approach. Saunders NR. **Can Fam Physician** 1995 Sep; 41:1507-12 (12 ref.)
How to differentiate ejection murmurs from systolic regurgitant murmurs. Constant J. **Keio J Med** 1995 Sep; 44(3):85-7 (3 ref.)

THERAPY

The preoperative management of the child with a heart murmur. McEwan AI, et al. **Paediatr Anaesth** 1995; 5(3):151-6 (28 ref.)

HEART NEOPLASMS

[Malignant non-Hodgkin lymphoma of cardiac localization.Apropos of a case] Ghannem M, et al. **Ann Cardiol Angeiol (Paris)** 1995 Sep;44(7):345-8 (26 ref.) (Eng. Abstr.) **(Fre)**

BLOOD SUPPLY

Intracardiac pheochromocytoma with dual coronary blood supply: case report and literature review. Fitzgerald PJ, et al. **Cardiovasc Surg** 1995 Oct;3(5):557-61 (20 ref.)

COMPLICATIONS

Congestive heart failure due to rapid right ventricular obliteration by metastatic malignant melanoma. Rusconi C, et al. **Minerva Cardioangiol** 1996 Mar;44(3):123-5 (8 ref.)
Non-immunological hydrops fetalis and intrapericardial teratoma: case report and review. Perez-Aytes A, et al. **Prenat Diagn** 1995 Sep;15(9):859-63 (20 ref.)
[Heart rupture at the right atrial level as the first manifestation of malignant lymphoma] Menotti A, et al. **Cardiologia** 1996 Jan;41(1):65-7 (10 ref.) (Eng. Abstr.) **(Ita)**

DIAGNOSIS

Chronic constrictive pericarditis presenting as mass lesion in infancy. Dharmapuran AK, et al. **Indian Heart J** 1996 May-Jun;48(3):290-1 (7 ref.)
MR evaluation of the pericardium and cardiac malignancies. White CS. **Magn Reson Imaging Clin N Am** 1996 May; 4(2):237-51 (48 ref.)
Cardiac myxomas [see comments] Reynen K. **N Engl J Med** 1995 Dec 14;333(24):1610-7 (128 ref.) Comment in: N Engl J Med 1996 May 23;334(21):1407-8; discussion 1408-9. Comment in: N Engl J Med 1996 May 23;334(21):1408; discussion 1408-9.
MR evaluation of cardiac/juxtacardiac masses. Link KM, et al. **Top Magn Reson Imaging** 1995 Fall;7(4):232-45 (46 ref.)
[Primary liposarcoma of the left ventricle. Apropos of a case and review of the literature] Pinelli G, et al. **Arch Mal Coeur Vaiss** 1996 Feb;89(2):257-60 (10 ref.) (Eng. Abstr.) **(Fre)**
[A pseudomass of the right atrium: an incidental echographic and magnetic resonance finding in a man over 100] Sessa M, et al. **Radiol Med (Torino)** 1996 Jan-Feb;91(1-2):135-7 (15 ref.) **(Ita)**
[The diagnostic problem of cardiac myxoma (editorial)] Zghaib Abad A, et al. **Arch Inst Cardiol Mex** 1995 May-Jun;65(3):193-5 (19 ref.) **(Spa)**

PATHOLOGY

Primary right atrial fibrosarcoma diagnosed by endocardial biopsy. Basso C, et al. **Am Heart J** 1996 Feb;131(2):399-402 (11 ref.)
Erythematous papules in a patient with cardiac myxoma: a case report and review of the literature. Misago N, et al. **J Dermatol** 1995 Aug;22(8):600-5 (22 ref.)
Malignant fibrous histiocytoma of the right ventricle of the heart. Teramoto N, et al. **Pathol Int** 1995 Apr;45(4):315-9 (17 ref.)

SECONDARY

Complete resection of a right atrial intracavitary metastatic melanoma. Chen RH, et al. **Ann Thorac Surg** 1996 Apr; 61(4):1255-7 (8 ref.)
Pericardial metastasis in carcinoma of the uterine cervix. Jamshed A, et al. **Gynecol Oncol** 1996 Jun;61(3):451-3 (16 ref.)
Congestive heart failure due to rapid right ventricular obliteration by metastatic malignant melanoma. Rusconi C, et al. **Minerva Cardioangiol** 1996 Mar;44(3):123-5 (8 ref.)
[Intracardiac metastases of germ cell tumors. Apropos of a case (letter)] Hauteville D, et al.

HEART NEOPLASMS

Ann Med Interne (Paris) 1996;147(3):218–21 (26 ref.) **(Fre)**

[Metastatic heart tumors] Reynen K. **Dtsch Med Wochenschr** 1995 Sep 22;120(38):1290–5 (78 ref.) **(Ger)**

[A rare form of heart metastasis: hypernephroma. Successful surgical treatment] Minale C, et al. **Z Kardiol** 1995 Aug; 84(8):643–7 (7 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Complete resection of a right atrial intracavitary metastatic melanoma. Chen RH, et al. **Ann Thorac Surg** 1996 Apr; 61(4):1255–7 (8 ref.)

Excision of papillary fibroelastoma arising from the septal leaflet of the tricuspid valve. Lee CC, et al. **J Card Surg** 1995 Sep;10(5):589–91 (11 ref.)

Right atrial lipoma. Case report. Matta R, et al. **J Cardiovasc Surg (Torino)** 1996 Apr;37(2):165–8 (8 ref.)

Mitral valve myxoma: a case report and brief review of the literature. Kulshrestha P, et al. **J Heart Valve Dis** 1995 Mar;4(2):196–8 (7 ref.)

Papillary fibroelastoma of the mitral valve. A rare cause of embolic events. Colucci V, et al. **Tex Heart Inst J** 1995; 22(4):327–31 (31 ref.)

[Myxoma of the mitral valve; apropos of 2 surgically treated cases. Review of the literature] Leude E, et al. **Arch Mal Coeur Vaiss** 1995 Sep;88(9):1345–8 (18 ref.) (Eng. Abstr.) **(Fre)**

HEART RATE

Atrial fibrillation: maintenance of sinus rhythm versus rate control. Sopher SM, et al. **Am J Cardiol** 1996 Jan 25; 77(3):24A–37A (128 ref.)

Restoration of sinus rhythm in patients with atrial fibrillation. Talajic M, et al. **Can J Cardiol** 1996 Jan;12 Suppl A:29A–35A (83 ref.)

Power spectral analysis of heart rate variability during upright tilt test: a comparison of patients with syncope and normal subjects. Boulos M, et al. **Cardiology** 1996 Jan–Feb; 87(1):28–32 (20 ref.)

ATPase activity, IF1 content, and proton conductivity of ESMP from control and ischemic slow and fast heart-rate hearts. Rouslin W, et al. **J Bioenerg Biomembr** 1995 Aug; 27(4):459–66 (30 ref.)

A review of heart rate and blood pressure responses in the cold in healthy subjects and coronary artery disease patients. Emmett JD. **J Cardpulm Rehabil** 1995 Jan–Feb; 15(1):19–24 (47 ref.)

Nonlinear forecasting and the dynamics of cardiac rhythm. Lippman N, et al. **J Electrocardiol** 1995;28 Suppl:65–70 (15 ref.)

Control of rapid heart rate in patients with atrial fibrillation: drugs or ablation? Brignole M, et al. **Pacing Clin Electrophysiol** 1996 Mar;19(3):348–56 (63 ref.)

[Measurement and importance of heart rate variability] Huikuri HV, et al. **Duodecim** 1995;111(4):307–14 (37 ref.) **(Fin)**

[Cardio-respirography in neonatal medicine: value, interpretation, indications] Favre A, et al. **Arch Pediatr** 1996 May;3(5):480–8 (43 ref.) (Eng. Abstr.) **(Fre)**

[How to regulate the heart rate in a wearer of a cardiac pacemaker] Rossi P. **Cardiologia** 1996 Mar;41(3):227–40 (29 ref.) **(Ita)**

DRUG EFFECTS

Heart rate reduction in the treatment of chronic stable angina pectoris: experiences with a sinus node inhibitor [editorial] Frishman WH, et al. **Am Heart J** 1996 Jan;131(1):204–10 (63 ref.)

Pharmacological stress echocardiography—practical considerations. Schröder K. **Br J Clin Pract Symp Suppl** 1995 Nov;82:6–9 (6 ref.)

Heart rate control in patients with atrial fibrillation. Gardner MJ, et al. **Can J Cardiol** 1996 Jan;12 Suppl A:21A–23A (26 ref.)

New potential uses for transdermal scopolamine (hyoscine). La Rovere MT, et al. **Drugs** 1995 Nov;50(5):769–76 (49 ref.)

[Variability of antiarrhythmic drug action in prolonging action potential duration during various rates of heart action] Zakrzewski D, et al. **Pol Arch Med Wewn** 1996 Apr;95(4):383–7 (20 ref.) **(Pol)**

PHYSIOLOGY

Functional roles of sodium–calcium exchange in normal and abnormal cardiac rhythm. Noble D, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:480–8 (17 ref.)

How good are patients with panic disorder at perceiving their heartbeats? Ehlers A, et al. **Biol Psychol** 1996 Jan 5;42(1–2):165–82 (55 ref.)

Linear and non-linear analyses of heart rate variability: a minireview. Mansier P, et al. **Cardiovasc Res** 1996 Mar; 31(3):371–9 (64 ref.)

Chronotropic incompetence—Part I: Normal regulation of the heart rate. Camm AJ, et al. **Clin Cardiol** 1996 May; 19(5):424–8 (45 ref.)

Effect of different interventions on heart rate variability after heart transplantation: non-autonomic vs autonomic factors. Bernardi L, et al. **Clin Sci (Colch)** 1996;91 Suppl:22–4 (24 ref.)

Analysis of heart rate and blood pressure variability in the assessment of autonomic regulation in arterial hypertension. Parati G, et al. **Clin Sci (Colch)** 1996;91 Suppl:129–32 (39 ref.)

Selecting training workloads using treadmill test heart rate/oxygen uptake regressions. McConnell TR. **J Cardpulm Rehabil** 1996 May–Jun;16(3):160–2 (8 ref.)

Heart rate and blood pressure variability: implications for psychiatric research. Yeragani VK. **Neuropsychobiology** 1995;32(4):182–91 (80 ref.)

The relationship between social support and physiological processes: a review with emphasis on underlying mechanisms and implications for health. Uchino BN, et al. **Psychol Bull** 1996 May;119(3):488–531 (276 ref.)

Normal sinus heart rate: appropriate rate thresholds for sinus tachycardia and bradycardia. Spodick DH. **South Med J** 1996 Jul;89(7):666–7 (9 ref.)

[Control of heart rate and atrial fibrillation] Gardner MJ, et al. **Can J Cardiol** 1996 Feb;12 Suppl A:18A–21A (26 ref.) **(Fre)**

[Analysis of heart rate variability. Background, method, and possible use in anesthesia] Baumert JH, et al. **Anaesthesist** 1995 Oct;44(10):677–86 (79 ref.) (Eng. Abstr.) **(Ger)**

[An analysis of heart rate variability. Spectrum analysis methods and complex signal demodulation] Burguera Pérez M, et al. **Rev Esp Cardiol** 1995 Oct;48(10):650–9 (49 ref.) (Eng. Abstr.) **(Spa)**

HEART RATE, FETAL

Intrapartum use of fetal heart rate monitoring, contraction monitoring, and amnioinfusion. Cusick W, et al. **Clin Perinatol** 1995 Dec;22(4):875–906 (130 ref.)

Medicolegal ramifications of electronic fetal monitoring during labor. Schifrin BS. **Clin Perinatol** 1995 Dec; 22(4):837–54 (42 ref.)

Improvements in computerized fetal heart rate analysis antepartum. Dawes GS, et al. **J Perinat Med** 1996; 24(1):25–36 (38 ref.)

[Fetal admission test and fetal heart rate response to vibratory stimuli test] Wu L. **Chung Hua Fu Chan Ko Tsa Chih** 1995 Oct;30(10):633–5 (18 ref.) **(Chi)**

PHYSIOLOGY

Intelligent fetal heart rate computer systems in intrapartum surveillance. Greene KR. **Curr Opin Obstet Gynecol** 1996 Apr;8(2):123–7 (19 ref.)

HEART RUPTURE

COMPLICATIONS

Acute ascites with blunt cardiac rupture. Dagenais F, et al. **Can J Cardiol** 1996 Jan;12(1):86–8 (12 ref.)

[Acute mitral valve insufficiency] Acar J. **Ann Cardiol Angeiol (Paris)** 1995 Dec;44(10):561–6 (22 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

[Heart rupture at the right atrial level as the first manifestation of malignant lymphoma] Menotti A, et al. **Cardiologia** 1996 Jan;41(1):65–7 (10 ref.) (Eng. Abstr.) **(Ita)**

ULTRASONOGRAPHY

[Morphological study by transesophageal echocardiography and clinical aspects of ruptured chordae tendineae in the elderly] Benhalima B, et al. **Arch Mal Coeur Vaiss** 1995 Mar;88(3):345–52 (29 ref.) (Eng. Abstr.) **(Fre)**

HEART RUPTURE, POST-INFARCTION

DIAGNOSIS

Postinfarction ventricular free wall rupture: strategies for diagnosis and treatment. Sutherland FW, et al. **Ann Thorac Surg** 1996 Apr;61(4):1281–5 (47 ref.)

Pitfalls in the diagnosis and management of papillary muscle rupture: a study of four cases and review of the literature. Samman B, et al. **Clin Cardiol** 1995 Oct;18(10):591–6 (34 ref.)

Recognition of mechanical complications of acute myocardial infarction. Warnick WC, et al. **Compr Ther** 1995 Jul; 21(7):362–6 (21 ref.)

SURGERY

Pitfalls in the diagnosis and management of papillary muscle rupture: a study of four cases and review of the literature. Samman B, et al. **Clin Cardiol** 1995 Oct;18(10):591–6 (34 ref.)

[Left free wall rupture complicating acute myocardial infarction—a case report of surgical success by a new modified method] Imura H, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Apr;44(4):511–5 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Papillary muscle rupture complicating acute myocardial infarction—treatment with mitral valve replacement and coronary bypass surgery in acute phase] Kyo S, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Jun;44(6):874–81 (23 ref.) (Eng. Abstr.) **(Jpn)**

ULTRASONOGRAPHY

[Value of transesophageal echocardiography in post-infarction septal ruptures] Maillier B, et al. **Arch Mal Coeur Vaiss** 1996 Jun;89(6):695–702 (27 ref.) (Eng. Abstr.) **(Fre)**

HEART RUPTURE, TRAUMATIC see **HEART INJURIES**

HEART SEPTAL DEFECTS

SURGERY

[The usefulness of inhaled nitric oxide in the treatment of pulmonary hypertension in the postoperative period of cardiac surgery in infancy] de Lucas García N, et al. **An Esp Pediatr** 1996 Apr;44(4):373–6 (27 ref.) **(Spa)**

HEART SEPTAL DEFECTS, ATRIAL

COMPLICATIONS

Paradoxical bullet embolism: case report and literature review. Schurr M, et al. **J Trauma** 1996 Jun;40(6):1034–6 (11 ref.)

[Five cases of ASD–PDA complex: a review of 38 cases reported in Japan] Iguchi T, et al. **Kyobu Geka** 1995 Aug; 48(9):732–4 (6 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

[The diagnosis, clinical significance and therapy of patent foramen ovale] Job FP, et al. **Dtsch Med Wochenschr** 1996 Jul 12;121(28–29):919–25 (29 ref.) **(Ger)**

[The integrated imaging of a rare case of partial anomalous pulmonary venous connections] Midiri M, et al. **Radiol Med (Torino)** 1995 Sep;90(3):320–3 (10 ref.) **(Ita)**

[Supraventricular cardiac arrhythmia and fenestrated aneurysm of the interatrial septum in a newborn infant] Armengol Rofes AJ, et al. **An Esp Pediatr** 1996 Jan; 44(1):63–4 (7 ref.) **(Spa)**

GENETICS

Cardiac malformation in two infants with hypochondrogenesis. Potocki L, et al. **Am J Med Genet** 1995 Nov 20;59(3):295–9 (17 ref.)

PHYSIOPATHOLOGY

Right-to-left flow through a patent foramen ovale in acute right ventricular infarction. Two case reports and a proposal for management. Amsel BJ, et al. **Chest** 1995 Nov; 108(5):1468–71 (23 ref.)

SURGERY

Combined valve replacement and coronary bypass grafting in osteogenesis imperfecta [see comments] Almassi GH, et al. **Ann Thorac Surg** 1995 Nov;60(5):1395–7 (15 ref.) Comment in: Ann Thorac Surg 1996 Apr;61(4):1294.

Closure of atrial septal defect in adult life. Oakley CM. **Cardiologia** 1996 Jan;41(1):31–4 (22 ref.)

THERAPY

[Which treatment for patients with cerebrovascular accident and patent foramen ovale?] Devuyst G, et al. **Rev Med Suisse Romande** 1996 Aug;116(8):639–43 (30 ref.) **(Fre)**

[The diagnosis, clinical significance and therapy of patent foramen ovale] Job FP, et al. **Dtsch Med Wochenschr** 1996 Jul 12;121(28–29):919–25 (29 ref.) **(Ger)**

ULTRASONOGRAPHY

[Atrial septal aneurysm. Report of two clinical cases and review of the literature] Perrotta S, et al. **Minerva Cardioangiol** 1995 Jul–Aug;43(7–8):339–43 (23 ref.) (Eng. Abstr.) **(Ita)**

[Transesophageal echocardiography. Indications and clinical impact] Campos Filho O. **Arq Bras Cardiol** 1995 Apr; 64(4):383–9 (47 ref.) **(Por)**

HEART SEPTAL DEFECTS, VENTRICULAR

COMPLICATIONS

Double outlet right ventricle with restrictive ventricular septal defect. Sardana R, et al. **Indian Heart J** 1996 Jan–Feb;48(1):59–60 (10 ref.)

SURGERY

[Double outlet left ventricle: a rare and unusual cardiopathy. Apropos of 7 new cases] Gouton M, et al. **Arch Mal Coeur Vaiss** 1996 May;89(5):553–9 (10 ref.) (Eng. Abstr.) **(Fre)**

[Pulmonary arborization abnormalities in complex forms of pulmonary atresia with ventricular septal defect: unification, unifocalization and complete repair] Macé L, et al. **Arch Mal Coeur Vaiss** 1996 May;89(5):561–8 (31 ref.) (Eng. Abstr.) **(Fre)**

HEART SEPTUM

[Value of transesophageal echocardiography in post-infarction septal ruptures] Maillier B, et al. **Arch Mal Coeur Vaiss** 1996 Jun;89(6):695-702 (27 ref.) (Eng. Abstr.) **(Fre)**

RADIOGRAPHY

The descending septal branch (Bonapace's branch). A case report and literature review of this often forgotten branch. First description in vivo. Said M, et al. **Eur Heart J** 1995 Oct;16(10):1443-7 (43 ref.)

HEART SOUNDS

see related
HEART AUSCULTATION
HEART MURMURS

HEART SURGERY

Role of echocardiography in perioperative management of patients undergoing open heart surgery. Joffe II, et al. **Am Heart J** 1996 Jan;131(1):162-76 (130 ref.)

Acute gastrointestinal complications after cardiac surgery. Halm MA. **Am J Crit Care** 1996 Mar;5(2):109-18; quiz 119-20 (34 ref.)

Individual factors that influence sleep after cardiac surgery. Simpson T, et al. **Am J Crit Care** 1996 May;5(3):182-9; quiz 190-1 (31 ref.)

Cardiac surgery and cold-reactive proteins. Agarwal SK, et al. **Ann Thorac Surg** 1995 Oct;60(4):1143-50 (47 ref.)

Inhaled nitric oxide: therapeutic applications in cardiothoracic surgery. Fullerton DA, et al. **Ann Thorac Surg** 1996 Jun;61(6):1856-64 (56 ref.)

Cardiac surgical implications of calcium dyshomeostasis in the heart. Meldrum DR, et al. **Ann Thorac Surg** 1996 Apr; 61(4):1273-80 (61 ref.)

Cardiopulmonary bypass in pregnancy. Pomini F, et al. **Ann Thorac Surg** 1996 Jan;61(1):259-68 (65 ref.)

Mycoplasma hominis infections occurring in cardiovascular surgical patients. Sielaff TD, et al. **Ann Thorac Surg** 1996 Jan;61(1):99-103 (21 ref.)

Fast-tracking in cardiac surgery. Aps C. **Br J Hosp Med** 1995 Aug 16-Sep 5;54(4):139-42 (5 ref.)

New strategies for intraoperative myocardial protection. Flameng W. **Curr Opin Cardiol** 1995 Nov;10(6):577-83 (37 ref.)

Blood use in cardiac surgery and the limitations of hemodilution. Mossad E, et al. **Curr Opin Cardiol** 1995 Nov; 10(6):584-90 (44 ref.)

Dopexamine after cardiac surgery. **Drug Ther Bull** 1995 Apr; 33(4):30-2 (17 ref.)

Co-induction of anaesthesia: the cardiac patient. Duthie DJ. **Eur J Anaesthesiol Suppl** 1995 Nov;12:21-4 (26 ref.)

Intraoperative blood salvage (IOBS) in cardiac and vascular surgery. Valbonesi M, et al. **Int J Artif Organs** 1995 Mar; 18(3):130-5 (19 ref.)

Timing of tracheal extubation in adult cardiac surgery patients [published erratum appears in J Card Surg 1995 Nov;10(6):following table of contents] Hickey RF, et al. **J Card Surg** 1995 Jul;10(4 Pt 1):340-8 (44 ref.)

Pro: early extubation after cardiac surgery decreases intensive care unit stay and cost [see comments] Cheng DC. **J Cardiothorac Vasc Anesth** 1995 Aug;9(4):460-4 (45 ref.) Comment in: J Cardiothorac Vasc Anesth 1995 Aug;9(4):465-7.

Magnetic resonance studies of the effects of cardiovascular surgery on brain metabolism and function. Deslauriers R, et al. **J Cardiothorac Vasc Anesth** 1996 Jan;10(1):127-37; quiz 137-8 (49 ref.)

The role of neuromonitoring in cardiovascular surgery. Edmonds HL Jr, et al. **J Cardiothorac Vasc Anesth** 1996 Jan;10(1):15-23 (51 ref.)

Con: early extubation after cardiac surgery does not decrease intensive care unit stay and cost [comment] Guenther CR. **J Cardiothorac Vasc Anesth** 1995 Aug;9(4):465-7 (12 ref.) Comment on: J Cardiothorac Vasc Anesth 1995 Aug;9(4):460-4.

Transcranial Doppler ultrasonography: what is its role in cardiac and vascular surgical patients? Kahn RA, et al. **J Cardiothorac Vasc Anesth** 1995 Oct;9(5):589-97 (71 ref.)

Ventricular tachycardia after myocardial infarction: from arrhythmia surgery to catheter ablation. Stevenson WG. **J Cardiovasc Electrophysiol** 1995 Oct;6(10 Pt 2):942-50 (52 ref.)

Perioperative use of propofol for cardiac surgery. Jain U. **J Clin Anesth** 1996 May;8(3 Suppl):61S-66S (81 ref.)

Is aprotinin safe when used in the context of profound hypothermia and circulatory arrest? A literary review [comment] Hornick P, et al. **J Heart Valve Dis** 1995 Nov; 4(6):669-73 (60 ref.) Comment on: J Heart Valve Dis 1995 Nov;4(6):674-7.

Statistical methods and strategies for working with large data bases. Marshall G, et al. **Med Care** 1995 Oct;33(10 Suppl):OS35-42 (20 ref.)

Radiologic evaluation of the patient after cardiac surgery. Henry DA. **Radiol Clin North Am** 1996 Jan;34(1):119-35 (43 ref.)

[Progresses in cardiovascular surgery in China, 1995] Chen B. **Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):738-9 (0 ref.) **(Chi)**

[Use of aprotinin in cardiovascular surgery] Colorio C, et al. **Sangre (Barc)** 1995 Jun;40(3):207-11 (34 ref.) **(Spa)**

ADVERSE EFFECTS

Atrial fibrillation following cardiac surgery. Pagé PL, et al. **Can J Cardiol** 1996 Jan;12 Suppl A:40A-44A (45 ref.)

The role of nitric oxide and NO-donor agents in myocardial protection from surgical ischemic-reperfusion injury. Vinten-Johansen J, et al. **Int J Cardiol** 1995 Jul; 50(3):273-81 (47 ref.)

Neuropsychologic change after cardiac surgery: a critical review. Borowicz LM, et al. **J Cardiothorac Vasc Anesth** 1996 Jan;10(1):105-11; quiz 111-2 (61 ref.)

Neurologic assessment and cardiac surgery. Heyer EJ, et al. **J Cardiothorac Vasc Anesth** 1996 Jan;10(1):99-103; quiz 103-4 (42 ref.)

Markers of cerebral ischemia after cardiac surgery. Johnsson P. **J Cardiothorac Vasc Anesth** 1996 Jan;10(1):120-6 (67 ref.)

Cerebral emboli and cognitive outcome after cardiac surgery. Stump DA, et al. **J Cardiothorac Vasc Anesth** 1996 Jan; 10(1):113-8; quiz 118-9 (43 ref.)

[Post-heart surgery auricular fibrillation] Pagé PL, et al. **Can J Cardiol** 1996 Feb;12 Suppl A:38A-43A (45 ref.) **(Fre)**

[Pericardial effusion in heart surgery interventions] Pepi M, et al. **Cardiologia** 1995 Apr;40(4):267-72 (31 ref.) **(Ita)**

[Heart surgery, cardiopulmonary bypass and inflammatory response. I. Changes in hemostasis and complement] Parolari A, et al. **G Ital Cardiol** 1996 Apr;26(4):431-46 (121 ref.) (Eng. Abstr.) **(Ita)**

[Performing surgery on patients in their 80's may be beneficial. Age alone is not a risk factor in heart surgery] Brattgård D, et al. **Lakartidningen** 1996 Jan 31;93(5):376-81 (25 ref.) **(Swe)**

ECONOMICS

Economic rationale for early extubation. Velasco FT, et al. **J Cardiothorac Vasc Anesth** 1995 Oct;9(5 Suppl 1):2-9 (17 ref.)

METHODS

Normothermic techniques during open heart operations. Birdi I, et al. **Ann Thorac Surg** 1996 May;61(5):1573-80 (75 ref.)

Optimal myocardial preservation: cooling, cardioplegia, and conditioning. Cleveland JC Jr, et al. **Ann Thorac Surg** 1996 Feb;61(2):760-8 (75 ref.)

Pharmacokinetic and pharmacodynamic principles in providing "fast-track" recovery. Glass PS. **J Cardiothorac Vasc Anesth** 1995 Oct;9(5 Suppl 1):16-20 (29 ref.)

Changes in cardiovascular surgical approaches to achieve early extubation. Verrier ED, et al. **J Cardiothorac Vasc Anesth** 1995 Oct;9(5 Suppl 1):10-5 (23 ref.)

Skeletal muscle as a myocardial substitute. Greer KA, et al. **Proc Soc Exp Biol Med** 1996 Apr;211(4):297-305 (36 ref.)

[Hypertrophic obstructive cardiomyopathy: surgical treatment] Schulte HD, et al. **Schweiz Med Wochenschr** 1995 Oct 14;125(41):1940-9 (18 ref.) (Eng. Abstr.) **(Ger)**

PSYCHOLOGY

A multidimensional model of the antecedents of stress and coping appraisals: an approach to studying patients' perceptions of post cardiac surgery pain and their coping strategies. Shih FJ, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1996 Apr; 12(4):202-15 (22 ref.)

STANDARDS

Standardizing care delivery for infants and children with common congenital cardiac lesions. Allen HD, et al. **Curr Opin Pediatr** 1995 Oct;7(5):601-5 (33 ref.)

Why it is important to demonstrate linkages between outcomes of care and processes and structures of care. Hammermeister KE, et al. **Med Care** 1995 Oct;33(10 Suppl):OS5-16 (58 ref.)

TRENDS

What's new in cardiac surgery. Rose EA. **J Am Coll Surg** 1996 Feb;182(2):83-8 (52 ref.)

HEART TRANSPLANTATION

Treatment of hyperlipidemia after heart transplantation and rationale for the Heart Transplant Lipid Registry. Ballantyne CM, et al. **Am J Cardiol** 1996 Sep 1;78(5):532-5 (34 ref.)

Heart transplantation for Chagas' cardiomyopathy. Blanche C, et al. **Ann Thorac Surg** 1995 Nov;60(5):1406-8; discussion 1408-9 (12 ref.)

Assessing appropriateness of treatment: a case study of transplantation in older patients with congestive heart failure. Montague T, et al. **Can J Cardiol** 1996 Jan; 12(1):47-52 (33 ref.)

Evolving concepts regarding selection of patients for cardiac transplantation. Assessing risks and benefits. Torre-Amione G, et al. **Chest** 1996 Jan;109(1):223-32 (63 ref.)

Selection and treatment of candidates for heart transplantation. A statement for health professionals from the Committee on Heart Failure and Cardiac Transplantation of the Council on Clinical Cardiology, American Heart Association. Costanzo MR, et al. **Circulation** 1995 Dec 15;92(12):3593-612 (139 ref.)

Mycophenolate mofetil (MMF) in heart transplantation: rejection prevention and treatment. Renlund DG, et al. **Clin Transplant** 1996 Feb;10(1 Pt 2):136-9 (29 ref.)

Newborn and infant heart transplantation. Webber SA. **Curr Opin Cardiol** 1996 Jan;11(1):68-74 (28 ref.)

Hypertension after cardiac transplantation: pathophysiology and management. Sander M, et al. **Curr Opin Nephrol Hypertens** 1995 Sep;4(5):443-51 (125 ref.)

Current trends in cardiac transplantation. Gopinathan SK, et al. **Indian Heart J** 1995 Jul-Aug;47(4):323-9 (43 ref.)

Heart transplantation. Pepper JR, et al. **J Antimicrob Chemother** 1995 Oct;36 Suppl B:23-38 (59 ref.)

When to transplant: Recipient selection for heart transplantation. Grady KL. **J Cardiovasc Nurs** 1996 Jan; 10(2):58-70 (55 ref.)

Atrioventricular block occurring late after heart transplantation: presentation of three cases and literature review. Cataldo R, et al. **Pacing Clin Electrophysiol** 1996 Mar;19(3):325-30 (15 ref.)

Cardiac Transplantation: a review. Sadowsky HS. **Phys Ther** 1996 May;76(5):498-515 (166 ref.)

Selection and treatment of candidates for heart transplantation. Costanzo MR. **Semin Thorac Cardiovasc Surg** 1996 Apr;8(2):113-25 (88 ref.)

The surgical management of allograft coronary disease: a paradigm shift. Miller LW, et al. **Semin Thorac Cardiovasc Surg** 1996 Apr;8(2):133-8 (54 ref.)

The vascular biology of heart and lung preservation for transplantation. Pinsky DJ. **Thromb Haemost** 1995 Jul; 74(1):58-65 (50 ref.)

Prevention and treatment of cytomegalovirus disease in thoracic organ transplant patients: evidence for a beneficial effect of hyperimmune globulin. Valantine HA. **Transplant Proc** 1995 Oct;27(5 Suppl 1):49-57 (62 ref.)

[Advances in the pathology of human cardiac transplantation] Zhao H, et al. **Chung Hua I Hsueh Tsa Chih** 1995 Jul; 75(7):440-3 (30 ref.) **(Chi)**

[Post-partum cardiomyopathy: medical aspects, role of heart transplantation] Bertrand É. **Arch Mal Coeur Vaiss** 1995 Nov;88(11):1635-40 (42 ref.) (Eng. Abstr.) **(Fre)**

[Exercise capacity after heart transplantation] Cohen-Solal A, et al. **Presse Med** 1995 Dec 9;24(38):1806-8 (29 ref.) (Eng. Abstr.) **(Fre)**

[Patient management following cardiac transplantation] Seydoux C, et al. **Schweiz Med Wochenschr** 1995 Oct 14; 125(41):1913-22 (103 ref.) (Eng. Abstr.) **(Fre)**

[Osteoporosis following heart transplantation. Pathogenesis and therapy] Stempfle HU. **Dtsch Med Wochenschr** 1996 Sep 6;121(36):1103-7 (44 ref.) **(Ger)**

[Coronary endothelial dysfunction and graft atheromatosis following heart transplantation] Vassalli G. **Schweiz Med Wochenschr** 1995 Oct 14;125(41):1923-30 (51 ref.) (Eng. Abstr.) **(Ger)**

[Does heart disease recur following heart transplantation?] Gallino A. **Ther Umsch** 1995 Sep;52(9):581-4 (24 ref.) (Eng. Abstr.) **(Ger)**

[When should the family physician contact the cardiological transplantation team?] Mohacsi P, et al. **Ther Umsch** 1995 Sep;52(9):617-25 (31 ref.) (Eng. Abstr.) **(Ger)**

[Indication and clinical results of heart transplantation in the terminal stage of ischemic cardiomyopathy] Kyo S, et al. **Nippon Geka Gakkai Zasshi** 1996 Mar;97(3):240-4 (9 ref.) (Eng. Abstr.) **(Jpn)**

[Pregnancy after heart transplantation] Almeida DR, et al. **Arq Bras Cardiol** 1995 Sep;65(3):237-42 (41 ref.) (Eng. Abstr.) **(Por)**

[Dynamic control of acute crisis of rejection of the transplanted heart based on echocardiography] Kuznetsova LM, et al. **Khirurgiia (Mosk)** 1995;(5):69-72 (47 ref.) **(Rus)**

[Epididymal malacoplakia in a heart transplant recipient: clinico-pathologic study of a case] Soria Corón MR, et al. **Arch Esp Urol** 1996 Mar;49(2):172-6 (15 ref.) (Eng. Abstr.) **(Spa)**

[The significance of cytomegalovirus infection in the period after a heart transplant] Manito N, et al. **Rev Esp Cardiol** 1995;48 Suppl 7:108-14 (36 ref.) (Eng. Abstr.) **(Spa)**

[Graft vascular disease. Its pathogenesis and diagnosis] Muñoz Aguilera R, et al. **Rev Esp Cardiol** 1995;48 Suppl 7:115-28 (164 ref.) (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Tuberculosis in heart transplant recipients. Muñoz P, et al. **Clin Infect Dis** 1995 Aug;21(2):398-402 (36 ref.)

Adhesion molecules and cell surface receptors in the heart transplant-associated arteriosclerosis. Hinek A. **Folia Histochem Cytobiol** 1996;34(1):3-19 (140 ref.)

Heart transplants for patients with Chagas' heart disease. Bocchi EA. **Rev Paul Med** 1995 Mar-Apr;113(2):873-9 (29 ref.)

[Value of dobutamine echocardiography in the detection of coronary disease in heart transplant patient. Groupe de

Recherche VACOMED] Derumeaux G, et al. **Arch Mal Coeur Vaiss** 1996 Jun;89(6):687–94 (30 ref.) (Eng. Abstr.) **(Fre)**

[Transplant vasculopathy following heart transplantation] Weis M, et al. **Dtsch Med Wochenschr** 1995 Sep 29; 120(39):1327–33 (50 ref.) **(Ger)**

[Lymphoproliferative disease and cancer in the transplant patient] Herreros J, et al. **Rev Esp Cardiol** 1995;48 Suppl 7:129–34 (44 ref.) (Eng. Abstr.) **(Spa)**

[Neurological complications after transplants: cerebrovascular complications] Martínez-Vila E, et al. **Rev Neurol** 1995;23 Suppl 1:S79–86 (49 ref.) **(Spa)**

IMMUNOLOGY

Pathogenesis and mechanisms of graft rejection in concordant xenotransplantation with special reference to hamster–to–rat cardiac transplantation. Steinbrüchel DA. **APMIS Suppl** 1996;58:5–45 (281 ref.)

Local cellular immunology of experimental transplant vascular sclerosis. Orosz CG. **Clin Transplant** 1996 Feb;10(1 Pt 2):100–3 (21 ref.)

The role of histoincompatibility in cardiac allograft vasculopathy. Costanzo MR. **J Heart Lung Transplant** 1995 Nov–Dec;14(6 Pt 2):S180–4 (19 ref.)

Acute rejection: culprit or coincidence in the pathogenesis of cardiac graft vascular disease? Hauptman PJ, et al. **J Heart Lung Transplant** 1995 Nov–Dec;14(6 Pt 2):S173–80 (55 ref.)

Role of heat shock proteins in heart transplant rejection. Liu K, et al. **J Heart Lung Transplant** 1996 Mar;15(3):222–8 (71 ref.)

Role of antibody and indirect antigen presentation in transplant–associated coronary artery vasculopathy. Rose ML. **J Heart Lung Transplant** 1996 Apr;15(4):342–9 (75 ref.)

Macrophages and transplant arteriosclerosis: known and novel molecules. Russell ME. **J Heart Lung Transplant** 1995 Nov–Dec;14(6 Pt 2):S111–5 (31 ref.)

VLA–4 and lymphocyte trafficking in immune–inflammatory states: novel therapeutic approaches in allograft arteriopathy. Molossi S, et al. **Springer Semin Immunopathol** 1995;16(4):443–65 (225 ref.)

Immunosuppression with the vitamin D analogue MC 1288 in experimental transplantation. Johnsson C, et al. **Transplant Proc** 1996 Apr;28(2):888–91 (35 ref.)

[Immunosuppressive guidelines. The differences and advantages] Arizón del Prado JM. **Rev Esp Cardiol** 1995; 48 Suppl 7:71–6 (32 ref.) (Eng. Abstr.) **(Spa)**

[Corticoid–resistant rejection and humoral rejection. The diagnostic criteria and therapeutic management] Crespo Leiro MG, et al. **Rev Esp Cardiol** 1995;48 Suppl 7:77–85 (29 ref.) (Eng. Abstr.) **(Spa)**

METHODS

Anaesthesia for heart transplantation. Hussain A. **Br J Hosp Med** 1995 Nov 1–14;54(9):466–8 (5 ref.)

[Osteo–articular complications of heart transplantation] Rozenberg S, et al. **Presse Med** 1995 Dec 9;24(38):1809–12 (26 ref.) (Eng. Abstr.) **(Fre)**

[Special anesthesia care in heart transplantation. The management of right ventricular failure] Gómez–Arnau J, et al. **Rev Esp Cardiol** 1995;48 Suppl 7:60–4 (22 ref.) (Eng. Abstr.) **(Spa)**

[The heart transplant in congenital cardiopathies. The surgical considerations] Ugarte J, et al. **Rev Esp Cardiol** 1995;48 Suppl 7:33–6 (14 ref.) (Eng. Abstr.) **(Spa)**

NURSING

Pregnancy after cardiac transplantation: principles of nursing care. Jordan E, et al. **J Obstet Gynecol Neonatal Nurs** 1996 Feb;25(2):131–5 (15 ref.)

PATHOLOGY

Pathogenesis and mechanisms of graft rejection in concordant xenotransplantation with special reference to hamster–to–rat cardiac transplantation. Steinbrüchel DA. **APMIS Suppl** 1996;58:5–45 (281 ref.)

Cardiac allograft vasculopathy: the central pathogenetic role of ischemia–induced endothelial cell injury. Day JD, et al. **J Heart Lung Transplant** 1995 Nov–Dec;14(6 Pt 2):S142–9 (84 ref.)

The pathogenesis of graft vascular disease: implications of vascular remodeling. Gibbons GH. **J Heart Lung Transplant** 1995 Nov–Dec;14(6 Pt 2):S149–58 (59 ref.)

The prognostic significance of intimal proliferation in cardiac allograft vasculopathy: a paradigm shift. Mehra MR, et al. **J Heart Lung Transplant** 1995 Nov–Dec;14(6 Pt 2):S207–11 (20 ref.)

Impact of converting enzyme inhibitors and calcium entry blockers on cardiac allograft vasculopathy: from bench to bedside. Mehra MR, et al. **J Heart Lung Transplant** 1995 Nov–Dec;14(6 Pt 2):S246–9 (16 ref.)

Fish oil and antioxidants after heart transplantation: future strategies or eye of newt and wing of bat revisited? Young JB. **J Heart Lung Transplant** 1995 Nov–Dec;14(6 Pt 2):S250–4 (29 ref.)

Allograft vascular disease: comparison of heart and other grafted organs. Radio S, et al. **Transplant Proc** 1996 Feb; 28(1):496–9 (34 ref.)

[A critical review of the role of endomyocardial biopsy in heart transplantation] Vázquez de Prada JA. **Rev Esp Cardiol** 1995;48 Suppl 7:86–91 (25 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

Endogenous nitric oxide in cardiovascular disease and transplantation. Dusting GJ, et al. **Ann Med** 1995 Jun; 27(3):395–406 (123 ref.)

Effect of different interventions on heart rate variability after heart transplantation: non–autonomic vs autonomic factors. Bernardi L, et al. **Clin Sci (Colch)** 1996;91 Suppl:22–4 (24 ref.)

The therapeutic role of exercise in patients with orthotopic heart transplant. Badenhop DT. **Med Sci Sports Exerc** 1995 Jul;27(7):975–85 (38 ref.)

Chimerism and thoracic organ transplantation. Gammie JS, et al. **Semin Thorac Cardiovasc Surg** 1996 Apr;8(2):149–55 (45 ref.)

Molecular strategies for clinical xenotransplantation in cardiothoracic surgery. Hoopes CW, et al. **Semin Thorac Cardiovasc Surg** 1996 Apr;8(2):156–74 (131 ref.)

[The importance of determining oxygen consumption in the indications for a heart transplant] Gómez Sánchez MA, et al. **Rev Esp Cardiol** 1995;48 Suppl 7:19–23 (25 ref.) (Eng. Abstr.) **(Spa)**

REHABILITATION

The therapeutic role of exercise in patients with orthotopic heart transplant. Badenhop DT. **Med Sci Sports Exerc** 1995 Jul;27(7):975–85 (38 ref.)

Review of literature on heart transplant recipients' return to work: predictors and outcomes. Botsford AL. **Soc Work Health Care** 1995;21(2):19–39 (55 ref.)

[Exercise physiology and the rehabilitation of the heart transplant patient] Martínez Martínez A, et al. **Rev Esp Cardiol** 1995;48 Suppl 7:135–9 (27 ref.) (Eng. Abstr.) **(Spa)**

TRENDS

The potential of xenotransplants. Bollinger RR. **Transplant Proc** 1996 Aug;28(4):2024–5 (9 ref.)

[The xenograft: its current status and the future prospects] Dunning JJ, et al. **Rev Esp Cardiol** 1995;48 Suppl 7:145–8 (31 ref.) **(Spa)**

ULTRASONOGRAPHY

Assessment of transplant arteriopathy by intracoronary two–dimensional ultrasound imaging and coronary flow velocity. Wolford T, et al. **Cathet Cardiovasc Diagn** 1995 Aug;35(4):335–42 (35 ref.)

HEART VALVE DISEASES

CHEMICALLY INDUCED

Aortic and mitral valve disease induced by ergotamine therapy for migraine: a case report and review of the literature. Hendrikx M, et al. **J Heart Valve Dis** 1996 Mar; 5(2):235–7 (14 ref.)

COMPLICATIONS

Prevention of thromboembolic events in valvular heart disease. Gohlke–Bärwolf C, et al. **Acta Cardiol** 1996; 51(2):129–42 (37 ref.)

Heart valve involvement (Libman–Sacks endocarditis) in the antiphospholipid syndrome. Hojnik M, et al. **Circulation** 1996 Apr 15;93(8):1579–87 (110 ref.)

Guidelines for prevention of thromboembolic events in valvular heart disease. Study Group of the Working Group on Valvular Heart Disease of the European Society of Cardiology. Gohlke–Bärwolf C, et al. **Eur Heart J** 1995 Oct;16(10):1320–30 (165 ref.)

A rare complication of aortic valve endocarditis: diagnosis with transesophageal echocardiography. Winslow TM, et al. **J Am Soc Echocardiogr** 1995 Jul–Aug;8(4):546–50 (25 ref.)

[Recommendations for prevention of thromboembolism in heart valve diseases. Working Group on Valvular Heart Disease, European Society of Cardiology] Gohlke–Bärwolf C, et al. **Z Kardiol** 1995 Dec;84(12):1018–32 (168 ref.) (Eng. Abstr.) **(Ger)**

DIAGNOSIS

Noninfective valvular masses: review of the literature with emphasis on imaging techniques and management. Joffe II, et al. **Am Heart J** 1996 Jun;131(6):1175–83 (61 ref.)

DRUG THERAPY

Antithrombotic therapy in valvular heart disease. Levine HJ, et al. **Chest** 1995 Oct;108(4 Suppl):360S–370S (137 ref.)

ETIOLOGY

Tricuspid valve endocarditis with large vegetations in a non–drug addict without underlying cardiac disease. Iwama T, et al. **Intern Med** 1996 Mar;35(3):203–6 (20 ref.)

PATHOLOGY

Intracardiac thrombi: frequency, location, etiology, and complications: a morphologic review—Part IV. Waller BF, et al. **Clin Cardiol** 1995 Nov;18(11):669–74 (44 ref.)

PHYSIOPATHOLOGY

The relationship of left ventricular geometry and hypertrophy to left ventricular function in valvular heart disease. Carabello BA. **J Heart Valve Dis** 1995 Oct;4 Suppl 2:S132–8; discussion S138–9 (39 ref.)

The effect of left ventricular function on the echocardiographic assessment of heart valve disease. Chambers J. **J Heart Valve Dis** 1995 Oct;4 Suppl 2:S145–52; discussion S152–3 (55 ref.)

Left ventricular function in valvular heart disease: invasive and non–invasive assessment of left ventricular function. Shah PM. **J Heart Valve Dis** 1995 Oct;4 Suppl 2:S140–3; discussion S143–4 (27 ref.)

RADIONUCLIDE IMAGING

Management decisions in valvular heart disease: the role of radionuclide–based assessment of ventricular function and performance. Borer JS, et al. **J Nucl Cardiol** 1996 Jan–Feb; 3(1):72–81 (83 ref.)

SURGERY

Surgical treatment of aortic valve disease in the nineties with special emphasis on the use of the pulmonary autograft (Ross–operation). Pettersson G. **Ann Chir Gynaecol** 1995; 84(3):251–9 (10 ref.)

THERAPY

[Cardiology update—II] Trappe HJ. **Med Klin** 1996 Apr 1; 91 Suppl 1:128–39 (139 ref.) **(Ger)**

ULTRASONOGRAPHY

The effect of left ventricular function on the echocardiographic assessment of heart valve disease. Chambers J. **J Heart Valve Dis** 1995 Oct;4 Suppl 2:S145–52; discussion S152–3 (55 ref.)

[The main indications for transesophageal echocardiography] Lesbre JP. **Ann Cardiol Angeiol (Paris)** 1995 Dec; 44(10):547–51 (21 ref.) (Eng. Abstr.) **(Fre)**

VETERINARY

[Doppler echocardiography of heart valve defects in the dog] Schneider M, et al. **Tierarztl Prax** 1996 Apr;24(2):177–89 (19 ref.) (Eng. Abstr.) **(Ger)**

HEART VALVE PROSTHESIS

Results with mechanical cardiac valvular prostheses [see comments] Akins CW. **Ann Thorac Surg** 1995 Dec; 60(6):1836–44 (43 ref.) Comment in: Ann Thorac Surg 1996 Aug;62(2):624–6.

Combined valve replacement and coronary bypass grafting in osteogenesis imperfecta [see comments] Almassi GH, et al. **Ann Thorac Surg** 1995 Nov;60(5):1395–7 (15 ref.) Comment in: Ann Thorac Surg 1996 Apr;61(4):1294.

Anticoagulants in pregnancy. Oakley CM. **Br Heart J** 1995 Aug;74(2):107–11 (54 ref.)

The leaking prosthetic valve. Brecker SJ. **Br J Hosp Med** 1996 Apr 3–16;55(7):415–8 (12 ref.)

The effect of prosthesis–patient mismatch on aortic bioprosthetic valve hemodynamic performance and patient clinical status. Pibarot P, et al. **Can J Cardiol** 1996 Apr; 12(4):379–87 (43 ref.)

Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Stein PD, et al. **Chest** 1995 Oct;108(4 Suppl):371S–379S (59 ref.)

Guidelines for prevention of thromboembolic events in valvular heart disease. Study Group of the Working Group on Valvular Heart Disease of the European Society of Cardiology. Gohlke–Bärwolf C, et al. **Eur Heart J** 1995 Oct;16(10):1320–30 (165 ref.)

How should we describe forward flow through replacement mitral valves using echocardiography? Chambers JB. **J Heart Valve Dis** 1995 Jul;4 Suppl 1:S55–8 (17 ref.)

Porcine bioprosthetic valves prepared with permanent pre–dilation of the aortic root: a review. Fisher J. **J Heart Valve Dis** 1995 Jul;4 Suppl 1:S81–3; discussion S83–4 (14 ref.)

Doppler echocardiography in normally functioning replacement heart valves: a literature review. Wang Z, et al. **J Heart Valve Dis** 1995 Nov;4(6):591–614 (70 ref.)

Thrombolytic therapy for obstruction of mechanical prosthetic valves. Hurrell DG, et al. **Mayo Clin Proc** 1996 Jun;71(6):605–13 (64 ref.)

A review of the in vitro evaluation of conduit–mounted cardiac valve prostheses. Leefe SE, et al. **Med Eng Phys** 1995 Oct;17(7):497–506 (73 ref.)

Prosthetic heart valves. Vongpatanasin W, et al. **N Engl J Med** 1996 Aug 8;335(6):407–16 (99 ref.)

Management of intracardiac device recalls: a consensus conference. Participants of the Consensus Conference. North American Society of Cardiac Pacing and Electrophysiology (NASPE). Goldman BS, et al. **Pacing Clin Electrophysiol** 1996 Jan;19(1):7–17 (14 ref.)

[Valvular replacement for aortic stenosis in octogenarians.

Apropos of a consecutive series of 200 cases] Logeais Y, et al. **Arch Mal Coeur Vaiss** 1995 Feb;88(2):189–95 (30 ref.) (Eng. Abstr.) **(Fre)**

[Echocardiographic and Doppler markers of heart valve prosthesis dysfunction] Faletra F, et al. **G Ital Cardiol** 1995 Nov;25(11):1513–32 (89 ref.) **(Ita)**

[Mitral valve insufficiency in asymptomatic patients: when to think about reparative surgical intervention, when to decide about replacement] La Canna G, et al. **G Ital Cardiol** 1996 Apr;26(4):463–75 (72 ref.) **(Ita)**

[Left ventricular rupture following aortic and mitral valve replacement in a patient with osteogenesis imperfecta: a case report] Ichikawa H, et al. **Kyobu Geka** 1996 Apr; 49(4):294–6 (13 ref.) (Eng. Abstr.) **(Jpn)**

[A case report of mitral valve plasty for traumatic mitral regurgitation] Shimokawa T, et al. **Kyobu Geka** 1996 Mar; 49(3):228–30 (9 ref.) (Eng. Abstr.) **(Jpn)**

[Traumatic tricuspid regurgitation: a case report and a review of operated cases in Japan] Yamada T, et al. **Kyobu Geka** 1996 Feb;49(2):146–50 (21 ref.) (Eng. Abstr.) **(Jpn)**

[Report of a case with re-mitral valve replacement for Björk-Shiley Delrin disc valve prosthesis—disc wear of the Delrin disc 20 years after implantation] Abe M, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Apr;44(4):545–7 (11 ref.) (Eng. Abstr.) **(Jpn)**

[A case report of a left atrial ball thrombus at 16 years after mitral valve replacement] Iida M, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Apr;44(4):539–44 (28 ref.) (Eng. Abstr.) **(Jpn)**

[Papillary muscle rupture complicating acute myocardial infarction—treatment with mitral valve replacement and coronary bypass surgery in acute phase] Kyo S, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Jun;44(6):874–81 (23 ref.) (Eng. Abstr.) **(Jpn)**

[Mitral valve replacement for congenital parachute mitral valve] Sasahashi N, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Jul;43(7):1092–6 (13 ref.) (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Prosthetic valve thrombosis: a case report and review of the literature. Goh PP, et al. **Ann Acad Med Singapore** 1996 Jan;25(1):147–51 (28 ref.)

Thrombolytic therapy of left-sided prosthetic valve thrombosis. Koller PT, et al. **Chest** 1995 Dec;108(6):1683–9 (21 ref.)

The role of prolonged thrombolytic infusions and transesophageal echocardiography in thrombosed prosthetic heart valves: case report and review of the literature. Puleo JA, et al. **Clin Cardiol** 1995 Nov; 18(11):679–84 (50 ref.)

Deep tissue infections caused by Scopulariopsis brevicaulis: report of a case of prosthetic valve endocarditis and review. Migrino RQ, et al. **Clin Infect Dis** 1995 Sep;21(3):672–4 (16 ref.)

Bacillus licheniformis prosthetic aortic valve endocarditis. Santini F, et al. **J Clin Microbiol** 1995 Nov;33(11):3070–3 (12 ref.)

Rationalizing antithrombotic management for patients with prosthetic heart valves [editorial] Butchart EG. **J Heart Valve Dis** 1995 Mar;4(2):106–13 (62 ref.)

Intracardiac thrombosis: patient-related and device-related factors. Horstkotte D, et al. **J Heart Valve Dis** 1995 Mar; 4(2):114–20 (70 ref.)

Prosthetic valve thrombosis. Horstkotte D, et al. **J Heart Valve Dis** 1995 Mar;4(2):141–53 (115 ref.)

Optimization of oral anticoagulation for patients with mechanical heart valve prostheses. Piper C, et al. **J Heart Valve Dis** 1995 Mar;4(2):127–37 (83 ref.)

Salmonella prosthetic valve endocarditis. Fukushima N, et al. **J Thorac Cardiovasc Surg** 1996 Sep;112(3):840–2 (5 ref.)

Is prosthetic valve thrombogenicity related to design or material? Edmunds LH Jr. **Tex Heart Inst J** 1996;23(1):24–7 (20 ref.)

Current status of anticoagulation and thrombosis-related issues in mechanical valves. Gray RJ. **Tex Heart Inst J** 1996;23(1):36–41 (34 ref.)

[Prognostic factors of prosthetic valve endocarditis. Apropos of 122 cases] Witchitz S, et al. **Arch Mal Coeur Vaiss** 1996 Jun;89(6):671–7 (30 ref.) (Eng. Abstr.) **(Fre)**

[A case of secondary valve replacement caused by pulmonary bioprosthetic valve endocarditis] Fujii H, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Jul;43(7):1081–5 (18 ref.) (Eng. Abstr.) **(Jpn)**

METHODS

Evolution of the surgical approach for replacement of degenerated mitral bioprostheses. Geha AS, et al. **Surgery** 1995 Oct;118(4):662–6; discussion 666–8 (14 ref.)

HEART VALVES

ABNORMALITIES

[Embryogenesis of atrioventricular valve anomalies] Berishvili II, et al. **Arkh Patol** 1995 Jul-Aug;57(4):92–5 (29 ref.) (Eng. Abstr.) **(Rus)**

ANATOMY & HISTOLOGY

Skirts, slits, scallops and semantics [see comments] Victor S, et al. **J Heart Valve Dis** 1995 Nov;4(6):576–9; discussion 580 (17 ref.) Comment in: J Heart Valve Dis 1995 Nov;4(6):568–70.

PHYSIOLOGY

Long-term ventricular wall actuation: can and should it be systematically explored? Melvin DB, et al. **Artif Organs** 1996 Jan;20(1):63–8 (13 ref.)

SURGERY

Indications for valve surgery in asymptomatic patients with aortic and mitral stenosis. Carabello BA. **Chest** 1995 Dec; 108(6):1678–82 (30 ref.)

ULTRASONOGRAPHY

Doppler echocardiography in normally functioning replacement heart valves: a literature review. Wang Z, et al. **J Heart Valve Dis** 1995 Nov;4(6):591–614 (70 ref.)

[Three-dimensional reconstruction of heart valves] Flachskampf FA, et al. **Herz** 1995 Aug;20(4):236–42 (21 ref.) (Eng. Abstr.) **(Ger)**

ULTRASTRUCTURE

Cell biology of valvular interstitial cells. Mulholland DL, et al. **Can J Cardiol** 1996 Mar;12(3):231–6 (23 ref.)

HEART VENTRICLE

see related
VENTRICULAR FUNCTION
VENTRICULAR PRESSURE

Ventricular remodeling. Maisch B. **Cardiology** 1996;87 Suppl 1:2–10 (22 ref.)

[Ventricular arrhythmias: diagnosis and drug therapy] Schüpfer C, et al. **Schweiz Rundsch Med Prax** 1996 May 14;85(20):647–54 (40 ref.) (Eng. Abstr.) **(Ger)**

ABNORMALITIES

[Normal pregnancy duration after maternal Fontan operation of univentricular heart] Osmers R, et al. **Z Geburtshilfe Neonatol** 1995 Sep-Oct;199(5):195–8 (15 ref.) (Eng. Abstr.) **(Ger)**

DRUG EFFECTS

Myocardial contractile response and IP3, cAMP and cGMP interrelationships. Martinussen HJ. **Ups J Med Sci** 1996; 101(1):1–33 (142 ref.)

METABOLISM

Ventricular remodeling in heart failure: the role of myocardial collagen. Janicki JS, et al. **Adv Exp Med Biol** 1995;382:239–45 (27 ref.)

PATHOLOGY

Role of electrophysiologic evaluation in patients with ventricular arrhythmias. Athill CA, et al. **Indian Heart J** 1996 Mar-Apr;48(2):179–85 (33 ref.)

Role of M cells in acquired long QT syndrome, U waves, and torsade de pointes. Antzelevitch C, et al. **J Electrocardiol** 1995;28 Suppl:131–8 (44 ref.)

Malignant fibrous histiocytoma of the right ventricle of the heart. Teramoto N, et al. **Pathol Int** 1995 Apr;45(4):315–9 (17 ref.)

[Significance of lymphoplasmocytic infiltration in arrhythmogenic right ventricular dysplasia. Apropos of 3 own cases and review of the literature] Fontaliran F, et al. **Arch Mal Coeur Vaiss** 1995 Jul;88(7):1021–8 (32 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Long-term ventricular wall actuation: can and should it be systematically explored? Melvin DB, et al. **Artif Organs** 1996 Jan;20(1):63–8 (13 ref.)

Ionic mechanisms of ischemia-related ventricular arrhythmias. Ducceschi V, et al. **Clin Cardiol** 1996 Apr; 19(4):325–31 (106 ref.)

Torsional deformation of the left ventricle. Yun KL, et al. **J Heart Valve Dis** 1995 Oct;4 Suppl 2:S214–20; discussion S220–2 (42 ref.)

PHYSIOPATHOLOGY

[Late ventricular potentials: significance, electrophysiology and clinical importance in coronary disease] Zimmermann M. **Schweiz Rundsch Med Prax** 1996 Apr 30;85(18):604–12 (51 ref.) (Eng. Abstr.) **(Fre)**

[Assessment of ventricular arrhythmias] Osswald S, et al. **Schweiz Rundsch Med Prax** 1996 Feb 13;85(7):179–87 (48 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Congenitally corrected transposition of the great arteries: ventricle to pulmonary artery connection strategies. Bove EL. **Semin Thorac Cardiovasc Surg** 1995 Jul;7(3):139–44 (19 ref.)

[Surgical treatment of aneurysms of the left ventricle. Immediate and long-term results. Apropos of a consecutive series of 121 cases] Valla J, et al. **Ann Chir** 1995; 49(9):816–23 (52 ref.) (Eng. Abstr.) **(Fre)**

ULTRASONOGRAPHY

[Trans-thoracic 3D echocardiography reconstruction for left ventricular volume determination] Kupferwasser I, et al. **Herz** 1995 Aug;20(4):243–51 (53 ref.) (Eng. Abstr.) **(Ger)**

HEART VENTRICLE, ARTIFICIAL see **HEART-ASSIST DEVICES**

HEART VOLUME see **CARDIAC VOLUME**

HEARTWATER DISEASE

Progress and priorities in research on heartwater. Uilenberg G. **Ann N Y Acad Sci** 1996 Jul 23;791:1–16 (105 ref.)

MICROBIOLOGY

Uncharacterized Ehrlichia spp. may contribute to clinical heartwater. Allsopp BA, et al. **Ann N Y Acad Sci** 1996 Jul 23;791:17–23 (24 ref.)

PREVENTION & CONTROL

Appropriate strategies for the control or eradication of ticks and tick-borne diseases. Wilson A. **Ann N Y Acad Sci** 1996 Jul 23;791:54–63 (21 ref.)

HEARTWORM DISEASE see **DIROFILARIASIS**

HEAT

see related
CALORIMETRY
HYPERTHERMIA, INDUCED
REWARMING
TROPICAL CLIMATE

Involvement of heat shock proteins and cellular membranes in the development of thermotolerance. Jóźwiak Z. **Arch Immunol Ther Exp (Warsz)** 1994;42(4):247–52 (70 ref.)

Caloric irrigators: air, open-loop water and closed-loop water [see comments] Anderson S. **Br J Audiol** 1995 Apr; 29(2):117–28 (43 ref.) Comment in: Br J Audiol 1995 Apr;29(2):83–6.

Adaptation in the oculomotor response to caloric irrigation and the merits of bithermal stimulation [see comments] Barnes G. **Br J Audiol** 1995 Apr;29(2):95–106 (22 ref.) Comment in: Br J Audiol 1995 Apr;29(2):83–6.

Comparison of assessment of caloric nystagmus by observation of duration and by electronystagmographic measurement of slow-phase velocity [see comments] Luxon L. **Br J Audiol** 1995 Apr;29(2):107–15 (29 ref.) Comment in: Br J Audiol 1995 Apr;29(2):83–6.

The caloric stimulus: mechanisms of heat transfer [see comments] O'Neill G. **Br J Audiol** 1995 Apr;29(2):87–94 (21 ref.) Comment in: Br J Audiol 1995 Apr;29(2):83–6.

Cellular, biological, and physicochemical basis for the hard-to-cook defect in legume seeds. Liu K. **Crit Rev Food Sci Nutr** 1995 Jul;35(4):263–98 (156 ref.)

Is thermophily a transferrable property in bacteria? Lindsay JA. **Crit Rev Microbiol** 1995;21(3):165–74 (55 ref.)

Engineering thermostability: lessons from thermophilic proteins. Russell RJ, et al. **Curr Opin Biotechnol** 1995 Aug; 6(4):370–4 (22 ref.)

Testicular heating and its possible contributions to male infertility: a review. Mieusset R, et al. **Int J Androl** 1995 Aug;18(4):169–84 (105 ref.)

Understanding physical inactivation processes: combined preservation opportunities using heat, ultrasound and pressure. Earnshaw RG, et al. **Int J Food Microbiol** 1995 Dec;28(2):197–219 (122 ref.)

Heat shock proteins, thermotolerance, and their relevance to clinical hyperthermia. Li GC, et al. **Int J Hyperthermia** 1995 Jul-Aug;11(4):459–88 (134 ref.)

Regulatory mechanism of stress response in mammalian nervous system during cerebral ischaemia or after heat shock. Higashi T, et al. **Neuropathol Appl Neurobiol** 1995 Dec;21(6):480–3 (19 ref.)

The heat-shock response. De Maio A. **New Horiz** 1995 May; 3(2):198–207 (96 ref.)

Heat shock and tissue protection. Perdrizet GA. **New Horiz** 1995 May;3(2):312–20 (46 ref.)

Heat sterilization of glucose-containing fluids for peritoneal dialysis: biological consequences of chemical alterations. Wieslander AP, et al. **Perit Dial Int** 1995;15(7 Suppl):S52–9; discussion S59–60 (32 ref.)

How to make my blood boil [comment] Goldman A. **Structure** 1995 Dec 15;3(12):1277–9 (18 ref.) Comment on: Structure 1995 Dec 15;3(12):1295–306.

ADVERSE EFFECTS

Toxicity of combustion products of polymeric materials. Cempel M. **Bull Inst Marit Trop Med Gdynia** 1993–94; 44–45(1–4):75–81 (21 ref.)

Adaptation to heat. Hori S. **Jpn J Physiol** 1995;45(6):921–46 (82 ref.)

Hyperthermia and birth defects. Edwards MJ, et al. **Reprod Toxicol** 1995 Sep-Oct;9(5):411–25 (109 ref.)

THERAPEUTIC USE

[Treatment of chronic congestive heart failure to improve their quality of life—clinical study of thermal vasodilation therapy] Tei C, et al. **Nippon Naika Gakkai Zasshi** 1995 Sep 10;84(9):1475–82 (35 ref.) **(Jpn)**

HEAT CRAMPS see **HEAT STRESS DISORDERS**

HEAT LOSS see **BODY TEMPERATURE REGULATION**

HEAT PRODUCTION see **BODY TEMPERATURE REGULATION**

HEAT-SHOCK PROTEINS

see related
MOLECULAR CHAPERONES

Heat-shock proteins in animal models for acute renal failure. Wakui H, et al. **Ren Fail** 1995 Nov;17(6):641–9 (26 ref.)

Prions of yeast and heat-shock protein 104: 'coprion' and cure. Wickner RB. **Trends Microbiol** 1995 Oct;3(10):367–9 (21 ref.)

[Heat shock protein and immunity] Nomaguchi H. **Nippon Rai Gakkai Zasshi** 1995 Nov;64(3):188–99 (66 ref.) **(Jpn)**

ANALYSIS

Heat-shock proteins as biomarkers of pollution. de Pomerai D. **Hum Exp Toxicol** 1996 Apr;15(4):279–85 (70 ref.)

BIOSYNTHESIS

Heat shock transcription factors: structure and regulation. Wu C. **Ann Rev Cell Dev Biol** 1995;11:441–69 (157 ref.)

Do heat shock proteins have a role in breast cancer? Conroy SE, et al. **Br J Cancer** 1996 Sep;74(5):717–21 (50 ref.)

Expression of stress genes during development. Arrigo AP. **Neuropathol Appl Neurobiol** 1995 Dec;21(6):488–91 (45 ref.)

The stress response. Brown IR. **Neuropathol Appl Neurobiol** 1995 Dec;21(6):473–5 (5 ref.)

Cell stress genes and chronic neurodegenerative disorders. Cheetham ME. **Neuropathol Appl Neurobiol** 1995 Dec; 21(6):486–8 (20 ref.)

Regulatory mechanism of stress response in mammalian nervous system during cerebral ischaemia or after heat shock. Higashi T, et al. **Neuropathol Appl Neurobiol** 1995 Dec;21(6):480–3 (19 ref.)

Cell stress genes and neuronal protection. Latchman DS. **Neuropathol Appl Neurobiol** 1995 Dec;21(6):475–7 (24 ref.)

Cell stress genes and acute CNS injury. McIntosh TK, et al. **Neuropathol Appl Neurobiol** 1995 Dec;21(6):477–9 (27 ref.)

BLOOD

[Heat shock proteins in diabetes mellitus] Parlapiano C, et al. **Riv Eur Sci Med Farmacol** 1995 Jan–Feb;17(1):27–33 (10 ref.) (Eng. Abstr.) **(Ita)**

CHEMISTRY

Heat shock transcription factors: structure and regulation. Wu C. **Ann Rev Cell Dev Biol** 1995;11:441–69 (157 ref.)

Structure-function relationships in the FK506-binding protein (FKBP) family of peptidylprolyl cis–trans isomerases. Kay JE. **Biochem J** 1996 Mar 1;314 (Pt 2):361–85 (308 ref.)

alpha-Crystallins, versatile stress-proteins. Boelens WC, et al. **Mol Biol Rep** 1995;21(2):75–80 (87 ref.)

Receptor (immunophilin-binding) assay for immunosuppressive drugs. Soldin SJ. **Ther Drug Monit** 1995 Dec;17(6):574–6 (18 ref.)

GENETICS

Cap-independent translation of heat shock messenger RNAs. Rhoads RE, et al. **Curr Top Microbiol Immunol** 1995; 203:131–53 (108 ref.)

Heat-shock and general stress response in Bacillus subtilis. Hecker M, et al. **Mol Microbiol** 1996 Feb;19(3):417–28 (49 ref.)

The stress response. Brown IR. **Neuropathol Appl Neurobiol** 1995 Dec;21(6):473–5 (5 ref.)

Cell stress genes and chronic neurodegenerative disorders. Cheetham ME. **Neuropathol Appl Neurobiol** 1995 Dec; 21(6):486–8 (20 ref.)

Cell stress genes and neuronal protection. Latchman DS. **Neuropathol Appl Neurobiol** 1995 Dec;21(6):475–7 (24 ref.)

Cell stress genes and acute CNS injury. McIntosh TK, et al. **Neuropathol Appl Neurobiol** 1995 Dec;21(6):477–9 (27 ref.)

Heat shock proteins in myocardial stress. Dillmann WH, et al. **Z Kardiol** 1995;84 Suppl 4:87–90 (10 ref.)

[Cardiac gene expression after brief coronary occlusion] Zimmermann R, et al. **Z Kardiol** 1995;84 Suppl 4:159–65 (23 ref.) (Eng. Abstr.) **(Ger)**

[Genes for cellular mortality] Mitsui Y, et al. **Tanpakushitsu Kakusan Koso** 1996 Mar;41(3):211–9 (44 ref.) **(Jpn)**

IMMUNOLOGY

Heat shock protein-peptide complexes for use in vaccines. Heike M, et al. **J Leukoc Biol** 1996 Aug;60(2):153–8 (75 ref.)

[Role of gamma-delta T-cells and heat shock proteins in immunological response and in pathogenesis of neurological diseases] Fiszer U. **Neurol Neurochir Pol** 1995 Sep–Oct;29(5):737–45 (30 ref.) (Eng. Abstr.) **(Pol)**

METABOLISM

Structure-function relationships in the FK506-binding protein (FKBP) family of peptidylprolyl cis–trans isomerases. Kay JE. **Biochem J** 1996 Mar 1;314 (Pt 2):361–85 (308 ref.)

NAD and poly(ADP-ribose) regulation of proteins involved in response to cellular stress and DNA damage. Berger NA, et al. **Biochimie** 1995;77(5):364–7 (16 ref.)

Mitogen and stress response pathways: MAP kinase cascades and phosphatase regulation in mammals and yeast. Waskiewicz AJ, et al. **Curr Opin Cell Biol** 1995 Dec; 7(6):798–805 (79 ref.)

Heat shock proteins and multiple sclerosis: a review. Brosnan CF, et al. **J Neuropathol Exp Neurol** 1996 Apr; 55(4):389–402 (77 ref.)

Hsp47: a collagen-specific molecular chaperone. Nagata K. **Trends Biochem Sci** 1996 Jan;21(1):22–6 (29 ref.)

PHARMACOLOGY

Cell stress and implications of the heat-shock response in skin. Charveron M, et al. **Cell Biol Toxicol** 1995 Aug; 11(3–4):161–5 (15 ref.)

PHYSIOLOGY

Involvement of heat shock proteins and cellular membranes in the development of thermotolerance. Jóźwiak Z. **Arch Immunol Ther Exp (Warsz)** 1994;42(4):247–52 (70 ref.)

Modulation of actin dynamics during stress and physiological stimulation by a signaling pathway involving p38 MAP kinase and heat-shock protein 27. Landry J, et al. **Biochem Cell Biol** 1995 Sep–Oct;73(9–10):703–7 (42 ref.)

Role of heat shock proteins in heart transplant rejection. Liu K, et al. **J Heart Lung Transplant** 1996 Mar;15(3):222–8 (71 ref.)

Heat shock proteins: a broader perspective [editorial] Moseley PL. **J Lab Clin Med** 1996 Sep;128(3):233–4 (20 ref.)

Immunophilins and the nervous system. Snyder SH, et al. **Nat Med** 1995 Jan;1(1):32–7 (82 ref.)

Heat shock proteins and the immunopathogenesis of multiple sclerosis. Linington C. **Neuropathol Appl Neurobiol** 1995 Dec;21(6):483–6 (31 ref.)

The heat-shock response. De Maio A. **New Horiz** 1995 May; 3(2):198–207 (96 ref.)

Hypoxia-associated proteins. Graven KK, et al. **New Horiz** 1995 May;3(2):208–18 (58 ref.)

Heat shock and tissue protection. Perdrizet GA. **New Horiz** 1995 May;3(2):312–20 (46 ref.)

Induction of the stress response to prevent organ injury. Ribeiro SP, et al. **New Horiz** 1995 May;3(2):301–11 (107 ref.)

Reconstitution of novel signalling cascades responding to cellular stresses. Woodgett JR, et al. **Philos Trans R Soc Lond B Biol Sci** 1996 Feb 29; 351(1336):135–41; discussion 142 (50 ref.)

Cellular functions of immunophilins. Marks AR. **Physiol Rev** 1996 Jul;76(3):631–49 (161 ref.)

Heat shock proteins and teratogenesis. Buckiová D, et al. **Reprod Toxicol** 1995 Nov–Dec;9(6):501–11 (120 ref.)

Stress proteins: their role in the normal central nervous system and in disease states, especially multiple sclerosis. Birnbaum G. **Springer Semin Immunopathol** 1995; 17(1):107–18 (75 ref.)

Heat-shock proteins in host–pathogen interactions: implications for cystic fibrosis. Polla BS, et al. **Trends Microbiol** 1995 Oct;3(10):392–6 (51 ref.)

[Inducing mechanism and contributing factors of heat shock proteins] Guo XZ, et al. **Sheng Li Ko Hsueh Chin Chan** 1995 Jul;26(3):263–6 (10 ref.) **(Chi)**

[Mammalian small stress proteins and responses to stress] Kato K, et al. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1996 Feb;16(1):1–9 (46 ref.) (Eng. Abstr.) **(Jpn)**

HEAT-SHOCK PROTEINS 60 see **CHAPERONIN 60**

HEAT-SHOCK PROTEINS 70

GENETICS

Heat shock protein 70 gene polymorphisms and multiple sclerosis. Ramachandran S, et al. **Tissue Antigens** 1995 Aug; 46(2):140–1 (18 ref.)

METABOLISM

Post-translational protein translocation: not all hsc70s are created equal. Brodsky JL. **Trends Biochem Sci** 1996 Apr; 21(4):122–6 (40 ref.)

PHYSIOLOGY

Heat shock proteins, thermotolerance, and their relevance to clinical hyperthermia. Li GC, et al. **Int J Hyperthermia** 1995 Jul–Aug;11(4):459–88 (134 ref.)

[Heat shock protein 70 and perinatal hypoxic-ischemic brain damage] Chang YQ, et al. **Sheng Li Ko Hsueh Chin Chan** 1995 Jul;26(3):267–9 (10 ref.) **(Chi)**

HEAT-SHOCK REACTION see **HEAT-SHOCK RESPONSE**

HEAT-SHOCK RESPONSE

see related
HEAT-SHOCK PROTEINS

Heat-shock proteins as biomarkers of pollution. de Pomerai D. **Hum Exp Toxicol** 1996 Apr;15(4):279–85 (70 ref.)

DRUG EFFECTS

Cell stress and implications of the heat-shock response in skin. Charveron M, et al. **Cell Biol Toxicol** 1995 Aug; 11(3–4):161–5 (15 ref.)

GENETICS

Expression of heat shock genes in Clostridium acetobutylicum. Bahl H, et al. **FEMS Microbiol Rev** 1995 Oct;17(3):341–3 (38 ref.)

PHYSIOLOGY

The stress protein response and its potential relationship to prolonged seizure activity. Lowenstein DH. **Clin Neuropharmacol** 1995 Apr;18(2):148–58 (64 ref.)

Heat shock proteins, thermotolerance, and their relevance to clinical hyperthermia. Li GC, et al. **Int J Hyperthermia** 1995 Jul–Aug;11(4):459–88 (134 ref.)

Stress-induced transcriptional activation. Mager WH, et al. **Microbiol Rev** 1995 Sep;59(3):506–31 (232 ref.)

[Regulation of Escherichia coli heat shock response] Liberek K. **Postepy Biochem** 1995;41(2):94–102 (110 ref.) **(Pol)**

HEAT STRESS DISORDERS

Heat illness—a review of military experience (Part 2). Bricknell MC. **J R Army Med Corps** 1996 Feb;142(1):34–42 (31 ref.)

ETIOLOGY

The potential health impacts of climate change: an overview. Kovats S, et al. **Med War** 1995 Oct–Dec;11(4):168–78 (28 ref.)

HISTORY

Heat illness—a review of military experience (Part 1). Bricknell MC. **J R Army Med Corps** 1995 Oct; 141(3):157–66 (47 ref.)

PREVENTION & CONTROL

Heat illness—a review of military experience (Part 2). Bricknell MC. **J R Army Med Corps** 1996 Feb;142(1):34–42 (31 ref.)

HEAT STRESS SYNDROMES see **HEAT STRESS DISORDERS**

HEAT STROKE

Heatstroke: a new look at an ancient disease [editorial] Bouchama A. **Intensive Care Med** 1995 Aug;21(8):623–5 (33 ref.)

Extremely elevated body temperature: case report and review of classical heat stroke. de Galan BE, et al. **Neth J Med** 1995 Dec;47(6):281–7 (24 ref.)

COMPLICATIONS

Epidemiology and pathoetiology of neurological syndromes with hyperthermia. Di Rosa AE, et al. **Funct Neurol** 1995 May–Jun;10(3):111–9 (49 ref.)

HEAT WAVES see **INFRARED RAYS**

HEAVY CHAIN DISEASE

see related
IMMUNOGLOBULINS, HEAVY-CHAIN

DIAGNOSIS

Crescentic nodular glomerulosclerosis secondary to truncated immunoglobulin alpha heavy chain deposition. Cheng IK, et al. **Am J Kidney Dis** 1996 Aug;28(2):283–8 (13 ref.)

HEDONISM see **PHILOSOPHY**

HEEL

see related
ACHILLES TENDON
CALCANEUS
TALUS

PATHOLOGY

Porocarcinoma of the heel. A case report with unusual

histologic features. D'Amato MS, et al. **Cancer** 1996 Aug 15;78(4):751–7 (27 ref.)
Magnetic resonance imaging of plantar fasciitis and other causes of heel pain. Kier R.
Magn Reson Imaging Clin N Am 1994 Feb;2(1):97–107 (35 ref.)

SURGERY

A retrospective comparison of endoscopic plantar fasciotomy to open plantar fasciotomy with heel spur resection for chronic plantar fasciitis/heel spur syndrome. Tomczak RL, et al. **J Foot Ankle Surg** 1995 May–Jun;34(3):305–11 (41 ref.)
[Fascial and fasciocutaneous flaps for treatment of posterior and distal area of the lower leg and heel area] Kulesza T. **Chir Narzadow Ruchu Ortop Pol** 1996;61(1):67–72 (11 ref.) **(Pol)**

HELIANTHUS

GENETICS

Hybrid speciation. Evolution under the microscope. Charlesworth D. **Curr Biol** 1995 Aug 1;5(8):835–6 (9 ref.)

HELICOBACTER

IMMUNOLOGY

Animal models and vaccine development. Lee A.
Baillieres Clin Gastroenterol 1995 Sep;9(3):615–32 (74 ref.)

HELICOBACTER INFECTIONS

The relationships between chronic gastritis and gastric acid secretion. Sipponen P, et al. **Aliment Pharmacol Ther** 1996 Apr;10 Suppl 1:103–18 (147 ref.)
Transmission and epidemiology of Helicobacter pylori. Cave DR. **Am J Med** 1996 May 20;100(5A):12S–17S; discussion 17S–18S (47 ref.)
Helicobacter pylori and complicated ulcer disease. Laine LA. **Am J Med** 1996 May 20;100(5A):52S–57S; discussion 57S–59S (47 ref.)
Helicobacter pylori in duodenal and gastric ulcer disease. Rauws EJ, et al. **Baillieres Clin Gastroenterol** 1995 Sep; 9(3):529–47 (119 ref.)
Helicobacter pylori in children. Sullivan PB.
Baillieres Clin Gastroenterol 1995 Sep;9(3):519–28 (71 ref.)
May Helicobacter pylori be important for dermatologists? Rebora A, et al. **Dermatology** 1995;191(1):6–8 (21 ref.)
We need to integrate new data concerning Helicobacter pylor into experimental ulcer research. Graham DY.
Dig Dis Sci 1995 Nov;40(11):2487–9 (35 ref.)
Critical issues in the pathophysiology and management of peptic ulcer disease. Hunt RH, et al.
Eur J Gastroenterol Hepatol 1995 Jul;7(7):685–99 (156 ref.)
H. pylori infection: its role in chronic gastritis, carcinoma and peptic ulcer. Pajares JM. **Hepatogastroenterology** 1995 Nov–Dec;42(6):827–41 (141 ref.)
Consensus conference. Medical treatment of peptic ulcer disease. Practice guidelines. Practice Parameters Committee of the American College of Gastroenterology [published erratum appears in JAMA 1996 May 1;275(17):1314] Soll AH. **JAMA** 1996 Feb 28;275(8):622–9 (99 ref.)
Helicobacter pylori and peptic disease in the pediatric patient. Bujanover Y, et al. **Pediatr Clin North Am** 1996 Feb; 43(1):213–34 (138 ref.)
Helicobacter pylori infection and peptic ulcer disease in children. Bourke B, et al. **Pediatr Infect Dis J** 1996 Jan; 15(1):1–13 (163 ref.)
Helicobacter pylori infection and its role in human disease—an overview. McColl KE. **Pharm World Sci** 1996 Apr;18(2):49–55 (84 ref.)
Helicobacter pylori in ulcerogenesis. Lin SK, et al.
Scand J Gastroenterol Suppl 1995;210:64–9 (72 ref.)
Helicobacter pylori in Japan. Shimoyama T, et al.
Scand J Gastroenterol Suppl 1996;214:61–3 (5 ref.)
The significance of Helicobacter pylori colonization of the stomach. Cilley RE, et al. **Semin Pediatr Surg** 1995 Nov; 4(4):221–7 (68 ref.)
[Peptic ulcer and gastritis in the time of Helicobacter pylori] **Ann Gastroenterol Hepatol (Paris)** 1996 Jan–Feb; 32(1):25–34 (0 ref.) **(Fre)**
[Helicobacter pylori and gastric cancer] Tanida N, et al.
Nippon Geka Gakkai Zasshi 1996 Apr;97(4):257–62 (41 ref.) (Eng. Abstr.) **(Jpn)**
[Helicobacter pylori infection in peptic ulcer and gastric cancer diseases] Matsukura N, et al.
Nippon Ika Daigaku Zasshi 1995 Aug;62(4):313–9 (22 ref.) **(Jpn)**

COMPLICATIONS

Helicobacter pylori infection and gastric cancer: usefulness of screening high risk groups. Buckley M, et al.
Acta Gastroenterol Belg 1995 Sep–Dec;58(5–6):382–7 (34 ref.)
Prevalence of Helicobacter pylori in non-ulcer dyspepsia. Buckley M, et al. **Aliment Pharmacol Ther** 1995;9 Suppl 2:53–8 (55 ref.)
Review article: the development of atrophic gastritis—Helicobacter pylori and the effects of acid suppressive therapy. Kuipers EJ, et al.
Aliment Pharmacol Ther 1995 Aug;9(4):331–40 (97 ref.)
Clinical expressions of Helicobacter pylori infection. Howden CW. **Am J Med** 1996 May 20;100(5A):27S–32S; discussion 32S–34S (48 ref.)
Helicobacter pylori and ulcerogenesis. Peura DA.
Am J Med 1996 May 20;100(5A):19S–25S; discussion 25S–26S (78 ref.)
Helicobacter pylori, duodenal ulcer, gastric cancer: tunnel vision or blinders? Graham DY, et al. **Ann Med** 1995 Oct; 27(5):589–94 (27 ref.)
Helicobacter pylori in peptic ulcer: have Koch's postulates been fulfilled? Marshall BJ. **Ann Med** 1995 Oct;27(5):565–8 (16 ref.)
Primary gastric lymphoma. Isaacson PG.
Br J Biomed Sci 1995 Dec;52(4):291–6 (40 ref.)
Peptic ulcers and gastric cancer. Mera SL.
Br J Biomed Sci 1995 Dec;52(4):271–81 (59 ref.)
Role of Helicobacter pylori in gastrointestinal disease: implications for primary care of a revolution in management of dyspepsia. Delaney BC. **Br J Gen Pract** 1995 Sep;45(398):489–94 (71 ref.)
Helicobacter pylori infection and peptic ulcer disease in children. Rowland M, et al. **Curr Opin Pediatr** 1995 Oct; 7(5):553–9 (65 ref.)
Helicobacter pylori as a promoter of intestinal metaplasia and gastric cancer: an alluring hypothesis in search of evidence. Genta RM. **Eur J Gastroenterol Hepatol** 1995 Aug;7 Suppl 1:S25–30 (53 ref.)
Antral G-cell hyperplasia: a vanishing disease? Kwan CP, et al. **Eur J Gastroenterol Hepatol** 1995 Nov; 7(11):1099–1103 (44 ref.)
Duodenal ulcer: the helicobacterization of a psychosomatic disease? Melmed RN, et al. **Isr J Med Sci** 1996 Mar–Apr; 32(3–4):211–6 (66 ref.)
Biology of gastric cancer: gastritis–metaplasia–dysplasia sequence, role of H Pylori, and molecular correlates of tumor progression. Lynch P. **J Infus Chemother** 1995 Summer;5(3):93–6 (23 ref.)
Helicobacter pylori infection and gastric cancer. Goldstone AR, et al. **J Pathol** 1996 Jun;179(2):129–37 (117 ref.)
Lymphomas of mucosa-associated lymphoid tissue and antigen drive [editorial; comment] Wright DH. **J Pathol** 1996 Feb;178(2):111–2 (14 ref.) Comment on: J Pathol 1996 Feb;178(2):122–7.
Gastric secretion and the pathogenesis of peptic ulcer in the Helicobacter pylori infection. Konturek PC, et al.
J Physiol Pharmacol 1996 Mar;47(1):5–19 (80 ref.)
Helicobacter pylori and gastric neoplasia: evolving concepts. Bolin TD, et al. **Med J Aust** 1995 Sep 4;163(5):253–5 (18 ref.)
Helicobacter pylori and gastric cancer. Forman D.
Scand J Gastroenterol Suppl 1996;214:31–3; discussion 40–3 (14 ref.)
Bacteria in the aetio-pathogenesis of gastric cancer: a review. Houben GM, et al. **Scand J Gastroenterol Suppl** 1995; 212:13–8 (61 ref.)
Simultaneous gastric adenocarcinoma and MALT-type lymphoma in Helicobacter pylori infection. von Herbay A, et al. **Virchows Arch** 1995;427(4):445–50 (62 ref.)
[Should Helicobacter pylori be eradicated in a patient with chronic gastritis?] Bouché O. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S143–S153 (127 ref.) **(Fre)**
[When should Helicobacter pylori be eradicated?] Buckley M, et al. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S95–S102 (80 ref.) **(Fre)**
[Stomach cancer: what's new? (editorial)] Faivre J, et al. **Gastroenterol Clin Biol** 1995 Oct;19(10):793–6 (22 ref.) **(Fre)**
[Helicobacter pylori as a cause of benign malignant peptic ulcer] Abou-Mouch S, et al. **Harefuah** 1995 Jun 15; 128(12):808–11 (44 ref.) **(Heb)**
[Helicobacter pylori infection and the risk of gastric cancer] Zaremba-Woroniecka A, et al. **Pol Arch Med Wewn** 1995 Aug;94(2):164–72 (40 ref.) **(Pol)**
[Treatment of peptic ulcer and gastritis associated with Helicobacter pylori] López-Brea M, et al.
Enferm Infecc Microbiol Clin 1995 Aug–Sep;13(7):422–8 (75 ref.) **(Spa)**
[Role of Helicobacter pylori (HP) in digestive pathology] Garrido Klinge G. **Rev Gastroenterol Peru** 1995;15 Suppl 1:S29–35 (20 ref.) (Eng. Abstr.) **(Spa)**
[Helicobacter pylori and gastric cancer] León-Barúa R, et al. **Rev Gastroenterol Peru** 1995;15 Suppl 1:S23–7 (38 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Breathtaking technology for the detection of Helicobacter pylori [editorial] [see comments] Phillips M.
Am J Gastroenterol 1995 Dec;90(12):2089–90 (9 ref.) Comment in: Am J Gastroenterol 1996 Jul;91(7):1468–9.
Testing for Helicobacter pylori in clinical practice. Cutler AF. **Am J Med** 1996 May 20;100(5A):35S–39S; discussion 39S–41S (44 ref.)
Diagnosis of Helicobacter pylori. Mégraud F.
Baillieres Clin Gastroenterol 1995 Sep;9(3):507–18 (47 ref.)
Helicobacter pylori: who is positive and who is not? Kuipers EJ, et al. **Eur J Gastroenterol Hepatol** 1995 Jun;7(6):533–6 (25 ref.)
The urea breath test: a non-invasive clinical tool for detecting Helicobacter pylori infection. Perri F, et al.
Ital J Gastroenterol 1995 Mar;27(2):55–63 (77 ref.)
Diagnosis of Helicobacter pylori infection. Mégraud F.
Scand J Gastroenterol Suppl 1996;214:44–6; discussion 57–60 (8 ref.)
[Diagnostic methods of Helicobacter pylori infection] Lozniewski A. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S111–S118 (100 ref.) **(Fre)**
[Helicobacter pylori and its role in gastric and duodenal ulcers] Mach T. **Przegl Lek** 1995;52(7):365–7 (24 ref.) **(Pol)**
[C13 urea breath test in the diagnosis of Helicobacter pylori infection in the gastric mucosa. Validation of the method] Pérez García JI, et al. **Rev Esp Enferm Dig** 1996 Mar; 88(3):202–8 (45 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Choosing the best anti-Helicobacter pylori therapy: effect of antimicrobial resistance. Graham DY, et al.
Am J Gastroenterol 1996 Jun;91(6):1072–6 (46 ref.)
The influence of drug dosage on Helicobacter pylori eradication: a cost-effectiveness analysis. Treiber G.
Am J Gastroenterol 1996 Feb;91(2):246–57 (227 ref.)
Eradication of Helicobacter pylori infection. Hunt RH.
Am J Med 1996 May 20;100(5A):42S–50S; discussion 50S–51S (72 ref.)
Triple therapy and Helicobacter pylori. Davis S.
Aust Fam Physician 1996 Jan;25(1):53, 56–9 (5 ref.)
Eradication of Helicobacter pylori. Harris AW, et al.
Baillieres Clin Gastroenterol 1995 Sep;9(3):583–613 (171 ref.)
Helicobacter pylori eradication: the best long-term prophylaxis for ulcer bleeding recurrence? Jaspersen D.
Endoscopy 1995 Oct;27(8):622–5 (21 ref.)
Clarithromycin for treatment of Helicobacter pylori infections. Graham DY. **Eur J Gastroenterol Hepatol** 1995 Aug;7 Suppl 1:S55–8 (46 ref.)
Rationale for the choice of antibiotics for the eradication of Helicobacter pylori. Mégraud F.
Eur J Gastroenterol Hepatol 1995 Aug;7 Suppl 1:S49–54 (46 ref.)
Evolving therapies for peptic ulcer disease: Helicobacter pylori treatment. Cohen JC. **Gastroenterologist** 1995 Dec; 3(4):289–300 (129 ref.)
Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review. Hopkins RJ, et al. **Gastroenterology** 1996 Apr; 110(4):1244–52 (48 ref.)
Bismuth therapy for Helicobacter pylori infection. A review of five years experience at a university hospital in Norway. Berstad A, et al. **J Physiol Pharmacol** 1996 Mar;47(1):31–49 (45 ref.)
Strategies for Helicobacter pylori eradication in 1995: a review of international and Belgian experience. Deltenre M, et al. **J Physiol Pharmacol** 1996 Mar;47(1):59–69 (66 ref.)
Critical evaluation of the treatment of peptic ulcer diseases associated with Helicobacter pylori infection.
Gabryelewicz A. **J Physiol Pharmacol** 1996 Mar;47(1):51–8 (44 ref.)
Eradication of Helicobacter pylori. Axon AT.
Scand J Gastroenterol Suppl 1996;214:47–53; discussion 57–60 (48 ref.)
Helicobacter pylori eradication: unravelling the facts. Dixon JS. **Scand J Gastroenterol Suppl** 1995;212:48–62 (244 ref.)
Helicobacter pylori eradication: a critical appraisal and current concerns. Hunt RH.
Scand J Gastroenterol Suppl 1995;210:73–6 (18 ref.)
Helicobacter pylori and peptic ulcer. Korman MG, et al.
Scand J Gastroenterol Suppl 1995;210:89–92–6 (61 ref.)
Sucralfate in Helicobacter pylori eradication strategies. Lam SK, et al. **Scand J Gastroenterol Suppl** 1995;210:89–91 (19 ref.)
H2-receptor antagonists an Helicobacter pylori eradication. Lamers CB. **Scand J Gastroenterol Suppl** 1995;212:126–7 (8 ref.)
Peptic ulcer and Helicobacter pylori: eradication and relapse. Tytgat GN. **Scand J Gastroenterol Suppl** 1995;210:70–2 (13 ref.)
[Treatment of Helicobacter pylori infection] van der Hulst RW, et al. **Ned Tijdschr Geneeskd** 1996 May 4; 140(18):967–70 (27 ref.) **(Dut)**
[How to eradicate Helicobacter pylori?] Cayla R.
Gastroenterol Clin Biol 1996 Jan;20(1 Pt 2):S119–S130 (83 ref.) **(Fre)**
[How to eradicate Helicobacter pylori in 1995? Critical review of available treatments] Deltenre M, et al.
Gastroenterol Clin Biol 1996 Jan;20(1 Pt 2):S44–S52 (122 ref.) **(Fre)**
[Treatment of stomach ulcer] Hudziak H.
Gastroenterol Clin Biol 1996 Jan;20(1 Pt 2):S136–S142 (51 ref.) **(Fre)**
[Therapeutic management of duodenal ulcer except in emergency: eradication of Helicobacter pylori] Lamouliatte H. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S58–S63 (63 ref.) **(Fre)**
[Helicobacter pylori and azithromycin] Mégraud F, et al.
Pathol Biol (Paris) 1995 Jun;43(6):555–60 (15 ref.) (Eng. Abstr.) **(Fre)**
[Influence of colloidal bismuth subcitrate, metronidazole, and amoxycillin on Helicobacter pylori and gastroduodenal ulcer healing] Quintero M, et al. **G E N** 1995 Apr–Jun; 49(2):116–22 (21 ref.) (Eng. Abstr.) **(Spa)**
[Omeprazole and amoxycillin in the eradicating treatment

of Helicobacter pylori] Gisbert JP, et al. **Rev Clin Esp** 1995 Nov;195(11):787–91 (74 ref.) **(Spa)**
[Treatment of Helicobacter pylori infection: current status] Ramírez Ramos A. **Rev Gastroenterol Peru** 1995;15 Suppl 1:S7–21 (67 ref.) (Eng. Abstr.) **(Spa)**
[Reconsider management of Helicobacter pylori infections. Time to go over to the triple therapy] Jaup BH. **Lakartidningen** 1996 Feb 28;93(9):800–1 (12 ref.) **(Swe)**

ECONOMICS

The economics of eradicating Helicobacter pylori infection in duodenal ulcer disease. Vakil N, et al. **Am J Med** 1996 May 20;100(5A):60S–63S; discussion 63S–64S (21 ref.)
Cost-effectiveness of H. pylori eradication. Roesch W. **J Physiol Pharmacol** 1996 Mar;47(1):71–7 (20 ref.)

EPIDEMIOLOGY

Accuracy of diagnostic methods used for epidemiological studies of Helicobacter pylori. Feldman RA, et al. **Aliment Pharmacol Ther** 1995;9 Suppl 2:21–31 (64 ref.)
The prevalence of Helicobacter pylori infection in gastric cancer. Forman D. **Aliment Pharmacol Ther** 1995;9 Suppl 2:71–6 (36 ref.)
The prevalence of Helicobacter pylori in peptic ulcer disease. Kuipers EJ, et al. **Aliment Pharmacol Ther** 1995;9 Suppl 2:59–69 (110 ref.)
The incidence of Helicobacter pylori infection. Parsonnet J. **Aliment Pharmacol Ther** 1995;9 Suppl 2:45–51 (29 ref.)
The prevalence of Helicobacter pylori infection in different countries. Pounder RE, et al. **Aliment Pharmacol Ther** 1995; 9 Suppl 2:33–9 (28 ref.)
Do socio-economic status, marital status and occupation influence the prevalence of Helicobacter pylori infection? Veldhuyzen van Zanten SJ. **Aliment Pharmacol Ther** 1995; 9 Suppl 2:41–4 (35 ref.)
Helicobacter pylori as a risk factor for cancer. Webb PM, et al. **Baillieres Clin Gastroenterol** 1995 Sep;9(3):563–82 (109 ref.)
Helicobacter pylori disease in childhood. Blecker U. **Clin Pediatr (Phila)** 1996 Apr;35(4):175–83 (97 ref.)
Helicobacter pylori disease in childhood [editorial] Wyllie R. **Clin Pediatr (Phila)** 1995 Sep;34(9):463–5 (34 ref.)
The transmission of Helicobacter pylori. A critical review of the evidence. Goodman KJ, et al. **Int J Epidemiol** 1995 Oct;24(5):875–87 (143 ref.)
Risk factors, Helicobacter pylori and a role for laparoscopic treatment of perforated peptic ulcer? [editorial; comment] Branicki FJ. **J Gastroenterol Hepatol** 1996 Jan;11(1):93–6 (43 ref.) Comment on: J Gastroenterol Hepatol 1996 Jan;11(1):82–7.
[Consensus conference: "Ulcer and gastritis at the time of Helicobacter pylori". Why and how? (editorial)] Bigard MA, et al. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S1–S4 (17 ref.) **(Fre)**
[Helicobacter pylori, gastric acid secretion, ulcer disease and HIV infection] Blondon H, et al. **Gastroenterol Clin Biol** 1996;20(3):248–53 (49 ref.) **(Fre)**
[Gastroduodenal ulcer disease and gastritis: general epidemiology, natural history and progression] Bommelaer G. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S5–S8 (45 ref.) **(Fre)**
[Helicobacter pylori infection: relationships between gastritis and clinical symptomatology] Bruley Des Varannes S, et al. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S84–S94 (92 ref.) **(Fre)**
[Role of Helicobacter pylori in the pathogenesis of ulcer disease and gastritis] Dorval ED. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S22–S26 (62 ref.) **(Fre)**
[Epidemiology of Helicobacter pylori: disparities in the distribution of the infection] Vincent P, et al. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S27–S33 (69 ref.) **(Fre)**

ETIOLOGY

[Helicobacter pylori, nonsteroidal anti-inflammatory agents and gastroduodenal changes] Teixeira AV. **Acta Med Port** 1995 Sep;8(9):517–21 (70 ref.) (Eng. Abstr.) **(Por)**

METABOLISM

Inflammation, acid and ulcers. Muller MJ, et al. **Yale J Biol Med** 1994 May-Aug;67(3–4):135–44 (93 ref.)

MICROBIOLOGY

Gastric carcinoma: the Helicobacter pylori trail. Deltenre M, et al. **Acta Gastroenterol Belg** 1995 Mar-Apr; 58(2):193–200 (56 ref.)
The role of Helicobacter pylori in gastritis and its progression to peptic ulcer disease. Blaser MJ. **Aliment Pharmacol Ther** 1995;9 Suppl 1:27–30 (27 ref.)
No Helicobacter pylori, no Helicobacter pylori-associated peptic ulcer disease. Tytgat GN. **Aliment Pharmacol Ther** 1995;9 Suppl 1:39–42 (15 ref.)
Unanswered questions about Helicobacter pylori. Walsh JH. **Aliment Pharmacol Ther** 1995;9 Suppl 1:31–7 (72 ref.)
Helicobacter pylori and gastrointestinal disease. Pezzi JS, et al. **Am Fam Physician** 1995 Nov 1;52(6):1717–24, 1729 (41 ref.)
The effect of Helicobacter pylori infection on gastric emptying of digestible and indigestible solids in patients with nonulcer dyspepsia. Chang CS, et al. **Am J Gastroenterol** 1996 Mar;91(3):474–9 (49 ref.)
Pathogenic mechanisms. Calam J. **Baillieres Clin Gastroenterol** 1995 Sep;9(3):487–506 (144 ref.)
The outcome of Helicobacter pylori infection. Allardyce R, et al. **Br J Hosp Med** 1995 Oct 18–31;54(8):372–7 (20 ref.)
Helicobacter pylori and peptic ulcer disease: current status [editorial] Greenberger NJ. **Hosp Pract (Off Ed)** 1995 Nov 15;30(11):11–2 (7 ref.)
Helicobacter pylori and gastrointestinal disease. Gibaldi M. **J Clin Pharmacol** 1995 Jul;35(7):647–54 (44 ref.)
[Cause-targeted treatment of ulcer disease] Seppälä K, et al. **Duodecim** 1994;110(20):1853–9 (39 ref.) **(Fin)**
[Role of Helicobacter infection in the causes and mechanisms of gastroduodenal ulcer and chronic gastritis] Chamouard P. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S103–S110 (120 ref.) **(Fre)**

PATHOLOGY

Histological responses to Helicobacter pylori infection: gastritis, atrophy and preneoplasia. Dixon MF. **Baillieres Clin Gastroenterol** 1995 Sep;9(3):467–86 (75 ref.)
Helicobacter pylori, gastric cancer and gastric epithelial kinetics: a review. Lynch DA, et al. **Eur J Gastroenterol Hepatol** 1995 Aug;7 Suppl 1:S17–23 (69 ref.)
The pathological sequence in the development of gastric cancer: I. Hattori T, et al. **Scand J Gastroenterol Suppl** 1996;214:34–5; discussion 40–3 (8 ref.)
[Chronic gastritis and gastroduodenal ulcers: anatomopathological aspects, course and progression] Fléjou JF. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S9–S13 (41 ref.) **(Fre)**

PHYSIOPATHOLOGY

The somatostatin-gastrin link of Helicobacter pylori infection. Calam J. **Ann Med** 1995 Oct;27(5):569–73 (46 ref.)
Helicobacter pylori, gastric MALT and B-cell clonality. Sorrentino D, et al. **Clin Exp Rheumatol** 1996 Jan-Feb;14 Suppl 14:S51–4 (25 ref.)
Helicobacter pylori infection and gastric motor dysfunction. Wingate DL. **J Physiol Pharmacol** 1996 Mar;47(1):21–9 (0 ref.)
[Role of acid secretion in the pathogenesis of duodenal ulcer] Mignon M, et al. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S14–S21 (105 ref.) **(Fre)**

PREVENTION & CONTROL

Prevention of Helicobacter pylori infection. Feldman RA. **Baillieres Clin Gastroenterol** 1995 Sep;9(3):447–65 (132 ref.)
Royal Society of Tropical Medicine and Hygiene Meeting at Manson House, London, 16 February 1995. Aspects of Helicobacter pylori infection in the developing and developed world. Helicobacter pylori infection, nutrition and growth of West African infants. Weaver LT. **Trans R Soc Trop Med Hyg** 1995 Jul-Aug;89(4):347–50 (24 ref.)
[When to look for Helicobacter pylori?] Delchier JC. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S34–S37 (32 ref.) **(Fre)**

PSYCHOLOGY

Organic and psychosocial risk factors for duodenal ulcer. Lewin J, et al. **J Psychosom Res** 1995 Jul;39(5):531–48 (85 ref.)

SURGERY

Peptic ulcer disease, Helicobacter pylori, and the surgeon: changing of the guard. al-Assi MT, et al. **Curr Opin Gen Surg** 1994;:120–4 (28 ref.)
[Management of stomach ulcer except in emergency: surgical treatment] Lacaine F. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S81–S83 (16 ref.) **(Fre)**

THERAPY

Helicobacter pylori in infants and children. Czinn SJ, et al. **Adv Pediatr Infect Dis** 1996;11:389–401 (54 ref.)
Animal models and vaccine development. Lee A. **Baillieres Clin Gastroenterol** 1995 Sep;9(3):615–32 (74 ref.)
[What is the right therapeutic management of duodenal ulcer except in emergency?] Bouhnik Y. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S131–S134 (40 ref.) **(Fre)**
[Medical treatment of stomach ulcer except in emergency] Bretagne JF. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S73–S80 (68 ref.) **(Fre)**

TRANSMISSION

Non-human reservoirs of Helicobacter pylori. Fox JG. **Aliment Pharmacol Ther** 1995;9 Suppl 2:93–103 (83 ref.)
Transmission of Helicobacter pylori: faecal-oral versus oral-oral route. Mégraud F. **Aliment Pharmacol Ther** 1995; 9 Suppl 2:85–91 (54 ref.)
Endoscopic transmission of Helicobacter pylori. Tytgat GN. **Aliment Pharmacol Ther** 1995;9 Suppl 2:105–10 (31 ref.)
Common infectious diseases. Bagg J. **Dent Clin North Am** 1996 Apr;40(2):385–93 (33 ref.)
The transmission of Helicobacter pylori. A critical review of the evidence. Goodman KJ, et al. **Int J Epidemiol** 1995 Oct;24(5):875–87 (143 ref.)

HELICOBACTER PYLORI

Helicobacter pylori infection and gastric cancer: usefulness of screening high risk groups. Buckley M, et al. **Acta Gastroenterol Belg** 1995 Sep-Dec;58(5–6):382–7 (34 ref.)
Gastric carcinoma: the Helicobacter pylori trail. Deltenre M, et al. **Acta Gastroenterol Belg** 1995 Mar-Apr; 58(2):193–200 (56 ref.)
Helicobacter pylori in infants and children. Czinn SJ, et al. **Adv Pediatr Infect Dis** 1996;11:389–401 (54 ref.)
The prevalence of Helicobacter pylori infection in gastric cancer. Forman D. **Aliment Pharmacol Ther** 1995;9 Suppl 2:71–6 (36 ref.)
The prevalence of Helicobacter pylori in peptic ulcer disease. Kuipers EJ, et al. **Aliment Pharmacol Ther** 1995;9 Suppl 2:59–69 (110 ref.)
Review article: the development of atrophic gastritis--Helicobacter pylori and the effects of acid suppressive therapy. Kuipers EJ, et al. **Aliment Pharmacol Ther** 1995 Aug;9(4):331–40 (97 ref.)
Transmission of Helicobacter pylori: faecal-oral versus oral-oral route. Mégraud F. **Aliment Pharmacol Ther** 1995; 9 Suppl 2:85–91 (54 ref.)
The incidence of Helicobacter pylori infection. Parsonnet J. **Aliment Pharmacol Ther** 1995;9 Suppl 2:45–51 (29 ref.)
The relationships between chronic gastritis and gastric acid secretion. Sipponen P, et al. **Aliment Pharmacol Ther** 1996 Apr;10 Suppl 1:103–18 (147 ref.)
Endoscopic transmission of Helicobacter pylori. Tytgat GN. **Aliment Pharmacol Ther** 1995;9 Suppl 2:105–10 (31 ref.)
Helicobacter pylori and gastrointestinal disease. Pezzi JS, et al. **Am Fam Physician** 1995 Nov 1;52(6):1717–24, 1729 (41 ref.)
The effect of Helicobacter pylori infection on gastric emptying of digestible and indigestible solids in patients with nonulcer dyspepsia. Chang CS, et al. **Am J Gastroenterol** 1996 Mar;91(3):474–9 (49 ref.)
Choosing the best anti-Helicobacter pylori therapy: effect of antimicrobial resistance. Graham DY, et al. **Am J Gastroenterol** 1996 Jun;91(6):1072–6 (46 ref.)
Breathtaking technology for the detection of Helicobacter pylori [editorial] [see comments] Phillips M. **Am J Gastroenterol** 1995 Dec;90(12):2089–90 (9 ref.) Comment in: Am J Gastroenterol 1996 Jul;91(7):1468–9.
The influence of drug dosage on Helicobacter pylori eradication: a cost-effectiveness analysis. Treiber G. **Am J Gastroenterol** 1996 Feb;91(2):246–57 (227 ref.)
Transmission and epidemiology of Helicobacter pylori. Cave DR. **Am J Med** 1996 May 20;100(5A):12S–17S; discussion 17S–18S (47 ref.)
Clinical expressions of Helicobacter pylori infection. Howden CW. **Am J Med** 1996 May 20;100(5A):27S–32S; discussion 32S–34S (48 ref.)
Eradication of Helicobacter pylori infection. Hunt RH. **Am J Med** 1996 May 20;100(5A):42S–50S; discussion 50S–51S (72 ref.)
Helicobacter pylori and complicated ulcer disease. Laine LA. **Am J Med** 1996 May 20;100(5A):52S–57S; discussion 57S–59S (47 ref.)
Helicobacter pylori and ulcerogenesis. Peura DA. **Am J Med** 1996 May 20;100(5A):19S–25S; discussion 25S–26S (78 ref.)
The economics of eradicating Helicobacter pylori infection in duodenal ulcer disease. Vakil N, et al. **Am J Med** 1996 May 20;100(5A):60S–63S; discussion 63S–64S (21 ref.)
The somatostatin-gastrin link of Helicobacter pylori infection. Calam J. **Ann Med** 1995 Oct;27(5):569–73 (46 ref.)
Helicobacter pylori, duodenal ulcer, gastric cancer: tunnel vision or blinders? Graham DY, et al. **Ann Med** 1995 Oct; 27(5):589–94 (27 ref.)
Helicobacter pylori in peptic ulcer: have Koch's postulates been fulfilled? Marshall BJ. **Ann Med** 1995 Oct;27(5):565–8 (16 ref.)
Triple therapy and Helicobacter pylori. Davis S. **Aust Fam Physician** 1996 Jan;25(1):53, 56–9 (5 ref.)
Histological responses to Helicobacter pylori infection: gastritis, atrophy and preneoplasia. Dixon MF. **Baillieres Clin Gastroenterol** 1995 Sep;9(3):467–86 (75 ref.)
Prevention of Helicobacter pylori infection. Feldman RA. **Baillieres Clin Gastroenterol** 1995 Sep;9(3):447–65 (132 ref.)
Eradication of Helicobacter pylori. Harris AW, et al. **Baillieres Clin Gastroenterol** 1995 Sep;9(3):583–613 (171 ref.)
Helicobacter pylori in duodenal and gastric ulcer disease. Rauws EJ, et al. **Baillieres Clin Gastroenterol** 1995 Sep; 9(3):529–47 (119 ref.)
Helicobacter pylori in children. Sullivan PB. **Baillieres Clin Gastroenterol** 1995 Sep;9(3):519–28 (71 ref.)
Helicobacter pylori as a risk factor for cancer. Webb PM, et al. **Baillieres Clin Gastroenterol** 1995 Sep;9(3):563–82 (109 ref.)
Primary gastric lymphoma. Isaacson PG. **Br J Biomed Sci** 1995 Dec;52(4):291–6 (40 ref.)
Peptic ulcers and gastric cancer. Mera SL. **Br J Biomed Sci** 1995 Dec;52(4):271–81 (59 ref.)

Role of Helicobacter pylori in gastrointestinal disease: implications for primary care of a revolution in management of dyspepsia. Delaney BC. **Br J Gen Pract** 1995 Sep;45(398):489–94 (71 ref.)

The outcome of Helicobacter pylori infection. Allardyce R, et al. **Br J Hosp Med** 1995 Oct 18–31;54(8):372–7 (20 ref.)

Helicobacter pylori disease in childhood [editorial] Wyllie R. **Clin Pediatr (Phila)** 1995 Sep;34(9):463–5 (34 ref.)

Peptic ulcer disease, Helicobacter pylori, and the surgeon: changing of the guard. al-Assi MT, et al. **Curr Opin Gen Surg** 1994;:120–4 (28 ref.)

Helicobacter pylori infection and peptic ulcer disease in children. Rowland M, et al. **Curr Opin Pediatr** 1995 Oct; 7(5):553–9 (65 ref.)

May Helicobacter pylori be important for dermatologists? Rebora A, et al. **Dermatology** 1995;191(1):6–8 (21 ref.)

We need to integrate new data concerning Helicobacter pylor into experimental ulcer research. Graham DY. **Dig Dis Sci** 1995 Nov;40(11):2487–9 (35 ref.)

Helicobacter pylori eradication: the best long-term prophylaxis for ulcer bleeding recurrence? Jaspersen D. **Endoscopy** 1995 Oct;27(8):622–5 (21 ref.)

Helicobacter pylori as a promoter of intestinal metaplasia and gastric cancer: an alluring hypothesis in search of evidence. Genta RM. **Eur J Gastroenterol Hepatol** 1995 Aug;7 Suppl 1:S25–30 (53 ref.)

Clarithromycin for treatment of Helicobacter pylori infections. Graham DY. **Eur J Gastroenterol Hepatol** 1995 Aug;7 Suppl 1:S55–8 (46 ref.)

Antral G-cell hyperplasia: a vanishing disease? Kwan CP, et al. **Eur J Gastroenterol Hepatol** 1995 Nov; 7(11):1099–1103 (44 ref.)

Helicobacter pylori, gastric cancer and gastric epithelial kinetics: a review. Lynch DA, et al. **Eur J Gastroenterol Hepatol** 1995 Aug;7 Suppl 1:S17–23 (69 ref.)

Evolving therapies for peptic ulcer disease: Helicobacter pylori treatment. Cohen JC. **Gastroenterologist** 1995 Dec; 3(4):289–300 (129 ref.)

Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review. Hopkins RJ, et al. **Gastroenterology** 1996 Apr; 110(4):1244–52 (48 ref.)

H. pylori infection: its role in chronic gastritis, carcinoma and peptic ulcer. Pajares JM. **Hepatogastroenterology** 1995 Nov–Dec;42(6):827–41 (141 ref.)

Helicobacter pylori and peptic ulcer disease: current status [editorial] Greenberger NJ. **Hosp Pract (Off Ed)** 1995 Nov 15;30(11):11–2 (7 ref.)

The transmission of Helicobacter pylori. A critical review of the evidence. Goodman KJ, et al. **Int J Epidemiol** 1995 Oct;24(5):875–87 (143 ref.)

Duodenal ulcer: the helicobacterization of a psychosomatic disease? Melmed RN, et al. **Isr J Med Sci** 1996 Mar–Apr; 32(3–4):211–6 (66 ref.)

The urea breath test: a non-invasive clinical tool for detecting Helicobacter pylori infection. Perri F, et al. **Ital J Gastroenterol** 1995 Mar;27(2):55–63 (77 ref.)

Helicobacter pylori and gastrointestinal disease. Gibaldi M. **J Clin Pharmacol** 1995 Jul;35(7):647–54 (44 ref.)

Risk factors, Helicobacter pylori and a role for laparoscopic treatment of perforated peptic ulcer? [editorial; comment] Branicki FJ. **J Gastroenterol Hepatol** 1996 Jan;11(1):93–6 (43 ref.) Comment on: J Gastroenterol Hepatol 1996 Jan;11(1):82–7.

Biology of gastric cancer: gastritis–metaplasia–dysplasia sequence, role of H Pylori, and molecular correlates of tumor progression. Lynch P. **J Infus Chemother** 1995 Summer;5(3):93–6 (23 ref.)

Helicobacter pylori infection and gastric cancer. Goldstone AR, et al. **J Pathol** 1996 Jun;179(2):129–37 (117 ref.)

Bismuth therapy for Helicobacter pylori infection. A review of five years experience at a university hospital in Norway. Berstad A, et al. **J Physiol Pharmacol** 1996 Mar;47(1):31–49 (45 ref.)

Strategies for Helicobacter pylori eradication in 1995: a review of international and Belgian experience. Deltenre M, et al. **J Physiol Pharmacol** 1996 Mar;47(1):59–69 (66 ref.)

Critical evaluation of the treatment of peptic ulcer diseases associated with Helicobacter pylori infection. Gabryelewicz A. **J Physiol Pharmacol** 1996 Mar;47(1):51–8 (44 ref.)

Gastric secretion and the pathogenesis of peptic ulcer in the Helicobacter pylori infection. Konturek PC, et al. **J Physiol Pharmacol** 1996 Mar;47(1):5–19 (80 ref.)

Cost-effectiveness of H. pylori eradication. Roesch W. **J Physiol Pharmacol** 1996 Mar;47(1):71–7 (20 ref.)

Helicobacter pylori infection and gastric motor dysfunction. Wingate DL. **J Physiol Pharmacol** 1996 Mar;47(1):21–9 (0 ref.)

Organic and psychosocial risk factors for duodenal ulcer. Lewin J, et al. **J Psychosom Res** 1995 Jul;39(5):531–48 (85 ref.)

Consensus conference. Medical treatment of peptic ulcer disease. Practice guidelines. Practice Parameters Committee of the American College of Gastroenterology [published erratum appears in JAMA 1996 May 1;275(17):1314] Soll AH. **JAMA** 1996 Feb 28;275(8):622–9 (99 ref.)

Helicobacter pylori and gastric neoplasia: evolving concepts. Bolin TD, et al. **Med J Aust** 1995 Sep 4;163(5):253–5 (18 ref.)

Helicobacter pylori and peptic disease in the pediatric patient. Bujanover Y, et al. **Pediatr Clin North Am** 1996 Feb; 43(1):213–34 (138 ref.)

Helicobacter pylori infection and peptic ulcer disease in children. Bourke B, et al. **Pediatr Infect Dis J** 1996 Jan; 15(1):1–13 (163 ref.)

Helicobacter pylori infection and its role in human disease--an overview. McColl KE. **Pharm World Sci** 1996 Apr;18(2):49–55 (84 ref.)

Eradication of Helicobacter pylori. Axon AT. **Scand J Gastroenterol Suppl** 1996;214:47–53; discussion 57–60 (48 ref.)

Helicobacter pylori eradication: unravelling the facts. Dixon JS. **Scand J Gastroenterol Suppl** 1995;212:48–62 (244 ref.)

Helicobacter pylori and gastric cancer. Forman D. **Scand J Gastroenterol Suppl** 1996;214:31–3; discussion 40–3 (14 ref.)

The pathological sequence in the development of gastric cancer: I. Hattori T, et al. **Scand J Gastroenterol Suppl** 1996;214:34–5; discussion 40–3 (8 ref.)

H2-receptor antagonists an Helicobacter pylori eradication. Lamers CB. **Scand J Gastroenterol Suppl** 1995;212:126–7 (8 ref.)

Helicobacter pylori in ulcerogenesis. Lin SK, et al. **Scand J Gastroenterol Suppl** 1995;210:64–9 (72 ref.)

Diagnosis of Helicobacter pylori infection. Mégraud F. **Scand J Gastroenterol Suppl** 1996;214:44–6; discussion 57–60 (8 ref.)

Helicobacter pylori in Japan. Shimoyama T, et al. **Scand J Gastroenterol Suppl** 1996;214:61–3 (5 ref.)

Peptic ulcer and Helicobacter pylori: eradication and relapse. Tytgat GN. **Scand J Gastroenterol Suppl** 1995;210:70–2 (13 ref.)

The significance of Helicobacter pylori colonization of the stomach. Cilley RE, et al. **Semin Pediatr Surg** 1995 Nov; 4(4):221–7 (68 ref.)

Simultaneous gastric adenocarcinoma and MALT-type lymphoma in Helicobacter pylori infection. von Herbay A, et al. **Virchows Arch** 1995;427(4):445–50 (62 ref.)

Inflammation, acid and ulcers. Muller MJ, et al. **Yale J Biol Med** 1994 May–Aug;67(3–4):135–44 (93 ref.)

[Cause-targeted treatment of ulcer disease] Seppälä K, et al. **Duodecim** 1994;110(20):1853–9 (39 ref.) **(Fin)**

[Peptic ulcer and gastritis in the time of Helicobacter pylori] **Ann Gastroenterol Hepatol (Paris)** 1996 Jan–Feb; 32(1):25–34 (0 ref.) **(Fre)**

[Helicobacter pylori as a cause of benign malignant peptic ulcer] Abou-Mouch S, et al. **Harefuah** 1995 Jun 15; 128(12):808–11 (44 ref.) **(Heb)**

[Helicobacter pylori and gastric cancer] Tanida N, et al. **Nippon Geka Gakkai Zasshi** 1996 Apr;97(4):257–62 (41 ref.) (Eng. Abstr.) **(Jpn)**

[Helicobacter pylori infection in peptic ulcer and gastric cancer diseases] Matsukura N, et al. **Nippon Ika Daigaku Zasshi** 1995 Aug;62(4):313–9 (22 ref.) **(Jpn)**

[Helicobacter pylori and gastroduodenal diseases] Nakazawa T. **Nippon Saikingaku Zasshi** 1995 Jul;50(3):777–86 (14 ref.) **(Jpn)**

[Treatment of peptic ulcer and gastritis associated with Helicobacter pylori] López-Brea M, et al. **Enferm Infece Microbiol Clin** 1995 Aug–Sep;13(7):422–8 (75 ref.) **(Spa)**

[Influence of colloidal bismuth subcitrate, metronidazole, and amoxycillin on Helicobacter pylori and gastroduodenal ulcer healing] Quintero M, et al. **G E N** 1995 Apr–Jun; 49(2):116–22 (21 ref.) (Eng. Abstr.) **(Spa)**

[Omeprazole and amoxycillin in the eradicating treatment of Helicobacter pylori] Gisbert JP, et al. **Rev Clin Esp** 1995 Nov;195(11):787–91 (74 ref.) **(Spa)**

[Role of Helicobacter pylori (HP) in digestive pathology] Garrido Klinge G. **Rev Gastroenterol Peru** 1995;15 Suppl 1:S29–35 (20 ref.) (Eng. Abstr.) **(Spa)**

[Helicobacter pylori and gastric cancer] León-Barúa R, et al. **Rev Gastroenterol Peru** 1995;15 Suppl 1:S23–7 (38 ref.) (Eng. Abstr.) **(Spa)**

[Treatment of Helicobacter pylori infection: current status] Ramírez Ramos A. **Rev Gastroenterol Peru** 1995;15 Suppl 1:S7–21 (67 ref.) (Eng. Abstr.) **(Spa)**

CLASSIFICATION

Intrastrain differences in Helicobacter pylori: a key question in mucosal damage? Blaser MJ. **Ann Med** 1995 Oct; 27(5):559–63 (56 ref.)

DRUG EFFECTS

Helicobacter pylori eradication: a critical appraisal and current concerns. Hunt RH. **Scand J Gastroenterol Suppl** 1995;210:73–6 (18 ref.)

Helicobacter pylori and peptic ulcer. Korman MG, et al. **Scand J Gastroenterol Suppl** 1995;210:92–6 (61 ref.)

Sucralfate in Helicobacter pylori eradication strategies. Lam SK, et al. **Scand J Gastroenterol Suppl** 1995;210:89–91 (19 ref.)

[Helicobacter pylori and azithromycin] Mégraud F, et al. **Pathol Biol (Paris)** 1995 Jun;43(6):555–60 (15 ref.) (Eng. Abstr.) **(Fre)**

[Reconsider management of Helicobacter pylori infections. Time to go over to the triple therapy] Jaup BH. **Lakartidningen** 1996 Feb 28;93(9):800–1 (12 ref.) **(Swe)**

ENZYMOLOGY

[Helicobacter pylori urease] Nagata K, et al. **Nippon Saikingaku Zasshi** 1995 Oct;50(4):961–70 (60 ref.) **(Jpn)**

GROWTH & DEVELOPMENT

Helicobacter pylori and gastric acid: biological and therapeutic implications [see comments] McGowan CC, et al. **Gastroenterology** 1996 Mar;110(3):926–38 (140 ref.) Comment in: Gastroenterology 1996 Mar;110(3):947–50.

IMMUNOLOGY

HP serology as a screening method prior to upper gastro-intestinal endoscopy in young dyspeptic patients: a different point of view. Denis P, et al. **Acta Gastroenterol Belg** 1995 Sep–Dec;58(5–6):378–81 (15 ref.)

Lymphomas of mucosa-associated lymphoid tissue and antigen drive [editorial; comment] Wright DH. **J Pathol** 1996 Feb;178(2):111–2 (14 ref.) Comment on: J Pathol 1996 Feb;178(2):122–7.

ISOLATION & PURIFICATION

Prevalence of Helicobacter pylori in non-ulcer dyspepsia. Buckley M, et al. **Aliment Pharmacol Ther** 1995;9 Suppl 2:53–8 (55 ref.)

Accuracy of diagnostic methods used for epidemiological studies of Helicobacter pylori. Feldman RA, et al. **Aliment Pharmacol Ther** 1995;9 Suppl 2:21–31 (64 ref.)

The prevalence of Helicobacter pylori infection in different countries. Pounder RE, et al. **Aliment Pharmacol Ther** 1995; 9 Suppl 2:33–9 (28 ref.)

Testing for Helicobacter pylori in clinical practice. Cutler AF. **Am J Med** 1996 May 20;100(5A):35S–39S; discussion 39S–41S (44 ref.)

Diagnosis of Helicobacter pylori. Mégraud F. **Baillieres Clin Gastroenterol** 1995 Sep;9(3):507–18 (47 ref.)

Helicobacter pylori, gastric MALT and B-cell clonality. Sorrentino D, et al. **Clin Exp Rheumatol** 1996 Jan–Feb;14 Suppl 14:S51–4 (25 ref.)

Helicobacter pylori disease in childhood. Blecker U. **Clin Pediatr (Phila)** 1996 Apr;35(4):175–83 (97 ref.)

Critical issues in the pathophysiology and management of peptic ulcer disease. Hunt RH, et al. **Eur J Gastroenterol Hepatol** 1995 Jul;7(7):685–99 (156 ref.)

Helicobacter pylori: who is positive and who is not? Kuipers EJ, et al. **Eur J Gastroenterol Hepatol** 1995 Jun;7(6):533–6 (25 ref.)

Rationale for the choice of antibiotics for the eradication of Helicobacter pylori. Mégraud F. **Eur J Gastroenterol Hepatol** 1995 Aug;7 Suppl 1:S49–54 (46 ref.)

Bacteria in the aetio-pathogenesis of gastric cancer: a review. Houben GM, et al. **Scand J Gastroenterol Suppl** 1995; 212:13–8 (61 ref.)

[Consensus conference: "Ulcer and gastritis at the time of Helicobacter pylori". Why and how? (editorial)] Bigard MA, et al. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S1–S4 (17 ref.) **(Fre)**

[Helicobacter pylori, gastric acid secretion, ulcer disease and HIV infection] Blondon H, et al. **Gastroenterol Clin Biol** 1996;20(3):248–53 (49 ref.) **(Fre)**

[Gastroduodenal ulcer disease and gastritis: general epidemiology, natural history and progression] Bommelaer G. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S5–S8 (45 ref.) **(Fre)**

[What is the right therapeutic management of duodenal ulcer except in emergency?] Bouhnik Y. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S131–S134 (40 ref.) **(Fre)**

[Helicobacter pylori infection: relationships between gastritis and clinical symptomatology] Bruley Des Varannes S, et al. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S84–S94 (92 ref.) **(Fre)**

[When should Helicobacter pylori be eradicated?] Buckley M, et al. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S95–S102 (80 ref.) **(Fre)**

[How to eradicate Helicobacter pylori?] Cayla R. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S119–S130 (83 ref.) **(Fre)**

[Role of Helicobacter infection in the causes and mechanisms of gastroduodenal ulcer and chronic gastritis] Chamouard P. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S103–S110 (120 ref.) **(Fre)**

[When to look for Helicobacter pylori?] Delchier JC. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S34–S37 (32 ref.) **(Fre)**

[Role of Helicobacter pylori in the pathogenesis of ulcer disease and gastritis] Dorval ED. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S22–S26 (62 ref.) **(Fre)**

[Stomach cancer: what's new? (editorial)] Faivre J, et al. **Gastroenterol Clin Biol** 1995 Oct;19(10):793–6 (22 ref.) **(Fre)**

[Chronic gastritis and gastroduodenal ulcers: anatomopathological aspects, course and progression] Fléjou JF. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S9–S13 (41 ref.) **(Fre)**

[Diagnostic methods of Helicobacter pylori infection] Lozniewski A. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt

HELICOBACTER PYLORI

2):S111-S118 (100 ref.) **(Fre)**
[How to look for Helicobacter pylori?] Mégraud F. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S38-S43 (35 ref.) **(Fre)**
[Role of acid secretion in the pathogenesis of duodenal ulcer] Mignon M, et al. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S14-S21 (105 ref.) **(Fre)**
[Epidemiology of Helicobacter pylori: disparities in the distribution of the infection] Vincent P, et al. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S27-S33 (69 ref.) **(Fre)**
[Helicobacter pylori infection and the risk of gastric cancer] Zaremba-Woroniecka A, et al. **Pol Arch Med Wewn** 1995 Aug;94(2):164-72 (40 ref.) **(Pol)**
[Helicobacter pylori and its role in gastric and duodenal ulcers] Mach T. **Przegl Lek** 1995;52(7):365-7 (24 ref.) **(Pol)**
[C13 urea breath test in the diagnosis of Helicobacter pylori infection in the gastric mucosa. Validation of the method] Pérez García JI, et al. **Rev Esp Enferm Dig** 1996 Mar; 88(3):202-8 (45 ref.) (Eng. Abstr.) **(Spa)**

METABOLISM

Adhesion properties of Helicobacter pylori. Evans DG, et al. **Methods Enzymol** 1995;253:336-60 (62 ref.)

PATHOGENICITY

The role of Helicobacter pylori in gastritis and its progression to peptic ulcer disease. Blaser MJ. **Aliment Pharmacol Ther** 1995;9 Suppl 1:27-30 (27 ref.)
The role of lipopolysaccharide in Helicobacter pylori pathogenesis. Moran AP. **Aliment Pharmacol Ther** 1996 Apr;10 Suppl 1:39-50 (112 ref.)
No Helicobacter pylori, no Helicobacter pylori-associated peptic ulcer disease. Tytgat GN. **Aliment Pharmacol Ther** 1995;9 Suppl 1:39-42 (15 ref.)
Unanswered questions about Helicobacter pylori. Walsh JH. **Aliment Pharmacol Ther** 1995;9 Suppl 1:31-7 (72 ref.)
Defining Helicobacter pylori as a pathogen: strain heterogeneity and virulence. Mobley HL. **Am J Med** 1996 May 20;100(5A):2S-9S; discussion 9S-11S (51 ref.)
Pathogenic mechanisms. Calam J. **Baillieres Clin Gastroenterol** 1995 Sep;9(3):487-506 (144 ref.)
Helicobacter pylori and peptic ulcer disease. Blum AL. **Scand J Gastroenterol Suppl** 1996;214:24-7; discussion 42-3 (24 ref.)
Helicobacter pylori and dyspepsia. O'Morain C, et al. **Scand J Gastroenterol Suppl** 1996;214:28-30; discussion 40-3 (16 ref.)
Helicobacter pylori and the evolution of gastritis. Stolte M, et al. **Scand J Gastroenterol Suppl** 1996;214:13-6; discussion 21-3 (31 ref.)
[Helicobacter pylori, nonsteroidal anti-inflammatory agents and gastroduodenal changes] Teixeira AV. **Acta Med Port** 1995 Sep;8(9):517-21 (70 ref.) (Eng. Abstr.) **(Por)**

PHYSIOLOGY

Non-human reservoirs of Helicobacter pylori. Fox JG. **Aliment Pharmacol Ther** 1995;9 Suppl 2:93-103 (83 ref.)
Do socio-economic status, marital status and occupation influence the prevalence of Helicobacter pylori infection? Veldhuyzen van Zanten SJ. **Aliment Pharmacol Ther** 1995; 9 Suppl 2:41-4 (35 ref.)
Bacteriology of Helicobacter pylori. Owen RJ. **Baillieres Clin Gastroenterol** 1995 Sep;9(3):415-46 (137 ref.)
Physiology and biochemistry of Helicobacter pylori. Stark RM, et al. **Br J Biomed Sci** 1995 Dec;52(4):282-90 (62 ref.)

HELICOPTER AMBULANCES see **AIR AMBULANCES**

HELICOPTERS see **AIRCRAFT**

HELIGMOSOMATOIDEA

IMMUNOLOGY

Role of B7 signaling in the differentiation of naive CD4+ T cells to effector interleukin-4-producing T helper cells. Gause WC, et al. **Immunol Res** 1995;14(3):176-88 (84 ref.)

HELIUM

ADMINISTRATION & DOSAGE

Helium insufflation in laparoscopic surgery. Naude GP, et al. **Endosc Surg Allied Technol** 1995 Aug;3(4):183-6 (28 ref.)

HELIX-LOOP-HELIX MOTIFS

A new subclass of helix-loop-helix transcription factors expressed in paraxial mesoderm and chondrogenic cell lineages. Olson EN, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:108-18 (30 ref.)
The helix-loop-helix gene SCL: implicated in T-cell acute lymphoblastic leukaemia and in normal haematopoietic development. Robb L, et al. **Int J Biochem Cell Biol** 1996 Jun;28(6):609-18 (84 ref.)
Combinatorial control of muscle development by basic helix-loop-helix and MADS-box transcription factors. Molkentin JD, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9366-73 (108 ref.)
Transcription factors 2: helix-loop-helix. Littlewood TD, et al. **Protein Profile** 1994;1(6):635-709 (1097 ref.)
[Regulation of neural differentiation by HES helix-loop-helix transcription factors] Kageyama R. **Seikagaku** 1995 Sep; 67(9):1093-114 (71 ref.) **(Jpn)**

GENETICS

Know your neighbors: three phenotypes in null mutants of the myogenic bHLH gene MRF4. Olson EN, et al. **Cell** 1996 Apr 5;85(1):1-4 (20 ref.)
Regulation of mammalian neural development by helix-loop-helix transcription factors. Kageyama R, et al. **Crit Rev Neurobiol** 1995;9(2-3):177-88 (84 ref.)

PHYSIOLOGY

Neural development. Spinning skin into neurons. Anderson DJ. **Curr Biol** 1995 Nov 1;5(11):1235-8 (16 ref.)
Transcription factors 2: helix-loop-helix. Littlewood TD, et al. **Protein Profile** 1995;2(6):621-702 (1294 ref.)

HELLP SYNDROME

ETIOLOGY

-Obstetric prognosis after pre-eclampsia, eclampsia or HELLP syndrome- Niesert S. **Geburtshilfe Frauenheilkd** 1996 Feb;56(2):93-6 (18 ref.) (Eng. Abstr.) **(Ger)**
[The HELLP syndrome. Notes on its pathogenesis and treatment] D'Anna R. **Minerva Ginecol** 1996 Apr; 48(4):147-54 (30 ref.) (Eng. Abstr.) **(Ita)**

MORTALITY

[HELLP syndrome. Critical state. Current concepts] Rojas Poceros G, et al. **Ginecol Obstet Mex** 1996 Feb;64:64-72 (60 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

[Aggressive versus conservative management of HELLP syndrome--a status assessment] Rath W. **Geburtshilfe Frauenheilkd** 1996 Jun;56(6):265-71 (46 ref.) (Eng. Abstr.) **(Ger)**
[The HELLP syndrome. Notes on its pathogenesis and treatment] D'Anna R. **Minerva Ginecol** 1996 Apr; 48(4):147-54 (30 ref.) (Eng. Abstr.) **(Ita)**

HELMINTH ANTIGENS see **ANTIGENS, HELMINTH**

HELMINTH DNA see **DNA, HELMINTH**

HELMINTH GENES see **GENES, HELMINTH**

HELMINTH PROTEINS

METABOLISM

LET-23-mediated signal transduction during Caenorhabditis elegans development. Sternberg PW, et al. **Mol Reprod Dev** 1995 Dec;42(4):523-8 (35 ref.)

PHYSIOLOGY

Mechanosensation and the DEG/ENaC ion channels [comment] Corey DP, et al. **Science** 1996 Jul 19; 273(5273):323-4 (21 ref.) Comment on: Science 1996 Jul 19;273(5273):361-4.

HELMINTHIASIS

see related
ANTHELMINTICS

DIAGNOSIS

Common intestinal helminths. Juckett G. **Am Fam Physician** 1995 Nov 15;52(7):2039-48, 2051-2 (17 ref.)

DRUG THERAPY

The pharmacology of FMRFamide-related neuropeptides in nematodes: new opportunities for rational anthelmintic discovery? Geary TG, et al. **Int J Parasitol** 1995 Nov; 25(11):1273-80 (42 ref.)
Antiparasitic drugs. Liu LX, et al. **N Engl J Med** 1996 May 2;334(18):1178-84 (100 ref.)
[Kidney reactivity in helminthiases and after anthelmintic treatment] Grishina EA, et al. **Med Parazitol (Mosk)** 1995 Apr-Jun;(2):27-30 (15 ref.) (Eng. Abstr.) **(Rus)**

EPIDEMIOLOGY

[Intestinal helminthiasis in the Mexican Republic] Tay J, et al. **Bol Chil Parasitol** 1995 Jan-Jun;50(1-2):10-6 (23 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

Rare, new and emerging helminth zoonoses. Smyth JD. **Adv Parasitol** 1995;36:1-45 (180 ref.)

HISTORY

Studies on helminthosis at the Centre for Tropical Veterinary Medicine (CTVM). Harrison LJ, et al. **Trop Anim Health Prod** 1996 Feb;28(1):23-39 (134 ref.)

IMMUNOLOGY

Immunology of human helminth infection. Allen JE, et al. **Int Arch Allergy Immunol** 1996 Jan;109(1):3-10 (80 ref.)
Interleukin-5, eosinophils and the control of helminth infections in man and laboratory animals. Tagboto SK. **J Helminthol** 1995 Dec;69(4):271-8 (80 ref.)

PREVENTION & CONTROL

Intestinal worms: our turn to turn. de Silva HJ, et al. **Ceylon Med J** 1995 Dec;40(4):134-6 (11 ref.)
Not by drugs alone: the fight against parasitic helminths. Evans AC, et al. **World Health Forum** 1995;16(3):258-61 (10 ref.)

VETERINARY

Parasitic disease in amphibians: control by the regulation of worm burdens. Tinsley RC. **Parasitology** 1995;111 Suppl:S153-78 (62 ref.)
Studies on helminthosis at the Centre for Tropical Veterinary Medicine (CTVM). Harrison LJ, et al. **Trop Anim Health Prod** 1996 Feb;28(1):23-39 (134 ref.)

HELMINTHS

GROWTH & DEVELOPMENT

Common intestinal helminths. Juckett G. **Am Fam Physician** 1995 Nov 15;52(7):2039-48, 2051-2 (17 ref.)

ISOLATION & PURIFICATION

Patterns in the evenness of gastrointestinal helminth communities. Poulin R. **Int J Parasitol** 1996 Feb; 26(2):181-6 (13 ref.)

METABOLISM

The mevalonate pathway in parasitic protozoa and helminths. Coppens I, et al. **Exp Parasitol** 1996 Jan;82(1):76-85 (60 ref.)

PHYSIOLOGY

Parasitic disease in amphibians: control by the regulation of worm burdens. Tinsley RC. **Parasitology** 1995;111 Suppl:S153-78 (62 ref.)

HELPER CELLS see **T-LYMPHOCYTES, HELPER-INDUCER**

HELPER-INDUCER T-LYMPHOCYTES see **T-LYMPHOCYTES, HELPER-INDUCER**

HEMADSORPTION VIRUS 2 see **PARAINFLUENZA VIRUS TYPE 1**

HEMAGGLUTINATING VIRUS OF JAPAN see **PARAINFLUENZA VIRUS TYPE 1**

HEMAGGLUTININS, PLANT see **LECTINS**

HEMAGGLUTININS, VIRAL

METABOLISM

Influenza virus M2 protein and haemagglutinin conformation changes during intracellular transport. Ciampor F, et al. **Acta Virol** 1995 Jun;39(3):171-81 (41 ref.)
CD46-mediated measles virus entry: a first key to host-range specificity. Gerlier D, et al. **Trends Microbiol** 1995 Sep; 3(9):338-45 (65 ref.)

PHYSIOLOGY

Influenza viruses, cell enzymes, and pathogenicity. Rott R, et al. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 2):S16-9 (45 ref.)

HEMANGIOBLASTOMA

[Hemangioblastoma and von Hippel-Lindau disease] Matsumoto K, et al. **Nippon Rinsho** 1995 Nov;53(11):2672-7 (12 ref.) (Eng. Abstr.) **(Jpn)**

HEMANGIOENDOTHELIOMA

[Infantile hemangioendothelioma of the liver] Horie H. **Ryoikibetsu Shokogun Shirizu** 1995;(7):483-5 (18 ref.) **(Jpn)**

COMPLICATIONS

Intravascular malignant lymphomatosis: a cause of subacute dementia. Treves TA, et al. **Dementia** 1995 Sep-Oct; 6(5):286-93 (107 ref.)

PATHOLOGY

Endovascular papillary angioendothelioma-like tumour associated with lymphoedema. Fukunaga M, et al. **Histopathology** 1995 Sep;27(3):243-9 (16 ref.)

[Intravascular malignant lymphoma (ex-malignant angioendotheliosis). 3 cases] Demolombe-Ragué S, et al. **Presse Med** 1995 Nov 25;24(36):1689-93 (10 ref.) (Eng. Abstr.) **(Fre)**

HEMANGIOENDOTHELIOMA, EPITHELIOID

[Epithelioid hemangioendothelioma] Shiga J. **Ryoikibetsu Shokogun Shirizu** 1995;(7):438-40 (7 ref.) **(Jpn)**

DIAGNOSIS

[Epithelioid hemangioendothelioma localized in the small intestine] Alvarez Sánchez JA, et al. **Gastroenterol Hepatol** 1995 Nov;18(9):464-7 (19 ref.) (Eng. Abstr.) **(Spa)**

PATHOLOGY

Primary epithelioid hemangioendothelioma of the brain. Nora FE, et al. **Am J Surg Pathol** 1996 Jun;20(6):707-14 (37 ref.)

Epithelioid hemangioendothelioma of the lung: pleural effusion cytology, ultrastructure, and brief literature review. Buggage RR, et al. **Diagn Cytopathol** 1995 Jul; 13(1):54-60 (14 ref.)

Primary intraoral epithelioid hemangioendothelioma presenting in childhood: review of the literature and case report. Flaitz CM, et al. **Ultrastruct Pathol** 1995 Jul-Aug; 19(4):275-9 (8 ref.)

ULTRASTRUCTURE

Epithelioid hemangioendothelioma of the lung: pleural effusion cytology, ultrastructure, and brief literature review. Buggage RR, et al. **Diagn Cytopathol** 1995 Jul; 13(1):54-60 (14 ref.)

HEMANGIOMA

The significance of birthmarks. Rogers M. **Med J Aust** 1996 May 20;164(10):618-23 (24 ref.)

[Placental chorioangioma. Two cases and review of the literature] Rousseau O, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(5):529-33 (27 ref.) (Eng. Abstr.) **(Fre)**

[Adrenal hemangioma: review of the literature] Llado Carbonell C, et al. **Prog Urol** 1996 Apr;6(2):292-6 (38 ref.) (Eng. Abstr.) **(Fre)**

[Hemangioma and hyalinized hemangioma of the liver] Haratake J, et al. **Ryoikibetsu Shokogun Shirizu** 1995; (7):336-8 (15 ref.) **(Jpn)**

COMPLICATIONS

[Giant hemangioma of the liver disclosed by fever and an inflammatory syndrome. Apropos of 3 cases] Taillandier J, et al. **Ann Med Interne (Paris)** 1995;146(5):319-21 (9 ref.) (Eng. Abstr.) **(Fre)**

CONGENITAL

Cutaneous angiosarcoma arising in the radiation site of a congenital hemangioma. Caldwell JB, et al. **J Am Acad Dermatol** 1995 Nov;33(5 Pt 2):865-70 (50 ref.)

Hepatic vascular anomalies in infancy: a twenty-seven-year experience. Boon LM, et al. **J Pediatr** 1996 Sep; 129(3):346-54 (52 ref.)

DIAGNOSIS

From the archives of the AFIP. Musculoskeletal angiomatous lesions: radiologic-pathologic correlation. Murphey MD, et al. **Radiographics** 1995 Jul;15(4):893-917 (84 ref.)

Synovial hemangioma: imaging features in eight histologically proven cases, review of the literature, and differential diagnosis. Greenspan A, et al. **Skeletal Radiol** 1995 Nov;24(8):583-90 (32 ref.)

Symptomatic spinal hemangiomas in association with cutaneous hemangiomas. A case report. Asumu TO, et al. **Spine** 1996 May 1;21(9):1082-4 (7 ref.)

Venous hemangioma of the mesoappendix: report of a case and a brief review of the Japanese literature. Hanatate F, et al. **Surg Today** 1995;25(11):962-4 (8 ref.)

ETIOLOGY

[Kartagener syndrome and hemangiomatous proliferation of lung capillaries: case report and literature review] Słodkowska J, et al. **Pneumonol Alergol Pol** 1996; 64(3-4):217-24 (24 ref.) (Eng. Abstr.) **(Pol)**

PATHOLOGY

Central hemangioma. Review and a case report. Mody RN, et al. **Ann Dent** 1995 Summer-Fall;54(1-2):22-4 (26 ref.)

Acquired tufted angioma frequently develops at sites other than the neck and upper trunk [letter] Ward KA, et al. **Clin Exp Dermatol** 1996 Jan;21(1):80 (8 ref.)

Hemangioma of the temporalis muscle: a case report and review of the literature. Lopez-Cedrun JL, et al. **J Oral Maxillofac Surg** 1996 Sep;54(9):1130-2 (15 ref.)

[Neurocutaneous syndromes with predominant vascular anomalies] Rodriguez-Barrionuevo AC. **Rev Neurol** 1996 Sep;24(133):1072-84 (121 ref.) **(Spa)**

RADIOTHERAPY

Cutaneous angiosarcoma arising in the radiation site of a congenital hemangioma. Caldwell JB, et al. **J Am Acad Dermatol** 1995 Nov;33(5 Pt 2):865-70 (50 ref.)

SURGERY

Vascular lesions of the cranial base. Shin JH, et al. **Clin Plast Surg** 1995 Jul;22(3):531-42 (21 ref.)

Hepatic artery ligation for hepatic vascular tumors with arteriovenous and arterioportal venous shunts in the newborn: successful management of two cases and review of the literature. Hazebroek FW, et al. **J Pediatr Surg** 1995 Aug;30(8):1127-30 (15 ref.)

THERAPY

Multimodal management of diffuse neonatal hemangiomatosis. Stratte EG, et al. **J Am Acad Dermatol** 1996 Feb;34(2 Pt 2):337-42 (36 ref.)

Management of congenital vascular lesions of the head and neck. Waner M, et al. **Oncology (Huntingt)** 1995 Oct; 9(10):989-94, 997; discussion 998 passim (16 ref.)

[Angioma in childhood: current criteria for therapy] Stagno D'Alcontres F, et al. **Minerva Chir** 1995 Sep;50(9):779-87 (60 ref.) (Eng. Abstr.) **(Ita)**

HEMANGIOMA, CAPILLARY

RADIOTHERAPY

[External electron irradiation in 2 cases of capillary hemangioma of the optic disk] Schlienger P, et al. **Bull Cancer Radiother** 1995;82(3):306-10 (29 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Laser therapy of childhood haemangiomas. Landthaler M, et al. **Br J Dermatol** 1995 Aug;133(2):275-81 (30 ref.)

HEMANGIOMA, CAVERNOUS

COMPLICATIONS

Ovarian hemangioma associated with concomitant stromal luteinization and ascites. Yamawaki T, et al. **Gynecol Oncol** 1996 Jun;61(3):438-41 (13 ref.)

DIAGNOSIS

[The diagnosis of mediastinal hemangioma with magnetic resonance. A case report] Falaschi F, et al. **Radiol Med (Torino)** 1996 Jan-Feb;91(1-2):138-40 (11 ref.) **(Ita)**

[Cavernous hemangioma of the penis] Sergienko NF, et al. **Urol Nefrol (Mosk)** 1996 Mar-Apr;(2):47-9 (3 ref.) **(Rus)**

EPIDEMIOLOGY

Hemangioma of the small intestine: case report and literature review. Ramanujam PS, et al. **Am J Gastroenterol** 1995 Nov;90(11):2063-4 (9 ref.)

PATHOLOGY

Cavernous angioma associated with oligo-astrocytoma-like proliferation. Report of two cases and review of the literature with a reappraisal of the term "angioglioma". Palma L, et al. **Acta Neurochir (Wien)** 1995;133(3-4):169-73 (36 ref.)

SURGERY

Cavernous malformations of the optic chiasma. Shibuya M, et al. **Acta Neurochir (Wien)** 1995;136(1-2):29-36 (26 ref.)

The surgery of cavernomas both supra-tentorial and infra-tentorial. Houtteville JP. **Adv Tech Stand Neurosurg** 1995;22:185-259 (134 ref.)

Symptomatic cavernous malformations affecting the spine and spinal cord. Harrison MJ, et al. **Neurosurgery** 1995 Aug;37(2):195-204; discussion 204-5 (87 ref.)

Intracranial cavernous malformations: lesion behavior and management strategies. Maraire JN, et al. **Neurosurgery** 1995 Oct;37(4):591-605 (123 ref.)

THERAPY

[The interferon alfa-2a treatment of the severe form of the Kasabach-Merritt syndrome with neonatal onset] González de Dios J, et al. **An Esp Pediatr** 1996 Feb;44(2):179-83 (67 ref.) **(Spa)**

HEMANGIOMA, HISTIOCYTOID see **HEMANGIOMA**

HEMANGIOMA, INTRAMUSCULAR see **HEMANGIOMA**

HEMANGIOMA, LOBULAR CAPILLARY see **GRANULOMA, PYOGENIC**

HEMANGIOPERICYTOMA

Renal hemangiopericytoma. Case report and review of the literature. Bowers DL, et al. **Urol Int** 1995;55(3):162-6 (11 ref.)

[Hemangiopericytoma of the liver] Maeda S, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):339-41 (12 ref.) **(Jpn)**

CONGENITAL

Infantile haemangiopericytoma of the hand. Templeton PA, et al. **J Hand Surg [Br]** 1996 Feb;21(1):121-3 (8 ref.)

PATHOLOGY

Haemangiopericytoma of the middle ear: case report and literature review. Sutbeyaz Y, et al. **J Laryngol Otol** 1995 Oct;109(10):977-9 (26 ref.)

Malignant hemangiopericytoma of the floor of the mouth: report of a case and review of the literature. Lin JC, et al. **J Oral Maxillofac Surg** 1996 Aug;54(8):1020-3 (15 ref.)

Hemangiopericytoma: histopathological pattern or clinicopathologic entity? Nappi O, et al. **Semin Diagn Pathol** 1995 Aug;12(3):221-32 (113 ref.)

RADIOGRAPHY

[Hemangiopericytoma with parotid localization. Apropos of a case] Oujilal A, et al. **Ann Otolaryngol Chir Cervicofac** 1995;112(7):350-2 (17 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Resection of primary pulmonary hemangiopericytoma: a report of two cases. Kuroya M, et al. **Surg Today** 1996; 26(3):208-12 (22 ref.)

HEMANGIOSARCOMA

[Breast angiosarcoma. Five case reports] Gamoudi A, et al. **Rev Fr Gynecol Obstet** 1995 Oct;90(10):435-41 (18 ref.) (Eng. Abstr.) **(Fre)**

[Hepatic angiosarcoma] Haratake J, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):342-4 (17 ref.) **(Jpn)**

COMPLICATIONS

Case report: angiosarcoma in a patient with von Recklinghausen's disease. Png MA, et al. **Clin Radiol** 1996 Jul;51(7):521-3 (8 ref.)

[A case of angiosarcoma of the pelvis associated with angiomatosis of the spine] Uribe Uribe NO, et al. **Rev Invest Clin** 1996 Jan-Feb;48(1):49-53 (9 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Immunocytochemistry in the diagnosis of Kaposi's sarcoma and angiosarcoma. Orchard GE, et al. **Br J Biomed Sci** 1995 Mar;52(1):35-49 (145 ref.)

A case of breast angiosarcoma: diagnostic imaging and review of the literature. Zincone GE, et al. **Tumori** 1995 Sep-Oct;81(5):387-96 (15 ref.)

[Angiosarcoma of the aorta--a case report] Düx M, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1995 Oct;163(4):361-3 (8 ref.) **(Ger)**

[Lymphedema-associated angiosarcoma (the Stewart-Treves syndrome) of the lower extremity: its MRT imaging] Gelmetti W, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Feb;164(2):168-70 (15 ref.) **(Ger)**

EPIDEMIOLOGY

Angiosarcoma. A report of 67 patients and a review of the literature. Mark RJ, et al. **Cancer** 1996 Jun 1;77(11):2400-6 (53 ref.)

ETIOLOGY

Low-grade dermal angiosarcoma of the breast following radiotherapy. Bolin DJ, et al. **Am Surg** 1996 Aug; 62(8):668-72 (19 ref.)

Radiation-associated angiosarcoma: diagnostic and therapeutic implications--two case reports and a review of the literature. Cafiero F, et al. **Cancer** 1996 Jun 15; 77(12):2496-502 (46 ref.)

Pericardial angiosarcoma after mediastinal irradiation for seminoma. A case report and a review of the literature. Killion MJ, et al. **Cancer** 1996 Aug 15;78(4):912-7 (30 ref.)

Three cases of breast angiosarcomas after breast-conserving treatment for carcinoma [letter] Weber B, et al. **Radiother Oncol** 1995 Dec;37(3):250-2 (21 ref.)

PATHOLOGY

Pericardial angiosarcoma after mediastinal irradiation for seminoma. A case report and a review of the literature. Killion MJ, et al. **Cancer** 1996 Aug 15;78(4):912-7 (30 ref.)

Cutaneous angiosarcoma arising in the radiation site of a congenital hemangioma. Caldwell JB, et al. **J Am Acad Dermatol** 1995 Nov;33(5 Pt 2):865-70 (50 ref.)

Angiosarcoma-like neoplasms of epithelial organs: true endothelial tumors or variants of carcinoma? Ritter JH,

HEMANGIOSARCOMA

et al. **Semin Diagn Pathol** 1995 Aug;12(3):270–82 (74 ref.)
[Primary angiosarcoma of the thyroid. Presentation of a case (epithelioid type) and nosological problems] Bisceglia M, et al. **Pathologica** 1995 Apr;87(2):154–61 (49 ref.) (Eng. Abstr.) **(Ita)**

HEMARTHROSIS

ETIOLOGY

Hemophilic ankle arthropathy. Ribbans WJ, et al. **Clin Orthop** 1996 Jul;(328):39–45 (10 ref.)
Hemophilic arthropathy. Lan HH, et al. **Radiol Clin North Am** 1996 Mar;34(2):446–50 (16 ref.)

HEMATEMESIS

ETIOLOGY

Gastric tuberculosis presenting with massive hematemesis in association with acute myeloid leukemia. Quantrill SJ, et al. **Am J Gastroenterol** 1996 Jun;91(6):1259–60 (11 ref.)

HEMATINICS

THERAPEUTIC USE

[Folic acid in the prevention of neural tube defects] Tönz O, et al. **Schweiz Med Wochenschr** 1996 Feb 3;126(5):177–87 (60 ref.) (Eng. Abstr.) **(Ger)**

HEMATOCHEZIA see **GASTROINTESTINAL HEMORRHAGE**

HEMATOCOLPOS

ETIOLOGY

[Acute urinary retention secondary to an imperforate hymen with hematocolpos] Gatius Tonda C, et al. **An Esp Pediatr** 1996 Apr;44(4):381–2 (8 ref.) **(Spa)**

HEMATO-ENCEPHALIC BARRIER see **BLOOD-BRAIN BARRIER**

HEMATOLOGIC DISEASES

[Epstein-Barr virus and hematologic diseases] Tatsumi E. **Nippon Naika Gakkai Zasshi** 1996 Apr 10;85(4):622–8 (21 ref.) **(Jpn)**

BLOOD

Disorders of neutrophil function. Bogomolski-Yahalom V, et al. **Blood Rev** 1995 Sep;9(3):183–90 (71 ref.)

CHEMICALLY INDUCED

Hematotoxic interactions: occurrence, mechanisms and predictability. Krishnan K, et al. **Toxicology** 1995 Dec 28; 105(2–3):355–64 (43 ref.)

COMPLICATIONS

Rheumatological manifestations of haematological diseases. Menon S, et al. **Ann Rheum Dis** 1995 Oct;54(10):787–95 (126 ref.)
[Varicella-zoster virus pancreatitis in hematologic diseases] Pulik M, et al. **Ann Med Interne (Paris)** 1995;146(5):292–4 (10 ref.) (Eng. Abstr.) **(Fre)**
[Tubulointerstitial changes in some hematological disorders] Morita H, et al. **Nippon Rinsho** 1995 Aug;53(8):2007–12 (17 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

[Morphologic analysis of blood cells] Kikuchi T, et al. **Rinsho Byori** 1995 Sep;43(9):917–24 (15 ref.) (Eng. Abstr.) **(Jpn)**

DRUG THERAPY

The importance of dose and schedule in cancer chemotherapy: haematological cancer. Sweetenham JW. **Anticancer Drugs** 1995 Oct;6 Suppl 5:7–15 (50 ref.)
[Value of corticoids in hematology/oncology in adulthood] Schlimok G, et al. **Med Klin** 1995 Oct 15;90(10):579–84 (23 ref.) **(Ger)**

ETIOLOGY

Management of the hematological manifestations of HIV infection and AIDS. Ownby KK. **J Assoc Nurses AIDS Care** 1995 Jul–Aug;6(4):9–15; quiz 17–8 (16 ref.)
[Extrahepatic manifestations of hepatitis A virus infection] Maïga MY, et al. **Gastroenterol Clin Biol** 1996;20(4):346–52 (110 ref.) **(Fre)**

GENETICS

The use of umbilical cord blood as a cellular source for correction of genetic diseases affecting the hematopoietic system. Clapp DW, et al. **Stem Cells (Dayt)** 1995 Nov; 13(6):613–21 (87 ref.)
[Significance of clonality study in hematological diseases] Karasawa M. **Nippon Naika Gakkai Zasshi** 1995 Nov 10; 84(11):1934–8 (12 ref.) **(Jpn)**
[Molecular biology and clinical study of hematologic diseases] Saito H. **Nippon Naika Gakkai Zasshi** 1995 Sep 10;84(9):1371–9 (15 ref.) **(Jpn)**

IMMUNOLOGY

[Immune cytopenias and some associated problems of immunohematology] Zotikov EA. **Biull Eksp Biol Med** 1996 Apr;121(4):364–9 (41 ref.) **(Rus)**

PATHOLOGY

Stem cell factor as a survival and growth factor in human normal and malignant hematopoiesis. Hassan HT, et al. **Acta Haematol** 1996;95(3–4):257–62 (50 ref.)
Tuberculosis-associated haemophagocytic syndrome: a report of two cases and a review of the literature. Undar L, et al. **Acta Haematol** 1996;96(2):73–8 (36 ref.)

SURGERY

[Preparing patients with hematologic diseases for surgical interventions] Podolak-Dawidziak M, et al. **Pol Arch Med Wewn** 1995 May;93(5):390–4 (21 ref.) **(Pol)**

THERAPY

The multidrug-resistance gene in gene therapy of cancer and hematopoietic disorders. Licht T, et al. **Ann Hematol** 1996 Apr;72(4):184–93 (118 ref.)
Immunotoxin therapy of hematological malignancies. Pasqualucci L, et al. **Haematologica** 1995 Nov–Dec; 80(6):546–56 (47 ref.)
An overview of the oral complications of adult patients with malignant haematological conditions who have undergone radiotherapy or chemotherapy. Coleman S. **J Adv Nurs** 1995 Dec;22(6):1085–91 (47 ref.)
Human umbilical cord blood for hematopoietic progenitor cells transplantation. Varadi G, et al. **Leuk Lymphoma** 1995 Dec;20(1–2):51–8 (54 ref.)
Alpha interferon: new associations in haematology/oncology. The Montpellier experience. Rossi JF. **Med Oncol** 1995 Mar;12(1):59–61 (23 ref.)
Blood component therapy in neonatal hemostatic disorders. Andrew M, et al. **Transfus Med Rev** 1995 Jul;9(3):231–50 (145 ref.)
[Indications for bone marrow and peripheral stem cell transplantation in malignant hematological diseases] Gratwohl A. **Ther Umsch** 1996 Feb;53(2):152–7 (15 ref.) (Eng. Abstr.) **(Ger)**
[Present status of peripheral hematopoietic stem cell transplantation] Harada M. **Nippon Naika Gakkai Zasshi** 1996 Mar 10;85(3):454–8 (17 ref.) **(Jpn)**
[Indication of bone marrow transplantation] Masaoka T. **Rinsho Byori** 1995 Jul;Suppl 99:1–7 (0 ref.) **(Jpn)**
[Treatment with growth factors and cytokines in hematologic diseases] Waage A, et al. **Tidsskr Nor Laegeforen** 1996 May 10;116(12):1465–9 (33 ref.) (Eng. Abstr.) **(Nor)**
[Allogeneic bone marrow transplantation in malignant blood diseases] Ruutu T. **Nord Med** 1995;110(12):310–3 (15 ref.) (Eng. Abstr.) **(Swe)**

HEMATOLOGIC TESTS

METHODS

[Morphologic analysis of blood cells] Kikuchi T, et al. **Rinsho Byori** 1995 Sep;43(9):917–24 (15 ref.) (Eng. Abstr.) **(Jpn)**

HEMATOLOGY

see related
HEMATOLOGIC DISEASES

HEMATOMA

Subepithelial hematoma of the renal pelvis (Antopol-Goldman lesion) Oza KN, et al. **J Urol** 1996 Mar; 155(3):1032–3 (4 ref.)
Retroperitoneal hematoma as a complication of pudendal block. Diagnosis made by computed tomography. Kurzel RB, et al. **West J Med** 1996 Jun;164(6):523–5 (15 ref.)
[Hemorrhoidal thrombosis and perianal hematoma: diagnosis and treatment] Delaini GG, et al. **Ann Ital Chir** 1995 Nov-Dec;66(6):783–5 (8 ref.) (Eng. Abstr.) **(Ita)**

CHEMICALLY INDUCED

Spermatic cord hematoma: case report and literature review. McKenney MG, et al. **Am Surg** 1996 Sep;62(9):768–9 (13 ref.)

COMPLICATIONS

[Femoral neuropathy due to a spontaneous hematoma of the iliopsoas muscle during therapy with heparin-calcium] Casoni P, et al. **Acta Biomed Ateneo Parmense** 1994; 65(5–6):289–96 (5 ref.) (Eng. Abstr.) **(Ita)**
[Unilateral spontaneous adrenal hematoma: an unusual cause of retroperitoneal hemorrhage] Vendrell JR, et al. **Actas Urol Esp** 1996 Jan;20(1):59–62 (12 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Spermatic cord hematoma: case report and literature review. McKenney MG, et al. **Am Surg** 1996 Sep;62(9):768–9 (13 ref.)
A new application for near-infrared spectroscopy: detection of delayed intracranial hematomas after head injury. Robertson CS, et al. **J Neurotrauma** 1995 Aug; 12(4):591–600 (64 ref.)
Spontaneous unilateral adrenal hemorrhage: computerized tomography and magnetic resonance imaging findings in 8 cases. Hoeffel C, et al. **J Urol** 1995 Nov;154(5):1647–51 (24 ref.)
Spontaneous clivus hematoma: case report and literature review. Tomaras C, et al. **Neurosurgery** 1995 Jul; 37(1):123–4 (5 ref.)
[Endemic sprue: its first diagnosis based on bleeding complications] Heidinger K, et al. **Dtsch Med Wochenschr** 1995 Nov 10;120(45):1543–6 (10 ref.) (Eng. Abstr.) **(Ger)**
[An intramural hematoma of the ascending aorta. The radiological trap] Bagnolesi P, et al. **Radiol Med (Torino)** 1995 Sep;90(3):317–20 (8 ref.) **(Ita)**
[Intrahepatic hematoma and subcapsular hematoma] Yamamoto M. **Ryoikibetsu Shokogun Shirizu** 1995; (8):499–501 (12 ref.) **(Jpn)**

ETIOLOGY

Impaired haemostasis and regional anaesthesia. Stafford-Smith M. **Can J Anaesth** 1996 May;43(5 Pt 2):R129–41 (33 ref.) **(Eng, Fre)**
Spontaneous iliopsoas hematoma in patients with unstable coronary syndromes receiving intravenous heparin in therapeutic doses. Sasson Z, et al. **Can J Cardiol** 1996 May; 12(5):490–4 (35 ref.)
The haemophilic pseudotumour. Rodriguez Merchan EC. **Int Orthop** 1995;19(4):255–60 (11 ref.)
Clinical syndrome of endocapsular hematoma: presentation of a collected series and review of the literature. Hagan JC 3rd, et al. **J Cataract Refract Surg** 1996 Apr;22(3):379–84 (18 ref.)
A new application for near-infrared spectroscopy: detection of delayed intracranial hematomas after head injury. Robertson CS, et al. **J Neurotrauma** 1995 Aug; 12(4):591–600 (64 ref.)
Peliosis of the spleen: possible association with chronic renal failure and erythropoietin therapy. Lam KY, et al. **Postgrad Med J** 1995 Aug;71(838):493–6 (30 ref.)

MICROBIOLOGY

Invasive staphylococcal infections complicating percutaneous transluminal coronary angioplasty: three cases and review. Cleveland KO, et al. **Clin Infect Dis** 1995 Jul;21(1):93–6 (17 ref.)

PATHOLOGY

Spinal epidural hematoma during anticoagulant therapy. A case report and review of the literature. Rodriguez y Baena R, et al. **J Neurosurg Sci** 1995 Mar;39(1):87–94 (90 ref.)

PHYSIOPATHOLOGY

Epidural hematoma associated with cephalohematoma in a neonate--case report. Yamamoto T, et al. **Neurol Med Chir (Tokyo)** 1995 Oct;35(10):749–52 (24 ref.)

SURGERY

Renal autotransplantation after horseshoe kidney injury: a case report and literature review. Murphy JT, et al. **J Trauma** 1996 May;40(5):840–4 (28 ref.)

THERAPY

Management of aortic intramural hematoma [editorial] Braverman AC, et al. **Curr Opin Cardiol** 1995 Sep; 10(5):501–4 (14 ref.)

HEMATOMA, EPIDURAL

[Spontaneous spinal epidural hematoma: 2 cases] Robin C, et al. **Rev Neurol (Paris)** 1996 Feb;152(2):139–42 (10 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Epidural hematoma associated with cephalohematoma in a neonate--case report. Yamamoto T, et al. **Neurol Med Chir (Tokyo)** 1995 Oct;35(10):749–52 (24 ref.)

ETIOLOGY

Acute intracranial epidural haematoma in a basketball player: a case report. Datti R, et al. **Br J Sports Med** 1995 Jun; 29(2):95–6 (9 ref.)
Spinal extradural hematoma in an infant with hemophilia A: an unusual presentation of a rare complication. Hutt PJ, et al. **J Pediatr** 1996 May;128(5 Pt 1):704–6 (8 ref.)
Epidural hematoma associated with cephalohematoma in a neonate--case report. Yamamoto T, et al. **Neurol Med Chir (Tokyo)** 1995 Oct;35(10):749–52 (24 ref.)

RADIOGRAPHY

Delayed post-traumatic epidural hematoma. A review.

Domenicucci M, et al. **Neurosurg Rev** 1995;18(2):109–22 (51 ref.)

SURGERY

Spinal epidural hematoma. Report of a case and review of the literature. Rainov NG, et al. **Neurosurg Rev** 1995; 18(1):53–60 (115 ref.)

HEMATOMA, SUBDURAL

ETIOLOGY

A neurologist's reflections on boxing. III. Vascular injuries. Unterharnscheidt F. **Rev Neurol** 1995 Jul–Aug; 23(122):847–55 (27 ref.)

PHYSIOPATHOLOGY

Ventral spinal subdural hematoma—case report. Yamagami T, et al. **Neurol Med Chir (Tokyo)** 1995 Dec;35(12):896–900 (22 ref.)

SURGERY

Acute traumatic posterior fossa subdural haematomas. Borzone M, et al. **Acta Neurochir (Wien)** 1995;135(1–2):32–7 (9 ref.)

Endoscopic treatment of septated chronic subdural hematoma. Hellwig D, et al. **Surg Neurol** 1996 Mar; 45(3):272–7 (15 ref.)

HEMATOPOIESIS

Stem cell factor as a survival and growth factor in human normal and malignant hematopoiesis. Hassan HT, et al. **Acta Haematol** 1996;95(3–4):257–62 (50 ref.)

The effect of age on hemopoiesis. Quaglino D, et al. **Aging (Milano)** 1996 Feb;8(1):1–12 (83 ref.)

Human B-cell development. Billips LG, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:1–8 (31 ref.)

Lymphopoiesis, apoptosis, and immune amnesia. Donnenberg AD, et al. **Ann N Y Acad Sci** 1995 Dec 29;770:213–26 (33 ref.)

Relative contributions of marrow microenvironment, growth factors, and stem cells to hematopoiesis in vivo in man. Review of results from autologous stem cell transplant trials and laboratory studies at the Moffitt Cancer Center. Elfenbein GJ, et al. **Ann N Y Acad Sci** 1995 Dec 29; 770:315–38 (21 ref.)

The potential for clinical ex vivo hematopoiesis. Emerson SG. **Ann N Y Acad Sci** 1995 Dec 29;770:99–104 (17 ref.)

B-lineage differentiation stages resolved by multiparameter flow cytometry. Hardy RR, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:19–24 (26 ref.)

The role of Bruton's tyrosine kinase in B-cell development and function in mice and man. Khan WN, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:27–38 (36 ref.)

In vitro studies of human B lymphopoiesis. Pribyl JR, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:9–18 (40 ref.)

Developmental biology of hematopoiesis. Zon LI. **Blood** 1995 Oct 15;86(8):2876–91 (107 ref.)

Source of stem cells impacts on hematopoietic recovery after high-dose chemotherapy. Zimmerman TM, et al. **Bone Marrow Transplant** 1995 Jun;15(6):923–7 (29 ref.)

Molecular signals for the production of lymphocytes in bone marrow. Kincade PW. **Braz J Med Biol Res** 1994 Nov; 27(11):2533–8 (23 ref.)

Cell surface antigens in leukemias and lymphomas. Freedman AS. **Cancer Invest** 1996;14(3):252–76 (354 ref.)

Joint features of metastasis formation and lymphocyte maturation and activation. Zöller M. **Curr Top Microbiol Immunol** 1996;213 (Pt 1):215–47 (330 ref.)

The extracellular matrix of the hematopoietic microenvironment. Klein G. **Experientia** 1995 Sep 29; 51(9–10):914–26 (123 ref.)

Topobiology in hematopoiesis. Naeim F. **Hematol Pathol** 1995;9(2):107–19 (76 ref.)

Growth hormone, growth factors and hematopoiesis. Kelley KW, et al. **Horm Res** 1996;45(1–2):38–45 (91 ref.)

Feedback inhibitors in normal and tumor tissues. Marshall E, et al. **Int Rev Cytol** 1996;167:185–261 (299 ref.)

Is interleukin 17, an inducible cytokine that stimulates production of other cytokines, merely a redundant player in a sea of other biomolecules? [comment] Broxmeyer HE. **J Exp Med** 1996 Jun 1;183(6):2411–5 (43 ref.) Comment on: J Exp Med 1996 Jun 1;183(6):2593–603.

Cytokine receptor genes: structure, chromosomal location, and involvement in human disease. Baird PN, et al. **Leuk Lymphoma** 1995 Aug;18(5–6):373–83 (130 ref.)

A role for ferritin in hematopoiesis and the immune system. Morikawa K, et al. **Leuk Lymphoma** 1995 Aug; 18(5–6):429–33 (27 ref.)

Characteristic biological features of human megakaryoblastic leukaemia cell lines. Hassan HT, et al. **Leuk Res** 1995 Sep; 19(9):589–94 (60 ref.)

Composition and function of the hemopoietic microenvironment in human myeloid leukemia. Mayani H. **Leukemia** 1996 Jun;10(6):1041–7 (76 ref.)

Receptor tyrosine kinases and the regulation of hematopoiesis. Paulson RF, et al. **Semin Immunol** 1995 Aug; 7(4):267–77 (84 ref.)

Megakaryocytopoiesis: the state of the art. Gewirtz AM. **Thromb Haemost** 1995 Jul;74(1):204–9 (86 ref.)

[Physiological (programmed) cell death in hemopoiesis] Kozinets GI, et al. **Klin Lab Diagn** 1996 Jan–Feb;(1):35–8 (24 ref.) (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

Thrombopoietic activity of recombinant human interleukin 11 in cancer patients receiving chemotherapy. Gordon MS. **Cancer Chemother Pharmacol** 1996;38 Suppl:S96–8 (18 ref.)

Effect of interleukin 11 on normal and pathological thrombopoiesis. Teramura M, et al. **Cancer Chemother Pharmacol** 1996;38 Suppl:S99–102 (27 ref.)

The effect of granulocyte–macrophage colony-stimulating factor on myeloid cells and its clinical applications. Hill AD, et al. **J Leukoc Biol** 1995 Dec;58(6):634–42 (103 ref.)

Inhibition of GM-CSF production by recombinant human interleukin-4: negative regulator of hematopoiesis. Sawada K, et al. **Leuk Lymphoma** 1995 Sep;19(1–2):33–42 (1661 ref.)

GENETICS

Identification of genes specifically expressed at discrete stages of B-cell development. Zhang Y, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:25–6 (3 ref.)

The transcriptional control of hematopoiesis. Shivdasani RA, et al. **Blood** 1996 May 15;87(10):4025–39 (175 ref.)

Hematopoietic transcriptional regulation by the myeloid zinc finger gene, MZF-1. Hromas R, et al. **Curr Top Microbiol Immunol** 1996;211:159–64 (15 ref.)

Interleukin-5 receptor alpha subunit gene regulation in human eosinophil development: identification of a unique cis-element that acts lie an enhancer in regulating activity of the IL-5R alpha promoter. Sun Z, et al. **Curr Top Microbiol Immunol** 1996;211:173–87 (64 ref.)

IMMUNOLOGY

In-vitro models of stroma-dependent lymphopoiesis. Péault B. **Semin Immunol** 1995 Jun;7(3):169–75 (76 ref.)

Natural killer cells wear different hats: effector cells of innate resistance and regulatory cells of adaptive immunity and of hematopoiesis. Trinchieri G. **Semin Immunol** 1995 Apr; 7(2):83–8 (43 ref.)

Making the in-vitro model closer to actual B lymphopoiesis in the bone marrow. Yasunaga M, et al. **Semin Immunol** 1995 Jun;7(3):185–96 (59 ref.)

The biology of the cytokine sequence cascade. Fraser JK, et al. **Semin Oncol** 1996 Apr;23(2 Suppl 4):2–8 (28 ref.)

PHYSIOLOGY

Parvovirus B19 infection and hematopoiesis. Brown KE, et al. **Blood Rev** 1995 Sep;9(3):176–82 (30 ref.)

Megakaryocytopoiesis: cellular aspects and regulation. Vainchenker W, et al. **Crit Rev Oncol Hematol** 1995 Aug; 20(1–2):165–92 (366 ref.)

Lymphopoiesis. Transcription factors controlling B-cell development. Desiderio S. **Curr Biol** 1995 Jun 1;5(6):605–8 (20 ref.)

Hematopoiesis: how does it happen? Orkin SH. **Curr Opin Cell Biol** 1995 Dec;7(6):870–7 (66 ref.)

A role for STAT family transcription factors in myeloid differentiation. Barahmand-pour F, et al. **Curr Top Microbiol Immunol** 1996;211:121–8 (25 ref.)

Self renewal and differentiation in primary avian hematopoietic cells: an alternative to mammalian in vitro models? Beug H, et al. **Curr Top Microbiol Immunol** 1996; 211:29–39 (61 ref.)

Retinoic acid receptors in hematopoiesis. Collins SJ, et al. **Curr Top Microbiol Immunol** 1996;211:7–15 (15 ref.)

Regulation of immature myeloid cell differentiation by PEBP2/CBF, Myb, C/EBP and Ets family members. Friedman AD. **Curr Top Microbiol Immunol** 1996; 211:149–57 (45 ref.)

Role of c-myc in myeloid differentiation, growth arrest and apoptosis. Hoffman B, et al. **Curr Top Microbiol Immunol** 1996;211:17–27 (51 ref.)

The effect of c-raf antisense oligonucleotides on growth factor-induced proliferation of hematopoietic cells. Keller JR, et al. **Curr Top Microbiol Immunol** 1996;211:43–53 (25 ref.)

Molecular control of development in normal and leukemic myeloid cells by cytokines, tumor suppressor and oncogenes. Sachs L. **Curr Top Microbiol Immunol** 1996; 211:3–5 (18 ref.)

Terminal myeloid gene expression and differentiation requires the transcription factor PU.1. Simon MC, et al. **Curr Top Microbiol Immunol** 1996;211:113–9 (26 ref.)

Function of PU.1 (Spi-1), C/EBP, and AML1 in early myelopoiesis: regulation of multiple myeloid CSF receptor promoters. Zhang DE, et al. **Curr Top Microbiol Immunol** 1996;211:137–47 (61 ref.)

Hemopoiesis in the thymus. Kendall MD. **Dev Immunol** 1995; 4(3):157–68 (107 ref.)

Hematopoiesis occurs in rhythms. Laerum OD. **Exp Hematol** 1995 Oct;23(11):1145–7 (38 ref.)

The helix-loop-helix gene SCL: implicated in T-cell acute lymphoblastic leukaemia and in normal haematopoietic development. Robb L, et al. **Int J Biochem Cell Biol** 1996 Jun;28(6):609–18 (84 ref.)

The role of MIP-1 alpha in inflammation and hematopoiesis. Cook DN. **J Leukoc Biol** 1996 Jan;59(1):61–6 (40 ref.)

Gp130, a shared signal transducing receptor component for hematopoietic and neuropoietic cytokines. Taga T. **J Neurochem** 1996 Jul;67(1):1–10 (90 ref.)

Regulation of human B cell lymphopoiesis by adhesion molecules and cytokines. Ryan DH, et al. **Leuk Lymphoma** 1995 May;17(5–6):375–89 (137 ref.)

Control of apoptosis in hematopoiesis and leukemia by cytokines, tumor suppressor and oncogenes. Lotem J, et al. **Leukemia** 1996 Jun;10(6):925–31 (131 ref.)

Gap junctions in blood forming tissues. Rosendaal M. **Microsc Res Tech** 1995 Aug 1;31(5):396–407 (70 ref.)

The control of hematopoiesis and leukemia: from basic biology to the clinic. Sachs L. **Proc Natl Acad Sci U S A** 1996 May 14;93(10):4742–9 (123 ref.)

The physiologic role and therapeutic potential of the Mpl-ligand in thrombopoiesis. Hunt P. **Stem Cells** 1995 Nov;13(6):579–87 (66 ref.)

Tyrosine kinases in megakaryocytopoiesis. Avraham H, et al. **Stem Cells (Dayt)** 1995 Jul;13(4):380–92 (141 ref.)

The use of umbilical cord blood as a cellular source for correction of genetic diseases affecting the hematopoietic system. Clapp DW, et al. **Stem Cells (Dayt)** 1995 Nov; 13(6):613–21 (87 ref.)

Regulation of gene transcription during the differentiation of megakaryocytes. Uzan G, et al. **Thromb Haemost** 1995 Jul;74(1):210–2 (20 ref.)

c-mpl, the thrombopoietin receptor. Vainchenker W, et al. **Thromb Haemost** 1995 Jul;74(1):526–8 (15 ref.)

[Development of the hematopoietic system in the human fetus] Alekseev IV, et al. **Gematol Transfuziol** 1995 Sep–Oct;40(5):26–9 (65 ref.) **(Rus)**

[Megakaryocytopoiesis] Koloskov AV. **Gematol Transfuziol** 1995 Sep–Oct;40(5):29–33 (165 ref.) **(Rus)**

[Morphology of apoptosis in normal and pathologic hematopoiesis] Pogorelov VM, et al. **Gematol Transfuziol** 1995 Sep–Oct;40(5):17–25 (61 ref.) **(Rus)**

[Dynamic bone marrow take and lymphohematopoietic chimerism following allogeneic bone marrow transplantation] Demidova IA, et al. **Ter Arkh** 1995; 67(8):74–80 (90 ref.) **(Rus)**

HEMATOPOIESIS, EXTRAMEDULLARY

Acute respiratory failure due to extramedullary hematopoiesis. Yusen RD, et al. **Chest** 1995 Oct; 108(4):1170–2 (17 ref.)

Development of TCR gamma delta iIELs. Barrett TA, et al. **Semin Immunol** 1995 Oct;7(5):299–305 (27 ref.)

T-lymphopoietic capacity of the mouse intestinal epithelium. Klein JR. **Semin Immunol** 1995 Oct;7(5):291–7 (38 ref.)

Mouse embryonic hematopoiesis. Dzierzak E, et al. **Trends Genet** 1995 Sep;11(9):359–66 (65 ref.)

[Intrathoracic extramedullary hematopoiesis in a case of hereditary spherocytosis] Takahashi R, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Jan;34(1):71–5 (13 ref.) (Eng. Abstr.) **(Jpn)**

HEMATOPOIETIC AGENTS see **HEMATINICS**

HEMATOPOIETIC CELL GROWTH FACTORS

see related

RECEPTORS, COLONY-STIMULATING FACTOR

Hematopoietic growth factors. DeLaPena L, et al. **Cancer Nurs** 1996 Apr;19(2):135–50 (12 ref.)

ADVERSE EFFECTS

Clinical toxicity of cytokines used as haemopoietic growth factors. Vial T, et al. **Drug Saf** 1995 Dec;13(6):371–406 (236 ref.)

Are growth factors leukemogenic? Brodsky RA, et al. **Leukemia** 1996 Jan;10(1):175–7 (26 ref.)

ECONOMICS

Economic evaluation of new treatments: haematopoietic growth factors. Johnson NJ, et al. **Clin Oncol (R Coll Radiol)** 1996;8(1):43–7 (29 ref.)

Economic outcomes associated with the use of hematopoietic growth factors. Glaspy JA. **Oncology (Huntingt)** 1995 Nov; 9(11 Suppl):93–105 (45 ref.)

PHARMACOLOGY

The effect of c-raf antisense oligonucleotides on growth factor-induced proliferation of hematopoietic cells. Keller JR, et al. **Curr Top Microbiol Immunol** 1996;211:43–53 (25 ref.)

The biology of the cytokine sequence cascade. Fraser JK, et al. **Semin Oncol** 1996 Apr;23(2 Suppl 4):2–8 (28 ref.)

Peripheral blood progenitor cells for marrow reconstitution: mobilization and collection strategies [see comments] Gillespie TW, et al. **Transfusion** 1996 Jul;36(7):611–24 (123 ref.) Comment in: Transfusion 1996 Jul;36(7):585–9.

HEMATOPOIETIC CELL GROWTH FACTORS

PHYSIOLOGY

Relative contributions of marrow microenvironment, growth factors, and stem cells to hematopoiesis in vivo in man. Review of results from autologous stem cell transplant trials and laboratory studies at the Moffitt Cancer Center. Elfenbein GJ, et al. **Ann N Y Acad Sci** 1995 Dec 29; 770:315–38 (21 ref.)

[Role of hematopoietic factors in regulation of proliferation and function of phagocytes] Czygier M, et al. **Postepy Hig Med Dosw** 1995;49(4):563–79 (80 ref.) (Eng. Abstr.) **(Pol)**

THERAPEUTIC USE

Hematopoietic growth factors [see comments] Bociek RG, et al. **CA Cancer J Clin** 1996 May–Jun;46(3):165–84 (138 ref.) Comment in: CA Cancer J Clin 1996 May–Jun;46(3):131–6.

Hematopoietic growth factors in cancer chemotherapy. Morstyn G, et al. **Cancer Chemother Biol Response Modif** 1996;16:295–314 (99 ref.)

Recombinant hematopoietic growth factors in bone marrow transplantation. Nemunaitis J. **Cancer Treat Res** 1995; 76:225–48 (151 ref.)

The new generation of recombinant human hematopoietic cytokines. Hunt P, et al. **Curr Opin Biotechnol** 1995 Dec; 6(6):692–7 (45 ref.)

High dose chemotherapy with haemopoietic support for breast cancer. Steward WP. **Eur J Cancer** 1995;31A Suppl 7:S21–4 (18 ref.)

Economic outcomes associated with the use of hematopoietic growth factors. Glaspy JA. **Oncology (Huntingt)** 1995 Nov; 9(11 Suppl):93–105 (45 ref.)

Hematopoietic growth factors in clinical practice. Pitler LR. **Semin Oncol Nurs** 1996 May;12(2):115–29 (115 ref.)

Allogeneic marrow transplantation and the use of hematopoietic growth factors. Appelbaum FR. **Stem Cells (Dayt)** 1995 Jul;13(4):344–50 (30 ref.)

Hematopoietic growth factors: frontiers for cure. Ogilvie GK. **Vet Clin North Am Small Anim Pract** 1995 Nov; 25(6):1441–56 (23 ref.)

[Erythropoiesis and use of hematopoietic growth factors in children] Illum NO. **Ugeskr Laeger** 1996 Jul 15; 158(29):4171–4 (10 ref.) **(Dan)**

[Use of hematopoietic growth factors] Elonen E. **Duodecim** 1995;111(8):733–40 (38 ref.) **(Fin)**

[Role of hematopoietic growth factors in bronchial cancerology] Lemarié E, et al. **Rev Mal Respir** 1995; 12(5):429–34 (31 ref.) (Eng. Abstr.) **(Fre)**

[Clinical use of hematopoietic growth factors—general principles] Borota R, et al. **Med Pregl** 1996;49(5–6):185–93 (57 ref.) (Eng. Abstr.) **(Ser)**

[Treatment of neutropenia in HIV infection with hematopoietic growth factors] Moreno Garcia M, et al. **Rev Clin Esp** 1996 Apr;196(4):248–54 (121 ref.) **(Spa)**

[Current clinical use of hematopoietic growth factors] Ramos FJ, et al. **Sangre (Barc)** 1995 Aug;40(4):311–25 (282 ref.) **(Spa)**

HEMATOPOIETIC GROWTH FACTORS RECEPTORS
see **RECEPTORS, COLONY-STIMULATING FACTOR**

HEMATOPOIETIC STEM CELL TRANSPLANTATION

High-dose chemotherapy with stem-cell rescue for the treatment of breast cancer. McCauley DL. **Am J Health Syst Pharm** 1996 Mar 1;53(5):521–34; quiz 561–2 (87 ref.)

Clinical application of allogeneic peripheral blood stem cells transplantation. Tanaka J, et al. **Ann Hematol** 1995 Dec; 71(6):265–9 (52 ref.)

High-dose chemotherapy for breast cancer. Gradishar WJ, et al. **Ann Intern Med** 1996 Oct 1;125(7):599–604 (55 ref.)

Relative contributions of marrow microenvironment, growth factors, and stem cells to hematopoiesis in vivo in man. Review of results from autologous stem cell transplant trials and laboratory studies at the Moffitt Cancer Center. Elfenbein GJ, et al. **Ann N Y Acad Sci** 1995 Dec 29; 770:315–38 (21 ref.)

Stem cell transplantation in acute leukemia. Gorin NC. **Ann N Y Acad Sci** 1995 Dec 29;770:262–87 (80 ref.)

T-cell subsets and their cytokine profiles in transplantation and tolerance. Groux H, et al. **Ann N Y Acad Sci** 1995 Dec 29;770:141–8 (27 ref.)

Mobilization of peripheral blood stem cells for autologous transplantation. Methods, mechanisms, and role in accelerating hematopoietic recovery. Janssen WE. **Ann N Y Acad Sci** 1995 Dec 29;770:116–29 (52 ref.)

Cytokines in stem cell transplantation. Stewart FM. **Ann N Y Acad Sci** 1995 Dec 29;770:53–69 (62 ref.)

High-dose chemotherapy for breast cancer: clinical advantages of autologous peripheral blood progenitor cells (PBPC) compared with autologous bone marrow transplantation (ABMT). Martin M. **Ann Oncol** 1995;6 Suppl 4:33–7 (18 ref.)

Practical applications for peripheral blood progenitor cells in the treatment of lymphomas and solid tumours. Pettengell R. **Ann Oncol** 1995;6 Suppl 4:9–12 (11 ref.)

Expanding the role of blood progenitor cells. Pettengell R. **Ann Oncol** 1995 Oct;6(8):759–67 (87 ref.)

Overview of peripheral blood progenitor cell usage in France. Reiffers J. **Ann Oncol** 1995;6 Suppl 4:17–20 (12 ref.)

Haematological support of high-dose sequential chemotherapy: clinical evidence for reduction of toxicity and high response rates in poor risk lymphomas. Tarella C, et al. **Ann Oncol** 1995;6 Suppl 4:3–8 (30 ref.)

The role of haematopoietic stem cell-supported myeloablative therapy for the management of multiple myeloma. Cavo M, et al. **Baillieres Clin Haematol** 1995 Dec;8(4):795–813 (58 ref.)

Is blood a better source of allogeneic hematopoietic stem cells for use after radiation accidents? Frickhofen N, et al. **Bone Marrow Transplant** 1996 Feb;17(2):131–5 (48 ref.)

Comparison of autologous bone marrow transplantation and peripheral blood stem cell transplantation after first remission induction treatment in multiple myeloma. Harousseau JL, et al. **Bone Marrow Transplant** 1995 Jun; 15(6):963–9 (35 ref.)

Safety of AlloPBPCT donors: biometrical considerations on monitoring long term risks. Hasenclever D, et al. **Bone Marrow Transplant** 1996 Mar;17 Suppl 2:S28–30 (14 ref.)

Source of stem cells impacts on hematopoietic recovery after high-dose chemotherapy. Zimmerman TM, et al. **Bone Marrow Transplant** 1995 Jun;15(6):923–7 (29 ref.)

High-dose chemotherapy with stem cell rescue for solid tumours. Protheroe AS, et al. **Br J Hosp Med** 1996 Apr 3–16;55(7):437–41 (29 ref.)

The use of bone marrow and peripheral blood stem cell transplantation in the treatment of cancer [see comments] Appelbaum FR. **CA Cancer J Clin** 1996 May–Jun; 46(3):142–64 (181 ref.) Comment in: CA Cancer J Clin 1996 May–Jun;46(3):131–6.

Peripheral blood stem cell transplantation. Bensinger W. **Cancer Treat Res** 1995;76:169–93 (114 ref.)

High-dose chemotherapy with peripheral blood progenitor autografting. Crown JP, et al. **Cancer Treat Res** 1995; 78:209–26 (115 ref.)

In vitro expansion of hematopoietic cells for clinical application. Emerson SG, et al. **Cancer Treat Res** 1995; 76:215–23 (14 ref.)

High-dose chemotherapy and autologous stem cell transplantation for breast cancer. Weaver CH, et al. **Cancer Treat Res** 1995;76:59–85 (104 ref.)

Haematopoietic stem-cell transplantation in multiple myeloma. Handelsman H. **Cancer Treat Rev** 1996 Mar; 22(2):119–25 (41 ref.)

Sources of human hematopoietic stem cells for transplantation--a review. Amos TA, et al. **Cell Transplant** 1995 Nov–Dec;4(6):547–69 (256 ref.)

Hematopoietic stem cell transplantation for cancer therapy. Reisner Y, et al. **Curr Opin Immunol** 1995 Oct;7(5):687–93 (69 ref.)

Umbilical cord blood as a new and promising source of unrelated-donor hematopoietic stem cells for transplantation. Newburger PE, et al. **Curr Opin Pediatr** 1996 Feb;8(1):29–32 (24 ref.)

The impact of cytokines on high dose chemotherapy followed by transplantation of purified and ex vivo expanded peripheral blood stem cells: achieving a state of minimal residual disease for tumor immunotherapy with cytokine gene transfected cells [editorial] Mertelsmann R. **Eur Cytokine Netw** 1995 Mar–Apr;6(2):79–82 (12 ref.)

High dose chemotherapy with haemopoietic support for breast cancer. Steward WP. **Eur J Cancer** 1995;31A Suppl 7:S21–4 (18 ref.)

Umbilical cord blood as a source of hematopoietic stem cells: from research to clinical application. Almici C, et al. **Haematologica** 1995 Sep–Oct;80(5):473–9 (53 ref.)

Autologous peripheral stem-cell transplantation. Handelsman H. **Health Technol Assess** 1995 Aug;(5):1–16 (196 ref.)

Transfusion and stem cell support in cancer treatment. Wuest DL. **Hematol Oncol Clin North Am** 1996 Apr;10(2):397–429 (223 ref.)

Autologous peripheral blood progenitor cell transplantation. Anderson KC. **J Clin Apheresis** 1995;10(3):131–8 (60 ref.)

CD34+ progenitor cell selection: clinical transplantation, tumor cell purging, gene therapy, ex vivo expansion, and cord blood processing. Colter M, et al. **J Hematother** 1996 Apr;5(2):179–84 (22 ref.)

Introducing graft-versus-leukemia into autologous stem cell transplantation. Klingemann HG. **J Hematother** 1995 Aug; 4(4):261–7 (71 ref.)

Immune functions of cord blood cells before and after transplantation. Roncarolo MG, et al. **J Hematother** 1996 Apr;5(2):157–60 (13 ref.)

In utero transplantation of fetal liver stem cells into human fetuses. Touraine JL. **J Hematother** 1996 Apr;5(2):195–9 (15 ref.)

Perspectives on investigational chemotherapy and biologic therapy for childhood brain tumors. Kadota RP. **J Pediatr Hematol Oncol** 1996 Feb;18(1):13–22 (110 ref.)

Peripheral blood progenitor cell transplant: a way forward. Shamsi TS. **JPMA J Pak Med Assoc** 1995 Jul;45(7):182–5 (48 ref.)

Intensive therapy and autologous stem cell transplantation for Hodgkin's disease in first relapse after combination chemotherapy. Reece DE, et al. **Leuk Lymphoma** 1996 Apr; 21(3–4):245–53 (55 ref.)

Human umbilical cord blood for hematopoietic progenitor cells transplantation. Varadi G, et al. **Leuk Lymphoma** 1995 Dec;20(1–2):51–8 (54 ref.)

New chemotherapeutic agents in acute myeloid leukemia. Kantarjian HM, et al. **Leukemia** 1996 Apr;10 Suppl 1:S4–6 (0 ref.)

Role of postinduction immunotherapy in acute myeloid leukemia. Klingemann HG. **Leukemia** 1996 Apr;10 Suppl 1:S21–2 (3 ref.)

Autografting in chronic myeloid leukemia: an overview. Reiffers J, et al. **Leukemia** 1996 Mar;10(3):385–8 (26 ref.)

Postremission therapy of acute myeloid leukemia in older adults. Schiller GJ. **Leukemia** 1996 Apr;10 Suppl 1:S18–20 (19 ref.)

Guidelines for efficient peripheral blood progenitor cell collection. Van Hoef ME. **Neth J Med** 1996 Jan;48(1):29–37 (65 ref.)

Umbilical cord blood for use in transplantation. Varadi G, et al. **Obstet Gynecol Surv** 1995 Aug;50(8):611–7 (30 ref.)

Transplantation of hematopoietic stem cells. Nash RA, et al. **Proc Assoc Am Physicians** 1995 Oct;107(3):288–95 (47 ref.)

Peripheral blood progenitor cells: a replacement for marrow transplantation? Champlin RE. **Semin Oncol** 1996 Apr;23(2 Suppl 4):15–21 (48 ref.)

Cytokine-mobilized peripheral blood progenitor cells. Nemunaitis J. **Semin Oncol** 1996 Apr;23(2 Suppl 4):9–14 (18 ref.)

Transplantation of allogeneic peripheral blood stem cells. Bensinger WI, et al. **Stem Cells** 1995 Dec;13 Suppl 3:63–70 (56 ref.)

Purging of peripheral blood stem cell grafts. Gee A. **Stem Cells** 1995 Dec;13 Suppl 3:52–62 (77 ref.)

Blood stem cell transplantation and gene therapy of cancer. Körbling M. **Stem Cells** 1995 Dec;13 Suppl 3:106–13 (55 ref.)

The contribution of marker gene studies to hemopoietic stem cell therapies. Brenner MK. **Stem Cells (Dayt)** 1995 Sep; 13(5):453–61 (44 ref.)

Do autologous peripheral blood cell transplants provide more than hematopoietic recovery? Kessinger A. **Stem Cells (Dayt)** 1995 Jul;13(4):351–4 (21 ref.)

Peripheral blood progenitor cells for marrow reconstitution: mobilization and collection strategies [see comments] Gillespie TW, et al. **Transfusion** 1996 Jul;36(7):611–24 (123 ref.) Comment in: Transfusion 1996 Jul;36(7):585–9.

[High-dose therapy and hematopoietic cell autotransplantation in the treatment of adult gynecologic tumors] Lotz JP, et al. **Contracept Fertil Sex** 1996 Apr; 24(4):307–18 (71 ref.) (Eng. Abstr.) **(Fre)**

[Mobilization and transplantation of autologous hematopoietic stem and progenitor cells from peripheral blood: principles and applications] Ghielmini M, et al. **Schweiz Med Wochenschr** 1996 Mar 2;126(9):348–56 (44 ref.) (Eng. Abstr.) **(Ger)**

[Somatic gene therapy: perspectives in the use of hematopoietic stem cells (editorial)] Wodnar-Filipowicz A. **Schweiz Rundsch Med Prax** 1996 Apr 9;85(15):469–72 (13 ref.) **(Ger)**

[Human umbilical cord blood as a source of hematopoietic progenitor cells for transplantations] Elchalal U, et al. **Harefuah** 1995 Jun 15;128(12):776–80 (38 ref.) **(Heb)**

[Mega-dose chemotherapy with peripheral blood stem cell transplantation (PBS-CT) for small cell lung cancer (SCLC)] Chou T, et al. **Gan To Kagaku Ryoho** 1995 Oct; 22(12):1741–8 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Myeloablative chemotherapy with autologous bone marrow and/or peripheral blood stem cell transplantation in children with high-risk solid tumor] Endo M, et al. **Gan To Kagaku Ryoho** 1995 Oct;22(12):1762–70 (32 ref.) (Eng. Abstr.) **(Jpn)**

[High-dose chemotherapy (HDCT) with peripheral blood stem cell transplantation (PBSCT) in ovarian cancer patients with poor prognosis] Hayakawa S, et al. **Gan To Kagaku Ryoho** 1995 Oct;22(12):1756–61 (13 ref.) (Eng. Abstr.) **(Jpn)**

[Germ cell tumor] Kasai M, et al. **Gan To Kagaku Ryoho** 1995 Oct;22(12):1749–55 (19 ref.) (Eng. Abstr.) **(Jpn)**

[High-dose chemotherapy with autologous bone marrow transplantation or peripheral blood stem cell transplantation--testicular cancer] Miyanaga N, et al. **Gan To Kagaku Ryoho** 1995 Oct;22(12):1771–6 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Autologous hematopoietic stem cell transplantation for the treatment of breast cancer] Mukaiyama T, et al. **Gan To Kagaku Ryoho** 1995 Oct;22(12):1731–40 (16 ref.) (Eng. Abstr.) **(Jpn)**

[High dose chemotherapy followed by hematopoietic stem cell transplantation for malignant lymphoma] Tobinai K. **Gan To Kagaku Ryoho** 1995 Oct;22(12):1724–30 (23 ref.) (Eng. Abstr.) **(Jpn)**

[Present status of peripheral hematopoietic stem cell transplantation] Harada M. **Nippon Naika Gakkai Zasshi** 1996 Mar 10;85(3):454–8 (17 ref.) **(Jpn)**

[Peripheral blood stem cell transplantation] Harada M. **Nippon Naika Gakkai Zasshi** 1995 Sep 10;84(9):1494–9 (15 ref.) **(Jpn)**

[Hematopoietic stem cell transplantation in multiple myeloma] Okamoto S. **Nippon Naika Gakkai Zasshi** 1995 Jul 10;84(7):1127–31 (4 ref.) **(Jpn)**

[Mobilization and harvest of peripheral blood stem cells] Inaba S, et al. **Rinsho Byori** 1995 Jul;Suppl 99:31–43 (20 ref.) **(Jpn)**

[Ex vivo purging for autologous hemopoietic progenitor cell

transplantation] Moriyama Y. **Rinsho Byori** 1995 Jul;Suppl 99:54–65 (26 ref.) **(Jpn)**
[Preservation of hematopoietic stem cells] Nakamura H, et al. **Rinsho Byori** 1995 Jul;Suppl 99:44–53 (14 ref.) **(Jpn)**

ADVERSE EFFECTS

Gonadal damage and effects on fertility in adult patients with haematological malignancy undergoing stem cell transplantation. Chatterjee R, et al. **Bone Marrow Transplant** 1996 Jan;17(1):5–11 (79 ref.)
Hemolytic uremic syndrome after high dose chemotherapy with autologous stem cell support. van der Lelie H, et al. **Cancer** 1995 Dec 1;76(11):2338–42 (21 ref.)

METHODS

Ex vivo expansion of hematopoietic precursors, progenitors, and stem cells: the next generation of cellular therapeutics. Emerson SG. **Blood** 1996 Apr 15;87(8):3082–8 (48 ref.)
The place of blood stem cells in allogeneic transplantation. Russel N, et al. **Br J Haematol** 1996 Jun 2;93(4):747–53 (55 ref.)
Clinical challenges and cord blood transplantation: are we asking the right questions? Lowry PA. **J Hematother** 1996 Apr;5(2):99–104 (37 ref.)
Methods of stem cell mobilization. Dasgupta A, et al. **J Infus Chemother** 1996 Winter;6(1):12–6 (26 ref.)
Stem cell cryopreservation. Gorlin J. **J Infus Chemother** 1996 Winter;6(1):23–7 (24 ref.)
Stem cell transplantation with chemoradiotherapy myeloablation and interleukin-2. Meehan KR, et al. **J Infus Chemother** 1996 Winter;6(1):28–32 (47 ref.)
Stem cell purging ex vivo. Seiden MV, et al. **J Infus Chemother** 1996 Winter;6(1):17–22 (56 ref.)
Allogeneic peripheral blood stem cell transplantation. Spitzer TR. **J Infus Chemother** 1996 Winter;6(1):33–8 (29 ref.)
[Hematopoietic stem cell transplantation ("Bone marrow graft"): indications, methods and risks] Beguin Y. **Rev Med Liege** 1996 Apr;51(4):270–5 (18 ref.) **(Fre)**
[Hematopoietic stem cell transplantation: principles and practice] Burdach S, et al. **Schweiz Rundsch Med Prax** 1996 Jun 4;85(23):741–8 (24 ref.) (Eng. Abstr.) **(Ger)**
[Indications for bone marrow and peripheral stem cell transplantation in malignant hematological diseases] Gratwohl A. **Ther Umsch** 1996 Feb;53(2):152–7 (15 ref.) (Eng. Abstr.) **(Ger)**
[Patient information and conditioning for allogeneic stem cell transplantation] Brinch L. **Nord Med** 1995;110(12):318–9, 322 (16 ref.) (Eng. Abstr.) **(Nor)**

NURSING

Chronic myelogenous leukemia and acute promyelocytic leukemia: new bone marrow transplantation options. Viele CS. **Oncol Nurs Forum** 1996 Apr;23(3):488–93 (22 ref.)

TRENDS

Hematopoietic "stem cell" transplantation: are there any clouds on an expanding horizon? Lowry PA. **J Infus Chemother** 1996 Winter;6(1):9–11 (23 ref.)
[Progress on the treatment of tumors—present status and future of bonemarrow and peripheral hematopoietic stem cell transplantation] Takaue Y. **Nippon Naika Gakkai Zasshi** 1996 Mar 10;85(3):347–50 (5 ref.) **(Jpn)**

HEMATOPOIETIC STEM CELLS

see related

COLONY-FORMING UNITS ASSAY

Strategies for efficient gene transfer into hematopoietic cells. The use of adeno-associated virus vectors in gene therapy. Chatterjee S, et al. **Ann N Y Acad Sci** 1995 Dec 29;770:79–90 (40 ref.)
Characterization of hematopoietic stem cells. Fritsch G, et al. **Ann N Y Acad Sci** 1995 Dec 29;770:42–52 (19 ref.)
Which are the hematopoietic stem cells? [or: don't debunk the history!] Lord BI, et al. **Exp Hematol** 1995 Nov; 23(12):1237–41 (49 ref.)
Umbilical cord blood as a source of hematopoietic stem cells: from research to clinical application. Almici C, et al. **Haematologica** 1995 Sep-Oct;80(5):473–9 (53 ref.)
CD34-positive cells: biology and clinical relevance. Stella CC, et al. **Haematologica** 1995 Jul-Aug;80(4):367–87 (156 ref.)
Methods of isolation and cryopreservation of stem cells from cord blood. Quillen K, et al. **J Hematother** 1996 Apr; 5(2):153–5 (12 ref.)
Gene transfer to hematopoietic cells. Brenner MK. **N Engl J Med** 1996 Aug 1;335(5):337–9 (0 ref.)
The contribution of marker gene studies to hemopoietic stem cell therapies. Brenner MK. **Stem Cells (Dayt)** 1995 Sep; 13(5):453–61 (44 ref.)
[Progress and prospectives in the use of hematopoietic stem cells in pediatric oncohematology] Pession A, et al. **Minerva Pediatr** 1995 Jul-Aug;47(7–8):265–76 (19 ref.) **(Ita)**
[Splenic colony forming method] Suzuki K, et al. **Rinsho Byori** 1995 Jul;Suppl 99:136–8 (12 ref.) **(Jpn)**
[Detection of hematopoietic stem cells using automated blood cell counter and flow cytometry] Takekawa K, et al. **Rinsho Byori** 1995 Jul;Suppl 99:117–22 (20 ref.) **(Jpn)**
[Gene expression in hematopoietic cells] Ozawa K. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2592–7 (11 ref.) **(Jpn)**
[Gene transfer into hematopoietic stem cells] Ozawa K. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2732–8 (24 ref.) **(Jpn)**

CHEMISTRY

Detection of minimal residual disease in hematopoietic tissues. Sharp JG, et al. **Ann N Y Acad Sci** 1995 Dec 29; 770:242–61 (89 ref.)

CLASSIFICATION

Surface markers and growth factor receptors of immature hemopoietic stem cell subsets. Wagemaker G, et al. **Stem Cells (Dayt)** 1995 May;13 Suppl 1:165–71 (29 ref.)

CYTOLOGY

Stem cell factor as a survival and growth factor in human normal and malignant hematopoiesis. Hassan HT, et al. **Acta Haematol** 1996;95(3–4):257–62 (50 ref.)
The significance of cultivating cells and hemopoietic tissue from tunicates. Cooper EL, et al. **Adv Exp Med Biol** 1995; 371A:321–5 (21 ref.)
Human B-cell development. Billips LG, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:1–8 (31 ref.)
Purification and expansion of human hematopoietic stem/progenitor cells. Civin CI, et al. **Ann N Y Acad Sci** 1995 Dec 29;770:91–8 (53 ref.)
The potential for clinical ex vivo hematopoiesis. Emerson SG. **Ann N Y Acad Sci** 1995 Dec 29;770:99–104 (17 ref.)
B-lineage differentiation stages resolved by multiparameter flow cytometry. Hardy RR, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:19–24 (26 ref.)
Mobilization of peripheral blood stem cells for autologous transplantation. Methods, mechanisms, and role in accelerating hematopoietic recovery. Janssen WE. **Ann N Y Acad Sci** 1995 Dec 29;770:116–29 (52 ref.)
In vitro studies of human B lymphopoiesis. Pribyl JR, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:9–18 (40 ref.)
Identification of genes specifically expressed at discrete stages of B-cell development. Zhang Y, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:25–6 (3 ref.)
Gene transfer to hematopoietic stem cells: implications for gene therapy of human disease. Dunbar CE. **Annu Rev Med** 1996;47:11–20 (43 ref.)
Biological characteristics of cells migrating into the bloodstream. Testa NG. **Bone Marrow Transplant** 1996 Mar;17 Suppl 2:S12–3 (13 ref.)
In vitro expansion of hematopoietic cells for clinical application. Emerson SG, et al. **Cancer Treat Res** 1995; 76:215–23 (14 ref.)
Sources of human hematopoietic stem cells for transplantation--a review. Amos TA, et al. **Cell Transplant** 1995 Nov-Dec;4(6):547–69 (256 ref.)
Hematopoietic stem cells and microenvironment: the proliferation and differentiation of stromal cells. Fukushima N, et al. **Crit Rev Oncol Hematol** 1995 Oct;20(3):255–70 (252 ref.)
Stem cells from bone marrow, umbilical cord blood and peripheral blood for clinical application: current status and future application. Lu L, et al. **Crit Rev Oncol Hematol** 1996 Mar;22(2):61–78 (243 ref.)
The effect of c-raf antisense oligonucleotides on growth factor-induced proliferation of hematopoietic cells. Keller JR, et al. **Curr Top Microbiol Immunol** 1996;211:43–53 (25 ref.)
Hematopoietic reserve provided by spleen colony-forming units (CFU-S). Nečas E, et al. **Exp Hematol** 1995 Nov; 23(12):1242–6 (47 ref.)
Specificity of hematopoietic stem cell homing. Hardy CL, et al. **Hematol Oncol** 1996 Mar;14(1):17–27 (69 ref.)
Growth hormone, growth factors and hematopoiesis. Kelley KW, et al. **Horm Res** 1996;45(1–2):38–45 (91 ref.)
Hematopoietic stem cell cytokine response. Lowry PA. **J Cell Biochem** 1995 Aug;58(4):410–5 (29 ref.)
CD34+ progenitor cell selection: clinical transplantation, tumor cell purging, gene therapy, ex vivo expansion, and cord blood processing. Colter M, et al. **J Hematother** 1996 Apr;5(2):179–84 (22 ref.)
From thymic lineages back to hematopoietic stem cells, sometimes using homing receptors. Weissman IL. **J Immunol** 1996 Mar 15;156(6):2019–25 (114 ref.)
Chemokines as inhibitors of hematopoietic progenitors [editorial; comment] VerFaillie CM. **J Lab Clin Med** 1996 Feb;127(2):148–50 (16 ref.) Comment on: J Lab Clin Med 1996 Feb;127(2):179–85.
Thrombopoietin: biological and preclinical properties. Kaushansky K. **Leukemia** 1996 Apr;10 Suppl 1:S46–8 (20 ref.)
Biological and clinical advances in stem cell expansion. Lange W, et al. **Leukemia** 1996 Jun;10(6):943–5 (21 ref.)
Heterogeneity of hematopoietic stem cells: implications for clinical applications. Morrison SJ, et al. **Proc Assoc Am Physicians** 1995 Jul;107(2):187–94 (30 ref.)
Expansion of myeloid stem cells in culture. Moore MA. **Semin Hematol** 1995 Jul;32(3):183–200 (131 ref.)
Lymphohematopoietic development from embryonic stem cells in vitro. Nakano T. **Semin Immunol** 1995 Jun; 7(3):197–203 (26 ref.)
Assessment and characterization of hemopoietic stem cells. Messner HA. **Stem Cells** 1995 Dec;13 Suppl 3:13–8 (51 ref.)
The stromal cells' guide to the stem cell universe. Müller-Sieburg CE, et al. **Stem Cells (Dayt)** 1995 Sep; 13(5):477–86 (67 ref.)
[Nuclear receptors and ontogenesis of the hematopoietic tissue] Chomienne C, et al. **C R Seances Soc Biol Fil** 1995; 189(4):493–501 (34 ref.) (Eng. Abstr.) **(Fre)**
[Do several waves of stem cells follow themselves during hematopoietic development?] Dieterlen-Lièvre F. **C R Seances Soc Biol Fil** 1995;189(4):591–6 (16 ref.) (Eng. Abstr.) **(Fre)**
[Hemopoietic colony formation in semisolid and liquid culture system] Ikebuchi K. **Rinsho Byori** 1995 Jul;Suppl 99:123–35 (14 ref.) **(Jpn)**
[Physiological (programmed) cell death in hemopoiesis] Kozinets GI, et al. **Klin Lab Diagn** 1996 Jan-Feb;(1):35–8 (24 ref.) (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

Ex vivo expansion of hematopoietic precursors, progenitors, and stem cells: the next generation of cellular therapeutics. Emerson SG. **Blood** 1996 Apr 15;87(8):3082–8 (48 ref.)
Colony-stimulating factors: current applications and perspectives. Bron D, et al. **Cancer Treat Res** 1995; 79:245–54 (63 ref.)
Haemopoietic stem cell inhibition: potential for dose intensification. Marshall E. **Eur J Cancer** 1995 Sep; 31A(10):1586–91 (92 ref.)
The NF-jun transcription factor in the hematopoietic response to mitogenic signals. Sott C, et al. **Immunobiology** 1995 Jul;193(2–4):149–54 (16 ref.)
Methods of stem cell mobilization. Dasgupta A, et al. **J Infus Chemother** 1996 Winter;6(1):12–6 (26 ref.)
Stem cell transplantation with chemoradiotherapy myeloablation and interleukin-2. Meehan KR, et al. **J Infus Chemother** 1996 Winter;6(1):28–32 (47 ref.)
Signal transduction mechanisms of parathyroid hormone- and parathyroid hormone-related-peptide-stimulated osteoclast-like cell formation from hemopoietic blast cells. Sugimoto T, et al. **Miner Electrolyte Metab** 1995; 21(1–3):161–5 (22 ref.)

ENZYMOLOGY

The role of Bruton's tyrosine kinase in B-cell development and function in mice and man. Khan WN, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:27–38 (36 ref.)
The Src and Csk families of tyrosine protein kinases in hemopoietic cells. Chow LM, et al. **Semin Immunol** 1995 Aug;7(4):207–26 (222 ref.)
The Janus protein tyrosine kinases in hematopoietic cytokine signaling. Ihle JN. **Semin Immunol** 1995 Aug;7(4):247–54 (57 ref.)
Receptor tyrosine kinases and the regulation of hematopoiesis. Paulson RF, et al. **Semin Immunol** 1995 Aug; 7(4):267–77 (84 ref.)
[Isoenzyme of nonspecific esterase in hemopoietic cells] Sasaki R. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:239–42 (10 ref.) **(Jpn)**

IMMUNOLOGY

Fetal versus adult PreB or B cells: the human VH repertoire. Tonnelle C, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:231–41 (38 ref.)
Pathways from hematopoietic stem cells to thymocytes. Rodewald HR. **Curr Opin Immunol** 1995 Apr;7(2):176–87 (83 ref.)
Immune functions of cord blood cells before and after transplantation. Roncarolo MG, et al. **J Hematother** 1996 Apr;5(2):157–60 (13 ref.)
CD45 (leucocyte common antigen) expression in T and B lymphocyte subsets. Poppema S, et al. **Leuk Lymphoma** 1996 Jan;20(3–4):217–22 (63 ref.)
Inhibition of GM-CSF production by recombinant human interleukin-4: negative regulator of hematopoiesis. Sawada K, et al. **Leuk Lymphoma** 1995 Sep;19(1–2):33–42 (1661 ref.)
Liver transplants contribute to their own success [comment] Starzl TE, et al. **Nat Med** 1996 Feb;2(2):163–5 (22 ref.) Comment on: Nat Med 1996 Feb;2(2):198–203.
B-lymphoid potential in pre-liver mouse embryo. Godin I, et al. **Semin Immunol** 1995 Jun;7(3):131–41 (70 ref.)
In-vitro models of B-lineage commitment. Kee BL, et al. **Semin Immunol** 1995 Jun;7(3):143–54 (115 ref.)
Development of human NK cells from the immature cell precursors. Poggi A, et al. **Semin Immunol** 1995 Apr; 7(2):61–6 (19 ref.)
In-vitro analyses of mechanisms of B-cell development. Rolink A, et al. **Semin Immunol** 1995 Jun;7(3):155–67 (72 ref.)
[Molecular and biological features of human CD34+ Hematopoietic stem/progenitor cells] Xi YZ. **Sheng Li Ke Hsueh Chin Chan** 1995 Oct;26(4):317–23 (20 ref.) (Eng. Abstr.) **(Chi)**

METABOLISM

The genetic regulation of sialyl-Lewisx expression in haemopoietic cells. Watkins WM, et al. **Adv Exp Med Biol** 1995;376:83–93 (64 ref.)
Intracellular signalling. Switching off signals. Imboden JB, et al. **Curr Biol** 1995 Jul 1;5(7):727–9 (12 ref.)

Transfer of the MDR1 gene into haematopoietic cells. Baudard M, et al. **Eur J Cancer** 1996 Jun;32A(6):1019–23 (52 ref.)
Surface markers and growth factor receptors of immature hemopoietic stem cell subsets. Wagemaker G, et al. **Stem Cells (Dayt)** 1995 May;13 Suppl 1:165–71 (29 ref.)

PATHOLOGY

Haemophagocytosis in bone marrow aspirate--a review of the clinical course of 10 cases. Linn YC, et al. **Acta Haematol** 1995;94(4):182–91 (25 ref.)
Stromal abnormalities in neoplastic bone marrow diseases. Dührsen U, et al. **Ann Hematol** 1996 Aug;73(2):53–70 (222 ref.)
Novel insights into the biology of myelodysplastic syndromes: excessive apoptosis and the role of cytokines. Raza A, et al. **Int J Hematol** 1996 Jun;63(4):265–78 (52 ref.)
Which progenitor is the target cell in the development of acute promyelocytic leukemia? Takatsuki H, et al. **Leuk Lymphoma** 1995 Apr;17(3–4):251–4 (29 ref.)
The hematopoietic stem cell in elderly patients with leukemia. Keating A. **Leukemia** 1996 Apr;10 Suppl 1:S30–2 (12 ref.)

PHYSIOLOGY

Signaling by the cytokine receptor superfamily in normal and transformed hematopoietic cells. Ihle JN. **Adv Cancer Res** 1996;68:23–65 (263 ref.)
Relative contributions of marrow microenvironment, growth factors, and stem cells to hematopoiesis in vivo in man. Review of results from autologous stem cell transplant trials and laboratory studies at the Moffitt Cancer Center. Elfenbein GJ, et al. **Ann N Y Acad Sci** 1995 Dec 29; 770:315–38 (21 ref.)
The biology of hematopoietic stem cells. Morrison SJ, et al. **Ann Rev Cell Dev Biol** 1995;11:35–71 (241 ref.)
Biology and clinical potential of stem-cell factor. Glaspy J, et al. **Cancer Chemother Pharmacol** 1996;38 Suppl:S53–7 (33 ref.)
Self renewal and differentiation in primary avian hematopoietic cells: an alternative to mammalian in vitro models? Beug H, et al. **Curr Top Microbiol Immunol** 1996; 211:29–39 (61 ref.)
Myelodysplastic syndrome associated with erythrophagocytosis by blasts and myeloid cells. Kuyama J, et al. **Int J Hematol** 1995 Dec;62(4):243–6 (14 ref.)
Biology of flt3 ligand and receptor. Lyman SD. **Int J Hematol** 1995 Aug;62(2):63–73 (42 ref.)
Feedback inhibitors in normal and tumor tissues. Marshall E, et al. **Int Rev Cytol** 1996;167:185–261 (299 ref.)
Hematopoietic stem cell cytokine response. Lowry PA. **J Cell Biochem** 1995 Aug;58(4):410–5 (29 ref.)
Is interleukin 17, an inducible cytokine that stimulates production of other cytokines, merely a redundant player in a sea of other biomolecules? [comment] Broxmeyer HE. **J Exp Med** 1996 Jun 1;183(6):2411–5 (43 ref.) Comment on: J Exp Med 1996 Jun 1;183(6):2593–603.
The biology and application of human bone marrow stromal cell precursors. Gronthos S, et al. **J Hematother** 1996 Feb; 5(1):15–23 (74 ref.)
TGF-beta and megakaryocytes in the pathogenesis of myelofibrosis in myeloproliferative disorders. Martyré MC. **Leuk Lymphoma** 1995 Dec;20(1–2):39–44 (58 ref.)
Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells. Drexler HG. **Leukemia** 1996 Apr; 10(4):588–99 (118 ref.)
Storage of haemopoietic stem cells for autologous bone marrow transplantation. Raju GM, et al. **Natl Med J India** 1995 Sep–Oct;8(5):216–21 (82 ref.)
Guidelines for efficient peripheral blood progenitor cell collection. Van Hoef ME. **Neth J Med** 1996 Jan;48(1):29–37 (65 ref.)
Retroviral transfer of the multidrug resistance-1 gene into lineage-committed and primitive hemopoietic cells. Fruehauf S, et al. **Stem Cells** 1995 Dec;13 Suppl 3:93–9 (43 ref.)
Preclinical biology of interleukin 11: a multifunctional hematopoietic cytokine with potent thrombopoietic activity. Goldman SJ. **Stem Cells (Dayt)** 1995 Sep; 13(5):462–71 (39 ref.)
Serum-free culture of hematopoietic stem cells: a review. Lebkowski JS, et al. **Stem Cells (Dayt)** 1995 Nov; 13(6):607–12 (40 ref.)
The stromal cells' guide to the stem cell universe. Müller-Sieburg CE, et al. **Stem Cells (Dayt)** 1995 Sep; 13(5):477–86 (67 ref.)
[Recent data and current studies of epidermal Langerhans cells] Dezutter-Dambuyant C. **Pathol Biol (Paris)** 1995 Dec;43(10):841–7 (78 ref.) (Eng. Abstr.) **(Fre)**
[In vitro differenciation and functions of dendritic cells obtained from CD34+ hematopoietic progenitors] Dubois B, et al. **Pathol Biol (Paris)** 1995 Dec;43(10):829–40 (88 ref.) (Eng. Abstr.) **(Fre)**

RADIATION EFFECTS

Hematologic side effects of radiolabeled immunoglobulin therapy. Vriesendorp HM, et al. **Exp Hematol** 1996 Aug; 24(10):1183–90 (52 ref.)
Heterogeneity of radiation sensitivity of hemopoietic stem cell subsets. Wagemaker G. **Stem Cells (Dayt)** 1995 May; 13 Suppl 1:257–60 (17 ref.)

ULTRASTRUCTURE

Ribosome-lamella complexes in sinus histiocytes [letter] Eyden BP, et al. **Ultrastruct Pathol** 1995 Nov–Dec; 19(6):511–5 (65 ref.)

VIROLOGY

Cytomegalovirus latency and latency-specific transcription in hematopoietic progenitors. Kondo K, et al. **Scand J Infect Dis Suppl** 1995;99:63–7 (24 ref.)

HEMATOPOIETIC SYSTEM

DRUG EFFECTS

Systemic aluminum toxicity: effects on bone, hematopoietic tissue, and kidney. Jeffery EH, et al. **J Toxicol Environ Health** 1996 Aug 30;48(6):649–65 (80 ref.)

EMBRYOLOGY

Developmental biology of hematopoiesis. Zon LI. **Blood** 1995 Oct 15;86(8):2876–91 (107 ref.)
[Early ontogeny of the human hematopoietic system] Charbord P, et al. **C R Seances Soc Biol Fil** 1995; 189(4):601–9 (28 ref.) (Eng. Abstr.) **(Fre)**
[Do several waves of stem cells follow themselves during hematopoietic development?] Dieterlen-Lièvre F. **C R Seances Soc Biol Fil** 1995;189(4):591–6 (16 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

The relevance of cell microenvironments for the appearance of lympho-haemopoietic tissues in primitive vertebrates. Zapata AG, et al. **Histol Histopathol** 1995 Jul;10(3):761–78 (82 ref.)
PECAM-1: its expression and function as a cell adhesion molecule on hemopoietic and endothelial cells. Watt SM, et al. **Leuk Lymphoma** 1995 Apr;17(3–4):229–44 (85 ref.)
Adhesive interactions in the hematopoietic system: regulation by cytokines. Fernández M, et al. **Proc Soc Exp Biol Med** 1996 Sep;212(4):313–23 (136 ref.)

HEMATOPOIETINS see **HEMATOPOIETIC CELL GROWTH FACTORS**

HEMATOPORPHYRIN D see **HEMATOPORPHYRIN DERIVATIVE**

HEMATOPORPHYRIN DERIVATIVE

see related
HEMATOPORPHYRIN PHOTORADIATION

THERAPEUTIC USE

Photodynamic therapy. Its use in the management of bronchogenic carcinoma. Edell ES, et al. **Clin Chest Med** 1995 Sep;16(3):455–63 (103 ref.)
[Mechanism of photodynamic therapy] Takemura T, et al. **Gan To Kagaku Ryoho** 1996 Jan;23(1):16–21 (6 ref.) (Eng. Abstr.) **(Jpn)**

HEMATOPORPHYRIN PHOTORADIATION

The use of porphyrins and non-ionizing radiation for treatment of cancer. Evensen JF. **Acta Oncol** 1995; 34(8):1103–10 (79 ref.)
Photodynamic therapy. Its use in the management of bronchogenic carcinoma. Edell ES, et al. **Clin Chest Med** 1995 Sep;16(3):455–63 (103 ref.)
[Photobiologic effects of porphyrins and their use in therapy of tumors] Hrkal Z, et al. **Cas Lek Cesk** 1996 Apr 17; 135(8):236–8 (20 ref.) (Eng. Abstr.) **(Cze)**

ADVERSE EFFECTS

Bronchoesophagopleural fistula after photodynamic therapy for malignant mesothelioma. Luketich JD, et al. **Ann Thorac Surg** 1996 Jul;62(1):283–4 (7 ref.)

HEMATURIA

[Hematuria, a major sign. Causes and practical diagnosis] Fernández Gómez JM, et al. **Rev Clin Esp** 1995 Nov; 195(11):773–80 (18 ref.) **(Spa)**

CHEMICALLY INDUCED

Poisoning from "Spanish fly" (cantharidin). Karras DJ, et al. **Am J Emerg Med** 1996 Sep;14(5):478–83 (17 ref.)

COMPLICATIONS

Loin pain haematuria syndrome. Burke JR, et al. **Pediatr Nephrol** 1996 Apr;10(2):216–20 (45 ref.)

DIAGNOSIS

Investigation of haematuria. Bryden AA, et al. **Br J Hosp Med** 1995 Nov 1–14;54(9):455–8 (14 ref.)
Microscopic hematuria diagnosis and management [editorial] Fogazzi GB, et al. **Nephron** 1996;72(2):125–34 (81 ref.)
[Isolated microhematuria as the manifestation of lupus nephritis] Shvetsov MIu, et al. **Ter Arkh** 1996;68(1):57–8 (8 ref.) (Eng. Abstr.) **(Rus)**

ETIOLOGY

Exercised-induced hematuria. Gambrell RC, et al. **Am Fam Physician** 1996 Feb 15;53(3):905–11 (28 ref.)
Investigation of haematuria. Bryden AA, et al. **Br J Hosp Med** 1995 Nov 1–14;54(9):455–8 (14 ref.)
Evaluation of asymptomatic microhematuria. Fracchia JA, et al. **Urology** 1995 Oct;46(4):484–9 (23 ref.)
[Hematuria--diagnostic procedure and therapeutic approaches] Allendorff J, et al. **Z Arztl Fortbild (Jena)** 1996 May;90(3):187–90 (12 ref.) (Eng. Abstr.) **(Ger)**

GENETICS

Recurrent hematuria: a novel clinical presentation of hereditary complete complement C4 deficiency. Lhotta K, et al. **Am J Kidney Dis** 1996 Mar;27(3):424–7 (10 ref.)

THERAPY

Microscopic hematuria diagnosis and management [editorial] Fogazzi GB, et al. **Nephron** 1996;72(2):125–34 (81 ref.)

HEME

ANALOGS & DERIVATIVES

[Discovery of heme O and heme A synthases] Saiki K. **Seikagaku** 1995 Aug;67(8):1048–53 (15 ref.) **(Jpn)**

BIOSYNTHESIS

Glutamate transfer RNA: a cofactor for heme and chlorophyll biosynthesis. Madan Kumar A, et al. **Indian J Biochem Biophys** 1996 Feb;33(1):30–4 (31 ref.)
Heme synthesis in the rhizobium-legume symbiosis: a palette for bacterial and eukaryotic pigments. O'Brian MR. **J Bacteriol** 1996 May;178(9):2471–8 (95 ref.)
Heme biosynthesis: biochemistry, molecular biology, and relationship to disease. Ferreira GC. **J Bioenerg Biomembr** 1995 Apr;27(2):147–50 (5 ref.)
5-Aminolevulinate synthase and the first step of heme biosynthesis. Ferreira GC, et al. **J Bioenerg Biomembr** 1995 Apr;27(2):151–9 (84 ref.)
Porphobilinogen synthase, the first source of heme's asymmetry. Jaffe EK. **J Bioenerg Biomembr** 1995 Apr; 27(2):169–79 (76 ref.)
[The molecular basis and genetics of diseases associated with disorders of heme biosynthesis] Fuchs O. **Cas Lek Cesk** 1996 Jan 17;135(2):54–8 (42 ref.) (Eng. Abstr.) **(Cze)**
[Discovery of heme O and heme A synthases] Saiki K. **Seikagaku** 1995 Aug;67(8):1048–53 (15 ref.) **(Jpn)**

CHEMISTRY

'As prepared' forms of fully oxidised haem/Cu terminal oxidases. Moody AJ. **Biochim Biophys Acta** 1996 Aug 7; 1276(1):6–20 (119 ref.)

GENETICS

[The molecular basis and genetics of diseases associated with disorders of heme biosynthesis] Fuchs O. **Cas Lek Cesk** 1996 Jan 17;135(2):54–8 (42 ref.) (Eng. Abstr.) **(Cze)**

PHYSIOLOGY

Nitric oxide and intracellular heme. Kim YM, et al. **Adv Pharmacol** 1995;34:277–91 (84 ref.)
Regulation of iron metabolism: translational effects mediated by iron, heme, and cytokines. Mascotti DP, et al. **Annu Rev Nutr** 1995;15:239–61 (143 ref.)

HEME OXYGENASE

PHYSIOLOGY

Heme oxygenase-1: function, regulation, and implication of a novel stress-inducible protein in oxidant-induced lung injury. Choi AM, et al. **Am J Respir Cell Mol Biol** 1996 Jul;15(1):9–19 (58 ref.)

HEME SYNTHETASE see **FERROCHELATASE**

HEMEL see **ALTRETAMINE**

HEMEPROTEINS

CHEMISTRY

Arylhydrazines as probes of hemoprotein structure and function. Ortiz de Montellano PR. **Biochimie** 1995; 77(7–8):581–93 (60 ref.)
Depletion and replacement of protein metal ligands. Barrick D. **Curr Opin Biotechnol** 1995 Aug;6(4):411–8 (59 ref.)
The unique structures of protozoan myoglobin and yeast hemoglobin: an evolutionary diversity. Shikama K, et al. **Int J Biochem Cell Biol** 1995 Nov;27(11):1107–15 (35 ref.)

HEMERALOPIA see **VISION DISORDERS**

HEMIBODY IRRADIATION

see related
WHOLE-BODY IRRADIATION

HEMICRANIA see **MIGRAINE**

HEMIFACIAL MICROSOMIA see **FACIAL ASYMMETRY**

HEMIMELIA see **ECTROMELIA**

HEMIPARESIS see **HEMIPLEGIA**

HEMIPLEGIA

ETIOLOGY

[Akinetic mutism with right hemiplegia caused by infarction in the territory of the left anterior cerebral artery] Lechevalier B, et al. **Rev Neurol (Paris)** 1996 Mar; 152(3):181–9 (27 ref.) (Eng. Abstr.) **(Fre)**

NURSING

Neurodevelopmental treatment: application to nursing and effects on the hemiplegic stroke patient. Hafsteinsdóttir TB. **J Neurosci Nurs** 1996 Feb;28(1):36–47 (45 ref.)

RADIONUCLIDE IMAGING

Hemiatrophy, juvenile-onset exertional alternating leg paresis, hypotonia, and hemidystonia and adult-onset hemiparkinsonism: the spectrum of hemiparkinsonism-hemiatrophy syndrome. Lang AE. **Mov Disord** 1995 Jul;10(4):489–95 (32 ref.)

REHABILITATION

[Stroke rehabilitation] Kallanranta T. **Duodecim** 1994; 110(15):1419–30 (76 ref.) **(Fin)**

HEMOBILIA

ETIOLOGY

A case of hemobilia after percutaneous liver biopsy treated by transcatheter arterial embolization with Histoacryl. Murata K, et al. **Am J Gastroenterol** 1996 Jan;91(1):160 (8 ref.)

Pancreatitis secondary to percutaneous liver biopsy-associated hemobilia. Van Os EC, et al. **Am J Gastroenterol** 1996 Mar;91(3):577–80 (18 ref.)

Acute cholecystitis resulting from hemobilia after tru-cut biopsy: a case report and brief review of the literature. Counihan TC, et al. **Am Surg** 1996 Sep;62(9):757–8 (5 ref.)

[Hemobilia due to a portobiliary fistula as a complication of a fine-needle liver biopsy] De Santis M, et al. **Radiol Med (Torino)** 1996 Apr;91(4):482–5 (18 ref.) **(Ita)**

[Hemobilia] Matsukawa M, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):187–9 (13 ref.) **(Jpn)**

[Hemobilia] Yamamoto M. **Ryoikibetsu Shokogun Shirizu** 1995;(8):566–8 (22 ref.) **(Jpn)**

THERAPY

A case of hemobilia after percutaneous liver biopsy treated by transcatheter arterial embolization with Histoacryl. Murata K, et al. **Am J Gastroenterol** 1996 Jan;91(1):160 (8 ref.)

HEMOCHROMATOSIS

Abdominal iron deposition: metabolism, MR findings, and clinical importance. Siegelman ES, et al. **Radiology** 1996 Apr;199(1):13–22 (170 ref.)

BLOOD

Iron overload: prevalence and impact on health. Lynch SR. **Nutr Rev** 1995 Sep;53(9):255–60 (38 ref.)

COMPLICATIONS

End stage liver disease in a 13-year old secondary to hepatitis C and hemochromatosis. Miller M, et al. **Am J Gastroenterol** 1996 Jul;91(7):1427–9 (20 ref.)

[Liver cirrhosis associated with metabolic disorders] Ono M, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):191–6 (26 ref.) **(Jpn)**

DIAGNOSIS

Hemochromatosis: diagnosis and management. Little DR. **Am Fam Physician** 1996 Jun;53(8):2623–8, 2631–2 (20 ref.)

Special imaging casebook. Neonatal hemochromatosis. Herman TE, et al. **J Perinatol** 1995 Jul-Aug;15(4):338–40 (10 ref.)

[Perinatal hemochromatosis] Ishii Y, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):534–7 (19 ref.) **(Jpn)**

[Hepatic iron overload] Yoshida H, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):493–5 (12 ref.) **(Jpn)**

ETIOLOGY

[Perinatal hemochromatosis] Ishii Y, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):534–7 (19 ref.) **(Jpn)**

GENETICS

Hereditary iron overload and African Americans [editorial; comment] Baer D. **Am J Med** 1996 Jul;101(1):5–8 (46 ref.) Comment on: Am J Med 1996 Jul;101(1):9–18.

Diabetes and haemochromatosis: current concepts, management and prevention. Yaouanq JM. **Diabete Metab** 1995 Dec;21(5):319–29 (71 ref.)

Haemochromatosis: strike while the iron is hot [news] Cox T. **Nat Genet** 1996 Aug;13(4):386–8 (18 ref.)

Hemochromatosis: the genetic disorder of the twenty-first century. Barton JC, et al. **Nat Med** 1996 Apr;2(4):394–5 (10 ref.)

Iron overload: prevalence and impact on health. Lynch SR. **Nutr Rev** 1995 Sep;53(9):255–60 (38 ref.)

Evolving expression of hereditary hemochromatosis. Adams PC, et al. **Semin Liver Dis** 1996 Feb;16(1):47–54 (27 ref.)

Hemochromatosis: genetics and pathogenesis. Powell LW, et al. **Semin Liver Dis** 1996 Feb;16(1):55–63 (84 ref.)

Inherited liver diseases in adults. Kumar A, et al. **West J Med** 1995 Oct;163(4):382–6 (20 ref.)

[Management of a family with genetic hemochromatosis] Moirand R, et al. **Gastroenterol Clin Biol** 1996;20(5 Pt 2):B9–14 (17 ref.) **(Fre)**

[Genetic hemochromatosis: importance of population screening?] Cartabellotta A, et al. **Recenti Prog Med** 1996 Mar;87(3):118–23 (27 ref.) (Eng. Abstr.) **(Ita)**

PHYSIOPATHOLOGY

Haemochromatosis—a clinical update. Burt MJ, et al. **Med J Aust** 1996 Mar 18;164(6):348–51 (27 ref.)

[Pituitary function in hemochromatosis] Pedersen-Bjergaard U, et al. **Ugeskr Laeger** 1996 Mar 25;158(13):1818–22 (35 ref.) (Eng. Abstr.) **(Dan)**

THERAPY

Hemochromatosis: diagnosis and management. Little DR. **Am Fam Physician** 1996 Jun;53(8):2623–8, 2631–2 (20 ref.)

Chelation therapy in beta-thalassemia: the benefits and limitations of desferrioxamine. Giardina PJ, et al. **Semin Hematol** 1995 Oct;32(4):304–12 (93 ref.)

HEMOCUPREIN see **SUPEROXIDE DISMUTASE**

HEMOCYANIN

CHEMISTRY

Hemocyanins. van Holde KE, et al. **Adv Protein Chem** 1995; 47:1–81 (252 ref.)

IMMUNOLOGY

Approaches to augmenting the immunogenicity of melanoma gangliosides: from whole melanoma cells to ganglioside-KLH conjugate vaccines. Livingston PO. **Immunol Rev** 1995 Jun;145:147–66 (68 ref.)

METABOLISM

Hemocyanins. van Holde KE, et al. **Adv Protein Chem** 1995; 47:1–81 (252 ref.)

HEMOCYTES

CYTOLOGY

The significance of cultivating cells and hemopoietic tissue from tunicates. Cooper EL, et al. **Adv Exp Med Biol** 1995; 371A:321–5 (21 ref.)

HEMODIAFILTRATION

Ultrafiltration failure in CAPD. Shetty A, et al. **J Postgrad Med** 1994 Jul-Sep;40(3):185–93 (47 ref.)

ADVERSE EFFECTS

Ultrafiltration and backfiltration during hemodialysis. Ofsthun NJ, et al. **Artif Organs** 1995 Nov;19(11):1143–61 (81 ref.)

Nutritional effect of continuous hemodiafiltration. Frankenfield DC, et al. **Nutrition** 1995 Jul-Aug; 11(4):388–93 (15 ref.)

INSTRUMENTATION

Push/pull hemodiafiltration: technical aspects and clinical effectiveness [editorial] Maeda K, et al. **Nephron** 1995; 71(1):1–9 (21 ref.)

METHODS

Hemodiafiltration in pentobarbital poisoning. Bironneau E, et al. **Ren Fail** 1996 Mar;18(2):299–303 (11 ref.)

HEMODIALYSIS

see related
KIDNEY, ARTIFICIAL

Recombinant human growth hormone (rhGH) in dialysis patients: update 1995. Fine RN. **Adv Perit Dial** 1995; 11:261–5 (15 ref.)

Refractory congestive heart failure: overview and application of extracorporeal ultrafiltration. Blake P, et al. **Adv Ren Replace Ther** 1996 Apr;3(2):166–73 (50 ref.)

Dialysate-based kinetic modeling. Garred LJ. **Adv Ren Replace Ther** 1995 Oct;2(4):305–18 (35 ref.)

Recombinant human erythropoietin therapy in children on dialysis. Jabs K, et al. **Adv Ren Replace Ther** 1996 Jan; 3(1):24–36 (98 ref.)

Solute disequilibrium and multicompartment modeling. Kaufman AM, et al. **Adv Ren Replace Ther** 1995 Oct; 2(4):319–29 (39 ref.)

Dialysis and renal transplantation in infants with irreversible renal failure. Neu AM, et al. **Adv Ren Replace Ther** 1996 Jan;3(1):48–59 (109 ref.)

Assessment of nutritional status in dialysis patients. Wolfson M, et al. **Adv Ren Replace Ther** 1996 Apr;3(2):174–9 (24 ref.)

Hemodialysis vascular access: effect on urea kinetics and the dialysis prescription. Butterly DW, et al. **Am J Nephrol** 1996;16(1):45–51 (32 ref.)

Quantifying hemodialysis. Depner TA. **Am J Nephrol** 1996; 16(1):17–28 (78 ref.)

Injectable medications for hemodialysis patients. Stivelman JC. **Am J Nephrol** 1996;16(1):73–8 (55 ref.)

Convective mass transfer in hemodialysis. Jaffrin MY. **Artif Organs** 1995 Nov;19(11):1162–71 (12 ref.)

Nutritional treatment of hemodialysis and peritoneal dialysis patients. Schmicker R. **Artif Organs** 1995 Aug;19(8):837–41 (34 ref.)

New methods for the investigation of blood-biomaterial interaction. Schütt W, et al. **Artif Organs** 1995 Aug; 19(8):847–51 (32 ref.)

Middle molecules: toxicity and removal by hemodialysis and related strategies. Vanholder R, et al. **Artif Organs** 1995 Nov;19(11):1120–5 (46 ref.)

Extracorporeal blood purification in the treatment of acute renal failure with multiorgan involvement. Kaplan AA. **Blood Purif** 1996;14(1):86–93 (45 ref.)

Drug removal in continuous haemofiltration and haemodialysis. Davies JG, et al. **Br J Hosp Med** 1995 Nov 15-Dec 12;54(10):524–8 (30 ref.)

Development of a PMMA membrane which can remove beta 2-microglobulin and its clinical significance. Kunitomo T, et al. **Contrib Nephrol** 1995;112:145–55 (22 ref.)

Economic, social, racial and age-related considerations in dialysis and transplantation. Dossetor JB. **Curr Opin Nephrol Hypertens** 1995 Nov;4(6):498–501 (39 ref.)

An update on peritoneal dialysis and hemodialysis in the pediatric population. Warady BA, et al. **Curr Opin Pediatr** 1996 Apr;8(2):135–40 (58 ref.)

Pharmacokinetics of cefotaxime in dialysis patients. Andrassy K. **Diagn Microbiol Infect Dis** 1995 May-Jun;22(1-2):85–7 (11 ref.)

Treatment of acute renal failure in intensive care patients. Böhler J. **Int J Artif Organs** 1996 Feb;19(2):108–10 (8 ref.)

Acute renal failure in infants and children. Ehrich JH. **Int J Artif Organs** 1996 Feb;19(2):121–3 (9 ref.)

Hepatitis C virus infection in dialysis and clinical nephrology [editorial] Fabrizi F, et al. **Int J Artif Organs** 1995 May; 18(5):235–44 (138 ref.)

Pharmacokinetics during continuous renal replacement therapy. Keller E. **Int J Artif Organs** 1996 Feb;19(2):113–7 (8 ref.)

Practical aspects of renal replacement therapy. Kox WJ, et al. **Int J Artif Organs** 1996 Feb;19(2):100–5 (17 ref.)

Urea monitoring in the dialysis patient. Panzetta G. **Int J Artif Organs** 1995 Sep;18(9):530–3 (24 ref.)

Role of cytokines in patients on dialysis [editorial] Pereira BJ, et al. **Int J Artif Organs** 1995 Jun;18(6):293–304 (101 ref.)

Use of continuous renal replacement therapy for detoxification? Riegel W. **Int J Artif Organs** 1996 Feb; 19(2):111–2 (9 ref.)

Basic mechanisms and definitions for continuous renal replacement therapies. Ronco C, et al. **Int J Artif Organs** 1996 Feb;19(2):95–9 (21 ref.)

Acute renal failure and membranes. Some medical and ethical questions [editorial] Schaefer K, et al. **Int J Artif Organs** 1996 Mar;19(3):145–6 (4 ref.)

Biocompatibility: is it a relevant consideration for today's haemodialysis? [editorial] Shaldon S, et al. **Int J Artif Organs** 1996 Apr;19(4):201–14 (105 ref.)

Dental considerations for the patient with renal disease receiving hemodialysis. De Rossi SS, et al. **J Am Dent Assoc** 1996 Feb;127(2):211–9 (52 ref.)

Contemporary vascular access surgery for chronic haemodialysis. Koo Seen Lin LC, et al. **J R Coll Surg Edinb** 1996 Jun;41(3):164–9 (75 ref.)

Why are lipids not predictive of cardiovascular death in the dialysis patient? Ritz E. **Miner Electrolyte Metab** 1996; 22(1-3):9–12 (25 ref.)

Lipoprotein(a) in chronic renal disease. Stenvinkel P, et al. **Miner Electrolyte Metab** 1996;22(1-3):16–21 (67 ref.)

rHuEpo before dialysis and in dialysed patients. López-Gómez JM, et al. **Nephrol Dial Transplant** 1995;10 Suppl 6:31–5 (39 ref.)

Simplified approaches to calculate Kt/V. It's time for agreement. Movilli E. **Nephrol Dial Transplant** 1996 Jan;

11(1):24–7 (31 ref.)
Chronic haemodialysis in elderly patients. Neves PL. **Nephrol Dial Transplant** 1995;10 Suppl 6:69–71 (30 ref.)
Balance between pro-inflammatory cytokines and their specific inhibitors in patients on dialysis. Pereira BJ. **Nephrol Dial Transplant** 1995;10 Suppl 7:27–32 (55 ref.)
Hypertension, cardiovascular complications and survival in diabetic patients on maintenance haemodialysis. Ritz E, et al. **Nephrol Dial Transplant** 1995;10 Suppl 7:43–6 (9 ref.)
On-line monitoring. Santoro A. **Nephrol Dial Transplant** 1995;10(5):615–8 (17 ref.)
The influence of dialysis time and dialyser reuse on survival. Shaldon S. **Nephrol Dial Transplant** 1995;10 Suppl 3:57–62 (51 ref.)
Weekly duration of dialysis treatment—does it matter for survival? Valderrábano F. **Nephrol Dial Transplant** 1996 Apr;11(4):569–72 (18 ref.)
Report on management of renal failure in Europe, XXV, 1994 end stage renal disease and dialysis report. The EDTA-ERA Registry. European Dialysis and Transplant Association-European Renal Association. Valderrábano F, et al. **Nephrol Dial Transplant** 1996;11 Suppl 1:2–21 (21 ref.)
Influence of uraemia and haemodialysis on host defence and infection. Vanholder R, et al. **Nephrol Dial Transplant** 1996 Apr;11(4):593–8 (69 ref.)
Azotemia control by extracorporeal therapy in patients with acute renal failure. Macias WL, et al. **New Horiz** 1995 Nov; 3(4):688–98 (62 ref.)
Clinicopathological study of dialysis patients with lupus nephritis. Kobayashi M, et al. **Nippon Jinzo Gakkai Shi** 1995 Aug;37(8):456–61 (22 ref.)
Chronic dialysis in the infant less than 1 year of age. Bunchman TE. **Pediatr Nephrol** 1995;9 Suppl:S18–22 (24 ref.)
Integration of peritoneal dialysis in active uremia treatment. Ronco C, et al. **Perit Dial Int** 1996;16 Suppl 1:S393–7 (8 ref.)
Thoughts about judging dialysis treatment: mathematics and measurements, mirrors in the mind. Lowrie EG. **Semin Nephrol** 1996 May;16(3):242–62 (86 ref.)
Lessons from vascular access procedures for hemodialysis. Shaffer D. **Surg Oncol Clin N Am** 1995 Jul;4(3):537–48 (70 ref.)
[Adequate dialysis revisited (editorial; comment)] Canaud B. **Nephrologie** 1995;16(6):393–7 (19 ref.) Comment on: Nephrologie 1995;16(6):407–11. Comment on: Nephrologie 1995;16(6):413–8. **(Fre)**
[Demand for the stopping of chronic hemodialysis. Apropos of 1 case] Lassaunière JM, et al. **Nephrologie** 1996; 17(4):237–41 (23 ref.) (Eng. Abstr.) **(Fre)**
[Kidney diseases in the elderly from the internal medicine viewpoint. Diagnosis and therapy] Verwiebe R, et al. **Fortschr Med** 1995 Oct 20;113(29):418–22 (17 ref.) (Eng. Abstr.) **(Ger)**
[25 years kidney replacement therapy in childhood and adolescence—success of somatic and psychosocial rehabilitation] Bulla M, et al. **Versicherungsmedizin** 1996 Jun 1;48(3):85–9 (56 ref.) (Eng. Abstr.) **(Ger)**
[Biocompatibility and extracorporeal circulation] Camici M. **Clin Ter** 1995 Nov;146(11):713–9 (30 ref.) (Eng. Abstr.) **(Ita)**
[Recent progress in hemodialysis] Akizawa T. **Nippon Naika Gakkai Zasshi** 1995 Oct 10;84(10):1617–21 (5 ref.) **(Jpn)**
[The role of dialysis membranes in elimination of uremic toxins] Grzeszczak W, et al. **Przegl Lek** 1996;53(5):439–42 (27 ref.) **(Pol)**
[Anticoagulants in hemodialysis therapy] Malyszko J, et al. **Przegl Lek** 1996;53(5):454–8 (49 ref.) **(Pol)**
[Physical exercise and chronic renal insufficiency] Bolaños L, et al. **Rev Med Univ Navarra** 1993 Jan-Mar;38(1):38–41 (25 ref.) **(Spa)**

ADVERSE EFFECTS

Hepatitis C virus infection in hemodialyzed patients and kidney allograft recipients. Pol S. **Adv Nephrol Necker Hosp** 1995;24:315–30 (69 ref.)
The renal bone diseases in children treated with dialysis. Sanchez CP, et al. **Adv Ren Replace Ther** 1996 Jan; 3(1):14–23 (78 ref.)
Spinal epidural abscess in hemodialysis patients: report of three cases and review of the literature. Obrador GT, et al. **Am J Kidney Dis** 1996 Jan;27(1):75–83 (34 ref.)
Brain swelling after dialysis: old urea or new osmoles? Silver SM, et al. **Am J Kidney Dis** 1996 Jul;28(1):1–13 (49 ref.)
Nutrition and the dialysis prescription. Chertow GM, et al. **Am J Nephrol** 1996;16(1):79–89 (85 ref.)
Carotid-jugular arteriovenous fistula: a complication of temporary hemodialysis catheter. el-Shahawy MA, et al. **Am J Nephrol** 1995;15(4):332–6 (51 ref.)
Dialysis-related amyloidosis: from raw clinical facts to unresolved questions. Charra B. **Contrib Nephrol** 1995; 112:119–28 (48 ref.)
Role of macrophages in beta 2-microglobulin-related dialysis amyloidosis. Gejyo F, et al. **Contrib Nephrol** 1995; 112:97–104 (18 ref.)
Beta 2-microglobulin modified with the AGE products of the Maillard reaction in dialysis-related amyloidosis. Miyata T, et al. **Contrib Nephrol** 1995;112:52–64 (52 ref.)
The patient with ADPKD on maintenance hemodialysis. Ritz E, et al. **Contrib Nephrol** 1995;115:33–8 (15 ref.)
Clinical aspects of dialysis-related amyloidosis. Schäffer J, et al. **Contrib Nephrol** 1995;112:90–6 (36 ref.)
Pathogenesis of dialysis-related amyloidosis. Miyata T, et al. **Curr Opin Nephrol Hypertens** 1995 Nov;4(6):493–7 (51 ref.)
Hypopigmentation in hemodialysis. Acquired hair and skin fairness in a uremic patient undergoing maintenance hemodialysis: case report and review of the literature. Hmida MB, et al. **Dermatology** 1996;192(2):148–52 (17 ref.)
Thermal balance and dialysis hypotension. Maggiore Q, et al. **Int J Artif Organs** 1995 Sep;18(9):518–25 (11 ref.)
L-carnitine in dialysed patients: the choice of dosage regimen. Berard E, et al. **Int J Clin Pharmacol Res** 1995; 15(3):127–33 (43 ref.)
Nutrition and mortality in hemodialysis [editorial] Bergström J. **J Am Soc Nephrol** 1995 Nov;6(5):1329–41 (146 ref.)
Evaluation of destructive spondyloarthropathies in hemodialysis by computerized tomographic scan and magnetic resonance imaging. Flipo RM, et al. **J Rheumatol** 1996 May;23(5):869–73 (28 ref.)
Interleukin-1 and interleukin-1 receptor antagonist production during haemodialysis: which cytokine is a surrogate marker for dialysis-related complications? Dinarello CA. **Nephrol Dial Transplant** 1995;10 Suppl 3:25–8 (32 ref.)
Will bone disease still remain one of the most serious complications in dialysis patients? Drüeke TB. **Nephrol Dial Transplant** 1995;10 Suppl 7:16–9 (24 ref.)
Hyperthyroidism in haemodialysis patients: report on a case and review of the literature. Koutsikos D, et al. **Nephrol Dial Transplant** 1995;10(9):1765–7 (18 ref.)
Hepatitis C virus infection in haemodialysis patients: lessons from epidemiology and prophylaxis. Loureiro A, et al. **Nephrol Dial Transplant** 1995;10 Suppl 6:83–7 (63 ref.)
Leukocyte—endothelial cell interactions in haemodialysis-induced neutropenia. Muñoz de Bustillo E, et al. **Nephrol Dial Transplant** 1996 Apr;11(4):572–4 (23 ref.)
Pathogenetic and diagnostic aspects of dialysis-related amyloidosis. Schaeffer J, et al. **Nephrol Dial Transplant** 1995;10 Suppl 3:4–8 (66 ref.)
The bleeding risk in chronic haemodialysis: preventive strategies in high-risk patients. Janssen MJ, et al. **Neth J Med** 1996 May;48(5):198–207 (134 ref.)
The immune system in uremia and during its treatment. Haag-Weber M, et al. **New Horiz** 1995 Nov;3(4):669–79 (172 ref.)
Biocompatible intermittent hemodialysis. Lang S, et al. **New Horiz** 1995 Nov;3(4):680–7 (56 ref.)
New aspects in the pathogenesis of dialysis-related amyloidosis: pathophysiology of advanced glycation end products in renal failure. Miyata T. **Nippon Jinzo Gakkai Shi** 1996 May;38(5):191–7 (51 ref.)
Hyperhomocysteinemia as a risk factor for cardiovascular disease in patients undergoing hemodialysis. Friedman JA, et al. **Nutr Rev** 1995 Jul;53(7):197–201 (17 ref.)
Anorexia in dialysis patients. Bergström J. **Semin Nephrol** 1996 May;16(3):222–9 (88 ref.)
Renal cortical neoplasm in a child with dialysis-acquired cystic kidney disease. Gentle DL, et al. **Urology** 1996 Feb; 47(2):254–5 (5 ref.)
[Colonic pseudo-obstruction caused by digestive amyloidosis in a chronic hemodialyzed patient. Apropos of a case] Tiffet O, et al. **Ann Chir** 1996;50(3):279–82 (11 ref.) (Eng. Abstr.) **(Fre)**
[What are the non transfusional modes of transmission of hepatitis C virus?] Serfaty L, et al. **Gastroenterol Clin Biol** 1995 May;19(5):525–33 (110 ref.) **(Fre)**
[Hepatitis C virus infection. Epidemiology] Bastie A, et al. **Pathol Biol (Paris)** 1995 Oct;43(8):674–80 (78 ref.) (Eng. Abstr.) **(Fre)**
[Hepatitis C virus infection in hemodialysis] Simon N. **Pathol Biol (Paris)** 1995 Oct;43(8):735–40 (33 ref.) (Eng. Abstr.) **(Fre)**
[Epidemiology and prevention of HCV infection in dialysis centers] Cialdea L, et al. **Ann Ist Super Sanita** 1995; 31(3):313–5 (23 ref.) (Eng. Abstr.) **(Ita)**
[Countermeasure for patients with bone disease due to hemodialysis] Fukagawa M, et al. **Nippon Naika Gakkai Zasshi** 1995 Oct 10;84(10):1668–72 (5 ref.) **(Jpn)**
[Countermeasure for patients with amyloidosis due to hemodialysis] Gejo F. **Nippon Naika Gakkai Zasshi** 1995 Oct 10;84(10):1673–7 (5 ref.) **(Jpn)**
[Countermeasure for patients with cerebrovascular disorders due to hemodialysis] Hirakata H. **Nippon Naika Gakkai Zasshi** 1995 Oct 10;84(10):1685–90 (9 ref.) **(Jpn)**
[Complications of dialysis] Hirasawa Y. **Nippon Naika Gakkai Zasshi** 1995 Sep 10;84(9):1532–7 (3 ref.) **(Jpn)**
[Nutritional management in chronic hemodialysis] Ishigai T, et al. **Nippon Naika Gakkai Zasshi** 1995 Oct 10; 84(10):1648–52 (5 ref.) **(Jpn)**
[Countermeasure for patients with endocrine disorders due to hemodialysis] Nihei H. **Nippon Naika Gakkai Zasshi** 1995 Oct 10;84(10):1691–5 (5 ref.) **(Jpn)**
[Problems in patients on long-term hemodialysis] Osawa G. **Nippon Naika Gakkai Zasshi** 1995 Oct 10;84(10):1658–62 (5 ref.) **(Jpn)**
[Countermeasure for patients with anemia due to hemodialysis] Suzuki M. **Nippon Naika Gakkai Zasshi** 1995 Oct 10;84(10):1663–7 (5 ref.) **(Jpn)**
[Countermeasure for patients with cardiovascular diseases due to hemodialysis] Tabei K, et al. **Nippon Naika Gakkai Zasshi** 1995 Oct 10;84(10):1678–84 (5 ref.) **(Jpn)**
[Anti-hypertensive therapy in chronic hemodialysis] Takabatake T. **Nippon Naika Gakkai Zasshi** 1995 Oct 10; 84(10):1643–7 (5 ref.) **(Jpn)**
[Countermeasure for patients with infectious disease due to hemodialysis] Yokoyama H, et al. **Nippon Naika Gakkai Zasshi** 1995 Oct 10;84(10):1696–700 (7 ref.) **(Jpn)**

INSTRUMENTATION

The dialysis prescription: reuse. Maidment HJ, et al. **Am J Nephrol** 1996;16(1):52–9 (73 ref.)
Hemodialyzer performance: biological indices. Holmes CJ. **Artif Organs** 1995 Nov;19(11):1126–35 (62 ref.)
Hemodialyzer performance: a review of the trends over the past two decades. Woffindin C, et al. **Artif Organs** 1995 Nov;19(11):1113–9 (14 ref.)
Biocompatibility aspects of chronic hemodialysis and their clinical relevance. Wauters JP. **Clin Nephrol** 1995 Nov;44 Suppl 1:S19–23 (43 ref.)
Membranes for dialysis. Klinkmann H, et al. **Nephrol Dial Transplant** 1995;10 Suppl 3:39–45 (43 ref.)
Biocompatible intermittent hemodialysis. Lang S, et al. **New Horiz** 1995 Nov;3(4):680–7 (56 ref.)
On-line monitoring of the delivery of the hemodialysis prescription. Keshaviah PR, et al. **Pediatr Nephrol** 1995;9 Suppl:S2–8 (23 ref.)
On-line dialyser clearance using conductivity. Polaschegg HD. **Pediatr Nephrol** 1995;9 Suppl:S9–11 (14 ref.)

METHODS

Vitamin B6 and hemodialysis: the impact of high-flux/high-efficiency dialysis and review of the literature. Kasama R, et al. **Am J Kidney Dis** 1996 May; 27(5):680–6 (17 ref.)
Water treatment for hemodialysis. Ismail N, et al. **Am J Nephrol** 1996;16(1):60–72 (86 ref.)
Pharmacokinetics of continuous renal replacement therapy. Schetz M, et al. **Intensive Care Med** 1995 Jul;21(7):612–20 (33 ref.)
Acute renal failure in the intensive care unit: adequacy of dialysis and the case for continuous therapies. Bellomo R, et al. **Nephrol Dial Transplant** 1996 Mar;11(3):424–8 (69 ref.)
Upper arm arteriovenous fistula for chronic hemodialysis: 20 years later. Dagher FJ. **Transplant Proc** 1996 Aug; 28(4):2325–7 (12 ref.)
[What are the advances in the treatment of acute kidney failure? (editorial)] Brivet F, et al. **Presse Med** 1996 Feb 17;25(6):227–9 (13 ref.) (Eng. Abstr.) **(Fre)**

MORTALITY

Morbidity and mortality in hemodialysis: the role of schedules. Berland Y, et al. **Artif Organs** 1995 Aug; 19(8):827–31 (24 ref.)

PSYCHOLOGY

Working with noncompliant and abusive dialysis patients: practical strategies based on ethics and the law. Johnson CC, et al. **Adv Ren Replace Ther** 1996 Jan;3(1):77–86 (40 ref.)
Psychosocial burdens of dialysis treatment modalities: do they differ and does it matter? Reynolds JM, et al. **Perit Dial Int** 1996;16 Suppl 1:S548–50 (13 ref.)

STANDARDS

Impaired delivery of dialysis: diagnosis and correction. Delmez JA, et al. **Am J Nephrol** 1996;16(1):29–34 (15 ref.)
Adequacy of dialysis in the acute renal failure of the critically ill: the case for continuous therapies. Bellomo R, et al. **Int J Artif Organs** 1996 Feb;19(2):129–42 (190 ref.)
[Index for ideal hemodialysis and the evaluation] Maeda K. **Nippon Naika Gakkai Zasshi** 1995 Oct 10;84(10):1627–31 (5 ref.) **(Jpn)**

STATISTICS & NUMERICAL DATA

[Dialysis therapy in the Czech Republic in 1994] Lachmanová J, et al. **Cas Lek Cesk** 1995 Nov 15; 134(22):711–5 (5 ref.) (Eng. Abstr.) **(Cze)**

TRENDS

Reading the changes: new frontiers in dialysis [editorial] Bonomini V. **Int J Artif Organs** 1995 Feb;18(2):59–63 (15 ref.)
Dialysis: current status, contemporary limitations and future challenges. Malluche HH, et al. **Kidney Int Suppl** 1995 Aug; 50:S37–9 (19 ref.)

HEMODIALYSIS, HOME

Home hemodialysis: survival, quality of life, and rehabilitation. Oberley ET, et al. **Adv Ren Replace Ther** 1996 Apr;3(2):147–53 (39 ref.)
[Present significance of home hemodialysis] Ota K.

Nippon Naika Gakkai Zasshi 1995 Oct 10;84(10):1653–7 (3 ref.) **(Jpn)**

METHODS

Daily home hemodialysis: a hybrid of hemodialysis and peritoneal dialysis. Twardowski ZJ.
Adv Ren Replace Ther 1996 Apr;3(2):124–32 (55 ref.)

HEMODILUTION

Blood use in cardiac surgery and the limitations of hemodilution. Mossad E, et al. **Curr Opin Cardiol** 1995 Nov; 10(6):584–90 (44 ref.)

Consensus conference on autologous transfusion. Acute normovolaemic haemodilution. Gillon J, et al.
Transfusion 1996 Jul;36(7):640–3 (45 ref.)

STANDARDS

From low hematocrit physiology to isovolemic hemodilution. Oriani G, et al. **Int J Artif Organs** 1995 Mar;18(3):143–9 (19 ref.)

HEMODYNAMICS

Cardiovascular effects of increasing hemoglobin in chronic renal failure [editorial] Mayer G, et al. **Am J Nephrol** 1996; 16(4):263–7 (40 ref.)

Newer methods of improving blood flow during CPR. Halperin HR, et al. **Ann Emerg Med** 1996 May;27(5):553–62 (69 ref.)

Hemodynamic mechanisms of neurogenic pulmonary edema. Chen HI. **Biol Signals** 1995 May–Jun;4(3):186–92 (40 ref.)

Hemodynamic changes as triggers of cardiovascular events. Deedwania PC. **Cardiol Clin** 1996 May;14(2):229–38 (57 ref.)

Hemodynamic variability and myocardial ischemia. Deedwania PC. **Cardiol Clin** 1995 Nov;13(4):491–500 (37 ref.)

Current concepts of renal hemodynamics in diabetes. Anderson S, et al. **J Diabetes Complications** 1995 Oct–Dec; 9(4):304–7 (35 ref.)

New concepts in the pathophysiology of heart failure: beneficial and deleterious interaction of endogenous haemodynamic and neurohormonal mechanisms. Packer M. **J Intern Med** 1996 Apr;239(4):327–33 (28 ref.)

Hemodynamic management of brain-injured patients. Tonnesen AS. **New Horiz** 1995 Aug;3(3):499–505 (33 ref.)

[Hemodynamic profile and serum cytokines in crush syndrome. Analogy with severe burns] Gueugniaud PY, et al. **Presse Med** 1996 Mar 16;25(9):449–51 (16 ref.) (Eng. Abstr.) **(Fre)**

[Hemodynamic management of septic shock. From a global approach to a gastrointestinal approach] Teboul JL, et al. **Presse Med** 1996 Mar 30;25(11):549–54 (28 ref.) (Eng. Abstr.) **(Fre)**

[From left hypertrophy to heart insufficiency: hemodynamic and clinical findings] Sütsch G, et al.
Schweiz Rundsch Med Prax 1996 Feb 20;85(8):218–26 (75 ref.) (Eng. Abstr.) **(Ger)**

[Hemodynamics in obesity] Sugimoto T, et al.
Nippon Rinsho 1995 Jun;53 Suppl:325–31 (9 ref.) **(Jpn)**

[Cardiovascular and hemodynamic changes after artificial pulmonary ventilation] Gecelovská V, et al.
Bratisl Lek Listy 1996 May;97(5):260–6 (45 ref.) (Eng. Abstr.) **(Slo)**

DRUG EFFECTS

Hemodynamic effects of renin inhibitors. Kleinert HD.
Am J Nephrol 1996;16(3):252–60 (58 ref.)

Circulatory effects of desflurane. Coriat P. **Anaesthesia** 1995 Oct;50 Suppl:18–21 (19 ref.)

Cardiovascular effects of desflurane in experimental animals and volunteers. Weiskopf RB. **Anaesthesia** 1995 Oct;50 Suppl:14–7 (29 ref.)

Vascular selective calcium entry blockers in the treatment of cardiovascular disorders: focus on felodipine. Little WC, et al. **Cardiovasc Drugs Ther** 1995 Oct;9(5):657–63 (49 ref.)

Vascular effects of selected antihypertensive drugs derived from traditional medicinal herbs. Kwan CY.
Clin Exp Pharmacol Physiol 1995 Dec;22 Suppl 1:S297–9 (12 ref.)

Amlodipine. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease [published erratum appears in Drugs 1995 Nov;50(5):896] Haria M, et al. **Drugs** 1995 Sep;50(3):560–86 (196 ref.)

Refocus on diuretics in the treatment of heart failure. Taylor SH. **Eur Heart J** 1995 Jul;16 Suppl F:7–15 (86 ref.)

Haemodynamic and rheological effects of contrast media: the role of viscosity and osmolality. Pugh ND.
Eur Radiol 1996;6 Suppl 2:S13–5 (12 ref.)

Drug differences between ACE inhibitors in experimental settings and clinical practice. Voors AA, et al.
J Cardiovasc Risk 1995 Oct;2(5):413–22 (105 ref.)

[Renal function during treatment with angiotensin converting enzyme inhibitors] Rasmussen K, et al. **Ugeskr Laeger** 1995 Sep 25;157(39):5377–81 (17 ref.) (Eng. Abstr.) **(Dan)**

[Influence of surfactants on hemodynamics during neonatal respiratory distress syndrome] Pladys P, et al.
Arch Pediatr 1996 Feb;3(2):156–63 (78 ref.) (Eng. Abstr.) **(Fre)**

[Pharmacology of nitrates and other NO donors] Dendorfer A. **Herz** 1996 Jun;21 Suppl 1:38–49 (54 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Arterial compliance in hypertension and diabetes mellitus. McVeigh GE. **Am J Nephrol** 1996;16(3):217–22 (52 ref.)

Arterial and cardiac changes in hypertension in the elderly. Asmar R, et al. **Blood Press Suppl** 1995;3:31–7 (48 ref.)

The effect of prosthesis-patient mismatch on aortic bioprosthetic valve hemodynamic performance and patient clinical status. Pibarot P, et al. **Can J Cardiol** 1996 Apr; 12(4):379–87 (43 ref.)

The renin-angiotensin-aldosterone system and myocardial collagen matrix remodelling in congestive heart failure. Brilla CG, et al. **Eur Heart J** 1995 Dec;16 Suppl O:107–9 (24 ref.)

Changes in neurohumoral systems during the development of congestive heart failure: impact on cardiovascular and renal function. Elsner D. **Eur Heart J** 1995 Dec;16 Suppl N:52–8 (37 ref.)

The cardiomyopathy of overload: an unnatural growth response. Katz AM. **Eur Heart J** 1995 Dec;16 Suppl O:110–4 (73 ref.)

Evolution of the neurohormonal hypothesis to explain the progression of chronic heart failure. Packer M.
Eur Heart J 1995 Jul;16 Suppl F:4–6 (40 ref.)

Autonomic cardiovascular control in pregnancy. Ekholm EM, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Jan; 64(1):29–36 (75 ref.)

The role of the autonomic nervous system in hypertension. Amerena J, et al. **Hypertens Res** 1995 Jun;18(2):99–110 (119 ref.)

Contribution of the cerebellar vermis to cardiovascular control. Ghelarducci B, et al. **J Auton Nerv Syst** 1996 Jan 5;56(3):149–56 (51 ref.)

Controlling the hemodynamic response to laryngoscopy and endotracheal intubation. Kovac AL. **J Clin Anesth** 1996 Feb;8(1):63–79 (166 ref.)

The role of nitric oxide in the hyperdynamic circulatory syndrome associated with portal hypertension. Sogni P, et al. **J Hepatol** 1995 Aug;23(2):218–24 (78 ref.)

Large artery function and alterations in hypertension. London GM. **J Hypertens Suppl** 1995 Aug;13(2):S35–8 (23 ref.)

The emerging concept of relaxin as a centrally acting peptide hormone with hemodynamic actions. Geddes BJ, et al.
J Neuroendocrinol 1995 Jun;7(6):411–7 (89 ref.)

Complications of Swan-Ganz catheterization for hemodynamic monitoring in patients with subarachnoid hemorrhage. Rosenwasser RH, et al. **Neurosurgery** 1995 Nov;37(5):872–5; discussion 875–6 (21 ref.)

Systemic hemodynamic changes in portal hypertension. Ready J, et al. **Semin Gastrointest Dis** 1995 Jul;6(3):134–9 (58 ref.)

Hemodynamic consequences of therapeutic portosystemic shunting: recent experience with transjugular intrahepatic portosystemic shunts. Somberg KA.
Semin Gastrointest Dis 1995 Jul;6(3):165–77 (58 ref.)

[Cardiovascular function during laparoscopic interventions in surgery and gynecology] Berg K, et al.
Anasthesiol Intensivmed Notfallmed Schmerzther 1995 Nov; 30(7):446–50 (28 ref.) **(Ger)**

[Methods of microcirculatory monitoring (laser Doppler flowmetry, photoplethysmography and computer-assisted venous occlusion plethysmography)] Christ F.
Anasthesiol Intensivmed Notfallmed Schmerzther 1996 May; 31(1 Suppl):S37–43 (77 ref.) **(Ger)**

[Pulmonary artery catheter. Theory and practice] Versprille A. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May;31(1 Suppl):S9–16 (22 ref.) **(Ger)**

[Nitric oxide: the endogenous nitrate in the cardiovascular system] Tschudi MR, et al. **Herz** 1996 Jun;21 Suppl 1:50–60 (104 ref.) (Eng. Abstr.) **(Ger)**

[Biomechanical heart and cardiovascular support] Lange R, et al. **Zentralbl Chir** 1996;121(4):263–77 (121 ref.) (Eng. Abstr.) **(Ger)**

[Shear stress and vascular formation] Ando J.
Nippon Yakurigaku Zasshi 1996 Mar;107(3):141–52 (50 ref.) (Eng. Abstr.) **(Jpn)**

[Hemodynamic evaluation of congenital heart defects by Doppler echocardiography] Martins TC, et al.
Arq Bras Cardiol 1995 Apr;64(4):409–15 (41 ref.) **(Por)**

[Cardiorespiratory system adaptation after surgical correction of intracardiac hemodynamics] Shevchenko IuL.
Fiziol Cheloveka 1996 Mar–Apr;22(2):20–4 (14 ref.) **(Rus)**

HEMOFILTRATION

Drug removal in continuous haemofiltration and haemodialysis. Davies JG, et al. **Br J Hosp Med** 1995 Nov 15–Dec 12;54(10):524–8 (30 ref.)

Nonrenal indications for continuous hemofiltration therapy in patients with normal renal function? Druml W.
Contrib Nephrol 1995;116:121–9 (36 ref.)

Complement fragments and cytokines: production and removal as consequences of hemofiltration. Journois D.
Contrib Nephrol 1995;116:80–5 (23 ref.)

Mediators in continuous extracorporeal treatment of multiple organ dysfunction syndrome. Sunder-Plassmann G, et al.
Contrib Nephrol 1995;116:10–5 (46 ref.)

Treatment of acute renal failure in intensive care patients. Böhler J. **Int J Artif Organs** 1996 Feb;19(2):108–10 (8 ref.)

Management of fluid imbalance. Eckart J, et al.
Int J Artif Organs 1996 Feb;19(2):106–7 (16 ref.)

Acute renal failure in infants and children. Ehrich JH.
Int J Artif Organs 1996 Feb;19(2):121–3 (9 ref.)

Elimination of inflammatory mediators by hemofiltration. Inthorn D, et al. **Int J Artif Organs** 1996 Feb;19(2):124–6 (29 ref.)

Pharmacokinetics during continuous renal replacement therapy. Keller E. **Int J Artif Organs** 1996 Feb;19(2):113–7 (8 ref.)

Practical aspects of renal replacement therapy. Kox WJ, et al. **Int J Artif Organs** 1996 Feb;19(2):100–5 (17 ref.)

Basic mechanisms and definitions for continuous renal replacement therapies. Ronco C, et al.
Int J Artif Organs 1996 Feb;19(2):95–9 (21 ref.)

Acute renal failure in infancy: treatment by continuous renal replacement therapy. Ronco C, et al.
Intensive Care Med 1995 Jun;21(6):490–9 (47 ref.)

Drug administration in critically ill patients with acute renal failure. Kroh UF. **New Horiz** 1995 Nov;3(4):748–59 (42 ref.)

Azotemia control by extracorporeal therapy in patients with acute renal failure. Macias WL, et al. **New Horiz** 1995 Nov; 3(4):688–98 (62 ref.)

ADVERSE EFFECTS

Impact of continuous renal replacement therapies on metabolism. Druml W. **Int J Artif Organs** 1996 Feb; 19(2):118–20 (1 ref.)

INSTRUMENTATION

[Current data on the counting of weak leukocyte concentrations in labile blood products] Masse M.
Transfus Clin Biol 1995;2(5):365–72 (19 ref.) (Eng. Abstr.) **(Fre)**

METHODS

Low blood flow extracorporeal carbon dioxide removal (ECCO2R): a review of the concept and a case report. Habashi NM, et al. **Intensive Care Med** 1995 Jul;21(7):594–7 (33 ref.)

Pharmacokinetics of continuous renal replacement therapy. Schetz M, et al. **Intensive Care Med** 1995 Jul;21(7):612–20 (33 ref.)

Continuous treatment modalities in acute renal failure. Kierdorf H, et al. **Nephrol Dial Transplant** 1995 Nov; 10(11):2001–8 (49 ref.)

Continuous hemofiltration as blood purification in sepsis. Bellomo R. **New Horiz** 1995 Nov;3(4):732–7 (30 ref.)

Continuous hemofiltration for the failing heart. Coraim FI, et al. **New Horiz** 1995 Nov;3(4):725–31 (44 ref.)

The management of renal failure in patients at risk of cerebral edema/hypoxia. Davenport A. **New Horiz** 1995 Nov; 3(4):717–24 (54 ref.)

Achievements and new directions in continuous renal replacement therapies. Ronco C, et al. **New Horiz** 1995 Nov;3(4):708–16 (35 ref.)

[What are the advances in the treatment of acute kidney failure? (editorial)] Brivet F, et al. **Presse Med** 1996 Feb 17;25(6):227–9 (13 ref.) (Eng. Abstr.) **(Fre)**

NURSING

Continuous hemofiltration: nursing perspectives in critical care. Baldwin IC, et al. **New Horiz** 1995 Nov;3(4):738–47 (34 ref.)

STANDARDS

Adequacy of dialysis in the acute renal failure of the critically ill: the case for continuous therapies. Bellomo R, et al.
Int J Artif Organs 1996 Feb;19(2):129–42 (190 ref.)

TRENDS

Achievements and new directions in continuous renal replacement therapies. Ronco C, et al. **New Horiz** 1995 Nov;3(4):708–16 (35 ref.)

HEMOFILTRATION, CONTINUOUS ARTERIOVENOUS
see HEMOFILTRATION

HEMOGLOBIN A, GLYCOSYLATED

ANALYSIS

Endocrine (standardization of glycohemoglobin measurement). Little RR, et al. **Anal Chem** 1995 Jun 15; 67(12):393R–397R (43 ref.)

Hemoglobin variants recently detected in Austria. Schnedl WJ, et al. **Ann Hematol** 1995 Oct;71(4):185–7 (23 ref.)

An alternative approach to the diagnosis of diabetes with a review of the literature. Davidson MB, et al.
Diabetes Care 1995 Jul;18(7):1065–71 (49 ref.)

[Respective value of glycated hemoglobin and fructosamine assays in the care of diabetes mellitus] Bernard M, et al. **Ann Biol Clin (Paris)** 1995;53(6):321–7 (52 ref.) (Eng. Abstr.) **(Fre)**

[Evaluation of assay methods of glycohemoglobin: reference method and parameter] Gillery P, et al.
Ann Biol Clin (Paris) 1995;53(7–8):395–8 (29 ref.) (Eng. Abstr.) **(Fre)**

HEMOGLOBIN A, GLYCOSYLATED

[Glycated Hb (glycated hemoglobin)] Kawahara R. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:543–5 (8 ref.) **(Jpn)**

HEMOGLOBIN A(1) see **HEMOGLOBIN A, GLYCOSYLATED**

HEMOGLOBIN, ERYTHROCYTE, MEAN CELL see **ERYTHROCYTE INDICES**

HEMOGLOBIN F see **FETAL HEMOGLOBIN**

HEMOGLOBIN F DISEASE see **BETA-THALASSEMIA**

HEMOGLOBIN H DISEASE see **ALPHA-THALASSEMIA**

HEMOGLOBIN SUBSTITUTES see **BLOOD SUBSTITUTES**

HEMOGLOBINOPATHIES

DIAGNOSIS

Advances in the prenatal and molecular diagnosis of the hemoglobinopathies and thalassemias. Embury SH. **Hemoglobin** 1995 Sep;19(5):237–61 (125 ref.)

Prenatal screening for haemoglobin disorders [see comments] Petrou M, et al. **Prenat Diagn** 1995 Dec;15(13):1275–95 (60 ref.) Comment in: Prenat Diagn 1995 Dec;15(13):1209–13.

[Hemoglobinopathy] Ohba Y. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:177–9 (9 ref.) **(Jpn)**

EMBRYOLOGY

Symmetrical terminal transverse limb defects: report of a twenty-week fetus. Harmon JV Jr, et al. **Teratology** 1995 Apr;51(4):237–42 (18 ref.)

PREVENTION & CONTROL

Adult screening for anemia and hemoglobinopathies. **Nurse Pract** 1995 Dec;20(12):48–51 (9 ref.)

Prenatal screening for haemoglobin disorders [see comments] Petrou M, et al. **Prenat Diagn** 1995 Dec;15(13):1275–95 (60 ref.) Comment in: Prenat Diagn 1995 Dec;15(13):1209–13.

THERAPY

Novel treatment options in the severe beta-globin disorders. Rodgers GP, et al. **Br J Haematol** 1995 Oct;91(2):263–8 (63 ref.)

Towards gene therapy of hemoglobinopathies. Beuzard Y. **Semin Hematol** 1996 Jan;33(1):43–52 (61 ref.)

HEMOGLOBINS

Haemoglobin engineering. For fun and money. Brunori M, et al. **Curr Biol** 1995 May 1;5(5):462–5 (18 ref.)

ANALYSIS

Cardiovascular effects of increasing hemoglobin in chronic renal failure [editorial] Mayer G, et al. **Am J Nephrol** 1996; 16(4):263–7 (40 ref.)

[Hemoglobin (Hb) and its components] Dan K. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:173–6 (11 ref.) **(Jpn)**

CHEMISTRY

Engineering and design of blood substitutes. Sanders KE, et al. **Curr Opin Struct Biol** 1996 Aug;6(4):534–40 (60 ref.)

Continuous fetal monitoring of HbO2 with pulse oximetry. Knitza R, et al. **J Perinat Med** 1996;24(1):55–9 (5 ref.)

DRUG EFFECTS

Hemoglobin adducts for in vivo dose monitoring and cancer risk estimation. Törnqvist M, et al. **J Occup Environ Med** 1995 Sep;37(9):1077–85 (41 ref.)

GENETICS

A brief history of hemoglobins: plant, animal, protist, and bacteria. Hardison RC. **Proc Natl Acad Sci U S A** 1996 Jun 11;93(12):5675–9 (33 ref.)

[Expression of recombinant human hemoglobin in plants] Dieryck W, et al. **Transfus Clin Biol** 1995;2(6):441–7 (40 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Production of monoclonal and polyclonal antibodies against various haemoglobins for the detection of thalassaemias. Gan YY, et al. **Ann Acad Med Singapore** 1996 Jan; 25(1):75–8 (20 ref.)

METABOLISM

The implications for risk assessment of measuring the relative contribution to exposure from occupation, environment and lifestyle: hemoglobin adducts from amino- and nitro-arenes. Neumann HG, et al. **Toxicol Lett** 1995 Dec; 82–83:771–8 (20 ref.)

Oxygen delivery and autoxidation of hemoglobin. Marden MC, et al. **Transfus Clin Biol** 1995;2(6):473–80 (21 ref.)

PHYSIOLOGY

The multiple functions of hemoglobin. Giardina B, et al. **Crit Rev Biochem Mol Biol** 1995;30(3):165–96 (110 ref.)

Haemoglobin function in intact lamprey erythrocytes: interactions with membrane function in the regulation of gas transport and acid-base balance. Nikinmaa M, et al. **J Exp Biol** 1995 Dec;198 (Pt 12):2423–30 (42 ref.)

THERAPEUTIC USE

Modified haemoglobins as oxygen-transporting blood substitutes. Mallick A, et al. **Br J Hosp Med** 1996 Apr 3–16;55(7):443–8 (20 ref.)

TOXICITY

Review of modified hemoglobin research at Letterman: attempts to delineate the toxicity of cell-free tetrameric hemoglobin. Hess JR. **Artif Cells Blood Substit Immobil Biotechnol** 1995; 23(3):277–89 (30 ref.)

HEMOGLOBINS, ABNORMAL

ANALYSIS

Characterizing abnormal hemoglobin by MS. Shackleton CH, et al. **Anal Chem** 1996 Jan 1;68(1):29A–33A (23 ref.)

Hemoglobin variants recently detected in Austria. Schnedl WJ, et al. **Ann Hematol** 1995 Oct;71(4):185–7 (23 ref.)

GENETICS

German population data on the loci low-density-lipoprotein receptor, glycophorin A, hemoglobin gamma G, D7S8 and group-specific component. Huckenbeck W, et al. **Anthropol Anz** 1995 Sep;53(3):193–8 (14 ref.)

Prevention of beta-thalassemia major and Hb Bart's hydrops fetalis syndrome. Beris P, et al. **Semin Hematol** 1995 Oct; 32(4):244–61 (86 ref.)

HEMOGLOBINURIA, PAROXYSMAL

BLOOD

[Characteristics and diagnostics of blood cell defects in paroxysmal nocturnal haemoglobinuria (NNH)] Bogdanik I. **Acta Haematol Pol** 1995;26(4):353–60 (36 ref.) (Eng. Abstr.) **(Pol)**

COMPLICATIONS

Cholangitis associated with paroxysmal nocturnal hemoglobinuria: another instance of ischemic cholangiopathy? Le Thi Huong D, et al. **Gastroenterology** 1995 Oct;109(4):1338–43 (52 ref.)

ETIOLOGY

[Etiology and pathogenesis of glycosylphosphatidylinositol anchor-linked membrane protein deficiency] Bogdanik I. **Acta Haematol Pol** 1995;26(3):239–46 (30 ref.) (Eng. Abstr.) **(Pol)**

GENETICS

Defective glycosyl phosphatidylinositol anchor synthesis and paroxysmal nocturnal hemoglobinuria. Kinoshita T, et al. **Adv Immunol** 1995;60:57–103 (275 ref.)

The molecular basis of paroxysmal nocturnal hemoglobinuria. Rosse WF, et al. **Blood** 1995 Nov 1;86(9):3277–86 (123 ref.)

The PIG-A gene somatic mutation responsible for paroxysmal nocturnal hemoglobinuria. Rotoli B, et al. **Haematologica** 1995 Nov-Dec;80(6):539–45 (44 ref.)

Glycosyl phosphatidylinositol-linked blood group antigens and paroxysmal nocturnal hemoglobinuria. Telen MJ. **Transfus Clin Biol** 1995;2(4):277–90 (73 ref.)

METABOLISM

Glycosylphosphatidylinositol (GPI)-anchored membrane proteins in clinical pathophysiology of paroxysmal nocturnal hemoglobinuria (PNH). Shichishima T. **Fukushima J Med Sci** 1995 Jun;41(1):1–13 (45 ref.)

PATHOLOGY

Defective glycosyl phosphatidylinositol anchor synthesis and paroxysmal nocturnal hemoglobinuria. Kinoshita T, et al. **Adv Immunol** 1995;60:57–103 (275 ref.)

PHYSIOPATHOLOGY

Role of phosphatidylinositol-linked proteins in paroxysmal nocturnal hemoglobinuria pathogenesis. Kinoshita T, et al. **Annu Rev Med** 1996;47:1–10 (48 ref.)

HEMOLYSINS

BIOSYNTHESIS

[Cytolysins and homologous proteins produced by gram-negative bacteria. I. Hemolysis and leukotoxins of Escherichia coli, Bordetella pertussis, Pasteurella haemolytica and Actinobacillus sp] Różalski A. **Postepy Hig Med Dosw** 1996;50(2):173–90 (103 ref.) (Eng. Abstr.) **(Pol)**

METABOLISM

Staphylococcal alpha-toxin, streptolysin-O, and Escherichia coli hemolysin: prototypes of pore-forming bacterial cytolysins. Bhakdi S, et al. **Arch Microbiol** 1996 Feb; 165(2):73–9 (45 ref.)

TOXICITY

Pathogenesis of sepsis syndrome: possible relevance of pore-forming bacterial toxins. Bhakdi S, et al. **Curr Top Microbiol Immunol** 1996;216:101–18 (64 ref.)

HEMOLYSIS

see related **ANEMIA, HEMOLYTIC**

HEMOLYTIC DISEASE OF NEWBORN see **ERYTHROBLASTOSIS, FETAL**

HEMOLYTIC-UREMIC SYNDROME

The hemolytic uremic syndrome. Remuzzi G, et al. **Kidney Int** 1995 Jul;48(1):2–19 (199 ref.)

COMPLICATIONS

Hyperglycemia in diarrhea-associated hemolytic-uremic syndrome. Robson WL, et al. **Nephron** 1995;71(1):54–8 (21 ref.)

DIAGNOSIS

[Neonatal hemolytic-uremic syndrome associated with methylmalonic aciduria and homocystinuria] Rogé Canales M, et al. **An Esp Pediatr** 1996 Jul;45(1):97–8 (8 ref.) **(Spa)**

EPIDEMIOLOGY

The hemolytic uremic syndrome. Siegler RL. **Pediatr Clin North Am** 1995 Dec;42(6):1505–29 (150 ref.)

ETIOLOGY

Hemolytic uremic syndrome after high dose chemotherapy with autologous stem cell support. van der Lelie H, et al. **Cancer** 1995 Dec 1;76(11):2338–42 (21 ref.)

Thrombotic microangiopathic syndromes after bone marrow transplantation [see comments] Byrnes JJ, et al. **Cancer Invest** 1996;14(2):151–7 (45 ref.) Comment in: Cancer Invest 1996;14(2):180–1.

Haemolytic uraemic syndrome following bone marrow transplantation. Case report and review of the literature. Verburgh CA, et al. **Nephrol Dial Transplant** 1996 Jul; 11(7):1332–7 (146 ref.)

Are there restrictions to vaccinating a child who has recovered from hemolytic uremic syndrome? Kaplan BS. **Pediatr Nephrol** 1996 Apr;10(2):138 (7 ref.)

Hemolytic uremic syndrome in solid-organ transplant recipients. Singh N, et al. **Transpl Int** 1996;9(1):68–75 (45 ref.)

GENETICS

[Familial and recurrent hemolytic-uremic syndrome: apropos a case] Barriuso Lapresa LM, et al. **An Esp Pediatr** 1996 Feb;44(2):167–9 (19 ref.) **(Spa)**

MICROBIOLOGY

Escherichia coli O157:H7 infections: a frequent cause of bloody diarrhea and the hemolytic-uremic syndrome. Cohen MB. **Adv Pediatr** 1996;43:171–207 (187 ref.)

[Infections with verocytotoxin-producing Escherichia coli and hemolytic-uremic syndrome] van de Kar NC, et al. **Ned Tijdschr Geneeskd** 1996 Jan 20;140(3):134–7 (22 ref.) (Eng. Abstr.) **(Dut)**

PHYSIOPATHOLOGY

Recurrent hemolytic uremic syndrome in an adult renal allograft recipient: current concepts and management. Agarwal A, et al. **J Am Soc Nephrol** 1995 Oct;6(4):1160–9 (41 ref.)

The hemolytic uremic syndrome. Siegler RL. **Pediatr Clin North Am** 1995 Dec;42(6):1505–29 (150 ref.)

THERAPY

Recurrent hemolytic uremic syndrome in an adult renal allograft recipient: current concepts and management. Agarwal A, et al. **J Am Soc Nephrol** 1995 Oct;6(4):1160–9 (41 ref.)

HEMOPERFUSION

Hybrid liver support [editorial] Gerlach J. **Int J Artif Organs** 1996 Jan;19(1):1–2 (8 ref.)

Assessment of bioartificial liver support in acute liver failure. Hughes RD, et al. **Int J Artif Organs** 1996 Jan;19(1):3–6 (18 ref.)

Use of continuous renal replacement therapy for detoxification? Riegel W. **Int J Artif Organs** 1996 Feb; 19(2):111–2 (9 ref.)

Basic mechanisms and definitions for continuous renal replacement therapies. Ronco C, et al.

Int J Artif Organs 1996 Feb;19(2):95-9 (21 ref.)

HEMOPERICARDIUM see PERICARDIAL EFFUSION

HEMOPERITONEUM

ETIOLOGY

Hemoperitoneum secondary to exogastric leiomyosarcoma: a case report. Tsianos GB, et al. **Hepatogastroenterology** 1995 Nov-Dec;42(6):885-7 (10 ref.)

Spontaneous hemoperitoneum. Lucha PA Jr. **J Am Osteopath Assoc** 1996 Jun;96(6):364-5 (7 ref.)

Autosomal dominant polycystic liver disease as an etiology for hemoperitoneum during CCPD. Rutecki GW, et al. **Perit Dial Int** 1995 Oct-Dec;15(8):367-9 (11 ref.)

[Hemoperitoneum due to coitus without vaginal lesions] Brühwiler H, et al. **Schweiz Med Wochenschr** 1995 Sep 2;125(35):1634-7 (14 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Interventional radiology in the treatment of blunt liver trauma: case report with review of literature. Harms J, et al. **Bildgebung** 1996 Mar;63(1):51-4 (22 ref.)

HEMOPEXIN

ANALYSIS

[Hemopexin] Matsuda J. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:224-6 (6 ref.) **(Jpn)**

CHEMISTRY

A helping hand for collagenases: the haemopexin-like domain. Bode W. **Structure** 1995 Jun 15;3(6):527-30 (49 ref.)

HEMOPHAGOCYTIC SYNDROME, INFECTION-ASSOCIATED see HISTIOCYTOSIS, NON-LANGERHANS-CELL

HEMOPHILIA

see related
HEMARTHROSIS

Sports and hemophilia: antagonist or protagonist. Buzzard BM. **Clin Orthop** 1996 Jul;(328):25-30 (29 ref.)

Hemophilia: an updated review. Bell B, et al. **Pediatr Rev** 1995 Aug;16(8):290-8 (24 ref.)

COMPLICATIONS

Prophylaxis and continuous infusion for hemophilia: can we afford it? Aledort LM, et al. **Blood Coagul Fibrinolysis** 1996 Mar;7 Suppl 1:S35-7 (5 ref.)

Acquired haemophilia: an important but often unrecognised cause of bleeding in elderly people. Evans EN, et al. **BMJ** 1995 Sep 9;311(7006):679 (3 ref.)

Hemophilic ankle arthropathy. Ribbans WJ, et al. **Clin Orthop** 1996 Jul;(328):39-45 (10 ref.)

Effects of hemophilia on articulations of children and adults. Rodríguez-Merchán EC. **Clin Orthop** 1996 Jul;(328):7-13 (17 ref.)

Why do hemophiliacs bleed? Agarwal BR, et al. **Indian Pediatr** 1995 Apr;32(4):505-9 (18 ref.)

The haemophilic pseudotumour. Rodriguez Merchan EC. **Int Orthop** 1995;19(4):255-60 (11 ref.)

A hemophiliac with human immunodeficiency virus (HIV)-1-associated dementia complex [see comments] Arimura H, et al. **Intern Med** 1995 Oct;34(10):995-9 (12 ref.) Comment in: Intern Med 1995 Oct;34(10):935.

Spinal extradural hematoma in an infant with hemophilia A: an unusual presentation of a rare complication. Hutt PJ, et al. **J Pediatr** 1996 May;128(5 Pt 1):704-6 (8 ref.)

Hemophilic arthropathy. Lan HH, et al. **Radiol Clin North Am** 1996 Mar;34(2):446-50 (16 ref.)

AIDS and hemophilia--current issues. Evatt BL. **Thromb Haemost** 1995 Jul;74(1):36-9 (46 ref.)

[Non-Hodgkin's lymphoma of the large intestine in an HIV-positive hemophiliac. A report of a case with an unusual presentation] Gigoni R, et al. **Radiol Med (Torino)** 1995 Sep;90(3):326-8 (11 ref.) **(Ita)**

[Spinal canal bleeding in hemophilia A] Morichika S, et al. **Rinsho Ketsueki** 1995 Jul;36(7):687-93 (16 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Hemophilia 1996. New approach to an old disease. DiMichele D. **Pediatr Clin North Am** 1996 Jun;43(3):709-36 (158 ref.)

[Hematologic causes of vascular diseases of the central nervous system] Arboix A, et al. **Rev Neurol** 1995;23 Suppl 1:S41-9 (62 ref.) **(Spa)**

DRUG THERAPY

Family issues in continuous infusion therapy with factor VIII. Manco-Johnson MJ. **Blood Coagul Fibrinolysis** 1996 Mar; 7 Suppl 1:S21-5 (13 ref.)

Factor VIII concentrates and the immune system--laboratory investigations. Wadhwa M, et al. **Blood Coagul Fibrinolysis** 1995 Jul;6 Suppl 2:S65-79 (73 ref.)

[Anti-hemophilia drugs: from cryoprecipitate to factor VIII concentrates of high purity] Gutsalo AE, et al. **Ukr Biokhim Zh** 1995 Jan-Feb;67(1):3-13 (62 ref.) (Eng. Abstr.) **(Rus)**

GENETICS

Molecular genetics of coagulation factor VIII gene and hemophilia A. Antonarakis SE. **Thromb Haemost** 1995 Jul; 74(1):322-8 (66 ref.)

NURSING

Hematologic problems in pediatric patients. Cahill M. **Semin Oncol Nurs** 1996 Feb;12(1):38-50 (42 ref.)

PHYSIOPATHOLOGY

Hemostasis: a practical review of conservative and operative care. Shopnick RI, et al. **Clin Orthop** 1996 Jul;(328):34-8 (39 ref.)

THERAPY

Continuous infusion of factor concentrates: review of use in hemophilia A and demonstration of safety and efficacy in hemophilia B. Martinowitz UP, et al. **Acta Haematol** 1995;94 Suppl 1:35-42 (30 ref.)

Modern treatment of haemophilia. Berntorp E, et al. **Bull World Health Organ** 1995;73(5):691-701 (45 ref.)

Haemophilia care in Zimbabwe. Adewuyi JO, et al. **Cent Afr J Med** 1996 May;42(5):153-6 (15 ref.)

Nonoperative management of a splenic tear in a Jehovah's Witness with hemophilia. Zieg PM, et al. **J Trauma** 1996 Feb;40(2):299-301 (21 ref.)

Hemophilia: yesterday, today, and tomorrow. Aledort LM. **Mt Sinai J Med** 1996 May-Sep;63(3-4):225-35 (21 ref.)

Hemophilia 1996. New approach to an old disease. DiMichele D. **Pediatr Clin North Am** 1996 Jun;43(3):709-36 (158 ref.)

State and prospects of gene therapy for the hemophilias. Fallaux FJ, et al. **Thromb Haemost** 1995 Jul;74(1):266-73 (64 ref.)

Effects of factor VIII concentrates on the immune system of patients with hemophilia. Mannucci PM. **Thromb Haemost** 1995 Jul;74(1):437-9 (19 ref.)

In vivo recovery of factor VIII following transfusion: a survey of recent data and publications to assess the influence of standards used for potency assignment. On behalf of the Subcommittee on Factor VIII and IX of the Scientific and Standardization Committee of the ISTH. Prowse CV. **Thromb Haemost** 1995 Oct;74(4):1191-6 (43 ref.)

Progress towards gene therapy for the hemophilias. Thompson AR. **Thromb Haemost** 1995 Jul;74(1):45-51 (58 ref.)

HEMOPHILIA A see HEMOPHILIA

HEMOPHILIA B see CHRISTMAS DISEASE

HEMOPHILIA, VASCULAR see VON WILLEBRAND'S DISEASE

HEMOPHILUS INFECTIONS see HAEMOPHILUS INFECTIONS

HEMOPHTHALMOS see EYE HEMORRHAGE

HEMOPNEUMOTHORAX

Spontaneous haemopneumothorax: a surgical emergency. Sharpe DA, et al. **Eur Respir J** 1995 Sep;8(9):1611-2 (16 ref.)

HEMOPTYSIS

DIAGNOSIS

Hemoptysis. Three questions that can direct management. Colice GL. **Postgrad Med** 1996 Jul;100(1):227-36 (16 ref.)

ETIOLOGY

Swan-Ganz catheter induced pulmonary artery perforation during cardiac surgery concerning two cases. Sekkal S, et al. **J Cardiovasc Surg (Torino)** 1996 Jun;37(3):313-7 (33 ref.)

[Hemoptysis in sarcoidosis. Apropos of 6 cases including 4 with fatal outcome] Lemay V, et al. **Rev Pneumol Clin** 1995;51(2):61-70 (45 ref.) (Eng. Abstr.) **(Fre)**

[Pulmonary endometriosis with recurrent catamenial hemoptysis] Ueno H, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Aug; 33(8):888-93 (19 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

[Menstruation-associated (catamenial) pneumothorax and catamenial hemoptysis] Hamacher J, et al. **Schweiz Med Wochenschr** 1996 May 25;126(21):924-32 (100 ref.) (Eng. Abstr.) **(Ger)**

RADIOGRAPHY

The role of radiology in the investigation and management of patients with haemoptysis. Marshall TJ, et al. **Clin Radiol** 1996 Jun;51(6):391-400 (66 ref.)

THERAPY

Hemoptysis. Three questions that can direct management. Colice GL. **Postgrad Med** 1996 Jul;100(1):227-36 (16 ref.)

[Failures and complications of bronchial artery embolization] Mesurolle B, et al. **Rev Mal Respir** 1996 Jul;13(3):217-25 (74 ref.) (Eng. Abstr.) **(Fre)**

HEMORHEOLOGY

Rheology of blood coagulation. Kaibara M. **Biorheology** 1996 Mar-Apr;33(2):101-17 (54 ref.)

Platelets and shear stress. Kroll MH, et al. **Blood** 1996 Sep 1;88(5):1525-41 (186 ref.)

Hemorheology in cerebrovascular accident: an overview. Hussain MA, et al. **J Assoc Physicians India** 1995 Apr; 43(4):283-6 (35 ref.)

Blood rheology in emergency medicine. Koppensteiner R. **Semin Thromb Hemost** 1996;22(1):89-91 (17 ref.)

Endothelial cell function, including tissue factor expression, under flow conditions. Grabowski EF, et al. **Thromb Haemost** 1995 Jul;74(1):123-8 (51 ref.)

Flow-related platelet deposition on subendothelium. Weiss HJ. **Thromb Haemost** 1995 Jul;74(1):117-22 (78 ref.)

[Rheologic and biophysical aspects of cellular adhesion and aggregation: importance in hemorheology] Stoltz JF, et al. **J Mal Vasc** 1995;20(4):247-51 (25 ref.) (Eng. Abstr.) **(Fre)**

[The importance of clinical hemorheology in the study of cerebral blood flow in normal conditions and in cerebrovascular ischemia] Melaragno Filho R. **Arq Neuropsiquiatr** 1995 Mar;53(1):157-68 (85 ref.) (Eng. Abstr.) **(Por)**

DRUG EFFECTS

Haemodynamic and rheological effects of contrast media: the role of viscosity and osmolality. Pugh ND. **Eur Radiol** 1996;6 Suppl 2:S13-5 (12 ref.)

TRENDS

[Outlook for clinical hemorheology] Stoltz JF. **J Mal Vasc** 1996;21(1):7-15 (131 ref.) (Eng. Abstr.) **(Fre)**

HEMORRHAGE

[Wünderlich syndrome. Review of its diagnosis and therapy. Report of 7 cases] López Cubillana P, et al. **Actas Urol Esp** 1995 Nov-Dec;19(10):772-6 (19 ref.) (Eng. Abstr.) **(Spa)**

CHEMICALLY INDUCED

Hemorrhagic complications of thrombolytic therapy in the treatment of myocardial infarction and venous thromboembolism. Levine MN, et al. **Chest** 1995 Oct;108(4 Suppl):291S-301S (86 ref.)

Hemorrhagic complications of anticoagulant treatment. Levine MN, et al. **Chest** 1995 Oct;108(4 Suppl):276S-290S (118 ref.)

Antithrombotic benefits and hemorrhagic risks of direct thrombin antagonists. Harker LA, et al. **Thromb Haemost** 1995 Jul;74(1):464-72 (80 ref.)

[Complications of thrombolytic therapy in pulmonary embolism] Meneveau N, et al. **Arch Mal Coeur Vaiss** 1995 Nov;88(11 Suppl):1769-76 (42 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

Primary angiitis of the central nervous system associated with Hodgkin's disease. Yuen RW, et al. **Arch Pathol Lab Med** 1996 Jun;120(6):573-6 (22 ref.)

The role of bacterial translocation on Kupffer cell immune function following hemorrhage. Chaudry IH, et al. **Prog Clin Biol Res** 1995;392:209-18 (54 ref.)

[Enterohaemorrhagic Escherichia coli O157:H7 infection] Michałowicz-Wojczyńska E, et al. **Pediatr Pol** 1996 May; 71(5):453-8 (40 ref.) (Eng. Abstr.) **(Pol)**

DIAGNOSIS

Spontaneous unilateral adrenal hemorrhage: computerized tomography and magnetic resonance imaging findings in 8 cases. Hoeffel C, et al. **J Urol** 1995 Nov;154(5):1647-51 (24 ref.)

[The diagnosis and therapy of acquired factor-VIII inhibitors in combination with lupus anticoagulants] Grossmann R, et al. **Dtsch Med Wochenschr** 1996 Jul 12;121(28-29):906-10 (14 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Massive endobronchial hemorrhage after pulmonary embolectomy. Shimokawa S, et al. **Ann Thorac Surg** 1996 Apr;61(4):1241-2 (11 ref.)

Acquired haemophilia: an important but often unrecognised cause of bleeding in elderly people. Evans EN, et al. **BMJ** 1995 Sep 9;311(7006):679 (3 ref.)

Bleeding and thrombosis in myeloproliferative disorders: mechanisms and treatment. Landolfi R, et al. **Crit Rev Oncol Hematol** 1995 Oct;20(3):203-22 (200 ref.)

Why do hemophiliacs bleed? Agarwal BR, et al.

Indian Pediatr 1995 Apr;32(4):505–9 (18 ref.)

Intramedullary haemorrhage due to AVM located within the medulla oblongata in a three year old child. Case report. Maggi G, et al. **J Neurosurg Sci** 1994 Dec;38(4):255–8 (15 ref.)

The effect of associated injuries, blood loss, and oxygen debt on death and disability in blunt traumatic brain injury: the need for early physiologic predictors of severity. Siegel JH. **J Neurotrauma** 1995 Aug;12(4):579–90 (18 ref.)

The bleeding risk in chronic haemodialysis: preventive strategies in high-risk patients. Janssen MJ, et al. **Neth J Med** 1996 May;48(5):198–207 (134 ref.)

Urethral prolapse: an often misdiagnosed cause of urogenital bleeding in girls. Anveden-Hertzberg L, et al. **Pediatr Emerg Care** 1995 Aug;11(4):212–4 (25 ref.)

Hemostatic complications in renal disorders of the young. Andrew M, et al. **Pediatr Nephrol** 1996 Feb;10(1):88–99 (135 ref.)

Hypothesis: vascular compromise is the central pathogenic mechanism for acute hemorrhagic pancreatitis. Blackstone MO. **Perspect Biol Med** 1995 Autumn;39(1):56–63 (23 ref.)

Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors. Skop BP, et al. **Psychosomatics** 1996 Jan–Feb;37(1):12–6 (41 ref.)

[Acute intrahepatic bleeding in a male patient with focal nodular hyperplasia] Dröge C, et al. **Dtsch Med Wochenschr** 1996 Jul 12;121(28–29):902–5 (22 ref.) (Eng. Abstr.) **(Ger)**

[Hemorrhage from the ORL area] Baerthold W. **Z Arztl Fortbild (Jena)** 1995 Dec;89(7):703–6 (0 ref.) (Eng. Abstr.) **(Ger)**

[Spinal canal bleeding in hemophilia A] Morichika S, et al. **Rinsho Ketsueki** 1995 Jul;36(7):687–93 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Hematologic disturbances in patients with nonhematologic neoplasms. II. Thrombosis, bleedings and leukemoid reaction] Kwiatkowski A, et al. **Przegl Lek** 1995; 52(8):410–2 (11 ref.) **(Pol)**

[Unilateral spontaneous adrenal hematoma: an unusual cause of retroperitoneal hemorrhage] Vendrell JR, et al. **Actas Urol Esp** 1996 Jan;20(1):59–62 (12 ref.) (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

The role of bacterial translocation on Kupffer cell immune function following hemorrhage. Chaudry IH, et al. **Prog Clin Biol Res** 1995;392:209–18 (54 ref.)

[Role of metabolic arachidonic acid cascade and prostaglandin E2 in the pathogenesis of immunodeficiency in traumatic shock and acute hemorrhage] Pavlovskii MP, et al. **Klin Khir** 1995;(4):35–8 (62 ref.) **(Ukr)**

PATHOLOGY

Henoch-Schonlein purpura presenting as hemorrhagic vesicles and bullae: case report and literature review. Wananukul S, et al. **Pediatr Dermatol** 1995 Dec;12(4):314–7 (17 ref.)

PHYSIOPATHOLOGY

The Ehlers-Danlos syndrome: a heritable collagen disorder as cause of bleeding. de Paepe A. **Thromb Haemost** 1996 Mar;75(3):379–86 (75 ref.)

PREVENTION & CONTROL

Efficacy of mesna for prevention of hemorrhagic cystitis after high-dose cyclophosphamide therapy. Haselberger MB, et al. **Ann Pharmacother** 1995 Sep;29(9):918–21 (21 ref.)

Prophylaxis and continuous infusion for hemophilia: can we afford it? Aledort LM, et al. **Blood Coagul Fibrinolysis** 1996 Mar;7 Suppl 1:S35–7 (5 ref.)

Oral administration of mesna with ifosfamide. Goren MP. **Semin Oncol** 1996 Jun;23(3 Suppl 6):91–6 (51 ref.)

THERAPY

Management of severe trauma. Part 2: Circulation and head injury. Pollard C. **Aust Fam Physician** 1995 Dec; 24(12):2230–3; quiz 2234–5 (0 ref.)

Bleeding and thrombosis in myeloproliferative disorders: mechanisms and treatment. Landolfi R, et al. **Crit Rev Oncol Hematol** 1995 Oct;20(3):203–22 (200 ref.)

Acute blood loss. Baron BJ, et al. **Emerg Med Clin North Am** 1996 Feb;14(1):35–55 (64 ref.)

Immune thrombocytopenia in children: the immune character of destructive thrombocytopenia and the treatment of bleeding. Imbach P. **Semin Thromb Hemost** 1995; 21(3):305–12 (69 ref.)

[Hemorrhage during the third stage of labor and the postpartum period] Hohlfeld P. **Rev Med Suisse Romande** 1996 Apr;116(4):261–5 (33 ref.) **(Fre)**

VETERINARY

Lameness, lesions of the claw of the dairy cow and subclinical laminitis [editorial; comment] Logue D. **Br Vet J** 1995 Jul–Aug;151(4):343–6 (16 ref.) Comment on: Br Vet J 1995 Jul–Aug;151(4):391–9.

Racing horses, nitroglycerin and exercise induced pulmonary haemorrhage (EIPH) [editorial; comment] Harkins JD, et al. **Equine Vet J** 1995 Jul;27(4):240–1 (12 ref.) Comment on: Equine Vet J 1995 Jul;27(4):275–9.

Autotransfusion in the emergency patient. Purvis D. **Vet Clin North Am Small Anim Pract** 1995 Nov; 25(6):1291–304 (59 ref.)

HEMORRHAGE, BILIARY TRACT see **HEMOBILIA**

HEMORRHAGE, CEREBRAL see **CEREBRAL HEMORRHAGE**

HEMORRHAGE, EYE see **EYE HEMORRHAGE**

HEMORRHAGE, FETOMATERNAL see **FETOMATERNAL TRANSFUSION**

HEMORRHAGE, GASTROINTESTINAL see **GASTROINTESTINAL HEMORRHAGE**

HEMORRHAGE, PEPTIC ULCER see **PEPTIC ULCER HEMORRHAGE**

HEMORRHAGE, POSTOPERATIVE see **POSTOPERATIVE HEMORRHAGE**

HEMORRHAGE, POSTPARTUM see **POSTPARTUM HEMORRHAGE**

HEMORRHAGE, RETINAL see **RETINAL HEMORRHAGE**

HEMORRHAGE, SUBARACHNOID see **SUBARACHNOID HEMORRHAGE**

HEMORRHAGE, SURGICAL see **BLOOD LOSS, SURGICAL**

HEMORRHAGE, UTERINE see **UTERINE HEMORRHAGE**

HEMORRHAGE, VITREOUS see **VITREOUS HEMORRHAGE**

HEMORRHAGIC DIATHESIS

DRUG THERAPY

Fibrin sealant in surgery of patients with a hemorrhagic diathesis. Martinowitz U, et al. **Thromb Haemost** 1995 Jul; 74(1):486–92 (81 ref.)

[Desmopressin in the treatment of hemorrhagic diathesis] Haar D, et al. **Ugeskr Laeger** 1995 Nov 27;157(48):6713–5 (35 ref.) (Eng. Abstr.) **(Dan)**

ETIOLOGY

[Delayed allergic reaction to Chlorambucil (Leukeran). Case report and literature review] Torricelli R, et al. **Schweiz Med Wochenschr** 1995 Oct 7;125(40):1870–3 (10 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Transient hemorrhagic diathesis associated with an inhibitor of prothrombin with lupus anticoagulant in a 1 1/2-year-old girl: report of a case and review of the literature. Lee MT, et al. **Am J Hematol** 1996 Apr; 51(4):307–14 (46 ref.)

HEMORRHAGIC DISEASE OF NEWBORN

Vitamin K deficiency and hemorrhage in infancy. Greer FR. **Clin Perinatol** 1995 Sep;22(3):759–77 (80 ref.)

HEMORRHAGIC DISEASE VIRUS, SIMIAN see **ARTERIVIRUS**

HEMORRHAGIC FEVER, DENGUE see **DENGUE**

HEMORRHAGIC FEVER, EBOLA

The role of molecular techniques in the understanding of emerging infections. Sable CA, et al. **Mol Med Today** 1996 Mar;2(3):120–8 (43 ref.)

[Ebola disease] Aizenstein O, et al. **Harefuah** 1995 Jun 15; 128(12):772–6 (43 ref.) **(Heb)**

DIAGNOSIS

Ebola virus disease. Recognizing the face of a rare killer. Sodhi A. **Postgrad Med** 1996 May;99(5):75–6, 78 (6 ref.)

EPIDEMIOLOGY

Lessons learned from the hantaviruses and other hemorrhagic fever viruses. Butler JC, et al. **Am J Med Sci** 1996 Jan; 311(1):55–9 (39 ref.)

Threat of Marburg and Ebola viral haemorrhagic fevers in Africa. Tukei PM. **East Afr Med J** 1996 Jan;73(1):27–31 (15 ref.)

HEMORRHAGIC FEVER, EPIDEMIC see **HEMORRHAGIC FEVER WITH RENAL SYNDROME**

HEMORRHAGIC FEVER, KOREAN see **HEMORRHAGIC FEVER WITH RENAL SYNDROME**

HEMORRHAGIC FEVER VIRUS, OMSK see **ENCEPHALITIS VIRUSES, TICK-BORNE**

HEMORRHAGIC FEVER WITH RENAL SYNDROME

DIAGNOSIS

Visualization of microcirculatory disorders in haemorrhagic fever with renal syndrome. Sirotin BZ, et al. **Nephrol Dial Transplant** 1996 Apr;11(4):721–2 (6 ref.)

ETIOLOGY

Hantaviruses are likely threat to NATO forces in Bosnia and Herzegovina and Croatia. Markotić A, et al. **Nat Med** 1996 Mar;2(3):269–70 (18 ref.)

[Problems in the pathogenesis and pathogenetic therapy of hemorrhagic fever with renal syndrome] Siromin BZ, et al. **Ter Arkh** 1995;67(11):30–3 (23 ref.) (Eng. Abstr.) **(Rus)**

PATHOLOGY

[Advances in pathology of infectious diseases in China] Liu Y. **Chung Hua Ping Li Hsueh Tsa Chih** 1995 Aug; 24(4):255–7 (19 ref.) **(Chi)**

THERAPY

[Problems in the pathogenesis and pathogenetic therapy of hemorrhagic fever with renal syndrome] Siromin BZ, et al. **Ter Arkh** 1995;67(11):30–3 (23 ref.) (Eng. Abstr.) **(Rus)**

HEMORRHAGIC FEVERS, VIRAL

Viral haemorrhagic fevers: current status, future threats. Speed BR, et al. **Med J Aust** 1996 Jan 15;164(2):79–83 (31 ref.)

[Viral hemorrhagic fever] Matsumoto K. **Ryoikibetsu Shokogun Shirizu** 1995;(8):291–3 (0 ref.) **(Jpn)**

PATHOLOGY

The lesional changes and pathogenesis in the kidney in African swine fever. Hervás J, et al. **Vet Res Commun** 1996; 20(3):285–99 (44 ref.)

PREVENTION & CONTROL

Patients infected with high-hazard viruses: scientific basis for infection control. Peters CJ, et al. **Arch Virol Suppl** 1996;11:141–68 (86 ref.)

TRANSMISSION

Patients infected with high-hazard viruses: scientific basis for infection control. Peters CJ, et al. **Arch Virol Suppl** 1996;11:141–68 (86 ref.)

Ebola virus transmission [editorial] Irving WL. **Int J Exp Pathol** 1995 Aug;76(4):225–6 (14 ref.)

HEMORRHAGIC NEPHROSO-NEPHRITIS see **HEMORRHAGIC FEVER WITH RENAL SYNDROME**

HEMORRHAGIC THROMBOCYTHEMIA see **THROMBOCYTHEMIA, HEMORRHAGIC**

HEMORRHOIDS

Anorectal disorders. Five common causes of pain, itching, and bleeding. Metcalf A. **Postgrad Med** 1995 Nov; 98(5):81–4, 87–9, 92–4 (19 ref.)

[Hemorrhoidal thrombosis and perianal hematoma: diagnosis and treatment] Delaini GG, et al. **Ann Ital Chir** 1995 Nov–Dec;66(6):783–5 (8 ref.) (Eng. Abstr.) **(Ita)**

DIAGNOSIS

[Clinical manifestations and diagnosis of hemorrhoids] Arullani A, et al. **Ann Ital Chir** 1995 Nov–Dec;66(6):751–6 (12 ref.) (Eng. Abstr.) **(Ita)**

ETIOLOGY

[Hemorrhoids. Review] Vanheuverzwyn R, et al. **Acta Gastroenterol Belg** 1995 Sep–Dec;58(5–6):452–64 (80 ref.) (Eng. Abstr.) **(Fre)**

[Etiopathogenesis and physiopathology of hemorrhoidal disease] Segre D. **Ann Ital Chir** 1995 Nov–Dec;66(6):747–50 (17 ref.) (Eng. Abstr.) **(Ita)**

PHYSIOPATHOLOGY

[Anorectal manometry in hemorrhoidal disease] Girardi S, et al. **Ann Ital Chir** 1995 Nov–Dec;66(6):757–60 (17 ref.) (Eng. Abstr.) **(Ita)**

[Etiopathogenesis and physiopathology of hemorrhoidal disease] Segre D. **Ann Ital Chir** 1995 Nov–Dec;66(6):747–50 (17 ref.) (Eng. Abstr.) **(Ita)**

SURGERY

[Hemorrhoidectomy: current status] Watson SJ, et al. **Chirurg** 1996 Mar;67(3):213–21 (92 ref.) (Eng. Abstr.) **(Ger)**

[Complications of the surgical treatment of hemorrhoids and its therapy] Corno F, et al. **Ann Ital Chir** 1995 Nov–Dec; 66(6):813–6 (15 ref.) (Eng. Abstr.) **(Ita)**

[Hemorrhoidectomy: Milligan and Morgan technique] Di Bella F, et al. **Ann Ital Chir** 1995 Nov–Dec;66(6):791–9 (20 ref.) (Eng. Abstr.) **(Ita)**

[Closed hemorrhoidectomy] Pescatori M. **Ann Ital Chir** 1995 Nov–Dec;66(6):787–90 (4 ref.) (Eng. Abstr.) **(Ita)**

[Submucosal reconstructive hemorrhoidectomy (A.G. Parks operation)] Rosa G, et al. **Ann Ital Chir** 1995 Nov–Dec; 66(6):805–8 (7 ref.) (Eng. Abstr.) **(Ita)**

THERAPY

[Conservative therapy of hemorrhoids] Battocchio F, et al. **Ann Ital Chir** 1995 Nov–Dec;66(6):761–7 (25 ref.) (Eng. Abstr.) **(Ita)**

[Sclerotherapy and elastic ligation of hemorrhoids] Dodi G, et al. **Ann Ital Chir** 1995 Nov–Dec;66(6):769–73 (9 ref.) (Eng. Abstr.) **(Ita)**

[Treatment of hemorrhoidal peduncles with diathermy probe] Milito G, et al. **Ann Ital Chir** 1995 Nov–Dec;66(6):801–3 (14 ref.) (Eng. Abstr.) **(Ita)**

[Infrared photocoagulation, cryosurgery and laser surgery in hemorrhoidal disease] Tajana A, et al. **Ann Ital Chir** 1995 Nov–Dec;66(6):775–82 (33 ref.) (Eng. Abstr.) **(Ita)**

HEMOSIDERIN

see related
SIDEROSIS

HEMOSIDEROSIS

[Idiopathic pulmonary hemosiderosis] Pedersen FM, et al. **Ugeskr Laeger** 1996 Feb 12;158(7):902–4 (39 ref.) (Eng. Abstr.) **(Dan)**

COMPLICATIONS

Hepatocellular carcinoma and African iron overload. Gangaidzo IT, et al. **Gut** 1995 Nov;37(5):727–30 (53 ref.)

DIAGNOSIS

[Diagnosis of hepatic siderosis] Turlin B, et al. **Ann Pathol** 1995;15(5):365–71 (40 ref.) **(Fre)**

[Idiopathic pulmonary hemosiderosis. Clinical and radiological assessment of re-exacerbation] Fiorucci F, et al. **Recenti Prog Med** 1996 May;87(5):223–6 (9 ref.) (Eng. Abstr.) **(Ita)**

DRUG THERAPY

Results of long-term iron-chelating therapy. Gabutti V, et al. **Acta Haematol** 1996;95(1):26–36 (109 ref.)

Long-term therapy with deferiprone. Olivieri NF. **Acta Haematol** 1996;95(1):37–48 (90 ref.)

RADIOGRAPHY

[Idiopathic pulmonary hemosiderosis] Pinto M, et al. **Acta Med Port** 1996 Jan;9(1):41–4 (15 ref.) (Eng. Abstr.) **(Por)**

HEMOSORPTION see **HEMOPERFUSION**

HEMOSTASIS

The role of the hemostasis laboratory in cardiopulmonary bypass surgery [editorial] Brandt JT. **Am J Clin Pathol** 1996 Jul;106(1):3–5 (26 ref.)

Thrombosis and hemostasis testing at the point of care. Oberhardt BJ. **Am J Clin Pathol** 1995 Oct;104(4 Suppl 1):S72–8 (19 ref.)

Impaired haemostasis and regional anaesthesia. Stafford-Smith M. **Can J Anaesth** 1996 May;43(5 Pt 2):R129–41 (33 ref.) **(Eng, Fre)**

Hemostatic factors as triggers of cardiovascular events. Rosito GB, et al. **Cardiol Clin** 1996 May;14(2):239–50 (95 ref.)

Hemostasis: a practical review of conservative and operative care. Shopnick RI, et al. **Clin Orthop** 1996 Jul;(328):34–8 (39 ref.)

Hemostasis in Ehlers-Danlos syndrome. Patient report and literature review. Nuss R, et al. **Clin Pediatr (Phila)** 1995 Oct;34(10):552–5 (10 ref.)

Antiplatelet effects of fibrinolytic agents: a potential contributor to the hemostatic defect after thrombolysis. Kamat SG, et al. **Coron Artery Dis** 1995 Dec;6(12):930–5 (55 ref.)

Exercise and haemostatic function. Meade TW. **J Cardiovasc Risk** 1995 Aug;2(4):323–9 (28 ref.)

A biological model for the regulation of peri-implantational hemostasis and menstruation. Lockwood CJ, et al. **J Soc Gynecol Investig** 1996 Jul–Aug;3(4):159–65 (79 ref.)

[Traumatic emergencies and hemostasis] Samama CM. **Cah Anesthesiol** 1995;43(5):479–82 (23 ref.) (Eng. Abstr.) **(Fre)**

[Heart surgery, cardiopulmonary bypass and inflammatory response. I. Changes in hemostasis and complement] Parolari A, et al. **G Ital Cardiol** 1996 Apr;26(4):431–46 (121 ref.) (Eng. Abstr.) **(Ita)**

[Hemostasis and self-defense in insect] Kotani E, et al. **Seikagaku** 1995 Sep;67(9):1148–56 (17 ref.) **(Jpn)**

[State of the hemostatic system in complicated cancer of the gastrointestinal tract] Kirichuk VF, et al. **Vopr Onkol** 1996; 42(3):15–21 (70 ref.) **(Rus)**

DRUG EFFECTS

Contrast media effects on hemostatic and thrombotic parameters. Possible consequences for practical techniques and prophylactic measures. Stormorken H, et al. **Acta Radiol Suppl** 1995;399:173–81 (67 ref.)

Homocysteine and hemostasis: pathogenic mechanisms predisposing to thrombosis. Harpel PC, et al. **J Nutr** 1996 Apr;126(4 Suppl):1285S–9S (33 ref.)

[Hormone replacement therapy and the cardiovascular system: on the role of hemostasis] Winkler UH. **Zentralbl Gynakol** 1995;117(10):510–5 (34 ref.) (Eng. Abstr.) **(Ger)**

[The effect of cardiovascular agents on the hemostatic system in myocardial ischemia] Denisova SV, et al. **Eksp Klin Farmakol** 1995 Jul–Aug;58(4):63–8 (82 ref.) **(Rus)**

GENETICS

The molecular mechanism of platelet adhesion. Berndt MC, et al. **Aust N Z J Med** 1995 Dec;25(6):822–30 (57 ref.)

PHYSIOLOGY

Role of endothelium in thrombosis and hemostasis. Wu KK, et al. **Annu Rev Med** 1996;47:315–31 (50 ref.)

Maintaining blood flow in the extracorporeal circuit: haemostasis and anticoagulation. Webb AR, et al. **Intensive Care Med** 1995 Jan;21(1):84–93 (77 ref.)

Platelet activation mechanisms and markers in arterial thrombosis. Wu KK. **J Intern Med** 1996 Jan;239(1):17–34 (110 ref.)

Developmental hemostasis: relevance to hemostatic problems during childhood. Andrew M. **Semin Thromb Hemost** 1995; 21(4):341–56 (166 ref.)

Developmental hemostasis: relevance to thromboembolic complications in pediatric patients. Andrew M. **Thromb Haemost** 1995 Jul;74(1):415–25 (141 ref.)

The versatility of adhesion receptor ligands in haemostasis: morpho-regulatory functions of vitronectin. Hess S, et al. **Thromb Haemost** 1995 Jul;74(1):258–65 (115 ref.)

Thrombopoietin: the primary regulator of megakaryocyte and platelet production. Kaushansky K. **Thromb Haemost** 1995 Jul;74(1):521–5 (43 ref.)

Function and regulation of the beta 3 integrins in hemostasis and vascular biology. Shattil SJ. **Thromb Haemost** 1995 Jul;74(1):149–55 (98 ref.)

[Role of the hemostasis laboratory in the etiologic approach to deep vein thrombosis] De Maistre E, et al. **J Mal Vasc** 1996;21(1):1–6 (19 ref.) (Eng. Abstr.) **(Fre)**

HEMOSTASIS, ENDOSCOPIC

Role of endoscopic injection therapy in the treatment of bleeding peptic ulcer. Kubba AK, et al. **Br J Surg** 1996 Apr;83(4):461–8 (88 ref.)

What should be done when initial endoscopic therapy for bleeding peptic ulcer fails? [editorial] Swain P. **Endoscopy** 1995 May;27(4):321–8 (69 ref.)

Therapeutic intervention for nonvariceal gastrointestinal hemorrhage. Wyllie R, et al. **J Pediatr Gastroenterol Nutr** 1996 Feb;22(2):123–33 (61 ref.)

ADVERSE EFFECTS

Complications related to endoscopic hemostasis techniques. Lee JG, et al. **Gastrointest Endosc Clin N Am** 1996 Apr; 6(2):305–21 (82 ref.)

HEMOSTASIS, SURGICAL

[Aprotinin in the control of surgical hemorrhage] Rocha E, et al. **Med Clin (Barc)** 1996 Mar 2;106(8):307–16 (161 ref.) **(Spa)**

INSTRUMENTATION

Surgical hemostasis by pneumatic ankle tourniquet during 3027 podiatric operations. Derner R, et al. **J Foot Ankle Surg** 1995 May–Jun;34(3):236–46 (87 ref.)

METHODS

Aprotinin [see comments] Robert S, et al. **Ann Pharmacother** 1996 Apr;30(4):372–80 (68 ref.) Comment in: Ann Pharmacother 1996 Apr;30(4):407–8.

[Fibrin sealing, a concept for early elective endoscopic therapy] Friedrichs O. **Wien Med Wochenschr** 1995; 145(14):313–8 (42 ref.) (Eng. Abstr.) **(Ger)**

[Use of aprotinin in cardiovascular surgery] Colorio C, et al. **Sangre (Barc)** 1995 Jun;40(3):207–11 (34 ref.) **(Spa)**

HEMOSTATIC TECHNIQUES

Maintaining blood flow in the extracorporeal circuit: haemostasis and anticoagulation. Webb AR, et al. **Intensive Care Med** 1995 Jan;21(1):84–93 (77 ref.)

[Possibilities and results of endoscopic hemostasis in peptic ulcer hemorrhage] Bode JC. **Bildgebung** 1995 Oct;62 Suppl 2:16–20 (29 ref.) **(Ger)**

[Surgical hemostasis in recurrent peptic ulcer hemorrhage after endoscopic hemostasis--indications and results] Thon KP, et al. **Bildgebung** 1995 Oct;62 Suppl 2:22–8 (29 ref.) (Eng. Abstr.) **(Ger)**

HEMOSTATICS

see related
VASOCONSTRICTOR AGENTS

[Fibrin glue--an effective hemostatic-adhesive system] Balint B, et al. **Vojnosanit Pregl** 1995 Sep–Oct;52(5):477–82 (33 ref.) **(Scr)**

ADVERSE EFFECTS

Adverse effects of bone wax in surgery of the orbit. Katz SE, et al. **Ophthal Plast Reconstr Surg** 1996 Jun;12(2):121–6 (15 ref.)

PHARMACOLOGY

Aprotinin [see comments] Robert S, et al. **Ann Pharmacother** 1996 Apr;30(4):372–80 (68 ref.) Comment in: Ann Pharmacother 1996 Apr;30(4):407–8.

THERAPEUTIC USE

Aprotinin in patients having coronary artery bypass graft surgery. Royston D. **Curr Opin Cardiol** 1995 Nov; 10(6):591–6 (50 ref.)

Is aprotinin safe when used in the context of profound hypothermia and circulatory arrest? A literary review [comment] Hornick P, et al. **J Heart Valve Dis** 1995 Nov; 4(6):669–73 (60 ref.) Comment on: J Heart Valve Dis 1995 Nov;4(6):674–7.

Fibrin sealant in surgery of patients with a hemorrhagic diathesis. Martinowitz U, et al. **Thromb Haemost** 1995 Jul; 74(1):486–92 (81 ref.)

Fibrin sealant in the United States: clinical use at the University of Virginia. Spotnitz WD. **Thromb Haemost** 1995 Jul;74(1):482–5 (54 ref.)

[Gastroduodenal hemorrhages of peptic origin and the outlook for using somatostatin (Stilamin)] Smakov GM. **Vestn Khir Im I I Grek** 1995;154(3):120–3 (37 ref.) **(Rus)**

[Aprotinin in the control of surgical hemorrhage] Rocha E, et al. **Med Clin (Barc)** 1996 Mar 2;106(8):307–16 (161 ref.) **(Spa)**

HEMOTHORAX

SURGERY

[Traumatic hemothorax treated by video-assisted thoracoscopic surgery] Freixinet J, et al. **Arch Bronconeumol** 1995 Oct;31(8):424–5 (10 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

Management of haemothorax. Parry GW, et al. **Ann R Coll Surg Engl** 1996 Jul;78(4):325–6 (7 ref.)

HEMOTOXINS see **HEMOLYSINS**

HEMP see **CANNABIS**

HEMPAS see **ANEMIA, DYSERYTHROPOIETIC, CONGENITAL**

HENDERSON-JONES SYNDROME see **CHONDROMATOSIS, SYNOVIAL**

HENOCH PURPURA see **PURPURA, SCHOENLEIN-HENOCH**

HEPADNAVIRIDAE INFECTIONS

THERAPY

Therapy of hepadnavirus infection using antisense oligonucleotides. Offensperger WB, et al. **Intervirology** 1995;38(1–2):113–9 (84 ref.)

HEPARAN SULFATE see **HEPARITIN SULFATE**

HEPARIN

Heparin-bonded surfaces in extracorporeal membrane oxygenation for cardiac support. von Segesser LK. **Ann Thorac Surg** 1996 Jan;61(1):330–5; discussion 340–1 (28 ref.)

New concepts in tissue repair: skin as an example. Meddahi A, et al. **Diabetes Metab** 1996 Jul;22(4):274–8 (28 ref.)

ADMINISTRATION & DOSAGE

Are you up to date on weight-based heparin dosing? Sparks KS. **Am J Nurs** 1996 Apr;96(4):33–6; quiz 37 (6 ref.)

Spontaneous iliopsoas hematoma in patients with unstable coronary syndromes receiving intravenous heparin in therapeutic doses. Sasson Z, et al. **Can J Cardiol** 1996 May;

12(5):490–4 (35 ref.)
Heparin as adjunctive therapy to coronary thrombolysis in acute myocardial infarction. Bowlby H, et al. **Heart Lung** 1995 Jul–Aug;24(4):292–304; quiz 304–6 (112 ref.)
Heparin dosing. Farnsworth TL. **S D J Med** 1995 Nov; 48(11):386–7 (13 ref.)

ADVERSE EFFECTS

Heparin–associated thrombocytopenia: an update. Fondu P. **Acta Clin Belg** 1995;50(6):343–57 (63 ref.)
Thrombolysis to treat arterial thrombotic complications of heparin–induced thrombocytopenia. Calligaro KD, et al. **Ann Vasc Surg** 1995 Jul;9(4):397–400 (8 ref.)
Skin necrosis following subcutaneous heparin injection. Mar AW, et al. **Australas J Dermatol** 1995 Nov;36(4):201–3 (14 ref.)
Heparin induced thrombocytopenia. Dryjski M, et al. **Eur J Vasc Endovasc Surg** 1996 Apr;11(3):260–9 (143 ref.)
[Expert discussion group and consensus conference on behalf of the Drug Committee of German Medical Community and Saarland Federal Medical Group 12 May 1995. Agreement on practical procedures for rapid, safe diagnosis and therapy of "white clot" syndrome. Blandfort R. **Chirurg** 1995 Nov;66(11):Suppl 262–4 (0 ref.) **(Ger)**
[Femoral neuropathy due to a spontaneous hematoma of the iliopsoas muscle during therapy with heparin–calcium] Casoni P, et al. **Acta Biomed Ateneo Parmense** 1994; 65(5–6):289–96 (5 ref.) (Eng. Abstr.) **(Ita)**

BLOOD

Relation between systemic anticoagulation as determined by activated partial thromboplastin time and heparin measurements and in–hospital clinical events in unstable angina and non–Q wave myocardiaL infarction. Thrombolysis in Myocardial Ischemia III B Investigators. Becker RC, et al. **Am Heart J** 1996 Mar;131(3):421–33 (66 ref.)
[Heparin] Sakuragawa N. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:1060–3 (20 ref.) **(Jpn)**

PHARMACOLOGY

Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Hirsh J, et al. **Chest** 1995 Oct;108(4 Suppl):258S–275S (268 ref.)
[Heparin––new perspectives on its antiinflammatory action] Krasnowska M, et al. **Postepy Hig Med Dosw** 1995; 49(5):661–9 (56 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOLOGY

Carbohydrate–and heparin–binding proteins in mammalian fertilization. Töpfer–Petersen E, et al. **Andrologia** 1995 Nov–Dec;27(6):303–24 (226 ref.)
[Role of heparin in neoplastic angiogenesis] Sikora J, et al. **Pneumonol Alergol Pol** 1995;63(5–6):344–8 (28 ref.) (Eng. Abstr.) **(Pol)**

THERAPEUTIC USE

Activated clotting time versus activated partial thromboplastin time for therapeutic monitoring of heparin [see comments] Simko RJ, et al. **Ann Pharmacother** 1995 Oct;29(10):1015–21; quiz 1061 (36 ref.) Comment in: Ann Pharmacother 1995 Oct;29(10):1045–6.
Aspirin augmentation of the efficacy of thrombolysis. O'Donnell CJ, et al. **Coron Artery Dis** 1995 Dec;6(12):936–9 (23 ref.)
Contemporary use of and future roles for heparin in antithrombotic therapy. Gibaldi M, et al. **J Clin Pharmacol** 1995 Nov;35(11):1031–45 (67 ref.)
Heparin therapy: current regimens and principles of monitoring. Berry BR, et al. **Postgrad Med** 1996 Jun; 99(6):64–6, 69–76 (19 ref.)
New developments in acute anticoagulation therapy: what improvements over traditional heparin are on the horizon? Carter CJ. **Postgrad Med** 1996 Jun;99(6):129–36 (22 ref.)
Anticoagulant therapy for deep vein thrombosis: its proper application. Rohrer MJ, et al. **Semin Vasc Surg** 1996 Mar; 9(1):13–20 (38 ref.)
[Anticoagulation in cardiology] Meier B. **Ann Cardiol Angeiol (Paris)** 1995 Dec;44(10):567–77 (53 ref.) (Eng. Abstr.) **(Fre)**
–New perspectives in therapy of unstable angina– Hamm CW. **Herz** 1996 Feb;21(1):37–43 (69 ref.) (Eng. Abstr.) **(Ger)**
[Drug therapy of deep venous thrombosis] Bounameaux H. **Ther Umsch** 1996 Apr;53(4):272–6 (16 ref.) (Eng. Abstr.) **(Ger)**
[Contemporary opinions on the use of aspirin, heparin and thrombolytic therapy in unstable angina pectoris––pathogenetic findings versus results of many clinical tests] Popiel M, et al. **Przegl Lek** 1996;53(1):33–40 (40 ref.) (Eng. Abstr.) **(Pol)**

HEPARIN–BINDING FIBROBLAST GROWTH FACTOR CLASS I see **FIBROBLAST GROWTH FACTOR, ACIDIC**

HEPARIN–BINDING GROWTH FACTOR, CLASS I see **FIBROBLAST GROWTH FACTOR, ACIDIC**

HEPARIN–BINDING GROWTH FACTOR CLASS II see **FIBROBLAST GROWTH FACTOR, BASIC**

HEPARIN–CLEARING FACTOR see **LIPOPROTEIN LIPASE**

HEPARIN COFACTOR see **ANTITHROMBIN III**

HEPARIN COFACTOR II

ANALYSIS

[Heparin cofactor II (HC II)] Takeya H, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:122–4 (22 ref.) **(Jpn)**

METABOLISM

Insight into the mechanism of action of heparin cofactor II. Tollefsen DM. **Thromb Haemost** 1995 Nov;74(5):1209–14 (64 ref.)

HEPARIN, LOW–MOLECULAR–WEIGHT

Low molecular weight heparins. Bergqvist D. **J Intern Med** 1996 Aug;240(2):63–72 (99 ref.)

ADMINISTRATION & DOSAGE

Treatment of a patient with an undefined hypercoagulable state with long–term low–molecular–weight heparin. Dobie SA, et al. **West J Med** 1996 Apr;164(4):350–3 (6 ref.)

PHARMACOLOGY

Low–molecular–weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans. Frydman A. **Haemostasis** 1996;26 Suppl 2:24–38 (77 ref.)

THERAPEUTIC USE

Low–molecular–weight heparins and new strategies for the treatment of patients with established venous thrombosis. Baglin TP. **Haemostasis** 1996;26 Suppl 2:10–5 (19 ref.)
Low molecular weight heparins in the initial treatment of deep vein thrombosis. Volteas SK, et al. **Int Angiol** 1996 Mar;15(1):67–74 (46 ref.)
[The treatment of deep venous thrombosis with low–molecular–weight heparin] Samama MM, et al. **Rev Med Brux** 1995 Jul–Aug;16(4):304–9 (30 ref.) (Eng. Abstr.) **(Fre)**

HEPARINIC ACID see **HEPARIN**

HEPARITIN SULFATE

METABOLISM

Heparan sulphate and protein recognition. Binding specificities and activation mechanisms. Gallagher JT. **Adv Exp Med Biol** 1995;376:125–34 (33 ref.)
Heparan sulfate proteoglycan/low density lipoprotein receptor–related protein pathway involved in type III hyperlipoproteinemia and Alzheimer's disease. Mahley RW. **Isr J Med Sci** 1996 Jun;32(6):414–29 (72 ref.)
Entry and egress of varicella–zoster virus: role of mannose 6–phosphate, heparan sulfate proteoglycan, and signal sequences in targeting virions and viral glycoproteins. Zhu Z, et al. **Neurology** 1995 Dec;45(12 Suppl 8):S15–7 (9 ref.)

PHYSIOLOGY

The role of heparan sulfate proteoglycans in the pathogenesis of Alzheimer's disease. Small DH, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:316–21 (18 ref.)
Heparan sulphate in the pathogenesis of diabetic nephropathy. Kofoed–Enevoldsen A. **Diabetes Metab Rev** 1995 Jul;11(2):137–60 (143 ref.)
Control of cell proliferation by heparan sulfate and heparin–binding growth factors. Vlodavsky I, et al. **Thromb Haemost** 1995 Jul;74(1):534–40 (33 ref.)
Cellular metabolism of triglyceride–rich lipoproteins: role of heparan sulfate, lipoprotein lipase and lipoprotein receptors. Sehayek E, et al. **Z Gastroenterol** 1996 Jun;34 Suppl 3:110–2 (16 ref.)

HEPATECTOMY

see related
LIVER REGENERATION

Surgical and multimodality approaches to liver metastases. Schlag PM, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 3):241–55 (78 ref.)
Repeated hepatic resections for recurrent metastasis of colorectal cancer. Gazzaniga GM, et al. **Hepatogastroenterology** 1995 Jul–Aug;42(4):383–6 (19 ref.)
Surgical treatment of an enormous aneurysmal portahepatic venous fistula: report of a case. Miyauchi A, et al. **Surg Today** 1995;25(9):855–8 (11 ref.)
Hepatocellular carcinoma associated with lupoid hepatitis: a review of Japanese reports. Sakaguchi T, et al. **Surg Today** 1995;25(9):838–42 (18 ref.)
Current perspectives on repeat hepatic resection for colorectal carcinoma: a review. Wanebo HJ, et al. **Surgery** 1996 Apr;119(4):361–71 (70 ref.)
[Regulation of liver regeneration after hepatectomy] Liu XQ, et al. **Sheng Li Ko Hsueh Chin Chan** 1995 Oct;26(4):349–51 (11 ref.) **(Chi)**

ADVERSE EFFECTS

Bile duct carcinoma arising from the anastomotic site of hepaticojejunostomy after the excision of congenital biliary dilatation: a case report. Yamamoto J, et al. **Surgery** 1996 Apr;119(4):476–9 (10 ref.)

METHODS

Colorectal cancer: hepatic–directed therapy––the role of surgery, regional chemotherapy, and novel modalities. Busch E, et al. **Semin Oncol** 1995 Oct;22(5):494–508 (110 ref.)
Advances in hepatic resection and results for hepatocellular carcinoma. Nonami T, et al. **Semin Surg Oncol** 1996 May–Jun;12(3):183–8 (51 ref.)
[Vascular exclusion of the liver] Frangov T, et al. **Khirurgiia (Sofiia)** 1995;48(4):41–5 (61 ref.) (Eng. Abstr.) **(Bul)**
[Development of safer liver surgery (editorial)] Belghiti J. **Gastroenterol Clin Biol** 1996 Mar;20(2):129–31 (24 ref.) **(Fre)**
[Treatment of hepatocellular carcinoma in the presence of liver cirrhosis] Ducreux M, et al. **J Chir (Paris)** 1995 Jun–Jul;132(6–7):279–86 (60 ref.) (Eng. Abstr.) **(Fre)**
[Effect of liver transplantation on general techniques of liver resection] Erhard J, et al. **Chirurg** 1996 Apr;67(4):331–40 (30 ref.) (Eng. Abstr.) **(Ger)**

HEPATIC AMEBIASIS see **LIVER ABSCESS, AMEBIC**

HEPATIC ARTERY

see related
LIVER CIRCULATION

Spontaneous dissection of the hepatic artery. Müller MF, et al. **Abdom Imaging** 1995 Sep–Oct;20(5):462–5 (13 ref.)
Arterial therapy of hepatic colorectal metastases. Vauthey JN, et al. **Br J Surg** 1996 Apr;83(4):447–55 (104 ref.)
Native hepatic artery pseudoaneurysm after liver transplantation: an unusual presentation with biliary leak. Soin AS, et al. **Eur J Vasc Endovasc Surg** 1995 Oct; 10(3):376–9 (9 ref.)
[Experiences with the endovascular embolization therapy of aneurysms of the splanchnic arteries––a report on 13 cases] Kramann B, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1995 Nov;163(5):417–23 (35 ref.) (Eng. Abstr.) **(Ger)**
[Selective embolization with an adhesive fluid of complicated aneurysms of the hepatic artery: 3 cases] Cotroneo AR, et al. **Radiol Med (Torino)** 1996 Apr;91(4):492–6 (21 ref.) **(Ita)**
[Hepatic artery aneurysm] Kojima K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):199–201 (10 ref.) **(Jpn)**
[Intrahepatic arterioportal shunt and arteriovenous shunt] Nagayama K, et al. **Ryoikibetsu Shokogun Shirizu** 1995; (8):210–3 (21 ref.) **(Jpn)**
[Intrahepatic arteriovenous fistula] Toshima K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):207–9 (23 ref.) **(Jpn)**

ABNORMALITIES

Hepatic vascular anomalies in infancy: a twenty–seven–year experience. Boon LM, et al. **J Pediatr** 1996 Sep; 129(3):346–54 (52 ref.)

INJURIES

Rapidly progressive portal hypertension 23 years after post–traumatic arterioportal fistula of the liver. Kayser S, et al. **Am J Gastroenterol** 1996 Jul;91(7):1442–6 (30 ref.)

SURGERY

Hepatic artery ligation for hepatic vascular tumors with arteriovenous and arterioportal venous shunts in the newborn: successful management of two cases and review of the literature. Hazebroek FW, et al. **J Pediatr Surg** 1995 Aug;30(8):1127–30 (15 ref.)

ULTRASONOGRAPHY

[Aneurysm of the right hepatic artery. Diagnosis by color Doppler echography] Cozza S, et al. **Radiol Med (Torino)** 1995 Dec;90(6):834–7 (17 ref.) **(Ita)**

HEPATIC CIRRHOSIS see **LIVER CIRRHOSIS**

HEPATIC COMA see **HEPATIC ENCEPHALOPATHY**

HEPATIC DUCT, COMMON

Cystic duct perforation as a complication of endoscopic stone extraction. Manbeck MA, et al. **Am J Gastroenterol** 1996 Mar;91(3):592–4 (12 ref.)
[Klatskin tumor] Kakita A, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):24–6 (15 ref.) **(Jpn)**

[Confluence stone] Takagi I, et al.
Ryoikibetsu Shokogun Shirizu 1996;(9):397-99 (19 ref.) **(Jpn)**

ABNORMALITIES

[Cholecystohepatic ducts] Ishihara Y.
Ryoikibetsu Shokogun Shirizu 1996;(9):131-5 (20 ref.) **(Jpn)**

PATHOLOGY

Bile ascites. Chaturvedi A, et al. **Indian Pediatr** 1995 Feb; 32(2):251-3 (6 ref.)

Temporary resolution of obstructive jaundice during ursodeoxycholic acid therapy in a patient with primary sclerosing cholangitis and a dominant biliary stricture. Fracchia M, et al. **Ital J Gastroenterol** 1995 Oct-Nov; 27(8):430-5 (38 ref.)

RADIOGRAPHY

[The role of ERCP in the diagnosis and therapy of Mirizzi's syndrome. Apropos a clinical case] De Monti M, et al. **Minerva Gastroenterol Dietol** 1996 Mar;42(1):39-43 (18 ref.) (Eng. Abstr.) **(Ita)**

SURGERY

Current status of surgery for Klatskin tumors. Lillemoe KD. **Curr Opin Gen Surg** 1994;:161-7 (25 ref.)

HEPATIC ENCEPHALOPATHY

[Clinical study of fulminant hepatitis type B of infant caused by vertical transmission] Harada Y, et al.
Nippon Rinsho 1995 Oct;53 Suppl:510-5 (7 ref.) **(Jpn)**

[Hepatic encephalopathy] Kato A, et al.
Ryoikibetsu Shokogun Shirizu 1995;(7):230-8 (28 ref.) **(Jpn)**

[Late onset hepatic failure (LOHF)] Komada T, et al.
Ryoikibetsu Shokogun Shirizu 1995;(7):259-61 (14 ref.) **(Jpn)**

[Fulminant hepatitis] Sugihara J, et al.
Ryoikibetsu Shokogun Shirizu 1995;(7):247-51 (13 ref.) **(Jpn)**

COMPLICATIONS

[The significance of acute renal failure in fulminant hepatitis--a comparison between type B and non B hepatitis] Nakano A, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:535-9 (21 ref.) **(Jpn)**

[A case of portal-systemic encephalopathy with slowly progressive, non-flapping tremor] Oue Y, et al.
Rinsho Shinkeigaku 1995 Aug;35(8):889-92 (20 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

[Focus: fulminant and subfulminant hepatic insufficiency] Fellay M, et al. **Rev Med Suisse Romande** 1996 Jun; 116(6):483-91 (36 ref.) **(Fre)**

[Diagnosis of hepatic encephalopathies] Nolte W, et al.
Dtsch Med Wochenschr 1996 May 17;121(20):665-9 (26 ref.) **(Ger)**

[Hepatic minimal encephalopathy. The most frequently overlooked, clinically occult "metabolic syndrome" on the cirrhosis patient] Eisenburg J. **Fortschr Med** 1996 Apr 30; 114(12):141-6 (33 ref.) (Eng. Abstr.) **(Ger)**

[Immunological markers for early diagnosis and foresight of HBV- related fulminant hepatitis] Onji M.
Nippon Rinsho 1995 Oct;53 Suppl:498-501 (13 ref.) **(Jpn)**

[Early diagnosis for hepatitis severity and fulminant hepatitis in patients with acute hepatitis (type B): biochemical, physiological and physical methods] Watanabe A.
Nippon Rinsho 1995 Oct;53 Suppl:502-9 (20 ref.) **(Jpn)**

DRUG THERAPY

Severe recurrent hepatic encephalopathy that responded to oral branched chain amino acids. Chalasani N, et al.
Am J Gastroenterol 1996 Jun;91(6):1266-8 (12 ref.)

ETIOLOGY

Urea cycle disorders: diagnosis, pathophysiology, and therapy. Brusilow SW, et al. **Adv Pediatr** 1996;43:127-70 (59 ref.)

[Physiopathology and surgical treatment of hepatic encephalopathy after porto-caval anastomosis] Porcheron J, et al. **Ann Gastroenterol Hepatol (Paris)** 1995 Oct; 31(5):287-94 (60 ref.) (Eng. Abstr.) **(Fre)**

[Diagnosis of hepatic encephalopathies] Nolte W, et al.
Dtsch Med Wochenschr 1996 May 17;121(20):665-9 (26 ref.) **(Ger)**

[Pathogenic mechanism of fulminant hepatic failure in HBs Ag carrier after withdrawal of cytotoxic chemotherapy] Inoue K, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:467-72 (22 ref.) **(Jpn)**

[The role of hepatitis C virus in fulminant hepatitis] Ohnishi H, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:528-33 (22 ref.) **(Jpn)**

[Clinical feature and pathogenesis of fulminant hepatitis caused by HAV] Onji M. **Nippon Rinsho** 1995 Oct;53 Suppl:863-7 (5 ref.) **(Jpn)**

[Posttransfusion fulminant hepatitis associated with HBV mutants] Shimizu M, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:516-21 (20 ref.) **(Jpn)**

[Eck fistula syndrome] Fukasawa M, et al.
Ryoikibetsu Shokogun Shirizu 1995;(7):220-5 (22 ref.) **(Jpn)**

[Congenital intrahepatic venous shunt as a cause of hepatic encephalopathy] Cosme Jiménez A, et al.
Gastroenterol Hepatol 1995 Nov;18(9):460-3 (25 ref.) (Eng. Abstr.) **(Spa)**

[Pathogenesis of cirrhotic hepatic encephalopathy. Treatment implications] García-Compean D, et al.
Rev Gastroenterol Mex 1995 Jul-Sep;60(3):159-68 (94 ref.) (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

[Virological and immunological pathogenesis of hepatitis C virus-associated fulminant and subacute hepatitis] Imawari M. **Nippon Rinsho** 1995 Sep;53 Suppl:546-8 (9 ref.) **(Jpn)**

[Immune mechanism of fulminant hepatitis type B] Kinoyama S, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:482-7 (20 ref.) **(Jpn)**

[Clinical and immuno-virological aspects in type C fulminant hepatitis] Sekiyama K, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:534-40 (20 ref.) **(Jpn)**

METABOLISM

Trace amines in hepatic encephalopathy. Mousseau DD, et al. **Prog Brain Res** 1995;106:277-84 (43 ref.)

PATHOLOGY

[Apoptosis and fulminant hepatitis] Sata M, et al.
Nippon Rinsho 1995 Oct;53 Suppl:488-91 (18 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Manganese toxicity, dopaminergic dysfunction and hepatic encephalopathy. Butterworth RF, et al.
Metab Brain Dis 1995 Dec;10(4):259-67 (37 ref.)

SURGERY

[Physiopathology and surgical treatment of hepatic encephalopathy after porto-caval anastomosis] Porcheron J, et al. **Ann Gastroenterol Hepatol (Paris)** 1995 Oct; 31(5):287-94 (60 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Fulminant and late onset hepatic failure. Gimson AE.
Br J Anaesth 1996 Jul;77(1):90-8 (104 ref.)

Review of support systems used in the management of fulminant hepatic failure. McGuire BM, et al. **Dig Dis** 1995 Nov-Dec;13(6):379-88 (58 ref.)

Fulminant liver failure: relevance of extracorporeal hybrid liver support systems. Gerlach J, et al.
Int J Artif Organs 1996 Jan;19(1):7-13 (79 ref.)

Overview of randomized clinical trials of oral branched-chain amino acid treatment in chronic hepatic encephalopathy. Fabbri A, et al.
JPEN J Parenter Enteral Nutr 1996 Mar-Apr;20(2):159-64 (44 ref.)

Conservative treatment of acute hepatic failure. Holstege A, et al. **Z Gastroenterol** 1996 Mar;34(3):192-201 (81 ref.)

[Therapy of hepatic encephalopathy] Nolte W, et al.
Dtsch Med Wochenschr 1996 May 24;121(21):699-701 (16 ref.) **(Ger)**

[An artificial liver on its way to clinical reality?] Thasler WE, et al. **Zentralbl Chir** 1995;120(8):614-23 (82 ref.) (Eng. Abstr.) **(Ger)**

[Emergency drug therapy of fulminant hepatitis] Tsubota A, et al. **Nippon Naika Gakkai Zasshi** 1995 Nov 10; 84(11):1821-5 (4 ref.) **(Jpn)**

[Treatment of type C fulminant and subfulminant hepatitis--featuring antiviral and immunosuppressive treatment] Yoshiba M. **Nippon Rinsho** 1995 Sep;53 Suppl:549-56 (34 ref.) **(Jpn)**

[Therapy program for fulminant hepatitis B and its clinical effects] Yoshiba M. **Nippon Rinsho** 1995 Oct;53 Suppl:527-34 (12 ref.) **(Jpn)**

[Pathogenesis of cirrhotic hepatic encephalopathy. Treatment implications] García-Compean D, et al.
Rev Gastroenterol Mex 1995 Jul-Sep;60(3):159-68 (94 ref.) (Eng. Abstr.) **(Spa)**

VIROLOGY

[Mutations in precore and core nucleotide sequence of hepatitis B virus correlated with fulminant and severe hepatitis] Ehata T, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:457-62 (10 ref.) **(Jpn)**

[Virological and immunological pathogenesis of hepatitis C virus-associated fulminant and subacute hepatitis] Imawari M. **Nippon Rinsho** 1995 Sep;53 Suppl:546-8 (9 ref.) **(Jpn)**

[Hepatitis B virus replication and fulminant hepatitis: special reference to genomic variants] Kamimura T.
Nippon Rinsho 1995 Oct;53 Suppl:473-6 (8 ref.) **(Jpn)**

[Probable implication of mutations of the X open reading frame in the onset of fulminant hepatitis B] Kaneko M, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:463-6 (14 ref.) **(Jpn)**

[Clinical and immuno-virological aspects in type C fulminant hepatitis] Sekiyama K, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:534-40 (20 ref.) **(Jpn)**

[Superinfection of hepatitis viruses in fulminant hepatitis (type B)] Watanabe A, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:477-81 (26 ref.) **(Jpn)**

HEPATIC ENTAMOEBIASIS see **LIVER ABSCESS, AMEBIC**

HEPATIC FAILURE, FULMINANT see **HEPATIC ENCEPHALOPATHY**

HEPATIC GLYCOGEN see **LIVER GLYCOGEN**

HEPATIC PORPHYRIA see **PORPHYRIA, HEPATIC**

HEPATIC PORTOENTEROSTOMY see **PORTOENTEROSTOMY, HEPATIC**

HEPATIC TRANSPLANTATION see **LIVER TRANSPLANTATION**

HEPATIC VEIN THROMBOSIS

Budd-Chiari syndrome. Wang ZG, et al. **Curr Probl Surg** 1996 Feb;33(2):83-211 (303 ref.)

[Hepatic vein obstruction and thrombosis] Tsukada K, et al.
Ryoikibetsu Shokogun Shirizu 1995;(8):187-90 (18 ref.) **(Jpn)**

[Budd-Chiari syndrome] Tsukada K, et al.
Ryoikibetsu Shokogun Shirizu 1995;(8):169-72 (20 ref.) **(Jpn)**

DIAGNOSIS

[The Budd-Chiari syndrome and the antiphospholipid antibody in childhood] Pérez Payarols J, et al.
An Esp Pediatr 1996 Jul;45(1):79-81 (12 ref.) **(Spa)**

DRUG THERAPY

Thrombolysis for acute Budd-Chiari syndrome: case report and literature review. Raju GS, et al.
Am J Gastroenterol 1996 Jun;91(6):1262-3 (11 ref.)

THERAPY

[Recanalization of 2 suprahepatic veins with metal stents via a percutaneous transhepatic approach in a case of the Budd-Chiari syndrome] Castrucci M, et al.
Radiol Med (Torino) 1996 Jan-Feb;91(1-2):148-52 (16 ref.) **(Ita)**

HEPATIC VEINS

see related
LIVER CIRCULATION

Hepatic-portal venous gas associated with ileus. Quirke TE.
Am Surg 1995 Dec;61(12):1084-6 (12 ref.)

[Recanalization of 2 suprahepatic veins with metal stents via a percutaneous transhepatic approach in a case of the Budd-Chiari syndrome] Castrucci M, et al.
Radiol Med (Torino) 1996 Jan-Feb;91(1-2):148-52 (16 ref.) **(Ita)**

[Intrahepatic portal-hepatic venous fistula] Iwahashi K.
Ryoikibetsu Shokogun Shirizu 1995;(8):214-7 (19 ref.) **(Jpn)**

[Intrahepatic arterioportal shunt and arteriovenous shunt] Nagayama K, et al. **Ryoikibetsu Shokogun Shirizu** 1995; (8):210-3 (21 ref.) **(Jpn)**

[Intrahepatic arteriovenous fistula] Toshima K, et al.
Ryoikibetsu Shokogun Shirizu 1995;(8):207-9 (23 ref.) **(Jpn)**

ABNORMALITIES

Hepatic vascular anomalies in infancy: a twenty-seven-year experience. Boon LM, et al. **J Pediatr** 1996 Sep; 129(3):346-54 (52 ref.)

[Congenital intrahepatic venous shunt as a cause of hepatic encephalopathy] Cosme Jiménez A, et al.
Gastroenterol Hepatol 1995 Nov;18(9):460-3 (25 ref.) (Eng. Abstr.) **(Spa)**

INJURIES

[Atrio-caval shunt in injury to the suprahepatic vena cava. Apropos of a case and review of the literature] Orsoni P, et al. **J Chir (Paris)** 1995 Nov;132(11):438-41 (24 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Transjugular intrahepatic portal-systemic shunt [editorial] Sherlock S. **J Intern Med** 1996 Feb;239(2):95-8 (25 ref.)

Surgical treatment of an enormous aneurysmal portahepatic venous fistula: report of a case. Miyauchi A, et al.
Surg Today 1995;25(9):855-8 (11 ref.)

HEPATIC VENO-OCCLUSIVE DISEASE

see related
HEPATIC VEIN THROMBOSIS

Obstruction of the hepatic veins or suprahepatic inferior vena cava. Valla D, et al. **Dig Dis** 1996 Mar-Apr;14(2):99-118 (182 ref.)

[Hepatic veno-occlusive disease] Kusakabe A, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):195-8 (21 ref.) **(Jpn)**

ETIOLOGY

Hepatic venooccluslve disease as a complication of whole abdominopelvic irradiation and treatment with the transjuglar intrahepatic portosystemic shunt: case report and literature review. Shen-Gunther J, et al. **Gynecol Oncol** 1996 May;61(2):282-6 (25 ref.)

[Veno-occlusive disease of small hepatic vein (Bush tea disease)] Saito K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):176-9 (24 ref.) **(Jpn)**

HEPATITIS

The variant forms of autoimmune hepatitis. Czaja AJ. **Ann Intern Med** 1996 Oct 1;125(7):588-98 (85 ref.)

Chronic hepatitis in children. Maggiore G. **Curr Opin Pediatr** 1995 Oct;7(5):539-46 (42 ref.)

[Subacute hepatitis (SAH)] Muto Y, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):226-9 (16 ref.) **(Jpn)**

[Neonatal hepatitis] Nagata I, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):122-6 (21 ref.) **(Jpn)**

[Early syphilitic hepatitis] Sakuma H, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):131-3 (20 ref.) **(Jpn)**

[Chronic hepatitis] Figueroa Barrios R. **Rev Gastroenterol Peru** 1995;15 Suppl 1:S77-88 (115 ref.) (Eng. Abstr.) **(Spa)**

COMPLICATIONS

Autoimmune hepatitis in a patient with sickle cell disease. el Younis CM, et al. **Am J Gastroenterol** 1996 May; 91(5):1016-8 (26 ref.)

Fever, abdominal pain and an intracranial mass. Wong M, et al. **Pediatr Infect Dis J** 1995 Aug;14(8):725-8 (18 ref.)

[HCV infection in autoimmune hepatitis] Komeda T, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:871-6 (23 ref.) **(Jpn)**

[Post hepatitis syndrome] Nishioka M, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):457-9 (9 ref.) **(Jpn)**

[Acute-on-chronic liver failure] Ohnishi H, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):217-9 (6 ref.) **(Jpn)**

[Giant cell hepatitis with virus associated hemophagocytic syndrome] Onuki M, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):520-2 (18 ref.) **(Jpn)**

[Hepatic diseases and ictus] Chamorro A. **Rev Neurol** 1995; 23 Suppl 1:S95-8 (24 ref.) **(Spa)**

DIAGNOSIS

Nonalcoholic steatohepatitis. Neuschwander-Tetri BA, et al. **Med Clin North Am** 1996 Sep;80(5):1147-66 (98 ref.)

[Chronic hepatitis--diagnosis and differential diagnosis] Brodanová M. **Cas Lek Cesk** 1995 Aug 23;134(16):499-503 (39 ref.) (Eng. Abstr.) **(Cze)**

[Diagnosis and therapy of autoimmune hepatitis] Heintges T, et al. **Z Gastroenterol** 1995 Aug;33(8):462-7 (52 ref.) (Eng. Abstr.) **(Ger)**

[Neonatal hepatitis] Itoh S, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):554-6 (11 ref.) **(Jpn)**

[Autoimmune hepatitis] Zeniya M, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):526-33 (25 ref.) **(Jpn)**

DRUG THERAPY

Risks and benefits of interferon-alpha in the treatment of hepatitis. Pardo M, et al. **Drug Saf** 1995 Nov;13(5):304-16 (129 ref.)

ETIOLOGY

Autoimmune hepatitis. Mieli-Vergani G, et al. **Arch Dis Child** 1996 Jan;74(1):2-5 (35 ref.)

[Incidence of post-transfusion hepatitis in Hungary 1987-1993] Sere G, et al. **Orv Hetil** 1996 Feb 25; 137(8):405-9 (42 ref.) (Eng. Abstr.) **(Hun)**

[Ischemic hepatitis: case reports and a review of the literature] Colivicchi F, et al. **Minerva Med** 1995 Sep; 86(9):379-86 (24 ref.) (Eng. Abstr.) **(Ita)**

[Autoimmune liver disease complicating Sjögren's syndrome] Masaki N, et al. **Nippon Rinsho** 1995 Oct;53(10):2530-5 (11 ref.) (Eng. Abstr.) **(Jpn)**

[A case of primary biliary cirrhosis complicated with autoimmune hepatitis] Nakao M, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Jan;93(1):49-53 (23 ref.) **(Jpn)**

[Nonalcoholic steatohepatitis (NASH)] Ishii H, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):28-31 (22 ref.) **(Jpn)**

[Perihepatitis] Iwata N, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):463-5 (20 ref.) **(Jpn)**

[Radiation hepatitis] Iwata N, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):588-90 (20 ref.) **(Jpn)**

[Granulomatous hepatitis and granulomatous abscess of the liver] Murakami Y, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):571-4 (11 ref.) **(Jpn)**

[Fitz-Hugh-Curtis syndrome] Sakai H, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):430-3 (7 ref.) **(Jpn)**

IMMUNOLOGY

Lymphocyte-endothelial cell interactions in hepatic inflammation. Adams DH. **Hepatogastroenterology** 1996 Jan-Feb;43(7):32-43 (82 ref.)

Autoimmune hepatitis. Krawitt EL. **N Engl J Med** 1996 Apr 4;334(14):897-903 (79 ref.)

[Autoimmune hepatitis and hepatitis C] Cacoub P, et al. **Rev Med Interne** 1996;17(2):131-4 (23 ref.) (Eng. Abstr.) **(Fre)**

[Autoimmune hepatitis] Dienes HP. **Verh Dtsch Ges Pathol** 1995;79:177-85 (18 ref.) (Eng. Abstr.) **(Ger)**

[Clinical manifestation and immunogenetic background of HCV-marker-positive autoimmune hepatitis] Zeniya M. **Nippon Rinsho** 1995 Sep;53 Suppl:877-84 (11 ref.) **(Jpn)**

[Autoimmune diseases of the liver. Autoimmune hepatitis] Garassini Serra MA, et al. **G E N** 1994 Oct-Dec; 48(4):256-63 (51 ref.) **(Spa)**

PATHOLOGY

Histological grading and staging of chronic hepatitis. Ishak K, et al. **J Hepatol** 1995 Jun;22(6):696-9 (10 ref.)

[Chronic hepatitis] Denk H. **Verh Dtsch Ges Pathol** 1995; 79:171-6 (23 ref.) (Eng. Abstr.) **(Ger)**

[Giant cell hepatitis] Onuki M, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):517-9 (22 ref.) **(Jpn)**

SURGERY

Hepatocellular carcinoma associated with lupoid hepatitis: a review of Japanese reports. Sakaguchi T, et al. **Surg Today** 1995;25(9):838-42 (18 ref.)

THERAPY

[Depressive disorders and interferon alpha (editorial)] Hardy P. **Gastroenterol Clin Biol** 1996;20(3):255-7 (13 ref.) **(Fre)**

[Selection of therapy for chronic hepatitis C with feature of autoimmune hepatitis] Kakumu S. **Nippon Rinsho** 1995 Sep;53 Suppl:892-6 (16 ref.) **(Jpn)**

HEPATITIS A

[Variation in clinical features of acute hepatitis type A] Naito Y, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:851-6 (20 ref.) **(Jpn)**

[Acute viral hepatitis (type A)] Baba M, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):5-8 (13 ref.) **(Jpn)**

COMPLICATIONS

Acute renal failure associated with nonfulminant hepatitis A viral infection. Faust RL, et al. **Am J Gastroenterol** 1996 Feb;91(2):369-72 (24 ref.)

Severe hyperbilirubinemia due to acute hepatitis A superimposed on a chronic hepatitis B carrier with glucose-6-phosphate dehydrogenase deficiency. Huo TI, et al. **Am J Gastroenterol** 1996 Jan;91(1):158-9 (10 ref.)

[Extrahepatic manifestations of hepatitis A virus infection] Maïga MY, et al. **Gastroenterol Clin Biol** 1996;20(4):346-52 (110 ref.) **(Fre)**

[An aggregate and analysis of cases of hepatitis A with complication] Baba M, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:868-77 (49 ref.) **(Jpn)**

[Clinical feature and pathogenesis of fulminant hepatitis caused by HAV] Onji M. **Nippon Rinsho** 1995 Oct;53 Suppl:863-7 (5 ref.) **(Jpn)**

EPIDEMIOLOGY

The epidemiology of hepatitis A in Italy. Panà A, et al. **Res Virol** 1995 Jul-Aug;146(4):249-52 (16 ref.)

[Epidemics of hepatitis A, a review of epidemiological and clinical studies] Hayakawa M. **Nippon Rinsho** 1995 Oct;53 Suppl:842-6 (16 ref.) **(Jpn)**

[Epidemiological trend of hepatitis type A in Japan] Tanikawa K, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:832-6 (10 ref.) **(Jpn)**

IMMUNOLOGY

[Hepatic injury of acute hepatitis A] Sata M, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:804-12 (17 ref.) **(Jpn)**

PHYSIOPATHOLOGY

[Relapsing hepatitis A] Saibara T, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:857-62 (20 ref.) **(Jpn)**

PREVENTION & CONTROL

Prevention of hepatitis A virus infection. Moyer L, et al. **Am Fam Physician** 1996 Jul;54(1):107-14 (27 ref.)

Preventing hepatitis A infections in travelers to endemic areas. Koff RS. **Am J Trop Med Hyg** 1995 Dec;53(6):586-90 (29 ref.)

[Hepatitis A vaccine] Ring-Larsen H. **Ugeskr Laeger** 1995 Dec 11;157(50):7024-7 (26 ref.) **(Dan)**

[For whom is the hepatitis A vaccination in 1995? (editorial)] Buisson Y. **Gastroenterol Clin Biol** 1995 Oct;19(10):745-6 (18 ref.) **(Fre)**

[The direct prophylaxis of hepatitis A] Bellante De Martiis G, et al. **Ann Ig** 1994 Jul-Dec;6(4-6):685-97 (39 ref.) (Eng. Abstr.) **(Ita)**

[Efficacy of immune serum globulin and hepatitis A vaccine with special reference to anti-HA antibody titers] Fujiyama S. **Nippon Rinsho** 1995 Oct;53 Suppl:884-91 (17 ref.) **(Jpn)**

[Inactivated antihepatitis A vaccine] Escolar M, et al. **Rev Med Univ Navarra** 1995 Apr-Jun;40(2):110-4 (14 ref.) **(Spa)**

[Vaccination against hepatitis A gives protection fast. Combination with gamma-globulin is probably unnecessary] Iwarson S. **Lakartidningen** 1996 May 22; 93(21):2045-6 (9 ref.) **(Swe)**

TRANSMISSION

Relative importance of the enterically transmitted human hepatitis viruses type A and E as a cause of foreign travel associated hepatitis. Langer BC, et al. **Arch Virol Suppl** 1996;11:171-9 (25 ref.)

[Fecal-oral transmission of viral hepatitis] Buisson Y, et al. **Med Trop (Mars)** 1995;55(4):305-11 (0 ref.) **(Fre)**

HEPATITIS A VIRUS see HEPATOVIRUS

HEPATITIS A VIRUS, HUMAN

IMMUNOLOGY

Hepatitis A vaccine. Bader TF. **Am J Gastroenterol** 1996 Feb;91(2):217-22 (41 ref.)

[Efficacy of immune serum globulin and hepatitis A vaccine with special reference to anti-HA antibody titers] Fujiyama S. **Nippon Rinsho** 1995 Oct;53 Suppl:884-91 (17 ref.) **(Jpn)**

[Approaches to development of hepatitis A vaccine and unresolved issues] Odoh K. **Nippon Rinsho** 1995 Oct;53 Suppl:878-83 (18 ref.) **(Jpn)**

HEPATITIS, ALCOHOLIC

COMPLICATIONS

Chronic liver disease: do alcohol and hepatitis C virus interact. Cooksley W. **J Gastroenterol Hepatol** 1996 Feb; 11(2):187-92 (45 ref.)

EPIDEMIOLOGY

Alcoholism is associated with hepatitis C but not hepatitis B in an urban population. Rosman AS, et al. **Am J Gastroenterol** 1996 Mar;91(3):498-505 (67 ref.)

IMMUNOLOGY

[Serologic signs of Epstein Barr virus activity in acute viral hepatitis, symptomless HbsAg carriers as well as in alcoholic liver diseases] Ternák G, et al. **Orv Hetil** 1996 Apr 21;137(16):851-5 (34 ref.) (Eng. Abstr.) **(Hun)**

HEPATITIS, ANIMAL

ETIOLOGY

Eosinophilic colitis and hepatitis in a horse with colonic intramucosal ciliated protozoa. French RA, et al. **Vet Pathol** 1996 Mar;33(2):235-8 (10 ref.)

IMMUNOLOGY

[Autoimmune hepatitis] Dienes HP. **Verh Dtsch Ges Pathol** 1995;79:177-85 (18 ref.) (Eng. Abstr.) **(Ger)**

HEPATITIS ANTIBODIES

ANALYSIS

[Interactions between chronic viral hepatitis C and pregnancy] Grangé JD, et al. **Gastroenterol Clin Biol** 1995 May;19(5):520-4 (29 ref.) (Eng. Abstr.) **(Fre)**

BLOOD

Hepatitis C virus serum markers and liver disease in children with leukemia. Locasciulli A, et al. **Leuk Lymphoma** 1995 Apr;17(3-4):245-9 (22 ref.)

HEPATITIS B

Hepatitis B virus transgenic mice: insights into the virus and the disease. Chisari FV. **Hepatology** 1995 Oct;22(4 Pt 1):1316-25 (60 ref.)

The woodchuck: an animal model for hepatitis B virus infection in man. Roggendorf M, et al. **Intervirology** 1995; 38(1-2):100-12 (111 ref.)

Hepatitis B-associated liver cirrhosis as an indication for liver

transplantation. Jansen PL, et al.
Scand J Gastroenterol Suppl 1995;212:19–22 (21 ref.)
[Clinical study of fulminant hepatitis type B of infant caused by vertical transmission] Harada Y, et al.
Nippon Rinsho 1995 Oct;53 Suppl:510–5 (7 ref.) **(Jpn)**
[Epidemic of hepatitis in Sashima] Aramaki T, et al.
Ryoikibetsu Shokogun Shirizu 1995;(7):118–21 (13 ref.) **(Jpn)**
[Hepatitis B] Kojima Y, et al.
Ryoikibetsu Shokogun Shirizu 1995;(7):9–12 (13 ref.) **(Jpn)**
[Hepatitis virus carrier] Nakajima S, et al.
Ryoikibetsu Shokogun Shirizu 1995;(7):54–7 (14 ref.) **(Jpn)**
[Chronic hepatitis] Figueroa Barrios R.
Rev Gastroenterol Peru 1995;15 Suppl 1:S77–88 (115 ref.) (Eng. Abstr.) **(Spa)**

COMPLICATIONS

Alcohol, hepatotropic viruses, and hepatocellular carcinoma [editorial] Nalpas B, et al. **Alcohol Clin Exp Res** 1995 Oct; 19(5):1089–95 (96 ref.)
Severe hyperbilirubinemia due to acute hepatitis A superimposed on a chronic hepatitis B carrier with glucose-6-phosphate dehydrogenase deficiency. Huo TI, et al. **Am J Gastroenterol** 1996 Jan;91(1):158–9 (10 ref.)
Glomerulonephritis associated with acute hepatitis B. Safadi R, et al. **Am J Gastroenterol** 1996 Jan;91(1):138–9 (21 ref.)
Role of hepatitis C virus in dual and triple hepatitis virus infection. Liaw YF. **Hepatology** 1995 Oct;22(4 Pt 1):1101–8 (84 ref.)
Acute exacerbation and superinfection in patients with chronic viral hepatitis. Liaw YF. **J Formos Med Assoc** 1995 Sep;94(9):521–8 (78 ref.)
Implications of chronic hepatitis B or hepatitis C infection for renal transplant candidates. Goffin E, et al.
Nephrol Dial Transplant 1995;10 Suppl 6:88–92 (44 ref.)
[Liver, biliary tracts and human immunodeficiency virus infection. 1:q liver, HIV and hepatitis B, C and D viruses] Vuitton DA, et al. **Gastroenterol Clin Biol** 1996; 20(3):269–80 (146 ref.) **(Fre)**
[High risk group of patients with hepatitis B virus infection developing hepatocellular carcinoma] Koike K.
Nippon Naika Gakkai Zasshi 1995 Dec 10;84(12):1980–4 (5 ref.) **(Jpn)**
[Pathogenic mechanism of fulminant hepatic failure in HBs Ag carrier after withdrawal of cytotoxic chemotherapy] Inoue K, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:467–72 (22 ref.) **(Jpn)**
[The significance of acute renal failure in fulminant hepatitis--a comparison between type B and non B hepatitis] Nakano A, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:535–9 (21 ref.) **(Jpn)**
[Clinical course and prognostic value of Child-Turcotte criteria and Child-Pugh score in medically treated cirrhosis positive for HCV antibody--in comparison with cirrhosis positive for HBs Ag] Shibata M. **Nippon Rinsho** 1995 Sep; 53 Suppl:711–9 (20 ref.) **(Jpn)**
[Progress of chronic hepatitis C to liver cirrhosis--comparison with chronic hepatitis B] Shimomura H, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:720–6 (15 ref.) **(Jpn)**
[Clinicopathological studies on juvenile hepatocellular carcinoma with hepatitis B virus infection--background factors, tumor spread and prognosis after hepatic resection] Yokoi H, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:698–703 (16 ref.) **(Jpn)**
[Cirrhosis of the liver due to hepatitis virus] Kiyosawa K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):158–60 (6 ref.) **(Jpn)**

DIAGNOSIS

Acute exacerbation in chronic hepatitis B virus infection. Santos MV, et al. **Rev Soc Bras Med Trop** 1996 May–Jun; 29(3):275–9 (9 ref.)
[Chronic viral hepatitis: diagnosis and treatment] Stazi F, et al. **Clin Ter** 1996 Mar;147(3):85–92 (33 ref.) (Eng. Abstr.) **(Ita)**
[Anti-HBs escape mutants--implication of neutralization escape and diagnostic escape] Okamoto H.
Nippon Rinsho 1995 Oct;53 Suppl:212–22 (21 ref.) **(Jpn)**
[Immunological markers for early diagnosis and foresight of HBV- related fulminant hepatitis] Onji M.
Nippon Rinsho 1995 Oct;53 Suppl:498–501 (13 ref.) **(Jpn)**
[Early diagnosis for hepatitis severity and fulminant hepatitis in patients with acute hepatitis (type B): biochemical, physiological and physical methods] Watanabe A.
Nippon Rinsho 1995 Oct;53 Suppl:502–9 (20 ref.) **(Jpn)**
[Competence of diagnosis: chronic generalized infection, caused by hepatitis virus (B, C) (editorial)] Serov VV, et al. **Arkh Patol** 1995 Jul–Aug;57(4):3–5 (20 ref.) **(Rus)**

DRUG THERAPY

New developments in antiviral therapy for chronic hepatitis B infection. De Man RA, et al.
Scand J Gastroenterol Suppl 1995;212:100–4 (26 ref.)
[Drug therapy in patients with chronic type B hepatitis] Chien RN, et al. **J Formos Med Assoc** 1995 Jun;94 Suppl 1:S1–9 (40 ref.) (Eng. Abstr.) **(Chi)**
[Alternative treatment to interferon therapy in chronic viral hepatitis] Salmerón Escobar FJ. **Gastroenterol Hepatol** 1995 Oct;18(8):430–6 (72 ref.) **(Spa)**

EPIDEMIOLOGY

Hepatitis B virus infection in Singapore. Guan R. **Gut** 1996; 38 Suppl 2:S13–7 (35 ref.)
Epidemiology of hepatitis B infection in the Western Pacific and South East Asia. Gust ID. **Gut** 1996;38 Suppl 2:S18–23 (50 ref.)
The epidemiology and prophylaxis of hepatitis B in sub-Saharan Africa: a view from tropical and subtropical Africa. Kiire CF. **Gut** 1996;38 Suppl 2:S5–12 (44 ref.)
Epidemiology and control of hepatitis B infection: a perspective from the Philippines, Asia. Lansang MA. **Gut** 1996;38 Suppl 2:S43–7 (36 ref.)
Epidemiology of hepatitis B virus infection in India. Tandon BN, et al. **Gut** 1996;38 Suppl 2:S56–9 (21 ref.)
Hepatitis B and hepatitis delta virus infection in South America. Torres JR. **Gut** 1996;38 Suppl 2:S48–55 (82 ref.)
Hepatitis B in the Middle East: aspects of epidemiology and liver disease after infection. Toukan AU. **Gut** 1996;38 Suppl 2:S2–4 (18 ref.)
Occupational risk of infection with hepatitis B and hepatitis C virus. Shapiro CN. **Surg Clin North Am** 1995 Dec; 75(6):1047–56 (51 ref.)

ETIOLOGY

Hepatitis B and transplantation. Davis CL, et al.
Infect Dis Clin North Am 1995 Dec;9(4):925–41 (102 ref.)
Hepatitis B virus immunopathology. Chisari FV, et al.
Springer Semin Immunopathol 1995;17(2–3):261–81 (83 ref.)
[Establishment of in vitro model for HBV infection via asialoglycoprotein receptor] Neda H, et al.
Nippon Rinsho 1995 Oct;53 Suppl:121–4 (15 ref.) **(Jpn)**
[Role of hepatitis B virus surface antigen in HBV infection--function of human hepatic sialoglycoprotein as HBV receptor] Suzuki T, et al. **Nippon Rinsho** 1995 Oct; 53 Suppl:132–7 (28 ref.) **(Jpn)**

GENETICS

[Precore region mutation in anti-HBe antibody positive asymptomatic healthy carriers] Fukuda R.
Nippon Rinsho 1995 Oct;53 Suppl:189–94 (16 ref.) **(Jpn)**
[Hepatitis B infections show a variety of clinical pictures. Variations in viral DNA is a possible explanation] Kidd-Ljunggren K. **Lakartidningen** 1996 Mar 27; 93(13):1212–6 (28 ref.) **(Swe)**

IMMUNOLOGY

Role of humoral immune responses in hepatitis B and C virus infections. Mondelli MU, et al. **Eur J Clin Invest** 1995 Aug; 25(8):543–7 (51 ref.)
Transplantation of hepatitis B immune lymphocytes as means for adoptive transfer of immunity to hepatitis B virus. Shouval D, et al. **J Hepatol** 1995 Jul;23(1):98–101 (18 ref.)
Hepatitis B virus immunopathology. Chisari FV, et al.
Springer Semin Immunopathol 1995;17(2–3):261–81 (83 ref.)
The humoral immune response in acute and chronic hepatitis B virus infection. Milich DR, et al.
Springer Semin Immunopathol 1995;17(2–3):149–66 (81 ref.)
Overview: practical insights from comparative immunology and pathogenesis of AIDS, hepatitis B, and measles for developing an HIV vaccine. Hilleman MR. **Vaccine** 1995 Dec;13(18):1733–40 (41 ref.)
[Effect of vaccination on the risk of hepatitis B infection in hospital personnel] Mihály I, et al. **Orv Hetil** 1996 Mar 31;137(13):681–5 (36 ref.) (Eng. Abstr.) **(Hun)**
[Function and regulation of adhesion molecules in CTLs induction of chronic hepatitis B--expression of ICAM-1 and VCAM-1 in liver tissues] Doi T. **Nippon Rinsho** 1995 Oct;53 Suppl:180–4 (19 ref.) **(Jpn)**
[Precore region mutation in anti-HBe antibody positive asymptomatic healthy carriers] Fukuda R.
Nippon Rinsho 1995 Oct;53 Suppl:189–94 (16 ref.) **(Jpn)**
[Cytokine gene expression in the liver of chronic hepatitis B] Fukuda R. **Nippon Rinsho** 1995 Oct;53 Suppl:223–7 (17 ref.) **(Jpn)**
[Immune mechanism of fulminant hepatitis type B] Kinoyama S, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:482–7 (20 ref.) **(Jpn)**
[Fas antigen expression and apoptosis in liver tissues of patients with chronic hepatitis B] Mochizuki K, et al.
Nippon Rinsho 1995 Oct;53 Suppl:228–33 (17 ref.) **(Jpn)**
[The clinical significance of immune response and immunological markers in chronic hepatitis B] Takaguchi K, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:580–5 (18 ref.) **(Jpn)**
[Immunohistochemical observation of Fas in the liver of chronic hepatitis B and its ultrastructural localization] Takatani M, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:234–40 (23 ref.) **(Jpn)**
[Possible roles of pre-S2 peptide in generation of chronic hepatitis B] Yamauchi K, et al. **Nippon Rinsho** 1995 Oct; 53 Suppl:144–7 (11 ref.) **(Jpn)**
[The assessment of the cellular indices of the immune status in patients with chronic forms of hepatitis B] Kokoreva LN, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1995 Sep–Oct;(5):112–5 (33 ref.) **(Rus)**

PATHOLOGY

[Immunohistochemical observation of Fas in the liver of chronic hepatitis B and its ultrastructural localization] Takatani M, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:234–40 (23 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Hepatitis B virus and hepatocellular carcinoma. Ren EC. **Ann Acad Med Singapore** 1996 Jan;25(1):17–21 (52 ref.)
[Acute exacerbation by reactivation of HBV in steroid withdrawal therapy] Arase Y. **Nippon Rinsho** 1995 Oct;53 Suppl:522–6 (6 ref.) **(Jpn)**

PREVENTION & CONTROL

DNA-mediated immunization to the hepatitis B surface antigen. Activation and entrainment of the immune response. Whalen RG, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:64–76 (31 ref.)
Hepatitis B immunization among adolescents. Middleman AB. **Curr Opin Pediatr** 1995 Aug;7(4):366–70 (25 ref.)
Hepatitis B virus infection. Current status in dentistry. Cottone JA, et al. **Dent Clin North Am** 1996 Apr; 40(2):293–307 (62 ref.)
Strategy for vaccination against hepatitis B in areas with high endemicity: focus on Korea. Ahn YO. **Gut** 1996;38 Suppl 2:S63–6 (16 ref.)
Immunisation against hepatitis B in Taiwan. Gust ID. **Gut** 1996;38 Suppl 2:S67–8 (10 ref.)
Epidemiology of hepatitis B infection in the Western Pacific and South East Asia. Gust ID. **Gut** 1996;38 Suppl 2:S18–23 (50 ref.)
Comprehensive control (or elimination) of hepatitis B virus transmission in the United States. Hollinger FB. **Gut** 1996; 38 Suppl 2:S24–30 (24 ref.)
Progress towards the comprehensive control of hepatitis B in Africa: a view from South Africa. Kew MC. **Gut** 1996; 38 Suppl 2:S31–6 (39 ref.)
The epidemiology and prophylaxis of hepatitis B in sub-Saharan Africa: a view from tropical and subtropical Africa. Kiire CF. **Gut** 1996;38 Suppl 2:S5–12 (44 ref.)
Developing new hepatitis B immunisation strategies. Zuckerman AJ. **Gut** 1996;38 Suppl 2:S60–2 (6 ref.)
Immunization against hepatitis B through adoptive transfer of immunity. Shouval D, et al. **Intervirology** 1995; 38(1–2):41–6 (37 ref.)
Critical issues surrounding hepatitis B vaccination for adolescents: a roundtable. Brookman RR, et al.
J Adolesc Health 1995 Oct;17(4):208–33 (0 ref.)
Hepatitis B immunization in adolescents. Lawrence MH, et al. **J Adolesc Health** 1995 Oct;17(4):234–43 (126 ref.)
Preventive care in obstetrics: toxoplasmosis, cytomegalovirus, and hepatitis B. Ledger WJ.
J Matern Fetal Med 1996 May–Jun;5(3):100–5 (26 ref.)
DNA-mediated immunization: prospects for hepatitis B vaccination. Michel ML. **Res Virol** 1995 Jul–Aug; 146(4):261–5 (28 ref.)
Postexposure prophylaxis for occupational exposures to hepatitis B, hepatitis C, and human immunodeficiency virus. Henderson DK. **Surg Clin North Am** 1995 Dec; 75(6):1175–87 (51 ref.)
[Screening for hepatitis B in pregnancy and sequelae for the newborn infant] Albrecht K. **Z Geburtshilfe Neonatol** 1995 Nov–Dec;199(6):253–6 (24 ref.) **(Ger)**
[Hepatitis B immune serum globulin] Iino S.
Nippon Rinsho 1995 Oct;53 Suppl:371–7 (16 ref.) **(Jpn)**
[Efficacy and safety of HB vaccine] Sodeyama T, et al.
Nippon Rinsho 1995 Oct;53 Suppl:386–93 (17 ref.) **(Jpn)**
[Vaccines against viral hepatitis B: results and prospects] Mukomolov SL. **Tr Inst Im Pastera** 1992;67:103–15 (68 ref.) **(Rus)**

THERAPY

Therapy for chronic hepatitis B infection. Terrault NA, et al. **Adv Exp Med Biol** 1996;394:189–205 (129 ref.)
Long-term effect of interferon alpha alone or after prednisone withdrawal in chronic hepatitis B. Interim report and review of the literature. Gonzalez-Mateos F, et al. **Hepatogastroenterology** 1995 Nov–Dec;42(6):893–9 (25 ref.)
Interferon therapy in chronic viral hepatitis. Guptan RC, et al. **J Assoc Physicians India** 1995;Suppl 3:44–51 (56 ref.)
Treatment of chronic hepatitis B. Lok AS. **J Viral Hepat** 1994;1(2):105–24 (147 ref.)
Therapy of chronic viral hepatitis. Fried MW.
Med Clin North Am 1996 Sep;80(5):957–72 (75 ref.)
What is the actual management of a child with membranous glomerulopathy associated with chronic hepatitis B? Chiu MC. **Pediatr Nephrol** 1996 Apr;10(2):146 (18 ref.)
Why we should treat chronic viral hepatitis. King PD. **Postgrad Med** 1996 Sep;100(3):68–70, 73; discussion 73, 78 (13 ref.)
Chronic viral hepatitis and use of interferon. Whom are we treating? Koretz RL. **Postgrad Med** 1996 Sep;100(3):55–7, 61–2, 68 (11 ref.)
[Interferon therapy of viral hepatitis] Suzuki S.
Nippon Naika Gakkai Zasshi 1995 Sep 10;84(9):1559–63 (4 ref.) **(Jpn)**
[Interferon therapy of chronic hepatitis B: results of three treatment schedules] Hamada M, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:624–8 (14 ref.) **(Jpn)**

HEPATITIS B

[Treatment planning of chronic hepatitis B] Iino S. **Nippon Rinsho** 1995 Oct;53 Suppl:617–23 (5 ref.) **(Jpn)**

[Therapy and prognosis of the acute hepatitis B] Uemura K, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:444–9 (23 ref.) **(Jpn)**

[Therapy program for fulminant hepatitis B and its clinical effects] Yoshiba M. **Nippon Rinsho** 1995 Oct;53 Suppl:527–34 (12 ref.) **(Jpn)**

TRANSMISSION

Significance of imported hepatitis B virus infections. Jilg W. **Arch Virol Suppl** 1996;11:181–3 (10 ref.)

Hepatitis B in the Middle East: aspects of epidemiology and liver disease after infection. Toukan AU. **Gut** 1996;38 Suppl 2:S2–4 (18 ref.)

Importance of perinatal versus horizontal transmission of hepatitis B virus infection in China. Yao GB. **Gut** 1996;38 Suppl 2:S39–42 (16 ref.)

Perinatal transmission of hepatitis B virus infection and vaccination in China. Yao JL. **Gut** 1996;38 Suppl 2:S37–8 (5 ref.)

[Posttransfusion fulminant hepatitis associated with HBV mutants] Shimizu M, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:516–21 (20 ref.) **(Jpn)**

[Hepatitis B virus infection in health care settings] Sodeyama T. **Nippon Rinsho** 1995 Oct;53 Suppl:362–70 (15 ref.) **(Jpn)**

[Mechanisms and factors for development of HBV asymptomatic carrier] Tanaka Y, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:394–400 (21 ref.) **(Jpn)**

VIROLOGY

Appearance of HBV mutants during chronic infection. Santantonio T, et al. **Ital J Gastroenterol** 1995 Jun; 27(5):265–9 (43 ref.)

The structure of hepatitis B envelope and molecular variants of hepatitis B virus. Howard CR. **J Viral Hepat** 1995; 2(4):165–70 (21 ref.)

[Mutations in precore and core nucleotide sequence of hepatitis B virus correlated with fulminant and severe hepatitis] Ehata T, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:457–62 (10 ref.) **(Jpn)**

[Precore/core mutation and clinical course of chronic hepatitis B virus infection from the view point of asymptomatic carriers] Fujiwara K, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:401–5 (20 ref.) **(Jpn)**

[Changes in precore and core region of hepatitis B virus during the course of chronic hepatitis B virus carriers] Hamasaki K, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:411–4 (9 ref.) **(Jpn)**

[Virological diagnosis—HBV mutant, HBV subtype, etc.] Ito Y, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:492–7 (12 ref.) **(Jpn)**

[Hepatitis B virus replication and fulminant hepatitis: special reference to genomic variants] Kamimura T. **Nippon Rinsho** 1995 Oct;53 Suppl:473–6 (8 ref.) **(Jpn)**

[Probable implication of mutations of the X open reading frame in the onset of fulminant hepatitis B] Kaneko M, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:463–6 (14 ref.) **(Jpn)**

[Posttransfusion fulminant hepatitis associated with HBV mutants] Shimizu M, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:516–21 (20 ref.) **(Jpn)**

[Mutation site-specific assay (MSSA) for the detection of hepatitis B virus precore defective mutant in hepatitis B infection] Tsubota A. **Nippon Rinsho** 1995 Oct;53 Suppl:321–4 (6 ref.) **(Jpn)**

[Superinfection of hepatitis viruses in fulminant hepatitis (type B)] Watanabe A, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:477–81 (26 ref.) **(Jpn)**

[Detection and characterization of pre-core mutants of hepatitis B virus (HBV) in chronically infected patients] López JL, et al. **Acta Gastroenterol Latinoam** 1995; 25(2):85–90 (27 ref.) (Eng. Abstr.) **(Spa)**

HEPATITIS B ANTIBODIES

ANALYSIS

[HBe antigen and HBe antibody] Arase Y, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:247–52 (5 ref.) **(Jpn)**

[Detection of hepatitis B core antigen and antibody] Chayama K. **Nippon Rinsho** 1995 Oct;53 Suppl:253–7 (12 ref.) **(Jpn)**

[Precore region mutation in anti-HBe antibody positive asymptomatic healthy carriers] Fukuda R. **Nippon Rinsho** 1995 Oct;53 Suppl:189–94 (16 ref.) **(Jpn)**

[Anti-HBs escape mutants—implication of neutralization escape and diagnostic escape] Okamoto H. **Nippon Rinsho** 1995 Oct;53 Suppl:212–22 (21 ref.) **(Jpn)**

BIOSYNTHESIS

DNA-mediated immunization to the hepatitis B surface antigen. Activation and entrainment of the immune response. Whalen RG, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:64–76 (31 ref.)

Role of humoral immune responses in hepatitis B and C virus infections. Mondelli MU, et al. **Eur J Clin Invest** 1995 Aug; 25(8):543–7 (51 ref.)

The human immune response to hepatitis B surface antigen. Alper CA. **Exp Clin Immunogenet** 1995;12(3):171–81 (82 ref.)

The humoral immune response in acute and chronic hepatitis B virus infection. Milich DR, et al. **Springer Semin Immunopathol** 1995;17(2–3):149–66 (81 ref.)

BLOOD

[IgM and IgA antibodies to hepatitis B core antigen] Suga M. **Nippon Rinsho** 1995 Oct;53 Suppl:258–64 (24 ref.) **(Jpn)**

HEPATITIS B ANTIGENS

GENETICS

[Molecular mechanism of HBV hepatocarcinogenesis] Koike K. **Nippon Rinsho** 1995 Oct;53 Suppl:65–74 (37 ref.) **(Jpn)**

[Association of human hepatitis B virus (HBV) X protein and hRPB5, a subunit of RNA polymerases, and X transactivation] Murakami S. **Nippon Rinsho** 1995 Oct;53 Suppl:75–81 (21 ref.) **(Jpn)**

IMMUNOLOGY

[Molecular biological research on protective antigens of HBV and improvement of HB vaccine by genetic engineering] Fujisawa Y. **Nippon Rinsho** 1995 Oct;53 Suppl:378–85 (28 ref.) **(Jpn)**

PHYSIOLOGY

[The potential attachment sites of hepatitis B virus to the hepatocyte—the pre-S(2) antigen and the receptor for polymerized human serum albumin of hepatitis B virus] Matsuura K, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:125–31 (25 ref.) **(Jpn)**

HEPATITIS B CORE ANTIGENS

ANALYSIS

[Detection of hepatitis B core antigen and antibody] Chayama K. **Nippon Rinsho** 1995 Oct;53 Suppl:253–7 (12 ref.) **(Jpn)**

BIOSYNTHESIS

Assembly and antigenicity of hepatitis B virus core particles. Seifer M, et al. **Intervirology** 1995;38(1–2):47–62 (61 ref.)

GENETICS

Variation in the core and X genes of hepatitis B virus. Carman WF. **Intervirology** 1995;38(1–2):75–88 (96 ref.)

Hepatitis B virus core particles as epitope carriers. Pumpens P, et al. **Intervirology** 1995;38(1–2):63–74 (84 ref.)

[Mutations in precore and core nucleotide sequence of hepatitis B virus correlated with fulminant and severe hepatitis] Ehata T, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:457–62 (10 ref.) **(Jpn)**

[Precore/core mutation and clinical course of chronic hepatitis B virus infection from the view point of asymptomatic carriers] Fujiwara K, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:401–5 (20 ref.) **(Jpn)**

[Precore region mutation in anti-HBe antibody positive asymptomatic healthy carriers] Fukuda R. **Nippon Rinsho** 1995 Oct;53 Suppl:189–94 (16 ref.) **(Jpn)**

[Changes in precore and core region of hepatitis B virus during the course of chronic hepatitis B virus carriers] Hamasaki K, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:411–4 (9 ref.) **(Jpn)**

[Detection of HBV precore mutation by PCR-RFLP] Niitsuma H, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:316–20 (7 ref.) **(Jpn)**

[Mutation site-specific assay (MSSA) for the detection of hepatitis B virus precore defective mutant in hepatitis B infection] Tsubota A. **Nippon Rinsho** 1995 Oct;53 Suppl:321–4 (6 ref.) **(Jpn)**

IMMUNOLOGY

Hepatitis B virus core particles as epitope carriers. Pumpens P, et al. **Intervirology** 1995;38(1–2):63–74 (84 ref.)

[Detection of hepatitis B core antigen and antibody] Chayama K. **Nippon Rinsho** 1995 Oct;53 Suppl:253–7 (12 ref.) **(Jpn)**

[IgM and IgA antibodies to hepatitis B core antigen] Suga M. **Nippon Rinsho** 1995 Oct;53 Suppl:258–64 (24 ref.) **(Jpn)**

HEPATITIS B E ANTIGENS

ANALYSIS

[HBe antigen and HBe antibody] Arase Y, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:247–52 (5 ref.) **(Jpn)**

GENETICS

[Detection and characterization of pre-core mutants of hepatitis B virus (HBV) in chronically infected patients] López JL, et al. **Acta Gastroenterol Latinoam** 1995; 25(2):85–90 (27 ref.) (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

[HBe antigen and HBe antibody] Arase Y, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:247–52 (5 ref.) **(Jpn)**

[Precore region mutation in anti-HBe antibody positive asymptomatic healthy carriers] Fukuda R. **Nippon Rinsho** 1995 Oct;53 Suppl:189–94 (16 ref.) **(Jpn)**

HEPATITIS B SURFACE ANTIGENS

ANALYSIS

[Pathogenic mechanism of fulminant hepatic failure in HBs Ag carrier after withdrawal of cytotoxic chemotherapy] Inoue K, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:467–72 (22 ref.) **(Jpn)**

[Clinical significance of the pre-S antigens and the binding activity of polymerized human serum albumin to the receptor on hepatitis B virus particles] Matsuura K, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:265–74 (26 ref.) **(Jpn)**

CLASSIFICATION

[Serological subtype (serotype) of hepatitis B virus surface antigen] Iwasaki Y, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:293–8 (23 ref.) **(Jpn)**

GENETICS

Hepatitis B surface antigen variation and protective immunity. Howard CR, et al. **Intervirology** 1995; 38(1–2):35–40 (24 ref.)

Subtypes, genotypes and molecular epidemiology of the hepatitis B virus as reflected by sequence variability of the S-gene. Magnius LO, et al. **Intervirology** 1995; 38(1–2):24–34 (57 ref.)

The structure of hepatitis B envelope and molecular variants of hepatitis B virus. Howard CR. **J Viral Hepat** 1995; 2(4):165–70 (21 ref.)

[Mutant of the pre-S and S region of HBV] Nishikawa M, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:47–51 (15 ref.) **(Jpn)**

[Possible roles of pre-S2 peptide in generation of chronic hepatitis B] Yamauchi K, et al. **Nippon Rinsho** 1995 Oct; 53 Suppl:144–7 (11 ref.) **(Jpn)**

[Detection and characterization of pre-core mutants of hepatitis B virus (HBV) in chronically infected patients] López JL, et al. **Acta Gastroenterol Latinoam** 1995; 25(2):85–90 (27 ref.) (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

DNA-mediated immunization to the hepatitis B surface antigen. Activation and entrainment of the immune response. Whalen RG, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:64–76 (31 ref.)

The human immune response to hepatitis B surface antigen. Alper CA. **Exp Clin Immunogenet** 1995;12(3):171–81 (82 ref.)

Hepatitis B surface antigen variation and protective immunity. Howard CR, et al. **Intervirology** 1995; 38(1–2):35–40 (24 ref.)

Immunization against hepatitis B through adoptive transfer of immunity. Shouval D, et al. **Intervirology** 1995; 38(1–2):41–6 (37 ref.)

[Effect of vaccination on the risk of hepatitis B infection in hospital personnel] Mihály I, et al. **Orv Hetil** 1996 Mar 31;137(13):681–5 (36 ref.) (Eng. Abstr.) **(Hun)**

[Serologic signs of Epstein Barr virus activity in acute viral hepatitis, symptomless HbsAg carriers as well as in alcoholic liver diseases] Ternák G, et al. **Orv Hetil** 1996 Apr 21;137(16):851–5 (34 ref.) (Eng. Abstr.) **(Hun)**

[Study of immune tolerance induced by HBs antigen specific suppressor T cell—establishment of human suppressor T cell clones] Isono E, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:185–8 (15 ref.) **(Jpn)**

[The potential attachment sites of hepatitis B virus to the hepatocyte—the pre-S(2) antigen and the receptor for polymerized human serum albumin of hepatitis B virus] Matsuura K, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:125–31 (25 ref.) **(Jpn)**

[Anti-HBs escape mutants—implication of neutralization escape and diagnostic escape] Okamoto H. **Nippon Rinsho** 1995 Oct;53 Suppl:212–22 (21 ref.) **(Jpn)**

METABOLISM

[Role of hepatitis B virus surface antigen in HBV infection—function of human hepatic sialoglycoprotein as HBV receptor] Suzuki T, et al. **Nippon Rinsho** 1995 Oct; 53 Suppl:132–7 (28 ref.) **(Jpn)**

HEPATITIS B VACCINES

DNA-mediated immunization to the hepatitis B surface antigen. Activation and entrainment of the immune response. Whalen RG, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:64–76 (31 ref.)

Immunisation against hepatitis B in Taiwan. Gust ID. **Gut** 1996;38 Suppl 2:S67–8 (10 ref.)

Progress towards the comprehensive control of hepatitis B in Africa: a view from South Africa. Kew MC. **Gut** 1996; 38 Suppl 2:S31–6 (39 ref.)

Developing new hepatitis B immunisation strategies. Zuckerman AJ. **Gut** 1996;38 Suppl 2:S60–2 (6 ref.)

[Molecular biological research on protective antigens of HBV and improvement of HB vaccine by genetic engiaeering] Fujisawa Y. **Nippon Rinsho** 1995 Oct;53 Suppl:378–85 (28 ref.) **(Jpn)**

ADMINISTRATION & DOSAGE

Comprehensive control (or elimination) of hepatitis B virus transmission in the United States. Hollinger FB. **Gut** 1996; 38 Suppl 2:S24–30 (24 ref.)

The epidemiology and prophylaxis of hepatitis B in sub-Saharan Africa: a view from tropical and subtropical Africa. Kiire CF. **Gut** 1996;38 Suppl 2:S5–12 (44 ref.)

Critical issues surrounding hepatitis B vaccination for adolescents: a roundtable. Brookman RR, et al. **J Adolesc Health** 1995 Oct;17(4):208–33 (0 ref.)

Hepatitis B immunization in adolescents. Lawrence MH, et al. **J Adolesc Health** 1995 Oct;17(4):234–43 (126 ref.)

[Effect of vaccination on the risk of hepatitis B infection in hospital personnel] Mihály I, et al. **Orv Hetil** 1996 Mar 31;137(13):681–5 (36 ref.) (Eng. Abstr.) **(Hun)**

IMMUNOLOGY

Hepatitis A and B vaccines in children. Lieberman JM, et al. **Adv Pediatr Infect Dis** 1996;11:333–63 (131 ref.)

DNA-mediated immunization: prospects for hepatitis B vaccination. Michel ML. **Res Virol** 1995 Jul–Aug; 146(4):261–5 (28 ref.)

STANDARDS

[Efficacy and safety of HB vaccine] Sodeyama T, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:386–93 (17 ref.) **(Jpn)**

THERAPEUTIC USE

[Vaccines against viral hepatitis B: results and prospects] Mukomolov SL. **Tr Inst Im Pastera** 1992;67:103–15 (68 ref.) **(Rus)**

HEPATITIS B VIRUS

see related
HEPATITIS B SURFACE ANTIGENS

Hepatitis B virus transgenic mice: insights into the virus and the disease. Chisari FV. **Hepatology** 1995 Oct;22(4 Pt 1):1316–25 (60 ref.)

CLASSIFICATION

[Molecular evolutionary classification of hepatitis B virus] Ohba K, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:299–304 (5 ref.) **(Jpn)**

DRUG EFFECTS

Therapy of hepadnavirus infection using antisense oligonucleotides. Offensperger WB, et al. **Intervirology** 1995;38(1–2):113–9 (84 ref.)

GENETICS

The clinical significance of hepatitis B mutations [editorial; comment] Kim LS, et al. **Am J Gastroenterol** 1996 Jul; 91(7):1297–8 (8 ref.) Comment on: Am J Gastroenterol 1996 Jul;91(7):1312–7.

DNA-mediated immunization to the hepatitis B surface antigen. Activation and entrainment of the immune response. Whalen RG, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:64–76 (31 ref.)

Hot spots of hepatitis B virus for genetic mutation in Chinese patients and its clinical significance. Luo K, et al. **Chin Med J (Engl)** 1996 Feb;109(2):118–21 (13 ref.)

Hepatitis B virus transgenic mice: models of viral immunobiology and pathogenesis. Chisari FV. **Curr Top Microbiol Immunol** 1996;206:149–73 (138 ref.)

Hepatitis B virus HBx gene and hepatocarcinogenesis. Koike K. **Intervirology** 1995;38(3–4):134–42 (49 ref.)

Subtypes, genotypes and molecular epidemiology of the hepatitis B virus as reflected by sequence variability of the S-gene. Magnius LO, et al. **Intervirology** 1995; 38(1–2):24–34 (57 ref.)

In vitro transformation by hepatitis B virus DNA. Schaefer S, et al. **Intervirology** 1995;38(3–4):143–54 (112 ref.)

Heterogeneity of HBV genome. Raimondo G, et al. **Ital J Gastroenterol** 1995 Mar;27(2):88–90 (22 ref.)

Appearance of HBV mutants during chronic infection. Santantonio T, et al. **Ital J Gastroenterol** 1995 Jun; 27(5):265–9 (43 ref.)

The structure of hepatitis B envelope and molecular variants of hepatitis B virus. Howard CR. **J Viral Hepat** 1995; 2(4):165–70 (21 ref.)

[Molecular biological characteristics of model cells of hepatitis B virus (HBV)-induced direct hepatocellular carcinogenesis] Baba M, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:97–103 (22 ref.) **(Jpn)**

[Mutations in precore and core nucleotide sequence of hepatitis B virus correlated with fulminant and severe hepatitis] Ehata T, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:457–62 (10 ref.) **(Jpn)**

[Precore/core mutation and clinical course of chronic hepatitis B virus infection from the view point of asymptomatic carriers] Fujiwara K, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:401–5 (20 ref.) **(Jpn)**

[Precore region mutation in anti-HBe antibody positive asymptomatic healthy carriers] Fukuda R. **Nippon Rinsho** 1995 Oct;53 Suppl:189–94 (16 ref.) **(Jpn)**

[Changes in precore and core region of hepatitis B virus during the course of chronic hepatitis B virus carriers] Hamasaki K, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:411–4 (9 ref.) **(Jpn)**

[Trends in molecular epidemiology of hepatitis B virus] Hijikata M. **Nippon Rinsho** 1995 Oct;53 Suppl:40–6 (17 ref.) **(Jpn)**

[Virological diagnosis--HBV mutant, HBV subtype, etc.] Ito Y, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:492–7 (12 ref.) **(Jpn)**

[Cellular proteins binding to the hot spot of DNA recombination on the HBV-DNA sequence] Kajino K, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:94–6 (8 ref.) **(Jpn)**

[Hepatitis B virus replication and fulminant hepatitis: special reference to genomic variants] Kamimura T. **Nippon Rinsho** 1995 Oct;53 Suppl:473–6 (8 ref.) **(Jpn)**

[Probable implication of mutations of the X open reading frame in the onset of fulminant hepatitis B] Kaneko M, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:463–6 (14 ref.) **(Jpn)**

[Nucleotide mutations in the precore and core region of hepatitis B virus] Karasawa T, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:52–7 (20 ref.) **(Jpn)**

[Transactivation function of X gene-cellular gene fusion product or 3' truncated pre S2/S gene cellular gene fusion product from integrated hepatitis B virus DNA] Mita E, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:89–93 (15 ref.) **(Jpn)**

[Structure and replication of HBV] Mitamura K. **Nippon Rinsho** 1995 Oct;53 Suppl:3–12 (21 ref.) **(Jpn)**

[The structure and function of HBV-DNA] Mitamura K. **Nippon Rinsho** 1995 Oct;53 Suppl:13–27 (47 ref.) **(Jpn)**

[Detection of HBV precore mutation by PCR-RFLP] Niitsuma H, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:316–20 (7 ref.) **(Jpn)**

[Mutant of the pre-S and S region of HBV] Nishikawa M, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:47–51 (15 ref.) **(Jpn)**

[Transcriptional machinery and its regulatory elements of HBV genome] Nishizono A, et al. **Nippon Rinsho** 1995 Oct; 53 Suppl:28–34 (30 ref.) **(Jpn)**

[Molecular evolutionary classification of hepatitis B virus] Ohba K, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:299–304 (5 ref.) **(Jpn)**

[Posttransfusion fulminant hepatitis associated with HBV mutants] Shimizu M, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:516–21 (20 ref.) **(Jpn)**

[Quantitative assay of HBV-DNA] Shimoda K, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:284–91 (5 ref.) **(Jpn)**

[Mutation site-specific assay (MSSA) for the detection of hepatitis B virus precore defective mutant in hepatitis B infection] Tsubota A. **Nippon Rinsho** 1995 Oct;53 Suppl:321–4 (6 ref.) **(Jpn)**

[Detection of HBV genomes in liver tissue by in situ hybridization] Yamada S, et al. **Nippon Rinsho** 1995 Oct; 53 Suppl:325–30 (19 ref.) **(Jpn)**

[Detection and characterization of pre-core mutants of hepatitis B virus (HBV) in chronically infected patients] López JL, et al. **Acta Gastroenterol Latinoam** 1995; 25(2):85–90 (27 ref.) (Eng. Abstr.) **(Spa)**

[Hepatitis B infections show a variety of clinical pictures. Variations in viral DNA is a possible explanation] Kidd-Ljunggren K. **Lakartidningen** 1996 Mar 27; 93(13):1212–6 (28 ref.) **(Swe)**

GROWTH & DEVELOPMENT

Hepatitis B and transplantation. Davis CL, et al. **Infect Dis Clin North Am** 1995 Dec;9(4):925–41 (102 ref.)

[Acute exacerbation by reactivation of HBV in steroid withdrawal therapy] Arase Y. **Nippon Rinsho** 1995 Oct;53 Suppl:522–6 (6 ref.) **(Jpn)**

IMMUNOLOGY

Hepatitis B virus transgenic mice: models of viral immunobiology and pathogenesis. Chisari FV. **Curr Top Microbiol Immunol** 1996;206:149–73 (138 ref.)

Transplantation of hepatitis B immune lymphocytes as means for adoptive transfer of immunity to hepatitis B virus. Shouval D, et al. **J Hepatol** 1995 Jul;23(1):98–101 (18 ref.)

Hepatitis B virus immunopathology. Chisari FV, et al. **Springer Semin Immunopathol** 1995;17(2–3):261–81 (83 ref.)

The humoral immune response in acute and chronic hepatitis B virus infection. Milich DR, et al. **Springer Semin Immunopathol** 1995;17(2–3):149–66 (81 ref.)

[Epitopes of hepatitis B virus nucleocapsid protein] Ehata T, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:148–54 (17 ref.) **(Jpn)**

[Expression of HLA molecules on the surface of hepatocytes and antigen presentation] Manabe K, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:166–72 (20 ref.) **(Jpn)**

[Immunological markers for early diagnosis and foresight of HBV- related fulminant hepatitis] Onji M. **Nippon Rinsho** 1995 Oct;53 Suppl:498–501 (13 ref.) **(Jpn)**

[Mechanism of hepatocyte destruction through HBV-specific T cell responses] Saibara T, et al. **Nippon Rinsho** 1995 Oct; 53 Suppl:138–43 (20 ref.) **(Jpn)**

PATHOGENICITY

Hepatitis B virus and hepatocellular carcinoma. Ren EC. **Ann Acad Med Singapore** 1996 Jan;25(1):17–21 (52 ref.)

Hepatitis B virus immunopathology. Chisari FV, et al. **Springer Semin Immunopathol** 1995;17(2–3):261–81 (83 ref.)

PHYSIOLOGY

[The potential attachment sites of hepatitis B virus to the hepatocyte--the pre-S(2) antigen and the receptor for polymerized human serum albumin of hepatitis B virus] Matsuura K, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:125–31 (25 ref.) **(Jpn)**

[Clinical significance of the pre-S antigens and the binding activity of polymerized human serum albumin to the receptor on hepatitis B virus particles] Matsuura K, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:265–74 (26 ref.) **(Jpn)**

[Hepatitis B virus-specific DNA polymerase activity as a sensitive marker of viral replication] Matsuura K, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:275–83 (19 ref.) **(Jpn)**

ULTRASTRUCTURE

[Structure and replication of HBV] Mitamura K. **Nippon Rinsho** 1995 Oct;53 Suppl:3–12 (21 ref.) **(Jpn)**

HEPATITIS B VIRUS, DUCK

DRUG EFFECTS

Therapy of hepadnavirus infection using antisense oligonucleotides. Offensperger WB, et al. **Intervirology** 1995;38(1–2):113–9 (84 ref.)

HEPATITIS B VIRUS, WOODCHUCK see **HEPATITIS VIRUS, WOODCHUCK**

HEPATITIS C

Hepatitis C. Sharara AI, et al. **Ann Intern Med** 1996 Oct 15;125(8):658–68 (203 ref.)

Hepatitis C. A clinical update. Colquhoun SD. **Arch Surg** 1996 Jan;131(1):18–23 (49 ref.)

Current perspectives in hepatitis C. Smith BC, et al. **Aust N Z J Med** 1995 Aug;25(4):350–7 (51 ref.)

Hepatitis C virus infection. Molinari JA. **Dent Clin North Am** 1996 Apr;40(2):309–25 (77 ref.)

The clinical and ethical implications of hepatitis C for organ transplantation in Australia. Kerridge IH, et al. **Med J Aust** 1996 Sep 2;165(5):282–5 (49 ref.)

[General remarks of acute hepatitis C] Kiyosawa K, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:487–93 (15 ref.) **(Jpn)**

[Natural course of infants with hepatitis C virus] Nishiguchi S, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:828–33 (16 ref.) **(Jpn)**

[An introduction to chronic hepatitis C] Yatsuhashi H, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:582–9 (6 ref.) **(Jpn)**

[Epidemic of hepatitis in Sashima] Aramaki T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):118–21 (13 ref.) **(Jpn)**

[Type C hepatitis] Furuta S. **Ryoikibetsu Shokogun Shirizu** 1995;(7):13–6 (8 ref.) **(Jpn)**

[Hepatitis virus carrier] Nakajima S, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):54–7 (14 ref.) **(Jpn)**

[Chronic hepatitis] Figueroa Barrios R. **Rev Gastroenterol Peru** 1995;15 Suppl 1:S77–88 (115 ref.) (Eng. Abstr.) **(Spa)**

BLOOD

Hepatitis C virus serum markers and liver disease in children with leukemia. Locasciulli A, et al. **Leuk Lymphoma** 1995 Apr;17(3–4):245–9 (22 ref.)

[Relation between histological findings by Scheuer's scores and serum levels of HCV-RNA, and HCV-genotype] Enomoto K, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:608–12 (16 ref.) **(Jpn)**

[Serum levels of HCV-RNA determined by branched DNA (bDNA) probe assay in chronic hepatitis C] Osada T, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:287–93 (13 ref.) **(Jpn)**

[Histological activity index score and levels of hepatitis C virus RNA in chronic hepatitis C] Takahashi M, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:602–7 (17 ref.) **(Jpn)**

[Significance of apoptosis in hepatitis C and possible involvement of soluble factor in hepatocyte apoptosis] Torimoto Y, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:186–91 (16 ref.) **(Jpn)**

CLASSIFICATION

["The FIND" classification for assessing histological staging and activity in chronic viral hepatitis] Kitamura M. **Nippon Rinsho** 1995 Sep;53 Suppl:595–9 (10 ref.) **(Jpn)**

COMPLICATIONS

Hepatitis C virus infection, cryoglobulinemia, and glomerulonephritis. Schifferli JA, et al. **Adv Nephrol Necker Hosp** 1995;24:107–29 (88 ref.)

Alcohol, hepatotropic viruses, and hepatocellular carcinoma [editorial] Nalpas B, et al. **Alcohol Clin Exp Res** 1995 Oct; 19(5):1089–95 (96 ref.)

End stage liver disease in a 13-year old secondary to hepatitis C and hemochromatosis. Miller M, et al. **Am J Gastroenterol** 1996 Jul;91(7):1427-9 (20 ref.)

Alcoholism is associated with hepatitis C but not hepatitis B in an urban population. Rosman AS, et al. **Am J Gastroenterol** 1996 Mar;91(3):498-505 (67 ref.)

Interferon or hepatitis C virus induced autoimmune aplastic anemia and severe thrombocytopenia? A case report. Siciliano R, et al. **Ann Ital Med Int** 1995 Jul-Sep; 10(3):193-4 (10 ref.)

Hepatitis C viral infection in liver transplantation. Johnson MW, et al. **Arch Surg** 1996 Mar;131(3):284-91 (26 ref.)

Recent pulmonary observations in alpha 1-antitrypsin deficiency, primary biliary cirrhosis, chronic hepatitis C, and other hepatic problems. Krowka MJ. **Clin Chest Med** 1996 Mar;17(1):67-82 (90 ref.)

Hepatitis C virus: from biology to clinical practice. Monteverde A, et al. **Clin Exp Rheumatol** 1995 Nov-Dec; 13 Suppl 13:S205-10 (9 ref.)

Role of hepatitis C virus in dual and triple hepatitis virus infection. Liaw YF. **Hepatology** 1995 Oct;22(4 Pt 1):1101-8 (84 ref.)

Acute exacerbation and superinfection in patients with chronic viral hepatitis. Liaw YF. **J Formos Med Assoc** 1995 Sep;94(9):521-8 (78 ref.)

Hepatitis C and liver transplantation. Chazouilleres O, et al. **J Gastroenterol Hepatol** 1995 Jul-Aug;10(4):471-80 (69 ref.)

Chronic liver disease: do alcohol and hepatitis C virus interact. Cooksley W. **J Gastroenterol Hepatol** 1996 Feb; 11(2):187-92 (45 ref.)

Hepatitis C virus infection complicating lupus nephritis. Albero MD, et al. **Nephrol Dial Transplant** 1996 Jul; 11(7):1342-5 (31 ref.)

Implications of chronic hepatitis B or hepatitis C infection for renal transplant candidates. Goffin E, et al. **Nephrol Dial Transplant** 1995;10 Suppl 6:88-92 (44 ref.)

Hepatitis C virus infection and disease in renal transplantation. Berthoux F. **Nephron** 1995;71(4):386-94 (62 ref.)

[Lichen planus and hepatitis C virus. Apropos of 5 new cases] Hyrailles V, et al. **Gastroenterol Clin Biol** 1995 Oct; 19(10):833-6 (21 ref.) (Eng. Abstr.) **(Fre)**

[Compared efficiency of three strategies of management of chronic hepatitis C. Effect on the risk of cirrhosis 8 years after diagnosis] Michel P, et al. **Gastroenterol Clin Biol** 1996 Feb;20(1):47-54 (61 ref.) (Eng. Abstr.) **(Fre)**

[Liver, biliary tracts and human immunodeficiency virus infection. 1: liver, HIV and hepatitis B, C and D viruses] Vuitton DA, et al. **Gastroenterol Clin Biol** 1996; 20(3):269-80 (146 ref.) **(Fre)**

[Natural history of hepatitis C virus infection] Marcellin P, et al. **Pathol Biol (Paris)** 1995 Oct;43(8):669-73 (34 ref.) (Eng. Abstr.) **(Fre)**

[Extrahepatic manifestations related to hepatitis C virus] Opolon P, et al. **Pathol Biol (Paris)** 1995 Oct;43(8):709-15 (59 ref.) (Eng. Abstr.) **(Fre)**

[Mixed cryoglobulinemia in hepatitis C virus infection] Musset L, et al. **Presse Med** 1996 Apr 6;25(12):595-8 (22 ref.) (Eng. Abstr.) **(Fre)**

[Skin manifestations related to hepatitis C viruses] Doutre MS, et al. **Rev Med Interne** 1995;16(9):666-72 (71 ref.) (Eng. Abstr.) **(Fre)**

[Immunologic diseases and hepatitis C virus] Malaguarnera M, et al. **Rev Med Interne** 1996;17(4):305-12 (51 ref.) (Eng. Abstr.) **(Fre)**

[Prediction of high risk group of patients with hepatitis-C-virus type liver cirrhosis developing to liver neoplasm] Tarao K, et al. **Nippon Naika Gakkai Zasshi** 1995 Dec 10;84(12):1985-91 (5 ref.) **(Jpn)**

[High risk group of patients with hepatitis C virus infection developing hepatocellular carcinoma] Yokosuka O, et al. **Nippon Naika Gakkai Zasshi** 1995 Dec 10;84(12):1975-9 (5 ref.) **(Jpn)**

[Causative incidence of hepatic cirrhosis and clinical statistics of hepatic cirrhosis type C] Arakawa Y, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:690-705 (13 ref.) **(Jpn)**

[Influence of heavy drinking for the development of hepatocellular carcinoma in type C cirrhosis] Chiba T, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:731-5 (23 ref.) **(Jpn)**

[Does interferon therapy on type C liver cirrhosis prevent the occurrence of hepatocellular carcinoma?] Harada H, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:754-8 (17 ref.) **(Jpn)**

[HCV infection in autoimmune hepatitis] Komeda T, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:871-6 (23 ref.) **(Jpn)**

[The role of hepatitis C virus in fulminant hepatitis] Ohnishi H, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:528-33 (22 ref.) **(Jpn)**

[Hepatitis C virus infection in alcoholic patients with chronic liver disease] Sata M, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:852-7 (18 ref.) **(Jpn)**

[Clinical course and prognostic value of Child-Turcotte criteria and Child-Pugh score in medically treated cirrhosis positive for HCV antibody—in comparison with cirrhosis positive for HBs Ag] Shibata M. **Nippon Rinsho** 1995 Sep; 53 Suppl:711-9 (20 ref.) **(Jpn)**

[Progress of chronic hepatitis C to liver cirrhosis—comparison with chronic hepatitis B] Shimomura H, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:720-6 (15 ref.) **(Jpn)**

[Histopathological characteristics of alcoholic liver injury in cases with serum HCV markers] Uchikoshi T, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:858-65 (15 ref.) **(Jpn)**

[HCV genome in type C hepatocellular carcinoma] Yamada G. **Nippon Rinsho** 1995 Sep;53 Suppl:777-81 (13 ref.) **(Jpn)**

[Cryoglobulinemia and its significance in hepatitis C virus infection] Kanoh T. **Ryoikibetsu Shokogun Shirizu** 1995; (8):321-4 (20 ref.) **(Jpn)**

[Cirrhosis of the liver due to hepatitis virus] Kiyosawa K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):158-60 (6 ref.) **(Jpn)**

[Extrahepatic manifestations of hepatitis C virus] Yuste JR, et al. **An Med Interna** 1995 Dec;12(12):609-16 (94 ref.) **(Spa)**

DIAGNOSIS

Hepatitis C virus infection in dialysis and clinical nephrology [editorial] Fabrizi F, et al. **Int J Artif Organs** 1995 May; 18(5):235-44 (138 ref.)

Cerebral ischemia in patients with hepatitis C virus infection and mixed cryoglobulinemia. Petty GW, et al. **Mayo Clin Proc** 1996 Jul;71(7):671-8 (57 ref.)

[Hepatitis C virus. Virological diagnosis] Lunel F, et al. **Pathol Biol (Paris)** 1995 Oct;43(8):681-90 (42 ref.) (Eng. Abstr.) **(Fre)**

[Chronic viral hepatitis: diagnosis and treatment] Stazi F, et al. **Clin Ter** 1996 Mar;147(3):85-92 (33 ref.) (Eng. Abstr.) **(Ita)**

[Extrahepatic manifestations of HCV infection] Marson P. **Minerva Med** 1995 Jul-Aug;86(7-8):305-14 (130 ref.) (Eng. Abstr.) **(Ita)**

[Anti-GOR antibodies] Kato M, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:241-6 (23 ref.) **(Jpn)**

[Serodiagnosis of HCV infection by means of HCV core antibodies (CP-9 Ab, CP-10 Ab)] Nagai K, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:224-9 (17 ref.) **(Jpn)**

[Competence of diagnosis: chronic generalized infection, caused by hepatitis virus (B, C) (editorial)] Serov VV, et al. **Arkh Patol** 1995 Jul-Aug;57(4):3-5 (20 ref.) **(Rus)**

DRUG THERAPY

Summary: antiviral treatment of hepatitis C virus. Dusheiko GM. **Antiviral Res** 1996 Jan;29(1):77-82 (30 ref.)

Sarcoidosis after interferon therapy for chronic active hepatitis C. Teragawa H, et al. **Intern Med** 1996 Jan; 35(1):19-23 (20 ref.)

Approaches to the development of novel inhibitors of hepatitis C virus replication. Clarke BE. **J Viral Hepat** 1995;2(1):1-8 (40 ref.)

[Chronic hepatitis C and interferon alpha treatment] Skarpetowski AC, et al. **Pediatr Pol** 1995 May;70(5):413-25 (94 ref.) (Eng. Abstr.) **(Pol)**

[Alternative treatment to interferon therapy in chronic viral hepatitis] Salmerón Escobar FJ. **Gastroenterol Hepatol** 1995 Oct;18(8):430-6 (72 ref.) **(Spa)**

EPIDEMIOLOGY

Genotypes of hepatitis C virus isolates from different parts of the world. Schreier E, et al. **Arch Virol Suppl** 1996; 11:185-93 (39 ref.)

Hepatitis C virus : prevalence in Lebanese blood donors and brief overview of the disease. Araj GF, et al. **J Med Liban** 1995;43(1):11-6 (44 ref.)

Hepatitis C genotypes: current trends and future implications. Zein NN, et al. **Mayo Clin Proc** 1996 May;71(5):458-62 (50 ref.)

Hepatitis C virus infection in haemodialysis patients: lessons from epidemiology and prophylaxis. Loureiro A, et al. **Nephrol Dial Transplant** 1995;10 Suppl 6:83-7 (63 ref.)

Hepatitis C virus infection and the renal allograft recipient [editorial] Roth D. **Nephron** 1995;71(3):249-53 (42 ref.)

Epidemiology and prevention of hepatitis type C in Italy. Zanetti AR, et al. **Res Virol** 1995 Jul-Aug;146(4):253-9 (31 ref.)

Occupational risk of infection with hepatitis B and hepatitis C virus. Shapiro CN. **Surg Clin North Am** 1995 Dec; 75(6):1047-56 (51 ref.)

[Hepatitis C, awakening of a giant] van Hattum J. **Ned Tijdschr Geneeskd** 1996 Jan 20;140(3):119-24 (32 ref.) (Eng. Abstr.) **(Dut)**

[Interactions between chronic viral hepatitis C and pregnancy] Grangé JD, et al. **Gastroenterol Clin Biol** 1995 May;19(5):520-4 (29 ref.) (Eng. Abstr.) **(Fre)**

[Hepatitis C virus infection. Epidemiology] Bastie A, et al. **Pathol Biol (Paris)** 1995 Oct;43(8):674-80 (78 ref.) (Eng. Abstr.) **(Fre)**

[Epidemiology and prevention of HCV infection in dialysis centers] Cialdea L, et al. **Ann Ist Super Sanita** 1995; 31(3):313-5 (23 ref.) (Eng. Abstr.) **(Ita)**

ETIOLOGY

Hepatitis C virus infection in hemodialyzed patients and kidney allograft recipients. Pol S. **Adv Nephrol Necker Hosp** 1995;24:315-30 (69 ref.)

The viral safety of intravenous immune globulin. Yap PL. **Clin Exp Immunol** 1996 May;104 Suppl 1:35-42 (69 ref.)

Hepatitis C infection in the transplant recipient. Terrault NA, et al. **Infect Dis Clin North Am** 1995 Dec;9(4):943-64 (111 ref.)

Hepatitis C and renal transplantation: outcome of patients. Morales JM. **Nephrol Dial Transplant** 1995;10 Suppl 6:125-8 (47 ref.)

Hepatitis C virus infection in liver allografts. Randhawa PS, et al. **Pathol Annu** 1995;30 Pt 2:203-26 (126 ref.)

[Digestive endoscopy and risk of transmission of hepatitis C virus: hygiene and discussion] René E, et al. **Gastroenterol Clin Biol** 1996 Feb;20(1):109-11 (8 ref.) **(Fre)**

[What are the non transfusional modes of transmission of hepatitis C virus?] Serfaty L, et al. **Gastroenterol Clin Biol** 1995 May;19(5):525-33 (110 ref.) **(Fre)**

[Transfusion and hepatitis C] Jullien AM. **Pathol Biol (Paris)** 1995 Oct;43(8):725-34 (74 ref.) (Eng. Abstr.) **(Fre)**

[Hepatitis C virus infection in hemodialysis] Simon N. **Pathol Biol (Paris)** 1995 Oct;43(8):735-40 (33 ref.) (Eng. Abstr.) **(Fre)**

[Mechanism of liver cell injury in type C hepatitis] Hayashi N, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(4):362-5 (11 ref.) **(Jpn)**

IMMUNOLOGY

Hepatitis C virus infection and clonal B-cell expansion. Sansonno D, et al. **Clin Exp Rheumatol** 1996 Jan-Feb;14 Suppl 14:S45-50 (42 ref.)

Role of humoral immune responses in hepatitis B and C virus infections. Mondelli MU, et al. **Eur J Clin Invest** 1995 Aug; 25(8):543-7 (51 ref.)

Autoimmune hepatitis versus viral hepatitis C. Strassburg CP, et al. **Liver** 1995 Oct;15(5):225-32 (72 ref.)

Immune-mediated liver damage in chronic hepatitis C. Wejstål R. **Scand J Gastroenterol** 1995 Jul;30(7):609-13 (62 ref.)

[Autoimmune hepatitis and hepatitis C] Cacoub P, et al. **Rev Med Interne** 1996;17(2):131-4 (23 ref.) (Eng. Abstr.) **(Fre)**

[HCV-RNA in the circulating immune complexes] Hada H, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:143-9 (24 ref.) **(Jpn)**

[Virological and immunological pathogenesis of hepatitis C virus-associated fulminant and subacute hepatitis] Imawari M. **Nippon Rinsho** 1995 Sep;53 Suppl:546-8 (9 ref.) **(Jpn)**

[Molecular mimicry between LKM 1-autoantigen and HCV-polyproteins] Miyakawa H, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:885-91 (20 ref.) **(Jpn)**

[Fas antigen expression and apoptosis in liver tissues of patients with chronic hepatitis B] Mochizuki K, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:228-33 (17 ref.) **(Jpn)**

[Analyses of cellular immune mechanism in chronic hepatitis C using recombinant vaccinia virus expression system] Nishizono A, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:179-85 (19 ref.) **(Jpn)**

[Clinical and immuno-virological aspects in type C fulminant hepatitis] Sekiyama K, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:534-40 (20 ref.) **(Jpn)**

[Immunohistochemical observation of Fas in the liver with chronic hepatitis C] Takatani M, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:667-74 (23 ref.) **(Jpn)**

[An immunohistochemical analysis in portal lymphocytic aggregation of chronic hepatitis C] Tsuno S, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:635-41 (24 ref.) **(Jpn)**

[Clinical manifestation and immunogenetic background of HCV-marker-positive autoimmune hepatitis] Zeniya M. **Nippon Rinsho** 1995 Sep;53 Suppl:877-84 (11 ref.) **(Jpn)**

METABOLISM

[Cytokine gene expression in the liver of chronic hepatitis C] Fukuda R. **Nippon Rinsho** 1995 Sep;53 Suppl:629-34 (14 ref.) **(Jpn)**

PATHOLOGY

Pathobiology of hepatitis C. Gerber MA. **Verh Dtsch Ges Pathol** 1995;79:162-70 (128 ref.)

[Advances in the pathological study of hepatitis C] Xie L, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1995 Oct; 24(5):329-31 (15 ref.) **(Chi)**

[Pathology of liver graft viral reinfection] Reynès M, et al. **Ann Pathol** 1995;15(5):396-402 (40 ref.) **(Fre)**

[Histopathology of viral hepatitis C] Chevallier M, et al. **Pathol Biol (Paris)** 1995 Oct;43(8):703-8 (44 ref.) (Eng. Abstr.) **(Fre)**

[Relation between histological findings by Scheuer's scores and serum levels of HCV-RNA, and HCV-genotype] Enomoto K, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:608-12 (16 ref.) **(Jpn)**

["The FIND" classification for assessing histological staging and activity in chronic viral hepatitis] Kitamura M. **Nippon Rinsho** 1995 Sep;53 Suppl:595-9 (10 ref.) **(Jpn)**

[Analysis of the mechanisms relating the localization of HCV core protein and hepatic injury--an immunohistochemical study] Masumoto T, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:174-8 (15 ref.) **(Jpn)**

[Role of Fas system in apoptosis induced by hepatitis C virus infection] Mita E, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:198-202 (14 ref.) **(Jpn)**

[A clinical and pathological features of children with hepatitis C virus infection] Nagata I, et al. **Nippon Rinsho** 1995 Sep; 53 Suppl:834-40 (22 ref.) **(Jpn)**

[Histological activity index score and levels of hepatitis C virus RNA in chronic hepatitis C] Takahashi M, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:602–7 (17 ref.) **(Jpn)**

[TUNEL method rarely revealed DNA fragmentation in chronic hepatitis C] Tanaka Y. **Nippon Rinsho** 1995 Sep; 53 Suppl:192–7 (17 ref.) **(Jpn)**

[Significance of apoptosis in hepatitis C and possible involvement of soluble factor in hepatocyte apoptosis] Torimoto Y, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:186–91 (16 ref.) **(Jpn)**

[An immunohistochemical analysis in portal lymphocytic aggregation of chronic hepatitis C] Tsuno S, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:635–41 (24 ref.) **(Jpn)**

[Fundamentals of chronic viral hepatitis and histopathological characteristics of chronic hepatitis C] Uchida T. **Nippon Rinsho** 1995 Sep;53 Suppl:590–4 (10 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Clinical evolution of HCV-related chronic hepatitis. Realdi G, et al. **Clin Exp Rheumatol** 1995 Nov–Dec;13 Suppl 13:S17–21 (21 ref.)

Pathophysiology of hepatitis C virus infection. Camps J, et al. **Pathol Biol (Paris)** 1995 Oct;43(8):691–702 (104 ref.)

PREVENTION & CONTROL

Hepatitis type C: modes of transmission and preventive measures. Tanzi E, et al. **Clin Exp Rheumatol** 1995 Nov–Dec;13 Suppl 13:S13–6 (24 ref.)

Hepatitis C virus infection in haemodialysis patients: lessons from epidemiology and prophylaxis. Loureiro A, et al. **Nephrol Dial Transplant** 1995;10 Suppl 6:83–7 (63 ref.)

Postexposure prophylaxis for occupational exposures to hepatitis B, hepatitis C, and human immunodeficiency virus. Henderson DK. **Surg Clin North Am** 1995 Dec; 75(6):1175–87 (51 ref.)

[Biological diagnosis of hepatitis C virus infection. Role of serological and molecular tests] Pawlotsky JM, et al. **Gastroenterol Clin Biol** 1996 Mar;20(2):146–61 (186 ref.) **(Fre)**

[Epidemiology and prevention of HCV infection in dialysis centers] Cialdea L, et al. **Ann Ist Super Sanita** 1995; 31(3):313–5 (23 ref.) (Eng. Abstr.) **(Ita)**

THERAPY

Treatment of chronic hepatitis C virus infection: a clinical and virological perspective. Gretch DR, et al. **Adv Exp Med Biol** 1996;394:207–24 (121 ref.)

A rational approach to the management of hepatitis C infection. Dusheiko GM, et al. **BMJ** 1996 Feb 10; 312(7027):357–64 (44 ref.)

Primary biliary cirrhosis induced by interferon-alpha therapy for hepatitis C virus infection. D'Amico E, et al. **Dig Dis Sci** 1995 Oct;40(10):2113–6 (20 ref.)

Predictors of a sustained beneficial response to interferon alfa therapy in chronic hepatitis C [editorial] Conjeevaram HS, et al. **Hepatology** 1995 Oct;22(4 Pt 1):1326–9 (30 ref.)

Treatment options for chronic hepatitis C infection. James DG. **J Antimicrob Chemother** 1995 Oct;36(4):591–3 (19 ref.)

Interferon therapy in chronic viral hepatitis. Guptan RC, et al. **J Assoc Physicians India** 1995;Suppl 3:44–51 (56 ref.)

The long-term efficacy of interferon alfa in chronic hepatitis C patients: a critical review. Saracco G, et al. **J Gastroenterol Hepatol** 1995 Nov–Dec;10(6):668–73 (64 ref.)

Future studies of combination therapy for chronic hepatitis C: optimizing response rates for each hepatitis C population. Main J. **J Hepatol** 1995;23 Suppl 2:32–5; discussion 35–6 (18 ref.)

Antiviral therapy for chronic hepatitis C viral infection. Sherlock S. **J Hepatol** 1995;23 Suppl 2:3–7 (31 ref.)

Therapy of chronic viral hepatitis. Fried MW. **Med Clin North Am** 1996 Sep;80(5):957–72 (75 ref.)

Why we should treat chronic viral hepatitis. King PD. **Postgrad Med** 1996 Sep;100(3):68–70, 73; discussion 73, 78 (13 ref.)

Chronic viral hepatitis and use of interferon. Whom are we treating? Koretz RL. **Postgrad Med** 1996 Sep;100(3):55–7, 61–2, 68 (11 ref.)

A rational approach to hepatitis C. Mills P, et al. **Practitioner** 1996 Mar;240(1560):172–6 (5 ref.)

[Treatment of hepatitis C] Trepo C, et al. **Pathol Biol (Paris)** 1995 Oct;43(8):716–24 (58 ref.) (Eng. Abstr.) **(Fre)**

[Current knowledge in the treatment of chronic hepatitis C] Pirotte J. **Rev Med Liege** 1995 Dec;50(12):501–4 (29 ref.) **(Fre)**

[Alpha-interferon in the treatment of chronic hepatitis C in children] Cinquetti M, et al. **Pediatr Med Chir** 1995 Nov–Dec;17(6):501–7 (78 ref.) (Eng. Abstr.) **(Ita)**

[Anti-platelet antibody and severe thrombocytopenia during interferon-alpha therapy for chronic active hepatitis C] Tanaka Y, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Apr;19(2):150–6 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Interferon therapy of viral hepatitis] Suzuki S. **Nippon Naika Gakkai Zasshi** 1995 Sep 10;84(9):1559–63 (4 ref.) **(Jpn)**

[HCV-serotype and IFN response] Abe K, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:959–64 (10 ref.) **(Jpn)**

[Changes of serum 2',5'-oligoadenylate synthetase activity and neopterin during interferon treatment for chronic hepatitis C] Daito K, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:981–5 (16 ref.) **(Jpn)**

[Selection of therapy for chronic hepatitis C with feature of autoimmune hepatitis] Kakumu S. **Nippon Rinsho** 1995 Sep;53 Suppl:892–6 (16 ref.) **(Jpn)**

[Therapeutic effects of interferon on chronic hepatitis C from the aspect of dosage and method of administration] Shoji S, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:997–1000 (10 ref.) **(Jpn)**

[Treatment of type C fulminant and subfulminant hepatitis—featuring antiviral and immunosuppressive treatment] Yoshiba M. **Nippon Rinsho** 1995 Sep;53 Suppl:549–56 (34 ref.) **(Jpn)**

[Treatment of hepatitis C] Schrumpf E, et al. **Tidsskr Nor Laegeforen** 1996 Jun 10;116(15):1792–4 (10 ref.) (Eng. Abstr.) **(Nor)**

[Is the treatment of chronic viral hepatitis C with interferon-alpha effective?] Beker S, et al. **G E N** 1995 Apr-Jun;49(2):165–9 (43 ref.) (Eng. Abstr.) **(Spa)**

[The interferon treatment of hepatitis C in the liver transplant patient (editorial)] de la Mata M, et al. **Gastroenterol Hepatol** 1996 May;19(5):259–61 (42 ref.) **(Spa)**

[Factors related to response to interferon in chronic hepatitis C] Pérez Alvarez R. **Gastroenterol Hepatol** 1996 Apr; 19(4):217–23 (98 ref.) **(Spa)**

TRANSMISSION

Hepatitis C virus (HCV)—an occupational risk to dentists? Porter SR, et al. **Br Dent J** 1996 Jun 22;180(12):473–4 (21 ref.)

Human Immunoglobulins for intravenous use and hepatitis C viral transmission. Slade HB. **Clin Diagn Lab Immunol** 1994 Nov;1(6):613–9 (84 ref.)

Hepatitis type C: modes of transmission and preventive measures. Tanzi E, et al. **Clin Exp Rheumatol** 1995 Nov–Dec;13 Suppl 13:S13–6 (24 ref.)

Methods of transmission of hepatitis C. Tibbs CJ. **J Viral Hepat** 1995;2(3):113–9 (75 ref.)

Hepatitis C virus infection and the renal allograft recipient [editorial] Roth D. **Nephron** 1995;71(3):249–53 (42 ref.)

Hepatitis C infection in cadaver organ donors: strategies to reduce transmission of infection and prevent organ waste. Pereira BJ, et al. **Pediatr Nephrol** 1995;9 Suppl:S23–8 (41 ref.)

Hepatitis C virus and organ transplantation. Fishman JA, et al. **Transplantation** 1996 Jul 27;62(2):147–54 (100 ref.)

Sexual, vertical and household transmission of hepatitis C. Caldwell SH, et al. **Va Med Q** 1995 Fall;122(4):270–4 (35 ref.)

VIROLOGY

Etiopathogenetic role of hepatitis C virus in mixed cryoglobulinemia, chronic liver diseases and lymphomas. Ferri C, et al. **Clin Exp Rheumatol** 1995 Nov–Dec;13 Suppl 13:S135–40 (49 ref.)

Viral arthritis including HIV. Naides SJ. **Curr Opin Rheumatol** 1995 Jul;7(4):337–42 (36 ref.)

Hepatitis C virus variants and the role of genotyping. Smith DB, et al. **J Hepatol** 1995;23 Suppl 2:26–31 (31 ref.)

Host and viral features in chronic HCV infection: relevance to interferon responsiveness. Craxì A, et al. **Res Virol** 1995 Jul-Aug;146(4):273–8 (41 ref.)

Hepatitis C virus quasispecies populations during chronic hepatitis C infection. Enomoto N, et al. **Trends Microbiol** 1995 Nov;3(11):445–7 (25 ref.)

[HCV-RNA in liver of chronic hepatitis C—plus strand RNA and minus strand RNA] Endo H, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:623–8 (17 ref.) **(Jpn)**

[Virological and immunological pathogenesis of hepatitis C virus-associated fulminant and subacute hepatitis] Imawari M. **Nippon Rinsho** 1995 Sep;53 Suppl:546–8 (9 ref.) **(Jpn)**

[Viral escape from humoral immune system by mutations in hypervariable region of HCV envelope protein and mechanism of persistent viral infection] Kato N, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:129–35 (13 ref.) **(Jpn)**

[The prognosis of chronic hepatitis C—comparison between patients with genotypes 1 and 2 hepatitis C viruses] Kobayashi M, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:648–51 (13 ref.) **(Jpn)**

[Fluctuation of hepatitis C virus quasispecies with interferon treatment and interferon-resistant variants in hepatitis C virus 1b] Sakuma I, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:930–5 (9 ref.) **(Jpn)**

[Clinical and immuno-virological aspects in type C fulminant hepatitis] Sekiyama K, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:534–40 (20 ref.) **(Jpn)**

[Distribution of HCV-infected hepatocytes in chronic hepatitis C] Tanaka Y. **Nippon Rinsho** 1995 Sep;53 Suppl:618–22 (16 ref.) **(Jpn)**

[Chronic hepatitis C and interferon alpha treatment] Skarpetowski AC, et al. **Pediatr Pol** 1995 May;70(5):413–25 (94 ref.) (Eng. Abstr.) **(Pol)**

HEPATITIS C ANTIBODIES

ANALYSIS

[Biological diagnosis of hepatitis C virus infection. Role of serological and molecular tests] Pawlotsky JM, et al. **Gastroenterol Clin Biol** 1996 Mar;20(2):146–61 (186 ref.) **(Fre)**

[Transfusion and hepatitis C] Jullien AM. **Pathol Biol (Paris)** 1995 Oct;43(8):725–34 (74 ref.) (Eng. Abstr.) **(Fre)**

[Hepatitis C virus. Virological diagnosis] Lunel F, et al. **Pathol Biol (Paris)** 1995 Oct;43(8):681–90 (42 ref.) (Eng. Abstr.) **(Fre)**

[Hepatitis C virus infection in hemodialysis] Simon N. **Pathol Biol (Paris)** 1995 Oct;43(8):735–40 (33 ref.) (Eng. Abstr.) **(Fre)**

[Progress in currently available anti-HCV assay systems] Ishikawa K, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:203–11 (17 ref.) **(Jpn)**

[Anti-GOR antibodies] Kato M, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:241–6 (23 ref.) **(Jpn)**

[Serodiagnosis of HCV infection by means of HCV core antibodies (CP-9 Ab, CP-10 Ab)] Nagai K, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:224–9 (17 ref.) **(Jpn)**

[Quantitative assay of anti-HCV core antibody with JCC-2 ELISA: anti-HCV core IgG antibody] Nakashima T, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:247–52 (19 ref.) **(Jpn)**

[C8-2 (NS5) antibody and epitope analysis] Nozaki C, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:230–5 (11 ref.) **(Jpn)**

[Antibodies generated against hepatitis C virus (HCV) core antigen: IgM and IgA antibody against HCV core] Sato S, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:253–9 (16 ref.) **(Jpn)**

[An assay system for ARIMA14 antibody] Sho Y, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:236–40 (14 ref.) **(Jpn)**

[Specific antibody assay for genotyping of hepatitis C virus] Yasui K, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:260–5 (13 ref.) **(Jpn)**

BIOSYNTHESIS

Role of humoral immune responses in hepatitis B and C virus infections. Mondelli MU, et al. **Eur J Clin Invest** 1995 Aug; 25(8):543–7 (51 ref.)

BLOOD

Hepatitis C virus : prevalence in Lebanese blood donors and brief overview of the disease. Araj GF, et al. **J Med Liban** 1995;43(1):11–6 (44 ref.)

[Histopathological characteristics of alcoholic liver injury in cases with serum HCV markers] Uchikoshi T, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:858–65 (15 ref.) **(Jpn)**

IMMUNOLOGY

[Hepatitis C virus antibody in the serum of blood donors] Barna TK, et al. **Orv Hetil** 1996 Mar 10;137(10):507–11 (48 ref.) (Eng. Abstr.) **(Hun)**

HEPATITIS C ANTIGENS

ANALYSIS

Immunohistochemical detection of hepatitis C virus-related proteins in liver tissue. Sansonno D, et al. **Clin Exp Rheumatol** 1995 Nov–Dec;13 Suppl 13:S29–32 (15 ref.)

[Hepatitis C virus. Virological diagnosis] Lunel F, et al. **Pathol Biol (Paris)** 1995 Oct;43(8):681–90 (42 ref.) (Eng. Abstr.) **(Fre)**

HEPATITIS C VIRUS see **HEPATITIS C VIRUSES**

HEPATITIS C VIRUSES

Hepatitis C virus in dermatology. A review. Pawlotsky JM, et al. **Arch Dermatol** 1995 Oct;131(10):1185–93 (138 ref.)

Hepatitis C virus and hepatocellular carcinoma. Colombo M, et al. **Clin Exp Rheumatol** 1995 Nov–Dec;13 Suppl 13:S23–7 (49 ref.)

Etiopathogenetic role of hepatitis C virus in mixed cryoglobulinemia, chronic liver diseases and lymphomas. Ferri C, et al. **Clin Exp Rheumatol** 1995 Nov–Dec;13 Suppl 13:S135–40 (49 ref.)

Viruses and cryoglobulinemia. Galli M. **Clin Exp Rheumatol** 1995 Nov–Dec;13 Suppl 13:S63–70 (66 ref.)

Hepatitis C virus: from biology to clinical practice. Monteverde A, et al. **Clin Exp Rheumatol** 1995 Nov–Dec; 13 Suppl 13:S205–10 (9 ref.)

Immunohistochemical detection of hepatitis C virus-related proteins in liver tissue. Sansonno D, et al. **Clin Exp Rheumatol** 1995 Nov–Dec;13 Suppl 13:S29–32 (15 ref.)

[Analysis of the mechanisms relating the localization of HCV core protein and hepatic injury—an immunohistochemical study] Masumoto T, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:174–8 (15 ref.) **(Jpn)**

CLASSIFICATION

[HCV-serotype and IFN response] Abe K, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:959–64 (10 ref.) **(Jpn)**

[Classification of hepatitis C virus genotypes and its application to molecular epidemiology] Okamoto H. **Nippon Rinsho** 1995 Sep;53 Suppl:71–9 (20 ref.) **(Jpn)**

HEPATITIS C VIRUSES

DRUG EFFECTS

Treatment of chronic hepatitis C virus infection: a clinical and virological perspective. Gretch DR, et al. **Adv Exp Med Biol** 1996;394:207-24 (121 ref.)

[Fluctuation of hepatitis C virus quasispecies with interferon treatment and interferon-resistant variants in hepatitis C virus 1b] Sakuma I, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:930-5 (9 ref.) **(Jpn)**

GENETICS

Genotypes of hepatitis C virus isolates from different parts of the world. Schreier E, et al. **Arch Virol Suppl** 1996; 11:185-93 (39 ref.)

Structure and function of the hepatitis C virus internal ribosome entry site. Wang C, et al. **Curr Top Microbiol Immunol** 1995;203:99-115 (81 ref.)

Hepatitis C virus variants and the role of genotyping. Smith DB, et al. **J Hepatol** 1995;23 Suppl 2:26-31 (31 ref.)

Hepatitis C virus : prevalence in Lebanese blood donors and brief overview of the disease. Araj GF, et al. **J Med Liban** 1995;43(1):11-6 (44 ref.)

Sequence variability of hepatitis C virus and its clinical relevance. Dusheiko G, et al. **J Viral Hepat** 1994;1(1):3-15 (107 ref.)

Hepatitis C virus serum markers and liver disease in children with leukemia. Locasciulli A, et al. **Leuk Lymphoma** 1995 Apr;17(3-4):245-9 (22 ref.)

Hepatitis C genotypes: current trends and future implications. Zein NN, et al. **Mayo Clin Proc** 1996 May;71(5):458-62 (50 ref.)

Hepatitis C virus quasispecies populations during chronic hepatitis C infection. Enomoto N, et al. **Trends Microbiol** 1995 Nov;3(11):445-7 (25 ref.)

[Current status of the study on hepatitis C virus envelope region gene and its vaccine] Li Q, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1995 Nov; 29(6):363-5 (18 ref.) **(Chi)**

[Hepatitis C, awakening of a giant] van Hattum J. **Ned Tijdschr Geneeskd** 1996 Jan 20;140(3):119-24 (32 ref.) (Eng. Abstr.) **(Dut)**

[Histopathology of viral hepatitis C] Chevallier M, et al. **Pathol Biol (Paris)** 1995 Oct;43(8):703-8 (44 ref.) (Eng. Abstr.) **(Fre)**

[Hepatitis C virus. Virological diagnosis] Lunel F, et al. **Pathol Biol (Paris)** 1995 Oct;43(8):681-90 (42 ref.) (Eng. Abstr.) **(Fre)**

[Treatment of hepatitis C] Trepo C, et al. **Pathol Biol (Paris)** 1995 Oct;43(8):716-24 (58 ref.) (Eng. Abstr.) **(Fre)**

[Expression of HCV proteins by using recombinant baculoviruses] Aizaki H, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:80-4 (16 ref.) **(Jpn)**

[Nucleotide sequence substitutions of hepatitis C virus] Chayama K. **Nippon Rinsho** 1995 Sep;53 Suppl:657-61 (14 ref.) **(Jpn)**

[Genotyping of hepatitis C virus by polymerase chain reaction with a mixed primer set derived from nucleotide sequences of NS5 region] Chayama K. **Nippon Rinsho** 1995 Sep;53 Suppl:321-5 (14 ref.) **(Jpn)**

[HCV-RNA in liver of chronic hepatitis C--plus strand RNA and minus strand RNA] Endo H, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:623-8 (17 ref.) **(Jpn)**

[Relation between histological findings by Scheuer's scores and serum levels of HCV-RNA, and HCV-genotype] Enomoto K, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:608-12 (16 ref.) **(Jpn)**

[Structure and organization of hepatitis C virus genome] Fuke I, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:17-24 (19 ref.) **(Jpn)**

[Structural and functional analysis of the internal ribosome entry site within 5' noncoding region of hepatitis C virus RNA] Fukushi S, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:36-42 (17 ref.) **(Jpn)**

[HCV-RNA in the circulating immune complexes] Hada H, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:143-9 (24 ref.) **(Jpn)**

[Quantitation of HCV-RNA by competitive-PCR] Kaneko S, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:281-6 (5 ref.) **(Jpn)**

[Highly conserved secondary structures predicted in 5' noncoding region of HCV: a possible connection to viral replication] Katayama K, et al. **Nippon Rinsho** 1995 Sep; 53 Suppl:43-50 (19 ref.) **(Jpn)**

[Genetic heterogeneity and variability of hepatitis C virus and hypervariable regions] Kato N, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:64-70 (17 ref.) **(Jpn)**

[Hypermethylation and inactivity of hepatitis C virus cDNA transgene in transgenic mice] Kato T, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:95-9 (16 ref.) **(Jpn)**

[Method of detecting plus and minus strands of hepatitis C viral RNA by strand specific reverse transcription-polymerase chain reaction] Kawashima T, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:294-9 (11 ref.) **(Jpn)**

[The prognosis of chronic hepatitis C--comparison between patients with genotypes 1 and 2 hepatitis C viruses] Kobayashi M, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:648-51 (13 ref.) **(Jpn)**

[Analysis of hepatitis C virus quasispecies populations using PCR-SSCP method] Kurosaki M, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:339-45 (16 ref.) **(Jpn)**

[Expression of HCV genes using adenovirus vector with CAG promoter] Makimura M, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:91-4 (9 ref.) **(Jpn)**

[Processing of hepatitis C virus envelope proteins] Matsuura Y, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:51-6 (17 ref.) **(Jpn)**

[PCR-based genotyping with genotype-specific primers derived from the C gene of HCV genome] Okamoto H. **Nippon Rinsho** 1995 Sep;53 Suppl:312-20 (26 ref.) **(Jpn)**

[Classification of hepatitis C virus genotypes and its application to molecular epidemiology] Okamoto H. **Nippon Rinsho** 1995 Sep;53 Suppl:71-9 (20 ref.) **(Jpn)**

[Serum levels of HCV-RNA determined by branched DNA (bDNA) probe assay in chronic hepatitis C] Osada T, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:287-93 (13 ref.) **(Jpn)**

[Expression and purification of hepatitis C virus serine proteinase] Shoji I, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:30-5 (18 ref.) **(Jpn)**

[Histological activity index score and levels of hepatitis C virus RNA in chronic hepatitis C] Takahashi M, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:602-7 (17 ref.) **(Jpn)**

[Cationic liposome-mediated expression of hepatitis C virus genome in adult rat liver] Takehara T, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:102-6 (13 ref.) **(Jpn)**

[Expression of the proteins encoded by the hepatitis C viral genome by vaccinia virus expression system] Tanaka T, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:85-90 (16 ref.) **(Jpn)**

[Mechanism of hepatitis C virus protein processing] Tanji Y, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:25-9 (12 ref.) **(Jpn)**

[HCV genome in type C hepatocellular carcinoma] Yamada G. **Nippon Rinsho** 1995 Sep;53 Suppl:777-81 (13 ref.) **(Jpn)**

[Detection of HCV-RNA in liver by in situ hybridization] Yamada S, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:300-6 (29 ref.) **(Jpn)**

[Specific antibody assay for genotyping of hepatitis C virus] Yasui K, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:260-5 (13 ref.) **(Jpn)**

[Hepatitis C virus genotypes] Pérez Ruiz M, et al. **Gastroenterol Hepatol** 1996 May;19(5):274-80 (70 ref.) **(Spa)**

IMMUNOLOGY

Human Immunoglobulins for intravenous use and hepatitis C viral transmission. Slade HB. **Clin Diagn Lab Immunol** 1994 Nov;1(6):613-9 (84 ref.)

Immunity elicited by hepatitis C virus. Farci P, et al. **Clin Exp Rheumatol** 1995 Nov-Dec;13 Suppl 13:S9-12 (24 ref.)

Hepatitis C virus infection and clonal B-cell expansion. Sansonno D, et al. **Clin Exp Rheumatol** 1996 Jan-Feb;14 Suppl 14:S45-50 (42 ref.)

Hepatitis C virus-specific T lymphocyte responses. Rice CM, et al. **Curr Opin Immunol** 1995 Aug;7(4):532-8 (79 ref.)

Hepatitis C virus serum markers and liver disease in children with leukemia. Locasciulli A, et al. **Leuk Lymphoma** 1995 Apr;17(3-4):245-9 (22 ref.)

[Hepatitis C virus antibody in the serum of blood donors] Barna TK, et al. **Orv Hetil** 1996 Mar 10;137(10):507-11 (48 ref.) (Eng. Abstr.) **(Hun)**

[Hypervariable region specific formation of immune complexes in a plasma with quasispecies of hepatitis C virus] Hijikata M, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:150-5 (19 ref.) **(Jpn)**

[Progress in currently available anti-HCV assay systems] Ishikawa K, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:203-11 (17 ref.) **(Jpn)**

[Viral escape from humoral immune system by mutations in hypervariable region of HCV envelope protein and mechanism of persistent viral infection] Kato N, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:129-35 (13 ref.) **(Jpn)**

[HCV core specific CTL and epitope] Kita H, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:156-62 (19 ref.) **(Jpn)**

[Development of hepatitis C virus vaccine] Matsuura Y, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:112-6 (18 ref.) **(Jpn)**

[Molecular mimicry between LKM 1-autoantigen and HCV-polyproteins] Miyakawa H, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:885-91 (20 ref.) **(Jpn)**

[Serodiagnosis of HCV infection by means of HCV core antibodies (CP-9 Ab, CP-10 Ab)] Nagai K, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:224-9 (17 ref.) **(Jpn)**

[Quantitative assay of anti-HCV core antibody with JCC-2 ELISA: anti-HCV core IgG antibody] Nakashima T, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:247-52 (19 ref.) **(Jpn)**

[C8-2 (NS5) antibody and epitope analysis] Nozaki C, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:230-5 (11 ref.) **(Jpn)**

[Antibodies generated against hepatitis C virus (HCV) core antigen: IgM and IgA antibody against HCV core] Sato S, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:253-9 (16 ref.) **(Jpn)**

[Clinical course and prognostic value of Child-Turcotte criteria and Child-Pugh score in medically treated cirrhosis positive for HCV antibody--in comparison with cirrhosis positive for HBs Ag] Shibata M. **Nippon Rinsho** 1995 Sep; 53 Suppl:711-9 (20 ref.) **(Jpn)**

[Induction of cytotoxic T cells specific for HCV-NS5 and cytokine] Shirai M, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:163-9 (17 ref.) **(Jpn)**

[An assay system for ARIMA14 antibody] Sho Y, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:236-40 (14 ref.) **(Jpn)**

[Histopathological characteristics of alcoholic liver injury in cases with serum HCV markers] Uchikoshi T, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:858-65 (15 ref.) **(Jpn)**

[Linear B cell epitopes located on core and NS3 regions of HCV] Ueda S. **Nippon Rinsho** 1995 Sep;53 Suppl:123-8 (21 ref.) **(Jpn)**

[Specific antibody assay for genotyping of hepatitis C virus] Yasui K, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:260-5 (13 ref.) **(Jpn)**

ISOLATION & PURIFICATION

Genotypes of hepatitis C virus isolates from different parts of the world. Schreier E, et al. **Arch Virol Suppl** 1996; 11:185-93 (39 ref.)

The new lymphotropic herpesviruses (HHV-6, HHV-7, HHV-8) and hepatitis C virus (HCV) in human lymphoproliferative diseases: an overview. Luppi M, et al. **Haematologica** 1996 May-Jun;81(3):265-81 (158 ref.)

Pathobiology of hepatitis C. Gerber MA. **Verh Dtsch Ges Pathol** 1995;79:162-70 (128 ref.)

[Biological diagnosis of hepatitis C virus infection. Role of serological and molecular tests] Pawlotsky JM, et al. **Gastroenterol Clin Biol** 1996 Mar;20(2):146-61 (186 ref.) **(Fre)**

[Detection of hepatitis C virus (HCV) infected cell using in situ hybridization and PCR in situ hybridization] Kawai H, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:307-11 (23 ref.) **(Jpn)**

[Distribution of HCV-infected hepatocytes in chronic hepatitis C] Tanaka Y. **Nippon Rinsho** 1995 Sep;53 Suppl:618-22 (16 ref.) **(Jpn)**

[Hepatitis C virus] Kato N, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):676-80 (19 ref.) **(Jpn)**

[Chronic hepatitis C and interferon alpha treatment] Skarpetowski AC, et al. **Pediatr Pol** 1995 May;70(5):413-25 (94 ref.) (Eng. Abstr.) **(Pol)**

METABOLISM

[Immunohistochemistry and in situ hybridization in the identification of the hepatitis C virus in liver tissue] Soguero Serrano C. **Gastroenterol Hepatol** 1996 May;19(5):262-73 (113 ref.) **(Spa)**

PATHOGENICITY

Hepatitis C virus as a lymphotropic agent: evidence and pathogenetic implications. Zignego AL, et al. **Clin Exp Rheumatol** 1995 Nov-Dec;13 Suppl 13:S33-7 (19 ref.)

Hepatitis C virus as a causative agent of hepatocellular carcinoma. Shimotohno K. **Intervirology** 1995; 38(3-4):162-9 (55 ref.)

[Mixed cryoglobulinemia and the hepatitis C virus (editorial)] Bulfoni A. **Minerva Med** 1995 May;86(5):193-8 (37 ref.) (Eng. Abstr.) **(Ita)**

PHYSIOLOGY

Biology and genetic heterogeneity of hepatitis C virus. Bukh J, et al. **Clin Exp Rheumatol** 1995 Nov-Dec;13 Suppl 13:S3-7 (29 ref.)

Replication of hepatitis C virus: catching it in the act [editorial; comment] Branch AD. **Hepatology** 1996 Feb; 23(2):372-5 (40 ref.) Comment on: Hepatology 1996 Feb;23(2):205-9.

Role of hepatitis C virus in dual and triple hepatitis virus infection. Liaw YF. **Hepatology** 1995 Oct;22(4 Pt 1):1101-8 (84 ref.)

Approaches to the development of novel inhibitors of hepatitis C virus replication. Clarke BE. **J Viral Hepat** 1995;2(1):1-8 (40 ref.)

Pathophysiology of hepatitis C virus infection. Camps J, et al. **Pathol Biol (Paris)** 1995 Oct;43(8):691-702 (104 ref.)

Host and viral features in chronic HCV infection: relevance to interferon responsiveness. Craxi A, et al. **Res Virol** 1995 Jul-Aug;146(4):273-8 (41 ref.)

ULTRASTRUCTURE

[Ultrastructural feature of HCV particle as revealed by immunoelectron microscopy] Watanabe S, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:11-6 (13 ref.) **(Jpn)**

[Searching for hepatitis C virus by immunoelectron microscopy and its morphology] Watanabe S, et al. **Nippon Rinsho** 1995 Aug;53(8):2069-78 (19 ref.) (Eng. Abstr.) **(Jpn)**

HEPATITIS, CHRONIC ACTIVE

[PBC-CAH overlapping syndrome] Takahashi H, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):565-8 (14 ref.) **(Jpn)**

[Chronic hepatitis] Figueroa Barrios R. **Rev Gastroenterol Peru** 1995;15 Suppl 1:S77-88 (115 ref.) (Eng. Abstr.) **(Spa)**

CLASSIFICATION

Histological classification and quantitation of the severity of chronic hepatitis: keep it simple! Hytiroglou P, et al.

Semin Liver Dis 1995 Nov;15(4):414–21 (27 ref.)

COMPLICATIONS

Severe hyperbilirubinemia due to acute hepatitis A superimposed on a chronic hepatitis B carrier with glucose-6-phosphate dehydrogenase deficiency. Huo TI, et al. **Am J Gastroenterol** 1996 Jan;91(1):158–9 (10 ref.)

[Lichen planus and hepatitis C virus. Apropos of 5 new cases] Hyrailles V, et al. **Gastroenterol Clin Biol** 1995 Oct; 19(10):833–6 (21 ref.) (Eng. Abstr.) **(Fre)**

[Compared efficiency of three strategies of management of chronic hepatitis C. Effect on the risk of cirrhosis 8 years after diagnosis] Michel P, et al. **Gastroenterol Clin Biol** 1996 Feb;20(1):47–54 (61 ref.) (Eng. Abstr.) **(Fre)**

[Liver, biliary tracts and human immunodeficiency virus infection. I:q liver, HIV and hepatitis B, C and D viruses] Vuitton DA, et al. **Gastroenterol Clin Biol** 1996; 20(3):269–80 (146 ref.) **(Fre)**

[Natural history of hepatitis C virus infection] Marcellin P, et al. **Pathol Biol (Paris)** 1995 Oct;43(8):669–73 (34 ref.) (Eng. Abstr.) **(Fre)**

[Collagen diseases and vasculitis] Takasaki Y. **Ryoikibetsu Shokogun Shirizu** 1995;(8):329–32 (19 ref.) **(Jpn)**

DIAGNOSIS

Acute exacerbation in chronic hepatitis B virus infection. Santos MV, et al. **Rev Soc Bras Med Trop** 1996 May–Jun; 29(3):275–9 (9 ref.)

[Significance of antineutrophil cytoplasmic antibodies (ANCA) in diagnosis and immunopathogenesis of chronic inflammatory liver diseases] Mayet WJ, et al. **Med Klin** 1996 Jun 15;91(6):384–8 (33 ref.) **(Ger)**

[Competence of diagnosis: chronic generalized infection, caused by hepatitis virus (B, C) (editorial)] Serov VV, et al. **Arkh Patol** 1995 Jul–Aug;57(4):3–5 (20 ref.) **(Rus)**

DRUG THERAPY

Therapeutic applications of alpha interferon for chronic viral hepatitis in pediatric patients. Kay MH, et al. **Clin Pediatr (Phila)** 1995 Jul;34(7):372–9 (50 ref.)

Sarcoidosis after interferon therapy for chronic active hepatitis C. Teragawa H, et al. **Intern Med** 1996 Jan; 35(1):19–23 (20 ref.)

New developments in antiviral therapy for chronic hepatitis B infection. De Man RA, et al. **Scand J Gastroenterol Suppl** 1995;212:100–4 (26 ref.)

[Alternative treatment to interferon therapy in chronic viral hepatitis] Salmerón Escobar FJ. **Gastroenterol Hepatol** 1995 Oct;18(8):430–6 (72 ref.) **(Spa)**

EPIDEMIOLOGY

[Interactions between chronic viral hepatitis C and pregnancy] Grangé JD, et al. **Gastroenterol Clin Biol** 1995 May;19(5):520–4 (29 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Immune-mediated liver damage in chronic hepatitis C. Wejstål R. **Scand J Gastroenterol** 1995 Jul;30(7):609–13 (62 ref.)

PATHOLOGY

Histopathological diagnosis and terminology of chronic hepatitis. Ludwig J. **J Hepatol** 1995;23 Suppl 1:49–53 (26 ref.)

Histological classification and quantitation of the severity of chronic hepatitis: keep it simple! Hytiroglou P, et al. **Semin Liver Dis** 1995 Nov;15(4):414–21 (27 ref.)

PREVENTION & CONTROL

[Treatment and prevention of chronic viral hepatitis] Lumio J, et al. **Duodecim** 1994;110(20):1883–92 (46 ref.) **(Fin)**

[Biological diagnosis of hepatitis C virus infection. Role of serological and molecular tests] Pawlotsky JM, et al. **Gastroenterol Clin Biol** 1996 Mar;20(2):146–61 (186 ref.) **(Fre)**

SURGERY

Hepatitis C viral infection in liver transplantation. Johnson MW, et al. **Arch Surg** 1996 Mar;131(3):284–91 (26 ref.)

THERAPY

Long-term effect of interferon alpha alone or after prednisone withdrawal in chronic hepatitis B. Interim report and review of the literature. Gonzalez-Mateos F, et al. **Hepatogastroenterology** 1995 Nov–Dec;42(6):893–9 (25 ref.)

Therapy of chronic viral hepatitis. Fried MW. **Med Clin North Am** 1996 Sep;80(5):957–72 (75 ref.)

Why we should treat chronic viral hepatitis. King PD. **Postgrad Med** 1996 Sep;100(3):68–70, 73; discussion 73, 78 (13 ref.)

Chronic viral hepatitis and use of interferon. Whom are we treating? Koretz RL. **Postgrad Med** 1996 Sep;100(3):55–7, 61–2, 68 (11 ref.)

[Depressive disorders and interferon alpha (editorial)] Hardy P. **Gastroenterol Clin Biol** 1996;20(3):255–7 (13 ref.) **(Fre)**

[Treatment of hepatitis C] Trepo C, et al. **Pathol Biol (Paris)** 1995 Oct;43(8):716–24 (58 ref.) (Eng. Abstr.) **(Fre)**

[Interferons as therapy in viral hepatitis: are promises kept?] Spengler U. **Ther Umsch** 1995 Oct;52(10):645–51 (57 ref.) (Eng. Abstr.) **(Ger)**

[Anti-platelet antibody and severe thrombocytopenia during interferon-alpha therapy for chronic active hepatitis C] Tanaka Y, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Apr;19(2):150–6 (17 ref.) (Eng. Abstr.) **(Jpn)**

VIROLOGY

Hepatitis C viral infection in liver transplantation. Johnson MW, et al. **Arch Surg** 1996 Mar;131(3):284–91 (26 ref.)

Etiopathogenetic role of hepatitis C virus in mixed cryoglobulinemia, chronic liver diseases and lymphomas. Ferri C, et al. **Clin Exp Rheumatol** 1995 Nov–Dec;13 Suppl 13:S135–40 (49 ref.)

HEPATITIS D see **DELTA INFECTION**

HEPATITIS D VIRUS see **DELTA AGENT**

HEPATITIS, DELTA see **DELTA INFECTION**

HEPATITIS E

[Hepatitis E] Uchida T. **Ryoikibetsu Shokogun Shirizu** 1995; (7):17–9 (9 ref.) **(Jpn)**

DIAGNOSIS

Hepatitis E: an overview. Mast EE, et al. **Annu Rev Med** 1996;47:257–66 (55 ref.)

EPIDEMIOLOGY

[Epidemiology of infection by hepatitis E virus—from the view as an imported infection to Japan] Tanaka T, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:895–900 (29 ref.) **(Jpn)**

TRANSMISSION

Relative importance of the enterically transmitted human hepatitis viruses type A and E as a cause of foreign travel associated hepatitis. Langer BC, et al. **Arch Virol Suppl** 1996;11:171–9 (25 ref.)

[Fecal-oral transmission of viral hepatitis] Buisson Y, et al. **Med Trop (Mars)** 1995;55(4):305–11 (0 ref.) **(Fre)**

[New hepatitis viruses "E, GB, etc."] Denis F, et al. **Transfus Clin Biol** 1996;3(1):19–25 (11 ref.) (Eng. Abstr.) **(Fre)**

[Hepatitis E: etiology and clinics of another enterically transmitted hepatitis] Nakazono N, et al. **Uirusu** 1995 Jun; 45(1):43–50 (41 ref.) **(Jpn)**

HEPATITIS E VIRUS

GENETICS

[Molecular study of hepatitis E virus] Uchida T. **Nippon Rinsho** 1995 Oct;53 Suppl:901–5 (18 ref.) **(Jpn)**

HEPATITIS, INFECTIOUS see **HEPATITIS A**

HEPATITIS, TOXIC

[Drug-induced hepatitis: epidemiologic, clinical, diagnostic and physiopathologic aspects in 1995] Larrey D. **Rev Med Interne** 1995;16(10):752–8 (18 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

[HIV (human immunodeficiency virus) disease and AIDS (acquired immunodeficiency syndrome)] Fujii T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):255–7 (10 ref.) **(Jpn)**

[Acute pancreatitis associated with hepatotoxicity induced by amoxicillin-clavulanic acid] Galindo C, et al. **Rev Esp Enferm Dig** 1995 Aug;87(8):597–600 (23 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

[Drug-induced hepatitis] Kawada N, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):63–5 (4 ref.) **(Jpn)**

ETIOLOGY

Hepatotoxicity of antibiotics. Hautekeete ML. **Acta Gastroenterol Belg** 1995 May–Aug;58(3–4):290–6 (64 ref.)

Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration. Guillaume MP, et al. **Am J Gastroenterol** 1996 Jan;91(1):165–8 (14 ref.)

Acute hepatitis associated with the use of a Chinese herbal product, ma-huang. Nadir A, et al. **Am J Gastroenterol** 1996 Jul;91(7):1436–8 (20 ref.)

Drug-induced "allergic hepatitis". Podevin P, et al. **Clin Rev Allergy Immunol** 1995 Fall;13(3):223–44 (165 ref.)

Granulomatous hepatitis associated with glyburide. Saw D, et al. **Dig Dis Sci** 1996 Feb;41(2):322–5 (11 ref.)

Flucloxacillin associated cholestatic hepatitis. An Australian and Swedish epidemic? Devereaux BM, et al. **Eur J Clin Pharmacol** 1995;49(1–2):81–5 (30 ref.)

Anti-tuberculosis medication and the liver: dangers and recommendations in management [see comments] Thompson NP, et al. **Eur Respir J** 1995 Aug;8(8):1384–8 (39 ref.) Comment in: Eur Respir J 1995 Aug;8(8):1247–9.

Drug related hepatic injuries. Sarin SK, et al. **J Assoc Physicians India** 1995 Oct;43(10):689–93 (20 ref.)

Hepatitis, rash and eosinophilia following trichloroethylene exposure: a case report and speculation on mechanistic similarity to halothane induced hepatitis. Bond GR. **J Toxicol Clin Toxicol** 1996;34(4):461–6 (11 ref.)

[Liver damage attributed to the use of disulfiram] Kerkhof SC, et al. **Ned Tijdschr Geneeskd** 1995 Nov 18; 139(46):2378–81 (24 ref.) (Eng. Abstr.) **(Dut)**

[Trimethoprim-sulfamethoxazole-induced cholestatic hepatitis. Clinico-immunological demonstration of its allergic origin] Cario E, et al. **Dtsch Med Wochenschr** 1996 Feb 2;121(5):129–32 (10 ref.) (Eng. Abstr.) **(Ger)**

[Acute hepatotoxicity from amiodarone] Tosetti C, et al. **Minerva Med** 1995 Sep;86(9):387–90 (21 ref.) (Eng. Abstr.) **(Ita)**

[Drug induced liver injury] Kawada N, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):66–9 (6 ref.) **(Jpn)**

[Chemical hepatitis (halothane, toluene)] Shiomi S, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):49–51 (17 ref.) **(Jpn)**

[Toxic cholestatic hepatitis due to phenytoin] de la Serna Higuera C, et al. **Gastroenterol Hepatol** 1995 Nov; 18(9):471–3 (11 ref.) (Eng. Abstr.) **(Spa)**

[Extramedullary toxicity in bone marrow transplantation using busulfan and cyclophosphamide conditioning] Pascual MJ, et al. **Sangre (Barc)** 1995 Jun;40(3):191–7 (31 ref.) (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

Drug-induced "allergic hepatitis". Podevin P, et al. **Clin Rev Allergy Immunol** 1995 Fall;13(3):223–44 (165 ref.)

PATHOLOGY

Idiosyncratic liver toxicity of nonsteroidal antiinflammatory drugs: molecular mechanisms and pathology. Boelsterli UA, et al. **Crit Rev Toxicol** 1995;25(3):207–35 (245 ref.)

PHYSIOPATHOLOGY

Role of reactive metabolites in drug-induced hepatitis. Pessayre D. **J Hepatol** 1995;23 Suppl 1:16–24 (39 ref.)

HEPATITIS, VIRAL, ANIMAL

VIROLOGY

[Mouse hepatitis virus] Homberger FR. **Schweiz Arch Tierheilkd** 1996;138(4):183–8 (10 ref.) (Eng. Abstr.) **(Ger)**

HEPATITIS, VIRAL, HUMAN

Viral hepatitis. Okoth FA. **East Afr Med J** 1996 May; 73(5):308–12 (29 ref.)

Update on viral hepatitis in children. Fishman LN, et al. **Pediatr Clin North Am** 1996 Feb;43(1):57–74 (63 ref.)

[Progresses in communicable diseases in China, 1995] Si C. **Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):726–8 (0 ref.) **(Chi)**

[Viral hepatitis in children] Lacaille F. **Gastroenterol Clin Biol** 1996;20(5 Pt 2):B63–73 (108 ref.) **(Fre)**

[Chronic hepatitis] Iino S. **Ryoikibetsu Shokogun Shirizu** 1995;(7):203–9 (10 ref.) **(Jpn)**

[Non-A, non-B, non-C viral hepatitis] Kaito M, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):137–40 (12 ref.) **(Jpn)**

[Hepatitis F virus] Kiyosawa K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):20–3 (6 ref.) **(Jpn)**

[Viral hepatitis] Kondo T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):30–2 (0 ref.) **(Jpn)**

[Herpesvirus hepatitis] Suto T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):144–7 (21 ref.) **(Jpn)**

[Molecular biology of infections caused by HIV and other hepatotropic viruses] Schüller Pérez A. **An R Acad Nac Med (Madr)** 1995;112(3):585–613; discussion 614–5 (107 ref.) **(Spa)**

COMPLICATIONS

Hepatitis and HIV: interrelationship and interactions. Newell A, et al. **Br J Clin Pract** 1995 Sep–Oct;49(5):247–51 (83 ref.)

[The significance of acute renal failure in fulminant hepatitis—a comparison between type B and non B hepatitis] Nakano A, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:535–9 (21 ref.) **(Jpn)**

DIAGNOSIS

Prevention, diagnosis, and management of viral hepatitis. A guide for primary care physicians. AMA Advisory Group on Prevention, Diagnosis, and Management of Viral Hepatitis. Noskin GA. **Arch Fam Med** 1995 Nov;

4(11):923–34 (28 ref.)
Immunodiagnosis of viral hepatitides A to E and non-A to -E. Yang G, et al. **Clin Diagn Lab Immunol** 1996 May; 3(3):247–56 (92 ref.)
Viral hepatitis. Joeres R, et al. **Curr Probl Dermatol** 1996; 24:57–66 (35 ref.)
Serologic diagnosis of viral hepatitis. Sjogren MH. **Med Clin North Am** 1996 Sep;80(5):929–56 (107 ref.)
[Acute viral hepatitides] Khazanov AI. **Voen Med Zh** 1996 Feb;317(2):45–50, 79 (23 ref.) (Eng. Abstr.) **(Rus)**

DRUG THERAPY

Interferon-alpha-2a. A review of its pharmacological properties and therapeutic use in the management of viral hepatitis. Haria M, et al. **Drugs** 1995 Nov;50(5):873–96 (149 ref.)
Hepatic purine and pyrimidine metabolism: implications for antiviral chemotherapy of viral hepatitis. Shaw T, et al. **Liver** 1995 Aug;15(4):169–84 (117 ref.)
[Treatment of viral hepatitis] Miguet J, et al. **Bratisl Lek Listy** 1995 Sep;96(9):487–92 (82 ref.) (Eng. Abstr.) **(Slo)**

EPIDEMIOLOGY

Viral hepatitis in East Asia. Chen DS. **J Formos Med Assoc** 1996 Jan;95(1):6–12 (55 ref.)

ETIOLOGY

Acute hepatitis in an adult with acquired rubella infection. Arai M, et al. **J Gastroenterol** 1995 Aug;30(4):539–42 (14 ref.)
Viral hepatitis: a review. Acorn CJ, et al. **Optom Vis Sci** 1995 Oct;72(10):763–9 (27 ref.)

IMMUNOLOGY

[Immunopathogenic aspects of chronic viral hepatitis] Moreno Otero R, et al. **Rev Clin Esp** 1996 Mar; 196(3):179–84 (54 ref.) **(Spa)**

PATHOLOGY

Histopathology of chronic viral hepatitis: guidelines for a revised classification. Callea F, et al. **Ital J Gastroenterol** 1995 Apr;27(3):137–40 (13 ref.)
[Advances in pathology of infectious diseases in China] Liu Y. **Chung Hua Ping Li Hsueh Tsa Chih** 1995 Aug; 24(4):255–7 (19 ref.) **(Chi)**
[Fundamentals of chronic viral hepatitis and histopathological characteristics of chronic hepatitis C] Uchida T. **Nippon Rinsho** 1995 Sep;53 Suppl:590–4 (10 ref.) **(Jpn)**
[Scar liver] Kawamoto H, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):585–7 (10 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Iron and chronic viral hepatitis: emerging evidence for an important interaction. Rubin RB, et al. **Dig Dis** 1995 Jul–Aug;13(4):223–38 (50 ref.)

PREVENTION & CONTROL

[Treatment and prevention of chronic viral hepatitis] Lumio J, et al. **Duodecim** 1994;110(20):1883–92 (46 ref.) **(Fin)**
[The screening of hepatitis virus and its efficacy] Kuroki T, et al. **Rinsho Byori** 1995 Nov;43(11):1095–100 (6 ref.) (Eng. Abstr.) **(Jpn)**

SURGERY

Liver transplantation for acute and chronic viral hepatitis. Tibbs CJ, et al. **J Viral Hepat** 1995;2(2):65–72 (38 ref.)

THERAPY

Prevention, diagnosis, and management of viral hepatitis. A guide for primary care physicians. AMA Advisory Group on Prevention, Diagnosis, and Management of Viral Hepatitis. Noskin GA. **Arch Fam Med** 1995 Nov; 4(11):923–34 (28 ref.)
[The therapy of viral hepatitis in HIV-infected patients] Rockstroh JK, et al. **Dtsch Med Wochenschr** 1995 Dec 8; 120(49):1705–8 (29 ref.) **(Ger)**
[Interferons as therapy in viral hepatitis: are promises kept?] Spengler U. **Ther Umsch** 1995 Oct;52(10):645–51 (57 ref.) (Eng. Abstr.) **(Ger)**
[Predictive factors of response to interferon in chronic hepatitis] Forns X, et al. **Gastroenterol Hepatol** 1995 Aug–Sep;18(7):388–95 (59 ref.) **(Spa)**

TRANSMISSION

Hazards to the orthopaedic trauma surgeon: occupational exposure to HIV and viral hepatitis (a review article). Chou L, et al. **J Orthop Trauma** 1996;10(4):289–96 (46 ref.)
Transfusion-dependent thalassemia: viral complications (epidemiology and follow-up). de Montalembert M, et al. **Semin Hematol** 1995 Oct;32(4):280–7 (46 ref.)
Beyond hepatitis A and B [editorial] Fock KM. **Singapore Med J** 1995 Dec;36(6):586–9 (36 ref.)
[New hepatitis viruses "E, GB, etc."] Denis F, et al. **Transfus Clin Biol** 1996;3(1):19–25 (11 ref.) (Eng. Abstr.) **(Fre)**

VIROLOGY

Fulminant adenovirus hepatitis after allogeneic bone marrow transplantation. Bertheau P, et al. **Bone Marrow Transplant** 1996 Feb;17(2):295–8 (14 ref.)
New hepatitis viruses: are there enough letters in the alphabet? Bowden DS, et al. **Med J Aust** 1996 Jan 15; 164(2):87–9 (21 ref.)
[An expanding spectrum of hepatitis viruses (editorial)] Ebeling F. **Duodecim** 1994;110(20):1839–41 (8 ref.) **(Fin)**
[Serologic signs of Epstein Barr virus activity in acute viral hepatitis, symptomless HbsAg carriers as well as in alcoholic liver diseases] Ternák G, et al. **Orv Hetil** 1996 Apr 21;137(16):851–5 (34 ref.) (Eng. Abstr.) **(Hun)**
[Hepatitis induced by HIV (human immunodeficiency virus)] Fujii T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):141–3 (14 ref.) **(Jpn)**
[Adenovirus hepatitis] Nishiyama Y, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):27–9 (3 ref.) **(Jpn)**

HEPATITIS, VIRAL, NON-A, NON-B, ENTERICALLY-TRANSMITTED see **HEPATITIS E**

HEPATITIS, VIRAL, NON-A, NON-B, PARENTERALLY-TRANSMITTED see **HEPATITIS C**

HEPATITIS, VIRAL, VACCINES see **VIRAL HEPATITIS VACCINES**

HEPATITIS VIRUS, HOMOLOGOUS SERUM see **HEPATITIS B VIRUS**

HEPATITIS VIRUS, INFECTIOUS see **HEPATOVIRUS**

HEPATITIS VIRUS, MARMOSET see **HEPATITIS VIRUSES**

HEPATITIS VIRUS, MOUSE see **GASTROENTERITIS VIRUS, MURINE**

HEPATITIS VIRUS, WOODCHUCK

The woodchuck: an animal model for hepatitis B virus infection in man. Roggendorf M, et al. **Intervirology** 1995; 38(1–2):100–12 (111 ref.)

IMMUNOLOGY

The woodchuck: an animal model for hepatitis B virus infection in man. Roggendorf M, et al. **Intervirology** 1995; 38(1–2):100–12 (111 ref.)

HEPATITIS VIRUSES

[Non-A, non-B, non-C viral hepatitis] Kaito M, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):137–40 (12 ref.) **(Jpn)**

CLASSIFICATION

New hepatitis viruses: are there enough letters in the alphabet? Bowden DS, et al. **Med J Aust** 1996 Jan 15; 164(2):87–9 (21 ref.)

ISOLATION & PURIFICATION

[Virus detection in the liver (editorial)] Degott C, et al. **Ann Pathol** 1995;15(5):319–23 (39 ref.) **(Fre)**

HEPATITIS, WATER-BORNE see **HEPATITIS E**

HEPATOBLASTOMA

[Hepatic teratoma, malignant teratoma] Kobayashi Y, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):329–32 (17 ref.) **(Jpn)**
[Hepatoblastoma] Saito A, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):323–6 (10 ref.) **(Jpn)**
[Hepatic tumor in children] Sasaki F, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):486–90 (10 ref.) **(Jpn)**

DRUG THERAPY

Pancreatic blastomatous tumor in a child responding to therapy used for hepatoblastoma: case report and review of the literature. Morgan ER, et al. **Med Pediatr Oncol** 1996 Apr;26(4):284–92 (29 ref.)
Conversion of unresectable to resectable hepatoblastoma and long-term follow-up study. Reynolds M. **World J Surg** 1995 Nov–Dec;19(6):814–6 (18 ref.)

EPIDEMIOLOGY

[Primary liver tumors in children] Vos A, et al. **Ned Tijdschr Geneeskd** 1995 Sep 23;139(38):1918–22 (35 ref.) **(Dut)**

SECONDARY

Neonatal hepatoblastoma metastatic to the choroid and iris. Endo EG, et al. **Arch Ophthalmol** 1996 Jun;114(6):757–61 (24 ref.)

SURGERY

Adult hepatoblastoma: case report and review of the literature. Harada T, et al. **Aust N Z J Surg** 1995 Sep; 65(9):686–8 (28 ref.)

HEPATOCELLULAR CARCINOMA see **CARCINOMA, HEPATOCELLULAR**

HEPATOCYTE GROWTH FACTOR

BIOSYNTHESIS

Regulation of scatter factor (hepatocyte growth factor) production by tumor-stroma interaction. Rosen EM, et al. **EXS** 1995;74:17–31 (51 ref.)
Regulation of HGF and HGFR gene expression. Zarnegar R. **EXS** 1995;74:33–49 (59 ref.)

BLOOD

[Hepatocyte growth factor (HGF)] Sugimoto K, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:826–9 (20 ref.) **(Jpn)**

PHYSIOLOGY

Scatter factor and angiogenesis. Rosen EM, et al. **Adv Cancer Res** 1995;67:257–79 (93 ref.)
Hepatocyte growth factor in lung morphogenesis and tumor invasion: role as a mediator in epithelium-mesenchyme and tumor-stroma interactions. Matsumoto K, et al. **Cancer Chemother Pharmacol** 1996;38 Suppl:S42–7 (36 ref.)
The Met-HGF/SF autocrine signaling mechanism is involved in sarcomagenesis. Cortner J, et al. **EXS** 1995; 74:89–121 (101 ref.)
Modulation of intercellular junctions of epithelia by scatter factor (hepatocyte growth factor). Nusrat A, et al. **EXS** 1995;74:69–87 (61 ref.)
The role of scatter factor and the c-met proto-oncogene in angiogenic responses. Polverini PJ, et al. **EXS** 1995; 74:51–67 (82 ref.)
Emerging multipotent aspects of hepatocyte growth factor. Matsumoto K, et al. **J Biochem (Tokyo)** 1996 Apr; 119(4):591–600 (139 ref.)
Hepatocyte growth factor—pleiotropic cytokine produced by human leukemia cells. Gohda E, et al. **Leuk Lymphoma** 1995 Oct;19(3–4):197–205 (97 ref.)
Hepatocyte growth factor/scatter factor and the placenta. Uehara Y, et al. **Placenta** 1996 Mar–Apr;17(2–3):97–101 (64 ref.)
HGF in liver regeneration and tumor promotion. Michalopoulos GK. **Prog Clin Biol Res** 1995;391:179–85 (29 ref.)
Hepatocyte growth factor/scatter factor (HGF/SF) in early development: evidence for a role in neural induction. Bronner-Fraser M. **Trends Genet** 1995 Nov;11(11):423–5 (18 ref.)
[Hepatocyte growth factor may accelerate the regeneration of nonhepatic tissues] Guo SH, et al. **Sheng Li Ko Hsueh Chin Chan** 1995 Oct;26(4):347–8 (10 ref.) **(Chi)**
[Regulation of liver regeneration by hepatocyte growth factor-humor and hepatocyte growth factor-cytosol] Qiu ZH, et al. **Sheng Li Ko Hsueh Chin Chan** 1995 Jul; 26(3):256–8 (9 ref.) **(Chi)**
[Growth factors in tubular cells] Okuda S. **Nippon Rinsho** 1995 Aug;53(8):1879–85 (18 ref.) (Eng. Abstr.) **(Jpn)**

HEPATOCYTE-STIMULATING FACTOR see **INTERLEUKIN-6**

HEPATOLENTICULAR DEGENERATION

Copper: not too little, not too much, but just right. Based on the triennial Pewterers Lecture delivered at the National Hospital for Neurology, London, on 23 March 1995. Walshe JM. **J R Coll Physicians Lond** 1995 Jul–Aug; 29(4):280–8 (57 ref.)
[Inherited neurological disease--relationship between an essential trace elements and Wilson/Menkes disease] Ozawa M, et al. **Nippon Rinsho** 1996 Jan;54(1):117–22 (18 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Rupture of the spleen as the initial manifestation of Wilson's disease. Ahmed A, et al. **Am J Gastroenterol** 1996 Jul; 91(7):1454–5 (11 ref.)
[Wilson's disease] Propst T, et al. **Dtsch Med Wochenschr** 1996 Mar 1;121(9):280–4 (16 ref.) **(Ger)**

DRUG THERAPY

Practical recommendations and new therapies for Wilson's disease. Brewer GJ. **Drugs** 1995 Aug;50(2):240–9 (46 ref.)

ETIOLOGY

Wilson disease and idiopathic copper toxicosis. Scheinberg IH, et al. **Am J Clin Nutr** 1996 May;63(5):842S–5S (34 ref.)

GENETICS

Menkes and Wilson diseases. Monaco AP, et al.

Adv Genet 1995;33:233–53 (91 ref.)
Genetic and molecular basis for copper toxicity. Harris ZL, et al. **Am J Clin Nutr** 1996 May;63(5):836S–41S (53 ref.)
Wilson's disease: a new gene and an animal model for an old disease. Cuthbert JA. **J Investig Med** 1995 Aug; 43(4):323–36 (121 ref.)
Wilson disease: genetic basis of copper toxicity and natural history. Schilsky ML. **Semin Liver Dis** 1996 Feb; 16(1):83–95 (92 ref.)
Inherited liver diseases in adults. Kumar A, et al. **West J Med** 1995 Oct;163(4):382–6 (20 ref.)

HISTORY

Treatment of Wilson's disease: the historical background. Walshe JM. **QJM** 1996 Jul;89(7):553–5 (27 ref.)

METABOLISM

Disordered copper metabolism in LEC rats, an animal model of Wilson disease: roles of metallothionein. Suzuki KT. **Res Commun Mol Pathol Pharmacol** 1995 Aug;89(2):221–40 (69 ref.)

HEPATOLOGY see **GASTROENTEROLOGY**

HEPATOMA see **CARCINOMA, HEPATOCELLULAR**

HEPATOMA, BENIGN see **ADENOMA, LIVER CELL**

HEPATOMA, EXPERIMENTAL see **LIVER NEOPLASMS, EXPERIMENTAL**

HEPATOMA, MORRIS see **LIVER NEOPLASMS, EXPERIMENTAL**

HEPATOMA, NOVIKOFF see **LIVER NEOPLASMS, EXPERIMENTAL**

HEPATOPOIETIN see **HEPATOCYTE GROWTH FACTOR**

HEPATOPOIETIN A see **HEPATOCYTE GROWTH FACTOR**

HEPATORENAL GLYCOGEN STORAGE DISEASE see **GLYCOGEN STORAGE DISEASE TYPE I**

HEPATORENAL SYNDROME

[Hepatorenal syndrome] Hidaka S, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):466–70 (21 ref.) **(Jpn)**

DIAGNOSIS

Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Arroyo V, et al. **Hepatology** 1996 Jan;23(1):164–76 (119 ref.)

ETIOLOGY

Cirrhosis: ascites and hepatorenal syndrome. Recent advances in pathogenesis. Henriksen JH. **J Hepatol** 1995; 23 Suppl 1:25–30 (74 ref.)
Renal dysfunction associated with liver transplantation. Jindal RM, et al. **Postgrad Med J** 1995 Sep;71(839):513–24 (130 ref.)
Hepato-renal syndrome: pathogenesis and management. Anand AC. **Trop Gastroenterol** 1995 Apr–Jun;16(2):74–91 (101 ref.)

PATHOLOGY

The hepatorenal syndrome. Van Roey G, et al. **Pediatr Nephrol** 1996 Feb;10(1):100–7 (110 ref.)

PHYSIOPATHOLOGY

Ascites and hepatorenal syndrome: pathophysiology and management. Roberts LR, et al. **Mayo Clin Proc** 1996 Sep; 71(9):874–81 (37 ref.)

THERAPY

Ascites and hepatorenal syndrome: pathophysiology and management. Roberts LR, et al. **Mayo Clin Proc** 1996 Sep; 71(9):874–81 (37 ref.)

HEPATOVIRUS

CLASSIFICATION

[Genotypic classification and molecular epidemiology of hepatitis A virus] Sata M, et al. **Nippon Rinsho** 1995 Oct; 53 Suppl:791–5 (17 ref.) **(Jpn)**

GENETICS

[Structure and function of hepatitis A virus RNA] Kuwabara Y. **Nippon Rinsho** 1995 Oct;53 Suppl:785–90 (16 ref.) **(Jpn)**
[Genotypic classification and molecular epidemiology of hepatitis A virus] Sata M, et al. **Nippon Rinsho** 1995 Oct; 53 Suppl:791–5 (17 ref.) **(Jpn)**
[Hepatitis A virus marker] Yotsuyanagi H, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:828–31 (7 ref.) **(Jpn)**

IMMUNOLOGY

Hepatitis A and B vaccines in children. Lieberman JM, et al. **Adv Pediatr Infect Dis** 1996;11:333–63 (131 ref.)
Hepatitis A vaccine. Bader TF. **Am J Gastroenterol** 1996 Feb;91(2):217–22 (41 ref.)
[Specific and non-specific immune mechanisms against hepatitis A virus (HAV)--research and recent progress] Baba M, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:796–803 (26 ref.) **(Jpn)**

HER-2 PROTO-ONCOGENE PROTEINS see **PROTO-ONCOGENE PROTEINS C-ERBB-2**

HERBAL TEAS see **BEVERAGES**

HERBALISM see **MEDICINE, HERBAL**

HERBICIDES

ANALYSIS

Monitoring of herbicide pollution in water by capillary electrophoresis. Dinelli G, et al. **J Chromatogr A** 1996 May 10;733(1–2):337–47 (60 ref.)
[Paraquat and diquat poisoning] Sugita K. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:1064–70 (36 ref.) **(Jpn)**

POISONING

[Paraquat and diquat poisoning] Sugita K. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:1064–70 (36 ref.) **(Jpn)**

HERBICIDES, TRIAZINE

METABOLISM

Atrazine retention and transport in soils. Ma L, et al. **Rev Environ Contam Toxicol** 1996;145:129–73 (209 ref.)

HERBS

see related
MEDICINE, HERBAL

POISONING

Hepatotoxicity of herbal remedies and mushrooms. Larrey D, et al. **Semin Liver Dis** 1995 Aug;15(3):183–8 (63 ref.)

HERBS, MEDICINAL see **PLANTS, MEDICINAL**

HEREDITARY DISEASES

Amyotrophic lateral sclerosis. A multifactorial disease. Eisen AA. **Adv Neurol** 1995;68:121–34 (108 ref.)
Overexpression of genes in health and sickness. A bird's eye view. Shastry BS. **Comp Biochem Physiol B Biochem Mol Biol** 1995 Sep; 112(1):1–13 (146 ref.)
Mutation and mutagenesis in inherited and acquired human disease. The first EEMS Frits Sobels Prize Lecture, Noordwijkerhout, The Netherlands, June 1995. Evans HJ. **Mutat Res** 1996 Apr 13;351(2):89–103 (120 ref.)
[From identification of mutation to population screening] Aula P, et al. **Duodecim** 1994;110(7):749–56 (20 ref.) **(Fin)**
[From the DNA laboratory to the clinical practice] Kääriäinen H. **Duodecim** 1994;110(7):757–61 (7 ref.) **(Fin)**

BLOOD

Red cell membrane polypeptides under normal conditions and in genetic disorders. Delaunay J. **Transfus Clin Biol** 1995;2(4):207–16 (29 ref.)

DIAGNOSIS

Update in preimplantation genetic diagnosis: successes, advances, and problems. Grifo JA, et al. **Curr Opin Obstet Gynecol** 1996 Apr;8(2):135–8 (31 ref.)
Advances in molecular diagnosis. Korf BR. **Curr Opin Obstet Gynecol** 1996 Apr;8(2):130–4 (24 ref.)
Presymptomatic testing for genetic diseases of later life. Pharmacoepidemiological considerations. Rossiter BJ, et al. **Drugs Aging** 1995 Aug;7(2):117–30 (131 ref.)
Prenatal diagnosis of genetic disorders. Kulkarni ML, et al. **Indian Pediatr** 1995 Nov;32(11):1229–38 (28 ref.)
Fluorescent PCR: a new technique for PGD of sex and single-gene defects. Findlay I, et al. **J Assist Reprod Genet** 1996 Feb;13(2):96–103 (28 ref.)
Genetic and congenital defect conditions that mimic child abuse. Wardinsky TD. **J Fam Pract** 1995 Oct;41(4):377–83 (26 ref.)
Medical genetics in Singapore. Tay JS. **Southeast Asian J Trop Med Public Health** 1995;26 Suppl 1:19–25 (32 ref.)
[Genetic analysis for hereditary disorders] Furihata K. **Rinsho Byori** 1995 Oct;43(10):1028–33 (10 ref.) (Eng. Abstr.) **(Jpn)**
[Molecular genetic analysis--a new stage in the study of hereditary diseases of the central nervous system] Ivanova-Smolenskaia IA, et al. **Vestn Ross Akad Med Nauk** 1996;(4):6–10 (45 ref.) (Eng. Abstr.) **(Rus)**

EPIDEMIOLOGY

Presymptomatic testing for genetic diseases of later life. Pharmacoepidemiological considerations. Rossiter BJ, et al. **Drugs Aging** 1995 Aug;7(2):117–30 (131 ref.)
Spontaneous mutation as a risk factor. Crow JF. **Exp Clin Immunogenet** 1995;12(3):121–8 (24 ref.)

ETIOLOGY

Neuro-ophthalmology and systemic disease--Part I. An annual review (1994). Newman NJ. **J Neuroophthalmol** 1995 Jun;15(2):109–21 (136 ref.)
Genetic bases for common polygenic diseases. Weissman SM. **Proc Natl Acad Sci U S A** 1995 Sep 12;92(19):8543–4 (18 ref.)

GENETICS

MZ female twins discordant for X-linked diseases: a review. Tiberio G. **Acta Genet Med Gemellol (Roma)** 1994; 43(3–4):207–14 (28 ref.)
Clinical implications of unstable DNA repeat sequences. Lindblad K, et al. **Acta Paediatr** 1996 Mar;85(3):265–71 (67 ref.)
New mechanisms for genetic disease and nontraditional modes of inheritance. Langlois S, et al. **Adv Pediatr** 1995; 42:91–111 (60 ref.)
Chromosomal duplications in bacteria, fruit flies, and humans. Lupski JR, et al. **Am J Hum Genet** 1996 Jan;58(1):21–7 (79 ref.)
The G protein-coupled receptor family and one of its members, the TSH receptor. Vassart G, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:23–30 (43 ref.)
The geneticist's approach to complex disease. Ghosh S, et al. **Annu Rev Med** 1996;47:333–53 (104 ref.)
Trinucleotide instability: a repeating theme in human inherited disorders. Gusella JF, et al. **Annu Rev Med** 1996; 47:201–9 (18 ref.)
Mechanisms of DNA expansion. McMurray CT. **Chromosoma** 1995 Oct;104(1):2–13 (103 ref.)
Evolution of ATP-binding cassette transporter genes. Dean M, et al. **Curr Opin Genet Dev** 1995 Dec;5(6):779–85 (42 ref.)
YAC transgenics and the study of genetics and human disease. Lamb BT, et al. **Curr Opin Genet Dev** 1995 Jun; 5(3):342–8 (54 ref.)
Trinucleotide repeat expansion and human disease. Hummerich H, et al. **Electrophoresis** 1995 Sep; 16(9):1698–704 (92 ref.)
Major gene analysis for diseases and disorders of complex etiology. Amos CI, et al. **Exp Clin Immunogenet** 1995; 12(3):141–55 (32 ref.)
Linkage and association to genetic markers. Elston RC. **Exp Clin Immunogenet** 1995;12(3):129–40 (39 ref.)
Genetic privacy: from the laboratory to the legislature. Andrews LB. **Genome Res** 1995 Oct;5(3):209–13 (17 ref.)
Relationship between genotype and phenotype in monogenic diseases: relevance to polygenic diseases. Summers KM. **Hum Mutat** 1996;7(4):283–93 (98 ref.)
Linear genetics, non-linear epigenetics: complementary approaches to understanding complex diseases. Strohman RC. **Integr Physiol Behav Sci** 1995 Sep–Dec;30(4):273–82 (24 ref.)
Use of genetically engineered mice as models for understanding human neurodegenerative disease. Andersen JK, et al. **J Am Geriatr Soc** 1996 Jun;44(6):717–22 (34 ref.)
Molecular basis of genetic instability of triplet repeats. Wells RD. **J Biol Chem** 1996 Feb 9;271(6):2875–8 (49 ref.)
The zebrafish: heritable disorders in transparent embryos. Driever W, et al. **J Clin Invest** 1996 Apr 15;97(8):1788–94 (67 ref.)
The new genetics and women. Mahowald MB, et al. **Milbank Q** 1996;74(2):239–83 (160 ref.)
Epigenetics and human disease. Issa JP, et al. **Nat Med** 1996 Mar;2(3):281–2 (18 ref.)
Molecular biology in the intensive care unit: a framework for interpretation. Buchman TG, et al. **New Horiz** 1995 May;3(2):139–45 (24 ref.)
Genetic bases for common polygenic diseases. Weissman SM. **Proc Natl Acad Sci U S A** 1995 Sep 12;92(19):8543–4 (18 ref.)
Transgenic livestock as genetic models of human disease. Petters RM. **Reprod Fertil Dev** 1994;6(5):643–5 (24 ref.)
Update in molecular genetics: mitochondrial energy transduction disorders. Marzuki S, et al. **Southeast Asian J Trop Med Public Health** 1995;26 Suppl 1:155–61 (37 ref.)
Medical genetics in Thailand. Sirinavin C. **Southeast Asian J Trop Med Public Health** 1995;26 Suppl 1:26–33 (41 ref.)
Fragile X syndrome and other dynamic mutation diseases. Sutherland GR, et al. **Southeast Asian J Trop Med Public Health** 1995;26 Suppl 1:77–85 (41 ref.)
Ethical concerns in the research and treatment of complex disease. Parker LS. **Trends Genet** 1995 Dec;11(12):520–3 (40 ref.)
Xenogenetics in multifactorial disease susceptibility. Sim E, et al. **Trends Genet** 1995 Dec;11(12):509–12 (52 ref.)

The HLA system and the analysis of multifactorial genetic disease. Tomlinson IP, et al. **Trends Genet** 1995 Dec; 11(12):493–8 (49 ref.)
Polygenic disease: methods for mapping complex disease traits. Weeks DE, et al. **Trends Genet** 1995 Dec; 11(12):513–9 (110 ref.)
[Linkage and linkage disequilibrium in the Finnish disease heritage] de la Chapelle A, et al. **Duodecim** 1994; 110(7):654–64 (23 ref.) **(Fin)**
[The new perspectives in gene diagnostics] Palotie L, et al. **Duodecim** 1994;110(7):647–53 (21 ref.) **(Fin)**
[Somatic gene therapy. Initial clinical applications and current research approach (see comments)]. Runge DM, et al. **Fortschr Med** 1995 Aug 30;113(24):337–40 (20 ref.) (Eng. Abstr.) Comment in: Fortschr Med 1995 Aug 30;113(24):341. **(Ger)**
[Medical genetics. Between consultation and molecular genetic research—an analysis of the current status] Schroeder-Kurth T. **Fortschr Med** 1995 Dec 20; 113(35–36):499–502 (11 ref.) (Eng. Abstr.) **(Ger)**
[Severe hereditary retinal diseases in childhood] Lorenz B. **Ther Umsch** 1996 Jan;53(1):7–19 (13 ref.) (Eng. Abstr.) **(Ger)**
[Genomic imprinting and human pathology. 2.] Cirillo Silengo M, et al. **Pediatr Med Chir** 1995 Sep–Oct; 17(5):389–94 (41 ref.) (Eng. Abstr.) **(Ita)**

METABOLISM

Human surfactant protein B: structure, function, regulation, and genetic disease. Whitsett JA, et al. **Physiol Rev** 1995 Oct;75(4):749–57 (66 ref.)

PREVENTION & CONTROL

Clinical applications of genetic testing: implications for the family physician [see comments] Whittaker L. **Am Fam Physician** 1996 May 1;53(6):2077–84 (37 ref.) Comment in: Am Fam Physician 1996 May 1;53(6):1976, 1978.

PSYCHOLOGY

Genetic counselling: communication and psychosocial aspects. Borreani C, et al. **Tumori** 1996 Mar–Apr; 82(2):147–50 (37 ref.)
Personal freedom and genetic overdetermination. Crotti N, et al. **Tumori** 1996 Mar–Apr;82(2):143–6 (04 ref.)

THERAPY

Gene therapy in pediatric medicine. Ledley FD. **Adv Pediatr** 1996;43:1–25 (90 ref.)
Treatment of inherited coagulation disorders. Cohen AJ, et al. **Am J Med** 1995 Dec;99(6):675–82 (17 ref.)
Liver-directed gene transfer and application to therapy. Sandig V, et al. **J Mol Med** 1996 Apr;74(4):205–12 (89 ref.)
Human umbilical cord blood for hematopoietic progenitor cells transplantation. Varadi G, et al. **Leuk Lymphoma** 1995 Dec;20(1–2):51–8 (54 ref.)
Gene therapy. Saksena S, et al. **Trop Gastroenterol** 1996 Jan–Mar;17(1):6–17 (119 ref.)
[Gene therapy for alpha 1-antitrypsin deficiency. Hopes, realities and perspectives] LeMarchand P. **Rev Mal Respir** 1996;13(1):7–12 (24 ref.) (Eng. Abstr.) **(Fre)**
[Principles and strategies of gene therapy] Brach MA, et al. **Internist (Berl)** 1996 Apr;37(4):343–9 (35 ref.) **(Ger)**
[First steps in clinical gene therapy] Körbling M. **Med Klin** 1996 Apr 10;91(4):218–25 (46 ref.) **(Ger)**

VETERINARY

Estimating disease prevalence with health surveys and genetic screening. Dodds WJ. **Adv Vet Sci Comp Med** 1995; 39:29–96 (125 ref.)
Testing for undesirable traits in cattle: an Australian perspective. Healy PJ. **J Anim Sci** 1996 Apr;74(4):917–22 (32 ref.)

HEREDITARY MOTOR AND SENSORY NEUROPATHIES see **NEUROPATHIES, HEREDITARY MOTOR AND SENSORY**

HEREDITARY MULTIPLE EXOSTOSES see **EXOSTOSES, MULTIPLE HEREDITARY**

HEREDITARY NONPOLYPOSIS COLORECTAL NEOPLASMS see **COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS**

HEREDITARY OPALESCENT DENTIN see **DENTINOGENESIS IMPERFECTA**

HEREDITARY OPTIC ATROPHY see **OPTIC ATROPHY, HEREDITARY**

HEREDITARY SPASTIC PARAPLEGIA see **SPASTIC PARAPLEGIA, HEREDITARY**

HEREDITARY SPINAL SCLEROSIS see **FRIEDREICH'S ATAXIA**

HEREDITARY TYPE I MOTOR AND SENSORY NEUROPATHY see **CHARCOT-MARIE DISEASE**

HEREDITARY TYPE IV MOTOR AND SENSORY NEUROPATHY see **REFSUM DISEASE**

HEREDITY see **GENETICS**

HEREDOPATHIA ATACTICA POLYNEURITIFORMIS see **REFSUM DISEASE**

HERELLEA see **ACINETOBACTER**

HERLITZ DISEASE see **EPIDERMOLYSIS BULLOSA, JUNCTIONAL**

HERMANSKI-PUDLAK SYNDROME see **ALBINISM, OCULOCUTANEOUS**

HERMAPHRODITISM

GENETICS

[True familial hermaphroditism: a report of a new case and a review of the literature] Aparicio Rodrigo M, et al. **An Esp Pediatr** 1996 Jul;45(1):93–6 (18 ref.) **(Spa)**

VETERINARY

Intersexuality in pigs: clinical, physiological and practical considerations. Hunter RH, et al. **Acta Vet Scand** 1996; 37(1):1–12 (29 ref.)

HERMES ANTIGEN FAMILY see **RECEPTORS, LYMPHOCYTE HOMING**

HERNIA

see related
TRUSSES

COMPLICATIONS

[On alleged radicular pain in patients with lumbar intervertebral disc hernias] Styczyński T, et al. **Neurol Neurochir Pol** 1995 Sep–Oct;29(5):747–52 (20 ref.) (Eng. Abstr.) **(Pol)**

ETIOLOGY

Parastomal hernia. Martin L, et al. **Ann R Coll Surg Engl** 1996 Mar;78(2):81–4 (31 ref.)

PHYSIOPATHOLOGY

[On alleged radicular pain in patients with lumbar intervertebral disc hernias] Styczyński T, et al. **Neurol Neurochir Pol** 1995 Sep–Oct;29(5):747–52 (20 ref.) (Eng. Abstr.) **(Pol)**

RADIOGRAPHY

[Petit's inferior lumbar hernia. A case report] Sandomenico F, et al. **Radiol Med (Torino)** 1996 Mar;91(3):319–20 (7 ref.) **(Ita)**

SURGERY

Technique of sacral hernia repair. Kaplan LJ, et al. **Am Surg** 1996 Sep;62(9):762–4 (4 ref.)
Parastomal hernia. Martin L, et al. **Ann R Coll Surg Engl** 1996 Mar;78(2):81–4 (31 ref.)
Radiographic diagnosis and surgical repair of a sciatic hernia: report of a case. Hayashi N, et al. **Surg Today** 1995; 25(12):1066–8 (11 ref.)
[Grynfelt's hernia. A case report and review of the literature] Alves Júnior A, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1995 Mar–Apr; 50(2):111–4 (27 ref.) (Eng. Abstr.) **(Por)**
[Biomaterials and hernia surgery. Rationale for using them] Amid PK, et al. **Rev Esp Enferm Dig** 1995 Aug;87(8):582–6 (30 ref.) (Eng. Abstr.) **(Spa)**

VETERINARY

The treatment of hernias. Bellenger CR. **Vet Q** 1995 Apr; 17 Suppl 1:S2–4 (11 ref.)

HERNIA, ABDOMINAL see **HERNIA, VENTRAL**

HERNIA, CEREBRAL see **ENCEPHALOCELE**

HERNIA, DIAPHRAGMATIC

[Hepatic hernia] Ishibashi H, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):509–12 (13 ref.) **(Jpn)**
[Morgagni's hernia of gallbladder] Suto T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):428–31 (10 ref.) **(Jpn)**

CONGENITAL

"State-of-the-art" management strategies for the fetus and neonate with congenital diaphragmatic hernia. Karamanoukian HL, et al. **J Perinatol** 1996 Mar–Apr;16(2 Pt 2 Su):S40–7 (76 ref.)
The fetal thorax: noncardiac chest anomalies. Sohaey R, et al. **Semin Ultrasound CT MR** 1996 Feb;17(1):34–50 (64 ref.)
[The immediate response to the administration of inhaled nitric oxide in a newborn infant with congenital diaphragmatic hernia and pulmonary hypertension] Figueras Aloy J, et al. **An Esp Pediatr** 1996 Jan;44(1):70–2 (24 ref.) **(Spa)**

DRUG THERAPY

[The immediate response to the administration of inhaled nitric oxide in a newborn infant with congenital diaphragmatic hernia and pulmonary hypertension] Figueras Aloy J, et al. **An Esp Pediatr** 1996 Jan;44(1):70–2 (24 ref.) **(Spa)**

GENETICS

Fryns syndrome survivors and neurologic outcome. Van Hove JL, et al. **Am J Med Genet** 1995 Nov 20;59(3):334–40 (39 ref.)

THERAPY

Congenital diaphragmatic hernia. Frenckner B. **Int J Artif Organs** 1995 Oct;18(10):579–83 (24 ref.)
"State-of-the-art" management strategies for the fetus and neonate with congenital diaphragmatic hernia. Karamanoukian HL, et al. **J Perinatol** 1996 Mar–Apr;16(2 Pt 2 Su):S40–7 (76 ref.)

ULTRASONOGRAPHY

[Diagnostic-therapeutic concept in abnormalities of the abdominal wall and diaphragm] Terinde R, et al. **Gynakologe** 1995 Oct;28(5):368–83 (84 ref.) **(Ger)**

HERNIA, DIAPHRAGMATIC, TRAUMATIC

SURGERY

Hernia of the diaphragm: a clinical case and review of the literature. Mehdi A, et al. **Acta Chir Belg** 1995 Nov–Dec; 95(6):281–3 (8 ref.)

HERNIA, FEMORAL

PHYSIOPATHOLOGY

Partial enterocele (Richter's hernia). Kadirov S, et al. **Eur J Surg** 1995 Jun;161(6):383–5 (26 ref.)

HERNIA, HIATAL

COMPLICATIONS

[A case of gastric cancer associated with esophageal-hiatus hernia presenting with upside down stomach] Satoh K, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Jan;93(1):26–9 (12 ref.) **(Jpn)**

HERNIA, INGUINAL

ABC of general paediatric surgery. Inguinal hernia, hydrocele, and the undescended testis. Davenport M. **BMJ** 1996 Mar 2;312(7030):564–7 (0 ref.)

COMPLICATIONS

Small bowel obstruction following endoscopic extraperitoneal-preperitoneal herniorrhaphy. Azurin DJ, et al. **J Laparoendosc Surg** 1995 Aug;5(4):263–6 (10 ref.)

ECONOMICS

The management of hernia. Considerations in cost effectiveness. Millikan KW, et al. **Surg Clin North Am** 1996 Feb;76(1):105–16 (33 ref.)

SURGERY

Hernia uteri (correction of: uterus) inguinale associated with unilateral renal agenesis. Keating JP, et al. **Aust N Z J Surg** 1995 Sep;65(9):688–90 (10 ref.)
Laparoscopic inguinal herniorrhaphy. Fallas MJ, et al. **Curr Opin Gen Surg** 1994;:198–202 (11 ref.)
Critical appraisal and current position of laparoscopic hernia repair. Macintyre IM, et al. **J R Coll Surg Edinb** 1995 Oct; 40(5):331–6 (59 ref.)
The management of hernia. Considerations in cost effectiveness. Millikan KW, et al. **Surg Clin North Am** 1996 Feb;76(1):105–16 (33 ref.)
Laparoscopic herniorrhaphy. Swanstrom LL. **Surg Clin North Am** 1996 Jun;76(3):483–91 (26 ref.)
[Use of prostheses in emergency surgery. Retrospective study of 204 strangulated inguinal hernias] Palot JP, et al. **Chirurgie** 1996;121(1):48–50 (16 ref.) **(Fre)**
[Surgery in childhood at the hospital for basic and routine general management] Willital GH. **Chirurg** 1996 Jun; 67(6):567–75 (28 ref.) (Eng. Abstr.) **(Ger)**
[Inguinal hernia operation: still or after all an open one? (editorial)] Feussner H, et al. **Dtsch Med Wochenschr** 1996 Jun 21;121(25–26):815–8 (35 ref.) **(Ger)**
[Progressive pneumoperitoneum in treatment of inguinal and scar hernias. Results of animal experiments and clinical

applications] Willis S, et al. **Langenbecks Arch Chir** 1996; 381(3):132–7 (37 ref.) (Eng. Abstr.) **(Ger)**

["Canadian" hernioplasty with embrication. Anatomy, surgical technic, and personal experience] Baita G, et al. **Minerva Chir** 1995 Sep;50(9):723–35 (24 ref.) (Eng. Abstr.) **(Ita)**

[Is inguinal hernia to be treated by laparoscopic surgery?] Arvidsson D, et al. **Lakartidningen** 1996 Aug 7; 93(32–33):2727–31 (16 ref.) **(Swe)**

THERAPY

Trusses in the management of hernia today. Cheek CM, et al. **Br J Surg** 1995 Dec;82(12):1611–3 (23 ref.)

VETERINARY

[Inguinal and scrotal hernias in steers] Brouwers EA, et al. **Tijdschr Diergeneeskd** 1996 Jan 1;121(1):2–5 (20 ref.) (Eng. Abstr.) **(Dut)**

HERNIA, OBTURATOR

DIAGNOSIS

[The obturator hernia: a diagnostic challenge?] Solli P, et al. **Acta Biomed Ateneo Parmense** 1994;65(5–6):235–40 (11 ref.) (Eng. Abstr.) **(Ita)**

HERNIA, UMBILICAL

see related
BECKWITH-WIEDEMANN SYNDROME

ULTRASONOGRAPHY

Fetal exomphalos and chromosomal defects: relationship to maternal age and gestation. Snijders RJ, et al. **Ultrasound Obstet Gynecol** 1995 Oct;6(4):250–5 (30 ref.)

HERNIA, VENTRAL

ETIOLOGY

Traumatic lumbar hernia: a seat belt injury. McCarthy MC, et al. **J Trauma** 1996 Jan;40(1):121–2 (10 ref.)

Intra-abdominal injury with handlebar hernia: case report and literature review. Yarbrough DR 3rd. **J Trauma** 1996 Jan;40(1):116–8 (21 ref.)

External abdominal hernia of mucocele of the appendix in drain-tube removal site. Bacchin P, et al. **Radiol Med (Torino)** 1995 Dec;90(6):827–9 (13 ref.)

PATHOLOGY

[Peritoneal mesothelioma and abdominal hernias] Mirabella F. **Minerva Med** 1996 Jan–Feb;87(1–2):21–4 (51 ref.) (Eng. Abstr.) **(Ita)**

PHYSIOPATHOLOGY

[Pathophysiology of the abdominal wall] Klinge U, et al. **Chirurg** 1996 Mar;67(3):229–33 (12 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Endoscopic abdominoplasty with repair of diastasis recti and abdominal wall hernia. Core GB, et al. **Clin Plast Surg** 1995 Oct;22(4):707–22 (14 ref.)

[Progressive pneumoperitoneum in treatment of inguinal and scar hernias. Results of animal experiments and clinical applications] Willis S, et al. **Langenbecks Arch Chir** 1996; 381(3):132–7 (37 ref.) (Eng. Abstr.) **(Ger)**

HEROIN DEPENDENCE

DRUG THERAPY

Methoclocinnamox: a mu partial agonist with pharmacotherapeutic potential for heroin abuse. Woods JH, et al. **NIDA Res Monogr** 1995;147:195–219 (29 ref.)

EPIDEMIOLOGY

Heroin epidemics revisited. Hughes PH, et al. **Epidemiol Rev** 1995;17(1):66–73 (52 ref.)

MORTALITY

[The risk factors in death from heroin (editorial; comment)] Camí J, et al. **Med Clin (Barc)** 1995 Oct 14;105(12):455–6 (16 ref.) Comment on: Med Clin (Barc) 1995 Oct 14;105(12):441–5. **(Spa)**

PSYCHOLOGY

The daily life of heroin-addicted persons: the biography of specific methodology. Kaplan CD, et al. **NIDA Res Monogr** 1995;157:100–16 (43 ref.)

REHABILITATION

Levo-alpha-acetylmethadol (LAAM): clinical, research, and policy issues of a new pharmacotherapy for opioid addiction. Prendergast ML, et al. **J Psychoactive Drugs** 1995 Jul–Sep;27(3):239–47 (57 ref.)

The demedicalization of methadone maintenance. Rosenbaum M. **J Psychoactive Drugs** 1995 Apr–Jun; 27(2):145–9 (43 ref.)

HERPES GENITALIS

Recent advances in genital herpes. Mindel A. **Ann Acad Med Singapore** 1995 Jul;24(4):584–92 (134 ref.)

Perinatal herpes: current status and obstetric management strategies. Scott LL. **Pediatr Infect Dis J** 1995 Oct; 14(10):827–32; discussion 832–5 (73 ref.)

DIAGNOSIS

Diagnosis of genital herpes simplex infections. Thin RN. **Curr Probl Dermatol** 1996;24:50–6 (16 ref.)

DRUG THERAPY

Management of genital herpes. Mertz GJ. **Adv Exp Med Biol** 1996;394:1–10 (30 ref.)

Developments in the antiviral treatment of genital herpes. Cheong WK. **Ann Acad Med Singapore** 1995 Jul; 24(4):593–7 (48 ref.)

Genital herpes. Beutner KR. **Curr Probl Dermatol** 1996; 24:132–9 (25 ref.)

Use of penciclovir and famciclovir in the management of genital herpes. Sacks SL. **Curr Probl Dermatol** 1996; 24:219–26 (34 ref.)

Aciclovir and its l-valyl ester, valaciclovir. Smiley ML, et al. **Curr Probl Dermatol** 1996;24:209–18 (56 ref.)

Antiviral chemotherapy in genital herpes simplex virus infections. Patel R, et al. **Int J STD AIDS** 1995 Sep–Oct; 6(5):320–8 (78 ref.)

ETIOLOGY

Herpesvirus infections of the vulva. Nader SN, et al. **Semin Dermatol** 1996 Mar;15(1):8–16 (75 ref.)

TRANSMISSION

Neonatal herpes simplex virus-2 encephalitis. Irani MT, et al. **Indian Pediatr** 1995 Apr;32(4):476–80 (15 ref.)

HERPES LABIALIS

see related
STOMATITIS, HERPETIC

IMMUNOLOGY

A review of anatomical and immunological links between epidural morphine and herpes simplex labialis in obstetric patients. Boyle RK. **Anaesth Intensive Care** 1995 Aug; 23(4):425–32 (41 ref.)

PATHOLOGY

A review of anatomical and immunological links between epidural morphine and herpes simplex labialis in obstetric patients. Boyle RK. **Anaesth Intensive Care** 1995 Aug; 23(4):425–32 (41 ref.)

HERPES LABIALIS VIRUS see **SIMPLEXVIRUS**

HERPES SIMPLEX

Recurrence of herpes simplex virus blepharitis after cesarean section and epidural morphine. James CF. **Anesth Analg** 1996 May;82(5):1094–6 (17 ref.)

COMPLICATIONS

Fulminant herpes colitis in a patient with Crohn's disease. el-Serag HB, et al. **J Clin Gastroenterol** 1996 Apr; 22(3):220–3 (41 ref.)

[Necrotizing herpes simplex encephalitis as the cause of a progressive dementia syndrome] Zachhuber C, et al. **Dtsch Med Wochenschr** 1995 Sep 22;120(38):1278–82 (19 ref.) (Eng. Abstr.) **(Ger)**

DIAGNOSIS

[Applications of the polymerase chain reaction (PCR) to the diagnosis of central nervous system infections] Querol JM, et al. **An Med Interna** 1996 May;13(5):235–8 (20 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Treatment of acyclovir-resistant herpes simplex and varicella zoster virus infections. Safrin S. **Adv Exp Med Biol** 1996; 394:59–66 (44 ref.)

Herpes simplex virus resistance to acyclovir: clinical relevance. Pottage JC Jr, et al. **Infect Agents Dis** 1995 Sep; 4(3):115–24 (111 ref.)

ETIOLOGY

Herpes simplex virus (HSV) colitis in a bone marrow transplant recipient. Naik HR, et al. **Bone Marrow Transplant** 1996 Feb;17(2):285–6 (11 ref.)

Herpesvirus infections of the vulva. Nader SN, et al. **Semin Dermatol** 1996 Mar;15(1):8–16 (75 ref.)

IMMUNOLOGY

Effects of varicella zoster virus or herpes simplex virus type 1 infection in vitro on response of human peripheral blood mononuclear cells to phytohemagglutinin. Horiuchi Y, et al. **Acta Med Okayama** 1995 Dec;49(6):309–12 (17 ref.)

Therapeutic immunization for recurrent herpes simplex virus infections. McKenzie R, et al. **Adv Exp Med Biol** 1996; 394:67–83 (91 ref.)

A review of anatomical and immunological links between epidural morphine and herpes simplex labialis in obstetric patients. Boyle RK. **Anaesth Intensive Care** 1995 Aug; 23(4):425–32 (41 ref.)

UV radiation and mouse models of herpes simplex virus infection. Norval M, et al. **Photochem Photobiol** 1996 Aug; 64(2):242–5 (26 ref.)

PATHOLOGY

[Inflammatory esophageal diseases caused by herpes simplex virus infections—overview and report of 15 personal cases] Becker K, et al. **Z Gastroenterol** 1996 May;34(5):286–95 (73 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

HSV-1 brain infection by the olfactory nerve route and virus latency and reactivation may cause learning and behavioral deficiencies and violence in children and adults: a point of view. Becker Y. **Virus Genes** 1995;10(3):217–26 (58 ref.)

THERAPY

Therapeutic immunization for recurrent herpes simplex virus infections. McKenzie R, et al. **Adv Exp Med Biol** 1996; 394:67–83 (91 ref.)

HERPES SIMPLEX, GENITAL see **HERPES GENITALIS**

HERPES SIMPLEX KERATITIS see **KERATITIS, HERPETIC**

HERPES SIMPLEX, LABIAL see **HERPES LABIALIS**

HERPES SIMPLEX, OCULAR see **KERATITIS, HERPETIC**

HERPES SIMPLEX, ORAL see **STOMATITIS, HERPETIC**

HERPES SIMPLEX VIRUS see **SIMPLEXVIRUS**

HERPES SIMPLEX VIRUS PROTEIN VMW65

GENETICS

Enhancing expression of recombinant proteins in mammalian cells using the herpesvirus VP16 transactivator. Hippenmeyer PJ, et al. **Curr Opin Biotechnol** 1995 Oct; 6(5):548–52 (15 ref.)

HERPES SIMPLEX VIRUS PROTEIN VP16 see **HERPES SIMPLEX VIRUS PROTEIN VMW65**

HERPES SIMPLEX VIRUS TRANSCRIPTIONAL ACTIVATOR VMW65 see **HERPES SIMPLEX VIRUS PROTEIN VMW65**

HERPES SIMPLEX VIRUS 1 see **HERPESVIRUS 1, HUMAN**

HERPES SIMPLEX VIRUS 2 see **HERPESVIRUS 2, HUMAN**

HERPES ZOSTER

Shingles in one family practice. Richards P. **Arch Fam Med** 1996 Jan;5(1):42–6 (20 ref.)

[Zoster and the nervous system] Malin JP. **Dtsch Med Wochenschr** 1996 May 10;121(19):635–8 (22 ref.) **(Ger)**

COMPLICATIONS

Necrotizing herpes zoster mimicking relapse of vasculitis in angioimmunoblastic lymphadenopathy with dysproteinaemia. Böni R, et al. **Br J Dermatol** 1995 Dec; 133(6):978–82 (29 ref.)

Cutaneous reactions following herpes zoster infections: report of three cases and a review of the literature. Gibney MD, et al. **Br J Dermatol** 1996 Mar;134(3):504–9 (22 ref.)

Postherpetic neuralgia—pathogenesis, treatment, and prevention. Kost RG, et al. **N Engl J Med** 1996 Jul 4; 335(1):32–42 (110 ref.)

Does sympathetic ganglionic block prevent postherpetic neuralgia? Literature review. Ali NM. **Reg Anesth** 1995 May–Jun;20(3):227–33 (44 ref.)

Herpes zoster and internal malignancy. Smith JB, et al. **South Med J** 1995 Nov;88(11):1089–92 (25 ref.)

DIAGNOSIS

Herpes zoster at school-age: a case presentation and discussion of the unique aspects within the pediatric population. Piette ML. **Hawaii Med J** 1996 Jul;55(7):118–21 (13 ref.)

[Varicella-zoster-virus myelitis without herpes. An important differential diagnosis of the radicular syndrome] Jacobs A, et al. **Dtsch Med Wochenschr** 1996 Mar 15;

121(11):331–5 (25 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Famciclovir: efficacy in zoster and issues in the assessment of pain. Boon RJ, et al. **Adv Exp Med Biol** 1996;394:17–31 (37 ref.)

Valacyclovir HCl (Valtrex): an acyclovir prodrug with improved pharmacokinetics and better efficacy for treatment of zoster. Smiley ML, et al. **Adv Exp Med Biol** 1996;394:33–9 (23 ref.)

Antiviral therapy of acute herpes zoster in older patients. Herne K, et al. **Drugs Aging** 1996 Feb;8(2):97–112 (89 ref.)

Efficacy of famciclovir in the treatment of herpes zoster: reduction of pain associated with zoster. Boon RJ, et al. **Neurology** 1995 Dec;45(12 Suppl 8):S76–7 (9 ref.)

The treatment of postherpetic neuralgia. Watson CP. **Neurology** 1995 Dec;45(12 Suppl 8):S58–60 (15 ref.)

Sorivudine: a promising drug for the treatment of varicella-zoster virus infection. Whitley RJ. **Neurology** 1995 Dec;45(12 Suppl 8):S73–5 (10 ref.)

ETIOLOGY

[Varicella–zoster virus pancreatitis in hematologic diseases] Pulik M, et al. **Ann Med Interne (Paris)** 1995;146(5):292–4 (10 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Effects of varicella zoster virus or herpes simplex virus type I infection in vitro on response of human peripheral blood mononuclear cells to phytohemagglutinin. Horiuchi Y, et al. **Acta Med Okayama** 1995 Dec;49(6):309–12 (17 ref.)

PATHOLOGY

[Pathologic anatomy of cytomegalovirus encephalomyelitis and varicella–zona virus encephalomyelitis] Henin D, et al. **J Neuroradiol** 1995 Sep;22(3):180–3 (14 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Pathophysiology of postherpetic neuralgia: towards a rational treatment. Bowsher D. **Neurology** 1995 Dec;45(12 Suppl 8):S56–7 (12 ref.)

Clinical features and pathophysiologic mechanisms of postherpetic neuralgia. Nurmikko T. **Neurology** 1995 Dec; 45(12 Suppl 8):S54–5 (19 ref.)

How should we measure pain in herpes zoster? Wood MJ. **Neurology** 1995 Dec;45(12 Suppl 8):S61–2 (5 ref.)

THERAPY

Clinical management of herpes zoster in the elderly patient. Beutner KR. **Compr Ther** 1996 Mar;22(3):183–6 (6 ref.)

Early treatment of herpes zoster. Tyring SK. **Hosp Pract (Off Ed)** 1996 Jul 15;31(7):137–44 (0 ref.)

HERPES ZOSTER AURICULARIS see **HERPES ZOSTER OTICUS**

HERPES ZOSTER, OCULAR see **HERPES ZOSTER OPHTHALMICUS**

HERPES ZOSTER OPHTHALMICUS

Herpes zoster ophthalmicus. Pavan-Langston D. **Neurology** 1995 Dec;45(12 Suppl 8):S50–1 (19 ref.)

DIAGNOSIS

[The clinico–microbiological diagnosis of encephalitis due to herpes zoster in an elderly patient: apropos a case] Muñoz García MD, et al. **An Med Interna** 1996 May; 13(5):243–4 (13 ref.) (Eng. Abstr.) **(Spa)**

HERPES ZOSTER OTICUS

DIAGNOSIS

Early diagnosis and treatment of Ramsay Hunt syndrome: the role of magnetic resonance imaging. Kuo MJ, et al. **J Laryngol Otol** 1995 Aug;109(8):777–80 (28 ref.)

HERPES ZOSTER VIRUS see **HERPESVIRUS 3, HUMAN**

HERPESVIRIDAE

GENETICS

Molecular interactions between retroviruses and herpesviruses. Kawaguchi Y, et al. **J Vet Med Sci** 1995 Oct;57(5):801–11 (139 ref.)

IMMUNOLOGY

Genetically altered herpesviruses as vaccines. Young PL, et al. **Vet Microbiol** 1995 Sep;46(1–3):175–9 (20 ref.)

ISOLATION & PURIFICATION

The new lymphotropic herpesviruses (HHV–6, HHV–7, HHV–8) and hepatitis C virus (HCV) in human lymphoproliferative diseases: an overview. Luppi M, et al. **Haematologica** 1996 May–Jun;81(3):265–81 (138 ref.)

Human herpesvirus 8 in lymphoma and Kaposi's sarcoma: now the virus can be propagated. Weiss RA. **Nat Med** 1996 Mar;2(3):277–8 (16 ref.)

[Human herpesvirus 8] Agut H, et al. **Transfus Clin Biol** 1996; 3(1):51–6 (26 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Molecular interactions between retroviruses and herpesviruses. Kawaguchi Y, et al. **J Vet Med Sci** 1995 Oct;57(5):801–11 (139 ref.)

HERPESVIRIDAE INFECTIONS

Human herpesvirus–6 in transplantation: an emerging pathogen. Singh N, et al. **Ann Intern Med** 1996 Jun 15; 124(12):1065–71 (58 ref.)

Viral infections in the immunocompetent patient. Miller CS. **Dermatol Clin** 1996 Apr;14(2):225–41 (206 ref.)

Post–transplant lymphoproliferative disorder. Basgoz N, et al. **Infect Dis Clin North Am** 1995 Dec;9(4):901–23 (69 ref.)

[Herpesvirus hepatitis] Suto T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):144–7 (21 ref.) **(Jpn)**

COMPLICATIONS

AIDS–related non–Hodgkin's lymphomas: molecular genetics, viral infection and cytokine deregulation. Gaidano G, et al. **Acta Haematol** 1996;95(3–4):193–8 (32 ref.)

Human herpesvirus–6 infections. Jones CA, et al. **Arch Dis Child** 1996 Feb;74(2):98–100 (54 ref.)

The role of Epstein–Barr virus in Hodgkin's disease from different geographical areas. Weinreb M, et al. **Arch Dis Child** 1996 Jan;74(1):27–31 (34 ref.)

Primary adrenal leiomyosarcoma in a man with acquired immunodeficiency syndrome (AIDS). Further evidence for an increase in smooth muscle tumors related to Epstein–Barr infection in AIDS. Zetler PJ, et al. **Arch Pathol Lab Med** 1995 Dec;119(12):1164–7 (19 ref.)

Epstein–Barr virus–related localized hepatic lymphoproliferative disorders after liver transplantation. Raymond E, et al. **Cancer** 1995 Oct 15;76(8):1344–51 (36 ref.)

Hemophagocytic syndrome in Epstein–Barr virus–associated T–lymphoproliferative disorders: disease spectrum, pathogenesis, and management. Su IJ, et al. **Leuk Lymphoma** 1995 Nov;19(5–6):401–6 (407 ref.)

Human herpesvirus 6 as a potential copathogen. Ablashi DV, et al. **Trends Microbiol** 1995 Aug;3(8):324–7 (34 ref.)

[Primary non–Hodgkin's lymphomas of the liver in human immunodeficiency virus infected patients. Three cases] Brugière O, et al. **Gastroenterol Clin Biol** 1996;20(3):307–11 (18 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

[New findings on the etiopathogenesis and clinical manifestations of Epstein–Barr virus infections] Brkić S, et al. **Med Pregl** 1996;49(5–6):194–8 (20 ref.) (Eng. Abstr.) **(Scr)**

DRUG THERAPY

Subclinical shedding of HSV: its potential for reduction by antiviral therapy. Corey L, et al. **Adv Exp Med Biol** 1996; 394:11–6 (7 ref.)

Herpesvirus infections in immunocompromised patients. Snoeck R, et al. **Cancer Treat Res** 1995;79:149–71 (172 ref.)

Pharmacokinetics of new antiherpetic agents. Rolan P. **Clin Pharmacokinet** 1995 Nov;29(5):333–40 (32 ref.)

Famciclovir. A review of its pharmacological properties and therapeutic efficacy in herpesvirus infections. Perry CM, et al. **Drugs** 1995 Aug;50(2):396–415 (64 ref.)

Management of herpesvirus infections in the healthy host. Dudley MN. **Pharmacotherapy** 1995 Sep–Oct;15(5 Pt 2):43S–48S (31 ref.)

[New medication for herpesvirus infections (editorial)] Vesikari T. **Duodecim** 1995;111(8):680, 683–4 (12 ref.) **(Fin)**

[Nucleoside analogues as anti–herpes agents and their mode of action] Maruyama T. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1242–9 (22 ref.) **(Jpn)**

EPIDEMIOLOGY

Herpesvirus infections in persons infected with human immunodeficiency virus. Stewart JA, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S114–20 (42 ref.)

IMMUNOLOGY

Immune regulation in Epstein–Barr virus–associated diseases. Khanna R, et al. **Microbiol Rev** 1995 Sep;59(3):387–405 (265 ref.)

PREVENTION & CONTROL

Strategies involved in developing an effective vaccine for EBV–associated diseases. Moss DJ, et al. **Adv Cancer Res** 1996;69:213–45 (201 ref.)

THERAPY

Treatment of pediatric malignant thymoma: long–term remission in a 14–year–old boy with EBV–associated thymic carcinoma by aggressive, combined modality treatment. Niehues T, et al. **Med Pediatr Oncol** 1996 Jun; 26(6):419–24 (37 ref.)

TRANSMISSION

Common infectious diseases. Bagg J. **Dent Clin North Am** 1996 Apr;40(2):385–93 (33 ref.)

VETERINARY

DNA immunization with bovine herpesvirus–1 genes. Babiuk LA, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:47–63 (56 ref.)

Genetically altered herpesviruses as vaccines. Young PL, et al. **Vet Microbiol** 1995 Sep;46(1–3):175–9 (20 ref.)

VIROLOGY

Herpesvirus infections. Greenberg MS. **Dent Clin North Am** 1996 Apr;40(2):359–68 (40 ref.)

Epstein–Barr virus (EBV) in extranodal T–cell non–Hodgkin's lymphomas (T–NHL). Identification of nasal T–NHL as a distinct clinicopathological entity associated with EBV. Kanavaros P, et al. **Leuk Lymphoma** 1995 Jun;18(1–2):27–34 (86 ref.)

[Human herpes viruses type 6 and 7; causative agents of, among others, exanthema subitum] Galama JM. **Ned Tijdschr Geneeskd** 1996 Jan 20;140(3):124–8 (20 ref.) (Eng. Abstr.) **(Dut)**

[Human herpesviruses 6 and 7. Basic principles and possible significance for dermatology] Lasch JA, et al. **Hautarzt** 1996 May;47(5):341–50 (85 ref.) (Eng. Abstr.) **(Ger)**

HERPESVIRUS 1 (ALPHA), BOVINE see **HERPESVIRUS 1, BOVINE**

HERPESVIRUS 1 (ALPHA), HUMAN see **HERPESVIRUS 1, HUMAN**

HERPESVIRUS 2 (ALPHA), HUMAN see **HERPESVIRUS 2, HUMAN**

HERPESVIRUS 3 (ALPHA), HUMAN see **HERPESVIRUS 3, HUMAN**

HERPESVIRUS 1 (ALPHA), SAIMIRINE see **SIMPLEXVIRUS**

HERPESVIRUS 1 (ALPHA), SUID see **HERPESVIRUS 1, SUID**

HERPESVIRUS 5 (BETA), HUMAN see **CYTOMEGALOVIRUS**

HERPESVIRUS 1, BOVINE

IMMUNOLOGY

DNA immunization with bovine herpesvirus–1 genes. Babiuk LA, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:47–63 (56 ref.)

HERPESVIRUS 4 (GAMMA), HUMAN see **HERPESVIRUS 4, HUMAN**

HERPESVIRUS HOMINIS see **SIMPLEXVIRUS**

HERPESVIRUS 1, HUMAN

HSV–1 brain infection by the olfactory nerve route and virus latency and reactivation may cause learning and behavioral deficiencies and violence in children and adults: a point of view. Becker Y. **Virus Genes** 1995;10(3):217–26 (58 ref.)

DRUG EFFECTS

Herpes simplex virus resistance to acyclovir: clinical relevance. Pottage JC Jr, et al. **Infect Agents Dis** 1995 Sep; 4(3):115–24 (111 ref.)

ENZYMOLOGY

Gene therapy against cancer and HIV infection using the gene encoding herpes simplex virus thymidine kinase. Caruso M. **Mol Med Today** 1996 May;2(5):212–7 (37 ref.)

GENETICS

Development and application of herpes simplex virus vectors for human gene therapy. Glorioso JC, et al. **Annu Rev Microbiol** 1995;49:675–710 (176 ref.)

[Herpes virus vector] Hidaka Y. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2545–9 (11 ref.) **(Jpn)**

ISOLATION & PURIFICATION

Herpesvirus infections of the vulva. Nader SN, et al. **Semin Dermatol** 1996 Mar;15(1):8–16 (75 ref.)

HERPESVIRUS 2, HUMAN

Subclinical shedding of HSV: its potential for reduction by antiviral therapy. Corey L, et al. **Adv Exp Med Biol** 1996; 394:11–6 (7 ref.)

[Necrotizing herpes simplex encephalitis as the cause of a progressive dementia syndrome] Zachhuber C, et al.

Dtsch Med Wochenschr 1995 Sep 22;120(38):1278–82 (19 ref.) (Eng. Abstr.) (Ger)

DRUG EFFECTS

Herpes simplex virus resistance to acyclovir: clinical relevance. Pottage JC Jr, et al. Infect Agents Dis 1995 Sep; 4(3):115–24 (111 ref.)

GENETICS

Cervical cancer: is herpes simplex virus type II a cofactor? Jones C. Clin Microbiol Rev 1995 Oct;8(4):549–56 (122 ref.)

ISOLATION & PURIFICATION

Neonatal herpes simplex virus-2 encephalitis. Irani MT, et al. Indian Pediatr 1995 Apr;32(4):476–80 (15 ref.)

Herpesvirus infections of the vulva. Nader SN, et al. Semin Dermatol 1996 Mar;15(1):8–16 (75 ref.)

HERPESVIRUS 3, HUMAN

Varicella-zoster virus: History, perspectives, and evolving concerns. Weller TH. Neurology 1995 Dec;45(12 Suppl 8):S9–10 (15 ref.)

DRUG EFFECTS

Treatment of acyclovir-resistant herpes simplex and varicella zoster virus infections. Safrin S. Adv Exp Med Biol 1996; 394:59–66 (44 ref.)

Sorivudine: a potent inhibitor of varicella zoster virus replication. Whitley RJ. Adv Exp Med Biol 1996;394:41–4 (11 ref.)

GENETICS

Analysis of varicella-zoster virus promoter sequences. Kantakamalakul W, et al. Neurology 1995 Dec;45(12 Suppl 8):S28–9 (3 ref.)

Molecular basis for a geographic variation of varicella-zoster virus recognized by a peptide antibody. Kinchington PR, et al. Neurology 1995 Dec;45(12 Suppl 8):S13–4 (7 ref.)

Varicella-zoster virus gene regulation. Piette J, et al. Neurology 1995 Dec;45(12 Suppl 8):S23–7 (37 ref.)

From molecular biology to medicine: two decades of achievement in varicella-zoster virus research. Straus SE. Neurology 1995 Dec;45(12 Suppl 8):S11–2 (17 ref.)

IMMUNOLOGY

Efficacy, immunogenicity, safety, and use of live attenuated chickenpox vaccine. Krause PR, et al. J Pediatr 1995 Oct; 127(4):518–25 (39 ref.)

Aspects of the host response to varicella-zoster virus: a review of recent observations. Arvin AM. Neurology 1995 Dec;45(12 Suppl 8):S36–7 (2 ref.)

Development of live attenuated varicella vaccine. Gershon AA. Proc Assoc Am Physicians 1995 Oct;107(3):365–8 (31 ref.)

Varicella vaccine [editorial] Ellis RW. Vaccine 1995; 13(15):1387–8 (21 ref.)

ULTRASTRUCTURE

Computer modeling of prototypic and aberrant nucleocapsids of varicella-zoster virus. Grose C, et al. Virology 1995 Dec 20;214(2):321–9 (24 ref.)

HERPESVIRUS 4, HUMAN

see related
FATIGUE SYNDROME, CHRONIC

Epstein-Barr virus-related localized hepatic lymphoproliferative disorders after liver transplantation. Raymond E, et al. Cancer 1995 Oct 15;76(8):1344–51 (36 ref.)

Post-transplant lymphoproliferative disorder. Basgoz N, et al. Infect Dis Clin North Am 1995 Dec;9(4):901–23 (69 ref.)

Epstein-Barr virus (EBV) in extranodal T-cell non-Hodgkin's lymphomas (T-NHL). Identification of nasal T-NHL as a distinct clinicopathological entity associated with EBV. Kanavaros P, et al. Leuk Lymphoma 1995 Jun;18(1–2):27–34 (86 ref.)

Hemophagocytic syndrome in Epstein-Barr virus-associated T-lymphoproliferative disorders: disease spectrum, pathogenesis, and management. Su IJ, et al. Leuk Lymphoma 1995 Nov;19(5–6):401–6 (407 ref.)

Treatment of pediatric malignant thymoma: long-term remission in a 14-year-old boy with EBV-associated thymic carcinoma by aggressive, combined modality treatment. Niehues T, et al. Med Pediatr Oncol 1996 Jun; 26(6):419–24 (37 ref.)

Immune regulation in Epstein-Barr virus-associated diseases. Khanna R, et al. Microbiol Rev 1995 Sep;59(3):387–405 (265 ref.)

[Epstein-Barr virus and hematologic diseases] Tatsumi E. Nippon Naika Gakkai Zasshi 1996 Apr 10;85(4):622–8 (21 ref.) (Jpn)

[EBER-1 expression in salivary glands of Sjögren's syndrome] Nomura H, et al. Nippon Rinsho 1995 Oct; 53(10):2490–4 (22 ref.) (Eng. Abstr.) (Jpn)

[New findings on the etiopathogenesis and clinical manifestations of Epstein-Barr virus infections] Brkić S, et al. Med Pregl 1996;49(5–6):194–8 (20 ref.) (Eng. Abstr.) (Scr)

IMMUNOLOGY

Strategies involved in developing an effective vaccine for EBV-associated diseases. Moss DJ, et al. Adv Cancer Res 1996;69:213–45 (201 ref.)

The Epstein-Barr virus in autoimmunity. Vaughan JH. Springer Semin Immunopathol 1995;17(2–3):203–30 (162 ref.)

[Screening of undifferentiated carcinoma of the nasopharynx] Sasco AJ. Bull Cancer (Paris) 1996 May;83(5):344–51 (70 ref.) (Eng. Abstr.) (Fre)

[Value of anti-Epstein-Barr antibody detection in the diagnosis and management of undifferentiated carcinoma of the nasopharynx] Mazeron MC. Bull Cancer Radiother 1996;83(1):3–7 (29 ref.) (Eng. Abstr.) (Fre)

[Serologic signs of Epstein Barr virus activity in acute viral hepatitis, symptomless HbsAg carriers as well as in alcoholic liver diseases] Ternák G, et al. Orv Hetil 1996 Apr 21;137(16):851–5 (34 ref.) (Eng. Abstr.) (Hun)

[Sero-epidemiologic study of Epstein-Barr virus markers in patients without mononucleosis at a department for infectious diseases] Ternák G, et al. Orv Hetil 1995 Dec 10;136(50):2727–30 (38 ref.) (Eng. Abstr.) (Hun)

[Immunological study of tissue-infiltrating lymphocytes in Sjögren's syndrome: virus specific T cell response] Takeda A, et al. Nippon Rinsho 1995 Oct;53(10):2484–9 (22 ref.) (Eng. Abstr.) (Jpn)

ISOLATION & PURIFICATION

Viruses in human tumors—reminiscences and perspectives. zur Hausen H. Adv Cancer Res 1996;68:1–22 (119 ref.)

Molecular diagnosis of nasopharyngeal carcinoma: a review. Gan YY, et al. Ann Acad Med Singapore 1996 Jan; 25(1):71–4 (32 ref.)

The role of Epstein-Barr virus in Hodgkin's disease from different geographical areas. Weinreb M, et al. Arch Dis Child 1996 Jan;74(1):27–31 (34 ref.)

Primary Epstein-Barr virus-related non-Hodgkin's lymphoma of the pleural cavity following long-standing tuberculous empyema. Molinie V, et al. Arch Pathol Lab Med 1996 Mar;120(3):288–91 (18 ref.)

Epstein-Barr virus in T and natural killer (NK) cell non-Hodgkin's lymphomas. Kanavaros P, et al. Leukemia 1996 Jun;10 Suppl 2:s84–7 (44 ref.)

[Primary non-Hodgkin's lymphomas of the liver in human immunodeficiency virus infected patients. Three cases] Brugière O, et al. Gastroenterol Clin Biol 1996;20(3):307–11 (18 ref.) (Eng. Abstr.) (Fre)

[Malignant lymphoma and EBV] Ohshima K, et al. Rinsho Byori 1996 Jan;44(1):24–31 (23 ref.) (Eng. Abstr.) (Jpn)

PATHOGENICITY

Adenovirus and Epstein-Barr virus in lung disease. Hogg JC, et al. Semin Respir Infect 1995 Dec;10(4):244–53 (34 ref.)

[Possible involvement of Epstein-Barr virus in the pathogenesis of Sjögren's syndrome] Haruta J, et al. Nippon Rinsho 1995 Oct;53(10):2479–83 (18 ref.) (Eng. Abstr.) (Jpn)

[Epstein-Barr virus oncogenesis: immortalization by a human ubiquitous virus and neoplastic conversion by risk factors] Osato T, et al. Tanpakushitsu Kakusan Koso 1995 Sep; 40(12):1822–34 (46 ref.) (Jpn)

PHYSIOLOGY

Role of Epstein-Barr virus gene latent membrane protein in nasopharyngeal carcinoma. Nicholson LJ, et al. Trends Microbiol 1996 Apr;4(4):132–3 (21 ref.)

Epstein-Barr virus and the B cell: that's all it takes. Thorley-Lawson DA, et al. Trends Microbiol 1996 May; 4(5):204–8 (27 ref.)

HERPESVIRUS 5, HUMAN see CYTOMEGALOVIRUS

HERPESVIRUS 6, HUMAN

see related
EXANTHEMA SUBITUM

Human herpesvirus-6 infections. Jones CA, et al. Arch Dis Child 1996 Feb;74(2):98–100 (54 ref.)

New pathogens, and diseases old and new. I) Afipia felis and Rochalimaea. II) Parvovirus B 19. III) herpesvirus 6. Zannolli R, et al. Panminerva Med 1995 Dec;37(4):238–47 (111 ref.)

[Human herpesviruses 6 and 7. Basic principles and possible significance for dermatology] Lasch JA, et al. Hautarzt 1996 May;47(5):341–50 (85 ref.) (Eng. Abstr.) (Ger)

ISOLATION & PURIFICATION

[Human herpes viruses type 6 and 7; causative agents of, among others, exanthema subitum] Galama JM. Ned Tijdschr Geneeskd 1996 Jan 20;140(3):124–8 (20 ref.) (Eng. Abstr.) (Dut)

PATHOGENICITY

Human herpesvirus-6 in transplantation: an emerging pathogen. Singh N, et al. Ann Intern Med 1996 Jun 15; 124(12):1065–71 (58 ref.)

Human herpesvirus 6 as a possible cause of pneumonia. Cone RW. Semin Respir Infect 1995 Dec;10(4):254–8 (32 ref.)

PHYSIOLOGY

Human herpesvirus 6 as a potential copathogen. Ablashi DV, et al. Trends Microbiol 1995 Aug;3(8):324–7 (34 ref.)

HERPESVIRUS 7, HUMAN

[Human herpesviruses 6 and 7. Basic principles and possible significance for dermatology] Lasch JA, et al. Hautarzt 1996 May;47(5):341–50 (85 ref.) (Eng. Abstr.) (Ger)

ISOLATION & PURIFICATION

[Human herpes viruses type 6 and 7; causative agents of, among others, exanthema subitum] Galama JM. Ned Tijdschr Geneeskd 1996 Jan 20;140(3):124–8 (20 ref.) (Eng. Abstr.) (Dut)

HERPESVIRUS INFECTIONS see HERPESVIRIDAE INFECTIONS

HERPESVIRUS PLATYRHINAE see SIMPLEXVIRUS

HERPESVIRUS 1, SAIMIRINE see SIMPLEXVIRUS

HERPESVIRUS 1, SUID

IMMUNOLOGY

Pseudorabies virus eradication by area-wide vaccination is feasible. Stegeman A. Vet Q 1995 Dec;17(4):150–6 (85 ref.)

PATHOGENICITY

Neurovirulence of pseudorabies virus. Card JP, et al. Crit Rev Neurobiol 1995;9(2–3):137–62 (125 ref.)

HERPESVIRUS VARICELLAE see HERPESVIRUS 3, HUMAN

HERPETOMONAS see TRYPANOSOMATINA

HESPERIDIN

THERAPEUTIC USE

Cellular basis of inflammation, edema and the activity of Daflon 500 mg. Friesenecker B, et al. Int J Microcirc Clin Exp 1995;15 Suppl 1:17–21 (44 ref.)

HETE see HYDROXYEICOSATETRAENOIC ACIDS

5,12-HETE see LEUKOTRIENE B4

HETEROANTIGENS see ANTIGENS, HETEROPHILE

HETEROCHROMATIN

GENETICS

Return of the H-word (heterochromatin). Lohe AR, et al. Curr Opin Genet Dev 1995 Dec;5(6):746–55 (67 ref.)

ICF syndrome (immunodeficiency, centromeric instability and facial anomalies): investigation of heterochromatin abnormalities and review of clinical outcome. Brown DC, et al. Hum Genet 1995 Oct;96(4):411–6 (15 ref.)

PHYSIOLOGY

Heterochromatin and gene regulation in Drosophila. Elgin SC. Curr Opin Genet Dev 1996 Apr;6(2):193–202 (65 ref.)

Return of the H-word (heterochromatin). Lohe AR, et al. Curr Opin Genet Dev 1995 Dec;5(6):746–55 (67 ref.)

Replicative senescence: considerations relating to the stability of heterochromatin domains. Howard BH. Exp Gerontol 1996 Jan–Apr;31(1–2):281–93 (79 ref.)

The regulation of euchromatin and heterochromatin by histones in yeast. Grunstein M, et al. J Cell Sci Suppl 1995; 19:29–36 (65 ref.)

HETEROCHROMIC CYCLITIS see IRIDOCYCLITIS

HETEROCYCLIC COMPOUNDS

ADVERSE EFFECTS

The food-derived heterocyclic amines and breast cancer: a 1995 perspective. Synderwine EG. Recent Results Cancer Res 1996;140:17–25 (54 ref.)

TOXICITY

Extrapolation of heterocyclic amine carcinogenesis data from rodents and nonhuman primates to humans. Adamson RH, et al. Arch Toxicol Suppl 1996;18:303–18 (56 ref.)

HETEROCYCLIC CPDS, BICYCLIC see BICYCLO COMPOUNDS, HETEROCYCLIC

HETERODUPLEXES, NUCLEIC ACID see NUCLEIC ACID HETERODUPLEXES

HETEROGRAFT

HETEROGRAFT see **TRANSPLANTATION, HETEROLOGOUS**

HETEROGRAFT BIOPROSTHESIS see **BIOPROSTHESIS**

HETEROGRAFT DRESSINGS see **BIOLOGICAL DRESSINGS**

HETEROLOGOUS ANTIGENS see **ANTIGENS, HETEROPHILE**

HETEROPHILE ANTIGENS see **ANTIGENS, HETEROPHILE**

HETEROSEXUALITY see **SEX BEHAVIOR**

HETEROTOPIC TISSUE see **CHORISTOMA**

HETEROZYGOTE

[From identification of mutation to population screening] Aula P, et al. **Duodecim** 1994;110(7):749–56 (20 ref.) **(Fin)**

[Physical exercise and increase in arterial pressure and temperature in a female heterozygote for anhidrotic ectodermal dysplasia] Bandinelli G, et al. **Ann Ital Med Int** 1996 Jan–Mar;11(1):59–61 (12 ref.) (Eng. Abstr.) **(Ita)**

HETEROZYGOTE DETECTION

Neonatal screening for sickle cell disorders: what about the carrier infants? Laird L, et al. **BMJ** 1996 Aug 17; 313(7054):407–11 (51 ref.)

Carrier screening in the community. Brock DJ. **J Inherit Metab Dis** 1995;18(4):525–32 (12 ref.)

[Biochemical, molecular and social aspects of carrier screening for Tay–Sachs disease] Peleg L, et al. **Harefuah** 1995 Dec 1;129(11):475–80 (43 ref.) **(Heb)**

HEX A see **BETA-N-ACETYLHEXOSAMINIDASE**

HEX B see **BETA-N-ACETYLHEXOSAMINIDASE**

HEXABRACHION see **TENASCIN**

HEXACHLOROCYCLOHEXANE see **LINDANE**

HEXADECADROL see **DEXAMETHASONE**

HEXADECANOATES see **PALMITATES**

HEXADECANOIC ACID see **PALMITIC ACIDS**

HEXAMETHYLENEIMINES see **AZEPINES**

HEXAMETHYLMELAMINE see **ALTRETAMINE**

HEXOSAMINES

BLOOD

[Respective value of glycated hemoglobin and fructosamine assays in the care of diabetes mellitus] Bernard M, et al. **Ann Biol Clin (Paris)** 1995;53(6):321–7 (52 ref.) (Eng. Abstr.) **(Fre)**

[Fructosamine] Kawanishi K, et al. **Nippon Rinsho** 1995 Feb; 53 Su Pt 1:546–8 (6 ref.) **(Jpn)**

PHYSIOLOGY

Hexosamines and insulin resistance. McClain DA, et al. **Diabetes** 1996 Aug;45(8):1003–9 (64 ref.)

HEXOSAMINIDASE see **BETA-N-ACETYLHEXOSAMINIDASE**

HEXOSAMINIDASE A see **BETA-N-ACETYLHEXOSAMINIDASE**

HEXOSAMINIDASE B see **BETA-N-ACETYLHEXOSAMINIDASE**

HEXOSAMINIDASE ISOENZYMES see **BETA-N-ACETYLHEXOSAMINIDASE**

HEXOSAMINIDASE ISOZYMES see **BETA-N-ACETYLHEXOSAMINIDASE**

HEXOSE MONOPHOSPHATE SHUNT see **PENTOSEPHOSPHATE PATHWAY**

HEXOSE TRANSPORT PROTEINS see **MONOSACCHARIDE TRANSPORT PROTEINS**

HEXOSEDIPHOSPHATASE DEFICIENCY see **FRUCTOSE-1,6-DIPHOSPHATASE DEFICIENCY**

HEYMANN NEPHRITIS see **GLOMERULONEPHRITIS**

HFRS see **HEMORRHAGIC FEVER WITH RENAL SYNDROME**

HIATAL HERNIA see **HERNIA, HIATAL**

HIBERNATION

The neuroendocrine system in hibernating mammals: present knowledge and open questions. Nürnberger F. **Cell Tissue Res** 1995 Sep;281(3):391–412 (145 ref.)

PHYSIOLOGY

The hibernator heart—nature's model of resistance to ventricular fibrillation. Johansson BW. **Cardiovasc Res** 1996 May;31(5):826–32 (39 ref.)

[Is the animal in hibernal sleep awake?] Canguilhem B, et al. **Neurophysiol Clin** 1996;26(1):1–7 (20 ref.) (Eng. Abstr.) **(Fre)**

[The physiology and genesis of hibernation] Karmanova IG. **Zh Evol Biokhim Fiziol** 1995 Mar–Apr;31(2):216–26 (61 ref.) **(Rus)**

HIBERNATION, ARTIFICIAL see **HYPOTHERMIA, INDUCED**

HIBERNOMA see **LIPOMA**

HIDRADENITIS SUPPURATIVA

COMPLICATIONS

Squamous cell carcinoma complicating perianal hidradenitis suppurativa. Pérez-Díaz D, et al. **Int J Colorectal Dis** 1995; 10(4):225–8 (23 ref.)

HIDRADENOMA see **ADENOMA, SWEAT GLAND**

HIDROTIC ECTODERMAL DYSPLASIA see **ECTODERMAL DYSPLASIA**

HIGH-DENSITY LIPOPROTEINS see **LIPOPROTEINS, HDL**

HIGH-FREQUENCY JET VENTILATION

[High frequency jet ventilation combined with conventional mechanical ventilation in the treatment of adult respiratory distress syndrome] Roustan JP. **Ann Fr Anesth Reanim** 1995;14(3):276–88 (55 ref.) (Eng. Abstr.) **(Fre)**

HIGH-FREQUENCY OSCILLATION see **HIGH-FREQUENCY VENTILATION**

HIGH-FREQUENCY POSITIVE PRESSURE VENTILATION see **HIGH-FREQUENCY VENTILATION**

HIGH-FREQUENCY VENTILATION

METHODS

Clinical approaches to the use of high-frequency oscillatory ventilation in neonatal respiratory failure. Kinsella JP, et al. **J Perinatol** 1996 Mar–Apr;16(2 Pt 2 Su):S52–5 (16 ref.)

HIGH MOBILITY GROUP PROTEINS

CHEMISTRY

hSRY: molecular gender bender. Bramham J, et al. **Structure** 1995 Jul 15;3(7):631–3 (19 ref.)

GENETICS

The HMG-14/-17 chromosomal protein family: architectural elements that enhance transcription from chromatin templates. Bustin M, et al. **Semin Cell Biol** 1995 Aug; 6(4):247–55 (39 ref.)

Selective distribution of histone H1 variants and high mobility group proteins in chromosomes. Grossbach U. **Semin Cell Biol** 1995 Aug;6(4):237–46 (62 ref.)

METABOLISM

Proteins that bind to and mediate the biological activity of platinum anticancer drug-DNA adducts. Whitehead JP, et al. **Met Ions Biol Syst** 1996;32:687–726 (111 ref.)

PHYSIOLOGY

DNA lesion-recognizing proteins and the p53 connection. Boulikas T. **Anticancer Res** 1996 Jan–Feb;16(1):225–42 (187 ref.)

HIGH-RISK PREGNANCY see **PREGNANCY, HIGH-RISK**

HIGH T4 SYNDROME see **EUTHYROID SICK SYNDROMES**

HIGHER NERVOUS ACTIVITY

PHYSIOLOGY

Steroid control of higher brain function and behavior. Mortaud S, et al. **Behav Genet** 1996 Jul;26(4):367–72 (22 ref.)

HILL-BURTON ACT see **FINANCING, GOVERNMENT**

HINDBRAIN see **RHOMBENCEPHALON**

HINDLIMB

INNERVATION

Functional reorganization of the partially denervated hindlimb extensor and flexor muscle in rat. Sławińska U, et al. **Acta Neurobiol Exp (Warsz)** 1996;56(1):441–7 (27 ref.)

HINDUISM

see related
MEDICINE, AYURVEDIC

HIP

INJURIES

Injuries about the hip and pelvis in the young athlete. Paletta GA Jr, et al. **Clin Sports Med** 1995 Jul;14(3):591–628 (224 ref.)

PATHOLOGY

CT and MR imaging of the hip. Conway WF, et al. **Radiology** 1996 Feb;198(2):297–307 (68 ref.)

PHYSIOLOGY

Exercise and bone mass in young and premenopausal women. Snow CM. **Bone** 1996 Jan;18(1 Suppl):51S–55S (30 ref.)

HIP DISLOCATION

Traumatic hip dislocation in a young child: a case report and discussion. Attia MW, et al. **Pediatr Emerg Care** 1995 Oct;11(5):291–3 (20 ref.)

ETIOLOGY

[Open post-traumatic anterior luxation of the hip in children. Apropos of a case and review of the literature] Rafai M, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1995; 81(2):178–81 (9 ref.) (Eng. Abstr.) **(Fre)**

RADIOGRAPHY

[The labrum acetabulare] Bellaïche L, et al. **Ann Radiol (Paris)** 1995;38(5):280–3 (16 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Total hip arthroplasty after acute displaced femoral neck fractures. Papandrea RF, et al. **Am J Orthop** 1996 Feb; 25(2):85–8 (21 ref.)

Toxic shock syndrome as a complication of orthopaedic surgery. Grimes J, et al. **J Pediatr Orthop** 1995 Sep–Oct; 15(5):666–71 (28 ref.)

VETERINARY

Fractures and luxations of the pelvis and proximal femur. Hull BL. **Vet Clin North Am Food Anim Pract** 1996 Mar; 12(1):47–58 (25 ref.)

HIP DISLOCATION, CONGENITAL

Developmental dysplasia of the hip. Novacheck TF. **Pediatr Clin North Am** 1996 Aug;43(4):829–48 (15 ref.)

Developmental dislocation of the hip: a clinical overview. Mooney JF 3rd, et al. **Pediatr Rev** 1995 Aug;16(8):299–303; quiz 304 (8 ref.)

COMPLICATIONS

Subcapital fracture of a congenitally dislocated hip: revival of Girdlestone resection arthroplasty. Taha AM. **Bull Hosp Jt Dis** 1995;54(1):35–42 (100 ref.)

DIAGNOSIS

CT and MR imaging of the hip. Conway WF, et al. **Radiology** 1996 Feb;198(2):297–307 (68 ref.)

PHYSIOPATHOLOGY

Avascular necrosis of the proximal femur in developmental dislocation of the hip. Incidence, risk factors, sequelae and MR imaging for diagnosis and prognosis. Kruczynski J. **Acta Orthop Scand Suppl** 1996 Apr;268:1–48 (167 ref.)

RADIOGRAPHY

Radiographic course after acetabuloplasty and femoral osteotomy in hip dysplasia. Fritsch EW, et al. **Clin Orthop** 1996 Feb;(323):215–25 (52 ref.)

[Hip dislocation and urinary tract. Two trends in pediatric radiology] Jorulf H, et al. **Lakartidningen** 1995 Nov 29; 92(48):4563–6 (20 ref.) **(Swe)**

SURGERY

Radiographic course after acetabuloplasty and femoral

osteotomy in hip dysplasia. Fritsch EW, et al. **Clin Orthop** 1996 Feb;(323):215–25 (52 ref.)

HIP DYSPLASIA, CANINE

DIAGNOSIS

The pathogenesis and diagnosis of canine hip dysplasia: a review. Fries CL, et al. **Can Vet J** 1995 Aug;36(8):494–502 (59 ref.)

ETIOLOGY

The pathogenesis and diagnosis of canine hip dysplasia: a review. Fries CL, et al. **Can Vet J** 1995 Aug;36(8):494–502 (59 ref.)

SURGERY

Canine cemented total hip replacements: state of the art. Olmstead ML. **J Small Anim Pract** 1995 Sep;36(9):395–9 (13 ref.)

THERAPY

Treatment of canine hip dysplasia: a review. Remedios AM, et al. **Can Vet J** 1995 Aug;36(8):503–9 (73 ref.)

HIP DYSPLASIA, CONGENITAL see **HIP DISLOCATION, CONGENITAL**

HIP FRACTURES

Perioperative aspects of hip fracture. Guidelines for intervention that will impact prevalence and outcome. Zohman GL, et al. **Am J Orthop** 1995 Sep;24(9):666–71 (40 ref.)

Hip fractures: incidence, risk factors, energy absorption, and prevention. Lauritzen JB. **Bone** 1996 Jan;18(1 Suppl):65S–75S (119 ref.)

COMPLICATIONS

Subcapital fracture of a congenitally dislocated hip: revival of Girdlestone resection arthroplasty. Taha AM. **Bull Hosp Jt Dis** 1995;54(1):35–42 (100 ref.)

[Trauma and thrombosis. High risk of embolism in patients with spinal cord injuries, hip fractures and leg fractures] Bergovist D. **Lakartidningen** 1996 Jul 24;93(30–31):2653–4 (19 ref.) **(Swe)**

DIAGNOSIS

CT and MR imaging of the hip. Conway WF, et al. **Radiology** 1996 Feb;198(2):297–307 (68 ref.)

EPIDEMIOLOGY

Evaluation of the risk of hip fracture. Kanis JA, et al. **Bone** 1996 Mar;18(3 Suppl):127S–132S (36 ref.)

Epidemiology of hip fractures. Kannus P, et al. **Bone** 1996 Jan;18(1 Suppl):57S–63S (59 ref.)

Epidemiology of hip fractures: implications of the exponential increase with age. Melton LJ 3rd. **Bone** 1996 Mar;18(3 Suppl):121S–125S (53 ref.)

Water fluoridation, bone density and hip fractures: a review of recent literature. Raheb J. **Community Dent Oral Epidemiol** 1995 Oct;23(5):309–16 (49 ref.)

ETIOLOGY

Nutritional aspects of hip fractures. Bonjour JP, et al. **Bone** 1996 Mar;18(3 Suppl):139S–144S (87 ref.)

Etiology and prevention of age-related hip fractures. Hayes WC, et al. **Bone** 1996 Jan;18(1 Suppl):77S–86S (110 ref.)

Are the etiologies of cervical and trochanteric hip fractures different? Mautalen CA, et al. **Bone** 1996 Mar;18(3 Suppl):133S–137S (39 ref.)

METABOLISM

Age-related endocrine deficiencies and fractures of the proximal femur. II implications of vitamin D deficiency in the elderly. Boonen S, et al. **J Endocrinol** 1996 Apr; 149(1):13–7 (57 ref.)

Age-related endocrine deficiencies and fractures of the proximal femur. I implications of growth hormone deficiency in the elderly. Boonen S, et al. **J Endocrinol** 1996 Apr;149(1):7–12 (72 ref.)

PREVENTION & CONTROL

Treatable and untreatable risk factors for hip fracture. Cummings SR. **Bone** 1996 Mar;18(3 Suppl):165S–167S (20 ref.)

Prevention of hip fractures: drug therapy. Lips P. **Bone** 1996 Mar;18(3 Suppl):159S–163S (46 ref.)

Present and future of osteoporosis therapy. Seeman E, et al. **Bone** 1995 Aug;17(2 Suppl):23S–29S (47 ref.)

[Prevention of fractures of the proximal end of the femur] Kannus P, et al. **Duodecim** 1994;110(1):27–33 (41 ref.) **(Fin)**

RADIOGRAPHY

[The labrum acetabulare] Bellaïche L, et al. **Ann Radiol (Paris)** 1995;38(5):280–3 (16 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Hip Fracture. Zuckerman JD. **N Engl J Med** 1996 Jun 6; 334(23):1519–25 (62 ref.)

[Current status of therapy of subtrochanteric femoral fractures] Hoffmann R, et al. **Unfallchirurg** 1996 Apr; 99(4):240–8 (44 ref.) (Eng. Abstr.) **(Ger)**

[Diagnosis and therapy of local infections after surgical management of proximal femoral fractures] Dávid A, et al. **Zentralbl Chir** 1995;120(11):887–92 (29 ref.) (Eng. Abstr.) **(Ger)**

[Pertrochanteric fractures] Stürmer KM, et al. **Zentralbl Chir** 1995;120(11):862–72 (25 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Orthopedic treatment of hip fracture. Obrant K. **Bone** 1996 Mar;18(3 Suppl):145S–148S (31 ref.)

VETERINARY

Canine cemented total hip replacements: state of the art. Olmstead ML. **J Small Anim Pract** 1995 Sep;36(9):395–9 (13 ref.)

HIP JOINT

Indomethacin hastens large joint osteoarthritis in humans--how strong is the evidence? [editorial] Doherty M, et al. **J Rheumatol** 1995 Nov;22(11):2013–6 (32 ref.)

Imaging of the total hip arthroplasty. Allen AM, et al. **J South Orthop Assoc** 1995 Summer;4(2):96–123 (71 ref.)

ANATOMY & HISTOLOGY

[Anatomy and development of the hip joint during growth. I. anatomy and development of the acetabulum] Wierusz-Kozłowska M. **Chir Narzadow Ruchu Ortop Pol** 1995;60(6):477–83 (59 ref.) (Eng. Abstr.) **(Pol)**

GROWTH & DEVELOPMENT

[Anatomy and development of the hip joint during growth. I. anatomy and development of the acetabulum] Wierusz-Kozłowska M. **Chir Narzadow Ruchu Ortop Pol** 1995;60(6):477–83 (59 ref.) (Eng. Abstr.) **(Pol)**

[Anatomy and development of the hip joint during growth. II. Anatomy and development of the proximal femur] Wierusz-Kozłowska M. **Chir Narzadow Ruchu Ortop Pol** 1996;61(1):59–62 (26 ref.) (Eng. Abstr.) **(Pol)**

PATHOLOGY

Magnetic resonance imaging of the musculoskeletal system. II. The hip. Hayes CW, et al. **Clin Orthop** 1996 Jan; (322):297–309 (45 ref.)

CT and MR imaging of the hip. Conway WF, et al. **Radiology** 1996 Feb;198(2):297–307 (68 ref.)

PHYSIOLOGY

[Biomechanics of the hip joint in children] Heimkes B, et al. **Z Orthop Ihre Grenzgeb** 1995 Jul–Aug;133(4):357–63 (32 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

[Biomechanical changes in the hip, femur and knee joint after removal of a tensor fasciae latae flap] Lattermann C, et al. **Handchir Mikrochir Plast Chir** 1996 Mar;28(2):76–82 (33 ref.) (Eng. Abstr.) **(Ger)**

RADIOGRAPHY

Recommended methodology for assessing the progression of osteoarthritis of the hip and knee joints. Dieppe PA. **Osteoarthritis Cartilage** 1995 Jun;3(2):73–7 (27 ref.)

[The labrum acetabulare] Bellaïche L, et al. **Ann Radiol (Paris)** 1995;38(5):280–3 (16 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Treatment of the unstable (acute) slipped capital femoral epiphysis. Aronsson DD, et al. **Clin Orthop** 1996 Jan; (322):99–110 (50 ref.)

Arthroscopic surgery of the hip: current status. Norman-Taylor FH, et al. **Knee Surg Sports Traumatol Arthrosc** 1994;2(4):255–8 (23 ref.)

[Development and uses of porous-coated hip prostheses] Yuan M, et al. **Chung Hua Wai Ko Tsa Chih** 1995 Jul; 33(7):445–8 (22 ref.) **(Chi)**

[Hip joint arthrodesis using the cobra plate. Indication, technique, outcome] Wagner M, et al. **Orthopade** 1996 Apr; 25(2):129–39 (69 ref.) (Eng. Abstr.) **(Ger)**

HIP PROSTHESIS

Total hip arthroplasty after acute displaced femoral neck fractures. Papandrea RF, et al. **Am J Orthop** 1996 Feb; 25(2):85–8 (21 ref.)

Revision of failed total hip replacement. Hubble MJ, et al. **Br J Hosp Med** 1996 Apr 3–16;55(7):432–6 (19 ref.)

The use of ceramic in prosthetic hip surgery. The state of the art. Toni A, et al. **Chir Organi Mov** 1995 Apr–Jun; 80(2):125–37 (65 ref.) **(Eng, Ita)**

Prosthetic joint infection due to Mycobacterium tuberculosis: report of three cases. Tokumoto JI, et al. **Clin Infect Dis** 1995 Jul;21(1):134–6 (14 ref.)

Metal on metal bearings in hip arthroplasty. Amstutz HC, et al. **Clin Orthop** 1996 Aug;(329 Suppl):S11–34 (101 ref.)

Metal versus polyethylene wear particles in total hip replacements. A review. Doorn PF, et al. **Clin Orthop** 1996 Aug;(329 Suppl):S206–16 (64 ref.)

Distribution of cobalt chromium wear and corrosion products and biologic reactions. Merritt K, et al. **Clin Orthop** 1996 Aug;(329 Suppl):S233–43 (71 ref.)

Systems view of optimizing metal on metal bearings. Schey JA. **Clin Orthop** 1996 Aug;(329 Suppl):S115–27 (53 ref.)

Factors correlating with long term survival of McKee-Farrar total hip prostheses. Schmalzried TP, et al. **Clin Orthop** 1996 Aug;(329 Suppl):S48–59 (39 ref.)

Cobalt chromium molybdenum metal combination for modular hip prostheses. Schmidt M, et al. **Clin Orthop** 1996 Aug;(329 Suppl):S35–47 (32 ref.)

Total hip arthroplasty. Thomas BJ, et al. **Curr Opin Rheumatol** 1996 Mar;8(2):148–53 (15 ref.)

The role of polyethylene properties in osteolysis after total hip replacement. Gómez-Barrena E, et al. **Instr Course Lect** 1996;45:187–97 (80 ref.)

Spontaneous fracture of the ceramic ball in a ceramic-polyethylene total hip arthroplasty. Michaud RJ, et al. **J Arthroplasty** 1995 Dec;10(6):863–7 (27 ref.)

Imaging of the total hip arthroplasty. Allen AM, et al. **J South Orthop Assoc** 1995 Summer;4(2):96–123 (71 ref.)

Diagnosis and management of the infected hip prosthesis. Fitzgerald RH Jr. **Orthopedics** 1995 Sep;18(9):833–5 (18 ref.)

[Development and uses of porous-coated hip prostheses] Yuan M, et al. **Chung Hua Wai Ko Tsa Chih** 1995 Jul; 33(7):445–8 (22 ref.) **(Chi)**

[Medical environment of total hip prosthesis] Anract P, et al. **Presse Med** 1996 Jun 29;25(23):1069–75 (23 ref.) (Eng. Abstr.) **(Fre)**

[Materials for hip endoprostheses--alternatives to standard materials] Bosdorf K, et al. **Biomed Tech (Berl)** 1995 Dec; 40(12):356–62 (35 ref.) (Eng. Abstr.) **(Ger)**

[15 years experience with the Ti-6Al-7Nb alloy for joint prostheses] Semlitsch M, et al. **Biomed Tech (Berl)** 1995 Dec;40(12):347–55 (38 ref.) (Eng. Abstr.) **(Ger)**

[Treatment of infected total prosthesis arthroplasty of the hip joint] Herzog R, et al. **Orthopade** 1995 Aug; 24(4):326–34 (75 ref.) (Eng. Abstr.) **(Ger)**

[Endoprosthesis and bone reaction] Kohn D, et al. **Orthopade** 1995 Sep;24(5):409–15 (52 ref.) (Eng. Abstr.) **(Ger)**

[Treatment of periprosthetic infection of the hip using one-stage exchange surgery] Steinbrink K, et al. **Orthopade** 1995 Aug;24(4):335–43 (30 ref.) (Eng. Abstr.) **(Ger)**

[Histological and morphometric studies of femurs with stable hip joint replacement. An autopsy study with special reference to factors leading to late loosening] Bos J, et al. **Z Orthop Ihre Grenzgeb** 1995 Sep–Oct;133(5):460–6 (46 ref.) (Eng. Abstr.) **(Ger)**

[Diagnosis and therapy of local infections after surgical management of proximal femoral fractures] Dávid A, et al. **Zentralbl Chir** 1995;120(11):887–92 (29 ref.) (Eng. Abstr.) **(Ger)**

[Pertrochanteric fractures] Stürmer KM, et al. **Zentralbl Chir** 1995;120(11):862–72 (25 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Cancer risk after metal on metal and polyethylene on metal total hip arthroplasty. Visuri T, et al. **Clin Orthop** 1996 Aug;(329 Suppl):S280–9 (51 ref.)

Bone cement as a seal protecting the femur from the ingress of particulate debris and femoral osteolysis. Harris WH, et al. **Instr Course Lect** 1996;45:183–5 (23 ref.)

Lymphadenopathy associated with total joint prostheses. A report of two cases and a review of the literature [see comments] Benz EB, et al. **J Bone Joint Surg Am** 1996 Apr;78(4):588–93 (28 ref.) Comment in: J Bone Joint Surg Am 1996 Apr;78(4):479–81.

Infection after total hip arthroplasty. Past, present, and future. Garvin KL, et al. **J Bone Joint Surg Am** 1995 Oct; 77(10):1576–88 (139 ref.)

METHODS

Hypotensive epidural anesthesia for total hip arthroplasty: a review [see comments] Sharrock NE, et al. **Acta Orthop Scand** 1996 Feb;67(1):91–107 (105 ref.) Comment in: Acta Orthop Scand 1996 Feb;67(1):1.

Acetabular allografts for restoration of bone stock in revision arthroplasty of the hip. Gross AE, et al. **Instr Course Lect** 1996;45:135–42 (41 ref.)

Periprosthetic osteolysis in total hip arthroplasty: the role of particulate wear debris. Maloney WJ, et al. **Instr Course Lect** 1996;45:171–82 (85 ref.)

Intraoperative complications during total hip arthroplasty. Patterson BM, et al. **Orthopedics** 1995 Nov;18(11):1089–95

HIP PROSTHESIS

(69 ref.)
[Acetabular implant in Charnley's total arthroplasty. Review of 309 cases with a minimum of 15 years follow-up] Avedikian J, et al.
Rev Chir Orthop Reparatrice Appar Mot 1996;82(2):116–24 (40 ref.) (Eng. Abstr.) **(Fre)**

REHABILITATION

Total hip and knee replacement treatment programs: a report using consensus. Enloe LJ, et al.
J Orthop Sports Phys Ther 1996 Jan;23(1):3–11 (20 ref.)

STANDARDS

Prostheses for primary total hip replacement. A critical appraisal of the literature. Cowley DE.
Int J Technol Assess Health Care 1995 Fall;11(4):770–8 (34 ref.)

TRENDS

Total hip replacement: the way forward. Bulstrode C.
Ann R Coll Surg Engl 1996 Mar;78(2):129–32 (20 ref.)

VETERINARY

Canine cemented total hip replacements: state of the art. Olmstead ML. **J Small Anim Pract** 1995 Sep;36(9):395–9 (13 ref.)

HIPPEL-LINDAU DISEASE

[Hemangioblastoma and von Hippel-Lindau disease] Matsumoto K, et al. **Nippon Rinsho** 1995 Nov;53(11):2672–7 (12 ref.) (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

Somatostatinoma of the pancreas associated with von Hippel-Lindau disease. Maki M, et al. **Intern Med** 1995 Jul;34(7):661–5 (20 ref.)
A symptomatic testicular cyst in a patient with von Hippel-Lindau disease. Brown JA, et al. **Urology** 1996 Sep; 48(3):494–5 (9 ref.)
[Tumors outside of the central nervous system in Von Hippel-Lindau disease] Veltman GA, et al.
Ned Tijdschr Geneeskd 1996 Apr 13;140(15):823–6 (33 ref.) **(Dut)**

DIAGNOSIS

Clinical features and molecular genetics of Von Hippel-Lindau disease. Maher ER, et al.
Ophthalmic Genet 1995 Sep;16(3):79–84 (43 ref.)

GENETICS

Molecular cloning of the von Hippel-Lindau tumor suppressor gene and its role in renal carcinoma. Gnarra JR, et al. **Biochim Biophys Acta** 1996 Mar 18;1242(3):201–10 (60 ref.)
Von Hippel-Lindau disease and sporadic renal cell carcinoma. Zbar B. **Cancer Surv** 1995;25:219–32 (32 ref.)
Von Hippel-Lindau tumor suppressor protein and transcription elongation: new insights into regulation of gene expression. Bertherat J. **Eur J Endocrinol** 1996 Feb; 134(2):157, 159 (2 ref.)
Neurofibromatosis type 2 and von Hippel-Lindau disease: from gene cloning to function. Kley N, et al. **Glia** 1995 Nov;15(3):297–307 (75 ref.)
von Hippel-Lindau syndrome: a rare syndrome as the clue for the molecular basis of common renal disorders [editorial] Neumann HP. **Nephrol Dial Transplant** 1995; 10(9):1498–9 (10 ref.)
Clinical features and molecular genetics of Von Hippel-Lindau disease. Maher ER, et al.
Ophthalmic Genet 1995 Sep;16(3):79–84 (43 ref.)
[Hippel-Lindau syndrome and sporadic renal cell carcinomas. Pathogenesis, morphologic spectrum and molecular genetics] Brauch H, et al. **Pathologe** 1995 Sep; 16(5):321–7 (41 ref.) (Eng. Abstr.) **(Ger)**

HIPPOCAMPAL FORMATION see **HIPPOCAMPUS**

HIPPOCAMPUS

see related
ENTORHINAL CORTEX

ANATOMY & HISTOLOGY

The economy of winter: phenotypic plasticity in behavior and brain structure. Jacobs LF. **Biol Bull** 1996 Aug; 191(1):92–100 (61 ref.)
Connection matrix of the hippocampal formation: I. The dentate gyrus. Patton PE, et al. **Hippocampus** 1995; 5(4):245–86 (410 ref.)
Anatomy of the medial temporal lobe. Van Hoesen GW. **Magn Reson Imaging** 1995;13(8):1047–55 (54 ref.)
[Basic neurobiology of hippocampal formation] Fernández-Espejo E. **Rev Neurol** 1996 Jul;24(131):779–84 (26 ref.) (Eng. Abstr.) **(Spa)**

CYTOLOGY

Mechanisms of neuronal plasticity as analyzed at the single cell level. Eberwine J, et al. **Prog Brain Res** 1995; 105:117–26 (18 ref.)

DRUG EFFECTS

Ethanol neurobehavioural teratogenesis and the role of L-glutamate in the fetal hippocampus. Reynolds JD, et al. **Can J Physiol Pharmacol** 1995 Sep;73(9):1209–23 (175 ref.)
Kainate-induced changes in gene expression in the rat hippocampus. Pennypacker KR, et al. **Prog Brain Res** 1995; 105:105–16 (64 ref.)

METABOLISM

The sodium-calcium exchanger and glutamate-induced calcium loads in aged hippocampal neurons in vitro. Mills LR. **Ann N Y Acad Sci** 1996 Apr 15;779:379–90 (39 ref.)
Aging-related increase in hippocampal calcium channels. Landfield PW. **Life Sci** 1996;59(5–6):399–404 (17 ref.)
A role for hippocampal opioids in long-term functional plasticity. Morris BJ, et al. **Trends Neurosci** 1995 Aug; 18(8):350–5 (59 ref.)

PATHOLOGY

Hippocampal and neocortical involvement in normal brain aging and dementia: morphological and neurochemical profile of the vulnerable circuits. Hof PR, et al.
J Am Geriatr Soc 1996 Jul;44(7):857–64 (83 ref.)
Neuropathology of Parkinson's disease. Forno LS.
J Neuropathol Exp Neurol 1996 Mar;55(3):259–72 (101 ref.)
Clinical correlations with hippocampal atrophy. Cascino GD.
Magn Reson Imaging 1995;13(8):1133–6 (18 ref.)
MRI-based hippocampal volumetrics: data acquisition, normal ranges, and optimal protocol. Jack CR Jr, et al.
Magn Reson Imaging 1995;13(8):1057–64 (36 ref.)
The diagnosis of hippocampal sclerosis: other techniques. Jackson GD. **Magn Reson Imaging** 1995;13(8):1081–93 (21 ref.)
MRI hippocampal volume and neuropsychology in epilepsy surgery. Trenerry MR, et al. **Magn Reson Imaging** 1995; 13(8):1125–32 (47 ref.)
Why stress is bad for your brain. Sapolsky RM. **Science** 1996 Aug 9;273(5276):749–50 (11 ref.)

PHYSIOLOGY

Monoamine modulation of the synaptic inhibition in the hippocampus. Bijak M. **Acta Neurobiol Exp (Warsz)** 1996; 56(1):385–95 (45 ref.)
Extracellular ATP as a neurotransmitter: its role in synaptic plasticity in the hippocampus. Wieraszko A.
Acta Neurobiol Exp (Warsz) 1996;56(2):637–48 (85 ref.)
Long-term potentiation and learning. Martinez JL Jr, et al.
Annu Rev Psychol 1996;47:173–203 (150 ref.)
The role of mesolimbic dopaminergic and retrohippocampal afferents to the nucleus accumbens in latent inhibition: implications for schizophrenia. Gray JA, et al.
Behav Brain Res 1995 Nov;71(1–2):19–31 (80 ref.)
What does the hippocampus really do? Jarrard LE.
Behav Brain Res 1995 Nov;71(1–2):1–10 (42 ref.)
Learning-related changes in hippocampal field potentials. Moser EI. **Behav Brain Res** 1995 Nov;71(1–2):11–8 (66 ref.)
Temporal structure in spatially organized neuronal ensembles: a role for interneuronal networks. Buzsáki G, et al. **Curr Opin Neurobiol** 1995 Aug;5(4):504–10 (61 ref.)
Synaptic plasticity: hippocampal LTP. Larkman AU, et al.
Curr Opin Neurobiol 1995 Jun;5(3):324–34 (120 ref.)
Modulation of inhibitory synapses in the mammalian brain. Marty A, et al. **Curr Opin Neurobiol** 1995 Jun;5(3):335–41 (38 ref.)
Individual differences in hypothalamic-pituitary-adrenal activity in later life and hippocampal aging. Meaney MJ, et al. **Exp Gerontol** 1995 May-Aug;30(3–4):229–51 (125 ref.)
Brain temperature and hippocampal function. Andersen P, et al. **Hippocampus** 1995;5(6):491–8 (35 ref.)
Fast rhythms in the hippocampus are a part of the diffuse gamma-response system [letter] Başar E, et al.
Hippocampus 1995;5(3):240–1 (14 ref.)
Simulation of spatial learning in the Morris water maze by a neural network model of the hippocampal formation and nucleus accumbens. Brown MA, et al. **Hippocampus** 1995; 5(3):171–88 (73 ref.)
The role of the hippocampus in declarative memory: a comment on Zola-Morgan, Squire, and Ramus (1994) [letter; comment] Nadel L. **Hippocampus** 1995;5(3):232–9 (20 ref.) Comment on: Hippocampus 1994 Aug;4(4):483–95.
Configural association theory and the hippocampal formation: an appraisal and reconfiguration. Rudy JW, et al. **Hippocampus** 1995;5(5):375–89 (80 ref.)
Deciphering the hippocampal polyglot: the hippocampus as a path integration system. McNaughton BL, et al.
J Exp Biol 1996 Jan;199 (Pt 1):173–85 (56 ref.)
Long-term hippocampal slices: a model system for investigating synaptic mechanisms and pathologic processes. Bahr BA. **J Neurosci Res** 1995 Oct 15; 42(3):294–305 (96 ref.)
Mechanisms of synaptogenesis in hippocampal neurons in primary culture. Matteoli M, et al. **J Physiol Paris** 1995; 89(1):51–5 (34 ref.)
Calcium-dependent afterhyperpolarization and learning in young and aging hippocampus. Disterhoft JF, et al.
Life Sci 1996;59(5–6):413–20 (54 ref.)
Ionotropic glutamate receptors. Their possible role in the expression of hippocampal synaptic plasticity. Asztély F, et al. **Mol Neurobiol** 1996 Feb;12(1):1–11 (122 ref.)
A computational model of cholinergic disruption of septohippocampal activity in classical eyeblink conditioning. Myers CE, et al. **Neurobiol Learn Mem** 1996 Jul;66(1):51–66 (90 ref.)
Induction of non-catalytic TrkB neurotrophin receptors during lesion-induced synaptic rearrangement in the adult rat hippocampus. Beck KD, et al. **Prog Brain Res** 1995; 105:197–210 (80 ref.)
Ensemble activity and behavior: what's the code? Deadwyler SA, et al. **Science** 1995 Nov 24;270(5240):1316–8 (24 ref.)
Selective neuronal vulnerability in the hippocampus—a role for gene expression? Schreiber SS, et al.
Trends Neurosci 1995 Oct;18(10):446–51 (93 ref.)
[Basic neurobiology of hippocampal formation] Fernández-Espejo E. **Rev Neurol** 1996 Jul;24(131):779–84 (26 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

Photosensitive temporal lobe epilepsy. Benbadis SR, et al.
Neurology 1996 Jun;46(6):1540–2 (10 ref.)

HIPPOCRATIC OATH

The Hippocratic Oath: a code for physicians, not a Pythagorean manifesto. Prioreschi P. **Med Hypotheses** 1995 Jun;44(6):447–62 (122 ref.)

HIRSCHSPRUNG DISEASE

Hirschsprung's disease. Skinner MA. **Curr Probl Surg** 1996 May;33(5):389–460 (190 ref.)

COMPLICATIONS

Colonic atresia combined with Hirschsprung's disease: a diagnostic and therapeutic challenge. Kim PC, et al.
J Pediatr Surg 1995 Aug;30(8):1216–7 (8 ref.)
Hirschsprung's disease associated with Ondine's curse: a special subgroup? Nakahara S, et al. **J Pediatr Surg** 1995 Oct;30(10):1481–4 (23 ref.)

DIAGNOSIS

Leukocyte adhesion deficiency mimicking Hirschsprung disease [see comments] Rivera-Matos IR, et al.
J Pediatr 1995 Nov;127(5):755–7 (16 ref.) Comment in: J Pediatr 1996 May;128(5 Pt 1):720.
[Constipation in children: from symptoms of Hirschsprung disease to chronic intestinal pseudo-obstruction syndromes] Goulet O. **Gastroenterol Clin Biol** 1996;20(5 Pt 2):B56–62 (39 ref.) **(Fre)**

ETIOLOGY

Hirschprung's disease. Sullivan PB. **Arch Dis Child** 1996 Jan; 74(1):5–7 (30 ref.)

GENETICS

Seminars in medicine of the Beth Israel Hospital, Boston. The RET proto-oncogene in multiple endocrine neoplasia type 2 and Hirschsprung's disease. Eng C.
N Engl J Med 1996 Sep 26;335(13):943–51 (89 ref.)

PATHOLOGY

[A case of segmental aganglionosis localized descending colon] Moriya H, et al.
Nippon Shokakibyo Gakkai Zasshi 1996 Jan;93(1):39–44 (9 ref.) **(Jpn)**

SURGERY

Inflammatory pseudocyst associated with trisomy 21 and Hirschsprung's disease. DuBois JJ, et al. **Mil Med** 1995 Sep;160(9):477–9 (28 ref.)

HIRSUTISM

see related
HYPERTRICHOSIS

A practical approach to hirsutism. Gilchrist VJ, et al.
Am Fam Physician 1995 Nov 1;52(6):1837–46 (22 ref.)
Advances in the diagnosis and treatment of the hirsute patient. Knochenhauer ES, et al.
Curr Opin Obstet Gynecol 1995 Oct;7(5):344–50 (59 ref.)

DIAGNOSIS

Evaluation of women with hirsutism. Kalve E, et al.
Am Fam Physician 1996 Jul;54(1):117–24 (22 ref.)

HIRUDIN

THERAPEUTIC USE

Pharmacological properties of hirudin and its derivatives. Potential clinical advantages over heparin. Monreal M, et al. **Drugs Aging** 1996 Mar;8(3):171–82 (52 ref.)
r-hirudin in unstable angina pectoris. Rationale and preliminary data from the APT pilot study. Fox KA.
Eur Heart J 1995 Jul;16 Suppl D:28–32 (15 ref.)

HIRUDINEA see LEECHES

HISPANIC AMERICANS

Occupational conditions and workers' sense of community: variations by gender and race. Lambert SJ, et al. **Am J Community Psychol** 1995 Apr;23(2):151–79 (78 ref.)

Hypertension in Hispanics. Comments on a major disease in a mix of ethnic groups. Martinez-Maldonado M. **Am J Hypertens** 1995 Dec;8(12 Pt 2):120s–123s (20 ref.)

Pediatric injury hospitalization in Hispanic children and non-Hispanic white children in southern California. Aagran PF, et al. **Arch Pediatr Adolesc Med** 1996 Apr; 150(4):400–6 (41 ref.)

Environmental health and Hispanic children. Metzger R, et al. **Environ Health Perspect** 1995 Sep;103 Suppl 6:25–32 (49 ref.)

Social theory, social action, and intervention research: implications for cancer prevention among Latinos. Flores ET, et al. **J Natl Cancer Inst Monogr** 1995;(18):101–8 (53 ref.)

Cancer in Hispanics: issues of concern. Modiano MR, et al. **J Natl Cancer Inst Monogr** 1995;(18):35–9 (48 ref.)

The emerging Hispanic population: a foundation for cancer prevention and control. Ramirez AG, et al. **J Natl Cancer Inst Monogr** 1995;(18):1–9 (32 ref.)

Drug prevention research with Hispanic populations: theoretical and methodological issues and a generic structural model. Castro FG, et al. **NIDA Res Monogr** 1994; 139:203–33 (51 ref.)

Cultural competence in assessing Hispanic youths and families: challenges in the assessment of treatment needs and treatment evaluation for Hispanic drug-abusing adolescents. Kurtines WM, et al. **NIDA Res Monogr** 1995; 156:172–89 (30 ref.)

Hispanic environmental health: ambient and indoor air pollution. National Coalition of Hispanic Health and Human Services Organizations (COSSMHO). **Otolaryngol Head Neck Surg** 1996 Feb;114(2):256–64 (27 ref.)

PSYCHOLOGY

Latinos and mutual support group: a case for considering culture. Simoni JM, et al. **Am J Orthopsychiatry** 1995 Jul; 65(3):440–5 (26 ref.)

Hispanic women and mental health. Gil RM. **Ann N Y Acad Sci** 1996 Jun 18;789:147–59 (53 ref.)

Health risk behaviors for Hispanic women. Torres S, et al. **Annu Rev Nurs Res** 1995;13:293–319 (94 ref.)

Eating disturbances among American minority groups: a review. Crago M, et al. **Int J Eat Disord** 1996 Apr; 19(3):239–48 (59 ref.)

Group therapy as an effective treatment modality for people of color. Fenster A. **Int J Group Psychother** 1996 Jul; 46(3):399–416 (42 ref.)

Somatization in Hispanics. Hulme PA. **J Psychosoc Nurs Ment Health Serv** 1996 Mar;34(3):33–7 (14 ref.)

Contraceptive methods: do Hispanic adolescents and their family planning care providers think about contraceptive methods the same way? Erickson PI. **Med Anthropol** 1996 May;17(1):65–82 (53 ref.)

Assessing, diagnosing and treating culturally diverse individuals: a Hispanic perspective. Ruiz P. **Psychiatr Q** 1995 Winter;66(4):329–41 (34 ref.)

STATISTICS & NUMERICAL DATA

Epidemiology of cancer among Hispanics in the United States. Trapido EJ, et al. **J Natl Cancer Inst Monogr** 1995; (18):17–28 (65 ref.)

HISTAMINASE see AMINE OXIDASE (COPPER-CONTAINING)

HISTAMINE

see related
HYPERSENSITIVITY, IMMEDIATE
RECEPTORS, HISTAMINE

ADVERSE EFFECTS

Wine and headache. Jarisch R, et al. **Int Arch Allergy Immunol** 1996 May;110(1):7–12 (45 ref.)

ANALYSIS

[Histamine] Yamatodani A. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:732–6 (19 ref.) **(Jpn)**

METABOLISM

Hypothalamic neuronal histamine modulates adaptive behavior and thermogenesis in response to endogenous pyrogen. Sakata T, et al. **Obes Res** 1995 Dec;3 Suppl 5:707S–712S (26 ref.)

PHYSIOLOGY

Neuroendocrine mechanisms during reversible hypovolaemic shock in humans with emphasis on the histaminergic and serotonergic system. Matzen SH. **Acta Physiol Scand Suppl** 1995;628:1–31 (208 ref.)

New aspects of the role of histamine in cardiovascular function: identification, characterization, and potential pathophysiological importance of H3 receptors. Göthert M, et al. **Can J Physiol Pharmacol** 1995 May;73(5):558–64 (23 ref.)

Histamine, histamine H2-receptor antagonists, gastric acid secretion and ulcers: an overview. Pattichis K, et al. **Drug Metabol Drug Interact** 1995;12(1):1–36 (43 ref.)

Homeostatic maintenance regulated by hypothalamic neuronal histamine. Sakata T, et al. **Methods Find Exp Clin Pharmacol** 1995 Nov;17 Suppl C:51–6 (39 ref.)

[Role of biogenic amines (catecholamines, histamine, serotonin, etc.) in food intake] Tsujii S. **Nippon Rinsho** 1995 Jun;53 Suppl:33–9 (20 ref.) **(Jpn)**

[Physiological and pathophysiological role of histamine in the gastrointestinal tract] Dyduch A, et al. **Pediatr Pol** 1996 May;71(5):391–5 (36 ref.) (Eng. Abstr.) **(Pol)**

HISTAMINE AGONISTS

PHARMACOLOGY

Molecular pharmacological aspects of histamine receptors. Leurs R, et al. **Pharmacol Ther** 1995 Jun;66(3):413–63 (386 ref.)

The medicinal chemistry and therapeutic potentials of ligands of the histamine H3 receptor. Leurs R, et al. **Prog Drug Res** 1995;45:107–65 (149 ref.)

HISTAMINE H1 AGONISTS see HISTAMINE AGONISTS

HISTAMINE H2 AGONISTS see HISTAMINE AGONISTS

HISTAMINE H3 AGONISTS see HISTAMINE AGONISTS

HISTAMINE ANTAGONISTS

PHARMACOLOGY

Molecular pharmacological aspects of histamine receptors. Leurs R, et al. **Pharmacol Ther** 1995 Jun;66(3):413–63 (386 ref.)

HISTAMINE H1 ANTAGONISTS

see related
ANTI-ALLERGIC AGENTS
BRONCHODILATOR AGENTS
HYPERSENSITIVITY, IMMEDIATE

[Antihistaminics] Gazca Aguilar A, et al. **Rev Alerg Mex** 1996 Mar-Apr;43(2):34–40 (51 ref.) (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Cardiac actions of antihistamines. Woosley RL. **Annu Rev Pharmacol Toxicol** 1996;36:233–52 (73 ref.)

Safety of antihistamines in the treatment of allergic rhinitis in elderly patients. McCue JD. **Arch Fam Med** 1996 Sep; 5(9):464–8 (40 ref.)

PHARMACOKINETICS

Pulmonary pharmacology. Hornby PJ, et al. **Clin Obstet Gynecol** 1996 Mar;39(1):17–35 (25 ref.)

The pharmacokinetic properties of topical levocabastine. A review. Heykants J, et al. **Clin Pharmacokinet** 1995 Oct; 29(4):221–30 (39 ref.)

PHARMACOLOGY

Of oocytes and runny noses [editorial; comment] Rosen MR. **Circulation** 1996 Aug 15;94(4):607–9 (20 ref.) Comment on: Circulation 1996 Aug 15;94(4):817–23.

Pulmonary pharmacology. Hornby PJ, et al. **Clin Obstet Gynecol** 1996 Mar;39(1):17–35 (25 ref.)

Levocabastine. An update of its pharmacology, clinical efficacy and tolerability in the topical treatment of allergic rhinitis and conjunctivitis. Noble S, et al. **Drugs** 1995 Dec; 50(6):1032–49 (60 ref.)

Ebastine. a review of its pharmacological properties and clinical efficacy in the treatment of allergic disorders. Wiseman LR, et al. **Drugs** 1996 Feb;51(2):260–77 (90 ref.)

[Mutagenesis of the human histamine H1 receptor and design of new antihistamine agents] Differding E, et al. **J Pharm Belg** 1996 May-Jun;51(3):155–60 (15 ref.) (Eng. Abstr.) **(Fre)**

THERAPEUTIC USE

Levocabastine. An update of its pharmacology, clinical efficacy and tolerability in the topical treatment of allergic rhinitis and conjunctivitis. Noble S, et al. **Drugs** 1995 Dec; 50(6):1032–49 (60 ref.)

Ebastine. a review of its pharmacological properties and clinical efficacy in the treatment of allergic disorders. Wiseman LR, et al. **Drugs** 1996 Feb;51(2):260–77 (90 ref.)

Allergic rhinoconjunctivitis: current therapy. Hollingsworth HM. **Hosp Pract (Off Ed)** 1996 Jun 15;31(6):61–2, 65–7, 71–3 (12 ref.)

Antihistamines and the common cold. A review and critique of the literature. Luks D, et al. **J Gen Intern Med** 1996 Apr;11(4):240–4 (27 ref.)

[Anti-allergic agent therapy of asthma] Fujimura M. **Nippon Naika Gakkai Zasshi** 1996 Feb 10;85(2):216–21 (5 ref.) **(Jpn)**

[Non-sedative antihistaminics in the treatment of chronic urticaria] Negro JM, et al. **Allergol Immunopathol (Madr)** 1995 May-Jun;23(3):137–44 (45 ref.) (Eng. Abstr.) **(Spa)**

[Prophylaxis of migraine] Liaño H. **Rev Neurol** 1995;23 Suppl 2:S212–8 (21 ref.) **(Spa)**

TOXICITY

Enhancement of tumor growth by drugs with some common molecular actions. LaBella FS, et al. **Mol Carcinog** 1996 Jun;16(2):68–76 (91 ref.)

HISTAMINE H2 ANTAGONISTS

see related
ANTI-ULCER AGENTS

ADVERSE EFFECTS

Thrombotic thrombo-cytopenic purpura associated with histamine H2-receptor antagonist therapy. Kallal SM, et al. **West J Med** 1996 May;164(5):446–8 (25 ref.)

PHARMACOLOGY

Histamine, histamine H2-receptor antagonists, gastric acid secretion and ulcers: an overview. Pattichis K, et al. **Drug Metabol Drug Interact** 1995;12(1):1–36 (43 ref.)

Ebrotidine. Patel SS, et al. **Drugs** 1996 Jun;51(6):974–80; discussion 981 (41 ref.)

Non-steroidal anti-inflammatory drug-induced gastric damage in experimental animals: underlying pathological mechanisms. Trevethick MA, et al. **Gen Pharmacol** 1995 Nov;26(7):1455–9 (63 ref.)

[Ranitidine: consequences on secretory function and gastric mucosa] Vallot T, et al. **Rev Med Suisse Romande** 1995 Oct;115(10):773–80 (23 ref.) **(Fre)**

THERAPEUTIC USE

The role of proton pump inhibitors in the treatment of gastro-oesophageal reflux disease. Bardhan KD. **Aliment Pharmacol Ther** 1995;9 Suppl 1:15–25 (73 ref.)

Drugs for pH control in upper gastrointestinal bleeding. Brunner G, et al. **Aliment Pharmacol Ther** 1995;9 Suppl 1:47–50 (26 ref.)

The role and limitations of H2-receptor antagonists in the treatment of gastro-oesophageal reflux disease. Colin-Jones DG. **Aliment Pharmacol Ther** 1995;9 Suppl 1:9–14 (29 ref.)

The relationship between the control of pH and healing and symptom relief in gastro-oesophageal reflux disease. Hunt RH. **Aliment Pharmacol Ther** 1995;9 Suppl 1:3–7 (38 ref.)

A plasma cell variant of Castleman's disease treated successfully with cimetidine. Case report and review of the literature. Barbounis V, et al. **Anticancer Res** 1996 Jan-Feb;16(1):545–7 (21 ref.)

Drug therapy of peptic ulcer disease. Ching CK, et al. **Br J Hosp Med** 1995 Jul 12-Aug 15;54(2–3):101–6 (39 ref.)

The medical management of gastro-oesophageal reflux. **Drug Ther Bull** 1996 Jan;34(1):1–4 (38 ref.)

Ebrotidine. Patel SS, et al. **Drugs** 1996 Jun;51(6):974–80; discussion 981 (41 ref.)

H2-receptor antagonists an Helicobacter pylori eradication. Lamers CB. **Scand J Gastroenterol Suppl** 1995;212:126–7 (8 ref.)

Medical management of esophageal reflux. Hirschowitz BI. **Yale J Biol Med** 1994 May-Aug;67(3–4):223–31 (35 ref.)

[Medical treatment of stomach ulcer except in emergency] Bretagne JF. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S73–S80 (68 ref.) **(Fre)**

[Treatment of stomach ulcer] Hudziak H. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S136–S142 (51 ref.) **(Fre)**

[Therapeutic management of duodenal ulcer except in emergency: eradication of Helicobacter pylori] Lamouliatte H. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S58–S63 (63 ref.) **(Fre)**

[Clinical aspects of Kvamatel (famotidine) administration] Golochevskaia VS. **Klin Med (Mosk)** 1996;74(1):45–7 (10 ref.) **(Rus)**

HISTAMINE BINDING SITES see RECEPTORS, HISTAMINE

HISTAMINE LIBERATION see HISTAMINE RELEASE

HISTAMINE METHYLTRANSFERASE

PHYSIOLOGY

The role of HMT (histamine N-methyltransferase) in airways: a review. Okinaga S, et al. **Methods Find Exp Clin Pharmacol** 1995 Nov;17 Suppl C:16–20 (52 ref.)

HISTAMINE-PRODUCING CELL-STIMULATING FACTOR see GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR

HISTAMINE H1 RECEPTOR ANTAGONISTS see HISTAMINE H1 ANTAGONISTS

HISTAMINE H2 RECEPTOR ANTAGONISTS see

HISTAMINE H2 RECEPTOR ANTAGONISTS

HISTAMINE H2 ANTAGONISTS

HISTAMINE H1 RECEPTOR BLOCKADERS see **HISTAMINE H1 ANTAGONISTS**

HISTAMINE H2 RECEPTOR BLOCKADERS see **HISTAMINE H2 ANTAGONISTS**

HISTAMINE RECEPTORS see **RECEPTORS, HISTAMINE**

HISTAMINE H1 RECEPTORS see **RECEPTORS, HISTAMINE H1**

HISTAMINE H3 RECEPTORS see **RECEPTORS, HISTAMINE H3**

HISTAMINE RELEASE

Muscle relaxants and histamine release. Moss J. **Acta Anaesthesiol Scand Suppl** 1995;106:7–12 (30 ref.)

[Excess of histamine as a possible cause of cardiac arrhythmias] Marra L, et al. **Clin Ter** 1996 Mar;147(3):145–7 (10 ref.) (Eng. Abstr.) **(Ita)**

DRUG EFFECTS

Relationship of histamine-releasing factors and histamine-releasing inhibitory factors to chemokine group of cytokine. Kuna P, et al. **Allergy Asthma Proc** 1996 Jan–Feb;17(1):5–11 (38 ref.)

IMMUNOLOGY

[Histamine releasing factors and chemotactic factors in evaluation of mucosal inflammation in bronchial asthma] Kuna P, et al. **Pneumonol Alergol Pol** 1995;63(5–6):322–7 (29 ref.) **(Pol)**

PHYSIOLOGY

Basophil histamine release in allergic and non-allergic patient populations. Applications of a novel washed blood histamine release assay. Nielsen BW. **Dan Med Bull** 1995 Nov;42(5):455–72 (305 ref.)

HISTIDINE

DRUG EFFECTS

Protein kinases and phosphatases that act on histidine, lysine, or arginine residues in eukaryotic proteins: a possible regulator of the mitogen-activated protein kinase cascade. Matthews HR. **Pharmacol Ther** 1995;67(3):323–50 (154 ref.)

METABOLISM

HPr: a model protein. Anderson JW. **Biochem Cell Biol** 1995 May–Jun;73(5–6):219–22 (15 ref.)

HISTIOCYTES

PATHOLOGY

Tuberculosis-associated haemophagocytic syndrome: a report of two cases and a review of the literature. Undar L, et al. **Acta Haematol** 1996;96(2):73–8 (36 ref.)

Axillary involvement in pediatric Kikuchi's disease. Heldenberg D, et al. **Eur J Pediatr Surg** 1996 Feb;6(1):32–4 (12 ref.)

Calcium oxalate crystal deposition in epithelioid histiocytes of granulomatous lymphadenitis: analysis by light and electronmicroscopy. Symmans PJ, et al. **Histopathology** 1995 Nov;27(5):423–9 (11 ref.)

ULTRASTRUCTURE

Calcium oxalate crystal deposition in epithelioid histiocytes of granulomatous lymphadenitis: analysis by light and electronmicroscopy. Symmans PJ, et al. **Histopathology** 1995 Nov;27(5):423–9 (11 ref.)

Ribosome-lamella complexes in sinus histiocytes [letter] Eyden BP, et al. **Ultrastruct Pathol** 1995 Nov–Dec; 19(6):511–5 (65 ref.)

HISTIOCYTIC DISORDERS, MALIGNANT

PATHOLOGY

[Nodal histiocytic hyperplasia and proliferation] Diebold J, et al. **Ann Pathol** 1995;15(4):238–51 (82 ref.) **(Fre)**

HISTIOCYTIC LYMPHOMA see **LYMPHOMA, LARGE-CELL**

HISTIOCYTIC LYMPHOMA, DIFFUSE see **LYMPHOMA, LARGE-CELL, DIFFUSE**

HISTIOCYTOMA see **DERMATOFIBROMA**

HISTIOCYTOMA, FIBROUS

Malignant fibrous histiocytoma of the spermatic cord. Glazier DB, et al. **J Urol** 1996 Mar;155(3):955–7 (26 ref.)

[Histiocytoma of the liver] Arakawa Y, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):392–4 (13 ref.) **(Jpn)**

[Malignant fibrous histiocytoma of the gallbladder] Miyakawa R, et al. **Ryoikibetsu Shokogun Shirizu** 1996; (9):243–4 (18 ref.) **(Jpn)**

[Malignant fibrous histiocytoma of the liver] Tamaki H, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):295–8 (23 ref.) **(Jpn)**

COMPLICATIONS

[A case of primary intracranial malignant fibrous histiocytoma associated with peritumoral hemorrhage] Matsuzaki K, et al. **No Shinkei Geka** 1996 Jun;24(6):557–62 (22 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

[Malignant histiocytofibroma. Apropos of 3 cases of cervicofacial localization] Bonnin P, et al. **Ann Otolaryngol Chir Cervicofac** 1995;112(7):336–44 (29 ref.) (Eng. Abstr.) **(Fre)**

EPIDEMIOLOGY

Malignant fibrous histiocytoma of the larynx—a rare case in an adolescent. A case report. Sharma AK. **Acta Radiol** 1996 May;37(3 Pt 1):321–2 (5 ref.)

PATHOLOGY

Malignant fibrous histiocytoma of the head and neck. Case report. Zapater E, et al. **Bull Group Int Rech Sci Stomatol Odontol** 1995 Sep–Oct; 38(3–4):121–4 (17 ref.)

Benign fibrous histiocytoma of the larynx: presentation of a case and review of the literature. Van Laer C, et al. **J Laryngol Otol** 1996 May;110(5):474–7 (28 ref.)

Fibrohistiocytic tumors. Fisher C. **Monogr Pathol** 1996; 38:162–80 (82 ref.)

Malignant fibrous histiocytoma of the right ventricle of the heart. Teramoto N, et al. **Pathol Int** 1995 Apr;45(4):315–9 (17 ref.)

Malignant fibrous histiocytoma: morphologic pattern or pathologic entity? Hollowood K, et al. **Semin Diagn Pathol** 1995 Aug;12(3):210–20 (58 ref.)

HISTIOCYTOSIS

DIAGNOSIS

Histiocytoses. Stéphan JL. **Eur J Pediatr** 1995 Aug; 154(8):600–9 (87 ref.)

DRUG THERAPY

Complete remission of multicentric reticulohistiocytosis with combination therapy of steroid, cyclophosphamide, and low-dose pulse methotrexate. Case report, review of the literature, and proposal for treatment. Liang GC, et al. **Arthritis Rheum** 1996 Jan;39(1):171–4 (15 ref.)

PATHOLOGY

[Nodal histiocytic hyperplasia and proliferation] Diebold J, et al. **Ann Pathol** 1995;15(4):238–51 (82 ref.) **(Fre)**

HISTIOCYTOSIS, LANGERHANS-CELL

Langerhans' cell histiocytosis. Velez-Yanguas MC, et al. **Orthop Clin North Am** 1996 Jul;27(3):615–23 (54 ref.)

[Langerhans cell histiocytosis] Thomas C, et al. **Arch Pediatr** 1996 Jan;3(1):63–9 (32 ref.) (Eng. Abstr.) **(Fre)**

[Histiocytosis X] Grzybowska L, et al. **Ann Univ Mariae Curie Sklodowska [Med]** 1993;48:159–66 (19 ref.) (Eng. Abstr.) **(Pol)**

COMPLICATIONS

Langerhans' cell granulomatosis and Hodgkin's lymphoma. Report of a case. Michetti G, et al. **Minerva Med** 1996 May;87(5):243–7 (26 ref.)

DIAGNOSIS

Magnetic resonance imaging in the evaluation of Langerhans' cell histiocytosis of the temporal bone: case report. Angeli SI, et al. **Otolaryngol Head Neck Surg** 1996 Jan; 114(1):120–4 (25 ref.)

[Langerhans-cell histiocytosis. Recent data on diagnosis and physiopathology] Emile JF, et al. **Ann Pathol** 1995; 15(4):252–9 (41 ref.) **(Fre)**

[Pulmonary eosinophilic granuloma (histiocytosis X)] Siemińska A. **Pneumonol Alergol Pol** 1995;63(7–8):453–9 (38 ref.) **(Pol)**

EPIDEMIOLOGY

Langerhans cell histiocytosis in children under 2 years of age. Rivera-Luna R, et al. **Med Pediatr Oncol** 1996 May; 26(5):334–43 (50 ref.)

IMMUNOLOGY

[Langerhans cell histiocytosis—immunologic and clinical aspects] Meleniewska-Maciszewska A. **Pol Arch Med Wewn** 1995 Feb;93(2):155–8 (20 ref.) **(Pol)**

PATHOLOGY

Langerhans cell histiocytosis of the thyroid: a series of seven cases and a review of the literature. Thompson LD, et al. **Mod Pathol** 1996 Feb;9(2):145–9 (37 ref.)

Langerhans' cell histiocytosis: case reports and literature review. Henry RJ, et al. **Pediatr Dent** 1996 Jan–Feb; 18(1):11–6 (45 ref.)

[Histiocytosis syndrome] Tsunematsu Y, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):379–87 (17 ref.) **(Jpn)**

PHYSIOPATHOLOGY

[Langerhans-cell histiocytosis. Recent data on diagnosis and physiopathology] Emile JF, et al. **Ann Pathol** 1995; 15(4):252–9 (41 ref.) **(Fre)**

HISTIOCYTOSIS, LIPID see **NIEMANN-PICK DISEASE**

HISTIOCYTOSIS, NON-LANGERHANS-CELL

[Hemophagocytic syndromes] Fléchaire A, et al. **Rev Med Interne** 1996;17(2):157–62 (55 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

Subcutaneous T-cell lymphoma with associated hemophagocytic syndrome and terminal leukemic transformation. Romero LS, et al. **J Am Acad Dermatol** 1996 May;34(5 Pt 2):904–10 (22 ref.)

ETIOLOGY

Hemophagocytic syndrome in Epstein-Barr virus-associated T-lymphoproliferative disorders: disease spectrum, pathogenesis, and management. Su IJ, et al. **Leuk Lymphoma** 1995 Nov;19(5–6):401–6 (407 ref.)

[Giant cell hepatitis with virus associated hemophagocytic syndrome] Onuki M, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):520–2 (18 ref.) **(Jpn)**

[Generalized angitis and recurrent infection associated hemophagocytic syndrome in a girl with XXX syndrome] Wada Y, et al. **Ryumachi** 1995 Jun;35(3):589–94 (11 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Leukophagocytosis in human parvovirus B19-induced transient bicytopenia in a healthy child. Wakamoto H, et al. **Acta Paediatr Jpn** 1996 Jun;38(3):278–81 (19 ref.)

PATHOLOGY

Indeterminate cell histiocytosis—a clinicopathological entity with features of both X- and non-X histiocytosis. Sidoroff A, et al. **Br J Dermatol** 1996 Mar;134(3):525–32 (34 ref.)

Xanthoma disseminatum with massive intracranial involvement. Hammond RR, et al. **Clin Neuropathol** 1995 Nov–Dec;14(6):314–21 (32 ref.)

[Histiocytosis syndrome] Tsunematsu Y, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):379–87 (17 ref.) **(Jpn)**

RADIOGRAPHY

Multicentric reticulohistiocytosis. A report of 3 cases and review of literature. Uhl M, et al. **Bildgebung** 1996 Jun; 63(2):126–9 (13 ref.)

HISTIOCYTOSIS, SEA-BLUE see **SEA-BLUE HISTIOCYTE SYNDROME**

HISTIOCYTOSIS, SINUS

DRUG THERAPY

Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): response to methotrexate and mercaptopurine. Horneff G, et al. **Med Pediatr Oncol** 1996 Sep;27(3):187–92 (24 ref.)

PATHOLOGY

Sinus histiocytosis confined to the skin. Case report and review of the literature. Pérez A, et al. **Am J Dermatopathol** 1995 Aug;17(4):384–8 (18 ref.)

HISTIOCYTOSIS X see **HISTIOCYTOSIS, LANGERHANS-CELL**

HISTOCOMPATIBILITY

Bone marrow transplantation for chronic myeloid leukemia with volunteer unrelated donors using ex vivo or in vivo T-cell depletion: major prognostic impact of HLA class I identity between donor and recipient. Spencer A, et al. **Blood** 1995 Nov 1;86(9):3590–7 (40 ref.)

HISTOCOMPATIBILITY ANTIGEN DNA PROBES see DNA PROBES, HLA

HISTOCOMPATIBILITY ANTIGENS

GENETICS

Quantifying the degree of convergence in primate Mhc-DRB genes. O hUigin C. **Immunol Rev** 1995 Feb;143:123-40 (24 ref.)

IMMUNOLOGY

T-cell recognition of antigen. A process controlled by transient intermolecular interactions. Boniface JJ, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:62-9 (34 ref.)

Mechanisms of oral tolerance by MHC peptides. Sayegh MH, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:338-45 (30 ref.)

PHYSIOLOGY

Coreceptors and adapter proteins in T-cell signaling. Ravichandran KS, et al. **Ann N Y Acad Sci** 1995 Sep 7; 766:117-33 (91 ref.)

HISTOCOMPATIBILITY ANTIGENS CLASS I

Bone marrow transplantation for chronic myeloid leukemia with volunteer unrelated donors using ex vivo or in vivo T-cell depletion: major prognostic impact of HLA class I identity between donor and recipient. Spencer A, et al. **Blood** 1995 Nov 1;86(9):3590-7 (40 ref.)

ANALYSIS

Analysis of MHC-specific peptide motifs. Applications in immunotherapy. Loftus DJ, et al. **Adv Exp Med Biol** 1995; 383:201-10 (71 ref.)

Interpreting MHC class I expression and class I/class II reciprocity in the CNS: reconciling divergent findings. Lampson LA. **Microsc Res Tech** 1995 Nov 1;32(4):267-85 (101 ref.)

BIOSYNTHESIS

HLA class I antigens in human tumors. Garrido F, et al. **Adv Cancer Res** 1995;67:155-95 (287 ref.)

Conformational changes induced in the MHC class I molecule by peptide and beta 2-microglobulin. Solheim JC, et al. **Immunol Res** 1995;14(3):200-17 (57 ref.)

Synthesis and assembly of MHC-peptide complexes. Benham A, et al. **Immunol Today** 1995 Jul;16(7):359-62 (20 ref.)

CHEMISTRY

Immunosuppressive peptides corresponding to MHC class I sequences. Clayberger C, et al. **Curr Opin Immunol** 1995 Oct;7(5):644-8 (34 ref.)

Analysis of the structure of naturally processed peptides bound by class I and class II major histocompatibility complex molecules. Appella E, et al. **EXS** 1995;73:105-19 (190 ref.)

Conformational changes induced in the MHC class I molecule by peptide and beta 2-microglobulin. Solheim JC, et al. **Immunol Res** 1995;14(3):200-17 (57 ref.)

Structural and functional characteristics of the class IB molecule, Qa-1. Soloski MJ, et al. **Immunol Rev** 1995 Oct; 147:67-89 (72 ref.)

Tissue-specific, peptide-binding transplantation antigens: lessons from the Qa-2 system. Stroynowski I. **Immunol Rev** 1995 Oct;147:91-108 (85 ref.)

HLA-derived peptides as novel immunosuppressives. Krensky AM. **Pediatr Res** 1995 Sep;38(3):275-9 (25 ref.)

GENETICS

HLA-G transgenic mice: a model for studying expression and function at the maternal/fetal interface. Schmidt CM, et al. **Immunol Rev** 1995 Oct;147:53-65 (32 ref.)

Haemochromatosis: strike while the iron is hot [news] Cox T. **Nat Genet** 1996 Aug;13(4):386-8 (18 ref.)

Missing self recognition by natural killer cells in MHC class I transgenic mice. A 'receptor calibration' model for how effector cells adapt to self. Sentman CL, et al. **Semin Immunol** 1995 Apr;7(2):109-19 (45 ref.)

[Regulation of the expression of HLA class I genes in human trophoblasts] Le Boutciller P. **Pathol Biol (Paris)** 1995 Sep; 43(7):628-35 (53 ref.) (Eng. Abstr.) **(Fre)**

[Abnormal T-cell differentiation and development of T-cell lymphomas in TL-transgenic mice] Obata Y, et al. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2054-61 (34 ref.) **(Jpn)**

IMMUNOLOGY

Antigen presentation by class I major histocompatibility complex molecules: a context for thinking about HLA-G. Parham P. **Am J Reprod Immunol** 1995 Jul;34(1):10-9 (48 ref.)

The role of natural killer cells in transplantation. Lanier LL. **Curr Opin Immunol** 1995 Oct;7(5):626-31 (65 ref.)

Presentation of antigen and MHC-restricted unresponsiveness. Říhová B. **Folia Biol (Praha)** 1995; 41(3-4):140-62 (28 ref.)

Principles of MHC class I-mediated antigen presentation and T cell selection. Ljunggren HG, et al. **Histol Histopathol** 1996 Jan;11(1):267-74 (39 ref.)

How selective is the transporter associated with antigen processing? Androlewicz MJ, et al. **Immunity** 1996 Jul; 5(1):1-5 (41 ref.)

Selective mechanisms utilized by persistent and oncogenic viruses to interfere with antigen processing and presentation. Ehrlich R. **Immunol Res** 1995;14(2):77-97 (165 ref.)

Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Ferrone S, et al. **Immunol Today** 1995 Oct;16(10):487-94 (57 ref.)

Regulation of NK susceptibility by target cell class I MHC molecules. Saxena RK, et al. **Indian J Biochem Biophys** 1995 Aug;32(4):179-85 (91 ref.)

Class I MHC presentation of exogenous antigens. Harding CV. **J Clin Immunol** 1996 Mar;16(2):90-6 (50 ref.)

Delivery of protein antigen to the major histocompatibility complex class I-restricted antigen presentation pathway. Zhou F, et al. **J Drug Target** 1995;3(2):91-109 (177 ref.)

Population biology of antigen presentation by MHC class I molecules [see comments] Parham P, et al. **Science** 1996 Apr 5;272(5258):67-74 (71 ref.) Comment in: Science 1996 Aug 9;273(5276):723-5.

[HLA-G: a non classical antigen of major histocompatibility complex (editorial)] Carosella E, et al. **C R Acad Sci III** 1995 Aug;318(8):827-30 (19 ref.) **(Fre)**

[Interaction between natural killer (NK) cells and the major histocompatibility system] Bishara A, et al. **Harefuah** 1996 Mar 1;130(5):322-6 (45 ref.) **(Heb)**

METABOLISM

Dendritic cells as stimulator cells of MHC class I-restricted immune responses. Elbe A, et al. **Adv Exp Med Biol** 1995; 378:341-5 (35 ref.)

Generation, translocation, and presentation of MHC class I-restricted peptides. Heemels MT, et al. **Annu Rev Biochem** 1995;64:463-91 (192 ref.)

Antigen processing by the class I pathway. Benham AM, et al. **Biochem Soc Trans** 1995 Aug;23(3):664-9 (45 ref.)

Presentation of N-formylated peptides by H2-M3. Lindahl KF, et al. **Biochem Soc Trans** 1995 Aug;23(3):669-74 (34 ref.)

Peptide binding to MHC class I molecules: implications for antigenic peptide prediction. Parker KC, et al. **Immunol Res** 1995;14(1):34-57 (129 ref.)

Proteasome and class I antigen processing and presentation. Belich MP, et al. **Mol Biol Rep** 1995;21(1):53-6 (39 ref.)

Receptors for HLA class I molecules in human NK cells. Bottino C, et al. **Semin Immunol** 1995 Apr;7(2):67-73 (23 ref.)

NK cell recognition of major histocompatibility complex class I molecules. Lanier LL, et al. **Semin Immunol** 1995 Apr;7(2):75-82 (67 ref.)

Decrypting class I MHC-bound peptides with peptide libraries. Udaka K. **Trends Biochem Sci** 1996 Jan;21(1):7-11 (23 ref.)

PHYSIOLOGY

Structural and functional characteristics of the class IB molecule, Qa-1. Soloski MJ, et al. **Immunol Rev** 1995 Oct; 147:67-89 (72 ref.)

THERAPEUTIC USE

Human leukocyte antigen-derived peptides as novel immunosuppressives. Krensky AM, et al. **Proc Assoc Am Physicians** 1995 Apr;107(1):81-5 (26 ref.)

HISTOCOMPATIBILITY ANTIGENS CLASS II

Molecular recognition of antigen involves lattice formation between CD4, MHC class II and TCR molecules. Sakihama T, et al. **Immunol Today** 1995 Dec;16(12):581-7 (43 ref.)

ANALYSIS

Analysis of MHC-specific peptide motifs. Applications in immunotherapy. Loftus DJ, et al. **Adv Exp Med Biol** 1995; 383:201-10 (71 ref.)

Interpreting MHC class I expression and class I/class II reciprocity in the CNS: reconciling divergent findings. Lampson LA. **Microsc Res Tech** 1995 Nov 1;32(4):267-85 (101 ref.)

BIOSYNTHESIS

Synthesis and assembly of MHC-peptide complexes. Benham A, et al. **Immunol Today** 1995 Jul;16(7):359-62 (20 ref.)

CHEMISTRY

Invariant chain structure and MHC class II function. Cresswell P. **Cell** 1996 Feb 23;84(4):505-7 (17 ref.)

Superantigen engineering. Abrahmsén L. **Curr Opin Struct Biol** 1995 Aug;5(4):464-70 (45 ref.)

Analysis of the structure of naturally processed peptides bound by class I and class II major histocompatibility complex molecules. Appella E, et al. **EXS** 1995;73:105-19 (190 ref.)

GENETICS

Retrovirus-mediated transfer of MHC class II cDNA into swine bone marrow cells. LeGuern C, et al. **J Mol Med** 1995 Jun;73(6):269-78 (86 ref.)

[Use of DNA analysis for determining HLA class II antigens] Brojer E. **Acta Haematol Pol** 1995;26(3):247-56 (30 ref.) (Eng. Abstr.) **(Pol)**

IMMUNOLOGY

Lonely MHC molecules seeking immunogenic peptides for meaningful relationships. Mellman I, et al. **Curr Opin Cell Biol** 1995 Aug;7(4):564-72 (72 ref.)

Presentation of antigen and MHC-restricted unresponsiveness. Říhová B. **Folia Biol (Praha)** 1995; 41(3-4):140-62 (28 ref.)

How selective is the transporter associated with antigen processing? Androlewicz MJ, et al. **Immunity** 1996 Jul; 5(1):1-5 (41 ref.)

Immunopathogenesis of juvenile rheumatoid arthritis: role of T cells and MHC. Sakkas LI, et al. **Immunol Res** 1995; 14(3):218-36 (179 ref.)

MHC class I-like, class II-like and CD1 molecules: distinct roles in immunity. Beckman EM, et al. **Immunol Today** 1995 Jul;16(7):349-52 (38 ref.)

[Characteristics of HLA II antigen expression in the rectal mucosa of children suffering form ulcerative colitis and Crohn disease] Hacsek G, et al. **Orv Hetil** 1995 Oct 15; 136(42):2279-82 (25 ref.) (Eng. Abstr.) **(Hun)**

METABOLISM

How MHC class II molecules acquire peptide cargo: biosynthesis and trafficking through the endocytic pathway. Wolf PR, et al. **Ann Rev Cell Dev Biol** 1995; 11:267-306 (169 ref.)

Endogenous pathway of class II presentation. Aichinger G, et al. **Biochem Soc Trans** 1995 Aug;23(3):657-60 (48 ref.)

The structural basis of CD4-MHC class II interactions: coreceptor contributions to T cell receptor antigen recognition and oligomerization-dependent signal transduction. König R, et al. **Curr Top Microbiol Immunol** 1996;205:19-46 (93 ref.)

Another twist to MHC-peptide recognition [comment] Wilson IA. **Science** 1996 May 17;272(5264):973-4 (20 ref.) Comment on: Nature 1996 May 17;272(5264):1001-4.

HISTOCOMPATIBILITY ANTIGENS, MINOR see MINOR HISTOCOMPATIBILITY ANTIGENS

HISTOCOMPATIBILITY COMPLEX see MAJOR HISTOCOMPATIBILITY COMPLEX

HISTOCOMPATIBILITY TESTING

Should patients with recent onset rheumatoid arthritis be offered genetic screening? Symmons DP, et al. **Ann Rheum Dis** 1996 Jul;55(7):407-10 (25 ref.)

Marrow transplantation from unrelated volunteer donors. Anasetti C, et al. **Cancer Treat Res** 1995;76:137-68 (45 ref.)

Effect of crossmatching on outcome in organ transplantation. Wang-Rodriguez J, et al. **Crit Rev Clin Lab Sci** 1995; 32(4):345-76 (194 ref.)

The role of histoincompatibility in cardiac allograft vasculopathy. Costanzo MR. **J Heart Lung Transplant** 1995 Nov-Dec;14(6 Pt 2):S180-4 (19 ref.)

HLA-DR matching in corneal transplantation. Systematic review of published evidence. Corneal Transplant Follow-up Study Collaborators. Gore SM, et al. **Transplantation** 1995 Nov 15;60(9):1033-9 (24 ref.)

[DNA typing of HLA] Kashiwase K, et al. **Rinsho Byori** 1995 Jul;Suppl 99:92-101 (17 ref.) **(Jpn)**

[Serological typing of HLA] Tanaka H, et al. **Rinsho Byori** 1995 Jul;Suppl 99:85-91 (4 ref.) **(Jpn)**

[Tests for donors of blood and bone marrow] Taniwaki K, et al. **Rinsho Byori** 1995 Jul;Suppl 99:102-10 (10 ref.) **(Jpn)**

[Problems with donor-recipient matching in kidney and bone marrow transplantation] Nowakowska B. **Postepy Hig Med Dosw** 1995;49(1):107-15 (11 ref.) (Eng. Abstr.) **(Pol)**

METHODS

Identification and analysis of Rh genes: application of PCR and RFLP typing tests. Hyland CA, et al. **Transfus Med Rev** 1995 Oct;9(4):289-301 (58 ref.)

New molecular approaches to tissue typing. Wade JA. **Transplant Proc** 1996 Aug;28(4):2022-3 (9 ref.)

STANDARDS

International Cell Exchange, 1994. Lau M, et al. **Clin Transpl** 1994;:467-88 (46 ref.)

HISTOCYTOCHEMISTRY

Histochemistry of nitric oxide synthase in the nervous system. Blottner D, et al. **Histochem J** 1995 Oct;27(10):785-811 (271 ref.)

Carbohydrate histochemistry of vertebrate taste organs. Witt M. **Prog Histochem Cytochem** 1996;30(4):1-168 (470 ref.)

[Advances in the technology applied to pathology in China] Wang B, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1995

HISTOCYTOCHEMISTRY

Aug;24(4):258–60 (21 ref.) **(Chi)**
[Progress in molecular histochemistry] Kiyama H. **Kaibogaku Zasshi** 1995 Aug;70(4):294–7 (8 ref.) **(Jpn)**
[Histochemistry of the organs—application of histochemistry to anatomy] Nagata T. **Kaibogaku Zasshi** 1995 Oct; 70(5):448–71 (175 ref.) (Eng. Abstr.) **(Jpn)**

METHODS

Selected histochemical and immunocytochemical markers of biological activity of brain blood vessels. Kałuża J. **Folia Neuropathol** 1995;33(4):195–200 (32 ref.)
Histochemical methods for detecting nitric oxide synthase. Beesley JE. **Histochem J** 1995 Oct;27(10):757–69 (69 ref.)
Studies on the localization and expression of nitric oxide synthase using histochemical techniques. Norris PJ, et al. **Histochem J** 1995 Oct;27(10):745–56 (28 ref.)
Recent advances in molecular histochemical techniques: in situ hybridization and southwestern histochemistry. Koji T, et al. **J Electron Microsc (Tokyo)** 1996 Apr;45(2):119–27 (71 ref.)
[Study of the reactivity of giant cell tumors of bones to different lectins] Illés T, et al. **Arch Anat Cytol Pathol** 1995; 43(5–6):331–7 (23 ref.) (Eng. Abstr.) **(Fre)**

HISTOCYTOLOGICAL PREPARATION TECHNIQUES

If you assume, you can make an ass out of u and me': a decade of the disector for stereological counting of particles in 3D space. Mayhew TM, et al. **J Anat** 1996 Feb;188 (Pt 1):1–15 (131 ref.)
[Recent improvement in histopathological technique] Kawatsu K. **Nippon Rai Gakkai Zasshi** 1995 Jul; 64(2):124–31 (43 ref.) **(Jpn)**

HISTOLOGICAL TECHNIQUES

Image analysis of tissue sections. Ong SH, et al. **Comput Biol Med** 1996 May;26(3):269–79 (68 ref.)

INSTRUMENTATION

Tissutal imaging by nuclear magnetic resonance. Sbarbati A, et al. **Histol Histopathol** 1996 Jan;11(1):229–35 (81 ref.)

HISTOMONIASIS see **PROTOZOAN INFECTIONS**

HISTONE DEACETYLASE

METABOLISM

Histone deacetylase: a regulator of transcription [comment] Wolffe AP. **Science** 1996 Apr 19;272(5260):371–2 (16 ref.) Comment on: Science 1996 Apr 19;272(5260):408–11.

HISTONE H1 KINASE, M-PHASE-SPECIFIC see **MATURATION-PROMOTING FACTOR**

HISTONE KINASE P34(CDC2) see **PROTEIN P34CDC2**

HISTONES

CHEMISTRY

Histones and chromatin structure in hyperthermophilic Archaea. Grayling RA, et al. **FEMS Microbiol Rev** 1996 May;18(2–3):203–13 (29 ref.)
The histone fold: evolutionary questions. Ramakrishnan V. **Proc Natl Acad Sci U S A** 1995 Dec 5;92(25):11328–30 (30 ref.)

GENETICS

Control of cell cycle regulated histone genes during proliferation and differentiation. Stein JL, et al. **Int J Obes Relat Metab Disord** 1996 Mar;20 Suppl 3:S84–90 (67 ref.)
Selective distribution of histone H1 variants and high mobility group proteins in chromosomes. Grosbach U. **Semin Cell Biol** 1995 Aug;6(4):237–46 (62 ref.)

METABOLISM

Targeting chromatin disruption: Transcription regulators that acetylate histones. Wolffe AP, et al. **Cell** 1996 Mar 22; 84(6):817–9 (15 ref.)
Histone deacetylase: a regulator of transcription [comment] Wolffe AP. **Science** 1996 Apr 19;272(5260):371–2 (16 ref.) Comment on: Science 1996 Apr 19;272(5260):408–11.
Histone phosphorylation during sea urchin development. Green GR, et al. **Semin Cell Biol** 1995 Aug;6(4):219–27 (43 ref.)
Histone acetylation in chromatin and chromosomes. Turner BM, et al. **Semin Cell Biol** 1995 Aug;6(4):229–36 (60 ref.)

PHYSIOLOGY

Histone H4, the cell cycle and a question of integrity. Turner BM. **Bioessays** 1995 Dec;17(12):1013–5 (18 ref.)
Centromeric chromatin. Histone deviants. Wolffe AP. **Curr Biol** 1995 May 1;5(5):452–4 (14 ref.)
The regulation of euchromatin and heterochromatin by histones in yeast. Grunstein M, et al. **J Cell Sci Suppl** 1995; 19:29–36 (65 ref.)

HISTOPLASMA

GENETICS

Molecular genetic technology transfer to pathogenic fungi. Goldman WE. **Arch Med Res** 1995 Winter;26(4):437–40 (14 ref.)

PHYSIOLOGY

Unraveling the secrets of Histoplasma capsulatum. A model to study morphogenic adaptation during parasite host/host interaction. Maresca B. **Verh K Acad Geneeskd Belg** 1995; 57(2):133–56 (49 ref.)

HISTOPLASMOSIS

Opportunistic fungal infections in patients with HIV disease: combating cryptococcosis and histoplasmosis. Kirchner JT. **Postgrad Med** 1996 Jun;99(6):209–16 (34 ref.)
Pulmonary histoplasmosis. Gurney JW, et al. **Radiology** 1996 May;199(2):297–306 (97 ref.)

COMPLICATIONS

Mucocutaneous histoplasmosis in AIDS. Souza Filho FJ, et al. **Br J Dermatol** 1995 Sep;133(3):472–4 (26 ref.)

DIAGNOSIS

Epididymal histoplasmosis diagnosed by isolation of Histoplasma capsulatum from semen. Randhawa HS, et al. **Mycopathologia** 1995 Sep;131(3):173–7 (20 ref.)
Case report and review of disseminated histoplasmosis in South-East Asia: clinical and epidemiological implications. Wang TL, et al. **Trop Med Int Health** 1996 Feb;1(1):35–42 (32 ref.)

EPIDEMIOLOGY

Disseminated histoplasmosis in persons infected with human immunodeficiency virus. Hajjeh RA. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S108–10 (27 ref.)
Intestinal histoplasmosis in AIDS patients: report of three cases observed in France and review of the literature. Trylesinski A, et al. **Eur J Gastroenterol Hepatol** 1995 Jul; 7(7):679–83 (23 ref.)
Case report and review of disseminated histoplasmosis in South-East Asia: clinical and epidemiological implications. Wang TL, et al. **Trop Med Int Health** 1996 Feb;1(1):35–42 (32 ref.)

ETIOLOGY

Histoplasmosis and blastomycosis. Bradsher RW. **Clin Infect Dis** 1996 May;22 Suppl 2:S102–11 (97 ref.)

MICROBIOLOGY

[Disseminated Histoplasma capsulatum histoplasmosis in African AIDS patients (3 cases)] Imbert P, et al. **Med Trop (Mars)** 1995;55(2):151–3 (12 ref.) (Eng. Abstr.) **(Fre)**

HISTORICAL COHORT STUDIES see **COHORT STUDIES**

HIV

see related
RECEPTORS, HIV
REVERSE TRANSCRIPTASE INHIBITORS

Network between main protagonists and events leading to AIDS. Larralde C, et al. **Arch Med Res** 1996 Summer; 27(2):107–13 (87 ref.)
The mythology of modern medicine—IV. HIV: heuristically important virus. AIDS: advances induced deficiency syndromes. Kothari MV, et al. **J Postgrad Med** 1994 Jan–Mar;40(1):42–5 (31 ref.)
[RNA ligands for HIV proteins] Iwai S. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1430–7 (64 ref.) **(Jpn)**

DRUG EFFECTS

Saquinavir: an HIV proteinase inhibitor. Bragman K. **Adv Exp Med Biol** 1996;394:305–17 (25 ref.)
Promising anti-HIV compounds in preclinical or early clinical development. Litterst C. **Adv Exp Med Biol** 1996; 394:397–404 (16 ref.)
Clinical significance of drug resistance in human immunodeficiency virus. Richman DD. **Clin Infect Dis** 1995 Oct;21 Suppl 2:S166–9 (26 ref.)
Therapeutic approaches to HIV infection based on virus structure and the host pathogen interaction. Pauza CD, et al. **Curr Top Microbiol Immunol** 1995;202:117–32 (94 ref.)
Knocking out human immunodeficiency virus through non-nucleoside reverse transcriptase inhibitors used as single agents or in combinations: a paradigm for the cure of AIDS? De Clercq E, et al. **Farmaco** 1995 Nov; 50(11):735–47 (48 ref.)
Therapeutic interventions in primary HIV infection. Kinloch-de Loës S, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995;10 Suppl 1:S69–76 (44 ref.)

GENETICS

Phylogeny and natural history of the primate lentiviruses, SIV and HIV. Hirsch VM, et al. **Curr Opin Genet Dev** 1995 Dec;5(6):798–806 (28 ref.)
Influence of redox status of lymphocytes and monocytes on HIV transcription and replication. Gougerot-Pocidalo MA, et al. **Immunobiology** 1995 Jul;193(2–4):204–9 (27 ref.)
HIV as the cause of AIDS. Barré-Sinoussi F. **Lancet** 1996 Jul 6;348(9019):31–5 (50 ref.)
[Gene transfer using recombinant HIV vectors] Miyake K, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec; 40(17):2519–24 (15 ref.) **(Jpn)**

IMMUNOLOGY

The immune response to HIV: potential for immunotherapy? Dalgleish AG. **Immunol Today** 1995 Jul;16(7):356–8 (19 ref.)
Pulmonary immune response to Mycobacterium tuberculosis and human immunodeficiency virus. Rich EA. **Infect Agents Dis** 1996 Mar;5(2):108–18 (61 ref.)

ISOLATION & PURIFICATION

HIV viral load quantification, HIV resistance, and antiretroviral therapy. Katzenstein DA, et al. **AIDS Clin Rev** 1995–96;:277–303 (107 ref.)

METABOLISM

HIV and CD26 [comment] Dalgleish A. **Nat Med** 1995 Sep; 1(9):881–2 (20 ref.) Comment on: Nat Med 1995 Sep;1(9):919–26.

PATHOGENICITY

Role of macrophages in the pathogenesis of human immunodeficiency virus (HIV) infection. Crowe SM. **Aust N Z J Med** 1995 Dec;25(6):777–83 (54 ref.)
Are HIV-specific CTL responses salutary or pathogenic? Zinkernagel RM. **Curr Opin Immunol** 1995 Aug;7(4):462–70 (92 ref.)

PHYSIOLOGY

Clonal expansion of T cells and HIV genotypes in microdissected splenic white pulps indicates viral replication in situ and infiltration of HIV-specific cytotoxic T lymphocytes. Cheynier R, et al. **Adv Exp Med Biol** 1995; 374:173–82 (47 ref.)
Regulation of macrophage activation and HIV replication. Montaner LJ, et al. **Adv Exp Med Biol** 1995;374:47–56 (69 ref.)
Immunosuppression by a noncytolytic virus via T cell mediated immunopathology. Implication for AIDS. Zinkernagel RM. **Adv Exp Med Biol** 1995;374:165–71 (78 ref.)
Viral dynamics of HIV: implications for drug development and therapeutic strategies. Havlir DV, et al. **Ann Intern Med** 1996 Jun 1;124(11):984–94 (112 ref.)
HIV interactions with cells of the nervous system. Dubois-Dalcq M, et al. **Curr Opin Neurobiol** 1995 Oct; 5(5):647–55 (65 ref.)
Viral phenotype and genotype as markers in clinical trials. Katzenstein DA. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995;10 Suppl 2:S25–34 (89 ref.)
AIDS pathogenesis: from models to viral dynamics in patients. Nowak MA. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995;10 Suppl 1:S1–5 (14 ref.)
HIV pathogenesis and treatment strategies. Vella S. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995;10 Suppl 1:S20–3 (22 ref.)
[In the name of Commission VII (Sexually transmissible diseases and AIDS). Heterosexual transmission of HIV in France] Montagnier L. **Bull Acad Natl Med** 1995 Jun; 179(6):1209–24 (22 ref.) **(Fre)**

RADIATION EFFECTS

Medical UV exposures and HIV activation. Zmudzka BZ, et al. **Photochem Photobiol** 1996 Aug;64(2):246–53 (62 ref.)

HIV ANTIBODIES

see related
AIDS SERODIAGNOSIS

Clonal expansion of T cells and HIV genotypes in microdissected splenic white pulps indicates viral replication in situ and infiltration of HIV-specific cytotoxic T lymphocytes. Cheynier R, et al. **Adv Exp Med Biol** 1995; 374:173–82 (47 ref.)

BIOSYNTHESIS

CD4+ and CD8+ T lymphocyte activation in HIV infection. Implications for immune pathogenesis and therapy. Laurence J. **Adv Exp Med Biol** 1995;374:1–15 (74 ref.)
Retroviral vectors for HIV immunotherapy. Warner JF, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:105–16 (36 ref.)

BLOOD

Consensus statement regarding the HIV "window period".

Can Commun Dis Rep 1995 Dec 30;21(24):213–5 (4 ref.) **(Eng, Fre)**

Routine voluntary antepartum HIV antibody counseling and testing: a sound public health prevention strategy. Lindsay MK. **Clin Obstet Gynecol** 1996 Jun;39(2):305–15 (59 ref.)

IMMUNOLOGY

Human antibody variable region gene usage in HIV-1 infection. Wisnewski A, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Jan 1;11(1):31–8 (57 ref.)

Toward an understanding of the correlates of protective immunity to HIV infection [see comments] Haynes BF, et al. **Science** 1996 Jan 19;271(5247):324–8 (73 ref.) Comment in: Science 1996 Feb 23;371(5252):1043. Comment in: Science 1996 May 31;272(5266):1362. Comment in: Science 1996 Jul 26;273(5274):415–6.

[Salivary HIV antibodies. Review of current data and future prospectives] Polimeni A, et al. **Minerva Stomatol** 1995 Dec;44(12):583–90 (20 ref.) (Eng. Abstr.) **(Ita)**

HIV ANTIBODY POSITIVITY see **HIV SEROPOSITIVITY**

HIV ANTIGENS

PHYSIOLOGY

HIV-1 virology. Simply Marvelous nuclear transport. Goldfarb DS. **Curr Biol** 1995 Jun 1;5(6):570–3 (19 ref.)

HIV-ASSOCIATED ANTIBODIES see **HIV ANTIBODIES**

HIV-ASSOCIATED ANTIGENS see **HIV ANTIGENS**

HIV-ASSOCIATED ENTEROPATHY see **HIV ENTEROPATHY**

HIV-ASSOCIATED NEPHROPATHY see **AIDS-ASSOCIATED NEPHROPATHY**

HIV DEMENTIA see **AIDS DEMENTIA COMPLEX**

HIV ENCEPHALOPATHY see **AIDS DEMENTIA COMPLEX**

HIV ENHANCER

see related
NF-KAPPA B

HIV ENTEROPATHY

DIAGNOSIS

[HIV infection and the lower gastrointestinal tract—characteristics of endoscopic diagnosis] Mauss S, et al. **Bildgebung** 1995 Dec;62(4):252–8 (46 ref.) (Eng. Abstr.) **(Ger)**

HIV ENVELOPE PROTEIN GP120

METABOLISM

[New anti-HIV drug which binds the oligosaccharides of HIV envelope glycoprotein] Mizuochi T, et al. **Nippon Rinsho** 1995 Sep;53(9):2340–9 (20 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

The role of CD4 in HIV envelope-mediated pathogenesis. Siliciano RF. **Curr Top Microbiol Immunol** 1996;205:159–79 (121 ref.)

HIV INFECTIONS

see related
LYMPHOMA, AIDS-RELATED

Oral candidiasis, HIV, and saliva glucocorticoids. Enwonwu CO, et al. **Am J Pathol** 1996 Apr;148(4):1313–8 (68 ref.)

Psychoneuroimmunological studies in HIV disease. McCain NL, et al. **Annu Rev Nurs Res** 1996;14:23–55 (75 ref.)

Ovine lentivirus infection: an animal model for pediatric HIV infection? de la Concha-Bermejillo A, et al. **Arch Med Res** 1995 Winter;26(4):345–54 (105 ref.)

Immunopathogenesis and detection of HIV infection in women and newborns. Smith DK, et al. **Clin Obstet Gynecol** 1996 Jun;39(2):277–91 (34 ref.)

Reproductive decision-making and determinants of contraceptive use in HIV-infected women. Williams HA, et al. **Clin Obstet Gynecol** 1996 Jun;39(2):333–43 (40 ref.)

Outpatient management of HIV infection in the adult: an update. Boswell SL. **Curr Clin Top Infect Dis** 1995; 15:301–43 (189 ref.)

The role of oxidative stress in HIV disease. Pace GW, et al. **Free Radic Biol Med** 1995 Oct;19(4):523–8 (93 ref.)

Consensus statement. Scientific Advisory Committee on Surrogate Markers of HIV. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995;10 Suppl 2:S114–6 (0 ref.)

Primary care of the HIV patient: standard practice and new developments in the era of managed care. Kocurek K. **Med Clin North Am** 1996 Mar;80(2):375–410 (204 ref.)

Women living with HIV infection. Abercrombie PD. **Nurs Clin North Am** 1996 Mar;31(1):97–106 (56 ref.)

Overview of perinatally transmitted HIV infection. Boland M. **Nurs Clin North Am** 1996 Mar;31(1):155–64 (36 ref.)

Pediatric HIV infection and its oral manifestations: a review. Chigurupati R, et al. **Pediatr Dent** 1996 Mar-Apr; 18(2):106–13 (68 ref.)

Confidentiality of HIV medical records: the computer age. Byrd CM, et al. **Prog Cardiovasc Nurs** 1995 Fall; 10(4):39–43, 45 (17 ref.)

Human immunodeficiency virus and acquired immunodeficiency syndrome: recent developments and their implications for pediatric surgeons. Cooper A. **Semin Pediatr Surg** 1995 Nov;4(4):252–61 (88 ref.)

[Primary HIV infection] Pedersen C, et al. **Ugeskr Laeger** 1996 Apr 29;158(18):2526–9 (28 ref.) (Eng. Abstr.) **(Dan)**

[Natural history of HIV infection in children] Blanche S. **Arch Pediatr** 1996;3 Suppl 1:20s–23s (27 ref.) **(Fre)**

[Human immunodeficiency virus infection in pregnancy. General aspects] d'Ercole C, et al. **Presse Med** 1996 Jan 20;25(2):77–80 (24 ref.) (Eng. Abstr.) **(Fre)**

[Clinical study of HIV infections] Kimura S. **Nippon Naika Gakkai Zasshi** 1996 Mar 10;85(3):438–42 (12 ref.) **(Jpn)**

[Molecular biology of infections caused by HIV and other hepatotropic viruses] Schüller Pérez A. **An R Acad Nac Med (Madr)** 1995;112(3):585–613; discussion 614–5 (107 ref.) **(Spa)**

BLOOD

Management of the hematological manifestations of HIV infection and AIDS. Ownby KK. **J Assoc Nurses AIDS Care** 1995 Jul-Aug;6(4):9–15; quiz 17–8 (16 ref.)

Managing HIV. Part 4: Primary therapy. 4.3 The laboratory in managing HIV infection. Dwyer DE, et al. **Med J Aust** 1996 Mar 4;164(5):301–3 (19 ref.)

COMPLICATIONS

Management of cytomegalovirus disease. Danner SA. **AIDS** 1995 Dec;9 Suppl 2:S3–S8 (16 ref.)

Bacterial infections in HIV disease. Currier JS, et al. **AIDS Clin Rev** 1995–96;:131–52 (102 ref.)

Ocular complication in HIV infected individuals. Harrison TJ. **Alaska Med** 1995 Jul-Sep;37(3):91–100 (78 ref.)

Thalidomide in diseases associated with human immunodeficiency virus infection. Minor JR, et al. **Am J Health Syst Pharm** 1996 Feb 15;53(4):429–31 (14 ref.)

Thalidomide for aphthous ulcers in patients infected with the human immunodeficiency virus. Weidle PJ. **Am J Health Syst Pharm** 1996 Feb 15;53(4):368, 371–2, 378 (12 ref.)

Controlling diarrhea in the HIV patient. Anastasi JK, et al. **Am J Nurs** 1996 Aug;96(8):35–41; quiz 42 (8 ref.)

Oral manifestations of HIV infection. Weinert M, et al. **Ann Intern Med** 1996 Sep 15;125(6):485–96 (89 ref.)

Surgery for anal lesions in HIV-infected patients. Weiss EG, et al. **Ann Med** 1995 Aug;27(4):467–75 (44 ref.)

Selective causes of fever in adult human immunodeficiency virus-infected patients relative to CD4+ cell counts. Czachor JS, et al. **Arch Fam Med** 1995 Oct;4(10):879–84 (77 ref.)

The use of silicone oil for HIV-related retinal detachment [editorial; comment] Blumenkranz MS. **Arch Ophthalmol** 1995 Nov;113(11):1366–8 (14 ref.) Comment on: Arch Ophthalmol 1995 Nov;113(11):1401–9.

Hepatitis and HIV: interrelationship and interactions. Newell A, et al. **Br J Clin Pract** 1995 Sep-Oct;49(5):247–51 (83 ref.)

Pityriasis rubra pilaris and human immunodeficiency virus infection. Miralles ES, et al. **Br J Dermatol** 1995 Dec; 133(6):990–3 (14 ref.)

Polyarteritis nodosa in human immunodeficiency virus infection: report of four cases and review of the literature. Font C, et al. **Br J Rheumatol** 1996 Aug;35(8):796–9 (31 ref.)

Testicular germ cell tumors in patients with human immunodeficiency virus infection. Hentrich MU, et al. **Cancer** 1996 May 15;77(10):2109–16 (55 ref.)

Symptomatic management of HIV associated gastrointestinal disease. McGowan I, et al. **Cancer Surv** 1994;21:157–77 (113 ref.)

Bacterial enteric infections in persons infected with human immunodeficiency virus. Angulo FJ, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S84–93 (96 ref.)

Cavitary pulmonary lesions in patients infected with human immunodeficiency virus. Gallant JE, et al. **Clin Infect Dis** 1996 Apr;22(4):671–82 (208 ref.)

Thrombocytopenia in patients infected with human immunodeficiency virus: treatment update. Glatt AE, et al. **Clin Infect Dis** 1995 Aug;21(2):415–23 (92 ref.)

Preventing bacterial respiratory tract infections among persons infected with human immunodeficiency virus. Keller DW, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S77–83 (66 ref.)

Prospects for preventing cryptococcosis in persons infected with human immunodeficiency virus. Pinner RW, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S103–7 (46 ref.)

Sinonasal non-Hodgkin's lymphoma in patients infected with human immunodeficiency virus: report of three cases and review. Pomilla PV, et al. **Clin Infect Dis** 1995 Jul; 21(1):137–49 (117 ref.)

Infections associated with Bartonella species in persons infected with human immunodeficiency virus. Regnery RL, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S94–8 (36 ref.)

Tuberculosis in patients infected with human immunodeficiency virus: perspective on the past decade. Shafer RW, et al. **Clin Infect Dis** 1996 Apr;22(4):683–704 (324 ref.)

Herpesvirus infections in persons infected with human immunodeficiency virus. Stewart JA, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S114–20 (42 ref.)

Human papillomavirus infection and associated disease in persons infected with human immunodeficiency virus. Vernon SD, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S121–4 (27 ref.)

Quality standard for the immunization of infants and children born to women infected with human immunodeficiency virus. Wilfert CM, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S136–7 (5 ref.)

Clinical manifestations and implications of coinfection with Mycobacterium kansasii and human immunodeficiency virus type 1. Witzig RS, et al. **Clin Infect Dis** 1995 Jul; 21(1):77–85 (69 ref.)

Cutaneous manifestations of opportunistic infections in patients infected with human immunodeficiency virus. Tappero JW, et al. **Clin Microbiol Rev** 1995 Jul;8(3):440–50 (68 ref.)

AIDS. Viruses, cytokines and Kaposi's sarcoma. Ganem D. **Curr Biol** 1995 May 1;5(5):469–71 (17 ref.)

An approach to acute fever and rash (AFR) in the adult. Levin S, et al. **Curr Clin Top Infect Dis** 1995;15:19–75 (234 ref.)

An integrated approach to the epidemiology of Kaposi's sarcoma. Jacobson LP, et al. **Curr Opin Oncol** 1995 Sep; 7(5):450–5 (71 ref.)

Human papillomavirus-associated malignancies in HIV-positive men and women. Palefsky J. **Curr Opin Oncol** 1995 Sep;7(5):437–41 (46 ref.)

Treatment strategies for epidemic Kaposi's sarcoma. Volm MD, et al. **Curr Opin Oncol** 1995 Sep;7(5):429–36 (76 ref.)

Myopathy and HIV infection. Chariot P, et al. **Curr Opin Rheumatol** 1995 Nov;7(6):497–502 (72 ref.)

Diagnosing sexually transmitted diseases in HIV-positive patients. Penneys NS. **Curr Probl Dermatol** 1996;24:77–81 (22 ref.)

Cytotoxic T lymphocytes and HIV-1 related neurologic disorders. Kalams SA, et al. **Curr Top Microbiol Immunol** 1995;202:79–88 (51 ref.)

Bronchiolitis obliterans organizing pneumonia in an AIDS patient. Sanito NJ, et al. **Eur Respir J** 1995 Jun;8(6):1021–4 (15 ref.)

Fever in patients with HIV infection. Sullivan M, et al. **Infect Dis Clin North Am** 1996 Mar;10(1):149–65 (94 ref.)

Management of mycoses associated with HIV disease. Coker RJ, et al. **Int J STD AIDS** 1995 Nov-Dec;6(6):408–12 (17 ref.)

Opioid use in HIV patients with neurological changes. Paice JA, et al. **J Assoc Nurses AIDS Care** 1995 Jul-Aug; 6(4):28–36 (27 ref.)

Treatment review. Testosterone (Testoderm). Porche DJ. **J Assoc Nurses AIDS Care** 1995 Jul-Aug;6(4):43–5 (3 ref.)

HIV infection and leprosy--an enigma. Sankaran JR. **J Assoc Physicians India** 1995 Aug;43(8):557–9 (20 ref.)

Pentoxifylline for the treatment of HIV infection and its complications. Dezube BJ, et al. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S139–42 (29 ref.)

The spectrum of non-AIDS-defining neoplastic disease in HIV infection. Remick SC. **J Investig Med** 1996 Jun; 44(5):205–15 (183 ref.)

Managing HIV. Part 3: Mechanisms of disease. 3.6 How HIV promotes malignancies. Boyle MJ, et al. **Med J Aust** 1996 Feb 19;164(4):230–2 (21 ref.)

Managing HIV. Part 3: Mechanisms of diseases. 3.7 How HIV leads to neurological disease. Brew BJ, et al. **Med J Aust** 1996 Feb 19;164(4):233–4 (19 ref.)

Managing HIV. Part 3: Mechanisms of disease. 3.5 How HIV leads to hypersensitivity reactions. Carr A, et al. **Med J Aust** 1996 Feb 19;164(4):227–9 (9 ref.)

Managing HIV. Part 5: Treating secondary outcomes. 5.2 HIV and oral disease. Foltyn P, et al. **Med J Aust** 1996 Mar 18;164(6):357–9 (6 ref.)

Managing HIV. Part 3. Mechanisms of disease. 3.4 How HIV leads to autoimmune disorders. Gala S, et al. **Med J Aust** 1996 Feb 19;164(4):224–6 (15 ref.)

Managing HIV. Part 5: Treating secondary outcomes. 5.18 HIV and sexually transmitted diseases. Plummer DC, et al. **Med J Aust** 1996 May 20;164(10):608–11 (611 ref.)

Managing HIV. Part 5: Treating secondary outcomes. 5.3 HIV, gastrointestinal and hepatobiliary disease. Sievert W, et al. **Med J Aust** 1996 Mar 18;164(6):360–5 (25 ref.)

Managing HIV. Part 5: Treating secondary outcomes. 5.1 HIV and skin disease. Wong D, et al. **Med J Aust** 1996 Mar 18;164(6):352–6 (9 ref.)

Managing HIV. Part 5: Treating secondary outcomes. 5.4 HIV-induced neurological disease. Wright EJ, et al. **Med J Aust** 1996 Apr 1;164(7):414–7 (31 ref.)

Oral manifestiations of pediatric human immunodeficeincy virus infection: a review of the literature. Kline MW. **Pediatrics** 1996 Mar;97(3):380–8 (67 ref.)

HIV medicine: drug side effects and interactions. Bates CM.

Postgrad Med J 1996 Jan;72(843):30–6 (27 ref.)
HIV arthritis. Eustace SJ, et al. **Radiol Clin North Am** 1996 Mar;34(2):450–3 (46 ref.)
Leydig cell tumour in a man with human immunodeficiency virus. Sanchez–Chapado M, et al. **Scand J Urol Nephrol** 1995 Sep;29(3):357–60 (18 ref.)
The typically 'atypical' radiographic presentation of tuberculosis in advanced HIV disease [editorial] Daley CL. **Tuber Lung Dis** 1995 Dec;76(6):475–6 (18 ref.)
[Lymphoepithelial hyperplasia of the parotid gland and HIV infection] Barry B, et al. **Ann Otolaryngol Chir Cervicofac** 1995;112(8):387–92 (28 ref.) (Eng. Abstr.) **(Fre)**
[Pregnant women with HIV infection: medical decision] Ciraru–Vigneron N. **Presse Med** 1996 May 25; 25(18):847–52 (29 ref.) (Eng. Abstr.) **(Fre)**
[Left vocal cord paralysis in cytomegalovirus multifocal neuropathy in a patient with HIV infection] de La Blanchardiere A, et al. **Presse Med** 1996 Jan 27;25(3):106–7 (7 ref.) (Eng. Abstr.) **(Fre)**
[Thrombotic microangiopathies in HIV infection: 4 cases] Ninin E, et al. **Rev Med Interne** 1996;17(3):238–42 (16 ref.) (Eng. Abstr.) **(Fre)**
[Prevention of opportunistic infections in HIV infection] Pesce A. **Rev Med Interne** 1995;16 Suppl 3:315s–319s (20 ref.) **(Fre)**
[Peripheral neuropathies in HIV infection] Gastaut JL. **Rev Neurol (Paris)** 1995 Oct;151(10):532–40 (96 ref.) **(Fre)**
[Muscular involvement in HIV infection] Gherardi R, et al. **Rev Neurol (Paris)** 1995 Nov;151(11):603–7 (44 ref.) (Eng. Abstr.) **(Fre)**
[Isolated peripheral facial paralysis and HIV infection: 7 cases] Kohler A, et al. **Rev Neurol (Paris)** 1995 May; 151(5):332–7 (48 ref.) (Eng. Abstr.) **(Fre)**
[HIV (human immunodeficiency virus) disease and AIDS (acquired immunodeficiency syndrome)] Fujii T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):255–7 (10 ref.) **(Jpn)**
[Rhodococcus equi pneumonia in patients with HIV infection: report of 2 cases and review of the literature] Berna JD, et al. **Enferm Infecc Microbiol Clin** 1996 Mar; 14(3):177–80 (57 ref.) (Eng. Abstr.) **(Spa)**
[Fever of unknown origin in HIV infection. New facets of an old problem (editorial)] Barbado Hernández FJ, et al. **Med Clin (Barc)** 1995 Nov 11;105(16):615–6 (24 ref.) **(Spa)**
[Treatment of neutropenia in HIV infection with hematopoietic growth factors] Moreno Garcia M, et al. **Rev Clin Esp** 1996 Apr;196(4):248–54 (121 ref.) **(Spa)**
[Strongyloides stercoralis hyperinfection syndrome in a patient with human immunodeficiency virus (HIV) infection: report of a case and review of the literature] Del Carpio D, et al. **Rev Gastroenterol Peru** 1995 Sep–Dec; 15(3):290–5 (31 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

The overlooked epidemic: HIV in older adults [see comments] Whipple B, et al. **Am J Nurs** 1996 Feb; 96(2):22–8; quiz 29 (9 ref.) Comment in: Am J Nurs 1996 May;96(5):18.
Pulmonary complications of HIV infection. Murray JF. **Annu Rev Med** 1996;47:117–26 (30 ref.)
Quality standard for the identification and treatment of persons coinfected with human immunodeficiency virus and Mycobacterium tuberculosis. Phair JP, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S130–1 (4 ref.)
The diagnosis and management of perinatal HIV infection. Nesheim SR. **Clin Obstet Gynecol** 1996 Jun;39(2):396–410 (84 ref.)
Primary care of children with HIV infection. Forsyth BW. **Curr Opin Pediatr** 1995 Oct;7(5):502–12 (57 ref.)
Difficulties and strategies of HIV diagnosis. Gürtler L. **Lancet** 1996 Jul 20;348(9021):176–9 (30 ref.)
HIV–related skin diseases. Tschachler E, et al. **Lancet** 1996 Sep 7;348(9028):659–63 (45 ref.)
Guidelines for assessing HIV in women. Sipes C. **MCN Am J Matern Child Nurs** 1995 Jan–Feb;20(1):29–33 (28 ref.)
Managing HIV. Part 6: People living with HIV. 6.3 Children with HIV. Ziegler JB, et al. **Med J Aust** 1996 Jun 3; 164(11):672–9 (54 ref.)
Pitfalls in HIV testing. Application and limitations of current tests. Cordes RJ, et al. **Postgrad Med** 1995 Nov; 98(5):177–80, 185–6, 189 (22 ref.)
Assessment of fever in HIV–infected patients. Gleckman R, et al. **Postgrad Med** 1996 Mar;99(3):78–80, 87–9, 93–4 passim (37 ref.)
[Endoscopy of the upper gastrointestinal tract in HIV disease] Caca K, et al. **Bildgebung** 1995 Dec;62(4):244–51 (56 ref.) (Eng. Abstr.) **(Ger)**
[HIV infection: findings in liver and bile ducts] Jablonowski H. **Bildgebung** 1995 Dec;62(4):260–70 (89 ref.) (Eng. Abstr.) **(Ger)**
[HIV infection and the lower gastrointestinal tract—characteristics of endoscopic diagnosis] Mauss S, et al. **Bildgebung** 1995 Dec;62(4):252–8 (46 ref.) (Eng. Abstr.) **(Ger)**
[Pseudomesotheliomatous carcinoma in HIV infection] Brunner–La Rocca HP, et al. **Dtsch Med Wochenschr** 1995 Sep 29;120(39):1312–7 (38 ref.) (Eng. Abstr.) **(Ger)**
[Current methods of immunological and genetic diagnosis of HIV infection (literature review)] Dmitriev VI, et al. **Klin Lab Diagn** 1995 Sep–Oct;(5):12–6 (83 ref.) **(Rus)**
[Bronchogenic carcinoma and human immunodeficiency virus infection] Carrasquer C, et al. **Arch Bronconeumol** 1995 Aug–Sep;31(7):362–4 (15 ref.) (Eng. Abstr.) **(Spa)**

DIET THERAPY

Nutrition and HIV infection. A continuum of care. Elbein RC. **J Am Podiatr Med Assoc** 1995 Aug;85(8):434–8 (10 ref.)

DRUG THERAPY

Saquinavir: an HIV proteinase inhibitor. Bragman K. **Adv Exp Med Biol** 1996;394:305–17 (25 ref.)
Current clinical experience with nevirapine for HIV infection. Carr A, et al. **Adv Exp Med Biol** 1996; 394:299–304 (17 ref.)
Zidovudine: anno 1995. Danner SA. **Adv Exp Med Biol** 1996; 394:225–43 (114 ref.)
Stavudine (d4T, Zerit). Friedland G, et al. **Adv Exp Med Biol** 1996;394:271–7 (21 ref.)
The clinical use of didanosine. Kahn J. **Adv Exp Med Biol** 1996;394:245–56 (47 ref.)
Clinical experience with non–nucleoside reverse transcriptase inhibitors: L–697,661 and nevirapine. Kilby JM, et al. **Adv Exp Med Biol** 1996;394:291–8 (23 ref.)
Promising anti–HIV compounds in preclinical or early clinical development. Litterst C. **Adv Exp Med Biol** 1996; 394:397–404 (16 ref.)
ddC (zalcitabine). Skowron G. **Adv Exp Med Biol** 1996; 394:257–69 (49 ref.)
Cytokine therapy of HIV infection. Sneller MC. **Adv Exp Med Biol** 1996;394:411–9 (54 ref.)
Inhibition of T lymphocyte activation and apoptotic cell death by cyclosporin A and tacrolimus (FK506). Its relevance to therapy of HIV infection. Thomson AW, et al. **Adv Exp Med Biol** 1995;374:211–6 (46 ref.)
Correlation between viral load measurements and outcome in clinical trials of antiviral drugs. Schooley RT. **AIDS** 1995 Dec;9 Suppl 2:S15–S19 (21 ref.)
Clinical experience with saquinavir. Vella S. **AIDS** 1995 Dec; 9 Suppl 2:S21–S25 (22 ref.)
Viral dynamics of HIV: implications for drug development and therapeutic strategies. Havlir DV, et al. **Ann Intern Med** 1996 Jun 1;124(11):984–94 (112 ref.)
Combination therapy for HIV–1 infection–overview: preclinical and clinical analysis of antiretroviral combinations. Johnson VA. **Antiviral Res** 1996 Jan; 29(1):35–9 (21 ref.)
Antiretroviral therapy of human immunodeficiency virus type–1 (HIV–1) infection. Emery S, et al. **Aust N Z J Med** 1995 Aug;25(4):344–9 (41 ref.)
Will we ever know when to treat HIV infection? Phillips AN, et al. **BMJ** 1996 Sep 7;313(7057):608–10 (25 ref.)
Zidovudine therapy in HIV infection: which patients should be treated and when. Barry MG, et al. **Br J Clin Pharmacol** 1995 Aug;40(2):107–10 (39 ref.)
Protease inhibitors: promising new weapons against HIV. Isada CM. **Cleve Clin J Med** 1996 Jul–Aug;63(4):204–8 (23 ref.)
Quality standard for the identification and treatment of persons coinfected with human immunodeficiency virus and Mycobacterium tuberculosis. Phair JP, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S130–1 (4 ref.)
The role of antiretroviral therapy in the management of HIV infection in women. Mofenson LM. **Clin Obstet Gynecol** 1996 Jun;39(2):361–85 (113 ref.)
The diagnosis and management of perinatal HIV infection. Nesheim SR. **Clin Obstet Gynecol** 1996 Jun;39(2):396–410 (84 ref.)
Pharmacokinetic optimisation of antiretroviral therapy in patients with HIV infection. Stretcher BN. **Clin Pharmacokinet** 1995 Jul;29(1):46–65 (135 ref.)
Therapeutic approaches to HIV infection based on virus structure and the host pathogen interaction. Pauza CD, et al. **Curr Top Microbiol Immunol** 1995;202:117–32 (94 ref.)
Guidelines for the use of zidovudine in pregnant women with HIV infection. De Santis M, et al. **Drugs** 1995 Jul;50(1):43–7 (34 ref.)
Knocking out human immunodeficiency virus through non–nucleoside reverse transcriptase inhibitors used as single agents or in combinations: a paradigm for the cure of AIDS? De Clercq E, et al. **Farmaco** 1995 Nov; 50(11):735–47 (48 ref.)
Ups and downs—and ups in the antiviral therapy of HIV infection. Weller IV, et al. **Genitourin Med** 1996 Feb; 72(1):2–5 (24 ref.)
Targeting HIV with liposome–encapsulated antivirals [editorial] Désormeaux A, et al. **Int J Med Microbiol Virol Parasitol Infect Dis** 1995 Apr; 282(3):225–31 (15 ref.)
Failure of antiretroviral therapy: role of viral and cellular factors. Cinatl J Jr, et al. **Intervirology** 1994;37(6):307–14 (76 ref.)
Combination therapy from a clinician's perspective. Goebel FD. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995; 10 Suppl 1:S62–8 (38 ref.)
Studies of zidovudine in combination with didanosine and zalcitabine. Jablonowski H. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995;10 Suppl 1:S52–6 (17 ref.)
Therapeutic interventions in primary HIV infection. Kinloch–de Loës S, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995;10 Suppl 1:S69–76 (44 ref.)
Current HIV clinical trial design issues. Lange JM. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995;10 Suppl 1:S47–51 (24 ref.)
Triple combinations: present and future. Lange JM. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995;10 Suppl 1:S77–82 (24 ref.)
Viral resistance and the selection of antiretroviral combinations. Larder BA. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995;10 Suppl 1:S28–33 (28 ref.)
Individualization of therapy using viral markers. Merigan T. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995;10 Suppl 1:S41–6 (28 ref.)
HIV pathogenesis and treatment strategies. Vella S. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995;10 Suppl 1:S20–3 (22 ref.)
Rationale and experience with reverse transcriptase inhibitors and protease inhibitors. Vella S. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995;10 Suppl 1:S58–61 (15 ref.)
Treatment of AIDS and HIV–related conditions—1996. Goldschmidt RH, et al. **J Am Board Fam Pract** 1996 Mar–Apr;9(2):125–48 (88 ref.)
Pentoxifylline for the treatment of HIV infection and its complications. Dezube BJ, et al. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S139–42 (29 ref.)
Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society–USA. Carpenter CC, et al. **JAMA** 1996 Jul 10;276(2):146–54 (109 ref.)
Does ozone therapy normalize the cellular redox balance? Implications for therapy of human immunodeficiency virus infection and several other diseases. Bocci V. **Med Hypotheses** 1996 Feb;46(2):150–4 (40 ref.)
Managing HIV. Common drug interactions in HIV medicine. Carey DL, et al. **Med J Aust** 1996 May 20;164(10):605–6 (0 ref.)
Managing HIV. Part 4: Primary therapy. 4.1 Antiretroviral therapies for HIV. Crowe S, et al. **Med J Aust** 1996 Mar 4;164(5):290–5 (20 ref.)
Managing HIV. Antiretroviral therapy. Fulcher D, et al. **Med J Aust** 1996 May 20;164(10):607 (0 ref.)
Management of HIV infection. A 1995–96 overview for the clinician. Henry K. **Minn Med** 1995 Nov;78(11):17–24 (25 ref.)
State of the art. Antiviral treatment of HIV infection. Bechtel–Boenning C. **Nurs Clin North Am** 1996 Mar; 31(1):1–13 (48 ref.)
Combination antiretroviral therapy for the treatment of human immunodeficiency virus type–1 infection. Wilson CC, et al. **Proc Assoc Am Physicians** 1995 Apr;107(1):19–27 (85 ref.)
Inhibitors of HIV proteinase. Martin JA, et al. **Prog Med Chem** 1995;32:239–87 (146 ref.)
Cyclosporine–induced apoptosis in CD4+ T lymphocytes and computer–simulated analysis: modeling a treatment scenario for HIV infection. Huss R, et al. **Res Immunol** 1995 Feb;146(2):101–8 (32 ref.)
[Immunomodulator treatments in HIV infection: rational bases and therapeutic prospects] Durant J, et al. **Rev Med Interne** 1995;16 Suppl 3:308s–312s (30 ref.) **(Fre)**
[Antiretroviral therapy in HIV infection] Jablonowski H. **Med Monatsschr Pharm** 1996 Jul;19(7):196–205 (38 ref.) **(Ger)**
[New strategies in anti–HIV therapy—consequences for the neurologist?] Enzensberger W, et al. **Nervenarzt** 1996 Jun; 67(6):506–8 (2 ref.) **(Ger)**
[New treatments in HIV] Turner D, et al. **Harefuah** 1996 Apr 1;130(7):467–70 (32 ref.) **(Heb)**

EPIDEMIOLOGY

The estimated prevalence and incidence of HIV in 96 large US metropolitan areas [see comments] Holmberg SD. **Am J Public Health** 1996 May;86(5):642–54 (139 ref.) Comment in: Am J Public Health 1996 May;86(5):627–8.
HIV infection and AIDS in China, 1985 through 1994. Yu ES, et al. **Am J Public Health** 1996 Aug;86(8 Pt 1):1116–22 (47 ref.)
Epidemiology of HIV infection in women and newborns. Gwinn M, et al. **Clin Obstet Gynecol** 1996 Jun; 39(2):292–304 (22 ref.)
Substance abuse and HIV pregnancy. Sprauve ME. **Clin Obstet Gynecol** 1996 Jun;39(2):316–32 (98 ref.)
Human immunodeficiency virus type 2: human biology of the other AIDS virus. D'Aquila RT. **Curr Clin Top Infect Dis** 1996;16:84–101 (86 ref.)
Human immunodeficiency virus and AIDS in Uganda. Mugerwa RD, et al. **East Afr Med J** 1996 Jan;73(1):20–6 (56 ref.)
Psychiatric disorders and HIV infection: impact on one another. Lyketsos CG, et al. **Epidemiol Rev** 1995; 17(1):152–64 (82 ref.)
HIV in UK prisons: a review of seroprevalence, transmission and patterns of risk [editorial] Curtis SP, et al. **Int J STD AIDS** 1995 Nov–Dec;6(6):387–91 (46 ref.)
Neuroepidemiology of HIV infection. Dal Pan GJ, et al. **Neurol Clin** 1996 May;14(2):359–82 (133 ref.)

Bringing the context in from the cold: substantive, technical, and statistical issues for AIDS research in the second decade. Brunswick AF. **NIDA Res Monogr** 1994; 143:187–201 (21 ref.)
HIV risk in drug-using adolescents. Smeriglio VL. **NIDA Res Monogr** 1994;143:132–4 (5 ref.)
The epidemiology of HIV/AIDS. Hughes MJ, et al. **Semin Dermatol** 1995 Sep;14(3):191–201 (123 ref.)
Occupational risk of infection with human immunodeficiency virus. Chamberland ME, et al. **Surg Clin North Am** 1995 Dec;75(6):1057–70 (36 ref.)
HIV and India: looking into the abyss. Pais P. **Trop Med Int Health** 1996 Jun;1(3):295–304 (54 ref.)
The impact of HIV-1 infection on child health in sub-Saharan Africa: the burden on the health services. Walraven G, et al. **Trop Med Int Health** 1996 Feb;1(1):3–14 (87 ref.)
[HIV infection in women (editorial)] Cordero M. **An Med Interna** 1995 Dec;12(12):573–574 (30 ref.) **(Spa)**

ETHNOLOGY

HIV/AIDS in the context of culture: selection of ethnocultural communities for study in Canada. Cappon P, et al. **Can J Public Health** 1996 May-Jun;87 Suppl 1:S11–4, S11–5 (50 ref.) **(Eng, Fre)**
The context of risk: ethnographic contributions to the study of drug use and HIV. Koester SK. **NIDA Res Monogr** 1994; 143:202–17 (36 ref.)

ETIOLOGY

Risk of HIV infection in psychiatrically ill patients. Grassi L. **AIDS Care** 1996 Feb;8(1):103–16 (79 ref.)
Are HIV-specific CTL responses salutary or pathogenic? Zinkernagel RM. **Curr Opin Immunol** 1995 Aug;7(4):462–70 (92 ref.)
Transgenic models of human immunodeficiency virus type-1. Klotman PE, et al. **Curr Top Microbiol Immunol** 1996; 206:197–222 (49 ref.)
Interleukin-2 and human immunodeficiency virus infection: pathogenic mechanisms and potential for immunologic enhancement. Kinter A, et al. **Immunol Res** 1996;15(1):1–15 (136 ref.)
The role of viral diversity in HIV pathogenesis. Goudsmit J. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995;10 Suppl 1:S15–9 (24 ref.)
HIV pathogenesis and treatment strategies. Vella S. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995;10 Suppl 1:S20–3 (22 ref.)
HIV viral load markers in clinical practice. Saag MS, et al. **Nat Med** 1996 Jun;2(6):625–9 (33 ref.)
[Long-term asymptomatic HIV infection—pathogenetic aspects] Radkowski M, et al. **Pol Arch Med Wewn** 1995 Sep;94(3):275–82 (48 ref.) **(Pol)**

GENETICS

HIV and HLA: confusion or complexity? [comment] Hill AV. **Nat Med** 1996 Apr;2(4):395–6 (10 ref.) Comment on: Nat Med 1996 Apr;2(4):405–11.
HIV viral load markers in clinical practice. Saag MS, et al. **Nat Med** 1996 Jun;2(6):625–9 (33 ref.)

IMMUNOLOGY

The role of surface CD4 in HIV-induced apoptosis. Corbeil J, et al. **Adv Exp Med Biol** 1995;374:91–9 (59 ref.)
T cell apoptosis as a consequence of chronic activation of the immune system in HIV infection. Gougeon ML. **Adv Exp Med Biol** 1995;374:121–7 (46 ref.)
CD4+ and CD8+ T lymphocyte activation in HIV infection. Implications for immune pathogenesis and therapy. Laurence J. **Adv Exp Med Biol** 1995;374:1–15 (74 ref.)
Pathogenesis and management of HIV-associated drug hypersensitivity. Carr A, et al. **AIDS Clin Rev** 1995–96; :65–97 (121 ref.)
Immunopathogenesis of HIV infection: a specific anti-HIV tolerance as a mechanism of control of disease progression. Sidorovitch IG, et al. **Allergy Proc** 1995 Jul-Aug; 16(4):203–7 (14 ref.)
Immunopathogenic mechanisms of HIV infection. Fauci AS, et al. **Ann Intern Med** 1996 Apr 1;124(7):654–63 (56 ref.)
Selective causes of fever in adult human immunodeficiency virus-infected patients relative to CD4+ cell counts. Czachor JS, et al. **Arch Fam Med** 1995 Oct;4(10):879–84 (77 ref.)
Autoimmune mechanisms of depletion of CD4 cells in HIV infection. Dalgleish AG. **Br J Haematol** 1995 Nov; 91(3):525–34 (106 ref.)
Cytokines in immune regulation/pathogenesis in HIV infection. Shearer GM, et al. **Ciba Found Symp** 1995; 195:142–7; discussion 147–53 (44 ref.)
Quality standard for the enumeration of CD4+ lymphocytes in adults and adolescents infected with human immunodeficiency virus. Gross PA, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S126–7 (7 ref.)
Quality standard for the enumeration of CD4+ lymphocytes in infants and children exposed to or infected with human immunodeficiency virus. Wilfert CM, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S134–5 (10 ref.)
The immunology of primary HIV infection: which immune responses control HIV replication? Safrit JT, et al. **Curr Opin Immunol** 1995 Aug;7(4):456–61 (36 ref.)
Are HIV-specific CTL responses salutary or pathogenic? Zinkernagel RM. **Curr Opin Immunol** 1995 Aug;7(4):462–70 (92 ref.)
The CD4 molecule. Roles in T lymphocytes and in HIV disease. Introduction. Littman DR. **Curr Top Microbiol Immunol** 1996;205:v–x (13 ref.)
Follicular dendritic cells initiate and maintain infection of the germinal centers by human immunodeficiency virus. Tenner-Racz K, et al. **Curr Top Microbiol Immunol** 1995; 201:141–59 (110 ref.)
Antibody-dependent cellular cytotoxicity in HIV infections. Ahmad A, et al. **FASEB J** 1996 Feb;10(2):258–66 (57 ref.)
Protective immunity against HIV infection: has nature done the experiment for us? Shearer GM, et al. **Immunol Today** 1996 Jan;17(1):21–4 (37 ref.)
Pulmonary immune response to Mycobacterium tuberculosis and human immunodeficiency virus. Rich EA. **Infect Agents Dis** 1996 Mar;5(2):108–18 (61 ref.)
Wellness and HIV: developing a model for progression from theoretical knowledge about psychosocial factors to application. Rayner-Brosnan D. **Int J Immunopharmacol** 1995 Aug;17(8):663–76 (95 ref.)
Evaluating surrogate markers. Hughes MD, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995;10 Suppl 2:S1–8 (22 ref.)
Human antibody variable region gene usage in HIV-1 infection. Wisnewski A, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Jan 1;11(1):31–8 (57 ref.)
Staphylococcus aureus colonisation and bacteraemia in persons infected with human immunodeficiency virus: a dynamic interaction with the host. Craven DE. **J Chemother** 1995 Jul;7 Suppl 3:19–28 (46 ref.)
HIV-mediated B-lymphocyte activation and lymphomagenesis. Monroe JG, et al. **J Clin Immunol** 1995 Mar;15(2):61–8 (73 ref.)
Chemoattractants attract HIV researchers [comment] Moore JP, et al. **J Exp Med** 1996 Aug 1;184(2):311–3 (35 ref.) Comment on: J Exp Med 1996 Aug 1;184(2):569–77.
Alveolar macrophages as a cell source of cytokine hyperproduction in HIV-related interstitial lung disease. Agostini C, et al. **J Leukoc Biol** 1995 Nov;58(5):495–500 (37 ref.)
Dendritic cells and the replication of HIV-1. Cameron P, et al. **J Leukoc Biol** 1996 Feb;59(2):158–71 (194 ref.)
Managing HIV. Part 4: Primary therapy. 4.3 The laboratory in managing HIV infection. Dwyer DE, et al. **Med J Aust** 1996 Mar 4;164(5):301–3 (19 ref.)
Envelope glycoproteins of human immunodeficiency virus type 1: profound influences on immune functions. Chirmule N, et al. **Microbiol Rev** 1996 Jun;60(2):386–406 (435 ref.)
Molecular biological bases of resistance to HIV/AIDS (the hypothesis with elements of the theory). Skripal IG. **Mikrobiol Z** 1995 Jul-Aug;57(4):89–105 (45 ref.)
Directions in HIV/AIDS research. A Minnesota perspective. Henry K, et al. **Minn Med** 1995 Nov;78(11):26–34 (17 ref.)
Immune-based therapy for HIV. Engle J. **Nurs Clin North Am** 1996 Mar;31(1):15–23 (45 ref.)
Nutrition and immunity with emphasis on infection and autoimmune disease. Harbige LS. **Nutr Health** 1996; 10(4):285–312 (136 ref.)
The skin immune system in the course of HIV-1 infection. Henry M, et al. **Photochem Photobiol** 1996 Aug;64(2):275–9 (42 ref.)
Toward an understanding of the correlates of protective immunity to HIV infection [see comments] Haynes BF, et al. **Science** 1996 Jan 19;271(5247):324–8 (73 ref.) Comment in: Science 1996 Feb 23;371(5252):1043. Comment in: Science 1996 May 31;272(5266):1362. Comment in: Science 1996 Jul 26;273(5274):415–6.
AIDS pathogenesis: a finite immune response to blame? [comment] Miedema F, et al. **Science** 1996 Apr 26; 272(5261):505–6 (18 ref.) Comment on: Science 1996 Apr 26;272(5261):537–42.
[Immunopathological mechanisms of HIV infection] Gluckman JC. **Rev Med Interne** 1995;16 Suppl 3:303s–307s (15 ref.) **(Fre)**
[Immunopathological mechanisms of human immunodeficiency virus infection] Gluckman JC. **Rev Med Interne** 1996;17(4):313–20 (69 ref.) (Eng. Abstr.) **(Fre)**
[Salivary HIV antibodies. Review of current data and future prospectives] Polimeni A, et al. **Minerva Stomatol** 1995 Dec;44(12):583–90 (20 ref.) (Eng. Abstr.) **(Ita)**
[The rapid and slow progression of HIV infection] Soriano V, et al. **Rev Clin Esp** 1995 Oct;195(10):708–14 (114 ref.) **(Spa)**

METABOLISM

Drug interactions with antiviral drugs. Taburet AM, et al. **Clin Pharmacokinet** 1996 May;30(5):385–401 (101 ref.)
Altered iron metabolism in HIV infection: mechanisms, possible consequences, and proposals for management. Boelaert JR, et al. **Infect Agents Dis** 1996 Jan;5(1):36–46 (99 ref.)
Carnitine in human immunodeficiency virus type 1 infection/acquired immune deficiency syndrome. Mintz M. **J Child Neurol** 1995 Nov;10 Suppl 2:S40–4 (50 ref.)
[Oxidative stress and HIV infection. A concept to be specified and a therapeutic approach to be studied] Constans J, et al. **Ann Med Interne (Paris)** 1995;146(7):514–9 (53 ref.) **(Fre)**

MICROBIOLOGY

The immunology of primary HIV infection: which immune responses control HIV replication? Safrit JT, et al. **Curr Opin Immunol** 1995 Aug;7(4):456–61 (36 ref.)
Bacillus piliformis infection (Tyzzer's disease) in a patient infected with HIV-1: confirmation with 16S ribosomal RNA sequence analysis. Smith KJ, et al. **J Am Acad Dermatol** 1996 Feb;34(2 Pt 2):343–8 (18 ref.)

NURSING

The overlooked epidemic: HIV in older adults [see comments] Whipple B, et al. **Am J Nurs** 1996 Feb; 96(2):22–8; quiz 29 (9 ref.) Comment in: Am J Nurs 1996 May;96(5):18.
HIV and homophobia: nurses as advocates. Mackereth PA. **J Adv Nurs** 1995 Oct;22(4):670–6 (42 ref.)
AIDS nursing care and standardized nursing language: an application of the nursing intervention classification. Davis KA. **J Assoc Nurses AIDS Care** 1995 Nov-Dec;6(6):37–44 (17 ref.)
Inquiry based learning, nursing student attitudes and the HIV patient. Cerny JE, et al. **J Nurs Educ** 1996 May; 35(5):219–22 (24 ref.)
Perinatally transmitted HIV infection. Supporting the helpers. Burr CK. **Nurs Clin North Am** 1996 Mar; 31(1):243–51 (21 ref.)
Advanced HIV disease in children. Czarniecki L. **Nurs Clin North Am** 1996 Mar;31(1):207–19 (16 ref.)
The child with HIV in day care and school. Gross EJ, et al. **Nurs Clin North Am** 1996 Mar;31(1):231–41 (24 ref.)
HIV infection. What nurses need to know. The consumer perspective. Schietinger H, et al. **Nurs Clin North Am** 1996 Mar;31(1):137–52 (21 ref.)
The specialist nurse in HIV/AIDS medicine. Whitehead CM. **Postgrad Med J** 1996 Apr;72(846):211–3 (6 ref.)

PATHOLOGY

Apoptosis during HIV infection. A cytopathic effect of HIV or an important host-defense mechanism against viruses in general? Martin SJ, et al. **Adv Exp Med Biol** 1995; 374:129–38 (46 ref.)
Programmed death of T cells in the course of HIV infection. Meyaard L, et al. **Adv Exp Med Biol** 1995;374:115–20 (27 ref.)
Systemic lupus erythematosus in two adults with human immunodeficiency virus infection. Contreras G, et al. **Am J Kidney Dis** 1996 Aug;28(2):292–5 (6 ref.)
Lymphoid changes of the nasopharyngeal and palatine tonsils that are indicative of human immunodeficiency virus infection. A clinicopathologic study of 12 cases. Wenig BM, et al. **Am J Surg Pathol** 1996 May;20(5):572–87 (76 ref.)
Langerhans cells and HIV infection. Zambruno G, et al. **Immunol Today** 1995 Nov;16(11):520–4 (43 ref.)
HIV-1-associated pathology in hemato-lymphoid organs and the experimental evaluation in the SCID-hu mouse. Kaneshima H. **Int J Hematol** 1996 Jun;63(4):253–64 (89 ref.)
Pathogenic insights from studies of lymphoid tissue from HIV-infected individuals [published erratum appears in J Acquir Immune Defic Syndr Hum Retrovirol 1996 Feb 1;11(2):210] Cohen OJ, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995;10 Suppl 1:S6–14 (59 ref.)
Role of apoptosis in HIV disease pathogenesis. Oyaizu N, et al. **J Clin Immunol** 1995 Sep;15(5):217–31 (165 ref.)
In vivo magnetic resonance spectroscopy in HIV and HIV-related brain diseases. Chang L. **Rev Neurosci** 1995 Oct-Dec;6(4):365–78 (63 ref.)
[A cystic lymphoepithelial lesion of the parotid in HIV-1-infected patients] Calderón-Osuna E, et al. **Med Clin (Barc)** 1995 Oct 14;105(12):461–3 (10 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

A decade of research on the natural history of HIV infection: Part 1. Markers. Strathdee SA, et al. **Clin Invest Med** 1996 Apr;19(2):111–20 (128 ref.)
A decade of research on the natural history of HIV infection: Part 2. Cofactors. Strathdee SA, et al. **Clin Invest Med** 1996 Apr;19(2):121–30 (118 ref.)
Markers and determinants of disease progression in children with HIV infection. The Pediatric AIDS Siena Workshop II. Pizzo PA, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995 Jan 1;8(1):30–44 (155 ref.)
Lymphoid cell resistance to glucocorticoids in HIV infection. Kawa SK, et al. **J Steroid Biochem Mol Biol** 1996 Mar; 57(5–6):259–63 (68 ref.)
Is phototherapy safe for HIV-infected individuals? Adams ML, et al. **Photochem Photobiol** 1996 Aug;64(2):234–7 (41 ref.)
99mTc DTPA transfer/permeability in patients with HIV disease. O'Doherty MJ. **Q J Nucl Med** 1995 Sep; 39(3):231–42 (60 ref.)
Long-term survivors of HIV-1 infection. Klein MR, et al. **Trends Microbiol** 1995 Oct;3(10):386–91 (53 ref.)
[Cofactors in the course of HIV infection] Meyer L, et al. **Presse Med** 1996 Mar 2–9;25(8):379–80, 382–4 (35 ref.) (Eng. Abstr.) **(Fre)**
[Clinical aspects of immunoneuroendocrine alterations in

HIV infection] Rondanelli M, et al. **Minerva Endocrinol** 1995 Jun;20(2):113–26 (78 ref.) (Eng. Abstr.) **(Ita)**

[Cytokines in persons infected with HIV and patients with AIDS] Piasecki E. **Postepy Hig Med Dosw** 1995; 49(1):125–35 (46 ref.) (Eng. Abstr.) **(Pol)**

PREVENTION & CONTROL

AIDS behind bars: preventing HIV spread among incarcerated drug injectors [editorial] Dolan K, et al. **AIDS** 1995 Aug;9(8):825–32 (72 ref.)

Economic analysis of needle exchange [editorial] Kaplan EH. **AIDS** 1995 Oct;9(10):1113–9 (20 ref.)

Enabling approaches for HIV/AIDS prevention: can we modify the environment and minimize the risk? [editorial] Tawil O, et al. **AIDS** 1995 Dec;9(12):1299–306 (76 ref.)

HIV sexual risk reduction interventions for women: a review. Wingood GM, et al. **Am J Prev Med** 1996 May–Jun; 12(3):209–17 (33 ref.)

More on women and the prevention of HIV infection [editorial; comment] Stein ZA. **Am J Public Health** 1995 Nov;85(11):1485–8 (44 ref.) Comment on: Am J Public Health 1995 Nov;85(11):1514–20. Comment on: Am J Public Health 1995 Nov;85(11):1521–5. Comment on: Am J Public Health 1995 Nov;85(11):1526–30.

Behavioural interventions in the control of human immunodeficiency virus and other sexually transmitted diseases—a review. Wong ML. **Ann Acad Med Singapore** 1995 Jul;24(4):602–7 (36 ref.)

Prophylaxis for occupational exposure to HIV. Gerberding JL. **Ann Intern Med** 1996 Sep 15;125(6):497–501 (31 ref.)

Prevention of HIV infection in primary care: current practices, future possibilities. Makadon HJ, et al. **Ann Intern Med** 1995 Nov 1;123(9):715–9 (65 ref.)

Quality of life and the spectrum of HIV infection. Holzemer WL, et al. **Annu Rev Nurs Res** 1995;13:3–29 (99 ref.)

Economic evaluation of HIV prevention programs. Holtgrave DR, et al. **Annu Rev Public Health** 1996; 17:467–88 (114 ref.)

HIV–1 prevention: interdisciplinary studies on the efficacy of bleach and development of prevention protocols. McCoy CB, et al. **Arch Immunol Ther Exp (Warsz)** 1995;43(1):1–9 (31 ref.)

Routine voluntary antepartum HIV antibody counseling and testing: a sound public health prevention strategy. Lindsay MK. **Clin Obstet Gynecol** 1996 Jun;39(2):305–15 (59 ref.)

HIV preventive vaccines. Progress to date. Esparza J, et al. **Drugs** 1995 Nov;50(5):792–804 (153 ref.)

Human immunodeficiency virus infection and AIDS in east Africa: challenges and possibilities for prevention and control. Mhalu FS, et al. **East Afr Med J** 1996 Jan; 73(1):13–9 (25 ref.)

A work–systems analysis of compliance with universal precautions among health care workers. DeJoy DM, et al. **Health Educ Q** 1996 May;23(2):159–74 (80 ref.)

Protective immunity against HIV infection: has nature done the experiment for us? Shearer GM, et al. **Immunol Today** 1996 Jan;17(1):21–4 (37 ref.)

Pediatric HIV infection: recent advances [editorial] Sen S. **Indian Pediatr** 1995 May;32(5):519–27 (41 ref.)

Syringe exchange: HIV prevention, key findings, and future directions. Paone D, et al. **Int J Addict** 1995;30(12):1647–83 (320 ref.)

Women, contraception and STDs including HIV [editorial] Carlin EM, et al. **Int J STD AIDS** 1995 Nov–Dec; 6(6):373–86 (234 ref.)

Development of vaginal microbicides for the prevention of heterosexual transmission of HIV. Pauwels R, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Mar 1;11(3):211–21 (70 ref.)

Gender–power relations and safer sex negotiation. Taylor BM. **J Adv Nurs** 1995 Oct;22(4):687–93 (46 ref.)

Reexamination of the paradigm of HIV risk reduction in adolescents. Earl DT. **J Am Osteopath Assoc** 1995 Dec; 95(12):725–8 (32 ref.)

At risk, infected, and invisible: older gay men and HIV/AIDS. Grossman AH. **J Assoc Nurses AIDS Care** 1995 Nov–Dec;6(6):13–9 (14 ref.)

Increased attention to human sexuality can improve HIV–AIDS prevention efforts: key research issues and directions. Kelly JA, et al. **J Consult Clin Psychol** 1995 Dec;63(6):907–18 (120 ref.)

HIV in adolescents. Nelson JA. **MCN Am J Matern Child Nurs** 1995 Jan–Feb;20(1):34–7 (37 ref.)

Managing HIV. Part 7: Professional issues. 7.1 HIV infection control in medical practice. Mitchell DH, et al. **Med J Aust** 1996 Jul 15;165(2):86–9 (19 ref.)

Assessing and enhancing readiness for change: implications for technology transfer. Backer TE. **NIDA Res Monogr** 1995;155:21–41 (40 ref.)

Promising social network research results and suggestions for a research agenda. Friedman SR. **NIDA Res Monogr** 1995;151:196–215 (28 ref.)

HIV and therapeutic communities. McCusker J, et al. **NIDA Res Monogr** 1994;144:232–58 (128 ref.)

Network models for HIV outreach and prevention programs for drug users. Trotter RT II, et al. **NIDA Res Monogr** 1995;151:144–80 (31 ref.)

State of the science. HIV vaccine development. Grady C, et al. **Nurs Clin North Am** 1996 Mar;31(1):25–39 (44 ref.)

Looking toward the twenty–first century. The role of nursing research in care of children and families affected by HIV. Sherwen LN, et al. **Nurs Clin North Am** 1996 Mar; 31(1):165–78 (35 ref.)

HIV infection in rural communities. Sowell RL, et al. **Nurs Clin North Am** 1996 Mar;31(1):107–23 (73 ref.)

Design of experimental synthetic peptide immunogens for prevention of HIV–1 and HTLV–I retroviral infections. Hart MK, et al. **Pharm Biotechnol** 1995;6:821–45 (175 ref.)

HIV infection in healthcare workers: risk for infection and methods of prevention. Beekmann SE, et al. **Semin Dermatol** 1995 Sep;14(3):212–8 (39 ref.)

Management of occupational exposure to HIV. Critchley SE, et al. **Semin Dermatol** 1995 Sep;14(3):235–9 (36 ref.)

The potential role of simple dermatologic surgery techniques in transmitting HIV infection. Spencer J, et al. **Semin Dermatol** 1995 Sep;14(3):219–27 (43 ref.)

Are universal precautions realistic? Gerberding JL, et al. **Surg Clin North Am** 1995 Dec;75(6):1091–104 (23 ref.)

Postexposure prophylaxis for occupational exposures to hepatitis B, hepatitis C, and human immunodeficiency virus. Henderson DK. **Surg Clin North Am** 1995 Dec; 75(6):1175–87 (51 ref.)

Are our information, education and communication–based interventions too superficial? Clarke I. **Trop Doct** 1995 Oct; 25(4):167–70 (7 ref.)

Use of BCG in high prevalence areas for HIV. Felten MK, et al. **Trop Med Parasitol** 1995 Jun;46(2):69–71 (30 ref.)

[Prevention of the risk of contamination in the operating room. Must a preoperative serologic HIV test be performed in each patients? (editorial)] Bell DM. **Ann Chir** 1996; 50(4):291–4 (25 ref.) **(Fre)**

[Acquired immunodeficiency syndrome—1995 (Part I)] Lasry Y, et al. **Harefuah** 1995 Dec 1;129(11):520–5 (50 ref.) **(Heb)**

[Effectiveness of condoms in the prevention of HIV infection in partners of seropositive subjects] Guillén Grima F, et al. **Med Clin (Barc)** 1995 Oct 28;105(14):541–8 (99 ref.) **(Spa)**

[Strategies for the prevention of human immunodeficiency virus infection] Soriano V, et al. **Rev Clin Esp** 1995 Oct; 195(10):701–7 (131 ref.) **(Spa)**

PSYCHOLOGY

Fear of AIDS and suicide in Finland: a review. Aro AR, et al. **AIDS Care** 1995;7 Suppl 2:5187–97 (60 ref.)

Suicide and AIDS: problem identification during counselling. Miller R. **AIDS Care** 1995;7 Suppl 2:5199–205 (18 ref.)

Psychological interventions in infection with the human immunodeficiency virus. Catalan J. **Br J Psychiatry** 1995 Jul;167(1):104–11 (65 ref.)

Psychiatric patients and HIV infection: a new population at risk? Stefan MD, et al. **Br J Psychiatry** 1995 Dec; 167(6):721–7 (32 ref.)

Wellness and HIV: developing a model for progression from theoretical knowledge about psychosocial factors to application. Rayner–Brosnan D. **Int J Immunopharmacol** 1995 Aug;17(8):663–76 (95 ref.)

Patients misrepresenting their risk factors for AIDS [editorial] Brody S. **Int J STD AIDS** 1995 Nov–Dec; 6(6):392–8 (75 ref.)

HIV and homophobia: nurses as advocates. Mackereth PA. **J Adv Nurs** 1995 Oct;22(4):670–6 (42 ref.)

Managing HIV. Part 3: Mechanisms of disease. 3.8 How psychosocial aspects of HIV infection can affect health. Ross MW. **Med J Aust** 1996 Feb 19;164(4):235–7 (5 ref.)

HIV risk in adolescents: the role of sexual activity and substance use behaviors. Boyer CB, et al. **NIDA Res Monogr** 1994;143:135–54 (51 ref.)

Future directions for studies on the context of HIV risk. Grace WC, et al. **NIDA Res Monogr** 1994;143:236–45 (6 ref.)

Context of HIV risk behavior among female injecting drug users and female sexual partners of injecting drug users. Hartel D. **NIDA Res Monogr** 1994;143:41–7 (31 ref.)

Substance use and HIV–transmitting behaviors among gay and bisexual men. Ostrow DG. **NIDA Res Monogr** 1994; 143:88–113 (35 ref.)

Going nowhere fast: methamphetamine use and HIV infection. Rotheram–Borus MJ, et al. **NIDA Res Monogr** 1994;143:155–82 (33 ref.)

Using focus groups in drug abuse and HIV/AIDS research. Shedlin MG, et al. **NIDA Res Monogr** 1995;157:136–55 (13 ref.)

Injection and sexual risk behaviors of male heterosexual injecting drug users. Stephens RC, et al. **NIDA Res Monogr** 1994;143:9–25 (48 ref.)

Network models for HIV outreach and prevention programs for drug users. Trotter RT II, et al. **NIDA Res Monogr** 1995;151:144–80 (31 ref.)

Drug use, AIDS, and ethnography: advanced ethnographic research methods exploring the HIV epidemic. Trotter RT 2nd. **NIDA Res Monogr** 1995;157:38–64 (10 ref.)

Ethical and legal issues in social network research: the real and the ideal. Woodhouse DE, et al. **NIDA Res Monogr** 1995;151:131–43 (11 ref.)

Pediatric and family HIV. Psychosocial concerns across the continuum of disease. Lewis SL, et al. **Nurs Clin North Am** 1996 Mar;31(1):221–30 (29 ref.)

Depression and HIV. A nursing perspective on a complex relationship. McEnany GW, et al. **Nurs Clin North Am** 1996 Mar;31(1):57–80 (103 ref.)

Stigma, HIV and AIDS: an exploration and elaboration of a stigma trajectory. Alonzo AA, et al. **Soc Sci Med** 1995 Aug;41(3):303–15 (79 ref.)

Anthropology, HIV and contingent identities. Gatter PN. **Soc Sci Med** 1995 Dec;41(11):1523–33 (71 ref.)

Health care workers and HIV/AIDS: a critical review of the literature. Horsman JM, et al. **Soc Sci Med** 1995 Dec; 41(11):1535–67 (164 ref.)

Afro–American women living with HIV infection: special therapeutic interventions for a growing population. Williams JK. **Soc Work Health Care** 1995;21(2):41–53 (30 ref.)

RADIOGRAPHY

[Differential radiologic diagnosis of HIV–associated lung diseases] Becker–Gaab C, et al. **Bildgebung** 1995 Dec; 62(4):302–9 (16 ref.) (Eng. Abstr.) **(Ger)**

REHABILITATION

Focused review: physiatric management of HIV–related disability. O'Dell MW, et al. **Arch Phys Med Rehabil** 1996 Mar;77(3 Suppl):S66–73 (59 ref.)

THERAPY

Gene therapy for HIV–1 infection. Kohn DB, et al. **Adv Exp Med Biol** 1996;394:421–8 (23 ref.)

Prospective views of HIV pathology. Clues for therapeutic strategies. Lu W, et al. **Adv Exp Med Biol** 1995;374:235–42 (74 ref.)

Enhancing HIV–1 specific immunity as a therapeutic strategy in AIDS. Schooley RT. **Adv Exp Med Biol** 1996;394:405–10 (24 ref.)

Haematopoietic growth factors as supportive therapy in HIV–infected patients. Hermans P. **AIDS** 1995 Dec;9 Suppl 2:S9–S14 (35 ref.)

Genetic therapies for HIV infections: promise for the future [editorial] Pomerantz RJ, et al. **AIDS** 1995 Sep;9(9):985–93 (64 ref.)

Gene therapy and HIV disease. Poeschla EM, et al. **AIDS Clin Rev** 1995–96;:1–45 (255 ref.)

Retroviral vectors for HIV immunotherapy. Warner JF, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:105–16 (36 ref.)

Immune–based therapies for treatment of HIV infection. Piscitelli SC, et al. **Ann Pharmacother** 1996 Jan;30(1):62–76 (45 ref.)

Management of HIV infection for the childbearing age woman. Bardeguez AD. **Clin Obstet Gynecol** 1996 Jun; 39(2):344–60 (107 ref.)

Common ethical dilemmas encountered in the management of HIV–infected women and newborns. Chervenak FA, et al. **Clin Obstet Gynecol** 1996 Jun;39(2):411–9 (16 ref.)

Progress towards gene therapy for HIV infection. Yu M, et al. **Gene Ther** 1994 Jan;1(1):13–26 (159 ref.)

Interleukin–2 and human immunodeficiency virus infection: pathogenic mechanisms and potential for immunologic enhancement. Kinter A, et al. **Immunol Res** 1996;15(1):1–15 (136 ref.)

The immune response to HIV: potential for immunotherapy? Dalgleish AG. **Immunol Today** 1995 Jul;16(7):356–8 (19 ref.)

Legal implications of treating patients with HIV. Katine M. **J Am Podiatr Med Assoc** 1995 Aug;85(8):406–19 (38 ref.)

Living wills, durable powers of attorney for health care, and HIV infection. The need for statutory reform. Loue S. **J Leg Med** 1995 Dec;16(4):461–80 (96 ref.)

Update of HIV and AIDS in North America. Flanigan TP, et al. **Med Health R I** 1996 May;79(5):180–7 (18 ref.)

Managing HIV. Part 4: Primary therapy. 4.2 Immune–based therapy for HIV infection. Benson EM, et al. **Med J Aust** 1996 Mar 4;164(5):297–300 (25 ref.)

Managing HIV. Part 5: Treating secondary outcomes. 5.19 HIV and palliative care. Glare PA, et al. **Med J Aust** 1996 May 20;164(10):612–5 (9 ref.)

Gene therapy against cancer and HIV infection using the gene encoding herpes simplex virus thymidine kinase. Caruso M. **Mol Med Today** 1996 May;2(5):212–7 (37 ref.)

Xenotransplantation at a crossroads: prevention versus progress. Allan JS. **Nat Med** 1996 Jan;2(1):18–21 (19 ref.)

Immune–based therapy for HIV. Engle J. **Nurs Clin North Am** 1996 Mar;31(1):15–23 (45 ref.)

HIV infection. Clinical research. Considerations for prospective participants. Hutchins SA, et al. **Nurs Clin North Am** 1996 Mar;31(1):125–35 (17 ref.)

Ambulatory care of the HIV–infected child. O'Hara MJ, et al. **Nurs Clin North Am** 1996 Mar;31(1):179–205 (46 ref.)

PUVA therapy is preferable to UVB phototherapy in the management of HIV–associated dermatoses. Morison WL. **Photochem Photobiol** 1996 Aug;64(2):267–8 (11 ref.)

Improving the quality of care for persons with HIV infection in sub–Saharan Africa. Colebunders R, et al. **Trop Geogr Med** 1995;47(2):78–81 (26 ref.)

[Palliative care and HIV infection. Medical benchmarks] Mallet D, et al. **Ann Med Interne (Paris)** 1995;146(7):510–3 (14 ref.) **(Fre)**

[Care for the HIV–infected person] Sierra–Madero JG. **Salud Publica Mex** 1995 Nov–Dec;37(6):520–4 (14 ref.) (Eng. Abstr.) **(Spa)**

TRANSMISSION

Rational problems associated with the development of cellular approaches in controlling HIV spread. Bourinbaiar AS, et al. **Adv Exp Med Biol** 1995;374:71–89 (142 ref.)

AIDS behind bars: preventing HIV spread among incarcerated drug injectors [editorial] Dolan K, et al. **AIDS** 1995 Aug;9(8):825–32 (72 ref.)
The sensitivity of HIV–1 DNA polymerase chain reaction in the neonatal period and the relative contributions of intra–uterine and intra–partum transmission. Dunn DT, et al. **AIDS** 1995 Sep;9(9):F7–11 (29 ref.)
Women and AIDS in Zambia: a review of the psychosocial factors implicated in the transmission of HIV. Campbell T, et al. **AIDS Care** 1995;7(3):365–73 (26 ref.)
Is there a moral obligation not to infect others? Harris J, et al. **BMJ** 1995 Nov 4;311(7014):1215–7 (9 ref.)
Injection drug use and human immunodeficiency virus infection. Alcabes P, et al. **Clin Infect Dis** 1995 Jun; 20(6):1467–79 (168 ref.)
Determinants of perinatal HIV–1 transmission. Orloff SL, et al. **Clin Obstet Gynecol** 1996 Jun;39(2):386–95 (39 ref.)
Heterosexual HIV transmission. Mayer KH, et al. **Infect Agents Dis** 1995 Dec;4(4):273–84 (112 ref.)
Women, contraception and STDs including HIV [editorial] Carlin EM, et al. **Int J STD AIDS** 1995 Nov–Dec; 6(6):373–86 (234 ref.)
The third wave: HIV infection among heterosexuals in the United States and Europe [editorial] Haverkos HW, et al. **Int J STD AIDS** 1995 Jul–Aug;6(4):227–32 (62 ref.)
Hazards to the orthopaedic trauma surgeon: occupational exposure to HIV and viral hepatitis (a review article). Chou L, et al. **J Orthop Trauma** 1996;10(4):289–96 (46 ref.)
Female drug abusers and the context of their HIV transmission risk behaviors. Allen K. **NIDA Res Monogr** 1994;143:48–63 (14 ref.)
Drug use and HIV risk among gay and bisexual men: an overview. Battjes RJ. **NIDA Res Monogr** 1994;143:82–7 (4 ref.)
Future directions for studies on the context of HIV risk. Grace WC, et al. **NIDA Res Monogr** 1994;143:236–45 (6 ref.)
Context of HIV risk behavior among female injecting drug users and female sexual partners of injecting drug users. Hartel D. **NIDA Res Monogr** 1994;143:41–7 (31 ref.)
HIV/AIDS risks among male, heterosexual noninjecting drug users who exchange crack for sex. Inciardi JA. **NIDA Res Monogr** 1994;143:26–40 (66 ref.)
Applying the methodology of participant observation to the study of injection–related HIV risks. Koester S. **NIDA Res Monogr** 1995;157:84–99 (31 ref.)
HIV risk behaviors of heterosexual male drug users. Needle RH. **NIDA Res Monogr** 1994;143:5–8 (2 ref.)
Substance use and HIV–transmitting behaviors among gay and bisexual men. Ostrow DG. **NIDA Res Monogr** 1994; 143:88–113 (35 ref.)
Drug use and HIV risk among male sex workers: results of two samples in San Francisco. Waldorf D. **NIDA Res Monogr** 1994;143:114–31 (18 ref.)
Overview of perinatally transmitted HIV infection. Boland M. **Nurs Clin North Am** 1996 Mar;31(1):155–64 (36 ref.)
Transmission of HIV infection. Cusini M. **Semin Dermatol** 1995 Sep;14(3):202–4 (34 ref.)
[HIV and family planning] Vartti AM. **Duodecim** 1994; 110(19):1765–9 (27 ref.) **(Fin)**
[Transmission of human immunodeficiency virus to the fetus during pregnancy] d'Ercole C, et al. **Presse Med** 1996 Jan 27;25(3):119–25 (41 ref.) (Eng. Abstr.) **(Fre)**
[The actual risk of retrovirus transmission from transfusions] Soriano V, et al. **Sangre (Barc)** 1995 Oct;40(5):407–16 (118 ref.) **(Spa)**

ULTRASONOGRAPHY

[Ultrasound skin findings in HIV infection by imaging with 7.5 MHz linear transducers] Bogner JR, et al. **Bildgebung** 1995 Dec;62(4):281–6 (14 ref.) (Eng. Abstr.) **(Ger)**
[Ultrasound findings in HIV patients] Lüthen R, et al. **Bildgebung** 1995 Dec;62(4):271–80 (45 ref.) (Eng. Abstr.) **(Ger)**

VIROLOGY

In vivo and in vitro infection of human Langerhans cells by HIV–1. Dezutter–Dambuyant C. **Adv Exp Med Biol** 1995;378:447–51 (26 ref.)
Correlation between viral load measurements and outcome in clinical trials of antiviral drugs. Schooley RT. **AIDS** 1995 Dec;9 Suppl 2:S15–S19 (21 ref.)
HIV viral load quantification, HIV resistance, and antiretroviral therapy. Katzenstein DA, et al. **AIDS Clin Rev** 1995–96;:277–303 (107 ref.)
Role of macrophages in the pathogenesis of human immunodeficiency virus (HIV) infection. Crowe SM. **Aust N Z J Med** 1995 Dec;25(6):777–83 (54 ref.)
Immune responses in HIV–exposed seronegatives: have they repelled the virus? Rowland–Jones SL, et al. **Curr Opin Immunol** 1995 Aug;7(4):448–55 (63 ref.)
Follicular dendritic cells and infection by human immunodeficiency virus type 1—a crucial target cell and virus reservoir. Schuurman HJ, et al. **Curr Top Microbiol Immunol** 1995;201:161–88 (170 ref.)
Knocking out human immunodeficiency virus through non–nucleoside reverse transcriptase inhibitors used as single agents or in combinations: a paradigm for the cure of AIDS? De Clercq E, et al. **Farmaco** 1995 Nov; 50(11):735–47 (48 ref.)
Viral load in peripheral blood mononuclear cells as surrogate for clinical progression. Ferre F, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995;10 Suppl 2:S51–6 (24 ref.)
Measuring viral load in the clinical setting. Harrigan R. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995;10 Suppl 1:S34–40 (26 ref.)
Viral phenotype and genotype as markers in clinical trials. Katzenstein DA. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995;10 Suppl 2:S25–34 (89 ref.)
Virologic parameters as surrogate markers for clinical outcome in HIV–1 disease: verification, variation, and validation. Reichelderfer PS, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995;10 Suppl 2:S19–24 (28 ref.)
New perspectives on HIV pathogenesis. Viral replication is continuous throughout the course of disease. **J Assoc Nurses AIDS Care** 1995 Jul–Aug;6(4):26–7 (7 ref.)
Changing the natural history of HIV disease. Feinberg MB. **Lancet** 1996 Jul 27;348(9022):239–46 (48 ref.)
Regulation of human immunodeficiency virus type 1 and cytokine gene expression in myeloid cells by NF–kappa B/Rel transcription factors. Roulston A, et al. **Microbiol Rev** 1995 Sep;59(3):481–505 (481 ref.)
Viral counts count in HIV infection [see comments] Ho DD. **Science** 1996 May 24;272(5265):1124–5 (13 ref.) Comment in: Science 1996 May 24;272(5265):1167–70.
AIDS pathogenesis: a finite immune response to blame? [comment] Miedema F, et al. **Science** 1996 Apr 26; 272(5261):505–6 (18 ref.) Comment on: Science 1996 Apr 26;272(5261):537–42.
Microbial parasites versus developing T cells: an evolutionary 'arms race' with implications for the timing of thymic involution and HIV pathogenesis. Turke PW. **Thymus** 1994–95;24(1):29–40 (52 ref.)

HIV LONG TERMINAL REPEAT

see related
GENE PRODUCTS, TAT
TRANSCRIPTION FACTOR, SP1

HIV PROTEASE

CHEMISTRY

Development of drug resistance to HIV–1 protease inhibitors. Ridky T, et al. **J Biol Chem** 1995 Dec 15;270(50):29621–3 (28 ref.)

METABOLISM

Prediction of human immunodeficiency virus protease cleavage sites in proteins. Chou KC. **Anal Biochem** 1996 Jan 1;233(1):1–14 (62 ref.)

HIV PROTEASE INHIBITORS

see related
ANTIVIRAL AGENTS

CHEMICAL SYNTHESIS

Design and synthesis of substrate–based peptidomimetic human immunodeficiency virus protease inhibitors containing the hydroxymethylcarbonyl isostere. Kiso Y. **Biopolymers** 1996;40(2):235–44 (27 ref.)

PHARMACOLOGY

Saquinavir: an HIV proteinase inhibitor. Bragman K. **Adv Exp Med Biol** 1996;394:305–17 (25 ref.)
In vivo selection of HIV–1 variants with reduced susceptibility to the protease inhibitor L–735,524 and related compounds. Emini EA, et al. **Adv Exp Med Biol** 1996;394:327–31 (8 ref.)
Perspectives in HIV protease inhibitors. Leonard JM. **Adv Exp Med Biol** 1996;394:319–25 (15 ref.)
Structural mechanisms of HIV drug resistance. Erickson JW, et al. **Annu Rev Pharmacol Toxicol** 1996;36:545–71 (74 ref.)
Development of drug resistance to HIV–1 protease inhibitors. Ridky T, et al. **J Biol Chem** 1995 Dec 15;270(50):29621–3 (28 ref.)
Closing in on human immunodeficiency virus–1 [see comments] Mellors JW. **Nat Med** 1996 Mar;2(3):274–5 (23 ref.) Comment in: Nat Med 1996 May;2(5):490.

THERAPEUTIC USE

Drug–resistance patterns of saquinavir and other HIV proteinase inhibitors. Roberts NA. **AIDS** 1995 Dec;9 Suppl 2:27–S32 (34 ref.)
Clinical experience with saquinavir. Vella S. **AIDS** 1995 Dec; 9 Suppl 2:S21–S25 (22 ref.)
Protease inhibitors: promising new weapons against HIV. Isada CM. **Cleve Clin J Med** 1996 Jul–Aug;63(4):204–8 (23 ref.)
Rationale and experience with reverse transcriptase inhibitors and protease inhibitors. Vella S. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995;10 Suppl 1:S58–61 (15 ref.)
Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society–USA. Carpenter CC, et al. **JAMA** 1996 Jul 10;276(2):146–54 (109 ref.)
Inhibitors of HIV proteinase. Martin JA, et al. **Prog Med Chem** 1995;32:239–87 (146 ref.)

HIV PROTEINASE see **HIV PROTEASE**

HIV RECEPTORS see **RECEPTORS, HIV**

HIV–RELATED LYMPHOMA see **LYMPHOMA, AIDS–RELATED**

HIV–RELATED OPPORTUNISTIC INFECTIONS see **AIDS–RELATED OPPORTUNISTIC INFECTIONS**

HIV REV GENE PRODUCT see **GENE PRODUCTS, REV**

HIV SEROCONVERSION see **HIV SEROPOSITIVITY**

HIV SERODIAGNOSIS see **AIDS SERODIAGNOSIS**

HIV SERONEGATIVITY

see related
HIV SEROPOSITIVITY

Cytomegalovirus colitis mimicking colon carcinoma in an HIV–negative patient with chronic renal failure. Falagas ME, et al. **Am J Gastroenterol** 1996 Jan;91(1):168–9 (11 ref.)
Pending problem of "silent" human immunodeficiency virus infection. Bentwich Z, et al. **Cell Mol Biol (Noisy–le–grand)** 1995 May;41(3):345–50 (42 ref.)
[Problems in the diagnosis and therapy of lymph node tuberculosis in HIV–negative patients] Canova CR, et al. **Schweiz Med Wochenschr** 1995 Dec 26;125(51–52):2511–7 (24 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Immune responses in HIV–exposed seronegatives: have they repelled the virus? Rowland–Jones SL, et al. **Curr Opin Immunol** 1995 Aug;7(4):448–55 (63 ref.)
Human studies in the development of human immunodeficiency virus vaccines. Dolin R. **J Infect Dis** 1995 Nov;172(5):1175–83 (91 ref.)

HIV SEROPOSITIVITY

see related
HIV SERONEGATIVITY
HIV SEROPREVALENCE

A surgeon with HIV. Cembrowicz S, et al. **Practitioner** 1996 Jan;240(1558):9–12 (2 ref.)
[Effectiveness of condoms in the prevention of HIV infection in partners of seropositive subjects] Guillén Grima F, et al. **Med Clin (Barc)** 1995 Oct 28;105(14):541–8 (99 ref.) **(Spa)**

COMPLICATIONS

Primary pulmonary hypertension and the human immunodeficiency virus. Report of two cases and a review of the literature. Weiss JR, et al. **Arch Intern Med** 1995 Nov 27;155(21):2350–4 (26 ref.)
Neuropathies in HIV infection. Dalakas MC, et al. **Baillieres Clin Neurol** 1996 Mar;5(1):199–218 (65 ref.)
Prevention and management of tuberculosis in HIV positive patients living in countries with a low prevalence of Mycobacterium tuberculosis. Brook MG, et al. **Genitourin Med** 1996 Apr;72(2):89–92 (34 ref.)
HIV–related primary non–Hodgkin's lymphoma of the vulva. Kaplan EJ, et al. **Gynecol Oncol** 1996 Apr;61(1):131–8 (41 ref.)
Human immunodeficiency virus and acquired immune deficiency syndrome AIDS–related hearing disorders. Madriz JJ, et al. **J Am Acad Audiol** 1995 Sep;6(5):358–64 (48 ref.)
[Cryptococcal whitlow in a HIV positive patient] Verneuil L, et al. **Ann Dermatol Venereol** 1995;122(10):688–91 (29 ref.) (Eng. Abstr.) **(Fre)**
[Pneumococcal septic arthritis in HIV infection] Trivalle C, et al. **Presse Med** 1995 Nov 4;24(33):1566–8 (13 ref.) (Eng. Abstr.) **(Fre)**
[Non–Hodgkin's lymphoma of the large intestine in an HIV–positive hemophiliac. A report of a case with an unusual presentation] Gigoni R, et al. **Radiol Med (Torino)** 1995 Sep;90(3):326–8 (11 ref.) **(Ita)**
[Primary cutaneous cryptococcosis and bacterial pneumonia caused by Pseudomonas aeruginosa in AIDS: clinical case and review of the literature] Dronda F, et al. **Enferm Infecc Microbiol Clin** 1996 Feb;14(2):101–5 (35 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

[Prevention of the risk of contamination in the operating room. Must a preoperative serologic HIV test be performed in each patients? (editorial)] Bell DM. **Ann Chir** 1996; 50(4):291–4 (25 ref.) **(Fre)**

IMMUNOLOGY

Consensus statement regarding the HIV "window period".

HIV SEROPOSITIVITY

Can Commun Dis Rep 1995 Dec 30;21(24):213–5 (4 ref.) **(Eng, Fre)**

Rethinking CD4+ T cell counts for individuals who recently seroconverted to human immunodeficiency virus. Weiss PJ, et al. **Clin Infect Dis** 1995 Sep;21(3):666–8 (17 ref.)

Opportunistic infections in HIV seropositive individuals. Gazzard BG. **J R Coll Physicians Lond** 1995 Jul–Aug; 29(4):335–9 (21 ref.)

PSYCHOLOGY

Do asymptomatic HIV-seropositive individuals show cognitive deficit? [editorial] Newman SP, et al. **AIDS** 1995 Nov;9(11):1211–20 (47 ref.)

HIV SEROPREVALENCE

Responding to the AIDS epidemic in Asia and the Pacific: report on the Third International Conference on AIDS in Asia and the Pacific, Chiang Mai, Thailand, 17–21 September, 1995. Ford NJ. **AIDS Care** 1996 Feb; 8(1):117–24 (7 ref.)

Problems in interpreting HIV sentinel seroprevalence studies. Strickler H, et al. **Ann Epidemiol** 1995 Nov;5(6):447–54 (51 ref.)

Human immunodeficiency virus infection and AIDS in east Africa: challenges and possibilities for prevention and control. Mhalu FS, et al. **East Afr Med J** 1996 Jan; 73(1):13–9 (25 ref.)

Human immunodeficiency virus and AIDS in Uganda. Mugerwa RD, et al. **East Afr Med J** 1996 Jan;73(1):20–6 (56 ref.)

Women living with HIV infection. Abercrombie PD. **Nurs Clin North Am** 1996 Mar;31(1):97–106 (56 ref.)

Use of BCG in high prevalence areas for HIV. Felten MK, et al. **Trop Med Parasitol** 1995 Jun;46(2):69–71 (30 ref.)

[The AIDS epidemic in Norway—where did it go?] Eskild A, et al. **Tidsskr Nor Laegeforen** 1996 Jan 30;116(3):382–6 (26 ref.) (Eng. Abstr.) **(Nor)**

HIV TAT PROTEIN see **GENE PRODUCTS, TAT**

HIV TRANSACTING TRANSCRIPTION PROTEIN see **GENE PRODUCTS, TAT**

HIV VACCINES see **AIDS VACCINES**

HIV-1

see related

ACQUIRED IMMUNODEFICIENCY SYNDROME

Current clinical experience with nevirapine for HIV infection. Carr A, et al. **Adv Exp Med Biol** 1996; 394:299–304 (17 ref.)

Stavudine (d4T, Zerit). Friedland G, et al. **Adv Exp Med Biol** 1996;394:271–7 (21 ref.)

Clinical experience with non-nucleoside reverse transcriptase inhibitors: L-697,661 and nevirapine. Kilby JM, et al. **Adv Exp Med Biol** 1996;394:291–8 (23 ref.)

Idiotype manipulation in disease management. Kohler H, et al. **Adv Exp Med Biol** 1995;383:117–22 (38 ref.)

Gene therapy for HIV-1 infection. Kohn DB, et al. **Adv Exp Med Biol** 1996;394:421–8 (23 ref.)

The role of the cell cycle in HIV-1 infection. Zack JA. **Adv Exp Med Biol** 1995;374:27–31 (26 ref.)

Primary esophageal lymphoma in AIDS presenting as a nonhealing esophageal ulcer. Chow DC, et al. **Am J Gastroenterol** 1996 Mar;91(3):602–3 (13 ref.)

Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration. Guillaume MP, et al. **Am J Gastroenterol** 1996 Jan;91(1):165–8 (14 ref.)

Systemic lupus erythematosus in two adults with human immunodeficiency virus infection. Contreras G, et al. **Am J Kidney Dis** 1996 Aug;28(2):292–5 (6 ref.)

HIV-1 prevention: interdisciplinary studies on the efficacy of bleach and development of prevention protocols. McCoy CB, et al. **Arch Immunol Ther Exp (Warsz)** 1995;43(1):1–9 (31 ref.)

Cytomegalovirus sinusitis. A new manifestation of AIDS. Marks SC, et al. **Arch Otolaryngol Head Neck Surg** 1996 Jul;122(7):789–91 (11 ref.)

Antiretroviral therapy of human immunodeficiency virus type-1 (HIV-1) infection. Emery S, et al. **Aust N Z J Med** 1995 Aug;25(4):344–9 (41 ref.)

Imaging methods as a diagnostic tool in neuro-AIDS. A review. Arendt G. **Bildgebung** 1995 Dec;62(4):310–9 (51 ref.)

Non Hodgkin's lymphoma of the maxilla as a first clinical manifestation of HIV infection. Report of a case. Berberi A, et al. **Bull Group Int Rech Sci Stomatol Odontol** 1995 Sep–Oct;38(3–4):77–80 (11 ref.)

Spontaneous pneumothorax in children with AIDS. Schroeder SA, et al. **Chest** 1995 Oct;108(4):1173–6 (25 ref.)

Laboratory tests for detection of human immunodeficiency virus type 1 infection. Nuwayhid NF. **Clin Diagn Lab Immunol** 1995 Nov;2(6):637–45 (126 ref.)

Thrombocytopenia in patients infected with human immunodeficiency virus: treatment update. Glatt AE, et al. **Clin Infect Dis** 1995 Aug;21(2):415–23 (92 ref.)

Clinical manifestations and implications of coinfection with Mycobacterium kansasii and human immunodeficiency virus type 1. Witzig RS, et al. **Clin Infect Dis** 1995 Jul; 21(1):77–85 (69 ref.)

Neurocognitive disorders in HIV-1 infection. HNRC Group. HIV Neurobehavioral Research Center. Grant I, et al. **Curr Top Microbiol Immunol** 1995;202:11–32 (77 ref.)

Cytotoxic T lymphocytes and HIV-1 related neurologic disorders. Kalams SA, et al. **Curr Top Microbiol Immunol** 1995;202:79–88 (51 ref.)

AIDS dementia complex and HIV-1 brain infection: a pathogenetic framework for treatment and evaluation. Price RW. **Curr Top Microbiol Immunol** 1995;202:33–54 (68 ref.)

Role for astrocytosis in HIV-1-associated dementia. Vitkovic L, et al. **Curr Top Microbiol Immunol** 1995;202:105–16 (49 ref.)

Quantitative neuropathologic assessment of HIV-1 encephalitis. Wiley CA. **Curr Top Microbiol Immunol** 1995; 202:55–61 (32 ref.)

Disseminated cutaneous Cryptococcus clinically mimicking basal cell carcinoma [letter] Murakawa GJ, et al. **Dermatol Surg** 1995 Nov;21(11):992–3 (8 ref.)

Effect of HIV infection on the incidence of lymphoma in Africa. Lucas SB, et al. **East Afr Med J** 1996 May;73(5 Suppl):S29–30 (2 ref.)

Progress towards gene therapy for HIV infection. Yu M, et al. **Gene Ther** 1994 Jan;1(1):13–26 (159 ref.)

Genetic predisposition to HIV-1 infection and acquired immune deficiency virus syndrome A review of the literature examining associations with HLA. Just JJ. **Hum Immunol** 1995 Nov;44(3):156–69 (92 ref.)

Langerhans cells and HIV infection. Zambruno G, et al. **Immunol Today** 1995 Nov;16(11):520–4 (43 ref.)

HIV-1-associated pathology in hemato-lymphoid organs and the experimental evaluation in the SCID-hu mouse. Kaneshima H. **Int J Hematol** 1996 Jun;63(4):253–64 (89 ref.)

Markers and determinants of disease progression in children with HIV infection. The Pediatric AIDS Siena Workshop II. Pizzo PA, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995 Jan 1;8(1):30–44 (155 ref.)

Virologic parameters as surrogate markers for clinical outcome in HIV-1 disease: verification, variation, and validation. Reichelderfer PS, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995;10 Suppl 2:S19–24 (28 ref.)

Immunologic and virologic markers determining progression to AIDS. Schellekens PT, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995;10 Suppl 2:S62–6 (30 ref.)

Bacillus piliformis infection (Tyzzer's disease) in a patient infected with HIV-1: confirmation with 16S ribosomal RNA sequence analysis. Smith KJ, et al. **J Am Acad Dermatol** 1996 Feb;34(2 Pt 2):343–8 (18 ref.)

Transmission of HIV-1 in the breast-feeding process. Black RF. **J Am Diet Assoc** 1996 Mar;96(3):267–74; quiz 275–6 (61 ref.)

HIV infection and leprosy—an enigma. Sankaran JR. **J Assoc Physicians India** 1995 Aug;43(8):557–9 (20 ref.)

Carnitine in human immunodeficiency virus type 1 infection/acquired immune deficiency syndrome. Mintz M. **J Child Neurol** 1995 Nov;10 Suppl 2:S40–4 (50 ref.)

Catheter-associated fungemia due to Wangiella (Exophiala) dermatitidis. Nachman S, et al. **J Clin Microbiol** 1996 Apr; 34(4):1011–3 (10 ref.)

The spectrum of non-AIDS-defining neoplastic disease in HIV infection. Remick SC. **J Investig Med** 1996 Jun; 44(5):205–15 (183 ref.)

HIV-related skin diseases. Tschachler E, et al. **Lancet** 1996 Sep 7;348(9028):659–63 (45 ref.)

AIDS and the lung. Huang L, et al. **Med Clin North Am** 1996 Jul;80(4):775–801 (114 ref.)

Managing HIV. Part 6: People living with HIV. 6.3 Children with HIV. Ziegler JB, et al. **Med J Aust** 1996 Jun 3; 164(11):672–9 (54 ref.)

Candidate AIDS vaccines. Graham BS, et al. **N Engl J Med** 1995 Nov 16;333(20):1331–9 (100 ref.)

Design of experimental synthetic peptide immunogens for prevention of HIV-1 and HTLV-1 retroviral infections. Hart MK, et al. **Pharm Biotechnol** 1995;6:821–45 (175 ref.)

The skin immune system in the course of HIV-1 infection. Henry M, et al. **Photochem Photobiol** 1996 Aug;64(2):275–9 (42 ref.)

AIDS-associated Kaposi's sarcoma: a new perspective of its pathogenesis and treatment. Ensoli B, et al. **Proc Assoc Am Physicians** 1995 Apr;107(1):8–18 (90 ref.)

HIV arthritis. Eustace SJ, et al. **Radiol Clin North Am** 1996 Mar;34(2):450–3 (46 ref.)

The gastrointestinal manifestations of pediatric AIDS. Stoane JM, et al. **Radiol Clin North Am** 1996 Jul;34(4):779–90 (44 ref.)

Human immunodeficiency virus-associated atypical mycobacterial skeletal infections. Hirsch R, et al. **Semin Arthritis Rheum** 1996 Apr;25(5):347–56 (46 ref.)

Severe pulmonary infections in AIDS patients. Gatell JM, et al. **Semin Respir Infect** 1996 Jun;11(2):119–28 (57 ref.)

Occupational risk of infection with human immunodeficiency virus. Chamberland ME, et al. **Surg Clin North Am** 1995 Dec;75(6):1057–70 (36 ref.)

Postexposure prophylaxis for occupational exposures to hepatitis B, hepatitis C, and human immunodeficiency virus. Henderson DK. **Surg Clin North Am** 1995 Dec; 75(6):1175–87 (51 ref.)

Long-term survivors of HIV-1 infection. Klein MR, et al. **Trends Microbiol** 1995 Oct;3(10):386–91 (53 ref.)

The impact of HIV-1 infection on child health in sub-Saharan Africa: the burden on the health services. Walraven G, et al. **Trop Med Int Health** 1996 Feb;1(1):3–14 (87 ref.)

Penile mass caused by the newly described organism Mycobacterium celatum. Dahl DM, et al. **Urology** 1996 Feb;47(2):266–8 (13 ref.)

Endemic mycosis complicating human immunodeficiency virus infection. Sarosi GA, et al. **West J Med** 1996 Apr; 164(4):335–40 (43 ref.)

[Left vocal cord paralysis in cytomegalovirus multifocal neuropathy in a patient with HIV infection] de La Blanchardiere A, et al. **Presse Med** 1996 Jan 27;25(3):106–7 (7 ref.) (Eng. Abstr.) **(Fre)**

[Pseudomesotheliomatous carcinoma in HIV infection] Brunner-La Rocca HP, et al. **Dtsch Med Wochenschr** 1995 Sep 29;120(39):1312–7 (38 ref.) (Eng. Abstr.) **(Ger)**

[The therapy of viral hepatitis in HIV-infected patients] Rockstroh JK, et al. **Dtsch Med Wochenschr** 1995 Dec 8; 120(49):1705–8 (29 ref.) **(Ger)**

[Cytomegalovirus disease in the AIDS patient. The current status of therapy and the outlook] Stoehr A, et al. **Dtsch Med Wochenschr** 1995 Dec 22;120(51–52):1785–8 (39 ref.) **(Ger)**

[The sexual transmission of the acquired immunodeficiency virus: the reasons for greater male-to-female than female-to-male transmission efficiency] Nicolosi A, et al. **Ann Ig** 1994 Jul–Dec;6(4–6):641–8 (88 ref.) (Eng. Abstr.) **(Ita)**

[Rhodococcus equi lung infection in AIDS patients. A report of 4 cases] Carli Moretti C, et al. **Radiol Med (Torino)** 1996 Apr;91(4):477–80 (13 ref.) **(Ita)**

[Clarithromycin combined with pyrimethamine in cerebral toxoplasmosis—a report of 2 cases] Dalston MO, et al. **Rev Soc Bras Med Trop** 1995 Oct–Dec;28(4):409–13 (11 ref.) (Eng. Abstr.) **(Por)**

[Central nervous system involvement in the acquired immunodeficiency syndrome] Gavura VV. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995; 95(2):96–100 (87 ref.) **(Rus)**

[Applications of the polymerase chain reaction (PCR) to the diagnosis of central nervous system infections] Querol JM, et al. **An Med Interna** 1996 May;13(5):235–8 (20 ref.) (Eng. Abstr.) **(Spa)**

[AIDS: the Spanish view] Schüller DA. **An R Acad Nac Med (Madr)** 1996;Spec No:157–81; discussion 181–2 (73 ref.) **(Spa)**

[Bronchogenic carcinoma and human immunodeficiency virus infection] Carrasquer C, et al. **Arch Bronconeumol** 1995 Aug–Sep;31(7):362–4 (15 ref.) (Eng. Abstr.) **(Spa)**

[Hospital pneumonia due to Xanthomonas maltophilia and AIDS (letter)] Sitges M, et al. **Arch Bronconeumol** 1996 May;32(5):259–60 (6 ref.) **(Spa)**

[Fever of unknown origin in HIV infection. New facets of an old problem (editorial)] Barbado Hernández FJ, et al. **Med Clin (Barc)** 1995 Nov 11;105(16):615–6 (24 ref.) **(Spa)**

[A cystic lymphoepithelial lesion of the parotid in HIV-1-infected patients] Calderón-Osuna E, et al. **Med Clin (Barc)** 1995 Oct 14;105(12):461–3 (10 ref.) (Eng. Abstr.) **(Spa)**

[Disseminated Kaposi's sarcoma with hepatosplenic involvement in AIDS] González-López A, et al. **Med Clin (Barc)** 1996 Apr 27;106(16):622–3 (15 ref.) (Eng. Abstr.) **(Spa)**

[Human immunodeficiency virus (HIV) infection in obstetrics and gynaecology] Balsdon MJ. **Rev Chil Obstet Ginecol** 1994;59(6):476–84 (0 ref.) (Eng. Abstr.) **(Spa)**

[Strategies for the prevention of human immunodeficiency virus infection] Soriano V, et al. **Rev Clin Esp** 1995 Oct; 195(10):701–7 (131 ref.) **(Spa)**

[The rapid and slow progression of HIV infection] Soriano V, et al. **Rev Clin Esp** 1995 Oct;195(10):708–14 (114 ref.) **(Spa)**

[Care for the patient with AIDS] Ponce-de León S, et al. **Salud Publica Mex** 1995 Nov–Dec;37(6):525–32 (30 ref.) (Eng. Abstr.) **(Spa)**

[Care for the HIV-infected person] Sierra-Madero JG. **Salud Publica Mex** 1995 Nov–Dec;37(6):520–4 (14 ref.) (Eng. Abstr.) **(Spa)**

[Two different HIV types are known. The differences may explain mechanisms of the infection] Andersson S, et al. **Lakartidningen** 1996 Jun 5;93(23):2230, 2235–6 (37 ref.) **(Swe)**

CHEMISTRY

Chemokine receptors and HIV-1: an attractive pair? Bates P. **Cell** 1996 Jul 12;86(1):1–3 (15 ref.)

HIV accessory proteins: emerging therapeutic targets. Miller RH, et al. **Mol Med** 1995 Jul;1(5):479–85 (11 ref.)

CLASSIFICATION

[HIV-1 group O (editorial)] Soriano V, et al. **Med Clin (Barc)** 1995 Oct 21;105(13):498–9 (25 ref.) **(Spa)**

DRUG EFFECTS

In vivo selection of HIV-1 variants with reduced susceptibility to the protease inhibitor L-735,524 and

related compounds. Emini EA, et al.
Adv Exp Med Biol 1996;394:327–31 (8 ref.)
Perspectives in HIV protease inhibitors. Leonard JM.
Adv Exp Med Biol 1996;394:319–25 (15 ref.)
New developments in antiretroviral drug therapy for HIV-1 infections. Johnson VA. **AIDS Clin Rev** 1995–96;:305–46 (106 ref.)
Structural mechanisms of HIV drug resistance. Erickson JW, et al. **Annu Rev Pharmacol Toxicol** 1996;36:545–71 (74 ref.)
Antiretroviral activity of stavudine (2',3'-didehydro-3'-deoxythymidine, D4T). Riddler SA, et al. **Antiviral Res** 1995 Jun;27(3):189–203 (48 ref.)
Failure of antiretroviral therapy: role of viral and cellular factors. Cinatl J Jr, et al. **Intervirology** 1994;37(6):307–14 (76 ref.)
Triple combinations: present and future. Lange JM.
J Acquir Immune Defic Syndr Hum Retrovirol 1995;10 Suppl 1:S77–82 (24 ref.)
Viral resistance and the selection of antiretroviral combinations. Larder BA.
J Acquir Immune Defic Syndr Hum Retrovirol 1995;10 Suppl 1:S28–33 (28 ref.)
Rapid screening of antiretroviral combinations. St Clair M, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995; 10 Suppl 1:S24–7 (15 ref.)
Development of drug resistance to HIV-1 protease inhibitors. Ridky T, et al. **J Biol Chem** 1995 Dec 15;270(50):29621–3 (28 ref.)
Closing in on human immunodeficiency virus-1 [see comments] Mellors JW. **Nat Med** 1996 Mar;2(3):274–5 (23 ref.) Comment in: Nat Med 1996 May;2(5):490.
Combination antiretroviral therapy for the treatment of human immunodeficiency virus type-1 infection. Wilson CC, et al. **Proc Assoc Am Physicians** 1995 Apr;107(1):19–27 (85 ref.)
[Antiretroviral therapy in HIV infection] Jablonowski H. **Med Monatsschr Pharm** 1996 Jul;19(7):196–205 (38 ref.) **(Ger)**
[The AIDS virus: strategies for attacking it] Carrasco L. **Enferm Infecc Microbiol Clin** 1995 Nov;13(9):540–9 (103 ref.) **(Spa)**

ENZYMOLOGY

Delavirdine mesylate, a potent non-nucleoside HIV-1 reverse transcriptase inhibitor. Freimuth WW.
Adv Exp Med Biol 1996;394:279–89 (42 ref.)
Non-nucleoside anti-HIV-1 reverse transcriptase inhibitors (NNRTIs): a chemical survey from lead compounds to selected drugs for clinical trials. Artico M. **Farmaco** 1996 May;51(5):305–31 (92 ref.)

GENETICS

The sensitivity of HIV-1 DNA polymerase chain reaction in the neonatal period and the relative contributions of intra-uterine and intra-partum transmission. Dunn DT, et al. **AIDS** 1995 Sep;9(9):F7–11 (29 ref.)
Retroviral vectors for HIV immunotherapy. Warner JF, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:105–16 (36 ref.)
Internal transcriptional regulatory elements in HIV-1 and other retroviruses. Verdin E, et al.
Cell Mol Biol (Noisy-le-grand) 1995 May;41(3):365–9 (26 ref.)
Transgenic models of human immunodeficiency virus type-1. Klotman PE, et al. **Curr Top Microbiol Immunol** 1996; 206:197–222 (49 ref.)
Viral load in peripheral blood mononuclear cells as surrogate for clinical progression. Ferre F, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1995;10 Suppl 2:S51–6 (24 ref.)
A defective HIV-1 vector for gene transfer to human lymphocytes. Parolin C, et al. **J Mol Med** 1995 Jun; 73(6):279–88 (176 ref.)
AIDS pathogenesis: a finite immune response to blame? [comment] Miedema F, et al. **Science** 1996 Apr 26; 272(5261):505–6 (18 ref.) Comment on: Science 1996 Apr 26;272(5261):537–42.
[Gene therapy for AIDS: current trends] Takatsuki K, et al. **Nippon Rinsho** 1996 Jan;54(1):233–41 (9 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Preferential entry and productive infection of CD4 expressing lymphoid dendritic cells by macrophage-tropic HIV-1. Cameron PU, et al. **Adv Exp Med Biol** 1995;378:429–33 (24 ref.)
Enhancing HIV-1 specific immunity as a therapeutic strategy in AIDS. Schooley RT. **Adv Exp Med Biol** 1996;394:405–10 (24 ref.)
Pending problem of "silent" human immunodeficiency virus infection. Bentwich Z, et al.
Cell Mol Biol (Noisy-le-grand) 1995 May;41(3):345–50 (42 ref.)
Unraveling the neuroimmune mechanisms for the HIV-1-associated cognitive/motor complex. Nottet HS, et al. **Immunol Today** 1995 Sep;16(9):441–8 (85 ref.)
Human antibody variable region gene usage in HIV-1 infection. Wisnewski A, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1996 Jan 1;11(1):31–8 (57 ref.)
Human studies in the development of human immunodeficiency virus vaccines. Dolin R. **J Infect Dis** 1995 Nov;172(5):1175–83 (91 ref.)
Envelope glycoproteins of human immunodeficiency virus type 1: profound influences on immune functions. Chirmule N, et al. **Microbiol Rev** 1996 Jun;60(2):386–406 (435 ref.)
Molecular biological bases of resistance to HIV/AIDS (the hypothesis with elements of the theory). Skripal IG. **Mikrobiol Z** 1995 Jul–Aug;57(4):89–105 (45 ref.)
HIV-1 Tat protein as a potential AIDS vaccine. Goldstein G. **Nat Med** 1996 Sep;2(9):960–4 (34 ref.)
Clinical considerations in vaccine trials with special reference to candidate HIV vaccines. Fast PE, et al.
Pharm Biotechnol 1995;6:97–134 (255 ref.)
AIDS pathogenesis: a finite immune response to blame? [comment] Miedema F, et al. **Science** 1996 Apr 26; 272(5261):505–6 (18 ref.) Comment on: Science 1996 Apr 26;272(5261):537–42.
[Non-Hodgkin's lymphoma of the large intestine in an HIV-positive hemophiliac. A report of a case with an unusual presentation] Gigoni R, et al.
Radiol Med (Torino) 1995 Sep;90(3):326–8 (11 ref.) **(Ita)**

ISOLATION & PURIFICATION

HIV-1 subtype O: epidemiology, pathogenesis, diagnosis, and perspectives of the evolution of HIV. Gürtler LG, et al. **Arch Virol Suppl** 1996;11:195–202 (15 ref.)
Follicular dendritic cells and infection by human immunodeficiency virus type 1—a crucial target cell and virus reservoir. Schuurman HJ, et al.
Curr Top Microbiol Immunol 1995;201:161–88 (170 ref.)
Measuring viral load in the clinical setting. Harrigan R.
J Acquir Immune Defic Syndr Hum Retrovirol 1995;10 Suppl 1:S34–40 (26 ref.)
[Novel molecular technology for HIV detection and analysis] Tamatsukuri S, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):686–95 (36 ref.) **(Jpn)**

PATHOGENICITY

In vivo and in vitro infection of human Langerhans cells by HIV-1. Dezutter-Dambuyant C. **Adv Exp Med Biol** 1995;378:447–51 (26 ref.)
Dendritic cell–T cell conjugates that migrate from normal human skin are an explosive site of infection for HIV-1. Pope M, et al. **Adv Exp Med Biol** 1995;378:457–60 (36 ref.)
Transgenic models of human immunodeficiency virus type-1. Klotman PE, et al. **Curr Top Microbiol Immunol** 1996; 206:197–222 (49 ref.)
Transgenic models to assess the neuropathogenic potential of HIV-1 proteins and cytokines. Mucke L, et al.
Curr Top Microbiol Immunol 1995;202:187–205 (98 ref.)
New perspectives on HIV pathogenesis. Viral replication is continuous throughout the course of disease.
J Assoc Nurses AIDS Care 1995 Jul–Aug;6(4):26–7 (7 ref.)
The role of human immunodeficiency virus type 1 envelope glycoproteins in virus infection. Freed EO, et al.
J Biol Chem 1995 Oct 13;270(41):23883–6 (153 ref.)
[How does HIV-1 and other retroviruses affect the nervous system?] Elovaara I. **Duodecim** 1995;111(9):826–35 (40 ref.) **(Fin)**
[Analysis of HIV-1 pathogenicity using SCID-hu mice] Kaneshima H. **Uirusu** 1995 Jun;45(1):84–7 (11 ref.) **(Jpn)**

PHYSIOLOGY

Cyclophilin and gag in HIV-1 replication and pathogenesis. Franke EK, et al. **Adv Exp Med Biol** 1995;374:217–28 (122 ref.)
Molecular basis of cell cycle dependent HIV-1 replication. Implications for control of virus burden. Stevenson M, et al. **Adv Exp Med Biol** 1995;374:33–45 (56 ref.)
Interactions of human immunodeficiency virus type 1 transactivator of transcription protein with signal transduction pathways. Garza HH Jr, et al.
Adv Neuroimmunol 1995;5(3):321–5 (27 ref.)
Role of immune activation and cytokine expression in HIV-1-associated neurologic diseases. Yoshioka M, et al. **Adv Neuroimmunol** 1995;5(3):335–58 (190 ref.)
HIV-1 virology. Simply Marvelous nuclear transport. Goldfarb DS. **Curr Biol** 1995 Jun 1;5(6):570–3 (19 ref.)
The role of CD4 in HIV envelope-mediated pathogenesis. Siliciano RF. **Curr Top Microbiol Immunol** 1996;205:159–79 (121 ref.)
The role of viral diversity in HIV pathogenesis. Goudsmit J. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995;10 Suppl 1:S15–9 (24 ref.)
Individualization of therapy using viral markers. Merigan T.
J Acquir Immune Defic Syndr Hum Retrovirol 1995;10 Suppl 1:S41–6 (28 ref.)
The role of human immunodeficiency virus type 1 envelope glycoproteins in virus infection. Freed EO, et al.
J Biol Chem 1995 Oct 13;270(41):23883–6 (153 ref.)
Oltipraz, a novel inhibitor of human immunodeficiency virus type 1 (HIV-1) replication. Prochaska HJ, et al.
J Cell Biochem Suppl 1995;22:117–25 (40 ref.)
Dendritic cells and the replication of HIV-1. Cameron P, et al. **J Leukoc Biol** 1996 Feb;59(2):158–71 (194 ref.)
Changing the natural history of HIV disease. Feinberg MB. **Lancet** 1996 Jul 27;348(9022):239–46 (48 ref.)
Regulation of human immunodeficiency virus type 1 and cytokine gene expression in myeloid cells by NF-kappa B/Rel transcription factors. Roulston A, et al.
Microbiol Rev 1995 Sep;59(3):481–505 (481 ref.)
Viral counts count in HIV infection [see comments] Ho DD. **Science** 1996 May 24;272(5265):1124–5 (13 ref.) Comment in: Science 1996 May 24;272(5265):1167–70.
[Epithelial dendritic cells and HIV-1 infection in vivo and in vitro] Dezutter-Dambuyant C, et al.
Pathol Biol (Paris) 1995 Dec;43(10):882–8 (71 ref.) (Eng. Abstr.) **(Fre)**
[Dendritic cells of spleen and blood and HIV-1 infection] Hosmalin A. **Pathol Biol (Paris)** 1995 Dec;43(10):889–96 (54 ref.) (Eng. Abstr.) **(Fre)**
[Inhibition of HIV replication by ribozyme strategy] Ohkawa J, et al. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1421–9 (32 ref.) **(Jpn)**
[Nucleosides and related compounds which act as inhibitors against replication of HIV-1] Tanaka H, et al.
Tanpakushitsu Kakusan Koso 1994 Jul;40(10):1250–60 (27 ref.) **(Jpn)**

HIV-1 ENVELOPE PROTEIN GP120 see HIV ENVELOPE PROTEIN GP120

HIV-1 PROTEASE see HIV PROTEASE

HIV-2

Effect of HIV infection on the incidence of lymphoma in Africa. Lucas SB, et al. **East Afr Med J** 1996 May;73(5 Suppl):S29–30 (2 ref.)
HIV infection and leprosy—an enigma. Sankaran JR.
J Assoc Physicians India 1995 Aug;43(8):557–9 (20 ref.)
[Infection with human immunodeficiency virus type 2—HIV-2] Christiansen CB. **Ugeskr Laeger** 1996 Mar 18; 158(12):1662–6 (37 ref.) (Eng. Abstr.) **(Dan)**
[Two different HIV types are known. The differences may explain mechanisms of the infection] Andersson S, et al.
Lakartidningen 1996 Jun 5;93(23):2230, 2235–6 (37 ref.) **(Swe)**

PATHOGENICITY

Human immunodeficiency virus type 2: human biology of the other AIDS virus. D'Aquila RT.
Curr Clin Top Infect Dis 1996;16:84–101 (86 ref.)

HIVES see URTICARIA

HL-60 CELLS

CHEMISTRY

G-protein-coupled receptors in HL-60 human leukemia cells. Klinker JF, et al. **Gen Pharmacol** 1996 Jan;27(1):33–54 (247 ref.)

HLA ANTIGENS

The human leucocyte antigen complex: its role in colorectal cancer. Ngoi SS, et al. **Ann Acad Med Singapore** 1996 Jan; 25(1):11–6 (34 ref.)
Bone marrow transplantation across HLA barriers by increasing the number of transplanted cells. Reisner Y, et al. **Immunol Today** 1995 Sep;16(9):437–40 (31 ref.)
[Human leukocyte antigen (HLA) and the related diseases] Mizuki N, et al. **Nippon Naika Gakkai Zasshi** 1995 Dec 10;84(12):2091–103 (12 ref.) **(Jpn)**

ANALYSIS

International Cell Exchange, 1994. Lau M, et al.
Clin Transpl 1994;:467–88 (46 ref.)
[Expression of HLA molecules on the surface of hepatocytes and antigen presentation] Manabe K, et al.
Nippon Rinsho 1995 Oct;53 Suppl:166–72 (20 ref.) **(Jpn)**

GENETICS

Polyglot and polymorphism. An HLA update. Nepom BS, et al. **Arthritis Rheum** 1995 Dec;38(12):1715–21 (4 ref.)
The evolution of major histocompatibility class I genes in primates. Watkins DI. **Crit Rev Immunol** 1995;15(1):1–29 (135 ref.)
Molecular genetics of systemic sclerosis. Reveille JD.
Curr Opin Rheumatol 1995 Nov;7(6):522–8 (65 ref.)
Advances in HLA genetics. Corzo D, et al.
Exp Clin Immunogenet 1995;12(3):156–70 (89 ref.)
The major histocompatibility complex in man. Buc M.
Folia Biol (Praha) 1995;41(3–4):119–22 (7 ref.)
The genetics of HLA. Schwartz DW, et al.
Folia Biol (Praha) 1995;41(3–4):123–39 (19 ref.)
Genetic predisposition to HIV-1 infection and acquired immune deficiency virus syndrome A review of the literature examining associations with HLA. Just JJ.
Hum Immunol 1995 Nov;44(3):156–69 (92 ref.)
Regulation of HLA class I loci by interferons. Girdlestone J. **Immunobiology** 1995 Jul;193(2–4):229–37 (37 ref.)
The origins of HLA-A,B,C polymorphism. Parham P, et al. **Immunol Rev** 1995 Feb;143:141–80 (57 ref.)
HLA-G transgenic mice: a model for studying expression and function at the maternal/fetal interface. Schmidt CM, et al. **Immunol Rev** 1995 Oct;147:53–65 (32 ref.)
Genetic background and environment contribute synergistically to the onset of autoimmune diseases. Luppi P, et al. **J Mol Med** 1995 Aug;73(8):381–93 (190 ref.)
Haemochromatosis: strike while the iron is hot [news] Cox T. **Nat Genet** 1996 Aug;13(4):386–8 (18 ref.)

HLA ANTIGENS

HIV and HLA: confusion or complexity? [comment] Hill AV. **Nat Med** 1996 Apr;2(4):395–6 (10 ref.) Comment on: Nat Med 1996 Apr;2(4):405–11.

The HLA system and the analysis of multifactorial genetic disease. Tomlinson IP, et al. **Trends Genet** 1995 Dec; 11(12):493–8 (49 ref.)

[Epidemiology and molecular epidemiology of type I diabetes mellitus] Yang Z, et al. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1995 Oct; 16(5):310–3 (19 ref.) **(Chi)**

[Genes and multiple sclerosis] Tienari P, et al. **Duodecim** 1994;110(7):741–8 (47 ref.) **(Fin)**

[Regulation of the expression of HLA class I genes in human trophoblasts] Le Bouteiller P. **Pathol Biol (Paris)** 1995 Sep; 43(7):628–35 (53 ref.) (Eng. Abstr.) **(Fre)**

[Genetic factors predisposing to multiple sclerosis: association with HLA system] Caminero AB, et al. **Rev Neurol** 1995 Mar–Apr;23(120):326–33 (125 ref.) **(Spa)**

IMMUNOLOGY

Antigen presentation by class I major histocompatibility complex molecules: a context for thinking about HLA–G. Parham P. **Am J Reprod Immunol** 1995 Jul;34(1):10–9 (48 ref.)

The immunology of coeliac disease. Goggins M, et al. **Ann Med Interne (Paris)** 1996;147(1):40–8 (118 ref.)

HLA and bone marrow transplantation. Eiermann TH. **Arch Immunol Ther Exp (Warsz)** 1995;43(2):83–7 (21 ref.)

Human leukocyte antigen system and the immune response to it. Nelson KA. **Clin Orthop** 1996 May;(326):35–42 (53 ref.)

Curing metastases? Gene and peptide therapy. Eisenbach L. **Curr Top Microbiol Immunol** 1996;213 (Pt 3):85–100 (150 ref.)

Histocompatibility antigens. Taylor CJ, et al. **Eye** 1995;9 (Pt 2):173–9 (81 ref.)

The role of histoincompatibility in cardiac allograft vasculopathy. Costanzo MR. **J Heart Lung Transplant** 1995 Nov–Dec;14(6 Pt 2):S180–4 (19 ref.)

Tissue antigens in tubulointerstitial and vascular rejection. van der Woude FJ, et al. **Kidney Int Suppl** 1995 Dec; 52:S11–3 (17 ref.)

Immunologic tolerance: tailored antigen. Krensky AM, et al. **Transplant Proc** 1996 Aug;28(4):2075–7 (15 ref.)

[HLA–G: a non classical antigen of major histocompatibility complex (editorial)] Carosella E, et al. **C R Acad Sci III** 1995 Aug;318(8):827–30 (19 ref.) **(Fre)**

[How do melanoma cells circumvent the immune response? Consequences for future therapy attempts and current biopsy processing] Dummer R, et al. **Schweiz Med Wochenschr** 1995 Sep 2;125(35):1638–41 (24 ref.) (Eng. Abstr.) **(Ger)**

[Characteristics of HLA II antigen expression in the rectal mucosa of children suffering form ulcerative colitis and Crohn disease] Hacsek G, et al. **Orv Hetil** 1995 Oct 15; 136(42):2279–82 (25 ref.) (Eng. Abstr.) **(Hun)**

METABOLISM

Receptors for HLA class I molecules in human NK cells. Bottino C, et al. **Semin Immunol** 1995 Apr;7(2):67–73 (23 ref.)

HLA–A2 ANTIGEN

GENETICS

Contribution of class I HLA–A2 antigen in immune reactions. Komlos L, et al. **Med Hypotheses** 1995 Jul;45(1):54–8 (41 ref.)

IMMUNOLOGY

Contribution of class I HLA–A2 antigen in immune reactions. Komlos L, et al. **Med Hypotheses** 1995 Jul;45(1):54–8 (41 ref.)

Immunologic tolerance: tailored antigen. Krensky AM, et al. **Transplant Proc** 1996 Aug;28(4):2075–7 (15 ref.)

HLA–B7 ANTIGEN

GENETICS

Direct gene transfer for treatment of human cancer. Nabel GJ, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:227–31 (40 ref.)

HLA–B27 ANTIGEN

HLA–B27 and its subtypes in world populations [editorial] Khan MA. **Curr Opin Rheumatol** 1995 Jul;7(4):263–9 (94 ref.)

Epidemiologic, clinical, and therapeutic aspects of reactive arthritis and ankylosing spondylitis. Toivanen A, et al. **Curr Opin Rheumatol** 1995 Jul;7(4):279–83 (53 ref.)

Role of HLA–B27 in spondyloarthropathies. Khare SD, et al. **Curr Top Microbiol Immunol** 1996;206:85–100 (77 ref.)

ANALYSIS

HLA–B27 and spondyloarthropathy: value for early diagnosis? Gran JT, et al. **J Med Genet** 1995 Jul; 32(7):497–501 (23 ref.)

IMMUNOLOGY

Clinical features and associated systemic diseases of HLA–B27 uveitis. Tay–Kearney ML, et al. **Am J Ophthalmol** 1996 Jan;121(1):47–56 (36 ref.)

PHYSIOLOGY

Etiopathogenesis of reactive arthritis and ankylosing spondylitis. Careless DJ, et al. **Curr Opin Rheumatol** 1995 Jul;7(4):290–8 (70 ref.)

The pathogenetic role of HLA–B27. Feltkamp TE, et al. **Immunol Today** 1996 Jan;17(1):5–7 (4 ref.)

HLA–BR ANTIGENS see **HLA–DR ANTIGENS**

HLA–C ANTIGENS

IMMUNOLOGY

[Biological role of HLA–C] Kuśnierczyk P. **Postepy Hig Med Dosw** 1995;49(1):33–45 (38 ref.) (Eng. Abstr.) **(Pol)**

HLA–D ANTIGENS

IMMUNOLOGY

Lonely MHC molecules seeking immunogenic peptides for meaningful relationships. Mellman I, et al. **Curr Opin Cell Biol** 1995 Aug;7(4):564–72 (72 ref.)

Presentation of antigen and MHC–restricted unresponsiveness. Říhová B. **Folia Biol (Praha)** 1995; 41(3–4):140–62 (28 ref.)

METABOLISM

How MHC class II molecules acquire peptide cargo: biosynthesis and trafficking through the endocytic pathway. Wolf PR, et al. **Ann Rev Cell Dev Biol** 1995; 11:267–306 (169 ref.)

On the issue of inappropriate HLA class II expression on endocrine cells: an answer to a sceptic. Todd I, et al. **J Autoimmun** 1995 Jun;8(3):313–22 (48 ref.)

PHYSIOLOGY

HLA–DM: an in vivo facilitator of MHC class II peptide loading. Roche PA. **Immunity** 1995 Sep;3(3):259–62 (31 ref.)

HLA–D–RELATED ANTIGENS see **HLA–DR ANTIGENS**

HLA–DC ANTIGENS see **HLA–DQ ANTIGENS**

HLA DNA PROBES see **DNA PROBES, HLA**

HLA–DQ ANTIGENS

GENETICS

HLA and glutamic acid decarboxylase in human insulin–dependent diabetes mellitus. Sanjeevi CB, et al. **Diabet Med** 1996 Mar;13(3):209–17 (68 ref.)

[The role of genes in the type–1 diabetes] Reijonen H, et al. **Duodecim** 1994;110(7):695–706 (54 ref.) **(Fin)**

HLA–DR ANTIGENS

HLA–DR matching in corneal transplantation. Systematic review of published evidence. Corneal Transplant Follow–up Study Collaborators. Gore SM, et al. **Transplantation** 1995 Nov 15;60(9):1033–9 (24 ref.)

ANALYSIS

[Aberrant expression of HLA–DR antigens on acinar and ductal epithelial cells of salivary glands in Sjögren's syndrome] Nakamura S, et al. **Nippon Rinsho** 1995 Oct; 53(10):2407–11 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Expression of primitive stem cell antigens on the blast cells of patients with chronic myeloid leukemia] Baryshnikov AIu. **Vestn Ross Akad Med Nauk** 1996;(3):9–13 (53 ref.) (Eng. Abstr.) **(Rus)**

GENETICS

Role of hydrophobic amino acids at position 74 of DRB1 chain in rheumatoid arthritis. Cerná M, et al. **Arch Immunol Ther Exp (Warsz)** 1995;43(2):139–44 (40 ref.)

HLA and glutamic acid decarboxylase in human insulin–dependent diabetes mellitus. Sanjeevi CB, et al. **Diabet Med** 1996 Mar;13(3):209–17 (68 ref.)

Exonic MHC–DRB polymorphisms and intronic simple repeat sequences: Janus faces of DNA sequence evolution. Schwaiger FW, et al. **Immunol Rev** 1995 Feb;143:199–224 (55 ref.)

[Allelic and haplotypic polymorphism of HLA–DR] Kuśnierczyk P. **Postepy Hig Med Dosw** 1996;50(1):1–8 (11 ref.) (Eng. Abstr.) **(Pol)**

METABOLISM

Immunologic roles of keratinocytes: expression of HLA–DR and ICAM–1 on cultured human keratinocytes and their influences on the alloimmune response. Haw CR. **J Dermatol** 1995 Nov;22(11):839–44 (20 ref.)

HLA–DR4 ANTIGEN

GENETICS

Are both genetic and reproductive associations with rheumatoid arthritis linked to prolactin? Brennan P, et al. **Lancet** 1996 Jul 13;348(9020):106–9 (40 ref.)

HLA–DR6 ANTIGEN

IMMUNOLOGY

Investigation of the association between mercury sensitization and HLA–DR6. Sato K, et al. **Contact Dermatitis** 1996 Apr;34(4):295 (5 ref.)

HLA–DRW6 see **HLA–DR6 ANTIGEN**

HLA–DW ANTIGENS see **HLA–D ANTIGENS**

HLA–MB ANTIGENS see **HLA–DQ ANTIGENS**

HLA–MT ANTIGENS see **HLA–DR ANTIGENS**

HLA TYPING see **HISTOCOMPATIBILITY TESTING**

HMG COA REDUCTASES see **HYDROXYMETHYLGLUTARYL COA REDUCTASES**

HMG PROTEINS see **HIGH MOBILITY GROUP PROTEINS**

HMN DISTAL TYPE I see **CHARCOT–MARIE DISEASE**

HMN PROXIMAL TYPE I see **WERDNIG–HOFFMANN DISEASE**

HMO see **HEALTH MAINTENANCE ORGANIZATIONS**

HMSN see **NEUROPATHIES, HEREDITARY MOTOR AND SENSORY**

HMSN TYPE I see **CHARCOT–MARIE DISEASE**

HMSN TYPE II see **NEUROPATHIES, HEREDITARY MOTOR AND SENSORY**

HMSN TYPE III see **NEUROPATHIES, HEREDITARY MOTOR AND SENSORY**

HMSN TYPE IV see **REFSUM DISEASE**

HMSN TYPE V see **SPASTIC PARAPLEGIA, HEREDITARY**

HMSN TYPE VI see **OPTIC ATROPHY, HEREDITARY**

HMSN TYPE VII see **NEUROPATHIES, HEREDITARY MOTOR AND SENSORY**

HOARSENESS

DIAGNOSIS

Two new otolaryngologic findings in child abuse. Drake AF, et al. **Arch Otolaryngol Head Neck Surg** 1995 Dec; 121(12):1417–20 (11 ref.)

The diagnosis and management of hoarseness. Berke GS, et al. **Compr Ther** 1996 Apr;22(4):251–5 (12 ref.)

HODGKIN'S DISEASE

see related
REED–STERNBERG CELLS

Hodgkin's disease: old and recent clinical concepts. Carbone A, et al. **Ann Otol Rhinol Laryngol** 1996 Sep;105(9):751–8 (69 ref.)

Who are the high–risk patients with Hodgkin's disease? Carde P. **Leukemia** 1996 Jun;10 Suppl 2:s62–7 (29 ref.)

Hodgkin's disease: from basic science to clinical application. Tesch H, et al. **Leukemia** 1996 Jun;10 Suppl 2:s74–7 (21 ref.)

CLASSIFICATION

Revised European–American Lymphoma Classification. Pileri SA, et al. **Curr Opin Oncol** 1995 Sep;7(5):401–7 (75 ref.)

Hodgkin's disease: a monoclonal lymphoproliferative disorder? Delabie J, et al. **Histopathology** 1995 Jul; 27(1):93–6 (29 ref.)

COMPLICATIONS

Coexistence of Hodgkin's disease and giant lymph node hyperplasia of the plasma–cell type (Castleman's disease). Abdel–Reheim FA, et al. **Arch Pathol Lab Med** 1996 Jan; 120(1):91–6 (27 ref.)

Primary angiitis of the central nervous system associated with Hodgkin's disease. Yuen RW, et al. **Arch Pathol Lab Med** 1996 Jun;120(6):573–6 (22 ref.)

Diamond–Blackfan anemia and malignancy. A case report and a review of the literature [see comments] van Dijken PJ, et al. **Cancer** 1995 Aug 1;76(3):517–20 (22 ref.)

Comment in: Cancer 1996 May 1;77(9):1961-2.
Langerhans' cell granulomatosis and Hodgkin's lymphoma. Report of a case. Michetti G, et al. **Minerva Med** 1996 May;87(5):243-7 (26 ref.)
Glomerulonephritis associated with malignant diseases of non-renal origin. A report of three cases and a review of the literature. Wągrowska-Danilewicz M, et al. **Pol J Pathol** 1995;46(3):195-8 (20 ref.)
[Association of mycosis fungoides and Hodgkin disease] Duhault P, et al. **Ann Med Interne (Paris)** 1995; 146(6):427-30 (17 ref.) **(Fre)**
[Mycosis fungoides and Hodgkin disease. Apropos of 2 cases] Modiano P, et al. **Ann Med Interne (Paris)** 1995; 146(6):424-7 (30 ref.) **(Fre)**
[Association between testicular germinal tumor and Hodgkin disease] Al-Aukla N, et al. **Bull Cancer (Paris)** 1995 Dec; 82(12):1072-5 (28 ref.) (Eng. Abstr.) **(Fre)**
[Hepatobiliary disease in malignant lymphoma, leukemia, and MDS] Ishikawa T. **Ryoikibetsu Shokogun Shirizu** 1995; (8):375-8 (21 ref.) **(Jpn)**
[Recurrent ulcers associated with Hodgkin's lymphoma] Lara Fernández A, et al. **Rev Clin Esp** 1996 May;196(5):337, 340-1 (15 ref.) **(Spa)**

DIAGNOSIS

Hodgkin's disease presenting as a solitary bone tumor. A report of four cases and review of the literature. Ozdemirli M, et al. **Cancer** 1996 Jan 1;77(1):79-88 (35 ref.)
Cancer and male infertility. Meirow D, et al. **Hum Reprod** 1995 Aug;10(8):2017-22 (59 ref.)

DRUG THERAPY

[Hodgkin disease: should high-risk patients be selected and chemotherapy be intensified?] Carde P. **Bull Cancer (Paris)** 1995 Aug;82(8):637-49 (58 ref.) (Eng. Abstr.) **(Fre)**

ENZYMOLOGY

Rising serum lactate dehydrogenase often caused by granulocyte-or Granulocyte-macrophage colony stimulating factor and not tumor progression in patients with lymphoma or myeloma. Sarris AH, et al. **Leuk Lymphoma** 1995 May;17(5-6):473-7 (25 ref.)

EPIDEMIOLOGY

Hodgkin's disease as an indicator of AIDS. Gerold M, et al. **Med Hypotheses** 1995 Jul;45(1):76-82 (113 ref.)
Review of Hodgkin's disease and lung cancer following non-Hodgkin's lymphoma in Rhode Island and review of the literature. Dores GM, et al. **R I Med** 1995 Nov; 78(11):317-9 (20 ref.)

ETIOLOGY

The origins of Hodgkin's disease. Michels KB. **Eur J Cancer Prev** 1995 Oct;4(5):379-88 (121 ref.)
Out of the Hodgkin's maze? [editorial] Wright DH. **J Pathol** 1995 Dec;177(4):331-3 (21 ref.)
Hodgkin's disease as an indicator of AIDS. Gerold M, et al. **Med Hypotheses** 1995 Jul;45(1):76-82 (113 ref.)
[Lymphomatoid papulosis] Dreno B. **Presse Med** 1995 Jun 24;24(23):1084-7 (13 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

t(2;5) translocations in anaplastic large cell lymphomas and Hodgkin's disease [editorial; comment] Herbst H. **J Pathol** 1996 Feb;178(2):113-5 (22 ref.) Comment on: J Pathol 1996 Feb;178(2):128-32.

IMMUNOLOGY

The immunodiagnosis of Hodgkin's disease [editorial] Carbone A, et al. **Int J Biol Markers** 1996 Jan-Mar; 11(1):1-5 (36 ref.)
Hodgkin's disease associated with IgA and IgG subclass deficiency. Zenone T, et al. **J Intern Med** 1996 Aug; 240(2):99-102 (29 ref.)
The antigen-presenting cell function of Reed-Sternberg cells. Delabie J, et al. **Leuk Lymphoma** 1995 Jun;18(1-2):35-40 (55 ref.)
[Hodgkin disease--pathogenesis and therapy] Wolf J, et al. **Ther Umsch** 1996 Feb;53(2):140-6 (24 ref.) (Eng. Abstr.) **(Ger)**

METABOLISM

Hodgkin's disease: a cytokine-producing tumor--a review. Gruss HJ, et al. **Crit Rev Oncog** 1994;5(5):473-538 (356 ref.)

PATHOLOGY

Hodgkin's disease. Lineage and clonality [editorial] Chan WC, et al. **Am J Clin Pathol** 1995 Oct;104(4):368-70 (30 ref.)
Acute cholecystitis resulting from hemobilia after tru-cut biopsy: a case report and brief review of the literature. Counihan TC, et al. **Am Surg** 1996 Sep;62(9):757-8 (5 ref.)
Hodgkin's disease developing after spontaneous remission of chronic lymphocytic leukemia. Schmidt HH, et al. **Ann Hematol** 1995 Nov;71(5):247-52 (46 ref.)
Hodgkin's disease primarily involving Waldeyer's ring. Case report and review of the literature. Dunphy CH, et al. **Arch Pathol Lab Med** 1996 Mar;120(3):285-7 (10 ref.)
The immunodiagnosis of Hodgkin's disease [editorial] Carbone A, et al. **Int J Biol Markers** 1996 Jan-Mar; 11(1):1-5 (36 ref.)
Granulomatous slack skin: a possible precursor of Hodgkin's disease. DeGregorio R, et al. **J Am Acad Dermatol** 1995 Dec;33(6):1044-7 (22 ref.)
Primary Hodgkin's disease of the lung. Chetty R, et al. **Pathology** 1995 Apr;27(2):111-4 (29 ref.)
Nodular lymphocyte predominant Hodgkin's disease and anaplastic large-cell (CD30+) lymphoma: distinct entities or nonspecific patterns? Menestrina F, et al. **Semin Diagn Pathol** 1995 Aug;12(3):256-69 (75 ref.)
[Cellular biology of Reed-Sternberg cells in Hodgkin's disease] Mikata A. **Rinsho Ketsueki** 1995 Jul;36(7):629-37 (81 ref.) **(Jpn)**
[Acute respiratory failure in hemoblastoses: the types of diffuse lung lesions] Gorelov VG, et al. **Ter Arkh** 1995; 67(7):52-6 (17 ref.) **(Rus)**

PHYSIOPATHOLOGY

[Clinical aspects and primary therapy of Hodgkin's lymphomas] Sieber M, et al. **Schweiz Rundsch Med Prax** 1996 Mar 19;85(12):364-70 (18 ref.) (Eng. Abstr.) **(Ger)**

RADIOGRAPHY

Progressive mediastinal widening after therapy for Hodgkin's disease. Michel F, et al. **Acta Clin Belg** 1995;50(5):282-7 (36 ref.)
[Hodgkin's lymphoma: an unusual pulmonary location. A case report] Drago A, et al. **Radiol Med (Torino)** 1996 Jan-Feb;91(1-2):132-5 (7 ref.) **(Ita)**

RADIONUCLIDE IMAGING

Somatostatin-receptor imaging in lymphoma. Goldsmith SJ, et al. **Semin Nucl Med** 1995 Jul;25(3):262-71 (13 ref.)

RADIOTHERAPY

Mantle irradiation for Hodgkin's disease during pregnancy: safe and practical? [editorial; comment] Byram D. **Australas Radiol** 1996 May;40(2):101-3 (30 ref.) Comment on: Australas Radiol 1996 May;40(2):146-8.
Breast cancer following treatment for Hodgkin's disease: the need for screening in a young population. Australasian Radiation Oncology Lymphoma Group (AROLG) [see comments] O'Brien PC, et al. **Australas Radiol** 1995 Aug; 39(3):271-6 (30 ref.) Comment in: Australas Radiol 1995 Aug;39(3):207.
The case against the routine use of radiation therapy in advanced-stage Hodgkin's disease. Longo DL. **Cancer Invest** 1996;14(4):353-60 (49 ref.)
The case for adjuvant radiation therapy in advanced Hodgkin's disease. Prosnitz LR, et al. **Cancer Invest** 1996; 14(4):361-70 (77 ref.)
Review of five consecutive studies of radiolabeled immunoglobulin therapy in Hodgkin's disease. Vriesendorp HM, et al. **Cancer Res** 1995 Dec 1;55(23 Suppl):5888s-5892s (15 ref.)
Current role of radiotherapy in Hodgkin's and non-Hodgkin's lymphoma. Shulman LN, et al. **Curr Opin Oncol** 1995 Sep;7(5):421-5 (12 ref.)
Supradiaphragmatic early stage Hodgkin's disease: does mantle radiation therapy still have a role? Frezza G, et al. **Haematologica** 1996 Mar-Apr;81(2):138-42 (50 ref.)
[Radiotherapy of lymphogranulomatosis in adulthood] Dühmke E. **Schweiz Rundsch Med Prax** 1996 Mar 19; 85(12):371-7 (35 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Hodgkin's disease: basing treatment decisions on prognostic factors. Faguet GB. **Leuk Lymphoma** 1995 Apr; 17(3-4):223-8 (34 ref.)
Intensive therapy and autologous stem cell transplantation for Hodgkin's disease in first relapse after combination chemotherapy. Reece DE, et al. **Leuk Lymphoma** 1996 Apr; 21(3-4):245-53 (55 ref.)
[Prognosis and therapy of Hodgkin's disease] Hartmann F, et al. **Med Klin** 1996 Apr 12;91 Suppl 3:75-9 (46 ref.) **(Ger)**
[Current therapy concepts in early and intermediate stages of Hodgkin diseases in adults] Glanzmann C, et al. **Schweiz Rundsch Med Prax** 1995 Oct 10;84(41):1140-7 (51 ref.) (Eng. Abstr.) **(Ger)**
[Clinical aspects and primary therapy of Hodgkin's lymphomas] Sieber M, et al. **Schweiz Rundsch Med Prax** 1996 Mar 19;85(12):364-70 (18 ref.) (Eng. Abstr.) **(Ger)**
[Second malignant disease in patients under treatment for malignant lymphoma] Várady E, et al. **Orv Hetil** 1995 Oct 22;136(43):2323-8 (35 ref.) (Eng. Abstr.) **(Hun)**
[Progress and controversy in treatment of Hodgkin's disease] Robak T. **Acta Haematol Pol** 1995;26(4):343-52 (42 ref.) (Eng. Abstr.) **(Pol)**

VIROLOGY

The role of Epstein-Barr virus in Hodgkin's disease from different geographical areas. Weinreb M, et al. **Arch Dis Child** 1996 Jan;74(1):27-31 (34 ref.)

HOG CHOLERA

IMMUNOLOGY

[Immune reactions and mechanisms in classical swine fever] Kolontsov AA, et al. **Mol Gen Mikrobiol Virusol** 1995 Apr-Jun;(2):18-21 (46 ref.) (Eng. Abstr.) **(Rus)**

HOGNESS BOX see **TATA BOX**

HOLISTIC HEALTH

Holistic risk assessment: an emerging process for environmental decisions. Harvey T, et al. **Regul Toxicol Pharmacol** 1995 Oct;22(2):110-7 (62 ref.)

HOLISTIC NURSING

The spiritual dimension: its importance to patients' health, well-being and quality of life and its implications for nursing practice. Ross L. **Int J Nurs Stud** 1995 Oct; 32(5):457-68 (66 ref.)
Spirituality as integrative energy': a philosophical analysis as requisite precursor to holistic nursing practice. Goddard NC. **J Adv Nurs** 1995 Oct;22(4):808-15 (40 ref.)
An analysis of altruism: a concept of caring. Smith A. **J Adv Nurs** 1995 Oct;22(4):785-90 (22 ref.)
Spiritual care of the school-age child with a chronic condition. Fulton RA, et al. **J Pediatr Nurs** 1995 Aug; 10(4):224-31 (56 ref.)

HOLOENZYMES see **COENZYMES**

HOLOPROSENCEPHALY

EMBRYOLOGY

Apoptosis in the developing CNS. Naruse I, et al. **Prog Neurobiol** 1995 Oct;47(2):135-55 (152 ref.)

HOLTER MONITORING see **ELECTROCARDIOGRAPHY, AMBULATORY**

HOME BLOOD GLUCOSE MONITORING see **BLOOD GLUCOSE SELF-MONITORING**

HOME CARE, NON-PROFESSIONAL see **HOME NURSING**

HOME CARE SERVICES

Domiciliary oxygen. Wilkinson J, et al. **Br J Clin Pract** 1996 Apr-May;50(3):151-3 (8 ref.)
Current status of home uterine activity monitoring. Iams JD. **Clin Obstet Gynecol** 1995 Dec;38(4):771-9 (35 ref.)
Intervention model for substance-using women. Tiedje LB, et al. **Image J Nurs Sch** 1996 Summer;28(2):113-8 (69 ref.)
A model of home care for high-risk childbearing families. Women with diabetes in pregnancy. Persily CA, et al. **Nurs Clin North Am** 1996 Jun;31(2):327-32 (11 ref.)
Use of ultrasonography in the home care of high-risk childbearing women. Stringer M. **Nurs Clin North Am** 1996 Jun;31(2):305-12 (17 ref.)
Pulmonary rehabilitation at home [editorial] Wijkstra PJ. **Thorax** 1996 Feb;51(2):117-8 (18 ref.)
[Prevalence of autistic states in a cohort of very young children followed up in home care] Drossart F, et al. **Acta Psychiatr Belg** 1995 May-Jun;95(3):122-38 (64 ref.) (Eng. Abstr.) **(Fre)**
[Respirator dependency. Intensive care unit or home ventilation?] Criée CP, et al. **Internist (Berl)** 1995 Aug; 36(8):812-7 (16 ref.) **(Ger)**
["Home monitoring" does not prevent crib death. Managing possibilities and results of new technology (see comments)] Rognum TO. **Tidsskr Nor Laegeforen** 1995 Sep 20; 115(22):2790-3 (21 ref.) (Eng. Abstr.) Comment in: Tidsskr Nor Laegeforen 1995 Nov 10;115(27):3419-20. **(Nor)**

ORGANIZATION & ADMINISTRATION

Quality of life and caregiving in technological home care. Smith CE. **Annu Rev Nurs Res** 1996;14:95-118 (141 ref.)
Technology and home care. Smith CE. **Annu Rev Nurs Res** 1995;13:137-67 (234 ref.)
A systematic overview of the effectiveness of home visiting as a delivery strategy for public health nursing interventions. Ciliska D, et al. **Can J Public Health** 1996 May-Jun;87(3):193-8 (17 ref.)
Haemophilia care in Zimbabwe. Adewuyi JO, et al. **Cent Afr J Med** 1996 May;42(5):153-6 (15 ref.)
The medical director in non-institutional long-term care programs. Finucane TE, et al. **Clin Geriatr Med** 1995 Aug; 11(3):391-402 (15 ref.)
Home healthcare: the role of the primary care physician. Goldberg AI. **Compr Ther** 1995 Nov;21(11):633-8 (20 ref.)
Care at home and quality of life: an overview of the issues. Henwood M. **J R Soc Health** 1995 Oct;115(5):323-5 (6 ref.)

STANDARDS

Applying the 1995 JCAHO standards to dietetics practice

HOME CARE SERVICES

in home care. Westbrook NH. **J Am Diet Assoc** 1996 Apr; 96(4):404–6 (5 ref.)

TRENDS

The development of Ontario's Home Care Program: a critical geographical analysis. Williams AM. **Soc Sci Med** 1996 Mar;42(6):937–48 (52 ref.)

HOME CARE SERVICES, HOSPITAL-BASED

[Home days ratio in patients treated with long-term oxygen therapy] Ando M, et al.
Nippon Kyobu Shikkan Gakkai Zasshi 1995 Oct; 33(10):1086–92 (7 ref.) (Eng. Abstr.) **(Jpn)**

HOME CHILDBIRTH

Home birth with certified nurse-midwife attendants in the United States. An overview. Jackson ME, et al.
J Nurse Midwifery 1995 Nov–Dec;40(6):493–507 (118 ref.)
Informed consent and home birth. Spindel PG, et al.
J Nurse Midwifery 1995 Nov–Dec;40(6):541–69 (56 ref.)
[Contra home delivery] Berg D. **Arch Gynecol Obstet** 1995; 257(1–4):520–4 (11 ref.) **(Ger)**

NURSING

Neonatal considerations when birth occurs at home. Toepke ML, et al. **J Nurse Midwifery** 1995 Nov–Dec;40(6):529–33 (29 ref.)

STANDARDS

In pursuit of excellence: quality assurance, documentation, and peer review by home birth CNMs. Morales ME, et al. **J Nurse Midwifery** 1995 Nov–Dec;40(6):555–69 (56 ref.)
Care of the at-risk neonate born at home. A model for nurse-midwife/physician collaboration. Sullivan NH, et al. **J Nurse Midwifery** 1995 Nov–Dec;40(6):534–40 (16 ref.)

HOME HEMODIALYSIS see **HEMODIALYSIS, HOME**

HOME INFUSION THERAPY

see related
PARENTERAL NUTRITION, HOME

[Continuous spinal analgesia in home care of oncologic pain] Ricci V, et al. **Minerva Med** 1995 Oct;86(10):409–14 (30 ref.) (Eng. Abstr.) **(Ita)**

HOME NURSING

The team approach to the management of children on chronic peritoneal dialysis. Harvey E, et al.
Adv Ren Replace Ther 1996 Jan;3(1):3–13 (59 ref.)
Home nebuliser-compressors. Ariyananda PL, et al.
Br J Hosp Med 1995 Nov 15–Dec 12;54(10):489–93 (22 ref.)
Believing and dreaming to improve cancer care. Given BA. **Oncol Nurs Forum** 1995 Jul;22(6):929–40 (36 ref.)
Explication of the construct of shared care and the prevention of pressure ulcers in home health care. Sebern MD.
Res Nurs Health 1996 Jun;19(3):183–92 (50 ref.)
["Home monitoring" does not prevent crib death. Managing possibilities and results of new technology (see comments)] Rognum TO. **Tidsskr Nor Laegeforen** 1995 Sep 20; 115(22):2790–3 (21 ref.) (Eng. Abstr.) Comment in: Tidsskr Nor Laegeforen 1995 Nov 10;115(27):3419–20. **(Nor)**

TRENDS

The household context for women's health care decisions: impacts of U.K. policy changes. Young R.
Soc Sci Med 1996 Mar;42(6):949–63 (92 ref.)

HOME PARENTERAL NUTRITION see **PARENTERAL NUTRITION, HOME**

HOME REMEDIES see **MEDICINE, TRADITIONAL**

HOMELESS CHILDREN see **HOMELESS YOUTH**

HOMELESS PERSONS

Physical health of homeless adults. Lindsey AM.
Annu Rev Nurs Res 1995;13:31–61 (112 ref.)
Mental health problems of homeless women and differences across subgroups. Robertson MJ, et al.
Annu Rev Public Health 1996;17:311–36 (74 ref.)
Access to substance abuse treatment for homeless women of reproductive age. Wenzel SL, et al.
J Psychoactive Drugs 1996 Jan–Mar;28(1):17–30 (110 ref.)
Enhancing perinatal outcome in homeless women: the challenge of providing comprehensive health care. Beal AC, et al. **Semin Perinatol** 1995 Aug;19(4):307–13 (19 ref.)

PSYCHOLOGY

Housing for persons with co-occurring mental and addictive disorders. Osher FC, et al. **New Dir Ment Health Serv** 1996 Summer;(70):53–64 (37 ref.)

HOMELESS YOUTH

Service delivery strategies for treating high-risk youth: delinquents, homeless, runaways, and sexual minorities. Farrow JA. **NIDA Res Monogr** 1995;156:39–48 (23 ref.)

HOMEOBOX PROTEINS see **HOMEODOMAIN PROTEINS**

HOMEOBOX SEQUENCE see **GENES, HOMEOBOX**

HOMEODOMAIN PROTEINS

BIOSYNTHESIS

Retinoids and Hox genes. Marshall H, et al. **FASEB J** 1996 Jul;10(9):969–78 (62 ref.)
Homeobox genes and male reproductive development. Lindsey S, et al. **J Assist Reprod Genet** 1996 Feb; 13(2):182–92 (49 ref.)

CHEMISTRY

Protein interactions of homeodomain proteins. Vershon AK. **Curr Opin Biotechnol** 1996 Aug;7(4):392–6 (36 ref.)
Homeodomain interactions. Wolberger C.
Curr Opin Struct Biol 1996 Feb;6(1):62–8 (39 ref.)
A heterodimeric transcriptional repressor becomes crystal clear [comment] Andrews BJ, et al. **Science** 1995 Oct 13; 270(5234):251–3 (18 ref.) Comment on: Science 1995 Oct 13;270(5234):262–9. Comment on: Science 1995 Oct 13;270(5234):262–9. Comment on: Science 1995 Oct 13;270(5234):290–3.
The enigma of LIM domains. Gill GN. **Structure** 1995 Dec 15;3(12):1285–9 (31 ref.)
Homeodomains: together again for the first time. Tullius T. **Structure** 1995 Nov 15;3(11):1143–5 (15 ref.)

GENETICS

The specificity of homeotic gene function. Mann RS.
Bioessays 1995 Oct;17(10):855–63 (74 ref.)
A class act: conservation of homeodomain protein functions. Manak JR, et al. **Dev Suppl** 1994;:61–77 (230 ref.)
Hox genes and the evolution of diverse body plans. Akam M. **Philos Trans R Soc Lond B Biol Sci** 1995 Sep 29; 349(1329):313–9 (52 ref.)
Developmental control of N-CAM expression by Hox and Pax gene products. Edelman GM, et al.
Philos Trans R Soc Lond B Biol Sci 1995 Sep 29; 349(1329):305–12 (33 ref.)

METABOLISM

Protein interactions of homeodomain proteins. Vershon AK. **Curr Opin Biotechnol** 1996 Aug;7(4):392–6 (36 ref.)
[Interaction of Oct-proteins with DNA] Stepchenko AG, et al. **Mol Biol (Mosk)** 1996 May–Jun;30(3):503–13 (46 ref.) **(Rus)**

PHYSIOLOGY

Function of homeobox genes in skeletal development. Capecchi MR. **Ann N Y Acad Sci** 1996 Jun 8;785:34–7 (11 ref.)
The role of transcription factors in the pituitary expression of the glycoprotein hormone alpha-subunit gene. Aylwin SJ, et al. **J Mol Endocrinol** 1995 Dec;15(3):221–31 (82 ref.)

HOMEOPATHY

Understanding homeopathy. Der Marderosian AH.
J Am Pharm Assoc (Wash) 1996 May;NS36(5):317–21 (7 ref.)

HOMEOPROTEINS see **HOMEODOMAIN PROTEINS**

HOMEOSTASIS

see related
NEUROIMMUNOMODULATION

Effect of hypoxaemia on water and sodium homeostatic hormones and renal function. Olsen NV.
Acta Anaesthesiol Scand Suppl 1995;107:165–70 (55 ref.)
Regulation of matrix metalloproteinases during extracellular matrix turnover. Corcoran ML, et al.
Adv Exp Med Biol 1995;385:151–9; discussion 179–84 (53 ref.)
Control of intermittent ventilation in lower vertebrates. A computer dynamic model. Topor ZL, et al.
Adv Exp Med Biol 1995;393:21–2 (4 ref.)
Regulation of sodium-calcium exchange in intact myocytes by ATP and calcium. Haworth RA, et al.
Ann N Y Acad Sci 1996 Apr 15;779:464–79 (42 ref.)
Sodium-calcium exchange and calcium homeostasis in transfected Chinese hamster ovary cells. Reeves JP, et al.
Ann N Y Acad Sci 1996 Apr 15;779:73–85 (27 ref.)
Regulation of the bovine retinal rod Na–Ca+K exchanger. Schnetkamp PP, et al. **Ann N Y Acad Sci** 1996 Apr 15; 779:336–45 (24 ref.)
The nature of the ponderostat: Hervey's hypothesis revived. Cabanac M, et al. **Appetite** 1996 Feb;26(1):45–54 (77 ref.)
Physiological control of metabolic flux: the requirement for multisite modulation. Fell DA, et al. **Biochem J** 1995 Oct 1;311 (Pt 1):35–9 (48 ref.)
Metabolic control and metabolic capacity: two aspects of creatine kinase functioning in the cells. Saks VA, et al. **Biochim Biophys Acta** 1996 Jun 13;1274(3):81–8 (57 ref.)
Behavioral regulation of gonadotropin-releasing hormone. Rissman EF. **Biol Reprod** 1996 Feb;54(2):413–9 (89 ref.)
Blood supply, blood flow and autoregulation in the adenohypophysis, and altered patterns in oestrogen-induced adenomatous hyperplasia. Jakubowski J. **Br J Neurosurg** 1995;9(3):331–46 (103 ref.)
Education, homeostasis, and longevity. Timiras PS.
Exp Gerontol 1995 May–Aug;30(3–4):189–98 (41 ref.)
Modulation of coronary autoregulatory responses by endothelium-derived nitric oxide. Canty JM Jr, et al.
Int J Cardiol 1995 Jul;50(3):207–15 (27 ref.)
Metabolic regulation: a control analytic perspective. Hofmeyr JH. **J Bioenerg Biomembr** 1995 Oct;27(5):479–90 (30 ref.)
Elusive control. Westerhoff HV, et al.
J Bioenerg Biomembr 1995 Oct;27(5):491–7 (54 ref.)
Intracellular calcium modulators for cardiac muscle in pathological conditions. Ishide N. **Jpn Heart J** 1996 Jan; 37(1):1–17 (80 ref.)
Homeostatic maintenance regulated by hypothalamic neuronal histamine. Sakata T, et al.
Methods Find Exp Clin Pharmacol 1995 Nov;17 Suppl C:51–6 (39 ref.)
Regulation of cell volume in health and disease. McManus ML, et al. **N Engl J Med** 1995 Nov 9;333(19):1260–6 (53 ref.)
Free radicals and disruption of neuronal ion homeostasis in AD: a role for amyloid beta-peptide? [comment] Mattson MP. **Neurobiol Aging** 1995 Jul–Aug;16(4):679–82; discussion 683 (40 ref.) Comment on: Neurobiol Aging 1995 Jul–Aug;16(4):661–74.
Drug addiction: the yin and yang of hedonic homeostasis. Koob GF. **Neuron** 1996 May;16(5):893–6 (25 ref.)
Energy homeostasis, autonomic activity and obesity. Scheurink AJ, et al. **Obes Res** 1995 Dec;3 Suppl 5:721S–727S (54 ref.)
Regulation of gut glutamine metabolism: role of hormones and cytokines. Abumrad NN, et al. **Proc Nutr Soc** 1995 Jul;54(2):525–33 (33 ref.)
[Natriuretic peptides and the homeostasis of renal circulation in cirrhosis (editorial)] Jiménez W.
Gastroenterol Hepatol 1995 Nov;18(9):477–9 (20 ref.) **(Spa)**

DRUG EFFECTS

Effects of growth hormone on phosphocalcium homeostasis and bone metabolism. Saggese G, et al. **Horm Res** 1995; 44 Suppl 3:55–63 (86 ref.)

IMMUNOLOGY

The immune system and integrated homeostasis. Husband AJ. **Immunol Cell Biol** 1995 Aug;73(4):377–82 (63 ref.)
Fas and FasL in the homeostatic regulation of immune responses. Lynch DH, et al. **Immunol Today** 1995 Dec; 16(12):569–74 (61 ref.)

PHYSIOLOGY

Membrane abnormalities and Ca homeostasis in muscles of the mdx mouse, an animal model of the Duchenne muscular dystrophy: a review. Gillis JM. **Acta Physiol Scand** 1996 Mar;156(3):397–406 (57 ref.)
Lactate/proton co-transport in skeletal muscle: regulation and importance for pH homeostasis. Juel C.
Acta Physiol Scand 1996 Mar;156(3):369–74 (29 ref.)
The need to consider functional endpoints in defining nutrient requirements. King J. **Am J Clin Nutr** 1996 Jun; 63(6):983S–984S (10 ref.)
Cardiac surgical implications of calcium dyshomeostasis in the heart. Meldrum DR, et al. **Ann Thorac Surg** 1996 Apr; 61(4):1273–80 (61 ref.)
Observations on delta homeostasis, the one-stimulus model of NREM-REM alternation and the neurobiologic implications of experimental dream studies. Feinberg I, et al. **Behav Brain Res** 1995 Jul–Aug;69(1–2):97–108 (56 ref.)
Atrial natriuretic peptide and body fluid homeostasis: leading actor or bit-part player? Richards AM, et al.
Cardiologia 1995 Sep;40(9):643–50 (71 ref.)
Calcium homeostasis in pregnancy. Hosking DJ.
Clin Endocrinol (Oxf) 1996 Jul;45(1):1–6 (45 ref.)
Anteroventral wall of the third ventricle and dorsal lamina terminalis: headquarters for control of body fluid homeostasis? McKinley MJ, et al.
Clin Exp Pharmacol Physiol 1996 Apr;23(4):271–81 (96 ref.)
Regulation of adipose maturation and energy homeostasis. Yeh WC, et al. **Curr Opin Cell Biol** 1995 Dec;7(6):885–90 (57 ref.)
Potassium homeostasis and hyperkalemic syndromes. Clark BA, et al. **Endocrinol Metab Clin North Am** 1995 Sep; 24(3):573–91 (84 ref.)
Cytokines in aging and muscle homeostasis. Cannon JG.
J Gerontol A Biol Sci Med Sci 1995 Nov;50 Spec No:120–3 (39 ref.)
Role of hepatic receptors in controlling body fluid homeostasis. Morita H, et al. **Jpn J Physiol** 1995; 45(3):355–68 (47 ref.)
The importance of calcium in the control of salt intake. Tordoff MG. **Neurosci Biobehav Rev** 1996;20(1):89–99 (104 ref.)

Normal and abnormal calcium homeostasis in neurons: a basis for the pathophysiology of traumatic and ischemic central nervous system injury. Tymianski M, et al. **Neurosurgery** 1996 Jun;38(6):1176–95 (300 ref.)
Biochemical aspects of iron metabolism, transport and regulation. Goldenberg H, et al. **Wien Klin Wochenschr** 1995;107(22):669–76 (102 ref.)
[Reactive oxygen species and homeostasis] Wilhelm J. **Cesk Fysiol** 1995 Jun;44(2):86–91 (50 ref.) (Eng. Abstr.) **(Cze)**
[Glutathione homeostasis: the cardinal physiological defense against oxygen toxicity induced by physical exercise] Sen CK, et al. **Fiziol Zh Im I M Sechenova** 1995 Nov; 81(11):143–50 (15 ref.) **(Rus)**
[Current concepts of the interactions of regulating systems: nervous, endocrine and immune] Akmaev IG. **Usp Fiziol Nauk** 1996 Jan–Mar;27(1):3–20 (129 ref.) (Eng. Abstr.) **(Rus)**
[The regulation of calcium homeostasis in nerve cells] Kozlovskii VL. **Usp Fiziol Nauk** 1995 Jul–Sep;26(3):14–24 (105 ref.) (Eng. Abstr.) **(Rus)**

HOMEOTIC GENES see **GENES, HOMEOBOX**

HOMES FOR THE AGED

see related
HOUSING FOR THE ELDERLY

Pain evaluation and management in the nursing home. Ferrell BA. **Ann Intern Med** 1995 Nov 1;123(9):681–7 (75 ref.)
Nutritional issues in nursing home care. Morley JE, et al. **Ann Intern Med** 1995 Dec 1;123(11):850–9 (90 ref.)
Epidemiology of adverse drug events in the nursing home setting. Monette J, et al. **Drugs Aging** 1995 Sep;7(3):203–11 (57 ref.)
The effect of living in a nursing home on socialization in elderly people. Jacelon CS. **J Adv Nurs** 1995 Sep; 22(3):539–46 (25 ref.)
Prevention and screening in the nursing home. Gershman K, et al. **Prim Care** 1995 Dec;22(4):731–53 (106 ref.)

ECONOMICS

Long-term care reimbursement issues. Stone D, et al. **Clin Geriatr Med** 1995 Aug;11(3):517–29 (19 ref.)

LEGISLATION & JURISPRUDENCE

Barriers to forgoing nutrition and hydration in nursing homes. Meisel A. **Am J Law Med** 1995;21(4):335–82 (274 ref.)

ORGANIZATION & ADMINISTRATION

Academics and the nursing home. Katz PR, et al. **Clin Geriatr Med** 1995 Aug;11(3):503–16 (36 ref.)
Policy and procedure development and implementation. Levenson SA. **Clin Geriatr Med** 1995 Aug;11(3):449–65 (8 ref.)
Current role of the medical director in community-based nursing facilities. Levinson MJ, et al. **Clin Geriatr Med** 1995 Aug;11(3):343–58 (10 ref.)
Total quality management and the medical director. Schnelle JF. **Clin Geriatr Med** 1995 Aug;11(3):433–48 (21 ref.)
The future of long-term care and the role of the medical director. Willging P. **Clin Geriatr Med** 1995 Aug; 11(3):531–45 (10 ref.)
Infection control in long-term care. Yoshikawa TT, et al. **Clin Geriatr Med** 1995 Aug;11(3):467–80 (65 ref.)
Geropsychiatric public sector nursing: placement challenges. Fuller K, et al. **J Psychosoc Nurs Ment Health Serv** 1995 Aug;33(8):20–2 (6 ref.)

STANDARDS

Ethical and legal issues in nursing home care. Hayley DC, et al. **Arch Intern Med** 1996 Feb 12;156(3):249–56 (65 ref.)

HOMESICKNESS see **ANXIETY, SEPARATION**

HOMICIDE

Combined homicide-suicides: a review. Felthous AR, et al. **J Forensic Sci** 1995 Sep;40(5):846–57 (40 ref.)
[Women and capital offense] Räsänen P, et al. **Duodecim** 1994; 110(4):403–6 (31 ref.) **(Fin)**

LEGISLATION & JURISPRUDENCE

[Some medico-psychological perspectives on sexual homicides. Three cases] Bénézech M. **Ann Med Psychol (Paris)** 1995 Oct;153(8):501–11 (22 ref.) (Eng. Abstr.) **(Fre)**

PSYCHOLOGY

Dangerous delusional misidentification and homicide. Silva JA, et al. **J Forensic Sci** 1996 Jul;41(4):641–4 (32 ref.)
[Some medico-psychological perspectives on sexual homicides. Three cases] Bénézech M. **Ann Med Psychol (Paris)** 1995 Oct;153(8):501–11 (22 ref.) (Eng. Abstr.) **(Fre)**

HOMING RECEPTORS, T-CELL see **RECEPTORS, LYMPHOCYTE HOMING**

HOMINIDAE

ANATOMY & HISTOLOGY

Genetic and morphological records of the Hominoidea and hominid origins: a synthesis. Pilbeam D. **Mol Phylogenet Evol** 1996 Feb;5(1):155–68 (121 ref.)

GENETICS

Chromosomal duplications in bacteria, fruit flies, and humans. Lupski JR, et al. **Am J Hum Genet** 1996 Jan;58(1):21–7 (79 ref.)
Genetic and morphological records of the Hominoidea and hominid origins: a synthesis. Pilbeam D. **Mol Phylogenet Evol** 1996 Feb;5(1):155–68 (121 ref.)
Human and rodent DNA sequence comparisons: a mosaic model of genomic evolution. Koop BF. **Trends Genet** 1995 Sep;11(9):367–71 (25 ref.)

HOMINIDS see **HOMINIDAE**

HOMO SAPIENS see **HOMINIDAE**

HOMOCYSTEINE

ADVERSE EFFECTS

Homocysteine and coronary atherosclerosis. Mayer EL, et al. **J Am Coll Cardiol** 1996 Mar 1;27(3):517–27 (127 ref.)

BLOOD

Molecular genetic aspects of hyperhomocysteinemia and its relation to folic acid. Rozen R. **Clin Invest Med** 1996 Jun; 19(3):171–8 (18 ref.)
New aspects of risk factors for the development of atherosclerosis, including small low-density lipoprotein, homocyst(e)ine, and lipoprotein(a). Superko HR. **Curr Opin Cardiol** 1995 Jul;10(4):347–54 (91 ref.)
Critical points for determining moderate hyperhomocyst(e)inaemia. Kang SS. **Eur J Clin Invest** 1995 Nov;25(11):806–8 (15 ref.)
Homocysteine as a risk factor for arteriosclerosis. Kuritzky L. **Hosp Pract (Off Ed)** 1996 Mar 15;31(3):37, 41 (5 ref.)
Vitamins as homocysteine-lowering agents. Brattström L. **J Nutr** 1996 Apr;126(4 Suppl):1276S–80S (48 ref.)
Plasma homocyst(e)ine: a risk factor for arterial occlusive diseases. Malinow MR. **J Nutr** 1996 Apr;126(4 Suppl):1238S–43S (38 ref.)
Reduced, oxidized and protein-bound forms of homocysteine and other aminothiols in plasma comprise the redox thiol status—a possible element of the extracellular antioxidant defense system. Ueland PM, et al. **J Nutr** 1996 Apr;126(4 Suppl):1281S–4S (28 ref.)
Hyperhomocysteinaemia; with reference to its neuroradiological aspects. van den Berg M, et al. **Neuroradiology** 1995 Jul;37(5):403–11 (78 ref.)
Hyperhomocysteinemia as a risk factor for cardiovascular disease in patients undergoing hemodialysis. Friedman JA, et al. **Nutr Rev** 1995 Jul;53(7):197–201 (17 ref.)
Is an elevated circulating maternal homocysteine concentration a risk factor for neural tube defects? Ubbink JB. **Nutr Rev** 1995 Jun;53(6):173–5 (14 ref.)
Homocysteine—an atherogenic and a thrombogenic factor? Ubbink JB. **Nutr Rev** 1995 Nov;53(11):323–5 (18 ref.)
Prospective studies of homocysteine and cardiovascular disease. Verhoef P, et al. **Nutr Rev** 1995 Oct;53(10):283–8 (19 ref.)
[Hyperhomocysteinemia] Sobra J. **Cas Lek Cesk** 1996 May 2;135(9):266–9 (31 ref.) (Eng. Abstr.) **(Cze)**
[P-methylmalonate and P-homocysteine: metabolic markers of vitamin deficiencies. Background, validity and applications] Rasmussen K. **Ugeskr Laeger** 1996 Jul 1; 158(27):3913–8 (40 ref.) (Eng. Abstr.) **(Dan)**
[Hyperhomocysteinemia as a risk factor in atherosclerotic and thrombotic vascular processes] Sela B. **Harefuah** 1995 Nov 15;129(10):407–12 (35 ref.) **(Heb)**
[Homocysteine—an independent risk factor of premature vascular disease] Mansoor MA, et al. **Tidsskr Nor Laegeforen** 1996 May 30;116(14):1663–7 (41 ref.) **(Nor)**
[Homocysteinemia as a risk factor for cerebrovascular disorders. The role of age and homocysteine levels] Reis RP, et al. **Acta Med Port** 1996 Jan;9(1):15–20 (43 ref.) (Eng. Abstr.) **(Por)**

METABOLISM

Nutritional ecogenetics: homocysteine-related arteriosclerotic vascular disease, neural tube defects, and folic acid [editorial; comment] Motulsky AG. **Am J Hum Genet** 1996 Jan;58(1):17–20 (28 ref.) Comment on: Am J Hum Genet 1996 Jan;58(1):35–41.
Homocysteine as a risk factor for coronary artery disease. Meleady RA, et al. **J Cardiovasc Risk** 1995 Jun;2(3):216–21 (52 ref.)
Homocysteine, vitamins and arterial occlusive disease: an overview. Rosenberg IH. **J Nutr** 1996 Apr;126(4 Suppl):1235S–7S (26 ref.)
[Homocysteine: relations to ischemic cardiovascular diseases] Piolot A, et al. **Rev Med Interne** 1996;17(1):34–45 (143 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Homocysteine and neural tube defects. Mills JL, et al. **J Nutr** 1996 Mar;126(3):756S–760S (28 ref.)
Homocysteine and vascular disease. McCully KS. **Nat Med** 1996 Apr;2(4):386–9 (20 ref.)
Homocysteine—an atherogenic and a thrombogenic factor? Ubbink JB. **Nutr Rev** 1995 Nov;53(11):323–5 (18 ref.)

TOXICITY

Homocysteine and hemostasis: pathogenic mechanisms predisposing to thrombosis. Harpel PC, et al. **J Nutr** 1996 Apr;126(4 Suppl):1285S–9S (33 ref.)
Homocysteine, EDRF, and endothelial function. Upchurch GR Jr, et al. **J Nutr** 1996 Apr;126(4 Suppl):1290S–4S (40 ref.)

HOMOCYSTINE

BLOOD

New aspects of risk factors for the development of atherosclerosis, including small low-density lipoprotein, homocyst(e)ine, and lipoprotein(a). Superko HR. **Curr Opin Cardiol** 1995 Jul;10(4):347–54 (91 ref.)

HOMOCYSTINURIA

COMPLICATIONS

Homocysteine as a risk factor for arteriosclerosis. Kuritzky L. **Hosp Pract (Off Ed)** 1996 Mar 15;31(3):37, 41 (5 ref.)
Chronic pancreatitis in homocystinuria. Patil RV, et al. **Indian Pediatr** 1995 Apr;32(4):469–70 (5 ref.)

DIAGNOSIS

[Neonatal hemolytic-uremic syndrome associated with methylmalonic aciduria and homocystinuria] Rogé Canales M, et al. **An Esp Pediatr** 1996 Jul;45(1):97–8 (8 ref.) **(Spa)**

DRUG THERAPY

New approaches to the prevention of atherosclerosis. Naito M, et al. **Drugs** 1995 Sep;50(3):440–53 (154 ref.)

GENETICS

Nutritional ecogenetics: homocysteine-related arteriosclerotic vascular disease, neural tube defects, and folic acid [editorial; comment] Motulsky AG. **Am J Hum Genet** 1996 Jan;58(1):17–20 (28 ref.) Comment on: Am J Hum Genet 1996 Jan;58(1):35–41.

HOMO-GAMMA LINOLENIC ACID see **8,11,14-EICOSATRIENOIC ACID**

HOMOGRAFT see **TRANSPLANTATION, HOMOLOGOUS**

HOMOGRAFT DRESSINGS see **BIOLOGICAL DRESSINGS**

HOMOGRAFT, ISOGENEIC see **TRANSPLANTATION, ISOGENEIC**

HOMOGRAFT, SYNGENEIC see **TRANSPLANTATION, ISOGENEIC**

HOMOLOGOUS RESTRICTION FACTOR 20 see **ANTIGENS, CD59**

HOMOLOGOUS SEQUENCES, AMINO ACID see **SEQUENCE HOMOLOGY, AMINO ACID**

HOMOLOGOUS SEQUENCES, NUCLEIC ACID see **SEQUENCE HOMOLOGY, NUCLEIC ACID**

HOMOLOGOUS WASTING DISEASE see **GRAFT VS HOST DISEASE**

HOMOPROTOCATECHUIC ACID see **3,4-DIHYDROXYPHENYLACETIC ACID**

HOMOSEXUALITY

Service delivery strategies for treating high-risk youth: delinquents, homeless, runaways, and sexual minorities. Farrow JA. **NIDA Res Monogr** 1995;156:39–48 (23 ref.)
[Homosexuality] Krieger I, et al. **Harefuah** 1996 Feb 1; 130(3):190–4 (30 ref.) **(Heb)**

GENETICS

Wilson's Panchreston: the inclusive fitness hypothesis of sociobiology re-examined. Dickemann M. **J Homosex** 1995; 28(1–2):147–83 (65 ref.)
Is homosexuality genetic? A critical review and some suggestions. McGuire TR. **J Homosex** 1995;28(1–2):115–45 (55 ref.)

PSYCHOLOGY

Hormones and sexual orientation: a questionable link. Banks

HOMOSEXUALITY

A, et al. **J Homosex** 1995;28(3–4):247–68 (70 ref.)
Science and belief: psychobiological research on sexual orientation. Byne W. **J Homosex** 1995;28(3–4):303–44 (140 ref.)
The biology of homosexuality: sexual orientation or sexual preference? De Cecco JP, et al. **J Homosex** 1995; 28(1–2):1–27 (55 ref.)
Sexuality in the brain. Doell RG. **J Homosex** 1995; 28(3–4):345–54 (27 ref.)
Animals models for the development of human sexuality: a critical evaluation. Fausto-Sterling A. **J Homosex** 1995; 28(3–4):217–36 (50 ref.)
Biomedical concepts of homosexuality: folk belief in a white coat. Gooren LJ. **J Homosex** 1995;28(3–4):237–46 (16 ref.)
Dexterity and sexuality: is there a relationship? Hamill JA. **J Homosex** 1995;28(3–4):375–96 (60 ref.)
Homosexuality, biology, and ideology. Haumann G. **J Homosex** 1995;28(1–2):57–77 (90 ref.)
Fear of AIDS and homophobia: implications for direct practice and advocacy. O'Hare T, et al. **Soc Work** 1996 Jan;41(1):51–8 (22 ref.)
Models of development: understanding risk in adolescence. Graber JA, et al. **Suicide Life Threat Behav** 1995;25 Suppl:18–25 (35 ref.)

STATISTICS & NUMERICAL DATA

Health care needs of gay men and lesbians in the United States. Council on Scientific Affairs, American Medical Association. **JAMA** 1996 May 1;275(17):1354–9 (126 ref.)

HOMOSEXUALITY, FEMALE

Primary care of lesbian and gay patients: educating ourselves and our students [see comments] Harrison AE. **Fam Med** 1996 Jan;28(1):10–23 (86 ref.) Comment in: Fam Med 1996 Jan;28(1):57–8.
Identity formation for lesbian, bisexual, and gay persons: beyond a "minoritizing" view. Eliason MJ. **J Homosex** 1996; 30(3):31–58 (40 ref.)
Heterosexism in nursing education. Gray DP, et al. **J Nurs Educ** 1996 May;35(5):204–10 (12 ref.)

GENETICS

[The genetics and endocrinology of homosexuality] Botella Llusiá J. **An R Acad Nac Med (Madr)** 1996;Spec No:19–29 (15 ref.) **(Spa)**

PSYCHOLOGY

Gay and lesbian identity development: a social identity perspective. Cox S, et al. **J Homosex** 1996;30(4):1–30 (54 ref.)
Female or male: the classification of homosexuality and gender. Oudshoorn N. **J Homosex** 1995;28(1–2):79–86 (15 ref.)
Sexual orientation and developmental challenges experienced by gay and lesbian youths. Rotheram-Borus MJ, et al. **Suicide Life Threat Behav** 1995;25 Suppl:26–34; discussion 35–9 (60 ref.)
[Between idealization and devaluation—problems and perspectives of theoretical analyses of female homo- and heterosexuality] Flaake K. **Psyche (Stuttg)** 1995 Sep–Oct; 49(9–10):867–85 (70 ref.) (Eng. Abstr.) **(Ger)**

STATISTICS & NUMERICAL DATA

Sampling homosexuals, bisexuals, gays, and lesbians for public health research: a review of the literature from 1990 to 1992. Sell RL, et al. **J Homosex** 1996;30(4):31–47 (19 ref.)

HOMOSEXUALITY, MALE

Primary care of lesbian and gay patients: educating ourselves and our students [see comments] Harrison AE. **Fam Med** 1996 Jan;28(1):10–23 (86 ref.) Comment in: Fam Med 1996 Jan;28(1):57–8.
At risk, infected, and invisible: older gay men and HIV/AIDS. Grossman AH. **J Assoc Nurses AIDS Care** 1995 Nov–Dec;6(6):13–9 (14 ref.)
Identity formation for lesbian, bisexual, and gay persons: beyond a "minoritizing" view. Eliason MJ. **J Homosex** 1996; 30(3):31–58 (40 ref.)
The etiology of male homosexuality. Roper WG. **Med Hypotheses** 1996 Feb;46(2):85–8 (20 ref.)
Drug use and HIV risk among gay and bisexual men: an overview. Battjes RJ. **NIDA Res Monogr** 1994;143:82–7 (4 ref.)
Qualitative research considerations and other issues in the study of methamphetamine use among men who have sex with other men. Gorman EM, et al. **NIDA Res Monogr** 1995;157:156–81 (77 ref.)
Substance use and HIV-transmitting behaviors among gay and bisexual men. Ostrow DG. **NIDA Res Monogr** 1994; 143:88–113 (35 ref.)
Drug use and HIV risk among male sex workers: results of two samples in San Francisco. Waldorf D. **NIDA Res Monogr** 1994;143:114–31 (18 ref.)

GENETICS

Present controversies in the genetics of male homosexuality. Lim LC. **Ann Acad Med Singapore** 1995 Sep;24(5):759–62 (24 ref.)
[The genetics and endocrinology of homosexuality] Botella Llusiá J. **An R Acad Nac Med (Madr)** 1996;Spec No:19–29 (15 ref.) **(Spa)**

PSYCHOLOGY

Gay men with AIDS and their families of origin: an analysis of social support. Kadushin G. **Health Soc Work** 1996 May; 21(2):141–9 (100 ref.)
HIV and homophobia: nurses as advocates. Mackereth PA. **J Adv Nurs** 1995 Oct;22(4):670–6 (42 ref.)
Gay and lesbian identity development: a social identity perspective. Cox S, et al. **J Homosex** 1996;30(4):1–30 (54 ref.)
Female or male: the classification of homosexuality and gender. Oudshoorn N. **J Homosex** 1995;28(1–2):79–86 (15 ref.)
Brain research, gender and sexual orientation. Swaab DF, et al. **J Homosex** 1995;28(3–4):283–301 (65 ref.)
Anthropology, HIV and contingent identities. Gatter PN. **Soc Sci Med** 1995 Dec;41(11):1523–33 (71 ref.)
Sexual orientation and developmental challenges experienced by gay and lesbian youths. Rotheram-Borus MJ, et al. **Suicide Life Threat Behav** 1995;25 Suppl:26–34; discussion 35–9 (60 ref.)
[Counseling male adolescents with homosexual orientation and their parents] Rauchfleisch U. **Prax Kinderpsychol Kinderpsychiatr** 1996 May–Jun; 45(5):166–70 (35 ref.) (Eng. Abstr.) **(Ger)**

STATISTICS & NUMERICAL DATA

Sampling homosexuals, bisexuals, gays, and lesbians for public health research: a review of the literature from 1990 to 1992. Sell RL, et al. **J Homosex** 1996;30(4):31–47 (19 ref.)

HOMOVANILLIC ACID

ANALYSIS

[Homovanillic acid (HVA)] Shigetomi S, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:520–3 (12 ref.) **(Jpn)**

URINE

Screening for neuroblastoma: a review of the evidence [see comments] Chamberlain J. **J Med Screen** 1994 Jul; 1(3):169–75 (37 ref.) Comment in: J Med Screen 1994 Jul;1(3):141–2.

HOMOZYGOTE

Reactivation of fetal hemoglobin in patients with beta-thalassemia. Olivieri NF. **Semin Hematol** 1996 Jan; 33(1):24–42 (121 ref.)

HONEY

POISONING

[Acute life-threatening bradycardia: food poisoning by Turkish wild honey] von Malottki K, et al. **Dtsch Med Wochenschr** 1996 Jul 26;121(30):936–8 (8 ref.) (Eng. Abstr.) **(Ger)**

HOOF AND CLAW

Lameness, lesions of the claw of the dairy cow and subclinical laminitis [editorial; comment] Logue D. **Br Vet J** 1995 Jul–Aug;151(4):343–6 (16 ref.) Comment on: Br Vet J 1995 Jul–Aug;151(4):391–9.

INJURIES

Tendon, tendon sheath, and ligament injuries in the pastern. Dyson SJ, et al. **Vet Clin North Am Equine Pract** 1995 Aug;11(2):217–33 (19 ref.)

HOOKWORM INFECTIONS

EPIDEMIOLOGY

Infantile hookworm disease in China. A review. Yu SH, et al. **Acta Trop** 1995 Aug;59(4):265–70 (42 ref.)

HOOKWORM, OLD WORLD see **ANCYLOSTOMA**

HORDEUM see **BARLEY**

HORIZONTAL TRANSMISSION see **DISEASE TRANSMISSION, HORIZONTAL**

HORMONAL ANTINEOPLASTIC AGENTS see **ANTINEOPLASTIC AGENTS, HORMONAL**

HORMONE ANALOGS see **HORMONES, SYNTHETIC**

HORMONE ANTAGONISTS

Role of allatostatins in the regulation of juvenile hormone synthesis. Stay B, et al. **Arch Insect Biochem Physiol** 1996; 32(3–4):287–97 (39 ref.)
[Induced labor by pharmacological methods. Advantages and disadvantages] Rotten D. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24 Suppl 1:13–27 (42 ref.) **(Fre)**

ADMINISTRATION & DOSAGE

Mifepristone: clinical application in general gynecology. Morales AJ, et al. **Clin Obstet Gynecol** 1996 Jun; 39(2):451–60 (33 ref.)

CHEMISTRY

Discovery of novel intracellular receptor modulating drugs. Jones TK, et al. **J Steroid Biochem Mol Biol** 1996 Jan; 56(1–6 Spec No):61–6 (26 ref.)

PHARMACOLOGY

Steroid hormones, receptors, and antagonists. Jensen EV. **Ann N Y Acad Sci** 1996 Apr 30;784:1–17 (68 ref.)
Antiprogestins: mechanism of action and contraceptive potential. Spitz IM, et al. **Annu Rev Pharmacol Toxicol** 1996;36:47–81 (161 ref.)
Surprises with antiprogestins: novel mechanisms of progesterone receptor action. Horwitz KB, et al. **Ciba Found Symp** 1995;191:235–49; discussion 250–3 (26 ref.)
Mifepristone and ovarian function. Curry TE Jr, et al. **Clin Obstet Gynecol** 1996 Jun;39(2):486–97 (64 ref.)
Clinical applications of the antiprogestins. Kettel LM. **Clin Obstet Gynecol** 1995 Dec;38(4):921–34 (56 ref.)
Mifepristone: clinical pharmacology. Robbins A, et al. **Clin Obstet Gynecol** 1996 Jun;39(2):436–50 (21 ref.)

THERAPEUTIC USE

Potential use of oxytocin and vasopressin V1a antagonists in the treatment of preterm labour and primary dysmenorrhoea. Akerlund M, et al. **Adv Exp Med Biol** 1995; 395:595–600 (32 ref.)
Progress in the development of oxytocin antagonists for use in preterm labor. Pettibone DJ, et al. **Adv Exp Med Biol** 1995;395:601–12 (49 ref.)
Mifepristone: antineoplastic studies. Sartor O, et al. **Clin Obstet Gynecol** 1996 Jun;39(2):498–505 (28 ref.)
Mifepristone: treatment of Cushing's syndrome. Sartor O, et al. **Clin Obstet Gynecol** 1996 Jun;39(2):506–10 (12 ref.)
Atosiban. Shubert PJ. **Clin Obstet Gynecol** 1995 Dec; 38(4):722–4 (12 ref.)
New drugs for hyperprolactinaemia. **Drug Ther Bull** 1995 Sep;33(9):65–7 (24 ref.)
[Multiple usages for antiprogestins] Heikinheimo O. **Duodecim** 1994;110(10):1001–8 (39 ref.) **(Fin)**
[Endocrine treatment of meningiomas: a review] da Motta LA, et al. **Arq Neuropsiquiatr** 1995 Jun;53(2):324–32 (45 ref.) (Eng. Abstr.) **(Por)**
[Somatostatin and its analogs in the treatment of gastrointestinal and liver diseases] Feu F, et al. **Gastroenterol Hepatol** 1996 Feb;19(2):68–77 (102 ref.) **(Spa)**

HORMONE-DEPENDENT NEOPLASMS see **NEOPLASMS, HORMONE-DEPENDENT**

HORMONE REPLACEMENT THERAPY, POST-MENOPAUSAL see **ESTROGEN REPLACEMENT THERAPY**

HORMONES

see related
HORMONE ANTAGONISTS
RECEPTORS, CELL SURFACE

Co-activators and co-repressors: mediators of gene activation by nuclear hormone receptors. Meier CA. **Eur J Endocrinol** 1996 Feb;134(2):158–9 (5 ref.)

ADVERSE EFFECTS

Perspectives in hormonal carcinogenesis: animal models to human disease. Li JJ. **Prog Clin Biol Res** 1996;394:447–54 (48 ref.)
To cell from environment. Palmlund I. **Prog Clin Biol Res** 1996;394:425–45 (95 ref.)
Hormonal and environmental factors affecting cell proliferation and neoplasia in the mammary gland. Snedeker SM, et al. **Prog Clin Biol Res** 1996;394:211–53 (315 ref.)

ANALYSIS

[Peptide hormone] Ohnami S, et al. **Nippon Rinsho** 1996 Jun; 54(6):1510–4 (15 ref.) (Eng. Abstr.) **(Jpn)**
[Present status and future of enzyme immunoassay—hormone] Uchimura H. **Nippon Rinsho** 1995 Sep;53(9):2245–9 (5 ref.) (Eng. Abstr.) **(Jpn)**

BIOSYNTHESIS

[Primary hormone-producing hepatic tumor] Himeno H, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):511–4 (22 ref.) **(Jpn)**

BLOOD

Hormones and behaviour. Fahlbusch R, et al.

Acta Neurochir (Wien) 1995;132(4):169–77 (75 ref.)
Intra-uterine growth retardation. Holmes RP, et al. **Curr Opin Obstet Gynecol** 1996 Apr;8(2):148–54 (51 ref.)
Methodological and statistical considerations for exercise-related hormone evaluations. Tremblay MS, et al. **Sports Med** 1995 Aug;20(2):90–108 (129 ref.)
Blood hormones as markers of training stress and overtraining. Urhausen A, et al. **Sports Med** 1995 Oct; 20(4):251–76 (233 ref.)
[Pitfalls in hormone assays] Pelkonen R. **Duodecim** 1994; 110(10):959–67 (23 ref.) **(Fin)**
[Humoral aspects of sleep deprivation] Ebert D, et al. **Fortschr Neurol Psychiatr** 1995 Nov;63(11):441–50 (60 ref.) (Eng. Abstr.) **(Ger)**
[Pulsatile hormone secretion for control of target organs] Schöfl C, et al. **Wien Med Wochenschr** 1995; 145(17–18):431–5 (23 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

The role of cytokines and neuroendocrine hormones in cutaneous immunity and inflammation. Luger TA, et al. **Allergy** 1995 Apr;50(4):292–302 (119 ref.)

METABOLISM

Neuroendocrine changes in heart failure and their clinical relevance. Parmley WW. **Clin Cardiol** 1995 Aug; 18(8):440–5 (27 ref.)
Steroid hormones. Membrane transporters of steroid hormones. Thompson EB. **Curr Biol** 1995 Jul 1;5(7):730–2 (12 ref.)
Oestrogens and calcium regulatory hormones: potential implications for bone. Naveh-Many T, et al. **Curr Opin Nephrol Hypertens** 1995 Jul;4(4):319–23 (50 ref.)
Endocrine aspects of obesity. Drent ML, et al. **Neth J Med** 1995 Sep;47(3):127–36 (98 ref.)
Endocrine bases of lactational anoestrus in the sow. Quesnel H, et al. **Reprod Nutr Dev** 1995;35(4):395–414 (107 ref.)
[Cell membrane targets and steroid hormones: the beginning or end of the dispute?] Sergeev PV, et al. **Biull Eksp Biol Med** 1995 Oct;120(10):342–8 (22 ref.) **(Rus)**

PHARMACOLOGY

Why do hormones stimulate Ca2+ mobilization? Taylor CW. **Biochem Soc Trans** 1995 Aug;23(3):637–42 (52 ref.)
Nutritional and hormonal regulation of fatty acid synthase. Wolf G. **Nutr Rev** 1996 Apr;54(4 Pt 1):122–3 (9 ref.)
[Hormone-dependent cell death (editorial)] Tapanainen J. **Duodecim** 1994;110(10):933–5 (13 ref.) **(Fin)**

PHYSIOLOGY

Effect of hypoxaemia on water and sodium homeostatic hormones and renal function. Olsen NV. **Acta Anaesthesiol Scand Suppl** 1995;107:165–70 (55 ref.)
In vitro studies of human skeletal muscle: hormonal and metabolic regulation of glucose transport. Zierath JR. **Acta Physiol Scand Suppl** 1995;626:1–96 (435 ref.)
Endocrine, paracrine and autocrine regulation of testicular steroidogenesis. Huhtaniemi I, et al. **Adv Exp Med Biol** 1995;377:33–54 (145 ref.)
Ovarian follicular growth, ovulation and atresia. Endocrine, paracrine and autocrine regulation. Moley KH, et al. **Adv Exp Med Biol** 1995;377:103–19 (105 ref.)
Ovulation as a tissue remodelling process. Proteolysis and cumulus expansion. Tsafriri A. **Adv Exp Med Biol** 1995; 377:121–40 (191 ref.)
Multihormonal regulation of nephron epithelia: achieved through combinational mode? De Rouffignac C. **Am J Physiol** 1995 Oct;269(4 Pt 2):R739–48 (59 ref.)
Steroid control of higher brain function and behavior. Mortaud S, et al. **Behav Genet** 1996 Jul;26(4):367–72 (22 ref.)
Hormonal and neurotransmitter regulation of GnRH gene expression and related reproductive behaviors. Sagrillo CA, et al. **Behav Genet** 1996 May;26(3):241–77 (360 ref.)
Endogenous and nutritional factors affecting bone. Marcus R. **Bone** 1996 Jan;18(1 Suppl):11S–13S (21 ref.)
Available animal models of osteopenia—small and large. Miller SC, et al. **Bone** 1995 Oct;17(4 Suppl):117S–123S (64 ref.)
Oestrogen-responsive finger protein suggests a transcriptional cascade of steroid hormone regulation. **Ciba Found Symp** 1995;191:43–51 (18 ref.)
Steroid hormone signalling system and fungi. Zakelj-Mavrič M, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1995 Dec;112(4):637–42 (69 ref.)
Hormonal regulation of cardiac fibroblast function. Brilla CG, et al. **Eur Heart J** 1995 May;16 Suppl C:45–50 (42 ref.)
Steroid hormones and adipose tissue [comment] Prins JB, et al. **Eur J Clin Invest** 1996 Apr;26(4):259–61 (24 ref.) Comment on: Eur J Clin Invest 1996 Apr;26(4):262–9.
Changes in tissue responsiveness to hormones and neurotransmitters during aging. Roth GS. **Exp Gerontol** 1995 May–Aug;30(3–4):361–8 (30 ref.)
On the physiology of metazoa. Ameen AR. **Experientia** 1996 Mar 15;52(3):189–211 (205 ref.)
Endocrine glia: roles of glial cells in the brain actions of steroid and thyroid hormones and in the regulation of hormone secretion. Garcia-Segura LM, et al. **Front Neuroendocrinol** 1996 Apr;17(2):180–211 (253 ref.)
Endocrine and auto-paracrine factors in the pathogenesis of primary hypertension. Takeda R, et al. **Hypertens Res** 1995 Sep;18(3):171–9 (120 ref.)
Looking beyond the dogma of genomic steroid action: insights and facts of the 1990s. Wehling M. **J Mol Med** 1995 Sep;73(9):439–47 (88 ref.)
Modulation of renal Na-Pi cotransport by hormones acting via genomic mechanism and by metabolic factors. Dousa TP. **Kidney Int** 1996 Apr;49(4):997–1004 (52 ref.)
Peptide hormone action on renal phosphate handling [see comments] Kempson SA. **Kidney Int** 1996 Apr;49(4):1005–9 (52 ref.) Comment in: Kidney Int 1996 Apr;49(4):1010–1.
Optimal physical performance in athletes: key roles of dopamine in a specific neurotransmitter/hormonal mechanism. Gilbert C. **Mech Ageing Dev** 1995 Oct 13; 84(2):83–102 (85 ref.)
Mechanisms of hormone-mediated carcinogenesis of the ovary in mice. Capen CC, et al. **Mutat Res** 1995 Dec; 333(1–2):143–51 (23 ref.)
Paracrine regulation of the renal microcirculation. Navar LG, et al. **Physiol Rev** 1996 Apr;76(2):425–536 (1214 ref.)
Regulation of gut glutamine metabolism: role of hormones and cytokines. Abumrad NN, et al. **Proc Nutr Soc** 1995 Jul;54(2):525–33 (33 ref.)
Catabolic hormones and growth hormone resistance in acquired immunodeficiency syndrome and other catabolic states. Rodgers BD. **Proc Soc Exp Biol Med** 1996 Sep; 212(4):324–31 (106 ref.)
Hormonal factors in carcinogenesis of the prostate and testis in humans and in animal models. Bosland MC. **Prog Clin Biol Res** 1996;394:309–52 (225 ref.)
Hormonal influence on hepatocarcinogenesis. Coe JE. **Prog Clin Biol Res** 1996;394:399–421 (189 ref.)
Modulating effects of hormones on carcinogenesis. Lijinsky W. **Prog Clin Biol Res** 1996;394:57–76 (09 ref.)
Endocrine regulation of fetal growth. Fowden AL. **Reprod Fertil Dev** 1995;7(3):351–63 (68 ref.)
Sperm antigens and immunocontraception. Kerr LE. **Reprod Fertil Dev** 1995;7(4):825–30 (74 ref.)
Functional development of fetal limb muscles: a review of the roles of activity, nerves and hormones. Walker DW, et al. **Reprod Fertil Dev** 1995;7(3):391–8 (27 ref.)
The interrelationships of body fat, exercise, and hormonal status and their impact on reproduction and bone health. Ramos RH, et al. **Semin Perinatol** 1995 Jun;19(3):163–70 (53 ref.)
Phosphorylation and steroid hormone action. Bai W, et al. **Vitam Horm** 1995;51:289–313 (115 ref.)
[Evolution of the endocrine system] Leinonen P. **Duodecim** 1994;110(10):939–48 (28 ref.) **(Fin)**
[Role of peptidergic mechanisms in thermoregulation] Marianovich AT. **Fiziol Cheloveka** 1996 Mar-Apr; 22(2):35–42 (83 ref.) **(Rus)**
[The effect of hormones on the development of bone tumors] Stoliarov VI, et al. **Vopr Onkol** 1996;42(3):7–14 (43 ref.) **(Rus)**
[Hypoglycemia—occurrence, causes and hormonal counterregulatory mechanisms in healthy persons and in patients with IDDM] Mokáň M. **Bratisl Lek Listy** 1995 Jun;96(6):311–6 (34 ref.) (Eng. Abstr.) **(Slo)**
[Hormones, growth factors, and drugs in metabolism and nutrition] García de Lorenzo A, et al. **Nutr Hosp** 1995 Sep–Oct;10(5):297–305 (91 ref.) (Eng. Abstr.) **(Spa)**

SECRETION

Endocrine glia: roles of glial cells in the brain actions of steroid and thyroid hormones and in the regulation of hormone secretion. Garcia-Segura LM, et al. **Front Neuroendocrinol** 1996 Apr;17(2):180–211 (253 ref.)
A peptide hormone causing abnormal hair-growth associated with malignancy. Pilsczek FH. **Med Hypotheses** 1995 Sep; 45(3):223–4 (6 ref.)
Baroreflex and chemoreflex control of fetal hormone secretion. Wood CE. **Reprod Fertil Dev** 1995;7(3):479–89 (94 ref.)

THERAPEUTIC USE

Effect of anabolic hormones and insulin-like growth factor-I on muscle mass and strength in elderly persons. Carter WJ. **Clin Geriatr Med** 1995 Nov;11(4):735–48 (63 ref.)
[Evaluation of hormonal treatments for idiopathic oligospermia] Buvat J. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(3):223–32 (76 ref.) (Eng. Abstr.) **(Fre)**

HORMONES, ECTOPIC

see related
NEOPLASTIC ENDOCRINE-LIKE SYNDROMES

BIOSYNTHESIS

[Ectopic hormone prōducing cholangiocarcinoma] Kawanami C, et al. **Ryoikibetsu Shokogun Shirizu** 1996; (9):99–102 (14 ref.) **(Jpn)**

BLOOD

Diagnosis and management of nonfunctioning pituitary tumors. Greenman Y, et al. **Annu Rev Med** 1996;47:95–106 (51 ref.)

HORMONES, INVERTEBRATE see **INVERTEBRATE HORMONES**

HORMONES, SYNTHETIC

CONTRAINDICATIONS

[Sex hormone substitution in hormone-dependent neoplasms—oil into the fire?] Kleeberg UR. **Med Klin** 1996 Apr 10;91(4):234–7 (38 ref.) **(Ger)**

THERAPEUTIC USE

[Conservative therapeutic possibilities in glandular or adenomatous endometrium hyperplasia] Schindler AE. **Zentralbl Gynakol** 1996;118(6):359–64 (29 ref.) (Eng. Abstr.) **(Ger)**

HORNER'S SYNDROME

[Abnormalities of the pupils] Furukawa T. **Nippon Naika Gakkai Zasshi** 1995 Sep 10;84(9):1417–21 (8 ref.) **(Jpn)**

HORNETS see **WASPS**

HORSE DISEASES

Salmonellosis in horses [comment] Murray MJ. **J Am Vet Med Assoc** 1996 Aug 1;209(3):558–60 (10 ref.) Comment on: J Am Vet Med Assoc 1996 Aug 1;209(3):626–8. Comment on: J Am Vet Med Assoc 1996 Aug 1;209(3):629–31.
Suspensory ligament desmitis. Dyson SJ, et al. **Vet Clin North Am Equine Pract** 1995 Aug;11(2):177–215 (34 ref.)
Miscellaneous conditions of tendons, tendon sheaths, and ligaments. Dyson SJ, et al. **Vet Clin North Am Equine Pract** 1995 Aug;11(2):315–37 (57 ref.)

DIAGNOSIS

Equine piroplasmosis an update on diagnosis, treatment and prevention. Brüning A. **Br Vet J** 1996 Mar;152(2):139–51 (58 ref.)
[Heart diseases in foals. A literature review exemplified by 2 case reports] de Groot J, et al. **Tijdschr Diergeneeskd** 1996 Jul 1;121(13):382–7 (18 ref.) (Eng. Abstr.) **(Dut)**

DRUG THERAPY

Antimicrobial agents for treatment of infectious keratitis in horses. Moore CP, et al. **J Am Vet Med Assoc** 1995 Oct 1;207(7):855–62 (29 ref.)

ETIOLOGY

Eosinophilic colitis and hepatitis in a horse with colonic intramucosal ciliated protozoa. French RA, et al. **Vet Pathol** 1996 Mar;33(2):235–8 (10 ref.)
['Oat bumps' in horses. Differential diagnosis and nutritional aspects] Hallebeek AJ, et al. **Tijdschr Diergeneeskd** 1995 Oct 15;120(20):588–91 (30 ref.) (Eng. Abstr.) **(Dut)**

METABOLISM

Joint structure, biochemistry and biochemical disequilibrium in synovitis and equine joint disease. Palmer JL, et al. **Equine Vet J** 1994 Jul;26(4):263–77 (131 ref.)

MORTALITY

The risks of the game: the confidential enquiry into perioperative equine fatalities [editorial] Johnston GM. **Br Vet J** 1995 Jul-Aug;151(4):347–50 (8 ref.)

PATHOLOGY

Joint structure, biochemistry and biochemical disequilibrium in synovitis and equine joint disease. Palmer JL, et al. **Equine Vet J** 1994 Jul;26(4):263–77 (131 ref.)
Aseptic tenosynovitis of the digital flexor tendon sheath, fetlock and pastern annular ligament constriction. Dik KJ, et al. **Vet Clin North Am Equine Pract** 1995 Aug; 11(2):151–62 (20 ref.)

PHYSIOPATHOLOGY

Infectious tenosynovitis. Bertone AL. **Vet Clin North Am Equine Pract** 1995 Aug;11(2):163–76 (24 ref.)

PREVENTION & CONTROL

Racing horses, nitroglycerin and exercise induced pulmonary haemorrhage (EIPH) [editorial; comment] Harkins JD, et al. **Equine Vet J** 1995 Jul;27(4):240–1 (12 ref.) Comment on: Equine Vet J 1995 Jul;27(4):275–9.
Disinfecting equine facilities. Dwyer RM. **Rev Sci Tech** 1995 Jun;14(2):403–18 (4 ref.)

RADIONUCLIDE IMAGING

Imaging infection and inflammation in veterinary practice [editorial; comment] Peters AM. **Equine Vet J** 1995 Jul; 27(4):242–4 (20 ref.) Comment on: Equine Vet J 1995 Jul;27(4):313–5.

HORSERADISH PEROXIDASE

[Properties of enzymes for enzyme immunoassay] Maekawa M. **Nippon Rinsho** 1995 Sep;53(9):2154–9 (11 ref.) (Eng. Abstr.) **(Jpn)**

HORSES

The potential of pasture to supply the nutritional requirements of grazing horses. Gallagher JR. **Aust Vet J** 1996 Feb;73(2):67–8 (19 ref.)

Dynamics of the regulation of the hypothalamo–pituitary–adrenal (HPA) axis determined using a nonsurgical method for collecting pituitary venous blood from horses. Alexander SL, et al. **Front Neuroendocrinol** 1996 Jan;17(1):1–50 (220 ref.)

ANATOMY & HISTOLOGY

Ligaments associated with joints. Wright IM. **Vet Clin North Am Equine Pract** 1995 Aug;11(2):249–91 (90 ref.)

EMBRYOLOGY

The equine embryonic capsule: practical implications of recent research. Oriol JG. **Equine Vet J** 1994 May; 26(3):184–6 (34 ref.)

INJURIES

Tendon lacerations. Bertone AL. **Vet Clin North Am Equine Pract** 1995 Aug;11(2):293–314 (15 ref.)

Soft tissue injuries of the tarsus. Dik KJ, et al. **Vet Clin North Am Equine Pract** 1995 Aug;11(2):235–47 (25 ref.)

Tendon, tendon sheath, and ligament injuries in the pastern. Dyson SJ, et al. **Vet Clin North Am Equine Pract** 1995 Aug;11(2):217–33 (19 ref.)

PHYSIOLOGY

Sodium bicarbonate loading and the rules of racing [editorial; comment] Williams RB. **Br Vet J** 1995 Sep–Oct; 151(5):473–5 (6 ref.) Comment on: Br Vet J 1995 Sep–Oct;151(5):523–45.

A review of the pharmacology, pharmacokinetics, and regulatory control in the US of local anaesthetics in the horse. Harkins JD, et al. **J Vet Pharmacol Ther** 1995 Dec; 18(6):397–406 (56 ref.)

HORSESHOE CRABS

PHYSIOLOGY

Distinguishing between roles for calcium in Limulus photoreceptor excitation. Richard EA, et al. **Cell Calcium** 1995 Oct;18(4):331–41 (45 ref.)

HOSPICE CARE

see related
RESPITE CARE

Hospice and palliative care. Rousseau P. **Dis Mon** 1995 Dec; 41(12):769–842 (196 ref.)

Prognosis in advanced pulmonary disease. Herbst LH. **J Palliat Care** 1996 Summer;12(2):54–6 (27 ref.)

Concerns about analgesics among patients and family caregivers in a hospice setting. Ward SE, et al. **Res Nurs Health** 1996 Jun;19(3):205–11 (31 ref.)

ORGANIZATION & ADMINISTRATION

Pediatric hospice nursing. Martinson IM. **Annu Rev Nurs Res** 1995;13:195–214 (66 ref.)

HOSPICE PROGRAMS see **HOSPICE CARE**

HOSPICES

Supportive palliative treatment, psychological care and the hospice movement in Hungary. Muszbek K, et al. **Support Care Cancer** 1996 Jan;4(1):7–9 (10 ref.)

ECONOMICS

Cost savings at the end of life. What do the data show? Emanuel EJ. **JAMA** 1996 Jun 26;275(24):1907–14 (42 ref.)

HOSPITAL-ADDICTION SYNDROME see **MUNCHAUSEN SYNDROME**

HOSPITAL ADMINISTRATION

see related
PROFESSIONAL STAFF COMMITTEES

Advance directives. Most patients don't have one. Do yours? Berrio MW, et al. **Am J Nurs** 1996 Aug;96(8):24–8; quiz 29 (7 ref.)

METHODS

[Clinical engineering. Rationale for implementing the technology in hospitals] Prieto Hernández F, et al. **Gac Med Mex** 1995 Jan–Feb;131(1):83–90 (13 ref.) (Eng. Abstr.) **(Spa)**

STANDARDS

Total quality management: field of dreams? [see comments] Bigelow B, et al. **Health Care Manage Rev** 1995 Fall; 20(4):15–25; discussion 28–9, 30–33 (127 ref.) Comment in: Health Care Manage Rev 1996 Winter;21(1):93–4.

TRENDS

Mergers, networking, and vertical integration: managed care and investor-owned hospitals. Brown M. **Health Care Manage Rev** 1996 Winter;21(1):29–37 (7 ref.)

HOSPITAL ADMISSION TESTS see **DIAGNOSTIC TESTS, ROUTINE**

HOSPITAL-BASED HOME CARE see **HOME CARE SERVICES, HOSPITAL-BASED**

HOSPITAL CARDIOLOGY SERVICE see **CARDIOLOGY SERVICE, HOSPITAL**

HOSPITAL CHARGES

Effects of availability of patient-related charges on practice patterns and cost containment in the pediatric intensive care unit. Sachdeva RC, et al. **Crit Care Med** 1996 Mar; 24(3):501–6 (44 ref.)

STATISTICS & NUMERICAL DATA

Managing gallbladder disease in a cost-effective manner. Orlando R 3rd, et al. **Surg Clin North Am** 1996 Feb; 76(1):117–28 (36 ref.)

HOSPITAL COSTS

You are in charge of cost. Loop FD. **Ann Thorac Surg** 1995 Nov;60(5):1509–12 (3 ref.)

The cost of sedating and paralyzing the critically ill patient. Cheng EY. **Crit Care Clin** 1995 Oct;11(4):1005–19 (29 ref.)

Pro: early extubation after cardiac surgery decreases intensive care unit stay and cost [see comments] Cheng DC. **J Cardiothorac Vasc Anesth** 1995 Aug;9(4):460–4 (45 ref.) Comment in: J Cardiothorac Vasc Anesth 1995 Aug;9(4):465–7.

Con: early extubation after cardiac surgery does not decrease intensive care unit stay and cost [comment] Guenther CR. **J Cardiothorac Vasc Anesth** 1995 Aug;9(4):465–7 (12 ref.) Comment on: J Cardiothorac Vasc Anesth 1995 Aug;9(4):460–4.

Cost effectiveness in trauma care. Elliott DC, et al. **Surg Clin North Am** 1996 Feb;76(1):47–62 (101 ref.)

Cost effectiveness in the intensive care unit. Kirton OC, et al. **Surg Clin North Am** 1996 Feb;76(1):175–200 (54 ref.)

STATISTICS & NUMERICAL DATA

A cost-effective approach to the patient with peptic ulcer bleeding. Jiranek GC, et al. **Surg Clin North Am** 1996 Feb; 76(1):83–103 (124 ref.)

The management of hernia. Considerations in cost effectiveness. Millikan KW, et al. **Surg Clin North Am** 1996 Feb;76(1):105–16 (33 ref.)

HOSPITAL DESIGN AND CONSTRUCTION

Building a pediatric cardiac catheterization laboratory and conference room: design considerations and filmless imaging. Mathewson JW. **Pediatr Cardiol** 1996 Sep–Oct; 17(5):279–94 (30 ref.)

HOSPITAL DIVERSIFICATION see **HOSPITAL RESTRUCTURING**

HOSPITAL EMERGENCY SERVICE see **EMERGENCY SERVICE, HOSPITAL**

HOSPITAL ENGINEERING see **MAINTENANCE AND ENGINEERING, HOSPITAL**

HOSPITAL FINANCIAL MANAGEMENT see **FINANCIAL MANAGEMENT, HOSPITAL**

HOSPITAL FOOD SERVICE see **FOOD SERVICE, HOSPITAL**

HOSPITAL GROUNDSKEEPING see **MAINTENANCE AND ENGINEERING, HOSPITAL**

HOSPITAL INCIDENT REPORTING see **RISK MANAGEMENT**

HOSPITAL INFECTIONS see **CROSS INFECTION**

HOSPITAL INFORMATION SYSTEMS

ABC of medical computing. Hospital based computer systems. Lee N, et al. **BMJ** 1995 Oct 14;311(7011):1013–6 (0 ref.)

The hospital information system—integrated patient records. Scherrer JR. **Comput Methods Programs Biomed** 1995 Sep–Oct;48(1–2):1–6 (17 ref.)

Nursing information management and processing: a framework and definition for systems analysis, design and evaluation. Goossen WT. **Int J Biomed Comput** 1996 Jan; 40(3):187–95 (34 ref.)

Clinical computing: a view from the United Kingdom. Wyatt JC. **MD Comput** 1995 Sep–Oct;12(5):382–9 (57 ref.)

[Informatics in the hospital] Melino C, et al. **Ann Ig** 1994 Jul–Dec;6(4–6):439–52 (39 ref.) (Eng. Abstr.) **(Ita)**

ECONOMICS

What value do computers provide to NHS hospitals? [see comments] Lock C. **BMJ** 1996 Jun 1;312(7043):1407–10 (65 ref.) Comment in: BMJ 1996 Jun 1;312(7043):1371–2.

ORGANIZATION & ADMINISTRATION

Computers and networks in medical and healthcare systems. Egan GF, et al. **Comput Biol Med** 1995 May;25(3):355–65 (25 ref.)

HOSPITAL LABORATORIES see **LABORATORIES, HOSPITAL**

HOSPITAL MAINTENANCE see **MAINTENANCE AND ENGINEERING, HOSPITAL**

HOSPITAL MEDICAL STAFF see **MEDICAL STAFF, HOSPITAL**

HOSPITAL MERGER see **HEALTH FACILITY MERGER**

HOSPITAL MORTALITY

TRENDS

Changing patterns in pediatric mortality, Maputo Central Hospital, Mozambique, 1980–1990. Julien M, et al. **J Trop Pediatr** 1995 Dec;41(6):366–8 (7 ref.)

HOSPITAL NURSING SERVICE see **NURSING SERVICE, HOSPITAL**

HOSPITAL NURSING STAFF see **NURSING STAFF, HOSPITAL**

HOSPITAL OBSTETRICS AND GYNECOLOGY DEPARTMENT see **OBSTETRICS AND GYNECOLOGY DEPARTMENT, HOSPITAL**

HOSPITAL ORGANIZATION AND ADMINISTRATION see **HOSPITAL ADMINISTRATION**

HOSPITAL OUTPATIENT CLINICS see **OUTPATIENT CLINICS, HOSPITAL**

HOSPITAL PATHOLOGY DEPARTMENT see **PATHOLOGY DEPARTMENT, HOSPITAL**

HOSPITAL-PATIENT RELATIONS

Physical restraint use in the hospital setting: unresolved issues and directions for research. Mion LC, et al. **Milbank Q** 1996;74(3):411–33 (80 ref.)

HOSPITAL PERSONNEL see **PERSONNEL, HOSPITAL**

HOSPITAL PHARMACY SERVICE see **PHARMACY SERVICE, HOSPITAL**

HOSPITAL-PHYSICIAN JOINT VENTURES

ECONOMICS

The effects of hospital-physician integration strategies on hospital financial performance. Goes JB, et al. **Health Serv Res** 1995 Oct;30(4):507–30 (40 ref.)

HOSPITAL-PHYSICIAN RELATIONS

The effects of hospital-physician integration strategies on hospital financial performance. Goes JB, et al. **Health Serv Res** 1995 Oct;30(4):507–30 (40 ref.)

The leadership dance. Ehrat KS, et al. **J Nurs Adm** 1996 Apr;26(4):13–5 (14 ref.)

HOSPITAL PLANNING

METHODS

Information systems and strategic management. Austin CJ, et al. **Health Care Manage Rev** 1995 Summer;20(3):26–33; discussion 34–42 (17 ref.)

Strategic planning in hospitals: a review and proposal. Bruton GD, et al. **Health Care Manage Rev** 1995 Summer; 20(3):16–25 (45 ref.)

HOSPITAL PSYCHIATRIC DEPARTMENT see **PSYCHIATRIC DEPARTMENT, HOSPITAL**

HOSPITAL RADIOLOGY DEPARTMENT see **RADIOLOGY DEPARTMENT, HOSPITAL**

HOSPITAL READMISSION see **PATIENT READMISSION**

HOSPITAL RECORDS

see related
FORMS AND RECORDS CONTROL

HOSPITAL RECOVERY ROOM see **RECOVERY ROOM**

HOSPITAL REFERRAL see **REFERRAL AND CONSULTATION**

HOSPITAL RENOVATION see **HOSPITAL DESIGN AND CONSTRUCTION**

HOSPITAL REORGANIZATION see **HOSPITAL RESTRUCTURING**

HOSPITAL RESTRUCTURING

ORGANIZATION & ADMINISTRATION

Organizational redesign: effect on institutional and consumer outcomes. Ingersoll GL. **Annu Rev Nurs Res** 1996; 14:121–43 (52 ref.)

Integration of emerging designs for the practice and management of nursing. Blouin AS, et al. **J Nurs Adm** 1996 Mar;26(3):38–46 (54 ref.)

HOSPITAL UNITS

ORGANIZATION & ADMINISTRATION

Improving postoperative care: the role of the surgeon in the high dependency unit. Coggins R, et al.
Ann R Coll Surg Engl 1996 May;78(3 (Pt 1)):163–7 (29 ref.)

The medical director in hospital-based transitional care units. Smith RL, et al. **Clin Geriatr Med** 1995 Aug;11(3):373–89 (11 ref.)

Nursing development units: an opportunity for evaluation. Draper J. **J Adv Nurs** 1996 Feb;23(2):267–71 (24 ref.)

HOSPITALIZATION

see related
CHILD, HOSPITALIZED
INSTITUTIONALIZATION
LENGTH OF STAY
PATIENT DISCHARGE

Individual factors that influence sleep after cardiac surgery. Simpson T, et al. **Am J Crit Care** 1996 May;5(3):182–9; quiz 190–1 (31 ref.)

Pediatric injury hospitalization in Hispanic children and non-Hispanic white children in southern California. Aagran PF, et al. **Arch Pediatr Adolesc Med** 1996 Apr; 150(4):400–6 (41 ref.)

ABC of atrial fibrillation. Atrial fibrillation in general and hospital practice [see comments] Lip GY, et al. **BMJ** 1996 Jan 20;312(7024):175–8 (5 ref.) Comment in: BMJ 1996 Apr 27;312(7028):1101.

Drug related hospital admissions in subspecialities of internal medicine. Hallas J. **Dan Med Bull** 1996 Apr;43(2):141–55 (178 ref.)

The feeding of patients in hospital: a review. McGlone PC, et al. **J R Soc Health** 1995 Oct;115(5):282–8 (49 ref.)

Nutrition support in hospitalized patients with diabetes mellitus. McMahon MM, et al. **Mayo Clin Proc** 1996 Jun; 71(6):587–94 (9 ref.)

[The problem of the frequent hospitalizations of the mentally ill] Dolgov SA.
Zh Nevropatol Psikhiatr Im S S Korsakova 1995;95(4):103–6 (73 ref.) **(Rus)**

ECONOMICS

An economic evaluation of schizophrenia—1991. Wyatt RJ, et al. **Soc Psychiatry Psychiatr Epidemiol** 1995 Aug; 30(5):196–205 (49 ref.)

HOSPITALIZED CHILD see **CHILD, HOSPITALIZED**

HOSPITALS

see related
HOSPITAL ADMINISTRATION

[Accreditation. Priority and challenge] Imperatori E.
Acta Med Port 1996 Jan;9(1):59–66 (16 ref.) (Eng. Abstr.) **(Por)**

STANDARDS

Strategic service quality management for health care. Anderson EA, et al. **Am J Med Qual** 1996 Spring; 11(1):3–10 (48 ref.)

UTILIZATION

The design and analysis of hospital utilization studies. Ash A. **Int J Qual Health Care** 1995 Sep;7(3):245–52 (18 ref.)

Appropriateness of hospital use: an overview of Italian studies. Fellin G, et al. **Int J Qual Health Care** 1995 Sep; 7(3):219–25 (12 ref.)

A European project assessing the appropriateness of hospital utilization: background, objectives and preliminary results. The Project Steering Group and the Coordinating Center. Liberati A, et al. **Int J Qual Health Care** 1995 Sep; 7(3):187–99 (111 ref.)

An overview of Spanish studies on appropriateness of hospital use. Lorenzo S, et al. **Int J Qual Health Care** 1995 Sep;7(3):213–8 (28 ref.)

The evolution of hospital utilization review methods in the United States. Restuccia JD. **Int J Qual Health Care** 1995 Sep;7(3):253–60 (19 ref.)

Medical appropriateness of hospital utilization: an overview of the Swiss experience. Santos-Eggimann B, et al.
Int J Qual Health Care 1995 Sep;7(3):227–32 (24 ref.)

[Wrong beds and wrong care] Hertogh CM, et al.
Ned Tijdschr Geneeskd 1996 Apr 20;140(16):868–70 (18 ref.) **(Dut)**

HOSPITALS, AIR FORCE see **HOSPITALS, MILITARY**

HOSPITALS, ANIMAL

[Occupational environment in veterinary clinics] Jensen BS, et al. **Ugeskr Laeger** 1996 Jan 15;158(3):265–9 (28 ref.) (Eng. Abstr.) **(Dan)**

HOSPITALS, ARMY see **HOSPITALS, MILITARY**

HOSPITALS, CANCER see **CANCER CARE FACILITIES**

HOSPITALS, CITY see **HOSPITALS, URBAN**

HOSPITALS, CITY, NON-PUBLIC-OWNED see **HOSPITALS, URBAN**

HOSPITALS, COUNTY

ORGANIZATION & ADMINISTRATION

Policy issues for improving institutional response to domestic violence. Langford DR. **J Nurs Adm** 1996 Jan;26(1):39–45 (29 ref.)

HOSPITALS, GROUP PRACTICE

ECONOMICS

You are in charge of cost. Loop FD. **Ann Thorac Surg** 1995 Nov;60(5):1509–12 (3 ref.)

HOSPITALS, METROPOLITAN see **HOSPITALS, URBAN**

HOSPITALS, MILITARY

Certified nurse midwives: over twenty years of military service. Davis LJ. **Mil Med** 1995 Aug;160(8):401–4 (20 ref.)

MANPOWER

Command of military medical units: grounding the paradigm. Jeffer EK. **Mil Med** 1996 Jun;161(6):346–8 (9 ref.)

ORGANIZATION & ADMINISTRATION

Managed care at Eisenhower Army Medical Center: an initial experience. Reinhart SI, et al. **Mil Med** 1995 Aug; 160(8):384–8 (23 ref.)

HOSPITALS, NAVY see **HOSPITALS, MILITARY**

HOSPITALS, PEDIATRIC

Building a pediatric cardiac catheterization laboratory and conference room: design considerations and filmless imaging. Mathewson JW. **Pediatr Cardiol** 1996 Sep–Oct; 17(5):279–94 (30 ref.)

HOSPITALS, PSYCHIATRIC

[The deconstructions of schizophrenia (I)] Moriyama K.
Seishin Shinkeigaku Zasshi 1995;97(5):309–25 (41 ref.) (Eng. Abstr.) **(Jpn)**

HOSPITALS, PUBLIC

ECONOMICS

What value do computers provide to NHS hospitals? [see comments] Lock C. **BMJ** 1996 Jun 1;312(7043):1407–10 (65 ref.) Comment in: BMJ 1996 Jun 1;312(7043):1371–2.

ORGANIZATION & ADMINISTRATION

Infection control in public hospitals. Wurtz R.
Infect Control Hosp Epidemiol 1995 Nov;16(11):642–6 (7 ref.)

UTILIZATION

Appropriateness of hospital use in the United Kingdom: a review of activity in the field. O'Neill D, et al.
Int J Qual Health Care 1995 Sep;7(3):239–44 (22 ref.)

HOSPITALS, TEACHING

Nurse practitioners in a teaching hospital. Genet CA, et al. **Nurse Pract** 1995 Sep;20(9):47–52, 54 (33 ref.)

Morning report and work rounds: opportunities for teaching and learning. Schiffman FJ.
Trans Am Clin Climatol Assoc 1995;107:275–86 (19 ref.)

UTILIZATION

Appropriateness of admissions: the French experience. Lang T, et al. **Int J Qual Health Care** 1995 Sep;7(3):233–8 (16 ref.)

HOSPITALS, URBAN

ORGANIZATION & ADMINISTRATION

Local markets and systems: hospital consolidations in metropolitan areas. Luke RD, et al. **Health Serv Res** 1995 Oct;30(4):555–75 (23 ref.)

Inner-city hospitals: a call for research. Gautam K, et al. **J Health Care Poor Underserved** 1995;6(4):387–402 (49 ref.)

UTILIZATION

Appropriateness of admissions: the French experience. Lang T, et al. **Int J Qual Health Care** 1995 Sep;7(3):233–8 (16 ref.)

HOSPITALS, VETERANS

STANDARDS

Identifying complications and low provider adherence to normative practices using administrative data. Kuykendall DH, et al. **Health Serv Res** 1995 Oct;30(4):531–54 (28 ref.)

HOSPITALS, VETERINARY see **HOSPITALS, ANIMAL**

HOST-PARASITE RELATIONS

A ubiquitous intracellular parasite: the cellular biology of Toxoplasma gondii. Smith JE. **Int J Parasitol** 1995 Nov; 25(11):1301–9 (88 ref.)

Interactions between parasites and insects vectors. Hurd H. **Mem Inst Oswaldo Cruz** 1994;89 Suppl 2:27–30 (20 ref.)

Parasites and carotenoid-based signal intensity: how general should the relationship be? Shykoff JA, et al.
Naturwissenschaften 1996 Mar;83(3):113–21 (66 ref.)

Dynamic interactions in malaria: host heterogeneity meets parasite polymorphism. Gupta S, et al.
Proc R Soc Lond B Biol Sci 1995 Sep 22;261(1362):271–7 (39 ref.)

Adenovirus and Epstein-Barr virus in lung disease. Hogg JC, et al. **Semin Respir Infect** 1995 Dec;10(4):244–53 (34 ref.)

[Microsporidia—biology and clinical relevance] Franzen C, et al. **Med Klin** 1996 May 15;91(5):284–94 (106 ref.) **(Ger)**

[Parasitologic significance of the alteration of the causative Anisakidae worm and of the Pseudoterranova decipiens female immature adult worm, casting off the cuticles, and excreted from human in Kanazawa City] Ishikura H, et al. **Hokkaido Igaku Zasshi** 1995 Sep;70(5):667–85 (48 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Pathogen-based models favoring MHC genetic diversity. Potts WK, et al. **Immunol Rev** 1995 Feb;143:181–97 (37 ref.)

IMMUNOLOGY

Of microbes and macrophages: entry, survival and persistence. Russell DG. **Curr Opin Immunol** 1995 Aug; 7(4):479–84 (59 ref.)

Immune mechanisms underlying the premunition against Plasmodium falciparum malaria. Pérignon JL, et al.
Mem Inst Oswaldo Cruz 1994;89 Suppl 2:51–3 (13 ref.)

PHYSIOLOGY

"Adaptive" changes in the behaviour of parasitized animals: a critical review. Poulin R. **Int J Parasitol** 1995 Dec; 25(12):1371–83 (102 ref.)

HOST VS GRAFT REACTION

Can graft endothelial cells initiate a host anti-graft immune response? Pober JS, et al. **Transplantation** 1996 Feb 15; 61(3):343–9 (72 ref.)

HOSTILITY

Working with noncompliant and abusive dialysis patients: practical strategies based on ethics and the law. Johnson CC, et al. **Adv Ren Replace Ther** 1996 Jan;3(1):77–86 (40 ref.)

The difficult elderly patient: curable hostile depression or personality disorder? Monfort JC. **Int Psychogeriatr** 1995; 7 Suppl:95–111 (50 ref.)

Work group culture, stress, and hostility. Correlations with organizational outcomes. Seago JA. **J Nurs Adm** 1996 Jun; 26(6):39–47 (56 ref.)

HOUSE CALLS

Drugs for the doctor's bag [see comments]
Drug Ther Bull 1995 Jan 19;33(1):3–5 (8 ref.) Comment in: Drug Ther Bull 1995 Jul;33(7):56.

HOUSE STAFF see **INTERNSHIP AND RESIDENCY**

HOUSING

Foodborne disease and other hygiene issues in the home. Scott E. **J Appl Bacteriol** 1996 Jan;80(1):5–9 (37 ref.)
Housing for persons with co-occurring mental and addictive disorders. Osher FC, et al. **New Dir Ment Health Serv** 1996 Summer;(70):53–64 (37 ref.)
Exposure of children to pollutants in house dust and indoor air. Roberts JW, et al. **Rev Environ Contam Toxicol** 1995; 143:59–78 (74 ref.)

STANDARDS

Condensation and mould: the Canadian experience. Rayner KF. **J R Soc Health** 1996 Apr;116(2):83–6 (19 ref.)

HOUSING, ANIMAL

STANDARDS

Recommended biocontainment features for research and diagnostic facilities where animal pathogens are used. First International Veterinary Biosafety Workshop. Barbeito MS, et al. **Rev Sci Tech** 1995 Sep;14(3):873–87 (8 ref.)
Disinfecting equine facilities. Dwyer RM. **Rev Sci Tech** 1995 Jun;14(2):403–18 (4 ref.)
Disinfection of stockyards. Fotheringham VJ. **Rev Sci Tech** 1995 Jun;14(2):293–307 (21 ref.)
Disinfection of livestock production premises. Fotheringham VJ. **Rev Sci Tech** 1995 Mar;14(1):191–205 (21 ref.)
Use of disinfectants in zoos and game parks. Heuschele WP. **Rev Sci Tech** 1995 Jun;14(2):447–54 (14 ref.)
Disinfecting poultry production premises. Meroz M, et al. **Rev Sci Tech** 1995 Jun;14(2):273–91 (27 ref.)
Disinfection of farrowing pens. Owen JM. **Rev Sci Tech** 1995 Jun;14(2):381–91 (18 ref.)

TRENDS

[Developmental trends in farm animal husbandry from an ethological point of view] Graf B. **Schweiz Arch Tierheilkd** 1995;137(9):423–31 (12 ref.) (Eng. Abstr.) **(Ger)**

HOUSING FOR THE ELDERLY

see related
HOMES FOR THE AGED

Embodiment and emplacement: identities, representation and landscape in Sun City retirement communities. Laws G. **Int J Aging Hum Dev** 1995;40(4):253–80 (60 ref.)

ORGANIZATION & ADMINISTRATION

The medical director in the multi-level long-term care facility. Applebaum GE. **Clin Geriatr Med** 1995 Aug; 11(3):359–72 (4 ref.)

HPLC see **CHROMATOGRAPHY, HIGH PRESSURE LIQUID**

4-HPR see **FENRETINIDE**

HPRT see **HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE**

HRF20 see **ANTIGENS, CD59**

HSAN TYPE III see **DYSAUTONOMIA, FAMILIAL**

HSP60 FAMILY see **CHAPERONIN 60**

HSP70 FAMILY see **HEAT-SHOCK PROTEINS 70**

HSV-1 PROTEIN VP16 see **HERPES SIMPLEX VIRUS PROTEIN VMW65**

5-HT see **SEROTONIN**

5-HT AGONISTS see **SEROTONIN AGONISTS**

5-HT ANTAGONISTS see **SEROTONIN ANTAGONISTS**

5-HT RECEPTORS see **RECEPTORS, SEROTONIN**

5-HT UPTAKE INHIBITORS see **SEROTONIN UPTAKE INHIBITORS**

HTLV-BLV INFECTIONS

TRANSMISSION

[The actual risk of retrovirus transmission from transfusions] Soriano V, et al. **Sangre (Barc)** 1995 Oct;40(5):407–16 (118 ref.) **(Spa)**

HTLV-BLV VIRUSES

METABOLISM

Proteins of bovine leukemia virus and human T-cell leukemia viruses. Hrušková-Heidingsfeldová O. **Folia Biol (Praha)** 1995;41(5):201–12 (66 ref.)

HTLV INFECTIONS see **HTLV-BLV INFECTIONS**

HTLV VIRUSES see **HTLV-BLV VIRUSES**

HTLV-I

HTLV-I in Australia and Oceania: long-term resident or recent immigrant? Doherty RR. **Med J Aust** 1996 Jan 15; 164(2):84–6 (35 ref.)

GENETICS

Activation of NF-kappa B by the Tax protein of HTLV-1. Munoz E, et al. **Immunobiology** 1995 Jul;193(2–4):128–36 (54 ref.)
Examining the molecular genetics of HTLV-I with an infectious molecular clone of the virus and permissive cell culture systems. Derse D, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 May 1;12(1):1–5 (36 ref.)
Role of kinases in HTLV-I transformation. Xu X, et al. **J Investig Med** 1996 Apr;44(4):113–23 (169 ref.)
Clinical implication of the integration patterns of human T-cell lymphotropic virus type I proviral DNA in adult T-cell leukemia/lymphoma. Shimamoto Y, et al. **Leuk Lymphoma** 1996 Jan;20(3–4):207–15 (51 ref.)
Parathyroid hormone-related protein gene expression and human T cell leukemia virus-1 infection. Ejima E, et al. **Miner Electrolyte Metab** 1995;21(1–3):143–7 (53 ref.)
[Gene structure and transformation mechanism of HTLV-I] Matsumoto K. **Nippon Rinsho** 1995 Nov;53(11):2837–45 (21 ref.) (Eng. Abstr.) **(Jpn)**
[Expression of sequences homologous to HTLV-I pXIV gene in the labial salivary glands of Japanese patients with Sjögren's syndrome and pathogenesis] Yonaha-Nagato F, et al. **Nippon Rinsho** 1995 Oct;53(10):2473–8 (13 ref.) (Eng. Abstr.) **(Jpn)**
[Chronic rheumatoid arthritis model mice transgenic for the HTLV-I tax gene] Iwakura Y. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2074–82 (33 ref.) **(Jpn)**

IMMUNOLOGY

Human T lymphotropic virus, type-I myelopathy: an immunopathologically mediated chronic progressive disease of the central nervous system. Jacobson S. **Curr Opin Neurol** 1995 Jun;8(3):179–83 (35 ref.)

ISOLATION & PURIFICATION

No detection of HTLV-I proviral DNA in lesional skin biopsies from Swiss and German patients with cutaneous T-cell lymphoma. Böni R, et al. **Br J Dermatol** 1996 Feb; 134(2):282–4 (20 ref.)
Human T-lymphotropic retrovirus type-1 (HTLV-1) and its distribution in Asian populations. Ishida T. **Southeast Asian J Trop Med Public Health** 1995;26 Suppl 1:182–9 (28 ref.)
[In situ PCR detection of HTLV-1 provirus in spinal cord lesions with HAM/TSP] Izumo S, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):656–9 (16 ref.) **(Jpn)**
[Analysis of HTLV-1 expression in vivo] Saito M, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):681–5 (13 ref.) **(Jpn)**

METABOLISM

Molecular interactions between HTLV-1 Tax protein and the NF-kappa B/kappa B transcription complex. Hiscott J, et al. **Virology** 1995 Dec 1;214(1):3–11 (77 ref.)

PATHOGENICITY

Cellular transformation by human T-cell leukemia virus type I. Ressler S, et al. **FEMS Microbiol Lett** 1996 Jul 1; 140(2–3):99–109 (60 ref.)

PHYSIOLOGY

Molecular mechanisms of human T-cell leukemia/lymphotropic virus type I infection. Franchini G. **Blood** 1995 Nov 15;86(10):3619–39 (318 ref.)
The natural history and evolution of human and simian T cell leukemia/lymphotropic viruses. Dekaban GA, et al. **Curr Opin Genet Dev** 1995 Dec;5(6):807–13 (42 ref.)
[The role of the HTLV-I virus in transformation of T lymphocytes] Papież M. **Postepy Hig Med Dosw** 1995; 49(5):585–97 (64 ref.) (Eng. Abstr.) **(Pol)**

HTLV-I-ASSOCIATED MYELOPATHY see **PARAPARESIS, TROPICAL SPASTIC**

HTLV-I-ASSOCIATED T-CELL LEUKEMIA-LYMPHOMA see **LEUKEMIA-LYMPHOMA, T-CELL, ACUTE, HTLV-I-ASSOCIATED**

HTLV-I INFECTIONS

Molecular mechanisms of human T-cell leukemia/lymphotropic virus type I infection. Franchini G. **Blood** 1995 Nov 15;86(10):3619–39 (318 ref.)
Chronic progressive myeloneuropathy in WKAH rats induced by HTLV-I infection as an animal model for HAM/TSP in humans. Yoshiki T. **Intervirology** 1995; 38(3–4):229–37 (40 ref.)

COMPLICATIONS

Human T lymphotropic virus type I in arthropathy and autoimmune disorders. Nishioka K, et al. **Arthritis Rheum** 1996 Aug;39(8):1410–8 (55 ref.)
Human T-lymphotropic virus type 1 and its ocular manifestations. Mochizuki M. **Int Ophthalmol Clin** 1995 Spring;35(2):107–20 (28 ref.)
[HTLV-I infection in primary Sjögren's syndrome--epidemiological, clinical and virological studies] Eguchi K, et al. **Nippon Rinsho** 1995 Oct; 53(10):2467–72 (20 ref.) (Eng. Abstr.) **(Jpn)**

EPIDEMIOLOGY

Human T-lymphotropic retrovirus type-1 (HTLV-1) and its distribution in Asian populations. Ishida T. **Southeast Asian J Trop Med Public Health** 1995;26 Suppl 1:182–9 (28 ref.)
Heterosexual transmission of HTLV-I. Epidemiological aspects. Figueroa JP. **West Indian Med J** 1996 Mar; 45(1):4–8 (80 ref.)

ETIOLOGY

Transgenic models of HTLV-I mediated disease and latency. Nerenberg M, et al. **Curr Top Microbiol Immunol** 1996; 206:175–96 (58 ref.)

IMMUNOLOGY

[The viewpoints of viral vertical transmission from fetal neonatal immunologic aspects] Ichijo M. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Aug; 47(8):713–23 (0 ref.) (Eng. Abstr.) **(Jpn)**

PREVENTION & CONTROL

Design of experimental synthetic peptide immunogens for prevention of HIV-1 and HTLV-I retroviral infections. Hart MK, et al. **Pharm Biotechnol** 1995;6:821–45 (175 ref.)

THERAPY

Gene therapy against retroviral diseases. Essex M, et al. **Leukemia** 1995 Oct;9 Suppl 1:S71–4 (13 ref.)

TRANSMISSION

Adult T-cell leukemia. Takatsuki K. **Intern Med** 1995 Oct; 34(10):947–52 (68 ref.)
Heterosexual transmission of HTLV-I. Epidemiological aspects. Figueroa JP. **West Indian Med J** 1996 Mar; 45(1):4–8 (80 ref.)
[The viewpoints of viral vertical transmission from fetal neonatal immunologic aspects] Ichijo M. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Aug; 47(8):713–23 (0 ref.) (Eng. Abstr.) **(Jpn)**

VIROLOGY

HTLV-I in Australia and Oceania: long-term resident or recent immigrant? Doherty RR. **Med J Aust** 1996 Jan 15; 164(2):84–6 (35 ref.)

HTLV-I REX GENES see **GENES, PX**

HTLV-I TAX GENES see **GENES, PX**

HTLV-I TAX PROTEIN see **GENE PRODUCTS, TAX**

HTLV-I TRANS-ACTIVATOR PROTEIN see **GENE PRODUCTS, TAX**

HTLV-II

PHYSIOLOGY

The natural history and evolution of human and simian T cell leukemia/lymphotropic viruses. Dekaban GA, et al. **Curr Opin Genet Dev** 1995 Dec;5(6):807–13 (42 ref.)

HTLV-II REX GENES see **GENES, PX**

HTLV-II TAX GENES see **GENES, PX**

HTLV-II TAX PROTEIN see **GENE PRODUCTS, TAX**

HTLV-II TRANS-ACTIVATOR PROTEIN see **GENE PRODUCTS, TAX**

HTLV-III see **HIV**

HTLV-III ANTIBODIES see **HIV ANTIBODIES**

HTLV-III ANTIGENS see **HIV ANTIGENS**

HTLV-III GP120 see **HIV ENVELOPE PROTEIN GP120**

HTLV-III INFECTIONS see **HIV INFECTIONS**

HTLV-III-LAV ANTIBODIES see **HIV ANTIBODIES**

HTLV-III-LAV ANTIGENS see **HIV ANTIGENS**

HTLV-III-LAV INFECTIONS see **HIV INFECTIONS**

HTLV-III PROTEASE see **HIV PROTEASE**

HTLV-III RECEPTORS see **RECEPTORS, HIV**

HTLV-III SEROCONVERSION see **HIV SEROPOSITIVITY**

HTLV-III SERODIAGNOSIS see **AIDS SERODIAGNOSIS**

HTLV-III SEROLOGY see **AIDS SERODIAGNOSIS**

HTLV-III SERONEGATIVITY see **HIV SERONEGATIVITY**

HTLV-III SEROPOSITIVITY see **HIV SEROPOSITIVITY**

HTLV-IV see **HIV-2**

HUMAN CHORIONIC GONADOTROPIN, ALPHA SUBUNIT see **GLYCOPROTEIN HORMONES, ALPHA SUBUNIT**

HUMAN CHORIONIC GONADOTROPIN, BETA SUBUNIT see **CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN**

HUMAN CHORIONIC GONADOTROPIN RECEPTORS see **RECEPTORS, LH**

HUMAN CLASS II ANTIGENS see **HLA-D ANTIGENS**

HUMAN DEVELOPMENT

Constructivist developmental theory and therapy: implications for counseling adolescents. Crespi TD, et al. **Adolescence** 1995 Fall;30(119):735–43 (20 ref.)

Life-span intellectual development of people with mental retardation. Trower T, et al. **Dev Med Child Neurol** 1996 Jul;38(7):645–50 (25 ref.)

Human development in the context of aging and chronic illness: the role of attachment in Alzheimer's disease and stroke. Wright LK, et al. **Int J Aging Hum Dev** 1995; 41(2):133–50 (82 ref.)

HUMAN ENGINEERING

Improving workplace environments and working conditions at worksites providing school lunch service in Japan. Koda S, et al. **J Hum Ergol (Tokyo)** 1995 Jun;24(1):93–101 (26 ref.)

Participatory ergonomics that builds on local solutions. Kogi K. **J Hum Ergol (Tokyo)** 1995 Jun;24(1):37–45 (17 ref.)

The need for ergonomics considerations for the design and development of agricultural machinery in Thailand. Mamansari DU, et al. **J Hum Ergol (Tokyo)** 1995 Jun; 24(1):61–72 (11 ref.)

Ergonomics for industrially developing countries: an alternative approach. Rubio CA. **J Hum Ergol (Tokyo)** 1995 Jun;24(1):119–23 (3 ref.)

The irruption of new technologies: a new challenge for ergonomics and anthropotechnology. Wisner A. **J Hum Ergol (Tokyo)** 1995 Jun;24(1):45–55 (30 ref.)

HUMAN EXPERIMENTATION

Competing or complementary? Ethical considerations and the quality of randomized trials. Lumley J, et al. **Int J Technol Assess Health Care** 1996 Spring;12(2):247–63 (103 ref.)

Questing for grails: duplicity, betrayal and self-deception in postmodern medical research. Annas GJ. **J Contemp Health Law Policy** 1996 Spring;12(2):297–324 (101 ref.)

Deception in medical and behavioral research: is it ever acceptable? Wendler D. **Milbank Q** 1996;74(1):87–114 (18 ref.)

[Informed consent and mental competence of the elderly in medical-scientific studies] Olde Rikkert MG, et al. **Tijdschr Gerontol Geriatr** 1995 Aug;26(4):152–62 (40 ref.) (Eng. Abstr.) **(Dut)**

HUMAN FOAMY VIRUS see **SPUMAVIRUS**

HUMAN FOREFOOT see **FOREFOOT, HUMAN**

HUMAN GENOME see **GENOME, HUMAN**

HUMAN GENOME PROJECT

The role of the genome project in determining gene function: insights from model organisms. Miklos GL, et al. **Cell** 1996 Aug 23;86(4):521–9 (92 ref.)

Ethics, genomics, and information retrieval. Goodman KW. **Comput Biol Med** 1996 May;26(3):223–9 (23 ref.)

A cell biological perspective on genome research. McIntosh JR, et al. **J Cell Biol** 1995 Dec;131(6 Pt 1):1361–4 (12 ref.)

Genotoxicology and risk assessment in the era of the human genome project. Vorce RL, et al. **J Toxicol Clin Toxicol** 1996;34(5):521–3 (10 ref.)

The new genetics and women. Mahowald MB, et al. **Milbank Q** 1996;74(2):239–83 (160 ref.)

Pressing ahead with human genome sequencing. Gibbs RA. **Nat Genet** 1995 Oct;11(2):121–5 (35 ref.)

The Human Genome Project: an overview of ethical issues and public policy concerns. Ott BB. **Nurs Outlook** 1995 Sep–Oct;43(5):228–31 (13 ref.)

[Progresses in medical genetics in China, 1995] Wu M, et al. **Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):780 (0 ref.) **(Chi)**

[The high fork of genome programs (editorial)] Weissenbach J. **C R Acad Sci III** 1996 Apr;319(4):247–8 (11 ref.) **(Fre)**

[The Russian human genome program] Baev AA. **Mol Biol (Mosk)** 1995 May–Jun;29(3):489–99 (35 ref.) **(Rus)**

HUMAN IDENTIFICATION see **FORENSIC ANTHROPOLOGY**

HUMAN IMMUNODEFICIENCY VIRUS-ASSOCIATED NEPHROPATHY see **AIDS-ASSOCIATED NEPHROPATHY**

HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 see **HIV-1**

HUMAN IMMUNODEFICIENCY VIRUS TYPE 2 see **HIV-2**

HUMAN IMMUNODEFICIENCY VIRUSES see **HIV**

HUMAN LEUKOCYTE ANTIGEN DNA PROBES see **DNA PROBES, HLA**

HUMAN B-LYMPHOTROPIC VIRUS see **HERPESVIRUS 6, HUMAN**

HUMAN T LYMPHOTROPIC VIRUS-ASSOCIATED LEUKEMIA-LYMPHOMA see **LEUKEMIA-LYMPHOMA, T-CELL, ACUTE, HTLV-I-ASSOCIATED**

HUMAN T-LYMPHOTROPIC VIRUS II see **HTLV-II**

HUMAN T-LYMPHOTROPIC VIRUS TYPE III see **HIV**

HUMAN T-LYMPHOTROPIC VIRUS TYPE IV see **HIV-2**

HUMAN PARVOVIRUS B19 see **PARVOVIRUS B19, HUMAN**

HUMAN-PET BONDING see **BONDING, HUMAN-PET**

HUMAN PLATELET ANTIGENS see **ANTIGENS, HUMAN PLATELET**

HUMAN RIGHTS

see related
CIVIL RIGHTS
WOMEN'S RIGHTS

Drug use and human rights: privacy, vulnerability, disability, and human rights infringements. Gilmore N. **J Contemp Health Law Policy** 1996 Spring;12(2):355–447 (348 ref.)

Fetal viability as a threshold to personhood. A legal analysis. Peterfy A. **J Leg Med** 1995 Dec;16(4):607–36 (344 ref.)

Human rights and medical practice, including reference to the joint Oslo statements of September 1993 and March 1994. Aldershade R. **J Public Health Med** 1995 Sep; 17(3):335–42 (7 ref.)

Fashioning a work-based strategy for welfare reform based on international human rights doctrine. Harvey P. **J Public Health Policy** 1995;16(3):269–85 (22 ref.)

LEGISLATION & JURISPRUDENCE

[The disabled in the community—towards equal opportunity] Ohry A, et al. **Harefuah** 1996 Apr 1;130(7):483–5 (26 ref.) **(Heb)**

HUMAN T-CELL LEUKEMIA-LYMPHOMA see **LEUKEMIA-LYMPHOMA, T-CELL, ACUTE, HTLV-I-ASSOCIATED**

HUMAN T-CELL LEUKEMIA-LYMPHOMA VIRUSES see **HTLV-BLV VIRUSES**

HUMAN T-CELL LEUKEMIA VIRUS I see **HTLV-I**

HUMAN T-CELL LEUKEMIA VIRUS II see **HTLV-II**

HUMAN T-CELL LEUKEMIA VIRUS TYPE I TAX PROTEIN see **GENE PRODUCTS, TAX**

HUMAN T-CELL LEUKEMIA VIRUSES see **HTLV-BLV VIRUSES**

HUMAN T-CELL LYMPHOTROPIC VIRUS TYPE III see **HIV**

HUMANISM

Nationally speaking. Life history and narrative research: generating a humanistic knowledge base for occupational therapy. Larson EA, et al. **Am J Occup Ther** 1996 Apr; 50(4):247–50 (27 ref.)

Nursing, humanism and transcultural theory: the 'bracketing-out' of reality. Mulholland J. **J Adv Nurs** 1995 Sep;22(3):442–9 (43 ref.)

Humanism and positivism in nursing: contradictions and conflicts. Playle JF. **J Adv Nurs** 1995 Nov;22(5):979–84 (46 ref.)

HUMANITARIANISM see **ALTRUISM**

HUMERAL FRACTURES

COMPLICATIONS

Dislocation of the shoulder and ipsilateral fracture of the humeral shaft: case reports and literature review. Kontakis GM, et al. **J Trauma** 1995 Nov;39(5):990–2 (18 ref.)

Anterior glenohumeral dislocation with ipsilateral humeral shaft fracture. Davick J, et al. **Orthopedics** 1995 Aug; 18(8):745–8 (6 ref.)

SURGERY

The rationales of interlocking nailing of the femur, tibia, and humerus. Brumback RJ. **Clin Orthop** 1996 Mar; (324):292–320 (142 ref.)

[Plate osteosynthesis in humerus shaft fracture] Kuner EH, et al. **Chirurg** 1995 Nov;66(11):1085–91 (14 ref.) (Eng. Abstr.) **(Ger)**

[Intramedullary nailing of the humerus as an alternative to conservative therapy and to plate osteosynthesis] Kessler SB, et al. **Orthopade** 1996 Jun;25(3):216–22 (57 ref.) (Eng. Abstr.) **(Ger)**

[Fractures of the distal humerus and proximal forearm] Dorow C, et al. **Unfallchirurg** 1996 Jun;99(6):440–9 (10 ref.) **(Ger)**

VETERINARY

Fractures of the humerus. Rakestraw PC. **Vet Clin North Am Food Anim Pract** 1996 Mar;12(1):153–68 (31 ref.)

HUMERAL FRACTURES, PROXIMAL see **SHOULDER FRACTURES**

HUMERUS

Recurrent endometrial adenocarcinoma presenting as a solitary humeral metastasis. Schöls WA, et al. **Gynecol Oncol** 1995 Oct;59(1):148–50 (14 ref.)

[Radiotherapy in advanced osseous destruction in chronic myeloid leukemia. A case report] Sadick M, et al. **Strahlenther Onkol** 1996 Jun;172(6):330–1 (9 ref.) (Eng. Abstr.) **(Ger)**

ABNORMALITIES

Autosomal recessive omodysplasia. Stoll C, et al. **Ann Genet** 1995;38(2):97–101 (8 ref.)

[Congenital humeroradial synostosis] Fernández Torrico J, et al. **An Esp Pediatr** 1996 Jun;44(6):612–4 (10 ref.) **(Spa)**

RADIOGRAPHY

Fracture-dislocation of the shoulder with intrathoracic displacement of the humeral head. Kaar TK, et al. **Injury** 1995 Nov;26(9):638–9 (4 ref.)

HUMIDITY

Condensation and mould: the Canadian experience. Rayner KF. **J R Soc Health** 1996 Apr;116(2):83–6 (19 ref.)

ADVERSE EFFECTS

[Hypersensitivity pneumonitis caused by a home humidifier] Hagiwara S, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Sep; 33(9):1024–9 (10 ref.) (Eng. Abstr.) **(Jpn)**

HUNTER'S SYNDROME see **MUCOPOLYSACCHARIDOSIS II**

HUNTINGTON CHOREA see **HUNTINGTON'S DISEASE**

HUNTINGTON'S DISEASE

DIAGNOSIS

[Pre-symptomatic diagnosis of Huntington disease by polymerase chain reaction] Tóth T, et al. **Orv Hetil** 1996 Mar 3;137(9):451–4 (25 ref.) (Eng. Abstr.) **(Hun)**

HUNTINGTON'S DISEASE

GENETICS

Huntington disease—another chapter rewritten [editorial] Nance MA. **Am J Hum Genet** 1996 Jul;59(1):1–6 (59 ref.)
Huntington's disease. Their loss is our gain? Feero W, et al. **Curr Biol** 1995 Nov 1;5(11):1229–31 (17 ref.)
Huntington's disease: CAG genetics expands neurobiology. Gusella JF, et al. **Curr Opin Neurobiol** 1995 Oct;5(5):656–62 (56 ref.)
Origins and evolution of Huntington disease chromosomes. Andrew SE, et al. **Neurodegeneration** 1995 Sep;4(3):239–44 (50 ref.)
[Molecular genetics of Huntington's disease] Achiron A, et al. **Harefuah** 1996 Jan 1;130(1):30–2 (33 ref.) **(Heb)**
[Gene analysis of Huntington's disease] Kanazawa I. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1995 Oct; 15(5):419–24 (13 ref.) **(Jpn)**
[Huntington's disease gene: molecular genetics and molecular biology] Kanazawa I. **No To Shinkei** 1996 Apr;48(4):333–44 (57 ref.) **(Jpn)**

METABOLISM

Free radical damage and oxidative stress in Huntington's disease. Borlongan CV, et al. **J Fla Med Assoc** 1996 May; 83(5):335–41 (0 ref.)

SURGERY

Neural transplantation for Huntington's disease: experimental rationale and recommendations for clinical trials. Shannon KM, et al. **Cell Transplant** 1996 Mar–Apr;5(2):339–52 (107 ref.)
Core Assessment Program for Intracerebral Transplantation in Huntington's Disease (CAPIT–HD). Quinn N, et al. **Mov Disord** 1996 Mar;11(2):143–50 (44 ref.)

THERAPY

Development of the human striatum: implications for fetal striatal transplantation in the treatment of Huntington's disease. Freeman TB, et al. **Cell Transplant** 1995 Nov–Dec; 4(6):539–45 (61 ref.)
Rationale for intrastriatal grafting of striatal neuroblasts in patients with Huntington's disease. Peschanski M, et al. **Neuroscience** 1995 Sep;68(2):273–85 (159 ref.)

HURLER-SCHEIE SYNDROME see **MUCOPOLYSACCHARIDOSIS I**

HURLER'S SYNDROME see **MUCOPOLYSACCHARIDOSIS I**

HURRICANES see **NATURAL DISASTERS**

HUSBANDS see **SPOUSES**

HUTCHINSON'S MELANOTIC FRECKLE

Lentigo maligna and lentigo maligna melanoma. Cohen LM. **J Am Acad Dermatol** 1995 Dec;33(6):923–36; quiz 937–40 (225 ref.)

HUTCHINSON'S TEETH see **SYPHILIS, CONGENITAL**

HY ANTIGEN see **H–Y ANTIGEN**

HYALIN

[Hyalinizing clear cell carcinoma of the salivary glands] Seifert G, et al. **Pathologe** 1996 Mar;17(2):110–5 (26 ref.) (Eng. Abstr.) **(Ger)**

HYALIN SUBSTANCE see **HYALIN**

HYALINE MEMBRANE DISEASE

DRUG THERAPY

[Natural or artificial surfactants? Arguments in favour of natural surfactants] Walti H. **Arch Pediatr** 1996 Feb; 3(2):165–75 (93 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

[Exogenous surfactants in neonatology] Zupan V, et al. **Rev Mal Respir** 1995;12(6):642–5 (17 ref.) **(Fre)**

HYALINOSIS, SEGMENTAL see **GLOMERULOSCLEROSIS, FOCAL**

HYALURONAN-BINDING PROTEIN see **ANTIGENS, CD44**

HYALURONAN RECEPTORS see **ANTIGENS, CD44**

HYALURONIC ACID

Musculoskeletal applications of hyaluronan and hylan. Potential uses in the foot and ankle. Weiss C, et al. **Clin Podiatr Med Surg** 1995 Jul;12(3):497–517 (44 ref.)

ANALOGS & DERIVATIVES

Musculoskeletal applications of hyaluronan and hylan. Potential uses in the foot and ankle. Weiss C, et al. **Clin Podiatr Med Surg** 1995 Jul;12(3):497–517 (44 ref.)

BIOSYNTHESIS

Does DG42 synthesize hyaluronan or chitin?: A controversy about oligosaccharides in vertebrate development. Varki A. **Proc Natl Acad Sci U S A** 1996 May 14;93(10):4523–5 (53 ref.)

BLOOD

Hyaluronan in inflammatory joint disease. Laurent TC, et al. **Acta Orthop Scand Suppl** 1995 Oct;266:116–20 (39 ref.)

METABOLISM

Tumor-associated hyaluronan. Providing an extracellular matrix that facilitates invasion [comment] Knudson W. **Am J Pathol** 1996 Jun;148(6):1721–6 (36 ref.) Comment on: Am J Pathol 1996 Jun;148(6):1861–9.
Interactions between CD44 and hyaluronic acid: their role in tumor growth and metastasis. Sy MS, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 3):129–53 (150 ref.)

PHYSIOLOGY

Hyaluronan: RHAMM mediated cell locomotion and signaling in tumorigenesis. Hall CL, et al. **J Neurooncol** 1995 Dec;26(3):221–9 (84 ref.)

THERAPEUTIC USE

Hyaluronan receptor antagonists alter skin inflammation and fibrosis following injury. Savani RC, et al. **Proc West Pharmacol Soc** 1995;38:131–6 (68 ref.)

HYALURONIDASE

Hyaluronidases—a group of neglected enzymes. Kreil G. **Protein Sci** 1995 Sep;4(9):1666–9 (52 ref.)

ADVERSE EFFECTS

Posttraumatic macroglossia complicated by hyaluronidase injection. Dort JC. **Otolaryngol Head Neck Surg** 1996 Feb; 114(2):308–9 (9 ref.)

HYBRID CELLS

Mapping of mammalian genomes with radiation (Goss and Harris) hybrids. Leach RJ, et al. **Adv Genet** 1995;33:63–99 (82 ref.)

PHYSIOLOGY

Transdifferentiation induced by gene transfer. Boukamp P. **Semin Cell Biol** 1995 Jun;6(3):157–63 (35 ref.)

HYBRIDIZATION

GENETICS

Hybrid speciation. Evolution under the microscope. Charlesworth D. **Curr Biol** 1995 Aug 1;5(8):835–6 (9 ref.)

HYBRIDIZATION IN SITU see **IN SITU HYBRIDIZATION**

HYBRIDIZATION IN SITU, FLUORESCENCE see **IN SITU HYBRIDIZATION, FLUORESCENCE**

HYBRIDOMA GROWTH FACTOR see **INTERLEUKIN–6**

HYBRIDOMAS

see related
ANTIBODIES, MONOCLONAL

HYDATID CYST see **ECHINOCOCCOSIS**

HYDATID CYST, HEPATIC see **ECHINOCOCCOSIS, HEPATIC**

HYDATIDIFORM MOLE

GENETICS

Flow cytometric and clinicopathologic study of 197 hydatidiform moles with special reference to the significance of cytometric aneuploidy and literature review. Fukunaga M, et al. **Cytometry** 1995 Jun 15;22(2):135–8 (21 ref.)

HYDATIDOSIS see **ECHINOCOCCOSIS**

HYDATIDOSIS, HEPATIC see **ECHINOCOCCOSIS, HEPATIC**

HYDRALAZINE

ADVERSE EFFECTS

Hydralazine-induced constrictive pericarditis. Franssen CF, et al. **Neth J Med** 1996 May;48(5):193–7 (21 ref.)

HYDRALLAZIN see **HYDRALAZINE**

HYDRAMNIOS see **POLYHYDRAMNIOS**

HYDRASES see **HYDRO–LYASES**

HYDRATED ALUMINA see **ALUMINUM HYDROXIDE**

HYDRAZINES

CHEMISTRY

Arylhydrazines as probes of hemoprotein structure and function. Ortiz de Montellano PR. **Biochimie** 1995; 77(7–8):581–93 (60 ref.)

HYDRO–LYASES

CHEMISTRY

Structure and function of PCD/DCoH, an enzyme with regulatory properties. Suck D, et al. **FEBS Lett** 1996 Jun 24;389(1):35–9 (31 ref.)
PCD/DCoH: more than a second molecular saddle. Kim JL, et al. **Structure** 1995 Jun 15;3(6):531–4 (21 ref.)

METABOLISM

Structure and function of PCD/DCoH, an enzyme with regulatory properties. Suck D, et al. **FEBS Lett** 1996 Jun 24;389(1):35–9 (31 ref.)
PCD/DCoH: more than a second molecular saddle. Kim JL, et al. **Structure** 1995 Jun 15;3(6):531–4 (21 ref.)
[Metabolic pathway of the degradation of macromolecules by lysosomal enzymes] Arai K, et al. **Nippon Rinsho** 1995 Dec;53(12):2904–10 (12 ref.) (Eng. Abstr.) **(Jpn)**

HYDROCARBONS

CHEMISTRY

Nickel-catalyzed oxidations: from hydrocarbons to DNA. Burrows CJ, et al. **Acta Chem Scand** 1996 Apr;50(4):337–44 (35 ref.)
Contribution of activity coefficients of methylene homologues to odor and flavor detection thresholds. Yamanaka T. **Chem Senses** 1995 Aug;20(4):471–5 (19 ref.)
Fragmentation reactions of aromatic cation radicals: a tool for the detection of electron transfer mechanisms in biomimetic and enzymatic oxidations. Baciocchi E. **Xenobiotica** 1995 Jul;25(7):653–66 (37 ref.)

METABOLISM

Coenzyme A ligases involved in anaerobic biodegradation of aromatic compounds. Villemur R. **Can J Microbiol** 1995 Oct;41(10):855–61 (49 ref.)
Environmental hazard assessment of chemicals and products. Part VI. Abiotic degradation in the troposphere. Klöpffer W. **Chemosphere** 1996 Sep;33(6):1083–99 (71 ref.)
Carbon dioxide recovery in ready biodegradation tests: mass transfer and kinetic considerations. Larson RJ, et al. **Chemosphere** 1996 Sep;33(6):1195–210 (16 ref.)
Anaerobic biodegradation of hydrocarbons. Holliger C, et al. **Curr Opin Biotechnol** 1996 Jun;7(3):326–30 (40 ref.)

POISONING

Benefits of extracorporeal membrane oxygenation for hydrocarbon pneumonitis. Chyka PA. **J Toxicol Clin Toxicol** 1996;34(4):357–63 (34 ref.)

TOXICITY

Variable responses of species and strains to white mineral oils and paraffin waxes. Miller MJ, et al. **Regul Toxicol Pharmacol** 1996 Feb;23(1 Pt 1):55–68 (78 ref.)
Hematotoxic interactions: occurrence, mechanisms and predictability. Krishnan K, et al. **Toxicology** 1995 Dec 28; 105(2–3):355–64 (43 ref.)

HYDROCARBONS, CHLORINATED

ADVERSE EFFECTS

Organochlorine compounds and estrogen-related cancers in women. Adami HO, et al. **Cancer Causes Control** 1995 Nov; 6(6):551–66 (105 ref.)
Organochlorine compounds in relation to breast cancer, endometrial cancer, and endometriosis: an assessment of the biological and epidemiological evidence. Ahlborg UG, et al. **Crit Rev Toxicol** 1995;25(6):463–531 (318 ref.)
Factors associated with respiratory problems in swimmers. Potts J. **Sports Med** 1996 Apr;21(4):256–61 (43 ref.)

ANALYSIS

Sources, behaviour and fate of organic contaminants during sewage treatment and in sewage sludges. Rogers HR. **Sci Total Environ** 1996 Jun 21;185(1–3):3–26 (141 ref.)

METABOLISM

Biodegradation of chlorinated aliphatic compounds. Leisinger T. **Curr Opin Biotechnol** 1996 Jun;7(3):295–300

(51 ref.)
Aerobic and anaerobic PCB biodegradation in the environment. Abramowicz DA. **Environ Health Perspect** 1995 Jun;103 Suppl 5:97–9 (27 ref.)
Genetic adaptation of bacteria to halogenated aliphatic compounds. Janssen DB, et al. **Environ Health Perspect** 1995 Jun;103 Suppl 5:29–32 (27 ref.)
Bacterial growth with chlorinated methanes. Leisinger T, et al. **Environ Health Perspect** 1995 Jun;103 Suppl 5:33–6 (13 ref.)
In situ bioremediation of chlorinated solvents. Semprini L. **Environ Health Perspect** 1995 Jun;103 Suppl 5:101–5 (17 ref.)

TOXICITY

Considerations concerning the murine hepatocarcinogenicity of selected chlorinated hydrocarbons. Maronpot RR, et al. **Prog Clin Biol Res** 1995;391:305–23 (80 ref.)
[An outline of chloro-organic compound toxicology] Starek A. **Rocz Panstw Zakl Hig** 1996;47(1):1–12 (72 ref.) (Eng. Abstr.) **(Pol)**

HYDROCARBONS, FLUORINATED

TOXICITY

An overview of the toxicology of HFA-134a (1,1,1,2-tetrafluoroethane). Alexander DJ, et al. **Hum Exp Toxicol** 1995 Sep;14(9):715–20 (8 ref.)

HYDROCARBONS, HALOGENATED

Organic halogens in the environment: studies of environmental biodegradability and human exposure. Salkinoja-Salonen M, et al. **Environ Health Perspect** 1995 Jun;103 Suppl 5:63–9 (40 ref.)

ADMINISTRATION & DOSAGE

Ingestion of sludge applied organic chemicals by animals. Fries GF. **Sci Total Environ** 1996 Jun 21;185(1-3):93–108 (112 ref.)

METABOLISM

Organic halogens in the environment: studies of environmental biodegradability and human exposure. Salkinoja-Salonen M, et al. **Environ Health Perspect** 1995 Jun;103 Suppl 5:63–9 (40 ref.)
Recruitment of co-metabolic enzymes for environmental detoxification of organohalides. Wackett LP. **Environ Health Perspect** 1995 Jun;103 Suppl 5:45–8 (20 ref.)

PHARMACOKINETICS

Ingestion of sludge applied organic chemicals by animals. Fries GF. **Sci Total Environ** 1996 Jun 21;185(1-3):93–108 (112 ref.)

TOXICITY

Contaminant-induced immunotoxicity in harbour seals: wildlife at risk? Ross P, et al. **Toxicology** 1996 Aug 16; 112(2):157–69 (91 ref.)

HYDROCARBONS, POLYCYCLIC see **POLYCYCLIC HYDROCARBONS**

HYDROCELE

ABC of general paediatric surgery. Inguinal hernia, hydrocele, and the undescended testis. Davenport M. **BMJ** 1996 Mar 2;312(7030):564–7 (0 ref.)
Bilateral giant abdominoscrotal hydroceles in childhood. Serels S, et al. **Urology** 1996 May;47(5):763–5 (15 ref.)

DIAGNOSIS

[Hydrocele in Kawasaki disease] Sacco MC, et al. **Pediatr Med Chir** 1995 May-Jun;17(3):279–80 (10 ref.) (Eng. Abstr.) **(Ita)**

ULTRASONOGRAPHY

[Abdominal-scrotal hydrocele: a report of 4 cases and a review of the literature] Patti G, et al. **Pediatr Med Chir** 1995 May-Jun;17(3):245–7 (26 ref.) (Eng. Abstr.) **(Ita)**

HYDROCEPHALUS

CLASSIFICATION

Current concept of hydrocephalus: evolution of new classifications. Mori K. **Childs Nerv Syst** 1995 Sep; 11(9):523–31; discussion p 531–2 (31 ref.)

COMPLICATIONS

Hydrocephalus in mumps meningoencephalitis: case report. Oran B, et al. **Pediatr Infect Dis J** 1995 Aug;14(8):724–5 (10 ref.)

DIAGNOSIS

Neuroimaging and functional examination in hydrocephalus: a comment. Kang JK. **Childs Nerv Syst** 1995 Aug; 11(8):478–82 (20 ref.)
Current concept of hydrocephalus: evolution of new classifications. Mori K. **Childs Nerv Syst** 1995 Sep; 11(9):523–31; discussion p 531–2 (31 ref.)

EMBRYOLOGY

Apoptosis in the developing CNS. Naruse I, et al. **Prog Neurobiol** 1995 Oct;47(2):135–55 (152 ref.)

ETIOLOGY

Tremor as the result of shunt obstruction: four patients with cysticercosis and secondary parkinsonism: report of four cases. Keane JR. **Neurosurgery** 1995 Sep;37(3):520–2 (3 ref.)

GENETICS

Casey Holter Essay Prize. The pathogenesis of X-linked hydrocephalus. Jouet M. **Eur J Pediatr Surg** 1995 Dec;5 Suppl 1:5–7 (36 ref.)
[A family with X-linked hydrocephalus resulting from mutations in the neural cell adhesion molecule L1] Maruta K, et al. **Rinsho Shinkeigaku** 1996 Mar;36(3):462–6 (16 ref.) (Eng. Abstr.) **(Jpn)**
[Congenital hydrocephalus] Nazar N. **Rev Neurol** 1995;23 Suppl 3:S376–7 (5 ref.) **(Spa)**

PATHOLOGY

Distinct skeletal abnormalities in four girls with Shprintzen-Goldberg syndrome. Adès LC, et al. **Am J Med Genet** 1995 Jul 17;57(4):565–72 (13 ref.)

SURGERY

Hydrocephalus and shunts in children with brain tumors. Ryan JA, et al. **J Pediatr Oncol Nurs** 1995 Oct;12(4):223–9 (19 ref.)
Cerebrospinal fluid shunt complications: an emergency medicine perspective. Key CB, et al. **Pediatr Emerg Care** 1995 Oct;11(5):265–73 (56 ref.)

ULTRASONOGRAPHY

Intracranial pressure and cerebral arterial flow velocity indices in childhood hydrocephalus: current review. Goh D, et al. **Childs Nerv Syst** 1995 Jul;11(7):392–6 (25 ref.)
Value of transcranial Doppler indices in predicting raised ICP in infantile hydrocephalus. A study with review of the literature. Hanlo PW, et al. **Childs Nerv Syst** 1995 Oct; 11(10):595–603 (45 ref.)
[Diagnostic-therapeutic concept in hydrocephalus] Voigt HJ. **Gynakologe** 1995 Oct;28(5):346–55 (27 ref.) **(Ger)**

HYDROCEPHALUS, NORMAL PRESSURE

DIAGNOSIS

Chronic ("normal pressure") hydrocephalus in childhood and adolescence. A review of 16 cases and reappraisal of the syndrome. Bret P, et al. **Childs Nerv Syst** 1995 Dec; 11(12):687–91 (16 ref.)
Regional cerebral blood flow, white matter abnormalities, and cerebrospinal fluid hydrodynamics in patients with idiopathic adult hydrocephalus syndrome. Kristensen B, et al. **J Neurol Neurosurg Psychiatry** 1996 Mar;60(3):282–8 (41 ref.)

PHYSIOPATHOLOGY

Regional cerebral blood flow, white matter abnormalities, and cerebrospinal fluid hydrodynamics in patients with idiopathic adult hydrocephalus syndrome. Kristensen B, et al. **J Neurol Neurosurg Psychiatry** 1996 Mar;60(3):282–8 (41 ref.)

HYDROCHLORIC ACID

see related
GASTRIC ACID

HYDROCHLORIC ACID, GASTRIC see **GASTRIC ACID**

HYDROCHLOROTHIAZIDE

Low-dose thiazides in the treatment of hypertension: benefits and risks in perspective. Silverberg DS, et al. **J Hum Hypertens** 1995 Nov;9(11):869–73 (80 ref.)

18-HYDROCORTICOSTERONE see **18-HYDROXYCORTICOSTERONE**

HYDROCORTISONE

ADVERSE EFFECTS

Ototoxicity of ear drops: a clinical perspective. Linder TE, et al. **Am J Otol** 1995 Sep;16(5):653–7 (23 ref.)
Experimental studies on cortisol-induced hypertension in humans. Whitworth JA, et al. **J Hum Hypertens** 1995 Jun; 9(6):395–9 (32 ref.)

ANALOGS & DERIVATIVES

[6 beta-Hydroxycortisol] Chiba H. **Nippon Rinsho** 1995 Mar; 53 Su Pt 2:479–82 (24 ref.) **(Jpn)**
[18-Hydroxycortisol (18-OH-F) and 18-oxocortisol (18-oxoF)] Chiba H. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:467–70 (20 ref.) **(Jpn)**

ANALYSIS

Effect of chronic stress associated with unemployment on salivary cortisol: overall cortisol levels, diurnal rhythm, and acute stress reactivity. Ockenfels MC, et al. **Psychosom Med** 1995 Sep-Oct;57(5):460–7 (61 ref.)
[Cortisol] Tanaka K. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:437–40 (10 ref.) **(Jpn)**

BLOOD

Hypercortisolism and obesity. Peeke PM, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:665–76 (57 ref.)
Differential diagnosis and management of Cushing's syndrome. Tsigos C, et al. **Annu Rev Med** 1996;47:443–61 (52 ref.)

METABOLISM

The potential role of excessive cortisol induced by HPA hyperfunction in the pathogenesis of depression. Stokes PE. **Eur Neuropsychopharmacol** 1995;5 Suppl:77–82 (48 ref.)
[Role of hormonal exploration in avoiding of the failures of anterior pituitary gland surgery in Cushing disease] Bachelot I, et al. **Ann Endocrinol (Paris)** 1995;56(6):620–4 (15 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Cortisol as mineralocorticoid [editorial] Ulick S. **J Clin Endocrinol Metab** 1996 Apr;81(4):1307–8 (21 ref.)

HYDROELECTRIC POWER PLANTS see **POWER PLANTS**

HYDROFLUORIC ACID

ADVERSE EFFECTS

Hydrofluoric acid burns: a review. Kirkpatrick JJ, et al. **Burns** 1995 Nov;21(7):483–93 (158 ref.)

HYDROGEN

METABOLISM

Mechanisms and uses of hydrogen exchange. Englander SW, et al. **Curr Opin Struct Biol** 1996 Feb;6(1):18–23 (92 ref.)
[Hydrogen metabolism in the large intestine—physiology and clinical implications] Christl SU, et al. **Z Gastroenterol** 1995 Jul;33(7):408–13 (66 ref.) (Eng. Abstr.) **(Ger)**

HYDROGEN CARBONATES see **BICARBONATES**

HYDROGEN FLUORIDE see **HYDROFLUORIC ACID**

HYDROGEN-ION CONCENTRATION

Molecular responses of microbes to environmental pH stress. Hall HK, et al. **Adv Microb Physiol** 1995;37:229–72 (240 ref.)
Is the intracellular pH threshold an anaerobic threshold from the view point of intracellular events?: a brief review. Iwanaga K, et al. **Appl Human Sci** 1996 Mar;15(2):59–65 (53 ref.)
The role of intracellular pH in the control of adenosine output from red skeletal muscle. Ballard HJ. **Biol Signals** 1995 May-Jun;4(3):168–73 (21 ref.)
[Significance of skin surface pH] Yosipovitch G, et al. **Harefuah** 1996 Apr 1;130(7):478–80 (30 ref.) **(Heb)**

HYDROGEN IONS see **PROTONS**

HYDROGEN PEROXIDE

Gas plasma sterilization--application of space-age technology. Crow S, et al. **Infect Control Hosp Epidemiol** 1995 Aug;16(8):483–7 (7 ref.)
Role of guanosine triphosphate in ferric ion-linked Fenton chemistry. Biaglow JE, et al. **Radiat Res** 1996 May; 145(5):554–62 (69 ref.)
Role of Fenton chemistry in thiol-induced toxicity and apoptosis. Held KD, et al. **Radiat Res** 1996 May; 145(5):542–53 (81 ref.)
Fenton chemistry: an introduction. Wardman P, et al. **Radiat Res** 1996 May;145(5):523–31 (73 ref.)
[Gas sterilization with gas hydrogen peroxide: a new technology in the pharmaceutical industry] Manzati C. **Boll Chim Farm** 1995 Sep;134(8):413–33 (23 ref.) (Eng. Abstr.) **(Ita)**

ADVERSE EFFECTS

Disinfectant colitis. Rinse as well as you wash [editorial] Ryan CK, et al. **J Clin Gastroenterol** 1995 Jul;21(1):6–9 (23 ref.)

CHEMISTRY

Fenton chemistry: an introduction. Wardman P, et al. **Radiat Res** 1996 May;145(5):523–31 (73 ref.)

HYDROGEN PEROXIDE

METABOLISM

Free radicals and aging of anterior segment tissues of the eye: a hypothesis. Green K. **Ophthalmic Res** 1995;27 Suppl 1:143–9 (41 ref.)

PHARMACOLOGY

Regulation of endothelial permeability by second messengers. Siflinger-Birnboim A, et al. **New Horiz** 1996 Feb;4(1):87–98 (86 ref.)

POISONING

Hydrogen peroxide 3% exposures. Henry MC, et al. **J Toxicol Clin Toxicol** 1996;34(3):323–7 (21 ref.)

THERAPEUTIC USE

Hydrogen peroxide: a review of its use in dentistry. Marshall MV, et al. **J Periodontol** 1995 Sep;66(9):786–96 (100 ref.)

TOXICITY

Toxicity of iron and hydrogen peroxide: the Fenton reaction. Winterbourn CC. **Toxicol Lett** 1995 Dec;82–83:969–74 (25 ref.)

HYDROGEN, POTASSIUM, ADENOSINETRIPHOSPHATASE see **H(+)-K(+)-EXCHANGING ATPASE**

HYDROGEN, POTASSIUM ATPASE see **H(+)-K(+)-EXCHANGING ATPASE**

HYDROGENOMONAS see **PSEUDOMONAS**

HYDROLASES

ANTAGONISTS & INHIBITORS

[Design of S-adenosylhomocystein hydrolase (SHAase) inhibitors as potent anti-RNA viral agents] Shuto S. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1261–7 (27 ref.) **(Jpn)**

CHEMISTRY

[Lysosomal hydrolases have specific conformational domains for acquisition of mannose-6-phosphate] Himeno M, et al. **Nippon Rinsho** 1995 Dec;53(12):2892–7 (18 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Enzymatic degradation of glycosaminoglycans. Ernst S, et al. **Crit Rev Biochem Mol Biol** 1995;30(5):387–444 (267 ref.)

PHARMACOLOGY

Pharmacological effects of oral enzyme combinations. Stauder G. **Cas Lek Cesk** 1995 Oct 4;134(19):620–4 (24 ref.)

HYDRONEPHROSIS

Urinary tract obstruction in children. Peters CA. **J Urol** 1995 Nov;154(5):1874–83; discussion 1883–4 (101 ref.)

ETIOLOGY

[Renovascular hypertension and hydronephrosis due to a renal artery aneurysm] Hering M, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Feb;164(2):176–8 (12 ref.) **(Ger)**

PHYSIOPATHOLOGY

Neonatal hydronephrosis—the controversy and the management. Tripp BM, et al. **Pediatr Nephrol** 1995 Aug; 9(4):503–9 (49 ref.)

SURGERY

[Pediatric ureteral ureteral outlet obstruction and obstructive megaureter: observation or operation?] Goepel M, et al. **Urologe A** 1996 Mar;35(2):91–6 (31 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Neonatal hydronephrosis—the controversy and the management. Tripp BM, et al. **Pediatr Nephrol** 1995 Aug; 9(4):503–9 (49 ref.)

HYDROPHOBIA see **RABIES**

HYDROPHTHALMOS

DIAGNOSIS

[Persistence of the primordial vitreous body and buphthalmos] Cernea P, et al. **Oftalmologia** 1995 Oct–Dec; 39(4):338–42 (8 ref.) (Eng. Abstr.) **(Fre)**

HYDROPNEUMOTHORAX

ETIOLOGY

Boerhaave's syndrome presenting with abdominal pain and right hydropneumothorax. Jagminas L, et al. **Am J Emerg Med** 1996 Jan;14(1):53–6 (46 ref.)

HYDROPS see **EDEMA**

HYDROPS FETALIS

COMPLICATIONS

Non-immunological hydrops fetalis and intrapericardial teratoma: case report and review. Perez-Aytes A, et al. **Prenat Diagn** 1995 Sep;15(9):859–63 (20 ref.)

DIAGNOSIS

Prenatal diagnosis of Blackfan-Diamond syndrome: case report and review of the literature. McLennan AC, et al. **Prenat Diagn** 1996 Apr;16(4):349–53 (15 ref.)

ETIOLOGY

The presence of hydrops fetalis in a fetus with congenital mesoblastic nephroma. Liu YC, et al. **Prenat Diagn** 1996 Apr;16(4):363–5 (8 ref.)

MORTALITY

Cytogenetic evaluation of cystic hygroma associated with hydrops fetalis, oligohydramnios or intrauterine fetal death: the roles of amniocentesis, postmortem chorionic villus sampling and cystic hygroma paracentesis. Chen CP, et al. **Acta Obstet Gynecol Scand** 1996 May;75(5):454–8 (29 ref.)

PREVENTION & CONTROL

Prevention of beta-thalassemia major and Hb Bart's hydrops fetalis syndrome. Beris P, et al. **Semin Hematol** 1995 Oct; 32(4):244–61 (86 ref.)

HYDROQUINONES

PHARMACOLOGY

[Inhibitors of protein-tyrosine kinases: pharmacological perspectives? (editorial)] Jacquemin-Sablon A, et al. **Pathol Biol (Paris)** 1995 May;43(5):389–94 (66 ref.) **(Fre)**

TOXICITY

Oxidative DNA lesions in V79 cells mediated by pentachlorophenol metabolites. Dahlhaus M, et al. **Arch Toxicol** 1996;70(7):457–60 (39 ref.)

HYDROSTATIC PRESSURE

Microbiology to 10,500 meters in the deep sea. Yayanos AA. **Annu Rev Microbiol** 1995;49:777–805 (170 ref.)

The use of hydrostatic pressure as a tool to study viruses and other macromolecular assemblages. Silva JL, et al. **Curr Opin Struct Biol** 1996 Apr;6(2):166–75 (79 ref.)

High pressure effects on protein structure and function. Mozhaev VV, et al. **Proteins** 1996 Jan;24(1):81–91 (56 ref.)

HYDROTHORAX

ETIOLOGY

[Hepatic hydrothorax] Nakagawara M, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):474–7 (20 ref.) **(Jpn)**

HYDROXAMIC ACIDS

[Uses of hydroxamic acids and of N-alkoxyimidoyl halides in organic synthesis] Kikugawa Y. **Yakugaku Zasshi** 1995 Nov;115(11):909–27 (75 ref.) (Eng. Abstr.) **(Jpn)**

HYDROXY ACIDS

METABOLISM

Poly(alpha-hydroxy acids): carriers for bone morphogenetic proteins. Hollinger JO, et al. **Biomaterials** 1996 Jan; 17(2):187–94 (101 ref.)

THERAPEUTIC USE

Alpha hydroxy acids in skin care. Clark CP 3rd. **Clin Plast Surg** 1996 Jan;23(1):49–56 (48 ref.)

Treatment of photoaged skin. Efficacy, tolerability and costs of available agents. Helander SD. **Drugs Aging** 1996 Jan; 8(1):12–6 (34 ref.)

HYDROXYACETANILIDE see **ACETAMINOPHEN**

S-HYDROXYALKYL GLUTATHIONE LYASE see **GLUTATHIONE TRANSFERASES**

HYDROXYAMPICILLIN see **AMOXICILLIN**

HYDROXYANDROSTANES see **ANDROSTANOLS**

HYDROXYAPATITE see **DURAPATITE**

P-HYDROXYBENZOATE HYDROXYLASE see **4-HYDROXYBENZOATE-3-MONOOXYGENASE**

4-HYDROXYBENZOATE-3-MONOOXYGENASE

METABOLISM

Unifying concepts in flavin-dependent catalysis. Vervoort J, et al. **Biochem Soc Trans** 1996 Feb;24(1):127–30 (14 ref.)

HYDROXYBUTYRATES

CHEMICAL SYNTHESIS

Production of poly(hydroxyalkanoic acid). Lee SY, et al. **Adv Biochem Eng Biotechnol** 1995;52:27–58 (131 ref.)

4-HYDROXYBUTYRIC ACID LACTONE see **4-BUTYROLACTONE**

HYDROXYCARBAMID see **HYDROXYUREA**

HYDROXYCHLOROCHIN see **HYDROXYCHLOROQUINE**

HYDROXYCHLOROQUINE

ADVERSE EFFECTS

Slow-acting antirheumatic drugs. Drug interactions of clinical significance. Munro RA, et al. **Drug Saf** 1995 Jul; 13(1):25–30 (34 ref.)

25-HYDROXYCHOLECALCIFEROL 1-HYDROXYLASE

METABOLISM

Recent progress in enzymology and molecular biology of enzymes involved in vitamin D metabolism. Okuda K, et al. **J Lipid Res** 1995 Aug;36(8):1641–52 (89 ref.)

HYDROXYCHOLECALCIFEROLS

BLOOD

[Vitamin D and its metabolites] Masuda S, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:712–5 (11 ref.) **(Jpn)**

THERAPEUTIC USE

The use of alfacalcidol in the prevention of bone disease in early renal failure. Kanis JA. **Nephrol Dial Transplant** 1995; 10 Suppl 4:23–8; discussion 37–43 (42 ref.)

1-alpha-Hydroxyvitamin D3 derivatives in the treatment of renal bone diseases: justification and optimal modalities of administration. Fournier A, et al. **Nephron** 1995; 71(3):254–83 (194 ref.)

HYDROXYCHOLESTANES see **CHOLESTANOLS**

HYDROXYCORTICOSTEROID ANALOGS see **GLUCOCORTICOIDS, SYNTHETIC**

17-HYDROXYCORTICOSTEROID ANALOGS see **GLUCOCORTICOIDS, SYNTHETIC**

11-HYDROXYCORTICOSTEROIDS

ANALYSIS

[11-Hydroxycorticosteroid (11-OHCS)] Ogino Y, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:434–6 (9 ref.) **(Jpn)**

17-HYDROXYCORTICOSTEROIDS

URINE

[17-Hydroxycorticoids (17-OHCS) and its fractions] Takebe K. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:429–33 (4 ref.) **(Jpn)**

11-HYDROXYCORTICOSTEROID ANALOGS see **GLUCOCORTICOIDS, SYNTHETIC**

HYDROXYCORTICOSTEROIDS, SYNTHETIC see **GLUCOCORTICOIDS, SYNTHETIC**

11-HYDROXYCORTICOSTEROIDS, SYNTHETIC see **GLUCOCORTICOIDS, SYNTHETIC**

17-HYDROXYCORTICOSTEROIDS, SYNTHETIC see **GLUCOCORTICOIDS, SYNTHETIC**

18-HYDROXYCORTICOSTERONE

BLOOD

[18-Hydroxycorticosterone (18-OH-B)] Izumi Y, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:502–6 (13 ref.) **(Jpn)**

20-HYDROXYECDYSONE see ECDYSTERONE

HYDROXYEICOSATETRAENOIC ACIDS

BIOSYNTHESIS

Lipoxin biosynthesis and actions: role of the human platelet LX-synthase. Serhan CN, et al. **J Lipid Mediat Cell Signal** 1995 Oct;12(2-3):293-306 (41 ref.)

THERAPEUTIC USE

Lipoxygenases as therapeutic targets in the acute and subacute phases of glomerular immune injury. Badr KF. **Contrib Nephrol** 1996;118:113-25 (75 ref.)

HYDROXYIMINO COMPOUNDS see OXIMES

HYDROXYINDOLEACETIC ACID

ANALYSIS

[5-Hydroxyindole acetic acid (5HIAA)] Saijoh K. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:531-3 (12 ref.) **(Jpn)**

CEREBROSPINAL FLUID

Cerebrospinal fluid 5-hydroxyindolacetic acid and aggression: a critical reappraisal of the clinical data. Tuinier S, et al. **Int Clin Psychopharmacol** 1995 Sep;10(3):147-56 (82 ref.)

URINE

The clinical and laboratory correlates of an increased urinary 5-hydroxyindoleacetic acid. Tormey WP, et al. **Postgrad Med J** 1995 Sep;71(839):542-5 (16 ref.)

HYDROXYL RADICAL

The hydroxyl radical: from chemistry to human disease. Lubec G. **J Investig Med** 1996 Aug;44(6):324-46 (211 ref.)

Fenton chemistry: an introduction. Wardman P, et al. **Radiat Res** 1996 May;145(5):523-31 (73 ref.)

ADVERSE EFFECTS

Use of iron chelators in preventing hydroxyl radical damage: adult respiratory distress syndrome as an experimental model for the pathophysiology and treatment of oxygen-radical-mediated tissue damage. Marx JJ, et al. **Acta Haematol** 1996;95(1):49-62 (181 ref.)

[Free radicals and antioxidants. Advantages of antioxidants in clinical medicine, truth or fiction? (editorial)] Huttunen J. **Duodecim** 1994;110(17):1606-8 (25 ref.) **(Fin)**

METABOLISM

How do Ca2+ and 5-aminolevulinic acid-derived oxyradicals promote injury to isolated mitochondria? Hermes-Lima M. **Free Radic Biol Med** 1995 Sep; 19(3):381-90 (87 ref.)

HYDROXYLAPATITE see DURAPATITE

HYDROXYLASES

ANTAGONISTS & INHIBITORS

Topical beta-adrenergic antagonists and quinidine. A risky interaction [editorial] Higginbotham EJ. **Arch Ophthalmol** 1996 Jun;114(6):745-6 (7 ref.)

Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6. Ereshefsky L, et al. **Clin Pharmacokinet** 1995;29 Suppl 1:10-8; discussion 18-9 (38 ref.)

CHEMISTRY

NADPH-P-450 reductase: structural and functional comparisons of the eukaryotic and prokaryotic isoforms. Sevrioukova IF, et al. **Biochimie** 1995;77(7-8):562-72 (59 ref.)

Structural domains of P450-containing monooxygenase systems. Degtyarenko KN. **Protein Eng** 1995 Aug; 8(8):737-47 (119 ref.)

GENETICS

Gene-environment interaction in parkinson's disease. The case of CYP2D6 gene polymorphism. Landi MT, et al. **Adv Neurol** 1996;69:61-72 (80 ref.)

Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Bertilsson L. **Clin Pharmacokinet** 1995 Sep;29(3):192-209 (103 ref.)

Molecular genetics of cytochrome P450 IID. Anomalies of drug metabolism. Jacqz-Aigrain E, et al. **Clin Rev Allergy Immunol** 1995 Fall;13(3):211-21 (50 ref.)

Lung cancer and CYP2D6 (the debrisoquine polymorphism): sources of heterogeneity in the proposed association. Caporaso N, et al. **Pharmacogenetics** 1995;5 Spec No:S129-34 (44 ref.)

METABOLISM

Gene-environment interaction in parkinson's disease. The case of CYP2D6 gene polymorphism. Landi MT, et al. **Adv Neurol** 1996;69:61-72 (80 ref.)

Unifying concepts in flavin-dependent catalysis. Vervoort J, et al. **Biochem Soc Trans** 1996 Feb;24(1):127-30 (14 ref.)

Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Bertilsson L. **Clin Pharmacokinet** 1995 Sep;29(3):192-209 (103 ref.)

Prostaglandin-metabolizing enzymes during pregnancy: characterization of NAD(+)-dependent prostaglandin dehydrogenase, carbonyl reductase, and cytochrome P450-dependent prostaglandin omega-hydroxylase. Okita RT, et al. **Crit Rev Biochem Mol Biol** 1996 Apr; 31(2):101-26 (100 ref.)

Substrates of human hepatic cytochrome P450 3A4. Li AP, et al. **Toxicology** 1995 Dec 15;104(1-3):1-8 (37 ref.)

HYDROXYMETHOLONE see OXYMETHOLONE

HYDROXYMETHOXYPHENYLGLYCOL see METHOXYHYDROXYPHENYLGLYCOL

HYDROXYMETHYLBILANE SYNTHASE see PORPHOBILINOGEN DEAMINASE

HYDROXYMETHYLGLUTARYL COA REDUCTASES

ANTAGONISTS & INHIBITORS

Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors. Garnett WR. **Am J Health Syst Pharm** 1995 Aug 1;52(15):1639-45 (44 ref.)

Fluvastatin for the prevention of restenosis after coronary balloon angioplasty: angiographic and methodological background of the fluvastatin angioplasty restenosis trial. Foley DP, et al. **Br J Clin Pract Symp Suppl** 1996 Jan; 77A:40-53 (53 ref.)

Development and pharmacology of fluvastatin. Jokubaitis LA. **Br J Clin Pract Symp Suppl** 1996 Jan;77A:11-5 (4 ref.)

Lipids and progressive renal failure. Keane WF, et al. **Contrib Nephrol** 1996;118:17-23 (22 ref.)

Statin therapy in clinical practice: new developments. Shepherd J. **Curr Opin Lipidol** 1995 Oct;6(5):254-5 (13 ref.)

Simvastatin. A reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolaemia. Plosker GL, et al. **Drugs** 1995 Aug;50(2):334-63 (239 ref.)

The 4S study. Implications for prescribing. van Boven AJ, et al. **Drugs** 1996 Apr;51(4):507-14 (55 ref.)

Dual roles of HMG-CoA reductase inhibitors in solid organ transplantation: lipid lowering and immunosuppression. Katznelson S, et al. **Kidney Int Suppl** 1995 Dec;52:S112-5 (30 ref.)

Inhibition of the mevalonate pathway: benefits beyond cholesterol reduction? [see comments] Massy ZA, et al. **Lancet** 1996 Jan 13;347(8994):102-3 (18 ref.) Comment in: Lancet 1996 Feb 24;347(9000):551.

Effects of lipids on the pathogenesis of progressive renal failure: role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in the prevention of glomerulosclerosis. Guijarro C, et al. **Miner Electrolyte Metab** 1996; 22(1-3):147-52 (45 ref.)

Oxylanosterols as modifiers of cholesterol biosynthesis. Trzaskos JM. **Prog Lipid Res** 1995;34(2):99-116 (28 ref.)

PHYSIOLOGY

The biology of HMG-CoA reductase: the pros of contra-regulation. Hampton R, et al. **Trends Biochem Sci** 1996 Apr;21(4):140-5 (39 ref.)

HYDROXYMETHYLGLUTARYL-COA SYNTHASE

GENETICS

Regulation of mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase gene expression in liver and intestine from the rat. Hegardt FG. **Biochem Soc Trans** 1995 Aug;23(3):486-90 (23 ref.)

HYDROXYNAPHTHALENES see NAPHTHOLS

HYDROXYPREGNENOLONE

BLOOD

[17 alpha-hydroxypregnenolone] Shimizu Y, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:474-7 (477 ref.) **(Jpn)**

21-HYDROXYPROGESTERONE see DESOXYCORTICOSTERONE

HYDROXYPROGESTERONES

BLOOD

[17-Hydroxyprogesterone] Watanabe F. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:471-3 (6 ref.) **(Jpn)**

HYDROXYPROLINE

URINE

[Hydroxyproline] Igarashi S. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:489-92 (13 ref.) **(Jpn)**

HYDROXYPROSTAGLANDIN DEHYDROGENASES

Prostaglandin D, E, and F synthases. Urade Y, et al. **J Lipid Mediat Cell Signal** 1995 Oct;12(2-3):257-73 (67 ref.)

METABOLISM

Prostaglandin-metabolizing enzymes during pregnancy: characterization of NAD(+)-dependent prostaglandin dehydrogenase, carbonyl reductase, and cytochrome P450-dependent prostaglandin omega-hydroxylase. Okita RT, et al. **Crit Rev Biochem Mol Biol** 1996 Apr; 31(2):101-26 (100 ref.)

15-Hydroxyprostaglandin dehydrogenase. Ensor CM, et al. **J Lipid Mediat Cell Signal** 1995 Oct;12(2-3):313-9 (39 ref.)

HYDROXYQUINOLINES

ADVERSE EFFECTS

[Kidney insufficiency: toxicity factor of methyl-bromo-hydroxyquinoline (letter)] Zeraidi N, et al. **Ann Med Interne (Paris)** 1995;146(8):593-5 (16 ref.) **(Fre)**

HYDROXYSTEROID DEHYDROGENASES

DEFICIENCY

Apparent mineralocorticoid excess due to 11 beta-hydroxysteroid dehydrogenase deficiency: a possible cause of intrauterine growth retardation. Kitanaka S, et al. **Clin Endocrinol (Oxf)** 1996 Mar;44(3):353-9 (33 ref.)

11 beta-Hydroxysteroid dehydrogenase: implications for clinical medicine. Stewart PM. **Clin Endocrinol (Oxf)** 1996 May;44(5):493-9 (55 ref.)

GENETICS

Unusual evolution of 11beta- and 17beta-hydroxysteroid and retinol dehydrogenases. Baker ME. **Bioessays** 1996 Jan; 18(1):63-70 (47 ref.)

11 beta-Hydroxysteroid dehydrogenase: implications for clinical medicine. Stewart PM. **Clin Endocrinol (Oxf)** 1996 May;44(5):493-9 (55 ref.)

Ovine 11 beta-hydroxysteroid dehydrogenase: from gene to function. Yang K. **Endocr Res** 1995 Feb-May; 21(1-2):367-77 (49 ref.)

METABOLISM

The promiscuous receptor: a case for the guardian enzyme. Weber KT, et al. **Cardiovasc Res** 1995 Aug;30(2):176-80 (34 ref.)

Apparent mineralocorticoid excess. Funder JW. **Endocrinol Metab Clin North Am** 1995 Sep;24(3):613-21 (41 ref.)

Placental 11 beta-hydroxysteroid dehydrogenase and the programming of hypertension. Seckl JR, et al. **J Steroid Biochem Mol Biol** 1995 Dec;55(5-6):447-55 (104 ref.)

11 beta-hydroxysteroid dehydrogenase--why is it important for the nephrologist? [editorial] Escher G, et al. **Nephrol Dial Transplant** 1995;10(9):1506-9 (38 ref.)

PHYSIOLOGY

Clinical investigation of 11 beta-hydroxysteroid dehydrogenase. Walker BR, et al. **Endocr Res** 1995 Feb-May;21(1-2):379-87 (39 ref.)

11 beta-Hydroxysteroid dehydrogenase: new answers, new questions [comment] Funder JW. **Eur J Endocrinol** 1996 Mar;134(3):267-8 (10 ref.) Comment on: Eur J Endocrinol 1996 Mar;134(3):301-7.

17-HYDROXYSTEROID DEHYDROGENASES

GENETICS

Unusual evolution of 11beta- and 17beta-hydroxysteroid and retinol dehydrogenases. Baker ME. **Bioessays** 1996 Jan; 18(1):63-70 (47 ref.)

Molecular genetics of androgenic 17 beta-hydroxysteroid dehydrogenases. Andersson S. **J Steroid Biochem Mol Biol** 1995 Dec;55(5-6):533-4 (20 ref.)

METABOLISM

Regulation of oestrogen action: role of 17 beta-hydroxysteroid dehydrogenases. Poutanen M, et al. **Ann Med** 1995 Dec;27(6):675–82 (44 ref.)

New 17 beta-hydroxysteroid dehydrogenases. Molecular and cell biology of the type IV porcine and human enzymes. Adamski J, et al. **Ann N Y Acad Sci** 1996 Apr 30;784:124–36 (46 ref.)

Kinetic analysis of enzymic activities: prediction of multiple forms of 17 beta-hydroxysteroid dehydrogenase. Blomquist CH. **J Steroid Biochem Mol Biol** 1995 Dec;55(5–6):515–24 (44 ref.)

PHYSIOLOGY

Role of 17 beta-hydroxysteroid dehydrogenase type 1 in endocrine and intracrine estradiol biosynthesis. Poutanen M, et al. **J Steroid Biochem Mol Biol** 1995 Dec; 55(5–6):525–32 (52 ref.)

HYDROXYTHIAMINE see **OXYTHIAMINE**

5-HYDROXYTRYPTAMINE see **SEROTONIN**

5-HYDROXYTRYPTAMINE AGONISTS see **SEROTONIN AGONISTS**

5-HYDROXYTRYPTAMINE ANTAGONISTS see **SEROTONIN ANTAGONISTS**

5-HYDROXYTRYPTAMINE RECEPTORS see **RECEPTORS, SEROTONIN**

5-HYDROXYTRYPTAMINE UPTAKE INHIBITORS see **SEROTONIN UPTAKE INHIBITORS**

HYDROXYTYRAMINE see **DOPAMINE**

HYDROXYUREA

ADVERSE EFFECTS

Hydroxyurea-induced dermatomyositis-like eruption. Senet P, et al. **Br J Dermatol** 1995 Sep;133(3):455–9 (32 ref.)

Longitudinal melanonychia induced by hydroxyurea: four case reports and review of the literature. Delmas-Marsalet B, et al. **Nouv Rev Fr Hematol** 1995;37(3):205–10 (17 ref.)

[Osteitis secondary to toxic dermatitis caused by hydroxyurea. Apropos ofa case, review of the literature (letter)] Mounier N, et al. **Ann Med Interne (Paris)** 1995; 146(8):590–1 (14 ref.) **(Fre)**

ANALOGS & DERIVATIVES

Zileuton. McGill KA, et al. **Lancet** 1996 Aug 24; 348(9026):519–24 (38 ref.)

PHARMACOLOGY

Use of hydroxyurea to alter drug resistance of human tumor cells. Van den Berg C, et al. **Cancer Treat Res** 1995; 78:95–114 (123 ref.)

25-HYDROXYVITAMIN D(3) 1 ALPHA-HYDROXYLASE see **25-HYDROXYCHOLECALCIFEROL 1-HYDROXYLASE**

HYDROXYVITAMINS D see **HYDROXYCHOLECALCIFEROLS**

HYGIENE

Foodborne disease and other hygiene issues in the home. Scott E. **J Appl Bacteriol** 1996 Jan;80(1):5–9 (37 ref.)

[Infectious diseases from the hygienic viewpoint with special reference to environmental infections—a retrospective and prospective view] Exner M. **Zentralbl Hyg Umweltmed** 1995 Apr;197(1–3):134–61 (79 ref.) (Eng. Abstr.) **(Ger)**

HYGROMA see **LYMPHANGIOMA, CYSTIC**

HYGROMA, CYSTIC see **LYMPHANGIOMA, CYSTIC**

HYMEN

ABNORMALITIES

[Acute urinary retention secondary to an imperforate hymen with hematocolpos] Gatius Tonda C, et al. **An Esp Pediatr** 1996 Apr;44(4):381–2 (8 ref.) **(Spa)**

HYMENOLEPIS

PHYSIOLOGY

Interactions between parasites and insects vectors. Hurd H. **Mem Inst Oswaldo Cruz** 1994;89 Suppl 2:27–30 (20 ref.)

HYMENOPTERA

PHYSIOLOGY

Sex determination in Hymenoptera: a need for genetic and molecular studies. Beukeboom LW. **Bioessays** 1995 Sep; 17(9):813–7 (47 ref.)

HYOSCINE see **SCOPOLAMINE**

HYPERACTIVITY, MOTOR see **HYPERKINESIS**

HYPERALDOSTERONISM

CHEMICALLY INDUCED

[Licorice, aldosterone and blood pressure] Sane T. **Duodecim** 1994;110(10):974–80 (27 ref.) **(Fin)**

COMPLICATIONS

Hypertension: a case of the gratuitous rider. Weber KT. **Cardiovasc Res** 1996 Jun;31(6):868–9 (16 ref.)

[Primary hyperaldosteronism as a cause of hypertension; diagnosis] ter Maaten JC, et al. **Ned Tijdschr Geneeskd** 1996 Mar 2;140(9):483–7 (26 ref.) **(Dut)**

DIAGNOSIS

Primary aldosteronism. Part I. Diagnosis of primary hyperaldosteronism. Vallotton MB. **Clin Endocrinol (Oxf)** 1996 Jul;45(1):47–52 (31 ref.)

Primary aldosteronism. Part II. Differential diagnosis of primary hyperaldosteronism and pseudoaldosteronism. Vallotton MB. **Clin Endocrinol (Oxf)** 1996 Jul;45(1):53–60 (73 ref.)

[11-beta-hydroxylase deficiency and glucocorticoid-sensitive hyperaldosteronism] Merino Arribas JM, et al. **An Esp Pediatr** 1996 Jun;44(6):609–11 (12 ref.) **(Spa)**

DRUG THERAPY

Dexamethasone-suppressible hyperaldosteronism: clinical, biochemical and genetic relations. Connell JM, et al. **J Hum Hypertens** 1995 Jun;9(6):505–9 (19 ref.)

ETIOLOGY

Secondary aldosteronism. Corry DB, et al. **Endocrinol Metab Clin North Am** 1995 Sep;24(3):511–29 (79 ref.)

Conn syndrome in a child, caused by adrenal adenoma. Abasiyanik A, et al. **J Pediatr Surg** 1996 Mar;31(3):430–2 (15 ref.)

Aldosteronoma in childhood [letter; comment] Etker S. **J Pediatr Surg** 1995 Jul;30(7):1113 (15 ref.) Comment on: J Pediatr Surg 1994 Oct;29(10):1388–91.

Isolated clinical syndrome of primary aldosteronism in a patient with adrenocortical carcinoma. Case report and review of the literature. Weingärtner K, et al. **Urol Int** 1995;55(4):232–5 (15 ref.)

GENETICS

Glucocorticoid-remediable aldosteronism. Dluhy RG, et al. **Cardiovasc Res** 1996 Jun;31(6):870–2 (16 ref.)

Glucocorticoid-remediable aldosteronism. Litchfield WR, et al. **Compr Ther** 1995 Oct;21(10):553–8 (21 ref.)

PHYSIOPATHOLOGY

Secondary aldosteronism. Corry DB, et al. **Endocrinol Metab Clin North Am** 1995 Sep;24(3):511–29 (79 ref.)

Dexamethasone-suppressible hyperaldosteronism: clinical, biochemical and genetic relations. Connell JM, et al. **J Hum Hypertens** 1995 Jun;9(6):505–9 (19 ref.)

[New data on mineralocorticoid hormones. Physiopathological implications (editorial)] Corvol P, et al. **Presse Med** 1995 Sep 23;24(27):1235–7 (12 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Primary aldosteronism. Results of surgical treatment. Lo CY, et al. **Ann Surg** 1996 Aug;224(2):125–30 (23 ref.)

Primary aldosteronism in pregnancy—should it be treated surgically? Aboud E, et al. **Ir J Med Sci** 1995 Oct–Dec; 164(4):279–80 (12 ref.)

HYPERALGESIA

DRUG THERAPY

Future directions in the pharmacological management of hyperalgesic and allodynic pain states: the NMDA receptor. Yaksh TL, et al. **NIDA Res Monogr** 1995; 147:84–103 (63 ref.)

METABOLISM

Regulation of spinal neuropeptide genes in a rat model of peripheral inflammation and hyperalgesia. Ruda MA, et al. **Prog Brain Res** 1995;104:349–65 (121 ref.)

PHYSIOPATHOLOGY

Mechanisms of hyperalgesia and morphine tolerance: a current view of their possible interactions. Mao J, et al. **Pain** 1995 Sep;62(3):259–74 (150 ref.)

HYPERALIMENTATION, PARENTERAL see **PARENTERAL NUTRITION, TOTAL**

HYPERANDROGENISM

see related
HIRSUTISM
VIRILISM

Androgen excess in women. Derman RJ. **Int J Fertil Menopausal Stud** 1996 Mar-Apr;41(2):172–6 (28 ref.)

COMPLICATIONS

The android woman—a risky condition. Björntorp P. **J Intern Med** 1996 Feb;239(2):105–10 (38 ref.)

ETIOLOGY

Massive edema of the ovary associated with androgenic manifestations. Siller BS, et al. **South Med J** 1995 Nov; 88(11):1153–5 (45 ref.)

PSYCHOLOGY

The android woman—a risky condition. Björntorp P. **J Intern Med** 1996 Feb;239(2):105–10 (38 ref.)

THERAPY

From physiology to clinics—20 years of experience with pulsatile GnRH. Leyendecker G, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Apr;65 Suppl:S3–12 (107 ref.)

HYPERBARIC OXYGENATION

Infectious disease indications for hyperbaric oxygen therapy. Brown RB, et al. **Compr Ther** 1995 Nov;21(11):663–7 (17 ref.)

Hyperbaric-oxygen therapy. Tibbles PM, et al. **N Engl J Med** 1996 Jun 20;334(25):1642–8 (89 ref.)

Hypothermia and hyperbaric oxygen as treatment modalities for severe head injury. Clifton GL. **New Horiz** 1995 Aug; 3(3):474–8 (42 ref.)

Hyperbaric oxygen reduces ischemia-induced skeletal muscle injury. Haapaniemi T, et al. **Plast Reconstr Surg** 1996 Mar; 97(3):602–7; discussion 608–9 (42 ref.)

Toxic and therapeutic properties of oxygen—a review. Doležal V. **Sb Lek** 1995;96(3):231–4 (28 ref.)

METHODS

Hyperbaric oxygen therapy in pediatrics. Santamaria JP, et al. **Adv Pediatr** 1995;42:335–66 (48 ref.)

[Hyperbaric oxygen therapy in chronic radiation injury of soft tissues] Kooijman R, et al. **Ned Tijdschr Geneeskd** 1996 Aug 17;140(33):1671–4 (43 ref.) **(Dut)**

[Hyperbaric oxygen therapy. Now an established treatment in Norway] Brattebø G, et al. **Tidsskr Nor Laegeforen** 1996 May 30;116(14):1675–8 (33 ref.) (Eng. Abstr.) **(Nor)**

HYPERBETALIPOPROTEINEMIA see **HYPERCHOLESTEROLEMIA, FAMILIAL**

HYPERBILIRUBINEMIA

ETIOLOGY

Severe hyperbilirubinemia due to acute hepatitis A superimposed on a chronic hepatitis B carrier with glucose-6-phosphate dehydrogenase deficiency. Huo TI, et al. **Am J Gastroenterol** 1996 Jan;91(1):158–9 (10 ref.)

[Sepsis] Fukazawa T. **Ryoikibetsu Shokogun Shirizu** 1995; (8):403–6 (19 ref.) **(Jpn)**

METABOLISM

[Fasting hyperbilirubinemia] Nakanishi T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):427–9 (10 ref.) **(Jpn)**

HYPERBILIRUBINEMIA, HEREDITARY

[Lucey-Driscoll syndrome] Imai T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):440–1 (5 ref.) **(Jpn)**

CLASSIFICATION

[Congenital nonhemolytic hyperbilirubinemia] Tazuma S, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):562–5 (15 ref.) **(Jpn)**

METABOLISM

[Rotor's syndrome] Tazuma S, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):446–8 (12 ref.) **(Jpn)**

HYPERBILIRUBINEMIA, NEONATAL see **JAUNDICE, NEONATAL**

HYPERCALCEMIA

BLOOD

[Hypercalcitoninemia in conditions other than medullary cancers of the thyroid] Niccoli P, et al. **Ann Endocrinol (Paris)** 1996;57(1):15–21 (53 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

Vitamin D, calcium, and sarcoidosis. Sharma OP. **Chest** 1996 Feb;109(2):535–9 (78 ref.)

ETIOLOGY

The humoral hypercalcemia of benignancy. A newly appreciated syndrome [see comments] Knecht TP, et al. **Am J Clin Pathol** 1996 Apr;105(4):487–92 (42 ref.) Comment in: Am J Clin Pathol 1996 Apr;105(4):377–9.

Acute management of cancer-related hypercalcemia. Chisholm MA, et al. **Ann Pharmacother** 1996 May; 30(5):507–13 (58 ref.)

Pathogenesis and management of cancer associated hypercalcaemia. Ralston SH. **Cancer Surv** 1994;21:179–96 (104 ref.)

Hypercalcemia associated with adult T-cell leukemia/lymphoma (ATL). Peter SA, et al. **J Natl Med Assoc** 1995 Oct;87(10):746–8 (15 ref.)

1,25-dihydroxyvitamin D-mediated hypercalcemia in a renal transplant recipient. Golconda MS, et al. **Mayo Clin Proc** 1996 Jan;71(1):32–6 (25 ref.)

Hypercalcaemia complicating systemic oxalosis in primary hyperoxaluria type 1. Toussaint C, et al. **Nephrol Dial Transplant** 1995;10 Suppl 8:17–21 (21 ref.)

[Hypercalcemic crisis. Exacerbation of an existing hypercalcemia syndrome] Hehrmann R. **Fortschr Med** 1996 Apr 10;114(10):118–22 (13 ref.) (Eng. Abstr.) **(Ger)**

[Malignancy associated with hypercalcemia] Eto S. **Nippon Naika Gakkai Zasshi** 1996 Mar 10;85(3):371–6 (10 ref.) **(Jpn)**

[Nephropathy associated with electrolyte disorders] Tsuchiya K, et al. **Nippon Rinsho** 1995 Aug;53(8):1995–2000 (15 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

A case of acute lymphoblastic leukemia accompanied with the production of parathyroid hormone-related protein. Harutsumi M, et al. **Miner Electrolyte Metab** 1995; 21(1–3):171–6 (24 ref.)

Parathyroid hormone-related peptide in hypercalcemia associated with adult T cell leukemia/lymphoma: molecular and cellular mechanism of parathyroid hormone-related peptide overexpression in HTLV-I-infected T cells. Ikeda K, et al. **Miner Electrolyte Metab** 1995;21(1–3):166–70 (36 ref.)

PATHOLOGY

Quantitative and three-dimensional aspects of the rat parathyroid gland in normo-, hypo-, and hypercalcemia. Wernerson A, et al. **Microsc Res Tech** 1995 Oct 1; 32(2):129–47 (172 ref.)

THERAPY

Acute management of cancer-related hypercalcemia. Chisholm MA, et al. **Ann Pharmacother** 1996 May; 30(5):507–13 (58 ref.)

Pathogenesis and management of cancer associated hypercalcaemia. Ralston SH. **Cancer Surv** 1994;21:179–96 (104 ref.)

HYPERCAPNIA

Permissive hypercapnia in ARDS and its effect on tissue oxygenation. Hickling KG, et al. **Acta Anaesthesiol Scand Suppl** 1995;107:201–8 (53 ref.)

ETIOLOGY

Permissive hypercapnia in ARDS: just do it? [editorial; comment] Lewandowski K. **Intensive Care Med** 1996 Mar; 22(3):179–81 (13 ref.) Comment on: Intensive Care Med 1996 Mar;22(3):182–91.

[Anesthesia for celiosurgery] Schoeffler P, et al. **Ann Chir** 1995;49(10):878–80 (19 ref.) **(Fre)**

PHYSIOPATHOLOGY

Ventilatory responses to hypoxia and hypercapnia during inhalation anaesthesia and subparalytical muscle relaxation in humans [see comments] Lindahl SG. **Acta Anaesthesiol Sin** 1995 Dec;33(4):223–6 (13 ref.) Comment in: Acta Anaesthesiol Sin 1995 Dec;33(4):i–ii.

Influence of body temperature on responses to hypoxia and hypercapnia: implications for SIDS. Maskrey M. **Clin Exp Pharmacol Physiol** 1995 Aug;22(8):527–32 (60 ref.)

Permissive hypercapnia. Dries DJ. **J Trauma** 1995 Nov; 39(5):984–9 (48 ref.)

HYPERCHOLESTEREMIA see **HYPERCHOLESTEROLEMIA**

HYPERCHOLESTEROLEMIA

BLOOD

Thrombin generation in myocardial infarction and hypercholesterolemia: effects of aspirin. Szczeklik A. **Thromb Haemost** 1995 Jul;74(1):77–80 (34 ref.)

COMPLICATIONS

Cardiovascular risk-factor reduction in elderly patients with cardiac disease. Williams MA. **Phys Ther** 1996 May; 76(5):469–80 (103 ref.)

[Dyslipidemia, lipid lowering drugs and thrombosis] Ambrosi P, et al. **Arch Mal Coeur Vaiss** 1995 Nov;88(11):1641–5 (31 ref.) (Eng. Abstr.) **(Fre)**

[The importance of the dyslipidemia-arterial hypertension link in coronary atherosclerosis] Diament J, et al. **Arq Bras Cardiol** 1995 Sep;65(3):279–82 (35 ref.) **(Por)**

DIAGNOSIS

[Normocytic anemia and hypercholesterolemia as the manifestation of a variant of Hashimoto's thyroiditis] Buitrago Ramírez F, et al. **An Esp Pediatr** 1996 Jul; 45(1):76–8 (10 ref.) **(Spa)**

DIET THERAPY

Dietary fibre and plasma lipids. Truswell AS. **Eur J Clin Nutr** 1995 Oct;49 Suppl 3:S105–9 (30 ref.)

The role of fiber in the treatment of hypercholesterolemia in children and adolescents. Kwiterovich PO Jr. **Pediatrics** 1995 Nov;96(5 Pt 2):1005–9 (20 ref.)

Hypercholesterolemia. Dietary advice for patients regarding meat [see comments] Keenan JM, et al. **Postgrad Med** 1995 Oct;98(4):113–4, 117–8, 120–1 passim (20 ref.) Comment in: Postgrad Med 1996 Feb;99(2):47–8.

[Dietary treatment of hypercholesterolemia] Richter WO. **Wien Klin Wochenschr** 1995;107(18):549–54 (83 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Lowering risk without lowering cholesterol: implications for national cholesterol policy. Avins AL, et al. **Ann Intern Med** 1996 Sep 15;125(6):502–6 (35 ref.)

Cholesterol agonistics [comment] LaRosa JC. **Ann Intern Med** 1996 Mar 1;124(5):505–8 (42 ref.) Comment on: Ann Intern Med 1996 Mar 1;124(5):515–7. Comment on: Ann Intern Med 1996 Mar 1;124(5):518–31.

The cholesterol controversy [see comments] Geurian KL. **Ann Pharmacother** 1996 May;30(5):495–500 (60 ref.) Comment in: Ann Pharmacother 1996 May;30(5):539–42.

Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia [see comments] Hsu I, et al. **Ann Pharmacother** 1995 Jul–Aug; 29(7–8):743–59 (114 ref.) Comment in: Ann Pharmacother 1995 Dec;29(12):1304.

Cholesterol-lowering therapy: is there really a controversy? [comment] Jungnickel PW. **Ann Pharmacother** 1996 May; 30(5):539–42 (33 ref.) Comment on: Ann Pharmacother 1996 May;30(5):495–500.

Fluvastatin in combination with other lipid-lowering agents. Jokubaitis LA. **Br J Clin Pract Symp Suppl** 1996 Jan; 77A:28–32 (4 ref.)

Treatment of dyslipidaemias with fluvastatin. Peters TK. **Br J Clin Pract Symp Suppl** 1996 Jan;77A:16–9 (7 ref.)

Statin therapy in clinical practice: new developments. Shepherd J. **Curr Opin Lipidol** 1995 Oct;6(5):254–5 (13 ref.)

Treating elevated cholesterol levels: the great Satan in perspective. Gibaldi M, et al. **J Clin Pharmacol** 1996 Mar; 36(3):189–97 (45 ref.)

Oxylanosterols as modifiers of cholesterol biosynthesis. Trzaskos JM. **Prog Lipid Res** 1995;34(2):99–116 (28 ref.)

[Cholesterol synthesis inhibitors: lowering of cholesterol for everybody?] Westendorp RG, et al. **Ned Tijdschr Geneeskd** 1996 Feb 24;140(8):411–4 (14 ref.) **(Dut)**

[The drug therapy of hypercholesterolemia] Berthold HK, et al. **Dtsch Med Wochenschr** 1996 May 31;121(22):729–34 (30 ref.) **(Ger)**

[Drug therapy of hypercholesterolemia] Schwandt P, et al. **Wien Klin Wochenschr** 1995;107(18):544–8 (64 ref.) (Eng. Abstr.) **(Ger)**

[An update on the use of fluvastatin in primary hypercholesterolemia] Baggio G. **Ann Ital Med Int** 1995 Oct;10 Suppl:43S (5 ref.) **(Ita)**

[The treatment of hypercholesterolemia in primary and secondary prevention] Sirtori CR. **Ann Ital Med Int** 1995 Oct;10 Suppl:48S–52S (22 ref.) (Eng. Abstr.) **(Ita)**

[The pharmacological treatment of hypercholesterolemia] Pérez Jiménez F. **Rev Esp Cardiol** 1995;48 Suppl 5:31–8 (53 ref.) (Eng. Abstr.) **(Spa)**

[Lowered cholesterol beneficial for vascular endothelium] Strandberg T, et al. **Nord Med** 1996 Jan;111(1):10–2 (10 ref.) (Eng. Abstr.) **(Swe)**

ECONOMICS

Cost effectiveness of cholesterol-lowering drugs: a review of the evidence. Thorvik E, et al. **Wien Klin Wochenschr** 1996;108(8):234–43 (23 ref.)

GENETICS

[The Finnish genes of coronary heart disease] Kontula K, et al. **Duodecim** 1994;110(7):721–9 (43 ref.) **(Fin)**

METABOLISM

Anatomical heterogeneity of the intestinal mucosa and cholesterol homeostasis. A review of studies with normal and genetically hypercholesterolemic (RICO) Rat. Lutton C. **Digestion** 1996;57(1):1–10 (40 ref.)

MORTALITY

[Cholesterolemia reduction and mortality. Critical analysis] Feitosa GS. **Arq Bras Cardiol** 1995 Sep;65(3):301–4 (43 ref.) **(Por)**

PHYSIOPATHOLOGY

Effects of oxidized low-density lipoprotein on vascular contraction and relaxation: clinical and pharmacological implications in atherosclerosis. Cox DA, et al. **Pharmacol Rev** 1996 Mar;48(1):3–19 (182 ref.)

PREVENTION & CONTROL

Atherosclerosis and cholesterol. The end of the controversy? [editorial] Heller FR. **Acta Clin Belg** 1996;51(1):1–7 (50 ref.)

Cholesterol screening in children. Benuck I. **Curr Probl Pediatr** 1995 Sep;25(8):254–60 (45 ref.)

[1995 consensus guidelines for cholesterol. Society of Physicians in Vienna] Sinzinger H, et al. **Wien Klin Wochenschr** 1995;107(18):537–9 (5 ref.) **(Ger)**

[Levels and criteria for evaluation of primary preventive interventions and their relevance for the cholesterol problem] Heyll U. **Z Kardiol** 1996 Mar;85(3):166–70 (14 ref.) (Eng. Abstr.) **(Ger)**

[The treatment of hypercholesterolemia in primary and secondary prevention] Sirtori CR. **Ann Ital Med Int** 1995 Oct;10 Suppl:48S–52S (22 ref.) (Eng. Abstr.) **(Ita)**

THERAPY

Meta-analysis, clinical trials, and transferability of research results into practice. The case of cholesterol-lowering interventions in the secondary prevention of coronary heart disease. Marchioli R, et al. **Arch Intern Med** 1996 Jun 10; 156(11):1158–72 (163 ref.)

Applications of bio-techniques on treatment of cardiovascular diseases. Tang J, et al. **Chin Med J (Engl)** 1996 Feb;109(2):108–10 (0 ref.)

Lipid-regulating and antiatherosclerotic therapy: current options and future approaches. Gotto AM Jr. **Cleve Clin J Med** 1996 Jan–Feb;63(1):31–41 (48 ref.)

[Modifying increased plasma cholesterol levels in secondary prevention of coronary heart disease] Jost S, et al. **Z Kardiol** 1995 Aug;84(8):577–95 (159 ref.) (Eng. Abstr.) **(Ger)**

HYPERCHOLESTEROLEMIA, ESSENTIAL see **HYPERCHOLESTEROLEMIA, FAMILIAL**

HYPERCHOLESTEROLEMIA, FAMILIAL

[Diagnosis and treatment of familial hypercholesterolemia in children and adolescents (see comments)] Ose L, et al. **Tidsskr Nor Laegeforen** 1995 Nov 20;115(28):3499–503 (27 ref.) (Eng. Abstr.) Comment in: Tidsskr Nor Laegeforen 1996 Jan 20;116(2):299–300. **(Nor)**

DIET THERAPY

Lipid lowering in the young [editorial] Thompson GR. **Heart** 1996 Jul;76(1):1–2 (17 ref.)

GENETICS

[Dyslipoproteinemias in Quebec: primary deficit in lipoprotein lipase and familial hypercholesterolemia] Gagné C, et al. **Union Med Can** 1995 Sep;124(2):61–7 (32 ref.) **(Fre)**

[Molecular biology in the diagnosis and phenotypic expression of familial hypercholesterolemia in French Canadians] Vohl MC, et al. **Union Med Can** 1995 Sep; 124(2):48–53 (23 ref.) **(Fre)**

[Hypercholesterolemia] Schmidt H, et al. **Wien Med Wochenschr** 1994;144(12–13):312–7 (29 ref.) (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

[Hyperlipoproteinemias in childhood] Widhalm K. **Wien Med Wochenschr** 1994;144(12–13):320–3 (5 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Gene therapy of familial hypercholesterolemia. Cai H. **Chin Med J (Engl)** 1996 Feb;109(2):104–6 (9 ref.)

Apolipoprotein B mRNA editing protein: a tool for dissecting lipoprotein metabolism and a potential therapeutic gene for hypercholesterolemia. Chan L, et al. **Z Gastroenterol** 1996 Jun;34 Suppl 3:31–2 (16 ref.)

Reconstitution of apoB mRNA editing in liver by gene-transfer as a potential approach for the treatment of

severe forms of polygenic hypercholesterolemia--an outline of the rationale. Greeve J, et al. **Z Gastroenterol** 1996 Jun;34 Suppl 3:27-30 (70 ref.)

Gene therapy: prospects for treatment of liver disease. Sandig V, et al. **Z Gastroenterol** 1996 Jun;34 Suppl 3:25-6 (32 ref.)

[Extracorporeal elimination of LDL-cholesterol in the treatment of hypercholesterolemia: indications and methods] Bláha V, et al. **Vnitr Lek** 1995 Oct;41(10):724-9 (40 ref.) (Eng. Abstr.) **(Cze)**

[Radical therapy of refractory hyperlipidemia: extracorporeal cholesterol elimination] Kostner KM. **Wien Med Wochenschr** 1994;144(12-13):333-5 (13 ref.) (Eng. Abstr.) **(Ger)**

HYPERCHYLOMICRONEMIA, FAMILIAL see **LIPOPROTEIN LIPASE DEFICIENCY, FAMILIAL**

HYPERCORTICISM see **ADRENAL GLAND HYPERFUNCTION**

HYPEREMESIS GRAVIDARUM

Hyperolfaction and hyperemesis gravidarum: what is the relationship? Erick M. **Nutr Rev** 1995 Oct;53(10):289-95 (75 ref.)

HYPEREMIA

ULTRASONOGRAPHY

Colour Doppler energy (power) mode ultrasound. MacSweeney JE, et al. **Clin Radiol** 1996 Jun;51(6):387-90 (21 ref.)

HYPEREOSINOPHILIC SYNDROME

COMPLICATIONS

Specific mucosal erosions in hypereosinophilic syndrome. Evidence for eosinophil protein deposition [see comments] Aractingi S, et al. **Arch Dermatol** 1996 May;132(5):535-41 (37 ref.) Comment in: Arch Dermatol 1996 May;132(5):583-5.

GENETICS

Further evidence for the clonal nature of the idiopathic hypereosinophilic syndrome: complete haematological and cytogenetic remission induced by interferon-alpha in a case with a unique chromosomal abnormality. Malbrain ML, et al. **Br J Haematol** 1996 Jan;92(1):176-83 (55 ref.)

METABOLISM

Deposits of eosinophil granule proteins in eosinophilic cholecystitis and eosinophilic colitis associated with hypereosinophilic syndrome. Tajima K, et al. **Dig Dis Sci** 1996 Feb;41(2):282-8 (25 ref.)

THERAPY

Further evidence for the clonal nature of the idiopathic hypereosinophilic syndrome: complete haematological and cytogenetic remission induced by interferon-alpha in a case with a unique chromosomal abnormality. Malbrain ML, et al. **Br J Haematol** 1996 Jan;92(1):176-83 (55 ref.)

HYPERGAMMAGLOBULINEMIA

Children with hyperimmunoglobulinemia D and periodic fever syndrome. Grose C, et al. **Pediatr Infect Dis J** 1996 Jan;15(1):72-7 (16 ref.)

COMPLICATIONS

Necrotizing herpes zoster mimicking relapse of vasculitis in angioimmunoblastic lymphadenopathy with dysproteinaemia. Böni R, et al. **Br J Dermatol** 1995 Dec; 133(6):978-82 (29 ref.)

[Hyperimmunoglobulinemia D or periodic fever syndrome. Cutaneous manifestations in 3 cases] Cartier H, et al. **Ann Dermatol Venereol** 1996;123(5):314-21 (34 ref.) (Eng. Abstr.) **(Fre)**

[Hyperimmunoglobulin D syndrome] Drenth JP, et al. **Presse Med** 1995 Sep 16;24(26):1211-3 (21 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Systemic lupus erythematosus diagnosed during interferon alfa therapy. Morris LF, et al. **South Med J** 1996 Aug; 89(8):810-4 (30 ref.)

GENETICS

CD40-CD40 ligand (CD40L) interactions and X-linked hyperIgM syndrome (HIGMX-1). Ramesh N, et al. **Clin Immunol Immunopathol** 1995 Sep;76(3 Pt 2):S208-13 (37 ref.)

IMMUNOLOGY

Molecular anatomy and the pathological expression of antibody light chains [comment] Schiffer M. **Am J Pathol** 1996 May;148(5):1339-44 (31 ref.) Comment on: Am J Pathol 1996 May;148(5):1397-406.

CD40-CD40 ligand (CD40L) interactions and X-linked hyperIgM syndrome (HIGMX-1). Ramesh N, et al. **Clin Immunol Immunopathol** 1995 Sep;76(3 Pt 2):S208-13 (37 ref.)

HYPERGLYCEMIA

Transient and permanent neonatal diabetes. Fösel S. **Eur J Pediatr** 1995 Dec;154(12):944-8 (105 ref.)

CHEMICALLY INDUCED

Do KCa channels and carbonic anhydrase play a role in thiazide-induced hyperglycaemia? Pickkers P, et al. **J Hum Hypertens** 1995 Aug;9(8):691-3 (22 ref.)

COMPLICATIONS

Hyperglycemia-induced latent scurvy and atherosclerosis: the scorbutic-metaplasia hypothesis. Price KD, et al. **Med Hypotheses** 1996 Feb;46(2):119-29 (136 ref.)

Mediators of hyperglycemia and the pathogenesis of matrix accumulation in diabetic renal disease. Ziyadeh FN. **Miner Electrolyte Metab** 1995;21(4-5):292-302 (157 ref.)

Diabetes complications: why is glucose potentially toxic? [see comments] Porte D Jr, et al. **Science** 1996 May 3; 272(5262):699-700 (12 ref.) Comment in: Science 1996 May 3;272(5262):728-31.

DRUG THERAPY

The pharmacological treatment of hyperglycemia in NIDDM. American Diabetes Association. **Diabetes Care** 1995 Nov;18(11):1510-8 (0 ref.)

ETIOLOGY

Hyperglycemia in diarrhea-associated hemolytic-uremic syndrome. Robson WL, et al. **Nephron** 1995;71(1):54-8 (21 ref.)

PHYSIOPATHOLOGY

Glucose toxicity: the implications of hyperglycemia in the pathophysiology of diabetes mellitus. Rossetti L. **Clin Invest Med** 1995 Aug;18(4):255-60 (22 ref.)

Hyperglycemia and diabetic kidney disease. The case for transforming growth factor-beta as a key mediator. Sharma K, et al. **Diabetes** 1995 Oct;44(10):1139-46 (124 ref.)

Oxidative stress and diabetic vascular complications. Giugliano D, et al. **Diabetes Care** 1996 Mar;19(3):257-67 (152 ref.)

Mechanism of postprandial hyperglycaemia in diabetes mellitus. Dinneen SF. **Eur J Gastroenterol Hepatol** 1995 Aug;7(8):724-9 (39 ref.)

Advanced glycation endproducts and diabetic nephropathy. Makita Z, et al. **J Diabetes Complications** 1995 Oct-Dec; 9(4):265-8 (26 ref.)

Hyperglycaemia--pathophysiological aspects at the cellular level [editorial] Wolf G, et al. **Nephrol Dial Transplant** 1995; 10(7):1109-12 (25 ref.)

PREVENTION & CONTROL

Tight glycaemic control prevents diabetic complications [editorial] Pirart J. **Acta Clin Belg** 1995;50(6):321-5 (31 ref.)

THERAPY

Emergency management of hypoglycemia and hyperglycemia. Bavitz JB. **Dent Clin North Am** 1995 Jul; 39(3):587-94 (13 ref.)

HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC COMA

Review: diabetic ketoacidosis and hyperglycemic hyperosmolar nonketotic syndrome. Umpierrez GE, et al. **Am J Med Sci** 1996 May;311(5):225-33 (75 ref.)

THERAPY

The emergency management of hyperglycemic-hyperosmolar nonketotic coma in the pediatric patient. Gottschalk ME, et al. **Pediatr Emerg Care** 1996 Feb;12(1):48-51 (26 ref.)

Diabetic ketoacidosis and hyperosmolar nonketotic state: gaining control over extreme hyperglycemic complications. Gonzalez-Campoy JM, et al. **Postgrad Med** 1996 Jun; 99(6):143-52 (21 ref.)

[Emergency drug therapy of diabetic coma] Morita S, et al. **Nippon Naika Gakkai Zasshi** 1995 Nov 10;84(11):1843-7 (4 ref.) **(Jpn)**

HYPERGLYCEMIC MICE see **MICE, OBESE**

HYPERHIDROSIS

ETIOLOGY

[Autonomic nervous system disease--sweat disorders] Kihara M, et al. **Nippon Naika Gakkai Zasshi** 1995 Sep 10; 84(9):1435-7 (12 ref.) **(Jpn)**

SURGERY

[Upper thoracic sympathectomy by thoracoscopic approach. A method of choice for the treatment of palmar hyperhidrosis] Lévy I, et al. **Ann Chir** 1995;49(9):858-62 (35 ref.) (Eng. Abstr.) **(Fre)**

[Treatment of primary hyperhidrosis of the upper limbs by transthoracic endoscopic sympathectomy] Lesèche G, et al. **Presse Med** 1995 Nov 4;24(33):1569-73 (36 ref.) (Eng. Abstr.) **(Fre)**

HYPERHIDROSIS, GUSTATORY see **SWEATING, GUSTATORY**

HYPERIMMUNOGLOBULIN E-RECURRENT INFECTION SYNDROME see **JOB'S SYNDROME**

HYPERINSULINISM

Development and consequences of insulin resistance: lessons from animals with hyperinsulinaemia. Shafrir E. **Diabetes Metab** 1996 Apr;22(2):122-31 (63 ref.)

COMPLICATIONS

Hyperinsulinemia and atherosclerosis. Stout RW. **Diabetes** 1996 Jul;45 Suppl 3:S45-6 (26 ref.)

ETIOLOGY

beta-cell stimulus - secretion coupling defects in rodent models of obesity. Chan CB. **Can J Physiol Pharmacol** 1995 Oct;73(10):1414-24 (138 ref.)

Hyperinsulinemia and atherosclerosis. Standl E. **Clin Invest Med** 1995 Aug;18(4):261-6 (40 ref.)

[Nesidioblastosis of the pancreas as a cause of hyperinsulinemic hypoglycemia in adults] Tavčar I, et al. **Vojnosanit Pregl** 1994 Jan-Feb;51(1):73-81 (31 ref.) **(Ser)**

GENETICS

Genetics and the metabolic syndrome. Bouchard C. **Int J Obes Relat Metab Disord** 1995 May;19 Suppl 1:S52-9 (43 ref.)

METABOLISM

Hyperinsulinemia and triglyceride-rich lipoproteins. Steiner G, et al. **Diabetes** 1996 Jul;45 Suppl 3:S24-6 (29 ref.)

PATHOLOGY

Nesidioblastosis and persistent neonatal hyperinsulinism. Sempoux C, et al. **Diabete Metab** 1995 Dec;21(6):402-7 (32 ref.)

PHYSIOPATHOLOGY

Hyperinsulinemia, hyperproinsulinemia and insulin resistance in the metabolic syndrome. Schrezenmeir J. **Experientia** 1996 May 15;52(5):426-32 (26 ref.)

Are insulin resistance and/or compensatory hyperinsulinemia involved in the etiology and clinical course of patients with hypertension? Reaven GM. **Int J Obes Relat Metab Disord** 1995 May;19 Suppl 1:S2-5 (49 ref.)

Insulin resistance and hyperinsulinemia in hypertension. Weidmann P, et al. **J Hypertens Suppl** 1995 Aug; 13(2):S65-72 (104 ref.)

SURGERY

[Is preoperative site diagnosis in organic hyperinsulinism from the viewpoint of the surgeon still necessary today? Results of a consecutive series and analysis of the literature] Böttger T, et al. **Chirurg** 1996 Mar;67(3):268-72 (17 ref.) (Eng. Abstr.) **(Ger)**

HYPERKALEMIA

CHEMICALLY INDUCED

Mechanisms of hyperkalemia caused by nafamostat mesilate. Muto S, et al. **Gen Pharmacol** 1995 Dec;26(8):1627-32 (34 ref.)

ETIOLOGY

[Iatrogenic hyperkalemia] Krapf R. **Schweiz Med Wochenschr** 1996 Apr 13;126(15):626-31 (29 ref.) (Eng. Abstr.) **(Ger)**

METABOLISM

Potassium homeostasis and hyperkalemic syndromes. Clark BA, et al. **Endocrinol Metab Clin North Am** 1995 Sep; 24(3):573-91 (84 ref.)

PHYSIOPATHOLOGY

Potassium homeostasis and hyperkalemic syndromes. Clark BA, et al. **Endocrinol Metab Clin North Am** 1995 Sep; 24(3):573-91 (84 ref.)

Hyperkalemia in end-stage renal disease: mechanisms and management [editorial] Allon M. **J Am Soc Nephrol** 1995 Oct;6(4):1134-42 (79 ref.)

THERAPY

Cecal perforation associated with sodium polystyrene sulfonate-sorbitol enemas in a 650 gram infant with hyperkalemia. Bennett LN, et al. **Am J Perinatol** 1996 Apr;

13(3):167-70 (12 ref.)
Hyperkalemia in end-stage renal disease: mechanisms and management [editorial] Allon M. **J Am Soc Nephrol** 1995 Oct;6(4):1134-42 (79 ref.)

HYPERKERATOSIS PALMARIS ET PLANTARIS see **KERATODERMA, PALMOPLANTAR**

HYPERKINESIS

ETIOLOGY

New opinions of pathomechanisms of involuntary movements. Iłżecka J.
Ann Univ Mariae Curie Sklodowska [Med] 1994;49:99-104 (16 ref.)
Hyperactivity: is candy causal? Krummel DA, et al.
Crit Rev Food Sci Nutr 1996 Jan;36(1-2):31-47 (57 ref.)

THERAPY

The management of hyperactive children. **Drug Ther Bull** 1995 Aug;33(8):57-60 (22 ref.)

HYPERKINETIC HEART SYNDROME see **NEUROCIRCULATORY ASTHENIA**

HYPERKINETIC SYNDROME see **ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY**

HYPERLIPEMIA see **HYPERLIPIDEMIA**

HYPERLIPIDEMIA

see related
ANTILIPEMIC AGENTS

BLOOD

The role of lipids in cardiovascular disease: lessons from rare mutations and special populations. Hegele RA.
Clin Invest Med 1996 Jun;19(3):161-70 (42 ref.)

COMPLICATIONS

Do glomerular atherosclerosis and lipid-mediated tubulo-interstitial disease cause progressive renal failure in man? Moorhead JF, et al. **Blood Purif** 1996;14(1):58-66 (69 ref.)
Mechanisms of cardiovascular injury in renal disease. Rabelink TJ, et al. **Blood Purif** 1996;14(1):67-74 (64 ref.)
Hyperlipidemia and its management in renal disease. Massy ZA, et al. **Curr Opin Nephrol Hypertens** 1996 Mar; 5(2):141-6 (63 ref.)
The insulin resistance-dyslipidemic syndrome: contribution of visceral obesity and therapeutic implications. Després JP, et al. **Int J Obes Relat Metab Disord** 1995 May;19 Suppl 1:S76-86 (72 ref.)
Thrombogenic and lipid risk factors in hypertension and coronary artery disease. Ding YA. **Jpn Circ J** 1996 Feb; 60(2):75-84 (41 ref.)
[Diabetic dyslipidemia and its treatment] Urbánek R, et al. **Vnitr Lek** 1996 Jan;42(1):26-30 (27 ref.) (Eng. Abstr.) **(Cze)**
[Dyslipidemias and endothelial changes] Bertolami MC. **Arq Bras Cardiol** 1995 Sep;65(3):267-72 (59 ref.) **(Por)**
[The importance of the dyslipidemia-arterial hypertension link in coronary atherosclerosis] Diament J, et al. **Arq Bras Cardiol** 1995 Sep;65(3):279-82 (35 ref.) **(Por)**
[Hyperlipidemia and nephropathy: cause or consequence? (editorial)] Guijarro C, et al. **Med Clin (Barc)** 1995 Oct 21;105(13):496-7 (25 ref.) **(Spa)**

DIAGNOSIS

A practical approach to the laboratory diagnosis of dyslipidemia. Jialal I. **Am J Clin Pathol** 1996 Jul; 106(1):128-38 (33 ref.)
Diagnosis and classification of dyslipidemia in renal disease. Attman PO, et al. **Blood Purif** 1996;14(1):49-57 (60 ref.)
[Diagnosis of the metabolic syndrome] Hanefeld M, et al. **Internist (Berl)** 1996 Jul;37(7):705-11 (32 ref.) **(Ger)**
[Progress in the diagnosis of endocrine and metabolic disorders: hyperlipidemia] Yamashita S. **Rinsho Byori** 1995 Nov;43(11):1120-7 (18 ref.) (Eng. Abstr.) **(Jpn)**

DIET THERAPY

Dietary fibre in the treatment of metabolic diseases. Rivellese AA, et al. **Eur J Clin Nutr** 1995 Oct;49 Suppl 3:S110-2 (12 ref.)
[Diet in hyperlipidemia, hypertension and gout] Wolfram G. **Internist (Berl)** 1995 Nov;36(11):1070-6 (35 ref.) **(Ger)**

DRUG THERAPY

Treatment of hyperlipidemia after heart transplantation and rationale for the Heart Transplant Lipid Registry. Ballantyne CM, et al. **Am J Cardiol** 1996 Sep 1;78(5):532-5 (34 ref.)
Approaches to the treatment of hyperlipidemia in the solid organ transplant recipient. Kirk JK, et al.
Ann Pharmacother 1995 Sep;29(9):879-91 (98 ref.)
Treatment of lipids. Implications for the general practitioner. Simons LA. **Aust Fam Physician** 1996 Jul;25(7):1053-9 (6 ref.)
Lipid management: past, present, and future. Betteridge DJ. **Br J Clin Pract Symp Suppl** 1996 Jan;77A:1-10 (49 ref.)
Management of hyperlipidemia in diabetes. Vinik AI, et al. **Compr Ther** 1995 Oct;21(10):602-9 (50 ref.)
Hyperlipidemia and its management in renal disease. Massy ZA, et al. **Curr Opin Nephrol Hypertens** 1996 Mar; 5(2):141-6 (63 ref.)
The effects of metformin on cardiovascular risk factors. Grant PJ. **Diabetes Metab Rev** 1995 Sep;11 Suppl 1:S43-50 (56 ref.)
Gemfibrozil. A reappraisal of its pharmacological properties and place in the management of dyslipidaemia. Spencer CM, et al. **Drugs** 1996 Jun;51(6):982-1018 (234 ref.)
Dual roles of HMG-CoA reductase inhibitors in solid organ transplantation: lipid lowering and immunosuppression. Katznelson S, et al. **Kidney Int Suppl** 1995 Dec;52:S112-5 (30 ref.)
Hyperlipidemia. When does treatment make a difference? Wise GR, et al. **Postgrad Med** 1996 Jul;100(1):138-49 (17 ref.)
[Integrated drug therapy of the metabolic syndrome] Julius U, et al. **Internist (Berl)** 1996 Jul;37(7):722-30 (32 ref.) **(Ger)**

EPIDEMIOLOGY

Hyperlipidemia, hypertension and atherosclerosis in women. Reality and perspectives. Bugliosi R, et al. **Clin Ter** 1995 Aug-Sep;146(8-9):503-18 (66 ref.)
[Epidemiology of the metabolic syndrome] Janka HU. **Internist (Berl)** 1996 Jul;37(7):681-6 (59 ref.) **(Ger)**

ETIOLOGY

Dyslipoproteinemias in diabetes. Steiner G.
Clin Invest Med 1995 Aug;18(4):282-7 (23 ref.)
Clinical correlation between renal allograft failure and hyperlipidemia. Guijarro C, et al. **Kidney Int Suppl** 1995 Dec;52:S56-9 (22 ref.)
Dyslipidemia in renal disease. Mittman N, et al.
Semin Nephrol 1996 May;16(3):202-13 (144 ref.)
[Obesity and the related diseases: hyperlipidemia] Koizumi J, et al. **Nippon Naika Gakkai Zasshi** 1995 Aug 10; 84(8):1256-61 (5 ref.) **(Jpn)**
[Therapy of diabetes mellitus associated with hyperlipidemia] Yamada N. **Nippon Naika Gakkai Zasshi** 1996 Apr 10; 85(4):519-24 (4 ref.) **(Jpn)**
[Obesity and hyperlipidemia] Funahashi T, et al.
Nippon Rinsho 1995 Jun;53 Suppl:304-9 (34 ref.) **(Jpn)**
[The role of trace elements concerning to disorders of lipid metabolism] Miyake N. **Nippon Rinsho** 1996 Jan;54(1):73-8 (17 ref.) (Eng. Abstr.) **(Jpn)**
[Hyperlipidemia and nephropathy: cause or consequence? (editorial)] Guijarro C, et al. **Med Clin (Barc)** 1995 Oct 21;105(13):496-7 (25 ref.) **(Spa)**

GENETICS

The genetic determinants of plasma cholesterol and response to diet. Humphries SE, et al.
Baillieres Clin Endocrinol Metab 1995 Oct;9(4):797-823 (148 ref.)
Dyslipidaemia and coronary heart disease: nature vs nurture. Hegele RA. **Br J Hosp Med** 1995 Aug 16-Sep 5;54(4):143-6 (15 ref.)
The role of lipids in cardiovascular disease: lessons from rare mutations and special populations. Hegele RA.
Clin Invest Med 1996 Jun;19(3):161-70 (42 ref.)
[The metabolic syndrome and chronic vascular disease. Cellular mechanisms and potential candidate genes] Haller H, et al. **Internist (Berl)** 1996 Jul;37(7):687-97 (100 ref.) **(Ger)**

PHYSIOPATHOLOGY

Dyslipidemia and coronary artery disease in the elderly. LaRosa JC. **Clin Geriatr Med** 1996 Feb;12(1):33-40 (34 ref.)
Insulin resistance in the pathogenesis of dyslipidemia. Garg A. **Diabetes Care** 1996 Apr;19(4):387-9 (34 ref.)
An update on hyperlipidemia and its management. Memon RA, et al. **JPMA J Pak Med Assoc** 1995 Oct;45(10):275-82 (65 ref.)
[Metabolic syndrome and fatal quartet] Standl E.
Internist (Berl) 1996 Jul;37(7):698-704 (36 ref.) **(Ger)**
[Dyslipidemia in women. Physiopathological and therapeutic aspects] Barros MA, et al. **Arq Bras Cardiol** 1995 Sep; 65(3):283-8 (44 ref.) **(Por)**

PREVENTION & CONTROL

Exercise and the prevention of dyslipidemia and coronary heart disease. Després JP, et al.
Int J Obes Relat Metab Disord 1995 Oct;19 Suppl 4:S45-51 (72 ref.)

THERAPY

Management of disorders of cholesterol, triglyceride, and lipoprotein metabolism. Report 6 of the Council on Scientific Affairs. **Arch Fam Med** 1995 Oct;4(10):869-78 (74 ref.)
Review of new guidelines for management of dyslipidaemia. Betteridge DJ, et al. **Baillieres Clin Endocrinol Metab** 1995 Oct;9(4):867-90 (64 ref.)
Treatment of dyslipidemia in chronic renal failure. Toto RD. **Blood Purif** 1996;14(1):75-82 (48 ref.)
Diabetic dyslipidemia: effects of diabetes control, diet and drug therapy. Bar-On H. **Isr J Med Sci** 1996 Jun; 32(6):397-406 (105 ref.)
An update on hyperlipidemia and its management. Memon RA, et al. **JPMA J Pak Med Assoc** 1995 Oct;45(10):275-82 (65 ref.)
Clinical utility of antilipidemic therapies in chronic renal allograft failure. Wanner C, et al. **Kidney Int Suppl** 1995 Dec;52:S60-2 (38 ref.)
[Diabetic dyslipidemia and its treatment] Urbánek R, et al. **Vnitr Lek** 1996 Jan;42(1):26-30 (27 ref.) (Eng. Abstr.) **(Cze)**
[Non-medicamentous therapy of metabolic syndrome] Reimers CD, et al. **Internist (Berl)** 1996 Jul;37(7):712-21 (70 ref.) **(Ger)**
[Therapy of hyperlipidemia] Keller C.
Wien Med Wochenschr 1994;144(12-13):330-2 (21 ref.) (Eng. Abstr.) **(Ger)**
[Treatment of hyperlipidemia] Murase T.
Nippon Naika Gakkai Zasshi 1995 Sep 10;84(9):1517-22 (16 ref.) **(Jpn)**
[Dyslipidemia in women. Physiopathological and therapeutic aspects] Barros MA, et al. **Arq Bras Cardiol** 1995 Sep; 65(3):283-8 (44 ref.) **(Por)**
[The value of the treatment of dyslipidemias in the prognosis of patients with coronary artery disease] Giannini SD, et al. **Arq Bras Cardiol** 1995 Sep;65(3):297-9 (42 ref.) **(Por)**

HYPERLIPIDEMIA, FAMILIAL COMBINED

COMPLICATIONS

[Secondary disorders of lipid metabolism, metabolic syndrome and familial combined hyperlipidemia] Steinmetz A, et al. **Wien Med Wochenschr** 1994;144(12-13):299-307 (64 ref.) (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

[Hyperlipoproteinemias in childhood] Widhalm K.
Wien Med Wochenschr 1994;144(12-13):320-3 (5 ref.) (Eng. Abstr.) **(Ger)**

HYPERLIPIDEMIA, MULTIPLE LIPOPROTEIN-TYPE see **HYPERLIPIDEMIA, FAMILIAL COMBINED**

HYPERLIPOPROTEINEMIA

CLASSIFICATION

[Classification of hyperlipoproteinemias and interpretation of laboratory parameters] Herrmann W, et al.
Wien Med Wochenschr 1994;144(12-13):292-9 (44 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

[Mixed dyslipoproteinemias: new therapeutic opportunities] Capurso A. **Ann Ital Med Int** 1995 Oct;10 Suppl:44S-47S (20 ref.) (Eng. Abstr.) **(Ita)**

EPIDEMIOLOGY

[Nutrition and metabolic syndrome] Hauner H.
Internist (Berl) 1995 Nov;36(11):1040-5 (37 ref.) **(Ger)**

ETIOLOGY

Metabolic disruptions in the adipocyte-hepatocyte fatty acid axis as causes of HyperapoB. Sniderman AD, et al.
Int J Obes Relat Metab Disord 1995 May;19 Suppl 1:S27-33 (68 ref.)
[Secondary disorders of lipid metabolism, metabolic syndrome and familial combined hyperlipidemia] Steinmetz A, et al. **Wien Med Wochenschr** 1994;144(12-13):299-307 (64 ref.) (Eng. Abstr.) **(Ger)**
[Cholesteryl ester transfer protein (CETP) deficiency and increased HDL cholesterol levels (hyperalphalipoproteinemia)] Inazu A, et al.
Rinsho Byori 1996 Apr;44(4):322-6 (15 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

[Genetic aspects of primary atherogenic dyslipoproteinemia] Turpin G, et al. **C R Seances Soc Biol Fil** 1995; 189(5):905-17 (33 ref.) (Eng. Abstr.) **(Fre)**
[The relationship of apoB gene polymorphism to dyslipoproteinemia as the cause of atherosclerosis] Kravchenko NA. **Tsitol Genet** 1995 Jul-Aug;29(4):84-7 (33 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

[Physiology and pathophysiology of the metabolism of lipoproteins] Sandhofer F. **Wien Med Wochenschr** 1994; 144(12-13):286-90 (0 ref.) (Eng. Abstr.) **(Ger)**

HYPERLIPOPROTEINEMIA TYPE I see **LIPOPROTEIN LIPASE DEFICIENCY, FAMILIAL**

HYPERLIPOPROTEINEMIA TYPE II see **HYPERCHOLESTEROLEMIA, FAMILIAL**

HYPERLIPOPROTEINEMIA TYPE III

HYPERLIPOPROTEINEMIA TYPE III

METABOLISM

Heparan sulfate proteoglycan/low density lipoprotein receptor-related protein pathway involved in type III hyperlipoproteinemia and Alzheimer's disease. Mahley RW. **Isr J Med Sci** 1996 Jun;32(6):414–29 (72 ref.)

HYPERLIPOPROTEINEMIA TYPE IV

GENETICS

Mutations affecting human lipoprotein lipase gene. Antikainen M, et al. **Z Gastroenterol** 1996 Jun;34 Suppl 3:59–61 (20 ref.)

HYPERMENORRHEA see **MENORRHAGIA**

HYPERMETROPIA see **HYPEROPIA**

HYPERMOBILITY, JOINT see **JOINT INSTABILITY**

HYPERNATREMIA

Renal sodium retention in liver disease. Epstein M. **Hosp Pract (Off Ed)** 1995 Sep 15;30(9):33–7, 41–2 (12 ref.)

DIAGNOSIS

From plasma [Na+] to diagnosis and treatment. Engquist A. **Acta Anaesthesiol Scand Suppl** 1995;107:273–9 (35 ref.)

HYPERNEPHROMA see **CARCINOMA, RENAL CELL**

HYPEROPIA

SURGERY

Automated lamellar keratoplasty. American Academy of Ophthalmology [see comments] **Ophthalmology** 1996 May; 103(5):852–61 (15 ref.) Comment in: Ophthalmology 1996 May;103(5):703–4.

HYPEROSTOSIS

Why the "SAPHO" syndrome? [editorial] Kahn MF. **J Rheumatol** 1995 Nov;22(11):2017–9 (20 ref.)

HYPEROSTOSIS CORTICALIS GENERALISATA see **OSTEOCHONDRODYSPLASIAS**

HYPEROSTOSIS, DIFFUSE IDIOPATHIC SKELETAL

RADIOGRAPHY

Diffuse idiopathic skeletal hyperostosis (DISH): a review of radiographic features and report of four cases. Hoffman LE, et al. **J Manipulative Physiol Ther** 1995 Oct; 18(8):547–53 (17 ref.)

HYPEROSTOSIS, STERNOCOSTOCLAVICULAR

COMPLICATIONS

[Reflexions on the Tietze syndrome. Clinical contribution] Pappalardo A, et al. **Clin Ter** 1995 Nov;146(11):675–82 (32 ref.) (Eng. Abstr.) **(Ita)**

HYPEROXALURIA

COMPLICATIONS

Experimental calcium oxalate nephrolithiasis and the formation of human urinary stones. Khan SR. **Scanning Microsc** 1995 Mar;9(1):89–100; discussion 100–1 (79 ref.)

ENZYMOLOGY

Advances in the enzymology and molecular genetics of primary hyperoxaluria type 1. Prospects for gene therapy. Danpure CJ. **Nephrol Dial Transplant** 1995;10 Suppl 8:24–9 (29 ref.)

GENETICS

Advances in the enzymology and molecular genetics of primary hyperoxaluria type 1. Prospects for gene therapy. Danpure CJ. **Nephrol Dial Transplant** 1995;10 Suppl 8:24–9 (29 ref.)

HYPEROXALURIA, PRIMARY

[Primary hyperoxaluria] Toussaint C, et al. **Nephrologie** 1995; 16(6):399–406 (36 ref.) (Eng. Abstr.) **(Fre)**

[Mechanisms and treatment of primary type I hyperoxaluria] Dallaporta B, et al. **Presse Med** 1996 Jun 22;25(22):1033–8 (25 ref.) (Eng. Abstr.) **(Fre)**

BLOOD

Plasma and urine measurements for monitoring of treatment in the primary hyperoxaluric patient. Kasidas GP. **Nephrol Dial Transplant** 1995;10 Suppl 8:8–10 (25 ref.)

COMPLICATIONS

Hypercalcaemia complicating systemic oxalosis in primary hyperoxaluria type 1. Toussaint C, et al. **Nephrol Dial Transplant** 1995;10 Suppl 8:17–21 (21 ref.)

DIAGNOSIS

What are the present possibilities for the prenatal diagnosis of primary hyperoxaluria? Danpure CJ. **Pediatr Nephrol** 1996 Apr;10(2):190 (7 ref.)

METABOLISM

Hypercalcaemia complicating systemic oxalosis in primary hyperoxaluria type 1. Toussaint C, et al. **Nephrol Dial Transplant** 1995;10 Suppl 8:17–21 (21 ref.)

[Primary hyperoxaluria] De Pauw L, et al. **Rev Med Brux** 1996 Apr;17(2):67–74 (25 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

[Oxalosis] Cordonnier C, et al. **Ann Pathol** 1995;15(6):415–23 (88 ref.) **(Fre)**

[A case of oxalosis with heart and lung involvement] Magnani G, et al. **Cardiologia** 1992 Jul;37(7):507–11 (10 ref.) (Eng. Abstr.) **(Ita)**

SURGERY

Selection of transplantation procedures and perioperative management in primary hyperoxaluria type 1. Latta K, et al. **Nephrol Dial Transplant** 1995;10 Suppl 8:53–7 (34 ref.)

THERAPY

Primary hyperoxaluria type 1: the therapeutic dilemma. Cochat P, et al. **Adv Nephrol Necker Hosp** 1995;24:227–42 (64 ref.)

URINE

Plasma and urine measurements for monitoring of treatment in the primary hyperoxaluric patient. Kasidas GP. **Nephrol Dial Transplant** 1995;10 Suppl 8:8–10 (25 ref.)

HYPEROXIA

ETIOLOGY

Implications of middle ear hyperoxia induced by ventilation tubes in otitis media with effusion. Ovesen T. **APMIS Suppl** 1995;54:1–36 (233 ref.)

HYPERPARATHYROIDISM

see related
MULTIPLE ENDOCRINE NEOPLASIA TYPE 1

BLOOD

Normocalcemic hyperparathyroidism. Monchik JM. **Surgery** 1995 Dec;118(6):917–23 (27 ref.)

COMPLICATIONS

Familial hyperparathyroidism associated with jaw fibroma: case report and literature review. Inoue H, et al. **Clin Endocrinol (Oxf)** 1995 Aug;43(2):225–9; discussion 230 (10 ref.)

Cutaneous gangrene due to hyperparathyroidism secondary to chronic renal failure (uraemic gangrene syndrome). Török L, et al. **Clin Exp Dermatol** 1996 Jan;21(1):75–7 (10 ref.)

Extensive necrotizing livedo reticularis in a patient with chronic renal failure, hyperparathyroidism and coagulation disorder: regression after subtotal parathyroidectomy. Dereure O, et al. **Dermatology** 1996;192(2):167–70 (33 ref.)

Slipped capital femoral epiphysis associated with hyperparathyroidism. A case report. Kinoshita J, et al. **Int Orthop** 1995;19(4):245–7 (14 ref.)

Hyperparathyroidism and pancreatitis during pregnancy. Inabnet WB, et al. **Surgery** 1996 Jun;119(6):710–3 (32 ref.)

[Monoclonal gammopathy and primary hyperparathyroidism. Apropos of 2 cases and review of the literature] Bellou A, et al. **Rev Med Interne** 1996;17(4):325–8 (29 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

[The imaging diagnosis of primary hyperparathyroidism due to parathyroid adenocarcinoma. A case report] Prato N, et al. **Radiol Med (Torino)** 1995 Sep;90(3):323–6 (11 ref.) **(Ita)**

DRUG THERAPY

Injectable medications for hemodialysis patients. Stivelman JC. **Am J Nephrol** 1996;16(1):73–8 (55 ref.)

ETIOLOGY

Primary hyperparathyroidism associated with multiple myeloma. Goto S, et al. **Intern Med** 1995 Oct;34(10):988–91 (20 ref.)

Unusual cases of hyperparathyroidism [see comments] Vázquez-Quintana E, et al. **P R Health Sci J** 1995 Sep; 14(3):227–32 (8 ref.) Comment in: P R Health Sci J 1995 Sep;14(3):191–3.

GENETICS

Primary hyperparathyroidism: genetic heterogeneity suggesting different pathogenesis in sporadic and familial forms of parathyroid hyperplasia and tumors [comment] Calender A, et al. **Eur J Endocrinol** 1996 Mar;134(3):263–6 (20 ref.) Comment on: Eur J Endocrinol 1996 Mar;134(3):314–9.

Molecular overtones of primary hyperparathyroidism [editorial; comment] el-Deiry S, et al. **J Clin Endocrinol Metab** 1995 Nov;80(11):3105–6 (17 ref.) Comment on: J Clin Endocrinol Metab 1995 Nov;80(11):3377–80.

PATHOLOGY

Asymptomatic primary hyperparathyroidism. Birkenhäger JC, et al. **Postgrad Med J** 1996 Jun;72(848):323–6 (31 ref.)

RADIONUCLIDE IMAGING

Parathyroid imaging. Coakley AJ. **Nucl Med Commun** 1995 Jul;16(7):522–33 (96 ref.)

Sestamibi parathyroid imaging. McBiles M, et al. **Semin Nucl Med** 1995 Jul;25(3):221–34 (62 ref.)

SURGERY

Reoperation for persistent or recurrent primary hyperparathyroidism. Shen W, et al. **Arch Surg** 1996 Aug; 131(8):861–7; discussion 867–9 (20 ref.)

Medical and radiologic evaluation and operative treatment of primary hyperparathyroidism. Akerström G, et al. **Curr Opin Gen Surg** 1993;:130–8 (49 ref.)

HYPERPARATHYROIDISM, SECONDARY

BLOOD

Treatment of hyperparathyroidism—why is it crucial to control serum phosphate? [editorial] Brancaccio D, et al. **Nephrol Dial Transplant** 1996 Mar;11(3):420–3 (23 ref.)

DIAGNOSIS

[Secondary hyperparathyroidism] Diaconescu MR, et al. **Chirurgia (Bucur)** 1995;44(1):27–34 (31 ref.) (Eng. Abstr.) **(Rum)**

DRUG THERAPY

Treatment of hyperparathyroidism—why is it crucial to control serum phosphate? [editorial] Brancaccio D, et al. **Nephrol Dial Transplant** 1996 Mar;11(3):420–3 (23 ref.)

ETIOLOGY

Pathogenesis of secondary hyperparathyroidism. Slatopolsky E, et al. **Miner Electrolyte Metab** 1995;21(1–3):91–6 (35 ref.)

Genesis of disturbed vitamin D metabolism in renal failure. Ritz E, et al. **Nephrol Dial Transplant** 1995;10 Suppl 4:3–10; discussion 37–43 (53 ref.)

Unusual cases of hyperparathyroidism [see comments] Vázquez-Quintana E, et al. **P R Health Sci J** 1995 Sep; 14(3):227–32 (8 ref.) Comment in: P R Health Sci J 1995 Sep;14(3):191–3.

PHYSIOPATHOLOGY

Pathophysiology and treatment of secondary hyperparathyroidism in patients with chronic renal failure. Tsukamoto Y. **Nephrol Dial Transplant** 1995;10 Suppl 3:22–4 (12 ref.)

HYPERPHAGIA

see related
OBESITY

The effects of overfeeding and moderate dietary restriction on Sprague-Dawley rat survival, pathology, carcinogenicity, and the toxicity of pharmaceutical agents. Keenan KP, et al. **Exp Toxicol Pathol** 1996 Feb; 48(2–3):139–44 (24 ref.)

PHYSIOPATHOLOGY

Probing the causes of high-fat diet hyperphagia: a mechanistic and behavioral dissection. Warwick ZS. **Neurosci Biobehav Rev** 1996;20(1):155–61 (33 ref.)

THERAPY

Interrupting the binge-purge cycle in bulimia: the use of planned binges. Steel ZP, et al. **Int J Eat Disord** 1995 Nov; 18(3):199–208 (46 ref.)

HYPERPIGMENTATION

CONGENITAL

Gastrointestinal problems in a child with dyskeratosis

congenita. Berezin S, et al. **Am J Gastroenterol** 1996 Jun; 91(6):1271–2 (6 ref.)

PATHOLOGY

Hutchinson's sign: a reappraisal. Baran R, et al. **J Am Acad Dermatol** 1996 Jan;34(1):87–90 (21 ref.)

Odontotrichodysplasia: a case report with a review of conditions combining ectodermal dysplasia (subgroup 1–2) with skin manifestations. Yadav TP, et al. **J Dermatol** 1995 Aug;22(8):606–10 (14 ref.)

HYPERPIPECOLIC ACIDEMIA see **PEROXISOMAL DISORDERS**

HYPERPLASIA

see related
PRECANCEROUS CONDITIONS

Liver regeneration versus direct hyperplasia. Columbano A, et al. **FASEB J** 1996 Aug;10(10):1118–28 (88 ref.)

PATHOLOGY

[Non-neoplastic hypercalcitoninemia. Pathological anatomy] Saint-André JP, et al. **Ann Endocrinol (Paris)** 1996; 57(1):23–6 (14 ref.) (Eng. Abstr.) **(Fre)**

[Adenomatoid hyperplasia of the minor salivary glands. Report of a clinical case] Tucci E, et al. **Minerva Stomatol** 1996 Jan–Feb;45(1–2):49–52 (9 ref.) (Eng. Abstr.) **(Ita)**

HYPERPLASIA, GIANT LYMPH NODE see **GIANT LYMPH NODE HYPERPLASIA**

HYPERPOTASSEMIA see **HYPERKALEMIA**

HYPERPREBETALIPOPROTEINEMIA see **HYPERLIPOPROTEINEMIA TYPE IV**

HYPERPROLACTINEMIA

Hyperprolactinemia. Causes, consequences, and treatment options. Kaye TB. **Postgrad Med** 1996 May;99(5):265–8 (9 ref.)

DRUG THERAPY

A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation. Webster J. **Drug Saf** 1996 Apr; 14(4):228–38 (59 ref.)

New drugs for hyperprolactinaemia. **Drug Ther Bull** 1995 Sep;33(9):65–7 (24 ref.)

Cabergoline: a new drug for the treatment of hyperprolactinaemia. Ferrari C, et al. **Hum Reprod** 1995 Jul;10(7):1647–52 (46 ref.)

HYPERPYREXIA, MALIGNANT see **MALIGNANT HYPERTHERMIA**

HYPERSALIVATION see **SIALORRHEA**

HYPERSENSITIVITY

see related
ANTI-ALLERGIC AGENTS
DESENSITIZATION, IMMUNOLOGIC
MULTIPLE CHEMICAL SENSITIVITY

Fire ant venom allergy. Hoffman DR. **Allergy** 1995 Jul; 50(7):535–44 (89 ref.)

Changing patterns of childhood infection and the rise in allergic disease. Shaheen SO. **Clin Exp Allergy** 1995 Nov; 25(11):1034–7 (46 ref.)

Chemokines active on eosinophils: potential roles in allergic inflammation [comment] Kita H, et al. **J Exp Med** 1996 Jun 1;183(6):2421–6 (60 ref.) Comment on: J Exp Med 1996 Jun 1;183(6):2437–48.

Platelets and hypersensitivity. de Sousa JR, et al. **J Investig Allergol Clin Immunol** 1995 Jan–Feb;5(1):12–7 (50 ref.)

BLOOD

Eosinophils in allergy: role in disease, degranulation, and cytokines. Martin LB, et al. **Int Arch Allergy Immunol** 1996 Mar;109(3):207–15 (147 ref.)

COMPLICATIONS

Middle ear effusion—allergy relationships [see comments] Mattucci KF, et al. **Ear Nose Throat J** 1995 Nov; 74(11):752–6, 758 (18 ref.) Comment in: Ear Nose Throat J 1995 Nov;74(11):739.

Role of allergy in eustachian tube blockage and otitis media with effusion: a review. Bernstein JM. **Otolaryngol Head Neck Surg** 1996 Apr;114(4):562–8 (28 ref.)

[Cutaneous immunoallergic reactions caused by vaccines] Barbaud A, et al. **Ann Dermatol Venereol** 1995; 122(3):129–38 (120 ref.) **(Fre)**

[Current views on pathophysiology of migraine. Part II: Further development and current status of the vascular theory. Migraine and allergy] Prusiński A, et al. **Neurol Neurochir Pol** 1995 Nov–Dec;29(6):857–66 (28 ref.) (Eng. Abstr.) **(Pol)**

[Allergic bronchitis in bronchial asthma] Fal AM, et al. **Wiad Lek** 1994 Sep;47(17–18):688–93 (26 ref.) (Eng. Abstr.) **(Pol)**

DIAGNOSIS

Recombinant allergens for diagnosis and therapy of allergic diseases. Valenta R, et al. **Curr Opin Immunol** 1995 Dec; 7(6):751–6 (68 ref.)

[Enzyme immunoassay of substances related to allergy] Midoro-Horiuti T. **Nippon Rinsho** 1995 Sep;53(9):2262–8 (20 ref.) (Eng. Abstr.) **(Jpn)**

DRUG THERAPY

Anti-inflammatory agents in allergic diseases [editorial] Bonham CA, et al. **Clin Exp Immunol** 1995 Oct;102(1):1–5 (45 ref.)

Ebastine. a review of its pharmacological properties and clinical efficacy in the treatment of allergic disorders. Wiseman LR, et al. **Drugs** 1996 Feb;51(2):260–77 (90 ref.)

Cold, cough, and allergy medications: uses and abuses. Katcher ML. **Pediatr Rev** 1996 Jan;17(1):12–7 (11 ref.)

EPIDEMIOLOGY

Time trends in asthma and allergy: ten questions, fewer answers [editorial; comment] Strachan DP. **Clin Exp Allergy** 1995 Sep;25(9):791–4 (30 ref.) Comment on: Clin Exp Allergy 1995 Sep;25(9):815–9.

[Allergic diseases in the indoor environment] Schata M. **Zentralbl Hyg Umweltmed** 1995 Apr;197(1–3):196–211 (8 ref.) (Eng. Abstr.) **(Ger)**

[Cockroach allergy: a study of its prevalence using skin tests with commercial extracts] Cuesta C, et al. **Allergol Immunopathol (Madr)** 1995 Nov–Dec; 23(6):295–300 (34 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

Aerobiologic and clinical aspects of mould allergy in Europe. D'Amato G, et al. **Allergy** 1995 Nov;50(11):870–7 (62 ref.)

The role of the bone marrow in allergy and asthma. Denburg JA, et al. **Allergy** 1996 Mar;51(3):141–8 (109 ref.)

Allergy to bee and wasp venom. Gelder C, et al. **Br J Hosp Med** 1996 Mar 20–Apr 2;55(6):349–52 (30 ref.)

Atopic dermatitis: the skin as a window into the pathogenesis of chronic allergic diseases. Leung DY. **J Allergy Clin Immunol** 1995 Sep;96(3):302–18; quiz 319 (47 ref.)

Thalasselis syndrome and genetic theories on keratoconus. Thalasselis A. **J Am Optom Assoc** 1995 Aug;66(8):495–9 (64 ref.)

Allergic and immunologic pediatric disorders of the eye. Bielory L, et al. **J Investig Allergol Clin Immunol** 1995 Nov–Dec;5(6):309–17 (33 ref.)

Infections and the development of allergy. Holt PG. **Toxicol Lett** 1996 Aug;86(2–3):205–10 (27 ref.)

Socioeconomic factors and the development of allergy. Strachan D. **Toxicol Lett** 1996 Aug;86(2–3):199–203 (33 ref.)

Mechanisms and pharmacological manipulation of eosinophil accumulation in vivo. Teixeira MM, et al. **Trends Pharmacol Sci** 1995 Dec;16(12):418–23 (69 ref.)

[Surgical gloves, condoms, rubber balloons and other latex objects. A look at their pathogenic aspects] Piérard GE, et al. **Rev Med Liege** 1995 Sep;50(9):388–9 (26 ref.) **(Fre)**

[Allergies to dental prostheses and to amalgam: various data from the literature] Dejobert Y, et al. **Rev Stomatol Chir Maxillofac** 1995;96(4):243–6 (16 ref.) **(Fre)**

[Amalgam allergy and amalgam controversy] Lübbe J, et al. **Schweiz Med Wochenschr** 1996 Apr 20;126(16):661–5 (48 ref.) (Eng. Abstr.) **(Ger)**

[Allergies in agriculture] Gassner M. **Schweiz Rundsch Med Prax** 1996 Aug 13;85(33):950–60 (37 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Biology of interleukin-5 and its relevance to allergic disease. Egan RW, et al. **Allergy** 1996 Feb;51(2):71–81 (145 ref.)

Hypersensitivity to fire ant venom [see comments] Stafford CT. **Ann Allergy Asthma Immunol** 1996 Aug;77(2):87–95; quiz 96–9 (50 ref.) Comment in: Ann Allergy Asthma Immunol 1996 Aug;77(2):85.

Cytokines, chemokines, T cells and allergy [editorial] Frew AJ. **Clin Exp Allergy** 1996 Jan;26(1):2–4 (29 ref.)

Atopic allergy and other hypersensitivities editorial overview: technological advances and new insights into pathogenesis prelude novel therapeutic strategies [editorial] Romagnani S. **Curr Opin Immunol** 1995 Dec;7(6):745–50 (62 ref.)

Chemokines and the allergic response. Kaplan AP, et al. **Exp Dermatol** 1995 Aug;4(4 Pt 2):260–5 (36 ref.)

Glucocorticosteroid inhibition of cytokine production: relevance to antiallergic actions. Schwiebert LA, et al. **J Allergy Clin Immunol** 1996 Jan;97(1 Pt 2):143–52 (105 ref.)

Allergic and immunologic pediatric disorders of the eye. Bielory L, et al. **J Investig Allergol Clin Immunol** 1995 Nov–Dec;5(6):309–17 (33 ref.)

Chemicals and proteins as allergens and adjuvants. Kapsenberg ML. **Toxicol Lett** 1996 Aug;86(2–3):79–83 (30 ref.)

[CD23/sCD23--receptor/cytokine in IgE-dependent reactions] Rogala B, et al. **Postepy Hig Med Dosw** 1995; 49(3):425–32 (35 ref.) (Eng. Abstr.) **(Pol)**

METABOLISM

Adhesion molecules in allergy. Passalacqua G, et al. **Allerg Immunol (Paris)** 1996 Feb;28(2):34–8 (37 ref.)

Activation and regulation of chemokines in allergic airway inflammation. Lukacs NW, et al. **J Leukoc Biol** 1996 Jan; 59(1):13–7 (34 ref.)

MICROBIOLOGY

[Allergy to house dust mite: a public health problem] Maroli M, et al. **Ann Ist Super Sanita** 1995;31(3):343–50 (44 ref.) (Eng. Abstr.) **(Ita)**

PATHOLOGY

"The good, the bad, and the ugly." The role of chemokines in models of human disease. Strieter RM, et al. **J Immunol** 1996 May 15;156(10):3583–6 (33 ref.)

Activation and regulation of chemokines in allergic airway inflammation. Lukacs NW, et al. **J Leukoc Biol** 1996 Jan; 59(1):13–7 (34 ref.)

PHYSIOPATHOLOGY

The role of the basophil in allergic inflammation. Schroeder JT, et al. **Allergy** 1995 Jun;50(6):463–72 (113 ref.)

PREVENTION & CONTROL

Health hazards to humans associated with domestic pets. Plaut M, et al. **Annu Rev Public Health** 1996;17:221–45 (87 ref.)

Cat allergy. Ferguson BJ. **Ear Nose Throat J** 1995 Oct; 74(10):677, 680 (9 ref.)

Vitamin C and the genesis of autoimmune disease and allergy (review). Kodama M, et al. **In Vivo** 1995 May–Jun; 9(3):231–8 (38 ref.)

[Role of breast milk feeding in avoidance of asthma and other allergic disorders] Barr J, et al. **Harefuah** 1995 Oct; 129(7–8):274–8 (43 ref.) **(Heb)**

[The primary and secondary prevention of allergic diseases in the child "at risk" for atopy: a review of the literature and the authors' personal experience] Bruno G, et al. **Pediatr Med Chir** 1995 May–Jun;17(3):199–207 (125 ref.) (Eng. Abstr.) **(Ita)**

THERAPY

Therapeutic interference with interferon-gamma (IFN-gamma) and soluble IL-4 receptor (sIL-4R) in allergic diseases. Nasert S, et al. **Behring Inst Mitt** 1995 Jun;(96):118–30 (55 ref.)

Controlling allergy with anti-idiotypic antibodies [editorial] Shakib F. **Clin Exp Allergy** 1995 Oct;25(10):908–9 (18 ref.)

Adhesion molecules as therapeutic targets in the treatment of allergic and immunologically mediated diseases. Kavanaugh A. **Clin Immunol Immunopathol** 1996 Sep;80(3 Pt 2):S15–22 (37 ref.)

Peptide therapy for treatment of allergic diseases. Wallner BP, et al. **Clin Immunol Immunopathol** 1996 Aug; 80(2):105–9 (51 ref.)

Specific immunotherapy in house dust mite allergy. Bousquet J, et al. **Clin Rev Allergy Immunol** 1995 Summer;13(2):151–9 (57 ref.)

Anti-IgE therapy. Jardieu P. **Curr Opin Immunol** 1995 Dec; 7(6):779–82 (36 ref.)

Atopic allergy and other hypersensitivities editorial overview: technological advances and new insights into pathogenesis prelude novel therapeutic strategies [editorial] Romagnani S. **Curr Opin Immunol** 1995 Dec;7(6):745–50 (62 ref.)

Recombinant allergens for diagnosis and therapy of allergic diseases. Valenta R, et al. **Curr Opin Immunol** 1995 Dec; 7(6):751–6 (68 ref.)

Atopic disease, rhinitis and conjunctivitis, and upper respiratory infections. Wood RA, et al. **Curr Opin Pediatr** 1995 Oct;7(5):615–27 (63 ref.)

Induction of antigen-specific unresponsiveness with synthetic peptides: specific immunotherapy for treatment of allergic and autoimmune conditions. Wraith DC. **Int Arch Allergy Immunol** 1995 Dec;108(4):355–9 (29 ref.)

Immunotherapy basics. Gordon BR. **Otolaryngol Head Neck Surg** 1995 Nov;113(5):597–602 (51 ref.)

Safe allergen immunotherapy. The correct allergen, the appropriate patient, the adequate dose. Schoenwetter WF. **Postgrad Med** 1996 Aug;100(2):123–6, 131–5 (17 ref.)

[Hyposensitization in general practice. A strategic concept] Jorde W. HNO 1995 Dec;43(12):741–4 (6 ref.) **(Ger)**

VIROLOGY

The effects of rhinovirus infections on allergic airway responses. Gern JE, et al. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 2):S40–5 (40 ref.)

HYPERSENSITIVITY ANGIITIS see **VASCULITIS, HYPERSENSITIVITY**

HYPERSENSITIVITY, ATOPIC see **HYPERSENSITIVITY, IMMEDIATE**

HYPERSENSITIVITY, CONTACT see **DERMATITIS, CONTACT**

HYPERSENSITIVITY, DELAYED

see related
ENCEPHALOMYELITIS, ACUTE DISSEMINATED

ETIOLOGY

Hypersensitivity reactions to etoposide. Hoetelmans RM, et al. **Ann Pharmacother** 1996 Apr;30(4):367-71 (25 ref.)
Atopic dermatitis and delayed hypersensitivity to dust mites. Castelain M. **Clin Rev Allergy Immunol** 1995 Summer; 13(2):161-72 (53 ref.)
[Delayed allergic reaction to Chlorambucil (Leukeran). Case report and literature review] Torricelli R, et al. **Schweiz Med Wochenschr** 1995 Oct 7;125(40):1870-3 (10 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Role of IL-4 in delayed type hypersensitivity. Asherson GL, et al. **Clin Exp Immunol** 1996 Jan;103(1):1-4 (46 ref.)
Investigation of the association between mercury sensitization and HLA-DR6. Sato K, et al. **Contact Dermatitis** 1996 Apr;34(4):295 (5 ref.)

THERAPY

Treatment of delayed-type hypersensitivity with inhibitors of the VLA-4 integrin. Tamraz S, et al. **Springer Semin Immunopathol** 1995;16(4):437-41 (36 ref.)

HYPERSENSITIVITY, DRUG see **DRUG HYPERSENSITIVITY**

HYPERSENSITIVITY, ENVIRONMENTAL see **ENVIRONMENTAL ILLNESS**

HYPERSENSITIVITY, FOOD see **FOOD HYPERSENSITIVITY**

HYPERSENSITIVITY, IMMEDIATE

Atopic dermatitis: is it an allergic disease? Halbert AR, et al. **J Am Acad Dermatol** 1995 Dec;33(6):1008-18 (114 ref.)

CHEMICALLY INDUCED

Issues of latex safety in dentistry. Field EA, et al. **Br Dent J** 1995 Oct 7;179(7):247-53 (51 ref.)
Contact allergens in toothpastes and a review of their hypersensitivity. Sainio EL, et al. **Contact Dermatitis** 1995 Aug;33(2):100-5 (74 ref.)
[A possible hypersensitivity reaction to total parenteral nutrition] Vázquez Mora JR, et al. **Nutr Hosp** 1996 Mar-Apr;11(2):148-50 (13 ref.) (Eng. Abstr.) **(Spa)**

COMPLICATIONS

[Type I hypersensitivity reactions and etiopathogenesis of hemorrhagic rectocolitis] Leprince E, et al. **Presse Med** 1995 Dec 16-23;24(39):1902-6 (58 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Allergen testing in patients with type I hypersensitivity. **Drug Ther Bull** 1995 Jun;33(6):45-7 (17 ref.)
[Atopy, asthma and the judgement of preemployment fitness] Innocenti A. **Med Lav** 1995 Jul-Aug;86(4):303-8 (36 ref.) (Eng. Abstr.) **(Ita)**

ETIOLOGY

Immediate contact reactions. Lahti A. **Curr Probl Dermatol** 1995;22:17-23 (13 ref.)
[Allergy to house dust mites] Horak B. **Wiad Parazytol** 1995; 41(3):355-68 (47 ref.) (Eng. Abstr.) **(Pol)**

GENETICS

The genetics of asthma and atopy. Panhuysen CI, et al. **Allergy** 1995 Nov;50(11):863-9 (62 ref.)
11q and high-affinity IgE receptor in asthma and allergy. Cookson WO. **Clin Exp Allergy** 1995 Nov;25 Suppl 2:71-3; discussion 95-6 (23 ref.)
HLA genetics and allergic disease [editorial] Howell WM, et al. **Thorax** 1995 Aug;50(8):815-8 (32 ref.)
Genetics of asthma and atopy. Rosenwasser LJ. **Toxicol Lett** 1996 Aug;86(2-3):73-7 (19 ref.)
[Problems with genetic studies of atopy] Kruszewski J. **Pneumonol Alergol Pol** 1995;63(9-10):560-5 (18 ref.) **(Pol)**
[Genetic aspects of atopic diseases] Bochenek G, et al. **Pol Arch Med Wewn** 1996 Feb;95(2):160-5 (40 ref.) **(Pol)**

IMMUNOLOGY

Role and modulation of T-cell cytokines in allergy. Daser A, et al. **Curr Opin Immunol** 1995 Dec;7(6):762-70 (61 ref.)
Peptide modulation of allergen-specific immune responses. Hoyne GF, et al. **Curr Opin Immunol** 1995 Dec;7(6):757-61 (41 ref.)
Atopic allergy and other hypersensitivities editorial overview: technological advances and new insights into pathogenesis prelude novel therapeutic strategies [editorial] Romagnani S. **Curr Opin Immunol** 1995 Dec;7(6):745-50 (62 ref.)
The central rôle of T-cells in allergic sensitization and IgE regulation. Renz H. **Exp Dermatol** 1995 Aug;4(4 Pt 1):173-82 (91 ref.)
Consequences of IgE/CD23-mediated antigen presentation in allergy. Mudde GC, et al. **Immunol Today** 1995 Aug; 16(8):380-3 (41 ref.)
Type 1 allergic reactions to plant-derived food: a consequence of primary sensitization to pollen allergens. Valenta R, et al. **J Allergy Clin Immunol** 1996 Apr; 97(4):893-5 (29 ref.)
Role of the immune system in allergic children. Baert MR, et al. **Pediatr Allergy Immunol** 1995;6 Suppl 7:27-30 (18 ref.)
[Immunoglobulins E and inflammatory cells] Tunon de Lara JM. **Rev Mal Respir** 1996;13(1):27-36 (32 ref.) (Eng. Abstr.) **(Fre)**
[Atopy score in infancy and the severity of asthma at 7 years of age] Uhereczky G, et al. **Orv Hetil** 1996 Jan 28; 137(4):175-8 (46 ref.) (Eng. Abstr.) **(Hun)**

METABOLISM

Production and modulation of T-cell cytokines in atopic allergy. Kapsenberg ML, et al. **Int Arch Allergy Immunol** 1996 Jun;110(2):107-13 (68 ref.)

PHYSIOPATHOLOGY

Relationship of histamine-releasing factors and histamine-releasing inhibitory factors to chemokine group of cytokine. Kuna P, et al. **Allergy Asthma Proc** 1996 Jan-Feb;17(1):5-11 (38 ref.)

THERAPY

Atopic allergy and other hypersensitivities editorial overview: technological advances and new insights into pathogenesis prelude novel therapeutic strategies [editorial] Romagnani S. **Curr Opin Immunol** 1995 Dec;7(6):745-50 (62 ref.)
Management of immediate allergic reactions. Becker DE. **Dent Clin North Am** 1995 Jul;39(3):577-86 (41 ref.)

HYPERSENSITIVITY, MILK see **MILK HYPERSENSITIVITY**

HYPERSENSITIVITY PNEUMONITIS see **ALVEOLITIS, EXTRINSIC ALLERGIC**

HYPERSENSITIVITY PNEUMONITIS, AVIAN see **BIRD FANCIER'S LUNG**

HYPERSENSITIVITY, RESPIRATORY see **RESPIRATORY HYPERSENSITIVITY**

HYPERSENSITIVITY, TUBERCULIN-TYPE see **HYPERSENSITIVITY, DELAYED**

HYPERSENSITIVITY, TYPE I see **HYPERSENSITIVITY, IMMEDIATE**

HYPERSENSITIVITY, TYPE IV see **HYPERSENSITIVITY, DELAYED**

HYPERSENSITIVITY VASCULITIS see **VASCULITIS, HYPERSENSITIVITY**

HYPERSOMNIA

ETIOLOGY

An unusual case of hypersomnolence syndrome. Gandhi MK, et al. **Clin Lab Haematol** 1995 Sep;17(3):247-50 (14 ref.)

HYPERSOMNIA WITH PERIODIC RESPIRATION see **SLEEP APNEA SYNDROMES**

HYPERTELORISM

PHYSIOPATHOLOGY

Hypertelorism: interorbital growth, measurements, and pathogenetic considerations. Cohen MM Jr, et al. **Int J Oral Maxillofac Surg** 1995 Dec;24(6):387-95 (60 ref.)

SURGERY

[Surgery of craniofacial abnormalities] Mühling J, et al. **Fortschr Kiefer Gesichtschir** 1995;40:72-7 (67 ref.) **(Ger)**

HYPERTENSINOGEN see **ANGIOTENSINOGEN**

HYPERTENSION

see related
ANTIHYPERTENSIVE AGENTS
VASCULAR RESISTANCE
Preeclampsia and hypertensive disorders of pregnancy. Zamorski MA, et al. **Am Fam Physician** 1996 Apr; 53(5):1595-610 (32 ref.)
Hypertension in women. Robitaille NM. **Can J Cardiol** 1996 Jun;12 Suppl D:6D-8D (17 ref.)
Community control of hypertension. Liu L. **Chin Med J (Engl)** 1996 Feb;109(2):99-102 (0 ref.)
Hypertension and coronary artery disease in the elderly. Messerli FH, et al. **Clin Geriatr Med** 1996 Feb;12(1):41-56 (88 ref.)
Mild hypertension: the mysterious viability of a faulty concept [editorial] Ménard J, et al. **J Hypertens** 1995 Oct; 13(10):1071-7 (87 ref.)
Cell calcium and arterial blood pressure. Gonzalez JM, et al. **Semin Nephrol** 1995 Nov;15(6):564-8 (56 ref.)
Mechanisms of calcium's effects on blood pressure. Hatton DC, et al. **Semin Nephrol** 1995 Nov;15(6):593-602 (111 ref.)
Dietary calcium intake: effects on central blood pressure control. Pörsti I, et al. **Semin Nephrol** 1995 Nov; 15(6):550-63 (176 ref.)
Blood pressure effects of calcium intake in experimental models of hypertension. Schleiffer R, et al. **Semin Nephrol** 1995 Nov;15(6):526-35 (91 ref.)
Hypertension and kidney stones: hypotheses and implications. Strazzullo P, et al. **Semin Nephrol** 1995 Nov;15(6):519-25 (54 ref.)
[Cardiologic progress in China, 1995] Chen S. **Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):715-6 (0 ref.) **(Chi)**
[Hypertensive crises. 1. Pathogenesis and symptomatology] Fog L, et al. **Ugeskr Laeger** 1995 Dec 18;157(51):7135-9 (40 ref.) (Eng. Abstr.) **(Dan)**
[Guidelines for diagnosis, treatment and follow-up of high blood pressure] Paran E. **Harefuah** 1995 Jun 1; 128(11):723-7 (27 ref.) **(Heb)**
[Characteristic and therapy of hypertension in the aged] Ogihara T. **Nippon Naika Gakkai Zasshi** 1996 Mar 10; 85(3):423-7 (8 ref.) **(Jpn)**
[Hypertension in old age] García-Palmieri M. **P R Health Sci J** 1995 Sep;14(3):217-21 (11 ref.) (Eng. Abstr.) **(Spa)**

BLOOD

Toward the biochemical assessment of myocardial fibrosis in hypertensive patients. Diez J, et al. **Am J Cardiol** 1995 Nov 2;76(13):14D-17D (36 ref.)
The role of platelets in essential hypertension. Islim IF, et al. **Blood Press** 1995 Jul;4(4):199-214 (214 ref.)
Metabolic abnormalities in cardiac ischemia. Walsh MF, et al. **Cardiol Clin** 1995 Nov;13(4):529-38 (155 ref.)
Should cholesterol be measured in all hypertensives? Haq IU, et al. **J Hum Hypertens** 1995 Jun;9(6):417-21 (41 ref.)
[Hypertension and hemorheology] Klein W, et al. **Wien Med Wochenschr** 1995;145(15-16):355-7 (22 ref.) (Eng. Abstr.) **(Ger)**

CHEMICALLY INDUCED

Steroids, hypertension and cardiac fibrosis. Funder JW. **Blood Press Suppl** 1995;2:39-42 (15 ref.)
Ethanol- and threonine-induced hypertension in rats: a common mechanism. Vasdev S, et al. **Can J Cardiol** 1995 Oct;11(9):807-15 (56 ref.)
Alcohol and hypertension. Klatsky AL. **Clin Chim Acta** 1996 Mar 15;246(1-2):91-105 (28 ref.)
Dietary salt and hypertension. Hatton DC, et al. **Curr Opin Nephrol Hypertens** 1996 Mar;5(2):166-9 (22 ref.)
Hypertension after cardiac transplantation: pathophysiology and management. Sander M, et al. **Curr Opin Nephrol Hypertens** 1995 Sep;4(5):443-51 (125 ref.)
Nonsteroidal anti-inflammatory drugs and hypertension. The risks in perspective. de Leeuw PW. **Drugs** 1996 Feb; 51(2):179-87 (49 ref.)
Role of dietary salt in hypertension. Haddy FJ, et al. **J Am Coll Nutr** 1995 Oct;14(5):428-38 (147 ref.)
Cardiovascular safety in depressed patients: focus on venlafaxine. Feighner JP. **J Clin Psychiatry** 1995 Dec; 56(12):574-9 (44 ref.)
Experimental studies on cortisol-induced hypertension in humans. Whitworth JA, et al. **J Hum Hypertens** 1995 Jun; 9(6):395-9 (32 ref.)
Vascular structure in NG-nitro-L-arginine methyl ester-induced hypertension: methodological considerations for studies of small arteries in hypertension [editorial] [see comments] Schiffrin EL. **J Hypertens** 1995 Aug; 13(8):817-21 (40 ref.) Comment in: J Hypertens 1995 Oct;13(10):1217-21.
Dietary salt and blood pressure [comment] Dyer AR, et al. **Nat Med** 1995 Oct;1(10):994-6 (18 ref.) Comment on: Nat Med 1995 Oct;1(10):1009-16.
Arterial hypertension in uraemic patients treated with erythropoietin [editorial] Kokot F, et al. **Nephron** 1995; 71(2):127-32 (52 ref.)
[Monoamine oxidase inhibitors and food precautions. A comparison of utilization in Belgian psychiatric education institutes and current findings in the literature] Mallet L, et al. **Acta Psychiatr Belg** 1996 Mar-Apr;96(2):74-100 (52 ref.) (Eng. Abstr.) **(Fre)**
[The role of lead and its compounds in the development of arterial hypertension] Solomenchuk TM. **Lik Sprava** 1995 May-Jun;(5-6):40-4 (48 ref.) **(Ukr)**

CLASSIFICATION

A new diagnostic classification for hypertension. Yi JY, et al. **Cardiol Clin** 1995 Nov;13(4):509–18 (69 ref.)

[Emergency situations in hypertension] Nagy V, et al. **Orv Hetil** 1996 Apr 28;137(17):913–21 (55 ref.) (Eng. Abstr.) **(Hun)**

COMPLICATIONS

Links between hypertension and myocardial infarction. Rakugi H, et al. **Am Heart J** 1996 Jul;132(1 Pt 2 Su):213–21 (67 ref.)

Evidence favoring the hypothesis that ventricular arrhythmias have prognostic significance in left ventricular hypertrophy secondary to systemic hypertension. Almendral J, et al. **Am J Cardiol** 1995 Nov 2; 76(13):60D–63D (27 ref.)

Cardiac arrhythmias and left ventricular hypertrophy in systemic hypertension and their influences on prognosis. Bayés-Genís A, et al. **Am J Cardiol** 1995 Nov 2; 76(13):54D–59D (53 ref.)

Congestive heart failure due to hypertensive ventricular diastolic dysfunction. Iriarte MM, et al. **Am J Cardiol** 1995 Nov 2;76(13):43D–47D (20 ref.)

Microvascular angina in systemic hypertension: diagnosis and treatment with enalapril. Iriarte MM, et al. **Am J Cardiol** 1995 Nov 2;76(13):31D–34D (18 ref.)

Systolic ventricular dysfunction and heart failure due to coronary microangiopathy in hypertensive heart disease. Vogt M, et al. **Am J Cardiol** 1995 Nov 2;76(13):48D–53D (34 ref.)

Organ protection and optimal blood pressure control. Meredith PA. **Am J Hypertens** 1995 Oct;8(10 Pt 2):59S–62S (22 ref.)

Hypertension in patients with diabetes mellitus. Skyler JS, et al. **Am J Hypertens** 1995 Dec;8(12 Pt 2):100s–105s (60 ref.)

Role of hypertension in coronary artery disease. Weber MA. **Am J Nephrol** 1996;16(3):210–6 (45 ref.)

Diabetic and hypertensive heart disease. Grossman E, et al. **Ann Intern Med** 1996 Aug 15;125(4):304–10 (100 ref.)

The role of hypertension in the pathogenesis of heart failure. A clinical mechanistic overview. Vasan RS, et al. **Arch Intern Med** 1996 Sep 9;156(16):1789–96 (159 ref.)

Hypertensive left ventricular hypertrophy: pathophysiology, assessment and treatment. Otterstad JE, et al. **Blood Press** 1996 Jan;5(1):5–15 (88 ref.)

Cardiac hypertrophy and hypertension. Dunn FG. **Blood Press Suppl** 1995;2:17–21 (23 ref.)

Cardiovascular hypertrophy and hypertension: causes and consequences. Korner PI. **Blood Press Suppl** 1995;2:6–16 (94 ref.)

Quantifying cardiovascular risk in hypertension. Alderman MH. **Cardiol Clin** 1995 Nov;13(4):519–27 (38 ref.)

Hypertension and left-ventricular hypertrophy. Messerli FH, et al. **Cardiol Clin** 1995 Nov;13(4):549–57 (97 ref.)

Sympathetic nervous system as a coronary risk factor in hypertension. Julius S, et al. **Cardiologia** 1996 Apr; 41(4):309–17 (85 ref.)

Ventricular tachyarrhythmias, myocardial ischemia, and sudden cardiac death in patients with hypertensive heart disease. Zehender M, et al. **Clin Cardiol** 1995 Jul; 18(7):377–83 (84 ref.)

Treatment of renal anemia by erythropoietin substitution. The effects on the cardiovascular system. Radermacher J, et al. **Clin Nephrol** 1995 Nov;44 Suppl 1:S56–60 (51 ref.)

Glomerular hypertension and progressive renal disease: the interplay of mesangial cell stretch, cytokine formation and extracellular matrix synthesis. Cortes P, et al. **Contrib Nephrol** 1996;118:229–33 (14 ref.)

Hypertensive heart disease and the diabetic patient. Grossman E, et al. **Curr Opin Cardiol** 1995 Sep;10(5):458–65 (92 ref.)

The interface of hypertension and ischemic heart disease. Pell AC, et al. **Curr Opin Cardiol** 1995 Sep;10(5):473–9 (42 ref.)

Cardiac hypertrophy and failure in hypertension. Johnson DB, et al. **Curr Opin Nephrol Hypertens** 1996 Mar; 5(2):186–91 (44 ref.)

Treatment of post-stroke hypertension. A practical guide. O'Connell JE, et al. **Drugs Aging** 1996 Jun;8(6):408–15 (50 ref.)

Framingham study insights into hypertensive risk of cardiovascular disease. Kannel WB. **Hypertens Res** 1995 Sep;18(3):181–96 (65 ref.)

Diabetes mellitus and associated hypertension, vascular disease, and nephropathy. An update. Sowers JR, et al. **Hypertension** 1995 Dec;26(6 Pt 1):869–79 (59 ref.)

Association of macronutrients and energy intake with hypertension. Preuss HG, et al. **J Am Coll Nutr** 1996 Feb; 15(1):21–35 (207 ref.)

Cardiovascular hypertrophy: role of angiotensin II and bradykinin. Waeber B, et al. **J Cardiovasc Pharmacol** 1996; 27 Suppl 2:S36–40 (37 ref.)

Salt and left ventricular hypertrophy: what are the links? Langenfeld MR, et al. **J Hum Hypertens** 1995 Nov; 9(11):909–16 (78 ref.)

Haemodynamic basis for the development of left ventricular failure in systolic hypertension and for its logical therapy [editorial] Westerhof N, et al. **J Hypertens** 1995 Sep; 13(9):943–52 (55 ref.)

Multiple risk factors for coronary heart disease in patients with hypertension. Kaplan NM. **J Hypertens Suppl** 1995 Aug;13(2):S1–5 (30 ref.)

Role of hypertension in chronic renal allograft dysfunction. Sanders CE Jr, et al. **Kidney Int Suppl** 1995 Dec;52:S43–7 (97 ref.)

Microalbuminuria as a marker of cardiovascular and renal disease in essential hypertension. Bigazzi R, et al. **Nephrol Dial Transplant** 1995;10 Suppl 6:10–4 (58 ref.)

Chronic rejection and hypertension: a chicken-and-egg problem [editorial; comment] Bock HA. **Nephrol Dial Transplant** 1995;10(7):1126–8 (13 ref.) Comment on: Nephrol Dial Transplant 1995;10(7):1206–11.

Hypertension, cardiovascular complications and survival in diabetic patients on maintenance haemodialysis. Ritz E, et al. **Nephrol Dial Transplant** 1995;10 Suppl 7:43–6 (9 ref.)

Renal involvement in essential hypertension and treatment effects. de Leeuw PW, et al. **Neth J Med** 1995 Oct; 47(4):199–204 (43 ref.)

Current considerations in patients with coexistent diabetes and hypertension. Wood MH. **Nurse Pract** 1996 Apr; 21(4):19–20, 27–31 (24 ref.)

Cardiovascular risk-factor reduction in elderly patients with cardiac disease. Williams MA. **Phys Ther** 1996 May; 76(5):469–80 (103 ref.)

[Ventricular arrhythmias and arterial hypertension] Dorobantu M, et al. **Ann Cardiol Angeiol (Paris)** 1996 May; 45(5):291–5 (23 ref.) (Eng. Abstr.) **(Fre)**

[Arterial hypertension and diabetes. Members of the Board of Directors and Scientific Directors of ALFEDIAM] Bauduceau B, et al. **Diabetes Metab** 1996 Feb;22(1):64–76 (65 ref.) **(Fre)**

[Heart, brain and hypertension] Lüscher TF, et al. **Schweiz Med Wochenschr** 1996 Aug 24;126(34):1449–56 (43 ref.) (Eng. Abstr.) **(Ger)**

[The cardiovascular risk of essential arterial hypertension: general concepts] Gallo P. **Ann Ig** 1994 Jul–Dec; 6(4–6):501–9 (43 ref.) (Eng. Abstr.) **(Ita)**

[The organ damage in arterial hypertension] Agabiti-Rosei E, et al. **Ann Ital Med Int** 1995 Oct;10 Suppl:99S–107S (54 ref.) (Eng. Abstr.) **(Ita)**

[The role of the sympathetic nervous system in essential arterial hypertension and organ damage] Grassi G, et al. **Ann Ital Med Int** 1995 Oct;10 Suppl:115S–120S (46 ref.) (Eng. Abstr.) **(Ita)**

[Myocardial hypertrophy and arterial hypertension] Trevi G, et al. **G Ital Cardiol** 1995 Oct;25(10):1331–8 (37 ref.) (Eng. Abstr.) **(Ita)**

[Arterial hypertension, left ventricular hypertrophy and cardiovascular risk (editorial)] Nogueira JB. **Acta Med Port** 1995 Dec;8(12):663–6 (30 ref.) **(Por)**

[The importance of the dyslipidemia-arterial hypertension link in coronary atherosclerosis] Diament J, et al. **Arq Bras Cardiol** 1995 Sep;65(3):279–82 (35 ref.) **(Por)**

[Left ventricular hypertrophy in patients with arterial hypertension] Diadyk AI, et al. **Lik Sprava** 1995 Jul–Aug; (7–8):68–73 (52 ref.) **(Rus)**

[State of microcirculation in the bulbar conjunctiva in retinal thrombosis of patients with hypertension and diabetes mellitus] Polunin GS, et al. **Vestn Oftalmol** 1996 Jan–Mar; 112(1):51–3 (60 ref.) **(Rus)**

[Hypertensive cardiopathy. Studies on left ventricular hypertrophy] Domingo Sagastagoitia J, et al. **Rev Esp Cardiol** 1995;48 Suppl 4:28–34 (13 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Management of hypertension, Part I [see comments] Moser M. **Am Fam Physician** 1996 May 15;53(7):2295–302 (38 ref.) Comment in: Am Fam Physician 1996 May 15;53(7):2272, 2275.

Ambulatory blood pressure monitoring: methodologic issues. Prisant LM, et al. **Am J Nephrol** 1996;16(3):190–201 (119 ref.)

Ambulatory blood pressure monitoring in the diagnosis of hypertension. Prisant LM. **Cardiol Clin** 1995 Nov; 13(4):479–90 (119 ref.)

New diagnostic inroads in hypertension and atherosclerosis. Ayers CR. **Curr Opin Cardiol** 1995 Sep;10(5):480–4 (14 ref.)

Ambulatory blood pressure monitoring in current clinical practice and research. Mansoor GA, et al. **Curr Opin Nephrol Hypertens** 1995 Nov;4(6):531–7 (46 ref.)

Hypertension in a child: diagnostic aspects. Jhamb U, et al. **Indian Pediatr** 1995 Jun;32(6):705–12 (26 ref.)

Diagnosis and treatment of concomitant hypertension and stroke. Kenton EJ 3rd. **J Natl Med Assoc** 1996 Jun; 88(6):364–8 (25 ref.)

Is listening for abdominal bruits useful in the evaluation of hypertension? Turnbull JM. **JAMA** 1995 Oct 25; 274(16):1299–301 (26 ref.)

The hypertensive elder: a review for the primary care provider. Sadowski AV, et al. **Nurse Pract** 1996 May; 21(5):99–102, 105–12, 118 (44 ref.)

[Hypertension. A new way to approach an old problem] Aubin M. **Can Fam Physician** 1996 Apr;42:702–8 (30 ref.) (Eng. Abstr.) **(Fre)**

[Arterial hypertension in children] Davin JC. **Rev Med Liege** 1995 Aug;50(8):323–31 (14 ref.) **(Fre)**

[Diagnosis and treatment of arterial hypertension in the elderly] Waeber B, et al. **Schweiz Rundsch Med Prax** 1996 Feb 6;85(6):150–4 (19 ref.) (Eng. Abstr.) **(Fre)**

[Diagnosis of arterial hypertension] Bonner G. **Acta Med Austriaca** 1995;22(3):32–4 (26 ref.) (Eng. Abstr.) **(Ger)**

[New aspects in evaluating the hypertensive patient: measuring blood pressure in the physician's office—ambulatory blood pressure monitoring—blood pressure self-measurement] Magometschnigg D. **Acta Med Austriaca** 1995;22(3):38–43 (9 ref.) (Eng. Abstr.) **(Ger)**

[Diagnosis of the metabolic syndrome] Hanefeld M, et al. **Internist (Berl)** 1996 Jul;37(7):705–11 (32 ref.) **(Ger)**

[Long-term ambulatory blood pressure determination—I: Current status in the diagnosis and management of hypertension] Wellhausen CE, et al. **Med Klin** 1996 Mar 15;91(3):155–62 (0 ref.) **(Ger)**

[White-coat hypertension] Verdecchia P, et al. **G Ital Cardiol** 1995 Jul;25(7):899–909 (37 ref.) (Eng. Abstr.) **(Ita)**

[Impairment of endothelial function in hypertension and possible laboratory evaluation of its state] Krasnowski R, et al. **Postepy Hig Med Dosw** 1996;50(1):65–80 (93 ref.) (Eng. Abstr.) **(Pol)**

[Ergometry in the diagnosis and prognosis of arterial hypertension] Grima Serrano A. **Rev Esp Cardiol** 1995;48 Suppl 4:40–4 (23 ref.) (Eng. Abstr.) **(Spa)**

[The clinical utility of the automatic ambulatory recording of the arterial pressure in the diagnosis, prognosis and treatment of arterial hypertension] Palma Gámiz JL, et al. **Rev Esp Cardiol** 1995;48 Suppl 4:57–65 (34 ref.) (Eng. Abstr.) **(Spa)**

DIET THERAPY

Dietary factors and blood pressure regulation. Moore TJ, et al. **Endocrinol Metab Clin North Am** 1995 Sep; 24(3):643–55 (54 ref.)

Are low-sodium diets appropriate for treated hypertensive men? Fleet JC. **Nutr Rev** 1995 Oct;53(10):296–8 (10 ref.)

Calcium intake and blood pressure: epidemiology revisited. Morris CD, et al. **Semin Nephrol** 1995 Nov;15(6):490–5 (31 ref.)

[Diet in hyperlipidemia, hypertension and gout] Wolfram G. **Internist (Berl)** 1995 Nov;36(11):1070–6 (35 ref.) **(Ger)**

DRUG THERAPY

Risk factors and differential antihypertensive therapies. Os I. **Acta Med Austriaca** 1995;22(3):45–7 (31 ref.)

Management of hypertension, Part I [see comments] Moser M. **Am Fam Physician** 1996 May 15;53(7):2295–302 (38 ref.) Comment in: Am Fam Physician 1996 May 15;53(7):2272, 2275.

Management of hypertension, Part II [see comments] Moser M. **Am Fam Physician** 1996 Jun;53(8):2553–60 (21 ref.) Comment in: Am Fam Physician 1996 Jun;53(8):2427–8.

Angiotensin-II receptor antagonists: a new class of antihypertensive agents. Weir MR. **Am Fam Physician** 1996 Feb 1;53(2):589–94 (26 ref.)

Direct selective blockade of the vascular angiotensin II receptors in therapy for hypertension and severe congestive heart failure. Awan NA, et al. **Am Heart J** 1996 Jan; 131(1):177–85 (81 ref.)

Renin inhibition: a novel therapy for cardiovascular disease. Lin C, et al. **Am Heart J** 1996 May;131(5):1024–34 (115 ref.)

Implications of the links between hypertension and myocardial infarction for choice of drug therapy in patients with hypertension. Meredith PA. **Am Heart J** 1996 Jul; 132(1 Pt 2 Su):222–8 (29 ref.)

Comparative effects of indapamide and captopril on blood pressure and albumin excretion rate in diabetic microalbuminuria. Donnelly R, et al. **Am J Cardiol** 1996 Feb 22;77(6):26B–30B (33 ref.)

Microvascular angina in systemic hypertension: diagnosis and treatment with enalapril. Iriarte MM, et al. **Am J Cardiol** 1995 Nov 2;76(13):31D–34D (18 ref.)

Cardioprotection and antihypertensive therapy: the key importance of addressing the associated coronary risk factors (the Framingham experience). Kannel WB. **Am J Cardiol** 1996 Feb 22;77(6):6B–11B (19 ref.)

Diuretics: cornerstone of antihypertensive therapy. Kaplan NM. **Am J Cardiol** 1996 Feb 22;77(6):3B–5B (22 ref.)

Response of hypertensive left ventricular hypertrophy and coronary microvascular disease to calcium antagonists. Vogt M, et al. **Am J Cardiol** 1995 Nov 2;76(13):24D–30D (52 ref.)

Torsemide: a new loop diuretic. Fowler SF, et al. **Am J Health Syst Pharm** 1995 Aug 15;52(16):1771–80; quiz 1814–5 (60 ref.)

The coronary artery disease paradox. Black HR. **Am J Hypertens** 1996 Apr;9(4 Pt 3):2S–10S (66 ref.)

The heart in hypertension. Thinking small! [editorial; comment] Cannon RO 3rd. **Am J Hypertens** 1996 Apr;9(4 Pt 1):406–8 (19 ref.) Comment on: Am J Hypertens 1996 Apr;9(4 Pt 1):361–9.

Organ protection and optimal blood pressure control. Meredith PA. **Am J Hypertens** 1995 Oct;8(10 Pt 2):59S–62S (22 ref.)

Compliance in the treatment of hypertension. A need for action. Sanson-Fisher RW, et al. **Am J Hypertens** 1995 Oct;8(10 Pt 2):82S–88S (57 ref.)

Stratification of vascular risk in hypertension and therapeutic perspective. Simon A, et al. **Am J Hypertens** 1995 Oct;8(10 Pt 2):45S–48S (18 ref.)

A chronotherapeutic approach to the management of

hypertension. White WB. **Am J Hypertens** 1996 Apr;9(4 Pt 3):29S–33S (27 ref.)

Absolute cardiovascular risk: the basis for deciding to treat. Alderman MH. **Am J Nephrol** 1996;16(3):182–9 (40 ref.)

Differing effects of antihypertensive agents on urinary albumin excretion. Weir MR. **Am J Nephrol** 1996; 16(3):237–45 (69 ref.)

Angiotensin II receptor blockers. A new class of antihypertensive drugs. Velasquez MT. **Arch Fam Med** 1996 Jun;5(6):351–6 (60 ref.)

Calcium antagonists should continue to be used for first–line treatment of hypertension [see comments] Epstein M. **Arch Intern Med** 1995 Nov 13;155(20):2150–6 (52 ref.) Comment in: Arch Intern Med 1995 Nov 13;155(20):2145. Comment in: Arch Intern Med 1996 May 27;156(10):1115–6.

Should dihydropyridines be used as first–line drugs in the treatment of hypertension? The con side [see comments] Furberg CD, et al. **Arch Intern Med** 1995 Nov 13; 155(20):2157–61 (32 ref.) Comment in: Arch Intern Med 1995 Nov 13;155(20):2145. Comment in: Arch Intern Med 1996 May 27;156(10):1115–6.

Beta–blockers in hypertensive and coronary heart disease. Goldstein S. **Arch Intern Med** 1996 Jun 24;156(12):1267–76 (89 ref.)

Review of studies with urapidil in elderly hypertensives. Hansson L, et al. **Blood Press** 1995;Suppl 3:21–5 (21 ref.)

Characteristics of an ideal antihypertensive therapy for elderly hypertensives. Hansson L, et al. **Blood Press** 1995; Suppl 3:68–72 (25 ref.)

Pharmacological backgrounds of the drug treatment of hypertension in the elderly. van Zwieten PA. **Blood Press** 1995;Suppl 3:15–20 (33 ref.)

Morphology of isolated small arteries from patients with essential hypertension. Aalkjaer C, et al. **Blood Press Suppl** 1995;2:113–6 (33 ref.)

Review of studies with urapidil in elderly hypertensives. Hansson L, et al. **Blood Press Suppl** 1995;3:21–5 (21 ref.)

Factors influencing the success of withdrawal of antihypertensive drug therapy. Jennings GL, et al. **Blood Press Suppl** 1995;2:99–107 (28 ref.)

Pharmacological backgrounds of the drug treatment of hypertension in the elderly. Van Zwieten PA. **Blood Press Suppl** 1995;3:15–20 (33 ref.)

Short acting dihydropyridine (vasodilating) calcium channel blockers for hypertension: is there a risk? Beevers DG, et al. **BMJ** 1996 May 4;312(7039):1143–5 (19 ref.)

Therapeutic options in diabetic renal disease and hypertension. Savage MW, et al. **Br J Hosp Med** 1995 Nov 1–14;54(9):429–34 (26 ref.)

Modern approaches to initiating antihypertensive therapy. Gavras H, et al. **Cardiol Clin** 1995 Nov;13(4):593–8 (65 ref.)

Immediate management of severe hypertension. Ram CV. **Cardiol Clin** 1995 Nov;13(4):579–91 (46 ref.)

The evolving paradigm of hypertension. Weber MA. **Cardiol Clin** 1995 Nov;13(4):473–8 (40 ref.)

Ambulatory blood pressure monitoring in the evaluation of hypertension therapy. White WB. **Cardiol Clin** 1995 Nov; 13(4):569–77 (40 ref.)

Drug treatment of hypertension in the elderly. Lund–Johansen P. **Cardiologia** 1995 Jul;40(7):465–75 (88 ref.)

Vascular protective effects of ACE inhibitors and calcium antagonists: theoretical basis for a combination therapy in hypertension and other cardiovascular diseases. Lüscher TF, et al. **Cardiovasc Drugs Ther** 1995 Aug;9 Suppl 3:509–23 (89 ref.)

Cardiovascular structural alterations in hypertension: effect of treatment. Agabiti–Rosei E, et al. **Clin Exp Hypertens** 1996 Apr–May;18(3–4):513–22 (42 ref.)

Key issues regarding lifestyle in the prevention and treatment of hypertension. Beilin LJ. **Clin Exp Hypertens** 1996 Apr–May;18(3–4):473–87 (41 ref.)

Impact of guidelines for antihypertensive treatment on clinical practice. Chalmers J. **Clin Exp Hypertens** 1996 Apr–May;18(3–4):415–23 (15 ref.)

Compliance with antihypertensive treatment. Costa FV. **Clin Exp Hypertens** 1996 Apr–May;18(3–4):463–72 (20 ref.)

The case for a greater blood pressure fall. Hansson L. **Clin Exp Hypertens** 1996 Apr–May;18(3–4):425–34 (19 ref.)

Diuretics and risk of sudden death in hypertension—evidence and potential implications. Hoes AW, et al. **Clin Exp Hypertens** 1996 Apr–May;18(3–4):523–35 (22 ref.)

Antihypertensive treatment in the elderly. Lindholm LH. **Clin Exp Hypertens** 1996 Apr–May;18(3–4):435–47 (33 ref.)

Ambulatory blood pressure, blood pressure variability and antihypertensive treatment. Mancia G, et al. **Clin Exp Hypertens** 1996 Apr–May;18(3–4):449–62 (22 ref.)

Cost–effectiveness of hypertension treatment. Ménard J. **Clin Exp Hypertens** 1996 Apr–May;18(3–4):399–413 (77 ref.)

Experimental approaches to determining the choice of first–step therapy for patients with hypertension. The ALLHAT Research Group Antihypertensive and Lipid–Lowering Treatment to Prevent Heart Attack Trial. Whelton PK, et al. **Clin Exp Hypertens** 1996 Apr–May; 18(3–4):569–79 (17 ref.)

Angiotensin II receptor antagonism: losartan – sites and mechanisms of action. Triggle DJ. **Clin Ther** 1995 Nov–Dec;17(6):1005–30 (132 ref.)

Diabetes and hypertension. Smolar EN. **Compr Ther** 1995 Oct;21(10):597–601 (25 ref.)

Treatment modalities for hypertensive patients with intracranial pathology: options and risks. Tietjen CS, et al. **Crit Care Med** 1996 Feb;24(2):311–22 (86 ref.)

Measuring the effects of antihypertensive therapy upon the quality of life. Fletcher A. **Curr Opin Nephrol Hypertens** 1995 Nov;4(6):538–42 (33 ref.)

The effects of metformin on cardiovascular risk factors. Grant PJ. **Diabetes Metab Rev** 1995 Sep;11 Suppl 1:S43–50 (56 ref.)

Carvedilol for hypertension. **Drug Ther Bull** 1995 May; 33(5):39–40 (19 ref.)

Nifedipine gastrointestinal therapeutic system (GITS). A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in hypertension and angina pectoris. Brogden RN, et al. **Drugs** 1995 Sep; 50(3):495–512 (82 ref.)

Amlodipine. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease [published erratum appears in Drugs 1995 Nov;50(5):896] Haria M, et al. **Drugs** 1995 Sep;50(3):560–86 (196 ref.)

Approaches to meeting the criteria for fixed dose antihypertensive combinations. Focus on metoprolol. Kendall MJ. **Drugs** 1995 Sep;50(3):454–64 (51 ref.)

Optimising diuretic therapy in elderly patients with hypertension. Cushman WC. **Drugs Aging** 1995 Aug; 7(2):88–96 (30 ref.)

Celiprolol. An evaluation of its pharmacological properties and clinical efficacy in the management of hypertension and angina pectoris. Dunn CJ, et al. **Drugs Aging** 1995 Nov; 7(5):394–411 (111 ref.)

ACE inhibitors. Differential use in elderly patients with hypertension. Israili ZH, et al. **Drugs Aging** 1995 Nov; 7(5):355–71 (225 ref.)

The changing face of hypertension and antihypertensive agents. Kitler ME. **Drugs Aging** 1996 Jan;8(1):5–11 (43 ref.)

Treatment of post–stroke hypertension. A practical guide. O'Connell JE, et al. **Drugs Aging** 1996 Jun;8(6):408–15 (50 ref.)

ACE inhibitors in elderly patients with hypertension. Special considerations. Ravid M, et al. **Drugs Aging** 1996 Jan; 8(1):29–37 (89 ref.)

Hypertensive emergencies. Murphy C. **Emerg Med Clin North Am** 1995 Nov;13(4):973–1007 (141 ref.)

Nonemergent hypertension. New perspectives for the emergency medicine physician. Thach AM, et al. **Emerg Med Clin North Am** 1995 Nov;13(4):1009–35 (107 ref.)

Carvedilol, a novel multiple action antihypertensive agent with antioxidant activity and the potential for myocardial and vascular protection. Feuerstein GZ, et al. **Eur Heart J** 1995 Jul;16 Suppl F:38–42 (21 ref.)

Directions in antihypertensive treatment—our future from the past. Maisch B, et al. **Eur Heart J** 1995 May;16 Suppl C:74–83 (75 ref.)

Neuropsychological consequences of antihypertensive medication use. Muldoon MF, et al. **Exp Aging Res** 1995 Oct–Dec;21(4):353–68 (68 ref.)

Should calcium antagonists be first line drugs in hypertension? Furberg CD, et al. **Herz** 1995 Dec; 20(6):365–9 (10 ref.)

Calcium channel blockers and hypertension: 1. New trials. Townsend RR, et al. **Hosp Pract (Off Ed)** 1996 Jul 15; 31(7):125–8, 133–6 (10 ref.)

Hypertension and CHD risk: whither alpha–1 blockers? Pandit RB. **Indian Heart J** 1996 May–Jun;48(3):265–71 (41 ref.)

Controversy in the pharmacologic treatment of hypertension in African Americans [see comments] Lockette W. **J Assoc Acad Minor Phys** 1995;6(4):125–9 (32 ref.) Comment in: J Assoc Acad Minor Phys 1995;6(4):124.

Newer calcium antagonists for treatment of systemic hypertension. Singh NK. **J Assoc Physicians India** 1995 Apr;43(4):277–81 (47 ref.)

Cardiovascular hypertrophy: role of angiotensin II and bradykinin. Waeber B, et al. **J Cardiovasc Pharmacol** 1996; 27 Suppl 2:S36–40 (37 ref.)

Management of hypertensive urgencies and emergencies. Abdelwahab W, et al. **J Clin Pharmacol** 1995 Aug; 35(8):747–62 (100 ref.)

Hypertension trial results: consensus and conflicts. Dollery C. **J Hum Hypertens** 1995 Jun;9(6):403–8 (30 ref.)

Managing hypertension in general practice: can we do better? Hosie J, et al. **J Hum Hypertens** 1995 Jul;9 Suppl 2:S15–8 (7 ref.)

What are the implications for the community of the discrepancy between the theory and practice of BP control? Jackson R. **J Hum Hypertens** 1995 Jul;9 Suppl 2:S25–8 (8 ref.)

Improving the management of hypertension in clinical practice. Mancia G. **J Hum Hypertens** 1995 Jul;9 Suppl 2:S29–31 (13 ref.)

Limiting factors in the control of BP: why is there a gap between theory and practice? Ménard J, et al. **J Hum Hypertens** 1995 Jul;9 Suppl 2:S19–23 (17 ref.)

The hidden truth: what do the clinical trials really tell us about BP control? Ruilope LM. **J Hum Hypertens** 1995 Jul;9 Suppl 2:S3–7 (13 ref.)

New ideas for treating hypertension. Schachter M. **J Hum Hypertens** 1995 Aug;9(8):663–7 (40 ref.)

The heterogeneity of hypertension: why doesn't every patient respond to every antihypertensive drug? Sever P. **J Hum Hypertens** 1995 Jul;9 Suppl 2:S33–6 (8 ref.)

The continuing challenge of hypertension. Sever P. **J Hum Hypertens** 1995 Jul;9 Suppl 2:S49–51 (13 ref.)

Low–dose thiazides in the treatment of hypertension: benefits and risks in perspective. Silverberg DS, et al. **J Hum Hypertens** 1995 Nov;9(11):869–73 (80 ref.)

Management guidelines for hypertension: is anyone taking notice? Swales JD. **J Hum Hypertens** 1995 Jul;9 Suppl 2:S9–13 (13 ref.)

Discovery of losartan, the first angiotensin II receptor antagonist. Timmermans PB, et al. **J Hum Hypertens** 1995 Nov;9 Suppl 5:S3–18 (199 ref.)

The benefits of lowering elevated blood pressure: a critical review of studies of cardiovascular morbidity and mortality in hypertension [editorial] Hansson L. **J Hypertens** 1996 May;14(5):537–44 (51 ref.)

Angiotensin converting enzyme inhibitors in hypertension: potential problems. Antonios TF, et al. **J Hypertens Suppl** 1995 Sep;13 Suppl 3:S11–6 (87 ref.)

Angiotensin converting enzyme inhibitors and calcium antagonists alone or combined: does the progression of diabetic renal disease differ? Bakris GL, et al. **J Hypertens Suppl** 1995 Aug;13(2):S95–101 (52 ref.)

Managing the elderly hypertensive patient beyond blood pressure reduction. Holzgreve H. **J Hypertens Suppl** 1995 Aug;13(2):S103–7 (15 ref.)

Guidelines for the treatment of hypertension: an American view. Fifth Joint National Committee. Kaplan NM. **J Hypertens Suppl** 1995 Aug;13(2):S113–7 (16 ref.)

Metabolic aspects of the treatment of hypertension. Lithell H. **J Hypertens Suppl** 1995 Aug;13(2):S77–80 (29 ref.)

The pharmacological basis for the combination of calcium channel antagonists and angiotensin converting enzyme inhibitors in the treatment of hypertension. Osswald H, et al. **J Hypertens Suppl** 1995 Aug;13(2):S21–8 (58 ref.)

Update on the use of angiotensin converting enzyme inhibitors and calcium antagonists in postinfarction patients. Persson S. **J Hypertens Suppl** 1995 Aug;13(2):S57–63 (33 ref.)

Hypertension in the non–insulin–dependent diabetes mellitus syndrome: a critical review of therapeutic intervention. Rett K, et al. **J Hypertens Suppl** 1995 Aug;13(2):S81–5 (26 ref.)

Main objectives and new aspects of combination treatment of hypertension. Waeber B, et al. **J Hypertens Suppl** 1995 Aug;13(2):S15–9 (17 ref.)

Guidelines for the management of hypertension: the World Health Organization/International Society of Hypertension view. World Health Organization. International Society of Hypertension. Zanchetti A. **J Hypertens Suppl** 1995 Aug; 13(2):S119–22 (19 ref.)

Practical relevance of the 24–hour trough: peak ratio of antihypertensive drugs. Zannad F. **J Hypertens Suppl** 1995 Aug;13(2):S109–12 (41 ref.)

Diagnosis and treatment of concomitant hypertension and stroke. Kenton EJ 3rd. **J Natl Med Assoc** 1996 Jun; 88(6):364–8 (25 ref.)

Management of hypertension in the child with chronic renal disease. Feld LG, et al. **J Pediatr** 1996 Aug;129(2):s18–26 (31 ref.)

Long–term therapy of hypertension. Yoo WS. **Korean J Intern Med** 1995 Jul;10(2):79–86 (25 ref.)

A practical guideline for management of hypertension in patients with diabetes. Fatourechi V, et al. **Mayo Clin Proc** 1996 Jan;71(1):53–8 (37 ref.)

Treatment of hypertension in pregnant women. Sibai BM. **N Engl J Med** 1996 Jul 25;335(4):257–65 (93 ref.)

Calcium channel blockers and renal dysfunction in arterial hypertension. Diez J. **Nephrol Dial Transplant** 1995;10 Suppl 6:22–6 (50 ref.)

Antihypertensive treatment with diuretics: antediluvian or up to date? Dorhout Mees EJ. **Nephrol Dial Transplant** 1996 Apr;11(4):587–92 (43 ref.)

Effects of ACE inhibitors and calcium channel blockers on the development of glomerular sclerosis in models of renal damage. Raij L. **Nephrol Dial Transplant** 1995 Oct;10 Suppl 9:23–7 (55 ref.)

Effects of ACE inhibitors and calcium channel blockers on insulin sensitivity and other components of the syndrome. Sowers JR. **Nephrol Dial Transplant** 1995 Oct;10 Suppl 9:52–5 (41 ref.)

Effects of antihypertensive drugs on large artery compliance. Slama M, et al. **Neth J Med** 1995 Oct;47(4):162–8 (48 ref.)

Acute hypertension and calcium–channel blockers. Kanneganti M, et al. **New Horiz** 1996 Feb;4(1):19–25 (46 ref.)

The use of calcium–channel blockers in pregnancy. Lewis R, et al. **New Horiz** 1996 Feb;4(1):115–22 (45 ref.)

Current trends in cardiovascular pharmacology. Ciccone CD. **Phys Ther** 1996 May;76(5):481–97 (184 ref.)

At risk nephrons and the decline in renal function in response to treatment of hypertension. Walker WG, et al. **Trans Am Clin Climatol Assoc** 1995;107:134–43; discussion 143–5 (26 ref.)

Cost–effective therapy for hypertension. Barrie W. **West J Med** 1996 Apr;164(4):303–9 (36 ref.)

Non–responders. Os I. **Wien Med Wochenschr** 1995; 145(15–16):357–60 (32 ref.)

[Angiotensin converting enzyme inhibitors in the treatment of arterial hypertension] Widimský J Jr. **Vnitr Lek** 1995 Aug;41(8):560–4 (16 ref.) (Eng. Abstr.) **(Cze)**

[Hypertensive crises. 2. Treatment] Fog L, et al. **Ugeskr Laeger** 1995 Dec 18;157(51):7140–5 (40 ref.) (Eng. Abstr.) **(Dan)**

[Hypertension. A new way to approach an old problem] Aubin M. **Can Fam Physician** 1996 Apr;42:702–8 (30 ref.) (Eng. Abstr.) **(Fre)**

[Psychotropic effects of angiotensin-converting enzyme inhibitors: what are the arguments?] Mesure G, et al. **Encephale** 1995 Sep–Oct;21(5):609–14 (59 ref.) (Eng. Abstr.) **(Fre)**

[Diagnosis and treatment of hypertensive emergencies] Burnier M, et al. **Schweiz Med Wochenschr** 1995 Nov 25; 125(47):2261–6 (8 ref.) (Eng. Abstr.) **(Fre)**

[Diagnosis and treatment of arterial hypertension in the elderly] Waeber B, et al. **Schweiz Rundsch Med Prax** 1996 Feb 6;85(6):150–4 (19 ref.) (Eng. Abstr.) **(Fre)**

[Antihypertensive therapy in stroke: acute therapy, primary and secondary prevention] Brainin M. **Acta Med Austriaca** 1995;22(3):54–7 (36 ref.) (Eng. Abstr.) **(Ger)**

[Refractory hypertension—principles of combination therapy] Hitzenberger G. **Acta Med Austriaca** 1995; 22(3):43–5 (14 ref.) (Eng. Abstr.) **(Ger)**

[Antihypertensive therapy and coronary heart disease: significance of the effect of concomitant cardiovascular risk factors] Huber K, et al. **Acta Med Austriaca** 1995; 22(3):48–51 (47 ref.) (Eng. Abstr.) **(Ger)**

[Antihypertensive therapy in renal failure] Mayer G. **Acta Med Austriaca** 1995;22(3):51–3 (19 ref.) (Eng. Abstr.) **(Ger)**

[Angiotensin receptor antagonists. A new class of antihypertensive agents] Mann J. **Dtsch Med Wochenschr** 1996 Apr 26;121(17):568–71 (22 ref.) **(Ger)**

[Retrospective studies and prospects of therapy for hypertension] Maisch B, et al. **Herz** 1995 Dec;20(6):370–89 (96 ref.) (Eng. Abstr.) **(Ger)**

[Integrated drug therapy of the metabolic syndrome] Julius U, et al. **Internist (Berl)** 1996 Jul;37(7):722–30 (32 ref.) **(Ger)**

[Angiotensin II receptor antagonists. Clinical relevance] Scholze J. **Internist (Berl)** 1996 Jun;37(6):636–42 (47 ref.) **(Ger)**

[Therapy of hypertension 1996. Effectiveness, tolerance, cost–benefit aspects] Rahn KH. **Med Klin** 1996 Jun 15; 91(6):380–3 (8 ref.) **(Ger)**

[Calcium antagonists—much noise about nothing?] Oberpichler-Schwenk H. **Med Monatsschr Pharm** 1995 Dec;18(12):344–9 (14 ref.) **(Ger)**

[Hypertension in the elderly] Reinhart WH. **Schweiz Med Wochenschr** 1996 Aug 24;126(34):1442–5 (19 ref.) (Eng. Abstr.) **(Ger)**

[Arterial hypertension in the elderly. Is there still room for diuretics?] Dubois D, et al. **Schweiz Rundsch Med Prax** 1996 Jan 30;85(5):117–25 (77 ref.) (Eng. Abstr.) **(Ger)**

[Treatment of hypertension in elderly patients] Vetter W, et al. **Schweiz Rundsch Med Prax** 1995 Oct 31; 84(44):1277–81 (25 ref.) (Eng. Abstr.) **(Ger)**

[Results of the 3rd Consensus Conference on "Individualized Therapy of Hypertension" and brief explanation of individual evaluation] **Wien Med Wochenschr** 1995; 145(15–16):339–49 (0 ref.) **(Ger)**

[Evaluation of the antihypertensive drugs carvedilol, doxazosin and moxonidine] Dominiak P. **Wien Med Wochenschr** 1995;145(15–16):373–82 (92 ref.) (Eng. Abstr.) **(Ger)**

[Interactions between antihypertensive agents of different mechanisms of action] Hitzenberger G. **Wien Med Wochenschr** 1995;145(15–16):352–4 (22 ref.) (Eng. Abstr.) **(Ger)**

[What are the therapeutic consequences of evaluating hypertensive patients with 24-hour blood pressure monitors and blood pressure self-measurement?] Zweiker R, et al. **Wien Med Wochenschr** 1995;145(15–16):365–72 (74 ref.) (Eng. Abstr.) **(Ger)**

[Hypertensive treatment in light of the latest discoveries in the renin–angiotensin system] Traub Y. **Harefuah** 1996 Feb 1;130(3):195–9 (49 ref.) **(Heb)**

[Selected passages from the clinical trials of Cordaflex] Somogyi M, et al. **Acta Pharm Hung** 1996 Jan;66(1):47–51 (16 ref.) (Eng. Abstr.) **(Hun)**

[Basic principles of current trends in the management of hypertension and kidney disease in pregnancy] Vajó Z, et al. **Orv Hetil** 1995 Nov 19;136(47):2561–6 (45 ref.) (Eng. Abstr.) **(Hun)**

[New therapeutic outlooks in the treatment of the hypertensive patient] Ambrosioni E, et al. **Ann Ital Med Int** 1995 Oct;10 Suppl:78S–81S (20 ref.) (Eng. Abstr.) **(Ita)**

[The treatment of hypertension in patients with a metabolic disorder] Dal Palù C, et al. **Ann Ital Med Int** 1995 Oct; 10 Suppl:130S–132S (21 ref.) (Eng. Abstr.) **(Ita)**

[Metabolic tolerance of isradipine. Evaluation after three months of therapy] Panuccio D, et al. **Clin Ter** 1995 Nov; 146(11):729–36 (82 ref.) (Eng. Abstr.) **(Ita)**

[The treatment of intraoperative arterial hypertension with Urapidil] Filosso PL. **Minerva Cardioangiol** 1996 Apr; 44(4):197–207 (45 ref.) **(Ita)**

[New perspectives in the treatment of hypertension] Rossi G. **Recenti Prog Med** 1996 Jan;87(1):27–30 (44 ref.) **(Ita)**

[Hypertension] Matsuoka H. **Nippon Ronen Igakkai Zasshi** 1996 Apr;33(4):245–8 (11 ref.) **(Jpn)**

[Treatment of hypertension in renal parenchymal diseases] Iversen BM, et al. **Tidsskr Nor Laegeforen** 1996 Jun 30; 116(17):2022–6 (28 ref.) (Eng. Abstr.) **(Nor)**

[Imidazol receptor agonists—new possibilities for treating hypertension] Nowicki M, et al. **Postepy Hig Med Dosw** 1995;49(5):631–43 (56 ref.) (Eng. Abstr.) **(Pol)**

[Role of ambulatory blood pressure monitoring in the evaluation of the therapeutic efficacy of antihypertensive drugs. Trough/peak relation] Nobre F. **Arq Bras Cardiol** 1995 Mar;64(3):247–9 (27 ref.) **(Por)**

[Our point of view. Trough to peak ratio of antihypertensive drugs: methodologic issues and clinical implications] Polónia J. **Rev Port Cardiol** 1996 Apr;15(4):281–92 (30 ref.) **(Por)**

[The effect of angiotensin-converting enzyme inhibitors on left ventricular hypertrophy in patients with arterial hypertension] Diadyk AI, et al. **Ter Arkh** 1995;67(8):65–8 (88 ref.) **(Rus)**

[The use of perindopril (prestarium) in arterial hypertension] Filatova NP. **Ter Arkh** 1995;67(9):81–3 (35 ref.) **(Rus)**

[Controversies in the treatment of arterial hypertension: other drugs as the first step (calcium antagonists, ACE inhibitors and alpha-blockers)] Castro Beiras A, et al. **Rev Esp Cardiol** 1995;48 Suppl 4:72–80 (31 ref.) (Eng. Abstr.) **(Spa)**

[Diuretics and beta-blockers as the first option in the treatment of arterial hypertension] Ferreira Montero IJ, et al. **Rev Esp Cardiol** 1995;48 Suppl 4:66–71 (41 ref.) (Eng. Abstr.) **(Spa)**

[Combination drugs in the treatment of hypertension. Simpler for patients, physicians and pharmacies] Himmelmann A, et al. **Lakartidningen** 1995 Sep 27;92(39):3557–8, 3563 (20 ref.) **(Swe)**

ECONOMICS

Economics of hypertension control. World Hypertension League. **Bull World Health Organ** 1995;73(4):417–24 (43 ref.)

Cost-effectiveness of hypertension treatment. Ménard J. **Clin Exp Hypertens** 1996 Apr–May;18(3–4):399–413 (77 ref.)

Cost-effective therapy for hypertension. Barrie W. **West J Med** 1996 Apr;164(4):303–9 (36 ref.)

EPIDEMIOLOGY

Hypertension in children and adolescents. Falkner B, et al. **Am J Hypertens** 1995 Dec;8(12 Pt 2):106s–110s (24 ref.)

The epidemiology of hypertension control in populations. Langer RD. **Clin Exp Hypertens** 1995 Oct;17(7):1127–44 (33 ref.)

Hypertension, coronary artery and cerebrovascular diseases in the population. Has epidemiology changed in the last decades? Pessina AC, et al. **Clin Exp Hypertens** 1996 Apr–May;18(3–4):363–70 (18 ref.)

Hyperlipidemia, hypertension and atherosclerosis in women. Reality and perspectives. Bugliosi R, et al. **Clin Ter** 1995 Aug–Sep;146(8–9):503–18 (66 ref.)

Fetal influences on adult hypertension. Law C. **J Hum Hypertens** 1995 Aug;9(8):649–51 (30 ref.)

Epidemiology of hypertension in African Americans. Lackland DT, et al. **Semin Nephrol** 1996 Mar;16(2):63–70 (51 ref.)

[What can we think about diastolic hypertension?] Salvador M, et al. **Ann Cardiol Angeiol (Paris)** 1995 Dec;44(10):543–6 (9 ref.) (Eng. Abstr.) **(Fre)**

[Epidemiologic and medical sociological aspects of hypertension] Siegrist J. **Herz** 1995 Oct;20(5):302–8 (40 ref.) (Eng. Abstr.) **(Ger)**

[Arterial hypertension and atherosclerosis: their epidemiology and physiopathology] Lembo G, et al. **Ann Ital Med Int** 1995 Oct;10 Suppl:69S–72S (13 ref.) (Eng. Abstr.) **(Ita)**

[Hypertension and diabetes] Navalesi R, et al. **Ann Ital Med Int** 1995 Oct;10 Suppl:121S–129S (37 ref.) (Eng. Abstr.) **(Ita)**

[Obesity as a risk factor of hypertension (prospective study)] Yoshikawa A, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:271–5 (18 ref.) **(Jpn)**

[Arterial hypertension in the elderly. The outstanding aspects] González García P, et al. **Rev Esp Cardiol** 1995; 48 Suppl 4:9–17 (51 ref.) (Eng. Abstr.) **(Spa)**

ETHNOLOGY

Epidemiology of hypertension in African American women. Gillum RF. **Am Heart J** 1996 Feb;131(2):385–95 (72 ref.)

The Bell Curve: on race, social class, and epidemiologic research. Muntaner C, et al. **Am J Epidemiol** 1996 Sep 15; 144(6):531–6 (76 ref.)

Hypertension in East Asia. Jones DW. **Am J Hypertens** 1995 Dec;8(12 Pt 2):111s–114s (14 ref.)

Hypertension in Hispanics. Comments on a major disease in a mix of ethnic groups. Martinez-Maldonado M. **Am J Hypertens** 1995 Dec;8(12 Pt 2):120s–123s (20 ref.)

Lessons on the interaction of race and antihypertensive drugs from the VA cooperative study group on antihypertensive agents. Materson BJ. **Am J Hypertens** 1995 Dec;8(12 Pt 2):91s–93s (13 ref.)

Hypertension in minorities: blacks. Saunders E. **Am J Hypertens** 1995 Dec;8(12 Pt 2):115s–119s (19 ref.)

Hypertension and other cardiac risk factors among Asian Indians. Venkata C, et al. **Am J Hypertens** 1995 Dec;8(12 Pt 2):124s–127s (14 ref.)

Racial differences in the pathogenesis of hypertension. Calhoun DA, et al. **Am J Med Sci** 1995 Dec;310 Suppl 1:S86–90 (29 ref.)

Role of dietary factors in the hypertension of African Americans. Adrogué HJ, et al. **Semin Nephrol** 1996 Mar; 16(2):94–101 (45 ref.)

Possible mediators in hypertension: renal factors. Bergman SM, et al. **Semin Nephrol** 1996 Mar;16(2):134–9 (36 ref.)

Hypertension in the African American community: social, cultural, and psychological factors. Dressler WW. **Semin Nephrol** 1996 Mar;16(2):71–82 (52 ref.)

The role of cardiovascular reactivity as a mediator of hypertension in African Americans. Falkner B. **Semin Nephrol** 1996 Mar;16(2):117–25 (52 ref.)

Blood pressure variation in blacks: genetic factors. Grim CE, et al. **Semin Nephrol** 1996 Mar;16(2):83–93 (49 ref.)

Renovasculopathies of hypertension and the rise of blood pressure with age in blacks and whites. Tracy RE. **Semin Nephrol** 1996 Mar;16(2):126–33 (21 ref.)

Hypertension in African Americans: the role of sodium chloride and extracellular fluid volume. Weinberger MH. **Semin Nephrol** 1996 Mar;16(2):110–6 (49 ref.)

Hypertension in African Americans: a paradigm of metabolic disarray. Weir MR, et al. **Semin Nephrol** 1996 Mar; 16(2):102–9 (78 ref.)

ETIOLOGY

The early natural history of atherosclerosis and hypertension in the young: National Institutes of Health perspectives. Lenfant C, et al. **Am J Med Sci** 1995 Dec;310 Suppl 1:S3–7 (16 ref.)

Vascular remodeling in hypertension: role of autocrine–paracrine factors. Gibbons GH. **Blood Press Suppl** 1995;2:49–54 (56 ref.)

Women, hormones and blood pressure. Khaw KT. **Can J Cardiol** 1996 Jun;12 Suppl D:9D–12D (16 ref.)

Impact of the social environment on blood pressure in women. Wielgosz AT. **Can J Cardiol** 1996 Jun;12 Suppl D:13D–15D (10 ref.)

Alterations in sodium metabolism as an etiological model for hypertension. Lijnen P. **Cardiovasc Drugs Ther** 1995 Jun; 9(3):377–99 (238 ref.)

Hypertension: a case of the gratuitous rider. Weber KT. **Cardiovasc Res** 1996 Jun;31(6):868–9 (16 ref.)

Insulin sensitivity in the pathogenesis of hypertension and hypertensive complications. Landsberg L. **Clin Exp Hypertens** 1996 Apr–May;18(3–4):337–46 (31 ref.)

Pathogenetic factors in hypertension. Endothelial factors. Taddei S, et al. **Clin Exp Hypertens** 1996 Apr–May; 18(3–4):323–35 (34 ref.)

Alcohol and hypertension. Beilin LJ. **Clin Exp Pharmacol Physiol** 1995 Mar;22(3):185–8 (35 ref.)

Alcohol, hypertension, coronary disease and stroke. Lip GY, et al. **Clin Exp Pharmacol Physiol** 1995 Mar;22(3):189–94 (66 ref.)

Ambulatory blood pressure monitoring for evaluating the relationships between lifestyle, hypertension and cardiovascular risk. Pickering TG, et al. **Clin Exp Pharmacol Physiol** 1995 Mar;22(3):226–31 (58 ref.)

Hypertension in ADPKD. Watson ML, et al. **Contrib Nephrol** 1995;115:59–64 (21 ref.)

Corticosteroid hypertension. Funder JW. **Curr Opin Nephrol Hypertens** 1995 Sep;4(5):432–7 (39 ref.)

Hypertension in postmenopausal women: pathophysiology and management. Oparil S. **Curr Opin Nephrol Hypertens** 1995 Sep;4(5):438–42 (26 ref.)

Hypertension in autosomal dominant polycystic kidney disease. Parfrey PS, et al. **Curr Opin Nephrol Hypertens** 1995 Sep;4(5):460–4 (27 ref.)

Koch's postulates and the digitalis-like factor. Hollenberg NK, et al. **Hypertens Res** 1995 Mar;18(1):1–6 (32 ref.)

Are insulin resistance and/or compensatory hyperinsulinemia involved in the etiology and clinical course of patients with hypertension? Reaven GM. **Int J Obes Relat Metab Disord** 1995 May;19 Suppl 1:S2–5 (49 ref.)

Is obstructive sleep apnea a common cause of essential hypertension? [see comments] Silverberg DS, et al. **Isr J Med Sci** 1995 Sep;31(9):527–35 (87 ref.) Comment in: Isr J Med Sci 1995 Sep;31(9):561–2.

Insulin resistance in systemic hypertension: pharmacotherapeutic implications. Mediratta S, et al. **J Clin Pharmacol** 1995 Oct;35(10):943–56 (162 ref.)

Placental 11 beta-hydroxysteroid dehydrogenase and the programming of hypertension. Seckl JR, et al. **J Steroid Biochem Mol Biol** 1995 Dec;55(5–6):447–55 (104 ref.)

Thrombogenic and lipid risk factors in hypertension and coronary artery disease. Ding YA. **Jpn Circ J** 1996 Feb; 60(2):75–84 (41 ref.)

Role of intrarenal endothelin in the generation and maintenance of hypertension. Markewitz BA, et al. **Miner Electrolyte Metab** 1995;21(4–5):342–52 (115 ref.)

A renocentric view of essential hypertension: lessons to be learnt from kidney transplantation [editorial] Jelakovic B, et al. **Nephrol Dial Transplant** 1995;10(9):1510–2 (31 ref.)

Renin and hypertension. Kurtz A. **Nephrol Dial Transplant** 1995;10(9):1521–3 (8 ref.)

Salt and hypertension: where things stand. Luft FC.

Nephrol Dial Transplant 1995;10(9):1524–5 (11 ref.)
Hypertension and the kidney: new insights from results of renal transplantation studies. Rettig R, et al. **Nephrol Dial Transplant** 1995 Oct;10 Suppl 9:9–16 (45 ref.)
Is blood pressure in later life affected by events in infancy? Holliday MA. **Pediatr Nephrol** 1995 Oct;9(5):663–6 (30 ref.)
When is hypertension a cause for concern? Redman C. **Practitioner** 1996 Apr;240(1561):264–8 (0 ref.)
Genetic determinants of human hypertension. Lifton RP. **Proc Natl Acad Sci U S A** 1995 Sep 12;92(19):8545–51 (56 ref.)
Is low birth weight a risk factor for adult hypertension? A literature review with particular reference to Africa. Woelk GB. **S Afr Med J** 1995 Dec;85(12 Pt 2):1348–9, 1352–3 (53 ref.)
Essential hypertension: a renal perspective [editorial] Woo KT. **Singapore Med J** 1995 Jun;36(3):252–4 (14 ref.)
Obesity-related hypertension and the insulin resistance syndrome. Landsberg L. **Trans Am Clin Climatol Assoc** 1994;106:69–75; discussion 75–6 (32 ref.)
[Primary hyperaldosteronism as a cause of hypertension; diagnosis] ter Maaten JC, et al. **Ned Tijdschr Geneeskd** 1996 Mar 2;140(9):483–7 (26 ref.) **(Dut)**
[Diagnosis of endocrine-induced forms of hypertension] Vierhapper H. **Acta Med Austriaca** 1995;22(3):35–7 (20 ref.) (Eng. Abstr.) **(Ger)**
[Atresia of the aortic arch. A rare cause of asymmetrical arterial hypertension in adulthood] Heinrich U, et al. **Dtsch Med Wochenschr** 1996 May 31;121(22):719–22 (34 ref.) (Eng. Abstr.) **(Ger)**
[Experimental types of hypertension—models for essential hypertension in the human?] Rupp H, et al. **Herz** 1995 Oct; 20(5):315–21 (34 ref.) (Eng. Abstr.) **(Ger)**
[Differential diagnosis and therapy of essential hypertension] Spieker C, et al. **Z Arztl Fortbild (Jena)** 1996 May; 90(3):213–20 (12 ref.) (Eng. Abstr.) **(Ger)**
[Essential arterial hypertension: risk factors, pathogenetic mechanisms, possibilities for control] Pasquarella A, et al. **Ann Ig** 1994 Jul–Dec;6(4–6):511–7 (56 ref.) (Eng. Abstr.) **(Ita)**
[Therapy of diabetes mellitus associated with hypertension] Katayama H. **Nippon Naika Gakkai Zasshi** 1996 Apr 10; 85(4):514–8 (10 ref.) **(Jpn)**
[Obesity and the related diseases: hypertension] Ouchi Y, et al. **Nippon Naika Gakkai Zasshi** 1995 Aug 10;84(8):1241–5 (6 ref.) **(Jpn)**
[Trace elements and blood pressure regulation] Ito Y, et al. **Nippon Rinsho** 1996 Jan;54(1):106–10 (28 ref.) (Eng. Abstr.) **(Jpn)**
[Role of renin angiotensin system in the vasopressor mechanisms of hypertension—gene analyses and tissue renin angiotensin system] Nishimura M, et al. **Rinsho Byori** 1995 Nov;43(11):1128–32 (15 ref.) (Eng. Abstr.) **(Jpn)**
[Arterial hypertension induced by erythropoietin] Lietz K, et al. **Pol Arch Med Wewn** 1996 Feb;95(2):153–9 (60 ref.) **(Pol)**
[Obesity and hypertension] Gus M, et al. **Arq Bras Cardiol** 1995 Jun;64(6):565–70 (53 ref.) **(Por)**
[Cardiovascular impact of alcoholism] Faintuch JJ. **Rev Hosp Clin Fac Med Sao Paulo** 1995 Jan–Feb;50(1):76–9 (47 ref.) (Eng. Abstr.) **(Por)**
[The role of endothelial dysfunction in the genesis of hypertensive states in pregnant women] Supriaga OM. **Akush Ginekol (Mosk)** 1995;(6):5–9 (40 ref.) **(Rus)**
[Systemic arterial hypertension in chronic bronchial obstruction: current views and new understandings] Bobrov VA, et al. **Klin Med (Mosk)** 1995;73(3):24–8 (82 ref.) **(Rus)**
[Arterial hypertension in patients with terminal kidney failure: pathogenetic variants and treatment principles] Nikolaev AIu, et al. **Urol Nefrol (Mosk)** 1996 Jan–Feb; (1):44–8 (106 ref.) **(Rus)**
[The role of neurohumoral factors and hemodynamic disorders in the development of primary juvenile arterial hypertension] Byhar VP. **Lik Sprava** 1995 May–Jun; (5–6):51–5 (50 ref.) **(Ukr)**

GENETICS

The hypertensive Ren-2 transgenic rat TGR (mREN2)27 in hypertension research. Characteristics and functional aspects. Langheinrich M, et al. **Am J Hypertens** 1996 May; 9(5):506–12 (36 ref.)
Physiological characterization of the hypertensive transgenic rat TGR(mREN2)27. Lee MA, et al. **Am J Physiol** 1996 Jun;270(6 Pt 1):E919–29 (92 ref.)
Molecular basis of human hypertension: the role of angiotensin. Peters J. **Baillieres Clin Endocrinol Metab** 1995 Jul;9(3):657–78 (80 ref.)
Environmentally-regulated genes of hypertension. Hamet P. **Clin Exp Hypertens** 1996 Apr–May;18(3–4):267–78 (35 ref.)
A genetic approach to the pathogenesis of primary hypertension and to its treatment. Bianchi G, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22(12):S399–405 (60 ref.)
Animal models of genetic hypertension: what can we learn for human hypertension? Rubattu S, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22(12):S386–93 (48 ref.)
Gene targeting and its application to basic hypertension research [editorial] Clark AF, et al. **Clin Sci (Colch)** 1996 Jun;90(6):435–46 (71 ref.)
The genetics of hypertension. Thibonnier M, et al. **Curr Opin Genet Dev** 1995 Jun;5(3):362–70 (76 ref.)
Recent advances in the molecular genetics of hypertension. Shimkets RA, et al. **Curr Opin Nephrol Hypertens** 1996 Mar;5(2):162–5 (31 ref.)
The biological cascade leading to cardiac hypertrophy. Neyses L, et al. **Eur Heart J** 1995 Dec;16 Suppl N:8–11 (27 ref.)
Genetics in arterial hypertension—clinical and experimental aspects. Hübner N, et al. **Herz** 1995 Oct;20(5):309–14 (32 ref.)
Genetic determinants of dopaminergic activity: potential role in blood pressure regulation. Kuchel O. **Hypertens Res** 1995 Jun;18 Suppl 1:S1–10 (72 ref.)
Does keloid pathogenesis hold the key to understanding black/white differences in hypertension severity? [clinical conference] Dustan HP. **Hypertension** 1995 Dec;26(6 Pt 1):858–62 (40 ref.)
Genetics and the metabolic syndrome. Bouchard C. **Int J Obes Relat Metab Disord** 1995 May;19 Suppl 1:S52–9 (43 ref.)
Vascular smooth muscle polyploidy in genetic hypertension: the role of angiotensin II. Devlin AM, et al. **J Hum Hypertens** 1995 Jun;9(6):497–500 (16 ref.)
SA gene and hypertension. Samani NJ, et al. **J Hum Hypertens** 1995 Jun;9(6):501–3 (16 ref.)
Role of angiotensinogen in the genetics of essential hypertension. Hata A. **Life Sci** 1995 Nov 17;57(26):2385–95 (73 ref.)
Identifying the genes for human hypertension. Hingorani AD, et al. **Nephrol Dial Transplant** 1996 Apr;11(4):575–86 (133 ref.)
Genetic determinants of human hypertension. Lifton RP. **Proc Natl Acad Sci U S A** 1995 Sep 12;92(19):8545–51 (56 ref.)
Molecular genetics of human blood pressure variation. Lifton RP. **Science** 1996 May 3;272(5262):676–80 (33 ref.)
Calcium metabolism and familial risk of hypertension. Grobbee DE, et al. **Semin Nephrol** 1995 Nov;15(6):512–8 (39 ref.)
[Research on genes causing hypertension] Hamet P. **Union Med Can** 1995 Sep;124(2):37–47 (86 ref.) **(Fre)**
[Molecular adaptation of the heart to hypertension] Neyses L, et al. **Z Kardiol** 1995;84 Suppl 4:71–6 (21 ref.) (Eng. Abstr.) **(Ger)**
[Transgenic rats as a model for investigation of the pathogenesis of hypertension] Paul M. **Z Kardiol** 1995;84 Suppl 4:55–60 (32 ref.) (Eng. Abstr.) **(Ger)**
[Digoxin-like immunoreactive factors. Review of the literature] Ozzola G, et al. **Minerva Med** 1995 Nov; 86(11):475–80 (42 ref.) (Eng. Abstr.) **(Ita)**
[Genetic aspects of hypertension—etiology of essential hypertension] Ogihara T. **Nippon Naika Gakkai Zasshi** 1995 Jul 10;84(7):1172–7 (16 ref.) **(Jpn)**

HISTORY

[The etiology of Leningrad blockade-related hypertension] Klebanov IuA. **Klin Med (Mosk)** 1995;73(3):18–21 (38 ref.) **(Rus)**

IMMUNOLOGY

Abnormal immune system and hypertension: where are we? Fu ML. **Ann Med** 1995 Dec;27(6):671–4 (35 ref.)

METABOLISM

AT1 receptors and angiotensin actions in the brain and neuronal cultures of normotensive and hypertensive rats. Raizada MK, et al. **Adv Exp Med Biol** 1995;377:331–48 (124 ref.)
Dopamine receptor signaling defects in spontaneous hypertension. Jose PA, et al. **Am J Hypertens** 1996 Apr; 9(4 Pt 1):400–5 (53 ref.)
Glucose and insulin metabolism in hypertension. Corry DB, et al. **Am J Nephrol** 1996;16(3):223–36 (188 ref.)
Elastin in systemic and pulmonary hypertension. Keeley FW, et al. **Ciba Found Symp** 1995;192:259–73; discussion 273–8 (65 ref.)
Renal medullary antihypertensive mechanisms. Anderson WP, et al. **Clin Exp Pharmacol Physiol** 1995 Dec; 22(12):S426–9 (26 ref.)
Anterior hypothalamic norepinephrine, atrial natriuretic peptide, and hypertension. Oparil S, et al. **Front Neuroendocrinol** 1996 Apr;17(2):212–46 (122 ref.)
Sodium-proton exchange and primary hypertension. An update. Siffert W, et al. **Hypertension** 1995 Oct;26(4):649–55 (82 ref.)
Calcium metabolism in hypertension. McCarron DA. **Keio J Med** 1995 Dec;44(4):105–14 (118 ref.)
Hypertension and associated metabolic abnormalities—the role of insulin resistance and the sympathoadrenal system. Reaven GM, et al. **N Engl J Med** 1996 Feb 8;334(6):374–81 (85 ref.)
Calcium metabolism and familial risk of hypertension. Grobbee DE, et al. **Semin Nephrol** 1995 Nov;15(6):512–8 (39 ref.)
Calcium metabolism in normal and hypertensive pregnancy. Hojo M, et al. **Semin Nephrol** 1995 Nov;15(6):504–11 (51 ref.)
Genes of intracellular calcium metabolism and blood pressure control in primary hypertension. Orlov SN, et al. **Semin Nephrol** 1995 Nov;15(6):569–92 (240 ref.)
Systemic and cellular calcium metabolism and hypertension. Oshima T, et al. **Semin Nephrol** 1995 Nov;15(6):496–503 (77 ref.)

NURSING

Blood pressure. Thomas SA, et al. **Annu Rev Nurs Res** 1996; 14:3–22 (87 ref.)

PATHOLOGY

Morphology of isolated small arteries from patients with essential hypertension. Aalkjaer C, et al. **Blood Press Suppl** 1995;2:113–6 (33 ref.)
Cardiovascular structural alterations in hypertension: effect of treatment. Agabiti-Rosei E, et al. **Clin Exp Hypertens** 1996 Apr–May;18(3–4):513–22 (42 ref.)
Molecular mechanisms of vascular hypertrophy in the spontaneously hypertensive rat. Marche P, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22 Suppl 1:S114–6 (23 ref.)
Myocardial fibrosis in hypertensive heart disease: an overview of potential regulatory mechanisms. Weber KT, et al. **Eur Heart J** 1995 May;16 Suppl C:24–8 (49 ref.)
Sick vessel syndrome: vascular changes in hypertension and atherosclerosis. Heistad DD, et al. **J Hum Hypertens** 1995 Jun;9(6):449–53 (38 ref.)
Vascular structure, smooth muscle cell phenotype and growth in hypertension. Lindop GB, et al. **J Hum Hypertens** 1995 Jun;9(6):475–8 (44 ref.)
Structural changes of large conduit arteries in hypertension. Safar ME, et al. **J Hypertens** 1996 May;14(5):545–55 (67 ref.)
Vascular structure in NG-nitro-L-arginine methyl ester-induced hypertension: methodological considerations for studies of small arteries in hypertension [editorial] [see comments] Schiffrin EL. **J Hypertens** 1995 Aug; 13(8):817–21 (40 ref.) Comment in: J Hypertens 1995 Oct;13(10):1217–21.

PHYSIOPATHOLOGY

Na+, K(+)-pump activity and skeletal muscle contractile deficits in the spontaneously hypertensive rat. Carlsen RC, et al. **Acta Physiol Scand** 1996 Mar;156(3):237–45 (24 ref.)
AT1 receptors and angiotensin actions in the brain and neuronal cultures of normotensive and hypertensive rats. Raizada MK, et al. **Adv Exp Med Biol** 1995;377:331–48 (124 ref.)
The cardiac renin-angiotensin-aldosterone system and hypertensive cardiac hypertrophy. Raman VK, et al. **Am J Cardiol** 1995 Nov 2;76(13):18D–23D (44 ref.)
Disparate effects of antihypertensive drugs on large artery distensibility and compliance in hypertension. Van Bortel LM, et al. **Am J Cardiol** 1995 Nov 24;76(15):46E–49E (24 ref.)
Stratification of vascular risk in hypertension and therapeutic perspective. Simon A, et al. **Am J Hypertens** 1995 Oct;8(10 Pt 2):45S–48S (18 ref.)
Endothelins as cardiovascular peptides. Levin ER. **Am J Nephrol** 1996;16(3):246–51 (64 ref.)
Arterial compliance in hypertension and diabetes mellitus. McVeigh GE. **Am J Nephrol** 1996;16(3):217–22 (52 ref.)
Physiological characterization of the hypertensive transgenic rat TGR(mREN2)27. Lee MA, et al. **Am J Physiol** 1996 Jun;270(6 Pt 1):E919–29 (92 ref.)
Transgenic animals in the study of blood pressure regulation and hypertension. Thompson MW, et al. **Am J Physiol** 1995 Nov;269(5 Pt 1):E793–803 (101 ref.)
Impaired exercise tolerance in hypertensive patients. Lim PO, et al. **Ann Intern Med** 1996 Jan 1;124(1 Pt 1):41–55 (170 ref.)
Nitric oxide in hypertension and renal diseases. Tikkanen I, et al. **Ann Med** 1995 Jun;27(3):353–7 (48 ref.)
Alcohol, coronary disease, and hypertension. Klatsky AL. **Annu Rev Med** 1996;47:149–60 (95 ref.)
The role of hypertension in the pathogenesis of heart failure. A clinical mechanistic overview. Vasan RS, et al. **Arch Intern Med** 1996 Sep 9;156(16):1789–96 (159 ref.)
Arterial and cardiac changes in hypertension in the elderly. Asmar R, et al. **Blood Press** 1995;Suppl 3:31–7 (48 ref.)
Normotension and hypertension defined by 24-hour ambulatory blood pressure monitoring. O'Brien E, et al. **Blood Press** 1995 Sep;4(5):266–82 (133 ref.)
Evidence in vivo for induction of cardiovascular growth processes by vasoconstrictor systems. Adams MA, et al. **Blood Press Suppl** 1995;2:61–7 (64 ref.)
Arterial and cardiac changes in hypertension in the elderly. Asmar R, et al. **Blood Press Suppl** 1995;3:31–7 (48 ref.)
Pathophysiology of smooth muscle in hypertension. Lee RM, et al. **Can J Physiol Pharmacol** 1995 May;73(5):574–84 (103 ref.)
The concept of vascular overload in hypertension. Franklin SS. **Cardiol Clin** 1995 Nov;13(4):501–7 (64 ref.)
Left-ventricular diastolic function and hypertension. Graettinger WF, et al. **Cardiol Clin** 1995 Nov;13(4):559–67 (57 ref.)
Metabolic and cardiovascular characteristics of hypertension. Familial aspects. Neutel JM, et al. **Cardiol Clin** 1995 Nov; 13(4):539–47 (31 ref.)
The case for a greater blood pressure fall. Hansson L. **Clin Exp Hypertens** 1996 Apr–May;18(3–4):425–34 (19 ref.)
The evidence for a pathophysiologic significance of the sympathetic overactivity in hypertension. Julius S.

Clin Exp Hypertens 1996 Apr-May;18(3-4):305-21 (65 ref.)
Ambulatory blood pressure, blood pressure variability and antihypertensive treatment. Mancia G, et al.
Clin Exp Hypertens 1996 Apr-May;18(3-4):449-62 (22 ref.)
Role of the kidney in the genesis of hypertension: aberrant renal response to excess salt intake. Kurokawa K.
Clin Exp Pharmacol Physiol 1995 Dec;22(12):S417-22 (23 ref.)
Prostaglandins and sodium handling in Lyon hypertensive rats. Sassard J, et al. **Clin Exp Pharmacol Physiol** 1995 Dec; 22(12):S423-5 (18 ref.)
Insulin resistance, hypertension and the insulin-responsive glucose transporter, GLUT4 [editorial] Livingstone C, et al. **Clin Sci (Colch)** 1995 Aug;89(2):109-16 (61 ref.)
Analysis of heart rate and blood pressure variability in the assessment of autonomic regulation in arterial hypertension. Parati G, et al. **Clin Sci (Colch)** 1996;91 Suppl:129-32 (39 ref.)
Hypertensive heart disease and heart failure. Cody RJ.
Curr Opin Cardiol 1995 Sep;10(5):450-7 (13 ref.)
The natriuretic peptides in hypertension. Januszewicz A.
Curr Opin Cardiol 1995 Sep;10(5):495-500 (32 ref.)
Endothelin in hypertension. Schiffrin EL.
Curr Opin Cardiol 1995 Sep;10(5):485-94 (110 ref.)
Sexual dimorphism of hypertension. Chen YF.
Curr Opin Nephrol Hypertens 1996 Mar;5(2):181-5 (33 ref.)
Nitric oxide and hypertension in 1995. Dominiczak AF, et al. **Curr Opin Nephrol Hypertens** 1996 Mar;5(2):174-80 (64 ref.)
Role of the renin-angiotensin system in essential hypertension. Paran E, et al.
Curr Opin Nephrol Hypertens 1995 Jul;4(4):295-9 (65 ref.)
Natriuretic peptides and hypertension. Prins BA, et al.
Curr Opin Nephrol Hypertens 1996 Mar;5(2):170-3 (29 ref.)
Apparent mineralocorticoid excess. Funder JW.
Endocrinol Metab Clin North Am 1995 Sep;24(3):613-21 (41 ref.)
The ageing spontaneously hypertensive rat as a model of the transition from stable compensated hypertrophy to heart failure. Boluyt MO, et al. **Eur Heart J** 1995 Dec;16 Suppl N:19-30 (49 ref.)
Hypertensive heart disease: cardioreparation by reversal of interstitial collagen in patients. Motz W, et al.
Eur Heart J 1995 May;16 Suppl C:69-73 (45 ref.)
Myocardial fibrosis in hypertensive heart disease: an overview of potential regulatory mechanisms. Weber KT, et al. **Eur Heart J** 1995 May;16 Suppl C:24-8 (49 ref.)
Blood pressure regulation by the kallikrein-kinin system. Sharma JN, et al. **Gen Pharmacol** 1996 Jan;27(1):55-63 (149 ref.)
The role of the autonomic nervous system in hypertension. Amerena J, et al. **Hypertens Res** 1995 Jun;18(2):99-110 (119 ref.)
Cerebral blood flow and brain function in hypertension. Fujishima M, et al. **Hypertens Res** 1995 Jun;18(2):111-7 (23 ref.)
Altered L-DOPA systems for blood pressure regulation in the lower brainstem of spontaneously hypertensive rats. Misu Y, et al. **Hypertens Res** 1995 Dec;18(4):267-77 (77 ref.)
Mechanism of glucocorticoid-induced hypertension. Saruta T. **Hypertens Res** 1996 Mar;19(1):1-8 (11 ref.)
Endocrine and auto-paracrine factors in the pathogenesis of primary hypertension. Takeda R, et al. **Hypertens Res** 1995 Sep;18(3):171-9 (120 ref.)
Recent advances in the study of renin and angiotensinogen genes: from molecules to the whole body. Tamura K, et al. **Hypertens Res** 1995 Mar;18(1):7-18 (134 ref.)
Nitroxidergic nerves and hypertension. Toda N.
Hypertens Res 1995 Mar;18(1):19-26 (68 ref.)
Endothelium-dependent responses in hypertension. Vanhoutte PM, et al. **Hypertens Res** 1995 Jun;18(2):87-98 (122 ref.)
Diagnostic significance of dopamine estimation using plasma and urine in patients with adrenal and renal insufficiency, renal transplantation and hypertension. Yoshimura M, et al. **Hypertens Res** 1995 Jun;18 Suppl 1:S87-92 (31 ref.)
Salt sensitivity of blood pressure in humans. Weinberger MH.
Hypertension 1996 Mar;27(3 Pt 2):481-90 (104 ref.)
Protein synthesis in the heart in vivo, its measurement and patho-physiological alterations. Preedy VR, et al.
Int J Cardiol 1995 Jun 30;50(2):95-106 (48 ref.)
Are insulin resistance and/or compensatory hyperinsulinemia involved in the etiology and clinical course of patients with hypertension? Reaven GM.
Int J Obes Relat Metab Disord 1995 May;19 Suppl 1:S2-5 (49 ref.)
Sympathetic nervous system: contribution to human hypertension and related cardiovascular diseases. Esler M.
J Cardiovasc Pharmacol 1995;26 Suppl 2:S24-8 (32 ref.)
Baroreflexes and cardiovascular regulation in hypertension. Head GA. **J Cardiovasc Pharmacol** 1995;26 Suppl 2:S7-16 (86 ref.)
Regulation of blood pressure by nitroxidergic nerve. Toda N. **J Diabetes Complications** 1995 Oct-Dec;9(4):200-2 (21 ref.)
Vascular smooth muscle polyploidy in genetic hypertension: the role of angiotensin II. Devlin AM, et al.
J Hum Hypertens 1995 Jun;9(6):497-500 (16 ref.)
Role of angiotensin II in blood pressure regulation and in the pathophysiology of cardiovascular disorders. Fyhrquist F, et al. **J Hum Hypertens** 1995 Nov;9 Suppl 5:S19-24 (50 ref.)
Sick vessel syndrome: vascular changes in hypertension and atherosclerosis. Heistad DD, et al. **J Hum Hypertens** 1995 Jun;9(6):449-53 (38 ref.)
The heterogeneity of hypertension: why doesn't every patient respond to every antihypertensive drug? Sever P.
J Hum Hypertens 1995 Jul;9 Suppl 2:S33-6 (8 ref.)
The parasympathetic system and its muscarinic receptors in hypertensive disease. van Zwieten PA, et al.
J Hypertens 1995 Oct;13(10):1079-90 (79 ref.)
New insights into the role of endothelial dysfunction in hypertension [editorial] van Zwieten PA, et al.
J Hypertens 1995 Jul;13(7):713-6 (42 ref.)
The heart and vascular changes in hypertension. Leonetti G, et al. **J Hypertens Suppl** 1995 Aug;13(2):S29-34 (54 ref.)
Large artery function and alterations in hypertension. London GM. **J Hypertens Suppl** 1995 Aug;13(2):S35-8 (23 ref.)
Hypertension and coronary artery disease: cause and effect. McInnes GT. **J Hypertens Suppl** 1995 Aug;13(2):S49-56 (77 ref.)
Structural cardiovascular alterations and blood pressure variability in human hypertension. Mancia G, et al.
J Hypertens Suppl 1995 Aug;13(2):S7-14 (39 ref.)
Endothelium-derived vasoactive factors in hypertension: nitric oxide and endothelin. Nava E, et al.
J Hypertens Suppl 1995 Aug;13(2):S39-48 (97 ref.)
Prognostic significance of albuminuria for the development of nephropathy. Viberti GF. **J Hypertens Suppl** 1995 Aug; 13(2):S87-9 (15 ref.)
Insulin resistance and hyperinsulinemia in hypertension. Weidmann P, et al. **J Hypertens Suppl** 1995 Aug; 13(2):S65-72 (104 ref.)
A proposed sequence of reactions leading to collagen biosynthesis, fibrosis, and hypertension in alcoholics. Brecher AS, et al. **J Investig Med** 1996 Feb;44(2):36-41 (107 ref.)
The role of the kidney in hypertension. Cowley AW Jr, et al. **JAMA** 1996 May 22-29;275(20):1581-9 (112 ref.)
Up-regulation of intracellular signalling pathways may play a central pathogenic role in hypertension, atherogenesis, insulin resistance, and cancer promotion--the 'PKC syndrome'. McCarty MF. **Med Hypotheses** 1996 Mar; 46(3):191-221 (402 ref.)
Local renin-angiotensin systems. Danser AH.
Mol Cell Biochem 1996 Apr 12-26;157(1-2):211-6 (25 ref.)
Defective ANF-R2/ANP-C receptor-mediated signalling in hypertension. Marcil J, et al. **Mol Cell Biochem** 1995 Aug-Sep;149-150:223-31 (92 ref.)
Ambulatory blood pressure measurement and the occurrence of hypertensive organ involvement. O'Brien E, et al.
Neth J Med 1995 Oct;47(4):145-51 (60 ref.)
Arterial distensibility and compliance in hypertension. Reneman RS, et al. **Neth J Med** 1995 Oct;47(4):152-61 (30 ref.)
Cerebral blood flow in untreated and treated hypertension. Strandgaard S, et al. **Neth J Med** 1995 Oct;47(4):180-4 (32 ref.)
Malignant cerebral edema and intracranial hypertension. Bingaman WE, et al. **Neurol Clin** 1995 Aug;13(3):479-509 (175 ref.)
Renal reserve in patients with high blood pressure. Gabbai FB. **Semin Nephrol** 1995 Sep;15(5):482-7 (35 ref.)
Pseudohypertension. Zuschke CA, et al. **South Med J** 1995 Dec;88(12):1185-90 (24 ref.)
At risk nephrons and the decline in renal function in response to treatment of hypertension. Walker WG, et al.
Trans Am Clin Climatol Assoc 1995;107:134-43; discussion 143-5 (26 ref.)
[New data on mineralocorticoid hormones. Physiopathological implications (editorial)] Corvol P, et al. **Presse Med** 1995 Sep 23;24(27):1235-7 (12 ref.) (Eng. Abstr.) **(Fre)**
[Arterial hypertension and vascular resistance] Krzesinski JM, et al. **Rev Med Liege** 1995 Sep;50(9):365-72 (41 ref.) **(Fre)**
[Hypertension and pregnancy. Diagnosis, physiopathology and treatment] Fournier A, et al.
Schweiz Med Wochenschr 1995 Nov 25;125(47):2273-98 (145 ref.) (Eng. Abstr.) **(Fre)**
[Cardiac structure-function relationship and the renin-angiotensin-aldosterone system in hypertensive heart disease] Funck RC, et al. **Herz** 1995 Oct;20(5):330-9 (56 ref.) (Eng. Abstr.) **(Ger)**
[Role of the cardiac renin-angiotensin system in hypertensive heart disease] Holmer SR, et al. **Herz** 1995 Oct;20(5):322-9 (51 ref.) (Eng. Abstr.) **(Ger)**
[Coronary microangiopathy in hypertensive heart disease: pathogenesis, diagnosis and therapy] Motz W, et al.
Herz 1995 Dec;20(6):355-64 (52 ref.) (Eng. Abstr.) **(Ger)**
[Metabolic syndrome and fatal quartet] Standl E.
Internist (Berl) 1996 Jul;37(7):698-704 (36 ref.) **(Ger)**
[Sleep apnea syndrome, arterial hypertension and cardiovascular risks] Russi EW, et al.
Schweiz Med Wochenschr 1995 Nov 25;125(47):2267-72 (36 ref.) (Eng. Abstr.) **(Ger)**
[Hypertension in the elderly: definition, indications for treatment and clarification] Greminger P, et al.
Schweiz Rundsch Med Prax 1995 Oct 31;84(44):1252-5 (23 ref.) (Eng. Abstr.) **(Ger)**
[Treatment when blood pressure rises or falls in hypertension--new considerations for optimal prevention of cardiovascular damage] Zimlichman R. **Harefuah** 1996 Mar 15;130(6):404-6 (11 ref.) **(Heb)**
[The role of the sympathetic nervous system in essential arterial hypertension and organ damage] Grassi G, et al. **Ann Ital Med Int** 1995 Oct;10 Suppl:115S-120S (46 ref.) (Eng. Abstr.) **(Ita)**
[Endothelial function and arterial hypertension] Taddei S, et al. **Ann Ital Med Int** 1995 Oct;10 Suppl:85S-90S (34 ref.) (Eng. Abstr.) **(Ita)**
[Endothelial function and coronary microcirculation in arterial hypertension] Salvetti A. **Cardiologia** 1996 Apr; 41(4):319-25 (41 ref.) **(Ita)**
[The vascular changes in arterial hypertension] Ponte E, et al. **Minerva Med** 1995 Sep;86(9):357-65 (60 ref.) (Eng. Abstr.) **(Ita)**
[Diurnal blood pressure rhythm in patients with hypertension] Dąbrowska E, et al. **Pol Arch Med Wewn** 1996 Feb;95(2):147-52 (48 ref.) **(Pol)**
[Hypertension in woman. A special case?] Furtado MR, et al. **Arq Bras Cardiol** 1995 Feb;64(2):141-4 (52 ref.) **(Por)**
[The arterial pressure problem in dental practice] Abraham-Inpyain L, et al. **Stomatologiia (Mosk)** 1996; 75(1):37-9 (40 ref.) (Eng. Abstr.) **(Rus)**
[Arterial hypertension and cerebrovascular disease] Matías-Guiu J, et al. **Rev Neurol** 1995;23 Suppl 1:S50-2 (24 ref.) **(Spa)**
[Does a defective endothelial function influence blood pressure? Complex relation between endothelium and hypertension] Lind L. **Lakartidningen** 1995 Nov 15; 92(46):4321-4 (54 ref.) **(Swe)**

PREVENTION & CONTROL

Role of whole-day ambulatory blood pressure monitoring in the management of hypertension. Neutel JM.
Am J Nephrol 1996;16(3):202-9 (32 ref.)
Economics of hypertension control. World Hypertension League. **Bull World Health Organ** 1995;73(4):417-24 (43 ref.)
Women, hormones and blood pressure. Khaw KT.
Can J Cardiol 1996 Jun;12 Suppl D:9D-12D (16 ref.)
Key issues regarding lifestyle in the prevention and treatment of hypertension. Beilin LJ. **Clin Exp Hypertens** 1996 Apr-May;18(3-4):473-87 (41 ref.)
The World Hypertension League: goals and perspectives. Ganten D, et al. **Clin Exp Hypertens** 1995 Oct; 17(7):1079-89 (7 ref.)
The epidemiology of hypertension control in populations. Langer RD. **Clin Exp Hypertens** 1995 Oct;17(7):1127-44 (33 ref.)
Can we recommend fish oil for hypertension? Howe PR. **Clin Exp Pharmacol Physiol** 1995 Mar;22(3):199-203 (33 ref.)
Are angiotensin-converting enzyme inhibitors the renal protective antihypertensive drugs of choice? [editorial] Bauer JH. **Curr Opin Nephrol Hypertens** 1995 Sep; 4(5):427-31 (23 ref.)
The effects of endurance and resistance training on blood pressure. Schwartz RS, et al.
Int J Obes Relat Metab Disord 1995 Oct;19 Suppl 4:S52-7 (38 ref.)
The making of a user friendly MAOI diet. Gardner DM, et al. **J Clin Psychiatry** 1996 Mar;57(3):99-104 (53 ref.)
Dietary calcium and blood pressure: a review of the observational studies. Pryer J, et al. **J Hum Hypertens** 1995 Aug;9(8):597-604 (53 ref.)
The role of stress management in blood pressure control: why the promissory note has failed to deliver. Hunyor SN, et al. **J Hypertens** 1996 Apr;14(4):413-8 (55 ref.)
Treatment and prevention of hypertension: where have we been and where are we going? Luft FC.
Kidney Int Suppl 1995 Aug;50:S14-8 (49 ref.)
Calcium supplementation prevents pregnancy-induced hypertension by increasing the production of vascular nitric oxide. López-Jaramillo P, et al. **Med Hypotheses** 1995 Jul; 45(1):68-72 (73 ref.)
Calcium, why and how much? Palmieri GM.
Miner Electrolyte Metab 1995;21(1-3):236-41 (44 ref.)
Hypertension control. Report of a WHO Expert Committee. **World Health Organ Tech Rep Ser** 1996;862:1-83 (120 ref.)
[Hypertension and coronary heart disease. Global risk moderation through control of body weight] Suter PM, et al. **Schweiz Rundsch Med Prax** 1996 Jan 30;85(5):113-6 (18 ref.) (Eng. Abstr.) **(Ger)**
[Essential arterial hypertension: risk factors, pathogenetic mechanisms, possibilities for control] Pasquarella A, et al. **Ann Ig** 1994 Jul-Dec;6(4-6):511-7 (56 ref.) (Eng. Abstr.) **(Ita)**
[Prevention of coronary disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension] Pyörälä K, et al. **Cardiologia** 1996 Feb;41(2):149-82 (192 ref.) **(Ita)**

PSYCHOLOGY

White coat hypertension. Pickering TG.
Curr Opin Nephrol Hypertens 1996 Mar;5(2):192-8 (36 ref.)
Neuropsychological consequences of antihypertensive medication use. Muldoon MF, et al. **Exp Aging Res** 1995 Oct-Dec;21(4):353-68 (68 ref.)

HYPERTENSION

[Stress and arterial hypertension] Iakobson GS, et al. **Patol Fiziol Eksp Ter** 1996 Jan-Mar;(1):30-4 (104 ref.) **(Rus)**

RADIONUCLIDE IMAGING

[Diagnostic methods and the prognosis of the heart-hypertension interaction. Isotopes] del Río Ligorit A, et al. **Rev Esp Cardiol** 1995;48 Suppl 4:45-8 (22 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

Characteristics and treatment of hypertension in women: a review of the literature. Lewis CE. **Am J Med Sci** 1996 Apr;311(4):193-9 (89 ref.)

Graphic format for teaching long-term control of systemic arterial pressure. Faber JJ. **Am J Physiol** 1996 Jun;270(6 Pt 3):S40-9 (22 ref.)

Hypertension in the elderly: benefits of treatment. Chalmers J. **Blood Press** 1995;Suppl 3:6-10 (24 ref.)

Diabetes and hypertension: prognostic and therapeutic considerations. Gilbert RE, et al. **Blood Press** 1995 Nov; 4(6):329-38 (101 ref.)

Status of current therapies for hypertension. Hansson L. **Blood Press Suppl** 1995;2:93-8 (35 ref.)

The management of hypertension in diabetes: with special reference to diabetic kidney disease. Leese GP, et al. **Diabet Med** 1996 May;13(5):401-10 (145 ref.)

Care of the patient with severe pregnancy induced hypertension. Walker JJ. **Eur J Obstet Gynecol Reprod Biol** 1996 Mar;65(1):127-35 (34 ref.)

Attenuation of hypertension by insulin-sensitizing agents. Kotchen TA. **Hypertension** 1996 Aug;28(2):219-23 (79 ref.)

Does exercise training play a role in the treatment of essential hypertension? Hagberg JM, et al. **J Cardiovasc Risk** 1995 Aug;2(4):296-302 (40 ref.)

Current issues in the control of hypertension. Lund-Johansen P. **J Hum Hypertens** 1995 Nov;9 Suppl 5:S25-8 (31 ref.)

Might non-pharmacological treatment disadvantage patients with hypertension? Ramsay LE, et al. **J Hum Hypertens** 1995 Aug;9(8):653-7 (30 ref.)

Treatment of hypertension in the elderly. Lever AF, et al. **J Hypertens** 1995 Jun;13(6):571-9 (44 ref.)

Treatment and prevention of hypertension: where have we been and where are we going? Luft FC. **Kidney Int Suppl** 1995 Aug;50:S14-8 (49 ref.)

Effectiveness versus efficacy of treatment of hypertension for stroke prevention. Whisnant JP. **Neurology** 1996 Feb; 46(2):301-7 (22 ref.)

Does counselling for angina and hypertension work? Browne D. **Practitioner** 1995 Nov;239(1556):679-81 (13 ref.)

Hypertension: targets for treatment. MacLeod M, et al. **Practitioner** 1995 Nov;239(1556):670-3 (6 ref.)

[Indications for pregnancy termination in cases of pre-eclampsia, hypertension, intrauterine growth retardation, liver and heart disease] Uzan S, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24 Suppl 1:33-40 (54 ref.) **(Fre)**

[Non-medicamentous therapy of metabolic syndrome] Reimers CD, et al. **Internist (Berl)** 1996 Jul;37(7):712-21 (70 ref.) **(Ger)**

[Treatment when blood pressure rises or falls in hypertension--new considerations for optimal prevention of cardiovascular damage] Zimlichman R. **Harefuah** 1996 Mar 15;130(6):404-6 (11 ref.) **(Heb)**

[Anti-hypertensive therapy in chronic hemodialysis] Takabatake T. **Nippon Naika Gakkai Zasshi** 1995 Oct 10; 84(10):1643-7 (5 ref.) **(Jpn)**

[Effects of aerobic physical conditioning on blood pressure control] Waib PH, et al. **Arq Bras Cardiol** 1995 Mar; 64(3):243-6 (80 ref.) **(Por)**

ULTRASONOGRAPHY

[Diagnostic methods and the prognosis of the heart-hypertension interaction: cardiac echo-Doppler] Sánchez Domínguez J. **Rev Esp Cardiol** 1995;48 Suppl 4:49-56 (32 ref.) (Eng. Abstr.) **(Spa)**

URINE

Microalbuminuria: prognostic and therapeutic implications in diabetic and hypertensive pregnancy. Bar J, et al. **Diabet Med** 1995 Aug;12(8):649-56 (110 ref.)

HYPERTENSION-EDEMA-PROTEINURIA GESTOSIS see **GESTOSIS, EPH**

HYPERTENSION, GOLDBLATT see **HYPERTENSION, RENOVASCULAR**

HYPERTENSION, MALIGNANT

COMPLICATIONS

Apparent mineralocorticoid excess due to 11 beta-hydroxysteroid dehydrogenase deficiency: a possible cause of intrauterine growth retardation. Kitanaka S, et al. **Clin Endocrinol (Oxf)** 1996 Mar;44(3):353-9 (33 ref.)

DRUG THERAPY

Hypertensive crises. The need for urgent management [see comments] Varon J, et al. **Postgrad Med** 1996 Jan; 99(1):189-91, 195-6, 199-200, passim (21 ref.) Comment in: Postgrad Med 1996 Mar;99(3):70-1.

PHYSIOPATHOLOGY

[Emergency situations in hypertension] Nagy V, et al. **Orv Hetil** 1996 Apr 28;137(17):913-21 (55 ref.) (Eng. Abstr.) **(Hun)**

HYPERTENSION, PORTAL

see related
PORTASYSTEMIC SHUNT, SURGICAL

[Idiopathic portal hypertension] Kojima K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):225-7 (6 ref.) **(Jpn)**

[Prehepatic portal hypertensive syndrome] Kuroda H, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):191-4 (18 ref.) **(Jpn)**

[Circulatory disturbance of the portal system--portal hypertension] Nonami T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):221-4 (6 ref.) **(Jpn)**

COMPLICATIONS

Pulmonary hypertension in chronic liver disease. Mandell MS, et al. **Clin Chest Med** 1996 Mar;17(1):17-33 (137 ref.)

Classification of gastric lesions associated with portal hypertension. Hashizume M, et al. **J Gastroenterol Hepatol** 1995 May-Jun;10(3):339-43 (20 ref.)

Management of portal hypertension and its complications. Jaffe DL, et al. **Med Clin North Am** 1996 Sep;80(5):1021-34 (82 ref.)

Portal hypertensive hemorrhage: pathogenesis and risk factors. Boyer TD. **Semin Gastrointest Dis** 1995 Jul; 6(3):125-33 (75 ref.)

[Pulmonary disorders in portal hypertension. Pulmonary hypertension and hepatopulmonary syndrome] Wettstein M, et al. **Dtsch Med Wochenschr** 1996 Apr 12; 121(15):487-91 (47 ref.) **(Ger)**

[Portal hypertension-induced stomach disease] Hermann R, et al. **Schweiz Med Wochenschr** 1996 Jun 15; 126(24):1066-73 (46 ref.) (Eng. Abstr.) **(Ger)**

[Endoscopic sclerotherapy of esophageal and gastric varicose veins in liver cirrhosis with portal hypertension] Bulanov KI, et al. **Klin Khir** 1995;(4):38-40 (49 ref.) **(Rus)**

[The gastropathy of portal hypertension] Piqué JM. **Med Clin (Barc)** 1995 Oct 14;105(12):470-5 (57 ref.) **(Spa)**

DIAGNOSIS

Portal hypertension: diagnosis and treatment. Pagliaro L, et al. **J Hepatol** 1995;23 Suppl 1:36-44 (55 ref.)

Management of portal hypertension and its complications. Jaffe DL, et al. **Med Clin North Am** 1996 Sep;80(5):1021-34 (82 ref.)

[Diagnosis in portal hypertension] Gerbes AL, et al. **Dtsch Med Wochenschr** 1996 Feb 16;121(7):210-6 (64 ref.) **(Ger)**

DRUG THERAPY

Pharmacological therapy for portal hypertension: rationale and results. Burroughs AK, et al. **Semin Gastrointest Dis** 1995 Jul;6(3):148-64 (148 ref.)

ETIOLOGY

Rapidly progressive portal hypertension 23 years after post-traumatic arterioportal fistula of the liver. Kayser S, et al. **Am J Gastroenterol** 1996 Jul;91(7):1442-6 (30 ref.)

[Intrahepatic portal hypertensive syndrome] Harada A, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):202-6 (20 ref.) **(Jpn)**

[Disorders of portal circulation] Kawai Y, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):235-8 (26 ref.) **(Jpn)**

PATHOLOGY

Hepatoportal sclerosis. Bioulac-Sage P, et al. **Semin Liver Dis** 1995 Nov;15(4):329-39 (32 ref.)

[Portal hypertensive gastropathy] Brinch K, et al. **Ugeskr Laeger** 1995 Nov 13;157(46):6421-5 (31 ref.) (Eng. Abstr.) **(Dan)**

[A case of primary biliary cirrhosis presenting histopathological similarity to idiopathic portal hypertension with huge splenomegaly] Kasuga Y, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Oct;92(10):1776-81 (18 ref.) **(Jpn)**

[Cavernous transformation of the portal vein] Ukita M, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):228-30 (18 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Gastrointestinal dysfunction in liver disease and portal hypertension. Gut-liver interactions revisited [editorial] Quigley EM. **Dig Dis Sci** 1996 Mar;41(3):557-61 (48 ref.)

The role of nitric oxide in the hyperdynamic circulatory syndrome associated with portal hypertension. Sogni P, et al. **J Hepatol** 1995 Aug;23(2):218-24 (78 ref.)

The role of vasoactive mediators in portal hypertension. García-Pagán JC, et al. **Semin Gastrointest Dis** 1995 Jul; 6(3):140-7 (70 ref.)

Systemic hemodynamic changes in portal hypertension. Ready J, et al. **Semin Gastrointest Dis** 1995 Jul;6(3):134-9 (58 ref.)

PREVENTION & CONTROL

[Hemorrhage caused by rupture of gastroesophageal varices: should we dilate the liver or strangulate the varices? (editorial)- Calès P. **Gastroenterol Clin Biol** 1995 Nov; 19(11):899-902 (34 ref.) **(Fre)**

SURGERY

Portal hypertension. Rhee P, et al. **Curr Opin Gen Surg** 1993; :249-56 (36 ref.)

Transjugular intrahepatic portosystemic shunt: a medical perspective. Sanyal AJ, et al. **Dig Dis** 1995 May-Jun; 13(3):153-62 (47 ref.)

The role of transjugular intrahepatic portosystemic shunt for treatment of portal hypertension and its complications: a conference sponsored by the National Digestive Diseases Advisory Board. Shiffman ML, et al. **Hepatology** 1995 Nov; 22(5):1591-7 (78 ref.)

Hemodynamic consequences of therapeutic portosystemic shunting: recent experience with transjugular intrahepatic portosystemic shunts. Somberg KA. **Semin Gastrointest Dis** 1995 Jul;6(3):165-77 (58 ref.)

[Recurrent bleeding from colonic varices in portal hypertension. The successful prevention of recurrence by the implantation of a transjugular intrahepatic stent-shunt (TIPS)] Allgaier HP, et al. **Dtsch Med Wochenschr** 1995 Dec 22;120(51-52):1773-6 (29 ref.) (Eng. Abstr.) **(Ger)**

[Portal hypertension and splenic circulation] Romero Torres R. **Rev Gastroenterol Peru** 1995;15 Suppl 1:S110-7 (31 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

Portal hypertension: diagnosis and treatment. Pagliaro L, et al. **J Hepatol** 1995;23 Suppl 1:36-44 (55 ref.)

[Emergency medical treatment of portal hypertension] Heresbach D, et al. **Presse Med** 1995 Sep 30;24(28):1311-4 (26 ref.) (Eng. Abstr.) **(Fre)**

[Treatment of portal hypertension] Sauerbruch T, et al. **Med Klin** 1995 Sep 15;90(9):532-40 (86 ref.) **(Ger)**

ULTRASONOGRAPHY

Ultrasound and duplex-Doppler in the diagnosis and follow-up of portal hypertension. Michielsen PP, et al. **Acta Gastroenterol Belg** 1995 Sep-Dec;58(5-6):409-21 (28 ref.)

Portal hypertension: review of data and influence on management. Caletti GC, et al. **Gastrointest Endosc Clin N Am** 1995 Jul;5(3):655-65 (29 ref.)

HYPERTENSION, PULMONARY

see related
PULMONARY HEART DISEASE

[New etiopathogenic, diagnostic and therapeutic aspects in primary pulmonary hypertension] Fernández A, et al. **An Med Interna** 1995 Jun;12(6):294-8 (67 ref.) (Eng. Abstr.) **(Spa)**

CHEMICALLY INDUCED

[Iatrogenic pulmonary artery hypertension] Weitzenblum E, et al. **Rev Mal Respir** 1996;13(2):133-9 (32 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

Primary pulmonary hypertension and the human immunodeficiency virus. Report of two cases and a review of the literature. Weiss JR, et al. **Arch Intern Med** 1995 Nov 27;155(21):2350-4 (26 ref.)

CONGENITAL

[The immediate response to the administration of inhaled nitric oxide in a newborn infant with congenital diaphragmatic hernia and pulmonary hypertension] Figueras Aloy J, et al. **An Esp Pediatr** 1996 Jan;44(1):70-2 (24 ref.) **(Spa)**

DIAGNOSIS

MR imaging of pulmonary hypertension and right ventricular dysfunction. Boxt LM. **Magn Reson Imaging Clin N Am** 1996 May;4(2):307-25 (94 ref.)

DRUG THERAPY

Clinical applications of inhaled nitric oxide in children with pulmonary hypertension. Wessel DL, et al. **Adv Pharmacol** 1995;34:475-504 (136 ref.)

Treatment of pulmonary hypertension in patients with chronic obstructive pulmonary disease: position of vasodilators with special focus on urapidil. Adnot S, et al. **Blood Press** 1995;Suppl 3:47-57 (43 ref.)

Medical treatment of pulmonary hypertension. McGoon MD.

Cardiologia 1995 Aug;40(8):561–77 (128 ref.)
The role of nitric oxide in the treatment of neonatal pulmonary hypertension. Mariani G, et al. **Curr Opin Pediatr** 1996 Apr;8(2):118–25 (80 ref.)
Prostacyclin in primary pulmonary hypertension. Magnani B, et al. **Eur Heart J** 1996 Jan;17(1):18–24 (36 ref.)
Calcium blockage in pulmonary hypertension and hypoxic vasoconstriction. Neely CF, et al. **New Horiz** 1996 Feb; 4(1):99–106 (74 ref.)
[The usefulness of inhaled nitric oxide in the treatment of pulmonary hypertension in the postoperative period of cardiac surgery in infancy] de Lucas García N, et al. **An Esp Pediatr** 1996 Apr;44(4):373–6 (27 ref.) **(Spa)**
[The immediate response to the administration of inhaled nitric oxide in a newborn infant with congenital diaphragmatic hernia and pulmonary hypertension] Figueras Aloy J, et al. **An Esp Pediatr** 1996 Jan;44(1):70–2 (24 ref.) **(Spa)**

ETIOLOGY

Pulmonary vascular aspects of systemic sclerosis [editorial] Wallman LL, et al. **Aust N Z J Med** 1996 Apr;26(2):150–3 (20 ref.)
Pulmonary hypertension in chronic liver disease. Mandell MS, et al. **Clin Chest Med** 1996 Mar;17(1):17–33 (137 ref.)
Structural and pathologic changes in the lung vasculature in chronic liver disease. Schraufnagel DE, et al. **Clin Chest Med** 1996 Mar;17(1):1–15 (94 ref.)
Cellular and molecular mechanisms in the pathogenesis of severe pulmonary hypertension. Voelkel NF, et al. **Eur Respir J** 1995 Dec;8(12):2129–38 (77 ref.)
Pulmonary hypertension: considerations in the liver transplant candidate. Kuo P. **Transpl Int** 1996;9(2):141–50 (55 ref.)
[Pulmonary disorders in portal hypertension. Pulmonary hypertension and hepatopulmonary syndrome] Wettstein M, et al. **Dtsch Med Wochenschr** 1996 Apr 12; 121(15):487–91 (47 ref.) **(Ger)**
[Kartagener syndrome and hemangiomatous proliferation of lung capillaries: case report and literature review] Słodkowska J, et al. **Pneumonol Alergol Pol** 1996; 64(3–4):217–24 (24 ref.) (Eng. Abstr.) **(Pol)**
[Pathogenic mechanisms and natural history of pulmonary hypertension in chronic obstructive pulmonary disease] Tobiasz M. **Pol Arch Med Wewn** 1995 Jun;93(6):509–14 (56 ref.) **(Pol)**

METABOLISM

Elastin in systemic and pulmonary hypertension. Keeley FW, et al. **Ciba Found Symp** 1995;192:259–73; discussion 273–8 (65 ref.)
Alterations in extracellular matrix protein expression in neonatal pulmonary hypertension: implications for vascular function. Durmowicz AG, et al. **J Perinatol** 1996 Mar–Apr; 16(2 Pt 2 Su):S11–8 (39 ref.)

PATHOLOGY

[A case of oxalosis with heart and lung involvement] Magnani G, et al. **Cardiologia** 1992 Jul;37(7):507–11 (10 ref.) (Eng. Abstr.) **(Ita)**

PHYSIOPATHOLOGY

The role of thrombosis in severe pulmonary hypertension. Chaouat A, et al. **Eur Respir J** 1996 Feb;9(2):356–63 (86 ref.)
Development of the normal and hypertensive pulmonary vasculature. Haworth SG. **Exp Physiol** 1995 Sep; 80(5):843–53 (19 ref.)
Calcium blockage in pulmonary hypertension and hypoxic vasoconstriction. Neely CF, et al. **New Horiz** 1996 Feb; 4(1):99–106 (74 ref.)

SURGERY

[Chronic thromboembolic pulmonary hypertension: a surgical syndrome? (editorial)] Visioli O, et al. **G Ital Cardiol** 1995 Aug;25(8):1077–82 (37 ref.) **(Ita)**
[Lung transplantation in primary pulmonary hypertension (editorial)] Román A. **Arch Bronconeumol** 1996 May; 32(5):213–5 (22 ref.) **(Spa)**

THERAPY

Advanced ventilation in the neonate. Antunes MJ, et al. **Nurs Clin North Am** 1996 Jun;31(2):405–22 (123 ref.)
[Oxygen therapy and pulmonary hypertension in chronic obstructive bronchopneumopathies] Gensini G, et al. **Recenti Prog Med** 1996 Feb;87(2):81–5 (31 ref.) (Eng. Abstr.) **(Ita)**

HYPERTENSION, PULMONARY, OF NEWBORN, PERSISTENT see **PERSISTENT FETAL CIRCULATION SYNDROME**

HYPERTENSION, RENAL

COMPLICATIONS

Microalbuminuria as a marker of cardiovascular and renal disease in essential hypertension. Bigazzi R, et al. **Nephrol Dial Transplant** 1995;10 Suppl 6:10–4 (58 ref.)
[Eye fundus of the diabetic patient with nephropathy and hypertensive retinopathy. Macroangiopathic complications] Leys AM. **Bull Soc Belge Ophtalmol** 1995; 256:49–59 (29 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

Calcium antagonists and the kidney. Pearce CJ, et al. **New Horiz** 1996 Feb;4(1):123–8 (47 ref.)
[Antihypertensive therapy in renal failure] Mayer G. **Acta Med Austriaca** 1995;22(3):51–3 (19 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Post-transplant hypertension and chronic renal allograft failure. Paul LC, et al. **Kidney Int Suppl** 1995 Dec;52:S34–7 (25 ref.)
11 beta-hydroxysteroid dehydrogenase—why is it important for the nephrologist? [editorial] Escher G, et al. **Nephrol Dial Transplant** 1995;10(9):1506–9 (38 ref.)
Essential hypertension: a renal perspective [editorial] Woo KT. **Singapore Med J** 1995 Jun;36(3):252–4 (14 ref.)

PHYSIOPATHOLOGY

Renal Parenchymal Hypertension: current concepts of pathogenesis and management. Preston RA, et al. **Arch Intern Med** 1996 Mar 25;156(6):602–11 (116 ref.)

PREVENTION & CONTROL

Calcium channel blockers and renal dysfunction in arterial hypertension. Díez J. **Nephrol Dial Transplant** 1995;10 Suppl 6:22–6 (50 ref.)

SURGERY

[Laparoscopic nephrectomy in a patient with a parenchymatous form of nephrogenic hypertension] Troitskiĭ OA, et al. **Urol Nefrol (Mosk)** 1996 Mar–Apr; (2):8–11 (9 ref.) (Eng. Abstr.) **(Rus)**

THERAPY

Renal Parenchymal Hypertension: current concepts of pathogenesis and management. Preston RA, et al. **Arch Intern Med** 1996 Mar 25;156(6):602–11 (116 ref.)

HYPERTENSION, RENOVASCULAR

Pediatric renovascular hypertension. Wells TG, et al. **Curr Opin Pediatr** 1996 Apr;8(2):128–34 (59 ref.)
[Intraglomerular hypertension. Physiopathology and therapeutic implications] Mourad G. **Presse Med** 1996 Jun 1;25(19):900–6 (37 ref.) (Eng. Abstr.) **(Fre)**
[Physiopathology and clinical aspects of renovascular hypertension] Botta GC, et al. **G Chir** 1996 Mar;17(3):132–6 (10 ref.) **(Ita)**
[Renovascular arterial hypertension. From physiopathology to therapy] Cunha Telles E, et al. **Rev Port Cardiol** 1996 Jan;15(1):59–69 (32 ref.) (Eng. Abstr.) **(Por)**

DIAGNOSIS

Diagnostic imaging evaluation of renovascular hypertension. King BF Jr. **Abdom Imaging** 1995 Sep–Oct;20(5):395–405 (45 ref.)
Renovascular hypertension. Mitty HA, et al. **Radiol Clin North Am** 1996 Sep;34(5):1017–36 (49 ref.)

DRUG THERAPY

Blood pressure-lowering effect of adding grapefruit juice to nifedipine and terazosin in a patient with severe renovascular hypertension. Pisarik P. **Arch Fam Med** 1996 Jul–Aug;5(7):413–6 (17 ref.)

ETIOLOGY

Renal neural mechanisms in salt-sensitive hypertension. DiBona GF. **Blood Press Suppl** 1995;2:81–7 (61 ref.)
[Renovascular hypertension and hydronephrosis due to a renal artery aneurysm] Hering M, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Feb;164(2):176–8 (12 ref.) **(Ger)**
[Renovascular hypertension] Greminger P. **Schweiz Med Wochenschr** 1996 Jul 27;126(30):1314–20 (45 ref.) (Eng. Abstr.) **(Ger)**

METABOLISM

Enhancement of intrarenal angiotensin II levels in 2 kidney 1 clip and angiotensin II induced hypertension. Navar LG, et al. **Blood Press Suppl** 1995;2:88–92 (23 ref.)

PHYSIOPATHOLOGY

Pre-glomerular structural changes in the renal vasculature in hypertension. Anderson WP, et al. **Blood Press Suppl** 1995;2:74–80 (56 ref.)
Renal neural mechanisms in salt-sensitive hypertension. DiBona GF. **Blood Press Suppl** 1995;2:81–7 (61 ref.)

RADIONUCLIDE IMAGING

Radionuclide techniques for the evaluation of renal function: advantages over conventional methodology. Bubeck B. **Curr Opin Nephrol Hypertens** 1995 Nov;4(6):514–9 (15 ref.)

SURGERY

Ischemic nephropathy as an indication for renal artery reconstruction in renovascular hypertension. Newman VS, et al. **Curr Opin Gen Surg** 1994;:272–6 (30 ref.)

THERAPY

[Preservation of renal function by revascularization in renovascular disease] Halimi JM, et al. **J Mal Vasc** 1995; 20(4):241–6 (55 ref.) (Eng. Abstr.) **(Fre)**

ULTRASONOGRAPHY

[Renovascular hypertension due to unilateral renal artery stenosis with hypokalemic alkalosis, the salt-losing syndrome and reversible hyperechogenicity of the contralateral kidney. A study of 2 infants] Castelló Girona F, et al. **An Esp Pediatr** 1996 Jul;45(1):49–52 (14 ref.) (Eng. Abstr.) **(Spa)**

HYPERTHERMIA see **FEVER**

HYPERTHERMIA, INDUCED

Thermoradiotherapy for brain tumors. Three cases of recurrent malignant astrocytoma and review of clinical experience. Seegenschmiedt MH, et al. **Am J Clin Oncol** 1995 Dec;18(6):510–8 (53 ref.)
Whole body hyperthermia as a potential therapeutic option. Shecterle LM, et al. **Cancer Biother** 1995 Winter; 10(4):253–6 (31 ref.)
Hyperthermia: an update [editorial] Vernon CC. **Clin Oncol (R Coll Radiol)** 1995;7(6):345–6 (11 ref.)
Radiotherapy and hyperthermia. González González D, et al. **Eur J Cancer** 1995 Jul–Aug;31A(7–8):1351–5 (27 ref.)
Accumulation of purine catabolites in solid tumors exposed to therapeutic hyperthermia. Busse M, et al. **Experientia** 1996 May 15;52(5):469–73 (26 ref.)
Heat shock proteins, thermotolerance, and their relevance to clinical hyperthermia. Li GC, et al. **Int J Hyperthermia** 1995 Jul–Aug;11(4):459–88 (134 ref.)
Two approaches for enhancing radioimmunotherapy: alpha emitters and hyperthermia. Zalutsky MR, et al. **Recent Results Cancer Res** 1996;141:101–22 (41 ref.)
Hyperthermia—its actual role in radiation oncology. Part IV: Thermo-radiotherapy for malignant brain tumors. Seegenschmiedt MH, et al. **Strahlenther Onkol** 1995 Oct; 171(10):560–72 (115 ref.)
[Clinical studies on combination of ifosfamide, carboplatin and etoposide (ICE) with whole body hyperthermia] Wiedemann GJ, et al. **Med Klin** 1996 May 15;91(5):279–83 (59 ref.) **(Ger)**
[Prophylaxis and treatment of peritoneal metastasis from gastric cancer] Kaibara N. **Nippon Geka Gakkai Zasshi** 1996 Apr;97(4):308–11 (10 ref.) (Eng. Abstr.) **(Jpn)**
[Current and prospective uses of hyperthermia in medicine] Kurpeshev OK. **Klin Med (Mosk)** 1996;74(1):14–6 (61 ref.) **(Rus)**

INSTRUMENTATION

Field analysis of a tape helix with embedded bio-media for microwave hyperthermia. Pathak SK, et al. **J Med Eng Technol** 1996 Jan–Feb;20(1):24–33 (23 ref.)
[Transurethral radiofrequency thermotherapy using the Thermex unit in benign prostatic hyperplasia] Dolgopiatov DG, et al. **Urol Nefrol (Mosk)** 1995 Nov–Dec;(6):48–50 (38 ref.) **(Rus)**

METHODS

[Immediate intraperitoneal chemotherapy after surgery for the reduction of peritoneal malignancies: for what purpose and for whom? (editorial)] Elias D. **Ann Chir** 1995; 49(7):567–72 (34 ref.) (Eng. Abstr.) **(Fre)**
[Hyperthermia: principles, techniques. Current role in the treatment of cancer] Dubois JB. **Bull Cancer Radiother** 1995;82(2):207–24 (91 ref.) **(Fre)**
[Non-surgical instrumental treatment of benign hypertrophy of the prostate] Anidjar M, et al. **Presse Med** 1995 Oct 28;24(32):1477–80 (9 ref.) (Eng. Abstr.) **(Fre)**
[Minimal invasive therapy of benign prostatic hyperplasia] Madersbacher S, et al. **Wien Med Wochenschr** 1996; 146(8):169–75 (31 ref.) (Eng. Abstr.) **(Ger)**

HYPERTHERMIA, LOCAL see **HYPERTHERMIA, INDUCED**

HYPERTHERMIA, MALIGNANT see **MALIGNANT HYPERTHERMIA**

HYPERTHERMIA, THERAPEUTIC see **HYPERTHERMIA, INDUCED**

HYPERTHYROIDISM

see related
ANTITHYROID AGENTS

BLOOD

[Secretion of thyrotropin during states of wakefulness and sleep. Physiological data and clinical applications] Goichot B, et al. **Presse Med** 1996 Jun 15;25(21):980–4 (25 ref.) (Eng. Abstr.) **(Fre)**

HYPERTHYROIDISM

CHEMICALLY INDUCED

Effects of iodine on thyroid function. Braverman LE, et al. **Acta Med Austriaca** 1996;23(1-2):4-9 (71 ref.)

[Effects of amiodarone on thyroid function] Caron P. **Presse Med** 1995 Dec 2;24(37):1747-51 (25 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

[Heart and thyroid] Klein M, et al. **Ann Endocrinol (Paris)** 1995;56(5):473-86 (176 ref.) (Eng. Abstr.) **(Fre)**

CONGENITAL

Compound W: a potential marker in maternal serum for assessing fetal thyroid function. Wu SY, et al. **Compr Ther** 1995 Oct;21(10):594-6 (17 ref.)

DIAGNOSIS

Thyrotropin-secreting pituitary tumors in hyper- and hypothyroidism. Beck-Peccoz P, et al. **Acta Med Austriaca** 1996;23(1-2):41-6 (45 ref.)

The ABCs of managing hyperthyroidism in the older patient. Kennedy JW, et al. **Geriatrics** 1996 May;51(5):22-4,27,31-2 (20 ref.)

DRUG THERAPY

[Treatment of hyperthyroidism with antithyroid drugs] Eber O. **Acta Med Austriaca** 1995;22(5):83-90 (21 ref.) (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

[Post-partum dysthyroidism. Prospective study in a French region (1986-1988)] Mesrine S, et al. **Ann Endocrinol (Paris)** 1995;56(6):579-84 (38 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Hyperthyroidism in haemodialysis patients: report on a case and review of the literature. Koutsikos D, et al. **Nephrol Dial Transplant** 1995;10(9):1765-7 (18 ref.)

GENETICS

Activating mutations of the TSH receptor gene cause thyroid diseases. Vassart G, et al. **Ann Endocrinol (Paris)** 1996; 57(1):50-4 (31 ref.)

METABOLISM

Thyroid status and exercise tolerance. Cardiovascular and metabolic considerations. McAllister RM, et al. **Sports Med** 1995 Sep;20(3):189-98 (64 ref.)

SURGERY

[Thyroid carcinoma in hyperthyroid syndromes] Ragni F, et al. **G Chir** 1996 Apr;17(4):158-65 (26 ref.) (Eng. Abstr.) **(Ita)**

THERAPY

Consensus statement for good practice and audit measures in the management of hypothyroidism and hyperthyroidism. The Research Unit of the Royal College of Physicians of London, the Endocrinology and Diabetes Committee of the Royal College of Physicians of London, and the Society for Endocrinology. Vanderpump MP, et al. **BMJ** 1996 Aug 31;313(7056):539-44 (29 ref.)

The ABCs of managing hyperthyroidism in the older patient. Kennedy JW, et al. **Geriatrics** 1996 May;51(5):22-4,27,31-2 (20 ref.)

Clinical review 80: Management of hyperthyroidism and hypothyroidism in the pregnant woman. Roti E, et al. **J Clin Endocrinol Metab** 1996 May;81(5):1679-82 (15 ref.)

HYPERTHYROXINEMIA

DIAGNOSIS

[Hyperthyroxinemia in nonsuppressed TSH. Its differential diagnosis and therapy] Feldkamp J, et al. **Dtsch Med Wochenschr** 1995 Sep 29;120(39):1323-6 (15 ref.) **(Ger)**

HYPERTONIC SALINE SOLUTION see **SALINE SOLUTION, HYPERTONIC**

HYPERTONIC SOLUTION, SALINE see **SALINE SOLUTION, HYPERTONIC**

HYPERTRICHOSIS

see related
HIRSUTISM

ETIOLOGY

A peptide hormone causing abnormal hair-growth associated with malignancy. Pilszek FH. **Med Hypotheses** 1995 Sep; 45(3):223-4 (6 ref.)

HYPERTRIGLYCERIDEMIA

BLOOD

Postprandial state and atherosclerosis. Ebenbichler CF, et al. **Curr Opin Lipidol** 1995 Oct;6(5):286-90 (37 ref.)

COMPLICATIONS

[Dyslipidemia, lipid lowering drugs and thrombosis] Ambrosi P, et al. **Arch Mal Coeur Vaiss** 1995 Nov;88(11):1641-5 (31 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

[Hypertriglyceridemia] Föger B, et al. **Wien Med Wochenschr** 1994;144(12-13):308-11 (17 ref.) (Eng. Abstr.) **(Ger)**

HYPERTRIGLYCERIDEMIA, FAMILIAL see **HYPERLIPOPROTEINEMIA TYPE IV**

HYPERTROPHY

PHYSIOPATHOLOGY

[Comparative study of most recent surgical techniques for the treatment of the hypertrophy of inferior turbinates] Passali D, et al. **Acta Otorhinolaryngol Ital** 1995 Jun; 15(3):219-28 (78 ref.) (Eng. Abstr.) **(Ita)**

SURGERY

[Comparative study of most recent surgical techniques for the treatment of the hypertrophy of inferior turbinates] Passali D, et al. **Acta Otorhinolaryngol Ital** 1995 Jun; 15(3):219-28 (78 ref.) (Eng. Abstr.) **(Ita)**

HYPERTROPHY, LEFT VENTRICULAR

Cardiac hypertrophy and hypertension. Dunn FG. **Blood Press Suppl** 1995;2:17-21 (23 ref.)

Effect of angiotensin II blockade on cardiac hypertrophy and remodelling: a review. Dahlöf B. **J Hum Hypertens** 1995 Nov;9 Suppl 5:S37-44 (84 ref.)

COMPLICATIONS

Cardiovascular hypertrophy and hypertension: causes and consequences. Korner PI. **Blood Press Suppl** 1995;2:6-16 (94 ref.)

Left atrial enlargement in healthy obese: prevalence and relation to left ventricular mass and diastolic function. Sasson Z, et al. **Can J Cardiol** 1996 Mar;12(3):257-63 (39 ref.)

Left ventricular hypertrophy and diastolic dysfunction: their relation to coronary heart disease. Störk T, et al. **Cardiovasc Drugs Ther** 1995 Aug;9 Suppl 3:533-7 (33 ref.)

Salt and left ventricular hypertrophy: what are the links? Langenfeld MR, et al. **J Hum Hypertens** 1995 Nov; 9(11):909-16 (78 ref.)

Haemodynamic basis for the development of left ventricular failure in systolic hypertension and for its logical therapy [editorial] Westerhof N, et al. **J Hypertens** 1995 Sep; 13(9):943-52 (55 ref.)

[Left-ventricular hypertrophy as a cardiac risk factor: role of the renin-angiotensin-aldosterone system] Erne P. **Schweiz Rundsch Med Prax** 1996 Feb 20;85(8):227-33 (34 ref.) (Eng. Abstr.) **(Ger)**

[Arterial hypertension, left ventricular hypertrophy and cardiovascular risk (editorial)] Nogueira JB. **Acta Med Port** 1995 Dec;8(12):663-6 (30 ref.) **(Por)**

DIAGNOSIS

Serum insulin, IGF-I,IGF-II and growth hormone, and left ventricular mass in noninsulin-dependent mellitus. Rabkin SW, et al. **Can J Cardiol** 1996 Mar;12(3):264-70 (52 ref.)

DRUG THERAPY

Response of hypertensive left ventricular hypertrophy and coronary microvascular disease to calcium antagonists. Vogt M, et al. **Am J Cardiol** 1995 Nov 2;76(13):24D-30D (52 ref.)

Treatment of renal anemia by erythropoietin substitution. The effects on the cardiovascular system. Radermacher J, et al. **Clin Nephrol** 1995 Nov;44 Suppl 1:S56-60 (51 ref.)

Risk and management of hypertension-related left ventricular hypertrophy. Teo KK. **Drugs** 1995 Dec;50(6):959-70 (80 ref.)

Reversibility of left ventricular hypertrophy by antihypertensive drugs. Fagard RH. **Neth J Med** 1995 Oct; 47(4):173-9 (47 ref.)

[Angiotensin II receptor antagonists. Clinical relevance] Scholze J. **Internist (Berl)** 1996 Jun;37(6):636-42 (47 ref.) **(Ger)**

[The effect of angiotensin-converting enzyme inhibitors on left ventricular hypertrophy in patients with arterial hypertension] Diadyk AI, et al. **Ter Arkh** 1995;67(8):65-8 (88 ref.) **(Rus)**

ETIOLOGY

Evidence favoring the hypothesis that ventricular arrhythmias have prognostic significance in left ventricular hypertrophy secondary to systemic hypertension. Almendral J, et al. **Am J Cardiol** 1995 Nov 2; 76(13):60D-63D (27 ref.)

Cardiac arrhythmias and left ventricular hypertrophy in systemic hypertension and their influences on prognosis. Bayés-Genis A, et al. **Am J Cardiol** 1995 Nov 2; 76(13):54D-59D (53 ref.)

Salt intake as a determinant of cardiac hypertrophy. Beil AH, et al. **Blood Press Suppl** 1995;2:30-4 (47 ref.)

Hypertension and left-ventricular hypertrophy. Messerli FH, et al. **Cardiol Clin** 1995 Nov;13(4):549-57 (97 ref.)

Left ventricular remodelling after acute myocardial infarction--solved and unsolved issues. Bassand JP. **Eur Heart J** 1995 Aug;16 Suppl I:58-63 (53 ref.)

The relationship of left ventricular geometry and hypertrophy to left ventricular function in valvular heart disease. Carabello BA. **J Heart Valve Dis** 1995 Oct;4 Suppl 2:S132-8; discussion S138-9 (39 ref.)

[Left ventricular hypertrophy in patients with arterial hypertension] Diadyk AI, et al. **Lik Sprava** 1995 Jul-Aug; (7-8):68-73 (52 ref.) **(Rus)**

[Hypertensive cardiopathy. Studies on left ventricular hypertrophy] Domingo Sagastagoitia J, et al. **Rev Esp Cardiol** 1995;48 Suppl 4:28-34 (13 ref.) (Eng. Abstr.) **(Spa)**

METABOLISM

Substrate metabolism, hormone interaction, and angiotensin-converting enzyme inhibitors in left ventricular hypertrophy. Zhu YC, et al. **Diabetes** 1996 Jan;45 Suppl 1:S59-65 (85 ref.)

Myocardial phenotypic changes in Na+, K+ ATPase in left ventricular hypertrophy: pharmacological consequences. Charlemagne D, et al. **Eur Heart J** 1995 May;16 Suppl C:20-3 (16 ref.)

PATHOLOGY

Gender differences in older patients with pressure-overload hypertrophy of the left ventricle. Aurigemma GP, et al. **Cardiology** 1995;86(4):310-7 (29 ref.)

[Morphofunctional features of left ventricular hypertrophy] Ghione S, et al. **G Ital Cardiol** 1995 Dec;25(12):1659-68 (55 ref.) **(Ita)**

PHYSIOPATHOLOGY

Evidence favoring the hypothesis that ventricular arrhythmias have prognostic significance in left ventricular hypertrophy secondary to systemic hypertension. Almendral J, et al. **Am J Cardiol** 1995 Nov 2; 76(13):60D-63D (27 ref.)

The renin-angiotensin system in left ventricular remodeling. Blaufarb IS, et al. **Am J Cardiol** 1996 May 30; 77(13):8C-16C (121 ref.)

Hypertensive left ventricular hypertrophy: pathophysiology, assessment and treatment. Otterstad JE, et al. **Blood Press** 1996 Jan;5(1):5-15 (88 ref.)

Diastolic dysfunction. Tardif JC, et al. **Can J Cardiol** 1996 Apr;12(4):389-98 (73 ref.)

Gender differences in older patients with pressure-overload hypertrophy of the left ventricle. Aurigemma GP, et al. **Cardiology** 1995;86(4):310-7 (29 ref.)

Hypertensive heart disease and heart failure. Cody RJ. **Curr Opin Cardiol** 1995 Sep;10(5):450-7 (13 ref.)

Reversal of hypertrophy: an active biologic process. Susic D, et al. **Curr Opin Cardiol** 1995 Sep;10(5):466-72 (57 ref.)

Models of volume overload hypertrophy. Carabello BA. **J Card Fail** 1996 Mar;2(1):55-64 (50 ref.)

The heart and vascular changes in hypertension. Leonetti G, et al. **J Hypertens Suppl** 1995 Aug;13(2):S29-34 (54 ref.)

Structural cardiovascular alterations and blood pressure variability in human hypertension. Mancia G, et al. **J Hypertens Suppl** 1995 Aug;13(2):S7-14 (39 ref.)

[Cardiac structure-function relationship and the renin-angiotensin-aldosterone system in hypertensive heart disease] Funck RC, et al. **Herz** 1995 Oct;20(5):330-9 (56 ref.) (Eng. Abstr.) **(Ger)**

[Role of the cardiac renin-angiotensin system in hypertensive heart disease] Holmer SR, et al. **Herz** 1995 Oct;20(5):322-9 (51 ref.) (Eng. Abstr.) **(Ger)**

[From left hypertrophy to heart insufficiency: hemodynamic and clinical findings] Sütsch G, et al. **Schweiz Rundsch Med Prax** 1996 Feb 20;85(8):218-26 (75 ref.) (Eng. Abstr.) **(Ger)**

[Morphofunctional features of left ventricular hypertrophy] Ghione S, et al. **G Ital Cardiol** 1995 Dec;25(12):1659-68 (55 ref.) **(Ita)**

[Basic and clinical study of left ventricular remodeling] Sasayama S. **Nippon Naika Gakkai Zasshi** 1995 Jul 10; 84(7):1178-85 (20 ref.) **(Jpn)**

[Electrophysiologic approach to the diagnosis of left ventricular hypertrophy] de Micheli A, et al. **Arch Inst Cardiol Mex** 1995 Jul-Aug;65(4):365-74 (12 ref.) **(Spa)**

PREVENTION & CONTROL

Effect of nitrates on myocardial remodeling after acute myocardial infarction. Jugdutt BI. **Am J Cardiol** 1996 May 30;77(13):17C-23C (90 ref.)

Prevention and reduction of left ventricular hypertrophy in

the elderly. Lavie CJ, et al. **Clin Geriatr Med** 1996 Feb; 12(1):57–68 (68 ref.)
Angiotensin converting enzyme inhibitors, left ventricular hypertrophy and fibrosis. Linz W, et al. **Mol Cell Biochem** 1995 Jun 7–21;147(1–2):89–97 (73 ref.)

HYPERTROPHY, RIGHT VENTRICULAR

DIAGNOSIS

[The electrophysiological approach to the diagnosis of right ventricular enlargement] de Micheli A, et al. **Arch Inst Cardiol Mex** 1995 May–Jun;65(3):271–81 (16 ref.) **(Spa)**

HYPERTROPIA see **STRABISMUS**

HYPERVARIABLE REGION see **IMMUNOGLOBULIN VARIABLE REGION**

HYPERVENTILATION

[Chronic hyperventilation syndrome] Le Ber C, et al. **Rev Pneumol Clin** 1995;51(2):53–8 (39 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

[Hypocalcemic crisis.
Hypoparathyroidism—non-parathyroid origin—the most frequent form: hyperventilation syndrome] Hehrmann R. **Fortschr Med** 1996 Jun 20;114(17):223–6 (11 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

The pathophysiology of hyperventilation disorders. Gardner WN. **Chest** 1996 Feb;109(2):516–34 (221 ref.)

PSYCHOLOGY

Neurologic aspects of hyperventilation syndrome. Evans RW. **Semin Neurol** 1995 Jun;15(2):115–25 (65 ref.)

HYPERVITAMINOSIS A

ETIOLOGY

[Hypervitaminosis A] Yasuda K. **Ryoikibetsu Shokogun Shirizu** 1995;(8):55–8 (8 ref.) **(Jpn)**

HYPHOMYCETES

Chromomycosis. Bayles MA. **Curr Top Med Mycol** 1995; 6:221–43 (98 ref.)
[Subcutaneous phaeohyphomycosis in the state of Pará: a report of 3 cases] Arnaud MV, et al. **Rev Soc Bras Med Trop** 1996 May–Jun;29(3):271–4 (20 ref.) (Eng. Abstr.) **(Por)**

ISOLATION & PURIFICATION

Corneal phaeohyphomycosis due to Exserohilum rostratum. A case report and brief review. Kanungo R, et al. **Acta Ophthalmol Scand** 1996 Apr;74(2):197–9 (21 ref.)
Identification of dematiaceous fungi and their role in human disease. Fothergill AW. **Clin Infect Dis** 1996 May;22 Suppl 2:S179–84 (10 ref.)
Phaeohyphomycosis caused by Dactylaria (human dactylariosis): report of a case with review of the literature. Kralovic SM, et al. **J Infect** 1995 Sep;31(2):107–13 (54 ref.)
A case of cutaneous phaeohyphomycosis caused by Exserohilum rostratum, its in vitro sensitivity and review of literature. Agarwal A, et al. **Mycopathologia** 1995 Jul; 131(1):9–12 (26 ref.)

PATHOGENICITY

Identification of dematiaceous fungi and their role in human disease. Fothergill AW. **Clin Infect Dis** 1996 May;22 Suppl 2:S179–84 (10 ref.)
Deep tissue infections caused by Scopulariopsis brevicaulis: report of a case of prosthetic valve endocarditis and review. Migrino RQ, et al. **Clin Infect Dis** 1995 Sep;21(3):672–4 (16 ref.)

HYPNOSIS

Hypnotizability and traumatic experience: a diathesis–stress model of dissociative symptomatology. Butler LD, et al. **Am J Psychiatry** 1996 Jul;153(7 Suppl):42–63 (155 ref.)
Psychological and hypnotic preparation for anesthesia and surgery: an individual differences perspective. Kessler R, et al. **Int J Clin Exp Hypn** 1996 Jul;44(3):189–207 (60 ref.)
The state of hypnosis: evidence and applications. Gruzelier J. **QJM** 1996 Apr;89(4):313–7 (52 ref.)

METHODS

Does hypnosis pose special risks for negative effects? A master class commentary. Lynn SJ, et al. **Int J Clin Exp Hypn** 1996 Jan;44(1):7–19 (60 ref.)
Hypnosis: teaching children self-regulation. Sugarman LI. **Pediatr Rev** 1996 Jan;17(1):5–11 (35 ref.)

HYPNOSIS, ANESTHETIC

Hypnosis in the treatment of patients with severe burns. Patterson DR, et al. **Am J Clin Hypn** 1996 Jan;38(3):200–12; discussion 213 (50 ref.)
Hypnosis for pain and neuromuscular rehabilitation with multiple sclerosis: case summary, literature review, and analysis of outcomes. Dane JR. **Int J Clin Exp Hypn** 1996 Jul;44(3):208–31 (60 ref.)

METHODS

Hypnosis treatment of clinical pain: understanding why hypnosis is useful. Holroyd J. **Int J Clin Exp Hypn** 1996 Jan;44(1):33–51 (130 ref.)

HYPNOSIS, DENTAL

Theoretical concepts and practical applications of hypnosis in the treatment of children and adolescents with dental fear and anxiety. Shaw AJ, et al. **Br Dent J** 1996 Jan 6; 180(1):11–6 (28 ref.)
[Hypnotic desensitization as a supplemental method in dental care of patients with panic disorder. Report of a case] Fábián TK. **Fogorv Sz** 1996 Feb;89(2):57–62 (19 ref.) **(Hun)**

HYPNOTICS AND SEDATIVES

see related
HISTAMINE H1 ANTAGONISTS
TRANQUILIZING AGENTS

Management of patients before, during and after upper gastrointestinal endoscopy. Chuah SY. **Med J Malaysia** 1995 Jun;50(2):162–5 (31 ref.)
[Principles of analgesia and sedation] Behne M. **Anaesthesist** 1995 Dec;44 Suppl 3:S535–9 (21 ref.) (Eng. Abstr.) **(Ger)**
[Analgesia and sedation to supplement incomplete regional anesthesia] Wresch KP. **Anaesthesist** 1995 Dec;44 Suppl 3:S580–7 (102 ref.) (Eng. Abstr.) **(Ger)**
[Sedation in endoscopy] Pérez–Piqueras J, et al. **Rev Esp Enferm Dig** 1995 Oct;87(10):725–30 (95 ref.) **(Spa)**

ADMINISTRATION & DOSAGE

Sedation and sedative drugs in paediatrics. Ferguson S, et al. **Br J Hosp Med** 1996 May 15–Jun 4;55(10):611–5 (18 ref.)
Over-the-counter hypnotics and chronic insomnia in the elderly [editorial] [see comments] Lasagna L. **J Clin Psychopharmacol** 1995 Dec;15(6):383–6 (14 ref.) Comment in: J Clin Psychopharmacol 1996 Apr;16(2):191.
Techniques to reduce the discomfort of paediatric laceration repair. Roberts PA, et al. **Med J Aust** 1996 Jan 1; 164(1):32–5 (37 ref.)
Sedation with benzodiazepines. Gempeler F, et al. **Middle East J Anesthesiol** 1995 Jun;13(2):117–45 (73 ref.)
Use of oral premedicants in pediatric dental population. Krost BG, et al. **N Y State Dent J** 1996 Jan;62(1):40–3 (8 ref.)
[Sleep disorders—diagnosis and treatment. Recommendations of the German Society of Sleep Research and Sleep Medicine] Bornkessel B. **Med Monatsschr Pharm** 1996 Apr; 19(4):106–9 (0 ref.) **(Ger)**

ANTAGONISTS & INHIBITORS

Reversal of conscious sedation by flumazenil: current status and future prospects. McCloy RF. **Acta Anaesthesiol Scand Suppl** 1995;108:35–42 (51 ref.)

PHARMACOKINETICS

Pharmacokinetics of analgesics, sedatives and anaesthetic agents during cardiopulmonary bypass. Gedney JA, et al. **Br J Anaesth** 1995 Sep;75(3):344–51 (74 ref.)
Clinical pharmacokinetics of zopiclone. Fernandez C, et al. **Clin Pharmacokinet** 1995 Dec;29(6):431–41 (38 ref.)
Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications. Salvà P, et al. **Clin Pharmacokinet** 1995 Sep;29(3):142–53 (37 ref.)

PHARMACOLOGY

Assessing the residual effects of hypnotics. Hindmarch I, et al. **Acta Psychiatr Belg** 1994 Mar–Apr;94(2):88–95 (24 ref.)
Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications. Salvà P, et al. **Clin Pharmacokinet** 1995 Sep;29(3):142–53 (37 ref.)
Neurosteroids: molecular mechanisms of action and psychopharmacological significance. Rupprecht R, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1–6 Spec No):163–8 (50 ref.)
[Effects of analgesia and sedation on cerebrovascular circulation, cerebral blood volume, cerebral metabolism and intracranial pressure] Werner C. **Anaesthesist** 1995 Dec; 44 Suppl 3:S566–72 (83 ref.) (Eng. Abstr.) **(Ger)**
[The effect of sedation on pulmonary function] Wiedemann K, et al. **Anaesthesist** 1995 Dec;44 Suppl 3:S588–93 (53 ref.) (Eng. Abstr.) **(Ger)**

THERAPEUTIC USE

The pharmacological treatment of Menière's disease. Brookes GB. **Clin Otolaryngol** 1996 Feb;21(1):3–11 (78 ref.)
Sedation for the critically ill neurologic patient. Mirski MA, et al. **Crit Care Med** 1995 Dec;23(12):2038–53 (124 ref.)
An assessment of short-acting hypnotics. Mendelson WB, et al. **Drug Saf** 1995 Oct;13(4):257–70 (11 ref.)
Zolpidem—a hypnotic with a difference? **Drug Ther Bull** 1995 May;33(5):37–9 (17 ref.)
Adjunctive therapy in patients with Alzheimer's disease. A practical approach. Corey-Bloom J, et al. **Drugs Aging** 1995 Aug;7(2):79–87 (46 ref.)
Steroid anesthetics: old compounds, new drugs. Sear JW. **J Clin Anesth** 1996 May;8(3 Suppl):91S–98S (70 ref.)
Sedative and neuromuscular blocking drug use in critically ill patients with head injuries. Prielipp RC, et al. **New Horiz** 1995 Aug;3(3):456–68 (102 ref.)
Pharmacotherapy of insomnia: practice and prospects. Dingemanse J. **Pharm World Sci** 1995 May 26;17(3):67–75 (114 ref.)
A request for more hypnotics. Ewan G, et al. **Practitioner** 1996 Mar;240(1560):133–8 (1 ref.)
[Epidemiology of the use of anxiolytic and hypnotic drugs in France and in the world] Pélissolo A, et al. **Encephale** 1996 May–Jun;22(3):187–96 (68 ref.) (Eng. Abstr.) **(Fre)**
[Analgesia and sedation on patients with sepsis syndrome] Adams HA. **Anaesthesist** 1995 Dec;44 Suppl 3:S573–9 (30 ref.) (Eng. Abstr.) **(Ger)**
[Analgesia and sedation in patients with head–brain trauma] Gremmelt A, et al. **Anaesthesist** 1995 Dec;44 Suppl 3:S559–65 (71 ref.) (Eng. Abstr.) **(Ger)**
[Sleep disorders—what can be done when hypnotics no longer help? Overview and case report] Staedt J, et al. **Fortschr Neurol Psychiatr** 1995 Sep;63(9):368–72 (35 ref.) (Eng. Abstr.) **(Ger)**
[New non–benzodiazepine hypnotics. Progress in therapy of sleep disorders?] Hajak G, et al. **Internist (Berl)** 1995 Nov; 36(11):1085–90; discussion 1090–1 (51 ref.) **(Ger)**
[Recommendations for the diagnosis and therapy of insomnia. German Society of Sleep Research and Sleep Medicine DGSM] Clarenbach P, et al. **Nervenarzt** 1995 Oct; 66(10):723–9 (20 ref.) (Eng. Abstr.) **(Ger)**

HYPNOTICS, BARBITURATE see **SEDATIVES, BARBITURATE**

HYPNOTICS, NONBARBITURATE see **SEDATIVES, NONBARBITURATE**

HYPOBETALIPOPROTEINEMIA

ETIOLOGY

The hypobetalipoproteinemias. Schonfeld G. **Annu Rev Nutr** 1995;15:23–34 (53 ref.)

HYPOCALCEMIA

BLOOD

Why should ionized calcium be determined in acutely ill patients? Vincent JL, et al. **Acta Anaesthesiol Scand Suppl** 1995;107:281–6 (59 ref.)

ETIOLOGY

Hypocalcaemia and chronic alcohol intoxication: transient hypoparathyroidism secondary to magnesium deficiency. Hermans C, et al. **Clin Rheumatol** 1996 Mar;15(2):193–6 (31 ref.)
[Hypocalcemic crisis.
Hypoparathyroidism—non-parathyroid origin—the most frequent form: hyperventilation syndrome] Hehrmann R. **Fortschr Med** 1996 Jun 20;114(17):223–6 (11 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

Quantitative and three-dimensional aspects of the rat parathyroid gland in normo-, hypo-, and hypercalcemia. Wernerson A, et al. **Microsc Res Tech** 1995 Oct 1; 32(2):129–47 (172 ref.)

HYPOCAPNIA

see related
ALKALOSIS, RESPIRATORY

HYPOCHLORHYDRIA see **ACHLORHYDRIA**

HYPOCHOLESTEREMIC AGENTS see **ANTICHOLESTEREMIC AGENTS**

HYPOCHONDRIASIS

PSYCHOLOGY

[Psychoanalytic theories of hypochondria] Röder CH, et al. **Psyche (Stuttg)** 1995 Nov;49(11):1068–98 (65 ref.) (Eng. Abstr.) **(Ger)**
[A psychopathological study of hypochondriacal symptoms in manic-depressive psychosis] Okajima Y. **Seishin Shinkeigaku Zasshi** 1995;97(8):623–52 (63 ref.) (Eng. Abstr.) **(Jpn)**

HYPODONTIA see **ANODONTIA**

HYPODYNAMIA

HYPODYNAMIA see HYPOKINESIA

HYPOGALACTIA see LACTATION DISORDERS

HYPOGAMMAGLOBULINEMIA see AGAMMAGLOBULINEMIA

HYPOGLOSSAL NERVE

PATHOLOGY

Giant neurofibroma of the tongue. Sahota JS, et al. **Int J Pediatr Otorhinolaryngol** 1996 Jan;34(1-2):153-7 (10 ref.)

HYPOGLYCEMIA

Hypoglycaemia--real and unreal, lawful and unlawful: the 1994 Banting Lecture. Marks V. **Diabet Med** 1995 Oct; 12(10):850-64 (107 ref.)

CHEMICALLY INDUCED

Hypoglycemia following inadvertent and factitious sulfonylurea overdosages. Klonoff DC, et al. **Diabetes Care** 1995 Apr;18(4):563-7 (55 ref.)

COMPLICATIONS

Diabetes mellitus and traffic incidents. Veneman TF. **Neth J Med** 1996 Jan;48(1):24-8 (27 ref.)

DIAGNOSIS

Medical aspects of ketone body metabolism. Mitchell GA, et al. **Clin Invest Med** 1995 Jun;18(3):193-216 (168 ref.)

Can hypoglycaemia be predicted before its onset? (Comment). Maggs D. **Diabetologia** 1996 May;39(5):615-7 (16 ref.)

[Hypoglycemia: diagnostic approach] Waeber G, et al. **Schweiz Rundsch Med Prax** 1995 Sep 12;84(37):1000-4 (31 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Chromium and other insulin sensitizers may enhance glucagon secretion: implications for hypoglycemia and weight control. McCarty MF. **Med Hypotheses** 1996 Feb; 46(2):77-80 (35 ref.)

ETIOLOGY

Tumour-induced hypoglycaemia in a patient with insulin-dependent diabetes mellitus. Svartberg J, et al. **J Intern Med** 1996 Feb;239(2):181-5 (16 ref.)

Spontaneous hypoglycaemia in chronic renal failure [see comments] Bonapart IE, et al. **Neth J Med** 1996 May; 48(5):180-4 (19 ref.) Comment in: Neth J Med 1996 May;48(5):167-8.

Non-islet-cell tumour induced hypoglycaemia: a case report and review of literature. Kuenen BC, et al. **Neth J Med** 1996 May;48(5):175-9 (16 ref.)

Recurrent hypoglycaemia caused by the insulin autoimmune syndrome: the first Dutch case [see comments] Schlemper RJ, et al. **Neth J Med** 1996 May;48(5):188-92 (27 ref.) Comment in: Neth J Med 1996 May;48(5):167-8.

[Autoimmune hypoglycemia] Wiszniewski P, et al. **Pol Arch Med Wewn** 1995 Mar;93(3):250-2 (18 ref.) **(Pol)**

[Nesidioblastosis of the pancreas as a cause of hyperinsulinemic hypoglycemia in adults] Tavčar I, et al. **Vojnosanit Pregl** 1994 Jan-Feb;51(1):73-81 (31 ref.) **(Scr)**

[Hypoglycemia--occurrence, causes and hormonal counterregulatory mechanisms in healthy persons and in patients with IDDM] Mokáň M. **Bratisl Lek Listy** 1995 Jun;96(6):311-6 (34 ref.) (Eng. Abstr.) **(Slo)**

PATHOLOGY

Nesidioblastosis and persistent neonatal hyperinsulinism. Sempoux C, et al. **Diabete Metab** 1995 Dec;21(6):402-7 (32 ref.)

PHYSIOPATHOLOGY

Nocturnal hypoglycaemia in patients with insulin-dependent diabetes mellitus. Bendtson I. **Dan Med Bull** 1995 Jun; 42(3):269-84 (172 ref.)

Does fall in tissue glucose precede fall in blood glucose? Sternberg F, et al. **Diabetologia** 1996 May;39(5):609-12 (22 ref.)

Hypoglycemia-induced autonomic failure in insulin-dependent diabetes mellitus. Cryer PE. **Proc Assoc Am Physicians** 1995 Apr;107(1):67-70 (30 ref.)

[The phenomenon of hypoglycemia unawareness--definition, frequency, pathogenesis and clinical forms] Mokáň M. **Bratisl Lek Listy** 1995 Aug;96(8):413-9 (39 ref.) (Eng. Abstr.) **(Slo)**

PREVENTION & CONTROL

Can hypoglycaemia be predicted before its onset? Lönnroth P. **Diabetologia** 1996 May;39(5):613-4 (17 ref.)

THERAPY

Emergency management of hypoglycemia and hyperglycemia. Bavitz JB. **Dent Clin North Am** 1995 Jul; 39(3):587-94 (13 ref.)

Management of hypoglycemia and diabetic ketoacidosis in pregnancy. Whiteman VE, et al. **Obstet Gynecol Clin North Am** 1996 Mar;23(1):87-107 (90 ref.)

Managing hypoglycaemic emergencies. Hall MS. **Practitioner** 1996 Feb;240(1559):100-2 (6 ref.)

VETERINARY

Hypoglycemia in four dogs with smooth muscle tumors. Beaudry D, et al. **J Vet Intern Med** 1995 Nov-Dec; 9(6):415-8 (25 ref.)

HYPOGLYCEMIC AGENTS

ADMINISTRATION & DOSAGE

[Acarbose, a glucosidase inhibitor: a new therapeutic principle in diabetes mellitus] Hermansen K, et al. **Ugeskr Laeger** 1996 Apr 29;158(18):2564-8 (33 ref.) **(Dan)**

[Acarbose in therapy of diabetes] Mehnert H. **Internist (Berl)** 1995 Dec;36(12):1190-5 (21 ref.) **(Ger)**

ADVERSE EFFECTS

Granulomatous hepatitis associated with glyburide. Saw D, et al. **Dig Dis Sci** 1996 Feb;41(2):322-5 (11 ref.)

[Lactic acidosis associated with biguanides] Safadi R, et al. **Harefuah** 1996 Feb 15;130(4):280-3 (40 ref.) **(Heb)**

[Drug induced obesity] Murakami T, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:425-9 (16 ref.) **(Jpn)**

[Concomitant therapies in the clinical trial in Alzheimer's disease] Bermejo F, et al. **Rev Neurol** 1995 Jan-Feb; 23(119):118-24 (81 ref.) (Eng. Abstr.) **(Spa)**

PHARMACOKINETICS

Clinical pharmacokinetics of metformin. Scheen AJ. **Clin Pharmacokinet** 1996 May;30(5):359-71 (74 ref.)

PHARMACOLOGY

The mechanism of alpha-glucosidase inhibition in the management of diabetes. Bischoff H. **Clin Invest Med** 1995 Aug;18(4):303-11 (31 ref.)

Metformin and intestinal glucose handling. Bailey CJ. **Diabetes Metab Rev** 1995 Sep;11 Suppl 1:S23-32 (47 ref.)

Metformin and free fatty acid metabolism. Del Prato S, et al. **Diabetes Metab Rev** 1995 Sep;11 Suppl 1:S33-41 (56 ref.)

Mechanisms of metformin action in non-insulin-dependent diabetes mellitus. Perriello G. **Diabetes Metab Rev** 1995 Sep;11 Suppl 1:S51-6 (62 ref.)

Effect of metformin on liver insulin metabolism and regional blood flow. Signore A, et al. **Diabetes Metab Rev** 1995 Sep;11 Suppl 1:S13-21 (48 ref.)

The beta-cell response to oral hypoglycemic agents. Cook DL. **Diabetes Res Clin Pract** 1995 Aug;28 Suppl:S81-9 (72 ref.)

Alternative therapeutic principles in the prevention of microvascular and neuropathic complications. Gries FA. **Diabetes Res Clin Pract** 1995 Aug;28 Suppl:S201-7 (12 ref.)

Extrapancreatic effects of sulfonylurea drugs. Kaku K, et al. **Diabetes Res Clin Pract** 1995 Aug;28 Suppl:S105-8 (21 ref.)

Rationale and hurdles of inhibitors of hepatic gluconeogenesis in treatment of diabetes mellitus. Kashiwagi A. **Diabetes Res Clin Pract** 1995 Aug;28 Suppl:S195-200 (30 ref.)

The molecular interaction of sulfonylureas with beta-cell ATP-sensitive K(+)-channels. Kramer W, et al. **Diabetes Res Clin Pract** 1995 Aug;28 Suppl:S67-80 (25 ref.)

Extrapancreatic effects of sulfonylureas--a comparison between glimepiride and conventional sulfonylureas. Müller G, et al. **Diabetes Res Clin Pract** 1995 Aug;28 Suppl:S115-37 (109 ref.)

Potassium channels in the cardiovascular system. Pogátsa G. **Diabetes Res Clin Pract** 1995 Aug;28 Suppl:S91-8 (48 ref.)

Sulfonylurea receptors and mechanism of sulfonylurea action. Panten U, et al. **Exp Clin Endocrinol Diabetes** 1996; 104(1):1-9 (100 ref.)

Influence of etomoxir on the expression of several genes in liver, testis and heart. Hegardt FG, et al. **Gen Pharmacol** 1995 Sep;26(5):897-904 (33 ref.)

Stimulation of insulin release by non-sulfonylurea hypoglycemic agents: the meglitinide family. Malaisse WJ. **Horm Metab Res** 1995 Jun;27(6):263-6 (18 ref.)

Vanadium compounds as insulin mimics. Orvig C, et al. **Met Ions Biol Syst** 1995;31:575-94 (126 ref.)

[How to explore insulin sensitivity in man?] Scheen AJ, et al. **Ann Endocrinol (Paris)** 1995;56(5):523-30 (47 ref.) (Eng. Abstr.) **(Fre)**

[Insulin, diabetes and cholesterol metabolism] Monnier L, et al. **C R Seances Soc Biol Fil** 1995;189(5):919-31 (27 ref.) (Eng. Abstr.) **(Fre)**

POISONING

Hypoglycemia following inadvertent and factitious sulfonylurea overdosages. Klonoff DC, et al. **Diabetes Care** 1995 Apr;18(4):563-7 (55 ref.)

THERAPEUTIC USE

The therapy of respiratory chain encephalomyopathy: a critical review of the past and current perspective. Walker UA, et al. **Acta Neurol Scand** 1995 Oct;92(4):273-80 (77 ref.)

Glucose control and insulin resistance in non-insulin-dependent diabetes mellitus. Henry RR. **Ann Intern Med** 1996 Jan 1;124(1 Pt 2):97-103 (19 ref.)

Role of metformin in type II diabetes. Epstein S. **Cleve Clin J Med** 1995 Sep-Oct;62(5):278-9 (4 ref.)

Clinical experience with acarbose as first line therapy in NIDDM. Fölsch UR. **Clin Invest Med** 1995 Aug; 18(4):312-7 (28 ref.)

Review of previous impaired glucose tolerance intervention studies. Melander A. **Diabet Med** 1996;13(3 Suppl 2):S20-2 (5 ref.)

The pharmacological treatment of hyperglycemia in NIDDM. American Diabetes Association. **Diabetes Care** 1995 Nov;18(11):1510-8 (0 ref.)

The insulin-sparing effect of metformin in insulin-treated diabetic patients. Golay A, et al. **Diabetes Metab Rev** 1995 Sep;11 Suppl 1:S63-7 (34 ref.)

The effects of metformin on cardiovascular risk factors. Grant PJ. **Diabetes Metab Rev** 1995 Sep;11 Suppl 1:S43-50 (56 ref.)

Effects of metformin in obese patients with impaired glucose tolerance. Scheen AJ, et al. **Diabetes Metab Rev** 1995 Sep; 11 Suppl 1:S69-80 (75 ref.)

What therapy do our NIDDM patients need? Insulin releasers. Crepaldi G, et al. **Diabetes Res Clin Pract** 1995 Aug;28 Suppl:S159-65 (29 ref.)

Clinical profile of glimepiride. Draeger E. **Diabetes Res Clin Pract** 1995 Aug;28 Suppl:S139-46 (7 ref.)

Insulin therapy in type II diabetes. Holman RR, et al. **Diabetes Res Clin Pract** 1995 Aug;28 Suppl:S179-84 (16 ref.)

Sulphonylurea treatment of NIDDM patients with cardiovascular disease: a mixed blessing? Leibowitz G, et al. **Diabetologia** 1996 May;39(5):503-14 (140 ref.)

Drug therapy of non-insulin-dependent diabetes mellitus in the elderly. Mooradian AD. **Drugs** 1996 Jun;51(6):931-41 (57 ref.)

Prevention of complications in non-insulin-dependent diabetes mellitus (NIDDM). Wolffenbuttel BH, et al. **Drugs** 1995 Aug;50(2):263-88 (264 ref.)

Insulin treatment in elderly patients with non-insulin-dependent diabetes mellitus. A double-edged sword? Niskanen L. **Drugs Aging** 1996 Mar;8(3):183-92 (51 ref.)

Potential role of thiazolidinediones in older diabetic patients. Umeda F. **Drugs Aging** 1995 Nov;7(5):331-7 (23 ref.)

New therapeutic agents for the treatment of NIDDM. Kuehnle HF. **Exp Clin Endocrinol Diabetes** 1996; 104(2):93-101 (54 ref.)

Attenuation of hypertension by insulin-sensitizing agents. Kotchen TA. **Hypertension** 1996 Aug;28(2):219-23 (79 ref.)

Oral hypoglycemic agents as an alternative therapy for gestational diabetes [editorial; comment] Hod M, et al. **Isr J Med Sci** 1995 Oct;31(10):640-3 (47 ref.) Comment on: Isr J Med Sci 1995 Oct;31(10):623-5.

Metformin: a new treatment option for non-insulin-dependent diabetes mellitus. Goo AK, et al. **J Fam Pract** 1996 Jun;42(6):612-8 (52 ref.)

Pharmacologic treatment options for non-insulin-dependent diabetes mellitus. Tan GH, et al. **Mayo Clin Proc** 1996 Aug; 71(8):763-8 (26 ref.)

Metformin. Bailey CJ, et al. **N Engl J Med** 1996 Feb 29; 334(9):574-9 (66 ref.)

Metformin in noninsulin-dependent diabetes mellitus. Lee AJ. **Pharmacotherapy** 1996 May-Jun;16(3):327-51 (114 ref.)

Treatment of type II diabetes: what options have been added to traditional methods? Cefalu WT. **Postgrad Med** 1996 Mar;99(3):109-19, 122 (28 ref.)

Pathophysiologic information and therapy for non-insulin-dependent diabetes mellitus [editorial] Bressler R. **South Med J** 1996 Aug;89(8):831-3 (43 ref.)

[Desmopressin in the treatment of hemorrhagic diathesis] Haar D, et al. **Ugeskr Laeger** 1995 Nov 27;157(48):6713-5 (35 ref.) (Eng. Abstr.) **(Dan)**

[How I treat... A Type 2 diabetic patient who has become insulin-dependent] Scheen AJ. **Rev Med Liege** 1996 Apr; 51(4):263-5 (19 ref.) **(Fre)**

[alpha-Glucosidase inhibitors in the therapy of diabetes mellitus] Giorgino R, et al. **Ann Ital Med Int** 1995 Oct;10 Suppl:61S-65S (45 ref.) (Eng. Abstr.) **(Ita)**

[Insulin analogs] Scaglione L, et al. **Minerva Endocrinol** 1996 Mar;21(1):27-36 (31 ref.) (Eng. Abstr.) **(Ita)**

HYPOGONADISM

COMPLICATIONS

[Sports, bones and hormones. Multiple interactions (editorial)] Maugars Y, et al. **Presse Med** 1995 Sep 30; 24(28):1284-6 (15 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

[Delayed constitutional puberty or hypogonadotrophic hypogonadism?] Beas F. **Rev Med Chil** 1995 Feb;

123(2):233–40 (30 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

Juberg–Marsidi syndrome: report of an additional case. Tsukahara M, et al. **Am J Med Genet** 1995 Sep 25; 58(4):353–5 (7 ref.)

THERAPY

[Endocrinology update. II] Burgstaller M, et al. **Med Klin** 1996 Apr 10;91(4):207–17 (171 ref.) **(Ger)**

HYPOKALEMIA

CHEMICALLY INDUCED

[Encephalopathy, convulsions and hypopotassemia in theophylline poisoning: a case analysis] Suárez Ortega S, et al. **Arch Bronconeumol** 1995 Aug–Sep;31(7):368–70 (23 ref.) (Eng. Abstr.) **(Spa)**

COMPLICATIONS

Apparent mineralocorticoid excess due to 11 beta–hydroxysteroid dehydrogenase deficiency: a possible cause of intrauterine growth retardation. Kitanaka S, et al. **Clin Endocrinol (Oxf)** 1996 Mar;44(3):353–9 (33 ref.)

DIAGNOSIS

Thyrotoxic periodic paralysis associated with hypokalemia and hypophosphatemia. Norris KC, et al. **Am J Kidney Dis** 1996 Aug;28(2):270–3 (28 ref.)

Hypokalaemic periodic paralysis associated with thyrotoxicosis. Agarwal AK, et al. **J Indian Med Assoc** 1995 Sep;93(9):359–60, 358 (21 ref.)

ENZYMOLOGY

11 beta–Hydroxysteroid dehydrogenase: implications for clinical medicine. Stewart PM. **Clin Endocrinol (Oxf)** 1996 May;44(5):493–9 (55 ref.)

ETIOLOGY

[Nephropathy associated with electrolyte disorders] Tsuchiya K, et al. **Nippon Rinsho** 1995 Aug;53(8):1995–2000 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Severe hyponatremia and hypopotassemia induced by the consumption of Equisetum telmateia (letter)] Miró O, et al. **Med Clin (Barc)** 1996 Apr 27;106(16):639 (2 ref.) **(Spa)**

PHYSIOPATHOLOGY

Apparent mineralocorticoid excess. Funder JW. **Endocrinol Metab Clin North Am** 1995 Sep;24(3):613–21 (41 ref.)

ULTRASONOGRAPHY

[Renovascular hypertension due to unilateral renal artery stenosis with hypokalemic alkalosis, the salt–losing syndrome and reversible hyperechogenicity of the contralateral kidney. A study of 2 infants] Castelló Girona F, et al. **An Esp Pediatr** 1996 Jul;45(1):49–52 (14 ref.) (Eng. Abstr.) **(Spa)**

HYPOKINESIA

PSYCHOLOGY

[Stresses under conditions of a normal mode of life, during hypokinesia (simulating effects of weightlessness) and in space flights] Grigor'ev AI, et al. **Fiziol Cheloveka** 1996 Mar–Apr;22(2):10–9 (35 ref.) **(Rus)**

HYPOMENORRHEA see MENSTRUATION DISORDERS

HYPONATREMIA

CHEMICALLY INDUCED

Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotonin reuptake inhibitors: a review of spontaneous reports. Liu BA, et al. **Can Med Assoc J** 1996 Sep 1; 155(5):519–27 (50 ref.)

Hyponatremia with consciousness disturbance caused by omeprazole administration. A case report and literature review. Shiba S, et al. **Dig Dis Sci** 1996 Aug;41(8):1615–7 (5 ref.)

Antidepressant–induced hyponatraemia in the aged. Avoidance and management strategies. Sharma H, et al. **Drugs Aging** 1996 Jun;8(6):430–5 (26 ref.)

CLASSIFICATION

Intranasal desmopressin–induced hyponatremia. Williford SL, et al. **Pharmacotherapy** 1996 Jan–Feb;16(1):66–74 (26 ref.)

DIAGNOSIS

From plasma [Na+] to diagnosis and treatment. Engquist A. **Acta Anaesthesiol Scand Suppl** 1995;107:273–9 (35 ref.)

ETIOLOGY

Cerebral salt wasting in children: the role of atrial natriuretic hormone. Kappy MS, et al. **Adv Pediatr** 1996;43:271–308 (104 ref.)

Beer potomania: two cases and review of the literature. Fenves AZ, et al. **Clin Nephrol** 1996 Jan;45(1):61–4 (14 ref.)

Delayed onset of hyponatremia after transsphenoidal surgery for pituitary adenomas. Taylor SL, et al. **Neurosurgery** 1995 Oct;37(4):649–53; discussion 653–4 (26 ref.)

[Severe hyponatremia and hypopotassemia induced by the consumption of Equisetum telmateia (letter)] Miró O, et al. **Med Clin (Barc)** 1996 Apr 27;106(16):639 (2 ref.) **(Spa)**

PATHOLOGY

[A 27–year–old woman with abdominal pain, vomiting, dark urine and hyponatremia (clinical conference)] **Rev Clin Esp** 1995 Oct;195(10):726–36 (74 ref.) **(Spa)**

PHYSIOPATHOLOGY

Brain damage and postoperative hyponatremia: the role of gender. Ayus JC, et al. **Neurology** 1996 Feb;46(2):323–8 (72 ref.)

Cerebral salt wasting syndrome: a review. Harrigan MR. **Neurosurgery** 1996 Jan;38(1):152–60 (80 ref.)

THERAPY

Antidepressant–induced hyponatraemia in the aged. Avoidance and management strategies. Sharma H, et al. **Drugs Aging** 1996 Jun;8(6):430–5 (26 ref.)

Recommendations for treatment of symptomatic hyponatremia. Oh MS, et al. **Nephron** 1995;70(2):143–50 (61 ref.)

HYPOPARATHYROIDISM

DIAGNOSIS

A rare case of idiopathic hypoparathyroidism with varied neurological manifestations. Abe S, et al. **Intern Med** 1996 Feb;35(2):129–34 (37 ref.)

[The diagnosis and therapy of hypoparathyroidism] Schilling T, et al. **Dtsch Med Wochenschr** 1996 Jun 21; 121(25–26):841–4 (18 ref.) **(Ger)**

DRUG THERAPY

[The diagnosis and therapy of hypoparathyroidism] Schilling T, et al. **Dtsch Med Wochenschr** 1996 Jun 21; 121(25–26):841–4 (18 ref.) **(Ger)**

ETIOLOGY

Hypocalcaemia and chronic alcohol intoxication: transient hypoparathyroidism secondary to magnesium deficiency. Hermans C, et al. **Clin Rheumatol** 1996 Mar;15(2):193–6 (31 ref.)

[Analysis of complications of thyroid surgery: recurrent paralysis et hypoparathyroidism. On a series of 588 cases] Debry C, et al. **Ann Otolaryngol Chir Cervicofac** 1995; 112(5):211–7 (11 ref.) (Eng. Abstr.) **(Fre)**

[Hypocalcemic crisis. Hypoparathyroidism—non–parathyroid origin—the most frequent form: hyperventilation syndrome] Hehrmann R. **Fortschr Med** 1996 Jun 20;114(17):223–6 (11 ref.) (Eng. Abstr.) **(Ger)**

HYPOPHARYNGEAL NEOPLASMS

Hypopharyngeal carcinoma. Mansfield EL, et al. **J La State Med Soc** 1995 Nov;147(11):489–92 (12 ref.)

COMPLICATIONS

[Paraneoplastic pyoderma gangrenosum (letter)] Bayle–Lebey P, et al. **Ann Med Interne (Paris)** 1995; 146(8):585–7 (12 ref.) **(Fre)**

PATHOLOGY

Liposarcoma of the base of tongue and tonsillar fossa: A possibly underdiagnosed neoplasm. Saddik M, et al. **Arch Pathol Lab Med** 1996 Mar;120(3):292–5 (23 ref.)

[Distant metastases originating from tumors of the larynx and hypopharynx] Traserra J, et al. **Rev Laryngol Otol Rhinol (Bord)** 1989;110(3):267–71 (16 ref.) (Eng. Abstr.) **(Fre)**

RADIOGRAPHY

[Computerized tomography of malignancies of the oral cavity, the oropharynx and hypopharynx and invasiveness] Helmberger R, et al. **Radiologe** 1996 Mar;36(3):193–8 (19 ref.) (Eng. Abstr.) **(Ger)**

RADIOTHERAPY

Pre versus post–operative radiotherapy of resectable squamous cell carcinoma of the head and neck. Wennerberg J. **Acta Otolaryngol (Stockh)** 1995 Jul;115(4):465–74 (63 ref.)

SURGERY

Pre versus post–operative radiotherapy of resectable squamous cell carcinoma of the head and neck. Wennerberg J. **Acta Otolaryngol (Stockh)** 1995 Jul;115(4):465–74 (63 ref.)

HYPOPHARYNX

INJURIES

Perforation in hypopharynx and deep cervical emphysema caused by blunt external trauma. Kiukaanniemi H, et al. **Mil Med** 1995 Sep;160(9):479–81 (5 ref.)

RADIATION EFFECTS

Pre versus post–operative radiotherapy of resectable squamous cell carcinoma of the head and neck. Wennerberg J. **Acta Otolaryngol (Stockh)** 1995 Jul;115(4):465–74 (63 ref.)

SURGERY

Pre versus post–operative radiotherapy of resectable squamous cell carcinoma of the head and neck. Wennerberg J. **Acta Otolaryngol (Stockh)** 1995 Jul;115(4):465–74 (63 ref.)

HYPOPHOSPHATASIA

DIAGNOSIS

A clinical and research protocol for characterizing patients with hypophosphatasia. Hu CC, et al. **Pediatr Dent** 1996 Jan–Feb;18(1):17–23 (51 ref.)

[Perinatal congenital hypophosphatasia: a report of 3 cases, its prevalence in Spain and reflexions on its mode of inheritance] Lorda Sánchez I, et al. **An Esp Pediatr** 1996 Jun;44(6):601–4 (16 ref.) **(Spa)**

HYPOPHOSPHATEMIA

[Hypophosphatemia: etiology, pathogenesis, clinical manifestations and treatment] Malyshev VD, et al. **Anesteziol Reanimatol** 1995 Sep–Oct;(5):44–51 (55 ref.) **(Rus)**

COMPLICATIONS

Hypophosphatemic osteomalacia with plantar neurilemoma. A review of the literature (100 cases). Crouzet J, et al. **Rev Rhum Engl Ed** 1995 Jun;62(6):463–6 (34 ref.)

DIAGNOSIS

Thyrotoxic periodic paralysis associated with hypokalemia and hypophosphatemia. Norris KC, et al. **Am J Kidney Dis** 1996 Aug;28(2):270–3 (28 ref.)

ETIOLOGY

The refeeding syndrome: an approach to understanding its complications and preventing its occurrence. Brooks MJ, et al. **Pharmacotherapy** 1995 Nov–Dec;15(6):713–26 (76 ref.)

GENETICS

Positional cloning of the HYP gene: a review. Econs MJ. **Kidney Int** 1996 Apr;49(4):1033–7 (37 ref.)

HYPOPHOSPHATEMIA, FAMILIAL

DRUG THERAPY

Guide–lines to the treatment of patients with X–linked hypophosphatemic rickets. Reusz GS. **Acta Biomed Ateneo Parmense** 1995;66(3–4):147–51 (9 ref.)

HYPOPHYSECTOMY

[Prolactin producing hypophyseal carcinoma. Case report of an extremely rare metastatic tumor] Saeger W, et al. **Pathologe** 1995 Sep;16(5):354–8 (19 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Recovery of vision following transsphenoidal surgery for pituitary adenomas. Powell M. **Br J Neurosurg** 1995; 9(3):367–73 (7 ref.)

Delayed onset of hyponatremia after transsphenoidal surgery for pituitary adenomas. Taylor SL, et al. **Neurosurgery** 1995 Oct;37(4):649–53; discussion 653–4 (26 ref.)

HYPOPHYSIS see PITUITARY GLAND

HYPOPIGMENTATION

ETIOLOGY

Hypopigmentation in hemodialysis. Acquired hair and skin fairness in a uremic patient undergoing maintenance hemodialysis: case report and review of the literature. Hmida MB, et al. **Dermatology** 1996;192(2):148–52 (17 ref.)

Hypopigmented mycosis fungoides in a white female. Amichai B, et al. **J Dermatol** 1996 Jun;23(6):425–6 (9 ref.)

HYPOPITUITARISM

COMPLICATIONS

Basal encephaloceles with morning glory syndrome, and progressive hormonal and visual disturbances: case report and review of the literature. Morioka M, et al. **Brain Dev** 1995 May-Jun;17(3):196-201 (27 ref.)

CONGENITAL

The foetal pituitary, postmaturity and breech presentation [comment] de Zegher F, et al. **Acta Paediatr** 1995 Oct; 84(10):1100-2 (32 ref.) Comment on: Acta Paediatr 1995 Oct;84(10):1201-3.

DIAGNOSIS

Posterior pituitary ectopia and hypopituitarism--magnetic resonance appearances of four cases and a review of the literature. Denton ER, et al. **Br J Radiol** 1996 May; 69(821):402-6 (31 ref.)

[Acquired hypopituitarism in adults; diagnosis and optimalization of substitution therapy] de Herder WW, et al. **Ned Tijdschr Geneeskd** 1996 Jul 13;140(28):1432-6 (33 ref.) **(Dut)**

DRUG THERAPY

Growth hormone deficiency in adults: a new indication for recombinant human growth hormone [editorial] Bengtsson BA. **J Intern Med** 1996 Apr;239(4):283-6 (26 ref.)

ETIOLOGY

Hypopituitarism secondary to transfacial gunshot wound. D'Angelica M, et al. **J Trauma** 1995 Oct;39(4):768-71 (12 ref.)

[Diabetes insipidus and panhypopituitarism in an 8-year-old girl due to probable lymphocytic hypophysitis] Bastida Eizaguirre M, et al. **An Esp Pediatr** 1996 Apr;44(4):402-4 (20 ref.) **(Spa)**

PHYSIOPATHOLOGY

[Preservation of gonadotrophic function and pregnancy in Sheehan's syndrome: a case report and review of the literature] Vieira HB, et al. **Rev Assoc Med Bras** 1995 Mar-Apr;41(2):135-8 (17 ref.) (Eng. Abstr.) **(Por)**

PSYCHOLOGY

Growth hormone deficiency and quality of life. McGauley G, et al. **Horm Res** 1996;45(1-2):34-7 (23 ref.)

Links between growth hormone deficiency, adaptation and social phobia. Stabler B, et al. **Horm Res** 1996;45(1-2):30-3 (27 ref.)

HYPOPLASTIC LEFT HEART SYNDROME

COMPLICATIONS

[Cholestasis in congenital heart diseases (hypoplastic left heart syndrome, aortic coarctation)] Konno T. **Ryoikibetsu Shokogun Shirizu** 1995;(7):571-3 (9 ref.) **(Jpn)**

PATHOLOGY

Interruption of aortic arch and hypoplastic left heart syndrome. Devloo-Blancquaert A, et al. **Pediatr Cardiol** 1995 Nov-Dec;16(6):304-8 (10 ref.)

ULTRASONOGRAPHY

[Prenatal diagnosis of left cardiac abnormality] Hajdú J, et al. **Orv Hetil** 1995 Oct 22;136(43):2333-7 (22 ref.) (Eng. Abstr.) **(Hun)**

HYPOPOTASSEMIA see **HYPOKALEMIA**

HYPOPROCONVERTINEMIA see **FACTOR VII DEFICIENCY**

HYPOPROTEINEMIA

see related
PROTEIN-LOSING ENTEROPATHIES

HYPOPROTHROMBINEMIAS

PREVENTION & CONTROL

Oral vitamin K1: an option to reduce warfarin's activity. Harrell CC, et al. **Ann Pharmacother** 1995 Dec; 29(12):1228-32 (26 ref.)

HYPOSALIVATION see **XEROSTOMIA**

HYPOSENSITIZATION THERAPY see **DESENSITIZATION, IMMUNOLOGIC**

HYPOSPADIAS

Penile curvature. Baskin LS, et al. **Urology** 1996 Sep; 48(3):347-56 (57 ref.)

SURGERY

Buccal mucosa grafts in hypospadias surgery. Baskin LS, et al. **Br J Urol** 1995 Dec;76 Suppl 3:23-30 (40 ref.)

Hypospadias repair: the two-stage alternative. Bracka A. **Br J Urol** 1995 Dec;76 Suppl 3:31-41 (13 ref.)

The current hype in hypospadiology. Duckett JW. **Br J Urol** 1995 Dec;76 Suppl 3:1-7 (34 ref.)

Hypospadias repair: current principles and procedures. Mouriquand PD, et al. **Br J Urol** 1995 Dec;76 Suppl 3:9-22 (40 ref.)

[Current treatment of hypospadias] Mollard P, et al. **J Urol (Paris)** 1996;102(1):9-17 (35 ref.) (Eng. Abstr.) **(Fre)**

[Hypospadias--results of correction] Beintker M. **Urologe A** 1996 Mar;35(2):104-10 (31 ref.) (Eng. Abstr.) **(Ger)**

HYPOSTASIS, GENETIC see **EPISTASIS, GENETIC**

HYPOTENSION

CHEMICALLY INDUCED

Poisoning with anti-hypertensive drugs: angiotensin converting enzyme inhibitors. Lip GY, et al. **J Hum Hypertens** 1995 Sep;9(9):711-5 (27 ref.)

ENZYMOLOGY

11 beta-Hydroxysteroid dehydrogenase: implications for clinical medicine. Stewart PM. **Clin Endocrinol (Oxf)** 1996 May;44(5):493-9 (55 ref.)

ETIOLOGY

Post-prandial hypotension in the elderly. Aronow WS. **J R Soc Med** 1995 Sep;88(9):499-501 (12 ref.)

Secondary brain insults after head injury: clinical perspectives. Chesnut RM. **New Horiz** 1995 Aug; 3(3):366-75 (44 ref.)

[Orthostatic and postprandial hypotension] Koike Y, et al. **Nippon Naika Gakkai Zasshi** 1995 Sep 10;84(9):1429-34 (13 ref.) **(Jpn)**

GENETICS

Molecular genetics of human blood pressure variation. Lifton RP. **Science** 1996 May 3;272(5262):676-80 (33 ref.)

PHYSIOPATHOLOGY

Thermal balance and dialysis hypotension. Maggiore Q, et al. **Int J Artif Organs** 1995 Sep;18(9):518-25 (11 ref.)

HYPOTENSION, CONTROLLED

Pharmacologic drugs for controlled hypotension. Testa LD, et al. **J Clin Anesth** 1995 Jun;7(4):326-37 (64 ref.)

HYPOTENSION, ORTHOSTATIC

Orthostatic hypotension: epidemiology, pathophysiology and management. Jacob G, et al. **Curr Opin Nephrol Hypertens** 1995 Sep;4(5):452-4 (22 ref.)

The definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. **J Auton Nerv Syst** 1996 Apr 20;58(1-2):123-4 (1 ref.)

CLASSIFICATION

Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. The Consensus Committee of the American Autonomic Society and the American Academy of Neurology. **Neurology** 1996 May;46(5):1470 (1 ref.)

ETIOLOGY

[Orthostatic and postprandial hypotension] Koike Y, et al. **Nippon Naika Gakkai Zasshi** 1995 Sep 10;84(9):1429-34 (13 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Dangling: a review of relevant physiology, research, and practice. Winslow EH, et al. **Heart Lung** 1995 Jul-Aug; 24(4):263-72 (35 ref.)

Spontaneous intracranial hypotension. A review. Kosmorsky GS. **J Neuroophthalmol** 1995 Jun;15(2):79-83 (23 ref.)

[Body positions which increase orthostatic tolerance] Wieling W, et al. **Ned Tijdschr Geneeskd** 1996 Jul 6;140(27):1394-7 (22 ref.) **(Dut)**

[Orthostatic hypotension in the elderly] Büla C. **Schweiz Rundsch Med Prax** 1996 Feb 6;85(6):145-9 (31 ref.) (Eng. Abstr.) **(Fre)**

HYPOTENSION, POSTURAL see **HYPOTENSION, ORTHOSTATIC**

HYPOTHALAMIC DISEASES

COMPLICATIONS

Spontaneous episodic release of adenohypophyseal hormones in hypothalamic amenorrhea. Genazzani AD, et al. **Gynecol Endocrinol** 1995 Dec;9(4):325-34 (63 ref.)

[Etiology and physiopathology of obesity: obesity due to hypothalamic lesions] Tokunga K, et al. **Nippon Naika Gakkai Zasshi** 1995 Aug 10;84(8):1231-5 (5 ref.) **(Jpn)**

DIAGNOSIS

Role of magnetic resonance imaging in hypothalamic-pituitary disorders. Zucchini S, et al. **Horm Res** 1995;44 Suppl 3:8-14 (42 ref.)

Current concepts of imaging in patients with pituitary/hypothalamic dysfunction. Korogi Y, et al. **Semin Ultrasound CT MR** 1995 Aug;16(4):270-8 (36 ref.)

[Imaging in hypothalamo-hypophyseal diseases] Vézina JL. **Ann Endocrinol (Paris)** 1995;56(5):511-2 (5 ref.) **(Fre)**

GENETICS

Polysyndactyly and asymptomatic hypothalamic hamartoma in mother and son: a variant of Pallister-Hall syndrome. Löw M, et al. **Clin Genet** 1995 Oct;48(4):209-12 (15 ref.)

HYPOTHALAMIC HORMONES

see related
PITUITARY HORMONES, POSTERIOR

PHYSIOLOGY

[Gastric stress ulcers: the protective role of hormones of the hypothalamo-hypophyseal-adrenocortical system] Filaretova LP. **Fiziol Zh Im I M Sechenova** 1995 Mar; 81(3):50-60 (80 ref.) (Eng. Abstr.) **(Rus)**

[Neurospecific protein-hormonal complexes] Srapionian RM. **Usp Fiziol Nauk** 1996 Jan-Mar;27(1):21-31 (38 ref.) (Eng. Abstr.) **(Rus)**

HYPOTHALAMIC NEOPLASMS

THERAPY

[Treatment of hypothalamic-pituitary tumors--experiences at Hiroshima University School of Medicine] Uozumi T. **Nippon Naibunpi Gakkai Zasshi** 1995 Nov 20;71(7):1019-36 (43 ref.) (Eng. Abstr.) **(Jpn)**

HYPOTHALAMIC PARAVENTRICULAR NUCLEUS see **PARAVENTRICULAR HYPOTHALAMIC NUCLEUS**

HYPOTHALAMO-HYPOPHYSEAL SYSTEM

see related
PITUITARY HORMONE-RELEASING HORMONES

DRUG EFFECTS

Alcohol stimulates ACTH secretion in the rat: mechanisms of action and interactions with other stimuli. Rivier C. **Alcohol Clin Exp Res** 1996 Apr;20(2):240-54 (207 ref.)

IMMUNOLOGY

Activation of the HPA axis by immune insults: roles and interactions of cytokines, eicosanoids, glucocorticoids. Buckingham JC, et al. **Pharmacol Biochem Behav** 1996 May; 54(1):285-98 (138 ref.)

METABOLISM

The potential role of excessive cortisol induced by HPA hyperfunction in the pathogenesis of depression. Stokes PE. **Eur Neuropsychopharmacol** 1995;5 Suppl:77-82 (48 ref.)

Transgenic targeting of neuroendocrine peptide genes in the hypothalamic-pituitary axis. Waschek JA. **Mol Neurobiol** 1995 Apr-Jun;10(2-3):205-17 (50 ref.)

PATHOLOGY

Role of magnetic resonance imaging in hypothalamic-pituitary disorders. Zucchini S, et al. **Horm Res** 1995;44 Suppl 3:8-14 (42 ref.)

PHYSIOLOGY

The hypothalamo-neurohypophyseal system in birds. Grossmann R, et al. **Adv Exp Med Biol** 1995;395:657-66 (34 ref.)

The hypothalamic-pituitary-adrenocortical system and sleep in man. Friess E, et al. **Adv Neuroimmunol** 1995;5(2):111-25 (63 ref.)

Central regulation of ACTH release in stress. Assenmacher I, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:41-54 (81 ref.)

Neurotransmitter regulation of the hypothalamic corticotropin-releasing hormone neuron. Calogero AE. **Ann N Y Acad Sci** 1995 Dec 29;771:31-40 (68 ref.)

Aging is associated in the 344/N Fischer rat with decreased stress responsivity of central and peripheral catecholaminergic systems and impairment of the hypothalamic-pituitary-adrenal axis. Cizza G, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:491-511 (68 ref.)

The neural network that regulates energy balance is responsive to glucocorticoids and insulin and also regulates HPA axis responsivity at a site proximal to CRF neurons. Dallman MF, et al. **Ann N Y Acad Sci** 1995 Dec 29; 771:730-42 (43 ref.)

Mechanism of action of cytokines to induce the pattern of pituitary hormone secretion in infection. McCann SM, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:386–95 (29 ref.)
Brain POU–er. Sharp ZD, et al. **Bioessays** 1996 May; 18(5):347–50 (23 ref.)
The role of gonadal steroids in hypothalamic–pituitary–adrenal axis regulation. Young EA. **Crit Rev Neurobiol** 1995;9(4):371–81 (78 ref.)
Interactions of the endocrine and immune systems in children and young adults. Papanicolaou DA, et al. **Curr Opin Pediatr** 1995 Aug;7(4):440–4 (27 ref.)
Exploration of the somatotropic axis. Tauber M, et al. **Diabetes Metab** 1996 Jul;22(4):240–4 (6 ref.)
Individual differences in hypothalamic–pituitary–adrenal activity in later life and hippocampal aging. Meaney MJ, et al. **Exp Gerontol** 1995 May–Aug;30(3–4):229–51 (125 ref.)
Hypothalamic–pituitary–adrenal–glucocorticoid axis function in rheumatoid arthritis [editorial; comment] Masi AT, et al. **J Rheumatol** 1996 Apr;23(4):577–81 (19 ref.) Comment on: J Rheumatol 1996 Apr;23(4):596–602.
Serotonin and the regulation of hypothalamic–pituitary–adrenal axis function. Dinan TG. **Life Sci** 1996;58(20):1683–94 (146 ref.)
Parathyroid hormone and hypothalamo–pituitary function. Harvey S, et al. **Miner Electrolyte Metab** 1995;21(1–3):40–4 (35 ref.)
Hypothalamic–pituitary–thyroid axis and the immune system. Pawlikowski M, et al. **Neuroimmunomodulation** 1994 May–Jun;1(3):149–52 (56 ref.)
The hypothalamic–pituitary–adrenal axis in obesity. Chalew S, et al. **Obes Res** 1995 Jul;3(4):371–82 (136 ref.)
Endocrine–immunological homeostasis: the interrelationship between the immune system and sex steroids involves the hypothalamo–pituitary–gonadal axis. Drača SR. **Panminerva Med** 1995 Jun;37(2):71–6 (45 ref.)
Activation of the HPA axis by immune insults: roles and interactions of cytokines, eicosanoids, glucocorticoids. Buckingham JC, et al. **Pharmacol Biochem Behav** 1996 May; 54(1):285–98 (138 ref.)
Current topic: the placental corticotrophin–releasing hormone–adrenocorticotrophin axis. Challis JR, et al. **Placenta** 1995 Sep;16(6):481–502 (98 ref.)
[Immuno–endocrine interactions at the hypothalamo–hypophyseal level] Gaillard RC. **Ann Endocrinol (Paris)** 1995;56(6):561–6 (38 ref.) (Eng. Abstr.) **(Fre)**
[Regulation of hypothalamo–-hypophyseal–-ovarian function] Ibuki Y. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Aug;47(8):809–13 (15 ref.) **(Jpn)**
[Aging and the morphofunctional changes in the hypothalamo–hypophyseal–adrenal cortical system] Bazhanova ED. **Zh Evol Biokhim Fiziol** 1995 Jan–Feb; 31(1):92–102 (74 ref.) **(Rus)**

PHYSIOPATHOLOGY

The protective role of the hypothalamic–pituitary–adrenal axis against lethality produced by immune, infectious, and inflammatory stress. Kapcala LP, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:419–37 (87 ref.)
Effects of the immune/inflammatory reaction on the hypothalamic–pituitary–adrenal axis. Mastorakos G, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:438–48 (34 ref.)
Hormonal control of rheumatoid inflammation. Panayi GS. **Br Med Bull** 1995 Apr;51(2):462–71 (34 ref.)
Insulin therapy and GH–IGF–I axis disorders in diabetes: impact of glycaemic control and hepatic insulinization. Hanaire–Broutin H, et al. **Diabetes Metab** 1996 Jul; 22(4):245–50 (42 ref.)
Lymphoid cell resistance to glucocorticoids in HIV infection. Kawa SK, et al. **J Steroid Biochem Mol Biol** 1996 Mar; 57(5–6):259–63 (68 ref.)
[Endocrinology update—I] Allolio B, et al. **Med Klin** 1996 Apr 1;91 Suppl 1:24–32 (112 ref.) **(Ger)**
[Gastric stress ulcers: the protective role of hormones of the hypothalamo–hypophyseal–adrenocortical system] Filaretova LP. **Fiziol Zh Im I M Sechenova** 1995 Mar; 81(3):50–60 (80 ref.) (Eng. Abstr.) **(Rus)**

SECRETION

[Hypothalamic–pituitary stress hormones and serotonergic system in the brain] Yan J, et al. **Sheng Li Ko Hsueh Chin Chan** 1995 Oct;26(4):337–40 (8 ref.) **(Chi)**

HYPOTHALAMUS

ANATOMY & HISTOLOGY

Two distinct descending inputs to the cricothyroid motoneuron in the medulla originating from the amygdala and the lateral hypothalamic area. Arita H, et al. **Adv Exp Med Biol** 1995;393:53–8 (10 ref.)

DRUG EFFECTS

Estrogen–induced hypothalamic beta–endorphin neuron loss: a possible model of hypothalamic aging. Desjardins GC, et al. **Exp Gerontol** 1995 May–Aug;30(3–4):253–67 (143 ref.)

EMBRYOLOGY

Hypothalamic pituitary adrenal function in the sheep fetus. Matthews SG, et al. **Reprod Fertil Dev** 1995;7(3):509–16 (52 ref.)

GROWTH & DEVELOPMENT

Aging and the hypothalamus: research perspectives. Bernardis LL, et al. **Physiol Behav** 1996 Mar;59(3):523–36 (220 ref.)

METABOLISM

Hypothalamic neuronal histamine modulates adaptive behavior and thermogenesis in response to endogenous pyrogen. Sakata T, et al. **Obes Res** 1995 Dec;3 Suppl 5:707S–712S (26 ref.)

PHYSIOLOGY

Proenkephalin gene regulation in the neuroendocrine hypothalamus: a model of gene regulation in the CNS. Borsook D, et al. **Am J Physiol** 1995 Sep;269(3 Pt 1):E393–408 (203 ref.)
Hemodynamic mechanisms of neurogenic pulmonary edema. Chen HI. **Biol Signals** 1995 May–Jun;4(3):186–92 (40 ref.)
Neuroanatomical and neurochemical mechanisms underlying amygdaloid control of defensive rage behavior in the cat. Shaikh MB, et al. **Braz J Med Biol Res** 1994 Dec; 27(12):2759–79 (43 ref.)
Dynamics of the regulation of the hypothalamo–pituitary–adrenal (HPA) axis determined using a nonsurgical method for collecting pituitary venous blood from horses. Alexander SL, et al. **Front Neuroendocrinol** 1996 Jan;17(1):1–50 (220 ref.)
A neuroendocrine reappraisal of the dual–centre hypothesis: its implications for obesity and insulin resistance. Rohner–Jeanrenaud F. **Int J Obes Relat Metab Disord** 1995 Aug;19(8):517–34 (312 ref.)
IGFs in the feedback control of GH secretion: Hypothalamic and/or pituitary action? [editorial] Ceda GP. **J Endocrinol Invest** 1995 Oct;18(9):734–7 (26 ref.)
Brain research, gender and sexual orientation. Swaab DF, et al. **J Homosex** 1995;28(3–4):283–301 (65 ref.)
Homeostatic maintenance regulated by hypothalamic neuronal histamine. Sakata T, et al. **Methods Find Exp Clin Pharmacol** 1995 Nov;17 Suppl C:51–6 (39 ref.)
The hypothalamo–sympathetic nervous system modulates peripheral cellular immunity. Hori T, et al. **Neurobiology (Bp)** 1995;3(3–4):309–17 (30 ref.)
Aging and the hypothalamus: research perspectives. Bernardis LL, et al. **Physiol Behav** 1996 Mar;59(3):523–36 (220 ref.)
Hypothalamic integration of body fluid regulation. Denton DA, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9; 93(14):7397–404 (80 ref.)
Modulation of pulsatile GH release through a novel receptor in hypothalamus and pituitary gland. Smith RG, et al. **Recent Prog Horm Res** 1996;51:261–85; discussion 285–6 (59 ref.)
Menopause: the aging of multiple pacemakers. Wise PM, et al. **Science** 1996 Jul 5;273(5271):67–70 (67 ref.)
Sexual differentiation of the human hypothalamus in relation to gender and sexual orientation. Swaab DF, et al. **Trends Neurosci** 1995 Jun;18(6):264–70 (61 ref.)
[Correlation between the nervous system and immune system] Katafuchi T. **Fukuoka Igaku Zasshi** 1996 Jun;87(6):127–32 (3 ref.) **(Jpn)**
[Experimental animal models of obesity] Katoh J, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:599–603 (24 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Hypothalamic response to starvation: implications for the study of wasting disorders. Schwartz MW, et al. **Am J Physiol** 1995 Nov;269(5 Pt 2):R949–57 (83 ref.)
Antidepressants and hypothalamic–pituitary–adrenocortical regulation. Holsboer F, et al. **Endocr Rev** 1996 Apr; 17(2):187–205 (237 ref.)

ULTRASTRUCTURE

[A morphofunctional analysis of the nuclear apparatus of the nonapeptidergic neurosecretory cells in the vertebrate hypothalamus] Polenov AL, et al. **Tsitologiia** 1996; 38(1):28–38 (55 ref.) (Eng. Abstr.) **(Rus)**

HYPOTHALAMUS, ANTERIOR

METABOLISM

Anterior hypothalamic norepinephrine, atrial natriuretic peptide, and hypertension. Oparil S, et al. **Front Neuroendocrinol** 1996 Apr;17(2):212–46 (122 ref.)

HYPOTHALAMUS, INFUNDIBULAR see **HYPOTHALAMUS, MIDDLE**

HYPOTHALAMUS, MEDIAL see **HYPOTHALAMUS, MIDDLE**

HYPOTHALAMUS, MIDDLE

PHYSIOLOGY

The LHRH pulse generator: a mediobasal hypothalamic location. Maeda K, et al. **Neurosci Biobehav Rev** 1995 Fall; 19(3):427–37 (55 ref.)

HYPOTHALAMUS, SUPRAOPTIC see **HYPOTHALAMUS, ANTERIOR**

HYPOTHERMIA

see related
REWARMING

Accidental hypothermia. When thermoregulation is overwhelmed. Lee–Chiong TL Jr, et al. **Postgrad Med** 1996 Jan;99(1):77–80, 83–4, 87–8 (12 ref.)

DIAGNOSIS

Spontaneous periodic hypothermia. Kloos RT. **Medicine (Baltimore)** 1995 Sep;74(5):268–80 (131 ref.)

ETIOLOGY

The etiology and management of inadvertent perioperative hypothermia. Forstot RM. **J Clin Anesth** 1995 Dec; 7(8):657–74 (188 ref.)
Hypothermia in shaken infant syndrome. Wahl NG, et al. **Pediatr Emerg Care** 1995 Aug;11(4):233–4 (18 ref.)
[Hypothermia and the nervous system. Review of the literature apropos of 4 cases] Mouton P, et al. **Ann Med Interne (Paris)** 1996;147(2):107–14 (69 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Cerebral metabolic rate and hypothermia: their relationship with ischemic neurologic injury. Lanier WL. **J Neurosurg Anesthesiol** 1995 Jul;7(3):216–21 (31 ref.)

PHYSIOPATHOLOGY

Electrophysiological monitoring and mild hypothermia. Kochs E. **J Neurosurg Anesthesiol** 1995 Jul;7(3):222–8 (56 ref.)

THERAPY

Management of profound hypothermia. Antretter H, et al. **Br J Hosp Med** 1995 Sep 6–19;54(5):215–20 (26 ref.)
The rapid reversal of profound hypothermia using peritoneal dialysis. Vella J, et al. **Ir J Med Sci** 1996 Apr–Jun; 165(2):113–4 (9 ref.)

HYPOTHERMIA, INDUCED

see related
REWARMING

Cardiac surgery and cold–reactive proteins. Agarwal SK, et al. **Ann Thorac Surg** 1995 Oct;60(4):1143–50 (47 ref.)
Core temperature control in the management of CNS lesions. Raps EC, et al. **Clin Neuropharmacol** 1995 Apr;18(2):159–64 (41 ref.)
Neurological outcomes and cardiopulmonary temperature: a clinical review. Christakis GT, et al. **J Card Surg** 1995 Jul;10(4 Suppl):475–80 (33 ref.)
The management of temperature during cardiopulmonary bypass: effect on neuropsychological outcome. Nathan HJ, et al. **J Card Surg** 1995 Jul;10(4 Suppl):481–7 (50 ref.)
Normothermic versus hypothermic cardiopulmonary bypass: central nervous system outcomes. McLean RF, et al. **J Cardiothorac Vasc Anesth** 1996 Jan;10(1):45–52; quiz 52–3 (114 ref.)
Is aprotinin safe when used in the context of profound hypothermia and circulatory arrest? A literary review [comment] Hornick P, et al. **J Heart Valve Dis** 1995 Nov; 4(6):669–73 (60 ref.) Comment on: J Heart Valve Dis 1995 Nov;4(6):674–7.
Active cooling during anesthesia and critical care. Illievich UM, et al. **J Neurosurg Anesthesiol** 1996 Jan;8(1):78–82 (56 ref.)
Systemic hypothermia in treatment of severe brain injury: a review and update. Clifton GL. **J Neurotrauma** 1995 Oct; 12(5):923–7 (38 ref.)
[Profound hypothermia and circulatory arrest in cerebral aneurysm surgery] Nagao S. **No Shinkei Geka** 1996 Jun; 24(6):507–15 (70 ref.) **(Jpn)**
[Use of hypothermia in neurosurgery] Sogomonian SA, et al. **Anesteziol Reanimatol** 1996 Mar–Apr;(2):90–2 (30 ref.) **(Rus)**

ADVERSE EFFECTS

Neuromonitoring during hypothermic cardiopulmonary bypass. Gombotz H. **J Neurosurg Anesthesiol** 1995 Oct; 7(4):289–96 (82 ref.)

METHODS

Suspended animation for delayed resuscitation. Bellamy R, et al. **Crit Care Med** 1996 Feb;24(2 Suppl):S24–47 (137 ref.)
Resuscitative hypothermia. Marion DW, et al. **Crit Care Med** 1996 Feb;24(2 Suppl):S81–9 (75 ref.)
Selective brain cooling after cardiac arrest [editorial;

comment] Safar P, et al. **Crit Care Med** 1996 Jun; 24(6):911–4 (47 ref.) Comment on: Crit Care Med 1996 Jun;24(6):1009–17.

HYPOTHYROIDISM

BLOOD

[Secretion of thyrotropin during states of wakefulness and sleep. Physiological data and clinical applications] Goichot B, et al. **Presse Med** 1996 Jun 15;25(21):980–4 (25 ref.) (Eng. Abstr.) **(Fre)**

CHEMICALLY INDUCED

Effects of iodine on thyroid function. Braverman LE, et al. **Acta Med Austriaca** 1996;23(1–2):4–9 (71 ref.)

[Effects of amiodarone on thyroid function] Caron P. **Presse Med** 1995 Dec 2;24(37):1747–51 (25 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

[Heart and thyroid] Klein M, et al. **Ann Endocrinol (Paris)** 1995;56(5):473–86 (176 ref.) (Eng. Abstr.) **(Fre)**

[Endocrine obesity] Inoue S, et al. **Nippon Rinsho** 1995 Jun; 53 Suppl:419–24 (16 ref.) **(Jpn)**

CONGENITAL

Compound W: a potential marker in maternal serum for assessing fetal thyroid function. Wu SY, et al. **Compr Ther** 1995 Oct;21(10):594–6 (17 ref.)

DIAGNOSIS

Thyrotropin-secreting pituitary tumors in hyper- and hypothyroidism. Beck-Peccoz P, et al. **Acta Med Austriaca** 1996;23(1–2):41–6 (45 ref.)

[Diagnosis and therapy of hypothyroidism in adulthood] Meng W. **Z Arztl Fortbild (Jena)** 1996 Feb;90(1):43–9 (13 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

A therapeutic controversy. Thyroid hormone treatment: when and what? Oppenheimer JH, et al. **J Clin Endocrinol Metab** 1995 Oct;80(10):2873–83 (112 ref.)

EPIDEMIOLOGY

Hypothyroidism and spontaneous abortions among Hanford, Washington, downwinders. Grossman CM, et al. **Arch Environ Health** 1996 May–Jun;51(3):175–6 (8 ref.)

[Post-partum dysthyroidism. Prospective study in a French region (1986–1988)] Mesrine S, et al. **Ann Endocrinol (Paris)** 1995;56(6):579–84 (38 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

[Hypothyroidism and blocking antibodies] Ducornet B, et al. **Ann Med Interne (Paris)** 1995;146(8):559–74 (129 ref.) **(Fre)**

METABOLISM

'Til death do us part: a case of failed affection. Weber KT, et al. **Cardiovasc Res** 1995 Jul;30(1):26–30 (32 ref.)

Thyroid status and exercise tolerance. Cardiovascular and metabolic considerations. McAllister RM, et al. **Sports Med** 1995 Sep;20(3):189–98 (64 ref.)

PHYSIOPATHOLOGY

Modern concepts of primary thyroid gland failure. Ridgway EC. **Clin Chem** 1996 Jan;42(1):179–82 (15 ref.)

[Pathophysiology and clinical aspects of myxedema] Reisert PM. **Z Lymphol** 1996 Jun;20(1):6–10, 12–4 (27 ref.) (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

Administration of iodized oil during pregnancy: a summary of the published evidence. Delange F. **Bull World Health Organ** 1996;74(1):101–8 (74 ref.)

THERAPY

Consensus statement for good practice and audit measures in the management of hypothyroidism and hyperthyroidism. The Research Unit of the Royal College of Physicians of London, the Endocrinology and Diabetes Committee of the Royal College of Physicians of London, and the Society for Endocrinology. Vanderpump MP, et al. **BMJ** 1996 Aug 31;313(7056):539–44 (29 ref.)

Clinical review 80: Management of hyperthyroidism and hypothyroidism in the pregnant woman. Roti E, et al. **J Clin Endocrinol Metab** 1996 May;81(5):1679–82 (15 ref.)

ULTRASONOGRAPHY

Antenatal diagnosis and treatment of fetal goitrous hypothyroidism: case report and review of the literature. Abuhamad AZ, et al. **Ultrasound Obstet Gynecol** 1995 Nov; 6(5):368–71 (27 ref.)

HYPOTRICHOSIS

GENETICS

Studies on development of hairless descendants of Mexican hairless dogs and their usefulness in dermatological science. Kimura T. **Exp Anim** 1996 Jan;45(1):1–13 (36 ref.)

PATHOLOGY

Odontotrichodysplasia: a case report with a review of conditions combining ectodermal dysplasia (subgroup 1–2) with skin manifestations. Yadav TP, et al. **J Dermatol** 1995 Aug;22(8):606–10 (14 ref.)

HYPOVENTILATION, CENTRAL ALVEOLAR see **SLEEP APNEA SYNDROMES**

HYPOVOLEMIC SHOCK see **SHOCK**

HYPOXANTHINE-GUANINE PHOSPHORIBOSYLTRANSFERASE see **HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE**

HYPOXANTHINE OXIDASE see **XANTHINE OXIDASE**

HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE

GENETICS

Regulation of the hypoxanthine phosphoribosyltransferase gene: in vitro and in vivo approaches. Jiralerspong S, et al. **Proc Soc Exp Biol Med** 1996 Jun;212(2):116–27 (144 ref.)

Analysis of mutation at the hprt locus in human T lymphocytes. Lambert B, et al. **Toxicol Lett** 1995 Dec; 82–83:323–33 (54 ref.)

HYPOXANTHINES

ANALYSIS

[Oxypurine] Kono N. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:506–9 (15 ref.) **(Jpn)**

HYPOXEMIA see **ANOXEMIA**

HYPOXIA see **ANOXIA**

HYPOXIA, CELLULAR see **CELL HYPOXIA**

HYPSARRHYTHMIA see **SPASMS, INFANTILE**

HYSTERECTOMY

Prevention of ovarian cancer with bilateral oophorectomy at time of hysterectomy. McGuire PA, et al. **Alaska Med** 1996 Apr–Jun;38(2):69–70, 81 (13 ref.)

Effectiveness of vaginal Papanicolaou smear screening after total hysterectomy for benign disease. Fetters MD, et al. **JAMA** 1996 Mar 27;275(12):940–7 (90 ref.)

Early complications of abdominal and vaginal hysterectomy. Harris WJ. **Obstet Gynecol Surv** 1995 Nov;50(11):795–805 (65 ref.)

[Pro: a critical contribution to better understanding of possible functional disorders of the genital, bladder and pelvic floor system] Schüssler B. **Arch Gynecol Obstet** 1995; 257(1–4):359–62 (14 ref.) **(Ger)**

[Indications for hysterectomy—a time for re-evaluation] Lerner A, et al. **Harefuah** 1996 Mar 15;130(6):400–3 (25 ref.) **(Heb)**

ADVERSE EFFECTS

Lumbosacral plexopathy after gynecologic surgery: case report and review of the literature. Alsever JD. **Am J Obstet Gynecol** 1996 Jun;174(6):1769–77; discussion 1777–8 (32 ref.)

Pelvic pathology after hysterectomy. A pictorial essay. Kasales CJ, et al. **Clin Imaging** 1995 Jul–Sep;19(3):210–7 (5 ref.)

INSTRUMENTATION

Review on laparoscopic hysterectomy. Deprest JA, et al. **Zentralbl Gynakol** 1995;117(12):641–51 (75 ref.)

METHODS

Laparoscopic hysterectomy: does it work?: a bicontinental review of the literature and clinical commentary. Munro MG, et al. **Clin Obstet Gynecol** 1995 Jun;38(2):401–25 (67 ref.)

Laparoscopic hysterectomy. Mage G, et al. **Curr Opin Obstet Gynecol** 1995 Aug;7(4):283–9 (67 ref.)

Modified radical hysterectomy: morbidity and mortality. Magrina JF, et al. **Gynecol Oncol** 1995 Nov;59(2):277–82 (10 ref.)

Techniques of partial hysterectomy: an overview. Phillips G, et al. **Zentralbl Gynakol** 1995;117(12):625–8 (24 ref.)

[Total hysterectomy for benign pathologies. Conventional celiosurgical technique] Chapron C, et al. **Ann Chir** 1995; 49(7):613–20 (39 ref.) (Eng. Abstr.) **(Fre)**

[Total hysterectomy for benign pathologies: why is laparoscopy of value?] Chapron C, et al. **Contracept Fertil Sex** 1995 Nov;23(11):688–93 (63 ref.) (Eng. Abstr.) **(Fre)**

[Total laparoscopic hysterectomy. Operative technique, results and indications] Chapron C, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(8):802–10 (37 ref.) (Eng. Abstr.) **(Fre)**

[Alternatives and access routes in hysterectomies. Are randomizations dangerous?] Cosson M, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(3):257–63 (15 ref.) (Eng. Abstr.) **(Fre)**

[Laparoscopic hysterectomy. A series of 318 consecutive cases] Masson FN, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(4):340–52 (36 ref.) (Eng. Abstr.) **(Fre)**

[Contra cervix extirpation] Semm K. **Arch Gynecol Obstet** 1995;257(1–4):362–71 (25 ref.) **(Ger)**

[Laparoscopic hysterectomy—the future is here and now] Ben-Rafael Z, et al. **Harefuah** 1996 Apr 15;130(8):542–5 (19 ref.) **(Heb)**

[Surgical alternatives in hysterectomy] Hahlin M, et al. **Lakartidningen** 1996 Jun 26;93(26–27):2509–13 (61 ref.) **(Swe)**

PSYCHOLOGY

Psychological aspects of heavy periods: does endometrial ablation provide the answer? Wright JB, et al. **Br J Hosp Med** 1996 Mar 6–19;55(5):289–94 (77 ref.)

STANDARDS

Laparoscopy in surgical treatment of vaginal aplasia: laparoscopy-assisted colpopoiesis and perineal hysterectomy with colpopoiesis. Adamian LV, et al. **Int J Fertil Menopausal Stud** 1996 Jan–Feb;41(1):40–5 (10 ref.)

STATISTICS & NUMERICAL DATA

Hysterectomy in a Danish cohort. Prevalence, incidence and socio-demographic characteristics. Settnes A, et al. **Acta Obstet Gynecol Scand** 1996 Mar;75(3):274–80 (35 ref.)

HYSTERECTOMY, VAGINAL

Peritoneographic diagnosis of perineal enterocele after hysterectomy. Tepetes K, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1995 Oct;163(4):367–8 (12 ref.)

[Vaginal hysterectomy. Role of laparoscopic preparation. Our experience] Martin J, et al. **Chirurgie** 1996;121(2):91–5 (17 ref.) (Eng. Abstr.) **(Fre)**

INSTRUMENTATION

Laparoscopic assistance at vaginal hysterectomy: a literature review. Rempen A. **Arch Gynecol Obstet** 1996;258(2):57–64 (52 ref.)

Necrotizing fasciitis following laparoscopic surgery. Case report and review of the literature. Golshani S, et al. **Surg Endosc** 1996 Jul;10(7):751–4 (20 ref.)

Review on laparoscopic hysterectomy. Deprest JA, et al. **Zentralbl Gynakol** 1995;117(12):641–51 (75 ref.)

METHODS

[Complete hysterectomy for benign pathology and laparoscopy: respective indications of laparoscopic preparation and an exclusively laparoscopic approach] Chapron C, et al. **Contracept Fertil Sex** 1995 Dec; 23(12):741–8 (76 ref.) (Eng. Abstr.) **(Fre)**

STANDARDS

Laparoscopy in surgical treatment of vaginal aplasia: laparoscopy-assisted colpopoiesis and perineal hysterectomy with colpopoiesis. Adamian LV, et al. **Int J Fertil Menopausal Stud** 1996 Jan–Feb;41(1):40–5 (10 ref.)

HYSTERIA

[Hysterical psychoses revisited] Nava AS. **Acta Med Port** 1995 Dec;8(12):705–9 (11 ref.) (Eng. Abstr.) **(Por)**

DIAGNOSIS

Pseudoseizures: an update. Nash JL. **Compr Ther** 1995 Sep; 21(9):486–91 (29 ref.)

[Hysteria, dissociation and conversion. A review of concepts, classification and diagnostic instruments] Spitzer C, et al. **Psychiatr Prax** 1996 Mar;23(2):63–8 (55 ref.) (Eng. Abstr.) **(Ger)**

HYSTERIA, CONVERSION see **CONVERSION DISORDER**

HYSTERIA, DISSOCIATIVE see **DISSOCIATIVE DISORDERS**

HYSTERICAL NEUROSES see **HYSTERIA**

HYSTEROSALPINGOGRAPHY

Hysteroscopy and hysterography. Barbot J.
Obstet Gynecol Clin North Am 1995 Sep;22(3):591–603 (10 ref.)
[Role of hysterosalpingography in the evaluation of infertility in Black Africa] De Muylder X. **Med Trop (Mars)** 1995; 55(2):160–4 (53 ref.) (Eng. Abstr.) **(Fre)**

HYSTEROSCOPY

see related
HYSTEROSALPINGOGRAPHY
Hysteroscopy and anaesthesia. Ananthanarayan C, et al.
Can J Anaesth 1996 Jan;43(1):56–64 (56 ref.)
What is the role of hysteroscopy in the management of abnormal uterine bleeding? Brill AI.
Clin Obstet Gynecol 1995 Jun;38(2):319–45 (107 ref.)
The role of endoscopy in the management of the infertile patient. Graebe RA. **Curr Opin Obstet Gynecol** 1995 Aug; 7(4):265–72 (26 ref.)
Hysteroscopy and assisted reproductive technology. Balmaceda JP, et al. **Obstet Gynecol Clin North Am** 1995 Sep;22(3):507–18 (52 ref.)
Hysteroscopy and hysterography. Barbot J.
Obstet Gynecol Clin North Am 1995 Sep;22(3):591–603 (10 ref.)
Hysteroscopic diagnosis and operative therapy of submucous myoma. Corson SL. **Obstet Gynecol Clin North Am** 1995 Dec;22(4):739–55 (37 ref.)
Hysteroscopic endometrial ablation. Goldrath MH.
Obstet Gynecol Clin North Am 1995 Sep;22(3):559–72 (44 ref.)
Intrauterine adhesions. March CM.
Obstet Gynecol Clin North Am 1995 Sep;22(3):491–505 (58 ref.)
Hysteroscopy and adenocarcinoma. Mencaglia L.
Obstet Gynecol Clin North Am 1995 Sep;22(3):573–9 (30 ref.)
Hysteroscopic sterilization. Sciarra JJ, et al.
Obstet Gynecol Clin North Am 1995 Sep;22(3):581–9 (20 ref.)
Office hysteroscopy. Siegler AM.
Obstet Gynecol Clin North Am 1995 Sep;22(3):457–71 (34 ref.)
Tubal cannulation. Valle RF.
Obstet Gynecol Clin North Am 1995 Sep;22(3):519–40 (48 ref.)
[Operative hysteroscopy in 1995. Equipment, technique, indications and results] Merviel P, et al.
Contracept Fertil Sex 1995 Sep;23(9):516–23 (90 ref.) **(Fre)**
–Complications of hysteroscopy and laparoscopy from the anesthesiologic viewpoint– Zollinger A.
Arch Gynecol Obstet 1995;256 Suppl:S12–20 (25 ref.) **(Ger)**
[Gynecologic endoscopic surgery] Yoshida H, et al.
Hokkaido Igaku Zasshi 1995 May;70(3):397–400 (8 ref.) (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS
Contraindications and complications of hysteroscopy. Loffer FD. **Obstet Gynecol Clin North Am** 1995 Sep;22(3):445–55 (67 ref.)

CONTRAINDICATIONS
Contraindications and complications of hysteroscopy. Loffer FD. **Obstet Gynecol Clin North Am** 1995 Sep;22(3):445–55 (67 ref.)

INSTRUMENTATION
Power sources. Luciano AA.
Obstet Gynecol Clin North Am 1995 Sep;22(3):423–43 (36 ref.)
[Hysteroscopic surgery] Kimmig R. **Arch Gynecol Obstet** 1995;257(1–4):21–9 (53 ref.) **(Ger)**

METHODS
Endometrial resection. Holt EM, et al.
Baillieres Clin Obstet Gynaecol 1995 Jun;9(2):279–97 (38 ref.)
Endometrial ablation: indications and preliminary diagnostic hysteroscopy. Taylor PJ, et al.
Baillieres Clin Obstet Gynaecol 1995 Jun;9(2):251–60 (18 ref.)
Hysteroscopic metroplasty for septate uterus. Fedele L, et al. **Obstet Gynecol Clin North Am** 1995 Sep;22(3):473–89 (55 ref.)
Media and delivery systems. Marlow JL.
Obstet Gynecol Clin North Am 1995 Sep;22(3):409–22 (55 ref.)
[Adenomyosis: role of hysteroscopic treatment] Mergui JL, et al. **Contracept Fertil Sex** 1995 Oct;23(10):590–4 (64 ref.) **(Fre)**

NURSING
The nurse's role in office hysteroscopy. Prather C, et al.
J Obstet Gynecol Neonatal Nurs 1995 Nov–Dec; 24(9):813–6 (6 ref.)

HYSTRIX see RODENTIA

HZE PARTICLES see COSMIC RADIATION

I-CELL DISEASE see MUCOLIPIDOSIS

IA ANTIGENS see HISTOCOMPATIBILITY ANTIGENS CLASS II

IA-LIKE ANTIGENS see HISTOCOMPATIBILITY ANTIGENS CLASS II

IA-LIKE ANTIGENS, HUMAN see HLA-D ANTIGENS

IAP PERTUSSIS TOXIN see PERTUSSIS TOXINS

IATROGENIC DISEASE

see related
DISEASE TRANSMISSION, PROFESSIONAL-TO-PATIENT
Iatrogenically induced intracranial hypotension syndrome. Sell JJ, et al. **AJR Am J Roentgenol** 1995 Dec;165(6):1513–5 (8 ref.)
The surgical management of idiopathic facial pain produces intractable iatrogenic pain? [editorial] Harris M.
Br J Oral Maxillofac Surg 1996 Feb;34(1):1–3 (32 ref.)
Oropharyngeal dysphagia due to iatrogenic neurological dysfunction. Buchholz DW. **Dysphagia** 1995 Fall; 10(4):248–54 (51 ref.)
Recent insights into the mechanisms of iatrogenic arteriosclerosis [editorial] Ferns GA, et al. **J Pathol** 1995 Aug;176(4):331–2 (15 ref.)
Gas embolism in obstetrics and gynecology. A review. Weissman A, et al. **J Reprod Med** 1996 Feb;41(2):103–11 (89 ref.)
Iatrogenic and zoonotic Creutzfeldt-Jakob disease: the Australian perspective. Collins S, et al. **Med J Aust** 1996 May 20;164(10):598–602 (35 ref.)
[Vitamins and metals: possible hazards for humans] Ballmer PE. **Schweiz Med Wochenschr** 1996 Apr 13;126(15):607–11 (16 ref.) (Eng. Abstr.) **(Ger)**
[Iatrogenic driving incapacity] Beer JH, et al.
Schweiz Med Wochenschr 1996 Apr 6;126(14):584–93 (46 ref.) (Eng. Abstr.) **(Ger)**
[Iatrogenic respiratory and sleep disorders and snoring] Gugger M. **Schweiz Med Wochenschr** 1996 Apr 13; 126(15):632–6 (15 ref.) (Eng. Abstr.) **(Ger)**
[Nonsteroidal antirheumatic drugs and acetylsalicylic acid: adverse effects distal to the duodenum] Gut A, et al.
Schweiz Med Wochenschr 1996 Apr 13;126(15):616–25 (95 ref.) (Eng. Abstr.) **(Ger)**
[Adverse effects due to unstable blood products] Hauser SP, et al. **Schweiz Med Wochenschr** 1996 Apr 13;126(15):637–45 (45 ref.) (Eng. Abstr.) **(Ger)**
[Iatrogenic hyperkalemia] Krapf R.
Schweiz Med Wochenschr 1996 Apr 13;126(15):626–31 (29 ref.) (Eng. Abstr.) **(Ger)**
[Prognosis in iatrogenic gas embolism] Boussuges A, et al. **Minerva Med** 1995 Nov;86(11):453–7 (29 ref.) (Eng. Abstr.) **(Ita)**
[An impassable iatrogenic lesion of the common bile duct at its junction: its recanalization via a combined percutaneous-endoscopic approach. A case] Ferro C, et al. **Radiol Med (Torino)** 1996 Apr;91(4):488–91 (16 ref.) **(Ita)**
[Hepatitis B virus infection in health care settings] Sodeyama T. **Nippon Rinsho** 1995 Oct;53 Suppl:362–70 (15 ref.) **(Jpn)**
[Iatrogenic spinal epidermoid tumors. A late complication of spinal puncture] Reina MA, et al.
Rev Esp Anestesiol Reanim 1996 Apr;43(4):142–6 (84 ref.) (Eng. Abstr.) **(Spa)**
[Iatrogenic cerebrovascular disease] Rey A, et al.
Rev Neurol 1995;23 Suppl 1:S131–46 (200 ref.) **(Spa)**

EPIDEMIOLOGY
Splenectomy complicating left nephrectomy [see comments] Cooper CS, et al. **J Urol** 1996 Jan;155(1):30–6 (46 ref.) Comment in: J Urol 1996 Jan;155(1):37.
[Risks in diagnostic and therapeutic invasive cardiological procedures] Seiler C, et al. **Schweiz Med Wochenschr** 1996 Apr 6;126(14):559–65 (25 ref.) (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL
Viral iatrogenic contamination and safety of biologicals. Horaud F. **Blood Coagul Fibrinolysis** 1995 Jul;6 Suppl 2:S5–9 (21 ref.)
[Iatrogenic lesions of the facial nerve during parotid surgery for pleomorphic adenoma] Colella G, et al.
Minerva Stomatol 1995 Dec;44(12):591–6 (40 ref.) (Eng. Abstr.) **(Ita)**
[Puncture of the dura mater, diagnosis and treatment in obstetrics] Villalpando Bravo J, et al.
Ginecol Obstet Mex 1996 Feb;64:85–9 (35 ref.) (Eng. Abstr.) **(Spa)**

IBOGAINE

PHARMACOLOGY
100 years of ibogaine: neurochemical and pharmacological actions of a putative anti-addictive drug. Popik P, et al. **Pharmacol Rev** 1995 Jun;47(2):235–53 (224 ref.)

IBR-IPV VIRUS see HERPESVIRUS 1, BOVINE

IBUPROFEN

ADVERSE EFFECTS
When a randomised controlled trial is needed to assess drug safety. The case of paediatric ibuprofen. Mitchell AA, et al. **Drug Saf** 1995 Jul;13(1):15–24 (21 ref.)

ICAM-1 see INTERCELLULAR ADHESION MOLECULE-1

ICHTHYOSIFORM ERYTHRODERMA, CONGENITAL

GENETICS
The CHILD nevus: a distinct skin disorder. Happle R, et al. **Dermatology** 1995;191(3):210–6 (64 ref.)

ICHTHYOSIS

DIAGNOSIS
Differential diagnosis and management of very low second trimester maternal serum unconjugated estriol levels, with special emphasis on the diagnosis of X-linked ichthyosis. Zalel Y, et al. **Obstet Gynecol Surv** 1996 Mar;51(3):200–3 (24 ref.)

ICI-46474 see TAMOXIFEN

ICRF-159 see RAZOXANE

ICSH see LH

ICSH RECEPTORS see RECEPTORS, LH

ICTALURIDAE

PARASITOLOGY
Parasitisms of catfish and other farm-raised food fish [see comments] Klesius P, et al. **J Am Vet Med Assoc** 1995 Dec 1;207(11):1473–8 (40 ref.) Comment in: J Am Vet Med Assoc 1996 Feb 1;208(3):338.

ICTALURUS see ICTALURIDAE

ICTERUS see JAUNDICE

ICTERUS GRAVIS NEONATORUM see ERYTHROBLASTOSIS, FETAL

IDARUBICIN

PHARMACOLOGY
MDR1 reversal: criteria for clinical trials designed to overcome the multidrug resistance phenotype. Hegewisch-Becker S. **Leukemia** 1996 Jul;10 Suppl 3:S32–S38 (53 ref.)

IDDM see DIABETES MELLITUS, INSULIN-DEPENDENT

IDENTIFICATION (PSYCHOLOGY)

[Identity of the personality and personal identity: philosophical questions in relation to transplantation of brain tissue] Birnbacher D. **Zentralbl Neurochir** 1995; 56(4):180–5 (6 ref.) (Eng. Abstr.) **(Ger)**

IDENTIFICATION, SOCIAL see SOCIAL IDENTIFICATION

IDIOCY see MENTAL RETARDATION

IDIOPATHIC CD4-POSITIVE T-LYMPHOCYTOPENIA see T-LYMPHOCYTOPENIA, IDIOPATHIC CD4-POSITIVE

IDIOPATHIC HYPERCATABOLIC HYPOPROTEINEMIA see PROTEIN-LOSING ENTEROPATHIES

IDIOPATHIC HYPEREOSINOPHILIC SYNDROME see HYPEREOSINOPHILIC SYNDROME

IDIOPATHIC HYPERTROPHIC SUBAORTIC STENOSIS see CARDIOMYOPATHY, HYPERTROPHIC

IDIOPATHIC HYPERTROPHIC SUBVALVULAR STENOSIS see **CARDIOMYOPATHY, HYPERTROPHIC**

IDIOPATHIC INTRACRANIAL HYPERTENSION see **PSEUDOTUMOR CEREBRI**

IDIOPATHIC THROMBOCYTOPENIC PURPURA see **PURPURA, THROMBOCYTOPENIC, IDIOPATHIC**

IDIOTYPES, IMMUNOGLOBULIN see **IMMUNOGLOBULIN IDIOTYPES**

IDITOL DEHYDROGENASE

BLOOD

[Sorbitol dehydrogenase (SDH)] Okamoto Y, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:373–5 (11 ref.) **(Jpn)**

IDOXURIDINE

THERAPEUTIC USE

Preclinical animal studies with radioiododeoxyuridine. Kassis AI, et al. **J Nucl Med** 1996 Apr;37(4 Suppl):10S–12S (25 ref.)

IDURONIDASE

see related
MUCOPOLYSACCHARIDOSIS I

GENETICS

Molecular genetics of mucopolysaccharidosis type I: diagnostic, clinical, and biological implications. Scott HS, et al. **Hum Mutat** 1995;6(4):288–302 (66 ref.)

IFOSFAMIDE

ADMINISTRATION & DOSAGE

The role of ifosfamide in small cell lung cancer. Loehrer PJ Sr. **Semin Oncol** 1996 Jun;23(3 Suppl 7):40–4 (29 ref.)
The role of ifosfamide in the treatment of testicular and urothelial malignancies. Roth BJ. **Semin Oncol** 1996 Jun; 23(3 Suppl 7):19–27 (83 ref.)
The role of ifosfamide and systemic therapy in the management of carcinoma of the cervix. Thigpen T, et al. **Semin Oncol** 1996 Jun;23(3 Suppl 6):56–64 (52 ref.)

ADVERSE EFFECTS

Ifosfamide nephrotoxicity in children: histopathological features in two cases. Morland BJ, et al. **Med Pediatr Oncol** 1996 Jul;27(1):57–61 (17 ref.)
Oral administration of mesna with ifosfamide. Goren MP. **Semin Oncol** 1996 Jun;23(3 Suppl 6):91–6 (51 ref.)

THERAPEUTIC USE

Ifosfamide in the treatment of lymphoma. Coiffier B. **Semin Oncol** 1996 Jun;23(3 Suppl 7):2–7 (46 ref.)
Ifosfamide in the treatment of soft tissue sarcomas. Connelly EF, et al. **Semin Oncol** 1996 Jun;23(3 Suppl 6):16–21 (21 ref.)
High-dose ifosfamide in the treatment of sarcomas of soft tissues and bone. Demetri GD. **Semin Oncol** 1996 Jun;23(3 Suppl 6):22–6 (19 ref.)
Ifosfamide in the treatment of small cell lung cancer. Ettinger DS. **Semin Oncol** 1996 Jun;23(3 Suppl 6):2–6 (20 ref.)
Ifosfamide in non-small cell lung cancer. Johnson DH. **Semin Oncol** 1996 Jun;23(3 Suppl 6):7–10 (27 ref.)
Ifosfamide in the treatment of ovarian cancer. Markman M. **Semin Oncol** 1996 Jun;23(3 Suppl 6):47–9 (22 ref.)
Ifosfamide in the treatment of germ cell tumors. Nichols CR. **Semin Oncol** 1996 Jun;23(3 Suppl 6):65–73 (55 ref.)
Ifosfamide in the treatment of breast cancer. Overmoyer BA. **Semin Oncol** 1996 Jun;23(3 Suppl 6):38–41 (24 ref.)
Ifosfamide in the treatment of non-Hodgkin's lymphoma. Pohlman B. **Semin Oncol** 1996 Jun;23(3 Suppl 6):27–32 (24 ref.)
Ongoing clinical studies of ifosfamide for pediatric cancer in the United States. Pratt CB. **Semin Oncol** 1996 Jun;23(3 Suppl 6):84–90 (51 ref.)
Ifosfamide in the treatment of bladder cancer. Roth BJ. **Semin Oncol** 1996 Jun;23(3 Suppl 6):50–5 (48 ref.)
Dose-intensive ifosfamide for the treatment of non-Hodgkin's lymphoma. Vose JM. **Semin Oncol** 1996 Jun;23(3 Suppl 6):33–7 (20 ref.)

TOXICITY

Strategies to prevent nephrotoxicity of anticancer drugs. Skinner R. **Curr Opin Oncol** 1995 Jul;7(4):310–5 (38 ref.)

IGA

ANALYSIS

IgG and IgA antibodies to dietary antigens in food allergy and intolerance. Barnes RM. **Clin Exp Allergy** 1995 Jul;25 Suppl 1:7–9 (39 ref.)
[Antibodies generated against hepatitis C virus (HCV) core antigen: IgM and IgA antibody against HCV core] Sato S, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:253–9 (16 ref.) **(Jpn)**
[IgM and IgA antibodies to hepatitis B core antigen] Suga M. **Nippon Rinsho** 1995 Oct;53 Suppl:258–64 (24 ref.) **(Jpn)**
[Pancreatic lipase deficiency and linear IgA disease in childhood] Olivera Olmedo JE, et al. **An Esp Pediatr** 1996 Jan;44(1):73–5 (15 ref.) **(Spa)**

BIOSYNTHESIS

Cellular and molecular biologic approaches for analyzing the in vivo development and maintenance of gut mucosal IgA responses. Cebra JJ, et al. **Adv Exp Med Biol** 1995; 371A:429–34 (11 ref.)
Role of gamma delta T cells in the regulation of mucosal IgA response and oral tolerance. Fujihashi K, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:55–63 (42 ref.)
The role of Th1 and Th2 cells for mucosal IgA responses. Yamamoto M, et al. **Ann N Y Acad Sci** 1996 Feb 13; 778:64–71 (39 ref.)

BLOOD

[Diagnostic aspects of IgA-fibronectin in serum of patients with IgA nephropathy] Sela BA, et al. **Harefuah** 1995 Aug; 129(3–4):127–30 (20 ref.) **(Heb)**

CHEMISTRY

Structure of IgA: facts and gaps in our data on disulfide bonds. Biewenga J. **Adv Exp Med Biol** 1995;371A:575–9 (18 ref.)

GENETICS

In vivo switching: identification of germline transcripts for human IgA. Smith CI, et al. **Adv Exp Med Biol** 1995; 371A:9–13 (15 ref.)

METABOLISM

IgA glycosylation and disease. Dueymes M, et al. **Adv Exp Med Biol** 1995;376:217–20 (18 ref.)
Antigenic and genetic heterogeneity among Haemophilus influenzae and Neisseria IgA1 proteases. Lomholt H, et al. **Adv Exp Med Biol** 1995;371A:599–603 (18 ref.)
Lectin–carbohydrate interactions in disease. T-cell recognition of IgA and IgD; mannose binding protein recognition of IgG0. Rudd P, et al. **Adv Exp Med Biol** 1995;376:147–52 (10 ref.)
Abnormal glycosylation of IgA: is it related to the pathogenesis of IgA nephropathy? [editorial] Allen AC. **Nephrol Dial Transplant** 1995;10(7):1121–4 (11 ref.)

PHYSIOLOGY

Biological significance of IgA1 proteases in bacterial colonization and pathogenesis: critical evaluation of experimental evidence. Kilian M, et al. **APMIS** 1996 May; 104(5):321–38 (155 ref.)

IGA DEFICIENCY

COMPLICATIONS

Hodgkin's disease associated with IgA and IgG subclass deficiency. Zenone T, et al. **J Intern Med** 1996 Aug; 240(2):99–102 (29 ref.)

GENETICS

Genetics of IgA deficiency. Truedsson L, et al. **APMIS** 1995 Dec;103(12):833–42 (72 ref.)

IMMUNOLOGY

[Job syndrome (hyper-IgE) and hypo-IgA. A rare association of immunodeficiencies] Mazzone A, et al. **Recenti Prog Med** 1996 Feb;87(2):71–4 (20 ref.) (Eng. Abstr.) **(Ita)**

IGA, EXOCRINE see **IGA, SECRETORY**

IGA GLOMERULONEPHRITIS see **GLOMERULONEPHRITIS, IGA**

IGA NEPHROPATHY see **GLOMERULONEPHRITIS, IGA**

IGA, SECRETORY

[The IgA immune system for mucosal vaccine: role of levels one and two Th2 cytokine producing T cells] Shimaoka M, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Feb; 19(1):114–8 (15 ref.) **(Jpn)**

BIOSYNTHESIS

Modifiers of the human mucosal immune system. Gleeson M, et al. **Immunol Cell Biol** 1995 Oct;73(5):397–404 (49 ref.)

IGD

[Hyperimmunoglobulinemia D or periodic fever syndrome. Cutaneous manifestations in 3 cases] Cartier H, et al. **Ann Dermatol Venereol** 1996;123(5):314–21 (34 ref.) (Eng. Abstr.) **(Fre)**
[Hyperimmunoglobulin D syndrome] Drenth JP, et al. **Presse Med** 1995 Sep 16;24(26):1211–3 (21 ref.) (Eng. Abstr.) **(Fre)**
[IgD (lambda) multiple myeloma associated with myelofibrosis: an isolated case of nuclear physicist] Kanoh T, et al. **Rinsho Ketsueki** 1996 Mar;37(3):244–8 (14 ref.) (Eng. Abstr.) **(Jpn)**

ANALYSIS

IgD myeloma: clinical characteristics and a new staging system based on analysis of Japanese patients. Shimamoto Y. **Cancer Detect Prev** 1995;19(5):426–35 (148 ref.)

BIOSYNTHESIS

Children with hyperimmunoglobulinemia D and periodic fever syndrome. Grose C, et al. **Pediatr Infect Dis J** 1996 Jan;15(1):72–7 (16 ref.)

METABOLISM

Lectin–carbohydrate interactions in disease. T-cell recognition of IgA and IgD; mannose binding protein recognition of IgG0. Rudd P, et al. **Adv Exp Med Biol** 1995;376:147–52 (10 ref.)

IGE

see related
RECEPTORS, IGE

BIOSYNTHESIS

Modified allergen immunotherapy: effect on immunoglobulin E production. Babakhin AA, et al. **Allergy Proc** 1995 Jul–Aug;16(4):195–202 (46 ref.)
Regulation of IgE production and other immunopathogenetic mechanisms. Chowdhury BA. **Clin Rev Allergy Immunol** 1995 Winter;13(4):315–28 (74 ref.)
The central rôle of T-cells in allergic sensitization and IgE regulation. Renz H. **Exp Dermatol** 1995 Aug;4(4 Pt 1):173–82 (91 ref.)
Regulation of human IgE synthesis. Vercelli D, et al. **Int Rev Immunol** 1989;5(2):111–5 (35 ref.)
Functional significance of IL-4 receptor on B cells in IL-4–induced human IgE production. Yanagihara Y, et al. **J Allergy Clin Immunol** 1995 Dec;96(6 Pt 2):1145–51 (39 ref.)
Regulation of IgE synthesis in humans. Vercelli D. **J Biol Regul Homeost Agents** 1995 Jan–Mar;9(1):1–6 (48 ref.)

BLOOD

[Enzyme immunoassay of substances related to allergy] Midoro-Horiuti T. **Nippon Rinsho** 1995 Sep;53(9):2262–8 (20 ref.) (Eng. Abstr.) **(Jpn)**

DRUG EFFECTS

Modified allergen immunotherapy: effect on immunoglobulin E production. Babakhin AA, et al. **Allergy Proc** 1995 Jul–Aug;16(4):195–202 (46 ref.)

IMMUNOLOGY

IgE-mediated (and food-induced) intestinal disease. Strobel S. **Clin Exp Allergy** 1995 Jul;25 Suppl 1:3–6 (61 ref.)
Molecular regulation of the IgE immune response. Vercelli D. **Clin Exp Allergy** 1995 Nov;25 Suppl 2:43–5 (18 ref.)
Anti-IgE therapy. Jardieu P. **Curr Opin Immunol** 1995 Dec; 7(6):779–82 (36 ref.)
Consequences of IgE/CD23-mediated antigen presentation in allergy. Mudde GC, et al. **Immunol Today** 1995 Aug; 16(8):380–3 (41 ref.)
HLA genetics and allergic disease [editorial] Howell WM, et al. **Thorax** 1995 Aug;50(8):815–8 (32 ref.)
[Role of Langerhans cells in the physiopathology of atopic dermatitis] Bieber T. **Pathol Biol (Paris)** 1995 Dec; 43(10):871–5 (39 ref.) (Eng. Abstr.) **(Fre)**
[Immunoglobulins E and inflammatory cells] Tunon de Lara JM. **Rev Mal Respir** 1996;13(1):27–36 (32 ref.) (Eng. Abstr.) **(Fre)**
[Atopy score in infancy and the severity of asthma at 7 years of age] Uhereczky G, et al. **Orv Hetil** 1996 Jan 28; 137(4):175–8 (46 ref.) (Eng. Abstr.) **(Hun)**

IGE-MEDIATED HYPERSENSITIVITY see **HYPERSENSITIVITY, IMMEDIATE**

IGE RECEPTORS see **RECEPTORS, IGE**

IGF-BINDING PROTEINS see **INSULIN-LIKE GROWTH-FACTOR-BINDING PROTEINS**

IGF-I see **INSULIN-LIKE GROWTH FACTOR I**

IGF-I RECEPTORS see **RECEPTORS, INSULIN-LIKE-GROWTH FACTOR I**

IGF-II see **INSULIN-LIKE GROWTH FACTOR II**

IGF-II RECEPTORS see **RECEPTORS, INSULIN-LIKE-GROWTH-FACTOR II**

IGFBP see **INSULIN-LIKE GROWTH-FACTOR-BINDING PROTEINS**

IGG

see related
RECEPTORS, IGG

ANALYSIS

IgG and IgA antibodies to dietary antigens in food allergy and intolerance. Barnes RM. **Clin Exp Allergy** 1995 Jul;25 Suppl 1:7-9 (39 ref.)

Anti-endothelial cell antibodies in sera from patients with inflammatory bowel disease. Aldebert D, et al. **Gastroenterol Clin Biol** 1995 Nov;19(11):867-70 (20 ref.)

[Quantitative assay of anti-HCV core antibody with JCC-2 ELISA: anti-HCV core IgG antibody] Nakashima T, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:247-52 (19 ref.) **(Jpn)**

BIOSYNTHESIS

Phage libraries--a new route to clinically useful antibodies. Marks C, et al. **N Engl J Med** 1996 Sep 5;335(10):730-3 (0 ref.)

BLOOD

Abnormalities in the glycosylation of IgG and its clinical utility. Isenberg D. **Adv Exp Med Biol** 1995;376:179-83 (16 ref.)

Significance and molecular basis for IgG glycosylation changes in rheumatoid arthritis. Rademacher TW, et al. **Adv Exp Med Biol** 1995;376:193-204 (52 ref.)

Rubella immunity. Defining the level of protective antibody. Skendzel LP. **Am J Clin Pathol** 1996 Aug;106(2):170-4 (39 ref.)

The influence of gene deletions and duplications within the IGHC locus on serum immunoglobulin subclass levels. Rabbani H, et al. **Clin Immunol Immunopathol** 1995 Sep; 76(3 Pt 2):S214-8 (24 ref.)

[Chlamydia pneumoniae infection associated with autoimmune hemolytic anemia due to warm antibodies] Belda J, et al. **Arch Bronconeumol** 1996 May;32(5):251-2 (7 ref.) (Eng. Abstr.) **(Spa)**

CHEMISTRY

[Non-native conformational states of immunoglobulins: thermodynamic and functional analysis of rabbit IgG] Vlasov AP, et al. **Biokhimiia** 1996 Feb;61(2):212-35 (66 ref.) (Eng. Abstr.) **(Rus)**

CLASSIFICATION

The influence of gene deletions and duplications within the IGHC locus on serum immunoglobulin subclass levels. Rabbani H, et al. **Clin Immunol Immunopathol** 1995 Sep; 76(3 Pt 2):S214-8 (24 ref.)

DIAGNOSTIC USE

Use of polyclonal IgG in HIV infection and AIDS. Buscombe JR, et al. **Q J Nucl Med** 1995 Sep;39(3):212-20 (34 ref.)

IMMUNOLOGY

Mechanisms of T-cell-induced allotypic suppression of mouse IgG2a(b) and of tolerance acquisition to this allotype. Majlessi L, et al. **Res Immunol** 1995 May-Jun; 146(4-5):213-24 (71 ref.)

The effector functions of immunoglobulins: implications for therapy. Ward ES, et al. **Ther Immunol** 1995 Apr;2(2):77-94 (100 ref.)

METABOLISM

Lectin-carbohydrate interactions in disease. T-cell recognition of IgA and IgD; mannose binding protein recognition of IgG0. Rudd P, et al. **Adv Exp Med Biol** 1995;376:147-52 (10 ref.)

The effects of altered glycosylation of IgG on rheumatoid factor-binding and immune complex formation. Soltys AJ, et al. **Adv Exp Med Biol** 1995;376:155-60 (12 ref.)

Human Fc receptors for IgG. Unkeless JC. **Int Rev Immunol** 1989;5(2):165-71 (56 ref.)

[Fc gamma receptors. Properties and participation in IgG binding and other biological processes] Sokal I. **Postepy Hig Med Dosw** 1995;49(1):47-51 (21 ref.) (Eng. Abstr.) **(Pol)**

PHARMACOLOGY

Down regulation of Fc receptors by IVIgG. Mannhalter JW, et al. **Int Rev Immunol** 1989;5(2):173-9 (24 ref.)

THERAPEUTIC USE

TNF alpha is an effective therapeutic target for rheumatoid arthritis. Feldmann M, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:272-8 (20 ref.)

The effector functions of immunoglobulins: implications for therapy. Ward ES, et al. **Ther Immunol** 1995 Apr;2(2):77-94 (100 ref.)

The introduction of human monoclonal anti-D for therapeutic use. Fletcher A, et al. **Transfus Med Rev** 1995 Oct;9(4):314-26 (87 ref.)

IGG DEFICIENCY

COMPLICATIONS

Hodgkin's disease associated with IgA and IgG subclass deficiency. Zenone T, et al. **J Intern Med** 1996 Aug; 240(2):99-102 (29 ref.)

IGG RECEPTORS see **RECEPTORS, IGG**

IGM

X-linked agammaglobulinemia and immunoglobulin deficiency with normal or elevated IgM: immunodeficiencies of B cell development and differentiation. Fuleihan R, et al. **Adv Immunol** 1995; 60:37-56 (124 ref.)

[A case of Guillain-Barré syndrome associated with anti-GM2 antibody due to cytomegalovirus infection--special reference to the effect of ganciclovir] Niwa K, et al. **Rinsho Shinkeigaku** 1995 Jun;35(6):652-6 (18 ref.) (Eng. Abstr.) **(Jpn)**

ANALYSIS

[Antibodies generated against hepatitis C virus (HCV) core antigen: IgM and IgA antibody against HCV core] Sato S, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:253-9 (16 ref.) **(Jpn)**

[IgM and IgA antibodies to hepatitis B core antigen] Suga M. **Nippon Rinsho** 1995 Oct;53 Suppl:258-64 (24 ref.) **(Jpn)**

BIOSYNTHESIS

B-1 cells and autoimmunity. Murakami M, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:402-9 (34 ref.)

BLOOD

CD40-CD40 ligand (CD40L) interactions and X-linked hyperIgM syndrome (HIGMX-1). Ramesh N, et al. **Clin Immunol Immunopathol** 1995 Sep;76(3 Pt 2):S208-13 (37 ref.)

[The Schnitzler syndrome as a cause of recurrent fever of unknown origin] Winckelmann G, et al. **Dtsch Med Wochenschr** 1996 Jul 5;121(27):860-4 (14 ref.) (Eng. Abstr.) **(Ger)**

CHEMISTRY

Developmental regulation of the human beta-globin cluster. Jane SM, et al. **Aust N Z J Med** 1995 Dec;25(6):865-9 (30 ref.)

DEFICIENCY

[A case of selective IgM deficiency associated with systemic lupus erythematosus] Tanaka A, et al. **Nippon Jinzo Gakkai Shi** 1996 Apr;38(4):185-90 (21 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Cross-reactive idiotypes on cryoprecipitating monoclonal IgMk rheumatoid factors. Sinico RA, et al. **Clin Exp Rheumatol** 1995 Nov-Dec;13 Suppl 13:S105-7 (8 ref.)

IL-1 see **INTERLEUKIN-1**

IL-1 RECEPTORS see **RECEPTORS, INTERLEUKIN-1**

IL-2 see **INTERLEUKIN-2**

IL-2 RECEPTORS see **RECEPTORS, INTERLEUKIN-2**

IL-3 see **INTERLEUKIN-3**

IL-4 see **INTERLEUKIN-4**

IL-5 see **INTERLEUKIN-5**

IL-6 see **INTERLEUKIN-6**

IL-7 see **INTERLEUKIN-7**

IL-8 see **INTERLEUKIN-8**

IL-10 see **INTERLEUKIN-10**

IL-11 see **INTERLEUKIN-11**

IL-12 see **INTERLEUKIN-12**

ILEAL DISEASES

Intussusception. Winslow BT, et al. **Am Fam Physician** 1996 Jul;54(1):213-7, 220 (19 ref.)

COMPLICATIONS

A rare case of multiple intussusceptions: intense segmentary lipomatosis of the ileum. Young TH, et al. **Am J Gastroenterol** 1996 Jan;91(1):162-3 (10 ref.)

DIAGNOSIS

Gastrointestinal tuberculosis in renal transplantation: a case report and review. Ahsan N, et al. **Clin Transplant** 1995 Aug;9(4):349-52 (19 ref.)

An unusual presentation of intestinal duplication with a literature review. Otter MI, et al. **Dig Dis Sci** 1996 Mar; 41(3):627-9 (14 ref.)

ETIOLOGY

Small bowel intussusception and brown bowel syndrome in association with severe malnutrition. Drake WM, et al. **Am J Gastroenterol** 1996 Jul;91(7):1450-2 (20 ref.)

[Perforation in Crohn's ileitis and its impact on the natural history of the disease. Note 1. Pathogenic process of the event, its relationship with intestinal obstruction, and its immediate consequences] Tonelli P. **Ann Ital Chir** 1995 May-Jun;66(3):335-47 (24 ref.) (Eng. Abstr.) **(Ita)**

[Biliary ileus. A report of 2 cases] Ottenello M, et al. **Minerva Chir** 1996 Jan-Feb;51(1-2):67-9 (18 ref.) (Eng. Abstr.) **(Ita)**

[An adult case of intussusception due to inverted Meckel's diverticulum accompanied by angiolipoma] Kaneko T, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Apr;93(4):260-5 (14 ref.) **(Jpn)**

MICROBIOLOGY

Gastrointestinal tuberculosis in renal transplantation: a case report and review. Ahsan N, et al. **Clin Transplant** 1995 Aug;9(4):349-52 (19 ref.)

SURGERY

[Internal hernia of the small intestine through a breach of the broad ligament, apropos of a case. Review of the literature] Fafet P, et al. **J Chir (Paris)** 1995 Jun-Jul; 132(6-7):314-7 (14 ref.) (Eng. Abstr.) **(Fre)**

[Atopic stomach polyp as the cause of invagination of Meckel's diverticulum] Schütter FW, et al. **Chirurg** 1995 Oct;66(10):1016-8 (24 ref.) (Eng. Abstr.) **(Ger)**

ULTRASONOGRAPHY

[Ultrasound morphologic spectrum of Meckel's diverticulitis--3 case reports and overview of the literature] Demharter J, et al. **Rontgenpraxis** 1996 Jun;49(6):145-8 (11 ref.) **(Ger)**

ILEAL NEOPLASMS

CHEMICALLY INDUCED

[A case of rheumatoid arthritis with malignant lymphoma taking methotrexate] Hayakawa M, et al. **Ryumachi** 1995 Aug;35(4):678-82 (23 ref.) (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

[An adult case of intussusception due to inverted Meckel's diverticulum accompanied by angiolipoma] Kaneko T, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Apr;93(4):260-5 (14 ref.) **(Jpn)**

DIAGNOSIS

Small bowel carcinoid: review of a single institution experience and review of the literature. Box JC, et al. **Am Surg** 1996 Apr;62(4):280-6 (40 ref.)

Diffuse ganglioneuromatosis with plexiform neurofibromas limited to the gastrointestinal tract involving a large segment of small intestine. Hirata K, et al. **J Gastroenterol** 1996 Apr;31(2):263-7 (15 ref.)

ETIOLOGY

Recurrent polyps in the ileo-anal pouch or rectum in familial adenomatous polyposis. Tytgat GN, et al. **Eur J Cancer** 1995 Jul-Aug;31A(7-8):1154-9 (45 ref.)

GENETICS

K-ras mutation in a tubular adenoma originating at an ileostomy in a familial adenomatous polyposis patient. Herring JA, et al. **Am J Gastroenterol** 1996 Mar; 91(3):587-91 (38 ref.)

PATHOLOGY

Increased incidence of second primary malignancy in patients with carcinoid tumors: case report and literature review. Rivadeneira DE, et al. **J Natl Med Assoc** 1996 May; 88(5):310-2 (12 ref.)

ILEAL RESERVOIRS see **PROCTOCOLECTOMY, RESTORATIVE**

ILEITIS, REGIONAL see **CROHN DISEASE**

ILEITIS, TERMINAL see **CROHN DISEASE**

ILEOANAL POUCHES

ILEOANAL POUCHES see PROCTOCOLECTOMY, RESTORATIVE

ILEOCECAL VALVE

Intussusception. Winslow BT, et al. **Am Fam Physician** 1996 Jul;54(1):213–7, 220 (19 ref.)

A rare case of multiple intussusceptions: intense segmentary lipomatosis of the ileum. Young TH, et al. **Am J Gastroenterol** 1996 Jan;91(1):162–3 (10 ref.)

Intraoperative enteroscopy in the diagnosis of partial intestinal obstruction in infancy. Duggan C, et al. **Dig Dis Sci** 1995 Oct;40(10):2236–8 (12 ref.)

[Biliary ileus. A report of 2 cases] Ottenello M, et al. **Minerva Chir** 1996 Jan–Feb;51(1–2):67–9 (18 ref.) (Eng. Abstr.) **(Ita)**

ILEOCOLITIS see CROHN DISEASE

ILEOJEJUNAL BYPASS see JEJUNOILEAL BYPASS

ILEOSTOMY

K-ras mutation in a tubular adenoma originating at an ileostomy in a familial adenomatous polyposis patient. Herring JA, et al. **Am J Gastroenterol** 1996 Mar; 91(3):587–91 (38 ref.)

Suggested sterol-binding mechanisms of dietary fibre based on ileostomy studies. Andersson H. **Eur J Clin Nutr** 1995 Oct;49 Suppl 3:S173–7 (39 ref.)

Surgical options for familial adenomatous polyposis. Ambroze WL Jr, et al. **Semin Surg Oncol** 1995 Nov–Dec; 11(6):423–7 (27 ref.)

ADVERSE EFFECTS

The morbidity of defunctioning stomata. Chen F, et al. **Aust N Z J Surg** 1996 Apr;66(4):218–21 (25 ref.)

METHODS

[Surgical treatment of ulcero-hemorrhagic rectocolitis] Dozois RR, et al. **Ann Chir** 1995;49(7):628–36 (60 ref.) (Eng. Abstr.) **(Fre)**

ILEUM

see related
ILEOSTOMY

ABNORMALITIES

An unusual presentation of intestinal duplication with a literature review. Otter MI, et al. **Dig Dis Sci** 1996 Mar; 41(3):627–9 (14 ref.)

BLOOD SUPPLY

[A case of arteriovenous malformation of the ileum complicated with decompensated liver cirrhosis: effective case of home parenteral nutrition for intestinal bleeding] Fukushima M, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Nov;92(11):1871–5 (15 ref.) **(Jpn)**

PHYSIOLOGY

[Neurohormonal control of gallbladder motility by intra-ileal and intracolonic nutrients—a review] Niebergall-Roth E, et al. **Berl Munch Tierarztl Wochenschr** 1996 Mar; 109(3):87–94 (110 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Effect of some abdominal surgical operations on small bowel motility in humans: our experience. Bassotti G, et al. **J Clin Gastroenterol** 1995 Oct;21(3):211–6 (86 ref.)

[Endourologic treatment of uretero-ileal stenosis] del Hoyo Campos J, et al. **Arch Esp Urol** 1995 Sep;48(7):735–40 (23 ref.) (Eng. Abstr.) **(Spa)**

ILEUS see INTESTINAL OBSTRUCTION

ILIAC ARTERY

Presentation of Ehlers-Danlos syndrome: iliac artery pseudoaneurysm rupture. Meldon S, et al. **Ann Emerg Med** 1996 Aug;28(2):231–4 (14 ref.)

Deep venous thrombosis with pulmonary embolus after selective embolization of an internal iliac artery aneurysm. Su WT, et al. **J Vasc Surg** 1996 Jan;23(1):152–5 (13 ref.)

Infected iliac pseudoaneurysm after uncomplicated percutaneous balloon angioplasty and (Palmaz) stent insertion: a case report and literature review. Weinberg DJ, et al. **J Vasc Surg** 1996 Jan;23(1):162–6 (17 ref.)

Ureteroarterial fistula: case report and review of the literature. Batter SJ, et al. **Urology** 1996 Sep;48(3):481–9 (35 ref.)

SURGERY

Horseshoe kidney and aortic surgery. Wymenga LF, et al. **Scand J Urol Nephrol** 1995 Sep;29(3):331–4 (10 ref.)

ILIAC VEIN

Spontaneous rupture of left external iliac vein: case report and review of the literature. Lin BC, et al. **J Vasc Surg** 1996 Aug;24(2):284–7 (13 ref.)

Deep venous thrombosis with pulmonary embolus after selective embolization of an internal iliac artery aneurysm. Su WT, et al. **J Vasc Surg** 1996 Jan;23(1):152–5 (13 ref.)

Iliac vein compression as an anatomical cause of thrombophilia: Cockett's syndrome revisited. Verhaeghe R. **Thromb Haemost** 1995 Dec;74(6):1398–401 (24 ref.)

[Postappendectomy vascular complications in childhood] Díez García R, et al. **An Esp Pediatr** 1996 Mar;44(3):270–2 (19 ref.) **(Spa)**

ABNORMALITIES

Congenital absence of portal venous system associated with a large inferior mesenteric-caval shunt: a case report. Komatsu S, et al. **Hepatogastroenterology** 1995 Jul; 42(3):286–90 (17 ref.)

ILIUM

[A case of angiosarcoma of the pelvis associated with angiomatosis of the spine] Uribe Uribe NO, et al. **Rev Invest Clin** 1996 Jan–Feb;48(1):49–53 (9 ref.) (Eng. Abstr.) **(Spa)**

INJURIES

Fracture of the iliac crest following bone grafting: a case report and literature review. Friend KD, et al. **Bull Hosp Jt Dis** 1995;54(1):49–51 (8 ref.)

ILLICIT DRUGS see STREET DRUGS

ILLITERACY see EDUCATIONAL STATUS

ILLNESS BEHAVIOR see SICK ROLE

ILLUMINATING GAS POISONING see CARBON MONOXIDE POISONING

ILLUMINATION see LIGHTING

ILLUSTRATION, MEDICAL see MEDICAL ILLUSTRATION

IMAGE ANALYSIS, COMPUTER-ASSISTED see IMAGE PROCESSING, COMPUTER-ASSISTED

IMAGE CYTOMETRY

Image cytometry and chemoprevention in cervical cancer. Palcic B, et al. **J Cell Biochem Suppl** 1995;23:43–54 (18 ref.)

Diagnostic and prognostic decision support systems. Bartels PH, et al. **Pathologica** 1995 Jun;87(3):221–36 (33 ref.)

Applications of neural networks in histopathology. Becker RL JR. **Pathologica** 1995 Jun;87(3):246–54 (82 ref.)

Clinical applications of Bayesian belief networks in pathology. Hamilton PW, et al. **Pathologica** 1995 Jun; 87(3):237–45 (11 ref.)

3D reconstruction and quantitation of pathological tissues. Whimster WF, et al. **Pathologica** 1995 Jun;87(3):279–85 (40 ref.)

METHODS

Nuclear texture measurements in image cytometry. Doudkine A, et al. **Pathologica** 1995 Jun;87(3):286–99 (26 ref.)

Unbiased stereologic techniques for practical use in diagnostic histopathology. Sørensen FB. **Pathologica** 1995 Jun;87(3):263–78 (86 ref.)

Syntactic structure analysis. van Diest PJ, et al. **Pathologica** 1995 Jun;87(3):255–62 (41 ref.)

IMAGE ENHANCEMENT

see related
RADIOGRAPHIC IMAGE ENHANCEMENT

Why do we need contrast agents for ultrasound? Cosgrove D. **Clin Radiol** 1996 Feb;51 Suppl 1:1–4 (20 ref.)

MR mammography with pharmacokinetic mapping for monitoring of breast cancer treatment during neoadjuvant therapy. Knopp MV, et al. **Magn Reson Imaging Clin N Am** 1994 Nov;2(4):633–58 (42 ref.)

The specificity of contrast-enhanced breast MR imaging. Piccoli CW. **Magn Reson Imaging Clin N Am** 1994 Nov; 2(4):557–71 (75 ref.)

MR imaging of the breast. Imaging and tissue characterization without intravenous contrast. Santyr GE. **Magn Reson Imaging Clin N Am** 1994 Nov;2(4):673–90 (45 ref.)

INSTRUMENTATION

[Fast and ultra-fast sequences in MRI of the pelvis and retroperitoneum] Heuck A, et al. **Radiologe** 1995 Dec; 35(12):936–44 (44 ref.) (Eng. Abstr.) **(Ger)**

[Fast and ultra-fast MRI of the brain] Schuierer G, et al. **Radiologe** 1995 Dec;35(12):894–901 (25 ref.) (Eng. Abstr.) **(Ger)**

[Fast and ultra-fast magnetic resonance tomography. Basic principles, pulse sequences and special properties] Stehling MK, et al. **Radiologe** 1995 Dec;35(12):879–93 (41 ref.) (Eng. Abstr.) **(Ger)**

[Fast and ultra-fast imaging of the musculoskeletal system] Vahlensieck M. **Radiologe** 1995 Dec;35(12):973–80 (34 ref.) (Eng. Abstr.) **(Ger)**

[Fast and ultra-fast MRI imaging of the heart] von Schulthess GK, et al. **Radiologe** 1995 Dec;35(12):952–63 (69 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Sensitivity of contrast-enhanced MR imaging of the breast. Heywang-Koebrunner SH, et al. **Magn Reson Imaging Clin N Am** 1994 Nov;2(4):527–38 (32 ref.)

Magnetization transfer in magnetic resonance imaging. Thomas JD. **Radiol Technol** 1996 Mar–Apr;67(4):297–306 (26 ref.)

IMAGE INTERPRETATION, COMPUTER-ASSISTED

[Factors of image quality in spiral x-ray computed tomography] Ernst O, et al. **J Radiol** 1995 Dec; 76(12):1069–74 (13 ref.) (Eng. Abstr.) **(Fre)**

IMAGE PROCESSING, COMPUTER-ASSISTED

Diagnosis of coronary artery disease in women: roles of three dimensional imaging with magnetic resonance or positron emission tomography. Patterson RE, et al. **Am J Card Imaging** 1996 Jan;10(1):78–88 (86 ref.)

Image management in pathology. Weinberg DS, et al. **Am J Clin Pathol** 1996 Apr;105(4 Suppl 1):S54–9 (20 ref.)

Digital imaging of cephalometric radiography, Part 1: Advantages and limitations of digital imaging. Forsyth DB, et al. **Angle Orthod** 1996;66(1):37–42 (29 ref.)

ABC of medical computing. Digital imaging. Meire HB, et al. **BMJ** 1995 Nov 4;311(7014):1218–21 (0 ref.)

Aspects of enhanced three-dimensional radiotherapy treatment planning. Ten Haken RK, et al. **Bull Cancer (Paris)** 1995 Dec;82 Suppl 5:592s–600s (78 ref.)

Digital imaging in dermatology. Kenet RD. **Clin Dermatol** 1995 Jul–Aug;13(4):381–92 (50 ref.)

High-frequency sonography combined with image analysis: a noninvasive objective method for skin evaluation and description. Seidenari S. **Clin Dermatol** 1995 Jul–Aug; 13(4):349–59 (65 ref.)

Image analysis of tissue sections. Ong SH, et al. **Comput Biol Med** 1996 May;26(3):269–79 (68 ref.)

On-line portal imaging: contributions and limitations in clinical practice. Shalev S. **Front Radiat Ther Oncol** 1996; 29:156–67 (37 ref.)

Computer-assisted sperm analysis systems: morphometric aspects. Kruger T. **Hum Reprod** 1995 Oct;10 Suppl 1:46–52 (28 ref.)

The current state of the art in three dimensional oncologic imaging: an overview. Kuszyk BS, et al. **Int J Radiat Oncol Biol Phys** 1995 Dec 1;33(5):1029–39 (79 ref.)

Colour thresholding in video imaging. Fermin CD, et al. **J Anat** 1995 Jun;186 (Pt 3):469–81 (21 ref.)

Three-dimensional intracoronary ultrasound imaging. Methodology and clinical relevance for the assessment of coronary arteries and bypass grafts. Von Birgelen C, et al. **J Cardiovasc Surg (Torino)** 1996 Apr;37(2):129–39 (100 ref.)

The role of computerized morphometric and cytometric feature analysis in endometrial hyperplasia and cancer prognosis. Baak JP. **J Cell Biochem Suppl** 1995;23:137–46 (25 ref.)

Computer-assisted pathology of intraepithelial adenocarcinoma and related lesions: 3-D distribution, structural aberration and discrimination. Takahashi T, et al. **J Cell Biochem Suppl** 1995;23:25–32 (16 ref.)

Diffusion-weighted imaging in epilepsy. Helpern JA, et al. **Magn Reson Imaging** 1995;13(8):1227–31 (32 ref.)

Application of high field spectroscopic imaging in the evaluation of temporal lobe epilepsy. Hetherington HP, et al. **Magn Reson Imaging** 1995;13(8):1175–80 (14 ref.)

MRI-based hippocampal volumetrics: data acquisition, normal ranges, and optimal protocol. Jack CR Jr, et al. **Magn Reson Imaging** 1995;13(8):1057–64 (36 ref.)

Novel MR image contrast mechanisms in epilepsy. Tofts PS. **Magn Reson Imaging** 1995;13(8):1099–106 (67 ref.)

Frameless neuronavigation in modern neurosurgery. Spetzger U, et al. **Minim Invasive Neurosurg** 1995 Dec;38(4):163–6 (31 ref.)

Applications of neural networks in histopathology. Becker RL JR. **Pathologica** 1995 Jun;87(3):246–54 (82 ref.)

3D reconstruction and quantitation of pathological tissues. Whimster WF, et al. **Pathologica** 1995 Jun;87(3):279–85 (40 ref.)

Registration of multi-modal biomedical images of the heart. Gilardi MC, et al. **Q J Nucl Med** 1996 Mar;40(1):142–50 (43 ref.)

Image processing and computer-aided diagnosis. Giger M, et al. **Radiol Clin North Am** 1996 May;34(3):565–96 (115 ref.)

Three-dimensional imaging, surgical planning, and image-guided therapy. Vannier MW, et al. **Radiol Clin North Am** 1996 May;34(3):545–63 (131 ref.)

Workshop report: clinical CASA—the quest for consensus.

Mortimer D, et al. **Reprod Fertil Dev** 1995;7(4):951–9 (51 ref.)
Image representations for visual learning. Beymer D, et al. **Science** 1996 Jun 28;272(5270):1905–9 (61 ref.)
Lesions of the jaws. DelBalso AM. **Semin Ultrasound CT MR** 1995 Dec;16(6):487–512 (42 ref.)
[Comparative genomic hybridization in pathology. A new molecular cytogenetic method] Störkel S, et al. **Pathologe** 1996 May;17(3):189–94 (19 ref.) (Eng. Abstr.) **(Ger)**
[Possibilities of spiral-CT for diagnosis of focal liver lesions] Helmberger H, et al. **Rontgenpraxis** 1996 Mar;49(3):49–54 (35 ref.) **(Ger)**
[The use of computerized image analysis of tissue specimens and cell cultures in the early identification and the understanding of the pathogenesis of malignant tumors] Goshen R, et al. **Harefuah** 1995 Nov 1;129(9):329–36 (31 ref.) **(Heb)**
[Computer-assisted image analysis of calcium ion concentration] Kudo Y, et al. **Nippon Seirigaku Zasshi** 1996; 58(2):69–82 (17 ref.) **(Jpn)**

INSTRUMENTATION

Helical CT cholangiography. Stockberger SM, et al. **Abdom Imaging** 1996 Mar–Apr;21(2):98–104 (17 ref.)
Neuromedical Systems, Inc. Mango LJ. **Acta Cytol** 1996 Jan–Feb;40(1):53–9 (25 ref.)
NeoPath, Inc. NeoPath AutoPap 300 Automatic Pap Screener System. Patten SF Jr, et al. **Acta Cytol** 1996 Jan–Feb;40(1):45–52 (12 ref.)
Time-of-flight magnetic resonance angiography of aorta and renal arteries: state-of-the-art. Laissy JP, et al. **Eur J Radiol** 1996 Feb;21(3):201–11 (71 ref.)
Image storage. Venables CW. **Gastroenterologist** 1995 Dec; 3(4):268–72 (7 ref.)
Intravenous coronary angiography with dichromography using synchrotron radiation. Hamm CW, et al. **Herz** 1996 Apr;21(2):127–31 (13 ref.)
Coronary artery imaging by magnetic resonance. Scheidegger MB, et al. **Herz** 1996 Apr;21(2):90–6 (20 ref.)
Non-invasive visualization of coronary arteries with and without calcification by electron beam computed tomography. Schmermund A, et al. **Herz** 1996 Apr; 21(2):118–26 (49 ref.)
Coronary imaging using MRI. van Rossum AC, et al. **Herz** 1996 Apr;21(2):97–105 (38 ref.)
Three-dimensional reconstruction of coronary arteries with intravascular ultrasound. von Birgelen C, et al. **Herz** 1995 Aug;20(4):277–89 (85 ref.)
Design and implementation of a picture archiving and communication system: the second time. Huang HK, et al. **J Digit Imaging** 1996 May;9(2):47–59 (18 ref.)
Clinical applications of functional MRI in neuropsychiatry. Levin JM, et al. **J Neuropsychiatry Clin Neurosci** 1995 Fall; 7(4):511–22 (98 ref.)
New technical developments in magnetic resonance imaging of epilepsy. Riederer SJ, et al. **Magn Reson Imaging** 1995; 13(8):1095–8 (18 ref.)
Image-guided spine surgery. Foley KT, et al. **Neurosurg Clin N Am** 1996 Apr;7(2):171–86 (7 ref.)
A technique for interactive image-guided neurosurgical intervention in primary brain tumors. Maciunas RJ, et al. **Neurosurg Clin N Am** 1996 Apr;7(2):245–66 (111 ref.)
Image-guided surgery of epilepsy. Olivier A, et al. **Neurosurg Clin N Am** 1996 Apr;7(2):229–43 (23 ref.)
The evaluation and image-guided surgical treatment of the patient with a medically intractable seizure disorder. Roberts DW, et al. **Neurosurg Clin N Am** 1996 Apr; 7(2):215–27 (46 ref.)
Derivation and reliability of kinematic measures of sperm motion. Davis RO, et al. **Reprod Fertil Dev** 1995; 7(4):857–69 (54 ref.)
Vascular imaging before, during, and after endovascular repair. White RA, et al. **World J Surg** 1996 Jul–Aug; 20(6):622–9 (42 ref.)
[clinical application of multiplanar and 3D reconstruction of spiral CT in diagnosis of acetabulum fractures] Stroszczynski C, et al. **Aktuelle Radiol** 1996 Mar;6(2):91–5 (23 ref.) (Eng. Abstr.) **(Ger)**
[Transvaginal 3 D ultrasound in gynecology] Merz E, et al. **Gynakologe** 1995 Aug;28(4):270–5 (9 ref.) **(Ger)**
[Potential 3-dimensional (3D-)ultrasound in the diagnosis of fetal abnormalities] Steiner H. **Gynakologe** 1995 Oct; 28(5):315–20 (31 ref.) **(Ger)**
[Diagnosis of coronary heart disease using echocardiography 3D reconstructions. Diagnosis of global and regional left ventricular function] Buck T, et al. **Herz** 1995 Aug; 20(4):252–62 (57 ref.) (Eng. Abstr.) **(Ger)**
[Three-dimensional reconstruction of heart valves] Flachskampf FA, et al. **Herz** 1995 Aug;20(4):236–42 (21 ref.) (Eng. Abstr.) **(Ger)**
[Trans-thoracic 3D echocardiography reconstruction for left ventricular volume determination] Kupferwasser I, et al. **Herz** 1995 Aug;20(4):243–51 (53 ref.) (Eng. Abstr.) **(Ger)**
[3D echocardiography. Mathematical principles and technical realization] Wollschläger H. **Herz** 1995 Aug; 20(4):225–35 (15 ref.) (Eng. Abstr.) **(Ger)**
[Radiation dosage of various CT techniques in diagnostic lung imaging] Heinz-Peer G, et al. **Radiologe** 1996 Jun; 36(6):470–4 (18 ref.) (Eng. Abstr.) **(Ger)**
[Spiral CT in chronic lung thromboembolism] Kontrus M, et al. **Radiologe** 1996 Jun;36(6):496–502 (27 ref.) (Eng. Abstr.) **(Ger)**
[3-D imaging of the liver] Leppek R, et al. **Radiologe** 1995 Oct;35(10):769–77 (44 ref.) (Eng. Abstr.) **(Ger)**
[Spiral CT of the lung. Technique, findings, value] Prokop M, et al. **Radiologe** 1996 Jun;36(6):457–69 (42 ref.) (Eng. Abstr.) **(Ger)**
[Fast and ultra-fast imaging of the musculoskeletal system] Vahlensieck M. **Radiologe** 1995 Dec;35(12):973–80 (34 ref.) (Eng. Abstr.) **(Ger)**
[Virtual reality in medicine] Völter S, et al. **Radiologe** 1995 Sep;35(9):563–8 (25 ref.) (Eng. Abstr.) **(Ger)**
[Use of 3D ultrasound technique in prenatal diagnosis] Merz E. **Ultraschall Med** 1995 Aug;16(4):154–61 (28 ref.) (Eng. Abstr.) **(Ger)**
[Laparoscopic technique--which developments are possible?] Voges U. **Urologe A** 1996 May;35(3):208–14 (6 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Parametric imaging in nuclear medicine. Lassen NA, et al. **Ann Nucl Med** 1995 Nov;9(4):167–70 (8 ref.)
Modern image capture and data collection technology. Shafi MI, et al. **Clin Obstet Gynecol** 1995 Sep;38(3):640–3 (9 ref.)
Mechanics of image manipulation. Swobodnik W. **Gastroenterologist** 1995 Dec;3(4):266–7 (0 ref.)
Robert Feulgen Prize Lecture 1995. Electronic light microscopy: present capabilities and future prospects. Shotton DM. **Histochem Cell Biol** 1995 Aug;104(2):97–137 (150 ref.)
The use of computers in understanding how animal cells crawl. Soll DR. **Int Rev Cytol** 1995;163:43–104 (118 ref.)
Computerised image handling in pathology. Cheong SK, et al. **J Clin Pathol** 1995 Sep;48(9):796–802 (4 ref.)
Electron microscopy and three-dimensional image reconstruction. Hall DH. **Methods Cell Biol** 1995; 48:395–436 (49 ref.)
Use of flow chamber devices and image analysis methods to study microbial adhesion. Busscher HJ, et al. **Methods Enzymol** 1995;253:455–77 (43 ref.)
PAR Corneal Topography System (PAR CTS): the clinical application of close-range photogrammetry. Belin MW, et al. **Optom Vis Sci** 1995 Nov;72(11):828–37 (16 ref.)
Nuclear texture measurements in image cytometry. Doudkine A, et al. **Pathologica** 1995 Jun;87(3):286–99 (26 ref.)
Quantitation in immunohistochemistry. A research method or a diagnostic tool in surgical pathology? Fritz P, et al. **Pathologica** 1995 Jun;87(3):300–9 (76 ref.)
Unbiased stereologic techniques for practical use in diagnostic histopathology. Sørensen FB. **Pathologica** 1995 Jun;87(3):263–78 (86 ref.)
Building a pediatric cardiac catheterization laboratory and conference room: design considerations and filmless imaging. Mathewson JW. **Pediatr Cardiol** 1996 Sep–Oct; 17(5):279–94 (30 ref.)
A line imaging system for measurement of eyelid movements. Gittins J, et al. **Physiol Meas** 1995 Nov;16(4):303–11 (6 ref.)
[Computer-assisted surgery: assessment and perspectives] Demongeot J. **Chirurgie** 1994–95;120(11):19–25 (27 ref.) (Eng. Abstr.) **(Fre)**

STANDARDS

Modular extension of the ACR-NEMA DICOM standard to support new diagnostic imaging modalities and services. Bidgood WD Jr, et al. **J Digit Imaging** 1996 May;9(2):67–77 (37 ref.)

TRENDS

Approach to diagnostic image analysis of melanocytic tumors. Smolle J, et al. **J Cutan Pathol** 1995 Apr; 22(2):128–31 (25 ref.)

IMAGE RECONSTRUCTION see **IMAGE PROCESSING, COMPUTER-ASSISTED**

IMAGERY (PSYCHOTHERAPY)

The efficacy of imagery mnemonics in memory remediation. Richardson JT. **Neuropsychologia** 1995 Nov;33(11):1345–57 (103 ref.)

IMAGERY, GUIDED see **IMAGERY (PSYCHOTHERAPY)**

IMAGINATION

see related
IMAGERY (PSYCHOTHERAPY)

The empirical status of the clinical application of eye movement desensitization and reprocessing. Lohr JM, et al. **J Behav Ther Exp Psychiatry** 1995 Dec;26(4):285–302 (67 ref.)
Imagery, concreteness, emotionality, meaningfulness, and pleasantness of words. Campos A. **Percept Mot Skills** 1995 Jun;80(3 Pt 1):867–80 (50 ref.)
[Imagery and its neurological substrate] Decety J, et al. **Rev Neurol (Paris)** 1995 Aug–Sep;151(8–9):474–9 (50 ref.) (Eng. Abstr.) **(Fre)**
[Delusions and imagination] Schmidt-Degenhard M. **Fortschr Neurol Psychiatr** 1995 Sep;63(9):350–7 (57 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Mental motor imagery: a window into the representational stages of action. Jeannerod M, et al. **Curr Opin Neurobiol** 1995 Dec;5(6):727–32 (49 ref.)
Motor imagery: perception or action? Annett J. **Neuropsychologia** 1995 Nov;33(11):1395–417 (101 ref.)
Varieties of visual representation: how are we to analyze the concept of mental image? Cooper LA. **Neuropsychologia** 1995 Nov;33(11):1575–82 (38 ref.)
Current issues in the neuropsychology of image generation. Farah MJ. **Neuropsychologia** 1995 Nov;33(11):1455–71 (79 ref.)
The mental and the neural: psychological and neural studies of mental rotation and memory scanning. Georgopoulos AP, et al. **Neuropsychologia** 1995 Nov;33(11):1531–47 (25 ref.)
Mental imagery in the motor context. Jeannerod M. **Neuropsychologia** 1995 Nov;33(11):1419–32 (66 ref.)
The cognitive neuroscience of mental imagery. Kosslyn SM, et al. **Neuropsychologia** 1995 Nov;33(11):1335–44 (21 ref.)

IMAGING, DIAGNOSTIC see **DIAGNOSTIC IMAGING**

IMAGING, MEDICAL see **DIAGNOSTIC IMAGING**

IMAGING TECHNIQUES see **DIAGNOSTIC IMAGING**

IMIDAZOLES

Discovery of losartan, the first angiotensin II receptor antagonist. Timmermans PB, et al. **J Hum Hypertens** 1995 Nov;9 Suppl 5:S3–18 (199 ref.)
Angiotensin receptor antagonists: focus on losartan. Johnston CI. **Lancet** 1995 Nov 25;346(8987):1403–7 (36 ref.)

ADVERSE EFFECTS

Chemical methods for assessing systemic exposure to dietary heterocyclic amines in man. Davies DS, et al. **Arch Toxicol Suppl** 1996;18:251–8 (29 ref.)
Contact allergy to imidazoles used as antimycotic agents. Dooms-Goossens A, et al. **Contact Dermatitis** 1995 Aug; 33(2):73–7 (54 ref.)
Contact dermatitis due to imidazole antimycotics. Guidetti MS, et al. **Contact Dermatitis** 1995 Oct;33(4):282 (5 ref.)

METABOLISM

Formation and processing of reactive metabolites of the heterocyclic amines. Alexander J. **Arch Toxicol Suppl** 1996; 18:275–85 (52 ref.)
Enzymic and interindividual differences in the human metabolism of heterocyclic amines. Boobis AR, et al. **Arch Toxicol Suppl** 1996;18:286–302 (65 ref.)
The elusive family of imidazoline binding sites. Parini A, et al. **Trends Pharmacol Sci** 1996 Jan;17(1):13–6 (37 ref.)

PHARMACOLOGY

Angiotensin II antagonists: a new class of antihypertensive agent. Waeber B, et al. **Br J Clin Pract** 1996 Jul–Aug; 50(5):265–8 (35 ref.)
Angiotensin II receptor antagonism: losartan – sites and mechanisms of action. Triggle DJ. **Clin Ther** 1995 Nov–Dec;17(6):1005–30 (132 ref.)
Effect of angiotensin II blockade on cardiac hypertrophy and remodelling: a review. Dahlöf B. **J Hum Hypertens** 1995 Nov;9 Suppl 5:S37–44 (84 ref.)
Antipsychotics and neuropeptides: the atypical profile of CI-943 and its relationship to neurotensin. Liégeois JF, et al. **Neurosci Biobehav Rev** 1995 Winter;19(4):519–31 (101 ref.)
The elusive family of imidazoline binding sites. Parini A, et al. **Trends Pharmacol Sci** 1996 Jan;17(1):13–6 (37 ref.)
[Antagonists of angiotensin II receptor] Karasek D, et al. **Postepy Hig Med Dosw** 1996;50(1):21–32 (64 ref.) (Eng. Abstr.) **(Pol)**

POISONING

[Digital necrosis associated with fenoxazoline poisoning. Apropos of a case and review of the literature] Hauet T, et al. **Rev Med Interne** 1996;17(1):66–9 (19 ref.) (Eng. Abstr.) **(Fre)**

THERAPEUTIC USE

Angiotensin II receptor antagonists in heart failure: rationale and design of the evaluation of losartan in the elderly (ELITE) trial. Pitt B, et al. **Cardiovasc Drugs Ther** 1995 Oct;9(5):693–700 (80 ref.)
The future role of losartan. Hansson L. **J Hum Hypertens** 1995 Nov;9 Suppl 5:S55–8 (24 ref.)
A rationale for the selection of nasal decongestants in lacrimal drainage surgery. Hosal BM, et al. **Ophthal Plast Reconstr Surg** 1995 Sep;11(3):215–20 (29 ref.)
[Evaluation of the antihypertensive drugs carvedilol, doxazosin and moxonidine] Dominiak P. **Wien Med Wochenschr** 1995;145(15–16):373–82 (92 ref.) (Eng. Abstr.) **(Ger)**
[Losartan and the LIFE-study. Antihypertensive treatment with AT1-receptor antagonist] Kjeldsen SE, et al. **Tidsskr Nor Laegeforen** 1996 Feb 10;116(4):504–7 (25 ref.)

IMIDAZOLES

(Eng. Abstr.) **(Nor)**

IMIDAZOLIDINETHIONE see **ETHYLENETHIOUREA**

IMIDOBENZYLE see **IMIPRAMINE**

IMIPEMIDE see **IMIPENEM**

IMIPENEM

ADMINISTRATION & DOSAGE

[Multicenter comparative study of meropenem vs. imipenem in the intramuscular treatment of hospital infections of the urinary tract] Tallarigo C, et al. **Minerva Urol Nefrol** 1995 Sep;47(3):147–56 (16 ref.) (Eng. Abstr.) **(Ita)**

THERAPEUTIC USE

The newer cephalosporins. Aztreonam and imipenem. Ennis DM, et al. **Infect Dis Clin North Am** 1995 Sep;9(3):687–713 (123 ref.)

[Carbapenems in pediatrics] Aujard Y. **Arch Pediatr** 1996;3 Suppl 1:298s–301s (10 ref.) **(Fre)**

IMIPRAMINE

BLOOD

[Tricyclic antidepressants (imipramine, desipramine, amitriptyline, nortriptyline)] Yasuda K. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:934–7 (20 ref.) **(Jpn)**

IMIZIN see **IMIPRAMINE**

IMMEDIATE-EARLY GENES see **GENES, IMMEDIATE-EARLY**

IMMEDIATE RECALL see **MEMORY, SHORT-TERM**

IMMERSION

see related
DIVING
DROWNING

IMMIGRATION see **EMIGRATION AND IMMIGRATION**

IMMOBILIZATION

see related
HYPOKINESIA

History of rest and motion and the scientific basis for early continuous passive motion. Salter RB. **Hand Clin** 1996 Feb; 12(1):1–11 (66 ref.)

[Stabilization of the spine in accident victims] Meertens JH, et al. **Ned Tijdschr Geneeskd** 1996 Aug 10;140(32):1635–9 (30 ref.) **(Dut)**

ADVERSE EFFECTS

Bone metabolism in spinal cord injured individuals and in others who have prolonged immobilisation. A review. Uebelhart D, et al. **Paraplegia** 1995 Nov;33(11):669–73 (42 ref.)

IMMOBILIZED CELLS see **CELLS, IMMOBILIZED**

IMMOBILIZED ENZYMES see **ENZYMES, IMMOBILIZED**

IMMOTILE CILIA SYNDROME see **CILIARY MOTILITY DISORDERS**

IMMUNE-ASSOCIATED ANTIGENS see **HISTOCOMPATIBILITY ANTIGENS CLASS II**

IMMUNE-ASSOCIATED ANTIGENS, HUMAN see **HLA-D ANTIGENS**

IMMUNE COMPLEX see **ANTIGEN-ANTIBODY COMPLEX**

IMMUNE GLOBULIN, RH see **RHO(D) IMMUNE GLOBULIN**

IMMUNE GLOBULINS see **IMMUNOGLOBULINS**

IMMUNE MONITORING see **MONITORING, IMMUNOLOGIC**

IMMUNE RESPONSE ANTIGENS see **HISTOCOMPATIBILITY ANTIGENS CLASS II**

IMMUNE-RESPONSE ANTIGENS, HUMAN see **HLA-D ANTIGENS**

IMMUNE-RESPONSE-ASSOCIATED ANTIGENS see **HISTOCOMPATIBILITY ANTIGENS CLASS II**

IMMUNE RESPONSE-ASSOCIATED ANTIGENS, HUMAN see **HLA-D ANTIGENS**

IMMUNE RESPONSE GENES see **GENES, MHC CLASS II**

IMMUNE RESPONSE, MUCOSAL see **IMMUNITY, MUCOSAL**

IMMUNE RNA MANIPULATION see **IMMUNIZATION, PASSIVE**

IMMUNE SERA

see related
IMMUNIZATION, PASSIVE

Heterologous antisera and antivenins are essential biologicals: perspectives on a worldwide crisis. Wilde H, et al. **Ann Intern Med** 1996 Aug 1;125(3):233–6 (22 ref.)

IMMUNOLOGY

Polyclonal antisera elicited by lysozymes: insights into antigenic structure and evolution. Prager EM. **EXS** 1996; 75:261–76 (57 ref.)

IMMUNE SYSTEM

Influence of uraemia and haemodialysis on host defence and infection. Vanholder R, et al. **Nephrol Dial Transplant** 1996 Apr;11(4):593–8 (69 ref.)

Stress, reactivity, and disease [editorial] Cohen S, et al. **Psychosom Med** 1995 Sep–Oct;57(5):423–6 (14 ref.)

[Immunologic aspects of artificial nutrition] Braga M, et al. **Chir Ital** 1994;46(6):11–9 (75 ref.) (Eng. Abstr.) **(Ita)**

CYTOLOGY

Organization and development of the immune system. Relation to its reconstruction. Good RA. **Ann N Y Acad Sci** 1995 Dec 29;770:8–33 (169 ref.)

New insights into V(D)J recombination and its role in the evolution of the immune system. Thompson CB. **Immunity** 1995 Nov;3(5):531–9 (104 ref.)

The human immune system in hu-PBL-SCID mice. Tary-Lehmann M, et al. **Immunol Today** 1995 Nov; 16(11):529–33 (34 ref.)

Role of interferon-gamma in immune cell regulation. Young HA, et al. **J Leukoc Biol** 1995 Oct;58(4):373–81 (165 ref.)

Fuel utilization by cells of the immune system. Calder PC. **Proc Nutr Soc** 1995 Mar;54(1):65–82 (79 ref.)

The biochemistry and molecular biology of glucocorticoid-induced apoptosis in the immune system. Cidlowski JA, et al. **Recent Prog Horm Res** 1996;51:457–90; discussion 490–1 (161 ref.)

DRUG EFFECTS

Sentinel screening for human immunotoxicity. Descotes J, et al. **Arch Toxicol Suppl** 1996;18:29–33 (13 ref.)

Assessment of immunotoxic effects in humans. Descotes J, et al. **Clin Chem** 1995 Dec;41(12 Pt 2):1870–3 (36 ref.)

Immunotoxicity of heavy metals in relation to Great Lakes. Bernier J, et al. **Environ Health Perspect** 1995 Dec;103 Suppl 9:47–53 (85 ref.)

Immunological effects of chlorinated dibenzo-p-dioxins. Kerkvliet NI. **Environ Health Perspect** 1995 Dec;103 Suppl 9:43–34 (145 ref.)

Approaches to the evaluation of chemical-induced immunotoxicity. Krzystyniak K, et al. **Environ Health Perspect** 1995 Dec;103 Suppl 9:17–22 (75 ref.)

Pesticide-induced immunotoxicity: are Great Lakes residents at risk? Thomas PT. **Environ Health Perspect** 1995 Dec; 103 Suppl 9:55–61 (78 ref.)

Immunotoxicity of PCBs (Aroclors) in relation to Great Lakes. Tryphonas H. **Environ Health Perspect** 1995 Dec; 103 Suppl 9:35–46 (97 ref.)

Toxicology of deoxynivalenol (vomitoxin). Rotter BA, et al. **J Toxicol Environ Health** 1996 May;48(1):1–34 (244 ref.)

Clinical immunotoxicity of pesticides. Vial T, et al. **J Toxicol Environ Health** 1996 Jun 28;48(3):215–29 (59 ref.)

Silicone breast implants: immunotoxic and epidemiologic issues [see comments] Yoshida SH, et al. **Life Sci** 1995 Mar 10;56(16):1299–310 (95 ref.) Comment in: Life Sci 1995;57(19):1737–40.

The influence of petrochemicals and stress on the immune system of seabirds. Briggs KT, et al. **Regul Toxicol Pharmacol** 1996 Apr;23(2):145–55 (77 ref.)

Botanical lipids: effects on inflammation, immune responses, and rheumatoid arthritis. Rothman D, et al. **Semin Arthritis Rheum** 1995 Oct;25(2):87–96 (75 ref.)

Effects of factor VIII concentrates on the immune system of patients with hemophilia. Mannucci PM. **Thromb Haemost** 1995 Jul;74(1):437–9 (19 ref.)

Markers for immunotoxic effects in rodents and man. Vos JG, et al. **Toxicol Lett** 1995 Dec;82–83:385–94 (34 ref.)

Immunotoxicity assessment of biotechnology products: a regulatory point of view [editorial] Cavagnaro JA. **Toxicology** 1995 Dec 20;105(1):1–6 (12 ref.)

Side-effects of a monoclonal antibody, muromonab CD3/orthoclone OKT3: bibliographic review. Sgro C. **Toxicology** 1995 Dec 20;105(1):23–9 (45 ref.)

[Removal of toxic substances from the body as a method for normalization of the functioning of the immune system] Lebedev KA, et al. **Fiziol Cheloveka** 1995 Sep–Oct; 21(5):131–43 (22 ref.) **(Rus)**

GROWTH & DEVELOPMENT

Evolution and developmental regulation of the major histocompatibility complex. Salter-Cid L, et al. **Crit Rev Immunol** 1995;15(1):31–75 (389 ref.)

Introduction: the reshaping of the immune system with age. Franceschi C, et al. **Int Rev Immunol** 1995;12(1):1–4 (19 ref.)

Immunosenescence in humans: deterioration or remodelling? Franceschi C, et al. **Int Rev Immunol** 1995;12(1):57–74 (100 ref.)

IMMUNOLOGY

Blood transfusion-induced immunomodulation. Landers DF, et al. **Anesth Analg** 1996 Jan;82(1):187–204 (219 ref.)

The role of gp39 (CD40L) in immunity. Noelle RJ. **Clin Immunol Immunopathol** 1995 Sep;76(3 Pt 2):S203–7 (29 ref.)

Role of interferon-gamma in immune cell regulation. Young HA, et al. **J Leukoc Biol** 1995 Oct;58(4):373–81 (165 ref.)

Local regulation of the immune response by the autonomic nervous system. Esquifino AI, et al. **Neuroimmunomodulation** 1994 Sep–Oct;1(5):265–73 (61 ref.)

Role of the immune system in allergic children. Baert MR, et al. **Pediatr Allergy Immunol** 1995;6 Suppl 7:27–30 (18 ref.)

The aging immune system: primer and prospectus. Miller RA. **Science** 1996 Jul 5;273(5271):70–4 (77 ref.)

Recombinant human interleukin-6: safety issues of a pleiotropic growth factor. Kammüller ME. **Toxicology** 1995 Dec 20;105(1):91–107 (90 ref.)

[The immune system characteristics during normal aging and in Alzheimer's disease] Koliaskina GI, et al. **Vestn Ross Akad Med Nauk** 1996;(4):19–23 (32 ref.) (Eng. Abstr.) **(Rus)**

INNERVATION

[How are psychological processes, the neuroendocrine system and immune system integrated?] Kaschka WP. **Z Klin Psychol Psychopathol Psychother** 1996;44(3):280–9 (50 ref.) (Eng. Abstr.) **(Ger)**

METABOLISM

Prolactin receptors and the immune system. Leite De Moraes MC, et al. **Ann Endocrinol (Paris)** 1995;56(6):567–70 (19 ref.)

P-glycoprotein expression and regulation. Age-related changes and potential effects on drug therapy. Gupta S. **Drugs Aging** 1995 Jul;7(1):19–29 (81 ref.)

Interactions between nutrients and the immune system. Grimble RF. **Nutr Health** 1995;10(3):191–200 (15 ref.)

PHYSIOLOGY

Functional connections between the pineal gland and immune system. Skwarlo-Sońta K. **Acta Neurobiol Exp (Warsz)** 1996;56(1):341–57 (111 ref.)

Interactions between cytokines and nitric oxide. Liew FY. **Adv Neuroimmunol** 1995;5(2):201–9 (49 ref.)

Essential nutrients and immunologic functions. Kelley DS, et al. **Am J Clin Nutr** 1996 Jun;63(6):994S–996S (32 ref.)

Organization and development of the immune system. Relation to its reconstruction. Good RA. **Ann N Y Acad Sci** 1995 Dec 29;770:8–33 (169 ref.)

Luteinizing hormone-releasing hormone (LHRH) receptors in the neuroendocrine-immune network. Biochemical bases and implications for reproductive physiopathology. Marchetti B, et al. **Ann N Y Acad Sci** 1996 Apr 30; 784:209–36 (117 ref.)

Can n-3 polyunsaturated fatty acids be used as immunomodulatory agents? Calder PC. **Biochem Soc Trans** 1996 Feb;24(1):211–20 (83 ref.)

Nutrition and immunonutrition. O'Leary MJ, et al. **Br J Anaesth** 1996 Jul;77(1):118–27 (102 ref.)

Fifteenth Gaddum Memorial Lecture December 1994. Stress and the neuroendocrine-immune axis: the pivotal role of glucocorticoids and lipocortin 1. Buckingham JC. **Br J Pharmacol** 1996 May;118(1):1–19 (138 ref.)

Immunophysiology: the immune system as a multifunctional physiological unit. Deschaux P, et al. **Cell Mol Biol Res** 1995;41(1):1–10 (89 ref.)

Sex steroids and the immune system. Fox HS. **Ciba Found Symp** 1995;191:203–11; discussion 211–7 (31 ref.)

Synovium and epithelia: barriers between self and non-self? Berthelot JM, et al. **Clin Exp Rheumatol** 1995 Jul–Aug; 13(4):517–9 (40 ref.)

Interactions of the endocrine and immune systems in children and young adults. Papanicolaou DA, et al. **Curr Opin Pediatr** 1995 Aug;7(4):440–4 (27 ref.)

Immune-neuro-endocrine interactions: facts and hypotheses. Besedovsky HO, et al. **Endocr Rev** 1996 Feb;17(1):64–102 (578 ref.)

Effects of growth hormone and insulin-like growth factor I on the immune system. Auernhammer CJ, et al. **Eur J Endocrinol** 1995 Dec;133(6):635–45 (137 ref.)

The impact of exercise on the immune system: NK cells, interleukins 1 and 2, and related responses. Shephard RJ, et al. **Exerc Sport Sci Rev** 1995;23:215–41 (233 ref.)

The immune system and integrated homeostasis. Husband AJ. **Immunol Cell Biol** 1995 Aug;73(4):377–82 (63 ref.)

Neurotrophins and cytokines—intermediaries between the

immune and nervous systems. Otten U, et al. **Int J Dev Neurosci** 1995 Jun-Jul;13(3-4):147-51 (48 ref.)
Immunological aspects of endometriosis. Dmowski WP. **Int J Gynaecol Obstet** 1995 Sep;50 Suppl 1:S3-10 (41 ref.)
What is the role of the immune system in determining individually distinct body odours? Brown RE. **Int J Immunopharmacol** 1995 Aug;17(8):655-61 (58 ref.)
Immunoendocrine reshaping with age. Panerai AE, et al. **Int Rev Immunol** 1995;12(1):75-84 (73 ref.)
The role of calcineurin in immune system responses. Kincaid RL. **J Allergy Clin Immunol** 1995 Dec;96(6 Pt 2):1170-7 (40 ref.)
Immunologic rebound. Dau PC. **J Clin Apheresis** 1995; 10(4):210-7 (44 ref.)
Endocrine peptides 'moonlighting' as immune modulators: roles for somatostatin and GH-releasing factor. Campbell RM, et al. **J Endocrinol** 1995 Dec;147(3):383-96 (120 ref.)
Update of the NGF saga. Levi-Montalcini R, et al. **J Neurol Sci** 1995 Jun;130(2):119-27 (113 ref.)
Endocrine, paracrine and autocrine actions of prolactin on immune cells. Matera L. **Life Sci** 1996;59(8):599-614 (173 ref.)
Roles of cytokines in the neural-immune interactions: modulation of NMDA responses by IFN-alpha. Katafuchi T, et al. **Neurobiology (Bp)** 1995;3(3-4):319-27 (39 ref.)
Cytokines and food intake: the relevance of the immune system to the student of ingestive behavior. Weingarten HP. **Neurosci Biobehav Rev** 1996;20(1):163-70 (90 ref.)
Stress, immune function, and relationship to pregnancy outcome. Gennaro S, et al. **Nurs Clin North Am** 1996 Jun; 31(2):293-303 (69 ref.)
Total parenteral nutrition and immune system activity: a review [see comments] Gogos CA, et al. **Nutrition** 1995 Jul-Aug;11(4):339-44 (74 ref.) Comment in: Nutrition 1995 Jul-Aug;11(4):394-5.
Endocrine-immunological homeostasis: the interrelationship between the immune system and sex steroids involves the hypothalamo-pituitary-gonadal axis. Drača SR. **Panminerva Med** 1995 Jun;37(2):71-6 (45 ref.)
Neuroimmunomodulation and psychoneuroendocrinology: recent findings in adults and aged. Tricerri A, et al. **Panminerva Med** 1995 Jun;37(2):77-83 (70 ref.)
[Immuno-endocrine interactions at the hypothalamo-hypophyseal level] Gaillard RC. **Ann Endocrinol (Paris)** 1995;56(6):561-6 (38 ref.) (Eng. Abstr.) **(Fre)**
[The significance of vitamin A for the immune system (review)] Kolb E. **Berl Munch Tierarztl Wochenschr** 1995 Oct;108(10):385-90 (45 ref.) (Eng. Abstr.) **(Ger)**
[Intense physical exercise--excessive strain on the immune system?] Eliakim A, et al. **Harefuah** 1995 Dec 1; 129(11):498-502 (44 ref.) **(Heb)**
[Correlation between the nervous system and immune system] Katafuchi T. **Fukuoka Igaku Zasshi** 1996 Jun;87(6):127-32 (3 ref.) **(Jpn)**
[Immunophysiologic mechanisms of adaptation to extreme conditions] Novikov VS. **Fiziol Cheloveka** 1996 Mar-Apr; 22(2):25-34 (44 ref.) **(Rus)**
[Current concepts of the interactions of regulating systems: nervous, endocrine and immune] Akmaev IG. **Usp Fiziol Nauk** 1996 Jan-Mar;27(1):3-20 (129 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

AIDS as immune system activation. Key questions that remain. Ascher MS, et al. **Adv Exp Med Biol** 1995; 374:203-10 (89 ref.)
Sleep deprivation and human immune function. Dinges DF, et al. **Adv Neuroimmunol** 1995;5(2):97-110 (34 ref.)
Immune dysfunction in Down's syndrome: primary immune deficiency or early senescence of the immune system? Cuadrado E, et al. **Clin Immunol Immunopathol** 1996 Mar; 78(3):209-14 (61 ref.)
Immune activation: the role of pro-inflammatory cytokines in inflammation, illness responses and pathological pain states. Watkins LR, et al. **Pain** 1995 Dec;63(3):289-302 (135 ref.)
Stress and the immune system in the etiology of anxiety and depression. Leonard BE, et al. **Pharmacol Biochem Behav** 1996 May;54(1):299-303 (74 ref.)
[Intense physical exercise--excessive strain on the immune system?] Eliakim A, et al. **Harefuah** 1995 Dec 1; 129(11):498-502 (44 ref.) **(Heb)**
[Clinical aspects of immunoneuroendocrine alterations in HIV infection] Rondanelli M, et al. **Minerva Endocrinol** 1995 Jun;20(2):113-26 (78 ref.) (Eng. Abstr.) **(Ita)**

RADIATION EFFECTS

Risk assessment for the harmful effects of UVB radiation on the immunological resistance to infectious diseases. Van Loveren H, et al. **Arch Toxicol Suppl** 1996;18:21-8 (19 ref.)
Late effects of radiation on the human immune system: an overview of immune response among the atomic-bomb survivors. Akiyama M. **Int J Radiat Biol** 1995 Nov; 68(5):497-508 (79 ref.)
Physiological and pathophysiological aspects of the immune system contributing to a biomathematical model of lymphocytes. Wuestermann PR, et al. **Stem Cells (Dayt)** 1995 May;13 Suppl 1:268-75 (59 ref.)
[Very low frequency electric and magnetic fields and the immune system] Petrini C, et al. **Ann Ist Super Sanita** 1995; 31(3):369-80 (64 ref.) (Eng. Abstr.) **(Ita)**
[Endocrine function of the thymus and ionizing radiation] Grinevich IuA, et al. **Radiats Biol Radioecol** 1995 May-Jun; 35(3):391-404 (126 ref.) (Eng. Abstr.) **(Rus)**

VIROLOGY

Viral immunopathology. Introduction. Zinkernagel RM, et al. **Springer Semin Immunopathol** 1995;17(2-3):119-20 (0 ref.)

IMMUNE TOLERANCE

see related
GRAFT VS HOST DISEASE
IMMUNOCOMPROMISED HOST
IMMUNOSUPPRESSION

Immunosuppression by a noncytolytic virus via T cell mediated immunopathology. Implication for AIDS. Zinkernagel RM. **Adv Exp Med Biol** 1995;374:165-71 (78 ref.)
Immunopathogenesis of HIV infection: a specific anti-HIV tolerance as a mechanism of control of disease progression. Sidorovitch IG, et al. **Allergy Proc** 1995 Jul-Aug; 16(4):203-7 (14 ref.)
Donor-specific transfusion and donor bone marrow infusion in renal transplantation tolerance: a review of efficacy and mechanisms. Brennan DC, et al. **Am J Kidney Dis** 1995 Nov;26(5):701-15 (130 ref.)
Dose-dependent activation and deletion of antigen-specific T cells following oral tolerance. Chen YH, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:111-21 (60 ref.)
Cholera toxin B subunit as transmucosal carrier-delivery and immunomodulating system for induction of antiinfectious and antipathological immunity. Czerkinsky C, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:185-93 (32 ref.)
Oral tolerance in myasthenia gravis. Drachman DB, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:258-72 (58 ref.)
Active immunity or tolerance to foods in patients with celiac disease or inflammatory bowel disease. Ferguson A, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:202-16 (25 ref.)
Role of gamma delta T cells in the regulation of mucosal IgA response and oral tolerance. Fujihashi K, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:55-63 (42 ref.)
T-cell subsets and their cytokine profiles in transplantation and tolerance. Groux H, et al. **Ann N Y Acad Sci** 1995 Dec 29;770:141-8 (27 ref.)
Studying immunological tolerance by physically monitoring antigen-specific T cells in vivo. Khoruts A, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:72-9 (43 ref.)
Induction of tolerance in humans: effectiveness of oral and nasal immunization routes. Mestecky J, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:194-201 (25 ref.)
Intraocular inflammatory disease (uveitis) and the use of oral tolerance: a status report. Nussenblatt RB, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:325-37 (23 ref.)
Origins of anti-DNA antibodies and their implications for B-cell tolerance. Radic MZ, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:384-96 (13 ref.)
Multiple bone marrow infusions to enhance acceptance of allografts from the same donor. Ricordi C, et al. **Ann N Y Acad Sci** 1995 Dec 29;770:345-50 (23 ref.)
Mechanisms of oral tolerance by MHC peptides. Sayegh MH, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:338-45 (30 ref.)
Arthritis: animal models of oral tolerance. Staines NA, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:297-305 (14 ref.)
Neonatal oral tolerance. Strobel S. **Ann N Y Acad Sci** 1996 Feb 13;778:88-102 (92 ref.)
Oral tolerance in experimental autoimmune encephalomyelitis. Whitacre CC, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:217-27 (17 ref.)
Causes of immunosuppression in squamous cell carcinoma of the head and neck. Wustrow TP, et al. **Anticancer Res** 1996 Jul-Aug;16(4C):2433-68 (714 ref.)
Oral tolerance: mechanisms and possible role in inflammatory joint diseases. Kagnoff MF. **Baillieres Clin Rheumatol** 1996 Feb;10(1):41-54 (71 ref.)
Molecular mechanisms of APO-1/Fas(CD95)-mediated apoptosis in tolerance and AIDS. Dhein J, et al. **Behring Inst Mitt** 1995 Jun;(96):13-20 (37 ref.)
The contribution of animal models to the understanding of the pathogenesis of type 1 diabetes. Carnaud C. **Braz J Med Biol Res** 1995 Aug;28(8):925-9 (35 ref.)
Die and let live: eliminating dangerous lymphocytes. Abbas AK. **Cell** 1996 Mar 8;84(5):655-7 (15 ref.)
Differentiation and tolerance of CD4+ T lymphocytes. Abbas AK, et al. **Ciba Found Symp** 1995;195:7-13; discussion 13-9 (36 ref.)
Treatment of autoimmune disease by oral tolerance to autoantigens. Whitacre CC, et al. **Clin Immunol Immunopathol** 1996 Sep;80(3 Pt 2):S31-9 (75 ref.)
New concepts in tolerance. Wood KJ. **Clin Transplant** 1996 Feb;10(1 Pt 2):93-9 (47 ref.)
The regulation of self-reactive B cells. Cornall RJ, et al. **Curr Opin Immunol** 1995 Dec;7(6):804-11 (52 ref.)
Mechanisms of anergy in tuberculosis. Toossi Z, et al. **Curr Top Microbiol Immunol** 1996;215:221-38 (99 ref.)
Immunotolerance: from new knowledge of mechanisms of self-tolerance to future perspectives for induction of renal transplant tolerance [editorial] Remuzzi G, et al. **Exp Nephrol** 1995 Nov-Dec;3(6):319-30 (123 ref.)
From the forehead of Zeus: the ontogeny of the immune response. Silverstein AM. **Eye** 1995;9 (Pt 2):147-51 (36 ref.)
Immunological non-responsiveness and acquisition of tolerance in relation to immune privilege in the eye. Streilein JW. **Eye** 1995;9 (Pt 2):236-40 (28 ref.)
T-cell mediated immunosuppression and its implications for the development of protective immunity. Baker PJ, et al. **Folia Biol (Praha)** 1994;40(6):349-58 (50 ref.)
Immunological tolerance to xenogeneic grafts induced by cyclophosphamide in adult animals. Chernyakhovskaya IYu, et al. **Folia Biol (Praha)** 1994;40(6):371-80 (33 ref.)
Immunosuppressive mechanisms in semen: implications for contraception. Kelly RW. **Hum Reprod** 1995 Jul; 10(7):1686-93 (137 ref.)
The "clonal selection hypothesis" and current concepts of B cell tolerance. Klinman NR. **Immunity** 1996 Sep; 5(3):189-95 (100 ref.)
Tolerance induction as a therapeutic strategy for the control of autoimmune endocrine disease in mouse models. Parish NM, et al. **Immunol Rev** 1995 Apr;144:269-300 (103 ref.)
Immunosuppression in tuberculosis. Ellner JJ. **Infect Agents Dis** 1996 Mar;5(2):62-72 (30 ref.)
Costimulation in tolerance and autoimmunity. Guerder S, et al. **Int Rev Immunol** 1995;13(2):135-46 (49 ref.)
Regulation of CD4 T cell reactivity to self and non-self. Lo D, et al. **Int Rev Immunol** 1995;13(2):147-60 (38 ref.)
T cell costimulatory pathways: promising novel targets for immunosuppression and tolerance induction [editorial] Sayegh MH, et al. **J Am Soc Nephrol** 1995 Oct;6(4):1143-50 (49 ref.)
Insulin-dependent diabetes mellitus as a beta-cell targeted disease of immunoregulation. Bach JF. **J Autoimmun** 1995 Aug;8(4):439-63 (172 ref.)
Tolerance sensitivity of immature-stage B cells: can developmentally regulated B cell antigen receptor (BCR) signal transduction play a role? Monroe JG. **J Immunol** 1996 Apr 15;156(8):2657-60 (38 ref.)
New insight on immune tolerance from transgenic mouse models. Lee MS. **J Korean Med Sci** 1996 Feb;11(1):1-7 (29 ref.)
A role for ferritin in hematopoiesis and the immune system. Morikawa K, et al. **Leuk Lymphoma** 1995 Aug; 18(5-6):429-33 (27 ref.)
Anergy, AIDS and tuberculosis. Hegde HR. **Med Hypotheses** 1995 Nov;45(5):433-40 (48 ref.)
Antigen-specific therapy for autoimmune disease: prospects for the prevention of insulin-dependent diabetes. Harrison LC. **Mol Med** 1995 Nov;1(7):722-7 (34 ref.)
Tolerance and xenograft survival. Sachs DH, et al. **Nat Med** 1995 Sep;1(9):969 (6 ref.)
Liver transplants contribute to their own success [comment] Starzl TE, et al. **Nat Med** 1996 Feb;2(2):163-5 (22 ref.) Comment on: Nat Med 1996 Feb;2(2):198-203.
Balancing immunity and tolerance: deleting and tuning lymphocyte repertoires. Goodnow CC. **Proc Natl Acad Sci U S A** 1996 Mar 19;93(6):2264-71 (256 ref.)
The anatomy of T-cell activation and tolerance. Mondino A, et al. **Proc Natl Acad Sci U S A** 1996 Mar 19; 93(6):2245-52 (113 ref.)
T-cell activation, anergy and immunomodulation by molecules of viral, fungal and vegetal origin. Bemer V, et al. **Res Immunol** 1995 May-Jun;146(4-5):249-62 (81 ref.)
Mechanisms of T-cell-induced allotypic suppression of mouse IgG2a(b) and of tolerance acquisition to this allotype. Majlessi L, et al. **Res Immunol** 1995 May-Jun; 146(4-5):213-24 (71 ref.)
Unraveling immune privilege [comment] Streilein JW. **Science** 1995 Nov 17;270(5239):1158-9 (19 ref.) Comment on: Science 1995 Nov 17;270(5239):1189-92.
Xenobiotics, chimerism and the induction of tolerance following organ transplantation. Delaney CP, et al. **Ther Immunol** 1994 Jun;1(3):153-64 (118 ref.)
Induction of donor-specific tolerance by transplantation of bone marrow. Kaufman CL, et al. **Ther Immunol** 1994 Apr; 1(2):101-11 (123 ref.)
Mucosal tolerance and the immunotherapy of autoimmune disease: a commentary. Wraith DC, et al. **Ther Immunol** 1995 Feb;2(1):53-8 (49 ref.)
Current progress in chimerism and donor-specific tolerance. Jankowski RA, et al. **Transplant Proc** 1996 Aug; 28(4):2071-4 (39 ref.)
Immunologic tolerance: tailored antigen. Krensky AM, et al. **Transplant Proc** 1996 Aug;28(4):2075-7 (15 ref.)
The nonspecific nature of endotoxin tolerance. Cavaillon JM. **Trends Microbiol** 1995 Aug;3(8):320-4 (64 ref.)
[Immunological tolerance in prevention of diabetes (editorial)] Knip M. **Duodecim** 1994;110(17):1571-3 (13 ref.) **(Fin)**
[Immunologic tolerance of fetal allograft] Deneys V, et al. **Presse Med** 1995 Nov 18;24(35):1651-7 (31 ref.) (Eng. Abstr.) **(Fre)**
[Drug allergy--especially on the induction of the oral tolerance and its specificity] Ikezawa Z. **Arerugi** 1996 Apr; 45(4):363-70 (19 ref.) **(Jpn)**
[Recent development in immunology of leprosy: roles of immunoregulatory cytokines in the establishment of immuno-unresponsiveness to M. leprae in leprosy patients] Tomioka H. **Nippon Rai Gakkai Zasshi** 1995 Jul;64(2):69-84 (37 ref.) **(Jpn)**
[Study of immune tolerance induced by HBs antigen specific suppressor T cell--establishment of human suppressor T

cell clones] Isono E, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:185–8 (15 ref.) **(Jpn)**

[The mechanism of the development of nonspecific immunosuppression in viral infections] Zheleznikova GF. **Zh Mikrobiol Epidemiol Immunobiol** 1995 Sep–Oct; (5):122–4 (15 ref.) **(Rus)**

DRUG EFFECTS

Molecular mechanisms of toxicant-induced immunosuppression: role of second messengers. Holsapple MP, et al. **Annu Rev Pharmacol Toxicol** 1996;36:131–59 (112 ref.)

Immunobiology and immunopharmacology of organ allograft rejection. Suthanthiran M, et al. **J Clin Immunol** 1995 Jul; 15(4):161–71 (87 ref.)

IMMUNOLOGY

Strategies used by viruses to evade the immune response. Paroli M, et al. **Ital J Gastroenterol** 1995 Apr;27(3):133–6 (33 ref.)

Update on the mechanisms of immune suppression of injury and immune modulation. Faist E, et al. **World J Surg** 1996 May;20(4):454–9 (32 ref.)

[Early immunosuppression and implantation] Chaouat G. **Contracept Fertil Sex** 1995 Oct;23(10):617–21 (58 ref.) (Eng. Abstr.) **(Fre)**

[Trophoblastic interferons and embryonal immune tolerance] Martal J, et al. **Contracept Fertil Sex** 1995 Sep;23(9):562–72 (163 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

The use of oral tolerance as a therapy for ocular autoimmunity. Rizzo LV. **Braz J Med Biol Res** 1995 Aug; 28(8):931–6 (23 ref.)

The hypothalamo-sympathetic nervous system modulates peripheral cellular immunity. Hori T, et al. **Neurobiology (Bp)** 1995;3(3–4):309–17 (30 ref.)

The role of urocanic acid in UV-induced immunosuppression: recent advances (1992–1994). Norval M, et al. **Photochem Photobiol** 1995 Aug;62(2):209–17 (64 ref.)

RADIATION EFFECTS

Keratinocyte-derived cytokines and UVB-induced immunosuppression. Kondo S, et al. **J Dermatol** 1995 Nov; 22(11):888–93 (45 ref.)

The role of urocanic acid in UV-induced immunosuppression: recent advances (1992–1994). Norval M, et al. **Photochem Photobiol** 1995 Aug;62(2):209–17 (64 ref.)

The role of epidermal cytokines in the generation of cutaneous immune reactions and ultraviolet radiation-induced immune suppression. Ullrich SE. **Photochem Photobiol** 1995 Sep;62(3):389–401 (99 ref.)

IMMUNITY

see related
IMMUNOLOGIC TECHNIQUES

Organization and development of the immune system. Relation to its reconstruction. Good RA. **Ann N Y Acad Sci** 1995 Dec 29;770:8–33 (169 ref.)

Sympathetic nervous system—immune system interactions in young and old Fischer 344 rats. Madden KS, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:523–34 (36 ref.)

Immunologic consequences of nucleic acid therapy. Pisetsky DS. **Antisense Res Dev** 1995 Fall;5(3):219–25 (53 ref.)

Vitamins in the maintenance of optimum immune functions and in the prevention of phagocyte-mediated tissue damage and carcinogenesis. Anderson R, et al. **Bibl Nutr Dieta** 1995;(52):66–74 (34 ref.)

Ceramide signalling and the immune response. Ballou LR, et al. **Biochim Biophys Acta** 1996 Jun 11;1301(3):273–87 (134 ref.)

The role of ICAM expression in immunity and disease. Simmons DL. **Cancer Surv** 1995;24:141–55 (58 ref.)

Glycosaminoglycans contribute to multiple functions of vascular endothelial cells. Cockwell P, et al. **Clin Exp Immunol** 1996 Apr;104(1):1–3 (30 ref.)

Evolutionary immunology. A boost to immunity from nurse sharks. Parham P. **Curr Biol** 1995 Jul 1;5(7):696–9 (16 ref.)

Immune system stimulation by probiotics. Perdigon G, et al. **J Dairy Sci** 1995 Jul;78(7):1597–606 (18 ref.)

First-line defense mechanisms in the peritoneal cavity during peritoneal dialysis. Brulez HF, et al. **Perit Dial Int** 1995; 15(7 Suppl):S24–33; discussion S33–4 (79 ref.)

Co-stimulation and co-inhibition: equal partners in regulation. Sinclair NR, et al. **Scand J Immunol** 1996 Jun; 43(6):597–603 (78 ref.)

Transfusion and the immune system: a paradigm shift in progress? Blumberg N, et al. **Transfusion** 1995 Oct; 35(10):879–83 (55 ref.)

[Antioxidants in nutrition and their importance in the anti-/oxidative balance in the immune system] Biesalski HK, et al. **Immun Infekt** 1995 Oct;23(5):166–73 (72 ref.) (Eng. Abstr.) **(Ger)**

[Immune function during space flights] Nakahara K. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Apr;19(2):119–27 (52 ref.) **(Jpn)**

[Essential trace elements and immunity] Kodama H. **Nippon Rinsho** 1996 Jan;54(1):46–51 (21 ref.) (Eng. Abstr.) **(Jpn)**

DRUG EFFECTS

Antioxidants and immune response in aged persons: overview of present evidence. Meydani SN, et al. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1462S–1476S (146 ref.)

Immunomodulation: an important concept in modern anaesthesia. McBride WT, et al. **Anaesthesia** 1996 May; 51(5):465–73 (86 ref.)

Does DHEAS restore immune competence in aged animals through its capacity to function as a natural modulator of peroxisome activities? Spencer NF, et al. **Ann N Y Acad Sci** 1995 Dec 29;774:200–16 (129 ref.)

Some new aspects of molecular mechanisms of cyclosporin A effect on immune response. Zav'yalov VP, et al. **APMIS** 1995 Jun;103(6):401–15 (121 ref.)

Oestradiol inhibition of vascular myointimal proliferation following immune, chemical and mechanical injury. Foegh ML, et al. **Ciba Found Symp** 1995;191:139–45; discussion 145–9 (19 ref.)

Transcription factors as drug targets: opportunities for therapeutic selectivity. Butt TR, et al. **Gene Expr** 1995; 4(6):319–36 (137 ref.)

Immunologic and biologic markers for silicone. Vojdani A, et al. **Toxicol Ind Health** 1994 Jan–Apr;10(1–2):25–42 (92 ref.)

[Exposure to mercury and population health. I. Immunotoxicity of mercury] Moszczyński P, et al. **Med Pr** 1995;46(4):385–93 (91 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOLOGY

Malaria transmission-blocking immunity. Identification of epitopes and evaluation of immunogenicity. Kumar N, et al. **Adv Exp Med Biol** 1995;383:65–72 (18 ref.)

Host factors affecting disease transmission. Muzyka BC. **Dent Clin North Am** 1996 Apr;40(2):263–75 (28 ref.)

The use of conditioning to probe for CNS pathways that regulate fever and NK cell activity. Hiramoto R, et al. **Int J Neurosci** 1996 Feb;84(1–4):229–45 (55 ref.)

Behaviour of zinc in physical exercise: a special reference to immunity and fatigue. Cordova A, et al. **Neurosci Biobehav Rev** 1995 Fall;19(3):439–45 (101 ref.)

Activation of the HPA axis by immune insults: roles and interactions of cytokines, eicosanoids, glucocorticoids. Buckingham JC, et al. **Pharmacol Biochem Behav** 1996 May; 54(1):285–98 (138 ref.)

Flow cytometry. Principles and applications in exercise immunology. Gabriel H, et al. **Sports Med** 1995 Nov; 20(5):302–20 (121 ref.)

[Extracellular matrix proteins as regulators of the immune response] Matysiak W, et al. **Pol Arch Med Wewn** 1995 Aug;94(2):173–7 (33 ref.) **(Pol)**

IMMUNITY, ACTIVE

see related
IMMUNOTHERAPY

Immunity to intracellular microbial pathogens. Kaufmann SH. **Immunol Today** 1995 Jul;16(7):338–42 (32 ref.)

Characteristics of human antibody repertoires following active immune responses in vivo. Ohlin M, et al. **Mol Immunol** 1996 May-Jun;33(7–8):583–92 (79 ref.)

IMMUNOLOGY

The instructive role of innate immunity in the acquired immune response. Fearon DT, et al. **Science** 1996 Apr 5; 272(5258):50–3 (59 ref.)

IMMUNITY, CELLULAR

see related
HYPERSENSITIVITY, DELAYED

Rational problems associated with the development of cellular approaches in controlling HIV spread. Bourinbaiar AS, et al. **Adv Exp Med Biol** 1995;374:71–89 (142 ref.)

The human intestinal immune system: basic cellular and humoral mechanisms. Brandtzaeg P. **Baillieres Clin Rheumatol** 1996 Feb;10(1):1–24 (91 ref.)

Cellular immunity against DNA tumour viruses: possibilities for peptide-based vaccines and immune escape. Toes RE, et al. **Biochem Soc Trans** 1995 Aug;23(3):692–6 (52 ref.)

Costimulation of T-cell-mediated tumor immunity. Hellström KE, et al. **Cancer Chemother Pharmacol** 1996; 38 Suppl:S40–1 (30 ref.)

Induction and regulation of host cell-mediated immunity by Toxoplasma gondii. Sher A, et al. **Ciba Found Symp** 1995; 195:95–104; discussion 104–9 (36 ref.)

Immune response of the skin. Schmitt D. **Clin Rev Allergy Immunol** 1995 Fall;13(3):177–88 (42 ref.)

Local cellular immunology of experimental transplant vascular sclerosis. Orosz CG. **Clin Transplant** 1996 Feb;10(1 Pt 2):100–3 (21 ref.)

Functional domains of adenovirus E1A oncogenes which control interactions with effectors of cellular immunity. Raška K Jr. **Curr Top Microbiol Immunol** 1995;199 (Pt 3):131–48 (85 ref.)

T-cell mediated immunosuppression and its implications for the development of protective immunity. Baker PJ, et al. **Folia Biol (Praha)** 1994;40(6):349–58 (50 ref.)

Pulmonary immunity to Pseudomonas aeruginosa. Cripps AW, et al. **Immunol Cell Biol** 1995 Oct;73(5):418–24 (84 ref.)

The P2Z purinoceptor: an intriguing role in immunity, inflammation and cell death. Di Virgilio F. **Immunol Today** 1995 Nov;16(11):524–8 (37 ref.)

Linkage of cell-mediated immunity to iron metabolism. Weiss G, et al. **Immunol Today** 1995 Oct;16(10):495–500 (44 ref.)

Cell-mediated cytotoxicity in perforin-less mice. Clark WR, et al. **Int Rev Immunol** 1995;13(1):1–14 (39 ref.)

The hypothalamo-sympathetic nervous system modulates peripheral cellular immunity. Hori T, et al. **Neurobiology (Bp)** 1995;3(3–4):309–17 (30 ref.)

Aspects of the host response to varicella-zoster virus: a review of recent observations. Arvin AM. **Neurology** 1995 Dec;45(12 Suppl 8):S36–7 (2 ref.)

Postnatal maturation of immune competence during infancy and childhood. Holt PG. **Pediatr Allergy Immunol** 1995 May;6(2):59–70 (148 ref.)

Human host response to Mycobacterium tuberculosis. Rom WN, et al. **Schweiz Med Wochenschr** 1995 Nov 11; 125(45):2178–85 (46 ref.)

Role of cell-mediated immunity in bovine leukemia virus (BLV) infection in ruminants: its implication for the vaccination strategy against retroviruses. Sugimoto M, et al. **Ther Immunol** 1994 Oct;1(5):297–301 (30 ref.)

[Role of vitamin E and C, carotenoids, ubiquinone and selenium in the antioxidative defense system] Alho H, et al. **Duodecim** 1994;110(17):1621–8 (49 ref.) **(Fin)**

[Role of free radicals and antioxidants in the cell defense system] Antila E. **Duodecim** 1994;110(17):1611–9 (27 ref.) **(Fin)**

[Skin as an immune organ] Simon JC. **Med Monatsschr Pharm** 1995 Nov;18(11):316–9 (10 ref.) **(Ger)**

[Pathogenesis of infections—a complex interplay between microbes and the immune defence] Haug CJ, et al. **Tidsskr Nor Laegeforen** 1995 Oct 30;115(26):3254–8 (25 ref.) (Eng. Abstr.) **(Nor)**

[New immunopathogenetic aspects of infectious diseases] Müller F, et al. **Tidsskr Nor Laegeforen** 1995 Oct 30; 115(26):3259–62 (33 ref.) (Eng. Abstr.) **(Nor)**

[Immune reactions and mechanisms in classical swine fever] Kolontsov AA, et al. **Mol Gen Mikrobiol Virusol** 1995 Apr–Jun;(2):18–21 (46 ref.) (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

[Pentoxifylline] Paradowski PT, et al. **Postepy Hig Med Dosw** 1995;49(2):201–20 (112 ref.) (Eng. Abstr.) **(Pol)**

GENETICS

Tumors antigens encoded by oncogenes and the impact of oncogenes upon the immune responses. Appleman LJ, et al. **Cell Immunol** 1996 May 25;170(1):1–10 (129 ref.)

IMMUNOLOGY

T-cell responses and cellular immunity in coeliac disease. Trejdosiewicz LK, et al. **Baillieres Clin Gastroenterol** 1995 Jun;9(2):251–72 (160 ref.)

Human T lymphotropic virus, type-I myelopathy: an immunopathologically mediated chronic progressive disease of the central nervous system. Jacobson S. **Curr Opin Neurol** 1995 Jun;8(3):179–83 (35 ref.)

Design and testing of peptide-based cytotoxic T-cell-mediated immunotherapeutics to treat infectious diseases and cancer. Chesnut RW, et al. **Pharm Biotechnol** 1995;6:847–74 (170 ref.)

Parenchymal and nonparenchymal liver cells and their interaction in the local immune response. Knolle P, et al. **Z Gastroenterol** 1995 Oct;33(10):613–20 (94 ref.)

[Effect of menstrual cycle on the immune response to surgical stress] Lazzaretti MG, et al. **Minerva Ginecol** 1995 May; 47(5):197–205 (48 ref.) (Eng. Abstr.) **(Ita)**

[Biologic effects of immunotherapy] Dávila González I, et al. **Allergol Immunopathol (Madr)** 1996;24 Suppl 1:60–8 (85 ref.) **(Spa)**

PHYSIOLOGY

Control of the production of soluble interleukin-4 receptors: implications in immunoregulation. Fernandez-Botran R, et al. **J Leukoc Biol** 1996 Apr;59(4):499–504 (35 ref.)

Immunoregulation by interleukin-12. Trinchieri G, et al. **J Leukoc Biol** 1996 Apr;59(4):505–11 (51 ref.)

IMMUNITY, HUMORAL see **ANTIBODY FORMATION**

IMMUNITY, MATERNALLY-ACQUIRED

see related
IMMUNIZATION, PASSIVE

IMMUNOLOGY

What is the role of preterm breast milk supplementation in the host defenses of preterm infants? Science vs. fiction. Groër M, et al. **Adv Pediatr** 1996;43:335–58 (99 ref.)

Human milk and intestinal host defense in newborns: an update. Xanthou M, et al. **Adv Pediatr** 1995;42:171–208 (169

ref.)
The interference by maternally-derived antibody with active immunization of farm animals against foot-and-mouth disease. Kitching RP, et al. **Br Vet J** 1995 Jul-Aug; 151(4):379-89 (40 ref.)

IMMUNITY, MUCOSAL

see related
IGA, SECRETORY
Mucosal responsiveness as a determinant of protection mechanisms induced by oral immunization. Clancy R, et al. **Adv Exp Med Biol** 1995;371B:1417-22 (17 ref.)
Induction of specific immunity at mucosal surfaces: prospects for vaccine development. Czerkinsky C, et al. **Adv Exp Med Biol** 1995;371B:1409-16 (21 ref.)
Role of gamma delta T cells in the regulation of mucosal IgA response and oral tolerance. Fujihashi K, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:55-63 (42 ref.)
Antigen trafficking in the intestine. Mayer L, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:28-35 (16 ref.)
Cytokine mediated effects in mucosal immunity. Kramer DR, et al. **Immunol Cell Biol** 1995 Oct;73(5):389-96 (71 ref.)
Genetic and spontaneous models of inflammatory bowel disease in rodents: evidence for abnormalities in mucosal immune regulation. Powrie F, et al. **Ther Immunol** 1995 Apr;2(2):115-23 (57 ref.)

IMMUNOLOGY
Human milk and intestinal host defense in newborns: an update. Xanthou M, et al. **Adv Pediatr** 1995;42:171-208 (169 ref.)
Mucosal vaccines for the prevention of influenza. Clancy RL. **Drugs** 1995 Oct;50(4):587-94 (108 ref.)
Acute on chronic bronchitis: A model of mucosal immunology. Clancy R, et al. **Immunol Cell Biol** 1995 Oct; 73(5):414-7 (26 ref.)
Development of immune function in the intestine and its role in neonatal diseases. Insoft RM, et al. **Pediatr Clin North Am** 1996 Apr;43(2):551-71 (83 ref.)
Water-soluble phosphazene polymers for parenteral and mucosal vaccine delivery. Payne LG, et al. **Pharm Biotechnol** 1995;6:473-93 (15 ref.)

PHYSIOLOGY
Modifiers of the human mucosal immune system. Gleeson M, et al. **Immunol Cell Biol** 1995 Oct;73(5):397-404 (49 ref.)
The biology of airway dendritic cells. McWilliam AS, et al. **Immunol Cell Biol** 1995 Oct;73(5):405-13 (35 ref.)

IMMUNITY, NATURAL

Role of human natural killer cells in health and disease. Whiteside TL, et al. **Clin Diagn Lab Immunol** 1994 Mar; 1(2):125-33 (76 ref.)
Natural autoantibodies. Coutinho A, et al. **Curr Opin Immunol** 1995 Dec;7(6):812-8 (90 ref.)
Mechanisms of resistance to fungal infections. Romani L, et al. **Curr Opin Immunol** 1995 Aug;7(4):517-23 (74 ref.)
Of microbes and macrophages: entry, survival and persistence. Russell DG. **Curr Opin Immunol** 1995 Aug; 7(4):479-84 (59 ref.)
CD40 and its ligand in host defense. Noelle RJ. **Immunity** 1996 May;4(5):415-9 (43 ref.)
Immunity to intracellular microbial pathogens. Kaufmann SH. **Immunol Today** 1995 Jul;16(7):338-42 (32 ref.)
Protective immunity against HIV infection: has nature done the experiment for us? Shearer GM, et al. **Immunol Today** 1996 Jan;17(1):21-4 (37 ref.)
Natural autoantibodies: the other side of the immune system. Avrameas S, et al. **Res Immunol** 1995 May-Jun; 146(4-5):235-48 (116 ref.)
Simple developmental programs of gene expression and cellular composition of lymphoid organs at the origin of natural tolerance. Coutinho A. **Res Immunol** 1995 May-Jun;146(4-5):321-32 (0 ref.)
Peptide antibiotics: holy or heretic grails of innate immunity? Boman HG. **Scand J Immunol** 1996 May;43(5):475-82 (51 ref.)
Xenoreactive natural antibodies in the world of natural antibodies: typical or unique? Parker W, et al. **Transpl Immunol** 1995 Sep;3(3):181-91 (88 ref.)
[Nonspecific host defense mechanism by macrophages--analysis by NF-IL6 deficient mice] Tanaka T. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2083-96 (32 ref.) **(Jpn)**

GENETICS
Genetic resistance to coronavirus infection. A review. Buschman E, et al. **Adv Exp Med Biol** 1995;380:1-11 (52 ref.)
Immunogenetics in the analysis of resistance to intracellular pathogens. McLeod R, et al. **Curr Opin Immunol** 1995 Aug; 7(4):539-52 (139 ref.)
Pathogen-based models favoring MHC genetic diversity. Potts WK, et al. **Immunol Rev** 1995 Feb;143:181-97 (37 ref.)
A genetic herd-immunity model for the maintenance of MHC polymorphism. Wills C, et al. **Immunol Rev** 1995 Feb;143:263-92 (70 ref.)
Natural resistance to infection with intracellular parasites: molecular genetics identifies Nramp1 as the Bcg/Ity/Lsh locus. Vidal S, et al. **J Leukoc Biol** 1995 Oct;58(4):382-90 (61 ref.)
Transgenic strategies to increase disease resistance in livestock. Müller M, et al. **Reprod Fertil Dev** 1994; 6(5):605-13 (83 ref.)

IMMUNOLOGY
The instructive role of innate immunity in the acquired immune response. Fearon DT, et al. **Science** 1996 Apr 5; 272(5258):50-3 (59 ref.)
[NO, ambivalent effector of non-specific immunity and of inflammation] Drapier JC. **C R Seances Soc Biol Fil** 1995; 189(6):1081-96 (104 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY
Natural resistance and nitric oxide. Nathan C. **Cell** 1995 Sep 22;82(6):873-6 (30 ref.)

IMMUNITY, NON-SPECIFIC see **IMMUNITY, NATURAL**

IMMUNIZATION

Mucosal responsiveness as a determinant of protection mechanisms induced by oral immunization. Clancy R, et al. **Adv Exp Med Biol** 1995;371B:1417-22 (17 ref.)
Breaking the barriers to childhood immunization. Kimmel SR, et al. **Am Fam Physician** 1996 Apr;53(5):1648-66 (28 ref.)
What are the prospects for immunization? Holt PG. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 2):S27 (16 ref.)
Immunization of the pediatric patient in the emergency department. Robinson PF, et al. **Ann Emerg Med** 1996 Sep; 28(3):334-41 (48 ref.)
The use of oral tolerance as a therapy for ocular autoimmunity. Rizzo LV. **Braz J Med Biol Res** 1995 Aug; 28(8):931-6 (23 ref.)
Immunization in adults in the 1990s. Gardner P, et al. **Curr Clin Top Infect Dis** 1995;15:271-300 (115 ref.)
Update on immunization. Forrest JM, et al. **Curr Opin Pediatr** 1996 Feb;8(1):21-7 (102 ref.)
Immunizations, animal-induced injuries and disease, neonatal jaundice, and viral infections. Gerson WT. **Curr Opin Pediatr** 1995 Aug;7(4):477-86 (73 ref.)
Hepatitis B immunization among adolescents. Middleman AB. **Curr Opin Pediatr** 1995 Aug;7(4):366-70 (25 ref.)
Acute on chronic bronchitis: A model of mucosal immunology. Clancy R, et al. **Immunol Cell Biol** 1995 Oct; 73(5):414-7 (26 ref.)
Current prospects for immunization against cytomegaloviral disease. Adler SP. **Infect Agents Dis** 1996 Jan;5(1):29-35 (55 ref.)
Impact of immunization on Haemophilus influenzae type b disease. Madore DV. **Infect Agents Dis** 1996 Jan;5(1):8-20 (129 ref.)
Type 1 allergic reactions to plant-derived food: a consequence of primary sensitization to pollen allergens. Valenta R, et al. **J Allergy Clin Immunol** 1996 Apr; 97(4):893-5 (29 ref.)
Antimicrobial resistance in Streptococcus pneumoniae: can immunization prevent its spread? Munford RS, et al. **J Investig Med** 1994 Dec;42(4):613-21 (72 ref.)
Immunization and the prevention of childhood diseases. Bellig LL. **J Obstet Gynecol Neonatal Nurs** 1995 Sep; 24(7):669-77 (19 ref.)
A shot in the arm for cocaine addiction. Slusher BS, et al. **Nat Med** 1996 Jan;2(1):26-7 (13 ref.)
Anticholesterol antibodies and plaque formation. Ordovas JM. **Nutr Rev** 1996 Apr;54(4 Pt 1):124-7 (28 ref.)
Children and international travel: immunizations. Barnett ED, et al. **Pediatr Infect Dis J** 1995 Nov;14(11):982-92 (67 ref.)
Design and production of single-immunization vaccines using polylactide polyglycolide microsphere systems. Cleland JL. **Pharm Biotechnol** 1995;6:439-62 (57 ref.)
Lipid matrix-based vaccines for mucosal and systemic immunization. Mannino RJ, et al. **Pharm Biotechnol** 1995; 6:363-87 (59 ref.)
Vehicles for oral immunization. Santiago N, et al. **Pharm Biotechnol** 1995;6:413-38 (160 ref.)
Adenovirus vectors as recombinant viral vaccines. Imler JL. **Vaccine** 1995 Sep;13(13):1143-51 (72 ref.)
[Immunization in preterm and term infants] Bernatowska-Matuszkiewicz E, et al. **Pediatr Pol** 1995 Sep; 70(9):759-63 (20 ref.) (Eng. Abstr.) **(Pol)**

ADVERSE EFFECTS
Establishment of a mouse model of myasthenia gravis which mimics human myasthenia gravis pathogenesis for immune intervention. Christadoss P, et al. **Adv Exp Med Biol** 1995; 383:195-9 (16 ref.)

METHODS
Use of plasmid DNA for direct gene transfer and immunization. Davis HL, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:21-9 (29 ref.)
Induction of tolerance in humans: effectiveness of oral and nasal immunization routes. Mestecky J, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:194-201 (25 ref.)
Features of oral immunization. Ruedl C, et al. **Int Arch Allergy Immunol** 1995 Dec;108(4):334-9 (38 ref.)
Genetic immunization. Ertl HC, et al. **Viral Immunol** 1996; 9(1):1-9 (40 ref.)
[Benefits and risks of immunostimulation with interleukin 12] Ryffel B. **Dtsch Med Wochenschr** 1996 Feb 9;121(6):171-4 (20 ref.) **(Ger)**
[Mucosal immunity with implications for use in developing a new generation of vaccines] Osek J, et al. **Postepy Hig Med Dosw** 1995;49(4):469-86 (62 ref.) (Eng. Abstr.) **(Pol)**

STANDARDS
Quality standard for the immunization of infants and children born to women infected with human immunodeficiency virus. Wilfert CM, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S136-7 (5 ref.)

STATISTICS & NUMERICAL DATA
Childhood immunization registries. A national review of public health information systems and the protection of privacy [see comments] Gostin LO, et al. **JAMA** 1995 Dec 13;274(22):1793-9 (76 ref.) Comment in: JAMA 1996 May 1;275(17):1312-3.

TRENDS
Present trends in immunisation [editorial] Goubau P. **Acta Clin Belg** 1996;51(3):129-34 (35 ref.)
From defined human tumor antigens to effective immunization? Boon T, et al. **Immunol Today** 1995 Jul; 16(7):334-6 (18 ref.)

VETERINARY
[Immunity--technical aspects of vaccines. I. Immunoprophylaxis in dogs and cats] Overgaauw PA. **Tijdschr Diergeneeskd** 1996 Feb 15;121(4):90-5 (0 ref.) (Eng. Abstr.) **(Dut)**
[Present state of preclinical research on the efficacy and safety of para immunity inducers from poxviruses. A study of the literature] Mayr B, et al. **Tierarztl Prax** 1995 Dec; 23(6):542-52 (39 ref.) (Eng. Abstr.) **(Ger)**

IMMUNIZATION, ACTIVE see **VACCINATION**

IMMUNIZATION, PASSIVE

Passive immunity against diarrhoea. Bogstedt AK, et al. **Acta Paediatr** 1996 Feb;85(2):125-8 (20 ref.)
Preventing hepatitis A infections in travelers to endemic areas. Koff RS. **Am J Trop Med Hyg** 1995 Dec;53(6):586-90 (29 ref.)
Intravenous immune globulin: an alternative therapy in steroid-dependent allergic diseases. Gelfand EW, et al. **Clin Exp Immunol** 1996 May;104 Suppl 1:61-6 (56 ref.)
Immunization against hepatitis B through adoptive transfer of immunity. Shouval D, et al. **Intervirology** 1995; 38(1-2):41-6 (37 ref.)
The introduction of human monoclonal anti-D for therapeutic use. Fletcher A, et al. **Transfus Med Rev** 1995 Oct;9(4):314-26 (87 ref.)
[In utero vaccination to prevent neonatal infections] Lubin D, et al. **Harefuah** 1995 Jun 1;128(11):711-4 (40 ref.) **(Heb)**

METHODS
Heterologous antisera and antivenins are essential biologicals: perspectives on a worldwide crisis. Wilde H, et al. **Ann Intern Med** 1996 Aug 1;125(3):233-6 (22 ref.)
Therapeutic uses of intravenous immunoglobulin (IVIG) in children. Ramesh S, et al. **Pediatr Rev** 1995 Nov; 16(11):403-10; quiz 410 (12 ref.)
[Intravenous immunoglobulins. Basic principles, selection criteria and indications for preventive and therapeutic administration] Böger RH, et al. **Med Klin** 1995 Sep 15; 90(9):520-6 (58 ref.) **(Ger)**

IMMUNIZATION PROGRAMS

Immunisation against hepatitis B in Taiwan. Gust ID. **Gut** 1996;38 Suppl 2:S67-8 (10 ref.)
Measles elimination in the Americas. Evolving strategies [see comments] de Quadros CA, et al. **JAMA** 1996 Jan 17; 275(3):224-9 (47 ref.) Comment in: JAMA 1996 May 1;275(17):1311-2.
Inactivated polio vaccine for the United States: a missed vaccination opportunity. Plotkin SA. **Pediatr Infect Dis J** 1995 Oct;14(10):835-9 (0 ref.)

TRENDS
Immunization among African American children: implications for social work. Copeland VC. **Health Soc Work** 1996 May;21(2):105-14 (70 ref.)
Vaccinations in the Third World: a consideration of community demand. Nichter M. **Soc Sci Med** 1995 Sep; 41(5):617-32 (96 ref.)
Immunization to regulate fertility: biological and cultural frameworks. Schrater AF. **Soc Sci Med** 1995 Sep; 41(5):657-71 (85 ref.)

IMMUNIZATION PROGRAMS

Enhancing coverage and sustainability of vaccination programs: an explanatory framework with special reference to India. Streefland PH. **Soc Sci Med** 1995 Sep;41(5):647–56 (53 ref.)

IMMUNIZATION SCHEDULE

Quality standard for the immunization of infants and children born to women infected with human immunodeficiency virus. Wilfert CM, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S136–7 (5 ref.)

Vaccination update. Diphtheria, tetanus, pertussis, mumps, rubella, measles. Vetter RT, et al. **Postgrad Med** 1995 Oct; 98(4):133–7, 141–2, 144–5 passim (30 ref.)

IMMUNOACTIVATORS see **ADJUVANTS, IMMUNOLOGIC**

IMMUNOADJUVANTS see **ADJUVANTS, IMMUNOLOGIC**

IMMUNOADSORBENT TECHNIQUES see **IMMUNOSORBENT TECHNIQUES**

IMMUNOASSAY

Applications of electrochemical immunosensors to environmental monitoring. Sadik OA, et al. **Biosens Bioelectron** 1996;11(8):i–xi (32 ref.)

Immunosensors: technology and opportunities in laboratory medicine. Morgan CL, et al. **Clin Chem** 1996 Feb; 42(2):193–209 (186 ref.)

Cytokines and cytokine measurements in a clinical laboratory. Whiteside TL. **Clin Diagn Lab Immunol** 1994 May; 1(3):257–60 (24 ref.)

Optical immunosensors. Rabbany SY, et al. **Crit Rev Biomed Eng** 1994;22(5–6):307–46 (117 ref.)

Thyroglobulin measurement. Techniques, clinical benefits, and pitfalls. Spencer CA, et al. **Endocrinol Metab Clin North Am** 1995 Dec;24(4):841–63 (76 ref.)

Immunoassays for detecting cytokines: what are they really measuring? Mire-Sluis AR, et al. **J Immunol Methods** 1995 Oct 26;186(2):157–60 (15 ref.)

[Characteristics of various labeled chemiluminescent compounds] Uji Y, et al. **Nippon Rinsho** 1995 Sep; 53(9):2175–82 (15 ref.) (Eng. Abstr.) **(Jpn)**

INSTRUMENTATION

Clinical instrumentation (immunoassay analyzers). Chan DW. **Anal Chem** 1995 Jun 15;67(12):519R–524R (33 ref.)

METHODS

Immunoassays. Hage DS. **Anal Chem** 1995 Jun 15; 67(12):455R–462R (262 ref.)

Methods for the determination of beta-agonists in biological matrices. A review. Boyd D, et al. **Analyst** 1996 Jan; 121(1):1R–10R (115 ref.)

Oriented immobilization of antibodies and its applications in immunoassays and immunosensors. Lu B, et al. **Analyst** 1996 Mar;121(3):29R–32R (47 ref.)

Current status and performance goals for serum thyroglobulin assays. Spencer CA, et al. **Clin Chem** 1996 Jan;42(1):164–73 (54 ref.)

Immunosensors. Gizeli E, et al. **Curr Opin Biotechnol** 1996 Feb;7(1):66–71 (34 ref.)

Advances in immunoassay technology. Self CH, et al. **Curr Opin Biotechnol** 1996 Feb;7(1):60–5 (43 ref.)

Assays for measuring soluble cellular adhesion molecules and soluble cytokine receptors. Meager A, et al. **J Immunol Methods** 1996 May 27;191(2):97–112 (146 ref.)

Immune function assays. Nicklin S. **Methods Mol Biol** 1995; 43:245–56 (10 ref.)

Cyclosporin A: analytical methodology and factors affecting therapeutic drug monitoring. Holt DW, et al. **Ther Drug Monit** 1995 Dec;17(6):625–30 (29 ref.)

IMMUNOASSAY, ENZYME see **IMMUNOENZYME TECHNIQUES**

IMMUNOBLASTIC LARGE-CELL LYMPHOMA see **LYMPHOMA, LARGE-CELL, IMMUNOBLASTIC**

IMMUNOBLASTIC LYMPHADENOPATHY

COMPLICATIONS

Angioimmunoblastic lymphadenopathy: an etiology for gastrointestinal lymphomatous polyposis. Goenka MK, et al. **Am J Gastroenterol** 1996 Jun;91(6):1236–8 (16 ref.)

Necrotizing herpes zoster mimicking relapse of vasculitis in angioimmunoblastic lymphadenopathy with dysproteinaemia. Böni R, et al. **Br J Dermatol** 1995 Dec; 133(6):978–82 (29 ref.)

[Pulmonary involvement in immunoblastic lymphadenopathy: case reports and review of literature published in Japan] Sugiyama H, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Nov; 33(11):1276–82 (26 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Angioimmunoblastic T-cell lymphoma: new insights, but the clinical challenge remains [editorial] Jaffe ES. **Ann Oncol** 1995 Sep;6(7):631–2 (21 ref.)

PATHOLOGY

[Immunoblastic lymphadenitis: pathohistologic picture and differential diagnosis from malignant lymphoma] Pavlovskaia AI, et al. **Arkh Patol** 1995 Sep–Oct;57(5):21–5 (23 ref.) (Eng. Abstr.) **(Rus)**

IMMUNOBLASTIC LYMPHOSARCOMA, DIFFUSE see **LYMPHOMA, LARGE-CELL, IMMUNOBLASTIC**

IMMUNOBLASTOMA see **LYMPHOMA, LARGE-CELL, IMMUNOBLASTIC**

IMMUNOBLOTTING

see related
IMMUNOCHEMISTRY

[An immunoblot technique] Imai T. **Nippon Rinsho** 1995 Sep; 53(9):2119–25 (31 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOBLOTTING, WESTERN see **BLOTTING, WESTERN**

IMMUNOCHEMISTRY

see related
IMMUNOBLOTTING
IMMUNOLOGIC TECHNIQUES

METHODS

Immunocytochemical localization of receptor protein kinases in plants. Counihan VP, et al. **Methods Cell Biol** 1995; 49:515–29 (25 ref.)

IMMUNOCOMPETENCE

Localized soft-tissue infections with Mycobacterium avium/Mycobacterium intracellulare complex in immunocompetent patients: granulomatous tenosynovitis of the hand or wrist. Hellinger WC, et al. **Clin Infect Dis** 1995 Jul;21(1):65–9 (25 ref.)

Molecular mechanisms underlying functional T-cell unresponsiveness. Mueller DL, et al. **Curr Opin Immunol** 1995 Jun;7(3):375–81 (54 ref.)

Postnatal maturation of immune competence during infancy and childhood. Holt PG. **Pediatr Allergy Immunol** 1995 May;6(2):59–70 (148 ref.)

Survey of transfusion-associated graft-versus-host disease in immunocompetent recipients. Ohto H, et al. **Transfus Med Rev** 1996 Jan;10(1):31–43 (132 ref.)

[Cat scratch disease in immunocompetent children] Leclainche L, et al. **Arch Pediatr** 1996 Apr;3(4):378–82 (41 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Pathogen-based models favoring MHC genetic diversity. Potts WK, et al. **Immunol Rev** 1995 Feb;143:181–97 (37 ref.)

PHYSIOLOGY

Early dietary influence on later immunocompetence. Hanson LA, et al. **Nutr Rev** 1996 Feb;54(2 Pt 2):S23–30 (73 ref.)

IMMUNOCOMPROMISED HOST

Human herpesvirus-6 in transplantation: an emerging pathogen. Singh N, et al. **Ann Intern Med** 1996 Jun 15; 124(12):1065–71 (58 ref.)

Nystatin prophylaxis in immunocompromised children. Taylor TL. **Ann Pharmacother** 1996 May;30(5):534–5 (8 ref.)

Pseudallescheria boydii in an immunocompromised host. Successful treatment with debridement and itraconazole. Ruxin TA, et al. **Arch Dermatol** 1996 Apr;132(4):382–4 (23 ref.)

Reactivation toxoplasmic retinochoroiditis in patients undergoing bone marrow transplantation: is there a role for chemoprophylaxis? Peacock JE Jr, et al. **Bone Marrow Transplant** 1995 Jun;15(6):983–7 (23 ref.)

Cryptococcal meningitis. Jones GA, et al. **Br J Hosp Med** 1995 Nov 1–14;54(9):439–45 (38 ref.)

Vaccination in the immunocompromised person. Grabowsky M, et al. **Bull Rheum Dis** 1995 Dec;44(8):3–6 (9 ref.)

Herpesvirus infections in immunocompromised patients. Snoeck R, et al. **Cancer Treat Res** 1995;79:149–71 (172 ref.)

New antifungal compounds and strategies for treatment of invasive fungal infections in patients with neoplastic diseases. Walsh TJ, et al. **Cancer Treat Res** 1995;79:113–48 (268 ref.)

Infection control for oncology. Wiblin RT, et al. **Cancer Treat Res** 1995;79:83–100 (115 ref.)

Cutaneous alternariosis in an immunocompromised patient. Chaidemenos GC, et al. **Cutis** 1995 Sep;56(3):145–50 (40 ref.)

Dental health care workers at risk. Garfunkel AA, et al. **Dent Clin North Am** 1996 Apr;40(2):277–91 (44 ref.)

Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients. Goa KL, et al. **Drugs** 1995 Oct;50(4):658–90 (204 ref.)

Current drug therapy of systemic mycoses: a review. Yonga G. **East Afr Med J** 1995 Jun;72(6):394–8 (59 ref.)

An approach to the design and implementation of clinical trials of empirical antibiotic therapy in febrile and neutropenic cancer patients. Viscoli C, et al. **Eur J Cancer** 1995 Nov;31A(12):2013–22 (60 ref.)

Nosocomial colonization and infection in persons infected with human immunodeficiency virus. Craven DE, et al. **Infect Control Hosp Epidemiol** 1996 May;17(5):304–18 (90 ref.)

Fever in the compromised host. Donowitz GR. **Infect Dis Clin North Am** 1996 Mar;10(1):129–48 (50 ref.)

Drug resistance in cytomegalovirus: current knowledge and implications for patient management. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996;12 Suppl 1:S1–22 (81 ref.)

Malignant testicular neoplasms in immunosuppressed patients. Leibovitch I, et al. **J Urol** 1996 Jun;155(6):1938–42 (41 ref.)

Peracute disseminated fatal Aspergillus fumigatus sepsis as a complication of corticoid-treated systemic lupus erythematosus. Nenoff P, et al. **Mycoses** 1995 Nov–Dec; 38(11–12):467–71 (21 ref.)

Spinal infections in the immunocompromised host. Broner FA, et al. **Orthop Clin North Am** 1996 Jan;27(1):37–46 (38 ref.)

Anaesthesia and recently vaccinated children. van der Walt JH, et al. **Paediatr Anaesth** 1996;6(2):135–41 (18 ref.)

Burkholderia cepacia sepsis in neonates. Kahyaoglu O, et al. **Pediatr Infect Dis J** 1995 Sep;14(9):815–6 (9 ref.)

Fungal infections: a growing threat. Dixon DM, et al. **Public Health Rep** 1996 May–Jun;111(3):226–35 (70 ref.)

Corynebacterium CDC group JK (Corynebacterium jeikeium) sepsis in haematological patients: a report of three cases and a systematic literature review. van der Lelie H, et al. **Scand J Infect Dis** 1995;27(6):581–4 (36 ref.)

Opportunistic infections in immunocompromised patients. Chaignaud BE, et al. **Semin Pediatr Surg** 1995 Nov; 4(4):245–51 (91 ref.)

Mycotic infections in pediatric surgical patients. Hilfiker ML, et al. **Semin Pediatr Surg** 1995 Nov;4(4):239–44 (16 ref.)

Human herpesvirus 6 as a possible cause of pneumonia. Cone RW. **Semin Respir Infect** 1995 Dec;10(4):254–8 (32 ref.)

Cytomegalovirus pneumonia: presentation, diagnosis, and treatment. Ljungman P. **Semin Respir Infect** 1995 Dec; 10(4):209–15 (44 ref.)

Pathogenesis of cytomegalovirus pneumonia in immunocompromised hosts. Riddell SR. **Semin Respir Infect** 1995 Dec;10(4):199–208 (71 ref.)

Respiratory syncytial virus and parainfluenza virus infections in the immunocompromised host. Wendt CH, et al. **Semin Respir Infect** 1995 Dec;10(4):224–31 (35 ref.)

Acute lung disease in the immunocompromised host: differential diagnosis at high-resolution CT. Worthy S, et al. **Semin Ultrasound CT MR** 1995 Oct;16(5):353–60 (24 ref.)

Prevention and therapy of fungal infections in cancer patients. A review of recently published information [see comments] Klastersky J. **Support Care Cancer** 1995 Nov; 3(6):393–401 (42 ref.) Comment in: Support Care Cancer 1995 Nov;3(6):385–6.

[Varicella-zoster virus pancreatitis in hematologic diseases] Pulik M, et al. **Ann Med Interne (Paris)** 1995;146(5):292–4 (10 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

What is the role of preterm breast milk supplementation in the host defenses of preterm infants? Science vs. fiction. Groër M, et al. **Adv Pediatr** 1996;43:335–58 (99 ref.)

Subcutaneous phaeohyphomycosis in a renal transplant recipient: a case report and review of the literature. Jha V, et al. **Am J Kidney Dis** 1996 Jul;28(1):137–9 (21 ref.)

Host immune deficiency in immune complex nephritis [editorial] Ooi BS, et al. **J Am Soc Nephrol** 1995 Nov; 6(5):1342–6 (57 ref.)

[Immunology and immunopathology of African trypanosomiasis] Vincendeau P, et al. **Med Trop (Mars)** 1996;56(1):73–8 (56 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOCONJUGATES

Antibody-targeted polymer-bound drugs. Říhová B. **Folia Microbiol (Praha)** 1995;40(4):367–84 (121 ref.)

[Application of tumor marker for immunotargeting therapy of cancer] Yamaguchi T, et al. **Nippon Rinsho** 1996 Jun; 54(6):1674–9 (17 ref.) (Eng. Abstr.) **(Jpn)**

THERAPEUTIC USE

Radioimmunotherapy with alpha-particle emitting radioimmunoconjugates. Zalutsky MR, et al. **Acta Oncol** 1996;35(3):373–9 (36 ref.)

Immunoconjugates and immunotoxins for therapy of carcinomas. Heilström I, et al. **Adv Pharmacol** 1995; 33:349–88 (159 ref.)

Antibody fragments for controlled delivery of therapeutic agents. Verhoeyen ME, et al. **Biochem Soc Trans** 1995 Nov;

23(4):1067-73 (43 ref.)
Immunoconjugates and immunotoxins for therapy of solid tumors. Hellström I, et al. **Cancer Chemother Pharmacol** 1996;38 Suppl:S35-6 (13 ref.)
Recombinant antibody fusion proteins for cancer immunotherapy. Reisfeld RA, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 3):27-53 (67 ref.)
Antibody-enzyme conjugates for cancer therapy. Melton RG, et al. **J Natl Cancer Inst** 1996 Feb 21;88(3-4):153-65 (85 ref.)
The use of radioimmunotherapy in combination with bioreductive agents. Langmuir VK. **Recent Results Cancer Res** 1996;141:137-43 (40 ref.)
Two approaches for enhancing radioimmunotherapy: alpha emitters and hyperthermia. Zalutsky MR, et al. **Recent Results Cancer Res** 1996;141:101-22 (41 ref.)

IMMUNOCONTRACEPTION see **CONTRACEPTION, IMMUNOLOGIC**

IMMUNOCYTOCHEMISTRY see **IMMUNOHISTOCHEMISTRY**

IMMUNODEFICIENCY, COMMON VARIABLE see **COMMON VARIABLE IMMUNODEFICIENCY**

IMMUNODEFICIENCY, SEVERE COMBINED see **SEVERE COMBINED IMMUNODEFICIENCY**

IMMUNODEFICIENCY SYNDROME, ACQUIRED see **ACQUIRED IMMUNODEFICIENCY SYNDROME**

IMMUNODEFICIENCY VIRUS, FELINE

Feline immunodeficiency virus as a model for study of lentivirus infection of the central nervous system. Henriksen SJ, et al. **Curr Top Microbiol Immunol** 1995; 202:167-86 (88 ref.)

GENETICS

Coadaptation and immunodeficiency virus: lessons from the Felidae. Carpenter MA, et al. **Curr Opin Genet Dev** 1995 Dec;5(6):739-45 (53 ref.)
Molecular biology of the feline immunodeficiency virus auxiliary genes. Tomonaga K, et al. **J Gen Virol** 1996 Aug; 77 (Pt 8):1611-21 (137 ref.)

IMMUNOLOGY

[Vaccination against feline retrovirus infections] Horzinek MC. **Tierarztl Prax** 1996 Apr;24(2):197-202 (16 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

[Dendritic cells in dogs and cats: models of study in human pathology] Marchal T, et al. **Pathol Biol (Paris)** 1995 Dec; 43(10):910-20 (68 ref.) (Eng. Abstr.) **(Fre)**

IMMUNODIAGNOSIS see **IMMUNOLOGIC TESTS**

IMMUNOELECTROBLOTTING see **IMMUNOBLOTTING**

IMMUNOELECTRON MICROSCOPY see **MICROSCOPY, IMMUNOELECTRON**

IMMUNOENZYME TECHNIQUES

Beneath the surface of the mud... [editorial] Swanson PE. **Am J Clin Pathol** 1996 Jul;106(1):1-2 (9 ref.)
[Various types of immunoassay] Amino N, et al. **Nippon Rinsho** 1995 Sep;53(9):2107-11 (0 ref.) (Eng. Abstr.) **(Jpn)**
[Enzyme immunoassay for cytokines] Aoki C, et al. **Nippon Rinsho** 1995 Sep;53(9):2290-5 (10 ref.) (Eng. Abstr.) **(Jpn)**
[B/F separation systems in enzyme immunoassay] Chiba H. **Nippon Rinsho** 1995 Sep;53(9):2183-7 (11 ref.) (Eng. Abstr.) **(Jpn)**
[Enzyme amplification in enzyme immunoassay] Hosogaya S, et al. **Nippon Rinsho** 1995 Sep;53(9):2203-7 (17 ref.) (Eng. Abstr.) **(Jpn)**
[Cause and countermeasure for appearance of false positivity or false negativity in enzyme immunoassay (EIA)] Ishii M. **Nippon Rinsho** 1995 Sep;53(9):2239-44 (5 ref.) (Eng. Abstr.) **(Jpn)**
[Factors that affect analytical results in an enzyme immunoassay] Itoh Y, et al. **Nippon Rinsho** 1995 Sep; 53(9):2143-8 (7 ref.) (Eng. Abstr.) **(Jpn)**
[Enzyme labeling methods and it's specificities] Kambegawa A. **Nippon Rinsho** 1995 Sep;53(9):2160-7 (15 ref.) (Eng. Abstr.) **(Jpn)**
[Enzyme immunoassay of blood coagulation and fibrinolysis factors] Koike K, et al. **Nippon Rinsho** 1995 Sep; 53(9):2269-76 (20 ref.) (Eng. Abstr.) **(Jpn)**
[Enzyme immunoassay (EIA) as an assay system of tumor markers] Kuwabara M, et al. **Nippon Rinsho** 1995 Sep; 53(9):2256-61 (17 ref.) (Eng. Abstr.) **(Jpn)**
[The assay of enzyme activity in EIA—colorimetric, fluorometric and luminometric method] Maeda M. **Nippon Rinsho** 1995 Sep;53(9):2198-202 (16 ref.) (Eng. Abstr.) **(Jpn)**
[The effects of solid phase preparation on sensitivity of enzyme immunoassay] Maeda M. **Nippon Rinsho** 1995 Sep; 53(9):2140-2 (3 ref.) (Eng. Abstr.) **(Jpn)**
[Properties of enzymes for enzyme immunoassay] Maekawa M. **Nippon Rinsho** 1995 Sep;53(9):2154-9 (11 ref.) (Eng. Abstr.) **(Jpn)**
[Enzyme immunoassay of substances related to allergy] Midoro-Horiuti T. **Nippon Rinsho** 1995 Sep;53(9):2262-8 (20 ref.) (Eng. Abstr.) **(Jpn)**
[General properties and kinds of antibodies for enzyme immunoassay--characteristics and advantages of polyclonal and monoclonal antibodies] Miyanishi S. **Nippon Rinsho** 1995 Sep;53(9):2149-53 (16 ref.) (Eng. Abstr.) **(Jpn)**
[Enzyme immunoassay of drug in blood (serum)] Nishihara K. **Nippon Rinsho** 1995 Sep;53(9):2301-9 (2 ref.) (Eng. Abstr.) **(Jpn)**
[Enzyme immunoassay of pesticide residues in foods] Nishijima M. **Nippon Rinsho** 1995 Sep;53(9):2310-5 (16 ref.) (Eng. Abstr.) **(Jpn)**
[Characteristics of enzyme substrate used for enzyme immunoassay] Sato R. **Nippon Rinsho** 1995 Sep; 53(9):2168-74 (32 ref.) (Eng. Abstr.) **(Jpn)**
[Enzyme kinetics for enzyme immunoassay] Sudo K. **Nippon Rinsho** 1995 Sep;53(9):2134-9 (0 ref.) (Eng. Abstr.) **(Jpn)**
[Kinds and characteristics of solid-phase enzyme immunoassay] Sugiura M, et al. **Nippon Rinsho** 1995 Sep; 53(9):2188-91 (9 ref.) (Eng. Abstr.) **(Jpn)**
[Present status and future of enzyme immunoassay--hormone] Uchimura H. **Nippon Rinsho** 1995 Sep;53(9):2245-9 (5 ref.) (Eng. Abstr.) **(Jpn)**
[B/F non-separative method] Yabe S, et al. **Nippon Rinsho** 1995 Sep;53(9):2192-7 (9 ref.) (Eng. Abstr.) **(Jpn)**
[Enzyme-immunoassay for autoantibodies using recombinant antigens] Yamanaka K, et al. **Nippon Rinsho** 1995 Sep; 53(9):2283-9 (10 ref.) (Eng. Abstr.) **(Jpn)**
[Detection of food additives by enzyme immunoassay] Yoshida A, et al. **Nippon Rinsho** 1995 Sep;53(9):2316-21 (13 ref.) (Eng. Abstr.) **(Jpn)**

INSTRUMENTATION

[Automated analyzer of enzyme immunoassay] Osawa S. **Nippon Rinsho** 1995 Sep;53(9):2208-12 (0 ref.) (Eng. Abstr.) **(Jpn)**

STANDARDS

[1995: a decisive progress for the interlaboratory transferability of results by using enzyme and protein reference materials (editorial)] Férard G, et al. **Ann Biol Clin (Paris)** 1995;53(9):469-71 (14 ref.) (Eng. Abstr.) **(Fre)**
[Problems related to determination of reference interval and clinical decision limit in enzyme immunoassay] Ichihara K. **Nippon Rinsho** 1995 Sep;53(9):2220-30 (12 ref.) (Eng. Abstr.) **(Jpn)**
[Calibration and standardization in enzyme immunoassay] Kuwa K. **Nippon Rinsho** 1995 Sep;53(9):2232-8 (9 ref.) (Eng. Abstr.) **(Jpn)**
[Quality control of enzyme immunoassay--assurance and control of analytical sensitivity, accuracy and precision] Naka H. **Nippon Rinsho** 1995 Sep;53(9):2213-9 (10 ref.) (Eng. Abstr.) **(Jpn)**

TRENDS

[Past, present and future of enzyme immunoassay] Kawai T. **Nippon Rinsho** 1995 Sep;53(9):2101-6 (9 ref.) (Eng. Abstr.) **(Jpn)**
[Isozyme analysis by enzyme immunoassay (EIA)--clinical significance and future prospect] Takagi Y. **Nippon Rinsho** 1995 Sep;53(9):2250-5 (15 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOFLUORESCENCE MICROSCOPY see **MICROSCOPY, FLUORESCENCE**

IMMUNOGENS, SYNTHETIC see **VACCINES, SYNTHETIC**

IMMUNOGLOBULIN ALLOTYPES

GENETICS

Advances in human immunoglobulin allotypes. Grubb R. **Exp Clin Immunogenet** 1995;12(3):191-7 (30 ref.)
Immunoglobulin allotypes and RFLPs in disease association. Propert D. **Exp Clin Immunogenet** 1995;12(3):198-205 (42 ref.)

PHYSIOLOGY

Mechanisms of T-cell-induced allotypic suppression of mouse IgG2a(b) and of tolerance acquisition to this allotype. Majlessi L, et al. **Res Immunol** 1995 May-Jun; 146(4-5):213-24 (71 ref.)

IMMUNOGLOBULIN CLASS SWITCHING

In vivo switching: identification of germline transcripts for human IgA. Smith CI, et al. **Adv Exp Med Biol** 1995; 371A:9-13 (15 ref.)
Sequential triggering of apoptosis, somatic mutation and isotype switch during germinal center development. Liu YJ, et al. **Semin Immunol** 1996 Jun;8(3):169-77 (51 ref.)

GENETICS

Genetics of IgA deficiency. Truedsson L, et al. **APMIS** 1995 Dec;103(12):833-42 (72 ref.)

IMMUNOGLOBULIN ENHANCER-BINDING PROTEIN see **NF-KAPPA B**

IMMUNOGLOBULIN FRAGMENTS

BIOSYNTHESIS

Production of antibody fragments in Escherichia coli. Harrison JS, et al. **Ann N Y Acad Sci** 1996 May 15; 782:143-58 (81 ref.)
Chaperonins in phage display of antibody fragments. Söderlind E, et al. **Methods Mol Biol** 1995;51:343-53 (28 ref.)

IMMUNOLOGY

The use of antibody fragments for crystallization and structure determinations. Kovari LC, et al. **Structure** 1995 Dec 15;3(12):1291-3 (34 ref.)
Considerations in the design and production of small anti-receptor antibody forms: optimizing gains while reducing size. Peterson NC, et al. **Ther Immunol** 1994 Oct; 1(5):289-95 (58 ref.)

THERAPEUTIC USE

Antibody fragments for controlled delivery of therapeutic agents. Verhoeyen ME, et al. **Biochem Soc Trans** 1995 Nov; 23(4):1067-73 (43 ref.)

IMMUNOGLOBULIN GENES see **GENES, IMMUNOGLOBULIN**

IMMUNOGLOBULIN GM ALLOTYPES

GENETICS

IGHG3 G and the pathogenesis of hyperreactive malarious splenomegaly. Kelly KM. **Med Hypotheses** 1996 Feb; 46(2):135-9 (48 ref.)

IMMUNOGLOBULIN IDIOTYPES

Infections, idiotypes and SLE [editorial; comment] George J, et al. **Lupus** 1995 Oct;4(5):333-5 (40 ref.) Comment on: Lupus 1995 Oct;4(5):339-47.

GENETICS

The molecular origin of regulatory idiotypes. Victor-Kobrin C, et al. **Int Rev Immunol** 1989;5(2):117-29 (36 ref.)

IMMUNOLOGY

Idiotype manipulation in disease management. Kohler H, et al. **Adv Exp Med Biol** 1995;383:117-22 (38 ref.)
A genetic approach to idiotypic vaccination for B cell lymphoma. Stevenson FK, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:212-26 (23 ref.)
Cross-reactive idiotypes on cryoprecipitating monoclonal IgMk rheumatoid factors. Sinico RA, et al. **Clin Exp Rheumatol** 1995 Nov-Dec;13 Suppl 13:S105-7 (8 ref.)
Auto-anti-idiotypy, autoimmunity and some thoughts on the structure of internal images. Erlanger BF. **Int Rev Immunol** 1989;5(2):131-7 (29 ref.)
Properties of a system of public idiotypes of lupus autoantibodies. Schwartz RS. **Int Rev Immunol** 1989; 5(2):153-5 (13 ref.)

THERAPEUTIC USE

Idiotypic DNA vaccines against B-cell lymphoma. Stevenson FK, et al. **Immunol Rev** 1995 Jun;145:211-28 (40 ref.)

IMMUNOGLOBULIN ISOTYPES

GENETICS

B-1 cellular origin and VH segment structure of IgG, IgA, and IgM anti-DNA autoantibodies in patients with systemic lupus erythematosus. Kasaian MT, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:410-23 (52 ref.)
T-cell acute lymphoblastic leukemia occurring in the course of B cell chronic lymphocytic leukemia: a case report. Preudhomme C, et al. **Leuk Lymphoma** 1995 Jul; 18(3-4):361-4 (9 ref.)

IMMUNOGLOBULIN JOINING REGION

see related
GENES, IMMUNOGLOBULIN

IMMUNOGLOBULIN THERAPY see **IMMUNIZATION, PASSIVE**

IMMUNOGLOBULIN VARIABLE REGION

see related
BINDING SITES, ANTIBODY

CHEMISTRY

Structural and functional properties of human lambda-light-chain variable-region subgroups. Solomon A, et al. **Clin Diagn Lab Immunol** 1995 Jul;2(4):387-94 (52 ref.)
The structure of the antigen-binding site of immunoglobulins and T-cell receptors. Bentley GA, et al. **Res Immunol** 1995 May-Jun;146(4-5):277-90 (27 ref.)
Considerations in the design and production of small anti-receptor antibody forms: optimizing gains while reducing size. Peterson NC, et al. **Ther Immunol** 1994 Oct; 1(5):289-95 (58 ref.)

GENETICS

Somatic mutation of human immunoglobulin V genes: bias, rate, and regulation. Insel RA, et al.
Ann N Y Acad Sci 1995 Sep 29;764:158-69 (46 ref.)
B-1 cellular origin and VH segment structure of IgG, IgA, and IgM anti-DNA autoantibodies in patients with systemic lupus erythematosus. Kasaian MT, et al.
Ann N Y Acad Sci 1995 Sep 29;764:410-23 (52 ref.)
Development of the antibody repertoire in rabbits. Knight KL, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:198-206 (23 ref.)
Polymorphism and utilization of human VH Genes. Milner EC, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:50-61 (23 ref.)
Origins of anti-DNA antibodies and their implications for B-cell tolerance. Radic MZ, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:384-96 (13 ref.)
Developmental regulation of the human antibody repertoire. Schroeder HW Jr, et al. **Ann N Y Acad Sci** 1995 Sep 29; 764:242-60 (60 ref.)
A genetic approach to idiotypic vaccination for B cell lymphoma. Stevenson FK, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:212-26 (23 ref.)
The expressed heavy chain V gene repertoire of circulating B cells in normal adults. Stollar BD.
Ann N Y Acad Sci 1995 Sep 29;764:265-74 (82 ref.)
A complete map of the human immunoglobulin VH locus. Tomlinson IM, et al. **Ann N Y Acad Sci** 1995 Sep 29; 764:43-6 (12 ref.)
Fetal versus adult PreB or B cells: the human VH repertoire. Tonnelle C, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:231-41 (38 ref.)
Molecular analysis of VH regions expressed in the adult B-cell repertoire. van der Stoep N, et al.
Ann N Y Acad Sci 1995 Sep 29;764:275-84 (19 ref.)
Menage à trois: double strand break repair, V(D)J recombination and DNA-PK. Jeggo PA, et al.
Bioessays 1995 Nov;17(11):949-57 (67 ref.)
Somatic hypermutation: how many mechanisms diversify V region sequences? Maizels N. **Cell** 1995 Oct 6;83(1):9-12 (26 ref.)
Analysis of immunoglobulin gene rearrangements in single B cells. Ehlich A, et al. **Curr Opin Immunol** 1995 Apr; 7(2):281-4 (18 ref.)
Somatic hypermutation. Neuberger MS, et al.
Curr Opin Immunol 1995 Apr;7(2):248-54 (69 ref.)
Human antibody variable region gene usage in HIV-1 infection. Wisnewski A, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1996 Jan 1;11(1):31-8 (57 ref.)
Synthetic human antibodies. Barbas CF 3rd. **Nat Med** 1995 Aug;1(8):837-9 (32 ref.)
The targeting of somatic hypermutation. Jolly CJ, et al.
Semin Immunol 1996 Jun;8(3):159-68 (53 ref.)
Characterization of the cis-acting elements required for somatic hypermutation of murine antibody V genes using conventional transgenic and transgene homologous recombination approaches. Tumas-Brundage K, et al.
Semin Immunol 1996 Jun;8(3):141-50 (68 ref.)

IMMUNOLOGY

Redirection of cellular cytotoxicity. A two-step approach using recombinant single-chain Fv molecules. George AJ, et al. **Cell Biophys** 1995 Jun;26(3):153-65 (39 ref.)
Alternative triggering molecules and single chain bispecific antibodies. Segal DM, et al. **J Hematother** 1995 Oct; 4(5):377-82 (31 ref.)

IMMUNOGLOBULINS

see related
PARAPROTEINEMIAS

Hematologic side effects of radiolabeled immunoglobulin therapy. Vriesendorp HM, et al. **Exp Hematol** 1996 Aug; 24(10):1183-90 (52 ref.)
IgY: clues to the origins of modern antibodies. Warr GW, et al. **Immunol Today** 1995 Aug;16(8):392-8 (42 ref.)
Cell adhesion molecules. 1: immunoglobulin superfamily. Brümmendorf T, et al. **Protein Profile** 1994;1(9):951-1058 (925 ref.)

ADMINISTRATION & DOSAGE

Alloimmunization during pregnancy treated with high dose intravenous immunoglobulin. Effects on fetal hemoglobin concentration and anti-D concentrations in the mother and fetus. Gottvall T, et al. **Acta Obstet Gynecol Scand** 1995 Nov;74(10):777-83 (30 ref.)
Human Immunoglobulins for intravenous use and hepatitis C viral transmission. Slade HB.
Clin Diagn Lab Immunol 1994 Nov;1(6):613-9 (84 ref.)
[Efficacy of immune serum globulin and hepatitis A vaccine with special reference to anti-HA antibody titers] Fujiyama S. **Nippon Rinsho** 1995 Oct;53 Suppl:884-91 (17 ref.) **(Jpn)**
[Intravenous immunoglobulins in the treatment of neurologic diseases] Illa I, et al. **Neurologia** 1996 Jun-Jul;11(6):220-8 (56 ref.) **(Spa)**

BIOSYNTHESIS

Antibody production and engineering in plants. Ma JK, et al. **Ann N Y Acad Sci** 1996 May 25;792:72-81 (35 ref.)
Modulation of B-cell immunoglobulin synthesis by retinoic acid. Ballow M, et al. **Clin Immunol Immunopathol** 1996 Sep;80(3 Pt 2):S73-81 (37 ref.)
Soluble extracellular antigen-specific T cell immunoproteins. Cone RE. **J Leukoc Biol** 1996 May;59(5):605-12 (65 ref.)
Plant antibodies for immunotherapy. Ma JK, et al.
Plant Physiol 1995 Oct;109(2):341-6 (30 ref.)
[Immunoglobulin producing mechanism and their abnormalities] Hamano T. **Nippon Naika Gakkai Zasshi** 1995 Jul 10;84(7):1050-4 (8 ref.) **(Jpn)**

BLOOD

[Circulating anticoagulant] Watanabe K. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:147-9 (5 ref.) **(Jpn)**

CHEMISTRY

Sialoadhesin and related cellular recognition molecules of the immunoglobulin superfamily. Crocker PR, et al.
Biochem Soc Trans 1996 Feb;24(1):150-6 (50 ref.)

DIAGNOSTIC USE

Radiolabelled human immunoglobulins. Buscombe J.
Nucl Med Commun 1995 Dec;16(12):990-1001 (54 ref.)

GENETICS

Immunoglobulin diversity: rearranging by cutting and repairing. Lieber M. **Curr Biol** 1996 Feb 1;6(2):134-6 (30 ref.)
[Repertoire of rearranged immunoglobulin genes of human peripheral lymphocytes] Kraj P.
Postepy Hig Med Dosw 1995;49(1):9-22 (79 ref.) (Eng. Abstr.) **(Pol)**

IMMUNOLOGY

The Ku autoantigen: cast in a new light. Robinson A.
Can Med Assoc J 1996 Jun 15;154(12):1871-3 (8 ref.)

METABOLISM

[Enzyme-linked immunoglobulin] Sugita O.
Nippon Rinsho 1995 Feb;53 Su Pt 1:432-4 (20 ref.) **(Jpn)**

PHYSIOLOGY

Leukocyte adhesion molecules. Chapman PT, et al.
Br Med Bull 1995 Apr;51(2):296-311 (80 ref.)

THERAPEUTIC USE

Review of five consecutive studies of radiolabeled immunoglobulin therapy in Hodgkin's disease. Vriesendorp HM, et al. **Cancer Res** 1995 Dec 1;55(23 Suppl):5888s-5892s (15 ref.)
Alternative epilepsy therapies: the ketogenic diet, immunoglobulins, and steroids. Prasad AN, et al.
Epilepsia 1996;37 Suppl 1:S81-95 (106 ref.)
New therapeutic approaches in sepsis: a critical review. Eidelman LA, et al. **Intensive Care Med** 1995 Nov;21 Suppl 2:S269-72 (18 ref.)
Role of immunoglobulins and new antivirals in treatment of cytomegalovirus infection. Paya CV. **Transplant Proc** 1995 Oct;27(5 Suppl 1):28-30 (21 ref.)
[Hepatitis B immune serum globulin] Iino S.
Nippon Rinsho 1995 Oct;53 Suppl:371-7 (16 ref.) **(Jpn)**
[Intravenous immunoglobulins in the treatment of neurologic diseases] Illa I, et al. **Neurologia** 1996 Jun-Jul;11(6):220-8 (56 ref.) **(Spa)**

IMMUNOGLOBULINS, FAB

CHEMISTRY

The crystal structures of complexes formed between lysozyme and antibody fragments. Bentley GA. **EXS** 1996; 75:301-19 (42 ref.)

IMMUNOLOGY

Considerations in the design and production of small anti-receptor antibody forms: optimizing gains while reducing size. Peterson NC, et al. **Ther Immunol** 1994 Oct; 1(5):289-95 (58 ref.)

ISOLATION & PURIFICATION

Toward the production of bispecific antibody fragments for clinical applications. Carter P, et al. **J Hematother** 1995 Oct;4(5):463-70 (63 ref.)

PHARMACOLOGY

Anti-platelet monoclonal antibodies for the prevention of arterial thrombosis: experience with ReoPro, a monoclonal antibody directed against the platelet GPIIb/IIIa receptor. Weisman HF, et al. **Biochem Soc Trans** 1995 Nov; 23(4):1051-7 (25 ref.)

THERAPEUTIC USE

Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective. Tcheng JE. **Am J Cardiol** 1996 Aug 14; 78(3A):35-40 (27 ref.)
The clinical role of platelet glycoprotein IIb/IIIa receptor inhibitors in ischemic heart disease. Lefkovits J, et al.
Cleve Clin J Med 1996 May-Jun;63(3):181-9 (32 ref.)
Drug-specific antibodies as antidotes for tricyclic antidepressant overdose. Pentel PR, et al. **Toxicol Lett** 1995 Dec;82-83:801-6 (20 ref.)

IMMUNOGLOBULINS, FC

see related
RECEPTORS, FC

IMMUNOGLOBULINS, HEAVY-CHAIN

see related
HEAVY CHAIN DISEASE

GENETICS

Somatic mutation of human immunoglobulin V genes: bias, rate, and regulation. Insel RA, et al.
Ann N Y Acad Sci 1995 Sep 29;764:158-69 (46 ref.)
B-1 cellular origin and VH segment structure of IgG, IgA, and IgM anti-DNA autoantibodies in patients with systemic lupus erythematosus. Kasaian MT, et al.
Ann N Y Acad Sci 1995 Sep 29;764:410-23 (52 ref.)
Development of the antibody repertoire in rabbits. Knight KL, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:198-206 (23 ref.)
Polymorphism and utilization of human VH Genes. Milner EC, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:50-61 (23 ref.)
Origins of anti-DNA antibodies and their implications for B-cell tolerance. Radic MZ, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:384-96 (13 ref.)
The expressed heavy chain V gene repertoire of circulating B cells in normal adults. Stollar BD.
Ann N Y Acad Sci 1995 Sep 29;764:265-74 (82 ref.)
A complete map of the human immunoglobulin VH locus. Tomlinson IM, et al. **Ann N Y Acad Sci** 1995 Sep 29; 764:43-6 (12 ref.)
Fetal versus adult PreB or B cells: the human VH repertoire. Tonnelle C, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:231-41 (38 ref.)
Molecular analysis of VH regions expressed in the adult B-cell repertoire. van der Stoep N, et al.
Ann N Y Acad Sci 1995 Sep 29;764:275-84 (19 ref.)
Human antibodies from transgenic mice. Lonberg N, et al.
Int Rev Immunol 1995;13(1):65-93 (102 ref.)
Human antibody variable region gene usage in HIV-1 infection. Wisnewski A, et al.
J Acquir Immune Defic Syndr Hum Retrovirol 1996 Jan 1;11(1):31-8 (57 ref.)
Multiple myeloma: new evidence and insights from the immunoglobulin heavy chain gene and phenotypes. Takishita M, et al. **Leuk Lymphoma** 1995 Nov; 19(5-6):395-400 (36 ref.)

IMMUNOGLOBULINS, INTRAVENOUS

ADVERSE EFFECTS

Infectious risk of plasma donations: relationship to safety of intravenous immune globulins. Dodd RY.
Clin Exp Immunol 1996 May;104 Suppl 1:31-4 (25 ref.)
The viral safety of intravenous immune globulin. Yap PL.
Clin Exp Immunol 1996 May;104 Suppl 1:35-42 (69 ref.)

Acute renal failure after administration of intravenous immunoglobulin: review of the literature and case report. Winward DB, et al. **Pharmacotherapy** 1995 Nov-Dec; 15(6):765-72 (33 ref.)

IMMUNOLOGY

[Immunoglobulins for intravenous administration: the theoretical bases and their clinical use] Dizik GM, et al. **Lik Sprava** 1995 Jul-Aug;(7-8):74-8, 125 (23 ref.) **(Rus)**

PHARMACOLOGY

Mechanisms of action of intravenous immune globulin in immune-mediated diseases. Mouthon L, et al. **Clin Exp Immunol** 1996 May;104 Suppl 1:3-9 (63 ref.)

Down regulation of Fc receptors by IVIgG. Mannhalter JW, et al. **Int Rev Immunol** 1989;5(2):173-9 (24 ref.)

THERAPEUTIC USE

Intravenous immunoglobins (IVIGs) to prevent and treat infectious diseases. Cross AS. **Adv Exp Med Biol** 1995; 383:123-30 (19 ref.)

Dermatomyositis treated with high-dose intravenous immunoglobulins and associated with panniculitis. Sabroe RA, et al. **Clin Exp Dermatol** 1995 Mar;20(2):164-7 (16 ref.)

Clinical benefits and immunopathological correlates of intravenous immune globulin in the treatment of inflammatory myopathies. Dalakas MC. **Clin Exp Immunol** 1996 May;104 Suppl 1:55-60 (35 ref.)

Intravenous immune globulin in the treatment of intractable childhood epilepsy. Duse M, et al. **Clin Exp Immunol** 1996 May;104 Suppl 1:71-6 (68 ref.)

Intravenous immune globulin: an alternative therapy in steroid-dependent allergic diseases. Gelfand EW, et al. **Clin Exp Immunol** 1996 May;104 Suppl 1:61-6 (56 ref.)

Kawasaki syndrome: immunomodulatory benefit and potential toxin neutralization by intravenous immune globulin. Leung DY. **Clin Exp Immunol** 1996 May;104 Suppl 1:49-54 (41 ref.)

New treatment strategies for systemic vasculitis: the role of intravenous immune globulin therapy. Lockwood CM. **Clin Exp Immunol** 1996 May;104 Suppl 1:77-82 (48 ref.)

Immunomodulation in allogeneic marrow transplantation: use of intravenous immune globulin to suppress acute graft-versus-host disease. Sullivan KM. **Clin Exp Immunol** 1996 May;104 Suppl 1:43-8 (68 ref.)

Supplemental immune globulins in sepsis: a critical appraisal. Werdan K, et al. **Clin Exp Immunol** 1996 May;104 Suppl 1:83-90 (48 ref.)

Parvovirus infection and its treatment. Young NS. **Clin Exp Immunol** 1996 May;104 Suppl 1:26-30 (31 ref.)

A comparison between IVIg and plasma exchange in Guillain-Barré syndrome: a review and decision analysis of the two treatment modalities. Dawson WB, et al. **Clin Neuropharmacol** 1995 Oct;18(5):377-90 (44 ref.)

Treatment of inflammatory myopathy with intravenous gamma globulin. Sussman GL, et al. **Curr Opin Rheumatol** 1995 Nov;7(6):510-5 (57 ref.)

Adjuncts to antibacterial therapy. Frank MO, et al. **Infect Dis Clin North Am** 1995 Sep;9(3):769-81 (63 ref.)

Idiopathic thrombocytopenic purpura (ITP): immunomodulation by intravenous immunoglobulin (IVIg). Imbach P, et al. **Int Rev Immunol** 1989;5(2):181-8 (34 ref.)

The immunologic effects of IVIG in Kawasaki disease. Leung DY. **Int Rev Immunol** 1989;5(2):197-202 (24 ref.)

Current role of intravenous gammaglobulin. Lokeshwar MR, et al. **J Assoc Physicians India** 1995;Suppl 3:67-72 (25 ref.)

Is there a scientific rationale for therapeutic plasma exchange or intravenous immune globulin in the treatment of acute Guillain-Barré syndrome? Weinstein R. **J Clin Apheresis** 1995;10(3):150-7 (94 ref.)

Treatment of systemic and renal-limited vasculitic disorders with pooled human intravenous immune globulin. Jordan SC. **J Clin Immunol** 1995 Nov;15(6 Suppl):76S-85S (40 ref.)

Use of intravenous immune globulin in the therapy of children with rheumatological diseases. Roifman CM. **J Clin Immunol** 1995 Nov;15(6 Suppl):42S-51S (10 ref.)

Inflammatory neuropathies--pathogenesis and the role of intravenous immune globulin. van der Meché FG, et al. **J Clin Immunol** 1995 Nov;15(6 Suppl):63S-69S (64 ref.)

Immunotherapy and immunoprophylaxis in bone marrow transplantation. Barnes RA. **J Hosp Infect** 1995 Jun;30 Suppl:223-31 (53 ref.)

Intravenous immunoglobulin treatment in neurological diseases [editorial] Otten A, et al. **J Neurol Neurosurg Psychiatry** 1996 Apr;60(4):359-61 (44 ref.)

The potential role of therapeutic antibodies in the regulation of rejection. Ettenger RB, et al. **Transplant Proc** 1995 Oct; 27(5 Suppl 1):13-7 (28 ref.)

Prophylactic cytomegalovirus management strategies. Martin M. **Transplant Proc** 1995 Oct;27(5 Suppl 1):23-7 (30 ref.)

Antiviral antibodies in transplantation. Snydman DR. **Transplant Proc** 1995 Oct;27(5 Suppl 1):10-2 (22 ref.)

Prevention and treatment of cytomegalovirus disease in thoracic organ transplant patients: evidence for a beneficial effect of hyperimmune globulin. Valantine HA. **Transplant Proc** 1995 Oct;27(5 Suppl 1):49-57 (62 ref.)

[Therapy recommendations for the use of intravenously applicable immunoglobulins] Marschner JP, et al. **Med Klin** 1996 Mar 15;91(3):141-7 (78 ref.) **(Ger)**

[Indication for use and mechanisms of action of intravenous immune globulin in autoimmune diseases] Cohen AD, et al. **Harefuah** 1995 Aug;129(3-4):123-7 (50 ref.) **(Heb)**

[Myasthenic crisis during pregnancy: case report and literature survey] Kwieciński H, et al. **Pol Tyg Lek** 1995 Oct;50(40-44):50-2 (14 ref.) (Eng. Abstr.) **(Pol)**

[Immunoglobulins for intravenous administration: the theoretical bases and their clinical use] Dizik GM, et al. **Lik Sprava** 1995 Jul-Aug;(7-8):74-8, 125 (23 ref.) **(Rus)**

IMMUNOGLOBULINS, KAPPA-CHAIN

BLOOD

[The Schnitzler syndrome as a cause of recurrent fever of unknown origin] Winckelmann G, et al. **Dtsch Med Wochenschr** 1996 Jul 5;121(27):860-4 (14 ref.) (Eng. Abstr.) **(Ger)**

[kappa Light chain] Maruyama S. **Nippon Rinsho** 1995 Feb; 53 Su Pt 1:175-8 (16 ref.) **(Jpn)**

GENETICS

Expression and hypermutation of human immunoglobulin kappa genes. Klein R, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:74-83 (16 ref.)

Analysis of lambda repertoire in kappa-deficient mice. Pricop L, et al. **Clin Immunol Immunopathol** 1995 Sep;76(3 Pt 2):S179-87 (102 ref.)

IMMUNOGLOBULINS, LAMBDA-CHAIN

ANALYSIS

Intracerebral A lambda amyloidoma diagnosed by stereotactic biopsy. Schröder R, et al. **Clin Neuropathol** 1995 Nov-Dec;14(6):347-50 (34 ref.)

CHEMISTRY

Structural and functional properties of human lambda-light-chain variable-region subgroups. Solomon A, et al. **Clin Diagn Lab Immunol** 1995 Jul;2(4):387-94 (52 ref.)

IMMUNOLOGY

Analysis of lambda repertoire in kappa-deficient mice. Pricop L, et al. **Clin Immunol Immunopathol** 1995 Sep;76(3 Pt 2):S179-87 (102 ref.)

IMMUNOGLOBULINS, LIGHT-CHAIN

[Immunoglobulin light-chain type amyloidosis] Isobe T. **Nippon Naika Gakkai Zasshi** 1995 Jul 10;84(7):1112-6 (5 ref.) **(Jpn)**

CHEMISTRY

Molecular anatomy and the pathological expression of antibody light chains [comment] Schiffer M. **Am J Pathol** 1996 May;148(5):1339-44 (31 ref.) Comment on: Am J Pathol 1996 May;148(5):1397-406.

GENETICS

Regulation of human lambda light chain gene expression. Blomberg BB, et al. **Ann N Y Acad Sci** 1995 Sep 29; 764:84-98 (58 ref.)

Human antibodies from transgenic mice. Lonberg N, et al. **Int Rev Immunol** 1995;13(1):65-93 (102 ref.)

IMMUNOGLOBULINS, SURFACE

IMMUNOLOGY

A genetic approach to idiotypic vaccination for B cell lymphoma. Stevenson FK, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:212-26 (23 ref.)

PHYSIOLOGY

The one signal theory of B cell activation revisited: a role for surface immunoglobulin in regulating T-independent antibody responses? Mamchak AA, et al. **Immunol Cell Biol** 1995 Jun;73(3):266-71 (29 ref.)

IMMUNOGLOBULINS, THYROID-STIMULATING

see related
GRAVES' DISEASE
RECEPTORS, THYROTROPIN

IMMUNOGOLD-SILVER TECHNIQUES see **IMMUNOHISTOCHEMISTRY**

IMMUNOGOLD TECHNIQUES see **IMMUNOHISTOCHEMISTRY**

IMMUNOHISTOCHEMISTRY

Immunohistochemical parameters for the age estimation of human skin wounds. A review. Betz P. **Am J Forensic Med Pathol** 1995 Sep;16(3):203-9 (53 ref.)

Immunocytochemistry in the diagnosis of Kaposi's sarcoma and angiosarcoma. Orchard GE, et al. **Br J Biomed Sci** 1995 Mar;52(1):35-49 (145 ref.)

Immunohistochemistry in diagnostic dermatopathology. Wallace ML, et al. **J Am Acad Dermatol** 1996 Feb;34(2 Pt 1):163-83; quiz 184-6 (289 ref.)

Quantitation in immunohistochemistry. A research method or a diagnostic tool in surgical pathology? Fritz P, et al. **Pathologica** 1995 Jun;87(3):300-9 (76 ref.)

Colloidal gold post-embedding immunocytochemistry. Bendayan M. **Prog Histochem Cytochem** 1995;29(4):1-159 (465 ref.)

[Biochemical basis for detection of estrogen and progesterone receptors in breast tumors using immunohistochemistry] Goussard J. **Ann Pathol** 1996;16(2):91-7 (41 ref.) **(Fre)**

METHODS

Application of immunocytochemistry for detection of proliferating cell populations during tooth development. Casasco A. **Anat Rec** 1996 Jun;245(2):162-73 (146 ref.)

Diagnosis of systemic mycoses by specific immunohistochemical tests. Jensen HE, et al. **APMIS** 1996 Apr;104(4):241-58 (85 ref.)

Immunocytochemistry as a diagnostic tool. Stoll G. **Baillieres Clin Neurol** 1996 Mar;5(1):129-42 (54 ref.)

Detection of infectious disease agents in tissue by immunocytochemistry. Bacchi CE, et al. **Braz J Med Biol Res** 1994 Dec;27(12):2803-20 (52 ref.)

Immunohistochemical approaches to diagnosis in gynecologic pathology. Beckstead JH. **Clin Lab Med** 1995 Sep;15(3):727-42 (80 ref.)

Robert Feulgen Prize Lecture 1995. New approaches to in situ detection of nucleic acids. Thiry M. **Histochem Cell Biol** 1995 Aug;104(2):81-95 (81 ref.)

Detection of human cytokines in situ using antibody and probe based methods. Hoefakker S, et al. **J Immunol Methods** 1995 Sep 25;185(2):149-75 (159 ref.)

Methods in plant immunolight microscopy. Brown RC, et al. **Methods Cell Biol** 1995;49:85-107 (27 ref.)

Monoclonal antibodies to cell-specific cell surface carbohydrates in plant cell biology and development. Pennell RI, et al. **Methods Cell Biol** 1995;49:123-41 (61 ref.)

TRENDS

Update of immunocytochemistry in cytopathology. van Hoeven KH, et al. **Pathol Annu** 1995;30 Pt 2:245-67 (84 ref.)

IMMUNOHISTOCYTOCHEMISTRY see **IMMUNOHISTOCHEMISTRY**

IMMUNOLABELING TECHNIQUES see **IMMUNOHISTOCHEMISTRY**

IMMUNOLOGIC ACCESSORY CELLS see **ANTIGEN-PRESENTING CELLS**

IMMUNOLOGIC CAPPING

see related
IMMUNOGLOBULINS, SURFACE

IMMUNOLOGIC COMPETENCE see **IMMUNOCOMPETENCE**

IMMUNOLOGIC DEFICIENCY SYNDROME, ACQUIRED see **ACQUIRED IMMUNODEFICIENCY SYNDROME**

IMMUNOLOGIC DEFICIENCY SYNDROMES

see related
IMMUNOCOMPROMISED HOST

Immunodeficiency [editorial] Bolognesi DP, et al. **Curr Opin Immunol** 1995 Aug;7(4):433-5 (5 ref.)

Mycotic infections in pediatric surgical patients. Hilfiker ML, et al. **Semin Pediatr Surg** 1995 Nov;4(4):239-44 (16 ref.)

[Primary immunodeficiency diseases] Mukaida N. **Nippon Rinsho** 1995 Nov;53(11):2821-6 (19 ref.) (Eng. Abstr.) **(Jpn)**

[Primary lymphomas of the brain not related to immunodeficiency] Marques H, et al. **Acta Med Port** 1995 Mar;8(3):151-6 (38 ref.) (Eng. Abstr.) **(Por)**

COMPLICATIONS

Protracted cutaneous disorders in association with low CD4+ lymphocyte counts. Kurwa HA, et al. **Br J Dermatol** 1995 Oct;133(4):625-9 (19 ref.)

Gastrointestinal and nutritional problems in children with immunodeficiency and AIDS. Winter H, et al. **Pediatr Clin North Am** 1996 Apr;43(2):573-90 (40 ref.)

IMMUNOLOGIC DEFICIENCY SYNDROMES

CONGENITAL

[Cutaneous granulomatous lesions in congenital immune deficiencies. 5 cases] Paul C, et al. **Ann Dermatol Venereol** 1995;122(8):501–6 (34 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Evaluation of the child with suspected primary immunodeficiency. Wahn U. **Pediatr Allergy Immunol** 1995 May;6(2):71–9 (61 ref.)

ENZYMOLOGY

The role of Bruton's tyrosine kinase in B-cell development and function in mice and man. Khan WN, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:27–38 (36 ref.)

Nonreceptor protein tyrosine kinase involvement in signal transduction and immunodeficiency disease. Saouaf SJ, et al. **Clin Immunol Immunopathol** 1995 Sep;76(3 Pt 2):S151–7 (65 ref.)

ETIOLOGY

A role for CRH and the sympathetic nervous system in stress-induced immunosuppression. Friedman EM, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:396–418 (125 ref.)

[Outline of immune deficiency pathogenesis in patients with chronic renal failure] Zmonarski SC, et al. **Postepy Hig Med Dosw** 1995;49(4):487–512 (78 ref.) (Eng. Abstr.) **(Pol)**

[Disordered thymus function and endocrine control as one of the bases for the development of a late postradiation immunodeficiency (a review of the literature)] Savina NP, et al. **Radiats Biol Radioecol** 1995 Jul-Aug;35(4):463–80 (155 ref.) (Eng. Abstr.) **(Rus)**

[Role of metabolic arachidonic acid cascade and prostaglandin E2 in the pathogenesis of immunodeficiency in traumatic shock and acute hemorrhage] Pavlovskii MP, et al. **Klin Khir** 1995;(4):35–8 (62 ref.) **(Ukr)**

GENETICS

Positional cloning and the molecular basis of immunodeficiency. Smith CI, et al. **Ann Med** 1995 Aug; 27(4):477–9 (27 ref.)

Adenosine deaminase deficiency: molecular basis and recent developments. Hirschhorn R. **Clin Immunol Immunopathol** 1995 Sep;76(3 Pt 2):S219–27 (66 ref.)

Immunodeficiency in IL-2-knockout mice. Horak I. **Clin Immunol Immunopathol** 1995 Sep;76(3 Pt 2):S172–3 (18 ref.)

Analysis of lambda repertoire in kappa-deficient mice. Pricop L, et al. **Clin Immunol Immunopathol** 1995 Sep;76(3 Pt 2):S179–87 (102 ref.)

T lymphocyte receptor deficiencies. Kappes DJ, et al. **Curr Opin Immunol** 1995 Aug;7(4):441–7 (53 ref.)

ICF syndrome (immunodeficiency, centromeric instability and facial anomalies): investigation of heterochromatin abnormalities and review of clinical outcome. Brown DC, et al. **Hum Genet** 1995 Oct;96(4):411–6 (15 ref.)

Primary immunodeficiencies: a flurry of new genes. Conley ME. **Immunol Today** 1995 Jul;16(7):313–5 (14 ref.)

IMMUNOLOGY

X-linked agammaglobulinemia and immunoglobulin deficiency with normal or elevated IgM: immunodeficiencies of B cell development and differentiation. Fuleihan R, et al. **Adv Immunol** 1995; 60:37–56 (124 ref.)

Immunodeficiency in IL-2-knockout mice. Horak I. **Clin Immunol Immunopathol** 1995 Sep;76(3 Pt 2):S172–3 (18 ref.)

Superantigens: structure and relevance to human disease. Johnson HM, et al. **Proc Soc Exp Biol Med** 1996 Jun; 212(2):99–109 (88 ref.)

[Complement deficiencies] Meri S. **Duodecim** 1994; 110(2):185–94 (35 ref.) **(Fin)**

PATHOLOGY

T cell activation deficiencies. Le Deist F, et al. **Clin Immunol Immunopathol** 1995 Sep;76(3 Pt 2):S163–4 (20 ref.)

THERAPY

[Gene therapy of hereditary immunologic deficiencies] Fischer A, et al. **Arch Pediatr** 1996;3 Suppl 1:69s–76s (55 ref.) **(Fre)**

[Intravenous immunoglobulins. Basic principles, selection criteria and indications for preventive and therapeutic administration] Böger RH, et al. **Med Klin** 1995 Sep 15; 90(9):520–6 (58 ref.) **(Ger)**

[Bone marrow transplantation in primary immunodeficiency syndrome and in osteopetrosis] Fasth A. **Nord Med** 1995; 110(12):316–7 (15 ref.) (Eng. Abstr.) **(Swe)**

IMMUNOLOGIC DISEASES

CHEMICALLY INDUCED

Contaminant-induced immunotoxicity in harbour seals: wildlife at risk? Ross P, et al. **Toxicology** 1996 Aug 16; 112(2):157–69 (91 ref.)

COMPLICATIONS

Immune dysfunction—a potential target for treatment in endometriosis. Gleicher N. **Br J Obstet Gynaecol** 1995 Oct; 102 Suppl 12:4–7 (25 ref.)

Critical neurologic illness in the immunocompromised patient. Cohen JA, et al. **Neurol Clin** 1995 Aug;13(3):659–77 (93 ref.)

DIAGNOSIS

Indirect DNA/gene diagnoses via electrophoresis—an obsolete principle? Epplen JT, et al. **Electrophoresis** 1995 May;16(5):683–90 (53 ref.)

DRUG THERAPY

Thalidomide: rationale for renewed use in immunological disorders. Schuler U, et al. **Drug Saf** 1995 Jun;12(6):364–9 (61 ref.)

Innovative strategies for pharmacological intervention in immune damage to the kidney. Abbate M, et al. **Nephrol Dial Transplant** 1995;10(7):1131–6 (66 ref.)

ETIOLOGY

Dissection of the pathologies induced by transmembrane and wild-type tumor necrosis factor in transgenic mice. Probert L, et al. **J Leukoc Biol** 1996 Apr;59(4):518–25 (93 ref.)

Airborne pollutants and the immune system. Albright JF, et al. **Otolaryngol Head Neck Surg** 1996 Feb;114(2):232–8 (35 ref.)

[Immunologic diseases and hepatitis C virus] Malaguarnera M, et al. **Rev Med Interne** 1996;17(4):305–12 (51 ref.) (Eng. Abstr.) **(Fre)**

[Immune disorders in patients with nutrition disorders and renal insufficiency] Gajdosz R, et al. **Folia Med Cracov** 1994;35(1–4):87–90 (15 ref.) **(Pol)**

[Endocrine function of the thymus and ionizing radiation] Grinevich IuA, et al. **Radiats Biol Radioecol** 1995 May-Jun; 35(3):391–404 (126 ref.) (Eng. Abstr.) **(Rus)**

GENETICS

Immunoprinting reveals different genetic bases for (auto)immuno diseases. Epplen C, et al. **Electrophoresis** 1995 Sep;16(9):1693–7 (32 ref.)

IMMUNOLOGY

Extracellular matrix proteins, regulators of T-cell functions in healthy and diseased individuals. Gorski A, et al. **Clin Diagn Lab Immunol** 1995 Nov;2(6):646–51 (69 ref.)

[Superantigens and immunological diseases] Sugawara S, et al. **Arerugi** 1996 May;45(5):435–41 (35 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Th1 and Th2 in human diseases. Romagnani S. **Clin Immunol Immunopathol** 1996 Sep;80(3 Pt 1):225–35 (103 ref.)

THERAPY

Adhesion molecules as therapeutic targets in the treatment of allergic and immunologically mediated diseases. Kavanaugh A. **Clin Immunol Immunopathol** 1996 Sep;80(3 Pt 2):S15–22 (37 ref.)

Bone marrow transplantation in children with hereditary disorders. Gluckman E. **Curr Opin Pediatr** 1996 Feb; 8(1):42–4 (17 ref.)

Therapeutic potential for blockade of the CD40 ligand, gp39. Buhlmann JE, et al. **J Clin Immunol** 1996 Mar;16(2):83–9 (56 ref.)

Adverse clinical effects of immune sorption with staphylococcal protein A columns. Huestis DW, et al. **Transfus Med Rev** 1996 Jan;10(1):62–70 (59 ref.)

VIROLOGY

Syndromes induced by cytomegalovirus infection. Price P, et al. **Clin Immunol Immunopathol** 1996 Sep;80(3 Pt 1):215–24 (92 ref.)

IMMUNOLOGIC ENHANCEMENT OF GRAFTS see **GRAFT ENHANCEMENT, IMMUNOLOGIC**

IMMUNOLOGIC MARKERS see **BIOLOGICAL MARKERS**

IMMUNOLOGIC MEMORY

Induction and recall of the secondary immune response entirely in tissue culture. Sterzl J, et al. **Adv Exp Med Biol** 1995;371A:1–7 (11 ref.)

Lymphopoiesis, apoptosis, and immune amnesia. Donnenberg AD, et al. **Ann N Y Acad Sci** 1995 Dec 29;770:213–26 (33 ref.)

Characterization of immunological memory cells. A minireview. Vongsakul M. **Asian Pac J Allergy Immunol** 1995 Jun;13(1):75–9 (47 ref.)

Cytotoxic T cell effector and memory function in viral immunity. Doherty PC. **Curr Top Microbiol Immunol** 1996; 206:1–14 (108 ref.)

Follicular dendritic cells: antigen retention, B cell activation, and cytokine production. Kosco-Vilbois MH, et al. **Curr Top Microbiol Immunol** 1995;201:69–82 (30 ref.)

Aging associated changes in the generation and development of B cell memory. Klinman NR, et al. **Int Rev Immunol** 1995;12(1):5–12 (60 ref.)

Immunology taught by viruses [see comments] Zinkernagel RM. **Science** 1996 Jan 12;271(5246):173–8 (51 ref.) Comment in: Science 1996 May 3;272(5262):634–5.

IMMUNOLOGY

Immunological memory and protective immunity: understanding their relation. Ahmed R, et al. **Science** 1996 Apr 5;272(5258):54–60 (75 ref.)

IMMUNOLOGIC MONITORING see **MONITORING, IMMUNOLOGIC**

IMMUNOLOGIC RECEPTORS see **RECEPTORS, IMMUNOLOGIC**

IMMUNOLOGIC STIMULATION see **IMMUNIZATION**

IMMUNOLOGIC SUPPRESSOR FACTORS see **SUPPRESSOR FACTORS, IMMUNOLOGIC**

IMMUNOLOGIC SURVEILLANCE

IMMUNOLOGY

Immune surveillance and autoantigen recognition in the central nervous system. Sedgwick JD. **Aust N Z J Med** 1995 Dec;25(6):784–92 (46 ref.)

Viral evasion of cytokine-mediated host defense mechanisms. Gribaudo G, et al. **G Batteriol Virol Immunol** 1994 Jan-Dec;86(1–12):3–10 (41 ref.)

IMMUNOLOGIC TECHNIQUES

see related
BLOOD GROUPING AND CROSSMATCHING
IMMUNOLOGIC TESTS
IMMUNOTHERAPY

Molecular and immunological detection of circulating tumor cells and micrometastases from solid tumors. Pelkey TJ, et al. **Clin Chem** 1996 Sep;42(9):1369–81 (163 ref.)

Monitoring clonal expansion in the laboratory. Sala P, et al. **Clin Exp Rheumatol** 1996 Jan-Feb;14 Suppl 14:S31–5 (44 ref.)

IMMUNOLOGIC TESTS

Advances in immunoassay technology. Self CH, et al. **Curr Opin Biotechnol** 1996 Feb;7(1):60–5 (43 ref.)

Immunodiagnosis and immunotherapy of tetanus and botulinum neurotoxins. Middlebrook JL, et al. **Curr Top Microbiol Immunol** 1995;195:89–122 (179 ref.)

Allergen testing in patients with type I hypersensitivity. **Drug Ther Bull** 1995 Jun;33(6):45–7 (17 ref.)

[Determination of plasma proinsulins, insulin and C-peptide] Chevenne D, et al. **Ann Biol Clin (Paris)** 1995;53(1–2):3–9 (59 ref.) (Eng. Abstr.) **(Fre)**

METHODS

Human cytokine autoantibodies. Characteristics, test procedures and possible physiological and clinical significance. Hansen MB. **APMIS Suppl** 1996;59:1–33 (258 ref.)

IMMUNOLOGICAL MODELS see **MODELS, IMMUNOLOGICAL**

IMMUNOLOGY see **ALLERGY AND IMMUNOLOGY**

IMMUNOLOGY, TRANSPLANTATION see **TRANSPLANTATION IMMUNOLOGY**

IMMUNOMODULATORS see **ADJUVANTS, IMMUNOLOGIC**

IMMUNOPEROXIDASE TECHNIQUES see **IMMUNOENZYME TECHNIQUES**

IMMUNOPHENOTYPING

A new approach to analyzing the utility of immunophenotyping for predicting clinical outcome in acute leukemia. Eastern Cooperative Oncology Group [editorial] Paietta E, et al. **Leukemia** 1996 Jan;10(1):1–4 (30 ref.)

IMMUNOPOTENTIATORS see **ADJUVANTS, IMMUNOLOGIC**

IMMUNOPROLIFERATIVE DISORDERS

[Various immunoproliferative disorders] Shimazaki C, et al. **Nippon Naika Gakkai Zasshi** 1995 Jul 10;84(7):1107–11 (5 ref.) **(Jpn)**

ETIOLOGY

[Immunoglobulin abnormalities] Kosaka M, et al. **Nippon Naika Gakkai Zasshi** 1995 Jul 10;84(7):1061-9 (6 ref.) **(Jpn)**

IMMUNOLOGY

[Immune dysfunctions in patients with immunoproliferative disease] Tsuruoka N. **Nippon Naika Gakkai Zasshi** 1995 Jul 10;84(7):1086-90 (5 ref.) **(Jpn)**

IMMUNORADIOMETRIC ASSAY

[Competitive immunoassay and immunometric immunoassay] Miyachi Y. **Nippon Rinsho** 1995 Sep;53(9):2112-8 (8 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOSCINTIGRAPHY, RADIOLABELED see **RADIOIMMUNODETECTION**

IMMUNOSORBENT TECHNIQUES

Adverse clinical effects of immune sorption with staphylococcal protein A columns. Huestis DW, et al. **Transfus Med Rev** 1996 Jan;10(1):62-70 (59 ref.)

IMMUNOSORBENTS

see related
ENZYME-LINKED IMMUNOSORBENT ASSAY

IMMUNOSTIMULANTS see **ADJUVANTS, IMMUNOLOGIC**

IMMUNOSTIMULATING COMPLEXES see **ISCOMS**

IMMUNOSTIMULATION see **IMMUNIZATION**

IMMUNOSUPPRESSED HOST see **IMMUNOCOMPROMISED HOST**

IMMUNOSUPPRESSION

see related
ANTILYMPHOCYTE SERUM
IMMUNE TOLERANCE
IMMUNOCOMPROMISED HOST

Advances in selective immunosuppression. Adorini L, et al. **Adv Pharmacol** 1995;33:255-85 (146 ref.)

Insulin and prostaglandins as signals between tumor and the host immune system. Curi R, et al. **Braz J Med Biol Res** 1995 Jul;28(7):773-9 (46 ref.)

IL-10 immunosuppression in transplantation. Bromberg JS. **Curr Opin Immunol** 1995 Oct;7(5):639-43 (51 ref.)

Corticosteroids in kidney transplant recipients. Safety issues and timing of discontinuation. Tarantino A, et al. **Drug Saf** 1995 Sep;13(3):145-56 (120 ref.)

T cell costimulatory pathways: promising novel targets for immunosuppression and tolerance induction [editorial] Sayegh MH, et al. **J Am Soc Nephrol** 1995 Oct;6(4):1143-50 (49 ref.)

Mechanisms of immunosuppression induced by antithymocyte globulins and OKT3. Bonnefoy-Berard N, et al. **J Heart Lung Transplant** 1996 May;15(5):435-42 (52 ref.)

Proceedings of the International Consensus Conference on Immunosuppressive Drugs. Lake Louise, Alberta, Canada, May 5-7, 1995. **Ther Drug Monit** 1995 Dec;17(6):559-703 (0 ref.)

[Sense and nonsense in infection prevention following organ transplantation] Schaad HJ, et al. **Ther Umsch** 1995 Sep; 52(9):608-16 (74 ref.) (Eng. Abstr.) **(Ger)**

[CMV infection and cytomegalovirus disease in immunodepressed patients] Mustafa MM. **Pediatr Pol** 1995 May;70(5):443-7 (42 ref.) **(Pol)**

ADVERSE EFFECTS

Prebiopsy neo-adjuvant endocrine therapy for breast cancer to prevent post-surgery trauma-induced growth factor and immune-suppression mediated tumour progression. Oliver RT, et al. **Eur J Cancer** 1996 Mar;32A(3):396-7 (20 ref.)

Malignant testicular neoplasms in immunosuppressed patients. Leibovitch I, et al. **J Urol** 1996 Jun;155(6):1938-42 (41 ref.)

Minimizing the toxicity of antilymphocyte antibody therapy. Pascual M, et al. **Transplant Proc** 1996 Aug;28(4):2113-4 (15 ref.)

Testicular seminoma originating in an undescended testis in a renal allograft recipient. Modlin CS, et al. **Urology** 1996 Jul;48(1):145-8 (9 ref.)

METHODS

Pathogenesis and mechanisms of graft rejection in concordant xenotransplantation with special reference to hamster-to-rat cardiac transplantation. Steinbrüchel DA. **APMIS Suppl** 1996;58:5-45 (281 ref.)

Immunological tolerance to xenogeneic grafts induced by cyclophosphamide in adult animals. Chernyakhovskaya IYu, et al. **Folia Biol (Praha)** 1994;40(6):371-80 (33 ref.)

Oral tolerance: mobilizing the gut. Weiner HL. **Hosp Pract (Off Ed)** 1995 Sep 15;30(9):53-8 (6 ref.)

Immunosuppression through blockade of CD28:B7-mediated costimulatory signals. Judge TA, et al. **Immunol Res** 1996; 15(1):38-49 (34 ref.)

Developments in immunosuppressive therapy. Daar AS. **Transplant Proc** 1995 Oct;27(5):2671-5 (5 ref.)

Strategies for tolerance induction: potential applications in living donor liver transplantation. Emond JC, et al. **Transplant Proc** 1996 Aug;28(4):2371-4 (25 ref.)

Overview of a 10-year experience on methods and compositions for inducing site-specific immunosuppression with topical immunosuppressants. Hewitt CW, et al. **Transplant Proc** 1996 Apr;28(2):922-3 (12 ref.)

Immunologic tolerance: tailored antigen. Krensky AM, et al. **Transplant Proc** 1996 Aug;28(4):2075-7 (15 ref.)

New strategies of immune modulation by DNA viruses. McFadden G, et al. **Transplant Proc** 1996 Aug;28(4):2085-8 (32 ref.)

Peripheral tolerance induction: lessons from immune privileged sites and tissues. Streilein JW. **Transplant Proc** 1996 Aug;28(4):2066-70 (45 ref.)

Genetically engineered proteins for immunoregulation. Strom TB, et al. **Transplant Proc** 1995 Oct;27(5 Suppl 1):18-20 (20 ref.)

[Perspectives of immunosuppressive therapy] Meuer S, et al. **Chirurg** 1996 Apr;67(4):310-7 (53 ref.) (Eng. Abstr.) **(Ger)**

[Immunosuppressive guidelines. The differences and advantages] Arizón del Prado JM. **Rev Esp Cardiol** 1995; 48 Suppl 7:71-6 (32 ref.) (Eng. Abstr.) **(Spa)**

[Tacrolimus (FK 506): an immunosuppression alternative in solid organ transplantation. (Part 2)] Díaz M, et al. **Rev Med Univ Navarra** 1995 Apr-Jun;40(2):93-108 (170 ref.) **(Spa)**

TRENDS

The changing immunology of organ transplantation. Starzl TE, et al. **Hosp Pract (Off Ed)** 1995 Oct 15;30(10):31-4, 37-42 (11 ref.)

Mechanisms of action of new immunosuppressive drugs. Morris RE. **Ther Drug Monit** 1995 Dec;17(6):564-9 (10 ref.)

Immunosuppressive regimens of tomorrow. Groth CG. **Transplant Proc** 1995 Dec;27(6):2971-3 (15 ref.)

IMMUNOSUPPRESSION (PHYSIOLOGY) see **IMMUNE TOLERANCE**

IMMUNOSUPPRESSIVE AGENTS

see related
ANTILYMPHOCYTE SERUM

Tacrolimus: a new immuosuppressive agent [see comments] Kelly PA, et al. **Am J Health Syst Pharm** 1995 Jul 15; 52(14):1521-35 (118 ref.) Comment in: Am J Health Syst Pharm 1995 Jul 15;52(14):1569-71.

Immunosuppressive and anti-inflammatory properties of interleukin 10. de Vries JE. **Ann Med** 1995 Oct;27(5):537-41 (48 ref.)

Autoimmune connective tissue disease, chronic polyarthritides and B cell expansion: risks and perspectives with immunosuppressive drugs. Ferraccioli GF, et al. **Clin Exp Rheumatol** 1996 Jan-Feb;14 Suppl 14:S71-80 (100 ref.)

The panorama of cyclosporin research. Balakrishnan K, et al. **J Basic Microbiol** 1996;36(2):121-47 (292 ref.)

Proceedings of the International Consensus Conference on Immunosuppressive Drugs. Lake Louise, Alberta, Canada, May 5-7, 1995. **Ther Drug Monit** 1995 Dec;17(6):559-703 (0 ref.)

FK506 in solid organ transplantation. Fung JJ, et al. **Ther Drug Monit** 1995 Dec;17(6):592-5 (33 ref.)

Mycophenolate mofetil: a report of the consensus panel. Shaw LM, et al. **Ther Drug Monit** 1995 Dec;17(6):690-9 (27 ref.)

Rapamycin: distribution, pharmacokinetics, and therapeutic range investigations. Yatscoff RW, et al. **Ther Drug Monit** 1995 Dec;17(6):666-71 (32 ref.)

New immunosuppressive drugs--pharmacologic approaches to alter immunoregulation. Kahan BD. **Ther Immunol** 1994 Jan;1(1):33-44 (103 ref.)

[Enigma of rapamycin] Terada N. **Seikagaku** 1995 Oct; 67(10):1241-5 (17 ref.) **(Jpn)**

ADMINISTRATION & DOSAGE

Antibody-targeted polymer-bound drugs. Říhová B. **Folia Microbiol (Praha)** 1995;40(4):367-84 (121 ref.)

Mononeuritis multiplex in systemic lupus erythematosus: response to pulse intravenous cyclophosphamide. Martinez-Taboada VM, et al. **Lupus** 1996 Feb;5(1):74-6 (21 ref.)

Overview of a 10-year experience on methods and compositions for inducing site-specific immunosuppression with topical immunosuppressants. Hewitt CW, et al. **Transplant Proc** 1996 Apr;28(2):922-3 (12 ref.)

[Crohn disease: prevention and drug therapy] Gross V, et al. **Chirurg** 1995 Aug;66(8):757-63 (42 ref.) (Eng. Abstr.) **(Ger)**

[Chronic recurrent subileus due to Strongyloides stercoralis infection under immunosuppressive therapy] Birck R, et al. **Dtsch Med Wochenschr** 1996 May 31;121(22):723-6 (17 ref.) (Eng. Abstr.) **(Ger)**

[Pulse-dose cyclophosphamide therapy for steroid-refractory autoimmune neurological diseases] Watanabe T, et al. **Rinsho Shinkeigaku** 1995 Jun;35(6):611-6 (30 ref.) (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Review article: the risks of malignancy from either immunosuppression or diagnostic radiation in inflammatory bowel disease. Forbes A, et al. **Aliment Pharmacol Ther** 1995 Oct;9(5):465-70 (31 ref.)

Efficacy of mesna for prevention of hemorrhagic cystitis after high-dose cyclophosphamide therapy. Haselberger MB, et al. **Ann Pharmacother** 1995 Sep;29(9):918-21 (21 ref.)

Effects of immunosuppressive drugs during pregnancy. Bermas BL, et al. **Arthritis Rheum** 1995 Dec;38(12):1722-32 (107 ref.)

Side-effects of drugs used in the treatment of rheumatoid arthritis. Evans PJ, et al. **Biochem Soc Symp** 1995; 61:195-207 (49 ref.)

Cutaneous manifestations of non-HIV immunosuppression. Child FJ, et al. **Br J Hosp Med** 1995 Oct 18-31;54(8):395-9 (28 ref.)

Toxic effects of immunosuppressive drugs: mechanisms and strategies for controlling them. Shaw LM, et al. **Clin Chem** 1996 Aug;42(8 Pt 2):1316-21 (55 ref.)

Azathioprine hypersensitivity-like reactions--a case report and a review of the literature. Knowles SR, et al. **Clin Exp Dermatol** 1995 Jul;20(4):353-6 (35 ref.)

Acute lethal necrotising pancreatitis in childhood systemic lupus erythematosus--possible toxicity of immunosuppressive therapy. Kolk A, et al. **Clin Exp Rheumatol** 1995 May-Jun;13(3):399-403 (31 ref.)

Morphologic features of cyclosporin nephrotoxicity. D'Agati VD. **Contrib Nephrol** 1995;114:84-110 (93 ref.)

Complications of cyclosporin therapy. Hoyer PF. **Contrib Nephrol** 1995;114:111-23 (61 ref.)

Hypertension after cardiac transplantation: pathophysiology and management. Sander M, et al. **Curr Opin Nephrol Hypertens** 1995 Sep;4(5):443-51 (125 ref.)

Cutaneous alternariosis in an immunocompromised patient. Chaidemenos GC, et al. **Cutis** 1995 Sep;56(3):145-50 (40 ref.)

Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. Salloum E, et al. **J Clin Oncol** 1996 Jun;14(6):1943-9 (56 ref.)

Physiologic basis of steroid-induced immunosuppression. Effects on lymphocyte migration to lymph nodes. Sackstein R. **J Fla Med Assoc** 1995 Sep;82(9):613-5 (22 ref.)

The differential diagnosis between rejection and cyclosporine toxicity. Mihatsch MJ, et al. **Kidney Int Suppl** 1995 Dec; 52:S63-9 (9 ref.)

Cyclosporine-induced renal dysfunction in experimental animals and humans. Remuzzi G, et al. **Kidney Int Suppl** 1995 Dec;52:S70-4 (49 ref.)

Bacterial infections during immunosuppression - immunosuppressive agents interfere not only with immune response, but also with polymorphonuclear cell function. [editorial] Schmaldienst S, et al. **Nephrol Dial Transplant** 1996 Jul;11(7):1243-5 (26 ref.)

The role of calcium-channel antagonists in solid organ transplantation. Huntress JD, et al. **New Horiz** 1996 Feb; 4(1):129-33 (30 ref.)

Renal dysfunction associated with liver transplantation. Jindal RM, et al. **Postgrad Med J** 1995 Sep;71(839):513-24 (130 ref.)

Side-effects of a monoclonal antibody, muromonab CD3/orthoclone OKT3: bibliographic review. Sgro C. **Toxicology** 1995 Dec 20;105(1):23-9 (45 ref.)

Chronic cyclosporine nephropathy in renal transplantation. Bennett WM, et al. **Transplant Proc** 1996 Aug;28(4):2100-3 (29 ref.)

Renovascular elements of the cyclosporine injury. Curtis JJ. **Transplant Proc** 1996 Aug;28(4):2094-6 (18 ref.)

Minimizing the toxicity of antilymphocyte antibody therapy. Pascual M, et al. **Transplant Proc** 1996 Aug;28(4):2113-4 (15 ref.)

[Cutaneous pseudolymphoma during treatment of rheumatoid polyarthritis with low-dose methotrexate] Delaporte E, et al. **Ann Dermatol Venereol** 1995;122(8):521-5 (33 ref.) (Eng. Abstr.) **(Fre)**

[Hair-like hyperkeratoses in patients with kidney transplants. A new cyclosporin side-effect] Izakovic J, et al. **Hautarzt** 1995 Dec;46(12):841-6 (45 ref.) (Eng. Abstr.) **(Ger)**

[Two cases of therapy-related myelodysplastic syndrome] Takahashi A, et al. **Rinsho Ketsueki** 1996 Jan;37(1):53-9 (16 ref.) (Eng. Abstr.) **(Jpn)**

ANALYSIS

Factor VIII concentrates and the immune system--laboratory investigations. Wadhwa M, et al. **Blood Coagul Fibrinolysis** 1995 Jul;6 Suppl 2:S65-79 (73 ref.)

BLOOD

Lake Louise Consensus Conference on cyclosporin monitoring in organ transplantation: report of the consensus panel. Oellerich M, et al. **Ther Drug Monit** 1995 Dec; 17(6):642-54 (47 ref.)

[Blood level monitoring of immunosuppressive agent] Takahara S, et al. **Rinsho Byori** 1995 Jul;Suppl 99:154-62

(8 ref.) **(Jpn)**

CHEMISTRY

Immunosuppressive peptides corresponding to MHC class I sequences. Clayberger C, et al. **Curr Opin Immunol** 1995 Oct;7(5):644–8 (34 ref.)

Receptor (immunophilin–binding) assay for immunosuppressive drugs. Soldin SJ. **Ther Drug Monit** 1995 Dec;17(6):574–6 (18 ref.)

IMMUNOLOGY

Immunosuppressive retroviral peptides: cAMP and cytokine patterns. Haraguchi S, et al. **Immunol Today** 1995 Dec; 16(12):595–603 (97 ref.)

METABOLISM

Alternative cyclosporine metabolic pathways and toxicity. Christians U, et al. **Clin Biochem** 1995 Dec;28(6):547–59 (94 ref.)

Drug interactions in transplantation. Seifeldin R. **Clin Ther** 1995 Nov–Dec;17(6):1043–61 (102 ref.)

PHARMACOKINETICS

Clinical pharmacokinetics of tacrolimus. Venkataramanan R, et al. **Clin Pharmacokinet** 1995 Dec;29(6):404–30 (146 ref.)

Challenges in cyclosporine therapy: the role of therapeutic monitoring by area under the curve monitoring. Kahan BD, et al. **Ther Drug Monit** 1995 Dec;17(6):621–4 (15 ref.)

Pharmacokinetics and therapeutic drug monitoring of immunosuppressants. Lindholm A, et al. **Ther Drug Monit** 1995 Dec;17(6):570–3 (13 ref.)

Pharmacokinetics of mycophenolate mofetil (RS61443): a short review. Bullingham RE, et al. **Transplant Proc** 1996 Apr;28(2):925–9 (0 ref.)

Pharmacokinetic considerations in the therapeutic application of cyclosporine in renal transplantation. Kahan BD. **Transplant Proc** 1996 Aug;28(4):2143–6 (26 ref.)

Cyclosporine pharmacology. Lee JI, et al. **Transplant Proc** 1996 Aug;28(4):2156–8 (20 ref.)

Neoral in liver transplantation. Levy GA, et al. **Transplant Proc** 1996 Apr;28(2):1019–21 (9 ref.)

Deoxyspergualin: mechanism of action and pharmacokinetics. Ramos EL, et al. **Transplant Proc** 1996 Apr;28(2):873–5 (49 ref.)

Pharmacokinetics of rapamycin. Yatscoff RW. **Transplant Proc** 1996 Apr;28(2):970–3 (28 ref.)

PHARMACOLOGY

Inhibition of T lymphocyte activation and apoptotic cell death by cyclosporin A and tacrolimus (FK506). Its relevance to therapy of HIV infection. Thomson AW, et al. **Adv Exp Med Biol** 1995;374:211–6 (46 ref.)

Immunosuppressants: cellular and molecular mechanisms of action. Suthanthiran M, et al. **Am J Kidney Dis** 1996 Aug; 28(2):159–72 (109 ref.)

Some new aspects of molecular mechanisms of cyclosporin A effect on immune response. Zav'yalov VP, et al. **APMIS** 1995 Jun;103(6):401–15 (121 ref.)

Cladribine (2–chloro–2'–deoxyadenosine): new perspectives in clinical immunosuppression. Górski A, et al. **Arch Immunol Ther Exp (Warsz)** 1994;42(1):11–2 (10 ref.)

Discovery, mechanism and expected clinical significance of selective cytotoxicity of 2–chloro–2'–deoxyadenosine (2–CdA). Grieb P. **Arch Immunol Ther Exp (Warsz)** 1994; 42(1):1–5 (34 ref.)

The actions of cyclosporin A and FK506 on T–lymphocyte activation. Mattila PS. **Biochem Soc Trans** 1996 Feb; 24(1):45–9 (40 ref.)

The mechanism of action of cyclosporin A and FK506. Ho S, et al. **Clin Immunol Immunopathol** 1996 Sep;80(3 Pt 2):S40–5 (31 ref.)

Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF). Allison AC, et al. **Clin Transplant** 1996 Feb;10(1 Pt 2):77–84 (33 ref.)

Molecular mechanisms of new immunosuppressants. Halloran PF. **Clin Transplant** 1996 Feb;10(1 Pt 2):118–23 (45 ref.)

From mice to man: the preclinical history of mycophenolate mofetil. Sollinger HW. **Clin Transplant** 1996 Feb;10(1 Pt 2):85–92 (46 ref.)

Molecular mechanisms of immunosuppression by cyclosporine, FK506, and rapamycin. Cardenas ME, et al. **Curr Opin Nephrol Hypertens** 1995 Nov;4(6):472–7 (83 ref.)

Rapamycin (sirolimus, rapamune). Sehgal SN, et al. **Curr Opin Nephrol Hypertens** 1995 Nov;4(6):482–7 (49 ref.)

Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation. Fulton B, et al. **Drugs** 1996 Feb; 51(2):278–98 (78 ref.)

Important interactions of drugs with immunosuppressive agents used in transplant recipients. Lake KD, et al. **J Antimicrob Chemother** 1995 Oct;36 Suppl B:11–22 (115 ref.)

Immunobiology and immunopharmacology of organ allograft rejection. Suthanthiran M, et al. **J Clin Immunol** 1995 Jul; 15(4):161–71 (87 ref.)

Mechanisms of immunosuppression induced by antithymocyte globulins and OKT3. Bonnefoy–Berard N, et al. **J Heart Lung Transplant** 1996 May;15(5):435–42 (52 ref.)

Mechanism of action of the immunosuppressant rapamycin. Dumont FJ, et al. **Life Sci** 1996;58(5):373–95 (196 ref.)

Methotrexate for inflammatory bowel disease: pharmacology and preliminary results [see comments] Egan LJ, et al. **Mayo Clin Proc** 1996 Jan;71(1):69–80 (98 ref.) Comment in: Mayo Clin Proc 1996 Jan;71(1):104–5.

Immunophilins and the nervous system. Snyder SH, et al. **Nat Med** 1995 Jan;1(1):32–7 (82 ref.)

HLA–derived peptides as novel immunosuppressives. Krensky AM. **Pediatr Res** 1995 Sep;38(3):275–9 (25 ref.)

Cellular functions of immunophilins. Marks AR. **Physiol Rev** 1996 Jul;76(3):631–49 (161 ref.)

Mechanisms of action of immunosuppressive agents: cyclosporin A, FK506, and rapamycin. Bierer BE. **Proc Assoc Am Physicians** 1995 Apr;107(1):28–40 (135 ref.)

Mechanisms of action of new immunosuppressive drugs. Morris RE. **Ther Drug Monit** 1995 Dec;17(6):564–9 (10 ref.)

Mechanisms of action and overview of OKT3. Norman DJ. **Ther Drug Monit** 1995 Dec;17(6):615–20 (72 ref.)

Mechanism of action of mycophenolate mofetil. Ransom JT. **Ther Drug Monit** 1995 Dec;17(6):681–4 (14 ref.)

Rapamune (Sirolimus, rapamycin): an overview and mechanism of action. Sehgal SN. **Ther Drug Monit** 1995 Dec;17(6):660–5 (43 ref.)

Brequinar sodium. Cramer DV. **Transplant Proc** 1996 Apr; 28(2):960–3 (20 ref.)

Immunoregulatory and fibrogenic activities of cyclosporine: a unifying hypothesis based on transforming growth factor–beta expression. Khanna A, et al. **Transplant Proc** 1996 Aug;28(4):2015–8 (38 ref.)

Mechanism of action of rapamycin (Sirolimus, Rapamune). Molnar–Kimber KL. **Transplant Proc** 1996 Apr;28(2):964–9 (127 ref.)

Deoxyspergualin: mechanism of action and pharmacokinetics. Ramos EL, et al. **Transplant Proc** 1996 Apr;28(2):873–5 (49 ref.)

An anti–CD2 monoclonal antibody that elicits alloantigen–specific hyporesponsiveness. Schad V, et al. **Transplant Proc** 1996 Aug;28(4):2051–3 (17 ref.)

[The mechanism of action of cyclosporine: something more than immunosuppression?] Losa García JE, et al. **Rev Clin Esp** 1996 May;196(5):313–21 (78 ref.) **(Spa)**

STANDARDS

Analytic requirements for immunosuppressive drugs in clinical trials. Shaw LM, et al. **Ther Drug Monit** 1995 Dec; 17(6):577–83 (31 ref.)

THERAPEUTIC USE

A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6–mercaptopurine, cyclosporine, and methotrexate. Sandborn WJ. **Am J Gastroenterol** 1996 Mar;91(3):423–33 (65 ref.)

Immunotherapy in multiple sclerosis, Part 2. Becker CC, et al. **Am J Health Syst Pharm** 1995 Oct 1;52(19):2105–20; quiz 2132–4 (357 ref.)

Thalidomide in diseases associated with human immunodeficiency virus infection. Minor JR, et al. **Am J Health Syst Pharm** 1996 Feb 15;53(4):429–31 (14 ref.)

Thalidomide for aphthous ulcers in patients infected with the human immunodeficiency virus. Weidle PJ. **Am J Health Syst Pharm** 1996 Feb 15;53(4):368, 371–2, 378 (12 ref.)

The basis of current and future therapy for inflammatory bowel disease. Elson CO. **Am J Med** 1996 Jun; 100(6):656–62 (26 ref.)

Preparative regimens: chemotherapy versus chemoradiotherapy. A historical perspective. Santos GW. **Ann N Y Acad Sci** 1995 Dec 29;770:1–7 (38 ref.)

Psoriatic arthritis. New types, new treatments [editorial] Ruzicka T. **Arch Dermatol** 1996 Feb;132(2):215–9 (47 ref.)

Psoriasis: mechanisms and entry points for possible therapeutic interventions. Christophers E. **Australas J Dermatol** 1996 May;37 Suppl 1:S4–6 (27 ref.)

Drug trials in neuropathy. Hughes RA, et al. **Baillieres Clin Neurol** 1995 Nov;4(3):607–27 (87 ref.)

Overview of immunosuppressive therapy in organ transplantation. MacGregor MS, et al. **Br J Hosp Med** 1995 Sep 20–Oct 3;54(6):276–84 (32 ref.)

Mycophenolate mofetil (MMF) in heart transplantation: rejection prevention and treatment. Renlund DG, et al. **Clin Transplant** 1996 Feb;10(1 Pt 2):136–9 (29 ref.)

New concepts in tolerance. Wood KJ. **Clin Transplant** 1996 Feb;10(1 Pt 2):93–9 (47 ref.)

Use of cyclosporin in membranous and mesangioproliferative (IgA) nephropathy. Cattran DC. **Contrib Nephrol** 1995; 114:49–58 (47 ref.)

Use of cyclosporin in the treatment of idiopathic nephrotic syndrome in adults. Meyrier A. **Contrib Nephrol** 1995; 114:28–48 (47 ref.)

Use of cyclosporin in lupus nephritis. Radhakrishnan J, et al. **Contrib Nephrol** 1995;114:59–72 (53 ref.)

Cyclosporin in steroid–resistant idiopathic nephrotic syndrome. Tejani A, et al. **Contrib Nephrol** 1995;114:73–7 (32 ref.)

The treatment of multiple sclerosis: current and future. Polman CH, et al. **Curr Opin Neurol** 1995 Jun;8(3):200–9 (87 ref.)

Methotrexate and other chemotherapeutic agents used to treat psoriasis. Jeffes EW III, et al. **Dermatol Clin** 1995 Oct;13(4):875–90 (128 ref.)

Cyclosporine: what clinicians need to know. Koo J, et al. **Dermatol Clin** 1995 Oct;13(4):897–907 (69 ref.)

Thalidomide: rationale for renewed use in immunological disorders. Schuler U, et al. **Drug Saf** 1995 Jun;12(6):364–9 (61 ref.)

Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation. Fulton B, et al. **Drugs** 1996 Feb; 51(2):278–98 (78 ref.)

Deflazacort. A review of its pharmacological properties and therapeutic efficacy. Markham A, et al. **Drugs** 1995 Aug; 50(2):317–33 (68 ref.)

Cyclosporin. A review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion–based formulation (Neoral). Noble S, et al. **Drugs** 1995 Nov; 50(5):924–41 (60 ref.)

Pharmacological intervention in older patients with rheumatoid arthritis. Quality of life aspects. Bendtsen P, et al. **Drugs Aging** 1995 Nov;7(5):338–46 (55 ref.)

Immunosuppressive treatment for myocarditis and dilated cardiomyopathy. Maisch B, et al. **Eur Heart J** 1995 Dec; 16 Suppl O:153–61 (81 ref.)

The pharmacology of immunosuppressant drugs in skin transplant rejection in mice and other rodents. Gardner CR. **Gen Pharmacol** 1995 Mar;26(2):245–71 (217 ref.)

Cyclosporine in the treatment of idiopathic nephrosis. Niaudet P. **Indian Pediatr** 1995 Dec;32(12):1317–21 (17 ref.)

Treatment of aplastic anaemia with antilymphocyte globulin and cyclosporin. Marsh JC, et al. **Int J Hematol** 1995 Oct; 62(3):133–44 (79 ref.)

The vitamin D Endocrine system: manipulation of structure–function relationships to provide opportunities for development of new cancer chemopreventive and immunosuppressive agents. Norman AW. **J Cell Biochem Suppl** 1995;22:218–25 (39 ref.)

Adhesion molecules and liver transplantation: new strategies for therapeutic intervention. Adams DH. **J Hepatol** 1995 Aug;23(2):225–31 (58 ref.)

Immunotherapy and immunoprophylaxis in bone marrow transplantation. Barnes RA. **J Hosp Infect** 1995 Jun;30 Suppl:223–31 (53 ref.)

Busulfan. O'Marcaigh AS, et al. **J Pediatr Oncol Nurs** 1996 Jul;13(3):150–2 (12 ref.)

Mycophenolate mofetil in renal transplantation: results from the U.S. randomized trials. Danovitch GM. **Kidney Int Suppl** 1995 Dec;52:S93–6 (19 ref.)

Dual roles of HMG–CoA reductase inhibitors in solid organ transplantation: lipid lowering and immunosuppression. Katznelson S, et al. **Kidney Int Suppl** 1995 Dec;52:S112–5 (30 ref.)

Long–term use of cyclosporine A does not adversely impact on clinical outcomes following renal transplantation. Lewis RM. **Kidney Int Suppl** 1995 Dec;52:S75–8 (35 ref.)

Chronic renal allograft failure: clinical overview. The Leuven Collaborative Group for Transplantation. Peeters J, et al. **Kidney Int Suppl** 1995 Dec;52:S97–101 (50 ref.)

Mycophenolate mofetil. Sollinger HW. **Kidney Int Suppl** 1995 Dec;52:S14–7 (23 ref.)

Randomised trialomania? The multicentre liver transplant trials of tacrolimus [see comments] Starzl TE, et al. **Lancet** 1995 Nov 18;346(8986):1346–50 (28 ref.) Comment in: Lancet 1995 Nov 18;346(8986):1310–1.

Methotrexate in the treatment of systemic glucocorticoid–dependent severe persistent asthma: a word of caution. Fabbri L, et al. **Monaldi Arch Chest Dis** 1996 Apr;51(2):130–7 (118 ref.)

Immune–based therapy of multiple sclerosis. Kaufman MD. **N C Med J** 1995 Aug;56(8):379–84 (24 ref.)

Are corticosteroids really necessary in renal transplantation? Ponticelli C, et al. **Nephrol Dial Transplant** 1995; 10(9):1587–91 (36 ref.)

Mycophenolate mofetil (RS 61443): nothing new under the sun or an important break–through in the field of transplantation? [editorial] van der Woude FJ. **Nephrol Dial Transplant** 1995;10(7):1112–5 (10 ref.)

Deoxyspergualin: a new immunosuppressive drug for the treatment of auto–immune disease [editorial] Nikolic–Paterson DJ, et al. **Nephron** 1995;70(4):391–6 (63 ref.)

Nitric oxide synthase, immunophilins and poly(ADP–ribose) synthetase: novel targets for the development of neuroprotective drugs. Zhang J, et al. **Neurol Res** 1995 Aug;17(4):285–8 (37 ref.)

Brequinar sodium. Cramer DV. **Pediatr Nephrol** 1995;9 Suppl:S52–5 (29 ref.)

Clinical use of tacrolimus (FK–506) in infants and children with renal transplants. Ellis D. **Pediatr Nephrol** 1995 Aug; 9(4):487–94 (45 ref.)

Human leukocyte antigen–derived peptides as novel immunosuppressives. Krensky AM, et al. **Proc Assoc Am Physicians** 1995 Apr;107(1):81–5 (26 ref.)

Investigational agents for rheumatoid arthritis. Merkel PA, et al. **Rheum Dis Clin North Am** 1995 Aug;21(3):779–96 (85 ref.)

Consensus document: therapeutic monitoring of tacrolimus (FK–506). Jusko WJ, et al. **Ther Drug Monit** 1995 Dec; 17(6):606–14 (55 ref.)

Analysis of tacrolimus (FK 506) in relation to therapeutic drug monitoring. Jusko WJ. **Ther Drug Monit** 1995 Dec; 17(6):596–601 (42 ref.)

Challenges in cyclosporine therapy: the role of therapeutic monitoring by area under the curve monitoring. Kahan BD, et al. **Ther Drug Monit** 1995 Dec;17(6):621–4 (15 ref.)

Potential applications of therapeutic drug monitoring of sirolimus immunosuppression in clinical renal transplantation. Kahan BD, et al. **Ther Drug Monit** 1995 Dec;17(6):672–5 (17 ref.)
Cyclosporine A: clinical experience and therapeutic drug monitoring. Lindholm A. **Ther Drug Monit** 1995 Dec; 17(6):631–7 (46 ref.)
Pharmacokinetics and therapeutic drug monitoring of immunosuppressants. Lindholm A, et al. **Ther Drug Monit** 1995 Dec;17(6):570–3 (13 ref.)
Therapeutic drug monitoring of tacrolimus in clinical transplantation. McMaster P, et al. **Ther Drug Monit** 1995 Dec;17(6):602–5 (8 ref.)
Therapeutic drug monitoring of cyclosporin G. Yatscoff RW, et al. **Ther Drug Monit** 1995 Dec;17(6):655–9 (28 ref.)
Consensus guidelines for therapeutic drug monitoring of rapamycin: report of the consensus panel. Yatscoff RW, et al. **Ther Drug Monit** 1995 Dec;17(6):676–80 (28 ref.)
Xenobiotics, chimerism and the induction of tolerance following organ transplantation. Delaney CP, et al. **Ther Immunol** 1994 Jun;1(3):153–64 (118 ref.)
Brequinar sodium. Cramer DV. **Transplant Proc** 1996 Apr; 28(2):960–3 (20 ref.)
Developments in immunosuppressive therapy. Daar AS. **Transplant Proc** 1995 Oct;27(5):2671–5 (5 ref.)
Deoxyspergualin: clinical experience. Gores PF. **Transplant Proc** 1996 Apr;28(2):871–2 (12 ref.)
Immunosuppressive regimens of tomorrow. Groth CG. **Transplant Proc** 1995 Dec;27(6):2971–3 (15 ref.)
Neoral in liver transplantation. Jamieson NV, et al. **Transplant Proc** 1996 Aug;28(4):2229–31 (35 ref.)
Immunosuppression with the vitamin D analogue MC 1288 in experimental transplantation. Johnsson C, et al. **Transplant Proc** 1996 Apr;28(2):888–91 (35 ref.)
Pharmacokinetic considerations in the therapeutic application of cyclosporine in renal transplantation. Kahan BD. **Transplant Proc** 1996 Aug;28(4):2143–6 (26 ref.)
15–Deoxyspergualin in experimental transplant models: a review. Kaufman DB. **Transplant Proc** 1996 Apr; 28(2):868–70 (31 ref.)
Clinical use of FK 506 in liver transplantation. Klintmalm GB. **Transplant Proc** 1996 Apr;28(2):974–6 (13 ref.)
Neoral in liver transplantation. Levy GA, et al. **Transplant Proc** 1996 Apr;28(2):1019–21 (9 ref.)
Neoral therapy in liver transplantation. Levy GA. **Transplant Proc** 1996 Aug;28(4):2225–8 (27 ref.)
An overview of the first decade of cyclosporine. Stiller CR. **Transplant Proc** 1996 Aug;28(4):2005–12 (3 ref.)
Prevention of graft–versus–host disease after bone marrow transplantation. Storb R. **Transplant Proc** 1995 Oct; 27(5):2653–6 (20 ref.)
Chronic renal allograft function under cyclosporin treatment. Leuven Collaborative Group for Transplantation. Vanrenterghem Y, et al. **Transplant Proc** 1996 Aug; 28(4):2097–9 (11 ref.)
[Advances in transplantation biology and transplantation of vital organs in the era of immunosuppression with cyclosporin A] Hökl J, et al. **Cas Lek Cesk** 1995 Dec 13; 134(24):775–8 (21 ref.) (Eng. Abstr.) **(Cze)**
[[Therapeutic perspectives in multiple sclerosis (editorial)] Lubetzki C, et al. **Presse Med** 1996 Jun 15;25(21):964–6 (10 ref.) (Eng. Abstr.) **(Fre)**
[Pemphigus vulgaris. Clinical aspects, pathophysiology and therapy of a bullous autoimmune dermatosis] Sunderkötter CH, et al. **Med Monatsschr Pharm** 1995 Sep;18(9):255–63 (39 ref.) **(Ger)**
[Immunosuppressive therapy of vasculitis: current aspects and perspectives] Giacomelli R, et al. **Recenti Prog Med** 1996 Mar;87(3):124–34 (74 ref.) (Eng. Abstr.) **(Ita)**
[Cyclosporin and diffuse alveolar interstitial lung disease] Losa García JE, et al. **Arch Bronconeumol** 1996 Jun–Jul; 32(6):302–6 (65 ref.) **(Spa)**
[Approach to the diagnosis and therapy of vascular neuropathy] Hernández MA, et al. **Rev Neurol** 1995 Sep–Oct;23(123):1008–12 (40 ref.) (Eng. Abstr.) **(Spa)**
[New treatments for multiple sclerosis] Masdeu JC. **Rev Neurol** 1996 Jun;24(130):708–11 (38 ref.) **(Spa)**

TOXICITY

Review of the toxicology of beclomethasone dipropionate. Libretto SE. **Arch Toxicol** 1995;69(8):509–25 (68 ref.)
Alternative cyclosporine metabolic pathways and toxicity. Christians U, et al. **Clin Biochem** 1995 Dec;28(6):547–59 (94 ref.)
Pathogenesis of drug–induced gingival overgrowth. A review of studies in the rat model. Nishikawa S, et al. **J Periodontol** 1996 May;67(5):463–71 (94 ref.)
Pancreatic and nephrotoxicity of immunomodulator compounds. Hammond TG, et al. **Toxicol Lett** 1995 Dec; 82–83:99–105 (17 ref.)

IMMUNOSURVEILLANCE see MONITORING, IMMUNOLOGIC

IMMUNOTHERAPY

Analysis of MHC–specific peptide motifs. Applications in immunotherapy. Loftus DJ, et al. **Adv Exp Med Biol** 1995; 383:201–10 (71 ref.)
Modified allergen immunotherapy: effect on immunoglobulin E production. Babakhin AA, et al. **Allergy Proc** 1995 Jul–Aug;16(4):195–202 (46 ref.)
Vaccines in the treatment of cancer. Baltz JK. **Am J Health Syst Pharm** 1995 Nov 15;52(22):2574–85; quiz 2594–5 (37 ref.)
Immunotherapy in multiple sclerosis, Part 2. Becker CC, et al. **Am J Health Syst Pharm** 1995 Oct 1;52(19):2105–20; quiz 2132–4 (357 ref.)
Do monoclonal antibodies and anticytokines still have a future in infectious diseases? Cohen J, et al. **Am J Med** 1995 Dec 29;99(6A):45S–52S; discussion 52S–53S (36 ref.)
Antigen–presenting cell engineering. The molecular toolbox. Tykocinski ML, et al. **Am J Pathol** 1996 Jan;148(1):1–16 (180 ref.)
Immunotherapy of human cancers. Hui KM, et al. **Ann Acad Med Singapore** 1996 Jan;25(1):113–9 (19 ref.)
Immunotherapy for childhood asthma: is there a rationale for its use? Sigman K, et al. **Ann Allergy Asthma Immunol** 1996 Apr;76(4):299–305; quiz 305–9 (39 ref.)
Strategies to enhance the graft–versus–malignancy effect in allogeneic transplants. Barrett JA. **Ann N Y Acad Sci** 1995 Dec 29;770:203–12 (45 ref.)
Antitumor activity of syngeneic/autologous graft–versus–host disease. Hess AD, et al. **Ann N Y Acad Sci** 1995 Dec 29;770:189–202 (59 ref.)
Immune–based therapies for treatment of HIV infection. Piscitelli SC, et al. **Ann Pharmacother** 1996 Jan;30(1):62–76 (45 ref.)
Active specific immunotherapy of melanoma. Mitchell MS. **Br Med Bull** 1995 Jul;51(3):631–46 (40 ref.)
Engineering recombinant antibodies for immunotherapy. Neri D, et al. **Cell Biophys** 1995 Aug;27(1):47–61 (62 ref.)
Biological treatment of NSCLC. The need for conclusive studies. Jassem J. **Chest** 1996 May;109(5 Suppl):119S–124S (61 ref.)
Antigen–specific immunotherapy of autoimmune disease: a commentary [editorial] Wraith DC. **Clin Exp Immunol** 1996 Mar;103(3):349–52 (38 ref.)
Specific immunotherapy in house dust mite allergy. Bousquet J, et al. **Clin Rev Allergy Immunol** 1995 Summer;13(2):151–9 (57 ref.)
Vaccination for treatment of tumors: a critical comment. Sedlacek HH. **Crit Rev Oncog** 1994;5(6):555–87 (275 ref.)
Manipulation of costimulatory signals to enhance antitumor T–cell responses. Allison JP, et al. **Curr Opin Immunol** 1995 Oct;7(5):682–6 (34 ref.)
Biologic treatment of human cancer. Clark JI, et al. **Curr Probl Cancer** 1995 Jul–Aug;19(4):185–262 (315 ref.)
Immunological and biochemical modulation in the treatment of advanced colorectal cancer: update and future directions. Hilgenfeld RU, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 3):217–40 (93 ref.)
Immunodiagnosis and immunotherapy of tetanus and botulinum neurotoxins. Middlebrook JL, et al. **Curr Top Microbiol Immunol** 1995;195:89–122 (179 ref.)
Immunotherapy of metastases. Schirrmacher V, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 3):189–216 (112 ref.)
Intervention in receptor tyrosine kinase–mediated pathways: recombinant antibody fusion proteins targeted to ErbB2. Wels W, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 3):113–28 (47 ref.)
Immunopathogenesis and immunotherapy of psoriasis. Griffiths TW, et al. **Dermatol Clin** 1995 Oct;13(4):739–49 (159 ref.)
Dendritic cells and immune–based therapies. Steinman RM. **Exp Hematol** 1996 Jul;24(8):859–62 (16 ref.)
Mechanisms of the pathogenic autoimmune response in lupus: prospects for specific immunotherapy. Datta SK, et al. **Immunol Res** 1995;14(2):132–47 (156 ref.)
Tumor therapy by immune recruitment with bispecific antibodies. Renner C, et al. **Immunol Rev** 1995 Jun; 145:179–209 (153 ref.)
Vaccines to prevent and treat autoimmune diseases. Mor F, et al. **Int Arch Allergy Immunol** 1995 Dec;108(4):345–9 (42 ref.)
Tumor vaccine design: concepts, mechanisms, and efficacy testing. Schirrmacher V. **Int Arch Allergy Immunol** 1995 Dec;108(4):340–4 (25 ref.)
Induction of antigen–specific unresponsiveness with synthetic peptides: specific immunotherapy for treatment of allergic and autoimmune conditions. Wraith DC. **Int Arch Allergy Immunol** 1995 Dec;108(4):355–9 (29 ref.)
The treatment of zinc deficiency is an immunotherapy [editorial] Hadden JW. **Int J Immunopharmacol** 1995 Sep; 17(9):697–701 (37 ref.)
Introducing graft–versus–leukemia into autologous stem cell transplantation. Klingemann HG. **J Hematother** 1995 Aug; 4(4):261–7 (71 ref.)
The role of natural killer cells in the treatment of chronic myeloid leukemia. Silla LM, et al. **J Hematother** 1995 Aug; 4(4):269–79 (103 ref.)
More immunotherapy for multiple sclerosis [editorial; comment] Hughes RA, et al. **J Neurol Neurosurg Psychiatry** 1996 Sep;61(3):239–41 (44 ref.) Comment on: J Neurol Neurosurg Psychiatry 1996 Sep;61(3):251–8.
The clinical neuroimmunotherapeutic role of melatonin in oncology. Conti A, et al. **J Pineal Res** 1995 Oct; 19(3):103–10 (38 ref.)
Role of postinduction immunotherapy in acute myeloid leukemia. Klingemann HG. **Leukemia** 1996 Apr;10 Suppl 1:S21–2 (3 ref.)
Novel biologic therapies for malignant gliomas. Antiangiogenesis, immunotherapy, and gene therapy. Fine HA. **Neurol Clin** 1995 Nov;13(4):827–46 (128 ref.)
Immunotherapy basics. Gordon BR. **Otolaryngol Head Neck Surg** 1995 Nov;113(5):597–602 (51 ref.)
Design and testing of peptide–based cytotoxic T–cell–mediated immunotherapeutics to treat infectious diseases and cancer. Chesnut RW, et al. **Pharm Biotechnol** 1995;6:847–74 (170 ref.)
Development of active specific immunotherapeutic agents based on cancer–associated mucins. Samuel J, et al. **Pharm Biotechnol** 1995;6:875–90 (145 ref.)
Prospects of immunotherapy for rheumatoid arthritis. t Hart BA, et al. **Pharm World Sci** 1995 Nov 24;17(6):178–85 (112 ref.)
Plant antibodies for immunotherapy. Ma JK, et al. **Plant Physiol** 1995 Oct;109(2):341–6 (30 ref.)
Immunoprophylaxis against cytomegalovirus disease. Adler SP. **Scand J Infect Dis Suppl** 1995;99:105–9 (41 ref.)
Immunotherapy for cancer. Old LJ. **Sci Am** 1996 Sep; 275(3):136–43 (0 ref.)
Mucosal tolerance and the immunotherapy of autoimmune disease: a commentary. Wraith DC, et al. **Ther Immunol** 1995 Feb;2(1):53–8 (49 ref.)
Immunotherapy and gene transfer in the treatment of the oncology patient: role of transfusion medicine. Hillyer CD, et al. **Transfus Med Rev** 1996 Jan;10(1):1–14 (111 ref.)
Blood component and immunotherapy in neonatal sepsis. Sweetman RW, et al. **Transfus Med Rev** 1995 Jul;9(3):251–9 (47 ref.)
[Cytokine inhibitors in intensive care] Villard J, et al. **Rev Mal Respir** 1995;12(4):335–42 (66 ref.) (Eng. Abstr.) **(Fre)**
[Immunotherapy of patients with head and neck carcinomas] Tsukuda M. **Gan To Kagaku Ryoho** 1996 Feb;23(3):283–90 (32 ref.) (Eng. Abstr.) **(Jpn)**
[Protective properties of antibodies raised against conjugates of endotoxin core oligosaccharides with proteins] Jachymek W. **Postepy Hig Med Dosw** 1995;49(1):171–8 (6 ref.) (Eng. Abstr.) **(Pol)**
[The surgical opportunity in metastatic lesions of renal–cell carcinoma after a response to adjuvant immunotherapy] Olivier C, et al. **Actas Urol Esp** 1995 Mar;19(3):203–10 (27 ref.) (Eng. Abstr.) **(Spa)**
[Biologic effects of immunotherapy] Dávila González I, et al. **Allergol Immunopathol (Madr)** 1996;24 Suppl 1:60–8 (85 ref.) **(Spa)**

METHODS

Immunotherapy in multiple sclerosis, Part 1. Becker CC, et al. **Am J Health Syst Pharm** 1995 Sep 15;52(18):1985–2000 (197 ref.)
The basis of current and future therapy for inflammatory bowel disease. Elson CO. **Am J Med** 1996 Jun; 100(6):656–62 (26 ref.)
The immunotherapy of solid cancers based on cloning the genes encoding tumor–rejection antigens. Rosenberg SA. **Annu Rev Med** 1996;47:481–91 (38 ref.)
Human cancer detection and immunotherapy with conjugated and non–conjugated monoclonal antibodies. Bodey B, et al. **Anticancer Res** 1996 Mar–Apr;16(2):661–74 (172 ref.)
Manipulation of local and systemic host defence in the prevention of perioperative sepsis. Windsor AC, et al. **Br J Surg** 1995 Nov;82(11):1460–7 (128 ref.)
From epitopes to peptides to immunotherapy. Hoyne G, et al. **Clin Immunol Immunopathol** 1996 Sep;80(3 Pt 2):S23–30 (90 ref.)
The role of biological response modifiers in the management of patients with colorectal cancer. Wagstaff J. **Eur J Cancer** 1995 Jul–Aug;31A(7–8):1323–5 (29 ref.)
The treatment of cow's milk allergy. Isolauri E. **Eur J Clin Nutr** 1995 Sep;49 Suppl 1:S49–55 (26 ref.)
In vivo gene transfer: a potential approach for immunotherapy. Schmid RM. **Hybridoma** 1995 Apr; 14(2):135–7 (27 ref.)
Antibody–interleukin 2 fusion proteins: a new approach to cancer therapy. Reisfeld RA, et al. **J Clin Lab Anal** 1996; 10(3):160–6 (34 ref.)
G–CSF–stimulated PMN in immunotherapy of breast cancer with a bispecific antibody to Fc gamma RI and to HER–2/neu (MDX–210). Repp R, et al. **J Hematother** 1995 Oct;4(5):415–21 (26 ref.)
Pharmacologic treatment of neonatal sepsis: antimicrobial agents and immunotherapy. Cavaliere TA. **J Obstet Gynecol Neonatal Nurs** 1995 Sep;24(7):647–58 (77 ref.)
Managing HIV. Part 4: Primary therapy. 4.2 Immune–based therapy for HIV infection. Benson EM, et al. **Med J Aust** 1996 Mar 4;164(5):297–300 (25 ref.)
Immune–based therapy of multiple sclerosis. Kaufman MD. **N C Med J** 1995 Aug;56(8):379–84 (24 ref.)
Immune–based therapy for HIV. Engle J. **Nurs Clin North Am** 1996 Mar;31(1):15–23 (45 ref.)
New immunotherapies for sepsis. Young LS, et al. **Proc Assoc Am Physicians** 1995 Oct;107(3):361–4 (19 ref.)
CD80 (B7–1) and CD86 (B7–2): potential targets for immunotherapy? van Gool SW, et al. **Res Immunol** 1995 Mar–Apr;146(3):183–96 (106 ref.)

IMMUNOTHERAPY

In situ cytokine gene transfection using vaccinia virus vectors. Lattime EC, et al. **Semin Oncol** 1996 Feb; 23(1):88–100 (98 ref.)

[Immunotherapy in rheumatoid arthritis; current status] Breedveld FC, et al. **Ned Tijdschr Geneeskd** 1996 Jun 15; 140(24):1255–9 (30 ref.) **(Dut)**

[Are immunological therapies used in severe malaria?] Peyron F. **Med Trop (Mars)** 1995;55(3 Suppl):21–3 (11 ref.) **(Fre)**

[Immunotherapy in gynecologic oncology] Mallmann P. **Geburtshilfe Frauenheilkd** 1994 Nov;54(11):M137–9 (13 ref.) **(Ger)**

[Immunotherapy with genetically modified tumor cells] Topf N, et al. **Internist (Berl)** 1996 Apr;37(4):374–81 (55 ref.) **(Ger)**

[Immunotherapy of hemato-oncologic diseases] Winkler U, et al. **Med Klin** 1996 Apr 10;91(4):226–33 (49 ref.) **(Ger)**

[Tumor rejection antigen and cancer immunotherapy] Matsutake T, et al. **Gan To Kagaku Ryoho** 1995 Nov; 22(13):1871–7 (37 ref.) (Eng. Abstr.) **(Jpn)**

TRENDS

Antibodies proposed as therapeutic agents. Bismuth C, et al. **Arch Toxicol Suppl** 1996;18:321–32 (39 ref.)

The immune response to HIV: potential for immunotherapy? Dalgleish AG. **Immunol Today** 1995 Jul;16(7):356–8 (19 ref.)

IMMUNOTHERAPY, ACTIVE

Enhancing HIV-1 specific immunity as a therapeutic strategy in AIDS. Schooley RT. **Adv Exp Med Biol** 1996;394:405–10 (24 ref.)

Retroviral vectors for HIV immunotherapy. Warner JF, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:105–16 (36 ref.)

Vaccine therapy for cancer. Linehan DC, et al. **Ann Surg Oncol** 1996 Mar;3(2):219–28 (47 ref.)

Vaccine therapy for malignant melanoma. Morton DL, et al. **CA Cancer J Clin** 1996 Jul–Aug;46(4):225–44 (80 ref.)

"Kinoids": the basis for anticytokine immunization and their use in HIV infection. Bizzini B, et al. **Cell Mol Biol (Noisy-le-grand)** 1995 May;41(3):351–6 (38 ref.)

Tumor vaccination. Mallmann P. **Hybridoma** 1995 Apr; 14(2):187–90 (19 ref.)

MUC-1 epithelial tumor mucin-based immunity and cancer vaccines. Finn OJ, et al. **Immunol Rev** 1995 Jun;145:61–89 (112 ref.)

Tumor heterogeneity and immunotherapy of cancer. Fleuren GJ, et al. **Immunol Rev** 1995 Jun;145:91–122 (181 ref.)

Can co-stimulated tumor immunity be therapeutically efficacious? Hellström KE, et al. **Immunol Rev** 1995 Jun; 145:123–45 (110 ref.)

Approaches to augmenting the immunogenicity of melanoma gangliosides: from whole melanoma cells to ganglioside-KLH conjugate vaccines. Livingston PO. **Immunol Rev** 1995 Jun;145:147–66 (68 ref.)

T-cell immunotherapy of tumors by adoptive transfer of cytotoxic T lymphocytes and by vaccination with minimal essential epitopes. Melief CJ, et al. **Immunol Rev** 1995 Jun; 145:167–77 (42 ref.)

The case for therapeutic vaccines. Dalgleish A. **Melanoma Res** 1996 Feb;6(1):5–10 (45 ref.)

New treatment options for patients with melanoma: review of melanoma-derived T-cell epitope-based peptide vaccines. Maeurer MJ, et al. **Melanoma Res** 1996 Feb; 6(1):11–24 (102 ref.)

[Cancer vaccines: scientific bases and clinical developments] Bellet D. **Bull Cancer (Paris)** 1995 Nov;82(11):899–909 (49 ref.) (Eng. Abstr.) **(Fre)**

[Immunogene therapy of cancer using cytokine genes] Hanada K, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec; 40(17):2688–93 (23 ref.) **(Jpn)**

[Gene therapy of cancer using TNF gene] Sato Y, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2694–9 (30 ref.) **(Jpn)**

METHODS

Tumor vaccination. Mallmann P. **Hybridoma** 1995 Apr; 14(2):187–90 (19 ref.)

Immunotherapy of cancer with genetically modified tumor vaccines. Gilboa E. **Semin Oncol** 1996 Feb;23(1):101–7 (53 ref.)

[Immunotherapy of colorectal cancers] Bécouarn Y, et al. **Gastroenterol Clin Biol** 1996 Feb;20(1):20–32 (106 ref.) **(Fre)**

[Dendritic cells and tumor cell therapy] Pioche C, et al. **Pathol Biol (Paris)** 1995 Dec;43(10):904–9 (43 ref.) (Eng. Abstr.) **(Fre)**

[Adjuvant therapy of liver metastases: active specific immunotherapy] Hagmüller E, et al. **Zentralbl Chir** 1995; 120(10):780–5 (37 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOTHERAPY, ADOPTIVE

Assessment of engraftment and function of human tonsillar and blood mononuclear cells in immunodeficient mice. Albini B, et al. **Adv Exp Med Biol** 1995;371A:85–9 (28 ref.)

Enhancing HIV-1 specific immunity as a therapeutic strategy in AIDS. Schooley RT. **Adv Exp Med Biol** 1996;394:405–10 (24 ref.)

Graft-versus-leukemia and graft-versus-lymphoma effects of allogeneic bone marrow transplantation and of allogeneic donor leukocyte transfusions. Vandenberghe P, et al. **Ann Hematol** 1995 Nov;71(5):209–17 (65 ref.)

Tissue distribution and tumor localization of effector cells in adoptive immunotherapy of cancer. Basse PH. **APMIS Suppl** 1995;55:1–28 (107 ref.)

Cytotoxic lymphocyte-mediated immunotherapy. Smyth MJ, et al. **Aust N Z J Med** 1995 Dec;25(6):852–8 (57 ref.)

Adoptive immunotherapy. Curti BD. **Cancer Chemother Biol Response Modif** 1996;16:274–84 (48 ref.)

Cellular adoptive immunotherapy after bone marrow transplantation. Riddell SR, et al. **Cancer Treat Res** 1995; 76:337–69 (192 ref.)

Locoregional immuno-chemotherapy transplenic and transtumoral in vivo immunostimulation. Lygidakis NJ, et al. **Hepatogastroenterology** 1996 Mar–Apr;43(8):440–7 (38 ref.)

T-cell immunotherapy of tumors by adoptive transfer of cytotoxic T lymphocytes and by vaccination with minimal essential epitopes. Melief CJ, et al. **Immunol Rev** 1995 Jun; 145:167–77 (42 ref.)

Perspectives on investigational chemotherapy and biologic therapy for childhood brain tumors. Kadota RP. **J Pediatr Hematol Oncol** 1996 Feb;18(1):13–22 (110 ref.)

Adoptive immunotherapy for relapsed leukemia following allogeneic bone marrow transplantation. Porter DL, et al. **Leuk Lymphoma** 1995 Apr;17(3–4):191–7 (46 ref.)

Genetic approaches to adoptive cellular therapy of malignancy. Arca MJ, et al. **Semin Oncol** 1996 Feb; 23(1):108–17 (62 ref.)

[Immunogene therapy of cancer using cytokine genes] Hanada K, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec; 40(17):2688–93 (23 ref.) **(Jpn)**

[Gene therapy for diabetes: various approaches including adoptive transfer of cytokine gene-transduced lymphocytes] Moritani M, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2746–52 (23 ref.) **(Jpn)**

[Gene therapy of cancer using TNF gene] Sato Y, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2694–9 (30 ref.) **(Jpn)**

METHODS

Cellular immunotherapy of cancer. Yang JC. **Curr Opin Gen Surg** 1994;:238–44 (31 ref.)

Transplantation of hepatitis B immune lymphocytes as means for adoptive transfer of immunity to hepatitis B virus. Shouval D, et al. **J Hepatol** 1995 Jul;23(1):98–101 (18 ref.)

[Tumor-infiltrating lymphocytes (TIL)] Matysiak W. **Pol Arch Med Wewn** 1995 Jul;94(1):76–83 (47 ref.) **(Pol)**

TRENDS

[Future of malignant stage I melanoma. Immunology and immunotherapy] Nicolas JF, et al. **Ann Dermatol Venereol** 1995;122(5):324–35 (105 ref.) **(Fre)**

IMMUNOTHERAPY, ALLERGEN see **DESENSITIZATION, IMMUNOLOGIC**

IMMUNOTHERAPY, PASSIVE see **IMMUNOTHERAPY, ADOPTIVE**

IMMUNOTOXINS

Humanized immunotoxins. Gadina M, et al. **Ther Immunol** 1994 Jan;1(1):59–64 (46 ref.)

PHARMACOLOGY

Antibody-directed targeting of the vasculature of solid tumors. Thorpe PE, et al. **Breast Cancer Res Treat** 1995; 36(2):237–51 (55 ref.)

Single-chain fusion toxins for the treatment of breast cancer: antitumor activity of BR96 sFv-PE40 and heregulin-PE40. Siegall CB. **Recent Results Cancer Res** 1996;140:51–60 (21 ref.)

The performance of e23(Fv)PEs, recombinant toxins targeting the erbB-2 protein. King CR, et al. **Semin Cancer Biol** 1996 Apr;7(2):79–86 (48 ref.)

Targeting toxins to neural antigens and receptors. Wiley RG. **Semin Cancer Biol** 1996 Apr;7(2):71–7 (96 ref.)

THERAPEUTIC USE

Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies. Bodey B, et al. **Anticancer Res** 1996 Mar–Apr;16(2):661–74 (172 ref.)

Monoclonal antibodies used in the detection and treatment of epithelial ovarian cancer. Muto MG, et al. **Cancer** 1995 Nov 15;76(10 Suppl):2016–27 (100 ref.)

Immunoconjugates and immunotoxins for therapy of solid tumors. Hellström I, et al. **Cancer Chemother Pharmacol** 1996;38 Suppl:S35–6 (13 ref.)

Intervention in receptor tyrosine kinase-mediated pathways: recombinant antibody fusion proteins targeted to ErbB2. Weis W, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 3):113–28 (47 ref.)

Immunotoxin therapy of hematological malignancies. Pasqualucci L, et al. **Haematologica** 1995 Nov–Dec; 80(6):546–56 (47 ref.)

Immunotoxins for treatment of leukemia and lymphoma. Uckun FM, et al. **Leuk Lymphoma** 1995 Jul;18(3–4):195–201 (51 ref.)

Gold, electron microscopy, and cancer therapy. Hainfeld JF. **Scanning Microsc** 1995 Mar;9(1):239–54; discussion 254–6 (28 ref.)

Why toxins! Fitzgerald D. **Semin Cancer Biol** 1996 Apr; 7(2):87–95 (67 ref.)

Clinical trials of targeted toxins. Frankel AE, et al. **Semin Cancer Biol** 1995 Oct;6(5):307–17 (78 ref.)

Targeting Pseudomonas exotoxin to hematologic malignancies. Kreitman RJ, et al. **Semin Cancer Biol** 1995 Oct;6(5):297–306 (54 ref.)

Tumor targeting through fibroblast growth factor receptors. Lappi DA. **Semin Cancer Biol** 1995 Oct;6(5):279–88 (78 ref.)

Targeted therapy of carcinomas using BR96 sFv-PE40, a single-chain immunotoxin that binds to the Le(y) antigen. Siegall CB. **Semin Cancer Biol** 1995 Oct;6(5):289–95 (44 ref.)

Targeting T cells for GVHD therapy. Vallera DA. **Semin Cancer Biol** 1996 Apr;7(2):57–64 (57 ref.)

Immunotoxins for central nervous system malignancy. Youle RJ. **Semin Cancer Biol** 1996 Apr;7(2):65–70 (36 ref.)

Novel genetic immunotoxins and intracellular antibodies for cancer therapy. Chen SY, et al. **Semin Oncol** 1996 Feb; 23(1):148–53 (55 ref.)

Genetically engineered proteins for immunoregulation. Strom TB, et al. **Transplant Proc** 1995 Oct;27(5 Suppl 1):18–20 (20 ref.)

[Diagnosis and targeting therapy of colorectal cancer using antibody] Yamaguchi T, et al. **Gan To Kagaku Ryoho** 1996 Apr;23(5):549–53 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Application of tumor marker for immunotargeting therapy of cancer] Yamaguchi T, et al. **Nippon Rinsho** 1996 Jun; 54(6):1674–9 (17 ref.) (Eng. Abstr.) **(Jpn)**

TOXICITY

Molecular mechanisms of toxicant-induced immunosuppression: role of second messengers. Holsapple MP, et al. **Annu Rev Pharmacol Toxicol** 1996;36:131–59 (112 ref.)

Predictive immunotoxicological test systems: suitability of the popliteal lymph node assay in mice and rats. Bloksma N, et al. **Crit Rev Toxicol** 1995;25(5):369–96 (115 ref.)

Immunotoxicity assessment of biotechnology products: a regulatory point of view [editorial] Cavagnaro JA. **Toxicology** 1995 Dec 20;105(1):1–6 (12 ref.)

IMP DEHYDROGENASE

ANTAGONISTS & INHIBITORS

Mechanism of action of mycophenolate mofetil. Ransom JT. **Ther Drug Monit** 1995 Dec;17(6):681–4 (14 ref.)

[Inhibitors of inosine monophosphate dehydrogenase and their biological activities] Minakawa N, et al. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1299–305 (32 ref.) **(Jpn)**

IMP NUCLEOTIDASE see **5'-NUCLEOTIDASE**

IMP PHOSPHATASE see **5'-NUCLEOTIDASE**

IMP PYROPHOSPHORYLASE see **HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE**

IMPEDANCE see **ELECTRIC IMPEDANCE**

IMPETIGO

Impetigo. Shriner DL, et al. **Cutis** 1995 Jul;56(1):30–2 (32 ref.)

IMPETIGO CONTAGIOSA see **IMPETIGO**

IMPLANT, COCHLEAR see **COCHLEAR IMPLANT**

IMPLANT, MIDDLE EAR see **OSSICULAR REPLACEMENT PROSTHESIS**

IMPLANT RADIOTHERAPY see **BRACHYTHERAPY**

IMPLANT-SUPPORTED DENTAL PROSTHESIS see **DENTAL PROSTHESIS, IMPLANT-SUPPORTED**

IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS see **DEFIBRILLATORS, IMPLANTABLE**

IMPLANTABLE CATHETERS see **CATHETERS, INDWELLING**

IMPLANTABLE DEFIBRILLATORS see **DEFIBRILLATORS, IMPLANTABLE**

IMPLANTABLE INFUSION PUMPS see **INFUSION PUMPS, IMPLANTABLE**

IMPLANTATION, BLASTOCYST see **OVUM IMPLANTATION**

IMPLANTS, ARTIFICIAL

see related
BIOCOMPATIBLE MATERIALS
BIOFILMS

Osteoinductive agents. Basic science and clinical applications. Kale AA, et al. **Am J Orthop** 1995 Oct;24(10):752–61 (92 ref.)

Mastoidectomy reconstruction: management of the high facial ridge using hydroxylapatite implants. Black B, et al. **Am J Otol** 1994 Nov;15(6):785–92 (78 ref.)

The use of expanded polytetrafluoroethylene (Gore-Tex) in rhinoplasty. A 6-year experience. Godin MS, et al. **Arch Otolaryngol Head Neck Surg** 1995 Oct;121(10):1131–6 (20 ref.)

Hearing aids. II. Implantable hearing aids. Gulya AJ, et al. **Arch Otolaryngol Head Neck Surg** 1996 Apr;122(4):363–7 (22 ref.)

Implantable biohybrid artificial organs. Colton CK. **Cell Transplant** 1995 Jul–Aug;4(4):415–36 (72 ref.)

Metallic implants used in foot surgery. Chang TJ, et al. **Clin Podiatr Med Surg** 1995 Jul;12(3):457–74 (57 ref.)

Mechanical properties of implantable biomaterials. Meaney DF. **Clin Podiatr Med Surg** 1995 Jul;12(3):363–84 (6 ref.)

Musculoskeletal applications of hyaluronan and hylan. Potential uses in the foot and ankle. Weiss C, et al. **Clin Podiatr Med Surg** 1995 Jul;12(3):497–517 (44 ref.)

New developments in intracardiac and intravascular devices for congenital heart disease. Tabbutt S, et al. **Curr Opin Cardiol** 1996 Jan;11(1):61–7 (49 ref.)

The current status of expanded polytetrafluoroethylene (Gore-Tex) in facial plastic surgery. Levine B, et al. **Ear Nose Throat J** 1995 Oct;74(10):681–2, 684 (17 ref.)

Osteopontin at mineralized tissue interfaces in bone, teeth, and osseointegrated implants: ultrastructural distribution and implications for mineralized tissue formation, turnover, and repair. McKee MD, et al. **Microsc Res Tech** 1996 Feb 1;33(2):141–64 (112 ref.)

Induction of soft connective tissue formation by various prosthetic implants. Oryan A. **Transplant Proc** 1995 Oct; 27(5):2754–5 (23 ref.)

[Using temporal bone artificial implantation for the fixation of external ear prosthesis] Chen X, et al. **Chung Hua Cheng Hsing Shao Shang Wai Ko Tsa Chih** 1995 Sep;11(5):379–81 (15 ref.) **(Chi)**

[The implantable middle ear hearing aid] Niehaus HH. **HNO** 1995 Dec;43(12):697–701 (27 ref.) **(Ger)**

[Progression of arthrosis after alloplasty--what factors play a role?] Küllmer K, et al. **Unfallchirurgie** 1996 Jun; 22(3):130–8 (36 ref.) (Eng. Abstr.) **(Ger)**

[Use of porous plyethylene (Medpor) in maxillofacial surgery] Cenzi R, et al. **Minerva Stomatol** 1995 Dec; 44(12):559–82 (17 ref.) (Eng. Abstr.) **(Ita)**

[Use of irradiation technique for obtaining and modifying biopolymers. Review.] Lewandowska-Szumieł M, et al. **Polim Med** 1995;25(1–2):57–67 (35 ref.) (Eng. Abstr.) **(Pol)**

ADVERSE EFFECTS

Metal carcinogenesis in total joint arthroplasty. Animal models. Lewis CG, et al. **Clin Orthop** 1996 Aug;(329 Suppl):S264–8 (37 ref.)

[Complications from silicone implants and other so-called inert materials] Faure M. **Ann Dermatol Venereol** 1995; 122(6–7):455–9 (54 ref.) **(Fre)**

STANDARDS

Role of material surfaces in regulating bone and cartilage cell response. Boyan BD, et al. **Biomaterials** 1996 Jan; 17(2):137–46 (94 ref.)

Corrosion and other electrochemical aspects of biomaterials. Bundy KJ. **Crit Rev Biomed Eng** 1994;22(3–4):139–251 (1712 ref.)

A surgeon's perspective of medical device regulation. Brantigan JW. **J Spinal Disord** 1995 Oct;8(5):396–412 (74 ref.)

IMPLANTS, BREAST see **BREAST IMPLANTS**

IMPLANTS, DENTAL see **DENTAL IMPLANTS**

IMPOTENCE

Evaluation and treatment of erectile dysfunction. DeWire DM. **Am Fam Physician** 1996 May 1;53(6):2101–8 (35 ref.)

ABC of urology. Subfertility and male sexual dysfunction. Dawson C, et al. **BMJ** 1996 Apr 6;312(7035):902–5 (0 ref.)

A goal-oriented, cost-effective approach to the diagnosis and treatment of 24 male erectile dysfunction. Long RL Jr, et al. **J Ky Med Assoc** 1995 Nov;93(11):500–8 (24 ref.)

CHEMICALLY INDUCED

[Erection disorders and priapism due to drugs] Meinhardt W, et al. **Ned Tijdschr Geneeskd** 1995 Sep 16;139(37):1871–3 (24 ref.) **(Dut)**

DIAGNOSIS

Clinical evaluation of impotence. Li MK, et al. **Ann Acad Med Singapore** 1995 Sep;24(5):741–4 (21 ref.)

Use of nocturnal penile tumescence and rigidity in the evaluation of male erectile dysfunction. Levine LA, et al. **Urol Clin North Am** 1995 Nov;22(4):775–88 (58 ref.)

Diagnosis and management of endocrine disorders of erectile dysfunction. Zonszein J. **Urol Clin North Am** 1995 Nov; 22(4):789–802 (48 ref.)

New developments in the diagnosis and treatment of impotence. De Palma RG. **West J Med** 1996 Jan; 164(1):54–61 (48 ref.)

DRUG THERAPY

Alprostadil for erectile impotence. **Drug Ther Bull** 1995 Aug; 33(8):61–2 (13 ref.)

Pharmacological management of erectile dysfunction. Montorsi F, et al. **Drugs** 1995 Sep;50(3):465–79 (59 ref.)

Intracavernous alprostadil. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in erectile dysfunction. Lea AP, et al. **Drugs Aging** 1996 Jan;8(1):56–74 (123 ref.)

The rationale for prostaglandin E1 in erectile failure: a survey of worldwide experience. Porst H. **J Urol** 1996 Mar; 155(3):802–15 (219 ref.)

Intracavernous pharmacotherapy: treatment for the aging erectile response. Broderick GA. **Urol Clin North Am** 1996 Feb;23(1):111–26 (123 ref.)

Intracavernous injection therapy for male erectile dysfunction. Fallon B. **Urol Clin North Am** 1995 Nov; 22(4):833–45 (68 ref.)

Oral and topical treatment of erectile dysfunction. Present and future. Morales A, et al. **Urol Clin North Am** 1995 Nov;22(4):879–86 (31 ref.)

[Drugs for impotence] Lukkarinen O, et al. **Duodecim** 1995; 111(8):771–6 (25 ref.) **(Fin)**

[Impotence: non-hormonal drug therapy. Old and new drugs] Della Morte E, et al. **Arch Ital Urol Androl** 1995 Dec; 67(5):321–7 (29 ref.) (Eng. Abstr.) **(Ita)**

[Long-term results of the treatment with intracavernous injection of vasoactive drugs] Rodríguez Vela L, et al. **Arch Esp Urol** 1996 Apr;49(3):257–69 (25 ref.) (Eng. Abstr.) **(Spa)**

EPIDEMIOLOGY

The epidemiology of erectile dysfunction. Benet AE, et al. **Urol Clin North Am** 1995 Nov;22(4):699–709 (142 ref.)

ETIOLOGY

Impotence in diabetes mellitus. Close CF, et al. **Diabetes Metab Rev** 1995 Oct;11(3):279–85 (49 ref.)

Clinical approach to erectile dysfunction in spinal cord injured men. A review of clinical and experimental data. Courtois FJ, et al. **Paraplegia** 1995 Nov;33(11):628–35 (60 ref.)

[Aging and sexuality in the male] Tordjman G. **Contracept Fertil Sex** 1996 Jun;24(6):501–4 (14 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

[Electrophysiologic diagnosis in erectile dysfunction] Jost WH, et al. **Urologe A** 1996 Mar;35(2):120–6 (32 ref.) (Eng. Abstr.) **(Ger)**

PSYCHOLOGY

Psychology's role in the assessment of erectile dysfunction: historical precedents, current knowledge, and methods. Ackerman MD, et al. **J Consult Clin Psychol** 1995 Dec; 63(6):862–76 (185 ref.)

Psychological issues in diagnosis and treatment of erectile disorders. Tiefer L, et al. **Urol Clin North Am** 1995 Nov; 22(4):767–73 (27 ref.)

SURGERY

Overview of current operations for impotence. Pryor JP. **Ann Acad Med Singapore** 1995 Sep;24(5):763–6 (22 ref.)

THERAPY

Success with erectile dysfunction. Evans C. **Practitioner** 1995 Sep;239(1554):534–7 (0 ref.)

Management of erectile dysfunction after radical prostatectomy. Hall MC. **Semin Urol Oncol** 1995 Aug; 13(3):215–23 (46 ref.)

IMPOTENCE, ARTERIOGENIC see **IMPOTENCE, VASCULOGENIC**

IMPOTENCE, VASCULOGENIC

DIAGNOSIS

Investigation of erectile dysfunction. Diagnostic testing for vascular factors in erectile dysfunction. Meuleman EJ, et al. **Urol Clin North Am** 1995 Nov;22(4):803–19 (95 ref.)

PHYSIOPATHOLOGY

[Electrophysiologic diagnosis in erectile dysfunction] Jost WH, et al. **Urologe A** 1996 Mar;35(2):120–6 (32 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Current thoughts on penile prosthetic surgery. Pryor JP. **Acta Chir Hung** 1995–96;35(1–2):129–35 (4 ref.)

Penile revascularization: an overview. Shah RS, et al. **Ann Acad Med Singapore** 1995 Sep;24(5):749–54 (39 ref.)

[Apical ulceration of the glans penis in hypervascularization syndrome. Sequelae of revascularization operation in erectile dysfunction] Hartwig R, et al. **Hautarzt** 1995 Nov; 46(11):808–10 (12 ref.) (Eng. Abstr.) **(Ger)**

IMPOTENCE, VENOGENIC see **IMPOTENCE, VASCULOGENIC**

IMPULSE CONTROL DISORDERS

see related
PARAPHILIAS
SUBSTANCE USE DISORDERS

DIAGNOSIS

Compulsive buying: a review. Black DW. **J Clin Psychiatry** 1996;57 Suppl 8:50–4; discussion 55 (23 ref.)

Diagnosis, neurobiology, and treatment of pathological gambling. DeCaria CM, et al. **J Clin Psychiatry** 1996;57 Suppl 8:80–3; discussion 83–4 (36 ref.)

PSYCHOLOGY

Military shoplifting. Lande G. **Mil Med** 1995 Aug; 160(8):404–7 (28 ref.)

IMPULSE-RIDDEN PERSONALITY see **PERSONALITY DISORDERS**

IN-HOSPITAL MORTALITY see **HOSPITAL MORTALITY**

IN SITU HYBRIDIZATION

Mosaic vs. nonmosaic trisomy 9: report of a liveborn infant evaluated by fluorescence in situ hybridization and review of the literature. Cantú ES, et al. **Am J Med Genet** 1996 Apr 24;62(4):330–5 (39 ref.)

In situ molecular biological techniques. Su H, et al. **Chin Med J (Engl)** 1996 Mar;109(3):188–91 (0 ref.)

In situ PCR: pathologist's dream or nightmare? O'Leary JJ, et al. **J Pathol** 1996 Jan;178(1):11–20 (22 ref.)

In situ hybridization analysis of chick embryos in whole mount and tissue sections. Nieto MA, et al. **Methods Cell Biol** 1996;51:219–35 (9 ref.)

[Advances in the technology applied to pathology in China] Wang B, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1995 Aug;24(4):258–60 (21 ref.) **(Chi)**

[In situ PCR: principles, problems and application to molecular biology] Aoyagi K. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):608–13 (32 ref.) **(Jpn)**

[In situ PCR detection of HTLV-1 provirus in spinal cord lesions with HAM/TSP] Izumo S, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):656–9 (16 ref.) **(Jpn)**

[Histopathological application of in situ PCR (in situ hybridization after amplification by PCR)] Shindoh M, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):660–3 (10 ref.) **(Jpn)**

[Slide PCR for gene mapping] Yoshida MC. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):652–5 (3 ref.) **(Jpn)**

[Immunohistochemistry and in situ hybridization in the identification of the hepatitis C virus in liver tissue] Soguero Serrano C. **Gastroenterol Hepatol** 1996 May;19(5):262–73 (113 ref.) **(Spa)**

METHODS

Use of non-radioactive probes for mRNA detection by in situ hybridization: interests and applications in the central nervous system. Le Moine C, et al. **Cell Mol Biol (Noisy-le-grand)** 1995 Nov;41(7):917–23 (37 ref.)

Polymerase chain reaction in situ: an appraisal of an emerging technique. Teo IA, et al. **Histochem J** 1995 Sep; 27(9):647–59 (67 ref.)

Recent advances in molecular histochemical techniques: in situ hybridization and southwestern histochemistry. Koji T, et al. **J Electron Microsc (Tokyo)** 1996 Apr;45(2):119–27 (71 ref.)

Detection of human cytokines in situ using antibody and probe based methods. Hoefakker S, et al. **J Immunol Methods** 1995 Sep 25;185(2):149–75 (159 ref.)

In situ hybridization. McFadden GI. **Methods Cell Biol** 1995; 49:165–83 (32 ref.)

Whole-mount in situ hybridization for the detection of RNA in Caenorhabditis elegans embryos. Seydoux G, et al. **Methods Cell Biol** 1995;48:323–37 (19 ref.)

[Detection of hepatitis C virus (HCV) infected cell using in situ hybridization and PCR in situ hybridization] Kawai H, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:307–11 (23 ref.) **(Jpn)**

[Detection of HCV-RNA in liver by in situ hybridization] Yamada S, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:300–6 (29 ref.) **(Jpn)**

[Detection of HBV genomes in liver tissue by in situ hybridization] Yamada S, et al. **Nippon Rinsho** 1995 Oct;

53 Suppl:325–30 (19 ref.) **(Jpn)**

IN SITU HYBRIDIZATION, FLUORESCENCE

Detection of a subtle rearrangement of chromosome 22 using molecular techniques. Biesecker LG, et al. **Am J Med Genet** 1995 Sep 25;58(4):389–94 (15 ref.)

Isodicentric (X)(q13) in haematological malignancies: presentation of five new cases, application of fluorescence in situ hybridization (FISH) and review of the literature. Dierlamm J, et al. **Br J Haematol** 1995 Dec;91(4):885–91 (23 ref.)

Are we FISHing in troubled waters? Verma RS, et al. **Cell Mol Biol Res** 1995;41(2):81–4 (40 ref.)

Fluorescence in situ hybridization: powerful molecular tool for cancer prognosis. Fox JL, et al. **Clin Chem** 1995 Nov; 41(11):1554–9 (11 ref.)

Fluorescence in situ hybridization: a brief review. Swiger RR, et al. **Environ Mol Mutagen** 1996;27(4):245–54 (69 ref.)

Advantages and limitations of using fluorescence in situ hybridization for the detection of aneuploidy in interphase human cells. Eastmond DA, et al. **Mutat Res** 1995 Dec; 348(4):153–62 (46 ref.)

Applications of fluorescent in situ hybridization (FISH) to genetic analysis of human tumors. Wolman SR. **Pathol Annu** 1995;30 Pt 2:227–43 (50 ref.)

Molecular cytogenetics: unraveling of the genetic composition of individual cells by fluorescence in situ hybridization and digital imaging microscopy. Tanke HJ, et al. **World J Urol** 1995;13(3):138–42 (19 ref.)

INSTRUMENTATION

[Comparative genomic hybridization in pathology. A new molecular cytogenetic method] Störkel S, et al. **Pathologe** 1996 May;17(3):189–94 (19 ref.) (Eng. Abstr.) **(Ger)**

METHODS

The coloring of cytogenetics. Speicher MR, et al. **Nat Med** 1996 Sep;2(9):1046–8 (18 ref.)

FISH as a tool for genome mapping and positional cloning. Inazawa J. **Southeast Asian J Trop Med Public Health** 1995; 26 Suppl 1:86–8 (19 ref.)

[Fluorescent in-situ hybridization technique (FISH) in the diagnosis of Philadelphia translocation in chronic myeloid leukemia] Martinet D, et al. **Schweiz Med Wochenschr** 1996 May 18;126(20):855–63 (30 ref.) (Eng. Abstr.) **(Fre)**

TRENDS

FISH in genome research and molecular diagnostics. van Ommen GJ, et al. **Curr Opin Genet Dev** 1995 Jun;5(3):304–8 (45 ref.)

INADEQUATE PERSONALITY see **PERSONALITY DISORDERS**

INAPPROPRIATE ADH SYNDROME

CHEMICALLY INDUCED

Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotonin reuptake inhibitors: a review of spontaneous reports. Liu BA, et al. **Can Med Assoc J** 1996 Sep 1; 155(5):519–27 (50 ref.)

COMPLICATIONS

[A case of Guillain-Barré syndrome associated with SIADH, treated by intravenous gammaglobulins] De Decker V, et al. **Acta Clin Belg** 1996;51(3):170–4 (13 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Delayed onset of hyponatremia after transsphenoidal surgery for pituitary adenomas. Taylor SL, et al. **Neurosurgery** 1995 Oct;37(4):649–53; discussion 653–4 (26 ref.)

PHYSIOPATHOLOGY

Cerebral salt wasting syndrome: a review. Harrigan MR. **Neurosurgery** 1996 Jan;38(1):152–60 (80 ref.)

INBORN ERRORS OF METABOLISM see **METABOLISM, INBORN ERRORS**

INCENTIVES see **MOTIVATION**

INCEST

Forming a consortium: a design for interagency collaboration in the delivery of service following the disclosure of incest. Peck JS, et al. **Fam Process** 1995 Sep;34(3):287–302 (53 ref.)

INCIDENCE STUDIES see **COHORT STUDIES**

INCIDENT REPORTING, HOSPITAL see **RISK MANAGEMENT**

INCINERATION

Hospitals and plastics. Dioxin prevention and medical waste incinerators. Thornton J, et al. **Public Health Rep** 1996 Jul-Aug;111(4):299–313 (121 ref.)

INCIPIENT SCHIZOPHRENIA see **SCHIZOTYPAL PERSONALITY DISORDER**

INCISOR

ABNORMALITIES

The nasal tooth. Case report. Nastri AL, et al. **Aust Dent J** 1996 Jun;41(3):176–7 (7 ref.)

Lateral thinking: the management of missing upper lateral incisors. Millar BJ, et al. **Br Dent J** 1995 Aug 5; 179(3):99–106 (16 ref.)

Dens evaginatus of anterior teeth. Literature review and radiographic survey of 15,000 teeth. Dankner E, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Apr;81(4):472–5 (47 ref.)

Talon cusp affecting the primary maxillary central incisors in two sets of female twins: report of two cases. Liu JF, et al. **Pediatr Dent** 1995 Sep-Oct;17(5):362–4 (16 ref.)

INJURIES

Anterior tooth trauma in the primary dentition: incidence, classification, treatment methods, and sequelae: a review of the literature. Fried I, et al. **ASDC J Dent Child** 1995 Jul-Aug;62(4):256–61 (27 ref.)

PATHOLOGY

Review article. The rat incisor in toxicologic pathology. Kuijpers MH, et al. **Toxicol Pathol** 1996 May-Jun; 24(3):346–60 (28 ref.)

Dental dysplasia in rats and mice. Losco PE. **Toxicol Pathol** 1995 Nov-Dec;23(6):677–88 (36 ref.)

INCLUSION BODIES

METABOLISM

Thermolabile folding intermediates: inclusion body precursors and chaperonin substrates. King J, et al. **FASEB J** 1996 Jan;10(1):57–66 (63 ref.)

In vitro folding of inclusion body proteins. Rudolph R, et al. **FASEB J** 1996 Jan;10(1):49–56 (80 ref.)

INCLUSION DISEASE see **CYTOMEGALOVIRUS INFECTIONS**

INCOME

see related
SALARIES AND FRINGE BENEFITS

INCOMPETENCY, MENTAL see **MENTAL COMPETENCY**

INCOMPLETE VIRUSES see **DEFECTIVE VIRUSES**

INCONTINENTIA PIGMENTI

[Incontinentia pigmenti] Le Roux BP, et al. **Arch Pediatr** 1996 Feb;3(2):152–5 (20 ref.) (Eng. Abstr.) **(Fre)**

INCONTINENTIA PIGMENTI ACHROMIANS see **PIGMENTATION DISORDERS**

INDANS

PHARMACOLOGY

Endothelin receptor antagonism. Opgenorth TJ. **Adv Pharmacol** 1995;33:1–65 (316 ref.)

INDAPAMIDE

THERAPEUTIC USE

Comparative effects of indapamide and captopril on blood pressure and albumin excretion rate in diabetic microalbuminuria. Donnelly R, et al. **Am J Cardiol** 1996 Feb 22;77(6):26B–30B (33 ref.)

INDEPENDENT LIVING see **ACTIVITIES OF DAILY LIVING**

INDEPENDENT PRACTICE ASSOCIATIONS

ORGANIZATION & ADMINISTRATION

A glimpse of an IPA as a living system. Johnstone PM. **Behav Sci** 1995 Oct;40(4):304–13 (29 ref.)

INDEXING see **ABSTRACTING AND INDEXING**

INDIANS, NORTH AMERICAN

Evaluating government health and substance abuse programs for indigenous peoples: a comparative review. Gray D, et al. **Aust J Public Health** 1995 Dec;19(6):567–72 (62 ref.)

Issues in health policy for indigenous peoples in Canada. O'Neil JD. **Aust J Public Health** 1995 Dec;19(6):559–66 (50 ref.)

Drug prevention research with Native-American populations: some considerations. Powless Sage G. **NIDA Res Monogr** 1994;139:235–48 (18 ref.)

Toward comprehensive obesity prevention programs in Native American communities. Broussard BA, et al. **Obes Res** 1995 Sep;3 Suppl 2:289s–297s (50 ref.)

Prevention in practice. Ethnic groups. Millar J, et al. **Prim Care** 1995 Dec;22(4):713–30 (27 ref.)

Culture in treatment, culture as treatment. A critical appraisal of developments in addictions programs for indigenous North Americans and Australians. Brady M. **Soc Sci Med** 1995 Dec;41(11):1487–98 (78 ref.)

[Microfilament dysfunction (severe familial cholestasis in North American Indian children)] Terazawa S. **Ryoikibetsu Shokogun Shirizu** 1995;(7):535–8 (12 ref.) **(Jpn)**

PSYCHOLOGY

Eating disturbances among American minority groups: a review. Crago M, et al. **Int J Eat Disord** 1996 Apr; 19(3):239–48 (59 ref.)

INDIANS, SOUTH AMERICAN

GENETICS

Review of studies of polymorphic blood systems in the Aymara indigenous population from Bolivia, Peru, and Chile. Dittmar M. **Anthropol Anz** 1995 Dec;53(4):289–315 (55 ref.)

The evolution of major histocompatibility class I genes in primates. Watkins DI. **Crit Rev Immunol** 1995;15(1):1–29 (135 ref.)

INDICATOR DILUTION TECHNIQUES

[Total body water by D2O dilution] Koda M, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:170–3 (10 ref.) **(Jpn)**

INDICATORS AND REAGENTS

see related
CHELATING AGENTS
DYES
REAGENT KITS, DIAGNOSTIC

INDIGENCY see **POVERTY**

INDIGENCY, MEDICAL see **MEDICAL INDIGENCY**

INDIGENT CARE see **MEDICAL INDIGENCY**

INDIUM RADIOISOTOPES

DIAGNOSTIC USE

Remission of acromegaly caused by pituitary carcinoma after surgical excision of growth hormone-secreting metastasis detected by 111-indium pentetreotide scan. Greenman Y, et al. **J Clin Endocrinol Metab** 1996 Apr;81(4):1628–33 (29 ref.)

Radiolabelled peptides: now and the future. Thakur ML. **Nucl Med Commun** 1995 Sep;16(9):724–32 (41 ref.)

Use of polyclonal IgG in HIV infection and AIDS. Buscombe JR, et al. **Q J Nucl Med** 1995 Sep;39(3):212–20 (34 ref.)

Somatostatin-receptor imaging in lymphoma. Goldsmith SJ, et al. **Semin Nucl Med** 1995 Jul;25(3):262–71 (13 ref.)

Somatostatin receptor imaging of neuroendocrine tumors with indium-111 pentetreotide (Octreoscan). Olsen JO, et al. **Semin Nucl Med** 1995 Jul;25(3):251–61 (25 ref.)

[Indium III monoclonal antimyosin antibody scintigraphy for the detection of chronic myocardial infarction apart from the acute phase] Adrie C, et al. **Arch Mal Coeur Vaiss** 1995 Dec;88(12):1863–8 (33 ref.) (Eng. Abstr.) **(Fre)**

THERAPEUTIC USE

Therapy of neuroendocrine tumors with radiolabeled MIBG and somatostatin analogues. Wiseman GA, et al. **Semin Nucl Med** 1995 Jul;25(3):272–8 (39 ref.)

INDIVIDUAL DIFFERENCES see **INDIVIDUALITY**

INDIVIDUAL PRACTICE ASSOCIATIONS see **INDEPENDENT PRACTICE ASSOCIATIONS**

INDIVIDUALITY

Basic behavioral science research for mental health. Vulnerability and resilience. Basic Behavioral Science Task Force of the National Advisory Mental Health Council. **Am Psychol** 1996 Jan;51(1):22–8 (7 ref.)

Personality: individual differences and clinical assessment. Butcher JN, et al. **Annu Rev Psychol** 1996;47:87–111 (240 ref.)

Individual response patterns and treatment matching in the phobic disorders: a review. Menzies RG.

Br J Clin Psychol 1996 Feb;35 (Pt 1):1–10 (36 ref.)
Psychological and hypnotic preparation for anesthesia and surgery: an individual differences perspective. Kessler R, et al. **Int J Clin Exp Hypn** 1996 Jul;44(3):189–207 (60 ref.)
What is the role of the immune system in determining individually distinct body odours? Brown RE. **Int J Immunopharmacol** 1995 Aug;17(8):655–61 (58 ref.)
Women's sexuality: behaviors, responses, and individual differences. Andersen BL, et al. **J Consult Clin Psychol** 1995 Dec;63(6):891–906 (130 ref.)
Levels and domains in personality: an introduction. Emmons RA. **J Pers** 1995 Sep;63(3):341–64 (70 ref.)
Psychological needs and the facilitation of integrative processes. Ryan RM. **J Pers** 1995 Sep;63(3):397–427 (115 ref.)

INDIVIDUATION

Issues in personality as diathesis for depression: the case of sociotropy–dependency and autonomy–self–criticism. Coyne JC, et al. **Psychol Bull** 1995 Nov;118(3):358–78 (125 ref.)
[The question of cognitive activity in twins] Bak F. **Acta Genet Med Gemellol (Roma)** 1994;43(3–4):193–206 (30 ref.) **(Fre)**

INDOCYANINE GREEN

DIAGNOSTIC USE

Indocyanine green angiography. Can it help preserve the vision of our patients? [editorial; comment] Bressler NM, et al. **Arch Ophthalmol** 1996 Jun;114(6):747–9 (30 ref.) Comment on: Arch Ophthalmol 1996 Jun;114(6):693–7.
Indocyanine green angiography. Owens SL. **Br J Ophthalmol** 1996 Mar;80(3):263–6 (50 ref.)
Indocyanine green angiography. Lim JI, et al. **Int Ophthalmol Clin** 1995 Fall;35(4):59–70 (49 ref.)
[Indocyanine green (ICG)] Miyazaki A, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:1074–7 (9 ref.) **(Jpn)**

INDOLES

ADVERSE EFFECTS

[Psychotropic effects of angiotensin–converting enzyme inhibitors: what are the arguments?] Mesure G, et al. **Encephale** 1995 Sep–Oct;21(5):609–14 (59 ref.) (Eng. Abstr.) **(Fre)**

CHEMISTRY

DAPI: a DNA–specific fluorescent probe. Kapuscinski J. **Biotech Histochem** 1995 Sep;70(5):220–33 (184 ref.)

PHARMACOKINETICS

The pharmacokinetics of tenidap sodium: introduction. Pullar T. **Br J Clin Pharmacol** 1995;39 Suppl 1:1S–2S (0 ref.)
Development and pharmacology of fluvastatin. Jokubaitis LA. **Br J Clin Pract Symp Suppl** 1996 Jan;77A:11–5 (4 ref.)

PHARMACOLOGY

Delavirdine mesylate, a potent non–nucleoside HIV–1 reverse transcriptase inhibitor. Freimuth WW. **Adv Exp Med Biol** 1996;394:279–89 (42 ref.)
Vascular affinity of trandolapril. Miyazaki M, et al. **Am J Hypertens** 1995 Oct;8(10 Pt 2):63S–67S (21 ref.)
Light scattering of human skin: a comparison between zinc (II)–phthalocyanine and photofrin II. Ochsner M. **J Photochem Photobiol B** 1996 Jan;32(1–2):3–9 (23 ref.)
Modulation of pulsatile GH release through a novel receptor in hypothalamus and pituitary gland. Smith RG, et al. **Recent Prog Horm Res** 1996;51:261–85; discussion 285–6 (59 ref.)
[The pharmacology of the statins: the evidence of a direct antiatherosclerotic action] Raiteri M, et al. **Ann Ital Med Int** 1995 Oct;10 Suppl:35S–42S (74 ref.) (Eng. Abstr.) **(Ita)**
[Discovery and pharmacological properties of selective neurokinin–receptor antagonists, FK224 and FK888] Fujii T. **Nippon Yakurigaku Zasshi** 1995 Sep;106(3):193–204 (34 ref.) (Eng. Abstr.) **(Jpn)**

THERAPEUTIC USE

Trandolapril: a clinical profile. de Leeuw PW. **Am J Hypertens** 1995 Oct;8(10 Pt 2):68S–70S (17 ref.)
Indole–3–carbinol. A novel approach to breast cancer prevention. Bradlow HL, et al. **Ann N Y Acad Sci** 1995 Sep 30;768:180–200 (22 ref.)
Tenidap: not just another NSAID? Canvin JM, et al. **Ann Rheum Dis** 1996 Feb;55(2):79–82 (29 ref.)
Assessing the comparative clinical value of tropisetron. Olver IN. **Aust N Z J Med** 1995 Oct;25(5):523–7 (31 ref.)
Fluvastatin for the prevention of restenosis after coronary balloon angioplasty: angiographic and methodological background of the fluvastatin angioplasty restenosis trial. Foley DP, et al. **Br J Clin Pract Symp Suppl** 1996 Jan; 77A:40–53 (53 ref.)
Fluvastatin in combination with other lipid–lowering agents. Jokubaitis LA. **Br J Clin Pract Symp Suppl** 1996 Jan; 77A:28–32 (4 ref.)
Treatment of dyslipidaemias with fluvastatin. Peters TK. **Br J Clin Pract Symp Suppl** 1996 Jan;77A:16–9 (7 ref.)
Ropinirole in the symptomatic treatment of Parkinson's disease. Brooks DJ, et al. **J Neural Transm Suppl** 1995; 45:231–8 (15 ref.)
[An update on the use of fluvastatin in primary hypercholesterolemia] Baggio G. **Ann Ital Med Int** 1995 Oct;10 Suppl:43S (5 ref.) **(Ita)**
[The use of perindopril (prestarium) in arterial hypertension] Filatova NP. **Ter Arkh** 1995;67(9):81–3 (35 ref.) **(Rus)**

INDOMETHACIN

ADVERSE EFFECTS

Indomethacin hastens large joint osteoarthritis in humans—how strong is the evidence? [editorial] Doherty M, et al. **J Rheumatol** 1995 Nov;22(11):2013–6 (32 ref.)

PHARMACOLOGY

Indomethacin inhibits cell proliferation and increases cell losses in rat gastrointestinal epithelium. Uribe A, et al. **Dig Dis Sci** 1995 Nov;40(11):2490–4 (25 ref.)

THERAPEUTIC USE

Prophylactic indomethacin: systematic review and meta–analysis. Fowlie PW. **Arch Dis Child Fetal Neonatal Ed** 1996 Mar;74(2):F81–7 (35 ref.)
Indomethacin. Gordon MC, et al. **Clin Obstet Gynecol** 1995 Dec;38(4):697–705 (23 ref.)

TOXICITY

The developmental toxicity of indomethacin and sulindac. Lione A, et al. **Reprod Toxicol** 1995 Jan–Feb;9(1):7–20 (111 ref.)

INDOOR AIR POLLUTION see **AIR POLLUTION, INDOOR**

INDOOR AIR QUALITY see **AIR POLLUTION, INDOOR**

INDUCER CELLS see **T–LYMPHOCYTES, HELPER–INDUCER**

INDUSTRIAL ARTS see **TECHNOLOGY**

INDUSTRIAL HEALTH see **OCCUPATIONAL HEALTH**

INDUSTRIAL HYGIENE see **OCCUPATIONAL HEALTH**

INDUSTRIAL MEDICINE see **OCCUPATIONAL MEDICINE**

INDUSTRIAL MICROBIOLOGY

see related
GENETIC ENGINEERING

Molecular and industrial aspects of glucose isomerase. Bhosale SH, et al. **Microbiol Rev** 1996 Jun;60(2):280–300 (188 ref.)
Review: methylotrophic yeasts as factories for the production of foreign proteins. Faber KN, et al. **Yeast** 1995 Nov; 11(14):1331–44 (111 ref.)

METHODS

Biotechnological potentials of anoxygenic phototrophic bacteria. II. Biopolyesters, biopesticide, biofuel, and biofertilizer. Sasikala C, et al. **Adv Appl Microbiol** 1995; 41:227–78 (327 ref.)
Biotechnological potentials of anoxygenic phototrophic bacteria. I. Production of single–cell protein, vitamins, ubiquinones, hormones, and enzymes and use in waste treatment. Sasikala C, et al. **Adv Appl Microbiol** 1995; 41:173–226 (311 ref.)
Improving productivity of heterologous proteins in recombinant Saccharomyces cerevisiae fermentations. Vasavada A. **Adv Appl Microbiol** 1995;41:25–54 (182 ref.)

INDUSTRIALIZED COUNTRIES see **DEVELOPED COUNTRIES**

INDUSTRY

see related
COMMERCE
OCCUPATIONAL DISEASES
OCCUPATIONAL MEDICINE
WORKPLACE

Tobacco industry tactics. Sweda EL Jr, et al. **Br Med Bull** 1996 Jan;52(1):183–92 (23 ref.)
Report of the National Eye Institute/Industry workshop on Clinical Trials in Dry Eyes. Lemp MA. **CLAO J** 1995 Oct; 21(4):221–32 (106 ref.)
Clinical–epidemiologic study of alopecia areata. Roselino AM, et al. **Int J Dermatol** 1996 Mar;35(3):181–4 (8 ref.)
Skin hazards of the marine aquarium industry. Tong DW. **Int J Dermatol** 1996 Mar;35(3):153–8 (43 ref.)
Well–healed: inside lobbying for health care reform, Part II. Center for Public Integrity. **Int J Health Serv** 1995; 25(4):593–632 (76 ref.)
The role of UK tobacco advertising: no effect on the nation's health? Kinman BF, et al. **J R Soc Health** 1995 Oct; 115(5):296–302 (27 ref.)
[The effect of economic activities altering water resources on the parasitological situation] Artamoshin AS, et al. **Med Parazitol (Mosk)** 1995 Apr–Jun;(2):51–7 (50 ref.) (Eng. Abstr.) **(Rus)**

HISTORY

Forty years on: a war to recognise and win. How the tobacco industry has survived the revelations on smoking and health. Pollock D. **Br Med Bull** 1996 Jan;52(1):174–82 (25 ref.)

TRENDS

Health and development in the Hudson Bay/James Bay region. Stieb D, et al. **Arctic Med Res** 1995 Oct; 54(4):170–83 (101 ref.)
Time trends in schizophrenia: changes in obstetric risk factors with industrialization. Warner R. **Schizophr Bull** 1995; 21(3):483–500 (160 ref.)

INFANT CARE

see related
CHILD CARE
INTENSIVE CARE, NEONATAL

Management issues for the neonatal patient. Bowen FW. **Clin Perinatol** 1996 Mar;23(1):1–30 (161 ref.)
Intrapartum management of multiple gestations. Houlihan C, et al. **Clin Perinatol** 1996 Mar;23(1):91–116 (92 ref.)
Critical management of the very low birth weight infant and macrosomic fetus. Mastrogiannis DS, et al. **Clin Perinatol** 1996 Mar;23(1):51–89 (158 ref.)
The impact of early obstetric discharge on newborn health care. Lee KS, et al. **Curr Opin Pediatr** 1996 Apr;8(2):96–101 (42 ref.)

METHODS

Preventive interventions with low birth weight premature infants: an evaluation of their success. McCarton CM, et al. **Semin Perinatol** 1995 Aug;19(4):330–40 (62 ref.)

INFANT DEVELOPMENT see **CHILD DEVELOPMENT**

INFANT FOOD

Recombinant human milk proteins – an opportunity and a challenge. Lönnerdal B. **Am J Clin Nutr** 1996 Apr; 63(4):622S–6S (63 ref.)
The relationship between cow's milk exposure and type 1 diabetes. Gerstein HC, et al. **Diabet Med** 1996 Jan; 13(1):23–9 (89 ref.)
Energy requirements of infants. Butte NF. **Eur J Clin Nutr** 1996 Feb;50 Suppl 1:S24–36 (54 ref.)
The effect of hypo–allergenic formulas in infants at risk of allergic disease. Halken S, et al. **Eur J Clin Nutr** 1995 Sep; 49 Suppl 1:S77–83 (35 ref.)
Product development horizons—a view from industry. Hudson MJ. **Eur J Clin Nutr** 1995 Sep;49 Suppl 1:S64–70 (9 ref.)
The treatment of cow's milk allergy. Isolauri E. **Eur J Clin Nutr** 1995 Sep;49 Suppl 1:S49–55 (26 ref.)
Dietary fat content and energy density during infancy and childhood; the effect on energy intake and growth. Michaelsen KF, et al. **Eur J Clin Nutr** 1995 Jul;49(7):467–83 (75 ref.)
The use of hydrolysates in allergy prevention programmes. Vandenplas Y. **Eur J Clin Nutr** 1995 Sep;49 Suppl 1:S84–91 (52 ref.)
Neonatal nutritional requirements and formula composition: a review. Darby MK, et al. **J Obstet Gynecol Neonatal Nurs** 1996 Mar–Apr; 25(3):209–17 (49 ref.)
Early infant diets and insulin–dependent diabetes. Ellis TM, et al. **Lancet** 1996 May 25;347(9013):1464–5 (20 ref.)
[Interactions between drugs and food in pediatric age] Paci A, et al. **Pediatr Med Chir** 1996 Jan–Feb;18(1):47–52 (25 ref.) (Eng. Abstr.) **(Ita)**
[Infant formula follow–up: an update] Szajewska H, et al. **Pediatr Pol** 1995 Apr;70(4):291–301 (41 ref.) (Eng. Abstr.) **(Pol)**
[Nutrition of premature infants: current concepts, problems and prospects (literature review)] Netrebenko OK. **Vopr Pitan** 1995;(2):43–6 (35 ref.) **(Rus)**
[Many premature infants do not receive optimal nutrition. Importance of improving the feeding system!] Polberger S, et al. **Lakartidningen** 1996 Jun 19;93(25):2413–8 (62 ref.) **(Swe)**

ANALYSIS

Which formula in cow's milk protein intolerance? The dietitian's dilemma. MacDonald A. **Eur J Clin Nutr** 1995 Sep;49 Suppl 1:S56–63 (66 ref.)

STANDARDS

Infant formula, past and future: opportunities for improvement. Lo CW, et al. **Am J Clin Nutr** 1996 Apr;

INFANT FOOD

63(4):646S–50S (45 ref.)

INFANT HEALTH see INFANT WELFARE

INFANT HEALTH SERVICES see CHILD HEALTH SERVICES

INFANT, LOW BIRTH WEIGHT

Trend of birthweights of African newborns: an overview. Airede AK. **East Afr Med J** 1996 Apr;73(4):271–5 (48 ref.)
Psychiatric sequelae of low birth weight. Breslau N. **Epidemiol Rev** 1995;17(1):96–106 (70 ref.)
Bridging the gap between hospital and home for premature infants in Malawi. Mbweza E. **Int Nurs Rev** 1996 Mar–Apr; 43(2):53–7 (19 ref.)
Fetal influences on adult hypertension. Law C. **J Hum Hypertens** 1995 Aug;9(8):649–51 (30 ref.)
Social causes of low birth weight. Kogan MD. **J R Soc Med** 1995 Nov;88(11):611–5 (78 ref.)
Family response to the low birth weight infant. Gennaro S. **Nurs Clin North Am** 1996 Jun;31(2):341–50 (34 ref.)
State of the science. Breastfeeding for mothers and low birth weight infants. Meier PP, et al. **Nurs Clin North Am** 1996 Jun;31(2):351–65 (69 ref.)
Is low birth weight a risk factor for adult hypertension? A literature review with particular reference to Africa. Woelk GB. **S Afr Med J** 1995 Dec;85(12 Pt 2):1348–9, 1352–3 (53 ref.)
Cocaine using during pregnancy and low birth weight: the impact of prenatal care and drug treatment. Chazotte C, et al. **Semin Perinatol** 1995 Aug;19(4):293–300 (40 ref.)
Preventive interventions with low birth weight premature infants: an evaluation of their success. McCarton CM, et al. **Semin Perinatol** 1995 Aug;19(4):330–40 (62 ref.)
[Characteristics of delivery of the small premature infant] Schneider H, et al. **Arch Gynecol Obstet** 1995; 257(1–4):462–71 (51 ref.) **(Ger)**
[The "kangaroo mother" method (editorial)] Mosseri R, et al. **Harefuah** 1996 Jan 15;130(2):95–7 (15 ref.) **(Heb)**
[Hypertrophic cardiomyopathy in a low-birth-weight newborn treated with dexamethasone] Villa Alcázar M, et al. **An Esp Pediatr** 1996 Apr;44(4):393–4 (20 ref.) **(Spa)**

INFANT MORTALITY

see related
FETAL DEATH

Framing the debate: can prenatal care help to reduce the black-white disparity in infant mortality? Rowley DL. **J Am Med Wom Assoc** 1995 Sep–Oct;50(5):187–93 (119 ref.)
Separate black and white infant mortality models: differences in the importance of structural variables. Bird ST. **Soc Sci Med** 1995 Dec;41(11):1507–12 (37 ref.)
[Long-term results following premature birth] Eggermont E. **Verh K Acad Geneeskd Belg** 1996;58(2):141–54; discussion 154–6 (29 ref.) (Eng. Abstr.) **(Dut)**

TRENDS

Changing patterns in pediatric mortality, Maputo Central Hospital, Mozambique, 1980–1990. Julien M, et al. **J Trop Pediatr** 1995 Dec;41(6):366–8 (7 ref.)
Prevention of traumatic deaths to children in the United States: how far have we come and where do we need to go? Rivara FP, et al. **Pediatrics** 1996 Jun;97(6 Pt 1):791–7 (58 ref.)

INFANT, NEWBORN

see related
ANIMALS, NEWBORN

Minimizing donor blood exposure in the neonatal intensive care unit. Current trends and future prospects. Bifano EM, et al. **Clin Perinatol** 1995 Sep;22(3):657–69 (64 ref.)
Management issues for the neonatal patient. Bowen FW. **Clin Perinatol** 1996 Mar;23(1):1–30 (161 ref.)
Red blood cell transfusion practices in the neonate. Strauss RG. **Clin Perinatol** 1995 Sep;22(3):641–55 (48 ref.)
The impact of early obstetric discharge on newborn health care. Lee KS, et al. **Curr Opin Pediatr** 1996 Apr;8(2):96–101 (42 ref.)
Management of painful procedures in the newborn. Stevens B. **Curr Opin Pediatr** 1996 Apr;8(2):102–7 (55 ref.)
The fetal and infant origins of disease. Barker DJ. **Eur J Clin Invest** 1995 Jul;25(7):457–63 (51 ref.)
Ruptured aneurysm of the distal posterior inferior cerebellar artery in a neonate—case report. Hosotani K, et al. **Neurol Med Chir (Tokyo)** 1995 Dec;35(12):892–5 (11 ref.)
The infant of the diabetic mother. Tyrala EE. **Obstet Gynecol Clin North Am** 1996 Mar;23(1):221–41 (89 ref.)
Assessment of large and small for gestational age newborn infants using growth curves. Georgieff MK. **Pediatr Ann** 1995 Nov;24(11):599–607 (23 ref.)
Neonatal enteral and parenteral nutrition. Pittard WB 3rd, et al. **Pediatr Ann** 1995 Nov;24(11):592–8 (62 ref.)
Thrombocytopenia in the neonate. Homans A. **Pediatr Clin North Am** 1996 Jun;43(3):737–56 (77 ref.)
Problems associated with early discharge of newborn infants. Early discharge of newborns and mothers: a critical review of the literature. Braveman P, et al. **Pediatrics** 1995 Oct; 96(4 Pt 1):716–26 (74 ref.)
[Intraventricular hemorrhage in a newborn] Koenigsberger MR, et al. **Rev Neurol** 1995;23 Suppl 3:S285–8 (59 ref.) **(Spa)**
[Infantile epilepsy and sleep] Prats Viñas JM. **Rev Neurol** 1995 Nov–Dec;23(124):1284–6 (32 ref.) **(Spa)**

BLOOD

From oxygen content to pulse oximetry: completing the picture in the newborn. Whyte RK, et al. **Acta Anaesthesiol Scand Suppl** 1995;107:95–100 (28 ref.)

GROWTH & DEVELOPMENT

Postnatal maturation of immune competence during infancy and childhood. Holt PG. **Pediatr Allergy Immunol** 1995 May;6(2):59–70 (148 ref.)

IMMUNOLOGY

Modulation of B-cell immunoglobulin synthesis by retinoic acid. Ballow M, et al. **Clin Immunol Immunopathol** 1996 Sep;80(3 Pt 2):S73–81 (37 ref.)
Neonatal gastrointestinal mucosal immunity. Mannick E, et al. **Clin Perinatol** 1996 Jun;23(2):287–304 (111 ref.)
Physiology of the neonatal immune system. Crockett M. **J Obstet Gynecol Neonatal Nurs** 1995 Sep;24(7):627–34 (16 ref.)
Postnatal maturation of immune competence during infancy and childhood. Holt PG. **Pediatr Allergy Immunol** 1995 May;6(2):59–70 (148 ref.)
[Immunological restructuring in the newborn infant (editorial)] Elorza Arizmendi JF. **An Esp Pediatr** 1996 Jun; 44(6):529–30 (26 ref.) **(Spa)**

METABOLISM

Effect of dietary docosahexaenoic acid on brain composition and neural function in term infants. Gibson RA, et al. **Lipids** 1996 Mar;31 Suppl:S177–81 (28 ref.)
Observations on vitamin K deficiency in the fetus and newborn: has nature made a mistake? Israels LG, et al. **Semin Thromb Hemost** 1995;21(4):357–63 (36 ref.)

PHYSIOLOGY

Cerebral blood flow in the newborn infant. Pryds O, et al. **Arch Dis Child Fetal Neonatal Ed** 1996 Jan;74(1):F63–9 (57 ref.)
The function of fetal/neonatal rapid eye movement sleep. Mirmiran M. **Behav Brain Res** 1995 Jul–Aug;69(1–2):13–22 (64 ref.)
Physiological studies of gastro-oesophageal reflux and airway protective responses in the young animal and human infant. Jeffery HE, et al. **Clin Exp Pharmacol Physiol** 1995 Aug;22(8):544–9 (51 ref.)
Gastrointestinal motility in the neonate. Berseth CL. **Clin Perinatol** 1996 Jun;23(2):179–90 (38 ref.)
Digestion in the newborn. Hamosh M. **Clin Perinatol** 1996 Jun;23(2):191–209 (114 ref.)
Digestion, absorption, and fermentation of carbohydrates in the newborn. Kien CL. **Clin Perinatol** 1996 Jun; 23(2):211–28 (143 ref.)
Oral motor function in the neonate. Lau C, et al. **Clin Perinatol** 1996 Jun;23(2):161–78 (65 ref.)
Anaesthesia for caesarean section (epidural and general): effects on the neonate. Dick WF. **Eur J Obstet Gynecol Reprod Biol** 1995 May;59 Suppl:S61–7 (42 ref.)
Influence of epidural analgesia on fetal and neonatal well-being. Scherer R, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 May;59 Suppl:S17–29 (118 ref.)
Neonatal sucking behaviors. Medoff-Cooper B, et al. **Image J Nurs Sch** 1995 Fall;27(3):195–200 (60 ref.)
Issues of assessment of pain and discomfort in neonates. Stevens BJ, et al. **J Obstet Gynecol Neonatal Nurs** 1995 Nov–Dec;24(9):849–55 (53 ref.)
Does thermoregulatory feeding occur in newborn infants? A novel view of the role of brown adipose tissue thermogenesis in control of food intake. Himms-Hagen J. **Obes Res** 1995 Jul;3(4):361–9 (54 ref.)
Somatostatin levels during infancy, pregnancy, and lactation: a review. Goldstein A, et al. **Peptides** 1995;16(7):1321–6 (63 ref.)
[The role of erythropoietin in erythropoiesis regulation in fetuses and newborn infants] Ulman I. **Ginekol Pol** 1996 Apr;67(4):205–9 (29 ref.) (Eng. Abstr.) **(Pol)**

INFANT, NEWBORN, DISEASES

Neonatal infections. Greenough A. **Curr Opin Pediatr** 1996 Feb;8(1):6–10 (45 ref.)
Childhood systemic lupus erythematosus, vasculitis, and rheumatic fever and neonatal lupus. Pelkonen P. **Curr Opin Rheumatol** 1995 Sep;7(5):430–6 (62 ref.)

DRUG THERAPY

[Diuretics in the neonatal period] Guignard JP, et al. **Rev Med Suisse Romande** 1995 Aug;115(8):583–90 (89 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

The role of active Na+ transport by lung epithelium in the clearance of airspace fluid. O'Brodovich HM. **New Horiz** 1995 May;3(2):240–7 (55 ref.)

NURSING

Care of the at-risk neonate born at home. A model for nurse-midwife/physician collaboration. Sullivan NH, et al. **J Nurse Midwifery** 1995 Nov–Dec;40(6):534–40 (16 ref.)

PATHOLOGY

[Retrospect and prospect of pediatric pathology in China] Zheng G. **Chung Hua Ping Li Hsueh Tsa Chih** 1995 Aug; 24(4):232–4 (19 ref.) **(Chi)**

PREVENTION & CONTROL

The immunologic significance of breast milk. Orlando S. **J Obstet Gynecol Neonatal Nurs** 1995 Sep;24(7):678–83 (30 ref.)
[Immunization in preterm and term infants] Bernatowska-Matuszkiewicz E, et al. **Pediatr Pol** 1995 Sep; 70(9):759–63 (20 ref.) (Eng. Abstr.) **(Pol)**

THERAPY

Platelet transfusion therapy in newborn infants. Blanchette VS, et al. **Transfus Med Rev** 1995 Jul;9(3):215–30 (82 ref.)
Massive transfusion in the neonate. Luban NL. **Transfus Med Rev** 1995 Jul;9(3):200–14 (59 ref.)

INFANT, NEWBORN, INTENSIVE CARE see INTENSIVE CARE, NEONATAL

INFANT, NEWBORN, SCREENING see NEONATAL SCREENING

INFANT NUTRITION

see related
CHILD NUTRITION
MILK
MILK, HUMAN

Practical nutrition for the healthy term infant. Spencer JP. **Am Fam Physician** 1996 Jul;54(1):138–44 (29 ref.)
Anticipating public reaction to the use of genetic engineering in infant nutrition. Hoban TJ 4th. **Am J Clin Nutr** 1996 Apr;63(4):657S–62S (8 ref.)
Infant formula, past and future: opportunities for improvement. Lo CW, et al. **Am J Clin Nutr** 1996 Apr; 63(4):646S–50S (45 ref.)
Nutritional aspects of metabolic bone disease in the newborn. Ryan S. **Arch Dis Child Fetal Neonatal Ed** 1996 Mar; 74(2):F145–8 (43 ref.)
Infant nutrition. Part 2: Weaning–1 year. Lambert EJ, et al. **Br J Hosp Med** 1995 Oct 4–17;54(7):327–30 (5 ref.)
Nutrition of the preterm baby. Wilson DC. **Br J Obstet Gynaecol** 1995 Nov;102(11):854–60 (74 ref.)
Breast-milk vitamin A as an indicator of the vitamin A status of women and infants. Stoltzfus RJ, et al. **Bull World Health Organ** 1995;73(5):703–11 (44 ref.)
Neonatal nutritional requirements and formula composition: a review. Darby MK, et al. **J Obstet Gynecol Neonatal Nurs** 1996 Mar–Apr; 25(3):209–17 (49 ref.)
Calcium and phosphorus nutrition in infants. Demarini S, et al. **J Pediatr Gastroenterol Nutr** 1995 Nov;21(4):367–73 (85 ref.)
Early nutrition and later physical work capacity. Haas JD, et al. **Nutr Rev** 1996 Feb;54(2 Pt 2):S41–8 (22 ref.)
Early determinants of adult metabolic regulation: effects of infant nutrition on adult lipid and lipoprotein metabolism. McGill HC Jr, et al. **Nutr Rev** 1996 Feb;54(2 Pt 2):S31–40 (52 ref.)
Neonatal enteral and parenteral nutrition. Pittard WB 3rd, et al. **Pediatr Ann** 1995 Nov;24(11):592–8 (62 ref.)
[Nutrition in the neonatal period] Lapillonne A, et al. **Arch Pediatr** 1996;3 Suppl 1:189s–190s (8 ref.) **(Fre)**
[Nutrition of premature infants: current concepts, problems and prospects (literature review)] Netrebenko OK. **Vopr Pitan** 1995;(2):43–6 (35 ref.) **(Rus)**
[Many premature infants do not receive optimal nutrition. Importance of improving the feeding system!] Polberger S, et al. **Lakartidningen** 1996 Jun 19;93(25):2413–8 (62 ref.) **(Swe)**

PHYSIOLOGY

Calcium, magnesium and phosphorus in the nutrition of the newborn. Venkataraman PS, et al. **J Am Coll Nutr** 1995 Oct;14(5):439–47 (102 ref.)

INFANT NUTRITION DISORDERS

see related
CHILD NUTRITION DISORDERS

COMPLICATIONS

Nutritional anemias in infancy. Gallagher PG, et al. **Clin Perinatol** 1995 Sep;22(3):671–92 (127 ref.)

ETIOLOGY

Zinc deficiency [editorial] Bhaskaram P. **Indian Pediatr** 1995 Nov;32(11):1153–6 (15 ref.)

INFANT, POSTMATURE

The foetal pituitary, postmaturity and breech presentation [comment] de Zegher F, et al. **Acta Paediatr** 1995 Oct; 84(10):1100–2 (32 ref.) Comment on: Acta Paediatr 1995 Oct;84(10):1201–3.

INFANT, PREMATURE

Antioxidants in neonatal lung disease. Fardy CH, et al. **Arch Dis Child Fetal Neonatal Ed** 1995 Sep;73(2):F112–7 (66 ref.)

Perinatal management at the lower margin of viability. Rennie JM. **Arch Dis Child Fetal Neonatal Ed** 1996 May; 74(3):F214–8 (36 ref.)

The role of urogenital tract infections in the etiology of preterm birth: a review. Martius J, et al. **Arch Gynecol Obstet** 1996;258(1):1–19 (166 ref.)

The extremely preterm infant. Rutter N. **Br J Obstet Gynaecol** 1995 Sep;102(9):682–7 (22 ref.)

Nutrition of the preterm baby. Wilson DC. **Br J Obstet Gynaecol** 1995 Nov;102(11):854–60 (74 ref.)

Nutritional management and the multisystem organ failure/systemic inflammatory response syndrome in critically ill preterm neonates. Adan D, et al. **Crit Care Clin** 1995 Jul;11(3):751–84 (162 ref.)

Prevention of intraventricular hemorrhage in preterm infants. Wells JT, et al. **Early Hum Dev** 1995 Aug 18;42(3):209–33 (179 ref.)

Delayed interval delivery after intrauterine infection and immature birth of twin 1—a case report and literature review. de Jong MW, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Nov;63(1):91–4 (29 ref.)

Bridging the gap between hospital and home for premature infants in Malawi. Mbweza E. **Int Nurs Rev** 1996 Mar–Apr; 43(2):53–7 (19 ref.)

Transition to breast/bottle feedings: the premature infant. Lemons PK, et al. **J Am Coll Nutr** 1996 Apr;15(2):126–35 (34 ref.)

Fraser syndrome (cryptophthalmos [hidden eye]–syndactyly syndrome). Sarman G, et al. **J Perinatol** 1995 Nov–Dec; 15(6):503–6 (12 ref.)

Implementing a research–based kangaroo care program in the NICU. Bell RP, et al. **Nurs Clin North Am** 1996 Jun; 31(2):387–403 (22 ref.)

Respiratory distress syndrome for the practicing pediatrician. Haas M, et al. **Pediatr Ann** 1995 Nov;24(11):572–6, 579–80 (21 ref.)

Preterm birth in the African–American community. Hogue CJ, et al. **Semin Perinatol** 1995 Aug;19(4):255–62 (70 ref.)

Preventive interventions with low birth weight premature infants: an evaluation of their success. McCarton CM, et al. **Semin Perinatol** 1995 Aug;19(4):330–40 (62 ref.)

[Long–term results following premature birth] Eggermont E. **Verh K Acad Geneeskd Belg** 1996;58(2):141–54; discussion 154–6 (29 ref.) (Eng. Abstr.) **(Dut)**

[The "kangaroo mother" method (editorial)] Mosseri R, et al. **Harefuah** 1996 Jan 15;130(2):95–7 (15 ref.) **(Heb)**

[Nutrition of premature infants: current concepts, problems and prospects (literature review)] Netrebenko OK. **Vopr Pitan** 1995;(2):43–6 (35 ref.) **(Rus)**

[Many premature infants do not receive optimal nutrition. Importance of improving the feeding system!] Polberger S, et al. **Lakartidningen** 1996 Jun 19;93(25):2413–8 (62 ref.) **(Swe)**

IMMUNOLOGY

What is the role of preterm breast milk supplementation in the host defenses of preterm infants? Science vs. fiction. Groër M, et al. **Adv Pediatr** 1996;43:335–58 (99 ref.)

Modulation of B–cell immunoglobulin synthesis by retinoic acid. Ballow M, et al. **Clin Immunol Immunopathol** 1996 Sep;80(3 Pt 2):S73–81 (37 ref.)

PHYSIOLOGY

Use of evoked potentials in preterm neonates. Taylor MJ, et al. **Arch Dis Child Fetal Neonatal Ed** 1996 Jan; 74(1):F70–6 (74 ref.)

Delivery of the premature infant. Bottoms S. **Clin Obstet Gynecol** 1995 Dec;38(4):780–9 (26 ref.)

Nutrient absorption in the preterm neonate. Neu J, et al. **Clin Perinatol** 1996 Jun;23(2):229–43 (54 ref.)

A physiologic method for monitoring premature infants. Ludington–Hoe S, et al. **J Nurs Meas** 1995 Summer; 3(1):13–29 (16 ref.)

Special needs of preterm infants in the management of pain and discomfort. Stevens BJ, et al. **J Obstet Gynecol Neonatal Nurs** 1995 Nov–Dec; 24(9):856–62 (65 ref.)

Human milk and premature infants. Martinez FE, et al. **World Rev Nutr Diet** 1995;78:55–73 (93 ref.)

INFANT, PREMATURE, DISEASES

Necrotizing enterocolitis. Albanese CT, et al. **Semin Pediatr Surg** 1995 Nov;4(4):200–6 (62 ref.)

DIAGNOSIS

Gastroesophageal reflux in the preterm infant. Novak DA. **Clin Perinatol** 1996 Jun;23(2):305–20 (131 ref.)

[Procedures for Candida albicans systemic infections in premature infants] Lauterbach R. **Ginekol Pol** 1995 May; 66(5):289–93 (13 ref.) (Eng. Abstr.) **(Pol)**

ETIOLOGY

Nutritional aspects of metabolic bone disease in the newborn. Ryan S. **Arch Dis Child Fetal Neonatal Ed** 1996 Mar; 74(2):F145–8 (43 ref.)

–Neonatal asphyxia as the cause of brain damage in children?– Schneider H. **Arch Gynecol Obstet** 1995;256 Suppl:S32–42 (75 ref.) (Eng. Abstr.) **(Ger)**

GENETICS

Partial deletion of chromosome 6p: autopsy findings in a premature infant and review of the literature. Alashari M, et al. **Pediatr Pathol Lab Med** 1995 Nov–Dec;15(6):941–7 (20 ref.)

MICROBIOLOGY

Necrotizing enterocolitis: the search for a unifying pathogenic theory leading to prevention. Neu J. **Pediatr Clin North Am** 1996 Apr;43(2):409–32 (132 ref.)

Burkholderia cepacia sepsis in neonates. Kahyaoglu O, et al. **Pediatr Infect Dis J** 1995 Sep;14(9):815–6 (9 ref.)

PHYSIOPATHOLOGY

Near infrared spectroscopy: methodological principles and clinical application in preterm infants. Bernert G, et al. **Wien Klin Wochenschr** 1995;107(19):569–73 (36 ref.)

[Current aspects of premature labor] Briese V. **Zentralbl Gynakol** 1995;117(8):393–401 (47 ref.) (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

Necrotizing enterocolitis: the search for a unifying pathogenic theory leading to prevention. Neu J. **Pediatr Clin North Am** 1996 Apr;43(2):409–32 (132 ref.)

Preventive interventions with low birth weight premature infants: an evaluation of their success. McCarton CM, et al. **Semin Perinatol** 1995 Aug;19(4):330–40 (62 ref.)

[Characteristics of delivery of the small premature infant] Schneider H, et al. **Arch Gynecol Obstet** 1995; 257(1–4):462–71 (51 ref.) **(Ger)**

THERAPY

Cecal perforation associated with sodium polystyrene sulfonate–sorbitol enemas in a 650 gram infant with hyperkalemia. Bennett LN, et al. **Am J Perinatol** 1996 Apr; 13(3):167–70 (12 ref.)

Recombinant human erythropoietin in neonatal anemia. Shannon K. **Clin Perinatol** 1995 Sep;22(3):627–40 (26 ref.)

Neonatal ECMO: are indications changing? Short BL. **Int J Artif Organs** 1995 Oct;18(10):562–4 (20 ref.)

Respiratory distress syndrome for the practicing pediatrician. Haas M, et al. **Pediatr Ann** 1995 Nov;24(11):572–6, 579–80 (21 ref.)

Peritoneal dialysis prescription for neonates. Fischbach M. **Perit Dial Int** 1996;16 Suppl 1:S512–4 (23 ref.)

Small volume red blood cell transfusions for neonatal patients. Hume H, et al. **Transfus Med Rev** 1995 Jul; 9(3):187–99 (65 ref.)

[The treatment of a bronchopleural fistula with fibrin adhesive in a premature infant] Galiana Ferré C, et al. **An Esp Pediatr** 1996 Jun;44(6):596–8 (11 ref.) **(Spa)**

INFANT PSYCHOLOGY see CHILD PSYCHOLOGY

INFANT, SMALL FOR GESTATIONAL AGE

Transient and permanent neonatal diabetes. Fösel S. **Eur J Pediatr** 1995 Dec;154(12):944–8 (105 ref.)

Assessment of large and small for gestational age newborn infants using growth curves. Georgieff MK. **Pediatr Ann** 1995 Nov;24(11):599–607 (23 ref.)

INFANT, VERY LOW BIRTH WEIGHT

Managing acute renal failure in very low birthweight infants. Coulthard MG, et al. **Arch Dis Child Fetal Neonatal Ed** 1995 Nov;73(3):F187–92 (53 ref.)

Critical management of the very low birth weight infant and macrosomic fetus. Mastrogiannis DS, et al. **Clin Perinatol** 1996 Mar;23(1):51–89 (158 ref.)

Nutritional management and the multisystem organ failure/systemic inflammatory response syndrome in critically ill preterm neonates. Adan D, et al. **Crit Care Clin** 1995 Jul;11(3):751–84 (162 ref.)

PHYSIOLOGY

Use of cordocentesis in the management of preterm or growth–restricted fetuses with abnormal monitoring. Shalev E, et al. **Obstet Gynecol Surv** 1995 Dec; 50(12):839–44 (55 ref.)

INFANT WELFARE

Infant nutrition. Part 2: Weaning–1 year. Lambert EJ, et al. **Br J Hosp Med** 1995 Oct 4–17;54(7):327–30 (5 ref.)

The relationship between breast–feeding and infant health and development. Forsyth JS. **Proc Nutr Soc** 1995 Jul; 54(2):407–18 (45 ref.)

INFANTICIDE

Neonaticide, infanticide, and filicide: a review of the literature. Pitt SE, et al. **Bull Am Acad Psychiatry Law** 1995;23(3):375–86 (51 ref.)

INFANTILE PARALYSIS see POLIOMYELITIS

INFANTILE REFSUM DISEASE see PEROXISOMAL DISORDERS

INFANTILE SPINAL MUSCULAR ATROPHY see WERDNIG–HOFFMANN DISEASE

INFANTILISM, GENITAL see HYPOGONADISM

INFANTILISM, SEXUAL see HYPOGONADISM

INFARCTION

see related
MYOCARDIAL INFARCTION
SPLENIC INFARCTION

[Liver infarction] Hasebe C, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):184–6 (14 ref.) **(Jpn)**

COMPLICATIONS

[Renal arterial disease–induced tubulo–interstitial lesions] Kida H, et al. **Nippon Rinsho** 1995 Aug;53(8):2034–9 (10 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

[Focal infarction of the testis. Report of a case simulating a gonadal mass] Pellicé C Jr, et al. **Actas Urol Esp** 1995 Oct;19(9):716–20 (23 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

Renal infarction and thrombosis of the infrarenal aorta in a 35–year–old man with primary antiphospholipid syndrome. Poux JM, et al. **Am J Kidney Dis** 1996 May; 27(5):721–5 (20 ref.)

Fibrocartilaginous embolism of the spinal cord: a clinical and pathogenetic reconsideration. Tosi L, et al. **J Neurol Neurosurg Psychiatry** 1996 Jan;60(1):55–60 (44 ref.)

INFECTION

see related
ANTI–INFECTIVE AGENTS

Changing patterns of childhood infection and the rise in allergic disease. Shaheen SO. **Clin Exp Allergy** 1995 Nov; 25(11):1034–7 (46 ref.)

Neonatal infections. Greenough A. **Curr Opin Pediatr** 1996 Feb;8(1):6–10 (45 ref.)

Nonrheumatic conditions in children including infectious diseases and syndromes. Tucker LB. **Curr Opin Rheumatol** 1995 Sep;7(5):419–24 (31 ref.)

Infections during the postpartum period. Clark RA. **J Obstet Gynecol Neonatal Nurs** 1995 Jul–Aug;24(6):542–8 (19 ref.)

Biofilm infections: implications for diagnosis and treatment. Reid G, et al. **N Z Med J** 1996 Feb 23;109(1016):41–2 (17 ref.)

Management of infection and occlusion associated with vascular access devices. Rumsey KA, et al. **Semin Oncol Nurs** 1995 Aug;11(3):174–83 (59 ref.)

COMPLICATIONS

Herman Award Lecture, 1995: infection–induced malnutrition—from cholera to cytokines. Beisel WR. **Am J Clin Nutr** 1995 Oct;62(4):813–9 (91 ref.)

The anemia of inflammation. A common cause of childhood anemia. Abshire TC. **Pediatr Clin North Am** 1996 Jun; 43(3):623–37 (72 ref.)

Metabolic and infectious disorders associated with emesis in infants. Cohen R. **Semin Pediatr Surg** 1995 Aug;4(3):136–46 (46 ref.)

Infections and the development of allergy. Holt PG. **Toxicol Lett** 1996 Aug;86(2–3):205–10 (27 ref.)

[Infectious complications of drug addiction] de Marie S. **Ned Tijdschr Geneeskd** 1995 Dec 16;139(50):2618–22 (47 ref.) **(Dut)**

[Abdominal emergencies of infectious origin] Porcel A, et al. **Ann Radiol (Paris)** 1996;39(1):15–36 (20 ref.) (Eng. Abstr.) **(Fre)**

[Systemic diseases and infections: current questions] Lortholary O, et al. **Presse Med** 1996 Mar 2–9;25(8):370–5, 377–8 (96 ref.) (Eng. Abstr.) **(Fre)**

INFECTION

CONGENITAL

A nine-month-old boy with microcephaly, cataracts, intracerebral calcifications and dysmorphic signs: an additional observation of an autosomal recessive congenital infection-like syndrome? Wieczorek D, et al. **Genet Couns** 1995;6(4):297-302 (18 ref.)

The diagnosis of congenital infections: contemporary strategies. Souza IE, et al. **J Child Neurol** 1995 Jul; 10(4):271-82 (89 ref.)

DIAGNOSIS

Diagnosis and management of renal infections. Meyrier A. **Curr Opin Nephrol Hypertens** 1996 Mar;5(2):151-7 (57 ref.)

Inflammatory and infectious processes of the cervical spine. Ruiz A, et al. **Neuroimaging Clin N Am** 1995 Aug; 5(3):401-25 (80 ref.)

Cervical spine infections. Ghanayem AJ, et al. **Orthop Clin North Am** 1996 Jan;27(1):53-67 (92 ref.)

Diagnostic imaging: its role in evaluating chest, abdominal, and musculoskeletal infections. Stern EJ, et al. **Postgrad Med** 1996 Mar;99(3):175-83 (9 ref.)

DRUG THERAPY

Pharmacological aspects and therapeutic applications of lysozymes. Sava G. **EXS** 1996;75:433-49 (79 ref.)

Molecular and cellular basis of interleukin 12 activity in prophylaxis and therapy against infectious diseases. Gazzinelli RT. **Mol Med Today** 1996 Jun;2(6):258-67 (41 ref.)

EPIDEMIOLOGY

Late infections after allogeneic bone marrow transplantations: comparison of incidence in related and unrelated donor transplant recipients. Ochs L, et al. **Blood** 1995 Nov 15; 86(10):3979-86 (35 ref.)

ETIOLOGY

ABC of work related disorders. Occupational infections. Snashall D. **BMJ** 1996 Aug 31;313(7056):551-4 (0 ref.)

Infections in liver transplant recipients. Winston DJ, et al. **Clin Infect Dis** 1995 Nov;21(5):1077-89; quiz 1090-1 (55 ref.)

The immune system in uremia and during its treatment. Haag-Weber M, et al. **New Horiz** 1995 Nov;3(4):669-79 (172 ref.)

Vascular catheter related infections in cancer patients. Farr BM. **Surg Oncol Clin N Am** 1995 Jul;4(3):493-503 (83 ref.)

Shellfish-borne illnesses. A Hong Kong perspective. Chan TY. **Trop Geogr Med** 1995;47(6):305-7 (17 ref.)

[Sense and nonsense in infection prevention following organ transplantation] Schaad HJ, et al. **Ther Umsch** 1995 Sep; 52(9):608-16 (74 ref.) (Eng. Abstr.) **(Ger)**

[Countermeasure for patients with infectious disease due to hemodialysis] Yokoyama H, et al. **Nippon Naika Gakkai Zasshi** 1995 Oct 10;84(10):1696-700 (7 ref.) **(Jpn)**

[Arachnids as risk factors in occupational exposure] Dutkiewicz J. **Wiad Parazytol** 1995;41(3):253-66 (48 ref.) (Eng. Abstr.) **(Pol)**

GENETICS

Immunogenetics in the analysis of resistance to intracellular pathogens. McLeod R, et al. **Curr Opin Immunol** 1995 Aug; 7(4):539-52 (139 ref.)

Genetics of tumour necrosis factor-alpha in autoimmune, infectious, and neoplastic diseases. Wilson AG, et al. **J Inflamm** 1995;45(1):1-12 (114 ref.)

IMMUNOLOGY

NO inhibitions: antimicrobial properties of nitric oxide. De Groote MA, et al. **Clin Infect Dis** 1995 Oct;21 Suppl 2:S162-5 (55 ref.)

Immunogenetics in the analysis of resistance to intracellular pathogens. McLeod R, et al. **Curr Opin Immunol** 1995 Aug; 7(4):539-52 (139 ref.)

Induction of Th2 responses in infectious diseases. Pearce EJ, et al. **Curr Opin Immunol** 1995 Aug;7(4):497-504 (67 ref.)

Host factors affecting disease transmission. Muzyka BC. **Dent Clin North Am** 1996 Apr;40(2):263-75 (28 ref.)

Costimulation and the regulation of antimicrobial immunity. Kaye PM. **Immunol Today** 1995 Sep;16(9):423-7 (45 ref.)

Direct antimicrobial activity of T cells. Levitz SM, et al. **Immunol Today** 1995 Aug;16(8):387-91 (36 ref.)

Structure and function of the natural-resistance-associated macrophage protein (Nramp1), a candidate protein for infectious and autoimmune disease susceptibility. Blackwell JM. **Mol Med Today** 1996 May;2(5):205-11 (38 ref.)

Influence of uraemia and haemodialysis on host defence and infection. Vanholder R, et al. **Nephrol Dial Transplant** 1996 Apr;11(4):593-8 (69 ref.)

Interactions between nutrients and the immune system. Grimble RF. **Nutr Health** 1995;10(3):191-200 (15 ref.)

Spinal infections in the immunocompromised host. Broner FA, et al. **Orthop Clin North Am** 1996 Jan;27(1):37-46 (38 ref.)

General medicine and geriatrics, where is the difference? The example of infective disease. Evans JG. **Schweiz Med Wochenschr** 1995 Oct 7;125(40):1847-54 (34 ref.)

Immunopathogenesis and spectrum of infections in systemic lupus erythematosus. Iliopoulos AG, et al. **Semin Arthritis Rheum** 1996 Apr;25(5):318-36 (186 ref.)

[Antibody avidity in immune response and in the diagnosis of infectious diseases] Seppälä I, et al. **Duodecim** 1994; 110(2):178-84 (34 ref.) **(Fin)**

[Antimicrobial activity of NK cells] Cavallo R. **G Batteriol Virol Immunol** 1992 Jan-1993 Dec; 85(1-12):35-46 (60 ref.) (Eng. Abstr.) **(Ita)**

[Lactoferrin--its role in defense against infection and immunotropic properties] Adamik B, et al. **Postepy Hig Med Dosw** 1996;50(1):33-41 (67 ref.) (Eng. Abstr.) **(Pol)**

[Structure and function of the T-lymphocyte antigen receptor and its role in infectious diseases] Peralta Zaragoza O, et al. **Rev Invest Clin** 1996 Jan-Feb;48(1):69-79 (84 ref.) (Eng. Abstr.) **(Spa)**

METABOLISM

Interaction between nutrients, pro-inflammatory cytokines and inflammation [editorial] Grimble RF. **Clin Sci (Colch)** 1996 Aug;91(2):121-30 (102 ref.)

Metabolic responses of the critically ill patient. Kinney JM. **Crit Care Clin** 1995 Jul;11(3):569-85 (66 ref.)

Induction by cytokines of the pattern of pituitary hormone secretion in infection. McCann SM, et al. **Neuroimmunomodulation** 1994 Jan;1(1):2-13 (50 ref.)

Interactions between nutrients and the immune system. Grimble RF. **Nutr Health** 1995;10(3):191-200 (15 ref.)

MICROBIOLOGY

Emerging infectious agents and the forensic pathologist: the New Mexico model [editorial] Nolte KB, et al. **Arch Pathol Lab Med** 1996 Feb;120(2):125-8 (26 ref.)

MORTALITY

Causes of death in autosomal dominant polycystic kidney disease. Fick GM, et al. **J Am Soc Nephrol** 1995 Jun; 5(12):2048-56 (81 ref.)

PATHOLOGY

The Army Medical Museum/Armed Forces Institute of Pathology and Emerging Infections: from camp fevers and diarrhea during the American Civil War in the 1860's to global molecular epidemiology and pathology in the 1990s. Nelson AM, et al. **Arch Pathol Lab Med** 1996 Feb; 120(2):129-33 (21 ref.)

Infectious disease pathology and emerging infections: are we prepared? [editorial] Schwartz DA, et al. **Arch Pathol Lab Med** 1996 Feb;120(2):117-24 (38 ref.)

PHYSIOPATHOLOGY

Interactions between cytokines and nitric oxide. Liew FY. **Adv Neuroimmunol** 1995;5(2):201-9 (49 ref.)

Sleep, microbes and cytokines. Krueger JM, et al. **Neuroimmunomodulation** 1994 Mar-Apr;1(2):100-9 (121 ref.)

Nutritional status in the patient with spinal infection. Klein JD, et al. **Orthop Clin North Am** 1996 Jan;27(1):33-6 (30 ref.)

RADIONUCLIDE IMAGING

The contribution of nuclear medicine to the patient with infection. Becker W. **Eur J Nucl Med** 1995 Oct; 22(10):1195-211 (114 ref.)

The uptake mechanisms of inflammation- and infection-localizing agents. Oyen WJ, et al. **Eur J Nucl Med** 1996 Apr;23(4):459-65 (62 ref.)

SURGERY

Minimally invasive surgical techniques to treat spine infections. Parker LM, et al. **Orthop Clin North Am** 1996 Jan;27(1):183-99 (40 ref.)

THERAPY

Diagnosis and management of renal infections. Meyrier A. **Curr Opin Nephrol Hypertens** 1996 Mar;5(2):151-7 (57 ref.)

Will pathologists play as important a role in the future as they have in the past against the challenge of infectious diseases. Walker DH, et al. **Infect Agents Dis** 1995 Sep; 4(3):167-70 (8 ref.)

Approach to fever and infection in the nursing home. Yoshikawa TT, et al. **J Am Geriatr Soc** 1996 Jan; 44(1):74-82 (87 ref.)

Cervical spine infections. Ghanayem AJ, et al. **Orthop Clin North Am** 1996 Jan;27(1):53-67 (92 ref.)

Design and testing of peptide-based cytotoxic T-cell-mediated immunotherapeutics to treat infectious diseases and cancer. Chesnut RW, et al. **Pharm Biotechnol** 1995;6:847-74 (170 ref.)

VETERINARY

Imaging infection and inflammation in veterinary practice [editorial; comment] Peters AM. **Equine Vet J** 1995 Jul; 27(4):242-4 (20 ref.) Comment on: Equine Vet J 1995 Jul;27(4):313-5.

INFECTION CONTROL

Institutional control measures for tuberculosis in the era of multiple drug resistance. ACCP/ATS Consensus Conference. American College of Chest Physicians and the American Thoracic Society. **Chest** 1995 Dec; 108(6):1690-710 (143 ref.)

Intraoperative blood salvage (IOBS) in cardiac and vascular surgery. Valbonesi M, et al. **Int J Artif Organs** 1995 Mar; 18(3):130-5 (19 ref.)

Antiseptics and disinfectants. Current issues. Terleckyj B, et al. **J Am Podiatr Med Assoc** 1995 Aug;85(8):439-45 (32 ref.)

Managing HIV. Part 7: Professional issues. 7.1 HIV infection control in medical practice. Mitchell DH, et al. **Med J Aust** 1996 Jul 15;165(2):86-9 (19 ref.)

Managing the infectious waste of the surgery unit and laboratory. Hoeltge GA. **Semin Dermatol** 1995 Sep; 14(3):247-51 (9 ref.)

[Hospital hygiene and the medicosocial problems of preserving human health in medical institutions] Znamenskii AV, et al. **Voen Med Zh** 1995 Jul;(7):55-60, 80 (23 ref.) (Eng. Abstr.) **(Rus)**

METHODS

APIC guideline for handwashing and hand antisepsis in health care settings. Larson EL. **Am J Infect Control** 1995 Aug;23(4):251-69 (239 ref.)

Infection control. Miller CH. **Dent Clin North Am** 1996 Apr; 40(2):437-56 (38 ref.)

The analysis of disease clusters, Part I: State of the art. Jacquez GM, et al. **Infect Control Hosp Epidemiol** 1996 May;17(5):319-27 (35 ref.)

Basic microbiologic support for hospital epidemiology. McGowan JEJr, et al. **Infect Control Hosp Epidemiol** 1996 May;17(5):298-303 (30 ref.)

Compliance with handwashing and barrier precautions. Larson E, et al. **J Hosp Infect** 1995 Jun;30 Suppl:88-106 (81 ref.)

Molecular and cellular basis of interleukin 12 activity in prophylaxis and therapy against infectious diseases. Gazzinelli RT. **Mol Med Today** 1996 Jun;2(6):258-67 (41 ref.)

The resurgence of TB and its implications for radiology. Newman J. **Radiol Technol** 1996 May-Jun;67(5):379-96; quiz 397-400 (95 ref.)

Infection control precautions for surgical personnel in the surgery unit and for laboratory personnel in the Mohs surgery unit laboratory areas. Hruza GJ. **Semin Dermatol** 1995 Sep;14(3):228-34 (47 ref.)

Strategies for syphilis prevention in the 1990s. St Louis ME. **Sex Transm Dis** 1996 Jan-Feb;23(1):58-67 (47 ref.)

ORGANIZATION & ADMINISTRATION

Infection control in long-term care. Yoshikawa TT, et al. **Clin Geriatr Med** 1995 Aug;11(3):467-80 (65 ref.)

The computer-based patient record: the role of the hospital epidemiologist. Classen DC, et al. **Infect Control Hosp Epidemiol** 1995 Dec;16(12):729-36 (32 ref.)

Infection control in public hospitals. Wurtz R. **Infect Control Hosp Epidemiol** 1995 Nov;16(11):642-6 (7 ref.)

STANDARDS

The impact of surveys on hospital infection. Emmerson AM. **J Hosp Infect** 1995 Jun;30 Suppl:421-40 (68 ref.)

Strategies to Prevent and Control the Emergence and Spread of Antimicrobial-Resistant Microorganisms in Hospitals. A challenge to hospital leadership [see comments] Goldmann DA, et al. **JAMA** 1996 Jan 17;275(3):234-40 (81 ref.) Comment in: JAMA 1996 May 22-29;275(20):1544.

Disinfection of trucks and trailers. Mateost Poumian A. **Rev Sci Tech** 1995 Mar;14(1):165-76 (4 ref.) **(Eng, Spa)**

TRENDS

Infectious disease pathology and emerging infections: are we prepared? [editorial] Schwartz DA, et al. **Arch Pathol Lab Med** 1996 Feb;120(2):117-24 (38 ref.)

Will pathologists play as important a role in the future as they have in the past against the challenge of infectious diseases. Walker DH, et al. **Infect Agents Dis** 1995 Sep; 4(3):167-70 (8 ref.)

INFECTION CONTROL PRACTITIONERS

[Hospital management and the role of clinical microbiology laboratory for preventing nosocomial infection] Ichiyama S. **Rinsho Byori** 1995 Oct;43(10):1005-9 (4 ref.) (Eng. Abstr.) **(Jpn)**

INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS see **HERPESVIRUS 1, BOVINE**

INFECTIOUS DISEASE CONTACT TRACING see **CONTACT TRACING**

INFECTIOUS DISEASE REPORTING see **DISEASE**

NOTIFICATION

INFECTIOUS DISEASES see COMMUNICABLE DISEASES

INFECTIOUS HUMAN WART VIRUS see PAPILLOMAVIRUS, HUMAN

INFECTIOUS MONONUCLEOSIS

Infectious mononucleosis. Cozad J. **Nurse Pract** 1996 Mar; 21(3):14–6, 23, 27–8 (9 ref.)
Benign lymphoproliferative disorders. Shaffer S. **Semin Oncol Nurs** 1996 Feb;12(1):28–37 (44 ref.)

COMPLICATIONS

Severe respiratory insufficiency complicating Epstein–Barr virus infection: case report and review. Haller A, et al. **Clin Infect Dis** 1995 Jul;21(1):206–9 (24 ref.)

INFECTIOUS MONONUCLEOSIS–LIKE SYNDROME, CHRONIC see FATIGUE SYNDROME, CHRONIC

INFECTIOUS MONONUCLEOSIS VIRUS see HERPESVIRUS 4, HUMAN

INFECTIOUS PUSTULAR VULVOVAGINITIS VIRUS see HERPESVIRUS 1, BOVINE

INFERIOR COLLICULUS

PHYSIOLOGY

Central auditory aging: GABA changes in the inferior colliculus. Caspary DM, et al. **Exp Gerontol** 1995 May–Aug;30(3–4):349–60 (85 ref.)

INFERIOR VENA CAVA FILTERS see VENA CAVA FILTERS

INFERTILITY

The infertile couple. Trantham P. **Am Fam Physician** 1996 Sep 1;54(3):1001–10 (20 ref.)
Understanding infertility treatment plans. Carmichael JM. **Am Pharm** 1995 Nov;NS35(11):41–52; quiz 53–4 (12 ref.)

CHEMICALLY INDUCED

Sterility in neonatally androgenized female rats and the decidual cell reaction. Ohta Y. **Int Rev Cytol** 1995;160:1–52 (250 ref.)

DIAGNOSIS

When is the post–coital test normal? A critical appraisal. Oei SG, et al. **Hum Reprod** 1995 Jul;10(7):1711–4 (20 ref.)
Reflections on the way to conduct an investigation of subfertility. Puttemans P, et al. **Hum Reprod** 1995 Oct;10 Suppl 1:80–9 (32 ref.)

EPIDEMIOLOGY

[Fertility] Tica V. **Contracept Fertil Sex** 1996 Mar; 24(3):173–83 (110 ref.) **(Fre)**

ETIOLOGY

African endocrine infertility: a review. Kuku SF. **Afr J Med Med Sci** 1995 Jun;24(2):111–23 (60 ref.)
Mechanism and management of treatment–related gonadal failure in recipients of high dose chemoradiotherapy. Apperley JF, et al. **Blood Rev** 1995 Jun;9(2):93–116 (158 ref.)
When is the post–coital test normal? A critical appraisal. Oei SG, et al. **Hum Reprod** 1995 Jul;10(7):1711–4 (20 ref.)
[Role of essential trace elements on sexual function and its disorder] Shinohara A, et al. **Nippon Rinsho** 1996 Jan; 54(1):155–61 (20 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Genetic aspects of artificial fertilization. Vogt PH. **Hum Reprod** 1995 Oct;10 Suppl 1:128–37 (56 ref.)
[Karyotyping in couples with subfertility and infertility] Stora de Novion H. **Contracept Fertil Sex** 1995 Nov;23(11):655–9 (39 ref.) **(Fre)**

NURSING

The comfort and discomfort of infertility. Schoener CJ, et al. **J Obstet Gynecol Neonatal Nurs** 1996 Feb;25(2):167–72 (18 ref.)

PSYCHOLOGY

An infertility primer for family therapists: I. Medical, social, and psychological dimensions. Meyers M, et al. **Fam Process** 1995 Jun;34(2):219–29 (53 ref.)
An infertility primer for family therapists: II. Working with couples who struggle with infertility. Meyers M, et al. **Fam Process** 1995 Jun;34(2):231–40 (14 ref.)
The comfort and discomfort of infertility. Schoener CJ, et al. **J Obstet Gynecol Neonatal Nurs** 1996 Feb;25(2):167–72 (18 ref.)

THERAPY

In vitro fertilization, gamete intrafallopian transfer, and superovulation with intrauterine insemination: efficacy and potential health hazards on babies delivered. Dawood MY. **Am J Obstet Gynecol** 1996 Apr;174(4):1208–17 (26 ref.)
Ethical issues of fertility and reproduction. Baird PA. **Annu Rev Med** 1996;47:107–16 (30 ref.)
Infertility, involuntary infecundity, and the seeking of medical advice in industrialized countries 1970–1992: a review of concepts, measurements and results. Schmidt L, et al. **Hum Reprod** 1995 Jun;10(6):1407–18 (32 ref.)
[Is legislation needed in the treatment of infertility? (editorial)] Hovatta O. **Duodecim** 1994;110(2):123–6 (11 ref.) **(Fin)**
[Intra–uterine artificial insemination. Indications, techniques, results; 83 cases] Panel P, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(5):496–504 (23 ref.) (Eng. Abstr.) **(Fre)**

INFERTILITY AGENTS, FEMALE see FERTILITY AGENTS, FEMALE

INFERTILITY, FEMALE

CHEMICALLY INDUCED

Reproductive disorders due to chemical exposure among hairdressers. Kersemaekers WM, et al. **Scand J Work Environ Health** 1995 Oct;21(5):325–34 (85 ref.)
[Environment and reproduction] Gerhard I. **Arch Gynecol Obstet** 1995;257(1–4):239–46 (21 ref.) **(Ger)**

COMPLICATIONS

Ovulation induction, infertility, and ovarian cancer risk. Bristow RE, et al. **Fertil Steril** 1996 Oct;66(4):499–507 (49 ref.)

DIAGNOSIS

Hysteroscopy and assisted reproductive technology. Balmaceda JP, et al. **Obstet Gynecol Clin North Am** 1995 Sep;22(3):507–18 (52 ref.)
Radiological evaluation of infertility. Collins JI, et al. **Semin Ultrasound CT MR** 1995 Aug;16(4):304–16 (74 ref.)
[The value of diagnostic tests in infertility] Evers JL. **Ned Tijdschr Geneeskd** 1995 Oct 14;139(41):2077–80 (13 ref.) **(Dut)**

DRUG THERAPY

Induction of ovulation. Derman SG, et al. **Compr Ther** 1995 Oct;21(10):583–9 (16 ref.)
The risk of ovarian cancer after treatment for infertility. Bristow RE, et al. **Curr Opin Obstet Gynecol** 1996 Feb; 8(1):32–7 (35 ref.)
Clinical review 81: Gonadotropin–releasing hormone analogs in ovulation induction: current status and perspectives. Filicori M. **J Clin Endocrinol Metab** 1996 Jul;81(7):2413–6 (23 ref.)
[Gestagens and corpus luteum insufficiency] Rothe K. **Zentralbl Gynakol** 1995;117 Suppl:2–5 (24 ref.) **(Ger)**

ETIOLOGY

Oviductal function is critical for very early human life. Pulkkinen MO. **Ann Med** 1995 Jun;27(3):307–10 (12 ref.)
Pain and infertility—a rationale for different treatment approaches. Martin DC. **Br J Obstet Gynaecol** 1995 Oct; 102 Suppl 12:2–3 (20 ref.)
The investigation of female infertility. Kyei–Mensah AA, et al. **Clin Endocrinol (Oxf)** 1995 Sep;43(3):251–5 (30 ref.)
Induced midtrimester abortion and future fertility—where are we today? Lurie S, et al. **Int J Fertil Menopausal Stud** 1995 Nov–Dec;40(6):311–5 (39 ref.)
Corticotropin–releasing factor (CRF) and stress–related reproductive failure: the brain as a state of the art or the ovary as a novel clue? Nappi RE, et al. **J Endocrinol Invest** 1995 Dec;18(11):872–80 (89 ref.)
Myomata uteri and infertility. Wallach EE, et al. **Obstet Gynecol Clin North Am** 1995 Dec;22(4):791–9 (32 ref.)
[Treatment of uterine fibromas] Amiel C, et al. **Ann Chir** 1996;50(1):40–50 (79 ref.) (Eng. Abstr.) **(Fre)**
[Hydrosalpinx and sterility: indications for salpingectomy] Aubriot FX, et al. **Contracept Fertil Sex** 1995 Nov; 23(11):670–3 (36 ref.) **(Fre)**
[Uterine malformations and infertility] Brun JL. **Contracept Fertil Sex** 1996 May;24(5):343–6 (35 ref.) **(Fre)**

GENETICS

Reproductive phenotpes of the progesterone receptor null mutant mouse. Lydon JP, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1–6 Spec No):67–77 (78 ref.)

IMMUNOLOGY

[Immunologic reactions in the male and female reproductive system] Kasprzak M, et al. **Postepy Hig Med Dosw** 1995; 49(6):693–717 (47 ref.) (Eng. Abstr.) **(Pol)**

MICROBIOLOGY

Chlamydia: testing for the silent threat to fertility. Radcliffe K. **Practitioner** 1996 Apr;240(1561):260–3 (8 ref.)

PHYSIOPATHOLOGY

Exploring the mechanism(s) of endometriosis–related infertility: an analysis of embryo development and implantation in assisted reproduction. Pellicer A, et al. **Hum Reprod** 1995 Dec;10 Suppl 2:91–7 (33 ref.)

PREVENTION & CONTROL

[Characteristics of rare ovarian tumors—possibilities of organ preservation] Grischke EM, et al. **Zentralbl Gynakol** 1996; 118(6):322–5 (10 ref.) (Eng. Abstr.) **(Ger)**
[Results of fertility preserving operations in malignant ovarian tumors] Kleine W. **Zentralbl Gynakol** 1996; 118(6):317–21 (21 ref.) (Eng. Abstr.) **(Ger)**

RADIOGRAPHY

[Role of hysterosalpingography in the evaluation of infertility in Black Africa] De Muylder X. **Med Trop (Mars)** 1995; 55(2):160–4 (53 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Is there ever a role for tubal surgery? Penzias AS, et al. **Am J Obstet Gynecol** 1996 Apr;174(4):1218–21; discussion 1221–3 (17 ref.)
The role of endoscopy in the management of the infertile patient. Graebe RA. **Curr Opin Obstet Gynecol** 1995 Aug; 7(4):265–72 (26 ref.)
[Hysteroscopic surgery] Kimmig R. **Arch Gynecol Obstet** 1995;257(1–4):21–9 (53 ref.) **(Ger)**
[Pro and contra: pelviscopy and microsurgery of the fallopian tube] Semm K. **Arch Gynecol Obstet** 1995;257(1–4):302–10 (14 ref.) **(Ger)**
[Possibilities and limits of endoscopic fallopian tube surgery] Korell M, et al. **Zentralbl Gynakol** 1995;117(12):663–9 (21 ref.) (Eng. Abstr.) **(Ger)**
[Uterine myomectomy in the treatment of infertility] Reroń A. **Ginekol Pol** 1995 Feb;66(2):108–11 (24 ref.) (Eng. Abstr.) **(Pol)**

THERAPY

The application of transvaginal ultrasound for ovulation induction and in vitro fertilization. Nachtigall MJ, et al. **Clin Obstet Gynecol** 1996 Mar;39(1):231–47 (72 ref.)
In vitro fertilization versus tubal surgery: is pelvic reconstructive surgery obsolete? Benadiva CA, et al. **Fertil Steril** 1995 Dec;64(6):1051–61 (85 ref.)
Development and applications of luteinizing hormone–releasing hormone antagonists in the treatment of infertility: an overview. Reissmann T, et al. **Hum Reprod** 1995 Aug;10(8):1974–81 (62 ref.)
Primary therapy for tubal disease: surgery versus IVF. Gocial B. **Int J Fertil Menopausal Stud** 1995 Nov–Dec; 40(6):297–302 (20 ref.)
Tubal surgery of IVF—making the best choice in the 1990s. Novy MJ. **Int J Fertil Menopausal Stud** 1995 Nov–Dec; 40(6):292–7 (35 ref.)
Hysteroscopy and assisted reproductive technology. Balmaceda JP, et al. **Obstet Gynecol Clin North Am** 1995 Sep;22(3):507–18 (52 ref.)

ULTRASONOGRAPHY

[Vaginal ultrasound diagnosis of tubal diseases] Degenhardt F. **Gynakologe** 1995 Aug;28(4):247–53 (20 ref.) **(Ger)**
[Diagnosis of sterility and IVF] Deutinger J. **Gynakologe** 1995 Aug;28(4):240–6 (52 ref.) **(Ger)**

VETERINARY

Porcine reproductive and respiratory syndrome (PRRS): a review, with emphasis on pathological, virological and diagnostic aspects. Done SH, et al. **Br Vet J** 1996 Mar; 152(2):153–74 (142 ref.)

INFERTILITY, MALE

ABC of urology. Subfertility and male sexual dysfunction. Dawson C, et al. **BMJ** 1996 Apr 6;312(7035):902–5 (0 ref.)
Male subfertility: concepts in 1995. Yovich JL, et al. **Hum Reprod** 1995 Oct;10 Suppl 1:3–9 (43 ref.)
Contribution of the male factor to unexplained infertility: a review. Mackenna A. **Int J Androl** 1995 Jun;18 Suppl 1:58–61 (25 ref.)

BLOOD

Increased follicle stimulating hormone in infertile men. Is increased plasma FSH always due to damaged germinal epithelium? Martin–du–Pan RC, et al. **Hum Reprod** 1995 Aug;10(8):1940–5 (82 ref.)

DIAGNOSIS

Diagnostic and therapeutic approach to moderate and severe male subfertility in 1995. Comhaire F, et al. **Hum Reprod** 1995 Oct;10 Suppl 1:144–50 (40 ref.)
Computer assisted semen analysis systems: sperm motility

assessment. Irvine DS. **Hum Reprod** 1995 Oct;10 Suppl 1:53–9 (43 ref.)
An update on the laboratory assessment of male fertility. Oehninger S. **Hum Reprod** 1995 Oct;10 Suppl 1:38–45 (46 ref.)
[The value of diagnostic tests in infertility] Evers JL. **Ned Tijdschr Geneeskd** 1995 Oct 14;139(41):2077–80 (13 ref.) **(Dut)**

DRUG THERAPY

Enhancement of sperm function for treatment of male infertility. Naz RK, et al. **J Androl** 1995 Sep–Oct; 16(5):384–8 (22 ref.)
[Tamoxifen in male infertility. Analysis of a questionable therapy] Rolf C, et al. **Dtsch Med Wochenschr** 1996 Jan 5;121(1–2):33–9 (77 ref.) **(Ger)**
[Feminization: a paradoxical effect of stimulation with hCG/hMG in the infertile male] Arango Toro O, et al. **Actas Urol Esp** 1995 May;19(5):376–82 (48 ref.) (Eng. Abstr.) **(Spa)**

EPIDEMIOLOGY

[Is male fertility threatened?] Jégou B, et al. **Contracept Fertil Sex** 1995 Sep;23(9):513–5 (19 ref.) **(Fre)**

ETIOLOGY

Occupational hazards for the male reproductive system. Tas S, et al. **Crit Rev Toxicol** 1996 May;26(3):261–307 (460 ref.)
Debate on the pros and cons of varicocele treatment—in favour of varicocele treatment. Hargreave TB. **Hum Reprod** 1995 Oct;10 Suppl 1:151–7 (28 ref.)
Cancer and male infertility. Meirow D, et al. **Hum Reprod** 1995 Aug;10(8):2017–22 (59 ref.)
Testicular heating and its possible contributions to male infertility: a review. Mieusset R, et al. **Int J Androl** 1995 Aug;18(4):169–84 (105 ref.)
Reproductive issues for men with cancer: technology and nursing management. Sweet V, et al. **Oncol Nurs Forum** 1996 Jan–Feb;23(1):51–8 (53 ref.)
Free radicals, lipid peroxidation and sperm function. Aitken RJ. **Reprod Fertil Dev** 1995;7(4):659–68 (62 ref.)
[Surgical cure of varicocele and male infertility: for or against?] Adjiman M. **Contracept Fertil Sex** 1996 Jun; 24(6):439–41 (16 ref.) **(Fre)**
[Surgical cure of varicocele and male infertility: for or against?] Amar E. **Contracept Fertil Sex** 1996 Jun; 24(6):442–3 (7 ref.) **(Fre)**
[Temperature and male fertility] Bujan L, et al. **Contracept Fertil Sex** 1996 Jun;24(6):429–38 (40 ref.) **(Fre)**

GENETICS

Debate. Assisted reproductive techniques – are we avoiding the genetic issues? Baschat AA, et al. **Hum Reprod** 1996 May;11(5):926–8 (10 ref.)
Genetic anomaly and ICSI. Chandley AC, et al. **Hum Reprod** 1996 May;11(5):930–2 (26 ref.)
Concerns and recommendations for intracytoplasmic sperm injection (ICSI) treatment. Cummins JM, et al. **Hum Reprod** 1995 Oct;10 Suppl 1:138–43 (47 ref.)
Intracytoplasmic sperm injection—is there a need for an animal model, especially in assessing the genetic risks involved? Ng SC, et al. **Hum Reprod** 1995 Oct; 10(10):2523–5 (26 ref.)
Intracytoplasmic sperm injection (ICSI): potential genetic concerns. Patrizio P. **Hum Reprod** 1995 Oct;10(10):2520–3 (26 ref.)
Micro-assisted fertilization and sperm chromosome abnormalities. Rosenbusch B, et al. **Hum Reprod** 1996 May; 11(5):928–30 (29 ref.)
Is an animal model needed for intracytoplasmic sperm injection (ICSI) and other assisted reproduction technologies? Yanagimachi R. **Hum Reprod** 1995 Oct; 10(10):2525–6 (11 ref.)
Cytogenetics of human spermatozoa: what about the reproductive relevance of structural chromosome aberrations? Rosenbusch BE. **J Assist Reprod Genet** 1995 Jul;12(6):375–83 (53 ref.)
The potential of intracytoplasmic sperm injection (ICSI) to transmit genetic defects causing male infertility. de Kretser DM. **Reprod Fertil Dev** 1995;7(2):137–41; discussion 141–2 (36 ref.)
[Intracytoplasmic injection of spermatozoa (ICSI). Ethical requirements and assessment] Moutel G, et al. **Presse Med** 1996 Jun 15;25(21):989–93 (37 ref.) (Eng. Abstr.) **(Fre)**
[Cytogenetic abnormalities in sperm: a risk factor for application of medical reproduction techniques?] Rosenbusch B, et al. **Geburtshilfe Frauenheilkd** 1995 Sep; 55(9):518–25 (40 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Infertility due to antisperm antibodies. Ohl DA, et al. **Urology** 1995 Oct;46(4):591–602 (170 ref.)
[Immunologic reactions in the male and female reproductive system] Kasprzak M, et al. **Postepy Hig Med Dosw** 1995; 49(6):693–717 (47 ref.) (Eng. Abstr.) **(Pol)**

PATHOLOGY

Whither the investigation of male infertility? Is FSH measurement redundant and should all azoospermic patients have testicular biopsy? Wu FC. **Hum Reprod** 1995 Aug;10(8):1945–7 (25 ref.)

PHYSIOPATHOLOGY

Situs inversus and ciliary abnormalities. What is the connection? Afzelius BA. **Int J Dev Biol** 1995 Oct; 39(5):839–44 (57 ref.)
Male infertility: evaluation of human sperm function and its clinical application. Lenzi A. **J Endocrinol Invest** 1995 Jun; 18(6):468–83 (105 ref.)

THERAPY

Intracytoplasmic sperm injection: a powerful tool to overcome fertilization failure. Palermo GD, et al. **Fertil Steril** 1996 May;65(5):899–908 (80 ref.)
Debate. Assisted reproductive techniques – are we avoiding the genetic issues? Baschat AA, et al. **Hum Reprod** 1996 May;11(5):926–8 (10 ref.)
Diagnostic and therapeutic approach to moderate and severe male subfertility in 1995. Comhaire F, et al. **Hum Reprod** 1995 Oct;10 Suppl 1:144–50 (40 ref.)
Economic strategies in modern male subfertility treatment. Comhaire F. **Hum Reprod** 1995 Oct;10 Suppl 1:103–6 (16 ref.)
Intracytoplasmic sperm injection—what kind of reproduction is being assisted? De Jonge CJ, et al. **Hum Reprod** 1995 Oct;10(10):2518–20 (11 ref.)
Recent developments in assisted fertilization. Gordts S, et al. **Hum Reprod** 1995 Oct;10 Suppl 1:107–14 (45 ref.)
An argument for the past and continued use of pentoxifylline in assisted reproductive technology. Matson PL, et al. **Hum Reprod** 1995 Oct;10 Suppl 1:67–71 (38 ref.)
Intrauterine insemination: a first-step procedure in the algorithm of male subfertility treatment. Ombelet W, et al. **Hum Reprod** 1995 Oct;10 Suppl 1:90–102 (89 ref.)
Use of pentoxifylline in assisted reproductive technology. Tournaye H, et al. **Hum Reprod** 1995 Oct;10 Suppl 1:72–9 (48 ref.)
Intracytoplasmic sperm injection three years after the birth of the first ICSI child. Van Steirteghem A, et al. **Hum Reprod** 1995 Oct;10(10):2527–8 (16 ref.)
Micromanipulation of gametes—new horizons in the treatment of male infertility. Simon A, et al. **Isr J Med Sci** 1995 Nov;31(11):652–6 (35 ref.)
Male infertility: evaluation of human sperm function and its clinical application. Lenzi A. **J Endocrinol Invest** 1995 Jun; 18(6):468–83 (105 ref.)
The potential of intracytoplasmic sperm injection (ICSI) to transmit genetic defects causing male infertility. de Kretser DM. **Reprod Fertil Dev** 1995;7(2):137–41; discussion 141–2 (36 ref.)
[Risks of intracytoplasmatic sperm cell injection for offspring?] Hollanders JM, et al. **Ned Tijdschr Geneeskd** 1996 Jan 6;140(1):9–11 (20 ref.) **(Dut)**
[Treatment of obstructive azoospermia] Hovatta O, et al. **Duodecim** 1994;110(8):802–7 (28 ref.) **(Fin)**
[Male infertility can be treated] Hovatta O. **Duodecim** 1995; 111(4):316–21 (24 ref.) **(Fin)**
[Endocrinology update—II] Burgstaller M, et al. **Med Klin** 1996 Apr 1;91 Suppl 1:34–44 (171 ref.) **(Ger)**
[Endocrinology update. II] Burgstaller M, et al. **Med Klin** 1996 Apr 10;91(4):207–17 (171 ref.) **(Ger)**

INFIBULATION see **CIRCUMCISION, FEMALE**

INFLAMMATION

see related
ACUTE-PHASE REACTION
ANTI-INFLAMMATORY AGENTS

Chemokines active on eosinophils: potential roles in allergic inflammation [comment] Kita H, et al. **J Exp Med** 1996 Jun 1;183(6):2421–6 (60 ref.) Comment on: J Exp Med 1996 Jun 1;183(6):2437–48.
[Adhesion molecules in the development of inflammatory processes— clinical and investigational implications] Naftali T, et al. **Harefuah** 1996 Feb 1;130(3):182–5 (26 ref.) **(Heb)**

BLOOD

Glycoforms of serum alpha 1-acid glycoprotein as markers of inflammation and cancer. Mackiewicz A, et al. **Glycoconj J** 1995 Jun;12(3):241–7 (43 ref.)

COMPLICATIONS

The anemia of inflammation. A common cause of childhood anemia. Abshire TC. **Pediatr Clin North Am** 1996 Jun; 43(3):623–37 (72 ref.)
Phenotypic modification of primary sensory neurons: the role of nerve growth factor in the production of persistent pain. Woolf CJ. **Philos Trans R Soc Lond B Biol Sci** 1996 Mar 29;351(1338):441–8 (34 ref.)
[Cerebrovascular diseases and non-infectious inflammatory arteriopathies] Vivancos F, et al. **Rev Neurol** 1995;23 Suppl 1:S22–32 (84 ref.) **(Spa)**

DRUG THERAPY

The integrin alpha 4 beta 1 (VLA-4) as a therapeutic target. Elices MJ. **Ciba Found Symp** 1995;189:79–85; discussion 85–90, 174–6 (56 ref.)
Treatment of inflammatory diseases with a monoclonal antibody to intercellular adhesion molecule 1. Rothlein R, et al. **Ciba Found Symp** 1995;189:200–8; discussion 208–11 (41 ref.)
Cellular basis of inflammation, edema and the activity of Daflon 500 mg. Friesenecker B, et al. **Int J Microcirc Clin Exp** 1995;15 Suppl 1:17–21 (44 ref.)
Pentoxifylline in severe inflammatory response syndrome. Graninger W, et al. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S134–8 (37 ref.)
Modulation of inflammation and cytokine production by dietary (n-3) fatty acids. Blok WL, et al. **J Nutr** 1996 Jun; 126(6):1515–33 (131 ref.)
Botanical lipids: effects on inflammation, immune responses, and rheumatoid arthritis. Rothman D, et al. **Semin Arthritis Rheum** 1995 Oct;25(2):87–96 (75 ref.)
[Glucocorticoid treatment] Kauppinen-Mäkelin R. **Duodecim** 1995;111(8):725–31 (28 ref.) **(Fin)**
[Treatment of inflammation with anti-inflammatory cytokines: example in models of auto-immune diseases] Bessis N, et al. **C R Seances Soc Biol Fil** 1995;189(4):579–90 (33 ref.) (Eng. Abstr.) **(Fre)**
[The leukotriene signal pathway—a very promising point of entry for inhibitors in therapy of inflammatory diseases] Müller MJ. **Pharm Unserer Zeit** 1995 Sep;24(5):264–72 (53 ref.) **(Ger)**

ENZYMOLOGY

Regulation and function of inducible nitric oxide synthase during sepsis and acute inflammation. Wong JM, et al. **Adv Pharmacol** 1995;34:155–70 (68 ref.)
Cyclooxygenase-2: regulation and relevance in inflammation. Mitchell JA, et al. **Biochem Pharmacol** 1995 Nov 9; 50(10):1535–42 (92 ref.)
Inducible nitric oxide synthase in inflammation. Cattell V, et al. **Histochem J** 1995 Oct;27(10):777–84 (52 ref.)
Nitric oxide in physiology and pathology. Whittle BJ. **Histochem J** 1995 Oct;27(10):727–37 (61 ref.)

ETIOLOGY

Overview of neuroimmune stress interactions. Implications for susceptibility to inflammatory disease. Sternberg EM, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:364–71 (53 ref.)
Selectin-carbohydrate interactions and the initiation of the inflammatory response. Lasky LA. **Annu Rev Biochem** 1995;64:113–39 (150 ref.)
Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer. Wiseman H, et al. **Biochem J** 1996 Jan 1;313 (Pt 1):17–29 (213 ref.)
New aspects on the role of kinins in neurogenic inflammation. Geppetti P, et al. **Can J Physiol Pharmacol** 1995 Jul; 73(7):843–7 (30 ref.)
The role of endothelial cells in the systemic inflammatory response syndrome and multiple system organ failure. Wang X, et al. **Eur J Surg** 1995 Oct;161(10):703–13 (141 ref.)
Emerging roles of nitric oxide in inflammation. Lyons CR. **Hosp Pract (Off Ed)** 1996 Jul 15;31(7):69–73, 77–80, 85–6 (0 ref.)
Spinal opioid systems in inflammation. Stanfa L, et al. **Inflamm Res** 1995 Jun;44(6):231–41 (119 ref.)
Review: nomenclature and biologic significance of cytokines involved in inflammation and the host immune response. Liles WC, et al. **J Infect Dis** 1995 Dec;172(6):1573–80 (63 ref.)
Periarticular ankle sarcoidosis: a variant of Löfgren's syndrome. Mañá J, et al. **J Rheumatol** 1996 May;23(5):874–7 (21 ref.)
Cytokines and nitric oxide in islet inflammation and diabetes. McDaniel ML, et al. **Proc Soc Exp Biol Med** 1996 Jan; 211(1):24–32 (41 ref.)
[Giant hemangioma of the liver disclosed by fever and an inflammatory syndrome. Apropos of 3 cases] Taillandier J, et al. **Ann Med Interne (Paris)** 1995;146(5):319–21 (9 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Interleukin-10 gene knock-out mice: a model of chronic inflammation. Rennick D, et al. **Clin Immunol Immunopathol** 1995 Sep;76(3 Pt 2):S174–8 (33 ref.)
The hepatocyte nuclear factor-3/forkhead transcription regulatory family in development, inflammation, and neoplasia. Hromas R, et al. **Crit Rev Oncol Hematol** 1995 Aug;20(1–2):129–40 (64 ref.)
Transcription factors and inflammatory disease. Barnes PJ. **Hosp Pract (Off Ed)** 1996 Jun 15;31(6):93–100, 105–6 (0 ref.)
Genetic dissection of inflammatory responses. Nadeau JH, et al. **J Inflamm** 1995;45(1):27–48 (166 ref.)

IMMUNOLOGY

The role of cytokines and neuroendocrine hormones in cutaneous immunity and inflammation. Luger TA, et al. **Allergy** 1995 Apr;50(4):292–302 (119 ref.)

The role of mast cells and basophils in immunoregulation. Nolte H. **Allergy Asthma Proc** 1996 Jan–Feb;17(1):17–21 (13 ref.)
Endothelial–dependent mechanisms in chronic inflammatory leukocyte recruitment. Luscinskas FW, et al. **Annu Rev Med** 1996;47:413–21 (31 ref.)
The role of cellular adhesion molecules in surgery. Breidahl AF, et al. **Aust N Z J Surg** 1995 Dec;65(12):838–47 (54 ref.)
Intervention in the complement system: a therapeutic strategy in inflammation. Morgan BP. **Biochem Soc Trans** 1996 Feb; 24(1):224–9 (43 ref.)
The immuno–inflammatory cascade. Galley HF, et al. **Br J Anaesth** 1996 Jul;77(1):11–6 (24 ref.)
Superantigens. Saloga J, et al. **Exp Dermatol** 1996 Apr; 5(2):65–71 (109 ref.)
The P2Z purinoceptor: an intriguing role in immunity, inflammation and cell death. Di Virgilio F. **Immunol Today** 1995 Nov;16(11):524–8 (37 ref.)
Effects of modulation of inflammatory and immune parameters in patients with rheumatic and inflammatory disease receiving dietary supplementation of n–3 and n–6 fatty acids. Kremer JM. **Lipids** 1996 Mar;31 Suppl:S243–7 (50 ref.)
Monocyte chemoattractant protein 1: a potential regulator of monocyte recruitment in inflammatory disease. Rollins BJ. **Mol Med Today** 1996 May;2(5):198–204 (35 ref.)
Immune activation: the role of pro–inflammatory cytokines in inflammation, illness responses and pathological pain states. Watkins LR, et al. **Pain** 1995 Dec;63(3):289–302 (135 ref.)
A few autoreactive cells in an autoimmune infiltrate control a vast population of nonspecific cells: a tale of smart bombs and the infantry. Steinman L. **Proc Natl Acad Sci U S A** 1996 Mar 19;93(6):2253–6 (26 ref.)
[Characteristics of cells in inflammation and neoplastic processes] Bogunia–Kubik K. **Postepy Hig Med Dosw** 1995; 49(1):117–23 (9 ref.) (Eng. Abstr.) **(Pol)**

METABOLISM

Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer. Wiseman H, et al. **Biochem J** 1996 Jan 1;313 (Pt 1):17–29 (213 ref.)
Control of arachidonate levels within inflammatory cells. Chilton FH, et al. **Biochim Biophys Acta** 1996 Jan 5; 1299(1):1–15 (139 ref.)
Plasticity of calcitonin gene related peptide neurotransmission in the spinal cord during peripheral inflammation. Seybold VS, et al. **Can J Physiol Pharmacol** 1995 Jul;73(7):1007–14 (51 ref.)
Mechanisms of VCAM–1 and fibronectin binding to integrin alpha 4 beta 1: implications for integrin function and rational drug design. Humphries MJ, et al. **Ciba Found Symp** 1995;189:177–91; discussion 191–9 (43 ref.)
Interaction between nutrients, pro–inflammatory cytokines and inflammation [editorial] Grimble RF. **Clin Sci (Colch)** 1996 Aug;91(2):121–30 (102 ref.)
Regulation of spinal neuropeptide genes in a rat model of peripheral inflammation and hyperalgesia. Ruda MA, et al. **Prog Brain Res** 1995;104:349–65 (121 ref.)
Sites of tissue factor pathway inhibitor (TFPI) and tissue factor expression under physiologic and pathologic conditions. On behalf of the Subcommittee on Tissue factor Pathway Inhibitor (TFPI) of the Scientific and Standardization Committee of the ISTH. Osterud B, et al. **Thromb Haemost** 1995 May;73(5):873–5 (50 ref.)
[Exploration of cytokines in inflammation in biological fluids] Bienvenu J. **C R Seances Soc Biol Fil** 1995;189(4):545–55 (19 ref.) (Eng. Abstr.) **(Fre)**
[Cytokines in inflammation] Cavaillon JM. **C R Seances Soc Biol Fil** 1995;189(4):531–44 (61 ref.) (Eng. Abstr.) **(Fre)**
[NO, ambivalent effector of non–specific immunity and of inflammation] Drapier JC. **C R Seances Soc Biol Fil** 1995; 189(6):1081–96 (104 ref.) (Eng. Abstr.) **(Fre)**
[Acute–phase proteins in inflammation] Engler R. **C R Seances Soc Biol Fil** 1995;189(4):563–78 (20 ref.) (Eng. Abstr.) **(Fre)**
[Nitric oxide and oxidative metabolism: heads or tails in inflammatory gastric disease] Esteban Carretero J, et al. **Rev Esp Enferm Dig** 1996 Jun;88(6):423–30 (90 ref.) **(Spa)**

PATHOLOGY

The role of nitric oxide in inflammation. Lyons CR. **Adv Immunol** 1995;60:323–71 (340 ref.)
Interleukin–10 gene knock–out mice: a model of chronic inflammation. Rennick D, et al. **Clin Immunol Immunopathol** 1995 Sep;76(3 Pt 2):S174–8 (33 ref.)
Inflammatory mechanisms in Alzheimer's disease. Hüll M, et al. **Eur Arch Psychiatry Clin Neurosci** 1996;246(3):124–8 (36 ref.)
Pentoxifylline in severe inflammatory response syndrome. Graninger W, et al. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S134–8 (37 ref.)
Minor inflammatory lesions and sudden infant death: cause, coincidence, or epiphenomena? Byard RW, et al. **Pediatr Pathol Lab Med** 1995 Sep–Oct;15(5):649–54 (16 ref.)
Thrombosis and inflammation as multicellular processes: significance of cell–cell interactions. Marcus AJ, et al. **Thromb Haemost** 1995 Jul;74(1):213–7 (54 ref.)

PHYSIOPATHOLOGY

Brain injury and inflammation. A putative role of TNF alpha. Arvin B, et al. **Ann N Y Acad Sci** 1995 Sep 15;765:62–71; discussion 98–9 (67 ref.)
The protective role of the hypothalamic–pituitary–adrenal axis against lethality produced by immune, infectious, and inflammatory stress. Kapcala LP, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:419–37 (87 ref.)
Effects of the immune/inflammatory reaction on the hypothalamic–pituitary–adrenal axis. Mastorakos G, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:438–48 (34 ref.)
Possible modes of action of nimesulide in controlling neutrophilic inflammation. Dallegri F, et al. **Arzneimittelforschung** 1995 Oct;45(10):1114–7 (36 ref.)
The mast cell and inflammation. McNeil HP. **Aust N Z J Med** 1996 Apr;26(2):216–25 (67 ref.)
Biologic basis for interleukin–1 in disease. Dinarello CA. **Blood** 1996 Mar 15;87(6):2095–147 (586 ref.)
Inflammatory mediators of pain. Dray A. **Br J Anaesth** 1995 Aug;75(2):125–31 (60 ref.)
Developmental biology of inflammatory pain. Fitzgerald M. **Br J Anaesth** 1995 Aug;75(2):177–85 (124 ref.)
Inflammation in the nervous system. Perry VH, et al. **Curr Opin Neurobiol** 1995 Oct;5(5):636–41 (52 ref.)
Cytokine secretion by human mast cells. Krüger–Krasagakes S, et al. **Exp Dermatol** 1995 Aug;4(4 Pt 2):250–4 (26 ref.)
Alpha 1–acid glycoprotein (orosomucoid): pathophysiological changes in glycosylation in relation to its function. van Dijk W, et al. **Glycoconj J** 1995 Jun; 12(3):227–33 (90 ref.)
The role of MIP–1 alpha in inflammation and hematopoiesis. Cook DN. **J Leukoc Biol** 1996 Jan;59(1):61–6 (40 ref.)
The inflammatory response in interleukin–1 beta–deficient mice: comparison with other cytokine–related knock–out mice. Fantuzzi G, et al. **J Leukoc Biol** 1996 Apr; 59(4):489–93 (41 ref.)
Regulation of leukocyte adhesion and signaling in inflammation and disease. Wahl SM, et al. **J Leukoc Biol** 1996 Jun;59(6):789–96 (94 ref.)
The neuropeptide alpha–melanocyte–stimulating hormone: a key component of neuroimmunomodulation. Catania A, et al. **Neuroimmunomodulation** 1994 Mar–Apr;1(2):93–9 (65 ref.)
Calcium: a regulator of the inflammatory response in endotoxemia and sepsis. Hotchkiss RS, et al. **New Horiz** 1996 Feb;4(1):58–71 (70 ref.)
Nitric oxide: a novel mediator of inflammation. Clancy RM, et al. **Proc Soc Exp Biol Med** 1995 Nov;210(2):93–101 (98 ref.)
Pathophysiological aspects of VLA–4 interactions and possibilities for therapeutical interventions. Kuijpers TW. **Springer Semin Immunopathol** 1995;16(4):379–89 (89 ref.)
Chemokines, inflammation and the immune system. Taub DD, et al. **Ther Immunol** 1994 Aug;1(4):229–46 (190 ref.)
Pro–inflammatory cytokines in a ruminant model: pathophysiological, pharmacological, and therapeutic aspects. van Miert AS. **Vet Q** 1995 Jun;17(2):41–50 (167 ref.)
[Beta–receptor and inflammation] Jiang MZ, et al. **Sheng Li Ko Hsueh Chin Chan** 1995 Oct;26(4):370–2 (9 ref.) **(Chi)**
[Mast cells and cytokines––a new insight on the participation of mast cells in inflammatory reactions] Kupryś I, et al. **Postepy Hig Med Dosw** 1996;50(1):43–63 (78 ref.) (Eng. Abstr.) **(Pol)**
[Bronchial asthma––a chronic inflammatory disorder] Adamek–Guzik T, et al. **Przegl Lek** 1996;53(1):12–9 (25 ref.) (Eng. Abstr.) **(Pol)**
[Participation of the adhesion molecules in the development of inflammatory response] Farsky SP, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1995 Jan–Feb;50(1):80–9 (147 ref.) (Eng. Abstr.) **(Por)**
[Molecular and cellular mechanisms in inflammatory reactions] Ferenčík M. **Bratisl Lek Listy** 1995 Oct; 96(10):509–19 (52 ref.) (Eng. Abstr.) **(Slo)**

PREVENTION & CONTROL

alpha 1–Acid glycoprotein. A natural occurring anti–inflammatory molecule? van Dijk W. **Adv Exp Med Biol** 1995;376:223–9 (25 ref.)

RADIONUCLIDE IMAGING

The uptake mechanisms of inflammation– and infection–localizing agents. Oyen WJ, et al. **Eur J Nucl Med** 1996 Apr;23(4):459–65 (62 ref.)

THERAPY

Intervention in the complement system: a therapeutic strategy in inflammation. Morgan BP. **Biochem Soc Trans** 1996 Feb; 24(1):224–9 (43 ref.)
Pathophysiological aspects of VLA–4 interactions and possibilities for therapeutical interventions. Kuijpers TW. **Springer Semin Immunopathol** 1995;16(4):379–89 (89 ref.)
The adhesion cascade and anti–adhesion therapy: an overview. Sharar SR, et al. **Springer Semin Immunopathol** 1995;16(4):359–78 (139 ref.)
Blocking of adhesion molecules in vivo as anti–inflammatory therapy. Ward PA, et al. **Ther Immunol** 1994 Jun; 1(3):165–71 (22 ref.)

VETERINARY

Imaging infection and inflammation in veterinary practice [editorial; comment] **Peters AM. Equine Vet J** 1995 Jul; 27(4):242–4 (20 ref.) Comment on: Equine Vet J 1995 Jul;27(4):313–5.

INFLAMMATION MEDIATORS

ANTAGONISTS & INHIBITORS

Pro– and antiinflammatory cytokine balance in rheumatoid arthritis. Miossec P. **Clin Exp Rheumatol** 1995 Sep–Oct;13 Suppl 12:S13–6 (16 ref.)
Potential strategies for inflammatory mediator manipulation: retrospect and prospect. Fisher CJ Jr, et al. **World J Surg** 1996 May;20(4):447–53 (89 ref.)
Animal models as the basis of pharmacologic intervention in trauma and sepsis patients. Redl H, et al. **World J Surg** 1996 May;20(4):487–92 (81 ref.)

BLOOD

Inflammatory predictors for the development of the adult respiratory distress syndrome [editorial] Reid PT, et al. **Thorax** 1995 Oct;50(10):1023–6 (38 ref.)

IMMUNOLOGY

The two faces of interleukin 12: a pro–inflammatory cytokine and a key immunoregulatory molecule produced by antigen–presenting cells. Trinchieri G. **Ciba Found Symp** 1995;195:203–14; discussion 214–20 (59 ref.)
Is sepsis a mediator–inhibitor mismatch? Lamy M, et al. **Intensive Care Med** 1995 Nov;21 Suppl 2:S250–7 (55 ref.)
[Immunoglobulins E and inflammatory cells] Tunon de Lara JM. **Rev Mal Respir** 1996;13(1):27–36 (32 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Mediators and vascular effects in response to endotoxin [see comments] Olson NC, et al. **Br Vet J** 1995 Sep–Oct; 151(5):489–522 (152 ref.) Comment in: Br Vet J 1995 Sep–Oct;151(5):469–71.
Mediators, cytokines, and growth factors in liver–lung interactions. Panos RJ, et al. **Clin Chest Med** 1996 Mar; 17(1):151–69 (220 ref.)
Mediators in continuous extracorporeal treatment of multiple organ dysfunction syndrome. Sunder–Plassmann G, et al. **Contrib Nephrol** 1995;116:10–5 (46 ref.)
Deposits of eosinophil granule proteins in eosinophilic cholecystitis and eosinophilic colitis associated with hypereosinophilic syndrome. Tajima K, et al. **Dig Dis Sci** 1996 Feb;41(2):282–8 (25 ref.)
Elimination of inflammatory mediators by hemofiltration. Inthorn D, et al. **Int J Artif Organs** 1996 Feb;19(2):124–6 (29 ref.)

PHYSIOLOGY

The inflammatory response. Denburg JA. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 2):S11–3 (53 ref.)
New molecules in analgesia. Rang HP, et al. **Br J Anaesth** 1995 Aug;75(2):145–56 (145 ref.)
Pro– and antiinflammatory cytokine balance in rheumatoid arthritis. Miossec P. **Clin Exp Rheumatol** 1995 Sep–Oct;13 Suppl 12:S13–6 (16 ref.)
Interaction of inflammatory cytokines and erythropoeitin in iron metabolism and erythropoiesis in anaemia of chronic disease. Jongen–Lavrencic M, et al. **Clin Rheumatol** 1995 Sep;14(5):519–25 (93 ref.)
The inflammatory response to cardiopulmonary bypass and its impact on postoperative myocardial function. Menasché P. **Curr Opin Cardiol** 1995 Nov;10(6):597–604 (59 ref.)
Surgical infections: blocking the mediator cascade responsible for sepsis and septic shock. Fink MP. **Curr Opin Gen Surg** 1993;:19–25 (45 ref.)
Pain due to nerve damage: are inflammatory mediators involved? Tracey DJ, et al. **Inflamm Res** 1995 Oct; 44(10):407–11 (67 ref.)
Regulation of endothelial permeability by second messengers. Siflinger–Birnboim A, et al. **New Horiz** 1996 Feb;4(1):87–98 (86 ref.)
NGF as a mediator of inflammatory pain. McMahon SB. **Philos Trans R Soc Lond B Biol Sci** 1996 Mar 29; 351(1338):431–40 (86 ref.)
The pro–inflammatory and hyperplasiogenic action of interleukin–1 alpha in mouse skin. Fischer SM, et al. **Prog Clin Biol Res** 1995;391:161–77 (66 ref.)
Itch mediators. Hägermark O. **Semin Dermatol** 1995 Dec; 14(4):271–6 (76 ref.)
Cysteinyl leukotrienes in asthma: old mediators up to new tricks. Hay DW, et al. **Trends Pharmacol Sci** 1995 Sep; 16(9):304–9 (54 ref.)
MODS/SIRS: result of an overwhelming inflammatory response? Goris RJ. **World J Surg** 1996 May;20(4):418–21 (24 ref.)

INFLAMMATION MEDIATORS

Biologic control of injury and inflammation: much more than too little or too late. Guirao X, et al. **World J Surg** 1996 May;20(4):437–46 (135 ref.)

Mediators of injury and inflammation. Schlag G, et al. **World J Surg** 1996 May;20(4):406–10 (45 ref.)

[Cellular reactions of the lung to mineral fibers] Gillissen A, et al. **Pneumologie** 1996 Jan;50(1):5–17 (137 ref.) **(Ger)**

[Pathogenesis of bronchopulmonary dysplasia] Groneck P, et al. **Z Geburtshilfe Neonatol** 1995 Sep–Oct;199(5):181–9 (68 ref.) (Eng. Abstr.) **(Ger)**

[Inflammatory mediators in asthma] Ota K. **Nippon Naika Gakkai Zasshi** 1996 Feb 10;85(2):178–83 (5 ref.) **(Jpn)**

THERAPEUTIC USE

Why sepsis trials fail. Bone RC. **JAMA** 1996 Aug 21; 276(7):565–6 (28 ref.)

INFLAMMATORY BOWEL DISEASES

Experimental models of inflammatory bowel disease. Elson CO, et al. **Gastroenterology** 1995 Oct;109(4):1344–67 (97 ref.)

Inflammatory bowel disease. Willenbucher RF. **Semin Gastrointest Dis** 1996 Apr;7(2):94–104 (72 ref.)

[Inflammatory bowel diseases in children] Dupont C. **Ann Gastroenterol Hepatol (Paris)** 1995 Sep;31(4):237–53 (167 ref.) **(Fre)**

COMPLICATIONS

Hepatobiliary complications of inflammatory bowel disease. Bhutani MS, et al. **Am Fam Physician** 1995 Oct; 52(5):1440–4 (19 ref.)

Endoscopic appearance of dysplasia and cancer in inflammatory bowel disease. Tytgat GN, et al. **Eur J Cancer** 1995 Jul–Aug;31A(7–8):1174–7 (41 ref.)

The association of inflammatory bowel disease and leukemia—coincidence or not? Caspi O, et al. **Leuk Lymphoma** 1995 Apr;17(3–4):255–62 (45 ref.)

[Significance of intestinal inflammation in the pathogenesis of spondylarthropathies] Mielants H, et al. **Verh K Acad Geneeskd Belg** 1996;58(2):93–116 (70 ref.) (Eng. Abstr.) **(Dut)**

[Bone disorders in intestinal cryptogenetic inflammatory diseases] Abitbol V, et al. **Gastroenterol Clin Biol** 1995 Oct; 19(10):826–32 (54 ref.) **(Fre)**

[Liver dysfunction in patients with inflammatory bowel disease—with special reference to primary sclerosing cholangitis] Kakei N, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):301–4 (8 ref.) **(Jpn)**

DIAGNOSIS

Is endoscopic surveillance worthwhile in IBD? De Vos M, et al. **Acta Gastroenterol Belg** 1995 Sep–Dec;58(5–6):405–8 (28 ref.)

Inflammatory bowel disease in children. Aideyan UO, et al. **Radiol Clin North Am** 1996 Jul;34(4):885–902 (46 ref.)

[Consensus inflammatory intestinal diseases in children: ulcerative colitis and Crohn disease. Work Group Academic Medical Center, Amsterdam] Büller HA, et al. **Ned Tijdschr Geneeskd** 1996 Mar 9;140(10):544–50 (6 ref.) (Eng. Abstr.) **(Dut)**

[Emergency drug therapy of non-specific inflammatory bowel diseases—progress on diagnosis and therapy] Aasakura H, et al. **Nippon Naika Gakkai Zasshi** 1995 Nov 10;84(11):1815–20 (5 ref.) **(Jpn)**

DIET THERAPY

[Polyunsaturated fatty acids and their metabolites in chronic inflammatory bowel disease] Cabré i Gelada E, et al. **Gastroenterol Hepatol** 1995 Dec;18(10):515–25 (90 ref.) **(Spa)**

DRUG THERAPY

Effects of mesalazine on the formation of lipoxygenase and cyclooxygenase products. Lauritsen K, et al. **Adv Exp Med Biol** 1995;371B:1301–6 (66 ref.)

Review article: the risks of malignancy from either immunosuppression or diagnostic radiation in inflammatory bowel disease. Forbes A, et al. **Aliment Pharmacol Ther** 1995 Oct;9(5):465–70 (31 ref.)

My thoughts on using cyclosporine in the treatment of inflammatory bowel disease [editorial; comment] Korelitz BI. **Am J Gastroenterol** 1995 Dec;90(12):2085–6 (17 ref.) Comment on: Am J Gastroenterol 1995 Dec;90(12):2093–6.

A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Sandborn WJ. **Am J Gastroenterol** 1996 Mar;91(3):423–33 (65 ref.)

The basis of current and future therapy for inflammatory bowel disease. Elson CO. **Am J Med** 1996 Jun; 100(6):656–62 (26 ref.)

Use of old and new oral 5-aminosalicylic acid formulations in inflammatory bowel disease. Brzezinski A, et al. **Cleve Clin J Med** 1995 Sep–Oct;62(5):317–23 (37 ref.)

Aminosalicylates for the treatment of inflammatory bowel disease. Leichtner AM. **J Pediatr Gastroenterol Nutr** 1995 Oct;21(3):245–52 (66 ref.)

Methotrexate for inflammatory bowel disease: pharmacology and preliminary results [see comments] Egan LJ, et al. **Mayo Clin Proc** 1996 Jan;71(1):69–80 (98 ref.) Comment in: Mayo Clin Proc 1996 Jan;71(1):104–5.

Current medical therapy for inflammatory bowel disease. Bonner GF. **South Med J** 1996 Jun;89(6):556–66 (143 ref.)

[Consensus inflammatory intestinal diseases in children: ulcerative colitis and Crohn disease. Work Group Academic Medical Center, Amsterdam] Büller HA, et al. **Ned Tijdschr Geneeskd** 1996 Mar 9;140(10):544–50 (6 ref.) (Eng. Abstr.) **(Dut)**

[Changing treatment of inflammatory bowel diseases] Karvonen AL, et al. **Duodecim** 1994;110(20):1945–54 (58 ref.) **(Fin)**

[Cyclosporine A and chronic inflammatory diseases of the digestive tract] Brazier F, et al. **Gastroenterol Clin Biol** 1995 May;19(5):494–504 (118 ref.) **(Fre)**

[Emergency drug therapy of non-specific inflammatory bowel diseases—progress on diagnosis and therapy] Aasakura H, et al. **Nippon Naika Gakkai Zasshi** 1995 Nov 10;84(11):1815–20 (5 ref.) **(Jpn)**

EPIDEMIOLOGY

Relationships between sclerosing cholangitis, inflammatory bowel disease, and cancer in patients undergoing liver transplantation. Knechtle SJ, et al. **Surgery** 1995 Oct; 118(4):615–9; discussion 619–20 (18 ref.)

ETIOLOGY

Animal models of inflammatory bowel disease. Bhatti MA, et al. **Int J Exp Pathol** 1995 Oct;76(5):309–15 (56 ref.)

Pathogenetic mechanisms of inflammatory bowel disease. Caprilli R, et al. **Ital J Gastroenterol** 1995 Jul–Aug; 27(6):313–26 (98 ref.)

Inflammatory pseudocyst associated with trisomy 21 and Hirschsprung's disease. DuBois JJ, et al. **Mil Med** 1995 Sep;160(9):477–9 (28 ref.)

[Cytokines in chronic inflammatory intestinal diseases] Neurath MF, et al. **Dtsch Med Wochenschr** 1996 May 31; 121(22):735–41 (48 ref.) **(Ger)**

GENETICS

[Genetics of inflammatory bowel diseases] Hugot JP, et al. **Gastroenterol Clin Biol** 1995 Nov;19(11):890–8 (125 ref.) **(Fre)**

IMMUNOLOGY

The basis of current and future therapy for inflammatory bowel disease. Elson CO. **Am J Med** 1996 Jun; 100(6):656–62 (26 ref.)

Active immunity or tolerance to foods in patients with celiac disease or inflammatory bowel disease. Ferguson A, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:202–16 (25 ref.)

Signposts to therapy: recent advances in inflammatory bowel disease research. Hamilton J. **Can Med Assoc J** 1996 May 15;154(10):1513–6 (10 ref.)

Pathogenesis of inflammatory bowel disease: evolving concepts. Mayer L, et al. **Mt Sinai J Med** 1996 May–Sep; 63(3–4):202–9 (69 ref.)

Genetic and spontaneous models of inflammatory bowel disease in rodents: evidence for abnormalities in mucosal immune regulation. Powrie F, et al. **Ther Immunol** 1995 Apr;2(2):115–23 (57 ref.)

[Crohn disease, hemorrhagic rectocolitis: antibodies and humans (editorial)] Duclos B. **Gastroenterol Clin Biol** 1995 Nov;19(11):865–6 (21 ref.) **(Fre)**

METABOLISM

Effects of mesalazine on the formation of lipoxygenase and cyclooxygenase products. Lauritsen K, et al. **Adv Exp Med Biol** 1995;371B:1301–6 (66 ref.)

[Polyunsaturated fatty acids and their metabolites in chronic inflammatory bowel disease] Cabré i Gelada E, et al. **Gastroenterol Hepatol** 1995 Dec;18(10):515–25 (90 ref.) **(Spa)**

[Role of reactive oxygen metabolites in the pathogenesis of chronic inflammatory bowel disease] Fernández-Bañares F. **Gastroenterol Hepatol** 1995 Dec;18(10):526–36 (55 ref.) **(Spa)**

PATHOLOGY

Insulin-like growth factors and inflammatory bowel disease. Lund PK, et al. **Baillieres Clin Gastroenterol** 1996 Mar; 10(1):83–96 (77 ref.)

Course of gut inflammation in spondylarthropathies and therapeutic consequences. Mielants H, et al. **Baillieres Clin Rheumatol** 1996 Feb;10(1):147–64 (75 ref.)

PHYSIOPATHOLOGY

Adhesion molecules in inflammatory and neoplastic intestinal diseases. Pedersen G, et al. **Dig Dis** 1995 Sep–Oct; 13(5):322–36 (103 ref.)

Role of cytokines and platelet-activating factor in inflammatory bowel disease. Implications for therapy. Nassif A, et al. **Dis Colon Rectum** 1996 Feb;39(2):217–23 (66 ref.)

RADIOGRAPHY

Review article: the risks of malignancy from either immunosuppression or diagnostic radiation in inflammatory bowel disease. Forbes A, et al. **Aliment Pharmacol Ther** 1995 Oct;9(5):465–70 (31 ref.)

SURGERY

[Treatment of inflammatory bowel disease. Present and future perspective] Muto T. **Nippon Geka Gakkai Zasshi** 1995 Aug;96(8):511–7 (26 ref.) **(Jpn)**

[Recent advance in surgical treatment for inflammatory bowel disease] Sasaki I, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Oct;92(10):1715–23 (60 ref.) **(Jpn)**

THERAPY

Course of gut inflammation in spondylarthropathies and therapeutic consequences. Mielants H, et al. **Baillieres Clin Rheumatol** 1996 Feb;10(1):147–64 (75 ref.)

Signposts to therapy: recent advances in inflammatory bowel disease research. Hamilton J. **Can Med Assoc J** 1996 May 15;154(10):1513–6 (10 ref.)

Inflammatory bowel disease in children. von Allmen D, et al. **Curr Opin Pediatr** 1995 Oct;7(5):547–52 (42 ref.)

Nutritional support in inflammatory bowel disease. Zurita VF, et al. **Dig Dis** 1995 Mar–Apr;13(2):92–107 (91 ref.)

Effect of intervention in inflammatory bowel disease on health-related quality of life: a critical review. Maunder RG, et al. **Dis Colon Rectum** 1995 Nov;38(11):1147–61 (77 ref.)

[Chronic inflammatory bowel diseases and nutrition] Meier R. **Schweiz Med Wochenschr Suppl** 1996;79:14S–24S (101 ref.) (Eng. Abstr.) **(Ger)**

INFLAMMATORY RESPONSE SYNDROME, SYSTEMIC see **SEPSIS SYNDROME**

INFLUENZA

COMPLICATIONS

[Rhabdomyolysis and influenza infections] Baytner-Zamir H, et al. **Harefuah** 1996 Feb 1;130(3):208–10 (35 ref.) **(Heb)**

DIAGNOSIS

Influenza virus pneumonia: pathogenesis, treatment, and prevention. Piedra PA. **Semin Respir Infect** 1995 Dec; 10(4):216–23 (43 ref.)

DRUG THERAPY

Update on therapy of influenza and rhinovirus infections. Arruda E, et al. **Adv Exp Med Biol** 1996;394:175–87 (93 ref.)

[Are antibiotics necessary for a child with the flu? (editorial)] Mäkelä M, et al. **Duodecim** 1995;111(7):583–4 (12 ref.) **(Fin)**

EPIDEMIOLOGY

Patterns and predictability in emerging infections. Morse SS. **Hosp Pract (Off Ed)** 1996 Apr 15;31(4):85–91, 96–101, 104 passim (11 ref.)

The next pandemic influenza virus? Shortridge KF. **Lancet** 1995 Nov 4;346(8984):1210–2 (10 ref.)

[The nature of pandemic strains of the influenza virus] Golubev DB. **Tr Inst Im Pastera** 1992;67:65–73 (52 ref.) **(Rus)**

ETIOLOGY

Orthomyxoviral and paramyxoviral infections in transplant patients. Sable CA, et al. **Infect Dis Clin North Am** 1995 Dec;9(4):987–1003 (70 ref.)

IMMUNOLOGY

Interferons, Mx genes, and resistance to influenza virus. Horisberger MA. **Am J Respir Crit Care Med** 1995 Oct; 152(4 Pt 2):S67–71 (56 ref.)

PREVENTION & CONTROL

Mucosal vaccines for the prevention of influenza. Clancy RL. **Drugs** 1995 Oct;50(4):587–94 (108 ref.)

The value of influenza and pneumococcal vaccines in the elderly. Monto AS, et al. **Drugs Aging** 1996 Jun;8(6):445–51 (35 ref.)

Synthetic recombinant vaccines against viral agents. Arnon A, et al. **Int Arch Allergy Immunol** 1995 Dec;108(4):321–6 (48 ref.)

Influenza vaccines. Brede HD. **Int Arch Allergy Immunol** 1995 Dec;108(4):318–20 (2 ref.)

Preventing influenza and its complications: a public health initiative for the year 2000. Reece SM. **Nurse Pract** 1995 Sep;20(9):32–6, 44 (13 ref.)

Influenza in the elderly. Prevention is the best strategy in high-risk populations. Bradley SF. **Postgrad Med** 1996 Feb; 99(2):138–9, 143–9 (20 ref.)

Influenza vaccination in the elderly. Morgan R, et al. **Postgrad Med J** 1996 Jun;72(848):339–42 (30 ref.)

[Influenza vaccine for all the elderly!] Ligthart GJ. **Ned Tijdschr Geneeskd** 1995 Oct 21;139(42):2125–7 (20 ref.) **(Dut)**

[Vaccine prophylaxis of influenza] Fridman EA, et al. **Tr Inst Im Pastera** 1992;67:45–64 (51 ref.) **(Rus)**

[Effectiveness of influenza vaccine in the elderly. A critical review of the bibliography] Puig Barberà J, et al. **Med Clin (Barc)** 1995 Nov 18;105(17):645–8 (35 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

Reducing demand for physician visits through public education: a look at the pilot cold-and-flu campaign in London, Ontario. Brown EM, et al. **Can Med Assoc J** 1996 Mar 15;154(6):835–40 (21 ref.)

Influenza virus pneumonia: pathogenesis, treatment, and prevention. Piedra PA. **Semin Respir Infect** 1995 Dec; 10(4):216–23 (43 ref.)

TRANSMISSION

Interspecies transmission of influenza viruses. Webster RG, et al. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 2):S25–30 (27 ref.)

INFLUENZA D VIRUS see **PARAINFLUENZA VIRUS TYPE 1**

INFLUENZA VACCINE

Influenza in the elderly. Prevention is the best strategy in high-risk populations. Bradley SF. **Postgrad Med** 1996 Feb; 99(2):138–9, 143–9 (20 ref.)

[Influenza vaccine for all the elderly!] Ligthart GJ. **Ned Tijdschr Geneeskd** 1995 Oct 21;139(42):2125–7 (20 ref.) **(Dut)**

[Effectiveness of influenza vaccine in the elderly. A critical review of the bibliography] Puig Barberà J, et al. **Med Clin (Barc)** 1995 Nov 18;105(17):645–8 (35 ref.) (Eng. Abstr.) **(Spa)**

ADMINISTRATION & DOSAGE

Mucosal vaccines for the prevention of influenza. Clancy RL. **Drugs** 1995 Oct;50(4):587–94 (108 ref.)

ADVERSE EFFECTS

Influenza vaccine may enhance theophylline toxicity. A case report and review of the literature. Hamdy RC, et al. **J Tenn Med Assoc** 1995 Dec;88(12):463–4 (12 ref.)

GENETICS

A review of attenuation of influenza viruses by genetic manipulation. Belshe RB. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 2):S72–5 (26 ref.)

IMMUNOLOGY

Synthetic recombinant vaccines against viral agents. Arnon A, et al. **Int Arch Allergy Immunol** 1995 Dec;108(4):321–6 (48 ref.)

Influenza vaccines. Brede HD. **Int Arch Allergy Immunol** 1995 Dec;108(4):318–20 (2 ref.)

THERAPEUTIC USE

The value of influenza and pneumococcal vaccines in the elderly. Monto AS, et al. **Drugs Aging** 1996 Jun;8(6):445–51 (35 ref.)

[Vaccine prophylaxis of influenza] Fridman EA, et al. **Tr Inst Im Pastera** 1992;67:45–64 (51 ref.) **(Rus)**

INFLUENZA VIRUS, AVIAN see **ORTHOMYXOVIRUS TYPE A, AVIAN**

INFLUENZA VIRUS, EQUINE see **ORTHOMYXOVIRUSES TYPE A**

INFLUENZA VIRUS TYPE A, HUMAN see **ORTHOMYXOVIRUS TYPE A, HUMAN**

INFLUENZA VIRUSES see **ORTHOMYXOVIRIDAE**

INFLUENZA VIRUSES TYPE A see **ORTHOMYXOVIRUSES TYPE A**

INFLUENZA VIRUSES TYPE B see **ORTHOMYXOVIRUSES TYPE B**

INFORMATION DISPLAY see **DATA DISPLAY**

INFORMATION DISSEMINATION see **INFORMATION SERVICES**

INFORMATION PROCESSING, AUTOMATIC see **AUTOMATIC DATA PROCESSING**

INFORMATION PROCESSING, HUMAN see **MENTAL PROCESSES**

INFORMATION RETRIEVAL see **INFORMATION STORAGE AND RETRIEVAL**

INFORMATION RETRIEVAL SYSTEMS see **INFORMATION SYSTEMS**

INFORMATION SCIENCE

[Toward virtual life from bioinformatics] Sugawara H. **Tanpakushitsu Kakusan Koso** 1995 Sep;40(12):1809–21 (15 ref.) **(Jpn)**

[Development of information biology] Tateno Y. **Tanpakushitsu Kakusan Koso** 1995 Sep;40(12):1803–8 (16 ref.) **(Jpn)**

INFORMATION SERVICES

see related
LIBRARIES

Accessing and using the Internet's World Wide Web for emergency physicians. Yamamoto LG, et al. **Am J Emerg Med** 1996 May;14(3):302–8 (10 ref.)

Medical information: from Surgeon General to superhighway. Deering CM, et al. **Ann Trop Med Parasitol** 1995 Dec;89(6):579–91 (20 ref.)

Medical resources and the internet. Making the connection. Kramer JM, et al. **Arch Intern Med** 1996 Apr 22; 156(8):833–42 (13 ref.)

A field-based dissemination component in a drug abuse research center. Sorensen JL, et al. **NIDA Res Monogr** 1995;155:186–97 (24 ref.)

Communicating emerging scientific information. **Nutr Rev** 1996 May;54(5):153–7 (2 ref.)

On-line food and nutrition information resources. Institute of Food Science and Technology. **Nutr Rev** 1996 May; 54(5):158 (0 ref.)

[The Internet and clinical medicine. An introduction to the biomedical information services available in electronic form on the "net of all nets"] Tringali M, et al. **Recenti Prog Med** 1996 May;87(5):237–49 (11 ref.) (Eng. Abstr.) **(Ita)**

UTILIZATION

Improving the use of information in medical effectiveness research. Phillips KA, et al. **Int J Qual Health Care** 1996 Feb;8(1):21–30 (96 ref.)

INFORMATION STORAGE AND RETRIEVAL

Ethics, genomics, and information retrieval. Goodman KW. **Comput Biol Med** 1996 May;26(3):223–9 (23 ref.)

Taking a bite out of CRISP. Strategies on using and conducting searches in the Computer Retrieval of Information on Scientific Projects database. Bair AH, et al. **Comput Nurs** 1996 Jul-Aug;14(4):218–24; quiz 225–6 (10 ref.)

Recent progress in digital image formatting and current trends in computers: their role in digital image storage and telemedicine. Commentary. Thomas JD. **Curr Opin Cardiol** 1995 Nov;10(6):615–8 (14 ref.)

Benefits and lessons learned from stored electrogram information in implantable defibrillators. Marchlinski FE, et al. **J Cardiovasc Electrophysiol** 1995 Oct;6(10 Pt 1):832–51 (29 ref.)

A reader's guide to the evaluation of prognostic studies. van Walraven C, et al. **Postgrad Med J** 1996 Jan;72(843):6–11 (7 ref.)

[Use of computer base MEDIP in retrieving information on occupational medicine and hygiene] Przyłuska J. **Med Pr** 1996;47(2):183–8 (5 ref.) (Eng. Abstr.) **(Pol)**

INFORMATION SYSTEMS

Using hub technology to facilitate information system integration in a health-care enterprise. Gendler SM, et al. **Am J Clin Pathol** 1996 Apr;105(4 Suppl 1):S25–32 (5 ref.)

Developing a quality improvement database using health insurance data: a guided tour with application to Medicare's National Claims History file. Parente ST, et al. **Am J Med Qual** 1995 Winter;10(4):162–76 (21 ref.)

Testing models predicting severity of respiratory syncytial virus infection on the PICNIC RSV database. Pediatric Investigators Collaborative Network on Infections in Canada. Opavsky MA, et al. **Arch Pediatr Adolesc Med** 1995 Nov;149(11):1217–20 (25 ref.)

High-density gridding: techniques and applications. Southern EM. **Curr Opin Biotechnol** 1996 Feb;7(1):85–8 (21 ref.)

Recent progress in digital image formatting and current trends in computers: their role in digital image storage and telemedicine. Commentary. Thomas JD. **Curr Opin Cardiol** 1995 Nov;10(6):615–8 (14 ref.)

Deciding among interactive multimedia technologies. Locatis C. **J Biocommun** 1995;22(2):2–7 (20 ref.)

Childhood immunization registries. A national review of public health information systems and the protection of privacy [see comments] Gostin LO, et al. **JAMA** 1995 Dec 13;274(22):1793–9 (76 ref.) Comment in: JAMA 1996 May 1;275(17):1312–3.

ACeDB and macace. Eeckman FH, et al. **Methods Cell Biol** 1995;48:583–605 (5 ref.)

The Worm Community System, release 2.0 (WCSr2). Shoman LM, et al. **Methods Cell Biol** 1995;48:607–25 (17 ref.)

Transplant information transfer and analysis in cyberspace. Merion RM. **Transplant Proc** 1996 Aug;28(4):2026–8 (3 ref.)

The use of geographical information systems in studies on environment and health. Briggs DJ, et al. **World Health Stat Q** 1995;48(2):85–94 (31 ref.)

[Internet—an introduction not only for the physician] Schäfer N. **Z Arztl Fortbild (Jena)** 1996 Feb;90(1):33–42 (21 ref.) (Eng. Abstr.) **(Ger)**

[A practical approach to health information in Spain] Mirón Canelo JA, et al. **Rev Clin Esp** 1996 Mar;196(3):174–8 (57 ref.) **(Spa)**

ORGANIZATION & ADMINISTRATION

[Public health surveillance and the environment] Quénel P. **Rev Epidemiol Sante Publique** 1995;43(5):412–22 (38 ref.) (Eng. Abstr.) **(Fre)**

STANDARDS

The Weight-Control Information Network: a project of the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health. **Nutr Rev** 1995 Aug;53(8):232–3 (0 ref.)

International Poison Information Center data collection capabilities. Krenzelok EP, et al. **Vet Hum Toxicol** 1995 Jun;37(3):246–8 (3 ref.)

TRENDS

[Analytic review in the era of the scientific information explosion] Shats V, et al. **Harefuah** 1996 Mar 15; 130(6):414–5 (19 ref.) **(Heb)**

UTILIZATION

Reaping the benefits of medical information systems. Wong ET, et al. **Acad Med** 1996 Apr;71(4):353–7 (32 ref.)

INFORMATION THEORY

[Temporal organization and information in biological systems] Romanov IuA. **Aviakosm Ekolog Med** 1995; 29(4):4–9 (44 ref.) (Eng. Abstr.) **(Rus)**

[The information principle in physiology: an analysis from the position of the general theory of functional systems] Sudakov KV. **Usp Fiziol Nauk** 1995 Oct-Dec;26(4):3–27 (79 ref.) (Eng. Abstr.) **(Rus)**

INFORMED CONSENT

see related
HUMAN EXPERIMENTATION
TRUTH DISCLOSURE

Presumed consent: the solution to the critical organ donor shortage? Futterman LG. **Am J Crit Care** 1995 Sep; 4(5):383–8 (78 ref.)

Ethical considerations of ensuring an informed and autonomous consent in research involving critically ill patients. Silverman HJ. **Am J Respir Crit Care Med** 1996 Sep;154(3 Pt 1):582–6 (34 ref.)

Psychosocial and ethical implications of defining genetic risk for cancers. Kash KM. **Ann N Y Acad Sci** 1995 Sep 30; 768:41–52 (26 ref.)

How to do it. Get patients' consent to enter clinical trials [see comments] Wager E, et al. **BMJ** 1995 Sep 16; 311(7007):734–7 (36 ref.) Comment in: BMJ 1996 Jan 20;312(7024):185–6. Comment in: BMJ 1996 Jan 20;312(7024):186. Comment in: BMJ 1996 Mar 30;312(7034):847.

Decision-making capacity for informed consent in the older population. Christensen K, et al. **Bull Am Acad Psychiatry Law** 1995;23(3):353–65 (27 ref.)

Bioethics for clinicians: 1. Consent [see comments] Etchells E, et al. **Can Med Assoc J** 1996 Jul 15;155(2):177–80 (31 ref.) Comment in: Can Med Assoc J 1996 Jul 15;155(2):189–90.

Prevention. How much harm? How much benefit? 4. The ethics of informed consent for preventive screening programs. Marshall KG. **Can Med Assoc J** 1996 Aug 15; 155(4):377–83 (57 ref.)

Randomised consent designs in cancer clinical trials. Altman DG, et al. **Eur J Cancer** 1995 Nov;31A(12):1934–44 (53 ref.)

Logic, hermeneutics, and informed consent. Little JM, et al. **Eur J Surg** 1996 Jan;162(1):3–10 (31 ref.)

Informed consent and home birth. Spindel PG, et al. **J Nurse Midwifery** 1995 Nov-Dec;40(6):541–69 (56 ref.)

Informed consent for genetic research on stored tissue samples [see comments] Clayton EW, et al. **JAMA** 1995 Dec 13;274(22):1786–92 (31 ref.) Comment in: JAMA 1995 Dec 13;274(22):1806–7. Comment in: JAMA 1996 Apr 10;275(14):1085; discussion 1086. Comment in: JAMA 1996 Apr 10;275(14):1085–6.

Discussing cardiopulmonary resuscitation with patients and relatives. Stewart K. **Postgrad Med J** 1995 Oct; 71(840):585–9 (30 ref.)

Ethical aspects of prevention. Tomatis L. **Scand J Work Environ Health** 1995 Aug;21(4):245–51 (44 ref.)

Mental competence and the question of beneficent intervention. Checkland D, et al. **Theor Med** 1996 Jun; 17(2):121–34 (43 ref.)

Obtaining "informed" consent from the elderly. Alt-White AC. **West J Nurs Res** 1995 Dec;17(6):700–5 (12 ref.)

[Informed consent and mental competence of the elderly in medical-scientific studies] Olde Rikkert MG, et al. **Tijdschr Gerontol Geriatr** 1995 Aug;26(4):152–62 (40 ref.)

(Eng. Abstr.) **(Dut)**

[How should informed consent for an invasive radiologic procedure be phrased in order that responsibility for contrast agent reactions be blamed on the patient himself] Barzilai M. **Harefuah** 1995 Jun 1;128(11):732–4 (33 ref.) **(Heb)**

[The use of informed consensus forms. Some critical reflections] Zuppiroli A, et al. **G Ital Cardiol** 1995 Sep; 25(9):1223–9 (29 ref.) **(Ita)**

[Getting informed consent in clinical trials on Japanese cancer patients] Sasako M. **Gan To Kagaku Ryoho** 1996 Jan;23(2):146–50 (3 ref.) (Eng. Abstr.) **(Jpn)**

[Informed consent in phase I trial] Shimada Y. **Gan To Kagaku Ryoho** 1996 Jan;23(2):226–30 (2 ref.) (Eng. Abstr.) **(Jpn)**

[Decision making and informed consent in clinical medicine] Sakurai T. **Nippon Igaku Hoshasen Gakkai Zasshi** 1995 Oct; 55(13):459–62 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Cancer patient care—informed consent and disease notification] Eguchi K. **Nippon Naika Gakkai Zasshi** 1996 Mar 10;85(3):356–9 (25 ref.) **(Jpn)**

[Informed consent to the patient with hereditary ataxia] Takayanagi T, et al. **No To Shinkei** 1996 May;48(5):437–42 (16 ref.) **(Jpn)**

LEGISLATION & JURISPRUDENCE

Negligent infliction of emotional distress: a focus on relationships. Appleberry JM. **Am J Law Med** 1995; 21(2–3):301–22 (190 ref.)

Consent to neuroleptic medication for schizophrenia: clinical, ethical and legal issues. Brabbins C, et al. **Br J Psychiatry** 1996 May;168(5):540–4 (23 ref.)

Informed consent in chronic schizophrenia? [editorial] Jones GH. **Br J Psychiatry** 1995 Nov;167(5):565–8 (10 ref.)

How important is consent for controlled clinical trials? MacKinnon B. **Camb Q Healthc Ethics** 1996 Spring; 5(2):221–7 (6 ref.)

Informed consent issues in international research concerns. Porter JP. **Camb Q Healthc Ethics** 1996 Spring;5(2):237–43 (25 ref.)

Teenage abortion in Germany: with reference to the legal system in the United States. Belling DW, et al. **J Contemp Health Law Policy** 1996 Spring;12(2):475–502 (128 ref.)

Consent to medical treatment by older children in English & Scottish law. Bissett-Johnson A, et al. **J Contemp Health Law Policy** 1996 Spring;12(2):449–73 (117 ref.)

A visitation with informed consent and refusal. Hirsh HL. **Leg Med** 1995;:147–203 (131 ref.)

Informed consent: process and clinical issues. Berry DL, et al. **Oncol Nurs Forum** 1996 Apr;23(3):507–12 (19 ref.)

The contours of informed consent. Lanckton AV. **Surv Ophthalmol** 1996 Mar–Apr;40(5):391–4 (15 ref.)

[The physician's duty to inform in interventional radiological therapeutic procedures] Duda SH, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1995 Oct;163(4):335–40 (28 ref.) (Eng. Abstr.) **(Ger)**

[Legal aspects of treatment and care of elderly patients] Kaatsch HJ, et al. **Z Gerontol Geriatr** 1996 May–Jun; 29(3):176–9 (11 ref.) (Eng. Abstr.) **(Ger)**

[Legal aspects of neurotransplantation] Wolfslast G. **Zentralbl Neurochir** 1995;56(4):210–4 (35 ref.) (Eng. Abstr.) **(Ger)**

INFRARED RAYS

DIAGNOSTIC USE

[Near infrared interactance for measurement of body fat mass] Sawai S, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:183–8 (11 ref.) **(Jpn)**

INFRARED SPECTROPHOTOMETRY see **SPECTROPHOTOMETRY, INFRARED**

INFRATENTORIAL NEOPLASMS

SURGERY

The surgery of cavernomas both supra-tentorial and infra-tentorial. Houtteville JP. **Adv Tech Stand Neurosurg** 1995;22:185–259 (134 ref.)

INFUNDIBULAR NUCLEUS see **ARCUATE NUCLEUS**

INFUSION PUMPS

Review of pumps for continuous infusion of coagulation factor concentrates: what are the options? Martinowitz U, et al. **Blood Coagul Fibrinolysis** 1996 Mar;7 Suppl 1:S27–33 (10 ref.)

Design and assessment of clinical trials on continuous infusion. Schulman S, et al. **Blood Coagul Fibrinolysis** 1996 Mar;7 Suppl 1:S7–9 (8 ref.)

A model for technology assessment as applied to closed loop infusion systems. Technology Assessment Task Force of the Society of Critical Care Medicine. Jastremski M, et al. **Crit Care Med** 1995 Oct;23(10):1745–55 (105 ref.)

Target-controlled infusion delivery systems: application outside the operating room. Bovill JG, et al. **J Clin Anesth** 1996 May;8(3 Suppl):21S–25S (33 ref.)

Implications of automation surprises in aviation for the future of total intravenous anesthesia (TIVA). Cook RI, et al. **J Clin Anesth** 1996 May;8(3 Suppl):29S–37S (49 ref.)

Intravenous drug delivery systems: toward an intravenous "vaporizer". Egan TD. **J Clin Anesth** 1996 May;8(3 Suppl):8S–14S (38 ref.)

Target-controlled infusions: stress free anesthesia? Kenny GN, et al. **J Clin Anesth** 1996 May;8(3 Suppl):15S–20S (46 ref.)

Intravenous anesthesia and analgesia: what is the role of target-controlled infusion? White PF. **J Clin Anesth** 1996 May;8(3 Suppl):26S–28S (22 ref.)

ECONOMICS

Prophylaxis and continuous infusion for hemophilia: can we afford it? Aledort LM, et al. **Blood Coagul Fibrinolysis** 1996 Mar;7 Suppl 1:S35–7 (5 ref.)

INFUSION PUMPS, EXTERNAL see **INFUSION PUMPS**

INFUSION PUMPS, IMPLANTABLE

Implantable pumps for drug delivery to the brain. Bakhshi S, et al. **J Neurooncol** 1995 Nov;26(2):133–9 (68 ref.)

Intracerebroventricular administration of morphine for control of irreducible cancer pain. Lazorthes YR, et al. **Neurosurgery** 1995 Sep;37(3):422–8; discussion 428–9 (26 ref.)

Ambulatory infusion pumps: application to oncology. Rapsilber LM, et al. **Semin Oncol Nurs** 1995 Aug; 11(3):213–20 (46 ref.)

ADVERSE EFFECTS

[Fibrinolysis of deep venous thrombosis on implantable perfusion devices. Apropos of a consecutive series of 57 cases of thrombosis and 32 cases of fibrinolysis] Pucheu A, et al. **Bull Cancer (Paris)** 1996 Apr;83(4):293–9 (33 ref.) (Eng. Abstr.) **(Fre)**

INFUSION THERAPY, HOME see **HOME INFUSION THERAPY**

INFUSIONS, INTRA-ARTERIAL

Non-invasive loco-regional therapy for hepatocellular carcinoma. Tanikawa K. **Semin Surg Oncol** 1996 May–Jun; 12(3):189–92 (15 ref.)

[Results of resection and adjuvant therapy of liver metastases of primary colorectal tumors—a review of the literature] Lorenz M, et al. **Zentralbl Chir** 1995;120(10):769–79 (74 ref.) (Eng. Abstr.) **(Ger)**

[Regional adjuvant therapy in colorectal liver metastases: requirements for clinical therapy studies from the statistical viewpoint (see comments)] Müller HH, et al. **Zentralbl Chir** 1995;120(10):755–9 (10 ref.) (Eng. Abstr.) Comment in: Zentralbl Chir 1995;120(10):753–4. **(Ger)**

[Pharmacology of regional chemotherapy of colorectal liver metastases] Schalhorn A, et al. **Zentralbl Chir** 1995; 120(10):764–8 (15 ref.) (Eng. Abstr.) **(Ger)**

INSTRUMENTATION

Arterial, peritoneal, and intraventricular access devices. Almadrones L, et al. **Semin Oncol Nurs** 1995 Aug; 11(3):194–202 (23 ref.)

METHODS

Aortic-based therapy for cardiac arrest. Paradis NA. **Ann Emerg Med** 1996 May;27(5):563–8 (42 ref.)

INFUSIONS, INTRAVENOUS

see related
IMMUNOGLOBULINS, INTRAVENOUS

The use of gauze versus transparent dressings for peripheral intravenous catheter sites. Pettit DM, et al. **Nurs Clin North Am** 1995 Sep;30(3):495–506 (15 ref.)

[Mixtures of infusion solutions and drugs. Compatibility and incompatibility] Pecar A, et al. **Anaesthesist** 1995 Nov; 44(11):793–803 (20 ref.) (Eng. Abstr.) **(Ger)**

INFUSIONS, PARENTERAL

see related
FLUID THERAPY
HOME INFUSION THERAPY

[Lipid vehicles for the parenteral administration of drugs (1): emulsions] Bermejo Vicedo T, et al. **Nutr Hosp** 1996 Jan–Feb;11(1):7–16 (49 ref.) (Eng. Abstr.) **(Spa)**

INSTRUMENTATION

The potential for use of steam at atmospheric pressure to decontaminate or sterilize parenteral filling lines incorporating barrier isolation technology. Lysfjord JP, et al. **PDA J Pharm Sci Technol** 1995 Sep–Oct;49(5):212–9 (17 ref.)

Peripheral access options. Ryder MA. **Surg Oncol Clin N Am** 1995 Jul;4(3):395–427 (181 ref.)

INFUSIONS, REGIONAL ARTERIAL see **INFUSIONS, INTRA-ARTERIAL**

INFUSORS see **INFUSION PUMPS**

INGUINAL CANAL

BLOOD SUPPLY

[Current status of reconstructive surgery of the sub-inguinal artery] Testart J, et al. **Chirurgie** 1994–95;120(10):582–8 (55 ref.) (Eng. Abstr.) **(Fre)**

INGUINAL HERNIA see **HERNIA, INGUINAL**

INHALATION ANESTHETICS see **ANESTHETICS, INHALATION**

INHALATION BURNS see **BURNS, INHALATION**

INHALATION DEVICES see **NEBULIZERS AND VAPORIZERS**

INHALATION DRUG ADMINISTRATION see **ADMINISTRATION, INHALATION**

INHALATION OF DRUGS see **ADMINISTRATION, INHALATION**

INHALATION PROVOCATION TESTS see **BRONCHIAL PROVOCATION TESTS**

INHALATION THERAPY see **RESPIRATORY THERAPY**

INHALATORS see **NEBULIZERS AND VAPORIZERS**

INHALERS see **NEBULIZERS AND VAPORIZERS**

INHIBIN

Aspects of current and future inhibin research. Burger HG, et al. **Reprod Fertil Dev** 1995;7(5):997–1002 (33 ref.)

BIOSYNTHESIS

Inhibin and activin production in human placenta. Qu J, et al. **Endocr Rev** 1995 Aug;16(4):485–507 (258 ref.)

BLOOD

Measurement of circulating inhibin levels: revisiting the inhibin hypothesis [editorial; comment] Bhasin S, et al. **J Clin Endocrinol Metab** 1996 Apr;81(4):1318–20 (22 ref.) Comment on: J Clin Endocrinol Metab 1996 Apr;81(4):1321–5.

GENETICS

[Progress in the study of inhibin subunit gene expression and regulation in mammalian ovary] Kong DJ, et al. **Sheng Li Ko Hsueh Chin Chan** 1995 Jul;26(3):204–8 (17 ref.) (Eng. Abstr.) **(Chi)**

PHARMACOLOGY

[Inhibin and activin] Toppari J, et al. **Duodecim** 1994; 110(10):1029–34 (31 ref.) **(Fin)**

PHYSIOLOGY

Transgenic models to study the roles of inhibins and activins in reproduction, oncogenesis, and development. Matzuk MM, et al. **Recent Prog Horm Res** 1996;51:123–54; discussion 155–7 (107 ref.)

Implication of inhibin and related proteins in fetal development. Jenkin G, et al. **Reprod Fertil Dev** 1995; 7(3):323–31 (71 ref.)

INHIBITION, NEURAL see **NEURAL INHIBITION**

INJECTIONS, EPIDURAL

see related
ANESTHESIA, EPIDURAL

ADVERSE EFFECTS

Complications associated with epidural steroid injections. Abram SE, et al. **Reg Anesth** 1996 Mar–Apr;21(2):149–62 (134 ref.)

INJECTIONS, INTRAMUSCULAR

[Benefits and risks of intramuscular injection. Are expectations of physicians and patients irrational?] Sohn W. **Fortschr Med** 1996 Jun 20;114(17):217–20 (28 ref.) (Eng. Abstr.) **(Ger)**

NURSING

An explanation of the differences between expert and novice performance in the administration of an intramuscular injection of an analgesic agent to a patient in pain. Noyes J. **J Adv Nurs** 1995 Oct;22(4):800–7 (61 ref.)

INJECTIONS, INTRAPERITONEAL

INSTRUMENTATION

Arterial, peritoneal, and intraventricular access devices.

Almadrones L, et al. **Semin Oncol Nurs** 1995 Aug; 11(3):194–202 (23 ref.)

INJECTIONS, INTRASPINAL see **INJECTIONS, SPINAL**

INJECTIONS, INTRATHECAL see **INJECTIONS, SPINAL**

INJECTIONS, INTRAVENTRICULAR

INSTRUMENTATION

Intracerebroventricular administration of morphine for control of irreducible cancer pain. Lazorthes YR, et al. **Neurosurgery** 1995 Sep;37(3):422–8; discussion 428–9 (26 ref.)

Arterial, peritoneal, and intraventricular access devices. Almadrones L, et al. **Semin Oncol Nurs** 1995 Aug; 11(3):194–202 (23 ref.)

INJECTIONS, SCLEROSING see **SCLEROSING SOLUTIONS**

INJECTIONS, SPINAL

see related
ANESTHESIA, EPIDURAL
ANESTHESIA, SPINAL

Intrathecal narcotics: new approach for labor analgesia. Manning J. **J Obstet Gynecol Neonatal Nurs** 1996 Mar–Apr; 25(3):221–4 (9 ref.)

[Continuous spinal analgesia in home care of oncologic pain] Ricci V, et al. **Minerva Med** 1995 Oct;86(10):409–14 (30 ref.) (Eng. Abstr.) **(Ita)**

INJECTIONS, SUBCUTANEOUS

ADVERSE EFFECTS

Localized reactions to injected therapeutic materials. Part 1. Medical agents. Morgan AM. **J Cutan Pathol** 1995 Jun; 22(3):193–214 (90 ref.)

INJURIES see **WOUNDS AND INJURIES**

INJURIES, MULTIPLE see **MULTIPLE TRAUMA**

INJURIES, NONPENETRATING see **WOUNDS, NONPENETRATING**

INJURY SEVERITY SCORE

The Injury Severity Score is unable to differentiate between poor care and severe injury. Rutledge R. **J Trauma** 1996 Jun;40(6):944–50 (36 ref.)

INNOMINATE ARTERY see **BRACHIOCEPHALIC TRUNK**

INNOMINATE VEINS see **BRACHIOCEPHALIC VEINS**

INNOVATION DIFFUSION see **DIFFUSION OF INNOVATION**

INOCULATION LYMPHORETICULOSIS see **CAT-SCRATCH DISEASE**

INOSINATE PHOSPHATASE see **5'-NUCLEOTIDASE**

INOSINE

PHYSIOLOGY

RNA editing. An I for editing. Bass BL. **Curr Biol** 1995 Jun 1;5(6):598–600 (15 ref.)

INOSINE TRIPHOSPHATE

PHARMACOLOGY

Mechanisms responsible for quantal Ca2+ release from inositol trisphosphate-sensitive calcium stores. Parys JB, et al. **Pflugers Arch** 1996 Jul;432(3):359–67 (89 ref.)

INOSINIC ACID DEHYDROGENASE see **IMP DEHYDROGENASE**

INOSITOL

BLOOD

[Inositol] Nakashima S, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:738–41 (11 ref.) **(Jpn)**

METABOLISM

How does lithium work on manic depression? Clinical and psychological correlates of the inositol theory. Belmaker RH, et al. **Annu Rev Med** 1996;47:47–56 (23 ref.)

THERAPEUTIC USE

Chalcones, myo-inositol and other novel inhibitors of pulmonary carcinogenesis. Wattenberg L. **J Cell Biochem Suppl** 1995;22:162–8 (40 ref.)

INOSITOL HEXAPHOSPHATE see **PHYTIC ACID**

INOSITOL PHOSPHATES

BIOSYNTHESIS

Genetics of myo-inositol phosphate synthesis and accumulation. Raboy V, et al. **Subcell Biochem** 1996; 26:257–85 (161 ref.)

Synthesis, separation, and identification of different inositol phosphates. Schultz C, et al. **Subcell Biochem** 1996; 26:371–413 (195 ref.)

METABOLISM

Glycerophosphoinositols as potential markers of ras-induced transformation and novel second messengers. Corda D, et al. **Anticancer Res** 1996 May–Jun;16(3B):1341–50 (86 ref.)

Inositols do it all. Majerus PW. **Genes Dev** 1996 May 1; 10(9):1051–3 (11 ref.)

Inositol phosphates in the heart: controversy and consensus. Woodcock EA. **J Mol Med** 1995 Jun;73(6):313–23 (110 ref.)

Phosphoinositides as regulators in membrane traffic. De Camilli P, et al. **Science** 1996 Mar 15;271(5255):1533–9 (74 ref.)

Metabolism of myo-inositol phosphates and the alternative pathway in generation of myo-inositol trisphosphate involved in calcium mobilization in plants. Biswas S, et al. **Subcell Biochem** 1996;26:287–316 (203 ref.)

Inositol pentakis- and hexakisphosphate metabolism adds versatility to the actions of inositol polyphosphates. Novel effects on ion channels and protein traffic. Shears SB. **Subcell Biochem** 1996;26:187–226 (181 ref.)

PHYSIOLOGY

Inositol phosphates and their metabolism in plants. Murthy PP. **Subcell Biochem** 1996;26:227–55 (90 ref.)

Light-induced signal transduction pathway involving inositol phosphates. Sopory SK, et al. **Subcell Biochem** 1996; 26:345–70 (117 ref.)

INOSITOL PHOSPHOGLYCERIDES see **PHOSPHATIDYLINOSITOLS**

INOSITOL 1,4,5-TRIPHOSPHATE see **INOSITOL 1,4,5-TRISPHOSPHATE**

INOSITOL 1,4,5-TRISPHOSPHATE

METABOLISM

Inositol trisphosphate and calcium signaling. Berridge MJ. **Ann N Y Acad Sci** 1995 Sep 7;766:31–43 (43 ref.)

Intercellular calcium waves mediated by inositol trisphosphate. Sanderson MJ. **Ciba Found Symp** 1995; 188:175–89; discussion 189–94 (43 ref.)

The inositol 1,4,5-trisphosphate (InsP3) receptor. Bezprozvanny I, et al. **J Membr Biol** 1995 Jun; 145(3):205–16 (131 ref.)

Pharmacological modulators of the inositol 1,4,5-trisphosphate receptor. Michelangeli F, et al. **Neuropharmacology** 1995 Sep;34(9):1111–22 (108 ref.)

Myocardial contractile response and IP3, cAMP and cGMP interrelationships. Martinussen HJ. **Ups J Med Sci** 1996; 101(1):1–33 (142 ref.)

PHARMACOLOGY

[Molecular and functional diversity of inositol triphosphate-induced Ca(2+) release] De Smedt H, et al. **Verh K Acad Geneeskd Belg** 1995;57(5):423–58 (76 ref.) (Eng. Abstr.) **(Dut)**

PHYSIOLOGY

Ca2+ excitability of the ER membrane: an explanation for IP3-induced Ca2+ oscillations. Li YX, et al. **Am J Physiol** 1995 Nov;269(5 Pt 1):C1079–92 (103 ref.)

Inositol trisphosphate and cyclic ADP ribose as long range messengers generating local subcellular calcium signals. Petersen OH. **J Physiol Paris** 1995;89(3):125–7 (16 ref.)

InsP3-induced Ca2+ excitability of the endoplasmic reticulum. Keizer J, et al. **Mol Biol Cell** 1995 Aug; 6(8):945–51 (71 ref.)

Inositolpolyphosphates and their binding proteins--a short review. Huisamen B, et al. **Mol Cell Biochem** 1996 Apr 12–26;157(1–2):229–32 (29 ref.)

Control of the Ca2+ release induced by myo-inositol trisphosphate and the implication in signal transduction. Missiaen L, et al. **Subcell Biochem** 1996;26:59–95 (216 ref.)

INOTROPIC AGENTS, POSITIVE CARDIAC see **CARDIOTONIC AGENTS**

INOTROPISM see **MUSCLE CONTRACTION**

INOTROPISM, CARDIAC see **MYOCARDIAL CONTRACTION**

INPATIENTS

Inpatient management of adults with diabetes. Hirsch IB, et al. **Diabetes Care** 1995 Jun;18(6):870–8 (82 ref.)

Termination in inpatient groups. Brabender V, et al. **Int J Group Psychother** 1996 Jan;46(1):81–98 (25 ref.)

Undernutrition and elderly hospital patients: a review. Tierney AJ. **J Adv Nurs** 1996 Feb;23(2):228–36 (66 ref.)

PSYCHOLOGY

[Experienced quality of life of somatic nursing home patients: a review of measuring instruments] van Campen C, et al. **Tijdschr Gerontol Geriatr** 1996 Feb;27(1):20–8 (62 ref.) (Eng. Abstr.) **(Dut)**

INSANITY DEFENSE

Psychopathy--a clinical and legal dilemma [editorial] Reed J. **Br J Psychiatry** 1996 Jan;168(1):4–9 (20 ref.)

Denouement of an execution competency case: is Perry pyrrhic? Mossman D. **Bull Am Acad Psychiatry Law** 1995; 23(2):269–84 (113 ref.)

[Compliance with psychiatric legal ordinance section 63 STGB. Legal principles--current status--treatment concepts--perspectives] Nedopil N, et al. **Nervenarzt** 1995 Nov;66(11):793–801 (38 ref.) (Eng. Abstr.) **(Ger)**

[Forensic practice between commonality, the law and psychiatry. 2] Hoffmann-Richter U, et al. **Psychiatr Prax** 1996 May;23(3):150–4 (16 ref.) **(Ger)**

HISTORY

The evolution and definition of the concept of 'automatism' in Canadian case law. Jang D, et al. **Med Law** 1995; 14(3–4):221–38 (22 ref.)

INSECT BITES AND STINGS

What physicians should know about Africanized honeybees. Sherman RA. **West J Med** 1995 Dec;163(6):541–6 (75 ref.)

[Self-administration of adrenaline aerosol in anaphylactic reactions after insect stings] Ackermann RW, et al. **Ugeskr Laeger** 1996 Aug 5;158(32):4497–9 (27 ref.) (Eng. Abstr.) **(Dan)**

COMPLICATIONS

Venom immunotherapy: tolerance to a 3-day protocol of rush-immunotherapy. Diez Gómez ML, et al. **Allergol Immunopathol (Madr)** 1995 Nov–Dec;23(6):277–84 (40 ref.)

IMMUNOLOGY

Hypersensitivity to fire ant venom [see comments] Stafford CT. **Ann Allergy Asthma Immunol** 1996 Aug;77(2):87–95; quiz 96–9 (50 ref.) Comment in: Ann Allergy Asthma Immunol 1996 Aug;77(2):85.

PARASITOLOGY

Why do insects bite? A review of blood sucking behaviour. Dodd CS, et al. **J R Army Med Corps** 1995 Oct; 141(3):151–6 (52 ref.)

THERAPY

ED management of insect stings. Jerrard DA. **Am J Emerg Med** 1996 Jul;14(4):429–33 (44 ref.)

Significance of Africanized bees for public health. A review. Schumacher MJ, et al. **Arch Intern Med** 1995 Oct 23; 155(19):2038–43 (49 ref.)

INSECT CONTROL

see related
INSECTICIDE RESISTANCE
PEST CONTROL, BIOLOGICAL

Development of recombinant baculoviruses for insect control. Bonning BC, et al. **Annu Rev Entomol** 1996; 41:191–210 (113 ref.)

Site-specific integrated pest management for high value crops: sample units for map generation using the Colorado potato beetle (Coleoptera: Chrysomelidae) as a model system. Weisz R, et al. **J Econ Entomol** 1995 Oct; 88(5):1069–80 (36 ref.)

METHODS

Trapping the flies that cause myiasis: their responses to host-stimuli. Hall MJ. **Ann Trop Med Parasitol** 1995 Aug; 89(4):333–57 (162 ref.)

Phlebotomine sandflies (Diptera:, Psychodidae): their importance and some aspects of control. Mutinga MJ. **East Afr Med J** 1996 Jan;73(1):48–9 (9 ref.)

Vector control without chemicals: a public health perspective. Mulrennan JA Jr. **J Am Mosq Control Assoc** 1995 Jun;11(2 Pt 2):256–7 (5 ref.)

INSECT GENES see **GENES, INSECT**

INSECT GROWTH REGULATORS see **JUVENILE HORMONES**

INSECT HORMONES

GENETICS

Cosmic influences on the expression of a specific gene in the Colorado potato beetle: the diapause protein 1 gene. de Kort CA. **Arch Insect Biochem Physiol** 1996; 32(3–4):567–73 (15 ref.)

METABOLISM

Regulation and consequences of cellular changes in the prothoracic glands of Manduca sexta during the last larval instar: a review. Smith WA. **Arch Insect Biochem Physiol** 1995;30(2–3):271–93 (75 ref.)

TRP: its role in phototransduction and store-operated Ca2+ entry. Friel DD. **Cell** 1996 May 31;85(5):617–9 (20 ref.)

Calcium signalling. Cracking ICRAC in the eye. Bennett DL, et al. **Curr Biol** 1995 Nov 1;5(11):1225–8 (22 ref.)

Pattern formation. Gurken meets torpedo for the first time. Gavis ER. **Curr Biol** 1995 Nov 1;5(11):1252–4 (14 ref.)

Insect nuclear receptors: a developmental and comparative perspective. Henrich VC, et al. **Insect Biochem Mol Biol** 1995 Sep;25(8):881–97 (149 ref.)

PHYSIOLOGY

Cosmic influences on the expression of a specific gene in the Colorado potato beetle: the diapause protein 1 gene. de Kort CA. **Arch Insect Biochem Physiol** 1996; 32(3–4):567–73 (15 ref.)

How many signals does it take? Venkatesh TV, et al. **Bioessays** 1995 Sep;17(9):754–7 (31 ref.)

Phosphoinositide-mediated phototransduction in Drosophila photoreceptors: the role of Ca2+ and trp. Hardie RC, et al. **Cell Calcium** 1995 Oct;18(4):256–74 (125 ref.)

INSECT STRUCTURAL GENES see GENES, STRUCTURAL, INSECT

INSECT VECTORS

Community involvement in the control of Aedes aegypti. Gubler DJ, et al. **Acta Trop** 1996 Apr;61(2):169–79 (21 ref.)

Culicoides variipennis and bluetongue disease. Research on arthropod-borne animal diseases for control and prevention in the year 2000. Tabachnick WJ, et al. **Ann N Y Acad Sci** 1996 Jul 23;791:219–26 (30 ref.)

Culicoides variipennis and bluetongue-virus epidemiology in the United States. Tabachnick WJ. **Annu Rev Entomol** 1996; 41:23–43 (135 ref.)

The future of microbial insecticides as vector control agents. Federici BA. **J Am Mosq Control Assoc** 1995 Jun;11(2 Pt 2):260–8 (32 ref.)

The future of insect growth regulators in vector control. Mulla MS. **J Am Mosq Control Assoc** 1995 Jun;11(2 Pt 2):269–73 (32 ref.)

Vector control without chemicals: a public health perspective. Mulrennan JA Jr. **J Am Mosq Control Assoc** 1995 Jun;11(2 Pt 2):256–7 (5 ref.)

Global distribution and continuing spread of Aedes albopictus. Knudsen AB. **Parassitologia** 1995 Dec; 37(2–3):91–7 (44 ref.)

The role of Aedes albopictus as an arbovirus vector. Mitchell CJ. **Parassitologia** 1995 Dec;37(2–3):109–13 (17 ref.)

A North American model to contain the spread of Aedes albopictus through tire legislation. Novak RJ. **Parassitologia** 1995 Dec;37(2–3):129–39 (17 ref.)

Aedes albopictus: a potential problem in France. Rodhain F. **Parassitologia** 1995 Dec;37(2–3):115–9 (31 ref.)

History and updating on the spread of Aedes albopictus in Italy. Romi R. **Parassitologia** 1995 Dec;37(2–3):99–103 (16 ref.)

Localized permanent epidemics: the genesis of chloroquine resistance in Plasmodium falciparum. Verdrager J. **Southeast Asian J Trop Med Public Health** 1995 Mar; 26(1):23–8 (18 ref.)

Louse-borne relapsing fever and its treatment. Rahlenbeck SI, et al. **Trop Geogr Med** 1995;47(2):49–52 (35 ref.)

Veterinary arbovirus vectors in Australia—a retrospective. Muller MJ. **Vet Microbiol** 1995 Sep;46(1–3):101–16 (67 ref.)

[Hazards of insect vectors of parasites: from theory to practice] Alvar Ezquerra JP. **An R Acad Nac Med (Madr)** 1995;112(3):617–45; discussion 646 (93 ref.) **(Spa)**

[The role of the Aedes aegypti vector in the epidemiology of dengue in Mexico] Fernández-Salas I, et al. **Salud Publica Mex** 1995;37 Suppl:S45–52 (17 ref.) (Eng. Abstr.) **(Spa)**

[Vectors of dengue in Mexico: a critical review)] Ibáñez-Bernal S, et al. **Salud Publica Mex** 1995;37 Suppl:S53–63 (34 ref.) (Eng. Abstr.) **(Spa)**

PARASITOLOGY

Regulation of infectivity of Plasmodium to the mosquito vector. Sinden RE, et al. **Adv Parasitol** 1996;38:53–117 (314 ref.)

Phlebotomine sandflies (Diptera:, Psychodidae): their importance and some aspects of control. Mutinga MJ. **East Afr Med J** 1996 Jan;73(1):48–9 (9 ref.)

Early sporogonic development in local vectors of Plasmodium falciparum in rural Cameroon. Robert V, et al. **Mem Inst Oswaldo Cruz** 1994;89 Suppl 2:23–6 (10 ref.)

Development of Dirofilaria and Setaria nematodes in Aedes albopictus. Cancrini G, et al. **Parassitologia** 1995 Dec; 37(2–3):141–5 (24 ref.)

[Vector control, perspectives and realities] Carnevale P. **Med Trop (Mars)** 1995;55(4 Suppl):56–65 (89 ref.) (Eng. Abstr.) **(Fre)**

[The utilization of molecular biological tools in the study of malaria transmission: example of programs conducted in Senegal] Fontenille D, et al. **Med Trop (Mars)** 1995;55(4 Suppl):52–5 (15 ref.) (Eng. Abstr.) **(Fre)**

VIROLOGY

The role of dipterous insects in the mechanical transmission of animal viruses. Carn VM. **Br Vet J** 1996 Jul; 152(4):377–93 (55 ref.)

Handling small arbovirus vectors safely during biosafety level 3 containment: Culicoides variipennis sonorensis (Diptera:Ceratopogonidae) and exotic bluetongue viruses. Hunt GJ, et al. **J Med Entomol** 1996 May;33(3):271–7 (17 ref.)

INSECTICIDE RESISTANCE

Some emerging issues on the malaria problem in Kenya. Oloo AJ, et al. **East Afr Med J** 1996 Jan;73(1):50–3 (48 ref.)

Resistance and the control of sheep ectoparasites. Levot GW. **Int J Parasitol** 1995 Nov;25(11):1355–62 (35 ref.)

GENETICS

Molecular biology of insecticide resistance. Feyereisen R. **Toxicol Lett** 1995 Dec;82–83:83–90 (18 ref.)

INSECTICIDES

see related
CHOLINESTERASE INHIBITORS

ADMINISTRATION & DOSAGE

From efficacy to effectiveness: insecticide-treated bednets in Africa. Lengeler C, et al. **Bull World Health Organ** 1996; 74(3):325–32 (40 ref.)

METABOLISM

Regulation of insecticidal crystal protein production in Bacillus thuringiensis. Baum JA, et al. **Mol Microbiol** 1995 Oct;18(1):1–12 (50 ref.)

Environmental fate of rice pesticides in California. Mabury SA, et al. **Rev Environ Contam Toxicol** 1996;147:71–117 (202 ref.)

PHARMACOLOGY

Ion channels as targets for insecticides. Bloomquist JR. **Annu Rev Entomol** 1996;41:163–90 (124 ref.)

THERAPEUTIC USE

Resistance and the control of sheep ectoparasites. Levot GW. **Int J Parasitol** 1995 Nov;25(11):1355–62 (35 ref.)

TOXICITY

Sodium channels and GABAA receptor-channel complex as targets of environmental toxicants. Narahashi T, et al. **Toxicol Lett** 1995 Dec;82–83:239–45 (20 ref.)

Towards the development of ryanoid insecticides with low mammalian toxicity. Usherwood PN, et al. **Toxicol Lett** 1995 Dec;82–83:247–54 (13 ref.)

INSECTICIDES, BOTANICAL

ECONOMICS

Economic aspects of the use of impregnated mosquito nets for malaria control. Brinkmann U, et al. **Bull World Health Organ** 1995;73(5):651–8 (23 ref.)

INSECTICIDES, CARBAMATE

ADVERSE EFFECTS

Engineering of human cholinesterases explains and predicts diverse consequences of administration of various drugs and poisons. Schwarz M, et al. **Pharmacol Ther** 1995; 67(2):283–322 (198 ref.)

TOXICITY

International safety assessment of pesticides: dithiocarbamate pesticides, ETU, and PTU—a review and update. Vettorazzi G, et al. **Teratog Carcinog Mutagen** 1995–96; 15(6):313–37 (88 ref.)

INSECTICIDES, ORGANOCHLORINE

ADVERSE EFFECTS

Organochlorine compounds: Risk of non-Hodgkin's lymphoma and breast cancer? Hoffman W. **Arch Environ Health** 1996 May–Jun;51(3):189–92 (42 ref.)

Organochlorine compounds in relation to breast cancer, endometrial cancer, and endometriosis: an assessment of the biological and epidemiological evidence. Ahlborg UG, et al. **Crit Rev Toxicol** 1995;25(6):463–531 (318 ref.)

ATSDR evaluation of health effects of chemicals. II. Mirex and chlordecone: health effects, toxicokinetics, human exposure, and environmental fate. Faroon O, et al. **Toxicol Ind Health** 1995;11(6):1–203 (681 ref.)

CHEMISTRY

[Abiotic and biotic transformation of persistent organochlorine compounds in the environment] Struciński P, et al. **Rocz Panstw Zakl Hig** 1995;46(3):279–92 (51 ref.) (Eng. Abstr.) **(Pol)**

METABOLISM

Epidemiological analysis of persistent organochlorine contaminants in cetaceans. Colborn T, et al. **Rev Environ Contam Toxicol** 1996;146:91–172 (247 ref.)

PHARMACOKINETICS

Dermal exposure to environmental contaminants in the Great Lakes. Moody RP, et al. **Environ Health Perspect** 1995 Dec;103 Suppl 9:103–14 (88 ref.)

POISONING

Acute accidental lindane ingestion in toddlers. Aks SE, et al. **Ann Emerg Med** 1995 Nov;26(5):647–51 (17 ref.)

An overview of exposure to, and effects of, petroleum oil and organochlorine pollution in grey seals (Halichoerus grypus). Jenssen BM. **Sci Total Environ** 1996 Jul 16; 186(1–2):109–18 (54 ref.)

TOXICITY

A toxicologist's view of cancer risk assessment. Rozman KK, et al. **Drug Metab Rev** 1996 Feb–May;28(1–2):29–52 (27 ref.)

INSECTICIDES, ORGANOPHOSPHATE

see related
CHOLINESTERASE INHIBITORS

ADVERSE EFFECTS

Neuropsychopathological changes by organophosphorus compounds—a review. Eyer P. **Hum Exp Toxicol** 1995 Nov;14(11):857–64 (76 ref.)

Engineering of human cholinesterases explains and predicts diverse consequences of administration of various drugs and poisons. Schwarz M, et al. **Pharmacol Ther** 1995; 67(2):283–322 (198 ref.)

Risks from occupational and dietary exposure to mevinphos. Cochran RC, et al. **Rev Environ Contam Toxicol** 1996; 146:1–24 (76 ref.)

POISONING

Acute organophosphate pesticide poisoning in children. Mitchell A, et al. **MCN Am J Matern Child Nurs** 1995 Sep–Oct;20(5):261–8 (20 ref.)

[Late effects of organophosphate poisoning on the heart] Lev E, et al. **Harefuah** 1995 Dec 1;129(11):507–11 (40 ref.) **(Heb)**

TOXICITY

Regulatory and research issues related to cholinesterase inhibition. Padilla S. **Toxicology** 1995 Sep 1;102(1–2):215–20 (29 ref.)

INSECTICIDES, ORGANOTHIOPHOSPHATE

TOXICITY

Ectoxicology of chlorpyrifos. Barron MG, et al. **Rev Environ Contam Toxicol** 1995;144:1–93 (337 ref.)

INSECTS

ANATOMY & HISTOLOGY

Representation of perceptual dimensions of insect prey during terminal pursuit by echolocating bats. Simmons JA, et al. **Biol Bull** 1996 Aug;191(1):109–21 (56 ref.)

Neuroanatomy: mushrooming mushroom bodies. Davis RL, et al. **Curr Biol** 1996 Feb 1;6(2):146–8 (24 ref.)

EMBRYOLOGY

Homeotic genes and diversification of the insect body plan. Warren R, et al. **Curr Opin Genet Dev** 1995 Aug;5(4):459–65 (48 ref.)

ENZYMOLOGY

Insect lysozymes. Hultmark D. **EXS** 1996;75:87–102 (83 ref.)

GENETICS

[Genetic approaches to the study of memory in insects] Lopatina NG, et al. **Fiziol Zh Im I M Sechenova** 1995 Aug; 81(8):63–8 (12 ref.) (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

[Anti-infective defence strategies and methods of escape from entomologic pathogens under immunologic control of insects] Jarosz J. **Wiad Parazytol** 1996;42(1):3–27 (63 ref.) (Eng. Abstr.) **(Pol)**

METABOLISM

Discontinuous gas exchange in insects. Lighton JR. **Annu Rev Entomol** 1996;41:309–24 (55 ref.)

Riboflavin binding proteins and flavin assimilation in insects. Miller SG, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1995 Mar; 110(3):467–75 (48 ref.)

The regulation of trehalose metabolism in insects. Becker A, et al. **Experientia** 1996 May 15;52(5):433–9 (54 ref.)

Insect nuclear receptors: a developmental and comparative perspective. Henrich VC, et al. **Insect Biochem Mol Biol** 1995 Sep;25(8):881–97 (149 ref.)

G-protein-coupled receptors in insect cells. Vanden Broeck JJ. **Int Rev Cytol** 1996;164:189–268 (319 ref.)

MICROBIOLOGY

New insights into the mechanisms of fungal pathogenesis in insects. Clarkson JM, et al. **Trends Microbiol** 1996 May; 4(5):197–203 (68 ref.)

[Anti-infective defence strategies and methods of escape from entomologic pathogens under immunologic control of insects] Jarosz J. **Wiad Parazytol** 1996;42(1):3–27 (63 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOLOGY

Immune response in insects: the role of phenoloxidase in defense reactions in relation to melanization and sclerotization. Marmaras VJ, et al. **Arch Insect Biochem Physiol** 1996;31(2):119–33 (56 ref.)

Pattern recognition in insects. Heisenberg M. **Curr Opin Neurobiol** 1995 Aug;5(4):475–81 (68 ref.)

Flying insects: model systems in exercise physiology. Wegener G. **Experientia** 1996 May 15;52(5):404–12 (41 ref.)

Why do insects bite? A review of blood sucking behaviour. Dodd CS, et al. **J R Army Med Corps** 1995 Oct; 141(3):151–6 (52 ref.)

Neuropeptides implicated in the control of diuresis in insects. Coast GM. **Peptides** 1996;17(2):327–36 (61 ref.)

Insect sound production: transduction mechanisms and impedance matching. Bennet-Clark HC. **Symp Soc Exp Biol** 1995;49:199–218 (33 ref.)

Unsteady aerodynamics of insect flight. Ellington CP. **Symp Soc Exp Biol** 1995;49:109–29 (74 ref.)

[Hemostasis and self-defense in insect] Kotani E, et al. **Seikagaku** 1995 Sep;67(9):1148–56 (17 ref.) **(Jpn)**

ULTRASTRUCTURE

[The formation of the karyosphere in the oogenesis of insects and amphibians] Gruzova MN, et al. **Tsitologiia** 1995; 37(8):744–69 (156 ref.) (Eng. Abstr.) **(Rus)**

INSEMINATION, ARTIFICIAL

see related
FERTILIZATION IN VITRO
SEMEN PRESERVATION
SPERM BANKS

In vitro fertilization, gamete intrafallopian transfer, and superovulation with intrauterine insemination: efficacy and potential health hazards on babies delivered. Dawood MY. **Am J Obstet Gynecol** 1996 Apr;174(4):1208–17 (26 ref.)

METHODS

Intrauterine insemination: a first-step procedure in the algorithm of male subfertility treatment. Ombelet W, et al. **Hum Reprod** 1995 Oct;10 Suppl 1:90–102 (89 ref.)

[In vitro fertilization] Hoshi K. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Aug; 47(8):833–44 (60 ref.) **(Jpn)**

VETERINARY

Artificial insemination in rabbits. Morrell JM. **Br Vet J** 1995 Sep-Oct;151(5):477–88 (38 ref.)

INSEMINATION, ARTIFICIAL, HETEROLOGOUS

Should donors have the right to decide who receives their gametes? Pennings G. **Hum Reprod** 1995 Oct; 10(10):2736–40 (24 ref.)

METHODS

[Is legislation needed in the treatment of infertility? (editorial)] Hovatta O. **Duodecim** 1994;110(2):123–6 (11 ref.) **(Fin)**

INSEMINATION, ARTIFICIAL, HOMOLOGOUS

METHODS

[Risks of intracytoplasmatic sperm cell injection for offspring?] Hollanders JM, et al. **Ned Tijdschr Geneeskd** 1996 Jan 6;140(1):9–11 (20 ref.) **(Dut)**

[Intra-uterine artificial insemination: what indications and which technics should be retained?] Panel P, et al. **Contracept Fertil Sex** 1995 Dec;23(12):710–6 (37 ref.) **(Fre)**

[Intra-uterine artificial insemination. Indications, techniques, results; 83 cases] Panel P, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(5):496–504 (23 ref.) (Eng. Abstr.) **(Fre)**

INSEMINATION, ARTIFICIAL, HUMAN DONOR see **INSEMINATION, ARTIFICIAL, HETEROLOGOUS**

INSEMINATION, ARTIFICIAL, HUSBAND see **INSEMINATION, ARTIFICIAL, HOMOLOGOUS**

INSERTION ELEMENTS, DNA see **DNA INSERTION ELEMENTS**

INSERTION SEQUENCE see **DNA INSERTION ELEMENTS**

INSERTION SEQUENCE ELEMENTS see **DNA INSERTION ELEMENTS**

INSERTIONAL ACTIVATION see **MUTAGENESIS, INSERTIONAL**

INSERTIONAL MUTAGENESIS see **MUTAGENESIS, INSERTIONAL**

INSERVICE TRAINING

Does job-related training performance decline with age? Kubeck JE, et al. **Psychol Aging** 1996 Mar;11(1):92–107 (100 ref.)

ORGANIZATION & ADMINISTRATION

Refocusing the training of psychiatric rehabilitation staff. Corrigan PW, et al. **Psychiatr Serv** 1995 Nov;46(11):1172–7 (33 ref.)

TRENDS

Practice-building seminars in chiropractic: a Petit Bourgeois response to biomedical domination. Baer HA. **Med Anthropol Q** 1996 Mar;10(1):29–44 (45 ref.)

INSOMNIA

[Insomnia in infancy and childhood—causes, significance, assessment and approach to treatment] Pillar G, et al. **Harefuah** 1996 Feb 15;130(4):255–9 (41 ref.) **(Heb)**

DIAGNOSIS

Sleep disorders. Yousaf F, et al. **Br J Hosp Med** 1996 Mar 20–Apr 2;55(6):353–8 (21 ref.)

DRUG THERAPY

An assessment of short-acting hypnotics. Mendelson WB, et al. **Drug Saf** 1995 Oct;13(4):257–70 (11 ref.)

Zolpidem—a hypnotic with a difference? **Drug Ther Bull** 1995 May;33(5):37–9 (17 ref.)

Over-the-counter hypnotics and chronic insomnia in the elderly [editorial] [see comments] Lasagna L. **J Clin Psychopharmacol** 1995 Dec;15(6):383–6 (14 ref.) Comment in: J Clin Psychopharmacol 1996 Apr;16(2):191.

Benzodiazepines for insomnia in community-dwelling elderly: a review of benefit and risk. Grad RM. **J Fam Pract** 1995 Nov;41(5):473–81 (41 ref.)

Pharmacotherapy of insomnia: practice and prospects. Dingemanse J. **Pharm World Sci** 1995 May 26;17(3):67–75 (114 ref.)

A request for more hypnotics. Ewan G, et al. **Practitioner** 1996 Mar;240(1560):133–8 (1 ref.)

[Sleep disorders—what can be done when hypnotics no longer help? Overview and case report] Staedt J, et al. **Fortschr Neurol Psychiatr** 1995 Sep;63(9):368–72 (35 ref.) (Eng. Abstr.) **(Ger)**

[New non-benzodiazepine hypnotics. Progress in therapy of sleep disorders?] Hajak G, et al. **Internist (Berl)** 1995 Nov; 36(11):1085–90; discussion 1090–1 (51 ref.) **(Ger)**

[Sleep disorders—diagnosis and treatment. Recommendations of the German Society of Sleep Research and Sleep Medicine] Bornkessel B. **Med Monatsschr Pharm** 1996 Apr; 19(4):106–9 (0 ref.) **(Ger)**

[Recommendations for the diagnosis and therapy of insomnia. German Society of Sleep Research and Sleep Medicine DGSM] Clarenbach P, et al. **Nervenarzt** 1995 Oct; 66(10):723–9 (20 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

[Fatal familial insomnia and prion diseases] Seilhean D, et al. **Rev Neurol (Paris)** 1995 Apr;151(4):225–30 (61 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Fatal familial insomnia and familial Creutzfeldt-Jakob disease: a tale of two diseases with the same genetic mutation. Gambetti P. **Curr Top Microbiol Immunol** 1996; 207:19–25 (17 ref.)

THERAPY

Integration of behavioral and relaxation approaches into the treatment of chronic pain and insomnia. NIH Technology Assessment Panel on Integration of Behavioral and Relaxation Approaches into the Treatment of Chronic Pain and Insomnia. **JAMA** 1996 Jul 24–31;276(4):313–8 (0 ref.)

Management of insomnia. Mahendran R. **Singapore Med J** 1995 Feb;36(1):80–3 (25 ref.)

[Treatment of chronic insomnia. A recommendation with special emphasis on problems of the elderly] Neckelmann D. **Tidsskr Nor Laegeforen** 1996 Mar 10;116(7):854–9 (40 ref.) (Eng. Abstr.) **(Nor)**

INSOMNIA, FATAL FAMILIAL see **PRION DISEASES**

1,4,5-INSP3 see **INOSITOL 1,4,5-TRISPHOSPHATE**

INSPIRATORY POSITIVE-PRESSURE VENTILATION see **INTERMITTENT POSITIVE-PRESSURE VENTILATION**

INSTABILITY, JOINT see **JOINT INSTABILITY**

INSTINCT

see related
LIBIDO

INSTITUTES see **ACADEMIES AND INSTITUTES**

INSTITUTIONAL LIABILITY see **LIABILITY, LEGAL**

INSTITUTIONAL POLICY see **ORGANIZATIONAL POLICY**

INSTITUTIONAL REVIEW BOARD see **PROFESSIONAL STAFF COMMITTEES**

INSTITUTIONALIZATION

see related
DEINSTITUTIONALIZATION
HOSPITALIZATION

[The deconstructions of schizophrenia (I)] Moriyama K. **Seishin Shinkeigaku Zasshi** 1995;97(5):309–25 (41 ref.) (Eng. Abstr.) **(Jpn)**

INSTRUCTIONAL MODELS see **MODELS, EDUCATIONAL**

INSTRUMENTAL LEARNING see **CONDITIONING, OPERANT**

INSUFFLATION

ADVERSE EFFECTS

Gasless laparoscopy. Martin IG, et al. **J R Coll Surg Edinb** 1996 Apr;41(2):72–4 (31 ref.)

METHODS

Adjunctive ventilation with tracheal gas insufflation—good vibrations? [editorial; comment] Marini JJ. **Crit Care Med** 1996 Mar;24(3):375–8 (27 ref.) Comment on: Crit Care Med 1996 Mar;24(3):451–7.

Helium insufflation in laparoscopic surgery. Naude GP, et al. **Endosc Surg Allied Technol** 1995 Aug;3(4):183–6 (28 ref.)

Media and delivery systems. Marlow JL. **Obstet Gynecol Clin North Am** 1995 Sep;22(3):409–22 (55 ref.)

INSUFFLATION ANESTHESIA see **ANESTHESIA, INHALATION**

INSULA OF REIL see **CEREBRAL CORTEX**

INSULIN

see related
PROINSULIN
RECEPTORS, INSULIN

ADMINISTRATION & DOSAGE

The athlete with type I diabetes: managing insulin, diet and exercise. Fahey PJ, et al. **Am Fam Physician** 1996 Apr; 53(5):1611–24 (22 ref.)

Intensive insulin therapy in insulin-dependent diabetes mellitus, the results of the diabetes control and complications trial. Duron F. **Biomed Pharmacother** 1995; 49(6):278–82 (36 ref.)

Insulin injectors: a practical approach to insulin therapy

[editorial] Katoulis EC, et al. **Int J Artif Organs** 1995 Apr; 18(4):177–80 (19 ref.)

The impact of intraperitoneal glucose and insulin on the liver. Bargman JM. **Perit Dial Int** 1996;16 Suppl 1:S211–4 (27 ref.)

Peritoneal dialysis in diabetics. Optimal insulin therapy on CAPD: intraperitoneal versus subcutaneous treatment. Scarpioni L, et al. **Perit Dial Int** 1996;16 Suppl 1:S275–8 (33 ref.)

ADVERSE EFFECTS

Potentiation of vasculopathy by insulin: implications from an NHLBI clinical alert [editorial] Sobel BE. **Circulation** 1996 May 1;93(9):1613–5 (20 ref.)

Can hypoglycaemia be predicted before its onset? Lönnroth P. **Diabetologia** 1996 May;39(5):613–4 (17 ref.)

Can hypoglycaemia be predicted before its onset? (Comment). Maggs D. **Diabetologia** 1996 May;39(5):615–7 (16 ref.)

Does fall in tissue glucose precede fall in blood glucose? Sternberg F, et al. **Diabetologia** 1996 May;39(5):609–12 (22 ref.)

Diabetes mellitus and traffic incidents. Veneman TF. **Neth J Med** 1996 Jan;48(1):24–8 (27 ref.)

[Cutaneous allergies and insulin therapy. Current aspects, management] Barbaud A, et al. **Ann Dermatol Venereol** 1996;123(3):214–8 (36 ref.) **(Fre)**

ANALOGS & DERIVATIVES

[Insulin analogs] Scaglione L, et al. **Minerva Endocrinol** 1996 Mar;21(1):27–36 (31 ref.) (Eng. Abstr.) **(Ita)**

BIOSYNTHESIS

The role of prohormone convertases in insulin biosynthesis: evidence for inherited defects in their action in man and experimental animals. Steiner DF, et al. **Diabetes Metab** 1996 Apr;22(2):94–104 (72 ref.)

[Insulin producing cells as therapy in diabetes mellitus] Schnedl WJ, et al. **Naturwissenschaften** 1996 Jan;83(1):1–5 (41 ref.) (Eng. Abstr.) **(Ger)**

BLOOD

Carbohydrate–lipid interactions during gestation and their control by insulin. Herrera E, et al. **Braz J Med Biol Res** 1994 Nov;27(11):2499–519 (74 ref.)

Serum insulin, IGF-I,IGF-II and growth hormone, and left ventricular mass in noninsulin-dependent mellitus. Rabkin SW, et al. **Can J Cardiol** 1996 Mar;12(3):264–70 (52 ref.)

Unexplained improvement in diabetes control: a wolf in sheep's clothing. Snow KJ. **Compr Ther** 1995 Oct; 21(10):590–3 (16 ref.)

Associations between insulin levels and cardiovascular disease are confounded by comorbidity. McKeigue P, et al. **Diabetes Care** 1995 Sep;18(9):1294–8 (54 ref.)

Is insulin really a heart disease risk factor. Wingard DL, et al. **Diabetes Care** 1995 Sep;18(9):1299–304 (45 ref.)

Changes in autonomic nervous system activity and consecutive hyperinsulinaemia: respective roles in the development of obesity in rodents. Pénicaud L, et al. **Diabetes Metab** 1996 Feb;22(1):15–24 (67 ref.)

Hyperproinsulinemia in a three-generation Caucasian family due to mutant proinsulin (Arg65–His) not associated with imparied glucose tolerance: the contribution of mutant proinsulin to insulin bioactivity. Röder ME, et al. **J Clin Endocrinol Metab** 1996 Apr;81(4):1634–40 (29 ref.)

[Determination of plasma proinsulins, insulin and C-peptide] Chevenne D, et al. **Ann Biol Clin (Paris)** 1995;53(1–2):3–9 (59 ref.) (Eng. Abstr.) **(Fre)**

[Plasma IRI—assay method and its significance in clinical medicine] Yamamoto W, et al. **Nippon Rinsho** 1995 Mar; 53 Su Pt 2:659–61 (11 ref.) **(Jpn)**

DEFICIENCY

Insulin deficiency and insulin resistance in the pathogenesis of NIDDM: is a divorce possible? Cerasi E. **Diabetologia** 1995 Aug;38(8):992–7 (50 ref.)

GENETICS

The search for IDDM susceptibility genes: the next generation. Owerbach D, et al. **Diabetes** 1996 May; 45(5):544–51 (79 ref.)

Insulin gene: organisation, expression and regulation. Dumonteil E, et al. **Diabetes Metab** 1996 Jun;22(3):164–73 (82 ref.)

New connections in the regulation of PEPCK gene expression by insulin. Sutherland C, et al. **Philos Trans R Soc Lond B Biol Sci** 1996 Feb 29; 351(1336):191–9 (100 ref.)

[Control of gene expression. Cell specialization and adaptation of gene expression to current need] Neye H. **Med Monatsschr Pharm** 1996 Apr;19(4):94–8 (29 ref.) **(Ger)**

IMMUNOLOGY

[Human leukocyte antigen (HLA) and the related diseases] Mizuki N, et al. **Nippon Naika Gakkai Zasshi** 1995 Dec 10;84(12):2091–103 (12 ref.) **(Jpn)**

METABOLISM

Glucose and insulin metabolism in hypertension. Corry DB, et al. **Am J Nephrol** 1996;16(3):223–36 (188 ref.)

Insulin signal transduction and the IRS proteins. Myers MG Jr, et al. **Annu Rev Pharmacol Toxicol** 1996;36:615–58 (234 ref.)

Glucokinase mutations, insulin secretion, and diabetes mellitus. Bell GI, et al. **Annu Rev Physiol** 1996;58:171–86 (63 ref.)

Role of insulin in hepatic fatty acid partitioning: emerging concepts. Zammit VA. **Biochem J** 1996 Feb 15;314 (Pt 1):1–14 (186 ref.)

Relations of hormones and growth factors at the crossroad of pathogenesis and pharmacotherapeutics. The case of diabetes mellitus [editorial] Mathé G. **Biomed Pharmacother** 1995;49(5):221–4 (38 ref.)

beta-cell stimulus – secretion coupling defects in rodent models of obesity. Chan CB. **Can J Physiol Pharmacol** 1995 Oct;73(10):1414–24 (138 ref.)

Insulin-degrading enzyme. Authier F, et al. **Clin Invest Med** 1996 Jun;19(3):149–60 (56 ref.)

Mitochondria and diabetes. Genetic, biochemical, and clinical implications of the cellular energy circuit. Gerbitz KD, et al. **Diabetes** 1996 Feb;45(2):113–26 (152 ref.)

Effect of metformin on liver insulin metabolism and regional blood flow. Signore A, et al. **Diabetes Metab Rev** 1995 Sep;11 Suppl 1:S13–21 (48 ref.)

Prevention of complications in non-insulin-dependent diabetes mellitus (NIDDM). Wolffenbuttel BH, et al. **Drugs** 1995 Aug;50(2):263–88 (264 ref.)

Stimulation of insulin release by non-sulfonylurea hypoglycemic agents: the meglitinide family. Malaisse WJ. **Horm Metab Res** 1995 Jun;27(6):263–6 (18 ref.)

PHARMACOLOGY

Molecular actions of insulin on glucose transport. Czech MP. **Annu Rev Nutr** 1995;15:441–71 (214 ref.)

Insulin and the partitioning of hepatic fatty acid metabolism. Zammit VA. **Biochem Soc Trans** 1995 Aug;23(3):506–11 (43 ref.)

Cardiovascular actions of insulin: are they important in long-term blood pressure regulation? Hall JE, et al. **Clin Exp Pharmacol Physiol** 1995 Oct;22(10):689–700 (89 ref.)

Improving the action of insulin. Lefèbvre PJ, et al. **Clin Invest Med** 1995 Aug;18(4):340–7 (68 ref.)

Insulin resistance: a multifaceted metabolic syndrome. Insights gained using a low-dose insulin infusion technique. Krentz AJ, et al. **Diabet Med** 1996 Jan;13(1):30–9 (54 ref.)

Fatty acids and insulin resistance. Boden G. **Diabetes Care** 1996 Apr;19(4):394–5 (14 ref.)

Insulin action in man. Scheen AJ, et al. **Diabetes Metab** 1996 Apr;22(2):105–10 (51 ref.)

Insulin regulation of muscle glucose metabolism: role of pre-receptorial mechanisms. Capaldo B, et al. **Diabetes Metab Rev** 1995 Dec;11(4):365–82 (141 ref.)

Rationale and hurdles of inhibitors of hepatic gluconeogenesis in treatment of diabetes mellitus. Kashiwagi A. **Diabetes Res Clin Pract** 1995 Aug;28 Suppl:S195–200 (30 ref.)

The insulin/Ras pathway of adipocytic differentiation of 3T3 L1 cells: dissociation between Raf-1 kinase and the MAPK/RSK cascade. Porras A, et al. **Int J Obes Relat Metab Disord** 1996 Mar;20 Suppl 3:S43–51 (47 ref.)

Anabolic effects of insulin on bone suggest a role for chromium picolinate in preservation of bone density. McCarty MF. **Med Hypotheses** 1995 Sep;45(3):241–6 (69 ref.)

Vanadium compounds as insulin mimics. Orvig C, et al. **Met Ions Biol Syst** 1995;31:575–94 (126 ref.)

Effects of experimental diabetes and insulin on smooth muscle functions. Oztürk Y, et al. **Pharmacol Rev** 1996 Mar; 48(1):69–112 (728 ref.)

[How to explore insulin sensitivity in man?] Scheen AJ, et al. **Ann Endocrinol (Paris)** 1995;56(5):523–30 (47 ref.) (Eng. Abstr.) **(Fre)**

[Insulin, diabetes and cholesterol metabolism] Monnier L, et al. **C R Seances Soc Biol Fil** 1995;189(5):919–31 (27 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Diverse signaling pathways in the cellular actions of insulin. Saltiel AR. **Am J Physiol** 1996 Mar;270(3 Pt 1):E375–85 (97 ref.)

The neural network that regulates energy balance is responsive to glucocorticoids and insulin and also regulates HPA axis responsivity at a site proximal to CRF neurons. Dallman MF, et al. **Ann N Y Acad Sci** 1995 Dec 29; 771:730–42 (43 ref.)

Insulin and prostaglandins as signals between tumor and the host immune system. Curi R, et al. **Braz J Med Biol Res** 1995 Jul;28(7):773–9 (46 ref.)

The role of insulin in the control of hepatic fatty acid and glycerolipid metabolism assessed by studies in vivo. Zammit VA. **Braz J Med Biol Res** 1995 Oct;28(10):1027–31 (24 ref.)

Type III cyclic nucleotide phosphodiesterases and insulin action. Manganiello VC, et al. **Curr Top Cell Regul** 1996; 34:63–100 (265 ref.)

The coupling of glucose metabolism and perfusion in human skeletal muscle. The potential role of endothelium-derived nitric oxide. Baron AD. **Diabetes** 1996 Jan;45 Suppl 1:S105–9 (43 ref.)

Modulation of insulin receptor signaling. Potential mechanisms of a cross talk between bradykinin and the insulin receptor. Häring HU, et al. **Diabetes** 1996 Jan;45 Suppl 1:S115–9 (35 ref.)

Significance of insulin for glucose metabolism in skeletal muscle during contractions. Hespel P, et al. **Diabetes** 1996 Jan;45 Suppl 1:S99–104 (61 ref.)

Insulin-induced redistribution of GLUT4 glucose carriers in the muscle fiber. In search of GLUT4 trafficking pathways. Zorzano A, et al. **Diabetes** 1996 Jan;45 Suppl 1:S70–81 (120 ref.)

Acute effects of insulin in the control of VLDL production in humans. Implications for the insulin-resistant state. Lewis GF, et al. **Diabetes Care** 1996 Apr;19(4):390–3 (38 ref.)

Determinants of glucose turnover in the pathophysiology of diabetes: an in vivo analysis in diabetic dogs. Fisher SJ, et al. **Diabetes Metab** 1996 Apr;22(2):111–21 (78 ref.)

Insulin action in man. Scheen AJ, et al. **Diabetes Metab** 1996 Apr;22(2):105–10 (51 ref.)

Development and consequences of insulin resistance: lessons from animals with hyperinsulinaemia. Shafrir E. **Diabetes Metab** 1996 Apr;22(2):122–31 (63 ref.)

Insulin regulation of muscle glucose metabolism: role of pre-receptorial mechanisms. Capaldo B, et al. **Diabetes Metab Rev** 1995 Dec;11(4):365–82 (141 ref.)

Metformin-insulin interactions: from organ to cell. Wiernsperger N, et al. **Diabetes Metab Rev** 1995 Sep;11 Suppl 1:S3–12 (56 ref.)

Pathogenesis of insulin resistance: modulation of the insulin signal at receptor level. Kellerer M, et al. **Diabetes Res Clin Pract** 1995 Aug;28 Suppl:S173–7 (36 ref.)

The need for a 'tree radical initiative' [comment] Cominacini L, et al. **Diabetologia** 1996 Mar;39(3):364–6 (20 ref.) Comment on: Diabetologia 1996 Mar;39(3):357–63.

Insulin, corticosterone and the autonomic nervous system in animal obesities: a viewpoint. Jeanrenaud B. **Diabetologia** 1995 Aug;38(8):998–1002 (61 ref.)

Oxidative stress and insulin action: is there a relationship? [see comments] Paolisso G, et al. **Diabetologia** 1996 Mar; 39(3):357–63 (51 ref.) Comment in: Diabetologia 1996 Mar;39(3):364–6.

Role of insulin resistance in the pathogenesis of NIDDM. Yki-Järvinen H. **Diabetologia** 1995 Dec;38(12):1378–88 (123 ref.)

The ovarian insulin and insulin-like growth factor system with an emphasis on domestic animals. Spicer LJ, et al. **Domest Anim Endocrinol** 1995 Jul;12(3):223–45 (182 ref.)

Insulin signaling network — waiting for Copernicus [editorial; comment] Draznin B. **Endocrinology** 1996 Jul; 137(7):2647–8 (20 ref.) Comment on: Endocrinology 1996 Jul;137(7):2649–58.

Some thoughts on the importance of insulin in the regulation of the blood glucose level. Newsholme EA, et al. **Experientia** 1996 May 15;52(5):421–5 (21 ref.)

Hyperinsulinemia, hyperproinsulinemia and insulin resistance in the metabolic syndrome. Schrezenmeir J. **Experientia** 1996 May 15;52(5):426–32 (26 ref.)

Clinical review 79: Angiotensin II: an insulin-sensitizing vasoactive hormone? Morris AD, et al. **J Clin Endocrinol Metab** 1996 Apr;81(4):1303–6 (40 ref.)

Central insulin may up-regulate thyroid activity by suppressing neuropeptide Y release in the paraventricular nucleus. McCarty MF. **Med Hypotheses** 1995 Aug; 45(2):193–9 (114 ref.)

The insulin-like growth factor system in vascular smooth muscle: interaction with insulin and growth factors. Arnqvist HJ, et al. **Metabolism** 1995 Oct;44(10 Suppl 4):58–66 (102 ref.)

Role of insulin and proinsulin in diabetic vascular disease. Wareham NJ, et al. **Metabolism** 1995 Oct;44(10 Suppl 4):76–82 (56 ref.)

The evaluation of insulin as a metabolic signal influencing behavior via the brain. Woods SC, et al. **Neurosci Biobehav Rev** 1996;20(1):139–44 (42 ref.)

The IRS-signalling system in insulin and cytokine action. White MF. **Philos Trans R Soc Lond B Biol Sci** 1996 Feb 29;351(1336):181–9 (80 ref.)

[Role of peptide hormones in adipocyte metabolism] Kaneko T, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:100–5 (20 ref.) **(Jpn)**

POISONING

Hypoglycaemia—real and unreal, lawful and unlawful: the 1994 Banting Lecture. Marks V. **Diabet Med** 1995 Oct; 12(10):850–64 (107 ref.)

SECRETION

Glucagon-like peptide-1 and control of insulin secretion. Thorens B. **Diabete Metab** 1995 Dec;21(5):311–8 (83 ref.)

Banting Lecture 1995. A lesson in metabolic regulation inspired by the glucokinase glucose sensor paradigm. Matschinsky FM. **Diabetes** 1996 Feb;45(2):223–41 (86 ref.)

In praise of the hyperglycemic clamp. A method for assessment of beta-cell sensitivity and insulin resistance. Elahi D. **Diabetes Care** 1996 Mar;19(3):278–86 (26 ref.)

Insulin-secreting cell lines: classification, characteristics and potential applications. Poitout V, et al. **Diabetes Metab** 1996

Feb;22(1):7-14 (54 ref.)
Insulin secretion in obese and non-obese NIDDM. Cerasi E, et al. **Diabetes Res Clin Pract** 1995 Aug;28 Suppl:S27-37 (62 ref.)
What therapy do our NIDDM patients need? Insulin releasers. Crepaldi G, et al. **Diabetes Res Clin Pract** 1995 Aug;28 Suppl:S159-65 (29 ref.)
Insulin deficiency and insulin resistance in the pathogenesis of NIDDM: is a divorce possible? Cerasi E. **Diabetologia** 1995 Aug;38(8):992-7 (50 ref.)
The pathogenesis of NIDDM: the role of the pancreatic beta cell. Zawalich WS, et al. **Diabetologia** 1995 Aug; 38(8):986-91 (41 ref.)
New insights into pancreatic beta-cell metabolic signaling in insulin secretion. Prenki M. **Eur J Endocrinol** 1996 Mar; 134(3):272-86 (134 ref.)
The esters of carboxylic nutrients as insulinotropic tools in non-insulin-dependent diabetes mellitus. Malaisse WJ. **Gen Pharmacol** 1995 Oct;26(6):1133-41 (40 ref.)
Chromium and other insulin sensitizers may enhance glucagon secretion: implications for hypoglycemia and weight control. McCarty MF. **Med Hypotheses** 1996 Feb; 46(2):77-80 (35 ref.)
[How should insulin secretion be evaluated in practice?] Scheen AJ, et al. **Diabete Metab** 1995 Dec;21(6):458-64 (38 ref.) **(Fre)**
[Routes to normalization in the stimulation of insulin secretion] Ammon HP. **Pharm Unserer Zeit** 1996 May; 25(3):123-9 (101 ref.) **(Ger)**

THERAPEUTIC USE

Insulin therapy and GH-IGF-I axis disorders in diabetes: impact of glycaemic control and hepatic insulinization. Hanaire-Broutin H, et al. **Diabetes Metab** 1996 Jul; 22(4):245-50 (42 ref.)
The insulin-sparing effect of metformin in insulin-treated diabetic patients. Golay A, et al. **Diabetes Metab Rev** 1995 Sep;11 Suppl 1:S63-7 (34 ref.)
Insulin therapy in type II diabetes. Holman RR, et al. **Diabetes Res Clin Pract** 1995 Aug;28 Suppl:S179-84 (16 ref.)
Insulin treatment in elderly patients with non-insulin-dependent diabetes mellitus. A double-edged sword? Niskanen L. **Drugs Aging** 1996 Mar;8(3):183-92 (51 ref.)
Glucose monitoring and insulin therapy during pregnancy. Homko CJ, et al. **Obstet Gynecol Clin North Am** 1996 Mar; 23(1):47-74 (95 ref.)
Do more diabetic patients need insulin? Page S, et al. **Practitioner** 1996 Feb;240(1559):104-8 (7 ref.)
The role of vanadium in the management of diabetes. Brichard SM, et al. **Trends Pharmacol Sci** 1995 Aug; 16(8):265-70 (60 ref.)
[Is insulin therapy sufficiently used in type II diabetes? Minimal insulin therapy, or intensified insulin therapy?] Charbonnel B. **Diabete Metab** 1995 Jun;21(3):219-24 (15 ref.) **(Fre)**
[How I treat... A Type 2 diabetic patient who has become insulin-dependent] Scheen AJ. **Rev Med Liege** 1996 Apr; 51(4):263-5 (19 ref.) **(Fre)**
[Insulin analogs] Scaglione L, et al. **Minerva Endocrinol** 1996 Mar;21(1):27-36 (31 ref.) (Eng. Abstr.) **(Ita)**
[Emergency drug therapy of diabetic coma] Morita S, et al. **Nippon Naika Gakkai Zasshi** 1995 Nov 10;84(11):1843-7 (4 ref.) **(Jpn)**

INSULIN ANTIBODIES

BLOOD

Recurrent hypoglycaemia caused by the insulin autoimmune syndrome: the first Dutch case [see comments] Schlemper RJ, et al. **Neth J Med** 1996 May;48(5):188-92 (27 ref.) Comment in: Neth J Med 1996 May;48(5):167-8.

INSULIN INFUSION SYSTEMS

Treatment with insulin infusion pumps and ketoacidotic episodes: from physiology to troubleshooting. Castillo MJ, et al. **Diabetes Metab Rev** 1995 Jul;11(2):161-77 (87 ref.)
Application of computers in diabetes care--a review. II. Computers for decision support and education. Lehmann ED, et al. **Med Inf (Lond)** 1995 Oct-Dec;20(4):303-29 (147 ref.)
Application of computers in diabetes care--a review. I. Computers for data collection and interpretation. Lehmann ED, et al. **Med Inf (Lond)** 1995 Oct-Dec;20(4):281-302 (142 ref.)
Insulin pump therapy: acceptable alternative to injection therapy. Marcus AO, et al. **Postgrad Med** 1996 Mar; 99(3):125-32, 142-4 (22 ref.)
[The conditions, indications and contraindications of treatment of diabetes using subcutaneous infusion of insulin] Dryáková M. **Cas Lek Cesk** 1996 Jan 17;135(2):43-9 (36 ref.) (Eng. Abstr.) **(Cze)**
[Current role of external pumps in the treatment of insulin-dependent diabetes mellitus] Selam JL, et al. **Diabete Metab** 1995 Dec;21(5):378-82 (21 ref.) **(Fre)**

INSULIN-LIKE GROWTH FACTOR I

see related
RECEPTORS, INSULIN-LIKE-GROWTH FACTOR I

[Factors with insulin-like effects: IGF-I and GLP-1] Páv J. **Vnitr Lek** 1995 Sep;41(9):624-8 (35 ref.) (Eng. Abstr.) **(Cze)**
[Insulin-like growth factor-I controls animal growth] Takahashi SI, et al. **Tanpakushitsu Kakusan Koso** 1996 Mar; 41(3):267-80 (62 ref.) **(Jpn)**

ANALYSIS

Serum insulin, IGF-I,IGF-II and growth hormone, and left ventricular mass in noninsulin-dependent mellitus. Rabkin SW, et al. **Can J Cardiol** 1996 Mar;12(3):264-70 (52 ref.)
[IGF I, IGF II] Matsuzaki F. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:271-4 (12 ref.) **(Jpn)**

BIOSYNTHESIS

Exploration of the somatotropic axis. Tauber M, et al. **Diabetes Metab** 1996 Jul;22(4):240-4 (6 ref.)
The ontogeny of growth hormone, insulin-like growth factors and sex steroids: molecular aspects. Han VK. **Horm Res** 1996;45(1-2):61-6 (45 ref.)

GENETICS

The regulation of IGF-I receptor gene expression. Werner H, et al. **Int J Biochem Cell Biol** 1995 Oct;27(10):987-94 (46 ref.)

METABOLISM

Nutritional regulation of insulin-like growth factor-I. Ketelslegers JM, et al. **Metabolism** 1995 Oct;44(10 Suppl 4):50-7 (75 ref.)
[Growth hormone (GH) and insulin-like growth factor 1 (IGF-1) in nutritional status] Chevenne D, et al. **Ann Biol Clin (Paris)** 1995;53(10-11):527-38 (115 ref.) (Eng. Abstr.) **(Fre)**

PHARMACOLOGY

Metabolic effects of insulin-like growth factor-I: a focus on insulin sensitivity. Hussain MA, et al. **Metabolism** 1995 Oct; 44(10 Suppl 4):108-12 (48 ref.)
Insulin-like growth factor I in the kidney. Hirschberg R. **Miner Electrolyte Metab** 1996;22(1-3):128-32 (23 ref.)
[Growth hormone and bone metabolism] Manten JW, et al. **Ned Tijdschr Geneeskd** 1996 May 18;140(20):1064-8 (37 ref.) **(Dut)**

PHYSIOLOGY

Cardiac hypertrophy and related growth processes: the role of insulin-like growth factor-I. Friberg P, et al. **Blood Press Suppl** 1995;2:22-9 (57 ref.)
The insulin-like growth factor system and the coupling of formation to resorption. Hayden JM, et al. **Bone** 1995 Aug; 17(2 Suppl):93S-98S (32 ref.)
Insulin-like growth factor I and its binding proteins in the cardiovascular system. Delafontaine P. **Cardiovasc Res** 1995 Dec;30(6):825-34 (162 ref.)
The IGF system in metabolism regulation. Binoux M. **Diabete Metab** 1995 Dec;21(5):330-7 (101 ref.)
A novel whey to study effects of insulin-like growth factor-I on mammary development [editorial; comment] Kleinberg DL. **Endocrinology** 1996 Jan;137(1):1-2 (20 ref.) Comment on: Endocrinology 1996 Jan;137(1):321-30.
Effects of growth hormone and insulin-like growth factor I on the immune system. Auernhammer CJ, et al. **Eur J Endocrinol** 1995 Dec;133(6):635-45 (137 ref.)
Regulation of insulin-like growth factors and IGF-binding proteins in bone tumours. Zumkeller W, et al. **Growth Regul** 1996 Mar;6(1):10-5 (51 ref.)
Growth hormone, growth factors and hematopoiesis. Kelley KW, et al. **Horm Res** 1996;45(1-2):38-45 (91 ref.)
Sex steroids, growth hormone, insulin-like growth factor-1: neuroendocrine and metabolic regulation in puberty. Mauras N, et al. **Horm Res** 1996;45(1-2):74-80 (41 ref.)
Growth hormone axis in cushing's syndrome. Wajchenberg BL, et al. **Horm Res** 1996;45(1-2):99-107 (36 ref.)
IGF-I: a mitogen also involved in differentiation processes in mammalian cells. Benito M, et al. **Int J Biochem Cell Biol** 1996 May;28(5):499-510 (95 ref.)
Regulation of Leydig cell function by insulin-like growth factor-I and binding proteins. Lin T. **J Androl** 1995 May-Jun;16(3):193-6 (20 ref.)
The role of growth hormone/insulin-like growth factors in adipocyte differentiation. Wabitsch M, et al. **Metabolism** 1995 Oct;44(10 Suppl 4):45-9 (58 ref.)
Insulin-like growth factor I in the kidney. Hirschberg R. **Miner Electrolyte Metab** 1996;22(1-3):128-32 (23 ref.)
Growth hormone and malnutrition in dialysis patients. Blake PG. **Perit Dial Int** 1995 Jul-Sep;15(6):210-6 (49 ref.)
[Growth hormone--a pathogenetic factor in chronic congestive heart insufficiency?] Dreifuss PM. **Dtsch Med Wochenschr** 1996 Apr 12;121(15):492-6 (35 ref.) **(Ger)**
[Growth factors in tubular cells] Okuda S. **Nippon Rinsho** 1995 Aug;53(8):1879-85 (18 ref.) (Eng. Abstr.) **(Jpn)**

SECRETION

Growth hormone/insulin-like growth factor I axis in children treated for brain tumours: relationship to chemotherapy and nutrition. Rappaport R, et al. **Acta Paediatr Suppl** 1995 Sep;411:37-9; discussion 40 (19 ref.)
Insulin therapy and GH-IGF-I axis disorders in diabetes: impact of glycaemic control and hepatic insulinization. Hanaire-Broutin H, et al. **Diabetes Metab** 1996 Jul; 22(4):245-50 (42 ref.)

THERAPEUTIC USE

Growth hormone insensitivity syndrome (Laron syndrome): main characteristics and effects of IGF1 treatment. Carel JC, et al. **Diabetes Metab** 1996 Jul;22(4):251-6 (34 ref.)
Insulin-like growth factor-I in the therapy of non-insulin-dependent diabetes mellitus and insulin resistance. Froesch ER, et al. **Diabetes Metab** 1996 Jul; 22(4):261-7 (25 ref.)
Recombinant IGF-I therapy in insulin-dependent diabetes mellitus. Savage MO, et al. **Diabetes Metab** 1996 Jul; 22(4):257-60 (13 ref.)
Insulin-like growth factors (IGFs) and IGF-I treatment in the adolescent with insulin-dependent diabetes mellitus. Dunger DB, et al. **Metabolism** 1995 Oct;44(10 Suppl 4):119-23 (56 ref.)
Carbohydrate metabolism in primary growth hormone resistance (Laron syndrome) before and during insulin-like growth factor-I treatment. Laron Z, et al. **Metabolism** 1995 Oct;44(10 Suppl 4):113-8 (41 ref.)
Insulin-like growth factor 1 resistance in chronic renal failure. Fouque D. **Miner Electrolyte Metab** 1996; 22(1-3):133-7 (55 ref.)
[Human insulin-like growth factor I and treatment in diabetes] Koivisto VA. **Duodecim** 1994; 110(23-24):2197-201 (25 ref.) **(Fin)**

INSULIN-LIKE GROWTH FACTOR II

see related
RECEPTORS, INSULIN-LIKE-GROWTH-FACTOR II

ANALYSIS

[IGF I, IGF II] Matsuzaki F. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:271-4 (12 ref.) **(Jpn)**

BIOSYNTHESIS

Exploration of the somatotropic axis. Tauber M, et al. **Diabetes Metab** 1996 Jul;22(4):240-4 (6 ref.)
The ontogeny of growth hormone, insulin-like growth factors and sex steroids: molecular aspects. Han VK. **Horm Res** 1996;45(1-2):61-6 (45 ref.)
Normal development and neoplasia: the imprinting connection. Ohlsson R, et al. **Int J Dev Biol** 1995 Oct; 39(5):869-76 (54 ref.)

GENETICS

Epigenetics and human disease. Issa JP, et al. **Nat Med** 1996 Mar;2(3):281-2 (18 ref.)

PHYSIOLOGY

Insulin-like growth factor II/cation-independent mannose 6-phosphate receptor and lysosomal enzyme recognition. Dahms NM. **Biochem Soc Trans** 1996 Feb;24(1):136-41 (46 ref.)
The insulin-like growth factor system and the coupling of formation to resorption. Hayden JM, et al. **Bone** 1995 Aug; 17(2 Suppl):93S-98S (32 ref.)
The IGF system in metabolism regulation. Binoux M. **Diabete Metab** 1995 Dec;21(5):330-7 (101 ref.)
Regulation of insulin-like growth factors and IGF-binding proteins in bone tumours. Zumkeller W, et al. **Growth Regul** 1996 Mar;6(1):10-5 (51 ref.)

INSULIN-LIKE GROWTH-FACTOR-BINDING PROTEINS

Insulin-like growth factor receptors and binding proteins. LeRoith D. **Baillieres Clin Endocrinol Metab** 1996 Jan; 10(1):49-73 (186 ref.)

BIOSYNTHESIS

The ontogeny of growth hormone, insulin-like growth factors and sex steroids: molecular aspects. Han VK. **Horm Res** 1996;45(1-2):61-6 (45 ref.)

PHYSIOLOGY

Gene-targeting and transgenic approaches to IGF and IGF binding protein function. Wood TL. **Am J Physiol** 1995 Oct;269(4 Pt 1):E613-22 (101 ref.)
The insulin-like growth factor system and the coupling of formation to resorption. Hayden JM, et al. **Bone** 1995 Aug; 17(2 Suppl):93S-98S (32 ref.)
Insulin-like growth factor I and its binding proteins in the cardiovascular system. Delafontaine P. **Cardiovasc Res** 1995 Dec;30(6):825-34 (162 ref.)

INSULIN-LIKE GROWTH-FACTOR-BINDING PROTEINS

Regulation of insulin-like growth factors and IGF-binding proteins in bone tumours. Zumkeller W, et al. **Growth Regul** 1996 Mar;6(1):10-5 (51 ref.)
Growth hormone axis in cushing's syndrome. Wajchenberg BL, et al. **Horm Res** 1996;45(1-2):99-107 (36 ref.)
Insulin-like growth factor-binding proteins (IGFBPs) and their regulatory dynamics. Kelley KM, et al. **Int J Biochem Cell Biol** 1996 Jun;28(6):619-37 (162 ref.)
Insulin-like growth factors (IGFs) and IGF-binding proteins in diabetic kidney disease. Phillip M, et al. **Isr J Med Sci** 1995 Dec;31(12):712-6 (66 ref.)
Insulin-like growth factor binding proteins as glucoregulators. Baxter RC. **Metabolism** 1995 Oct;44(10 Suppl 4):12-7 (48 ref.)
The role of growth hormone, insulin-like growth factors (IGFs), and IGF-binding proteins in experimental diabetic kidney disease. Flyvbjerg A, et al. **Metabolism** 1995 Oct; 44(10 Suppl 4):67-71 (62 ref.)

INSULIN-LIKE GROWTH FACTORS see **SOMATOMEDINS**

INSULIN RECEPTOR KINASE see **INSULIN RECEPTOR PROTEIN-TYROSINE KINASE**

INSULIN RECEPTOR PROTEIN-TYROSINE KINASE

METABOLISM

Diverse signaling pathways in the cellular actions of insulin. Saltiel AR. **Am J Physiol** 1996 Mar;270(3 Pt 1):E375-85 (97 ref.)
Insulin signaling network -- waiting for Copernicus [editorial; comment] Draznin B. **Endocrinology** 1996 Jul; 137(7):2647-8 (20 ref.) Comment on: Endocrinology 1996 Jul;137(7):2649-58.
How do protein kinases discriminate between serine/threonine and tyrosine? Structural insights from the insulin receptor protein-tyrosine kinase. Taylor SS, et al. **FASEB J** 1995 Oct;9(13):1255-66 (41 ref.)
The focal adhesion kinase. Schaller MD. **J Endocrinol** 1996 Jul;150(1):1-7 (88 ref.)
Role of the time factor in signaling specificity: application to mitogenic and metabolic signaling by the insulin and insulin-like growth factor-I receptor tyrosine kinases. De Meyts P, et al. **Metabolism** 1995 Oct;44(10 Suppl 4):2-11 (88 ref.)

PHYSIOLOGY

Modulation of insulin receptor signaling. Potential mechanisms of a cross talk between bradykinin and the insulin receptor. Häring HU, et al. **Diabetes** 1996 Jan;45 Suppl 1:S115-9 (35 ref.)

INSULIN RECEPTORS see **RECEPTORS, INSULIN**

INSULIN RESISTANCE

Insulin resistance syndrome and atherosclerotic cardiovascular disease. Scheen AJ. **Acta Clin Belg** 1996; 51(2):65-9 (44 ref.)
Glucose control and insulin resistance in non-insulin-dependent diabetes mellitus. Henry RR. **Ann Intern Med** 1996 Jan 1;124(1 Pt 2):97-103 (19 ref.)
Do non-insulin-dependent diabetes mellitus and cardiovascular disease share common antecedents? Stern MP. **Ann Intern Med** 1996 Jan 1;124(1 Pt 2):110-6 (90 ref.)
Insulin resistance: a multifaceted metabolic syndrome. Insights gained using a low-dose insulin infusion technique. Krentz AJ, et al. **Diabet Med** 1996 Jan;13(1):30-9 (54 ref.)
Hexosamines and insulin resistance. McClain DA, et al. **Diabetes** 1996 Aug;45(8):1003-9 (64 ref.)
Insulin resistance and obesity. The role of fat distribution pattern. Abate N. **Diabetes Care** 1996 Mar;19(3):292-4 (25 ref.)
Fatty acids and insulin resistance. Boden G. **Diabetes Care** 1996 Apr;19(4):394-5 (14 ref.)
In praise of the hyperglycemic clamp. A method for assessment of beta-cell sensitivity and insulin resistance. Elahi D. **Diabetes Care** 1996 Mar;19(3):278-86 (26 ref.)
Insulin resistance in the pathogenesis of dyslipidemia. Garg A. **Diabetes Care** 1996 Apr;19(4):387-9 (34 ref.)
The insulin resistance syndrome revisited. Haffner SM. **Diabetes Care** 1996 Mar;19(3):275-7 (43 ref.)
Acute effects of insulin in the control of VLDL production in humans. Implications for the insulin-resistant state. Lewis GF, et al. **Diabetes Care** 1996 Apr;19(4):390-3 (38 ref.)
Insulin-like growth factor-I in the therapy of non-insulin-dependent diabetes mellitus and insulin resistance. Froesch ER, et al. **Diabetes Metab** 1996 Jul; 22(4):261-7 (25 ref.)
Development and consequences of insulin resistance: lessons from animals with hyperinsulinaemia. Shafrir E. **Diabetes Metab** 1996 Apr;22(2):122-31 (63 ref.)
Insulin deficiency and insulin resistance in the pathogenesis of NIDDM: is a divorce possible? Cerasi E. **Diabetologia** 1995 Aug;38(8):992-7 (50 ref.)
Role of insulin resistance in the pathogenesis of NIDDM. Yki-Järvinen H. **Diabetologia** 1995 Dec;38(12):1378-88 (123 ref.)
Hyperinsulinemia, hyperproinsulinemia and insulin resistance in the metabolic syndrome. Schrezenmeir J. **Experientia** 1996 May 15;52(5):426-32 (26 ref.)
Attenuation of hypertension by insulin-sensitizing agents. Kotchen TA. **Hypertension** 1996 Aug;28(2):219-23 (79 ref.)
Influence of exercise on insulin sensitivity. Henriksson J. **J Cardiovasc Risk** 1995 Aug;2(4):303-9 (62 ref.)
Skeletal muscle membrane lipids and insulin resistance. Storlien LH, et al. **Lipids** 1996 Mar;31 Suppl:S261-5 (39 ref.)
Metabolic effects of insulin-like growth factor-I: a focus on insulin sensitivity. Hussain MA, et al. **Metabolism** 1995 Oct; 44(10 Suppl 4):108-12 (48 ref.)
Obesity-related hypertension and the insulin resistance syndrome. Landsberg L. **Trans Am Clin Climatol Assoc** 1994;106:69-75; discussion 75-6 (32 ref.)
[Gestational diabetes and adult type of diabetes with relative insulin resistance] Forsén T, et al. **Duodecim** 1994; 110(8):808-14 (30 ref.) **(Fin)**
[How I explore... insulin resistance in clinical practice] Scheen AJ. **Rev Med Liege** 1996 Jun;51(6):439-42 (23 ref.) **(Fre)**
[Therapeutic approach to a multi-metabolic syndrome] Pernet A. **Rev Med Suisse Romande** 1995 Sep;115(9):635-40 (37 ref.) **(Fre)**
[Insulin resistance and arteriosclerosis] Matsuzawa Y. **Nippon Naika Gakkai Zasshi** 1995 Sep 10;84(9):1579-82 (8 ref.) **(Jpn)**
[Insulin-resistance syndrome] Saruta T. **Nippon Naika Gakkai Zasshi** 1996 Feb 10;85(2):285-91 (20 ref.) **(Jpn)**
[Abnormal glucose metabolism and insulin resistance in obesity] Inoue Y, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:299-303 (22 ref.) **(Jpn)**
[Insulin resistance and pathogenesis of non-insulin-dependent diabetes mellitus (I)] Martinka E, et al. **Vnitr Lek** 1996 Jan; 42(1):31-6 (41 ref.) (Eng. Abstr.) **(Slo)**
[Glucose toxicity--pros and cons. Useful adaptation and common cause of insulin resistance in diabetic patients] Yki-Järvinen H. **Nord Med** 1996 Mar;111(3):80-3 (15 ref.) (Eng. Abstr.) **(Swe)**

GENETICS

Mutant insulin receptors in syndromes of insulin resistance. Krook A, et al. **Baillieres Clin Endocrinol Metab** 1996 Jan; 10(1):97-122 (163 ref.)
Candidate genes for insulin resistance. Moller DE, et al. **Diabetes Care** 1996 Apr;19(4):396-400 (45 ref.)
[Fetal environment and coronary ischemia risk: review of the literature with particular reference to syndrome X] Lehingue Y. **Rev Epidemiol Sante Publique** 1996 Jun; 44(3):262-77 (57 ref.) (Eng. Abstr.) **(Fre)**
[The metabolic syndrome and chronic vascular disease. Cellular mechanisms and potential candidate genes] Haller H, et al. **Internist (Berl)** 1996 Jul;37(7):687-97 (100 ref.) **(Ger)**

PHYSIOLOGY

Clinical implications of insulin resistance syndromes. Davidson MB. **Am J Med** 1995 Oct;99(4):420-6 (57 ref.)
An integrated view of beta-cell dysfunction in type-II diabetes. Poitout V, et al. **Annu Rev Med** 1996;47:69-83 (42 ref.)
Understanding the pathogenesis of type 2 diabetes: can we get off the metabolic merry-go-rounds? Proietto J, et al. **Aust N Z J Med** 1995 Dec;25(6):870-5 (33 ref.)
Insulin sensitivity in the pathogenesis of hypertension and hypertensive complications. Landsberg L. **Clin Exp Hypertens** 1996 Apr-May;18(3-4):337-46 (31 ref.)
Insulin resistance, hypertension and the insulin-responsive glucose transporter, GLUT4 [editorial] Livingstone C, et al. **Clin Sci (Colch)** 1995 Aug;89(2):109-16 (61 ref.)
Pathogenesis of insulin resistance: modulation of the insulin signal at receptor level. Kellerer M, et al. **Diabetes Res Clin Pract** 1995 Aug;28 Suppl:S173-7 (36 ref.)
Insulin resistance: the consequence of a neuroendocrine disturbance? Björntorp P. **Int J Obes Relat Metab Disord** 1995 May;19 Suppl 1:S6-10 (27 ref.)
Role of glucocorticoids and fatty acids in the impairment of lipid metabolism observed in the metabolic syndrome. Brindley DN. **Int J Obes Relat Metab Disord** 1995 May; 19 Suppl 1:S69-75 (61 ref.)
The insulin resistance-dyslipidemic syndrome: contribution of visceral obesity and therapeutic implications. Després JP, et al. **Int J Obes Relat Metab Disord** 1995 May;19 Suppl 1:S76-86 (72 ref.)
Alterations in lipoprotein lipase in insulin resistance. Eckel RH, et al. **Int J Obes Relat Metab Disord** 1995 May;19 Suppl 1:S16-21 (22 ref.)
Are insulin resistance and/or compensatory hyperinsulinemia involved in the etiology and clinical course of patients with hypertension? Reaven GM. **Int J Obes Relat Metab Disord** 1995 May;19 Suppl 1:S2-5 (49 ref.)
A neuroendocrine reappraisal of the dual-centre hypothesis: its implications for obesity and insulin resistance. Rohner-Jeanrenaud F. **Int J Obes Relat Metab Disord** 1995 Aug;19(8):517-34 (312 ref.)
Nutritional determinants of the insulin resistance syndrome. Tremblay A. **Int J Obes Relat Metab Disord** 1995 May; 19 Suppl 1:S60-8 (72 ref.)
Hypofibrinolysis and the insulin resistance syndrome. Vague P, et al. **Int J Obes Relat Metab Disord** 1995 May;19 Suppl 1:S11-5 (59 ref.)
Insulin resistance in systemic hypertension: pharmacotherapeutic implications. Mediratta S, et al. **J Clin Pharmacol** 1995 Oct;35(10):943-56 (162 ref.)
Insulin receptor gene expression and insulin resistance. Brunetti A, et al. **J Endocrinol Invest** 1995 May; 18(5):398-405 (44 ref.)
Risk factors for non-insulin-dependent diabetes mellitus. Haffner SM. **J Hypertens Suppl** 1995 Aug;13(2):S73-6 (50 ref.)
Metabolic aspects of the treatment of hypertension. Lithell H. **J Hypertens Suppl** 1995 Aug;13(2):S77-80 (29 ref.)
Insulin resistance and hyperinsulinemia in hypertension. Weidmann P, et al. **J Hypertens Suppl** 1995 Aug; 13(2):S65-72 (104 ref.)
Up-regulation of intracellular signalling pathways may play a central pathogenic role in hypertension, atherogenesis, insulin resistance, and cancer promotion--the 'PKC syndrome'. McCarty MF. **Med Hypotheses** 1996 Mar; 46(3):191-221 (402 ref.)
Seminars in Medicine of the Beth Israel Hospital, Boston. Non-insulin-dependent diabetes mellitus - a genetically programmed failure of the beta cell to compensate for insulin resistance. Polonsky KS, et al. **N Engl J Med** 1996 Mar 21;334(12):777-83 (68 ref.)
Hypertension and associated metabolic abnormalities--the role of insulin resistance and the sympathoadrenal system. Reaven GM, et al. **N Engl J Med** 1996 Feb 8;334(6):374-81 (85 ref.)
Effects of ACE inhibitors and calcium channel blockers on insulin sensitivity and other components of the syndrome. Sowers JR. **Nephrol Dial Transplant** 1995 Oct;10 Suppl 9:52-5 (41 ref.)
Insulin resistance in obesity and its molecular control. Noguchi T, et al. **Obes Res** 1995 Sep;3 Suppl 2:195S-198S (20 ref.)
[How should insulin secretion be evaluated in practice?] Scheen AJ, et al. **Diabete Metab** 1995 Dec;21(6):458-64 (38 ref.) **(Fre)**
[Diagnosis of the metabolic syndrome] Hanefeld M, et al. **Internist (Berl)** 1996 Jul;37(7):705-11 (32 ref.) **(Ger)**
[Epidemiology of the metabolic syndrome] Janka HU. **Internist (Berl)** 1996 Jul;37(7):681-6 (59 ref.) **(Ger)**
[Integrated drug therapy of the metabolic syndrome] Julius U, et al. **Internist (Berl)** 1996 Jul;37(7):722-30 (32 ref.) **(Ger)**
[Non-medicamentous therapy of metabolic syndrome] Reimers CD, et al. **Internist (Berl)** 1996 Jul;37(7):712-21 (70 ref.) **(Ger)**
[Metabolic syndrome and fatal quartet] Standl E. **Internist (Berl)** 1996 Jul;37(7):698-704 (36 ref.) **(Ger)**
[Insulin resistance and pathogenesis of non-insulin-dependent diabetes mellitus (part II)] Martinka E, et al. **Vnitr Lek** 1996 Mar;42(3):200-4 (32 ref.) (Eng. Abstr.) **(Slo)**

INSULINASE

METABOLISM

Insulin-degrading enzyme. Authier F, et al. **Clin Invest Med** 1996 Jun;19(3):149-60 (56 ref.)

INSULINOMA

DIAGNOSIS

Endocrine tumors of the gastrointestinal tract. Perry RR, et al. **Annu Rev Med** 1996;47:57-68 (33 ref.)
Preoperative endocrine tumor localization utilizing a cost-effective approach. Leight GS Jr, et al. **Curr Opin Gen Surg** 1993;:108-14 (19 ref.)
Tumour-induced hypoglycaemia in a patient with insulin-dependent diabetes mellitus. Svartberg J, et al. **J Intern Med** 1996 Feb;239(2):181-5 (16 ref.)
[Imaging of endocrine tumors of the pancreas] Thérasse E, et al. **Ann Endocrinol (Paris)** 1995;56(5):509-10 (4 ref.) **(Fre)**
[How should insulin secretion be evaluated in practice?] Scheen AJ, et al. **Diabete Metab** 1995 Dec;21(6):458-64 (38 ref.) **(Fre)**

SECRETION

[Insulin producing cells as therapy in diabetes mellitus] Schnedl WJ, et al. **Naturwissenschaften** 1996 Jan;83(1):1-5 (41 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Laparoscopic excision of distal pancreas including insulinoma. Sussman LA, et al. **Aust N Z J Surg** 1996 Jun; 66(6):414-6 (15 ref.)

INSULOMA see **INSULINOMA**

INSURANCE, ACCIDENT

LEGISLATION & JURISPRUDENCE

Accident neurosis revisited [editorial] Mayou R.

Br J Psychiatry 1996 Apr;168(4):399–403 (26 ref.)
Medico-legal aspects of road traffic accidents. Mayou R. **J Psychosom Res** 1995 Aug;39(6):789–98 (13 ref.)

INSURANCE AUDIT see **INSURANCE CLAIM REVIEW**

INSURANCE CARRIERS

LEGISLATION & JURISPRUDENCE

1994 Le Tourneau Award. An insurer's right to settle versus its duty to defend nonmeritorious medical malpractice claims. Thomas SS. **J Leg Med** 1995 Dec;16(4):545–83 (204 ref.)

INSURANCE CASE MANAGEMENT see **MANAGED CARE PROGRAMS**

INSURANCE CLAIM REPORTING

Developing a quality improvement database using health insurance data: a guided tour with application to Medicare's National Claims History file. Parente ST, et al. **Am J Med Qual** 1995 Winter;10(4):162–76 (21 ref.)

INSURANCE CLAIM REVIEW

[Unclear pathomechanism behind neck-shoulder pain. Problem with insurance claim] Zetterberg C. **Lakartidningen** 1996 Feb 28;93(9):793–6 (68 ref.) **(Swe)**

INSURANCE CLAIMS PROCESSING see **INSURANCE CLAIM REVIEW**

INSURANCE, HEALTH

see related
MEDICALLY UNINSURED
PHYSICIAN'S PRACTICE PATTERNS

Genetic testing: employability, insurability, and health reform. Rothstein MA. **J Natl Cancer Inst Monogr** 1995; (17):87–90 (14 ref.)

ECONOMICS

Rural mental health coverage under health care reform. Shelton DA, et al. **Community Ment Health J** 1995 Dec; 31(6):539–52 (33 ref.)

INSURANCE, HEALTH, FOR AGED AND DISABLED see **MEDICARE**

INSURANCE, LIABILITY

LEGISLATION & JURISPRUDENCE

The Danish patient insurance scheme. A comparison with the Swedish system. Krenchel JV, et al. **J Leg Med** 1995 Sep;16(3):407–15 (38 ref.)
1994 Le Tourneau Award. An insurer's right to settle versus its duty to defend nonmeritorious medical malpractice claims. Thomas SS. **J Leg Med** 1995 Dec;16(4):545–83 (204 ref.)

INSURANCE, PHARMACEUTICAL SERVICES

STATISTICS & NUMERICAL DATA

The effect of pharmaceutical benefits managers: is it being evaluated? Schulman KA, et al. **Ann Intern Med** 1996 May 15;124(10):906–13 (62 ref.)

INSURERS see **INSURANCE CARRIERS**

INTEGRAL MEMBRANE PROTEINS see **MEMBRANE PROTEINS**

INTEGRATED DELIVERY SYSTEMS see **DELIVERY OF HEALTH CARE, INTEGRATED**

INTEGRATED HEALTH CARE SYSTEMS see **DELIVERY OF HEALTH CARE, INTEGRATED**

INTEGRATION, PROVIRUS see **VIRUS INTEGRATION**

INTEGRATION, VIRUS see **VIRUS INTEGRATION**

INTEGRIN ALPHA-5 BETA-1 see **RECEPTORS, FIBRONECTIN**

INTEGRIN ALPHA-IIB BETA-3 see **PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX**

INTEGRIN ALPHA-V BETA-3 see **RECEPTORS, VITRONECTIN**

INTEGRIN BETA 2 SUBUNIT see **ANTIGENS, CD18**

INTEGRINS

see related
ANTIGENS, CD18

CELL ADHESION MOLECULES

The beta 7 integrins in mucosal homing and retention. Shaw SK, et al. **Semin Immunol** 1995 Oct;7(5):335–42 (45 ref.)

ANALYSIS

The alpha 2 beta 1 integrin: a collagen receptor on platelets and other cells. Santoro SA, et al. **Thromb Haemost** 1995 Sep;74(3):813–21 (105 ref.)

ANTAGONISTS & INHIBITORS

Approach to discovering novel therapeutic agents for osteoporosis based on integrin receptor blockade. Chorev M, et al. **Biopolymers** 1995;37(6):367–75 (44 ref.)
The integrin alpha 4 beta 1 (VLA-4) as a therapeutic target. Elices MJ. **Ciba Found Symp** 1995;189:79–85; discussion 85–90, 174–6 (56 ref.)
Therapeutic approaches to asthma based on VLA-4 integrin and its counter receptors. Metzger WJ. **Springer Semin Immunopathol** 1995;16(4):467–78 (65 ref.)
Treatment of delayed-type hypersensitivity with inhibitors of the VLA-4 integrin. Tamraz S, et al. **Springer Semin Immunopathol** 1995;16(4):437–41 (36 ref.)

CHEMISTRY

Integrin-ligand binding. Do integrins use a 'MIDAS touch' to grasp an Asp? Bergelson JM, et al. **Curr Biol** 1995 Jun 1;5(6):615–7 (15 ref.)
Integrin signaling. LaFlamme SE, et al. **Semin Cancer Biol** 1996 Jun;7(3):111–8 (70 ref.)
Laminin-binding integrins in tumor progression and metastasis. Ziober BL, et al. **Semin Cancer Biol** 1996 Jun; 7(3):119–28 (106 ref.)

IMMUNOLOGY

The vitronectin receptor (alpha V beta 3) as an example for the role of integrins in T lymphocyte stimulation. Halvorson MJ, et al. **Immunol Res** 1996;15(1):16–29 (94 ref.)
Anti-integrin immunotherapy in rheumatoid arthritis: protective effect of anti-alpha 4 antibody in adjuvant arthritis. Barbadillo C, et al. **Springer Semin Immunopathol** 1995;16(4):427–36 (59 ref.)

METABOLISM

Recent insights into ligand binding, activation and signalling by integrin adhesion receptors. Garratt AN, et al. **Acta Anat (Basel)** 1995;154(1):34–45 (112 ref.)
Fibronectin and cell adhesion: specificity of integrin-ligand interaction. Aota S, et al. **Adv Enzymol Relat Areas Mol Biol** 1995;70:1–21 (81 ref.)
Association of TM4SF proteins with integrins: relevance to cancer. Hemler ME, et al. **Biochim Biophys Acta** 1996 Jun 7;1287(2–3):67–71 (58 ref.)
Integrin-mediated signaling in normal and malignant cells: a role of protein tyrosine kinases. Malik RK, et al. **Biochim Biophys Acta** 1996 Jun 7;1287(2–3):73–6 (61 ref.)
The alpha 6 beta 1 and alpha 6 beta 4 integrins in human prostate cancer progression. Cress AE, et al. **Cancer Metastasis Rev** 1995 Sep;14(3):219–28 (67 ref.)
Mechanisms of VCAM-1 and fibronectin binding to integrin alpha 4 beta 1: implications for integrin function and rational drug design. Humphries MJ, et al. **Ciba Found Symp** 1995;189:177–91; discussion 191–9 (43 ref.)
Integrin-ligand binding. Do integrins use a 'MIDAS touch' to grasp an Asp? Bergelson JM, et al. **Curr Biol** 1995 Jun 1;5(6):615–7 (15 ref.)
Integrin-mediated signalling: regulation by protein tyrosine kinases and small GTP-binding proteins. Parsons JT. **Curr Opin Cell Biol** 1996 Apr;8(2):146–52 (47 ref.)
The focal adhesion kinase. Schaller MD. **J Endocrinol** 1996 Jul;150(1):1–7 (88 ref.)
Adhesion of microbial pathogens to leukocyte integrins: methods to study ligand mimicry. Rozdzinski E, et al. **Methods Enzymol** 1995;253:3–12 (36 ref.)
Platelet integrins. Ginsberg MH, et al. **Thromb Haemost** 1995 Jul;74(1):352–9 (176 ref.)
Platelet adhesion to collagen. Sixma JJ, et al. **Thromb Haemost** 1995 Jul;74(1):454–9 (75 ref.)
[Modulation of integrin alpha-v-beta-1 expression on human tumor cells by leukemia inhibitory factor (LIF) and oncostatin M (OSM)] Heymann D, et al. **Bull Cancer (Paris)** 1996 Jan;83(1):13–21 (41 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Integrins: emerging paradigms of signal transduction. Schwartz MA, et al. **Ann Rev Cell Dev Biol** 1995;11:549–99 (402 ref.)
Adhesion molecules in health and disease. Faull RJ. **Aust N Z J Med** 1995 Dec;25(6):720–30 (86 ref.)
The role of cellular adhesion molecules in surgery. Breidahl AF, et al. **Aust N Z J Surg** 1995 Dec;65(12):838–47 (54 ref.)
Integrins: dynamic regulation of ligand binding. Ginsberg MH. **Biochem Soc Trans** 1995 Aug;23(3):439–46 (190 ref.)
Adhesion and direct integrin engagement differentially regulate gene transcription, transcript stabilization and translation. Mondal K, et al. **Biochem Soc Trans** 1995 Aug; 23(3):460–4 (39 ref.)
Epithelial integrins. Sheppard D. **Bioessays** 1996 Aug; 18(8):655–60 (65 ref.)
Fibronectin and integrins in invasion and metastasis. Akiyama SK, et al. **Cancer Metastasis Rev** 1995 Sep;14(3):173–89 (117 ref.)
Involvement of integrins in cell survival. Bates RC, et al. **Cancer Metastasis Rev** 1995 Sep;14(3):191–203 (85 ref.)
Integrin mediated signal transduction in oncogenesis: an overview. Dedhar S. **Cancer Metastasis Rev** 1995 Sep; 14(3):165–72 (59 ref.)
Growth factor regulation of integrin-mediated cell motility. Matsumoto K, et al. **Cancer Metastasis Rev** 1995 Sep; 14(3):205–17 (89 ref.)
Role of integrins as signal transducing cell adhesion molecules in human cutaneous melanoma. Danen EH, et al. **Cancer Surv** 1995;24:43–65 (130 ref.)
Integrins in tumour development and spread. Pignatelli M, et al. **Cancer Surv** 1995;24:113–27 (85 ref.)
Convergent signalling in the action of integrins, neuropeptides, growth factors and oncogenes. Rozengurt E. **Cancer Surv** 1995;24:81–96 (49 ref.)
Roles of airway epithelial integrins in health and disease. The Parker B. Francis Lectureship. Sheppard D, et al. **Chest** 1996 Mar;109(3 Suppl):29S–33S (44 ref.)
Lymphocyte migration. A new spin on lymphocyte homing. Mackay C. **Curr Biol** 1995 Jul 1;5(7):733–6 (30 ref.)
Leukocyte integrins. Stewart M, et al. **Curr Opin Cell Biol** 1995 Oct;7(5):690–6 (66 ref.)
Integrin transmembrane signaling and cytoskeletal control. Yamada KM, et al. **Curr Opin Cell Biol** 1995 Oct;7(5):681–9 (84 ref.)
Cell adhesion and regulatory molecules involved in tumor formation, hemostasis, and wound healing. Van Waes C. **Head Neck** 1995 Mar-Apr;17(2):140–7 (18 ref.)
Extracellular matrix and its receptors during development. Gullberg D, et al. **Int J Dev Biol** 1995 Oct;39(5):845–54 (109 ref.)
The integrin superfamily and the eye. Elner SG, et al. **Invest Ophthalmol Vis Sci** 1996 Apr;37(5):696–701 (12 ref.)
Integrin receptors and hairy cell leukaemia. Burthem J, et al. **Leuk Lymphoma** 1996 Apr;21(3–4):211–5 (33 ref.)
Adhesion molecules—Part 1. Frenette PS, et al. **N Engl J Med** 1996 Jun 6;334(23):1526–9 (0 ref.)
Adhesion molecules—Part II: Blood vessels and blood cells. Frenette PS, et al. **N Engl J Med** 1996 Jul 4;335(1):43–5 (0 ref.)
Integrins, selectins and CAMs—the 'glue of life'. Froese S, et al. **S Afr Med J** 1994 Nov;84(11):759–64 (27 ref.)
Regulation of integrin function. Sánchez-Mateos P, et al. **Semin Cancer Biol** 1996 Jun;7(3):99–109 (108 ref.)
Pathophysiological aspects of VLA-4 interactions and possibilities for therapeutical interventions. Kuijpers TW. **Springer Semin Immunopathol** 1995;16(4):379–89 (89 ref.)
Therapeutic approaches to asthma based on VLA-4 integrin and its counter receptors. Metzger WJ. **Springer Semin Immunopathol** 1995;16(4):467–78 (65 ref.)
VLA-4 and its ligands: relevance to kidney diseases. Rabb H, et al. **Springer Semin Immunopathol** 1995;16(4):417–25 (48 ref.)
Cell signalling by integrins and immunoglobulin receptors in primed neutrophils. Edwards SW. **Trends Biochem Sci** 1995 Sep;20(9):362–7 (34 ref.)
Integrin signaling and matrix assembly. Ruoslahti E. **Tumour Biol** 1996;17(2):117–24 (44 ref.)
[VLA and alpha6, beta4 integrins. Expression in normal and neoplastic human tissues] Hofman P, et al. **Arch Anat Cytol Pathol** 1995;43(5–6):309–24 (112 ref.) (Eng. Abstr.) **(Fre)**
[Adhesion and migration of epidermal dendritic cells] Staquet MJ. **Pathol Biol (Paris)** 1995 Dec;43(10):858–62 (41 ref.) (Eng. Abstr.) **(Fre)**
[Inhibition of integrin function prevents restenosis following vascular injury] Matsuno H, et al. **Nippon Yakurigaku Zasshi** 1995 Sep;106(3):143–55 (47 ref.) (Eng. Abstr.) **(Jpn)**
[Platelet collagen receptors] Kralisz U. **Postepy Biochem** 1995;41(3):188–94 (78 ref.) **(Pol)**

INTELLIGENCE

Psychiatric sequelae of low birth weight. Breslau N. **Epidemiol Rev** 1995;17(1):96–106 (70 ref.)

GENETICS

The Bell Curve: on race, social class, and epidemiologic research. Muntaner C, et al. **Am J Epidemiol** 1996 Sep 15; 144(6):531–6 (76 ref.)
The genetic basis for mental retardation. Raynham H, et al. **QJM** 1996 Mar;89(3):169–75 (51 ref.)

PHYSIOLOGY

Life-span intellectual development of people with mental retardation. Trower T, et al. **Dev Med Child Neurol** 1996 Jul;38(7):645–50 (25 ref.)
The anatomy of intelligence. Shobris JG. **Genet Soc Gen Psychol Monogr** 1996 May;122(2):133–58 (70 ref.)

INTELLIGENCE TESTS

Measurement of intelligence: misplaced trust and the lure of prophecy [see comments] Slack WV. **MD Comput** 1995 Sep-Oct;12(5):363-72 (127 ref.) Comment in: MD Comput 1995 Sep-Oct;12(5):325-6, 329.

INTENSIVE CARE

see related
CRITICAL CARE

Low-dose dopamine in surgical and intensive care unit patients. Bonde J, et al. **Acta Anaesthesiol Scand** 1996 Mar; 40(3):326-30 (34 ref.)

The use of neuromuscular blocking drugs in intensive care practice. Elliot JM, et al.
Acta Anaesthesiol Scand Suppl 1995;106:70-82 (166 ref.)

Knowing the score: using predictive scoring systems in clinical practice. Zollo MB, et al. **Am J Crit Care** 1996 Mar;5(2):147-51 (21 ref.)

Indications for intensive care in the management of infections in cancer patients. Sculier JP. **Cancer Treat Res** 1995; 79:233-44 (60 ref.)

Bronchoscopy in the intensive care unit. Shennib H, et al. **Chest Surg Clin N Am** 1996 May;6(2):349-61 (48 ref.)

Patients requiring sedation. Tung A, et al. **Crit Care Clin** 1995 Oct;11(4):791-802 (45 ref.)

Therapy of alcohol withdrawal syndrome in intensive care unit patients following trauma: results of a prospective, randomized trial. Spies CD, et al. **Crit Care Med** 1996 Mar; 24(3):414-22 (64 ref.)

Pro: early extubation after cardiac surgery decreases intensive care unit stay and cost [see comments] Cheng DC. **J Cardiothorac Vasc Anesth** 1995 Aug;9(4):460-4 (45 ref.) Comment in: J Cardiothorac Vasc Anesth 1995 Aug;9(4):465-7.

Con: early extubation after cardiac surgery does not decrease intensive care unit stay and cost [comment] Guenther CR. **J Cardiothorac Vasc Anesth** 1995 Aug;9(4):465-7 (12 ref.) Comment on: J Cardiothorac Vasc Anesth 1995 Aug;9(4):460-4.

Neuromuscular complications in the ICU: the spectrum of critical illness-related conditions causing muscular weakness and weaning failure. Hund EF. **J Neurol Sci** 1996 Mar;136(1-2):10-6 (75 ref.)

Neurophysiologic monitoring in the neuroscience intensive care unit. Jordan KG. **Neurol Clin** 1995 Aug;13(3):579-626 (95 ref.)

Sedative and neuromuscular blocking drug use in critically ill patients with head injuries. Prielipp RC, et al. **New Horiz** 1995 Aug;3(3):456-68 (102 ref.)

Transesophageal echocardiography in critical care units: Henry Ford Hospital experience and review of the literature. Alam M. **Prog Cardiovasc Dis** 1996 Jan-Feb; 38(4):315-28 (22 ref.)

Interventional procedures in the intensive care unit patient. Mewissen MW, et al. **Radiol Clin North Am** 1996 Jan; 34(1):157-76 (110 ref.)

Management of acquired coagulation disorders in emergency and intensive-care medicine. Staudinger T, et al. **Semin Thromb Hemost** 1996;22(1):93-104 (192 ref.)

[French Society of Anesthesia and Intensive Care. Arterial catheterization and invasive measurement of blood pressure in anesthesia and intensive care in adults]
Ann Fr Anesth Reanim 1995;14(5):444-53 (6611 ref.) (Eng. Abstr.) **(Fre)**

[Invasive aspergillosis in intensive care (see comments)] Le Conte P, et al. **Ann Fr Anesth Reanim** 1995;14(2):198-208 (78 ref.) (Eng. Abstr.) Comment in: Ann Fr Anesth Reanim 1995;14(5):454-6. **(Fre)**

[Clinical case of the month. Apropos a case of drowning] Moonen M, et al. **Rev Med Liege** 1996 Jul;51(7):453-60 (12 ref.) **(Fre)**

[Gastrointestinal motility disorders in intensive care patients] Grote R, et al. **Anaesthesist** 1995 Aug;44(8):595-609 (36 ref.) **(Ger)**

[Candida infections in intensive care] Presterl E, et al. **Anaesthesist** 1996 Feb;45(2):195-210 (47 ref.) **(Ger)**

[Kidney transplant procedures in intensive care medicine] Schaffartzik W, et al. **Anaesthesist** 1996 May;45(5):473-91 (16 ref.) **(Ger)**

[Intensive medical monitoring with transesophageal echocardiography in fulminant pulmonary embolism] Bruch C, et al. **Dtsch Med Wochenschr** 1996 Jun 21; 121(25-26):829-33 (23 ref.) (Eng. Abstr.) **(Ger)**

[Intensive care in acute ischemia] Steiner T, et al. **Ther Umsch** 1996 Jul;53(7):568-72 (15 ref.) (Eng. Abstr.) **(Ger)**

[Infections in intensive care units. A challenge for the specialist of infectious diseases?] von der Lippe E, et al. **Tidsskr Nor Laegeforen** 1995 Nov 20;115(28):3508-10 (12 ref.) (Eng. Abstr.) **(Nor)**

[Neuromuscular relaxants in the recovery room (see comments)] de la Cruz CA, et al.
Rev Esp Anestesiol Reanim 1995 Oct;42(8):344-8 (25 ref.) Comment in: Rev Esp Anestesiol Reanim 1995 Oct;42(8):301-2. **(Spa)**

METHODS

Maximizing oxygen delivery in critically ill patients: a methodologic appraisal of the evidence. Heyland DK, et al. **Crit Care Med** 1996 Mar;24(3):517-24 (42 ref.)

Stress bleeding prophylaxis in the ICU: obligate or obsolete? [editorial] Bonten MJ, et al. **Neth J Med** 1996 Jan;48(1):4-7 (24 ref.)

Molecular biology in the intensive care unit: a framework for interpretation. Buchman TG, et al. **New Horiz** 1995 May;3(2):139-45 (24 ref.)

Chest physical therapy for patients in the intensive care unit. Ciesla ND. **Phys Ther** 1996 Jun;76(6):609-25 (133 ref.)

ORGANIZATION & ADMINISTRATION

Acute renal replacement in the intensive care unit: now and tomorrow. Bellomo R, et al. **New Horiz** 1995 Nov; 3(4):760-7 (39 ref.)

Medical management of severe head injury: present and future. Chesnut RM. **New Horiz** 1995 Aug;3(3):581-93 (45 ref.)

PSYCHOLOGY

Sedation of the agitated, critically ill patient without an artificial airway. Durbin CG Jr. **Crit Care Clin** 1995 Oct; 11(4):913-36 (86 ref.)

TRENDS

[Recent trend and future of intensive care medicine] Fujimori M. **Masui** 1995;44 Suppl:S1-5 (7 ref.) **(Jpn)**

INTENSIVE CARE, NEONATAL

[Long-term results following premature birth] Eggermont E. **Verh K Acad Geneeskd Belg** 1996;58(2):141-54; discussion 154-6 (29 ref.) (Eng. Abstr.) **(Dut)**

METHODS

Symbiosis of nurse and machine through fuzzy logic: improved specificity of a neonatal pulse oximeter alarm. Bosque EM. **ANS Adv Nurs Sci** 1995 Dec;18(2):67-75 (60 ref.)

Assisted ventilation in neonates: the Indian perspective [editorial] Bhakoo ON. **Indian Pediatr** 1995 Dec; 32(12):1261-4 (15 ref.)

Infant lung function testing in the intensive care unit. Hammer J, et al. **Intensive Care Med** 1995 Sep;21(9):744-52 (66 ref.)

Nursing management of the infant with a congenital malignancy. Thompson DG, et al.
J Obstet Gynecol Neonatal Nurs 1996 Jan;25(1):32-8 (23 ref.)

Advanced ventilation in the neonate. Antunes MJ, et al. **Nurs Clin North Am** 1996 Jun;31(2):405-22 (123 ref.)

Implementing a research-based kangaroo care program in the NICU. Bell RP, et al. **Nurs Clin North Am** 1996 Jun; 31(2):387-403 (22 ref.)

ORGANIZATION & ADMINISTRATION

Implementing a research-based kangaroo care program in the NICU. Bell RP, et al. **Nurs Clin North Am** 1996 Jun; 31(2):387-403 (22 ref.)

Integrating family-centered developmental assessment and intervention into routine care in the neonatal intensive care unit. McGrath JM, et al. **Nurs Clin North Am** 1996 Jun; 31(2):367-86 (104 ref.)

INTENSIVE CARE, SURGICAL see **INTENSIVE CARE**

INTENSIVE CARE UNITS

Point-of-care testing in the intensive care unit. The intensive care physician's perspective. Castro HJ, et al. **Am J Clin Pathol** 1995 Oct;104(4 Suppl 1):S95-9 (22 ref.)

Prophylactic use of the new quinolones for prevention of nosocomial infection in the intensive care unit. Potgieter PD, et al. **Drugs** 1995;49 Suppl 2:86-91 (34 ref.)

Fever in the intensive care unit. Cunha BA, et al. **Infect Dis Clin North Am** 1996 Mar;10(1):185-209 (45 ref.)

Evolving role of the pharmacist in the critical care environment. Dasta JF. **J Clin Anesth** 1996 May;8(3 Suppl):99S-102S (31 ref.)

Acute renal failure in the intensive care unit: adequacy of dialysis and the case for continuous therapies. Bellomo R, et al. **Nephrol Dial Transplant** 1996 Mar;11(3):424-8 (69 ref.)

[Respirator dependency. Intensive care unit or home ventilation?] Criée CP, et al. **Internist (Berl)** 1995 Aug; 36(8):812-7 (16 ref.) **(Ger)**

ECONOMICS

The cost of sedating and paralyzing the critically ill patient. Cheng EY. **Crit Care Clin** 1995 Oct;11(4):1005-19 (29 ref.)

The economics and cost-effectiveness of critical care medicine. Chalfin DB, et al. **Intensive Care Med** 1995 Nov; 21(11):952-61 (67 ref.)

Neurologic intensive care unit management and economic issues. Sundrani S. **Neurol Clin** 1995 Aug;13(3):679-93 (57 ref.)

Cost effectiveness in the intensive care unit. Kirton OC, et al. **Surg Clin North Am** 1996 Feb;76(1):175-200 (54 ref.)

ORGANIZATION & ADMINISTRATION

Economic evaluations in the critical care literature: do they help us improve the efficiency of our unit? Heyland DK, et al. **Crit Care Med** 1996 Sep;24(9):1591-8 (46 ref.)

Reducing preventable deaths and containing costs: the expanding role of intensive care medicine [see comments] Hillman KM. **Med J Aust** 1996 Mar 4;164(5):308-9 (28 ref.) Comment in: Med J Aust 1996 May 6;164(9):573. Comment in: Med J Aust 1996 Jun 17;164(12):758-9.

STANDARDS

Adequacy of dialysis in the acute renal failure of the critically ill: the case for continuous therapies. Bellomo R, et al. **Int J Artif Organs** 1996 Feb;19(2):129-42 (190 ref.)

Treatment of acute renal failure in intensive care patients. Böhler J. **Int J Artif Organs** 1996 Feb;19(2):108-10 (8 ref.)

Practical guide to diagnosis and differential diagnosis of ARF in the ICU. Druml W, et al. **Int J Artif Organs** 1996 Feb; 19(2):87-9 (3 ref.)

Pathophysiology of ARF in the ICU. Hörl WH, et al. **Int J Artif Organs** 1996 Feb;19(2):84-6 (7 ref.)

Prophylaxis and conservative management of acute renal failure in the ICU. Stevens PE, et al.
Int J Artif Organs 1996 Feb;19(2):90-4 (20 ref.)

TRENDS

[Recent trend and future of intensive care medicine] Fujimori M. **Masui** 1995;44 Suppl:S1-5 (7 ref.) **(Jpn)**

UTILIZATION

The evolution of the intensivist: from health care provider to economic rationalist and ethicist [see comments] Scheinkestel CD. **Med J Aust** 1996 Mar 4;164(5):310-2 (14 ref.) Comment in: Med J Aust 1996 Jun 17;164(12):758-9.

INTENSIVE CARE UNITS, NEONATAL

Implementing a research-based kangaroo care program in the NICU. Bell RP, et al. **Nurs Clin North Am** 1996 Jun; 31(2):387-403 (22 ref.)

Integrating family-centered developmental assessment and intervention into routine care in the neonatal intensive care unit. McGrath JM, et al. **Nurs Clin North Am** 1996 Jun; 31(2):367-86 (104 ref.)

Regionalized care established by neonatal intensive care units. Chance GW. **Pediatr Ann** 1995 Oct;24(10):519-24, 527-8 (23 ref.)

INTENSIVE CARE UNITS, PEDIATRIC

ECONOMICS

Effects of availability of patient-related charges on practice patterns and cost containment in the pediatric intensive care unit. Sachdeva RC, et al. **Crit Care Med** 1996 Mar; 24(3):501-6 (44 ref.)

INTERAGENCY RELATIONS see
INTERINSTITUTIONAL RELATIONS

INTERCALATED NEURONS see **INTERNEURONS**

INTERCALATING AGENTS

Specific DNA cleavage by manganese(III) complexes. Gravert DJ, et al. **Met Ions Biol Syst** 1996;33:515-36 (32 ref.)

Electron transfer between metal complexes bound to DNA: is DNA a wire? Stemp ED, et al. **Met Ions Biol Syst** 1996; 33:325-65 (75 ref.)

CHEMISTRY

Evidences for a catalytic activity of the DNA double helix in the reaction between DNA, platinum(II), and intercalators. Boudvillain M, et al. **Met Ions Biol Syst** 1996; 33:87-104 (44 ref.)

Electron transfer reactions through the DNA double helix. Meade TJ. **Met Ions Biol Syst** 1996;32:453-78 (85 ref.)

METABOLISM

Intercalation, DNA kinking, and the control of transcription. Werner MH, et al. **Science** 1996 Feb 9;271(5250):778-84 (54 ref.)

INTERCELLULAR ADHESION MOLECULE-1

ANALYSIS

[Function and regulation of adhesion molecules in CTLs induction of chronic hepatitis B—expression of ICAM-1 and VCAM-1 in liver tissues] Doi T. **Nippon Rinsho** 1995 Oct;53 Suppl:180-4 (19 ref.) **(Jpn)**

GENETICS

Transcriptional regulation of the human intercellular adhesion molecule-1 gene: a short overview. Stratowa C, et al. **Immunobiology** 1995 Jul;193(2-4):293-304 (37 ref.)

New insights into the regulation of ICAM-1 gene expression. Ohh M, et al. **Leuk Lymphoma** 1996 Jan;20(3-4):223-8 (43 ref.)

IMMUNOLOGY

Treatment of inflammatory diseases with a monoclonal antibody to intercellular adhesion molecule 1. Rothlein R, et al. **Ciba Found Symp** 1995;189:200–8; discussion 208–11 (41 ref.)

METABOLISM

Immunologic roles of keratinocytes: expression of HLA-DR and ICAM-1 on cultured human keratinocytes and their influences on the alloimmune response. Haw CR. **J Dermatol** 1995 Nov;22(11):839–44 (20 ref.)

PHYSIOLOGY

The role of ICAM expression in immunity and disease. Simmons DL. **Cancer Surv** 1995;24:141–55 (58 ref.)

INTERCELLULAR ADHESION MOLECULES see **CELL ADHESION MOLECULES**

INTERCELLULAR JUNCTIONS

PHYSIOLOGY

Molecular interactions in the submembrane plaque of cell–cell and cell–matrix adhesions. Geiger B, et al. **Acta Anat (Basel)** 1995;154(1):46–62 (181 ref.)

Adherens junctions in the Drosophila embryo: the role of E-cadherin in their establishment and morphogenetic function. Knust E, et al. **Bioessays** 1996 Aug;18(8):609–12 (21 ref.)

The body language of cells: the intimate connection between cell adhesion and behavior. Klymkowsky MW, et al. **Cell** 1995 Oct 6;83(1):5–8 (25 ref.)

Modulation of intercellular junctions of epithelia by scatter factor (hepatocyte growth factor). Nusrat A, et al. **EXS** 1995;74:69–87 (61 ref.)

Molecular organization and functional regulation of cell to cell junctions in the endothelium. Dejana E, et al. **Thromb Haemost** 1995 Jul;74(1):309–12 (35 ref.)

ULTRASTRUCTURE

Advances in understanding permeability in fetal capillaries of the human placenta: a review of organization of the endothelial paracellular clefts and their junctional complexes. Leach L, et al. **Reprod Fertil Dev** 1995; 7(6):1451–6 (51 ref.)

INTERCELLULAR SPACE see **EXTRACELLULAR SPACE**

INTERCRINES see **CHEMOKINES**

INTERDIGITATING CELLS see **DENDRITIC CELLS**

INTERDISCIPLINARY HEALTH TEAM see **PATIENT CARE TEAM**

INTERFACE, USER COMPUTER see **USER-COMPUTER INTERFACE**

INTERFASCICULAR OLIGODENDROGLIA see **OLIGODENDROGLIA**

INTERFERON ALFA see **INTERFERON-ALPHA**

INTERFERON ALFA-2A

ADVERSE EFFECTS

Sarcoidosis after interferon therapy for chronic active hepatitis C. Teragawa H, et al. **Intern Med** 1996 Jan; 35(1):19–23 (20 ref.)

PHARMACOLOGY

Interferon-alpha-2a. A review of its pharmacological properties and therapeutic use in the management of viral hepatitis. Haria M, et al. **Drugs** 1995 Nov;50(5):873–96 (149 ref.)

THERAPEUTIC USE

Interferon-alpha-2a. A review of its pharmacological properties and therapeutic use in the management of viral hepatitis. Haria M, et al. **Drugs** 1995 Nov;50(5):873–96 (149 ref.)

Successful treatment of essential thrombocythemia in a pregnancy with recombinant interferon-alpha 2a. Milano V, et al. **J Matern Fetal Med** 1996 Mar–Apr;5(2):74–8 (30 ref.)

[The interferon alfa-2a treatment of the severe form of the Kasabach-Merritt syndrome with neonatal onset] González de Dios J, et al. **An Esp Pediatr** 1996 Feb;44(2):179–83 (67 ref.) **(Spa)**

INTERFERON ALFA-2B

ADVERSE EFFECTS

Interferon-induced acute renal failure: a case report and literature review. Horowitz R, et al. **Med Oncol** 1995 Mar; 12(1):55–7 (10 ref.)

[Anti-platelet antibody and severe thrombocytopenia during interferon-alpha therapy for chronic active hepatitis C] Tanaka Y, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Apr;19(2):150–6 (17 ref.) (Eng. Abstr.) **(Jpn)**

THERAPEUTIC USE

Recombinant alpha-interferon as treatment for chronic myelogenous leukemia in relapse after allogeneic bone marrow transplantation: a report from the Société Française de Greffe de Moelle. Pigneux A, et al. **Bone Marrow Transplant** 1995 Jun;15(6):819–24 (31 ref.)

Classic (non-AIDS-related) Kaposi's sarcoma in a Japanese patient, successfully treated with alpha-2b-interferon [letter] Shimizu S, et al. **Br J Dermatol** 1995 Aug; 133(2):332–4 (8 ref.)

Further evidence for the clonal nature of the idiopathic hypereosinophilic syndrome: complete haematological and cytogenetic remission induced by interferon-alpha in a case with a unique chromosomal abnormality. Malbrain ML, et al. **Br J Haematol** 1996 Jan;92(1):176–83 (55 ref.)

A phase I study of intraperitoneal interferon-alpha 2b and intravenous cis-platinum plus cyclophosphamide chemotherapy in patients with untreated stage III epithelial ovarian cancer: a Gynecologic Oncology Group pilot study. Moore DH, et al. **Gynecol Oncol** 1995 Nov; 59(2):267–72 (25 ref.)

Long-term effect of interferon alpha alone or after prednisone withdrawal in chronic hepatitis B. Interim report and review of the literature. Gonzalez-Mateos F, et al. **Hepatogastroenterology** 1995 Nov–Dec;42(6):893–9 (25 ref.)

Why we should treat chronic viral hepatitis. King PD. **Postgrad Med** 1996 Sep;100(3):68–70, 73; discussion 73, 78 (13 ref.)

Chronic viral hepatitis and use of interferon. Whom are we treating? Koretz RL. **Postgrad Med** 1996 Sep;100(3):55–7, 61–2, 68 (11 ref.)

[Treatment of metastatic carcinoid tumors with interferon-alpha. Five cases] Votte A, et al. **Presse Med** 1996 Jan 20;25(2):63–7 (30 ref.) (Eng. Abstr.) **(Fre)**

INTERFERON ALFA-2C see **INTERFERON ALFA, RECOMBINANT**

INTERFERON ALFA, RECOMBINANT

ADVERSE EFFECTS

Interferon or hepatitis C virus induced autoimmune aplastic anemia and severe thrombocytopenia? A case report. Siciliano R, et al. **Ann Ital Med Int** 1995 Jul–Sep; 10(3):193–4 (10 ref.)

Primary biliary cirrhosis induced by interferon-alpha therapy for hepatitis C virus infection. D'Amico E, et al. **Dig Dis Sci** 1995 Oct;40(10):2113–6 (20 ref.)

PHARMACOLOGY

The hypothalamo-sympathetic nervous system modulates peripheral cellular immunity. Hori T, et al. **Neurobiology (Bp)** 1995;3(3–4):309–17 (30 ref.)

THERAPEUTIC USE

Potential uses of interferon alpha 2 as adjuvant therapy in cancer. Agarwala SS, et al. **Ann Surg Oncol** 1995 Jul; 2(4):365–71 (44 ref.)

Efficacy of recombinant interferon-alpha (rIFN-alpha) in polycythaemia vera: a study of 17 patients and an analysis of published data. Taylor PC, et al. **Br J Haematol** 1996 Jan;92(1):55–9 (36 ref.)

Predictors of a sustained beneficial response to interferon alfa therapy in chronic hepatitis C [editorial] Conjeevaram HS, et al. **Hepatology** 1995 Oct;22(4 Pt 1):1326–9 (30 ref.)

The role of alpha-interferon in essential thrombocythaemia, polycythaemia vera and myelofibrosis with myeloid metaplasia (MMM): a concise update. Sacchi S. **Leuk Lymphoma** 1995 Sep;19(1–2):13–20 (86 ref.)

Interferon and multiple myeloma. Lauta VM. **Med Oncol** 1995 Mar;12(1):63–9 (31 ref.)

INTERFERON-ALPHA

ADVERSE EFFECTS

Cutaneous side effects associated with interferon-alpha therapy: a review. Chang LW, et al. **Cutis** 1995 Sep; 56(3):144 (14 ref.)

Risks and benefits of interferon-alpha in the treatment of hepatitis. Pardo M, et al. **Drug Saf** 1995 Nov;13(5):304–16 (129 ref.)

Philadelphia chromosome-negative cells with trisomy 8 after busulfan and interferon treatment of Ph1-positive chronic myelogenous leukemia. Izumi T, et al. **Int J Hematol** 1996 Jul;64(1):73–7 (17 ref.)

Systemic lupus erythematosus diagnosed during interferon alfa therapy. Morris LF, et al. **South Med J** 1996 Aug; 89(8):810–4 (30 ref.)

[Depressive disorders and interferon alpha (editorial)] Hardy P. **Gastroenterol Clin Biol** 1996;20(3):255–7 (13 ref.) **(Fre)**

[Side effects of interferon-alpha] Vial T, et al. **Gastroenterol Clin Biol** 1996;20(5):462–89 (305 ref.) **(Fre)**

[Nephrotic syndrome complicating treatment with interferon alpha] Dhib M, et al. **Presse Med** 1996 Jun 29;25(23):1066–8 (18 ref.) (Eng. Abstr.) **(Fre)**

[Nephropathies caused by interferon alpha: apropos of 2 cases] Cardineau E, et al. **Rev Med Interne** 1995;16(9):691–5 (38 ref.) (Eng. Abstr.) **(Fre)**

CEREBROSPINAL FLUID

The Aicardi-Goutières syndrome (familial, early onset encephalopathy with calcifications of the basal ganglia and chronic cerebrospinal fluid lymphocytosis). Tolmie JL, et al. **J Med Genet** 1995 Nov;32(11):881–4 (26 ref.)

CHEMISTRY

Human leukocyte interferon alpha: structure, pharmacology, and therapeutic applications. Viscomi GC, et al. **Med Res Rev** 1995 Sep;15(5):445–78 (289 ref.)

PHARMACOLOGY

The role of interferon-alpha as a modulator of fluorouracil and leucovorin. Grem JL, et al. **Eur J Cancer** 1995 Jul–Aug;31A(7–8):1316–20 (29 ref.)

Effects of alpha-interferon on serum beta-2-microglobulin. Remes K, et al. **Leuk Lymphoma** 1996 Apr;21(3–4):233–8 (57 ref.)

Interaction of alpha-interferon with chemotherapeutic agents: effects on cytotoxic drug metabolism and multiple drug resistance. Sewell GJ. **Med Oncol** 1995 Mar;12(1):9–14 (43 ref.)

Human leukocyte interferon alpha: structure, pharmacology, and therapeutic applications. Viscomi GC, et al. **Med Res Rev** 1995 Sep;15(5):445–78 (289 ref.)

Interferon-alpha hybrids. Horisberger MA, et al. **Pharmacol Ther** 1995 Jun;66(3):507–34 (132 ref.)

PHYSIOLOGY

Roles of cytokines in the neural-immune interactions: modulation of NMDA responses by IFN-alpha. Katafuchi T, et al. **Neurobiology (Bp)** 1995;3(3–4):319–27 (39 ref.)

THERAPEUTIC USE

Interferon-alpha therapy for chronic myelogenous leukemia. Wetzler M, et al. **Am J Med** 1995 Oct;99(4):402–11 (67 ref.)

Summary: antiviral treatment of hepatitis C virus. Dusheiko GM. **Antiviral Res** 1996 Jan;29(1):77–82 (30 ref.)

Therapeutic applications of alpha interferon for chronic viral hepatitis in pediatric patients. Kay MH, et al. **Clin Pediatr (Phila)** 1995 Jul;34(7):372–9 (50 ref.)

Risks and benefits of interferon-alpha in the treatment of hepatitis. Pardo M, et al. **Drug Saf** 1995 Nov;13(5):304–16 (129 ref.)

Interferon in multiple myeloma--does it pay? [editorial; comment] Kedar I, et al. **Isr J Med Sci** 1995 Oct; 31(10):635–7 (30 ref.) Comment on: Isr J Med Sci 1995 Oct;31(10):604–10.

Role of interferon-alpha in chronic myeloid leukemia. Kumar L, et al. **J Assoc Physicians India** 1995;Suppl 3:26–32 (47 ref.)

Interferon in the treatment of multiple myeloma and non Hodgkins lymphoma. Smruti BK, et al. **J Assoc Physicians India** 1995;Suppl 3:33–7 (27 ref.)

The long-term efficacy of interferon alfa in chronic hepatitis C patients: a critical review. Saracco G, et al. **J Gastroenterol Hepatol** 1995 Nov–Dec;10(6):668–73 (64 ref.)

Alpha-interferon in chronic myelogenous leukaemia [see comments] Kumar L, et al. **Lancet** 1995 Oct 14; 346(8981):984–6 (12 ref.) Comment in: Lancet 1996 Jan 6;347(8993):57–8.

Chronic myelogenous leukemia: does interferon alpha prolong life? [editorial] Hehlmann R. **Leukemia** 1996 Feb; 10(2):193–6 (22 ref.)

Alpha interferon as an immunomodulator in the treatment of patients with tumors. Alvarez-Mon M, et al. **Med Oncol** 1995 Mar;12(1):15–21 (45 ref.)

Interferon and multiple myeloma. Lauta VM. **Med Oncol** 1995 Mar;12(1):63–9 (31 ref.)

Alpha interferon: new associations in haematology/oncology. The Montpellier experience. Rossi JF. **Med Oncol** 1995 Mar;12(1):59–61 (23 ref.)

Treatment of essential thrombocythemia during pregnancy with interferon-alpha. Delage R, et al. **Obstet Gynecol** 1996 May;87(5 Pt 2):814–7 (15 ref.)

New developments in antiviral therapy for chronic hepatitis B infection. De Man RA, et al. **Scand J Gastroenterol Suppl** 1995;212:100–4 (26 ref.)

Is alpha-interferon treatment in multiple myeloma worthwhile? Avvisati G, et al. **Stem Cells (Dayt)** 1995 Aug; 13 Suppl 2:106–13 (44 ref.)

[Darier's erythema annulare centrifugum of neonatal onset with a 15 years' follow-up. Efficacy of interferon and role of cytokines] Guillet MH, et al. **Ann Dermatol Venereol** 1995;122(6–7):422–6 (31 ref.) (Eng. Abstr.) **(Fre)**

[Compared efficiency of three strategies of management of chronic hepatitis C. Effect on the risk of cirrhosis 8 years after diagnosis] Michel P, et al. **Gastroenterol Clin Biol** 1996 Feb;20(1):47–54 (61 ref.) (Eng. Abstr.) **(Fre)**

[Treatment of hepatitis C] Trepo C, et al.

INTERFERON-ALPHA

Pathol Biol (Paris) 1995 Oct;43(8):716-24 (58 ref.) (Eng. Abstr.) **(Fre)**

[Treatment of metastatic carcinoid tumors with interferon-alpha. Five cases] Votte A, et al. **Presse Med** 1996 Jan 20;25(2):63-7 (30 ref.) (Eng. Abstr.) **(Fre)**

[Use of interferon alpha in multiple myeloma] Harousseau JL, et al. **Rev Med Interne** 1996;17(6):488-95 (53 ref.) (Eng. Abstr.) **(Fre)**

[Current knowledge in the treatment of chronic hepatitis C] Pirotte J. **Rev Med Liege** 1995 Dec;50(12):501-4 (29 ref.) **(Fre)**

[Alpha-interferon in the treatment of chronic hepatitis C in children] Cinquetti M, et al. **Pediatr Med Chir** 1995 Nov-Dec;17(6):501-7 (78 ref.) (Eng. Abstr.) **(Ita)**

[Chronic hepatitis C and interferon alpha treatment] Skarpetowski AC, et al. **Pediatr Pol** 1995 May;70(5):413-25 (94 ref.) (Eng. Abstr.) **(Pol)**

[Is the treatment of chronic viral hepatitis C with interferon-alpha effective?] Beker S, et al. **G E N** 1995 Apr-Jun;49(2):165-9 (43 ref.) (Eng. Abstr.) **(Spa)**

INTERFERON-BETA

ADMINISTRATION & DOSAGE

[Therapy of multiple sclerosis with interferon-beta-1b. Educating the patient and managing side-effects] Walther EU, et al. **Nervenarzt** 1996 Jun;67(6):452-6 (16 ref.) (Eng. Abstr.) **(Ger)**

GENETICS

Mechanisms of transcriptional synergism of eukaryotic genes. The interferon-beta paradigm. Thanos D. **Hypertension** 1996 Apr;27(4):1025-9 (25 ref.)

Scaffold/matrix-attached regions: structural properties creating transcriptionally active loci. Bode J, et al. **Int Rev Cytol** 1995;162A:389-454 (230 ref.)

THERAPEUTIC USE

Recombinant beta-interferon in the treatment of patients with metastatic renal cell carcinoma. Mani S, et al. **Am J Clin Oncol** 1996 Apr;19(2):187-9 (19 ref.)

Interferon-beta treatment of human disease. Alam JJ. **Curr Opin Biotechnol** 1995 Dec;6(6):688-91 (26 ref.)

More immunotherapy for multiple sclerosis [editorial; comment] Hughes RA, et al. **J Neurol Neurosurg Psychiatry** 1996 Sep;61(3):239-41 (44 ref.) Comment on: J Neurol Neurosurg Psychiatry 1996 Sep;61(3):251-8.

The role of interferons in the treatment of multiple sclerosis. Kelley CL. **J Neurosci Nurs** 1996 Apr;28(2):114-20 (21 ref.)

Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conference. Lublin FD, et al. **Neurology** 1996 Jan;46(1):12-8 (18 ref.)

Long-lasting complete remission of pulmonary metastases consequent to renal cell carcinoma obtained with interferon-beta therapy: review of the literature and a case report. Scoponi C, et al. **Tumori** 1995 May-Jun;81(3):201-3 (24 ref.)

[Has it been indicated already to use beta-interferon in patients with multiple sclerosis?] Fernández O. **Rev Neurol** 1995 Sep-Oct;23(123):986-90 (54 ref.) **(Spa)**

[New treatments for multiple sclerosis] Masdeu JC. **Rev Neurol** 1996 Jun;24(130):708-11 (38 ref.) **(Spa)**

INTERFERON, FIBROBLAST see **INTERFERON-BETA**

INTERFERON-GAMMA see **INTERFERON TYPE II**

INTERFERON GAMMA-1B see **INTERFERON-GAMMA, RECOMBINANT**

INTERFERON GAMMA-2A see **INTERFERON-GAMMA, RECOMBINANT**

INTERFERON-GAMMA, RECOMBINANT

THERAPEUTIC USE

Single institution experience with recombinant gamma-interferon in the treatment of patients with metastatic renal cell carcinoma. Mani S, et al. **Am J Clin Oncol** 1996 Apr;19(2):149-53 (26 ref.)

INTERFERON, IMMUNE see **INTERFERON TYPE II**

INTERFERON INDUCERS

see related
ANTINEOPLASTIC AGENTS
ANTIVIRAL AGENTS

INTERFERON, LEUKOCYTE see **INTERFERON-ALPHA**

INTERFERON, LYMPHOBLAST see **INTERFERON-ALPHA**

INTERFERON RECEPTORS see **RECEPTORS, INTERFERON**

INTERFERON TYPE I

IMMUNOLOGY

Role of the type I interferons in allograft rejection. Tovey MG, et al. **J Leukoc Biol** 1996 Apr;59(4):512-7 (39 ref.)

INTERFERON TYPE I, RECOMBINANT see **INTERFERON ALFA, RECOMBINANT**

INTERFERON TYPE II

GENETICS

[Cancer gene therapy by IFN gene transfer] Watanabe Y. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2700-8 (46 ref.) **(Jpn)**

IMMUNOLOGY

Role of interferon-gamma in immune cell regulation. Young HA, et al. **J Leukoc Biol** 1995 Oct;58(4):373-81 (165 ref.)

PHARMACOLOGY

Novel approaches to tumor detection and therapy using a combination of monoclonal antibody and cytokine. Greiner JW, et al. **Anticancer Res** 1996 Jul-Aug;16(4B):2129-33 (23 ref.)

Cell death suffers a TKO. Osborne BA, et al. **Bioessays** 1995 Jun;17(6):557-9 (13 ref.)

Control of cytokeratin 17 expression by interferon gamma. Vogel U, et al. **Immunobiology** 1995 Jul;193(2-4):322-7 (16 ref.)

PHYSIOLOGY

The one-two of T helper cells: does interferon-gamma knock out the Th2 hypothesis for asthma? [comment] Holtzman MJ, et al. **Am J Respir Cell Mol Biol** 1996 Apr;14(4):316-8 (24 ref.) Comment on: Am J Respir Cell Mol Biol 1996 Apr;14(4):319-26.

TNF-alpha- and IFN-gamma-mediated signal transduction pathways: effects on glial cell gene expression and function. Benveniste EN, et al. **FASEB J** 1995 Dec;9(15):1577-84 (68 ref.)

New insights into the regulation of ICAM-1 gene expression. Ohh M, et al. **Leuk Lymphoma** 1996 Jan;20(3-4):223-8 (43 ref.)

THERAPEUTIC USE

Therapeutic interference with interferon-gamma (IFN-gamma) and soluble IL-4 receptor (sIL-4R) in allergic diseases. Nasert S, et al. **Behring Inst Mitt** 1995 Jun;(96):118-30 (55 ref.)

Adjuncts to antibacterial therapy. Frank MO, et al. **Infect Dis Clin North Am** 1995 Sep;9(3):769-81 (63 ref.)

Interferon-gamma in multiple myeloma. Palumbo A, et al. **Leuk Lymphoma** 1995 Jul;18(3-4):215-9 (35 ref.)

INTERFERON TYPE II, RECOMBINANT see **INTERFERON-GAMMA, RECOMBINANT**

INTERFERONS

see related
RECEPTORS, INTERFERON

ADMINISTRATION & DOSAGE

[Interferon therapy of chronic hepatitis B: results of three treatment schedules] Hamada M, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:624-8 (14 ref.) **(Jpn)**

[Therapeutic effects of interferon on chronic hepatitis C from the aspect of dosage and method of administration] Shoji S, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:997-1000 (10 ref.) **(Jpn)**

ADVERSE EFFECTS

Does interferon precipitate rejection of liver allografts? [editorial] Min AD, et al. **Hepatology** 1995 Oct;22(4 Pt 1):1333-5 (22 ref.)

Interferon-induced acute renal failure: a case report and literature review. Horowitz R, et al. **Med Oncol** 1995 Mar;12(1):55-7 (10 ref.)

[Adverse effect of interferon therapy and its prevention] Sainokami S, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:1026-33 (9 ref.) **(Jpn)**

BLOOD

[Interferon] Tada S, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:796-9 (26 ref.) **(Jpn)**

CHEMISTRY

[Human interferon: molecular mechanisms of antiviral activities] Yoshida I. **Nippon Rinsho** 1995 Sep;53 Suppl:909-22 (40 ref.) **(Jpn)**

IMMUNOLOGY

Interferons, Mx genes, and resistance to influenza virus. Horisberger MA. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 2):S67-71 (56 ref.)

[Trophoblastic interferons and embryonal immune tolerance] Martal J, et al. **Contracept Fertil Sex** 1995 Sep;23(9):562-72 (163 ref.) (Eng. Abstr.) **(Fre)**

PHARMACOLOGY

Interferons: laboratory to clinic investigations. Platanias LC. **Curr Opin Oncol** 1995 Nov;7(6):560-5 (73 ref.)

Regulation of HLA class I loci by interferons. Girdlestone J. **Immunobiology** 1995 Jul;193(2-4):229-37 (37 ref.)

Interferon response pathways--a paradigm for cytokine signalling? Müller M, et al. **J Viral Hepat** 1994;1(2):87-103 (150 ref.)

Modulation of 5-fluorouracil by interferon: a review of potential cellular targets. Horowitz R, et al. **Med Oncol** 1995 Mar;12(1):3-8 (48 ref.)

[Update on the use of interferons in clinical practice] Lauta VM. **Clin Ter** 1995 Jun-Jul;146(6-7):393-448 (160 ref.) (Eng. Abstr.) **(Ita)**

PHYSIOLOGY

An overview of the interferon system: signal transduction and mechanisms of action. Kalvakolanu DV, et al. **Cancer Invest** 1996;14(1):25-53 (347 ref.)

Interferons: laboratory to clinic investigations. Platanias LC. **Curr Opin Oncol** 1995 Nov;7(6):560-5 (73 ref.)

Signal transduction and activation of gene transcription by interferons. Gilmour KC, et al. **Gene Expr** 1995;5(1):1-18 (145 ref.)

Regulation of the interferon system and cell growth by the IRF transcription factors. Taniguchi T, et al. **J Cancer Res Clin Oncol** 1995;121(9-10):516-20 (34 ref.)

JAKs, STATs and signal transduction in response to the interferons and other cytokines. Briscoe J, et al. **Philos Trans R Soc Lond B Biol Sci** 1996 Feb 29; 351(1336):167-71 (12 ref.)

Interferon, the oxytocin receptor and the maternal recognition of pregnancy in ruminants and non-ruminants: a comparative approach. Flint AP. **Reprod Fertil Dev** 1995; 7(3):313-8 (31 ref.)

The interferons. Skalla K. **Semin Oncol Nurs** 1996 May; 12(2):97-105 (56 ref.)

THERAPEUTIC USE

Interferons: their role in clinical practice. Ucar R, et al. **Ann Allergy Asthma Immunol** 1995 Nov;75(5):377-86; quiz 386-9 (110 ref.)

The biology of hairy cell leukemia. A study of the practical aspects of interferon-treatment, its mechanism of action and on the pathogenesis of anemia. Nielsen B. **APMIS Suppl** 1995;52:1-39 (232 ref.)

The role of biotherapies (interleukins, interferons and erythropoietin) in multiple myeloma. Avvisati G, et al. **Baillieres Clin Haematol** 1995 Dec;8(4):815-29 (76 ref.)

Medical treatment of advanced renal cell carcinoma: present options and future directions. Canobbio L, et al. **Cancer Treat Rev** 1996 Mar;22(2):85-104 (123 ref.)

Interferons. Gross G. **Curr Probl Dermatol** 1996;24:233-46 (59 ref.)

Dermatologic uses of interferons. Berman B, et al. **Dermatol Clin** 1995 Jul;13(3):699-711 (101 ref.)

Interferon in the treatment of cutaneous T-cell lymphoma. Olsen EA, et al. **Hematol Oncol Clin North Am** 1995 Oct; 9(5):1089-107 (72 ref.)

Clinical application of interferons in large animal medicine. Moore BR. **J Am Vet Med Assoc** 1996 May 15; 208(10):1711-5 (50 ref.)

Treatment options for chronic hepatitis C infection. James DG. **J Antimicrob Chemother** 1995 Oct;36(4):591-3 (19 ref.)

Interferon therapy in chronic viral hepatitis. Guptan RC, et al. **J Assoc Physicians India** 1995;Suppl 3:44-51 (56 ref.)

Interferons in solid tumors. Parikh PM, et al. **J Assoc Physicians India** 1995;Suppl 3:38-43 (63 ref.)

Future studies of combination therapy for chronic hepatitis C: optimizing response rates for each hepatitis C population. Main J. **J Hepatol** 1995;23 Suppl 2:32-5; discussion 35-6 (18 ref.)

Interferons and other cytokines in head and neck cancer. Hamasaki VK, et al. **Med Oncol** 1995 Mar;12(1):23-33 (64 ref.)

Interferon and chronic myelogenous leukaemia. Lauta VM. **Med Oncol** 1995 Mar;12(1):41-6 (27 ref.)

Host and viral features in chronic HCV infection: relevance to interferon responsiveness. Craxi A, et al. **Res Virol** 1995 Jul-Aug;146(4):273-8 (41 ref.)

[[Therapeutic perspectives in multiple sclerosis (editorial)] Lubetzki C, et al. **Presse Med** 1996 Jun 15;25(21):964-6 (10 ref.) (Eng. Abstr.) **(Fre)**

[Interferons as therapy in viral hepatitis: are promises kept?] Spengler U. **Ther Umsch** 1995 Oct;52(10):645-51 (57 ref.) (Eng. Abstr.) **(Ger)**

[Interferons in the therapy of solid tumors] Tomao S, et al. **Clin Ter** 1995 Aug-Sep;146(8-9):491-502 (96 ref.) (Eng. Abstr.) **(Ita)**

[The role of cytokines in viral infections] Cavallo R, et al. **G Batteriol Virol Immunol** 1994 Jan-Dec;86(1-12):65-78 (44 ref.) (Eng. Abstr.) **(Ita)**

[Preventive use of interferons for liver neoplasms] Shiratori Y, et al. **Nippon Naika Gakkai Zasshi** 1995 Dec 10; 84(12):2038-42 (5 ref.) **(Jpn)**

[Interferon therapy of viral hepatitis] Suzuki S. **Nippon Naika Gakkai Zasshi** 1995 Sep 10;84(9):1559-63 (4

ref.) (Jpn)
[HCV-serotype and IFN response] Abe K, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:959–64 (10 ref.) (Jpn)
[Changes of serum 2',5'-oligoadenylate synthetase activity and neopterin during interferon treatment for chronic hepatitis C] Daito K, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:981–5 (16 ref.) (Jpn)
[Does interferon therapy on type C liver cirrhosis prevent the occurrence of hepatocellular carcinoma?] Harada H, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:754–8 (17 ref.) (Jpn)
[Fluctuation of hepatitis C virus quasispecies with interferon treatment and interferon-resistant variants in hepatitis C virus 1b] Sakuma I, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:930–5 (9 ref.) (Jpn)
[The interferon treatment of hepatitis C in the liver transplant patient (editorial)] de la Mata M, et al. **Gastroenterol Hepatol** 1996 May;19(5):259–61 (42 ref.) (Spa)
[Predictive factors of response to interferon in chronic hepatitis] Forns X, et al. **Gastroenterol Hepatol** 1995 Aug-Sep;18(7):388–95 (59 ref.) (Spa)
[Factors related to response to interferon in chronic hepatitis C] Pérez Alvarez R. **Gastroenterol Hepatol** 1996 Apr; 19(4):217–23 (98 ref.) (Spa)

INTERGENERATIONAL RELATIONS

Age related distributive justice and claims on resources. Irwin S. **Br J Sociol** 1996 Mar;47(1):68–92 (44 ref.)

INTERINSTITUTIONAL RELATIONS

Academics and the nursing home. Katz PR, et al. **Clin Geriatr Med** 1995 Aug;11(3):503–16 (36 ref.)
Forming a consortium: a design for interagency collaboration in the delivery of service following the disclosure of incest. Peck JS, et al. **Fam Process** 1995 Sep;34(3):287–302 (53 ref.)
The problematic fit of diagnosis and strategy for medical group stakeholders--including IDS/Ns. Blair JD, et al. **Health Care Manage Rev** 1996 Winter;21(1):7–28 (21 ref.)

INTERLEUKIN-1

see related
RECEPTORS, INTERLEUKIN-1
[Infection and cytokine] Onozaki K. **Nippon Rai Gakkai Zasshi** 1995 Nov;64(3):149–62 (76 ref.) (Jpn)

ANTAGONISTS & INHIBITORS

Anti-cytokine therapy in rheumatoid arthritis. Elliott MJ, et al. **Baillieres Clin Rheumatol** 1995 Nov;9(4):633–52 (81 ref.)

BIOSYNTHESIS

Regulation of IL-1 beta expression by cyclic AMP in myeloid cells. Hurme M. **Immunobiology** 1995 Jul; 193(2-4):224–8 (18 ref.)
n-3 polyunsaturated fatty acids and human cytokine synthesis. Endres S. **Lipids** 1996 Mar;31 Suppl:S239–42 (19 ref.)
Interleukin-1 and interleukin-1 receptor antagonist production during haemodialysis: which cytokine is a surrogate marker for dialysis-related complications? Dinarello CA. **Nephrol Dial Transplant** 1995;10 Suppl 3:25–8 (32 ref.)
Controlling the production of interleukin-1 and tumor necrosis factor in disease. Dinarello CA. **Nutrition** 1995 Sep-Oct;11(5 Suppl):695–7 (18 ref.)

BLOOD

[Interleukin 1 (IL-1)] Onozaki K. **Nippon Rinsho** 1995 Mar; 53 Su Pt 2:771–4 (11 ref.) (Jpn)

DEFICIENCY

The inflammatory response in interleukin-1 beta-deficient mice: comparison with other cytokine-related knock-out mice. Fantuzzi G, et al. **J Leukoc Biol** 1996 Apr; 59(4):489–93 (41 ref.)

GENETICS

Regulation of cytokine gene expression: tumor necrosis factor, interleukin-1, and the emerging biology of cytokine receptors. Williams G, et al. **New Horiz** 1995 May; 3(2):276–87 (123 ref.)

IMMUNOLOGY

ICE family proteases: mediators of all apoptotic cell death? Henkart PA. **Immunity** 1996 Mar;4(3):195–201 (52 ref.)
The clinical neuroimmunotherapeutic role of melatonin in oncology. Conti A, et al. **J Pineal Res** 1995 Oct; 19(3):103–10 (38 ref.)
[The interleukin-1 system during human implantation] Simon C, et al. **Contracept Fertil Sex** 1995 Oct;23(10):626–30 (41 ref.) (Eng. Abstr.) (Fre)

METABOLISM

Regulation of IL-1 activity by soluble IL-1 receptors. Kurrle R, et al. **Behring Inst Mitt** 1995 Jun;(96):45–57 (20 ref.)
[Relation between interleukin-1 and periodontal diseases] Zou S. **Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao** 1995 Jun; 17(3):234–6 (21 ref.) (Chi)

PHARMACOLOGY

The hypothalamo-sympathetic nervous system modulates peripheral cellular immunity. Hori T, et al. **Neurobiology (Bp)** 1995;3(3-4):309–17 (30 ref.)
Hypothalamic neuronal histamine modulates adaptive behavior and thermogenesis in response to endogenous pyrogen. Sakata T, et al. **Obes Res** 1995 Dec;3 Suppl 5:707S–712S (26 ref.)
Stimulation of phospholipase A2 expression in rat cultured astrocytes by LPS, TNF alpha and IL-1 beta. Sun GY, et al. **Prog Brain Res** 1995;105:231–8 (27 ref.)

PHYSIOLOGY

Biologic basis for interleukin-1 in disease. Dinarello CA. **Blood** 1996 Mar 15;87(6):2095–147 (586 ref.)
Intracellular signalling mechanisms of interleukin 1 and tumour necrosis factor: possible targets for therapy. Saklatvala J. **Br Med Bull** 1995 Apr;51(2):402–18 (69 ref.)
Does interleukin-1 induce hair loss? Hoffmann R, et al. **Dermatology** 1995;191(4):273–5 (17 ref.)
Role of embryonic factors in human implantation. Polan ML, et al. **Hum Reprod** 1995 Dec;10 Suppl 2:22–9 (32 ref.)
The role of prostaglandins in blastocyst implantation. Psychoyos A, et al. **Hum Reprod** 1995 Dec;10 Suppl 2:30–42 (105 ref.)
Interleukin-1 system crosstalk between embryo and endometrium in implantation. Simón C, et al. **Hum Reprod** 1995 Dec;10 Suppl 2:43–54 (67 ref.)
Interleukin-1 signal transduction. O'Neill LA. **Int J Clin Lab Res** 1995;25(4):169–77 (95 ref.)
Molecular mechanisms and neural pathways mediating the influence of interleukin-1 on the activity of neuroendocrine CRF motoneurons in the rat. Rivest S. **Int J Dev Neurosci** 1995 Jun-Jul;13(3-4):135–46 (96 ref.)
The inflammatory response in interleukin-1 beta-deficient mice: comparison with other cytokine-related knock-out mice. Fantuzzi G, et al. **J Leukoc Biol** 1996 Apr; 59(4):489–93 (41 ref.)
Interleukin-1 in crescentic glomerulonephritis. Atkins RC. **Kidney Int** 1995 Aug;48(2):576–86 (95 ref.)
Interleukin-1 signal transduction. Bankers-Fulbright JL, et al. **Life Sci** 1996;59(2):61–83 (237 ref.)
Interleukin-1 and interleukin-1 receptor antagonist. Dinarello CA. **Nutrition** 1995 Sep-Oct;11(5 Suppl):492–4 (17 ref.)
Interleukin 1 (IL1) and tumour necrosis factor (TNF) signal transduction. Saklatvala J, et al. **Philos Trans R Soc Lond B Biol Sci** 1996 Feb 29; 351(1336):151–7 (40 ref.)
The pro-inflammatory and hyperplasiogenic action of interleukin-1 alpha in mouse skin. Fischer SM, et al. **Prog Clin Biol Res** 1995;391:161–77 (66 ref.)
Interleukin-1, interleukin-6 and the germ cell-Sertoli cell cross-talk. Jégou B, et al. **Reprod Fertil Dev** 1995; 7(4):723–30 (68 ref.)
Interleukin-1 antagonists. Dower SK, et al. **Ther Immunol** 1994 Apr;1(2):113–22 (73 ref.)
[Biological properties and clinical importance of interleukin 1] Robak T. **Postepy Hig Med Dosw** 1995;49(2):263–85 (87 ref.) (Eng. Abstr.) (Pol)

SECRETION

Mechanisms regulating cytokine release from peritoneal macrophages during continuous ambulatory peritoneal dialysis. Fieren MW. **Blood Purif** 1996;14(2):179–87 (60 ref.)

INTERLEUKIN-1 RECEPTORS see **RECEPTORS, INTERLEUKIN-1**

INTERLEUKIN-2

see related
RECEPTORS, INTERLEUKIN-2

ADVERSE EFFECTS

Are interleukin-2 and interleukin-15 tumor promoting factors for human non-hematopoietic cells? Azzarone B, et al. **Eur Cytokine Netw** 1996 Jan-Mar;7(1):27–36 (49 ref.)

BLOOD

Current concepts of pathogenesis of nephrotic syndrome. Tejani A, et al. **Contrib Nephrol** 1995;114:1–5 (23 ref.)
[Interleukin-2 (IL-2)] Taniyama T. **Nippon Rinsho** 1995 Mar; 53 Su Pt 2:775–7 (12 ref.) (Jpn)

DEFICIENCY

Immunodeficiency in IL-2-knockout mice. Horak I. **Clin Immunol Immunopathol** 1995 Sep;76(3 Pt 2):S172–3 (18 ref.)

GENETICS

The architecture of the interleukin-2 promoter: a reflection of T lymphocyte activation. Serfling E, et al. **Biochim Biophys Acta** 1995 Sep 19;1263(3):181–200 (244 ref.)
Transcriptional regulation of the IL-2 gene. Jain J, et al. **Curr Opin Immunol** 1995 Jun;7(3):333–42 (112 ref.)
The role of IL-2 in gene therapy. Dalgleish AG. **Gene Ther** 1994 Mar;1(2):83–7 (51 ref.)
The impact of gene therapy on T cell function in cancer. Zier KS, et al. **Hum Gene Ther** 1995 Oct;6(10):1259–64 (45 ref.)
The interplay between lymphoid-specific and ubiquitous transcription factors controls the expression of interleukin 2 gene in T lymphocytes. Avots A, et al. **Immunobiology** 1995 Jul;193(2-4):254–8 (20 ref.)
IL-2 gene therapy of solid tumors: an approach for the prevention of signal transduction defects in T cells. Zier KS, et al. **J Mol Med** 1996 Mar;74(3):127–34 (78 ref.)
A dynamic assembly of diverse transcription factors integrates activation and cell-type information for interleukin 2 gene regulation. Rothenberg EV, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9358–65 (87 ref.)
Regulation of IL2 gene transcription via the T-cell accessory molecule CD28. Civil A, et al. **Res Immunol** 1995 Mar-Apr; 146(3):158–64 (19 ref.)

IMMUNOLOGY

The two faces of interleukin 12: a pro-inflammatory cytokine and a key immunoregulatory molecule produced by antigen-presenting cells. Trinchieri G. **Ciba Found Symp** 1995;195:203–14; discussion 214–20 (59 ref.)

PHARMACOLOGY

Alternative triggering molecules and single chain bispecific antibodies. Segal DM, et al. **J Hematother** 1995 Oct; 4(5):377–82 (31 ref.)
Stem cell transplantation with chemoradiotherapy myeloablation and interleukin-2. Meehan KR, et al. **J Infus Chemother** 1996 Winter;6(1):28–32 (47 ref.)
[Effects of IL-2 on the central nervous system] Jiang CL, et al. **Sheng Li Ko Hsueh Chin Chan** 1995 Oct;26(4):352–4 (10 ref.) (Chi)

PHYSIOLOGY

IL-2 signaling involves recruitment and activation of multiple protein tyrosine kinases by the IL-2 receptor. Taniguchi T, et al. **Ann N Y Acad Sci** 1995 Sep 7; 766:235–44 (22 ref.)
[Biological properties and therapeutic use of interleukin 2 (IL-2)] Robak T. **Postepy Hig Med Dosw** 1995;49(3):367–93 (102 ref.) (Eng. Abstr.) (Pol)

THERAPEUTIC USE

Interleukin 2 in the management of acute leukaemia. Foa R. **Br J Haematol** 1996 Jan;92(1):1–8 (85 ref.)
Rhabdoid tumor of the kidney in an adult: review of the literature and report of a case responding to interleukin-2. Ebbinghaus SW, et al. **Cancer Biother** 1995 Fall; 10(3):237–41 (21 ref.)
Interleukin-2 in bone marrow transplantation. Verma UN, et al. **Cancer Treat Res** 1995;76:315–36 (99 ref.)
Medical treatment of advanced renal cell carcinoma: present options and future directions. Canobbio L, et al. **Cancer Treat Rev** 1996 Mar;22(2):85–104 (123 ref.)
Improve the DNA recombination protein drugs. Lu S. **Chin Med J (Engl)** 1996 Mar;109(3):191–2 (0 ref.)
Interleukin-2 and human immunodeficiency virus infection: pathogenic mechanisms and potential for immunologic enhancement. Kinter A, et al. **Immunol Res** 1996;15(1):1–15 (136 ref.)
Antibody-interleukin 2 fusion proteins: a new approach to cancer therapy. Reisfeld RA, et al. **J Clin Lab Anal** 1996; 10(3):160–6 (34 ref.)
Interleukin-2 therapy for myelodysplastic syndrome: does it work? Ogata K, et al. **Leuk Lymphoma** 1995 May; 17(5-6):411–5 (44 ref.)
Interferons and other cytokines in head and neck cancer. Hamasaki VK, et al. **Med Oncol** 1995 Mar;12(1):23–33 (64 ref.)
Tumor-directed cytotoxicity in multiple myeloma--the basis for an experimental treatment approach with interleukin 2. Peest D, et al. **Stem Cells (Dayt)** 1995 Aug;13 Suppl 2:72–6 (20 ref.)
[Biological properties and therapeutic use of interleukin 2 (IL-2)] Robak T. **Postepy Hig Med Dosw** 1995;49(3):367–93 (102 ref.) (Eng. Abstr.) (Pol)

INTERLEUKIN-2 RECEPTORS see **RECEPTORS, INTERLEUKIN-2**

INTERLEUKIN-3

ADVERSE EFFECTS

Interleukin-3-induced urticaria-like eruption. Bridges AG, et al. **J Am Acad Dermatol** 1996 Jun;34(6):1076–8 (19 ref.)

INTERLEUKIN-3

BLOOD

[Interleukin-3 (IL-3)] Niho Y, et al. **Nippon Rinsho** 1995 Mar; 53 Su Pt 2:778-80 (15 ref.) **(Jpn)**

GENETICS

Regulation of granulocyte-macrophage colony-stimulating factor and interleukin 3 expression. Nimer SD, et al. **Stem Cells (Dayt)** 1995 Jul;13(4):324-35 (95 ref.)

PHARMACOLOGY

Cytokine-mobilized peripheral blood progenitor cells. Nemunaitis J. **Semin Oncol** 1996 Apr;23(2 Suppl 4):9-14 (18 ref.)

THERAPEUTIC USE

Is interleukin 3 active in anticancer drug-induced thrombocytopenia? Newland AC. **Cancer Chemother Pharmacol** 1996;38 Suppl:S83-8 (46 ref.)

INTERLEUKIN-4

see related
HISTOCOMPATIBILITY ANTIGENS CLASS II

BIOSYNTHESIS

Role of B7 signaling in the differentiation of naive CD4+ T cells to effector interleukin-4-producing T helper cells. Gause WC, et al. **Immunol Res** 1995;14(3):176-88 (84 ref.)

The role of B cells in the programming of T cells for IL-4 synthesis [see comments] Mason D. **J Exp Med** 1996 Mar 1;183(3):717-9 (15 ref.) Comment in: J Exp Med 1996 Mar 1;183(3):891-9.

BLOOD

[Interleukin-4 (IL-4)] Noma T. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:781-5 (19 ref.) **(Jpn)**

CHEMISTRY

Antagonistic mutant proteins of interleukin-4. Duschl A, et al. **Behring Inst Mitt** 1995 Jun;(96):87-94 (27 ref.)

GENETICS

NF-Y, IRF-2, and C/EBP proteins are involved in regulation of human IL-4 gene expression. Li-Weber M, et al. **Immunobiology** 1995 Jul;193(2-4):263-7 (9 ref.)

The inducible transcription factor NF-AT plays an important role in the activation of the murine interleukin-4 promoter. Schneider G, et al. **Immunobiology** 1995 Jul; 193(2-4):268-72 (14 ref.)

IMMUNOLOGY

Antagonistic mutant proteins of interleukin-4. Duschl A, et al. **Behring Inst Mitt** 1995 Jun;(96):87-94 (27 ref.)

METABOLISM

Biology of natural and recombinant soluble interleukin-4 receptor. Enssle K, et al. **Behring Inst Mitt** 1995 Jun; (96):103-17 (78 ref.)

Regulation of interleukin-4 activity by soluble interleukin-4 receptors. Enssle K, et al. **J Clin Lab Anal** 1995;9(6):450-5 (38 ref.)

PHARMACOLOGY

Inhibition of GM-CSF production by recombinant human interleukin-4: negative regulator of hematopoiesis. Sawada K, et al. **Leuk Lymphoma** 1995 Sep;19(1-2):33-42 (1661 ref.)

The role of CD28 in the activation of T lymphocytes to proliferate in response to IL4. Chiodetti L, et al. **Res Immunol** 1995 Mar-Apr;146(3):169-71 (23 ref.)

PHYSIOLOGY

Converging and diverging properties of human interleukin-4 and interleukin-10. Banchereau J. **Behring Inst Mitt** 1995 Jun;(96):58-77 (119 ref.)

MHC class I-selected CD4-CD8-TCR alpha beta+ T cells: an important source of IL-4. Leite-de-Moraes MC, et al. **Braz J Med Biol Res** 1995 Aug;28(8):903-5 (28 ref.)

Role of IL-4 in delayed type hypersensitivity. Asherson GL, et al. **Clin Exp Immunol** 1996 Jan;103(1):1-4 (46 ref.)

Transmembrane and intracellular signalling by interleukin-4: receptor dimerization and beyond. Duschl A, et al. **Eur Cytokine Netw** 1996 Jan-Mar;7(1):37-49 (122 ref.)

Current concepts of B cell modulation. Matsuda T, et al. **Int Rev Immunol** 1989;5(2):97-109 (37 ref.)

Regulation of human IgE synthesis. Vercelli D, et al. **Int Rev Immunol** 1989;5(2):111-5 (35 ref.)

Functional significance of IL-4 receptor on B cells in IL-4-induced human IgE production. Yanagihara Y, et al. **J Allergy Clin Immunol** 1995 Dec;96(6 Pt 2):1145-51 (39 ref.)

[Production and role of B cell growth factor (BCGF) in Sjögren's syndrome] Goto Y, et al. **Nippon Rinsho** 1995 Oct;53(10):2418-21 (15 ref.) (Eng. Abstr.) **(Jpn)**

INTERLEUKIN-5

BLOOD

[Interleukin-5 (IL-5)] Yasue T, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:786-9 (17 ref.) **(Jpn)**

IMMUNOLOGY

Interleukin-5, eosinophils and the control of helminth infections in man and laboratory animals. Tagboto SK. **J Helminthol** 1995 Dec;69(4):271-8 (80 ref.)

PHYSIOLOGY

Biology of interleukin-5 and its relevance to allergic disease. Egan RW, et al. **Allergy** 1996 Feb;51(2):71-81 (145 ref.)

Current concepts of B cell modulation. Matsuda T, et al. **Int Rev Immunol** 1989;5(2):97-109 (37 ref.)

INTERLEUKIN-6

see related
PLASMACYTOMA

ANTAGONISTS & INHIBITORS

Anti-cytokine therapy in rheumatoid arthritis. Elliott MJ, et al. **Baillieres Clin Rheumatol** 1995 Nov;9(4):633-52 (81 ref.)

BLOOD

Osteoclast function in Paget's disease and multiple myeloma. Roodman GD. **Bone** 1995 Aug;17(2 Suppl):57S-61S (30 ref.)

[Interleukin-6 (IL-6)] Yokoyama A. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:790-3 (17 ref.) **(Jpn)**

[Regulation of interleukin 6 (IL-6) and TNF-alpha through lactoferrin in mice] Machnicki M. **Postepy Hig Med Dosw** 1995;49(1):53-7 (4 ref.) (Eng. Abstr.) **(Pol)**

DEFICIENCY

[Nonspecific host defense mechanism by macrophages--analysis by NF-IL6 deficient mice] Tanaka T. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2083-96 (32 ref.) **(Jpn)**

IMMUNOLOGY

Alpha interferon: new associations in haematology/oncology. The Montpellier experience. Rossi JF. **Med Oncol** 1995 Mar;12(1):59-61 (23 ref.)

PHARMACOLOGY

Therapeutic strategies for inhibition of interleukin-6 mediated multiple myeloma cell growth. Ogata A, et al. **Leuk Res** 1996 Apr;20(4):303-7 (60 ref.)

PHYSIOLOGY

Cytokine involvement in central nervous system disease. Implications from transgenic mice. Campbell IL, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:301-12 (52 ref.)

Cytokine signal transduction through a homo- or heterodimer of gp130. Kishimoto T, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:224-34 (22 ref.)

Effects of the immune/inflammatory reaction on the hypothalamic-pituitary-adrenal axis. Mastorakos G, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:438-48 (34 ref.)

Modulation of osteoclast differentiation by local factors. Suda T, et al. **Bone** 1995 Aug;17(2 Suppl):87S-91S (30 ref.)

Gut-derived mediators of multiple organ failure: platelet-activating factor and interleukin-6. Biffl WL, et al. **Br J Hosp Med** 1995 Aug 16-Sep 5;54(4):134-8 (21 ref.)

Interleukin-6 and the skin. Paquet P, et al. **Int Arch Allergy Immunol** 1996 Apr;109(4):308-17 (44 ref.)

Current concepts of B cell modulation. Matsuda T, et al. **Int Rev Immunol** 1989;5(2):97-109 (37 ref.)

Regulation of human IgE synthesis. Vercelli D, et al. **Int Rev Immunol** 1989;5(2):111-5 (35 ref.)

Is IL-6 both a cytokine and a neurotrophic factor? [comment] Wagner JA. **J Exp Med** 1996 Jun 1;183(6):2417-9 (28 ref.) Comment on: J Exp Med 1996 Jun 1;183(6):2627-34.

The biological effects of interleukin 6. Barton BE. **Med Res Rev** 1996 Jan;16(1):87-109 (262 ref.)

Interleukin-1, interleukin-6 and the germ cell-Sertoli cell cross-talk. Jégou B, et al. **Reprod Fertil Dev** 1995; 7(4):723-30 (68 ref.)

[Cytokine binding proteins: a model of interleukin 6] Brailly H, et al. **Arch Inst Pasteur Tunis** 1994 Jul-Oct; 71(3-4):535-48 (35 ref.) **(Fre)**

[POEMS syndrome: role and value of interleukin-6] Andrès E, et al. **Rev Med Interne** 1996;17(2):145-9 (33 ref.) (Eng. Abstr.) **(Fre)**

[Myeloma cell growth and interleukin 6] Takahashi T. **Nippon Naika Gakkai Zasshi** 1995 Jul 10;84(7):1122-6 (5 ref.) **(Jpn)**

[Interleukin 6 (IL-6)--clinical significance] Kamińska B, et al. **Pol Arch Med Wewn** 1996 Mar;95(3):270-6 (24 ref.) **(Pol)**

[The importance of interleukin 6 (IL-6) in pathogenesis and diagnosis of renal glomerular diseases] Kacprzyk F. **Postepy Hig Med Dosw** 1995;49(4):513-22 (50 ref.) (Eng. Abstr.) **(Pol)**

TOXICITY

Recombinant human interleukin-6: safety issues of a pleiotropic growth factor. Kammüller ME. **Toxicology** 1995 Dec 20;105(1):91-107 (90 ref.)

INTERLEUKIN-7

[Role of IL-7 on early thymocyte development] Tian L, et al. **Sheng Li Ko Hsueh Chin Chan** 1995 Jul;26(3):249-52 (13 ref.) **(Chi)**

PHYSIOLOGY

Diverse immunological and hematological effects of interleukin 7: implications for clinical application. Komschlies KL, et al. **J Leukoc Biol** 1995 Dec;58(6):623-33 (138 ref.)

[Interleukin 7 in dermatology. Molecular, immunologic and preclinical aspects] Möller P, et al. **Hautarzt** 1995 Oct; 46(10):676-82 (84 ref.) (Eng. Abstr.) **(Ger)**

INTERLEUKIN-8

see related
NEUTROPHIL ACTIVATION

METABOLISM

Some aspects of IL-8 pathophysiology. III: Chemokine interaction with endothelial cells. Rot A, et al. **J Leukoc Biol** 1996 Jan;59(1):39-44 (34 ref.)

INTERLEUKIN-10

Immunosuppressive and anti-inflammatory properties of interleukin 10. de Vries JE. **Ann Med** 1995 Oct;27(5):537-41 (48 ref.)

GENETICS

Interleukin-10 gene knock-out mice: a model of chronic inflammation. Rennick D, et al. **Clin Immunol Immunopathol** 1995 Sep;76(3 Pt 2):S174-8 (33 ref.)

IMMUNOLOGY

IL-10 immunosuppression in transplantation. Bromberg JS. **Curr Opin Immunol** 1995 Oct;7(5):639-43 (51 ref.)

PHYSIOLOGY

Interleukin-10 and its implications for immunopathology. Goldman M, et al. **Adv Nephrol Necker Hosp** 1995;24:79-90 (71 ref.)

Converging and diverging properties of human interleukin-4 and interleukin-10. Banchereau J. **Behring Inst Mitt** 1995 Jun;(96):58-77 (119 ref.)

Models of T cell anergy: is there a common molecular mechanism? [comment] Schwartz RH. **J Exp Med** 1996 Jul 1;184(1):1-8 (69 ref.) Comment on: J Exp Med 1996 Jul 1;184(1):19-29.

Immunoregulation in human lymphatic filariasis: the role of interleukin 10. Mahanty S, et al. **Parasite Immunol** 1995 Aug;17(8):385-92 (51 ref.)

Interleukin-10 and its receptor. Ho AS, et al. **Ther Immunol** 1994 Jun;1(3):173-85 (136 ref.)

INTERLEUKIN-11

PHARMACOLOGY

Effect of interleukin 11 on normal and pathological thrombopoiesis. Teramura M, et al. **Cancer Chemother Pharmacol** 1996;38 Suppl:S99-102 (27 ref.)

Preclinical biology of interleukin 11: a multifunctional hematopoietic cytokine with potent thrombopoietic activity. Goldman SJ. **Stem Cells (Dayt)** 1995 Sep; 13(5):462-71 (39 ref.)

PHYSIOLOGY

Preclinical biology of interleukin 11: a multifunctional hematopoietic cytokine with potent thrombopoietic activity. Goldman SJ. **Stem Cells (Dayt)** 1995 Sep; 13(5):462-71 (39 ref.)

THERAPEUTIC USE

Thrombopoietic activity of recombinant human interleukin 11 in cancer patients receiving chemotherapy. Gordon MS. **Cancer Chemother Pharmacol** 1996;38 Suppl:S96-8 (18 ref.)

INTERLEUKIN-12

see related
IMMUNITY, CELLULAR

IMMUNOLOGY

Effects of IL-12 on immune responses to microbial infections: a key mediator in regulating disease outcome. Biron CA, et al. **Curr Opin Immunol** 1995 Aug;7(4):485-96 (93 ref.)

PHYSIOLOGY

The role of IL-12 in the induction of organ-specific autoimmune diseases. Trembleau S, et al. **Immunol Today** 1995 Aug;16(8):383-6 (51 ref.)

Interleukin-12. Germann T, et al. **Int Arch Allergy Immunol** 1995 Oct;108(2):103-12 (120 ref.)

Immunoregulation by interleukin-12. Trinchieri G, et al. **J Leukoc Biol** 1996 Apr;59(4):505-11 (51 ref.)

Interleukin-12 an integral cytokine in the immune response. Stern AS, et al. **Life Sci** 1996;58(8):639-54 (147 ref.)

Interleukin-12: a cytokine with therapeutic potential in oncology and infectious diseases. Gately MK, et al. **Ther Immunol** 1994 Jun;1(3):187-96 (70 ref.)

[Recent advances in studies of IL-12] Chen AH. **Sheng Li Ke Hsueh Chin Chan** 1995 Oct;26(4):355-8 (9 ref.) **(Chi)**

THERAPEUTIC USE

Antitumor activity of interleukin 12 in preclinical models. Brunda MJ, et al. **Cancer Chemother Pharmacol** 1996;38 Suppl:S16-21 (51 ref.)

Effects of IL-12 on immune responses to microbial infections: a key mediator in regulating disease outcome. Biron CA, et al. **Curr Opin Immunol** 1995 Aug;7(4):485-96 (93 ref.)

Antitumor and antimetastatic activity of interleukin-12. Hendrzak JA, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 3):65-83 (131 ref.)

Molecular and cellular basis of interleukin 12 activity in prophylaxis and therapy against infectious diseases. Gazzinelli RT. **Mol Med Today** 1996 Jun;2(6):258-67 (41 ref.)

[Benefits and risks of immunostimulation with interleukin 12] Ryffel B. **Dtsch Med Wochenschr** 1996 Feb 9;121(6):171-4 (20 ref.) **(Ger)**

[The potential of interleukin-12 for use in cancer therapy] Gately MK, et al. **Gan To Kagaku Ryoho** 1996 Jul; 23(8):961-71 (74 ref.) (Eng. Abstr.) **(Jpn)**

INTERLEUKIN RECEPTORS see **RECEPTORS, INTERLEUKIN**

INTERLEUKINS

Interleukins. Dhabhar B, et al. **J Assoc Physicians India** 1995; Suppl 3:58-64 (32 ref.)

ADVERSE EFFECTS

Are interleukin-2 and interleukin-15 tumor promoting factors for human non-hematopoietic cells? Azzarone B, et al. **Eur Cytokine Netw** 1996 Jan-Mar;7(1):27-36 (49 ref.)

BIOSYNTHESIS

Interleukins and colony stimulating factors in human myeloid leukemia cell lines. Hassan HT, et al. **Leuk Lymphoma** 1995 Dec;20(1-2):1-15 (196 ref.)

GENETICS

A genetic approach for the analysis of cytokine function in vivo. Müller W. **Behring Inst Mitt** 1995 Jun;(96):95-6 (10 ref.)

IL-15: a pleiotropic cytokine with diverse receptor/signaling pathways whose expression is controlled at multiple levels. Tagaya Y, et al. **Immunity** 1996 Apr;4(4):329-36 (42 ref.)

IMMUNOLOGY

Interleukin 15 and its receptor. Cosman D, et al. **Ciba Found Symp** 1995;195:221-9; discussion 229-33 (30 ref.)

Time course of cytokine levels in sepsis. Thijs LG, et al. **Intensive Care Med** 1995 Nov;21 Suppl 2:S258-63 (31 ref.)

METABOLISM

Grain dust, endotoxin, and airflow obstruction. Schwartz DA. **Chest** 1996 Mar;109(3 Suppl):57S-63S (51 ref.)

PHYSIOLOGY

A genetic approach for the analysis of cytokine function in vivo. Müller W. **Behring Inst Mitt** 1995 Jun;(96):95-6 (10 ref.)

IL-15: a pleiotropic cytokine with diverse receptor/signaling pathways whose expression is controlled at multiple levels. Tagaya Y, et al. **Immunity** 1996 Apr;4(4):329-36 (42 ref.)

Is interleukin 17, an inducible cytokine that stimulates production of other cytokines, merely a redundant player in a sea of other biomolecules? [comment] Broxmeyer HE. **J Exp Med** 1996 Jun 1;183(6):2411-5 (43 ref.) Comment on: J Exp Med 1996 Jun 1;183(6):2593-603.

IL-15: the role of translational regulation in their expression. Bamford RN, et al. **J Leukoc Biol** 1996 Apr;59(4):476-80 (28 ref.)

THERAPEUTIC USE

The role of biotherapies (interleukins, interferons and erythropoietin) in multiple myeloma. Avvisati G, et al. **Baillieres Clin Haematol** 1995 Dec;8(4):815-29 (76 ref.)

Interleukins: the search for an anticancer therapy. Wheeler VS. **Semin Oncol Nurs** 1996 May;12(2):106-14 (39 ref.)

INTERMEDIATE CARE FACILITIES

ECONOMICS

Level of care options for the low-functioning brain injury survivor. Walker WC, et al. **Brain Inj** 1996 Jan;10(1):65-75 (30 ref.)

INTERMEDIATE FILAMENT PROTEINS

ANALYSIS

[Intermediate filaments] Hirasawa T, et al. **Nippon Rinsho** 1996 Jun;54(6):1542-50 (28 ref.) (Eng. Abstr.) **(Jpn)**

BIOSYNTHESIS

What can be learned from intermediate filament gene regulation in the mouse embryo. Duprey P, et al. **Int J Dev Biol** 1995 Jun;39(3):443-57 (150 ref.)

GENETICS

What can be learned from intermediate filament gene regulation in the mouse embryo. Duprey P, et al. **Int J Dev Biol** 1995 Jun;39(3):443-57 (150 ref.)

PHYSIOLOGY

The intermediate filament cytoskeleton of the lens: an ever changing network through development and differentiation. A minireview. Prescott AR, et al. **Ophthalmic Res** 1996;28 Suppl 1:58-61 (33 ref.)

INTERMEDIATE FILAMENTS

GENETICS

[Cytoskeleton and differentiation. Genetic regulation of intermediate filaments in the neuromuscular system] Li Z, et al. **Arch Inst Pasteur Tunis** 1994 Jul-Oct;71(3-4):419-30 (48 ref.) **(Fre)**

PHYSIOLOGY

Integration of intermediate filaments into cellular organelles. Georgatos SD, et al. **Int Rev Cytol** 1996;164:91-138 (293 ref.)

ULTRASTRUCTURE

Alterations of intermediate filaments in various histopathological conditions. Cadrin M, et al. **Biochem Cell Biol** 1995 Sep-Oct;73(9-10):627-34 (103 ref.)

Remodeling of the specialized intermediate filament network in mammalian eggs and embryos during development: regulation by protein kinase C and protein kinase M. Gallicano GI, et al. **Curr Top Dev Biol** 1995;31:277-320 (95 ref.)

Intermediate filament organization, reorganization, and function in the clawed frog Xenopus. Klymkowsky MW. **Curr Top Dev Biol** 1995;31:455-86 (140 ref.)

INTERMEDINS see **MSH**

INTERMETATARSAL JOINT see **TARSAL JOINT**

INTERMITTENT CLAUDICATION

DIAGNOSIS

Claudication: diagnosis and treatment. Santilli JD, et al. **Am Fam Physician** 1996 Mar;53(4):1245-53 (35 ref.)

DRUG THERAPY

Pentoxifylline and intermittent claudication: review of clinical trials and cost-effectiveness analyses. Gillings DB. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S44-50 (20 ref.)

[Ginkgo biloba in treatment of intermittent claudication. A systematic research based on controlled studies in the literature] Ernst E. **Fortschr Med** 1996 Mar 20;114(8):85-7 (14 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Neurogenic claudication by epidural lipomatosis: a case report and review of literature. Kurt E, et al. **Clin Neurol Neurosurg** 1995 Nov;97(4):354-7 (14 ref.)

Cystic adventitial disease of the popliteal artery--a case of young boy. Ishibashi S, et al. **Tohoku J Exp Med** 1995 Jul;176(3):173-80 (20 ref.)

[Isolated stenosing calcified lesions of the aorta] Sapoval M, et al. **J Radiol** 1995 Nov;76(11):1021-4 (10 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Claudication: diagnosis and treatment. Santilli JD, et al. **Am Fam Physician** 1996 Mar;53(4):1245-53 (35 ref.)

Interventionalists' guide to the patient's experience of lower extremity arterial occlusive disease. McDaniel MD, et al. **J Vasc Interv Radiol** 1995 Nov-Dec;6(6 Pt 2 Su):30S-35S (27 ref.)

ULTRASONOGRAPHY

[Ultrasound diagnosis, follow-up and therapy of cystic degeneration of the adventitia. 2 case reports and review of the literature] Schäberle W, et al. **Ultraschall Med** 1996 Jun;17(3):131-7 (39 ref.) (Eng. Abstr.) **(Ger)**

INTERMITTENT POSITIVE-PRESSURE VENTILATION

METHODS

[Invasive ventilation. Classification, technique and clinical experiences with BiPAP/APRV (Biphasic Positive Airway Pressure/Airway Pressure Release Ventilation)] Antonsen K, et al. **Ugeskr Laeger** 1996 Jan 22;158(4):413-9 (23 ref.) (Eng. Abstr.) **(Dan)**

INTERNAL-EXTERNAL CONTROL

Correcting faulty appraisals of obsessional thoughts. Freeston MH, et al. **Behav Res Ther** 1996 May-Jun;34(5-6):433-46 (52 ref.)

Lifestyles of the risky and infamous. From managed care to managed lives. Morreim EH. **Hastings Cent Rep** 1995 Nov-Dec;25(6):5-12 (43 ref.)

Theoretical and empirical considerations of resourcefulness. Zauszniewski JA. **Image J Nurs Sch** 1995 Fall;27(3):177-80 (31 ref.)

Helping the vulnerable or condoning control within the family: where is nursing? Cody A. **J Adv Nurs** 1996 May; 23(5):882-6 (51 ref.)

Higher-order behavior classes: contingencies, beliefs, and verbal behavior [comment] Catania AC. **J Behav Ther Exp Psychiatry** 1995 Sep;26(3):191-200 (60 ref.) Comment on: J Behav Ther Exp Psychiatry 1995 Sep;26(3):179-90.

Causation and complexity: old lessons, new crusades [comment] Layng TV. **J Behav Ther Exp Psychiatry** 1995 Sep;26(3):249-58 (50 ref.) Comment on: J Behav Ther Exp Psychiatry 1995 Sep;26(3):179-90.

Seeing one's self: locating narrative memory in a framework of personality. Singer JA. **J Pers** 1995 Sep;63(3):429-57 (75 ref.)

Monitoring and control processes in the strategic regulation of memory accuracy. Koriat A, et al. **Psychol Rev** 1996 Jul;103(3):490-517 (140 ref.)

[Expectations of control in the context of personality. More about the factorial structure of Levenson's IPC scale] Verissimo R. **Acta Med Port** 1996 Jan;9(1):21-8 (42 ref.) (Eng. Abstr.) **(Por)**

INTERNAL FIXATORS

Mechanical testing of materials and the material-tissue interface. Ashry HR, et al. **Clin Podiatr Med Surg** 1995 Jul;12(3):385-401 (33 ref.)

Applications of biodegradable lactides and glycolides in podiatry. Athanasiou KA, et al. **Clin Podiatr Med Surg** 1995 Jul;12(3):475-95 (90 ref.)

[Miniplate rigid fixation in orthognathic surgery] Zhang X, et al. **Chung Hua Kou Chiang Hsueh Tsa Chih** 1995 May; 30(3):184-6 (26 ref.) **(Chi)**

TRENDS

Future materials for foot surgery. Latour RA Jr. **Clin Podiatr Med Surg** 1995 Jul;12(3):519-44 (76 ref.)

UTILIZATION

Public citizen opposition to spinal implant fixation. Yuan HA. **J Spinal Disord** 1995 Oct;8(5):413-8 (17 ref.)

INTERNAL MAMMARY ARTERY IMPLANTATION see **MYOCARDIAL REVASCULARIZATION**

INTERNAL MAMMARY-CORONARY ARTERY ANASTOMOSIS

Arterial switch operation: myocardial ischemia reversed by internal mammary artery graft. Merlo M, et al. **Ann Thorac Surg** 1996 Aug;62(2):586-8 (12 ref.)

Antithrombotic therapy in patients with saphenous vein and internal mammary artery bypass grafts. Stein PD, et al. **Chest** 1995 Oct;108(4 Suppl):424S-430S (30 ref.)

The use of the internal mammary artery for revascularization of the left anterior descending coronary artery. Puga J. **Eur Heart J** 1995 Jul;16 Suppl E:21-5 (11 ref.)

INTERNAL MEDICINE

Mechanical ventilation: a review for the internist. Gammon RB, et al. **Am J Med** 1995 Nov;99(5):553-62 (06 ref.)

Violence in intimate relationships and the practicing internist: new "disease" or new agenda? [comment] [see comments] Alpert EJ. **Ann Intern Med** 1995 Nov 15;123(10):774-81 (33 ref.) Comment on: Ann Intern Med 1995 Nov 15;123(10):737-46. Comment on: Ann Intern Med 1995 Nov 15;123(10):782-94. Comment on: Ann Intern Med 1995 Nov 15;123(10):800-2. Comment on: Ann Intern Med 1995 Nov 15;123(10):804-5. Comment in: Ann Intern Med

1996 Sep 1;125(5):426; discussion 426–7.
General medicine and geriatrics, where is the difference? The example of infective disease. Evans JG. **Schweiz Med Wochenschr** 1995 Oct 7;125(40):1847–54 (34 ref.)
[The internist's differential diagnosis of low back pains] Mau W, et al. **Dtsch Med Wochenschr** 1995 Nov 17; 120(46):1589–94 (19 ref.) **(Ger)**

ECONOMICS

Strategic business planning for internal medicine. Ervin FR. **Am J Med** 1996 Jul;101(1):95–9 (22 ref.)

EDUCATION

Refocusing on history-taking skills during internal medicine training. Schechter GP, et al. **Am J Med** 1996 Aug; 101(2):210–6 (54 ref.)
Women's health and enhancing generalism in internal medicine. Hoffman E, et al. **J Gen Intern Med** 1995 Aug; 10(8):451–4 (59 ref.)

METHODS

Prevention of venous thromboembolic risk in non-surgical patients. Bergmann JF, et al. **Haemostasis** 1996;26 Suppl 2:16–23 (16 ref.)
[Use of plasmapheresis in the treatment of internal diseases] Usnarska-Zubkiewicz L. **Pol Arch Med Wewn** 1995 Sep; 94(3):250–8 (110 ref.) **(Pol)**

TRENDS

Internal medicine update: seven important advances in medical diagnosis and management for the general internist. Goldman L. **J Gen Intern Med** 1995 Jun;10(6):331–41 (86 ref.)

INTERNATIONAL AGENCIES

International union against tuberculosis and lung disease (IUATLD): initiatives in non-tuberculous lung disease. Becklake MR. **Tuber Lung Dis** 1995 Dec;76(6):493–504 (82 ref.)

INTERNATIONAL COOPERATION

see related
CONGRESSES

Prevention of birth defects: a task for a world alliance. Wertelecki W, et al. **Acta Paediatr Sin** 1996 May–Jun; 37(3):168–72 (57 ref.)
Prognosis of alcoholic liver disease—100 years on and the need for international standards and guidelines. Harris D, et al. **Alcohol Alcohol** 1995 Sep;30(5):591–600 (50 ref.)
Informed consent issues in international research concerns. Porter JP. **Camb Q Healthc Ethics** 1996 Spring;5(2):237–43 (25 ref.)
International Cell Exchange, 1994. Lau M, et al. **Clin Transpl** 1994;:467–88 (46 ref.)
International harmonization of approaches to risk assessment: will resolution of scientific issues alone lead to success? Becking GC. **Drug Metab Rev** 1996 Feb–May; 28(1–2):269–83 (2 ref.)
The international political economy of food: a global crisis. Friedmann H. **Int J Health Serv** 1995;25(3):511–38 (55 ref.)
A European project assessing the appropriateness of hospital utilization: background, objectives and preliminary results. The Project Steering Group and the Coordinating Center. Liberati A, et al. **Int J Qual Health Care** 1995 Sep; 7(3):187–99 (111 ref.)
Accreditation of those who arrange adoptions under the Hague Convention on intercountry adoption as a means of protecting, through private international law, the rights of children. Pierce WL. **J Contemp Health Law Policy** 1996 Spring;12(2):535–61 (31 ref.)
The North American Free Trade Agreement's effect on pharmaceutical patents: a bitter pill to swallow or a therapeutic solution? Silbermann JM. **J Contemp Health Law Policy** 1996 Spring;12(2):607–36 (176 ref.)
The U.S.-Japan Cooperative Cancer Research Program: some highlights of seminars, interdisciplinary program area, 1981–1996. Miller RW. **Jpn J Cancer Res** 1996 Mar; 87(3):221–6 (20 ref.)
Rural general practice: international perspectives. Evans PR. **Occas Pap R Coll Gen Pract** 1995 Sep;(71):46–9 (20 ref.)
Nutrition in overseas aid: the investors' perspective. Lambert J. **Proc Nutr Soc** 1995 Jul;54(2):357–60 (3 ref.)
The role of international and regional organisations in the regulation of veterinary biologicals. Blancou J, et al. **Rev Sci Tech** 1995 Dec;14(4):1193–206 (11 ref.)
Risk analysis for the importation of veterinary biologicals into the United States of America. Roth HJ, et al. **Rev Sci Tech** 1995 Dec;14(4):1061–72 (6 ref.)
International Poison Information Center data collection capabilities. Krenzelok EP, et al. **Vet Hum Toxicol** 1995 Jun;37(3):246–8 (3 ref.)
Australian-Indonesian collaboration in veterinary arbovirology—a review. Daniels PW, et al. **Vet Microbiol** 1995 Sep;46(1–3):151–74 (108 ref.)
[Impact of rapid advancement of international standardization on technical requirements for new drug registration] Kurokawa T. **Gan To Kagaku Ryoho** 1996 Apr; 23(5):509–16 (3 ref.) (Eng. Abstr.) **(Jpn)**
[International collaboration for health] Umenai T. **Nippon Koshu Eisei Zasshi** 1996 Apr;43(4):263–6 (9 ref.) **(Jpn)**
[International cooperative study on mental diseases] Nakane A. **Seishin Shinkeigaku Zasshi** 1995;97(7):471–84 (37 ref.) **(Jpn)**

INTERNATIONAL COUNCIL OF NURSES

Promoting nursing practice through nursing research. Baumgart AJ. **Int Nurs Rev** 1996 Mar–Apr;43(2):45–8, 57 (7 ref.)

INTERNATIONAL HEALTH PROBLEMS see **WORLD HEALTH**

INTERNET see **COMPUTER COMMUNICATION NETWORKS**

INTERNEURONS

CHEMISTRY

Striatal interneurones: chemical, physiological and morphological characterization. Kawaguchi Y, et al. **Trends Neurosci** 1995 Dec;18(12):527–35 (107 ref.)

PHYSIOLOGY

Temporal structure in spatially organized neuronal ensembles: a role for interneuronal networks. Buzsáki G, et al. **Curr Opin Neurobiol** 1995 Aug;5(4):504–10 (61 ref.)
How multiple-synapse boutons could preserve input specificity during an interneuronal spread of LTP. Harris KM. **Trends Neurosci** 1995 Aug;18(8):365–9 (44 ref.)

INTERNSHIP AND RESIDENCY

Educating pediatric residents in community settings. DeWitt TG, et al. **Curr Opin Pediatr** 1995 Oct;7(5):489–93 (26 ref.)
Objectives to direct the training of emergency medicine residents on off-service rotations: Surgery, part 2. Rakowski RT, et al. **J Emerg Med** 1995 Nov–Dec; 13(6):823–9 (7 ref.)

MANPOWER

Recruitment and workforce issues in late 20th century American psychiatry. Weissman S. **Psychiatr Q** 1996 Summer;67(2):125–37 (8 ref.)

ORGANIZATION & ADMINISTRATION

Quality in residency training: toward a broader, multidimensional definition. Elliott RL, et al. **Acad Med** 1996 Mar;71(3):243–7 (15 ref.)

STATISTICS & NUMERICAL DATA

Global rating scales in residency education. Gray JD. **Acad Med** 1996 Jan;71(1 Suppl):S55–63 (119 ref.)

INTERNSHIP, DENTAL see **INTERNSHIP AND RESIDENCY**

INTERNSHIP, NONMEDICAL

TRENDS

Psychotherapy supervision in the 1990s: some observations and reflections. Watkins CE Jr. **Am J Psychother** 1995 Fall; 49(4):568–81 (87 ref.)

INTERPERSONAL RELATIONS

Professional networks: the influence of colleagues on the academic success of faculty. Hitchcock MA, et al. **Acad Med** 1995 Dec;70(12):1108–16 (47 ref.)
Negligent infliction of emotional distress: a focus on relationships. Appleberry JM. **Am J Law Med** 1995; 21(2–3):301–22 (190 ref.)
The design and analysis of social-interaction research. Kenny DA. **Annu Rev Psychol** 1996;47:59–86 (40 ref.)
Environmental psychology 1989–1994. Sundstrom E, et al. **Annu Rev Psychol** 1996;47:485–512 (255 ref.)
Pattern integrations in young depressed women: Part I. Beeber LS. **Arch Psychiatr Nurs** 1996 Jun;10(3):151–6 (21 ref.)
Transpersonal processes: a bridge between object relations and attachment theory in normal and psychopathological development. Muir RC. **Br J Med Psychol** 1995 Sep;68 (Pt 3):243–57 (85 ref.)
Implementing feminist perspectives in clinical care. Howe EG. **J Clin Ethics** 1996 Spring;7(1):2–12 (40 ref.)
Self-with-other representations and a taxonomy of motives: two approaches to studying persons. Ogilvie DM, et al. **J Pers** 1995 Sep;63(3):643–79 (80 ref.)
Perceiving persons and groups. Hamilton DL, et al. **Psychol Rev** 1996 Apr;103(2):336–55 (140 ref.)
Intrapersonal and interpersonal factors in athletic performance. Iso-Ahola SE. **Scand J Med Sci Sports** 1995 Aug;5(4):191–9 (20 ref.)
[Depressed patients and their family] Väisänen L, et al. **Duodecim** 1994;110(3):333–8 (11 ref.) **(Fin)**

INTERPHASE

Impact of rearrangements on function and position of chromosomes in the interphase nucleus and on human genetic disorders. Qumsiyeh MB. **Chromosome Res** 1995 Dec;3(8):455–65 (157 ref.)

GENETICS

Interphase cytogenetics on paraffin sections of paediatric extragonadal yolk sac tumours. Jenderny J, et al. **Virchows Arch** 1996 Apr;428(1):53–7 (13 ref.)

INTERPROFESSIONAL RELATIONS

Anger in nurses: don't lose it, use it. Droppleman PG, et al. **Am J Nurs** 1996 Apr;96(4):26–31; quiz 32 (11 ref.)
Agency and research team co-operation: an exploration of human territoriality. Ervin NE, et al. **J Adv Nurs** 1996 Apr;23(4):728–32 (11 ref.)
Nurse-physician collaboration: a poststructuralist view. Henneman EA. **J Adv Nurs** 1995 Aug;22(2):359–63 (15 ref.)
The nurse-doctor relationship: a selective literature review. Sweet SJ, et al. **J Adv Nurs** 1995 Jul;22(1):165–70 (41 ref.)
Joint nursing appointments: a vehicle for influencing health care change. Tamlyn D, et al. **J Adv Nurs** 1995 Sep; 22(3):490–3 (18 ref.)
Matching verbal repertoires: understanding the contingencies of practice in order to functionally communicate with clinicians. Montgomery RW, et al. **J Behav Ther Exp Psychiatry** 1995 Jun;26(2):99–105 (29 ref.)
Work group culture, stress, and hostility. Correlations with organizational outcomes. Seago JA. **J Nurs Adm** 1996 Jun; 26(6):39–47 (56 ref.)
Care of the at-risk neonate born at home. A model for nurse-midwife/physician collaboration. Sullivan NH, et al. **J Nurse Midwifery** 1995 Nov–Dec;40(6):534–40 (16 ref.)
Shifting boundaries in professional care. Hopkins A, et al. **J R Soc Med** 1996 Jul;89(7):364–71 (36 ref.)
New rules for the game: interdisciplinary education for health professionals [see comments] Larson EL. **Nurs Outlook** 1995 Jul–Aug;43(4):180–5 (32 ref.) Comment in: Nurs Outlook 1996 Jan–Feb;44(1):41.
[Management dialogue within multi-professional teams: contribution of psychoanalysis to integrated therapy of psychotic patients] Böker H. **Psychiatr Prax** 1995 Sep; 22(5):201–5 (18 ref.) (Eng. Abstr.) **(Ger)**

INTERSEXUALITY see **HERMAPHRODITISM**

INTERSTITIAL CELL-STIMULATING HORMONE see **LH**

INTERSTITIAL CELL TUMOR see **LEYDIG CELL TUMOR**

INTERSTITIAL CYSTITIS see **CYSTITIS, INTERSTITIAL**

INTERSTITIAL FLUID see **EXTRACELLULAR SPACE**

INTERSTITIAL LUNG DISEASES see **LUNG DISEASES, INTERSTITIAL**

INTERSTITIAL NEPHRITIS see **NEPHRITIS, INTERSTITIAL**

INTERTARSAL JOINT see **TARSAL JOINT**

INTERTROCHANTERIC FRACTURES see **HIP FRACTURES**

INTERVENING SEQUENCES see **INTRONS**

INTERVENTION STUDIES

Accounting for cluster randomization: a review of primary prevention trials, 1990 through 1993. Simpson JM, et al. **Am J Public Health** 1995 Oct;85(10):1378–83 (43 ref.)
Social theory, social action, and intervention research: implications for cancer prevention among Latinos. Flores ET, et al. **J Natl Cancer Inst Monogr** 1995;(18):101–8 (53 ref.)
Unrealistic optimism about diet-related risks: implications for interventions. Raats MM, et al. **Proc Nutr Soc** 1996 Nov; 54(3):737–45 (36 ref.)
Focus on qualitative methods: Using qualitative methods in intervention studies. Sandelowski M. **Res Nurs Health** 1996 Aug;19(4):359–64 (39 ref.)

INTERVERTEBRAL DISK

see related
DISKECTOMY

[Role of CT and MR in the assessment of lumbar degenerative disk disease] Gualdi GF, et al. **Clin Ter** 1995 Oct;146(10):635–48 (24 ref.) (Eng. Abstr.) **(Ita)**

ANATOMY & HISTOLOGY

Quantitative magnetic resonance imaging of the lumbar spine.

Potential for investigations of water content and biochemical composition. Boos N, et al. **Spine** 1995 Nov 1;20(21):2358–65; discussion 2366 (83 ref.)

PHYSIOPATHOLOGY

[Temperature and ablation measurements in laser therapy of intervertebral disk tissue] Schlangmann BA, et al. **Orthopade** 1996 Feb;25(1):3–9 (35 ref.) (Eng. Abstr.) **(Ger)**

[On alleged radicular pain in patients with lumbar intervertebral disc hernias] Styczyński T, et al. **Neurol Neurochir Pol** 1995 Sep–Oct;29(5):747–52 (20 ref.) (Eng. Abstr.) **(Pol)**

RADIOGRAPHY

Complications of cervical discography: analysis of 4400 diagnostic disc injections. Zeidman SM, et al. **Neurosurgery** 1995 Sep;37(3):414–7 (14 ref.)

Lumbar discography. Position statement from the North American Spine Society Diagnostic and Therapeutic Committee. Guyer RD, et al. **Spine** 1995 Sep 15; 20(18):2048–59 (89 ref.)

[Vertebral vacuum phenomena] Hamzé B, et al. **Ann Radiol (Paris)** 1995;38(4):186–91 (17 ref.) (Eng. Abstr.) **(Fre)**

[Magnetic resonance imaging for lumbar disk pathology. incidence of false negatives (editorial)] Berthelot JM, et al. **Presse Med** 1995 Oct 7;24(29):1329–31 (26 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

[Vascular complications of lumbar disk surgery. Report of two cases and review of the literature on 122 cases] Pillet JC, et al. **J Mal Vasc** 1995;20(3):219–23 (85 ref.) (Eng. Abstr.) **(Fre)**

INTERVERTEBRAL DISK CHEMOLYSIS

see related
CHYMOPAPAIN

Chemonucleolysis. Nordby EJ, et al. **Spine** 1996 May 1; 21(9):1102–5 (14 ref.)

[Percutaneous laser disk decompression. Experience since 1989] Siebert WE, et al. **Orthopade** 1996 Feb;25(1):42–8 (36 ref.) (Eng. Abstr.) **(Ger)**

METHODS

[Temperature and ablation measurements in laser therapy of intervertebral disk tissue] Schlangmann BA, et al. **Orthopade** 1996 Feb;25(1):3–9 (35 ref.) (Eng. Abstr.) **(Ger)**

INTERVERTEBRAL DISK DISPLACEMENT

see related
INTERVERTEBRAL DISK CHEMOLYSIS
SCIATICA

COMPLICATIONS

Fibrocartilaginous embolism of the spinal cord: a clinical and pathogenetic reconsideration. Tosi L, et al. **J Neurol Neurosurg Psychiatry** 1996 Jan;60(1):55–60 (44 ref.)

Spinal nerve root compression. Garfin SR, et al. **Spine** 1995 Aug 15;20(16):1810–20 (72 ref.)

DIAGNOSIS

The relationship between symptoms and abnormal magnetic resonance images of lumbar intervertebral disks. Beattie P. **Phys Ther** 1996 Jun;76(6):601–8 (32 ref.)

Intraradicular and intradural lumbar disc herniation: experiences with nine cases. Schisano G, et al. **Surg Neurol** 1995 Dec;44(6):536–43 (9 ref.)

[Extraligamentous lumbar intervertebral disk displacement] Mathieu P. **Ann Radiol (Paris)** 1995;38(4):204–10 (18 ref.) (Eng. Abstr.) **(Fre)**

[Magnetic resonance imaging for lumbar disk pathology. incidence of false negatives (editorial)] Berthelot JM, et al. **Presse Med** 1995 Oct 7;24(29):1329–31 (26 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

The relationship between symptoms and abnormal magnetic resonance images of lumbar intervertebral disks. Beattie P. **Phys Ther** 1996 Jun;76(6):601–8 (32 ref.)

RADIOGRAPHY

Computed tomography and myelography in the evaluation of cervical degenerative disease. Russell EJ. **Neuroimaging Clin N Am** 1995 Aug;5(3):329–48 (83 ref.)

[Vertebral vacuum phenomena] Hamzé B, et al. **Ann Radiol (Paris)** 1995;38(4):186–91 (17 ref.) (Eng. Abstr.) **(Fre)**

[Imaging of the lumbar spine after diskectomy] Laredo JD, et al. **Ann Radiol (Paris)** 1995;38(4):161–8 (34 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Assessment and exercise in low back pain. With special reference to the management of pain and disability following first time lumbar disc surgery. Manniche C. **Dan Med Bull** 1995 Sep;42(4):301–13 (155 ref.)

Different surgical approaches to far lateral lumbar disc herniations. Epstein NE. **J Spinal Disord** 1995 Oct; 8(5):383–94 (24 ref.)

Open discectomy as treatment for herniated nucleus pulposus of the lumbar spine. Errico TJ, et al. **Spine** 1995 Aug 15; 20(16):1829–33 (26 ref.)

Assessment of spinal fusion. Critical evaluation of imaging techniques. Herzog RJ, et al. **Spine** 1996 May 1; 21(9):1114–8 (5 ref.)

Controversy in spine care. Is fusion necessary after anterior cervical discectomy? Sonntag VK, et al. **Spine** 1996 May 1;21(9):1111–3 (15 ref.)

[Imaging of the lumbar spine after diskectomy] Laredo JD, et al. **Ann Radiol (Paris)** 1995;38(4):161–8 (34 ref.) (Eng. Abstr.) **(Fre)**

[Temperature and ablation measurements in laser therapy of intervertebral disk tissue] Schlangmann BA, et al. **Orthopade** 1996 Feb;25(1):3–9 (35 ref.) (Eng. Abstr.) **(Ger)**

[Percutaneous laser disk decompression. Experience since 1989] Siebert WE, et al. **Orthopade** 1996 Feb;25(1):42–8 (36 ref.) (Eng. Abstr.) **(Ger)**

[Long-term results in revision surgery following lumbar disk nucleotomy]] Jerosch J, et al. **Z Orthop Ihre Grenzgeb** 1996 Jan–Feb;134(1):89–96 (50 ref.) (Eng. Abstr.) **(Ger)**

[Lumbar discectomy: anatomical review and surgical techniques] Ono H. **No Shinkei Geka** 1996 May; 24(5):415–29 (56 ref.) **(Jpn)**

INTERVIEW, PSYCHOLOGICAL

The Autobiographical Memory Interview (AMI) in organic and psychogenic amnesia. Kopelman MD. **Memory** 1994 Jun;2(2):211–35 (66 ref.)

METHODS

Life histories in occupational therapy clinical practice. Frank G. **Am J Occup Ther** 1996 Apr;50(4):251–64 (121 ref.)

Nationally speaking. Life history and narrative research: generating a humanistic knowledge base for occupational therapy. Larson EA, et al. **Am J Occup Ther** 1996 Apr; 50(4):247–50 (27 ref.)

INTERVIEWS

METHODS

Interviewing the young child sexual abuse victim. Lewin L. **J Psychosoc Nurs Ment Health Serv** 1995 Jul;33(7):5–10 (26 ref.)

INTESTINAL ABSORPTION

see related
MALABSORPTION SYNDROMES

Bile acid malabsorption: mechanisms and treatment. Eusufzai S. **Dig Dis** 1995 Sep–Oct;13(5):312–21 (85 ref.)

Bioavailability of micronutrients in a fibre-rich diet, especially related to minerals. Frølich W. **Eur J Clin Nutr** 1995 Oct;49 Suppl 3:S116–22 (44 ref.)

Colonic fluid handling in health & acute diarrhoeal diseases. Ramakrishna BS. **Indian J Med Res** 1996 Jul;104:52–9 (47 ref.)

Bile acid structure and intestinal absorption in the animal model. Aldini R, et al. **Ital J Gastroenterol** 1995 Apr; 27(3):141–4 (33 ref.)

Intestinal absorption of bile acids: effect of ursodeoxycholic acid treatment. Stiehl A. **Ital J Gastroenterol** 1995 May; 27(4):193–5 (31 ref.)

The effect of infused nutrients and absorbed foods on daily food intake in rats. Koopmans HS. **Obes Res** 1995 Dec;3 Suppl 5:675S–684S (62 ref.)

Does fluid flow across the intestinal mucosa affect quantitative oral drug absorption? Is it time for a reevaluation? Lennernäs H. **Pharm Res** 1995 Nov; 12(11):1573–82 (71 ref.)

Intestinal absorption of water-soluble vitamins. Rose RC. **Proc Soc Exp Biol Med** 1996 Jul;212(3):191–8 (49 ref.)

[Systemic enzyme therapy: problems of resorption of enzyme macromolecules] Nouza K, et al. **Cas Lek Cesk** 1995 Oct 4;134(19):615–9 (56 ref.) (Eng. Abstr.) **(Cze)**

[Measurement of intestinal permeability] Jørgensen JR, et al. **Ugeskr Laeger** 1996 Mar 4;158(10):1358–61 (38 ref.) (Eng. Abstr.) **(Dan)**

[Physiology of intestinal absorption of phosphorus in animals] Barlet JP, et al. **Reprod Nutr Dev** 1995;35(5):475–89 (128 ref.) (Eng. Abstr.) **(Fre)**

DRUG EFFECTS

Influence of anti-rheumatic drugs on gut permeability and on the gut associated lymphoid tissue. Bjarnason I, et al. **Baillieres Clin Rheumatol** 1996 Feb;10(1):165–76 (75 ref.)

The human intestinal epithelial cell line Caco-2; pharmacological and pharmacokinetic applications. Meunier V, et al. **Cell Biol Toxicol** 1995 Aug; 11(3–4):187–94 (58 ref.)

Effects of dietary fat on drug absorption. Zhi J, et al. **Clin Pharmacol Ther** 1995 Nov;58(5):487–91 (47 ref.)

Metformin and intestinal glucose handling. Bailey CJ. **Diabetes Metab Rev** 1995 Sep;11 Suppl 1:S23–32 (47 ref.)

IMMUNOLOGY

Absorption and presentation of antigens by epithelial cells of the small intestine: hypotheses and predictions relating to the pathogenesis of coeliac disease. Mayrhofer G. **Immunol Cell Biol** 1995 Oct;73(5):433–9 (63 ref.)

PHYSIOLOGY

Regulation of tight-junction permeability during nutrient absorption across the intestinal epithelium. Ballard ST, et al. **Annu Rev Nutr** 1995;15:35–55 (105 ref.)

Nutrition-physiology link. Need to increase basic research. De Angelis RC. **Arq Gastroenterol** 1995 Jan–Mar; 32(1):35–9 (13 ref.)

Determinants of intestinal barrier failure in critical illness. Aranow JS, et al. **Br J Anaesth** 1996 Jul;77(1):71–81 (170 ref.)

Digestion, absorption, and fermentation of carbohydrates in the newborn. Kien CL. **Clin Perinatol** 1996 Jun; 23(2):211–28 (143 ref.)

Nutrient absorption in the preterm neonate. Neu J, et al. **Clin Perinatol** 1996 Jun;23(2):229–43 (54 ref.)

Nutrition and the gut mucosal barrier. Deitch EA. **Curr Opin Gen Surg** 1993;:85–91 (34 ref.)

Role of gastrointestinal motility in the delay of absorption by dietary fibre. Cherbut C. **Eur J Clin Nutr** 1995 Oct;49 Suppl 3:S74–80 (61 ref.)

Effect of reduced rate of carbohydrate absorption on carbohydrate and lipid metabolism. Jenkins DJ, et al. **Eur J Clin Nutr** 1995 Oct;49 Suppl 3:S68–73 (36 ref.)

Vitamin B12 in health and disease: part I—inherited disorders of function, absorption, and transport. Kapadia CR. **Gastroenterologist** 1995 Dec;3(4):329–44 (89 ref.)

Lipid microemulsions for improving drug dissolution and oral absorption: physical and biopharmaceutical aspects. Constantinides PP. **Pharm Res** 1995 Nov;12(11):1561–72 (50 ref.)

Role of the gut in multiple organ failure: bacterial translocation and permeability changes. Swank GM, et al. **World J Surg** 1996 May;20(4):411–7 (65 ref.)

INTESTINAL AMEBIASIS see DYSENTERY, AMEBIC

INTESTINAL ATRESIA

COMPLICATIONS

Colonic atresia combined with Hirschsprung's disease: a diagnostic and therapeutic challenge. Kim PC, et al. **J Pediatr Surg** 1995 Aug;30(8):1216–7 (8 ref.)

DIAGNOSIS

[Jejunal membranous atresia with a late presentation] Barrios Fontoba JE, et al. **An Esp Pediatr** 1996 Jul;45(1):85–6 (13 ref.) **(Spa)**

GENETICS

Familial arhinia, choanal atresia, and microphthalmia. Thiele H, et al. **Am J Med Genet** 1996 May 3;63(1):310–3 (7 ref.)

SURGERY

[Surgery of atresia of the gastrointestinal tract] Joppich I, et al. **Chirurg** 1996 Jun;67(6):576–83 (10 ref.) (Eng. Abstr.) **(Ger)**

INTESTINAL BYPASS see JEJUNOILEAL BYPASS

INTESTINAL DISEASES

Neuronal intestinal dysplasia: a role for surgery? Lugo-Vicente HL. **Bol Asoc Med P R** 1995 Mar–Apr; 87(3–4):60–3 (29 ref.)

Radiation enteropathy—incidence, aetiology, risk factors, pathology and symptoms. Rodier JF. **Tumori** 1995 May–Jun;81(3 Suppl):122–5 (12 ref.)

COMPLICATIONS

[Relationship between intestinal inflammation and arthritis] Helenius P, et al. **Duodecim** 1994;110(1):19–26 (36 ref.) **(Fin)**

CONGENITAL

Surgical conditions of the neonatal intestinal tract. Kays DW. **Clin Perinatol** 1996 Jun;23(2):353–75 (56 ref.)

DIAGNOSIS

Ambulatory manometry of the small bowel: indications and analysis. Wilmer A, et al. **Rev Esp Enferm Dig** 1996 Feb; 88(2):118–32 (45 ref.) **(Eng, Spa)**

[What is the usefulness of enteroscopy?] Gay G, et al. **Gastroenterol Clin Biol** 1996;20(5 Pt 2):B127–33 (58 ref.) **(Fre)**

[HIV infection and the lower gastrointestinal tract—characteristics of endoscopic diagnosis] Mauss S, et al. **Bildgebung** 1995 Dec;62(4):252–8 (46 ref.) (Eng. Abstr.)

INTESTINAL DISEASES

(Ger)

[Odelberg's lipomatosis] Aronescu M, et al. **Chirurgia (Bucur)** 1995;44(1):48–51 (20 ref.) (Rum)

EPIDEMIOLOGY

[The epidemiological characteristics of acute intestinal infections in wartime] Kartsev AD. **Voen Med Zh** 1996 May;317(5):40–3 (24 ref.) (Rus)

ETIOLOGY

IgE-mediated (and food-induced) intestinal disease. Strobel S. **Clin Exp Allergy** 1995 Jul;25 Suppl 1:3–6 (61 ref.)

Gastrointestinal gas formation and infantile colic. Sferra TJ, et al. **Pediatr Clin North Am** 1996 Apr;43(2):489–510 (116 ref.)

Radiation enteropathy. Bozzetti F, et al. **Tumori** 1995 May–Jun;81(3 Suppl):117–21 (26 ref.)

PATHOLOGY

Human intestinal spirochetosis [editorial] De Brito T, et al. **Rev Soc Bras Med Trop** 1996 Jul–Aug;29(4):313–7 (25 ref.) (Eng, Por)

PHYSIOPATHOLOGY

Towards understanding the process of intestinal adaptation. Wolvekamp MC, et al. **Dig Dis** 1996 Jan–Feb;14(1):59–72 (106 ref.)

Gastric and small intestinal motility in health and disease. Quigley EM. **Gastroenterol Clin North Am** 1996 Mar; 25(1):113–45 (164 ref.)

PREVENTION & CONTROL

Sucralfate: prophylaxis of mucosal damage during cancer therapy. Henriksson R, et al. **Scand J Gastroenterol Suppl** 1995;210:45–7 (29 ref.)

RADIONUCLIDE IMAGING

Whole-gut transit scintigraphy in the evaluation of small-bowel and colon transit disorders. Maurer AH, et al. **Semin Nucl Med** 1995 Oct;25(4):326–38 (69 ref.)

SURGERY

Surgical conditions of the neonatal intestinal tract. Kays DW. **Clin Perinatol** 1996 Jun;23(2):353–75 (56 ref.)

Severe endometriosis and operative laparoscopy. Nezhat C, et al. **Curr Opin Obstet Gynecol** 1995 Aug;7(4):299–306 (55 ref.)

Current controversies in laparoscopic colorectal surgery [editorial] Agachan F, et al. **G Chir** 1996 Mar;17(3):77–83 (67 ref.)

Small bowel transplantation: current progress and clinical application. Frezza EE, et al. **Hepatogastroenterology** 1996 Mar–Apr;43(8):363–76 (141 ref.)

What's new in colon and rectal surgery. Abel ME. **J Am Coll Surg** 1996 Feb;182(2):89–92 (21 ref.)

THERAPY

Intestinal complications of radiotherapy in gynecologic malignancy—clinical presentation and management. Kao MS. **Int J Gynaecol Obstet** 1995 Jul;49 Suppl:S69–75 (35 ref.)

INTESTINAL DISEASES, PARASITIC

Intestinal protozoa. Juckett G. **Am Fam Physician** 1996 Jun; 53(8):2507–18 (22 ref.)

[Update on microsporidiosis in humans] Atías A. **Rev Med Chil** 1995 Jun;123(6):762–72 (40 ref.) (Eng. Abstr.) (Spa)

DIAGNOSIS

Common intestinal helminths. Juckett G. **Am Fam Physician** 1995 Nov 15;52(7):2039–48, 2051–2 (17 ref.)

Enteric parasitology. Interpreting laboratory reports. MacPherson DW. **Can Fam Physician** 1995 Oct;41:1729–31 (9 ref.)

Strongyloidiasis: new endoscopic findings. Choudhry U, et al. **Gastrointest Endosc** 1995 Aug;42(2):170–3 (20 ref.)

Recent advances in the laboratory diagnosis of intestinal parasitoses [editorial] Singh S. **Trop Gastroenterol** 1996 Apr–Jun;17(2):1–5 (30 ref.)

DRUG THERAPY

Human antiprotozoal therapy: past, present, and future. Khaw M, et al. **Clin Microbiol Rev** 1995 Jul;8(3):427–39 (182 ref.)

[Treatment of intestinal parasitic diseases] Siikamäki H. **Duodecim** 1994;110(14):1349–55 (13 ref.) (Fin)

EPIDEMIOLOGY

Duodenal and hepatic toxoplasmosis in a patient with HIV infection: review of the literature. Bonacini M, et al. **Am J Gastroenterol** 1996 Sep;91(9):1838–40 (13 ref.)

[Intestinal helminthiasis in the Mexican Republic] Tay J, et al. **Bol Chil Parasitol** 1995 Jan–Jun;50(1–2):10–6 (23 ref.) (Eng. Abstr.) (Spa)

IMMUNOLOGY

T cell and cytokine basis of host variability in response to intestinal nematode infections. Grencis RK. **Parasitology** 1996;112 Suppl:S31–7 (45 ref.)

PREVENTION & CONTROL

Intestinal worms: our turn to turn. de Silva HJ, et al. **Ceylon Med J** 1995 Dec;40(4):134–6 (11 ref.)

VETERINARY

Effect of chemoprophylaxis on immunity to gastrointestinal nematodes in cattle. Vercruysse J, et al. **Verh K Acad Geneeskd Belg** 1996;58(1):51–60 (18 ref.)

INTESTINAL EPITHELIUM see **INTESTINAL MUCOSA**

INTESTINAL FISTULA

[Cholecystogastric fistula, cholecystoenteric fistula] Souda S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):436–8 (8 ref.) (Jpn)

[Parapapillary choledochoduodenal fistula] Uetsuji S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):528–9 (14 ref.) (Jpn)

DIAGNOSIS

Primary aortoenteric fistula: two new case reports and a review of 44 previously reported cases. Tareen AH, et al. **Eur J Vasc Endovasc Surg** 1996 Jul;12(1):5–10 (34 ref.)

Appendicovesical fistula. Athanassopoulos A, et al. **Int Urol Nephrol** 1995;27(6):705–8 (9 ref.)

DRUG THERAPY

[Gastrointestinal fistulas. Treatment with a somatostatin analogue (SMS 201–995)] Gerardo Pérez D, et al. **G E N** 1994 Oct–Dec;48(4):209–18 (51 ref.) (Eng. Abstr.) (Spa)

ETIOLOGY

Jejunal diverticulitis manifesting with abdominal wall abscess. Alvarez OA, et al. **Am J Gastroenterol** 1995 Nov; 90(11):2060–2 (10 ref.)

Fistula between duodenum and portal vein caused by peptic ulcer disease and complicated by hemorrhage and portal vein thrombosis. Soares MA, et al. **Am J Gastroenterol** 1996 Jul;91(7):1462–3 (7 ref.)

Colocutaneous fistula: a rare and silent complication of percutaneous endoscopic gastrostomy. Siddique I, et al. **Dig Dis Sci** 1996 Feb;41(2):301–4 (14 ref.)

Colocutaneous fistula as a complication of PEG tube placement. Kilmartin C, et al. **J Fam Pract** 1996 Jul; 43(1):76–8 (10 ref.)

Genital fistulas secondary to diverticular disease of the colon: a review. Tancer ML, et al. **Obstet Gynecol Surv** 1996 Jan; 51(1):67–73 (67 ref.)

Colonic duplication: an unusual cause of enterovesical fistula. Payne CE, et al. **Urology** 1995 Nov;46(5):726–8 (10 ref.)

[Post-appendectomy fistulas of the cecum. Apropos of 22 cases] Genier F, et al. **J Chir (Paris)** 1995 Oct;132(10):393–8 (17 ref.) (Eng. Abstr.) (Fre)

SURGERY

Primary aortoenteric fistula: report of eight new cases and review of the literature. Voorhoeve R, et al. **Ann Vasc Surg** 1996 Jan;10(1):40–8 (76 ref.)

Duodenocaval fistula complicating peptic ulcer disease: case report and review of the literature. Miller CA, et al. **Surgery** 1996 Jun;119(6):718–9 (14 ref.)

INTESTINAL HORMONE RECEPTORS see **RECEPTORS, GASTROINTESTINAL HORMONE**

INTESTINAL HORMONES see **GASTROINTESTINAL HORMONES**

INTESTINAL MOTILITY see **GASTROINTESTINAL MOTILITY**

INTESTINAL MUCOSA

Regenerative bladder augmentation: a review of the initial preclinical studies with porcine small intestinal submucosa. Kropp BP, et al. **Adv Exp Med Biol** 1995;385:229–35 (26 ref.)

The human intestinal epithelial cell line Caco-2; pharmacological and pharmacokinetic applications. Meunier V, et al. **Cell Biol Toxicol** 1995 Aug; 11(3–4):187–94 (58 ref.)

Development of TCR gamma delta iIELs. Barrett TA, et al. **Semin Immunol** 1995 Oct;7(5):299–305 (27 ref.)

T-lymphopoietic capacity of the mouse intestinal epithelium. Klein JR. **Semin Immunol** 1995 Oct;7(5):291–7 (38 ref.)

T-cell development and selection in the intestinal epithelium. Poussier P, et al. **Semin Immunol** 1995 Oct;7(5):321–34 (38 ref.)

The TCR-beta chain repertoire of gut-derived T lymphocytes. Regnault A, et al. **Semin Immunol** 1995 Oct; 7(5):307–19 (91 ref.)

The beta 7 integrins in mucosal homing and retention. Shaw SK, et al. **Semin Immunol** 1995 Oct;7(5):335–42 (45 ref.)

[Heterotopic tissues in the gallbladder (heterotopic gastric mucosa, heterotopic intestinal epithelium, heterotopic pancreatic tissue and ectopic liver in the gallbladder] Kodama T, et al. **Ryoikibetsu Shokogun Shirizu** 1996; (9):360–2 (17 ref.) (Jpn)

[Hepatic ciliated cyst] Ohmoto K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):99–101 (15 ref.) (Jpn)

ABNORMALITIES

[Jejunal membranous atresia with a late presentation] Barrios Fontoba JE, et al. **An Esp Pediatr** 1996 Jul;45(1):85–6 (13 ref.) (Spa)

BLOOD SUPPLY

[Lactate versus intramucosal pCO2 or pH?] Mertzlufft F. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Oct; 30 Suppl 1:S27–33 (41 ref.) (Ger)

CYTOLOGY

Effects of mesalazine on lamina propria white cell functions. Verspaget HW. **Adv Exp Med Biol** 1995;371A:317–20 (20 ref.)

The involvement of macrophages and lymphocytes in the apoptosis of enterocytes. Iwanaga T. **Arch Histol Cytol** 1995 Jun;58(2):151–9 (38 ref.)

Intestinal epithelial cell differentiation: new insights from mice, flies and nematodes. Simon TC, et al. **Curr Opin Genet Dev** 1995 Oct;5(5):577–86 (56 ref.)

Present views on restitution of gastrointestinal epithelium. Paimela H, et al. **Dig Dis Sci** 1995 Nov;40(11):2495–6 (25 ref.)

Indomethacin inhibits cell proliferation and increases cell losses in rat gastrointestinal epithelium. Uribe A, et al. **Dig Dis Sci** 1995 Nov;40(11):2490–4 (25 ref.)

DRUG EFFECTS

Colonoscopy preps: what's best? [editorial; comment] Keeffe EB. **Gastrointest Endosc** 1996 May;43(5):524–8 (30 ref.) Comment on: Gastrointest Endosc 1996 May;43(5):463–6. Comment on: Gastrointest Endosc 1996 May;43(5):467–9.

[Measurement of intestinal permeability] Jørgensen JR, et al. **Ugeskr Laeger** 1996 Mar 4;158(10):1358–61 (38 ref.) (Eng. Abstr.) (Dan)

ENZYMOLOGY

[Reverse cholesterol transport] Schmidt HH, et al. **Z Gastroenterol** 1996 Jun;34(6):386–91 (69 ref.) (Ger)

IMMUNOLOGY

Cellular and molecular biologic approaches for analyzing the in vivo development and maintenance of gut mucosal IgA responses. Cebra JJ, et al. **Adv Exp Med Biol** 1995; 371A:429–34 (11 ref.)

Splanchnic ischemia and gut mucosal injury in sepsis and the multiple organ dysfunction syndrome. Pastores SM, et al. **Am J Gastroenterol** 1996 Sep;91(9):1697–710 (145 ref.)

Cholera toxin B subunit as transmucosal carrier-delivery and immunomodulating system for induction of antiinfectious and antipathological immunity. Czerkinsky C, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:185–93 (32 ref.)

Role of gamma delta T cells in the regulation of mucosal IgA response and oral tolerance. Fujihashi K, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:55–63 (42 ref.)

Antigen trafficking in the intestine. Mayer L, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:28–35 (16 ref.)

Molecular mechanisms securing "unresponsiveness" in lamina propria T lymphocytes. Meuer SC, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:174–84 (24 ref.)

The role of Th1 and Th2 cells for mucosal IgA responses. Yamamoto M, et al. **Ann N Y Acad Sci** 1996 Feb 13; 778:64–71 (39 ref.)

The humoral immune system in coeliac disease. Mäki M. **Baillieres Clin Gastroenterol** 1995 Jun;9(2):231–49 (115 ref.)

T-cell responses and cellular immunity in coeliac disease. Trejdosiewicz LK, et al. **Baillieres Clin Gastroenterol** 1995 Jun;9(2):251–72 (160 ref.)

The human intestinal immune system: basic cellular and humoral mechanisms. Brandtzaeg P. **Baillieres Clin Rheumatol** 1996 Feb;10(1):1–24 (91 ref.)

Aetiological agents and immune mechanisms in enterogenic reactive arthritis. Sieper J, et al. **Baillieres Clin Rheumatol** 1996 Feb;10(1):105–21 (83 ref.)

Neonatal gastrointestinal mucosal immunity. Mannick E, et al. **Clin Perinatol** 1996 Jun;23(2):287–304 (111 ref.)

Entry of microbes into the host: using M cells to break the mucosal barrier. Jones B, et al. **Curr Opin Immunol** 1995 Aug;7(4):474–8 (46 ref.)

Extrathymic T cell differentiation. Rocha B, et al. **Curr Opin Immunol** 1995 Apr;7(2):235–42 (55 ref.)

Impact of aging on gastrointestinal mucosal immunity. Schmucker DL, et al. **Dig Dis Sci** 1996 Jun;41(6):1183–93 (76 ref.)

The gut as a lymphoepithelial organ: the role of intestinal epithelial cells in mucosal immunity. Tlaskalová-Hogenová H, et al. **Folia Microbiol (Praha)** 1995;40(4):385–91 (52 ref.)

Oral tolerance: mobilizing the gut. Weiner HL. **Hosp Pract (Off Ed)** 1995 Sep 15;30(9):53–8 (6 ref.)

Advances in intestinal T-cell development and function. Klein JR. **Immunol Today** 1995 Jul;16(7):322-4 (11 ref.)
Involvement of B-1 cells in mucosal immunity and autoimmunity. Murakami M, et al. **Immunol Today** 1995 Nov;16(11):534-9 (38 ref.)
Composition of TCR-CD3 complex in human intestinal intraepithelial lymphocytes: lack of Fc epsilon RI gamma chain. Balk SP, et al. **Int Immunol** 1995 Aug;7(8):1237-41 (40 ref.)
Changes in the intestinal lymphoid compartment throughout life: implications for the local generation of intestinal T cells. Rozing J, et al. **Int Rev Immunol** 1995;12(1):13-25 (45 ref.)
Pathogenesis of inflammatory bowel disease: evolving concepts. Mayer L, et al. **Mt Sinai J Med** 1996 May-Sep; 63(3-4):202-9 (69 ref.)
Development of immune function in the intestine and its role in neonatal diseases. Insoft RM, et al.
Pediatr Clin North Am 1996 Apr;43(2):551-71 (83 ref.)
Intestinal T lymphocytes. Robijn RJ, et al.
Scand J Gastroenterol Suppl 1995;212:23-33 (120 ref.)

METABOLISM

Biosynthesis of intestinal mucins: MUC1, MUC2, MUC3 and more. Van Klinken BJ, et al. **Biochem Soc Trans** 1995 Nov; 23(4):814-8 (42 ref.)
Gut mucosa reconditioning with species-specific lactobacilli, surfactants, pseudomucus, and fibers--an invited review. Bengmark S, et al. **Biotechnol Ther** 1994-95;5(3-4):171-94 (149 ref.)
Anatomical heterogeneity of the intestinal mucosa and cholesterol homeostasis. A review of studies with normal and genetically hypercholesterolemic (RICO) Rat. Lutton C. **Digestion** 1996;57(1):1-10 (40 ref.)
The role of glutamine, short-chain fatty acids, and nucleotides in intestinal adaptation to gastrointestinal disease. LeLeiko NS, et al. **Pediatr Clin North Am** 1996 Apr;43(2):451-70 (98 ref.)
Does fluid flow across the intestinal mucosa affect quantitative oral drug absorption? Is it time for a reevaluation? Lennernäs H. **Pharm Res** 1995 Nov; 12(11):1573-82 (71 ref.)
[Butyrate and hemorrhagic rectocolitis] Flourié B, et al.
Gastroenterol Clin Biol 1995 Jun-Jul;19(6-7):619-24 (51 ref.) **(Fre)**

MICROBIOLOGY

Aetiological agents and immune mechanisms in enterogenic reactive arthritis. Sieper J, et al.
Baillieres Clin Rheumatol 1996 Feb;10(1):105-21 (83 ref.)
Gut mucosa reconditioning with species-specific lactobacilli, surfactants, pseudomucus, and fibers--an invited review. Bengmark S, et al. **Biotechnol Ther** 1994-95;5(3-4):171-94 (149 ref.)
Entry of microbes into the host: using M cells to break the mucosal barrier. Jones B, et al. **Curr Opin Immunol** 1995 Aug;7(4):474-8 (46 ref.)

PATHOLOGY

Morphology of the mucosal lesion in gluten sensitivity. Marsh MN, et al. **Baillieres Clin Gastroenterol** 1995 Jun; 9(2):273-93 (60 ref.)
A comparison of small-intestinal mucosal biopsies in children obtained by blind suction capsule with those obtained by endoscopy. Branski D, et al.
J Pediatr Gastroenterol Nutr 1996 Feb;22(2):194-6 (17 ref.)

PHYSIOLOGY

An update on histamine H3 receptors and gastrointestinal functions. Bertaccini G, et al. **Dig Dis Sci** 1995 Sep; 40(9):2052-63 (90 ref.)
Peptides and gastrointestinal mucosal integrity. Playford RJ. **Gut** 1995 Nov;37(5):595-7 (24 ref.)
Gastrointestinal surface protection and mucosa reconditioning. Bengmark S, et al.
JPEN J Parenter Enteral Nutr 1995 Sep-Oct;19(5):410-5 (57 ref.)

PHYSIOPATHOLOGY

Intestinal permeability in Crohn's disease. Franchimont D, et al. **Acta Gastroenterol Belg** 1996 Jan-Mar;59(1):15-9 (35 ref.)
Mucosal healing and adaptation in the small intestine. Basson MD. **Curr Opin Gen Surg** 1994;:138-46 (62 ref.)
Nutrition and the gut mucosal barrier. Deitch EA.
Curr Opin Gen Surg 1993;:85-91 (34 ref.)
Electrolyte fluxes in the gut and oral rehydration solutions. Acra SA, et al. **Pediatr Clin North Am** 1996 Apr; 43(2):433-49 (64 ref.)
Role of the gut in multiple organ failure: bacterial translocation and permeability changes. Swank GM, et al. **World J Surg** 1996 May;20(4):411-7 (65 ref.)

SECRETION

Regulation of mucin exocytosis from intestinal goblet cells. Laboisse C, et al. **Biochem Soc Trans** 1995 Nov;23(4):810-3 (20 ref.)

ULTRASONOGRAPHY

[High frequency ultrasonography of the gastrointestinal wall] Odegaard S, et al. **Tidsskr Nor Laegeforen** 1996 May 10; 116(12):1455-9 (32 ref.) (Eng. Abstr.) **(Nor)**

ULTRASTRUCTURE

[Preparation of apical and basolateral membranes from small intestinal epithelium. Methodologic aspects] Usatiuk PV, et al. **Ukr Biokhim Zh** 1995 Sep-Oct;67(5):16-24 (94 ref.) (Eng. Abstr.) **(Ukr)**

INTESTINAL NEOPLASMS

[Intestinal non-Hodgkin's lymphoma] Heise W, et al.
Dtsch Med Wochenschr 1995 Oct 20;120(42):1447-51 (40 ref.) **(Ger)**
[6 cases of small intestine lymphoma] Sartini M, et al.
G Chir 1995 Oct;16(10):417-21 (29 ref.) (Eng. Abstr.) **(Ita)**

CHEMISTRY

[Biological markers of precancer of the large intestine] Zagrebin VM. **Arkh Patol** 1995 Jul-Aug;57(4):89-92 (50 ref.) (Eng. Abstr.) **(Rus)**

CLASSIFICATION

[Nosography of intestinal lymphomas] Greco AV, et al.
Riv Eur Sci Med Farmacol 1994 Sep-Dec;16 Suppl 1:3-13 (36 ref.) (Eng. Abstr.) **(Ita)**

COMPLICATIONS

[Intestinal malabsorption, celiac disease and associated lymphoma: from symptoms to diagnosis] Gasbarrini G, et al. **Riv Eur Sci Med Farmacol** 1994 Sep-Dec;16 Suppl 1:39-68 (115 ref.) (Eng. Abstr.) **(Ita)**

DIAGNOSIS

Multicentric primary adenocarcinomas of the midgut: the first case report. Liu KJ, et al. **Am J Gastroenterol** 1996 Jun;91(6):1239-43 (48 ref.)
[Epithelioid hemangioendothelioma localized in the small intestine] Alvarez Sánchez JA, et al.
Gastroenterol Hepatol 1995 Nov;18(9):464-7 (19 ref.) (Eng. Abstr.) **(Spa)**

EPIDEMIOLOGY

[Carcinoma of the large intestine among the aged Japanese] Kanazawa K. **Nippon Ronen Igakkai Zasshi** 1995 Jun; 32(6):397-402 (22 ref.) **(Jpn)**

ETIOLOGY

Intestinal lymphoma and enteropathy [editorial; comment] Isaacson PG. **J Pathol** 1995 Oct;177(2):111-3 (22 ref.)
Comment on: J Pathol 1995 Oct;177(2):115-22.
Premalignant conditions of the small intestine. Ryan JC.
Semin Gastrointest Dis 1996 Apr;7(2):88-93 (72 ref.)

GENETICS

Emergent issues in the genetics of intestinal neoplasia. Dove WF, et al. **Cancer Surv** 1995;25:335-55 (98 ref.)

PATHOLOGY

Neuroendocrine insights from the laboratory to the clinic. Ahlman H, et al. **Am J Surg** 1996 Jul;172(1):61-7 (40 ref.)
Leiomyosarcoma of the small intestine presenting as a pelvic mass. Kawagoe H, et al.
Eur J Obstet Gynecol Reprod Biol 1996 Jun;66(2):187-91 (14 ref.)
Endocrine tumors of the small and large intestine. Solcia E, et al. **Pathol Res Pract** 1995 May;191(4):366-72 (56 ref.)

SECONDARY

[Value of surgical treatment in patients with gastrointestinal metastatic tumors] Wang Z, et al.
Chung Hua Wai Ko Tsa Chih 1995 Sep;33(9):551-3 (6 ref.) (Eng. Abstr.) **(Chi)**

SURGERY

A complication of mesenteric lymphangioma: case report and brief review of literature. Takkal M, et al.
Acta Chir Belg 1996 Jun;96(3):130-2 (12 ref.)
Small bowel tumors. Basson MD. **Curr Opin Gen Surg** 1993; :219-24 (33 ref.)
[Value of surgical treatment in patients with gastrointestinal metastatic tumors] Wang Z, et al.
Chung Hua Wai Ko Tsa Chih 1995 Sep;33(9):551-3 (6 ref.) (Eng. Abstr.) **(Chi)**

VETERINARY

Intestinal adenocarcinomas in two beluga whales (Delphinapterus leucas) from the estuary of the St. Lawrence River. Martineau D, et al. **Can Vet J** 1995 Sep; 36(9):563-5 (14 ref.)

INTESTINAL OBSTRUCTION

CHEMICALLY INDUCED

Fibrosing colonopathy in cystic fibrosis. Smyth RL.
Arch Dis Child 1996 May;74(5):464-8 (24 ref.)
Fibrosing colonopathy: recent advances. Dodge JA.
J R Soc Med 1996;89 Suppl 27:19-23 (18 ref.)
[Current aspects of the use of clozapine in the Châlons-sur-Marne Psychiatric Hospital: intestinal occlusion with clozapine] Théret L, et al.
Ann Med Psychol (Paris) 1995 Aug-Sep;153(7):474-7 (24 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

[Intrahepatic cholestasis associated with neonatal small intestinal obstruction] Tajiri H, et al.
Ryoikibetsu Shokogun Shirizu 1995;(7):569-70 (9 ref.) **(Jpn)**

CONGENITAL

Intestinal obstruction caused by duplication of the caecum. Oudshoorn JH, et al. **Eur J Pediatr** 1996 Apr;155(4):338-40 (18 ref.)
Rectal atresia and stenosis. Zia-w-Miraj Ahmad M, et al.
J Pediatr Surg 1995 Nov;30(11):1546-50 (39 ref.)

DIAGNOSIS

Intraoperative enteroscopy in the diagnosis of partial intestinal obstruction in infancy. Duggan C, et al.
Dig Dis Sci 1995 Oct;40(10):2236-8 (12 ref.)
[Intestinal obstruction and pregnancy] Dufour P, et al.
J Gynecol Obstet Biol Reprod (Paris) 1996;25(3):297-300 (10 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Obturation of the small bowel. Gaddie D, et al.
Aust N Z J Surg 1995 Dec;65(12):902-5 (25 ref.)
Endometriosis as a cause of colonic obstruction. Valko GP, et al. **J Am Board Fam Pract** 1995 Nov-Dec;8(6):481-3 (8 ref.)
A case of abdominal cocoon. Yoon YW, et al.
J Korean Med Sci 1995 Jun;10(3):220-5 (18 ref.)
Small bowel obstruction following endoscopic extraperitoneal-preperitoneal herniorrhaphy. Azurin DJ, et al. **J Laparoendosc Surg** 1995 Aug;5(4):263-6 (10 ref.)
Annular constriction of the rectum secondary to transitional cell carcinoma of the bladder. Langenstroer P, et al.
Urology 1996 Mar;47(3):442-4 (6 ref.)
[A unusual cause of acute pancreatitis: obstruction of the afferent loop after gastrectomy according to Bilroth II. Apropos of a case and review of the literature] Moschopoulos C, et al. **Ann Radiol (Paris)** 1995; 38(7-8):426-9 (16 ref.) (Eng. Abstr.) **(Fre)**
[Sclerosing peritonitis. A series of 10 cases and review of the literature] Carbonnel F, et al.
Gastroenterol Clin Biol 1995 Nov;19(11):876-82 (33 ref.) (Eng. Abstr.) **(Fre)**
[Chronic recurrent subileus due to Strongyloides stercoralis infection under immunosuppressive therapy] Birck R, et al. **Dtsch Med Wochenschr** 1996 May 31;121(22):723-6 (17 ref.) (Eng. Abstr.) **(Ger)**
[Biliary ileus. A report of 2 cases] Ottenello M, et al.
Minerva Chir 1996 Jan-Feb;51(1-2):67-9 (18 ref.) (Eng. Abstr.) **(Ita)**
[Gallstone ileus] Numata M, et al.
Ryoikibetsu Shokogun Shirizu 1996;(9):503-5 (8 ref.) **(Jpn)**

PATHOLOGY

Obstructive colitis: an analysis of 50 cases and a review of the literature. Gratama S, et al. **Pathology** 1995 Oct; 27(4):324-9 (30 ref.)

RADIOGRAPHY

Imaging of intestinal obstruction. Traill ZC, et al.
Br J Hosp Med 1996 Mar 6-19;55(5):267-71 (20 ref.)
[Contrast agent retention in a jejunal diverticulum and small-intestine volvulus] Hüppe T, et al.
Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1995 Nov;163(5):443-5 (10 ref.) **(Ger)**

SURGERY

Colonic volvulus. Frizelle EA, et al. **Adv Surg** 1996;29:131-9 (36 ref.)
Laparoscopic surgery for intestinal obstruction. Reissman P, et al. **Surg Endosc** 1995 Aug;9(8):865-8 (19 ref.)
Laparoscopic treatment of Meckel's diverticulum. Obstruction and bleeding managed with minimal morbidity. Sanders LE. **Surg Endosc** 1995 Jun;9(6):724-7 (14 ref.)
[Colon volvulus] Monteferrante E, et al. **Minerva Chir** 1995 Dec;50(12):1085-8 (12 ref.) (Eng. Abstr.) **(Ita)**

THERAPY

Intestinal obstruction. Baines MJ. **Cancer Surv** 1994;21:147-56 (32 ref.)
[Medical treatment of chronic radiation induced enteritis] Cosnes J. **Ann Chir** 1996;50(1):36-9 (23 ref.) (Eng. Abstr.) **(Fre)**

INTESTINAL OBSTRUCTION

VETERINARY

[Right displacement of the abomasum in cattle. 1. Pathogenesis, clinical course and prognosis] Kümper H. **Tierarztl Prax** 1995 Aug;23(4):351–9 (30 ref.) (Eng. Abstr.) **(Ger)**

INTESTINAL PERFORATION

Spontaneous duodenal perforation in neonates: a case report and review of literature. Nazzal M, et al. **Am Surg** 1996 Sep;62(9):706–8 (16 ref.)

Perforated appendicitis: past and future controversies. Blewett CJ, et al. **Semin Pediatr Surg** 1995 Nov;4(4):234–8 (34 ref.)

CHEMICALLY INDUCED

Cecal perforation associated with sodium polystyrene sulfonate–sorbitol enemas in a 650 gram infant with hyperkalemia. Bennett LN, et al. **Am J Perinatol** 1996 Apr; 13(3):167–70 (12 ref.)

EPIDEMIOLOGY

Perforated jejunal diverticula: an analysis of reported cases. Chendrasekhar A, et al. **Am Surg** 1995 Nov;61(11):984–8 (40 ref.)

ETIOLOGY

[Spontaneous perforation of the small intestine in primary lung carcinoma] Kolarov I, et al. **Khirurgiia (Sofiia)** 1995; 48(6):47–9 (0 ref.) **(Bul)**

[Spontaneous colonic perforations revealing Ehlers–Danlos syndrome type IV] Henry C, et al. **Arch Pediatr** 1995 Nov; 2(11):1067–72 (19 ref.) (Eng. Abstr.) **(Fre)**

[Buerger's disease disclosed by a perforation in the digestive system. Apropos of a case and review of the literature] Nyuyen TB, et al. **Rev Med Interne** 1996;17(1):70–5 (30 ref.) (Eng. Abstr.) **(Fre)**

[Perforation in Crohn's ileitis and its impact on the natural history of the disease. Note 1. Pathogenic process of the event, its relationship with intestinal obstruction, and its immediate consequences] Tonelli P. **Ann Ital Chir** 1995 May–Jun;66(3):335–47 (24 ref.) (Eng. Abstr.) **(Ita)**

SURGERY

Laparoscopic treatment of a sigmoid perforation after colonoscopy. Case report and review of literature. Mehdi A, et al. **Surg Endosc** 1996 Jun;10(6):666–7 (19 ref.)

INTESTINAL POLYPS

ETIOLOGY

Angioimmunoblastic lymphadenopathy: an etiology for gastrointestinal lymphomatous polyposis. Goenka MK, et al. **Am J Gastroenterol** 1996 Jun;91(6):1236–8 (16 ref.)

GENETICS

Phenotype and cancer risk of various polyposis syndromes. Giardiello FM, et al. **Eur J Cancer** 1995 Jul–Aug; 31A(7–8):1085–7 (26 ref.)

PATHOLOGY

Polyps and polypectomy surveillance—role of the histopathologist. Riddell RH. **Eur J Cancer** 1995 Jul–Aug; 31A(7–8):1138–40 (6 ref.)

RADIOGRAPHY

Dilemma of an inverted cecal diverticulum simulating a pedunculated polyp: CT appearance. Posner R, et al. **Abdom Imaging** 1995 Sep–Oct;20(5):440–1 (5 ref.)

Barium enema: colorectal polyps and carcinoma. Ott DJ. **Semin Roentgenol** 1996 Apr;31(2):125–41 (64 ref.)

SURGERY

Interference with the adenoma–carcinoma sequence. Bond JH. **Eur J Cancer** 1995 Jul–Aug;31A(7–8):1115–7 (30 ref.)

Follow-up after polypectomy: consensus? Bond JH. **Eur J Cancer** 1995 Jul–Aug;31A(7–8):1141–4 (28 ref.)

INTESTINAL PSEUDO-OBSTRUCTION

Chronic intestinal pseudo-obstruction in childhood: progress in diagnosis and treatment. Hyman PE. **Scand J Gastroenterol Suppl** 1995;213:39–46 (60 ref.)

COMPLICATIONS

Hepatic-portal venous gas associated with ileus. Quirke TE. **Am Surg** 1995 Dec;61(12):1084–6 (12 ref.)

DIAGNOSIS

Chronic intestinal pseudo-obstruction: diagnosis and treatment. Patel R, et al. **Gastroenterologist** 1995 Dec; 3(4):345–56 (104 ref.)

[Constipation in children: from symptoms of Hirschsprung disease to chronic intestinal pseudo-obstruction syndromes] Goulet O. **Gastroenterol Clin Biol** 1996;20(5 Pt 2):B56–62 (39 ref.) **(Fre)**

ETIOLOGY

Chronic intestinal pseudo-obstruction. Verne GN, et al. **Dig Dis** 1995 May–Jun;13(3):163–81 (118 ref.)

Intestinal motility during ontogeny and intestinal pseudo-obstruction in children. Milla PJ. **Pediatr Clin North Am** 1996 Apr;43(2):511–32 (72 ref.)

PHYSIOPATHOLOGY

Intestinal motility during ontogeny and intestinal pseudo-obstruction in children. Milla PJ. **Pediatr Clin North Am** 1996 Apr;43(2):511–32 (72 ref.)

THERAPY

Chronic intestinal pseudo-obstruction: diagnosis and treatment. Patel R, et al. **Gastroenterologist** 1995 Dec; 3(4):345–56 (104 ref.)

INTESTINAL SECRETIONS

see related
GASTROINTESTINAL HORMONES

INTESTINE, LARGE

[Carcinoma of the large intestine among the aged Japanese] Kanazawa K. **Nippon Ronen Igakkai Zasshi** 1995 Jun; 32(6):397–402 (22 ref.) **(Jpn)**

CHEMISTRY

[Biological markers of precancer of the large intestine] Zagrebin VM. **Arkh Patol** 1995 Jul–Aug;57(4):89–92 (50 ref.) (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

Toxicity of nonsteroidal anti-inflammatory drugs in the large intestine. Davies NM. **Dis Colon Rectum** 1995 Dec; 38(12):1311–21 (105 ref.)

METABOLISM

Interactions between large intestine fermentation and dietary calcium. Demigné C, et al. **Eur J Clin Nutr** 1995 Oct;49 Suppl 3:S235–8 (13 ref.)

Oestrogen and colonic epithelial cell growth. Singh S, et al. **Gut** 1995 Dec;37(6):737–9 (42 ref.)

INTESTINE, SMALL

Multicentric primary adenocarcinomas of the midgut: the first case report. Liu KJ, et al. **Am J Gastroenterol** 1996 Jun;91(6):1239–43 (48 ref.)

Small bowel obstruction following endoscopic extraperitoneal–preperitoneal herniorrhaphy. Azurin DJ, et al. **J Laparoendosc Surg** 1995 Aug;5(4):263–6 (10 ref.)

Premalignant conditions of the small intestine. Ryan JC. **Semin Gastrointest Dis** 1996 Apr;7(2):88–93 (72 ref.)

[Spontaneous perforation of the small intestine in primary lung carcinoma] Kolarov I, et al. **Khirurgiia (Sofiia)** 1995; 48(6):47–9 (0 ref.) **(Bul)**

[Yersinia enterocolitica: a cause of acute intestinal intussusception] Barthod F, et al. **Presse Med** 1996 Apr 20;25(14):668–70 (13 ref.) (Eng. Abstr.) **(Fre)**

[Odelberg's lipomatosis] Aronescu M, et al. **Chirurgia (Bucur)** 1995;44(1):48–51 (20 ref.) **(Rum)**

[Epithelioid hemangioendothelioma localized in the small intestine] Alvarez Sánchez JA, et al. **Gastroenterol Hepatol** 1995 Nov;18(9):464–7 (19 ref.) (Eng. Abstr.) **(Spa)**

DRUG EFFECTS

Influence of anti-rheumatic drugs on gut permeability and on the gut associated lymphoid tissue. Bjarnason I, et al. **Baillieres Clin Rheumatol** 1996 Feb;10(1):165–76 (75 ref.)

Nonsteroidal anti-inflammatory drugs: gastroduodenal injury and beyond. Bernsdorff KR, et al. **Dig Dis** 1995 Jul–Aug; 13(4):251–66 (134 ref.)

[Effect of BBN on the small intestine transplanted to the urinary bladder of rat] Wu B, et al. **Hinyokika Kiyo** 1995 Sep;41(9):665–8 (16 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Absorption and presentation of antigens by epithelial cells of the small intestine: hypotheses and predictions relating to the pathogenesis of coeliac disease. Mayrhofer G. **Immunol Cell Biol** 1995 Oct;73(5):433–9 (63 ref.)

INJURIES

A review of intestinal injury from blunt abdominal trauma. Munns J, et al. **Aust N Z J Surg** 1995 Dec;65(12):857–60 (15 ref.)

METABOLISM

Amino acid transport in the small intestine [corrected and republished with original paging, article originally printed in Physiol Res 1994;43(6):335–45] Munck LK, et al. **Physiol Res** 1995;44(2):335–46 (116 ref.)

PATHOLOGY

A comparison of small-intestinal mucosal biopsies in children obtained by blind suction capsule with those obtained by endoscopy. Branski D, et al. **J Pediatr Gastroenterol Nutr** 1996 Feb;22(2):194–6 (17 ref.)

PHYSIOLOGY

Gastric and small intestinal motility in health and disease. Quigley EM. **Gastroenterol Clin North Am** 1996 Mar; 25(1):113–45 (164 ref.)

Effect of some abdominal surgical operations on small bowel motility in humans: our experience. Bassotti G, et al. **J Clin Gastroenterol** 1995 Oct;21(3):211–6 (86 ref.)

Ambulatory manometry of the small bowel: indications and analysis. Wilmer A, et al. **Rev Esp Enferm Dig** 1996 Feb; 88(2):118–32 (45 ref.) **(Eng, Spa)**

PHYSIOPATHOLOGY

Intestinal responses induced by enteral feeding. Bowling TE, et al. **Nutrition** 1995 May–Jun;11(3):304–7 (67 ref.)

[Intestinal adaptation in the short and ultrashort bowel syndrome. Nutritional support] Galiano Segovia MJ, et al. **An Esp Pediatr** 1996 Jun;44(6):605–8 (16 ref.) **(Spa)**

RADIATION EFFECTS

The prevention of radiation-induced small bowel complications. Letschert JG. **Eur J Cancer** 1995 Jul–Aug; 31A(7–8):1361–5 (26 ref.)

Radiation enteropathy—incidence, aetiology, risk factors, pathology and symptoms. Rodier JF. **Tumori** 1995 May–Jun;81(3 Suppl):122–5 (12 ref.)

RADIOGRAPHY

Current status of small bowel radiography. Maglinte DDT, et al. **Abdom Imaging** 1996 May–Jun;21(3):247–57 (89 ref.)

[Contrast agent retention in a jejunal diverticulum and small-intestine volvulus] Hüppe T, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1995 Nov;163(5):443–5 (10 ref.) **(Ger)**

SURGERY

Small bowel tumors. Basson MD. **Curr Opin Gen Surg** 1993; :219–24 (33 ref.)

[Value of surgical treatment in patients with gastrointestinal metastatic tumors] Wang Z, et al. **Chung Hua Wai Ko Tsa Chih** 1995 Sep;33(9):551–3 (6 ref.) (Eng. Abstr.) **(Chi)**

TRANSPLANTATION

The immune response in small bowel transplantation. Clark CL. **Ann R Coll Surg Engl** 1996 Mar;78(2):97–102 (22 ref.)

Small bowel transplantation: current progress and clinical application. Frezza EE, et al. **Hepatogastroenterology** 1996 Mar–Apr;43(8):363–76 (141 ref.)

Short bowel syndrome in children and small intestinal transplantation. Vanderhoof JA. **Pediatr Clin North Am** 1996 Apr;43(2):533–50 (84 ref.)

Intestinal transplantation: a clinical update. Ploeg RJ, et al. **Scand J Gastroenterol Suppl** 1995;212:79–89 (53 ref.)

Graft-versus-host reaction and rejection after experimental small-bowel transplantation. Minireview based on a doctoral thesis. Johnsson C. **Ups J Med Sci** 1995; 100(2):53–92 (178 ref.)

[Effect of BBN on the small intestine transplanted to the urinary bladder of rat] Wu B, et al. **Hinyokika Kiyo** 1995 Sep;41(9):665–8 (16 ref.) (Eng. Abstr.) **(Jpn)**

ULTRASTRUCTURE

[Preparation of apical and basolateral membranes from small intestinal epithelium. Methodologic aspects] Usatiuk PV, et al. **Ukr Biokhim Zh** 1995 Sep–Oct;67(5):16–24 (94 ref.) (Eng. Abstr.) **(Ukr)**

INTESTINES

see related
ENTEROSTOMY

Pharmacobezoar: an evolving new entity. Stack PE, et al. **Dig Dis** 1995 Nov–Dec;13(6):356–64 (38 ref.)

BLOOD SUPPLY

Gastrointestinal vascular and ischemic syndromes. Brophy CM. **Curr Opin Gen Surg** 1993;:225–31 (26 ref.)

Non-occlusive mesenteric ischemia. Lock G, et al. **Hepatogastroenterology** 1995 Jul;42(3):234–9 (36 ref.)

Chronic intestinal ischemia caused by intravenous cocaine use: report of two cases and review of the literature. Myers SI, et al. **J Vasc Surg** 1996 Apr;23(4):724–9 (23 ref.)

CHEMISTRY

[Collagens in intestinal smooth muscles] Le Blay G, et al. **Gastroenterol Clin Biol** 1996 Mar;20(2):185–92 (49 ref.) **(Fre)**

CYTOLOGY

Intestinal epithelial cell differentiation: new insights from mice, flies and nematodes. Simon TC, et al.

Curr Opin Genet Dev 1995 Oct;5(5):577–86 (56 ref.)
Macrophages in the external muscle layers of mammalian intestines. Mikkelsen HB. **Histol Histopathol** 1995 Jul; 10(3):719–36 (92 ref.)
M cells in Peyer's patches of the intestine. Gebert A, et al. **Int Rev Cytol** 1996;167:91–159 (310 ref.)
Fuel selection in intestinal cells. Duée PH, et al. **Proc Nutr Soc** 1995 Mar;54(1):83–94 (59 ref.)

DRUG EFFECTS

Gene expression in the intestine: the effect of dietary nucleotides. LeLeiko NS, et al. **Adv Pediatr** 1995;42:145–69 (65 ref.)
Nonsteroidal anti-inflammatory drugs and the gut. Hirschowitz BI. **South Med J** 1996 Mar;89(3):259–63 (20 ref.)

EMBRYOLOGY

Extracellular matrix components in intestinal development. Simon-Assmann P, et al. **Experientia** 1995 Sep 29; 51(9–10):883–900 (160 ref.)

ENZYMOLOGY

Regulation of mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase gene expression in liver and intestine from the rat. Hegardt FG. **Biochem Soc Trans** 1995 Aug;23(3):486–90 (23 ref.)
Intestinal brush border glycohydrolases: structure, function, and development. Van Beers EH, et al. **Crit Rev Biochem Mol Biol** 1995;30(3):197–262 (295 ref.)
[The maturation of intestinal digestive enzymes in ontogeny] Timofeeva NM. **Fiziol Zh Im I M Sechenova** 1995 Jul; 81(7):1–16 (59 ref.) **(Rus)**

GROWTH & DEVELOPMENT

Gene expression in the intestine: the effect of dietary nucleotides. LeLeiko NS, et al. **Adv Pediatr** 1995;42:145–69 (65 ref.)
[The maturation of intestinal digestive enzymes in ontogeny] Timofeeva NM. **Fiziol Zh Im I M Sechenova** 1995 Jul; 81(7):1–16 (59 ref.) **(Rus)**

IMMUNOLOGY

Human milk and intestinal host defense in newborns: an update. Xanthou M, et al. **Adv Pediatr** 1995;42:171–208 (169 ref.)
The gut associated addressins: lymphocyte homing in the gut. De Keyser F, et al. **Baillieres Clin Rheumatol** 1996 Feb;10(1):25–39 (65 ref.)
Extrathymic and thymic origin of murine IEL: are most IEL in euthymic mice derived from the thymus? Lin T, et al. **Immunol Cell Biol** 1995 Oct;73(5):469–73 (25 ref.)

INJURIES

The trauma celiotomy: the evolving concepts of damage control. Morris JA Jr, et al. **Curr Probl Surg** 1996 Aug; 33(8):611–700 (341 ref.)
CT scan of bowel trauma in the pediatric patient. Cox TD, et al. **Radiol Clin North Am** 1996 Jul;34(4):807–18 (23 ref.)
[Bowel complications in gynecologic laparoscopic surgery and their immediate repair without laparotomy. Four cases] Renault B, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996; 25(4):360–4 (16 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Intestinal permeability measurements – a new application for water soluble contrast media? Andersen R, et al. **Acta Radiol Suppl** 1995;399:247–52 (42 ref.)
Intestine-specific gene transcription. Traber PG, et al. **Annu Rev Physiol** 1996;58:275–97 (106 ref.)
Neonatal intestinal metabolism. Kimura RE. **Clin Perinatol** 1996 Jun;23(2):245–63 (39 ref.)
Regulation of gut glutamine metabolism: role of hormones and cytokines. Abumrad NN, et al. **Proc Nutr Soc** 1995 Jul;54(2):525–33 (33 ref.)
Intestinal oligopeptide transport. Boyd CA. **Proc Nutr Soc** 1995 Jul;54(2):519–23 (18 ref.)
Metabolic fuel selection by intestinal epithelium. Desjeux JF. **Proc Nutr Soc** 1995 Mar;54(1):157–63 (36 ref.)
Fuel selection in intestinal cells. Duée PH, et al. **Proc Nutr Soc** 1995 Mar;54(1):83–94 (59 ref.)
Intestinal lipoprotein synthesis and secretion. Field FJ, et al. **Prog Lipid Res** 1995;34(2):185–98 (158 ref.)
[Liver mechanisms for the elimination of lipoproteins of intestinal origin] Khallou J, et al. **C R Seances Soc Biol Fil** 1995;189(5):899–904 (22 ref.) (Eng. Abstr.) **(Fre)**

MICROBIOLOGY

Understanding intestinal spore-forming protozoa: cryptosporidia, microsporidia, isospora, and cyclospora. Goodgame RW. **Ann Intern Med** 1996 Feb 15; 124(4):429–41 (170 ref.)
Anticarcinogenic, hypocholesterolemic, and antagonistic activities of Lactobacillus acidophilus. Mital BK, et al. **Crit Rev Microbiol** 1995;21(3):175–214 (371 ref.)
Effect of quinolones on the human intestinal microflora. Nord CE. **Drugs** 1995;49 Suppl 2:81–5 (22 ref.)
Helicobacter pylori as a promoter of intestinal metaplasia and gastric cancer: an alluring hypothesis in search of evidence. Genta RM. **Eur J Gastroenterol Hepatol** 1995 Aug;7 Suppl 1:S25–30 (53 ref.)
Adherence & colonization properties of Vibrio cholerae & diarrhoeagenic Escherichia coli. Ghose AC. **Indian J Med Res** 1996 Jul;104:38–51 (160 ref.)
[Formation of so-called byproducts (propanols, butanols et al.) from ethanol by microorganisms] Stöhlmacher P. **Blutalkohol** 1996 May;33(3):113–41 (200 ref.) (Eng. Abstr.) **(Ger)**

PARASITOLOGY

The Biology of the intestinal trematode Echinostoma caproni. Fried B, et al. **Adv Parasitol** 1996;38:311–68 (170 ref.)

PATHOLOGY

Helicobacter pylori as a promoter of intestinal metaplasia and gastric cancer: an alluring hypothesis in search of evidence. Genta RM. **Eur J Gastroenterol Hepatol** 1995 Aug;7 Suppl 1:S25–30 (53 ref.)

PHYSIOLOGY

Regulation of tight-junction permeability during nutrient absorption across the intestinal epithelium. Ballard ST, et al. **Annu Rev Nutr** 1995;15:35–55 (105 ref.)
Slices and sacs: limitations on metabolic and functional studies in kidney cortex and intestine. Foulkes EC. **Proc Soc Exp Biol Med** 1996 Feb;211(2):155–62 (43 ref.)
[The muscarinic system of the gastrointestinal smooth muscle] Cuq P. **Gastroenterol Clin Biol** 1995 Aug–Sep; 19(8–9):675–84 (101 ref.) **(Fre)**
[The participation of enteral mechanisms in the sympathetic-adrenal inhibition of gastric secretion] Trefilov AB. **Usp Fiziol Nauk** 1995 Jan–Mar;26(1):76–92 (79 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Gastrointestinal dysfunction in liver disease and portal hypertension. Gut-liver interactions revisited [editorial] Quigley EM. **Dig Dis Sci** 1996 Mar;41(3):557–61 (48 ref.)

RADIOGRAPHY

CT scan of bowel trauma in the pediatric patient. Cox TD, et al. **Radiol Clin North Am** 1996 Jul;34(4):807–18 (23 ref.)

RADIONUCLIDE IMAGING

Whole-gut transit scintigraphy in the evaluation of small-bowel and colon transit disorders. Maurer AH, et al. **Semin Nucl Med** 1995 Oct;25(4):326–38 (69 ref.)

INTOXICATION see **POISONING**

INTOXICATION, ALCOHOLIC see **ALCOHOLIC INTOXICATION**

INTRA-ABDOMINAL INFUSIONS see **INFUSIONS, PARENTERAL**

INTRA-AORTIC BALLOON PUMPING

ADVERSE EFFECTS

Retained intraaortic balloon. Case report and review of the literature. Grande AM, et al. **Tex Heart Inst J** 1995; 22(4):332–4 (19 ref.)

METHODS

Aortic-based therapy for cardiac arrest. Paradis NA. **Ann Emerg Med** 1996 May;27(5):563–8 (42 ref.)

INTRA-ARTERIAL LINES see **CATHETERS, INDWELLING**

INTRACELLULAR ADHESION MOLECULES see **CELL ADHESION MOLECULES**

INTRACELLULAR FLUID

METABOLISM

Cell calcium and arterial blood pressure. Gonzalez JM, et al. **Semin Nephrol** 1995 Nov;15(6):564–8 (56 ref.)

INTRACELLULAR MEMBRANES

METABOLISM

Ca2+ excitability of the ER membrane: an explanation for IP3-induced Ca2+ oscillations. Li YX, et al. **Am J Physiol** 1995 Nov;269(5 Pt 1):C1079–92 (103 ref.)
Cardiac ATP-sensitive K+ channels: regulation by intracellular nucleotides and K+ channel-opening drugs. Terzic A, et al. **Am J Physiol** 1995 Sep;269(3 Pt 1):C525–45 (196 ref.)
Role of the steroidogenic acute regulatory protein (StAR) in steroidogenesis. Stocco DM, et al. **Biochem Pharmacol** 1996 Feb 9;51(3):197–205 (125 ref.)
Intracellular membranes in the synthesis, transport, and metabolism of proteoglycans. Silbert JE, et al. **Biochim Biophys Acta** 1995 Dec 20;1241(3):371–84 (163 ref.)
Membrane adhesion and other functions for the myelin basic proteins. Staugaitis SM, et al. **Bioessays** 1996 Jan;18(1):13–8 (45 ref.)
Membrane traffic. Is the Golgi complex? Armstrong J. **Curr Biol** 1995 Sep 1;5(9):980–1 (10 ref.)
Membrane transport in the endocytic pathway. Gruenberg J, et al. **Curr Opin Cell Biol** 1995 Aug;7(4):552–63 (127 ref.)
Receptor signalling and the regulation of endocytic membrane transport. Seaman MN, et al. **Curr Opin Cell Biol** 1996 Aug;8(4):549–56 (67 ref.)
The protein machinery of vesicle budding and fusion. Rothman JE. **Protein Sci** 1996 Feb;5(2):185–94 (92 ref.)
Phosphoinositides as regulators in membrane traffic. De Camilli P, et al. **Science** 1996 Mar 15;271(5255):1533–9 (74 ref.)
Protein sorting by transport vesicles. Rothman JE, et al. **Science** 1996 Apr 12;272(5259):227–34 (86 ref.)
Common principles of protein translocation across membranes. Schatz G, et al. **Science** 1996 Mar 15; 271(5255):1519–26 (60 ref.)
Coat proteins and vesicle budding. Schekman R, et al. **Science** 1996 Mar 15;271(5255):1526–33 (83 ref.)
Targeting of motor proteins. Vallee RB, et al. **Science** 1996 Mar 15;271(5255):1539–44 (108 ref.)

PHYSIOLOGY

Enigma variations: protein mediators of membrane fusion. Mellman I. **Cell** 1995 Sep 22;82(6):869–72 (17 ref.)
Potential roles of heterotrimeric G proteins of the endomembrane system. Nürnberg B, et al. **FEBS Lett** 1996 Jun 24;389(1):61–5 (66 ref.)
Sphingolipids: their role in intracellular signaling and renal growth [editorial] Shayman JA. **J Am Soc Nephrol** 1996 Feb;7(2):171–82 (106 ref.)
Intracellular membrane morphology. Warren G. **Philos Trans R Soc Lond B Biol Sci** 1995 Sep 29; 349(1329):291–5 (23 ref.)

INTRACELLULAR SECOND MESSENGERS see **SECOND MESSENGER SYSTEMS**

INTRACEREBRAL PRESSURE see **INTRACRANIAL PRESSURE**

INTRACRANIAL ANEURYSM see **CEREBRAL ANEURYSM**

INTRACRANIAL ARTERIOVENOUS MALFORMATIONS see **CEREBRAL ARTERIOVENOUS MALFORMATIONS**

INTRACRANIAL HYPERTENSION, BENIGN see **PSEUDOTUMOR CEREBRI**

INTRACRANIAL PRESSURE

see related
PAPILLEDEMA
PSEUDOTUMOR CEREBRI

Growth of the cranial vault: influence of intracranial and extracranial pressures. Huggare J, et al. **Acta Odontol Scand** 1995 Jun;53(3):192–5 (27 ref.)
Iatrogenically induced intracranial hypotension syndrome. Sell JJ, et al. **AJR Am J Roentgenol** 1995 Dec;165(6):1513–5 (8 ref.)
Spontaneous intracranial hypotension. A review. Kosmorsky GS. **J Neuroophthalmol** 1995 Jun;15(2):79–83 (23 ref.)

DRUG EFFECTS

Hypertonic saline as a safe and efficacious treatment of intracranial hypertension. Zornow MH. **J Neurosurg Anesthesiol** 1996 Apr;8(2):175–7 (26 ref.)
High-dose barbiturates for intracranial pressure control. Wilberger JE, et al. **New Horiz** 1995 Aug;3(3):469–73 (27 ref.)
[The effect of suxamethonium on intracranial pressure] Handberg G, et al. **Ugeskr Laeger** 1996 Apr 22; 158(17):2381–3 (17 ref.) (Eng. Abstr.) **(Dan)**
[Effects of analgesia and sedation on cerebrovascular circulation, cerebral blood volume, cerebral metabolism and intracranial pressure] Werner C. **Anaesthesist** 1995 Dec; 44 Suppl 3:S566–72 (83 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Intracranial pressure and cerebral arterial flow velocity indices in childhood hydrocephalus: current review. Goh D, et al. **Childs Nerv Syst** 1995 Jul;11(7):392–6 (25 ref.)
Value of transcranial Doppler indices in predicting raised ICP in infantile hydrocephalus. A study with review of the literature. Hanlo PW, et al. **Childs Nerv Syst** 1995 Oct; 11(10):595–603 (45 ref.)
Intracranial pressure monitoring techniques. Ghajar J. **New Horiz** 1995 Aug;3(3):395–9 (42 ref.)
Intracranial pressure and cerebral perfusion pressure in severe head injury. Lang EW, et al. **New Horiz** 1995 Aug; 3(3):400–9 (98 ref.)

INTRACRANIAL TUBERCULOMA see **TUBERCULOMA, INTRACRANIAL**

INTRACRANIAL TUBERCULOMA

INTRACRANIAL

INTRAMEDULLARY NAILING see **FRACTURE FIXATION, INTRAMEDULLARY**

INTRAOCULAR PRESSURE

see related
GLAUCOMA
OCULAR HYPERTENSION
TONOMETRY

PHYSIOLOGY

[Long-term reduction of intraocular pressure by goniotrepanation or laser trabeculoplasty] Funk J, et al. **Klin Monatsbl Augenheilkd** 1995 Oct;207(4):215-23 (38 ref.) (Eng. Abstr.) **(Ger)**

INTRAOPERATIVE CARE

Intraoperative ultrasonography. Reading CC. **Abdom Imaging** 1996 Jan-Feb;21(1):21-9 (62 ref.)

Role of echocardiography in perioperative management of patients undergoing open heart surgery. Joffe II, et al. **Am Heart J** 1996 Jan;131(1):162-76 (130 ref.)

New strategies for intraoperative myocardial protection. Flameng W. **Curr Opin Cardiol** 1995 Nov;10(6):577-83 (37 ref.)

Preoperative assessment and perioperative management of cardiac ischemic risk in noncardiac surgery. Coley CM, et al. **Curr Probl Cardiol** 1996 May;21(5):289-382 (325 ref.)

Intraoperative enteroscopy in the diagnosis of partial intestinal obstruction in infancy. Duggan C, et al. **Dig Dis Sci** 1995 Oct;40(10):2236-8 (12 ref.)

Intraoperative transesophageal echocardiographic evaluation of mitral regurgitation. Ammar T, et al. **J Cardiothorac Vasc Anesth** 1996 Apr;10(3):397-405 (44 ref.)

Perioperative fluid management for thoracic surgery: the puzzle of postpneumonectomy pulmonary edema. Slinger PD. **J Cardiothorac Vasc Anesth** 1995 Aug;9(4):442-51 (52 ref.)

[The treatment of intraoperative arterial hypertension with Urapidil] Filosso PL. **Minerva Cardioangiol** 1996 Apr; 44(4):197-207 (45 ref.) **(Ita)**

[Morbid obesity. Reflections on a surgical protocol (I). A clinical and peroperative protocol] Alastrué A, et al. **Nutr Hosp** 1995 Nov-Dec;10(6):307-20 (80 ref.) (Eng. Abstr.) **(Spa)**

METHODS

Use of Oxygent, a perfluorochemical-based oxygen carrier, as an alternative to intraoperative blood transfusion. Keipert PE. **Artif Cells Blood Substit Immobil Biotechnol** 1995; 23(3):381-94 (29 ref.)

Ensuring adequate cerebral perfusion during aneurysm surgery [editorial] Miller JD. **Br J Anaesth** 1995 Nov; 75(5):518-9 (12 ref.)

Intraoperative radiation therapy and Mohs micrographic surgery on an outpatient basis. Siegle RJ, et al. **Dermatol Surg** 1995 Nov;21(11):975-8 (16 ref.)

Intra-operative ultrasound in detection of liver metastases. Meijer S, et al. **Eur J Cancer** 1995 Jul-Aug; 31A(7-8):1210-1 (10 ref.)

Patient-controlled intraoperative sedation. Herrick IA. **J Clin Anesth** 1996 May;8(3 Suppl):73S-75S (13 ref.)

Perioperative use of propofol for cardiac surgery. Jain U. **J Clin Anesth** 1996 May;8(3 Suppl):61S-66S (81 ref.)

Intravascular ultrasound assessment in carotid interventions. Reid DB, et al. **J Endovasc Surg** 1996 May;3(2):203-10 (9 ref.)

Consensus conference on autologous transfusion. Perioperative red cell salvage. Desmond MJ, et al. **Transfusion** 1996 Jul;36(7):644-51 (49 ref.)

[Which technique should be chosen to reuse blood lost intraoperatively? Does the type of surgery constitute any contraindication for reutilization (cancer, infection)?] Lefevre P. **Ann Fr Anesth Reanim** 1995;14 Suppl 1:53-62 (104 ref.) **(Fre)**

[Intraoperative radiotherapy of ORL cancers. Review of the literature] Demange L. **Bull Cancer Radiother** 1996; 83(2):75-8 (25 ref.) (Eng. Abstr.) **(Fre)**

[Intraoperative radiotherapy in gastrointestinal tumors] Frommhold H, et al. **Schweiz Rundsch Med Prax** 1996 Mar 5;85(10):295-8 (25 ref.) (Eng. Abstr.) **(Ger)**

NURSING

Intraoperative positioning of surgical patients. McEwen DR. **AORN J** 1996 Jun;63(6):1059-63, 1066-79; quiz 1080-6 (38 ref.)

TRENDS

Past, present, and future of intraoperative irradiation for colorectal cancer [editorial] Gunderson LL. **Int J Radiat Oncol Biol Phys** 1996 Feb 1;34(3):741-4 (12 ref.)

INTRAOPERATIVE COMPLICATIONS

Assessment of cardiac risk in noncardiac surgery. Forgosh LB, et al. **Clin Cardiol** 1995 Oct;18(10):556-62 (45 ref.)

Intraoperative retinal phototoxicity. Michels M. **Int Ophthalmol Clin** 1995 Fall;35(4):157-72 (91 ref.)

Predicting perioperative stroke. Kim J, et al. **J Neurosurg Anesthesiol** 1995 Jul;7(3):211-5 (24 ref.)

Intraoperative fire with electrocautery. Brechtelsbauer PB, et al. **Otolaryngol Head Neck Surg** 1996 Feb;114(2):328-31 (17 ref.)

[Intraoperative cardiac risk and preoperative examinations from the anesthetic viewpoint] Rolf N, et al. **Dtsch Med Wochenschr** 1996 Apr 5;121(14):453-8 (47 ref.) **(Ger)**

BLOOD

Thrombophilia and the surgeon. Rhodes EG. **Ann R Coll Surg Engl** 1996 Jul;78(4):331-5 (33 ref.)

CHEMICALLY INDUCED

Perioperative angioedema in a patient on long-term angiotensin-converting enzyme (ACE)-inhibitor therapy. Ogbureke KU, et al. **J Oral Maxillofac Surg** 1996 Jul; 54(7):917-20 (18 ref.)

[Heart arrest in children after intravenous injection of succinylcholine in the ENT operating room (see comments)] Schulte-Sasse U. **HNO** 1995 Nov;43(11):676-9 (29 ref.) (Eng. Abstr.) Comment in: Hosp Formul 1995 Nov;43(11):640-1. **(Ger)**

DIAGNOSIS

Role of cytology in intraoperative diagnosis. A practical guide. Czerniak B, et al. **Pathol Annu** 1995;30 Pt 2:83-102 (52 ref.)

[Recommendations for initial diagnosis and therapy in acute blood coagulation disorders] Sütterlin R, et al. **Anaesthesiol Reanim** 1996;21(3):76-80 (24 ref.) (Eng. Abstr.) **(Ger)**

[Perioperative and postoperative normovolemic anemia. Physiological compensation, monitoring and risk evaluation] Ostgaard G. **Tidsskr Nor Laegeforen** 1996 Jan 10;116(1):57-60 (43 ref.) (Eng. Abstr.) **(Nor)**

DRUG THERAPY

[The treatment of intraoperative arterial hypertension with Urapidil] Filosso PL. **Minerva Cardioangiol** 1996 Apr; 44(4):197-207 (45 ref.) **(Ita)**

EPIDEMIOLOGY

Complications of gynecologic laparoscopic surgery. Querleu D, et al. **Curr Opin Obstet Gynecol** 1995 Aug;7(4):257-61 (18 ref.)

Splenectomy complicating left nephrectomy [see comments] Cooper CS, et al. **J Urol** 1996 Jan;155(1):30-6 (46 ref.) Comment in: J Urol 1996 Jan;155(1):37.

ETIOLOGY

Complications of laparoscopic cholecystectomy. Jones DB, et al. **Annu Rev Med** 1996;47:31-44 (45 ref.)

Tumor embolism to LAD during pneumonectomy. A case report. Shah R, et al. **J Cardiovasc Surg (Torino)** 1996 Jun; 37(3):319-21 (13 ref.)

The etiology and management of inadvertent perioperative hypothermia. Forstot RM. **J Clin Anesth** 1995 Dec; 7(8):657-74 (188 ref.)

Venous gas embolism during cryosurgery for bone tumors. Schreuder HW, et al. **J Surg Oncol** 1995 Nov;60(3):196-200 (11 ref.)

-Complications. Surgical endoscopy versus gynecologic minimal invasive surgery- Wallwiener D, et al. **Arch Gynecol Obstet** 1995;256 Suppl:S21-31 (18 ref.) **(Ger)**

-Complications of hysteroscopy and laparoscopy from the anesthesiologic viewpoint- Zollinger A. **Arch Gynecol Obstet** 1995;256 Suppl:S12-20 (25 ref.) **(Ger)**

[Local complications of intramedullary nailing] Strecker W, et al. **Orthopade** 1996 Jun;25(3):274-91 (59 ref.) (Eng. Abstr.) **(Ger)**

[Complications of patient positioning] Staender S. **Swiss Surg** 1995;(3):152-5 (16 ref.) (Eng. Abstr.) **(Ger)**

[Complications of laparoscopic interventions in urology] Fahlenkamp D, et al. **Urologe A** 1996 May;35(3):238-45 (20 ref.) (Eng. Abstr.) **(Ger)**

[Cytokines during the perisurgical period] Kawamura T. **Masui** 1996 May;45(5):536-46 (29 ref.) (Eng. Abstr.) **(Jpn)**

[Air embolism in neurosurgical interventions] Lubnin AIu, et al. **Zh Vopr Neirokhir Im N N Burdenko** 1995 Oct-Dec; (4):33-8 (80 ref.) **(Rus)**

IMMUNOLOGY

[Anesthesiologic pecularities in patients with latex allergy (see comments)] Kisch H, et al. **Anaesthesist** 1996 Jul; 45(7):587-96 (88 ref.) (Eng. Abstr.) Comment in: Anaesthesist 1996 Jul;45(7):585-6. **(Ger)**

PHYSIOPATHOLOGY

[Cardiovascular function during laparoscopic interventions in surgery and gynecology] Berg K, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Nov; 30(7):446-50 (28 ref.) **(Ger)**

[Anesthesiologic procedures in laparoscopic cholecystectomy] Wilhelm W, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Nov; 30(7):450-4 (18 ref.) **(Ger)**

PREVENTION & CONTROL

Minimising cardiac anaesthetic risk: the tortoise or the hare? Juste RN, et al. **Anaesthesia** 1996 Mar;51(3):255-62 (63 ref.)

Manipulation of local and systemic host defence in the prevention of perioperative sepsis. Windsor AC, et al. **Br J Surg** 1995 Nov;82(11):1460-7 (128 ref.)

Intraoperative complications during total hip arthroplasty. Patterson BM, et al. **Orthopedics** 1995 Nov;18(11):1089-95 (69 ref.)

[The high risk cardiac patient in anesthesia] Francke A. **Anaesthesiol Reanim** 1996;21(2):32-42 (89 ref.) (Eng. Abstr.) **(Ger)**

[Problems and limits in noninvasive oxygen monitoring] Bardenheuer HJ, et al. **Anaesthesist** 1996 Jul;45(7):614-25 (86 ref.) (Eng. Abstr.) **(Ger)**

[Medicamentous prevention of acid aspiration syndrome] Kurz-Müller K, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May; 31(4):261-5 (77 ref.) **(Ger)**

[Is traditional preoperative fasting still applicable?] Wrenger K, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May; 31(4):250-4 (36 ref.) **(Ger)**

[Function-controlled neurosurgery. Neurophysiologic and neuropsychological monitoring during surgery of the nervous system] Schmid UD, et al. **Nervenarzt** 1995 Aug; 66(8):582-95 (84 ref.) (Eng. Abstr.) **(Ger)**

PSYCHOLOGY

[Awareness during general anesthesia. Definition, incidence, clinical relevance, causes, avoidance and medicolegal aspects] Schwender D, et al. **Anaesthesist** 1995 Nov; 44(11):743-54 (84 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

[Bowel complications in gynecologic laparoscopic surgery and their immediate repair without laparotomy. Four cases] Renault B, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996; 25(4):360-4 (16 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

[Treatment of aspiration of gastric contents] Müller E. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May; 31(4):265-9 (24 ref.) **(Ger)**

[An impassable iatrogenic lesion of the common bile duct at its junction: its recanalization via a combined percutaneous-endoscopic approach. A case] Ferro C, et al. **Radiol Med (Torino)** 1996 Apr;91(4):488-91 (16 ref.) **(Ita)**

[Bronchospasm during anesthesia in a patient with Prader-Willi syndrome] Kawahito S, et al. **Masui** 1995 Dec;44(12):1675-9 (19 ref.) (Eng. Abstr.) **(Jpn)**

INTRAOPERATIVE MONITORING

Intra-operative monitoring is not essential. Malis LI. **Clin Neurosurg** 1995;42:203-13 (8 ref.)

Neurophysiologic monitoring during cranial base surgery: is it necessary? Sekhar LN, et al. **Clin Neurosurg** 1995; 42:180-202 (37 ref.)

The role of neuromonitoring in cardiovascular surgery. Edmonds HL Jr, et al. **J Cardiothorac Vasc Anesth** 1996 Jan;10(1):15-23 (51 ref.)

Neuromonitoring during hypothermic cardiopulmonary bypass. Gombotz H. **J Neurosurg Anesthesiol** 1995 Oct; 7(4):289-96 (82 ref.)

Intraoperative electrocorticography in children with medically intractable epilepsy. Tanaka T, et al. **Neurol Med Chir (Tokyo)** 1996 Jul;36(7):440-6 (21 ref.)

[Intraoperative awareness and auditory evoked potentials] Schwender D, et al. **Anaesthesist** 1996 Feb;45 Suppl 1:S46-51 (30 ref.) (Eng. Abstr.) **(Ger)**

[Clinical potency of nitrous oxide--is MAC the gold standard?] Schwilden H, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Oct; 30(6):337-40 (23 ref.) (Eng. Abstr.) **(Ger)**

[Clinical usefulness of neuromuscular monitor] Amaki Y. **Masui** 1995;44 Suppl:S100-5 (9 ref.) **(Jpn)**

[Establishment of the criteria to evaluate intraoperative changes of brainstem auditory evoked potentials during microvascular decompression and acoustic neurinoma excision] Sekiya T, et al. **No Shinkei Geka** 1996 May; 24(5):431-6 (55 ref.) (Eng. Abstr.) **(Jpn)**

INSTRUMENTATION

Neurophysiological monitoring of cranial nerves during posterior fossa surgery. Broggi G, et al. **Acta Neurochir Suppl (Wien)** 1995;64:35-9 (16 ref.)

Microelectrode monitoring of cortical and subcortical structures during stereotactic surgery. Lozano AM, et al. **Acta Neurochir Suppl (Wien)** 1995;64:30-4 (19 ref.)

[Anesthesia with low fresh gas flow in clinical routine use (see comments)] Hargasser S, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Aug;

30(5):268–75 (79 ref.) (Eng. Abstr.) Comment in: Anasthesiol Intensivmed Notfallmed Schmerzther 1995 Aug;30(5):265–7. **(Ger)**

METHODS

The gastric tonometer. A valuable monitor of splanchnic perfusion? Trinder TJ, et al. **Anaesthesia** 1996 Feb; 51(2):161–70 (142 ref.)

Intraoperative transoesophageal echocardiography for implantation of a pulsatile left ventricular assist device. George SJ, et al. **Br J Anaesth** 1995 Dec;75(6):794–7 (9 ref.)

Patient preparation and monitoring for carotid stenting: the operating room nurse's perspective. Plat S, et al. **J Endovasc Surg** 1996 May;3(2):224–7 (6 ref.)

[Problems and limits in noninvasive oxygen monitoring] Bardenheuer HJ, et al. **Anaesthesist** 1996 Jul;45(7):614–25 (86 ref.) (Eng. Abstr.) **(Ger)**

TRENDS

Spinal cord and nerve root monitoring in spine surgery and related procedures. Herdmann J, et al. **Spine** 1996 Apr 1; 21(7):879–85 (20 ref.)

INTRAOPERATIVE PERIOD

Perioperative management of drug therapy, clinical considerations. Smith MS, et al. **Drugs** 1996 Feb; 51(2):238–59 (181 ref.)

INTRAOSSEOUS GANGLION see **BONE CYSTS**

INTRAPERITONEAL INFUSIONS see **INFUSIONS, PARENTERAL**

INTRASPINAL INJECTIONS see **INJECTIONS, SPINAL**

INTRATHECAL INJECTIONS see **INJECTIONS, SPINAL**

INTRAUTERINE CROSS-TRANSFUSION see **FETOFETAL TRANSFUSION**

INTRAUTERINE DEVICES

Current assessment of the use of intrauterine devices. Westhoff CL. **J Nurse Midwifery** 1996 May–Jun; 41(3):218–23 (41 ref.)

IUDs—an update. **Popul Rep B** 1995 Dec;(6):1–35 (656 ref.)

ADVERSE EFFECTS

Intrauterine contraceptive device–associated actinomycotic abscess and Actinomyces detection on cervical smear. Fiorino AS. **Obstet Gynecol** 1996 Jan;87(1):142–9 (107 ref.)

[Uterine perforation and localization of an IUD in the bladder associated with bladder calculosis. Report of a case and review of the literature] Reyes-Acevedo J, et al. **Ginecol Obstet Mex** 1995 Oct;63:407–9 (13 ref.) (Eng. Abstr.) **(Spa)**

INTRAUTERINE DEVICES, COPPER

STANDARDS

Consensus statement on emergency contraception. **Contraception** 1995 Oct;52(4):211–3 (6 ref.)

INTRAUTERINE DEVICES, MEDICATED

Long-acting contraceptive options. Kaunitz AM. **Int J Fertil Menopausal Stud** 1996 Mar–Apr;41(2):69–76 (54 ref.)

[Levonorgestrel capsules: a big leap forward in intrauterine contraception] Hamerlynck JV. **Ned Tijdschr Geneeskd** 1996 Jun 8;140(23):1212–4 (17 ref.) **(Dut)**

STANDARDS

The progestin-only pills and the levonorgestrel-releasing IUD: two progestin-only contraceptives. Chi IC. **Clin Obstet Gynecol** 1995 Dec;38(4):872–89 (71 ref.)

Levonorgestrel-releasing IUD as a method of contraception with therapeutic properties. Luukkainen T, et al. **Contraception** 1995 Nov;52(5):269–76 (41 ref.)

INTRAUTERINE DIAGNOSIS see **PRENATAL DIAGNOSIS**

INTRAUTERINE GROWTH RETARDATION see **FETAL GROWTH RETARDATION**

INTRAUTERINE TRANSFUSION see **BLOOD TRANSFUSION, INTRAUTERINE**

INTRAVENOUS ANESTHETICS see **ANESTHETICS, INTRAVENOUS**

INTRAVENOUS DRIP see **INFUSIONS, INTRAVENOUS**

INTRAVENOUS DRUG ABUSE see **SUBSTANCE ABUSE, INTRAVENOUS**

INTRAVENOUS DRUG DELIVERY SYSTEMS see **INFUSION PUMPS**

INTRAVENOUS FEEDING see **PARENTERAL NUTRITION**

INTRAVENOUS HYPERALIMENTATION see **PARENTERAL NUTRITION, TOTAL**

INTRAVENOUS IMMUNOGLOBULINS see **IMMUNOGLOBULINS, INTRAVENOUS**

INTRAVENOUS INFUSIONS see **INFUSIONS, INTRAVENOUS**

INTRINSIC FACTOR

METABOLISM

Malabsorption of food cobalamin. Carmel R. **Baillieres Clin Haematol** 1995 Sep;8(3):639–55 (67 ref.)

Gastric intrinsic factor and its receptor. Nicolas JP, et al. **Baillieres Clin Haematol** 1995 Sep;8(3):515–31 (99 ref.)

INTRONS

Structure and activities of group II introns. Michel F, et al. **Annu Rev Biochem** 1995;64:435–61 (148 ref.)

Do imprinted genes have few and small introns? Haig D. **Bioessays** 1996 May;18(5):351–3 (21 ref.)

Secondary structure conservation of the U3 small nucleolar RNA introns in Saccharomyces. Brulé F, et al. **C R Acad Sci III** 1995 Dec;318(12):1197–206 (48 ref.)

Evolution of the intron–exon structure of eukaryotic genes. Long M, et al. **Curr Opin Genet Dev** 1995 Dec;5(6):774–8 (58 ref.)

General vectors for archaeal hyperthermophiles: strategies based on a mobile intron and a plasmid. Aagaard C, et al. **FEMS Microbiol Rev** 1996 May;18(2–3):93–104 (38 ref.)

Mechanisms of intron mobility. Belfort M, et al. **J Biol Chem** 1995 Dec 22;270(51):30237–40 (55 ref.)

Retention of CD44 introns in bladder cancer: understanding the alternative splicing of pre-mRNA opens new insights into the pathogenesis of human cancers [editorial] Cooper DL. **J Pathol** 1995 Sep;177(1):1–3 (28 ref.)

AT-AC introns: an ATtACk on dogma [comment] Mount SM. **Science** 1996 Mar 22;271(5256):1690–2 (12 ref.) Comment on: Science 1996 Mar 22;271(5256):1716–8.

[Mitochondrial introns of fungi and their role in evolution] Shnyreva AV. **Genetika** 1995 Jul;31(7):869–76 (46 ref.) (Eng. Abstr.) **(Rus)**

GENETICS

Retrohoming: cDNA-mediated mobility of group II introns requires a catalytic RNA. Curcio MJ, et al. **Cell** 1996 Jan 12;84(1):9–12 (15 ref.)

Exonic MHC-DRB polymorphisms and intronic simple repeat sequences: Janus' faces of DNA sequence evolution. Schwaiger FW, et al. **Immunol Rev** 1995 Feb;143:199–224 (55 ref.)

INTUBATION

Risk factors for asthmatic patients requiring intubation: A comprehensive review. LeSon S, et al. **Allergol Immunopathol (Madr)** 1995 Sep–Oct;23(5):235–47 (133 ref.)

Endoscopic intubation of oesophagogastric malignancy. Hill J, et al. **Eur J Gastroenterol Hepatol** 1995 Sep;7(9):815–6 (8 ref.)

INTUBATION, ENDOTRACHEAL see **INTUBATION, INTRATRACHEAL**

INTUBATION, GASTROINTESTINAL

A comparison of small-intestinal mucosal biopsies in children obtained by blind suction capsule with those obtained by endoscopy. Branski D, et al. **J Pediatr Gastroenterol Nutr** 1996 Feb;22(2):194–6 (17 ref.)

ADVERSE EFFECTS

Complications of percutaneous endoscopic gastrostomy. Schapiro GD, et al. **Gastrointest Endosc Clin N Am** 1996 Apr;6(2):409–22 (52 ref.)

INTUBATION, INTRATRACHEAL

Onset time and evaluation of intubating conditions: rocuronium in perspective. Agoston S. **Eur J Anaesthesiol Suppl** 1995 Sep;11:31–7 (14 ref.)

Pro: early extubation after cardiac surgery decreases intensive care unit stay and cost [see comments] Cheng DC. **J Cardiothorac Vasc Anesth** 1995 Aug;9(4):460–4 (45 ref.) Comment in: J Cardiothorac Vasc Anesth 1995 Aug;9(4):465–7.

Con: early extubation after cardiac surgery does not decrease intensive care unit stay and cost [comment] Guenther CR. **J Cardiothorac Vasc Anesth** 1995 Aug;9(4):465–7 (12 ref.) Comment on: J Cardiothorac Vasc Anesth 1995 Aug;9(4):460–4.

Management of upper airway obstruction: intubation vs tracheotomy. Bu Saba NY, et al. **J Med Liban** 1994; 42(4):235–9 (18 ref.)

Laser treatment of lower airway stenosis. Coleman JA Jr, et al. **Otolaryngol Clin North Am** 1995 Aug;28(4):771–83 (8 ref.)

[Difficult intubation in adults] Langenstein H, et al. **Anaesthesist** 1996 Apr;45(4):372–83 (39 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Controlling the hemodynamic response to laryngoscopy and endotracheal intubation. Kovac AL. **J Clin Anesth** 1996 Feb;8(1):63–79 (166 ref.)

Arytenoid dislocation. Faries PL, et al. **Otolaryngol Head Neck Surg** 1996 Jul;115(1):160–2 (9 ref.)

Histopathologic fundamentals of acquired laryngeal stenosis. Liu H, et al. **Pediatr Pathol Lab Med** 1995 Sep–Oct; 15(5):655–77 (26 ref.)

[Tracheal rupture secondary to intubation or tracheostomy] Varela G, et al. **Arch Bronconeumol** 1995 Oct;31(8):421–3 (11 ref.) (Eng. Abstr.) **(Spa)**

ECONOMICS

Economic rationale for early extubation. Velasco FT, et al. **J Cardiothorac Vasc Anesth** 1995 Oct;9(5 Suppl 1):2–9 (17 ref.)

INSTRUMENTATION

[Peculiarities of endotracheal intubation in the child] Grüness V, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Dec; 30(8):479–82 (10 ref.) **(Ger)**

[Intubation trauma of the larynx—a literature review with special reference to arytenoid cartilage dislocation (see comments)] Rieger A, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Jun; 31(5):281–7 (37 ref.) (Eng. Abstr.) Comment in: Anasthesiol Intensivmed Notfallmed Schmerzther 1996 Jun;31(5):279–80. **(Ger)**

METHODS

Rapid-sequence intubation of the pediatric patient. Pediatric Emergency Medicine Committee of the American College of Emergency Physicians [see comments] Gerardi MJ, et al. **Ann Emerg Med** 1996 Jul;28(1):55–74 (200 ref.) Comment in: Ann Emerg Med 1996 Jul;28(1):79–81.

Timing of tracheal extubation in adult cardiac surgery patients [published erratum appears in J Card Surg 1995 Nov;10(6):following table of contents] Hickey RF, et al. **J Card Surg** 1995 Jul;10(4 Pt 1):340–8 (44 ref.)

Safety issues regarding early extubation after coronary artery bypass surgery. Higgins TL. **J Cardiothorac Vasc Anesth** 1995 Oct;9(5 Suppl 1):24–9 (52 ref.)

Changes in cardiovascular surgical approaches to achieve early extubation. Verrier ED, et al. **J Cardiothorac Vasc Anesth** 1995 Oct;9(5 Suppl 1):10–5 (23 ref.)

NURSING

Mastering emergency airway management. Somerson SJ, et al. **Am J Nurs** 1996 May;96(5):24–30; quiz 31 (11 ref.)

INTUBATION, NASOGASTRIC see **INTUBATION, GASTROINTESTINAL**

INTUSSUSCEPTION

Intussusception. Winslow BT, et al. **Am Fam Physician** 1996 Jul;54(1):213–7, 220 (19 ref.)

DIAGNOSIS

Intussusception. Issues and controversies related to diagnosis and reduction. Daneman A, et al. **Radiol Clin North Am** 1996 Jul;34(4):743–56 (59 ref.)

ETIOLOGY

Small bowel intussusception and brown bowel syndrome in association with severe malnutrition. Drake WM, et al. **Am J Gastroenterol** 1996 Jul;91(7):1450–2 (20 ref.)

A rare case of multiple intussusceptions: intense segmentary lipomatosis of the ileum. Young TH, et al. **Am J Gastroenterol** 1996 Jan;91(1):162–3 (10 ref.)

[Yersinia enterocolitica: a cause of acute intestinal intussusception] Barthod F, et al. **Presse Med** 1996 Apr 20;25(14):668–70 (13 ref.) (Eng. Abstr.) **(Fre)**

[An adult case of intussusception due to inverted Meckel's diverticulum accompanied by angiolipoma] Kaneko T, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Apr;93(4):260–5 (14 ref.) **(Jpn)**

SURGERY

[Atopic stomach polyp as the cause of invagination of Meckel's diverticulum] Schütter FW, et al. **Chirurg** 1995 Oct;66(10):1016–8 (24 ref.) (Eng. Abstr.) **(Ger)**

INULIN

ANALYSIS

On the presence of inulin and oligofructose as natural ingredients in the western diet. van Loo J, et al. **Crit Rev Food Sci Nutr** 1995 Nov;35(6):525–52 (102 ref.)

BLOOD

[Inulin] Iino Y. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:1071–3 (13 ref.) **(Jpn)**

DIAGNOSTIC USE

Conventional measurement of renal function utilizing serum creatinine, creatinine clearance, inulin and para-aminohippuric acid clearance. Toto RD. **Curr Opin Nephrol Hypertens** 1995 Nov;4(6):505–9; discussion 503–4 (21 ref.)

[Inulin] Iino Y. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:1071–3 (13 ref.) **(Jpn)**

IMMUNOLOGY

Vaccine adjuvants based on gamma inulin. Cooper PD. **Pharm Biotechnol** 1995;6:559–80 (73 ref.)

INVASIVENESS, NEOPLASM see **NEOPLASM INVASIVENESS**

INVERSE PCR see **POLYMERASE CHAIN REACTION**

INVERSION (GENETICS)

Inversion duplication of the short arm of chromosome 8: clinical data on seven patients and review of the literature. de Die-Smulders CE, et al. **Am J Med Genet** 1995 Nov 20;59(3):369–74 (16 ref.)

Clinical and cytogenetic findings in seven cases of inverted duplication of 8p with evidence of a telomeric deletion using fluorescence in situ hybridization [see comments] Guo WJ, et al. **Am J Med Genet** 1995 Sep 11;58(3):230–6 (20 ref.) Comment in: Am J Med Genet 1995 Sep 11;58(3):237.

Transforming properties of the leukemic inv(16) fusion gene CBFB-MYH11. Hajra A, et al. **Curr Top Microbiol Immunol** 1996;211:289–98 (23 ref.)

Paracentric inversions: a review. Madan K. **Hum Genet** 1995 Nov;96(5):503–15 (109 ref.)

The cyclin D1/PRAD1 oncogene in human neoplasia. Arnold A. **J Investig Med** 1995 Dec;43(6):543–9 (44 ref.)

INVERTEBRATE GANGLIA see **GANGLIA, INVERTEBRATE**

INVERTEBRATE HORMONES

PHYSIOLOGY

Platyhelminth FMRFamide-related peptides. Shaw C, et al. **Int J Parasitol** 1996 Apr;26(4):335–45 (59 ref.)

INVERTEBRATE PEPTIDE RECEPTORS see **RECEPTORS, INVERTEBRATE PEPTIDE**

INVERTEBRATE PHOTORECEPTORS see **PHOTORECEPTORS, INVERTEBRATE**

INVERTEBRATES

[Specification of glial lineage in invertebrates] Vincent S, et al. **C R Seances Soc Biol Fil** 1995;189(2):245–52 (27 ref.) (Eng. Abstr.) **(Fre)**

ANATOMY & HISTOLOGY

Developmental evolution of metazoan bodyplans: the fossil evidence. Valentine JW, et al. **Dev Biol** 1996 Feb 1; 173(2):373–81 (88 ref.)

EMBRYOLOGY

Invertebrate versus vertebrate neurogenesis: variations on the same theme? Salzberg A, et al. **Dev Genet** 1996;18(1):1–10 (128 ref.)

ENZYMOLOGY

Nitric oxide synthase in invertebrates. Martínez A. **Histochem J** 1995 Oct;27(10):770–6 (55 ref.)

GENETICS

Protein families in the metazoan genome. Chothia C. **Dev Suppl** 1994;:27–33 (41 ref.)

Studies of DNA methylation in animals. Bird A, et al. **J Cell Sci Suppl** 1995;19:37–9 (23 ref.)

Concerted evolution of repetitive DNA sequences in eukaryotes. Elder JF Jr, et al. **Q Rev Biol** 1995 Sep; 70(3):297–320 (146 ref.)

[Comparison of 18S ribosomal RNA genes in invertebrate phylogeny] Aleshin VV, et al. **Mol Biol (Mosk)** 1995 Nov-Dec;29(6):1408–26 (58 ref.) **(Rus)**

GROWTH & DEVELOPMENT

Programmed cell death in development. Sanders EJ, et al. **Int Rev Cytol** 1995;163:105–73 (410 ref.)

METABOLISM

Vanadium transport in animal systems. Kustin K, et al. **Met Ions Biol Syst** 1995;31:511–42 (88 ref.)

PARASITOLOGY

The genus Hepatozoon (Apicomplexa: Adeleina). Smith TG. **J Parasitol** 1996 Aug;82(4):565–85 (118 ref.)

PHYSIOLOGY

Structure and cellular physiology of Ca2+ stores in invertebrate photoreceptors. Walz B, et al. **Cell Calcium** 1995 Oct;18(4):342–51 (52 ref.)

Molecular genetic analysis of circadian rhythms in vertebrates and invertebrates. Sehgal A. **Curr Opin Neurobiol** 1995 Dec;5(6):824–31 (73 ref.)

ULTRASTRUCTURE

Ultrastructure of invertebrate muscle cell types. Paniagua R, et al. **Histol Histopathol** 1996 Jan;11(1):181–201 (151 ref.)

INVERTED REPEAT SEQUENCE see **REPETITIVE SEQUENCES, NUCLEIC ACID**

INVESTIGATIONAL NEW DRUGS see **DRUGS, INVESTIGATIONAL**

INVOLUNTARY COMMITMENT see **COMMITMENT OF MENTALLY ILL**

IODAMOEBIASIS see **AMEBIASIS**

IODIDE PEROXIDASE

IMMUNOLOGY

Analytical and clinical performance goals for testing autoantibodies to thyroperoxidase, thyroglobulin, and thyrotropin receptor. Feldt-Rasmussen U. **Clin Chem** 1996 Jan;42(1):160–3 (20 ref.)

PHYSIOLOGY

Thyroid hormone deiodinases—a selenoenzyme family acting as gate keepers to thyroid hormone action. Köhrle J. **Acta Med Austriaca** 1996;23(1–2):17–30 (134 ref.)

Nutritional and hormonal regulation of thyroid hormone deiodinases. Larsen PR, et al. **Annu Rev Nutr** 1995; 15:323–52 (149 ref.)

IODINASE see **IODIDE PEROXIDASE**

IODINE

ADVERSE EFFECTS

Effects of iodine on thyroid function. Braverman LE, et al. **Acta Med Austriaca** 1996;23(1–2):4–9 (71 ref.)

DEFICIENCY

Administration of iodized oil during pregnancy: a summary of the published evidence. Delange F. **Bull World Health Organ** 1996;74(1):101–8 (74 ref.)

Role of goitrogens in iodine deficiency disorders & brain development. Rao PS, et al. **Indian J Med Res** 1995 Nov; 102:223–6 (16 ref.)

Seven deadly sins in confronting endemic iodine deficiency, and how to avoid them. Dunn JT. **J Clin Endocrinol Metab** 1996 Apr;81(4):1332–5 (22 ref.)

Iodine in the diet: perspectives for vegans. Lightowler HJ, et al. **J R Soc Health** 1996 Feb;116(1):14–20 (43 ref.)

Iodine deficiency disorders: a public health challenge in developing countries. Ali O. **Nutrition** 1995 Sep-Oct;11(5 Suppl):517–20 (23 ref.)

[Progresses in endemiology in China, 1995] Wang Z, et al. **Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):764–5 (0 ref.) **(Chi)**

[Endemic iodine deficiency in Hungary and possibilities of iodine substitution] Bogye G, et al. **Orv Hetil** 1996 Feb 11;137(6):287–90 (25 ref.) (Eng. Abstr.) **(Hun)**

PHARMACOLOGY

Evidence that iodolactones are the mediators of growth inhibition by iodine on the thyroid. Gärtner R, et al. **Acta Med Austriaca** 1996;23(1–2):47–51 (34 ref.)

STANDARDS

Human requirements of iodine & safe use of iodised salt. Ranganathan S, et al. **Indian J Med Res** 1995 Nov; 102:227–32 (21 ref.)

IODINE RADIOISOTOPES

Hypothyroidism and spontaneous abortions among Hanford, Washington, downwinders. Grossman CM, et al. **Arch Environ Health** 1996 May-Jun;51(3):175–6 (8 ref.)

ADMINISTRATION & DOSAGE

125I seeds implantation plus pelvic lymphadenectomy in the management of localized prostate cancer. D'Addessi A, et al. **Minerva Urol Nefrol** 1995 Sep;47(3):105–11 (33 ref.)

ADVERSE EFFECTS

Chronic myeloid leukaemia following 131I treatment for thyroid carcinoma: a report of two cases and review of the literature. Shimon I, et al. **Clin Endocrinol (Oxf)** 1995 Nov;43(5):651–4 (21 ref.)

DIAGNOSTIC USE

Radiopharmaceutical diagnosis and therapy of sympatho-medullary disorders. Shapiro B. **Ann Nucl Med** 1996 Feb;10(1):9–12 (34 ref.)

Imaging amyloidosis with radiolabelled SAP [editorial] Hawkins PN, et al. **Eur J Nucl Med** 1995 Jul;22(7):595–9 (29 ref.)

Cardiac studies with metaiodobenzylguanidine: a critique of methods and interpretation of results. Glowniak JV. **J Nucl Med** 1995 Nov;36(11):2133–7 (41 ref.)

Iodine-123-labeled glucose analogs: prospects for a single-photon-emitting analog of fluorine-18-labeled deoxyglucose [editorial; comment] Gatley SJ. **Nucl Med Biol** 1995 Oct;22(7):829–35 (49 ref.) Comment on: Nucl Med Biol 1995 Oct;22(7):875–85.

Radiolabelled peptides: now and the future. Thakur ML. **Nucl Med Commun** 1995 Sep;16(9):724–32 (41 ref.)

Radioimmunoguided Surgery system improves survival for patients with recurrent colorectal cancer. Bertsch DJ, et al. **Surgery** 1995 Oct;118(4):634–8; discussion 638–9 (9 ref.)

[Image diagnosis of heart diseases using new radioisotope compounds] Nishimural T. **Nippon Naika Gakkai Zasshi** 1995 Sep 10;84(9):1564–8 (8 ref.) **(Jpn)**

THERAPEUTIC USE

Radiopharmaceutical diagnosis and therapy of sympatho-medullary disorders. Shapiro B. **Ann Nucl Med** 1996 Feb;10(1):9–12 (34 ref.)

Radioiodine therapy for thyroid cancer. Sweeney DC, et al. **Endocrinol Metab Clin North Am** 1995 Dec;24(4):803–39 (127 ref.)

Radiolabelled mIBG in the treatment of neuroblastoma. Gaze MN, et al. **Eur J Cancer** 1996 Jan;32A(1):93–6 (33 ref.)

131I treatment of nodular non-toxic goitre. Nygaard B, et al. **Eur J Endocrinol** 1996 Jan;134(1):15–20 (60 ref.)

Operation and permanent low activity 125I brachytheraphy for recurrent high-grade astrocytomas. Halligan JB, et al. **Int J Radiat Oncol Biol Phys** 1996 Jun 1;35(3):541–7 (24 ref.)

Preclinical animal studies with radioiododeoxyuridine. Kassis AI, et al. **J Nucl Med** 1996 Apr;37(4 Suppl):10S–12S (25 ref.)

Radiation protection issues associated with nuclear medicine out-patients [see comments] Thomson WH, et al. **Nucl Med Commun** 1995 Nov;16(11):879–92 (43 ref.) Comment in: Nucl Med Commun 1995 Nov;16(11):877–8.

Therapy of neuroendocrine tumors with radiolabeled MIBG and somatostatin analogues. Wiseman GA, et al. **Semin Nucl Med** 1995 Jul;25(3):272–8 (39 ref.)

IODIZED OIL

ADVERSE EFFECTS

Delayed anoxic pseudolobular necrosis (terminal hepatic necrosis) after chemo-lipiodolization for hepatocellular carcinoma. Kozakai I, et al. **Am J Gastroenterol** 1996 Jun; 91(6):1263–5 (8 ref.)

THERAPEUTIC USE

Administration of iodized oil during pregnancy: a summary of the published evidence. Delange F. **Bull World Health Organ** 1996;74(1):101–8 (74 ref.)

IODOBENZENES

DIAGNOSTIC USE

Radiopharmaceutical diagnosis and therapy of sympatho-medullary disorders. Shapiro B. **Ann Nucl Med** 1996 Feb;10(1):9–12 (34 ref.)

Myocardial imaging of sympathetic nervous function by radiolabelled metaiodobenzylguanidine [editorial; comment] Nakagawa M. **Intern Med** 1996 Feb;35(2):85–6 (7 ref.) Comment on: Intern Med 1996 Feb;35(2):94–9.

Cardiac studies with metaiodobenzylguanidine: a critique of methods and interpretation of results. Glowniak JV. **J Nucl Med** 1995 Nov;36(11):2133–7 (41 ref.)

[Image diagnosis of heart diseases using new radioisotope compounds] Nishimural T. **Nippon Naika Gakkai Zasshi** 1995 Sep 10;84(9):1564–8 (8 ref.) **(Jpn)**

THERAPEUTIC USE

Radiopharmaceutical diagnosis and therapy of sympatho-medullary disorders. Shapiro B. **Ann Nucl Med** 1996 Feb;10(1):9–12 (34 ref.)

Radiolabelled mIBG in the treatment of neuroblastoma. Gaze MN, et al. **Eur J Cancer** 1996 Jan;32A(1):93–6 (33 ref.)

Therapy of neuroendocrine tumors with radiolabeled MIBG

and somatostatin analogues. Wiseman GA, et al. **Semin Nucl Med** 1995 Jul;25(3):272–8 (39 ref.)

IODODEOXYURIDINE see **IDOXURIDINE**

5-IODO-2'-DEOXYURIDINE see **IDOXURIDINE**

IODOPHORS

see related
ANTI-INFECTIVE AGENTS, LOCAL

IODOQUINOL

THERAPEUTIC USE

Is there any reason to continue treating Blastocystis infections? [editorial; comment] Markell EK. **Clin Infect Dis** 1995 Jul;21(1):104–5 (11 ref.) Comment on: Clin Infect Dis 1995 Jul;21(1):97–101.

IODOTHYRONINE DEIODINASE see **IODIDE PEROXIDASE**

IODOTHYRONINE 5'-DEIODINASE see **IODIDE PEROXIDASE**

IODOTYROSINE DEIODASE see **IODIDE PEROXIDASE**

IOHEXOL

ADVERSE EFFECTS

Case report: Pontine haemorrhage following iohexol lumbar myelography. Yeh YF, et al. **Br J Radiol** 1996 Apr; 69(820):368–70 (28 ref.)

ANALOGS & DERIVATIVES

Pharmacologic profile of iobitridol, a nonionic iodinated contrast medium. Idee JM, et al. **Acta Radiol Suppl** 1996; 400:35–48 (44 ref.)

ION CHANNEL GATING

Activation of ATP-sensitive potassium channels: a novel pharmacological approach to myocardial protection? Hearse DJ. **Cardiovasc Res** 1995 Jul;30(1):1–17 (94 ref.)
Ion channels. A physiological function for polyamines? Forsythe ID. **Curr Biol** 1995 Nov 1;5(11):1248–51 (19 ref.)
Ligand-gated calcium channels inside and out. Striggow F, et al. **Curr Opin Cell Biol** 1996 Aug;8(4):490–5 (57 ref.)
An anesthetic-sensitive superfamily of neurotransmitter-gated ion channels. Franks NP, et al. **J Clin Anesth** 1996 May;8(3 Suppl):3S–7S (32 ref.)
The molecular organization of voltage-dependent K+ channels in vivo. Sheng M, et al. **Prog Brain Res** 1995; 105:87–93 (30 ref.)

DRUG EFFECTS

Cyclic ADP-ribose, the ryanodine receptor and Ca2+ release. Sitsapesan R, et al. **Trends Pharmacol Sci** 1995 Nov; 16(11):386–91 (50 ref.)

PHYSIOLOGY

Cyclic nucleotide-gated ion channels: an extended family with diverse functions. Finn JT, et al. **Annu Rev Physiol** 1996;58:395–426 (246 ref.)
The structure, regulation and pathophysiology of potassium channels. Desir GV. **Curr Opin Nephrol Hypertens** 1995 Sep;4(5):402–5 (22 ref.)
Family of cyclic nucleotide gated ion channels. Kaupp UB. **Curr Opin Neurobiol** 1995 Aug;5(4):434–42 (92 ref.)
Hypoxic and metabolic regulation of voltage-gated K+ channels in rat pulmonary artery smooth muscle cells. Yuan XJ, et al. **Exp Physiol** 1995 Sep;80(5):803–13 (24 ref.)
Mechanisms of K+ channel regulation. Breitwieser GE. **J Membr Biol** 1996 Jul;152(1):1–11 (197 ref.)
Electrophysiological insights of type I and II Na/Pi transporters. Busch AE, et al. **Kidney Int** 1996 Apr; 49(4):986–7 (11 ref.)
Ca(2+)-activated K+ currents in neurones: types, physiological roles and modulation. Sah P. **Trends Neurosci** 1996 Apr;19(4):150–4 (66 ref.)

ION CHANNELS

see related
ION CHANNEL GATING
ION PUMPS

Aquaporin water channels: unanswered questions and unresolved controversies. Agre P, et al. **Curr Opin Cell Biol** 1995 Aug;7(4):472–83 (84 ref.)
Molecular mechanisms controlling calcium entry through AMPA-type glutamate receptor channels. Jonas P, et al. **Neuron** 1995 Nov;15(5):987–90 (30 ref.)
[Analysis of receptor-ion channel functions in Xenopus oocyte translation system] Kaneko S. **Nippon Yakurigaku Zasshi** 1995 Oct;106(4):243–53 (50 ref.) (Eng. Abstr.) **(Jpn)**
[SA channels are mechanosensors of cells?] Sokabe M, et al. **Tanpakushitsu Kakusan Koso** 1996 Jan;41(1):2–13 (43 ref.) **(Jpn)**

ANTAGONISTS & INHIBITORS

Ion channels. A physiological function for polyamines? Forsythe ID. **Curr Biol** 1995 Nov 1;5(11):1248–51 (19 ref.)
Basic concepts in cellular cardiac electrophysiology: Part II: Block of ion channels by antiarrhythmic drugs. Whalley DW, et al. **Pacing Clin Electrophysiol** 1995 Sep;18(9 Pt 1):1686–704 (119 ref.)

CHEMISTRY

Structure and function of the ion channel model system annexin V. Voges D, et al. **Adv Enzymol Relat Areas Mol Biol** 1995;71:209–39 (144 ref.)
Structure and function of voltage-gated ion channels. Catterall WA. **Annu Rev Biochem** 1995;64:493–531 (221 ref.)
Peptide models for membrane channels. Marsh D. **Biochem J** 1996 Apr 15;315 (Pt 2):345–61 (143 ref.)
Families of ion channels with two hydrophobic segments. North RA. **Curr Opin Cell Biol** 1996 Aug;8(4):474–83 (67 ref.)
The inhibitory glycine receptor: architecture, synaptic localization and molecular pathology of a postsynaptic ion-channel complex. Kuhse J, et al. **Curr Opin Neurobiol** 1995 Jun;5(3):318–23 (60 ref.)
Molecular mimicry in channel-protein structure. Montal M. **Curr Opin Struct Biol** 1995 Aug;5(4):501–6 (69 ref.)
Ion channel forming colicins. Stroud R. **Curr Opin Struct Biol** 1995 Aug;5(4):514–20 (27 ref.)
Computing the field in proteins and channels. Eisenberg RS. **J Membr Biol** 1996 Mar;150(1):1–25 (267 ref.)
Structure and function of the porin channel. Welte W, et al. **Kidney Int** 1995 Oct;48(4):930–40 (121 ref.)
A structural vignette common to voltage sensors and conduction pores: canaliculi. Goldstein SA. **Neuron** 1996 Apr;16(4):717–22 (52 ref.)

CLASSIFICATION

The ryanodine receptor family of intracellular calcium release channels. Sorrentino V. **Adv Pharmacol** 1995; 33:67–90 (119 ref.)
Families of ion channels with two hydrophobic segments. North RA. **Curr Opin Cell Biol** 1996 Aug;8(4):474–83 (67 ref.)

DRUG EFFECTS

Ion channels as targets for insecticides. Bloomquist JR. **Annu Rev Entomol** 1996;41:163–90 (124 ref.)
The cardiac ion channels: relevance to management of arrhythmias. Roden DM, et al. **Annu Rev Med** 1996; 47:135–48 (66 ref.)
Antiepileptic drug mechanisms of action. Macdonald RL, et al. **Epilepsia** 1995;36 Suppl 2:S2–12 (112 ref.)
Actions of anesthetics on ligand-gated ion channels: role of receptor subunit composition. Harris RA, et al. **FASEB J** 1995 Nov;9(14):1454–62 (59 ref.)
Ion channels: too complex for rational drug design? Goldstein SA, et al. **Neuron** 1996 May;16(5):913–9 (50 ref.)
Noncompetitive inhibitors of the acetylcholine receptor help paint a picture of its ion channel. Eterovic VA, et al. **P R Health Sci J** 1995 Sep;14(3):199–209 (71 ref.)
Pharmacological and physiological significance of ion channels and factors that modulate them in vascular tissues. Kuriyama H, et al. **Pharmacol Rev** 1995 Sep;47(3):387–573 (3527 ref.)
Noncompetitive NMDA receptor antagonists with fast open-channel blocking kinetics and strong voltage-dependency as potential therapeutic agents for Alzheimer's dementia. Müller WE, et al. **Pharmacopsychiatry** 1995 Jul;28(4):113–24 (90 ref.)
[The modulation of cellular ion channel activity by arachidonic acid, its metabolic products and other fatty acids] Krutetskaia ZI, et al. **Tsitologiia** 1995;37(1-2):5–65 (241 ref.) (Eng. Abstr.) **(Rus)**

GENETICS

Prospects for genetic manipulation of cardiac excitability. Lawrence JH, et al. **Adv Exp Med Biol** 1995;382:41–8 (44 ref.)
Clinical relevance of defects in signalling pathways. Kraus JE, et al. **Curr Opin Neurobiol** 1995 Jun;5(3):358–66 (66 ref.)
Molecular genetics of ion channel diseases. George AL Jr. **Kidney Int** 1995 Oct;48(4):1180–90 (97 ref.)
[Molecular evolution of voltage-gated ion channels] Iwabe N, et al. **Tanpakushitsu Kakusan Koso** 1995 Nov; 40(15):2311–8 (31 ref.) **(Jpn)**

IMMUNOLOGY

ABH and Colton blood group antigens on aquaporin-1, the human red cell water channel protein. Agre P, et al. **Transfus Clin Biol** 1995;2(4):303–8 (21 ref.)

METABOLISM

Ion channels in the sarcoplasmic reticulum of striated muscle. Dulhunty AF, et al. **Acta Physiol Scand** 1996 Mar; 156(3):375–85 (48 ref.)
Structure and function of voltage-gated ion channels. Catterall WA. **Annu Rev Biochem** 1995;64:493–531 (221 ref.)
Ionic channel rundown in excised membrane patches. Becq F. **Biochim Biophys Acta** 1996 May 6;1286(1):53–63 (58 ref.)
Ion channels as pharmacologic receptors: the chirality of drug interactions. Triggle DJ. **Chirality** 1996;8(1):35–8 (18 ref.)
Water channels. Fushimi K, et al. **Curr Opin Nephrol Hypertens** 1995 Sep;4(5):392–7 (37 ref.)
Family of cyclic nucleotide gated ion channels. Kaupp UB. **Curr Opin Neurobiol** 1995 Aug;5(4):434–42 (92 ref.)
G-protein regulation of ion channels. Wickman KD, et al. **Curr Opin Neurobiol** 1995 Jun;5(3):278–85 (77 ref.)
Cellular distribution of the aquaporins: a family of water channel proteins. Brown D, et al. **Histochem Cell Biol** 1995 Jul;104(1):1–9 (61 ref.)
Molecular genetics of ion channel diseases. George AL Jr. **Kidney Int** 1995 Oct;48(4):1180–90 (97 ref.)
Effects of phosphorylation on ion channel function. Ismailov II, et al. **Kidney Int** 1995 Oct;48(4):1167–79 (106 ref.)
Molecular mechanisms for the regulation of water transport in amphibian epithelia by antidiuretic hormone. Jo I, et al. **Kidney Int** 1995 Oct;48(4):1088–96 (113 ref.)
Properties and regulation of ion channels in MDCK cells. Lang F, et al. **Kidney Int** 1995 Oct;48(4):1200–5 (128 ref.)
Role of growth factors in mesangial cell ion channel regulation. Ling BN, et al. **Kidney Int** 1995 Oct; 48(4):1158–66 (39 ref.)
The renal cGMP-gated cation channel: its molecular structure and physiological role. McCoy DE, et al. **Kidney Int** 1995 Oct;48(4):1125–33 (77 ref.)
The aquaporin family of water channels in kidney. Nielsen S, et al. **Kidney Int** 1995 Oct;48(4):1057–68 (83 ref.)
Stretch-activated ion channels. Sackin H. **Kidney Int** 1995 Oct;48(4):1134–47 (86 ref.)
Water channels in the kidney collecting duct. Sasaki S, et al. **Kidney Int** 1995 Oct;48(4):1082–7 (43 ref.)
Swelling-activated organic osmolyte efflux: a new role for anion channels. Strange K, et al. **Kidney Int** 1995 Oct; 48(4):994–1003 (88 ref.)
Structure and function of kidney water channels. Verkman AS, et al. **Kidney Int** 1995 Oct;48(4):1069–81 (68 ref.)
Structure and function of the porin channel. Welte W, et al. **Kidney Int** 1995 Oct;48(4):930–40 (121 ref.)
Sodium channels and non-selective cation channels in the cortical collecting duct. Korbmacher C, et al. **Nephrol Dial Transplant** 1995;10(9):1546–50 (36 ref.)
Structure and function of the NMDA receptor channel. Mori H, et al. **Neuropharmacology** 1995 Oct;34(10):1219–37 (142 ref.)
Water channels in the peritoneum [editorial] Ho-dac-Pannekeet MM, et al. **Perit Dial Int** 1996 May-Jun;16(3):255–9 (62 ref.)
Ionotropic glutamate receptors--focus on non-NMDA receptors. Jørgensen M, et al. **Pharmacol Toxicol** 1995 May; 76(5):312–9 (48 ref.)
Cholinergic channel activators: novel opportunities for the treatment of CNS disorders. Sullivan JP, et al. **Proc West Pharmacol Soc** 1995;38:127–30 (29 ref.)
Inositol pentakis- and hexakisphosphate metabolism adds versatility to the actions of inositol polyphosphates. Novel effects on ion channels and protein traffic. Shears SB. **Subcell Biochem** 1996;26:187–226 (181 ref.)
Ion-channel defects and aberrant excitability in myotonia and periodic paralysis. Cannon SC. **Trends Neurosci** 1996 Jan; 19(1):3–10 (59 ref.)
[Aggrephores and aquaporins] Verbavatz JM. **C R Seances Soc Biol Fil** 1995;189(2):191–7 (34 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Ion gradients and contractility in skeletal muscle: the role of active Na+, K+ transport. Nielsen OB, et al. **Acta Physiol Scand** 1996 Mar;156(3):247–56 (70 ref.)
Structure and function of the ion channel model system annexin V. Voges D, et al. **Adv Enzymol Relat Areas Mol Biol** 1995;71:209–39 (144 ref.)
The ryanodine receptor family of intracellular calcium release channels. Sorrentino V. **Adv Pharmacol** 1995; 33:67–90 (119 ref.)
Cellular and molecular physiology of volume-sensitive anion channels. Strange K, et al. **Am J Physiol** 1996 Mar;270(3 Pt 1):C711–30 (146 ref.)
Cyclic nucleotide-gated ion channels: an extended family with diverse functions. Finn JT, et al. **Annu Rev Physiol** 1996;58:395–426 (246 ref.)
Pathophysiology of the aquaporin water channels. King LS, et al. **Annu Rev Physiol** 1996;58:619–48 (159 ref.)
Queer current and pacemaker: the hyperpolarization-activated cation current in neurons. Pape HC. **Annu Rev Physiol** 1996;58:299–327 (142 ref.)
Regulation of ionotropic receptors by protein phosphorylation. Pasqualotto BA, et al. **Biochem Pharmacol** 1996 Jun 14;51(11):1417–25 (77 ref.)
Developmental cardiac electrophysiology recent advances in cellular physiology. Wetzel GT, et al. **Cardiovasc Res** 1996 Feb;31 Spec No:E52–60 (76 ref.)
Ion channel hypothesis for Alzheimer amyloid peptide neurotoxicity. Pollard HB, et al. **Cell Mol Neurobiol** 1995 Oct;15(5):513–26 (67 ref.)

ION CHANNELS

Inward rectification and implications for cardiac excitability. Nichols CG, et al. **Circ Res** 1996 Jan;78(1):1-7 (52 ref.)
Proteins that interact with the pore-forming subunits of voltage-gated ion channels. Adelman JP. **Curr Opin Neurobiol** 1995 Jun;5(3):286-95 (83 ref.)
Cyclic nucleotide gated channels. Zimmerman AL. **Curr Opin Neurobiol** 1995 Jun;5(3):296-303 (62 ref.)
Physiology of Bergmann glial cells. Müller T, et al. **Int Rev Neurobiol** 1995;38:341-59 (76 ref.)
The resting membrane potential of cells are measures of electrical work, not of ionic currents. Veech RL, et al. **Integr Physiol Behav Sci** 1995 Sep-Dec;30(4):283-307 (46 ref.)
Brief report: pathophysiology of autism: neurochemistry. Cook EH Jr. **J Autism Dev Disord** 1996 Apr;26(2):221-5 (11 ref.)
Basic concepts in cellular cardiac electrophysiology: Part I: Ion channels, membrane currents, and the action potential. Whalley DW, et al. **Pacing Clin Electrophysiol** 1995 Aug; 18(8):1556-74 (72 ref.)
Aquaporin water channels in the kidney: localization and regulation. Nielsen S. **Perit Dial Int** 1996;16 Suppl 1:S25-7 (46 ref.)
Pharmacological and physiological significance of ion channels and factors that modulate them in vascular tissues. Kuriyama H, et al. **Pharmacol Rev** 1995 Sep;47(3):387-573 (3527 ref.)
Ion channel regulation by G proteins. Wickman K, et al. **Physiol Rev** 1995 Oct;75(4):865-85 (261 ref.)
Opioid receptors and the regulation of ion conductances. Grudt TJ, et al. **Rev Neurosci** 1995 Jul-Sep;6(3):279-86 (45 ref.)
From ion currents to genomic analysis: recent advances in GABAA receptor research. Rabow LE, et al. **Synapse** 1995 Nov;21(3):189-274 (675 ref.)
Ion-channel assembly. Green WN, et al. **Trends Neurosci** 1995 Jun;18(6):280-7 (57 ref.)
[Biologic characteristics and physiological significances of M current] Zheng JQ, et al. **Sheng Li Ko Hsueh Chin Chan** 1995 Oct;26(4):344-6 (9 ref.) **(Chi)**
[Developmental changes in the pacemaker current and membrane currents of the guinea pig myocardium] Shigenobu K, et al. **Nippon Yakurigaku Zasshi** 1996 Jun; 107(6):259-72 (48 ref.) (Eng. Abstr.) **(Jpn)**
[Desensitization of the nicotinic acetylcholine receptor] Quiñonez M, et al. **Acta Cient Venez** 1994;45(1):13-22 (78 ref.) (Eng. Abstr.) **(Spa)**

ION CHANNELS, CALCIUM see **CALCIUM CHANNELS**

ION CHANNELS, CHLORIDE see **CHLORIDE CHANNELS**

ION CHANNELS, POTASSIUM see **POTASSIUM CHANNELS**

ION CHANNELS, SODIUM see **SODIUM CHANNELS**

ION COTRANSPORT see **ION TRANSPORT**

ION EXCHANGE, INTRACELLULAR see **ION TRANSPORT**

ION PUMPS

METABOLISM

Developmental regulation of cation pumps in skeletal and cardiac muscle. Dauncey MJ, et al. **Acta Physiol Scand** 1996 Mar;156(3):313-23 (75 ref.)
Shuttling between two protein conformations: the common mechanism for sensory transduction and ion transport. Spudich JL, et al. **Curr Opin Cell Biol** 1996 Aug;8(4):452-7 (47 ref.)

ION TRANSPORT

see related
ANTIPORTERS
ION PUMPS

Ionic mechanisms of ischemia-related ventricular arrhythmias. Ducceschi V, et al. **Clin Cardiol** 1996 Apr; 19(4):325-31 (106 ref.)
[Ion transport in the colon] Caprilli R, et al. **Minerva Gastroenterol Dietol** 1995 Dec;41(4):289-301 (52 ref.) (Eng. Abstr.) **(Ita)**

IONIC STRENGTH see **OSMOLAR CONCENTRATION**

IONOPHORES

CHEMICAL SYNTHESIS

Synthesis and chemistry of the ionophore antibiotic tetronasin. Ley SV, et al. **Farmaco** 1996 Mar;51(3):147-57 (27 ref.)
[Synthesis of lactone ring-containing bioactive natural products. Cardiotonic steroids, naphthoquinone antibiotics, and tetronic acid ionophore antibiotics] Yoshii E. **Yakugaku Zasshi** 1996 Jan;116(1):1-20 (45 ref.) (Eng. Abstr.) **(Jpn)**

CHEMISTRY

Molecular structure and mechanisms of action of cyclic and linear ion transport antibiotics. Duax WL, et al. **Biopolymers** 1996;40(1):141-55 (44 ref.)

IONS

Multiple ligand-ion solutions: a guide for solution preparation and computer program understanding. Schubert R. **J Vasc Res** 1996 Jan-Feb;33(1):86-98 (44 ref.)
Ion localization and X-ray microanalysis. Hodson MJ. **Methods Cell Biol** 1995;49:21-31 (26 ref.)

IONTOPHORESIS

Physical enhancement of dermatologic drug delivery: iontophoresis and phonophoresis. Kassan DG, et al. **J Am Acad Dermatol** 1996 Apr;34(4):657-66 (74 ref.)
Iontophoresis for enhancing penetration of dermatologic and antiviral drugs. Gangarosa LP Sr, et al. **J Dermatol** 1995 Nov;22(11):865-75 (39 ref.)
Topical iontophoretic drug delivery: pathways, principles, factors, and skin irritation. Singh J, et al. **Med Res Rev** 1996 May;16(3):285-96 (88 ref.)
Iontophoretic dye labeling of embryonic cells. Fraser SE. **Methods Cell Biol** 1996;51:147-60 (13 ref.)

IOTALAMIC ACID see **IOTHALAMIC ACID**

IOTHALAMIC ACID

DIAGNOSTIC USE

Iothalamate clearance and its use in large-scale clinical trials. Hall PM, et al. **Curr Opin Nephrol Hypertens** 1995 Nov; 4(6):510-3 (22 ref.)

IPA (INDEPENDENT PRACTICE ASSOCIATION) see **INDEPENDENT PRACTICE ASSOCIATIONS**

IPPV see **INTERMITTENT POSITIVE-PRESSURE VENTILATION**

IPRATROPIUM

THERAPEUTIC USE

An international perspective on anticholinergic therapy. Chapman KR. **Am J Med** 1996 Jan 29;100(1A):2S-4S (19 ref.)
Use of anticholinergic bronchodilation in children. Rubin BK, et al. **Am J Med** 1996 Jan 29;100(1A):49S-53S (40 ref.)

IPROVERATRIL see **VERAPAMIL**

IR GENES see **GENES, MHC CLASS II**

IRIDIUM RADIOISOTOPES

THERAPEUTIC USE

[Place of iridium 192 implantation in irradiation of T1-T2 squamous cell carcinoma of the velopharyngeal arch] Mazeron JJ, et al. **Bull Cancer Radiother** 1996;83(1):47-53 (43 ref.) (Eng. Abstr.) **(Fre)**

IRIDOCYCLITIS

SURGERY

Cataract surgery in Fuchs' heterochromic uveitis: past, present, and future. Jones NP. **J Cataract Refract Surg** 1996 Mar;22(2):261-8 (41 ref.)

IRIS

METABOLISM

Cross talk between cyclic AMP and the polyphosphoinositide signaling cascade in iris sphincter and other nonvascular smooth muscle. Abdel-Latif AA. **Proc Soc Exp Biol Med** 1996 Feb;211(2):163-77 (126 ref.)

SURGERY

Argon laser peripheral iridoplasty. Ritch R, et al. **Ophthalmic Surg Lasers** 1996 Apr;27(4):289-300 (82 ref.)

ULTRASTRUCTURE

Ultrastructure of the iris. Freddo TF. **Microsc Res Tech** 1996 Apr 1;33(5):369-89 (41 ref.)

IRIS NEOPLASMS

SECONDARY

Neonatal hepatoblastoma metastatic to the choroid and iris. Endo EG, et al. **Arch Ophthalmol** 1996 Jun;114(6):757-61 (24 ref.)

THERAPY

Multimodal management of diffuse neonatal hemangiomatosis. Stratte EG, et al. **J Am Acad Dermatol** 1996 Feb;34(2 Pt 2):337-42 (36 ref.)

IRITIS

DIAGNOSIS

Iritis. How to recognize and manage a potentially sight-threatening disease. Nishimoto JY. **Postgrad Med** 1996 Feb;99(2):255-7, 261-2 (5 ref.)

DRUG THERAPY

Iritis. How to recognize and manage a potentially sight-threatening disease. Nishimoto JY. **Postgrad Med** 1996 Feb;99(2):255-7, 261-2 (5 ref.)

IRON

see related
FERRITIN
FERROUS COMPOUNDS
HEMOSIDEROSIS
SIDEROSIS
TRANSFERRIN

Targeting of nucleic acids by iron complexes. Draganescu A, et al. **Met Ions Biol Syst** 1996;33:453-84 (92 ref.)
Role of guanosine triphosphate in ferric ion-linked Fenton chemistry. Biaglow JE, et al. **Radiat Res** 1996 May; 145(5):554-62 (69 ref.)
Role of Fenton chemistry in thiol-induced toxicity and apoptosis. Held KD, et al. **Radiat Res** 1996 May; 145(5):542-53 (81 ref.)
Fenton chemistry: an introduction. Wardman P, et al. **Radiat Res** 1996 May;145(5):523-31 (73 ref.)
Chelation therapy in beta-thalassemia: the benefits and limitations of desferrioxamine. Giardina PJ, et al. **Semin Hematol** 1995 Oct;32(4):304-12 (93 ref.)

ADMINISTRATION & DOSAGE

Weekly versus daily oral iron administration: are we asking the right questions? Solomons NW. **Nutr Rev** 1995 Nov; 53(11):326-7 (13 ref.)
Interdependence of vitamin A and iron: an important association for programmes of anaemia control. Bloem MW. **Proc Nutr Soc** 1995 Jul;54(2):501-8 (39 ref.)
[Iron and pregnancy] Beaufrère B, et al. **Arch Pediatr** 1995 Dec;2(12):1209-18 (65 ref.) (Eng. Abstr.) **(Fre)**

ADVERSE EFFECTS

Iron and chronic viral hepatitis: emerging evidence for an important interaction. Rubin RB, et al. **Dig Dis** 1995 Jul-Aug;13(4):223-38 (50 ref.)
Iron as a hepatotoxin. Stål P. **Dig Dis** 1995 Jul-Aug; 13(4):205-22 (113 ref.)
Iron in liver diseases other than hemochromatosis. Bonkovsky HL, et al. **Semin Liver Dis** 1996 Feb;16(1):65-82 (135 ref.)
Metal-induced hepatotoxicity. Britton RS. **Semin Liver Dis** 1996 Feb;16(1):3-12 (105 ref.)
[Is iron administration, when indicated, causing any health hazard?] Schümann K, et al. **Dtsch Med Wochenschr** 1996 Feb 9;121(6):179-84 (39 ref.) **(Ger)**
[The endorem tolerance profile] Laniado M, et al. **Radiologe** 1995 Nov;35(11 Suppl 2):S266-70 (16 ref.) (Eng. Abstr.) **(Ger)**

BLOOD

Results of surveys to assess iron status in Europe. Hallberg L. **Nutr Rev** 1995 Nov;53(11):314-22 (46 ref.)
Methods to assess iron status in various NHANES surveys. Looker AC, et al. **Nutr Rev** 1995 Sep;53(9):246-54 (46 ref.)
Iron overload: prevalence and impact on health. Lynch SR. **Nutr Rev** 1995 Sep;53(9):255-60 (38 ref.)
[Iron] Kariyone S. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:804-11 (16 ref.) **(Jpn)**

CHEMISTRY

Arylhydrazines as probes of hemoprotein structure and function. Ortiz de Montellano PR. **Biochimie** 1995; 77(7-8):581-93 (60 ref.)

DEFICIENCY

[The causes, diagnosis and treatment of iron-deficiency states in the population (a review)] Nasolodin VV, et al. **Gig Sanit** 1996 Jan-Feb;(1):18-23 (65 ref.) (Eng. Abstr.) **(Rus)**

DIAGNOSTIC USE

Liver. II: Iron oxide-based reticuloendothelial contrast agents for MR imaging. Clinical review. Petersein J, et al. **Magn Reson Imaging Clin N Am** 1996 Feb;4(1):53-60 (38 ref.)
[Detection of liver tumors] Rummeny EJ, et al. **Radiologe** 1995 Nov;35(11 Suppl 2):S252-8 (29 ref.) (Eng. Abstr.) **(Ger)**

METABOLISM

Regulation of iron metabolism: translational effects mediated by iron, heme, and cytokines. Mascotti DP, et al. **Annu Rev Nutr** 1995;15:239–61 (143 ref.)

Proposed role for a combination of citric acid and ascorbic acid in the production of dietary iron overload: a fundamental cause of disease. Crawford RD. **Biochem Mol Med** 1995 Feb;54(1):1–11 (77 ref.)

The ferritins: molecular properties, iron storage function and cellular regulation. Harrison PM, et al. **Biochim Biophys Acta** 1996 Jul 31;1275(3):161–203 (477 ref.)

Mechanisms of iron uptake by mammalian cells. Qian ZM, et al. **Biochim Biophys Acta** 1995 Nov 30;1269(3):205–14 (109 ref.)

Interaction of inflammatory cytokines and erythropoeitin in iron metabolism and erythropoiesis in anaemia of chronic disease. Jongen-Lavrencic M, et al. **Clin Rheumatol** 1995 Sep;14(5):519–25 (93 ref.)

Environmental processes mediated by iron-reducing bacteria. Fredrickson JK, et al. **Curr Opin Biotechnol** 1996 Jun; 7(3):287–94 (48 ref.)

Iron-sulphur clusters as genetic regulatory switches: the bifunctional iron regulatory protein-1. Paraskeva E, et al. **FEBS Lett** 1996 Jun 24;389(1):40–3 (50 ref.)

Iron supplying systems of Salmonella in diagnostics, epidemiology and infection. Kingsley R, et al. **FEMS Immunol Med Microbiol** 1995 Jul;11(4):257–64 (36 ref.)

Linkage of cell-mediated immunity to iron metabolism. Weiss G, et al. **Immunol Today** 1995 Oct;16(10):495–500 (44 ref.)

Altered iron metabolism in HIV infection: mechanisms, possible consequences, and proposals for management. Boelaert JR, et al. **Infect Agents Dis** 1996 Jan;5(1):36–46 (99 ref.)

Overview of iron metabolism. Uchida T. **Int J Hematol** 1995 Dec;62(4):193–202 (74 ref.)

Siderophores: structure and function of microbial iron transport compounds. Neilands JB. **J Biol Chem** 1995 Nov 10;270(45):26723–6 (43 ref.)

The history of iron in the brain. Koeppen AH. **J Neurol Sci** 1995 Dec;134 Suppl:1–9 (47 ref.)

Magnetic resonance imaging of brain iron in health and disease. Vymazal J, et al. **J Neurol Sci** 1995 Dec;134 Suppl:19–26 (55 ref.)

Vitamin C-driven free radical generation from iron. Herbert V, et al. **J Nutr** 1996 Apr;126(4 Suppl):1213S–20S (61 ref.)

Iron and infection: new developments and their implications. Ward CG, et al. **J Trauma** 1996 Aug;41(2):356–64 (83 ref.)

Gene regulation of siderophore-mediated iron acquisition in Pseudomonas: not only the Fur repressor. Venturi V, et al. **Mol Microbiol** 1995 Aug;17(4):603–10 (40 ref.)

Overview and mechanisms of iron regulation. Bothwell TH. **Nutr Rev** 1995 Sep;53(9):237–45 (54 ref.)

The iron–copper connection: the link to ceruloplasmin grows stronger. Harris ED. **Nutr Rev** 1995 Jun;53(6):170–3 (12 ref.)

Molecular mechanisms of iron uptake in eukaryotes. de Silva DM, et al. **Physiol Rev** 1996 Jan;76(1):31–47 (170 ref.)

Molecular control of vertebrate iron metabolism: mRNA-based regulatory circuits operated by iron, nitric oxide, and oxidative stress. Hentze MW, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8175–82 (151 ref.)

Iron–zinc and calcium–Fe interactions in relation to Zn and Fe absorption. Fairweather-Tait SJ. **Proc Nutr Soc** 1995 Jul;54(2):465–73 (41 ref.)

Riboflavin–iron interactions with particular emphasis on the gastrointestinal tract. Powers HJ. **Proc Nutr Soc** 1995 Jul; 54(2):509–17 (45 ref.)

Effects of the ferritin open reading frame on translational induction by iron. Mascotti DP, et al. **Prog Nucleic Acid Res Mol Biol** 1996;55:121–34 (82 ref.)

Abdominal iron deposition: metabolism, MR findings, and clinical importance. Siegelman ES, et al. **Radiology** 1996 Apr;199(1):13–22 (170 ref.)

Iron metabolism in eukaryotes: Mars and Venus at it again [comment] Kaplan J, et al. **Science** 1996 Mar 15; 271(5255):1510–2 (25 ref.) Comment on: Science 1996 Mar 15;271(5255):1552–7.

Iron acquisition in the pathogenic Neisseria. Genco CA, et al. **Trends Microbiol** 1996 May;4(5):179–84 (47 ref.)

Biochemical aspects of iron metabolism, transport and regulation. Goldenberg H, et al. **Wien Klin Wochenschr** 1995;107(22):669–76 (102 ref.)

[Total iron binding capacity (TIBC), unsaturated iron binding capacity (UIBC)] Sakurada K, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:812–4 (7 ref.) **(Jpn)**

PHARMACOLOGY

Iron and infection: new developments and their implications. Ward CG, et al. **J Trauma** 1996 Aug;41(2):356–64 (83 ref.)

Iron–zinc and calcium–Fe interactions in relation to Zn and Fe absorption. Fairweather-Tait SJ. **Proc Nutr Soc** 1995 Jul;54(2):465–73 (41 ref.)

PHYSIOLOGY

Regulation of iron metabolism: translational effects mediated by iron, heme, and cytokines. Mascotti DP, et al. **Annu Rev Nutr** 1995;15:239–61 (143 ref.)

Iron and vitamins. Hallberg L. **Bibl Nutr Dieta** 1995;(52):20–9 (39 ref.)

The role of iron in cancer. Weinberg ED. **Eur J Cancer Prev** 1996 Feb;5(1):19–36 (204 ref.)

Free radical damage, iron, and Alzheimer's disease. Smith MA, et al. **J Neurol Sci** 1995 Dec;134 Suppl:92–4 (21 ref.)

[Iron: perspective on the athletic woman] Castillo MC, et al. **Sangre (Barc)** 1995 Jun;40(3):199–205 (82 ref.) **(Spa)**

POISONING

Chemical, pharmacological, toxicological and therapeutic advances of deferiprone (L1) and other iron and aluminium chelators. Kontoghiorghes GJ. **Arch Toxicol Suppl** 1996; 18:202–14 (56 ref.)

Risks of parenteral deferoxamine for acute iron poisoning. Howland MA. **J Toxicol Clin Toxicol** 1996;34(5):491–7 (50 ref.)

Benefits of parenteral deferoxamine for acute iron poisoning. Tenenbein M. **J Toxicol Clin Toxicol** 1996;34(5):485–9 (36 ref.)

STANDARDS

Iron supplementation during pregnancy. Roodenburg AJ. **Eur J Obstet Gynecol Reprod Biol** 1995 Jul;61(1):65–71 (66 ref.)

THERAPEUTIC USE

Is there a rationale for iron supplementation in the treatment of akathisia? A review of the evidence. Gold R, et al. **J Clin Psychiatry** 1995 Oct;56(10):476–83 (63 ref.)

TOXICITY

Ferritin as a source of iron and protection from iron-induced toxicities. Aust SD. **Toxicol Lett** 1995 Dec;82–83:941–4 (25 ref.)

Role of iron in the reactivity of mineral fibers. Fubini B, et al. **Toxicol Lett** 1995 Dec;82–83:951–60 (57 ref.)

Potential protection from toxicity by oral iron chelators. Hider RC. **Toxicol Lett** 1995 Dec;82–83:961–7 (23 ref.)

Toxicity of iron and hydrogen peroxide: the Fenton reaction. Winterbourn CC. **Toxicol Lett** 1995 Dec;82–83:969–74 (25 ref.)

IRON CHELATES

Evaluation of new iron chelators for clinical use. Porter JB. **Acta Haematol** 1996;95(1):13–25 (41 ref.)

ADVERSE EFFECTS

Results of long-term iron-chelating therapy. Gabutti V, et al. **Acta Haematol** 1996;95(1):26–36 (109 ref.)

Long-term therapy with deferiprone. Olivieri NF. **Acta Haematol** 1996;95(1):37–48 (90 ref.)

CHEMISTRY

Design of orally active iron chelators. Hider RC, et al. **Acta Haematol** 1996;95(1):6–12 (23 ref.)

PHARMACOLOGY

Iron chelators: mode of action as antimalarials. Cabantchik ZI, et al. **Acta Haematol** 1996;95(1):70–7 (40 ref.)

Potential protection from toxicity by oral iron chelators. Hider RC. **Toxicol Lett** 1995 Dec;82–83:961–7 (23 ref.)

THERAPEUTIC USE

Cardioprotective effect of desferrioxamine. Bel A, et al. **Acta Haematol** 1996;95(1):63–5 (21 ref.)

Role of deferoxamine in tumor therapy. Donfrancesco A, et al. **Acta Haematol** 1996;95(1):66–9 (16 ref.)

Results of long-term iron-chelating therapy. Gabutti V, et al. **Acta Haematol** 1996;95(1):26–36 (109 ref.)

Prevention of anthracycline cardiotoxicity by iron chelation. Hershko C, et al. **Acta Haematol** 1996;95(1):87–92 (68 ref.)

Clinical studies of iron chelators in malaria. Mabeza GF, et al. **Acta Haematol** 1996;95(1):78–86 (69 ref.)

Use of iron chelators in preventing hydroxyl radical damage: adult respiratory distress syndrome as an experimental model for the pathophysiology and treatment of oxygen-radical-mediated tissue damage. Marx JJ, et al. **Acta Haematol** 1996;95(1):49–62 (181 ref.)

Long-term therapy with deferiprone. Olivieri NF. **Acta Haematol** 1996;95(1):37–48 (90 ref.)

Chemical, pharmacological, toxicological and therapeutic advances of deferiprone (L1) and other iron and aluminium chelators. Kontoghiorghes GJ. **Arch Toxicol Suppl** 1996; 18:202–14 (56 ref.)

Therapeutic iron chelators and their potential side-effects. Singh S, et al. **Biochem Soc Symp** 1995;61:127–37 (21 ref.)

Oral iron chelation. Hoffbrand AV. **Semin Hematol** 1996 Jan; 33(1):1–8 (57 ref.)

IRON-DEFICIENCY ANEMIA see **ANEMIA, IRON-DEFICIENCY**

IRON OVERLOAD see **HEMOSIDEROSIS**

IRON-SULFUR PROTEIN REDUCTASE see **FERREDOXIN-NADP REDUCTASE**

IRON-SULFUR PROTEINS

CHEMISTRY

Glutamate synthase: a complex iron-sulphur flavoprotein. Curti B, et al. **Biochem Soc Trans** 1996 Feb;24(1):95–9 (20 ref.)

Functional implications of the structure of the 'Rieske' iron-sulfur protein of bovine heart mitochondrial cytochrome bc1 complex. Link TA, et al. **Biochim Biophys Acta** 1996 Jul 18;1275(1–2):54–60 (45 ref.)

Metal-carbon bonds in nature [comment] Kovacs JA, et al. **Science** 1995 Oct 27;270(5236):587–8 (22 ref.) Comment on: Science 1995 Oct 27;270(5236):628–30.

METABOLISM

CO dehydrogenase. Ferry JG. **Annu Rev Microbiol** 1995; 49:305–33 (132 ref.)

Glutamate synthase: a complex iron-sulphur flavoprotein. Curti B, et al. **Biochem Soc Trans** 1996 Feb;24(1):95–9 (20 ref.)

Role of iron–sulfur proteins in gene regulation. Kennedy MC. **Met Ions Biol Syst** 1996;32:579–602 (121 ref.)

PHYSIOLOGY

Iron-sulphur clusters as genetic regulatory switches: the bifunctional iron regulatory protein-1. Paraskeva E, et al. **FEBS Lett** 1996 Jun 24;389(1):40–3 (50 ref.)

Molecular control of vertebrate iron metabolism: mRNA-based regulatory circuits operated by iron, nitric oxide, and oxidative stress. Hentze MW, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8175–82 (151 ref.)

IRRIGATION

Ethanol monitoring of irrigating fluid absorption. Hahn RG. **Eur J Anaesthesiol** 1996 Mar;13(2):102–15 (60 ref.)

IRRIGATION, GASTRIC see **GASTRIC LAVAGE**

IRRITABLE BOWEL SYNDROME see **COLONIC DISEASES, FUNCTIONAL**

IRRITANT DERMATITIS see **DERMATITIS, IRRITANT**

IRRITANTS

ADVERSE EFFECTS

Respiratory irritants encountered at work. Taylor AJ. **Thorax** 1996 May;51(5):541–5 (17 ref.)

POISONING

Poisoning from "Spanish fly" (cantharidin). Karras DJ, et al. **Am J Emerg Med** 1996 Sep;14(5):478–83 (17 ref.)

Ingestion of a blister beetle (Mecoidae family). Mallari RQ, et al. **Pediatrics** 1996 Sep;98(3 Pt 1):458–9 (11 ref.)

TOXICITY

Limonene. Von Burg R. **J Appl Toxicol** 1995 Nov–Dec; 15(6):495–9 (65 ref.)

IS ELEMENTS see **DNA INSERTION ELEMENTS**

ISAACS' SYNDROME see **FASCICULATION**

ISCHEMIA

Non-occlusive mesenteric ischemia. Lock G, et al. **Hepatogastroenterology** 1995 Jul;42(3):234–9 (36 ref.)

[The ischemic diabetic foot] Tešić D. **Med Pregl** 1995; 48(7–8):235–40 (29 ref.) (Eng. Abstr.) **(Scr)**

CHEMICALLY INDUCED

Chronic intestinal ischemia caused by intravenous cocaine use: report of two cases and review of the literature. Myers SI, et al. **J Vasc Surg** 1996 Apr;23(4):724–9 (23 ref.)

[Digital necrosis associated with fenoxazoline poisoning. Apropos of a case and review of the literature] Hauet T, et al. **Rev Med Interne** 1996;17(1):66–9 (19 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

Cholangitis associated with paroxysmal nocturnal hemoglobinuria: another instance of ischemic cholangiopathy? Le Thi Huong D, et al. **Gastroenterology** 1995 Oct;109(4):1338–43 (52 ref.)

Ovarian cancer and gangrene of the digits: case report and review of the literature. Chow SF, et al. **Mayo Clin Proc** 1996 Mar;71(3):253–8 (45 ref.)

The role of medullary ischemia in acute renal failure. Heyman SN, et al. **New Horiz** 1995 Nov;3(4):597–607 (106 ref.)

Sepsis or ischemia in experimental acute renal failure: what have we learned? Johnson JP, et al. **New Horiz** 1995 Nov; 3(4):608–14 (79 ref.)

[Tubulointerstitial damage attributable to acute circulatory failure: postischemic acute renal failure] Yamamoto T, et al. **Nippon Rinsho** 1995 Aug;53(8):2027–33 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Vascular factors in the mechanism of acute pancreatitis] Sendur R, et al. **Przegl Lek** 1996;53(1):41–5 (38 ref.) (Eng. Abstr.) **(Pol)**

[Modern methods for treating spinal cord diseases of ischemic and traumatic origin in the late period (a review of the literature)] Mikhailenko AA, et al. **Voen Med Zh** 1995 Dec; (12):31–6 (28 ref.) **(Rus)**

DIAGNOSIS

Ischemic nephropathy: noninvasive testing. Wilcox CS. **Semin Nephrol** 1996 Jan;16(1):43–52 (52 ref.)

[Lactate versus intramucosal pCO2 or pH?] Mertzlufft F. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Oct; 30 Suppl 1:S27–33 (41 ref.) **(Ger)**

DRUG THERAPY

Thrombolysis in extremital arteries—indications and methods. Wellander E, et al. **Ann Chir Gynaecol** 1995; 84(4):341–8 (74 ref.)

Peripheral thrombolysis: state of the art. Earnshaw JJ, et al. **Cardiovasc Surg** 1995 Aug;3(4):357–67 (28 ref.)

Thrombolytic therapy for acute arterial occlusion. Ouriel K. **Curr Opin Gen Surg** 1994;:257–64 (39 ref.)

Pentoxifylline and critical leg ischemia. Colgan MP, et al. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S58–60 (19 ref.)

Thrombolytic therapy in acute lower limb ischemia. Pilger E. **Semin Thromb Hemost** 1996;22(1):61–7 (48 ref.)

Angiotensin converting enzyme inhibitors—do they have an anti-ischemic action? Rutherford JD. **Trans Am Clin Climatol Assoc** 1995;107:57–66; discussion 66–7 (47 ref.)

Lower limb intraarterial thrombolysis as an adjunct to the management of arterial and graft occlusions. Braithwaite BD, et al. **World J Surg** 1996 Jul–Aug;20(6):649–54 (38 ref.)

[Use of PGE1 in severe ischemia of the lower extremities. Clinical study] Occhionorelli S, et al. **Minerva Cardioangiol** 1995 Jun;43(6):247–56 (73 ref.) (Eng. Abstr.) **(Ita)**

ECONOMICS

Cost-efficacy issues in the treatment of peripheral vascular disease: primary amputation or revascularization for limb-threatening ischemia. Perler BA. **J Vasc Interv Radiol** 1995 Nov–Dec;6(6 Pt 2 Su):111S–115S (28 ref.)

EPIDEMIOLOGY

The natural history of renal artery stenosis: who should be evaluated for suspected ischemic nephropathy? Greco BA, et al. **Semin Nephrol** 1996 Jan;16(1):2–11 (54 ref.)

ETIOLOGY

Hypothenar hammer syndrome caused by playing tennis. Nakamura T, et al. **Eur J Vasc Endovasc Surg** 1996 Feb; 11(2):240–2 (8 ref.)

Colonic ischemia reveals thromboangiitis obliterans (Buerger's disease). Sauvaget F, et al. **Gastroenterology** 1996 Mar;110(3):900–3 (12 ref.)

Shock-associated right colon ischemia and necrosis. Ludwig KA, et al. **J Trauma** 1995 Dec;39(6):1171–4 (28 ref.)

The role of metals in ischemia/reperfusion injury of the liver. Arora AS, et al. **Semin Liver Dis** 1996 Feb;16(1):31–8 (65 ref.)

[Ischemic colitis after vascular surgery reconstruction of an abdominal aortic aneurysm] Kaiser MM, et al. **Chirurg** 1996 Apr;67(4):380–6 (30 ref.) (Eng. Abstr.) **(Ger)**

[Ischemic hepatitis: case reports and a review of the literature] Colivicchi F, et al. **Minerva Med** 1995 Sep; 86(9):379–86 (24 ref.) (Eng. Abstr.) **(Ita)**

[Ischemic cholecystitis] Takahashi M, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):210–2 (22 ref.) **(Jpn)**

[Chronic ischemic ophthalmopathy in Takayasu-Onishi disease] Chercotă G, et al. **Oftalmologia** 1996 Jan–Mar; 40(1):39–44 (19 ref.) (Eng. Abstr.) **(Rum)**

METABOLISM

Na(+)-Ca2+ exchange in anoxic/ischemic injury of CNS myelinated axons. Stys PK, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:366–78 (41 ref.)

PATHOLOGY

Mesenteric ischaemia: a multidisciplinary approach. Bradbury AW, et al. **Br J Surg** 1995 Nov;82(11):1446–59 (224 ref.)

The pathology of chronic renal ischemia. Shanley PF. **Semin Nephrol** 1996 Jan;16(1):21–32 (69 ref.)

Renovasculopathies of hypertension and the rise of blood pressure with age in blacks and whites. Tracy RE. **Semin Nephrol** 1996 Mar;16(2):126–33 (21 ref.)

PHYSIOPATHOLOGY

Mitochondrial dysfunction in ischaemia-reperfusion. Saris NE, et al. **Acta Anaesthesiol Scand Suppl** 1995;107:171–6 (75 ref.)

Splanchnic ischemia and gut mucosal injury in sepsis and the multiple organ dysfunction syndrome. Pastores SM, et al. **Am J Gastroenterol** 1996 Sep;91(9):1697–710 (145 ref.)

Calcium regulation and nonprotective properties of calcium in surgical ischemia. Shapiro MJ, et al. **New Horiz** 1996 Feb;4(1):134–8 (29 ref.)

Cellular and metabolic consequences of chronic ischemia on kidney function. Kellerman PS. **Semin Nephrol** 1996 Jan; 16(1):33–42 (75 ref.)

Microcirculatory disturbances secondary to ischemia-reperfusion. Menger MD. **Transplant Proc** 1995 Oct;27(5):2863–5 (20 ref.)

[Ischemic liver injury] Kurokawa T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):513–6 (20 ref.) **(Jpn)**

[Hypoxic factor and its significance in the onset of gastroduodenal diseases] Pogromov AP, et al. **Klin Med (Mosk)** 1996;74(1):3–7 (117 ref.) **(Rus)**

PREVENTION & CONTROL

Protection of the brain after aneurysmal rupture. Weir B. **Can J Neurol Sci** 1995 Aug;22(3):177–86 (73 ref.)

[Risk predictors and risk-adjusted prevention in peripheral arterial occlusive diseases] Rieger H. **Internist (Berl)** 1995 Sep;36(9):902–8 (30 ref.) **(Ger)**

SURGERY

Gastrointestinal vascular and ischemic syndromes. Brophy CM. **Curr Opin Gen Surg** 1993;:225–31 (26 ref.)

Ischemic nephropathy as an indication for renal artery reconstruction in renovascular hypertension. Newman VS, et al. **Curr Opin Gen Surg** 1994;:272–6 (30 ref.)

Surgery of the sympathetic nervous system. Lee BY, et al. **J Spinal Cord Med** 1996 Jan;19(1):20–6 (50 ref.)

Prosthetic grafts: when are they a reasonable alternative? Abbott WM, et al. **Semin Vasc Surg** 1995 Sep;8(3):236–45 (51 ref.)

Techniques and strategies using arm veins. Andros G. **Semin Vasc Surg** 1995 Sep;8(3):179–87 (28 ref.)

Preoperative assessment of alternative veins. Salles-Cunha SX, et al. **Semin Vasc Surg** 1995 Sep;8(3):172–8 (21 ref.)

[Decompressive neurovascular nose and skull-base surgery in primary headache with a rhinogenic trigger] Bonaccorsi P. **Ital J Neurol Sci** 1995 Nov;16(8 Suppl):69–100 (104 ref.) (Eng. Abstr.) **(Ita)**

THERAPY

Selection of treatment in acute ischaemia. Swedenborg J. **Ann Chir Gynaecol** 1995;84(4):354–7 (22 ref.)

Epidural spinal cord stimulation in the treatment of limb threatening vasospasm—report of a case with a five-year follow-up. Lepantalo M, et al. **Eur J Vasc Endovasc Surg** 1996 Apr;11(3):368–70 (5 ref.)

Angioplasty for the treatment of visceral ischemia. Hallisey MJ, et al. **J Vasc Interv Radiol** 1995 Sep–Oct;6(5):785–91 (26 ref.)

Interventionalists' guide to the patient's experience of lower extremity arterial occlusive disease. McDaniel MD, et al. **J Vasc Interv Radiol** 1995 Nov–Dec;6(6 Pt 2 Su):30S–35S (27 ref.)

Hyperbaric oxygen reduces ischemia-induced skeletal muscle injury. Haapaniemi T, et al. **Plast Reconstr Surg** 1996 Mar; 97(3):602–7; discussion 608–9 (42 ref.)

Infrapopliteal percutaneous transluminal angioplasty: what we know [comment] Bakal CW, et al. **Radiology** 1996 Jul; 200(1):36–43 (58 ref.) Comment on: Radiology 1996 Jul;200(1):33–6.

Percutaneous transluminal angioplasty of the infrapopliteal vessels: the evidence [see comments] Fraser SC, et al. **Radiology** 1996 Jul;200(1):33–6 (44 ref.) Comment in: Radiology 1996 Jul;200(1):36–43.

[Critical lower extremity ischemia] Lepäntalo M. **Duodecim** 1995;111(3):267–72 (25 ref.) **(Fin)**

ULTRASONOGRAPHY

Colour Doppler energy (power) mode ultrasound. MacSweeney JE, et al. **Clin Radiol** 1996 Jun;51(6):387–90 (21 ref.)

ISCHEMIA, MYOCARDIAL see **MYOCARDIAL ISCHEMIA**

ISCHEMIA-REPERFUSION INJURY see **REPERFUSION INJURY**

ISCHEMIC COLITIS see **COLITIS, ISCHEMIC**

ISCHEMIC HEART DISEASE see **MYOCARDIAL ISCHEMIA**

ISCHEMIC OPTIC NEUROPATHY see **OPTIC NEUROPATHY, ISCHEMIC**

ISCOMS

see related
SAPONINS

IMMUNOLOGY

A novel generation of viral vaccines based on the ISCOM matrix. Rimmelzwaan GF, et al. **Pharm Biotechnol** 1995; 6:543–58 (101 ref.)

ISLAND FLAPS see **SURGICAL FLAPS**

ISLANDS OF LANGERHANS see **ISLETS OF LANGERHANS**

ISLET-ACTIVATING PROTEIN see **PERTUSSIS TOXINS**

ISLET CELL TUMOR see **ADENOMA, ISLET CELL**

ISLET CELL TUMOR, ULCEROGENIC see **ZOLLINGER-ELLISON SYNDROME**

ISLETS OF LANGERHANS

The contribution of insulitis to diabetes development in tumor necrosis factor transgenic mice. Flavell RA, et al. **Curr Top Microbiol Immunol** 1996;206:33–50 (72 ref.)

BLOOD SUPPLY

Microcirculation of the islets of Langerhans. Long Beach Veterans Administration Regional Medical Education Center Symposium. Brunicardi FC, et al. **Diabetes** 1996 Apr;45(4):385–92 (84 ref.)

CYTOLOGY

Survival and function of islets during culture. Clayton HA, et al. **Cell Transplant** 1996 Jan–Feb;5(1):1–12; discussion 13–7, 19 (97 ref.)

In vivo cell transformation: neogenesis of beta cells from pancreatic ductal cells. Rosenberg L. **Cell Transplant** 1995 Jul–Aug;4(4):371–83 (80 ref.)

Differentiation and growth of pancreatic beta cells. Scharfmann R, et al. **Diabetes Metab** 1996 Jul;22(4):223–8 (52 ref.)

Islet cell neogenesis in the pancreas. Bouwens L, et al. **Virchows Arch** 1996 Mar;427(6):553–60 (64 ref.)

DRUG EFFECTS

Do KCa channels and carbonic anhydrase play a role in thiazide-induced hyperglycaemia? Pickkers P, et al. **J Hum Hypertens** 1995 Aug;9(8):691–3 (22 ref.)

ENZYMOLOGY

Intraislet expression of inducible nitric oxide synthase and islet cell death. Kolb-Bachofen V. **Biochem Soc Trans** 1996 Feb;24(1):233–4 (14 ref.)

IMMUNOLOGY

T-cell recognition of beta-cell autoantigens in insulin-dependent diabetes mellitus. Kallan AA, et al. **APMIS** 1996 Jan;104(1):3–11 (84 ref.)

Glutamic acid decarboxylase and other autoantigens in IDDM. Nepom GT. **Curr Opin Immunol** 1995 Dec; 7(6):825–30 (63 ref.)

Biocompatibility and immunology in the encapsulation of islets of Langerhans (bioartificial pancreas). Zekorn TD, et al. **Int J Artif Organs** 1996 Apr;19(4):251–7 (34 ref.)

Insulin-dependent diabetes mellitus as a beta-cell targeted disease of immunoregulation. Bach JF. **J Autoimmun** 1995 Aug;8(4):439–63 (172 ref.)

[Cytoplasmic islet cell antibodies and GAD antibodies in diagnosis of diabetes] Bieg S, et al. **Med Klin** 1995 Oct 15;90(10):594–8 (48 ref.) **(Ger)**

[The role of free radicals in pathogenesis of insulin dependent diabetes mellitus] Komosińska K, et al. **Postepy Hig Med Dosw** 1995;49(6):733–46 (64 ref.) (Eng. Abstr.) **(Pol)**

INNERVATION

Neural regulation of the endocrine pancreas. Brunicardi FC, et al. **Int J Pancreatol** 1995 Dec;18(3):177–95 (185 ref.)

METABOLISM

Metabolic coupling factors in pancreatic beta-cell signal transduction. Newgard CB, et al. **Annu Rev Biochem** 1995; 64:689–719 (161 ref.)

Islet amyloid in type 2 (non-insulin-dependent) diabetes. Clark A, et al. **APMIS** 1996 Jan;104(1):12–8 (47 ref.)

beta-cell stimulus – secretion coupling defects in rodent models of obesity. Chan CB. **Can J Physiol Pharmacol** 1995 Oct;73(10):1414–24 (138 ref.)

Mitochondria and diabetes. Genetic, biochemical, and clinical implications of the cellular energy circuit. Gerbitz KD, et al. **Diabetes** 1996 Feb;45(2):113–26 (152 ref.)

Banting Lecture 1995. A lesson in metabolic regulation inspired by the glucokinase glucose sensor paradigm. Matschinsky FM. **Diabetes** 1996 Feb;45(2):223–41 (86 ref.)

Are the beta-cell signaling molecules malonyl-CoA and cystolic long-chain acyl-CoA implicated in multiple tissue defects of obesity and NIDDM? Prentki M, et al. **Diabetes** 1996 Mar;45(3):273–83 (163 ref.)

Sulfonylurea receptors and mechanism of sulfonylurea action. Panten U, et al. **Exp Clin Endocrinol Diabetes** 1996; 104(1):1–9 (100 ref.)

[Behavior of pancreatic beta-cells in type I and II diabetes: clinical implications?] Waeber G. **Rev Med Suisse Romande** 1995 Sep;115(9):627–34 (37 ref.) **(Fre)**

PATHOLOGY

The pathology of the endocrine pancreas in type 1 (insulin-dependent) diabetes mellitus. Foulis AK. **APMIS** 1996 Mar;104(3):161-7 (32 ref.)
Intraislet expression of inducible nitric oxide synthase and islet cell death. Kolb-Bachofen V. **Biochem Soc Trans** 1996 Feb;24(1):233-4 (14 ref.)
Pancreatic pathology in non-insulin dependent diabetes (NIDDM). Clark A, et al. **Diabetes Res Clin Pract** 1995 Aug;28 Suppl:S39-47 (50 ref.)

PHYSIOLOGY

An integrated view of beta-cell dysfunction in type-II diabetes. Poitout V, et al. **Annu Rev Med** 1996;47:69-83 (42 ref.)
Survival and function of islets during culture. Clayton HA, et al. **Cell Transplant** 1996 Jan-Feb;5(1):1-12; discussion 13-7, 19 (97 ref.)
K+ channels: generating excitement in pancreatic beta-cells. Dukes ID, et al. **Diabetes** 1996 Jul;45(7):845-53 (143 ref.)
Reg protein: a potential beta-cell-specific growth factor? Baeza N, et al. **Diabetes Metab** 1996 Jul;22(4):229-34 (40 ref.)
The beta-cell response to oral hypoglycemic agents. Cook DL. **Diabetes Res Clin Pract** 1995 Aug;28 Suppl:S81-9 (72 ref.)
The role of potassium channels in excitable cells. Edwards G, et al. **Diabetes Res Clin Pract** 1995 Aug;28 Suppl:S57-66 (37 ref.)
The molecular interaction of sulfonylureas with beta-cell ATP-sensitive K(+)-channels. Kramer W, et al. **Diabetes Res Clin Pract** 1995 Aug;28 Suppl:S67-80 (25 ref.)
CACN4, the major alpha 1 subunit isoform of voltage-dependent calcium channels in pancreatic beta-cells: a minireview of current progress. Seino S. **Diabetes Res Clin Pract** 1995 Aug;28 Suppl:S99-103 (20 ref.)
Insulin, corticosterone and the autonomic nervous system in animal obesities: a viewpoint. Jeanrenaud B. **Diabetologia** 1995 Aug;38(8):998-1002 (61 ref.)
Diacylglycerol production, Ca2+ influx, and protein kinase C activation in sustained cellular responses. Rasmussen H, et al. **Endocr Rev** 1995 Oct;16(5):649-81 (268 ref.)
Cytokines and the endocrine system. II. Roles in substrate metabolism, modulation of thyroidal and pancreatic endocrine cell functions and autoimmune endocrine diseases. Mandrup-Poulsen T, et al. **Eur J Endocrinol** 1996 Jan;134(1):21-30 (174 ref.)
New insights into pancreatic beta-cell metabolic signaling in insulin secretion. Prenki M. **Eur J Endocrinol** 1996 Mar; 134(3):272-86 (134 ref.)
Role of the endocrine pancreas in control of fuel metabolism by the liver during exercise. Wasserman DH, et al. **Int J Obes Relat Metab Disord** 1995 Oct;19 Suppl 4:S22-30 (83 ref.)
[Routes to normalization in the stimulation of insulin secretion] Ammon HP. **Pharm Unserer Zeit** 1996 May; 25(3):123-9 (101 ref.) **(Ger)**

PHYSIOPATHOLOGY

The key role of islet dysfunction in type II diabetes mellitus. Porte D Jr, et al. **Clin Invest Med** 1995 Aug;18(4):247-54 (26 ref.)
Pancreas and islet transplantation in humans. Kendall DM, et al. **Diabetes Metab** 1996 Jun;22(3):157-63 (40 ref.)
The pathogenesis of NIDDM: the role of the pancreatic beta cell. Zawalich WS, et al. **Diabetologia** 1995 Aug; 38(8):986-91 (41 ref.)
Seminars in Medicine of the Beth Israel Hospital, Boston. Non-insulin-dependent diabetes mellitus - a genetically programmed failure of the beta cell to compensate for insulin resistance. Polonsky KS, et al. **N Engl J Med** 1996 Mar 21;334(12):777-83 (68 ref.)

SECRETION

In praise of the hyperglycemic clamp. A method for assessment of beta-cell sensitivity and insulin resistance. Elahi D. **Diabetes Care** 1996 Mar;19(3):278-86 (26 ref.)
Insulin-secreting cell lines: classification, characteristics and potential applications. Poitout V, et al. **Diabetes Metab** 1996 Feb;22(1):7-14 (54 ref.)
Insulin secretion in obese and non-obese NIDDM. Cerasi E, et al. **Diabetes Res Clin Pract** 1995 Aug;28 Suppl:S27-37 (62 ref.)
What therapy do our NIDDM patients need? Insulin releasers. Crepaldi G, et al. **Diabetes Res Clin Pract** 1995 Aug;28 Suppl:S159-65 (29 ref.)

ISLETS OF LANGERHANS TRANSPLANTATION

Pancreas and islet transplantation in humans. Kendall DM, et al. **Diabetes Metab** 1996 Jun;22(3):157-63 (40 ref.)
Biocompatibility and immunology in the encapsulation of islets of Langerhans (bioartificial pancreas). Zekorn TD, et al. **Int J Artif Organs** 1996 Apr;19(4):251-7 (34 ref.)
Transplantation in diabetes: a cell biological problem. Purrello F, et al. **J Endocrinol Invest** 1995 Apr;18(4):311-9 (72 ref.)
Pancreas transplantation. Stratta RJ, et al. **Ren Fail** 1995 Jul; 17(4):323-37 (85 ref.)

IMMUNOLOGY

Islet transplantation using immunoexclusion methods. Monaco AP, et al. **Transplant Proc** 1996 Aug;28(4):2042-5 (30 ref.)

METHODS

Whole-organ versus islet pancreatic transplantation. Brunicardi FC, et al. **Curr Opin Gen Surg** 1994;:179-85 (37 ref.)
Islet transplantation using immunoexclusion methods. Monaco AP, et al. **Transplant Proc** 1996 Aug;28(4):2042-5 (30 ref.)
[Islet of Langerhans transplantation] Boudjema K, et al. **Ann Chir** 1995;49(10):902-8 (69 ref.) (Eng. Abstr.) **(Fre)**

STATISTICS & NUMERICAL DATA

Pancreas and islet cell transplantation: now and then. Sutherland DE. **Transplant Proc** 1996 Aug;28(4):2131-3 (20 ref.)

ISOANTIBODIES

see related
BLOOD GROUPS

ANALYSIS

Detection of alloantibodies by flow cytometry: relevance to clinical transplantation. Scornik JC. **Cytometry** 1995 Dec 15;22(4):259-63 (37 ref.)
[Diagnosis and therapy of fetal alloimmune thrombocytopenia] Marzusch K, et al. **Geburtshilfe Frauenheilkd** 1995 Oct;55(10):587-91 (29 ref.) (Eng. Abstr.) **(Ger)**

BLOOD

Detection of red cell antibodies: current and future techniques. Knight RC, et al. **Br J Biomed Sci** 1995 Dec; 52(4):297-305 (67 ref.)
[Alloimmune neonatal neutropenia due to anti-NA1 antibodies] Buznego Sánchez R, et al. **An Esp Pediatr** 1996 Feb;44(2):176-8 (11 ref.) **(Spa)**

IMMUNOLOGY

Lewis histo-blood group system and associated secretory phenotypes. Henry S, et al. **Vox Sang** 1995;69(3):166-82 (158 ref.)

THERAPEUTIC USE

The introduction of human monoclonal anti-D for therapeutic use. Fletcher A, et al. **Transfus Med Rev** 1995 Oct;9(4):314-26 (87 ref.)

ISOANTIGENS

see related
BLOOD GROUPS

How T cells recognize alloantigen: evidence for two pathways of allorecognition. Watschinger B. **Nephrol Dial Transplant** 1995;10(9):1556-8 (29 ref.)

BLOOD

Circulating blood group related carbohydrate antigens as tumour markers. Örntoft TF, et al. **Glycoconj J** 1995 Jun; 12(3):200-5 (41 ref.)

IMMUNOLOGY

Human leukocyte antigen system and the immune response to it. Nelson KA. **Clin Orthop** 1996 May;(326):35-42 (53 ref.)
Alloantigen processing and presentation. Tambur AR, et al. **J Heart Lung Transplant** 1995 Nov-Dec;14(6 Pt 1):1031-7 (49 ref.)
An anti-CD2 monoclonal antibody that elicits alloantigen-specific hyporesponsiveness. Schad V, et al. **Transplant Proc** 1996 Aug;28(4):2051-3 (17 ref.)
Transmembrane signaling requirements of T cells: implications for regulation of alloimmunity. Suthanthiran M. **Transplant Proc** 1995 Oct;27(5 Suppl 1):5-7 (25 ref.)
Lewis histo-blood group system and associated secretory phenotypes. Henry S, et al. **Vox Sang** 1995;69(3):166-82 (158 ref.)

ISOASPARTIC ACID see ASPARTIC ACID

ISOCHROMOSOMES

GENETICS

Reviews of chromosome studies in urological tumors. III. Cytogenetics and genes in testicular tumors. Sandberg AA, et al. **J Urol** 1996 May;155(5):1531-56 (254 ref.)

ISOCITRATE DEHYDROGENASE

BLOOD

[Isocitrate dehydrogenase (ICD)] Matsushima T. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:346-9 (6 ref.) **(Jpn)**

METABOLISM

Laue crystallography. It's show time. Farber GK. **Curr Biol** 1995 Oct 1;5(10):1088-90 (13 ref.)

ISOCYANATES

ADVERSE EFFECTS

Occupational asthma due to isocyanates. Baur X. **Lung** 1996; 174(1):23-30 (50 ref.)
Overview of diisocyanate occupational asthma. Bernstein JA. **Toxicology** 1996 Jul 17;111(1-3):181-9 (24 ref.)
[Pneumonitis secondary to the inhalation of isocyanates. An analysis of 2 cases] Haro M, et al. **Arch Bronconeumol** 1995 Aug-Sep;31(7):365-7 (18 ref.) (Eng. Abstr.) **(Spa)**

ISOCYANIDES see CYANIDES

ISOELECTRIC FOCUSING

METHODS

Capillary isoelectric focusing as a tool in the examination of antibodies, peptides and proteins of pharmaceutical interest. Liu X, et al. **J Chromatogr A** 1996 May 31; 735(1-2):165-90 (72 ref.)

ISOENZYMES

PDE isoenzymes as targets for anti-asthma drugs. Schudt C, et al. **Eur Respir J** 1995 Jul;8(7):1179-83 (18 ref.)

ANALYSIS

Localization and characterization of cytochrome P450 in the brain. In vivo and in vitro investigations on phenytoin- and phenobarbital-inducible isoforms. Volk B, et al. **Toxicol Lett** 1995 Dec;82-83:655-62 (11 ref.)
The 1993 ISOBM Abbott Award Lecture. Isozymes, tumor markers and oncodevelopmental biology. Fishman WH. **Tumour Biol** 1995;16(6):394-402 (58 ref.)
[Isoenzyme] Ohta H, et al. **Nippon Rinsho** 1996 Jun; 54(6):1505-9 (16 ref.) (Eng. Abstr.) **(Jpn)**

ANTAGONISTS & INHIBITORS

Negative modulation of nitric oxide synthase by nitric oxide and nitroso compounds. Griscavage JM, et al. **Adv Pharmacol** 1995;34:215-34 (56 ref.)
Induction of cytotoxicity in melanoma cells through inhibition of catechol-O-methyltransferase. Smit NP, et al. **Biochem Pharmacol** 1995 Dec 22;50(12):1955-62 (68 ref.)
Selective pharmacological inhibition of distinct nitric oxide synthase isoforms. Southan GJ, et al. **Biochem Pharmacol** 1996 Feb 23;51(4):383-94 (131 ref.)
Selective inhibitors of monoamine oxidase (MAO-A and MAO-B) as probes of its catalytic site and mechanism. Kalgutkar AS, et al. **Med Res Rev** 1995 Jul;15(4):325-88 (229 ref.)
Diabetes complications: why is glucose potentially toxic? [see comments] Porte D Jr, et al. **Science** 1996 May 3; 272(5262):699-700 (12 ref.) Comment in: Science 1996 May 3;272(5262):728-31.

BIOSYNTHESIS

Expression and expressional control of nitric oxide synthases in various cell types. Förstermann U, et al. **Adv Pharmacol** 1995;34:171-86 (102 ref.)
Regulation of the expression of the inducible isoform of nitric oxide synthase. Szabó C, et al. **Adv Pharmacol** 1995; 34:113-53 (265 ref.)
Regulation and function of inducible nitric oxide synthase during sepsis and acute inflammation. Wong JM, et al. **Adv Pharmacol** 1995;34:155-70 (68 ref.)
Constitutive cyclooxygenase (COX-1) and inducible cyclooxygenase (COX-2): rationale for selective inhibition and progress to date. Griswold DE, et al. **Med Res Rev** 1996 Mar;16(2):181-206 (143 ref.)
Induction of cytochrome P450 isoforms by carcinogenic aromatic amines and carcinogenic susceptibility of rodent animals. Hashimoto Y, et al. **Pharmacogenetics** 1995;5 Spec No:S80-3 (22 ref.)

BLOOD

[Isoenzyme of nonspecific esterase in hemopoietic cells] Sasaki R. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:239-42 (10 ref.) **(Jpn)**
[Isozyme analysis by enzyme immunoassay (EIA)—clinical significance and future prospect] Takagi Y. **Nippon Rinsho** 1995 Sep;53(9):2250-5 (15 ref.) (Eng. Abstr.) **(Jpn)**

CHEMISTRY

Biochemical properties and function of poly(ADP-ribose) glycohydrolase. Desnoyers S, et al. **Biochimie** 1995;

77(6):433–8 (44 ref.)
Neuronal nitric oxide synthase, a modular enzyme formed by convergent evolution: structure studies of a cysteine thiolate–liganded heme protein that hydroxylates L–arginine to produce NO. as a cellular signal. Masters BS, et al. **FASEB J** 1996 Apr;10(5):552–8 (70 ref.)
Molecular aspects of carboxylesterase isoforms in comparison with other esterases. Satoh T, et al. **Toxicol Lett** 1995 Dec; 82–83:439–45 (17 ref.)

GENETICS

Regulation of the expression of the inducible isoform of nitric oxide synthase. Szabó C, et al. **Adv Pharmacol** 1995; 34:113–53 (265 ref.)
Nitric oxide synthases: gene structure and regulation. Wang Y, et al. **Adv Pharmacol** 1995;34:71–90 (99 ref.)
Diversity in cyclic nucleotide phosphodiesterase isoenzyme families. Manganiello VC, et al. **Arch Biochem Biophys** 1995 Sep 10;322(1):1–13 (156 ref.)
The glutathione S–transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Hayes JD, et al. **Crit Rev Biochem Mol Biol** 1995;30(6):445–600 (779 ref.)
Motor neuron disease caused by mutations in superoxide dismutase 1. Wong PC, et al. **Curr Opin Neurol** 1995 Aug; 8(4):294–301 (77 ref.)
Co–suppression of beta–1,3–glucanase genes in Nicotiana tabacum. de Carvalho Niebel F, et al. **Curr Top Microbiol Immunol** 1995;197:91–103 (39 ref.)
Ovine 11 beta–hydroxysteroid dehydrogenase: from gene to function. Yang K. **Endocr Res** 1995 Feb–May; 21(1–2):367–77 (49 ref.)
Molecular defects of erythroid 5–aminolevulinate synthase in X–linked sideroblastic anemia. Bottomley SS, et al. **J Bioenerg Biomembr** 1995 Apr;27(2):161–8 (50 ref.)
Nitric oxide synthase: expression and expressional control of the three isoforms. Förstermann U, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Oct; 352(4):351–64 (166 ref.)
[Cloning, expression, and regulation of tissue–specific genes in Drosophila] Korochkin LI. **Genetika** 1995 Aug; 31(8):1029–42 (68 ref.) (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

Nitric oxide synthase isozymes antibodies. Pollock JS, et al. **Histochem J** 1995 Oct;27(10):738–44 (61 ref.)

METABOLISM

Substrate binding pocket structure of human aldehyde dehydrogenases. A substrate specificity approach. Yin SJ, et al. **Adv Exp Med Biol** 1995;372:9–16 (48 ref.)
Why tetrahydrobiopterin? Mayer B, et al. **Adv Pharmacol** 1995;34:251–61 (50 ref.)
Prostaglandin endoperoxide synthase: why two isoforms? Williams CS, et al. **Am J Physiol** 1996 Mar;270(3 Pt 1):G393–400 (75 ref.)
New 17 beta–hydroxysteroid dehydrogenases. Molecular and cell biology of the type IV porcine and human enzymes. Adamski J, et al. **Ann N Y Acad Sci** 1996 Apr 30;784:124–36 (46 ref.)
Isoforms of nitric oxide synthase. Properties, cellular distribution and expressional control. Förstermann U, et al. **Biochem Pharmacol** 1995 Oct 26;50(9):1321–32 (134 ref.)
Cyclooxygenase–2: regulation and relevance in inflammation. Mitchell JA, et al. **Biochem Pharmacol** 1995 Nov 9; 50(10):1535–42 (92 ref.)
Intracellular targeting of protein kinase C isoenzymes: functional implications. Kiley SC, et al. **Biochem Soc Trans** 1995 Aug;23(3):601–5 (34 ref.)
Molecular study and regulation of D–myo–inositol 1,4,5–trisphosphate 3–kinase. Communi D, et al. **Cell Signal** 1995 Sep;7(7):643–50 (52 ref.)
Enzymology of mammalian phospholipases D: in vitro studies. Liscovitch M, et al. **Chem Phys Lipids** 1996 May 24;80(1–2):37–44 (82 ref.)
Protein kinase C isozymes and substrates. Jaken S. **Curr Opin Cell Biol** 1996 Apr;8(2):168–73 (58 ref.)
Protein kinase C–delta, an important signaling molecule in the platelet–derived growth factor beta receptor pathway. Li W, et al. **Curr Top Microbiol Immunol** 1996;211:55–65 (23 ref.)
Dopamine D1 receptor regulation of phospholipase C. Jose PA, et al. **Hypertens Res** 1995 Jun;18 Suppl 1:S39–42 (45 ref.)
Some aspects of the role of cytochrome P–450 isozymes in the N–oxidative transformation of secondary and tertiary amine compounds. Hlavica P, et al. **J Biochem Toxicol** 1995 Oct;10(5):275–285 (86 ref.)
Kinetic analysis of enzymic activities: prediction of multiple forms of 17 beta–hydroxysteroid dehydrogenase. Blomquist CH. **J Steroid Biochem Mol Biol** 1995 Dec;55(5–6):515–24 (44 ref.)
Specificity of human UDP–glucuronosyltransferases and xenobiotic glucuronidation. Burchell B, et al. **Life Sci** 1995; 57(20):1819–31 (64 ref.)
Polyunsaturated fatty acids and signalling via phospholipase C–beta and A2 in myocardium. de Jonge HW, et al. **Mol Cell Biochem** 1996 Apr 12–26;157(1–2):199–210 (79 ref.)
Signalling by protein kinase C isoforms in the heart. Pucéat M, et al. **Mol Cell Biochem** 1996 Apr 12–26;157(1–2):65–72 (72 ref.)
Transcriptional regulation by MAP kinases. Davis RJ. **Mol Reprod Dev** 1995 Dec;42(4):459–67 (31 ref.)
Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Beavo JA. **Physiol Rev** 1995 Oct; 75(4):725–48 (179 ref.)
[Cytochrome P–450 isoenzymes as predictors of drug interactions] Pelkonen O. **Duodecim** 1994;110(17):1575–9 (19 ref.) **(Fin)**
[Role of human cytochrome P–450 enzymes in the metabolism of xenobiotics] Monostory K, et al. **Acta Pharm Hung** 1995 Sep;65(5):147–56 (94 ref.) (Eng. Abstr.) **(Hun)**
[Cytochrome P–450 in tumors and during carcinogenesis] Kobliakov VA. **Biokhimiia** 1995 Nov;60(11):1747–64 (122 ref.) (Eng. Abstr.) **(Rus)**
[Functional role and properties of AMP–deaminase] Lushchak VI. **Biokhimiia** 1996 Feb;61(2):195–211 (59 ref.) (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

Immunomodulatory actions of xanthines and isoenzyme selective phosphodiesterase inhibitors. Banner KH, et al. **Monaldi Arch Chest Dis** 1995 Aug;50(4):286–92 (96 ref.)

PHYSIOLOGY

Multifunctional calcium and calmodulin–dependent kinase II in neuronal function and disease. Churn SB. **Adv Neuroimmunol** 1995;5(3):241–59 (141 ref.)
Regulation and function of inducible nitric oxide synthase during sepsis and acute inflammation. Wong JM, et al. **Adv Pharmacol** 1995;34:155–70 (68 ref.)
Multi–dynein hypothesis. Asai DJ. **Cell Motil Cytoskeleton** 1995;32(2):129–32 (36 ref.)
Dynein family of motor proteins: present status and future questions. Gibbons IR. **Cell Motil Cytoskeleton** 1995; 32(2):136–44 (48 ref.)
Phosphatidate phosphohydrolase and signal transduction. Brindley DN, et al. **Chem Phys Lipids** 1996 May 24; 80(1–2):45–57 (78 ref.)
Regulation of phospholipase D by protein kinase C. Kiss Z. **Chem Phys Lipids** 1996 May 24;80(1–2):81–102 (243 ref.)
Type III cyclic nucleotide phosphodiesterases and insulin action. Manganiello VC, et al. **Curr Top Cell Regul** 1996; 34:63–100 (265 ref.)
Clinical investigation of 11 beta–hydroxysteroid dehydrogenase. Walker BR, et al. **Endocr Res** 1995 Feb–May;21(1–2):379–87 (39 ref.)
The role of glutathione S–transferases in head and neck squamous cell carcinogenesis. Bongers V, et al. **Eur J Cancer B Oral Oncol** 1995 Nov;31B(6):349–54 (63 ref.)
The emerging role of cytochrome P450 3A in psychopharmacology. Ketter TA, et al. **J Clin Psychopharmacol** 1995 Dec;15(6):387–98 (173 ref.)
Cyclooxygenase 2 induction: molecular mechanism and pathophysiologic roles. Wu KK. **J Lab Clin Med** 1996 Sep; 128(3):242–5 (28 ref.)
Tetrameric (G4) acetylcholinesterase: structure, localization, and physiological regulation. Fernandez HL, et al. **J Neurochem** 1996 Apr;66(4):1335–46 (120 ref.)
Cytochrome P450 isoenzymes—importance for the internist. Kerremans AL. **Neth J Med** 1996 Jun;48(6):237–43 (36 ref.)
Secretory type II phospholipase A2 and the generation of intrauterine signals. Rice GE. **Reprod Fertil Dev** 1995; 7(6):1471–9 (99 ref.)
The biology of HMG–CoA reductase: the pros of contra–regulation. Hampton R, et al. **Trends Biochem Sci** 1996 Apr;21(4):140–5 (39 ref.)
[Progress in the study of cyclic nucleotide phosphodiesterases] Zhou HL, et al. **Sheng Li Ko Hsueh Chin Chan** 1995 Jul;26(3):213–7 (16 ref.) (Eng. Abstr.) **(Chi)**
[Regulation of phospholipase C–delta 1] Hirata M, et al. **Seikagaku** 1995 Sep;67(9):1128–32 (15 ref.) **(Jpn)**

ISOEPHEDRINE see **EPHEDRINE**

ISOETRETIN see **ACITRETIN**

ISOFLAVONES

[The ipriflavone story] György L, et al. **Acta Pharm Hung** 1995 Nov;65(6):191–4 (20 ref.) (Eng. Abstr.) **(Hun)**

PHARMACOLOGY

Phytoestrogens: epidemiology and a possible role in cancer protection. Adlercreutz H. **Environ Health Perspect** 1995 Oct;103 Suppl 7:103–12 (133 ref.)
[Inhibitors of protein–tyrosine kinases: pharmacological perspectives? (editorial)] Jacquemin–Sablon A, et al. **Pathol Biol (Paris)** 1995 May;43(5):389–94 (66 ref.) **(Fre)**

THERAPEUTIC USE

[Overview of clinical studies with ipriflavone] Attila BK. **Acta Pharm Hung** 1995 Nov;65(6):223–8 (20 ref.) (Eng. Abstr.) **(Hun)**
[Place of ipriflavone in the therapy of osteoporosis] Zsuzsanna B. **Acta Pharm Hung** 1995 Nov;65(6):229–32 (32 ref.) (Eng. Abstr.) **(Hun)**

ISOFLURANE

ANALOGS & DERIVATIVES

Which inhalation anaesthetic agent is best for pediatric use? Lindahl SG. **Acta Anaesthesiol Belg** 1996;47(1):23–7 (14 ref.)
Circulatory effects of desflurane. Coriat P. **Anaesthesia** 1995 Oct;50 Suppl:18–21 (19 ref.)
Physicochemical properties and pharmacodynamics of desflurane. Eger EI 2nd. **Anaesthesia** 1995 Oct;50 Suppl:3–8 (41 ref.)
Economic analysis and pharmaceutical policy: a consideration of the economics of the use of desflurane. Eger EI 2nd. **Anaesthesia** 1995 Oct;50 Suppl:45–8 (22 ref.)
Cardiovascular effects of desflurane in experimental animals and volunteers. Weiskopf RB. **Anaesthesia** 1995 Oct;50 Suppl:14–7 (29 ref.)
Implications of chemical and physical properties of desflurane for longer surgery. Weiskopf RB. **Anaesthesia** 1995 Oct;50 Suppl:9–13 (57 ref.)
Desflurane. A review of its pharmacodynamic and pharmacokinetic properties and its efficacy in general anaesthesia. Patel SS, et al. **Drugs** 1995 Oct;50(4):742–67 (201 ref.)
Inhalational anesthetics: desflurane and sevoflurane. Young CJ, et al. **J Clin Anesth** 1995 Nov;7(7):564–77 (198 ref.)

ISOFOSFAMIDE see **IFOSFAMIDE**

ISOGRAFT see **TRANSPLANTATION, ISOGENEIC**

ISOIMMUNIZATION, RHESUS see **RH ISOIMMUNIZATION**

ISOLATION PERFUSION THERAPY see **PERFUSION, REGIONAL**

ISOLATION, SOCIAL see **SOCIAL ISOLATION**

ISOLEUCINE

BIOSYNTHESIS

Construction of L–lysine–, L–threonine–, and L–isoleucine–overproducing strains of Corynebacterium glutamicum. Sahm H, et al. **Ann N Y Acad Sci** 1996 May 15;782:25–39 (34 ref.)

3–ISOLEUCYL VASOPRESSIN see **VASOTOCIN**

ISOMERASES

Prostaglandin D, E, and F synthases. Urade Y, et al. **J Lipid Mediat Cell Signal** 1995 Oct;12(2–3):257–73 (67 ref.)

CHEMISTRY

Structure–function features of flaxseed allene oxide synthase. Brash AR, et al. **J Lipid Mediat Cell Signal** 1995 Oct; 12(2–3):275–82 (26 ref.)

METABOLISM

Tyrosinase and related proteins in mammalian pigmentation. del Marmol V, et al. **FEBS Lett** 1996 Mar 4;381(3):165–8 (48 ref.)
Structure–function features of flaxseed allene oxide synthase. Brash AR, et al. **J Lipid Mediat Cell Signal** 1995 Oct; 12(2–3):275–82 (26 ref.)
Hydroperoxide isomerases. Hamberg M. **J Lipid Mediat Cell Signal** 1995 Oct;12(2–3):283–92 (37 ref.)
Prostacyclin and thromboxane synthases. Tanabe T, et al. **J Lipid Mediat Cell Signal** 1995 Oct;12(2–3):243–55 (67 ref.)

PHYSIOLOGY

Prostaglandins and sleep. Hayaishi O, et al. **Adv Neuroimmunol** 1995;5(2):211–6 (9 ref.)

ISOMETRIC CONTRACTION

PHYSIOLOGY

The senses of effort and force during fatiguing contractions. Jones LA. **Adv Exp Med Biol** 1995;384:305–13 (38 ref.)

ISOMETRIC EXERCISE see **EXERCISE**

ISONIAZID

PHARMACOLOGY

Antimicrobial agent resistance in mycobacteria: molecular genetic insights. Musser JM. **Clin Microbiol Rev** 1995 Oct; 8(4):496–514 (181 ref.)
The structure and function of the isoniazid target in M. tuberculosis. Sacchettini JC, et al. **Res Microbiol** 1996 Jan–Feb;147(1–2):36–43 (29 ref.)

POISONING

Isoniazid overdose: four case reports and review of the

literature. Alvarez FG, et al. **Intensive Care Med** 1995 Aug; 21(8):641–4 (28 ref.)
Treatment of acute isoniazid overdose in dogs. Villar D, et al. **Vet Hum Toxicol** 1995 Oct;37(5):473–7 (50 ref.)

THERAPEUTIC USE

Preventive therapy for tuberculosis in HIV infection: the promise and the reality [editorial] O'Brien RJ, et al. **AIDS** 1995 Jul;9(7):665–73 (83 ref.)
Current problems with tuberculosis treatment. Grosset J. **Res Microbiol** 1996 Jan–Feb;147(1–2):10–6 (32 ref.)
Solving the dilemma of antimycobacterial chemotherapy. Rastogi N, et al. **Res Microbiol** 1996 Jan–Feb;147(1–2):7–10 (30 ref.)

ISONICOTINIC ACID HYDRAZIDE see **ISONIAZID**

ISONIPECAIN see **MEPERIDINE**

ISONYMY see **NAMES**

ISOPHOSPHAMIDE see **IFOSFAMIDE**

ISOPRENALINE see **ISOPROTERENOL**

ISOPRENYLATION see **PROTEIN ISOPRENYLATION**

ISOPROPANOL see **ALCOHOL, PROPYL**

ISOPROPYL ALCOHOL see **ALCOHOL, PROPYL**

ISOPROPYLARTERENOL see **ISOPROTERENOL**

N-ISOPROPYLATROPINE see **IPRATROPIUM**

ISOPROTERENOL

TOXICITY

Structural and biochemical remodelling in catecholamine-induced cardiomyopathy: comparative and ontogenetic aspects. Oštádal B, et al. **Mol Cell Biochem** 1995 Jun 7–21;147(1–2):83–8 (49 ref.)

ISOQUINOLINES

Mivacurium chloride—a comparative profile. Diffenbach C, et al. **Acta Anaesthesiol Scand Suppl** 1995;106:23–5 (10 ref.)

ADMINISTRATION & DOSAGE

Mivacurium in special patient groups. Jones RM. **Acta Anaesthesiol Scand Suppl** 1995;106:47–54 (57 ref.)

METABOLISM

Endogenous morphine. Hosztafi S, et al. **Pharmacol Res** 1995 Jul–Aug;32(1–2):15–20 (51 ref.)
Dopamine-derived 6,7-dihydroxy-1,2,3,4-tetrahydroisoquinolines; oxidation and neurotoxicity. Naoi M, et al. **Prog Brain Res** 1995; 106:227–39 (42 ref.)

PHARMACOKINETICS

Pharmacokinetics and pharmacodynamics of the benzylisoquinolinium muscle relaxants. Hull CJ. **Acta Anaesthesiol Scand Suppl** 1995;106:13–7 (19 ref.)

PHARMACOLOGY

Pharmacokinetics and pharmacodynamics of the benzylisoquinolinium muscle relaxants. Hull CJ. **Acta Anaesthesiol Scand Suppl** 1995;106:13–7 (19 ref.)
The clinical and basic pharmacology of mivacurium: a short-acting nondepolarizing benzylisoquinolinium diester neuromuscular blocking drug. Savarese JJ, et al. **Acta Anaesthesiol Scand Suppl** 1995;106:18–22 (16 ref.)
Saquinavir: an HIV proteinase inhibitor. Bragman K. **Adv Exp Med Biol** 1996;394:305–17 (25 ref.)

THERAPEUTIC USE

Drug-resistance patterns of saquinavir and other HIV proteinase inhibitors. Roberts NA. **AIDS** 1995 Dec;9 Suppl 2:27–S32 (34 ref.)
Clinical experience with saquinavir. Vella S. **AIDS** 1995 Dec; 9 Suppl 2:S21–S25 (22 ref.)
A chronotherapeutic approach to the management of hypertension. White WB. **Am J Hypertens** 1996 Apr;9(4 Pt 3):29S–33S (27 ref.)

TOXICITY

Dopamine-derived 6,7-dihydroxy-1,2,3,4-tetrahydroisoquinolines; oxidation and neurotoxicity. Naoi M, et al. **Prog Brain Res** 1995; 106:227–39 (42 ref.)

ISOSORBIDE DINITRATE

THERAPEUTIC USE

Organic nitrates: new formulations and their clinical advantages. Parker JA. **Am J Cardiol** 1996 May 30; 77(13):38C–40C (23 ref.)

ISOTACHOPHORESIS see **ELECTROPHORESIS**

ISOTHIOCYANATES

THERAPEUTIC USE

Chemoprevention by isothiocyanates. Hecht SS. **J Cell Biochem Suppl** 1995;22:195–209 (33 ref.)

ISOTONIC SOLUTIONS

THERAPEUTIC USE

[What are the advances in the treatment of acute kidney failure? (editorial)] Brivet F, et al. **Presse Med** 1996 Feb 17;25(6):227–9 (13 ref.) (Eng. Abstr.) **(Fre)**

ISOTOPE LABELING

METHODS

In vivo stationary flux analysis by 13C labeling experiments. Wiechert W, et al. **Adv Biochem Eng Biotechnol** 1996; 54:109–54 (144 ref.)
Doubly labelled water measurement of total energy expenditure. Ritz P, et al. **Diabete Metab** 1995 Oct; 21(4):241–51 (68 ref.)
Radiolabelled peptides: now and the future. Thakur ML. **Nucl Med Commun** 1995 Sep;16(9):724–32 (41 ref.)

ISOTOPES

The role of stable isotopes in the investigation of plasma lipoprotein metabolism. Packard CJ. **Baillieres Clin Endocrinol Metab** 1995 Oct;9(4):755–72 (46 ref.)
Theoretical calculations of heavy-atom isotope effects. Paneth P. **Comput Chem** 1995 Sep;19(3):231–40 (70 ref.)
Stable isotopes of lead for source identification. Rabinowitz MB. **J Toxicol Clin Toxicol** 1995;33(6):649–55 (37 ref.)
[Stable isotopes in biomedical diagnosis and research] Martínez JA, et al. **Rev Med Univ Navarra** 1995 Jul–Sep; 39(3):141–52 (118 ref.) (Eng. Abstr.) **(Spa)**

ISOTRETINOIN

ADMINISTRATION & DOSAGE

[The oral treatment of rosacea with isotretinoin] Jansen T, et al. **Dtsch Med Wochenschr** 1995 Dec 15;120(50):1745–7 (32 ref.) **(Ger)**

ADVERSE EFFECTS

Oral retinoids and pregnancy. Chan A, et al. **Med J Aust** 1996 Aug 5;165(3):164–7 (20 ref.)
[Isotretinoin (RoAccutane) embryopathy. A case report] Pilorget H, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(5):511–5 (14 ref.) (Eng. Abstr.) **(Fre)**

THERAPEUTIC USE

[Pharma-clinics. How I treat... rosacea] Piérard-Franchimont C, et al. **Rev Med Liege** 1996 Jun; 51(6):393–5 (25 ref.) **(Fre)**

ISOTYPE SWITCHING see **IMMUNOGLOBULIN CLASS SWITCHING**

ISOXAZOLES

BLOOD

[Zonisamide] Shuto H, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:931–3 (6 ref.) **(Jpn)**

THERAPEUTIC USE

Innovative treatment approaches for rheumatoid arthritis. Cyclosporin, leflunomide and nitrogen mustard. Furst DE. **Baillieres Clin Rheumatol** 1995 Nov;9(4):711–29 (41 ref.)

ISOZYMES see **ISOENZYMES**

ISRADIPINE

THERAPEUTIC USE

[Metabolic tolerance of isradipine. Evaluation after three months of therapy] Panuccio D, et al. **Clin Ter** 1995 Nov; 146(11):729–36 (82 ref.) (Eng. Abstr.) **(Ita)**

ISS SCORE see **INJURY SEVERITY SCORE**

ITAI-ITAI see **CADMIUM POISONING**

ITCHING see **PRURITUS**

ITO SYNDROME see **PIGMENTATION DISORDERS**

ITP see **INOSINE TRIPHOSPHATE**

ITRACONAZOLE

THERAPEUTIC USE

Peritoneal dialysis complicated by Bipolaris hawaiiensis peritonitis: successful therapy with catheter removal and oral itraconazol without the use of amphotericin-B. Gadallah MF, et al. **Am J Nephrol** 1995;15(4):348–52 (19 ref.)
Pseudallescheria boydii in an immunocompromised host. Successful treatment with debridement and itraconazole. Ruxin TA, et al. **Arch Dermatol** 1996 Apr;132(4):382–4 (23 ref.)
Role of azoles in antifungal therapy. Kauffman CA. **Clin Infect Dis** 1996 May;22 Suppl 2:S148–53 (72 ref.)
Itraconazole and therapy of fungal infections. Van Cutsem J. **Curr Probl Dermatol** 1996;24:194–202 (29 ref.)
Itraconazole. A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections. Haria M, et al. **Drugs** 1996 Apr;51(4):585–620 (245 ref.)
Successfully treated invasive pulmonary aspergillosis associated with smoking marijuana in a renal transplant recipient. Marks WH, et al. **Transplantation** 1996 Jun 27; 61(12):1771–4 (8 ref.)
[Multiple digestive involvement in visceral leishmaniasis in a patient with HIV infection: favourable course with itraconazole] Béchade D, et al. **Rev Med Interne** 1996; 17(3):234–7 (20 ref.) (Eng. Abstr.) **(Fre)**

IUDR see **IDOXURIDINE**

IUGR see **FETAL GROWTH RETARDATION**

IVERMECTIN

ANALOGS & DERIVATIVES

Avermectins. MacNeil DJ. **Biotechnology** 1995;28:421–42 (59 ref.)
Structure and activity of avermectins and milbemycins in animal health. Shoop WL, et al. **Vet Parasitol** 1995 Sep; 59(2):139–56 (54 ref.)

CHEMISTRY

Structure and activity of avermectins and milbemycins in animal health. Shoop WL, et al. **Vet Parasitol** 1995 Sep; 59(2):139–56 (54 ref.)

METABOLISM

Avermectins. MacNeil DJ. **Biotechnology** 1995;28:421–42 (59 ref.)

THERAPEUTIC USE

Endectocidal drugs: ecological risks and counter-measures. Herd R. **Int J Parasitol** 1995 Aug;25(8):875–85 (82 ref.)
[Role of ivermectin in the prophylaxis of lymphatic filariasis] Cartel JL, et al. **Med Trop (Mars)** 1995;55(3 Suppl):30–3 (26 ref.) **(Fre)**

IVIG see **IMMUNOGLOBULINS, INTRAVENOUS**

IXODES

A case of tick bite by a spontaneously retreated Ixodes nipponensis. Cho BK, et al. **Korean J Parasitol** 1995 Sep; 33(3):239–42 (15 ref.)
[The interrelationships of ixodid ticks (Ixodidae) with the causative agents of transmissible vertebrate infections] Balashov IuS. **Parazitologiia** 1995 Sep–Oct;29(5):337–52 (90 ref.) (Eng. Abstr.) **(Rus)**

MICROBIOLOGY

Ticks and Lyme disease. Bennett CE. **Adv Parasitol** 1995; 36:343–405 (396 ref.)
[Lyme borreliosis: epidemiologic and etiopathogenic aspects] Oteo-Revuelta JA, et al. **Enferm Infecc Microbiol Clin** 1995 Nov;13(9):550–5 (53 ref.) **(Spa)**

PHYSIOLOGY

The life-cycle of Amblyomma variegatum (Acari: Ixodidae): a literature synthesis with a view to modelling. Yonow T. **Int J Parasitol** 1995 Sep;25(9):1023–60 (118 ref.)

VIROLOGY

Persistence and transmission of tick-borne viruses: Ixodes ricinus and louping-ill virus in red grouse populations. Hudson PJ, et al. **Parasitology** 1995;111 Suppl:S49–58 (27 ref.)

IXODES DAMMINI see **IXODES**

IXODES RICINUS see **IXODES**

IXODES SCAPULARIS see **IXODES**

J-POUCH see **PROCTOCOLECTOMY, RESTORATIVE**

JACKKNIFE SEIZURES see **SPASMS, INFANTILE**

JACKSONIAN SEIZURE see EPILEPSY, PARTIAL

JAKOB-CREUTZFELDT SYNDROME see CREUTZFELDT-JAKOB SYNDROME

JANSKY-BIELSCHOWSKY DISEASE see NEURONAL CEROID-LIPOFUSCINOSIS

JAPANESE AMERICANS see ASIAN AMERICANS

JAPANESE MONKEY see MACACA

JAPANESE QUAIL see COTURNIX

JAUNDICE

ETIOLOGY

[Lemmel's syndrome caused by a giant diverticulum in the third portion of the duodenum, report of a case] Hirano A, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Nov; 92(11):1863–70 (11 ref.) **(Jpn)**

[Postoperative liver damage, postoperative jaundice, and benign postoperative cholestasis] Ouchi K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):538–40 (6 ref.) **(Jpn)**

JAUNDICE, CHOLESTATIC see CHOLESTASIS

JAUNDICE, CHOLESTATIC, EXTRAHEPATIC see BILE DUCT OBSTRUCTION, EXTRAHEPATIC

JAUNDICE, CHOLESTATIC, INTRAHEPATIC see CHOLESTASIS, INTRAHEPATIC

JAUNDICE, CHRONIC IDIOPATHIC

METABOLISM

[Dubin–Johnson syndrome] Tazuma S, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):424–6 (18 ref.) **(Jpn)**

JAUNDICE, HEMOLYTIC see ANEMIA, HEMOLYTIC

JAUNDICE, MECHANICAL see CHOLESTASIS

JAUNDICE, NEONATAL

Immunizations, animal-induced injuries and disease, neonatal jaundice, and viral infections. Gerson WT. **Curr Opin Pediatr** 1995 Aug;7(4):477–86 (73 ref.)

Neonatal cholestasis. Arora NK. **Trop Gastroenterol** 1996 Apr–Jun;17(2):61–9 (26 ref.)

DIAGNOSIS

Prediction and non-invasive assessment of neonatal jaundice in the term healthy newborn infant. Knudsen A. **Acta Paediatr** 1996 Apr;85(4):393–7 (32 ref.)

Advances in the diagnosis and treatment of neonatal hyperbilirubinemia. Yao TC, et al. **Clin Perinatol** 1995 Sep; 22(3):741–58 (120 ref.)

ETIOLOGY

[Breast-milk jaundice] Ishii M, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):591–4 (20 ref.) **(Jpn)**

THERAPY

Advances in the diagnosis and treatment of neonatal hyperbilirubinemia. Yao TC, et al. **Clin Perinatol** 1995 Sep; 22(3):741–58 (120 ref.)

Neonatal jaundice: when to treat, when to watch and wait. Lasker MR, et al. **Postgrad Med** 1996 Mar;99(3):187–93, 197–8 (20 ref.)

[Jaundice of newborn, neonatal jaundice] Gotani T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):547–51 (12 ref.) **(Jpn)**

JAUNDICE, OBSTRUCTIVE see CHOLESTASIS

JAUNDICE, OBSTRUCTIVE, EXTRAHEPATIC see BILE DUCT OBSTRUCTION, EXTRAHEPATIC

JAUNDICE, OBSTRUCTIVE, INTRAHEPATIC see CHOLESTASIS, INTRAHEPATIC

JAUNDICE, SPIROCHETAL see WEIL'S DISEASE

JAW

see related
DENTAL ARCH
TEMPOROMANDIBULAR JOINT

ANATOMY & HISTOLOGY

[Gnathologic concepts and their practical role in dentistry] Fazekas A, et al. **Fogorv Sz** 1996 Feb;89(2):39–49 (26 ref.) **(Hun)**

PHYSIOLOGY

Fatigue of jaw muscles and speech mechanisms. Miles TS, et al. **Adv Exp Med Biol** 1995;384:415–26 (55 ref.)

[Jaw position, head position, body posture: development of an integrated system of examination, Part I] Takigawa T, et al. **Kokubyo Gakkai Zasshi** 1995 Sep;62(3):441–50 (23 ref.) (Eng. Abstr.) **(Jpn)**

RADIOGRAPHY

Use of orthopantomography in forensic identification. Doychinov I, et al. **Folia Med (Plovdiv)** 1994;36(3):57–61 (6 ref.)

Temporomandibular joint and dental imaging. Westesson PL. **Neuroimaging Clin N Am** 1996 May;6(2):333–55 (31 ref.)

Anatomy of the jaw, dentition, and related regions. Abrahams JJ, et al. **Semin Ultrasound CT MR** 1995 Dec;16(6):453–67 (13 ref.)

SURGERY

Removal of asymptomatic bone plates used for orthognathic surgery and facial fractures. Alpert B, et al. **J Oral Maxillofac Surg** 1996 May;54(5):618–21 (41 ref.)

Retention of asymptomatic bone plates used for orthognathic surgery and facial fractures. Haug RH. **J Oral Maxillofac Surg** 1996 May;54(5):611–7 (90 ref.)

Prolonged dysphagia after orthognathic surgery: report of a case and review of the literature. Nagler RM, et al. **J Oral Maxillofac Surg** 1996 Apr;54(4):523–5 (21 ref.)

Economic analysis and its application to oral and maxillofacial surgery. Sandler NA, et al. **J Oral Maxillofac Surg** 1996 May;54(5):622–6 (12 ref.)

JAW ABNORMALITIES

EPIDEMIOLOGY

[Congenital developmental defects of the face and jaws: their morbidity, mortality and risk factors] Beliakov SV, et al. **Stomatologiia (Mosk)** 1995;74(5):72–5 (66 ref.) **(Rus)**

SURGERY

[Miniplate rigid fixation in orthognathic surgery] Zhang X, et al. **Chung Hua Kou Chiang Hsueh Tsa Chih** 1995 May; 30(3):184–6 (26 ref.) **(Chi)**

JAW CYSTS

PATHOLOGY

Orofacial biopsies: a survey of 1,723 cases seen over a 10 year period. Chidzonga MM, et al. **Cent Afr J Med** 1996 Apr;42(4):102–8 (17 ref.)

JAW DISEASES

DIAGNOSIS

Differential diagnosis of jaw pain in the elderly. Sandler NA, et al. **J Am Dent Assoc** 1995 Sep;126(9):1263–72 (40 ref.)

Differential diagnosis of oral enlargements in children. Flaitz CM, et al. **Pediatr Dent** 1995 Jul–Aug;17(4):294–300 (12 ref.)

PATHOLOGY

Recurrent multifocal Langerhans cell eosinophilic granuloma of the jaws: report of a case. Uckan S, et al. **J Oral Maxillofac Surg** 1996 Jul;54(7):906–9 (15 ref.)

A clinical and histopathological study of radicular cysts associated with primary molars. Mass E, et al. **J Oral Pathol Med** 1995 Nov;24(10):458–61 (9 ref.)

RADIOGRAPHY

Traumatic bone cysts in the jaws of a Hong Kong Chinese population. MacDonald-Jankowski DS. **Clin Radiol** 1995 Nov;50(11):787–91 (29 ref.)

JAW, EDENTULOUS

REHABILITATION

Implant prosthodontic treatment options for the edentulous patient. Zarb GA, et al. **J Oral Rehabil** 1995 Aug; 22(8):661–71 (17 ref.)

Factors to consider in selecting an occlusal concept for patients with implants in the edentulous mandible. Wismeijer D, et al. **J Prosthet Dent** 1995 Oct;74(4):380–4 (26 ref.)

JAW, EDENTULOUS, PARTIALLY

REHABILITATION

The role of the shortened dental arch concept in the management of reduced dentitions. Allen PF, et al. **Br Dent J** 1995 Nov 11;179(9):355–7 (24 ref.)

Restoration of the partially edentulous mouth—a comparison of overdentures, removable partial dentures, fixed partial dentures and implant treatment. Budtz-Jörgensen E. **J Dent** 1996 Jul;24(4):237–44 (89 ref.)

Prosthodontic treatment for the Applegate-Kennedy class V partially edentulous patient. Shifman A, et al. **J Prosthet Dent** 1996 Aug;76(2):212–8 (39 ref.)

JAW NEOPLASMS

CLASSIFICATION

Maxillofacial fibro-osseous lesions: classification and differential diagnosis. Slootweg PJ. **Semin Diagn Pathol** 1996 May;13(2):104–12 (22 ref.)

DIAGNOSIS

Differential diagnosis of oral enlargements in children. Flaitz CM, et al. **Pediatr Dent** 1995 Jul–Aug;17(4):294–300 (12 ref.)

Maxillofacial fibro-osseous lesions: classification and differential diagnosis. Slootweg PJ. **Semin Diagn Pathol** 1996 May;13(2):104–12 (22 ref.)

PATHOLOGY

Calcifying odontogenic cyst associated with compound odontoma: a study on undemineralized material. Piattelli A, et al. **Bull Group Int Rech Sci Stomatol Odontol** 1995 Sep–Oct;38(3–4):105–9 (18 ref.)

Adenomatoid odontogenic tumours in Ibadan, Nigeria. Arotiba JT, et al. **East Afr Med J** 1995 Dec;72(12):783–6 (21 ref.)

JAW RELATION RECORD

[Predictive soft tissue factors in bimaxillary operations] Steinhäuser EW, et al. **Fortschr Kiefer Gesichtschir** 1995; 40:50–7 (31 ref.) **(Ger)**

METHODS

Trouble-shooting dual arch impressions. Kaplowitz GJ. **J Am Dent Assoc** 1996 Feb;127(2):234–40 (24 ref.)

JC VIRUS see POLYOMAVIRUS HOMINIS 2

JE PROTEIN see MONOCYTE CHEMOATTRACTANT PROTEIN-1

JEALOUSY

[Othello syndrome--jealousy and jealous delusions as symptoms of psychiatric disorders] Soyka M. **Fortschr Neurol Psychiatr** 1995 Dec;63(12):487–94 (93 ref.) (Eng. Abstr.) **(Ger)**

JEHOVAH'S WITNESSES see CHRISTIANITY

JEJUNAL DISEASES

[Jejunal diverticulosis: report of a case and review of the literature] Clemente A, et al. **Minerva Chir** 1995 May; 50(5):497–500 (15 ref.) (Eng. Abstr.) **(Ita)**

COMPLICATIONS

Jejunal diverticulitis manifesting with abdominal wall abscess. Alvarez OA, et al. **Am J Gastroenterol** 1995 Nov; 90(11):2060–2 (10 ref.)

Complicated jejunal diverticulosis: report of a case. Fronticelli CM, et al. **Surg Today** 1996;26(3):192–5 (10 ref.)

DIAGNOSIS

Primary aortoenteric fistula: two new case reports and a review of 44 previously reported cases. Tareen AH, et al. **Eur J Vasc Endovasc Surg** 1996 Jul;12(1):5–10 (34 ref.)

EPIDEMIOLOGY

Perforated jejunal diverticula: an analysis of reported cases. Chendrasekhar A, et al. **Am Surg** 1995 Nov;61(11):984–8 (40 ref.)

ETIOLOGY

Multifocal stenosing ulcerations of the small intestine revealing vasculitis associated with C2 deficiency. Perlemuter G, et al. **Gastroenterology** 1996 May; 110(5):1628–32 (23 ref.)

Jejunal phlebectasia presenting with massive gastrointestinal hemorrhage. Mejia EM, et al. **J Clin Gastroenterol** 1996 Apr;22(3):215–7 (7 ref.)

[Buerger's disease disclosed by a perforation in the digestive system. Apropos of a case and review of the literature] Nyuyen TB, et al. **Rev Med Interne** 1996;17(1):70–5 (30 ref.) (Eng. Abstr.) **(Fre)**

RADIOGRAPHY

[Contrast agent retention in a jejunal diverticulum and small-intestine volvulus] Hüppe T, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1995 Nov;163(5):443–5 (10 ref.) **(Ger)**

JEJUNAL NEOPLASMS

DIAGNOSIS

Small bowel carcinoid: review of a single institution

experience and review of the literature. Box JC, et al. **Am Surg** 1996 Apr;62(4):280–6 (40 ref.)
Solitary intestinal fibromatosis mimicking malabsorption syndromes. Türken A, et al. **J Pediatr Surg** 1995 Sep; 30(9):1387–9 (9 ref.)
[A rare case of leiomyosarcoma of the jejunum and review of the literature] Maccioni F, et al. **Radiol Med (Torino)** 1996 May;91(5):655–8 (13 ref.) **(Ita)**

EPIDEMIOLOGY

Hemangioma of the small intestine: case report and literature review. Ramanujam PS, et al. **Am J Gastroenterol** 1995 Nov;90(11):2063–4 (9 ref.)

JEJUNOILEAL BYPASS

Human models: Whipple's disease, coeliac disease and jejunoileal bypass. Utsinger PD, et al. **Baillieres Clin Rheumatol** 1996 Feb;10(1):77–103 (129 ref.)

ADVERSE EFFECTS

[Pathogenesis of chronic diarrhoea after surgery for extreme obesity] Lemieszewski A. **Pol Tyg Lek** 1996 Jan; 51(1–5):37–9 (32 ref.) **(Pol)**

METHODS

[Is there still a place for biliointestinal bypass in the treatment of super obesity? (editorial)] Benhamou G, et al. **G Chir** 1996 Apr;17(4):149–53 (16 ref.) **(Ita)**

JEJUNOSTOMY

ADVERSE EFFECTS

Pneumatosis intestinalis and portal venous air associated with needle catheter jejunostomy. North JH Jr, et al. **Am Surg** 1995 Dec;61(12):1045–8 (25 ref.)
Bile duct carcinoma arising from the anastomotic site of hepaticojejunostomy after the excision of congenital biliary dilatation: a case report. Yamamoto J, et al. **Surgery** 1996 Apr;119(4):476–9 (10 ref.)

JEJUNUM

see related
JEJUNOSTOMY

ABNORMALITIES

[Jejunal membranous atresia with a late presentation] Barrios Fontoba JE, et al. **An Esp Pediatr** 1996 Jul;45(1):85–6 (13 ref.) **(Spa)**

BLOOD SUPPLY

Jejunal phlebectasia presenting with massive gastrointestinal hemorrhage. Mejia EM, et al. **J Clin Gastroenterol** 1996 Apr;22(3):215–7 (7 ref.)
Massive lower gastrointestinal bleeding due to 'Dieulafoy's vascular malformation' of the jejunum: case report. Goins WA, et al. **J Natl Med Assoc** 1995 Oct;87(10):766–70 (27 ref.)

TRANSPLANTATION

Oesophageal substitution. Isolauri J. **Ann Chir Gynaecol** 1995; 84(2):241–6 (30 ref.)

JELLYFISH

CYTOLOGY

Transdifferentiation of isolated striated muscle of jellyfish in vitro: the initiation process. Schmid V, et al. **Semin Cell Biol** 1995 Jun;6(3):109–16 (18 ref.)

JELLYFISH VENOMS see **CNIDARIAN VENOMS**

JERUSALEM ARTICHOKE see **HELIANTHUS**

JERVELL-LANGE NIELSEN SYNDROME see **LONG QT SYNDROME**

JEWS

see related
JUDAISM

JIMSONWEED see **STRAMONIUM**

JIRD see **GERBILLINAE**

JOB DESCRIPTION

Member responsibilities on a nursing research committee. Martin PA. **Appl Nurs Res** 1996 Aug;9(3):154–7 (15 ref.)
The future of the clinical nurse specialist in the USA. Briody ME. **Int Nurs Rev** 1996 Jan–Feb;43(1):17–20, 31 (25 ref.)
Nurse practitioners in a teaching hospital. Genet CA, et al. **Nurse Pract** 1995 Sep;20(9):47–52, 54 (33 ref.)

JOB LADDERS see **CAREER MOBILITY**

JOB SATISFACTION

Mental health, work, and gender. Dennerstein L. **Int J Health Serv** 1995;25(3):503–9 (27 ref.)

JOB'S SYNDROME

IMMUNOLOGY

[Job syndrome (hyper-IgE) and hypo-IgA. A rare association of immunodeficiencies] Mazzone A, et al. **Recenti Prog Med** 1996 Feb;87(2):71–4 (20 ref.) (Eng. Abstr.) **(Ita)**

JOINT DEFORMITIES, ACQUIRED

SURGERY

[Stabilization of interligamentous valgus procedure in tibial head osteotomy using staples] Zügel N, et al. **Z Orthop Ihre Grenzgeb** 1995 Sep–Oct;133(5):437–41 (31 ref.) (Eng. Abstr.) **(Ger)**

JOINT DISEASES

CHEMICALLY INDUCED

[Osteo-articular complications of heart transplantation] Rozenberg S, et al. **Presse Med** 1995 Dec 9;24(38):1809–12 (26 ref.) (Eng. Abstr.) **(Fre)**

CLASSIFICATION

Amyloidosis and silicone synovitis: updated classification, updated pathophysiology, and synovial articular abnormalities. Goldman AB, et al. **Radiol Clin North Am** 1996 Mar;34(2):375–94, xi (73 ref.)

DIAGNOSIS

Objective measures of joint stiffness. Roberson L, et al. **J Hand Ther** 1995 Apr–Jun;8(2):163–6 (15 ref.)
Synovial lesions of the hand and wrist. Bergman AG. **Magn Reson Imaging Clin N Am** 1995 May;3(2):265–79 (31 ref.)
MR imaging of periarticular soft-tissue lesions. Van Slyke MA, et al. **Magn Reson Imaging Clin N Am** 1995 Nov; 3(4):651–67 (49 ref.)
Ganglia and cysts around joints. Steiner E, et al. **Radiol Clin North Am** 1996 Mar;34(2):395–425, xi–xii (127 ref.)
CT and MR imaging of the hip. Conway WF, et al. **Radiology** 1996 Feb;198(2):297–307 (68 ref.)
Synovial hemangioma: imaging features in eight histologically proven cases, review of the literature, and differential diagnosis. Greenspan A, et al. **Skeletal Radiol** 1995 Nov;24(8):583–90 (32 ref.)
[MR tomography (MRT) of the skeleton, peripheral soft tissues and joints--current overview] Bohndorf K, et al. **Aktuelle Radiol** 1996 May;6(3):136–43 (47 ref.) (Eng. Abstr.) **(Ger)**
[Lateral release of the patella. I—Diagnostics, indications] Latosiewicz R. **Chir Narzadow Ruchu Ortop Pol** 1994; 59(3):231–4 (19 ref.) (Eng. Abstr.) **(Pol)**

DRUG THERAPY

[Use of methotrexate in spondylarthropathies. Review of the literature] Toussirot E, et al. **Rev Med Interne** 1996; 17(4):333–9 (40 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Pathogenesis of spondylarthropathies. Persistent bacterial antigen, autoimmunity, or both? Sieper J, et al. **Arthritis Rheum** 1995 Nov;38(11):1547–54 (80 ref.)
Effects of hemophilia on articulations of children and adults. Rodríguez-Merchán EC. **Clin Orthop** 1996 Jul;(328):7–13 (17 ref.)
Clinical and molecular aspects of the pathogenesis of Staphylococcus aureus bone and joint infections. Cunningham R, et al. **J Med Microbiol** 1996 Mar; 44(3):157–64 (55 ref.)
[Extracutaneous manifestations of neutrophilic dermatosis] Rodot S, et al. **Ann Dermatol Venereol** 1996;123(2):129–34 (45 ref.) **(Fre)**

IMMUNOLOGY

Autoantibodies to cytokines in inflammatory joint disorders [editorial] Jouvenne P, et al. **Rev Rhum Engl Ed** 1995 Oct; 62(9):541–5 (20 ref.)

METABOLISM

Changes in chondroitin sulphate structure induced by joint disease. Hardingham T. **Acta Orthop Scand Suppl** 1995 Oct; 266:107–10 (13 ref.)
Keratan sulfate in body fluids in joint disease. Thonar EJ, et al. **Acta Orthop Scand Suppl** 1995 Oct;266:103–6 (19 ref.)

PHYSIOPATHOLOGY

Collagen II turnover in joint diseases. Poole AR, et al. **Acta Orthop Scand Suppl** 1995 Oct;266:88–91 (28 ref.)
Pathophysiology of joint pain. Kidd BL, et al. **Ann Rheum Dis** 1996 May;55(5):276–83 (100 ref.)

RADIOGRAPHY

Imaging of arthropathies. Crystal disease. Uri DS, et al. **Radiol Clin North Am** 1996 Mar;34(2):359–74, xi (48 ref.)

RADIONUCLIDE IMAGING

Scintigraphy in the evaluation of arthropathy. Tumeh SS. **Radiol Clin North Am** 1996 Mar;34(2):215–31, ix (35 ref.)

SURGERY

Arthroscopic treatment of rotator cuff disease. Gartsman GM. **J Shoulder Elbow Surg** 1995 May–Jun;4(3):228–41 (27 ref.)
Discoid medial meniscus: report of a case treated by arthroscopy. Adriani E, et al. **Knee Surg Sports Traumatol Arthrosc** 1993;1(2):107–9 (27 ref.)
[Holmium-YAG laser in outlet impingement of the shoulder. Mid-term results] De Simoni C, et al. **Orthopade** 1996 Feb; 25(1):84–90 (51 ref.) (Eng. Abstr.) **(Ger)**
[Arthroscopy and arthroscopic surgery of the shoulder joint] Landsied F. **Wien Med Wochenschr** 1996;146(6–7):146–8 (18 ref.) (Eng. Abstr.) **(Ger)**
[Rheumatoid orthopedics and endoprosthetics of the shoulder joint] Schwägerl W, et al. **Wien Med Wochenschr** 1996; 146(6–7):124–9 (31 ref.) (Eng. Abstr.) **(Ger)**
[Current advances and future direction of arthroscopic surgery for disorders in the knee joint] Yasuda K. **Hokkaido Igaku Zasshi** 1995 May;70(3):383–9 (10 ref.) (Eng. Abstr.) **(Jpn)**

THERAPY

The dose effect of continuous passive motion in postoperative rehabilitation of the first metatarsophalangeal joint. Lawrence BR. **J Foot Ankle Surg** 1996 Mar–Apr; 35(2):155–61; discussion 190–1 (73 ref.)

VETERINARY

Joint structure, biochemistry and biochemical disequilibrium in synovitis and equine joint disease. Palmer JL, et al. **Equine Vet J** 1994 Jul;26(4):263–77 (131 ref.)

VIROLOGY

Human T lymphotropic virus type I in arthropathy and autoimmune disorders. Nishioka K, et al. **Arthritis Rheum** 1996 Aug;39(8):1410–8 (55 ref.)

JOINT INSTABILITY

Shoulder instability in the overhand or throwing athlete. Kvitne RS, et al. **Clin Sports Med** 1995 Oct;14(4):917–35 (25 ref.)
Examining separated symphysis pubis. Davidson MR. **J Nurse Midwifery** 1996 May–Jun;41(3):259–62 (15 ref.)
Glenohumeral instability. Friedman RJ, et al. **J South Orthop Assoc** 1995 Fall;4(3):182–99 (85 ref.)

CLASSIFICATION

Analysis of carpal instability: I. Description of the scheme. Larsen CF, et al. **J Hand Surg [Am]** 1995 Sep;20(5):757–64 (84 ref.)

DIAGNOSIS

Shoulder instability in athletes. The Asian perspective. Chan KM, et al. **Clin Orthop** 1996 Feb;(323):106–12 (47 ref.)
The clinical presentation of shoulder instability including on field management. Bahr R, et al. **Clin Sports Med** 1995 Oct;14(4):761–76 (26 ref.)
Imaging of shoulder instability. Gusmer PB, et al. **Clin Sports Med** 1995 Oct;14(4):777–95 (26 ref.)
Arthroscopic evaluation of the unstable shoulder. Wall MS, et al. **Clin Sports Med** 1995 Oct;14(4):817–39 (102 ref.)
Chronic anterior glenohumeral instability. Walch G. **J Bone Joint Surg Br** 1996 Jul;78(4):670–7 (25 ref.)
Analysis of carpal instability: I. Description of the scheme. Larsen CF, et al. **J Hand Surg [Am]** 1995 Sep;20(5):757–64 (84 ref.)
Upper cervical instability: fact or fiction? Swinkels RA, et al. **J Manipulative Physiol Ther** 1996 Mar–Apr;19(3):185–94 (93 ref.)
Magnetic resonance imaging of glenohumeral instability. Rafii M, et al. **Magn Reson Imaging Clin N Am** 1993 Sep; 1(1):87–104 (68 ref.)
[Posterolateral rotatory knee joint instability. I. Anatomy of injuries and diagnosis] Latosiewicz R. **Chir Narzadow Ruchu Ortop Pol** 1996;61(2):183–8 (15 ref.) (Eng. Abstr.) **(Pol)**

ETIOLOGY

Recurrent locking of the wrist due to dorsal midcarpal subluxation. Craigen MA. **J Bone Joint Surg Br** 1996 Jul; 78(4):664–6 (5 ref.)

PHYSIOPATHOLOGY

Is prophylactic bracing of the ankle cost effective? Jerosch J, et al. **Orthopedics** 1996 May;19(5):405–14 (47 ref.)

JOINT INSTABILITY

PREVENTION & CONTROL

Is prophylactic bracing of the ankle cost effective? Jerosch J, et al. **Orthopedics** 1996 May;19(5):405–14 (47 ref.)

RADIOGRAPHY

Chronic patellofemoral instability. Dandy DJ. **J Bone Joint Surg Br** 1996 Mar;78(2):328–35 (21 ref.)

[Imaging of external instabilities of the patella. State of the art] Frot B, et al. **J Radiol** 1996 Jan;77(1):5–15 (36 ref.) (Eng. Abstr.) **(Fre)**

REHABILITATION

The conservative management of the unstable shoulder including rehabilitation. Dines DM, et al. **Clin Sports Med** 1995 Oct;14(4):797–816 (76 ref.)

SURGERY

Treatment of the unstable (acute) slipped capital femoral epiphysis. Aronsson DD, et al. **Clin Orthop** 1996 Jan; (322):99–110 (50 ref.)

Revision instability surgery. Barron OA, et al. **Clin Sports Med** 1995 Oct;14(4):955–72 (44 ref.)

The surgical treatment of posterior shoulder instability. Murrell GA, et al. **Clin Sports Med** 1995 Oct;14(4):903–15 (48 ref.)

The surgical treatment of anterior shoulder instability. Payne LZ, et al. **Clin Sports Med** 1995 Oct;14(4):863–83 (45 ref.)

Arthroscopic shoulder stabilization. Overview of indications, technique, and efficacy. Swenson TM, et al. **Clin Sports Med** 1995 Oct;14(4):841–62 (41 ref.)

Complications of shoulder instability surgery. Wall MS, et al. **Clin Sports Med** 1995 Oct;14(4):973–1000 (153 ref.)

Management of multidirectional instability. Yamaguchi K, et al. **Clin Sports Med** 1995 Oct;14(4):885–902 (40 ref.)

The arthroscopic treatment of anterior and multidirectional shoulder instability. McIntyre LF, et al. **Instr Course Lect** 1996;45:47–56 (72 ref.)

Arthroscopic transglenoid suture capsulorrhaphy for anterior shoulder instability. Rose DJ. **Instr Course Lect** 1996; 45:57–64 (54 ref.)

New method for reconstruction in lateral ankle instability. Bauer GR. **J Am Podiatr Med Assoc** 1995 Sep;85(9):459–63 (32 ref.)

Transfibular osteotomy in the correction of ankle joint incongruity. Davis JL, et al. **J Foot Ankle Surg** 1995 Jul–Aug;34(4):389–99 (23 ref.)

Arthroscopic Bankart procedures for anterior shoulder instability. A review of the literature. el Akad AM, et al. **Knee Surg Sports Traumatol Arthrosc** 1993;1(2):113–22 (61 ref.)

Revision total knee arthroplasty: how much constraint is necessary? Cuckler JM. **Orthopedics** 1995 Sep;18(9):932–3, 936 (11 ref.)

[Sense and nonsense of cruciate ligament prostheses] Neumann K, et al. **Chirurg** 1995 Nov;66(11):1079–84 (32 ref.) (Eng. Abstr.) **(Ger)**

[Possibilities and limits of conservative management of cruciate ligament injuries] Paar O, et al. **Chirurg** 1995 Nov; 66(11):1050–60 (48 ref.) (Eng. Abstr.) **(Ger)**

[Critical considerations in arthroscopic stabilization of the unstable shoulder joint] Jerosch J. **Sportverletz Sportschaden** 1996 Mar;10(1):1–12 (93 ref.) (Eng. Abstr.) **(Ger)**

[Rupture of the posterior cruciate ligament: status of current treatment] Lobenhoffer P, et al. **Unfallchirurg** 1996 Jun; 99(6):382–99 (118 ref.) (Eng. Abstr.) **(Ger)**

[Diagnosis and therapy of shoulder instability] Habermeyer P, et al. **Wien Med Wochenschr** 1996;146(6–7):149–54 (16 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Carpal instability. Ruby LK. **Instr Course Lect** 1996;45:3–13 (44 ref.)

JOINT LOOSE BODIES

ETIOLOGY

Malignant joint effusions secondary to solid tumor metastasis. Munn RK, et al. **J Rheumatol** 1995 May;22(5):973–5 (15 ref.)

JOINT PROSTHESIS

Early motion after arthroplasty. Kirkpatrick WH, et al. **Hand Clin** 1996 Feb;12(1):73–86 (45 ref.)

Is polyethylene still the best prosthetic bearing surface? [editorial] Amis AA. **J Bone Joint Surg Br** 1996 May; 78(3):345–8 (39 ref.)

Bilateral posterior fracture-dislocation of the shoulders: management by bilateral shoulder hemiarthroplasties. Page AE, et al. **J Orthop Trauma** 1995;9(6):526–9 (31 ref.)

[Role of antibiotics in the treatment of infected joint prosthesis] Zimmerli W. **Orthopade** 1995 Aug;24(4):308–13 (22 ref.) (Eng. Abstr.) **(Ger)**

[Rheumatoid orthopedics and endoprosthetics of the shoulder joint] Schwägerl W, et al. **Wien Med Wochenschr** 1996; 146(6–7):124–9 (31 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

The microscopic interaction between silicone and the surrounding tissues. Needelman L. **Clin Podiatr Med Surg** 1995 Jul;12(3):415–23 (31 ref.)

Complications of total shoulder-replacement arthroplasty. Wirth MA, et al. **J Bone Joint Surg Am** 1996 Apr; 78(4):603–16 (110 ref.)

[Preventive treatment alternatives for deep-vein thromboembolism after total joint replacement] Velan G, et al. **Harefuah** 1995 Sep;129(5–6):211–4 (44 ref.) **(Heb)**

METHODS

[Infection following shoulder and elbow arthroplasty. Diagnosis and therapy] Schwyzer HK, et al. **Orthopade** 1995 Aug;24(4):367–75 (44 ref.) (Eng. Abstr.) **(Ger)**

TRENDS

Future materials for foot surgery. Latour RA Jr. **Clin Podiatr Med Surg** 1995 Jul;12(3):519–44 (76 ref.)

JOINT TUBERCULOSIS see **TUBERCULOSIS, OSTEOARTICULAR**

JOINT VENTURES, HOSPITAL-PHYSICIAN see **HOSPITAL-PHYSICIAN JOINT VENTURES**

JOINTS

see related
ARTHROGRAPHY
ARTHROPLASTY
ARTHROSCOPY

ABNORMALITIES

Microcephaly, characteristic facies, joint abnormalities, and deficient leucocyte chemotaxis: a further case of the syndrome of Say et al. Perandones C, et al. **J Med Genet** 1996 Mar;33(3):227–9 (7 ref.)

BLOOD SUPPLY

Hormonal and pregnancy relationships to rheumatoid arthritis: convergent effects with immunologic and microvascular systems. Masi AT, et al. **Semin Arthritis Rheum** 1995 Aug;25(1):1–27 (166 ref.)

CHEMISTRY

Joint structure, biochemistry and biochemical disequilibrium in synovitis and equine joint disease. Palmer JL, et al. **Equine Vet J** 1994 Jul;26(4):263–77 (131 ref.)

CYTOLOGY

[The cellular aspects of the development of synovial joints and articular cartilage] Archer CW, et al. **Ontogenez** 1995 Jul–Aug;26(4):259–69 (42 ref.) (Eng. Abstr.) **(Rus)**

INJURIES

History of rest and motion and the scientific basis for early continuous passive motion. Salter RB. **Hand Clin** 1996 Feb; 12(1):1–11 (66 ref.)

Management of penetrating joint injuries. Lewis DD. **Vet Clin North Am Small Anim Pract** 1995 Sep; 25(5):1197–223 (107 ref.)

Traumatic joint luxations in small animals. McLaughlin RM Jr. **Vet Clin North Am Small Anim Pract** 1995 Sep; 25(5):1175–96 (28 ref.)

METABOLISM

Biochemical markers of joint damage: is there any hope? Wollheim FA. **Clin Exp Rheumatol** 1995 Sep–Oct;13 Suppl 12:S3–5 (21 ref.)

PATHOLOGY

Joint structure, biochemistry and biochemical disequilibrium in synovitis and equine joint disease. Palmer JL, et al. **Equine Vet J** 1994 Jul;26(4):263–77 (131 ref.)

Magnetic resonance imaging of rheumatoid arthritis. Winalski CS, et al. **Radiol Clin North Am** 1996 Mar;34(2):243–58, x (59 ref.)

[MR tomography (MRT) of the skeleton, peripheral soft tissues and joints—current overview] Bohndorf K, et al. **Aktuelle Radiol** 1996 May;6(3):136–43 (47 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Predictors of joint damage in rheumatoid arthritis. Wollheim FA. **APMIS** 1996 Feb;104(2):81–93 (103 ref.)

Why does an inflammation in the joint hurt? [editorial] Schaible HG. **Br J Rheumatol** 1996 May;35(5):405–6 (11 ref.)

Single-joint rapid arm movements in normal subjects and in patients with motor disorders. Berardelli A, et al. **Brain** 1996 Apr;119 (Pt 2):661–74 (78 ref.)

Objective measures of joint stiffness. Roberson L, et al. **J Hand Ther** 1995 Apr–Jun;8(2):163–6 (15 ref.)

RADIONUCLIDE IMAGING

Scintigraphy in the evaluation of arthropathy. Tumeh SS. **Radiol Clin North Am** 1996 Mar;34(2):215–31, ix (35 ref.)

JOSEPH AZOREAN DISEASE see **MACHADO-JOSEPH DISEASE**

JOSEPH DISEASE see **MACHADO-JOSEPH DISEASE**

JOURNALS see **PERIODICALS**

JUDAISM

The effectiveness of words: religion and healing among the Lubavitch of Stamford Hill. Littlewood R, et al. **Cult Med Psychiatry** 1995 Sep;19(3):339–83 (125 ref.)

Jewish medical ethics [see comments] Rosner F. **J Clin Ethics** 1995 Fall;6(3):202–17 (48 ref.) Comment in: J Clin Ethics 1995 Fall;6(3):218–21. Comment in: J Clin Ethics 1995 Fall;6(3):232–6.

Face to face, not eye to eye: further conversations on Jewish medical ethics. Zoloth-Dorfman L. **J Clin Ethics** 1995 Fall; 6(3):222–31 (34 ref.)

JUDGMENT

Judging the other. Responding to traditional female genital surgeries. Lane SD, et al. **Hastings Cent Rep** 1996 May–Jun; 26(3):31–40 (61 ref.)

Intuition and expertise: comments on the Benner debate. Paley J. **J Adv Nurs** 1996 Apr;23(4):665–71 (38 ref.)

Critical thinking and intuitive nursing practice. Paul RW, et al. **J Adv Nurs** 1995 Jul;22(1):40–7 (5 ref.)

Perceiving persons and groups. Hamilton DL, et al. **Psychol Rev** 1996 Apr;103(2):336–55 (140 ref.)

JUGULAR VEINS

Carotid-jugular arteriovenous fistula: a complication of temporary hemodialysis catheter. el-Shahawy MA, et al. **Am J Nephrol** 1995;15(4):332–6 (51 ref.)

An aneurysm of the internal jugular vein. Refson JS, et al. **Eur J Vasc Endovasc Surg** 1996 Apr;11(3):371–2 (5 ref.)

PHYSIOPATHOLOGY

Embryological basis of some aspects of cerebral vascular fistulas and malformations. Mullan S, et al. **J Neurosurg** 1996 Jul;85(1):1–8 (20 ref.)

SURGERY

Transjugular intrahepatic portal-systemic shunt [editorial] Sherlock S. **J Intern Med** 1996 Feb;239(2):95–8 (25 ref.)

JUN B PROTEINS see **PROTO-ONCOGENE PROTEINS C-JUN**

JUN D PROTEINS see **PROTO-ONCOGENE PROTEINS C-JUN**

JUN ONCOGENE PROTEIN see **ONCOGENE PROTEIN P65(GAG-JUN)**

JUN PROTO-ONCOGENE PROTEINS see **PROTO-ONCOGENE PROTEINS C-JUN**

JUNCTIONAL ECTOPIC TACHYCARDIA see **TACHYCARDIA, ECTOPIC JUNCTIONAL**

JUNCTIONAL EPIDERMOLYSIS BULLOSA see **EPIDERMOLYSIS BULLOSA, JUNCTIONAL**

JUNGIAN THEORY

Jungian metapsychology and neurobiological theory. Tresan DI. **J Anal Psychol** 1996 Jul;41(3):399–436 (140 ref.)

[The evolution of the concept of archetypes in Jungian psychology] Pérez Urdaniz A, et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1995 Sep–Oct;23(5):262–5 (25 ref.) (Eng. Abstr.) **(Spa)**

JURISPRUDENCE

see related
FORENSIC DENTISTRY
FORENSIC MEDICINE

AIDS phobia, public health warnings, and lawsuits: deterring harm or rewarding ignorance? Mariner WK. **Am J Public Health** 1995 Nov;85(11):1562–8 (42 ref.)

Ethical and policy issues in human embryo twinning. Bonnicksen AL. **Camb Q Healthc Ethics** 1995 Summer; 4(3):268–84 (94 ref.)

The generalisability of confidence-accuracy studies in eyewitnessing. Gruneberg MM, et al. **Memory** 1993 Sep; 1(3):185–9 (8 ref.)

JURISPRUDENCE, PSYCHIATRIC see **FORENSIC PSYCHIATRY**

JUVENILE DELINQUENCY

Predicting antisocial behavior in youngsters displaying poor academic achievement: a review of risk factors. Brier N. **J Dev Behav Pediatr** 1995 Aug;16(4):271–6 (90 ref.)

Service delivery strategies for treating high-risk youth:

delinquents, homeless, runaways, and sexual minorities. Farrow JA. **NIDA Res Monogr** 1995;156:39–48 (23 ref.)
Aggressive behavior in childhood and early adolescence: an ecological–developmental perspective on youth violence. Fraser MW. **Soc Work** 1996 Jul;41(4):347–61 (120 ref.)

PSYCHOLOGY

[White walls for black holes: essay on graffiti psychopathology] Catheline-Antipoff N, et al. **Psychiatr Enfant** 1995;38(2):625–53 (16 ref.) (Eng. Abstr.) **(Fre)**

JUVENILE HORMONES

The future of insect growth regulators in vector control. Mulla MS. **J Am Mosq Control Assoc** 1995 Jun;11(2 Pt 2):269–73 (32 ref.)

BIOSYNTHESIS

Role of allatostatins in the regulation of juvenile hormone synthesis. Stay B, et al. **Arch Insect Biochem Physiol** 1996; 32(3–4):287–97 (39 ref.)

METABOLISM

Biochemistry of proteins that bind and metabolize juvenile hormones. Prestwich GD, et al. **Arch Insect Biochem Physiol** 1996;32(3–4):407–19 (39 ref.)

PHYSIOLOGY

Juvenile hormone: the status of its "status quo" action. Riddiford LM. **Arch Insect Biochem Physiol** 1996; 32(3–4):271–86 (60 ref.)

JUXTAGLOMERULAR APPARATUS

see related
RENIN

BLOOD SUPPLY

The structure of glomeruli and juxtaglomerular arterioles in the early phase of diabetic nephropathy—relationship between progression and metabolic control. Osterby R, et al. **Contrib Nephrol** 1996;118:195–205 (24 ref.)

CYTOLOGY

Juxtaglomerular cells in culture. Della Bruna R, et al. **Exp Nephrol** 1995 Jul–Aug;3(4):219–22 (17 ref.)

K CELLS see **KILLER CELLS**

KAHN TEST see **SYPHILIS SERODIAGNOSIS**

KAINIC ACID

PHARMACOLOGY

Kainate-induced changes in gene expression in the rat hippocampus. Pennypacker KR, et al. **Prog Brain Res** 1995; 105:105–16 (64 ref.)
Kainic acid seizures in the rat. Sperk G. **Prog Neurobiol** 1994 Jan;42(1):1–32 (415 ref.)

KALA-AZAR see **LEISHMANIASIS, VISCERAL**

KALLIKREIN

ANALYSIS

[Kallikrein, kininogen and kinin in health and disease] Omata K, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:721–5 (17 ref.) **(Jpn)**

BIOSYNTHESIS

Expression and androgenic regulation of human prostate-specific kallikreins. Young CY, et al. **J Androl** 1995 Mar–Apr;16(2):97–9 (16 ref.)

PHYSIOLOGY

Kallikreins and kinins. Molecular characteristics and cellular and tissue responses. Margolius HS. **Diabetes** 1996 Jan;45 Suppl 1:S14–9 (53 ref.)
Skeletal muscle kallikrein. Potential role in metabolic regulation. Mayfield RK, et al. **Diabetes** 1996 Jan;45 Suppl 1:S20–3 (34 ref.)

KALLIKREIN-KININ SYSTEM

PHYSIOLOGY

Stimulation of bone resorption by the kallikrein-kinin system and the coagulation cascade. Lerner UH. **Acta Orthop Scand Suppl** 1995 Oct;266:45–50 (30 ref.)
Blood pressure regulation by the kallikrein-kinin system. Sharma JN, et al. **Gen Pharmacol** 1996 Jan;27(1):55–63 (149 ref.)
Possible mediators in hypertension: renal factors. Bergman SM, et al. **Semin Nephrol** 1996 Mar;16(2):134–9 (36 ref.)

KALLIKREIN-TRYPSIN INACTIVATOR see
APROTININ

KALLMANN SYNDROME

GENETICS

A molecular approach to the pathophysiology of the X chromosome-linked Kallmann's syndrome. Hardelin JP, et al. **Baillieres Clin Endocrinol Metab** 1995 Jul;9(3):489–507 (108 ref.)

KAMPO see **MEDICINE, CHINESE TRADITIONAL**

KANDINSKY SYNDROME see **ORGANIC MENTAL DISORDERS, PSYCHOTIC**

KANNER'S SYNDROME see **AUTISM, INFANTILE**

KANPO see **MEDICINE, CHINESE TRADITIONAL**

KAOLIN-CEPHALIN COAGULATION TIME see **PARTIAL THROMBOPLASTIN TIME**

KAPOSI'S DISEASE see **XERODERMA PIGMENTOSUM**

KAPOSI'S SARCOMA see **SARCOMA, KAPOSI'S**

KAPOSI'S VARICELLIFORM ERUPTION

COMPLICATIONS

Kaposi's varicelliform eruption in a patient with healing second degree burns. Bartralot R, et al. **Clin Exp Dermatol** 1996 Mar;21(2):127–30 (0 ref.)

KAPPA ALLOTYPES see **IMMUNOGLOBULIN ALLOTYPES**

KAPPA B ENHANCER BINDING PROTEIN see **NF-KAPPA B**

KAPPA IMMUNOGLOBULINS see **IMMUNOGLOBULINS, KAPPA-CHAIN**

KAPPA RECEPTORS see **RECEPTORS, OPIOID, KAPPA**

KARTAGENER'S SYNDROME

DIAGNOSIS

[Primary ciliary dyskinesia, immotile cilia syndrome, and Kartagener syndrome: diagnostic criteria] Dombi VH, et al. **Schweiz Med Wochenschr** 1996 Mar 16;126(11):421–33 (129 ref.) (Eng. Abstr.) **(Ger)**
[Kartagener syndrome and hemangiomatous proliferation of lung capillaries: case report and literature review] Slodkowska J, et al. **Pneumonol Alergol Pol** 1996; 64(3–4):217–24 (24 ref.) (Eng. Abstr.) **(Pol)**

KARTAGENER'S TRIAD see **KARTAGENER'S SYNDROME**

KARYOKINESIS see **MITOSIS**

KARYOTYPING

METHODS

The coloring of cytogenetics. Speicher MR, et al. **Nat Med** 1996 Sep;2(9):1046–8 (18 ref.)
[Karyotyping in couples with subfertility and infertility] Stora de Novion H. **Contracept Fertil Sex** 1995 Nov;23(11):655–9 (39 ref.) **(Fre)**

KAWASAKI DISEASE see **MUCOCUTANEOUS LYMPH NODE SYNDROME**

KAZAL PANCREATIC TRYPSIN INHIBITOR see **TRYPSIN INHIBITOR, KAZAL PANCREATIC**

KEARNS-SAYRE-SHY-DAROFF SYNDROME see **KEARNS SYNDROME**

KEARNS SYNDROME

COMPLICATIONS

Surgical treatment of myogenic blepharoptosis. De Wilde F, et al. **Bull Soc Belge Ophtalmol** 1995;255:139–46 (9 ref.)

KELL BLOOD-GROUP SYSTEM

The Kell blood group system. Redman CM, et al. **Transfus Clin Biol** 1995;2(4):243–9 (11 ref.)

KELOID

see related
CICATRIX, HYPERTROPHIC

Aetiology and management of hypertrophic scars and keloids. O'Sullivan ST, et al. **Ann R Coll Surg Engl** 1996 May;78(3 (Pt 1)):168–75 (100 ref.)

ETIOLOGY

Does keloid pathogenesis hold the key to understanding black/white differences in hypertension severity? [clinical conference] Dustan HP. **Hypertension** 1995 Dec;26(6 Pt 1):858–62 (40 ref.)

METABOLISM

[Collagen metabolism in hypertrophic and keloid scars] Del'Vig AA. **Vestn Ross Akad Med Nauk** 1995;(12):41–5 (34 ref.) (Eng. Abstr.) **(Rus)**

SURGERY

Management of scar contractures, hypertrophic scars, and keloids. Sherris DA, et al. **Otolaryngol Clin North Am** 1995 Oct;28(5):1057–68 (29 ref.)

THERAPY

Adjunct therapies to surgical management of keloids. Berman B, et al. **Dermatol Surg** 1996 Feb;22(2):126–30 (79 ref.)
[Treatment of keloids of the earlobe (see comments)] Vegter F, et al. **Ned Tijdschr Geneeskd** 1995 Aug 19; 139(33):1678–80 (18 ref.) Comment in: Ned Tijdschr Geneeskd 1995 Oct 14;139(41):2110–1. Comment in: Ned Tijdschr Geneeskd 1995 Nov 25;139(47):2453. **(Dut)**

KEPONE see **CHLORDECONE**

KERATAN SULFATE

METABOLISM

Keratan sulfate in body fluids in joint disease. Thonar EJ, et al. **Acta Orthop Scand Suppl** 1995 Oct;266:103–6 (19 ref.)

KERATECTOMY, EXCIMER LASER see **KERATECTOMY, PHOTOREFRACTIVE, EXCIMER LASER**

KERATECTOMY, EXCIMER LASER PHOTOREFRACTIVE see **KERATECTOMY, PHOTOREFRACTIVE, EXCIMER LASER**

KERATECTOMY, PHOTOREFRACTIVE, EXCIMER LASER

Excimer laser photorefractive keratectomy (PRK) for myopia—present status: aerospace considerations. Diamond S. **Aviat Space Environ Med** 1995 Jul;66(7):690–3 (38 ref.)
Do topical corticosteroids have a role following excimer laser photorefractive keratectomy? [see comments] Corbett MC, et al. **J Refract Surg** 1995 Sep–Oct;11(5):380–7 (64 ref.) Comment in: J Refract Surg 1995 Sep–Oct;11(5):339–40.
Control of pain after photorefractive keratectomy. Verma S, et al. **J Refract Surg** 1996 Mar–Apr;12(3):358–64 (37 ref.)
Changing concepts in excimer laser corneal surgery [editorial] Waring GO 3rd. **J Refract Surg** 1995 May–Jun; 11(3 Suppl):S224–6 (7 ref.)
Photorefractive keratectomy for myopia. Wu HK, et al. **Ophthalmic Surg Lasers** 1996 Jan;27(1):29–44 (96 ref.)
Photorefractive and phototherapeutic procedures. LaRussa FP, et al. **Optom Clin** 1995;4(4):51–67 (30 ref.)
How predictable are the results of excimer laser photorefractive keratectomy? A review. Grosvenor T. **Optom Vis Sci** 1995 Oct;72(10):698–712 (55 ref.)
Excimer laser photorefractive keratectomy. Seiler T, et al. **Surv Ophthalmol** 1995 Sep–Oct;40(2):89–118 (210 ref.)
[Current evaluation of myopia correction with the excimer laser] Seiler T. **Ophthalmologe** 1995 Aug;92(4):379–84 (18 ref.) (Eng. Abstr.) **(Ger)**

METHODS

[Critical thoughts on current laser surgery of the cornea] Gloor B, et al. **Ophthalmologe** 1995 Aug;92(4):389–96 (42 ref.) (Eng. Abstr.) **(Ger)**

KERATIN

ANALYSIS

[Cyfra 21-1—new marker for lung cancer] Luczak E, et al. **Pneumonol Alergol Pol** 1996;64(1–2):96–101 (19 ref.) (Eng. Abstr.) **(Pol)**

BLOOD

[CYFRA 21-1 and bronchial cancer] Pujol JL, et al. **Rev Mal Respir** 1995;12(6):533–41 (33 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Overexpression of human keratin 16 produces a distinct skin phenotype in transgenic mouse skin. Coulombe PA, et al. **Biochem Cell Biol** 1995 Sep–Oct;73(9–10):611–8 (42 ref.)
Cytokeratin expression, fibrillar organization, and subtle function in liver cells. Marceau N, et al. **Biochem Cell Biol** 1995 Sep–Oct;73(9–10):619–25 (56 ref.)

KERATIN

Keratins and skin disorders. Rao KS, et al. **Cell Biol Int** 1996 Apr;20(4):261–74 (100 ref.)
Control of cytokeratin 17 expression by interferon gamma. Vogel U, et al. **Immunobiology** 1995 Jul;193(2–4):322–7 (16 ref.)

PHYSIOLOGY

Keratins and the skin. Fuchs E. **Ann Rev Cell Dev Biol** 1995; 11:123–53 (171 ref.)
The latest fashions in skin disease. Carroll JM, et al. **Mol Med** 1995 Jan;1(2):123–6 (29 ref.)

KERATINOCYTES

CYTOLOGY

[Discovery of epidermal cell differentiation inhibitor (EDIN) produced by Staphylococcus aureus and studies on the mode of action of EDIN] Sugai M. **Nippon Saikingaku Zasshi** 1995 Oct;50(4):937–46 (43 ref.) **(Jpn)**

DRUG EFFECTS

Modulatory effects of selenium and strontium salts on keratinocyte–derived inflammatory cytokines. Celerier P, et al. **Arch Dermatol Res** 1995;287(7):680–2 (11 ref.)

IMMUNOLOGY

Immunologic roles of keratinocytes: expression of HLA–DR and ICAM–1 on cultured human keratinocytes and their influences on the alloimmune response. Haw CR. **J Dermatol** 1995 Nov;22(11):839–44 (20 ref.)

PHYSIOLOGY

Retinoid receptors and keratinocytes. Fisher C, et al. **Crit Rev Oral Biol Med** 1995;6(4):284–301 (172 ref.)
Escape from senescence in human keratinocyte cultures. Littlefield JW. **Exp Gerontol** 1996 Jan–Apr;31(1–2):29–32 (30 ref.)

RADIATION EFFECTS

Keratinocyte–derived cytokines and UVB–induced immunosuppression. Kondo S, et al. **J Dermatol** 1995 Nov; 22(11):888–93 (45 ref.)

KERATITIS

COMPLICATIONS

Cogan's syndrome: ophthalmic, audiovestibular, and systemic manifestations and therapy. Chynn EW, et al. **Int Ophthalmol Clin** 1996 Winter;36(1):61–72 (46 ref.)

ETIOLOGY

Contact lens wear by hospital health care staff: is there cause for concern? Hay J, et al. **J Hosp Infect** 1995 Jun;30 Suppl:275–81 (40 ref.)

MICROBIOLOGY

[A case of keratitis due to Mycobacterium chelonae] Duchesne B, et al. **Bull Soc Belge Ophtalmol** 1994;254:59–62 (10 ref.) (Eng. Abstr.) **(Fre)**
[A case report of Mycobacterium chelonei keratitis] Sasagawa T, et al. **Nippon Ganka Gakkai Zasshi** 1996 Jun; 100(6):464–70 (30 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Infections of the eyelid, lacrimal system, conjunctiva, and cornea. Durand M, et al. **Curr Clin Top Infect Dis** 1996; 16:125–50 (150 ref.)

VETERINARY

Antimicrobial agents for treatment of infectious keratitis in horses. Moore CP, et al. **J Am Vet Med Assoc** 1995 Oct 1;207(7):855–62 (29 ref.)

KERATITIS, HERPETIC

DIAGNOSIS

[Problems in the diagnosis and therapy of herpetic keratitis] Kraus H. **Cesk Slov Oftalmol** 1996 Jul;52(3):185–8 (0 ref.) **(Cze)**

IMMUNOLOGY

Immune reactions in corneal herpetic disease. You T, et al. **Int Ophthalmol Clin** 1996 Winter;36(1):31–9 (12 ref.)

PREVENTION & CONTROL

Herpetic eye disease study. You can help [editorial] Dawson CR, et al. **Arch Ophthalmol** 1996 Jan;114(1):89–90 (8 ref.)

THERAPY

[Problems in the diagnosis and therapy of herpetic keratitis] Kraus H. **Cesk Slov Oftalmol** 1996 Jul;52(3):185–8 (0 ref.) **(Cze)**

KERATITIS, ULCERATIVE see **CORNEAL ULCER**

KERATOACANTHOMA

[Muir–Torre syndrome] Yoshikawa R, et al. **Nippon Rinsho** 1995 Nov;53(11):2803–6 (11 ref.) (Eng. Abstr.) **(Jpn)**

KERATOCONJUNCTIVITIS, VERNAL see **CONJUNCTIVITIS, ALLERGIC**

KERATOCONUS

ETIOLOGY

Thalasselis syndrome and genetic theories on keratoconus. Thalasselis A. **J Am Optom Assoc** 1995 Aug;66(8):495–9 (64 ref.)

KERATODERMA, PALMOPLANTAR

COMPLICATIONS

[Squamous cell carcinoma of the lung associated with palmo–plantar hyperkeratosis] Nomori H, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Jan;34(1):76–9 (15 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Linkage of an American pedigree with palmoplantar keratoderma and malignancy (palmoplantar ectodermal dysplasia type III) to 17q24. Literature survey and proposed updated classification of the keratodermas. Stevens HP, et al. **Arch Dermatol** 1996 Jun;132(6):640–51 (143 ref.)

PATHOLOGY

Olmsted syndrome. Case report and identification of a keratin abnormality. Kress DW, et al. **Arch Dermatol** 1996 Jul; 132(7):797–800 (14 ref.)

KERATOLYTIC AGENTS

ADVERSE EFFECTS

Prolonged treatment with oral retinoids in adults: no influence on the frequency and severity of spinal abnormalities. Van Dooren–Greebe RJ, et al. **Br J Dermatol** 1996 Jan;134(1):71–6 (30 ref.)
Salicylism from topical salicylates: review of the literature. Brubacher JR, et al. **J Toxicol Clin Toxicol** 1996; 34(4):431–6 (31 ref.)
Oral retinoids and pregnancy. Chan A, et al. **Med J Aust** 1996 Aug 5;165(3):164–7 (20 ref.)

PHARMACOKINETICS

[Trans–acitretin is metabolized back to etretinate. Importance for oral retinoid therapy] Almond–Roesler B, et al. **Hautarzt** 1996 Mar;47(3):173–7 (29 ref.) (Eng. Abstr.) **(Ger)**

THERAPEUTIC USE

Benzamycin gel for acne. **Drug Ther Bull** 1995 Aug; 33(8):62–4 (13 ref.)
Tretinoin for sun–aged skin. **Drug Ther Bull** 1996 Jul; 34(7):55–6 (13 ref.)
[Pharma–clinics. How I treat... rosacea] Piérard–Franchimont C, et al. **Rev Med Liege** 1996 Jun; 51(6):393–5 (25 ref.) **(Fre)**

KERATOMA see **KERATOSIS**

KERATOPLASTY see **CORNEAL TRANSPLANTATION**

KERATOPLASTY, LAMELLAR see **CORNEAL TRANSPLANTATION**

KERATOPLASTY, PENETRATING

A review of methods for storage of corneas for keratoplasty. Basu PK. **Indian J Ophthalmol** 1995 Jun;43(2):55–8 (30 ref.)
[Penetrating keratoplasty after graft preservation in organ culture at +37 degrees centigrade. 1–year results] Borderie V, et al. **J Fr Ophtalmol** 1995;18(10):570–7 (27 ref.) (Eng. Abstr.) **(Fre)**
[Indications of penetrating keratoplasty from a histopathological study of 1129 corneal buttons (from 1982 to 1991)] Leger F, et al. **J Fr Ophtalmol** 1995;18(5):331–7 (16 ref.) (Eng. Abstr.) **(Fre)**

ADVERSE EFFECTS

Primary corneal graft failure. A national reporting system [editorial; comment] Brightbill FS. **Arch Ophthalmol** 1995 Dec;113(12):1554–5 (9 ref.) Comment on: Arch Ophthalmol 1995 Dec;113(12):1497–502.

KERATOSIS

Knuckle pads—a forgotten skin condition: report of a case and review of the literature. Guberman D, et al. **Cutis** 1996 Apr;57(4):241–2 (20 ref.)

CHEMICALLY INDUCED

[Hair–like hyperkeratoses in patients with kidney transplants. A new cyclosporin side–effect] Izakovic J, et al. **Hautarzt** 1995 Dec;46(12):841–6 (45 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

Premalignant keratinocytic neoplasms. Schwartz RA. **J Am Acad Dermatol** 1996 Aug;35(2 Pt 1):223–42 (399 ref.)

KERATOSIS PALMARIS ET PLANTARIS see **KERATODERMA, PALMOPLANTAR**

KERATOSIS, PALMOPLANTAR see **KERATODERMA, PALMOPLANTAR**

KERATOSIS, SEBORRHEIC

PATHOLOGY

Sign of Leser–Trélat. Schwartz RA. **J Am Acad Dermatol** 1996 Jul;35(1):88–95 (129 ref.)

KERATOSULFATE see **KERATAN SULFATE**

KERATOTOMY, RADIAL

Ruptured globes following radial and hexagonal keratotomy surgery [see comments] Vinger PF, et al. **Arch Ophthalmol** 1996 Feb;114(2):129–34 (51 ref.) Comment in: Arch Ophthalmol 1996 Feb;114(2):211–2.

ADVERSE EFFECTS

Sight–threatening complications after radial keratotomy [editorial; comment] McDonnell PJ. **Arch Ophthalmol** 1996 Feb;114(2):211–2 (5 ref.) Comment on: Arch Ophthalmol 1996 Feb;114(2):129–34.

METHODS

Photorefractive and phototherapeutic procedures. LaRussa FP, et al. **Optom Clin** 1995;4(4):51–67 (30 ref.)

KETAMINE

PHARMACOLOGY

NMDA antagonists: antiepileptic–neuroprotective drugs with diversified neuropharmacological profiles. Sagratella S. **Pharmacol Res** 1995 Jul–Aug;32(1–2):1–13 (124 ref.)

KETO ACIDS

BLOOD

Can a severe degree of ketoacidosis develop overnight? Schreiber M, et al. **J Am Soc Nephrol** 1996 Feb;7(2):192–7 (20 ref.)

3–KETO–5–ALPHA–STEROID DELTA–4–DEHYDROGENASE see **TESTOSTERONE 5–ALPHA–REDUCTASE**

KETOACID–LYASES

ANTAGONISTS & INHIBITORS

Inhibition of citrate lyase may aid aerobic endurance. McCarty MF. **Med Hypotheses** 1995 Sep;45(3):247–54 (77 ref.)

KETOACIDOSIS, DIABETIC see **DIABETIC KETOACIDOSIS**

3–KETOACYL COA THIOLASE see **ACETYL COA ACYLTRANSFERASE**

KETOCONAZOLE

THERAPEUTIC USE

Ketoconazole to prevent acute respiratory distress syndrome in critically ill patients. Frazee LA, et al. **Ann Pharmacother** 1995 Jul–Aug;29(7–8):784–6 (20 ref.)

KETOGLUTARATE GLUTAMINE AMIDOTRANSFERASE see **GLUTAMATE SYNTHASE**

KETONE BODIES

BIOSYNTHESIS

Hormonal and nutritional control of liver fatty acid oxidation and ketogenesis during development. Prip–Buus C, et al. **Biochem Soc Trans** 1995 Aug;23(3):500–6 (47 ref.)

BLOOD

Tests of glycemia in diabetes. Goldstein DE, et al. **Diabetes Care** 1995 Jun;18(6):896–909 (144 ref.)
[Ketone bodies: measurement and its clinical significance] Hidaka H, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:603–5 (10 ref.) **(Jpn)**

METABOLISM

Medical aspects of ketone body metabolism. Mitchell GA, et al. **Clin Invest Med** 1995 Jun;18(3):193–216 (168 ref.)

KETOQUINOLINES see **QUINOLONES**

KETOSIS

DIAGNOSIS

Medical aspects of ketone body metabolism. Mitchell GA, et al. **Clin Invest Med** 1995 Jun;18(3):193–216 (168 ref.)

ETIOLOGY

[Ketoacidotic coma in an infant as the form of onset of a mitochondrial 2-methylacetoacetyl-CoA thiolase deficiency] Yeste Fernández D, et al. **An Esp Pediatr** 1996 Jun;44(6):620–2 (9 ref.) **(Spa)**

KETOSIS, DIABETIC see **DIABETIC KETOACIDOSIS**

3-KETOSTEROID ISOMERASES see **STEROID ISOMERASES**

17-KETOSTEROIDS

URINE

[Urinary 17-ketosteroids (17-KS) and 17-KS fractions] Okatani Y. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:421–4 (6 ref.) **(Jpn)**

[Urinary 17-ketogenic steroids (17-KGS) and 17-KGS fractions] Okatani Y. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:425–8 (6 ref.) **(Jpn)**

3-KETOTHIOLASE see **ACETYL COA ACYLTRANSFERASE**

KI-1 ANTIGENS see **ANTIGENS, CD30**

KI-1 LARGE-CELL LYMPHOMA see **LYMPHOMA, LARGE-CELL, KI-1**

KI-1 LYMPHOMA see **LYMPHOMA, LARGE-CELL, KI-1**

KI-1-POSITIVE ANAPLASTIC LARGE-CELL LYMPHOMA see **LYMPHOMA, LARGE-CELL, KI-1**

KI-RAS GENES see **GENES, RAS**

KIDD BLOOD-GROUP SYSTEM

GENETICS

Urea transport and Kidd blood groups. Cartron JP, et al. **Transfus Clin Biol** 1995;2(4):309–15 (24 ref.)

KIDNAPPING see **CRIME**

KIDNEY

see related
DIURESIS
NEPHRECTOMY
RENAL CIRCULATION

Tissue engineering of a bioartificial kidney: a universal donor organ. Humes HD. **Transplant Proc** 1996 Aug;28(4):2032–5 (24 ref.)

ABNORMALITIES

Unilateral renal agenesis. Robson WL, et al. **Adv Pediatr** 1995;42:575–92 (92 ref.)

Occipital encephalocele and MURCS association: case report and review of central nervous system anomalies in MURCS patients. Lin HJ, et al. **Am J Med Genet** 1996 Jan 2; 61(1):59–62 (23 ref.)

Hernia uteri (correction of: uterus) inguinale associated with unilateral renal agenesis. Keating JP, et al. **Aust N Z J Surg** 1995 Sep;65(9):688–90 (10 ref.)

Agenesis of bladder associated with multiple organ anomalies. Sarica K, et al. **Int Urol Nephrol** 1995; 27(6):697–703 (10 ref.)

A complex cystic dysplastic urogenital anomaly—an odd presentation. Singh G, et al. **Int Urol Nephrol** 1995; 27(6):687–90 (5 ref.)

Renal autotransplantation after horseshoe kidney injury: a case report and literature review. Murphy JT, et al. **J Trauma** 1996 May;40(5):840–4 (28 ref.)

Horseshoe kidney and aortic surgery. Wymenga LF, et al. **Scand J Urol Nephrol** 1995 Sep;29(3):331–4 (10 ref.)

Clinical impact and biological basis of renal malformations. Woolf AS. **Semin Nephrol** 1995 Jul;15(4):361–71 (122 ref.)

[Diagnostic-therapeutic concept in abnormalities of the kidneys and efferent urinary tract] Tutschek B, et al. **Gynakologe** 1995 Oct;28(5):356–67 (59 ref.) **(Ger)**

[A case of huge renal hamartoma] Yanaihara H, et al. **Nippon Hinyokika Gakkai Zasshi** 1995 Aug;86(8):1394–7 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Conceptual review of simple renal ectopy and suggestion of a unifying embryogenetic hypothesis] Sánchez Chapado M, et al. **Actas Urol Esp** 1995 May;19(5):420–3 (19 ref.) (Eng. Abstr.) **(Spa)**

ANATOMY & HISTOLOGY

Structure and concentrating ability of the mammalian kidney: correlations with habitat. Beuchat CA. **Am J Physiol** 1996 Jul;271(1 Pt 2):R157–79 (179 ref.)

Evidence for the role of angiotensin in the establishment and maintenance of renal morphology. Niimura F, et al. **Contrib Nephrol** 1996;118:234–7 (4 ref.)

BLOOD SUPPLY

Pan-nephritis (glomerulonephritis, arteriolitis, and tubulointerstitial nephritis) associated with predominant mesangial C1q deposition and hypocomplementemia: a variant type of C1q nephropathy? Imai H, et al. **Am J Kidney Dis** 1996 Apr;27(4):583–7 (15 ref.)

Renal infarction and thrombosis of the infrarenal aorta in a 35-year-old man with primary antiphospholipid syndrome. Poux JM, et al. **Am J Kidney Dis** 1996 May; 27(5):721–5 (20 ref.)

Renal ischaemia—reperfusion injury. Weight SC, et al. **Br J Surg** 1996 Feb;83(2):162–70 (159 ref.)

Ischemic nephropathy as an indication for renal artery reconstruction in renovascular hypertension. Newman VS, et al. **Curr Opin Gen Surg** 1994;:272–6 (30 ref.)

Growth factor control of developing kidney endothelial cells. Loughna S, et al. **Exp Nephrol** 1996 Mar-Apr;4(2):112–8 (36 ref.)

Current concepts of renal hemodynamics in diabetes. Anderson S, et al. **J Diabetes Complications** 1995 Oct-Dec; 9(4):304–7 (35 ref.)

The cell biology of reperfusion injury in the kidney. Paller MS. **J Investig Med** 1994 Dec;42(4):632–9 (85 ref.)

Sepsis or ischemia in experimental acute renal failure: what have we learned? Johnson JP, et al. **New Horiz** 1995 Nov; 3(4):608–14 (79 ref.)

Possible mediators in hypertension: renal factors. Bergman SM, et al. **Semin Nephrol** 1996 Mar;16(2):134–9 (36 ref.)

The natural history of renal artery stenosis: who should be evaluated for suspected ischemic nephropathy? Greco BA, et al. **Semin Nephrol** 1996 Jan;16(1):2–11 (54 ref.)

Cellular and metabolic consequences of chronic ischemia on kidney function. Kellerman PS. **Semin Nephrol** 1996 Jan; 16(1):33–42 (75 ref.)

The pathology of chronic renal ischemia. Shanley PF. **Semin Nephrol** 1996 Jan;16(1):21–32 (69 ref.)

Renovasculopathies of hypertension and the rise of blood pressure with age in blacks and whites. Tracy RE. **Semin Nephrol** 1996 Mar;16(2):126–33 (21 ref.)

Ischemic nephropathy: noninvasive testing. Wilcox CS. **Semin Nephrol** 1996 Jan;16(1):43–52 (52 ref.)

[Vascular complications in kidney transplantation (a review of the literature and the authors' own experience)] Nikolovski M, et al. **Khirurgiia (Sofiia)** 1994;47(5):30–3 (60 ref.) (Eng. Abstr.) **(Bul)**

[Generalities on vascular renal aging] Schaeverbeke J. **C R Seances Soc Biol Fil** 1995;189(6):955–8 (14 ref.) (Eng. Abstr.) **(Fre)**

[Is preventive perioperative dopamine administration of value?] Bund M, et al. **Anaesthesiol Reanim** 1995; 20(3):76–81 (45 ref.) (Eng. Abstr.) **(Ger)**

[Renal arterial disease-induced tubulo-interstitial lesions] Kida H, et al. **Nippon Rinsho** 1995 Aug;53(8):2034–9 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Tubulointerstitial damage attributable to acute circulatory failure: postischemic acute renal failure] Yamamoto T, et al. **Nippon Rinsho** 1995 Aug;53(8):2027–33 (17 ref.) (Eng. Abstr.) **(Jpn)**

[The participation of the arteriolar endothelium in regulating renin secretion] Rudychenko VM, et al. **Vrach Delo** 1995 Jan-Feb;(1-2):19–25 (42 ref.) **(Ukr)**

CHEMISTRY

The kidney sodium-calcium exchanger. Lytton J, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:58–72 (30 ref.)

CYTOLOGY

A cloned extracellular Ca(2+)-sensing receptor: molecular mediator of the actions of extracellular Ca2+ on parathyroid and kidney cells? Brown EM, et al. **Kidney Int** 1996 Apr;49(4):1042–6 (37 ref.)

Renal fibroblast heterogeneity. Müller GA, et al. **Kidney Int Suppl** 1995 Aug;50:S33–6 (49 ref.)

The fibroblast—a (trans-) differentiated cell? [editorial] Strutz F. **Nephrol Dial Transplant** 1995;10(9):1504–6 (13 ref.)

[The culture of renal epithelial cells: the physiological and pharmacological aspects] Berkhin EB. **Eksp Klin Farmakol** 1995 Jul-Aug;58(4):69–75 (82 ref.) (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

Effects of contrast media on renal epithelial cells in culture. Andersen KJ, et al. **Acta Radiol Suppl** 1995;399:213–8 (40 ref.)

Biochemical and morphological effects of contrast media on the kidney. Dobrota M, et al. **Acta Radiol Suppl** 1995; 399:196–203 (42 ref.)

The renal effects of nonsteroidal anti-inflammatory drugs: summary and recommendations. Bennett WM, et al. **Am J Kidney Dis** 1996 Jul;28(1 Suppl 1):S56–62 (28 ref.)

Acetaminophen: acute and chronic effects on renal function. Blantz RC. **Am J Kidney Dis** 1996 Jul;28(1 Suppl 1):S3–6 (23 ref.)

Nephrogenic diabetes insipidus and renal tubular acidosis secondary to foscarnet therapy. Navarro JF, et al. **Am J Kidney Dis** 1996 Mar;27(3):431–4 (16 ref.)

The organ toxicity of inhaled anesthetics. Kenna JG, et al. **Anesth Analg** 1995 Dec;81(6 Suppl):S51–66 (143 ref.)

Sevoflurane and renal function. Malan TP Jr. **Anesth Analg** 1995 Dec;81(6 Suppl):S39–45 (34 ref.)

Biotransformation and renal processing of nephrotoxic agents. Dekant W. **Arch Toxicol Suppl** 1996;18:163–72 (63 ref.)

Opioid mechanisms controlling renal function. Kapusta DR. **Clin Exp Pharmacol Physiol** 1995 Dec;22(12):891–902 (95 ref.)

Biotransformation and membrane transport in nephrotoxicity. Dekant W, et al. **Crit Rev Toxicol** 1996 May;26(3):309–34 (203 ref.)

Strategies to prevent nephrotoxicity of anticancer drugs. Skinner R. **Curr Opin Oncol** 1995 Jul;7(4):310–5 (38 ref.)

Safety aspects of cyclosporin in rheumatoid arthritis. Dijkmans BA. **Drugs** 1995;50 Suppl 1:41–7 (37 ref.)

Gentamicin nephrotoxicity in humans and animals: some recent research. Ali BH. **Gen Pharmacol** 1995 Nov; 26(7):1477–87 (119 ref.)

Pharmacological characterisation and autoradiographic localisation of dopamine receptor subtypes in the cardiovascular system and in the kidney. Amenta F, et al. **Hypertens Res** 1995 Jun;18 Suppl 1:S23–7 (10 ref.)

Amphotericin B nephrotoxicity: the adverse consequences of altered membrane properties [editorial] Sawaya BP, et al. **J Am Soc Nephrol** 1995 Aug;6(2):154–64 (133 ref.)

Systemic aluminum toxicity: effects on bone, hematopoietic tissue, and kidney. Jeffery EH, et al. **J Toxicol Environ Health** 1996 Aug 30;48(6):649–65 (80 ref.)

Calcium channel blockers and renal dysfunction in arterial hypertension. Díez J. **Nephrol Dial Transplant** 1995;10 Suppl 6:22–6 (50 ref.)

Effects of agmatine, an active metabolite of arginine metabolism, on the kidney [editorial] Morrissey JJ, et al. **Nephrol Dial Transplant** 1996 Jul;11(7):1217–9 (25 ref.)

Renal effects of calcium antagonists. Rodicio JL, et al. **Nephrol Dial Transplant** 1995 Oct;10 Suppl 9:17–22 (57 ref.)

Calcium antagonists and the kidney. Pearce CJ, et al. **New Horiz** 1996 Feb;4(1):123–8 (47 ref.)

Interactions of drugs with the developing kidney. Blowey DL, et al. **Pediatr Clin North Am** 1995 Dec;42(6):1415–31 (97 ref.)

Prevention of nephrotoxicity of ochratoxin A, a food contaminant. Creppy EE, et al. **Toxicol Lett** 1995 Dec; 82–83:869–77 (54 ref.)

Pancreatic and nephrotoxicity of immunomodulator compounds. Hammond TG, et al. **Toxicol Lett** 1995 Dec; 82–83:99–105 (17 ref.)

At risk nephrons and the decline in renal function in response to treatment of hypertension. Walker WG, et al. **Trans Am Clin Climatol Assoc** 1995;107:134–43; discussion 143–5 (26 ref.)

[Renal function during treatment with angiotensin converting enzyme inhibitors] Rasmussen K, et al. **Ugeskr Laeger** 1995 Sep 25;157(39):5377–81 (17 ref.) (Eng. Abstr.) **(Dan)**

[Nephrotoxicity and fluoride from the viewpoint of the nephrologist] Bosch T. **Anaesthesist** 1996 Feb;45 Suppl 1:S41–5 (28 ref.) (Eng. Abstr.) **(Ger)**

[Fluoride-induced nephrotoxicity: factor fiction?] Nuscheler M, et al. **Anaesthesist** 1996 Feb;45 Suppl 1:S32–40 (54 ref.) (Eng. Abstr.) **(Ger)**

[Drug-induced nephrotoxicity] Takeda M, et al. **Nippon Yakurigaku Zasshi** 1996 Jan;107(1):1–8 (50 ref.) (Eng. Abstr.) **(Jpn)**

[Kidney reactivity in helminthiases and after anthelmintic treatment] Grishina EA, et al. **Med Parazitol (Mosk)** 1995 Apr-Jun;(2):27–30 (15 ref.) (Eng. Abstr.) **(Rus)**

[Vasodilators and renal function in cirrhosis] Albillos A, et al. **Gastroenterol Hepatol** 1995 Nov;18(9):488–92 (46 ref.) **(Spa)**

[Aminoglycoside nephrotoxicity and obstructive jaundice (editorial)] Lucena MI, et al. **Med Clin (Barc)** 1995 Oct 14;105(12):457–60 (55 ref.) **(Spa)**

EMBRYOLOGY

Programmed cell death and its clearance in the developing mammalian kidney. Camp V, et al. **Exp Nephrol** 1996 Mar-Apr;4(2):105–11 (29 ref.)

Inductive interactions between the mesenchyme and the ureteric bud. Davies JA, et al. **Exp Nephrol** 1996 Mar-Apr; 4(2):77–85 (82 ref.)

Extracellular matrix and cell adhesion molecules in nephrogenesis. Ekblom P. **Exp Nephrol** 1996 Mar-Apr; 4(2):92–6 (30 ref.)

Growth factor control of developing kidney endothelial cells. Loughna S, et al. **Exp Nephrol** 1996 Mar-Apr;4(2):112–8 (36 ref.)

Roles of Paxgenes in nephrogenesis. Rothenpieler UW. **Exp Nephrol** 1996 Mar-Apr;4(2):86–91 (35 ref.)

Does the kidney express redundant or important molecules during nephrogenesis? Sariola H. **Exp Nephrol** 1996 Mar-Apr;4(2):70–6 (43 ref.)

Growth factors and metanephrogenesis. Schofield PN, et al. **Exp Nephrol** 1996 Mar–Apr;4(2):97–104 (49 ref.)
Interactions of drugs with the developing kidney. Blowey DL, et al. **Pediatr Clin North Am** 1995 Dec;42(6):1415–31 (97 ref.)
Development of renal function in the fetus: a review. Lumbers ER. **Reprod Fertil Dev** 1995;7(3):415–26 (103 ref.)
Transcription factors in renal development: the WT1 and Pax–2 story. Dressler GR. **Semin Nephrol** 1995 Jul; 15(4):263–71 (86 ref.)
Growth factors in renal development. Hammerman MR. **Semin Nephrol** 1995 Jul;15(4):291–9 (56 ref.)
Inductive interactions during kidney development. Herzlinger D. **Semin Nephrol** 1995 Jul;15(4):255–62 (42 ref.)
[The immature kidney] Guignard JP, et al. **Rev Med Suisse Romande** 1995 Aug;115(8):565–74 (42 ref.) (Eng. Abstr.) **(Fre)**

ENZYMOLOGY

Physiology and biochemistry of the kidney vacuolar H+–ATPase. Gluck SL, et al. **Annu Rev Physiol** 1996; 58:427–45 (129 ref.)
Ovine 11 beta–hydroxysteroid dehydrogenase: from gene to function. Yang K. **Endocr Res** 1995 Feb–May; 21(1–2):367–77 (49 ref.)
Renal cytochrome P450. Schwartzman ML, et al. **J Lipid Mediat Cell Signal** 1995 Oct;12(2–3):229–42 (58 ref.)

GROWTH & DEVELOPMENT

Angiotensin as a renal growth promoting factor. Wolf G. **Adv Exp Med Biol** 1995;377:225–36 (99 ref.)
Transgenic animal models of renal development and pathogenesis. Kopp JB, et al. **Am J Physiol** 1995 Nov;269(5 Pt 2):F601–20 (216 ref.)
Tenascin expression in nephrogenesis and in normal or pathologic glomerulus morphologic features and functional implications [editorial] Truong LD, et al. **Nephron** 1996; 72(4):499–506 (43 ref.)
The role of the cytoskeleton in renal development. Bacallao R. **Semin Nephrol** 1995 Jul;15(4):285–90 (61 ref.)
Effects of ureteral obstruction on renal growth. Chevalier RL. **Semin Nephrol** 1995 Jul;15(4):353–60 (73 ref.)
[Nitric oxide and the kidney during the development] Simeoni U, et al. **Arch Pediatr** 1996;3 Suppl 1:284s–286s (16 ref.) **(Fre)**

INJURIES

ABC of urology. Urological trauma and bladder reconstruction. Dawson C, et al. **BMJ** 1996 May 25; 312(7042):1352–4 (5 ref.)
Ischemia, injury, and renal allograft rejection. Lu CY. **Curr Opin Nephrol Hypertens** 1996 Mar;5(2):107–10 (52 ref.)
Renal autotransplantation after horseshoe kidney injury: a case report and literature review. Murphy JT, et al. **J Trauma** 1996 May;40(5):840–4 (28 ref.)
Radiation nephropathy: a review. Robbins ME, et al. **Scanning Microsc** 1995 Jun;9(2):535–60 (210 ref.)
Hyperfiltration of renal injury: pathophysiology and clinical implications. Grady RW, et al. **Urology** 1996 Feb; 47(2):273–83 (133 ref.)

INNERVATION

Renal neural mechanisms in salt–sensitive hypertension. DiBona GF. **Blood Press Suppl** 1995;2:81–7 (61 ref.)

METABOLISM

Corticosteroid metabolism in isolated perfused rat liver and kidney. Experimental studies with emphasis on aldosterone. Egfjord M. **Acta Physiol Scand Suppl** 1995;627:1–42 (226 ref.)
Extrarenal potassium adaptation: review of a concept [editorial] Spital A, et al. **Am J Nephrol** 1995;15(5):367–73 (29 ref.)
Expression of newly cloned brain dopamine receptors in peripheral organs. O'Connell DP. **Biochem Soc Trans** 1996 Feb;24(1):169–72 (16 ref.)
Enhancement of intrarenal angiotensin II levels in 2 kidney 1 clip and angiotensin II induced hypertension. Navar LG, et al. **Blood Press Suppl** 1995;2:88–92 (23 ref.)
Cloning and functional characterization of extracellular Ca(2+)–sensing receptors from parathyroid and kidney. Brown EM, et al. **Bone** 1995 Aug;17(2 Suppl):7S–11S (30 ref.)
Renal medullary antihypertensive mechanisms. Anderson WP, et al. **Clin Exp Pharmacol Physiol** 1995 Dec; 22(12):S426–9 (26 ref.)
Endothelin receptors in normal and diseased kidneys. Nambi P. **Clin Exp Pharmacol Physiol** 1996 Apr;23(4):326–30 (86 ref.)
Water channels. Fushimi K, et al. **Curr Opin Nephrol Hypertens** 1995 Sep;4(5):392–7 (37 ref.)
Facilitative glucose transport proteins and sodium–glucose co–transporters in the kidney. Hoffman BB, et al. **Curr Opin Nephrol Hypertens** 1995 Sep;4(5):406–11 (52 ref.)
Renal sodium excretion and edematous disorders. Martin PY, et al. **Endocrinol Metab Clin North Am** 1995 Sep; 24(3):459–79 (114 ref.)
1994 Homer W. Smith Award. From flies to physiology—accidental findings along the trail of renal NaCl transport. Aronson PS. **J Am Soc Nephrol** 1995 Jun; 5(12):2001–13 (104 ref.)
Molecular characterization of voltage and cyclic nucleotide–gated potassium channels in kidney. Desir GV. **Kidney Int** 1995 Oct;48(4):1031–5 (57 ref.)
Modulation of renal Na–Pi cotransport by hormones acting via genomic mechanism and by metabolic factors. Dousa TP. **Kidney Int** 1996 Apr;49(4):997–1004 (52 ref.)
Renal sodium channels: regulation and single channel properties. Eaton DC, et al. **Kidney Int** 1995 Oct; 48(4):941–9 (88 ref.)
Role of renal handling of extracellular nucleotides in modulation of phosphate transport. Friedlander G, et al. **Kidney Int** 1996 Apr;49(4):1019–22 (43 ref.)
Renal potassium channels: an overview. Giebisch G. **Kidney Int** 1995 Oct;48(4):1004–9 (46 ref.)
An ATP–regulated, inwardly rectifying potassium channel from rat kidney (ROMK). Hebert SC. **Kidney Int** 1995 Oct; 48(4):1010–6 (66 ref.)
Peptide hormone action on renal phosphate handling [see comments] Kempson SA. **Kidney Int** 1996 Apr;49(4):1005–9 (52 ref.) Comment in: Kidney Int 1996 Apr;49(4):1010–1.
Properties and regulation of ion channels in MDCK cells. Lang F, et al. **Kidney Int** 1995 Oct;48(4):1200–5 (128 ref.)
The renal cGMP–gated cation channel: its molecular structure and physiological role. McCoy DE, et al. **Kidney Int** 1995 Oct;48(4):1125–33 (77 ref.)
The aquaporin family of water channels in kidney. Nielsen S, et al. **Kidney Int** 1995 Oct;48(4):1057–68 (83 ref.)
The cellular basis of metabolic alkalosis. Sabatini S. **Kidney Int** 1996 Mar;49(3):906–17 (88 ref.)
Structure and function of kidney water channels. Verkman AS, et al. **Kidney Int** 1995 Oct;48(4):1069–81 (68 ref.)
Identification and localization of calcium channel alpha 1 and beta subunit isoforms in the kidney. Yu AS. **Kidney Int** 1995 Oct;48(4):1097–101 (58 ref.)
Molecular mechanisms in renal phosphate reabsorption [editorial] Murer H, et al. **Nephrol Dial Transplant** 1995; 10(9):1501–4 (19 ref.)
In vivo gene transfer: focus on the kidney. Wagner J, et al. **Nephrol Dial Transplant** 1995 Oct;10(10):1801–7 (53 ref.)
Tenascin expression in nephrogenesis and in normal or pathologic glomerulus morphologic features and functional implications [editorial] Truong LD, et al. **Nephron** 1996; 72(4):499–506 (43 ref.)
Chloride transport across kidney epithelia through CLC chloride channels. Uchida S, et al. **Nippon Jinzo Gakkai Shi** 1996 Jul;38(7):285–9 (17 ref.)
The kidney in acid–base balance. Hanna JD, et al. **Pediatr Clin North Am** 1995 Dec;42(6):1365–95 (85 ref.)
Fuel selection by the kidney: adaptation to starvation. Baverel G, et al. **Proc Nutr Soc** 1995 Mar;54(1):197–212 (116 ref.)
Heat–shock proteins in animal models for acute renal failure. Wakui H, et al. **Ren Fail** 1995 Nov;17(6):641–9 (26 ref.)

PATHOLOGY

Outcomes of percutaneous kidney biopsy, including those of solitary native kidneys. Mendelssohn DC, et al. **Am J Kidney Dis** 1995 Oct;26(4):580–5 (15 ref.)
Proteinuria: a mediator of interstitial fibrosis? Harris KP, et al. **Contrib Nephrol** 1996;118:173–9 (28 ref.)
Possible mechanisms of renal fibrosis. Okada H, et al. **Contrib Nephrol** 1996;118:147–54 (37 ref.)
Extracellular matrix and the kidney. Furness PN. **J Clin Pathol** 1996 May;49(5):355–9 (70 ref.)
Role of transforming growth factor–beta in diabetic glomerulosclerosis and renal hypertrophy. Ziyadeh FN, et al. **Kidney Int Suppl** 1995 Sep;51:S34–6 (34 ref.)
Contrast–enhanced MR imaging of the kidneys and adrenal glands. Huch Böni RA, et al. **Magn Reson Imaging Clin N Am** 1996 Feb;4(1):101–31 (61 ref.)
Fibrosis causes progressive kidney failure. Cohen EP. **Med Hypotheses** 1995 Nov;45(5):459–62 (35 ref.)
Renal biopsy: why and when. Reisman L, et al. **Mt Sinai J Med** 1996 May–Sep;63(3–4):178–90 (17 ref.)
Novel aspects of renal fibrogenesis. Strutz F. **Nephrol Dial Transplant** 1995;10(9):1526–32 (70 ref.)
A review of renal scarring in children. MacKenzie JR. **Nucl Med Commun** 1996 Mar;17(3):176–90 (44 ref.)
High–resolution light microscopy for interpretation of renal biopsies. Hoffmann EO. **Pediatr Nephrol** 1995 Dec; 9(6):763–9 (81 ref.)
Renal transplant fine needle aspiration and cytokine gene expression. Nast CC. **Pediatr Nephrol** 1995;9 Suppl:S56–60 (31 ref.)
Spinal cord and bone metastasizing renal tumor of childhood. Arrotegui JI, et al. **Rev Neurol** 1995 Nov–Dec; 23(124):1231–2 (15 ref.)
Renal epithelial cell hyperplasia and hypertrophy. Preisig PA, et al. **Semin Nephrol** 1995 Jul;15(4):327–40 (97 ref.)
Renovascular elements of the cyclosporine injury. Curtis JJ. **Transplant Proc** 1996 Aug;28(4):2094–6 (18 ref.)
The lesional changes and pathogenesis in the kidney in African swine fever. Hervás J, et al. **Vet Res Commun** 1996; 20(3):285–99 (44 ref.)
[The role of tubulointerstitial changes in progression of kidney function failure in patients with chronic glomerulonephritis (GN)] Idasiak–Piechocka I, et al. **Przegl Lek** 1996;53(5):443–53 (72 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOLOGY

A re–evaluation of the determinants of glomerular filtration rate. Karlsen FM, et al. **Acta Physiol Scand** 1995 Dec; 155(4):335–50 (61 ref.)
The First Annual Bayard D. Catherwood Memorial Lecture. Ca2+–receptor–mediated regulation of parathyroid and renal function. Brown EM, et al. **Am J Med Sci** 1996 Sep; 312(3):99–109 (69 ref.)
Structure and concentrating ability of the mammalian kidney: correlations with habitat. Beuchat CA. **Am J Physiol** 1996 Jul;271(1 Pt 2):R157–79 (179 ref.)
Phosphodiesterase activity as a mediator of renal resistance to ANP in pathological salt retention. Lee EY, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):F3–6 (27 ref.)
Serum creatinine and urea: make the most of these simple test. Isles CG, et al. **Br J Hosp Med** 1996 Apr 17–30; 55(8):513–6 (3 ref.)
Can the kidney prevent cardiovascular diseases? Rodicio JL. **Clin Exp Hypertens** 1996 Apr–May;18(3–4):501–11 (31 ref.)
Signalling pathways activated by endothelin stimulation of renal cells. Nord EP. **Clin Exp Pharmacol Physiol** 1996 Apr;23(4):331–6 (54 ref.)
Prostaglandins and sodium handling in Lyon hypertensive rats. Sassard J, et al. **Clin Exp Pharmacol Physiol** 1995 Dec; 22(12):S423–5 (18 ref.)
Determination of individual renal function through noninvasive methodologies. Dondi M, et al. **Curr Opin Nephrol Hypertens** 1995 Nov;4(6):520–4 (42 ref.)
Special considerations for the evaluation of renal function in the pediatric patient. Geva P, et al. **Curr Opin Nephrol Hypertens** 1995 Nov;4(6):525–30 (26 ref.)
Studies on the nature of the antagonistic actions of dopamine and 5–hydroxytryptamine in renal tissues. Soares–da–Silva P, et al. **Hypertens Res** 1995 Jun;18 Suppl 1:S47–51 (21 ref.)
Phosphate load as the evolutionary driving force for the development of a high filtration rate based excretory organ: a hypothesis. Ilani A. **J Basic Clin Physiol Pharmacol** 1993 Apr–Jun;4(1–2):123–38 (32 ref.)
The role of the kidney in hypertension. Cowley AW Jr, et al. **JAMA** 1996 May 22–29;275(20):1581–9 (112 ref.)
The physiologic and pathologic roles of Tamm–Horsfall glycoprotein in urinary system. Yu CL, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1995 Sep; 11(9):481–95 (88 ref.)
Growth hormone, insulin–like growth factor and the kidney [editorial] Krieg RJ Jr, et al. **Kidney Int** 1995 Aug; 48(2):321–36 (259 ref.)
Impaired proteolytic activity as a potential cause of progressive renal disease. Heidland A, et al. **Miner Electrolyte Metab** 1996;22(1–3):157–61 (52 ref.)
Insulin–like growth factor I in the kidney. Hirschberg R. **Miner Electrolyte Metab** 1996;22(1–3):128–32 (23 ref.)
Liver and kidney in acid–base regulation. Hüssinger D. **Nephrol Dial Transplant** 1995;10(9):1536 (5 ref.)
Intrarenal renin–angiotensin system and its contribution to the regulation of glomerular haemodynamics. Rosivall L. **Nephrol Dial Transplant** 1995;10(9):1565–8 (33 ref.)
Transmembrane signaling in kidney health and disease. Hack N, et al. **Pediatr Nephrol** 1995 Aug;9(4):514–25 (126 ref.)
Protein trafficking and polarity in kidney epithelium: from cell biology to physiology. Brown D, et al. **Physiol Rev** 1996 Jan;76(1):245–97 (357 ref.)
Development of renal function in the fetus: a review. Lumbers ER. **Reprod Fertil Dev** 1995;7(3):415–26 (103 ref.)
Renal functional reserve in children. Anastasio P, et al. **Semin Nephrol** 1995 Sep;15(5):454–62 (38 ref.)
Renal reserve: a functional view of glomerular filtration rate. Bosch JP. **Semin Nephrol** 1995 Sep;15(5):381–5 (10 ref.)
Renal response to an acute oral protein load in healthy humans and in patients with renal disease or liver cirrhosis. De Santo NG, et al. **Semin Nephrol** 1995 Sep;15(5):433–48 (127 ref.)
Renal reserve in the elderly. Fliser D, et al. **Semin Nephrol** 1995 Sep;15(5):463–7 (47 ref.)
Role of angiotensin in the regulation of renal response to proteins. Gabbai FB, et al. **Semin Nephrol** 1995 Sep; 15(5):396–404 (56 ref.)
Renal reserve in pregnancy. Gaboury CL, et al. **Semin Nephrol** 1995 Sep;15(5):449–53 (27 ref.)
Nitric oxide and the renal hemodynamic response to proteins. King AJ. **Semin Nephrol** 1995 Sep;15(5):405–14 (88 ref.)
Renal hemodynamic response to intravenous and oral amino acids in animals. Lang F, et al. **Semin Nephrol** 1995 Sep; 15(5):415–8 (65 ref.)
Renal effects of intravenous amino acid administration in humans with and without renal disease: hormonal correlates. ter Wee PM. **Semin Nephrol** 1995 Sep; 15(5):426–32 (76 ref.)
Intrarenal mechanisms of renal reserve. Woods LL. **Semin Nephrol** 1995 Sep;15(5):386–95 (68 ref.)
[Nitric oxide and the kidney during the development] Simeoni U, et al. **Arch Pediatr** 1996;3 Suppl 1:284s–286s (16 ref.) **(Fre)**
[Generalities on vascular renal aging] Schaeverbeke J. **C R Seances Soc Biol Fil** 1995;189(6):955–8 (14 ref.) (Eng. Abstr.) **(Fre)**
[Diagnostic and pathophysiological aspects of the determination of kidney function in animals (corrected and republished with original paging, article originally printed in Zentralbl Veterinarmed A 1994 May;41(4):253–67)]

Reder S, et al. **Zentralbl Veterinarmed A** 1995 May; 42(3):253–67 (56 ref.) (Eng. Abstr.) **(Ger)**

[Dopamine and the kidney—renal sparing effect: fact or fiction?] Yussim E, et al. **Harefuah** 1996 Apr 1;130(7):480–3 (26 ref.) **(Heb)**

[The physiology of the kidney and water–salt metabolism: the basic research trends in Russia] Ivanova LN. **Usp Fiziol Nauk** 1995 Jul–Sep;26(3):3–13 (74 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Effect of hypoxaemia on water and sodium homeostatic hormones and renal function. Olsen NV. **Acta Anaesthesiol Scand Suppl** 1995;107:165–70 (55 ref.)

Review: new aspects of acute renal failure. Simon EE. **Am J Med Sci** 1995 Nov;310(5):217–21 (48 ref.)

Role of the kidney in the genesis of hypertension: aberrant renal response to excess salt intake. Kurokawa K. **Clin Exp Pharmacol Physiol** 1995 Dec;22(12):S417–22 (23 ref.)

Role of angiotensin–converting enzyme gene polymorphism in progressive loss of renal function in chronic renal diseases. Yoshida H, et al. **Contrib Nephrol** 1996;118:249–53 (21 ref.)

Reliability of experimental models of iodinated contrast media–induced acute renal failure. From methodological considerations to pathophysiology. Idée JM, et al. **Invest Radiol** 1996 Apr;31(4):230–41 (96 ref.)

Sphingolipids: their role in intracellular signaling and renal growth [editorial] Shayman JA. **J Am Soc Nephrol** 1996 Feb;7(2):171–82 (106 ref.)

Surgical considerations to preserve renal function in children with chronic renal failure. Ross JH. **J Pediatr** 1996 Aug; 129(2):s27–32 (26 ref.)

A renocentric view of essential hypertension: lessons to be learnt from kidney transplantation [editorial] Jelakovic B, et al. **Nephrol Dial Transplant** 1995;10(9):1510–2 (31 ref.)

Renal scarring: the role of angiotensin II. el Nahas AM. **Nephrol Dial Transplant** 1995 Oct;10 Suppl 9:28–32 (53 ref.)

Chronic rejection and late renal allograft dysfunction. Laine J, et al. **Pediatr Nephrol** 1996 Apr;10(2):221–9 (83 ref.)

The impact of peritoneal permeability and residual renal function on PD prescription. Harty J, et al. **Perit Dial Int** 1996;16 Suppl 1:S147–52 (18 ref.)

Aquaporin water channels in the kidney: localization and regulation. Nielsen S. **Perit Dial Int** 1996;16 Suppl 1:S25–7 (46 ref.)

Renal reserve in patients with high blood pressure. Gabbai FB. **Semin Nephrol** 1995 Sep;15(5):482–7 (35 ref.)

Renal functional reserve in subjects with diabetes mellitus. Jones SL, et al. **Semin Nephrol** 1995 Sep;15(5):475–81 (51 ref.)

Cellular and metabolic consequences of chronic ischemia on kidney function. Kellerman PS. **Semin Nephrol** 1996 Jan; 16(1):33–42 (75 ref.)

Renal reserve in patients with solitary kidneys. Rugiu C, et al. **Semin Nephrol** 1995 Sep;15(5):468–74 (52 ref.)

At risk nephrons and the decline in renal function in response to treatment of hypertension. Walker WG, et al. **Trans Am Clin Climatol Assoc** 1995;107:134–43; discussion 143–5 (26 ref.)

Hyperfiltration of renal injury: pathophysiology and clinical implications. Grady RW, et al. **Urology** 1996 Feb; 47(2):273–83 (133 ref.)

[Kidney function problems in rheumatoid arthritis] Nordin H, et al. **Ugeskr Laeger** 1996 May 27;158(22):3137–40 (40 ref.) (Eng. Abstr.) **(Dan)**

[Substitutive treatment of renal function] Abensur H. **Arq Bras Cardiol** 1995 Jul;65(1):81–3 (14 ref.) **(Por)**

[Diabetic nephropathy and molecular biology of the renin–angiotensin system in the diabetic kidney] Rodriguez Pérez JC, et al. **Med Clin (Barc)** 1995 Nov 25; 105(18):708–15 (103 ref.) **(Spa)**

RADIATION EFFECTS

Bone marrow transplant nephropathy: radiation nephritis revisited. Cohen EP, et al. **Nephron** 1995;70(2):217–22 (54 ref.)

Radiation nephropathy: a review. Robbins ME, et al. **Scanning Microsc** 1995 Jun;9(2):535–60 (210 ref.)

RADIOGRAPHY

An unusual manifestation of xanthogranulomatous pyelonephritis: bilateral focal solid renal masses [letter] Ozcan H, et al. **AJR Am J Roentgenol** 1995 Dec; 165(6):1552–3 (4 ref.)

RADIONUCLIDE IMAGING

Radionuclide techniques for the evaluation of renal function: advantages over conventional methodology. Bubeck B. **Curr Opin Nephrol Hypertens** 1995 Nov;4(6):514–9 (15 ref.)

[Tubulointerstitial nephropathy—radionuclide imaging diagnosis] Kawamura J, et al. **Nippon Rinsho** 1995 Aug; 53(8):1944–53 (9 ref.) (Eng. Abstr.) **(Jpn)**

SECRETION

Nitric oxide and the control of renin secretion. Reid IA, et al. **Fundam Clin Pharmacol** 1995;9(4):309–23 (118 ref.)

ULTRASONOGRAPHY

An unusual manifestation of xanthogranulomatous pyelonephritis: bilateral focal solid renal masses [letter] Ozcan H, et al. **AJR Am J Roentgenol** 1995 Dec; 165(6):1552–3 (4 ref.)

[Renovascular hypertension due to unilateral renal artery stenosis with hypokalemic alkalosis, the salt–losing syndrome and reversible hyperechogenicity of the contralateral kidney. A study of 2 infants] Castelló Girona F, et al. **An Esp Pediatr** 1996 Jul;45(1):49–52 (14 ref.) (Eng. Abstr.) **(Spa)**

KIDNEY, ARTIFICIAL

Application of gene and cell therapies in the tissue engineering of a bioartificial kidney [editorial] Humes HD. **Int J Artif Organs** 1996 Apr;19(4):215–7 (22 ref.)

KIDNEY–BRUSH–BORDER NEUTRAL PROTEINASE see **MEMBRANE METALLO–ENDOPEPTIDASE**

KIDNEY CALCULI

Hypertension and kidney stones: hypotheses and implications. Strazzullo P, et al. **Semin Nephrol** 1995 Nov;15(6):519–25 (54 ref.)

[Evaluation and treatment of patients with kidney calculi] Daugaard H, et al. **Ugeskr Laeger** 1996 Apr 29; 158(18):2521–5 (9 ref.) (Eng. Abstr.) **(Dan)**

CHEMISTRY

Calcium oxalate monohydrate renal calculi. Formation and development mechanism. Söhnel O, et al. **Adv Colloid Interface Sci** 1995 Aug 31;59:1–17 (36 ref.)

COMPLICATIONS

Nephrobronchial fistula and lung abscess resulting from nephrolithiasis and pyelonephritis. O'Brien JD, et al. **Chest** 1995 Oct;108(4):1166–8 (6 ref.)

[Bone involvement in idiopathic calcium lithiasis] Ghazali A, et al. **Nephrologie** 1995;16(5):351–69 (129 ref.) (Eng. Abstr.) **(Fre)**

[Prevalence of medullary sponge kidney in patients with and without nephrolithiasis] Laube M, et al. **Schweiz Rundsch Med Prax** 1995 Oct 24;84(43):1224–30 (41 ref.) (Eng. Abstr.) **(Ger)**

[Squamous cell carcinoma of the renal pelvis associated with renal stones in a patient with chronic renal failure: a case report and a review of the Japanese literature] Nakamura Y, et al. **Hinyokika Kiyo** 1996 Jun;42(6):451–5 (13 ref.) (Eng. Abstr.) **(Jpn)**

ETIOLOGY

Nutritional determinants of nephrolithiasis. Jaeger P, et al. **Adv Nephrol Necker Hosp** 1995;24:217–25 (45 ref.)

Experimental calcium oxalate nephrolithiasis and the formation of human urinary stones. Khan SR. **Scanning Microsc** 1995 Mar;9(1):89–100; discussion 100–1 (79 ref.)

[Endocrine abnormalities in active nephrolithiasis] Kuczera M, et al. **Pol Arch Med Wewn** 1995 Mar;93(3):243–9 (53 ref.) **(Pol)**

METABOLISM

[Diagnostic markers in calcium nephrolithiasis—current and traditional ideas with a new look] Hess B. **Schweiz Med Wochenschr** 1995 Dec 26;125(51–52):2460–70 (56 ref.) (Eng. Abstr.) **(Ger)**

[Metabolic evaluation at the time of the first renal lithiasis episode] del Valle EE, et al. **Medicina (B Aires)** 1995; 55(1):69–74 (27 ref.) (Eng. Abstr.) **(Spa)**

PREVENTION & CONTROL

Inhibitors of crystallization. Daudon M, et al. **Adv Nephrol Necker Hosp** 1995;24:167–216 (261 ref.)

Calcium, why and how much? Palmieri GM. **Miner Electrolyte Metab** 1995;21(1–3):236–41 (44 ref.)

SURGERY

[Surgery of kidney calculus. Current practice] Ibarz L, et al. **Ann Urol (Paris)** 1995;29(6–7):370–7 (15 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

[The double J catheter in the shock wave treatment of kidney calculi] Pilar Laguna M, et al. **Ann Urol (Paris)** 1995; 29(6–7):364–9 (20 ref.) (Eng. Abstr.) **(Fre)**

[Treatment of renal and ureteral lithiasis] Doré B. **Presse Med** 1995 Oct 28;24(32):1495–7 (17 ref.) (Eng. Abstr.) **(Fre)**

[Extracorporeal lithotripsy in the treatment of upper urinary tract lithiasis] Guillonneau B, et al. **Presse Med** 1995 Dec 2;24(37):1743–6 (25 ref.) (Eng. Abstr.) **(Fre)**

[Flexible ureterorenoscopy: a method for minimally invasive diagnosis and therapy in the upper urinary tract] Fuchs GJ. **Wien Med Wochenschr** 1995;145(11–12):267–73 (22 ref.) (Eng. Abstr.) **(Ger)**

[The small urinary calculus: natural course and current treatment concepts] Hübner WA, et al. **Wien Med Wochenschr** 1995;145(11–12):276–9 (23 ref.) (Eng. Abstr.) **(Ger)**

[Current status of percutaneous calculus therapy] Kaldenbach U, et al. **Wien Med Wochenschr** 1995;145(11–12):260–7 (62 ref.) (Eng. Abstr.) **(Ger)**

[The dissolution of cystine lithiasis with n–acetylcysteine] Benítez Navio J, et al. **Arch Esp Urol** 1995 Nov;48(9):944–8 (13 ref.) (Eng. Abstr.) **(Spa)**

KIDNEY CALICES

[Percutaneous treatment of Fraley syndrome] Fernández Arjona M, et al. **Arch Esp Urol** 1996 Jan–Feb;49(1):55–8 (6 ref.) (Eng. Abstr.) **(Spa)**

ULTRASONOGRAPHY

Megacalycosis on duplex system upper moiety. Cacciaguerra S, et al. **Eur J Pediatr Surg** 1996 Feb;6(1):42–4 (23 ref.)

KIDNEY CIRCULATION see **RENAL CIRCULATION**

KIDNEY COLLECTING DUCTS see **KIDNEY TUBULES, COLLECTING**

KIDNEY CONCENTRATING ABILITY

Structure and concentrating ability of the mammalian kidney: correlations with habitat. Beuchat CA. **Am J Physiol** 1996 Jul;271(1 Pt 2):R157–79 (179 ref.)

[Water and chloride channels and urine concentrating system] Marumo F. **Nippon Naika Gakkai Zasshi** 1995 Dec 10; 84(12):2080–4 (12 ref.) **(Jpn)**

KIDNEY CORTEX

Renal cortical neoplasm in a child with dialysis–acquired cystic kidney disease. Gentle DL, et al. **Urology** 1996 Feb; 47(2):254–5 (5 ref.)

PHYSIOLOGY

Slices and sacs: limitations on metabolic and functional studies in kidney cortex and intestine. Foulkes EC. **Proc Soc Exp Biol Med** 1996 Feb;211(2):155–62 (43 ref.)

ULTRASTRUCTURE

Morphology of interstitial cells in the healthy kidney. Kaissling B, et al. **Anat Embryol (Berl)** 1996 Apr; 193(4):303–18 (80 ref.)

KIDNEY CORTEX NECROSIS

DIAGNOSIS

Bilateral renal cortical necrosis with the changes in clinical features over the past 15 years (1980–1995). Kim HJ. **J Korean Med Sci** 1995 Apr;10(2):132–41 (50 ref.)

PATHOLOGY

Bilateral renal cortical necrosis with the changes in clinical features over the past 15 years (1980–1995). Kim HJ. **J Korean Med Sci** 1995 Apr;10(2):132–41 (50 ref.)

RADIOGRAPHY

CT scan as an important diagnostic tool in the initial phase of diffuse bilateral renal cortical necrosis. Kim HJ, et al. **Clin Nephrol** 1996 Feb;45(2):125–30 (24 ref.)

KIDNEY, CYSTIC

COMPLICATIONS

Alagille's syndrome associated with cystic renal disease. Martin SR, et al. **Arch Dis Child** 1996 Mar;74(3):232–5 (14 ref.)

Cystic degeneration and carcinogenesis of the kidney. Ogawa Y. **Int J Urol** 1996 Jan;3(1):1–17 (204 ref.)

Renal cortical neoplasm in a child with dialysis–acquired cystic kidney disease. Gentle DL, et al. **Urology** 1996 Feb; 47(2):254–5 (5 ref.)

DIAGNOSIS

Multilocular renal cyst. Report of two cases and review of the literature. Ala–Opas MY, et al. **Ann Chir Gynaecol** 1995; 84(3):318–22 (9 ref.)

[Diagnosis and treatment of renal cell carcinoma accompanying the cystic lesion] Terachi T. **Hinyokika Kiyo** 1995 Sep;41(9):697–701 (12 ref.) (Eng. Abstr.) **(Jpn)**

[Cystic disease of the kidney] Tanabe N, et al. **Nippon Rinsho** 1995 Aug;53(8):2013–8 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Juvenile nephronophthisis with tapetoretinal degeneration, skeletal changes and special phenotypic traits] Castro–Gago M, et al. **An Esp Pediatr** 1996 Jul;45(1):90–2 (16 ref.) **(Spa)**

GENETICS

Toward the identification of a gene for familial juvenile nephronophthisis (autosomal recessive medullary cystic kidney disease). Antignac C, et al.

Adv Nephrol Necker Hosp 1995;24:379–93 (68 ref.)
Genetics and molecular pathology of cystic renal disease. Sandford R, et al. **Exp Nephrol** 1996 Mar–Apr;4(2):127–34 (36 ref.)
Cystic maldevelopment of the kidney. Orellana SA, et al. **Semin Nephrol** 1995 Jul;15(4):341–52 (104 ref.)

PATHOLOGY

The Ivemark syndrome: prenatal diagnosis of an uncommon cystic renal lesion with heterogeneous associations. Larson RS, et al. **Pediatr Nephrol** 1995 Oct;9(5):594–8 (16 ref.)

SURGERY

Surgical management of complex renal cysts: a series of 32 cases. Cloix P, et al. **J Urol** 1996 Jul;156(1):28–30 (8 ref.)
[Current status of laparoscopic surgery in pediatric urology] Fuchs GJ, et al. **Urologe A** 1996 May;35(3):175–84 (62 ref.) (Eng. Abstr.) **(Ger)**

KIDNEY DISEASES

Renal amyloidosis in childhood. An overview of the topic with 25 years experience. Tinaztepe K. **Turk J Pediatr** 1995 Oct–Dec;37(4):357–73 (18 ref.)
Nephrobronchocutaneous fistula. Aly SA, et al. **Ulster Med J** 1994 Apr;63(1):116–8 (5 ref.)
[Multiple bilateral renal hydatidosis. A case report] Bennani S, et al. **Ann Urol (Paris)** 1995;29(3):150–3 (31 ref.) (Eng. Abstr.) **(Fre)**
[Wünderlich syndrome. Review of its diagnosis and therapy. Report of 7 cases] López Cubillana P, et al. **Actas Urol Esp** 1995 Nov–Dec;19(10):772–6 (19 ref.) (Eng. Abstr.) **(Spa)**

BLOOD

Diagnosis and classification of dyslipidemia in renal disease. Attman PO, et al. **Blood Purif** 1996;14(1):49–57 (60 ref.)
Lipoprotein(a) in chronic renal disease. Stenvinkel P, et al. **Miner Electrolyte Metab** 1996;22(1–3):16–21 (67 ref.)
Balance between pro-inflammatory cytokines and their specific inhibitors in patients on dialysis. Pereira BJ. **Nephrol Dial Transplant** 1995;10 Suppl 7:27–32 (55 ref.)

CHEMICALLY INDUCED

Renal and electrolyte complications associated with antibiotic therapy. Kasama R, et al. **Am Fam Physician** 1996 Jan; 53(1):227–32 (23 ref.)
Combination analgesic-induced kidney disease: the Australian experience. Duggin GG. **Am J Kidney Dis** 1996 Jul;28(1 Suppl 1):S39–47 (41 ref.)
Combination analgesic involvement in the pathogenesis of analgesic nephropathy: the European perspective. Elseviers MM, et al. **Am J Kidney Dis** 1996 Jul;28(1 Suppl 1):S48–55 (20 ref.)
Morphologic features of cyclosporin nephrotoxicity. D'Agati VD. **Contrib Nephrol** 1995;114:84–110 (93 ref.)
Drugs of abuse and renal disease. Bakir AA, et al. **Curr Opin Nephrol Hypertens** 1996 Mar;5(2):122–6 (46 ref.)
Occupational renal diseases. de Broe ME, et al. **Curr Opin Nephrol Hypertens** 1996 Mar;5(2):114–21 (68 ref.)
Contrast media-associated nephrotoxicity. Rudnick MR, et al. **Curr Opin Nephrol Hypertens** 1996 Mar;5(2):127–33 (83 ref.)
Renal toxicity of albumin and other lipoproteins. Schreiner GF. **Curr Opin Nephrol Hypertens** 1995 Jul;4(4):369–73 (33 ref.)
Amphotericin B nephrotoxicity: the adverse consequences of altered membrane properties [editorial] Sawaya BP, et al. **J Am Soc Nephrol** 1995 Aug;6(2):154–64 (133 ref.)
Renal complications associated with use of nonsteroidal anti-inflammatory agents. Palmer BF. **J Investig Med** 1995 Dec;43(6):516–33 (174 ref.)
Cyclosporine-induced renal dysfunction in experimental animals and humans. Remuzzi G, et al. **Kidney Int Suppl** 1995 Dec;52:S70–4 (49 ref.)
Ifosfamide nephrotoxicity in children: histopathological features in two cases. Morland BJ, et al. **Med Pediatr Oncol** 1996 Jul;27(1):57–61 (17 ref.)
Sulfadiazine-associated nephrotoxicity in patients with the acquired immunodeficiency syndrome. Becker K, et al. **Medicine (Baltimore)** 1996 Jul;75(4):185–94 (56 ref.)
Renal disease--another effect of silica exposure? [editorial; comment] Kallenberg CG. **Nephrol Dial Transplant** 1995; 10(7):1117–9 (25 ref.) Comment on: Nephrol Dial Transplant 1995;10(7):1162–5.
Cadmium-associated renal disease. Savolainen H. **Ren Fail** 1995 Sep;17(5):483–7 (30 ref.)
[Early manifestation of harmful effects of methylmercury on organism] Lin X, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1995 Jul;29(4):240–1 (7 ref.) **(Chi)**
[Nephropathies caused by interferon alpha: apropos of 2 cases] Cardineau E, et al. **Rev Med Interne** 1995;16(9):691–5 (38 ref.) (Eng. Abstr.) **(Fre)**
[Drug-induced kidney damage] Schwarz A. **Z Arztl Fortbild (Jena)** 1996 May;90(3):205–12 (23 ref.) (Eng. Abstr.) **(Ger)**
[Drug-induced nephrotoxicity] Takeda M, et al. **Nippon Yakurigaku Zasshi** 1996 Jan;107(1):1–8 (50 ref.) (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

Mechanisms of cardiovascular injury in renal disease. Rabelink TJ, et al. **Blood Purif** 1996;14(1):67–74 (64 ref.)
Hyperlipidemia and its management in renal disease. Massy ZA, et al. **Curr Opin Nephrol Hypertens** 1996 Mar; 5(2):141–6 (63 ref.)
When does amyloidosis complicate systemic lupus erythematosus? Orellana C, et al. **Lupus** 1995 Oct; 4(5):415–7 (26 ref.)
Lipoprotein(a) in chronic renal disease. Stenvinkel P, et al. **Miner Electrolyte Metab** 1996;22(1–3):16–21 (67 ref.)
Hemostatic complications in renal disorders of the young. Andrew M, et al. **Pediatr Nephrol** 1996 Feb;10(1):88–99 (135 ref.)
Dyslipidemia in renal disease. Mittman N, et al. **Semin Nephrol** 1996 May;16(3):202–13 (144 ref.)
[Acute kidney failure in a recurrence of sarcoidosis at the height of summer] Wiemeyer A, et al. **Dtsch Med Wochenschr** 1996 Feb 9;121(6):165–8 (15 ref.) (Eng. Abstr.) **(Ger)**
[A case of mitochondrial encephalomyopathy (MELAS)] Suzuki T, et al. **Nippon Jinzo Gakkai Shi** 1996 Feb; 38(2):109–14 (25 ref.) (Eng. Abstr.) **(Jpn)**
[Hyperlipidemia and nephropathy: cause or consequence? (editorial)] Guijarro C, et al. **Med Clin (Barc)** 1995 Oct 21;105(13):496–7 (25 ref.) **(Spa)**

CONGENITAL

Congenital nephropathies and uropathies. Becker N, et al. **Pediatr Clin North Am** 1995 Dec;42(6):1319–41 (45 ref.)

DIAGNOSIS

Malacoplakia. Two case reports and a comparison of treatment modalities based on a literature review. van der Voort HJ, et al. **Arch Intern Med** 1996 Mar 11; 156(5):577–83 (118 ref.)
Renal masses in the neonate. Pinto E, et al. **Biol Neonate** 1995;68(3):175–84 (43 ref.)
Diagnosis and management of renal infections. Meyrier A. **Curr Opin Nephrol Hypertens** 1996 Mar;5(2):151–7 (57 ref.)
Urinary N-acetyl-beta-D-glucosaminidase determination in newborns and children: methods and diagnostic applications. Csáthy L, et al. **Eur J Clin Chem Clin Biochem** 1995 Sep;33(9):575–87 (188 ref.)
Diagnostic significance of dopamine estimation using plasma and urine in patients with adrenal and renal insufficiency, renal transplantation and hypertension. Yoshimura M, et al. **Hypertens Res** 1995 Jun;18 Suppl 1:S87–92 (31 ref.)
Contrast-enhanced MR imaging of the kidneys and adrenal glands. Huch Böni RA, et al. **Magn Reson Imaging Clin N Am** 1996 Feb;4(1):101–31 (61 ref.)
Clinical features, predictors of disease progression and results of renal transplantation in fibrillary/immunotactoid glomerulopathy. Pronovost PH, et al. **Nephrol Dial Transplant** 1996 May;11(5):837–42 (39 ref.)
Renal calcification in the first year of life. Karlowicz MG, et al. **Pediatr Clin North Am** 1995 Dec;42(6):1397–413 (87 ref.)
The current approach to the assessment of fetal renal function: fact or fiction? Spitzer A. **Pediatr Nephrol** 1996 Apr;10(2):230–5 (27 ref.)
[The image diagnoses on renal diseases; techniques of CT, MRI and ultrasound] Higashi TS. **Nippon Rinsho** 1995 Aug; 53(8):1939–43 (6 ref.) (Eng. Abstr.) **(Jpn)**
[Diagnosis of kidney diseases in children] Ringerts G. **Vestn Rentgenol Radiol** 1995 Jul–Aug;(4):32–5 (6 ref.) **(Rus)**
[Renal cystic mass: the diagnostic dilemma] Albisu Tristán A, et al. **Arch Esp Urol** 1995 Oct;48(8):767–72 (13 ref.) (Eng. Abstr.) **(Spa)**

DIET THERAPY

Effect of low-protein diets on renal disease: are non-haemodynamic factors involved? [editorial] Heidland A, et al. **Nephrol Dial Transplant** 1995;10(9):1512–4 (27 ref.)
[Diet therapy in diffuse progressive nephropathies] Ratner MI. **Klin Med (Mosk)** 1996;74(1):7–8 (11 ref.) **(Rus)**

DRUG THERAPY

Therapeutic uses of aspirin in renal diseases. Winchester JF. **Am J Kidney Dis** 1996 Jul;28(1 Suppl 1):S20–3 (44 ref.)
Complications of cyclosporin therapy. Hoyer PF. **Contrib Nephrol** 1995;114:111–23 (61 ref.)
Glycosaminoglycans: a new paradigm in the prevention of proteinuria and progression of glomerular disease [editorial] Gambaro G, et al. **Nephrol Dial Transplant** 1996 May; 11(5):762–4 (17 ref.)
Poor response to erythropoietin: practical guidelines on investigation and management. Macdougall IC. **Nephrol Dial Transplant** 1995;10(5):607–14 (62 ref.)
[Treatment of hypertension in renal parenchymal diseases] Iversen BM, et al. **Tidsskr Nor Laegeforen** 1996 Jun 30; 116(17):2022–6 (28 ref.) (Eng. Abstr.) **(Nor)**

ENZYMOLOGY

Urinary N-acetyl-beta-D-glucosaminidase determination in newborns and children: methods and diagnostic applications. Csáthy L, et al. **Eur J Clin Chem Clin Biochem** 1995 Sep;33(9):575–87 (188 ref.)
Association studies, ACE polymorphisms and renal disease [editorial] Harden PN, et al. **Nephrol Dial Transplant** 1996 May;11(5):757–9 (31 ref.)

ETIOLOGY

Growth factors and the glomerulus: relationships between development and injury. Alpers CE, et al. **Adv Nephrol Necker Hosp** 1995;24:33–52 (85 ref.)
Renal involvement in type I glycogen storage disease. Chen YT, et al. **Adv Nephrol Necker Hosp** 1995;24:357–65 (52 ref.)
Lipoprotein(a) in renal disease. Kronenberg F, et al. **Am J Kidney Dis** 1996 Jan;27(1):1–25 (202 ref.)
Transgenic animal models of renal development and pathogenesis. Kopp JB, et al. **Am J Physiol** 1995 Nov;269(5 Pt 2):F601–20 (216 ref.)
Nephrobronchial fistula and lung abscess resulting from nephrolithiasis and pyelonephritis. O'Brien JD, et al. **Chest** 1995 Oct;108(4):1166–8 (6 ref.)
Glomerular hypertension and progressive renal disease: the interplay of mesangial cell stretch, cytokine formation and extracellular matrix synthesis. Cortes P, et al. **Contrib Nephrol** 1996;118:229–33 (14 ref.)
Proteins abnormally filtered throughout glomerular capillary have an intrinsic renal toxicity. Remuzzi G, et al. **Contrib Nephrol** 1996;118:164–72 (66 ref.)
Cryoglobulinemia: recent findings in cutaneous and extracutaneous manifestations. Davis MD, et al. **Int J Dermatol** 1996 Apr;35(4):240–8 (50 ref.)
The renal toxicity of sustained glomerular protein traffic. Benigni A, et al. **Lab Invest** 1995 Oct;73(4):461–8 (78 ref.)
Multiple roles for platelet-derived growth factor in renal disease. Floege J, et al. **Miner Electrolyte Metab** 1995; 21(4–5):271–82 (108 ref.)
Angiotensin II-mediated renal injury. Harris RC, et al. **Miner Electrolyte Metab** 1995;21(4–5):328–35 (83 ref.)
Renal involvement in essential hypertension and treatment effects. de Leeuw PW, et al. **Neth J Med** 1995 Oct; 47(4):199–204 (43 ref.)
Autoimmune disease of the kidney: an update. Biancone L, et al. **Proc Soc Exp Biol Med** 1996 Jul;212(3):225–38 (175 ref.)
Radiation nephropathy: a review. Robbins ME, et al. **Scanning Microsc** 1995 Jun;9(2):535–60 (210 ref.)
Essential hypertension: a renal perspective [editorial] Woo KT. **Singapore Med J** 1995 Jun;36(3):252–4 (14 ref.)
Traumatic pyeloduodenal fistula: a case report and review of the literature. Ginsberg DA, et al. **Urology** 1996 Apr; 47(4):588–91 (20 ref.)
[Renal involvement in monoclonal gammopathies] Spička I, et al. **Cas Lek Cesk** 1996 Jun 12;135(12):374–7 (29 ref.) (Eng. Abstr.) **(Cze)**
[Extrahepatic manifestations of hepatitis A virus infection] Maïga MY, et al. **Gastroenterol Clin Biol** 1996;20(4):346–52 (110 ref.) **(Fre)**
[Renal disorders in patients with immunoproliferative disorder] Horiuchi A, et al. **Nippon Naika Gakkai Zasshi** 1995 Jul 10;84(7):1081–5 (5 ref.) **(Jpn)**
[Renal disease and trace elements] Marumo F, et al. **Nippon Rinsho** 1996 Jan;54(1):93–8 (7 ref.) (Eng. Abstr.) **(Jpn)**
[Obstructive and reflux nephropathy] Orikasa S, et al. **Nippon Rinsho** 1995 Aug;53(8):2019–26 (18 ref.) (Eng. Abstr.) **(Jpn)**
[Renal diseases in disturbance of urate metabolism] Tofuku Y. **Nippon Rinsho** 1995 Aug;53(8):1988–94 (22 ref.) (Eng. Abstr.) **(Jpn)**
[Cystometry in neurogenic bladder disorders. Methodologic problems and assessment of risk of renal complications] Thyberg M, et al. **Tidsskr Nor Laegeforen** 1995 Sep 30; 115(23):2904–8 (23 ref.) (Eng. Abstr.) **(Nor)**
[Kidney involvement in multiple myeloma] Gordovskaia NB. **Klin Med (Mosk)** 1995;73(3):71–7 (78 ref.) **(Rus)**
[Hyperlipidemia and nephropathy: cause or consequence? (editorial)] Guijarro C, et al. **Med Clin (Barc)** 1995 Oct 21;105(13):496–7 (25 ref.) **(Spa)**

GENETICS

Mitochondrial genome mutations and kidney disease. Singh PJ, et al. **Am J Kidney Dis** 1996 Jul;28(1):140–6 (47 ref.)
A family with two sisters with collagenofibrotic glomerulonephropathy. Tamura H, et al. **Am J Kidney Dis** 1996 Apr;27(4):588–95 (23 ref.)
Renal involvement in mitochondrial cytopathies [editorial] Grünfeld JP, et al. **Nephrol Dial Transplant** 1996 May; 11(5):760–1 (16 ref.)
Association studies, ACE polymorphisms and renal disease [editorial] Harden PN, et al. **Nephrol Dial Transplant** 1996 May;11(5):757–9 (31 ref.)
von Hippel-Lindau syndrome: a rare syndrome as the clue for the molecular basis of common renal disorders [editorial] Neumann HP. **Nephrol Dial Transplant** 1995; 10(9):1498–9 (10 ref.)

IMMUNOLOGY

VLA-4 and its ligands: relevance to kidney diseases. Rabb H, et al. **Springer Semin Immunopathol** 1995;16(4):417-25 (48 ref.)

[Lymphocytes and renal damage] Amoroso A, et al. **Minerva Urol Nefrol** 1996 Jun;48(2):109-15 (36 ref.) **(Ita)**

[Immune disorders in patients with nutrition disorders and renal insufficiency] Gajdosz R, et al. **Folia Med Cracov** 1994;35(1-4):87-90 (15 ref.) **(Pol)**

METABOLISM

Endothelin receptors in normal and diseased kidneys. Nambi P. **Clin Exp Pharmacol Physiol** 1996 Apr;23(4):326-30 (86 ref.)

Abnormal protein traffic through the glomerular barrier induces proximal tubular cell dysfunction and causes renal injury [editorial] Remuzzi G. **Curr Opin Nephrol Hypertens** 1995 Jul;4(4):339-42 (20 ref.)

Perspectives in endothelin research: tubulointerstitial actions of endothelins in the kidney: roles in health and disease. Ong AC. **Nephrol Dial Transplant** 1996 Feb;11(2):251-7 (86 ref.)

Tenascin expression in nephrogenesis and in normal or pathologic glomerulus morphologic features and functional implications [editorial] Truong LD, et al. **Nephron** 1996; 72(4):499-506 (43 ref.)

PATHOLOGY

Extracellular matrix and the kidney. Furness PN. **J Clin Pathol** 1996 May;49(5):355-9 (70 ref.)

Ifosfamide nephrotoxicity in children: histopathological features in two cases. Morland BJ, et al. **Med Pediatr Oncol** 1996 Jul;27(1):57-51 (17 ref.)

Renal biopsy: why and when. Reisman L, et al. **Mt Sinai J Med** 1996 May-Sep;63(3-4):178-90 (17 ref.)

[Morphology of basement membrane and associated matrix proteins in normal and pathological tissues] Nerlich A. **Veroff Pathol** 1995;145:1-139 (336 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Chemokines and renal disease. Wenzel UO, et al. **Am J Kidney Dis** 1995 Dec;26(6):982-94 (111 ref.)

Nitric oxide in hypertension and renal diseases. Tikkanen I, et al. **Ann Med** 1995 Jun;27(3):353-7 (48 ref.)

Role of angiotensin-converting enzyme gene polymorphism in progressive loss of renal function in chronic renal diseases. Yoshida H, et al. **Contrib Nephrol** 1996;118:249-53 (21 ref.)

Defining the role of endothelins in renal pathophysiology on the basis of selective and unselective endothelin receptor antagonist studies. Benigni A. **Curr Opin Nephrol Hypertens** 1995 Jul;4(4):349-53 (51 ref.)

Iothalamate clearance and its use in large-scale clinical trials. Hall PM, et al. **Curr Opin Nephrol Hypertens** 1995 Nov; 4(6):510-3 (22 ref.)

Sphingolipids: their role in intracellular signaling and renal growth [editorial] Shayman JA. **J Am Soc Nephrol** 1996 Feb;7(2):171-82 (106 ref.)

Adhesion molecules in renal disease. Dal Canton A. **Kidney Int** 1995 Dec;48(6):1687-96 (100 ref.)

The renal toxicity of sustained glomerular protein traffic. Benigni A, et al. **Lab Invest** 1995 Oct;73(4):461-8 (78 ref.)

Impaired proteolytic activity as a potential cause of progressive renal disease. Heidland A, et al. **Miner Electrolyte Metab** 1996;22(1-3):157-61 (52 ref.)

Insulin-like growth factor I in the kidney. Hirschberg R. **Miner Electrolyte Metab** 1996;22(1-3):128-32 (23 ref.)

Role of atherogenic lipoproteins in cytokine-mediated renovascular injury. Kirschenbaum MA, et al. **Miner Electrolyte Metab** 1996;22(1-3):47-50 (20 ref.)

Endothelin and endothelin antagonists: potential role in cardiovascular and renal disease. Noll G, et al. **Mol Cell Biochem** 1996 Apr 12-26;157(1-2):259-67 (105 ref.)

Cytokines and growth factors in renal disease. Noronha IL, et al. **Nephrol Dial Transplant** 1995;10(6):775-86 (156 ref.)

Transmembrane signaling in kidney health and disease. Hack N, et al. **Pediatr Nephrol** 1995 Aug;9(4):514-25 (126 ref.)

Possible mediators in hypertension: renal factors. Bergman SM, et al. **Semin Nephrol** 1996 Mar;16(2):134-9 (36 ref.)

Renal response to an acute oral protein load in healthy humans and in patients with renal disease or liver cirrhosis. De Santo NG, et al. **Semin Nephrol** 1995 Sep;15(5):433-48 (127 ref.)

Renal reserve in the elderly. Fliser D, et al. **Semin Nephrol** 1995 Sep;15(5):463-7 (47 ref.)

Renal reserve in patients with solitary kidneys. Rugiu C, et al. **Semin Nephrol** 1995 Sep;15(5):468-74 (52 ref.)

Renal effects of intravenous amino acid administration in humans with and without renal disease: hormonal correlates. ter Wee PM. **Semin Nephrol** 1995 Sep; 15(5):426-32 (76 ref.)

[The immature kidney] Guignard JP, et al. **Rev Med Suisse Romande** 1995 Aug;115(8):565-74 (42 ref.) (Eng. Abstr.) **(Fre)**

[Dopamine and the kidney--renal sparing effect: fact or fiction?] Yussim E, et al. **Harefuah** 1996 Apr 1;130(7):480-3 (26 ref.) **(Heb)**

PREVENTION & CONTROL

Are antihypertensive drugs similar in protecting the kidney? Ritz E. **Am J Hypertens** 1995 Oct;8(10 Pt 2):53S-58S (45 ref.)

Strategies to prevent nephrotoxicity of anticancer drugs. Skinner R. **Curr Opin Oncol** 1995 Jul;7(4):310-5 (38 ref.)

SURGERY

[Lipoprotein glomerulopathy: a new French case with recurrence on the transplant] Djamali A, et al. **Presse Med** 1996 May 18;25(17):798-802 (23 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

ABC of Urology. Urological emergencies in general practice [see comments] Dawson C, et al. **BMJ** 1996 Mar 30; 312(7034):838-40 (0 ref.) Comment in: BMJ 1996 Jul 13;313(7049):112; discussion 112-3.

Diagnosis and management of renal infections. Meyrier A. **Curr Opin Nephrol Hypertens** 1996 Mar;5(2):151-7 (57 ref.)

Therapeutic plasma exchange in renal diseases [editorial] Madore F, et al. **J Am Soc Nephrol** 1996 Mar;7(3):367-86 (133 ref.)

Gene transfer into the kidney: promise for unravelling disease mechanisms, limitations for human gene therapy [editorial] Fine LG. **Kidney Int** 1996 Mar;49(3):612-9 (61 ref.)

On-line monitoring. Santoro A. **Nephrol Dial Transplant** 1995;10(5):615-8 (17 ref.)

[Basic principles of current trends in the management of hypertension and kidney disease in pregnancy] Vajó Z, et al. **Orv Hetil** 1995 Nov 19;136(47):2561-6 (45 ref.) (Eng. Abstr.) **(Hun)**

[Strategy changes in the treatment of ureteral lithiasis and nephritic colic] González Enguita C, et al. **Actas Urol Esp** 1996 Apr;20(4):351-60 (35 ref.) (Eng. Abstr.) **(Spa)**

VETERINARY

[Diagnostic and pathophysiological aspects of the determination of kidney function in animals (corrected and republished with original paging, article originally printed in Zentralbl Veterinarmed A 1994 May;41(4):253-67)] Reder S, et al. **Zentralbl Veterinarmed A** 1995 May; 42(3):253-67 (56 ref.) (Eng. Abstr.) **(Ger)**

KIDNEY FAILURE

BLOOD

Hemodialysis vascular access: effect on urea kinetics and the dialysis prescription. Butterly DW, et al. **Am J Nephrol** 1996;16(1):45-51 (32 ref.)

Treatment of hyperparathyroidism--why is it crucial to control serum phosphate? [editorial] Brancaccio D, et al. **Nephrol Dial Transplant** 1996 Mar;11(3):420-3 (23 ref.)

[Clinical pharmacokinetics of azithromycin] Singlas E. **Pathol Biol (Paris)** 1995 Jun;43(6):505-11 (16 ref.) (Eng. Abstr.) **(Fre)**

CHEMICALLY INDUCED

Delayed renal revascularisation after enalapril induced renal failure in renal artery stenosis. Khaira HS, et al. **Eur J Vasc Endovasc Surg** 1996 Apr;11(3):375-7 (17 ref.)

COMPLICATIONS

Renal bone disease--an ongoing challenge to the nephrologist. Malluche HH. **Clin Nephrol** 1995 Nov;44 Suppl 1:S38-41 (17 ref.)

The need to treat predialysis patients. Hamdy NA. **Nephrol Dial Transplant** 1995;10 Suppl 4:19-22; discussion 37-43 (25 ref.)

The use of alfacalcidol in the prevention of bone disease in early renal failure. Kanis JA. **Nephrol Dial Transplant** 1995; 10 Suppl 4:23-8; discussion 37-43 (42 ref.)

1-alpha-Hydroxyvitamin D3 derivatives in the treatment of renal bone diseases: justification and optimal modalities of administration. Fournier A, et al. **Nephron** 1995; 71(3):254-83 (194 ref.)

The management of renal failure in patients at risk of cerebral edema/hypoxia. Davenport A. **New Horiz** 1995 Nov; 3(4):717-24 (54 ref.)

DIAGNOSIS

[Hemolytic anemia and kidney failure in a female splenectomy patient] Vargas Pabón M, et al. **Rev Clin Esp** 1996 May;196(5):335-6, 339 (10 ref.) **(Spa)**

DRUG THERAPY

Calcium antagonists and the kidney. Pearce CJ, et al. **New Horiz** 1996 Feb;4(1):123-8 (47 ref.)

ETIOLOGY

The rate of progression of renal failure in ADPKD. Choukroun G, et al. **Contrib Nephrol** 1995;115:28-32 (12 ref.)

Progression of renal failure: what is the role of cytokines? Floege J, et al. **Nephrol Dial Transplant** 1995;10(9):1575-86 (161 ref.)

Renal dysfunction associated with liver transplantation. Jindal RM, et al. **Postgrad Med J** 1995 Sep;71(839):513-24 (130 ref.)

[Progression of renal insufficiency and platelet activating factor (PAF)] Camici M. **Minerva Med** 1996 Jun; 87(6):289-98 (100 ref.) (Eng. Abstr.) **(Ita)**

[Giant schwannoma in the pelvic cavity presenting as renal failure: a case report] Gotoh T, et al. **Hinyokika Kiyo** 1995 Aug;41(8):621-4 (10 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Quantifying hemodialysis. Depner TA. **Am J Nephrol** 1996; 16(1):17-28 (78 ref.)

Lipids and progressive renal failure. Keane WF, et al. **Contrib Nephrol** 1996;118:17-23 (22 ref.)

Altered vitamin D metabolism and receptor interaction with the target genes in renal failure: calcitriol receptor interaction with its target gene in renal failure. Hsu CH, et al. **Curr Opin Nephrol Hypertens** 1995 Jul;4(4):302-6 (36 ref.)

Antibacterial agents in renal failure. Livornese LL Jr, et al. **Infect Dis Clin North Am** 1995 Sep;9(3):591-614 (41 ref.)

Pharmacokinetics during continuous renal replacement therapy. Keller E. **Int J Artif Organs** 1996 Feb;19(2):113-7 (8 ref.)

Pharmacokinetics of sparfloxacin in healthy volunteers and patients: a review. Montay G. **J Antimicrob Chemother** 1996 May;37 Suppl A:27-39 (20 ref.)

Genesis of disturbed vitamin D metabolism in renal failure. Ritz E, et al. **Nephrol Dial Transplant** 1995;10 Suppl 4:3-10; discussion 37-43 (53 ref.)

[Pharmacokinetics of fluoroquinolones in patients with renal insufficiency] Iakovlev SV, et al. **Antibiot Khimioter** 1995 Oct;40(10):39-47 (57 ref.) **(Rus)**

PHYSIOPATHOLOGY

Volaemia and blood pressure in renal failure: have old truths been forgotten? Mees EJ. **Nephrol Dial Transplant** 1995; 10(8):1297-8 (8 ref.)

THERAPY

What do we learn from the European Registry: what will be the underlying problems in the year 2000? Mallick NP. **Nephrol Dial Transplant** 1995;10 Suppl 7:2-6 (0 ref.)

Report on management of renal failure in Europe, XXV, 1994. The child-adult interface. The EDTA-ERA Registry. European Dialysis and Transplant Association-European Renal Association. Mehls O, et al. **Nephrol Dial Transplant** 1996;11 Suppl 1:22-36 (13 ref.)

Simplified approaches to calculate Kt/V. It's time for agreement. Movilli E. **Nephrol Dial Transplant** 1996 Jan; 11(1):24-7 (31 ref.)

The management of renal failure in patients at risk of cerebral edema/hypoxia. Davenport A. **New Horiz** 1995 Nov; 3(4):717-24 (54 ref.)

Peritoneal dialysis prescription for neonates. Fischbach M. **Perit Dial Int** 1996;16 Suppl 1:S512-4 (23 ref.)

KIDNEY FAILURE, ACUTE

see related

HEMODIALYSIS

Review: new aspects of acute renal failure. Simon EE. **Am J Med Sci** 1995 Nov;310(5):217-21 (48 ref.)

Acute renal failure in infants and children. Ehrich JH. **Int J Artif Organs** 1996 Feb;19(2):121-3 (9 ref.)

Acute renal failure. Thadhani R, et al. **N Engl J Med** 1996 May 30;334(22):1448-60 (153 ref.)

The immune system in uremia and during its treatment. Haag-Weber M, et al. **New Horiz** 1995 Nov;3(4):669-79 (172 ref.)

BLOOD

Acute renal failure with hyperuricemia as initial presentation of leukemia in children. Larsen G, et al. **J Pediatr Hematol Oncol** 1996 May;18(2):191-4 (16 ref.)

CHEMICALLY INDUCED

Oral sodium phosphate catharsis and acute renal failure. Ahmed M, et al. **Am J Gastroenterol** 1996 Jun;91(6):1261-2 (9 ref.)

Does aspirin cause acute or chronic renal failure in experimental animals and in humans? D'Agati V. **Am J Kidney Dis** 1996 Jul;28(1 Suppl 1):S24-9 (34 ref.)

Reliability of experimental models of iodinated contrast media-induced acute renal failure. From methodological considerations to pathophysiology. Idée JM, et al. **Invest Radiol** 1996 Apr;31(4):230-41 (96 ref.)

Acute renal failure due to acetaminophen ingestion: a case report and review of the literature. Blakely P, et al. **J Am Soc Nephrol** 1995 Jul;6(1):48-53 (21 ref.)

Contrast media nephropathy. Mallat SG. **J Med Liban** 1995; 43(1):26-9 (44 ref.)

Acute renal failure after administration of intravenous immunoglobulin: review of the literature and case report. Winward DB, et al. **Pharmacotherapy** 1995 Nov-Dec; 15(6):765-72 (33 ref.)

Acute renal failure induced by angiotensin converting enzyme inhibitor in a patient with polyarteritis nodosa. Wang AY, et al. **Ren Fail** 1996 Mar;18(2):293-8 (17 ref.)

KIDNEY FAILURE, ACUTE

[Kidney insufficiency: toxicity factor of methyl-bromo-hydroxyquinoline (ietter)] Zeraidi N, et al. **Ann Med Interne (Paris)** 1995;146(8):593–5 (16 ref.) **(Fre)**

COMPLICATIONS

Renal disease in pregnancy. Marwah D, et al. **Curr Opin Nephrol Hypertens** 1996 Mar;5(2):147–50 (18 ref.)

Carnitine palmitoyltransferase deficiency in a college athlete: a case report and literature review. Faigel HC. **J Am Coll Health** 1995 Sep;44(2):51–4 (40 ref.)

Acute renal failure with hyperuricemia as initial presentation of leukemia in children. Larsen G, et al. **J Pediatr Hematol Oncol** 1996 May;18(2):191–4 (16 ref.)

Acute myeloma kidney. Winearls CG. **Kidney Int** 1995 Oct; 48(4):1347–61 (65 ref.)

Systemic mucormycosis complicating acute renal failure: case report and review of the literature. Melnick JZ, et al. **Ren Fail** 1995 Sep;17(5):619–27 (31 ref.)

DIAGNOSIS

Practical guide to diagnosis and differential diagnosis of ARF in the ICU. Druml W, et al. **Int J Artif Organs** 1996 Feb; 19(2):87–9 (3 ref.)

[Acute renal failure—differential diagnosis and therapeutic procedure] Neumann F. **Z Arztl Fortbild (Jena)** 1996 May; 90(3):191–8 (16 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Pathophysiology of renal tubular obstruction: therapeutic role of synthetic RGD peptides in acute renal failure. Noiri E, et al. **Kidney Int** 1995 Nov;48(5):1375–85 (91 ref.)

Vasoactive drugs and the importance of renal perfusion pressure. Bersten AD, et al. **New Horiz** 1995 Nov; 3(4):650–61 (94 ref.)

Nitric oxide in the regulation of renal blood flow. Ito S, et al. **New Horiz** 1995 Nov;3(4):615–23 (68 ref.)

Drug administration in critically ill patients with acute renal failure. Kroh UF. **New Horiz** 1995 Nov;3(4):748–59 (42 ref.)

Natriuretic peptides and acute renal failure. Weinmann M. **New Horiz** 1995 Nov;3(4):624–33 (110 ref.)

[The therapeutic effect of dopamine in acute kidney failure] Mühlbauer B. **Anaesthesist** 1996 Jul;45(7):657–69 (50 ref.) **(Ger)**

ETIOLOGY

Acute renal failure associated with nonfulminant hepatitis A viral infection. Faust RL, et al. **Am J Gastroenterol** 1996 Feb;91(2):369–72 (24 ref.)

Rapidly reversible acute renal failure from ureteral obstruction in pregnancy. Jena M, et al. **Am J Kidney Dis** 1996 Sep;28(3):457–60 (22 ref.)

Acute renal failure secondary to solid tumor renal metastases: case report and review of the literature. Manning EC, et al. **Am J Kidney Dis** 1996 Feb;27(2):284–91 (30 ref.)

Case report: polymyositis-induced myoglobinuric acute renal failure. Thakur V, et al. **Am J Med Sci** 1996 Aug; 312(2):85–7 (11 ref.)

Acute renal failure [see comments] Brady HR, et al. **Lancet** 1995 Dec 9;346(8989):1533–40 (50 ref.) Comment in: Lancet 1996 Feb 17;347(8999):478; discussion 479. Comment in: Lancet 1996 Feb 17;347(8999):478–9; discussion 479. Comment in: Lancet 1996 Feb 17;347(8999):479; discussion 479.

Interferon-induced acute renal failure: a case report and literature review. Horowitz R, et al. **Med Oncol** 1995 Mar; 12(1):55–7 (10 ref.)

The role of medullary ischemia in acute renal failure. Heyman SN, et al. **New Horiz** 1995 Nov;3(4):597–607 (106 ref.)

Sepsis or ischemia in experimental acute renal failure: what have we learned? Johnson JP, et al. **New Horiz** 1995 Nov; 3(4):608–14 (79 ref.)

Rhabdomyolysis and acute renal failure following radical perineal prostatectomy. Bruce RG, et al. **Urology** 1996 Mar; 47(3):427–30 (14 ref.)

[Acute kidney failure in a recurrence of sarcoidosis at the height of summer] Wiemeyer A, et al. **Dtsch Med Wochenschr** 1996 Feb 9;121(6):165–8 (15 ref.) (Eng. Abstr.) **(Ger)**

[The significance of acute renal failure in fulminant hepatitis—a comparison between type B and non B hepatitis] Nakano A, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:535–9 (21 ref.) **(Jpn)**

[Tubulointerstitial damage attributable to acute circulatory failure: postischemic acute renal failure] Yamamoto T, et al. **Nippon Rinsho** 1995 Aug;53(8):2027–33 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Rhabdomyolysis and acute kidney failure after an orthopedic intervention] Méndez Bustelo MJ, et al. **An Esp Pediatr** 1996 Apr;44(4):385–6 (20 ref.) **(Spa)**

[Acute kidney failure due to Corinarius orellanus (letter)] Romanillos T, et al. **Med Clin (Barc)** 1995 Oct 7;105(11):437 (10 ref.) **(Spa)**

IMMUNOLOGY

Sepsis or ischemia in experimental acute renal failure: what have we learned? Johnson JP, et al. **New Horiz** 1995 Nov; 3(4):608–14 (79 ref.)

Biocompatible intermittent hemodialysis. Lang S, et al. **New Horiz** 1995 Nov;3(4):680–7 (56 ref.)

METABOLISM

Expression of apoptosis-related molecules in acute renal injury. Yoshimura A, et al. **Exp Nephrol** 1996 Jan–Feb; 4(1):15–8 (18 ref.)

Heat-shock proteins in animal models for acute renal failure. Wakui H, et al. **Ren Fail** 1995 Nov;17(6):641–9 (26 ref.)

PATHOLOGY

Renal tubule cell repair following acute renal injury. Humes HD, et al. **Miner Electrolyte Metab** 1995;21(4–5):353–65 (157 ref.)

The histopathology of acute renal failure. Racusen LC. **New Horiz** 1995 Nov;3(4):662–8 (69 ref.)

[Interstitial nephritis with acute renal failure in Ascaris lumbricoides infection] Meister P, et al. **Pathologe** 1995 Nov;16(6):434–8 (16 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Mechanisms of acute renal failure. Lote CJ, et al. **Br J Anaesth** 1996 Jul;77(1):82–9 (36 ref.)

Pathophysiology of ARF in the ICU. Hörl WH, et al. **Int J Artif Organs** 1996 Feb;19(2):84–6 (7 ref.)

Reliability of experimental models of iodinated contrast media-induced acute renal failure. From methodological considerations to pathophysiology. Idée JM, et al. **Invest Radiol** 1996 Apr;31(4):230–41 (96 ref.)

Prognosis of acute renal failure 1975–1995 [editorial] Druml W. **Nephron** 1996;73(1):8–15 (51 ref.)

Vasoactive drugs and the importance of renal perfusion pressure. Bersten AD, et al. **New Horiz** 1995 Nov; 3(4):650–61 (94 ref.)

Nitric oxide in the regulation of renal blood flow. Ito S, et al. **New Horiz** 1995 Nov;3(4):615–23 (68 ref.)

Molecular and cell biology of acute renal failure: new therapeutic strategies. Wagener OE, et al. **New Horiz** 1995 Nov;3(4):634–49 (164 ref.)

Natriuretic peptides and acute renal failure. Weinmann M. **New Horiz** 1995 Nov;3(4):624–33 (110 ref.)

PREVENTION & CONTROL

Low-dose dopamine in surgical and intensive care unit patients. Bonde J, et al. **Acta Anaesthesiol Scand** 1996 Mar; 40(3):326–30 (34 ref.)

Prevention of acute renal failure. New DI, et al. **Br J Hosp Med** 1996 Feb 21–Mar 5;55(4):162–6 (19 ref.)

Prophylaxis and conservative management of acute renal failure in the ICU. Stevens PE, et al. **Int J Artif Organs** 1996 Feb;19(2):90–4 (20 ref.)

Communication breakdown: a preventable cause of acute renal failure in a newborn infant [see comments] Craig JC, et al. **Med J Aust** 1996 Jun 3;164(11):663–4 (8 ref.) Comment in: Med J Aust 1996 Jun 3;164(11):645–6.

SURGERY

Anaesthesia for patients with renal impairment. Cranshaw J, et al. **Br J Hosp Med** 1996 Feb 21–Mar 5;55(4):171–5 (23 ref.)

THERAPY

Extracorporeal treatment of acute renal failure: methods, indications, quantified and personalized therapeutic approach. Canaud B, et al. **Adv Nephrol Necker Hosp** 1995; 24:271–313 (109 ref.)

Management of acute renal failure: new perspectives. Alkhunaizi AM, et al. **Am J Kidney Dis** 1996 Sep; 28(3):315–28 (127 ref.)

Interventions in clinical acute renal failure: what are the data? Conger JD. **Am J Kidney Dis** 1995 Oct;26(4):565–76 (70 ref.)

Managing acute renal failure in very low birthweight infants. Coulthard MG, et al. **Arch Dis Child Fetal Neonatal Ed** 1995 Nov;73(3):F187–92 (53 ref.)

Nutritional aspects in patients with acute renal failure/multiorgan failure. Alvestrand A. **Blood Purif** 1996; 14(1):109–14 (31 ref.)

Extracorporeal blood purification in the treatment of acute renal failure with multiorgan involvement. Kaplan AA. **Blood Purif** 1996;14(1):86–93 (45 ref.)

The management of acute renal failure. Morgan AG. **Br J Hosp Med** 1996 Feb 21–Mar 5;55(4):167–70 (5 ref.)

Nutritional support in the patient with renal failure. Molina MF, et al. **Crit Care Clin** 1995 Jul;11(3):685–704 (83 ref.)

An update on peritoneal dialysis and hemodialysis in the pediatric population. Warady BA, et al. **Curr Opin Pediatr** 1996 Apr;8(2):135–40 (58 ref.)

Adequacy of dialysis in the acute renal failure of the critically ill: the case for continuous therapies. Bellomo R, et al. **Int J Artif Organs** 1996 Feb;19(2):129–42 (190 ref.)

Treatment of acute renal failure in intensive care patients. Böhler J. **Int J Artif Organs** 1996 Feb;19(2):108–10 (8 ref.)

Management of fluid imbalance. Eckart J, et al. **Int J Artif Organs** 1996 Feb;19(2):106–7 (16 ref.)

Practical aspects of renal replacement therapy. Kox WJ, et al. **Int J Artif Organs** 1996 Feb;19(2):100–5 (17 ref.)

Use of continuous renal replacement therapy for detoxification? Riegel W. **Int J Artif Organs** 1996 Feb; 19(2):111–2 (9 ref.)

Basic mechanisms and definitions for continuous renal replacement therapies. Ronco C, et al. **Int J Artif Organs** 1996 Feb;19(2):95–9 (21 ref.)

Acute renal failure and membranes. Some medical and ethical questions [editorial] Schaefer K, et al. **Int J Artif Organs** 1996 Mar;19(3):145–6 (4 ref.)

Acute renal failure in infancy: treatment by continuous renal replacement therapy. Ronco C, et al. **Intensive Care Med** 1995 Jun;21(6):490–9 (47 ref.)

The elderly patient with acute renal failure [editorial] Pascual J, et al. **J Am Soc Nephrol** 1995 Aug;6(2):144–53 (197 ref.)

The nutrition management of the patient with acute renal failure. Kopple JD. **JPEN J Parenter Enteral Nutr** 1996 Jan–Feb;20(1):3–12 (70 ref.)

Acute renal failure: prevailing challenges and prospects for the future. Humes HD. **Kidney Int Suppl** 1995 Aug; 50:S26–32 (71 ref.)

Insulin-like growth factor 1 resistance in chronic renal failure. Fouque D. **Miner Electrolyte Metab** 1996; 22(1–3):133–7 (55 ref.)

Acute renal failure in the intensive care unit: adequacy of dialysis and the case for continuous therapies. Bellomo R, et al. **Nephrol Dial Transplant** 1996 Mar;11(3):424–8 (69 ref.)

Does continuous renal replacement therapy favourably influence the outcome of the patients? Jakob SM, et al. **Nephrol Dial Transplant** 1996 Jul;11(7):1250–5 (71 ref.)

Continuous treatment modalities in acute renal failure. Kierdorf H, et al. **Nephrol Dial Transplant** 1995 Nov; 10(11):2001–8 (49 ref.)

Acute renal replacement in the intensive care unit: now and tomorrow. Bellomo R, et al. **New Horiz** 1995 Nov; 3(4):760–7 (39 ref.)

The nutritional management of acute renal failure in the intensive care unit. Kierdorf HP. **New Horiz** 1995 Nov; 3(4):699–707 (101 ref.)

Biocompatible intermittent hemodialysis. Lang S, et al. **New Horiz** 1995 Nov;3(4):680–7 (56 ref.)

Azotemia control by extracorporeal therapy in patients with acute renal failure. Macias WL, et al. **New Horiz** 1995 Nov; 3(4):688–98 (62 ref.)

Achievements and new directions in continuous renal replacement therapies. Ronco C, et al. **New Horiz** 1995 Nov;3(4):708–16 (35 ref.)

Molecular and cell biology of acute renal failure: new therapeutic strategies. Wagener OE, et al. **New Horiz** 1995 Nov;3(4):634–49 (164 ref.)

[What are the advances in the treatment of acute kidney failure? (editorial)] Brivet F, et al. **Presse Med** 1996 Feb 17;25(6):227–9 (13 ref.) (Eng. Abstr.) **(Fre)**

[Emergency therapy of acute kidney failure and water-electrolyte imbalance] Ando K, et al. **Nippon Naika Gakkai Zasshi** 1995 Nov 10;84(11):1852–7 (6 ref.) **(Jpn)**

[Renal replacement therapy of patients with acute renal failure] Kishimoto T. **Nippon Naika Gakkai Zasshi** 1995 Oct 10;84(10):1637–42 (16 ref.) **(Jpn)**

[A case of the successful treatment of true scleroderma kidney] Nikolaev AIu, et al. **Klin Med (Mosk)** 1995; 73(3):104–5 (6 ref.) **(Rus)**

[New prospects in the treatment of acute kidney failure] López Martínez J, et al. **Nutr Hosp** 1996 Mar–Apr; 11(2):82–93 (95 ref.) (Eng. Abstr.) **(Spa)**

KIDNEY FAILURE, CHRONIC

see related
HEMODIALYSIS
UREMIA

Diabetic nephropathy in type II diabetes. Ritz E, et al. **Am J Kidney Dis** 1996 Feb;27(2):167–94 (218 ref.)

End-stage renal disease and systemic lupus erythematosus. Mojcik CF, et al. **Am J Med** 1996 Jul;101(1):100–7 (59 ref.)

Renal failure in a living-related kidney donor: case report and review of the literature. Said R, et al. **Am J Nephrol** 1996;16(4):334–8 (30 ref.)

Etiology, pathophysiology, diagnosis, and management of chronic renal failure in children. Friedman AL. **Curr Opin Pediatr** 1996 Apr;8(2):148–51 (39 ref.)

Dental considerations for the patient with renal disease receiving hemodialysis. De Rossi SS, et al. **J Am Dent Assoc** 1996 Feb;127(2):211–9 (52 ref.)

[Chronic renal insufficiency 2000. Livre Blanc de la Néphrologie] **Nephrologie** 1996;17(1):1–103 (73 ref.) **(Fre)**

[Intraglomerular hypertension. Physiopathology and therapeutic implications] Mourad G. **Presse Med** 1996 Jun 1;25(19):900–6 (37 ref.) (Eng. Abstr.) **(Fre)**

[Pregnancy course in women with terminal kidney failure treated with hemodialysis] Gumprecht J, et al. **Ginekol Pol** 1995 Jul;66(7):425–9 (36 ref.) (Eng. Abstr.) **(Pol)**

[Chronic renal insufficiency. Present views on pathogenesis, clinical aspects and treatment] Kováč A, et al. **Vnitr Lek** 1996 Jan;42(1):49–53 (22 ref.) (Eng. Abstr.) **(Slo)**

BLOOD

Middle molecules: toxicity and removal by hemodialysis and related strategies. Vanholder R, et al. **Artif Organs** 1995 Nov;19(11):1120–5 (46 ref.)

Treatment of dyslipidemia in chronic renal failure. Toto RD. **Blood Purif** 1996;14(1):75–82 (48 ref.)
Hyperkalemia in end-stage renal disease: mechanisms and management [editorial] Allon M. **J Am Soc Nephrol** 1995 Oct;6(4):1134–42 (79 ref.)
Lipoprotein(a) in chronic renal disease. Stenvinkel P, et al. **Miner Electrolyte Metab** 1996;22(1–3):16–21 (67 ref.)
Hyperhomocysteinemia as a risk factor for cardiovascular disease in patients undergoing hemodialysis. Friedman JA, et al. **Nutr Rev** 1995 Jul;53(7):197–201 (17 ref.)

CHEMICALLY INDUCED

Acetaminophen and adverse chronic renal outcomes: an appraisal of the epidemiologic evidence. Barrett BJ. **Am J Kidney Dis** 1996 Jul;28(1 Suppl 1):S14–9 (15 ref.)
Habitual use of acetaminophen as a risk factor for chronic renal failure: a comparison with phenacetin. Buckalew VM Jr. **Am J Kidney Dis** 1996 Jul;28(1 Suppl 1):S7–13 (31 ref.)
Does aspirin cause acute or chronic renal failure in experimental animals and in humans? D'Agati V. **Am J Kidney Dis** 1996 Jul;28(1 Suppl 1):S24–9 (34 ref.)

COMPLICATIONS

Cytomegalovirus colitis mimicking colon carcinoma in an HIV-negative patient with chronic renal failure. Falagas ME, et al. **Am J Gastroenterol** 1996 Jan;91(1):168–9 (11 ref.)
Tuberculosis in patients with chronic renal failure in China. Zhang X. **Chin Med J (Engl)** 1996 Feb;109(2):115–7 (0 ref.)
Cutaneous gangrene due to hyperparathyroidism secondary to chronic renal failure (uraemic gangrene syndrome). Török L, et al. **Clin Exp Dermatol** 1996 Jan;21(1):75–7 (10 ref.)
Delirium associated with acyclovir treatment in a patient with renal failure. Revankar SG, et al. **Clin Infect Dis** 1995 Aug;21(2):435–6 (14 ref.)
Treatment of renal anemia by erythropoietin substitution. The effects on the cardiovascular system. Radermacher J, et al. **Clin Nephrol** 1995 Nov;44 Suppl 1:S56–60 (51 ref.)
Beta 2-microglobulin amyloidosis: why and how to look for it. Schaeffer J, et al. **Clin Nephrol** 1995 Nov;44 Suppl 1:S3–9 (93 ref.)
Renal disease in pregnancy. Marwah D, et al. **Curr Opin Nephrol Hypertens** 1996 Mar;5(2):147–50 (18 ref.)
Extensive necrotizing livedo reticularis in a patient with chronic renal failure, hyperparathyroidism and coagulation disorder: regression after subtotal parathyroidectomy. Dereure O, et al. **Dermatology** 1996;192(2):167–70 (33 ref.)
Epoetin beta. A review of its pharmacological properties and clinical use in the management of anaemia associated with chronic renal failure. Dunn CJ, et al. **Drugs** 1996 Feb; 51(2):299–318 (91 ref.)
Epoetin alfa. A review of its clinical efficacy in the management of anaemia associated with renal failure and chronic disease and its use in surgical patients. Dunn CJ, et al. **Drugs Aging** 1995 Aug;7(2):131–56 (186 ref.)
Hepatitis C virus infection in dialysis and clinical nephrology [editorial] Fabrizi F, et al. **Int J Artif Organs** 1995 May; 18(5):235–44 (138 ref.)
L-carnitine in dialysed patients: the choice of dosage regimen. Berard E, et al. **Int J Clin Pharmacol Res** 1995; 15(3):127–33 (43 ref.)
Uremic small-artery disease with medial calcification and intimal hyperplasia (so-called calciphylaxis): a complication of chronic renal failure and benefit from parathyroidectomy. Hafner J, et al. **J Am Acad Dermatol** 1995 Dec;33(6):954–62 (61 ref.)
Management of hypertension in the child with chronic renal disease. Feld LG, et al. **J Pediatr** 1996 Aug;129(2):s18–26 (31 ref.)
The pathogenesis of parathyroid gland hyperplasia in chronic renal failure. Drüeke TB. **Kidney Int** 1995 Jul;48(1):259–72 (119 ref.)
Pathogenesis and management of parathyroid hyperplasia in chronic renal failure: role of calcitriol. Fukagawa M, et al. **Miner Electrolyte Metab** 1995;21(1–3):97–100 (22 ref.)
Lipoprotein(a) in chronic renal disease. Stenvinkel P, et al. **Miner Electrolyte Metab** 1996;22(1–3):16–21 (67 ref.)
Is it necessary to treat metabolic acidosis in chronic renal insufficiency? Hörl WH. **Nephrol Dial Transplant** 1995; 10(9):1542–3 (27 ref.)
Pathophysiology and treatment of secondary hyperparathyroidism in patients with chronic renal failure. Tsukamoto Y. **Nephrol Dial Transplant** 1995;10 Suppl 3:22–4 (12 ref.)
Hepatitis C virus infection and disease in renal transplantation. Berthoux F. **Nephron** 1995;71(4):386–94 (62 ref.)
Peliosis of the spleen: possible association with chronic renal failure and erythropoietin therapy. Lam KY, et al. **Postgrad Med J** 1995 Aug;71(838):493–6 (30 ref.)
Bilateral renal oncocytomatosis in a patient with renal failure. Israeli RS, et al. **Urology** 1995 Dec;46(6):873–5 (15 ref.)
[Erythropoietin, a milestone in the history of nephrology] Uehlinger DE, et al. **Ther Umsch** 1995 Oct;52(10):672–7 (16 ref.) (Eng. Abstr.) **(Ger)**
[A nephropathic patient with lung problems ...] Cole TJ, et al. **Radiol Med (Torino)** 1995 Dec;90(6):847–50 (9 ref.) **(Ita)**
[Squamous cell carcinoma of the renal pelvis associated with renal stones in a patient with chronic renal failure: a case report and a review of the Japanese literature] Nakamura Y, et al. **Hinyokika Kiyo** 1996 Jun;42(6):451–5 (13 ref.) (Eng. Abstr.) **(Jpn)**
[Outline of immune deficiency pathogenesis in patients with chronic renal failure] Zmonarski SC, et al. **Postepy Hig Med Dosw** 1995;49(4):487–512 (78 ref.) (Eng. Abstr.) **(Pol)**
[Vitamin disturbances in chronic renal insufficiency. II. Fat soluble vitamins] Pietrzak I. **Przegl Lek** 1996;53(1):29–32 (22 ref.) (Eng. Abstr.) **(Pol)**
[Arterial hypertension in patients with terminal kidney failure: pathogenetic variants and treatment principles] Nikolaev AIu, et al. **Urol Nefrol (Mosk)** 1996 Jan–Feb; (1):44–8 (106 ref.) **(Rus)**

DIAGNOSIS

Imaging of children with chronic renal failure. Frankel DG, et al. **J Pediatr** 1996 Aug;129(2):s33–8 (24 ref.)

DIET THERAPY

Kidney protection: how to prevent or delay chronic renal failure. Steinman TI. **Geriatrics** 1996 Aug;51(8):28–35 (22 ref.)
Low-protein diets in the treatment of chronic renal failure. Mitch WE. **J Am Coll Nutr** 1995 Aug;14(4):311–6 (34 ref.)
Dietary protein restriction and the progression of chronic renal insufficiency: a review of the literature. Holm EA, et al. **J Intern Med** 1996 Feb;239(2):99–104 (60 ref.)

DRUG THERAPY

Enhancement of erythroid colony growth by triiodothyronine in cell cultures from bone marrow of normal and anemic rats with chronic renal failure. Malgor LA, et al. **Acta Physiol Pharmacol Ther Latinoam** 1995; 45(2):79–86 (40 ref.)
Recombinant human growth hormone for children with renal failure. Tönshoff B, et al. **Adv Ren Replace Ther** 1996 Jan; 3(1):37–47 (63 ref.)
Effects of ACE inhibitors and calcium antagonists on progression of chronic renal disease. Epstein M. **Blood Press Suppl** 1995;2:108–12 (41 ref.)
Effects of lipids on the pathogenesis of progressive renal failure: role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in the prevention of glomerulosclerosis. Guijarro C, et al. **Miner Electrolyte Metab** 1996; 22(1–3):147–52 (45 ref.)
Loop diuretics and thiazides—the case for their combination in chronic renal failure [editorial] Fliser D. **Nephrol Dial Transplant** 1996 Mar;11(3):408–10 (10 ref.)
New hormones in the therapeutic arsenal of chronic renal failure. Growth hormone and erythropoietin. Warady BA, et al. **Pediatr Clin North Am** 1995 Dec;42(6):1551–77 (124 ref.)
[Progress on research of mechanism of Rheum palmatum in delaying the chronic renal failure] Huang CL, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Aug; 15(8):506–8 (22 ref.) **(Chi)**
[Antihypertensive therapy in renal failure] Mayer G. **Acta Med Austriaca** 1995;22(3):51–3 (19 ref.) (Eng. Abstr.) **(Ger)**

ECONOMICS

View from across the Atlantic. America struggles with health care reform. Friedman EA. **Nephrol Dial Transplant** 1996 Jan;11(1):203–7 (37 ref.)
Health-care economics and peritoneal dialysis. Nissenson AR. **Perit Dial Int** 1996;16 Suppl 1:S373–7 (17 ref.)

ENZYMOLOGY

Chronic renal disease: do metalloproteinase inhibitors have a demonstrable role in extracellular matrix accumulation? Baricos WH. **Curr Opin Nephrol Hypertens** 1995 Jul; 4(4):365–8 (24 ref.)

EPIDEMIOLOGY

Acetaminophen and adverse chronic renal outcomes: an appraisal of the epidemiologic evidence. Barrett BJ. **Am J Kidney Dis** 1996 Jul;28(1 Suppl 1):S14–9 (15 ref.)
End-stage renal disease: magnitude of the problem, prognosis of future trends and possible solutions. Port FK. **Kidney Int Suppl** 1995 Aug;50:S3–6 (17 ref.)

ETIOLOGY

Do glomerular atherosclerosis and lipid-mediated tubulo-interstitial disease cause progressive renal failure in man? Moorhead JF, et al. **Blood Purif** 1996;14(1):58–66 (69 ref.)
Taking control of diabetes. Jaspan JB. **Hosp Pract (Off Ed)** 1995 Oct 15;30(10):55–62 (9 ref.)
Fibrosis causes progressive kidney failure. Cohen EP. **Med Hypotheses** 1995 Nov;45(5):459–62 (35 ref.)
Bone marrow transplant nephropathy: radiation nephritis revisited. Cohen EP, et al. **Nephron** 1995;70(2):217–22 (54 ref.)
Organic acids and the uremic syndrome: protein metabolite hypothesis in the progression of chronic renal failure. Niwa T. **Semin Nephrol** 1996 May;16(3):167–82 (204 ref.)
[Renal involvement in multiple myeloma. Physiopathology and therapy] Fiorini F, et al. **Minerva Urol Nefrol** 1995 Sep;47(3):125–31 (41 ref.) (Eng. Abstr.) **(Ita)**
[The role of tubulointerstitial changes in progression of kidney function failure in patients with chronic glomerulonephritis (GN)] Idasiak-Piechocka I, et al. **Przegl Lek** 1996;53(5):443–53 (72 ref.) (Eng. Abstr.) **(Pol)**
[Diabetic nephropathy and molecular biology of the renin-angiotensin system in the diabetic kidney] Rodríguez Pérez JC, et al. **Med Clin (Barc)** 1995 Nov 25; 105(18):708–15 (103 ref.) **(Spa)**

IMMUNOLOGY

T cells and B cells in chronic renal failure. Descamps-Latscha B, et al. **Semin Nephrol** 1996 May; 16(3):183–91 (83 ref.)

METABOLISM

Function and metabolism of brain synaptosomes in chronic renal failure. Smogorzewski M, et al. **Artif Organs** 1995 Aug;19(8):795–800 (55 ref.)
Acidosis and glucocorticoids induce branched-chain amino acid catabolism. England BK, et al. **Miner Electrolyte Metab** 1996;22(1–3):69–71 (26 ref.)
Metabolic acidosis stimulates protein metabolism in uremia. Mitch WE. **Miner Electrolyte Metab** 1996;22(1–3):62–5 (20 ref.)
Trace elements in renal failure: are they clinically important? [editorial] Gallieni M, et al. **Nephrol Dial Transplant** 1996 Jul;11(7):1232–5 (38 ref.)
'Toxicity of glucose: is AGE the answer?' Makita Z. **Nephrol Dial Transplant** 1995;10 Suppl 7:33–7 (32 ref.)
New aspects in the pathogenesis of dialysis-related amyloidosis: pathophysiology of advanced glycation end products in renal failure. Miyata T. **Nippon Jinzo Gakkai Shi** 1996 May;38(5):191–7 (51 ref.)
Bone and mineral metabolism in childhood end-stage renal disease. Salusky IB. **Pediatr Clin North Am** 1995 Dec; 42(6):1531–50 (103 ref.)

MORTALITY

Morbidity and mortality in hemodialysis: the role of schedules. Berland Y, et al. **Artif Organs** 1995 Aug; 19(8):827–31 (24 ref.)
Nutrition and mortality in hemodialysis [editorial] Bergström J. **J Am Soc Nephrol** 1995 Nov;6(5):1329–41 (146 ref.)

NURSING

Strategies to support families of children with end-stage renal failure. Watson AR. **Pediatr Nephrol** 1995 Oct;9(5):628–31 (22 ref.)

PHYSIOPATHOLOGY

Muscular function in chronic renal failure. Laville M, et al. **Adv Nephrol Necker Hosp** 1995;24:245–69 (120 ref.)
The role of proteinuria in the progression of chronic renal failure. Burton C, et al. **Am J Kidney Dis** 1996 Jun; 27(6):765–75 (94 ref.)
Cardiovascular effects of increasing hemoglobin in chronic renal failure [editorial] Mayer G, et al. **Am J Nephrol** 1996; 16(4):263–7 (40 ref.)
Hyperkalemia in end-stage renal disease: mechanisms and management [editorial] Allon M. **J Am Soc Nephrol** 1995 Oct;6(4):1134–42 (79 ref.)
Meperidine associated mental status changes in a patient with chronic renal failure. Stock SL, et al. **J Fla Med Assoc** 1996 May;83(5):315–9 (16 ref.)
Growth in children with moderate renal insufficiency: measurement, evaluation, and treatment. Abitbol c, et al. **J Pediatr** 1996 Aug;129(2):s3–8 (25 ref.)
Carbamylation of proteins and atherogenesis in renal failure. Roxborough HE, et al. **Med Hypotheses** 1995 Aug; 45(2):125–8 (28 ref.)
Insulin-like growth factor 1 resistance in chronic renal failure. Fouque D. **Miner Electrolyte Metab** 1996; 22(1–3):133–7 (55 ref.)
Effects of lipids on the pathogenesis of progressive renal failure: role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in the prevention of glomerulosclerosis. Guijarro C, et al. **Miner Electrolyte Metab** 1996; 22(1–3):147–52 (45 ref.)
Renal scarring: the role of angiotensin II. el Nahas AM. **Nephrol Dial Transplant** 1995 Oct;10 Suppl 9:28–32 (53 ref.)
Spontaneous hypoglycaemia in chronic renal failure [see comments] Bonapart IE, et al. **Neth J Med** 1996 May; 48(5):180–4 (19 ref.) Comment in: Neth J Med 1996 May;48(5):167–8.
Gastrointestinal function in chronic renal failure. Ravelli AM. **Pediatr Nephrol** 1995 Dec;9(6):756–62 (90 ref.)
The impact of intraperitoneal glucose and insulin on the liver. Bargman JM. **Perit Dial Int** 1996;16 Suppl 1:S211–4 (27 ref.)
How to reach optimal creatinine clearances in automated peritoneal dialysis. Durand PY, et al. **Perit Dial Int** 1996; 16 Suppl 1:S167–70 (14 ref.)
The importance of the interstitium in peritoneal transport. Flessner MF. **Perit Dial Int** 1996;16 Suppl 1:S76–9 (19 ref.)
Low turnover bone disease. Hutchison AJ, et al. **Perit Dial Int** 1996;16 Suppl 1:S295–9 (21 ref.)
Peritoneal dialysis and endocrinology. Lim VS.

Perit Dial Int 1996;16 Suppl 1:S257–9 (6 ref.)
Optimal use of glucose polymer (icodextrin) in peritoneal dialysis. Mistry CD, et al. **Perit Dial Int** 1996;16 Suppl 1:S104–8 (23 ref.)
Peritoneal equilibration in children. Morgenstern BZ. **Perit Dial Int** 1996;16 Suppl 1:S532–9 (43 ref.)
Theoretical analysis of osmotic agents in peritoneal dialysis. What size is an ideal osmotic agent? Rippe B, et al. **Perit Dial Int** 1996;16 Suppl 1:S97–103 (18 ref.)
Peritoneal blood flow: does it matter? Ronco C, et al. **Perit Dial Int** 1996;16 Suppl 1:S70–5 (15 ref.)
[Function of the autonomic nervous system in uremia] Rozentryt P, et al. **Postepy Hig Med Dosw** 1995; 49(4):551–61 (100 ref.) (Eng. Abstr.) **(Pol)**
[Physical exercise and chronic renal insufficiency] Bolaños L, et al. **Rev Med Univ Navarra** 1993 Jan–Mar;38(1):38–41 (25 ref.) **(Spa)**

PREVENTION & CONTROL

Preventing disease progression in chronic renal failure [see comments] Lafayette RA. **Am Fam Physician** 1995 Nov 1;52(6):1783–91 (34 ref.) Comment in: Am Fam Physician 1995 Nov 1;52(6):1660, 1662.
Kidney protection: how to prevent or delay chronic renal failure. Steinman TI. **Geriatrics** 1996 Aug;51(8):28–35 (22 ref.)
Taking control of diabetes. Jaspan JB. **Hosp Pract (Off Ed)** 1995 Oct 15;30(10):55–62 (9 ref.)
Dietary protein restriction and the progression of chronic renal insufficiency: a review of the literature. Holm EA, et al. **J Intern Med** 1996 Feb;239(2):99–104 (60 ref.)
Treatment of the pre-azotaemic phases of kidney disease in diabetes. Viberti GC. **Nephrol Dial Transplant** 1995;10 Suppl 7:38–42 (58 ref.)
[Possibilities for inhibiting the progression of chronic renal diseases (editorial)] Klinger M. **Pol Arch Med Wewn** 1995 May;93(5):405–10 (17 ref.) **(Pol)**

PSYCHOLOGY

Psychosocial aspects of care of the child with moderate renal failure. Fennell RS, et al. **J Pediatr** 1996 Aug;129(2):s8–12 (50 ref.)
Strategies to support families of children with end-stage renal failure. Watson AR. **Pediatr Nephrol** 1995 Oct;9(5):628–31 (22 ref.)
Psychosocial burdens of dialysis treatment modalities: do they differ and does it matter? Reynolds JM, et al. **Perit Dial Int** 1996;16 Suppl 1:S548–50 (13 ref.)

RADIOGRAPHY

Bone densitometry: patients with end-stage renal disease. Erlichman M, et al. **Health Technol Assess** 1996 Mar; (8):1–27 (174 ref.)

REHABILITATION

[25 years kidney replacement therapy in childhood and adolescence—success of somatic and psychosocial rehabilitation] Bulla M, et al. **Versicherungsmedizin** 1996 Jun 1;48(3):85–9 (56 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Anaesthesia for patients with renal impairment. Cranshaw J, et al. **Br J Hosp Med** 1996 Feb 21–Mar 5;55(4):171–5 (23 ref.)
Surgical considerations to preserve renal function in children with chronic renal failure. Ross JH. **J Pediatr** 1996 Aug; 129(2):s27–32 (26 ref.)
Long-term failure of renal transplants: adding insult to injury. Carpenter CB. **Kidney Int Suppl** 1995 Aug;50:S40–4 (43 ref.)
Renal transplantation in patients with type 2 diabetes mellitus. Hirschl MM. **Nephrol Dial Transplant** 1995;10 Suppl 7:58–60 (12 ref.)
[Screening of patients waiting for kidney transplantation] Járay J, et al. **Orv Hetil** 1995 Nov 12;136(46):2501–5 (40 ref.) (Eng. Abstr.) **(Hun)**

THERAPY

Dialysis and renal transplantation in infants with irreversible renal failure. Neu AM, et al. **Adv Ren Replace Ther** 1996 Jan;3(1):48–59 (109 ref.)
Home hemodialysis: survival, quality of life, and rehabilitation. Oberley ET, et al. **Adv Ren Replace Ther** 1996 Apr;3(2):147–53 (39 ref.)
Foregoing renal dialysis: a case study and review of ethical issues. The End-Stage Renal Disease Group. Tobe SW, et al. **Am J Kidney Dis** 1996 Jul;28(1):147–53 (33 ref.)
Nutrition and the dialysis prescription. Chertow GM, et al. **Am J Nephrol** 1996;16(1):79–89 (85 ref.)
Water treatment for hemodialysis. Ismail N, et al. **Am J Nephrol** 1996;16(1):60–72 (86 ref.)
The dialysis prescription: reuse. Maidment HJ, et al. **Am J Nephrol** 1996;16(1):52–9 (73 ref.)
Injectable medications for hemodialysis patients. Stivelman JC. **Am J Nephrol** 1996;16(1):73–8 (55 ref.)
The patient with ADPKD on maintenance hemodialysis. Ritz E, et al. **Contrib Nephrol** 1995;115:33–8 (15 ref.)
Economic, social, racial and age-related considerations in dialysis and transplantation. Dossetor JB. **Curr Opin Nephrol Hypertens** 1995 Nov;4(6):498–501 (39 ref.)
Pediatric renal transplantation. Singh A, et al. **Curr Opin Nephrol Hypertens** 1995 Nov;4(6):478–81 (27 ref.)
Hypopigmentation in hemodialysis. Acquired hair and skin fairness in a uremic patient undergoing maintenance hemodialysis: case report and review of the literature. Hmida MB, et al. **Dermatology** 1996;192(2):148–52 (17 ref.)
Nutrition and mortality in hemodialysis [editorial] Bergström J. **J Am Soc Nephrol** 1995 Nov;6(5):1329–41 (146 ref.)
Initiation of dialysis [editorial] Hakim RM, et al. **J Am Soc Nephrol** 1995 Nov;6(5):1319–28 (64 ref.)
Nutritional management of the child with mild to moderate chronic renal failure. Sedman A, et al. **J Pediatr** 1996 Aug; 129(2):s13–8 (26 ref.)
Differences in the care of ESRD patients worldwide: required resources and future outlook. Chugh KS, et al. **Kidney Int Suppl** 1995 Aug;50:S7–13 (38 ref.)
Dialysis: current status, contemporary limitations and future challenges. Malluche HH, et al. **Kidney Int Suppl** 1995 Aug; 50:S37–9 (19 ref.)
Insulin-like growth factor 1 resistance in chronic renal failure. Fouque D. **Miner Electrolyte Metab** 1996; 22(1–3):133–7 (55 ref.)
Observations on renal replacement services in Russia, Belarus and Lithuania. Boesken WH, et al. **Nephrol Dial Transplant** 1995 Nov;10(11):2013–6 (5 ref.)
Interleukin-1 and interleukin-1 receptor antagonist production during haemodialysis: which cytokine is a surrogate marker for dialysis-related complications? Dinarello CA. **Nephrol Dial Transplant** 1995;10 Suppl 3:25–8 (32 ref.)
Will bone disease still remain one of the most serious complications in dialysis patients? Drüeke TB. **Nephrol Dial Transplant** 1995;10 Suppl 7:16–9 (24 ref.)
Management choices in diabetic end-stage renal disease. Friedman EA. **Nephrol Dial Transplant** 1995;10 Suppl 7:61–9 (73 ref.)
Which treatment for which patient in the future? Possible modifications in CAPD. Maiorca R, et al. **Nephrol Dial Transplant** 1995;10 Suppl 7:20–6 (68 ref.)
Pathogenetic and diagnostic aspects of dialysis-related amyloidosis. Schaeffer J, et al. **Nephrol Dial Transplant** 1995;10 Suppl 3:4–8 (66 ref.)
The influence of dialysis time and dialyser reuse on survival. Shaldon S. **Nephrol Dial Transplant** 1995;10 Suppl 3:57–62 (51 ref.)
Report on management of renal failure in Europe, XXV, 1994 end stage renal disease and dialysis report. The EDTA-ERA Registry. European Dialysis and Transplant Association-European Renal Association. Valderrábano F, et al. **Nephrol Dial Transplant** 1996;11 Suppl 1:2–21 (21 ref.)
Chronic dialysis in the infant less than 1 year of age. Bunchman TE. **Pediatr Nephrol** 1995;9 Suppl:S18–22 (24 ref.)
Host defences in continuous ambulatory peritoneal dialysis and the genesis of peritonitis. Cameron JS. **Pediatr Nephrol** 1995 Oct;9(5):647–62 (203 ref.)
Endocrinology and PD: optimal treatment of anemia in peritoneal dialysis patients. Bárány P. **Perit Dial Int** 1996; 16 Suppl 1:S260–6 (65 ref.)
Appetite in CAPD patients. Bergström J. **Perit Dial Int** 1996; 16 Suppl 1:S181–4 (29 ref.)
Peritoneal dialysis catheter complications. Bernardini J. **Perit Dial Int** 1996;16 Suppl 1:S486–71 (42 ref.)
Targets in CAPD and APD prescription. Blake PG. **Perit Dial Int** 1996;16 Suppl 1:S143–6 (17 ref.)
Long-term consequences of peritonitis. Boeschoten EW. **Perit Dial Int** 1996;16 Suppl 1:S349–54 (43 ref.)
Significance, epidemiology, and prevention of peritoneal dialysis catheter infections. Burkart JM. **Perit Dial Int** 1996; 16 Suppl 1:S340–6 (38 ref.)
Nutritional status in children receiving chronic peritoneal dialysis. Canepa A, et al. **Perit Dial Int** 1996;16 Suppl 1:S526–31 (37 ref.)
Peritoneoscopic placement of Swan neck peritoneal dialysis catheters. Copley JB, et al. **Perit Dial Int** 1996;16 Suppl 1:S330–2 (18 ref.)
Implantation techniques for peritoneal dialysis catheters. Cruz C. **Perit Dial Int** 1996;16 Suppl 1:S319–21 (14 ref.)
Advanced glycation end products in peritoneal dialysis. Dawnay A. **Perit Dial Int** 1996;16 Suppl 1:S50–3 (39 ref.)
Infectious complications in pediatric patients treated with chronic peritoneal dialysis (CPD). Edefonti A, et al. **Perit Dial Int** 1996;16 Suppl 1:S543–7 (11 ref.)
CAPD overview. Gokal R. **Perit Dial Int** 1996;16 Suppl 1:S13–8 (38 ref.)
The impact of peritoneal permeability and residual renal function on PD prescription. Harty J, et al. **Perit Dial Int** 1996;16 Suppl 1:S147–52 (18 ref.)
Markers of peritoneal membrane status. Krediet RT, et al. **Perit Dial Int** 1996;16 Suppl 1:S42–9 (89 ref.)
The peritoneal access. Lee HB, et al. **Perit Dial Int** 1996;16 Suppl 1:S322–6 (24 ref.)
Dialysis in patients with diabetic nephropathy: CAPD versus hemodialysis. Lee HB, et al. **Perit Dial Int** 1996;16 Suppl 1:S269–74 (28 ref.)
Quality of life elderly and diabetic patients on peritoneal dialysis. Nissenson AR. **Perit Dial Int** 1996;16 Suppl 1:S406–9 (33 ref.)
Bicarbonate: the alternative buffer for peritoneal dialysis. Passlick-Deetjen J, et al. **Perit Dial Int** 1996;16 Suppl 1:S109–13 (44 ref.)
Exit-site care. Piraino B. **Perit Dial Int** 1996;16 Suppl 1:S336–9 (28 ref.)
Cardiovascular disease in peritoneal dialysis. Prichard S, et al. **Perit Dial Int** 1996;16 Suppl 1:S19–22 (33 ref.)
Prescription of calcium concentration and PTH control. Ritz E, et al. **Perit Dial Int** 1996;16 Suppl 1:S300–4 (31 ref.)
Integration of peritoneal dialysis in active uremia treatment. Ronco C, et al. **Perit Dial Int** 1996;16 Suppl 1:S393–7 (8 ref.)
Quality-of-life assessment in patients on peritoneal dialysis: a review of the state of the art. Salek S. **Perit Dial Int** 1996;16 Suppl 1:S398–401 (13 ref.)
Peritoneal dialysis in diabetics. Optimal insulin therapy on CAPD: intraperitoneal versus subcutaneous treatment. Scarpioni L, et al. **Perit Dial Int** 1996;16 Suppl 1:S275–8 (33 ref.)
Effect of different buffers on the biocompatibility of CAPD solutions. Schambye HT. **Perit Dial Int** 1996;16 Suppl 1:S130–6 (48 ref.)
Peritoneal dialysis in liver disorders. Selgas R, et al. **Perit Dial Int** 1996;16 Suppl 1:S215–9 (35 ref.)
Management of foot problems in diabetes. Shaw JE, et al. **Perit Dial Int** 1996;16 Suppl 1:S279–82 (26 ref.)
Treatment of sexual dysfunction. Uttley L. **Perit Dial Int** 1996;16 Suppl 1:S402–5 (13 ref.)
Prevention of infection dropout in PD. Viglino G, et al. **Perit Dial Int** 1996;16 Suppl 1:S355–61 (56 ref.)
Nasogastric tube feeding in infants on peritoneal dialysis. Warady BA, et al. **Perit Dial Int** 1996;16 Suppl 1:S521–5 (32 ref.)
Options for therapy of ischemic nephropathy: role of angioplasty and surgery. Novick AC. **Semin Nephrol** 1996 Jan;16(1):53–60 (61 ref.)
Upper arm arteriovenous fistula for chronic hemodialysis: 20 years later. Dagher FJ. **Transplant Proc** 1996 Aug; 28(4):2325–7 (12 ref.)
[Treatment of chronic kidney failure in diabetics with peritoneal dialysis] Bednářová V, et al. **Cas Lek Cesk** 1996 May 29;135(11):340–3 (27 ref.) (Eng. Abstr.) **(Cze)**
[Preservation of renal function by revascularization in renovascular disease] Halimi JM, et al. **J Mal Vasc** 1995; 20(4):241–6 (55 ref.) (Eng. Abstr.) **(Fre)**
[Kidney diseases in the elderly from the internal medicine viewpoint. Diagnosis and therapy] Verwiebe R, et al. **Fortschr Med** 1995 Oct 20;113(29):418–22 (17 ref.) (Eng. Abstr.) **(Ger)**
[Update nephrology—II. Causes of chronic kidney insufficiency and possibilities of affecting its progression] Stein G, et al. **Med Klin** 1996 Mar 15;91(3):148–54 (155 ref.) **(Ger)**
[Nephrology update—I. Causes and possibilities of modifying the progression of chronic renal failure] Stein G, et al. **Med Klin** 1996 Apr 1;91 Suppl 1:153–8 (155 ref.) **(Ger)**
[Nephrology update—II. Causes and possibilities for modifying the progression of chronic renal failure] Stein G, et al. **Med Klin** 1996 Apr 1;91 Suppl 1:159–65 (155 ref.) **(Ger)**
[Present significance of home hemodialysis] Ota K. **Nippon Naika Gakkai Zasshi** 1995 Oct 10;84(10):1653–7 (3 ref.) **(Jpn)**
[Substitutive treatment of renal function] Abensur H. **Arq Bras Cardiol** 1995 Jul;65(1):81–3 (14 ref.) **(Por)**

VETERINARY

The hyperfiltration theory: progression of chronic renal failure and the effects of diet in dogs. Gonin-Jmaa D, et al. **J Am Vet Med Assoc** 1995 Dec 1;207(11):1411–5 (54 ref.)

KIDNEY FUNCTION TESTS

Radionuclide techniques for the evaluation of renal function: advantages over conventional methodology. Bubeck B. **Curr Opin Nephrol Hypertens** 1995 Nov;4(6):514–9 (15 ref.)
Determination of individual renal function through noninvasive methodologies. Dondi M, et al. **Curr Opin Nephrol Hypertens** 1995 Nov;4(6):520–4 (42 ref.)
Special considerations for the evaluation of renal function in the pediatric patient. Geva P, et al. **Curr Opin Nephrol Hypertens** 1995 Nov;4(6):525–30 (26 ref.)
Conventional measurement of renal function utilizing serum creatinine, creatinine clearance, inulin and para-aminohippuric acid clearance. Toto RD. **Curr Opin Nephrol Hypertens** 1995 Nov;4(6):505–9; discussion 503–4 (21 ref.)
Changes in neurohumoral systems during the development of congestive heart failure: impact on cardiovascular and renal function. Elsner D. **Eur Heart J** 1995 Dec;16 Suppl N:52–8 (37 ref.)
The current approach to the assessment of fetal renal function: fact or fiction? Spitzer A. **Pediatr Nephrol** 1996 Apr;10(2):230–5 (27 ref.)
[Is preventive perioperative dopamine administration of value?] Bund M, et al. **Anaesthesiol Reanim** 1995; 20(3):76–81 (45 ref.) (Eng. Abstr.) **(Ger)**
[General examination and renal function test for tubulointerstitial nephropathy] Tajima A, et al. **Nippon Rinsho** 1995 Aug;53(8):1925–30 (16 ref.) (Eng.

Abstr.) (Jpn)

METHODS

Renal function (microalbuminuria). Ward KM. **Anal Chem** 1995 Jun 15;67(12):383R-391R (144 ref.)
[Phenolsulfonphthalein (PSP)] Tomita K. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:1085-7 (5 ref.) (Jpn)

KIDNEY GLOMERULUS

see related
GLOMERULAR FILTRATION RATE

[Lipoprotein glomerulopathy: a new French case with recurrence on the transplant] Djamali A, et al. **Presse Med** 1996 May 18;25(17):798-802 (23 ref.) (Eng. Abstr.) (Fre)

ANATOMY & HISTOLOGY

Analyzing renal glomeruli with the new stereology. Bertram JF. **Int Rev Cytol** 1995;161:111-72 (141 ref.)

BLOOD SUPPLY

Pre-glomerular structural changes in the renal vasculature in hypertension. Anderson WP, et al. **Blood Press Suppl** 1995;2:74-80 (56 ref.)
Do glomerular atherosclerosis and lipid-mediated tubulo-interstitial disease cause progressive renal failure in man? Moorhead JF, et al. **Blood Purif** 1996;14(1):58-66 (69 ref.)
Hypercoagulability, intraglomerular coagulation, and thromboembolism in nephrotic syndrome [editorial] Sagripanti A, et al. **Nephron** 1995;70(3):271-81 (118 ref.)
Influence of anti-hypertensive drugs on glomerular hemodynamics. Ito S, et al. **Nippon Jinzo Gakkai Shi** 1996 Mar;38(3):115-8 (20 ref.)
Origin of the glomerular vasculature in the developing kidney. Hyink DP, et al. **Semin Nephrol** 1995 Jul; 15(4):300-14 (140 ref.)
Charge structure of the glomerular capillary membrane. Wolgast M. **Ups J Med Sci** 1995;100(1):19-31 (16 ref.)

CYTOLOGY

Structure and function of podocytes: an update. Mundel P, et al. **Anat Embryol (Berl)** 1995 Nov;192(5):385-97 (126 ref.)

DRUG EFFECTS

Site specific drug and xenobiotic induced renal toxicity. Hawksworth GM, et al. **Arch Toxicol Suppl** 1996;18:184-92 (19 ref.)

GROWTH & DEVELOPMENT

Tenascin expression in nephrogenesis and in normal or pathologic glomerulus morphologic features and functional implications [editorial] Truong LD, et al. **Nephron** 1996; 72(4):499-506 (43 ref.)

IMMUNOLOGY

Lipoxygenases as therapeutic targets in the acute and subacute phases of glomerular immune injury. Badr KF. **Contrib Nephrol** 1996;118:113-25 (75 ref.)

METABOLISM

A family with two sisters with collagenofibrotic glomerulonephropathy. Tamura H, et al. **Am J Kidney Dis** 1996 Apr;27(4):588-95 (23 ref.)
Tumor necrosis factor in glomerular injury. Ardaillou R, et al. **Contrib Nephrol** 1996;118:59-67 (30 ref.)
Immunohistologic findings in Alport syndrome. Kashtan CE, et al. **Contrib Nephrol** 1996;117:142-53 (58 ref.)
Proteins abnormally filtered throughout glomerular capillary have an intrinsic renal toxicity. Remuzzi G, et al. **Contrib Nephrol** 1996;118:164-72 (66 ref.)
The alpha chains of type IV collagen. Zhou J, et al. **Contrib Nephrol** 1996;117:80-104 (96 ref.)
Mathematical description of transport of water and macromolecules through the glomerular capillary wall. Remuzzi A. **Curr Opin Nephrol Hypertens** 1995 Jul; 4(4):343-8 (23 ref.)
Abnormal protein traffic through the glomerular barrier induces proximal tubular cell dysfunction and causes renal injury [editorial] Remuzzi G. **Curr Opin Nephrol Hypertens** 1995 Jul;4(4):339-42 (20 ref.)
Tenascin expression in nephrogenesis and in normal or pathologic glomerulus morphologic features and functional implications [editorial] Truong LD, et al. **Nephron** 1996; 72(4):499-506 (43 ref.)
Glomerular protein trafficking and progression of renal disease to terminal uremia. Benigni A, et al. **Semin Nephrol** 1996 May;16(3):151-9 (85 ref.)
[Effects of glycation process on the macromolecular structure of the glomerular basement membranes and on the glomerular functions in aging and diabetes mellitus] Sternberg M, et al. **C R Seances Soc Biol Fil** 1995; 189(6):967-85 (47 ref.) (Eng. Abstr.) (Fre)

PATHOLOGY

The structure of glomeruli and juxtaglomerular arterioles in the early phase of diabetic nephropathy--relationship between progression and metabolic control. Osterby R, et al. **Contrib Nephrol** 1996;118:195-205 (24 ref.)

PHYSIOLOGY

Growth factors and the glomerulus: relationships between development and injury. Alpers CE, et al. **Adv Nephrol Necker Hosp** 1995;24:33-52 (85 ref.)
Role of nitric oxide in glomerular physiology and pathophysiology. Gabbai FB, et al. **Adv Nephrol Necker Hosp** 1995;24:3-18 (72 ref.)
Glomerular hypertension and progressive renal disease: the interplay of mesangial cell stretch, cytokine formation and extracellular matrix synthesis. Cortes P, et al. **Contrib Nephrol** 1996;118:229-33 (14 ref.)
Glomerular healing. Johnson RJ, et al. **Contrib Nephrol** 1996; 118:54-8 (23 ref.)
Tubuloglomerular feedback. Ito S, et al. **Jpn Heart J** 1996 Mar;37(2):153-63 (52 ref.)
Glomerular actions of nitric oxide [editorial] Raij L, et al. **Kidney Int** 1995 Jul;48(1):20-32 (216 ref.)
The renal toxicity of sustained glomerular protein traffic. Benigni A, et al. **Lab Invest** 1995 Oct;73(4):461-8 (78 ref.)

PHYSIOPATHOLOGY

Heparan sulphate in the pathogenesis of diabetic nephropathy. Kofoed-Enevoldsen A. **Diabetes Metab Rev** 1995 Jul;11(2):137-60 (143 ref.)
Role of platelets in progressive glomerular diseases. Zoja C, et al. **Pediatr Nephrol** 1995 Aug;9(4):495-502 (86 ref.)
[Intraglomerular hypertension. Physiopathology and therapeutic implications] Mourad G. **Presse Med** 1996 Jun 1;25(19):900-6 (37 ref.) (Eng. Abstr.) (Fre)

ULTRASTRUCTURE

Molecular properties of the glomerular basement membrane. Pihlajaniemi T. **Contrib Nephrol** 1996;117:46-79 (160 ref.)

KIDNEY INSUFFICIENCY see **KIDNEY FAILURE**

KIDNEY INSUFFICIENCY, ACUTE see **KIDNEY FAILURE, ACUTE**

KIDNEY INSUFFICIENCY, CHRONIC see **KIDNEY FAILURE, CHRONIC**

KIDNEY MEDULLA

Toward the identification of a gene for familial juvenile nephronophthisis (autosomal recessive medullary cystic kidney disease). Antignac C, et al. **Adv Nephrol Necker Hosp** 1995;24:379-93 (68 ref.)

BLOOD SUPPLY

Renal medullary microcirculation: architecture and exchange. Michel CC. **Microcirculation** 1995 Aug; 2(2):125-39 (56 ref.)
The role of medullary ischemia in acute renal failure. Heyman SN, et al. **New Horiz** 1995 Nov;3(4):597-607 (106 ref.)

DRUG EFFECTS

Pathophysiologic mechanisms in analgesic-induced papillary necrosis. Sabatini S. **Am J Kidney Dis** 1996 Jul;28(1 Suppl 1):S34-8 (37 ref.)
Site specific drug and xenobiotic induced renal toxicity. Hawksworth GM, et al. **Arch Toxicol Suppl** 1996;18:184-92 (19 ref.)

PATHOLOGY

[Juvenile nephronophthisis with tapetoretinal degeneration, skeletal changes and special phenotypic traits] Castro-Gago M, et al. **An Esp Pediatr** 1996 Jul;45(1):90-2 (16 ref.) (Spa)

PHYSIOPATHOLOGY

Pathophysiologic mechanisms in analgesic-induced papillary necrosis. Sabatini S. **Am J Kidney Dis** 1996 Jul;28(1 Suppl 1):S34-8 (37 ref.)

KIDNEY NEOPLASMS

ABC of urology. Urological malignancy--III: Renal and testicular carcinoma. Dawson C, et al. **BMJ** 1996 May 4; 312(7039):1146-8 (4 ref.)
Wilms tumor. Green DM, et al. **CA Cancer J Clin** 1996 Jan-Feb;46(1):46-63 (108 ref.)
Renal-cell carcinoma. Motzer RJ, et al. **N Engl J Med** 1996 Sep 19;335(12):865-75 (150 ref.)
Renal hemangiopericytoma. Case report and review of the literature. Bowers DL, et al. **Urol Int** 1995;55(3):162-6 (11 ref.)
Primary renal osteosarcoma. Case report and review of the literature. Messen S, et al. **Urol Int** 1995;55(3):158-61 (17 ref.)
[Progresses in pediatric surgery in China, 1995] Jin B. **Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):753-4 (0 ref.) (Chi)
[Renal cell carcinoma. Significance of prognostic factors & current treatment] Fiori E, et al. **G Chir** 1995 Nov-Dec; 16(11-12):517-23 (108 ref.) (Eng. Abstr.) (Ita)
[Appearance in 2 brothers of double primary neoplasms: right renal carcinoma and gastric adenocarcinoma] Casetta G, et al. **Minerva Urol Nefrol** 1995 Mar;47(1):49-51 (11 ref.) (Eng. Abstr.) (Ita)
[A case of renal capsular liposarcoma] Doi T, et al. **Hinyokika Kiyo** 1995 Nov;41(11):873-7 (29 ref.) (Eng. Abstr.) (Jpn)
[Hereditary renal tumors: Wilms' tumor--congenital anomalies' syndrome] Tsuchida Y, et al. **Nippon Rinsho** 1995 Nov;53(11):2742-8 (20 ref.) (Eng. Abstr.) (Jpn)

BLOOD SUPPLY

[Invasion, metastasis and angiogenesis of renal cell carcinoma] Tsukamoto T. **Nippon Hinyokika Gakkai Zasshi** 1996 Jan;87(1):1-12 (82 ref.) (Jpn)

CHEMICALLY INDUCED

Molecular mechanisms of estrogen carcinogenesis. Yager JD, et al. **Annu Rev Pharmacol Toxicol** 1996;36:203-32 (226 ref.)
Estrogen carcinogenesis in the hamster kidney: a hormone-driven multistep process. Li JJ, et al. **Prog Clin Biol Res** 1996;394:255-67 (57 ref.)

COMPLICATIONS

Acute renal failure secondary to solid tumor renal metastases: case report and review of the literature. Manning EC, et al. **Am J Kidney Dis** 1996 Feb;27(2):284-91 (30 ref.)
Cystic degeneration and carcinogenesis of the kidney. Ogawa Y. **Int J Urol** 1996 Jan;3(1):1-17 (204 ref.)
Acute myeloma kidney. Winearls CG. **Kidney Int** 1995 Oct; 48(4):1347-61 (65 ref.)
Bence Jones proteinuria and myeloma kidney [editorial] Chauveau D, et al. **Nephrol Dial Transplant** 1996 Mar; 11(3):413-5 (7 ref.)
Varicocele as a presenting feature of Wilms' tumor. Monroe K, et al. **Pediatr Emerg Care** 1995 Oct;11(5):300-1 (7 ref.)
The presence of hydrops fetalis in a fetus with congenital mesoblastic nephroma. Liu YC, et al. **Prenat Diagn** 1996 Apr;16(4):363-5 (8 ref.)
Bilateral renal oncocytomatosis in a patient with renal failure. Israeli RS, et al. **Urology** 1995 Dec;46(6):873-5 (15 ref.)
[Tumors outside of the central nervous system in Von Hippel-Lindau disease] Veltman GA, et al. **Ned Tijdschr Geneeskd** 1996 Apr 13;140(15):823-6 (33 ref.) (Dut)
[Arteriovenous fistula with cardiac insufficiency disclosing kidney cancer] Jan N, et al. **Rev Med Interne** 1996; 17(4):329-32 (30 ref.) (Eng. Abstr.) (Fre)
[Squamous cell carcinoma of the renal pelvis associated with renal stones in a patient with chronic renal failure: a case report and a review of the Japanese literature] Nakamura Y, et al. **Hinyokika Kiyo** 1996 Jun;42(6):451-5 (13 ref.) (Eng. Abstr.) (Jpn)

DIAGNOSIS

Renal oncocytomatosis. Katz DS, et al. **Am J Kidney Dis** 1996 Apr;27(4):579-82 (19 ref.)
Multilocular renal cyst. Report of two cases and review of the literature. Ala-Opas MY, et al. **Ann Chir Gynaecol** 1995; 84(3):318-22 (9 ref.)
Imaging patients with Wilms tumor. Babyn P, et al. **Hematol Oncol Clin North Am** 1995 Dec;9(6):1217-52 (117 ref.)
Screening for Wilms tumor in high-risk individuals. Clericuzio CL, et al. **Hematol Oncol Clin North Am** 1995 Dec;9(6):1253-65 (43 ref.)
Contrast-enhanced MR imaging of the kidneys and adrenal glands. Huch Böni RA, et al. **Magn Reson Imaging Clin N Am** 1996 Feb;4(1):101-31 (61 ref.)
The indeterminate renal mass. Kawashima A, et al. **Radiol Clin North Am** 1996 Sep;34(5):997-1015 (43 ref.)
Observation of small incidentally detected renal masses. Bosniak MA. **Semin Urol Oncol** 1995 Nov;13(4):267-72 (18 ref.)
The current role of percutaneous biopsy in the evaluation of renal masses. Herts BR, et al. **Semin Urol Oncol** 1995 Nov;13(4):254-61 (40 ref.)
Renal adenoma and oncocytoma. Licht MR. **Semin Urol Oncol** 1995 Nov;13(4):262-6 (60 ref.)
Differential diagnosis and evaluation of the incidentally discovered renal mass. Rodriguez R, et al. **Semin Urol Oncol** 1995 Nov;13(4):246-53 (36 ref.)
The value of ultrastructural evaluation in the diagnosis of renal tumors: a general overview. Herrera GA. **Ultrastruct Pathol** 1996 Jan-Feb;20(1):1-6 (36 ref.)
Practical electron microscopy of pediatric renal tumors. Weeks DA, et al. **Ultrastruct Pathol** 1996 Jan-Feb; 20(1):31-3 (2 ref.)
Neurilemoma of the kidney. Singer AJ, et al. **Urology** 1996 Apr;47(4):575-81 (18 ref.)
Diagnosis and prognosis of renal-cell tumors: a molecular approach. Wilhelm M, et al. **World J Urol** 1995;13(3):143-8 (17 ref.)
[Pseudotumoral xanthogranulomatous pyelonephritis. A propos of 2 cases] Mozziconacci JG, et al. **J Radiol** 1996 Jul;77(7):503-8 (28 ref.) (Eng. Abstr.) (Fre)
[A case of genitourinary double cancers detected by health

screening] Ito T, et al. **Hinyokika Kiyo** 1996 Jun; 42(6):461–4 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Renal cell carcinoma in childhood: a case report] Sato T, et al. **Hinyokika Kiyo** 1996 Jun;42(6):439–41 (9 ref.) (Eng. Abstr.) **(Jpn)**

[Diagnosis and treatment of renal cell carcinoma accompanying the cystic lesion] Terachi T. **Hinyokika Kiyo** 1995 Sep;41(9):697–701 (12 ref.) (Eng. Abstr.) **(Jpn)**

[Lumbago–sciatica syndrome as the first manifestation of metastatic renal adenocarcinoma] Amat Cecilia M, et al. **Actas Urol Esp** 1996 Jan;20(1):54–8 (7 ref.) (Eng. Abstr.) **(Spa)**

[Renal angiomyolipoma located intrasinusally. An anomalous location which poses diagnostic problems] Franco A, et al. **Actas Urol Esp** 1995 Mar;19(3):239–41; discussion 241–2 (7 ref.) (Eng. Abstr.) **(Spa)**

[Carcinoma of the Bellini's collecting duct: report of 2 new cases] Garmendia Larrea JC, et al. **Actas Urol Esp** 1995 Oct;19(9):721–3 (11 ref.) (Eng. Abstr.) **(Spa)**

[Transitional–cell sarcomatoid carcinoma of the renal pelvis with osteoclast–type giant cells. Review of the literature] Meseguer García P, et al. **Actas Urol Esp** 1996 Jan; 20(1):63–7 (26 ref.) (Eng. Abstr.) **(Spa)**

[Clinical study of incidentally diagnosed renal adenocarcinoma] Herranz Amo F, et al. **Arch Esp Urol** 1995 Dec;48(10):991–8; discussion 998–9 (24 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Rhabdoid tumor of the kidney in an adult: review of the literature and report of a case responding to interleukin–2. Ebbinghaus SW, et al. **Cancer Biother** 1995 Fall; 10(3):237–41 (21 ref.)

[Resistance to chemotherapy in cancers of the kidney and therapeutic perspectives] Oudard S, et al. **J Urol (Paris)** 1995;101(3):122–4 (25 ref.) (Eng. Abstr.) **(Fre)**

EPIDEMIOLOGY

Epidemiologic features of Wilms tumor. Birch JM, et al. **Hematol Oncol Clin North Am** 1995 Dec;9(6):1157–78 (84 ref.)

ETIOLOGY

Etiology of Wilms' tumor. Sharpe CR, et al. **Epidemiol Rev** 1995;17(2):415–32 (108 ref.)

Renal cortical neoplasm in a child with dialysis–acquired cystic kidney disease. Gentle DL, et al. **Urology** 1996 Feb; 47(2):254–5 (5 ref.)

[Tumorigenesis of kidney tubule] Ishikawa I. **Nippon Rinsho** 1995 Aug;53(8):1900–7 (20 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Molecular cloning of the von Hippel–Lindau tumor suppressor gene and its role in renal carcinoma. Gnarra JR, et al. **Biochim Biophys Acta** 1996 Mar 18;1242(3):201–10 (60 ref.)

Cytogenetic investigation of synchronous bilateral renal tumors. Dal Cin P, et al. **Cancer Genet Cytogenet** 1996 Jul 1;89(1):57–60 (25 ref.)

Genetics of embryonal tumours of childhood: retinoblastoma, Wilms' tumour and neuroblastoma. Brodeur GM. **Cancer Surv** 1995;25:67–99 (209 ref.)

Von Hippel–Lindau disease and sporadic renal cell carcinoma. Zbar B. **Cancer Surv** 1995;25:219–32 (32 ref.)

RNA processing. Wilms' tumour—the splicing connection? Lamond AI. **Curr Biol** 1995 Aug 1;5(8):862–5 (10 ref.)

Distinct Xp11.2 breakpoints in two renal cell carcinomas exhibiting X;autosome translocations. Dijkhuizen T, et al. **Genes Chromosomes Cancer** 1995 Sep;14(1):43–50 (20 ref.)

Familial renal cell carcinoma: review of recent molecular genetics. Yao M, et al. **Int J Urol** 1995 May;2(2):61–70 (134 ref.)

Molecular genetics of Wilms' tumour. Tay JS. **J Paediatr Child Health** 1995 Oct;31(5):379–83 (64 ref.)

[Hippel–Lindau syndrome and sporadic renal cell carcinomas. Pathogenesis, morphologic spectrum and molecular genetics] Brauch H, et al. **Pathologe** 1995 Sep; 16(5):321–7 (41 ref.) (Eng. Abstr.) **(Ger)**

[Traditional and future criteria for progression in renal cell carcinoma. Molecular biology and clinical aspects] Pomer S, et al. **Urologe A** 1996 May;35(3):254–62 (57 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

Focal versus diffuse anaplasia in Wilms tumor—new definitions with prognostic significance: a report from the National Wilms Tumor Study Group. Faria P, et al. **Am J Surg Pathol** 1996 Aug;20(8):909–20 (14 ref.)

Current management of renal cell carcinoma. Sokoloff MH, et al. **CA Cancer J Clin** 1996 Sep–Oct;46(5):284–302 (121 ref.)

Various features and surgical approach of solitary pancreatic metastasis from renal cell carcinoma. Fabre JM, et al. **Eur J Surg Oncol** 1995 Dec;21(6):683–6 (47 ref.)

Imaging in the staging of renal cell carcinoma. Reznek RH. **Eur Radiol** 1996;6(2):120–8 (61 ref.)

Histopathology of childhood renal tumors. Schmidt D, et al. **Hematol Oncol Clin North Am** 1995 Dec;9(6):1179–200 (26 ref.)

Solitary pancreatic metastasis occurring eight years after nephrectomy for renal cell carcinoma. A case report and surgical review. Hirota T, et al. **Int J Pancreatol** 1996 Apr; 19(2):145–53 (63 ref.)

Angiomyolipoma of the kidney with extension into the inferior vena cava. Hibi H, et al. **Int J Urol** 1995 Nov; 2(5):332–5 (14 ref.)

Solitary contralateral psoas metastasis 14 years after radical nephrectomy for organ confined renal cell carcinoma. Linn JF, et al. **J Urol** 1996 Jul;156(1):173 (2 ref.)

Carcinoma of the tongue in a long–term survivor of clear cell sarcoma of the kidney. Ferbend P, et al. **Pediatr Pathol Lab Med** 1995 Mar–Apr;15(2):327–32 (22 ref.)

Ossifying renal tumor of infancy: a clinicopathologic study of nine cases. Sotelo–Avila C, et al. **Pediatr Pathol Lab Med** 1995 Sep–Oct;15(5):745–62 (9 ref.)

Late presentation of a solitary metastasis of renal cell carcinoma as an obstructive duodenal mass. Toh SK, et al. **Postgrad Med J** 1996 Mar;72(845):178–9 (10 ref.)

Spinal cord and bone metastasizing renal tumor of childhood. Arrotegui JI, et al. **Rev Neurol** 1995 Nov–Dec; 23(124):1231–2 (15 ref.)

Malignant rhabdoid tumors: a clinicopathologic review and conceptual discussion. Wick MR, et al. **Semin Diagn Pathol** 1995 Aug;12(3):233–48 (119 ref.)

Metastatic renal cell carcinoma to ampulla of Vater: an unusual lesion amenable to surgical resection. Leslie KA, et al. **Surgery** 1996 Mar;119(3):349–51 (14 ref.)

Long–lasting complete remission of pulmonary metastases consequent to renal cell carcinoma obtained with interferon–beta therapy: review of the literature and a case report. Scoponi C, et al. **Tumori** 1995 May–Jun;81(3):201–3 (24 ref.)

The role of ultrastructural pathology in the diagnosis of epithelial and unusual renal tumors. Herrera GA, et al. **Ultrastruct Pathol** 1996 Jan–Feb;20(1):7–26 (68 ref.)

Verrucous carcinoma of the renal pelvis: case presentation and review of the literature. Sheaff M, et al. **Virchows Arch** 1996 Aug;428(6):375–9 (22 ref.)

Late solitary cerebral metastasis from renal cell carcinoma: a case report and review of the literature. Jubelirer SJ. **W V Med J** 1996 Jan–Feb;92(1):26–7 (28 ref.)

[Ultrasonography and tomodensitometry staging of kidney tumors: anatomo–radiologic correlations in 46 patients] Boyer L, et al. **Prog Urol** 1995 Dec;5(6):951–60 (24 ref.) (Eng. Abstr.) **(Fre)**

[Angiomyolipoma: the role of puncture–aspiration cytodiagnosis] Farina LA, et al. **Prog Urol** 1995 Sep; 5(4):575–7 (36 ref.) (Eng. Abstr.) **(Fre)**

[Renal cell carcinoma with solitary asynchronous adrenal metastasis] Maeda Y, et al. **Hinyokika Kiyo** 1996 Jan; 42(1):39–42 (22 ref.) (Eng. Abstr.) **(Jpn)**

[A case of solitary metastasis from renal cell carcinoma to the thyroid gland] Muramoto M, et al. **Hinyokika Kiyo** 1996 Feb;42(2):123–5 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Double cancers of renal cell carcinoma and testicular seminoma: a case report] Nozawa M, et al. **Hinyokika Kiyo** 1995 Dec;41(12):999–1002 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Invasion, metastasis and angiogenesis of renal cell carcinoma] Tsukamoto T. **Nippon Hinyokika Gakkai Zasshi** 1996 Jan;87(1):1–12 (82 ref.) **(Jpn)**

[Single metastasis of renal adenocarcinoma in contralateral adrenal gland] Diego García A, et al. **Actas Urol Esp** 1995 Apr;19(4):314–8; discussion 318–9 (20 ref.) (Eng. Abstr.) **(Spa)**

[Renal adenocarcinoma with venous tumor extension to the right atrium: diagnostic and therapeutic considerations] Herranz Amo F, et al. **Arch Esp Urol** 1996 Jan–Feb; 49(1):17–25 (61 ref.) (Eng. Abstr.) **(Spa)**

[Metachronous metastasis in ureteral stump secondary to ipsilateral renal adenocarcinoma] Pereira Arias JG, et al. **Arch Esp Urol** 1995 Sep;48(7):746–8 (9 ref.) (Eng. Abstr.) **(Spa)**

[Synchronous bilateral renal oncocytoma] Sánchez–Chapado M, et al. **Arch Esp Urol** 1995 Nov;48(9):909–13 (35 ref.) (Eng. Abstr.) **(Spa)**

RADIOGRAPHY

[Ultrasonography and tomodensitometry staging of kidney tumors: anatomo–radiologic correlations in 46 patients] Boyer L, et al. **Prog Urol** 1995 Dec;5(6):951–60 (24 ref.) (Eng. Abstr.) **(Fre)**

RADIOTHERAPY

Damage to the urinary tract secondary to irradiation. Fichtner J, et al. **World J Urol** 1995;13(4):240–2 (23 ref.)

SECONDARY

Acute renal failure secondary to solid tumor renal metastases: case report and review of the literature. Manning EC, et al. **Am J Kidney Dis** 1996 Feb;27(2):284–91 (30 ref.)

[Renal metastasis originating from liver cancer] Fukushima M, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 Mar; 87(3):710–3 (8 ref.) (Eng. Abstr.) **(Jpn)**

SURGERY

Nephrectomy for metastatic renal cell carcinoma and surgery for distant metastases. Van Poppel H, et al. **Acta Urol Belg** 1996 May;64(2):11–7 (45 ref.)

Fibroepithelial polyps of the renal pelvis: report of two cases and review of the literature. Fernández Aceñero MJ, et al. **Minerva Urol Nefrol** 1995 Sep;47(3):133–6 (10 ref.)

Laparoscopic extirpation of renal cell cancer: feasibility, questions, and concerns. Nakada SY, et al. **Semin Surg Oncol** 1996 Mar–Apr;12(2):100–12 (34 ref.)

Laparoscopic approaches to transitional cell carcinomas of the upper urinary tract. Patel A, et al. **Semin Surg Oncol** 1996 Mar–Apr;12(2):113–20 (12 ref.)

Surgical technique and morbidity of elective partial nephrectomy. Campbell SC, et al. **Semin Urol Oncol** 1995 Nov;13(4):281–7 (27 ref.)

Preservation of renal function and the risk of hyperfiltration nephropathy. Goldfarb DA. **Semin Urol Oncol** 1995 Nov; 13(4):292–5 (24 ref.)

Rationale for total nephrectomy for suspected renal cell carcinoma. Marsh CL, et al. **Semin Urol Oncol** 1995 Nov; 13(4):273–80 (65 ref.)

Clinical experience with nephron–sparing surgery in the presence of a normal contralateral kidney. Steinbach F, et al. **Semin Urol Oncol** 1995 Nov;13(4):288–91 (18 ref.)

Current controversies in nephron–sparing surgery for renal–cell carcinoma. Steinbach F, et al. **World J Urol** 1995; 13(3):163–5 (29 ref.)

[Conservative surgery in cancer of the kidney] Ferrière JM, et al. **Presse Med** 1995 Oct 28;24(32):1507–8 (10 ref.) (Eng. Abstr.) **(Fre)**

[Malignant tumors in infancy and childhood] Daum R. **Chirurg** 1996 Jun;67(6):584–92 (18 ref.) (Eng. Abstr.) **(Ger)**

[A rare form of heart metastasis: hypernephroma. Successful surgical treatment] Minale C, et al. **Z Kardiol** 1995 Aug; 84(8):643–7 (7 ref.) (Eng. Abstr.) **(Ger)**

[The surgical opportunity in metastatic lesions of renal–cell carcinoma after a response to adjuvant immunotherapy] Olivier C, et al. **Actas Urol Esp** 1995 Mar;19(3):203–10 (27 ref.) (Eng. Abstr.) **(Spa)**

[Definitive endourological treatment in urothelial tumors of the upper urinary tract] Rodríguez Rodríguez R, et al. **Arch Esp Urol** 1995 Nov;48(9):937–43 (41 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

Metastatic renal cell carcinoma: systemic treatment. Abi–Aad AS, et al. **Acta Urol Belg** 1996 May;64(2):3–8 (26 ref.)

Recombinant beta–interferon in the treatment of patients with metastatic renal cell carcinoma. Mani S, et al. **Am J Clin Oncol** 1996 Apr;19(2):187–9 (19 ref.)

Single institution experience with recombinant gamma–interferon in the treatment of patients with metastatic renal cell carcinoma. Mani S, et al. **Am J Clin Oncol** 1996 Apr;19(2):149–53 (26 ref.)

Medical treatment of advanced renal cell carcinoma: present options and future directions. Canobbio L, et al. **Cancer Treat Rev** 1996 Mar;22(2):85–104 (123 ref.)

Improve the DNA recombination protein drugs. Lu S. **Chin Med J (Engl)** 1996 Mar;109(3):191–2 (0 ref.)

The path to progress in medical science: a Wilms tumor conspectus. Coppes MJ, et al. **Hematol Oncol Clin North Am** 1995 Dec;9(6):xiii–xviii (27 ref.)

Preoperative strategies in the management of Wilms tumor. de Kraker J, et al. **Hematol Oncol Clin North Am** 1995 Dec;9(6):1275–85 (12 ref.)

Late effects of treatment for Wilms tumor. Green DM, et al. **Hematol Oncol Clin North Am** 1995 Dec;9(6):1317–27 (83 ref.)

The treatment of Wilms tumor. Results of the National Wilms Tumor Studies. Green DM, et al. **Hematol Oncol Clin North Am** 1995 Dec;9(6):1267–74 (13 ref.)

Future directions in clinical research in Wilms tumor. Green DM, et al. **Hematol Oncol Clin North Am** 1995 Dec; 9(6):1329–39 (57 ref.)

The management of relapsed Wilms tumor. Miser JS, et al. **Hematol Oncol Clin North Am** 1995 Dec;9(6):1287–302 (51 ref.)

The management of synchronous bilateral Wilms tumor. Ritchey ML, et al. **Hematol Oncol Clin North Am** 1995 Dec;9(6):1303–15 (68 ref.)

Progress and controversies in modern treatment of Wilms' tumors. Gutjahr P. **World J Urol** 1995;13(4):209–12 (8 ref.)

Gene therapy on renal–cell carcinoma: magic bullet or tragic insanity? Mickisch GH. **World J Urol** 1995;13(3):178–85 (37 ref.)

[Wilms' tumor] Graf N. **Schweiz Rundsch Med Prax** 1996 Jun 4;85(23):753–61 (48 ref.) (Eng. Abstr.) **(Ger)**

[Retroperitoneal abscess formation accompanied by intraabdominal free air, a rare complication of transcatheter arterial embolization of renal tumor: a case report] Koga F, et al. **Hinyokika Kiyo** 1996 Jun;42(6):443–6 (7 ref.) (Eng. Abstr.) **(Jpn)**

ULTRASTRUCTURE

The value of ultrastructural evaluation in the diagnosis of renal tumors: a general overview. Herrera GA. **Ultrastruct Pathol** 1996 Jan–Feb;20(1):1–6 (36 ref.)

The role of ultrastructural pathology in the diagnosis of epithelial and unusual renal tumors. Herrera GA, et al. **Ultrastruct Pathol** 1996 Jan–Feb;20(1):7–26 (68 ref.)
Practical electron microscopy of pediatric renal tumors. Weeks DA, et al. **Ultrastruct Pathol** 1996 Jan–Feb; 20(1):31–3 (2 ref.)

KIDNEY PAPILLA see **KIDNEY MEDULLA**

KIDNEY PELVIS

Subepithelial hematoma of the renal pelvis (Antopol–Goldman lesion) Oza KN, et al. **J Urol** 1996 Mar; 155(3):1032–3 (4 ref.)
[Fibroepithelial polyps of the ureter and the kidney pelvis. Report of 3 cases] Robert M, et al. **Prog Urol** 1996 Apr; 6(2):282–7 (31 ref.) (Eng. Abstr.) **(Fre)**
[Squamous cell carcinoma of the renal pelvis associated with renal stones in a patient with chronic renal failure: a case report and a review of the Japanese literature] Nakamura Y, et al. **Hinyokika Kiyo** 1996 Jun;42(6):451–5 (13 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Verrucous carcinoma of the renal pelvis: case presentation and review of the literature. Sheaff M, et al. **Virchows Arch** 1996 Aug;428(6):375–9 (22 ref.)

SURGERY

[Principles, technics and indications of endopyelotomy] Gelet A, et al. **Prog Urol** 1995 Sep;5(4):596–604 (22 ref.) **(Fre)**

KIDNEY, POLYCYSTIC

COMPLICATIONS

Bacillus subtilis as a cause of cholangitis in polycystic kidney and liver disease [letter] Wallet F, et al. **Am J Gastroenterol** 1996 Jul;91(7):1477–8 (11 ref.)
Segmental multicystic kidney and ipsilateral duplication anomalies. Corrales JG, et al. **J Urol** 1996 Apr; 155(4):1398–401 (24 ref.)

DIAGNOSIS

Inherited cystic diseases of the kidney. Choyke PL. **Radiol Clin North Am** 1996 Sep;34(5):925–46 (57 ref.)
Acquired cystic kidney disease. Levine E. **Radiol Clin North Am** 1996 Sep;34(5):947–64 (66 ref.)

ETIOLOGY

Polycystic kidney disease: etiology, pathogenesis, and treatment. Martinez JR, et al. **Dis Mon** 1995 Nov; 41(11):693–765 (292 ref.)

GENETICS

Gene defect in polycystic kidney disease. Breuning MH. **Exp Nephrol** 1995 Sep–Oct;3(5):267–9 (28 ref.)
Inherited cystic diseases of the kidney. Choyke PL. **Radiol Clin North Am** 1996 Sep;34(5):925–46 (57 ref.)

THERAPY

Polycystic kidney disease: etiology, pathogenesis, and treatment. Martinez JR, et al. **Dis Mon** 1995 Nov; 41(11):693–765 (292 ref.)

KIDNEY, POLYCYSTIC, AUTOSOMAL DOMINANT

Autosomal dominant polycystic kidney disease [see comments] Beebe DK. **Am Fam Physician** 1996 Feb 15; 53(3):925–31 (23 ref.) Comment in: Am Fam Physician 1996 Feb 15;53(3):847–50.
Causes of death in autosomal dominant polycystic kidney disease. Fick GM, et al. **J Am Soc Nephrol** 1995 Jun; 5(12):2048–56 (81 ref.)

COMPLICATIONS

The rate of progression of renal failure in ADPKD. Choukroun G, et al. **Contrib Nephrol** 1995;115:28–32 (12 ref.)
ADPKD–associated intracranial aneurysm: new insights and unanswered questions. Pirson Y, et al. **Contrib Nephrol** 1995;115:53–8 (21 ref.)
Hypertension in ADPKD. Watson ML, et al. **Contrib Nephrol** 1995;115:59–64 (21 ref.)
Hypertension in autosomal dominant polycystic kidney disease. Parfrey PS, et al. **Curr Opin Nephrol Hypertens** 1995 Sep;4(5):460–4 (27 ref.)
Subarachnoid haemorrhage in ADPKD patients: how to recognize and how to manage? [editorial] Pirson Y, et al. **Nephrol Dial Transplant** 1996 Jul;11(7):1236–8 (10 ref.)

EPIDEMIOLOGY

ADPKD: practical implications of population genetics. Bear JC. **Contrib Nephrol** 1995;115:20–7 (40 ref.)

GENETICS

Molecular genetics of ADPKD. Harris PC. **Contrib Nephrol** 1995;115:8–15 (23 ref.)
Autosomal dominant polycystic kidney disease: molecular analysis. Harris PC, et al. **Hum Mol Genet** 1995;4 Spec No:1745–9 (45 ref.)
Polycystic kidney disease. 1: Identification and analysis of the primary defect [editorial] Harris PC, et al. **J Am Soc Nephrol** 1995 Oct;6(4):1125–33 (72 ref.)
Identification of a gene for autosomal dominant polycystic kidney disease: implications for understanding the pathogenesis and treatment of the disease. Harris PC. **Nephrol Dial Transplant** 1996 Feb;11(2):258–62 (60 ref.)
Clinical developments in polycystic kidney disease [editorial] Watson ML. **Nephrol Dial Transplant** 1996 May;11(5):764–6 (13 ref.)

METABOLISM

Polycystic kidney disease. 1: Identification and analysis of the primary defect [editorial] Harris PC, et al. **J Am Soc Nephrol** 1995 Oct;6(4):1125–33 (72 ref.)
The inscrutable renal cyst in ADPKD [editorial] Grantham JJ. **Nephrol Dial Transplant** 1995;10(7):1106–9 (15 ref.)

PATHOLOGY

Polycystic kidney disease: growth of cysts and recognition of phenotypes. Gardner KD Jr. **Contrib Nephrol** 1995; 115:1–7 (15 ref.)
Pathogenesis of renal cysts in dominantly inherited polycystic kidney disease. Grantham JJ. **Contrib Nephrol** 1995; 115:16–9 (11 ref.)

PSYCHOLOGY

Ethical issues and genetic counselling. Grantham JJ. **Contrib Nephrol** 1995;115:39–43 (6 ref.)

THERAPY

The patient with ADPKD on maintenance hemodialysis. Ritz E, et al. **Contrib Nephrol** 1995;115:33–8 (15 ref.)

KIDNEY, POLYCYSTIC, AUTOSOMAL RECESSIVE

COMPLICATIONS

Autosomal recessive polycystic kidney disease in 115 children: clinical presentation, course and influence of gender. Arbeitsgemeinschaft für Pädiatrische, Nephrologie. Zerres K, et al. **Acta Paediatr** 1996 Apr;85(4):437–45 (23 ref.)

GENETICS

Course of autosomal recessive polycystic kidney disease (ARPKD) in siblings: a clinical comparison of 20 sibships. Deget F, et al. **Clin Genet** 1995 May;47(5):248–53 (23 ref.)

KIDNEY REPLACEMENT THERAPY see **RENAL REPLACEMENT THERAPY**

KIDNEY, SPONGE

COMPLICATIONS

[Prevalence of medullary sponge kidney in patients with and without nephrolithiasis] Laube M, et al. **Schweiz Rundsch Med Prax** 1995 Oct 24;84(43):1224–30 (41 ref.) (Eng. Abstr.) **(Ger)**

KIDNEY STONES see **KIDNEY CALCULI**

KIDNEY TRANSPLANTATION

Dialysis and renal transplantation in infants with irreversible renal failure. Neu AM, et al. **Adv Ren Replace Ther** 1996 Jan;3(1):48–59 (109 ref.)
Spontaneous bacterial peritonitis in a patient with nephrogenic ascites during an episode of acute renal transplant rejection. Horn S, et al. **Am J Kidney Dis** 1996 Mar;27(3):441–3 (22 ref.)
Renal failure in a living-related kidney donor: case report and review of the literature. Said R, et al. **Am J Nephrol** 1996;16(4):334–8 (30 ref.)
Aortic reconstruction in kidney transplant recipients. Panneton JM, et al. **Ann Vasc Surg** 1996 Mar;10(2):97–108 (44 ref.)
Ethical issues in renal transplantation in developing countries. Naqvi SA, et al. **Br J Urol** 1995 Nov;76 Suppl 2:97–101 (16 ref.)
Cisplatin–based chemotherapy in renal transplant recipients. A case report and a review of the literature. Benisovich VI, et al. **Cancer** 1996 Jan 1;77(1):160–3 (22 ref.)
Optimizing the use of cyclosporine in renal transplantation. Sketris I, et al. **Clin Biochem** 1995 Jun;28(3):195–211 (182 ref.)
Gastrointestinal tuberculosis in renal transplantation: a case report and review. Ahsan N, et al. **Clin Transplant** 1995 Aug;9(4):349–52 (19 ref.)
Economic, social, racial and age–related considerations in dialysis and transplantation. Dossetor JB. **Curr Opin Nephrol Hypertens** 1995 Nov;4(6):498–501 (39 ref.)
Corticosteroids in kidney transplant recipients. Safety issues and timing of discontinuation. Tarantino A, et al. **Drug Saf** 1995 Sep;13(3):145–56 (120 ref.)
Hepatitis C virus infection in dialysis and clinical nephrology [editorial] Fabrizi F, et al. **Int J Artif Organs** 1995 May; 18(5):235–44 (138 ref.)
Recurrent hemolytic uremic syndrome in an adult renal allograft recipient: current concepts and management. Agarwal A, et al. **J Am Soc Nephrol** 1995 Oct;6(4):1160–9 (41 ref.)
The evaluation of renal transplant candidates: clinical practice guidelines. Patient Care and Education Committee of the American Society of Transplant Physicians. Kasiske BL, et al. **J Am Soc Nephrol** 1995 Jul;6(1):1–34 (438 ref.)
Renal transplantation: current status, complications and prevention. Rigg KM. **J Antimicrob Chemother** 1995 Oct; 36 Suppl B:51–7 (14 ref.)
Long–term failure of renal transplants: adding insult to injury. Carpenter CB. **Kidney Int Suppl** 1995 Aug;50:S40–4 (43 ref.)
1,25–dihydroxyvitamin D–mediated hypercalcemia in a renal transplant recipient. Golconda MS, et al. **Mayo Clin Proc** 1996 Jan;71(1):32–6 (25 ref.)
Chronic rejection and hypertension: a chicken–and–egg problem [editorial; comment] Bock HA. **Nephrol Dial Transplant** 1995;10(7):1126–8 (13 ref.) Comment on: Nephrol Dial Transplant 1995;10(7):1206–11.
Renal transplantation in patients with type 2 diabetes mellitus. Hirschl MM. **Nephrol Dial Transplant** 1995;10 Suppl 7:58–60 (12 ref.)
The patient with type II diabetes and uraemia—to transplant or not to transplant [editorial] Hirschl MM. **Nephrol Dial Transplant** 1995;10(9):1515–6 (7 ref.)
Selection of transplantation procedures and perioperative management in primary hyperoxaluria type 1. Latta K, et al. **Nephrol Dial Transplant** 1995;10 Suppl 8:53–7 (34 ref.)
Are corticosteroids really necessary in renal transplantation? Ponticelli C, et al. **Nephrol Dial Transplant** 1995; 10(9):1587–91 (36 ref.)
Clinical criteria for selecting recipients of renal transplantation. Ponticelli C, et al. **Nephrol Dial Transplant** 1995;10 Suppl 6:97–9 (22 ref.)
Hypertension and the kidney: new insights from results of renal transplantation studies. Rettig R, et al. **Nephrol Dial Transplant** 1995 Oct;10 Suppl 9:9–16 (45 ref.)
Hepatitis C virus infection and disease in renal transplantation. Berthoux F. **Nephron** 1995;71(4):386–94 (62 ref.)
Hepatitis C virus infection and the renal allograft recipient [editorial] Roth D. **Nephron** 1995;71(3):249–53 (42 ref.)
Pediatric renal transplantation. Bereket G, et al. **Pediatr Clin North Am** 1995 Dec;42(6):1603–28 (116 ref.)
Pediatric renal transplantation into the abnormal urinary tract. Churchill BM, et al. **Pediatr Nephrol** 1996 Feb; 10(1):113–20 (17 ref.)
Clinical use of tacrolimus (FK–506) in infants and children with renal transplants. Ellis D. **Pediatr Nephrol** 1995 Aug; 9(4):487–94 (45 ref.)
Chronic rejection and late renal allograft dysfunction. Laine J, et al. **Pediatr Nephrol** 1996 Apr;10(2):221–9 (83 ref.)
Renal transplant fine needle aspiration and cytokine gene expression. Nast CC. **Pediatr Nephrol** 1995;9 Suppl:S56–60 (31 ref.)
Integration of peritoneal dialysis in active uremia treatment. Ronco C, et al. **Perit Dial Int** 1996;16 Suppl 1:S393–7 (8 ref.)
Pancreas transplantation. Stratta RJ, et al. **Ren Fail** 1995 Jul; 17(4):323–37 (85 ref.)
Potential applications of therapeutic drug monitoring of sirolimus immunosuppression in clinical renal transplantation. Kahan BD, et al. **Ther Drug Monit** 1995 Dec;17(6):672–5 (17 ref.)
Testicular seminoma originating in an undescended testis in a renal allograft recipient. Modlin CS, et al. **Urology** 1996 Jul;48(1):145–8 (9 ref.)
[Use of related live donors in renal transplantation] Broyer M. **Presse Med** 1996 Jun 1;25(19):891–9 (32 ref.) (Eng. Abstr.) **(Fre)**
[Cadaver donor nephrectomy. Surgical technique in the context of multi–organ donation] Benoit G, et al. **Prog Urol** 1996 Feb;6(1):114–22 (48 ref.) (Eng. Abstr.) **(Fre)**
[Is preventive perioperative dopamine administration of value?] Bund M, et al. **Anaesthesiol Reanim** 1995; 20(3):76–81 (45 ref.) (Eng. Abstr.) **(Ger)**
[Kidney transplant procedures in intensive care medicine] Schaffartzik W, et al. **Anaesthesist** 1996 May;45(5):473–91 (16 ref.) **(Ger)**
[Kidney transplantation in patients with diseases of the gastrointestinal tract and the liver] Kliem V, et al. **Dtsch Med Wochenschr** 1995 Dec 1;120(48):1673–7 (43 ref.) **(Ger)**
[Does the primary disease recur in kidney transplantation?] Weinreich T, et al. **Ther Umsch** 1995 Sep;52(9):566–71 (16 ref.) (Eng. Abstr.) **(Ger)**
[Screening of patients waiting for kidney transplantation] Járay J, et al. **Orv Hetil** 1995 Nov 12;136(46):2501–5 (40 ref.) (Eng. Abstr.) **(Hun)**
[Hepatic dysfunction associated with renal transplantation] Nakashima T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;

(8):544–6 (20 ref.) **(Jpn)**
[Use of urinary enzymes in diagnostic follow-up in kidney transplantation] Jovanović SD. **Med Pregl** 1995; 48(5–6):163–6 (21 ref.) (Eng. Abstr.) **(Scr)**

ADVERSE EFFECTS

Hepatitis C virus infection in hemodialyzed patients and kidney allograft recipients. Pol S.
Adv Nephrol Necker Hosp 1995;24:315–30 (69 ref.)
An interesting case of failed renal transplant complicated by a lymphocele infected with Pasteurella multocida and a review of the literature. Mayo RR, et al.
Am J Nephrol 1996;16(4):361–6 (38 ref.)
Cholesterol emboli presenting as acute allograft dysfunction after renal transplantation. Singh I, et al.
J Am Soc Nephrol 1995 Aug;6(2):165–70 (25 ref.)
Nephrogenic adenoma of the bladder in renal transplant recipients: a report of 9 cases with assessment of deoxyribonucleic acid ploidy and long-term followup. Fournier G, et al. **J Urol** 1996 Jul;156(1):41–4 (21 ref.)
Post-transplant hypertension and chronic renal allograft failure. Paul LC, et al. **Kidney Int Suppl** 1995 Dec;52:S34–7 (25 ref.)
Role of hypertension in chronic renal allograft dysfunction. Sanders CE Jr, et al. **Kidney Int Suppl** 1995 Dec;52:S43–7 (97 ref.)
Fracturing osteoporosis after kidney transplantation--what are the options? Coen G. **Nephrol Dial Transplant** 1996 Apr;11(4):567–9 (17 ref.)
Is cholesterol embolic disease an unrecognized cause of renal graft dysfunction? de Takats DL, et al.
Nephrol Dial Transplant 1996 Jul;11(7):1325–7 (13 ref.)
Tuberculosis in renal transplant units [editorial] Drobniewski FA, et al. **Nephrol Dial Transplant** 1996 May;11(5):768–70 (13 ref.)
Hepatitis C and renal transplantation: outcome of patients. Morales JM. **Nephrol Dial Transplant** 1995;10 Suppl 6:125–8 (47 ref.)
Effector mechanisms in renal allograft rejection. Tax WJ, et al. **Nephrol Dial Transplant** 1995;10(9):1569–71 (15 ref.)
Pneumonia due to blastomyces dermatitidis in a European renal transplant recipient. Winkler S, et al.
Nephrol Dial Transplant 1996 Jul;11(7):1376–9 (13 ref.)
Critical neurologic illness in the immunocompromised patient. Cohen JA, et al. **Neurol Clin** 1995 Aug;13(3):659–77 (93 ref.)
Renal transplantation exposes patients with previous Kaposi's sarcoma to a high risk of recurrence. Doutrelepont JM, et al. **Transplantation** 1996 Aug 27;62(4):463–6 (15 ref.)
Successfully treated invasive pulmonary aspergillosis associated with smoking marijuana in a renal transplant recipient. Marks WH, et al. **Transplantation** 1996 Jun 27; 61(12):1771–4 (8 ref.)
[Vascular complications in kidney transplantation (a review of the literature and the authors' own experience)] Nikolovski M, et al. **Khirurgiia (Sofiia)** 1994;47(5):30–3 (60 ref.) (Eng. Abstr.) **(Bul)**
[Ureteral stenoses and fistulas after kidney transplantation] Hajri M, et al. **Ann Urol (Paris)** 1995;29(3):177–85 (32 ref.) (Eng. Abstr.) **(Fre)**
[Human papilloma virus infection and renal transplantation. Two personally observed cases and a review of the literature] Lefebvre G, et al.
J Gynecol Obstet Biol Reprod (Paris) 1995;24(6):600–3 (20 ref.) (Eng. Abstr.) **(Fre)**
[Ureteral obstruction in the kidney transplant patient] Vennarecci G, et al. **Minerva Urol Nefrol** 1995 Jun; 47(2):59–64 (9 ref.) (Eng. Abstr.) **(Ita)**
[Tubulo-interstitial lesions in human renal allograft] Morozumi K, et al. **Nippon Rinsho** 1995 Aug;53(8):2040–6 (16 ref.) (Eng. Abstr.) **(Jpn)**
[Pathogenesis of polyglobulia after kidney transplantation] Darocha Z, et al. **Postepy Hig Med Dosw** 1995;49(2):181–7 (46 ref.) (Eng. Abstr.) **(Pol)**
[Toxoplasmosis as a risk factor in pregnant women after renal transplantation] Ejmocka-Ambroziak A, et al. **Wiad Lek** 1994 Sep;47(17–18):700–1 (9 ref.) (Eng. Abstr.) **(Pol)**
[Percutaneous surgical interventions and extracorporeal lithotripsy in the treatment of the urological complications after a kidney transplant] Urenkov SB, et al.
Urol Nefrol (Mosk) 1995 Jul–Aug;(4):45–9 (122 ref.) **(Rus)**
[Neurological complications after transplants: cerebrovascular complications] Martínez-Vila E, et al.
Rev Neurol 1995;23 Suppl 1:S79–86 (49 ref.) **(Spa)**

CONTRAINDICATIONS

Implications of chronic hepatitis B or hepatitis C infection for renal transplant candidates. Goffin E, et al.
Nephrol Dial Transplant 1995;10 Suppl 6:88–92 (44 ref.)

ECONOMICS

Commerce in transplantation in Third World countries. Chugh KS, et al. **Kidney Int** 1996 May;49(5):1181–6 (34 ref.)

IMMUNOLOGY

Transplant allograft loss in the adolescent patient. Warady BA, et al. **Adv Ren Replace Ther** 1996 Apr;3(2):154–65 (57 ref.)
Donor-specific transfusion and donor bone marrow infusion in renal transplantation tolerance: a review of efficacy and mechanisms. Brennan DC, et al. **Am J Kidney Dis** 1995 Nov;26(5):701–15 (130 ref.)
Subcutaneous phaeohyphomycosis in a renal transplant recipient: a case report and review of the literature. Jha V, et al. **Am J Kidney Dis** 1996 Jul;28(1):137–9 (21 ref.)
Transplantation immunology. Ball ST, et al.
Curr Opin Nephrol Hypertens 1995 Nov;4(6):465–71 (72 ref.)
Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation. Fulton B, et al. **Drugs** 1996 Feb; 51(2):278–98 (78 ref.)
Immunotolerance: from new knowledge of mechanisms of self-tolerance to future perspectives for induction of renal transplant tolerance [editorial] Remuzzi G, et al.
Exp Nephrol 1995 Nov–Dec;3(6):319–30 (123 ref.)
Immune and nonimmune mechanisms of chronic rejection of kidney allografts. Azuma H, et al.
J Heart Lung Transplant 1995 Nov–Dec;14(6 Pt 2):S136–42 (50 ref.)
Mycophenolate mofetil in renal transplantation: results from the U.S. randomized trials. Danovitch GM.
Kidney Int Suppl 1995 Dec;52:S93–6 (19 ref.)
Clinical correlation between renal allograft failure and hyperlipidemia. Guijarro C, et al. **Kidney Int Suppl** 1995 Dec;52:S56–9 (22 ref.)
Chronic renal allograft rejection and clinical trial design. Kasiske BL, et al. **Kidney Int Suppl** 1995 Dec;52:S116–9 (12 ref.)
Molecular mechanisms of chronic renal allograft rejection. Lemström K, et al. **Kidney Int Suppl** 1995 Dec;52:S2–10 (88 ref.)
Long-term use of cyclosporine A does not adversely impact on clinical outcomes following renal transplantation. Lewis RM. **Kidney Int Suppl** 1995 Dec;52:S75–8 (35 ref.)
Recurrence of the original disease. Does this influence renal graft failure? Michielsen P. **Kidney Int Suppl** 1995 Dec; 52:S79–84 (68 ref.)
The differential diagnosis between rejection and cyclosporine toxicity. Mihatsch MJ, et al. **Kidney Int Suppl** 1995 Dec; 52:S63–9 (9 ref.)
Chronic renal allograft failure: clinical overview. The Leuven Collaborative Group for Transplantation. Peeters J, et al. **Kidney Int Suppl** 1995 Dec;52:S97–101 (50 ref.)
Tissue antigens in tubulointerstitial and vascular rejection. van der Woude FJ, et al. **Kidney Int Suppl** 1995 Dec; 52:S11–3 (17 ref.)
Clinical utility of antilipidemic therapies in chronic renal allograft failure. Wanner C, et al. **Kidney Int Suppl** 1995 Dec;52:S60–2 (38 ref.)
Pulmonary acremonium abscesses and gastrointestinal tuberculosis manifested as massive upper gastrointestinal bleeding. Miró O, et al. **Nephrol Dial Transplant** 1995; 10(8):1444–6 (17 ref.)
Effector mechanisms in renal allograft rejection. Tax WJ, et al. **Nephrol Dial Transplant** 1995;10(9):1569–71 (15 ref.)
Eicosanoids and renal allograft rejection. Wardle EN.
Nephron 1995;70(2):151–4 (48 ref.)
Brequinar sodium. Cramer DV. **Pediatr Nephrol** 1995;9 Suppl:S52–5 (29 ref.)
Pharmacokinetics of mycophenolate mofetil (RS61443): a short review. Bullingham RE, et al. **Transplant Proc** 1996 Apr;28(2):925–9 (0 ref.)
Pharmacokinetic considerations in the therapeutic application of cyclosporine in renal transplantation. Kahan BD.
Transplant Proc 1996 Aug;28(4):2143–6 (26 ref.)
Chronic rejection: pathogenesis and treatment. Lee HM.
Transplant Proc 1996 Jun;28(3):1146–7 (14 ref.)
Use of intragraft gene expression in the diagnosis of kidney allograft rejection. Pavlakis M, et al. **Transplant Proc** 1996 Aug;28(4):2019–21 (24 ref.)
Protocol core biopsy as intermediate efficacy end-point in chronic kidney allograft rejection. Yilmaz S, et al.
Transplant Proc 1996 Feb;28(1):491–3 (15 ref.)
[Hair-like hyperkeratoses in patients with kidney transplants. A new cyclosporin side-effect] Izakovic J, et al.
Hautarzt 1995 Dec;46(12):841–6 (45 ref.) (Eng. Abstr.) **(Ger)**
[Immunological aspects of kidney transplantation in Switzerland 1981–1992. Swiss Transplant Work Group Kidney Transplantation (see comments)] Speiser DE, et al. **Schweiz Med Wochenschr** 1995 Aug 26;125(34):1573–82 (42 ref.) (Eng. Abstr.) Comment in: Schweiz Med Wochenschr 1995 Aug 26;125(34):1571–2. **(Ger)**
[Problems with donor-recipient matching in kidney and bone marrow transplantation] Nowakowska B.
Postepy Hig Med Dosw 1995;49(1):107–15 (11 ref.) (Eng. Abstr.) **(Pol)**

METHODS

Urinary tract reconstruction in children undergoing renal transplantation. Ewalt DH, et al. **Adv Ren Replace Ther** 1996 Jan;3(1):69–76 (19 ref.)
Progress in surgical techniques in renal graft plantation. Anastomosis with titanium staplers. Gao W.
Chin Med J (Engl) 1996 Feb;109(2):130–1 (0 ref.)
Simultaneous pancreas-kidney and sequential pancreas-after-kidney transplantation. Holohan TV.
Health Technol Assess 1995 Aug;(4):1–53 (110 ref.)
Renal autotransplantation after horseshoe kidney injury: a case report and literature review. Murphy JT, et al.
J Trauma 1996 May;40(5):840–4 (28 ref.)
[Renal transplantation from related live donors. Results and survival] Hajri M, et al. **Ann Urol (Paris)** 1995;29(3):186–92 (17 ref.) (Eng. Abstr.) **(Fre)**
[Advantages and disadvantages of combination kidney and pancreas transplantation] Marti HP, et al. **Ther Umsch** 1995 Sep;52(9):594–601 (44 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

Dilemmas in renal transplantation: when the clinical course and histological findings differ. Curtis JJ, et al.
Am J Kidney Dis 1996 Mar;27(3):435–40 (13 ref.)
Human polyoma virus infection of renal allografts: histopathologic diagnosis, clinical significance, and literature review. Pappo O, et al. **Mod Pathol** 1996 Feb; 9(2):105–9 (23 ref.)
Liver allograft rejection: current status of classification and grading. Batts K. **Transplant Proc** 1996 Feb;28(1):453–6 (17 ref.)
Chronic cyclosporine nephropathy in renal transplantation. Bennett WM, et al. **Transplant Proc** 1996 Aug;28(4):2100–3 (29 ref.)
The Banff classification of renal allograft pathology: where do we go from here? Racusen L, et al. **Transplant Proc** 1996 Feb;28(1):486–8 (22 ref.)
The Banff classification of renal allograft pathology: where do we go from here? Racusen LC, et al.
Transplant Proc 1995 Oct;27(5):2561–3 (22 ref.)
Report of the Third Banff Conference on Allograft Pathology (July 20–24, 1995) on classification and lesion scoring in renal allograft pathology. Solez K, et al.
Transplant Proc 1996 Feb;28(1):441–4 (51 ref.)
Adhesion molecules as markers of acute cellular rejection of renal allografts. Truong L, et al. **Transplant Proc** 1996 Feb;28(1):519–22 (31 ref.)
Protocol core biopsy as intermediate efficacy end-point in chronic kidney allograft rejection. Yilmaz S, et al.
Transplant Proc 1996 Feb;28(1):491–3 (15 ref.)

PHYSIOLOGY

Kidney transplantation from asystolic donors. Nicholson M.
Br J Hosp Med 1996 Jan 17–Feb 6;55(1–2):51–6 (19 ref.)
Ischemia, injury, and renal allograft rejection. Lu CY.
Curr Opin Nephrol Hypertens 1996 Mar;5(2):107–10 (52 ref.)
Pediatric renal transplantation. Singh A, et al.
Curr Opin Nephrol Hypertens 1995 Nov;4(6):478–81 (27 ref.)
Diagnostic significance of dopamine estimation using plasma and urine in patients with adrenal and renal insufficiency, renal transplantation and hypertension. Yoshimura M, et al. **Hypertens Res** 1995 Jun;18 Suppl 1:S87–92 (31 ref.)
Delayed graft function in renal transplantation: etiology, management and long-term significance. Shoskes DA, et al. **J Urol** 1996 Jun;155(6):1831–40 (141 ref.)
A renocentric view of essential hypertension: lessons to be learnt from kidney transplantation [editorial] Jelakovic B, et al. **Nephrol Dial Transplant** 1995;10(9):1510–2 (31 ref.)
Erythropoietin and erythropoiesis in renal transplantation. Kessler M. **Nephrol Dial Transplant** 1995;10 Suppl 6:114–6 (26 ref.)
Living-related donor transplants should be performed with caution in patients with focal segmental glomerulosclerosis. First MR. **Pediatr Nephrol** 1995;9 Suppl:S40–2 (35 ref.)
An analytical review of growth hormone studies in children after renal transplantation. Ingulli E, et al.
Pediatr Nephrol 1995;9 Suppl:S61–5 (22 ref.)
Chronic renal allograft function under cyclosporin treatment. Leuven Collaborative Group for Transplantation. Vanrenterghem Y, et al. **Transplant Proc** 1996 Aug; 28(4):2097–9 (11 ref.)

REHABILITATION

[25 years kidney replacement therapy in childhood and adolescence--success of somatic and psychosocial rehabilitation] Bulla M, et al. **Versicherungsmedizin** 1996 Jun 1;48(3):85–9 (56 ref.) (Eng. Abstr.) **(Ger)**

STATISTICS & NUMERICAL DATA

[Immunological aspects of kidney transplantation in Switzerland 1981–1992. Swiss Transplant Work Group Kidney Transplantation (see comments)] Speiser DE, et al. **Schweiz Med Wochenschr** 1995 Aug 26;125(34):1573–82 (42 ref.) (Eng. Abstr.) Comment in: Schweiz Med Wochenschr 1995 Aug 26;125(34):1571–2. **(Ger)**

TRENDS

Progress in renal transplantation for children. McDonald RA, et al. **Adv Ren Replace Ther** 1996 Jan;3(1):60–8 (53 ref.)
Mycophenolate mofetil (RS 61443): nothing new under the sun or an important break-through in the field of transplantation? [editorial] van der Woude FJ.
Nephrol Dial Transplant 1995;10(7):1112–5 (10 ref.)

KIDNEY TUBULAR NECROSIS, ACUTE

Delayed graft function in renal transplantation: etiology, management and long-term significance. Shoskes DA, et

al. **J Urol** 1996 Jun;155(6):1831–40 (141 ref.)

CHEMICALLY INDUCED

[Amidazophen. Yes or no?] Jákó J, et al. **Orv Hetil** 1995 Sep 24;136(39):2121–4 (50 ref.) (Eng. Abstr.) **(Hun)**

PREVENTION & CONTROL

Prevention of clinical acute tubular necrosis with drug therapy. Lameire N, et al. **Nephrol Dial Transplant** 1995 Nov;10(11):1992–2000 (99 ref.)

KIDNEY TUBULES

Endothelins: renal tubule synthesis and actions. Kohan DE. **Clin Exp Pharmacol Physiol** 1996 Apr;23(4):337–44 (91 ref.)

BLOOD SUPPLY

[Microcirculation in renal interstitium] Kawabata M, et al. **Nippon Rinsho** 1995 Aug;53(8):1846–53 (19 ref.) (Eng. Abstr.) **(Jpn)**

CYTOLOGY

[Receptors and its signal transduction pathway in the renal interstitial cells] Arima S, et al. **Nippon Rinsho** 1995 Aug; 53(8):1861–7 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Biosynthesis of hormones in renal tubular and interstitial cells] Kuwahara M, et al. **Nippon Rinsho** 1995 Aug; 53(8):1873–8 (22 ref.) (Eng. Abstr.) **(Jpn)**

[The structure and function of the renal interstitial cells] Yamaguchi Y. **Nippon Rinsho** 1995 Aug;53(8):1841–5 (9 ref.) (Eng. Abstr.) **(Jpn)**

DRUG EFFECTS

Renal handling of drugs and amino acids after impairment of kidney or liver function--influences of maturity and protective treatment. Fleck C, et al. **Pharmacol Ther** 1995; 67(1):53–77 (341 ref.)

EMBRYOLOGY

Epithelial tubulogenesis through branching morphogenesis: relevance to collecting system development [editorial] Stuart RO, et al. **J Am Soc Nephrol** 1995 Oct;6(4):1151–9 (68 ref.)

Development of the tubular nephron. Stuart RO, et al. **Semin Nephrol** 1995 Jul;15(4):315–26 (56 ref.)

IMMUNOLOGY

[Immune reactions that mediate tubulointerstitial nephritis] Ueda S. **Nippon Rinsho** 1995 Aug;53(8):1886–93 (24 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Molecular mechanisms of renal apical Na/phosphate cotransport. Murer H, et al. **Annu Rev Physiol** 1996; 58:607–18 (48 ref.)

Regulation of sodium transport. Aperia AC. **Curr Opin Nephrol Hypertens** 1995 Sep;4(5):416–20 (36 ref.)

Amino acid transporters. Kinne RK. **Curr Opin Nephrol Hypertens** 1995 Sep;4(5):412–5 (36 ref.)

Tubular function and acid–base disturbances. Bleich M. **Nephrol Dial Transplant** 1995;10(9):1540–1 (13 ref.)

[Biosynthesis of hormones in renal tubular and interstitial cells] Kuwahara M, et al. **Nippon Rinsho** 1995 Aug; 53(8):1873–8 (22 ref.) (Eng. Abstr.) **(Jpn)**

[Electrolyte metabolism in renal tubules] Takahashi N, et al. **Nippon Rinsho** 1995 Aug;53(8):1868–72 (8 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Renal tubule cell repair following acute renal injury. Humes HD, et al. **Miner Electrolyte Metab** 1995;21(4–5):353–65 (157 ref.)

Cellular mechanisms of tubule hypertrophy and hyperplasia in renal injury. Wolf G. **Miner Electrolyte Metab** 1995; 21(4–5):303–16 (147 ref.)

The Banff classification of renal allograft pathology: where do we go from here? Racusen L, et al. **Transplant Proc** 1996 Feb;28(1):486–8 (22 ref.)

The Banff classification of renal allograft pathology: where do we go from here? Racusen LC, et al. **Transplant Proc** 1995 Oct;27(5):2561–3 (22 ref.)

[Prevention and treatment of toxic and adverse effects of cisplatin] Deng C, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1995 Jun;30(6):376–9 (30 ref.) **(Chi)**

[Hypertrophy and hyperplasia of renal tubular interstitial cells--regulatory factors] Kanetake H, et al. **Nippon Rinsho** 1995 Aug;53(8):1894–9 (22 ref.) (Eng. Abstr.) **(Jpn)**

[Renal biopsy for diagnosis of interstitial nephritis] Kimura K. **Nippon Rinsho** 1995 Aug;53(8):1931–8 (6 ref.) (Eng. Abstr.) **(Jpn)**

[Tubulointerstitial changes in some hematological disorders] Morita H, et al. **Nippon Rinsho** 1995 Aug;53(8):2007–12 (17 ref.) (Eng. Abstr.) **(Jpn)**

[The renal tubulointerstitium in diabetes mellitus] Ueno M, et al. **Nippon Rinsho** 1995 Aug;53(8):1981–7 (23 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Tubuloglomerular feedback. Ito S, et al. **Jpn Heart J** 1996 Mar;37(2):153–63 (52 ref.)

[Receptors and its signal transduction pathway in the renal interstitial cells] Arima S, et al. **Nippon Rinsho** 1995 Aug; 53(8):1861–7 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Role of interstitium in the regulation of renal tubular solute transport] Imai M, et al. **Nippon Rinsho** 1995 Aug; 53(8):1854–60 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Growth factors in tubular cells] Okuda S. **Nippon Rinsho** 1995 Aug;53(8):1879–85 (18 ref.) (Eng. Abstr.) **(Jpn)**

[The structure and function of the renal interstitial cells] Yamaguchi Y. **Nippon Rinsho** 1995 Aug;53(8):1841–5 (9 ref.) (Eng. Abstr.) **(Jpn)**

[The structure and function of renal tubulointerstitium] Yamaguchi Y. **Nippon Rinsho** 1995 Aug;53(8):1836–9 (5 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Pathophysiology of renal tubular obstruction: therapeutic role of synthetic RGD peptides in acute renal failure. Noiri E, et al. **Kidney Int** 1995 Nov;48(5):1375–85 (91 ref.)

Perspectives in endothelin research: tubulointerstitial actions of endothelins in the kidney: roles in health and disease. Ong AC. **Nephrol Dial Transplant** 1996 Feb;11(2):251–7 (86 ref.)

ULTRASTRUCTURE

Morphology of interstitial cells in the healthy kidney. Kaissling B, et al. **Anat Embryol (Berl)** 1996 Apr; 193(4):303–18 (80 ref.)

[The structure and function of renal tubulointerstitium] Yamaguchi Y. **Nippon Rinsho** 1995 Aug;53(8):1836–9 (5 ref.) **(Jpn)**

KIDNEY TUBULES, COLLECTING

[Carcinoma of the Bellini's collecting duct: report of 2 new cases] Garmendia Larrea JC, et al. **Actas Urol Esp** 1995 Oct;19(9):721–3 (11 ref.) (Eng. Abstr.) **(Spa)**

CYTOLOGY

Plasticity in epithelial polarity of renal intercalated cells: targeting of the H(+)-ATPase and band 3. Al-Awqati Q. **Am J Physiol** 1996 Jun;270(6 Pt 1):C1571–80 (67 ref.)

EMBRYOLOGY

Epithelial tubulogenesis through branching morphogenesis: relevance to collecting system development [editorial] Stuart RO, et al. **J Am Soc Nephrol** 1995 Oct;6(4):1151–9 (68 ref.)

METABOLISM

K+ channels in the basolateral membrane of rat cortical collecting duct. Hirsch J, et al. **Kidney Int** 1995 Oct; 48(4):1036–46 (89 ref.)

Water channels in the kidney collecting duct. Sasaki S, et al. **Kidney Int** 1995 Oct;48(4):1082–7 (43 ref.)

View of K+ secretion through the apical K channel of cortical collecting duct. Wang WH. **Kidney Int** 1995 Oct; 48(4):1024–30 (87 ref.)

Sodium channels and non-selective cation channels in the cortical collecting duct. Korbmacher C, et al. **Nephrol Dial Transplant** 1995;10(9):1546–50 (36 ref.)

Cloning of a pH sensitive K+ channel in the kidney. Suzuki M. **Nippon Jinzo Gakkai Shi** 1995 Aug;37(8):422–7 (15 ref.)

PHYSIOLOGY

Plasticity in epithelial polarity of renal intercalated cells: targeting of the H(+)-ATPase and band 3. Al-Awqati Q. **Am J Physiol** 1996 Jun;270(6 Pt 1):C1571–80 (67 ref.)

ULTRASTRUCTURE

Experimental calcium oxalate nephrolithiasis and the formation of human urinary stones. Khan SR. **Scanning Microsc** 1995 Mar;9(1):89–100; discussion 100–1 (79 ref.)

KIDNEY TUBULES, PROXIMAL

CHEMISTRY

Renal Na/Pi-cotransporters. Biber J, et al. **Kidney Int** 1996 Apr;49(4):981–5 (33 ref.)

DRUG EFFECTS

Site specific drug and xenobiotic induced renal toxicity. Hawksworth GM, et al. **Arch Toxicol Suppl** 1996;18:184–92 (19 ref.)

Methods for studying renal toxicity. Kruidering M, et al. **Arch Toxicol Suppl** 1996;18:173–83 (38 ref.)

METABOLISM

Abnormal protein traffic through the glomerular barrier induces proximal tubular cell dysfunction and causes renal injury [editorial] Remuzzi G. **Curr Opin Nephrol Hypertens** 1995 Jul;4(4):339–42 (20 ref.)

Regulation of vesicular transport by GTP-binding proteins. Stow JL. **Curr Opin Nephrol Hypertens** 1995 Sep;4(5):421–5 (42 ref.)

Chronic regulation of the proximal tubular Na/H antiporter: from HCO3 to SRC [editorial] Alpern RJ, et al. **Kidney Int** 1995 Nov;48(5):1386–96 (113 ref.)

Cross-talk and the role of KATP channels in the proximal tubule. Welling PA. **Kidney Int** 1995 Oct;48(4):1017–23 (79 ref.)

PATHOLOGY

Tissue antigens in tubulointerstitial and vascular rejection. van der Woude FJ, et al. **Kidney Int Suppl** 1995 Dec; 52:S11–3 (17 ref.)

PHYSIOLOGY

Function and significance of the renal DOPA/DA system. Armando I, et al. **Acta Physiol Pharmacol Ther Latinoam** 1995;45(3):135–46 (111 ref.)

Ontogeny of proximal tubule acidification [editorial] Baum M, et al. **Kidney Int** 1995 Dec;48(6):1697–704 (90 ref.)

Tubule effects of glomerular hyperfiltration: an integrated view. Capasso G, et al. **Semin Nephrol** 1995 Sep; 15(5):419–25 (52 ref.)

KIENBOECK'S DISEASE see OSTEOCHONDRITIS

KILLED VACCINES see VACCINES, INACTIVATED

KILLER CELLS

see related
ANTIBODY-DEPENDENT CELL CYTOTOXICITY

IMMUNOLOGY

Perforin and lymphocyte-mediated cytolysis. Liu CC, et al. **Immunol Rev** 1995 Aug;146:145–75 (155 ref.)

KILLER CELLS, LYMPHOKINE-ACTIVATED

see related
IMMUNOTHERAPY, ADOPTIVE
INTERLEUKIN-2

IMMUNOLOGY

Regulation of NK susceptibility by target cell class I MHC molecules. Saxena RK, et al. **Indian J Biochem Biophys** 1995 Aug;32(4):179–85 (91 ref.)

METABOLISM

Interleukin-2 therapy for myelodysplastic syndrome: does it work? Ogata K, et al. **Leuk Lymphoma** 1995 May; 17(5–6):411–5 (44 ref.)

PATHOLOGY

Tissue distribution and tumor localization of effector cells in adoptive immunotherapy of cancer. Basse PH. **APMIS Suppl** 1995;55:1–28 (107 ref.)

TRANSPLANTATION

Interleukin-2 in bone marrow transplantation. Verma UN, et al. **Cancer Treat Res** 1995;76:315–36 (99 ref.)

KILLER CELLS, NATURAL

CYTOLOGY

Development of human NK cells from the immature cell precursors. Poggi A, et al. **Semin Immunol** 1995 Apr; 7(2):61–6 (19 ref.)

ENZYMOLOGY

Granzyme B plays a critical role in cytotoxic lymphocyte-induced apoptosis. Shresta S, et al. **Immunol Rev** 1995 Aug;146:211–21 (32 ref.)

IMMUNOLOGY

Cytotoxic lymphocyte-mediated immunotherapy. Smyth MJ, et al. **Aust N Z J Med** 1995 Dec;25(6):852–8 (57 ref.)

Target cell apoptosis induced by cytotoxic T cells and natural killer cells involves synergy between the pore-forming protein, perforin, and the serine protease, granzyme B. Trapani JA. **Aust N Z J Med** 1995 Dec;25(6):793–9 (63 ref.)

C-type lectins of natural killer cells: carbohydrate ligands and role in tumour cell lysis. Bezouška K. **Biochem Soc Trans** 1996 Feb;24(1):156–61 (24 ref.)

Natural killer cells and cancer. Brittenden J, et al. **Cancer** 1996 Apr 1;77(7):1226–43 (266 ref.)

Role of human natural killer cells in health and disease. Whiteside TL, et al. **Clin Diagn Lab Immunol** 1994 Mar; 1(2):125–33 (76 ref.)

Humoral immune response and natural killer activity in patients with mixed cryoglobulinemia. Gabrielli A, et al. **Clin Exp Rheumatol** 1995 Nov–Dec;13 Suppl 13:S95–9 (21 ref.)

Natural killer cells. Right-side-up and up-side-down

NK-cell receptors. Yokoyama WM. **Curr Biol** 1995 Sep 1;5(9):982-5 (33 ref.)
Mouse NK1+ T cells. Bendelac A. **Curr Opin Immunol** 1995 Jun;7(3):367-74 (54 ref.)
The role of natural killer cells in transplantation. Lanier LL. **Curr Opin Immunol** 1995 Oct;7(5):626-31 (65 ref.)
The role of natural killer cells in immune surveillance of cancer. Whiteside TL, et al. **Curr Opin Immunol** 1995 Oct; 7(5):704-10 (57 ref.)
Lymphocyte-mediated cytotoxicity in vitro and in vivo: mechanisms and significance. Kägi D, et al. **Immunol Rev** 1995 Aug;146:95-115 (102 ref.)
Unlocking the secrets of CTL and NK cells. Berke G. **Immunol Today** 1995 Jul;16(7):343-6 (14 ref.)
Regulation of NK susceptibility by target cell class I MHC molecules. Saxena RK, et al. **Indian J Biochem Biophys** 1995 Aug;32(4):179-85 (91 ref.)
Alternative triggering molecules and single chain bispecific antibodies. Segal DM, et al. **J Hematother** 1995 Oct; 4(5):377-82 (31 ref.)
The role of natural killer cells in the treatment of chronic myeloid leukemia. Silla LM, et al. **J Hematother** 1995 Aug; 4(4):269-79 (103 ref.)
The enigma of the natural killer cell. Gumperz JE, et al. **Nature** 1995 Nov 16;378(6554):245-8 (90 ref.)
Hybrid resistance: 'negative' and 'positive' signaling of murine natural killer cells. Bennett M, et al. **Semin Immunol** 1995 Apr;7(2):121-7 (24 ref.)
Inhibitory effects of class I molecules on murine NK cells: speculations on function, specificity and self-tolerance. Raulet DH, et al. **Semin Immunol** 1995 Apr;7(2):103-7 (24 ref.)
Missing self recognition by natural killer cells in MHC class I transgenic mice. A 'receptor calibration' model for how effector cells adapt to self. Sentman CL, et al. **Semin Immunol** 1995 Apr;7(2):109-19 (45 ref.)
Natural killer cells wear different hats: effector cells of innate resistance and regulatory cells of adaptive immunity and of hematopoiesis. Trinchieri G. **Semin Immunol** 1995 Apr; 7(2):83-8 (43 ref.)
[Interaction between natural killer (NK) cells and the major histocompatibility system] Bishara A, et al. **Harefuah** 1996 Mar 1;130(5):322-6 (45 ref.) **(Heb)**
[Antimicrobial activity of NK cells] Cavallo R. **G Batteriol Virol Immunol** 1992 Jan-1993 Dec; 85(1-12):35-46 (60 ref.) (Eng. Abstr.) **(Ita)**

METABOLISM

Receptors for HLA class I molecules in human NK cells. Bottino C, et al. **Semin Immunol** 1995 Apr;7(2):67-73 (23 ref.)
NK cell recognition of major histocompatibility complex class I molecules. Lanier LL, et al. **Semin Immunol** 1995 Apr;7(2):75-82 (67 ref.)
A family of murine NK cell receptors specific for target cell MHC class I molecules. Yokoyama WM, et al. **Semin Immunol** 1995 Apr;7(2):89-101 (93 ref.)

PATHOLOGY

Lymphoproliferative disorders of natural killer cells. Oshimi K. **Int J Hematol** 1996 Jun;63(4):279-90 (108 ref.)
B-cell lymphoproliferative disorder complicated by a natural killer cell lymphoproliferative disorder of granular lymphocytes associated with T-cell gene rearrangement: case report and review of the literature. Dunphy CH, et al. **Mod Pathol** 1995 Oct;8(8):803-10 (30 ref.)

PHYSIOLOGY

Role of human natural killer cells in health and disease. Whiteside TL, et al. **Clin Diagn Lab Immunol** 1994 Mar; 1(2):125-33 (76 ref.)
The use of conditioning to probe for CNS pathways that regulate fever and NK cell activity. Hiramoto R, et al. **Int J Neurosci** 1996 Feb;84(1-4):229-45 (55 ref.)

VIROLOGY

Epstein-Barr virus in T and natural killer (NK) cell non-Hodgkin's lymphomas. Kanavaros P, et al. **Leukemia** 1996 Jun;10 Suppl 2:s84-7 (44 ref.)

KILLER PHENOTYPE see **PHENOTYPE**

KIMURA DISEASE see **ANGIOLYMPHOID HYPERPLASIA WITH EOSINOPHILIA**

KINASES see **PHOSPHOTRANSFERASES**

KINDLING (NEUROLOGY)

Sensitization induced by kindling and kindling-related phenomena as a model for multiple chemical sensitivity. Rossi J 3rd. **Toxicology** 1996 Jul 17;111(1-3):87-100 (93 ref.)

PHYSIOLOGY

The development of psychosis in epilepsy: a re-examination of the kindling hypothesis. Smith PF, et al. **Behav Brain Res** 1996 Feb;75(1-2):59-66 (94 ref.)
Analyses of the molecular basis of kindling development. McNamara JO. **Psychiatry Clin Neurosci** 1995 Jun; 49(3):S175-8 (33 ref.)
A cognitive science perspective on kindling and episode sensitization in recurrent affective disorder. Segal ZV, et al. **Psychol Med** 1996 Mar;26(2):371-80 (70 ref.)

KINESICS

[The prosody of speech and wordless messages] Toivanen JH, et al. **Duodecim** 1995;111(7):606-10 (23 ref.) **(Fin)**

KINESIN

Motor proteins. 1: kinesins. Bloom GS, et al. **Protein Profile** 1994;1(10):1059-116 (309 ref.)

CHEMISTRY

Kinesin-II, a membrane traffic motor in axons, axonemes, and spindles. Scholey JM. **J Cell Biol** 1996 Apr;133(1):1-4 (29 ref.)

METABOLISM

The movement of kinesin along microtubules. Howard J. **Annu Rev Physiol** 1996;58:703-29 (77 ref.)
Biochemical and functional diversity of microtubule motors in the nervous system. Brady ST, et al. **Curr Opin Neurobiol** 1995 Oct;5(5):551-8 (65 ref.)
Targeting of motor proteins. Vallee RB, et al. **Science** 1996 Mar 15;271(5255):1539-44 (108 ref.)

PHYSIOLOGY

The kinetic cycles of myosin, kinesin, and dynein. Hackney DD. **Annu Rev Physiol** 1996;58:731-50 (126 ref.)
Roles for microtubules and kinesin in membrane traffic between the endoplasmic reticulum and the Golgi complex. Lippincott-Schwartz J, et al. **Biochem Soc Trans** 1995 Aug; 23(3):544-8 (24 ref.)
Kinesin-related proteins at mitotic spindle poles: function and regulation. Walczak CE, et al. **Cell** 1996 Jun 28; 85(7):943-6 (18 ref.)
Flagellar kinesins: new moves with an old beat. Bernstein M. **Cell Motil Cytoskeleton** 1995;32(2):125-8 (27 ref.)
Motor proteins 1: kinesins. Bloom GS, et al. **Protein Profile** 1995;2(10):1105-71 (481 ref.)

KINESTHESIS

Motor problems in children with developmental coordination disorder: review of the literature. Willoughby C, et al. **Am J Occup Ther** 1995 Sep;49(8):787-94 (40 ref.)

KINETICS, DRUG see **PHARMACOKINETICS**

KINETOCHORES

PHYSIOLOGY

Structure and function of kinetochores in budding yeast. Hyman AA, et al. **Ann Rev Cell Dev Biol** 1995;11:471-95 (97 ref.)
Microtubule dynamics. Kinetochores get a grip. Hyman AA. **Curr Biol** 1995 May 1;5(5):483-4 (15 ref.)
The Saccharomyces cerevisiae kinetochore. Lechner J, et al. **FEBS Lett** 1996 Jun 24;389(1):70-4 (42 ref.)
The centromere: kinetochore complex. Vig BK. **Southeast Asian J Trop Med Public Health** 1995;26 Suppl 1:68-76 (48 ref.)

KINETOPLASTIDA

GENETICS

Mechanism and evolution of RNA editing in kinetoplastida. Arts GJ, et al. **Biochim Biophys Acta** 1996 Jun 3; 1307(1):39-54 (150 ref.)

PHYSIOLOGY

Protein trafficking in kinetoplastid protozoa. Clayton C, et al. **Microbiol Rev** 1995 Sep;59(3):325-44 (250 ref.)

KININASE II see **PEPTIDYL-DIPEPTIDASE A**

KININASE II INHIBITORS see **ANGIOTENSIN-CONVERTING ENZYME INHIBITORS**

KININOGENASE see **KALLIKREIN**

KININOGENS

ANALYSIS

[Kallikrein, kininogen and kinin in health and disease] Omata K, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:721-5 (17 ref.) **(Jpn)**
[Fletcher factor, Fitzgerald factor] Saito H. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:167-70 (10 ref.) **(Jpn)**

KININOGENS, HIGH MOLECULAR WEIGHT see **KININOGENS**

KININOGENS, LOW MOLECULAR WEIGHT see **KININOGENS**

KININS

ANALYSIS

[Kallikrein, kininogen and kinin in health and disease] Omata K, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:721-5 (17 ref.) **(Jpn)**

METABOLISM

Angiotensin converting enzyme (ACE) inhibitors and kinin metabolism: evidence that ACE inhibitors may inhibit a kininase other than ACE. Campbell DJ. **Clin Exp Pharmacol Physiol** 1995 Dec;22(12):903-11 (99 ref.)

PHYSIOLOGY

New aspects on the role of kinins in neurogenic inflammation. Geppetti P, et al. **Can J Physiol Pharmacol** 1995 Jul; 73(7):843-7 (30 ref.)
Kallikreins and kinins. Molecular characteristics and cellular and tissue responses. Margolius HS. **Diabetes** 1996 Jan;45 Suppl 1:S14-9 (53 ref.)

KINKY HAIR SYNDROME

Copper: not too little, not too much, but just right. Based on the triennial Pewterers Lecture delivered at the National Hospital for Neurology, London, on 23 March 1995. Walshe JM. **J R Coll Physicians Lond** 1995 Jul-Aug; 29(4):280-8 (57 ref.)
[Inherited neurological disease--relationship between an essential trace elements and Wilson/Menkes disease] Ozawa M, et al. **Nippon Rinsho** 1996 Jan;54(1):117-22 (18 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Menkes and Wilson diseases. Monaco AP, et al. **Adv Genet** 1995;33:233-53 (91 ref.)
Genetic and molecular basis for copper toxicity. Harris ZL, et al. **Am J Clin Nutr** 1996 May;63(5):836S-41S (53 ref.)

KIT PROTO-ONCOGENE PROTEINS see **PROTO-ONCOGENE PROTEINS C-KIT**

KLATSKIN'S TUMOR

[Klatskin tumor] Kakita A, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):24-6 (15 ref.) **(Jpn)**

SURGERY

Current status of surgery for Klatskin tumors. Lillemoe KD. **Curr Opin Gen Surg** 1994;:161-7 (25 ref.)

KLEBSIELLA

PATHOGENICITY

[The adhesive activity of clinical strains of Klebsiella] Bondarenko VM, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Mar-Apr; (2):104-9 (50 ref.) **(Rus)**

KLEBSIELLA AEROGENES see **KLEBSIELLA PNEUMONIAE**

KLEBSIELLA INFECTIONS

[Falciform ligament abscess] Kaneko K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):61-2 (14 ref.) **(Jpn)**
[K-antigen as a marker of Klebsiella pneumoniae and its use in clinical and epidemiological analysis (literature review)] Priamukhina NS, et al. **Klin Lab Diagn** 1996 Mar-Apr; (2):47-9 (29 ref.) **(Rus)**

KLEBSIELLA PNEUMONIAE

[K-antigen as a marker of Klebsiella pneumoniae and its use in clinical and epidemiological analysis (literature review)] Priamukhina NS, et al. **Klin Lab Diagn** 1996 Mar-Apr; (2):47-9 (29 ref.) **(Rus)**

DRUG EFFECTS

Antimicrobial-resistant pathogens in the 1990s. Jacoby GA. **Annu Rev Med** 1996;47:169-79 (62 ref.)
Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Craig WA. **Diagn Microbiol Infect Dis** 1995 May-Jun;22(1-2):89-96 (31 ref.)

KLEIN-WAARDENBURG SYNDROME see **WAARDENBURG'S SYNDROME**

KLEPTOMANIA see **IMPULSE CONTROL DISORDERS**

KLINEFELTER'S SYNDROME

COMPLICATIONS

[Klinefelter's syndrome as the only pathology associated with priapism. A clinical case] Fernández Fernández A, et al. **Arch Esp Urol** 1995 Nov;48(9):962–3 (4 ref.) (Eng. Abstr.) **(Spa)**

KLORAMFENIKOL see **CHLORAMPHENICOL**

KLUYVEROMYCES

METABOLISM

Reoxidation of the NADPH produced by the pentose phosphate pathway is necessary for the utilization of glucose by Kluyveromyces lactis rag2 mutants. González Siso MI, et al. **FEBS Lett** 1996 May 27;387(1):7–10 (27 ref.)

KNEE

[Atypical algodystrophy of the knee: apropos 2 partial cases] Macho Fernández JM, et al. **Rev Clin Esp** 1996 May; 196(5):306–9 (28 ref.) (Eng. Abstr.) **(Spa)**

ABNORMALITIES

Genu varum and genu valgum in children: differential diagnosis and guidelines for evaluation. Greene WB. **Compr Ther** 1996 Jan;22(1):22–9 (15 ref.)

ANATOMY & HISTOLOGY

Magnetic resonance imaging of the musculoskeletal system. Part 4. The knee. Crotty JM, et al. **Clin Orthop** 1996 Sep; (330):288–303 (75 ref.)

PATHOLOGY

MRI of posterior knee masses. Butler MG, et al. **Skeletal Radiol** 1996 May;25(4):309–17 (11 ref.)

A case of juxta-articular myxoma of the knee. Daluiski A, et al. **Skeletal Radiol** 1995 Jul;24(5):389–91 (23 ref.)

PHYSIOLOGY

Concentric and eccentric knee extension strength in older and younger men and women. Porter MM, et al. **Can J Appl Physiol** 1995 Dec;20(4):429–39 (38 ref.)

Knee joint function, meniscal disease, and osteoarthritis. Bellenger CR. **Vet Q** 1995 Apr;17 Suppl 1:S5–6 (6 ref.)

KNEE INJURIES

Knee injuries in young athletes. Smith AD, et al. **Clin Sports Med** 1995 Jul;14(3):629–50 (76 ref.)

Diagnosis and treatment of common knee injuries in athletes. Honari DB, et al. **Wis Med J** 1996 Jun;95(6):361–6 (20 ref.)

[Arthroscopy of the knee joint. Conclusions and recommendations] **Rev Chir Orthop Reparatrice Appar Mot** 1996;82(2):175–86 (0 ref.) **(Fre)**

COMPLICATIONS

Pathological infrapatellar plica: a report of two cases and literature review. Kim SJ, et al. **Arthroscopy** 1996 Apr; 12(2):236–9 (18 ref.)

DIAGNOSIS

Magnetic resonance imaging of knee ligaments. Marks PH, et al. **Am J Knee Surg** 1995 Fall;8(4):181–7 (33 ref.)

Magnetic resonance imaging of the musculoskeletal system. Part 4. The knee. Crotty JM, et al. **Clin Orthop** 1996 Sep; (330):288–303 (75 ref.)

MR imaging of knee ligaments. Pope TL Jr. **J South Orthop Assoc** 1996 Spring;5(1):46–62 (73 ref.)

Magnetic resonance imaging of the extensor mechanism. Sonin AH. **Magn Reson Imaging Clin N Am** 1994 Aug; 2(3):401–11 (30 ref.)

Magnetic resonance imaging of bone marrow and osteochondral injury. Vellet D. **Magn Reson Imaging Clin N Am** 1994 Aug;2(3):413–23 (22 ref.)

[Posterolateral rotatory knee joint instability. I. Anatomy of injuries and diagnosis] Latosiewicz R. **Chir Narzadow Ruchu Ortop Pol** 1996;61(2):183–8 (15 ref.) (Eng. Abstr.) **(Pol)**

EPIDEMIOLOGY

Knee injury patterns among men and women in collegiate basketball and soccer. NCAA data and review of literature. Arendt E, et al. **Am J Sports Med** 1995 Nov–Dec; 23(6):694–701 (34 ref.)

Athletic knee injuries. Similarities and differences between Asian and Western experience. Maffulli N, et al. **Clin Orthop** 1996 Feb;(323):98–105 (90 ref.)

ETIOLOGY

Noncontact knee dislocation in a female basketball player: a case report. Putukian M, et al. **Clin J Sport Med** 1995 Oct;5(4):258–61 (15 ref.)

PREVENTION & CONTROL

Use of knee braces in sport. Current recommendations [editorial] Albright JP, et al. **Sports Med** 1995 Nov; 20(5):281–301 (49 ref.)

REHABILITATION

Rehabilitation following arthroscopic meniscectomy. St-Pierre DM. **Sports Med** 1995 Nov;20(5):338–47 (147 ref.)

SURGERY

Revision ACL surgery. Etiology, indications, techniques, and results. Johnson DL, et al. **Am J Knee Surg** 1995 Fall; 8(4):155–67 (106 ref.)

Posterior cruciate ligament injuries. New treatment options. Miller MD, et al. **Am J Knee Surg** 1995 Fall;8(4):145–54 (53 ref.)

Graft selection in knee surgery. Current concepts. Safran MR. **Am J Knee Surg** 1995 Fall;8(4):168–80 (115 ref.)

Biologic incorporation of allograft anterior cruciate ligament replacements. Jackson DW, et al. **Clin Orthop** 1996 Mar; (324):126–33 (26 ref.)

[The "gold standard" in cruciate ligament replacement] Benedetto KP. **Chirurg** 1995 Nov;66(11):1061–70 (57 ref.) (Eng. Abstr.) **(Ger)**

[Cruciate ligament allograft transplant: a reliable alternative?] Lobenhoffer P, et al. **Chirurg** 1995 Nov;66(11):1071–8 (69 ref.) (Eng. Abstr.) **(Ger)**

[Sense and nonsense of cruciate ligament prostheses] Neumann K, et al. **Chirurg** 1995 Nov;66(11):1079–84 (32 ref.) (Eng. Abstr.) **(Ger)**

[Possibilities and limits of conservative management of cruciate ligament injuries] Paar O, et al. **Chirurg** 1995 Nov; 66(11):1050–60 (48 ref.) (Eng. Abstr.) **(Ger)**

[Arthroscopic holmium-YAG laser compared to conventional procedures on the knee joint. 2-year results of a randomized prospective study] Lübbers C, et al. **Orthopade** 1996 Feb;25(1):64–72 (35 ref.) (Eng. Abstr.) **(Ger)**

[Arthroscopic approaches to reconstruction of the cruciate ligament: refresher course] Kohn D. **Sportverletz Sportschaden** 1995 Dec;9(4):A31–42 (0 ref.) **(Ger)**

[Acute isolated ventral dislocation of the head of the fibula] Kohler G, et al. **Unfallchirurg** 1996 Mar;99(3):221–2 (10 ref.) (Eng. Abstr.) **(Ger)**

[Rupture of the posterior cruciate ligament: status of current treatment] Lobenhoffer P, et al. **Unfallchirurg** 1996 Jun; 99(6):382–99 (118 ref.) (Eng. Abstr.) **(Ger)**

[Progression of arthrosis after alloplasty—what factors play a role?] Küllmer K, et al. **Unfallchirurgie** 1996 Jun; 22(3):130–8 (36 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Traumatic dislocation of the knee: a review of the literature. Ghalambor N, et al. **Bull Hosp Jt Dis** 1995;54(1):19–24 (39 ref.)

VETERINARY

Knee joint function, meniscal disease, and osteoarthritis. Bellenger CR. **Vet Q** 1995 Apr;17 Suppl 1:S5–6 (6 ref.)

KNEE JOINT

Invasive staphylococcal infections complicating percutaneous transluminal coronary angioplasty: three cases and review. Cleveland KO, et al. **Clin Infect Dis** 1995 Jul;21(1):93–6 (17 ref.)

Chronic patellofemoral instability. Dandy DJ. **J Bone Joint Surg Br** 1996 Mar;78(2):328–35 (21 ref.)

Indomethacin hastens large joint osteoarthritis in humans—how strong is the evidence? [editorial] Doherty M, et al. **J Rheumatol** 1995 Nov;22(11):2013–6 (32 ref.)

Malignant joint effusions secondary to solid tumor metastasis. Munn RK, et al. **J Rheumatol** 1995 May;22(5):973–5 (15 ref.)

Emphysematous septic arthritis: case report and review of the literature. Roy R, et al. **J Rheumatol** 1995 Sep; 22(9):1776–8 (29 ref.)

Challenges for clinical decision making in the management of osteoarthritis of the knee [editorial; comment] Williams MH. **J Rheumatol** 1996 Apr;23(4):586–9 (63 ref.) Comment on: J Rheumatol 1996 Apr;23(4):730–8.

Idiopathic eosinophilic synovitis. Case report and review of the literature. Atanes A, et al. **Scand J Rheumatol** 1996; 25(3):183–5 (13 ref.)

[Arthroscopy of the knee joint. Conclusions and recommendations] **Rev Chir Orthop Reparatrice Appar Mot** 1996;82(2):175–86 (0 ref.) **(Fre)**

ABNORMALITIES

Joint dislocation and cerebral anomalies are consistently associated with oral-facial-digital syndrome type IV. Digilio MC, et al. **Clin Genet** 1995 Sep;48(3):156–9 (11 ref.)

ANATOMY & HISTOLOGY

MR imaging of knee ligaments. Pope TL Jr. **J South Orthop Assoc** 1996 Spring;5(1):46–62 (73 ref.)

MR imaging of the menisci. Fundamentals of anatomy and pathology. Firooznia H, et al. **Magn Reson Imaging Clin N Am** 1994 Aug;2(3):325–47 (46 ref.)

Medial and lateral supporting structures of the knee. Normal MR imaging anatomy and pathologic findings. Ruiz ME, et al. **Magn Reson Imaging Clin N Am** 1994 Aug;2(3):381–99 (18 ref.)

BLOOD SUPPLY

Microvascular architecture and exchange in synovial joints. Levick JR. **Microcirculation** 1995 Sep;2(3):217–33 (92 ref.)

Synovial perfusion in the human knee: a methodologic analysis. Simkin PA, et al. **Semin Arthritis Rheum** 1995 Aug;25(1):56–66 (33 ref.)

MICROBIOLOGY

Lemierre syndrome: postanginal sepsis. Leugers CM, et al. **J Am Board Fam Pract** 1995 Sep–Oct;8(5):384–91 (40 ref.)

PATHOLOGY

Magnetic resonance imaging of the knee: diagnostic performance studies. Mackenzie R, et al. **Clin Radiol** 1996 Apr;51(4):251–7 (50 ref.)

Magnetic resonance imaging of bone marrow disorders of the knee. Beltran J, et al. **Magn Reson Imaging Clin N Am** 1994 Aug;2(3):463–73 (41 ref.)

Kinematic magnetic resonance imaging of the knee. Brown SM, et al. **Magn Reson Imaging Clin N Am** 1994 Aug; 2(3):441–9 (24 ref.)

Magnetic resonance imaging of the meniscus. Advanced concepts. Fitzgerald SW. **Magn Reson Imaging Clin N Am** 1994 Aug;2(3):349–64 (49 ref.)

Magnetic resonance imaging of the knee. A senior musculoskeletal radiologist's perspective. Kaye JJ. **Magn Reson Imaging Clin N Am** 1994 Aug;2(3):497–500 (40 ref.)

Cost effectiveness of magnetic resonance imaging of the knee. Ruwe PA, et al. **Magn Reson Imaging Clin N Am** 1994 Aug;2(3):475–9 (25 ref.)

Magnetic resonance imaging in synovial disorders and arthropathy of the knee. White EM. **Magn Reson Imaging Clin N Am** 1994 Aug;2(3):451–61 (11 ref.)

Synovial hemangioma: imaging features in eight histologically proven cases, review of the literature, and differential diagnosis. Greenspan A, et al. **Skeletal Radiol** 1995 Nov;24(8):583–90 (32 ref.)

PHYSIOPATHOLOGY

Postpoliomyelitis syndrome problems of knee function: a review. Grant AD, et al. **Bull Hosp Jt Dis** 1993–95; 53(4):27–9 (16 ref.)

Electromyography and biomechanics of a dynamic knee brace for anterior cruciate ligament deficiency. Acierno SP, et al. **Orthopedics** 1995 Nov;18(11):1101–7 (33 ref.)

The role of quadriceps exercise in the treatment of patellofemoral pain syndrome. Callaghan MJ, et al. **Sports Med** 1996 May;21(5):384–91 (55 ref.)

[Biomechanical changes in the hip, femur and knee joint after removal of a tensor fasciae latae flap] Lattermann C, et al. **Handchir Mikrochir Plast Chir** 1996 Mar;28(2):76–82 (33 ref.) (Eng. Abstr.) **(Ger)**

RADIOGRAPHY

Recommended methodology for assessing the progression of osteoarthritis of the hip and knee joints. Dieppe PA. **Osteoarthritis Cartilage** 1995 Jun;3(2):73–7 (27 ref.)

Hemophilic arthropathy. Lan HH, et al. **Radiol Clin North Am** 1996 Mar;34(2):446–50 (16 ref.)

SURGERY

Medial compartment arthrosis of the knee. Dearborn JT, et al. **Am J Orthop** 1996 Jan;25(1):18–26 (64 ref.)

Complications of extensor mechanism surgery for patellar malalignment. Flandry F, et al. **Am J Orthop** 1995 Jul; 24(7):534–43 (25 ref.)

Contemporary magnetic resonance imaging of the knee. The orthopedic surgeon's perspective. Bonamo JJ, et al. **Magn Reson Imaging Clin N Am** 1994 Aug;2(3):481–95 (99 ref.)

Isolated patellofemoral arthritis. Dennis DA. **Orthopedics** 1995 Sep;18(9):893–5 (33 ref.)

Limb salvage procedures in osteosarcomas around the knee joint. Rodriguez Merchán EC, et al. **Rev Paul Med** 1994 Oct–Dec;112(4):661–7 (42 ref.)

[Primary arthrodesis of the knee joint] Gossé F, et al. **Orthopade** 1996 Apr;25(2):146–52 (27 ref.) (Eng. Abstr.) **(Ger)**

[Arthrodesis following revision of a knee endoprosthesis. Literature review 1984–1994] Kohn D, et al. **Orthopade** 1996 Apr;25(2):153–7 (27 ref.) (Eng. Abstr.) **(Ger)**

[Arthroscopic holmium-YAG laser compared to conventional procedures on the knee joint. 2-year results of a randomized prospective study] Lübbers C, et al. **Orthopade** 1996 Feb;25(1):64–72 (35 ref.) (Eng. Abstr.) **(Ger)**

KNEE JOINT

[Stabilization of interligamentous valgus procedure in tibial head osteotomy using staples] Zügel N, et al. **Z Orthop Ihre Grenzgeb** 1995 Sep-Oct;133(5):437-41 (31 ref.) (Eng. Abstr.) **(Ger)**

[Current advances and future direction of arthroscopic surgery for disorders in the knee joint] Yasuda K. **Hokkaido Igaku Zasshi** 1995 May;70(3):383-9 (10 ref.) (Eng. Abstr.) **(Jpn)**

KNEE PROSTHESIS

Should total prosthetization of the patella be used in knee surgery? A review of the literature and personal experience. Murena PF, et al. **Chir Organi Mov** 1995 Jul-Aug; 80(3):323-8 (30 ref.)

Prosthetic joint infection due to Mycobacterium tuberculosis: report of three cases. Tokumoto JI, et al. **Clin Infect Dis** 1995 Jul;21(1):134-6 (14 ref.)

Factors influencing the longevity of UHMWPE tibial components. Heim CS, et al. **Instr Course Lect** 1996; 45:303-12 (110 ref.)

Periprosthetic infections due to Mycobacterium tuberculosis in patients with no prior history of tuberculosis. Spinner RJ, et al. **J Arthroplasty** 1996 Feb;11(2):217-22 (46 ref.)

Review on tension in the natural and reconstructed anterior cruciate ligament. Andersen HN, et al. **Knee Surg Sports Traumatol Arthrosc** 1994;2(4):192-202 (90 ref.)

Revision total knee arthroplasty: how much constraint is necessary? Cuckler JM. **Orthopedics** 1995 Sep;18(9):932-3, 936 (11 ref.)

Isolated patellofemoral arthritis. Dennis DA. **Orthopedics** 1995 Sep;18(9):893-5 (33 ref.)

[15 years experience with the Ti-6Al-7Nb alloy for joint prostheses] Semlitsch M, et al. **Biomed Tech (Berl)** 1995 Dec;40(12):347-55 (38 ref.) (Eng. Abstr.) **(Ger)**

[Knee arthroplasty. Nine out of ten patients experience relief from pain and improved quality of life] Weidenhielm L. **Lakartidningen** 1996 Mar 6;93(10):893-6 (18 ref.) **(Swe)**

ADVERSE EFFECTS

Lymphadenopathy associated with total joint prostheses. A report of two cases and a review of the literature [see comments] Benz EB, et al. **J Bone Joint Surg Am** 1996 Apr;78(4):588-93 (28 ref.) Comment in: J Bone Joint Surg Am 1996 Apr;78(4):479-81.

REHABILITATION

Total hip and knee replacement treatment programs: a report using consensus. Enloe LJ, et al. **J Orthop Sports Phys Ther** 1996 Jan;23(1):3-11 (20 ref.)

STANDARDS

Survivorship analysis of the Kinematic Stabilizer total knee replacement: a 10- to 14-year follow-up. Emmerson KP, et al. **J Bone Joint Surg Br** 1996 May;78(3):441-5 (11 ref.)

KNEE REPLACEMENT, TOTAL see **KNEE PROSTHESIS**

KNOCKOUT MICE see **MICE, KNOCKOUT**

KNOWLEDGE ACQUISITION (COMPUTER) see **ARTIFICIAL INTELLIGENCE**

KNOWLEDGE, ATTITUDES, PRACTICE

Wellness and HIV: developing a model for progression from theoretical knowledge about psychosocial factors to application. Rayner-Brosnan D. **Int J Immunopharmacol** 1995 Aug;17(8):663-76 (95 ref.)

Adolescent condom use, the health belief model, and the prevention of sexually transmitted disease. Hiltabiddle SJ. **J Obstet Gynecol Neonatal Nurs** 1996 Jan;25(1):61-6 (36 ref.)

Nurses' attitudes about acquired immunodeficiency syndrome care: what research tells us. Bennett JA. **J Prof Nurs** 1995 Nov-Dec;11(6):339-50 (67 ref.)

Barriers to cancer screening. Womeodu RJ, et al. **Med Clin North Am** 1996 Jan;80(1):115-33 (81 ref.)

Cancer fatalism among African-Americans: a review of the literature. Powe BD. **Nurs Outlook** 1996 Jan-Feb; 44(1):18-21 (25 ref.)

College health providers' knowledge, attitudes, and management practices of genital HPV infection. Linnehan MJ, et al. **Nurse Pract** 1996 May;21(5):122-4, 127-9 (55 ref.)

Reaching out to the African American community through innovative strategies. Robinson KD, et al. **Oncol Nurs Forum** 1995 Oct;22(9):1383-91 (28 ref.)

Self-efficacy in pediatric resuscitation: implications for education and performance. Maibach EW, et al. **Pediatrics** 1996 Jan;97(1):94-9 (33 ref.)

Physicians' prevention counseling behaviors: current status and future directions [editorial; comment] Frank E, et al. **Prev Med** 1995 Nov;24(6):543-5 (26 ref.) Comment on: Prev Med 1995 Nov;24(6):546-2.

Health care workers and HIV/AIDS: a critical review of the literature. Horsman JM, et al. **Soc Sci Med** 1995 Dec; 41(11):1535-67 (164 ref.)

Withdrawal: a review of the literature and an agenda for research [see comments] Rogow D, et al. **Stud Fam Plann** 1995 May-Jun;26(3):140-53 (92 ref.) Comment in: Stud Fam Plann 1995 Sep-Oct;26(5):305-6.

Are our information, education and communication-based interventions too superficial? Clarke I. **Trop Doct** 1995 Oct; 25(4):167-70 (7 ref.)

[AIDS-related knowledge and sex behavior: a review of Italian studies of young people] Aloisi MS, et al. **Ann Ig** 1995 Sep-Oct;7(5):349-58 (38 ref.) (Eng. Abstr.) **(Ita)**

KNOWLEDGE BASES (COMPUTER) see **ARTIFICIAL INTELLIGENCE**

KNOWLEDGE REPRESENTATION (COMPUTER) see **ARTIFICIAL INTELLIGENCE**

KO-1173 see **MEXILETINE**

KOCK POUCH see **PROCTOCOLECTOMY, RESTORATIVE**

KOEHLER'S DISEASE see **OSTEOCHONDRITIS**

KOLMOGOROV-SMIRNOV TEST see **STATISTICS, NONPARAMETRIC**

KORO

CLASSIFICATION

The definition and classification of Koro. Chowdhury AN. **Cult Med Psychiatry** 1996 Mar;20(1):41-65 (147 ref.)

EPIDEMIOLOGY

A critical review of Chinese Koro. Cheng ST. **Cult Med Psychiatry** 1996 Mar;20(1):67-82 (26 ref.)

ETIOLOGY

A critical review of Chinese Koro. Cheng ST. **Cult Med Psychiatry** 1996 Mar;20(1):67-82 (26 ref.)

PSYCHOLOGY

Transculturation, psychosis and koro symptoms. Rosca-Rebaudengo P, et al. **Isr J Psychiatry Relat Sci** 1996; 33(1):54-62 (41 ref.)

KORSAKOFF PSYCHOSIS see **ALCOHOL AMNESTIC DISORDER**

KORSAKOFF SYNDROME see **ALCOHOL AMNESTIC DISORDER**

KRABBE'S DISEASE see **LEUKODYSTROPHY, GLOBOID CELL**

KRAIT see **BUNGARUS**

KRAUROSIS PENIS see **BALANITIS**

KRAUROSIS VULVAE

ETIOLOGY

Lichen sclerosus. Leibowitch M. **Semin Dermatol** 1996 Mar; 15(1):42-6 (12 ref.)

KRAUSE'S END BULBS see **MECHANORECEPTORS**

KRILL see **CRUSTACEA**

KRUSKAL-WALLIS H STATISTIC see **STATISTICS, NONPARAMETRIC**

KRYPTOSTEROL see **LANOSTEROL**

KUFS DISEASE see **NEURONAL CEROID-LIPOFUSCINOSIS**

KUNITZ PANCREATIC TRYPSIN INHIBITOR see **APROTININ**

KUNJIN VIRUS see **ENCEPHALITIS VIRUSES, JAPANESE**

KUPFFER CELLS

CYTOLOGY

Lymphocyte and macrophage populations in the liver. Bioulac-Sage P, et al. **Hepatogastroenterology** 1996 Jan-Feb;43(7):4-14 (35 ref.)

IMMUNOLOGY

The role of bacterial translocation on Kupffer cell immune function following hemorrhage. Chaudry IH, et al. **Prog Clin Biol Res** 1995;392:209-18 (54 ref.)

PHYSIOLOGY

Mediators of hepatic fibrogenesis. Gressner AM. **Hepatogastroenterology** 1996 Jan-Feb;43(7):92-103 (84 ref.)

KWASHIORKOR

[Malnutrition] Hosoda S, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):297-300 (9 ref.) **(Jpn)**

[Kwashiorkor syndrome] Nakajo S, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):11-3 (17 ref.) **(Jpn)**

ETIOLOGY

New views on the pathogenesis of kwashiorkor: methionine and other amino acids. Roediger WE. **J Pediatr Gastroenterol Nutr** 1995 Aug;21(2):130-6 (75 ref.)

KYASANUR FOREST DISEASE VIRUS see **ENCEPHALITIS VIRUSES, TICK-BORNE**

KYPHOSIS

[Kyphoscoliosis: etiology, pathology, complications and treatment] Malawski S. **Chir Narzadow Ruchu Ortop Pol** 1995;60(4):269-74 (23 ref.) (Eng. Abstr.) **(Pol)**

CONGENITAL

Congenital spinal deformity. Winter RB, et al. **Instr Course Lect** 1996;45:117-27 (47 ref.)

Progressive kyphosis and neurologic compromise complicating spondylothoracic dysplasia in infancy (Jarcho-Levin syndrome). Mooney JF 3rd, et al. **Spine** 1995 Sep 1;20(17):1938-42 (8 ref.)

MICROBIOLOGY

Severe kyphotic deformity in tuberculosis of the spine. Tuli SM. **Int Orthop** 1995;19(5):327-31 (24 ref.)

L3T4 ANTIGENS see **ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE**

L-MYC GENES see **GENES, MYC**

L-MYC PROTEINS see **PROTO-ONCOGENE PROTEINS C-MYC**

L SELECTIN see **L-SELECTIN**

LABELING, DRUG see **DRUG LABELING**

LABELING, FOOD see **FOOD LABELING**

LABOR

see related
FETAL MONITORING
OXYTOCICS
TRIAL OF LABOR

Intrapartum fetal pulse oximetry: past, present, and future. Dildy GA, et al. **Am J Obstet Gynecol** 1996 Jul;175(1):1-9 (57 ref.)

Birth under water--to breathe or not to breathe. Johnson P. **Br J Obstet Gynaecol** 1996 Mar;103(3):202-8 (37 ref.)

The active mismanagement of labour [comment] Oláh KS, et al. **Br J Obstet Gynaecol** 1996 Aug;103(8):729-31 (12 ref.) Comment on: Br J Obstet Gynaecol 1996 Aug;103(8):763-8. Comment on: Br J Obstet Gynaecol 1996 Aug;103(8):769-75.

Preserving the pelvic floor and perineum during childbirth--elective caesarean section? Sultan AH, et al. **Br J Obstet Gynaecol** 1996 Aug;103(8):731-4 (21 ref.)

The use of ultrasonography in the labor and delivery suite. Benito CW, et al. **Clin Perinatol** 1996 Mar;23(1):117-39 (87 ref.)

Intrapartum use of fetal heart rate monitoring, contraction monitoring, and amnioinfusion. Cusick W, et al. **Clin Perinatol** 1995 Dec;22(4):875-906 (130 ref.)

Medicolegal ramifications of electronic fetal monitoring during labor. Schifrin BS. **Clin Perinatol** 1995 Dec; 22(4):837-54 (42 ref.)

Intrapartum management of breech presentation. Scorza WE. **Clin Perinatol** 1996 Mar;23(1):31-49 (83 ref.)

Management of labor and labor complications. Weinstein D, et al. **Curr Opin Obstet Gynecol** 1995 Dec;7(6):437-41 (37 ref.)

Controversial issues surrounding early postpartum discharge. Brown LP, et al. **Nurs Clin North Am** 1996 Jun;31(2):333-9 (23 ref.)

Retroperitoneal hematoma as a complication of pudendal block. Diagnosis made by computed tomography. Kurzel RB, et al. **West J Med** 1996 Jun;164(6):523-5 (15 ref.)

[Labor and delivery in twin pregnancy] Wirthner D, et al. **Rev Med Suisse Romande** 1996 Apr;116(4):255-60 (49 ref.) **(Fre)**

[A case report of vaginal delivery controlled by epidural anesthesia in a woman with high spinal cord injury] Kase H, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Sep; 47(9):957-60 (14 ref.) **(Jpn)**

[A case report of congenital liver fibrosis tolerated 3 normal deliveries] Yonekawa H, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Mar;93(3):201-5

(10 ref.) **(Jpn)**

DRUG EFFECTS

Epidural analgesia during labor: continuous infusion or patient-controlled administration? Benhamou D. **Eur J Obstet Gynecol Reprod Biol** 1995 May;59 Suppl:S55-6 (9 ref.)

Effects of epidural analgesia on the progress of labor and the mode of delivery. Finster M. **Eur J Obstet Gynecol Reprod Biol** 1995 May;59 Suppl:S31-3 (35 ref.)

Opioids in combination with local anesthetics for epidural analgesia during labor. Vertommen JD. **Eur J Obstet Gynecol Reprod Biol** 1995 May;59 Suppl:S35-8 (23 ref.)

Epidurals redefined in analgesia and anesthesia: a distinction with a difference. Youngstrom PC, et al. **J Obstet Gynecol Neonatal Nurs** 1996 May;25(4):350-4 (14 ref.)

ETHNOLOGY

Cultural aspects of pain in childbearing women. Weber SE. **J Obstet Gynecol Neonatal Nurs** 1996 Jan;25(1):67-72 (20 ref.)

METABOLISM

Glycerophospholipid metabolism and human labour. Rice GE. **Reprod Fertil Dev** 1995;7(3):613-22 (118 ref.)

PHYSIOLOGY

Pathways to parturition. Douglas AJ, et al. **Adv Exp Med Biol** 1995;395:381-94 (69 ref.)

Parturition: activation of stimulatory pathways or loss of uterine quiescence? López Bernal A, et al. **Adv Exp Med Biol** 1995;395:435-51 (107 ref.)

Cervical assessment. Fuentes A, et al. **Clin Obstet Gynecol** 1995 Jun;38(2):224-31 (22 ref.)

Anatomy and physiology of cervical ripening. Leppert PC. **Clin Obstet Gynecol** 1995 Jun;38(2):267-79 (21 ref.)

Relaxin used to produce the cervical ripening of labor. Weiss G. **Clin Obstet Gynecol** 1995 Jun;38(2):293-300 (16 ref.)

Using and archiving the labor curves. Cohen WR, et al. **Clin Perinatol** 1995 Dec;22(4):855-74 (17 ref.)

The nature and consequences of childbirth pain. Brownridge P. **Eur J Obstet Gynecol Reprod Biol** 1995 May;59 Suppl:S9-15 (64 ref.)

Role of patient-controlled epidural analgesia in obstetrics. Gambling DR, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 May;59 Suppl:S39-46 (45 ref.)

Some aspects on the mechanism of human labor and delivery. Husslein P, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 May;59 Suppl:S3-7 (32 ref.)

Parturition and fetal adaptation. Lowe NK, et al. **J Obstet Gynecol Neonatal Nurs** 1996 May;25(4):339-49 (71 ref.)

The Nutrition Society 1994 Silver Medal Lecture. Pregnancy, parturition and neonatal development: interactions between nutrition and thyroid hormones. Symonds ME. **Proc Nutr Soc** 1995 Jul;54(2):329-43 (97 ref.)

Chronic stress--the key to parturition? McMillen IC, et al. **Reprod Fertil Dev** 1995;7(3):499-507 (50 ref.)

Prostaglandins and parturition. Mitchell MD, et al. **Reprod Fertil Dev** 1995;7(3):623-32 (79 ref.)

PSYCHOLOGY

Nursing support of the laboring woman. Hodnett E. **J Obstet Gynecol Neonatal Nurs** 1996 Mar-Apr; 25(3):257-64 (11 ref.)

The experience of maternity in a woman's life. Simkin P. **J Obstet Gynecol Neonatal Nurs** 1996 Mar-Apr; 25(3):247-52 (12 ref.)

Helping survivors of sexual abuse through labor. Burian J. **MCN Am J Matern Child Nurs** 1995 Sep-Oct;20(5):252-6 (14 ref.)

LABOR COMPLICATIONS

Serious haemorrhage during delivery. Ravina JH. **Eur J Obstet Gynecol Reprod Biol** 1996 Mar;65(1):137-40 (17 ref.)

[Definition of pathological second stage in labor: theory and practice] Gull I, et al. **Harefuah** 1995 Oct;129(7-8):268-70 (16 ref.) **(Heb)**

DIAGNOSIS

The diagnosis of foetal distress: a challenge to midwives. Mead M. **J Adv Nurs** 1996 May;23(5):975-83 (73 ref.)

ETHNOLOGY

Cultural aspects of pain in childbearing women. Weber SE. **J Obstet Gynecol Neonatal Nurs** 1996 Jan;25(1):67-72 (20 ref.)

ETIOLOGY

[Uterine inversion] Gerber S. **Rev Med Suisse Romande** 1996 Apr;116(4):277-83 (26 ref.) **(Fre)**

[Emergencies in obstetrics] Ludwig H. **Ther Umsch** 1996 Jun; 53(6):477-96 (54 ref.) (Eng. Abstr.) **(Ger)**

[Labor and delivery in a pregnancy involving fetal macrosomia] Rech F, et al. **Minerva Ginecol** 1995 Oct; 47(10):431-8 (36 ref.) (Eng. Abstr.) **(Ita)**

NURSING

Treating disseminated intravascular coagulation. Corbett JV, et al. **MCN Am J Matern Child Nurs** 1995 Sep-Oct; 20(5):290 (9 ref.)

PHYSIOPATHOLOGY

The pain and discomfort of labor and birth. Lowe NK. **J Obstet Gynecol Neonatal Nurs** 1996 Jan;25(1):82-92 (56 ref.)

PREVENTION & CONTROL

Preserving the pelvic floor and perineum during childbirth--elective caesarean section? Sultan AH, et al. **Br J Obstet Gynaecol** 1996 Aug;103(8):731-4 (21 ref.)

Management of labor and labor complications. Weinstein D, et al. **Curr Opin Obstet Gynecol** 1995 Dec;7(6):437-41 (37 ref.)

The relationship of episiotomy to third and fourth degree lacerations. Golden WE, et al. **J Ark Med Soc** 1996 Feb; 92(9):447-8 (15 ref.)

[Uterine rupture: literature review and Genevan experience (1980-1994)] Valiton-Crusi A. **Rev Med Suisse Romande** 1996 Apr;116(4):273-6 (26 ref.) **(Fre)**

[Characteristics of delivery of the small premature infant] Schneider H, et al. **Arch Gynecol Obstet** 1995; 257(1-4):462-71 (51 ref.) **(Ger)**

PSYCHOLOGY

Treatment strategies for anxiety, stress, and developmental conflict during reproduction [see comments] Lederman RP. **Behav Med** 1995 Fall;21(3):113-22 (69 ref.) Comment in: Behav Med 1996 Fall;21(3):123-9.

The pain and discomfort of labor and birth. Lowe NK. **J Obstet Gynecol Neonatal Nurs** 1996 Jan;25(1):82-92 (56 ref.)

[Sense and success of psychosomatic preparation for labor] Stauber M. **Arch Gynecol Obstet** 1995;257(1-4):129-35 (8 ref.) **(Ger)**

THERAPY

Place of emergency arterial embolisation in obstetric haemorrhage about 16 personal cases. Merland JJ, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Mar;65(1):141-3 (20 ref.)

Meconium stained liquor: a view from a district hospital. Apers LM. **Trop Doct** 1996 Jan;26(1):14-7 (18 ref.)

[Hemorrhage during the third stage of labor and the postpartum period] Hohlfeld P. **Rev Med Suisse Romande** 1996 Apr;116(4):261-5 (33 ref.) **(Fre)**

[Methods of gravitational surgery on the blood in obstetrics and gynecology] Abubakirova AM, et al. **Akush Ginekol (Mosk)** 1995;(5):40-3 (45 ref.) **(Rus)**

LABOR, INDUCED

see related
OXYTOCICS

Cervical ripening and labor induction after previous cesarean delivery. Chez RA. **Clin Obstet Gynecol** 1995 Jun; 38(2):287-92 (45 ref.)

Cervical assessment. Fuentes A, et al. **Clin Obstet Gynecol** 1995 Jun;38(2):224-31 (22 ref.)

Oxytocin to induce labor. Shyken JM, et al. **Clin Obstet Gynecol** 1995 Jun;38(2):232-45 (70 ref.)

The role of prostaglandins in labor and delivery. O'Brien WF. **Clin Perinatol** 1995 Dec;22(4):973-84 (40 ref.)

Indications for induction of labour. Lampé LG. **Eur J Obstet Gynecol Reprod Biol** 1996 Mar;65(1):71-3 (6 ref.)

[Consensus Conference on Induced Labor. Paris, November 29-30, 1995] **J Gynecol Obstet Biol Reprod (Paris)** 1995; 24 Suppl 1:1-128 (0 ref.) **(Fre)**

ADVERSE EFFECTS

[What are the medico-legal implications of induced labor?] Pierre F, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995; 24 Suppl 1:120-8 (0 ref.) **(Fre)**

METHODS

Novel approach to oxytocin induction-augmentation of labor. Application of oxytocin physiology during pregnancy. Dawood MY. **Adv Exp Med Biol** 1995; 395:585-94 (41 ref.)

Amniotomy to induce labor. Busowski JD, et al. **Clin Obstet Gynecol** 1995 Jun;38(2):246-58 (41 ref.)

Mechanical methods of cervical ripening. Krammer J, et al. **Clin Obstet Gynecol** 1995 Jun;38(2):280-6 (42 ref.)

Labor induced using methods that do not involve oxytocin. Mastrogiannis DS, et al. **Clin Obstet Gynecol** 1995 Jun; 38(2):259-66 (23 ref.)

The use of oxytocin. Shyken JM, et al. **Clin Perinatol** 1995 Dec;22(4):907-31 (93 ref.)

Induction of labor. Reichler A, et al. **Curr Opin Obstet Gynecol** 1995 Dec;7(6):432-6 (52 ref.)

Induction of labor by PGE2 and other local methods. Physiology, methods and guidelines for patient selection. Lyndrup J. **Dan Med Bull** 1995 Jun;42(3):227-43 (218 ref.)

[Induced delivery in fetal malformations] Boog G. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24 Suppl 1:54-6 (22 ref.) **(Fre)**

[Strategies for induction of labor] Cabrol D. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24 Suppl 1:28-32 (38 ref.) **(Fre)**

[Induced labor by mechanical methods. Advantages and disadvantages] Dubecq JP, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24 Suppl 1:8-12 (28 ref.) **(Fre)**

[Induced labor by pharmacological methods. Advantages and disadvantages] Rotten D. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24 Suppl 1:13-27 (42 ref.) **(Fre)**

NURSING

[Advantages and disadvantages of induced labor without medical indications: the viewpoint of the midwife] Kovacs C. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24 Suppl 1:89-93 (22 ref.) **(Fre)**

PSYCHOLOGY

[Induced labor without medical indications: the viewpoint of women. Bibliographic review] Garel M. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24 Suppl 1:116-9 (22 ref.) **(Fre)**

STANDARDS

[Advantages and disadvantages of induced labor without medical indications: the viewpoint of the pediatrician] Dehan M. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24 Suppl 1:94-6 (5 ref.) **(Fre)**

[Induced labor without medical indications: the viewpoint of women. Bibliographic review] Garel M. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24 Suppl 1:116-9 (22 ref.) **(Fre)**

[Advantages and disadvantages of induced labor without medical indication: the viewpoint of the epidemiologist] Goffinet F. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24 Suppl 1:108-15 (21 ref.) **(Fre)**

[Advantages and disadvantages of induced labor without medical indications: the viewpoint of the anesthesiologist] Hamza J. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24 Suppl 1:97-107 (49 ref.) **(Fre)**

[Advantages and disadvantages of induced labor without medical indications: the viewpoint of the midwife] Kovacs C. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24 Suppl 1:89-93 (22 ref.) **(Fre)**

[Advantages and disadvantages of induced labor without medical indications: the viewpoint of the obstetrician in hospital practice] Maria B. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24 Suppl 1:67-77 (52 ref.) **(Fre)**

[Advantages and disadvantages of induced labor without medical indication: the viewpoint of obstetricians in private practice] Peter J. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24 Suppl 1:78-88 (40 ref.) **(Fre)**

[What are the medico-legal implications of induced labor?] Pierre F, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995; 24 Suppl 1:120-8 (0 ref.) **(Fre)**

[Is induced labor justified in cases of scarred uterus, breech presentation and multiple pregnancy?] Schaal JP, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24 Suppl 1:57-61 (39 ref.) **(Fre)**

[The epidemiologists' point of view on medical indications for induced labor] Subtil D. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24 Suppl 1:62-6 (29 ref.) **(Fre)**

[Is induced labor justified in diabetes, macrosomia and prolonged pregnancy?] Treisser A, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24 Suppl 1:41-7 (38 ref.) **(Fre)**

LABOR ONSET

PHYSIOLOGY

The onset of labor. Ulmsten U. **Eur J Obstet Gynecol Reprod Biol** 1996 Mar;65(1):95-8 (0 ref.)

LABOR, PREMATURE

see related
INFANT, PREMATURE
TOCOLYTIC AGENTS

Preterm breech babies and randomised trials of rare conditions [comment] Thornton JG, et al. **Br J Obstet Gynaecol** 1996 Jul;103(7):611-3 (5 ref.) Comment on: Br J Obstet Gynaecol 1996 Jul;103(7):684-9.

Use of cordocentesis in the management of preterm or growth-restricted fetuses with abnormal monitoring. Shalev E, et al. **Obstet Gynecol Surv** 1995 Dec; 50(12):839-44 (55 ref.)

CHEMICALLY INDUCED

[Is smoking during pregnancy a cause of premature delivery?]

Wisborg K, et al. **Ugeskr Laeger** 1995 Nov 27; 157(48):6707–12 (32 ref.) (Eng. Abstr.) **(Dan)**

DIAGNOSIS

The diagnosis of preterm labor and the prediction of preterm delivery. Lockwood CJ. **Clin Obstet Gynecol** 1995 Dec; 38(4):675–87 (95 ref.)

DRUG THERAPY

Potential use of oxytocin and vasopressin V1a antagonists in the treatment of preterm labour and primary dysmenorrhoea. Akerlund M, et al. **Adv Exp Med Biol** 1995; 395:595–600 (32 ref.)

Progress in the development of oxytocin antagonists for use in preterm labor. Pettibone DJ, et al. **Adv Exp Med Biol** 1995;395:601–12 (49 ref.)

Beta-adrenergic agonists. Boyle JG. **Clin Obstet Gynecol** 1995 Dec;38(4):688–96 (36 ref.)

Indomethacin. Gordon MC, et al. **Clin Obstet Gynecol** 1995 Dec;38(4):697–705 (23 ref.)

Magnesium sulfate. Gordon MC, et al. **Clin Obstet Gynecol** 1995 Dec;38(4):706–12 (25 ref.)

Calcium channel blockers. Ray D, et al. **Clin Obstet Gynecol** 1995 Dec;38(4):713–21 (40 ref.)

Atosiban. Shubert PJ. **Clin Obstet Gynecol** 1995 Dec; 38(4):722–4 (12 ref.)

Delayed interval delivery after intrauterine infection and immature birth of twin 1—a case report and literature review. de Jong MW, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Nov;63(1):91–4 (29 ref.)

[Indication of corticotherapy for fetal pulmonary maturation] Tchobroutsky C. **Contracept Fertil Sex** 1996 May; 24(5):413–6 (11 ref.) (Eng. Abstr.) **(Fre)**

[Tocolytic drugs] Thoulon JM. **Contracept Fertil Sex** 1996 Feb;24(2):111–6 (30 ref.) **(Fre)**

[Drug treatment of threatened premature labor] Savey L, et al. **Rev Fr Gynecol Obstet** 1995 May-Jun; 90(5–6):297–301 (20 ref.) (Eng. Abstr.) **(Fre)**

EPIDEMIOLOGY

Trend of birthweights of African newborns: an overview. Airede AK. **East Afr Med J** 1996 Apr;73(4):271–5 (48 ref.)

ETHNOLOGY

Racial disparities in preterm births. The role of urogenital infections [see comments] Fiscella K. **Public Health Rep** 1996 Mar-Apr;111(2):104–13 (15 ref.) Comment in: Public Health Rep 1996 Mar-Apr;111(2):114–5.

Preterm birth in the African-American community. Hogue CJ, et al. **Semin Perinatol** 1995 Aug;19(4):255–62 (70 ref.)

ETIOLOGY

The role of urogenital tract infections in the etiology of preterm birth: a review. Martius J, et al. **Arch Gynecol Obstet** 1996;258(1):1–19 (166 ref.)

Preterm labor: emerging role of genital tract infections. Andrews WW, et al. **Infect Agents Dis** 1995 Dec; 4(4):196–211 (185 ref.)

[Smoking and pregnancy] Wenderlein JM. **Z Arztl Fortbild (Jena)** 1995 Oct;89(5):467–71 (15 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

[Intra-amniotic infection, cytokines and premature labor] Baumann P, et al. **Wien Klin Wochenschr** 1995; 107(20):598–607 (102 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Delivery of the premature infant. Bottoms S. **Clin Obstet Gynecol** 1995 Dec;38(4):780–9 (26 ref.)

[Current aspects of premature labor] Briese V. **Zentralbl Gynakol** 1995;117(8):393–401 (47 ref.) (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

Prevention of preterm birth. Owen P, et al. **Baillieres Clin Obstet Gynaecol** 1995 Sep;9(3):465–79 (96 ref.)

Risks and complications of tocolysis. Hill WC. **Clin Obstet Gynecol** 1995 Dec;38(4):725–45 (133 ref.)

Current status of home uterine activity monitoring. Iams JD. **Clin Obstet Gynecol** 1995 Dec;38(4):771–9 (35 ref.)

Adjunctive care of preterm labor—the use of antibiotics. Lewis R, et al. **Clin Obstet Gynecol** 1995 Dec;38(4):755–70 (69 ref.)

New perspectives on the prevention of extreme prematurity. Novy MJ, et al. **Clin Obstet Gynecol** 1995 Dec; 38(4):790–808 (77 ref.)

Antenatal Care. Bréart G. **Curr Opin Obstet Gynecol** 1995 Dec;7(6):417–9 (10 ref.)

Working conditions, maternity legislation, and preterm birth. Berkowitz GS, et al. **Semin Perinatol** 1995 Aug;19(4):272–8 (40 ref.)

[Prevention of infection and therapy of premature labor] Martius J. **Arch Gynecol Obstet** 1995;257(1–4):451–7 (35 ref.) **(Ger)**

[Therapy of threatened premature labor] Spätling L. **Arch Gynecol Obstet** 1995;257(1–4):458–62 (13 ref.) **(Ger)**

PSYCHOLOGY

[Pregnancy, labor and partnership in a family with an IVF child] Pastor VS, et al. **Geburtshilfe Frauenheilkd** 1995 Aug; 55(8):M83–7 (45 ref.) **(Ger)**

SURGERY

[Are there still indications for cerclage in 1995?] Dufour P, et al. **Rev Fr Gynecol Obstet** 1995 Oct;90(10):423–30 (26 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

ACOG technical bulletin. Preterm labor. Number 206—June 1995 (Replaces No. 133, October 1989). **Int J Gynaecol Obstet** 1995 Sep;50(3):303–13 (65 ref.)

ULTRASONOGRAPHY

Sonography in the evaluation of the cervix during pregnancy. Guzman ER, et al. **Curr Opin Obstet Gynecol** 1996 Apr; 8(2):99–105 (16 ref.)

[Diagnostic and clinical value of Doppler ultrasound in obstetrics] Gonser M, et al. **Geburtshilfe Frauenheilkd** 1995 Nov;55(11):605–15 (127 ref.) (Eng. Abstr.) **(Ger)**

LABOR PRESENTATION

see related
DELIVERY

LABOR PRESENTATION, BREECH see **BREECH PRESENTATION**

LABOR UNIONS

LEGISLATION & JURISPRUDENCE

Regional harmonization of occupational health rules: the European example. Raworth P. **Am J Law Med** 1995; 21(1):7–44 (339 ref.)

LABORATORIES

Managed health care. Managing the risks of laboratory testing in an integrated delivery system. Cooney MM. **Am J Clin Pathol** 1995 Oct;104(4 Suppl 1):S50–3 (14 ref.)

Robotics and automated workstations for rapid response testing. Felder RA. **Am J Clin Pathol** 1995 Oct;104(4 Suppl 1):S26–32 (13 ref.)

The satellite laboratory and point-of-care testing. Integration of information. Jacobs E, et al. **Am J Clin Pathol** 1995 Oct;104(4 Suppl 1):S33–9 (17 ref.)

Clinical laboratories are laboratories for re-engineering. Lincoln TL. **Am J Clin Pathol** 1996 Apr;105(4 Suppl 1):S33–9 (12 ref.)

College of American Pathologists Conference XXVIII on alternate site testing: introduction. Handorf CR. **Arch Pathol Lab Med** 1995 Oct;119(10):867–73 (9 ref.)

Factor VIII concentrates and the immune system—laboratory investigations. Wadhwa M, et al. **Blood Coagul Fibrinolysis** 1995 Jul;6 Suppl 2:S65–79 (73 ref.)

Formaldehyde disinfection in laboratories: limitations and hazards. Cheney JE, et al. **Br J Biomed Sci** 1995 Sep; 52(3):195–201 (53 ref.)

The poisoned patient: the role of the laboratory. Flanagan RJ. **Br J Biomed Sci** 1995 Sep;52(3):202–13 (30 ref.)

Use of artificial intelligence in analytical systems for the clinical laboratory. Place JF, et al. **Clin Biochem** 1995 Aug; 28(4):373–89 (84 ref.)

How to evaluate and implement new technologies in an era of managed care and cost containment. Koch DD. **Clin Chem** 1996 May;42(5):797–802 (34 ref.)

Artificial neural networks in pathology and medical laboratories [see comments] Dybowski R, et al. **Lancet** 1995 Nov 4;346(8984):1203–7 (34 ref.) Comment in: Lancet 1995 Nov 4;346(8984):1175–7. Comment in: Lancet 1995 Dec 23–30;346(8991–8992):1712.

Sterilization and disinfection of instruments and materials in the surgery unit and laboratory areas. Best M, et al. **Semin Dermatol** 1995 Sep;14(3):243–6 (14 ref.)

Managing the infectious waste of the surgery unit and laboratory. Hoeltge GA. **Semin Dermatol** 1995 Sep; 14(3):247–51 (9 ref.)

Reducing risks in blood transfusion: process and outcome. McClelland DB, et al. **Transfus Med** 1996 Mar;6(1):1–10 (35 ref.)

[Role of the hemostasis laboratory in the etiologic approach to deep vein thrombosis] De Maistre E, et al. **J Mal Vasc** 1996;21(1):1–6 (19 ref.) (Eng. Abstr.) **(Fre)**

ECONOMICS

Impact of cost cutting on laboratories: new business strategies for laboratories. Ash KO. **Clin Chem** 1996 May;42(5):822–6 (6 ref.)

Federal reimbursement to laboratories. Logue J. **Clin Chem** 1996 May;42(5):817–21 (7 ref.)

ORGANIZATION & ADMINISTRATION

The future of blood groups and other markers in reference laboratories. Rouger P, et al. **Transfus Clin Biol** 1995; 2(4):329–34 (8 ref.)

STANDARDS

Closing the clinical laboratory testing loop with information technology. Connelly DP, et al. **Am J Clin Pathol** 1996 Apr;105(4 Suppl 1):S40–7 (23 ref.)

Analytical specifications of reference methods compilation and critical discussion (from the members of the European EQA-Organizers Working Group B). Stöckl D, et al. **Eur J Clin Chem Clin Biochem** 1996 Apr;34(4):319–37 (221 ref.)

Analytical quality specifications for reference methods and operating specifications for networks of reference laboratories. discussion paper from the members of the external quality assessment (EQA) Working Group B1) on target values in EQAS. Thienpont L, et al. **Eur J Clin Chem Clin Biochem** 1995 Dec;33(12):949–57 (52 ref.)

Crime laboratory proficiency testing results, 1978–1991, II: Resolving questions of common origin. Peterson JL, et al. **J Forensic Sci** 1995 Nov;40(6):1009–29 (4 ref.)

Crime laboratory proficiency testing results, 1978–1991, I: Identification and classification of physical evidence. Peterson JL, et al. **J Forensic Sci** 1995 Nov;40(6):994–1008 (52 ref.)

TRENDS

The challenge of managing laboratory information in a managed care environment. Friedman BA. **Am J Clin Pathol** 1996 Apr;105(4 Suppl 1):S3–9 (23 ref.)

Impact of cost cutting on laboratories: new business strategies for laboratories. Ash KO. **Clin Chem** 1996 May;42(5):822–6 (6 ref.)

Progress in clinical laboratories. Macias AE, et al. **Rev Invest Clin** 1995 Sep-Oct;47(5):415–9 (50 ref.)

LABORATORIES, HOSPITAL

Why is the laboratory an afterthought for managed care organizations? Forsman RW. **Clin Chem** 1996 May; 42(5):813–6 (5 ref.)

Basic microbiologic support for hospital epidemiology. McGowan JEJr, et al. **Infect Control Hosp Epidemiol** 1996 May;17(5):298–303 (30 ref.)

[Laboratory management] Kawai T. **Rinsho Byori** 1995 Oct; 43(10):991–3 (0 ref.) (Eng. Abstr.) **(Jpn)**

ECONOMICS

[Cost performance and TQC in laboratory management from the aspect of a commercial laboratory] Takahashi M. **Rinsho Byori** 1995 Oct;43(10):999–1004 (5 ref.) (Eng. Abstr.) **(Jpn)**

ORGANIZATION & ADMINISTRATION

[Hospital management and the role of clinical microbiology laboratory for preventing nosocomial infection] Ichiyama S. **Rinsho Byori** 1995 Oct;43(10):1005–9 (4 ref.) (Eng. Abstr.) **(Jpn)**

STANDARDS

Storage and preservation of blood and urine for trace element analysis. A review. Subramanian KS. **Biol Trace Elem Res** 1995 Aug-Sep;49(2–3):187–210 (96 ref.)

TRENDS

Technological trends in clinical laboratory science. Burtis CA. **Clin Biochem** 1995 Jun;28(3):213–9 (77 ref.)

LABORATORY ANIMALS see **ANIMALS, LABORATORY**

LABORATORY DIAGNOSIS see **DIAGNOSIS, LABORATORY**

LABORATORY INFECTION

MICROBIOLOGY

Laboratory-associated infections and biosafety. Sewell DL. **Clin Microbiol Rev** 1995 Jul;8(3):389–405 (158 ref.)

LABORATORY INFORMATION SYSTEMS see **CLINICAL LABORATORY INFORMATION SYSTEMS**

LABORATORY MARKERS see **BIOLOGICAL MARKERS**

LABORATORY PERSONNEL

Infection control precautions for surgical personnel in the surgery unit and for laboratory personnel in the Mohs surgery unit laboratory areas. Hruza GJ. **Semin Dermatol** 1995 Sep;14(3):228–34 (47 ref.)

EDUCATION

[Strategy for getting many experts in clinical pathology] Ohkubo A. **Rinsho Byori** 1995 Oct;43(10):1010–3 (0 ref.) (Eng. Abstr.) **(Jpn)**

STANDARDS

A critical review of personnel standards. Peddecord KM.

Clin Chem 1996 May;42(5):790–6 (25 ref.)

LABORATORY TECHNICIANS see **LABORATORY PERSONNEL**

LABYRINTH

Inflammatory meningiomas of the internal auditory canals. Doyle KJ, et al. **Otolaryngol Head Neck Surg** 1995 Nov; 113(5):617–20 (8 ref.)

ABNORMALITIES

[Malformation of the internal ear and recurrent meningitis: radio–surgical correlations] Ruaux C, et al. **Ann Otolaryngol Chir Cervicofac** 1995;112(3):118–22 (21 ref.) (Eng. Abstr.) **(Fre)**

INNERVATION

Structural diversity in the inner ear of teleost fishes: implications for connections to the Mauthner cell. Popper AN, et al. **Brain Behav Evol** 1995;46(3):131–40 (70 ref.)

PHYSIOLOGY

'Vestibular compensation': neural plasticity and its relations to functional recovery after labyrinthine lesions in frogs and other vertebrates. Dieringer N. **Prog Neurobiol** 1995 Jun;46(2–3):97–129 (225 ref.)

PHYSIOPATHOLOGY

Preservation of cochlear function after extensive labyrinthine destruction. Ars B, et al. **Am J Otol** 1996 Jan;17(1):40–5 (49 ref.)

LABYRINTH DISEASES

ETIOLOGY

Labyrinthine fistulae. Vantrappen G, et al. **Acta Otorhinolaryngol Belg** 1996;50(1):63–8 (13 ref.)

Persistent dizziness following head trauma and perilymphatic fistula. Fitzgerald DC. **Arch Phys Med Rehabil** 1995 Nov; 76(11):1017–20 (26 ref.)

RADIOGRAPHY

Osteoma of the internal auditory canal: case report. Coakley DJ, et al. **J Laryngol Otol** 1996 Feb;110(2):158–60 (10 ref.)

LAC OPERON

Molecular handles on adaptive mutation. Rosenberg SM, et al. **Mol Microbiol** 1995 Oct;18(2):185–9 (33 ref.)

GENETICS

Inactivation in vivo of metabotropic glutamate receptor 1 by specific chromosomal insertion of reporter gene lacZ. Conquet F. **Neuropharmacology** 1995 Aug;34(8):865–70 (14 ref.)

LAC REPRESSORS see **REPRESSOR PROTEINS**

LACHESIS see **VIPERIDAE**

LACRIMAL APPARATUS

see related
TEARS

[A case of Sjögren's syndrome with an eyelid tumor, a so–termed pseudolymphoma of the lacrimal gland] Takeshita S, et al. **Ryumachi** 1996 Feb;36(1):43–9 (17 ref.) (Eng. Abstr.) **(Jpn)**

ANATOMY & HISTOLOGY

Nuclear dacryoscintigraphy: its role in oral and maxillofacial surgery. Ziccardi VB, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1995 Dec;80(6):645–9 (24 ref.)

INJURIES

Primary surgical repair of traumatic lacerations of the lacrimal canaliculi. MacGillivray RF, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Feb;81(2):157–63 (23 ref.)

SURGERY

Treatment of dry eye by blocking the lacrimal canaliculi. Murube J, et al. **Surv Ophthalmol** 1996 May–Jun; 40(6):463–80 (109 ref.)

LACRIMAL APPARATUS DISEASES

Malignant melanoma of the lacrimal sac. Owens RM, et al. **Otolaryngol Head Neck Surg** 1995 Nov;113(5):634–40 (27 ref.)

CONGENITAL

Congenital lacrimal sac mucoceles with intranasal extension. Hulka GF, et al. **Otolaryngol Head Neck Surg** 1995 Nov; 113(5):651–5 (22 ref.)

DIAGNOSIS

Clinical and computed tomographic characteristics of amyloid tumor of the lacrimal gland. Massry GG, et al. **Ophthalmology** 1996 Aug;103(8):1233–6 (11 ref.)

PATHOLOGY

Infections of the eyelid, lacrimal system, conjunctiva, and cornea. Durand M, et al. **Curr Clin Top Infect Dis** 1996; 16:125–50 (150 ref.)

SURGERY

Surgery of the lacrimal system. Schauss F, et al. **Acta Otorhinolaryngol Belg** 1996;50(2):143–6 (19 ref.)

LACRIMAL DUCT OBSTRUCTION

CHEMICALLY INDUCED

Punctal and canalicular stenosis associated with systemic fluorouracil therapy. Report of five cases and review of the literature. Brink HM, et al. **Doc Ophthalmol** 1995; 90(1):1–6 (23 ref.)

COMPLICATIONS

Respiratory distress in the neonate. Sequela of a congenital dacryocystocele. Hepler KM, et al. **Arch Otolaryngol Head Neck Surg** 1995 Dec;121(12):1423–5 (16 ref.)

RADIONUCLIDE IMAGING

Nuclear dacryoscintigraphy: its role in oral and maxillofacial surgery. Ziccardi VB, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1995 Dec;80(6):645–9 (24 ref.)

SURGERY

A rationale for the selection of nasal decongestants in lacrimal drainage surgery. Hosal BM, et al. **Ophthal Plast Reconstr Surg** 1995 Sep;11(3):215–20 (29 ref.)

THERAPY

[Analysis of the efficacy of the large mono–canalicular intubation stent in the treatment of lacrimation caused by congenital obstruction of the lacrimal ducts in infants] Ruban JM, et al. **J Fr Ophtalmol** 1995;18(5):377–83 (11 ref.) (Eng. Abstr.) **(Fre)**

LACRIMAL GLAND see **LACRIMAL APPARATUS**

LACTALBUMIN

CHEMISTRY

alpha–Lactalbumins and lysozymes. McKenzie HA. **EXS** 1996;75:365–409 (215 ref.)

The molten globule state of alpha–lactalbumin. Kuwajima K. **FASEB J** 1996 Jan;10(1):102–9 (103 ref.)

Investigation of protein folding by mass spectrometry. Miranker A, et al. **FASEB J** 1996 Jan;10(1):93–101 (47 ref.)

METABOLISM

alpha–Lactalbumins and lysozymes. McKenzie HA. **EXS** 1996;75:365–409 (215 ref.)

LACTASES see **BETA–GALACTOSIDASE**

LACTATE DEHYDROGENASE

BLOOD

Rising serum lactate dehydrogenase often caused by granulocyte–or Granulocyte–macrophage colony stimulating factor and not tumor progression in patients with lymphoma or myeloma. Sarris AH, et al. **Leuk Lymphoma** 1995 May;17(5–6):473–7 (25 ref.)

[Lactate dehydrogenase] Kanno T. **Nippon Rinsho** 1995 Feb; 53 Su Pt 1:272–5 (4 ref.) **(Jpn)**

CHEMISTRY

Flavocytochrome b2: an ideal model system for studying protein–mediated electron transfer. Chapman SK, et al. **Biochem Soc Trans** 1996 Feb;24(1):73–7 (17 ref.)

The chemical mechanism of flavoprotein–catalysed alpha–hydroxy acid dehydrogenation: a mutational analysis. Lederer F, et al. **Biochem Soc Trans** 1996 Feb; 24(1):77–83 (50 ref.)

Flavocytochrome b2–cytochrome c interactions: the electron transfer reaction revisited. Capeillere–Blandin C. **Biochimie** 1995;77(7–8):516–30 (107 ref.)

METABOLISM

Flavocytochrome b2: an ideal model system for studying protein–mediated electron transfer. Chapman SK, et al. **Biochem Soc Trans** 1996 Feb;24(1):73–7 (17 ref.)

The chemical mechanism of flavoprotein–catalysed alpha–hydroxy acid dehydrogenation: a mutational analysis. Lederer F, et al. **Biochem Soc Trans** 1996 Feb; 24(1):77–83 (50 ref.)

[Kinetic analysis of enzyme reactions within cells] Nakae Y, et al. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(13):1927–35 (80 ref.) **(Jpn)**

LACTATE DEHYDROGENASE VIRUS

IMMUNOLOGY

Lactate dehydrogenase–elevating virus: an ideal persistent virus? Plagemann PG, et al. **Springer Semin Immunopathol** 1995;17(2–3):167–86 (78 ref.)

LACTATES

Applications of biodegradable lactides and glycolides in podiatry. Athanasiou KA, et al. **Clin Podiatr Med Surg** 1995 Jul;12(3):475–95 (90 ref.)

ANALYSIS

[Lactic acid] Totani M. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:582–5 (7 ref.) **(Jpn)**

BLOOD

Lactate levels in critically ill patients. Vincent JL. **Acta Anaesthesiol Scand Suppl** 1995;107:261–6 (29 ref.)

Physiology and regulation. Ionized calcium, magnesium and lactate measurements in critical care settings. Toffaletti J. **Am J Clin Pathol** 1995 Oct;104(4 Suppl 1):S88–94 (20 ref.)

The concept of lactate threshold. A short review. Antonutto G, et al. **J Sports Med Phys Fitness** 1995 Mar;35(1):6–12 (39 ref.)

[Is sepsis and septic shock due to a global oxygen insufficiency? A review in 2 parts. 2: Sepsis and lactate] Ensinger H, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May; 31(4):205–15 (175 ref.) **(Ger)**

[Lactate versus intramucosal pCO2 or pH?] Mertzlufft F. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Oct; 30 Suppl 1:S27–33 (41 ref.) **(Ger)**

METABOLISM

Lactate/proton co–transport in skeletal muscle: regulation and importance for pH homeostasis. Juel C. **Acta Physiol Scand** 1996 Mar;156(3):369–74 (29 ref.)

Post–exercise lactate metabolism: a comparative review of sites, pathways, and regulation. Gleeson TT. **Annu Rev Physiol** 1996;58:565–81 (105 ref.)

Substrate selection and oxygen uptake by the lactating mammary gland. Williamson DH, et al. **Proc Nutr Soc** 1995 Mar;54(1):165–75 (62 ref.)

PHARMACOLOGY

Lactate–versus bicarbonate–based peritoneal dialysis solutions. Pedersen FB. **Perit Dial Int** 1995;15(7 Suppl):S47–50; discussion S51 (33 ref.)

LACTATION

see related
BREAST FEEDING
COLOSTRUM
MILK
MILK, HUMAN

The diagnosis and management of breast problems during pregnancy and lactation. Scott–Conner CE, et al. **Am J Surg** 1995 Oct;170(4):401–5 (47 ref.)

Neuropeptides in anxiety disorders. Effects of lactation. Altemus M. **Ann N Y Acad Sci** 1995 Dec 29;771:697–707 (80 ref.)

Treatment of migraine during pregnancy and lactation. Miles CB. **S D J Med** 1995 Nov;48(11):373–7 (24 ref.)

Breast cancer in pregnancy and lactation. DiFronzo LA, et al. **Surg Clin North Am** 1996 Apr;76(2):267–78 (45 ref.)

[Lactational amenorrhea as a method of family planning] Canto–de Cetina T, et al. **Salud Publica Mex** 1996 Jan–Feb; 38(1):58–63 (38 ref.) (Eng. Abstr.) **(Spa)**

DRUG EFFECTS

A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation. Webster J. **Drug Saf** 1996 Apr; 14(4):228–38 (59 ref.)

Psychotropic drugs and lactation. Maitra R, et al. **N Z Med J** 1996 Jun 28;109(1024):217–8 (20 ref.)

[The use of drugs in pregnant and nursing women with dermatologic diseases] Miteva L, et al. **Akush Ginekol (Sofiia)** 1995;34(2):42–6 (20 ref.) **(Bul)**

METABOLISM

Energy requirements of pregnant and lactating women. Prentice AM, et al. **Eur J Clin Nutr** 1996 Feb;50 Suppl 1:S82–110; discussion S10–1 (114 ref.)

Regulation of organic nutrient metabolism during transition from late pregnancy to early lactation. Bell AW. **J Anim Sci** 1995 Sep;73(9):2804–19 (117 ref.)

Impact of changes in organic nutrient metabolism on feeding the transition dairy cow. Grummer RR. **J Anim Sci** 1995 Sep;73(9):2820–33 (81 ref.)

Selenium in human lactation. Sanz Alaejos M, et al. **Nutr Rev** 1995 Jun;53(6):159–66 (101 ref.)

LACTATION

PHYSIOLOGY

The effects of lactation on the fertility of dairy cows. Macmillan KL, et al. **Aust Vet J** 1996 Apr;73(4):141–7 (56 ref.)

Physiological signals and pathological mediators of lipid metabolism during lactation. Evans RD. **Biochem Soc Trans** 1995 Aug;23(3):516–22 (49 ref.)

Nutrition and breast-feeding. Koppe JG. **Eur J Obstet Gynecol Reprod Biol** 1995 Jul;61(1):73–8 (11 ref.)

Feeding behavior and management factors during the transition period in dairy cattle. Grant RJ, et al. **J Anim Sci** 1995 Sep;73(9):2791–803 (86 ref.)

Pregnancy, lactation, and menopause: how physiology and gender affect the toxicity of chemicals. Roberts JS, et al. **Mt Sinai J Med** 1995 Oct;62(5):343–55 (66 ref.)

Somatostatin levels during infancy, pregnancy, and lactation: a review. Goldstein A, et al. **Peptides** 1995;16(7):1321–6 (63 ref.)

Maternal nutrition and the regulation of milk synthesis. Hartmann P, et al. **Proc Nutr Soc** 1995 Jul;54(2):379–89 (45 ref.)

Evolutionary and environmental influences on human lactation. Prentice AM, et al. **Proc Nutr Soc** 1995 Jul; 54(2):391–400 (25 ref.)

Breast-feeding: matching supply with demand in human lactation. Wilde CJ, et al. **Proc Nutr Soc** 1995 Jul; 54(2):401–6 (20 ref.)

Substrate selection and oxygen uptake by the lactating mammary gland. Williamson DH, et al. **Proc Nutr Soc** 1995 Mar;54(1):165–75 (62 ref.)

Endocrine bases of lactational anoestrus in the sow. Quesnel H, et al. **Reprod Nutr Dev** 1995;35(4):395–414 (107 ref.)

LACTATION DISORDERS

THERAPY

[The treatment of prolactinomas during pregnancy and the lactation period] Rau H, et al. **Dtsch Med Wochenschr** 1996 Jan 5;121(1–2):28–32 (46 ref.) **(Ger)**

LACTIC ACIDOSIS see **ACIDOSIS, LACTIC**

LACTIC CYTOCHROME REDUCTASE see **LACTATE DEHYDROGENASE**

LACTOBACILLUS

The role of lactic acid bacteria in colon cancer prevention. Rafter JJ. **Scand J Gastroenterol** 1995 Jun;30(6):497–502 (56 ref.)

GENETICS

New and safe "oral" live vaccines based on lactobacillus. Claassen E, et al. **Adv Exp Med Biol** 1995;371B:1553–8 (23 ref.)

PHYSIOLOGY

Gut mucosa reconditioning with species-specific lactobacilli, surfactants, pseudomucus, and fibers—an invited review. Bengmark S, et al. **Biotechnol Ther** 1994–95;5(3–4):171–94 (149 ref.)

LACTOBACILLUS ACIDOPHILUS

PHYSIOLOGY

Anticarcinogenic, hypocholesterolemic, and antagonistic activities of Lactobacillus acidophilus. Mital BK, et al. **Crit Rev Microbiol** 1995;21(3):175–214 (371 ref.)

LACTOCOCCUS

The role of lactic acid bacteria in colon cancer prevention. Rafter JJ. **Scand J Gastroenterol** 1995 Jun;30(6):497–502 (56 ref.)

ENZYMOLOGY

Contribution of lactic acid bacteria to cheese ripening. Steele JL. **Adv Exp Med Biol** 1995;367:209–20 (43 ref.)

METABOLISM

Role of scalar protons in metabolic energy generation in lactic acid bacteria. Lolkema JS, et al. **J Bioenerg Biomembr** 1995 Aug;27(4):467–73 (13 ref.)

VIROLOGY

Bacteriophage resistance in Lactococcus. Dinsmore PK, et al. **Mol Biotechnol** 1995 Dec;4(3):297–314 (115 ref.)

LACTOCOCCUS LACTIS

ENZYMOLOGY

The proteolytic pathway of Lactococcus lactis. Poolman B, et al. **Soc Appl Bacteriol Symp Ser** 1995;24:65S–75S (46 ref.)

GENETICS

Physical and genetic maps of the chromosome of the Lactococcus lactis subsp. lactis strain IL1403 and Lactococcus lactis subsp. cremoris strain MG1363. Le Bourgeois P, et al. **Dev Biol Stand** 1995;85:597–603 (33 ref.)

PHYSIOLOGY

Lactococcal bacteriocins: mode of action and immunity. Venema K, et al. **Trends Microbiol** 1995 Aug;3(8):299–304 (48 ref.)

LACTOFERRIN

CHEMISTRY

Lactoferrin: molecular structure and biological function. Lönnerdal B, et al. **Annu Rev Nutr** 1995;15:93–110 (111 ref.)

GENETICS

Mouse lactoferrin gene: a marker for estrogen and epidermal growth factor. Teng C. **Environ Health Perspect** 1995 Oct; 103 Suppl 7:17–20 (37 ref.)

IMMUNOLOGY

[Lactoferrin—its role in defense against infection and immunotropic properties] Adamik B, et al. **Postepy Hig Med Dosw** 1996;50(1):33–41 (67 ref.) (Eng. Abstr.) **(Pol)**

METABOLISM

A new role for lactoferrin: DNA binding and transcription activation. Fleet JC. **Nutr Rev** 1995 Aug;53(8):226–7 (7 ref.)

PHYSIOLOGY

Lactoferrin: molecular structure and biological function. Lönnerdal B, et al. **Annu Rev Nutr** 1995;15:93–110 (111 ref.)

A new role for lactoferrin: DNA binding and transcription activation. Fleet JC. **Nutr Rev** 1995 Aug;53(8):226–7 (7 ref.)

[Regulation of interleukin 6 (IL-6) and TNF-alpha through lactoferrin in mice] Machnicki M. **Postepy Hig Med Dosw** 1995;49(1):53–7 (4 ref.) (Eng. Abstr.) **(Pol)**

LACTOGEN HORMONE, PLACENTAL see **PLACENTAL LACTOGEN**

LACTOGENIC HORMONE, PITUITARY see **PROLACTIN**

LACTONES

Peptidolactones. Keller U. **Biotechnology** 1995;28:173–96 (74 ref.)

[Role of miscellaneous substances (organic acids, lactone, etc) in regulation of food intake] Aou S, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:85–9 (19 ref.) **(Jpn)**

[Synthesis of lactone ring-containing bioactive natural products. Cardiotonic steroids, naphthoquinone antibiotics, and tetronic acid ionophore antibiotics] Yoshii E. **Yakugaku Zasshi** 1996 Jan;116(1):1–20 (45 ref.) (Eng. Abstr.) **(Jpn)**

PHARMACOKINETICS

Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers. Zhi J, et al. **J Clin Pharmacol** 1995 Nov;35(11):1103–8 (9 ref.)

PHARMACOLOGY

The neuroprotective properties of the Ginkgo biloba leaf: a review of the possible relationship to platelet-activating factor (PAF). Smith PF, et al. **J Ethnopharmacol** 1996 Mar; 50(3):131–9 (62 ref.)

THERAPEUTIC USE

First clinical studies with orlistat: a short review. Drent ML, et al. **Obes Res** 1995 Nov;3 Suppl 4:623S–625S (6 ref.)

[Ginkgo biloba in treatment of intermittent claudication. A systematic research based on controlled studies in the literature] Ernst E. **Fortschr Med** 1996 Mar 20;114(8):85–7 (14 ref.) (Eng. Abstr.) **(Ger)**

LACTOPEROXIDASE

METABOLISM

The role of peroxidase-catalyzed activation of aromatic amines in breast cancer. Josephy PD. **Mutagenesis** 1996 Jan;11(1):3–7 (65 ref.)

LACTOSE

Novel products and new technologies for use of a familiar carbohydrate, milk lactose. Yang ST, et al. **J Dairy Sci** 1995 Nov;78(11):2541–62 (128 ref.)

METABOLISM

Molecular biology of the lactose carrier of Escherichia coli. Varela MF, et al. **Biochim Biophys Acta** 1996 Aug 7; 1276(1):21–34 (120 ref.)

LACTOSE INTOLERANCE

ETIOLOGY

[Lactose intolerance after gastroenteritis. Not the serious clinical problem as supposed earlier] Gothefors L, et al. **Lakartidningen** 1995 Oct 4;92(40):3694, 3698–9 (16 ref.) **(Swe)**

LACTOYL GLUTATHIONE LYASE

METABOLISM

[Role of glyoxalases and methylglyoxal in cell proliferation and differentiation] Piskorska D, et al. **Postepy Hig Med Dosw** 1995;49(3):433–44 (56 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOLOGY

Advances in glyoxalase research. Glyoxalase expression in malignancy, anti-proliferative effects of methylglyoxal, glyoxalase I inhibitor diesters and S-D-lactoylglutathione, and methylglyoxal-modified protein binding and endocytosis by the advanced glycation endproduct receptor. Thornalley PJ. **Crit Rev Oncol Hematol** 1995 Aug;20(1–2):99–128 (225 ref.)

LACTULOSE

THERAPEUTIC USE

Lactulose in clinical use. Ray J, et al. **Trop Gastroenterol** 1996 Apr–Jun;17(2):12–4 (11 ref.)

LACUNAR DEMENTIA see **DEMENTIA, MULTI-INFARCT**

LACZ GENES see **LAC OPERON**

LAFORA DISEASE see **EPILEPSY, MYOCLONIC**

LAGOTHRIX see **CEBIDAE**

LAK CELLS see **KILLER CELLS, LYMPHOKINE-ACTIVATED**

LAKI-LORAND FACTOR see **FACTOR XIII**

LAMBDA IMMUNOGLOBULINS see **IMMUNOGLOBULINS, LAMBDA-CHAIN**

LAMBDA PHAGE see **BACTERIOPHAGE LAMBDA**

LAMBERT-EATON MYASTHENIC SYNDROME

COMPLICATIONS

Adenocarcinoma of the prostate and Eaton-Lambert syndrome. A previously unreported association. Agarawal SK, et al. **Scand J Urol Nephrol** 1995 Sep;29(3):351–3 (8 ref.)

DIAGNOSIS

[Differential diagnosis of disorders of neuromuscular transmission: myasthenia gravis and myasthenic syndrome] Martić V, et al. **Vojnosanit Pregl** 1994 May–Jun; 51(3):237–41 (55 ref.) **(Ser)**

ETIOLOGY

[Pathophysiology on the disorder of neuromuscular transmission defects] Sahashi K, et al. **Rinsho Byori** 1995 Sep;43(9):902–9 (15 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Immunopathology of the Lambert-Eaton myasthenic syndrome. Lang B, et al. **Springer Semin Immunopathol** 1995;17(1):3–15 (69 ref.)

PATHOLOGY

Immunopathology of the Lambert-Eaton myasthenic syndrome. Lang B, et al. **Springer Semin Immunopathol** 1995;17(1):3–15 (69 ref.)

LAMBLIA see **GIARDIA**

LAMBLIA INTESTINALIS see **GIARDIA LAMBLIA**

LAMBLIASIS see **GIARDIASIS**

LAMENESS, ANIMAL

DIAGNOSIS

Arthroscopy in the diagnosis and treatment of front leg

lameness. van Bree H, et al. **Vet Q** 1995 Apr;17 Suppl 1:S32–4 (0 ref.)

ETIOLOGY

Lameness, lesions of the claw of the dairy cow and subclinical laminitis [editorial; comment] Logue D. **Br Vet J** 1995 Jul–Aug;151(4):343–6 (16 ref.) Comment on: Br Vet J 1995 Jul–Aug;151(4):391–9.

THERAPY

Arthroscopy in the diagnosis and treatment of front leg lameness. van Bree H, et al. **Vet Q** 1995 Apr;17 Suppl 1:S32–4 (0 ref.)

LAMINAR AIR-FLOW AREAS see **ENVIRONMENT, CONTROLLED**

LAMINARIA

Biochemical changes in the cervical mucus after application of laminaria tent. El Maradny E, et al.
Acta Obstet Gynecol Scand 1996 Mar;75(3):203–7 (35 ref.)

LAMINARIA TENTS see **LAMINARIA**

LAMININ

see related
RECEPTORS, LAMININ

Laminins: a family of diverse multifunctional molecules of basement membranes. Aumailley M, et al.
J Invest Dermatol 1996 Feb;106(2):209–214 (67 ref.)

BIOSYNTHESIS

Laminin-binding integrins in tumor progression and metastasis. Ziober BL, et al. **Semin Cancer Biol** 1996 Jun; 7(3):119–28 (106 ref.)

BLOOD

[Measurement of serum laminin—in reference to diseases] Niiyama T, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:254–7 (13 ref.) **(Jpn)**

IMMUNOLOGY

[Adhesion molecules and trophoblastic invasion] Loke YW, et al. **Contracept Fertil Sex** 1995 Sep;23(9):573–5 (40 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Role of laminin-nidogen complexes in basement membrane formation during embryonic development. Dziadek M. **Experientia** 1995 Sep 29;51(9–10):901–13 (136 ref.)

LAMININ RECEPTORS see **RECEPTORS, LAMININ**

LAMPREYS

PHYSIOLOGY

Haemoglobin function in intact lamprey erythrocytes: interactions with membrane function in the regulation of gas transport and acid-base balance. Nikinmaa M, et al. **J Exp Biol** 1995 Dec;198 (Pt 12):2423–30 (42 ref.)
Neural networks that co-ordinate locomotion and body orientation in lamprey. Grillner S, et al.
Trends Neurosci 1995 Jun;18(6):270–9 (64 ref.)

LANADIGENIN see **DIGOXIGENIN**

LANDAU-KLEFFNER SYNDROME

DIAGNOSIS

Acquired epileptiform opercular syndrome: a second case report, review of the literature, and comparison to the Landau-Kleffner syndrome. Shafrir Y, et al. **Epilepsia** 1995 Oct;36(10):1050–7 (32 ref.)
The Landau-Kleffner Syndrome: a review. Mouridsen SE. **Eur Child Adolesc Psychiatry** 1995 Oct;4(4):223–8 (70 ref.)

NURSING

Multiple subpial transection for Landau-Kleffner syndrome. Buelow JM, et al. **AORN J** 1996 Apr;63(4):727–9, 732–5, 737–9; quiz 741–4 (26 ref.)

SURGERY

Multiple subpial transection for Landau-Kleffner syndrome. Buelow JM, et al. **AORN J** 1996 Apr;63(4):727–9, 732–5, 737–9; quiz 741–4 (26 ref.)

LANDSCAPING, HOSPITAL see **MAINTENANCE AND ENGINEERING, HOSPITAL**

LANGAT VIRUS see **ENCEPHALITIS VIRUSES, TICK-BORNE**

LANGERHANS-CELL GRANULOMATOSIS see **HISTIOCYTOSIS, LANGERHANS-CELL**

LANGERHANS CELLS

CYTOLOGY

Review of the characteristics of six cell lines with Langerhans cell phenotype. Nunez R. **Adv Exp Med Biol** 1995;378:35–7 (21 ref.)

IMMUNOLOGY

Studies on Langerhans cell phenotype in human afferent skin lymph from allergic contact dermatitis. Brand CU, et al. **Adv Exp Med Biol** 1995;378:523–5 (14 ref.)
Rosettes of Langerhans cells and activated T cells in human skin lymph derived from irritant contact dermatitis. Brand CU, et al. **Adv Exp Med Biol** 1995;378:527–9 (17 ref.)
Review of the characteristics of six cell lines with Langerhans cell phenotype. Nunez R. **Adv Exp Med Biol** 1995;378:35–7 (21 ref.)
Structure and role of Langerhans' cells in the human oesophageal epithelium. Terris B, et al. **Digestion** 1995;56 Suppl 1:9–14 (47 ref.)
Calcitonin gene-related peptide modulates Langerhans cell antigen-presenting function. Asahina A, et al.
Proc Assoc Am Physicians 1995 Jul;107(2):242–4 (18 ref.)
[Langerhans cells and cutaneous immune reactions] Barták P, et al. **Cas Lek Cesk** 1996 Mar 20;135(6):170–3 (27 ref.) (Eng. Abstr.) **(Cze)**
[Role of Langerhans cells in the physiopathology of atopic dermatitis] Bieber T. **Pathol Biol (Paris)** 1995 Dec; 43(10):871–5 (39 ref.) (Eng. Abstr.) **(Fre)**
[Dendritic cells and immune function in cancer] Chaux P. **Pathol Biol (Paris)** 1995 Dec;43(10):897–903 (53 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Modulation of Langerhans cell function by epidermal nerves. Asahina A, et al. **J Allergy Clin Immunol** 1995 Dec;96(6 Pt 2):1178–82 (32 ref.)
[Recent data and current studies of epidermal Langerhans cells] Dezutter-Dambuyant C. **Pathol Biol (Paris)** 1995 Dec;43(10):841–7 (78 ref.) (Eng. Abstr.) **(Fre)**
[Interactions of neuromediators and neurohormones on dendritic cells, monocytes and macrophages (out of the central nervous system)] Misery L, et al.
Pathol Biol (Paris) 1995 Dec;43(10):876–81 (66 ref.) (Eng. Abstr.) **(Fre)**
[The function of antigen presentation of dendritic cells] Péguet-Navarro J. **Pathol Biol (Paris)** 1995 Dec; 43(10):863–70 (54 ref.) (Eng. Abstr.) **(Fre)**
[Adhesion and migration of epidermal dendritic cells] Staquet MJ. **Pathol Biol (Paris)** 1995 Dec;43(10):858–62 (41 ref.) (Eng. Abstr.) **(Fre)**

RADIATION EFFECTS

UVB-dependent modulation of epidermal cytokine network: roles in UVB-induced depletion of Langerhans cells and dendritic epidermal T cells. Takashima A. **J Dermatol** 1995 Nov;22(11):876–87 (100 ref.)

ULTRASTRUCTURE

Oral mucosal Langerhans' cells. Barrett AW, et al.
Crit Rev Oral Biol Med 1996;7(1):36–58 (180 ref.)
Langerhans cells and vasculitis. Romagnoli P, et al.
Int Angiol 1995 Jun;14(2):113–8 (88 ref.)
[Dendritic cells in dogs and cats: models of study in human pathology] Marchal T, et al. **Pathol Biol (Paris)** 1995 Dec; 43(10):910–20 (68 ref.) (Eng. Abstr.) **(Fre)**

VIROLOGY

In vivo and in vitro infection of human Langerhans cells by HIV-1. Dezutter-Dambuyant C. **Adv Exp Med Biol** 1995;378:447–51 (26 ref.)
Langerhans cells and HIV infection. Zambruno G, et al.
Immunol Today 1995 Nov;16(11):520–4 (43 ref.)
[Epithelial dendritic cells and HIV-1 infection in vivo and in vitro] Dezutter-Dambuyant C, et al.
Pathol Biol (Paris) 1995 Dec;43(10):882–8 (71 ref.) (Eng. Abstr.) **(Fre)**

LANGUAGE

Noun and verb retrieval by normal subjects. Studies with PET. Warburton E, et al. **Brain** 1996 Feb;119 (Pt 1):159–79 (85 ref.)
Language and pain expression. Waddie NA. **J Adv Nurs** 1996 May;23(5):868–72 (15 ref.)
Tasks and timing in the perception of linguistic anomaly. Fodor JD, et al. **J Psycholinguist Res** 1996 Jan;25(1):25–57 (36 ref.)
Constraint satisfaction as a theory of sentence processing. Frazier L. **J Psycholinguist Res** 1995 Nov;24(6):437–68 (59 ref.)
Interference in short-term memory: the magical number two (or three) in sentence processing. Lewis RL.
J Psycholinguist Res 1996 Jan;25(1):93–115 (80 ref.)
A prosody tutorial for investigators of auditory sentence processing. Shattuck-Hufnagel S, et al.
J Psycholinguist Res 1996 Mar;25(2):193–247 (156 ref.)
Behavioral genetics: concepts for research and practice in language development and disorders. Gilger JW.
J Speech Hear Res 1995 Oct;38(5):1126–42 (119 ref.)
Hebb's concept of cell assemblies and the psychophysiology of word processing. Pulvermüller F. **Psychophysiology** 1996 Jul;33(4):317–33 (145 ref.)
Words and sentences: event-related brain potential measures. van Petten C. **Psychophysiology** 1995 Nov;32(6):511–25 (141 ref.)
[Cognitive neuroanatomy of language: contribution of functional cerebral imaging] Habib M, et al.
Rev Neurol (Paris) 1996 Apr;152(4):249–60 (63 ref.) (Eng. Abstr.) **(Fre)**
[The discourse as the practice component. (The study of Foucault's theory of objects of discourse, represented in psychopathology)] Díaz Marsa M.
Actas Luso Esp Neurol Psiquiatr Cienc Afines 1995 Sep–Oct;23(5):266–72 (53 ref.) (Eng. Abstr.) **(Spa)**
[Pictures of the psyche. Imaging the highest functions of the brain: consciousness, language, emotions, is now possible] Ingvar DH. **Lakartidningen** 1995 Dec 20;92(51–52):4885–9 (20 ref.) **(Swe)**

LANGUAGE DELAY see **LANGUAGE DEVELOPMENT DISORDERS**

LANGUAGE DEVELOPMENT

see related
SPEECH

Behavioral genetics: concepts for research and practice in language development and disorders. Gilger JW.
J Speech Hear Res 1995 Oct;38(5):1126–42 (119 ref.)

LANGUAGE DEVELOPMENT DISORDERS

GENETICS

Floating-Harbor syndrome: description of a further patient, review of the literature, and suggestion of autosomal dominant inheritance. Lacombe D, et al. **Eur J Pediatr** 1995 Aug;154(8):658–61 (9 ref.)

LANGUAGE DISORDERS

see related
SPEECH DISORDERS

COMPLICATIONS

ADHD and co-morbidities in infants, toddlers, and preschoolers at risk. Billeaud FP. **Semin Speech Lang** 1995 Nov;16(4):289–302 (50 ref.)

DIAGNOSIS

The time course of syntactic activation during language processing: a model based on neuropsychological and neurophysiological data. Friederici AD. **Brain Lang** 1995 Sep;50(3):259–81 (61 ref.)
A restrictive theory of agrammatic comprehension. Grodzinsky Y. **Brain Lang** 1995 Jul;50(1):27–51 (62 ref.)
Agrammatism as evidence about grammar. Linebarger MC. **Brain Lang** 1995 Jul;50(1):52–91 (74 ref.)
Syndromes of language dissolution in aging and dementia. Kirshner HS, et al. **Compr Ther** 1995 Sep;21(9):519–23 (30 ref.)
Memory tools for the researcher and clinician. Gathercole SE, et al. **Memory** 1994 Jun;2(2):97–101 (14 ref.)

ETIOLOGY

Issues arising in contemporary studies of disorders of syntactic processing in sentence comprehension in agrammatic patients. Caplan D. **Brain Lang** 1995 Sep; 50(3):325–38 (37 ref.)
On the relation between representational and processing models of asyntactic comprehension. Cornell TL.
Brain Lang 1995 Sep;50(3):304–24 (19 ref.)
The time course of syntactic activation during language processing: a model based on neuropsychological and neurophysiological data. Friederici AD. **Brain Lang** 1995 Sep;50(3):259–81 (61 ref.)
The breakdown of functional categories and the economy of derivation. Hagiwara H. **Brain Lang** 1995 Jul; 50(1):92–116 (50 ref.)
The elusive character of agrammatism. Kean ML.
Brain Lang 1995 Sep;50(3):369–84 (50 ref.)
A time-based approach to agrammatic production. Kolk H. **Brain Lang** 1995 Sep;50(3):282–303 (53 ref.)
Examining the empirical and linguistic bases of current theories of agrammatism. Mauner G. **Brain Lang** 1995 Sep; 50(3):339–68 (48 ref.)
Functional categories in agrammatism. Reznik M.
Brain Lang 1995 Jul;50(1):117–33 (26 ref.)

PSYCHOLOGY

A reverse length effect in dysphasic naming: when elephant is easier than ant. Best W. **Cortex** 1995 Dec;31(4):637–52 (50 ref.)

LANGUAGE THERAPY

Speech and language therapy: does it work? Enderby P, et

LANGUAGE THERAPY

al. **BMJ** 1996 Jun 29;312(7047):1655–8 (34 ref.)

LANGUAGE TRAINING see **LANGUAGE THERAPY**

LANGURS see **CERCOPITHECIDAE**

LANOSTEROL

ANALOGS & DERIVATIVES

Oxylanosterols as modifiers of cholesterol biosynthesis. Trzaskos JM. **Prog Lipid Res** 1995;34(2):99–116 (28 ref.)

LANTHANIDES see **METALS, RARE EARTH**

LANUGO see **HAIR**

LAPAROSCOPIC CHOLECYSTECTOMY see **CHOLECYSTECTOMY, LAPAROSCOPIC**

LAPAROSCOPIC SURGERY see **SURGERY, LAPAROSCOPIC**

LAPAROSCOPY

Laparoscopy in urology: present status, controversies, and future directions. Matsuda T, et al. **Int J Urol** 1996 Mar; 3(2):83–97 (211 ref.)

Office laparoscopy as a screening tool for early detection of ovarian cancer. Runowicz CD.
J Cell Biochem Suppl 1995;23:238–42 (12 ref.)

Laparoscopy and laparoscopic ultrasound in the staging of gastric cancer. Conlon KC, et al. **Semin Oncol** 1996 Jun; 23(3):347–51 (22 ref.)

Role of laparoscopy in the diagnosis and treatment of prostate cancer. Moore RG, et al. **Semin Surg Oncol** 1996 Mar–Apr; 12(2):139–44 (51 ref.)

–Complications of hysteroscopy and laparoscopy from the anesthesiologic viewpoint– Zollinger A.
Arch Gynecol Obstet 1995;256 Suppl:S12–20 (25 ref.) **(Ger)**

ADVERSE EFFECTS

Port site recurrences after laparoscopic and thoracoscopic procedures in malignancy. Johnstone PA, et al.
J Clin Oncol 1996 Jun;14(6):1950–6 (38 ref.)

INSTRUMENTATION

Peritoneoscopic placement of Swan neck peritoneal dialysis catheters. Copley JB, et al. **Perit Dial Int** 1996;16 Suppl 1:S330–2 (18 ref.)

[Current status of laparoscopic surgery in pediatric urology] Fuchs GJ, et al. **Urologe A** 1996 May;35(3):175–84 (62 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Critical appraisal and current position of laparoscopic hernia repair. Macintyre IM, et al. **J R Coll Surg Edinb** 1995 Oct; 40(5):331–6 (59 ref.)

Colonoscopic polypectomy: indication, technique, and therapeutic implications. Greene FL. **Semin Surg Oncol** 1995 Nov–Dec;11(6):416–22 (19 ref.)

Initial experience with retroperitoneoscopic nephroureterectomy: use of a double–balloon technique. Gill IS, et al. **Urology** 1995 Nov;46(5):747–50 (22 ref.)

[Ultrasonic laparoscopy in digestive diseases] Catheline JM, et al. **Ann Chir** 1996;50(1):51–7 (30 ref.) (Eng. Abstr.) **(Fre)**

[Place of celioscopy in the diagnosis of invasiveness of digestive cancers] Chambon JP, et al. **Ann Chir** 1995; 49(6):513–8 (25 ref.) (Eng. Abstr.) **(Fre)**

TRENDS

[Will surgical wounds and pain be history? (editorial)] Kivilaakso E. **Duodecim** 1995;111(4):293–6 (16 ref.) **(Fin)**

VETERINARY

[Clinical use of rigid endoscopes in avian patients] Hochleithner M, et al. **Tierarztl Prax** 1995 Oct;23(5):469–74 (23 ref.) (Eng. Abstr.) **(Ger)**

LAPAROTOMY

Conservative surgery for severe endometriosis: should laparotomy be abandoned definitively? Crosignani PG, et al. **Hum Reprod** 1995 Sep;10(9):2412–8 (63 ref.)

Polypropylene mesh closure after emergency laparotomy: morbidity and outcome. Brandt CP, et al. **Surgery** 1995 Oct;118(4):736–40; discussion 740–1 (17 ref.)

[The use of laparostomy in treating peritonitis] Komarov NV, et al. **Klin Khir** 1995;(9–10):45–8 (45 ref.) **(Rus)**

METHODS

Second–look laparotomy for stage III epithelial ovarian cancer: rationale and current issues. Muderspach L, et al. **Cancer Treat Rev** 1996 Nov;21(6):499–511 (60 ref.)

LARVA

CYTOLOGY

Diversification of cell cycle controls in developing embryos. Edgar B. **Curr Opin Cell Biol** 1995 Dec;7(6):815–24 (77 ref.)

METABOLISM

Energetics of fish larvae, the smallest vertebrates. Wieser W. **Acta Physiol Scand** 1995 Jul;154(3):279–90 (62 ref.)

LARVA MIGRANS

Larva migrans in Italy. Albanese G, et al.
Int J Dermatol 1995 Jul;34(7):464–5 (5 ref.)

[Larva migrans] Chabasse D, et al. **Sante** 1995 Nov–Dec; 5(6):341–5 (29 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

[A case of Dirofilaria repens migration in man] Artamonova AA, et al. **Med Parazitol (Mosk)** 1996 Jan–Mar;(1):44 (6 ref.) (Eng. Abstr.) **(Rus)**

LARVA MIGRANS, CUTANEOUS see **LARVA MIGRANS**

LARVA MIGRANS, OCULAR see **LARVA MIGRANS**

LARVA MIGRANS, VISCERAL

[Hepatic toxocariasis] Ishibashi H, et al.
Ryoikibetsu Shokogun Shirizu 1995;(7):48–50 (20 ref.) **(Jpn)**

COMPLICATIONS

Visceral larva migrans induced eosinophilic cardiac pseudotumor: a cause of sudden death in a child. Boschetti A, et al. **J Forensic Sci** 1995 Nov;40(6):1097–9 (12 ref.)

DIAGNOSIS

[Visceral larva migrans: a mixed form of presentation in an adult. The clinical and laboratory aspects] Barra LA, et al. **Rev Soc Bras Med Trop** 1996 Jul–Aug;29(4):373–6 (18 ref.) (Eng. Abstr.) **(Por)**

LARYNGEAL CARTILAGES

PATHOLOGY

Impact of cartilage invasion on treatment and prognosis of laryngeal cancer. Castelijns JA, et al. **Eur Radiol** 1996; 6(2):156–69 (54 ref.)

LARYNGEAL DISEASES

[Progresses in otorhinolaryngology in China, 1995] Liu C, et al. **Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):758–9 (0 ref.) **(Chi)**

COMPLICATIONS

Airway obstruction secondary to rhinoscleroma during pregnancy. Armstrong WB, et al. **Ear Nose Throat J** 1995 Nov;74(11):768–73 (40 ref.)

Laryngeal squamous carcinoma associated with longstanding localised amyloidosis. A case report. Navani SS, et al. **Indian J Cancer** 1995 Mar;32(1):43–5 (7 ref.)

CONGENITAL

Congenital vallecular cyst: a cause of failure to thrive. Oluwole M. **Br J Clin Pract** 1996 Apr–May;50(3):170 (9 ref.)

DIAGNOSIS

Two new otolaryngologic findings in child abuse. Drake AF, et al. **Arch Otolaryngol Head Neck Surg** 1995 Dec; 121(12):1417–20 (11 ref.)

Imaging of the larynx. Castelijns JA, et al.
Neuroimaging Clin N Am 1996 May;6(2):401–15 (68 ref.)

Invasive aspergillosis of the larynx: case report and review of the literature. Richardson BE, et al.
Otolaryngol Head Neck Surg 1996 Mar;114(3):471–3 (5 ref.)

[Functional laryngeal obstruction] Alonso Peces ME, et al. **Arch Bronconeumol** 1995 Dec;31(10):543–5 (12 ref.) (Eng. Abstr.) **(Spa)**

LARYNGEAL MASK AIRWAY see **LARYNGEAL MASKS**

LARYNGEAL MASKS

The laryngeal mask airway—anatomical and physiological implications. Brimacombe J, et al.
Acta Anaesthesiol Scand 1996 Feb;40(2):201–9 (124 ref.)

Review of uses of the laryngeal mask in ENT anaesthesia [see comments] Nair I, et al. **Anaesthesia** 1995 Oct; 50(10):898–900 (27 ref.) Comment in: Anaesthesia 1996 Apr;51(4):409.

Laryngeal mask airway and the ASA difficult airway algorithm. Benumof JL. **Anesthesiology** 1996 Mar; 84(3):686–99 (115 ref.)

Anaesthetic management of the Kenny–Caffey syndrome using the laryngeal mask. Janke EL, et al.
Paediatr Anaesth 1996;6(3):235–8 (16 ref.)

Laryngeal mask airway: uses in anesthesiology. Pinosky M. **South Med J** 1996 Jun;89(6):551–5 (21 ref.)

LARYNGEAL MUCOSA

Primary mucosal malignant melanoma of the larynx: case report and review of the literature. Mattavelli F, et al.
Tumori 1995 Nov–Dec;81(6):460–3 (25 ref.)

LARYNGEAL NEOPLASMS

Laryngeal pleomorphic rhabdomyosarcoma. A critical review of the literature. Da Mosto MC, et al.
Ann Otol Rhinol Laryngol 1996 Apr;105(4):289–94 (22 ref.)

Primary mucosal malignant melanoma of the larynx: case report and review of the literature. Mattavelli F, et al.
Tumori 1995 Nov–Dec;81(6):460–3 (25 ref.)

CHEMICALLY INDUCED

[Do employees in the rubber industry have an increased risk of laryngeal cancer?] Tisch M, et al. **HNO** 1995 Nov; 43(11):649–53 (24 ref.) (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

Malignant fibrous histiocytoma of the larynx—a rare case in an adolescent. A case report. Sharma AK.
Acta Radiol 1996 May;37(3 Pt 1):321–2 (5 ref.)

Laryngeal involvement in pediatric neurofibromatosis: a case report and review of the literature. Masip MJ, et al.
Pediatr Radiol 1996 Jul;26(7):488–92 (22 ref.)

ETIOLOGY

Laryngeal squamous carcinoma associated with longstanding localised amyloidosis. A case report. Navani SS, et al.
Indian J Cancer 1995 Mar;32(1):43–5 (7 ref.)

The association of occupational asbestos dust exposure and laryngeal carcinoma [see comments] Kraus T, et al.
Isr J Med Sci 1995 Sep;31(9):540–8 (76 ref.) Comment in: Isr J Med Sci 1995 Sep;31(9):563–4.

[Current concepts concerning the role of sex hormones and gonadotropins in the development of laryngeal cancer] Shadyev KhD, et al. **Vestn Ross Akad Med Nauk** 1995; (10):22–4 (30 ref.) **(Rus)**

PATHOLOGY

"Early" cancer of the larynx: the concept as defined by clinicians, pathologists, and biologists. Ferlito A, et al.
Ann Otol Rhinol Laryngol 1996 Mar;105(3):245–50 (18 ref.)

Mucosal adenoid squamous cell carcinoma of the head and neck. Ferlito A, et al. **Ann Otol Rhinol Laryngol** 1996 May; 105(5):409–13 (18 ref.)

Biological characterization of laryngeal squamous–cell carcinoma. Tomasino RM, et al. **Anticancer Res** 1996 Jul–Aug;16(4B):2257–67 (96 ref.)

Laryngeal oncocytic cystadenomas. Eight cases and a literature review. Brandwein M, et al.
Arch Otolaryngol Head Neck Surg 1995 Nov; 121(11):1302–5 (38 ref.)

Pathologic quiz case 2. Oncocytic cyst of the larynx. Kleidermacher P, et al.
Arch Otolaryngol Head Neck Surg 1995 Dec; 121(12):1430–1, 1433 (5 ref.)

Skin metastases from a laryngeal carcinoma: report of a case. Debois JM. **Cutis** 1996 Apr;57(4):264–6 (14 ref.)

Impact of cartilage invasion on treatment and prognosis of laryngeal cancer. Castelijns JA, et al. **Eur Radiol** 1996; 6(2):156–69 (54 ref.)

Laryngeal carcinoma ex–papilloma in a non–irradiated, non–smoking patient: a clinical record and review of the literature. Hasan S, et al. **J Laryngol Otol** 1995 Aug; 109(8):762–6 (33 ref.)

Schwannoma of the larynx: a case report. Ingels K, et al.
J Laryngol Otol 1996 Mar;110(3):294–6 (12 ref.)

Bilateral ventricular neurofibroma of the larynx. Koc C, et al. **J Laryngol Otol** 1996 Apr;110(4):385–6 (18 ref.)

Laryngeal paraganglioma. A review and report of a single case. Ozünlü A, et al. **J Laryngol Otol** 1996 Jun; 110(6):519–26 (60 ref.)

Benign fibrous histiocytoma of the larynx: presentation of a case and review of the literature. Van Laer C, et al.
J Laryngol Otol 1996 May;110(5):474–7 (28 ref.)

Involvement of the larynx by hemopoietic neoplasms. An investigation of autopsy cases and review of the literature. Horny HP, et al. **Pathol Res Pract** 1995 Mar;191(2):130–8 (88 ref.)

Coping with laryngeal cancer. Shanks JC.
Semin Speech Lang 1995 Aug;16(3):180–90 (37 ref.)

[Distant metastases originating from tumors of the larynx and hypopharynx] Traserra J, et al.
Rev Laryngol Otol Rhinol (Bord) 1989;110(3):267–71 (16 ref.) (Eng. Abstr.) **(Fre)**

RADIOGRAPHY

[Radiological criteria for laryngeal tumors and cervical metastases] Melchor Diaz MA, et al.
Acta Otorrinolaringol Esp 1996 Jan–Feb;47(1):1–7 (17 ref.) (Eng. Abstr.) **(Spa)**

RADIOTHERAPY

Pre versus post-operative radiotherapy of resectable squamous cell carcinoma of the head and neck. Wennerberg J. **Acta Otolaryngol (Stockh)** 1995 Jul;115(4):465–74 (63 ref.)

SECONDARY

Involvement of the larynx by hemopoietic neoplasms. An investigation of autopsy cases and review of the literature. Horny HP, et al. **Pathol Res Pract** 1995 Mar;191(2):130–8 (88 ref.)

SURGERY

Pre versus post-operative radiotherapy of resectable squamous cell carcinoma of the head and neck. Wennerberg J. **Acta Otolaryngol (Stockh)** 1995 Jul;115(4):465–74 (63 ref.)

Dysphagia after pharyngolaryngeal cancer surgery. Part II: Implications for reconstructive procedures. Herberhold C, et al. **Dysphagia** 1995 Fall;10(4):279–81 (28 ref.)

Dysphagia after pharyngolaryngeal cancer surgery. Part I: Pathophysiology of postsurgical deglutition. Walther EK. **Dysphagia** 1995 Fall;10(4):275–8 (25 ref.)

Management of carcinoma of the supraglottic larynx: evolution, current concepts, and future trends. Myers EN, et al. **Laryngoscope** 1996 May;106(5 Pt 1):559–67 (46 ref.)

The role of computed tomography and magnetic resonance imaging in planning for conservation laryngeal surgery. Weinstein GS, et al. **Neuroimaging Clin N Am** 1996 May; 6(2):497–504 (25 ref.)

Laser vestibulectomy for endolaryngeal neurofibroma. Hisa Y, et al. **Otolaryngol Head Neck Surg** 1995 Oct; 113(4):459–61 (19 ref.)

Surgical treatment of laryngeal cancer. Hamaker RC, et al. **Semin Speech Lang** 1995 Aug;16(3):221–32 (12 ref.)

Coping with laryngeal cancer. Shanks JC. **Semin Speech Lang** 1995 Aug;16(3):180–90 (37 ref.)

[A case of vascular leiomyoma in the larynx] Kamata T, et al. **Nippon Jibiinkoka Gakkai Kaiho** 1995 Jul;98(7):1119–24 (29 ref.) (Eng. Abstr.) **(Jpn)**

ULTRASONOGRAPHY

[Contribution of echography in the detection of lymph node diseases in epidermoid carcinoma of the larynx: therapeutic implications] Heitzmann P, et al. **Ann Otolaryngol Chir Cervicofac** 1995;112(5):229–33 (15 ref.) (Eng. Abstr.) **(Fre)**

ULTRASTRUCTURE

[Primary microcytoma of the larynx. Case report, ultrastructural study and review of the literature] Nirchio V, et al. **Pathologica** 1995 Apr;87(2):171–4 (17 ref.) (Eng. Abstr.) **(Ita)**

VIROLOGY

Recurrent laryngeal papillomatosis developing into laryngeal carcinoma with human papilloma virus (HPV) type 18: a case report. Sakakura A, et al. **J Laryngol Otol** 1996 Jan; 110(1):75–7 (18 ref.)

LARYNGEAL PARALYSIS see **VOCAL CORD PARALYSIS**

LARYNGEAL PROSTHESIS see **LARYNX, ARTIFICIAL**

LARYNGEAL STENOSIS see **LARYNGOSTENOSIS**

LARYNGECTOMY

see related
LARYNX, ARTIFICIAL
SPEECH, ALARYNGEAL

Management of carcinoma of the supraglottic larynx: evolution, current concepts, and future trends. Myers EN, et al. **Laryngoscope** 1996 May;106(5 Pt 1):559–67 (46 ref.)

The role of computed tomography and magnetic resonance imaging in planning for conservation laryngeal surgery. Weinstein GS, et al. **Neuroimaging Clin N Am** 1996 May; 6(2):497–504 (25 ref.)

Surgical treatment of laryngeal cancer. Hamaker RC, et al. **Semin Speech Lang** 1995 Aug;16(3):221–32 (12 ref.)

Counseling laryngectomees and families. Renner MJ. **Semin Speech Lang** 1995 Aug;16(3):215–20 (5 ref.)

LARYNGITIS

DIAGNOSIS

Cryptococcosis of the larynx. Isaacson JE, et al. **Otolaryngol Head Neck Surg** 1996 Jan;114(1):106–9 (10 ref.)

MICROBIOLOGY

Cryptococcosis of the larynx. Isaacson JE, et al. **Otolaryngol Head Neck Surg** 1996 Jan;114(1):106–9 (10 ref.)

LARYNGOPHARYNX see **HYPOPHARYNX**

LARYNGOSCOPY

ADVERSE EFFECTS

Controlling the hemodynamic response to laryngoscopy and endotracheal intubation. Kovac AL. **J Clin Anesth** 1996 Feb;8(1):63–79 (166 ref.)

INSTRUMENTATION

[Intubation trauma of the larynx--a literature review with special reference to arytenoid cartilage dislocation (see comments)] Rieger A, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Jun; 31(5):281–7 (37 ref.) (Eng. Abstr.) Comment in: Anasthesiol Intensivmed Notfallmed Schmerzther 1996 Jun;31(5):279–80. **(Ger)**

LARYNGOSTENOSIS

COMPLICATIONS

Fraser syndrome (cryptophthalmos [hidden eye]-syndactyly syndrome). Sarman G, et al. **J Perinatol** 1995 Nov-Dec; 15(6):503–6 (12 ref.)

DIAGNOSIS

Diagnosis and management of pediatric laryngeal stenosis. Werkhaven JA, et al. **Otolaryngol Clin North Am** 1995 Aug; 28(4):797–808 (30 ref.)

ETIOLOGY

Histopathologic fundamentals of acquired laryngeal stenosis. Liu H, et al. **Pediatr Pathol Lab Med** 1995 Sep–Oct; 15(5):655–77 (26 ref.)

PATHOLOGY

Histopathologic fundamentals of acquired laryngeal stenosis. Liu H, et al. **Pediatr Pathol Lab Med** 1995 Sep–Oct; 15(5):655–77 (26 ref.)

SURGERY

Augmentation techniques in laryngotracheal reconstruction. Eliachar I, et al. **Acta Otorhinolaryngol Belg** 1995; 49(4):397–406 (43 ref.)

Subglottic resection with primary tracheal anastomosis including synchronous laryngotracheal reconstruction. Pearson FG, et al. **Acta Otorhinolaryngol Belg** 1995; 49(4):389–96 (19 ref.)

CO2 laser posterior transverse cordotomy for isolated type IV posterior glottic stenosis. Gaboriau H, et al. **Am J Otolaryngol** 1995 Sep–Oct;16(5):350–3 (20 ref.)

Laser treatment of lower airway stenosis. Coleman JA Jr, et al. **Otolaryngol Clin North Am** 1995 Aug;28(4):771–83 (8 ref.)

Open surgical techniques for laryngotracheal stenosis. Duncavage JA, et al. **Otolaryngol Clin North Am** 1995 Aug; 28(4):785–95 (18 ref.)

Operative evaluation of airway obstruction. Gardner GM, et al. **Otolaryngol Clin North Am** 1995 Aug;28(4):737–50 (12 ref.)

Diagnosis and management of pediatric laryngeal stenosis. Werkhaven JA, et al. **Otolaryngol Clin North Am** 1995 Aug; 28(4):797–808 (30 ref.)

THERAPY

Endoscopic management of benign airway stenosis. Mehta AC, et al. **Clin Chest Med** 1995 Sep;16(3):401–13 (29 ref.)

LARYNX

see related
LARYNGECTOMY
LARYNGOSCOPY

ABNORMALITIES

Prenatal sonographic diagnosis of upper airway obstruction: a challenge that can be achieved. Golan-Porat N, et al. **J Laryngol Otol** 1996 Jun;110(6):583–5 (16 ref.)

ANATOMY & HISTOLOGY

Anatomy of the larynx, trachea, and bronchi. Armstrong WB, et al. **Otolaryngol Clin North Am** 1995 Aug;28(4):685–99 (24 ref.)

INJURIES

[Intubation trauma of the larynx--a literature review with special reference to arytenoid cartilage dislocation (see comments)] Rieger A, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Jun; 31(5):281–7 (37 ref.) (Eng. Abstr.) Comment in: Anasthesiol Intensivmed Notfallmed Schmerzther 1996 Jun;31(5):279–80. **(Ger)**

PATHOLOGY

Mucosal adenoid squamous cell carcinoma of the head and neck. Ferlito A, et al. **Ann Otol Rhinol Laryngol** 1996 May; 105(5):409–13 (18 ref.)

Coping with laryngeal cancer. Shanks JC. **Semin Speech Lang** 1995 Aug;16(3):180–90 (37 ref.)

PHYSIOLOGY

Esophago/pharyngo/laryngeal interrelationships: airway protection mechanisms. Kidder TM. **Dysphagia** 1995 Fall; 10(4):228–31 (21 ref.)

Airway protective mechanisms: current concepts. Shaker R. **Dysphagia** 1995 Fall;10(4):216–27 (112 ref.)

Laryngograph: speech pattern element tools for therapy, training and assessment. Fourcin A, et al. **Eur J Disord Commun** 1995;30(2):101–15 (0 ref.)

External laryngeal frame function in voice production revisited: a review. Vilkman E, et al. **J Voice** 1996 Mar; 10(1):78–92 (90 ref.)

Anatomy of the larynx, trachea, and bronchi. Armstrong WB, et al. **Otolaryngol Clin North Am** 1995 Aug;28(4):685–99 (24 ref.)

RADIATION EFFECTS

Pre versus post-operative radiotherapy of resectable squamous cell carcinoma of the head and neck. Wennerberg J. **Acta Otolaryngol (Stockh)** 1995 Jul;115(4):465–74 (63 ref.)

RADIOGRAPHY

[Radiological criteria for laryngeal tumors and cervical metastases] Melchor Díaz MA, et al. **Acta Otorrinolaringol Esp** 1996 Jan-Feb;47(1):1–7 (17 ref.) (Eng. Abstr.) **(Spa)**

SURGERY

Pre versus post-operative radiotherapy of resectable squamous cell carcinoma of the head and neck. Wennerberg J. **Acta Otolaryngol (Stockh)** 1995 Jul;115(4):465–74 (63 ref.)

Dysphagia after pharyngolaryngeal cancer surgery. Part II: Implications for reconstructive procedures. Herberhold C, et al. **Dysphagia** 1995 Fall;10(4):279–81 (28 ref.)

Dysphagia after pharyngolaryngeal cancer surgery. Part I: Pathophysiology of postsurgical deglutition. Walther EK. **Dysphagia** 1995 Fall;10(4):275–8 (25 ref.)

Unilateral vocal fold paralysis: a review of the current methods of surgical rehabilitation. Harries ML. **J Laryngol Otol** 1996 Feb;110(2):111–6 (57 ref.)

Surgical treatment of laryngeal cancer. Hamaker RC, et al. **Semin Speech Lang** 1995 Aug;16(3):221–32 (12 ref.)

Coping with laryngeal cancer. Shanks JC. **Semin Speech Lang** 1995 Aug;16(3):180–90 (37 ref.)

LARYNX, ARTIFICIAL

see related
SPEECH, ALARYNGEAL

The artificial larynx. Watterson TL, et al. **Semin Speech Lang** 1995 Aug;16(3):205–14 (13 ref.)

LASER-ASSISTED BALLOON ANGIOPLASTY see **ANGIOPLASTY, BALLOON, LASER-ASSISTED**

LASER COAGULATION

What should be done when initial endoscopic therapy for bleeding peptic ulcer fails? [editorial] Swain P. **Endoscopy** 1995 May;27(4):321–8 (69 ref.)

Laparoscopic coagulation of myoma (myolysis). Goldfarb HA. **Obstet Gynecol Clin North Am** 1995 Dec;22(4):807–19 (32 ref.)

Laser therapy in the palliation of dysphagia in oesophageal malignancy. Lewis-Jones CM, et al. **Palliat Med** 1995 Oct; 9(4):327–30 (15 ref.)

[The treatment of bladder tumors with the Nd:YAG laser] Khinev A. **Khirurgiia (Sofiia)** 1995;48(5):58–62 (29 ref.) (Eng. Abstr.) **(Bul)**

[Treatment of refractory glaucoma by diode semiconductor laser cyclophotocoagulation] Hamard P, et al. **J Fr Ophtalmol** 1995;18(6-7):447–54 (26 ref.) (Eng. Abstr.) **(Fre)**

ADVERSE EFFECTS

Macular epiretinal membrane formation and treated retinal breaks. Saran BR, et al. **Am J Ophthalmol** 1995 Oct; 120(4):480–5 (27 ref.)

METHODS

Laser photocoagulation using binocular indirect ophthalmoscope laser delivery systems. Friberg TR. **Ophthalmic Surg Lasers** 1995 Nov-Dec;26(6):549–59 (18 ref.)

Laser-tissue interactions. Carr LW 3rd, et al. **Optom Clin** 1995;4(4):17–31 (31 ref.)

[Treatment of diabetic retinopathy. Clinical experience with various lasers. Complications associated with lasers] De Laey JJ. **Bull Soc Belge Ophtalmol** 1995;256:97–103 (24 ref.) (Eng. Abstr.) **(Fre)**

[Proliferative diabetic retinopathy: laser photocoagulation treatment] Snyers B. **Bull Soc Belge Ophtalmol** 1995; 256:87–94 (19 ref.) (Eng. Abstr.) **(Fre)**

LASER DESORPTION-IONIZATION MASS SPECTROMETRY, MATRIX-ASSISTED see **SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION**

LASER-DOPPLER FLOWMETRY

Evaluation of skin blood flow by laser Doppler flowmetry. Eun HC. **Clin Dermatol** 1995 Jul-Aug;13(4):337-47 (151 ref.)

[Methods of microcirculatory monitoring (laser Doppler flowmetry, photoplethysmography and computer-assisted venous occlusion plethysmography)] Christ F. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May; 31(1 Suppl):S37-43 (77 ref.) **(Ger)**

[Skin circulation--measurements with laser-doppler] Marszalek A. **Med Pr** 1996;47(4):411-8 (16 ref.) (Eng. Abstr.) **(Pol)**

UTILIZATION

Umbilical artery Doppler velocimetry: clinical utility in high-risk pregnancies. Divon MY. **Am J Obstet Gynecol** 1996 Jan;174(1 Pt 1):10-4 (36 ref.)

LASER-DOPPLER VELOCIMETRY see **LASER-DOPPLER FLOWMETRY**

LASER KNIFE see **LASER SURGERY**

LASER SCALPEL see **LASER SURGERY**

LASER SCANNING CONFOCAL MICROSCOPY see **MICROSCOPY, CONFOCAL**

LASER SURGERY

Cosmetic laser surgery. Alster TS. **Adv Dermatol** 1996; 11:51-80; discussion 81 (93 ref.)

CO2 laser posterior transverse cordotomy for isolated type IV posterior glottic stenosis. Gaboriau H, et al. **Am J Otolaryngol** 1995 Sep-Oct;16(5):350-3 (20 ref.)

Transurethral laser therapy and urinary tract infections. Miller J, et al. **Ann Urol (Paris)** 1996;30(3):131-8 (38 ref.)

Laser skin resurfacing [editorial; comment] Hruza GJ, et al. **Arch Dermatol** 1996 Apr;132(4):451-5 (61 ref.) Comment on: Arch Dermatol 1996 Apr;132(4):395-402. Comment on: Arch Dermatol 1996 APR;132(4):425-8. Comment on: Arch Dermatol 1996 APR;132(4):469-71.

Is laser sclerostomy surgery ready for 'prime time'? [editorial] Higginbotham EJ. **Arch Ophthalmol** 1995 Oct; 113(10):1243-4 (22 ref.)

Eruptive pyogenic granulomas: a successfully treated patient and review of the literature. Shah M, et al. **Br J Dermatol** 1995 Nov;133(5):795-6 (27 ref.)

Laser technology in research, diagnosis and therapy in rhinology. Soh KB. **Clin Otolaryngol** 1996 Apr;21(2):102-5 (34 ref.)

Lasers in aesthetic surgery. Rosenberg GJ, et al. **Clin Plast Surg** 1996 Jan;23(1):29-48 (60 ref.)

Dermabrasion, chemabrasion, and laserabrasion. Historical perspectives, modern dermabrasion techniques, and future trends. Fulton JE Jr. **Dermatol Surg** 1996 Jul;22(7):619-28 (52 ref.)

Lasers in otorhinolaryngology-head and neck surgery. Rebeiz EE. **J Med Liban** 1994;42(4):242-9 (21 ref.)

Lasers in gynecology: why pragmatic surgeons have not abandoned this valuable technology. Reid R, et al. **Lasers Surg Med** 1995;17(3):201-301 (209 ref.)

Argon laser peripheral iridoplasty. Ritch R, et al. **Ophthalmic Surg Lasers** 1996 Apr;27(4):289-300 (82 ref.)

Laser therapy and angle-closure glaucoma. Fleming JB. **Optom Clin** 1995;4(4):97-111 (39 ref.)

Capsulotomy. Murrill CA, et al. **Optom Clin** 1995;4(4):69-83 (58 ref.)

Integrating lasers into clinical practice. Rounds RS, et al. **Optom Clin** 1995;4(4):125-40 (10 ref.)

Laser therapy for open-angle glaucoma. Talley DK. **Optom Clin** 1995;4(4):85-96 (22 ref.)

Laser treatment of lower airway stenosis. Coleman JA Jr, et al. **Otolaryngol Clin North Am** 1995 Aug;28(4):771-83 (8 ref.)

Wound healing after laser surgery. Hendrick DA, et al. **Otolaryngol Clin North Am** 1995 Oct;28(5):969-86 (89 ref.)

An overview of treatment options for lower airway obstruction. Wanamaker JR, et al. **Otolaryngol Clin North Am** 1995 Aug;28(4):751-70 (52 ref.)

Laser vestibulectomy for endolaryngeal neurofibroma. Hisa Y, et al. **Otolaryngol Head Neck Surg** 1995 Oct; 113(4):459-61 (19 ref.)

Applications of laser technology in breast cancer therapy. Lanzafame RJ. **Semin Surg Oncol** 1995 Jul-Aug; 11(4):328-32 (40 ref.)

Laser surgery in gynecologic oncology. Schellhas HF. **Semin Surg Oncol** 1995 Jul-Aug;11(4):299-306 (53 ref.)

[Direct revascularization of ischemic myocardium by laser] Wang G, et al. **Chung Hua Wai Ko Tsa Chih** 1995 Apr; 33(4):243-5 (20 ref.) **(Chi)**

[Clinical progress in the therapy of myopia with excimer laser keratotomy] Zhu RY, et al. **Chung Hua Yen Ko Tsa Chih** 1995 May;31(3):221-5 (31 ref.) **(Chi)**

[Transmyocardial laser revascularization. A new possible method for treatment of ischemic heart disease] Andreasen JJ. **Ugeskr Laeger** 1996 Jun 24;158(26):3764-7 (29 ref.) (Eng. Abstr.) **(Dan)**

[Infrared photocoagulation, cryosurgery and laser surgery in hemorrhoidal disease] Tajana A, et al. **Ann Ital Chir** 1995 Nov-Dec;66(6):775-82 (33 ref.) (Eng. Abstr.) **(Ita)**

[Laser technology in prostatic surgery] Kornev AI, et al. **Urol Nefrol (Mosk)** 1996 Mar-Apr;(2):49-52 (39 ref.) **(Rus)**

ADVERSE EFFECTS

Complications of anterior segment laser procedures. Carr LW 3rd, et al. **Optom Clin** 1995;4(4):33-49 (50 ref.)

INSTRUMENTATION

The techniques and uses of lasers in general surgery. Daly CJ. **Curr Opin Gen Surg** 1993;:3-7 (29 ref.)

Laser-assisted removal of a foreign body in the bronchial system of an infant. Boelcskei PL, et al. **Lasers Surg Med** 1995;17(4):375-7 (20 ref.)

Lasers in ophthalmology. Krauss JM, et al. **Lasers Surg Med** 1995;17(2):102-59 (536 ref.)

[Laser therapy of the skin] Hohenleutner U, et al. **HNO** 1995 Sep;43(9):557-71 (64 ref.) **(Ger)**

[Percutaneous laser disk decompression. Experience since 1989] Siebert WE, et al. **Orthopade** 1996 Feb;25(1):42-8 (36 ref.) (Eng. Abstr.) **(Ger)**

[30 years of experience in using lasers in dentistry] Prokhonchukov AA. **Stomatologiia (Mosk)** 1995; 74(4):68-73 (25 ref.) **(Rus)**

METHODS

Laser therapy of childhood haemangiomas. Landthaler M, et al. **Br J Dermatol** 1995 Aug;133(2):275-81 (30 ref.)

Laser bronchoscopy. Colt HG. **Chest Surg Clin N Am** 1996 May;6(2):277-91 (60 ref.)

Laser bronchoscopy. Ramser ER, et al. **Clin Chest Med** 1995 Sep;16(3):415-26 (66 ref.)

Laser tissue welding: a comprehensive review of current and future clinical applications. Bass LS, et al. **Lasers Surg Med** 1995;17(4):315-49 (155 ref.)

Lasers and liability. Classé JG. **Optom Clin** 1995;4(4):113-23 (19 ref.)

[Non-surgical instrumental treatment of benign hypertrophy of the prostate] Anidjar M, et al. **Presse Med** 1995 Oct 28;24(32):1477-80 (9 ref.) (Eng. Abstr.) **(Fre)**

[Long-term reduction of intraocular pressure by goniotrepanation or laser trabeculoplasty] Funk J, et al. **Klin Monatsbl Augenheilkd** 1995 Oct;207(4):215-23 (38 ref.) (Eng. Abstr.) **(Ger)**

[Holmium-YAG laser in outlet impingement of the shoulder. Mid-term results] De Simoni C, et al. **Orthopade** 1996 Feb; 25(1):84-90 (51 ref.) (Eng. Abstr.) **(Ger)**

[Arthroscopic holmium-YAG laser compared to conventional procedures on the knee joint. 2-year results of a randomized prospective study] Lübbers C, et al. **Orthopade** 1996 Feb;25(1):64-72 (35 ref.) (Eng. Abstr.) **(Ger)**

[Temperature and ablation measurements in laser therapy of intervertebral disk tissue] Schlangmann BA, et al. **Orthopade** 1996 Feb;25(1):3-9 (35 ref.) (Eng. Abstr.) **(Ger)**

TRENDS

[Current status and 21 century in the laser transmyocardial revascularization (LTMR)] Okada M. **Nippon Geka Gakkai Zasshi** 1996 Mar;97(3):234-9 (5 ref.) (Eng. Abstr.) **(Jpn)**

VETERINARY

[Application of laser surgery in veterinary medicine. 1. Fundamentals] Weigand K, et al. **Tierarztl Prax** 1995 Oct; 23(5):432-6 (6 ref.) (Eng. Abstr.) **(Ger)**

LASERS

Molecular inactivation. Spatially and temporally defined molecular knockouts. Müller BK, et al. **Curr Biol** 1995 Nov 1;5(11):1255-6 (9 ref.)

Cell optical displacement assay (CODA)--measurements of cytoskeletal tension in living plant cells with a laser optical trap. Schindler M. **Methods Cell Biol** 1995;49:71-84 (44 ref.)

Laser photochemotherapy: a less invasive approach for treatment of cancer. Saxton RE, et al. **Semin Surg Oncol** 1995 Jul-Aug;11(4):283-9 (76 ref.)

Physical characteristics and biological effects of laser-induced stress waves. Doukas AG, et al. **Ultrasound Med Biol** 1996;22(2):151-64 (82 ref.)

[Biophysical bases of the effects of holmium laser on articular cartilage and their impact on clinical application technics] Gerber BE, et al. **Orthopade** 1996 Feb;25(1):21-9 (37 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Ignition potential of the 585-nm pulsed-dye laser. Review of the literature and safety recommendations. Fretzin S, et al. **Dermatol Surg** 1996 Aug;22(8):699-702 (13 ref.)

DIAGNOSTIC USE

Laser technology in research, diagnosis and therapy in rhinology. Soh KB. **Clin Otolaryngol** 1996 Apr;21(2):102-5 (34 ref.)

STANDARDS

Laser hazards and safety. Monaco WA, et al. **Optom Clin** 1995;4(4):1-15 (4 ref.)

THERAPEUTIC USE

The role of pulsed laser in the management of cosmetically significant pigmented lesions. Bekhor PS. **Australas J Dermatol** 1995 Nov;36(4):221-3 (5 ref.)

Laser therapy. Küng EE. **Curr Probl Dermatol** 1996; 24:247-54 (20 ref.)

The effects of laser irradiation of the dental tissues--a review. Love RM. **N Z Dent J** 1995 Dec;91(406):134-7 (26 ref.)

[Progresses in laser medicine in China, 1995] Xu S. **Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):774-6 (0 ref.) **(Chi)**

[Effect of low-intensity laser radiation on the metabolic and restorative processes of the body] Briskin BS, et al. **Klin Med (Mosk)** 1996;74(1):54-5 (08 ref.) **(Rus)**

[Use of low-intensity lasers in tuberculosis] Kul'chavenia EV. **Probl Tuberk** 1995;(4):19-21 (38 ref.) **(Rus)**

[30 years of experience in using lasers in dentistry] Prokhonchukov AA. **Stomatologiia (Mosk)** 1995; 74(4):68-73 (25 ref.) **(Rus)**

[Low-intensity laser therapy in urology] Kul'chavenia EV. **Urol Nefrol (Mosk)** 1996 Jan-Feb;(1):41-4 (95 ref.) **(Rus)**

LASSITUDE see **FATIGUE**

LATE GENE TRANSCRIPTION see **TRANSCRIPTION, GENETIC**

LATE PROMOTERS see **PROMOTER REGIONS (GENETICS)**

LATENT SCHIZOPHRENIA see **SCHIZOTYPAL PERSONALITY DISORDER**

LATERAL GENICULATE BODY see **GENICULATE BODIES**

LATERAL LIGAMENTS see **COLLATERAL LIGAMENTS**

LATERAL SCLEROSIS see **AMYOTROPHIC LATERAL SCLEROSIS**

LATERALITY

Is there a sex difference in human laterality? II. An exhaustive survey of visual laterality studies from six neuropsychology journals. Hiscock M, et al. **J Clin Exp Neuropsychol** 1995 Aug;17(4):590-610 (60 ref.)

The accuracy of automated and clinical detection of brain damage and lateralization in neuropsychology. Russell EW. **Neuropsychol Rev** 1995 Mar;5(1):1-68 (105 ref.)

[Is there a pathological basis for lefthandedness?] Reiss M. **Schweiz Rundsch Med Prax** 1996 Aug 20;85(34):997-1000 (15 ref.) (Eng. Abstr.) **(Ger)**

[Simultaneous bilateral facial paralysis] Morales Angulo C, et al. **Acta Otorrinolaringol Esp** 1995 Jul-Aug;46(4):305-9 (71 ref.) (Eng. Abstr.) **(Spa)**

[Neuropsychology of left-handedness: current knowledge] Estévez-González A, et al. **Rev Neurol** 1996 May; 24(129):515-22 (183 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

In defence of the right shift theory. Annett M. **Percept Mot Skills** 1996 Feb;82(1):115-37 (62 ref.)

PHYSIOLOGY

Hemispheric asymmetry for visual information processing. Hellige JB. **Acta Neurobiol Exp (Warsz)** 1996;56(1):485-97 (66 ref.)

Dexterity and sexuality: is there a relationship? Hamill JA. **J Homosex** 1995;28(3-4):375-96 (60 ref.)

Unilateral spatial neglect due to a haemorrhagic contusion in the right frontal lobe. Maeshima S, et al. **J Neurol** 1995 Oct;242(10):613-7 (15 ref.)

Hemiatrophy, juvenile-onset exertional alternating leg paresis, hypotonia, and hemidystonia and adult-onset hemiparkinsonism: the spectrum of hemiparkinsonism-hemiatrophy syndrome. Lang AE. **Mov Disord** 1995 Jul;10(4):489-95 (32 ref.)

Theory meets experiment: correlated neural activity helps determine ocular dominance column periodicity. Goodhill GJ, et al. **Trends Neurosci** 1995 Oct;18(10):437-9 (38 ref.)

LATEX

ADVERSE EFFECTS

Issues of latex safety in dentistry. Field EA, et al. **Br Dent J** 1995 Oct 7;179(7):247-53 (51 ref.)

Latex allergy precautions. A research-based protocol. Steelman VM. **Nurs Clin North Am** 1995 Sep;30(3):475-93 (85 ref.)

[Surgical gloves, condoms, rubber balloons and other latex objects. A look at their pathogenic aspects] Piérard GE, et al. **Rev Med Liege** 1995 Sep;50(9):388-9 (26 ref.) **(Fre)**

[Anesthesiologic pecularities in patients with latex allergy

(see comments)] Kisch H, et al. **Anaesthesist** 1996 Jul; 45(7):587–96 (88 ref.) (Eng. Abstr.) Comment in: Anaesthesist 1996 Jul;45(7):585–6. **(Ger)**
[Latex allergy] Schürer NY, et al. **Hautarzt** 1995 Oct; 46(10):742–53 (10 ref.) **(Ger)**
[Latex allergy: from contact urticaria to asthma] Helbling A. **Schweiz Rundsch Med Prax** 1996 Aug 13;85(33):978–82 (22 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Food reactions in pollen and latex allergic patients [editorial] Frankland AW. **Clin Exp Allergy** 1995 Jul;25(7):580–1 (22 ref.)

LATEX RUBBER see **RUBBER**

LATHYRUS see **LEGUMES**

LATINOS see **HISPANIC AMERICANS**

LATRODECTUS MACTANS see **BLACK WIDOW SPIDER**

LATS RECEPTORS see **RECEPTORS, THYROID HORMONE**

LAUNDRY SERVICE, HOSPITAL

see related
BEDDING AND LINENS

LAURENCE-MOON-BIEDL SYNDROME

COMPLICATIONS

[Genetic syndrome with obesity] Tsuda K, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:436–40 (19 ref.) **(Jpn)**

LAV-2 see **HIV-2**

LAV ANTIBODIES see **HIV ANTIBODIES**

LAV ANTIGENS see **HIV ANTIGENS**

LAV-HTLV-III see **HIV**

LAVAGE see **IRRIGATION**

LAVAGE, GASTRIC see **GASTRIC LAVAGE**

LAXATIVES see **CATHARTICS**

LAXITY, JOINT see **JOINT INSTABILITY**

LCM VIRUSES see **LYMPHOCYTIC CHORIOMENINGITIS VIRUS**

LDL CHOLESTEROL see **LIPOPROTEINS, LDL CHOLESTEROL**

LDL RECEPTORS see **RECEPTORS, LDL**

LE CELLS see **NEUTROPHILS**

LE(X) ANTIGEN see **ANTIGENS, CD15**

LEAD

Measurements of environmental lead contamination and human exposure. Flegal AR, et al. **Rev Environ Contam Toxicol** 1995;143:1–45 (231 ref.)
[Exposure of children to lead from contaminated soil] Jacobsen P. **Ugeskr Laeger** 1996 Mar 11;158(11):1499–502 (22 ref.) (Eng. Abstr.) **(Dan)**

ADVERSE EFFECTS

Health effects of outdoor air pollution. Part 2. Committee of the Environmental and Occupational Health Assembly of the American Thoracic Society. **Am J Respir Crit Care Med** 1996 Feb;153(2):477–98 (226 ref.)
The neurobehavioural toxicology and teratology of lead. Winneke G, et al. **Arch Toxicol Suppl** 1996;18:57–70 (60 ref.)
Neurotoxicity of lead, methylmercury, and PCBs in relation to the Great Lakes. Rice DC. **Environ Health Perspect** 1995 Dec;103 Suppl 9:71–87 (221 ref.)
Unraveling the chronic toxicity of lead: an essential priority for environmental health. Todd AC, et al. **Environ Health Perspect** 1996 Mar;104 Suppl 1:141–6 (68 ref.)
[The role of lead and its compounds in the development of arterial hypertension] Solomenchuk TM. **Lik Sprava** 1995 May-Jun;(5–6):40–4 (48 ref.) **(Ukr)**

ANALYSIS

Stable isotopes of lead for source identification. Rabinowitz MB. **J Toxicol Clin Toxicol** 1995;33(6):649–55 (37 ref.)
[Lead] Seki Y, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:826–9 (18 ref.) **(Jpn)**

BLOOD

The accuracy of a lead questionnaire in predicting elevated pediatric blood lead levels. France EK, et al. **Arch Pediatr Adolesc Med** 1996 Sep;150(9):958–63 (14 ref.)
Relating tooth and blood lead levels in children. Rabinowitz MB. **Bull Environ Contam Toxicol** 1995 Dec;55(6):853–7 (14 ref.)

METABOLISM

The use of chelating agents in occupational lead poisoning. Porru S, et al. **Occup Med (Oxf)** 1996 Feb;46(1):41–8 (34 ref.)

PHARMACOKINETICS

PBK modeling for metals. Examples with lead, uranium, and chromium. O'Flaherty EJ. **Toxicol Lett** 1995 Dec; 82–83:367–72 (6 ref.)

TOXICITY

Immunotoxicity of heavy metals in relation to Great Lakes. Bernier J, et al. **Environ Health Perspect** 1995 Dec;103 Suppl 9:23–34 (145 ref.)

LEAD POISONING

Lead poisoning. Landrigan PJ, et al. **Mt Sinai J Med** 1995 Oct;62(5):360–4 (18 ref.)
Commonly asked questions about childhood lead poisoning. Glotzer DE, et al. **Pediatr Ann** 1995 Dec;24(12):630–2, 637–9 (50 ref.)

BLOOD

The accuracy of a lead questionnaire in predicting elevated pediatric blood lead levels. France EK, et al. **Arch Pediatr Adolesc Med** 1996 Sep;150(9):958–63 (14 ref.)

COMPLICATIONS

Neuro-behavioral effects of childhood lead exposure. vonKoss Krowchuk H. **Annu Rev Nurs Res** 1995;13:87–114 (108 ref.)
Mixed urinary incontinence secondary to lead poisoning. Crewalk JA, et al. **J Urol** 1996 Jun;155(6):2029 (3 ref.)
[Tubulointerstitial injuries in heavy metal intoxications] Kaizu K, et al. **Nippon Rinsho** 1995 Aug;53(8):2052–6 (19 ref.) (Eng. Abstr.) **(Jpn)**
[Lead gout] Lebedeva MV, et al. **Klin Med (Mosk)** 1995; 73(3):103–4 (8 ref.) **(Rus)**

DIAGNOSIS

Trace metals (lead and cadmium exposure screening). Daher RT. **Anal Chem** 1995 Jun 15;67(12):405R–410R (66 ref.)

EPIDEMIOLOGY

[Lead poisoning in children: from epidemiology to public health] Roustit C. **Arch Pediatr** 1995 Sep;2(9):886–90 (33 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

[A wine pitcher, cause of lead poisoning] Jouglard J, et al. **Presse Med** 1996 Feb 17;25(6):243–6 (8 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Is lead toxicosis a reflection of altered energy metabolism in brain synaptosomes? Rafałowska U, et al. **Acta Neurobiol Exp (Warsz)** 1996;56(2):611–7 (30 ref.)

PREVENTION & CONTROL

Nutrition and lead: strategies for public health. Mahaffey KR. **Environ Health Perspect** 1995 Sep;103 Suppl 6:191–6 (60 ref.)

THERAPY

The use of chelating agents in occupational lead poisoning. Porru S, et al. **Occup Med (Oxf)** 1996 Feb;46(1):41–8 (34 ref.)
Getting the lead out: when is treatment necessary? Trachtenbarg DE. **Postgrad Med** 1996 Mar;99(3):201–2, 207–18 (14 ref.)

LEADER SIGNAL PEPTIDES see **SIGNAL PEPTIDES**

LEADERSHIP

The surgeon as a leader in cancer care: lessons learned from the study of soft tissue sarcoma. Brennan MF. **J Am Coll Surg** 1996 Jun;182(6):520–9 (35 ref.)
The leadership dance. Ehrat KS, et al. **J Nurs Adm** 1996 Apr;26(4):13–5 (14 ref.)
Improving nursing practice, education, and research. Fagin CM. **J Nurs Adm** 1996 Mar;26(3):30–7 (12 ref.)
Past-present-future messages for nursing leadership. Kelley LS. **J Prof Nurs** 1996 Mar-Apr;12(2):76–85 (33 ref.)

LEARNING

Teaching and learning in ambulatory care settings: a thematic review of the literature. Irby DM. **Acad Med** 1995 Oct; 70(10):898–931 (152 ref.)
Sleep stages, memory and learning. Dotto L. **Can Med Assoc J** 1996 Apr 15;154(8):1193–6 (12 ref.)
Ontogenetic differences in variability on simple measures of learning: theoretical and practical implications. Wenger MJ, et al. **Dev Psychobiol** 1996 Apr;29(3):219–39 (61 ref.)
Observations on task-related behaviour of Macaca arctoides. Linnankoski I, et al. **Folia Primatol (Basel)** 1995;65(1):34–7 (7 ref.)
Synthesizing animal and human behavior research via neural network learning theory. Tryon WW. **J Behav Ther Exp Psychiatry** 1995 Dec;26(4):303–12 (98 ref.)
Dimensions of stimulus complexity. Fetterman JG. **J Exp Psychol Anim Behav Process** 1996 Jan;22(1):3–18 (176 ref.)
Proper names and how they are learned. La Palme Reyes M, et al. **Memory** 1993 Dec;1(4):433–55 (32 ref.)
Flies, genes, learning, and memory. Greenspan RJ. **Neuron** 1995 Oct;15(4):747–50 (29 ref.)
Separate digits tests: a brief history, a literature review, and a reexamination of the factor structure of the Test of Memory and Learning (TOMAL). Ramsay MC, et al. **Neuropsychol Rev** 1995 Sep;5(3):151–71 (58 ref.)
Technology transfer as collaborative learning. Tenkasi RV, et al. **NIDA Res Monogr** 1995;155:147–68 (53 ref.)
Habitual physical activity and academic performance. Shephard RJ. **Nutr Rev** 1996 Apr;54(4 Pt 2):S32–6 (42 ref.)
Metals and school learning: a review of investigative techniques. Ittenbach RF, et al. **Percept Mot Skills** 1995 Dec;81(3 Pt 2):1079–90 (48 ref.)
Physiology and biochemistry of Drosophila learning mutants. Davis RL. **Physiol Rev** 1996 Apr;76(2):299–317 (97 ref.)
How food preferences are learned: laboratory animal models. Sclafani A. **Proc Nutr Soc** 1995 Jul;54(2):419–27 (63 ref.)
Morning report and work rounds: opportunities for teaching and learning. Schiffman FJ. **Trans Am Clin Climatol Assoc** 1995;107:275–86 (19 ref.)
Limits of natural science: brain research and computers. Stieve H. **Z Naturforsch [C]** 1995 May-Jun;50(5–6):317–36 (86 ref.)
[Genes and the modulation of learning and memory] Xiong Y, et al. **Sheng Li Ko Hsueh Chin Chan** 1995 Oct; 26(4):293–8 (19 ref.) (Eng. Abstr.) **(Chi)**
[Neurobiology of learning and memory and anti-dementia drug] Ishikawa K. **Nippon Yakurigaku Zasshi** 1995 Aug; 106(2):67–76 (76 ref.) (Eng. Abstr.) **(Jpn)**
[Molecular mechanism of learning and memory with genetics] Yagi T. **Tanpakushitsu Kakusan Koso** 1995 Oct; 40(14):2175–80 (31 ref.) **(Jpn)**

DRUG EFFECTS

Learning during anaesthesia: a review. Andrade J. **Br J Psychol** 1995 Nov;86 (Pt 4):479–506 (110 ref.)
NO honey, I don't remember. Hawkins RD. **Neuron** 1996 Mar;16(3):465–7 (18 ref.)

PHYSIOLOGY

Towards understanding of the role of transcription factors in learning processes. Kaczmarek L. **Acta Biochim Pol** 1995;42(2):221–6 (59 ref.)
Analogical transfer in sequence learning. Human and neural-network models of frontostriatal function. Dominey PF, et al. **Ann N Y Acad Sci** 1995 Dec 15;769:369–73 (5 ref.)
Procedural learning and prefrontal cortex. Pascual-Leone A, et al. **Ann N Y Acad Sci** 1995 Dec 15;769:61–70 (20 ref.)
Long-term potentiation and learning. Martinez JL Jr, et al. **Annu Rev Psychol** 1996;47:173–203 (150 ref.)
Processing of learned information in paradoxical sleep: relevance for memory. Hennevin E, et al. **Behav Brain Res** 1995 Jul-Aug;69(1–2):125–35 (97 ref.)
What does the hippocampus really do? Jarrard LE. **Behav Brain Res** 1995 Nov;71(1–2):1–10 (42 ref.)
Learning-related changes in hippocampal field potentials. Moser EI. **Behav Brain Res** 1995 Nov;71(1–2):11–8 (66 ref.)
A role for immediate-early transcription factors in learning and memory. Dragunow M. **Behav Genet** 1996 May; 26(3):293–9 (55 ref.)
The use of null mutant mice to study complex learning and memory processes. Wehner JM, et al. **Behav Genet** 1996 May;26(3):301–12 (75 ref.)
Flies, genes, and memory engineering. Gelperin A. **Biol Bull** 1996 Aug;191(1):139–43 (95 ref.)
The role of attention in learning about odorants. Smith BH. **Biol Bull** 1996 Aug;191(1):76–83 (54 ref.)
Short- and long-term modification of reflex function during learning and metamorphosis in Manduca. Weeks JC, et al. **Biol Bull** 1996 Aug;191(1):62–9 (34 ref.)
Behavioral learning. The illuminated songbird. Mooney R. **Curr Biol** 1995 Jun 1;5(6):609–11 (611 ref.)
Building action repertoires: memory and learning functions of the basal ganglia. Graybiel AM. **Curr Opin Neurobiol** 1995 Dec;5(6):733–41 (89 ref.)
Olfactory learning. Keverne EB. **Curr Opin Neurobiol** 1995 Aug;5(4):482–8 (34 ref.)
Simulation of spatial learning in the Morris water maze by a neural network model of the hippocampal formation and nucleus accumbens. Brown MA, et al. **Hippocampus** 1995;

5(3):171–88 (73 ref.)
Biochemistry of insect learning: lessons from bees and flies. Meller VH, et al. **Insect Biochem Mol Biol** 1996 Apr; 26(4):327–35 (81 ref.)
Does breakfast make a difference in school? Pollitt E. **J Am Diet Assoc** 1995 Oct;95(10):1134–9 (24 ref.)
The King Solomon Lectures in Neuroethology. A white canary on Mount Acropolis. Nottebohm F. **J Comp Physiol** [A] 1996 Aug;179(2):149–56 (57 ref.)
Sexually dimorphic spatial learning in meadow voles Microtus pennsylvanicus and deer mice Peromyscus maniculatus. Galea LA, et al. **J Exp Biol** 1996 Jan;199 (Pt 1):195–200 (29 ref.)
Calcium-dependent afterhyperpolarization and learning in young and aging hippocampus. Disterhoft JF, et al. **Life Sci** 1996;59(5–6):413–20 (54 ref.)
Neuropoiesis: proposal for a connectionistic neurobiology. Jobe TH, et al. **Med Hypotheses** 1995 Aug;45(2):147–63 (145 ref.)
The biochemistry of learning and memory. Fagnou DD, et al. **Mol Cell Biochem** 1995 Aug–Sep;149–150:279–86 (84 ref.)
Molecular enhancement of memory formation. Carew TJ. **Neuron** 1996 Jan;16(1):5–8 (24 ref.)
Role of basal ganglia in behavioral learning. Kimura M. **Neurosci Res** 1995 Jul;22(4):353–8 (33 ref.)
The gene knockout technology for the analysis of learning and memory, and neural development. Tonegawa S, et al. **Prog Brain Res** 1995;105:3–14 (43 ref.)
Amygdala role in conditioned associative learning. Ono T, et al. **Prog Neurobiol** 1995 Jul;46(4):401–22 (142 ref.)
Long-term depression: a learning-related type of synaptic plasticity in the mammalian central nervous system. Zhuo M, et al. **Rev Neurosci** 1995 Jul–Sep;6(3):259–77 (142 ref.)
The cerebellum: a neuronal learning machine? Raymond JL, et al. **Science** 1996 May 24;272(5265):1126–31 (49 ref.)
[Neurogenesis of brain space of song learning in adult songbirds] Li DF. **Sheng Li Ke Hsueh Chin Chan** 1995 Jul;26(3):273–5 (10 ref.) **(Chi)**
[Genetic aspects of learning mechanisms] Ponomarenko VV, et al. **Fiziol Zh Im I M Sechenova** 1995 Aug;81(8):57–62 (20 ref.) (Eng. Abstr.) **(Rus)**

LEARNING DISORDERS

see related
DYSLEXIA
Learning disabilities. Lyon GR. **Future Child** 1996 Spring; 6(1):54–76 (71 ref.)
Children who have difficulty in school: a primary pediatrician's approach. McInerny TK. **Pediatr Rev** 1995 Sep;16(9):325–32; quiz 332 (18 ref.)

PHYSIOPATHOLOGY
Biological correlates of learning and attention: what is relevant to learning disability and attention-deficit hyperactivity disorder? Denckla MB. **J Dev Behav Pediatr** 1996 Apr;17(2):114–9 (37 ref.)

PSYCHOLOGY
Perils and pitfalls on the path to normal potential: the role of impaired attention. Homage to Herbert G. Birch. Mirsky AF. **J Clin Exp Neuropsychol** 1995 Aug;17(4):481–98 (36 ref.)
[The development and learning] Evrard P, et al. **Arch Pediatr** 1996;3 Suppl 1:44s–52s (97 ref.) **(Fre)**

VIROLOGY
HSV-1 brain infection by the olfactory nerve route and virus latency and reactivation may cause learning and behavioral deficiencies and violence in children and adults: a point of view. Becker Y. **Virus Genes** 1995;10(3):217–26 (58 ref.)

LEBER'S OPTIC ATROPHY see **OPTIC ATROPHY, HEREDITARY**

LECAM-1 see **L-SELECTIN**

LECAM-2 see **E-SELECTIN**

LECAM-3 see **P-SELECTIN**

LECITHIN ACYLTRANSFERASE

BLOOD
[Lecithin-cholesterol acyltransferase (LCAT)] Itakura H. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:647–50 (8 ref.) **(Jpn)**

GENETICS
Two novel molecular defects in the LCAT gene are associated with fish eye disease. Kuivenhoven JA, et al. **Arterioscler Thromb Vasc Biol** 1996 Feb;16(2):294–303 (33 ref.)

LECITHIN ACYLTRANSFERASE DEFICIENCY

GENETICS
[LCAT deficiency] Imai Y, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):258–61 (18 ref.) **(Jpn)**

LECITHIN CHOLESTEROL ACYLTRANSFERASE see **LECITHIN ACYLTRANSFERASE**

LECITHINASE A1 see **PHOSPHOLIPASES A**

LECITHINASE A2 see **PHOSPHOLIPASES A**

LECITHINASE C see **PHOSPHOLIPASE C**

LECITHINASE D see **PHOSPHOLIPASE D**

LECITHINASES see **PHOSPHOLIPASES**

LECTINS

[Galectins: decoder of glyco-code] Hirabayashi J, et al. **Seikagaku** 1995 Dec;67(12):1366–87 (98 ref.) **(Jpn)**

BIOSYNTHESIS
Galectins in mouse embryogenesis. Colnot C, et al. **Biochem Soc Trans** 1996 Feb;24(1):141–6 (41 ref.)

CHEMISTRY
Ca(2+)-dependent sugar recognition by animal lectins. Drickamer K. **Biochem Soc Trans** 1996 Feb;24(1):146–50 (20 ref.)
Increasing diversity of animal lectin structures. Drickamer K. **Curr Opin Struct Biol** 1995 Oct;5(5):612–6 (53 ref.)
X-ray crystal structures of animal lectins. Rini JM. **Curr Opin Struct Biol** 1995 Oct;5(5):617–21 (36 ref.)
Fractionation of glycoprotein-derived oligosaccharides by affinity chromatography using immobilized lectin columns. Endo T. **J Chromatogr A** 1996 Jan 12;720(1–2):251–61 (66 ref.)

IMMUNOLOGY
T-cell activation, anergy and immunomodulation by molecules of viral, fungal and vegetal origin. Bemer V, et al. **Res Immunol** 1995 May–Jun;146(4–5):249–62 (81 ref.)

METABOLISM
Lectin-carbohydrate interactions in disease. T-cell recognition of IgA and IgD; mannose binding protein recognition of IgG0. Rudd P, et al. **Adv Exp Med Biol** 1995;376:147–52 (10 ref.)
Carbohydrate-protein interactions in vascular biology. Nelson RM, et al. **Ann Rev Cell Dev Biol** 1995;11:601–31 (185 ref.)
Ca(2+)-dependent sugar recognition by animal lectins. Drickamer K. **Biochem Soc Trans** 1996 Feb;24(1):146–50 (20 ref.)
[Study of the reactivity of giant cell tumors of bones to different lectins] Illés T, et al. **Arch Anat Cytol Pathol** 1995; 43(5–6):331–7 (23 ref.) (Eng. Abstr.) **(Fre)**
[CD22: a cell adhesion molecule that displays alpha 2-6-linked sialic acid-binding lectin activity] Hanasaki K. **Seikagaku** 1995 Aug;67(8):1040–7 (15 ref.) **(Jpn)**

PHYSIOLOGY
Lectins as plant defense proteins. Peumans WJ, et al. **Plant Physiol** 1995 Oct;109(2):347–52 (27 ref.)
[Protein-carbohydrate recognition. Foundation and medical application with illustrations of tumor lectin studies] Gabius HJ, et al. **Naturwissenschaften** 1995 Dec;82(12):533–43 (162 ref.) (Eng. Abstr.) **(Ger)**

LEECHES

Leech therapy in digital replantation. Golden MA, et al. **AORN J** 1995 Sep;62(3):364–6, 369, 371–2, passim (0 ref.)
Indications and complications of medicinal leech therapy. Haycox CL, et al. **J Am Acad Dermatol** 1995 Dec; 33(6):1053–5 (10 ref.)

CHEMISTRY
Proteinase inhibitors from the European medicinal leech Hirudo medicinalis: structural, functional and biomedical aspects. Ascenzi P, et al. **Mol Aspects Med** 1995; 16(3):215–313 (319 ref.)

LEFT ATRIAL FUNCTION see **ATRIAL FUNCTION, LEFT**

LEFT HEART SYNDROME, HYPOPLASTIC see **HYPOPLASTIC LEFT HEART SYNDROME**

LEFT VENTRICULAR DYSFUNCTION see **VENTRICULAR DYSFUNCTION, LEFT**

LEFT VENTRICULAR FUNCTION see **VENTRICULAR FUNCTION, LEFT**

LEFT VENTRICULAR HYPERTROPHY see **HYPERTROPHY, LEFT VENTRICULAR**

LEG

see related
HINDLIMB
Lower extremity bursitis [published erratum appears in Am Fam Physician 1996 Aug;54(2):468] Butcher JD, et al. **Am Fam Physician** 1996 May 15;53(7):2317–24 (13 ref.)
Leg cramps: differential diagnosis and management [see comments] Riley JD, et al. **Am Fam Physician** 1995 Nov 1;52(6):1794–8 (25 ref.) Comment in: Am Fam Physician 1996 May 15;53(7):2284.
Quinine for nocturnal leg cramps? **Drug Ther Bull** 1996 Jan; 34(1):7–8 (15 ref.)
Posttraumatic pseudolipoma. David LR, et al. **J Trauma** 1996 Mar;40(3):396–400 (15 ref.)
Venous obstruction due to a distended urinary bladder. Evans JM, et al. **Mayo Clin Proc** 1995 Nov;70(11):1077–9 (17 ref.)
Benign nocturnal leg cramps. Current controversies over use of quinine. Leclerc KM, et al. **Postgrad Med** 1996 Feb; 99(2):177–8, 181–4 (13 ref.)
Exercise-induced lower leg pain. Rochcongar P. **Rev Rhum Engl Ed** 1995 Nov;62(10):627–31 (35 ref.)

BLOOD SUPPLY
Thrombolysis in extremital arteries--indications and methods. Wellander E, et al. **Ann Chir Gynaecol** 1995; 84(4):341–8 (74 ref.)
Classification and grading of chronic venous disease in the lower limbs: a consensus statement. American Venous Forum [editorial] Myers KA. **Aust N Z J Surg** 1995 Nov; 65(11):769–72 (44 ref.)
Diagnosis of arterial disease of the lower extremities with duplex ultrasonography. Koelemay MJ, et al. **Br J Surg** 1996 Mar;83(3):404–9 (48 ref.)
Thrombolytic therapy for acute arterial occlusion. Ouriel K. **Curr Opin Gen Surg** 1994;:257–64 (39 ref.)
The role of surveillance after infrainguinal bypass grafting. Giannoukas AD, et al. **Eur J Vasc Endovasc Surg** 1996 Apr;11(3):279–89 (107 ref.)
Epidural spinal cord stimulation in the treatment of limb threatening vasospasm--report of a case with a five-year follow-up. Lepantalo M, et al. **Eur J Vasc Endovasc Surg** 1996 Apr;11(3):368–70 (5 ref.)
Classification and grading of chronic venous disease in the lower limbs. A consensus statement. Beebe HG, et al. **Int Angiol** 1995 Jun;14(2):197–201 (45 ref.)
Microcirculation in venous disorders: the role of the white blood cells. Dormandy JA. **Int J Microcirc Clin Exp** 1995; 15 Suppl 1:3–8 (16 ref.)
Aneurysm of a congenitally persistent sciatic artery presenting as a soft-tissue mass of the buttock. A case report. Benevenia J, et al. **J Bone Joint Surg Am** 1995 Nov; 77(11):1724–8 (33 ref.)
Interposition vein cuffs. Harris P, et al. **J Mal Vasc** 1996; 21 Suppl A:178–80 (11 ref.)
Surgery of the sympathetic nervous system. Lee BY, et al. **J Spinal Cord Med** 1996 Jan;19(1):20–6 (50 ref.)
Are type IIIC lower extremity injuries an indication for primary amputation. Quirke TE, et al. **J Trauma** 1996 Jun; 40(6):992–6 (45 ref.)
Interventionalists' guide to the patient's experience of lower extremity arterial occlusive disease. McDaniel MD, et al. **J Vasc Interv Radiol** 1995 Nov–Dec;6(6 Pt 2 Su):30S–35S (27 ref.)
Cost-efficacy issues in the treatment of peripheral vascular disease: primary amputation or revascularization for limb-threatening ischemia. Perler BA. **J Vasc Interv Radiol** 1995 Nov–Dec;6(6 Pt 2 Su):111S–115S (28 ref.)
Magnetic resonance angiography of the peripheral arteries. Yucel EK. **Magn Reson Imaging Clin N Am** 1993 Dec; 1(2):229–38 (39 ref.)
Diagnosis of chronic venous disease of the lower extremities: the "CEAP" classification [see comments] Kistner RL, et al. **Mayo Clin Proc** 1996 Apr;71(4):338–45 (6 ref.) Comment in: Mayo Clin Proc 1996 Apr;71(4):422–3.
Lower limb salvage: microvascular reconstruction of post-traumatic soft tissue and skeletal defects. Tomaino MM. **Orthopedics** 1995 Jul;18(7):665–72 (68 ref.)
Infrapopliteal percutaneous transluminal angioplasty: what we know [comment] Bakal CW, et al. **Radiology** 1996 Jul; 200(1):36–43 (58 ref.) Comment on: Radiology 1996 Jul;200(1):33–6.
Percutaneous transluminal angioplasty of the infrapopliteal vessels: the evidence [see comments] Fraser SC, et al. **Radiology** 1996 Jul;200(1):33–6 (44 ref.) Comment in: Radiology 1996 Jul;200(1):36–43.
The role of thrombolysis in the management of acute arterial occlusions of the lower limb. Browning NG, et al. **S Afr J Surg** 1995 Dec;33(4):170–4 (52 ref.)
Thrombolytic therapy in acute lower limb ischemia. Pilger E. **Semin Thromb Hemost** 1996;22(1):61–7 (48 ref.)
Prosthetic grafts: when are they a reasonable alternative? Abbott WM, et al. **Semin Vasc Surg** 1995 Sep;8(3):236–45 (51 ref.)
Techniques and strategies using arm veins. Andros G. **Semin Vasc Surg** 1995 Sep;8(3):179–87 (28 ref.)

Preoperative assessment of alternative veins. Salles-Cunha SX, et al. **Semin Vasc Surg** 1995 Sep;8(3):172–8 (21 ref.)
Arterial reconstruction for limb salvage: is the terminal peroneal artery a disadvantaged outflow tract? Darling RC 3rd, et al. **Surgery** 1995 Oct;118(4):763–7 (24 ref.)
Lower limb intraarterial thrombolysis as an adjunct to the management of arterial and graft occlusions. Braithwaite BD, et al. **World J Surg** 1996 Jul–Aug;20(6):649–54 (38 ref.)
[Catheterization therapy of thromboembolic arterial occlusions of the lower extremities] Staněk F, et al. **Cas Lek Cesk** 1995 Aug 2;134(15):471–3 (28 ref.) (Eng. Abstr.) **(Cze)**
[Critical lower extremity ischemia] Lepäntalo M. **Duodecim** 1995;111(3):267–72 (25 ref.) **(Fin)**
[Platelet antiaggregants and atheromatous arteriopathy of the lower limbs] Lévesque H, et al. **Rev Med Interne** 1996; 17(2):163–8 (47 ref.) (Eng. Abstr.) **(Fre)**
[Venous allografts for salvage of lower limbs: hope and reality] Van Damme H, et al. **Rev Med Liege** 1995 Oct; 50(10):433–42 (72 ref.) **(Fre)**
[Risk predictors and risk-adjusted prevention in peripheral arterial occlusive diseases] Rieger H. **Internist (Berl)** 1995 Sep;36(9):902–8 (30 ref.) **(Ger)**
[Use of PGE1 in severe ischemia of the lower extremities. Clinical study] Occhionorelli S, et al. **Minerva Cardioangiol** 1995 Jun;43(6):247–56 (73 ref.) (Eng. Abstr.) **(Ita)**
[Surgical treatment of vascular injuries of the legs] D'Aloia N. **Minerva Chir** 1995 May;50(5):455–62 (35 ref.) (Eng. Abstr.) **(Ita)**

PHYSIOLOGY

Eccentric activation and muscle damage: biomechanical and physiological considerations during downhill running. Eston RG, et al. **Br J Sports Med** 1995 Jun;29(2):89–94 (53 ref.)
The study of kinematic transients in locomotion using the integrated kinematic sensor. Wu G, et al. **IEEE Trans Rehabil Eng** 1996 Sep;4(3):193–200 (18 ref.)

SURGERY

Amputation surgery and prostheses. Rodriguez RP. **Orthop Clin North Am** 1996 Jul;27(3):525–39 (59 ref.)
[Surgery of soft tissue sarcoma (with the exception of the retroperitoneum)] Stöckle E, et al. **Ann Chir** 1996; 50(3):263–75 (85 ref.) (Eng. Abstr.) **(Fre)**
[Surgical treatment of vascular injuries of the legs] D'Aloia N. **Minerva Chir** 1995 May;50(5):455–62 (35 ref.) (Eng. Abstr.) **(Ita)**
[Fascial and fasciocutaneous flaps for treatment of posterior and distal area of the lower leg and heel area] Kulesza T. **Chir Narzadow Ruchu Ortop Pol** 1996;61(1):67–72 (11 ref.) **(Pol)**

LEG INJURIES

Lower leg, foot, and ankle injuries in young athletes. Stanish WD. **Clin Sports Med** 1995 Jul;14(3):651–68 (71 ref.)
The effects of weapons: surgical challenge and medical dilemma. Coupland RM. **J R Coll Surg Edinb** 1996 Apr; 41(2):65–71 (6 ref.)
Lower leg overuse injuries in athletes. Järvinen M. **Knee Surg Sports Traumatol Arthrosc** 1993;1(2):126–30 (33 ref.)
Overuse injuries of the lower extremity in runners. Rolf C. **Scand J Med Sci Sports** 1995 Aug;5(4):181–90 (105 ref.)

COMPLICATIONS

Fourth-degree burn induced thrombosis of the femoral artery and vein. De Santis F, et al. **Eur J Vasc Endovasc Surg** 1996 Apr;11(3):378–80 (9 ref.)
Posttraumatic pseudolipoma. David LR, et al. **J Trauma** 1996 Mar;40(3):396–400 (15 ref.)
Calcific myonecrosis following compartment syndrome: report of two cases, review of the literature, and recommendations for treatment. Snyder BJ, et al. **J Trauma** 1995 Oct;39(4):792–5 (6 ref.)
[Trauma and thrombosis. High risk of embolism in patients with spinal cord injuries, hip fractures and leg fractures] Bergqvist D. **Lakartidningen** 1996 Jul 24;93(30–31):2653–4 (19 ref.) **(Swe)**

CONGENITAL

Congenital annular constricting band: a case report with pseudarthrosis and review of the literature. Martinot-Duquennoy V, et al. **Eur J Pediatr Surg** 1995 Dec;5(6):380–4 (23 ref.)

ETIOLOGY

Injuries due to antipersonnel land mines in Sri Lanka. Goonetilleke G. **Ceylon Med J** 1995 Dec;40(4):141–5 (8 ref.)
Stress fractures of the sacrum and lower extremity. Fanciullo JJ, et al. **Curr Opin Rheumatol** 1996 Mar;8(2):158–62 (26 ref.)

SURGERY

[Concept for the management of combined bone-soft tissue defects of the lower extremity] Amgwerd MG, et al. **Swiss Surg** 1995;(2):90–5 (30 ref.) (Eng. Abstr.) **(Ger)**
[Surgical treatment of vascular injuries of the legs] D'Aloia N. **Minerva Chir** 1995 May;50(5):455–62 (35 ref.) (Eng. Abstr.) **(Ita)**

THERAPY

Lower extremity injuries in runners. Helping athletic patients return to form. Wexler RK. **Postgrad Med** 1995 Oct; 98(4):185–7, 191–3 (29 ref.)

LEG LENGTH INEQUALITY

see related
BONE LENGTHENING

CONGENITAL

Distraction osteogenesis in congenital limb length discrepancy: a review. Maffuli N, et al. **J R Coll Surg Edinb** 1996 Aug;41(4):258–64 (77 ref.)

SURGERY

Management of pediatric limb length inequality. Guidera KJ, et al. **Adv Pediatr** 1995;42:501–43 (66 ref.)
Transfibular osteotomy in the correction of ankle joint incongruity. Davis JL, et al. **J Foot Ankle Surg** 1995 Jul–Aug;34(4):389–99 (23 ref.)
Toxic shock syndrome as a complication of orthopaedic surgery. Grimes J, et al. **J Pediatr Orthop** 1995 Sep–Oct; 15(5):666–71 (28 ref.)
Distraction osteogenesis in congenital limb length discrepancy: a review. Maffuli N, et al. **J R Coll Surg Edinb** 1996 Aug;41(4):258–64 (77 ref.)

LEG ULCER

CLASSIFICATION

Martorell's ulcer. Shutler SD, et al. **Postgrad Med J** 1995 Dec;71(842):717–9 (12 ref.)

COMPLICATIONS

Cutaneous gangrene due to hyperparathyroidism secondary to chronic renal failure (uraemic gangrene syndrome). Török L, et al. **Clin Exp Dermatol** 1996 Jan;21(1):75–7 (10 ref.)

ETIOLOGY

Recurrent and chronic leg ulcers secondary to furosemide-induced bullous pemphigoid [letter] Siddiqui MA, et al. **J Am Geriatr Soc** 1995 Oct;43(10):1183–4 (7 ref.)

NURSING

Managing vascular leg ulcers. Part 2: treatment [see comments] Harris AH, et al. **Am J Nurs** 1996 Feb; 96(2):40–6; quiz 47 (7 ref.) Comment in: Am J Nurs 1996 Jun;96(6):17.
Managing vascular leg ulcers. Part 1: Assessment [see comments] Harris AH, et al. **Am J Nurs** 1996 Jan; 96(1):38–43; quiz 44 (5 ref.) Comment in: Am J Nurs 1996 Jun;96(6):17.

THERAPY

Managing vascular leg ulcers. Part 2: treatment [see comments] Harris AH, et al. **Am J Nurs** 1996 Feb; 96(2):40–6; quiz 47 (7 ref.) Comment in: Am J Nurs 1996 Jun;96(6):17.

LEGAL GUARDIANS

[Legal aspects of treatment and care of elderly patients] Kaatsch HJ, et al. **Z Gerontol Geriatr** 1996 May–Jun; 29(3):176–9 (11 ref.) (Eng. Abstr.) **(Ger)**

LEGISLATION & JURISPRUDENCE

Can healthcare providers obtain judicial intervention against surrogates who demand "medically inappropriate" life support for incompetent patients? [see comments] Cantor NL. **Crit Care Med** 1996 May;24(5):883–7 (28 ref.) Comment in: Crit Care Med 1996 May;24(5):730–2.

LEGAL MEDICINE see **FORENSIC MEDICINE**

LEGIONELLA

[Comparative biology of Legionella species—with special reference to host-parasite relationships] Yoshida S, et al. **Nippon Saikingaku Zasshi** 1995 Jul;50(3):745–64 (139 ref.) **(Jpn)**

DRUG EFFECTS

Review of azithromycin activity against Legionella spp. Edelstein PH. **Pathol Biol (Paris)** 1995 Jun;43(6):569–72 (18 ref.)

LEGIONELLA PNEUMOPHILA

CHEMISTRY

The lipopolysaccharide of Legionella pneumophila serogroup 1 (strain Philadelphia 1): chemical structure and biological significance. Zähringer U, et al. **Prog Clin Biol Res** 1995; 392:113–39 (76 ref.)

DRUG EFFECTS

Review of azithromycin activity against Legionella spp. Edelstein PH. **Pathol Biol (Paris)** 1995 Jun;43(6):569–72 (18 ref.)

GENETICS

Speculations on the influence of infecting phenotype on virulence and antibiotic susceptibility of Legionella pneumophila. Barker J, et al. **J Antimicrob Chemother** 1995 Jul;36(1):7–21 (131 ref.)

ISOLATION & PURIFICATION

Legionella urinary antigen testing: potential impact on diagnosis and antibiotic therapy. Kashuba AD, et al. **Diagn Microbiol Infect Dis** 1996 Mar;24(3):129–39 (31 ref.)

PATHOGENICITY

Speculations on the influence of infecting phenotype on virulence and antibiotic susceptibility of Legionella pneumophila. Barker J, et al. **J Antimicrob Chemother** 1995 Jul;36(1):7–21 (131 ref.)

LEGIONELLA PNEUMOPHILA INFECTIONS see **LEGIONNAIRES' DISEASE**

LEGIONELLOSIS

DIAGNOSIS

Legionella urinary antigen testing: potential impact on diagnosis and antibiotic therapy. Kashuba AD, et al. **Diagn Microbiol Infect Dis** 1996 Mar;24(3):129–39 (31 ref.)

MICROBIOLOGY

[Comparative biology of Legionella species—with special reference to host-parasite relationships] Yoshida S, et al. **Nippon Saikingaku Zasshi** 1995 Jul;50(3):745–64 (139 ref.) **(Jpn)**

URINE

Legionella urinary antigen testing: potential impact on diagnosis and antibiotic therapy. Kashuba AD, et al. **Diagn Microbiol Infect Dis** 1996 Mar;24(3):129–39 (31 ref.)

LEGIONNAIRES' DISEASE

COMPLICATIONS

[Legionnaires' disease with acute respiratory insufficiency. Clinical and biological characteristics, comparison with pneumococcal pneumonia] Mallet JP, et al. **Presse Med** 1996 Apr 27;25(15):702–6 (17 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Legionnaires' disease and acute renal insufficiency: report of a case and review of the literature. Verhaeverbeke I, et al. **Acta Clin Belg** 1995;50(6):363–7 (26 ref.)

DRUG THERAPY

Recurrent infection of Legionella pneumonia: a case report. Ko YY, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1996 May;57(5):365–9 (19 ref.)
Antimicrobial chemotherapy for legionnaires' disease: a review. Edelstein PH. **Clin Infect Dis** 1995 Dec;21 Suppl 3:S265–76 (157 ref.)
Speculations on the influence of infecting phenotype on virulence and antibiotic susceptibility of Legionella pneumophila. Barker J, et al. **J Antimicrob Chemother** 1995 Jul;36(1):7–21 (131 ref.)
Review of azithromycin activity against Legionella spp. Edelstein PH. **Pathol Biol (Paris)** 1995 Jun;43(6):569–72 (18 ref.)
[Azithromycin, pharmacodynamic evaluation in animal models] Lagrange PH. **Pathol Biol (Paris)** 1995 Jun; 43(6):515–23 (37 ref.) (Eng. Abstr.) **(Fre)**

LEGISLATION

[Professional profile of primary health care personnel. A Delphi study] Molina Durán F, et al. **Aten Primaria** 1996 Jan;17(1):24–32 (21 ref.) (Eng. Abstr.) **(Spa)**

TRENDS

Realistic risk assessment. Stöhrer G. **Regul Toxicol Pharmacol** 1995 Oct;22(2):118–21 (26 ref.)

LEGISLATION, DRUG

Cosmeceuticals. A proposal for rational definition, evaluation, and regulation [editorial] Vermeer BJ, et al.

LEGISLATION, DRUG

Arch Dermatol 1996 Mar;132(3):337–40 (23 ref.)
Government regulatory influences on opioid prescribing and their impact on the treatment of pain of nonmalignant origin. Hill CS Jr. **J Pain Symptom Manage** 1996 May; 11(5):287–98 (38 ref.)
The role of international and regional organisations in the regulation of veterinary biologicals. Blancou J, et al. **Rev Sci Tech** 1995 Dec;14(4):1193–206 (11 ref.)
Regulation of immunological veterinary medicinal products in the European Union. Brunko P. **Rev Sci Tech** 1995 Dec; 14(4):1133–41 (12 ref.)
Registration of veterinary products in Argentina. Butler E, et al. **Rev Sci Tech** 1995 Dec;14(4):1121–31 (4 ref.) **(Eng, Spa)**
Present systems and future needs for risk assessment of veterinary biologicals in Australia: the perspective of the regulator. Doyle KA. **Rev Sci Tech** 1995 Dec;14(4):1157–70 (16 ref.)
Present systems and future needs for risk assessment of biologicals in the United States of America: the perspective of the regulator. Espeseth DA. **Rev Sci Tech** 1995 Dec; 14(4):1143–55 (3 ref.)
Present systems and future needs for risk assessments of biologicals: the perspective of the regulator in the People's Republic of China. Xia Y, et al. **Rev Sci Tech** 1995 Dec; 14(4):1185–91 (4 ref.)

LEGISLATION, FOOD

Use of disinfectants in open-air dairying. Hutchinson RE. **Rev Sci Tech** 1995 Jun;14(2):261–72 (46 ref.)
[Adulteration of food and luxuries and the origins of uniform state food legislation in Germany] Teuteberg HJ. **Z Ernahrungswiss** 1995 Jun;34(2):95–112 (192 ref.) (Eng. Abstr.) **(Ger)**

LEGISLATION, HOSPITAL

The Danish patient insurance scheme. A comparison with the Swedish system. Krenchel JV, et al. **J Leg Med** 1995 Sep;16(3):407–15 (38 ref.)
Unwinding the COBRA: new perspectives on EMTALA. Diekema DS. **Pediatr Emerg Care** 1995 Aug;11(4):243–8 (41 ref.)

LEGISLATION, MEDICAL

Current differences and consequences of legislation on practice of assisted reproductive technology in the Nordic countries. The Nordic Committee on Assisted Reproduction of the Scandinavian Federation of Societies of Obstetrics and Gynecology. Hazekamp JT. **Acta Obstet Gynecol Scand** 1996 Feb;75(2):198–200 (6 ref.)
Working with noncompliant and abusive dialysis patients: practical strategies based on ethics and the law. Johnson CC, et al. **Adv Ren Replace Ther** 1996 Jan;3(1):77–86 (40 ref.)
Legal implications of treating patients with HIV. Katine M. **J Am Podiatr Med Assoc** 1995 Aug;85(8):406–19 (38 ref.)
Recent medical-legal proceedings and their effect on the practice of medicine in Chicago. Heim SE, et al. **J Spinal Disord** 1995 Oct;8(5):419–21 (13 ref.)
Ethical and legal barriers to futility policies. King NM. **N C Med J** 1995 Sep;56(9):444–8 (35 ref.)
The legislative role in defining medical futility. Warren DG. **N C Med J** 1995 Sep;56(9):453–5 (11 ref.)
Defining neurotoxicity in a decision-making context. Tilson HA, et al. **Neurotoxicology** 1995 Summer;16(2):363–75 (49 ref.)
Regulating assisted reproductive technologies: an ethical framework. Steinbock B. **Womens Health Issues** 1996 May-Jun;6(3):167–74 (12 ref.)
Regulating assisted reproductive technologies: public health, consumer protection, and public resources. Wilcox LS, et al. **Womens Health Issues** 1996 May-Jun;6(3):175–80 (22 ref.)
[What are the complications likely to lead to medicolegal problems? How to manage them?] Samii K, et al. **Cah Anesthesiol** 1995;43(6):521–4 (20 ref.) **(Fre)**
[European regulations concerning medical devices] Savarino L, et al. **Minerva Med** 1995 Nov;86(11):481–93 (26 ref.) (Eng. Abstr.) **(Ita)**
[Legislation related to mental health: a review of various international experiences] Bertolote JM. **Rev Saude Publica** 1995 Apr;29(2):152–6 (14 ref.) (Eng. Abstr.) **(Por)**

ECONOMICS

Current challenges to the principles of medical law and their new interpretation. Paaso I. **Med Law** 1995;14(7–8):611–21 (15 ref.)

TRENDS

Legal trends in bioethics. Davis D. **J Clin Ethics** 1995 Fall; 6(3):285–8 (12 ref.)
Regulatory considerations in vaccine design. Davenport LW. **Pharm Biotechnol** 1995;6:81–96 (7 ref.)

LEGISLATION, NURSING

Becoming knowledgeable in the legislative process can help nurses shape their own future. Porter J, et al. **AORN J** 1996 Mar;63(3):618–21; quiz 622–4 (0 ref.)

LEGISLATION, VETERINARY

Benefits and burdens: legal and ethical issues raised by veterinary specialization. Tannenbaum J. **Adv Vet Sci Comp Med** 1995;39:253–96 (31 ref.)
The role of international and regional organisations in the regulation of veterinary biologicals. Blancou J, et al. **Rev Sci Tech** 1995 Dec;14(4):1193–206 (11 ref.)
Regulation of immunological veterinary medicinal products in the European Union. Brunko P. **Rev Sci Tech** 1995 Dec; 14(4):1133–41 (12 ref.)
Registration of veterinary products in Argentina. Butler E, et al. **Rev Sci Tech** 1995 Dec;14(4):1121–31 (4 ref.) **(Eng, Spa)**
Present systems and future needs for risk assessment of veterinary biologicals in Australia: the perspective of the regulator. Doyle KA. **Rev Sci Tech** 1995 Dec;14(4):1157–70 (16 ref.)
Present systems and future needs for risk assessment of biologicals in the United States of America: the perspective of the regulator. Espeseth DA. **Rev Sci Tech** 1995 Dec; 14(4):1143–55 (3 ref.)
Present systems and future needs for risk assessments of biologicals: the perspective of the regulator in the People's Republic of China. Xia Y, et al. **Rev Sci Tech** 1995 Dec; 14(4):1185–91 (4 ref.)

LEGUMES

see related
PLANTS, EDIBLE
Cellular, biological, and physicochemical basis for the hard-to-cook defect in legume seeds. Liu K. **Crit Rev Food Sci Nutr** 1995 Jul;35(4):263–98 (156 ref.)
From legumes to leukocytes: biological roles for sulfated carbohydrates. Hooper LV, et al. **FASEB J** 1996 Aug; 10(10):1137–46 (88 ref.)

CHEMISTRY

Cowpea flour: a potential ingredient in food products. Prinyawiwatkul W, et al. **Crit Rev Food Sci Nutr** 1996 May; 36(5):413–36 (130 ref.)

IMMUNOLOGY

Biochemical features of grain legume allergens in humans and animals. Lallès JP, et al. **Nutr Rev** 1996 Apr;54(4 Pt 1):101–7 (65 ref.)

METABOLISM

Heme synthesis in the rhizobium-legume symbiosis: a palette for bacterial and eukaryotic pigments. O'Brian MR. **J Bacteriol** 1996 May;178(9):2471–8 (95 ref.)

STANDARDS

Desirable characteristics of forage legumes for improving protein utilization in ruminants. Broderick GA. **J Anim Sci** 1995 Sep;73(9):2760–73 (60 ref.)

LEIOMYOBLASTOMA see LEIOMYOMA, EPITHELIOID

LEIOMYOMA

The myomatous erythrocytosis syndrome: a review. LevGur M, et al. **Obstet Gynecol** 1995 Dec;86(6):1026–30 (38 ref.)
[Leiomyoma, lipoma, myxoma, and fibroma of the gallbladder] Furukawa H. **Ryoikibetsu Shokogun Shirizu** 1996;(9):333–4 (8 ref.) **(Jpn)**
[Smooth muscle tumors of the extra-hepatic bile duct] Saito K. **Ryoikibetsu Shokogun Shirizu** 1996;(9):64–7 (22 ref.) **(Jpn)**
[Primary leiomyoma of the liver] Shiraki K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):432–4 (12 ref.) **(Jpn)**
[Bladder leiomyoma. Review and report of a case] Alapont Pérez FM, et al. **Arch Esp Urol** 1995 Dec;48(10):1035–7 (10 ref.) (Eng. Abstr.) **(Spa)**
[Characteristics of bladder leiomyoma in our setting] Blasco Casares FJ, et al. **Arch Esp Urol** 1995 Dec;48(10):987–90 (13 ref.) (Eng. Abstr.) **(Spa)**

COMPLICATIONS

Myomas and pregnancy. Phelan JP. **Obstet Gynecol Clin North Am** 1995 Dec;22(4):801–5 (28 ref.)
Myomata uteri and infertility. Wallach EE, et al. **Obstet Gynecol Clin North Am** 1995 Dec;22(4):791–9 (32 ref.)

DIAGNOSIS

Hysteroscopic diagnosis and operative therapy of submucous myoma. Corson SL. **Obstet Gynecol Clin North Am** 1995 Dec;22(4):739–55 (37 ref.)
Uterine fibroids. Diagnosis and indications for treatment. Hutchins FL Jr. **Obstet Gynecol Clin North Am** 1995 Dec; 22(4):659–65 (12 ref.)
Ultrasonography and magnetic resonance imaging of uterine fibroids. Mayer DP, et al. **Obstet Gynecol Clin North Am** 1995 Dec;22(4):667–725 (91 ref.)
[Treatment of uterine fibromas] Amiel C, et al. **Ann Chir** 1996;50(1):40–50 (79 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

Treatment of fibromas. Jourdain O, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Jun;66(2):99–107 (99 ref.)

ECONOMICS

Medical and socioeconomic impact of uterine fibroids. Greenberg MD, et al. **Obstet Gynecol Clin North Am** 1995 Dec;22(4):625–36 (40 ref.)

EPIDEMIOLOGY

[Muscular tumors of the digestive tract: an analysis of 53 cases] Larequi A, et al. **Rev Clin Esp** 1995 Dec; 195(12):836–40 (30 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

[Relation between progesterone and pathogenesis of uterine leiomyomas] Yang Y, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1996 Mar;31(3):184–5 (13 ref.) **(Chi)**

PATHOLOGY

Retroareolar leiomyoma [letter] Way JC. **Can J Surg** 1996 Aug;39(4):339 (7 ref.)
Benign cervical leiomyoma leading to disseminated fatal malignancy. O'Connell MP, et al. **Gynecol Oncol** 1996 Jul; 62(1):119–22 (5 ref.)
Leiomyoma of the nasal septum: report of a case and review of the literature. Llorente JL, et al. **J Laryngol Otol** 1996 Jan;110(1):65–8 (18 ref.)
Pathologic considerations of uterine smooth muscle tumors. Prayson RA, et al. **Obstet Gynecol Clin North Am** 1995 Dec;22(4):637–57 (69 ref.)
Myofibroma of the mandible. Clinicopathologic study and review of the literature. Sugatani T, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1995 Sep;80(3):303–9 (22 ref.)
Adrenal gland leiomyoma in a child with acquired immunodeficiency syndrome. Jimenez-Heffernan JA, et al. **Pediatr Pathol Lab Med** 1995 Nov-Dec;15(6):923–9 (22 ref.)
[Expansive uterine myoma during tamoxifen therapy. 11 cases] Le Bouëdec G, et al. **Presse Med** 1995 Nov 25; 24(36):1694–6 (18 ref.) (Eng. Abstr.) **(Fre)**
[Case of benign metastaxsizing leiomyoma of the lungs] Nishida T, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Feb;44(2):182–7 (23 ref.) (Eng. Abstr.) **(Jpn)**

SURGERY

Uterine fibroids: place and modalities of laparoscopic treatment. Dubuisson JB, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Mar;65(1):91–4 (17 ref.)
Treatment of fibromas. Jourdain O, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Jun;66(2):99–107 (99 ref.)
The controversy of laparoscopic myomectomy. Dicker D, et al. **Hum Reprod** 1996 May;11(5):935–7 (8 ref.)
Laparoscopic myomectomy today. A good technique when correctly indicated. Dubuisson JB, et al. **Hum Reprod** 1996 May;11(5):934–5 (21 ref.)
Laparoscopic myomectomy today. Why, when and for whom? Nezhat F, et al. **Hum Reprod** 1996 May;11(5):933–4 (13 ref.)
Hysteroscopic diagnosis and operative therapy of submucous myoma. Corson SL. **Obstet Gynecol Clin North Am** 1995 Dec;22(4):739–55 (37 ref.)
Laparoscopic coagulation of myoma (myolysis). Goldfarb HA. **Obstet Gynecol Clin North Am** 1995 Dec;22(4):807–19 (32 ref.)
Abdominal myomectomy as a treatment for symptomatic uterine fibroids. Hutchins FL Jr. **Obstet Gynecol Clin North Am** 1995 Dec;22(4):781–9 (28 ref.)
Laparoscopic myomectomy. Reich H. **Obstet Gynecol Clin North Am** 1995 Dec;22(4):757–80 (18 ref.)
Necrotizing fasciitis following laparoscopic surgery. Case report and review of the literature. Golshani S, et al. **Surg Endosc** 1996 Jul;10(7):751–4 (20 ref.)
Endobronchial leiomyoma: report of a case treated by bronchoplasty and a review of the literature. Ayabe H, et al. **Surg Today** 1995;25(12):1057–60 (17 ref.)
Review on laparoscopic hysterectomy. Deprest JA, et al. **Zentralbl Gynakol** 1995;117(12):641–51 (75 ref.)
[Laparoscopic surgery of large uterine fibromas. Operative technique and results] Dubuisson JB, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(7):705–10 (22 ref.) (Eng. Abstr.) **(Fre)**
[Uterine myomectomy in the treatment of infertility] Reroń A. **Ginekol Pol** 1995 Feb;66(2):108–11 (24 ref.) (Eng. Abstr.) **(Pol)**

THERAPY

Medical management of uterine fibromyomata. Davis KM, et al. **Obstet Gynecol Clin North Am** 1995 Dec;22(4):727–38 (44 ref.)

VETERINARY

Hypoglycemia in four dogs with smooth muscle tumors. Beaudry D, et al. **J Vet Intern Med** 1995 Nov–Dec; 9(6):415–8 (25 ref.)

LEIOMYOMA, EPITHELIOID

[Primary leiomyosarcoma of the liver 37 years after successful treatment of hereditary retinoblastoma] Abdelli N, et al. **Gastroenterol Clin Biol** 1996;20(5):502–5 (31 ref.) (Eng. Abstr.) **(Fre)**

[Gastric leiomyoblastoma: report of our case load] Canini T, et al. **Ann Ital Chir** 1995 May–Jun;66(3):329–34 (30 ref.) (Eng. Abstr.) **(Ita)**

COMPLICATIONS

Hemoperitoneum secondary to exogastric leiomyosarcoma: a case report. Tsianos GB, et al. **Hepatogastroenterology** 1995 Nov–Dec;42(6):885–7 (10 ref.)

EPIDEMIOLOGY

Epithelioid gastric stromal tumors (leiomyoblastomas): a study of fifty-five cases. Lee JS, et al. **Surgery** 1995 Oct; 118(4):653–60; discussion 660–1 (19 ref.)

PATHOLOGY

[A case report of epithelioid smooth muscle tumor (leiomyoblastoma) of the stomach prolapsing into the duodenal bulbus] Takashima Y, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Nov; 92(11):1858–62 (16 ref.) **(Jpn)**

LEIOMYOMA, VASCULAR see **ANGIOMYOMA**

LEIOMYOMATOSIS

COMPLICATIONS

Lymphangioleiomyomatosis, chylous ascites, and diet. Calvo E, et al. **Dig Dis Sci** 1996 Mar;41(3):591–3 (8 ref.)

GENETICS

Mutations in Alport syndrome associated with diffuse esophageal leiomyomatosis. Antignac C, et al. **Contrib Nephrol** 1996;117:172–82 (37 ref.)

PATHOLOGY

Leiomyomatosis peritonealis disseminata: clinicopathologic analysis of five cases. Hardman WJ 3rd, et al. **South Med J** 1996 Mar;89(3):291–4 (22 ref.)

SURGERY

Myomectomy: laparoscopy or laparotomy? Parker WH. **Clin Obstet Gynecol** 1995 Jun;38(2):392–400 (25 ref.)

LEIOMYOSARCOMA

Leiomyosarcoma of the superior vena cava. Spaggiari L, et al. **Ann Thorac Surg** 1996 Jul;62(1):274–6 (8 ref.)

Primary leiomyosarcoma of the abdominal aorta. Malone MD, et al. **J Vasc Surg** 1996 Sep;24(3):487–93 (36 ref.)

[Primary hepatic leiomyosarcoma and rhabdomyosarcoma] Hiyama Y. **Ryoikibetsu Shokogun Shirizu** 1995;(7):463–6 (22 ref.) **(Jpn)**

[Leiomyosarcoma of the gallbladder] Ikuno N, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):335–7 (18 ref.) **(Jpn)**

[Smooth muscle tumors of the extra-hepatic bile duct] Saito K. **Ryoikibetsu Shokogun Shirizu** 1996;(9):64–7 (22 ref.) **(Jpn)**

DIAGNOSIS

Leiomyosarcoma of the pancreas. Aranha GV, et al. **Int J Pancreatol** 1995 Feb;17(1):95–7 (5 ref.)

Primary leiomyosarcoma of the ureter. Griffin JH, et al. **J Surg Oncol** 1996 Jun;62(2):148–52 (15 ref.)

[Bucco-sinusal site of primary leiomyosarcoma] Le Toux G, et al. **Ann Otolaryngol Chir Cervicofac** 1995;112(5):244–7 (26 ref.) (Eng. Abstr.) **(Fre)**

[A rare case of leiomyosarcoma of the jejunum and review of the literature] Maccioni F, et al. **Radiol Med (Torino)** 1996 May;91(5):655–8 (13 ref.) **(Ita)**

EPIDEMIOLOGY

[Muscular tumors of the digestive tract: an analysis of 53 cases] Larequi A, et al. **Rev Clin Esp** 1995 Dec; 195(12):836–40 (30 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

Primary adrenal leiomyosarcoma in a man with acquired immunodeficiency syndrome (AIDS). Further evidence for an increase in smooth muscle tumors related to Epstein-Barr infection in AIDS. Zetler PJ, et al. **Arch Pathol Lab Med** 1995 Dec;119(12):1164–7 (19 ref.)

PATHOLOGY

Leiomyosarcoma of the skin. Treatment of 34 cases. Bernstein SC, et al. **Dermatol Surg** 1996 Jul;22(7):631–5 (27 ref.)

Leiomyosarcoma of the small intestine presenting as a pelvic mass. Kawagoe H, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Jun;66(2):187–91 (14 ref.)

Myxoid leiomyosarcoma of the uterus with unusual malignant histologic pattern—a case report. Schneider D, et al. **Gynecol Oncol** 1995 Oct;59(1):156–8 (7 ref.)

Leiomyosarcoma of the parotid gland. Oncel S, et al. **J Laryngol Otol** 1996 Apr;110(4):401–3 (9 ref.)

Leiomyosarcoma of the mandible: report of a case and literature review. Karlis V, et al. **J Oral Maxillofac Surg** 1996 Sep;54(9):1127–30 (18 ref.)

Pathologic considerations of uterine smooth muscle tumors. Prayson RA, et al. **Obstet Gynecol Clin North Am** 1995 Dec;22(4):637–57 (69 ref.)

Primary leiomyosarcoma of the maxilla with regional lymph node metastasis. Report of a case and review of the literature. Izumi K, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1995 Sep;80(3):310–9 (56 ref.)

Leiomyosarcoma of the spermatic cord: report of two cases and review of the literature. Stein A, et al. **World J Urol** 1996;14(1):59–61 (12 ref.)

[Leiomyosarcoma of the stomach—clinical aspects, morphology and therapy] Peitgen K, et al. **Med Klin** 1996 Mar 15;91(3):123–30 (35 ref.) (Eng. Abstr.) **(Ger)**

[A case report: giant gastric leiomyosarcoma, showing pedunculated extragastric development] Inoue K, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Dec;92(12):1942–6 (19 ref.) **(Jpn)**

[A case of leiomyosarcoma of the pancreas] Ishida K, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Mar;93(3):220–5 (12 ref.) **(Jpn)**

RADIOTHERAPY

[Leiomyosarcoma of the prostate: a case report of remission for 9 years by radiotherapy] Sakano Y, et al. **Hinyokika Kiyo** 1995 Aug;41(8):629–32 (15 ref.) (Eng. Abstr.) **(Jpn)**

SECONDARY

Primary leiomyosarcoma of the maxilla with regional lymph node metastasis. Report of a case and review of the literature. Izumi K, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1995 Sep;80(3):310–9 (56 ref.)

SURGERY

Retroperitoneal leiomyosarcoma: eight cases and a literature review. Todd CS, et al. **Gynecol Oncol** 1995 Dec; 59(3):333–7 (24 ref.)

[Surgical therapy of leiomyosarcoma of the inferior vena cava] Zieren J, et al. **Zentralbl Chir** 1995;120(8):641–9 (105 ref.) (Eng. Abstr.) **(Ger)**

[Leiomyosarcoma of the scrotum: a case report] Ozeki S, et al. **Hinyokika Kiyo** 1996 Mar;42(3):229–31 (13 ref.) (Eng. Abstr.) **(Jpn)**

VETERINARY

Hypoglycemia in four dogs with smooth muscle tumors. Beaudry D, et al. **J Vet Intern Med** 1995 Nov–Dec; 9(6):415–8 (25 ref.)

LEIOMYOSARCOMA, EPITHELIOID see **LEIOMYOSARCOMA**

LEIOMYOSARCOMA, MYXOID see **LEIOMYOSARCOMA**

LEISHMANIA

CLASSIFICATION

Discovery and study of Leishmania turanica for the first time in China. Guan LR, et al. **Bull World Health Organ** 1995; 73(5):667–72 (35 ref.)

Use of molecular probes and PCR for detection and typing of Leishmania—a mini-review. Degrave W, et al. **Mem Inst Oswaldo Cruz** 1994 Jul–Sep;89(3):463–9 (31 ref.)

DRUG EFFECTS

[Mechanism of anti-leishmanial drugs on the basis of the nucleoside structures] Shin I, et al. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1293–8 (28 ref.) **(Jpn)**

GENETICS

Molecular genetics of the parasitic protozoan Leishmania. Wong AK. **Biochem Cell Biol** 1995 May–Jun; 73(5–6):235–40 (31 ref.)

IMMUNOLOGY

Parasite escape mechanisms: the role of Leishmania lipophosphoglycan on the human phagocyte functions. A review. Panaro MA, et al. **Immunopharmacol Immunotoxicol** 1995 Aug;17(3):595–605 (50 ref.)

ISOLATION & PURIFICATION

New World tegumentar leishmaniasis: chemotherapeutic activity of rifampicin in humans and experimental murine model. Do Valle TZ, et al. **Pathol Biol (Paris)** 1995 Sep; 43(7):618–21 (25 ref.)

PHYSIOLOGY

Cohabitation of Leishmania amazonensis and Coxiella burnetii. Rabinovitch M, et al. **Trends Microbiol** 1996 Apr; 4(4):158–61 (32 ref.)

[Leishmania-macrophage interactions: role of cytokines and molecules co-involved in killing] Faliero SM, et al. **Parassitologia** 1995 Apr;37(1):5–15 (126 ref.) (Eng. Abstr.) **(Ita)**

LEISHMANIA BRAZILIENSIS

ISOLATION & PURIFICATION

New World tegumentar leishmaniasis: chemotherapeutic activity of rifampicin in humans and experimental murine model. Do Valle TZ, et al. **Pathol Biol (Paris)** 1995 Sep; 43(7):618–21 (25 ref.)

LEISHMANIA BRAZILIENSIS BRAZILIENSIS see **LEISHMANIA BRAZILIENSIS**

LEISHMANIA DONOVANI

[Visceral leishmaniasis refractory to treatment: the efficacy of amphotericin B] Pérez Brea A, et al. **An Esp Pediatr** 1996 Feb;44(2):161–3 (8 ref.) **(Spa)**

IMMUNOLOGY

Immunobiology of visceral leishmaniasis. Tanner CE. **Clin Immunol Immunopathol** 1996 Feb;78(2):105–11 (65 ref.)

LEISHMANIA DONOVANI CHAGASI see **LEISHMANIA INFANTUM**

LEISHMANIA DONOVANI INFANTUM see **LEISHMANIA INFANTUM**

LEISHMANIA INFANTUM

[Multiple digestive involvement in visceral leishmaniasis in a patient with HIV infection: favourable course with itraconazole] Béchade D, et al. **Rev Med Interne** 1996; 17(3):234–7 (20 ref.) (Eng. Abstr.) **(Fre)**

LEISHMANIA (LEISHMANIA) see **LEISHMANIA**

LEISHMANIA (LEISHMANIA) DONOVANI see **LEISHMANIA DONOVANI**

LEISHMANIA (LEISHMANIA) INFANTUM see **LEISHMANIA INFANTUM**

LEISHMANIA (LEISHMANIA) MAJOR see **LEISHMANIA MAJOR**

LEISHMANIA MAJOR

IMMUNOLOGY

Dendritic cells seclude Leishmania parasites that persist in cured mice—a role in the maintenance of T-cell memory? Moll H, et al. **Adv Exp Med Biol** 1995;378:507–9 (13 ref.)

Reversal of polarized T helper 1 and T helper 2 cell populations in murine leishmaniasis. Coffman RL, et al. **Ciba Found Symp** 1995;195:20–5; discussion 25–33 (30 ref.)

The development of effector T cell subsets in murine Leishmania major infection. Locksley RM, et al. **Ciba Found Symp** 1995;195:110–7; discussion 117–22 (41 ref.)

ISOLATION & PURIFICATION

Dendritic cells seclude Leishmania parasites that persist in cured mice—a role in the maintenance of T-cell memory? Moll H, et al. **Adv Exp Med Biol** 1995;378:507–9 (13 ref.)

LEISHMANIA TROPICA MAJOR see **LEISHMANIA MAJOR**

LEISHMANIA (VIANNIA) see **LEISHMANIA**

LEISHMANIA (VIANNIA) BRAZILIENSIS see **LEISHMANIA BRAZILIENSIS**

LEISHMANIASIS

[Progresses in tropical medicine in China, 1995] He L. **Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):730–1 (0 ref.) **(Chi)**

LEISHMANIASIS

COMPLICATIONS

Visceral leishmaniasis emerging as an important opportunistic infection in HIV-infected persons living in areas nonendemic for Leishmania donovani. Albrecht H, et al. **Arch Pathol Lab Med** 1996 Feb;120(2):189–98 (53 ref.)

DIAGNOSIS

[Identification of leishmaniasis: current clinical and epidemiological tools] Dumon PH, et al. **Med Trop (Mars)** 1995;55(2):123–6 (16 ref.) **(Fre)**

EPIDEMIOLOGY

Epidemiology of the leishmaniases. Magill AJ. **Dermatol Clin** 1995 Jul;13(3):505–23 (209 ref.)

IMMUNOLOGY

The contrasting roles of CD4+ T cells in intracellular infections in humans: leishmaniasis as an example. Kemp M, et al. **Immunol Today** 1996 Jan;17(1):13–6 (37 ref.)

Genetic susceptibility to leishmanial infections: studies in mice and man. Blackwell JM. **Parasitology** 1996;112 Suppl:S67–74 (54 ref.)

PATHOLOGY

Leishmaniasis. Grevelink SA, et al. **J Am Acad Dermatol** 1996 Feb;34(2 Pt 1):257–72 (94 ref.)

PHYSIOPATHOLOGY

[Leishmania–macrophage interactions: role of cytokines and molecules co-involved in killing] Faliero SM, et al. **Parassitologia** 1995 Apr;37(1):5–15 (126 ref.) (Eng. Abstr.) **(Ita)**

TRANSMISSION

Phlebotomine sandflies (Diptera:, Psychodidae): their importance and some aspects of control. Mutinga MJ. **East Afr Med J** 1996 Jan;73(1):48–9 (9 ref.)

LEISHMANIASIS, AMERICAN see **LEISHMANIASIS, CUTANEOUS**

LEISHMANIASIS, CUTANEOUS

Cutaneous and mucocutaneous leishmaniasis. Samady JA, et al. **Cutis** 1996 Jan;57(1):13–20 (73 ref.)

Cutaneous leishmaniasis in Egypt (review and comment). Morsy TA. **J Egypt Soc Parasitol** 1996 Apr;26(1):105–30 (116 ref.)

DRUG THERAPY

New World tegumentar leishmaniasis: chemotherapeutic activity of rifampicin in humans and experimental murine model. Do Valle TZ, et al. **Pathol Biol (Paris)** 1995 Sep; 43(7):618–21 (25 ref.)

EPIDEMIOLOGY

Ecoepidemiological aspects of American cutaneous leishmaniasis in the state of São Paulo, Brazil. Tolezano JE. **Mem Inst Oswaldo Cruz** 1994 Jul–Sep;89(3):427–34 (58 ref.)

IMMUNOLOGY

Dendritic cells seclude Leishmania parasites that persist in cured mice—a role in the maintenance of T-cell memory? Moll H, et al. **Adv Exp Med Biol** 1995;378:507–9 (13 ref.)

Reversal of polarized T helper 1 and T helper 2 cell populations in murine leishmaniasis. Coffman RL, et al. **Ciba Found Symp** 1995;195:20–5; discussion 25–33 (30 ref.)

The development of effector T cell subsets in murine Leishmania major infection. Locksley RM, et al. **Ciba Found Symp** 1995;195:110–7; discussion 117–22 (41 ref.)

PARASITOLOGY

Progress in studies on Central Asian foci of zoonotic cutaneous leishmaniasis: a review. Strelkova MV. **Folia Parasitol (Praha)** 1996;43(1):1–6 (18 ref.)

LEISHMANIASIS, DIFFUSE CUTANEOUS

COMPLICATIONS

Diabetes mellitus associated with pentamidine isethionate in diffuse cutaneous leishmaniasis. Costa JM, et al. **Rev Soc Bras Med Trop** 1995 Oct–Dec;28(4):405–7 (13 ref.)

LEISHMANIASIS, MUCOCUTANEOUS

EPIDEMIOLOGY

Ecoepidemiological aspects of American cutaneous leishmaniasis in the state of São Paulo, Brazil. Tolezano JE. **Mem Inst Oswaldo Cruz** 1994 Jul–Sep;89(3):427–34 (58 ref.)

LEISHMANIASIS, NEW WORLD see **LEISHMANIASIS, CUTANEOUS**

LEISHMANIASIS, OLD WORLD see **LEISHMANIASIS, CUTANEOUS**

LEISHMANIASIS, VISCERAL

DIAGNOSIS

[Renal and urinary tract leishmaniasis. A disease to keep in mind] Romero Maroto J, et al. **Actas Urol Esp** 1995 Nov–Dec;19(10):789–94 (25 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

[Visceral leishmaniasis refractory to treatment: the efficacy of amphotericin B] Pérez Brea A, et al. **An Esp Pediatr** 1996 Feb;44(2):161–3 (8 ref.) **(Spa)**

ETIOLOGY

[Multiple digestive involvement in visceral leishmaniasis in a patient with HIV infection: favourable course with itraconazole] Béchade D, et al. **Rev Med Interne** 1996; 17(3):234–7 (20 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Immunobiology of visceral leishmaniasis. Tanner CE. **Clin Immunol Immunopathol** 1996 Feb;78(2):105–11 (65 ref.)

PREVENTION & CONTROL

Control of parasitic diseases in China. Current status and prospects. Yu S. **Chin Med J (Engl)** 1996 Apr;109(4):259–65 (16 ref.)

LEMMINGS see **MICROTINAE**

LEMMUS see **MICROTINAE**

LENGTH OF LIFE see **LONGEVITY**

LENGTH OF STAY

Interpreting the evidence on brief interventions for excessive drinkers: the need for caution. Heather N. **Alcohol Alcohol** 1995 May;30(3):287–96 (35 ref.)

Fast-tracking in cardiac surgery. Aps C. **Br J Hosp Med** 1995 Aug 16–Sep 5;54(4):139–42 (5 ref.)

The impact of early obstetric discharge on newborn health care. Lee KS, et al. **Curr Opin Pediatr** 1996 Apr;8(2):96–101 (42 ref.)

Pro: early extubation after cardiac surgery decreases intensive care unit stay and cost [see comments] Cheng DC. **J Cardiothorac Vasc Anesth** 1995 Aug;9(4):460–4 (45 ref.) Comment in: J Cardiothorac Vasc Anesth 1995 Aug;9(4):465–7.

Con: early extubation after cardiac surgery does not decrease intensive care unit stay and cost [comment] Guenther CR. **J Cardiothorac Vasc Anesth** 1995 Aug;9(4):465–7 (12 ref.) Comment on: J Cardiothorac Vasc Anesth 1995 Aug;9(4):460–4.

Impact of early discharge on newborns. Kotagal UR, et al. **J Pediatr Gastroenterol Nutr** 1996 May;22(4):402–4 (14 ref.)

Predictors of retention in therapeutic communities. Condelli WS. **NIDA Res Monogr** 1994;144:117–27 (22 ref.)

Controversial issues surrounding early postpartum discharge. Brown LP, et al. **Nurs Clin North Am** 1996 Jun;31(2):333–9 (23 ref.)

Problems associated with early discharge of newborn infants. Early discharge of newborns and mothers: a critical review of the literature. Braveman P, et al. **Pediatrics** 1995 Oct; 96(4 Pt 1):716–26 (74 ref.)

STATISTICS & NUMERICAL DATA

Assisted reproductive technologies: estimates of their contribution to multiple births and newborn hospital days in the United States. Wilcox LS, et al. **Fertil Steril** 1996 Feb;65(2):361–6 (25 ref.)

Identifying complications and low provider adherence to normative practices using administrative data. Kuykendall DH, et al. **Health Serv Res** 1995 Oct;30(4):531–54 (28 ref.)

Adolescents in therapeutic communities: retention and posttreatment outcome. Pompi KF. **NIDA Res Monogr** 1994;144:128–61 (28 ref.)

TRENDS

Retention in therapeutic communities: challenges for the nineties. Lewis BF, et al. **NIDA Res Monogr** 1994; 144:99–116 (45 ref.)

LENS CAPSULE, CRYSTALLINE

Clinical syndrome of endocapsular hematoma: presentation of a collected series and review of the literature. Hagan JC 3rd, et al. **J Cataract Refract Surg** 1996 Apr;22(3):379–84 (18 ref.)

INJURIES

Flexible open-loop anterior chamber intraocular lens implantation after posterior capsule complications in extracapsular cataract extraction. Rattigan SM, et al. **J Cataract Refract Surg** 1996 Mar;22(2):243–6 (10 ref.)

SURGERY

Capsulotomy. Murrill CA, et al. **Optom Clin** 1995;4(4):69–83 (58 ref.)

LENS, CRYSTALLINE

GROWTH & DEVELOPMENT

Lens development and crystallin gene expression: many roles for Pax-6. Cvekl A, et al. **Bioessays** 1996 Aug;18(8):621–30 (72 ref.)

The intermediate filament cytoskeleton of the lens: an ever changing network through development and differentiation. A minireview. Prescott AR, et al. **Ophthalmic Res** 1996;28 Suppl 1:58–61 (33 ref.)

METABOLISM

Lens crystallins of invertebrates—diversity and recruitment from detoxification enzymes and novel proteins. Tomarev SI, et al. **Eur J Biochem** 1996 Feb 1;235(3):449–65 (225 ref.)

PATHOLOGY

Infantile Cataracts. Lambert SR, et al. **Surv Ophthalmol** 1996 May–Jun;40(6):427–58 (291 ref.)

PHYSIOLOGY

Neuronal circuitry controlling the near response. Mays LE, et al. **Curr Opin Neurobiol** 1995 Dec;5(6):763–8 (29 ref.)

The optics of the eye–lens and lenticular senescence. A review. Pierscionek BK, et al. **Doc Ophthalmol** 1995; 89(4):321–35 (96 ref.)

Cataract mutations as a tool for developmental geneticists. Graw J. **Ophthalmic Res** 1996;28 Suppl 1:8–18 (62 ref.)

[Cell sources, regulatory factors and gene expression in the regeneration of the crystalline lens and retina in vertebrate animals] Mitashov VI. **Izv Akad Nauk Ser Biol** 1996 May–Jun;(3):298–318 (183 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

The aetiology of presbyopia: a summary of the role of lenticular and extralenticular structures. Gilmartin B. **Ophthalmic Physiol Opt** 1995 Sep;15(5):431–7 (82 ref.)

RADIATION EFFECTS

Epidemiological studies of sunlight and cataract: the critical factor of ultraviolet exposure geometry [see comments] Sliney DH. **Ophthalmic Epidemiol** 1994 Jun;1(2):107–19 (33 ref.) Comment in: Int J Food Sci Nutr 1994 Jun;1(2):63–5.

ULTRASTRUCTURE

The ultrastructure of epithelial and fiber cells in the crystalline lens. Kuszak JR. **Int Rev Cytol** 1995;163:305–50 (105 ref.)

Ocular lens gap junctions: protein expression, assembly, and structure–function analysis. Kistler J, et al. **Microsc Res Tech** 1995 Aug 1;31(5):347–56 (60 ref.)

Electron microscopic observations of the crystalline lens. Kuszak JR, et al. **Microsc Res Tech** 1996 Apr 15; 33(6):441–79 (110 ref.)

LENS IMPLANTATION, INTRAOCULAR see **LENSES, INTRAOCULAR**

LENS OPACITIES see **CATARACT**

LENS PROTEINS see **CRYSTALLINS**

LENSES, CONTACT see **CONTACT LENSES**

LENSES, INTRAOCULAR

Intraocular lens implantation in patients with juvenile rheumatoid arthritis–associated uveitis: an unresolved management issue [editorial; comment] Holland GN. **Am J Ophthalmol** 1996 Aug;122(2):255–7 (10 ref.) Comment on: Am J Ophthalmol 1996 Aug;122(2):161–70.

Intraocular lens implantation in patients with juvenile rheumatoid arthritis [see comments] Probst LE, et al. **Am J Ophthalmol** 1996 Aug;122(2):161–70 (24 ref.) Comment in: Am J Ophthalmol 1996 Aug;122(2):255–7.

Flexible open-loop anterior chamber intraocular lens implantation after posterior capsule complications in extracapsular cataract extraction. Rattigan SM, et al. **J Cataract Refract Surg** 1996 Mar;22(2):243–6 (10 ref.)

Intraocular lens power calculation for eyes after refractive keratotomy. Hoffer KJ. **J Refract Surg** 1995 Nov–Dec; 11(6):490–3 (4 ref.)

Infantile Cataracts. Lambert SR, et al. **Surv Ophthalmol** 1996 May–Jun;40(6):427–58 (291 ref.)

LENTICULAR NUCLEUS see **CORPUS STRIATUM**

LENTIFORM NUCLEUS see **CORPUS STRIATUM**

LENTIGINOSIS see **LENTIGO**

LENTIGINOSIS, PERIORAL see **PEUTZ-JEGHERS SYNDROME**

LENTIGO

LEOPARD syndrome (cardiocutaneous lentiginosis syndrome). Józwiak S, et al. **Cutis** 1996 Apr;57(4):208-14 (129 ref.)

PATHOLOGY

Partial unilateral lentiginosis: report of seven cases and review of the literature. Piqué E, et al. **Clin Exp Dermatol** 1995 Jul;20(4):319-22 (32 ref.)

Lentigo. Ber Rahman S, et al. **Int J Dermatol** 1996 Apr; 35(4):229-39 (69 ref.)

LENTIGO, MALIGNANT see **HUTCHINSON'S MELANOTIC FRECKLE**

LENTILS see **LEGUMES**

LENTIVIRINAE see **LENTIVIRUS**

LENTIVIRUS

GENETICS

Phylogeny and natural history of the primate lentiviruses, SIV and HIV. Hirsch VM, et al. **Curr Opin Genet Dev** 1995 Dec;5(6):798-806 (28 ref.)

IMMUNOLOGY

Early events in infection of lymphoid tissue by a lentivirus, maedi-visna. Blacklaws B, et al. **Trends Microbiol** 1995 Nov;3(11):434-40 (48 ref.)

PATHOGENICITY

Molecular biology and pathogenesis of animal lentivirus infections. Clements JE, et al. **Clin Microbiol Rev** 1996 Jan; 9(1):100-17 (224 ref.)

PHYSIOLOGY

Phylogeny and natural history of the primate lentiviruses, SIV and HIV. Hirsch VM, et al. **Curr Opin Genet Dev** 1995 Dec;5(6):798-806 (28 ref.)

LENTIVIRUS INFECTIONS

Ovine lentivirus infection: an animal model for pediatric HIV infection? de la Concha-Bermejillo A, et al. **Arch Med Res** 1995 Winter;26(4):345-54 (105 ref.)

VETERINARY

Simian immunodeficiency virus variants: threat of new lentiviruses. McClure HM, et al. **Am J Med Sci** 1996 Jan; 311(1):30-3 (46 ref.)

Selected models of HIV-induced neurological disease. Narayan O, et al. **Curr Top Microbiol Immunol** 1995; 202:151-66 (61 ref.)

Characteristics of ovine and caprine lentivirus infections. Perk K. **Leukemia** 1995 Oct;9 Suppl 1:S98-100 (25 ref.)

Recent advances in the understanding of Jembrana disease. Wilcox GE, et al. **Vet Microbiol** 1995 Sep;46(1-3):249-55 (23 ref.)

LENTIVIRUSES, SIMIAN see **SIV**

LEPIDOPTERA

GENETICS

How is pheromone specificity encoded in proteins? Prestwich GD, et al. **Chem Senses** 1995 Aug;20(4):461-9 (36 ref.)

Sex chromatin in lepidoptera. Traut W, et al. **Q Rev Biol** 1996 Jun;71(2):239-56 (71 ref.)

GROWTH & DEVELOPMENT

[Advances in the study on artificial cultivation of Cordyceps sinensis] Yin D, et al. **Chung Kuo Chung Yao Tsa Chih** 1995 Dec;20(12):707-9, inside back cover (29 ref.) **(Chi)**

PHYSIOLOGY

Pheromone biosynthesis activating neuropeptides: functions and chemistry. Teal PE, et al. **Peptides** 1996;17(2):337-44 (69 ref.)

LEPROSTATIC AGENTS

[Present status of studies on antileprosy drugs] Gidoh M, et al. **Nippon Rai Gakkai Zasshi** 1995 Nov;64(3):174-87 (62 ref.) **(Jpn)**

POISONING

A case of acute dapsone poisoning: toxicological data and review of the literature. Tracqui A, et al. **J Anal Toxicol** 1995 Jul-Aug;19(4):229-35 (72 ref.)

THERAPEUTIC USE

New World tegumentar leishmaniasis: chemotherapeutic activity of rifampicin in humans and experimental murine model. Do Valle TZ, et al. **Pathol Biol (Paris)** 1995 Sep; 43(7):618-21 (25 ref.)

[The problem of resistance in the treatment of Mycobacterium infections: new experimental results and combinations for the treatment of tuberculosis and leprosy] Seydel JK, et al. **Pharm Unserer Zeit** 1995 Nov; 24(6):313-23 (14 ref.) **(Ger)**

LEPROSY

see related
LEPROSTATIC AGENTS

Leprosy. Sugita Y. **Clin Dermatol** 1995 May-Jun;13(3):235-43 (62 ref.)

Leprosy. The beginning of an end to a public health problem? Pönnighaus JM. **Dermatol Clin** 1995 Jul;13(3):525-36 (54 ref.)

Pregnancy and leprosy neuropathy. Duncan ME. **Indian J Lepr** 1996 Jan-Mar;68(1):23-34 (34 ref.)

Hansen's Disease. Wathen PI. **South Med J** 1996 Jul; 89(7):647-52 (31 ref.)

[Leprosy and vaccine] Matsumoto S, et al. **Nippon Rai Gakkai Zasshi** 1995 Nov;64(3):163-73 (63 ref.) **(Jpn)**

[Present and future in leprosy research] Saito H, et al. **Nippon Rai Gakkai Zasshi** 1995 Nov;64(3):200-13 (74 ref.) **(Jpn)**

COMPLICATIONS

Posterior tibial neurovascular decompression for restoration of plantar sweating and sensibility. Oommen PK. **Indian J Lepr** 1996 Jan-Mar;68(1):75-82 (35 ref.)

HIV infection and leprosy--an enigma. Sankaran JR. **J Assoc Physicians India** 1995 Aug;43(8):557-9 (20 ref.)

DIAGNOSIS

Leprous neuropathies. Waters MF, et al. **Baillieres Clin Neurol** 1996 Mar;5(1):171-97 (61 ref.)

[New technique: PCR method for diagnosis of patients with leprosy] Sugita Y. **Nippon Rai Gakkai Zasshi** 1995 Jul; 64(2):100-4 (17 ref.) **(Jpn)**

DRUG THERAPY

[The problem of resistance in the treatment of Mycobacterium infections: new experimental results and combinations for the treatment of tuberculosis and leprosy] Seydel JK, et al. **Pharm Unserer Zeit** 1995 Nov; 24(6):313-23 (14 ref.) **(Ger)**

HISTORY

[Leprosy--current aspects of a disease from biblical times] Sticht-Groh V, et al. **Immun Infekt** 1995 Dec;23(6):216-21 (71 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

St. John Dermatological Society Oration, 1994. Immune responses in leprosy, cytokines and new archetypes for dermatology. Rea TH. **Clin Exp Dermatol** 1995 Mar; 20(2):89-97 (48 ref.)

Leprous neuropathy as an autoimmune phenomenon. Desikan P. **Indian J Lepr** 1996 Jan-Mar;68(1):15-21 (34 ref.)

Nerve tissue culture as an approach towards the study of onset of reactions in the nerve in leprosy--observations and hypothesis. Mistry NF, et al. **Indian J Lepr** 1996 Jan-Mar;68(1):67-73 (18 ref.)

The immunology of leprosy; unravelling an enigma [editorial] Choudhuri K. **Int J Lepr Other Mycobact Dis** 1995 Sep; 63(3):430-47 (62 ref.)

Cytokine responses in leprosy lesions. Modlin RL. **Nippon Rai Gakkai Zasshi** 1995 Jul;64(2):85-8 (14 ref.)

[Recent development in immunology of leprosy: roles of immunoregulatory cytokines in the establishment of immuno-unresponsiveness to M. leprae in leprosy patients] Tomioka H. **Nippon Rai Gakkai Zasshi** 1995 Jul;64(2):69-84 (37 ref.) **(Jpn)**

PATHOLOGY

Neuritic leprosy: further progression and significance. Mishra B, et al. **Acta Leprol** 1995;9(4):187-94 (28 ref.)

Animal model for leprous neuropathy: our contribution. Shetty VP, et al. **Indian J Lepr** 1996 Jan-Mar;68(1):95-104 (28 ref.)

Host parasite response in nerve in leprosy. Turk JL. **Indian J Lepr** 1996 Jan-Mar;68(1):113-7 (15 ref.)

[Recent improvement in histopathological technique] Kawatsu K. **Nippon Rai Gakkai Zasshi** 1995 Jul; 64(2):124-31 (43 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Neuritic leprosy. Girdhar BK. **Indian J Lepr** 1996 Jan-Mar; 68(1):35-42 (22 ref.)

Nerve in reversal reaction. Job CK. **Indian J Lepr** 1996 Jan-Mar;68(1):43-7 (11 ref.)

Autonomic nerve affection in leprosy. Katoch K. **Indian J Lepr** 1996 Jan-Mar;68(1):49-54 (33 ref.)

The leprosy granuloma in nerve: summary of recent work. Ridley MJ. **Indian J Lepr** 1996 Jan-Mar;68(1):93-4 (5 ref.)

Assessment of nerve function under field conditions and its usefulness in leprosy. van Brakel WH. **Indian J Lepr** 1996 Jan-Mar;68(1):119-25 (33 ref.)

SURGERY

Role of surgery of nerves in leprosy in the restoration of sensibility in hands and feet of leprosy patients. Kazen R. **Indian J Lepr** 1996 Jan-Mar;68(1):55-65 (44 ref.)

LEPROSY, CUTANEOUS see **LEPROSY, LEPROMATOUS**

LEPROSY, LEPROMATOUS

Erythema nodosum leprosum. Meyerson MS. **Int J Dermatol** 1996 Jun;35(6):389-92 (65 ref.)

COMPLICATIONS

[Rheumatic involvement in Hansen's disease] Cossermelli-Messina W, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1995 Mar-Apr; 50(2):107-10 (50 ref.) (Eng. Abstr.) **(Por)**

LEPROSY, NODULAR see **LEPROSY, LEPROMATOUS**

LEPTOCONOPS see **CERATOPOGONIDAE**

LEPTOMENINGEAL CYSTS see **ARACHNOID CYSTS**

LEPTOMONAS see **TRYPANOSOMATINA**

LEPTOSPIROSIS

ETIOLOGY

Leptospirosis. Farr RW. **Clin Infect Dis** 1995 Jul;21(1):1-6; quiz 7-8 (35 ref.)

LEPTOSPIROSIS, ICTEROHEMORRHAGIC see **WEIL'S DISEASE**

LESBIANISM see **HOMOSEXUALITY, FEMALE**

LESS-DEVELOPED COUNTRIES see **DEVELOPING COUNTRIES**

LETHAL JUNCTIONAL EPIDERMOLYSIS BULLOSA see **EPIDERMOLYSIS BULLOSA, JUNCTIONAL**

LETHAL MIDLINE GRANULOMA see **GRANULOMA, LETHAL MIDLINE**

LETHARGY see **SLEEP STAGES**

LETS PROTEINS see **FIBRONECTINS**

LEU ANTIGENS see **ANTIGENS, DIFFERENTIATION**

LEU ANTIGENS, B-LYMPHOCYTE see **ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE**

LEU ANTIGENS, T-LYMPHOCYTE see **ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE**

LEU-2 ANTIGENS see **ANTIGENS, CD8**

LEU-M1 ANTIGENS see **ANTIGENS, CD15**

LEUCINE

CHEMISTRY

Proteins with leucine-rich repeats. Kobe B, et al. **Curr Opin Struct Biol** 1995 Jun;5(3):409-16 (53 ref.)

LEUCINE AMINOPEPTIDASE

BLOOD

[Leucine aminopeptidase (LAP)] Sakai T. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:303-6 (7 ref.) **(Jpn)**

LEUCINE ZIPPERS

Toward the production of bispecific antibody fragments for clinical applications. Carter P, et al. **J Hematother** 1995 Oct;4(5):463-70 (63 ref.)

Transcription factors. 1: bZIP proteins. Hurst HC. **Protein Profile** 1994;1(2):123-68 (471 ref.)

PHYSIOLOGY

AP-1 transcription factor complexes in CNS disorders and development. Pennypacker KR. **J Fla Med Assoc** 1995 Aug;82(8):551-4 (26 ref.)

LEUCOTOMY see **PSYCHOSURGERY**

LEUCOVORIN

METABOLISM

Aspects of one-carbon folate cycling related to fluoropyrimidine and antifolate therapy. Spears CP, et al.

LEUCOVORIN

Cancer Treat Res 1995;78:115–34 (128 ref.)

PHARMACOLOGY

The role of interferon–alpha as a modulator of fluorouracil and leucovorin. Grem JL, et al. **Eur J Cancer** 1995 Jul–Aug;31A(7–8):1316–20 (29 ref.)

Role of leucovorin dosing and administration schedule. Jolivet J. **Eur J Cancer** 1995 Jul–Aug;31A(7–8):1311–5 (52 ref.)

Biochemical modulation of fluoropyrimidines: is there an optimal (6R,S) leucovorin dose and schedule? [editorial; comment] Doroshow JH. **J Natl Cancer Inst** 1996 Apr 3; 88(7):393–5 (24 ref.) Comment on: J Natl Cancer Inst 1996 Apr 3;88(7):430–6.

THERAPEUTIC USE

Folate supplementation and methotrexate. Dijkmans BA. **Br J Rheumatol** 1995 Dec;34(12):1172–4 (22 ref.)

Conservative management options for cervical pregnancy; case reports and literature review. Creinin MD, et al. **Int J Fertil Menopausal Stud** 1995 Jul–Aug;40(4):175–86 (67 ref.)

Biochemical modulation of fluoropyrimidines: is there an optimal (6R,S) leucovorin dose and schedule? [editorial; comment] Doroshow JH. **J Natl Cancer Inst** 1996 Apr 3; 88(7):393–5 (24 ref.) Comment on: J Natl Cancer Inst 1996 Apr 3;88(7):430–6.

Prognostic variable in patients with advanced colorectal cancer treated with fluorouracil and leucovorin–based chemotherapy. Fountzilas G, et al. **Med Pediatr Oncol** 1996 May;26(5):305–17 (45 ref.)

LEUKAPHERESIS

[Biological effects of allogenic leukocytes and leukocyte–depleted blood cell products] Válová I, et al. **Vnitr Lek** 1995 Oct;41(10):713–8 (39 ref.) (Eng. Abstr.) **(Cze)**

[Plasma– and lymphapheresis in autoimmune diseases] Schneider M. **Z Rheumatol** 1996 Mar–Apr;55(2):90–104 (165 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Guidelines for efficient peripheral blood progenitor cell collection. Van Hoef ME. **Neth J Med** 1996 Jan;48(1):29–37 (65 ref.)

Leukocyte–reduced blood components: patient benefits and practical applications. Higgins VL. **Oncol Nurs Forum** 1996 May;23(4):659–67 (57 ref.)

Peripheral blood progenitor cells for marrow reconstitution: mobilization and collection strategies [see comments] Gillespie TW, et al. **Transfusion** 1996 Jul;36(7):611–24 (123 ref.) Comment in: Transfusion 1996 Jul;36(7):585–9.

LEUKEMIA

see related

LEUKEMIC INFILTRATION

Hematologic malignancies during pregnancy. Sadural E, et al. **Clin Obstet Gynecol** 1995 Sep;38(3):535–46 (26 ref.)

MDR1/P–glycoprotein in haematological neoplasms. Marie JP, et al. **Eur J Cancer** 1996 Jun;32A(6):1034–8 (81 ref.)

Cancer in pregnancy: a review of the literature. Part II. Antonelli NM, et al. **Obstet Gynecol Surv** 1996 Feb; 51(2):135–42 (185 ref.)

Growth factor requirements for normal and leukemic cells. Minden M. **Semin Hematol** 1995 Jul;32(3):162–82 (242 ref.)

[Progresses in hematology in China, 1995] Shan Y, et al. **Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):720–1 (0 ref.) **(Chi)**

[Oro–dental manifestations of leukemia in children] Nikoui M, et al. **J Can Dent Assoc** 1996 May;62(5):443–6, 449–50 (41 ref.) (Eng. Abstr.) **(Fre)**

BLOOD

Hepatitis C virus serum markers and liver disease in children with leukemia. Locasciulli A, et al. **Leuk Lymphoma** 1995 Apr;17(3–4):245–9 (22 ref.)

CLASSIFICATION

[Present and future of classification for white cells and leukemic cells in the routine clinical laboratory] Tatsumi N, et al. **Rinsho Byori** 1995 Sep;43(9):913–6 (16 ref.) (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

The association of inflammatory bowel disease and leukemia—coincidence or not? Caspi O, et al. **Leuk Lymphoma** 1995 Apr;17(3–4):255–62 (45 ref.)

Orthopedic manifestations of acute pediatric leukemia. Gallagher DJ, et al. **Orthop Clin North Am** 1996 Jul; 27(3):635–44 (28 ref.)

[Hepatobiliary disease in malignant lymphoma, leukemia, and MDS] Ishikawa T. **Ryoikibetsu Shokogun Shirizu** 1995; (8):375–8 (21 ref.) **(Jpn)**

CONGENITAL

Transient leukemia with trisomy 21: description of a case and review of the literature. Bhatt S, et al. **Am J Med Genet** 1995 Sep 25;58(4):310–4 (23 ref.)

Immunophenotyping of congenital leukemia. McCoy JP Jr, et al. **Cytometry** 1995 Jun 15;22(2):85–8 (27 ref.)

DIAGNOSIS

Monoclonal antibodies in the management of acute leukemia. Wang JC, et al. **Am J Hematol** 1995 Nov;50(3):188–99 (159 ref.)

Techniques for detection of minimal residual disease. Carlo–Stella C, et al. **Leuk Lymphoma** 1995;18 Suppl 1:75–80 (29 ref.)

CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy. Scheuermann RH, et al. **Leuk Lymphoma** 1995 Aug;18(5–6):385–97 (94 ref.)

[Neoplasias in hematopoietic tissues] Kamada N, et al. **Nippon Rinsho** 1996 Jun;54(6):1626–30 (5 ref.) (Eng. Abstr.) **(Jpn)**

[Hexosaminidase isoenzyme pattern in leukemia] Sasaki R. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:190–4 (13 ref.) **(Jpn)**

[Gene diagnosis for patients with leukemia] Kitamura K. **Rinsho Byori** 1995 Jul;Suppl 99:139–45 (6 ref.) **(Jpn)**

DRUG THERAPY

On the phosphorylation of 2–chlorodeoxyadenosine (CdA) and its correlation with clinical response in leukemia treatment. Arnér ES. **Leuk Lymphoma** 1996 Apr; 21(3–4):225–31 (64 ref.)

The water–insoluble camptothecin analogues: promising drugs for the effective treatment of haematological malignancies. Pantazis P. **Leuk Res** 1995 Nov;19(11):775–88 (151 ref.)

Intrinsic and acquired resistance to methotrexate in acute leukemia. Gorlick R, et al. **N Engl J Med** 1996 Oct 3; 335(14):1041–8 (59 ref.)

Intracellular pharmacodynamics in leukemia therapy. Gandhi V, et al. **Rinsho Ketsueki** 1996 May;37(5):369–79 (44 ref.)

Antisense strategies in the treatment of leukemias. Calabretta B, et al. **Semin Oncol** 1996 Feb;23(1):78–87 (47 ref.)

[Exploration of clinical study of antileukemia cell drug–resistance by traditional Chinese medicine] Li D, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Oct; 15(10):636–7 (8 ref.) **(Chi)**

[Current therapeutic methods in onco–hematology] Madelaine–Chambrin I, et al. **Ann Pharm Fr** 1996; 54(2):73–6 (15 ref.) (Eng. Abstr.) **(Fre)**

[A new concept: treatment using differentiation of the malignant cell in man] Degos L. **Bull Acad Natl Med** 1995 Nov;179(8):1689–700 (39 ref.) (Eng. Abstr.) **(Fre)**

[Clinical phase I studies in oncology and hematology. Concepts, implementation and ethical considerations] Hanauske AR. **Med Klin** 1996 Apr 12;91 Suppl 3:68–70 (28 ref.) **(Ger)**

[Value of corticoids in hematology/oncology in adulthood] Schlimok G, et al. **Med Klin** 1995 Oct 15;90(10):579–84 (23 ref.) **(Ger)**

[Interferons in the therapy of solid tumors] Tomao S, et al. **Clin Ter** 1995 Aug–Sep;146(8–9):491–502 (96 ref.) (Eng. Abstr.) **(Ita)**

[Drug therapy of hematologic malignancy] Shimoyama M. **Nippon Naika Gakkai Zasshi** 1996 Mar 10;85(3):337–41 (15 ref.) **(Jpn)**

[Mechanism of action of antileukemic agents in leukemia chemotherapy] Nakamura T. **Rinsho Ketsueki** 1996 May; 37(5):380–91 (29 ref.) **(Jpn)**

ENZYMOLOGY

Telomeres and telomerase in human leukemias. Shay JW, et al. **Leukemia** 1996 Aug;10(8):1255–61 (59 ref.)

EPIDEMIOLOGY

Do power frequency magnetic fields cause leukemia in children? Levallois P. **Am J Prev Med** 1995 Jul–Aug; 11(4):263–70 (61 ref.)

Incidence and time trends for lymphomas, leukemias and myelomas: hypothesis generation. Working Group on the Epidemiology of Hematolymphopoietic Malignancies in Italy. Vineis P. **Leuk Res** 1996 Apr;20(4):285–90 (39 ref.)

ETIOLOGY

Leukemia and lymphoma in ataxia telangiectasia. Taylor AM, et al. **Blood** 1996 Jan 15;87(2):423–38 (110 ref.)

Structural alterations in the transcription factor PEBP2/CBF linked to four different types of leukemia. Ito Y. **J Cancer Res Clin Oncol** 1996;122(5):266–74 (46 ref.)

The control of hematopoiesis and leukemia: from basic biology to the clinic. Sachs L. **Proc Natl Acad Sci U S A** 1996 May 14;93(10):4742–9 (123 ref.)

Down syndrome and leukemia, an update. Drabkin HA, et al. **Prog Clin Biol Res** 1995;393:169–76 (14 ref.)

EMFs: cutting through the controversy. Wartenberg D. **Public Health Rep** 1996 May–Jun;111(3):204–17 (81 ref.)

GENETICS

Acute leukemias expressing p210–and p 190–type bcr/abl mRNAs: report of two cases and review of the literature. Yamashita S, et al. **Acta Haematol** 1996;96(2):99–104 (23 ref.)

Oncogenic role of "master" transcription factors in human leukemias and sarcomas: a developmental model. Look AT. **Adv Cancer Res** 1995;67:25–57 (162 ref.)

The TEL gene and human leukemia. Golub TR, et al. **Biochim Biophys Acta** 1996 Aug 8;1288(1):M7–10 (27 ref.)

Trisomy 15 in hematological malignancies: six cases and review of the literature. Smith SR, et al. **Cancer Genet Cytogenet** 1996 Jul 1;89(1):27–30 (19 ref.)

Leukaemogenic progression: the importance of differentiation and associated genetic events. Ho ES, et al. **Immunol Cell Biol** 1995 Jun;73(3):193–7 (52 ref.)

Detection of chromosomal translocations in leukemia–lymphoma cells by polymerase chain reaction. Drexler HG, et al. **Leuk Lymphoma** 1995 Nov; 19(5–6):359–80 (278 ref.)

DCC (deleted in colorectal cancer) inactivation in hematological malignancies. Porfiri E. **Leuk Lymphoma** 1995 Jun;18(1–2):69–72 (49 ref.)

Abnormalities of retinoblastoma gene expression in hematological malignancies. Zhu YM, et al. **Leuk Lymphoma** 1995 Jun;18(1–2):61–7 (80 ref.)

BCR/ABL and leukemia. Butturini A, et al. **Leuk Res** 1996 Jun;20(6):523–9 (87 ref.)

11q23 rearrangements in acute leukemia. Rubnitz JE, et al. **Leukemia** 1996 Jan;10(1):74–82 (75 ref.)

Telomeres and telomerase in human leukemias. Shay JW, et al. **Leukemia** 1996 Aug;10(8):1255–61 (59 ref.)

Fusion genes and their hybrid proteins in human leukemias and lymphomas. Look AT. **Proc Assoc Am Physicians** 1995 Jul;107(2):175–80 (76 ref.)

[Significance, diagnosis and prognosis in the cytogenetic analysis in acute leukemias and myelodysplastic syndromes] Jotterand Bellomo M. **Ther Umsch** 1996 Feb;53(2):103–10 (23 ref.) (Eng. Abstr.) **(Fre)**

[Chromosomal translocation and molecular characteristics in hematological malignancies] Inokuchi K. **Nippon Ika Daigaku Zasshi** 1996 Jun;63(3):175–80 (23 ref.) **(Jpn)**

[Tumor suppressor genes in hematopoietic tumors] Hirai H. **Rinsho Ketsueki** 1996 May;37(5):398–403 (22 ref.) **(Jpn)**

IMMUNOLOGY

Graft–versus–leukemia and graft–versus–lymphoma effects of allogeneic bone marrow transplantation and of allogeneic donor leukocyte transfusions. Vandenberghe P, et al. **Ann Hematol** 1995 Nov;71(5):209–17 (65 ref.)

Cell surface antigens in leukemias and lymphomas. Freedman AS. **Cancer Invest** 1996;14(3):252–76 (354 ref.)

Immunophenotyping of congenital leukemia. McCoy JP Jr, et al. **Cytometry** 1995 Jun 15;22(2):85–8 (27 ref.)

Introducing graft–versus–leukemia into autologous stem cell transplantation. Klingemann HG. **J Hematother** 1995 Aug; 4(4):261–7 (71 ref.)

A new approach to analyzing the utility of immunophenotyping for predicting clinical outcome in acute leukemia. Eastern Cooperative Oncology Group [editorial] Paietta E, et al. **Leukemia** 1996 Jan;10(1):1–4 (30 ref.)

METABOLISM

Plasminogen activation on tumor cell surface and its involvement in human leukemia. Tapiovaara H, et al. **Adv Cancer Res** 1996;69:101–33 (317 ref.)

On the phosphorylation of 2–chlorodeoxyadenosine (CdA) and its correlation with clinical response in leukemia treatment. Arnér ES. **Leuk Lymphoma** 1996 Apr; 21(3–4):225–31 (64 ref.)

Hepatocyte growth factor—pleiotropic cytokine produced by human leukemia cells. Gohda E, et al. **Leuk Lymphoma** 1995 Oct;19(3–4):197–205 (97 ref.)

Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells. Drexler HG. **Leukemia** 1996 Apr; 10(4):588–99 (118 ref.)

NURSING

Psychoneuroimmunology and innovative behavioral interventions in patients with leukemia. Caudell KA. **Oncol Nurs Forum** 1996 Apr;23(3):493–502 (60 ref.)

PATHOLOGY

Stromal abnormalities in neoplastic bone marrow diseases. Dührsen U, et al. **Ann Hematol** 1996 Aug;73(2):53–70 (222 ref.)

Some cytogenetic and molecular aspects of cancer therapy. Sandberg AA, et al. **Compr Ther** 1996 Feb;22(2):76–80 (11 ref.)

Subcutaneous T–cell lymphoma with associated hemophagocytic syndrome and terminal leukemic transformation. Romero LS, et al. **J Am Acad Dermatol** 1996 May;34(5 Pt 2):904–10 (22 ref.)

Thrombopoietin: expression of its receptor MPL and proliferative effects on leukemic cells. Drexler HG, et al. **Leukemia** 1996 Sep;10(9):1405–21 (136 ref.)

The hematopoietic stem cell in elderly patients with leukemia. Keating A. **Leukemia** 1996 Apr;10 Suppl 1:S30–2 (12 ref.)

Control of apoptosis in hematopoiesis and leukemia by cytokines, tumor suppressor and oncogenes. Lotem J, et al. **Leukemia** 1996 Jun;10(6):925–31 (131 ref.)

Involvement of the larynx by hemopoietic neoplasms. An investigation of autopsy cases and review of the literature.

Horny HP, et al. **Pathol Res Pract** 1995 Mar;191(2):130–8 (88 ref.)

PHYSIOPATHOLOGY

Severe combined immunodeficient mouse models of human leukemia. Uckun FM. **Blood** 1996 Aug 15;88(4):1135–46 (47 ref.)

Apoptosis overview emphasizing the role of oxidative stress, DNA damage and signal-transduction pathways. Payne CM, et al. **Leuk Lymphoma** 1995 Sep;19(1–2):43–93 (720 ref.)

THERAPY

T cells, graft-versus-host disease and graft-versus-leukemia: innovative approaches for blood and marrow transplantation. Champlin R, et al. **Acta Haematol** 1996; 95(3–4):157–63 (67 ref.)

Childhood leukemias—current status and future perspective. Pui CH. **Acta Paediatr Sin** 1995 Sep–Oct;36(5):322–7 (59 ref.)

Growth hormone deficiency in children treated for leukaemia. Leiper A. **Acta Paediatr Suppl** 1995 Sep; 411:41–4 (21 ref.)

Monoclonal antibody therapy of leukemia and lymphoma. Jurcic JG, et al. **Adv Pharmacol** 1995;33:287–314 (104 ref.)

Monoclonal antibodies in the management of acute leukemia. Wang JC, et al. **Am J Hematol** 1995 Nov;50(3):188–99 (159 ref.)

Orthodontic management of patients with hematologic malignancies. Sheller B, et al. **Am J Orthod Dentofacial Orthop** 1996 Jun;109(6):575–80 (11 ref.)

Strategies to enhance the graft-versus-malignancy effect in allogeneic transplants. Barrett JA. **Ann N Y Acad Sci** 1995 Dec 29;770:203–12 (45 ref.)

Expanding the role of blood progenitor cells. Pettengell R. **Ann Oncol** 1995 Oct;6(8):759–67 (87 ref.)

Gonadal damage and effects on fertility in adult patients with haematological malignancy undergoing stem cell transplantation. Chatterjee R, et al. **Bone Marrow Transplant** 1996 Jan;17(1):5–11 (79 ref.)

Graft-versus-leukaemia: understanding and using the alloimmune response to treat haematological malignancies. Barrett AJ, et al. **Br J Haematol** 1996 Jun 2;93(4):754–61 (89 ref.)

Interleukin 2 in the management of acute leukaemia. Foa R. **Br J Haematol** 1996 Jan;92(1):1–8 (85 ref.)

Leukemias and myeloma. Wiernik PH. **Cancer Chemother Biol Response Modif** 1996;16:347–75 (164 ref.)

Graft versus leukemia in humans. Butturini A, et al. **Cancer Treat Res** 1995;76:299–314 (102 ref.)

Cellular adoptive immunotherapy after bone marrow transplantation. Riddell SR, et al. **Cancer Treat Res** 1995; 76:337–69 (192 ref.)

An overview of the oral complications of adult patients with malignant haematological conditions who have undergone radiotherapy or chemotherapy. Coleman S. **J Adv Nurs** 1995 Dec;22(6):1085–91 (47 ref.)

Introducing graft-versus-leukemia into autologous stem cell transplantation. Klingemann HG. **J Hematother** 1995 Aug; 4(4):261–7 (71 ref.)

Adoptive immunotherapy for relapsed leukemia following allogeneic bone marrow transplantation. Porter DL, et al. **Leuk Lymphoma** 1995 Apr;17(3–4):191–7 (46 ref.)

Immunotoxins for treatment of leukemia and lymphoma. Uckun FM, et al. **Leuk Lymphoma** 1995 Jul;18(3–4):195–201 (51 ref.)

Progress in treating leukaemia. Jones L. **Practitioner** 1996 Feb;240(1559):80–6 (5 ref.)

Targeting Pseudomonas exotoxin to hematologic malignancies. Kreitman RJ, et al. **Semin Cancer Biol** 1995 Oct;6(5):297–306 (54 ref.)

Antisense strategies in the treatment of hematological malignancies. Szczakiel G. **Stem Cells** 1995 Dec;13 Suppl 3:88–92 (22 ref.)

Transfusion of donor buffy coat cells in the treatment of persistent or recurrent malignancy after allogeneic bone marrow transplantation. Collins RH Jr, et al. **Transfusion** 1995 Nov–Dec;35(11):891–8 (41 ref.)

Bone marrow transplantation. Storb R. **Transplant Proc** 1995 Oct;27(5):2649–52 (6 ref.)

[Immunotherapy of hemato-oncologic diseases] Winkler U, et al. **Med Klin** 1996 Apr 10;91(4):226–33 (49 ref.) **(Ger)**

[Pregnancy outcome in long-term survivors with adult acute leukemia, malignant lymphoma and breast cancer] Kawamura S, et al. **Gan To Kagaku Ryoho** 1996 Jun; 23(7):821–6 (30 ref.) (Eng. Abstr.) **(Jpn)**

LEUKEMIA, ADULT T-CELL see **LEUKEMIA, T-CELL**

LEUKEMIA, B-CELL

PATHOLOGY

CD27–CD70 interaction: unravelling its implication in normal and neoplastic B-cell growth. Lens SM, et al. **Leuk Lymphoma** 1995 Jun;18(1–2):51–9 (78 ref.)

THERAPY

Performance of CD3xCD19 bispecific monoclonal antibodies in B cell malignancy. Haagen IA. **Leuk Lymphoma** 1995 Nov;19(5–6):381–93 (160 ref.)

LEUKEMIA, B-CELL, CHRONIC

DRUG THERAPY

Tumor lysis syndrome induced by fludarabine monophosphate: a case report [letter] Nakhoul F, et al. **Eur J Haematol** 1996 Apr;56(4):254–5 (12 ref.)

GENETICS

Immunoglobulin gene rearrangement in T-cell-rich reactive pleural effusion of a patient with B-cell chronic lymphocytic leukemia. Miyahara M, et al. **Acta Haematol** 1996;96(1):41–4 (24 ref.)

Clinical heterogeneity reflects biologic diversity in chronic lymphocytic leukemia. Moore JS, et al. **Crit Rev Oncol Hematol** 1995 Aug;20(1–2):141–64 (237 ref.)

Tumor suppressor genes and clonal evolution in B-CLL. Kay NE, et al. **Leuk Lymphoma** 1995 Jun;18(1–2):41–9 (103 ref.)

T-cell acute lymphoblastic leukemia occurring in the course of B cell chronic lymphocytic leukemia: a case report. Preudhomme C, et al. **Leuk Lymphoma** 1995 Jul; 18(3–4):361–4 (9 ref.)

A unique spectrum of p53 mutations in B-cell chronic lymphocytic leukemia distinct from that of other lymphoid malignancies. Newcomb EW, et al. **Mol Carcinog** 1995 Dec; 14(4):227–32 (64 ref.)

PATHOLOGY

Clinical heterogeneity reflects biologic diversity in chronic lymphocytic leukemia. Moore JS, et al. **Crit Rev Oncol Hematol** 1995 Aug;20(1–2):141–64 (237 ref.)

Tumor suppressor genes and clonal evolution in B-CLL. Kay NE, et al. **Leuk Lymphoma** 1995 Jun;18(1–2):41–9 (103 ref.)

PHYSIOPATHOLOGY

Defects in signal transduction pathways in chronic B lymphocytic leukemia cells. Jabbar SA, et al. **Leuk Lymphoma** 1995 Jun;18(1–2):163–70 (52 ref.)

LEUKEMIA, BOVINE see **ENZOOTIC BOVINE LEUKOSIS**

LEUKEMIA, CALLA-POSITIVE

PATHOLOGY

Acute myelofibrosis terminating in acute lymphoblastic leukemia: case report and review of the literature. Dunphy CH, et al. **Am J Hematol** 1996 Jan;51(1):85–9 (21 ref.)

LEUKEMIA, EOSINOPHILIC see **HYPEREOSINOPHILIC SYNDROME**

LEUKEMIA, ERYTHROBLASTIC, ACUTE

COMPLICATIONS

[A case of erythroleukemia found after multiple cerebral hemorrhage] Izumi M, et al. **Rinsho Shinkeigaku** 1996 Jan; 36(1):58–60 (7 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

[The appearance of Sweet's syndrome during the transition from a myelodysplastic syndrome to erythroleukemia] Grüne S, et al. **Dtsch Med Wochenschr** 1996 Jul 26; 121(30):939–42 (18 ref.) (Eng. Abstr.) **(Ger)**

LEUKEMIA, EXPERIMENTAL

[An experimental model for gene therapy of murine retroviral leukemias] Aizaki K, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2679–85 (19 ref.) **(Jpn)**

IMMUNOLOGY

[Use of anti-H-Y/Db transgenic mice in studies on T-lymphocyte development and mechanisms of leukemogenesis] Matuszyk J. **Postepy Hig Med Dosw** 1995; 49(1):61–5 (12 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOPATHOLOGY

Severe combined immunodeficient mouse models of human leukemia. Uckun FM. **Blood** 1996 Aug 15;88(4):1135–46 (47 ref.)

VIROLOGY

Operating under a Gag order: a block against incoming virus by the Fv1 gene. Goff SP. **Cell** 1996 Sep 6;86(5):691–3 (20 ref.)

LEUKEMIA, GRANULOCYTIC see **LEUKEMIA, MYELOID**

LEUKEMIA, GRANULOCYTIC, CHRONIC see **LEUKEMIA, MYELOID, CHRONIC**

LEUKEMIA, GRANULOCYTIC, CHRONIC-PHASE see **LEUKEMIA, MYELOID, CHRONIC-PHASE**

LEUKEMIA, HAIRY CELL

[Hairy cell leukemia: review of the literature] Gonsalez D, et al. **Rev Assoc Med Bras** 1995 May–Jun;41(3):243–8 (65 ref.) **(Por)**

COMPLICATIONS

Vasculitides in hairy cell leukemia. Hasler P, et al. **Semin Arthritis Rheum** 1995 Oct;25(2):134–42 (48 ref.)

DRUG THERAPY

The role of cladribine in the treatment of lymphoid malignancies. Nelson MC, et al. **Oncol Nurs Forum** 1995 Oct;22(9):1395–400 (22 ref.)

[Hairy cell leukemia: therapeutic approaches] Paitel JF, et al. **Rev Med Interne** 1996;17(5):399–406 (67 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Integrin receptors and hairy cell leukaemia. Burthem J, et al. **Leuk Lymphoma** 1996 Apr;21(3–4):211–5 (33 ref.)

Autocrine and paracrine regulation of neoplastic cell growth in hairy cell leukemia. Schmid M, et al. **Leuk Lymphoma** 1995 May;17(5–6):401–10 (127 ref.)

PHYSIOPATHOLOGY

The biology of hairy cell leukemia. A study of the practical aspects of interferon-treatment, its mechanism of action and on the pathogenesis of anemia. Nielsen B. **APMIS Suppl** 1995;52:1–39 (232 ref.)

Defects in signal transduction pathways in chronic B lymphocytic leukemia cells. Jabbar SA, et al. **Leuk Lymphoma** 1995 Jun;18(1–2):163–70 (52 ref.)

THERAPY

The biology of hairy cell leukemia. A study of the practical aspects of interferon-treatment, its mechanism of action and on the pathogenesis of anemia. Nielsen B. **APMIS Suppl** 1995;52:1–39 (232 ref.)

[Interferon-alpha in therapy of malignant hemoblastoses] Schuler M, et al. **Internist (Berl)** 1995 Dec;36(12):1133–8 (36 ref.) **(Ger)**

LEUKEMIA L1210

PATHOLOGY

[Cisplatin resistance in a murine leukemia cell line associated with defect of apoptosis] Segal-Bendirdjian E, et al. **Bull Cancer (Paris)** 1996 May;83(5):371–8 (37 ref.) (Eng. Abstr.) **(Fre)**

LEUKEMIA, LYMPHOBLASTIC see **LEUKEMIA, LYMPHOCYTIC**

LEUKEMIA, LYMPHOBLASTIC, ACUTE see **LEUKEMIA, LYMPHOCYTIC, ACUTE**

LEUKEMIA, LYMPHOBLASTIC, ACUTE, COMMON ALL ANTIGEN-POSITIVE see **LEUKEMIA, CALLA-POSITIVE**

LEUKEMIA, LYMPHOBLASTIC, ACUTE, L1 see **LEUKEMIA, LYMPHOCYTIC, ACUTE, L1**

LEUKEMIA, LYMPHOBLASTIC, ACUTE, L2 see **LEUKEMIA, LYMPHOCYTIC, ACUTE, L2**

LEUKEMIA, LYMPHOBLASTIC, ACUTE, PHILADELPHIA-POSITIVE see **LEUKEMIA, LYMPHOCYTIC, ACUTE, L2**

LEUKEMIA, LYMPHOBLASTIC, ACUTE, T-CELL see **LEUKEMIA, T-CELL, ACUTE**

LEUKEMIA, LYMPHOBLASTIC, CHRONIC see **LEUKEMIA, LYMPHOCYTIC, CHRONIC**

LEUKEMIA, LYMPHOCYTIC

DIAGNOSIS

[Leukocyte surface antigen] Nakahara K. **Nippon Rinsho** 1996 Jun;54(6):1536–41 (8 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Leukemic phase of mantle cell lymphoma two case reports and review of the literature [see comments] Vadlamudi G, et al. **Arch Pathol Lab Med** 1996 Jan;120(1):35–40 (31 ref.) Comment in: Arch Pathol Lab Med 1996 Jan;120(1):12–4.

LEUKEMIA, LYMPHOCYTIC, ACUTE

Acute lymphoblastic leukemia. A comprehensive review with emphasis on biology and therapy. Cortes JE, et al. **Cancer** 1995 Dec 15;76(12):2393–417 (366 ref.)

LEUKEMIA, LYMPHOCYTIC, ACUTE

COMPLICATIONS

Vertebral collapse in childhood leukemia. Meehan PL, et al. **J Pediatr Orthop** 1995 Sep-Oct;15(5):592-5 (31 ref.)

DIAGNOSIS

Monoclonal antibodies in the management of acute leukemia. Wang JC, et al. **Am J Hematol** 1995 Nov;50(3):188-99 (159 ref.)

The clinical significance of residual disease in childhood acute lymphoblastic leukemia as detected by polymerase chain reaction amplification by antigen-receptor gene sequences. Roberts WM, et al. **Leuk Lymphoma** 1996 Jan; 20(3-4):181-97 (50 ref.)

Testicular lymphoblastic leukemia/lymphoma. Gutjahr P, et al. **World J Urol** 1995;13(4):230-2 (5 ref.)

[Monoclonal antibodies in diagnosis of acute leukemias] Krawczyńska A, et al. **Przegl Lek** 1996;53(1):20-5 (41 ref.) (Eng. Abstr.) **(Pol)**

DRUG THERAPY

Risk analysis in acute lymphoblastic leukaemia: problems and pitfalls. Chessells JM. **Eur J Cancer** 1995 Sep; 31A(10):1656-9 (36 ref.)

The use of GM-CSF and G-CSF in the treatment of acute leukemias. Harousseau JL, et al. **Leuk Lymphoma** 1995 Aug;18(5-6):405-12 (70 ref.)

Drug development train gathering steam. Ito T, et al. **Nat Med** 1996 Apr;2(4):403-4 (12 ref.)

GENETICS

Involvement of the TEL gene in hematologic malignancy by diverse molecular genetic mechanisms. Golub TR, et al. **Curr Top Microbiol Immunol** 1996;211:279-88 (21 ref.)

Cell cycle regulation and human leukemias: the role of p16INK4 gene inactivation in the development of human acute lymphoblastic leukemia. Della Ragione F, et al. **Haematologica** 1995 Nov-Dec;80(6):557-68 (87 ref.)

HRX gene rearrangement in secondary acute lymphoblastic leukemia. Kobayashi Y, et al. **Leuk Lymphoma** 1995 May; 17(5-6):391-9 (71 ref.)

IMMUNOLOGY

Biological characteristics of CD7(+) acute leukemia. Miwa H, et al. **Leuk Lymphoma** 1996 Apr;21(3-4):239-44 (21 ref.)

PATHOLOGY

Interaction of acute leukemia cells with the bone marrow microenvironment: implications for control of minimal residual disease. Bradstock KF, et al. **Leuk Lymphoma** 1995 Jun;18(1-2):1-16 (152 ref.)

[Hand-mirror cells acute lymphoblastic leukemia (L3)] Uemura K, et al. **Rinsho Byori** 1995 Nov;43(11):1173-7 (24 ref.) (Eng. Abstr.) **(Jpn)**

[Acute respiratory failure in hemoblastoses: the types of diffuse lung lesions] Gorelov VG, et al. **Ter Arkh** 1995; 67(7):52-6 (17 ref.) **(Rus)**

PREVENTION & CONTROL

Case report: late aggressive meningioma following prophylactic cranial irradiation for acute lymphoblastic leukaemia. Stein ME, et al. **Br J Radiol** 1995 Oct; 68(814):1123-5 (13 ref.)

THERAPY

Monoclonal antibodies in the management of acute leukemia. Wang JC, et al. **Am J Hematol** 1995 Nov;50(3):188-99 (159 ref.)

Stem cell transplantation in acute leukemia. Gorin NC. **Ann N Y Acad Sci** 1995 Dec 29;770:262-87 (80 ref.)

Do G-CSF and GM-CSF contribute to the management of acute lymphoblastic leukemia? [editorial] Ottmann OG, et al. **Leukemia** 1996 Jul;10(7):1111-6 (33 ref.)

Current management of acute lymphoblastic leukemia in adults. Ong ST, et al. **Oncology (Huntingt)** 1995 May; 9(5):433-42; discussion 442-4, 449-50 (32 ref.)

LEUKEMIA, LYMPHOCYTIC, ACUTE, CALLA-POSITIVE see **LEUKEMIA, CALLA-POSITIVE**

LEUKEMIA, LYMPHOCYTIC, ACUTE, L1

BLOOD

Acute renal failure with hyperuricemia as initial presentation of leukemia in children. Larsen G, et al. **J Pediatr Hematol Oncol** 1996 May;18(2):191-4 (16 ref.)

Hemostasis in childhood acute lymphoblastic leukemia: coagulopathy induced by disease and treatment. Mitchell LG, et al. **Semin Thromb Hemost** 1995;21(4):390-401 (80 ref.)

DIAGNOSIS

Acute renal failure with hyperuricemia as initial presentation of leukemia in children. Larsen G, et al. **J Pediatr Hematol Oncol** 1996 May;18(2):191-4 (16 ref.)

Acute lymphoblastic leukemia and the lymphoblastic lymphomas of childhood. Head DR, et al. **Semin Diagn Pathol** 1995 Nov;12(4):325-34 (31 ref.)

METABOLISM

A case of acute lymphoblastic leukemia accompanied with the production of parathyroid hormone-related protein. Harutsumi M, et al. **Miner Electrolyte Metab** 1995; 21(1-3):171-6 (24 ref.)

PSYCHOLOGY

Acute lymphocytic leukemia and psychosis: treatment with electroconvulsive therapy. Magen JG, et al. **Ann Clin Psychiatry** 1995 Sep;7(3):133-7 (27 ref.)

THERAPY

[Hematopoietic stem cell transplantation: principles and practice] Burdach S, et al. **Schweiz Rundsch Med Prax** 1996 Jun 4;85(23):741-8 (24 ref.) (Eng. Abstr.) **(Ger)**

LEUKEMIA, LYMPHOCYTIC, ACUTE, L2

DRUG THERAPY

Role of anthracyclines in the treatment of adult acute lymphoblastic leukemia. Bassan R, et al. **Acta Haematol** 1996;95(3-4):188-92 (22 ref.)

High-dose methotrexate in the treatment of adult acute lymphoblastic leukemia. Gökbuget N, et al. **Ann Hematol** 1996 Apr;72(4):194-201 (58 ref.)

The role of anthracyclines in adult acute lymphoblastic leukaemia. Bassan R, et al. **Leukemia** 1996 Jun;10 Suppl 2:s58-61 (11 ref.)

PATHOLOGY

Acute myelofibrosis terminating in acute lymphoblastic leukemia: case report and review of the literature. Dunphy CH, et al. **Am J Hematol** 1996 Jan;51(1):85-9 (21 ref.)

RADIOTHERAPY

An unusual case of hypersomnolence syndrome. Gandhi MK, et al. **Clin Lab Haematol** 1995 Sep;17(3):247-50 (14 ref.)

LEUKEMIA, LYMPHOCYTIC, ACUTE, T-CELL see **LEUKEMIA, T-CELL, ACUTE**

LEUKEMIA, LYMPHOCYTIC, B-CELL see **LEUKEMIA, B-CELL**

LEUKEMIA, LYMPHOCYTIC, CHRONIC

Chronic lymphocytic leukemia. Flinn IW, et al. **Cancer Treat Rev** 1996 Jan;22(1):1-13 (68 ref.)

COMPLICATIONS

Paraneoplastic pemphigus: report of a case. Izaki S, et al. **J Dermatol** 1996 Jun;23(6):397-404 (24 ref.)

[Paraneoplastic pemphigus: review of the literature, apropos of a case associated with chronic lymphoid leukemia] Rodot S, et al. **Rev Med Interne** 1995;16(12):938-43 (25 ref.) (Eng. Abstr.) **(Fre)**

[Delayed allergic reaction to Chlorambucil (Leukeran). Case report and literature review] Torricelli R, et al. **Schweiz Med Wochenschr** 1995 Oct 7;125(40):1870-3 (10 ref.) (Eng. Abstr.) **(Ger)**

DIAGNOSIS

Diagnosis and monitoring of chromosome aberrations in hematological malignancies by fluorescence in situ hybridization. Döhner H, et al. **Stem Cells** 1995 Dec;13 Suppl 3:76-82 (28 ref.)

DRUG THERAPY

[Fludarabine in the treatment of chronic lymphocytic leukemia and other lymphoproliferative disorders] Pawelski S. **Acta Haematol Pol** 1995;26(3):263-8 (32 ref.) (Eng. Abstr.) **(Pol)**

GENETICS

Alterations of the retinoblastoma a susceptibility gene in chronic lymphocytic leukemia. Neubauer A, et al. **Leuk Lymphoma** 1995 Aug;18(5-6):399-404 (44 ref.)

IMMUNOLOGY

[Acquired factor VIII inhibitor and chronic lymphoid leukemia: apropos of a case] Ceballos P, et al. **Rev Med Interne** 1996;17(2):150-3 (15 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Hodgkin's disease developing after spontaneous remission of chronic lymphocytic leukemia. Schmidt HH, et al. **Ann Hematol** 1995 Nov;71(5):247-52 (46 ref.)

Transformation of chronic lymphocytic leukemia to lymphoma of true histiocytic type. Wetzler M, et al. **Cancer** 1995 Aug 15;76(4):609-17 (62 ref.)

Chronic lymphocytic leukemia and the central nervous system: a clinical and pathological study. Cramer SC, et al. **Neurology** 1996 Jan;46(1):19-25 (67 ref.)

Hearing loss and leukocytosis. Lossos IS, et al. **Postgrad Med J** 1996 Mar;72(845):183-5 (7 ref.)

PHYSIOPATHOLOGY

Chronic lymphocytic leukemia and the central nervous system: a clinical and pathological study. Cramer SC, et al. **Neurology** 1996 Jan;46(1):19-25 (67 ref.)

THERAPY

Key issues in the treatment of chronic lymphocytic leukaemia (CLL) [see comments] Catovsky D, et al. **Eur J Cancer** 1995 Dec;31A(13-14):2146-54 (114 ref.) Comment in: Eur J Cancer 1995 Dec;31A(13-14):2135-7.

Chronic lymphocytic leukaemia--new drugs and management. Hamblin TJ. **J R Coll Physicians Lond** 1995 Sep-Oct;29(5):419-21 (20 ref.)

[The current aspects of the treatment of patients with chronic lympholeukemia] Klimenko VI, et al. **Lik Sprava** 1995 May-Jun;(5-6):45-51 (46 ref.) **(Rus)**

LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL see **LEUKEMIA, B-CELL, CHRONIC**

LEUKEMIA, LYMPHOCYTIC, T-CELL see **LEUKEMIA, T-CELL**

LEUKEMIA, LYMPHOID see **LEUKEMIA, LYMPHOCYTIC**

LEUKEMIA-LYMPHOMA, ADULT T-CELL see **LEUKEMIA-LYMPHOMA, T-CELL, ACUTE, HTLV-I-ASSOCIATED**

LEUKEMIA-LYMPHOMA, T-CELL, ACUTE, HTLV-I-ASSOCIATED

COMPLICATIONS

Hypercalcemia associated with adult T-cell leukemia/lymphoma (ATL). Peter SA, et al. **J Natl Med Assoc** 1995 Oct;87(10):746-8 (15 ref.)

DRUG THERAPY

[Significance of PUVA therapy for adult T-cell leukemia/lymphoma--PUVA therapy can induce apoptosis in leukemic cells] Takemori N, et al. **Hum Cell** 1995 Sep; 8(3):121-6 (30 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Parathyroid hormone-related peptide in hypercalcemia associated with adult T cell leukemia/lymphoma: molecular and cellular mechanism of parathyroid hormone-related peptide overexpression in HTLV-I-infected T cells. Ikeda K, et al. **Miner Electrolyte Metab** 1995;21(1-3):166-70 (36 ref.)

VIROLOGY

Role of kinases in HTLV-I transformation. Xu X, et al. **J Investig Med** 1996 Apr;44(4):113-23 (169 ref.)

LEUKEMIA, MAST-CELL

PATHOLOGY

Biology, classification and treatment of human mastocytosis. Valent P. **Wien Klin Wochenschr** 1996;108(13):385-97 (106 ref.)

LEUKEMIA, MEGAKARYOBLASTIC, ACUTE see **LEUKEMIA, MEGAKARYOCYTIC, ACUTE**

LEUKEMIA, MEGAKARYOCYTIC see **LEUKEMIA, MEGAKARYOCYTIC, ACUTE**

LEUKEMIA, MEGAKARYOCYTIC, ACUTE

COMPLICATIONS

Leukemia with megakaryocytic differentiation following essential thrombocythemia and myelofibrosis. Case report and review of the literature. Patiño-Sarcinelli F, et al. **Acta Haematol** 1996;95(2):122-8 (53 ref.)

GENETICS

der(1;15)(q10;10): a nonrandom chromosomal abnormality of myeloid neoplasia. Wong KF, et al. **Cancer Genet Cytogenet** 1995 Sep;83(2):144-7 (12 ref.)

PATHOLOGY

Acute megakaryoblastic leukemia. Gassmann W, et al. **Leuk Lymphoma** 1995;18 Suppl 1:69-73 (19 ref.)

PHYSIOPATHOLOGY

Characteristic biological features of human megakaryoblastic leukaemia cell lines. Hassan HT, et al. **Leuk Res** 1995 Sep;

19(9):589–94 (60 ref.)

LEUKEMIA, MONOBLASTIC, ACUTE see LEUKEMIA, MONOCYTIC, ACUTE

LEUKEMIA, MONOCYTIC, ACUTE

DIAGNOSIS

Neuroblastoma presenting as acute monoblastic leukemia. Boyd JE, et al. **J Pediatr Hematol Oncol** 1996 May; 18(2):206–12 (37 ref.)

GENETICS

Therapy-related acute leukemia associated with t(11q23) after primary acute myeloid leukemia with t(8;21): a report of two cases [letter] Roulston D, et al. **Blood** 1995 Nov 1;86(9):3613–4 (7 ref.)

LEUKEMIA, MYELOBLASTIC, ACUTE see LEUKEMIA, MYELOCYTIC, ACUTE

LEUKEMIA, MYELOCYTIC see LEUKEMIA, MYELOID

LEUKEMIA, MYELOCYTIC, ACUTE

CHEMICALLY INDUCED

[A case of secondary leukemia in anaplastic seminoma patient treated with long-term chemotherapy] Kamai T, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 May;87(5):875–9 (12 ref.) (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

Corynebacterium CDC group JK (Corynebacterium jeikeium) sepsis in haematological patients: a report of three cases and a systematic literature review. van der Lelie H, et al. **Scand J Infect Dis** 1995;27(6):581–4 (36 ref.)

DIAGNOSIS

Monoclonal antibodies in the management of acute leukemia. Wang JC, et al. **Am J Hematol** 1995 Nov;50(3):188–99 (159 ref.)

Recent-onset myelodysplastic syndrome mimicking acute leukemia during infection. Friedman HD, et al. **Ann Hematol** 1996 Feb;72(2):85–8 (23 ref.)

[Spinal chloroma as the initial manifestation of the transformation of essential thrombocythemia into acute myeloid leukemia] Stroszczynski C, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Mar;164(3):261–3 (13 ref.) (Eng. Abstr.) **(Ger)**

[Monoclonal antibodies in diagnosis of acute leukemias] Krawczyńska A, et al. **Przegl Lek** 1996;53(1):20–5 (41 ref.) (Eng. Abstr.) **(Pol)**

DRUG THERAPY

Rationale for high-dose chemotherapy and application of haematopoietic growth factors in acute myeloid leukaemia. Hiddemann W, et al. **Ann Oncol** 1995;6 Suppl 4:27–31 (33 ref.)

Successful hematopoietic reconstitution with granulocyte colony-stimulating factor in a patient with hypoplastic acute myelogenous leukemia. Lee M, et al. **Intern Med** 1995 Jul;34(7):692–4 (15 ref.)

Use of cytokines in the treatment of acute myelocytic leukemia: a critical review. Geller RB. **J Clin Oncol** 1996 Apr;14(4):1371–82 (65 ref.)

The use of GM-CSF and G-CSF in the treatment of acute leukemias. Harousseau JL, et al. **Leuk Lymphoma** 1995 Aug;18(5–6):405–12 (70 ref.)

G-CSF in the biology and treatment of acute myeloid leukemias. Visani G, et al. **Leuk Lymphoma** 1995 Aug; 18(5–6):423–8 (62 ref.)

Role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia. List AF. **Leukemia** 1996 Jun;10(6):937–42 (43 ref.)

Differentiating therapy with all-trans retinoic acid in acute myeloid leukemia. Tallman MS. **Leukemia** 1996 Apr;10 Suppl 1:S12–5 (28 ref.)

Atypical MRI findings in treatment-related leukoencephalopathy: case report. Ohmoto Y, et al. **Neuroradiology** 1996 Feb;38(2):128–33 (30 ref.)

Cytokines and their antagonists in myeloid disorders. Estrov Z, et al. **Semin Hematol** 1995 Jul;32(3):220–31 (124 ref.)

[Bases for intravenous administration of cytosine arabinoside in the treatment of adult acute myeloid leukemia] Thomas X, et al. **Bull Cancer (Paris)** 1995 Nov;82(11):911–22 (57 ref.) (Eng. Abstr.) **(Fre)**

[Modern strategies in therapy of acute myeloid leukemia (AML) in adulthood. I. Primary treatment of de novo AML] Jehn U, et al. **Internist (Berl)** 1996 Jun;37(6):661–8 (17 ref.) **(Ger)**

[II. Leukemia in the elderly, secondary, recurrent and refractory leukemia, chloroma] Jehn U, et al. **Internist (Berl)** 1996 Jun;37(6):669–77 (18 ref.) **(Ger)**

ETIOLOGY

The secondary leukemias: challenges and research directions. Smith MA, et al. **J Natl Cancer Inst** 1996 Apr 3; 88(7):407–18 (199 ref.)

Are growth factors leukemogenic? Brodsky RA, et al. **Leukemia** 1996 Jan;10(1):175–7 (26 ref.)

GENETICS

Therapy-related acute leukemia associated with t(11q23) after primary acute myeloid leukemia with t(8;21): a report of two cases [letter] Roulston D, et al. **Blood** 1995 Nov 1;86(9):3613–4 (7 ref.)

The role of prognostic factors in acute myeloid leukemia. Büchner T, et al. **Leukemia** 1996 Apr;10 Suppl 1:S28–9 (19 ref.)

[Therapy-related leukemia with t(8;21) initially diagnosed as MDS (RAEB in T)] Hanamura A, et al. **Rinsho Ketsueki** 1995 Aug;36(8):755–61 (15 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Biological characteristics of CD7(+) acute leukemia. Miwa H, et al. **Leuk Lymphoma** 1996 Apr;21(3–4):239–44 (21 ref.)

PATHOLOGY

Acute myelogenous leukemia presenting with bulky lymphadenopathy. Case report and literature review. Gollard RP, et al. **Acta Haematol** 1996;95(2):129–34 (26 ref.)

Cell differentiation in acute myeloid leukemia. Olsson I, et al. **Eur J Haematol** 1996 Jul;57(1):1–16 (122 ref.)

PHYSIOPATHOLOGY

Minimally differentiated acute myeloid leukemia (AML-M0): a distinct clinico-biologic entity with poor prognosis. Amadori S, et al. **Ann Hematol** 1996 Apr;72(4):208–15 (65 ref.)

G-CSF in the biology and treatment of acute myeloid leukemias. Visani G, et al. **Leuk Lymphoma** 1995 Aug; 18(5–6):423–8 (62 ref.)

THERAPY

Monoclonal antibodies in the management of acute leukemia. Wang JC, et al. **Am J Hematol** 1995 Nov;50(3):188–99 (159 ref.)

Allogenic bone marrow transplantation or chemotherapy for patients with acute myeloid leukemia in first complete remission: a decision analysis approach. Hertenstein B, et al. **Ann Hematol** 1996 Apr;72(4):223–30 (47 ref.)

Therapy of childhood acute myelogenous leukemias. Vormoor J, et al. **Ann Hematol** 1996 Jul;73(1):11–24 (24 ref.)

Stem cell transplantation in acute leukemia. Gorin NC. **Ann N Y Acad Sci** 1995 Dec 29;770:262–87 (80 ref.)

The role of prognostic factors in acute myeloid leukemia. Büchner T, et al. **Leukemia** 1996 Apr;10 Suppl 1:S28–9 (19 ref.)

Treatment of refractory AML. Estey E. **Leukemia** 1996 Jun; 10(6):932–6 (19 ref.)

Postremission therapy of acute myeloid leukemia in older adults. Schiller GJ. **Leukemia** 1996 Apr;10 Suppl 1:S18–20 (19 ref.)

[Hematopoietic stem cell transplantation: principles and practice] Burdach S, et al. **Schweiz Rundsch Med Prax** 1996 Jun 4;85(23):741–8 (24 ref.) (Eng. Abstr.) **(Ger)**

LEUKEMIA, MYELOCYTIC, CHRONIC see LEUKEMIA, MYELOID, CHRONIC

LEUKEMIA, MYELOGENOUS see LEUKEMIA, MYELOID

LEUKEMIA, MYELOGENOUS, ACUTE see LEUKEMIA, MYELOCYTIC, ACUTE

LEUKEMIA, MYELOGENOUS, CHRONIC see LEUKEMIA, MYELOID, CHRONIC

LEUKEMIA, MYELOGENOUS, CHRONIC-PHASE see LEUKEMIA, MYELOID, CHRONIC-PHASE

LEUKEMIA, MYELOGENOUS, PH1-NEGATIVE see LEUKEMIA, MYELOID, PHILADELPHIA-NEGATIVE

LEUKEMIA, MYELOGENOUS, PH1-POSITIVE see LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE

LEUKEMIA, MYELOID

COMPLICATIONS

Gastric tuberculosis presenting with massive hematemesis in association with acute myeloid leukemia. Quantrill SJ, et al. **Am J Gastroenterol** 1996 Jun;91(6):1259–60 (11 ref.)

DIAGNOSIS

Diagnosis and monitoring of chromosome aberrations in hematological malignancies by fluorescence in situ hybridization. Döhner H, et al. **Stem Cells** 1995 Dec;13 Suppl 3:76–82 (28 ref.)

[Multiple intracerebral granulocytic sarcomas in a patient with chronic myeloid leukemia] Grondin L, et al. **Can Assoc Radiol J** 1996 Apr;47(2):132–5 (12 ref.) (Eng. Abstr.) **(Fre)**

[Spinal chloroma as the initial manifestation of the transformation of essential thrombocythemia into acute myeloid leukemia] Stroszczynski C, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Mar;164(3):261–3 (13 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Reversal of multidrug resistance in acute myeloid leukaemia and other haematological malignancies. Sonneveld P. **Eur J Cancer** 1996 Jun;32A(6):1062–9 (97 ref.)

All-trans retinoic acid (ATRA) and the regulation of adhesion molecules in acute myeloid leukemia. Di Noto R, et al. **Leuk Lymphoma** 1996 Apr;21(3–4):201–9 (74 ref.)

High-dose chemotherapy in adult acute myeloid leukemia: rationale and results. Stasi R, et al. **Leuk Res** 1996 Jul; 20(7):535–49 (70 ref.)

Does it matter how remission is achieved in acute leukemia? Bishop JF. **Leukemia** 1996 Apr;10 Suppl 1:S7–9 (6 ref.)

Treatment of acute myeloid leukemia with antecedent myelodysplastic syndrome. Larson RA. **Leukemia** 1996 Apr;10 Suppl 1:S23–5 (7 ref.)

[II. Leukemia in the elderly, secondary, recurrent and refractory leukemia, chloroma] Jehn U, et al. **Internist (Berl)** 1996 Jun;37(6):669–77 (18 ref.) **(Ger)**

ETIOLOGY

Therapy-related myeloid leukemia. Thirman MJ, et al. **Hematol Oncol Clin North Am** 1996 Apr;10(2):293–320 (139 ref.)

GENETICS

Involvement of the TEL gene in hematologic malignancy by diverse molecular genetic mechanisms. Golub TR, et al. **Curr Top Microbiol Immunol** 1996;211:279–88 (21 ref.)

Transforming properties of the leukemic inv(16) fusion gene CBFB-MYH11. Hajra A, et al. **Curr Top Microbiol Immunol** 1996;211:289–98 (23 ref.)

The neurofibromatosis type 1 (NF1) tumor suppressor gene and myeloid leukemia. Largaespada DA, et al. **Curr Top Microbiol Immunol** 1996;211:233–9 (29 ref.)

Altered retinoic acid receptors. de Thé H. **FASEB J** 1996 Jul;10(9):955–60 (43 ref.)

TCR delta gene rearrangements in acute myeloid leukemia with T-lymphoid antigen expression. Schmidt CA, et al. **Leuk Lymphoma** 1995 Dec;20(1–2):45–9 (57 ref.)

Immunophenotyping and cytogenetics in older adults with acute myeloid leukemia: significance of expression of the multidrug resistance gene-1 (MDR1). Willman CL. **Leukemia** 1996 Apr;10 Suppl 1:S33–5 (27 ref.)

IMMUNOLOGY

Interleukins and colony stimulating factors in human myeloid leukemia cell lines. Hassan HT, et al. **Leuk Lymphoma** 1995 Dec;20(1–2):1–15 (196 ref.)

TCR delta gene rearrangements in acute myeloid leukemia with T-lymphoid antigen expression. Schmidt CA, et al. **Leuk Lymphoma** 1995 Dec;20(1–2):45–9 (57 ref.)

Immunophenotyping and cytogenetics in older adults with acute myeloid leukemia: significance of expression of the multidrug resistance gene-1 (MDR1). Willman CL. **Leukemia** 1996 Apr;10 Suppl 1:S33–5 (27 ref.)

METABOLISM

All-trans retinoic acid (ATRA) and the regulation of adhesion molecules in acute myeloid leukemia. Di Noto R, et al. **Leuk Lymphoma** 1996 Apr;21(3–4):201–9 (74 ref.)

Interleukins and colony stimulating factors in human myeloid leukemia cell lines. Hassan HT, et al. **Leuk Lymphoma** 1995 Dec;20(1–2):1–15 (196 ref.)

PATHOLOGY

Stem cell factor as a survival and growth factor in human normal and malignant hematopoiesis. Hassan HT, et al. **Acta Haematol** 1996;95(3–4):257–62 (50 ref.)

Interaction of acute leukemia cells with the bone marrow microenvironment: implications for control of minimal residual disease. Bradstock KF, et al. **Leuk Lymphoma** 1995 Jun;18(1–2):1–16 (152 ref.)

Composition and function of the hemopoietic microenvironment in human myeloid leukemia. Mayani H. **Leukemia** 1996 Jun;10(6):1041–7 (76 ref.)

PHYSIOPATHOLOGY

Molecular control of development in normal and leukemic myeloid cells by cytokines, tumor suppressor and oncogenes. Sachs L. **Curr Top Microbiol Immunol** 1996; 211:3–5 (18 ref.)

THERAPY

New chemotherapeutic agents in acute myeloid leukemia. Kantarjian HM, et al. **Leukemia** 1996 Apr;10 Suppl 1:S4–6 (0 ref.)

Role of postinduction immunotherapy in acute myeloid leukemia. Klingemann HG. **Leukemia** 1996 Apr;10 Suppl 1:S21–2 (3 ref.)

The role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia. List AF. **Leukemia** 1996 Apr;10 Suppl 1:S36–8 (0 ref.)

Use of growth factors during induction therapy for acute

myeloid leukemia. Rowe JM. **Leukemia** 1996 Apr;10 Suppl 1:S40–3 (10 ref.)

VIROLOGY

Molecular analysis of Evi1, a zinc finger oncogene involved in myeloid leukemia. Lopingco MC, et al. **Curr Top Microbiol Immunol** 1996;211:211–22 (63 ref.)

Molecular analysis and characterization of two myeloid leukemia inducing murine retroviruses. Rassart E, et al. **Curr Top Microbiol Immunol** 1996;211:201–10 (36 ref.)

LEUKEMIA, MYELOID, ACUTE, M1 see **LEUKEMIA, MYELOCYTIC, ACUTE**

LEUKEMIA, MYELOID, ACUTE, M2 see **LEUKEMIA, MYELOCYTIC, ACUTE**

LEUKEMIA, MYELOID, ACUTE, M3 see **LEUKEMIA, PROMYELOCYTIC, ACUTE**

LEUKEMIA, MYELOID, ACUTE, M4 see **LEUKEMIA, MYELOMONOCYTIC, ACUTE**

LEUKEMIA, MYELOID, ACUTE, M5 see **LEUKEMIA, MONOCYTIC, ACUTE**

LEUKEMIA, MYELOID, ACUTE, M6 see **LEUKEMIA, ERYTHROBLASTIC, ACUTE**

LEUKEMIA, MYELOID, ACUTE, M7 see **LEUKEMIA, MEGAKARYOCYTIC, ACUTE**

LEUKEMIA, MYELOID, CHRONIC

Chronic myelogenous leukemia: a review. Cortes JE, et al. **Am J Med** 1996 May;100(5):555–70 (195 ref.)

[Chronic myeloproliferative diseases. New knowledge about well known diseases] Aulitzky WE, et al. **Dtsch Med Wochenschr** 1996 May 3;121(18):600–4 (42 ref.) (Eng. Abstr.) **(Ger)**

[Hereditary hematopoietic malignancy with emphasis of juvenile chronic myelogenous leukemia and 7 monosomy syndrome] Hayashi Y. **Nippon Rinsho** 1995 Nov; 53(11):2737–41 (21 ref.) (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

Sweet's syndrome after splenic irradiation for chronic myelogenous leukemia. Pertusi RM, et al. **J Am Osteopath Assoc** 1996 Jun;96(6):366–7 (8 ref.)

Mixed intranasal infection caused by Fusarium solani and a zygomycete in a leukaemic patient. Lopes JO, et al. **Mycoses** 1995 Jul–Aug;38(7–8):281–4 (26 ref.)

DIAGNOSIS

Juvenile chronic myelogenous leukemia. Hess JL, et al. **Am J Clin Pathol** 1996 Feb;105(2):238–48 (74 ref.)

Diagnosis and monitoring of chromosome aberrations in hematological malignancies by fluorescence in situ hybridization. Döhner H, et al. **Stem Cells** 1995 Dec;13 Suppl 3:76–82 (28 ref.)

[Multiple intracerebral granulocytic sarcomas in a patient with chronic myeloid leukemia] Grondin L, et al. **Can Assoc Radiol J** 1996 Apr;47(2):132–5 (12 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

Interferon-alpha therapy for chronic myelogenous leukemia. Wetzler M, et al. **Am J Med** 1995 Oct;99(4):402–11 (67 ref.)

Update on the diagnosis of and therapy for acute promyelocytic leukemia and chronic myelogenous leukemia. Wujcik D. **Oncol Nurs Forum** 1996 Apr; 23(3):478–87 (70 ref.)

Cytokines and their antagonists in myeloid disorders. Estrov Z, et al. **Semin Hematol** 1995 Jul;32(3):220–31 (124 ref.)

ETIOLOGY

Chronic myeloid leukaemia following 1311 treatment for thyroid carcinoma: a report of two cases and review of the literature. Shimon I, et al. **Clin Endocrinol (Oxf)** 1995 Nov;43(5):651–4 (21 ref.)

GENETICS

Translocation (Y;1)(q12;q12) in hematologic malignancies. Report on two new cases, FISH characterization, and review of the literature. Michaux L, et al. **Cancer Genet Cytogenet** 1996 Jan;86(1):35–8 (13 ref.)

Genetic approaches to defining signaling by the CML-associated tyrosine kinase BCR-ABL. Afar DE, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:589–94 (49 ref.)

BCR-ABL: an anti-apoptosis gene in chronic myelogenous leukemia. Cotter TG. **Leuk Lymphoma** 1995 Jul; 18(3–4):231–6 (32 ref.)

Chromosome 17 abnormalities and inactivation of the p53 gene in chronic myeloid leukemia and their prognostic significance. Nakai H, et al. **Leuk Lymphoma** 1995 Oct; 19(3–4):213–21 (58 ref.)

Role of p53 in leukemogenesis of chronic myeloid leukemia. Lanza F, et al. **Stem Cells (Dayt)** 1995 Jul;13(4):445–52 (54 ref.)

[Chronic myeloid leukemia, biological aspects] Costello R, et al. **Rev Med Interne** 1996;17(3):213–23 (139 ref.) (Eng. Abstr.) **(Fre)**

[Granulocyte abnormal chromatin clumping syndrome: report of a new case and review of the literature] Esteve J, et al. **Sangre (Barc)** 1995 Aug;40(4):327–30 (22 ref.) (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

Separation of graft-vs.-host disease and graft-vs.-leukemia effect against chronic myelogenous leukemia [editorial; comment] Champlin R. **Exp Hematol** 1995 Oct; 23(11):1148–51 (48 ref.) Comment on: Exp Hematol 1995 Oct;23(11):1167–72.

The role of natural killer cells in the treatment of chronic myeloid leukemia. Silla LM, et al. **J Hematother** 1995 Aug; 4(4):269–79 (103 ref.)

METABOLISM

Platelet derived growth factor expression, myelofibrosis and chronic myelogenous leukemia. Kimura A, et al. **Leuk Lymphoma** 1995 Jul;18(3–4):237–42 (47 ref.)

PATHOLOGY

Widespread eruptive dermal and atypical melanocytic nevi in association with chronic myelocytic leukemia: case report and review of the literature. Richert S, et al. **J Am Acad Dermatol** 1996 Aug;35(2 Pt 2):326–9 (25 ref.)

[Expression of primitive stem cell antigens on the blast cells of patients with chronic myeloid leukemia] Baryshnikov Alu. **Vestn Ross Akad Med Nauk** 1996;(3):9–13 (53 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

The repression of apoptosis by activated abl oncogenes in chronic myelogenous leukaemia. Fernandes RS, et al. **Leukemia** 1996 Jun;10 Suppl 2:s17–21 (39 ref.)

RADIOTHERAPY

Sweet's syndrome after splenic irradiation for chronic myelogenous leukemia. Pertusi RM, et al. **J Am Osteopath Assoc** 1996 Jun;96(6):366–7 (8 ref.)

[Radiotherapy in advanced osseous destruction in chronic myeloid leukemia. A case report] Sadick M, et al. **Strahlenther Onkol** 1996 Jun;172(6):330–1 (9 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Chronic myeloid leukaemia: a therapeutic challenge. Mughal TI, et al. **Ann Oncol** 1995 Sep;6(7):637–44 (93 ref.)

Bone marrow transplantation for chronic myeloid leukemia with volunteer unrelated donors using ex vivo or in vivo T-cell depletion: major prognostic impact of HLA class I identity between donor and recipient. Spencer A, et al. **Blood** 1995 Nov 1;86(9):3590–7 (40 ref.)

Options for therapy in chronic myeloid leukaemia. Spencer A, et al. **Br J Haematol** 1995 Sep;91(1):2–7 (50 ref.)

Marrow transplantation for chronic myeloid leukemia. Clift RA. **Cancer Treat Res** 1995;76:1–42 (125 ref.)

Separation of graft-vs.-host disease and graft-vs.-leukemia effect against chronic myelogenous leukemia [editorial; comment] Champlin R. **Exp Hematol** 1995 Oct; 23(11):1148–51 (48 ref.) Comment on: Exp Hematol 1995 Oct;23(11):1167–72.

Role of interferon-alpha in chronic myeloid leukemia. Kumar L, et al. **J Assoc Physicians India** 1995;Suppl 3:26–32 (47 ref.)

Immunomodulatory effects of donor lymphocyte infusions following allogeneic bone marrow transplantation. Soiffer RJ, et al. **J Clin Apheresis** 1995;10(3):139–43 (36 ref.)

The role of natural killer cells in the treatment of chronic myeloid leukemia. Silla LM, et al. **J Hematother** 1995 Aug; 4(4):269–79 (103 ref.)

Alpha-interferon in chronic myelogenous leukaemia [see comments] Kumar L, et al. **Lancet** 1995 Oct 14; 346(8981):984–6 (12 ref.) Comment in: Lancet 1996 Jan 6;347(8993):57–8.

Chronic myelogenous leukemia: does interferon alpha prolong life? [editorial] Hehlmann R. **Leukemia** 1996 Feb; 10(2):193–6 (22 ref.)

Interferon and chronic myelogenous leukaemia. Lauta VM. **Med Oncol** 1995 Mar;12(1):41–6 (27 ref.)

Chronic myelogenous leukemia and acute promyelocytic leukemia: new bone marrow transplantation options. Viele CS. **Oncol Nurs Forum** 1996 Apr;23(3):488–93 (22 ref.)

[Interferon-alpha in therapy of malignant hemoblastoses] Schuler M, et al. **Internist (Berl)** 1995 Dec;36(12):1133–8 (36 ref.) **(Ger)**

[Chronic myeloid leukemia—latest aspects and practical progress in recent years] Griesshammer M, et al. **Med Klin** 1995 Sep 15;90(9):527–31 (51 ref.) **(Ger)**

LEUKEMIA, MYELOID, CHRONIC-PHASE

THERAPY

Autografting in chronic myeloid leukemia: an overview. Reiffers J, et al. **Leukemia** 1996 Mar;10(3):385–8 (26 ref.)

LEUKEMIA, MYELOID, NAEGELI-TYPE see **LEUKEMIA, MYELOMONOCYTIC, ACUTE**

LEUKEMIA, MYELOID, PH1-NEGATIVE see **LEUKEMIA, MYELOID, PHILADELPHIA-NEGATIVE**

LEUKEMIA, MYELOID, PH1-POSITIVE see **LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE**

LEUKEMIA, MYELOID, PHILADELPHIA-NEGATIVE

see related
PHILADELPHIA CHROMOSOME

GENETICS

Philadelphia chromosome-negative cells with trisomy 8 after busulfan and interferon treatment of Ph1-positive chronic myelogenous leukemia. Izumi T, et al. **Int J Hematol** 1996 Jul;64(1):73–7 (17 ref.)

LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE

see related
PHILADELPHIA CHROMOSOME

GENETICS

The molecular biology of chronic myeloid leukaemia. Melo JV. **Leukemia** 1996 May;10(5):751–6 (58 ref.)

[Fluorescent in-situ hybridization technique (FISH) in the diagnosis of Philadelphia translocation in chronic myeloid leukemia] Martinet D, et al. **Schweiz Med Wochenschr** 1996 May 18;126(20):855–63 (30 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Platelet derived growth factor expression, myelofibrosis and chronic myelogenous leukemia. Kimura A, et al. **Leuk Lymphoma** 1995 Jul;18(3–4):237–42 (47 ref.)

PATHOLOGY

Monitoring of residual disease in chronic myelogenous leukemia: methodological approaches and clinical aspects. Lion T. **Leukemia** 1996 May;10(5):896–900; discussion 901–6 (43 ref.)

THERAPY

Treatment of myelogenous leukemia: current status and investigational options [see comments] Kantarjian HM, et al. **Blood** 1996 Apr 15;87(8):3069–81 (91 ref.) Comment in: Blood 1996 Aug 15;88(4):1517.

Fulminant adenovirus hepatitis after allogeneic bone marrow transplantation. Bertheau P, et al. **Bone Marrow Transplant** 1996 Feb;17(2):295–8 (14 ref.)

Recombinant alpha-interferon as treatment for chronic myelogenous leukemia in relapse after allogeneic bone marrow transplantation: a report from the Société Française de Greffe de Moelle. Pigneux A, et al. **Bone Marrow Transplant** 1995 Jun;15(6):819–24 (31 ref.)

Philadelphia chromosome-negative cells with trisomy 8 after busulfan and interferon treatment of Ph1-positive chronic myelogenous leukemia. Izumi T, et al. **Int J Hematol** 1996 Jul;64(1):73–7 (17 ref.)

Interferon and chronic myelogenous leukaemia. Lauta VM. **Med Oncol** 1995 Mar;12(1):41–6 (27 ref.)

LEUKEMIA, MYELOID, SCHILLING-TYPE see **LEUKEMIA, MONOCYTIC, ACUTE**

LEUKEMIA, MYELOID, STABLE-PHASE see **LEUKEMIA, MYELOID, CHRONIC-PHASE**

LEUKEMIA, MYELOMONOCYTIC, ACUTE

Leukemia during pregnancy. Ramirez-Smiley M, et al. **Oncol Nurs Forum** 1995 Oct;22(9):1363–8 (16 ref.)

GENETICS

Retroviral insertional mutagenesis in murine promonocytic leukemias: c-myb and Mml1. Wolff L, et al. **Curr Top Microbiol Immunol** 1996;211:191–9 (33 ref.)

PATHOLOGY

The SKM-1 leukemic cell line established from a patient with progression to myelomonocytic leukemia in myelodysplastic syndrome (MDS)-contribution to better understanding of MDS. Nakagawa T, et al. **Leuk Lymphoma** 1995 Apr;17(3–4):335–9 (63 ref.)

[Acute respiratory failure in hemoblastoses: the types of diffuse lung lesions] Gorelov VG, et al. **Ter Arkh** 1995; 67(7):52–6 (17 ref.) **(Rus)**

THERAPY

[Leukemia and pregnancy. Review apropos of a clinical case]

Perucca E, et al. **Rev Chil Obstet Ginecol** 1995; 60(2):118–23; discussion 123–4 (13 ref.) (Eng. Abstr.) **(Spa)**

LEUKEMIA, MYELOMONOCYTIC, CHRONIC

GENETICS

Involvement of the TEL gene in hematologic malignancy by diverse molecular genetic mechanisms. Golub TR, et al. **Curr Top Microbiol Immunol** 1996;211:279–88 (21 ref.)

LEUKEMIA, NEUTROPHILIC, CHRONIC

COMPLICATIONS

Chronic neutrophilic leukemia associated with monoclonal gammopathy of undetermined significance. Ito T, et al. **Acta Haematol** 1996;95(2):140–3 (24 ref.)

LEUKEMIA, NONLYMPHOBLASTIC, ACUTE see **LEUKEMIA, NONLYMPHOCYTIC, ACUTE**

LEUKEMIA, NONLYMPHOCYTIC, ACUTE

ETIOLOGY

[Second malignant disease in patients under treatment for malignant lymphoma] Várady E, et al. **Orv Hetil** 1995 Oct 22;136(43):2323–8 (35 ref.) (Eng. Abstr.) **(Hun)**

GENETICS

Acute non-lymphoblastic leukaemia with t(16;21): case report with a review of the literature. Hiyoshi M, et al. **Clin Lab Haematol** 1995 Sep;17(3):243–6 (15 ref.)

LEUKEMIA, PRE-B-CELL

GENETICS

Emergence of novel transient clonal chromosomal bone marrow changes in remission of acute lymphoblastic leukemia. Andreasson P, et al. **Leukemia** 1996 Feb; 10(2):378–83 (14 ref.)

PATHOLOGY

Acute myelofibrosis terminating in acute lymphoblastic leukemia: case report and review of the literature. Dunphy CH, et al. **Am J Hematol** 1996 Jan;51(1):85–9 (21 ref.)

LEUKEMIA, PROGRANULOCYTIC see **LEUKEMIA, PROMYELOCYTIC, ACUTE**

LEUKEMIA, PROLYMPHOCYTIC

[Cutaneous localization of T-cell prolymphocytic leukemia] Thomas A, et al. **Ann Dermatol Venereol** 1995;122(8):526–9 (17 ref.) (Eng. Abstr.) **(Fre)**

LEUKEMIA, PROMYELOCYTIC, ACUTE

COMPLICATIONS

[The pathogenesis and treatment of the hemostatic disorder in acute promyelocytic leukemia] Velasco F, et al. **Med Clin (Barc)** 1996 Jun 8;107(2):59–61 (27 ref.) **(Spa)**

DRUG THERAPY

Pathogenesis and management of acute promyelocytic leukemia. Warrell RP Jr. **Annu Rev Med** 1996;47:555–65 (44 ref.)

Differentiation therapy of acute promyelocytic leukemia: clinical and molecular features [see comments] Miller WH Jr. **Cancer Invest** 1996;14(2):142–50 (65 ref.) Comment in: Cancer Invest 1996;14(2):182–3.

Differentiation therapy of acute promyelocytic leukemia. Chen Z. **Chin Med J (Engl)** 1996 Mar;109(3):179–82 (9 ref.)

Tretinoin. A review of its pharmacodynamic and pharmacokinetic properties and use in the management of acute promyelocytic leukaemia. Gillis JC, et al. **Drugs** 1995 Nov;50(5):897–923 (160 ref.)

Retinoid differentiation therapy in promyelocytic leukemia. Chomienne C, et al. **FASEB J** 1996 Jul;10(9):1025–30 (67 ref.)

All-trans-retinoic acid and pseudotumor cerebri in a young adult with acute promyelocytic leukemia: a possible disease association. Visani G, et al. **Haematologica** 1996 Mar–Apr; 81(2):152–4 (12 ref.)

Sweet's syndrome in a patient with acute promyelocytic leukemia during treatment with all-trans retinoic acid. Shirono K, et al. **Int J Hematol** 1995 Oct;62(3):183–7 (16 ref.)

Acute promyelocytic leukemia: retinoic acid response and resistance. Early E, et al. **J Investig Med** 1995 Aug; 43(4):337–44 (108 ref.)

Induction of retinoid resistance by all-trans retinoic acid in acute promyelocytic leukemia after remission. Cornic M, et al. **Leuk Lymphoma** 1995 Jul;18(3–4):249–57 (108 ref.)

Sweet's syndrome involoving the musculoskeletal system during treatment of promyelocytic leukemia with all-trans retinoic acid. Christ E, et al. **Leukemia** 1996 Apr; 10(4):731–4 (10 ref.)

Differentiating therapy with all-trans retinoic acid in acute myeloid leukemia. Tallman MS. **Leukemia** 1996 Apr;10 Suppl 1:S12–5 (28 ref.)

Differentiating therapy in acute myeloid leukemia. Tallman MS. **Leukemia** 1996 Aug;10(8):1262–8 (62 ref.)

Update on the diagnosis of and therapy for acute promyelocytic leukemia and chronic myelogenous leukemia. Wujcik D. **Oncol Nurs Forum** 1996 Apr; 23(3):478–87 (70 ref.)

[Retinoids and acute promyelocytic leukemia. A therapeutic revolution] Hermanne JP, et al. **Rev Med Liege** 1996 Mar; 51(3):217–23 (23 ref.) **(Fre)**

[Differentiation therapy of leukemia] Ono R. **Nippon Naika Gakkai Zasshi** 1995 Sep 10;84(9):1574–8 (8 ref.) **(Jpn)**

[Clinical pharmacology of all-trans retinoic acid (ATRA)] Robak T. **Acta Haematol Pol** 1995;26(3):269–77 (34 ref.) (Eng. Abstr.) **(Pol)**

ETIOLOGY

Therapy-related acute promyelocytic leukemia with t(15;17)(q22;q12) following chemotherapy with drugs targeting DNA topoisomerase II. A report of two cases and a review of the literature [see comments] Hoffmann L, et al. **Ann Oncol** 1995 Oct;6(8):781–8 (32 ref.) Comment in: Ann Oncol 1995 Oct;6(8):751–3.

Which progenitor is the target cell in the development of acute promyelocytic leukemia? Takatsuki H, et al. **Leuk Lymphoma** 1995 Apr;17(3–4):251–4 (29 ref.)

Acute promyelocytic leukemia after treatment of malignant glioma in a patient with von Recklinghausen's disease: case report and review of the literature. Wiernik PH, et al. **Leukemia** 1996 Jan;10(1):178–82 (49 ref.)

GENETICS

Retinoic acid regulatory pathways, chromosomal translocations, and acute promyelocytic leukemia. Chen Z, et al. **Genes Chromosomes Cancer** 1996 Mar;15(3):147–56 (123 ref.)

Acute promyelocytic leukemia: retinoic acid response and resistance. Early E, et al. **J Investig Med** 1995 Aug; 43(4):337–44 (108 ref.)

METABOLISM

[Acute promyelocytic leukemia: molecular aspects] de Thé H. **C R Seances Soc Biol Fil** 1995;189(4):503–14 (40 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Acute promyelocytic leukemia and pregnancy. A case report. Hoffman MA, et al. **Cancer** 1995 Dec 1;76(11):2237–41 (32 ref.)

Which progenitor is the target cell in the development of acute promyelocytic leukemia? Takatsuki H, et al. **Leuk Lymphoma** 1995 Apr;17(3–4):251–4 (29 ref.)

Leukemia cell lines: in vitro models for the study of acute promyelocytic leukemia. Drexler HG, et al. **Leuk Res** 1995 Oct;19(10):681–91 (45 ref.)

PHYSIOPATHOLOGY

Pathogenetic role of the PML1RAR alpha fusion protein in acute promyelocytic leukemia. Grignani F, et al. **Curr Top Microbiol Immunol** 1996;211:269–78 (52 ref.)

Retinoic acid regulatory pathways, chromosomal translocations, and acute promyelocytic leukemia. Chen Z, et al. **Genes Chromosomes Cancer** 1996 Mar;15(3):147–56 (123 ref.)

THERAPY

Differentiating therapy in acute myeloid leukemia. Tallman MS. **Leukemia** 1996 Jun;10 Suppl 2:s33–8 (62 ref.)

Chronic myelogenous leukemia and acute promyelocytic leukemia: new bone marrow transplantation options. Viele CS. **Oncol Nurs Forum** 1996 Apr;23(3):488–93 (22 ref.)

Plesiomonas shigelloides septicemia: case report and literature review. Lee AC, et al. **Pediatr Hematol Oncol** 1996 May–Jun;13(3):265–9 (23 ref.)

LEUKEMIA, RADIATION-INDUCED

see related
NEOPLASMS, SECOND PRIMARY

ETIOLOGY

Chronic myeloid leukaemia following 131I treatment for thyroid carcinoma: a report of two cases and review of the literature. Shimon I, et al. **Clin Endocrinol (Oxf)** 1995 Nov;43(5):651–4 (21 ref.)

The risk of childhood cancer from intrauterine and preconceptional exposure to ionizing radiation. Wakeford R. **Environ Health Perspect** 1995 Nov;103(11):1018–25 (84 ref.)

[Is the risk of leukemia increased for children near nuclear installations?] Auvinen A. **Duodecim** 1994;110(5):479–86 (39 ref.) **(Fin)**

GENETICS

[Therapy-related leukemia with t(8;21) initially diagnosed as MDS (RAEB in T)] Hanamura A, et al. **Rinsho Ketsueki** 1995 Aug;36(8):755–61 (15 ref.) (Eng. Abstr.) **(Jpn)**

LEUKEMIA, SMOULDERING see **ANEMIA, REFRACTORY, WITH EXCESS OF BLASTS**

LEUKEMIA, T-CELL

[Cutaneous localization of T-cell prolymphocytic leukemia] Thomas A, et al. **Ann Dermatol Venereol** 1995;122(8):526–9 (17 ref.) (Eng. Abstr.) **(Fre)**

CLASSIFICATION

[Clinical classification of adult T-cell leukemia and its complications] Tamura K. **Rinsho Byori** 1996 Jan; 44(1):19–23 (7 ref.) (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

[Clinical classification of adult T-cell leukemia and its complications] Tamura K. **Rinsho Byori** 1996 Jan; 44(1):19–23 (7 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Adult T-cell leukemia. Takatsuki K. **Intern Med** 1995 Oct; 34(10):947–52 (68 ref.)

GENETICS

The helix-loop-helix gene SCL: implicated in T-cell acute lymphoblastic leukaemia and in normal haematopoietic development. Robb L, et al. **Int J Biochem Cell Biol** 1996 Jun;28(6):609–18 (84 ref.)

METABOLISM

Parathyroid hormone-related protein gene expression and human T cell leukemia virus-1 infection. Ejima E, et al. **Miner Electrolyte Metab** 1995;21(1–3):143–7 (53 ref.)

MICROBIOLOGY

Clinical implication of the integration patterns of human T-cell lymphotropic virus type I proviral DNA in adult T-cell leukemia/lymphoma. Shimamoto Y, et al. **Leuk Lymphoma** 1996 Jan;20(3–4):207–15 (51 ref.)

PATHOLOGY

[Mechanism of cell proliferation of adult T cell leukemia (ATL) cells] Uchiyama T. **Rinsho Ketsueki** 1996 May; 37(5):392–7 (20 ref.) **(Jpn)**

VIROLOGY

Adult T-cell leukemia. Takatsuki K. **Intern Med** 1995 Oct; 34(10):947–52 (68 ref.)

Primary adult T cell leukemia of bone: two patients with primary bone lesion showing monoclonal integration of HTLV-I proviral DNA. Takemoto S, et al. **Leukemia** 1996 Feb;10(2):333–7 (24 ref.)

[The role of the HTLV-I virus in transformation of T lymphocytes] Papież M. **Postepy Hig Med Dosw** 1995; 49(5):585–97 (64 ref.) (Eng. Abstr.) **(Pol)**

LEUKEMIA, T-CELL, ACUTE

GENETICS

Therapy-related acute leukemia associated with t(11q23) after primary acute myeloid leukemia with t(8;21): a report of two cases [letter] Roulston D, et al. **Blood** 1995 Nov 1;86(9):3613–4 (7 ref.)

The role of chromosome translocations in T cell acute leukemia. Hwang LY, et al. **Curr Opin Immunol** 1995 Oct; 7(5):659–64 (54 ref.)

T-cell acute lymphoblastic leukemia occurring in the course of B cell chronic lymphocytic leukemia: a case report. Preudhomme C, et al. **Leuk Lymphoma** 1995 Jul; 18(3–4):361–4 (9 ref.)

PATHOLOGY

The role of intracellular signalling pathways regulating thymocyte and leukemic T cell apoptosis. Conroy LA, et al. **Leukemia** 1996 Sep;10(9):1422–35 (205 ref.)

THERAPY

Gene therapy against retroviral diseases. Essex M, et al. **Leukemia** 1995 Oct;9 Suppl 1:S71–4 (13 ref.)

LEUKEMIA VIRUS, BOVINE

IMMUNOLOGY

Role of cell-mediated immunity in bovine leukemia virus (BLV) infection in ruminants: its implication for the vaccination strategy against retroviruses. Sugimoto M, et al. **Ther Immunol** 1994 Oct;1(5):297–301 (30 ref.)

LEUKEMIA VIRUS, BOVINE

METABOLISM

Proteins of bovine leukemia virus and human T-cell leukemia viruses. Hrušková-Heidingsfeldová O. **Folia Biol (Praha)** 1995;41(5):201-12 (66 ref.)

LEUKEMIA VIRUS, FELINE

IMMUNOLOGY

[Vaccination against feline retrovirus infections] Horzinek MC. **Tierarztl Prax** 1996 Apr;24(2):197-202 (16 ref.) (Eng. Abstr.) **(Ger)**

LEUKEMIA VIRUS I, HUMAN T-CELL see **HTLV-I**

LEUKEMIA VIRUS II, HUMAN T-CELL see **HTLV-II**

LEUKEMIA VIRUSES, HUMAN T-CELL see **HTLV-BLV VIRUSES**

LEUKEMIA VIRUSES, MURINE

[An experimental model for gene therapy of murine retroviral leukemias] Aizaki K, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2679-85 (19 ref.) **(Jpn)**

GENETICS

Molecular analysis of Evi1, a zinc finger oncogene involved in myeloid leukemia. Lopingco MC, et al. **Curr Top Microbiol Immunol** 1996;211:211-22 (63 ref.)

Molecular analysis and characterization of two myeloid leukemia inducing murine retroviruses. Rassart E, et al. **Curr Top Microbiol Immunol** 1996;211:201-10 (36 ref.)

Retroviral insertional mutagenesis in murine promonocytic leukemias: c-myb and Mml1. Wolff L, et al. **Curr Top Microbiol Immunol** 1996;211:191-9 (33 ref.)

PATHOGENICITY

Cells and cytokines in the pathogenesis of MAIDS, a retrovirus-induced immunodeficiency syndrome of mice. Morse HC 3rd, et al. **Springer Semin Immunopathol** 1995; 17(2-3):231-45 (66 ref.)

PHYSIOLOGY

Operating under a Gag order: a block against incoming virus by the Fv1 gene. Goff SP. **Cell** 1996 Sep 6;86(5):691-3 (20 ref.)

LEUKEMIC GENE EXPRESSION REGULATION see **GENE EXPRESSION REGULATION, LEUKEMIC**

LEUKEMIC INFILTRATION

COMPLICATIONS

Hearing loss and leukocytosis. Lossos IS, et al. **Postgrad Med J** 1996 Mar;72(845):183-5 (7 ref.)

DIAGNOSIS

[Multiple intracerebral granulocytic sarcomas in a patient with chronic myeloid leukemia] Grondin L, et al. **Can Assoc Radiol J** 1996 Apr;47(2):132-5 (12 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

[Acute respiratory failure in hemoblastoses: the types of diffuse lung lesions] Gorelov VG, et al. **Ter Arkh** 1995; 67(7):52-6 (17 ref.) **(Rus)**

LEUKEMIC RETICULOENDOTHELIOSIS see **LEUKEMIA, HAIRY CELL**

LEUKEMOGENIC VIRUSES see **RETROVIRIDAE**

LEUKEMOID REACTION

ETIOLOGY

[Hematologic disturbances in patients with nonhematologic neoplasms. II. Thrombosis, bleedings and leukemoid reaction] Kwiatkowski A, et al. **Przegl Lek** 1995; 52(8):410-2 (11 ref.) **(Pol)**

LEUKOCYTAPHERESIS see **LEUKAPHERESIS**

LEUKOCYTE ADHESION DEFICIENCY SYNDROME

Leukocyte adhesion deficiency: report of a case and review of the literature. Lipnick RN, et al. **Clin Exp Rheumatol** 1996 Jan-Feb;14(1):95-8 (25 ref.)

DIAGNOSIS

Leukocyte adhesion deficiency mimicking Hirschsprung disease [see comments] Rivera-Matos IR, et al. **J Pediatr** 1995 Nov;127(5):755-7 (16 ref.) Comment in: J Pediatr 1996 May;128(5 Pt 1):720.

LEUKOCYTE ADHESION INHIBITOR see **INTERLEUKIN-8**

LEUKOCYTE ADHESION MOLECULES see **CELL ADHESION MOLECULES**

LEUKOCYTE ANTIGENS see **HLA ANTIGENS**

LEUKOCYTE COMMON ANTIGENS see **ANTIGENS, CD45**

LEUKOCYTE COUNT

INSTRUMENTATION

[Further evolution and leukocyte differential using an automated blood cell counter] Takubo T, et al. **Rinsho Byori** 1995 Sep;43(9):925-30 (15 ref.) (Eng. Abstr.) **(Jpn)**

METHODS

[Current data on the counting of weak leukocyte concentrations in labile blood products] Masse M. **Transfus Clin Biol** 1995;2(5):365-72 (19 ref.) (Eng. Abstr.) **(Fre)**

LEUKOCYTE COUNT, DIFFERENTIAL see **LEUKOCYTE COUNT**

LEUKOCYTE CULTURE TEST, MIXED see **LYMPHOCYTE CULTURE TEST, MIXED**

LEUKOCYTE DIFFERENTIATION ANTIGENS, HUMAN see **ANTIGENS, CD**

LEUKOCYTE FUNCTION ASSOCIATED ANTIGEN-1 see **LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1**

LEUKOCYTE NUMBER see **LEUKOCYTE COUNT**

LEUKOCYTE TRANSFUSION

see related
LYMPHOCYTE TRANSFUSION

Graft-versus-leukemia and graft-versus-lymphoma effects of allogeneic bone marrow transplantation and of allogeneic donor leukocyte transfusions. Vandenberghe P, et al. **Ann Hematol** 1995 Nov;71(5):209-17 (65 ref.)

Clinical perspectives of granulocyte transfusions: efficacy to date. Strauss RG. **J Clin Apheresis** 1995;10(3):114-8 (23 ref.)

Transfusion of donor buffy coat cells in the treatment of persistent or recurrent malignancy after allogeneic bone marrow transplantation. Collins RH Jr, et al. **Transfusion** 1995 Nov-Dec;35(11):891-8 (41 ref.)

[Biological effects of allogenic leukocytes and leukocyte-depleted blood cell products] Vášová I, et al. **Vnitr Lek** 1995 Oct;41(10):713-8 (39 ref.) (Eng. Abstr.) **(Cze)**

TRENDS

Blood center perspective of granulocyte transfusions: future applications. Price TH. **J Clin Apheresis** 1995;10(3):119-23 (34 ref.)

LEUKOCYTES

see related
PHAGOCYTOSIS

Advances in the study on rheological behavior of leukocyte during severe shock. Zhao K. **Chin Med J (Engl)** 1996 Feb; 109(2):110-1 (8 ref.)

Measurement of apoptotic cells in peripheral blood. Carbonari M, et al. **Cytometry** 1995 Sep 15;22(3):161-7 (52 ref.)

Imaging infection and inflammation in veterinary practice [editorial; comment] Peters AM. **Equine Vet J** 1995 Jul; 27(4):242-4 (20 ref.) Comment on: Equine Vet J 1995 Jul;27(4):313-5.

From legumes to leukocytes: biological roles for sulfated carbohydrates. Hooper LV, et al. **FASEB J** 1996 Aug; 10(10):1137-46 (88 ref.)

CHEMISTRY

Leukocyte adhesion molecules. Chapman PT, et al. **Br Med Bull** 1995 Apr;51(2):296-311 (80 ref.)

Structure and function of adhesion receptors in leukocyte trafficking. Hogg N, et al. **Immunol Today** 1995 Jul; 16(7):327-30 (42 ref.)

CLASSIFICATION

[Further evolution and leukocyte differential using an automated blood cell counter] Takubo T, et al. **Rinsho Byori** 1995 Sep;43(9):925-30 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Present and future of classification for white cells and leukemic cells in the routine clinical laboratory] Tatsumi N, et al. **Rinsho Byori** 1995 Sep;43(9):913-6 (16 ref.) (Eng. Abstr.) **(Jpn)**

CYTOLOGY

Peripheral blood leukocytes and lymphocyte subpopulations as determined by flow cytometric measurements in healthy children. Kawiak J, et al. **Folia Histochem Cytobiol** 1995; 33(1):33-8 (31 ref.)

DRUG EFFECTS

Effects of mesalazine on lamina propria white cell functions. Verspaget HW. **Adv Exp Med Biol** 1995;371A:317-20 (20 ref.)

ENZYMOLOGY

The NADPH oxidase complex of phagocytic leukocytes: a biochemical and cytochemical view. Robinson JM, et al. **Histochem Cell Biol** 1995 Mar;103(3):163-80 (197 ref.)

Positive and negative regulation of leukocyte activation by protein tyrosine phosphatases. Thomas ML. **Semin Immunol** 1995 Aug;7(4):279-88 (85 ref.)

[Serum elastin peptide concentration and human leukocyte elastase/antiproteinase balance in peripheral obstructive atherosclerosis] Mohácsi A, et al. **Orv Hetil** 1996 Jan 7; 137(1):15-21 (49 ref.) (Eng. Abstr.) **(Hun)**

[Acid phosphatase] Otani K, et al. **Nippon Rinsho** 1995 Mar; 53 Su Pt 2:247-50 (8 ref.) **(Jpn)**

IMMUNOLOGY

Mast-cell-leukocyte cytokine cascades in allergic inflammation. Galli SJ, et al. **Allergy** 1995 Nov; 50(11):851-62 (129 ref.)

Structure and function of adhesion receptors in leukocyte trafficking. Hogg N, et al. **Immunol Today** 1995 Jul; 16(7):327-30 (42 ref.)

Trauma-induced suppression of antigen presentation and expression of major histocompatibility class II antigen complex in leukocytes [editorial] Ayala A, et al. **Shock** 1996 Feb;5(2):79-90 (140 ref.)

[Leukocyte surface antigen] Nakahara K. **Nippon Rinsho** 1996 Jun;54(6):1536-41 (8 ref.) (Eng. Abstr.) **(Jpn)**

[ICAM-3, the role and significance of leukocyte interactions] Matysiak W, et al. **Pol Arch Med Wewn** 1996 Jan; 95(1):79-86 (35 ref.) **(Pol)**

METABOLISM

Leukocyte and endothelial adhesion molecules in ischaemia/reperfusion injuries. Winn RK, et al. **Ciba Found Symp** 1995;189:63-71; discussion 72-6, 77-8 (52 ref.)

Association of leukocyte surface receptors with protein kinases. Hořejší V. **Int Arch Allergy Immunol** 1996 May; 110(1):1-6 (27 ref.)

The mechanism of uptake of ascorbic acid into osteoblasts and leukocytes. Wolf G. **Nutr Rev** 1996 May;54(5):150-2 (12 ref.)

Tissue factor expression in human leukocytes and tumor cells. Rickles FR, et al. **Thromb Haemost** 1995 Jul;74(1):391-5 (45 ref.)

MICROBIOLOGY

Adhesion of microbial pathogens to leukocyte integrins: methods to study ligand mimicry. Rozdzinski E, et al. **Methods Enzymol** 1995;253:3-12 (36 ref.)

PHYSIOLOGY

The dichotomous functions of passenger leukocytes in solid-organ transplantation. Demetris AJ, et al. **Adv Nephrol Necker Hosp** 1995;24:341-54 (66 ref.)

Disturbance of leucocyte circulation and adhesion to the endothelium as factors in circulatory pathology. Adams DH, et al. **Br J Anaesth** 1996 Jul;77(1):17-31 (114 ref.)

Leukocyte integrins. Stewart M, et al. **Curr Opin Cell Biol** 1995 Oct;7(5):690-6 (66 ref.)

Leucocyte migration into autoimmune diseased endocrine tissues [comment] Delemarre FG, et al. **Eur J Endocrinol** 1996 Jan;134(1):9-11 (35 ref.) Comment on: Eur J Endocrinol 1996 Jan;134(1):51-60.

Seminal leukocytes: passengers, terrorists or good samaritans? Aitken RJ, et al. **Hum Reprod** 1995 Jul;10(7):1736-9 (30 ref.)

Microcirculation in venous disorders: the role of the white blood cells. Dormandy JA. **Int J Microcirc Clin Exp** 1995; 15 Suppl 1:3-8 (16 ref.)

Cellular basis of inflammation, edema and the activity of Daflon 500 mg. Friesenecker B, et al. **Int J Microcirc Clin Exp** 1995;15 Suppl 1:17-21 (44 ref.)

Regulation and selectivity of leukocyte emigration. Schleiffenbaum B, et al. **J Lab Clin Med** 1996 Feb; 127(2):151-68 (251 ref.)

Regulation of leukocyte adhesion and signaling in inflammation and disease. Wahl SM, et al. **J Leukoc Biol** 1996 Jun;59(6):789-96 (94 ref.)

Regulation of human immunodeficiency virus type 1 and cytokine gene expression in myeloid cells by NF-kappa B/Rel transcription factors. Roulston A, et al. **Microbiol Rev** 1995 Sep;59(3):481-505 (481 ref.)

In vitro studies on the effect of dialysis solutions on peritoneal leukocytes. Jörres A, et al. **Perit Dial Int** 1995;15(7 Suppl):S41-5; discussion S45-6 (28 ref.)

Role of adhesion molecules in the pathogenesis of rheumatoid arthritis. Liao HX, et al. **Rheum Dis Clin North Am** 1995

Aug;21(3):715–40 (150 ref.)
Inflammatory cell participation in coagulation. Altieri DC. **Semin Cell Biol** 1995 Oct;6(5):269–74 (47 ref.)
Platelet–activating factor mediates procoagulant activity on the surface of endothelial cells by promoting leukocyte adhesion. Lorant DE, et al. **Semin Cell Biol** 1995 Oct; 6(5):295–303 (78 ref.)
Measles virus infection of cerebral endothelial cells and effect on their adhesive properties. Cosby SL, et al. **Vet Microbiol** 1995 May;44(2–4):135–9 (21 ref.)
[Neutrophilic leukocytes, thrombotic risk factors in vascular diseases] Berti F. **Cardiologia** 1996 Feb;41(2):107–16 (95 ref.) **(Ita)**
[Significance of PUVA therapy for adult T–cell leukemia/lymphoma—PUVA therapy can induce apoptosis in leukemic cells] Takemori N, et al. **Hum Cell** 1995 Sep; 8(3):121–6 (30 ref.) (Eng. Abstr.) **(Jpn)**
[Adhesion molecules in leukocyte and endothelium interactions] Horváthová M. **Bratisl Lek Listy** 1995 Apr; 96(4):217–22 (48 ref.) (Eng. Abstr.) **(Slo)**

RADIONUCLIDE IMAGING

Review article: quantitative leucocyte scanning in the assessment of inflammatory bowel disease activity and its response to therapy. Weldon MJ, et al. **Aliment Pharmacol Ther** 1996 Apr;10(2):123–32 (70 ref.)

LEUKOCYTES, MONONUCLEAR

PHYSIOLOGY

Traffic of hematogenous cells through the central nervous system. Williams KC, et al. **Curr Top Microbiol Immunol** 1995;202:221–45 (156 ref.)

VIROLOGY

Viral load in peripheral blood mononuclear cells as surrogate for clinical progression. Ferre F, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995;10 Suppl 2:S51–6 (24 ref.)

LEUKOCYTES, POLYMORPHONUCLEAR see **NEUTROPHILS**

LEUKOCYTOPENIA see **LEUKOPENIA**

LEUKOCYTOSIS

CHEMICALLY INDUCED

Acute febrile toxic reaction in patients with refractory rheumatoid arthritis who are receiving combined therapy with methotrexate and azathioprine. Blanco R, et al. **Arthritis Rheum** 1996 Jun;39(6):1016–20 (19 ref.)

COMPLICATIONS

Hearing loss and leukocytosis. Lossos IS, et al. **Postgrad Med J** 1996 Mar;72(845):183–5 (7 ref.)

IMMUNOLOGY

Endothelial–dependent mechanisms in chronic inflammatory leukocyte recruitment. Luscinskas FW, et al. **Annu Rev Med** 1996;47:413–21 (31 ref.)

LEUKODYSTROPHY, GLOBOID CELL

[Krabbe disease (globoid cell leukodystrophy)] Sakai N, et al. **Nippon Rinsho** 1995 Dec;53(12):2947–51 (15 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

The twitcher mouse: a model for Krabbe disease and for experimental therapies. Suzuki K, et al. **Brain Pathol** 1995 Jul;5(3):249–58 (63 ref.)

PATHOLOGY

Murine model of genetic demyelinating disease: the twitcher mouse. Suzuki K, et al. **Microsc Res Tech** 1995 Oct 15; 32(3):204–14 (61 ref.)

PSYCHOLOGY

Neuropsychological outcomes of several storage diseases with and without bone marrow transplantation. Shapiro EG, et al. **J Inherit Metab Dis** 1995;18(4):413–29 (29 ref.)

SURGERY

The future for treatment by bone marrow transplantation for adrenoleukodystrophy, metachromatic leukodystrophy, globoid cell leukodystrophy and Hurler syndrome. Krivit W, et al. **J Inherit Metab Dis** 1995;18(4):398–412 (23 ref.)
Neuropsychological outcomes of several storage diseases with and without bone marrow transplantation. Shapiro EG, et al. **J Inherit Metab Dis** 1995;18(4):413–29 (29 ref.)

LEUKODYSTROPHY, METACHROMATIC

[Metachromatic leukodystrophy (MLD) and Multiple sulphatase deficiency (MSD)] Eto Y, et al. **Nippon Rinsho** 1995 Dec;53(12):2994–3003 (24 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Degenerative central nervous system disease. Vadasz AG, et al. **Pediatr Rev** 1995 Nov;16(11):426–31 (0 ref.)

SURGERY

The future for treatment by bone marrow transplantation for adrenoleukodystrophy, metachromatic leukodystrophy, globoid cell leukodystrophy and Hurler syndrome. Krivit W, et al. **J Inherit Metab Dis** 1995;18(4):398–412 (23 ref.)

THERAPY

Bone marrow transplantation for metabolic diseases. Parkman R, et al. **Cancer Treat Res** 1995;76:87–96 (33 ref.)

LEUKODYSTROPHY, SPONGIFORM see **CANAVAN DISEASE**

LEUKOENCEPHALITIS, SUBACUTE SCLEROSING see **SUBACUTE SCLEROSING PANENCEPHALITIS**

LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL

CHEMICALLY INDUCED

Atypical MRI findings in treatment–related leukoencephalopathy: case report. Ohmoto Y, et al. **Neuroradiology** 1996 Feb;38(2):128–33 (30 ref.)
[Leukoencephalopathy under cisplatin therapy] David–Götting I, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1995 Nov;163(5):460–1 (0 ref.) **(Ger)**

DIAGNOSIS

Radiologic and laboratory evaluation of enhancing brain lesions in patients with AIDS. Johnson MD, et al. **Compr Ther** 1995 Nov;21(11):645–52 (45 ref.)
Progressive multifocal leukoencephalopathy: clinical and laboratory observations on a viral induced demyelinating disease in the immunodeficient patient. Major EO, et al. **Curr Opin Neurol** 1995 Jun;8(3):184–90 (58 ref.)
Clinical presentation, diagnosis and therapy of progressive multifocal leukoencephalopathy. Brink NS, et al. **J Infect** 1996 Mar;32(2):97–102 (37 ref.)
[MRI aspects of progressive multifocal leukoencephalopathy] Sarrazin JL, et al. **J Neuroradiol** 1995 Sep;22(3):172–9 (16 ref.) (Eng. Abstr.) **(Fre)**
[Magnetic resonance in AIDS–related encephalopathy] Gualdi GF, et al. **Clin Ter** 1995 Dec;146(12):843–56 (42 ref.) (Eng. Abstr.) **(Ita)**

PATHOLOGY

Progressive multifocal leukoencephalopathy: a review of the pathology and pathogenesis. Aksamit AJ Jr. **Microsc Res Tech** 1995 Nov 1;32(4):302–11 (39 ref.)

LEUKOMA see **CORNEAL OPACITY**

LEUKOPENIA

IMMUNOLOGY

Leukophagocytosis in human parvovirus B19–induced transient bicytopenia in a healthy child. Wakamoto H, et al. **Acta Paediatr Jpn** 1996 Jun;38(3):278–81 (19 ref.)

LEUKOPHERESIS see **LEUKAPHERESIS**

LEUKOPLAKIA

CONGENITAL

Gastrointestinal problems in a child with dyskeratosis congenita. Berezin S, et al. **Am J Gastroenterol** 1996 Jun; 91(6):1271–2 (6 ref.)

LEUKOPLAKIA, ORAL

Oral leukoplakia. Sciubba JJ. **Crit Rev Oral Biol Med** 1995; 6(2):147–60 (120 ref.)
[Oral leukoplakia] Iriarte Ortabe JI, et al. **Med Clin (Barc)** 1996 Mar 16;106(10):387–94 (122 ref.) **(Spa)**

PATHOLOGY

Oral white lesions with special reference to precancerous and tobacco– related lesions: conclusions of an international symposium held in Uppsala, Sweden, May 18–21 1994. International Collaborative Group on Oral White Lesions. Axéll T, et al. **J Oral Pathol Med** 1996 Feb;25(2):49–54 (3 ref.)
[The malignant transformation of leukoplakia of the oral cavity. A review of the literature and clinical case reports] Colella G, et al. **Minerva Stomatol** 1995 Jun;44(6):291–300 (62 ref.) (Eng. Abstr.) **(Ita)**

PREVENTION & CONTROL

Retinoids in cancer chemoprevention. Clinical trials with the synthetic analogue fenretinide. Costa A, et al. **Ann N Y Acad Sci** 1995 Sep 30;768:148–62 (49 ref.)
Controlled clinical trials with fenretinide in breast cancer, basal cell carcinoma and oral leukoplakia. De Palo G, et al. **J Cell Biochem Suppl** 1995;22:11–7 (16 ref.)

THERAPY

[The therapy of leukoplakia of the oral cavity. A review of the literature] Colella G, et al. **Minerva Stomatol** 1995 Jun;44(6):301–10 (84 ref.) (Eng. Abstr.) **(Ita)**

LEUKOSIS, AVIAN see **AVIAN LEUKOSIS**

LEUKOSIS, BOVINE see **ENZOOTIC BOVINE LEUKOSIS**

LEUKOTAXIS see **CHEMOTAXIS, LEUKOCYTE**

LEUKOTOMY see **PSYCHOSURGERY**

LEUKOTRIENE B4

METABOLISM

Leukotriene A4 hydrolase and leukotriene B4 metabolism. Yokomizo T, et al. **J Lipid Mediat Cell Signal** 1995 Oct; 12(2–3):321–32 (77 ref.)

LEUKOTRIENE B4 RECEPTORS see **RECEPTORS, LEUKOTRIENE B4**

LEUKOTRIENE C4

BIOSYNTHESIS

Leukotriene C4 synthase. Lam BK, et al. **J Lipid Mediat Cell Signal** 1995 Oct;12(2–3):333–41 (52 ref.)

LEUKOTRIENE RECEPTORS see **RECEPTORS, LEUKOTRIENE**

LEUKOTRIENES

see related
RECEPTORS, LEUKOTRIENE

ANTAGONISTS & INHIBITORS

Leukotriene inhibitors and antagonists in asthma. Spector SL. **Ann Allergy Asthma Immunol** 1995 Dec;75(6 Pt 1):463–70, 473; quiz 473–4 (78 ref.)
Drugs affecting the leukotriene pathway in asthma. Barnes NC, et al. **Br J Clin Pract** 1995 Sep–Oct;49(5):262–6 (55 ref.)
Leukotriene antagonists and synthesis inhibitors: new directions in asthma therapy. Holgate ST, et al. **J Allergy Clin Immunol** 1996 Jul;98(1):1–13 (89 ref.)
[Leukotriene blockade in asthma—a new anti–inflammatory therapeutic principle] Griese M, et al. **Dtsch Med Wochenschr** 1996 Jun 21;121(25–26):845–51 (61 ref.) **(Ger)**
[Anti–allergic agent therapy of asthma] Fujimura M. **Nippon Naika Gakkai Zasshi** 1996 Feb 10;85(2):216–21 (5 ref.) **(Jpn)**

BIOSYNTHESIS

Leukotriene antagonists and synthesis inhibitors: new directions in asthma therapy. Holgate ST, et al. **J Allergy Clin Immunol** 1996 Jul;98(1):1–13 (89 ref.)
Modulators of leukotriene biosynthesis and receptor activation. Brooks CD, et al. **J Med Chem** 1996 Jul 5; 39(14):2629–54 (296 ref.)

BLOOD

[Leukotriene] Mito Y. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:752–5 (17 ref.) **(Jpn)**

METABOLISM

Cysteinyl leukotrienes in asthma: current state of therapeutic evaluation. Taylor IK. **Thorax** 1995 Sep;50(9):1005–10 (93 ref.)

PHYSIOLOGY

Leukotrienes and 15–lipoxygenase products in glomerulonephritis. Badr KF. **Adv Nephrol Necker Hosp** 1995;24:19–31 (58 ref.)
Leukotrienes as therapeutic target in asthma. Pauwels RA, et al. **Allergy** 1995 Aug;50(8):615–22 (73 ref.)
Leukotrienes as mediators of airway obstruction and inflammation in asthma. Dahlén B, et al. **Clin Exp Allergy** 1995 Nov;25 Suppl 2:50–4 (42 ref.)
Role of leukotrienes in coronary artery surgery. Allen SP, et al. **Curr Opin Cardiol** 1995 Nov;10(6):605–13 (93 ref.)
Role of leukotrienes and lipoxygenases in glomerular injury. Nassar GM, et al. **Miner Electrolyte Metab** 1995; 21(4–5):262–70 (76 ref.)
Eicosanoids and renal allograft rejection. Wardle EN. **Nephron** 1995;70(2):151–4 (48 ref.)

LEUKOTRIENES

Development of novel anti-inflammatory agents: a pharmacologic perspective on leukotrienes and their receptors. Jackson WT, et al. **Prog Drug Res** 1996; 46:115–68 (322 ref.)

Cysteinyl leukotrienes in asthma: old mediators up to new tricks. Hay DW, et al. **Trends Pharmacol Sci** 1995 Sep; 16(9):304–9 (54 ref.)

[Lipid mediators and liver injury] Liu Y, et al. **Sheng Li Ko Hsueh Chin Chan** 1995 Oct;26(4):363–6 (10 ref.) **(Chi)**

[The leukotriene signal pathway—a very promising point of entry for inhibitors in therapy of inflammatory diseases] Müller MJ. **Pharm Unserer Zeit** 1995 Sep;24(5):264–72 (53 ref.) **(Ger)**

LEUKOVIRUS PROTEINS see **RETROVIRIDAE PROTEINS**

LEUKOVIRUSES see **RETROVIRIDAE**

LEUROCRISTINE see **VINCRISTINE**

LEVAMETHADYL see **METHADYL ACETATE**

LEVAMISOLE

THERAPEUTIC USE

[Immunotherapy of colorectal cancers] Bécouarn Y, et al. **Gastroenterol Clin Biol** 1996 Feb;20(1):20–32 (106 ref.) **(Fre)**

LEVARTERENOL see **NOREPINEPHRINE**

LEVEEN SHUNT see **PERITONEOVENOUS SHUNT**

LEVEL OF HEALTH see **HEALTH STATUS**

LEVODOPA

ADMINISTRATION & DOSAGE

The response to levodopa in Parkinson's disease: imposing pharmacological law and order. Nutt JG, et al. **Ann Neurol** 1996 May;39(5):561–73 (98 ref.)

ADVERSE EFFECTS

Involvement of serotonin in clinical features of Parkinson's disease and complications of L-DOPA therapy. Melamed E, et al. **Adv Neurol** 1996;69:545–50 (47 ref.)

[Levodopa and malignant melanoma—case report and review of the literature. A contribution to causal relationship between levodopa and the development of malignant melanoma] Kleinhans M, et al. **Hautarzt** 1996 Jun; 47(6):432–7 (29 ref.) (Eng. Abstr.) **(Ger)**

PHARMACOKINETICS

Effects of catechol-O-methyltransferase (COMT) inhibition on the pharmacokinetics of L-DOPA. Nutt JG. **Adv Neurol** 1996;69:493–6 (15 ref.)

Concentration–effect relationship of levodopa in patients with Parkinson's disease. Harder S, et al. **Clin Pharmacokinet** 1995 Oct;29(4):243–56 (51 ref.)

PHARMACOLOGY

Is striatal dopaminergic receptor imbalance responsible for levodopa-induced dyskinesia? Blanchet PJ, et al. **Fundam Clin Pharmacol** 1995;9(5):434–42 (103 ref.)

L-DOPA systems for blood pressure regulation in the lower brainstem. Misu Y, et al. **Neurosci Res** 1995 Sep; 23(2):147–58 (58 ref.)

PHYSIOLOGY

Altered L-DOPA systems for blood pressure regulation in the lower brainstem of spontaneously hypertensive rats. Misu Y, et al. **Hypertens Res** 1995 Dec;18(4):267–77 (77 ref.)

L-DOPA systems for blood pressure regulation in the lower brainstem. Misu Y, et al. **Neurosci Res** 1995 Sep; 23(2):147–58 (58 ref.)

THERAPEUTIC USE

Controversies in the therapy of Parkinson's disease. Fahn S. **Adv Neurol** 1996;69:477–86 (72 ref.)

Treatment options for early Parkinson's disease. Stacy M, et al. **Am Fam Physician** 1996 Mar;53(4):1281–7 (29 ref.)

Concentration–effect relationship of levodopa in patients with Parkinson's disease. Harder S, et al. **Clin Pharmacokinet** 1995 Oct;29(4):243–56 (51 ref.)

Dopa-responsive dystonia. Nygaard TG. **Curr Opin Neurol** 1995 Aug;8(4):310–3 (24 ref.)

Dopa-responsive dystonia: a widening spectrum. Gordon N. **Dev Med Child Neurol** 1996 Jun;38(6):554–9 (39 ref.)

Moderate Parkinson's disease. Strategies for maximizing treatment. Silverstein PM. **Postgrad Med** 1996 Jan; 99(1):52–4, 61–3, 67–8, passim (21 ref.)

[L-dopa-responsive dystonia: 2 familial cases of adult onset with sleep disorders] el Alaoui-Faris M, et al. **Rev Neurol (Paris)** 1995 May;151(5):347–9 (10 ref.) (Eng. Abstr.) **(Fre)**

[Treatment of Parkinson disease] Cardoso F. **Arq Neuropsiquiatr** 1995 Mar;53(1):1–10 (34 ref.) (Eng. Abstr.) **(Por)**

LEVOMYCETIN see **CHLORAMPHENICOL**

LEVONOREPINEPHRINE see **NOREPINEPHRINE**

LEVONORGESTREL

Materials, methods and results of the Norplant training program. Bromham DR, et al. **Adv Contracept** 1995 Sep; 11(3):255–62 (4 ref.)

ADMINISTRATION & DOSAGE

[Levonorgestrel capsules: a big leap forward in intrauterine contraception] Hamerlynck JV. **Ned Tijdschr Geneeskd** 1996 Jun 8;140(23):1212–4 (17 ref.) **(Dut)**

PHARMACOLOGY

Implantable levonorgestrel contraception: 4 years of experience with Norplant. Hatasaka H. **Clin Obstet Gynecol** 1995 Dec;38(4):859–71 (26 ref.)

STANDARDS

The progestin-only pills and the levonorgestrel-releasing IUD: two progestin-only contraceptives. Chi IC. **Clin Obstet Gynecol** 1995 Dec;38(4):872–89 (71 ref.)

Levonorgestrel-releasing IUD as a method of contraception with therapeutic properties. Luukkainen T, et al. **Contraception** 1995 Nov;52(5):269–76 (41 ref.)

THERAPEUTIC USE

Levonorgestrel-releasing IUD as a method of contraception with therapeutic properties. Luukkainen T, et al. **Contraception** 1995 Nov;52(5):269–76 (41 ref.)

LEVOTETRAMISOLE see **LEVAMISOLE**

LEVOTHYROXINE

THERAPEUTIC USE

A therapeutic controversy. Thyroid hormone treatment: when and what? Oppenheimer JH, et al. **J Clin Endocrinol Metab** 1995 Oct;80(10):2873–83 (112 ref.)

[Osteopenia and treatment with L-thyroxine] Medeiros-Neto GA. **Rev Assoc Med Bras** 1995 Jan–Feb;41(1):34–6 (16 ref.) (Eng. Abstr.) **(Por)**

LEVOTHYROXINE SODIUM see **LEVOTHYROXINE**

LEVULOSE see **FRUCTOSE**

LEWANDOWSKY-LUTZ DISEASE see **EPIDERMODYSPLASIA VERRUCIFORMIS**

LEWIS BLOOD-GROUP SYSTEM

GENETICS

Molecular genetics of H, Se, Lewis and other fucosyltransferase genes. Mollicone R, et al. **Transfus Clin Biol** 1995;2(4):235–42 (60 ref.)

[Molecular biology of Lewis antigens—histo-blood type antigens and sialyl Lewis antigens as tumor associated antigens] Narimatsu H. **Nippon Geka Gakkai Zasshi** 1996 Feb;97(2):115–22 (39 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Targeted therapy of carcinomas using BR96 sFv-PE40, a single-chain immunotoxin that binds to the Le(y) antigen. Siegall CB. **Semin Cancer Biol** 1995 Oct;6(5):289–95 (44 ref.)

Lewis histo-blood group system and associated secretory phenotypes. Henry S, et al. **Vox Sang** 1995;69(3):166–82 (158 ref.)

LEWIS SYSTEM see **LEWIS BLOOD-GROUP SYSTEM**

LEWIS X ANTIGEN see **ANTIGENS, CD15**

LEWY BODIES

Lewy body diseases with dementia: pathophysiology and treatment. Cummings JL. **Brain Cogn** 1995 Aug; 28(3):266–80 (64 ref.)

Genetic evidence that the Lewy body variant is indeed a phenotypic variant of Alzheimer's disease. Katzman R, et al. **Brain Cogn** 1995 Aug;28(3):259–65 (43 ref.)

[Multiple system atrophy with Lewy bodies] Tison F, et al. **Rev Neurol (Paris)** 1995 Jun–Jul;151(6–7):398–403 (35 ref.) (Eng. Abstr.) **(Fre)**

ULTRASTRUCTURE

Neuropsychiatric features of Lewy body disease. Filley CM. **Brain Cogn** 1995 Aug;28(3):229–39 (33 ref.)

Neuropathology of Parkinson's disease. Forno LS. **J Neuropathol Exp Neurol** 1996 Mar;55(3):259–72 (101 ref.)

LEWY BODY DISEASE see **PARKINSON DISEASE**

LEYDIG CELL TUMOR

CHEMICALLY INDUCED

A review of drug-induced Leydig cell hyperplasia and neoplasia in the rat and some comparisons with man. Prentice DE, et al. **Hum Exp Toxicol** 1995 Jul;14(7):562–72 (98 ref.)

COMPLICATIONS

Leydig cell tumour in a man with human immunodeficiency virus. Sanchez-Chapado M, et al. **Scand J Urol Nephrol** 1995 Sep;29(3):357–60 (18 ref.)

LEYDIG CELLS

DRUG EFFECTS

A review of drug-induced Leydig cell hyperplasia and neoplasia in the rat and some comparisons with man. Prentice DE, et al. **Hum Exp Toxicol** 1995 Jul;14(7):562–72 (98 ref.)

PATHOLOGY

A review of drug-induced Leydig cell hyperplasia and neoplasia in the rat and some comparisons with man. Prentice DE, et al. **Hum Exp Toxicol** 1995 Jul;14(7):562–72 (98 ref.)

PHYSIOLOGY

Regulation of Leydig cell function by insulin-like growth factor-I and binding proteins. Lin T. **J Androl** 1995 May–Jun;16(3):193–6 (20 ref.)

[Paracrine regulation of Leydig cells] Lejeune H, et al. **Ann Endocrinol (Paris)** 1996;57(1):55–63 (38 ref.) (Eng. Abstr.) **(Fre)**

LFA-1 see **LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1**

LH

see related
RECEPTORS, LH

ANALYSIS

Ovarian hemangioma associated with concomitant stromal luteinization and ascites. Yamawaki T, et al. **Gynecol Oncol** 1996 Jun;61(3):438–41 (13 ref.)

BLOOD

Human androgen insensitivity syndrome. Brown TR. **J Androl** 1995 Jul–Aug;16(4):299–303 (17 ref.)

GENETICS

Gonadotropin gene modulation by steroids and gonadotropin-releasing hormone. Shupnik MA. **Biol Reprod** 1996 Feb;54(2):279–86 (60 ref.)

The gonadotropin genes: evolution of distinct mechanisms for hormonal control. Albanese C, et al. **Recent Prog Horm Res** 1996;51:23–58; discussion 59–61 (140 ref.)

PHYSIOLOGY

[Isoforms of luteinizing hormone] Szewczuk A, et al. **Postepy Hig Med Dosw** 1996;50(1):9–20 (54 ref.) (Eng. Abstr.) **(Pol)**

SECRETION

Gonadotrophin surge-inhibiting/attenuating factor governs luteinizing hormone secretion during the ovarian cycle: physiology and pathology. de Koning J. **Hum Reprod** 1995 Nov;10(11):2854–61 (86 ref.)

[Ethanol mechanism(s) of action on LHRH secretion] Canteros MG, et al. **Acta Physiol Pharmacol Ther Latinoam** 1995;45(1):55–63 (18 ref.) **(Spa)**

LH, ALPHA SUBUNIT see **GLYCOPROTEIN HORMONES, ALPHA SUBUNIT**

LH-FSH RELEASING HORMONE see **GONADORELIN**

LH-HCG RECEPTORS see **RECEPTORS, LH**

LH RECEPTORS see **RECEPTORS, LH**

LH-RELEASING HORMONE see **GONADORELIN**

LHFSHRH RECEPTORS see **RECEPTORS, LHRH**

LHRH see **GONADORELIN**

LHRH RECEPTORS see **RECEPTORS, LHRH**

LI-FRAUMENI SYNDROME

see related
GENES, P53

GENETICS

Germline mutations in the TP53 gene. Eeles RA. **Cancer Surv** 1995;25:101–24 (106 ref.)
Role of transgenic mice in identification and characterization of tumour suppressor genes. Sharan SK, et al. **Cancer Surv** 1995;25:143–59 (103 ref.)
[Hereditary mutations in the p53 tumor suppressor gene; significance for clinical practice. National Work Group Hereditary Mamma Carcinoma] Menko FH, et al. **Ned Tijdschr Geneeskd** 1996 Jun 29;140(26):1347–50 (21 ref.) **(Dut)**
[Li–Fraumeni syndrome] Tokunaga A, et al. **Nippon Rinsho** 1995 Nov;53(11):2797–802 (20 ref.) (Eng. Abstr.) **(Jpn)**
[Cancer family syndrome in lung cancer—Li–Fraumeni syndrome in lung cancer] Tomita M, et al. **Nippon Rinsho** 1995 Nov;53(11):2716–21 (17 ref.) (Eng. Abstr.) **(Jpn)**

LIABILITY, LEGAL

Liability for managed care decisions: the Employee Retirement Income Security Act (ERISA) and the uneven playing field. Mariner WK. **Am J Public Health** 1996 Jun; 86(6):863–9 (66 ref.)
Interhospital transfers of obstetric patients under the Emergency Medical Treatment and Active Labor Act. Cardwell MS. **J Leg Med** 1995 Sep;16(3):357–72 (98 ref.)
An overview and analysis of the impact of the Emergency Medical Treatment and Active Labor Act. Furrow BR. **J Leg Med** 1995 Sep;16(3):325–55 (157 ref.)
Emergency room follow-up care and malpractice liability. Morgan D. **J Leg Med** 1995 Sep;16(3):373–406 (143 ref.)
Legal and medical aspects of liability for negligently occasioned nervous shock: a current perspective. Mendelson D. **J Psychosom Res** 1995 Aug;39(6):721–35 (81 ref.)
Liability for psychiatric illness [editorial] Wessely S. **J Psychosom Res** 1995 Aug;39(6):659–69 (35 ref.)
Alternative dispute resolution for medical malpractice actions: an efficient approach to the law and health care. White WF. **Leg Med** 1995;:227–39 (47 ref.)
Repetitive strain injury (RSI) or cumulative trauma disorder (CTD) as legal and clinical entities. The need for a total reappraisal of this concept as being occupationally caused and therefore compensatable. Lam SJ. **Med Sci Law** 1995 Oct;35(4):279–86 (10 ref.)
Post traumatic stress disorder: turning the tide without opening the floodgates. McCulloch M, et al. **Med Sci Law** 1995 Oct;35(4):287–93 (38 ref.)
Lasers and liability. Classé JG. **Optom Clin** 1995;4(4):113–23 (19 ref.)
Privileges, credentialing, and liability. Musallam LS. **Prim Care** 1995 Sep;22(3):491–8 (12 ref.)
[What are the complications likely to lead to medicolegal problems? How to manage them?] Samii K, et al. **Cah Anesthesiol** 1995;43(6):521–4 (20 ref.) **(Fre)**
[The physician's duty to inform in interventional radiological therapeutic procedures] Duda SH, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1995 Oct;163(4):335–40 (28 ref.) (Eng. Abstr.) **(Ger)**

LIBIDO

Hypoactive sexual desire disorder: an overview. Beck JG. **J Consult Clin Psychol** 1995 Dec;63(6):919–27 (60 ref.)

DRUG EFFECTS

Psychological and sexual symptoms associated with the menopause and the effects of hormone replacement therapy. Pearce J, et al. **Br J Psychiatry** 1995 Aug; 167(2):163–73 (60 ref.)

PHYSIOLOGY

The neurophysiology of sexual desire, with particular reference to paedophilia. Howard RC. **Ann Acad Med Singapore** 1995 Sep;24(5):724–7 (11 ref.)

LIBMAN–SACKS DISEASE see **LUPUS ERYTHEMATOSUS, SYSTEMIC**

LIBRARIES

[Risk control in libraries] Bellante De Martiis G, et al. **Ann Ig** 1996 Jan–Feb;8(1):35–46 (30 ref.) (Eng. Abstr.) **(Ita)**

LICE

see related
PEDICULOSIS

Human lice and their management. Burgess IF. **Adv Parasitol** 1995;36:271–342 (410 ref.)
Louse-borne relapsing fever and its treatment. Rahlenbeck SI, et al. **Trop Geogr Med** 1995;47(2):49–52 (35 ref.)

PATHOGENICITY

Lice, cospeciation and parasitism. Barker SC. **Int J Parasitol** 1996 Feb;26(2):219–22 (23 ref.)
Lice and cospeciation: a response to Barker. Page RD, et al. **Int J Parasitol** 1996 Feb;26(2):213–8 (41 ref.)

LICE, PLANT see **APHIDS**

LICENSURE

see related
ACCREDITATION
CERTIFICATION

LICENSURE, MEDICAL

LEGISLATION & JURISPRUDENCE

Formal complaints and disciplinary proceedings involving medical practitioners: recent developments in New South Wales, Australia. Buetow SA. **Med Law** 1995; 14(7–8):559–69 (33 ref.)

LICENSURE, NURSING

Regulation of advanced nursing practice: Part One—Second licensure. Greco KE. **Oncol Nurs Forum** 1995 Sep;22(8 Suppl):35–8 (7 ref.)
Focus on quantitative methods. Determining cut-off scores. Goodwin LD. **Res Nurs Health** 1996 Jun;19(3):249–56 (60 ref.)

LICHEN NITIDUS

COMPLICATIONS

Coexistence of atopic dermatitis and lichen nitidus in three patients. Lestringant GG, et al. **Dermatology** 1996; 192(2):171–3 (14 ref.)

LICHEN PLANUS

ETIOLOGY

[Lichen planus and hepatitis C virus. Apropos of 5 new cases] Hyrailles V, et al. **Gastroenterol Clin Biol** 1995 Oct; 19(10):833–6 (21 ref.) (Eng. Abstr.) **(Fre)**
[Extrahepatic manifestations related to hepatitis C virus] Opolon P, et al. **Pathol Biol (Paris)** 1995 Oct;43(8):709–15 (59 ref.) (Eng. Abstr.) **(Fre)**
[Skin manifestations related to hepatitis C viruses] Doutre MS, et al. **Rev Med Interne** 1995;16(9):666–72 (71 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Lichen planus of the eyelids. Itin PH, et al. **Dermatology** 1995;191(4):350–1 (8 ref.)
Dermatitis herpetiformis associated with lichen planopilaris. Isaac M, et al. **J Am Acad Dermatol** 1995 Dec;33(6):1050–1 (3 ref.)

LICHEN PLANUS, ORAL

DRUG THERAPY

Diagnosis and management of oral lichen planus. Miles DA, et al. **Dermatol Clin** 1996 Apr;14(2):281–90 (31 ref.)

ETIOLOGY

Assessing the characteristics of patients with oral lichen planus. Burkhart NW, et al. **J Am Dent Assoc** 1996 May; 127(5):648, 651–2, 655–6 passim (42 ref.)

LICHEN RUBER PLANUS see **LICHEN PLANUS**

LICHEN SCLEROSUS see **LICHEN SCLEROSUS ET ATROPHICUS**

LICHEN SCLEROSUS ET ATROPHICUS

Lichen sclerosus in childhood. Fischer GO. **Australas J Dermatol** 1995 Aug;36(3):166–7 (15 ref.)

ETIOLOGY

Lichen sclerosus. Leibowitch M. **Semin Dermatol** 1996 Mar; 15(1):42–6 (12 ref.)

SURGERY

Surgical treatment of vulvar lichen sclerosus: a review. Abramov Y, et al. **Obstet Gynecol Surv** 1996 Mar; 51(3):193–9 (55 ref.)

LICORICE see **GLYCYRRHIZA**

LIDOCAINE

[Use of topical anesthesia—EMLA cream] Raveh T, et al. **Harefuah** 1996 Apr 1;130(7):490–1 (26 ref.) **(Heb)**
[Temperature changes and thermoregulatory responses during epidural anesthesia in women undergoing cesarean delivery] Negishi C, et al. **Masui** 1996 May;45(5):558–64 (17 ref.) (Eng. Abstr.) **(Jpn)**

ADMINISTRATION & DOSAGE

Evaluation of intrapleural analgesia in the management of blunt traumatic chest wall pain: a clinical trial. Short K, et al. **Am Surg** 1996 Jun;62(6):488–93 (50 ref.)

ADVERSE EFFECTS

Ambulatory phlebectomy. A rare complication of local anesthetic: case report and literature review. Olivencia JA. **Dermatol Surg** 1996 Jan;22(1):53–5 (15 ref.)

BLOOD

[Lidocaine hydrochloride] Saito Y, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:983–5 (9 ref.) **(Jpn)**

DIAGNOSTIC USE

Update on the use of metabolic probes to quantify liver function: caffeine versus lidocaine. Ziebell J, et al. **Dig Dis** 1995 Jul–Aug;13(4):239–50 (74 ref.)

THERAPEUTIC USE

Assessing patient comfort: local infiltration of lidocaine during femoral sheath removal. Bowden SM, et al. **Am J Crit Care** 1995 Sep;4(5):368–9 (4 ref.)
[Value of prophylactic use of lidocaine in acute myocardial infarction] Zawadzka-Byśko M, et al. **Pol Arch Med Wewn** 1995 Jun;93(6):515–9 (47 ref.) **(Pol)**
[Prophylactic use of lidocaine in the acute period of myocardial infarction] Fomichev VI, et al. **Klin Med (Mosk)** 1995;73(4):17–20 (26 ref.) **(Rus)**

LIFE CARE CENTERS, RETIREMENT see **HOUSING FOR THE ELDERLY**

LIFE CHANGE EVENTS

Depression, stressful events and the risk of cancer [editorial] Mathé G. **Biomed Pharmacother** 1996;50(1):1–2 (22 ref.)
Reminiscence: a continuity theory framework. Parker RG. **Gerontologist** 1995 Aug;35(4):515–25 (81 ref.)
Life event timing synchrony. Sorenson DL. **Image J Nurs Sch** 1995 Winter;27(4):297–300 (40 ref.)
Say it once again: effects of repeated questions on children's event recall. Fivush R, et al. **J Trauma Stress** 1995 Oct; 8(4):555–80 (75 ref.)
Children's long-term retention of salient personal experiences. Ornstein PA. **J Trauma Stress** 1995 Oct; 8(4):581–605 (60 ref.)
The disclosure of the diagnosis of cancer. Carnes JW, et al. **Med Clin North Am** 1996 Jan;80(1):145–51 (10 ref.)
Flashbulb memories: conceptual and methodological issues. Wright DB, et al. **Memory** 1995 Mar;3(1):67–80 (55 ref.)
Are life events related to the onset of breast cancer [editorial] McGee R, et al. **Psychol Med** 1996 May;26(3):441–7 (35 ref.)
Psychobiologic reactivity to stress and childhood respiratory illnesses: results of two prospective studies. Boyce WT, et al. **Psychosom Med** 1995 Sep–Oct;57(5):411–22 (113 ref.)
Stress, reactivity, and disease [editorial] Cohen S, et al. **Psychosom Med** 1995 Sep–Oct;57(5):423–6 (14 ref.)
Social influences on bipolar affective disorders. Ramana R, et al. **Soc Psychiatry Psychiatr Epidemiol** 1995 Jul; 30(4):152–60 (55 ref.)
Risk factors for adolescent suicide and suicidal behavior: mental and substance abuse disorders, family environmental factors, and life stress. Brent DA. **Suicide Life Threat Behav** 1995;25 Suppl:52–63 (44 ref.)
[Life review: promoting the developmental potentials in aging] Lohmann R, et al. **Z Gerontol Geriatr** 1995 Jul–Aug; 28(4):236–41 (35 ref.) (Eng. Abstr.) **(Ger)**
[Synaptic reorganization in early childhood experience and learning processes: relevance for the development of psychological diseases] Braun K. **Z Klin Psychol Psychopathol Psychother** 1996;44(3):253–66 (60 ref.) (Eng. Abstr.) **(Ger)**
[Measuring scales for assessment of coping behavior: a critical evaluation] Wendt A, et al. **Z Klin Psychol Psychopathol Psychother** 1996;44(1):3–32 (90 ref.) (Eng. Abstr.) **(Ger)**

LIFE EXPECTANCY

see related
LONGEVITY

Aging and disease: extending functional life span. Harman D. **Ann N Y Acad Sci** 1996 Jun 15;786:321–36 (87 ref.)
Health care expenditure and life expectancy in Australia: how well do we perform? Taylor R, et al. **Aust N Z J Public Health** 1996 Jun;20(3):233–40 (12 ref.)

LIFE EXPERIENCES see **LIFE CHANGE EVENTS**

LIFE SCIENCES see **BIOLOGICAL SCIENCES**

LIFE STYLE

see related
HEALTH BEHAVIOR
QUALITY OF LIFE

Key issues regarding lifestyle in the prevention and treatment of hypertension. Beilin LJ. **Clin Exp Hypertens** 1996 Apr–May;18(3–4):473–87 (41 ref.)

New World syndrome in Western Australian aborigines. Gracey M. **Clin Exp Pharmacol Physiol** 1995 Mar; 22(3):220–5 (38 ref.)

Economic comparison of drug and lifestyle treatment of cardiovascular risk factors in high-risk patients. Millar JA. **Clin Exp Pharmacol Physiol** 1995 Mar;22(3):217–9 (22 ref.)

Ambulatory blood pressure monitoring for evaluating the relationships between lifestyle, hypertension and cardiovascular risk. Pickering TG, et al. **Clin Exp Pharmacol Physiol** 1995 Mar;22(3):226–31 (58 ref.)

Physical inactivity and coronary heart disease in elderly patients. Wenger NK. **Clin Geriatr Med** 1996 Feb; 12(1):79–88 (88 ref.)

Lifestyles of the risky and infamous. From managed care to managed lives. Morreim EH. **Hastings Cent Rep** 1995 Nov–Dec;25(6):5–12 (43 ref.)

The importance of life style after menopause. Zichella L. **Int J Fertil Menopausal Stud** 1995;40 Suppl 1:9–15 (19 ref.)

Risk profile screening. Froelicher ES, et al. **J Cardiovasc Nurs** 1995 Oct;10(1):30–50 (89 ref.)

Current issues in the control of hypertension. Lund-Johansen P. **J Hum Hypertens** 1995 Nov;9 Suppl 5:S25–8 (31 ref.)

Bone mass, nutrition, and other lifestyle factors. Heaney RP. **Nutr Rev** 1996 Apr;54(4 Pt 2):S3–10 (56 ref.)

Lifestyle change for coronary artery disease. What to tell patients. O'Keefe JH Jr, et al. **Postgrad Med** 1996 Feb; 99(2):89–92, 95–6, 102–6 (34 ref.)

[Physical activity and prevention and treatment of metabolic syndrome] Eriksson J, et al. **Duodecim** 1994;110(12):1193–9 (46 ref.) **(Fin)**

[Effects of lifestyle on health status] Takeshita T, et al. **Rinsho Byori** 1995 Nov;43(11):1087–94 (15 ref.) (Eng. Abstr.) **(Jpn)**

[TV and sedentary life result in more overweight people] Sjöström L. **Lakartidningen** 1996 Jan 17;93(3):167–70 (37 ref.) **(Swe)**

LIFE SUPPORT CARE

see related
RESUSCITATION ORDERS

Recommended guidelines for uniform reporting of pediatric advanced life support: the pediatric Utstein style. American Academy of Pediatrics, American Heart Association and the European Resuscitation Council. Zaritsky A, et al. **Ann Emerg Med** 1995 Oct;26(4):487–503 (60 ref.)

Recommended guidelines for uniform reporting of pediatric advanced life support: the pediatric Utstein style. A statement for healthcare professionals from a task force of the American Academy of Pediatrics, the American Heart Association, and the European Resuscitation Council. Zaritsky A, et al. **Pediatrics** 1995 Oct;96(4 Pt 1):765–79 (60 ref.)

Recommended guidelines for uniform reporting of pediatric advanced life support: the Pediatric Utstein Style. A statement for healthcare professionals from a task force of the American Academy of Pediatrics, the American Heart Association, and the European Resuscitation Council. Zaritsky A, et al. **Resuscitation** 1995 Oct; 30(2):95–115 (60 ref.)

[Ambivalence to prolonging life from the medical ethics viewpoint] Fritsche P. **Anaesthesist** 1996 Jan;45(1):99–109 (48 ref.) **(Ger)**

LEGISLATION & JURISPRUDENCE

Can healthcare providers obtain judicial intervention against surrogates who demand "medically inappropriate" life support for incompetent patients? [see comments] Cantor NL. **Crit Care Med** 1996 May;24(5):883–7 (28 ref.) Comment in: Crit Care Med 1996 May;24(5):730–2.

Social work and end-of-life decisions: self-determination and the common good. Wesley CA. **Health Soc Work** 1996 May;21(2):115–21 (52 ref.)

METHODS

[Treatment strategies in mechanical and electrical cardiovascular failure] Oechslin E. **Ther Umsch** 1996 Aug; 53(8):646–57 (21 ref.) (Eng. Abstr.) **(Ger)**

STANDARDS

Terminating life-sustaining treatment of the demented. Callahan D. **Hastings Cent Rep** 1995 Nov–Dec;25(6):25–31 (11 ref.)

LIFE VALUATION, ECONOMIC see **ECONOMIC VALUE OF LIFE**

LIFTING

ADVERSE EFFECTS

Use of back belts in occupational settings. Minor SD. **Phys Ther** 1996 Apr;76(4):403–8 (21 ref.)

LIGAMENTS

Induction of soft connective tissue formation by various prosthetic implants. Oryan A. **Transplant Proc** 1995 Oct; 27(5):2754–5 (23 ref.)

Suspensory ligament desmitis. Dyson SJ, et al. **Vet Clin North Am Equine Pract** 1995 Aug;11(2):177–215 (34 ref.)

Miscellaneous conditions of tendons, tendon sheaths, and ligaments. Dyson SJ, et al. **Vet Clin North Am Equine Pract** 1995 Aug;11(2):315–37 (57 ref.)

ABNORMALITIES

[The surgical correction of the right aortic arch with aberrant left subclavian artery and left ligamentum arteriosum--a rare case from clinical practice] Baev B, et al. **Khirurgiia (Sofiia)** 1995;48(1):48–50 (14 ref.) (Eng. Abstr.) **(Bul)**

CYTOLOGY

Electron microscopic observations of the crystalline lens. Kuszak JR, et al. **Microsc Res Tech** 1996 Apr 15; 33(6):441–79 (110 ref.)

RADIOGRAPHY

Anatomic CT demonstration of the peritoneal spaces, ligaments, and mesenteries: normal and pathologic processes. DeMeo JH, et al. **Radiographics** 1995 Jul; 15(4):755–70 (18 ref.)

SURGERY

[The surgical correction of the right aortic arch with aberrant left subclavian artery and left ligamentum arteriosum--a rare case from clinical practice] Baev B, et al. **Khirurgiia (Sofiia)** 1995;48(1):48–50 (14 ref.) (Eng. Abstr.) **(Bul)**

LIGAMENTS, ARTICULAR

Ligaments associated with joints. Wright IM. **Vet Clin North Am Equine Pract** 1995 Aug;11(2):249–91 (90 ref.)

ANATOMY & HISTOLOGY

MR imaging of knee ligaments. Pope TL Jr. **J South Orthop Assoc** 1996 Spring;5(1):46–62 (73 ref.)

MR imaging of normal and injured wrist ligaments. Smith DK. **Magn Reson Imaging Clin N Am** 1995 May;3(2):229–48 (63 ref.)

MR imaging of the triangular fibrocartilage complex. Totterman SM, et al. **Magn Reson Imaging Clin N Am** 1995 May;3(2):213–28 (24 ref.)

INJURIES

Magnetic resonance imaging of knee ligaments. Marks PH, et al. **Am J Knee Surg** 1995 Fall;8(4):181–7 (33 ref.)

Superior glenoid lesions: a diagnostic and therapeutic challenge. D'Alessandro DF, et al. **J South Orthop Assoc** 1995 Fall;4(3):214–27 (35 ref.)

Tendon, tendon sheath, and ligament injuries in the pastern. Dyson SJ, et al. **Vet Clin North Am Equine Pract** 1995 Aug;11(2):217–33 (19 ref.)

[Injuries of the bifurcate ligament] Ruland WO, et al. **Unfallchirurg** 1995 Dec;98(12):640–4 (5 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

Magnetic resonance imaging of knee ligaments. Marks PH, et al. **Am J Knee Surg** 1995 Fall;8(4):181–7 (33 ref.)

PHYSIOLOGY

Glenohumeral stability. Biomechanical properties of passive and active stabilizers. Bigliani LU, et al. **Clin Orthop** 1996 Sep;(330):13–30 (79 ref.)

Glenohumeral joint stability. Selective cutting studies on the static capsular restraints. Curl LA, et al. **Clin Orthop** 1996 Sep;(330):54–65 (36 ref.)

LIGAMENTS, COLLATERAL see **COLLATERAL LIGAMENTS**

LIGAMENTS, LATERAL see **COLLATERAL LIGAMENTS**

LIGAMENTUM LONGITUDINALE see **LONGITUDINAL LIGAMENTS**

LIGAMENTUM PATELLAE see **PATELLAR LIGAMENT**

LIGANDINS see **GLUTATHIONE TRANSFERASES**

LIGANDS

see related
RECEPTORS, CELL SURFACE

Fibronectin and cell adhesion: specificity of integrin-ligand interaction. Aota S, et al. **Adv Enzymol Relat Areas Mol Biol** 1995;70:1–21 (81 ref.)

Current computational tools for de novo ligand design. Böhm HJ. **Curr Opin Biotechnol** 1996 Aug;7(4):433–6 (61 ref.)

Modeling protein-ligand complexes. Bamborough P, et al. **Curr Opin Struct Biol** 1996 Apr;6(2):236–41 (54 ref.)

Towards prediction of cognate complexes between the WW domain and proline-rich ligands. Einbond A, et al. **FEBS Lett** 1996 Apr 8;384(1):1–8 (53 ref.)

Multiple ligand-ion solutions: a guide for solution preparation and computer program understanding. Schubert R. **J Vasc Res** 1996 Jan–Feb;33(1):86–98 (44 ref.)

[Gas6: a ligand for receptor tyrosine kinase containing gamma-carboxyglutamic acids] Nakano T. **Seikagaku** 1996 Apr;68(4):299–302 (11 ref.) **(Jpn)**

LIGASES

DEFICIENCY

[Cloning of the holocarboxylase synthetase cDNA and identification of mutations prevalent in Japanese HCS-deficient patients] Narisawa K, et al. **Nippon Rinsho** 1996 Jan;54(1):259–67 (14 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Peptidolactones. Keller U. **Biotechnology** 1995;28:173–96 (74 ref.)

[Cloning of the holocarboxylase synthetase cDNA and identification of mutations prevalent in Japanese HCS-deficient patients] Narisawa K, et al. **Nippon Rinsho** 1996 Jan;54(1):259–67 (14 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Vitamin K and energy transduction: a base strength amplification mechanism [see comments] Dowd P, et al. **Science** 1995 Sep 22;269(5231):1684–91 (39 ref.) Comment in: Science 1995 Nov 24;270(5240):1285.

LIGATION

Proximal ligation of large distal posterior inferior cerebellar artery aneurysm. Yamaguchi N, et al. **Neurol Med Chir (Tokyo)** 1996 Jan;36(1):31–5 (20 ref.)

New approaches to endoscopic therapy for hemostasis of upper GI bleed. Rauws EA, et al. **Scand J Gastroenterol Suppl** 1995;212:90–5 (66 ref.)

LIGATION, TUBAL see **STERILIZATION, TUBAL**

LIGHT

see related
LIGHTING
PHOTIC STIMULATION
PHOTOBIOLOGY
PHOTOCHEMOTHERAPY
PHOTOMETRY
PHOTOSENSITIVITY DISORDERS
PHOTOSYNTHESIS
PHOTOTHERAPY
SUNLIGHT
ULTRAVIOLET THERAPY

Light, immediate-early genes, and circadian rhythms. Kornhauser JM, et al. **Behav Genet** 1996 May;26(3):221–40 (120 ref.)

Photomorphogenesis. Seeing the light in plant development. Terzaghi WB, et al. **Curr Biol** 1995 May 1;5(5):466–8 (11 ref.)

Gene expression in plant cell cultures under continuous blue light irradiation of high intensity. Kaldenhoff R. **J Photochem Photobiol B** 1995 Dec;31(3):97–100 (35 ref.)

Visible light induced changes in the immune response through an eye-brain mechanism (photoneuroimmunology). Roberts JE. **J Photochem Photobiol B** 1995 Jul;29(1):3–15 (86 ref.)

Separating colour and luminance information in the visual system. Kingdom FA, et al. **Spat Vis** 1995;9(2):191–219 (77 ref.)

[Measuring the level of tonic accomodation as a function of wavelength] Dechriste S, et al. **J Fr Ophtalmol** 1995; 18(6–7):439–46 (26 ref.) (Eng. Abstr.) **(Fre)**

[Role of signal transduction mechanisms in light-induced entrainment of biological clocks] Shibata S. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(16):2408–17 (46 ref.) **(Jpn)**

ADVERSE EFFECTS

Light damage revisited: converging evidence, diverging views? Remé C, et al. **Graefes Arch Clin Exp Ophthalmol** 1996 Jan;234(1):2–11 (88 ref.)

[The effect of painful dazzle on the perception process] Janosik E. **Med Pr** 1996;47(2):175–81 (16 ref.) (Eng. Abstr.) **(Pol)**

LIGHT COAGULATION

[Infrared photocoagulation, cryosurgery and laser surgery in hemorrhoidal disease] Tajana A, et al. **Ann Ital Chir** 1995 Nov–Dec;66(6):775–82 (33 ref.) (Eng. Abstr.) **(Ita)**

INSTRUMENTATION

Lasers in ophthalmology. Krauss JM, et al. **Lasers Surg Med** 1995;17(2):102–59 (536 ref.)

METHODS

[Effective mechanisms of laser photocoagulation for neovascularization in diabetic retinopathy] Funatsu H, et al. **Nippon Ganka Gakkai Zasshi** 1996 May;100(5):339–49 (64 ref.) (Eng. Abstr.) **(Jpn)**

TRENDS

Treatment of choroidal neovascularization: updated information from recent macular photocoagulation study group reports. Zimmer-Galler IE, et al. **Int Ophthalmol Clin** 1995 Fall;35(4):37–57 (13 ref.)

LIGHT, LUMINESCENT see **LUMINESCENCE**

LIGHT, VISIBLE see **LIGHT**

LIGHTING

Bactericidal UV-C lamp misuse [letter] [corrected] [published erratum appears in Isr J Med Sci 1995 Nov;31(11):701] Zamir E. **Isr J Med Sci** 1995 Sep;31(9):578 (5 ref.)

Luminance and chromatic contrast effects on reading and object recognition in low vision: a review of the literature. Eperjesi F, et al. **Ophthalmic Physiol Opt** 1995 Nov; 15(6):561–8 (20 ref.)

[The effect of painful dazzle on the perception process] Janosik E. **Med Pr** 1996;47(2):175–81 (16 ref.) (Eng. Abstr.) **(Pol)**

LIGHTNING

Safety in the presence of lightning. Holle RL, et al. **Semin Neurol** 1995 Dec;15(4):375–80 (9 ref.)

Cloud-to-ground lightning: mechanisms of damage and methods of protection. Krider EP, et al. **Semin Neurol** 1995 Sep;15(3):227–32 (17 ref.)

LIGHTNING INJURIES

Lightning injury of the tympanic membrane. Gordon MA, et al. **Am J Otol** 1995 May;16(3):373–6 (7 ref.)

[Electrocution and lightning strikes--pathophysiology and treatment] Leibovici D, et al. **Harefuah** 1995 Jul; 129(1-2):62–8 (38 ref.) **(Heb)**

COMPLICATIONS

Central nervous system complications of lightning and electrical injuries. Cherington M. **Semin Neurol** 1995 Sep; 15(3):233–40 (107 ref.)

Autonomic nervous system disorders and reflex sympathetic dystrophy in lightning and electrical injuries. Cohen JA. **Semin Neurol** 1995 Dec;15(4):387–90 (23 ref.)

Involuntary movement disorders following lightning and electrical injuries. O'Brien CF. **Semin Neurol** 1995 Sep; 15(3):263–7 (18 ref.)

Peripheral nerve disorders in electrical and lightning injuries. Wilbourn AJ. **Semin Neurol** 1995 Sep;15(3):241–55 (95 ref.)

EPIDEMIOLOGY

Lightning and transportation. Cherington M. **Semin Neurol** 1995 Dec;15(4):362–6 (47 ref.)

Demographics of lightning casualties. López RE, et al. **Semin Neurol** 1995 Sep;15(3):286–95 (19 ref.)

PATHOLOGY

Forensic perspectives of electrical and lightning injuries. Jumbelic MI. **Semin Neurol** 1995 Dec;15(4):342–50 (31 ref.)

PHYSIOPATHOLOGY

Lightning accident with eight victims: case report and brief review of the literature. Graber J, et al. **J Trauma** 1996 Feb;40(2):288–90 (14 ref.)

Structural changes after lightning strike, with special emphasis on special sense orifices as portals of entry. Andrews C. **Semin Neurol** 1995 Sep;15(3):296–303 (18 ref.)

Lightning and electrical injuries: neuro-ophthalmologic aspects. Grover S, et al. **Semin Neurol** 1995 Dec; 15(4):335–41 (37 ref.)

Neuropathology of lightning-strike injuries. Kleinschmidt-DeMasters BK. **Semin Neurol** 1995 Dec; 15(4):323–8 (34 ref.)

PREVENTION & CONTROL

Safety in the presence of lightning. Holle RL, et al. **Semin Neurol** 1995 Dec;15(4):375–80 (9 ref.)

PSYCHOLOGY

Behavioral consequences of lightning and electrical injury. Primeau M, et al. **Semin Neurol** 1995 Sep;15(3):279–85 (31 ref.)

REHABILITATION

Neurorehabilitation of lightning and electrical injuries. Yarnell PR, et al. **Semin Neurol** 1995 Dec;15(4):391–6 (51 ref.)

THERAPY

Emergent care of lightning and electrical injuries. Cooper MA. **Semin Neurol** 1995 Sep;15(3):268–78 (114 ref.)

LIGHTNING STROKE see **LIGHTNING INJURIES**

LIGNAC-FANCONI SYNDROME see **FANCONI SYNDROME**

LIGNANS

PHARMACOLOGY

Phytoestrogens: epidemiology and a possible role in cancer protection. Adlercreutz H. **Environ Health Perspect** 1995 Oct;103 Suppl 7:103–12 (133 ref.)

LIGNIN

CHEMISTRY

Radical intermediates during degradation of lignin-model compounds and environmental pollutants: an electron spin resonance study. Kalyanaraman B. **Xenobiotica** 1995 Jul; 25(7):667–75 (18 ref.)

METABOLISM

Mechanisms of degradation by white rot fungi. Aust SD. **Environ Health Perspect** 1995 Jun;103 Suppl 5:59–61 (19 ref.)

Mechanisms for polycyclic aromatic hydrocarbon degradation by ligninolytic fungi. Hammel KE. **Environ Health Perspect** 1995 Jun;103 Suppl 5:41–3 (14 ref.)

Lignocellulose degradation by Phanerochaete chrysosporium: gene families and gene expression for a complex process. Broda P, et al. **Mol Microbiol** 1996 Mar; 19(5):923–32 (78 ref.)

LIGNOCAINE see **LIDOCAINE**

LIKELIHOOD FUNCTIONS

Reconciling simplicity and likelihood principles in perceptual organization. Chater N. **Psychol Rev** 1996 Jul;103(3):566–81 (80 ref.)

LIMB BUD

CYTOLOGY

Morphology and significance of programmed cell death in the developing limb bud of the vertebrate embryo. Hurle JM, et al. **Microsc Res Tech** 1996 Jun 15;34(3):236–46 (86 ref.)

PHYSIOLOGY

Retinoid signaling in vertebrate limb development. Thaller C, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:1–11 (58 ref.)

Morphology and significance of programmed cell death in the developing limb bud of the vertebrate embryo. Hurle JM, et al. **Microsc Res Tech** 1996 Jun 15;34(3):236–46 (86 ref.)

LIMBIC SYSTEM

PHYSIOLOGY

Development of oscillatory activity in the limbic cortex in vitro. Konopacki J. **Acta Neurobiol Exp (Warsz)** 1996; 56(1):407–21 (51 ref.)

Personality, emotions and the temporolimbic system: a neuropsychological approach. Beeckmans K, et al. **Acta Neurol Belg** 1996 Mar;96(1):35–42 (51 ref.)

The role of mesolimbic dopaminergic and retrohippocampal afferents to the nucleus accumbens in latent inhibition: implications for schizophrenia. Gray JA, et al. **Behav Brain Res** 1995 Nov;71(1-2):19–31 (80 ref.)

The limbic system of tetrapods: a comparative analysis of cortical and amygdalar populations. Bruce LL, et al. **Brain Behav Evol** 1995;46(4-5):224–34 (90 ref.)

Functional significance of mesolimbic dopamine. Kiyatkin EA. **Neurosci Biobehav Rev** 1995 Winter;19(4):573–98 (187 ref.)

Role for the mesocortical dopamine system in the motivating effects of cocaine. Koob GF, et al. **NIDA Res Monogr** 1994;145:1–18 (44 ref.)

PHYSIOPATHOLOGY

Cognitive functioning in "diffuse" pathology. Role of prefrontal and limbic structures. Boller F, et al. **Ann N Y Acad Sci** 1995 Dec 15;769:23–39 (51 ref.)

LIMBS see **EXTREMITIES**

LIMITATION OF ACTIVITY, CHRONIC see **ACTIVITIES OF DAILY LIVING**

LIMULUS see **HORSESHOE CRABS**

LINAC RADIOSURGERY see **RADIOSURGERY**

LINDANE

POISONING

Acute accidental lindane ingestion in toddlers. Aks SE, et al. **Ann Emerg Med** 1995 Nov;26(5):647–51 (17 ref.)

[Lindane] Surber C, et al. **Hautarzt** 1995 Aug;46(8):528–36 (100 ref.) (Eng. Abstr.) **(Ger)**

LINEAR ACCELERATOR RADIOSURGERY see **RADIOSURGERY**

LINEAR ACCELERATORS see **PARTICLE ACCELERATORS**

LINEAR MODELS

Capture-recapture and multiple-record systems estimation I: History and theoretical development. International Working Group for Disease Monitoring and Forecasting. **Am J Epidemiol** 1995 Nov 15;142(10):1047–58 (47 ref.)

Capture-recapture and multiple-record systems estimation II: Applications in human diseases. International Working Group for Disease Monitoring and Forecasting. **Am J Epidemiol** 1995 Nov 15;142(10):1059–68 (87 ref.)

Tutorial in biostatistics. Designing studies for dose response. Wong WK, et al. **Stat Med** 1996 Feb 28;15(4):343–59 (16 ref.)

LINEAR REGRESSION see **LINEAR MODELS**

LINENS see **BEDDING AND LINENS**

LINGUAL FRENUM

ABNORMALITIES

Tongue-tie. Wright JE. **J Paediatr Child Health** 1995 Aug; 31(4):276–8 (13 ref.)

LINGUAL NERVE

INJURIES

Lingual nerve damage during lower third molar removal: a comparison of two surgical methods. Robinson PP, et al. **Br Dent J** 1996 Jun 22;180(12):456–61 (29 ref.)

PATHOLOGY

Giant neurofibroma of the tongue. Sahota JS, et al. **Int J Pediatr Otorhinolaryngol** 1996 Jan;34(1-2):153–7 (10 ref.)

LINGUISTICS

Linguistic entrapment: medico-nursing biographies as fictions. Crawford P, et al. **J Adv Nurs** 1995 Dec; 22(6):1141–8 (52 ref.)

LINKAGE (GENETICS)

Molecular and cellular aspects of X-linked agammaglobulinemia. Sideras P, et al. **Adv Immunol** 1995; 59:135–223 (445 ref.)

Linkage results in schizophrenia [editorial] Baron M. **Am J Med Genet** 1995 Apr 9;67(2):121–3 (24 ref.)

Chromosome 12-linked autosomal dominant scapuloperoneal muscular dystrophy. Wilhelmsen KC, et al. **Ann Neurol** 1996 Apr;39(4):507–20 (75 ref.)

Dietary management of X-linked adrenoleukodystrophy. Moser HW, et al. **Annu Rev Nutr** 1995;15:379–97 (77 ref.)

Application of linked markers for genetic diagnosis of Alport syndrome. Barker DF, et al. **Contrib Nephrol** 1996; 117:29–45 (33 ref.)

Linkage and association to genetic markers. Elston RC. **Exp Clin Immunogenet** 1995;12(3):129–40 (39 ref.)

The use of discordant sibling pairs for finding genetic loci linked to obesity: practical considerations. Allison DB. **Int J Obes Relat Metab Disord** 1996 Jun;20(6):553–60 (54 ref.)

X-linked recessive bulbospinal neuronopathy (SBMA). Sobue G. **Nagoya J Med Sci** 1995 Dec;58(3-4):95–106 (41 ref.)

X-linked lymphoproliferative disease: twenty-five years after the discovery. Seemayer TA, et al. **Pediatr Res** 1995 Oct; 38(4):471–8 (67 ref.)

Dopamine D2 receptor gene variants: association and linkage studies in impulsive-addictive-compulsive behaviour. Blum K, et al. **Pharmacogenetics** 1995 Jun;5(3):121–41 (122 ref.)

DNA methylation, molecular genetic, and linkage studies in prostate cancer. Jarrard DF, et al. **Prostate Suppl** 1996; 6:36–44 (88 ref.)

Searching for complex disease genes: can it be made any easier? Baron M. **Psychiatr Genet** 1995 Summer;5(2):89–91 (26 ref.)

Polygenic disease: methods for mapping complex disease traits. Weeks DE, et al. **Trends Genet** 1995 Dec; 11(12):513–9 (110 ref.)

[Linkage and linkage disequilibrium in the Finnish disease heritage] de la Chapelle A, et al. **Duodecim** 1994;

LINKAGE (GENETICS)

110(7):654–64 (23 ref.) **(Fin)**

[X-linked genodermatoses] Vabres P, et al. **Ann Dermatol Venereol** 1995;122(4):154–60 (33 ref.) (Eng. Abstr.) **(Fre)**

[Linkage analysis of hereditary cancer syndrome] Nakamura Y. **Nippon Rinsho** 1995 Nov;53(11):2640–6 (4 ref.) (Eng. Abstr.) **(Jpn)**

[A family with X-linked hydrocephalus resulting from mutations in the neural cell adhesion molecule L1] Maruta K, et al. **Rinsho Shinkeigaku** 1996 Mar;36(3):462–6 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Autosomal recessive limb-girdle muscular dystrophy probably linked to chromosome 15] Noguera Moya A, et al. **An Esp Pediatr** 1996 Mar;44(3):267–9 (17 ref.) **(Spa)**

GENETICS

Genes and psychosis: old wine in new bottles? Baron M. **Acta Psychiatr Scand** 1995 Aug;92(2):81–6 (74 ref.)

The molecular basis of X-linked severe combined immunodeficiency: defective cytokine receptor signaling. Leonard WJ. **Annu Rev Med** 1996;47:229–39 (52 ref.)

Adrenoleukodystrophy. Moser HW. **Curr Opin Neurol** 1995 Jun;8(3):221–6 (37 ref.)

Casey Holter Essay Prize. The pathogenesis of X-linked hydrocephalus. Jouet M. **Eur J Pediatr Surg** 1995 Dec;5 Suppl 1:5–7 (36 ref.)

LINKAGE MAPPING see **CHROMOSOME MAPPING**

LINKER-INSERTION MUTAGENESIS see **MUTAGENESIS, INSERTIONAL**

LINOLEIC ACIDS

BIOSYNTHESIS

Investigations on the mechanism of adipocere formation and its relation to other biochemical reactions. Takatori T. **Forensic Sci Int** 1996 Jun 28;80(1-2):49–61 (25 ref.)

LINOLENIC ACID see **ALPHA-LINOLENIC ACID**

LIOTHYRONINE see **TRIIODOTHYRONINE**

LIP

ABNORMALITIES

Van der Woude syndrome. Kulkarni ML, et al. **Ann Dent** 1995 Summer-Fall;54(1-2):34–5 (7 ref.)

BLOOD SUPPLY

Reflex parasympathetic vasodilatation in facial skin. Izumi H. **Gen Pharmacol** 1995 Mar;26(2):237–44 (74 ref.)

LIP DISEASES

DIAGNOSIS

Oral myiasis: report of case and review of management. Felices RR, et al. **J Oral Maxillofac Surg** 1996 Feb; 54(2):219–20 (8 ref.)

ETIOLOGY

Senile lip licking [letter] Hisa T, et al. **Dermatology** 1995; 191(4):339–40 (4 ref.)

PATHOLOGY

Angiolymphoid hyperplasia with eosinophilia affecting the oral mucosa: report of a case and a review of the literature. Bartralot R, et al. **Br J Dermatol** 1996 Apr;134(4):744–8 (28 ref.)

SURGERY

Treatment of post-traumatic lower lip ptosis: report of case. Motamedi MH. **J Oral Maxillofac Surg** 1996 Feb; 54(2):230–3 (8 ref.)

LIP NEOPLASMS

Lip cancer: a review. Awde JD, et al. **J Can Dent Assoc** 1996 Aug;62(8):634–6 (22 ref.)

DIAGNOSIS

[Malignant histiocytofibroma. Apropos of 3 cases of cervicofacial localization] Bonnin P, et al. **Ann Otolaryngol Chir Cervicofac** 1995;112(7):336–44 (29 ref.) (Eng. Abstr.) **(Fre)**

SECONDARY

Pulmonary blastoma presenting as a solitary lip metastasis: case report and review of the literature. Lee BY, et al. **J Spinal Cord Med** 1995 Jul;18(3):203–7 (19 ref.)

LIPANTHYL see **PROCETOFEN**

LIPASE

ADMINISTRATION & DOSAGE

[Differential therapy of exocrine pancreatic insufficiency—current aspects and future prospects of substitution therapy with pancreatic enzymes] Löser C, et al. **Z Gastroenterol** 1995 Dec;33(12):715–22 (65 ref.) (Eng. Abstr.) **(Ger)**

ANTAGONISTS & INHIBITORS

Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers. Zhi J, et al. **J Clin Pharmacol** 1995 Nov;35(11):1103–8 (9 ref.)

First clinical studies with orlistat: a short review. Drent ML, et al. **Obes Res** 1995 Nov;3 Suppl 4:623S–625S (6 ref.)

BLOOD

[Hepatic triglyceride lipase] Murase T. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:644–6 (12 ref.) **(Jpn)**

[Pancreatic lipase] Sugano K. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:435–7 (8 ref.) **(Jpn)**

DEFICIENCY

[Acid lipase deficiency: Wolman disease and cholesteryl ester storage disease] Tanaka A. **Nippon Rinsho** 1995 Dec; 53(12):3004–8 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Pancreatic lipase deficiency and linear IgA disease in childhood] Olivera Olmedo JE, et al. **An Esp Pediatr** 1996 Jan;44(1):73–5 (15 ref.) **(Spa)**

GENETICS

ACAT/CEH and ACEH/LAL: two key enzymes in hepatic cellular cholesterol homeostasis and their involvement in genetic disorders. Schmitz G, et al. **Z Gastroenterol** 1996 Jun;34 Suppl 3:68–72 (19 ref.)

METABOLISM

Triglyceride lipases and atherosclerosis. Olivecrona G, et al. **Curr Opin Lipidol** 1995 Oct;6(5):291–305 (122 ref.)

Lipase structures at the interface between chemistry and biochemistry. Carrière F, et al. **EXS** 1995;73:3–26 (96 ref.)

[The physiological and pathologic role of human gastric lipase] Tomasik P. **Przegl Lek** 1995;52(6):323–5 (20 ref.) **(Pol)**

PHARMACOKINETICS

Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers. Zhi J, et al. **J Clin Pharmacol** 1995 Nov;35(11):1103–8 (9 ref.)

LIPECTOMY

Liposuction. Lawrence N, et al. **Adv Dermatol** 1996;11:19–49, 403–5; discussion 50 (106 ref.)

METHODS

A "bicycle-handlebar" type of incision for primary and secondary abdominoplasty. Baroudi R, et al. **Aesthetic Plast Surg** 1995 Jul-Aug;19(4):307–20 (27 ref.)

Addressing difficult areas in body contouring with emphasis on combined tumescent and syringe techniques. Hunstad JP. **Clin Plast Surg** 1996 Jan;23(1):57–80 (67 ref.)

LIPEMIA-CLEARING FACTOR see **LIPOPROTEIN LIPASE**

LIPID A

Monophosphoryl lipid A as an adjuvant. Past experiences and new directions. Ulrich JT, et al. **Pharm Biotechnol** 1995;6:495–524 (150 ref.)

LIPID BILAYERS

see related
LIPOSOMES

Supported membranes: scientific and practical applications. Sackmann E. **Science** 1996 Jan 5;271(5245):43–8 (40 ref.)

CHEMISTRY

X-ray diffraction studies of oriented lipid bilayers. Katsaras J. **Biochem Cell Biol** 1995 May-Jun;73(5-6):209–18 (41 ref.)

Model of a sub-main transition in phospholipid bilayers. Nielsen M, et al. **Biochim Biophys Acta** 1996 Sep 4; 1283(2):170–6 (20 ref.)

Bending membranes to the task: structural intermediates in bilayer fusion. Chernomordik LV, et al. **Curr Opin Struct Biol** 1995 Aug;5(4):541–7 (67 ref.)

[Effect of the lipid composition of the cell membrane on the domain structure of the bilayer and lateral transport] Gol'tsov AN, et al. **Fiziol Cheloveka** 1995 Nov-Dec; 21(6):113–26 (26 ref.) **(Rus)**

METABOLISM

[Sidedness of biomembrane: asymmetrical distribution and flip-flop of phospholipids across lipid bilayer] Anzai K. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(16):2418–26 (93 ref.) **(Jpn)**

LIPID EMULSIONS, INTRAVENOUS see **FAT EMULSIONS, INTRAVENOUS**

LIPID METABOLISM, INBORN ERRORS

Carnitine disorders. Stanley CA. **Adv Pediatr** 1995;42:209–42 (24 ref.)

ENZYMOLOGY

Possible role for protein kinase C in the pathogenesis of inborn errors of metabolism. Boneh A. **J Cell Biochem** 1995 Sep;59(1):27–32 (38 ref.)

[Hepatic mitochondrial fatty acid oxidation disorders] Matsubara Y. **Ryoikibetsu Shokogun Shirizu** 1995;(8):312–6 (21 ref.) **(Jpn)**

METABOLISM

Disorders of mitochondrial long-chain fatty acid oxidation. Pollitt RJ. **J Inherit Metab Dis** 1995;18(4):473–90 (78 ref.)

THERAPY

The management and outcome of propionic and methylmalonic acidaemia. Leonard JV. **J Inherit Metab Dis** 1995;18(4):430–4 (29 ref.)

LIPID MOBILIZATION

PHYSIOLOGY

Lipid fuel metabolism in health and disease. Miles JM. **Curr Opin Gen Surg** 1993;:78–84 (34 ref.)

Impact of exercise on adipose tissue metabolism in humans. Arner P. **Int J Obes Relat Metab Disord** 1995 Oct;19 Suppl 4:S18–21 (25 ref.)

LIPID PEROXIDATION

The Yin and Yang of oxidation in the development of the fatty streak. A review based on the 1994 George Lyman Duff Memorial Lecture. Navab M, et al. **Arterioscler Thromb Vasc Biol** 1996 Jul;16(7):831–42 (108 ref.)

Low-density lipoprotein oxidation, antioxidants, and atherosclerosis: a clinical biochemistry perspective. Jialal I, et al. **Clin Chem** 1996 Apr;42(4):498–506 (92 ref.)

Oxidatively modified LDL and atherosclerosis: an evolving plausible scenario. Jialal I, et al. **Crit Rev Food Sci Nutr** 1996 Apr;36(4):341–55 (115 ref.)

Lipid oxidation on foods. St Angelo AJ. **Crit Rev Food Sci Nutr** 1996 Feb;36(3):175–224 (324 ref.)

Lipid peroxidation: a review of causes, consequences, measurement and dietary influences. Benzie IF. **Int J Food Sci Nutr** 1996 May;47(3):233–61 (222 ref.)

[Role of lipid oxidation in the development of atherosclerosis] Ylä-Herttuala S, et al. **Duodecim** 1994;110(17):1643–52 (55 ref.) **(Fin)**

DRUG EFFECTS

The chemistry of lipid alkoxyl radicals and their role in metal-amplified lipid peroxidation. Marnett LJ, et al. **Biochem Soc Symp** 1995;61:65–72 (34 ref.)

Carvedilol, a novel multiple action antihypertensive agent with antioxidant activity and the potential for myocardial and vascular protection. Feuerstein GZ, et al. **Eur Heart J** 1995 Jul;16 Suppl F:38–42 (21 ref.)

The inhibition of peroxide formation as a possible substrate for the neuroprotective action of dihydroergocryptine. Favit A, et al. **J Neural Transm Suppl** 1995;45:297–305 (30 ref.)

[Lipid peroxidation in the presence of inorganic compounds. Relation to oxidative stress mechanisms] Fournier J, et al. **C R Seances Soc Biol Fil** 1995;189(3):429–42 (36 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Ethanol-induced oxidative stress in the liver. Kurose I, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1 Suppl):77A–85A (88 ref.)

Lipid peroxidation and antioxidants as biomarkers of tissue damage. Gutteridge JM. **Clin Chem** 1995 Dec;41(12 Pt 2):1819–28 (56 ref.)

Free radicals and exercise: effects of nutritional antioxidant supplementation. Kanter M. **Exerc Sport Sci Rev** 1995; 23:375–97 (142 ref.)

Fish oil, lipid peroxidation and mammary tumor growth. Gonzalez MJ. **J Am Coll Nutr** 1995 Aug;14(4):325–35 (159 ref.)

Inhibition of lipid peroxidation in central nervous system trauma and ischemia. Hall ED. **J Neurol Sci** 1995 Dec;134 Suppl:79–83 (44 ref.)

Free radicals, lipid peroxidation and sperm function. Aitken RJ. **Reprod Fertil Dev** 1995;7(4):659–68 (62 ref.)

Anti-oxidants and coronary heart disease. Ubbink JB, et al. **S Afr Med J** 1995 Dec;85(12):1279–81 (46 ref.)

LIPID PEROXIDES

BLOOD

[Lipid peroxides] Shimasaki H. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:627–31 (10 ref.) **(Jpn)**

CHEMISTRY

The isoprostanes. Current knowledge and directions for future research. Morrow JD, et al. **Biochem Pharmacol** 1996 Jan 12;51(1):1–9 (54 ref.)

METABOLISM

Hydroperoxide isomerases. Hamberg M. **J Lipid Mediat Cell Signal** 1995 Oct;12(2–3):283–92 (37 ref.)

[Cell damage as reason for the formation of unsaturated fatty acid hydroperoxides] Hölzel C, et al. **Naturwissenschaften** 1995 Oct;82(10):452–60 (74 ref.) (Eng. Abstr.) **(Ger)**

LIPIDS

Improved cationic lipid formulations for in vivo gene therapy. Felgner PL, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:126–39 (51 ref.)

Vesicle–forming synthetic amphiphiles. Engberts JB, et al. **Biochim Biophys Acta** 1995 Dec 20;1241(3):323–40 (157 ref.)

Lipid formulations of amphotericin B. Less toxicity but at what economic cost? Tollemar J, et al. **Drug Saf** 1995 Oct; 13(4):207–18 (86 ref.)

Lipid microemulsions for improving drug dissolution and oral absorption: physical and biopharmaceutical aspects. Constantinides PP. **Pharm Res** 1995 Nov;12(11):1561–72 (50 ref.)

[Prevention of coronary atherosclerosis. Determination and evaluation of lipid metabolism values] Cremer P, et al. **Fortschr Med** 1995 Nov 20;113(32):453–8 (18 ref.) (Eng. Abstr.) **(Ger)**

ADMINISTRATION & DOSAGE

[Injected fat for correction of soft tissue defects] Shoshani O, et al. **Harefuah** 1995 Dec 1;129(11):489–93 (40 ref.) **(Heb)**

ANALYSIS

Improving the sensory characteristics of reduced–fat cheese. Mistry VV. **Adv Exp Med Biol** 1995;367:371–82 (19 ref.)

Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death. Farb A, et al. **Circulation** 1996 Apr 1; 93(7):1354–63 (46 ref.)

Quantitative evaluation of skin surface lipids. Clarys P, et al. **Clin Dermatol** 1995 Jul–Aug;13(4):307–21 (85 ref.)

Lipids in predentine and dentine. Goldberg M, et al. **Connect Tissue Res** 1995;33(1–3):105–14 (56 ref.)

Lipid–based fat substitutes. Akoh CC. **Crit Rev Food Sci Nutr** 1995 Sep;35(5):405–30 (131 ref.)

Chromatographic methods in the analysis of cholesterol and related lipids. Hoving EB. **J Chromatogr B Biomed Appl** 1995 Sep 15;671(1–2):341–62 (113 ref.)

Application of tandem mass spectrometry for the analysis of long–chain carboxylic acids. Kuksis A, et al. **J Chromatogr B Biomed Appl** 1995 Sep 15;671(1–2):35–70 (116 ref.)

General strategies in chromatographic analysis of lipids. Myher JJ, et al. **J Chromatogr B Biomed Appl** 1995 Sep 15;671(1–2):3–33 (171 ref.)

[Effect of the lipid composition of the cell membrane on the domain structure of the bilayer and lateral transport] Gol'sov AN, et al. **Fiziol Cheloveka** 1995 Nov–Dec; 21(6):113–26 (26 ref.) **(Rus)**

BIOSYNTHESIS

Synthesis of fat in response to alterations in diet: insights from new stable isotope methodologies. Hellerstein MK. **Lipids** 1996 Mar;31 Suppl:S117–25 (73 ref.)

Xenobiotic lipids: the inclusion of xenobiotic compounds in pathways of lipid biosynthesis. Dodds PF. **Prog Lipid Res** 1995;34(3):219–47 (209 ref.)

Glycerolipid biosynthesis in peroxisomes (microbodies). Hajra AK. **Prog Lipid Res** 1995;34(4):343–64 (208 ref.)

[Regulation of liver carbohydrate and lipid metabolism by cell volume] Hue L. **Ann Endocrinol (Paris)** 1995; 56(6):599–601 (22 ref.) (Eng. Abstr.) **(Fre)**

BLOOD

Extending the benefit of lipid–regulating therapy to primary prevention. Jones PH, et al. **Am J Cardiol** 1995 Sep 28; 76(9):118C–121C (17 ref.)

Impact of apolipoprotein E genotype variation on means, variances, and correlations of plasma lipid, lipoprotein, and apolipoprotein traits in octogenarians. Haviland MB, et al. **Am J Med Genet** 1995 Sep 25;58(4):315–31 (64 ref.)

Review: the effects of antihypertensive agents on serum lipids. Madu EC, et al. **Am J Med Sci** 1996 Aug; 312(2):76–84 (143 ref.)

Effect of vitamin C on plasma lipids. Howard PA, et al. **Ann Pharmacother** 1995 Nov;29(11):1129–36 (58 ref.)

Plasma lipid transfer proteins. Tall A. **Annu Rev Biochem** 1995;64:235–57 (119 ref.)

Plasma lipid profiles and epidemiology of atherosclerotic diseases in Taiwan—a unique experience. Pan WH, et al. **Atherosclerosis** 1995 Dec;118(2):285–95 (47 ref.)

Post–prandial lipaemia. Kirchmair R, et al. **Baillieres Clin Endocrinol Metab** 1995 Oct;9(4):705–19 (115 ref.)

Are changes in lipoproteins during HRT important? Stevenson JC. **Br J Obstet Gynaecol** 1996 May;103 Suppl 13:39–43; discussion 43–4 (37 ref.)

Effect of konjac fibre (glucomannan) on glucose and lipids. Doi K. **Eur J Clin Nutr** 1995 Oct;49 Suppl 3:S190–7 (18 ref.)

Effect of royal jelly on serum lipids in experimental animals and humans with atherosclerosis. Vittek J. **Experientia** 1995 Sep 29;51(9–10):927–35 (68 ref.)

Lipid lowering and coronary risk. Gotto AM Jr. **Isr J Med Sci** 1996 Jun;32(6):355–9 (27 ref.)

Exercise and postprandial lipaemia. Föger B, et al. **J Cardiovasc Risk** 1995 Aug;2(4):316–22 (59 ref.)

Clinical utility of antilipidemic therapies in chronic renal allograft failure. Wanner C, et al. **Kidney Int Suppl** 1995 Dec;52:S60–2 (38 ref.)

Early determinants of adult metabolic regulation: effects of infant nutrition on adult lipid and lipoprotein metabolism. McGill HC Jr, et al. **Nutr Rev** 1996 Feb;54(2 Pt 2):S31–40 (52 ref.)

New targets for lipid lowering and atherosclerosis prevention. Sirtori CR. **Pharmacol Ther** 1995;67(3):433–47 (108 ref.)

Androgen and progestagen effects on plasma lipids. Bagatell CJ, et al. **Prog Cardiovasc Dis** 1995 Nov–Dec;38(3):255–71 (125 ref.)

[Prevention of coronary atherosclerosis. Determination and evaluation of lipid metabolism values] Cremer P, et al. **Fortschr Med** 1995 Nov 20;113(32):453–8 (18 ref.) (Eng. Abstr.) **(Ger)**

[Classification of hyperlipoproteinemias and interpretation of laboratory parameters] Herrmann W, et al. **Wien Med Wochenschr** 1994;144(12–13):292–9 (44 ref.) (Eng. Abstr.) **(Ger)**

[PLasma lipids and cardiovascular risk: lesions in the community] Farinaro E, et al. **Ann Ital Med Int** 1995 Oct; 10 Suppl:31S–34S (33 ref.) (Eng. Abstr.) **(Ita)**

[To normalize the lipidogram. Why, how, and how much?] Azevedo A de C. **Arq Bras Cardiol** 1995 Feb;64(2):145–8 (26 ref.) **(Por)**

[The effect of beta–adrenoblockaders on the lipid composition of the blood] Velkin AK, et al. **Ter Arkh** 1995; 67(8):30–3 (28 ref.) **(Rus)**

[The practical aspects of lipid management in secondary prevention] de Teresa Galván E, et al. **Rev Esp Cardiol** 1995;48 Suppl 5:52–6 (16 ref.) (Eng. Abstr.) **(Spa)**

[Why the cardiologists should be interested in lipids?] López–Sendón JL, et al. **Rev Esp Cardiol** 1995;48 Suppl 2:23–32 (61 ref.) (Eng. Abstr.) **(Spa)**

CHEMISTRY

Immunolocalization and microstructure of milk proteins and fat mimetics in reduced fat cheese. Armbruster BL, et al. **Adv Exp Med Biol** 1995;367:277–94 (47 ref.)

Kinetics of lipid phase changes. Caffrey M, et al. **Curr Opin Struct Biol** 1995 Aug;5(4):548–55 (24 ref.)

Perilipin: possible roles in structure and metabolism of intracellular neutral lipids in adipocytes and steroidogenic cells. Londos C, et al. **Int J Obes Relat Metab Disord** 1996 Mar;20 Suppl 3:S97–101 (13 ref.)

Fatty acid profiles of lipid samples. Gutnikov G. **J Chromatogr B Biomed Appl** 1995 Sep 15;671(1–2):71–89 (218 ref.)

Analytical technologies for lipid oxidation products analysis. Kinter M. **J Chromatogr B Biomed Appl** 1995 Sep 15; 671(1–2):223–36 (81 ref.)

Lipid matrix–based vaccines for mucosal and systemic immunization. Mannino RJ, et al. **Pharm Biotechnol** 1995; 6:363–87 (59 ref.)

ISOLATION & PURIFICATION

Thin–layer chromatographic procedures for lipid separation. Touchstone JC. **J Chromatogr B Biomed Appl** 1995 Sep 15;671(1–2):169–95 (128 ref.)

METABOLISM

Interfacial enzymology of glycerolipid hydrolases: lessons from secreted phospholipases A2. Gelb MH, et al. **Annu Rev Biochem** 1995;64:653–88 (208 ref.)

Neutral lipids production, transport, utilization. Cantafora A, et al. **Anticancer Res** 1996 May–Jun;16(3B):1441–9 (54 ref.)

Intratumoral lipids in 1H MRS in vivo in brain tumors: experience of the Siemens cooperative clinical trial. Negendank W, et al. **Anticancer Res** 1996 May–Jun; 16(3B):1533–8 (25 ref.)

Magnetic resonance spectroscopy in cancer: phospholipid, neutral lipid and lipoprotein metabolism and function. Podo F, et al. **Anticancer Res** 1996 May–Jun;16(3B):1305–15 (57 ref.)

Transformations and effects of lipids in the rumen: three decades of research at Gent University. Demeyer DI, et al. **Arch Tierernahr** 1995;48(1–2):119–34 (41 ref.)

Lipid nutritional pathology in farmed fish. Tacon AG. **Arch Tierernahr** 1996;49(1):33–9 (71 ref.)

Development of the lipid–rich core in human atherosclerosis. Guyton JR, et al. **Arterioscler Thromb Vasc Biol** 1996 Jan; 16(1):4–11 (104 ref.)

The chemistry of lipid alkoxyl radicals and their role in metal–amplified lipid peroxidation. Marnett LJ, et al. **Biochem Soc Symp** 1995;61:65–72 (34 ref.)

Physiological signals and pathological mediators of lipid metabolism during lactation. Evans RD. **Biochem Soc Trans** 1995 Aug;23(3):516–22 (49 ref.)

Effects of endotoxin on lipid metabolism. Hardardóttir I, et al. **Biochem Soc Trans** 1995 Nov;23(4):1013–8 (62 ref.)

Perilipin: unique proteins associated with intracellular neutral lipid droplets in adipocytes and steroidogenic cells. Londos C, et al. **Biochem Soc Trans** 1995 Aug;23(3):611–5 (16 ref.)

The functional relationship of plant lipid–derived second messengers and plant lipid–activated protein kinase. Scherer GF. **Biochem Soc Trans** 1995 Nov;23(4):871–5 (48 ref.)

The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation. Schoonjans K, et al. **Biochim Biophys Acta** 1996 Jul 26;1302(2):93–109 (259 ref.)

Synovial fluid lipids and apolipoproteins: a contemporary perspective. Prete PE, et al. **Biorheology** 1995 Jan–Feb; 32(1):1–16 (103 ref.)

Carbohydrate–lipid interactions during gestation and their control by insulin. Herrera E, et al. **Braz J Med Biol Res** 1994 Nov;27(11):2499–519 (74 ref.)

Lipids and progressive renal failure. Keane WF, et al. **Contrib Nephrol** 1996;118:17–23 (22 ref.)

Intracellular signalling. New directions for phosphatidylinositol transfer. Martin T. **Curr Biol** 1995 Sep 1;5(9):990–2 (13 ref.)

Lipid fuel metabolism in health and disease. Miles JM. **Curr Opin Gen Surg** 1993;:78–84 (34 ref.)

Assessment of delipidization as an enhancing factor in percutaneous penetration. Menczel E. **Curr Probl Dermatol** 1995;22:189–94 (11 ref.)

The IGF system in metabolism regulation. Binoux M. **Diabete Metab** 1995 Dec;21(5):330–7 (101 ref.)

Effect of reduced rate of carbohydrate absorption on carbohydrate and lipid metabolism. Jenkins DJ, et al. **Eur J Clin Nutr** 1995 Oct;49 Suppl 3:S68–73 (36 ref.)

Dietary fibres: effects on lipid metabolism and mechanisms of action. Lairon D. **Eur J Clin Nutr** 1996 Mar;50(3):125–33 (59 ref.)

The cascade mechanism to explain ozone toxicity: the role of lipid ozonation products. Pryor WA, et al. **Free Radic Biol Med** 1995 Dec;19(6):935–41 (42 ref.)

Role of glucocorticoids and fatty acids in the impairment of lipid metabolism observed in the metabolic syndrome. Brindley DN. **Int J Obes Relat Metab Disord** 1995 May; 19 Suppl 1:S69–75 (61 ref.)

Perilipin: possible roles in structure and metabolism of intracellular neutral lipids in adipocytes and steroidogenic cells. Londos C, et al. **Int J Obes Relat Metab Disord** 1996 Mar;20 Suppl 3:S97–101 (13 ref.)

Human obesity: from lipid abnormalities to lipid oxidation. Van Gaal LF, et al. **Int J Obes Relat Metab Disord** 1995 Sep;19 Suppl 3:S21–6 (40 ref.)

Design of the oxygen and substrate pathways. I. Model and strategy to test symmorphosis in a network structure. Taylor CR, et al. **J Exp Biol** 1996 Aug;199 (Pt 8):1643–9 (25 ref.)

Lipid status and fatty acid metabolism in phenylketonuria. Giovannini M, et al. **J Inherit Metab Dis** 1995;18(3):265–72 (28 ref.)

Saposin–like proteins (SAPLIP) carry out diverse functions on a common backbone structure. Munford RS, et al. **J Lipid Res** 1995 Aug;36(8):1653–63 (83 ref.)

Interleukin–1 signal transduction. Bankers–Fulbright JL, et al. **Life Sci** 1996;59(2):61–83 (237 ref.)

Lipids and atherosclerosis. Halpern MJ. **Mol Aspects Med** 1995;16(6):509–710 (1120 ref.)

The role of stereospecific saturated fatty acid positions on lipid nutrition. Decker EA. **Nutr Rev** 1996 Apr;54(4 Pt 1):108–10 (18 ref.)

The adrenergic regulation of the lipid metabolism. Ferlito S. **Panminerva Med** 1996 Mar;38(1):33–6 (30 ref.)

[Physiopathology of lipid metabolism and liver changes in obesity] Cotrozzi G, et al. **Clin Ter** 1995 Aug–Sep; 146(8–9):483–90 (53 ref.) (Eng. Abstr.) **(Ita)**

[Sex hormones, glycolipid metabolism, and atherogenesis] Sarubbi B, et al. **Minerva Med** 1995 Jun;86(6):265–73 (67 ref.) (Eng. Abstr.) **(Ita)**

[Pathogenesis of visceral fat accumulation] Keno Y, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:121–6 (20 ref.) **(Jpn)**

[Metabolic steps related to fat accumulation] Shimomura I, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:127–32 (20 ref.) **(Jpn)**

[Characteristics of adipose] Yamamura M, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:133–7 (7 ref.) **(Jpn)**

[Lipids—liposomes—biological membranes] Bandorowicz–Pikuła J. **Postepy Biochem** 1995;41(2):149–50 (21 ref.) **(Pol)**

[Lipid metabolism and new dietetic recommendations in diabetes mellitus] Sanz París A, et al. **An Med Interna** 1996 Mar;13(3):136–45 (78 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

Lipid films in water conservation of biological systems.

LIPIDS

Tiffany JM. **Cell Biochem Funct** 1995 Sep;13(3):177–80 (29 ref.)
Signal transduction through lipid second messengers. Spiegel S, et al. **Curr Opin Cell Biol** 1996 Apr;8(2):159–67 (82 ref.)
Lipid mediator networks in cell signaling: update and impact of cytokines. Serhan CN, et al. **FASEB J** 1996 Aug; 10(10):1147–58 (62 ref.)

SECRETION

The role of mdr2 P–glycoprotein in biliary lipid secretion. Cross–talk between cancer research and biliary physiology. Oude Elferink RP, et al. **J Hepatol** 1995 Nov;23(5):617–25 (62 ref.)

LIPOCHONDRODYSTROPHY see **MUCOPOLYSACCHARIDOSIS I**

LIPOCORTIN I see **ANNEXIN I**

LIPOCORTIN II see **ANNEXIN II**

LIPOCORTIN V see **ANNEXIN V**

LIPOCORTIN VI see **ANNEXIN VI**

LIPOCORTINS see **ANNEXINS**

LIPODYSTROPHY

[Mesenteric lipodystrophy] Obelar Bernal L, et al. **Rev Esp Enferm Dig** 1995 Sep;87(9):658–64 (82 ref.) (Eng. Abstr.) **(Spa)**

COMPLICATIONS

[Lipedema] Herpertz U. **Z Lymphol** 1995 Aug;19(1):1–11 (5 ref.) (Eng. Abstr.) **(Ger)**

LIPODYSTROPHY, INTESTINAL see **WHIPPLE'S DISEASE**

LIPOFUSCIN

METABOLISM

Small bowel intussusception and brown bowel syndrome in association with severe malnutrition. Drake WM, et al. **Am J Gastroenterol** 1996 Jul;91(7):1450–2 (20 ref.)
Lipofuscin and ceroid pigments in aging and brain pathology. A review. I. Biochemical and morphological properties. Riga D, et al. **Rom J Neurol Psychiatry** 1995 Apr–Jun; 33(2):121–36 (107 ref.)

LIPOIDPROTEINOSIS

PATHOLOGY

Hyalinosis cutis et mucosae. Review with a case report. Chaudhary SJ, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1995 Aug:80(2):168–71 (33 ref.)

THERAPY

[Alveolar lipoproteinosis treated by bronchopulmonary lavage] Montero MC, et al. **Arch Bronconeumol** 1995 Dec; 31(10):537–9 (22 ref.) (Eng. Abstr.) **(Spa)**

LIPOLYSIS

Differences in lipolysis between human subcutaneous and omental adipose tissues. Arner P. **Ann Med** 1995 Aug; 27(4):435–8 (27 ref.)

PHYSIOLOGY

Fat cell alpha 2–adrenoceptors: the regulation of fat cell function and lipolysis. Lafontan M, et al. **Endocr Rev** 1995 Dec;16(6):716–38 (234 ref.)

LIPOLYSIS, SUCTION see **LIPECTOMY**

LIPOMA

Thymolipoma—a rare mediastinal tumour—report of two cases and review of literature. Sirpal YM, et al. **Indian J Cancer** 1995 Mar;32(1):23–6 (17 ref.)
[Lipoma and liposarcoma of the extrahepatic bile ducts] Fukusato T, et al. **Ryoikibetsu Shokogun Shirizu** 1996; (9):34–6 (21 ref.) **(Jpn)**
[Leiomyoma, lipoma, myxoma, and fibroma of the gallbladder] Furukawa H. **Ryoikibetsu Shokogun Shirizu** 1996;(9):333–4 (8 ref.) **(Jpn)**
[Lipomatous tumors (lipoma, angiomyolipoma, myelolipoma, focal fatty change) in the liver] Imaoka S, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):288–91 (24 ref.) **(Jpn)**
[Lipoma of the gallbladder] Takagi I, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):514–5 (5 ref.) **(Jpn)**

DIAGNOSIS

Agenesis and lipoma of corpus callosum. Case report. Silva DF, et al. **Arq Neuropsiquiatr** 1995 Sep;53(3–B):667–70 (34 ref.)
[A report of an intrathoracic case of hibernoma] Ninov B, et al. **Khirurgiia (Sofiia)** 1994;47(3):41–4 (23 ref.) (Eng. Abstr.) **(Bul)**
[Intrathoracic lipoma in children. Apropos of a case (letter)] Hoeffel JC, et al. **Ann Med Interne (Paris)** 1996;147(1):66–8 (33 ref.) **(Fre)**
[Endo–bronchial lipoma. Apropos of a case] Drira I, et al. **Rev Pneumol Clin** 1995;51(4):247–9 (15 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Posttraumatic pseudolipoma. David LR, et al. **J Trauma** 1996 Mar;40(3):396–400 (15 ref.)

PATHOLOGY

Spindle–cell lipoma of the skin. Duve S, et al. **Am J Dermatopathol** 1995 Oct;17(5):529–33 (24 ref.)
Massive primary lipoma of the scrotum. Greeley DJ Jr, et al. **Am Surg** 1995 Nov;61(11):954–5 (10 ref.)
Intraoral spindle–cell lipoma: report of a case and literature review. Khoo SP, et al. **Ann Dent** 1995 Summer–Fall; 54(1–2):53–5 (14 ref.)
Spindle cell lipoma of the oral cavity. Tosios K, et al. **Int J Oral Maxillofac Surg** 1995 Oct;24(5):363–4 (10 ref.)
Nasopharyngeal lipoma—a rare clinico–pathological entity. Fagan JJ, et al. **J Laryngol Otol** 1996 Mar;110(3):275–6 (12 ref.)
Tonsillar lipoma: a case report. Harada H, et al. **J Laryngol Otol** 1995 Jul;109(7):662–4 (7 ref.)
Lipomatous tumors. Weiss SW. **Monogr Pathol** 1996; 38:207–39 (38 ref.)
Lipoblastoma of the foot. Gilbert TJ, et al. **Skeletal Radiol** 1996 Apr;25(3):283–6 (25 ref.)
Lipomatous tumours of soft tissues: an update. Mentzel T, et al. **Virchows Arch** 1995;427(4):353–63 (57 ref.)

SURGERY

Right atrial lipoma. Case report. Matta R, et al. **J Cardiovasc Surg (Torino)** 1996 Apr;37(2):165–8 (8 ref.)
[Endobronchial lipoma: endoscopic resection or surgical excision? Report of a case and review of the literature] Destito C, et al. **G Chir** 1995 Oct;16(10):445–7 (19 ref.) (Eng. Abstr.) **(Ita)**
[Accessory scrotum with lipoma: a case report] Konya E, et al. **Hinyokika Kiyo** 1996 Mar;42(3):233–6 (28 ref.) (Eng. Abstr.) **(Jpn)**

LIPOMA, PLEOMORPHIC see **LIPOMA**

LIPOMATOSIS

COMPLICATIONS

A rare case of multiple intussusceptions: intense segmentary lipomatosis of the ileum. Young TH, et al. **Am J Gastroenterol** 1996 Jan;91(1):162–3 (10 ref.)
Neurogenic claudication by epidural lipomatosis: a case report and review of literature. Kurt E, et al. **Clin Neurol Neurosurg** 1995 Nov;97(4):354–7 (14 ref.)
Ophthalmologic abnormalities in encephalocraniocutaneous lipomatosis. MacLaren MJ, et al. **Doc Ophthalmol** 1995; 90(1):87–98 (31 ref.)
Cauda equina compression by epidural lipomatosis in obesity. Effectiveness of weight reduction. Pouchot J, et al. **J Rheumatol** 1995 Sep;22(9):1771–5 (20 ref.)

DIAGNOSIS

Idiopathic spinal epidural lipomatosis. Case report and review of literature. Sato M, et al. **Clin Orthop** 1995 Nov; (320):129–34 (11 ref.)
Shwachman–Diamond syndrome: the clinical imitator of cystic fibrosis. Lozada–Muñoz L, et al. **P R Health Sci J** 1995 Dec;14(4):275–7 (15 ref.)
[Odelberg's lipomatosis] Aronescu M, et al. **Chirurgia (Bucur)** 1995;44(1):48–51 (20 ref.) **(Rum)**

ETIOLOGY

Spinal epidural lipomatosis as a complication of prolonged corticosteroid therapy. Zentner J, et al. **J Neurosurg Sci** 1995 Mar;39(1):81–5 (23 ref.)

PATHOLOGY

Neurogenic claudication by epidural lipomatosis: a case report and review of literature. Kurt E, et al. **Clin Neurol Neurosurg** 1995 Nov;97(4):354–7 (14 ref.)

VETERINARY

Bovine fat necrosis (Lipomatosis): an overview. el–Sebaie A, et al. **Berl Munch Tierarztl Wochenschr** 1995 Nov; 108(11):427–30 (49 ref.)

LIPOMUCOPOLYSACCHARIDOSIS see **MUCOLIPIDOSIS**

LIPOPOLYSACCHARIDE RECEPTORS see **ANTIGENS, CD14**

LIPOPOLYSACCHARIDES

ADVERSE EFFECTS

Grain dust, endotoxin, and airflow obstruction. Schwartz DA. **Chest** 1996 Mar;109(3 Suppl):57S–63S (51 ref.)

ANTAGONISTS & INHIBITORS

Inhibition of lipopolysaccharide–induced TNF–alpha production by semisynthetic polymyxin–B conjugated dextran. Coyne CP, et al. **Biotechnol Ther** 1994–95; 5(3–4):137–62 (108 ref.)
Endotoxin–based molecular strategies for the prevention and treatment of gram–negative sepsis and septic shock. Pollack M, et al. **Curr Top Microbiol Immunol** 1996;216:275–97 (185 ref.)

CHEMISTRY

The role of lipopolysaccharide in Helicobacter pylori pathogenesis. Moran AP. **Aliment Pharmacol Ther** 1996 Apr;10 Suppl 1:39–50 (112 ref.)
Molecular mechanisms and implications for infection of lipopolysaccharide variation in Neisseria. van Putten JP, et al. **Mol Microbiol** 1995 Jun;16(5):847–53 (53 ref.)
The lipopolysaccharide of Legionella pneumophila serogroup 1 (strain Philadelphia 1): chemical structure and biological significance. Zähringer U, et al. **Prog Clin Biol Res** 1995; 392:113–39 (76 ref.)
Heterogeneity of Brucella abortus lipopolysaccharides. Freer E, et al. **Res Microbiol** 1995 Sep;146(7):569–78 (45 ref.)

IMMUNOLOGY

Antibodies to lipopolysaccharide. Poxton IR. **J Immunol Methods** 1995 Oct 12;186(1):1–15 (85 ref.)

METABOLISM

Knowledge of cellular receptors for bacterial endotoxin—1995. Viriyakosol S, et al. **Clin Infect Dis** 1995 Oct;21 Suppl 2:S190–5 (41 ref.)

PHARMACOLOGY

Lipopolysaccharide signal transduction, regulation of tumor necrosis factor biosynthesis, and signaling by tumor necrosis factor itself. Beutler B, et al. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S1–8 (65 ref.)
Molecular mechanism in tolerance to lipopolysaccharide. Ziegler–Heitbrock HW. **J Inflamm** 1995;45(1):13–26 (131 ref.)
Role of CSB/p38/RK stress response kinase in LPS and cytokine signaling mechanisms. Lee JC, et al. **J Leukoc Biol** 1996 Feb;59(2):152–7 (62 ref.)
Endotoxin signal transduction in macrophages. Sweet MJ, et al. **J Leukoc Biol** 1996 Jul;60(1):8–26 (304 ref.)
Stimulation of phospholipase A2 expression in rat cultured astrocytes by LPS, TNF alpha and IL–1 beta. Sun GY, et al. **Prog Brain Res** 1995;105:231–8 (27 ref.)
Biological effects of RTX toxins: the possible role of lipopolysaccharide. Czuprynski CJ, et al. **Trends Microbiol** 1995 Dec;3(12):480–3 (48 ref.)

TOXICITY

Bacterial endotoxin effects on carbohydrate utilization and transport. Spitzer JJ. **Biochem Soc Trans** 1995 Nov; 23(4):998–1002 (38 ref.)
Inhibition of lipopolysaccharide–induced TNF–alpha production by semisynthetic polymyxin–B conjugated dextran. Coyne CP, et al. **Biotechnol Ther** 1994–95; 5(3–4):137–62 (108 ref.)
Examination of the role of MAP kinase in the response of macrophages to lipopolysaccharide. DeFranco AL, et al. **Prog Clin Biol Res** 1995;392:407–20 (30 ref.)
[Role of gram–negative bacterial endotoxins in infectious and non–infectious diseases] Likhoded VG, et al. **Arkh Patol** 1996 Mar–Apr;58(2):8–13 (43 ref.) (Eng. Abstr.) **(Rus)**

LIPOPROTEIN(A)

BLOOD

The role of lipoprotein(a) in atherogenesis and thrombosis. Hajjar KA, et al. **Annu Rev Med** 1996;47:423–42 (137 ref.)
Beyond low–density lipoprotein cholesterol. A perspective on low high–density lipoprotein disorders and Lp(a) lipoprotein excess. Rosenson RS. **Arch Intern Med** 1996 Jun 24;156(12):1278–84 (89 ref.)
Lipoprotein (a). Durrington PN. **Baillieres Clin Endocrinol Metab** 1995 Oct;9(4):773–95 (151 ref.)
Lipoprotein(a) as a marker for coronary heart disease. Duriez P, et al. **Br J Clin Pract Symp Suppl** 1996 Jan;77A:54–61 (72 ref.)
New aspects of risk factors for ,the development of atherosclerosis, including small low–density lipoprotein, homocyst(e)ine, and lipoprotein(a). Superko HR. **Curr Opin Cardiol** 1995 Jul;10(4):347–54 (91 ref.)
Lipoprotein(a) in chronic renal disease. Stenvinkel P, et al. **Miner Electrolyte Metab** 1996;22(1–3):16–21 (67 ref.)
[Is plasma lipoprotein (a) level a reliable indicator predicting restenosis after angioplasty?] Bussière JL, et al.

Arch Mal Coeur Vaiss 1996 Apr;89(4):425–9 (24 ref.) (Eng. Abstr.) **(Fre)**
[Lipoprotein (a) and mid-band lipoprotein] Noma A. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:651–3 (9 ref.) **(Jpn)**
[Determination of lipoprotein Lp(a) in clinical practice: personal experience] Derić M, et al. **Med Pregl** 1994; 47(9–10):327–33 (327 ref.) (Eng. Abstr.) **(Scr)**

CHEMISTRY

Lipoprotein (a). Durrington PN. **Baillieres Clin Endocrinol Metab** 1995 Oct;9(4):773–95 (151 ref.)

METABOLISM

Lipoprotein(a) in renal disease. Kronenberg F, et al. **Am J Kidney Dis** 1996 Jan;27(1):1–25 (202 ref.)
Lipoprotein (a): a prothrombotic risk factor for coronary artery disease. Seed M, et al. **J Cardiovasc Risk** 1995 Jun; 2(3):206–15 (67 ref.)

PHYSIOLOGY

Many roads lead to atheroma [comment] Hayden MR, et al. **Nat Med** 1995 Jan;1(1):22–3 (18 ref.) Comment on: Nat Med 1995 Jan;1(1):74–9.
Lipoprotein(a), plasmin modulation, and atherogenesis. Harpel PC, et al. **Thromb Haemost** 1995 Jul;74(1):382–6 (83 ref.)
Lipoprotein(a): searching for a function. Harpel PC, et al. **Trans Am Clin Climatol Assoc** 1995;107:125–33 (50 ref.)
[Lipoprotein (a): a genetic risk factor with atherogenic and thrombogenic properties] Vaverková H, et al. **Vnitr Lek** 1995 Sep;41(9):618–23 (52 ref.) (Eng. Abstr.) **(Cze)**

LIPOPROTEIN LDL RECEPTORS see **RECEPTORS, LDL**

LIPOPROTEIN LIPASE

BLOOD

[The measurements of lipoprotein lipase activity] Takagi A, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:639–43 (16 ref.) **(Jpn)**

GENETICS

Mutations affecting human lipoprotein lipase gene. Antikainen M, et al. **Z Gastroenterol** 1996 Jun;34 Suppl 3:59–61 (20 ref.)
[Lipoprotein lipase: a multifunctional enzyme in lipoprotein metabolism] Foubert L, et al. **Presse Med** 1996 Feb 10; 25(5):207–10 (25 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Triglyceride lipases and atherosclerosis. Olivecrona G, et al. **Curr Opin Lipidol** 1995 Oct;6(5):291–305 (122 ref.)
Lipase structures at the interface between chemistry and biochemistry. Carrière F, et al. **EXS** 1995;73:3–26 (96 ref.)

PHYSIOLOGY

Nutritional regulation of lipoprotein lipase. Olivecrona T, et al. **Can J Cardiol** 1995 Oct;11 Suppl G:73G–78G (31 ref.)
Alterations in lipoprotein lipase in insulin resistance. Eckel RH, et al. **Int J Obes Relat Metab Disord** 1995 May;19 Suppl 1:S16–21 (22 ref.)
Cellular metabolism of triglyceride-rich lipoproteins: role of heparan sulfate, lipoprotein lipase and lipoprotein receptors. Sehayek E, et al. **Z Gastroenterol** 1996 Jun;34 Suppl 3:110–2 (16 ref.)

LIPOPROTEIN LIPASE DEFICIENCY, FAMILIAL

COMPLICATIONS

[Lipoprotein lipase: a multifunctional enzyme in lipoprotein metabolism] Foubert L, et al. **Presse Med** 1996 Feb 10; 25(5):207–10 (25 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

[Dyslipoproteinemias in Quebec: primary deficit in lipoprotein lipase and familial hypercholesterolemia] Gagné C, et al. **Union Med Can** 1995 Sep;124(2):61–7 (32 ref.) **(Fre)**

LIPOPROTEIN RECEPTORS see **RECEPTORS, LIPOPROTEIN**

LIPOPROTEIN-X

BLOOD

[Lipoprotein-X (LP-X)] Seishima M. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:636–8 (9 ref.) **(Jpn)**

LIPOPROTEINS

see related
APOLIPOPROTEINS
HYPERLIPOPROTEINEMIA
LIPOIDPROTEINOSIS
PROTEOLIPIDS
RECEPTORS, LIPOPROTEIN

Tissue factor pathway inhibitor. Broze GJ Jr. **Thromb Haemost** 1995 Jul;74(1):90–3 (50 ref.)
[Lipoprotein glomerulopathy: a new French case with recurrence on the transplant] Djamali A, et al. **Presse Med** 1996 May 18;25(17):798–802 (23 ref.) (Eng. Abstr.) **(Fre)**

ANALYSIS

A practical approach to the laboratory diagnosis of dyslipidemia. Jialal I. **Am J Clin Pathol** 1996 Jul; 106(1):128–38 (33 ref.)
[Tissue factor pathway inhibitor (TFPI)] Matsuo T, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:157–61 (10 ref.) **(Jpn)**

BIOSYNTHESIS

Biosynthesis of apolipoprotein B48-containing lipoproteins. Regulation by novel post-transcriptional mechanisms. Innerarity TL, et al. **J Biol Chem** 1996 Feb 2;271(5):2353–6 (78 ref.)
Intestinal lipoprotein synthesis and secretion. Field FJ, et al. **Prog Lipid Res** 1995;34(2):185–98 (158 ref.)
Sites of tissue factor pathway inhibitor (TFPI) and tissue factor expression under physiologic and pathologic conditions. On behalf of the Subcommittee on Tissue factor Pathway Inhibitor (TFPI) of the Scientific and Standardization Committee of the ISTH. Osterud B, et al. **Thromb Haemost** 1995 May;73(5):873–5 (50 ref.)

BLOOD

Impact of apolipoprotein E genotype variation on means, variances, and correlations of plasma lipid, lipoprotein, and apolipoprotein traits in octogenarians. Haviland MB, et al. **Am J Med Genet** 1995 Sep 25;58(4):315–31 (64 ref.)
Childhood lipoprotein profiles and implications for adult coronary artery disease: the Bogalusa Heart Study. Srinivasan SR, et al. **Am J Med Sci** 1995 Dec;310 Suppl 1:S62–7 (36 ref.)
Trans fatty acids and their effects on lipoproteins in humans. Katan MB, et al. **Annu Rev Nutr** 1995;15:473–93 (53 ref.)
Proton nuclear magnetic resonance spectroscopy of plasma lipoprotein: technical problems and potential interest in cancer disease. de Certaines JD, et al. **Anticancer Res** 1996 May-Jun;16(3B):1451–60 (46 ref.)
Magnetic resonance spectroscopy of blood plasma lipoproteins in malignant disease: methodological aspects and clinical relevance. Engan T. **Anticancer Res** 1996 May-Jun;16(3B):1461–71 (85 ref.)
Lipoproteins and the progression/regression of atherosclerosis. Barth JD. **Baillieres Clin Endocrinol Metab** 1995 Oct;9(4):849–66 (74 ref.)
Oxidized lipoproteins. Bruckdorfer KR. **Baillieres Clin Endocrinol Metab** 1995 Oct;9(4):721–37 (64 ref.)
The role of stable isotopes in the investigation of plasma lipoprotein metabolism. Packard CJ. **Baillieres Clin Endocrinol Metab** 1995 Oct;9(4):755–72 (46 ref.)
Saturated fats and blood lipids: new slant on an old story. Hayes KC. **Can J Cardiol** 1995 Oct;11 Suppl G:39G–46G (48 ref.)
Role of dietary fish protein in the regulation of plasma lipids. Jacques H, et al. **Can J Cardiol** 1995 Oct;11 Suppl G:63G–71G (45 ref.)
Individuality of lipemic responses to diet. McGill HC Jr, et al. **Can J Cardiol** 1995 Oct;11 Suppl G:15G–27G (184 ref.)
Genetic variation of apolipoprotein B can produce both low and high levels of apoB-containing lipoproteins in plasma. Schonfeld G. **Can J Cardiol** 1995 Oct;11 Suppl G:86G–92G (79 ref.)
Effects of alcohol on plasma lipoprotein metabolism. Frohlich JJ. **Clin Chim Acta** 1996 Mar 15;246(1-2):39–49 (30 ref.)
The role of lipids in cardiovascular disease: lessons from rare mutations and special populations. Hegele RA. **Clin Invest Med** 1996 Jun;19(3):161–70 (42 ref.)
Dyslipoproteinemias in diabetes. Steiner G. **Clin Invest Med** 1995 Aug;18(4):282–7 (23 ref.)
Postprandial state and atherosclerosis. Ebenbichler CF, et al. **Curr Opin Lipidol** 1995 Oct;6(5):286–90 (37 ref.)
Metabolic disruptions in the adipocyte-hepatocyte fatty acid axis as causes of HyperapoB. Sniderman AD, et al. **Int J Obes Relat Metab Disord** 1995 May;19 Suppl 1:S27–33 (68 ref.)
Role of atherogenic lipoproteins in cytokine-mediated renovascular injury. Kirschenbaum MA, et al. **Miner Electrolyte Metab** 1996;22(1-3):47–50 (20 ref.)
Early determinants of adult metabolic regulation: effects of infant nutrition on adult lipid and lipoprotein metabolism. McGill HC Jr, et al. **Nutr Rev** 1996 Feb;54(2 Pt 2):S31–40 (52 ref.)
Cellular metabolism of triglyceride-rich lipoproteins: role of heparan sulfate, lipoprotein lipase and lipoprotein receptors. Sehayek E, et al. **Z Gastroenterol** 1996 Jun;34 Suppl 3:110–2 (16 ref.)
[Physiology and pathophysiology of the metabolism of lipoproteins] Sandhofer F. **Wien Med Wochenschr** 1994; 144(12-13):286–90 (0 ref.) (Eng. Abstr.) **(Ger)**
[Reverse cholesterol transport] Schmidt HH, et al. **Z Gastroenterol** 1996 Jun;34(6):386–91 (69 ref.) **(Ger)**
[Lipoprotein and lipoprotein fractions] Itakura H. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:632–5 (7 ref.) **(Jpn)**
[Glycated lipoproteins] Ueno Y, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:566–70 (16 ref.) **(Jpn)**
[The effects of androgens and other sex hormones on serum lipoproteins] Reiner Z. **Lijec Vjesn** 1996 Mar;118 Suppl 1:33–7 (55 ref.) (Eng. Abstr.) **(Scr)**

DRUG EFFECTS

New approaches to the prevention of atherosclerosis. Naito M, et al. **Drugs** 1995 Sep;50(3):440–53 (154 ref.)
Danazol and plasma lipoprotein metabolism. Shepherd J. **Int J Gynaecol Obstet** 1995 Sep;50 Suppl 1:S23–6 (17 ref.)

ISOLATION & PURIFICATION

Chromatographic techniques for the isolation and purification of lipoproteins. Tadey T, et al. **J Chromatogr B Biomed Appl** 1995 Sep 15;671(1-2):237–53 (105 ref.)

METABOLISM

Magnetic resonance spectroscopy in cancer: phospholipid, neutral lipid and lipoprotein metabolism and function. Podo F, et al. **Anticancer Res** 1996 May-Jun;16(3B):1305–15 (57 ref.)
Remnant particles and their metabolism. Eisenberg S, et al. **Baillieres Clin Endocrinol Metab** 1995 Oct;9(4):739–53 (40 ref.)
Viral lipoproteins: the role of myristoylation. Harper DR, et al. **Biochem Soc Trans** 1995 Aug;23(3):553–7 (49 ref.)
Potential pathogenic roles of aberrant lipoprotein and fatty acid metabolism in pre-eclampsia. Sattar N, et al. **Br J Obstet Gynaecol** 1996 Jul;103(7):614–20 (57 ref.)
Smoking and plasma lipoprotein metabolism [editorial] Freeman DJ, et al. **Clin Sci (Colch)** 1995 Oct;89(4):333–42 (94 ref.)
Use of somatic gene transfer to study lipoprotein metabolism in experimental animals in vivo. Chan L. **Curr Opin Lipidol** 1995 Oct;6(5):335–40 (56 ref.)
The stimulation of the cholesterol esterification pathway by atherogenic lipoproteins in macrophages. Tabas I. **Curr Opin Lipidol** 1995 Oct;6(5):260–8 (112 ref.)
Insulin resistance in the pathogenesis of dyslipidemia. Garg A. **Diabetes Care** 1996 Apr;19(4):387–9 (34 ref.)
Lipoprotein metabolism in renal replacement therapy: a review. Kronenberg F, et al. **Isr J Med Sci** 1996 Jun; 32(6):371–89 (184 ref.)
Exercise and lipoprotein metabolism. Superko HR. **J Cardiovasc Risk** 1995 Aug;2(4):310–5 (70 ref.)
Antioxidants, lipoprotein oxidation, and arterial function. Bruckdorfer KR. **Lipids** 1996 Mar;31 Suppl:S83–5 (17 ref.)
[Value of transgenic mouse as model for the study of human lipoprotein metabolism] Fournier N, et al. **Ann Biol Clin (Paris)** 1995;53(4):209–20 (64 ref.) (Eng. Abstr.) **(Fre)**
[The important role of apolipoprotein C-III in lipoprotein metabolism] Fruchart JC, et al. **C R Seances Soc Biol Fil** 1995;189(5):889–97 (30 ref.) (Eng. Abstr.) **(Fre)**
[Lipoprotein lipase: a multifunctional enzyme in lipoprotein metabolism] Foubert L, et al. **Presse Med** 1996 Feb 10; 25(5):207–10 (25 ref.) (Eng. Abstr.) **(Fre)**
[Oxidized lipoproteins and atherogenesis] Bellomo G, et al. **Cardiologia** 1996 May;41(5):417–25 (61 ref.) **(Ita)**
[Dyslipidemia and blood coagulation] Serrano Júnior CV, et al. **Arq Bras Cardiol** 1995 Sep;65(3):273–7 (46 ref.) **(Por)**

PHYSIOLOGY

Fungal lipopeptide mating pheromones: a model system for the study of protein prenylation. Caldwell GA, et al. **Microbiol Rev** 1995 Sep;59(3):406–22 (181 ref.)
Regulation of the extrinsic pathway system in health and disease: the role of factor VIIa and tissue factor pathway inhibitor. Petersen LC, et al. **Thromb Res** 1995 Jul 1; 79(1):1–47 (256 ref.)

TOXICITY

Renal toxicity of albumin and other lipoproteins. Schreiner GF. **Curr Opin Nephrol Hypertens** 1995 Jul;4(4):369–73 (33 ref.)

LIPOPROTEINS, HDL

BLOOD

High density lipoproteins and coronary heart disease. Barter PJ, et al. **Atherosclerosis** 1996 Mar;121(1):1–12 (96 ref.)
[Regulation of HDL lipoprotein plasma levels in relation to atherogenesis] Ružek V. **Vnitr Lek** 1995 Aug;41(8):555–9 (56 ref.) (Eng. Abstr.) **(Cze)**

CHEMISTRY

Pre-beta HDL: structure and metabolism. Barrans A, et al. **Biochim Biophys Acta** 1996 Apr 19;1300(2):73–85 (150 ref.)

LIPOPROTEINS, HDL

METABOLISM

Pre-beta HDL: structure and metabolism. Barrans A, et al. **Biochim Biophys Acta** 1996 Apr 19;1300(2):73–85 (150 ref.)
Anti-atherogenicity of high density lipoprotein. Stein Y, et al. **Isr J Med Sci** 1996 Jun;32(6):503–8 (61 ref.)
A docking receptor for HDL cholesterol esters [comment] Steinberg D. **Science** 1996 Jan 26;271(5248):460–1 (15 ref.) Comment on: Science 1996 Jan 26;271(5248):518–20.
[Biological consequences of lipoprotein modification] Wehr H. **Postepy Biochem** 1995;41(3):201–5 (45 ref.) **(Pol)**
[Transport of cholesterol by high density lipoproteins from the standpoint of protein biochemistry] Titov VN. **Vopr Med Khim** 1995 May–Jun;41(3):2–8 (85 ref.) **(Rus)**

LIPOPROTEINS, HDL CHOLESTEROL

see related
HYPERCHOLESTEROLEMIA
HYPERCHOLESTEROLEMIA, FAMILIAL

BLOOD

Beyond low-density lipoprotein cholesterol. A perspective on low high-density lipoprotein disorders and Lp(a) lipoprotein excess. Rosenson RS. **Arch Intern Med** 1996 Jun 24;156(12):1278–84 (89 ref.)
Testosterone and risk factors for cardiovascular disease in men. Barrett-Connor EL. **Diabete Metab** 1995 Jun; 21(3):156–61 (41 ref.)
High-density lipoprotein-cholesterol: determining hygienic factors for intervention [published erratum appears in J Occup Environ Med 1995 Sep;37(9):1121] Anzalone DA, et al. **J Occup Environ Med** 1995 Jul;37(7):856–61 (32 ref.)
[HDL-cholesterol] Nakai T, et al. **Nippon Rinsho** 1995 Feb; 53 Su Pt 1:617–22 (8 ref.) **(Jpn)**
[Cholesteryl ester transfer protein (CETP) deficiency and increased HDL cholesterol levels (hyperalphalipoproteinemia)] Inazu A, et al. **Rinsho Byori** 1996 Apr;44(4):322–6 (15 ref.) (Eng. Abstr.) **(Jpn)**
[The control of cholesterol in the prevention of coronary cardiopathy] Vintró IB. **Rev Esp Salud Publica** 1995 Nov–Dec;69(6):439–43 (21 ref.) **(Spa)**

LIPOPROTEINS, LDL

see related
RECEPTORS, LDL

BLOOD

Do glomerular atherosclerosis and lipid-mediated tubulo-interstitial disease cause progressive renal failure in man? Moorhead JF, et al. **Blood Purif** 1996;14(1):58–66 (69 ref.)
Low-density lipoprotein oxidation, antioxidants, and atherosclerosis: a clinical biochemistry perspective. Jialal I, et al. **Clin Chem** 1996 Apr;42(4):498–506 (92 ref.)
New aspects of risk factors for the development of atherosclerosis, including small low-density lipoprotein, homocyst(e)ine, and lipoprotein(a). Superko HR. **Curr Opin Cardiol** 1995 Jul;10(4):347–54 (91 ref.)
[Atherogenicity of low-density lipoproteins (LDL). A problem of quantity or quality?] Dejager S, et al. **Presse Med** 1995 Dec 9;24(38):1772–6 (16 ref.) (Eng. Abstr.) **(Fre)**
[Multiple modifications of low density lipoproteins in blood of patients with atherosclerosis] Orekhov AN, et al. **Biull Eksp Biol Med** 1995 Aug;120(8):118–21 (38 ref.) **(Rus)**

CHEMISTRY

Chemistry and pathophysiology of oxidation of LDL. Esterbauer H, et al. **Rev Physiol Biochem Pharmacol** 1996; 127:31–64 (161 ref.)
[Conformation of apolipoprotein B-100—structure and functional classification of low density lipoproteins] Titov VN. **Biokhimiia** 1996 Jan;61(1):3–23 (93 ref.) (Eng. Abstr.) **(Rus)**

CLASSIFICATION

Low-density lipoprotein heterogeneity. Griffin BA. **Baillieres Clin Endocrinol Metab** 1995 Oct;9(4):687–703 (81 ref.)

IMMUNOLOGY

Cytokines, modified lipoproteins, and arteriosclerosis in diabetes. Lopes-Virella MF, et al. **Diabetes** 1996 Jul;45 Suppl 3:S40–4 (49 ref.)

METABOLISM

Coantioxidants make alpha-tocopherol an efficient antioxidant for low-density lipoprotein. Thomas SR, et al. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1357S–1364S (66 ref.)
Effect of vitamin E, vitamin C and beta-carotene on LDL oxidation and atherosclerosis. Jialal I, et al. **Can J Cardiol** 1995 Oct;11 Suppl G:97G–103G (97 ref.)
Free radicals, oxidative stress, oxidized low density lipoprotein (LDL), and the heart: antioxidants and other strategies to limit cardiovascular damage. Sinatra ST, et al. **Conn Med** 1995 Oct;59(10):579–88 (94 ref.)
Oxidatively modified LDL and atherosclerosis: an evolving plausible scenario. Jialal I, et al. **Crit Rev Food Sci Nutr** 1996 Apr;36(4):341–55 (115 ref.)
Structure of cholesterol-containing particles accumulating in atherosclerotic lesions and the mechanisms of their derivation. Hoff HF, et al. **Curr Opin Lipidol** 1995 Oct; 6(5):317–25 (91 ref.)
The role of oxidized lipoproteins in atherogenesis. Berliner JA, et al. **Free Radic Biol Med** 1996;20(5):707–27 (265 ref.)
The effect of NO/EDRF and monocytes/macrophages on LDL-oxidation. Leitinger N, et al. **J Physiol Pharmacol** 1995 Dec;46(4):385–408 (144 ref.)
Effects of oxidized low-density lipoprotein on vascular contraction and relaxation: clinical and pharmacological implications in atherosclerosis. Cox DA, et al. **Pharmacol Rev** 1996 Mar;48(1):3–19 (182 ref.)
LDL-platelet interaction under oxidative stress induces macrophage foam cell formation. Aviram M. **Thromb Haemost** 1995 Jul;74(1):560–4 (41 ref.)
[The significance of ixidized low density lipoprotein in atherosclerosis] Hansen PR. **Ugeskr Laeger** 1996 May 6; 158(19):2706–10 (40 ref.) (Eng. Abstr.) **(Dan)**
[Role of lipid oxidation in the development of atherosclerosis] Ylä-Herttuala S, et al. **Duodecim** 1994;110(17):1643–52 (55 ref.) **(Fin)**
[Serum lipoprotein and atherogenicity—relationship with particle size and composition of low density lipoproteins, and their modifications by oxidation and glycation] Takeuchi N, et al. **Rinsho Byori** 1995 Aug;43(8):753–62 (47 ref.) (Eng. Abstr.) **(Jpn)**
[Biological consequences of lipoprotein modification] Wehr H. **Postepy Biochem** 1995;41(3):201–5 (45 ref.) **(Pol)**
[Lipoproteins, antioxidants, and coronary cardiopathy] Guimarães AC. **Arq Bras Cardiol** 1995 Sep;65(3):289–95 (31 ref.) **(Por)**
[Conformation of apolipoprotein B-100—structure and functional classification of low density lipoproteins] Titov VN. **Biokhimiia** 1996 Jan;61(1):3–23 (93 ref.) (Eng. Abstr.) **(Rus)**
[New discoveries on atherosclerosis. LDL oxidation plays a central role] Nilsson J. **Lakartidningen** 1995 Oct 4; 92(40):3684–6, 3691 (19 ref.) **(Swe)**

PHARMACOKINETICS

Targeting lipoproteins to Fc gamma receptors with bispecific antibodies. Morganelli PM. **J Hematother** 1995 Oct; 4(5):457–61 (19 ref.)

PHYSIOLOGY

The role of oxidized low density lipoprotein in atherogenesis. Jialal I, et al. **J Nutr** 1996 Apr;126(4 Suppl):1053S–7S (39 ref.)
Beyond oxidized LDL: the initiation and progression of atherosclerosis. Hirose N, et al. **Keio J Med** 1996 Jun; 45(2):90–4 (26 ref.)
Chemistry and pathophysiology of oxidation of LDL. Esterbauer H, et al. **Rev Physiol Biochem Pharmacol** 1996; 127:31–64 (161 ref.)

LIPOPROTEINS, LDL CHOLESTEROL

see related
HYPERCHOLESTEROLEMIA
HYPERCHOLESTEROLEMIA, FAMILIAL

BLOOD

The influence of pretreatment low density lipoprotein cholesterol concentrations on the effect of hypocholesterolemic therapy on coronary atherosclerosis in angiographic trials. Harvard Atherosclerosis Reversibility Project Research Group. Sacks FM, et al. **Am J Cardiol** 1995 Sep 28;76(9):78C–85C (30 ref.)
Beyond low-density lipoprotein cholesterol. A perspective on low high-density lipoprotein disorders and Lp(a) lipoprotein excess. Rosenson RS. **Arch Intern Med** 1996 Jun 24;156(12):1278–84 (89 ref.)
Direct LDL. A cost-effective replacement for the Friedewald equation? [editorial] Eckfeldt JH. **Arch Pathol Lab Med** 1996 Jan;120(1):15–7 (10 ref.)
Why are lipids not predictive of cardiovascular death in the dialysis patient? Ritz E. **Miner Electrolyte Metab** 1996; 22(1–3):9–12 (25 ref.)
Atherosclerotic lesions in humans—plaque stabilization and regression. Kritz H, et al. **Wien Klin Wochenschr** 1995; 107(18):555–66 (60 ref.)
[Extracorporeal elimination of LDL-cholesterol in the treatment of hypercholesterolemia: indications and methods] Bláha V, et al. **Vnitr Lek** 1995 Oct;41(10):724–9 (40 ref.) (Eng. Abstr.) **(Cze)**
[Drug therapy of hypercholesterolemia] Schwandt P, et al. **Wien Klin Wochenschr** 1995;107(18):544–8 (64 ref.) (Eng. Abstr.) **(Ger)**
[The control of cholesterol in the prevention of coronary cardiopathy] Vintró IB. **Rev Esp Salud Publica** 1995 Nov–Dec;69(6):439–43 (21 ref.) **(Spa)**

METABOLISM

The importance of vitamin E in reducing cardiovascular risk. Abbey M. **Nutr Rev** 1995 Sep;53(9 Pt 2):S28–32 (44 ref.)
[Cholesterol turnover in triglyceride transport and effect of probucol] Titov VN. **Vopr Med Khim** 1995 Sep–Oct; 41(5):2–8 (80 ref.) **(Rus)**

LIPOPROTEINS, VLDL

BIOSYNTHESIS

The enzymology of hepatic very-low-density lipoprotein assembly. Gibbons GF, et al. **Biochem Soc Trans** 1995 Aug; 23(3):495–500 (40 ref.)

METABOLISM

The role of insulin in the control of hepatic fatty acid and glycerolipid metabolism assessed by studies in vivo. Zammit VA. **Braz J Med Biol Res** 1995 Oct;28(10):1027–31 (24 ref.)
Hyperinsulinemia and triglyceride-rich lipoproteins. Steiner G, et al. **Diabetes** 1996 Jul;45 Suppl 3:S24–6 (29 ref.)
Acute effects of insulin in the control of VLDL production in humans. Implications for the insulin-resistant state. Lewis GF, et al. **Diabetes Care** 1996 Apr;19(4):390–3 (38 ref.)

LIPOSARCOMA

Head and neck liposarcoma. Golledge J, et al. **Cancer** 1995 Sep 15;76(6):1051–8 (53 ref.)
[Retroperitoneal liposarcoma. Two cases] Bennani S, et al. **Ann Urol (Paris)** 1995;29(3):154–8 (21 ref.) (Eng. Abstr.) **(Fre)**
[A case of renal capsular liposarcoma] Doi T, et al. **Hinyokika Kiyo** 1995 Nov;41(11):873–7 (29 ref.) (Eng. Abstr.) **(Jpn)**
[Lipoma and liposarcoma of the extrahepatic bile ducts] Fukusato T, et al. **Ryoikibetsu Shokogun Shirizu** 1996; (9):34–6 (21 ref.) **(Jpn)**

DIAGNOSIS

Primary retroperitoneal liposarcoma: a case report and review of the literature. Ulusoy E, et al. **Int Urol Nephrol** 1995;27(6):691–5 (19 ref.)
[Primary liposarcoma of the left ventricle. Apropos of a case and review of the literature] Pinelli G, et al. **Arch Mal Coeur Vaiss** 1996 Feb;89(2):257–60 (10 ref.) (Eng. Abstr.) **(Fre)**
[Retroperitoneal liposarcoma with lung, skin and pancreatic metastases] Alcalá Pedrajas JN, et al. **Arch Bronconeumol** 1996 Jun–Jul;32(6):313–5 (21 ref.) (Eng. Abstr.) **(Spa)**

EPIDEMIOLOGY

Thymus-related liposarcoma: report of a case and review of the literature. Sekine Y, et al. **Surg Today** 1996; 26(3):203–7 (21 ref.)

PATHOLOGY

Retropharyngeal liposarcoma. Yueh B, et al. **Am J Otolaryngol** 1995 Sep–Oct;16(5):331–40 (65 ref.)
Liposarcoma of the base of tongue and tonsillar fossa: A possibly underdiagnosed neoplasm. Saddik M, et al. **Arch Pathol Lab Med** 1996 Mar;120(3):292–5 (23 ref.)
Lipomatous tumors. Weiss SW. **Monogr Pathol** 1996; 38:207–39 (38 ref.)

LIPOSARCOMA, DEDIFFERENTIATED see **LIPOSARCOMA**

LIPOSARCOMA, MYXOID

Myxoid liposarcoma of the ankle. Werd MB, et al. **J Foot Ankle Surg** 1995 Sep–Oct;34(5):465–74 (39 ref.)

DIAGNOSIS

[Adipose retroperitoneal tumors. Apropos a giant myxoid liposarcoma] Romero Pérez P, et al. **Actas Urol Esp** 1996 Jan;20(1):79–84 (14 ref.) (Eng. Abstr.) **(Spa)**

SURGERY

[Voluminous retroperitoneal liposarcoma. Apropos of a case and review of the literature] Lachachi F, et al. **J Chir (Paris)** 1995 Jun–Jul;132(6–7):309–13 (20 ref.) (Eng. Abstr.) **(Fre)**

LIPOSARCOMA, PLEOMORPHIC see **LIPOSARCOMA**

LIPOSOMES

Vesicle-forming synthetic amphiphiles. Engberts JB, et al. **Biochim Biophys Acta** 1995 Dec 20;1241(3):323–40 (157 ref.)
Recent advances in liposomal drug-delivery systems. Chonn A, et al. **Curr Opin Biotechnol** 1995 Dec;6(6):698–708 (120 ref.)
Liposomes as delivery agents for medical imaging. Torchilin VP. **Mol Med Today** 1996 Jun;2(6):242–9 (36 ref.)
Liposome design and vaccine development. Pietrobon PJ. **Pharm Biotechnol** 1995;6:347–61 (145 ref.)
Liposomes: presentation and actual applicative trends in

medicine. Bejan A, et al. **Rom J Intern Med** 1995 Jul-Dec; 33(3-4):141-9 (40 ref.)
[Cationic liposome-mediated expression of hepatitis C virus genome in adult rat liver] Takehara T, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:102-6 (13 ref.) **(Jpn)**
[Fusogenic liposomes: a new system for gene transfer] Nakanishi M. **Tanpakushitsu Kakusan Koso** 1995 Dec; 40(17):2550-5 (16 ref.) **(Jpn)**
[Cationic liposomes] Yagi K. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2577-82 (6 ref.) **(Jpn)**
[Basic study and application of functional liposomes] Oku N. **Yakugaku Zasshi** 1995 Jul;115(7):483-98 (32 ref.) (Eng. Abstr.) **(Jpn)**

CHEMISTRY

Improved cationic lipid formulations for in vivo gene therapy. Felgner PL, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:126-39 (51 ref.)
Reconstitution of membrane proteins into liposomes: application to energy-transducing membrane proteins. Rigaud JL, et al. **Biochim Biophys Acta** 1995 Oct 10; 1231(3):223-46 (128 ref.)

IMMUNOLOGY

Liposomes as carriers of peptide antigens: induction of antibodies and cytotoxic T lymphocytes to conjugated and unconjugated peptides. Alving CR, et al. **Immunol Rev** 1995 Jun;145:5-31 (104 ref.)

METABOLISM

[Lipids--liposomes--biological membranes] Bandorowicz-Pikula J. **Postepy Biochem** 1995;41(2):149-50 (21 ref.) **(Pol)**

LIPOSUCTION see **LIPECTOMY**

LIPOTROPIN

BLOOD

[Lipotropin (LPH) and melanocyte-stimulating hormone (MSH)] Tanaka K. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:315-8 (13 ref.) **(Jpn)**

LIPOTROPIN 61-91 see **BETA-ENDORPHIN**

LIPOXIDASE see **LIPOXYGENASE**

LIPOXYGENASE

CHEMISTRY

Plant lipoxygenases. Shibata D, et al. **J Lipid Mediat Cell Signal** 1995 Oct;12(2-3):213-28 (80 ref.)

GENETICS

Plant lipoxygenases. Shibata D, et al. **J Lipid Mediat Cell Signal** 1995 Oct;12(2-3):213-28 (80 ref.)

METABOLISM

Effects of mesalazine on the formation of lipoxygenase and cyclooxygenase products. Lauritsen K, et al. **Adv Exp Med Biol** 1995;371B:1301-6 (66 ref.)
Lipoxygenases in plants--their role in development and stress response. Rosahl S. **Z Naturforsch [C]** 1996 Mar-Apr; 51(3-4):123-38 (139 ref.)

PHYSIOLOGY

Lipoxygenases as therapeutic targets in the acute and subacute phases of glomerular immune injury. Badr KF. **Contrib Nephrol** 1996;118:113-25 (75 ref.)
Role of leukotrienes and lipoxygenases in glomerular injury. Nassar GM, et al. **Miner Electrolyte Metab** 1995; 21(4-5):262-70 (76 ref.)

5-LIPOXYGENASE see **ARACHIDONATE 5-LIPOXYGENASE**

12-LIPOXYGENASE see **ARACHIDONATE 12-LIPOXYGENASE**

15-LIPOXYGENASE see **ARACHIDONATE 15-LIPOXYGENASE**

LIPOXYGENASE INHIBITORS

Leukotriene receptor antagonists and biosynthesis inhibitors: potential breakthrough in asthma therapy. Chung KF. **Eur Respir J** 1995 Jul;8(7):1203-13 (117 ref.)

THERAPEUTIC USE

Zileuton. McGill KA, et al. **Lancet** 1996 Aug 24; 348(9026):519-24 (38 ref.)
Cysteinyl leukotrienes in asthma: current state of therapeutic evaluation. Taylor IK. **Thorax** 1995 Sep;50(9):1005-10 (93 ref.)

LIQUID PARAFFIN see **MINERAL OIL**

LISINOPRIL

ADVERSE EFFECTS

Acute renal failure induced by angiotensin converting enzyme inhibitor in a patient with polyarteritis nodosa. Wang AY, et al. **Ren Fail** 1996 Mar;18(2):293-8 (17 ref.)

LISTERIA INFECTIONS

[Hepatic listeriosis] Ito A. **Ryoikibetsu Shokogun Shirizu** 1995;(7):112-4 (16 ref.) **(Jpn)**

COMPLICATIONS

[Cerebrovascular manifestations of infectious diseases] Martínez Vázquez F, et al. **Rev Neurol** 1995;23 Suppl 1:S11-21 (88 ref.) **(Spa)**

DRUG THERAPY

[Azithromycin, pharmacodynamic evaluation in animal models] Lagrange PH. **Pathol Biol (Paris)** 1995 Jun; 43(6):515-23 (37 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Intracellular pathogenesis of listeriosis. Southwick FS, et al. **N Engl J Med** 1996 Mar 21;334(12):770-6 (47 ref.)

IMMUNOLOGY

Functional T cell subsets in mycobacterial and listerial infections: lessons from other intracellular pathogens. Szalay G, et al. **Curr Top Microbiol Immunol** 1996; 215:283-302 (102 ref.)

MICROBIOLOGY

The cell biology of infection by intracellular bacterial pathogens. Theriot JA. **Ann Rev Cell Dev Biol** 1995; 11:213-39 (106 ref.)
Joint infections due to Listeria monocytogenes: case report and review. Ellis LC, et al. **Clin Infect Dis** 1995 Jun; 20(6):1548-50 (15 ref.)

LISTERIA MONOCYTOGENES

IMMUNOLOGY

Listeria monocytogenes: a live vector able to deliver heterologous protein within the cytosol and to drive a CD8 dependent T cell response. Goossens PL, et al. **Biologicals** 1995 Jun;23(2):135-43 (92 ref.)

PHYSIOLOGY

The cell biology of infection by intracellular bacterial pathogens. Theriot JA. **Ann Rev Cell Dev Biol** 1995; 11:213-39 (106 ref.)
Intracellular pathogenesis of listeriosis. Southwick FS, et al. **N Engl J Med** 1996 Mar 21;334(12):770-6 (47 ref.)

LITERACY PROGRAMS see **EDUCATION**

LITERATURE

Why literature and medicine? McLellan MF, et al. **Lancet** 1996 Jul 13;348(9020):109-11 (38 ref.)

LITHIUM

ADMINISTRATION & DOSAGE

[Initiating thymoregulator treatment] Olié JP, et al. **Encephale** 1995 Mar;21 Spec No 2:71-8 (86 ref.) (Eng. Abstr.) **(Fre)**
[Efficacy of antidepressants and thymoregulators in the long-term evolution of depression] Pringuey D, et al. **Encephale** 1995 Mar;21 Spec No 2:61-70 (18 ref.) (Eng. Abstr.) **(Fre)**
[Calcium antagonists and lithium in preventive treatment of manic-depressive disorder] Sarfati Y, et al. **Encephale** 1996 Mar-Apr;22(2):149-53 (43 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Alterations in sodium metabolism as an etiological model for hypertension. Lijnen P. **Cardiovasc Drugs Ther** 1995 Jun; 9(3):377-99 (238 ref.)

PHARMACOKINETICS

Clinical relevance of drug interactions with lithium. Finley PR, et al. **Clin Pharmacokinet** 1995 Sep;29(3):172-91 (147 ref.)

PHARMACOLOGY

Inositol monophosphatase--a putative target for Li+ in the treatment of bipolar disorder. Atack JR, et al. **Trends Neurosci** 1995 Aug;18(8):343-9 (97 ref.)

POISONING

Cerebellar lithium toxicity: a review of recent literature and tentative pathophysiology. Grignon S, et al. **Therapie** 1996 Mar-Apr;51(2):101-6 (33 ref.)

THERAPEUTIC USE

Lithium therapy: limitations and alternatives in the treatment of bipolar disorders. Calabrese JR, et al. **Ann Clin Psychiatry** 1995 Jun;7(2):103-12 (80 ref.)
How does lithium work on manic depression? Clinical and psychological correlates of the inositol theory. Belmaker RH, et al. **Annu Rev Med** 1996;47:47-56 (23 ref.)
Lithium revisited. A re-examination of the placebo-controlled trials of lithium prophylaxis in manic-depressive disorder [editorial] Moncrieff J. **Br J Psychiatry** 1995 Nov;167(5):569-73; discussion 573-4 (26 ref.)
Clinical relevance of drug interactions with lithium. Finley PR, et al. **Clin Pharmacokinet** 1995 Sep;29(3):172-91 (147 ref.)
Psychopharmacology in child and adolescent psychiatry: a review of the past seven years. Part II. Campbell M, et al. **J Am Acad Child Adolesc Psychiatry** 1995 Oct; 34(10):1262-72 (138 ref.)
Predictors of response to mood stabilizers. Calabrese JR, et al. **J Clin Psychopharmacol** 1996 Apr;16(2 Suppl 1):24S-31S (88 ref.)
Inositol monophosphatase--a putative target for Li+ in the treatment of bipolar disorder. Atack JR, et al. **Trends Neurosci** 1995 Aug;18(8):343-9 (97 ref.)
[Prophylactic treatment of episodic forms of cluster headache] Liaño H, et al. **Rev Neurol** 1995;23 Suppl 4:S525-9 (29 ref.) **(Spa)**

TOXICITY

Lithium-pilocarpine neurotoxicity: a potential model of status epilepticus. Kulkarni SK, et al. **Methods Find Exp Clin Pharmacol** 1995 Oct;17(8):551-67 (195 ref.)

LITHIUM CARBONATE

ADVERSE EFFECTS

Lithium-induced diabetes insipidus in a surgical patient: report of a case and review of the literature. Gray EJ, et al. **J Oral Maxillofac Surg** 1996 Jul;54(7):909-12 (20 ref.)

BLOOD

[Lithium carbonate] Higuchi S, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:942-4 (9 ref.) **(Jpn)**

THERAPEUTIC USE

[Prophylactic treatment of chronic cluster headache] Alberca R. **Rev Neurol** 1995;23 Suppl 4:S530-4 (55 ref.) **(Spa)**

LITHIUM COMPOUNDS

ADVERSE EFFECTS

Mutagenicity, carcinogenicity and teratogenicity of lithium compounds. Léonard A, et al. **Mutat Res** 1995 Oct; 339(3):131-7 (69 ref.)

TOXICITY

Mutagenicity, carcinogenicity and teratogenicity of lithium compounds. Léonard A, et al. **Mutat Res** 1995 Oct; 339(3):131-7 (69 ref.)

LITHOLAPAXY see **LITHOTRIPSY**

LITHOTRIPSY

Extracorporeal shock-wave lithotripsy of middle ureteral stones: are ureteral stents necessary? Nakada SY, et al. **Urology** 1995 Nov;46(5):649-52 (18 ref.)
[Treatment of renal and ureteral lithiasis] Doré B. **Presse Med** 1995 Oct 28;24(32):1495-7 (17 ref.) (Eng. Abstr.) **(Fre)**
[Extracorporeal lithotripsy in the treatment of upper urinary tract lithiasis] Guillonneau B, et al. **Presse Med** 1995 Dec 2;24(37):1743-6 (25 ref.) (Eng. Abstr.) **(Fre)**
[Percutaneous surgical interventions and extracorporeal lithotripsy in the treatment of the urological complications after a kidney transplant] Urenkov SB, et al. **Urol Nefrol (Mosk)** 1995 Jul-Aug;(4):45-9 (122 ref.) **(Rus)**
[Strategy changes in the treatment of ureteral lithiasis and nephritic colic] González Enguita C, et al. **Actas Urol Esp** 1996 Apr;20(4):351-60 (35 ref.) (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Extracorporeal gall bladder lithotripsy--a review of tissue and cellular effects. Stephenson TJ. **J Pathol** 1996 May; 179(1):4-9 (51 ref.)
The use of ungating with the Medstone lithotriptor. Cass AS. **J Urol** 1996 Sep;156(3):896-8 (15 ref.)

INSTRUMENTATION

The use of ungating with the Medstone lithotriptor. Cass AS. **J Urol** 1996 Sep;156(3):896-8 (15 ref.)
[The double J catheter in the shock wave treatment of kidney calculi] Pilar Laguna M, et al. **Ann Urol (Paris)** 1995;

29(6-7):364-9 (20 ref.) (Eng. Abstr.) **(Fre)**

[Current status and future developments in noninvasive treatment of urinary calculi with extracorporeal shockwave lithotripsy (ESWL)] Hofbauer J, et al. **Wien Med Wochenschr** 1995;145(11-12):254-8 (52 ref.) (Eng. Abstr.) **(Ger)**

[Urolithiasis in children] Türk C, et al. **Wien Med Wochenschr** 1995;145(11-12):258-60 (11 ref.) (Eng. Abstr.) **(Ger)**

METHODS

[Role of extracorporeal shock wave lithotripsy in the treatment of common bile duct and intrahepatic calculi] Dagenais M, et al. **Ann Chir** 1995;49(8):659-63 (15 ref.) (Eng. Abstr.) **(Fre)**

[Treatment of renal and ureteral lithiasis] Doré B. **Presse Med** 1995 Oct 28;24(32):1495-7 (17 ref.) (Eng. Abstr.) **(Fre)**

LITIGATION see **JURISPRUDENCE**

LITTLE'S DISEASE see **CEREBRAL PALSY**

LIVEDO RETICULARIS see **SKIN DISEASES, VASCULAR**

LIVER

see related

HEPATECTOMY

Artificial liver. Evolution and future perspectives. Rozga J, et al. **ASAIO J** 1995 Oct-Dec;41(4):831-7 (58 ref.)

[Primary hepatic pregnancy] Kato K. **Ryoikibetsu Shokogun Shirizu** 1995;(8):523-5 (14 ref.) **(Jpn)**

[Heterotopic tissues in the gallbladder (heterotopic gastric mucosa, heterotopic intestinal epithelium, heterotopic pancreatic tissue and ectopic liver in the gallbladder] Kodama T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):360-2 (17 ref.) **(Jpn)**

[Ectopic liver] Okanoue T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):151-3 (19 ref.) **(Jpn)**

[Foreign body in the liver] Tanimura H. **Ryoikibetsu Shokogun Shirizu** 1995;(8):496-8 (17 ref.) **(Jpn)**

ABNORMALITIES

The Ivemark syndrome: prenatal diagnosis of an uncommon cystic renal lesion with heterogeneous associations. Larson RS, et al. **Pediatr Nephrol** 1995 Oct;9(5):594-8 (16 ref.)

Diagnosis and treatment of porto-systemic shunts. Bellenger CR, et al. **Vet Q** 1995 Apr;17 Suppl 1:S4-5 (6 ref.)

[The torsion of an accessory liver lobe as the rare cause of acute abdomen] Betge L. **Dtsch Med Wochenschr** 1995 Sep 29;120(39):1318-20 (11 ref.) (Eng. Abstr.) **(Ger)**

[A rare anatomical variant of the left hepatic lobe. Report of a case] Solivetti FM, et al. **Radiol Med (Torino)** 1995 Dec;90(6):832-4 (8 ref.) **(Ita)**

[A case of the hypoplasia of the hepatic left lobe complicated with cholangiocarcinoma] Suzuki T, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Apr;93(4):276-81 (20 ref.) **(Jpn)**

[Mesenchymal hamartoma of the liver] Fukuhara K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):327-8 (14 ref.) **(Jpn)**

[Hypoplasia of the hepatic lobe] Ishiguro N, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):162-4 (20 ref.) **(Jpn)**

[Hepatocellular carcinoma of accessory liver] Kakita A, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):279-81 (19 ref.) **(Jpn)**

[Intrahepatic gallbladder] Matsuzaki M, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):154-5 (20 ref.) **(Jpn)**

[Riedel's lobe (caudal prolongation)] Okanoue T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):149-50 (6 ref.) **(Jpn)**

[Accessory liver] Okanoue T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):165-6 (10 ref.) **(Jpn)**

[von Meyenburg's complex (biliary microhamartoma)] Tetsuka I, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):277-8 (5 ref.) **(Jpn)**

[Accessory liver lobe] Tsuchihashi T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):156-8 (20 ref.) **(Jpn)**

[Hepatic anomalous lobulation] Yoshinouchi T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):159-61 (8 ref.) **(Jpn)**

ANATOMY & HISTOLOGY

Overview of imaging in living related donor hepatic transplantation. Cheng YF, et al. **Transplant Proc** 1996 Aug;28(4):2412-4 (19 ref.)

BLOOD SUPPLY

Large spleno-caval shunt not accompanied by cirrhosis or encephalopathy. Mitsui H, et al. **J Gastroenterol** 1996 Apr;31(2):278-83 (33 ref.)

Human liver-associated lymphocytes: an overview. Winnock M, et al. **J Gastroenterol Hepatol** 1995;10 Suppl 1:S43-6 (21 ref.)

Hepatic artery ligation for hepatic vascular tumors with arteriovenous and arterioportal venous shunts in the newborn: successful management of two cases and review of the literature. Hazebroek FW, et al. **J Pediatr Surg** 1995 Aug;30(8):1127-30 (15 ref.)

The role of metals in ischemia/reperfusion injury of the liver. Arora AS, et al. **Semin Liver Dis** 1996 Feb;16(1):31-8 (65 ref.)

Mechanism and prevention of ischemia-reperfusion injury of the liver. Kurokawa T, et al. **Semin Surg Oncol** 1996 May-Jun;12(3):179-82 (21 ref.)

[Vascular exclusion of the liver] Frangov T, et al. **Khirurgiia (Sofiia)** 1995;48(4):41-5 (61 ref.) (Eng. Abstr.) **(Bul)**

[Microcirculation and oxygen supply to the liver in hemorrhagic shock and sepsis] Vollmar B. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Oct; 30 Suppl 1:S52-4 (21 ref.) **(Ger)**

[Effect of organ preservation conditions on reperfusion after liver transplantation] Walcher F, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Oct; 30 Suppl 1:S55-7 (27 ref.) **(Ger)**

[Ischemic hepatitis: case reports and a review of the literature] Colivicchi F, et al. **Minerva Med** 1995 Sep; 86(9):379-86 (24 ref.) (Eng. Abstr.) **(Ita)**

[Liver infarction] Hasebe C, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):184-6 (14 ref.) **(Jpn)**

[Ischemic liver injury] Kurokawa T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):513-6 (20 ref.) **(Jpn)**

CHEMISTRY

[HCV-RNA in liver of chronic hepatitis C--plus strand RNA and minus strand RNA] Endo H, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:623-8 (17 ref.) **(Jpn)**

[Detection of HCV-RNA in liver by in situ hybridization] Yamada S, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:300-6 (29 ref.) **(Jpn)**

CYTOLOGY

Disruption of polarized function in hepatocytes. Chipman JK, et al. **Arch Toxicol Suppl** 1996;18:115-26 (61 ref.)

Acquisition and use of human in vitro liver preparations. Guillouzo A. **Cell Biol Toxicol** 1995 Aug;11(3-4):141-5 (17 ref.)

Use of mammalian liver cells for artificial liver support. Jauregui HO, et al. **Cell Transplant** 1996 May-Jun; 5(3):353-67 (130 ref.)

The mechanism of clinical effectiveness of human fetal liver cell transfusion. Wu Z. **Chin Med J (Engl)** 1995 Sep; 108(9):650-2 (8 ref.)

Liver-enriched transcription factors and hepatocyte differentiation. Cereghini S. **FASEB J** 1996 Feb; 10(2):267-82 (101 ref.)

Lymphocyte and macrophage populations in the liver. Bioulac-Sage P, et al. **Hepatogastroenterology** 1996 Jan-Feb;43(7):4-14 (35 ref.)

Chemotactic and suppressor cytokine networks. Thompson K, et al. **Hepatogastroenterology** 1996 Jan-Feb;43(7):15-31 (132 ref.)

Mass transfer limitations to the performance of membrane bioartificial liver support devices. Catapano G. **Int J Artif Organs** 1996 Jan;19(1):18-35 (70 ref.)

Hybrid liver support [editorial] Gerlach J. **Int J Artif Organs** 1996 Jan;19(1):1-2 (8 ref.)

Fulminant liver failure: relevance of extracorporeal hybrid liver support systems. Gerlach J, et al. **Int J Artif Organs** 1996 Jan;19(1):7-13 (79 ref.)

Assessment of bioartificial liver support in acute liver failure. Hughes RD, et al. **Int J Artif Organs** 1996 Jan;19(1):3-6 (18 ref.)

Role of transport proteins in bioartificial liver assist systems. Mitzner S, et al. **Int J Artif Organs** 1996 Jan;19(1):49-52 (6 ref.)

Hepatocyte encapsulation--initial intentions and new aspects for its use in bioartificial liver support. Stange J, et al. **Int J Artif Organs** 1996 Jan;19(1):45-8 (26 ref.)

Cell sources for bioartificial liver support. Stange J, et al. **Int J Artif Organs** 1996 Jan;19(1):14-7 (25 ref.)

Molecular organization of hepatocyte peroxisomes. Makita T. **Int Rev Cytol** 1995;160:303-52 (220 ref.)

Hepatic epithelial stem-like cells. Grisham JW. **Verh Dtsch Ges Pathol** 1995;79:47-54 (38 ref.)

[Hepatocyte culture in the study of liver diseases] Wang Y, et al. **Chung Hua I Hsueh Tsa Chih** 1995 Jul;75(7):437-9 (14 ref.) **(Chi)**

[Hepatic neoductules] Fischer HP, et al. **Verh Dtsch Ges Pathol** 1995;79:36-46 (42 ref.) (Eng. Abstr.) **(Ger)**

[Control of liver proliferation: structural, functional and molecular aspects] Rabes HM. **Verh Dtsch Ges Pathol** 1995; 79:61-71 (50 ref.) (Eng. Abstr.) **(Ger)**

[An artificial liver on its way to clinical reality?] Thasler WE, et al. **Zentralbl Chir** 1995;120(8):614-23 (82 ref.) (Eng. Abstr.) **(Ger)**

[Hepatocyte transplantation: current status] Arranz Caso JA, et al. **Med Clin (Barc)** 1996 Jan 13;106(1):27-35 (144 ref.) **(Spa)**

DRUG EFFECTS

Hepatotoxicity of antibiotics. Hautekeete ML. **Acta Gastroenterol Belg** 1995 May-Aug;58(3-4):290-6 (64 ref.)

Alcohol and energy intake. Lands WE. **Am J Clin Nutr** 1995 Nov;62(5 Suppl):1101S-1106S (55 ref.)

Liver copper storage and transport during development: implications for cytotoxicity. Luza SC, et al. **Am J Clin Nutr** 1996 May;63(5):812S-20S (105 ref.)

The hepatic effects of sevoflurane. Frink EJ Jr. **Anesth Analg** 1995 Dec;81(6 Suppl):S46-50 (29 ref.)

The organ toxicity of inhaled anesthetics. Kenna JG, et al. **Anesth Analg** 1995 Dec;81(6 Suppl):S51-66 (143 ref.)

Biotransformation and renal processing of nephrotoxic agents. Dekant W. **Arch Toxicol Suppl** 1996;18:163-72 (63 ref.)

Insulin and the partitioning of hepatic fatty acid metabolism. Zammit VA. **Biochem Soc Trans** 1995 Aug;23(3):506-11 (43 ref.)

Acquisition and use of human in vitro liver preparations. Guillouzo A. **Cell Biol Toxicol** 1995 Aug;11(3-4):141-5 (17 ref.)

Manifestations of chemically induced liver damage. Batt AM, et al. **Clin Chem** 1995 Dec;41(12 Pt 2):1882-7 (40 ref.)

Idiosyncratic liver toxicity of nonsteroidal antiinflammatory drugs: molecular mechanisms and pathology. Boelsterli UA, et al. **Crit Rev Toxicol** 1995;25(3):207-35 (245 ref.)

Effect of metformin on liver insulin metabolism and regional blood flow. Signore A, et al. **Diabetes Metab Rev** 1995 Sep;11 Suppl 1:S13-21 (48 ref.)

Iron as a hepatotoxin. Stål P. **Dig Dis** 1995 Jul-Aug; 13(4):205-22 (113 ref.)

Anti-tuberculosis medication and the liver: dangers and recommendations in management [see comments] Thompson NP, et al. **Eur Respir J** 1995 Aug;8(8):1384-8 (39 ref.) Comment in: Eur Respir J 1995 Aug;8(8):1247-9.

Medium-term liver and multi-organ carcinogenesis bioassays for carcinogens and chemopreventive agents. Ito N, et al. **Exp Toxicol Pathol** 1996 Feb;48(2-3):113-9 (40 ref.)

Drug-induced hepatotoxicity [see comments] Lee WM. **N Engl J Med** 1995 Oct 26;333(17):1118-27 (101 ref.) Comment in: N Engl J Med 1996 Mar 28;334(13):863; discussion 864. Comment in: N Engl J Med 1996 Mar 28;334(13):863-4; discussion 864. Comment in: N Engl J Med 1996 Mar 28;334(13):864.

The impact of intraperitoneal glucose and insulin on the liver. Bargman JM. **Perit Dial Int** 1996;16 Suppl 1:S211-4 (27 ref.)

Peroxisome proliferators: potential role of altered hepatocyte growth and differentiation in tumor development. Cattley RC, et al. **Prog Clin Biol Res** 1995;391:295-303 (55 ref.)

Metal-induced hepatotoxicity. Britton RS. **Semin Liver Dis** 1996 Feb;16(1):3-12 (105 ref.)

Metals, oxidative stress, and hepatic fibrogenesis. Pietrangelo A. **Semin Liver Dis** 1996 Feb;16(1):13-30 (117 ref.)

Cultured hepatocytes as investigational models for hepatic toxicity: practical applications in drug discovery and development. Ulrich RG, et al. **Toxicol Lett** 1995 Dec; 82-83:107-15 (28 ref.)

Possible association of liver damage with the use of Chinese herbal medicine for skin disease. Perharic L, et al. **Vet Hum Toxicol** 1995 Dec;37(6):562-6 (30 ref.)

EMBRYOLOGY

Normal development and neoplasia: the imprinting connection. Ohlsson R, et al. **Int J Dev Biol** 1995 Oct; 39(5):869-76 (54 ref.)

B-lymphoid potential in pre-liver mouse embryo. Godin I, et al. **Semin Immunol** 1995 Jun;7(3):131-41 (70 ref.)

ENZYMOLOGY

Mammalian phosphoribosyl-pyrophosphate synthetase. Tatibana M, et al. **Adv Enzyme Regul** 1995;35:229-49 (60 ref.)

Hepatic inducible nitric oxide synthase: regulation and function. de Vera ME, et al. **Biochem Soc Trans** 1995 Nov; 23(4):1008-13 (51 ref.)

Cytochromes and psychotropic drug interactions [editorial] Taylor D, et al. **Br J Psychiatry** 1996 May;168(5):529-32 (30 ref.)

Clinical importance of hepatic cytochrome P450 in drug metabolism. Spatzenegger M, et al. **Drug Metab Rev** 1995; 27(3):397-417 (146 ref.)

The effects of hypoxia on drug-metabolizing enzymes. Woodrooffe AJ, et al. **Drug Metab Rev** 1995;27(3):471-95 (73 ref.)

Ovine 11 beta-hydroxysteroid dehydrogenase: from gene to function. Yang K. **Endocr Res** 1995 Feb-May; 21(1-2):367-77 (49 ref.)

Constitutive expression of hepatic cytochrome P450 genes. Gonzalez FJ, et al. **FASEB J** 1996 Aug;10(10):1112-7 (49 ref.)

Regulation of glycogen synthase activation in isolated hepatocytes. Pugazhenthi S, et al. **Mol Cell Biochem** 1995 Aug-Sep;149-150:95-101 (66 ref.)

Induction of cytochrome P450 isoforms by carcinogenic aromatic amines and carcinogenic susceptibility of rodent animals. Hashimoto Y, et al. **Pharmacogenetics** 1995;5 Spec No:S80-3 (22 ref.)

Covalent control of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase: insights into autoregulation of a bifunctional enzyme. Kurland IJ, et al. **Protein Sci** 1995 Jun;4(6):1023-37 (70 ref.)

Substrates of human hepatic cytochrome P450 3A4. Li AP, et al. **Toxicology** 1995 Dec 15;104(1-3):1-8 (37 ref.)

ACAT/CEH and ACEH/LAL: two key enzymes in hepatic cellular cholesterol homeostasis and their involvement in genetic disorders. Schmitz G, et al. **Z Gastroenterol** 1996 Jun;34 Suppl 3:68-72 (19 ref.)

[Reverse cholesterol transport] Schmidt HH, et al. **Z Gastroenterol** 1996 Jun;34(6):386-91 (69 ref.) **(Ger)**

[Hepatic triglyceride lipase] Murase T. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:644-6 (12 ref.) **(Jpn)**

[Metabolic zonation in rat hepatocytes] Ogawa H, et al. **Seikagaku** 1995 Oct;67(10):1221-27 (16 ref.) **(Jpn)**

GROWTH & DEVELOPMENT

Molecular genetics of early liver development. Zaret KS. **Annu Rev Physiol** 1996;58:231-51 (132 ref.)

Cooperation between transcription factors regulates liver development. Aran A, et al. **Biol Neonate** 1995;67(6):387-96 (46 ref.)

Analysis of liver development, regeneration, and carcinogenesis by genetic marking studies. Ponder KP. **FASEB J** 1996 May;10(7):673-82 (59 ref.)

Normal development and neoplasia: the imprinting connection. Ohlsson R, et al. **Int J Dev Biol** 1995 Oct; 39(5):869-76 (54 ref.)

IMMUNOLOGY

Lymphocyte-endothelial cell interactions in hepatic inflammation. Adams DH. **Hepatogastroenterology** 1996 Jan-Feb;43(7):32-43 (82 ref.)

B-lymphoid potential in pre-liver mouse embryo. Godin I, et al. **Semin Immunol** 1995 Jun;7(3):131-41 (70 ref.)

Parenchymal and nonparenchymal liver cells and their interaction in the local immune response. Knolle P, et al. **Z Gastroenterol** 1995 Oct;33(10):613-20 (94 ref.)

[Function and regulation of adhesion molecules in CTLs induction of chronic hepatitis B--expression of ICAM-1 and VCAM-1 in liver tissues] Doi T. **Nippon Rinsho** 1995 Oct;53 Suppl:180-4 (19 ref.) **(Jpn)**

[Expression of HLA molecules on the surface of hepatocytes and antigen presentation] Manabe K, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:166-72 (20 ref.) **(Jpn)**

[Fas antigen expression and apoptosis in liver tissues of patients with chronic hepatitis B] Mochizuki K, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:228-33 (17 ref.) **(Jpn)**

[Mechanism of hepatocyte destruction through HBV-specific T cell responses] Saibara T, et al. **Nippon Rinsho** 1995 Oct; 53 Suppl:138-43 (20 ref.) **(Jpn)**

[Hepatic injury of acute hepatitis A] Sata M, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:804-12 (17 ref.) **(Jpn)**

[Immunohistochemical observation of Fas in the liver of chronic hepatitis B and its ultrastructural localization] Takatani M, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:234-40 (23 ref.) **(Jpn)**

INJURIES

Rapidly progressive portal hypertension 23 years after post-traumatic arterioportal fistula of the liver. Kayser S, et al. **Am J Gastroenterol** 1996 Jul;91(7):1442-6 (30 ref.)

Management of upper abdominal solid organ injuries. Richardson JD, et al. **AORN J** 1996 May;63(5):907-16 (15 ref.)

Selective nonoperative management of liver and spleen injuries in neurologically impaired adult patients. Archer LP, et al. **Arch Surg** 1996 Mar;131(3):309-15 (57 ref.)

Interventional radiology in the treatment of blunt liver trauma: case report with review of literature. Harms J, et al. **Bildgebung** 1996 Mar;63(1):51-4 (22 ref.)

Complex hepatic injuries. Pachter HL, et al. **Surg Clin North Am** 1996 Aug;76(4):763-82 (66 ref.)

[Resuscitation in severe hepatic injuries] Wodey E, et al. **Cah Anesthesiol** 1996;44(1):55-69 (131 ref.) (Eng. Abstr.) **(Fre)**

[Traumatic hepatic cyst] Kurumi Y, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):87-9 (17 ref.) **(Jpn)**

[Liver injury] Yamamoto M. **Ryoikibetsu Shokogun Shirizu** 1995;(8):487-92 (19 ref.) **(Jpn)**

METABOLISM

Corticosteroid metabolism in isolated perfused rat liver and kidney. Experimental studies with emphasis on aldosterone. Egfjord M. **Acta Physiol Scand Suppl** 1995;627:1-42 (226 ref.)

Class 3 aldehyde dehydrogenase. A northern perspective in the land down under. Feimer J, et al. **Adv Exp Med Biol** 1995;372:137-41 (12 ref.)

Liver copper storage and transport during development: implications for cytotoxicity. Luza SC, et al. **Am J Clin Nutr** 1996 May;63(5):812S-20S (105 ref.)

Molecular mechanisms of hepatic bile salt transport from sinusoidal blood into bile. Meier PJ. **Am J Physiol** 1995 Dec;269(6 Pt 1):G801-12 (190 ref.)

Is reverse cholesterol transport a misnomer for suggesting its role in the prevention of atheroma formation? Quintão EC. **Atherosclerosis** 1995 Jul;116(1):1-14 (162 ref.)

Role of insulin in hepatic fatty acid partitioning: emerging concepts. Zammit VA. **Biochem J** 1996 Feb 15;314 (Pt 1):1-14 (186 ref.)

The enzymology of hepatic very-low-density lipoprotein assembly. Gibbons GF, et al. **Biochem Soc Trans** 1995 Aug; 23(3):495-500 (40 ref.)

Hormonal and nutritional control of liver fatty acid oxidation and ketogenesis during development. Prip-Buus C, et al. **Biochem Soc Trans** 1995 Aug;23(3):500-6 (47 ref.)

Insulin and the partitioning of hepatic fatty acid metabolism. Zammit VA. **Biochem Soc Trans** 1995 Aug;23(3):506-11 (43 ref.)

Hormonal regulation of cytosolic calcium levels in the liver. Kraus-Friedmann N. **Braz J Med Biol Res** 1995 Mar; 28(3):275-84 (61 ref.)

The role of insulin in the control of hepatic fatty acid and glycerolipid metabolism assessed by studies in vivo. Zammit VA. **Braz J Med Biol Res** 1995 Oct;28(10):1027-31 (24 ref.)

Essentiality of omega-3 and omega-6 fatty acids for efficient liver sterol metabolism. Levy E. **Can J Cardiol** 1995 Oct; 11 Suppl G:29G-35G (79 ref.)

The 1994 G. Malcolm Brown Lecture. Biological barriers and medicine. Goresky CA. **Clin Invest Med** 1995 Dec; 18(6):484-501 (23 ref.)

Clinical pharmacokinetics of therapeutic bile acids. Crosignani A, et al. **Clin Pharmacokinet** 1996 May; 30(5):333-58 (156 ref.)

Molecular genetics of cytochrome P450 IID. Anomalies of drug metabolism. Jacqz-Aigrain E, et al. **Clin Rev Allergy Immunol** 1995 Fall;13(3):211-21 (50 ref.)

New insight into the biochemical pathology of liver in choline deficiency. Ghoshal AK. **Crit Rev Biochem Mol Biol** 1995;30(4):263-73 (42 ref.)

C/EBP alpha: a critical regulator of genes governing integrative metabolic processes. Darlington GJ, et al. **Curr Opin Genet Dev** 1995 Oct;5(5):565-70 (37 ref.)

Chylomicron remnants: hepatic receptors and metabolism. Havel RJ. **Curr Opin Lipidol** 1995 Oct;6(5):312-6 (41 ref.)

Regulation of hepatic glucose production in healthy subjects and patients with non-insulin-dependent diabetes mellitus. Tappy L. **Diabete Metab** 1995 Oct;21(4):233-40 (71 ref.)

Extrapancreatic effects of sulfonylurea drugs. Kaku K, et al. **Diabetes Res Clin Pract** 1995 Aug;28 Suppl:S105-8 (21 ref.)

Rationale and hurdles of inhibitors of hepatic gluconeogenesis in treatment of diabetes mellitus. Kashiwagi A. **Diabetes Res Clin Pract** 1995 Aug;28 Suppl:S195-200 (30 ref.)

Update on the use of metabolic probes to quantify liver function: caffeine versus lidocaine. Ziebell J, et al. **Dig Dis** 1995 Jul-Aug;13(4):239-50 (74 ref.)

Gender effects in pharmacokinetics and pharmacodynamics. Harris RZ, et al. **Drugs** 1995 Aug;50(2):222-39 (170 ref.)

Pharmacokinetics and molecular detoxication. Cashman JR, et al. **Environ Health Perspect** 1996 Mar;104 Suppl 1:23-40 (143 ref.)

Influence of etomoxir on the expression of several genes in liver, testis and heart. Hegardt FG, et al. **Gen Pharmacol** 1995 Sep;26(5):897-904 (33 ref.)

Metabolic disruptions in the adipocyte-hepatocyte fatty acid axis as causes of HyperapoB. Sniderman AD, et al. **Int J Obes Relat Metab Disord** 1995 May;19 Suppl 1:S27-33 (68 ref.)

Role of the endocrine pancreas in control of fuel metabolism by the liver during exercise. Wasserman DH, et al. **Int J Obes Relat Metab Disord** 1995 Oct;19 Suppl 4:S22-30 (83 ref.)

TUDCA and UDCA are incorporated into hepatocyte membranes: different sites, but similar effects. Leuschner U, et al. **Ital J Gastroenterol** 1995 Sep;27(7):376-7 (11 ref.)

Role of Ito cells in the degradation of matrix in liver. Arthur MJ. **J Gastroenterol Hepatol** 1995;10 Suppl 1:S57-62 (61 ref.)

Liver-directed gene therapy: molecular tools and current preclinical and clinical studies. Alt M, et al. **J Hepatol** 1995 Dec;23(6):746-58 (96 ref.)

Increased expression of DNA cointroduced with nuclear protein in adult rat liver. Kaneda Y, et al. **J Mol Med** 1995 Jun;73(6):289-97 (14 ref.)

Polyunsaturated fatty acid regulation of hepatic gene transcription. Clarke SD, et al. **J Nutr** 1996 Apr;126(4 Suppl):1105S-9S (52 ref.)

Polyunsaturated fatty acid regulation of hepatic gene transcription. Clarke SD, et al. **Lipids** 1996 Mar;31 Suppl:S7-11 (50 ref.)

Hepatic purine and pyrimidine metabolism: implications for antiviral chemotherapy of viral hepatitis. Shaw T, et al. **Liver** 1995 Aug;15(4):169-84 (117 ref.)

Recent advances in carrier-mediated hepatic uptake and biliary excretion of xenobiotics. Yamazaki M, et al. **Pharm Res** 1996 Apr;13(4):497-513 (77 ref.)

Hepatic fuel selection. Müller MJ. **Proc Nutr Soc** 1995 Mar; 54(1):139-50 (67 ref.)

Role of aldehyde oxidase in biogenic amine metabolism. Beedham C, et al. **Prog Brain Res** 1995;106:345-53 (52 ref.)

Targeting of drugs to the liver. Meijer DK, et al. **Semin Liver Dis** 1995 Aug;15(3):202-56 (408 ref.)

Assessment of hepatic function with xenobiotics. Reichen J. **Semin Liver Dis** 1995 Aug;15(3):189-201 (212 ref.)

Inhibition of biotransformation by nitric oxide (NO) overproduction and toxic consequences. Stadler J, et al. **Toxicol Lett** 1995 Dec;82-83:215-9 (26 ref.)

Applications and prospects for physiologically based pharmacokinetic (PB-PK) models involving pharmaceutical agents. Suzuki H, et al. **Toxicol Lett** 1995 Dec;82-83:349-55 (31 ref.)

A new voyage of discovery: transport through the hepatocyte. Gollan JL, et al. **Trans Am Clin Climatol Assoc** 1995;107:48-55; discussion 55-6 (7 ref.)

Reconstitution of apoB mRNA editing in liver by gene-transfer as a potential approach for the treatment of severe forms of polygenic hypercholesterolemia--an outline of the rationale. Greeve J, et al. **Z Gastroenterol** 1996 Jun;34 Suppl 3:27-30 (70 ref.)

[Development of metabolic parameters in the early phases of liver regeneration] Bláha V, et al. **Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove** 1995;38(1 Suppl):37-55 (67 ref.) (Eng. Abstr.) **(Cze)**

[Recent aspects of liver biochemistry: from physiopathology to functional liver exploration] Guéchot J, et al. **Ann Biol Clin (Paris)** 1995;53(7-8):373-94 (195 ref.) (Eng. Abstr.) **(Fre)**

[Regulation of liver carbohydrate and lipid metabolism by cell volume] Hue L. **Ann Endocrinol (Paris)** 1995; 56(6):599-601 (22 ref.) (Eng. Abstr.) **(Fre)**

[Liver mechanisms for the elimination of lipoproteins of intestinal origin] Khallou J, et al. **C R Seances Soc Biol Fil** 1995;189(5):899-904 (22 ref.) (Eng. Abstr.) **(Fre)**

[Cytokine gene expression in the liver of chronic hepatitis C] Fukuda R. **Nippon Rinsho** 1995 Sep;53 Suppl:629-34 (14 ref.) **(Jpn)**

[Cytokine gene expression in the liver of chronic hepatitis B] Fukuda R. **Nippon Rinsho** 1995 Oct;53 Suppl:223-7 (17 ref.) **(Jpn)**

[Role of hepatitis B virus surface antigen in HBV infection--function of human hepatic sialoglycoprotein as HBV receptor] Suzuki T, et al. **Nippon Rinsho** 1995 Oct; 53 Suppl:132-7 (28 ref.) **(Jpn)**

[Kinetic analysis of hepatobiliary transport of drugs: importance of carrier-mediated transport] Yamazaki M, et al. **Yakugaku Zasshi** 1995 Dec;115(12):953-77 (101 ref.) (Eng. Abstr.) **(Jpn)**

[Hepatic metabolism of cholesterol] García Mediavilla V, et al. **Nutr Hosp** 1996 Jan-Feb;11(1):37-42 (43 ref.) (Eng. Abstr.) **(Spa)**

PARASITOLOGY

[Parasitic diseases of the liver] Seitz HM. **Verh Dtsch Ges Pathol** 1995;79:241-8 (0 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

Type Ia glycogen storage disease with focal nodular hyperplasia in siblings. Takamura M, et al. **Acta Paediatr Jpn** 1995 Aug;37(4):510-3 (20 ref.)

Metastatic carcinoma resulting in hepar lobatum. Gravel DH, et al. **Am J Clin Pathol** 1996 May;105(5):621-7 (15 ref.)

Delayed anoxic pseudolobular necrosis (terminal hepatic necrosis) after chemo-lipiodolization for hepatocellular carcinoma. Kozakai I, et al. **Am J Gastroenterol** 1996 Jun; 91(6):1263-5 (8 ref.)

A case of hemobilia after percutaneous liver biopsy treated by transcatheter arterial embolization with Histoacryl. Murata K, et al. **Am J Gastroenterol** 1996 Jan;91(1):160 (8 ref.)

Liver biopsy complications and routine ultrasound [editorial; comment] Stotland BR, et al. **Am J Gastroenterol** 1996 Jul; 91(7):1295-6 (10 ref.) Comment on: Am J Gastroenterol 1996 Jul;91(7):1318-21.

Pancreatitis secondary to percutaneous liver biopsy-associated hemobilia. Van Os EC, et al. **Am J Gastroenterol** 1996 Mar;91(3):577-80 (18 ref.)

Methotrexate hepatotoxicity and the role of routine liver biopsy: a collective opinion [letter] Sinclair RD, et al. **Australas J Dermatol** 1995 Nov;36(4):228-9 (5 ref.)

Liver biopsy: review of methodology and complications. Tobkes AI, et al. **Dig Dis** 1995 Sep-Oct;13(5):267-74 (36 ref.)

Liver regeneration versus direct hyperplasia. Columbano A, et al. **FASEB J** 1996 Aug;10(10):1118-28 (88 ref.)

Focal nodular hyperplasia of the liver in children: review of follow-up and outcome. Reymond D, et al. **J Pediatr Surg** 1995 Nov;30(11):1590-3 (32 ref.)

Liver. III: Gadolinium-based hepatobiliary contrast agents (Gd-EOB-DTPA and Gd-BOPTA/Dimeg). Giovagnoni A, et al. **Magn Reson Imaging Clin N Am** 1996 Feb; 4(1):61-72 (34 ref.)

Liver I: Currently available gadolinium chelates. Mitchell DG. **Magn Reson Imaging Clin N Am** 1996 Feb;4(1):37-51 (15 ref.)

Liver. II: Iron oxide-based reticuloendothelial contrast agents for MR imaging. Clinical review. Petersein J, et al. **Magn Reson Imaging Clin N Am** 1996 Feb;4(1):53-60 (38 ref.)

Non-neoplastic nodular lesions in the liver. Nakanuma Y. **Pathol Int** 1995 Oct;45(10):703-14 (54 ref.)

Ductular reaction in the liver. Desmet V, et al. **Pathol Res Pract** 1995 Jul;191(6):513-24 (153 ref.)

LIVER

Detection of hepatic fibrogenesis: a review of available techniques. Wu J, et al. **Scand J Gastroenterol** 1995 Sep; 30(9):817–25 (78 ref.)

Macroregenerative (dysplastic) nodules and hepatocarcinogenesis: theoretical and clinical considerations. Theise ND. **Semin Liver Dis** 1995 Nov; 15(4):360–71 (51 ref.)

Liver biopsy in the mid–1990s: questions and answers. van Leeuwen DJ, et al. **Semin Liver Dis** 1995 Nov;15(4):340–59 (98 ref.)

A cascade–mechanism of fat storing cell activation forms the basis of the fibrogenic reaction of the liver. Gressner AM, et al. **Verh Dtsch Ges Pathol** 1995;79:1–14 (80 ref.)

Alcoholic liver disease: molecular–pathologic aspects. Zatloukal K, et al. **Verh Dtsch Ges Pathol** 1995;79:28–35 (37 ref.)

[Special issue of pathology of liver (editorial)] Voigt JJ, et al. **Ann Pathol** 1995;15(5):313–5 (12 ref.) **(Fre)**

[Hepatoportal sclerosis, nodular regenerative hyperplasia, incomplete septal cirrhosis: lesions of hepatic microcirculation?] Bernard PH, et al. **Gastroenterol Clin Biol** 1996;20(4):335–8 (30 ref.) **(Fre)**

[Histopathology of viral hepatitis C] Chevallier M, et al. **Pathol Biol (Paris)** 1995 Oct;43(8):703–8 (44 ref.) (Eng. Abstr.) **(Fre)**

[Acute intrahepatic bleeding in a male patient with focal nodular hyperplasia] Dröge C, et al. **Dtsch Med Wochenschr** 1996 Jul 12;121(28–29):902–5 (22 ref.) (Eng. Abstr.) **(Ger)**

[3–D imaging of the liver] Leppek R, et al. **Radiologe** 1995 Oct;35(10):769–77 (44 ref.) (Eng. Abstr.) **(Ger)**

[Hepatocellular nodular hyperplasias, adenomas and carcinomas] Altmann HW. **Verh Dtsch Ges Pathol** 1995; 79:84–108 (144 ref.) (Eng. Abstr.) **(Ger)**

[Sequential cellular and molecular changes during hepatocarcinogenesis] Bannasch P. **Verh Dtsch Ges Pathol** 1995;79:72–83 (65 ref.) (Eng. Abstr.) **(Ger)**

[Hepatic neoductules] Fischer HP, et al. **Verh Dtsch Ges Pathol** 1995;79:36–46 (42 ref.) (Eng. Abstr.) **(Ger)**

[Fibrogenesis and fibrolysis in the liver] Herbst H, et al. **Verh Dtsch Ges Pathol** 1995;79:15–27 (47 ref.) (Eng. Abstr.) **(Ger)**

[The risk of liver biopsy] Glaser J, et al. **Z Gastroenterol** 1995 Nov;33(11):673–6 (31 ref.) (Eng. Abstr.) **(Ger)**

[Hemobilia due to a portobiliary fistula as a complication of a fine–needle liver biopsy] De Santis M, et al. **Radiol Med (Torino)** 1996 Apr;91(4):482–5 (18 ref.) **(Ita)**

[Fas antigen expression and apoptosis in liver tissues of patients with chronic hepatitis B] Mochizuki K, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:228–33 (17 ref.) **(Jpn)**

[Benign cirrhotic nodule, macronodular cirrhosis] Higashi T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):165–7 (11 ref.) **(Jpn)**

[Sclerosing hepatic carcinoma] Kakita A, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):467–9 (11 ref.) **(Jpn)**

[Atypical adenomatous hyperplasia] Kanai T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):317–20 (10 ref.) **(Jpn)**

[Scar liver] Kawamoto H, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):585–7 (10 ref.) **(Jpn)**

[Hepatic tumors resembling hepatocellular carcinoma] Kojiro M. **Ryoikibetsu Shokogun Shirizu** 1995;(7):374–7 (14 ref.) **(Jpn)**

[Hepatocellular carcinoma of specific developmental type (massive type, pedunculated type, extrahepatic type, diffuse type, and intra–bile duct developmental type)] Nakanishi T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):495–7 (11 ref.) **(Jpn)**

[Liver cell dysplasia] Okanoue T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):273–6 (18 ref.) **(Jpn)**

[Congenital cystic fibrosis] Sakai T. **Ryoikibetsu Shokogun Shirizu** 1995;(8):370 (1 ref.) **(Jpn)**

[Potato liver] Sakanishi Y, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):582–4 (9 ref.) **(Jpn)**

[Borderline lesions of adenomatous hyperplasia and hepatocellular carcinoma] Sakon M, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):441–5 (14 ref.) **(Jpn)**

[Hepatocellular carcinoma in adenomatous hyperplasia] Shiga J. **Ryoikibetsu Shokogun Shirizu** 1995;(7):371–3 (7 ref.) **(Jpn)**

[Histiocytosis syndrome] Tsunematsu Y, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):379–87 (17 ref.) **(Jpn)**

PHYSIOLOGY

Control of energy intake by energy metabolism. Friedman MI. **Am J Clin Nutr** 1995 Nov;62(5 Suppl):1096S–1100S (45 ref.)

Cytokeratin expression, fibrillar organization, and subtle function in liver cells. Marceau N, et al. **Biochem Cell Biol** 1995 Sep–Oct;73(9–10):619–25 (56 ref.)

Does nitric oxide play a role in liver function? Milbourne EA, et al. **Cell Signal** 1995 May;7(4):313–8 (35 ref.)

Pancreastatin action in the liver: dual coupling to different G proteins. Sánchez–Margalet V, et al. **Cell Signal** 1996 Jan;8(1):9–12 (53 ref.)

Subcellular organization of calcium signalling in hepatocytes and the intact liver. Thomas AP, et al. **Ciba Found Symp** 1995;188:18–35; discussion 35–49 (56 ref.)

The extracellular matrix in hepatic regeneration. Martinez–Hernandez A, et al. **FASEB J** 1995 Nov; 9(14):1401–10 (60 ref.)

Hepatobiliary function and toxicity in vitro using isolated hepatocyte couplets. Coleman R, et al. **Gen Pharmacol** 1995 Nov;26(7):1445–53 (63 ref.)

Second international Ringberg conference: cell biology and molecular basis of liver transport. Wehner F, et al. **Hepatology** 1996 Jul;24(1):259–67 (113 ref.)

Role of hepatic receptors in controlling body fluid homeostasis. Morita H, et al. **Jpn J Physiol** 1995; 45(3):355–68 (47 ref.)

Liver and kidney in acid–base regulation. Hüssinger D. **Nephrol Dial Transplant** 1995;10(9):1536 (5 ref.)

Role of the liver in the metabolic control of eating: what we know—and what we do not know. Langhans W. **Neurosci Biobehav Rev** 1996;20(1):145–53 (122 ref.)

A cascade–mechanism of fat storing cell activation forms the basis of the fibrogenic reaction of the liver. Gressner AM, et al. **Verh Dtsch Ges Pathol** 1995;79:1–14 (80 ref.)

[Several transcription factors participate in the functioning of the alpha–fetoprotein gene promoter] Bois–Joyeux B, et al. **Bull Cancer (Paris)** 1995 Jul;82(7):541–50 (51 ref.) (Eng. Abstr.) **(Fre)**

[Anesthesia and the liver] Nöldge–Schomburg GF, et al. **Anaesthesist** 1996 Jun;45(6):567–83 (10 ref.) **(Ger)**

[Fibrogenesis and fibrolysis in the liver] Herbst H, et al. **Verh Dtsch Ges Pathol** 1995;79:15–27 (47 ref.) (Eng. Abstr.) **(Ger)**

[Control of liver proliferation: structural, functional and molecular aspects] Rabes HM. **Verh Dtsch Ges Pathol** 1995; 79:61–71 (50 ref.) (Eng. Abstr.) **(Ger)**

[The role of muscle, adipose tissue and liver in development of metabolic syndrome] Krotkiewski M. **Pol Tyg Lek** 1996 Jan;51(1–5):40–5 (55 ref.) **(Pol)**

PHYSIOPATHOLOGY

Gastrointestinal dysfunction in liver disease and portal hypertension. Gut–liver interactions revisited [editorial] Quigley EM. **Dig Dis Sci** 1996 Mar;41(3):557–61 (48 ref.)

Liver and biliary tract changes and injury associated with total parenteral nutrition: pathogenesis and prevention. Briones ER, et al. **J Am Coll Nutr** 1995 Jun;14(3):219–28 (119 ref.)

Drug administration to liver patients: aspects of liver pathophysiology. Keiding S. **Semin Liver Dis** 1995 Aug; 15(3):268–82 (115 ref.)

[Liver metabolism and acid–base balance] Zander R. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Oct; 30 Suppl 1:S48–51 (26 ref.) **(Ger)**

[Physiopathology of lipid metabolism and liver changes in obesity] Cotrozzi G, et al. **Clin Ter** 1995 Aug–Sep; 146(8–9):483–90 (53 ref.) (Eng. Abstr.) **(Ita)**

RADIATION EFFECTS

Preoperative chemoradiation for adenocarcinoma of the pancreas: excessive toxicity of prophylactic hepatic irradiation [see comments] Evans DB, et al. **Int J Radiat Oncol Biol Phys** 1995 Nov 1;33(4):913–8 (35 ref.) Comment in: Int J Radiat Oncol Biol Phys 1995 Nov 1;33(4):969–70.

RADIOGRAPHY

[Hepatic portal venous gas] Kudo M, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):595–7 (18 ref.) **(Jpn)**

RADIONUCLIDE IMAGING

[Hepatobiliary radionuclide imaging. Clinical applications] Zerbib E. **Ann Chir** 1995;49(7):637–43 (35 ref.) (Eng. Abstr.) **(Fre)**

SECRETION

Factors affecting the regulation of apo B secretion by liver cells. Hahn SE, et al. **J Clin Lab Anal** 1995;9(6):431–49 (149 ref.)

Bile secretion—models, mechanisms, and malfunctions. A perspective on the development of modern cellular and molecular concepts of bile secretion and cholestasis. Boyer JL. **J Gastroenterol** 1996 Jun;31(3):475–81 (78 ref.)

SURGERY

Planning of liver surgery using three dimensional imaging techniques. van Leeuwen MS, et al. **Eur J Cancer** 1995 Jul–Aug;31A(7–8):1212–5 (16 ref.)

Laparoscopic fenestration of giant posterolateral liver cyst. Watson DI, et al. **J Laparoendosc Surg** 1995 Aug;5(4):255–7 (7 ref.)

[Advances in liver surgery] Krawczyk M, et al. **Pol Tyg Lek** 1995 Oct;50(40–44):56–9 (28 ref.) **(Pol)**

ULTRASONOGRAPHY

Liver biopsy complications and routine ultrasound [editorial; comment] Stotland BR, et al. **Am J Gastroenterol** 1996 Jul; 91(7):1295–6 (10 ref.) Comment on: Am J Gastroenterol 1996 Jul;91(7):1318–21.

Intraoperative ultrasonography of the liver. Kruskal JB, et al. **Crit Rev Diagn Imaging** 1995;36(3):175–226 (81 ref.)

ULTRASTRUCTURE

Pathobiology of hepatic stellate cells. Mathew J, et al. **Hepatogastroenterology** 1996 Jan–Feb;43(7):72–91 (201 ref.)

[Immunohistochemical observation of Fas in the liver of chronic hepatitis B and its ultrastructural localization] Takatani M, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:234–40 (23 ref.) **(Jpn)**

VIROLOGY

Relative importance of the enterically transmitted human hepatitis viruses type A and E as a cause of foreign travel associated hepatitis. Langer BC, et al. **Arch Virol Suppl** 1996;11:171–9 (25 ref.)

Immunohistochemical detection of hepatitis C virus–related proteins in liver tissue. Sansonno D, et al. **Clin Exp Rheumatol** 1995 Nov–Dec;13 Suppl 13:S29–32 (15 ref.)

[Virus detection in the liver (editorial)] Degott C, et al. **Ann Pathol** 1995;15(5):319–23 (39 ref.) **(Fre)**

[Detection of hepatitis C virus (HCV) infected cell using in situ hybridization and PCR in situ hybridization] Kawai H, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:307–11 (23 ref.) **(Jpn)**

[The potential attachment sites of hepatitis B virus to the hepatocyte—the pre–S(2) antigen and the receptor for polymerized human serum albumin of hepatitis B virus] Matsuura K, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:125–31 (25 ref.) **(Jpn)**

[Cationic liposome–mediated expression of hepatitis C virus genome in adult rat liver] Takehara T, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:102–6 (13 ref.) **(Jpn)**

[Distribution of HCV–infected hepatocytes in chronic hepatitis C] Tanaka Y. **Nippon Rinsho** 1995 Sep;53 Suppl:618–22 (16 ref.) **(Jpn)**

[Detection of HBV genomes in liver tissue by in situ hybridization] Yamada S, et al. **Nippon Rinsho** 1995 Oct; 53 Suppl:325–30 (19 ref.) **(Jpn)**

[Immunohistochemistry and in situ hybridization in the identification of the hepatitis C virus in liver tissue] Soguero Serrano C. **Gastroenterol Hepatol** 1996 May;19(5):262–73 (113 ref.) **(Spa)**

LIVER ABSCESS

Liver abscess: an unusual manifestation of pneumococcal infection. Lund–Tønnesen S. **Scand J Infect Dis** 1995; 27(4):397–8 (5 ref.)

[Falciform ligament abscess] Kaneko K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):61–2 (14 ref.) **(Jpn)**

[Liver abscess (solitary liver abscess, multiple liver abscess, subcapsular liver abscess] Kodama T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):100–3 (16 ref.) **(Jpn)**

DIAGNOSIS

Liver abscess secondary to intrahepatic perforation of the gallbladder, presenting as a liver mass. Bakalakos EA, et al. **Am J Gastroenterol** 1996 Aug;91(8):1644–6 (12 ref.)

ETIOLOGY

Liver abscess secondary to intrahepatic perforation of the gallbladder, presenting as a liver mass. Bakalakos EA, et al. **Am J Gastroenterol** 1996 Aug;91(8):1644–6 (12 ref.)

Pyogenic liver abscess: warning indicator of silent colonic cancer. Report of a case and review of the literature. Teitz S, et al. **Dis Colon Rectum** 1995 Nov;38(11):1220–3 (18 ref.)

[Granulomatous hepatitis and granulomatous abscess of the liver] Murakami Y, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):571–4 (11 ref.) **(Jpn)**

MICROBIOLOGY

Multiple hepatic abscesses due to Yersinia enterocolitica. Strungs I, et al. **Pathology** 1995 Oct;27(4):374–7 (14 ref.)

[Pyogenic liver abscess] Yokoyama T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):39–42 (7 ref.) **(Jpn)**

LIVER ABSCESS, AMEBIC

[Hepatic amebiasis, amebic liver abscess] Nishioka M, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):45–7 (13 ref.) **(Jpn)**

COMPLICATIONS

Intrapericardial rupture of amebic liver abscess managed with percutaneous drainage of liver abscess alone. Takhtani D, et al. **Am J Gastroenterol** 1996 Jul;91(7):1460–2 (9 ref.)

SURGERY

Intrapericardial rupture of amebic liver abscess managed with percutaneous drainage of liver abscess alone. Takhtani D, et al. **Am J Gastroenterol** 1996 Jul;91(7):1460–2 (9 ref.)

LIVER CELL ADHESION MOLECULES see

CADHERINS

LIVER CIRCULATION

see related
ENTEROHEPATIC CIRCULATION
PORTAL SYSTEM

Molecular mechanisms of hepatic bile salt transport from sinusoidal blood into bile. Meier PJ. **Am J Physiol** 1995 Dec;269(6 Pt 1):G801–12 (190 ref.)

Overview of imaging in living related donor hepatic transplantation. Cheng YF, et al. **Transplant Proc** 1996 Aug; 28(4):2412–4 (19 ref.)

Circulatory disorders of the liver in dogs and cats. van den Ingh TS, et al. **Vet Q** 1995 Jun;17(2):70–6 (40 ref.)

[Late manifestation of congenital intrahepatic portacaval shunt in a healthy liver] Kerleau JM, et al.
Rev Med Interne 1995;16(8):616–8 (7 ref.) (Eng. Abstr.) **(Fre)**

DRUG EFFECTS

Effect of metformin on liver insulin metabolism and regional blood flow. Signore A, et al. **Diabetes Metab Rev** 1995 Sep;11 Suppl 1:S13–21 (48 ref.)

[Effects of sevoflurane on the area of the liver and spleen] Schindler E, et al. **Anaesthesist** 1996 Feb;45 Suppl 1:S29–31 (30 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Hemodynamic consequences of therapeutic portosystemic shunting: recent experience with transjugular intrahepatic portosystemic shunts. Somberg KA.
Semin Gastrointest Dis 1995 Jul;6(3):165–77 (58 ref.)

[Hepatoportal sclerosis, nodular regenerative hyperplasia, incomplete septal cirrhosis: lesions of hepatic microcirculation?] Bernard PH, et al.
Gastroenterol Clin Biol 1996;20(4):335–8 (30 ref.) **(Fre)**

LIVER CIRRHOSIS

[Gastroenterologic progresses in China, 1995] Fan D, et al. **Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):716–7 (0 ref.) **(Chi)**

[Benign cirrhotic nodule, macronodular cirrhosis] Higashi T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):165–7 (11 ref.) **(Jpn)**

[Cirrhosis of the liver and its definition, classification and clinical feature] Katsuta Y, et al.
Ryoikibetsu Shokogun Shirizu 1995;(7):161–4 (12 ref.) **(Jpn)**

[Hepatic fibrosis] Mizuta T, et al.
Ryoikibetsu Shokogun Shirizu 1995;(8):482–6 (20 ref.) **(Jpn)**

[Juvenile fatty cirrhosis] Nagamine T, et al.
Ryoikibetsu Shokogun Shirizu 1995;(7):185–7 (17 ref.) **(Jpn)**

[Compensated cirrhosis, decompensated cirrhosis] Satomura K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):197–9 (2 ref.) **(Jpn)**

[Juvenile cirrhosis] Takahashi T, et al.
Ryoikibetsu Shokogun Shirizu 1995;(7):181–4 (7 ref.) **(Jpn)**

[Postsinusoidal portal hypertensive syndrome] Takeda S, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):173–5 (10 ref.) **(Jpn)**

[Autoimmune liver cirrhosis] Yamada G, et al.
Ryoikibetsu Shokogun Shirizu 1995;(7):175–80 (13 ref.) **(Jpn)**

CHEMICALLY INDUCED

Wilson disease and idiopathic copper toxicosis. Scheinberg IH, et al. **Am J Clin Nutr** 1996 May;63(5):842S–5S (34 ref.)

Metals, oxidative stress, and hepatic fibrogenesis. Pietrangelo A. **Semin Liver Dis** 1996 Feb;16(1):13–30 (117 ref.)

[Drug-induced cirrhosis, chemical cirrhosis] Kawasaki H, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):210–3 (10 ref.) **(Jpn)**

CLASSIFICATION

[Child-Pugh classification in liver cirrhosis] Terada H, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):151–4 (19 ref.) **(Jpn)**

COMPLICATIONS

Glutamine—a conditionally essential amino acid in cirrhosis? Teran JC, et al. **Am J Clin Nutr** 1995 Nov;62(5):897–900 (40 ref.)

A 37-year-old woman with end-stage cirrhosis, progressive dyspnea, platypnea, and hypoxemia. Lange PA, et al.
Cleve Clin J Med 1996 Jan–Feb;63(1):8–11 (6 ref.)

Mechanisms of gas exchange impairment in patients with liver cirrhosis. Agusti AG, et al. **Clin Chest Med** 1996 Mar; 17(1):49–66 (159 ref.)

Experience with cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis. Rimola A, et al.
Diagn Microbiol Infect Dis 1995 May–Jun;22(1–2):141–5 (30 ref.)

Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Arroyo V, et al. **Hepatology** 1996 Jan;23(1):164–76 (119 ref.)

Cirrhotic cardiomyopathy: getting to the heart of the matter. Ma Z, et al. **Hepatology** 1996 Aug;24(2):451–9 (115 ref.)

Renal sodium retention in liver disease. Epstein M.
Hosp Pract (Off Ed) 1995 Sep 15;30(9):33–7, 41–2 (12 ref.)

Large-volume paracentesis in the treatment of cirrhotic patients with refractory ascites. The role of postparacentesis plasma volume expansion. Forouzandeh B, et al. **J Clin Gastroenterol** 1996 Apr;22(3):207–10 (51 ref.)

Transient abnormal myelopoiesis accompanied by hepatic fibrosis in two infants with Down syndrome. Yagihashi N, et al. **J Clin Pathol** 1995 Oct;48(10):973–5 (10 ref.)

Malnutrition in cirrhosis. Müller MJ. **J Hepatol** 1995;23 Suppl 1:31–5 (36 ref.)

[Current attitude to severe acute digestive hemorrhage caused by rupture of esophageal varices in cirrhotic patients] Castaing D, et al. **Ann Chir** 1995;49(6):463–8; discussion 468–70 (37 ref.) **(Fre)**

[Intrahepatic portasystemic shunt and hemorrhagic emergencies in the cirrhotic patient] Perarnau JM, et al. **Ann Chir** 1995;49(7):580–6; discussion 587–8 (17 ref.) (Eng. Abstr.) **(Fre)**

[Hemorrhage caused by rupture of gastroesophageal varices: should we dilate the liver or strangulate the varices? (editorial)- Calès P. **Gastroenterol Clin Biol** 1995 Nov; 19(11):899–902 (34 ref.) **(Fre)**

[Sclerosing peritonitis. A series of 10 cases and review of the literature] Carbonnel F, et al.
Gastroenterol Clin Biol 1995 Nov;19(11):876–82 (33 ref.) (Eng. Abstr.) **(Fre)**

[Lichen planus and hepatitis C virus. Apropos of 5 new cases] Hyrailles V, et al. **Gastroenterol Clin Biol** 1995 Oct; 19(10):833–6 (21 ref.) (Eng. Abstr.) **(Fre)**

[Treatment of hepatocellular carcinoma in the presence of liver cirrhosis] Ducreux M, et al. **J Chir (Paris)** 1995 Jun–Jul;132(6–7):279–86 (60 ref.) (Eng. Abstr.) **(Fre)**

[Natural history of hepatitis C virus infection] Marcellin P, et al. **Pathol Biol (Paris)** 1995 Oct;43(8):669–73 (34 ref.) (Eng. Abstr.) **(Fre)**

[A case of Pasteurella multocida subsp. multocida septicemia due to cat bites in liver cirrhosis patient] Shimizu T, et al. **Kansenshogaku Zasshi** 1995 Nov;69(11):1302–6 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Prediction of high risk group of patients with hepatitis-C-virus type liver cirrhosis developing to liver neoplasm] Tarao K, et al. **Nippon Naika Gakkai Zasshi** 1995 Dec 10;84(12):1985–91 (5 ref.) **(Jpn)**

[A case of arteriovenous malformation of the ileum complicated with decompensated liver cirrhosis: effective case of home parenteral nutrition for intestinal bleeding] Fukushima M, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Nov;92(11):1871–5 (15 ref.) **(Jpn)**

[Hepatocellular carcinoma with cirrhosis] Aoyagi Y, et al.
Ryoikibetsu Shokogun Shirizu 1995;(7):352–6 (20 ref.) **(Jpn)**

[Hepatic hilar cyst with or without cirrhosis] Fukusato T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):77–9 (11 ref.) **(Jpn)**

[Hepatic hydrothorax] Nakagawara M, et al.
Ryoikibetsu Shokogun Shirizu 1995;(8):474–7 (20 ref.) **(Jpn)**

[Cholangiocellular carcinoma associated with liver cirrhosis] Suzuki Y, et al. **Ryoikibetsu Shokogun Shirizu** 1995; (7):357–9 (20 ref.) **(Jpn)**

[Watermelon stomach and gastric carcinoid tumor in a cirrhotic patient] Oliveira CV, et al. **Arq Gastroenterol** 1995 Apr–Jun;32(2):66–70 (34 ref.) (Eng. Abstr.) **(Por)**

[Endoscopic sclerotherapy of esophageal and gastric varicose veins in liver cirrhosis with portal hypertension] Bulanov KI, et al. **Klin Khir** 1995;(4):38–40 (49 ref.) **(Rus)**

[Liver transplantation and neurological complications of hepatopathy] Gisbert C, et al. **Rev Neurol** 1995 Sep–Oct; 23(123):1033–6 (7 ref.) **(Spa)**

CONGENITAL

[A case report of congenital liver fibrosis tolerated 3 normal deliveries] Yonekawa H, et al.
Nippon Shokakibyo Gakkai Zasshi 1996 Mar;93(3):201–5 (10 ref.) **(Jpn)**

[Congenital hepatic fibrosis] Sakai T.
Ryoikibetsu Shokogun Shirizu 1995;(8):557–8 (3 ref.) **(Jpn)**

DIAGNOSIS

Detection of hepatic fibrogenesis: a review of available techniques. Wu J, et al. **Scand J Gastroenterol** 1995 Sep; 30(9):817–25 (78 ref.)

[Clinical course and prognostic value of Child-Turcotte criteria and Child-Pugh score in medically treated cirrhosis positive for HCV antibody—in comparison with cirrhosis positive for HBs Ag] Shibata M. **Nippon Rinsho** 1995 Sep; 53 Suppl:711–9 (20 ref.) **(Jpn)**

DRUG THERAPY

[Vasodilators and renal function in cirrhosis] Albillos A, et al. **Gastroenterol Hepatol** 1995 Nov;18(9):488–92 (46 ref.) **(Spa)**

EPIDEMIOLOGY

Cirrhosis: a risk factor for cryptococcal peritonitis. Mabee CL, et al. **Am J Gastroenterol** 1995 Nov;90(11):2042–5 (20 ref.)

ETIOLOGY

Present interpretation of the role of copper in Indian childhood cirrhosis. Pandit A, et al. **Am J Clin Nutr** 1996 May;63(5):830S–5S (59 ref.)

Cirrhosis: ascites and hepatorenal syndrome. Recent advances in pathogenesis. Henriksen JH. **J Hepatol** 1995; 23 Suppl 1:25–30 (74 ref.)

[Compared efficiency of three strategies of management of chronic hepatitis C. Effect on the risk of cirrhosis 8 years after diagnosis] Michel P, et al. **Gastroenterol Clin Biol** 1996 Feb;20(1):47–54 (61 ref.) (Eng. Abstr.) **(Fre)**

[Causative incidence of hepatic cirrhosis and clinical statistics of hepatic cirrhosis type C] Arakawa Y, et al.
Nippon Rinsho 1995 Sep;53 Suppl:690–705 (13 ref.) **(Jpn)**

[Influence of heavy drinking for the development of hepatocellular carcinoma in type C cirrhosis] Chiba T, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:731–5 (23 ref.) **(Jpn)**

[Clinical course and prognostic value of Child-Turcotte criteria and Child-Pugh score in medically treated cirrhosis positive for HCV antibody—in comparison with cirrhosis positive for HBs Ag] Shibata M. **Nippon Rinsho** 1995 Sep; 53 Suppl:711–9 (20 ref.) **(Jpn)**

[Progress of chronic hepatitis C to liver cirrhosis—comparison with chronic hepatitis B] Shimomura H, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:720–6 (15 ref.) **(Jpn)**

[Splenomegalic liver cirrhosis] Itakura M, et al.
Ryoikibetsu Shokogun Shirizu 1995;(7):171–4 (15 ref.) **(Jpn)**

[Cirrhosis of the liver due to hepatitis virus] Kiyosawa K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):158–60 (6 ref.) **(Jpn)**

[Progressive neuronal degeneration and childhood cirrhosis] Kumada S, et al. **Ryoikibetsu Shokogun Shirizu** 1995; (8):442–5 (15 ref.) **(Jpn)**

[Liver cirrhosis associated with metabolic disorders] Ono M, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):191–6 (26 ref.) **(Jpn)**

[Parasitic liver cirrhosis] Sekiya C.
Ryoikibetsu Shokogun Shirizu 1995;(7):168–70 (12 ref.) **(Jpn)**

[Cardiac cirrhosis] Yanagisawa N, et al.
Ryoikibetsu Shokogun Shirizu 1995;(7):188–90 (9 ref.) **(Jpn)**

METABOLISM

The pharmacokinetics of rocuronium bromide in hepatic cirrhosis. Hunter JM. **Eur J Anaesthesiol Suppl** 1995 Sep; 11:39–41 (6 ref.)

Glucose metabolism and liver cirrhosis. Nolte W, et al.
Exp Clin Endocrinol Diabetes 1995;103(2):63–74 (99 ref.)

Matrix turnover in fibrogenesis. Iredale JP.
Hepatogastroenterology 1996 Jan–Feb;43(7):56–71 (136 ref.)

Pharmacokinetics of sparfloxacin in healthy volunteers and patients: a review. Montay G. **J Antimicrob Chemother** 1996 May;37 Suppl A:27–39 (20 ref.)

Role of Ito cells in the degradation of matrix in liver. Arthur MJ. **J Gastroenterol Hepatol** 1995;10 Suppl 1:S57–62 (61 ref.)

MICROBIOLOGY

Hepatitis B-associated liver cirrhosis as an indication for liver transplantation. Jansen PL, et al.
Scand J Gastroenterol Suppl 1995;212:19–22 (21 ref.)

PATHOLOGY

Molecular mechanisms of liver fibrogenesis—a homage to the role of activated fat-storing cells. Gressner AM, et al. **Digestion** 1995;56(5):335–46 (99 ref.)

Is necroinflammation a prerequisite for fibrogenesis? Day CP. **Hepatogastroenterology** 1996 Jan–Feb;43(7):104–20 (155 ref.)

Mediators of hepatic fibrogenesis. Gressner AM.
Hepatogastroenterology 1996 Jan–Feb;43(7):92–103 (84 ref.)

Extracellular matrix proteins and hepatic fibrosis. Johnson SJ. **Hepatogastroenterology** 1996 Jan–Feb;43(7):44–55 (149 ref.)

A cascade-mechanism of fat storing cell activation forms the basis of the fibrogenic reaction of the liver. Gressner AM, et al. **Verh Dtsch Ges Pathol** 1995;79:1–14 (80 ref.)

[Liver fibrosis] Chevallier M, et al. **Ann Pathol** 1995; 15(5):372–9 (50 ref.) **(Fre)**

[Current approach to hepatic carcinogenesis. From cirrhosis to hepatocellular carcinoma] Le Bail B, et al.
Ann Pathol 1995;15(5):332–47 (92 ref.) **(Fre)**

[Histopathology of viral hepatitis C] Chevallier M, et al. **Pathol Biol (Paris)** 1995 Oct;43(8):703–8 (44 ref.) (Eng. Abstr.) **(Fre)**

[Fibrogenesis and fibrolysis in the liver] Herbst H, et al.
Verh Dtsch Ges Pathol 1995;79:15–27 (47 ref.) (Eng. Abstr.) **(Ger)**

LIVER CIRRHOSIS

PHYSIOPATHOLOGY

Clinical evolution of HCV-related chronic hepatitis. **Realdi G, et al. Clin Exp Rheumatol** 1995 Nov–Dec;13 Suppl 13:S17–21 (21 ref.)

Renal response to an acute oral protein load in healthy humans and in patients with renal disease or liver cirrhosis. De Santo NG, et al. **Semin Nephrol** 1995 Sep;15(5):433–48 (127 ref.)

A cascade-mechanism of fat storing cell activation forms the basis of the fibrogenic reaction of the liver. Gressner AM, et al. **Verh Dtsch Ges Pathol** 1995;79:1–14 (80 ref.)

[Nitric oxide and hyperdynamic circulation in liver cirrhosis] Wang Y, et al. **Chung Hua Nei Ko Tsa Chih** 1995 Nov; 34(11):779–81 (19 ref.) **(Chi)**

[Hepatoportal sclerosis, nodular regenerative hyperplasia, incomplete septal cirrhosis: lesions of hepatic microcirculation?] Bernard PH, et al. **Gastroenterol Clin Biol** 1996;20(4):335–8 (30 ref.) **(Fre)**

[Liver cirrhosis and cardiovascular system] Ponte E, et al. **Minerva Med** 1996 Jun;87(6):299–310 (80 ref.) (Eng. Abstr.) **(Ita)**

[Natriuretic peptides and the homeostasis of renal circulation in cirrhosis (editorial)] Jiménez W. **Gastroenterol Hepatol** 1995 Nov;18(9):477–9 (20 ref.) **(Spa)**

SURGERY

Peritoneovenous shunting in cirrhosis: its role in the management of refractory ascites in the 1990s [editorial; comment] Wong F, et al. **Am J Gastroenterol** 1995 Dec; 90(12):2086–9 (39 ref.) Comment on: Am J Gastroenterol 1995 Dec;90(12):2097–102.

Liver transplantation for hepatic cirrhosis in cystic fibrosis. Noble-Jamieson G, et al. **J R Soc Med** 1996;89 Suppl 27:31–7 (24 ref.)

Hepatitis B-associated liver cirrhosis as an indication for liver transplantation. Jansen PL, et al. **Scand J Gastroenterol Suppl** 1995;212:19–22 (21 ref.)

[Liver transplantation and neurological complications of hepatopathy] Gisbert C, et al. **Rev Neurol** 1995 Sep–Oct; 23(123):1033–6 (7 ref.) **(Spa)**

THERAPY

[Does interferon therapy on type C liver cirrhosis prevent the occurrence of hepatocellular carcinoma?] Harada H, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:754–8 (17 ref.) **(Jpn)**

LIVER CIRRHOSIS, ALCOHOLIC

[Alcoholic liver cirrhosis] Takakuwa T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):155–7 (9 ref.) **(Jpn)**

COMPLICATIONS

Alcohol and oesophageal varices. Sutton R, et al. **Alcohol Alcohol** 1995 Sep;30(5):581–9 (60 ref.)

Exposure to domestic cats: risk factor for Pasteurella multocida peritonitis in liver cirrhosis? Koch CA, et al. **Am J Gastroenterol** 1996 Jul;91(7):1447–9 (29 ref.)

[Intrahepatic portasystemic shunt and hemorrhagic emergencies in the cirrhotic patient] Perarnau JM, et al. **Ann Chir** 1995;49(7):580–6; discussion 587–8 (17 ref.) (Eng. Abstr.) **(Fre)**

[Techniques and indications of endoscopic treatment of esophago-gastric varices in 1995] Ramond MJ. **Gastroenterol Clin Biol** 1995 Nov;19(11):921–34 (130 ref.) **(Fre)**

IMMUNOLOGY

[Immunologic changes in alcoholic liver cirrhosis] Calamita Z, et al. **Arq Gastroenterol** 1995 Apr–Jun;32(2):79–84 (46 ref.) (Eng. Abstr.) **(Por)**

PATHOLOGY

Alcohol and liver fibrosis--pathobiochemistry and treatment. Schuppan D, et al. **Z Gastroenterol** 1995 Sep;33(9):546–50 (46 ref.)

PHYSIOPATHOLOGY

A proposed sequence of reactions leading to collagen biosynthesis, fibrosis, and hypertension in alcoholics. Brecher AS, et al. **J Investig Med** 1996 Feb;44(2):36–41 (107 ref.)

SURGERY

[Liver transplantation and neurological complications of hepatopathy] Gisbert C, et al. **Rev Neurol** 1995 Sep–Oct; 23(123):1033–6 (7 ref.) **(Spa)**

LIVER CIRRHOSIS, BILIARY

Primary biliary cirrhosis. O'Donohue J, et al. **QJM** 1996 Jan; 89(1):5–13 (78 ref.)

[Chronic non-suppurative destructive cholangitis (CNSDC)] Shiraki K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):20–3 (20 ref.) **(Jpn)**

[PBC-CAH overlapping syndrome] Takahashi H, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):565–8 (14 ref.) **(Jpn)**

CHEMICALLY INDUCED

Primary biliary cirrhosis induced by interferon-alpha therapy for hepatitis C virus infection. D'Amico E, et al. **Dig Dis Sci** 1995 Oct;40(10):2113–6 (20 ref.)

COMPLICATIONS

Recent pulmonary observations in alpha 1-antitrypsin deficiency, primary biliary cirrhosis, chronic hepatitis C, and other hepatic problems. Krowka MJ. **Clin Chest Med** 1996 Mar;17(1):67–82 (90 ref.)

[Dermatopolymyositis and primary biliary cirrhosis. A rare association] Rain F, et al. **Presse Med** 1996 Apr 6; 25(12):581–2 (12 ref.) (Eng. Abstr.) **(Fre)**

[A case of primary biliary cirrhosis complicated with autoimmune hepatitis] Nakao M, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Jan;93(1):49–53 (23 ref.) **(Jpn)**

[Hepatic granuloma] Shiga J, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):420–2 (6 ref.) **(Jpn)**

[Collagen diseases and vasculitis] Takasaki Y. **Ryoikibetsu Shokogun Shirizu** 1995;(8):329–32 (19 ref.) **(Jpn)**

DIAGNOSIS

Recognizing primary biliary cirrhosis and primary sclerosing cholangitis. Buckley SE, et al. **Am Fam Physician** 1996 Jan;53(1):195–200 (11 ref.)

DRUG THERAPY

[Primary biliary cirrhosis and ursodeoxycholic acid therapy] Makino I. **Nippon Naika Gakkai Zasshi** 1996 Mar 10; 85(3):399–403 (10 ref.) **(Jpn)**

ETIOLOGY

Current problems in primary biliary cirrhosis. Neuberger J. **Z Gastroenterol** 1993 Feb;31 Suppl 2:90–3 (26 ref.)

[Primary biliary cirrhosis in patients with Sjögren's syndrome] Furuya T, et al. **Nippon Rinsho** 1995 Oct; 53(10):2536–9 (18 ref.) (Eng. Abstr.) **(Jpn)**

[Secondary biliary cirrhosis] Ohsuga M, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):200–2 (9 ref.) **(Jpn)**

IMMUNOLOGY

Immunological control in primary biliary cirrhosis: the cytokine story [editorial] O'Donohue J, et al. **Clin Exp Immunol** 1996 Aug;105(2):199–201 (25 ref.)

Primary biliary cirrhosis: the molecule and the mimic. Coppel RL, et al. **Immunol Rev** 1995 Apr;144:17–49 (140 ref.)

Mitochondrial antigen/antibody systems in primary biliary cirrhosis: revisited. Berg PA, et al. **Liver** 1995 Dec; 15(6):281–92 (73 ref.)

Pathology and immunopathology of primary biliary cirrhosis with emphasis on bile duct lesions: recent progress. Nakanuma Y, et al. **Semin Liver Dis** 1995 Nov;15(4):313–28 (132 ref.)

[Intrahepatic cholangitis with presumably immunologic bases] Klinge O. **Verh Dtsch Ges Pathol** 1995;79:198–232 (128 ref.) (Eng. Abstr.) **(Ger)**

[Primary biliary cirrhosis--antimitochondrial antibody and the reactive antigens] Ishibashi H. **Fukuoka Igaku Zasshi** 1995 Oct;86(10):385–8 (4 ref.) **(Jpn)**

[Antimitochondrial antibody negative primary biliary cirrhosis] Aizawa Y, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):527–30 (12 ref.) **(Jpn)**

[Liver autoimmune diseases. II. Primary biliary cirrhosis] Garassini Serra MA, et al. **G E N** 1995 Jan–Mar;49(1):82–9 (55 ref.) **(Spa)**

PATHOLOGY

Pathology and immunopathology of primary biliary cirrhosis with emphasis on bile duct lesions: recent progress. Nakanuma Y, et al. **Semin Liver Dis** 1995 Nov;15(4):313–28 (132 ref.)

[Intrahepatic cholangitis with presumably immunologic bases] Klinge O. **Verh Dtsch Ges Pathol** 1995;79:198–232 (128 ref.) (Eng. Abstr.) **(Ger)**

[A case of primary biliary cirrhosis presenting histopathological similarity to idiopathic portal hypertension with huge splenomegaly] Kasuga Y, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Oct;92(10):1776–81 (18 ref.) **(Jpn)**

PHYSIOPATHOLOGY

[Primary biliary cirrhosis (PBC) (symptomatic, asymptomatic)] Okuaki Y, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):560–4 (27 ref.) **(Jpn)**

LIVER CIRRHOSIS, EXPERIMENTAL

PATHOLOGY

[Fibrogenesis and fibrolysis in the liver] Herbst H, et al. **Verh Dtsch Ges Pathol** 1995;79:15–27 (47 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Phosphodiesterase activity as a mediator of renal resistance to ANP in pathological salt retention. Lee EY, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):F3–6 (27 ref.)

Pulmonary intravascular phagocytosis in liver disease. Chang SW, et al. **Clin Chest Med** 1996 Mar;17(1):137–50 (62 ref.)

[Natriuretic peptides and the homeostasis of renal circulation in cirrhosis (editorial)] Jiménez W. **Gastroenterol Hepatol** 1995 Nov;18(9):477–9 (20 ref.) **(Spa)**

LIVER CIRRHOSIS, OBSTRUCTIVE see **LIVER CIRRHOSIS, BILIARY**

LIVER DISEASES

Polycystic liver disease. Torres VE. **Contrib Nephrol** 1995; 115:44–52 (31 ref.)

Liver disease in pregnancy. Knox TA, et al. **N Engl J Med** 1996 Aug 22;335(8):569–76 (60 ref.)

Pediatric gastroenterology. Update on metabolic liver disease. Schwarzenberg SJ, et al. **Pediatr Clin North Am** 1996 Feb;43(1):27–56 (166 ref.)

[Pathogenesis, diagnosis and therapy of hepatopulmonary syndrome] Liu S, et al. **Chung Hua Nei Ko Tsa Chih** 1995 Aug;34(8):565–7 (20 ref.) **(Chi)**

[Pseudolymphoma of the liver] Hiroshige K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):333–5 (20 ref.) **(Jpn)**

[Rickettsiosis] Hosoi H, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):109–11 (5 ref.) **(Jpn)**

[Hepatic hernia] Ishibashi H, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):509–12 (13 ref.) **(Jpn)**

[Hepatic actinomycosis] Ito A. **Ryoikibetsu Shokogun Shirizu** 1995;(7):104–5 (8 ref.) **(Jpn)**

[Hepatic listeriosis] Ito A. **Ryoikibetsu Shokogun Shirizu** 1995;(7):112–4 (16 ref.) **(Jpn)**

[Hepatic candidiasis] Ito A. **Ryoikibetsu Shokogun Shirizu** 1995;(7):63–5 (11 ref.) **(Jpn)**

[Hepatic cryptococcosis] Ito A. **Ryoikibetsu Shokogun Shirizu** 1995;(7):73–4 (6 ref.) **(Jpn)**

[Hepatic mycosis, mycotic liver abscess] Ito A. **Ryoikibetsu Shokogun Shirizu** 1995;(7):87–9 (12 ref.) **(Jpn)**

[Hepatic aspergillosis] Ito A. **Ryoikibetsu Shokogun Shirizu** 1995;(7):43–4 (5 ref.) **(Jpn)**

[Inflammatory pseudotumor of the liver] Iwamoto S, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):321–2 (9 ref.) **(Jpn)**

[Liver disease in pregnancy] Kato K. **Ryoikibetsu Shokogun Shirizu** 1995;(8):400–2 (12 ref.) **(Jpn)**

[Simple hepatic cyst] Kodama M, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):132–5 (23 ref.) **(Jpn)**

[Eosinophilic granuloma of the liver] Nakabayashi S, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):349–51 (16 ref.) **(Jpn)**

[Leptospirosis, Weil's disease] Sakurai Y. **Ryoikibetsu Shokogun Shirizu** 1995;(7):115–7 (11 ref.) **(Jpn)**

[Ectopic liver and ectopic hepatocellular carcinoma] Sasaki K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):282–4 (14 ref.) **(Jpn)**

[Gas-containing liver abscess, hepatic gas gangrene] Takesue Y, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):36–8 (7 ref.) **(Jpn)**

[Intrahepatic stones] Tanimura H. **Ryoikibetsu Shokogun Shirizu** 1995;(8):502–4 (14 ref.) **(Jpn)**

[Gummatous syphilis of the liver] Ponomarev AA. **Klin Med (Mosk)** 1995;73(5):20–3 (36 ref.) **(Rus)**

[Hepatopulmonary syndrome: a new concept. A new treatment? (clinical conference) (see comments)] Rodriguez Roisin R. **Med Clin (Barc)** 1995 Sep 9;105(7):269–74 (41 ref.) Comment in: Med Clin (Barc) 1996 Apr 20;106(15):597–8. **(Spa)**

BLOOD

Evaluating asymptomatic patients with abnormal liver function test results. Theal RM, et al. **Am Fam Physician** 1996 May 1;53(6):2111–9 (21 ref.)

[Endothelin-1 and liver disease] Regev A, et al. **Harefuah** 1995 Jun 1;128(11):703–7 (40 ref.) **(Heb)**

CHEMICALLY INDUCED

Methotrexate hepatotoxicity and the role of routine liver biopsy: a collective opinion [letter] Sinclair RD, et al. **Australas J Dermatol** 1995 Nov;36(4):228–9 (5 ref.)

Manifestations of chemically induced liver damage. Batt AM, et al. **Clin Chem** 1995 Dec;41(12 Pt 2):1882–7 (40 ref.)

Nafcillin-associated hepatotoxicity. Report of a case and review of the literature. Presti ME, et al. **Dig Dis Sci** 1996 Jan;41(1):180–4 (24 ref.)

The evaluation of potential human carcinogens: a histopathologist's point of view. Greaves P. **Exp Toxicol Pathol** 1996 Feb;48(2–3):169–74 (17 ref.)

Hepar lobatum carcinomatosum due to chemotherapy of a

metastatic breast carcinoma. Uhlmann F, et al. **Gen Diagn Pathol** 1996 Mar;141(3–4):279–84 (21 ref.)

Chronic liver disease: do alcohol and hepatitis C virus interact. Cooksley W. **J Gastroenterol Hepatol** 1996 Feb; 11(2):187–92 (45 ref.)

Drug-induced hepatotoxicity [see comments] Lee WM. **N Engl J Med** 1995 Oct 26;333(17):1118–27 (101 ref.) Comment in: N Engl J Med 1996 Mar 28;334(13):863; discussion 864. Comment in: N Engl J Med 1996 Mar 28;334(13):863–4; discussion 864. Comment in: N Engl J Med 1996 Mar 28;334(13):864.

Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity. Fromenty B, et al. **Pharmacol Ther** 1995; 67(1):101–54 (520 ref.)

The role of cytochrome P450 enzymes in hepatic and extrahepatic human drug toxicity. Park BK, et al. **Pharmacol Ther** 1995;68(3):385–424 (369 ref.)

Iron in liver diseases other than hemochromatosis. Bonkovsky HL, et al. **Semin Liver Dis** 1996 Feb;16(1):65–82 (135 ref.)

Epidemiological identification and evaluation of hepatic adverse drug reactions. Bruppacher R. **Semin Liver Dis** 1995 Aug;15(3):301–8 (40 ref.)

Antioxidant defenses in metal-induced liver damage. Sokol RJ. **Semin Liver Dis** 1996 Feb;16(1):39–46 (40 ref.)

Efficient tissue repair underlies the resiliency of postnatally developing rats to chlordecone + CCl4 hepatotoxicity. Dalu A, et al. **Toxicology** 1996 Jul 17;111(1–3):29–42 (41 ref.)

CLASSIFICATION

Non-neoplastic nodular lesions in the liver. Nakanuma Y. **Pathol Int** 1995 Oct;45(10):703–14 (54 ref.)

[Benign polycystic liver disease] Kuronuma Y, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):144–6 (17 ref.) **(Jpn)**

[Liver cysts (cystic liver diseases)] Ohmoto K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):136–43 (40 ref.) **(Jpn)**

COMPLICATIONS

Obstructive jaundice due to multiple hepatic peribiliary cysts. Stevens W, et al. **Am J Gastroenterol** 1996 Jan;91(1):155–7 (5 ref.)

Bacillus subtilis as a cause of cholangitis in polycystic kidney and liver disease [letter] Wallet F, et al. **Am J Gastroenterol** 1996 Jul;91(7):1477–8 (11 ref.)

Hepatopulmonary syndrome. A pulmonary vascular complication of liver disease. Castro M, et al. **Clin Chest Med** 1996 Mar;17(1):35–48 (81 ref.)

The hepatopulmonary syndrome. Effect of liver transplantation. Lange PA, et al. **Clin Chest Med** 1996 Mar; 17(1):115–23 (46 ref.)

Structural and pathologic changes in the lung vasculature in chronic liver disease. Schraufnagel DE, et al. **Clin Chest Med** 1996 Mar;17(1):1–15 (94 ref.)

Pulmonary manifestations of chronic liver disease. King PD, et al. **Dig Dis** 1996 Mar-Apr;14(2):73–82 (95 ref.)

A practical approach to nutritional support in liver disease. Levinson MJ. **Gastroenterologist** 1995 Sep;3(3):234–40 (38 ref.)

Hepatobiliary pruritus: what are effective treatments? Connolly CS, et al. **J Am Acad Dermatol** 1995 Nov;33(5 Pt 1):801–5 (32 ref.)

Clinical associations between thyroid and liver diseases. Huang MJ, et al. **J Gastroenterol Hepatol** 1995 May-Jun; 10(3):344–50 (70 ref.)

Management of upper gastrointestinal bleeding in the patient with chronic liver disease. Jutabha R, et al. **Med Clin North Am** 1996 Sep;80(5):1035–68 (261 ref.)

The spectrum of liver disease in systemic lupus erythematosus. van Hoek B. **Neth J Med** 1996 Jun; 48(6):244–53 (134 ref.)

Autosomal dominant polycystic liver disease as an etiology for hemoperitoneum during CCPD. Rutecki GW, et al. **Perit Dial Int** 1995 Oct-Dec;15(8):367–9 (11 ref.)

[Liver, biliary tracts and human immunodeficiency virus infection. 2: hepatobiliary complications of AIDS] Vuitton DA, et al. **Gastroenterol Clin Biol** 1996;20(3):281–93 (146 ref.) **(Fre)**

[Acute intrahepatic bleeding in a male patient with focal nodular hyperplasia] Dröge C, et al. **Dtsch Med Wochenschr** 1996 Jul 12;121(28–29):902–5 (22 ref.) (Eng. Abstr.) **(Ger)**

[Kidney transplantation in patients with diseases of the gastrointestinal tract and the liver] Kliem V, et al. **Dtsch Med Wochenschr** 1995 Dec 1;120(48):1673–7 (43 ref.) **(Ger)**

[Hepatic IgA nephropathy] Abe H, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):471–3 (15 ref.) **(Jpn)**

[Hepatopulmonary syndrome] Akahane T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):505–8 (18 ref.) **(Jpn)**

[Preeclamptic liver disease] Kato K. **Ryoikibetsu Shokogun Shirizu** 1995;(8):575–7 (12 ref.) **(Jpn)**

[Infected liver cysts] Kiryu Y, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):94–8 (19 ref.) **(Jpn)**

[Inflammatory hepatic cyst] Kurumi Y, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):83–6 (20 ref.) **(Jpn)**

[Hepatic osteodystrophy] Murawaki Y, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):478–81 (19 ref.) **(Jpn)**

CONGENITAL

Neonatal hepatobiliary disorders. Andres JM. **Clin Perinatol** 1996 Jun;23(2):321–52 (172 ref.)

[Polycystic liver disease] Furukawa R, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):102–5 (20 ref.) **(Jpn)**

[Congenital liver cysts (solitary and multiple)] Kakita A, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):125–7 (18 ref.) **(Jpn)**

[Ciliated hepatic foregut cyst and hepatic foregut cyst] Kakita A, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):128–31 (19 ref.) **(Jpn)**

[Fibropolycystic disease] Mizuta T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):120–4 (20 ref.) **(Jpn)**

[Fibropolycystic disease of the liver] Okazaki K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):90–3 (13 ref.) **(Jpn)**

DIAGNOSIS

Pyoderma gangrenosum with hepatopancreatic manifestations in a patient with rheumatoid arthritis. Hastier P, et al. **Dig Dis Sci** 1996 Mar;41(3):594–7 (9 ref.)

Systemic cat scratch disease: hepatic and splenic involvement about 3 pediatric cases. Destuynder O, et al. **Eur J Pediatr Surg** 1995 Dec;5(6):365–8 (43 ref.)

Inflammatory pseudotumor of the liver in children. A case report and review of the literature. Passalides A, et al. **Eur J Pediatr Surg** 1996 Feb;6(1):35–7 (14 ref.)

Current concepts in diagnosis and therapy of pediatric liver diseases. Burdelski M. **J Hepatol** 1995;23 Suppl 1:45–8 (25 ref.)

Liver. III: Gadolinium-based hepatobiliary contrast agents (Gd-EOB-DTPA and Gd-BOPTA/Dimeg). Giovagnoni A, et al. **Magn Reson Imaging Clin N Am** 1996 Feb; 4(1):61–72 (34 ref.)

Liver I: Currently available gadolinium chelates. Mitchell DG. **Magn Reson Imaging Clin N Am** 1996 Feb;4(1):37–51 (15 ref.)

Liver. II: Iron oxide-based reticuloendothelial contrast agents for MR imaging. Clinical review. Petersein J, et al. **Magn Reson Imaging Clin N Am** 1996 Feb;4(1):53–60 (38 ref.)

Diagnosis and therapy of autoimmune liver disease. Czaja AJ. **Med Clin North Am** 1996 Sep;80(5):973–94 (100 ref.)

Liver disease in pregnancy. Wolf JL. **Med Clin North Am** 1996 Sep;80(5):1167–87 (86 ref.)

Assessment of hepatic function with xenobiotics. Reichen J. **Semin Liver Dis** 1995 Aug;15(3):189–201 (212 ref.)

Liver biopsy in the mid-1990s: questions and answers. van Leeuwen DJ, et al. **Semin Liver Dis** 1995 Nov;15(4):340–59 (98 ref.)

Magnetic resonance imaging of focal liver lesions. Schnall M. **Semin Roentgenol** 1995 Oct;30(4):347–61 (34 ref.)

[Diagnosis of hepatic siderosis] Turlin B, et al. **Ann Pathol** 1995;15(5):365–71 (40 ref.) **(Fre)**

[Imaging of ciliated hepatic or biliary cysts. 4 cases] Benlolo D, et al. **Gastroenterol Clin Biol** 1996;20(5):497–501 (10 ref.) (Eng. Abstr.) **(Fre)**

[When is magnetic resonance imaging of liver diseases required?] Vilgrain V. **Gastroenterol Clin Biol** 1996;20(5 Pt 2):B134–9 (24 ref.) **(Fre)**

[HIV infection: findings in liver and bile ducts] Jablonowski H. **Bildgebung** 1995 Dec;62(4):260–70 (89 ref.) (Eng. Abstr.) **(Ger)**

[The endorem tolerance profile] Laniado M, et al. **Radiologe** 1995 Nov;35(11 Suppl 2):S266–70 (16 ref.) (Eng. Abstr.) **(Ger)**

[Value of MRI in diagnosis of focal liver lesions] Taupitz M, et al. **Radiologe** 1995 Nov;35(11 Suppl 2):S243–7 (39 ref.) (Eng. Abstr.) **(Ger)**

[1995 literature review: diagnostic imaging of the liver] Merkle E. **Rontgenpraxis** 1996 Mar;49(3):64–70 (100 ref.) **(Ger)**

[Inflammatory pseudotumor of the liver. Case report of a rare differential diagnosis of hepatocellular carcinoma] Strohm WD, et al. **Z Gastroenterol** 1996 Feb;34(2):132–7 (45 ref.) (Eng. Abstr.) **(Ger)**

[Solitary non-parasitic liver cyst] Kuronuma Y, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):113–5 (9 ref.) **(Jpn)**

[Intrahepatic hematoma and subcapsular hematoma] Yamamoto M. **Ryoikibetsu Shokogun Shirizu** 1995; (8):499–501 (12 ref.) **(Jpn)**

[Hepatic iron overload] Yoshida H, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):493–5 (12 ref.) **(Jpn)**

DRUG THERAPY

Diagnosis and therapy of autoimmune liver disease. Czaja AJ. **Med Clin North Am** 1996 Sep;80(5):973–94 (100 ref.)

Drug administration to liver patients: aspects of liver pathophysiology. Keiding S. **Semin Liver Dis** 1995 Aug; 15(3):268–82 (115 ref.)

Targeting of drugs to the liver. Meijer DK, et al. **Semin Liver Dis** 1995 Aug;15(3):202–56 (408 ref.)

[Bile acids in liver diseases—current indications] Stiehl A. **Ther Umsch** 1995 Oct;52(10):682–6 (29 ref.) (Eng. Abstr.) **(Ger)**

[Somatostatin and its analogs in the treatment of gastrointestinal and liver diseases] Feu F, et al. **Gastroenterol Hepatol** 1996 Feb;19(2):68–77 (102 ref.) **(Spa)**

ETIOLOGY

Hepatobiliary complications of inflammatory bowel disease. Bhutani MS, et al. **Am Fam Physician** 1995 Oct; 52(5):1440–4 (19 ref.)

Epstein-Barr virus-related localized hepatic lymphoproliferative disorders after liver transplantation. Raymond E, et al. **Cancer** 1995 Oct 15;76(8):1344–51 (36 ref.)

Liver dysfunction in the early post-bone marrow transplant period. Storek J. **Cas Lek Cesk** 1996 May 15;135(10):295–8 (64 ref.)

Cryoglobulinemia: recent findings in cutaneous and extracutaneous manifestations. Davis MD, et al. **Int J Dermatol** 1996 Apr;35(4):240–8 (50 ref.)

Liver and biliary tract changes and injury associated with total parenteral nutrition: pathogenesis and prevention. Briones ER, et al. **J Am Coll Nutr** 1995 Jun;14(3):219–28 (119 ref.)

Managing HIV. Part 5: Treating secondary outcomes. 5.3 HIV, gastrointestinal and hepatobiliary disease. Sievert W, et al. **Med J Aust** 1996 Mar 18;164(6):360–5 (25 ref.)

Hepatotoxicity of herbal remedies and mushrooms. Larrey D, et al. **Semin Liver Dis** 1995 Aug;15(3):183–8 (63 ref.)

Spontaneous liver rupture in amyloidosis. Ooi LL, et al. **Surgery** 1996 Jul;120(1):117–9 (9 ref.)

[Pulmonary disorders in portal hypertension. Pulmonary hypertension and hepatopulmonary syndrome] Wettstein M, et al. **Dtsch Med Wochenschr** 1996 Apr 12; 121(15):487–91 (47 ref.) **(Ger)**

[Hepatic complications in parenteral nutrition] Müller MJ. **Z Gastroenterol** 1996 Jan;34(1):36–40 (50 ref.) (Eng. Abstr.) **(Ger)**

[Physiopathology of lipid metabolism and liver changes in obesity] Cotrozzi G, et al. **Clin Ter** 1995 Aug-Sep; 146(8–9):483–90 (53 ref.) (Eng. Abstr.) **(Ita)**

[Liver disease in systemic lupus erythematosus] Suzuki A, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Feb; 18(1):53–9 (21 ref.) (Eng. Abstr.) **(Jpn)**

[Therapy of diabetes mellitus associated with liver disease] Totani E, et al. **Nippon Naika Gakkai Zasshi** 1996 Apr 10;85(4):525–9 (6 ref.) **(Jpn)**

[Liver diseases and essential trace elements] Suzuki K, et al. **Nippon Rinsho** 1996 Jan;54(1):85–92 (18 ref.) (Eng. Abstr.) **(Jpn)**

[Disorders of fructose and galactose metabolism] Abukawa D, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):371–4 (12 ref.) **(Jpn)**

[Hepatobiliary disease in malignant lymphoma, leukemia, and MDS] Ishikawa T. **Ryoikibetsu Shokogun Shirizu** 1995; (8):375–8 (21 ref.) **(Jpn)**

[Liver dysfunction in endocrine disorders (thyroid diseases)] Kanamori A, et al. **Ryoikibetsu Shokogun Shirizu** 1995; (8):396–9 (13 ref.) **(Jpn)**

[Traumatic hepatic cyst] Kurumi Y, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):87–9 (17 ref.) **(Jpn)**

[Hepatic dysfunction associated with renal transplantation] Nakashima T, et al. **Ryoikibetsu Shokogun Shirizu** 1995; (8):544–6 (20 ref.) **(Jpn)**

[Parasitic cyst of the liver] Ohmoto K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):109–12 (18 ref.) **(Jpn)**

[Postoperative liver damage, postoperative jaundice, and benign postoperative cholestasis] Ouchi K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):538–40 (6 ref.) **(Jpn)**

[The liver in shock and acute heart failure] Sekiyama T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):341–4 (9 ref.) **(Jpn)**

[Hepatic granuloma] Shiga J, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):420–2 (6 ref.) **(Jpn)**

[Liver injury due to thorotrast] Ukida M. **Ryoikibetsu Shokogun Shirizu** 1995;(8):52–4 (6 ref.) **(Jpn)**

[Hepatic biloma] Watanabe H, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):106–8 (22 ref.) **(Jpn)**

[The liver in congestive heart failure] Yanagisawa N, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):294–6 (9 ref.) **(Jpn)**

[Hepatic changes in patients with nonspecific ulcerative colitis] Pontes RM, et al. **Arq Gastroenterol** 1995 Apr-Jun; 32(2):48–53 (62 ref.) (Eng. Abstr.) **(Por)**

[Spontaneous hepatic rupture during pregnancy. Report of a case. Review of the literature] Villarreal Peral C, et al. **Ginecol Obstet Mex** 1995 Sep;63:395–7 (9 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

Inherited liver diseases in adults. Kumar A, et al. **West J Med** 1995 Oct;163(4):382–6 (20 ref.)

LIVER DISEASES

IMMUNOLOGY

Activated liver macrophages in human liver diseases. Yamamoto K, et al. **J Gastroenterol Hepatol** 1995;10 Suppl 1:S72–6 (29 ref.)

Molecular basis of drug-induced immunological liver injury. Van Pelt FN, et al. **Semin Liver Dis** 1995 Aug; 15(3):283–300 (133 ref.)

[Immunopathology of chronic liver diseases] Meyer zum Büschenfelde KH. **Verh Dtsch Ges Pathol** 1995;79:186–97 (38 ref.) (Eng. Abstr.) **(Ger)**

[Autoantibodies in liver diseases: interpretation and pathogenic importance] Pons Romero F, et al. **Gastroenterol Hepatol** 1996 Jun-Jul;19(6):326–33 (70 ref.) **(Spa)**

METABOLISM

Mediators, cytokines, and growth factors in liver-lung interactions. Panos RJ, et al. **Clin Chest Med** 1996 Mar; 17(1):151–69 (220 ref.)

Clinical pharmacokinetics of therapeutic bile acids. Crosignani A, et al. **Clin Pharmacokinet** 1996 May; 30(5):333–58 (156 ref.)

Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. An update. Morgan DJ, et al. **Clin Pharmacokinet** 1995 Nov; 29(5):370–91 (145 ref.)

Nitric oxide and liver disease. Abrams GA, et al. **Gastroenterologist** 1995 Sep;3(3):220–33 (187 ref.)

Nutritional and metabolic considerations of the adult liver transplant candidate and organ donor. Driscoll DF, et al. **Nutrition** 1995 May-Jun;11(3):255–63 (85 ref.)

PATHOLOGY

Alterations of intermediate filaments in various histopathological conditions. Cadrin M, et al. **Biochem Cell Biol** 1995 Sep-Oct;73(9–10):627–34 (103 ref.)

The evaluation of potential human carcinogens: a histopathologist's point of view. Greaves P. **Exp Toxicol Pathol** 1996 Feb;48(2–3):169–74 (17 ref.)

Hepatic stellate (ITO) cells: expanding roles for a liver-specific pericyte. Pinzani M. **J Hepatol** 1995 Jun; 22(6):700–6 (61 ref.)

Solitary nonparasitic cysts of the liver: the Boston Children's Hospital experience. Donovan MJ, et al. **Pediatr Pathol Lab Med** 1995 May-Jun;15(3):419–28 (30 ref.)

Pathology and biopsy diagnosis of the transplanted liver. Portmann B, et al. **Verh Dtsch Ges Pathol** 1995;79:277–90 (40 ref.)

Alcoholic liver disease: molecular-pathologic aspects. Zatloukal K, et al. **Verh Dtsch Ges Pathol** 1995;79:28–35 (37 ref.)

[Role of fine needle puncture in the diagnosis of a hepatic mass] Fabre M, et al. **Ann Pathol** 1995;15(5):380–7 (31 ref.) **(Fre)**

[Immunohistochemistry in liver pathology] Selves J, et al. **Ann Pathol** 1995;15(5):388–95 (56 ref.) **(Fre)**

[Special issue of pathology of liver (editorial)] Voigt JJ, et al. **Ann Pathol** 1995;15(5):313–5 (12 ref.) **(Fre)**

[Hepatic neoductules] Fischer HP, et al. **Verh Dtsch Ges Pathol** 1995;79:36–46 (42 ref.) (Eng. Abstr.) **(Ger)**

[Immunopathology of chronic liver diseases] Meyer zum Büschenfelde KH. **Verh Dtsch Ges Pathol** 1995;79:186–97 (38 ref.) (Eng. Abstr.) **(Ger)**

[The risk of liver biopsy] Glaser J, et al. **Z Gastroenterol** 1995 Nov;33(11):673–6 (31 ref.) (Eng. Abstr.) **(Ger)**

[Hepatic hilar cyst with or without cirrhosis] Fukusato T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):77–9 (11 ref.) **(Jpn)**

[Neonatal hepatic necrosis] Gotani T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):552–3 (6 ref.) **(Jpn)**

[Anomalous positions of the gallbladder] Higashi S. **Ryoikibetsu Shokogun Shirizu** 1996;(9):363–6 (13 ref.) **(Jpn)**

[Hepatic ciliated cyst] Ohmoto K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):99–101 (15 ref.) **(Jpn)**

[Cystic hepatic neoplasm] Ohmoto K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):116–9 (20 ref.) **(Jpn)**

[Sarcoidosis of the liver and intrahepatic biliary system] Tachibana T. **Ryoikibetsu Shokogun Shirizu** 1995;(8):333–6 (22 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Lung-liver interactions in sepsis and multiple organ failure syndrome. Matuschak GM. **Clin Chest Med** 1996 Mar; 17(1):83–98 (191 ref.)

Pulmonary intravascular macrophages. Role in acute lung injury. Warner AE. **Clin Chest Med** 1996 Mar;17(1):125–35 (60 ref.)

Gastrointestinal dysfunction in liver disease and portal hypertension. Gut-liver interactions revisited [editorial] Quigley EM. **Dig Dis Sci** 1996 Mar;41(3):557–61 (48 ref.)

Serum bile acids: physiology and clinical relevance [see comments] Reichel C, et al. **Eur J Gastroenterol Hepatol** 1995 Oct;7(10):951–3 (13 ref.) Comment in: Eur J Gastroenterol Hepatol 1995 Oct;7(10):1011.

The role of mdr2 P-glycoprotein in biliary lipid secretion. Cross-talk between cancer research and biliary physiology. Oude Elferink RP, et al. **J Hepatol** 1995 Nov;23(5):617–25 (62 ref.)

The hepatic glycogen storage diseases—problems beyond childhood. Lee PJ, et al. **J Inherit Metab Dis** 1995; 18(4):462–72 (42 ref.)

[Lipid mediators and liver injury] Liu Y, et al. **Sheng Li Ko Hsueh Chin Chan** 1995 Oct;26(4):363–6 (10 ref.) **(Chi)**

[Methods and clinical significance of an oral tolerance test of essential trace element, especially an oral zinc tolerance test] Arakawa Y, et al. **Nippon Rinsho** 1996 Jan; 54(1):162–71 (35 ref.) (Eng. Abstr.) **(Jpn)**

[Hepatic reticuloendothelial failure (HREF)] Masumoto A, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):437–9 (20 ref.) **(Jpn)**

[Prostaglandins in chronic liver diseases] Loginov AS, et al. **Vestn Ross Akad Med Nauk** 1995;(12):32–8 (83 ref.) (Eng. Abstr.) **(Rus)**

RADIOGRAPHY

Computed tomography imaging of focal hepatic lesions. Jacobs JE, et al. **Semin Roentgenol** 1995 Oct;30(4):308–23 (48 ref.)

RADIONUCLIDE IMAGING

Nuclear imaging of solid hepatic masses. Kinnard MF, et al. **Semin Roentgenol** 1995 Oct;30(4):375–95 (140 ref.)

SURGERY

Liver, biliary tract, and pancreas [editorial] Rikkers LF, et al. **Curr Opin Gen Surg** 1993;:233–8 (16 ref.)

Liver transplantation. Shaw BW Jr. **Curr Opin Gen Surg** 1993;:239–48 (50 ref.)

What's new in gastrointestinal and hepatobiliary surgery. Meyers WC. **J Am Coll Surg** 1996 Feb;182(2):100–6 (52 ref.)

Laparoscopic fenestration of giant posterolateral liver cyst. Watson DI, et al. **J Laparoendosc Surg** 1995 Aug;5(4):255–7 (7 ref.)

[Development of safer liver surgery (editorial)] Belghiti J. **Gastroenterol Clin Biol** 1996 Mar;20(2):129–31 (24 ref.) **(Fre)**

[Liver transplantation in children] Valayer J. **Presse Med** 1995 Oct 21;24(31):1438–43 (21 ref.) (Eng. Abstr.) **(Fre)**

[Orthotopic liver transplantation in therapy of advanced polycystic liver disease] Klupp J, et al. **Chirurg** 1996 May; 67(5):515–21 (25 ref.) (Eng. Abstr.) **(Ger)**

[Does the primary disease recur following liver transplantation?] Renner EL. **Ther Umsch** 1995 Sep; 52(9):572–80 (61 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Artificial liver. Evolution and future perspectives. Rozga J, et al. **ASAIO J** 1995 Oct-Dec;41(4):831–7 (58 ref.)

Liver-directed gene therapy: prospects and problems. Strauss M. **Gene Ther** 1994 May;1(3):156–64 (66 ref.)

Liver-directed gene therapy: molecular tools and current preclinical and clinical studies. Alt M, et al. **J Hepatol** 1995 Dec;23(6):746–58 (96 ref.)

Current concepts in diagnosis and therapy of pediatric liver diseases. Burdelski M. **J Hepatol** 1995;23 Suppl 1:45–8 (25 ref.)

Liver-directed gene transfer and application to therapy. Sandig V, et al. **J Mol Med** 1996 Apr;74(4):205–12 (89 ref.)

Liver-directed gene therapy. Nunes FA, et al. **Med Clin North Am** 1996 Sep;80(5):1201–13 (74 ref.)

Peritoneal dialysis in liver disorders. Selgas R, et al. **Perit Dial Int** 1996;16 Suppl 1:S215–9 (35 ref.)

Prospects of therapy of liver diseases with foreign genes. Kormis KK, et al. **Semin Liver Dis** 1995 Aug;15(3):257–67 (184 ref.)

[Hepatocyte culture in the study of liver diseases] Wang Y, et al. **Chung Hua I Hsueh Tsa Chih** 1995 Jul;75(7):437–9 (14 ref.) **(Chi)**

[Indications for pregnancy termination in cases of pre-eclampsia, hypertension, intrauterine growth retardation, liver and heart disease] Uzan S, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24 Suppl 1:33–40 (54 ref.) **(Fre)**

[1995 gastroenterology update—II] Layer P, et al. **Med Klin** 1996 Apr 1;91 Suppl 1:81–8 (88 ref.) **(Ger)**

ULTRASONOGRAPHY

Ultrasound of focal hepatic lesions. Nisenbaum HL, et al. **Semin Roentgenol** 1995 Oct;30(4):324–46 (53 ref.)

VETERINARY

Diagnosis and treatment of hepatic disease. Strombeck DR. **Vet Q** 1995 Apr;17 Suppl 1:S14–5 (0 ref.)

Circulatory disorders of the liver in dogs and cats. van den Ingh TS, et al. **Vet Q** 1995 Jun;17(2):70–6 (40 ref.)

VIROLOGY

Chronic liver disease: do alcohol and hepatitis C virus interact. Cooksley W. **J Gastroenterol Hepatol** 1996 Feb; 11(2):187–92 (45 ref.)

LIVER DISEASES, ALCOHOLIC

[30-year progress of Japanese Medical Society of Alcohol and Drug Studies—present status and future of alcohol studies] Takase S. **Nihon Arukoru Yakubutsu Igakkai Zasshi** 1996 Feb; 31(1):54–66 (25 ref.) **(Jpn)**

[Alcoholic liver disease] Kato S, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):3–6 (10 ref.) **(Jpn)**

COMPLICATIONS

Alcohol, hepatotropic viruses, and hepatocellular carcinoma [editorial] Nalpas B, et al. **Alcohol Clin Exp Res** 1995 Oct; 19(5):1089–95 (96 ref.)

[Hepatitis C virus infection in alcoholic patients with chronic liver disease] Sata M, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:852–7 (18 ref.) **(Jpn)**

DIAGNOSIS

[Who has alcoholic liver disease?] Salaspuro M. **Duodecim** 1994;110(20):1895–900 (22 ref.) **(Fin)**

MORTALITY

Prognosis of alcoholic liver disease—100 years on and the need for international standards and guidelines. Harris D, et al. **Alcohol Alcohol** 1995 Sep;30(5):591–600 (50 ref.)

PATHOLOGY

Alcoholic liver disease: molecular-pathologic aspects. Zatloukal K, et al. **Verh Dtsch Ges Pathol** 1995;79:28–35 (37 ref.)

[Alcoholic liver disease. From morphology to pathogenesis] Bedossa P, et al. **Ann Pathol** 1995;15(5):324–31 (47 ref.) **(Fre)**

[Histopathological characteristics of alcoholic liver injury in cases with serum HCV markers] Uchikoshi T, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:858–65 (15 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Ethanol-induced oxidative stress in the liver. Kurose I, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1 Suppl):77A–85A (88 ref.)

Cellular signals in alcohol-induced liver injury: a review. Lands WE. **Alcohol Clin Exp Res** 1995 Aug;19(4):928–38 (112 ref.)

Alcohol and endotoxin: another path to alcoholic liver injury? Schenker S, et al. **Alcohol Clin Exp Res** 1995 Oct; 19(5):1364–6 (40 ref.)

Alcoholic liver disease: pathobiological aspects. Lindros KO. **J Hepatol** 1995;23 Suppl 1:7–15 (68 ref.)

Alcoholic liver disease: molecular-pathologic aspects. Zatloukal K, et al. **Verh Dtsch Ges Pathol** 1995;79:28–35 (37 ref.)

[Alcohol and free radicals: from basic research to clinical prospects] Nordmann R, et al. **Bull Acad Natl Med** 1995 Dec;179(9):1839–50; discussion 1850–3 (41 ref.) (Eng. Abstr.) **(Fre)**

[Physiopathology and therapy of alcoholic liver disease] Ishii H. **Nippon Naika Gakkai Zasshi** 1996 Mar 10;85(3):404–7 (11 ref.) **(Jpn)**

SURGERY

Liver transplantation for alcoholic liver disease [editorial] Sherman D, et al. **J Hepatol** 1995 Oct;23(4):474–9 (32 ref.)

THERAPY

Nutritional support in liver disease. Cabré E, et al. **Eur J Gastroenterol Hepatol** 1995 Jun;7(6):528–32 (42 ref.)

[New suggestions for the management of alcoholic liver diseases] Jmelnitzky AC. **Acta Gastroenterol Latinoam** 1995;25(2):73–84 (34 ref.) (Eng. Abstr.) **(Spa)**

LIVER DISEASES, PARASITIC

[Hepatic toxocariasis] Ishibashi H, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):48–50 (20 ref.) **(Jpn)**

[Liver cryptosporidiosis] Ito A, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):75–8 (13 ref.) **(Jpn)**

[Clonorchiasis] Kawashima T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):70–2 (6 ref.) **(Jpn)**

[Schistosomiasis japonica of the liver] Kawashima T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):97–9 (6 ref.) **(Jpn)**

[Schistosoma haematobium] Kawashima T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):106–8 (5 ref.) **(Jpn)**

[Toxoplasmosis of the liver] Kume H, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):93–5 (9 ref.) **(Jpn)**

[Infectious diseases of the liver due to protozoa] Kume H, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):82–6 (8 ref.) **(Jpn)**

[Hepatic ascariasis] Nakasaki H, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):58–60 (16 ref.) **(Jpn)**

COMPLICATIONS

[Parasitic cyst of the liver] Ohmoto K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):109–12 (18 ref.) **(Jpn)**

EPIDEMIOLOGY

Duodenal and hepatic toxoplasmosis in a patient with HIV infection: review of the literature. Bonacini M, et al. **Am J Gastroenterol** 1996 Sep;91(9):1838–40 (13 ref.)

PARASITOLOGY

[Porocephalosis, a little known parasitosis, literature review and a Congolese case report] Faisy C, et al. **Med Trop (Mars)** 1995;55(3):258–62 (26 ref.) (Eng. Abstr.) **(Fre)**

[Parasitic liver disease] Sekiya C. **Ryoikibetsu Shokogun Shirizu** 1995;(7):66–9 (10 ref.) **(Jpn)**

PATHOLOGY

[Parasitic diseases of the liver] Seitz HM. **Verh Dtsch Ges Pathol** 1995;79:241–8 (0 ref.) (Eng. Abstr.) **(Ger)**

LIVER FAILURE

[Late onset hepatic failure (LOHF)] Komada T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):259–61 (14 ref.) **(Jpn)**

[Liver failure (hepatic failure)] Muto Y, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):239–42 (6 ref.) **(Jpn)**

BLOOD

[Clinical pharmacokinetics of azithromycin] Singlas E. **Pathol Biol (Paris)** 1995 Jun;43(6):505–11 (16 ref.) (Eng. Abstr.) **(Fre)**

CHEMICALLY INDUCED

Acetaminophen toxicity: report of case and review of the literature. Schueler L, et al. **J Oral Maxillofac Surg** 1995 Oct;53(10):1208–12 (13 ref.)

COMPLICATIONS

Nutritional support during liver failure. Gecelter GR, et al. **Crit Care Clin** 1995 Jul;11(3):675–83 (52 ref.)

Renal dysfunction associated with liver transplantation. Jindal RM, et al. **Postgrad Med J** 1995 Sep;71(839):513–24 (130 ref.)

Pulmonary hypertension: considerations in the liver transplant candidate. Kuo P. **Transpl Int** 1996;9(2):141–50 (55 ref.)

ETIOLOGY

End stage liver disease in a 13-year old secondary to hepatitis C and hemochromatosis. Miller M, et al. **Am J Gastroenterol** 1996 Jul;91(7):1427–9 (20 ref.)

Endoscopic stenting of gallbladder for symptomatic cholelithiasis in patients with end-stage liver disease awaiting orthotopic liver transplantation. Shrestha R, et al. **Am J Gastroenterol** 1996 Mar;91(3):595–8 (21 ref.)

Hepatitis C and liver transplantation. Chazouilleres O, et al. **J Gastroenterol Hepatol** 1995 Jul–Aug;10(4):471–80 (69 ref.)

Orthotopic liver transplantation in hemophilia B: a case report. Kadry Z, et al. **Transpl Int** 1995;8(6):485–7 (26 ref.)

[Liver failure after severe trauma] Omori Y, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):252–5 (20 ref.) **(Jpn)**

[Post-operative liver failure] Omori Y, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):256–8 (18 ref.) **(Jpn)**

RADIONUCLIDE IMAGING

[Hepatobiliary radionuclide imaging. Clinical applications] Zerbib E. **Ann Chir** 1995;49(7):637–43 (35 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Use of mammalian liver cells for artificial liver support. Jauregui HO, et al. **Cell Transplant** 1996 May–Jun; 5(3):353–67 (130 ref.)

Orthotopic liver transplantation in hemophilia B: a case report. Kadry Z, et al. **Transpl Int** 1995;8(6):485–7 (26 ref.)

[Liver transplantation as school for visceral surgery—experiences for perioperative management] Neuhaus P, et al. **Chirurg** 1996 Apr;67(4):341–7 (31 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Treatment of hepatic failure—1996: current concepts and progress toward liver dialysis. Sussman NL, et al. **Am J Kidney Dis** 1996 May;27(5):605–21 (138 ref.)

LIVER FAILURE, ACUTE

Controversies and current trends in subacute hepatic failure. Singh NK, et al. **J Assoc Physicians India** 1995 Oct; 43(10):694, 699–701 (25 ref.)

[Acute liver failure] Ohnishi H, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):243–6 (8 ref.) **(Jpn)**

DIAGNOSIS

[Focus: fulminant and subfulminant hepatic insufficiency] Fellay M, et al. **Rev Med Suisse Romande** 1996 Jun; 116(6):483–91 (36 ref.) **(Fre)**

[Diagnosis of acute liver failure] Paar WD, et al. **Dtsch Med Wochenschr** 1996 Mar 8;121(10):305–9 (27 ref.) **(Ger)**

ETIOLOGY

Hepatic steatosis revealing celiac disease: a case complicated by transitory liver failure [letter] Cassagnou M, et al. **Am J Gastroenterol** 1996 Jun;91(6):1291–2 (8 ref.)

[Acute-on-chronic liver failure] Ohnishi H, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):217–9 (6 ref.) **(Jpn)**

THERAPY

Mass transfer limitations to the performance of membrane bioartificial liver support devices. Catapano G. **Int J Artif Organs** 1996 Jan;19(1):18–35 (70 ref.)

Hybrid liver support [editorial] Gerlach J. **Int J Artif Organs** 1996 Jan;19(1):1–2 (8 ref.)

Assessment of bioartificial liver support in acute liver failure. Hughes RD, et al. **Int J Artif Organs** 1996 Jan;19(1):3–6 (18 ref.)

Role of transport proteins in bioartificial liver assist systems. Mitzner S, et al. **Int J Artif Organs** 1996 Jan;19(1):49–52 (6 ref.)

Hepatocyte encapsulation—initial intentions and new aspects for its use in bioartificial liver support. Stange J, et al. **Int J Artif Organs** 1996 Jan;19(1):45–8 (26 ref.)

[Conservative therapy of acute liver failure] Paar WD, et al. **Dtsch Med Wochenschr** 1996 Mar 15;121(11):343–5 (27 ref.) **(Ger)**

LIVER FAILURE, FULMINANT see **HEPATIC ENCEPHALOPATHY**

LIVER FIBROSIS see **LIVER CIRRHOSIS**

LIVER FLUKE see **FASCIOLA HEPATICA**

LIVER FUNCTION TESTS

Gamma-glutamyltranspeptidase and carbohydrate deficient transferrin: alternative measures of excessive alcohol consumption. Litten RZ, et al. **Alcohol Clin Exp Res** 1995 Dec;19(6):1541–6 (37 ref.)

Evaluation of abnormal liver function tests. Moseley RH. **Med Clin North Am** 1996 Sep;80(5):887–906 (96 ref.)

Assessment of hepatic function with xenobiotics. Reichen J. **Semin Liver Dis** 1995 Aug;15(3):189–201 (212 ref.)

[Hepatic complications in parenteral nutrition] Müller MJ. **Z Gastroenterol** 1996 Jan;34(1):36–40 (50 ref.) (Eng. Abstr.) **(Ger)**

[Rational laboratory diagnosis of cholestasis syndrome] Nilius R, et al. **Z Gastroenterol** 1993 Feb;31 Suppl 2:33–8 (24 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Evaluating asymptomatic patients with abnormal liver function test results. Theal RM, et al. **Am Fam Physician** 1996 May 1;53(6):2111–9 (21 ref.)

Evaluation of hepatic function. Ozawa K, et al. **Curr Opin Gen Surg** 1994;:17–23 (31 ref.)

[Indocyanine green (ICG)] Miyazaki A, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:1074–7 (9 ref.) **(Jpn)**

LIVER GLYCOGEN

BIOSYNTHESIS

[Regulation of liver carbohydrate and lipid metabolism by cell volume] Hue L. **Ann Endocrinol (Paris)** 1995; 56(6):599–601 (22 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

[Endotoxemia and carbonhydrate metabolism] Zhai Z, et al. **Chung Hua Cheng Hsing Shao Shang Wai Ko Tsa Chih** 1996 Jan;12(1):62–5 (21 ref.) **(Chi)**

LIVER MICROSOMES see **MICROSOMES, LIVER**

LIVER MITOCHONDRIA see **MITOCHONDRIA, LIVER**

LIVER NEOPLASMS

Recent advances in clinical research of hepatocellular carcinoma in China. Tang Z. **Chin Med J (Engl)** 1995 Aug; 108(8):568–70 (0 ref.)

Primary liver cancers. Weimann A, et al. **Curr Opin Oncol** 1995 Jul;7(4):387–96 (84 ref.)

Hepatocellular carcinoma: clinical features, evaluation and treatment. Khurshid H, et al. **JPMA J Pak Med Assoc** 1995 May;45(5):136–43 (85 ref.)

Hepatic neoplasia: reflections and ruminations. Aterman K. **Virchows Arch** 1995;427(1):1–18 (361 ref.)

[Gastroenterologic progresses in China, 1995] Fan D, et al. **Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):716–7 (0 ref.) **(Chi)**

[Prognostic factors of hepatocellular carcinoma: a multivariate analysis in 113 patients] Ychou M, et al. **Bull Cancer (Paris)** 1995 Nov;82(11):971–4 (11 ref.) (Eng. Abstr.) **(Fre)**

[Primary leiomyosarcoma of the liver 37 years after successful treatment of hereditary retinoblastoma] Abdelli N, et al. **Gastroenterol Clin Biol** 1996;20(5):502–5 (31 ref.) (Eng. Abstr.) **(Fre)**

[Histiocytoma of the liver] Arakawa Y, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):392–4 (13 ref.) **(Jpn)**

[Hepatocellular carcinoma (HCC)] Ebara M. **Ryoikibetsu Shokogun Shirizu** 1995;(7):363–6 (10 ref.) **(Jpn)**

[Sarcomatoid carcinoma] Fukuhara K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):504–6 (16 ref.) **(Jpn)**

[Hemangioma and hyalinized hemangioma of the liver] Haratake J, et al. **Ryoikibetsu Shokogun Shirizu** 1995; (7):336–8 (15 ref.) **(Jpn)**

[Hepatic angiosarcoma] Haratake J, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):342–4 (17 ref.) **(Jpn)**

[Hepatic lymphangiomatosis and its related tumors and tumor-like conditions] Haratake J, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):292–4 (12 ref.) **(Jpn)**

[Adenosquamous carcinoma of the liver] Hayashi M, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):405–7 (18 ref.) **(Jpn)**

[Primary hormone-producing hepatic tumor] Himeno H, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):511–4 (22 ref.) **(Jpn)**

[Primary hepatic leiomyosarcoma and rhabdomyosarcoma] Hiyama Y. **Ryoikibetsu Shokogun Shirizu** 1995;(7):463–6 (22 ref.) **(Jpn)**

[Infantile hemangioendothelioma of the liver] Horie H. **Ryoikibetsu Shokogun Shirizu** 1995;(7):483–5 (18 ref.) **(Jpn)**

[Osteoclast-like giant cell tumor of the liver] Horie Y, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):429–31 (8 ref.) **(Jpn)**

[Lipomatous tumors (lipoma, angiomyolipoma, myelolipoma, focal fatty change) in the liver] Imaoka S, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):288–91 (24 ref.) **(Jpn)**

[Osteosarcoma of the liver] Itoh A, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):360–2 (19 ref.) **(Jpn)**

[Mantle cell lymphoma of the liver] Itoh Y, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):299–301 (11 ref.) **(Jpn)**

[Sclerosing hepatic carcinoma] Kakita A, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):467–9 (11 ref.) **(Jpn)**

[Hepatocellular carcinoma of nodular type] Kanamaru T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):446–9 (17 ref.) **(Jpn)**

[Small liver cancer] Kitamra T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):480–2 (4 ref.) **(Jpn)**

[Hepatic teratoma, malignant teratoma] Kobayashi Y, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):329–32 (17 ref.) **(Jpn)**

[Hepatic tumors resembling hepatocellular carcinoma] Kojiro M. **Ryoikibetsu Shokogun Shirizu** 1995;(7):374–7 (14 ref.) **(Jpn)**

[Primary hepatic tumor] Komatsu M, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):456–9 (14 ref.) **(Jpn)**

[Primary hepatic sarcoma] Komatsu M, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):460–2 (8 ref.) **(Jpn)**

[Malignant mixed tumor of the liver] Kubo Y. **Ryoikibetsu Shokogun Shirizu** 1995;(7):345–8 (3 ref.) **(Jpn)**

[Hemangiopericytoma of the liver] Maeda S, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):339–41 (12 ref.) **(Jpn)**

[Adrenal rest tumor of the liver] Miyazaki I, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):285–7 (10 ref.) **(Jpn)**

[Malignant lymphoma of liver] Mohri N, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):314–6 (20 ref.) **(Jpn)**

[Neurofibroma of the liver, schwannoma of the liver] Nakajima M. **Ryoikibetsu Shokogun Shirizu** 1995;(7):381–3 (14 ref.) **(Jpn)**

[Hepatocellular carcinoma of specific developmental type (massive type, pedunculated type, extrahepatic type, diffuse type, and intra-bile duct developmental type)] Nakanishi T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):495–7 (11 ref.) **(Jpn)**

[Fibrolamellar carcinoma of the liver] Nakano M. **Ryoikibetsu Shokogun Shirizu** 1995;(7):269–72 (20 ref.) **(Jpn)**

[Combined hepatocellular and cholangiocarcinoma] Omagari

K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):473–5 (14 ref.) **(Jpn)**

[Hepatoblastoma] Saito A, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):323–6 (10 ref.) **(Jpn)**

[Borderline lesions of adenomatous hyperplasia and hepatocellular carcinoma] Sakon M, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):441–5 (14 ref.) **(Jpn)**

[Hepatic tumor in children] Sasaki F, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):486–90 (10 ref.) **(Jpn)**

[Ectopic liver and ectopic hepatocellular carcinoma] Sasaki K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):282–4 (14 ref.) **(Jpn)**

[Yolk sac tumor of the liver] Sasaki M. **Ryoikibetsu Shokogun Shirizu** 1995;(7):306–9 (13 ref.) **(Jpn)**

[Malignant germ cell tumor of the liver] Sasaki M. **Ryoikibetsu Shokogun Shirizu** 1995;(7):310–3 (7 ref.) **(Jpn)**

[Mucoepidermoid carcinoma of the liver or the intrahepatic bile duct] Sasaki Y, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):426–8 (13 ref.) **(Jpn)**

[Epithelioid hemangioendothelioma] Shiga J. **Ryoikibetsu Shokogun Shirizu** 1995;(7):438–40 (7 ref.) **(Jpn)**

[Undifferentiated hepatic carcinoma] Shijo H, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):515–7 (16 ref.) **(Jpn)**

[Primary hepatic carcinoid tumor] Shima K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):450–2 (8 ref.) **(Jpn)**

[Primary leiomyoma of the liver] Shiraki K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):432–4 (12 ref.) **(Jpn)**

[Paraneoplastic syndrome of hepatocellular carcinoma] Tagawa K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):453–5 (13 ref.) **(Jpn)**

[Liver adenoma and hepatobiliary cystadenoma] Takahama T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):387–91 (7 ref.) **(Jpn)**

[Primary hepatic choriocarcinoma] Takemori Y, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):378–80 (18 ref.) **(Jpn)**

[Malignant fibrous histiocytoma of the liver] Tamaki H, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):295–8 (23 ref.) **(Jpn)**

[Primary fibroma of the liver, primary fibrosarcoma of the liver] Tameda Y, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):384–6 (19 ref.) **(Jpn)**

[Well-differentiated hepatocellular carcinoma] Umeshita K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):470–2 (11 ref.) **(Jpn)**

[Hepatocellular carcinoma originated in the caudate lobe] Yamasaki S, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):507–10 (2 ref.) **(Jpn)**

BLOOD

[Assessing high risk group of patients for liver neoplasm by platelet count] Okamoto M, et al. **Nippon Naika Gakkai Zasshi** 1995 Dec 10;84(12):1965–9 (4 ref.) **(Jpn)**

BLOOD SUPPLY

The vascularity of colorectal liver metastases. Shankar A, et al. **Eur J Surg Oncol** 1996 Aug;22(4):389–96 (88 ref.)

Blood supply of early hepatocellular carcinoma. Bhattacharya S, et al. **Semin Liver Dis** 1995 Nov;15(4):390–401 (96 ref.)

CHEMICALLY INDUCED

Molecular mechanisms of estrogen carcinogenesis. Yager JD, et al. **Annu Rev Pharmacol Toxicol** 1996;36:203–32 (226 ref.)

Fish models for environmental carcinogenesis: the rainbow trout. Bailey GS, et al. **Environ Health Perspect** 1996 Mar;104 Suppl 1:5–21 (174 ref.)

Hepatocellular carcinoma associated with anabolic steroid therapy: report of a case and review of the Japanese literature. Kosaka A, et al. **J Gastroenterol** 1996 Jun;31(3):450–4 (24 ref.)

PPAR: a mediator of peroxisome proliferator action. Green S. **Mutat Res** 1995 Dec;333(1–2):101–9 (65 ref.)

Role of receptors in human and rodent hepatocarcinogenesis. Schwarz M, et al. **Mutat Res** 1995 Dec;333(1–2):69–79 (52 ref.)

The potential role of oxidative stress in nongenotoxic carcinogenesis in the mouse liver. Bachowski S, et al. **Prog Clin Biol Res** 1995;391:385–96 (48 ref.)

Peroxisome proliferators: potential role of altered hepatocyte growth and differentiation in tumor development. Cattley RC, et al. **Prog Clin Biol Res** 1995;391:295–303 (55 ref.)

A case study of cancer data set combinations for PCBs. Vater ST, et al. **Regul Toxicol Pharmacol** 1995 Aug;22(1):2–10 (26 ref.)

[The regression of a hepatocellular adenoma after the withdrawal of hormonal contraception] Daldrup HE, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1995 Nov;163(5):449–51 (12 ref.) **(Ger)**

[Steroid-induced liver tumor] Nishizawa Y, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):449–52 (21 ref.) **(Jpn)**

[Liver neoplasms due to Thorotrast] Ukida M. **Ryoikibetsu Shokogun Shirizu** 1995;(7):501–3 (19 ref.) **(Jpn)**

[Peroxisome proliferators and hepatocarcinogenesis] Tamura H. **Seikagaku** 1995 Aug;67(8):1044–7 (15 ref.) **(Jpn)**

COMPLICATIONS

Spontaneous rupture of hepatocellular carcinoma. Zhu LX, et al. **Br J Surg** 1996 May;83(5):602–7 (33 ref.)

Case report: angiosarcoma in a patient with von Recklinghausen's disease. Png MA, et al. **Clin Radiol** 1996 Jul;51(7):521–3 (8 ref.)

Long term survival after obstruction of the common bile duct by ductal hepatocellular carcinoma. Jan YY, et al. **Eur J Surg** 1995 Oct;161(10):771–4 (17 ref.)

Non-islet-cell tumour induced hypoglycaemia: a case report and review of literature. Kuenen BC, et al. **Neth J Med** 1996 May;48(5):175–9 (16 ref.)

[Giant hemangioma of the liver disclosed by fever and an inflammatory syndrome. Apropos of 3 cases] Taillandier J, et al. **Ann Med Interne (Paris)** 1995;146(5):319–21 (9 ref.) (Eng. Abstr.) **(Fre)**

[Primary non-Hodgkin's lymphomas of the liver in human immunodeficiency virus infected patients. Three cases] Brugière O, et al. **Gastroenterol Clin Biol** 1996;20(3):307–11 (18 ref.) (Eng. Abstr.) **(Fre)**

[Hepatocellular carcinoma with cirrhosis] Aoyagi Y, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):352–6 (20 ref.) **(Jpn)**

[Hepatocarcinoma associated to fatty liver degeneration. Report of a clinical case] Pacheco R, et al. **G E N** 1995 Jul-Sep;49(3):234–7 (16 ref.) (Eng. Abstr.) **(Spa)**

CONGENITAL

Hepatic vascular anomalies in infancy: a twenty-seven-year experience. Boon LM, et al. **J Pediatr** 1996 Sep;129(3):346–54 (52 ref.)

DIAGNOSIS

Screening for hepatocellular carcinoma: a regained enthusiasm due to new therapeutic options? Henrion J, et al. **Acta Gastroenterol Belg** 1995 Sep-Dec;58(5–6):426–32 (28 ref.)

Hepatocellular carcinoma: update on diagnosis and treatment. Ramsey WH, et al. **Dig Dis** 1995 Mar-Apr;13(2):81–91 (65 ref.)

Carbohydrate-based measurements on alpha-fetoprotein in the early diagnosis of hepatocellular carcinoma. Aoyagi Y. **Glycoconj J** 1995 Jun;12(3):194–9 (66 ref.)

Secondary prevention of hepatocellular carcinoma. Tang ZY, et al. **J Gastroenterol Hepatol** 1995 Nov-Dec;10(6):683–90 (85 ref.)

Liver. III: Gadolinium-based hepatobiliary contrast agents (Gd-EOB-DTPA and Gd-BOPTA/Dimeg). Giovagnoni A, et al. **Magn Reson Imaging Clin N Am** 1996 Feb;4(1):61–72 (34 ref.)

Liver I: Currently available gadolinium chelates. Mitchell DG. **Magn Reson Imaging Clin N Am** 1996 Feb;4(1):37–51 (15 ref.)

Liver. II: Iron oxide-based reticuloendothelial contrast agents for MR imaging. Clinical review. Petersein J, et al. **Magn Reson Imaging Clin N Am** 1996 Feb;4(1):53–60 (38 ref.)

Evaluation of the solid hepatic mass. Rubin RA, et al. **Med Clin North Am** 1996 Sep;80(5):907–28 (114 ref.)

Benign schwannoma of the liver: a case report. Yoshida M, et al. **Nippon Geka Hokan** 1994 Nov 1;63(6):208–14 (13 ref.)

Hepatic metastases: basic principles and implications for radiologists. Baker ME, et al. **Radiology** 1995 Nov;197(2):329–37 (113 ref.)

Magnetic resonance imaging of focal liver lesions. Schnall M. **Semin Roentgenol** 1995 Oct;30(4):347–61 (34 ref.)

Radiologic diagnosis of hepatocellular carcinoma. Ishiguchi T, et al. **Semin Surg Oncol** 1996 May-Jun;12(3):164–9 (17 ref.)

[Changed diagnosis and treatment of hepatocellular carcinoma] van Nieuwkerk CM, et al. **Ned Tijdschr Geneeskd** 1996 Apr 27;140(17):922–6 (39 ref.) **(Dut)**

[When is magnetic resonance imaging of liver diseases required?] Vilgrain V. **Gastroenterol Clin Biol** 1996;20(5 Pt 2):B134–9 (24 ref.) **(Fre)**

[The endorem tolerance profile] Laniado M, et al. **Radiologe** 1995 Nov;35(11 Suppl 2):S266–70 (16 ref.) (Eng. Abstr.) **(Ger)**

[Value of MRI in diagnosis of focal liver lesions] Taupitz M, et al. **Radiologe** 1995 Nov;35(11 Suppl 2):S243–7 (39 ref.) (Eng. Abstr.) **(Ger)**

[1995 literature review: diagnostic imaging of the liver] Merkle E. **Rontgenpraxis** 1996 Mar;49(3):64–70 (100 ref.) **(Ger)**

[Inflammatory pseudotumor of the liver. Case report of a rare differential diagnosis of hepatocellular carcinoma] Strohm WD, et al. **Z Gastroenterol** 1996 Feb;34(2):132–7 (45 ref.) (Eng. Abstr.) **(Ger)**

[Early diagnosis of hepatocellular carcinoma by serum AFP and PIVKA-II analysis] Aoyagi Y, et al. **Nippon Naika Gakkai Zasshi** 1995 Dec 10;84(12):2003–7 (5 ref.) **(Jpn)**

[Early diagnosis of hepatocellular carcinoma using computed tomography and magnetic resonance imaging] Moriyama N. **Nippon Naika Gakkai Zasshi** 1995 Dec 10;84(12):1997–2002 (4 ref.) **(Jpn)**

[Use of morphometry and DNA flow cytometry in the differential diagnosis, prognosis and treatment of primary tumors of the liver (review of the literature)] Pimenova EL, et al. **Klin Lab Diagn** 1996 Mar-Apr;(2):7–11 (47 ref.) **(Rus)**

[A functioning carcinoid tumor with liver involvement without the associated carcinoid syndrome] Sánchez A, et al. **Gastroenterol Hepatol** 1995 Nov;18(9):468–70 (7 ref.) (Eng. Abstr.) **(Spa)**

[Leukocytoclastic vasculitis as the form of presentation of hepatocarcinoma] Sánchez-Angulo JI, et al. **Gastroenterol Hepatol** 1996 May;19(5):255–8 (35 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Cancers of the large bowel and hepatobiliary tract. Vaughn DJ, et al. **Cancer Chemother Biol Response Modif** 1996;16:495–510 (63 ref.)

Regional chemotherapy of colorectal cancer. Kemeny NE. **Eur J Cancer** 1995 Jul-Aug;31A(7–8):1271–6 (45 ref.)

Pancreatic blastomatous tumor in a child responding to therapy used for hepatoblastoma: case report and review of the literature. Morgan ER, et al. **Med Pediatr Oncol** 1996 Apr;26(4):284–92 (29 ref.)

Conversion of unresectable to resectable hepatoblastoma and long-term follow-up study. Reynolds M. **World J Surg** 1995 Nov-Dec;19(6):814–6 (18 ref.)

[Chemotherapy of hepatocellular carcinoma] Okada S. **Nippon Naika Gakkai Zasshi** 1995 Dec 10;84(12):2028–31 (5 ref.) **(Jpn)**

[Percutaneous ethanol injection therapy of hepatoma] Shiina S, et al. **Nippon Naika Gakkai Zasshi** 1995 Dec 10;84(12):2008–11 (5 ref.) **(Jpn)**

ENZYMOLOGY

Neuroendocrine tumors of the liver and pancreas associated with elevated serum prostatic acid phosphatase. Kaneko Y, et al. **Intern Med** 1995 Sep;34(9):886–91 (35 ref.)

EPIDEMIOLOGY

Epidemiology of hepatocellular carcinoma. Colombo M. **Ital J Gastroenterol** 1995 Mar;27(2):83–7 (31 ref.)

Molecular biomarkers for aflatoxins and their application to human liver cancer. Scholl P, et al. **Pharmacogenetics** 1995;5 Spec No:S171–6 (33 ref.)

[Primary liver tumors in children] Vos A, et al. **Ned Tijdschr Geneeskd** 1995 Sep 23;139(38):1918–22 (35 ref.) **(Dut)**

[Epidemiology of hepatocellular carcinoma] Okuda K. **Gan To Kagaku Ryoho** 1996 Aug;23(9):1105–15 (101 ref.) (Eng. Abstr.) **(Jpn)**

[High risk group of patients with hepatitis C virus infection developing hepatocellular carcinoma] Yokosuka O, et al. **Nippon Naika Gakkai Zasshi** 1995 Dec 10;84(12):1975–9 (5 ref.) **(Jpn)**

ETIOLOGY

Alcohol, hepatotropic viruses, and hepatocellular carcinoma [editorial] Nalpas B, et al. **Alcohol Clin Exp Res** 1995 Oct;19(5):1089–95 (96 ref.)

Hepatocellular carcinoma and African iron overload. Gangaidzo IT, et al. **Gut** 1995 Nov;37(5):727–30 (53 ref.)

Hepatocarcinogenesis in rodents and humans. Kitagawa T, et al. **J Cancer Res Clin Oncol** 1995;121(9–10):511–5 (39 ref.)

The molecular pathogenesis of hepatocellular carcinoma. Moradpour D, et al. **J Viral Hepat** 1994;1(1):17–31 (218 ref.)

Etiology, screening, and treatment of hepatocellular carcinoma. Khakoo SI, et al. **Med Clin North Am** 1996 Sep;80(5):1121–45 (151 ref.)

Hormonal influence on hepatocarcinogenesis. Coe JE. **Prog Clin Biol Res** 1996;394:399–421 (189 ref.)

Pathogenesis of hepatocellular carcinoma: a review from the viewpoint of molecular analysis. Kasai Y, et al. **Semin Surg Oncol** 1996 May-Jun;12(3):155–9 (40 ref.)

Hepatocellular carcinoma--carcinogenesis updated. Yap I. **Singapore Med J** 1995 Dec;36(6):597–9 (63 ref.)

Role of cell proliferation at early stages of hepatocarcinogenesis. Schwarz M, et al. **Toxicol Lett** 1995 Dec;82–83:27–32 (17 ref.)

Hepatocarcinogenesis: a polygenic model of inherited predisposition to cancer. Dragani TA, et al. **Tumori** 1996 Jan-Feb;82(1):1–5 (45 ref.)

[Natural history of hepatitis C virus infection] Marcellin P, et al. **Pathol Biol (Paris)** 1995 Oct;43(8):669–73 (34 ref.) (Eng. Abstr.) **(Fre)**

[Hepatocellular carcinoma] Propst A, et al. **Schweiz Med Wochenschr** 1995 Nov 4;125(44):2137–42 (15 ref.) (Eng. Abstr.) **(Ger)**

[High risk group of patients with hepatitis B virus infection developing hepatocellular carcinoma] Koike K. **Nippon Naika Gakkai Zasshi** 1995 Dec 10;84(12):1980–4 (5 ref.) **(Jpn)**

[Prediction of high risk group of patients with hepatitis-C-virus type liver cirrhosis developing to liver neoplasm] Tarao K, et al. **Nippon Naika Gakkai Zasshi**

1995 Dec 10;84(12):1985–91 (5 ref.) **(Jpn)**

[Influence of heavy drinking for the development of hepatocellular carcinoma in type C cirrhosis] Chiba T, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:731–5 (23 ref.) **(Jpn)**

[Molecular mechanism of HBV hepatocarcinogenesis] Koike K. **Nippon Rinsho** 1995 Oct;53 Suppl:65–74 (37 ref.) **(Jpn)**

[Clinicopathological studies on juvenile hepatocellular carcinoma with hepatitis B virus infection—background factors, tumor spread and prognosis after hepatic resection] Yokoi H, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:698–703 (16 ref.) **(Jpn)**

[Hepatocellular carcinoma of accessory liver] Kakita A, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):279–81 (19 ref.) **(Jpn)**

GENETICS

Tumour suppressor p53 and Rb genes in human hepatocellular carcinoma. Lin Y, et al. **Ann Acad Med Singapore** 1996 Jan;25(1):22–30 (72 ref.)

Report of a complex karyotype in recurrent metastatic fibrolamellar hepatocellular carcinoma and a review of hepatocellular carcinoma cytogenetics. Lowichik A, et al. **Cancer Genet Cytogenet** 1996 Jun;88(2):170–4 (42 ref.)

Altered retinoic acid receptors. de Thé H. **FASEB J** 1996 Jul;10(9):955–60 (43 ref.)

p53 proteins and aflatoxin b1: the good, the bad, and the ugly [editorial] Liang TJ. **Hepatology** 1995 Oct;22(4 Pt 1):1330–2 (21 ref.)

Molecular biomarkers for aflatoxins and their application to human liver cancer. Scholl P, et al. **Pharmacogenetics** 1995; 5 Spec No:S171–6 (33 ref.)

Liver tumor promotion: a process of natural selection. Jirtle RL. **Prog Clin Biol Res** 1995;391:149–59 (59 ref.)

Pathogenesis of hepatocellular carcinoma: a review from the viewpoint of molecular analysis. Kasai Y, et al. **Semin Surg Oncol** 1996 May–Jun;12(3):155–9 (40 ref.)

[Molecular biological characteristics of model cells of hepatitis B virus (HBV)-induced direct hepatocellular carcinogenesis] Baba M, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:97–103 (22 ref.) **(Jpn)**

[Use of morphometry and DNA flow cytometry in the differential diagnosis, prognosis and treatment of primary tumors of the liver (review of the literature)] Pimenova EL, et al. **Klin Lab Diagn** 1996 Mar–Apr;(2):7–11 (47 ref.) **(Rus)**

METABOLISM

[Alpha-fetoprotein producing hepatocellular carcinoma, AT-III producing hepatocellular carcinoma] Nakamura K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):265–8 (11 ref.) **(Jpn)**

PATHOLOGY

Neonatal hepatoblastoma metastatic to the choroid and iris. Endo EG, et al. **Arch Ophthalmol** 1996 Jun;114(6):757–61 (24 ref.)

Analysis of liver development, regeneration, and carcinogenesis by genetic marking studies. Ponder KP. **FASEB J** 1996 May;10(7):673–82 (59 ref.)

Plexiform neurofibromatosis of the liver: case report and review of the literature. Ghalib R, et al. **Hepatology** 1995 Oct;22(4 Pt 1):1154–7 (25 ref.)

Hepatocellular carcinoma metastatic to bones (Case report with review of literature). Doval DC, et al. **Indian J Cancer** 1995 Mar;32(1):31–5 (25 ref.)

Undifferentiated embryonal sarcoma of the liver in childhood. Mistry RC, et al. **Indian J Cancer** 1995 Dec; 32(4):175–8 (11 ref.)

Mucin-producing adenoma associated with pancreas divisum and hepatic hilar carcinoma: an autopsy case. Origuchi N, et al. **J Gastroenterol** 1996 Jun;31(3):455–9 (40 ref.)

Preneoplastic conditions of the liver. Riegler JL. **Semin Gastrointest Dis** 1996 Apr;7(2):74–87 (79 ref.)

Macroregenerative (dysplastic) nodules and hepatocarcinogenesis: theoretical and clinical considerations. Theise ND. **Semin Liver Dis** 1995 Nov; 15(4):360–71 (51 ref.)

[Retrospect and recent progress of pathology of hepatobiliary system] Zhu S, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1995 Aug;24(4):217–20 (22 ref.) **(Chi)**

[Role of fine needle puncture in the diagnosis of a hepatic mass] Fabre M, et al. **Ann Pathol** 1995;15(5):380–7 (31 ref.) **(Fre)**

[Current approach to hepatic carcinogenesis. From cirrhosis to hepatocellular carcinoma] Le Bail B, et al. **Ann Pathol** 1995;15(5):332–47 (92 ref.) **(Fre)**

[Immunohistochemistry in liver pathology] Selves J, et al. **Ann Pathol** 1995;15(5):388–95 (56 ref.) **(Fre)**

[Special issue of pathology of liver (editorial)] Voigt JJ, et al. **Ann Pathol** 1995;15(5):313–5 (12 ref.) **(Fre)**

[Hepatocellular nodular hyperplasias, adenomas and carcinomas] Altmann HW. **Verh Dtsch Ges Pathol** 1995; 79:84–108 (144 ref.) (Eng. Abstr.) **(Ger)**

[Sequential cellular and molecular changes during hepatocarcinogenesis] Bannasch P. **Verh Dtsch Ges Pathol** 1995;79:72–83 (65 ref.) (Eng. Abstr.) **(Ger)**

[Hepatic neoductules] Fischer HP, et al. **Verh Dtsch Ges Pathol** 1995;79:36–46 (42 ref.) (Eng. Abstr.) **(Ger)**

[Control of liver proliferation: structural, functional and molecular aspects] Rabes HM. **Verh Dtsch Ges Pathol** 1995; 79:61–71 (50 ref.) (Eng. Abstr.) **(Ger)**

[Growth factors in liver regeneration and hepatocarcinogenesis] Schirmacher P, et al. **Verh Dtsch Ges Pathol** 1995;79:55–60 (47 ref.) (Eng. Abstr.) **(Ger)**

[Prognostic factors in liver tumors] Wittekind C. **Verh Dtsch Ges Pathol** 1995;79:109–15 (61 ref.) (Eng. Abstr.) **(Ger)**

[Precancerous stages of hepatocellular carcinoma] Tanikawa K. **Gan To Kagaku Ryoho** 1995 Dec;22(14):2055–61 (29 ref.) (Eng. Abstr.) **(Jpn)**

[Renal metastasis originating from liver cancer] Fukushima M, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 Mar; 87(3):710–3 (8 ref.) (Eng. Abstr.) **(Jpn)**

[Assessing high risk group of patients for liver neoplasms by pathological findings] Yamada G. **Nippon Naika Gakkai Zasshi** 1995 Dec 10;84(12):1970–4 (10 ref.) **(Jpn)**

[Clinicopathological studies on juvenile hepatocellular carcinoma with hepatitis B virus infection—background factors, tumor spread and prognosis after hepatic resection] Yokoi H, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:698–703 (16 ref.) **(Jpn)**

[A rare case of cranial metastasis from hepatocellular carcinoma] Momoji J, et al. **No Shinkei Geka** 1995 Nov; 23(11):997–1002 (25 ref.) (Eng. Abstr.) **(Jpn)**

[A case of cranial metastasis of hepatocellular carcinoma] Shibukawa M, et al. **No To Shinkei** 1995 Nov; 47(11):1087–91 (28 ref.) (Eng. Abstr.) **(Jpn)**

[Hepatocellular carcinoma (scirrhous type)] Hirooka N, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):367–70 (8 ref.) **(Jpn)**

[Extrahepatic intrabile duct tumor growth of hepatocellular carcinoma] Kashihara T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):57–60 (20 ref.) **(Jpn)**

[Cystic hepatic neoplasm] Ohmoto K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):116–9 (20 ref.) **(Jpn)**

[Liver cell dysplasia] Okanoue T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):273–6 (18 ref.) **(Jpn)**

[Hepatocellular carcinoma in adenomatous hyperplasia] Shiga J. **Ryoikibetsu Shokogun Shirizu** 1995;(7):371–3 (7 ref.) **(Jpn)**

PHYSIOPATHOLOGY

[Sequential cellular and molecular changes during hepatocarcinogenesis] Bannasch P. **Verh Dtsch Ges Pathol** 1995;79:72–83 (65 ref.) (Eng. Abstr.) **(Ger)**

[Growth factors in liver regeneration and hepatocarcinogenesis] Schirmacher P, et al. **Verh Dtsch Ges Pathol** 1995;79:55–60 (47 ref.) (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

Preoperative chemoradiation for adenocarcinoma of the pancreas: excessive toxicity of prophylactic hepatic irradiation [see comments] Evans DB, et al. **Int J Radiat Oncol Biol Phys** 1995 Nov 1;33(4):913–8 (35 ref.) Comment in: Int J Radiat Oncol Biol Phys 1995 Nov 1;33(4):969–70.

Primary prevention of hepatocellular carcinoma. Yu SZ. **J Gastroenterol Hepatol** 1995 Nov–Dec;10(6):674–82 (24 ref.)

Etiology, screening, and treatment of hepatocellular carcinoma. Khakoo SI, et al. **Med Clin North Am** 1996 Sep;80(5):1121–45 (151 ref.)

[Preventive use of retinoids for occurrence of liver neoplasm] Muto Y. **Nippon Naika Gakkai Zasshi** 1995 Dec 10; 84(12):2032–7 (5 ref.) **(Jpn)**

[Preventive use of interferons for liver neoplasms] Shiratori Y, et al. **Nippon Naika Gakkai Zasshi** 1995 Dec 10; 84(12):2038–42 (5 ref.) **(Jpn)**

[Does interferon therapy on type C liver cirrhosis prevent the occurrence of hepatocellular carcinoma?] Harada H, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:754–8 (17 ref.) **(Jpn)**

RADIOGRAPHY

Hepatic metastases from granulosa cell tumor of the ovary: CT and sonographic findings. Neste MG, et al. **AJR Am J Roentgenol** 1996 May;166(5):1122–4 (8 ref.)

Hepatocellular adenoma. al-Otaibi L, et al. **AJR Am J Roentgenol** 1995 Dec;165(6):1426 (6 ref.)

CT during arterial portography. Soyer P. **Eur Radiol** 1996; 6(3):349–57 (69 ref.)

Computed tomography imaging of focal hepatic lesions. Jacobs JE, et al. **Semin Roentgenol** 1995 Oct;30(4):308–23 (48 ref.)

[Place of celioscopy in the diagnosis of invasiveness of digestive cancers] Chambon JP, et al. **Ann Chir** 1995; 49(6):513–8 (25 ref.) (Eng. Abstr.) **(Fre)**

[Possibilities of spiral-CT for diagnosis of focal liver lesions] Helmberger H, et al. **Rontgenpraxis** 1996 Mar;49(3):49–54 (35 ref.) **(Ger)**

RADIONUCLIDE IMAGING

Nuclear imaging of solid hepatic masses. Kinnard MF, et al. **Semin Roentgenol** 1995 Oct;30(4):375–95 (140 ref.)

[Hepatobiliary radionuclide imaging. Clinical applications] Zerbib E. **Ann Chir** 1995;49(7):637–43 (35 ref.) (Eng. Abstr.) **(Fre)**

RADIOTHERAPY

[Radiotherapy of hepatocellular carcinoma] Tanaka N, et al. **Nippon Naika Gakkai Zasshi** 1995 Dec 10;84(12):2019–23 (7 ref.) **(Jpn)**

SECONDARY

Hepatic metastases from granulosa cell tumor of the ovary: CT and sonographic findings. Neste MG, et al. **AJR Am J Roentgenol** 1996 May;166(5):1122–4 (8 ref.)

Metastatic carcinoma resulting in hepar lobatum. Gravel DH, et al. **Am J Clin Pathol** 1996 May;105(5):621–7 (15 ref.)

Hepatic cryotherapy for metastatic liver tumours. McCall JL, et al. **Br J Hosp Med** 1995 Oct 18–31;54(8):378–81 (26 ref.)

Chemotherapy of metastatic bowel cancer. Ross PJ, et al. **Br J Hosp Med** 1996 Mar 6–19;55(5):263–6 (20 ref.)

Liver metastases from colorectal cancer: lessons from past and present clinical studies. Taylor I. **Br J Surg** 1996 Apr; 83(4):456–60 (35 ref.)

Adhesion mechanisms in liver metastasis formation. Kemperman H, et al. **Cancer Surv** 1995;24:67–79 (54 ref.)

Nonsurgical treatment of liver metastases. McCulloch P. **Curr Opin Gen Surg** 1994;:151–5 (33 ref.)

Surgical and multimodality approaches to liver metastases. Schlag PM, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 3):241–55 (78 ref.)

Regional chemotherapy of colorectal cancer. Kemeny NE. **Eur J Cancer** 1995 Jul–Aug;31A(7–8):1271–6 (45 ref.)

Intra-operative ultrasound in detection of liver metastases. Meijer S, et al. **Eur J Cancer** 1995 Jul–Aug; 31A(7–8):1210–1 (10 ref.)

Treatment of colorectal cancer metastases confined to the liver. Vahrmeijer AL, et al. **Eur J Cancer** 1995 Jul–Aug; 31A(7–8):1238–42 (43 ref.)

Planning of liver surgery using three dimensional imaging techniques. van Leeuwen MS, et al. **Eur J Cancer** 1995 Jul–Aug;31A(7–8):1212–5 (16 ref.)

The vascularity of colorectal liver metastases. Shankar A, et al. **Eur J Surg Oncol** 1996 Aug;22(4):389–96 (88 ref.)

Hepar lobatum carcinomatosum due to chemotherapy of a metastatic breast carcinoma. Uhlmann F, et al. **Gen Diagn Pathol** 1996 Mar;141(3–4):279–84 (21 ref.)

Repeated hepatic resections for recurrent metastasis of colorectal cancer. Gazzaniga GM, et al. **Hepatogastroenterology** 1995 Jul–Aug;42(4):383–6 (19 ref.)

Liver cryosurgery. McMasters KM, et al. **J Ky Med Assoc** 1996 Jun;94(6):222–9 (55 ref.)

Colorectal liver metastases. Burke D, et al. **Postgrad Med J** 1996 Aug;72(850):464–9 (53 ref.)

Hepatic metastases: basic principles and implications for radiologists. Baker ME, et al. **Radiology** 1995 Nov; 197(2):329–37 (113 ref.)

p53 gene therapy in vivo of herpatocellular and liver metastatic colorectal cancer. Bookstein R, et al. **Semin Oncol** 1996 Feb;23(1):66–77 (109 ref.)

Colorectal cancer: hepatic-directed therapy—the role of surgery, regional chemotherapy, and novel modalities. Busch E, et al. **Semin Oncol** 1995 Oct;22(5):494–508 (110 ref.)

Current perspectives on repeat hepatic resection for colorectal carcinoma: a review. Wanebo HJ, et al. **Surgery** 1996 Apr;119(4):361–71 (70 ref.)

[Management of disclosed hepatic metastases] Rougier P, et al. **Gastroenterol Clin Biol** 1996;20(5 Pt 2):B120–26 (28 ref.) **(Fre)**

[Resections of recurrence in the liver of primary and secondary liver cancers] Herfarth C, et al. **Chirurg** 1995 Oct;66(10):949–58 (78 ref.) (Eng. Abstr.) **(Ger)**

[Prolactin producing hypophyseal carcinoma. Case report of an extremely rare metastatic tumor] Saeger W, et al. **Pathologe** 1995 Sep;16(5):354–8 (19 ref.) (Eng. Abstr.) **(Ger)**

[Detection of liver tumors] Rummeny EJ, et al. **Radiologe** 1995 Nov;35(11 Suppl 2):S252–8 (29 ref.) (Eng. Abstr.) **(Ger)**

[Adjuvant therapy of liver metastases: active specific immunotherapy] Hagmüller E, et al. **Zentralbl Chir** 1995; 120(10):780–5 (37 ref.) (Eng. Abstr.) **(Ger)**

[Results of resection and adjuvant therapy of liver metastases of primary colorectal tumors—a review of the literature] Lorenz M, et al. **Zentralbl Chir** 1995;120(10):769–79 (74 ref.) (Eng. Abstr.) **(Ger)**

[Regional adjuvant therapy in colorectal liver metastases: requirements for clinical therapy studies from the statistical viewpoint (see comments)] Müller HH, et al. **Zentralbl Chir** 1995;120(10):755–9 (10 ref.) (Eng. Abstr.) Comment in: Zentralbl Chir 1995;120(10):753–4. **(Ger)**

[Pharmacology of regional chemotherapy of colorectal liver metastases] Schalhorn A, et al. **Zentralbl Chir** 1995; 120(10):764–8 (15 ref.) (Eng. Abstr.) **(Ger)**

[Classification and documentation of liver metastases of colorectal carcinomas] Wittekind C. **Zentralbl Chir** 1995; 120(10):760–3 (18 ref.) (Eng. Abstr.) **(Ger)**

[A case report of the VIP producing tumor with liver

metastasis presenting WDHA syndrome] Inoue S, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Aug;92(8):1217-22 (13 ref.) **(Jpn)**

[Metastatic liver tumor] Yamasaki S, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):491-4 (4 ref.) **(Jpn)**

[Disseminated Kaposi's sarcoma with hepatosplenic involvement in AIDS] González-López A, et al. **Med Clin (Barc)** 1996 Apr 27;106(16):622-3 (15 ref.) (Eng. Abstr.) **(Spa)**

[Current status of the regional treatment of hepatic metastasis from colorectal carcinoma] de Castro Carpeño J, et al. **Rev Clin Esp** 1995 Aug;195(8):565-70 (79 ref.) **(Spa)**

SECRETION

Primary carcinoid tumor of the liver: report of four resected cases including one with gastrin production. Krishnamurthy SC, et al. **J Surg Oncol** 1996 Jul; 62(3):218-21 (19 ref.)

SURGERY

Adult hepatoblastoma: case report and review of the literature. Harada T, et al. **Aust N Z J Surg** 1995 Sep; 65(9):686-8 (28 ref.)

Repeated liver resection for recurrent liver cancer. Neeleman N, et al. **Br J Surg** 1996 Jul;83(7):893-901 (73 ref.)

Experimental and clinical study on hepatobiliary surgery in China. Wu M. **Chin Med J (Engl)** 1996 Feb;109(2):131-3 (19 ref.)

Primary and secondary hepatic malignancies. Gallinger S, et al. **Curr Opin Gen Surg** 1993;:257-64 (47 ref.)

Liver transplantation. Shaw BW Jr. **Curr Opin Gen Surg** 1993;:239-48 (50 ref.)

Planning of liver surgery using three dimensional imaging techniques. van Leeuwen MS, et al. **Eur J Cancer** 1995 Jul-Aug;31A(7-8):1212-5 (16 ref.)

Repeated hepatic resections for recurrent metastasis of colorectal cancer. Gazzaniga GM, et al. **Hepatogastroenterology** 1995 Jul-Aug;42(4):383-6 (19 ref.)

Resection of a fibrolamellar carcinoma of the liver originating in the caudate lobe. Machado MC, et al. **Hepatogastroenterology** 1995 Nov-Dec;42(6):993-5 (21 ref.)

Liver cryosurgery. McMasters KM, et al. **J Ky Med Assoc** 1996 Jun;94(6):222-9 (55 ref.)

Hepatic artery ligation for hepatic vascular tumors with arteriovenous and arterioportal venous shunts in the newborn: successful management of two cases and review of the literature. Hazebroek FW, et al. **J Pediatr Surg** 1995 Aug;30(8):1127-30 (15 ref.)

Primary carcinoid tumor of the liver: report of four resected cases including one with gastrin production. Krishnamurthy SC, et al. **J Surg Oncol** 1996 Jul; 62(3):218-21 (19 ref.)

Hepatic cryosurgery for metastatic colorectal carcinoma. Brandt BT, et al. **Oncol Nurs Forum** 1996 Jan-Feb; 23(1):29-36; quiz 37-8 (20 ref.)

Advances in hepatic resection and results for hepatocellular carcinoma. Nonami T, et al. **Semin Surg Oncol** 1996 May-Jun;12(3):183-8 (51 ref.)

Liver transplantation and hepatocellular carcinoma. Yokoyama I, et al. **Semin Surg Oncol** 1996 May-Jun; 12(3):212-6 (30 ref.)

Laparoscopic resection of a large hepatic tumor. Ferzli G, et al. **Surg Endosc** 1995 Jun;9(6):733-5 (9 ref.)

Hepatocellular carcinoma associated with lupoid hepatitis: a review of Japanese reports. Sakaguchi T, et al. **Surg Today** 1995;25(9):838-42 (18 ref.)

Liver transplantation for primary liver cancer. Ringe B, et al. **Transplant Proc** 1996 Jun;28(3):1174-5 (10 ref.)

[Development of safer liver surgery (editorial)] Belghiti J. **Gastroenterol Clin Biol** 1996 Mar;20(2):129-31 (24 ref.) **(Fre)**

[Percutaneous treatment of malignant stenoses of the hilum] Bonnel D, et al. **Gastroenterol Clin Biol** 1995 Jun-Jul; 19(6-7):564-71 (24 ref.) (Eng. Abstr.) **(Fre)**

[Treatment of tumoral stenoses of the hepatic hilum (editorial)] Valette PJ. **Gastroenterol Clin Biol** 1995 Jun-Jul;19(6-7):561-3 (17 ref.) **(Fre)**

[Resections of recurrence in the liver of primary and secondary liver cancers] Herfarth C, et al. **Chirurg** 1995 Oct;66(10):949-58 (78 ref.) (Eng. Abstr.) **(Ger)**

[Microwave coagulation therapy of hepatocellular carcinoma] Seki T, et al. **Nippon Naika Gakkai Zasshi** 1995 Dec 10;84(12):2024-7 (5 ref.) **(Jpn)**

THERAPY

Delayed anoxic pseudolobular necrosis (terminal hepatic necrosis) after chemo-lipiodolization for hepatocellular carcinoma. Kozakai I, et al. **Am J Gastroenterol** 1996 Jun; 91(6):1263-5 (8 ref.)

Hepatic cryotherapy for metastatic liver tumours. McCall JL, et al. **Br J Hosp Med** 1995 Oct 18-31;54(8):378-81 (26 ref.)

Primary liver cancers. Weimann A, et al. **Curr Opin Oncol** 1995 Jul;7(4):387-96 (84 ref.)

Hepatocellular carcinoma: update on diagnosis and treatment. Ramsey WH, et al. **Dig Dis** 1995 Mar-Apr;13(2):81-91 (65 ref.)

Why can't we cure primary liver cancer? [editorial] Johnson PJ. **Eur J Cancer** 1995 Sep;31A(10):1562-4 (19 ref.)

Treatment of colorectal cancer metastases confined to the liver. Vahrmeijer AL, et al. **Eur J Cancer** 1995 Jul-Aug; 31A(7-8):1238-42 (43 ref.)

Update on regional treatments for hepatobiliary malignancies. Curley SA. **Gan To Kagaku Ryoho** 1995 Sep;22(11):1437-52 (23 ref.)

Liver-directed gene therapy: prospects and problems. Strauss M. **Gene Ther** 1994 May;1(3):156-64 (66 ref.)

Multimodal management of diffuse neonatal hemangiomatosis. Stratte EG, et al. **J Am Acad Dermatol** 1996 Feb;34(2 Pt 2):337-42 (36 ref.)

Secondary prevention of hepatocellular carcinoma. Tang ZY, et al. **J Gastroenterol Hepatol** 1995 Nov-Dec;10(6):683-90 (85 ref.)

p53 gene therapy in vivo of herpatocellular and liver metastatic colorectal cancer. Bookstein R, et al. **Semin Oncol** 1996 Feb;23(1):66-77 (109 ref.)

Colorectal cancer: hepatic-directed therapy--the role of surgery, regional chemotherapy, and novel modalities. Busch E, et al. **Semin Oncol** 1995 Oct;22(5):494-508 (110 ref.)

Non-invasive loco-regional therapy for hepatocellular carcinoma. Tanikawa K. **Semin Surg Oncol** 1996 May-Jun; 12(3):189-92 (15 ref.)

Conversion of unresectable to resectable liver cancer: an approach and follow-up study. Sitzmann JV. **World J Surg** 1995 Nov-Dec;19(6):790-4 (32 ref.)

[Treatment of hepatocellular carcinoma in the presence of liver cirrhosis] Ducreux M, et al. **J Chir (Paris)** 1995 Jun-Jul;132(6-7):279-86 (60 ref.) (Eng. Abstr.) **(Fre)**

[1995 gastroenterology update--II] Layer P, et al. **Med Klin** 1996 Apr 1;91 Suppl 1:81-8 (88 ref.) **(Ger)**

[Current status of treatment for small hepatocellular carcinoma] Yokoi H, et al. **Gan To Kagaku Ryoho** 1996 Jun;23(7):855-61 (21 ref.) (Eng. Abstr.) **(Jpn)**

[TAE therapy of hepatocellular carcinoma] Kudo M. **Nippon Naika Gakkai Zasshi** 1995 Dec 10;84(12):2012-8 (7 ref.) **(Jpn)**

[Human alpha-fetoprotein transcriptional regulatory regions: application to gene therapy] Tamaoki T, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2613-7 (25 ref.) **(Jpn)**

[Current status of the regional treatment of hepatic metastasis from colorectal carcinoma] de Castro Carpeño J, et al. **Rev Clin Esp** 1995 Aug;195(8):565-70 (79 ref.) **(Spa)**

ULTRASONOGRAPHY

Hepatic metastases from granulosa cell tumor of the ovary: CT and sonographic findings. Neste MG, et al. **AJR Am J Roentgenol** 1996 May;166(5):1122-4 (8 ref.)

Ultrasound of focal hepatic lesions. Nisenbaum HL, et al. **Semin Roentgenol** 1995 Oct;30(4):324-46 (53 ref.)

[Ultrasonic laparoscopy in digestive diseases] Catheline JM, et al. **Ann Chir** 1996;50(1):51-7 (30 ref.) (Eng. Abstr.) **(Fre)**

[Primary malignant tumor of the breast. Monitoring after treatment (editorial)] Guastalla JP, et al. **Presse Med** 1995 Oct 21;24(31):1415-7 (22 ref.) (Eng. Abstr.) **(Fre)**

[Ultrasonographic screening of hepatocellular carcinoma] Majima Y. **Nippon Naika Gakkai Zasshi** 1995 Dec 10; 84(12):1992-6 (4 ref.) **(Jpn)**

VETERINARY

Genetics of liver tumor susceptibility in mice. Dragani TA, et al. **Toxicol Lett** 1995 Dec;82-83:613-9 (36 ref.)

VIROLOGY

Hepatitis B virus and hepatocellular carcinoma. Ren EC. **Ann Acad Med Singapore** 1996 Jan;25(1):17-21 (52 ref.)

Hepatitis C virus and hepatocellular carcinoma. Colombo M, et al. **Clin Exp Rheumatol** 1995 Nov-Dec;13 Suppl 13:S23-7 (49 ref.)

In vitro transformation by hepatitis B virus DNA. Schaefer S, et al. **Intervirology** 1995;38(3-4):143-54 (112 ref.)

Hepatitis C virus as a causative agent of hepatocellular carcinoma. Shimotohno K. **Intervirology** 1995; 38(3-4):162-9 (55 ref.)

[HCV genome in type C hepatocellular carcinoma] Yamada G. **Nippon Rinsho** 1995 Sep;53 Suppl:777-81 (13 ref.) **(Jpn)**

LIVER NEOPLASMS, EXPERIMENTAL

CHEMICALLY INDUCED

Role of oxidative stress in non-genotoxic carcinogenesis with special reference to liver tumors induced by peroxisome proliferators. Sai-Kato K, et al. **Biomed Environ Sci** 1995 Sep;8(3):269-79 (64 ref.)

The evaluation of potential human carcinogens: a histopathologist's point of view. Greaves P. **Exp Toxicol Pathol** 1996 Feb;48(2-3):169-74 (17 ref.)

Apoptosis and multistage carcinogenesis in rat liver. Schulte-Hermann R, et al. **Mutat Res** 1995 Dec; 333(1-2):81-7 (43 ref.)

Role of receptors in human and rodent hepatocarcinogenesis. Schwarz M, et al. **Mutat Res** 1995 Dec;333(1-2):69-79 (52 ref.)

Phenobarbital mouse liver tumors: implications of hepatic tumor promotion for cancer risk assessment. McClain RM. **Prog Clin Biol Res** 1995;391:325-36 (35 ref.)

Considerations concerning the murine hepatocarcinogenicity of selected chlorinated hydrocarbons. Maronpot RR, et al. **Prog Clin Biol Res** 1995;391:305-23 (80 ref.)

The species specificity of dieldrin- or phenobarbital- induced hepatocarcinogenesis: case studies with implications for human health risk assessment. Stevenson DE, et al. **Prog Clin Biol Res** 1995;391:337-45 (28 ref.)

Peroxisome proliferation: current mechanisms relating to nongenotoxic carcinogenesis. Lake BG. **Toxicol Lett** 1995 Dec;82-83:673-81 (33 ref.)

Relationship of DNA adducts derived from 2-acetylaminofluorene to cell proliferation and the induction of rodent liver and bladder tumors. Cohen SM, et al. **Toxicol Pathol** 1995 Mar-Apr;23(2):136-42 (21 ref.)

Negative selection in hepatic tumor promotion in relation to cancer risk assessment. Andersen ME, et al. **Toxicology** 1995 Sep 1;102(1-2):223-37 (82 ref.)

Comparison of experimental and theoretical parameters of the Moolgavkar-Venzon-Knudson incidence function for the stages of initiation and promotion in rat hepatocarcinogenesis. Dragan YP, et al. **Toxicology** 1995 Sep 1;102(1-2):161-75 (65 ref.)

Biochemical mechanisms and cancer risk assessment models for dioxin. Kohn MC. **Toxicology** 1995 Sep 1; 102(1-2):133-8 (31 ref.)

GENETICS

Immunochemical and genetic analysis of the p53 gene in liver preneoplastic nodules from aflatoxin-induced rats in one year. Liu YP, et al. **Ann Acad Med Singapore** 1996 Jan; 25(1):31-6 (51 ref.)

Stage-specific gene expression during hepatocarcinogenesis in the rat. Pitot HC. **J Cancer Res Clin Oncol** 1996; 122(5):257-65 (98 ref.)

Hypomethylation of DNA: a possible epigenetic mechanism involved in tumor promotion. Counts JL, et al. **Prog Clin Biol Res** 1995;391:81-101 (112 ref.)

Liver tumor promotion: a process of natural selection. Jirtle RL. **Prog Clin Biol Res** 1995;391:149-59 (59 ref.)

Hepatocarcinogenesis in transgenic mice. Sandgren EP, et al. **Prog Clin Biol Res** 1995;391:213-22 (35 ref.)

Transgenic models for detection of mutations in tumors and normal tissues of rodents. Mirsalis JC. **Toxicol Lett** 1995 Dec;82-83:131-4 (12 ref.)

Negative selection in hepatic tumor promotion in relation to cancer risk assessment. Andersen ME, et al. **Toxicology** 1995 Sep 1;102(1-2):223-37 (82 ref.)

METABOLISM

Phosphatidylethanolamine methylation and hepatoma cell growth. Vance DE, et al. **Anticancer Res** 1996 May-Jun; 16(3B):1413-6 (17 ref.)

PATHOLOGY

The evaluation of potential human carcinogens: a histopathologist's point of view. Greaves P. **Exp Toxicol Pathol** 1996 Feb;48(2-3):169-74 (17 ref.)

PHYSIOPATHOLOGY

Hormonal and genetic interactions in murine hepatocarcinogenesis. Poole TM, et al. **Prog Clin Biol Res** 1995;391:187-94 (24 ref.)

VIROLOGY

Hepatitis B virus HBx gene and hepatocarcinogenesis. Koike K. **Intervirology** 1995;38(3-4):134-42 (49 ref.)

LIVER REGENERATION

Liver regeneration versus direct hyperplasia. Columbano A, et al. **FASEB J** 1996 Aug;10(10):1118-28 (88 ref.)

Liver regeneration 3: Regulation of signal transduction during liver regeneration. Diehl AM, et al. **FASEB J** 1996 Feb;10(2):215-27 (77 ref.)

Posttranscriptional regulation of gene expression in liver regeneration: role of mRNA stability. Kren BT, et al. **FASEB J** 1996 Apr;10(5):559-73 (93 ref.)

The extracellular matrix in hepatic regeneration. Martinez-Hernandez A, et al. **FASEB J** 1995 Nov; 9(14):1401-10 (60 ref.)

Liver regeneration 7. Prometheus' myth revisited: transgenic mice as a powerful tool to study liver regeneration. Pistoi S, et al. **FASEB J** 1996 Jun;10(8):819-28 (68 ref.)

Analysis of liver development, regeneration, and carcinogenesis by genetic marking studies. Ponder KP. **FASEB J** 1996 May;10(7):673-82 (59 ref.)

Liver regeneration. Steer CJ. **FASEB J** 1995 Nov; 9(14):1396-400 (28 ref.)

Liver regeneration 4: transcriptional control of liver regeneration. Taub R. **FASEB J** 1996 Mar;10(4):413-27 (95 ref.)

Macroregenerative (dysplastic) nodules and hepatocarcinogenesis: theoretical and clinical considerations. Theise ND. **Semin Liver Dis** 1995 Nov; 15(4):360-71 (51 ref.)

[Development of metabolic parameters in the early phases of liver regeneration] Bláha V, et al. **Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove** 1995;38(1 Suppl):37-55 (67 ref.) (Eng. Abstr.) **(Cze)**

[Control of liver proliferation: structural, functional and molecular aspects] Rabes HM. **Verh Dtsch Ges Pathol** 1995; 79:61–71 (50 ref.) (Eng. Abstr.) **(Ger)**

[Growth factors in liver regeneration and hepatocarcinogenesis] Schirmacher P, et al. **Verh Dtsch Ges Pathol** 1995;79:55–60 (47 ref.) (Eng. Abstr.) **(Ger)**

DRUG EFFECTS

A review of the role of tissue repair as an adaptive strategy: why low doses are often non-toxic and why high doses can be fatal. Calabrese EJ, et al. **Food Chem Toxicol** 1996 Mar;34(3):301–11 (49 ref.)

Efficient tissue repair underlies the resiliency of postnatally developing rats to chlordecone + CCl4 hepatotoxicity. Dalu A, et al. **Toxicology** 1996 Jul 17;111(1–3):29–42 (41 ref.)

PHYSIOLOGY

Liver regeneration. 2. Role of growth factors and cytokines in hepatic regeneration. Fausto N, et al. **FASEB J** 1995 Dec;9(15):1527–36 (68 ref.)

HGF in liver regeneration and tumor promotion. Michalopoulos GK. **Prog Clin Biol Res** 1995;391:179–85 (29 ref.)

[Regulation of liver regeneration after hepatectomy] Liu XQ, et al. **Sheng Li Ko Hsueh Chin Chan** 1995 Oct;26(4):349–51 (11 ref.) **(Chi)**

[Regulation of liver regeneration by hepatocyte growth factor–humor and hepatocyte growth factor–cytosol] Qiu ZH, et al. **Sheng Li Ko Hsueh Chin Chan** 1995 Jul; 26(3):256–8 (9 ref.) **(Chi)**

LIVER TRANSPLANTATION

Endoscopic stenting of gallbladder for symptomatic cholelithiasis in patients with end-stage liver disease awaiting orthotopic liver transplantation. Shrestha R, et al. **Am J Gastroenterol** 1996 Mar;91(3):595–8 (21 ref.)

Hepatitis C viral infection in liver transplantation. Johnson MW, et al. **Arch Surg** 1996 Mar;131(3):284–91 (26 ref.)

The hepatopulmonary syndrome. Effect of liver transplantation. Lange PA, et al. **Clin Chest Med** 1996 Mar; 17(1):115–23 (46 ref.)

Does interferon precipitate rejection of liver allografts? [editorial] Min AD, et al. **Hepatology** 1995 Oct;22(4 Pt 1):1333–5 (22 ref.)

Prevention of bacterial infection in the transplant recipient. The role of selective bowel decontamination. Arnow PM. **Infect Dis Clin North Am** 1995 Dec;9(4):849–62 (63 ref.)

Fulminant liver failure: relevance of extracorporeal hybrid liver support systems. Gerlach J, et al. **Int J Artif Organs** 1996 Jan;19(1):7–13 (79 ref.)

HIV-1-associated pathology in hemato-lymphoid organs and the experimental evaluation in the SCID-hu mouse. Kaneshima H. **Int J Hematol** 1996 Jun;63(4):253–64 (89 ref.)

Hepatitis C and liver transplantation. Chazouilleres O, et al. **J Gastroenterol Hepatol** 1995 Jul–Aug;10(4):471–80 (69 ref.)

In utero transplantation of fetal liver stem cells into human fetuses. Touraine JL. **J Hematother** 1996 Apr;5(2):195–9 (15 ref.)

Liver allograft rejection—current concepts on diagnosis and treatment. Neuberger J. **J Hepatol** 1995;23 Suppl 1:54–61 (52 ref.)

Liver transplantation for alcoholic liver disease [editorial] Sherman D, et al. **J Hepatol** 1995 Oct;23(4):474–9 (32 ref.)

Infections in liver transplantation: risk factors and strategies for prevention. Kibbler CC. **J Hosp Infect** 1995 Jun;30 Suppl:209–17 (40 ref.)

Liver transplantation for hepatic cirrhosis in cystic fibrosis. Noble-Jamieson G, et al. **J R Soc Med** 1996;89 Suppl 27:31–7 (24 ref.)

Liver transplantation for acute and chronic viral hepatitis. Tibbs CJ, et al. **J Viral Hepat** 1995;2(2):65–72 (38 ref.)

Randomised trialomania? The multicentre liver transplant trials of tacrolimus [see comments] Starzl TE, et al. **Lancet** 1995 Nov 18;346(8986):1346–50 (28 ref.) Comment in: Lancet 1995 Nov 18;346(8986):1310–1.

Indications for and timing of liver transplantation. Rosen HR, et al. **Med Clin North Am** 1996 Sep;80(5):1069–102 (260 ref.)

The clinical and ethical implications of hepatitis C for organ transplantation in Australia. Kerridge IH, et al. **Med J Aust** 1996 Sep 2;165(5):282–5 (49 ref.)

Selection of transplantation procedures and perioperative management in primary hyperoxaluria type I. Latta K, et al. **Nephrol Dial Transplant** 1995;10 Suppl 8:53–7 (34 ref.)

Liver transplantation and its long-term management in children. Lee H, et al. **Pediatr Clin North Am** 1996 Feb; 43(1):99–124 (107 ref.)

Hepatitis B-associated liver cirrhosis as an indication for liver transplantation. Jansen PL, et al. **Scand J Gastroenterol Suppl** 1995;212:19–22 (21 ref.)

Liver transplantation and hepatocellular carcinoma. Yokoyama I, et al. **Semin Surg Oncol** 1996 May-Jun; 12(3):212–6 (30 ref.)

Relationships between sclerosing cholangitis, inflammatory bowel disease, and cancer in patients undergoing liver transplantation. Knechtle SJ, et al. **Surgery** 1995 Oct; 118(4):615–9; discussion 619–20 (18 ref.)

Orthotopic liver transplantation in hemophilia B: a case report. Kadry Z, et al. **Transpl Int** 1995;8(6):485–7 (26 ref.)

Overview of imaging in living related donor hepatic transplantation. Cheng YF, et al. **Transplant Proc** 1996 Aug; 28(4):2412–4 (19 ref.)

Anesthesia for living related donor liver transplantation. Jawan B, et al. **Transplant Proc** 1996 Aug;28(4):2409–11 (39 ref.)

[Spare parts for the abdominal region] Höckerstedt K, et al. **Duodecim** 1994;110(20):1901–11 (33 ref.) **(Fin)**

[Is preventive perioperative dopamine administration of value?] Bund M, et al. **Anaesthesiol Reanim** 1995; 20(3):76–81 (45 ref.) (Eng. Abstr.) **(Ger)**

[Orthotopic liver transplantation in therapy of advanced polycystic liver disease] Klupp J, et al. **Chirurg** 1996 May; 67(5):515–21 (25 ref.) (Eng. Abstr.) **(Ger)**

[Does the primary disease recur following liver transplantation?] Renner EL. **Ther Umsch** 1995 Sep; 52(9):572–80 (61 ref.) (Eng. Abstr.) **(Ger)**

[Living related liver transplantation] Mor E. **Harefuah** 1995 Dec 15;129(12):564–9 (22 ref.) **(Heb)**

[Liver transplantation in Norway. Results after 10 years and 114 transplantations] Bjøro K, et al. **Tidsskr Nor Laegeforen** 1996 Jan 10;116(1):19–24 (32 ref.) (Eng. Abstr.) **(Nor)**

[Familial amyloidotic polyneuropathy and liver transplantation (editorial)] Buades Reinés J, et al. **Gastroenterol Hepatol** 1995 Nov;18(9):480–2 (23 ref.) **(Spa)**

[The interferon treatment of hepatitis C in the liver transplant patient (editorial)] de la Mata M, et al. **Gastroenterol Hepatol** 1996 May;19(5):259–61 (42 ref.) **(Spa)**

[Liver transplantation and neurological complications of hepatopathy] Gisbert C, et al. **Rev Neurol** 1995 Sep-Oct; 23(123):1033–6 (7 ref.) **(Spa)**

ADVERSE EFFECTS

Epstein-Barr virus-related localized hepatic lymphoproliferative disorders after liver transplantation. Raymond E, et al. **Cancer** 1995 Oct 15;76(8):1344–51 (36 ref.)

Pulmonary complications of liver transplantation. O'Brien JD, et al. **Clin Chest Med** 1996 Mar;17(1):99–114 (95 ref.)

Infections in liver transplant recipients. Winston DJ, et al. **Clin Infect Dis** 1995 Nov;21(5):1077–89; quiz 1090–1 (55 ref.)

Endoscopic diagnosis and management of biliary complications following orthotopic liver transplantation. Gholson CF, et al. **Dig Dis Sci** 1996 Jun;41(6):1045–53 (49 ref.)

Native hepatic artery pseudoaneurysm after liver transplantation: an unusual presentation with biliary leak. Soin AS, et al. **Eur J Vasc Endovasc Surg** 1995 Oct; 10(3):376–9 (9 ref.)

Aspergillus endophthalmitis. An unrecognized endemic disease in orthotopic liver transplantation. Hunt KE, et al. **Ophthalmology** 1996 May;103(5):757–67 (65 ref.)

Hepatitis C virus infection in liver allografts. Randhawa PS, et al. **Pathol Annu** 1995;30 Pt 2:203–26 (126 ref.)

Renal dysfunction associated with liver transplantation. Jindal RM, et al. **Postgrad Med J** 1995 Sep;71(839):513–24 (130 ref.)

Hepatitis C virus and organ transplantation. Fishman JA, et al. **Transplantation** 1996 Jul 27;62(2):147–54 (100 ref.)

[Cholangiopathy after orthotopic liver transplantation: Rejection cholangiopathy] Hashimoto E, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):550–2 (20 ref.) **(Jpn)**

[Neurological complications after liver transplantation] Casanova B, et al. **Rev Neurol** 1995 Sep-Oct; 23(123):1037–40 (28 ref.) **(Spa)**

[Neurological complications after transplants: cerebrovascular complications] Martinez-Vila E, et al. **Rev Neurol** 1995;23 Suppl 1:S79–86 (49 ref.) **(Spa)**

IMMUNOLOGY

Liver transplantation: current status, complications and prevention. Buckels JA. **J Antimicrob Chemother** 1995 Oct; 36 Suppl B:39–49 (12 ref.)

Adhesion molecules and liver transplantation: new strategies for therapeutic intervention. Adams DH. **J Hepatol** 1995 Aug;23(2):225–31 (58 ref.)

Liver transplants contribute to their own success [comment] Starzl TE, et al. **Nat Med** 1996 Feb;2(2):163–5 (22 ref.) Comment on: Nat Med 1996 Feb;2(2):198–203.

Strategies for tolerance induction: potential applications in living donor liver transplantation. Emond JC, et al. **Transplant Proc** 1996 Aug;28(4):2371–4 (25 ref.)

Neoral in liver transplantation. Jamieson NV, et al. **Transplant Proc** 1996 Aug;28(4):2229–31 (35 ref.)

Clinical use of FK 506 in liver transplantation. Klintmalm GB. **Transplant Proc** 1996 Apr;28(2):974–6 (13 ref.)

Neoral in liver transplantation. Levy GA, et al. **Transplant Proc** 1996 Apr;28(2):1019–21 (9 ref.)

Neoral therapy in liver transplantation. Levy GA. **Transplant Proc** 1996 Aug;28(4):2225–8 (27 ref.)

[Immunologic tolerance after experimental liver transplantation] Knoop M, et al. **Langenbecks Arch Chir** 1995;380(5):281–7 (68 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Liver transplantation. Shaw BW Jr. **Curr Opin Gen Surg** 1993;:239–48 (50 ref.)

Surgical research in orthotopic liver transplantation: experiences in the pig model. Filipponi F, et al. **G Chir** 1996 Apr;17(4):201–9 (58 ref.)

Ethical issues in living related donor liver transplantation. Strong RW, et al. **Transplant Proc** 1996 Aug;28(4):2366–9 (21 ref.)

[Technical progress in liver transplantation] Boillot O, et al. **Ann Chir** 1996;50(3):231–40 (43 ref.) (Eng. Abstr.) **(Fre)**

[Treatment of hepatocellular carcinoma in the presence of liver cirrhosis] Ducreux M, et al. **J Chir (Paris)** 1995 Jun-Jul;132(6–7):279–86 (60 ref.) (Eng. Abstr.) **(Fre)**

[Liver transplantation. Current aspects] Soubrane O, et al. **Presse Med** 1996 Feb 3;25(4):167–70 (19 ref.) (Eng. Abstr.) **(Fre)**

[Liver transplantation in children] Valayer J. **Presse Med** 1995 Oct 21;24(31):1438–43 (21 ref.) (Eng. Abstr.) **(Fre)**

[Liver transplantation: results with living donors] Gertsch P. **Ther Umsch** 1995 Sep;52(9):585–9 (23 ref.) (Eng. Abstr.) **(Fre)**

[Effect of liver transplantation on general techniques of liver resection] Erhard J, et al. **Chirurg** 1996 Apr;67(4):331–40 (30 ref.) (Eng. Abstr.) **(Ger)**

[Liver transplantation as school for visceral surgery—experiences for perioperative management] Neuhaus P, et al. **Chirurg** 1996 Apr;67(4):341–7 (31 ref.) (Eng. Abstr.) **(Ger)**

[Hepatocyte transplantation: current status] Arranz Caso JA, et al. **Med Clin (Barc)** 1996 Jan 13;106(1):27–35 (144 ref.) **(Spa)**

PATHOLOGY

Diagnosis and grading of liver allograft rejection: a European perspective. Hübscher S. **Transplant Proc** 1996 Feb; 28(1):504–7 (23 ref.)

Clinical and immunological aspects of liver allograft rejection. Schlitt HJ. **Transplant Proc** 1996 Feb;28(1):514–6 (13 ref.)

Pathology and biopsy diagnosis of the transplanted liver. Portmann B, et al. **Verh Dtsch Ges Pathol** 1995;79:277–90 (40 ref.)

[Pathology of liver graft viral reinfection] Reynès M, et al. **Ann Pathol** 1995;15(5):396–402 (40 ref.) **(Fre)**

PHYSIOLOGY

Liver transplantation for primary liver cancer. Ringe B, et al. **Transplant Proc** 1996 Jun;28(3):1174–5 (10 ref.)

Clinical and immunological aspects of liver allograft rejection. Schlitt HJ. **Transplant Proc** 1996 Feb;28(1):514–6 (13 ref.)

[Effect of organ preservation conditions on reperfusion after liver transplantation] Walcher F, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Oct; 30 Suppl 1:S55–7 (27 ref.) **(Ger)**

[Cholestatic erythrohepatic protoporphyria: porphyrin metabolism before and after liver transplantation] Doss MO, et al. **Z Gastroenterol** 1993 Feb;31 Suppl 2:85–9 (31 ref.) (Eng. Abstr.) **(Ger)**

RADIOGRAPHY

Imaging in liver transplantation. Bowen A, et al. **Radiol Clin North Am** 1996 Jul;34(4):757–78 (85 ref.)

REHABILITATION

Long-term management of the liver transplant recipient. Muñoz SJ. **Med Clin North Am** 1996 Sep;80(5):1103–20 (72 ref.)

STANDARDS

Nutritional and metabolic considerations of the adult liver transplant candidate and organ donor. Driscoll DF, et al. **Nutrition** 1995 May-Jun;11(3):255–63 (85 ref.)

TRENDS

Artificial liver. Evolution and future perspectives. Rozga J, et al. **ASAIO J** 1995 Oct-Dec;41(4):831–7 (58 ref.)

Clinical and experimental progress in liver transplantation. Cortesini R. **Transplant Proc** 1996 Aug;28(4):2319–21 (13 ref.)

ULTRASONOGRAPHY

Imaging in liver transplantation. Bowen A, et al. **Radiol Clin North Am** 1996 Jul;34(4):757–78 (85 ref.)

LIVESTOCK see **ANIMALS, DOMESTIC**

LIVING WILLS

see related
RIGHT TO DIE

LEGISLATION & JURISPRUDENCE

Living wills, durable powers of attorney for health care, and HIV infection. The need for statutory reform. Loue S. **J Leg Med** 1995 Dec;16(4):461–80 (96 ref.)

LIVOR MORTIS

LIVOR MORTIS see **POSTMORTEM CHANGES**

LIZARDS

Bioactive peptides from lizard venoms. Raufman JP. **Regul Pept** 1996 Jan 16;61(1):1–18 (165 ref.)

LMWH see **HEPARIN, LOW-MOLECULAR-WEIGHT**

LOBAR PNEUMONIA see **PNEUMONIA, LOBAR**

LOBBYING

Well-healed: inside lobbying for health care reform, Part II. Center for Public Integrity. **Int J Health Serv** 1995; 25(4):593–632 (76 ref.)

Harry and Louise go to Washington: political advertising and health care reform. West DM, et al. **J Health Polit Policy Law** 1996 Spring;21(1):35–68 (57 ref.)

LOBOTOMY see **PSYCHOSURGERY**

LOBSTEIN'S DISEASE see **OSTEOGENESIS IMPERFECTA**

LOCKED-IN SYNDROME see **QUADRIPLEGIA**

LOCOMOTION

see related
GAIT

PHYSIOLOGY

Evidence for a spinal stepping generator in man. Electrophysiological study. Bussel B, et al. **Acta Neurobiol Exp (Warsz)** 1996;56(1):465–8 (25 ref.)

Locomotor capacities after complete and partial lesions of the spinal cord. Rossignol S, et al. **Acta Neurobiol Exp (Warsz)** 1996;56(1):449–63 (135 ref.)

Proprioceptive regulation of locomotion. Pearson KG. **Curr Opin Neurobiol** 1995 Dec;5(6):786–91 (38 ref.)

The study of kinematic transients in locomotion using the integrated kinematic sensor. Wu G, et al. **IEEE Trans Rehabil Eng** 1996 Sep;4(3):193–200 (18 ref.)

Optimum gradient of mountain paths. Minetti AE. **J Appl Physiol** 1995 Nov;79(5):1698–703 (11 ref.)

Path integration in mammals and its interaction with visual landmarks. Etienne AS, et al. **J Exp Biol** 1996 Jan;199 (Pt 1):201–9 (49 ref.)

Muscle function and mobility biomechanics in the elderly: an overview of some recent research. Schultz AB. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:60–3 (29 ref.)

Modular organization of motor behavior in the frog's spinal cord. Bizzi E, et al. **Trends Neurosci** 1995 Oct;18(10):442–6 (30 ref.)

Neural networks that co-ordinate locomotion and body orientation in lamprey. Grillner S, et al. **Trends Neurosci** 1995 Jun;18(6):270–9 (64 ref.)

[Control mechanisms of locomotor movements from a viewpoint of behavioral control] Mori S. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1995 Jun; 15(3):281–7 (22 ref.) (Eng. Abstr.) **(Jpn)**

[The perception of muscle loading and the role of locomotor and respiratory sensation] Breslav IS. **Fiziol Zh Im I M Sechenova** 1994 Dec;80(12):10–20 (69 ref.) **(Rus)**

[Principles controlling movement] Arshavskiĭ Iul, et al. **Mol Biol (Mosk)** 1995 Nov–Dec;29(6):1427–35 (19 ref.) **(Rus)**

LOCOMOTION, CELL see **CELL MOVEMENT**

LOCUS COERULEUS

METABOLISM

The role of the locus coeruleus and N-methyl-D-aspartic acid (NMDA) and AMPA receptors in opiate withdrawal. Rasmussen K. **Neuropsychopharmacology** 1995 Dec; 13(4):295–300 (165 ref.)

PATHOLOGY

Noradrenergic locus coeruleus neurons [letter] Halliday G, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1):191–2 (15 ref.)

LOCUS OF CONTROL see **INTERNAL-EXTERNAL CONTROL**

LOCUSTS see **GRASSHOPPERS**

LOEFFLER SYNDROME see **PULMONARY EOSINOPHILIA**

LOEFFLER'S ENDOCARDITIS see **HYPEREOSINOPHILIC SYNDROME**

LOG-LINEAR MODELS see **LINEAR MODELS**

LOGIC, FUZZY see **FUZZY LOGIC**

LOGISTIC MODELS

Multivariate statistical analysis for pathologist. Part I, The logistic model. Vollmer RT. **Am J Clin Pathol** 1996 Jan; 105(1):115–26 (16 ref.)

LOGISTIC REGRESSION see **LOGISTIC MODELS**

LOGIT MODELS see **LOGISTIC MODELS**

LONELINESS

Caring for older people. Loneliness. Forbes A. **BMJ** 1996 Aug 10;313(7053):352–4 (0 ref.)

LONG-ACTING THYROID STIMULATOR

see related
RECEPTORS, THYROID HORMONE

LONG-CHAIN ACYL COA see **ACYL COENZYME A**

LONG QT SYNDROME

Torsades de pointes and long QT syndromes. Janeira LF. **Am Fam Physician** 1995 Oct;52(5):1447–53 (36 ref.)

CHEMICALLY INDUCED

Tricyclic medication in children and the QT interval: case report and discussion. Alderton HR. **Can J Psychiatry** 1995 Aug;40(6):325–9 (30 ref.)

COMPLICATIONS

Infants with long-QT syndrome and 2:1 atrioventricular block. Trippel DL, et al. **Am Heart J** 1995 Nov; 130(5):1130–4 (21 ref.)

CONGENITAL

The molecular genetics of the congenital long QT syndromes. Russell MW, et al. **Curr Opin Cardiol** 1996 Jan;11(1):45–51 (33 ref.)

GENETICS

The molecular genetics of the congenital long QT syndromes. Russell MW, et al. **Curr Opin Cardiol** 1996 Jan;11(1):45–51 (33 ref.)

Recent advances in understanding the molecular mechanisms of the long QT syndrome. Roden DM, et al. **J Cardiovasc Electrophysiol** 1995 Nov;6(11):1023–31 (49 ref.)

The long QT syndrome. A review of recent molecular genetic and physiologic discoveries. Keating MT. **Medicine (Baltimore)** 1996 Jan;75(1):1–5 (21 ref.)

PATHOLOGY

Role of M cells in acquired long QT syndrome, U waves, and torsade de pointes. Antzelevitch C, et al. **J Electrocardiol** 1995;28 Suppl:131–8 (44 ref.)

PHYSIOPATHOLOGY

Mechanisms and management of congenital and acquired long QT syndromes. Lazzara R. **Arch Mal Coeur Vaiss** 1996 Feb;89 Spec No 1:51–5 (34 ref.)

THERAPY

Mechanisms and management of congenital and acquired long QT syndromes. Lazzara R. **Arch Mal Coeur Vaiss** 1996 Feb;89 Spec No 1:51–5 (34 ref.)

LONG-TERM CARE

Antimicrobial resistance patterns in long term geriatric care. Implications for drug therapy. Mao CA, et al. **Drugs Aging** 1996 Mar;8(3):162–70 (66 ref.)

Physician-assisted death in The Netherlands: impact on long-term care. Fenigsen R. **Issues Law Med** 1995 Winter; 11(3):283–97 (59 ref.)

ECONOMICS

Long-term care reimbursement issues. Stone D, et al. **Clin Geriatr Med** 1995 Aug;11(3):517–29 (19 ref.)

METHODS

Liver transplantation and its long-term management in children. Lee H, et al. **Pediatr Clin North Am** 1996 Feb; 43(1):99–124 (107 ref.)

ORGANIZATION & ADMINISTRATION

The medical director in non-institutional long-term care programs. Finucane TE, et al. **Clin Geriatr Med** 1995 Aug; 11(3):391–402 (15 ref.)

The corporate medical director. Krein K. **Clin Geriatr Med** 1995 Aug;11(3):403–17 (10 ref.)

The acute and long-term care interface. Integrating the continuum. Phillips-Harris C, et al. **Clin Geriatr Med** 1995 Aug;11(3):481–501 (24 ref.)

The future of long-term care and the role of the medical director. Willging P. **Clin Geriatr Med** 1995 Aug; 11(3):531–45 (10 ref.)

Infection control in long-term care. Yoshikawa TT, et al. **Clin Geriatr Med** 1995 Aug;11(3):467–80 (65 ref.)

A contextual approach for understanding individual autonomy in managed community long-term care. Capitman J, et al. **Gerontologist** 1995 Aug;35(4):533–40 (55 ref.)

STANDARDS

Applying the 1996 JCAHO nutrition care standards in a long-term-care setting. Robinson GE. **J Am Diet Assoc** 1996 Apr;96(4):400–3 (8 ref.)

STATISTICS & NUMERICAL DATA

Antihypertensive drug use in the long-term care facility: a pilot study and review of the literature. Fish JT, et al. **Pharmacotherapy** 1995 Nov-Dec;15(6):785–8 (11 ref.)

LONG-TERM POTENTIATION

Ionotropic glutamate receptors. Their possible role in the expression of hippocampal synaptic plasticity. Asztély F, et al. **Mol Neurobiol** 1996 Feb;12(1):1–11 (122 ref.)

The involvement of PKC and multifunctional CaM kinase II of the postsynaptic neuron in induction and maintenance of long-term potentiation. Feng TP. **Prog Brain Res** 1995; 105:55–63 (27 ref.)

GENETICS

A role for immediate-early transcription factors in learning and memory. Dragunow M. **Behav Genet** 1996 May; 26(3):293–9 (55 ref.)

The use of null mutant mice to study complex learning and memory processes. Wehner JM, et al. **Behav Genet** 1996 May;26(3):301–12 (75 ref.)

The gene knockout technology for the analysis of learning and memory, and neural development. Tonegawa S, et al. **Prog Brain Res** 1995;105:3–14 (43 ref.)

PHYSIOLOGY

Long-term potentiation and long-term depression of horizontal connections in rat motor cortex. Hess G, et al. **Acta Neurobiol Exp (Warsz)** 1996;56(1):397–405 (32 ref.)

Long-term potentiation and learning. Martinez JL Jr, et al. **Annu Rev Psychol** 1996;47:173–203 (150 ref.)

Long-term potentiation. The cell biology connection. Meldolesi J. **Curr Biol** 1995 Sep 1;5(9):1006–8 (14 ref.)

Synaptic plasticity: hippocampal LTP. Larkman AU, et al. **Curr Opin Neurobiol** 1995 Jun;5(3):324–34 (120 ref.)

Involvement of LTP in memory: are we "searching under the street light"? Barnes CA. **Neuron** 1995 Oct;15(4):751–4 (21 ref.)

The critical period for long-term potentiation in primary sensory cortex. Fox K. **Neuron** 1995 Sep;15(3):485–8 (21 ref.)

The site of expression of NMDA receptor-dependent LTP: new fuel for an old fire. Kullmann DM, et al. **Neuron** 1995 Nov;15(5):997–1002 (22 ref.)

Long-term potentiation and N-methyl-D-aspartate receptors: foundations of memory and neurologic disease? Rison RA, et al. **Neurosci Biobehav Rev** 1995 Winter; 19(4):533–52 (223 ref.)

How multiple-synapse boutons could preserve input specificity during an interneuronal spread of LTP. Harris KM. **Trends Neurosci** 1995 Aug;18(8):365–9 (44 ref.)

[The simultaneous activation of excitatory and inhibitory inputs as a condition for the induction of homo-, hetero- and associative long-term excitation depression] Sil'kis IG. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1995 Nov–Dec; 45(6):1151–66 (58 ref.) (Eng. Abstr.) **(Rus)**

LONG-TERM SURVIVORS see **SURVIVORS**

LONG TERMINAL REPEAT see **REPETITIVE SEQUENCES, NUCLEIC ACID**

LONGEVITY

see related
AGED
AGED, 80 AND OVER
LIFE EXPECTANCY

Education, homeostasis, and longevity. Timiras PS. **Exp Gerontol** 1995 May-Aug;30(3–4):189–98 (41 ref.)

Rapid development and a long life: an association expected under a stress theory of aging. Parsons PA. **Experientia** 1996 Jul 15;52(7):643–6 (54 ref.)

Induction and repair of benzo[a]pyrene-DNA adducts in C57BL/6 and BALB/c mice: association with aging and longevity. Boerrigter ME, et al. **Mech Ageing Dev** 1995 Jul 28;82(1):31–50 (50 ref.)

DRUG EFFECTS

Are lifespan rodent carcinogenicity studies defensible for pharmaceutical agents? Monro A. **Exp Toxicol Pathol** 1996 Feb;48(2-3):155–66 (70 ref.)

GENETICS

Longevity assurance genes: how do they influence aging and

life span? Hodes RJ, et al. **J Am Geriatr Soc** 1996 Aug; 44(8):988–91 (32 ref.)
Evolution of longevity in mammals. Smith DW. **Mech Ageing Dev** 1995 Jun 30;81(1):51–60 (50 ref.)
Longevity, genes, and aging. Jazwinski SM. **Science** 1996 Jul 5;273(5271):54–9 (73 ref.)

IMMUNOLOGY

Immunosenescence in humans: deterioration or remodelling? Franceschi C, et al. **Int Rev Immunol** 1995;12(1):57–74 (100 ref.)

PHYSIOLOGY

Role of caloric restriction in the prolongation of life. McCarter RJ. **Clin Geriatr Med** 1995 Nov;11(4):553–65 (53 ref.)
Selection for increased longevity in Drosophila melanogaster: reflections on new data. Baret PV, et al. **Gerontology** 1996; 42(1):14–7 (10 ref.)
McCay's hypothesis: undernutrition and longevity. Masoro EJ. **Proc Nutr Soc** 1996 Nov;54(3):657–64 (39 ref.)
[Enterosorption as a method for prolonging life] Mamai AV, et al. **Fiziol Cheloveka** 1996 May–Jun;22(3):131–5 (32 ref.) **(Rus)**

LONGITUDINAL LIGAMENTS

RADIOGRAPHY

An unusual location for heterotopic ossification: lumbar anterior longitudinal ligament. Czyrny JJ, et al. **J Spinal Cord Med** 1995 Jul;18(3):194–9 (32 ref.)

LONGITUDINAL STUDIES

Model selection techniques for the covariance matrix for incomplete longitudinal data. Grady JJ, et al. **Stat Med** 1995 Jul 15;14(13):1397–416 (20 ref.)

LOOP ILEOSTOMY see **ILEOSTOMY**

LOOP OF HENLE

DRUG EFFECTS

The role of continuous infusion loop diuretics. Yelton SL, et al. **Ann Pharmacother** 1995 Oct;29(10):1010–4; quiz 1060–1 (19 ref.)

LOOSE BODIES, JOINT see **JOINT LOOSE BODIES**

LORAZEPAM

ADMINISTRATION & DOSAGE

The management of opioid and benzodiazepine dependence in infants, children, and adolescents. Yaster M, et al. **Pediatrics** 1996 Jul;98(1):135–40 (41 ref.)

LORDOSIS

CONGENITAL

Congenital spinal deformity. Winter RB, et al. **Instr Course Lect** 1996;45:117–27 (47 ref.)

LORR'S INPATIENT MULTIDIMENSIONAL PSYCHIATRIC RATING SCALE see **PSYCHIATRIC STATUS RATING SCALES**

LOU GEHRIG'S DISEASE see **AMYOTROPHIC LATERAL SCLEROSIS**

LOUIS-BAR SYNDROME see **ATAXIA TELANGIECTASIA**

LOUPING ILL

TRANSMISSION

Persistence and transmission of tick-borne viruses: Ixodes ricinus and louping-ill virus in red grouse populations. Hudson PJ, et al. **Parasitology** 1995;111 Suppl:S49–58 (27 ref.)

LOUPING ILL VIRUS see **ENCEPHALITIS VIRUSES, TICK-BORNE**

LOVASTATIN

ANALOGS & DERIVATIVES

Treatment of hyperlipidemia after heart transplantation and rationale for the Heart Transplant Lipid Registry. Ballantyne CM, et al. **Am J Cardiol** 1996 Sep 1;78(5):532–5 (34 ref.)
Statin therapy in clinical practice: new developments. Shepherd J. **Curr Opin Lipidol** 1995 Oct;6(5):254–5 (13 ref.)
Simvastatin. A reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolaemia. Plosker GL, et al. **Drugs** 1995 Aug;50(2):334–63 (239 ref.)
The 4S study. Implications for prescribing. van Boven AJ, et al. **Drugs** 1996 Apr;51(4):507–14 (55 ref.)
[The pharmacology of the statins: the evidence of a direct antiatherosclerotic action] Raiteri M, et al. **Ann Ital Med Int** 1995 Oct;10 Suppl:35S–42S (74 ref.) (Eng. Abstr.) **(Ita)**

PHARMACOLOGY

[The pharmacology of the statins: the evidence of a direct antiatherosclerotic action] Raiteri M, et al. **Ann Ital Med Int** 1995 Oct;10 Suppl:35S–42S (74 ref.) (Eng. Abstr.) **(Ita)**

THERAPEUTIC USE

Treatment of hyperlipidemia after heart transplantation and rationale for the Heart Transplant Lipid Registry. Ballantyne CM, et al. **Am J Cardiol** 1996 Sep 1;78(5):532–5 (34 ref.)

LOVE

The healing energy of love. Green J, et al. **Altern Ther Health Med** 1996 May;2(3):46–56 (58 ref.)
Desire and the female analyst. Schaverien J. **J Anal Psychol** 1996 Apr;41(2):261–87 (91 ref.)

LOW BACK PAIN

see related
SCIATICA

Diagnosis and management of low back pain and sciatica. Wheeler AH. **Am Fam Physician** 1995 Oct;52(5):1333–41, 1347–8 (33 ref.)
Low back pain. Brody M. **Ann Emerg Med** 1996 Apr; 27(4):454–6 (8 ref.)
Spinal dorsal ramus syndrome. Shao Z, et al. **Chin Med J (Engl)** 1996 Apr;109(4):317–21 (36 ref.)

COMPLICATIONS

Loin pain haematuria syndrome. Burke JR, et al. **Pediatr Nephrol** 1996 Apr;10(2):216–20 (45 ref.)

DIAGNOSIS

Assessment and exercise in low back pain. With special reference to the management of pain and disability following first time lumbar disc surgery. Manniche C. **Dan Med Bull** 1995 Sep;42(4):301–13 (155 ref.)
Clinical efficacy of imaging modalities in the diagnosis of low-back pain disorders. Boos N, et al. **Eur Spine J** 1996; 5(1):2–22 (142 ref.)
Functional disability scales for back pain. Kopec JA, et al. **Spine** 1995 Sep 1;20(17):1943–9 (19 ref.)
[The internist's differential diagnosis of low back pains] Mau W, et al. **Dtsch Med Wochenschr** 1995 Nov 17; 120(46):1589–94 (19 ref.) **(Ger)**
[Lumbago-sciatica syndrome as the first manifestation of metastatic renal adenocarcinoma] Amat Cecilia M, et al. **Actas Urol Esp** 1996 Jan;20(1):54–8 (7 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Lumbar zygapophysial (facet) joint injections. Dreyfuss PH, et al. **Spine** 1995 Sep 15;20(18):2040–7 (89 ref.)

EPIDEMIOLOGY

Epidemiology, etiology, diagnostic evaluation, and treatment of low back pain. Borenstein D. **Curr Opin Rheumatol** 1996 Mar;8(2):124–9 (27 ref.)

ETIOLOGY

Low back pain and the zygapophysial (facet) joints. Dreyer SJ, et al. **Arch Phys Med Rehabil** 1996 Mar;77(3):290–300 (145 ref.)
Smoking and low back pain: is the association real? Leboeuf-Yde C, et al. **J Manipulative Physiol Ther** 1995 Sep;18(7):457–63 (24 ref.)
The relationship between symptoms and abnormal magnetic resonance images of lumbar intervertebral disks. Beattie P. **Phys Ther** 1996 Jun;76(6):601–8 (32 ref.)
Neural mechanisms of lumbar pain. Cavanaugh JM. **Spine** 1995 Aug 15;20(16):1804–9 (44 ref.)
Magnetic resonance imaging. Use in patients with low back or radicular pain. Herzog RJ, et al. **Spine** 1995 Aug 15; 20(16):1834–8 (31 ref.)

PATHOLOGY

The role of inflammation in lumbar pain. Saal JS. **Spine** 1995 Aug 15;20(16):1821–7 (45 ref.)

PHYSIOPATHOLOGY

Low back pain and the zygapophysial (facet) joints. Dreyer SJ, et al. **Arch Phys Med Rehabil** 1996 Mar;77(3):290–300 (145 ref.)

PREVENTION & CONTROL

Use of back belts in occupational settings. Minor SD. **Phys Ther** 1996 Apr;76(4):403–8 (21 ref.)

RADIOGRAPHY

Radiographic assessment for patients with low back pain. Simmons ED Jr, et al. **Spine** 1995 Aug 15;20(16):1839–41 (4 ref.)

REHABILITATION

Spine update. Functional restoration. Hazard RG. **Spine** 1995 Nov 1;20(21):2345–8 (20 ref.)
Functional restoration. Returning patients with chronic low back pain to work--revolution or fad? Teasell RW, et al. **Spine** 1996 Apr 1;21(7):844–7 (17 ref.)

SURGERY

Urinary bladder dysfunction following anterior lumbosacral spine fusion: case report and review of the literature. Faraj AA, et al. **Eur Spine J** 1996;5(2):121–4 (11 ref.)

THERAPY

Assessment and exercise in low back pain. With special reference to the management of pain and disability following first time lumbar disc surgery. Manniche C. **Dan Med Bull** 1995 Sep;42(4):301–13 (155 ref.)
Impact of varying panel membership on ratings of appropriateness in consensus panels: a comparison of a multi- and single disciplinary panel. Coulter I, et al. **Health Serv Res** 1995 Oct;30(4):577–91 (34 ref.)
MUJA: manipulation under joint anesthesia/analgesia: a treatment approach for recalcitrant low back pain of synovial joint origin. Dreyfuss P, et al. **J Manipulative Physiol Ther** 1995 Oct;18(8):537–46 (107 ref.)
Promises and limitations of the Patient Outcome Research Teams: the low-back pain example. Deyo RA. **Proc Assoc Am Physicians** 1995 Oct;107(3):324–8 (22 ref.)

LOW CARDIAC OUTPUT see **CARDIAC OUTPUT, LOW**

LOW-DENSITY LIPOPROTEINS see **LIPOPROTEINS, LDL**

LOW-INCOME POPULATION see **POVERTY**

LOW-MOLECULAR-WEIGHT HEPARIN see **HEPARIN, LOW-MOLECULAR-WEIGHT**

LOW MOLECULAR WEIGHT NUCLEAR RNA see **RNA, SMALL NUCLEAR**

LOW-PROTEIN DIET see **DIET, PROTEIN-RESTRICTED**

LOW T3 AND T4 SYNDROME see **EUTHYROID SICK SYNDROMES**

LOW T3 SYNDROME see **EUTHYROID SICK SYNDROMES**

LOWER EXTREMITY see **LEG**

LOWER NEPHRON NEPHROSIS see **KIDNEY TUBULAR NECROSIS, ACUTE**

LP(A) see **LIPOPROTEIN(A)**

LP-X see **LIPOPROTEIN-X**

LSD see **LYSERGIC ACID DIETHYLAMIDE**

LTB4 see **LEUKOTRIENE B4**

LTB4 RECEPTORS see **RECEPTORS, LEUKOTRIENE B4**

LTC4 see **LEUKOTRIENE C4**

LUCIFERASE

DRUG EFFECTS

Rapid measurement of antimycobacterial drug activity. Gordon S, et al. **Res Microbiol** 1996 Jan–Feb; 147(1–2):79–86 (31 ref.)

METABOLISM

Biochemistry of bacterial bioluminescence. Tu SC, et al. **Photochem Photobiol** 1995 Oct;62(4):615–24 (106 ref.)

LUCIFERIN

CHEMISTRY

Chemical aspects of bioluminescence. Mager HI, et al. **Photochem Photobiol** 1995 Oct;62(4):607–14 (70 ref.)

LUDWIG'S ANGINA

Ludwig's angina: case report and review. Spitalnic SJ, et al. **J Emerg Med** 1995 Jul–Aug;13(4):499–503 (36 ref.)

ETIOLOGY

Uncommon complications of odontogenic infections. Ferrera

LUDWIG'S ANGINA

PC, et al. **Am J Emerg Med** 1996 May;14(3):317–22 (49 ref.)

LULIBERIN see **GONADORELIN**

LULIBERIN RECEPTORS see **RECEPTORS, LHRH**

LUMBAGO see **LOW BACK PAIN**

LUMBAR PLEXUS see **LUMBOSACRAL PLEXUS**

LUMBAR PUNCTURE see **SPINAL PUNCTURE**

LUMBAR REGION see **LUMBOSACRAL REGION**

LUMBAR VERTEBRAE

Assessment and exercise in low back pain. With special reference to the management of pain and disability following first time lumbar disc surgery. Manniche C. **Dan Med Bull** 1995 Sep;42(4):301–13 (155 ref.)

The use of radiographic imaging studies in the evaluation of patients who have degenerative disorders of the lumbar spine. Boden SD. **J Bone Joint Surg Am** 1996 Jan; 78(1):114–24 (128 ref.)

Multifocal metachronous epidural abscesses of the spine. A case report. Chow GH, et al. **Spine** 1996 May 1; 21(9):1094–7 (11 ref.)

[Role of CT and MR in the assessment of lumbar degenerative disk disease] Gualdi GF, et al. **Clin Ter** 1995 Oct;146(10):635–48 (24 ref.) (Eng. Abstr.) **(Ita)**

[Contiguity spondylodiscitis following percutaneous femoral artery catheterization. A case report] Mascalchi M, et al. **Radiol Med (Torino)** 1996 Mar;91(3):325–6 (9 ref.) **(Ita)**

ABNORMALITIES

Lumbar spine anomalies in a pycnodysostosis case. Beguiristain JL, et al. **Eur Spine J** 1995;4(5):320–1 (22 ref.)

Thoracic and lumbar meningocele in neurofibromatosis type 1. Report of two cases and review of the literature. Rainov NG, et al. **Neurosurg Rev** 1995;18(2):127–34 (47 ref.)

[The caudal regression syndrome] Méndez Bustelo MJ, et al. **An Esp Pediatr** 1996 Apr;44(4):405–8 (23 ref.) **(Spa)**

ANATOMY & HISTOLOGY

Quantitative magnetic resonance imaging of the lumbar spine. Potential for investigations of water content and biochemical composition. Boos N, et al. **Spine** 1995 Nov 1;20(21):2358–65; discussion 2366 (83 ref.)

[Lumbar discectomy: anatomical review and surgical techniques] Ono H. **No Shinkei Geka** 1996 May; 24(5):415–29 (56 ref.) **(Jpn)**

DRUG EFFECTS

Lumbar zygapophysial (facet) joint injections. Dreyfuss PH, et al. **Spine** 1995 Sep 15;20(18):2040–7 (89 ref.)

INJURIES

Lumbosacral fracture-subluxation associated with bilateral fractures of the first sacral pedicles: a case report and review of the literature. Shirado O, et al. **J Orthop Trauma** 1995;9(4):354–8 (28 ref.)

Lumbar compression fractures secondary to lap–belt use in children. Sturm PF, et al. **J Pediatr Orthop** 1995 Jul–Aug; 15(4):521–3 (27 ref.)

The treatment of thoracolumbar fractures: one point of view. Rea GL, et al. **J Spinal Disord** 1995 Oct;8(5):368–82 (59 ref.)

Thoracolumbar burst fracture: evaluating stability. Petersilge CA, et al. **Semin Ultrasound CT MR** 1996 Apr;17(2):105–13 (40 ref.)

Retroperitoneal pseudomeningocele complicated by meningitis following a lumbar burst fracture. A case report. Nairus JG, et al. **Spine** 1996 May 1;21(9):1090–3 (13 ref.)

INNERVATION

Neural mechanisms of lumbar pain. Cavanaugh JM. **Spine** 1995 Aug 15;20(16):1804–9 (44 ref.)

PATHOLOGY

Clinical efficacy of imaging modalities in the diagnosis of low-back pain disorders. Boos N, et al. **Eur Spine J** 1996; 5(1):2–22 (142 ref.)

Lumbar zygapophysial (facet) joint injections. Dreyfuss PH, et al. **Spine** 1995 Sep 15;20(18):2040–7 (89 ref.)

Magnetic resonance imaging. Use in patients with low back or radicular pain. Herzog RJ, et al. **Spine** 1995 Aug 15; 20(16):1834–8 (31 ref.)

PHYSIOPATHOLOGY

Low back pain and the zygapophysial (facet) joints. Dreyer SJ, et al. **Arch Phys Med Rehabil** 1996 Mar;77(3):290–300 (145 ref.)

RADIOGRAPHY

Quantitative computed tomography (QCT) of the lumbar spine and appendicular skeleton. Glüer CC, et al. **Eur J Radiol** 1995 Sep;20(3):173–8 (55 ref.)

Lumbar discography. Position statement from the North American Spine Society Diagnostic and Therapeutic Committee. Guyer RD, et al. **Spine** 1995 Sep 15; 20(18):2048–59 (89 ref.)

Radiographic assessment for patients with low back pain. Simmons ED Jr, et al. **Spine** 1995 Aug 15;20(16):1839–41 (4 ref.)

[Vertebral localizations of Paget disease] Chrétien J. **Ann Radiol (Paris)** 1995;38(4):169–76 (7 ref.) (Eng. Abstr.) **(Fre)**

[Vertebral vacuum phenomena] Hamzé B, et al. **Ann Radiol (Paris)** 1995;38(4):186–91 (17 ref.) (Eng. Abstr.) **(Fre)**

[Imaging of the lumbar spine after diskectomy] Laredo JD, et al. **Ann Radiol (Paris)** 1995;38(4):161–8 (34 ref.) (Eng. Abstr.) **(Fre)**

[Extraligamentous lumbar intervertebral disk displacement] Mathieu P. **Ann Radiol (Paris)** 1995;38(4):204–10 (18 ref.) (Eng. Abstr.) **(Fre)**

[Magnetic resonance imaging for lumbar disk pathology. incidence of false negatives (editorial)] Berthelot JM, et al. **Presse Med** 1995 Oct 7;24(29):1329–31 (26 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Urinary bladder dysfunction following anterior lumbosacral spine fusion: case report and review of the literature. Faraj AA, et al. **Eur Spine J** 1996;5(2):121–4 (11 ref.)

Perioperative risk factors for wound infections after lower back fusions. Capen DA, et al. **Orthop Clin North Am** 1996 Jan;27(1):83–6 (24 ref.)

Open discectomy as treatment for herniated nucleus pulposus of the lumbar spine. Errico TJ, et al. **Spine** 1995 Aug 15; 20(16):1829–33 (26 ref.)

Interbody, posterior, and combined lumbar fusions. Fraser RD. **Spine** 1995 Dec 15;20(24 Suppl):167S–177S (83 ref.)

The indications for lumbar spinal fusion with and without instrumentation. Hanley EN Jr. **Spine** 1995 Dec 15;20(24 Suppl):143S–153S (108 ref.)

Assessment of spinal fusion. Critical evaluation of imaging techniques. Herzog RJ, et al. **Spine** 1996 May 1; 21(9):1114–8 (5 ref.)

Lumbar spinal fusion. Surgical rates, costs, and complications. Katz JN. **Spine** 1995 Dec 15;20(24 Suppl):78S–83S (26 ref.)

Is fusion indicated for lumbar spinal disorders? Sonntag VK, et al. **Spine** 1995 Dec 15;20(24 Suppl):138S–142S (23 ref.)

Internal fixation (pedicle screw fixation) for fusions of the lumbar spine. Vaccaro AR, et al. **Spine** 1995 Dec 15;20(24 Suppl):157S–165S (54 ref.)

[Long-term results in revision surgery following lumbar disk nucleotomy]] Jerosch J, et al. **Z Orthop Ihre Grenzgeb** 1996 Jan–Feb;134(1):89–96 (50 ref.) (Eng. Abstr.) **(Ger)**

LUMBOSACRAL PLEXUS

Lumbosacral plexopathy after gynecologic surgery: case report and review of the literature. Alsever JD. **Am J Obstet Gynecol** 1996 Jun;174(6):1769–77; discussion 1777–8 (32 ref.)

LUMBOSACRAL REGION

see related
LOW BACK PAIN

PHYSIOPATHOLOGY

[On alleged radicular pain in patients with lumbar intervertebral disc hernias] Styczyński T, et al. **Neurol Neurochir Pol** 1995 Sep–Oct;29(5):747–52 (20 ref.) (Eng. Abstr.) **(Pol)**

SURGERY

The treatment of degenerative lumbar disorders. A critical review of the literature. Zdeblick TA. **Spine** 1995 Dec 15; 20(24 Suppl):126S–137S (165 ref.)

LUMINESCENCE

see related
CHEMILUMINESCENCE

Chemiluminescence and bioluminescence. Kricka LJ. **Anal Chem** 1995 Jun 15;67(12):499R–502R (98 ref.)

Chemistries and colors of bioluminescent reactions: a review. Hastings JW. **Gene** 1996;173(1 Spec No):5–11 (33 ref.)

Chemical aspects of bioluminescence. Mager HI, et al. **Photochem Photobiol** 1995 Oct;62(4):607–14 (70 ref.)

Biochemistry of bacterial bioluminescence. Tu SC, et al. **Photochem Photobiol** 1995 Oct;62(4):615–24 (106 ref.)

[Applications of luminescence reactions in life science] Nicolas JC, et al. **C R Seances Soc Biol Fil** 1995; 189(5):740–53 (91 ref.) (Eng. Abstr.) **(Fre)**

LUMINESCENCE, BACTERIAL

Luminescence-based systems for detection of bacteria in the environment. Prosser JI, et al. **Crit Rev Biotechnol** 1996; 16(2):157–83 (90 ref.)

LUMINESCENT PROTEINS

Green fluorescent protein: applications in cell biology. Gerdes HH, et al. **FEBS Lett** 1996 Jun 24;389(1):44–7 (37 ref.)

Using GFP to see the light. Prasher DC. **Trends Genet** 1995 Aug;11(8):320–3 (29 ref.)

[Tobacco shining mosaic virus] Watanabe Y. **Tanpakushitsu Kakusan Koso** 1996 May;41(6):786–92 (9 ref.) **(Jpn)**

ANALYSIS

Bioluminescence in scale-worm photosomes: the photoprotein polynoidin is specific for the detection of superoxide radicals. Bassot JM, et al. **Histochem Cell Biol** 1995 Sep;104(3):199–210 (79 ref.)

CHEMISTRY

Fluorescence resonance energy transfer between blue-emitting and red-shifted excitation derivatives of the green fluorescent protein. Mitra RD, et al. **Gene** 1996;173(1 Spec No):13–7 (18 ref.)

Green fluorescent protein. Chalfie M. **Photochem Photobiol** 1995 Oct;62(4):651–6 (42 ref.)

Biochemistry of bacterial bioluminescence. Tu SC, et al. **Photochem Photobiol** 1995 Oct;62(4):615–24 (106 ref.)

Understanding, improving and using green fluorescent proteins. Cubitt AB, et al. **Trends Biochem Sci** 1995 Nov; 20(11):448–55 (43 ref.)

METABOLISM

Understanding, improving and using green fluorescent proteins. Cubitt AB, et al. **Trends Biochem Sci** 1995 Nov; 20(11):448–55 (43 ref.)

LUMPECTOMY see **MASTECTOMY, SEGMENTAL**

LUNAR CYCLE see **MOON**

LUNAR PHASES see **MOON**

LUNDBORG–UNVERRICHT SYNDROME see **EPILEPSY, MYOCLONIC**

LUNG

see related
PNEUMONECTOMY
PULMONARY CIRCULATION
RESPIRATION

Lung preservation: the importance of endothelial and alveolar type II cell integrity. Novick RJ, et al. **Ann Thorac Surg** 1996 Jul;62(1):302–14 (141 ref.)

Use of cardiopulmonary bypass during bronchoscopy following sand aspiration. A case report. Mellema JD, et al. **Chest** 1995 Oct;108(4):1176–7 (6 ref.)

Chest percussion. Yernault JC, et al. **Eur Respir J** 1995 Oct; 8(10):1756–60 (33 ref.)

Foreign body aspiration in dentistry: a review. Cameron SM, et al. **J Am Dent Assoc** 1996 Aug;127(8):1224–9 (30 ref.)

ABNORMALITIES

Fryns syndrome survivors and neurologic outcome. Van Hove JL, et al. **Am J Med Genet** 1995 Nov 20;59(3):334–40 (39 ref.)

The dysmorphic lung: imaging findings. Mata JM, et al. **Eur Radiol** 1996;6(4):403–14 (56 ref.)

Bilateral agenesis/aplasia of the lungs: report of a second case in the offspring of one woman. Podlech J, et al. **Pediatr Pathol Lab Med** 1995 Sep–Oct;15(5):781–90 (26 ref.)

The fetal thorax: noncardiac chest anomalies. Sohaey R, et al. **Semin Ultrasound CT MR** 1996 Feb;17(1):34–50 (64 ref.)

[A case report of pulmonary sequestration (Pryce I) associated with incomplete lobulation of the left lung] Ichihashi T, et al. **Kyobu Geka** 1995 Nov;48(12):1057–60 (12 ref.) (Eng. Abstr.) **(Jpn)**

[Clinical analysis of lung cancer in patients with chondromatous hamartoma] Umemori Y, et al. **Kyobu Geka** 1995 Nov;48(12):1061–4 (11 ref.) (Eng. Abstr.) **(Jpn)**

BLOOD SUPPLY

Hepatopulmonary syndrome. A pulmonary vascular complication of liver disease. Castro M, et al. **Clin Chest Med** 1996 Mar;17(1):35–48 (81 ref.)

Structural and pathologic changes in the lung vasculature in chronic liver disease. Schraufnagel DE, et al. **Clin Chest Med** 1996 Mar;17(1):1–15 (94 ref.)

Control of vascular reactivity. McCormack DG. **New Horiz** 1995 May;3(2):248–56 (83 ref.)

CHEMISTRY

Analysis and interpretation of inorganic mineral particles in "lung" tissues. Gibbs AR, et al. **Thorax** 1996 Mar; 51(3):327–34 (60 ref.)

CYTOLOGY

Regulation of gene transcription in respiratory epithelial cells. Whitsett JA, et al. **Am J Respir Cell Mol Biol** 1996 Feb; 14(2):118–20 (25 ref.)

Lymphocytes in the lung: an often neglected cell. Numbers,

characterization and compartmentalization. Pabst R, et al. **Anat Embryol (Berl)** 1995 Oct;192(4):293–9 (64 ref.)

DRUG EFFECTS

Mineral fiber–induced oxidative stress in phagocytes. Savolainen KM, et al. **Arch Toxicol Suppl** 1996;18:236–47 (53 ref.)

Nitric oxide: physiological roles and therapeutic implications in the lung. Brett SJ, et al. **Br J Hosp Med** 1996 Apr 17–30; 55(8):487–90 (20 ref.)

Tachykinin NK2 receptors further characterized in the lung with nonpeptide receptor antagonists. Advenier C. **Can J Physiol Pharmacol** 1995 Jul;73(7):878–84 (73 ref.)

Stimulant–induced pulmonary toxicity. Albertson TE, et al. **Chest** 1995 Oct;108(4):1140–9 (134 ref.)

Lung injury: cell–specific bioactivation/deactivation of circulating pneumotoxins. Dinsdale D. **Int J Exp Pathol** 1995 Dec;76(6):393–401 (71 ref.)

Risk assessment of adverse pulmonary effects induced by adrenaline beta–receptor antagonists and rational drug dosage regimen based on receptor occupancy. Yamada Y, et al. **J Pharmacokinet Biopharm** 1995 Oct;23(5):463–78 (30 ref.)

Effects of streptozotocin–induced diabetes on postpneumonectomy lung growth and connective tissue levels. Ofulue AF, et al. **Pediatr Pulmonol** 1995 Jun; 19(6):365–70 (29 ref.)

An evaluation of possible mechanisms underlying amiodarone–induced pulmonary toxicity. Reasor MJ, et al. **Proc Soc Exp Biol Med** 1996 Sep;212(4):297–304 (89 ref.)

[Early diagnosis of amiodarone–induced pulmonary toxicity: are repeated lung function tests of any value?] Ulrik CS, et al. **Ugeskr Laeger** 1996 Jun 10;158(24):3445–7 (17 ref.) (Eng. Abstr.) **(Dan)**

[Azithromycin: tissue pharmacology] Bcrgogne–Bérézin E. **Pathol Biol (Paris)** 1995 Jun;43(6):498–504 (29 ref.) (Eng. Abstr.) **(Fre)**

[The effect of sedation on pulmonary function] Wiedemann K, et al. **Anaesthesist** 1995 Dec;44 Suppl 3:S588–93 (53 ref.) (Eng. Abstr.) **(Ger)**

[Evaluation of pulmonary toxicity of heavy metal compounds] Hirano S. **Nippon Eiseigaku Zasshi** 1996 Feb; 50(6):1013–25 (70 ref.) (Eng. Abstr.) **(Jpn)**

EMBRYOLOGY

Transcription factors and pattern formation in the developing lung. Cardoso WV. **Am J Physiol** 1995 Oct;269(4 Pt 1):L429–42 (185 ref.)

Hox genes in the lung. Kappen C. **Am J Respir Cell Mol Biol** 1996 Aug;15(2):156–62 (91 ref.)

Morphogenesis of the lung: control of embryonic and fetal branching. Hilfer SR. **Annu Rev Physiol** 1996;58:93–113 (71 ref.)

Retinoids in lung development. Chytil F. **FASEB J** 1996 Jul; 10(9):986–92 (53 ref.)

Thyrotrophin–releasing hormone (TRH) and lung maturation. Liggins GC. **Reprod Fertil Dev** 1995; 7(3):443–50 (54 ref.)

[Nitric oxide and regulation of fetal and neonatal pulmonary circulation. Group Français Pédiatrique d'étude du NO inhalé] Mercier JC, et al. **Arch Pediatr** 1996;3 Suppl 1:280s–283s (15 ref.) **(Fre)**

GROWTH & DEVELOPMENT

Nitric oxide in the developing lung. Shaul PW. **Adv Pediatr** 1995;42:367–414 (182 ref.)

Mechanisms of gene expression and cell fate determination in the developing pulmonary epithelium. Hackett BP, et al. **Annu Rev Physiol** 1996;58:51–71 (90 ref.)

Hepatocyte growth factor in lung morphogenesis and tumor invasion: role as a mediator in epithelium–mesenchyme and tumor–stroma interactions. Matsumoto K, et al. **Cancer Chemother Pharmacol** 1996;38 Suppl:S42–7 (36 ref.)

Retinoids in lung development. Chytil F. **FASEB J** 1996 Jul; 10(9):986–92 (53 ref.)

IMMUNOLOGY

The regulation of pulmonary immunity. Lipscomb MF, et al. **Adv Immunol** 1995;59:369–455 (534 ref.)

Pulmonary immunity to Pseudomonas aeruginosa. Cripps AW, et al. **Immunol Cell Biol** 1995 Oct;73(5):418–24 (84 ref.)

INJURIES

Roles of bombesin–like peptides in lung development and lung injury [comment] Spindel ER. **Am J Respir Cell Mol Biol** 1996 May;14(5):407–8 (18 ref.) Comment on: Am J Respir Cell Mol Biol 1996 May;14(5):409–16.

Epithelial dysfunction in acute lung injury. Edelson JD. **New Horiz** 1995 May;3(2):229–39 (188 ref.)

Control of vascular reactivity. McCormack DG. **New Horiz** 1995 May;3(2):248–56 (83 ref.)

Barotrauma. Tocino I, et al. **Radiol Clin North Am** 1996 Jan; 34(1):59–81 (126 ref.)

CT in blunt chest trauma: pulmonary, tracheobronchial, and diaphragmatic injuries. Kang EY, et al. **Semin Ultrasound CT MR** 1996 Apr;17(2):114–8 (39 ref.)

[Arterial air embolism in explosive trauma to the lungs] Fomin NF, et al. **Vestn Khir Im I I Grek** 1995;154(2):120–3 (26 ref.) **(Rus)**

METABOLISM

Quantifying pulmonary oxygen transfer deficits in critically ill patients. Wandrup JH. **Acta Anaesthesiol Scand Suppl** 1995;107:37–44 (54 ref.)

Endothelins and the lung. Michael JR, et al. **Am J Respir Crit Care Med** 1996 Sep;154(3 Pt 1):555–81 (446 ref.)

What is the role of absorption atelectasis in the genesis of perioperative pulmonary collapse? Joyce CJ, et al. **Anaesth Intensive Care** 1995 Dec;23(6):691–6 (57 ref.)

Pulmonary oxygen uptake kinetics in nonsteady state. Koga S, et al. **Appl Human Sci** 1996 Jan;15(1):1–4 (26 ref.)

Elastin in lung development and disease. Pierce RA, et al. **Ciba Found Symp** 1995;192:199–212; discussion 212–4 (37 ref.)

The penetration of novel intravenous cephalosporins into the lung. Baldwin DR. **J Chemother** 1996 Feb;8 Suppl 2:71–82 (89 ref.)

The role of active Na+ transport by lung epithelium in the clearance of airspace fluid. O'Brodovich HM. **New Horiz** 1995 May;3(2):240–7 (55 ref.)

PATHOLOGY

The staging of lung cancer by bronchoscopic transbronchial needle aspiration. Harrow EM, et al. **Chest Surg Clin N Am** 1996 May;6(2):223–35 (35 ref.)

Bronchoscopic biopsies and bronchoalveolar lavage. Kvale PA. **Chest Surg Clin N Am** 1996 May;6(2):205–22 (73 ref.)

Transbronchial needle aspiration and percutaneous needle aspiration for staging and diagnosis of lung cancer. Wang KP. **Clin Chest Med** 1995 Sep;16(3):535–52 (26 ref.)

Pulmonary reactions to organic dust exposures: development of an animal model. Castranova V, et al. **Environ Health Perspect** 1996 Mar;104 Suppl 1:41–53 (115 ref.)

The current status of intratracheal–pulmonary ventilation (ITPV). Kolobow T, et al. **Int J Artif Organs** 1995 Oct; 18(10):670–3 (13 ref.)

Clinical application of novel ventilation techniques. Müller E. **Int J Artif Organs** 1995 Oct;18(10):656–69 (140 ref.)

Tryptase immunoreactive mast cell hyperplasia in bronchopulmonary dysplasia. Lyle RE, et al. **Pediatr Pulmonol** 1995 Jun;19(6):336–43 (39 ref.)

The fibroproliferative phase of late adult respiratory distress syndrome. Meduri GU, et al. **Semin Respir Infect** 1995 Sep; 10(3):154–75 (118 ref.)

Diagnosing the indeterminate pulmonary nodule: percutaneous biopsy versus thoracoscopy. Mitruka S, et al. **Surgery** 1995 Oct;118(4):676–84 (25 ref.)

[Interstitial lung involvement in collagen diseases with special reference to bronchoalveolar lavage and lung biopsy] Witt C, et al. **Pneumologie** 1995 Sep;49(9):487–91 (64 ref.) **(Ger)**

[Acute respiratory failure in hemoblastoses: the types of diffuse lung lesions] Gorelov VG, et al. **Ter Arkh** 1995; 67(7):52–6 (17 ref.) **(Rus)**

PHYSIOLOGY

The regulation of normal lung function. Braman SS. **Allergy Proc** 1995 Sep–Oct;16(5):223–6 (6 ref.)

Differential display RT–PCR for identifying novel gene expression in the lung. Sunday ME. **Am J Physiol** 1995 Sep;269(3 Pt 1):L273–84 (72 ref.)

Roles of bombesin–like peptides in lung development and lung injury [comment] Spindel ER. **Am J Respir Cell Mol Biol** 1996 May;14(5):407–8 (18 ref.) Comment on: Am J Respir Cell Mol Biol 1996 May;14(5):409–16.

Pulmonary intravascular phagocytosis in liver disease. Chang SW, et al. **Clin Chest Med** 1996 Mar;17(1):137–50 (62 ref.)

Gene transfer for cytokine functional studies in the lung: the multifunctional role of GM–CSF in pulmonary inflammation. Xing Z, et al. **J Leukoc Biol** 1996 Apr; 59(4):481–8 (55 ref.)

NO in the lung. Adnot S, et al. **Respir Physiol** 1995 Aug; 101(2):109–20 (32 ref.)

[Pulmonary surfactant system] van Golde LM. **Ned Tijdschr Geneeskd** 1996 Feb 3;140(5):236–40 (19 ref.) **(Dut)**

[The lung and trips by plane] Ibáñez Cuerda MD, et al. **Arch Bronconeumol** 1995 Dec;31(10):526–33 (65 ref.) **(Spa)**

PHYSIOPATHOLOGY

Lung surfactants and asthma [editorial] Postle AD. **Clin Exp Allergy** 1995 Nov;25(11):1030–3 (31 ref.)

Permissive hypercapnia. Dries DJ. **J Trauma** 1995 Nov; 39(5):984–9 (48 ref.)

How 'dry' must the septic patient be kept – potentially conflicting interests of lung and peripheral circulation? [editorial] Reinhart K. **Nephrol Dial Transplant** 1996 Jul; 11(7):1241–2 (12 ref.)

Air pollution: brown skies research. Tattersfield AE. **Thorax** 1996 Jan;51(1):13–22 (43 ref.)

RADIATION EFFECTS

[Radiogenic lung reactions. Pathogenesis—prevention—therapy] Herrmann T, et al. **Strahlenther Onkol** 1995 Sep;171(9):490–8 (73 ref.) (Eng. Abstr.) **(Ger)**

RADIOGRAPHY

CT of the pulmonary hilum: evaluation with thin–section ultrafast CT. Murata K, et al. **Crit Rev Diagn Imaging** 1996 Feb;37(1):39–77 (57 ref.)

Pulmonary complications of cystic fibrosis in adults. Shah RM, et al. **Crit Rev Diagn Imaging** 1995;36(6):441–77 (46 ref.)

Identification and evaluation of centrilobular opacities on high–resolution CT. Gruden JF, et al. **Semin Ultrasound CT MR** 1995 Oct;16(5):435–49 (30 ref.)

CT of the lungs in patients with pulmonary emphysema. Stern EJ, et al. **Semin Ultrasound CT MR** 1995 Oct; 16(5):345–52 (43 ref.)

Acute lung disease in the immunocompromised host: differential diagnosis at high–resolution CT. Worthy S, et al. **Semin Ultrasound CT MR** 1995 Oct;16(5):353–60 (24 ref.)

[Standard radiological characteristics of thoracic sites of tuberculosis in patients with AIDS in a Tunisian population] Tiouiri H, et al. **Rev Pneumol Clin** 1995; 51(6):321–4 (12 ref.) (Eng. Abstr.) **(Fre)**

[High–resolution computerized tomography of the lungs: bases, findings, indications] Hauser M, et al. **Schweiz Med Wochenschr** 1996 Mar 9;126(10):398–408 (52 ref.) (Eng. Abstr.) **(Ger)**

RADIONUCLIDE IMAGING

Disorders associated with extensive unilateral abnormalities in ventilation/perfusion or perfusion scintigraphy. Dunn EK. **Crit Rev Diagn Imaging** 1995;36(4):339–83 (94 ref.)

Comprehensive analysis of the results of the PIOPED Study. Prospective Investigation of Pulmonary Embolism Diagnosis Study. Worsley DF, et al. **J Nucl Med** 1995 Dec; 36(12):2380–7 (32 ref.)

99mTc DTPA transfer/permeability in patients with HIV disease. O'Doherty MJ. **Q J Nucl Med** 1995 Sep; 39(3):231–42 (60 ref.)

[Pulmonary nuclear medicine] Isawa T. **Kaku Igaku** 1995 Nov;32(11):1281–8 (64 ref.) (Eng. Abstr.) **(Jpn)**

SURGERY

Lung volume reduction surgery for emphysema. Brenner M, et al. **Chest** 1996 Jul;110(1):205–18 (61 ref.)

Video–assisted thoracoscopic pulmonary surgery—current status and potential evolution. Walker WS, et al. **Eur J Cardiothorac Surg** 1996;10(3):161–7 (62 ref.)

ULTRASONOGRAPHY

Resolving fetal hyperechogenic lung lesions: an unresolved issue [see comments] Sepulveda W, et al. **Ultrasound Obstet Gynecol** 1995 Jul;6(1):4–5 (26 ref.) Comment in: Ultrasound Obstet Gynecol 1995 Nov;6(5):372–3.

LUNG ABSCESS

COMPLICATIONS

Pulmonary acremonium abscesses and gastrointestinal tuberculosis manifested as massive upper gastrointestinal bleeding. Miró O, et al. **Nephrol Dial Transplant** 1995; 10(8):1444–6 (17 ref.)

DIAGNOSIS

[Diagnosis of lung abscesses] Schülin T, et al. **Dtsch Med Wochenschr** 1996 Feb 2;121(5):135–6 (14 ref.) **(Ger)**

ETIOLOGY

Nephrobronchial fistula and lung abscess resulting from nephrolithiasis and pyelonephritis. O'Brien JD, et al. **Chest** 1995 Oct;108(4):1166–8 (6 ref.)

[Rhodococcus equi pulmonary abscess in HIV infection] About I, et al. **Rev Med Interne** 1996;17(5):410–4 (25 ref.) (Eng. Abstr.) **(Fre)**

[Pneumococcal pneumonia in a patient with HIV infection. Development to excavation. Apropos of a case] Venot P, et al. **Rev Pneumol Clin** 1996;52(1):29–32 (11 ref.) (Eng. Abstr.) **(Fre)**

MICROBIOLOGY

Lung abscess due to nontyphoid Salmonella in an immunocompromised host. Case report with review of the literature. Ridha AG, et al. **Acta Clin Belg** 1996; 51(3):175–83 (41 ref.)

Lemierre syndrome: postanginal sepsis. Leugers CM, et al. **J Am Board Fam Pract** 1995 Sep–Oct;8(5):384–91 (40 ref.)

THERAPY

[Therapy of lung abscesses] Schülin T, et al. **Dtsch Med Wochenschr** 1996 Feb 2;121(5):137–8 (15 ref.) **(Ger)**

LUNG CAPACITIES see LUNG VOLUME MEASUREMENTS

LUNG DISEASES

see related

PULMONARY HEART DISEASE

Diagnostic imaging of the lung during pregnancy. Diethelm L, et al. **Clin Obstet Gynecol** 1996 Mar;39(1):36–55 (41 ref.)

HIV-associated respiratory diseases. Miller R. **Lancet** 1996 Aug 3;348(9023):307–12 (50 ref.)

[Idiopathic pulmonary hemosiderosis] Pedersen FM, et al. **Ugeskr Laeger** 1996 Feb 12;158(7):902–4 (39 ref.) (Eng. Abstr.) **(Dan)**

[Sarcoidosis: diagnosis, clinical aspects, course and therapy] Ozerova LV. **Probl Tuberk** 1995;(4):51–4 (0 ref.) **(Rus)**

[Hepatopulmonary syndrome: a new concept. A new treatment? (clinical conference) (see comments)] Rodriguez Roisin R. **Med Clin (Barc)** 1995 Sep 9;105(7):269–74 (41 ref.) Comment in: Med Clin (Barc) 1996 Apr 20;106(15):597–8. **(Spa)**

CHEMICALLY INDUCED

Mesalamine-induced lung toxicity. Bitton A, et al. **Am J Gastroenterol** 1996 May;91(5):1039–40 (10 ref.)

Heme oxygenase-1: function, regulation, and implication of a novel stress-inducible protein in oxidant-induced lung injury. Choi AM, et al. **Am J Respir Cell Mol Biol** 1996 Jul;15(1):9–19 (58 ref.)

Long-term canine exposure studies with ambient air pollutants. Heyder J, et al. **Eur Respir J** 1996 Mar; 9(3):571–84 (101 ref.)

Lung injury: cell-specific bioactivation/deactivation of circulating pneumotoxins. Dinsdale D. **Int J Exp Pathol** 1995 Dec;76(6):393–401 (71 ref.)

Drug-induced pulmonary disease. Rosenow EC 3rd, et al. **Semin Respir Infect** 1995 Jun;10(2):86–95 (20 ref.)

Factors associated with respiratory problems in swimmers. Potts J. **Sports Med** 1996 Apr;21(4):256–61 (43 ref.)

Lung disease induced by drug addiction [editorial] [see comments] Benson MK, et al. **Thorax** 1995 Nov; 50(11):1125–7 (36 ref.) Comment in: Thorax 1996 May;51(5):556.

Ozone-induced human respiratory dysfunction and disease. Bromberg PA, et al. **Toxicol Lett** 1995 Dec;82–83:307–16 (57 ref.)

[Early diagnosis of amiodarone-induced pulmonary toxicity: are repeated lung function tests of any value?] Ulrik CS, et al. **Ugeskr Laeger** 1996 Jun 10;158(24):3445–7 (17 ref.) (Eng. Abstr.) **(Dan)**

[Pulmonary toxicity of drugs and thoracic irradiation in children] Fauroux B, et al. **Rev Mal Respir** 1996 Jul; 13(3):235–42 (58 ref.) (Eng. Abstr.) **(Fre)**

[Physiopathologic mechanisms of drug-induced lung diseases in man] Israël-Biet D, et al. **Rev Mal Respir** 1996; 13(2):127–32 (48 ref.) (Eng. Abstr.) **(Fre)**

[Recurrent amiodarone lung toxicity after withdrawal of the drug and treatment with corticoids] Donado Uña JR, et al. **Arch Bronconeumol** 1995 Oct;31(8):426–8 (13 ref.) (Eng. Abstr.) **(Spa)**

COMPLICATIONS

Lung cancer in patients with bullous disease. Zulueta JJ, et al. **Am J Respir Crit Care Med** 1996 Aug;154(2 Pt 1):519–22 (28 ref.)

The hepatopulmonary syndrome. Effect of liver transplantation. Lange PA, et al. **Clin Chest Med** 1996 Mar; 17(1):115–23 (46 ref.)

Cavitary pulmonary lesions in patients infected with human immunodeficiency virus. Gallant JE, et al. **Clin Infect Dis** 1996 Apr;22(4):671–82 (208 ref.)

[Pulmonary infection due to Mycobacterium szulgai associated with multiple bullous disease of the lung] Mori K, et al. **Kekkaku** 1995 Sep;70(9):511–6 (12 ref.) (Eng. Abstr.) **(Jpn)**

[Pulmonary endometriosis with recurrent catamenial hemoptysis] Ueno H, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Aug; 33(8):888–93 (19 ref.) (Eng. Abstr.) **(Jpn)**

[Sarcoidosis with pulmonary cavitation and calcification] Yokogawa K, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Nov; 33(11):1259–64 (27 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

The laboratory evaluation of opportunistic pulmonary infections. Shelhamer JH, et al. **Ann Intern Med** 1996 Mar 15;124(6):585–99 (94 ref.)

Pulmonary complications of HIV infection. Murray JF. **Annu Rev Med** 1996;47:117–26 (30 ref.)

Medical thoracoscopy. Role in pleural and lung diseases. Mathur PN, et al. **Clin Chest Med** 1995 Sep;16(3):487–96 (85 ref.)

Cavitary pulmonary lesions in patients infected with human immunodeficiency virus. Gallant JE, et al. **Clin Infect Dis** 1996 Apr;22(4):671–82 (208 ref.)

AIDS and the lung. Huang L, et al. **Med Clin North Am** 1996 Jul;80(4):775–801 (114 ref.)

Role of exercise in the evaluation and management of pulmonary disease in children and youth. Nixon PA. **Med Sci Sports Exerc** 1996 Apr;28(4):414–20 (86 ref.)

Airways and lung: correlation of CT with fiberoptic bronchoscopy. Naidich DP, et al. **Radiology** 1995 Oct; 197(1):1–12 (98 ref.)

Collagen vascular diseases. Corley DE, et al. **Semin Respir Infect** 1995 Jun;10(2):78–85 (18 ref.)

Granulomatous vasculitis. Hammar SP. **Semin Respir Infect** 1995 Jun;10(2):107–20 (47 ref.)

Differential diagnosis of fever and pulmonary densities in mechanically ventilated patients. Louthan FB, et al. **Semin Respir Infect** 1996 Jun;11(2):77–95 (136 ref.)

Hypersensitivity pneumonitis: a noninfectious granulomatosis. Sharma OP, et al. **Semin Respir Infect** 1995 Jun;10(2):96–106 (32 ref.)

Exhaled nitric oxide: a new lung function test [editorial] Barnes PJ, et al. **Thorax** 1996 Mar;51(3):233–7 (73 ref.)

[Modern examination methods in pneumology] Frank W, et al. **Versicherungsmedizin** 1995 Dec 1;47(6):191–200 (40 ref.) (Eng. Abstr.) **(Ger)**

[Idiopathic pulmonary hemosiderosis. Clinical and radiological assessment of re-exacerbation] Fiorucci F, et al. **Recenti Prog Med** 1996 May;87(5):223–6 (9 ref.) (Eng. Abstr.) **(Ita)**

[Principles for assessment and diagnosis of work-related pulmonary and pleural diseases] Aasen TB, et al. **Tidsskr Nor Laegeforen** 1996 Feb 28;116(6):739–41 (23 ref.) (Eng. Abstr.) **(Nor)**

[Pulmonary actinomycosis. The difficulties in its diagnosis and treatment] Márquez Rivas FJ, et al. **An Esp Pediatr** 1996 Jun;44(6):588–90 (12 ref.) **(Spa)**

[Cutaneous lesions and lung infiltrates after a trip to Thailand] Martínez-Fernández R, et al. **Rev Clin Esp** 1995 Oct; 195(10):721–2 (15 ref.) **(Spa)**

[Valuable methods for lung function measurements. Spirometry at ambulatory centers is excellent for early diagnosis] Larsson M. **Lakartidningen** 1995 Nov 22; 92(47):4427–30, 4435–7 (27 ref.) **(Swe)**

DRUG THERAPY

Nitric oxide: physiological roles and therapeutic implications in the lung. Brett SJ, et al. **Br J Hosp Med** 1996 Apr 17–30; 55(8):487–90 (20 ref.)

Guidelines for the use of nebulizers in the home and at domiciliary sites. Report of a consensus conference. National Association for Medical Direction of Respiratory Care (NAMDRC) Consensus Group. O'Donohue WJ Jr. **Chest** 1996 Mar;109(3):814–20 (32 ref.)

Future therapeutic procedures. Edell ES. **Chest Surg Clin N Am** 1996 May;6(2):381–95 (93 ref.)

Lower respiratory tract infection therapy—the role of ciprofloxacin. Ball AP, et al. **J Int Med Res** 1995 Sep–Oct; 23(5):315–27 (55 ref.)

Inhalational nitric oxide in pulmonary parenchymal and vascular disease. Cornfield DN, et al. **J Lab Clin Med** 1996 Jun;127(6):530–9 (64 ref.)

Inhalers and nebulizers: which to choose and why. Pedersen S. **Respir Med** 1996 Feb;90(2):69–77 (65 ref.)

[Recent advances in experimental and clinical study on ligustrazine in treating respiratory disease] Zhang KJ, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Oct; 15(10):638–40 (22 ref.) **(Chi)**

[Bronchial mucolytic agents] Leuenberger P. **Rev Med Suisse Romande** 1996 May;116(5):335–9 (16 ref.) **(Fre)**

[Pulmonary actinomycosis. The difficulties in its diagnosis and treatment] Márquez Rivas FJ, et al. **An Esp Pediatr** 1996 Jun;44(6):588–90 (12 ref.) **(Spa)**

EPIDEMIOLOGY

The integration of epidemiology and fundamental biology in occupational lung disease. Thomas A. Neff Lecture. Weill H. **Chest** 1996 Mar;109(3 Suppl):2S–5S (14 ref.)

The yellowed archives of yellowcake. Silver K. **Public Health Rep** 1996 Mar–Apr;111(2):116–27 (55 ref.)

ETIOLOGY

Fifth Seah Cheng Siang Memorial Lecture. Human immunodeficiency virus and the respiratory system—pulmonary manifestations of acquired immunodeficiency syndrome. Dudley A, et al. **Ann Acad Med Singapore** 1995 May;24(3):482–9 (35 ref.)

Antioxidants in neonatal lung disease. Fardy CH, et al. **Arch Dis Child Fetal Neonatal Ed** 1995 Sep;73(2):F112–7 (66 ref.)

Pulmonary complications in cancer patients. Stover DE, et al. **CA Cancer J Clin** 1996 Sep–Oct;46(5):303–20 (58 ref.)

Environmental lung disease: exposures and mechanisms. Brain JD. **Chest** 1996 Mar;109(3 Suppl):74S–78S (14 ref.)

Usefulness of animal models for predicting human responses to long-term inhalation of particles. Mauderly JL. **Chest** 1996 Mar;109(3 Suppl):65S–68S (24 ref.)

Pulmonary complications of bone marrow transplantation. Soubani AO, et al. **Chest** 1996 Apr;109(4):1066–77 (91 ref.)

Hepatopulmonary syndrome. A pulmonary vascular complication of liver disease. Castro M, et al. **Clin Chest Med** 1996 Mar;17(1):35–48 (81 ref.)

Recent pulmonary observations in alpha 1-antitrypsin deficiency, primary biliary cirrhosis, chronic hepatitis C, and other hepatic problems. Krowka MJ. **Clin Chest Med** 1996 Mar;17(1):67–82 (90 ref.)

Pulmonary complications of liver transplantation. O'Brien JD, et al. **Clin Chest Med** 1996 Mar;17(1):99–114 (95 ref.)

Pulmonary complications of cystic fibrosis in adults. Shah RM, et al. **Crit Rev Diagn Imaging** 1995;36(6):441–77 (46 ref.)

Pulmonary manifestations of chronic liver disease. King PD, et al. **Dig Dis** 1996 Mar–Apr;14(2):73–82 (95 ref.)

Traumatic pneumatoceles in an infant: case report and review of the literature. Schimpl G, et al. **Eur J Pediatr Surg** 1996 Apr;6(2):104–6 (14 ref.)

Respiratory health effects of man-made vitreous (mineral) fibres. De Vuyst P, et al. **Eur Respir J** 1995 Dec; 8(12):2149–73 (169 ref.)

Occupational exposure to dusts containing asbestos and chronic airways disease. Zejda JE. **Int J Occup Med Environ Health** 1996;9(2):117–25 (50 ref.)

Perioperative fluid management for thoracic surgery: the puzzle of postpneumonectomy pulmonary edema. Slinger PD. **J Cardiothorac Vasc Anesth** 1995 Aug;9(4):442–51 (52 ref.)

The riddle of sarcoidosis: have novel techniques brought any new insights as to the causative agent? [editorial] Eklund A, et al. **J Intern Med** 1996 Aug;240(2):59–62 (24 ref.)

Congenital and acquired lung hernias. Moncada R, et al. **J Thorac Imaging** 1996 Winter;11(1):75–82 (25 ref.)

Pulmonary complications after bone marrow transplantation. Winer-Muram HT, et al. **Radiol Clin North Am** 1996 Jan; 34(1):97–117 (36 ref.)

The free radical basis of air pollution: focus on ozone. Kelly FJ, et al. **Respir Med** 1995 Nov;89(10):647–56 (77 ref.)

Non-sarcoid granulomatous disease with involvement of the lungs. Müns G, et al. **Sarcoidosis** 1995 Sep;12(2):99–110 (91 ref.)

Herniation of the lung following video-assisted minithoracotomy. van den Brink WA, et al. **Surg Endosc** 1995 Jun;9(6):706–8 (10 ref.)

[Extracutaneous manifestations of neutrophilic dermatosis] Rodot S, et al. **Ann Dermatol Venereol** 1996;123(2):129–34 (45 ref.) **(Fre)**

[Pleuropulmonary manifestations of rheumatoid arthritis] Crestani B, et al. **Presse Med** 1996 May 18;25(17):807–12 (25 ref.) (Eng. Abstr.) **(Fre)**

[Cystic fibrosis in adults] Durieu I, et al. **Presse Med** 1995 Dec 16–23;24(39):1882–7 (23 ref.) (Eng. Abstr.) **(Fre)**

[Pulmonary toxicity of drugs and thoracic irradiation in children] Fauroux B, et al. **Rev Mal Respir** 1996 Jul; 13(3):235–42 (58 ref.) (Eng. Abstr.) **(Fre)**

[CFTR protein and molecular mechanisms of pulmonary involvement in cystic fibrosis] Chinet T. **Rev Pneumol Clin** 1995;51(3):122–9 (87 ref.) (Eng. Abstr.) **(Fre)**

[Pulmonary disorders in portal hypertension. Pulmonary hypertension and hepatopulmonary syndrome] Wettstein M, et al. **Dtsch Med Wochenschr** 1996 Apr 12; 121(15):487–91 (47 ref.) **(Ger)**

[A nephropathic patient with lung problems ...] Cole TJ, et al. **Radiol Med (Torino)** 1995 Dec;90(6):847–50 (9 ref.) **(Ita)**

[Pulmonary involvement in immunoblastic lymphadenopathy: case reports and review of literature published in Japan] Sugiyama H, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Nov; 33(11):1276–82 (26 ref.) (Eng. Abstr.) **(Jpn)**

[Acute, post-transfusion lung injury (TRALI) and related states] Kotlarek-Haus S. **Pol Arch Med Wewn** 1995 May; 93(5):372–6 (27 ref.) **(Pol)**

[Pulmonary manifestations in a case of toxic shock syndrome] Stoica R. **Pneumoftiziologia** 1995 Jan–Jun;44(1–2):63–6 (9 ref.) (Eng. Abstr.) **(Rum)**

[Lung toxicity of cancer treatment] de Castro Carpeño J, et al. **Med Clin (Barc)** 1995 Nov 18;105(17):661–8 (76 ref.) **(Spa)**

GENETICS

Neonatal respiratory disease due to surfactant protein B deficiency. Ballard PL. **J Perinatol** 1996 Mar–Apr;16(2 Pt 2 Su):S28–34 (42 ref.)

IMMUNOLOGY

The regulation of pulmonary immunity. Lipscomb MF, et al. **Adv Immunol** 1995;59:369–455 (534 ref.)

[Sarcoidosis: immunopathology and criteria of biological activity] Müller-Quernheim J, et al. **Rev Mal Respir** 1995; 12(6):525–31 (39 ref.) (Eng. Abstr.) **(Fre)**

[The immunological approach to systemic and pulmonary vasculitis] Ancochea Bermúdez J. **Arch Bronconeumol** 1995 Aug–Sep;31(7):350–61 (103 ref.) **(Spa)**

METABOLISM

Use of biomarkers to investigate occupational and environmental lung disorders. Schulte PA. **Chest** 1996 Mar; 109(3 Suppl):9S–12S (26 ref.)

Mediators, cytokines, and growth factors in liver-lung interactions. Panos RJ, et al. **Clin Chest Med** 1996 Mar; 17(1):151–69 (220 ref.)

Analysis and interpretation of inorganic mineral particles in "lung" tissues. Gibbs AR, et al. **Thorax** 1996 Mar; 51(3):327–34 (60 ref.)

[Concentration of cephems in sputum from patients with pulmonary infection: relationship between MICs of pathogenic bacteria, levels of antibiotic and efficacy] Rikitomi N. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:1020–3 (10 ref.) **(Jpn)**

MICROBIOLOGY

Pulmonary melioidosis. Ip M, et al. **Chest** 1995 Nov; 108(5):1420–4 (32 ref.)

The changing spectrum of pulmonary infections due to nontuberculous mycobacteria. Boggs DS. **J Okla State Med Assoc** 1995 Sep;88(9):373–82 (52 ref.)

Pseudomonas aeruginosa, mucoidy and the chronic infection phenotype in cystic fibrosis. Deretic V, et al. **Trends Microbiol** 1995 Sep;3(9):351–6 (59 ref.)

[Non-tuberculous mycobacterium pulmonary infection in children] Albertini M, et al. **Rev Pneumol Clin** 1996; 52(3):171–4 (26 ref.) **(Fre)**

[Eikenella corrodens pleuro-pulmonary infection. Apropos of a case] Salem M, et al. **Rev Pneumol Clin** 1996; 52(3):192–5 (23 ref.) (Eng. Abstr.) **(Fre)**

[Concentration of cephems in sputum from patients with pulmonary infection: relationship between MICs of pathogenic bacteria, levels of antibiotic and efficacy] Rikitomi N. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:1020–3 (10 ref.) **(Jpn)**

NURSING

Advanced ventilation in the neonate. Antunes MJ, et al. **Nurs Clin North Am** 1996 Jun;31(2):405–22 (123 ref.)

PATHOLOGY

Bronchoscopic biopsies and bronchoalveolar lavage. Kvale PA. **Chest Surg Clin N Am** 1996 May;6(2):205–22 (73 ref.)

Anatomic distribution and histopathologic patterns in diffuse lung disease: correlation with HRCT. Colby TV, et al. **J Thorac Imaging** 1996 Winter;11(1):1–26 (51 ref.)

Experimental models in pulmonary pathology. Kumar RK. **Pathology** 1995 Apr;27(2):130–2 (35 ref.)

[Retrospect and prospect of respiratory pathology in China] Liao S, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1995 Aug;24(4):214–6 (20 ref.) **(Chi)**

[Pulmonary lymphomatoid granulomatosis—peripheral T cell lymphoma—pathomorphologic characteristics] Maryniak RK. **Pneumonol Alergol Pol** 1995;63(5–6):336–8 (19 ref.) **(Pol)**

PHYSIOPATHOLOGY

Environmental lung disease: exposures and mechanisms. Brain JD. **Chest** 1996 Mar;109(3 Suppl):74S–78S (14 ref.)

The integration of epidemiology and fundamental biology in occupational lung disease. Thomas A. Neff Lecture. Weill H. **Chest** 1996 Mar;109(3 Suppl):2S–5S (14 ref.)

Lung–liver interactions in sepsis and multiple organ failure syndrome. Matuschak GM. **Clin Chest Med** 1996 Mar; 17(1):83–98 (191 ref.)

Pulmonary intravascular macrophages. Role in acute lung injury. Warner AE. **Clin Chest Med** 1996 Mar;17(1):125–35 (60 ref.)

Long-term canine exposure studies with ambient air pollutants. Heyder J, et al. **Eur Respir J** 1996 Mar; 9(3):571–84 (101 ref.)

Lung disease and pulmonary endothelial nitric oxide. Higenbottam T. **Exp Physiol** 1995 Sep;80(5):855–64 (29 ref.)

Epithelial dysfunction in acute lung injury. Edelson JD. **New Horiz** 1995 May;3(2):229–39 (188 ref.)

Considerations when testing and training the respiratory muscles. Reid WD, et al. **Phys Ther** 1995 Nov; 75(11):971–82 (55 ref.)

Air pollution: brown skies research. Tattersfield AE. **Thorax** 1996 Jan;51(1):13–22 (43 ref.)

[Physiopathologic mechanisms of drug-induced lung diseases in man] Israël-Biet D, et al. **Rev Mal Respir** 1996; 13(2):127–32 (48 ref.) (Eng. Abstr.) **(Fre)**

[Bronchial mucolytic agents] Leuenberger P. **Rev Med Suisse Romande** 1996 May;116(5):335–9 (16 ref.) **(Fre)**

[Cardiopulmonary involvement in thyroid gland diseases] Hellermann J, et al. **Pneumologie** 1996 May;50(5):375–80 (48 ref.) (Eng. Abstr.) **(Ger)**

[Tumor necrosis factor—friend and enemy] Zabel P. **Pneumologie** 1996 Apr;50(4):293–302 (104 ref.) **(Ger)**

[Lung problems in acute to subacute exposure to medium altitudes] Marugg D. **Schweiz Rundsch Med Prax** 1995 Oct 3;84(40):1101–7 (41 ref.) (Eng. Abstr.) **(Ger)**

[Role of alveolar epithelial cells in the repair process after lung injury] Sugahara K. **Masui** 1995;44 Suppl:S134–9 (11 ref.) **(Jpn)**

[Disorders of clearance of pollutants from the lung] Mustajbegović J, et al. **Lijec Vjesn** 1996 Jan–Feb; 118(1–2):39–43 (88 ref.) (Eng. Abstr.) **(Scr)**

[Clinical approach to physiologic dispnea in pregnancy] Garcia Rio F, et al. **Aten Primaria** 1996 Jan;17(1):70–4 (23 ref.) **(Spa)**

PREVENTION & CONTROL

Postoperative pulmonary complications: risk assessment, prevention, and treatment. Hayden SP, et al. **Cleve Clin J Med** 1995 Nov–Dec;62(6):401–7 (27 ref.)

International union against tuberculosis and lung disease (IUATLD): initiatives in non-tuberculous lung disease. Becklake MR. **Tuber Lung Dis** 1995 Dec;76(6):493–504 (82 ref.)

[Current topics of the artificial ventilation and respiratory management] Marukawa S. **Masui** 1995;44 Suppl:S33–9 (12 ref.) **(Jpn)**

[Mechanisms of radiation to the lung. Pentoxifylline—a new radioprotective drug?] Remiszewski P, et al. **Pneumonol Alergol Pol** 1995;63(5–6):349–54 (17 ref.) **(Pol)**

RADIOGRAPHY

Castleman's disease of the lung: radiographic, high-resolution CT, and pathologic findings. Barrie JR, et al. **AJR Am J Roentgenol** 1996 May;166(5):1055–6 (8 ref.)

The role of radiology in the investigation and management of patients with haemoptysis. Marshall TJ, et al. **Clin Radiol** 1996 Jun;51(6):391–400 (66 ref.)

Anatomic distribution and histopathologic patterns in diffuse lung disease: correlation with HRCT. Colby TV, et al. **J Thorac Imaging** 1996 Winter;11(1):1–26 (51 ref.)

Radiographic mimics of pneumonia. Pulmonary disorders to consider in differential diagnosis. Cabreros LJ, et al. **Postgrad Med** 1996 Jan;99(1):139–42, 145–6 (0 ref.)

Radiologic evaluation of the patient after cardiac surgery. Henry DA. **Radiol Clin North Am** 1996 Jan;34(1):119–35 (43 ref.)

Identification and evaluation of centrilobular opacities on high-resolution CT. Gruden JF, et al. **Semin Ultrasound CT MR** 1995 Oct;16(5):435–49 (30 ref.)

Acute lung disease in the immunocompromised host: differential diagnosis at high-resolution CT. Worthy S, et al. **Semin Ultrasound CT MR** 1995 Oct;16(5):353–60 (24 ref.)

[Differential radiologic diagnosis of HIV-associated lung diseases] Becker-Gaab C, et al. **Bildgebung** 1995 Dec; 62(4):302–9 (16 ref.) (Eng. Abstr.) **(Ger)**

[Radiation dosage of various CT techniques in diagnostic lung imaging] Heinz-Peer G, et al. **Radiologe** 1996 Jun; 36(6):470–4 (18 ref.) (Eng. Abstr.) **(Ger)**

[Spiral CT of the lung. Technique, findings, value] Prokop M, et al. **Radiologe** 1996 Jun;36(6):457–69 (42 ref.) (Eng. Abstr.) **(Ger)**

[High-resolution computerized tomography of the lungs: bases, findings, indications] Hauser M, et al. **Schweiz Med Wochenschr** 1996 Mar 9;126(10):398–408 (52 ref.) (Eng. Abstr.) **(Ger)**

[High resolution CT in the evaluation of pulmonary parenchymal diseases] Pirolli FM, et al. **Clin Ter** 1995 Nov; 146(11):747–57 (20 ref.) (Eng. Abstr.) **(Ita)**

[Rhodococcus equi lung infection in AIDS patients. A report of 4 cases] Carli Moretti C, et al. **Radiol Med (Torino)** 1996 Apr;91(4):477–80 (13 ref.) **(Ita)**

[Idiopathic pulmonary hemosiderosis] Pinto M, et al. **Acta Med Port** 1996 Jan;9(1):41–4 (15 ref.) (Eng. Abstr.) **(Por)**

RADIONUCLIDE IMAGING

Pulmonary studies using positron emission tomography. Rhodes CG, et al. **Eur Respir J** 1995 Jun;8(6):1001–17 (80 ref.)

[Pulmonary nuclear medicine] Isawa T. **Kaku Igaku** 1995 Nov;32(11):1281–8 (64 ref.) (Eng. Abstr.) **(Jpn)**

REHABILITATION

Cardiovascular, pulmonary, and cancer rehabilitation. 2. Pulmonary rehabilitation. Bach JR, et al. **Arch Phys Med Rehabil** 1996 Mar;77(3 Suppl):S45–51 (58 ref.)

Role of exercise in the evaluation and management of pulmonary disease in children and youth. Nixon PA. **Med Sci Sports Exerc** 1996 Apr;28(4):414–20 (86 ref.)

Computerized patient record for a department of respiratory rehabilitation. Ballardini L, et al. **Monaldi Arch Chest Dis** 1996 Apr;51(2):153–8 (12 ref.)

Outcomes in cardiopulmonary rehabilitation. Pashkow P. **Phys Ther** 1996 Jun;76(6):643–56 (164 ref.)

Considerations when testing and training the respiratory muscles. Reid WD, et al. **Phys Ther** 1995 Nov; 75(11):971–82 (55 ref.)

Evaluation in pulmonary rehabilitation. Ambrosino N, et al. **Respir Med** 1996 Aug;90(7):395–400 (50 ref.)

SURGERY

Role of thoracoscopy (VATS) in pleural and pulmonary pathology. Van Schil P, et al. **Acta Chir Belg** 1996 Feb; 96(1):23–7 (28 ref.)

Operative technique of bullectomy. Dartevelle P, et al. **Chest Surg Clin N Am** 1995 Nov;5(4):735–49 (12 ref.)

Future therapeutic procedures. Edell ES. **Chest Surg Clin N Am** 1996 May;6(2):381–95 (93 ref.)

Video-assisted thoracoscopic pulmonary surgery—current status and potential evolution. Walker WS, et al. **Eur J Cardiothorac Surg** 1996;10(3):161–7 (62 ref.)

Acute lung injury following lung resection: is one lung anaesthesia to blame? [editorial] Williams EA, et al. **Thorax** 1996 Feb;51(2):114–6 (41 ref.)

THERAPY

Gene therapy approaches for inherited and acquired lung diseases. Curiel DT, et al. **Am J Respir Cell Mol Biol** 1996 Jan;14(1):1–18 (211 ref.)

Age and reversible lung disease. Let's grow old, but not be forgotten or ignored! [editorial] Berger R. **Chest** 1995 Oct; 108(4):897–8 (10 ref.)

Respiratory emergencies in the dental office. Shafer DM. **Dent Clin North Am** 1995 Jul;39(3):541–54 (12 ref.)

Prognosis in advanced pulmonary disease. Herbst LH. **J Palliat Care** 1996 Summer;12(2):54–6 (27 ref.)

Neonatal ventilator management and the role for pulmonary function tests. Greenspan JS. **J Perinatol** 1996 Mar–Apr; 16(2 Pt 2 Su):S56–60 (11 ref.)

Management of pulmonary disease in patients with cystic fibrosis. Ramsey BW. **N Engl J Med** 1996 Jul 18; 335(3):179–88 (96 ref.)

Advanced ventilation in the neonate. Antunes MJ, et al. **Nurs Clin North Am** 1996 Jun;31(2):405–22 (123 ref.)

Interventional procedures in the intensive care unit patient. Mewissen MW, et al. **Radiol Clin North Am** 1996 Jan; 34(1):157–76 (110 ref.)

[Vectors of gene transfer. Applications in pneumology] Demoly P, et al. **Rev Mal Respir** 1996 Jul;13(3):251–7 (43 ref.) (Eng. Abstr.) **(Fre)**

['94 pneumology update. Progress and prospects in pneumology. Paradigm of change—I] Kroegel C, et al. **Med Klin** 1996 Apr 1;91 Suppl 1:89–101 (177 ref.) **(Ger)**

['95 pneumology update. Progress and prospects in pneumology. Paradigm of change—II] Kroegel C, et al. **Med Klin** 1996 Apr 1;91 Suppl 1:103–17 (178 ref.) **(Ger)**

ULTRASONOGRAPHY

Resolving fetal hyperechogenic lung lesions: an unresolved issue [see comments] Sepulveda W, et al. **Ultrasound Obstet Gynecol** 1995 Jul;6(1):4–5 (26 ref.) Comment in: Ultrasound Obstet Gynecol 1995 Nov;6(5):372–3.

VETERINARY

Porcine reproductive and respiratory syndrome (PRRS): a review, with emphasis on pathological, virological and diagnostic aspects. Done SH, et al. **Br Vet J** 1996 Mar; 152(2):153–74 (142 ref.)

Racing horses, nitroglycerin and exercise induced pulmonary haemorrhage (EIPH) [editorial; comment] Harkins JD, et al. **Equine Vet J** 1995 Jul;27(4):240–1 (12 ref.) Comment on: Equine Vet J 1995 Jul;27(4):275–9.

VIROLOGY

Adenovirus and Epstein-Barr virus in lung disease. Hogg JC, et al. **Semin Respir Infect** 1995 Dec;10(4):244–53 (34 ref.)

LUNG DISEASES, FUNGAL

Pulmonary histoplasmosis. Gurney JW, et al. **Radiology** 1996 May;199(2):297–306 (97 ref.)

COMPLICATIONS

Commentary: unusual manifestations of aspergillosis [comment] Denning DW. **Thorax** 1995 Jul;50(7):812–3 (23 ref.) Comment on: Thorax 1995 Jul;50(7):805–6. Comment on: Thorax 1995 Jul;50(7):807–8. Comment on: Thorax 1995 Jul;50(7):809–10. Comment on: Thorax 1995 Jul;50(7):810–1.

DIAGNOSIS

Tools and trends in the detection of Aspergillus fumigatus. Latgé JP. **Curr Top Med Mycol** 1995;6:245–81 (137 ref.)

[Pulmonary cryptococcosis—a pathology of the future?] Mihăltan F. **Pneumoftiziologia** 1995 Jan–Jun;44(1–2):71–5 (57 ref.) **(Rum)**

DRUG THERAPY

New antifungal drugs for pulmonary mycoses. Klein NC, et al. **Chest** 1996 Aug;110(2):525–32 (100 ref.)

Successfully treated invasive pulmonary aspergillosis associated with smoking marijuana in a renal transplant recipient. Marks WH, et al. **Transplantation** 1996 Jun 27; 61(12):1771–4 (8 ref.)

[Curative antifungal treatment of invasive pulmonary aspergillosis] Andrès E, et al. **Rev Pneumol Clin** 1995; 51(4):228–31 (31 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Pneumonia due to blastomyces dermatitidis in a European renal transplant recipient. Winkler S, et al. **Nephrol Dial Transplant** 1996 Jul;11(7):1376–9 (13 ref.)

Successfully treated invasive pulmonary aspergillosis associated with smoking marijuana in a renal transplant recipient. Marks WH, et al. **Transplantation** 1996 Jun 27; 61(12):1771–4 (8 ref.)

[A case of bronchial asthma complicated by mycosis] Andronova NV, et al. **Ter Arkh** 1995;67(11):33–5 (7 ref.) **(Rus)**

RADIOGRAPHY

CT manifestations of pulmonary aspergillosis. Logan PM, et al. **Crit Rev Diagn Imaging** 1996 Feb;37(1):1–37 (43 ref.)

Varied radiologic appearances of pulmonary aspergillosis. Thompson BH, et al. **Radiographics** 1995 Nov; 15(6):1273–84 (36 ref.)

LUNG DISEASES, INTERSTITIAL

CHEMICALLY INDUCED

[ACE inhibitor-associated interstitial lung infiltrates (see comments)] Obergassel L, et al. **Dtsch Med Wochenschr** 1995 Sep 22;120(38):1273-7 (22 ref.) (Eng. Abstr.) Comment in: Dtsch Med Wochenschr 1996 Jan 19;121(3):81. **(Ger)**

[Pneumonitis secondary to the inhalation of isocyanates. An analysis of 2 cases] Haro M, et al. **Arch Bronconeumol** 1995 Aug-Sep;31(7):365-7 (18 ref.) (Eng. Abstr.) **(Spa)**

COMPLICATIONS

Human T-cell lymphotropic virus type 1-associated myelopathy, Sjögren syndrome, and lymphocytic pneumonitis. Kompoliti A, et al. **Arch Neurol** 1996 Sep; 53(9):940-2 (31 ref.)

Acute respiratory failure due to extramedullary hematopoiesis. Yusen RD, et al. **Chest** 1995 Oct; 108(4):1170-2 (17 ref.)

[An autopsy case of dermatomyositis with rapidly progressive interstitial pneumonia] Ozawa Y, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Oct;18(5):552-8 (29 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

[Interstitial pneumonia and sepsis due to a Pasteurella multocida infection] Schlichthaar H, et al. **Dtsch Med Wochenschr** 1995 Nov 17;120(46):1582-6 (19 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

[Emergency therapy of collagen diseases and their complications] Ichikawa Y, et al. **Nippon Naika Gakkai Zasshi** 1995 Nov 10;84(11):1865-9 (5 ref.) **(Jpn)**

[Cyclosporin and diffuse alveolar interstitial lung disease] Losa Garcia JE, et al. **Arch Bronconeumol** 1996 Jun-Jul; 32(6):302-6 (65 ref.) **(Spa)**

IMMUNOLOGY

Alveolar macrophages as a cell source of cytokine hyperproduction in HIV-related interstitial lung disease. Agostini C, et al. **J Leukoc Biol** 1995 Nov;58(5):495-500 (37 ref.)

RADIOGRAPHY

[What does high-resolution CAT contribute in the study of diffuse interstitial diseases? (editorial)] Agustí C, et al. **Arch Bronconeumol** 1995 Aug-Sep;31(7):311-3 (24 ref.) **(Spa)**

THERAPY

[Progresses in respiratory diseases in China, 1995] Lin Y. **Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):718-9 (0 ref.) **(Chi)**

VIROLOGY

[Laboratory examinations and therapy for infections after bone marrow transplantation] Kimura Y, et al. **Rinsho Byori** 1995 Jul;Suppl 99:146-53 (16 ref.) **(Jpn)**

LUNG DISEASES, OBSTRUCTIVE

see related

AIRWAY OBSTRUCTION

What's in a name? Names, definitions, descriptions, and diagnostic criteria of diseases, with emphasis on chronic obstructive pulmonary disease. Snider GL. **Respiration** 1995;62(6):297-301 (19 ref.)

CHEMICALLY INDUCED

[Chronic obstructive bronchopneumopathy after acute inhalation of sulfur anhydride. Apropos of a case] Ramakers M, et al. **Rev Pneumol Clin** 1995;51(6):343-7 (31 ref.) (Eng. Abstr.) **(Fre)**

[Persistent reactive airway dysfunction syndrome after exposure to chromate] Nagasaka Y, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Jul;33(7):759-64 (16 ref.) (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

Treatment of pulmonary hypertension in patients with chronic obstructive pulmonary disease: position of vasodilators with special focus on urapidil. Adnot S, et al. **Blood Press** 1995;Suppl 3:47-57 (43 ref.)

Lung cancer and chronic obstructive pulmonary disease. Petty TL. **Med Clin North Am** 1996 May;80(3):645-55 (19 ref.)

Acute bronchial infection in chronic obstructive pulmonary disease. Dorca J. **Monaldi Arch Chest Dis** 1995 Oct; 50(5):366-71 (43 ref.)

Nocturnal hypoxaemia in patients with chronic obstructive pulmonary disease: who should be treated and how? Heijdra YF, et al. **Neth J Med** 1995 Dec;47(6):296-301 (30 ref.)

Severe exacerbations of COPD patients: the role of pulmonary infections. Fagon JY, et al. **Semin Respir Infect** 1996 Jun;11(2):109-18 (62 ref.)

[Malnutrition in chronic obstructive bronchopulmonary diseases] Horáček J, et al. **Vnitr Lek** 1995 Jul;41(7):493-7 (35 ref.) (Eng. Abstr.) **(Cze)**

[Pathogenic mechanisms and natural history of pulmonary hypertension in chronic obstructive pulmonary disease] Tobiasz M. **Pol Arch Med Wewn** 1995 Jun;93(6):509-14 (56 ref.) **(Pol)**

DIAGNOSIS

Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Thoracic Society. **Am J Respir Crit Care Med** 1995 Nov;152(5 Pt 2):S77-121 (265 ref.)

Clinical exercise testing in chronic airflow limitation. Marciniuk DD, et al. **Med Clin North Am** 1996 May; 80(3):565-87 (105 ref.)

[Diagnosis of bronchial asthma and chronic obstructive lung disease by the family physician. Ad hoc consensus group 'Diagnosis of asthma/chronic obstructive lung disease by the family physician' (see comments)] van Schayck CP. **Ned Tijdschr Geneeskd** 1995 Sep 30;139(39):1966-71 (22 ref.) Comment in: Ned Tijdschr Geneeskd 1995 Dec 2;139(48):2512-3. **(Dut)**

[Sleep apnea and chronic obstructive respiratory tract disease (COPD): diagnostic and therapeutic consequences] Schäfer H, et al. **Pneumologie** 1996 Apr;50(4):278-85 (73 ref.) **(Ger)**

[Diagnosing bronchospastic states] Oklek K. **Pneumonol Alergol Pol** 1995;63(5-6):328-31 (9 ref.) **(Pol)**

[Asthma and chronic obstructive pulmonary disease. Similarities and differences] Pierzchała W. **Pneumonol Alergol Pol** 1995;63(5-6):332-5 (24 ref.) **(Pol)**

[Guidelines on the diagnosis and treatment of chronic obstructive lung disease. The SEPAR Working Group. The Spanish Society of Pneumology and Thoracic Surgery] Montemayor T, et al. **Arch Bronconeumol** 1996 Jun-Jul; 32(6):285-301 (184 ref.) **(Spa)**

DIET THERAPY

Dietary fish oil and airways obstruction. Britton J. **Thorax** 1995 Sep;50 Suppl 1:S11-5 (28 ref.)

DRUG THERAPY

An international perspective on anticholinergic therapy. Chapman KR. **Am J Med** 1996 Jan 29;100(1A):2S-4S (19 ref.)

Therapeutic approaches to chronic obstructive pulmonary disease: an emerging consensus. Chapman KR. **Am J Med** 1996 Jan 29;100(1A):5S-10S (37 ref.)

Use of anticholinergic bronchodilation in children. Rubin BK, et al. **Am J Med** 1996 Jan 29;100(1A):49S-53S (40 ref.)

Optimal pharmacologic treatment of the critically ill patient with obstructive airways disease. Siefkin AD. **Am J Med** 1996 Jan 29;100(1A):54S-61S (37 ref.)

Home nebuliser-compressors. Ariyananda PL, et al. **Br J Hosp Med** 1995 Nov 15-Dec 12;54(10):489-93 (22 ref.)

Pulmonary pharmacology. Hornby PJ, et al. **Clin Obstet Gynecol** 1996 Mar;39(1):17-35 (25 ref.)

Influenza vaccine may enhance theophylline toxicity. A case report and review of the literature. Hamdy RC, et al. **J Tenn Med Assoc** 1995 Dec;88(12):463-4 (12 ref.)

The role of N-acetylcysteine in the treatment of chronic obstructive pulmonary disease [editorial] van Herwaarden CL, et al. **Neth J Med** 1995 Aug;47(2):45-8 (21 ref.)

[Drug treatment of chronic obstructive pulmonary disease] van Herwaarden CL, et al. **Ned Tijdschr Geneeskd** 1996 Apr 6;140(14):761-5 (35 ref.) **(Dut)**

[Treatment of respiratory insufficiency in chronic nonspecific lung diseases] Kazanbiev NK. **Klin Med (Mosk)** 1995; 73(4):24-7 (16 ref.) **(Rus)**

ETIOLOGY

Occupationally induced airways obstruction. Garshick E, et al. **Med Clin North Am** 1996 Jul;80(4):851-78 (132 ref.)

Risk factors for the development of chronic obstructive pulmonary disease. Silverman EK, et al. **Med Clin North Am** 1996 May;80(3):501-22 (76 ref.)

Relationship of acute obstructive airway change to chronic (fixed) obstruction. Becklake MR. **Thorax** 1995 Sep;50 Suppl 1:S16-21 (57 ref.)

PHYSIOPATHOLOGY

Pathophysiology of chronic obstructive pulmonary disease. Celli BR. **Chest Surg Clin N Am** 1995 Nov;5(4):623-34 (39 ref.)

Diffusing capacity in the clinical assessment of chronic airflow limitation. Cotton DJ, et al. **Med Clin North Am** 1996 May;80(3):549-64 (121 ref.)

Obstructive lung disease and sleep. Jokic R, et al. **Med Clin North Am** 1996 Jul;80(4):821-50 (210 ref.)

Respiratory muscle function and COPD. Nardini S. **Monaldi Arch Chest Dis** 1995 Aug;50(4):325-6 (6 ref.)

Respiratory muscle training for patients with chronic obstructive pulmonary disease. Reid WD, et al. **Phys Ther** 1995 Nov;75(11):996-1005 (65 ref.)

[Indications for respiratory function tests (RFT). The role of RFT and blood gases in the monitoring of asthma and chronic obstructive bronchopnumopathies] **Rev Mal Respir** 1995;12 Suppl 3:R115-31 (57 ref.) **(Fre)**

[Acute decompensation in chronic obstructive respiratory insufficiency. Pathogenesis of edema and role of noninvasive mechanical ventilation] Chevrolet JC. **Schweiz Rundsch Med Prax** 1996 Mar 12;85(11):329-36 (49 ref.) (Eng. Abstr.) **(Fre)**

[Patients with lung diseases and sports] Villiger B. **Schweiz Rundsch Med Prax** 1995 Sep 5;84(36):953-62 (38 ref.) (Eng. Abstr.) **(Ger)**

[Cholinergic-dependent airway obstruction] Małolepszy J. **Pneumonol Alergol Pol** 1995;63(5-6):319-21 (17 ref.) **(Pol)**

PREVENTION & CONTROL

Prevention of chronic obstructive pulmonary disease: a challenge for the health professions. O'Hagan J. **N Z Med J** 1996 Jan 26;109(1014):1-2 (24 ref.)

Smoking cessation: time for action. Jarvis MJ. **Thorax** 1995 Sep;50 Suppl 1:S22-4 (24 ref.)

REHABILITATION

Functional status instruments: outcome measure in the evaluation of patients with chronic obstructive pulmonary disease. Lareau SC, et al. **Heart Lung** 1996 May-Jun; 25(3):212-24 (63 ref.)

Breathing retraining in chronic obstructive pulmonary disease. Breslin EH. **J Cardpulm Rehabil** 1995 Jan-Feb; 15(1):25-33 (51 ref.)

Respiratory muscle training for patients with chronic obstructive pulmonary disease. Reid WD, et al. **Phys Ther** 1995 Nov;75(11):996-1005 (65 ref.)

Selection criteria for pulmonary rehabilitation. Ambrosino N, et al. **Respir Med** 1996 Jul;90(6):317-22 (36 ref.)

Pulmonary rehabilitation at home [editorial] Wijkstra PJ. **Thorax** 1996 Feb;51(2):117-8 (18 ref.)

[Exercise training: its value in chronic obstructive lung disease] Sergysels R. **Rev Mal Respir** 1996;13(2):95-100 (40 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

A perspective on the role of surgery in chronic obstructive lung disease. Deslauriers J. **Chest Surg Clin N Am** 1995 Nov;5(4):575-602 (129 ref.)

Lung transplantation in chronic airflow limitation. Lynch JP, et al. **Med Clin North Am** 1996 May;80(3):657-70 (43 ref.)

Lung reduction surgery in chronic obstructive lung disease. Rogers RM, et al. **Med Clin North Am** 1996 May; 80(3):623-44 (42 ref.)

[Respiratory insufficiency. Role of lung and heart/lung transplantation. Indications and results] Wagner TO. **Internist (Berl)** 1995 Aug;36(8):818-27 (37 ref.) **(Ger)**

[Pulmonary emphysema--lung transplantation] Matthys H. **Versicherungsmedizin** 1995 Dec 1;47(6):201-3 (14 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Thoracic Society. **Am J Respir Crit Care Med** 1995 Nov;152(5 Pt 2):S77-121 (265 ref.)

Domiciliary oxygen. Wilkinson J, et al. **Br J Clin Pract** 1996 Apr-May;50(3):151-3 (8 ref.)

The changing role of mechanical ventilation in COPD [editorial] Shneerson JM. **Eur Respir J** 1996 Mar;9(3):393-8 (74 ref.)

Current thoughts regarding treatment of chronic obstructive pulmonary disease. Celli BR. **Med Clin North Am** 1996 May;80(3):589-609 (120 ref.)

Home oxygen therapy. O'Donohue WJ Jr. **Med Clin North Am** 1996 May;80(3):611-22 (38 ref.)

Noninvasive ventilation in the management of decompensated COPD. Polkey MI, et al. **Monaldi Arch Chest Dis** 1995 Oct;50(5):378-82 (31 ref.)

[Ventilatory assistance in acute exacerbations of chronic respiratory insufficiency in adults (with the exclusion of neuromuscular pathology and weaning). 13th Consensus Conference in Resuscitation and Emergency Medicine. 2 December 1994, Strasbourg] **Rev Mal Respir** 1995;12 Suppl 3:R158-61 (0 ref.) **(Fre)**

[Respirator dependency. Intensive care unit or home ventilation?] Criée CP, et al. **Internist (Berl)** 1995 Aug; 36(8):812-7 (16 ref.) **(Ger)**

[Oxygen therapy and pulmonary hypertension in chronic obstructive bronchopneumopathies] Gensini G, et al. **Recenti Prog Med** 1996 Feb;87(2):81-5 (31 ref.) (Eng. Abstr.) **(Ita)**

[Guidelines on the diagnosis and treatment of chronic obstructive lung disease. The SEPAR Working Group. The Spanish Society of Pneumology and Thoracic Surgery] Montemayor T, et al. **Arch Bronconeumol** 1996 Jun-Jul; 32(6):285-301 (184 ref.) **(Spa)**

LUNG DISEASES, PARASITIC

PARASITOLOGY

[Extracerebral toxoplasmosis in immunodepressed subjects.

Case report of a case of pulmonary toxoplasmosis in an HIV-positive patient and literature review] **Kamm W, et al. Rev Med Suisse Romande** 1996 May;116(5):385–90 (23 ref.) **(Fre)**

[A case of pulmonary dirofilariasis] **Itoh K, et al. Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Feb;34(2):231–5 (14 ref.) (Eng. Abstr.) **(Jpn)**

LUNG FUNCTION TESTS see **RESPIRATORY FUNCTION TESTS**

LUNG INJURY, ACUTE see **RESPIRATORY DISTRESS SYNDROME, ADULT**

LUNG LAVAGE see **BRONCHOALVEOLAR LAVAGE**

LUNG LAVAGE FLUID see **BRONCHOALVEOLAR LAVAGE FLUID**

LUNG NEOPLASMS

see related
CARCINOMA, NON-SMALL-CELL LUNG
CARCINOMA, SMALL CELL

Female lung cancer. Ernster VL. **Annu Rev Public Health** 1996;17:97–114 (94 ref.)

Update in the treatment and molecular biology of non-small cell lung cancer. Erlich R, et al. **Compr Ther** 1995 Aug; 21(8):445–57 (76 ref.)

Small cell lung cancer: biological and therapeutic aspects. Kristensen CA, et al. **Crit Rev Oncol Hematol** 1996 Jan; 22(1):27–60 (373 ref.)

Bronchioloalveolar carcinoma. Barkley JE, et al. **J Clin Oncol** 1996 Aug;14(8):2377–86 (96 ref.)

Pleuro-pulmonary blastoma: a case report and review of the literature. Schmaltz C, et al. **Med Pediatr Oncol** 1995 Dec; 25(6):479–84 (18 ref.)

[Pulmonary carcinoma nowadays: notes on epidemiology, primary prevention, and therapeutic planning (editorial)] Motta G. **Ann Ital Chir** 1995 May–Jun;66(3):301–10 (37 ref.) (Eng. Abstr.) **(Ita)**

BLOOD

Clinical applications of serum markers for lung cancer. Ferrigno D, et al. **Respir Med** 1995 Oct;89(9):587–97 (158 ref.)

CHEMICALLY INDUCED

Review of occupational lung carcinogens. Steenland K, et al. **Am J Ind Med** 1996 May;29(5):474–90 (167 ref.)

Synthesis of tobacco-specific N-nitrosamines and their metabolites and results of related bioassays. Amin S, et al. **Crit Rev Toxicol** 1996;26(2):139–47 (32 ref.)

Diesel engine exhaust and lung cancer: an unproven association. Muscat JE, et al. **Environ Health Perspect** 1995 Sep;103(9):812–8 (77 ref.)

[Advances in the study on biological effects of diesel exhaust] Lu Y, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1995 Sep;29(5):305–6 (15 ref.) **(Chi)**

CHEMISTRY

[Cyfra 21-1--new marker for lung cancer] Luczak E, et al. **Pneumonol Alergol Pol** 1996;64(1–2):96–101 (19 ref.) (Eng. Abstr.) **(Pol)**

COMPLICATIONS

Hypertrophic pulmonary osteoarthropathy: is there a role for radiotherapy to symptomatic sites? Case report and literature review. Roos DE. **Acta Oncol** 1996;35(1):101–3 (16 ref.)

Lung cancer in patients with bullous disease. Zulueta JJ, et al. **Am J Respir Crit Care Med** 1996 Aug;154(2 Pt 1):519–22 (28 ref.)

Clinical characteristics of synchronous multiple lung cancer associated with idiopathic pulmonary fibrosis. A review of Japanese cases [see comments] Mizushima Y, et al. **Chest** 1995 Nov;108(5):1272–7 (37 ref.) Comment in: Chest 1995 Nov;108(5):1193–4.

Cavitary pulmonary lesions in patients infected with human immunodeficiency virus. Gallant JE, et al. **Clin Infect Dis** 1996 Apr;22(4):671–82 (208 ref.)

Facial pain as a symptom of nonmetastatic lung cancer. Capobianco DJ. **Headache** 1995 Nov–Dec;35(10):581–5 (18 ref.)

Tumor-induced osteomalacia. Schapira D, et al. **Semin Arthritis Rheum** 1995 Aug;25(1):35–46 (79 ref.)

[Spontaneous perforation of the small intestine in primary lung carcinoma] Kolarov I, et al. **Khirurgiia (Sofiia)** 1995; 48(6):47–9 (0 ref.) **(Bul)**

[Pulmonary cancer and recurrent arterial and venous thromboses] Auvray E, et al. **Rev Pneumol Clin** 1996; 52(3):188–91 (16 ref.) (Eng. Abstr.) **(Fre)**

[Clinical analysis of lung cancer in patients with chondromatous hamartoma] Umemori Y, et al. **Kyobu Geka** 1995 Nov;48(12):1061–4 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Squamous cell carcinoma of the lung associated with palmo-plantar hyperkeratosis] Nomori H, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Jan;34(1):76–9 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Paraneoplastic syndromes of the nervous system and muscles during the course of small cell lung carcinoma] Joachimowicz-Jaśkowiak E. **Pneumonol Pol** 1990 Nov–Dec;58(11–12):647–50 (21 ref.) **(Pol)**

DIAGNOSIS

Lung cancer and ipsilateral pleural effusion. Rodriguez Panadero F. **Ann Oncol** 1995;6 Suppl 3:S25–7 (13 ref.)

Pulmonary complications of HIV infection. Murray JF. **Annu Rev Med** 1996;47:117–26 (30 ref.)

Does the assessment of serum markers in patients with lung cancer aid in the clinical decision making process? Ebert W, et al. **Anticancer Res** 1996 Jul–Aug;16(4B):2161–8 (27 ref.)

Pulmonary artery aneurysm presenting as a lung mass. Chung CW, et al. **Chest** 1995 Oct;108(4):1164–6 (10 ref.)

Future diagnostic procedures. Lam S, et al. **Chest Surg Clin N Am** 1996 May;6(2):363–80 (81 ref.)

Molecular and biological factors in the prognosis of non-small cell lung cancer. Kanters SD, et al. **Eur Respir J** 1995 Aug;8(8):1389–97 (89 ref.)

Use of tumor markers in lung cancer. Strauss GM, et al. **Hematol Oncol Clin North Am** 1994 Jun;8(3):507–32 (109 ref.)

Bilateral patellar metastases as the clinical presentation of bronchogenic adenocarcinoma. Pauzner R, et al. **J Rheumatol** 1996 May;23(5):939–41 (22 ref.)

Biological prognostic factors in non-small cell lung cancer. Scagliotti GV, et al. **Lung Cancer** 1995 Apr;12 Suppl 1:S13–25 (70 ref.)

Prognostic factors in NSCLC. Recent experiences. van Zandwijk N, et al. **Lung Cancer** 1995 Apr;12 Suppl 1:S27–33 (30 ref.)

Lung cancer and chronic obstructive pulmonary disease. Petty TL. **Med Clin North Am** 1996 May;80(3):645–55 (19 ref.)

The lung in HIV infection: can pulmonary function testing help? Mitchell DM, et al. **Monaldi Arch Chest Dis** 1996 Jun;51(3):214–22 (30 ref.)

Neoplastic mimics of pneumonia. Casey KR. **Semin Respir Infect** 1995 Sep;10(3):131–42 (86 ref.)

Cardiac tamponade as the initial presentation of bronchioloalveolar cell carcinoma. Hourany J, et al. **Tenn Med** 1996 Jul;89(7):247–8 (12 ref.)

[Pulmonary plasmacytoma. Apropos of a case. Review of the literature] Etienne G, et al. **Rev Pneumol Clin** 1995; 51(5):280–3 (22 ref.) (Eng. Abstr.) **(Fre)**

[Pseudomesotheliomatous carcinoma in HIV infection] Brunner-La Rocca HP, et al. **Dtsch Med Wochenschr** 1995 Sep 29;120(39):1312–7 (38 ref.) (Eng. Abstr.) **(Ger)**

[Modern examination methods in pneumology] Frank W, et al. **Versicherungsmedizin** 1995 Dec 1;47(6):191–200 (40 ref.) (Eng. Abstr.) **(Ger)**

[Usefulness and limitation of serum tumor markers in diagnosis of lung cancer] Fukuda M, et al. **Nippon Rinsho** 1996 Jun;54(6):1610–5 (13 ref.) (Eng. Abstr.) **(Jpn)**

[Application of molecular diagnosis to human lung cancer] Isobe T. **Rinsho Byori** 1995 Aug;43(8):792–8 (30 ref.) (Eng. Abstr.) **(Jpn)**

[The role of serum markers in diagnosis and treatment monitoring in patients with lung cancer] Jassem E, et al. **Przegl Lek** 1995;52(8):392–4 (22 ref.) **(Pol)**

[Bronchogenic carcinoma and human immunodeficiency virus infection] Carrasquer C, et al. **Arch Bronconeumol** 1995 Aug–Sep;31(7):362–4 (15 ref.) (Eng. Abstr.) **(Spa)**

[Large-cell lung carcinoma producing chorionic gonadotropin hormone: the difficulty in its differential diagnosis from choriocarcinoma] Cremades Romero MJ, et al. **Arch Bronconeumol** 1996 May;32(5):253–5 (10 ref.) (Eng. Abstr.) **(Spa)**

[Metastatic pulmonary fibrosarcoma: apropos a case and a review of the literature] Quintana González JI, et al. **Arch Bronconeumol** 1996 May;32(5):256–8 (17 ref.) (Eng. Abstr.) **(Spa)**

[Choroidal metastases as the form of presentation of 2 bronchiolo-alveolar carcinomas] de Frutos Arribas JF, et al. **Rev Clin Esp** 1995 Dec;195(12):853–5 (19 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Adjuvant and neo-adjuvant chemotherapy in non-small cell carcinoma. Cullen MH. **Ann Oncol** 1995;6 Suppl 1:43–7; discussion 47–8 (23 ref.)

Is there a role for chemotherapy of non-small cell lung cancer? Hansen HH. **Ann Oncol** 1995;6 Suppl 1:79–82 (23 ref.)

Dealing with initial chemotherapy doses: a new basis for treatment optimisation in limited small-cell lung cancer. Le Cesne A, et al. **Ann Oncol** 1995;6 Suppl 3:S53–6 (26 ref.)

New drugs in the treatment of non-small cell lung cancer. Steward WP, et al. **Ann Oncol** 1995;6 Suppl 1:49–54 (38 ref.)

Chemotherapy in non-small cell lung cancer. Thatcher N, et al. **Ann Oncol** 1995;6 Suppl 1:83–94; discussion 94–5 (97 ref.)

Vinorelbine: a new antineoplastic drug for the treatment of non-small-cell lung cancer. Jones SF, et al. **Ann Pharmacother** 1996 May;30(5):501–6 (29 ref.)

Current chemotherapy of advanced non-small cell lung cancer. Abratt RP. **Anticancer Drugs** 1995 Dec;6 Suppl 6:15–8 (29 ref.)

Docetaxel: meeting the challenge of non-small cell lung cancer management. Le Chevalier T. **Anticancer Drugs** 1995 Jul;6 Suppl 4:13–7 (23 ref.)

The importance of dose and schedule in chemotherapy for small cell lung cancer. Ranson M, et al. **Anticancer Drugs** 1995 Oct;6 Suppl 5:53–63 (112 ref.)

Phase II trials of single-agent activity of gemcitabine in patients with advanced non-small cell lung cancer: an overview. Shepherd FA. **Anticancer Drugs** 1995 Dec;6 Suppl 6:19–25 (13 ref.)

Symptomatic benefit from gemcitabine and other chemotherapy in advanced non-small cell lung cancer: changes in performance status and tumour-related symptoms. Thatcher N, et al. **Anticancer Drugs** 1995 Dec; 6 Suppl 6:39–48 (68 ref.)

New drugs for the management of lung cancer. Giaccone G. **Br J Hosp Med** 1996 May 15–Jun 4;55(10):634–8 (45 ref.)

Promising new agents in the treatment of non-small cell lung cancer. Edelman, MJ, et al. **Cancer Chemother Pharmacol** 1996;37(5):385–93 (96 ref.)

Aggressive vs nonaggressive therapy for metastatic NSCLC. Thatcher N, et al. **Chest** 1996 May;109(5 Suppl):87S–92S (52 ref.)

Future therapeutic procedures. Edell ES. **Chest Surg Clin N Am** 1996 May;6(2):381–95 (93 ref.)

Photodynamic therapy. Its use in the management of bronchogenic carcinoma. Edell ES, et al. **Clin Chest Med** 1995 Sep;16(3):455–63 (103 ref.)

Long-term follow-up of a randomised trial of combined chemoradiotherapy induction treatment, with and without maintenance chemotherapy in patients with small cell carcinoma of the lung. Beith JM, et al. **Eur J Cancer** 1996 Mar;32A(3):438–43 (21 ref.)

Colony-stimulating factors as an adjunct to chemotherapy in small cell lung cancer. Urban T, et al. **Eur Respir J** 1996 Mar;9(3):596–602 (66 ref.)

Camptothecin analogues in the treatment of non-small cell lung cancer. Ardizzoni A. **Lung Cancer** 1995 Apr;12 Suppl 1:S177–85 (19 ref.)

Scheduling of chemotherapy and radiotherapy in locally advanced non-small cell lung cancer. Bishop JF. **Lung Cancer** 1995 Jun;12 Suppl 2:S53–61 (52 ref.)

Carboplatin/etoposide combination chemotherapy in the treatment of poor prognosis patients with small cell lung cancer. Carney DN. **Lung Cancer** 1995 Jun;12 Suppl 3:S77–83 (10 ref.)

New chemotherapy agents in the treatment of advanced non-small cell lung cancer: an update including data from the Seventh World Conference on Lung Cancer. Comis RL, et al. **Lung Cancer** 1995 Jun;12 Suppl 2:S63–99 (163 ref.)

Trials with mitomycin, ifosfamide and cisplatin in non-small cell lung cancer. Cullen MH. **Lung Cancer** 1995 Apr;12 Suppl 1:S95–106 (12 ref.)

New drugs for treating small cell lung cancer. Ettinger DS. **Lung Cancer** 1995 Jun;12 Suppl 3:S53–61 (20 ref.)

Adjuvant chemotherapy: results and perspectives. Evans WK. **Lung Cancer** 1995 Apr;12 Suppl 1:S35–45 (27 ref.)

Paclitaxel (Taxol) and docetaxel (Taxotere): active chemotherapeutic agents in lung cancer. Francis PA, et al. **Lung Cancer** 1995 Apr;12 Suppl 1:S163–72 (40 ref.)

New drugs in non-small cell lung cancer. An overview. Giaccone G. **Lung Cancer** 1995 Apr;12 Suppl 1:S155–62 (35 ref.)

Edatrexate studies in non-small cell lung cancer. Gralla RJ. **Lung Cancer** 1995 Apr;12 Suppl 1:S187–91 (21 ref.)

Oral therapy for small cell lung cancer. Postmus PE, et al. **Lung Cancer** 1995 Jun;12 Suppl 3:S63–70 (29 ref.)

Neoadjuvant chemotherapy of locally advanced non-small cell lung cancer. Pujol JL, et al. **Lung Cancer** 1995 Apr; 12 Suppl 1:S107–18 (46 ref.)

Gemcitabine in non-small cell lung cancer. Sørensen JB. **Lung Cancer** 1995 Apr;12 Suppl 1:S173–5 (8 ref.)

Combined platinum etoposide with radiation therapy in limited stage small cell lung cancer: an effective treatment strategy. Turrisi AT 3rd. **Lung Cancer** 1995 Jun;12 Suppl 3:S41–51 (26 ref.)

Combined-modality therapy for advanced non-small cell lung cancer: paclitaxel and thoracic irradiation. Choy H, et al. **Semin Oncol** 1995 Dec;22(6 Suppl 15):38–44 (41 ref.)

Update: vinorelbine (navelbine) in non-small cell lung cancer. Crawford J. **Semin Oncol** 1996 Apr;23(2 Suppl 5):2–7 (24 ref.)

Ifosfamide in the treatment of small cell lung cancer. Ettinger DS. **Semin Oncol** 1996 Jun;23(3 Suppl 6):2–6 (20 ref.)

Ifosfamide in non-small cell lung cancer. Johnson DH. **Semin Oncol** 1996 Jun;23(3 Suppl 6):7–10 (27 ref.)

The role of ifosfamide in small cell lung cancer. Loehrer PJ Sr. **Semin Oncol** 1996 Jun;23(3 Suppl 7):40–4 (29 ref.)

Neoadjuvant chemotherapy in stage IIIa non-small cell lung cancer. Milroy R, et al. **Thorax** 1995 Sep;50 Suppl 1:S25–30 (54 ref.)

Long-lasting complete remission of pulmonary metastases consequent to renal cell carcinoma obtained with interferon-beta therapy: review of the literature and a case report. Scoponi C, et al. **Tumori** 1995 May–Jun;81(3):201–3 (24 ref.)

Resection of stage III non-small cell lung cancer following induction therapy. Rusch VW. **World J Surg** 1995

Nov-Dec;19(6):817-22 (35 ref.)
[Role of chemotherapy in non-small cell lung carcinoma] Giaccone G, et al. **Ned Tijdschr Geneeskd** 1996 May 25; 140(21):1111-4 (21 ref.) **(Dut)**
[Localized small-cell lung cancers: prospects of concomitant radiochemotherapy] Reboul F, et al. **Bull Cancer (Paris)** 1995 Dec;82(12):996-1004 (53 ref.) (Eng. Abstr.) **(Fre)**
[Therapeutic role of coagulation in small cell lung cancers] LeBeau B. **Rev Mal Respir** 1996;13(1):21-6 (41 ref.) (Eng. Abstr.) **(Fre)**
[Role of hematopoietic growth factors in bronchial cancerology] Lemarié E, et al. **Rev Mal Respir** 1995; 12(5):429-34 (31 ref.) (Eng. Abstr.) **(Fre)**
[Value of chemotherapy in multi-modal treatment of non-small-cell bronchial carcinoma] Thomas M, et al. **Dtsch Med Wochenschr** 1995 Nov 24;120(47):1627-30 (25 ref.) **(Ger)**
[Chemotherapy of gastrointestinal carcinomas and non-small-cell pulmonary carcinoma: a controversy] Fey MF, et al. **Schweiz Med Wochenschr** 1996 May 18; 126(20):872-8 (26 ref.) (Eng. Abstr.) **(Ger)**
[An elderly case of squamous cell lung cancer showing partial response by daily administration of oral etoposide] Fukabori T, et al. **Gan To Kagaku Ryoho** 1996 Aug; 23(9):1187-90 (12 ref.) (Eng. Abstr.) **(Jpn)**
[Photodynamic therapy of centrally located early-stage lung cancer] Furuse K. **Gan To Kagaku Ryoho** 1996 Jan; 23(1):27-30 (17 ref.) (Eng. Abstr.) **(Jpn)**
[Chemotherapy of small cell lung cancer] Komiya T, et al. **Gan To Kagaku Ryoho** 1996 Aug;23(9):1116-23 (36 ref.) (Eng. Abstr.) **(Jpn)**
[Photodynamic therapy for multiple primary lung cancer] Konaka C, et al. **Gan To Kagaku Ryoho** 1996 Jan;23(1):31-5 (8 ref.) (Eng. Abstr.) **(Jpn)**

ECONOMICS

The cost of managing lung cancer in Canada. Evans WK, et al. **Oncology (Huntingt)** 1995 Nov;9(11 Suppl):147-53 (37 ref.)

ENZYMOLOGY

[Glutathione S-transferase as a metabolic biomarker for predisposition to lung neoplasms induced by chemical carcinogens] Lutz W, et al. **Med Pr** 1995;46(5):497-503 (14 ref.) (Eng. Abstr.) **(Pol)**

EPIDEMIOLOGY

Passive smoking and lung cancer. Reynolds P, et al. **Ann Med** 1995 Dec;27(6):633-40 (50 ref.)
Lung cancer at the University College Hospital, Ibadan, Nigeria [see comments] Ogunbiyi JO. **East Afr Med J** 1995 May;72(5):271-5 (26 ref.) Comment in: East Afr Med J 1995 May;72(5):269-70.
Diet, nutrition, and avoidable cancer. Willett WC. **Environ Health Perspect** 1995 Nov;103 Suppl 8:165-70 (58 ref.)
The changing epidemiology of smoking and lung cancer histology. Wynder EL, et al. **Environ Health Perspect** 1995 Nov;103 Suppl 8:143-8 (67 ref.)
Principal cancers among women: breast, lung and colorectal. Rozenberg S, et al. **Int J Fertil Menopausal Stud** 1996 Mar-Apr;41(2):166-71 (33 ref.)
Lung cancer and CYP2D6 (the debrisoquine polymorphism): sources of heterogeneity in the proposed association. Caporaso N, et al. **Pharmacogenetics** 1995;5 Spec No:S129-34 (44 ref.)
Review of Hodgkin's disease and lung cancer following non-Hodgkin's lymphoma in Rhode Island and review of the literature. Dores GM, et al. **R I Med** 1995 Nov; 78(11):317-9 (20 ref.)

ETHNOLOGY

Malignant mesothelioma in Pilbara Aborigines. Musk AW, et al. **Aust J Public Health** 1995 Oct;19(5):520-2 (10 ref.)

ETIOLOGY

Airborne fibre concentrations and lung burden compared to the tumour response in rats and humans exposed to asbestos. Rödelsperger K, et al. **Ann Occup Hyg** 1995 Oct; 39(5):715-25 (27 ref.)
Mechanisms of carcinogenesis and clinical features of asbestos-associated cancers. Mossman BT, et al. **Cancer Invest** 1996;14(5):466-80 (126 ref.)
Molecular mechanisms of lung cancer. Interaction of environmental and genetic factors. Giles F. Filley Lecture. Devereux TR, et al. **Chest** 1996 Mar;109(3 Suppl):14S-19S (80 ref.)
Recent studies on mechanisms of bioactivation and detoxification of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), a tobacco-specific lung carcinogen. Hecht SS. **Crit Rev Toxicol** 1996;26(2):163-81 (83 ref.)
The biological significance of tobacco-specific N-nitrosamines: smoking and adenocarcinoma of the lung. Hoffmann D, et al. **Crit Rev Toxicol** 1996;26(2):199-211 (76 ref.)
Lung cancer and air pollution. Cohen AJ, et al. **Environ Health Perspect** 1995 Nov;103 Suppl 8:219-24 (50 ref.)
Risk factors for lung cancer among nonsmokers with emphasis on lifestyle factors. Gao YT. **Lung Cancer** 1996 Mar;14 Suppl 1:S39-45 (24 ref.)
Diet as a confounder of the association between air pollution and female lung cancer: Hong Kong studies on exposures to environmental tobacco smoke, incense, and cooking fumes as examples. Koo LC, et al. **Lung Cancer** 1996 Mar; 14 Suppl 1:S47-61 (21 ref.)
Exposure to crystalline silica and risk of lung cancer: the epidemiological evidence. Weill H, et al. **Thorax** 1996 Jan; 51(1):97-102 (48 ref.)
[Susceptibility to bronchial cancer: an example of genetic-environmental interaction] Benhamou S, et al. **Ann Biol Clin (Paris)** 1995;53(9):507-13 (73 ref.) (Eng. Abstr.) **(Fre)**
[Two complications of bullous emphysema. Apropos of a case] Guichenez P, et al. **Rev Pneumol Clin** 1995; 51(4):250-2 (14 ref.) (Eng. Abstr.) **(Fre)**
[Kartagener syndrome and hemangiomatous proliferation of lung capillaries: case report and literature review] Slodkowska J, et al. **Pneumonol Alergol Pol** 1996; 64(3-4):217-24 (24 ref.) (Eng. Abstr.) **(Pol)**

GENETICS

Genetics of murine lung tumors. Dragani TA, et al. **Adv Cancer Res** 1995;67:83-112 (181 ref.)
Pathways of chromosome alteration in human epithelial cancers. Dutrillaux B. **Adv Cancer Res** 1995;67:59-82 (80 ref.)
Inactivation of tumor suppressor proteins in lung cancer. Weintraub SJ. **Am J Respir Cell Mol Biol** 1996 Aug; 15(2):150-5 (39 ref.)
Molecular genetic tumor markers in the early diagnosis and screening of non-small-cell lung cancer. Jacobson DR, et al. **Ann Oncol** 1995;6 Suppl 3:S3-8 (44 ref.)
Somatic genetic changes in lung cancer and precancerous lesions. Sundaresan V, et al. **Ann Oncol** 1995;6 Suppl 1:27-31; discussion 31-2 (14 ref.)
Molecular genetics of lung cancer. Greenblatt MS, et al. **Cancer Surv** 1995;25:293-313 (141 ref.)
Molecular mechanisms of lung cancer. Interaction of environmental and genetic factors. Giles F. Filley Lecture. Devereux TR, et al. **Chest** 1996 Mar;109(3 Suppl):14S-19S (80 ref.)
Oncogenes and antioncogenes in lung tumorigenesis. Giaccone G. **Chest** 1996 May;109(5 Suppl):130S-134S (46 ref.)
Molecular genetic changes found in human lung cancer and its precursor lesions. Gazdar AF, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:565-72 (77 ref.)
Biology of small cell lung cancer. Johnson BE, et al. **Lung Cancer** 1995 Jun;12 Suppl 3:S5-16 (88 ref.)
Molecular events in lung cancer. Roth JA. **Lung Cancer** 1995 Jun;12 Suppl 2:S3-15 (51 ref.)
Lung cancer and CYP2D6 (the debrisoquine polymorphism): sources of heterogeneity in the proposed association. Caporaso N, et al. **Pharmacogenetics** 1995;5 Spec No:S129-34 (44 ref.)
Assessment of cancer susceptibility in humans by use of genetic polymorphisms in carcinogen metabolism. Ikawa S, et al. **Pharmacogenetics** 1995;5 Spec No:S154-60 (42 ref.)
Genetic polymorphisms of drug-metabolizing enzymes and lung cancer susceptibility. Kawajiri K, et al. **Pharmacogenetics** 1995;5 Spec No:S70-3 (17 ref.)
[Susceptibility to bronchial cancer: an example of genetic-environmental interaction] Benhamou S, et al. **Ann Biol Clin (Paris)** 1995;53(9):507-13 (73 ref.) (Eng. Abstr.) **(Fre)**
[Genetic abnormalities in lung cancer and their prognostic implications] Mitsudomi T, et al. **Gan To Kagaku Ryoho** 1996 Jul;23(8):990-6 (54 ref.) (Eng. Abstr.) **(Jpn)**
[Molecular biology of lung neoplasms--progress of the basic understandings of solid tumors in general and the application to clinical study] Nukiwa T. **Nippon Naika Gakkai Zasshi** 1996 Mar 10;85(3):443-8 (8 ref.) **(Jpn)**
[Cancer family syndrome in lung cancer--Li-Fraumeni syndrome in lung cancer] Tomita M, et al. **Nippon Rinsho** 1995 Nov;53(11):2716-21 (17 ref.) (Eng. Abstr.) **(Jpn)**
[Clinicopathological study on primary lung cancer--immunohistochemical expression of p53 suppressor gene and bcl-2 oncogene in relation to prognosis] Irie K, et al. **Rinsho Byori** 1996 Jan;44(1):32-41 (23 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

[Angiocentric T-cell lymphoma of the lung] Csanaky G, et al. **Orv Hetil** 1996 Mar 3;137(9):473-6 (28 ref.) (Eng. Abstr.) **(Hun)**
[Expression of carbohydrate antigen in lung cancers] Miyake M. **Nippon Geka Gakkai Zasshi** 1996 Feb;97(2):160-4 (19 ref.) **(Jpn)**
[A case of bronchiolo-alveolar carcinoma with high production of carbohydrate antigen (CA19-9)] Shioji Y, et al. **Nippon Geka Gakkai Zasshi** 1996 Apr;97(4):325-9 (20 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Nuclear p53 overexpression is an independent prognostic parameter in node-negative non-small cell lung carcinoma. Dalquen P, et al. **J Pathol** 1996 Jan;178(1):53-8 (41 ref.)
AFP-producing squamous cell carcinoma of the lung in an adolescent. Asamura H, et al. **Jpn J Clin Oncol** 1996 Apr; 26(2):103-6 (12 ref.)
Retinoid receptors in human lung cancer and breast cancer. Zhang XK, et al. **Mutat Res** 1996 Feb 19;350(1):267-77 (87 ref.)

PATHOLOGY

The staging of lung cancer by bronchoscopic transbronchial needle aspiration. Harrow EM, et al. **Chest Surg Clin N Am** 1996 May;6(2):223-35 (35 ref.)
Transbronchial needle aspiration and percutaneous needle aspiration for staging and diagnosis of lung cancer. Wang KP. **Clin Chest Med** 1995 Sep;16(3):535-52 (26 ref.)
Pineal and suprasellar metastasis of lung cancer: case report and review of the literature. Izumihara A, et al. **Comput Med Imaging Graph** 1995 Sep-Oct;19(5):435-7 (14 ref.)
Epithelioid hemangioendothelioma of the lung: pleural effusion cytology, ultrastructure, and brief literature review. Buggage RR, et al. **Diagn Cytopathol** 1995 Jul; 13(1):54-60 (14 ref.)
Pulmonary blastoma--a case and review of literature. Prabhakar BR, et al. **Indian J Pathol Microbiol** 1994 Dec; 37 Suppl:S35-6 (3 ref.)
Tumor embolism to LAD during pneumonectomy. A case report. Shah R, et al. **J Cardiovasc Surg (Torino)** 1996 Jun; 37(3):319-21 (13 ref.)
Rates of growth of human neoplasms: Part II. Spratt JS, et al. **J Surg Oncol** 1996 Jan;61(1):68-83 (68 ref.)
Familial adenomatous polyposis and lung cancer. Wong RP, et al. **J Surg Oncol** 1995 Nov;60(3):213-4 (11 ref.)
Primary pulmonary rhabdomyosarcoma in childhood: clinico-biologic features in two cases with review of the literature. Schiavetti A, et al. **Med Pediatr Oncol** 1996 Mar; 26(3):201-7 (26 ref.)
Intracranial meningioma masquerading as a primary pleuropulmonary tumor. Hishima T, et al. **Pathol Int** 1995 Aug;45(8):617-21 (23 ref.)
Primary Hodgkin's disease of the lung. Chetty R, et al. **Pathology** 1995 Apr;27(2):111-4 (29 ref.)
Lung pathology: the molecular genetics of non-small cell lung cancer. Fong KM, et al. **Pathology** 1995 Oct; 27(4):295-301 (161 ref.)
Experimental models in pulmonary pathology. Kumar RK. **Pathology** 1995 Apr;27(2):130-2 (35 ref.)
Recurrent intrapulmonary malignant small cell tumor of the thoracopulmonary region with metastasis to the oral cavity: review of literature and case report. Hicks MJ, et al. **Ultrastruct Pathol** 1995 Jul-Aug;19(4):297-303 (21 ref.)
[Surgical vein reconstruction in patients with tumor invasiveness of the superior caval system. Retrospective study of 7 cases] Jeanfaivre T, et al. **J Chir (Paris)** 1996 Apr;133(2):61-4 (19 ref.) (Eng. Abstr.) **(Fre)**
[False Merkel cell tumor of the gingival mucosa disclosed by small cell bronchial carcinoma] Paume P, et al. **Rev Stomatol Chir Maxillofac** 1995;96(6):352-5 (14 ref.) (Eng. Abstr.) **(Fre)**
[Meningeal carcinomatosis from pulmonary adenocarcinoma: two clinical cases with review of the literature] Rostagno C, et al. **Ann Ital Med Int** 1995 Oct-Dec;10(4):253-6 (11 ref.) (Eng. Abstr.) **(Ita)**
[Reevaluation of preneoplastic lung lesions in lung carcinoma? In bronchial carcinoma?] Kato H, et al. **Gan To Kagaku Ryoho** 1995 Dec;22(14):2048-54 (32 ref.) (Eng. Abstr.) **(Jpn)**
[Double-primary cancer of the lung and trachea] Kishiro I, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Feb; 34(2):216-9 (13 ref.) (Eng. Abstr.) **(Jpn)**
[Carcinoid lung tumors: clinico-morphologic characteristics, diagnosis] Samsonov VA. **Arkh Patol** 1995 Jul-Aug; 57(4):20-4 (32 ref.) (Eng. Abstr.) **(Rus)**
[Skin metastases, unusual presentation of lung cancer] Jurado Gámez B, et al. **An Med Interna** 1995 Jul;12(7):346-8 (15 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

Primary paraganglioma of the lung. Report of two cases and review of the literature. Skødt V, et al. **APMIS** 1995 Jul-Aug;103(7-8):597-603 (57 ref.)
Resistance mechanisms in human lung cancer. Mattern J, et al. **Invasion Metastasis** 1995;15(3-4):81-94 (108 ref.)

PREVENTION & CONTROL

Lung cancer screening. Petty TL. **Compr Ther** 1995 Aug; 21(8):432-7 (28 ref.)
N-acetylcysteine (NAC) and glutathione (GSH): antioxidant and chemopreventive properties, with special reference to lung cancer. van Zandwijk N. **J Cell Biochem Suppl** 1995; 22:24-32 (48 ref.)
Chalcones, myo-inositol and other novel inhibitors of pulmonary carcinogenesis. Wattenberg L. **J Cell Biochem Suppl** 1995;22:162-8 (40 ref.)
Early detection in lung cancer. Case finding and screening. Wolpaw DR. **Med Clin North Am** 1996 Jan;80(1):63-82 (74 ref.)

PSYCHOLOGY

Comparison of instruments for measuring quality of life in

patients with lung cancer. Hollen PJ, et al. **Semin Oncol** 1996 Apr;23(2 Suppl 5):31–40 (31 ref.)

RADIOGRAPHY

Carboplatin/etoposide combination chemotherapy in the treatment of poor prognosis patients with small cell lung cancer. Carney DN. **Lung Cancer** 1995 Jun;12 Suppl 3:S77–83 (10 ref.)

Roentgenographically occult small-cell lung cancer: case report and review of the literature. Sekine I, et al. **Mayo Clin Proc** 1996 May;71(5):481–4 (15 ref.)

The solitary pulmonary nodule. Is it malignant or benign? Dholakia S, et al. **Postgrad Med** 1996 Feb;99(2):246–50 (4 ref.)

A case of pulmonary pseudolymphoma: five years' roentgenographic observation. Takeshita T, et al. **Radiat Med** 1995 Sep–Oct;13(5):243–6 (9 ref.)

CT of pulmonary metastases with pathological correlation. Hirakata K, et al. **Semin Ultrasound CT MR** 1995 Oct; 16(5):379–94 (63 ref.)

Sclerosing haemangioma of the lung. Liam CK, et al. **Singapore Med J** 1995 Jun;36(3):333–4 (9 ref.)

[Primary malignant tumor of the breast. Monitoring after treatment (editorial)] Guastalla JP, et al. **Presse Med** 1995 Oct 21;24(31):1415–7 (22 ref.) (Eng. Abstr.) **(Fre)**

[Differential radiologic diagnosis of HIV-associated lung diseases] Becker-Gaab C, et al. **Bildgebung** 1995 Dec; 62(4):302–9 (16 ref.) (Eng. Abstr.) **(Ger)**

[Radiation dosage of various CT techniques in diagnostic lung imaging] Heinz-Peer G, et al. **Radiologe** 1996 Jun; 36(6):470–4 (18 ref.) (Eng. Abstr.) **(Ger)**

[Spiral CT of the lung. Technique, findings, value] Prokop M, et al. **Radiologe** 1996 Jun;36(6):457–69 (42 ref.) (Eng. Abstr.) **(Ger)**

[High resolution CT in the evaluation of pulmonary parenchymal diseases] Pirolli FM, et al. **Clin Ter** 1995 Nov; 146(11):747–57 (20 ref.) (Eng. Abstr.) **(Ita)**

[Hodgkin's lymphoma: an unusual pulmonary location. A case report] Drago A, et al. **Radiol Med (Torino)** 1996 Jan–Feb;91(1–2):132–5 (7 ref.) **(Ita)**

[Acute respiratory failure and multiple pulmonary nodules. Pulmonary metastases of colonic adenocarcinoma] Cordero PJ, et al. **Rev Clin Esp** 1995 Dec;195(12):845–6 (7 ref.) **(Spa)**

RADIONUCLIDE IMAGING

Imaging and staging of small-cell lung cancer: is there a future role for octreotide scintigraphy? Stokkel MP, et al. **Br J Clin Pract** 1995 Sep–Oct;49(5):235–8 (41 ref.)

RADIOTHERAPY

Radiotherapy of lung cancer. Gregor A. **Ann Oncol** 1995;6 Suppl 1:37–41 (52 ref.)

Endoscopic brachytherapy. Spratling L, et al. **Chest Surg Clin N Am** 1996 May;6(2):293–304 (17 ref.)

Endobronchial brachytherapy. Villanueva AG, et al. **Clin Chest Med** 1995 Sep;16(3):445–54 (45 ref.)

Long-term follow-up of a randomised trial of combined chemoradiotherapy induction treatment, with and without maintenance chemotherapy in patients with small cell carcinoma of the lung. Beith JM, et al. **Eur J Cancer** 1996 Mar;32A(3):438–43 (21 ref.)

Tissue inhomogeneity in the thorax: implications for 3-D treatment planning. Ten Haken RK, et al. **Front Radiat Ther Oncol** 1996;29:180–7 (15 ref.)

Local irradiation alone for peripheral stage I lung cancer: could we omit the elective regional nodal irradiation? Krol AD, et al. **Int J Radiat Oncol Biol Phys** 1996 Jan 15; 34(2):297–302 (20 ref.)

Scheduling of chemotherapy and radiotherapy in locally advanced non-small cell lung cancer. Bishop JF. **Lung Cancer** 1995 Jun;12 Suppl 2:S53–61 (52 ref.)

Prophylactic cranial irradiation in small cell lung cancer--an update. Kristjansen PE, et al. **Lung Cancer** 1995 Jun;12 Suppl 3:S23–40 (82 ref.)

Radiotherapy in non-small cell lung cancer: optimal doses and schedules. Schaake-Koning C. **Lung Cancer** 1995 Apr; 12 Suppl 1:S119–23 (17 ref.)

Combined platinum etoposide with radiation therapy in limited stage small cell lung cancer: an effective treatment strategy. Turrisi AT 3rd. **Lung Cancer** 1995 Jun;12 Suppl 3:S41–51 (26 ref.)

A palliative accelerated irradiation regimen (PAIR) for advanced non-small-cell lung cancer (NSCLC). Nestle U, et al. **Radiother Oncol** 1996 Mar;38(3):195–203 (48 ref.)

Combined-modality therapy for advanced non-small cell lung cancer: paclitaxel and thoracic irradiation. Choy H, et al. **Semin Oncol** 1995 Dec;22(6 Suppl 15):38–44 (41 ref.)

Treatment of unresectable lung cancer with brachytherapy. Aygun C, et al. **World J Surg** 1995 Nov–Dec;19(6):823–7 (27 ref.)

[Localized small-cell lung cancers: prospects of concomitant radiochemotherapy] Reboul F, et al. **Bull Cancer (Paris)** 1995 Dec;82(12):996–1004 (53 ref.) (Eng. Abstr.) **(Fre)**

SECONDARY

Chemotherapy of metastatic bowel cancer. Ross PJ, et al. **Br J Hosp Med** 1996 Mar 6–19;55(5):263–6 (20 ref.)

Lu-ECAM-1 and DPP IV in lung metastasis. Eible RC, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 1):107–22 (77 ref.)

Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide. Kleinerman ES. **Hematol Oncol Clin North Am** 1995 Aug;9(4):927–38 (37 ref.)

Surgical treatment for pulmonary metastases from sarcoma. Putnam JB Jr, et al. **Hematol Oncol Clin North Am** 1995 Aug;9(4):869–87 (86 ref.)

Giant cell tumour of metacarpal with pulmonary and skeletal metastases. Sanjay BK, et al. **J Hand Surg [Br]** 1996 Feb; 21(1):126–32 (22 ref.)

CT of pulmonary metastases with pathological correlation. Hirakata K, et al. **Semin Ultrasound CT MR** 1995 Oct; 16(5):379–94 (63 ref.)

[Extracerebral metastases of a glioblastoma, in the absence of surgery] Chretien F, et al. **Arch Anat Cytol Pathol** 1995; 43(5–6):342–9 (16 ref.) (Eng. Abstr.) **(Fre)**

[Incidence and risk factors of second primary cancers in patients treated for primary pharyngeal cancer] Brochet F, et al. **Bull Cancer Radiother** 1996;83(1):8–11 (34 ref.) (Eng. Abstr.) **(Fre)**

[Case of benign metastaxsizing leiomyoma of the lungs] Nishida T, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Feb;44(2):182–7 (23 ref.) (Eng. Abstr.) **(Jpn)**

[Indications for surgical resection of pulmonary metastases] Haddad R, et al. **Rev Assoc Med Bras** 1995 Jan–Feb; 41(1):63–6 (21 ref.) **(Por)**

[The surgical opportunity in metastatic lesions of renal-cell carcinoma after a response to adjuvant immunotherapy] Olivier C, et al. **Actas Urol Esp** 1995 Mar;19(3):203–10 (27 ref.) (Eng. Abstr.) **(Spa)**

[Retroperitoneal liposarcoma with lung, skin and pancreatic metastases] Alcalá Pedrajas JN, et al. **Arch Bronconeumol** 1996 Jun–Jul;32(6):313–5 (21 ref.) (Eng. Abstr.) **(Spa)**

[Metastatic pulmonary fibrosarcoma: apropos a case and a review of the literature] Quintana González JI, et al. **Arch Bronconeumol** 1996 May;32(5):256–8 (17 ref.) (Eng. Abstr.) **(Spa)**

[Acute respiratory failure and multiple pulmonary nodules. Pulmonary metastases of colonic adenocarcinoma] Cordero PJ, et al. **Rev Clin Esp** 1995 Dec;195(12):845–6 (7 ref.) **(Spa)**

SECRETION

[Large-cell lung carcinoma producing chorionic gonadotropin hormone: the difficulty in its differential diagnosis from choriocarcinoma] Cremades Romero MJ, et al. **Arch Bronconeumol** 1996 May;32(5):253–5 (10 ref.) (Eng. Abstr.) **(Spa)**

SURGERY

Current principles in the surgical treatment of lung cancer. Trojan I, et al. **Acta Med Hung** 1994;50(3–4):175–83 (17 ref.)

The surgery of lung cancer. Morgan WE. **Ann Oncol** 1995; 6 Suppl 1:33–5; discussion 35–6 (20 ref.)

Resection of an unsuspected primary pulmonary choriocarcinoma. Canver CC, et al. **Ann Thorac Surg** 1996 Apr;61(4):1249–51 (8 ref.)

Long-term survival following surgical treatment of solitary brain metastasis in non-small cell lung cancer. Shahidi H, et al. **Chest** 1996 Jan;109(1):271–6 (53 ref.)

Future therapeutic procedures. Edell ES. **Chest Surg Clin N Am** 1996 May;6(2):381–95 (93 ref.)

Laser bronchoscopy. Ramser ER, et al. **Clin Chest Med** 1995 Sep;16(3):415–26 (66 ref.)

The messages from recently completed surgical trials on lung cancer. Goldstraw P, et al. **Eur J Surg Oncol** 1996 Feb; 22(1):1–4 (13 ref.)

Lung cancer surgery: questions for future trials. Rocmans PA. **Eur J Surg Oncol** 1996 Feb;22(1):9–12 (14 ref.)

Tumor embolism to LAD during pneumonectomy. A case report. Shah R, et al. **J Cardiovasc Surg (Torino)** 1996 Jun; 37(3):319–21 (13 ref.)

Pulmonary blastoma presenting as a solitary lip metastasis: case report and review of the literature. Lee BY, et al. **J Spinal Cord Med** 1995 Jul;18(3):203–7 (19 ref.)

The role of surgery in small cell carcinoma of the lung (SCLC). Holmes EC. **Lung Cancer** 1995 Jun;12 Suppl 3:S17–21 (9 ref.)

Resection of primary pulmonary hemangiopericytoma: a report of two cases. Kuroya M, et al. **Surg Today** 1996; 26(3):208–12 (22 ref.)

New prognostic factors in resectable non-small cell lung cancer. Smit EF, et al. **Thorax** 1996 Jun;51(6):638–46 (95 ref.)

[New techniques in thoracic surgery. I] Andreassian B. **Presse Med** 1995 Jun 24;24(23):1078–83 (53 ref.) (Eng. Abstr.) **(Fre)**

[A case of resected small-sized (4 mm in diameter) lung cancer and its way of surgical treatment] Morita H. **Kyobu Geka** 1996 Mar;49(3):175–8; discussion 179–81 (15 ref.) (Eng. Abstr.) **(Jpn)**

[A case report of pulmonary blastoma--well differentiated fetal adenocarcinoma] Okano T, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Jan;44(1):69–73 (13 ref.) (Eng. Abstr.) **(Jpn)**

[A case of resected lung cancer associated with bullous pemphigoid] Sato Y, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Apr;44(4):524–8 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Indications for surgical resection of pulmonary metastases] Haddad R, et al. **Rev Assoc Med Bras** 1995 Jan–Feb; 41(1):63–6 (21 ref.) **(Por)**

[Early peripheral cancer of the lung: long-term results of combined therapy using sparing resection techniques] Kharchenko VP, et al. **Vopr Onkol** 1996;42(2):77–81 (13 ref.) (Eng. Abstr.) **(Rus)**

THERAPY

Endobronchial treatment modalities in thoracic oncology [see comments] Baas P, et al. **Ann Oncol** 1995 Jul;6(6):523–31 (85 ref.) Comment in: Ann Oncol 1995 Nov;6(9):951–2.

The role of induction therapy and surgery for stage IIIA lung cancer. Ginsberg RJ. **Ann Oncol** 1995;6 Suppl 3:S29–32 (32 ref.)

Gene therapy for lung cancer. Lee CT, et al. **Ann Oncol** 1995;6 Suppl 3:S61–3 (16 ref.)

Induction or concomitant chemotherapy and radiotherapy for non-small-cell lung cancer: myth or reality. Van Houtte P. **Ann Oncol** 1995;6 Suppl 3:S37–40 (21 ref.)

Gene therapy for lung cancer. Woll PJ, et al. **Ann Oncol** 1995;6 Suppl 1:73–7 (35 ref.)

Multimodality therapy in stage III non-small cell lung cancer. Edelman MJ, et al. **Ann Thorac Surg** 1996 May; 61(5):1564–72 (60 ref.)

Isolated incisional recurrence after curative resection for primary lung cancer. Yokoi K, et al. **Ann Thorac Surg** 1996 Apr;61(4):1236–7 (9 ref.)

Lung cancer. Hansen HH, et al. **Cancer Chemother Biol Response Modif** 1996;16:474–86 (91 ref.)

Biological treatment of NSCLC. The need for conclusive studies. Jassem J. **Chest** 1996 May;109(5 Suppl):119S–124S (61 ref.)

Ongoing clinical trials in lung cancer. Giaccone G, et al. **Eur J Surg Oncol** 1996 Feb;22(1):4–9 (24 ref.)

Locally advanced non-small cell lung cancer: do we know the questions? A survey of randomized trials from 1966–1993. Brundage MD, et al. **J Clin Epidemiol** 1996 Feb;49(2):183–92 (39 ref.)

Extensive-disease small-cell lung cancer: the thrill of victory; the agony of defeat. Aisner J. **J Clin Oncol** 1996 Feb; 14(2):658–65 (70 ref.)

Perioperative therapy for locoregional nonsmall-cell lung cancer. Takita H. **J Surg Oncol** 1996 May;62(1):65–74 (51 ref.)

Combined modality treatment for stage III non-small cell lung cancer. Bonomi P. **Lung Cancer** 1995 Jun;12 Suppl 2:S41–52 (44 ref.)

Biological response modifiers. Calabresi F, et al. **Lung Cancer** 1995 Apr;12 Suppl 1:S193–8 (28 ref.)

New chemotherapy agents in the treatment of advanced non-small cell lung cancer: an update including data from the Seventh World Conference on Lung Cancer. Comis RL, et al. **Lung Cancer** 1995 Jun;12 Suppl 2:S63–99 (163 ref.)

Neoadjuvant (induction) treatment for non-small cell lung cancer. Ginsberg RJ. **Lung Cancer** 1995 Jun;12 Suppl 2:S33–40 (22 ref.)

Multimodality therapy in unresected stage III non-small cell lung cancer: the American Cooperative Groups' Experience. Green MR. **Lung Cancer** 1995 Apr;12 Suppl 1:S87–94 (20 ref.)

An historical perspective of multi-modality treatment for resectable non-small cell lung cancer. Jaklitsch MT, et al. **Lung Cancer** 1995 Jun;12 Suppl 2:S17–32 (56 ref.)

Future directions in the management of small cell lung cancer. Johnson DH. **Lung Cancer** 1995 Jun;12 Suppl 3:S71–5 (39 ref.)

Therapy of non-small cell lung cancer. Klastersky J. **Lung Cancer** 1995 Apr;12 Suppl 1:S133–45 (38 ref.)

Effectiveness and toxicity of preoperative therapy in stage IIIA non-small cell lung cancer including the Memorial Sloan-Kettering experience with induction MVP in patients with bulky mediastinal lymph node metastases (Clinical N2). Kris MG, et al. **Lung Cancer** 1995 Apr;12 Suppl 1:S47–57 (38 ref.)

Impact of chemotherapy on survival in locally advanced non-small cell lung cancer: the Gustave-Roussy experience. Le Cesne A, et al. **Lung Cancer** 1995 Apr;12 Suppl 1:S79–85 (25 ref.)

Future directions in non-small cell lung cancer. A personal view. Ruckdeschel JC. **Lung Cancer** 1995 Jun;12 Suppl 2:S147–52 (36 ref.)

Perioperative therapy of non-small cell lung cancer: a review of adjuvant and neoadjuvant approaches. Friedland DM, et al. **Semin Oncol** 1995 Dec;22(6):571–81 (41 ref.)

Management of lung cancer [editorial; comment] Muers MF, et al. **Thorax** 1996 Jun;51(6):557–60 (40 ref.) Comment on: Thorax 1996 Jun;51(6):564–8. Comment on: Thorax 1996 Jun;51(6):569–74.

['94 pneumology update. Progress and prospects in pneumology. Paradigm of change--I] Kroegel C, et al. **Med Klin** 1996 Apr 1;91 Suppl 1:89–101 (177 ref.) **(Ger)**

['95 pneumology update. Progress and prospects in pneumology. Paradigm of change--II] Kroegel C, et al. **Med Klin** 1996 Apr 1;91 Suppl 1:103–17 (178 ref.) **(Ger)**

[Mega-dose chemotherapy with peripheral blood stem cell transplantation (PBS-CT) for small cell lung cancer

(SCLC)] Chou T, et al. **Gan To Kagaku Ryoho** 1995 Oct; 22(12):1741–8 (14 ref.) (Eng. Abstr.) **(Jpn)**

ULTRASTRUCTURE

Epithelioid hemangioendothelioma of the lung: pleural effusion cytology, ultrastructure, and brief literature review. Buggage RR, et al. **Diagn Cytopathol** 1995 Jul; 13(1):54–60 (14 ref.)

VETERINARY

Retroviral aetiopathogenesis of ovine pulmonary carcinoma: a critical appraisal [see comments] Hecht SJ, et al. **Br Vet J** 1996 Jul;152(4):395–409 (56 ref.) Comment in: Br Vet J 1996 Jul;152(4):369–72.

Aggressive, undifferentiated sarcoma with widespread metastasis in a six-month-old Neopolitan mastiff. Sanders NA, et al. **J Am Anim Hosp Assoc** 1996 Mar–Apr; 32(2):97–101 (18 ref.)

LUNG PURPURA WITH NEPHRITIS see **GOODPASTURE'S SYNDROME**

LUNG TRANSPLANTATION

see related
HEART–LUNG TRANSPLANTATION

Lung preservation: the importance of endothelial and alveolar type II cell integrity. Novick RJ, et al. **Ann Thorac Surg** 1996 Jul;62(1):302–14 (141 ref.)

Delayed right heart failure following lung transplantation. Kirshbom PM, et al. **Chest** 1996 Feb;109(2):575–7 (9 ref.)

Lung transplantation for cystic fibrosis: special considerations. Kotloff RM, et al. **Chest** 1996 Mar; 109(3):787–98 (74 ref.)

Lung transplantation in chronic airflow limitation. Lynch JP, et al. **Med Clin North Am** 1996 May;80(3):657–70 (43 ref.)

The vascular biology of heart and lung preservation for transplantation. Pinsky DJ. **Thromb Haemost** 1995 Jul; 74(1):58–65 (50 ref.)

Prevention and treatment of cytomegalovirus disease in thoracic organ transplant patients: evidence for a beneficial effect of hyperimmune globulin. Valantine HA. **Transplant Proc** 1995 Oct;27(5 Suppl 1):49–57 (62 ref.)

[Pulmonary and cardiopulmonary transplantation in mucoviscidosis] Haloun A, et al. **Rev Pneumol Clin** 1995; 51(3):207–14 (47 ref.) (Eng. Abstr.) **(Fre)**

[Indications for lung transplantation and selection of recipients] Schwaiblmair M, et al. **Dtsch Med Wochenschr** 1996 Mar 22;121(12):377–81 (36 ref.) **(Ger)**

[Pulmonary emphysema—lung transplantation] Matthys H. **Versicherungsmedizin** 1995 Dec 1;47(6):201–3 (14 ref.) (Eng. Abstr.) **(Ger)**

[The first case of severe pneumopathy due to hard metals successfully undergoing a lung transplant] Tomasini M, et al. **Med Lav** 1995 Jul–Aug;86(4):325–31 (6 ref.) (Eng. Abstr.) **(Ita)**

[Lung transplantation in primary pulmonary hypertension (editorial)] Román A. **Arch Bronconeumol** 1996 May; 32(5):213–5 (22 ref.) **(Spa)**

ADVERSE EFFECTS

Vascular complications of lung transplantation. Clark SC, et al. **Ann Thorac Surg** 1996 Apr;61(4):1079–82 (7 ref.)

METHODS

Anesthesia for living-related (lobar) lung transplantation. Quinlan JJ, et al. **J Cardiothorac Vasc Anesth** 1996 Apr; 10(3):391–6 (35 ref.)

[New techniques in thoracic surgery. I] Andreassian B. **Presse Med** 1995 Jun 24;24(23):1078–83 (53 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Chimerism and thoracic organ transplantation. Gammie JS, et al. **Semin Thorac Cardiovasc Surg** 1996 Apr;8(2):149–55 (45 ref.)

[Respiratory insufficiency. Role of lung and heart/lung transplantation. Indications and results] Wagner TO. **Internist (Berl)** 1995 Aug;36(8):818–27 (37 ref.) **(Ger)**

REHABILITATION

Physical therapy in lung transplantation. Downs AM. **Phys Ther** 1996 Jun;76(6):626–42 (102 ref.)

LUNG VOLUME MEASUREMENTS

[Early diagnosis of amiodarone-induced pulmonary toxicity: are repeated lung function tests of any value?] Ulrik CS, et al. **Ugeskr Laeger** 1996 Jun 10;158(24):3445–7 (17 ref.) (Eng. Abstr.) **(Dan)**

[Valuable methods for lung function measurements. Spirometry at ambulatory centers is excellent for early diagnosis] Larsson M. **Lakartidningen** 1995 Nov 22; 92(47):4427–30, 4435–7 (27 ref.) **(Swe)**

LUPUS

Childhood systemic lupus erythematosus, vasculitis, and rheumatic fever and neonatal lupus. Pelkonen P. **Curr Opin Rheumatol** 1995 Sep;7(5):430–6 (62 ref.)

CHEMICALLY INDUCED

New concepts in the pathogenesis of drug-induced lupus. Yung RL, et al. **Lab Invest** 1995 Dec;73(6):746–59 (189 ref.)

LUPUS ANTICOAGULANT see **LUPUS COAGULATION INHIBITOR**

LUPUS COAGULATION INHIBITOR

see related
ANTIPHOSPHOLIPID SYNDROME

ANALYSIS

Diagnostic methodologies for circulating anticoagulants. Exner T. **Thromb Haemost** 1995 Jul;74(1):338–44 (59 ref.)

BLOOD

The lupus anticoagulant/antiphospholipid syndrome. Shapiro SS. **Annu Rev Med** 1996;47:533–53 (182 ref.)

[The diagnosis and therapy of acquired factor-VIII inhibitors in combination with lupus anticoagulants] Grossmann R, et al. **Dtsch Med Wochenschr** 1996 Jul 12;121(28–29):906–10 (14 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Transient hemorrhagic diathesis associated with an inhibitor of prothrombin with lupus anticoagulant in a 1 1/2-year-old girl: report of a case and review of the literature. Lee MT, et al. **Am J Hematol** 1996 Apr; 51(4):307–14 (46 ref.)

METABOLISM

Progressive thrombosis after treatment of diffuse large cell non-Hodgkin's lymphoma and concomitant lupus anticoagulant. Keung YK, et al. **Leuk Lymphoma** 1996 Jan; 20(3–4):341–5 (22 ref.)

LUPUS ERYTHEMATOSUS, CHRONIC CUTANEOUS see **LUPUS ERYTHEMATOSUS, DISCOID**

LUPUS ERYTHEMATOSUS, CUTANEOUS

ETIOLOGY

Cutaneous manifestations of selected rheumatologic diseases. Ostezan LB, et al. **Am Fam Physician** 1996 Apr; 53(5):1625–36 (14 ref.)

LUPUS ERYTHEMATOSUS, CUTANEOUS, CHRONIC see **LUPUS ERYTHEMATOSUS, DISCOID**

LUPUS ERYTHEMATOSUS, CUTANEOUS, SUBACUTE see **LUPUS ERYTHEMATOSUS, CUTANEOUS**

LUPUS ERYTHEMATOSUS, DISCOID

see related
PANNICULITIS, LUPUS ERYTHEMATOSUS

PATHOLOGY

Violaceous rash of dorsal fingers in a woman. Diagnosis: chilblain lupus erythematosus (perniosis). Fisher DA, et al. **Arch Dermatol** 1996 Apr;132(4):459, 462 (8 ref.)

LUPUS ERYTHEMATOSUS DISSEMINATUS see **LUPUS ERYTHEMATOSUS, SYSTEMIC**

LUPUS ERYTHEMATOSUS PROFUNDUS see **PANNICULITIS, LUPUS ERYTHEMATOSUS**

LUPUS ERYTHEMATOSUS, SUBACUTE CUTANEOUS see **LUPUS ERYTHEMATOSUS, CUTANEOUS**

LUPUS ERYTHEMATOSUS, SYSTEMIC

see related
ANTIPHOSPHOLIPID SYNDROME
LUPUS COAGULATION INHIBITOR

End-stage renal disease and systemic lupus erythematosus. Mojcik CF, et al. **Am J Med** 1996 Jul;101(1):100–7 (59 ref.)

Systemic lupus erythematosus. Hay EM. **Baillieres Clin Rheumatol** 1995 Aug;9(3):437–70 (60 ref.)

Childhood systemic lupus erythematosus, vasculitis, and rheumatic fever and neonatal lupus. Pelkonen P. **Curr Opin Rheumatol** 1995 Sep;7(5):430–6 (62 ref.)

Mechanisms of the pathogenic autoimmune response in lupus: prospects for specific immunotherapy. Datta SK, et al. **Immunol Res** 1995;14(2):132–47 (156 ref.)

A practical guide to systemic lupus erythematosus. Lehman TJ. **Pediatr Clin North Am** 1995 Oct;42(5):1223–38 (22 ref.)

[Prognosis in systemic lupus erythematosus] Abu-Shakra M, et al. **Harefuah** 1995 Nov 1;129(9):358–61 (29 ref.) **(Heb)**

[Prognostic factors in systemic lupus erythematosus: their relationship with the choice of treatment] Pérez García R, et al. **Rev Clin Esp** 1995 Aug;195(8):578–82 (31 ref.) **(Spa)**

BLOOD

The antiphospholipid syndrome and SLE: is there a clue in the link between complement and coagulation? Merrill JT, et al. **Lupus** 1996 Feb;5(1):6–10 (63 ref.)

CHEMICALLY INDUCED

Drug-induced lupus. The list of culprits grows. Rich MW. **Postgrad Med** 1996 Sep;100(3):299–302, 307–8 (6 ref.)

[A case of SLE-like syndrome and severe hemolytic anemia caused by methyldopa] Sakurai Y, et al. **Nippon Naika Gakkai Zasshi** 1995 Dec 10;84(12):2069–71 (9 ref.) **(Jpn)**

CLASSIFICATION

A critical appraisal of classification criteria for systemic lupus erythematosus. Meyer O. **Rev Rhum Engl Ed** 1995 Jun; 62(6):447–54 (33 ref.)

COMPLICATIONS

The coexistence of psoriasis with lupus erythematosus and other photosensitive disorders. Zalla MJ, et al. **Acta Derm Venereol Suppl (Stockh)** 1996;195:1–15 (103 ref.)

Pathology and pathogenesis of vascular injury in systemic lupus erythematosus. Interactions of inflammatory cells and activated endothelium. Belmont HM, et al. **Arthritis Rheum** 1996 Jan;39(1):9–22 (147 ref.)

Enterococcal arthritis with avascular necrosis in a lupus patient. Markov G, et al. **Br J Rheumatol** 1996 Jun; 35(6):595–7 (11 ref.)

Clinical features of systemic lupus erythematosus. Petri M. **Curr Opin Rheumatol** 1995 Sep;7(5):395–401 (83 ref.)

Lupus cystitis in the Japanese [editorial; comment] Koike T, et al. **Intern Med** 1996 Feb;35(2):87–8 (14 ref.) Comment on: Intern Med 1996 Feb;35(2):155–8.

Mitral valve repair in lupus valvulitis—report of a case and review of the literature. Kalangos A, et al. **J Heart Valve Dis** 1995 Mar;4(2):202–7 (29 ref.)

Successful treatment of pure red cell aplasia in systemic lupus erythematosus with erythropoietin. Orbach H, et al. **J Rheumatol** 1995 Nov;22(11):2166–9 (27 ref.)

Mononeuritis multiplex in systemic lupus erythematosus: response to pulse intravenous cyclophosphamide. Martinez-Taboada VM, et al. **Lupus** 1996 Feb;5(1):74–6 (21 ref.)

When does amyloidosis complicate systemic lupus erythematosus? Orellana C, et al. **Lupus** 1995 Oct; 4(5):415–7 (26 ref.)

The spectrum of liver disease in systemic lupus erythematosus. van Hoek B. **Neth J Med** 1996 Jun; 48(6):244–53 (134 ref.)

Evans' syndrome, myelofibrosis and systemic lupus erythematosus: role of procollagens in myelofibrosis. Ramakrishna R, et al. **Pathology** 1995 Jul;27(3):255–9 (23 ref.)

Pseudotumor cerebri in systemic lupus erythematosus. Green L, et al. **Semin Arthritis Rheum** 1995 Oct;25(2):103–8 (14 ref.)

Obstetric outcome in systemic lupus erythematosus. Lima F, et al. **Semin Arthritis Rheum** 1995 Dec;25(3):184–92 (43 ref.)

Systemic lupus erythematosus in a child with sickle cell disease. Eissa MM, et al. **South Med J** 1995 Nov; 88(11):1176–8 (14 ref.)

[Panniculitis-fasciitis syndrome disclosing systemic erythematous lupus] Carsuzaa F, et al. **Ann Dermatol Venereol** 1996;123(4):259–61 (23 ref.) (Eng. Abstr.) **(Fre)**

[Progressive lupus dementia. 2 cases with or without antiphospholipid antibodies] Robin C, et al. **Rev Neurol (Paris)** 1995 Dec;151(12):699–707 (48 ref.) (Eng. Abstr.) **(Fre)**

[Liver disease in systemic lupus erythematosus] Suzuki A, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Feb; 18(1):53–9 (21 ref.) (Eng. Abstr.) **(Jpn)**

[A case of SLE associated with antiphospholipid syndrome and mitral stenosis] Takahashi M, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Feb;18(1):90–7 (28 ref.) (Eng. Abstr.) **(Jpn)**

[The ocular manifestations in systemic lupus erythematosus] Gheorghiu M. **Oftalmologia** 1996 Apr–Jun;40(2):100–4 (22 ref.) (Eng. Abstr.) **(Rum)**

[The characteristics of kidney involvement in a female patient with systemic lupus erythematosus and the antiphospholipid syndrome] Kozlovskaia NL, et al. **Klin Med (Mosk)** 1995;73(3):93–6 (27 ref.) (Eng. Abstr.) **(Rus)**

DIAGNOSIS

The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Gladman D, et al. **Arthritis Rheum** 1996 Mar;39(3):363–9 (9 ref.)

Systemic lupus erythematosus diagnosed during interferon alfa therapy. Morris LF, et al. **South Med J** 1996 Aug;

89(8):810–4 (30 ref.)
[Assessment of disease activity in systemic lupus erythematosus] Kano S. **Ryumachi** 1996 Feb;36(1):69–81 (28 ref.) **(Jpn)**
[Systemic lupus erythematosus in the elderly] Sousa CA, et al. **Acta Med Port** 1995 Mar;8(3):165–7 (9 ref.) (Eng. Abstr.) **(Por)**

DRUG THERAPY

Update on pharmacotherapy of systemic lupus erythematosus. Redford TW, et al. **Am J Health Syst Pharm** 1995 Dec 1;52(23):2686–95 (119 ref.)
Acute lethal necrotising pancreatitis in childhood systemic lupus erythematosus—possible toxicity of immunosuppressive therapy. Kolk A, et al. **Clin Exp Rheumatol** 1995 May–Jun;13(3):399–403 (31 ref.)
The beneficial effect of the estrogen antagonist tamoxifen on experimental systemic lupus erythematosus [letter; comment] Thylan S. **J Rheumatol** 1995 Aug;22(8):1606–7 (11 ref.) Comment on: J Rheumatol 1994 Dec;21(12):2231–8.
Pharmacological intervention in antibody mediated disease. Coutts SM, et al. **Lupus** 1996 Apr;5(2):158–9 (13 ref.)
Peracute disseminated fatal Aspergillus fumigatus sepsis as a complication of corticoid-treated systemic lupus erythematosus. Nenoff P, et al. **Mycoses** 1995 Nov–Dec; 38(11–12):467–71 (21 ref.)

EPIDEMIOLOGY

The elusive search for geographic clusters of systemic lupus erythematosus. Critical review. Wallace DJ, et al. **Arthritis Rheum** 1995 Nov;38(11):1564–7 (15 ref.)

ETIOLOGY

DNA methylation: a potential pathway to abnormal autoreactive lupus B cells. Huck S, et al. **Clin Immunol Immunopathol** 1996 Jul;80(1):1–8 (85 ref.)
Lupus: key pathogenic mechanisms and contributing factors. Mohan C, et al. **Clin Immunol Immunopathol** 1995 Dec; 77(3):209–20 (198 ref.)
Etiology, environmental relationships, epidemiology, and genetics of systemic lupus erythematosus. Hess EV, et al. **Curr Opin Rheumatol** 1995 Sep;7(5):371–5 (39 ref.)
The Yaa gene model of systemic lupus erythematosus. Izui S, et al. **Immunol Rev** 1995 Apr;144:137–56 (62 ref.)
CpG DNA: a pathogenic factor in systemic lupus erythematosus? Krieg AM. **J Clin Immunol** 1995 Nov; 15(6):284–92 (77 ref.)
Central role for nucleosomes in lupus [editorial] van Bruggen MC, et al. **Nephrol Dial Transplant** 1996 Jul;11(7):1219–22 (22 ref.)
Nervous system lupus: pathogenesis and rationale for therapy. Denburg JA, et al. **Scand J Rheumatol** 1995;24(5):263–73 (155 ref.)
[A case of selective IgM deficiency associated with systemic lupus erythematosus] Tanaka A, et al. **Nippon Jinzo Gakkai Shi** 1996 Apr;38(4):185–90 (21 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Etiology, environmental relationships, epidemiology, and genetics of systemic lupus erythematosus. Hess EV, et al. **Curr Opin Rheumatol** 1995 Sep;7(5):371–5 (39 ref.)
Genetic contributions to lupus-like disease in (NZB x NZW)F1 mice. Drake CG, et al. **Immunol Rev** 1995 Apr; 144:51–74 (59 ref.)
The Yaa gene model of systemic lupus erythematosus. Izui S, et al. **Immunol Rev** 1995 Apr;144:137–56 (62 ref.)
CpG DNA: a pathogenic factor in systemic lupus erythematosus? Krieg AM. **J Clin Immunol** 1995 Nov; 15(6):284–92 (77 ref.)
The mosaic of SLE-II: highlights of the fourth international conference on systemic lupus erythematosus—March 1995. Abu-Shakra M, et al. **Lupus** 1995 Dec;4(6):438–49 (2 ref.)
DNA repair deficiency in systemic lupus erythematosus; cause or consequence of disease and implications for management. Herrick AL, et al. **Lupus** 1995 Dec;4(6):423–4 (11 ref.)
Genetics of systemic lupus erythematosus. Schur PH. **Lupus** 1995 Dec;4(6):425–37 (243 ref.)
Genetics of tumour necrosis factor in systemic lupus erythematosus [editorial] Wilson AG, et al. **Lupus** 1996 Apr;5(2):87–8 (29 ref.)
[Progress in the study on immunogenetics of systemic lupus erythematosus] Lu Y, et al. **Chung Hua Nei Ko Tsa Chih** 1995 Jul;34(7):491–4 (17 ref.) **(Chi)**

IMMUNOLOGY

B-1 cellular origin and VH segment structure of IgG, IgA, and IgM anti-DNA autoantibodies in patients with systemic lupus erythematosus. Kasaian MT, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:410–23 (52 ref.)
The T cell enigma in lupus. Dayal AK, et al. **Arthritis Rheum** 1996 Jan;39(1):23–33 (92 ref.)
Systemic lupus erythematosus. Kotzin BL. **Cell** 1996 May 3;85(3):303–6 (29 ref.)
Autoimmune connective tissue disease, chronic polyarthritides and B cell expansion: risks and perspectives with immunosuppressive drugs. Ferraccioli GF, et al. **Clin Exp Rheumatol** 1996 Jan–Feb;14 Suppl 14:S71–80 (100 ref.)
DNA methylation: a potential pathway to abnormal autoreactive lupus B cells. Huck S, et al. **Clin Immunol Immunopathol** 1996 Jul;80(1):1–8 (85 ref.)
Lupus: key pathogenic mechanisms and contributing factors. Mohan C, et al. **Clin Immunol Immunopathol** 1995 Dec; 77(3):209–20 (198 ref.)
Autoantibodies in systemic lupus erythematosus. Elkon K. **Curr Opin Rheumatol** 1995 Sep;7(5):384–8 (40 ref.)
Lymphocytes, cytokines, inflammation, and immune trafficking. Tsokos GC. **Curr Opin Rheumatol** 1995 Sep; 7(5):376–83 (84 ref.)
Inquiry into murine and human lupus. Klinman DM, et al. **Immunol Rev** 1995 Apr;144:157–93 (181 ref.)
Lupus autoimmunity: from peptides to particles. Mamula MJ. **Immunol Rev** 1995 Apr;144:301–14 (58 ref.)
Properties of a system of public idiotypes of lupus autoantibodies. Schwartz RS. **Int Rev Immunol** 1989; 5(2):153–5 (13 ref.)
Pathogenic aspects of systemic lupus erythematosus. Kalden JR. **Isr J Med Sci** 1996 Jan;32(1):3–6 (28 ref.)
Autoepitopes in lupus. Harley JB, et al. **J Lab Clin Med** 1995 Dec;126(6):509–16 (75 ref.)
Lupus in the Fas lane? Singh AK. **J R Coll Physicians Lond** 1995 Nov–Dec;29(6):475–8 (40 ref.)
Infections, idiotypes and SLE [editorial; comment] George J, et al. **Lupus** 1995 Oct;4(5):333–5 (40 ref.) Comment on: Lupus 1995 Oct;4(5):339–47.
Anticardiolipin antibodies and beta 2-glycoprotein I. Koike T, et al. **Lupus** 1996 Apr;5(2):156–7 (13 ref.)
Photoimmunology of lupus erythematosus and dermatomyositis: a speculative review. Sontheimer RD. **Photochem Photobiol** 1996 May;63(5):583–94 (155 ref.)
Apoptosis: relevance to rheumatology. Tebib JG. **Rev Rhum Engl Ed** 1995 Nov;62(10):618–26 (52 ref.)
Immunopathogenesis and spectrum of infections in systemic lupus erythematosus. Iliopoulos AG, et al. **Semin Arthritis Rheum** 1996 Apr;25(5):318–36 (186 ref.)
Systemic lupus erythematosus: immunopathogenesis of neurologic dysfunction. Moore PM, et al. **Springer Semin Immunopathol** 1995;17(1):43–60 (123 ref.)

METABOLISM

Michael Mason Prize Essay 1995. Complement, immune complexes and systemic lupus erythematosus. Davies KA. **Br J Rheumatol** 1996 Jan;35(1):5–23 (69 ref.)

MICROBIOLOGY

Infections, idiotypes and SLE [editorial; comment] George J, et al. **Lupus** 1995 Oct;4(5):333–5 (40 ref.) Comment on: Lupus 1995 Oct;4(5):339–47.
Immunopathogenesis and spectrum of infections in systemic lupus erythematosus. Iliopoulos AG, et al. **Semin Arthritis Rheum** 1996 Apr;25(5):318–36 (186 ref.)

PATHOLOGY

Systemic lupus erythematosus in two adults with human immunodeficiency virus infection. Contreras G, et al. **Am J Kidney Dis** 1996 Aug;28(2):292–5 (6 ref.)
Placental changes in a first trimester missed abortion in maternal systemic lupus erythematosus with antiphospholipid syndrome; a case report and review of the literature. Nayar R, et al. **Hum Pathol** 1996 Feb; 27(2):201–6 (36 ref.)
Apoptosis, nucleosomes, and nephritis in systemic lupus erythematosus [editorial] Tax WJ, et al. **Kidney Int** 1995 Sep;48(3):666–73 (88 ref.)
[Amidazophen. Yes or no?] Jákó J, et al. **Orv Hetil** 1995 Sep 24;136(39):2121–4 (50 ref.) (Eng. Abstr.) **(Hun)**

PHYSIOPATHOLOGY

Lymphocytes, cytokines, inflammation, and immune trafficking. Tsokos GC. **Curr Opin Rheumatol** 1995 Sep; 7(5):376–83 (84 ref.)
Neurological and obstetric manifestations of the antiphospholipid syndrome. Gatenby PA. **Lupus** 1996 Apr; 5(2):170–2 (13 ref.)
SLE and osteoporosis: dependence and/or independence on glucocorticoids. Sels F, et al. **Lupus** 1996 Apr;5(2):89–92 (23 ref.)
Systemic lupus erythematosus: immunopathogenesis of neurologic dysfunction. Moore PM, et al. **Springer Semin Immunopathol** 1995;17(1):43–60 (123 ref.)

PSYCHOLOGY

Research methods for investigating causal relations between SLE disease variables and psychiatric symptomatology. Iverson GL, et al. **Lupus** 1995 Aug;4(4):249–54 (29 ref.)

SURGERY

Hepatocellular carcinoma associated with lupoid hepatitis: a review of Japanese reports. Sakaguchi T, et al. **Surg Today** 1995;25(9):838–42 (18 ref.)

THERAPY

Prognosis and treatment of systemic lupus erythematosus. Gladman DD. **Curr Opin Rheumatol** 1995 Sep;7(5):402–8 (55 ref.)
Nervous system lupus: pathogenesis and rationale for therapy. Denburg JA, et al. **Scand J Rheumatol** 1995;24(5):263–73 (155 ref.)

LUPUS GLOMERULONEPHRITIS see **LUPUS NEPHRITIS**

LUPUS NEPHRITIS

End-stage renal disease and systemic lupus erythematosus. Mojcik CF, et al. **Am J Med** 1996 Jul;101(1):100–7 (59 ref.)
[Progresses in nephrology in China, 1995] Lin S. **Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):719–20 (0 ref.) **(Chi)**

COMPLICATIONS

Hepatitis C virus infection complicating lupus nephritis. Albero MD, et al. **Nephrol Dial Transplant** 1996 Jul; 11(7):1342–5 (31 ref.)

DIAGNOSIS

[Isolated microhematuria as the manifestation of lupus nephritis] Shvetsov MIu, et al. **Ter Arkh** 1996;68(1):57–8 (8 ref.) (Eng. Abstr.) **(Rus)**

DRUG THERAPY

Use of cyclosporin in lupus nephritis. Radhakrishnan J, et al. **Contrib Nephrol** 1995;114:59–72 (53 ref.)

ETIOLOGY

Lupus: key pathogenic mechanisms and contributing factors. Mohan C, et al. **Clin Immunol Immunopathol** 1995 Dec; 77(3):209–20 (198 ref.)
Apoptosis, nucleosomes, and nephritis in systemic lupus erythematosus [editorial] Tax WJ, et al. **Kidney Int** 1995 Sep;48(3):666–73 (88 ref.)
Immunopathogenesis of lupus nephritis: new insights from experimental models. Izui S. **Nippon Jinzo Gakkai Shi** 1995 Nov;37(11):610–5 (57 ref.)
[The characteristics of kidney involvement in a female patient with systemic lupus erythematosus and the antiphospholipid syndrome] Kozlovskaia NL, et al. **Klin Med (Mosk)** 1995;73(3):93–6 (27 ref.) (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

Nephritogenic autoantibodies in lupus: current concepts and continuing controversies. Lefkowith JB, et al. **Arthritis Rheum** 1996 Jun;39(6):894–903 (100 ref.)
Lupus: key pathogenic mechanisms and contributing factors. Mohan C, et al. **Clin Immunol Immunopathol** 1995 Dec; 77(3):209–20 (198 ref.)

PATHOLOGY

Predominant tubulointerstitial lupus nephritis. Singh AK, et al. **Am J Kidney Dis** 1996 Feb;27(2):273–8 (21 ref.)

PHYSIOPATHOLOGY

Emerging concepts regarding B cells and autoantibodies in murine lupus nephritis. B cells have multiple roles; all autoantibodies are not equal [editorial] Madaio MP, et al. **J Am Soc Nephrol** 1996 Mar;7(3):387–96 (104 ref.)

THERAPY

Clinicopathological study of dialysis patients with lupus nephritis. Kobayashi M, et al. **Nippon Jinzo Gakkai Shi** 1995 Aug;37(8):456–61 (22 ref.)
[The treatment of LED-nephritis] Mustonen J. **Duodecim** 1994;110(11):1090–5 (6 ref.) **(Fin)**

LUPUS PANNICULITIS see **PANNICULITIS, LUPUS ERYTHEMATOSUS**

LUPUS VULGARIS see **LUPUS**

LURCHER MICE see **MICE, NEUROLOGIC MUTANTS**

LUTEAL MAINTENANCE see **CORPUS LUTEUM MAINTENANCE**

LUTEINIZING HORMONE see **LH**

LUTEINIZING HORMONE, ALPHA SUBUNIT see **GLYCOPROTEIN HORMONES, ALPHA SUBUNIT**

LUTEINIZING HORMONE RECEPTORS see **RECEPTORS, LH**

LUTEINIZING HORMONE-RELEASING HORMONE see **GONADORELIN**

LUTEOTROPIN see **PROLACTIN**

LUTHERAN BLOOD-GROUP SYSTEM

Lutheran antigens, CD44-related antigens, and Lutheran regulatory genes. Telen MJ. **Transfus Clin Biol** 1995;

2(4):291-301 (70 ref.)

LUTROPIN see **LH**

LUTROPIN RECEPTORS see **RECEPTORS, LH**

LY ANTIGENS see **ANTIGENS, LY**

LYASES

CHEMISTRY

Escherichia coli chorismate synthase. Bornemann S, et al. **Biochem Soc Trans** 1996 Feb;24(1):84–8 (36 ref.)

METABOLISM

Escherichia coli chorismate synthase. Bornemann S, et al. **Biochem Soc Trans** 1996 Feb;24(1):84–8 (36 ref.)

Enzymatic degradation of glycosaminoglycans. Ernst S, et al. **Crit Rev Biochem Mol Biol** 1995;30(5):387–444 (267 ref.)

LYCINE see **BETAINE**

LYCOPERSICON ESCULENTUM see **TOMATOES**

LYCOREMINE see **GALANTHAMINE**

LYELL'S SYNDROME see **EPIDERMAL NECROLYSIS, TOXIC**

LYING

Patients misrepresenting their risk factors for AIDS [editorial] Brody S. **Int J STD AIDS** 1995 Nov–Dec; 6(6):392–8 (75 ref.)

Deception/trust. Sobel R. **Isr J Med Sci** 1996 Mar–Apr; 32(3–4):256–9 (15 ref.)

Deception in medical and behavioral research: is it ever acceptable? Wendler D. **Milbank Q** 1996;74(1):87–114 (18 ref.)

LYME BORRELIOSIS see **LYME DISEASE**

LYME DISEASE

Lyme disease. Dennis DT. **Dermatol Clin** 1995 Jul; 13(3):537–51 (151 ref.)

[Lyme disease--human borreliosis redefined] Ionescu M, et al. **Bacteriol Virusol Parazitol Epidemiol** 1995 Jul–Dec; 40(3–4):261–70 (64 ref.) **(Rum)**

COMPLICATIONS

Lyme borreliosis neuropathy. A case report. Deltombe T, et al. **Am J Phys Med Rehabil** 1996 Jul–Aug;75(4):314–6 (21 ref.)

Cardiac manifestations of Lyme disease: a review. Nagi KS, et al. **Can J Cardiol** 1996 May;12(5):503–6 (38 ref.)

Lyme disease. Evans J. **Curr Opin Rheumatol** 1995 Jul; 7(4):322–8 (63 ref.)

[Neurologic manifestations of Lyme disease. Apropos of 25 cases] Ragnaud JM, et al. **Rev Med Interne** 1995; 16(7):487–94 (54 ref.) (Eng. Abstr.) **(Fre)**

[The involvement of the locomotor system in Lyme borreliosis] Lesniak OM. **Klin Med (Mosk)** 1995;73(3):28–30 (44 ref.) **(Rus)**

DIAGNOSIS

The Lyme disease controversy. Social and financial costs of misdiagnosis and mismanagement. Sigal LH. **Arch Intern Med** 1996 Jul 22;156(14):1493–500 (30 ref.)

Polymerase chain reaction of Borrelia burgdorferi flagellin gene in Shulman syndrome. Hashimoto Y, et al. **Dermatology** 1996;192(2):136–9 (26 ref.)

Lyme disease overdiagnosis: causes and cure [editorial] Sigal LH. **Hosp Pract (Off Ed)** 1996 May 15;31(5):13–5, 20, 26 passim (12 ref.)

Practice parameters for the diagnosis of patients with nervous system Lyme borreliosis (Lyme disease).Quality Standards Subcommittee of the American Academy of Neurology. Halperin JJ, et al. **Neurology** 1996 Mar;46(3):619–27 (66 ref.)

[Lyme borreliosis in childhood] Christen HJ, et al. **HNO** 1995 Aug;43(8):507–19 (6 ref.) **(Ger)**

[A case of Lyme disease detected in Romania] Pop O, et al. **Bacteriol Virusol Parazitol Epidemiol** 1995 Jul–Dec; 40(3–4):245–7 (14 ref.) **(Rum)**

DRUG THERAPY

[Critical approach to antibiotic therapy in Lyme disease] Bojić I. **Vojnosanit Pregl** 1994 May–Jun;51(3):233–6 (30 ref.) **(Scr)**

ECONOMICS

The Lyme disease controversy. Social and financial costs of misdiagnosis and mismanagement. Sigal LH. **Arch Intern Med** 1996 Jul 22;156(14):1493–500 (30 ref.)

EPIDEMIOLOGY

Does Lyme disease occur in the south?: a survey of emerging tick-borne infections in the region. Barbour AG. **Am J Med Sci** 1996 Jan;311(1):34–40 (66 ref.)

Lyme disease. Evans J. **Curr Opin Rheumatol** 1995 Jul; 7(4):322–8 (63 ref.)

[The role of ticks in the epidemiology of Lyme borreliosis] Wegner Z, et al. **Przegl Epidemiol** 1995;49(3):245–50 (33 ref.) (Eng. Abstr.) **(Pol)**

IMMUNOLOGY

A role for T cells in the pathogenesis of treatment-resistant Lyme arthritis. Kamradt T, et al. **Mol Med** 1995 Jul; 1(5):486–90 (35 ref.)

Lyme vaccine enhancement. N-terminal acylation of a protein antigen and inclusion of a saponin adjuvant. Coughlin RT, et al. **Pharm Biotechnol** 1995;6:719–35 (126 ref.)

MICROBIOLOGY

[Lyme borreliosis: epidemiologic and etiopathogenic aspects] Oteo-Revuelta JA, et al. **Enferm Infece Microbiol Clin** 1995 Nov;13(9):550–5 (53 ref.) **(Spa)**

PREVENTION & CONTROL

Prospects for a vaccine to prevent Lyme disease in humans. Wormser GP. **Clin Infect Dis** 1995 Nov;21(5):1267–74 (113 ref.)

Lyme vaccine enhancement. N-terminal acylation of a protein antigen and inclusion of a saponin adjuvant. Coughlin RT, et al. **Pharm Biotechnol** 1995;6:719–35 (126 ref.)

[Prevention of Lyme disease] Drndarević D, et al. **Vojnosanit Pregl** 1994 Sep–Oct;51(5):412–6 (24 ref.) **(Scr)**

RADIOGRAPHY

Lyme arthropathy. Eustace SJ, et al. **Radiol Clin North Am** 1996 Mar;34(2):454–5 (22 ref.)

THERAPY

A role for T cells in the pathogenesis of treatment-resistant Lyme arthritis. Kamradt T, et al. **Mol Med** 1995 Jul; 1(5):486–90 (35 ref.)

TRANSMISSION

Ticks and Lyme disease. Bennett CE. **Adv Parasitol** 1995; 36:343–405 (396 ref.)

General framework for comparative quantitative studies on transmission of tick-borne diseases using Lyme borreliosis in Europe as an example. Randolph SE, et al. **J Med Entomol** 1995 Nov;32(6):765–77 (70 ref.)

LYMPH

CYTOLOGY

Studies on Langerhans cell phenotype in human afferent skin lymph from allergic contact dermatitis. Brand CU, et al. **Adv Exp Med Biol** 1995;378:523–5 (14 ref.)

IMMUNOLOGY

Studies on Langerhans cell phenotype in human afferent skin lymph from allergic contact dermatitis. Brand CU, et al. **Adv Exp Med Biol** 1995;378:523–5 (14 ref.)

Rosettes of Langerhans cells and activated T cells in human skin lymph derived from irritant contact dermatitis. Brand CU, et al. **Adv Exp Med Biol** 1995;378:527–9 (17 ref.)

METABOLISM

Lymph transport in the skin. Ikomi F, et al. **Clin Dermatol** 1995 Sep–Oct;13(5):419–27 (40 ref.)

PHYSIOLOGY

Assessment of abnormal lymph drainage for the diagnosis of lymphedema by isotopic lymphangiography and by indirect lymphography. Partsch H. **Clin Dermatol** 1995 Sep–Oct;13(5):445–50 (45 ref.)

Physiology and immunology of lymphatic drainage of interstitial and cerebrospinal fluid from the brain. Knopf PM, et al. **Neuropathol Appl Neurobiol** 1995 Jun; 21(3):175–80 (16 ref.)

[Lymph--biochemical composition, importance of its circulation in the physiology and pathology of the organism] Beck B, et al. **Postepy Hig Med Dosw** 1995; 49(3):353–66 (97 ref.) (Eng. Abstr.) **(Pol)**

[The cellular mechanisms in the regulation of lymph transport] Lobov GI, et al. **Fiziol Zh Im I M Sechenova** 1995 Jun;81(6):19–28 (25 ref.) **(Rus)**

[Dynamic bone marrow take and lymphohematopoietic chimerism following allogeneic bone marrow transplantation] Demidova IA, et al. **Ter Arkh** 1995; 67(8):74–80 (90 ref.) **(Rus)**

LYMPH NODE DISSECTION see **LYMPH NODE EXCISION**

LYMPH NODE EXCISION

Lymphadenectomy in gastrointestinal cancer surgery. Horváth OP. **Acta Med Hung** 1994;50(3–4):221–8 (21 ref.)

Extended lymph node dissection (D2 resection) should now be performed routinely in the curative surgical treatment of gastric carcinoma. Ravichandran D, et al. **Ann R Coll Surg Engl** 1995 Nov;77(6):431–6 (50 ref.)

Prognostic significance and surgical management of lymph node metastasis in gastric cancer. Noguchi M, et al. **Br J Surg** 1996 Feb;83(2):156–61 (62 ref.)

Laparoscopic lymphadenectomy. Melendez TD, et al. **Curr Opin Obstet Gynecol** 1995 Aug;7(4):307–10 (20 ref.)

Routine or delayed axillary dissection for primary breast cancer? Epstein RJ. **Eur J Cancer** 1995 Sep;31A(10):1570–3 (29 ref.)

Transhiatal oesophagectomy compared with transthoracic resection and systematic lymphadenectomy for the treatment of oesophageal cancer. Horstmann O, et al. **Eur J Surg** 1995 Aug;161(8):557–67 (62 ref.)

The role of clinical trials in assessing optimal treatment of cutaneous melanoma not extending beyond the regional nodes. Cascinelli N. **Eur J Surg Oncol** 1996 Apr;22(2):123–7 (49 ref.)

Changes in significance of axillary lymph node dissection for patients with breast cancer. Ogawa Y, et al. **Gan To Kagaku Ryoho** 1996 Mar;23 Suppl 1:43–9 (24 ref.)

125I seeds implantation plus pelvic lymphadenectomy in the management of localized prostate cancer. D'Addessi A, et al. **Minerva Urol Nefrol** 1995 Sep;47(3):105–11 (33 ref.)

Role of extended lymph node dissection in the treatment of gastrointestinal tumours: a review of the literature. Taat CW, et al. **Scand J Gastroenterol Suppl** 1995;212:109–16 (63 ref.)

Laparoscopic staging pelvic lymphadenectomy: extraperitoneal approach. Das S. **Semin Surg Oncol** 1996 Mar–Apr;12(2):134–8 (27 ref.)

Laparoscopic pelvic lymphadenectomy: transperitoneal approach. Gill IS. **Semin Surg Oncol** 1996 Mar–Apr; 12(2):126–33 (39 ref.)

[Lymphatic mapping and biopsy of sentinel nodes--a new approach in lymphadenectomy. Review] Fait V, et al. **Rozhl Chir** 1995 Dec;74(8):425–8 (25 ref.) (Eng. Abstr.) **(Cze)**

[Lymph node excision in cancer of the esophagus] Collard JM. **Ann Chir** 1996;50(2):121–9 (79 ref.) (Eng. Abstr.) **(Fre)**

[Prognostic value of extensive lymph node excision in curative resections of stomach cancers. Apropos of a series of 100 patients] Berthet B, et al. **Chirurgie** 1996; 121(2):108–12 (21 ref.) (Eng. Abstr.) **(Fre)**

[Lymphadenectomies in the surgery of stomach cancer] Cirenei A. **Chirurgie** 1994–95;120(12):66–9 (31 ref.) (Eng. Abstr.) **(Fre)**

[Stage I and II endometrial cancer: should lymphadenectomy still be done?] Descamps P, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(8):794–801 (48 ref.) (Eng. Abstr.) **(Fre)**

-Breast neoplasms: axillary lymph node excision--at what price- Rageth JC. **Arch Gynecol Obstet** 1995;256 Suppl:S85–92 (45 ref.) **(Ger)**

-Therapy of vulvar carcinoma in the early stages- Gitsch G. **Geburtshilfe Frauenheilkd** 1996 Feb;56(2):63–9 (66 ref.) (Eng. Abstr.) **(Ger)**

[Primary therapy of advanced ovarian carcinoma: current status and perspectives] Köchli OR, et al. **Gynakol Geburtshilfliche Rundsch** 1996;36(1):3–8 (25 ref.) (Eng. Abstr.) **(Ger)**

[Axillary lymph node dissection in breast cancer--is it always necessary?] Merin O, et al. **Harefuah** 1996 Feb 15; 130(4):260–2 (17 ref.) **(Heb)**

[A case report of pulmonary blastoma--well differentiated fetal adenocarcinoma] Okano T, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Jan;44(1):69–73 (13 ref.) (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

[Postoperative lymphoceles and lymphatic fistula in gynecologic and breast neoplasms] Brun JL. **Bull Cancer (Paris)** 1995 Sep;82(9):711–6 (37 ref.) (Eng. Abstr.) **(Fre)**

[Complications of inguinal lymphadenectomy for penile carcinoma. Origin, management, and prevention] Martín Martínez JC, et al. **Actas Urol Esp** 1995 Nov–Dec; 19(10):759–71 (68 ref.) (Eng. Abstr.) **(Spa)**

METHODS

The case for minimal margins and delayed regional node dissection for high-risk cutaneous melanoma. Cascinelli N, et al. **Curr Opin Gen Surg** 1993;:310–5 (31 ref.)

The case for wide local excision and regional node dissection for high-risk cutaneous melanoma. Karakousis CP. **Curr Opin Gen Surg** 1993;:303–9 (40 ref.)

Lymph node dissection in gynaecologic malignancy: the role of laparoscopy. Montz FJ. **Endosc Surg Allied Technol** 1995 Apr–Jun;3(2–3):96–100 (33 ref.)

-Axillary lymph node excision: for what reasons and indications- Schäfer P. **Arch Gynecol Obstet** 1995;256 Suppl:S81–4 (14 ref.) **(Fre)**

[Clinico-pathological studies and problems on para-aortic lymph node dissection--D4 dissection] Kitamura M, et al. **Nippon Geka Gakkai Zasshi** 1996 Apr;97(4):302–7 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Vagus-saving D2 procedure for early gastric carcinoma]

Miwa K, et al. **Nippon Geka Gakkai Zasshi** 1996 Apr; 97(4):286–90 (11 ref.) (Eng. Abstr.) **(Jpn)**

LYMPH NODE HYPERPLASIA, GIANT see **GIANT LYMPH NODE HYPERPLASIA**

LYMPH NODE SYNDROME, MUCOCUTANEOUS see **MUCOCUTANEOUS LYMPH NODE SYNDROME**

LYMPH NODES

see related
LYMPHOGRAPHY
RADICAL NECK DISSECTION

Broncholithiasis: case report and literature review. Ryberg AA, et al. **Nebr Med J** 1996 Jan;81(1):14–7 (17 ref.)

DRUG EFFECTS

Predictive immunotoxicological test systems: suitability of the popliteal lymph node assay in mice and rats. Bloksma N, et al. **Crit Rev Toxicol** 1995;25(5):369–96 (115 ref.)

IMMUNOLOGY

Mechanism of immune complex trapping by follicular dendritic cells. Van den Berg TK, et al.
Curr Top Microbiol Immunol 1995;201:49–67 (110 ref.)

Physiologic basis of steroid-induced immunosuppression. Effects on lymphocyte migration to lymph nodes. Sackstein R. **J Fla Med Assoc** 1995 Sep;82(9):613–5 (22 ref.)

PATHOLOGY

Extragonadal germ cell tumor: a clinical study. Bassetto MA, et al. **Anticancer Res** 1995 Nov–Dec;15(6B):2751–4 (17 ref.)

Coexistence of Hodgkin's disease and giant lymph node hyperplasia of the plasma-cell type (Castleman's disease). Abdel-Reheim FA, et al. **Arch Pathol Lab Med** 1996 Jan; 120(1):91–6 (27 ref.)

Leukemic phase of mantle cell lymphoma two case reports and review of the literature [see comments] Vadlamudi G, et al. **Arch Pathol Lab Med** 1996 Jan;120(1):35–40 (31 ref.)
Comment in: Arch Pathol Lab Med 1996 Jan;120(1):12–4.

Axillary lymph nodes and breast cancer: a review. Recht A, et al. **Cancer** 1995 Nov 1;76(9):1491–512 (229 ref.)

Transbronchial needle aspiration and percutaneous needle aspiration for staging and diagnosis of lung cancer. Wang KP. **Clin Chest Med** 1995 Sep;16(3):535–52 (26 ref.)

Prognostic factors in squamous cell cancer of the vulva and the implications for treatment. van der Velden J, et al. **Curr Opin Obstet Gynecol** 1996 Feb;8(1):3–7 (36 ref.)

Axillary involvement in pediatric Kikuchi's disease. Heldenberg D, et al. **Eur J Pediatr Surg** 1996 Feb;6(1):32–4 (12 ref.)

The prognostic significance of axillary node metastasis in breast cancer. Miura S. **Gan To Kagaku Ryoho** 1996 Mar; 23 Suppl 1:36–42 (4 ref.)

Detection of breast cancer micrometastases in lymph nodes by amplification of keratin 19 mRNA with reverse-transcriptase polymerase chain reaction. Noguchi S, et al. **Gan To Kagaku Ryoho** 1996 Mar;23 Suppl 1:50–5 (9 ref.)

Value of cancer-related oncoprotein expression as prognostic factors in breast-cancer with one to three axillary lymph nodes positive. Zhang G, et al. **Gan To Kagaku Ryoho** 1996 Mar;23 Suppl 1:66–74 (22 ref.)

Cavitation of mesenteric lymph nodes: a rare complication of coeliac disease, associated with a poor outcome. Howat AJ, et al. **Histopathology** 1995 Oct;27(4):349–54 (8 ref.)

Work-up of lymphadenopathy in children. Perkins SL, et al. **Semin Diagn Pathol** 1995 Nov;12(4):284–7 (18 ref.)

Intranodal myofibroblastoma: report of a case. Eyden BP, et al. **Ultrastruct Pathol** 1996 Jan–Feb;20(1):79–88 (35 ref.)

[Lymphatic mapping and biopsy of sentinel nodes—a new approach in lymphadenectomy. Review] Fait V, et al. **Rozhl Chir** 1995 Dec;74(8):425–8 (25 ref.) (Eng. Abstr.) **(Cze)**

[Nodal histiocytic hyperplasia and proliferation] Diebold J, et al. **Ann Pathol** 1995;15(4):238–51 (82 ref.) **(Fre)**

[Primary plasmacytoma of the lymph node (plasmocytic lymphoma). The differential diagnosis of nodal plasma-cell proliferates] Horny HP, et al. **Dtsch Med Wochenschr** 1995 Dec 15;120(50):1734–8 (15 ref.) (Eng. Abstr.) **(Ger)**

[Lymph node diagnosis with imaging methods. An overview with special reference to recent developments in the area of MR contrast media] Mohr U, et al. **Z Lymphol** 1996 Jun;20(1):15–20 (59 ref.) (Eng. Abstr.) **(Ger)**

[Lymph node problem in cutaneous head and neck carcinomas] Spriano G, et al. **Acta Otorhinolaryngol Ital** 1995 Jun;15(3):159–62; discussion 163 (32 ref.) (Eng. Abstr.) **(Ita)**

PHYSIOLOGY

[Follicular dendritic cells: phenotype, origin and functions] Heinen E. **Pathol Biol (Paris)** 1995 Dec;43(10):848–57 (43 ref.) (Eng. Abstr.) **(Fre)**

RADIOGRAPHY

Radiographic demonstration of intercostal lymphatics and lymph nodes. Iyer RB, et al. **Lymphology** 1995 Jun; 28(2):89–94 (4 ref.)

ULTRASONOGRAPHY

In vitro studies of lymph node analysis. Heintz A, et al. **Gastrointest Endosc Clin N Am** 1995 Jul;5(3):577–86 (21 ref.)

Endoscopic ultrasonography-guided puncture of the lymph nodes: first experience and clinical consequences. Hoffman BJ, et al. **Gastrointest Endosc Clin N Am** 1995 Jul; 5(3):587–93 (17 ref.)

ULTRASTRUCTURE

Intranodal myofibroblastoma: report of a case. Eyden BP, et al. **Ultrastruct Pathol** 1996 Jan–Feb;20(1):79–88 (35 ref.)

VIROLOGY

Follicular dendritic cells and infection by human immunodeficiency virus type 1—a crucial target cell and virus reservoir. Schuurman HJ, et al.
Curr Top Microbiol Immunol 1995;201:161–88 (170 ref.)

[Dendritic cells of spleen and blood and HIV-1 infection] Hosmalin A. **Pathol Biol (Paris)** 1995 Dec;43(10):889–96 (54 ref.) (Eng. Abstr.) **(Fre)**

LYMPHADENECTOMY see **LYMPH NODE EXCISION**

LYMPHADENITIS

[Aagenaes syndrome] Nittono H, et al.
Ryoikibetsu Shokogun Shirizu 1995;(7):521–2 (5 ref.) **(Jpn)**

METABOLISM

Calcium oxalate crystal deposition in epithelioid histiocytes of granulomatous lymphadenitis: analysis by light and electronmicroscopy. Symmans PJ, et al. **Histopathology** 1995 Nov;27(5):423–9 (11 ref.)

MICROBIOLOGY

Lymphocutaneous Nocardia brasiliensis infection: a case report and review. Seddon M, et al. **N Z Med J** 1995 Sep 22;108(1008):385–6 (08 ref.)

PATHOLOGY

Axillary involvement in pediatric Kikuchi's disease. Heldenberg D, et al. **Eur J Pediatr Surg** 1996 Feb;6(1):32–4 (12 ref.)

Calcium oxalate crystal deposition in epithelioid histiocytes of granulomatous lymphadenitis: analysis by light and electronmicroscopy. Symmans PJ, et al. **Histopathology** 1995 Nov;27(5):423–9 (11 ref.)

LYMPHADENITIS, TUBERCULOUS see **TUBERCULOSIS, LYMPH NODE**

LYMPHADENOPATHY-ASSOCIATED ANTIBODIES see **HIV ANTIBODIES**

LYMPHADENOPATHY-ASSOCIATED ANTIGENS see **HIV ANTIGENS**

LYMPHADENOPATHY-ASSOCIATED VIRUS see **HIV**

LYMPHADENOPATHY, IMMUNOBLASTIC see **IMMUNOBLASTIC LYMPHADENOPATHY**

LYMPHANGIECTASIS, INTESTINAL

DIAGNOSIS

[Intestinal lymphangiectasis in adults] Rossi P, et al.
G Chir 1996 Apr;17(4):171–4 (18 ref.) (Eng. Abstr.) **(Ita)**

LYMPHANGIOENDOTHELIOMA see **LYMPHANGIOMA**

LYMPHANGIOENDOTHELIOMA, MALIGNANT see **LYMPHANGIOSARCOMA**

LYMPHANGIOGRAPHY see **LYMPHOGRAPHY**

LYMPHANGIOMA

[Hepatic lymphangiomatosis and its related tumors and tumor-like conditions] Haratake J, et al.
Ryoikibetsu Shokogun Shirizu 1995;(7):292–4 (12 ref.) **(Jpn)**

DIAGNOSIS

[Simple lymphangioma of the breast. A case report] Occhiato R, et al. **Radiol Med (Torino)** 1996 Jan–Feb;91(1–2):130–2 (4 ref.) **(Ita)**

PATHOLOGY

Perianal lymphangioma circumscriptum mistaken for genital warts. Darmstadt GL. **Pediatrics** 1996 Sep;98(3 Pt 1):461–3 (18 ref.)

LYMPHANGIOMA, CAVERNOUS see **LYMPHANGIOMA**

LYMPHANGIOMA, CYSTIC

DIAGNOSIS

Cystic hygroma of the arm: a case report and review of the literature. Carpenter CT, et al. **Skeletal Radiol** 1996 Feb; 25(2):201–4 (8 ref.)

[The diagnosis of mediastinal lymphangioma in children] Hoeffel JC, et al. **Rev Mal Respir** 1996 Jul;13(3):287–93 (27 ref.) (Eng. Abstr.) **(Fre)**

[Cystic lymphangioma, lymphangiomatosis] Hutzelmann A, et al.
Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1995 Oct;163(4):358–60 (11 ref.) **(Ger)**

[Cystic lymphangioma of the adrenal gland] Duca S, et al. **Chirurgia (Bucur)** 1995;44(1):43–7 (8 ref.) **(Rum)**

MORTALITY

Cytogenetic evaluation of cystic hygroma associated with hydrops fetalis, oligohydramnios or intrauterine fetal death: the roles of amniocentesis, postmortem chorionic villus sampling and cystic hygroma paracentesis. Chen CP, et al. **Acta Obstet Gynecol Scand** 1996 May;75(5):454–8 (29 ref.)

PATHOLOGY

Retroperitoneal cystic lymphangioma. Nuzzo G, et al.
J Surg Oncol 1996 Mar;61(3):234–7 (22 ref.)

SURGERY

A complication of mesenteric lymphangioma: case report and brief review of literature. Takkal M, et al.
Acta Chir Belg 1996 Jun;96(3):130–2 (12 ref.)

LYMPHANGIOMYOMATOSIS

[Lymphangioleiomyomatosis] Zielonka TM, et al.
Pneumonol Pol 1990 Sep–Oct;58(9–10):565–71 (33 ref.) **(Pol)**

COMPLICATIONS

Lymphangioleiomyomatosis, chylous ascites, and diet. Calvo E, et al. **Dig Dis Sci** 1996 Mar;41(3):591–3 (8 ref.)

PHYSIOPATHOLOGY

Lymphangioleiomyomatosis and tuberous sclerosis: where is the border? [editorial] Bonetti F, et al. **Eur Respir J** 1996 Mar;9(3):399–401 (19 ref.)

LYMPHANGIOSARCOMA

ETIOLOGY

Lymphangiosarcoma following mastectomy. Stewart NJ, et al. **Clin Orthop** 1995 Nov;(320):135–41 (15 ref.)

VETERINARY

Chylothorax and chylous ascites in a dog with mediastinal lymphangiosarcoma. Myers NC 3rd, et al.
J Am Anim Hosp Assoc 1996 May–Jun;32(3):263–9 (32 ref.)

LYMPHAPHERESIS see **LEUKAPHERESIS**

LYMPHATIC CAPILLARIES see **LYMPHATIC SYSTEM**

LYMPHATIC CYST see **LYMPHOCELE**

LYMPHATIC DISEASES

see related
CHYLOTHORAX
LEUKEMIA, LYMPHOCYTIC
LYMPHOMA

The brain and the lymphatic system (II). Földi M.
Lymphology 1996 Mar;29(1):10–4 (29 ref.)

DIAGNOSIS

Lymphadenopathy [see comments] Morland B.
Arch Dis Child 1995 Nov;73(5):476–9 (21 ref.) Comment in: Arch Dis Child 1996 Apr;74(4):368.

Imaging of cervical lymphadenopathy. van den Brekel MW, et al. **Neuroimaging Clin N Am** 1996 May;6(2):417–34 (137 ref.)

Work-up of lymphadenopathy in children. Perkins SL, et al. **Semin Diagn Pathol** 1995 Nov;12(4):284–7 (18 ref.)

DRUG THERAPY

P53 gene mutations in lymphoid diseases and their possible relevance to drug resistance. Newcomb EW.
Leuk Lymphoma 1995 Apr;17(3–4):211–21 (86 ref.)

ETIOLOGY

Causes and clinical manifestations of lymphatic failure. Harwood CA, et al. **Clin Dermatol** 1995 Sep–Oct; 13(5):459–71 (84 ref.)

Lymphadenopathy associated with total joint prostheses. A report of two cases and a review of the literature [see comments] Benz EB, et al. **J Bone Joint Surg Am** 1996 Apr;78(4):588–93 (28 ref.) Comment in: J Bone Joint Surg

LYMPHATIC DISEASES

Am 1996 Apr;78(4):479–81.
[Postoperative lymphoceles and lymphatic fistula in gynecologic and breast neoplasms] Brun JL. **Bull Cancer (Paris)** 1995 Sep;82(9):711–6 (37 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

P53 gene mutations in lymphoid diseases and their possible relevance to drug resistance. Newcomb EW. **Leuk Lymphoma** 1995 Apr;17(3–4):211–21 (86 ref.)

PATHOLOGY

Cavitation of mesenteric lymph nodes: a rare complication of coeliac disease, associated with a poor outcome. Howat AJ, et al. **Histopathology** 1995 Oct;27(4):349–54 (8 ref.)
Benign lymphadenopathies in children and adolescents. Segal GH, et al. **Semin Diagn Pathol** 1995 Nov;12(4):288–302 (116 ref.)
Intranodal myofibroblastoma: report of a case. Eyden BP, et al. **Ultrastruct Pathol** 1996 Jan–Feb;20(1):79–88 (35 ref.)

PHYSIOPATHOLOGY

[Lymph—biochemical composition, importance of its circulation in the physiology and pathology of the organism] Beck B, et al. **Postepy Hig Med Dosw** 1995; 49(3):353–66 (97 ref.) (Eng. Abstr.) **(Pol)**

RADIOGRAPHY

CT evaluation of soft tissue and muscle infection and inflammation: a systematic compartmental approach. Beauchamp NJ Jr, et al. **Skeletal Radiol** 1995 Jul; 24(5):317–24 (8 ref.)

ULTRASONOGRAPHY

[Contribution of echography in the detection of lymph node diseases in epidermoid carcinoma of the larynx: therapeutic implications] Heitzmann P, et al. **Ann Otolaryngol Chir Cervicofac** 1995;112(5):229–33 (15 ref.) (Eng. Abstr.) **(Fre)**

LYMPHATIC ENDOTHELIUM see **ENDOTHELIUM, LYMPHATIC**

LYMPHATIC FILARIASIS see **ELEPHANTIASIS, FILARIAL**

LYMPHATIC METASTASIS

What to do if the lymph nodes are positive. Evans CP, et al. **Semin Urol Oncol** 1996 May;14(2):96–102 (22 ref.)

DIAGNOSIS

Multimodality imaging of cervical adenopathies. Giron J, et al. **Eur J Radiol** 1996 Feb;21(3):159–66 (21 ref.)
Imaging of abdominal nodal spread in malignant disease. Delorme S, et al. **Eur Radiol** 1996;6(3):262–74 (47 ref.)
Oncology imaging: nodal spread–intrathoracic nodes. Verschakelen JA, et al. **Eur Radiol** 1996;6(3):251–61 (76 ref.)
[Lymph node diagnosis with imaging methods. An overview with special reference to recent developments in the area of MR contrast media] Mohr U, et al. **Z Lymphol** 1996 Jun;20(1):15–20 (59 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

Primary leiomyosarcoma of the maxilla with regional lymph node metastasis. Report of a case and review of the literature. Izumi K, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1995 Sep;80(3):310–9 (56 ref.)
[Principles of lymphogenic and hematogenous metastasis and metastasis classification] Wittekind C. **Zentralbl Chir** 1996; 121(6):435–41 (16 ref.) (Eng. Abstr.) **(Ger)**

LYMPHATIC SYSTEM

see related
LYMPHOGRAPHY

ANATOMY & HISTOLOGY

The interstitium, the connective tissue environment of the lymphatic, and angiogenesis in human skin. Ryan TJ, et al. **Clin Dermatol** 1995 Sep–Oct;13(5):451–8 (54 ref.)
Lymphatics and adipose tissue. Ryan TJ. **Clin Dermatol** 1995 Sep–Oct;13(5):493–8 (38 ref.)
The role of the diaphragm in lymphatic absorption from the peritoneal cavity. Abu-Hijleh MF, et al. **J Anat** 1995 Jun; 186 (Pt 3):453–67 (89 ref.)
The brain and the lymphatic system (I). Földi M. **Lymphology** 1996 Mar;29(1):1–9 (46 ref.)
Physiology and immunology of lymphatic drainage of interstitial and cerebrospinal fluid from the brain. Knopf PM, et al. **Neuropathol Appl Neurobiol** 1995 Jun; 21(3):175–80 (16 ref.)

CYTOLOGY

[The cellular mechanisms in the regulation of lymph transport] Lobov GI, et al. **Fiziol Zh Im I M Sechenova** 1995 Jun;81(6):19–28 (25 ref.) **(Rus)**

IMMUNOLOGY

Immune cell traffic from blood through the normal human skin to lymphatics. Olszewski WL, et al. **Clin Dermatol** 1995 Sep–Oct;13(5):473–83 (29 ref.)
Lymphatics and the processing of antigen. Ryan TJ, et al. **Clin Dermatol** 1995 Sep–Oct;13(5):485–92 (34 ref.)

METABOLISM

Anatomical pathways for lymphatic drainage of the brain and their pathological significance. Kida S, et al. **Neuropathol Appl Neurobiol** 1995 Jun;21(3):181–4 (17 ref.)

MICROBIOLOGY

[Cat scratch disease. Bartonella henselae antibodies and DNA detection in regional lymphadenopathy] Heizmann WR, et al. **Dtsch Med Wochenschr** 1996 May 10;121(19):622–6 (33 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Mechanical resilience of skin: a function of blood supply and lymphatic drainage. Ryan TJ. **Clin Dermatol** 1995 Sep–Oct; 13(5):429–32 (22 ref.)
The relevance of cell microenvironments for the appearance of lympho–haemopoietic tissues in primitive vertebrates. Zapata AG, et al. **Histol Histopathol** 1995 Jul;10(3):761–78 (82 ref.)
The brain and the lymphatic system (II). Földi M. **Lymphology** 1996 Mar;29(1):10–4 (29 ref.)

LYMPHEDEMA

Managing lymphoedema. Mortimer PS. **Clin Exp Dermatol** 1995 Mar;20(2):98–106 (26 ref.)
The brain and the lymphatic system (II). Földi M. **Lymphology** 1996 Mar;29(1):10–4 (29 ref.)
Lymphedema: incidence, pathophysiology, management, and nursing care. Humble CA. **Oncol Nurs Forum** 1995 Nov–Dec;22(10):1503–9; quiz 1510–1 (46 ref.)

COMPLICATIONS

Endovascular papillary angioendothelioma–like tumour associated with lymphoedema. Fukunaga M, et al. **Histopathology** 1995 Sep;27(3):243–9 (16 ref.)

DIAGNOSIS

The diagnosis and treatment of peripheral lymphedema. Consensus document of the International Society of Lymphology Executive Committee. **Lymphology** 1995 Sep; 28(3):113–7 (0 ref.)
[Lymphedema–associated angiosarcoma (the Stewart–Treves syndrome) of the lower extremity: its MRT imaging] Gelmetti W, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Feb;164(2):168–70 (15 ref.) **(Ger)**

ETIOLOGY

Focused review: postmastectomy lymphedema. Brennan MJ, et al. **Arch Phys Med Rehabil** 1996 Mar;77(3 Suppl):S74–80 (55 ref.)
[Radiotherapy of ENT tumors and risk of lymphedema] Ewald H. **Z Lymphol** 1996 Jun;20(1):21–6 (10 ref.) (Eng. Abstr.) **(Ger)**
[Lipedema] Herpertz U. **Z Lymphol** 1995 Aug;19(1):1–11 (5 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

Intravital capillaroscopy in patients with chronic venous insufficiency and lymphoedema: relevance to Daflon 500 mg. Bollinger A, et al. **Int J Microcirc Clin Exp** 1995;15 Suppl 1:41–4 (24 ref.)

RADIOGRAPHY

Assessment of abnormal lymph drainage for the diagnosis of lymphedema by isotopic lymphangiography and by indirect lymphography. Partsch H. **Clin Dermatol** 1995 Sep–Oct;13(5):445–50 (45 ref.)

RADIONUCLIDE IMAGING

Assessment of abnormal lymph drainage for the diagnosis of lymphedema by isotopic lymphangiography and by indirect lymphography. Partsch H. **Clin Dermatol** 1995 Sep–Oct;13(5):445–50 (45 ref.)

REHABILITATION

Focused review: postmastectomy lymphedema. Brennan MJ, et al. **Arch Phys Med Rehabil** 1996 Mar;77(3 Suppl):S74–80 (55 ref.)
[Adjuvant therapy in lymphedema] Brenke R, et al. **Z Lymphol** 1996 Jun;20(1):31–5 (10 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Managing lymphedema. Mortimer PS. **Clin Dermatol** 1995 Sep–Oct;13(5):499–505 (21 ref.)
The diagnosis and treatment of peripheral lymphedema. Consensus document of the International Society of Lymphology Executive Committee. **Lymphology** 1995 Sep; 28(3):113–7 (0 ref.)
[Effectiveness, indications and contraindications of manual lymph drainage therapy in painful edema] Asdonk J. **Z Lymphol** 1995 Aug;19(1):16–22 (22 ref.) **(Ger)**

LYMPHOBLAST TRANSFORMATION see **LYMPHOCYTE TRANSFORMATION**

LYMPHOBLASTIC LARGE-CELL LYMPHOMA see **LYMPHOMA, LYMPHOBLASTIC**

LYMPHOBLASTIC LEUKEMIA see **LEUKEMIA, LYMPHOCYTIC**

LYMPHOBLASTIC LEUKEMIA, ACUTE see **LEUKEMIA, LYMPHOCYTIC, ACUTE**

LYMPHOBLASTIC LEUKEMIA, ACUTE, ADULT see **LEUKEMIA, LYMPHOCYTIC, ACUTE, L2**

LYMPHOBLASTIC LEUKEMIA, ACUTE, CALLA-POSITIVE see **LEUKEMIA, CALLA-POSITIVE**

LYMPHOBLASTIC LEUKEMIA, ACUTE, CHILDHOOD see **LEUKEMIA, LYMPHOCYTIC, ACUTE, L1**

LYMPHOBLASTIC LEUKEMIA, ACUTE, L1 see **LEUKEMIA, LYMPHOCYTIC, ACUTE, L1**

LYMPHOBLASTIC LEUKEMIA, ACUTE, L2 see **LEUKEMIA, LYMPHOCYTIC, ACUTE, L2**

LYMPHOBLASTIC LEUKEMIA, ACUTE, T-CELL see **LEUKEMIA, T-CELL, ACUTE**

LYMPHOBLASTIC LEUKEMIA, CHRONIC see **LEUKEMIA, LYMPHOCYTIC, CHRONIC**

LYMPHOBLASTIC LYMPHOMA see **LYMPHOMA, LYMPHOBLASTIC**

LYMPHOBLASTIC LYMPHOSARCOMA, DIFFUSE see **LYMPHOMA, LYMPHOBLASTIC**

LYMPHOCELE

ETIOLOGY

An interesting case of failed renal transplant complicated by a lymphocele infected with Pasteurella multocida and a review of the literature. Mayo RR, et al. **Am J Nephrol** 1996;16(4):361–6 (38 ref.)
[Postoperative lymphoceles and lymphatic fistula in gynecologic and breast neoplasms] Brun JL. **Bull Cancer (Paris)** 1995 Sep;82(9):711–6 (37 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Lymphoepithelial cyst of the pancreas. Report of two cases and review of the literature. Iacono C, et al. **Int J Pancreatol** 1996 Feb;19(1):71–6 (20 ref.)
Lymphoepithelial cyst of the pancreas: a preoperatively diagnosed case based on an aspiration biopsy. Rino Y, et al. **Surg Today** 1995;25(12):1043–6 (11 ref.)

LYMPHOCYTAPHERESIS see **LEUKAPHERESIS**

LYMPHOCYTE-ACTIVATING FACTOR see **INTERLEUKIN-1**

LYMPHOCYTE ACTIVATION see **LYMPHOCYTE TRANSFORMATION**

T-LYMPHOCYTE ANTIGEN RECEPTOR DELTA-CHAIN GENE REARRANGEMENT see **GENE REARRANGEMENT, DELTA-CHAIN T-CELL ANTIGEN RECEPTOR**

LYMPHOCYTE COOPERATION

PHYSIOLOGY

Current concepts of B cell modulation. Matsuda T, et al. **Jpt Rev Immunol** 1989;5(2):97–109 (37 ref.)

LYMPHOCYTE COUNT, CD4 see **CD4 LYMPHOCYTE COUNT**

T4 LYMPHOCYTE COUNT see **CD4 LYMPHOCYTE COUNT**

LYMPHOCYTE CULTURE TEST, MIXED

Reverse transcription polymerase chain reaction for cytokines in the mixed lymphocyte culture. Is there a role in renal transplantation? [editorial] Danzer SG, et al. **Nephrol Dial Transplant** 1996 Jul;11(7):1246–7 (10 ref.)

LYMPHOCYTE DEPLETION

Dose-dependent activation and deletion of antigen-specific T cells following oral tolerance. Chen YH, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:111-21 (60 ref.)

Targeting T cells for GVHD therapy. Vallera DA. **Semin Cancer Biol** 1996 Apr;7(2):57-64 (57 ref.)

METHODS

Bone marrow transplantation for chronic myeloid leukemia with volunteer unrelated donors using ex vivo or in vivo T-cell depletion: major prognostic impact of HLA class I identity between donor and recipient. Spencer A, et al. **Blood** 1995 Nov 1;86(9):3590-7 (40 ref.)

B-LYMPHOCYTE DIFFERENTIATION ANTIGENS see **ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE**

T-LYMPHOCYTE DIFFERENTIATION ANTIGENS see **ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE**

LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1

PHYSIOLOGY

Ins and outs of LFA-1. Lub M, et al. **Immunol Today** 1995 Oct;16(10):479-83 (39 ref.)

B-LYMPHOCYTE GENE REARRANGEMENT see **GENE REARRANGEMENT, B-LYMPHOCYTE**

T-LYMPHOCYTE GENE REARRANGEMENT see **GENE REARRANGEMENT, T-LYMPHOCYTE**

B-LYMPHOCYTE HEAVY CHAIN GENE REARRANGEMENT see **GENE REARRANGEMENT, B-LYMPHOCYTE, HEAVY CHAIN**

LYMPHOCYTE HOMING RECEPTORS see **RECEPTORS, LYMPHOCYTE HOMING**

LYMPHOCYTE IMMUNOPHENOTYPING see **IMMUNOPHENOTYPING**

B-LYMPHOCYTE KAPPA-CHAIN GENE REARRANGEMENT see **GENE REARRANGEMENT, B-LYMPHOCYTE, LIGHT CHAIN**

B-LYMPHOCYTE LAMBDA-CHAIN GENE REARRANGEMENT see **GENE REARRANGEMENT, B-LYMPHOCYTE, LIGHT CHAIN**

B-LYMPHOCYTE LIGHT CHAIN GENE REARRANGEMENT see **GENE REARRANGEMENT, B-LYMPHOCYTE, LIGHT CHAIN**

LYMPHOCYTE MEDIATORS see **LYMPHOKINES**

LYMPHOCYTE MITOGENIC FACTOR see **INTERLEUKIN-2**

B-LYMPHOCYTE MU CHAIN GENE REARRANGEMENT see **GENE REARRANGEMENT, B-LYMPHOCYTE, HEAVY CHAIN**

LYMPHOCYTE STIMULATION see **LYMPHOCYTE TRANSFORMATION**

LYMPHOCYTE SUBPOPULATIONS see **LYMPHOCYTE SUBSETS**

LYMPHOCYTE SUBSETS

see related
IMMUNOPHENOTYPING

Determination of lymphocyte subsets and cytokine levels in cynomolgus monkeys. Verdier F, et al. **Toxicology** 1995 Dec 20;105(1):81-90 (27 ref.)

CYTOLOGY

Peripheral blood leukocytes and lymphocyte subpopulations as determined by flow cytometric measurements in healthy children. Kawiak J, et al. **Folia Histochem Cytobiol** 1995; 33(1):33-8 (31 ref.)

PHYSIOLOGY

Lymphocyte migration. A new spin on lymphocyte homing. Mackay C. **Curr Biol** 1995 Jul 1;5(7):733-6 (30 ref.)

B-LYMPHOCYTE SUBSETS

IMMUNOLOGY

Cellular and molecular biologic approaches for analyzing the in vivo development and maintenance of gut mucosal IgA responses. Cebra JJ, et al. **Adv Exp Med Biol** 1995; 371A:429-34 (11 ref.)

Induction and recall of the secondary immune response entirely in tissue culture. Sterzl J, et al. **Adv Exp Med Biol** 1995;371A:1-7 (11 ref.)

B-1 cellular origin and VH segment structure of IgG, IgA, and IgM anti-DNA autoantibodies in patients with systemic lupus erythematosus. Kasaian MT, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:410-23 (52 ref.)

B-1 cells and autoimmunity. Murakami M, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:402-9 (34 ref.)

Fetal versus adult PreB or B cells: the human VH repertoire. Tonnelle C, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:231-41 (38 ref.)

CD45 (leucocyte common antigen) expression in T and B lymphocyte subsets. Poppema S, et al. **Leuk Lymphoma** 1996 Jan;20(3-4):217-22 (63 ref.)

T-LYMPHOCYTE SUBSETS

Th1 and Th2 subsets: paradigms lost? Kelso A. **Immunol Today** 1995 Aug;16(8):374-9 (41 ref.)

Development of TCR gamma delta iIELs. Barrett TA, et al. **Semin Immunol** 1995 Oct;7(5):299-305 (27 ref.)

The TCR-beta chain repertoire of gut-derived T lymphocytes. Regnault A, et al. **Semin Immunol** 1995 Oct; 7(5):307-19 (91 ref.)

CLASSIFICATION

Expression of CD11a and CD45R isoforms defines distinct subsets of CD8+ TCR alpha beta and TCR gamma delta CTL in vivo. Hedlund G, et al. **Immunol Rev** 1995 Aug; 146:82-94 (33 ref.)

CYTOLOGY

Differentiation of subsets of CD4+ and CD8+ T cells. Mosmann TR, et al. **Ciba Found Symp** 1995;195:42-50; discussion 50-4 (49 ref.)

T-cell subsets. Who does the polarizing? Swain SL. **Curr Biol** 1995 Aug 1;5(8):849-51 (25 ref.)

IMMUNOLOGY

Induction of anergy in Th1 lymphocytes by oral tolerance. Importance of antigen dosage and frequency of feeding. Friedman A. **Ann N Y Acad Sci** 1996 Feb 13;778:103-10 (47 ref.)

Role of gamma delta T cells in the regulation of mucosal IgA response and oral tolerance. Fujihashi K, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:55-63 (42 ref.)

T-cell subsets and their cytokine profiles in transplantation and tolerance. Groux H, et al. **Ann N Y Acad Sci** 1995 Dec 29;770:141-8 (27 ref.)

TCR gamma delta cells: a specialized T-cell subset in the immune system. Bluestone JA, et al. **Ann Rev Cell Dev Biol** 1995;11:307-53 (241 ref.)

T-cell responses and cellular immunity in coeliac disease. Trejdosiewicz LK, et al. **Baillieres Clin Gastroenterol** 1995 Jun;9(2):251-72 (160 ref.)

Cytokines, differentiation and functions of subsets of CD4 and CD8 T cells. Mosmann TR. **Behring Inst Mitt** 1995 Jun;(96):1-6 (34 ref.)

Developmental regulation of alpha beta T cell antigen receptor assembly in immature CD4+CD8+ thymocytes. Kearse KP, et al. **Bioessays** 1995 Dec;17(12):1049-54 (41 ref.)

The role of subsets of CD4+ T cells in autoimmunity. Fowell D, et al. **Ciba Found Symp** 1995;195:173-82; discussion 182-8 (42 ref.)

The development of effector T cell subsets in murine Leishmania major infection. Locksley RM, et al. **Ciba Found Symp** 1995;195:110-7; discussion 117-22 (41 ref.)

T cell subsets in infectious and autoimmune diseases. Introduction. Mitchison NA. **Ciba Found Symp** 1995; 195:1-5; discussion 5-6 (9 ref.)

Mouse NK1+ T cells. Bendelac A. **Curr Opin Immunol** 1995 Jun;7(3):367-74 (54 ref.)

The protective immune response to Mycobacterium tuberculosis. Cooper AM, et al. **Curr Opin Immunol** 1995 Aug;7(4):512-6 (53 ref.)

Functions of T-cell subsets and cytokines in mycobacterial infections. Munk ME, et al. **Eur Respir J Suppl** 1995 Sep; 20:668s-675s (91 ref.)

T-cell recognition of mycobacterial antigens. Vordermeier HM. **Eur Respir J Suppl** 1995 Sep;20:657s-667s (121 ref.)

The human immune response to hepatitis B surface antigen. Alper CA. **Exp Clin Immunogenet** 1995;12(3):171-81 (82 ref.)

T-cell mediated immunosuppression and its implications for the development of protective immunity. Baker PJ, et al. **Folia Biol (Praha)** 1994;40(6):349-58 (50 ref.)

Receptors and signals in early thymic selection. Levelt CN, et al. **Immunity** 1995 Dec;3(6):667-72 (68 ref.)

The origin of CD4-CD8-TCR alpha beta+ thymocytes: a model based on T-cell receptor avidity. Budd RC, et al. **Immunol Today** 1995 Sep;16(9):428-31 (27 ref.)

Direct antimicrobial activity of T cells. Levitz SM, et al. **Immunol Today** 1995 Aug;16(8):387-91 (36 ref.)

The role of T-cell subsets in Mycobacterium tuberculosis infection. Boom WH. **Infect Agents Dis** 1996 Mar; 5(2):73-81 (68 ref.)

Dysregulation of cytokines during graft-versus-host disease. Krenger W, et al. **J Hematother** 1996 Feb;5(1):3-14 (136 ref.)

Psoriasis, T cells and autoimmunity. Griffiths CE, et al. **J R Soc Med** 1996 Jun;89(6):315-9 (60 ref.)

CD45 (leucocyte common antigen) expression in T and B lymphocyte subsets. Poppema S, et al. **Leuk Lymphoma** 1996 Jan;20(3-4):217-22 (63 ref.)

gamma/delta and other unconventional T lymphocytes: what do they see and what do they do? Kaufmann SH. **Proc Natl Acad Sci U S A** 1996 Mar 19;93(6):2272-9 (135 ref.)

[Gamma delta lymphocytes] Szczepanik M, et al. **Przegl Lek** 1995;52(8):400-2 (41 ref.) **(Pol)**

PHYSIOLOGY

Regulation of T lymphocyte subsets. Fitch FW, et al. **Ciba Found Symp** 1995;195:68-80; discussion 80-5 (42 ref.)

Functional T cell subsets in mycobacterial and listerial infections: lessons from other intracellular pathogens. Szalay G, et al. **Curr Top Microbiol Immunol** 1996; 215:283-302 (102 ref.)

Gastrointestinal intra-epithelial lymphocytes in man: the saga continues. Trejdosiewicz LK, et al. **Eur J Gastroenterol Hepatol** 1995 Jun;7(6):537-40 (55 ref.)

LYMPHOCYTE SUBTYPING see **IMMUNOPHENOTYPING**

LYMPHOCYTE TRANSFORMATION

From cell activation to cell depletion. The programmed cell death hypothesis of AIDS pathogenesis. Ameisen JC. **Adv Exp Med Biol** 1995;374:139-63 (159 ref.)

AIDS as immune system activation. Key questions that remain. Ascher MS, et al. **Adv Exp Med Biol** 1995; 374:203-10 (89 ref.)

CD4+ and CD8+ T lymphocyte activation in HIV infection. Implications for immune pathogenesis and therapy. Laurence J. **Adv Exp Med Biol** 1995;374:1-15 (74 ref.)

Dendritic cells "in vivo": their role in the initiation of intestinal immune responses. Liu L, et al. **Adv Exp Med Biol** 1995;371A:271-4 (5 ref.)

Glycosylation and maturation rate of membrane and secretory forms of human CD8 alpha glycoprotein. Implications in the activation of T-lymphocytes. Serafini-Cessi F, et al. **Adv Exp Med Biol** 1995;376:135-45 (33 ref.)

Suppression of experimental glomerulonephritis by interference with T- or B-cell activation signals or adhesion molecules. Andres G, et al. **Adv Nephrol Necker Hosp** 1995;24:91-105 (51 ref.)

Dose-dependent activation and deletion of antigen-specific T cells following oral tolerance. Chen YH, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:111-21 (60 ref.)

The kinase-dependent function of Lck in T-cell activation requires an intact site for tyrosine autophosphorylation. Xu H, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:99-116 (46 ref.)

A molecular basis for T-dependent B cell activation. Lane P. **Behring Inst Mitt** 1995 Jun;(96):7-12 (46 ref.)

Phosphoinositide 3-kinase and CD28-mediated T-cell co-stimulation. Ward SG. **Biochem Soc Trans** 1996 Feb; 24(1):240-5 (50 ref.)

T-cell activation. Two for T. Guerder S, et al. **Curr Biol** 1995 Aug 1;5(8):866-8 (22 ref.)

CD23 and B-cell activation. Bonnefoy JY, et al. **Curr Opin Immunol** 1995 Jun;7(3):355-9 (39 ref.)

Antagonizing the differentiation and functions of human T helper type 2 cells. de Vries JE, et al. **Curr Opin Immunol** 1995 Dec;7(6):771-8 (63 ref.)

Activation-induced death of mature T cells in the regulation of immune responses. Russell JH. **Curr Opin Immunol** 1995 Jun;7(3):382-8 (43 ref.)

Analysis of lymphocyte costimulation in vivo using transgenic and 'knockout' mice. Sharpe AH. **Curr Opin Immunol** 1995 Jun;7(3):389-95 (55 ref.)

Role of follicular dendritic cells in the regulation of B cell proliferation. Freedman AS, et al. **Curr Top Microbiol Immunol** 1995;201:83-92 (45 ref.)

Regulation of human B cell activation by follicular dendritic cell and T cell signals. Grouard G, et al. **Curr Top Microbiol Immunol** 1995;201:105-17 (55 ref.)

Joint features of metastasis formation and lymphocyte maturation and activation. Zöller M. **Curr Top Microbiol Immunol** 1996;213 (Pt 1):215-47 (330 ref.)

The one signal theory of B cell activation revisited: a role for surface immunoglobulin in regulating T-independent antibody responses? Mamchak AA, et al. **Immunol Cell Biol** 1995 Jun;73(3):266-71 (29 ref.)

Role of B7 signaling in the differentiation of naive CD4+ T cells to effector interleukin-4-producing T helper cells. Gause WC, et al. **Immunol Res** 1995;14(3):176-88 (84 ref.)

The vitronectin receptor (alpha V beta 3) as an example for the role of integrins in T lymphocyte stimulation. Halvorson MJ, et al. **Immunol Res** 1996;15(1):16-29 (94 ref.)

B7-mediated costimulation can either provoke or prevent clinical manifestations of experimental allergic encephalomyelitis. Perrin PJ, et al. **Immunol Res** 1995; 14(3):189-99 (47 ref.)

Role of extracellular ATP and P1 and P2 classes of purinergic receptors in T-cell development and cytotoxic T

LYMPHOCYTE TRANSFORMATION

lymphocyte effector functions. Apasov S, et al. **Immunol Rev** 1995 Aug;146:5–19 (40 ref.)

Molecular interactions in the activation of effector and precursor cytotoxic T lymphocytes. Mescher MF. **Immunol Rev** 1995 Aug;146:177–210 (108 ref.)

T-cell activation: integration of signals from the antigen receptor and costimulatory molecules. Robey E, et al. **Immunol Today** 1995 Jul;16(7):306–10 (29 ref.)

Role of tyrosine kinases in lymphocyte activation: targets for drug intervention. Hanke JH, et al. **Inflamm Res** 1995 Sep;44(9):357–71 (190 ref.)

The ontogeny of class–regulation of CD4+ T lymphocyte populations. Carneiro J, et al. **Int Immunol** 1995 Aug; 7(8):1265–77 (37 ref.)

Gaining insights into the ontogeny and activation of T cells through the use of gene–targeted mutant mice. Mak TW. **J Inflamm** 1995;45(2):79–84 (22 ref.)

The anatomy of T–cell activation and tolerance. Mondino A, et al. **Proc Natl Acad Sci U S A** 1996 Mar 19; 93(6):2245–52 (113 ref.)

T–cell activation, anergy and immunomodulation by molecules of viral, fungal and vegetal origin. Bemer V, et al. **Res Immunol** 1995 May–Jun;146(4–5):249–62 (81 ref.)

The role of CD28 in the activation of T lymphocytes to proliferate in response to IL4. Chiodetti L, et al. **Res Immunol** 1995 Mar–Apr;146(3):169–71 (23 ref.)

Lymphocyte costimulation: multiple pathways, multiple functions? Kuiper HM, et al. **Res Immunol** 1995 Mar–Apr; 146(3):180–3 (41 ref.)

Molecular mechanism of T–cell activation: role of protein tyrosine kinases in antigen receptor–mediated signal transduction. Thome M, et al. **Res Immunol** 1995 May–Jun; 146(4–5):291–307 (104 ref.)

The Yin and Yang of T cell costimulation [see comments] Allison JP, et al. **Science** 1995 Nov 10;270(5238):932–3 (17 ref.) Comment in: Science 1995 Nov 10;270(5238):985–8.

Hierarchical control of lymphocyte survival. Boise LH, et al. **Science** 1996 Oct 4;274(5284):67–8 (17 ref.)

How T cells count [comment] Rothenberg EV. **Science** 1996 Jul 5;273(5271):78–9 (14 ref.) Comment on: Science 1996 Jul 5;273(5271):104–6.

The CD28 costimulatory pathway. Leung HT, et al. **Ther Immunol** 1994 Aug;1(4):217–28 (104 ref.)

[Superantigens] Palkama T, et al. **Duodecim** 1994; 110(2):202–6 (22 ref.) **(Fin)**

[Self–defence power fighting against AIDS. Cellular immunity and its activation] Takahashi H. **Nippon Ika Daigaku Zasshi** 1995 Oct;62(5):539–46 (23 ref.) **(Jpn)**

[Towards immuno–modulation through the molecular mechanism of lymphocyte activation] Aoe T, et al. **Nippon Rinsho** 1995 Sep;53(9):2331–9 (45 ref.) (Eng. Abstr.) **(Jpn)**

[The molecular mechanism of costimulatory signal for T cell activation] Uede T. **Nippon Rinsho** 1995 Oct; 53(10):2597–603 (25 ref.) (Eng. Abstr.) **(Jpn)**

[T cell activation] Takase K, et al. **Ryumachi** 1995 Oct; 35(5):853–61 (38 ref.) **(Jpn)**

DRUG EFFECTS

Inhibition of T lymphocyte activation and apoptotic cell death by cyclosporin A and tacrolimus (FK506). Its relevance to therapy of HIV infection. Thomson AW, et al. **Adv Exp Med Biol** 1995;374:211–6 (46 ref.)

The actions of cyclosporin A and FK506 on T–lymphocyte activation. Mattila PS. **Biochem Soc Trans** 1996 Feb; 24(1):45–9 (40 ref.)

Beta chemokines costimulate lymphocyte cytolysis, proliferation, and lymphokine production. Taub DD, et al. **J Leukoc Biol** 1996 Jan;59(1):81–9 (33 ref.)

Mode of action of tacrolimus (FK506): molecular and cellular mechanisms. Thomson AW, et al. **Ther Drug Monit** 1995 Dec;17(6):584–91 (79 ref.)

Mechanism of action of rapamycin (Sirolimus, Rapamune). Molnar–Kimber KL. **Transplant Proc** 1996 Apr;28(2):964–9 (127 ref.)

[Comparison of 2 techniques for measuring lymphocyte proliferation: tritiated methyl–thymidine incorporation and propidium iodide fluorometry] Brohee D, et al. **Rev Med Brux** 1995 Nov;16(5):368–71 (10 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

The architecture of the interleukin–2 promoter: a reflection of T lymphocyte activation. Serfling E, et al. **Biochim Biophys Acta** 1995 Sep 19;1263(3):181–200 (244 ref.)

IMMUNOLOGY

The gluten–host interaction. Tighe MR, et al. **Baillieres Clin Gastroenterol** 1995 Jun;9(2):211–30 (42 ref.)

B–cell lymphoproliferation in primary Sjögren's syndrome. Tzioufas AG. **Clin Exp Rheumatol** 1996 Jan–Feb;14 Suppl 14:S65–70 (41 ref.)

T cell differentiation: control by the pre–TCR and alpha beta TCR. von Boehmer H. **Clin Immunol Immunopathol** 1995 Sep;76(3 Pt 2):S145–50 (47 ref.)

Manipulation of costimulatory signals to enhance antitumor T–cell responses. Allison JP, et al. **Curr Opin Immunol** 1995 Oct;7(5):682–6 (34 ref.)

B–cell stimulation. Armitage RJ, et al. **Curr Opin Immunol** 1995 Apr;7(2):243–7 (50 ref.)

HIV–mediated B–lymphocyte activation and lymphomagenesis. Monroe JG, et al. **J Clin Immunol** 1995 Mar;15(2):61–8 (73 ref.)

[Clinical and immunobiological observations on the inflammatory activity of sarcoidosis] Müller–Quernheim J. **Pneumologie** 1996 Jan;50(1):40–8 (101 ref.) **(Ger)**

PHYSIOLOGY

Costimulation and its role in organ transplantation. Bluestone JA. **Clin Transplant** 1996 Feb;10(1 Pt 2):104–9 (23 ref.)

T cell costimulatory pathways: promising novel targets for immunosuppression and tolerance induction [editorial] Sayegh MH, et al. **J Am Soc Nephrol** 1995 Oct;6(4):1143–50 (49 ref.)

Molecular mechanisms of lymphocyte activation. Gulbins E, et al. **Nephrol Dial Transplant** 1995;10(9):1533–5 (72 ref.)

[Transgenic mice for analysis of neoplasm transformation processes of T and B lymphocytes] Kobzdej M, et al. **Postepy Hig Med Dosw** 1996;50(2):113–29 (61 ref.) (Eng. Abstr.) **(Pol)**

[The role of the HTLV–I virus in transformation of T lymphocytes] Papież M. **Postepy Hig Med Dosw** 1995; 49(5):585–97 (64 ref.) (Eng. Abstr.) **(Pol)**

LYMPHOCYTE TRANSFUSION

T–cell responses in photoimmune therapy. Heald PW, et al. **J Clin Apheresis** 1995;10(3):144–9 (26 ref.)

Immunomodulatory effects of donor lymphocyte infusions following allogeneic bone marrow transplantation. Soiffer RJ, et al. **J Clin Apheresis** 1995;10(3):139–43 (36 ref.)

[The study of the biological activation induced by the lymphocyte transfusion—the induction of the bio–reproducing protein (BRP)] Sato I. **Hum Cell** 1995 Sep; 8(3):77–84 (18 ref.) (Eng. Abstr.) **(Jpn)**

STANDARDS

Transplantation of hepatitis B immune lymphocytes as means for adoptive transfer of immunity to hepatitis B virus. Shouval D, et al. **J Hepatol** 1995 Jul;23(1):98–101 (18 ref.)

LYMPHOCYTES

see related

ANTILYMPHOCYTE SERUM

Lymphocytes in the lung: an often neglected cell. Numbers, characterization and compartmentalization. Pabst R, et al. **Anat Embryol (Berl)** 1995 Oct;192(4):293–9 (64 ref.)

Lymphocyte adhesion to endothelium. Dianzani U, et al. **Crit Rev Immunol** 1995;15(2):167–200 (258 ref.)

A defective HIV–1 vector for gene transfer to human lymphocytes. Parolin C, et al. **J Mol Med** 1995 Jun; 73(6):279–88 (176 ref.)

The beta 7 integrins in mucosal homing and retention. Shaw SK, et al. **Semin Immunol** 1995 Oct;7(5):335–42 (45 ref.)

[Lymphocytic ascites revealing systemic mastocytosis] Essner C, et al. **Gastroenterol Clin Biol** 1995 Nov; 19(11):948–51 (23 ref.) (Eng. Abstr.) **(Fre)**

[Lymphocytic hypophysitis: a reality] Virally–Monod ML, et al. **Presse Med** 1996 Jun 8;25(20):933–8 (15 ref.) (Eng. Abstr.) **(Fre)**

[Gene therapy for diabetes: various approaches including adoptive transfer of cytokine gene–transduced lymphocytes] Moritani M, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2746–52 (23 ref.) **(Jpn)**

[Diabetes insipidus and panhypopituitarism in an 8–year–old girl due to probable lymphocytic hypophysitis] Bastida Elzaguirre M, et al. **An Esp Pediatr** 1996 Apr;44(4):402–4 (20 ref.) **(Spa)**

CYTOLOGY

The interdependence of lymphocyte, stromal cell, and follicular dendritic cell maturation. Clark EA. **Adv Exp Med Biol** 1995;378:285–8 (26 ref.)

Immune cell traffic from blood through the normal human skin to lymphatics. Olszewski WL, et al. **Clin Dermatol** 1995 Sep–Oct;13(5):473–83 (29 ref.)

Joint features of metastasis formation and lymphocyte maturation and activation. Zöller M. **Curr Top Microbiol Immunol** 1996;213 (Pt 1):215–47 (330 ref.)

Lymphocyte and macrophage populations in the liver. Bioulac–Sage P, et al. **Hepatogastroenterology** 1996 Jan–Feb;43(7):4–14 (35 ref.)

Lifespan of lymphocytes. Tough DF, et al. **Immunol Res** 1995;14(1):1–12 (73 ref.)

Hierarchical control of lymphocyte survival. Boise LH, et al. **Science** 1996 Oct 4;274(5284):67–8 (17 ref.)

Lymphocyte development in genetically manipulated mice. Killeen N, et al. **Ther Immunol** 1994 Apr;1(2):123–33 (140 ref.)

DRUG EFFECTS

Physiologic basis of steroid–induced immunosuppression. Effects on lymphocyte migration to lymph nodes. Sackstein R. **J Fla Med Assoc** 1995 Sep;82(9):613–5 (22 ref.)

IMMUNOLOGY

Effects of varicella zoster virus or herpes simplex virus type I infection in vitro on response of human peripheral blood mononuclear cells to phytohemagglutinin. Horiuchi Y, et al. **Acta Med Okayama** 1995 Dec;49(6):309–12 (17 ref.)

The role of adrenoceptor–mediated signals in the modulation of lymphocyte function. Sanders VM. **Adv Neuroimmunol** 1995;5(3):283–98 (112 ref.)

Regulation of lymphocyte functions by nitric oxide. Liew FY. **Curr Opin Immunol** 1995 Jun;7(3):396–9 (43 ref.)

High endothelial venules (HEVs): specialized endothelium for lymphocyte migration. Girard JP, et al. **Immunol Today** 1995 Sep;16(9):449–57 (83 ref.)

Physiologic basis of steroid–induced immunosuppression. Effects on lymphocyte migration to lymph nodes. Sackstein R. **J Fla Med Assoc** 1995 Sep;82(9):613–5 (22 ref.)

Human liver–associated lymphocytes: an overview. Winnock M, et al. **J Gastroenterol Hepatol** 1995;10 Suppl 1:S43–6 (21 ref.)

Transplantation of hepatitis B immune lymphocytes as means for adoptive transfer of immunity to hepatitis B virus. Shouval D, et al. **J Hepatol** 1995 Jul;23(1):98–101 (18 ref.)

Balancing immunity and tolerance: deleting and tuning lymphocyte repertoires. Goodnow CC. **Proc Natl Acad Sci U S A** 1996 Mar 19;93(6):2264–71 (256 ref.)

Lymphocytes in a model ecosystem. Freitas AA. **Res Immunol** 1995 May–Jun;146(4–5):225–33 (54 ref.)

Effects of selenium and vitamin E on the immune responses of domestic animals. Finch JM, et al. **Res Vet Sci** 1996 Mar;60(2):97–106 (108 ref.)

Hierarchical control of lymphocyte survival. Boise LH, et al. **Science** 1996 Oct 4;274(5284):67–8 (17 ref.)

VLA–4 and lymphocyte trafficking in immune–inflammatory states: novel therapeutic approaches in allograft arteriopathy. Molossi S, et al. **Springer Semin Immunopathol** 1995;16(4):443–65 (225 ref.)

Physiological and pathophysiological aspects of the immune system contributing to a biomathematical model of lymphocytes. Wuestermann PR, et al. **Stem Cells (Dayt)** 1995 May;13 Suppl 1:268–75 (59 ref.)

[Intense physical exercise—excessive strain on the immune system?] Eliakim A, et al. **Harefuah** 1995 Dec 1; 129(11):498–502 (44 ref.) **(Heb)**

[Macrophages and lymphocytes in immune reactions during the course of tuberculosis] Dubaniewicz A, et al. **Pneumonol Alergol Pol** 1995;63(7–8):469–73 (29 ref.) **(Pol)**

METABOLISM

Calcium uptake by ACTH–stimulated lymphocytes: what is the physiological significance? Clarke BL. **Adv Neuroimmunol** 1995;5(3):271–81 (48 ref.)

Lymphocyte–specific genetic instability and cancer. Kirsch IR, et al. **Cold Spring Harb Symp Quant Biol** 1994; 59:287–95 (77 ref.)

Immunomodulatory role of melatonin: specific binding sites in human and rodent lymphoid cells. Calvo JR, et al. **J Pineal Res** 1995 Apr;18(3):119–26 (64 ref.)

Lymphocytes and neutrophils as peripheral models to study the effect of beta–amyloid on cellular calcium signalling in Alzheimer's disease. Eckert A, et al. **Life Sci** 1996; 59(5–6):499–510 (47 ref.)

[Analysis of Fas and bcl–2 expression on peripheral blood lymphocytes from primary Sjögren's syndrome] Ohashi H, et al. **Nippon Rinsho** 1995 Oct;53(10):2451–5 (24 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

[Sjögren's syndrome as a lymphoaggressive disorder; bcl–2 expression in lymphocytes infiltrated in salivary glands] Takeshita S, et al. **Nippon Rinsho** 1995 Oct;53(10):2440–5 (10 ref.) (Eng. Abstr.) **(Jpn)**

[An immunohistochemical analysis in portal lymphocytic aggregation of chronic hepatitis C] Tsuno S, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:635–41 (24 ref.) **(Jpn)**

[Lymph follicular cholecystitis] Nakashiro H, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):234–6 (5 ref.) **(Jpn)**

PHYSIOLOGY

The molecular biology of the Na(+)–Ca2+ exchanger and its functional roles in heart, smooth muscle cells, neurons, glia, lymphocytes, and nonexcitable cells. Lederer WJ, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:7–17 (60 ref.)

Lymphocyte migration following bone marrow transplantation. Sackstein R. **Ann N Y Acad Sci** 1995 Dec 29;770:177–88 (65 ref.)

The involvement of macrophages and lymphocytes in the apoptosis of enterocytes. Iwanaga T. **Arch Histol Cytol** 1995 Jun;58(2):151–9 (38 ref.)

Lymphocytes, cytokines, inflammation, and immune trafficking. Tsokos GC. **Curr Opin Rheumatol** 1995 Sep; 7(5):376–83 (84 ref.)

The role of cell adhesion molecules in the development of IDDM: implications for pathogenesis and therapy. Yang XD, et al. **Diabetes** 1996 Jun;45(6):705–10 (61 ref.)

The possible role of glutamine in some cells of the immune system and the possible consequence for the whole animal. Newsholme EA. **Experientia** 1996 May 15;52(5):455–9 (20

ref.)
Co-stimulation and co-inhibition: equal partners in regulation. Sinclair NR, et al. **Scand J Immunol** 1996 Jun; 43(6):597–603 (78 ref.)
[Lymphocytic migration and related adhesion molecules] Hajos SE. **Rev Argent Microbiol** 1995 Jan–Mar;27(1):38–55 (43 ref.) **(Spa)**

RADIATION EFFECTS

Quantification of low-level radiation exposure by conventional chromosome aberration analysis. Bauchinger M. **Mutat Res** 1995 Oct;339(3):177–89 (61 ref.)
Physiological and pathophysiological aspects of the immune system contributing to a biomathematical model of lymphocytes. Wuestermann PR, et al. **Stem Cells (Dayt)** 1995 May;13 Suppl 1:268–75 (59 ref.)

VIROLOGY

Hepatitis C virus as a lymphotropic agent: evidence and pathogenetic implications. Zignego AL, et al. **Clin Exp Rheumatol** 1995 Nov–Dec;13 Suppl 13:S33–7 (19 ref.)
Influence of redox status of lymphocytes and monocytes on HIV transcription and replication. Gougerot-Pocidalo MA, et al. **Immunobiology** 1995 Jul;193(2–4):204–9 (27 ref.)

B-LYMPHOCYTES

see related
GERMINAL CENTER
LYMPHOCYTE COOPERATION

Chronic B-cell lymphocytosis with binucleated lymphocytes (LWBL): a review of 38 cases. Troussard X, et al. **Leuk Lymphoma** 1996 Jan;20(3–4):275–9 (19 ref.)

CHEMISTRY

Analysis of immunoglobulin gene rearrangements in single B cells. Ehlich A, et al. **Curr Opin Immunol** 1995 Apr; 7(2):281–4 (18 ref.)

CYTOLOGY

Human B-cell development. Billips LG, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:1–8 (31 ref.)
B-lineage differentiation stages resolved by multiparameter flow cytometry. Hardy RR, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:19–24 (26 ref.)
The role of Bruton's tyrosine kinase in B-cell development and function in mice and man. Khan WN, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:27–38 (36 ref.)
In vitro studies of human B lymphopoiesis. Pribyl JR, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:9–18 (40 ref.)
Identification of genes specifically expressed at discrete stages of B-cell development. Zhang Y, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:25–6 (3 ref.)
B cell differentiation in bone marrow. Melchers F. **Clin Immunol Immunopathol** 1995 Sep;76(3 Pt 2):S188–91 (23 ref.)
Lymphopoiesis. Transcription factors controlling B-cell development. Desiderio S. **Curr Biol** 1995 Jun 1;5(6):605–8 (20 ref.)
Positive and negative selection events during B lymphopoiesis. Melchers F, et al. **Curr Opin Immunol** 1995 Apr;7(2):214–27 (119 ref.)
Expanding the role of Peyer's patches in B-cell ontogeny. Griebel PJ, et al. **Immunol Today** 1996 Jan;17(1):30–9 (76 ref.)
Tolerance sensitivity of immature-stage B cells: can developmentally regulated B cell antigen receptor (BCR) signal transduction play a role? Monroe JG. **J Immunol** 1996 Apr 15;156(8):2657–60 (38 ref.)
T cells commit suicide, but B cells are murdered! Scott DW, et al. **J Immunol** 1996 Apr 1;156(7):2352–6 (42 ref.)
CD27–CD70 interaction: unravelling its implication in normal and neoplastic B-cell growth. Lens SM, et al. **Leuk Lymphoma** 1995 Jun;18(1–2):51–9 (78 ref.)
Regulation of human B cell lymphopoiesis by adhesion molecules and cytokines. Ryan DH, et al. **Leuk Lymphoma** 1995 May;17(5–6):375–89 (137 ref.)
Receptor tails unlock developmental checkpoints for B lymphocytes [comment] Roth PE, et al. **Science** 1996 Jun 21;272(5269):1752–4 (7 ref.) Comment on: Science 1996 Jun 21;272(5269):1804–8.
B-lymphoid potential in pre-liver mouse embryo. Godin I, et al. **Semin Immunol** 1995 Jun;7(3):131–41 (70 ref.)
In-vitro analyses of mechanisms of B-cell development. Rolink A, et al. **Semin Immunol** 1995 Jun;7(3):155–67 (72 ref.)
Making the in-vitro model closer to actual B lymphopoiesis in the bone marrow. Yasunaga M, et al. **Semin Immunol** 1995 Jun;7(3):185–96 (59 ref.)
[A role of AP-1 in proliferation and differentiation of lymphocytes] Tokuhisa T, et al. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2045–53 (16 ref.) **(Jpn)**

DRUG EFFECTS

Modulation of B-cell immunoglobulin synthesis by retinoic acid. Ballow M, et al. **Clin Immunol Immunopathol** 1996 Sep;80(3 Pt 2):S73–81 (37 ref.)

ENZYMOLOGY

Syk deficiency—a knockout for B-cell development. Harnett M. **Immunol Today** 1996 Jan;17(1):4 (6 ref.)

IMMUNOLOGY

Evidence for a generalized signaling abnormality in B cells from patients with common variable immunodeficiency. Eisenstein EM, et al. **Adv Exp Med Biol** 1995;371B:699–704 (11 ref.)
Self-tolerance checkpoints in B lymphocyte development. Goodnow CC, et al. **Adv Immunol** 1995;59:279–368 (475 ref.)
In situ studies of the germinal center reaction. Kelsoe G. **Adv Immunol** 1995;60:267–88 (128 ref.)
Molecular and cellular aspects of X-linked agammaglobulinemia. Sideras P, et al. **Adv Immunol** 1995; 59:135–223 (445 ref.)
Suppression of experimental glomerulonephritis by interference with T- or B-cell activation signals or adhesion molecules. Andres G, et al. **Adv Nephrol Necker Hosp** 1995;24:91–105 (51 ref.)
Signal transduction by the B-cell antigen receptor. DeFranco AL, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:195–201 (26 ref.)
Development of the mouse B-cell repertoire. Martin F, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:207–21 (56 ref.)
Origins of anti-DNA antibodies and their implications for B-cell tolerance. Radic MZ, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:384–96 (13 ref.)
Unconventional B-cell antigens and human immune repertoires. Silverman GJ. **Ann N Y Acad Sci** 1995 Sep 29;764:342–55 (42 ref.)
The expressed heavy chain V gene repertoire of circulating B cells in normal adults. Stollar BD. **Ann N Y Acad Sci** 1995 Sep 29;764:265–74 (82 ref.)
Molecular analysis of VH regions expressed in the adult B-cell repertoire. van der Stoep N, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:275–84 (19 ref.)
Characterization of immunological memory cells. A minireview. Vongsakul M. **Asian Pac J Allergy Immunol** 1995 Jun;13(1):75–9 (47 ref.)
Converging and diverging properties of human interleukin-4 and interleukin-10. Banchereau J. **Behring Inst Mitt** 1995 Jun;(96):58–77 (119 ref.)
A molecular basis for T-dependent B cell activation. Lane P. **Behring Inst Mitt** 1995 Jun;(96):7–12 (46 ref.)
Therapeutic interference with interferon-gamma (IFN-gamma) and soluble IL-4 receptor (sIL-4R) in allergic diseases. Nasert S, et al. **Behring Inst Mitt** 1995 Jun;(96):118–30 (55 ref.)
Rheumatoid factors, B cells and immunoglobulin genes. Jefferis R. **Br Med Bull** 1995 Apr;51(2):312–31 (46 ref.)
Cell surface antigens in leukemias and lymphomas. Freedman AS. **Cancer Invest** 1996;14(3):252–76 (354 ref.)
The role of molecular analyses of B-cell and T-cell clonality in the study of B-cell lymphomagenesis. De Vita S, et al. **Clin Exp Rheumatol** 1996 Jan–Feb;14 Suppl 14:S21–9 (51 ref.)
Monitoring clonal expansion in the laboratory. Sala P, et al. **Clin Exp Rheumatol** 1996 Jan–Feb;14 Suppl 14:S31–5 (44 ref.)
Hepatitis C virus infection and clonal B-cell expansion. Sansonno D, et al. **Clin Exp Rheumatol** 1996 Jan–Feb;14 Suppl 14:S45–50 (42 ref.)
B-cell lymphoproliferation in primary Sjögren's syndrome. Tzioufas AG. **Clin Exp Rheumatol** 1996 Jan–Feb;14 Suppl 14:S65–70 (41 ref.)
Selection of ligands for polyclonal antibodies from random peptide libraries: potential identification of (auto)antigens that may trigger B and T cell responses in autoimmune diseases. Sioud M, et al. **Clin Immunol Immunopathol** 1996 May;79(2):105–14 (65 ref.)
B lymphocytes and humoral immune responses in rheumatoid arthritis. De Clerck LS. **Clin Rheumatol** 1995 Sep;14 Suppl 2:14–8 (56 ref.)
B-cell stimulation. Armitage RJ, et al. **Curr Opin Immunol** 1995 Apr;7(2):243–7 (50 ref.)
CD23 and B-cell activation. Bonnefoy JY, et al. **Curr Opin Immunol** 1995 Jun;7(3):355–9 (39 ref.)
The regulation of self-reactive B cells. Cornall RJ, et al. **Curr Opin Immunol** 1995 Dec;7(6):804–11 (52 ref.)
Somatic hypermutation. Neuberger MS, et al. **Curr Opin Immunol** 1995 Apr;7(2):248–54 (69 ref.)
Role of follicular dendritic cells in the regulation of B cell proliferation. Freedman AS, et al. **Curr Top Microbiol Immunol** 1995;201:83–92 (45 ref.)
Regulation of human B cell activation by follicular dendritic cell and T cell signals. Grouard G, et al. **Curr Top Microbiol Immunol** 1995;201:105–17 (55 ref.)
Follicular dendritic cells: antigen retention, B cell activation, and cytokine production. Kosco-Vilbois MH, et al. **Curr Top Microbiol Immunol** 1995;201:69–82 (30 ref.)
T-cell mediated immunosuppression and its implications for the development of protective immunity. Baker PJ, et al. **Folia Biol (Praha)** 1994;40(6):349–58 (50 ref.)
The regulation of expression of histocompatibility antigens on the cell surface; molecular genetic basis. Petrányi GG. **Folia Biol (Praha)** 1995;41(3–4):163–77 (57 ref.)
Aging and immune function: a possible role for growth hormone. Gelato MC. **Horm Res** 1996;45(1–2):46–9 (25 ref.)
The "clonal selection hypothesis" and current concepts of B cell tolerance. Klinman NR. **Immunity** 1996 Sep; 5(3):189–95 (100 ref.)
The one signal theory of B cell activation revisited: a role for surface immunoglobulin in regulating T-independent antibody responses? Mamchak AA, et al. **Immunol Cell Biol** 1995 Jun;73(3):266–71 (29 ref.)
Chronicity of tissue-specific experimental autoimmune disease: a role for B cells? Holmdahl R, et al. **Immunol Rev** 1995 Apr;144:109–35 (164 ref.)
Murine CD38: an immunoregulatory ectoenzyme. Lund F, et al. **Immunol Today** 1995 Oct;16(10):469–73 (46 ref.)
Involvement of B-1 cells in mucosal immunity and autoimmunity. Murakami M, et al. **Immunol Today** 1995 Nov;16(11):534–9 (38 ref.)
BSAP: a key regulator of B-cell development and differentiation. Neurath MF, et al. **Immunol Today** 1995 Dec;16(12):564–9 (22 ref.)
B-cell superantigens: implications for selection of the human antibody repertoire. Zouali M. **Immunol Today** 1995 Aug; 16(8):399–405 (73 ref.)
Aging associated changes in the generation and development of B cell memory. Klinman NR, et al. **Int Rev Immunol** 1995;12(1):5–12 (60 ref.)
Current concepts of B cell modulation. Matsuda T, et al. **Int Rev Immunol** 1989;5(2):97–109 (37 ref.)
HIV-mediated B-lymphocyte activation and lymphomagenesis. Monroe JG, et al. **J Clin Immunol** 1995 Mar;15(2):61–8 (73 ref.)
The role of B cells in the programming of T cells for IL-4 synthesis [see comments] Mason D. **J Exp Med** 1996 Mar 1;183(3):717–9 (15 ref.) Comment in: J Exp Med 1996 Mar 1;183(3):891–9.
Clonal anergy of B cells: a flexible, reversible, and quantitative concept [comment] Nossal GJ. **J Exp Med** 1996 May 1;183(5):1953–6 (27 ref.) Comment on: J Exp Med 1996 May 1;183(5):2313–28.
CD40-mediated signaling in B cells. Balancing cell survival, growth, and death. Kehry MR. **J Immunol** 1996 Apr 1; 156(7):2345–8 (77 ref.)
B cell lineage-specific activator protein (BSAP). A player at multiple stages of B cell development. Michaelson JS, et al. **J Immunol** 1996 Apr 1;156(7):2349–51 (50 ref.)
Tolerance sensitivity of immature-stage B cells: can developmentally regulated B cell antigen receptor (BCR) signal transduction play a role? Monroe JG. **J Immunol** 1996 Apr 15;156(8):2657–60 (38 ref.)
T cells commit suicide, but B cells are murdered! Scott DW, et al. **J Immunol** 1996 Apr 1;156(7):2352–6 (42 ref.)
The role of early growth response gene 1 (egr-1) in regulation of the immune response. McMahon SB, et al. **J Leukoc Biol** 1996 Aug;60(2):159–66 (101 ref.)
CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy. Scheuermann RH, et al. **Leuk Lymphoma** 1995 Aug;18(5–6):385–97 (94 ref.)
Pharmacological intervention in antibody mediated disease. Coutts SM, et al. **Lupus** 1996 Apr;5(2):158–9 (13 ref.)
Clonal selection and learning in the antibody system. Rajewsky K. **Nature** 1996 Jun 27;381(6585):751–8 (182 ref.)
Fc gamma RII-mediated regulation of human B cells. Gergely J, et al. **Scand J Immunol** 1996 Jul;44(1):1–10 (70 ref.)
Immunological memory and protective immunity: understanding their relation. Ahmed R, et al. **Science** 1996 Apr 5;272(5258):54–60 (75 ref.)
Lymphocyte homing and homeostasis. Butcher EC, et al. **Science** 1996 Apr 5;272(5258):60–6 (57 ref.)
Receptor tails unlock developmental checkpoints for B lymphocytes [comment] Roth PE, et al. **Science** 1996 Jun 21;272(5269):1752–4 (7 ref.) Comment on: Science 1996 Jun 21;272(5269):1804–8.
Immunology taught by viruses [see comments] Zinkernagel RM. **Science** 1996 Jan 12;271(5246):173–8 (51 ref.) Comment in: Science 1996 May 3;272(5262):634–5.
In-vitro models of B-lineage commitment. Kee BL, et al. **Semin Immunol** 1995 Jun;7(3):143–54 (115 ref.)
Lymphohematopoietic development from embryonic stem cells in vitro. Nakano T. **Semin Immunol** 1995 Jun; 7(3):197–203 (26 ref.)
T cells and B cells in chronic renal failure. Descamps-Latscha B, et al. **Semin Nephrol** 1996 May; 16(3):183–91 (83 ref.)
Relationships between B cell cytokine production in secondary lymphoid follicles and apoptosis of germinal center B lymphocytes. Pistoia V, et al. **Stem Cells (Dayt)** 1995 Sep;13(5):487–500 (105 ref.)
Transcription factors of T and B lymphocytes--basic research and clinical perspectives for gastroenterology. Neurath MF, et al. **Z Gastroenterol** 1996 Feb;34(2):138–50 (138 ref.)
[B-cell function and autoimmunity in humans] Zouali M. **Arch Inst Pasteur Tunis** 1994 Jul–Oct;71(3–4):511–6 (27 ref.) **(Fre)**
[Activation of the immune system in periapical infection. 1. Lympho-monocytoid and plasma cellular elements of reactive soft tissue cells] Milia E, et al. **Minerva Stomatol** 1996 Jan–Feb;45(1–2):37–48 (47 ref.) (Eng. Abstr.) **(Ita)**
[Lymphocytes and renal damage] Amoroso A, et al. **Minerva Urol Nefrol** 1996 Jun;48(2):109–15 (36 ref.) **(Ita)**
[Linear B cell epitopes located on core and NS3 regions of HCV] Ueda S. **Nippon Rinsho** 1995 Sep;53 Suppl:123–8

(21 ref.) **(Jpn)**
[Transgenic mice for analysis of neoplasm transformation processes of T and B lymphocytes] Kobzdej M, et al. **Postepy Hig Med Dosw** 1996;50(2):113-29 (61 ref.) (Eng. Abstr.) **(Pol)**

METABOLISM

DNA methylation: a potential pathway to abnormal autoreactive lupus B cells. Huck S, et al. **Clin Immunol Immunopathol** 1996 Jul;80(1):1-8 (85 ref.)
Antigen receptor 'capacity' and the sensitivity of self-tolerance. Nemazee D. **Immunol Today** 1996 Jan; 17(1):25-9 (28 ref.)
The B-cell antigen receptor complex and co-receptors. Reth M. **Immunol Today** 1995 Jul;16(7):310-3 (9 ref.)
B cell lineage-specific activator protein (BSAP). A player at multiple stages of B cell development. Michaelson JS, et al. **J Immunol** 1996 Apr 1;156(7):2349-51 (50 ref.)
Fc gamma RII-mediated regulation of human B cells. Gergely J, et al. **Scand J Immunol** 1996 Jul;44(1):1-10 (70 ref.)

PATHOLOGY

Is rheumatoid arthritis a failure of B cell death in synovium? Edwards JC, et al. **Ann Rheum Dis** 1995 Sep;54(9):696-700 (37 ref.)
B-cell lymphoproliferative disorder complicated by a natural killer cell lymphoproliferative disorder of granular lymphocytes associated with T-cell gene rearrangement: case report and review of the literature. Dunphy CH, et al. **Mod Pathol** 1995 Oct;8(8):803-10 (30 ref.)

PHYSIOLOGY

Molecular signals for the production of lymphocytes in bone marrow. Kincade PW. **Braz J Med Biol Res** 1994 Nov; 27(11):2533-8 (23 ref.)
Cellular and molecular bases of B-cell clonal expansions. Dolcetti R, et al. **Clin Exp Rheumatol** 1996 Jan-Feb;14 Suppl 14:S3-13 (101 ref.)
Helicobacter pylori, gastric MALT and B-cell clonality. Sorrentino D, et al. **Clin Exp Rheumatol** 1996 Jan-Feb;14 Suppl 14:S51-4 (25 ref.)
The role of BSAP (Pax-5) in B-cell development. Busslinger M, et al. **Curr Opin Genet Dev** 1995 Oct;5(5):595-601 (53 ref.)
Molecular principles of Oct2-mediated gene activation in B cells. Wirth T, et al. **Immunobiology** 1995 Jul; 193(2-4):161-70 (45 ref.)
B-cell neoplasia in a developmental framework. Klein G. **Int J Dev Biol** 1995 Oct;39(5):713-8 (33 ref.)
Functional significance of IL-4 receptor on B cells in IL-4-induced human IgE production. Yanagihara Y, et al. **J Allergy Clin Immunol** 1995 Dec;96(6 Pt 2):1145-51 (39 ref.)
Emerging concepts regarding B cells and autoantibodies in murine lupus nephritis. B cells have multiple roles; all autoantibodies are not equal [editorial] Madaio MP, et al. **J Am Soc Nephrol** 1996 Mar;7(3):387-96 (104 ref.)
Induction of genes during apoptosis: examples from the immune system. Osborne BA. **Semin Cancer Biol** 1995 Feb; 6(1):27-33 (61 ref.)
Relationships between B cell cytokine production in secondary lymphoid follicles and apoptosis of germinal center B lymphocytes. Pistoia V, et al. **Stem Cells (Dayt)** 1995 Sep;13(5):487-500 (105 ref.)

VIROLOGY

Epstein-Barr virus and the B cell: that's all it takes. Thorley-Lawson DA, et al. **Trends Microbiol** 1996 May; 4(5):204-8 (27 ref.)

T-LYMPHOCYTES

see related
IMMUNITY, CELLULAR
LYMPHOCYTE COOPERATION

Lymphopoiesis, apoptosis, and immune amnesia. Donnenberg AD, et al. **Ann N Y Acad Sci** 1995 Dec 29;770:213-26 (33 ref.)
Cytokines, chemokines, T cells and allergy [editorial] Frew AJ. **Clin Exp Allergy** 1996 Jan;26(1):2-4 (29 ref.)
T-cell activation, anergy and immunomodulation by molecules of viral, fungal and vegetal origin. Bemer V, et al. **Res Immunol** 1995 May-Jun;146(4-5):249-62 (81 ref.)
Intestinal T lymphocytes. Robijn RJ, et al. **Scand J Gastroenterol Suppl** 1995;212:23-33 (120 ref.)
T-lymphopoietic capacity of the mouse intestinal epithelium. Klein JR. **Semin Immunol** 1995 Oct;7(5):291-7 (38 ref.)
T-cell development and selection in the intestinal epithelium. Poussier P, et al. **Semin Immunol** 1995 Oct;7(5):321-34 (38 ref.)
Cells and cytokines in the pathogenesis of MAIDS, a retrovirus-induced immunodeficiency syndrome of mice. Morse HC 3rd, et al. **Springer Semin Immunopathol** 1995; 17(2-3):231-45 (66 ref.)
[Future of malignant stage I melanoma. Immunology and immunotherapy] Nicolas JF, et al. **Ann Dermatol Venereol** 1995;122(5):324-35 (105 ref.) **(Fre)**
[Gamma delta T cells--gene to biology] Itohara S. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2118-25 (31 ref.) **(Jpn)**

CHEMISTRY

Single T cell probes for antigen/MHC expression. Shastri N. **Curr Opin Immunol** 1995 Apr;7(2):258-62 (33 ref.)

CYTOLOGY

Receptors that regulate T-cell susceptibility to apoptotic cell death. Boise LH, et al. **Ann N Y Acad Sci** 1995 Sep 7; 766:70-80 (32 ref.)
T cell differentiation: control by the pre-TCR and alpha beta TCR. von Boehmer H. **Clin Immunol Immunopathol** 1995 Sep;76(3 Pt 2):S145-50 (47 ref.)
Extrathymic T cell differentiation. Rocha B, et al. **Curr Opin Immunol** 1995 Apr;7(2):235-42 (55 ref.)
Immunoregulation mediated by T-cell clusters. Brunner MC, et al. **Folia Biol (Praha)** 1994;40(6):359-69 (21 ref.)
Changes in the intestinal lymphoid compartment throughout life: implications for the local generation of intestinal T cells. Rozing J, et al. **Int Rev Immunol** 1995;12(1):13-25 (45 ref.)
T cells commit suicide, but B cells are murdered! Scott DW, et al. **J Immunol** 1996 Apr 1;156(7):2352-6 (42 ref.)
Recognition of nonpeptide antigens by T cells. Tanaka Y, et al. **J Mol Med** 1996 May;74(5):223-31 (63 ref.)
The role of intracellular signalling pathways regulating thymocyte and leukemic T cell apoptosis. Conroy LA, et al. **Leukemia** 1996 Sep;10(9):1422-35 (205 ref.)
The role of the thymus during T-lymphocyte development in vitro. Anderson G, et al. **Semin Immunol** 1995 Jun; 7(3):177-83 (49 ref.)
In-vitro models of stroma-dependent lymphopoiesis. Péault B. **Semin Immunol** 1995 Jun;7(3):169-75 (76 ref.)
[Regulation of T cell development by T cell receptor complex--analysis by TCR-CD3 chains-deficient mice] Saito T, et al. **Tanpakushitsu Kakusan Koso** 1995 Oct; 40(14):2097-106 (18 ref.) **(Jpn)**

DRUG EFFECTS

A perspective on anti-cytokine and anti-T cell-directed therapies in rheumatoid arthritis. Maini RN. **Clin Exp Rheumatol** 1995 Sep-Oct;13 Suppl 12:S35-40 (40 ref.)
Autocrine feedback death and the regulation of mature T lymphocyte antigen responses. Lenardo MJ, et al. **Int Rev Immunol** 1995;13(2):115-34 (76 ref.)
T-cell responses in photoimmune therapy. Heald PW, et al. **J Clin Apheresis** 1995;10(3):144-9 (26 ref.)
Beta chemokines costimulate lymphocyte cytolysis, proliferation, and lymphokine production. Taub DD, et al. **J Leukoc Biol** 1996 Jan;59(1):81-9 (33 ref.)
Mechanism of action of the immunosuppressant rapamycin. Dumont FJ, et al. **Life Sci** 1996;58(5):373-95 (196 ref.)
Targeting T cells for GVHD therapy. Vallera DA. **Semin Cancer Biol** 1996 Apr;7(2):57-64 (57 ref.)
Mode of action of tacrolimus (FK506): molecular and cellular mechanisms. Thomson AW, et al. **Ther Drug Monit** 1995 Dec;17(6):584-91 (79 ref.)

ENZYMOLOGY

Molecular mechanism of T-cell activation: role of protein tyrosine kinases in antigen receptor-mediated signal transduction. Thome M, et al. **Res Immunol** 1995 May-Jun; 146(4-5):291-307 (104 ref.)
Analysis of mutation at the hprt locus in human T lymphocytes. Lambert B, et al. **Toxicol Lett** 1995 Dec; 82-83:323-33 (54 ref.)

IMMUNOLOGY

T cells, graft-versus-host disease and graft-versus-leukemia: innovative approaches for blood and marrow transplantation. Champlin R, et al. **Acta Haematol** 1996; 95(3-4):157-63 (67 ref.)
Development and evolutionary aspects of thymic T cell education to neuroendocrine self. Geenen V, et al. **Acta Haematol** 1996;95(3-4):263-7 (27 ref.)
Rosettes of Langerhans cells and activated T cells in human skin lymph derived from irritant contact dermatitis. Brand CU, et al. **Adv Exp Med Biol** 1995;378:527-9 (17 ref.)
Dendritic cells "in vivo": their role in the initiation of intestinal immune responses. Liu L, et al. **Adv Exp Med Biol** 1995;371A:271-4 (5 ref.)
Glycosylation and maturation rate of membrane and secretory forms of human CD8 alpha glycoprotein. Implications in the activation of T-lymphocytes. Serafini-Cessi F, et al. **Adv Exp Med Biol** 1995;376:135-45 (33 ref.)
Immunosuppression by a noncytolytic virus via T cell mediated immunopathology. Implication for AIDS. Zinkernagel RM. **Adv Exp Med Biol** 1995;374:165-71 (78 ref.)
Suppression of experimental glomerulonephritis by interference with T- or B-cell activation signals or adhesion molecules. Andres G, et al. **Adv Nephrol Necker Hosp** 1995;24:91-105 (51 ref.)
Advances in selective immunosuppression. Adorini L, et al. **Adv Pharmacol** 1995;33:255-85 (146 ref.)
Receptors that regulate T-cell susceptibility to apoptotic cell death. Boise LH, et al. **Ann N Y Acad Sci** 1995 Sep 7; 766:70-80 (32 ref.)
T-cell recognition of antigen. A process controlled by transient intermolecular interactions. Boniface JJ, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:62-9 (34 ref.)
Dose-dependent activation and deletion of antigen-specific T cells following oral tolerance. Chen YH, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:111-21 (60 ref.)
Effects of oral antigen in T-cell receptor transgenic mice. Hurst SD, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:163-73 (20 ref.)
Studying immunological tolerance by physically monitoring antigen-specific T cells in vivo. Khoruts A, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:72-9 (43 ref.)
Molecular mechanisms securing "unresponsiveness" in lamina propria T lymphocytes. Meuer SC, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:174-84 (24 ref.)
Signal transduction mediated by the T-cell antigen receptor. Samelson LE, et al. **Ann N Y Acad Sci** 1995 Sep 7; 766:157-72 (68 ref.)
Mechanisms of oral tolerance by MHC peptides. Sayegh MH, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:338-45 (30 ref.)
Cell growth signal transduction is quantal. Smith KA. **Ann N Y Acad Sci** 1995 Sep 7;766:263-71 (27 ref.)
Control of T-cell development by the pre-T and alpha beta T-cell receptor. Von Boehmer H. **Ann N Y Acad Sci** 1995 Sep 7;766:52-61 (47 ref.)
Molecular and genetic insights into T-cell antigen receptor signaling. Weiss A, et al. **Ann N Y Acad Sci** 1995 Sep 7; 766:149-56 (39 ref.)
The kinase-dependent function of Lck in T-cell activation requires an intact site for tyrosine autophosphorylation. Xu H, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:99-116 (46 ref.)
How MHC class II molecules acquire peptide cargo: biosynthesis and trafficking through the endocytic pathway. Wolf PR, et al. **Ann Rev Cell Dev Biol** 1995; 11:267-306 (169 ref.)
T-cell recognition of beta-cell autoantigens in insulin-dependent diabetes mellitus. Kallan AA, et al. **APMIS** 1996 Jan;104(1):3-11 (84 ref.)
Characterization of immunological memory cells. A minireview. Vongsakul M. **Asian Pac J Allergy Immunol** 1995 Jun;13(1):75-9 (47 ref.)
The gluten-host interaction. Tighe MR, et al. **Baillieres Clin Gastroenterol** 1995 Jun;9(2):211-30 (42 ref.)
Converging and diverging properties of human interleukin-4 and interleukin-10. Banchereau J. **Behring Inst Mitt** 1995 Jun;(96):58-77 (119 ref.)
Molecular mechanisms of APO-1/Fas(CD95)-mediated apoptosis in tolerance and AIDS. Dhein J, et al. **Behring Inst Mitt** 1995 Jun;(96):13-20 (37 ref.)
A molecular basis for T-dependent B cell activation. Lane P. **Behring Inst Mitt** 1995 Jun;(96):7-12 (46 ref.)
Therapeutic interference with interferon-gamma (IFN-gamma) and soluble IL-4 receptor (sIL-4R) in allergic diseases. Nasert S, et al. **Behring Inst Mitt** 1995 Jun;(96):118-30 (55 ref.)
Phosphoinositide 3-kinase and CD28-mediated T-cell co-stimulation. Ward SG. **Biochem Soc Trans** 1996 Feb; 24(1):240-5 (50 ref.)
Gamete and immune cell recognition revisited. Belton RJ Jr, et al. **Bioessays** 1995 Dec;17(12):1075-80 (61 ref.)
The role of T-lymphocytes in rheumatoid arthritis. Salmon M, et al. **Br Med Bull** 1995 Apr;51(2):332-45 (51 ref.)
Apoptosis as a cause of T-cell unresponsiveness in experimental Chagas' disease. Lopes MF, et al. **Braz J Med Biol Res** 1995 Aug;28(8):913-8 (35 ref.)
Cell surface antigens in leukemias and lymphomas. Freedman AS. **Cancer Invest** 1996;14(3):252-76 (354 ref.)
Die and let live: eliminating dangerous lymphocytes. Abbas AK. **Cell** 1996 Mar 8;84(5):655-7 (15 ref.)
T cells and cytokines in intracellular bacterial infections: experiences with Mycobacterium bovis BCG. Kaufmann SH, et al. **Ciba Found Symp** 1995;195:123-32; discussion 132-6 (33 ref.)
Extracellular matrix proteins, regulators of T-cell functions in healthy and diseased individuals. Gorski A, et al. **Clin Diagn Lab Immunol** 1995 Nov;2(6):646-51 (69 ref.)
Are polysaccharide antibody responses independent: the T cell enigma? Lane P. **Clin Exp Immunol** 1996 Jul; 105(1):10-1 (16 ref.)
The role of molecular analyses of B-cell and T-cell clonality in the study of B-cell lymphomagenesis. De Vita S, et al. **Clin Exp Rheumatol** 1996 Jan-Feb;14 Suppl 14:S21-9 (51 ref.)
Monitoring clonal expansion in the laboratory. Sala P, et al. **Clin Exp Rheumatol** 1996 Jan-Feb;14 Suppl 14:S31-5 (44 ref.)
T cell activation deficiencies. Le Deist F, et al. **Clin Immunol Immunopathol** 1995 Sep;76(3 Pt 2):S163-4 (20 ref.)
Adhesion molecules as targets for the treatment of autoimmune diseases. Oppenheimer-Marks N, et al. **Clin Immunol Immunopathol** 1996 Jun;79(3):203-10 (58 ref.)
Selection of ligands for polyclonal antibodies from random peptide libraries: potential identification of (auto)antigens that may trigger B and T cell responses in autoimmune diseases. Sioud M, et al. **Clin Immunol Immunopathol** 1996 May;79(2):105-14 (65 ref.)
T cell differentiation: control by the pre-TCR and alpha beta TCR. von Boehmer H. **Clin Immunol Immunopathol** 1995 Sep;76(3 Pt 2):S145-50 (47 ref.)

The immune response: the afferent arm. Czitrom AA. **Clin Orthop** 1996 May;(326):11–24 (115 ref.)
The immune response: the efferent arm. Horowitz MC, et al. **Clin Orthop** 1996 May;(326):25–34 (45 ref.)
Costimulation and its role in organ transplantation. Bluestone JA. **Clin Transplant** 1996 Feb;10(1 Pt 2):104–9 (23 ref.)
T-lymphocyte interactions with endothelium and extracellular matrix. Hunt SW 3rd, et al. **Crit Rev Oral Biol Med** 1996;7(1):59–86 (199 ref.)
Gamma delta T cells. T cells with B-cell-like recognition properties. Chien YH, et al. **Curr Biol** 1995 Oct 1; 5(10):1116–8 (11 ref.)
T-cell activation. Two for T. Guerder S, et al. **Curr Biol** 1995 Aug 1;5(8):866–8 (22 ref.)
Manipulation of costimulatory signals to enhance antitumor T-cell responses. Allison JP, et al. **Curr Opin Immunol** 1995 Oct;7(5):682–6 (34 ref.)
T-cell regulation of macrophage function. Doherty TM. **Curr Opin Immunol** 1995 Jun;7(3):400–4 (43 ref.)
Molecular mechanisms underlying functional T-cell unresponsiveness. Mueller DL, et al. **Curr Opin Immunol** 1995 Jun;7(3):375–81 (54 ref.)
Activation-induced death of mature T cells in the regulation of immune responses. Russell JH. **Curr Opin Immunol** 1995 Jun;7(3):382–8 (43 ref.)
Intrathymic and extrathymic clonal deletion of T cells. Sprent J, et al. **Curr Opin Immunol** 1995 Apr;7(2):196–205 (118 ref.)
New tumor antigens recognized by T cells. Van den Eynde B, et al. **Curr Opin Immunol** 1995 Oct;7(5):674–81 (71 ref.)
Transplantation immunology. Ball ST, et al. **Curr Opin Nephrol Hypertens** 1995 Nov;4(6):465–71 (72 ref.)
The role of T-cells in inflammatory kidney disease. Main IW, et al. **Curr Opin Nephrol Hypertens** 1995 Jul;4(4):354–8 (41 ref.)
T cell-mediated immune mechanisms in myositis. O'Hanlon TP, et al. **Curr Opin Rheumatol** 1995 Nov;7(6):503–9 (51 ref.)
Regulation of human B cell activation by follicular dendritic cell and T cell signals. Grouard G, et al. **Curr Top Microbiol Immunol** 1995;201:105–17 (55 ref.)
The CD4 molecule. Roles in T lymphocytes and in HIV disease. Introduction. Littman DR. **Curr Top Microbiol Immunol** 1996;205:v–x (13 ref.)
T-cell responses to autoantigens in IDDM. The search for the Holy Grail. Roep BO. **Diabetes** 1996 Sep;45(9):1147–56 (123 ref.)
The central rôle of T-cells in allergic sensitization and IgE regulation. Renz H. **Exp Dermatol** 1995 Aug;4(4 Pt 1):173–82 (91 ref.)
Dendritic cells and immune-based therapies. Steinman RM. **Exp Hematol** 1996 Jul;24(8):859–62 (16 ref.)
Immunoregulation mediated by T-cell clusters. Brunner MC, et al. **Folia Biol (Praha)** 1994;40(6):359–69 (21 ref.)
Biological meaning of the MHC. Ivanyi P. **Folia Biol (Praha)** 1995;41(3–4):178–89 (25 ref.)
The regulation of expression of histocompatibility antigens on the cell surface; molecular genetic basis. Petrányi GG. **Folia Biol (Praha)** 1995;41(3–4):163–77 (57 ref.)
Lymphocyte-endothelial cell interactions in hepatic inflammation. Adams DH. **Hepatogastroenterology** 1996 Jan-Feb;43(7):32–43 (82 ref.)
Principles of MHC class I-mediated antigen presentation and T cell selection. Ljunggren HG, et al. **Histol Histopathol** 1996 Jan;11(1):267–74 (39 ref.)
Aging and immune function: a possible role for growth hormone. Gelato MC. **Horm Res** 1996;45(1–2):46–9 (25 ref.)
The impact of gene therapy on T cell function in cancer. Zier KS, et al. **Hum Gene Ther** 1995 Oct;6(10):1259–64 (45 ref.)
Upstream-downstream: CD28 cosignaling pathways and T cell function. Rudd CE. **Immunity** 1996 Jun;4(6):527–34 (71 ref.)
Extrathymic and thymic origin of murine IEL: are most IEL in euthymic mice derived from the thymus? Lin T, et al. **Immunol Cell Biol** 1995 Oct;73(5):469–73 (25 ref.)
The vitronectin receptor (alpha V beta 3) as an example for the role of integrins in T lymphocyte stimulation. Halvorson MJ, et al. **Immunol Res** 1996;15(1):16–29 (94 ref.)
B7-mediated costimulation can either provoke or prevent clinical manifestations of experimental allergic encephalomyelitis. Perrin PJ, et al. **Immunol Res** 1995; 14(3):189–99 (47 ref.)
Immunopathogenesis of juvenile rheumatoid arthritis: role of T cells and MHC. Sakkas LI, et al. **Immunol Res** 1995; 14(3):218–36 (179 ref.)
The enigmatic specificity of gamma delta T cells. Weintraub BC, et al. **Immunol Res** 1995;14(3):163–75 (92 ref.)
Therapeutic regulation of T cells in rheumatoid arthritis. Breedveld FC, et al. **Immunol Rev** 1995 Apr;144:5–16 (48 ref.)
Can co-stimulated tumor immunity be therapeutically efficacious? Hellström KE, et al. **Immunol Rev** 1995 Jun; 145:123–45 (110 ref.)
Evolution of the T-cell repertoire during the course of experimental immune-mediated demyelinating diseases. Miller SD, et al. **Immunol Rev** 1995 Apr;144:225–44 (66 ref.)
Critical influences of the cytokine orchestration on the outcome of myelin antigen-specific T-cell autoimmunity in experimental autoimmune encephalomyelitis and multiple sclerosis. Olsson T. **Immunol Rev** 1995 Apr; 144:245–68 (169 ref.)
Interplay of T cells and cytokines in the context of enzymatically modified extracellular matrix. Gilat D, et al. **Immunol Today** 1996 Jan;17(1):16–20 (40 ref.)
Costimulation and the regulation of antimicrobial immunity. Kaye PM. **Immunol Today** 1995 Sep;16(9):423–7 (45 ref.)
Advances in intestinal T-cell development and function. Klein JR. **Immunol Today** 1995 Jul;16(7):322–4 (11 ref.)
T-cell activation: integration of signals from the antigen receptor and costimulatory molecules. Robey E, et al. **Immunol Today** 1995 Jul;16(7):306–10 (29 ref.)
Preventing abnormalities in signal transduction of T cells in cancer: the promise of cytokine gene therapy. Zier K, et al. **Immunol Today** 1996 Jan;17(1):39–45 (62 ref.)
Immunoregulatory mechanisms of T-cell-dependent shock induced by a bacterial superantigen in mice. Florquin S, et al. **Infect Immun** 1996 Sep;64(9):3443–5 (31 ref.)
The immunopathology of psoriasis. Christophers E. **Int Arch Allergy Immunol** 1996 Jul;110(3):199–206 (81 ref.)
Composition of TCR-CD3 complex in human intestinal intraepithelial lymphocytes: lack of Fc epsilon RI gamma chain. Balk SP, et al. **Int Immunol** 1995 Aug;7(8):1237–41 (40 ref.)
The treatment of zinc deficiency is an immunotherapy [editorial] Hadden JW. **Int J Immunopharmacol** 1995 Sep; 17(9):697–701 (37 ref.)
T cell development in CD3-zeta mutant mice. Huang MT. **Int Rev Immunol** 1995;13(1):29–41 (81 ref.)
Autoantigen-induced deletion of peripheral self-reactive T cells. Miller JF. **Int Rev Immunol** 1995;13(2):107–14 (47 ref.)
Lymphocyte development and function in T-cell receptor and RAG-1 mutant mice. Mombaerts P. **Int Rev Immunol** 1995;13(1):43–63 (23 ref.)
Central tolerance of T cells. Sprent J. **Int Rev Immunol** 1995; 13(2):95–105 (85 ref.)
Class I MHC presentation of exogenous antigens. Harding CV. **J Clin Immunol** 1996 Mar;16(2):90–6 (50 ref.)
Human tumor antigens recognized by T lymphocytes. Boon T, et al. **J Exp Med** 1996 Mar 1;183(3):725–9 (60 ref.)
Fas and the art of lymphocyte maintenance [comment] Lenardo MJ. **J Exp Med** 1996 Mar 1;183(3):721–4 (31 ref.) Comment on: J Exp Med 1996 Mar 1;183(3):1071–82.
The role of B cells in the programming of T cells for IL-4 synthesis [see comments] Mason D. **J Exp Med** 1996 Mar 1;183(3):717–9 (15 ref.) Comment in: J Exp Med 1996 Mar 1;183(3):891–9.
Chemoattractants attract HIV researchers [comment] Moore JP, et al. **J Exp Med** 1996 Aug 1;184(2):311–3 (35 ref.) Comment on: J Exp Med 1996 Aug 1;184(2):569–77.
Models of T cell anergy: is there a common molecular mechanism? [comment] Schwartz RH. **J Exp Med** 1996 Jul 1;184(1):1–8 (69 ref.) Comment on: J Exp Med 1996 Jul 1;184(1):19–29.
CD1 and the expanding universe of T cell antigens. Porcelli SA, et al. **J Immunol** 1995 Oct 15;155(8):3709–10 (18 ref.)
Anergy as a mechanism of peripheral T cell tolerance. Quill H. **J Immunol** 1996 Feb 15;156(4):1325–7 (36 ref.)
T cells commit suicide, but B cells are murdered! Scott DW, et al. **J Immunol** 1996 Apr 1;156(7):2352–6 (42 ref.)
Gaining insights into the ontogeny and activation of T cells through the use of gene-targeted mutant mice. Mak TW. **J Inflamm** 1995;45(2):79–84 (22 ref.)
Soluble extracellular antigen-specific T cell immunoproteins. Cone RE. **J Leukoc Biol** 1996 May;59(5):605–12 (65 ref.)
The role of early growth response gene 1 (egr-1) in regulation of the immune response. McMahon SB, et al. **J Leukoc Biol** 1996 Aug;60(2):159–66 (101 ref.)
Cryptocrine signaling in the thymus network and T cell education to neuroendocrine self-antigens. Geenen V, et al. **J Mol Med** 1995 Sep;73(9):449–55 (49 ref.)
IL-2 gene therapy of solid tumors: an approach for the prevention of signal transduction defects in T cells. Zier KS, et al. **J Mol Med** 1996 Mar;74(3):127–34 (78 ref.)
Human melanoma antigens recognized by T lymphocytes. Kawakami Y, et al. **Keio J Med** 1996 Jun;45(2):100–8 (78 ref.)
TCR delta gene rearrangements in acute myeloid leukemia with T-lymphoid antigen expression. Schmidt CA, et al. **Leuk Lymphoma** 1995 Dec;20(1–2):45–9 (57 ref.)
The macrophage-T-lymphocyte theory of schizophrenia: additional evidence. Smith RS, et al. **Med Hypotheses** 1995 Aug;45(2):135–41 (84 ref.)
New treatment options for patients with melanoma: review of melanoma-derived T-cell epitope-based peptide vaccines. Maeurer MJ, et al. **Melanoma Res** 1996 Feb; 6(1):11–24 (102 ref.)
A role for T cells in the pathogenesis of treatment-resistant Lyme arthritis. Kamradt T, et al. **Mol Med** 1995 Jul; 1(5):486–90 (35 ref.)
Extrathymic T cells stand at an intermediate phylogenetic position between natural killer cells and thymus-derived T cells. Abo T, et al. **Nat Immun** 1995 Apr;14(4):173–87 (59 ref.)
Essential flexibility in the T-cell recognition of antigen. Kersh GJ, et al. **Nature** 1996 Apr 11;380(6574):495–8 (69 ref.)
How T cells recognize alloantigen: evidence for two pathways of allorecognition. Watschinger B. **Nephrol Dial Transplant** 1995;10(9):1556–8 (29 ref.)
Heat shock proteins and the immunopathogenesis of multiple sclerosis. Linington C. **Neuropathol Appl Neurobiol** 1995 Dec;21(6):483–6 (31 ref.)
T cell and cytokine basis of host variability in response to intestinal nematode infections. Grencis RK. **Parasitology** 1996;112 Suppl:S31–7 (45 ref.)
The anatomy of T-cell activation and tolerance. Mondino A, et al. **Proc Natl Acad Sci U S A** 1996 Mar 19; 93(6):2245–52 (113 ref.)
A hypothesis to explain the immune defects in Down syndrome. Murphy M, et al. **Prog Clin Biol Res** 1995; 393:147–67 (48 ref.)
The critical role of CD28 signalling in the prevention of human T-cell anergy. Boussiotis VA, et al. **Res Immunol** 1995 Mar-Apr;146(3):140–9 (72 ref.)
The role of CD28 in the activation of T lymphocytes to proliferate in response to IL4. Chiodetti L, et al. **Res Immunol** 1995 Mar-Apr;146(3):169–71 (23 ref.)
Regulation of IL2 gene transcription via the T-cell accessory molecule CD28. Civil A, et al. **Res Immunol** 1995 Mar-Apr; 146(3):158–64 (19 ref.)
Thoughtful cruises in oceans of peptides and T cells. Kourilsky P. **Res Immunol** 1995 May-Jun;146(4–5):309–20 (33 ref.)
Lymphocyte costimulation: multiple pathways, multiple functions? Kuiper HM, et al. **Res Immunol** 1995 Mar-Apr; 146(3):180–3 (41 ref.)
CD28/CTLA-4 receptor structure, binding stoichiometry and aggregation during T-cell activation. Linsley PS, et al. **Res Immunol** 1995 Mar-Apr;146(3):130–40 (78 ref.)
T-cell costimulation via CD28-CD80/CD86 and CD40-CD40 ligand interactions. Somoza C, et al. **Res Immunol** 1995 Mar-Apr;146(3):171–6 (50 ref.)
Immunological memory and protective immunity: understanding their relation. Ahmed R, et al. **Science** 1996 Apr 5;272(5258):54–60 (75 ref.)
The Yin and Yang of T cell costimulation [see comments] Allison JP, et al. **Science** 1995 Nov 10;270(5238):932–3 (17 ref.) Comment in: Science 1995 Nov 10;270(5238):985–8.
Lymphocyte homing and homeostasis. Butcher EC, et al. **Science** 1996 Apr 5;272(5258):60–6 (57 ref.)
Toward an understanding of the correlates of protective immunity to HIV infection [see comments] Haynes BF, et al. **Science** 1996 Jan 19;271(5247):324–8 (73 ref.) Comment in: Science 1996 Feb 23;371(5252):1043. Comment in: Science 1996 May 31;272(5266):1362. Comment in: Science 1996 Jul 26;273(5274):415–6.
The aging immune system: primer and prospectus. Miller RA. **Science** 1996 Jul 5;273(5271):70–4 (77 ref.)
How T cells count [comment] Rothenberg EV. **Science** 1996 Jul 5;273(5271):78–9 (14 ref.) Comment on: Science 1996 Jul 5;273(5271):104–6.
Immunology taught by viruses [see comments] Zinkernagel RM. **Science** 1996 Jan 12;271(5246):173–8 (51 ref.) Comment in: Science 1996 May 3;272(5262):634–5.
The germinal center: a crucible for lymphocyte selection. Kelsoe G. **Semin Immunol** 1996 Jun;8(3):179–84 (52 ref.)
T cells and B cells in chronic renal failure. Descamps-Latscha B, et al. **Semin Nephrol** 1996 May; 16(3):183–91 (83 ref.)
Microbial parasites versus developing T cells: an evolutionary 'arms race' with implications for the timing of thymic involution and HIV pathogenesis. Turke PW. **Thymus** 1994–95;24(1):29–40 (52 ref.)
T cell immune responses to haptens. Structural models for allergic and autoimmune reactions. Weltzien HU, et al. **Toxicology** 1996 Feb 22;107(2):141–51 (54 ref.)
Comparative study of the role of professional versus semiprofessional or nonprofessional antigen presenting cells in the rejection of vascularized organ allografts. Sundstrom JB, et al. **Transpl Immunol** 1995 Dec;3(4):273–89 (147 ref.)
Review and preview of anti-T-cell antibodies. Helderman JH. **Transplant Proc** 1995 Oct;27(5 Suppl 1):8–9 (7 ref.)
Immunoregulatory and fibrogenic activities of cyclosporine: a unifying hypothesis based on transforming growth factor-beta expression. Khanna A, et al. **Transplant Proc** 1996 Aug;28(4):2015–8 (38 ref.)
Mechanism of action of rapamycin (Sirolimus, Rapamune). Molnar-Kimber KL. **Transplant Proc** 1996 Apr;28(2):964–9 (127 ref.)
An anti-CD2 monoclonal antibody that elicits alloantigen-specific hyporesponsiveness. Schad V, et al. **Transplant Proc** 1996 Aug;28(4):2051–3 (17 ref.)
Transmembrane signaling requirements of T cells: implications for regulation of alloimmunity. Suthanthiran M. **Transplant Proc** 1995 Oct;27(5 Suppl 1):5–7 (25 ref.)
Transcription factors of T and B lymphocytes--basic research and clinical perspectives for gastroenterology. Neurath MF, et al. **Z Gastroenterol** 1996 Feb;34(2):138–50 (138 ref.)
[Superantigens] Palkama T, et al. **Duodecim** 1994; 110(2):202–6 (22 ref.) **(Fin)**
[Clinical and immunobiological observations on the inflammatory activity of sarcoidosis] Müller-Quernheim J. **Pneumologie** 1996 Jan;50(1):40–8 (101 ref.) **(Ger)**
[Hodgkin disease--pathogenesis and therapy] Wolf J, et al. **Ther Umsch** 1996 Feb;53(2):140–6 (24 ref.) (Eng. Abstr.) **(Ger)**
[Activation of the immune system in periapical infection. 1. Lympho-monocytoid and plasma cellular elements of reactive soft tissue cells] Milia E, et al. **Minerva Stomatol** 1996 Jan-Feb;45(1–2):37–48 (47 ref.)

(Eng. Abstr.) **(Ita)**

[Lymphocytes and renal damage] Amoroso A, et al. **Minerva Urol Nefrol** 1996 Jun;48(2):109–15 (36 ref.) **(Ita)**

[The mechanism of induction and expression of protective immunity with special reference to the role of cytokines] Mitsuyama M. **Kekkaku** 1995 Nov;70(11):651–7 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Towards immuno-modulation through the molecular mechanism of lymphocyte activation] Aoe T, et al. **Nippon Rinsho** 1995 Sep;53(9):2331–9 (45 ref.) (Eng. Abstr.) **(Jpn)**

[Analyses of T cell clonality in mice with autoimmune sialoadenitis] Masuko K. **Nippon Rinsho** 1995 Oct; 53(10):2401–6 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Mechanism of hepatocyte destruction through HBV-specific T cell responses] Saibara T, et al. **Nippon Rinsho** 1995 Oct; 53 Suppl:138–43 (20 ref.) **(Jpn)**

[Immunological study of tissue-infiltrating lymphocytes in Sjögren's syndrome: virus specific T cell response] Takeda A, et al. **Nippon Rinsho** 1995 Oct;53(10):2484–9 (22 ref.) (Eng. Abstr.) **(Jpn)**

[The molecular mechanism of costimulatory signal for T cell activation] Uede T. **Nippon Rinsho** 1995 Oct; 53(10):2597–603 (25 ref.) (Eng. Abstr.) **(Jpn)**

[T cell activation] Takase K, et al. **Ryumachi** 1995 Oct; 35(5):853–61 (38 ref.) **(Jpn)**

[Transgenic mice for analysis of neoplasm transformation processes of T and B lymphocytes] Kobzdej M, et al. **Postepy Hig Med Dosw** 1996;50(2):113–29 (61 ref.) (Eng. Abstr.) **(Pol)**

[Use of anti-H-Y/Db transgenic mice in studies on T-lymphocyte development and mechanisms of leukemogenesis] Matuszyk J. **Postepy Hig Med Dosw** 1995; 49(1):61–5 (12 ref.) (Eng. Abstr.) **(Pol)**

[Structure and function of the T-lymphocyte antigen receptor and its role in infectious diseases] Peralta Zaragoza O, et al. **Rev Invest Clin** 1996 Jan–Feb;48(1):69–79 (84 ref.) (Eng. Abstr.) **(Spa)**

METABOLISM

Influence of the anterior chamber of the eye on T-cell production of extracellular antigen-specific proteins. Cone RE, et al. **Adv Exp Med Biol** 1995;383:237–48 (31 ref.)

Lectin-carbohydrate interactions in disease. T-cell recognition of IgA and IgD; mannose binding protein recognition of IgG0. Rudd P, et al. **Adv Exp Med Biol** 1995;376:147–52 (10 ref.)

With platelets, as with T lymphocytes, the blood cell system behaves as a neuron [editorial] Mathé G. **Biomed Pharmacother** 1995;49(10):433–4 (25 ref.)

Cytokine production and requirements during T-cell development. Zlotnik A, et al. **Curr Opin Immunol** 1995 Apr;7(2):206–13 (53 ref.)

The regulation and function of the CD4 coreceptor during T lymphocyte development. Killeen N, et al. **Curr Top Microbiol Immunol** 1996;205:89–106 (82 ref.)

The interplay between lymphoid-specific and ubiquitous transcription factors controls the expression of interleukin 2 gene in T lymphocytes. Avots A, et al. **Immunobiology** 1995 Jul;193(2–4):254–8 (20 ref.)

Calcium signals in T lymphocytes from old mice. Miller RA. **Life Sci** 1996;59(5–6):469–75 (22 ref.)

[Production and role of B cell growth factor (BCGF) in Sjögren's syndrome] Goto Y, et al. **Nippon Rinsho** 1995 Oct;53(10):2418–21 (15 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

T cell apoptosis as a consequence of chronic activation of the immune system in HIV infection. Gougeon ML. **Adv Exp Med Biol** 1995;374:121–7 (46 ref.)

T cell activation deficiencies. Le Deist F, et al. **Clin Immunol Immunopathol** 1995 Sep;76(3 Pt 2):S163–4 (20 ref.)

CD28 and apoptosis. Boise LH, et al. **Curr Opin Immunol** 1995 Oct;7(5):620–5 (49 ref.)

The immunopathology of psoriasis. Christophers E. **Int Arch Allergy Immunol** 1996 Jul;110(3):199–206 (81 ref.)

[Abnormal T-cell differentiation and development of T-cell lymphomas in TL-transgenic mice] Obata Y, et al. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2054–61 (34 ref.) **(Jpn)**

PHYSIOLOGY

Cell cycle-related protein kinases and T cell death. Lahti JM, et al. **Adv Exp Med Biol** 1995;376:247–58 (84 ref.)

Coreceptors and adapter proteins in T-cell signaling. Ravichandran KS, et al. **Ann N Y Acad Sci** 1995 Sep 7; 766:117–33 (91 ref.)

The T cell enigma in lupus. Dayal AK, et al. **Arthritis Rheum** 1996 Jan;39(1):23–33 (92 ref.)

Innovative treatment approaches for rheumatoid arthritis. T-cell regulation. Choy EH, et al. **Baillieres Clin Rheumatol** 1995 Nov;9(4):653–71 (76 ref.)

Redox signalling by transcription factors NF-kappa B and AP-1 in lymphocytes. Schulze-Osthoff K, et al. **Biochem Pharmacol** 1995 Sep 7;50(6):735–41 (69 ref.)

The actions of cyclosporin A and FK506 on T-lymphocyte activation. Mattila PS. **Biochem Soc Trans** 1996 Feb; 24(1):45–9 (40 ref.)

Towards unraveling the complexity of T cell signal transduction. Zenner G, et al. **Bioessays** 1995 Nov; 17(11):967–75 (54 ref.)

The role of T cells in rheumatoid arthritis. De Keyser F, et al. **Clin Rheumatol** 1995 Sep;14 Suppl 2:5–9 (21 ref.)

Superantigen-mediated lethal shock: the functional state of ligand-reactive T cells. Heeg K, et al. **Curr Top Microbiol Immunol** 1996;216:83–100 (95 ref.)

T lymphocyte chemotaxis and skin diseases. Tan J, et al. **Exp Dermatol** 1995 Oct;4(5):281–90 (87 ref.)

Insights on immunological aging derived from the T lymphocyte cellular senescence model. Effros RB. **Exp Gerontol** 1996 Jan–Apr;31(1–2):21–7 (46 ref.)

Knockouts of Src-family kinases: stiff bones, wimpy T cells, and bad memories. Lowell CA, et al. **Genes Dev** 1996 Aug 1;10(15):1845–57 (111 ref.)

Complex complexes: signaling at the TCR. Wange RL, et al. **Immunity** 1996 Sep;5(3):197–205 (82 ref.)

Advances in intestinal T-cell development and function. Klein JR. **Immunol Today** 1995 Jul;16(7):322–4 (11 ref.)

T cell repertoire usage in humans, from newborns to centenarians. Cossarizza A, et al. **Int Rev Immunol** 1995; 12(1):41–55 (71 ref.)

V beta gene repertoire in the aging mouse: a developmental perspective. González-Quintial R, et al. **Int Rev Immunol** 1995;12(1):27–40 (81 ref.)

T cell costimulatory pathways: promising novel targets for immunosuppression and tolerance induction [editorial] Sayegh MH, et al. **J Am Soc Nephrol** 1995 Oct;6(4):1143–50 (49 ref.)

T cells in rheumatoid arthritis. Paradigms and facts. Goronzy JJ, et al. **Rheum Dis Clin North Am** 1995 Aug;21(3):655–74 (102 ref.)

Induction of genes during apoptosis: examples from the immune system. Osborne BA. **Semin Cancer Biol** 1995 Feb; 6(1):27–33 (61 ref.)

The CD28 costimulatory pathway. Leung HT, et al. **Ther Immunol** 1994 Aug;1(4):217–28 (104 ref.)

Thymocyte and T cell apoptosis: is all death created equal? King LB, et al. **Thymus** 1994–95;23(3–4):209–30 (123 ref.)

[Role of antigen specific T-cell in collagen diseases] Yamamoto K. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Feb;18(1):1–13 (40 ref.) **(Jpn)**

[The function and role of extrathymic T cells] Seki S, et al. **Nippon Rinsho** 1995 Nov;53(11):2846–57 (22 ref.) (Eng. Abstr.) **(Jpn)**

[Past, present, and future problems in lymphoid regulation of nonlymphoid cell proliferation] Babaeva AG. **Biull Eksp Biol Med** 1995 Sep;120(9):230–4 (35 ref.) **(Rus)**

RADIATION EFFECTS

Irradiation in the prevention of transfusion associated graft-versus-host disease. Webb DK. **Arch Dis Child** 1995 Nov;73(5):388–9 (38 ref.)

UVB-dependent modulation of epidermal cytokine network: roles in UVB-induced depletion of Langerhans cells and dendritic epidermal T cells. Takashima A. **J Dermatol** 1995 Nov;22(11):876–87 (100 ref.)

VIROLOGY

Dendritic cell-T cell conjugates that migrate from normal human skin are an explosive site of infection for HIV-1. Pope M, et al. **Adv Exp Med Biol** 1995;378:457–60 (36 ref.)

Hemophagocytic syndrome in Epstein-Barr virus-associated T-lymphoproliferative disorders: disease spectrum, pathogenesis, and management. Su IJ, et al. **Leuk Lymphoma** 1995 Nov;19(5–6):401–6 (407 ref.)

T-LYMPHOCYTES, CYTOTOXIC

Clonal expansion of T cells and HIV genotypes in microdissected splenic white pulps indicates viral replication in situ and infiltration of HIV-specific cytotoxic T lymphocytes. Cheynier R, et al. **Adv Exp Med Biol** 1995; 374:173–82 (47 ref.)

CLASSIFICATION

Expression of CD11a and CD45R isoforms defines distinct subsets of CD8+ TCR alpha beta and TCR gamma delta CTL in vivo. Hedlund G, et al. **Immunol Rev** 1995 Aug; 146:82–94 (33 ref.)

ENZYMOLOGY

Granzyme B plays a critical role in cytotoxic lymphocyte-induced apoptosis. Shresta S, et al. **Immunol Rev** 1995 Aug;146:211–21 (32 ref.)

IMMUNOLOGY

Stimulation of human anti-viral CD8+ cytolytic T lymphocytes by dendritic cells. Bhardwaj N, et al. **Adv Exp Med Biol** 1995;378:375–9 (35 ref.)

Dendritic cells as stimulator cells of MHC class I-restricted immune responses. Elbe A, et al. **Adv Exp Med Biol** 1995; 378:341–5 (35 ref.)

Cytotoxic T lymphocytes: the newly identified Fas (CD95)-mediated killing mechanism and a novel aspect of their biological functions. Takayama H, et al. **Adv Immunol** 1995;60:289–321 (180 ref.)

Protective efficacy of intramuscular immunization with naked DNA. Donnelly JJ, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:40–6 (26 ref.)

Retroviral vectors for HIV immunotherapy. Warner JF, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:105–16 (36 ref.)

DNA-mediated immunization to the hepatitis B surface antigen. Activation and entrainment of the immune response. Whalen RG, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:64–76 (31 ref.)

Cytotoxic lymphocyte-mediated immunotherapy. Smyth MJ, et al. **Aust N Z J Med** 1995 Dec;25(6):852–8 (57 ref.)

Target cell apoptosis induced by cytotoxic T cells and natural killer cells involves synergy between the pore-forming protein, perforin, and the serine protease, granzyme B. Trapani JA. **Aust N Z J Med** 1995 Dec;25(6):793–9 (63 ref.)

Human tumour antigens recognized by T-cells: perspectives for new cancer vaccines. Van den Eynde B, et al. **Biochem Soc Trans** 1995 Aug;23(3):681–6 (38 ref.)

Elucidation of T-cell epitopes: a synthetic approach with random peptide libraries. Walden P, et al. **Biochem Soc Trans** 1995 Aug;23(3):678–81 (16 ref.)

Dual mechanisms of lymphocyte-mediated cytotoxicity serve to control and deliver the immune response. Smyth MJ. **Bioessays** 1995 Oct;17(10):891–8 (70 ref.)

Redirection of cellular cytotoxicity. A two-step approach using recombinant single-chain Fv molecules. George AJ, et al. **Cell Biophys** 1995 Jun;26(3):153–65 (39 ref.)

Natural killer cells. Right-side-up and up-side-down NK-cell receptors. Yokoyama WM. **Curr Biol** 1995 Sep 1;5(9):982–5 (33 ref.)

The cell biology of CTL killing. Griffiths GM. **Curr Opin Immunol** 1995 Jun;7(3):343–8 (44 ref.)

Are HIV-specific CTL responses salutary or pathogenic? Zinkernagel RM. **Curr Opin Immunol** 1995 Aug;7(4):462–70 (92 ref.)

Cytotoxic T cell effector and memory function in viral immunity. Doherty PC. **Curr Top Microbiol Immunol** 1996; 206:1–14 (108 ref.)

Cytotoxic T lymphocytes and HIV-1 related neurologic disorders. Kalams SA, et al. **Curr Top Microbiol Immunol** 1995;202:79–88 (51 ref.)

Virus-neuron-cytotoxic T lymphocyte interactions. Rall GF, et al. **Curr Top Microbiol Immunol** 1995;202:261–73 (33 ref.)

Principles of cytotoxic T lymphocyte induction and recognition. Whitton JL, et al. **Curr Top Microbiol Immunol** 1995;202:247–59 (42 ref.)

Liposomes as carriers of peptide antigens: induction of antibodies and cytotoxic T lymphocytes to conjugated and unconjugated peptides. Alving CR, et al. **Immunol Rev** 1995 Jun;145:5–31 (104 ref.)

Role of extracellular ATP and P1 and P2 classes of purinergic receptors in T-cell development and cytotoxic T lymphocyte effector functions. Apasov S, et al. **Immunol Rev** 1995 Aug;146:5–19 (40 ref.)

PELs and the perforin and granzyme independent mechanism of CTL-mediated lysis. Berke G. **Immunol Rev** 1995 Aug; 146:21–31 (52 ref.)

Molecular pathways of CTL-mediated cytotoxicity. Clark WR, et al. **Immunol Rev** 1995 Aug;146:33–44 (37 ref.)

Lymphocyte-mediated cytotoxicity in vitro and in vivo: mechanisms and significance. Kägi D, et al. **Immunol Rev** 1995 Aug;146:95–115 (102 ref.)

Induction of lytic pathways in T cell clones derived from wild-type or protein tyrosine kinase Fyn mutant mice. Lancki DW, et al. **Immunol Rev** 1995 Aug;146:117–44 (56 ref.)

Perforin and lymphocyte-mediated cytolysis. Liu CC, et al. **Immunol Rev** 1995 Aug;146:145–75 (155 ref.)

Molecular interactions in the activation of effector and precursor cytotoxic T lymphocytes. Mescher MF. **Immunol Rev** 1995 Aug;146:177–210 (108 ref.)

Nuclear changes in the cytotoxic T lymphocyte-induced model of apoptosis. Sellins KS, et al. **Immunol Rev** 1995 Aug;146:241–66 (104 ref.)

Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Van Pel A, et al. **Immunol Rev** 1995 Jun; 145:229–50 (92 ref.)

Unlocking the secrets of CTL and NK cells. Berke G. **Immunol Today** 1995 Jul;16(7):343–6 (14 ref.)

Antagonists or altruists: do viral mutants modulate T-cell responses? Davenport MP. **Immunol Today** 1995 Sep; 16(9):432–6 (30 ref.)

Alternative triggering molecules and single chain bispecific antibodies. Segal DM, et al. **J Hematother** 1995 Oct; 4(5):377–82 (31 ref.)

Does graft-versus-host disease attack epithelial stem cells? Sale GE. **Mol Med Today** 1996 Mar;2(3):114–9 (32 ref.)

Influence of host and parasite genotypes on immunological control of Theileria parasites. Morrison WI. **Parasitology** 1996;112 Suppl:S53–66 (89 ref.)

Design and testing of peptide-based cytotoxic T-cell-mediated immunotherapeutics to treat infectious diseases and cancer. Chesnut RW, et al. **Pharm Biotechnol** 1995;6:847–74 (170 ref.)

AIDS pathogenesis: a finite immune response to blame? [comment] Miedema F, et al. **Science** 1996 Apr 26; 272(5261):505–6 (18 ref.) Comment on: Science 1996 Apr 26;272(5261):537–42.

Antigens recognized on human tumors by cytolytic T lymphocytes: towards vaccination? Coulie PG. **Stem Cells (Dayt)** 1995 Jul;13(4):393–403 (65 ref.)

[Tumor rejection antigen and cancer immunotherapy] Matsutake T, et al. **Gan To Kagaku Ryoho** 1995 Nov;

22(13):1871–7 (37 ref.) (Eng. Abstr.) **(Jpn)**
[Tumor–rejection antigens expressed on human squamous cell carcinoma] Itoh K, et al. **Hum Cell** 1995 Dec;8(4):149–54 (7 ref.) (Eng. Abstr.) **(Jpn)**
[Mucin antigen gene and host immune response] Imai K. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Feb;19(1):109–13 (12 ref.) **(Jpn)**
[Function and regulation of adhesion molecules in CTLs induction of chronic hepatitis B—expression of ICAM-1 and VCAM-1 in liver tissues] Doi T. **Nippon Rinsho** 1995 Oct;53 Suppl:180–4 (19 ref.) **(Jpn)**
[HCV core specific CTL and epitope] Kita H, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:156–62 (19 ref.) **(Jpn)**
[Induction of cytotoxic T cells specific for HCV–NS5 and cytokine] Shirai M, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:163–9 (17 ref.) **(Jpn)**
[Analysis of tumor rejection antigen peptides recognized by specific CTL] Uenaka A, et al. **Nippon Rinsho** 1996 Jan; 54(1):242–9 (20 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

T–cell–mediated ganglionitis associated with acute sensory neuronopathy. Hainfellner JA, et al. **Ann Neurol** 1996 Apr; 39(4):543–7 (20 ref.)

TRANSPLANTATION

T–cell immunotherapy of tumors by adoptive transfer of cytotoxic T lymphocytes and by vaccination with minimal essential epitopes. Melief CJ, et al. **Immunol Rev** 1995 Jun; 145:167–77 (42 ref.)

T-LYMPHOCYTES, HELPER see **T-LYMPHOCYTES, HELPER-INDUCER**

T-LYMPHOCYTES, HELPER-INDUCER

see related
INTERLEUKIN-2
LYMPHOCYTE COOPERATION

T helper cell dichotomy to Candida albicans: implications for pathology, therapy, and vaccine design. Romani L, et al. **Immunol Res** 1995;14(2):148–62 (105 ref.)

IMMUNOLOGY

T helper cell differentiation in immune response. Reiner SL, et al. **Curr Opin Immunol** 1995 Jun;7(3):360–6 (65 ref.)
T–helper 1–type immunity to trophoblast: evidence for a new immunological mechanism for recurrent abortion in women. Hill JA. **Hum Reprod** 1995 Dec;10 Suppl 2:114–20 (75 ref.)
Environmental factors and primary T–cell sensitisation to inhalant allergens in infancy: reappraisal of the role of infections and air pollution. Holt PG. **Pediatr Allergy Immunol** 1995 Feb;6(1):1–10 (85 ref.)
A new approach to vaccine adjuvants. Immunopotentiation by intracellular T–helper–like signals transmitted by loxoribine. Goodman MG. **Pharm Biotechnol** 1995; 6:581–609 (73 ref.)
Infection, evolution and autoimmunity: a hypothesis. Jones DE, et al. **QJM** 1995 Dec;88(12):919–25 (56 ref.)

METABOLISM

Production and modulation of T–cell cytokines in atopic allergy. Kapsenberg ML, et al. **Int Arch Allergy Immunol** 1996 Jun;110(2):107–13 (68 ref.)

T-LYMPHOCYTES, INDUCER see **T-LYMPHOCYTES, HELPER-INDUCER**

T-LYMPHOCYTES, REGULATORY see **T-LYMPHOCYTES**

T-LYMPHOCYTES, SUPPRESSOR-EFFECTOR

IMMUNOLOGY

Molecular interactions in the activation of effector and precursor cytotoxic T lymphocytes. Mescher MF. **Immunol Rev** 1995 Aug;146:177–210 (108 ref.)
Dysregulation of cytokines during graft–versus–host disease. Krenger W, et al. **J Hematother** 1996 Feb;5(1):3–14 (136 ref.)
Mechanisms of T–cell–induced allotypic suppression of mouse IgG2a(b) and of tolerance acquisition to this allotype. Majlessi L, et al. **Res Immunol** 1995 May–Jun; 146(4–5):213–24 (71 ref.)
[Immunologic tolerance after experimental liver transplantation] Knoop M, et al. **Langenbecks Arch Chir** 1995;380(5):281–7 (68 ref.) (Eng. Abstr.) **(Ger)**
[Study of immune tolerance induced by HBs antigen specific suppressor T cell—establishment of human suppressor T cell clones] Isono E, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:185–8 (15 ref.) **(Jpn)**

PATHOLOGY

Alterations in cell signaling and related effector functions in T lymphocytes in burn/trauma/septic injuries [editorial] Sayeed MM. **Shock** 1996 Mar;5(3):157–66 (111 ref.)

T4 LYMPHOCYTES see **CD4-POSITIVE T-LYMPHOCYTES**

T8 LYMPHOCYTES see **CD8-POSITIVE T-LYMPHOCYTES**

LYMPHOCYTES, TUMOR-INFILTRATING

see related
IMMUNOTHERAPY, ADOPTIVE

IMMUNOLOGY

The role of CD4+ tumor–infiltrating lymphocytes in human solid tumors. Goedegebuure PS, et al. **Immunol Res** 1995; 14(2):119–31 (56 ref.)

PATHOLOGY

Tissue distribution and tumor localization of effector cells in adoptive immunotherapy of cancer. Basse PH. **APMIS Suppl** 1995;55:1–28 (107 ref.)

TRANSPLANTATION

[Tumor–infiltrating lymphocytes (TIL)] Matysiak W. **Pol Arch Med Wewn** 1995 Jul;94(1):76–83 (47 ref.) **(Pol)**

LYMPHOCYTIC CHORIOMENINGITIS

COMPLICATIONS

Virus–induced autoimmune disease: transgenic approach to mimic insulin–dependent diabetes mellitus and multiple sclerosis. Oldstone MB, et al. **Curr Top Microbiol Immunol** 1996;206:67–83 (34 ref.)

IMMUNOLOGY

Immune conflicts in lymphocytic choriomeningitis virus. Asano MS, et al. **Springer Semin Immunopathol** 1995; 17(2–3):247–59 (70 ref.)

LYMPHOCYTIC CHORIOMENINGITIS VIRUS

IMMUNOLOGY

Immune conflicts in lymphocytic choriomeningitis virus. Asano MS, et al. **Springer Semin Immunopathol** 1995; 17(2–3):247–59 (70 ref.)

LYMPHOCYTIC LEUKEMIA see **LEUKEMIA, LYMPHOCYTIC**

B-LYMPHOCYTIC LEUKEMIA see **LEUKEMIA, B-CELL**

T-LYMPHOCYTIC LEUKEMIA see **LEUKEMIA, T-CELL**

LYMPHOCYTIC LEUKEMIA, ACUTE see **LEUKEMIA, LYMPHOCYTIC, ACUTE**

T-LYMPHOCYTIC LEUKEMIA, ACUTE see **LEUKEMIA, T-CELL, ACUTE**

LYMPHOCYTIC LEUKEMIA, B-CELL see **LEUKEMIA, B-CELL**

LYMPHOCYTIC LEUKEMIA, CALLA-POSITIVE see **LEUKEMIA, CALLA-POSITIVE**

LYMPHOCYTIC LEUKEMIA, CHRONIC see **LEUKEMIA, LYMPHOCYTIC, CHRONIC**

B-LYMPHOCYTIC LEUKEMIA, CHRONIC see **LEUKEMIA, B-CELL, CHRONIC**

LYMPHOCYTIC LEUKEMIA, CHRONIC, B-CELL see **LEUKEMIA, B-CELL, CHRONIC**

LYMPHOCYTIC LEUKEMIA, L1 see **LEUKEMIA, LYMPHOCYTIC, ACUTE, L1**

LYMPHOCYTIC LEUKEMIA, L2 see **LEUKEMIA, LYMPHOCYTIC, ACUTE, L2**

LYMPHOCYTIC LEUKEMIA, T-CELL see **LEUKEMIA, T-CELL**

LYMPHOCYTIC LEUKEMIA, T-CELL, ACUTE see **LEUKEMIA, T-CELL, ACUTE**

LYMPHOCYTIC LYMPHOMA see **LYMPHOMA, SMALL-CELL**

LYMPHOCYTIC LYMPHOMA, DIFFUSE, WELL-DIFFERENTIATED see **LYMPHOMA, SMALL LYMPHOCYTIC**

LYMPHOCYTIC LYMPHOMA, WELL-DIFFERENTIATED see **LYMPHOMA, SMALL LYMPHOCYTIC**

LYMPHOCYTOMA see **LYMPHOMA, SMALL LYMPHOCYTIC**

LYMPHOCYTOPENIA see **LYMPHOPENIA**

T-LYMPHOCYTOPENIA, IDIOPATHIC CD4-POSITIVE

DIAGNOSIS

[Idiopathic CD4+ lymphocytopenia: a case report] Frassanito MA, et al. **Ann Ital Med Int** 1995 Jul–Sep; 10(3):188–92 (22 ref.) (Eng. Abstr.) **(Ita)**

LYMPHOCYTOSIS

CEREBROSPINAL FLUID

The Aicardi–Goutières syndrome (familial, early onset encephalopathy with calcifications of the basal ganglia and chronic cerebrospinal fluid lymphocytosis). Tolmie JL, et al. **J Med Genet** 1995 Nov;32(11):881–4 (26 ref.)

EPIDEMIOLOGY

The epidemiology of infectious myocarditis, lymphocytic myocarditis and dilated cardiomyopathy. Friman G, et al. **Eur Heart J** 1995 Dec;16 Suppl O:36–41 (85 ref.)

PATHOLOGY

Chronic B–cell lymphocytosis with binucleated lymphocytes (LWBL): a review of 38 cases. Troussard X, et al. **Leuk Lymphoma** 1996 Jan;20(3–4):275–9 (19 ref.)

PHYSIOPATHOLOGY

Chronic B–cell lymphocytosis with binucleated lymphocytes (LWBL): a review of 38 cases. Troussard X, et al. **Leuk Lymphoma** 1996 Jan;20(3–4):275–9 (19 ref.)

LYMPHOCYTOTOXIC ANTIBODIES see **ANTILYMPHOCYTE SERUM**

LYMPHOGRANULOMA, MALIGNANT see **HODGKIN'S DISEASE**

LYMPHOGRAPHY

Assessment of abnormal lymph drainage for the diagnosis of lymphedema by isotopic lymphangiography and by indirect lymphography. Partsch H. **Clin Dermatol** 1995 Sep–Oct;13(5):445–50 (45 ref.)
Radiographic demonstration of intercostal lymphatics and lymph nodes. Iyer RB, et al. **Lymphology** 1995 Jun; 28(2):89–94 (4 ref.)

LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC see **HISTIOCYTOSIS, NON-LANGERHANS-CELL**

LYMPHOID CELLS see **LYMPHOCYTES**

LYMPHOID LEUKEMIA see **LEUKEMIA, LYMPHOCYTIC**

LYMPHOID TISSUE

CYTOLOGY

Epithelial M cells: gateways for mucosal infection and immunization. Neutra MR, et al. **Cell** 1996 Aug 9; 86(3):345–8 (19 ref.)

DRUG EFFECTS

Influence of anti–rheumatic drugs on gut permeability and on the gut associated lymphoid tissue. Bjarnason I, et al. **Baillieres Clin Rheumatol** 1996 Feb;10(1):165–76 (75 ref.)

GROWTH & DEVELOPMENT

Simple developmental programs of gene expression and cellular composition of lymphoid organs at the origin of natural tolerance. Coutinho A. **Res Immunol** 1995 May–Jun;146(4–5):321–32 (0 ref.)

IMMUNOLOGY

Cellular and molecular biologic approaches for analyzing the in vivo development and maintenance of gut mucosal IgA responses. Cebra JJ, et al. **Adv Exp Med Biol** 1995; 371A:429–34 (11 ref.)
The gut as a lymphoepithelial organ: the role of intestinal epithelial cells in mucosal immunity. Tlaskalová–Hogenová H, et al. **Folia Microbiol (Praha)** 1995;40(4):385–91 (52 ref.)
Changes in the intestinal lymphoid compartment throughout life: implications for the local generation of intestinal T cells. Rozing J, et al. **Int Rev Immunol** 1995;12(1):13–25 (45 ref.)
Local regulation of the immune response by the autonomic

nervous system. Esquifino AI, et al. **Neuroimmunomodulation** 1994 Sep-Oct;1(5):265-73 (61 ref.)

METABOLISM

Increased substance P receptor expression by blood vessels and lymphoid aggregates in Clostridium difficile-induced pseudomembranous colitis. Mantyh CR, et al. **Dig Dis Sci** 1996 Mar;41(3):614-20 (22 ref.)

The interplay between lymphoid-specific and ubiquitous transcription factors controls the expression of interleukin 2 gene in T lymphocytes. Avots A, et al. **Immunobiology** 1995 Jul;193(2-4):254-8 (20 ref.)

PATHOLOGY

Gastric gland heterotopia with extensive lymphoid stroma: a gastric lymphoepithelial cyst. Delvaux S, et al. **Am J Gastroenterol** 1996 Mar;91(3):599-601 (17 ref.)

Lymphoid changes of the nasopharyngeal and palatine tonsils that are indicative of human immunodeficiency virus infection. A clinicopathologic study of 12 cases. Wenig BM, et al. **Am J Surg Pathol** 1996 May;20(5):572-87 (76 ref.)

HIV-1-associated pathology in hemato-lymphoid organs and the experimental evaluation in the SCID-hu mouse. Kaneshima H. **Int J Hematol** 1996 Jun;63(4):253-64 (89 ref.)

Pathogenic insights from studies of lymphoid tissue from HIV-infected individuals [published erratum appears in J Acquir Immune Defic Syndr Hum Retrovirol 1996 Feb 1;11(2):210] Cohen OJ, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995;10 Suppl 1:S6-14 (59 ref.)

[Reactive lymphoid hyperplasia (RLH) of the gallbladder] Hayasaka T, et al. **Ryoikibetsu Shokogun Shirizu** 1996; (9):326-8 (14 ref.) **(Jpn)**

PHYSIOPATHOLOGY

[Low-grade non-Hodgkin's lymphomas and their cytofunctional correlation with peripheral compartments of normal lymphoid tissue] Sánchez Fayos J, et al. **Rev Clin Esp** 1995 Dec;195(12):864-72 (47 ref.) **(Spa)**

VIROLOGY

Early events in infection of lymphoid tissue by a lentivirus, maedi-visna. Blacklaws B, et al. **Trends Microbiol** 1995 Nov;3(11):434-40 (48 ref.)

LYMPHOKINE-ACTIVATED KILLER CELLS see **KILLER CELLS, LYMPHOKINE-ACTIVATED**

LYMPHOKINES

see related
IMMUNITY, CELLULAR

[Involvement of the VEGF-Flt-receptor family in angiogenesis] Shibuya M. **Nippon Yakurigaku Zasshi** 1996 Mar;107(3):119-31 (44 ref.) (Eng. Abstr.) **(Jpn)**

ANALYSIS

[Osteoclast activating factor (OAF)] Kamihagi K, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:756-8 (14 ref.) **(Jpn)**

BIOSYNTHESIS

Regulation of the expression of the VEGF/VPS and its receptors: role in tumor angiogenesis. Kolch W, et al. **Breast Cancer Res Treat** 1995;36(2):139-55 (156 ref.)

Beta chemokines costimulate lymphocyte cytolysis, proliferation, and lymphokine production. Taub DD, et al. **J Leukoc Biol** 1996 Jan;59(1):81-9 (33 ref.)

IMMUNOLOGY

Receptors that regulate T-cell susceptibility to apoptotic cell death. Boise LH, et al. **Ann N Y Acad Sci** 1995 Sep 7; 766:70-80 (32 ref.)

Unconventional B-cell antigens and human immune repertoires. Silverman GJ. **Ann N Y Acad Sci** 1995 Sep 29;764:342-55 (42 ref.)

PHYSIOLOGY

Role of VEGF-flt receptor system in normal and tumor angiogenesis. Shibuya M. **Adv Cancer Res** 1995;67:281-316 (141 ref.)

Vasculogenesis. Risau W, et al. **Ann Rev Cell Dev Biol** 1995; 11:73-91 (122 ref.)

The role of vascular endothelial growth factor in pathological angiogenesis. Ferrara N. **Breast Cancer Res Treat** 1995; 36(2):127-37 (91 ref.)

VEGF-mediated tumour angiogenesis: a new target for cancer therapy. Martiny-Baron G, et al. **Curr Opin Biotechnol** 1995 Dec;6(6):675-80 (40 ref.)

Vascular endothelial growth factor and retinal neovascularisation: a new therapeutic approach for diabetic retinopathy. Favard C, et al. **Diabetes Metab** 1996 Jul; 22(4):268-73 (67 ref.)

Immuno-endocrine interactions in early pregnancy. Chaouat G, et al. **Hum Reprod** 1995 Dec;10 Suppl 2:55-9 (45 ref.)

Role of embryonic factors in human implantation. Polan ML, et al. **Hum Reprod** 1995 Dec;10 Suppl 2:22-9 (32 ref.)

Vascular endothelial growth factor, a potent and selective angiogenic agent. Thomas KA. **J Biol Chem** 1996 Jan 12; 271(2):603-6 (51 ref.)

THERAPEUTIC USE

[Leukoregulin--a new possibility in the treatment of virus infections and malignant tumors] Bojić I. **Vojnosanit Pregl** 1994 Nov-Dec;51(6):540-2 (20 ref.) **(Scr)**

LYMPHOMA

Hematologic malignancies during pregnancy. Sadural E, et al. **Clin Obstet Gynecol** 1995 Sep;38(3):535-46 (26 ref.)

Primary gastrointestinal lymphomas. Cooper DL, et al. **Gastroenterologist** 1996 Mar;4(1):54-64 (94 ref.)

Cancer in pregnancy: a review of the literature. Part II. Antonelli NM, et al. **Obstet Gynecol Surv** 1996 Feb; 51(2):135-42 (185 ref.)

[New findings on the classification, diagnosis and therapy of primary gastrointestinal lymphomas] Krč I, et al. **Vnitr Lek** 1995 Jul;41(7):498-503 (29 ref.) (Eng. Abstr.) **(Cze)**

[6 cases of small intestine lymphoma] Sartini M, et al. **G Chir** 1995 Oct;16(10):417-21 (29 ref.) (Eng. Abstr.) **(Ita)**

[Malignant lymphoma of liver] Mohri N, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):314-6 (20 ref.) **(Jpn)**

[Malignant lymphoma of the gallbladder] Murakami H, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):245-7 (16 ref.) **(Jpn)**

CHEMICALLY INDUCED

[Cutaneous pseudolymphoma during treatment of rheumatoid polyarthritis with low-dose methotrexate] Delaporte E, et al. **Ann Dermatol Venereol** 1995;122(8):521-5 (33 ref.) (Eng. Abstr.) **(Fre)**

CLASSIFICATION

Molecular findings and classification of malignant lymphomas. Pileri SA, et al. **Acta Haematol** 1996; 95(3-4):181-7 (51 ref.)

Revised European-American Lymphoma Classification. Pileri SA, et al. **Curr Opin Oncol** 1995 Sep;7(5):401-7 (75 ref.)

[Nosography of intestinal lymphomas] Greco AV, et al. **Riv Eur Sci Med Farmacol** 1994 Sep-Dec;16 Suppl 1:3-13 (36 ref.) (Eng. Abstr.) **(Ita)**

COMPLICATIONS

Haemophagocytosis in bone marrow aspirate--a review of the clinical course of 10 cases. Linn YC, et al. **Acta Haematol** 1995;94(4):182-91 (25 ref.)

Lymphoma in coeliac disease. Mathus-Vliegen EM. **J R Soc Med** 1995 Dec;88(12):672-7 (64 ref.)

1,25-dihydroxyvitamin D-mediated hypercalcemia in a renal transplant recipient. Golconda MS, et al. **Mayo Clin Proc** 1996 Jan;71(1):32-6 (25 ref.)

[Intestinal malabsorption, celiac disease and associated lymphoma: from symptoms to diagnosis] Gasbarrini G, et al. **Riv Eur Sci Med Farmacol** 1994 Sep-Dec;16 Suppl 1:39-68 (115 ref.) (Eng. Abstr.) **(Ita)**

DIAGNOSIS

Primary central nervous system lymphoma in immunocompetent patients. Ferreri AJ, et al. **Cancer Treat Rev** 1995 Sep;21(5):415-46 (229 ref.)

Malignant lymphoma of the pancreas [letter] Tanaka T, et al. **Dig Dis Sci** 1996 Feb;41(2):402-4 (18 ref.)

CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy. Scheuermann RH, et al. **Leuk Lymphoma** 1995 Aug;18(5-6):385-97 (94 ref.)

[Neoplasias in hematopoietic tissues] Kamada N, et al. **Nippon Rinsho** 1996 Jun;54(6):1626-30 (5 ref.) (Eng. Abstr.) **(Jpn)**

[Primary lymphomas of the brain not related to immunodeficiency] Marques H, et al. **Actz Med Port** 1995 Mar;8(3):151-6 (38 ref.) (Eng. Abstr.) **(Por)**

[Hematologic causes of vascular diseases of the central nervous system] Arboix A, et al. **Rev Neurol** 1995;23 Suppl 1:S41-9 (62 ref.) **(Spa)**

DRUG THERAPY

Haematological support of high-dose sequential chemotherapy: clinical evidence for reduction of toxicity and high response rates in poor risk lymphomas. Tarella C, et al. **Ann Oncol** 1995;6 Suppl 4:3-8 (30 ref.)

The water-insoluble camptothecin analogues: promising drugs for the effective treatment of haematological malignancies. Pantazis P. **Leuk Res** 1995 Nov;19(11):775-88 (151 ref.)

[Clinical phase I studies in oncology and hematology. Concepts, implementation and ethical considerations] Hanauske AR. **Med Klin** 1996 Apr 12;91 Suppl 3:68-70 (28 ref.) **(Ger)**

[Value of corticoids in hematology/oncology in adulthood] Schlimok G, et al. **Med Klin** 1995 Oct 15;90(10):579-84 (23 ref.) **(Ger)**

[Drug therapy of hematologic malignancy] Shimoyama M. **Nippon Naika Gakkai Zasshi** 1996 Mar 10;85(3):337-41 (15 ref.) **(Jpn)**

EPIDEMIOLOGY

Incidence and time trends for lymphomas, leukemias and myelomas: hypothesis generation. Working Group on the Epidemiology of Hematolymphopoietic Malignancies in Italy. Vineis P. **Leuk Res** 1996 Apr;20(4):285-90 (39 ref.)

ETIOLOGY

Angioimmunoblastic lymphadenopathy: an etiology for gastrointestinal lymphomatous polyposis. Goenka MK, et al. **Am J Gastroenterol** 1996 Jun;91(6):1236-8 (16 ref.)

Leukemia and lymphoma in ataxia telangiectasia. Taylor AM, et al. **Blood** 1996 Jan 15;87(2):423-38 (110 ref.)

Helicobacter pylori and gastric neoplasia: evolving concepts. Bolin TD, et al. **Med J Aust** 1995 Sep 4;163(5):253-5 (18 ref.)

[Lymphoproliferative disorders in patients with Sjögren's syndrome--Vg gene rearrangement and expression of bcl-2 protein] Sugai S, et al. **Nippon Rinsho** 1995 Oct; 53(10):2580-6 (15 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Primary adrenal lymphoma with chromosomal abnormalities. Sasagawa I, et al. **Acta Haematol** 1995;94(3):156-62 (34 ref.)

New models of lymphoma in transgenic mice. Seldin DC. **Curr Opin Immunol** 1995 Oct;7(5):665-73 (53 ref.)

Detection of chromosomal translocations in leukemia-lymphoma cells by polymerase chain reaction. Drexler HG, et al. **Leuk Lymphoma** 1995 Nov; 19(5-6):359-80 (278 ref.)

DCC (deleted in colorectal cancer) inactivation in hematological malignancies. Porfiri E. **Leuk Lymphoma** 1995 Jun;18(1-2):69-72 (49 ref.)

Abnormalities of retinoblastoma gene expression in hematological malignancies. Zhu YM, et al. **Leuk Lymphoma** 1995 Jun;18(1-2):61-7 (80 ref.)

Fusion genes and their hybrid proteins in human leukemias and lymphomas. Look AT. **Proc Assoc Am Physicians** 1995 Jul;107(2):175-80 (76 ref.)

[Chromosomal translocation and molecular characteristics in hematological malignancies] Inokuchi K. **Nippon Ika Daigaku Zasshi** 1996 Jun;63(3):175-80 (23 ref.) **(Jpn)**

[Tumor suppressor genes in hematopoietic tumors] Hirai H. **Rinsho Ketsueki** 1996 May;37(5):398-403 (22 ref.) **(Jpn)**

IMMUNOLOGY

Graft-versus-leukemia and graft-versus-lymphoma effects of allogeneic bone marrow transplantation and of allogeneic donor leukocyte transfusions. Vandenberghe P, et al. **Ann Hematol** 1995 Nov;71(5):209-17 (65 ref.)

Cell surface antigens in leukemias and lymphomas. Freedman AS. **Cancer Invest** 1996;14(3):252-76 (354 ref.)

PATHOLOGY

Recent developments in our understanding of gastric lymphomas. Isaacson PG. **Am J Surg Pathol** 1996;20 Suppl 1:S1-7 (29 ref.)

Early gastric lymphoma: a clinicopathologic study of ten patients, literature review, and comparison with early gastric adenocarcinoma. Kitamura K, et al. **Cancer** 1996 Mar 1;77(5):850-7 (70 ref.)

Some cytogenetic and molecular aspects of cancer therapy. Sandberg AA, et al. **Compr Ther** 1996 Feb;22(2):76-80 (11 ref.)

Primary brain tumors in the acquired immunodeficiency syndrome. DeAngelis LM. **Curr Opin Neurol** 1995 Dec; 8(6):419-23 (35 ref.)

Follicular dendritic cells in malignant lymphomas. Petrasch S. **Curr Top Microbiol Immunol** 1995;201:189-203 (60 ref.)

Unusual cutaneous lymphomas. Perniciaro C. **Dermatol Surg** 1996 Mar;22(3):288-92 (21 ref.)

Primary central nervous system lymphomas--new pathological developments. Jellinger KA, et al. **J Neurooncol** 1995;24(1):33-6 (23 ref.)

Involvement of the larynx by hemopoietic neoplasms. An investigation of autopsy cases and review of the literature. Horny HP, et al. **Pathol Res Pract** 1995 Mar;191(2):130-8 (88 ref.)

Primary gastric lymphoma. Lopez M, et al. **Riv Eur Sci Med Farmacol** 1994 Sep-Dec;16 Suppl 1:31-7 (41 ref.)

[Retrospect and prospect of pathology in lympho-reticulo-endothelial system] Wang B, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1995 Aug;24(4):235-8 (16 ref.) **(Chi)**

[Intravascular malignant lymphoma (ex-malignant angioendotheliosis). 3 cases] Demolombe-Ragué S, et al. **Presse Med** 1995 Nov 25;24(36):1689-93 (10 ref.) (Eng. Abstr.) **(Fre)**

[Spontaneous regression of primary cerebral lymphoma] Heinzlef O, et al. **Rev Neurol (Paris)** 1996 Feb;152(2):135-8 (10 ref.) (Eng. Abstr.) **(Fre)**

[Gastrointestinal lymphomas] Baroni CD. **Riv Eur Sci Med Farmacol** 1994 Sep-Dec;16 Suppl 1:15-23 (20 ref.) (Eng. Abstr.) **(Ita)**

[Primary lymphomas of the gastrointestinal tract: clinical picture] Grieco A, et al. **Riv Eur Sci Med Farmacol** 1994 Sep-Dec;16 Suppl 1:25-9 (9 ref.) (Eng. Abstr.) **(Ita)**

[Procedures for staging primary gastrointestinal lymphoma] Tedeschi L. **Riv Eur Sci Med Farmacol** 1994 Sep–Dec;16 Suppl 1:69–74 (17 ref.) (Eng. Abstr.) **(Ita)**

[Immunoblastic lymphadenitis: pathohistologic picture and differential diagnosis from malignant lymphoma] Pavlovskaia AI, et al. **Arkh Patol** 1995 Sep–Oct;57(5):21–5 (23 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Apoptosis overview emphasizing the role of oxidative stress, DNA damage and signal–transduction pathways. Payne CM, et al. **Leuk Lymphoma** 1995 Sep;19(1–2):43–93 (720 ref.)

RADIOGRAPHY

Intrathoracic lymphoproliferative disorders and lymphoma. Murray KA, et al. **Curr Probl Diagn Radiol** 1996 May–Jun; 25(3):78–106 (133 ref.)

[Gastric lymphoma: diagnostic radiology in the staging of the disease] Falappa PG, et al.
Riv Eur Sci Med Farmacol 1994 Sep–Dec;16 Suppl 1:83–8 (8 ref.) (Eng. Abstr.) **(Ita)**

RADIONUCLIDE IMAGING

Role of 67Ga scintigraphy in localization of lymphoma. van Amsterdam JA, et al. **Ann Hematol** 1996 Apr;72(4):202–7 (56 ref.)

SURGERY

Primary cavernous sinus malignant lymphoma treated by gamma knife radiosurgery: case report and review of the literature. Nakatomi H, et al. **Surg Neurol** 1996 Sep; 46(3):272–8; discussion 278–9 (15 ref.)

THERAPY

Monoclonal antibody therapy of leukemia and lymphoma. Jurcic JG, et al. **Adv Pharmacol** 1995;33:287–314 (104 ref.)

Orthodontic management of patients with hematologic malignancies. Sheller B, et al.
Am J Orthod Dentofacial Orthop 1996 Jun;109(6):575–80 (11 ref.)

Practical applications for peripheral blood progenitor cells in the treatment of lymphomas and solid tumours. Pettengell R. **Ann Oncol** 1995;6 Suppl 4:9–12 (11 ref.)

Expanding the role of blood progenitor cells. Pettengell R. **Ann Oncol** 1995 Oct;6(8):759–67 (87 ref.)

Gonadal damage and effects on fertility in adult patients with haematological malignancy undergoing stem cell transplantation. Chatterjee R, et al.
Bone Marrow Transplant 1996 Jan;17(1):5–11 (79 ref.)

Lymphomas. Kwak LW, et al.
Cancer Chemother Biol Response Modif 1996;16:376–440 (303 ref.)

Primary central nervous system lymphoma in immunocompetent patients. Ferreri AJ, et al.
Cancer Treat Rev 1995 Sep;21(5):415–46 (229 ref.)

New therapies of primary CNS lymphomas and oligodendrogliomas. Macdonald DR. **J Neurooncol** 1995; 24(1):97–101 (26 ref.)

Immunotoxins for treatment of leukemia and lymphoma. Uckun FM, et al. **Leuk Lymphoma** 1995 Jul;18(3–4):195–201 (51 ref.)

Targeting Pseudomonas exotoxin to hematologic malignancies. Kreitman RJ, et al. **Semin Cancer Biol** 1995 Oct;6(5):297–306 (54 ref.)

Perspective of rhGM–CSF in the treatment of neutropenic infections and aggressive lymphomas. Gerhartz HH.
Stem Cells (Dayt) 1995 Sep;13(5):472–6 (27 ref.)

[Interferon–alpha in therapy of malignant hemoblastoses] Schuler M, et al. **Internist (Berl)** 1995 Dec;36(12):1133–8 (36 ref.) **(Ger)**

[Immunotherapy of hemato–oncologic diseases] Winkler U, et al. **Med Klin** 1996 Apr 10;91(4):226–33 (49 ref.) **(Ger)**

[High dose chemotherapy followed by hematopoietic stem cell transplantation for malignant lymphoma] Tobinai K. **Gan To Kagaku Ryoho** 1995 Oct;22(12):1724–30 (23 ref.) (Eng. Abstr.) **(Jpn)**

ULTRASONOGRAPHY

[The role of ultrasonography in the diagnosis and staging of gastroenteric lymphoma] Rapaccini GL, et al.
Riv Eur Sci Med Farmacol 1994 Sep–Dec;16 Suppl 1:75–81 (17 ref.) (Eng. Abstr.) **(Ita)**

VIROLOGY

Etiopathogenetic role of hepatitis C virus in mixed cryoglobulinemia, chronic liver diseases and lymphomas. Ferri C, et al. **Clin Exp Rheumatol** 1995 Nov–Dec;13 Suppl 13:S135–40 (49 ref.)

Human herpesvirus 8 in lymphoma and Kaposi's sarcoma: now the virus can be propagated. Weiss RA. **Nat Med** 1996 Mar;2(3):277–8 (16 ref.)

[Malignant lymphoma and EBV] Ohshima K, et al.
Rinsho Byori 1996 Jan;44(1):24–31 (23 ref.) (Eng. Abstr.) **(Jpn)**

LYMPHOMA, AIDS–RELATED

AIDS–related non–Hodgkin's lymphomas: molecular genetics, viral infection and cytokine deregulation. Gaidano G, et al. **Acta Haematol** 1996;95(3–4):193–8 (32 ref.)

[Lymphoma with skin manifestations in HIV infection: 8 cases] Estève E, et al. **Ann Dermatol Venereol** 1995; 122(8):488–93 (40 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Non Hodgkin's lymphoma of the maxilla as a first clinical manifestation of HIV infection. Report of a case. Berberi A, et al. **Bull Group Int Rech Sci Stomatol Odontol** 1995 Sep–Oct;38(3–4):77–80 (11 ref.)

Radiologic and laboratory evaluation of enhancing brain lesions in patients with AIDS. Johnson MD, et al.
Compr Ther 1995 Nov;21(11):645–52 (45 ref.)

[The diagnosis of primary cerebral lymphoma in AIDS. The contribution of imaging] Laissy JP, et al. **J Neuroradiol** 1995 Sep;22(3):207–17 (25 ref.) (Eng. Abstr.) **(Fre)**

[Magnetic resonance in AIDS–related encephalopathy] Gualdi GF, et al. **Clin Ter** 1995 Dec;146(12):843–56 (42 ref.) (Eng. Abstr.) **(Ita)**

[Non–Hodgkin's lymphoma of the large intestine in an HIV–positive hemophiliac. A report of a case with an unusual presentation] Gigoni R, et al.
Radiol Med (Torino) 1995 Sep;90(3):326–8 (11 ref.) **(Ita)**

DRUG THERAPY

AIDS–related malignancies. Spittle MF. **J R Soc Med** 1996 Jan;89(1):35P–6P (0 ref.)

EPIDEMIOLOGY

AIDS–related lymphoma: an emerging epidemic. Denton AS, et al. **Br J Hosp Med** 1996 Mar 6–19;55(5):282–8 (27 ref.)

[The epidemiology of cerebral lymphoma in AIDS] Mikol J, et al. **J Neuroradiol** 1995 Sep;22(3):204–6 (25 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Molecular pathogenesis of AIDS–related lymphomas. Gaidano G, et al. **Adv Cancer Res** 1995;67:113–53 (264 ref.)

IMMUNOLOGY

HIV–mediated B–lymphocyte activation and lymphomagenesis. Monroe JG, et al. **J Clin Immunol** 1995 Mar;15(2):61–8 (73 ref.)

PATHOLOGY

Primary esophageal lymphoma in AIDS presenting as a nonhealing esophageal ulcer. Chow DC, et al.
Am J Gastroenterol 1996 Mar;91(3):602–3 (13 ref.)

THERAPY

AIDS–associated malignancies. Krown SE.
Cancer Chemother Biol Response Modif 1996;16:441–61 (141 ref.)

Treatment of AIDS–related lymphomas. Sparano JA.
Curr Opin Oncol 1995 Sep;7(5):442–9 (61 ref.)

Primary central nervous system lymphoma. Freilich RJ, et al. **Neurol Clin** 1995 Nov;13(4):901–14 (75 ref.)

VIROLOGY

Effect of HIV infection on the incidence of lymphoma in Africa. Lucas SB, et al. **East Afr Med J** 1996 May;73(5 Suppl):S29–30 (2 ref.)

LYMPHOMA, B–CELL

Cellular and molecular bases of B–cell clonal expansions. Dolcetti R, et al. **Clin Exp Rheumatol** 1996 Jan–Feb;14 Suppl 14:S3–13 (101 ref.)

Primary non–Hodgkin's lymphoma of the male urethra. A case report and review of the literature. Hofmockel G, et al. **Urol Int** 1995;55(3):177–80 (26 ref.)

CLASSIFICATION

Mantle cell lymphoma–– an entity comes of age. Weisenburger DD, et al. **Blood** 1996 Jun 1;87(11):4483–94 (119 ref.)

DIAGNOSIS

Mantle cell lymphoma. Accurate diagnosis yields new clinical insights [editorial; comment] Campo E, et al.
Arch Pathol Lab Med 1996 Jan;120(1):12–4 (37 ref.)
Comment on: Arch Pathol Lab Med 1996 Jan;120(1):35–40.

Leukemic phase of mantle cell lymphoma two case reports and review of the literature [see comments] Vadlamudi G, et al. **Arch Pathol Lab Med** 1996 Jan;120(1):35–40 (31 ref.)
Comment in: Arch Pathol Lab Med 1996 Jan;120(1):12–4.

Evaluation of cutaneous lymphomas. Breneman DL.
Compr Ther 1996 Mar;22(3):169–74 (18 ref.)

Primary T–cell lymphoma of the cerebellum. A case report. Kleopa K, et al. **J Neurooncol** 1996 Mar;27(3):225–30 (28 ref.)

ETIOLOGY

BCL–6 and the molecular pathogenesis of B–cell lymphoma. Dalla–Favera R, et al.
Cold Spring Harb Symp Quant Biol 1994;59:117–23 (49 ref.)

[Lymphomas of the colon complicating hemorrhagic rectocolitis] Baron P, et al. **Gastroenterol Clin Biol** 1995 Nov;19(11):935–9 (32 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Molecular genetics of B–cell lymphomas: a review. Lim LC.
Ann Acad Med Singapore 1996 Jan;25(1):37–41 (35 ref.)

BCL–6 and the molecular pathogenesis of B–cell lymphoma. Dalla–Favera R, et al.
Cold Spring Harb Symp Quant Biol 1994;59:117–23 (49 ref.)

Bone and brain involvement in a case of diffuse large B cell lymphoma associated with t(2;3)(p12;q27). Utsumi S, et al.
Int J Hematol 1995 Dec;62(4):247–52 (16 ref.)

[Genetic abnormalities in B cell neoplasms: special reference to diffuse large cell lymphoma] Ohno H, et al.
Rinsho Ketsueki 1996 May;37(5):404–7 (10 ref.) **(Jpn)**

IMMUNOLOGY

The role of molecular analyses of B–cell and T–cell clonality in the study of B–cell lymphomagenesis. De Vita S, et al.
Clin Exp Rheumatol 1996 Jan–Feb;14 Suppl 14:S21–9 (51 ref.)

PATHOLOGY

General lessons from cutaneous lymphoma [editorial] Slater DN. **Br J Hosp Med** 1995 Nov 1–14;54(9):426–8 (6 ref.)

Bilateral primary breast lymphoma in pregnancy: a case report and literature review. Kirkpatrick AW, et al.
Can J Surg 1996 Aug;39(4):333–5 (26 ref.)

Primary non–Hodgkin's lymphoma of the temporal bone. Bockmühl U, et al. **Eur Arch Otorhinolaryngol** 1995; 252(6):376–8 (16 ref.)

CD27–CD70 interaction: unravelling its implication in normal and neoplastic B–cell growth. Lens SM, et al.
Leuk Lymphoma 1995 Jun;18(1–2):51–9 (78 ref.)

Angiogenesis in B cell lymphoproliferative diseases. Biological and clinical studies. Vacca A, et al.
Leuk Lymphoma 1995 Dec;20(1–2):27–38 (61 ref.)

Mantle cell lymphoma: a lymphoproliferative disorder associated with aberrant function of the cell cycle. Garcia–Conde J, et al. **Leukemia** 1996 Jun;10 Suppl 2:s78–83 (22 ref.)

[Lymphocytic mastopathy. A case report and review of the literature] Pellerin P, et al.
J Gynecol Obstet Biol Reprod (Paris) 1995;24(7):683–5 (10 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

B–cell neoplasia in a developmental framework. Klein G.
Int J Dev Biol 1995 Oct;39(5):713–8 (33 ref.)

PREVENTION & CONTROL

A genetic approach to idiotypic vaccination for B cell lymphoma. Stevenson FK, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:212–26 (23 ref.)

RADIOGRAPHY

[Primary orbital lymphoma within the context of Sjögren's syndrome secondary to rheumatoid arthritis] Rasquin F, et al. **Bull Soc Belge Ophtalmol** 1994;254:125–32 (40 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Myeloablative radiolabeled antibody therapy with autologous bone marrow transplantation for relapsed B cell lymphomas. Press OW, et al. **Cancer Treat Res** 1995; 76:281–97 (68 ref.)

Oral verruca vulgaris in a bone marrow transplant patient: a case report and review of literature. Barasch A, et al.
Eur J Cancer B Oral Oncol 1996 Mar;32B(2):137–9 (13 ref.)

Idiotypic DNA vaccines against B–cell lymphoma. Stevenson FK, et al. **Immunol Rev** 1995 Jun;145:211–28 (40 ref.)

Performance of CD3xCD19 bispecific monoclonal antibodies in B cell malignancy. Haagen IA. **Leuk Lymphoma** 1995 Nov;19(5–6):381–93 (160 ref.)

LYMPHOMA, BOVINE see **ENZOOTIC BOVINE LEUKOSIS**

LYMPHOMA, BURKITT'S see **BURKITT'S LYMPHOMA**

LYMPHOMA, CONVOLUTED T–CELL see **LYMPHOMA, LYMPHOBLASTIC**

LYMPHOMA, DIFFUSE, LARGE FOLLICULAR CENTER–CELL see **LYMPHOMA, LARGE–CELL, DIFFUSE**

LYMPHOMA, HIGH–GRADE

DIAGNOSIS

[High–grade non–Hodgkin lymphoma: diagnosis and therapy] Trümper L, et al. **Ther Umsch** 1996 Feb; 53(2):133–9 (20 ref.) (Eng. Abstr.) **(Ger)**

LYMPHOMA, HIGH-GRADE

THERAPY

[High-grade non-Hodgkin lymphoma: diagnosis and therapy] Trümper L, et al. **Ther Umsch** 1996 Feb; 53(2):133-9 (20 ref.) (Eng. Abstr.) **(Ger)**

LYMPHOMA, HISTIOCYTIC see **LYMPHOMA, LARGE-CELL**

LYMPHOMA, HISTIOCYTIC, DIFFUSE see **LYMPHOMA, LARGE-CELL, DIFFUSE**

LYMPHOMA, HIV-RELATED see **LYMPHOMA, AIDS-RELATED**

LYMPHOMA, IMMUNOBLASTIC, LARGE-CELL see **LYMPHOMA, LARGE-CELL, IMMUNOBLASTIC**

LYMPHOMA, INTERMEDIATE-GRADE

DRUG THERAPY

Chemotherapy of intermediate-grade non-Hodgkin's lymphoma: is "more" or "less" better? Gaynor ER, et al. **Oncology (Huntingt)** 1995 Dec;9(12):1273-9; discussion 1283-4 (18 ref.)

THERAPY

[Treatment of intermediate-grade non-Hodgkin lymphoma in adults] Gisselbrecht C. **Rev Med Interne** 1995; 16(8):608-15 (34 ref.) (Eng. Abstr.) **(Fre)**

LYMPHOMA, KI-1 see **LYMPHOMA, LARGE-CELL, KI-1**

LYMPHOMA, LARGE-CELL

Primary tracheal non-Hodgkin's lymphoma. A case report and review of the literature. Fidias P, et al. **Cancer** 1996 Jun 1;77(11):2332-8 (38 ref.)

[Malignant non-Hodgkin lymphoma of cardiac localization.Apropos of a case] Ghannem M, et al. **Ann Cardiol Angeiol (Paris)** 1995 Sep;44(7):345-8 (26 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Transcalvarial primary lymphoma of bone. A report of two cases. Paige ML, et al. **Neuroradiology** 1995 Aug; 37(6):456-8 (11 ref.)

ETIOLOGY

Transformation of chronic lymphocytic leukemia to lymphoma of true histiocytic type. Wetzler M, et al. **Cancer** 1995 Aug 15;76(4):609-17 (62 ref.)

PATHOLOGY

Angiotropic large cell lymphoma presenting as primary adrenal insufficiency. Chu P, et al. **Hum Pathol** 1996 Feb; 27(2):209-11 (24 ref.)

Histiocytic sarcomas. Lauritzen AF, et al. **Leuk Lymphoma** 1995 Jun;18(1-2):73-80 (74 ref.)

THERAPY

Reactivation toxoplasmic retinochoroiditis in patients undergoing bone marrow transplantation: is there a role for chemoprophylaxis? Peacock JE Jr, et al. **Bone Marrow Transplant** 1995 Jun;15(6):983-7 (23 ref.)

LYMPHOMA, LARGE-CELL, DIFFUSE

CHEMICALLY INDUCED

[A case of rheumatoid arthritis with malignant lymphoma taking methotrexate] Hayakawa M, et al. **Ryumachi** 1995 Aug;35(4):678-82 (23 ref.) (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

Progressive thrombosis after treatment of diffuse large cell non-Hodgkin's lymphoma and concomitant lupus anticoagulant. Keung YK, et al. **Leuk Lymphoma** 1996 Jan; 20(3-4):341-5 (22 ref.)

[Primary non-Hodgkin's lymphomas of the liver in human immunodeficiency virus infected patients. Three cases] Brugière O, et al. **Gastroenterol Clin Biol** 1996;20(3):307-11 (18 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Bone and brain involvement in a case of diffuse large B cell lymphoma associated with t(2;3)(p12;q27). Utsumi S, et al. **Int J Hematol** 1995 Dec;62(4):247-52 (16 ref.)

[Genetic abnormalities in B cell neoplasms: special reference to diffuse large cell lymphoma] Ohno H, et al. **Rinsho Ketsueki** 1996 May;37(5):404-7 (10 ref.) **(Jpn)**

PATHOLOGY

Primary lymphoma of the ovary. A case report and critical review of the literature. Granovsky-Grisaru S, et al. **Eur J Gynaecol Oncol** 1995;16(5):392-5 (14 ref.)

LYMPHOMA, LARGE-CELL, DIFFUSE, UNDIFFERENTIATED see **LYMPHOMA, LARGE-CELL, DIFFUSE**

LYMPHOMA, LARGE-CELL, IMMUNOBLASTIC

see related
LYMPHOMA, T-CELL, PERIPHERAL

COMPLICATIONS

[Primary non-Hodgkin's lymphomas of the liver in human immunodeficiency virus infected patients. Three cases] Brugière O, et al. **Gastroenterol Clin Biol** 1996;20(3):307-11 (18 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

[Non-Hodgkin's lymphoma of the large intestine in an HIV-positive hemophiliac. A report of a case with an unusual presentation] Gigoni R, et al. **Radiol Med (Torino)** 1995 Sep;90(3):326-8 (11 ref.) **(Ita)**

ETIOLOGY

Primary Epstein-Barr virus-related non-Hodgkin's lymphoma of the pleural cavity following long-standing tuberculous empyema. Molinie V, et al. **Arch Pathol Lab Med** 1996 Mar;120(3):288-91 (18 ref.)

THERAPY

[Lymphomas of the colon complicating hemorrhagic rectocolitis] Baron P, et al. **Gastroenterol Clin Biol** 1995 Nov;19(11):935-9 (32 ref.) (Eng. Abstr.) **(Fre)**

LYMPHOMA, LARGE-CELL, KI-1

see related
ANTIGENS, CD30

COMPLICATIONS

[Ki-1 positive non-Hodgkin's lymphoma disclosed by mucocutaneous ulcerations and glomerulonephritis] Bellou A, et al. **Rev Med Interne** 1995;16(12):913-8 (26 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Anaplastic large cell Ki-1 lymphoma: primary bone presentation in an elderly man. Wang JC, et al. **Acta Haematol** 1996;96(1):45-9 (20 ref.)

Primary Ki-1-positive T-cell lymphoma of the brain--an aggressive subtype of lymphoma: case report and review of the literature. Goldbrunner R, et al. **Surg Neurol** 1996 Jul;46(1):37-41 (24 ref.)

GENETICS

t(2;5) translocations in anaplastic large cell lymphomas and Hodgkin's disease [editorial; comment] Herbst H. **J Pathol** 1996 Feb;178(2):113-5 (22 ref.) Comment on: J Pathol 1996 Feb;178(2):128-32.

PATHOLOGY

Primary esophageal lymphoma in AIDS presenting as a nonhealing esophageal ulcer. Chow DC, et al. **Am J Gastroenterol** 1996 Mar;91(3):602-3 (13 ref.)

Anaplastic large cell lymphoma: update of findings. Pileri SA, et al. **Leuk Lymphoma** 1995 Jun;18(1-2):17-25 (75 ref.)

Nodular lymphocyte predominant Hodgkin's disease and anaplastic large-cell (CD30+) lymphoma: distinct entities or nonspecific patterns? Menestrina F, et al. **Semin Diagn Pathol** 1995 Aug;12(3):256-69 (75 ref.)

THERAPY

Successful autologous bone marrow transplant for relapsed Ki-1 lymphoma. Takamura M, et al. **Acta Paediatr Jpn** 1995 Aug;37(4):541-4 (9 ref.)

LYMPHOMA, LARGE LYMPHOID, DIFFUSE see **LYMPHOMA, LARGE-CELL, DIFFUSE**

LYMPHOMA, LOW-GRADE

CLASSIFICATION

[Low-grade malignant non-Hodgkin lymphomas--current status and trends in therapy] Hiddemann W. **Ther Umsch** 1996 Feb;53(2):123-32 (91 ref.) (Eng. Abstr.) **(Ger)**

DIAGNOSIS

[Diagnosis and treatment of low-grade non-Hodgkin lymphoma in 1996] Mandigers CM, et al. **Ned Tijdschr Geneeskd** 1996 Aug 3;140(31):1587-91 (35 ref.) **(Dut)**

DRUG THERAPY

[Diagnosis and treatment of low-grade non-Hodgkin lymphoma in 1996] Mandigers CM, et al. **Ned Tijdschr Geneeskd** 1996 Aug 3;140(31):1587-91 (35 ref.) **(Dut)**

IMMUNOLOGY

[Value of the blood picture and flow cytometry immunotyping in the early diagnosis of low-grade lymphoma] Schleiffenbaum B, et al. **Ther Umsch** 1996 Feb; 53(2):117-22 (15 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

[Low-grade non-Hodgkin's lymphomas and their cytofunctional correlation with peripheral compartments of normal lymphoid tissue] Sánchez Fayos J, et al. **Rev Clin Esp** 1995 Dec;195(12):864-72 (47 ref.) **(Spa)**

THERAPY

Bone marrow transplantation in low-grade non-Hodgkin's lymphoma. Lazarus HM. **Leuk Lymphoma** 1995 Apr; 17(3-4):199-210 (172 ref.)

[Therapy of low-grade non-Hodgkin lymphomas] Hiddemann W, et al. **Schweiz Rundsch Med Prax** 1996 Mar 19;85(12):357-63 (68 ref.) (Eng. Abstr.) **(Ger)**

[Low-grade malignant non-Hodgkin lymphomas--current status and trends in therapy] Hiddemann W. **Ther Umsch** 1996 Feb;53(2):123-32 (91 ref.) (Eng. Abstr.) **(Ger)**

LYMPHOMA, LYMPHOBLASTIC

see related
LEUKEMIA, T-CELL, ACUTE

CHEMICALLY INDUCED

Lymphoblastic lymphoma following prenatal exposure to phenytoin. Murray JC, et al. **J Pediatr Hematol Oncol** 1996 May;18(2):241-3 (23 ref.)

DIAGNOSIS

Acute lymphoblastic leukemia and the lymphoblastic lymphomas of childhood. Head DR, et al. **Semin Diagn Pathol** 1995 Nov;12(4):325-34 (31 ref.)

[Primary non-Hodgkin's lymphoma of the skull in an 11-year-old girl. Follow-up and review of the literature] Daldrup HE, et al. **Radiologe** 1996 Apr;36(4):354-9 (31 ref.) (Eng. Abstr.) **(Ger)**

LYMPHOMA, LYMPHOBLASTIC, CONVOLUTED see **LYMPHOMA, LYMPHOBLASTIC**

LYMPHOMA, LYMPHOBLASTIC, DIFFUSE see **LYMPHOMA, LYMPHOBLASTIC**

LYMPHOMA, LYMPHOBLASTIC, LARGE-CELL see **LYMPHOMA, LYMPHOBLASTIC**

LYMPHOMA, LYMPHOBLASTIC, NONCONVOLUTED see **LYMPHOMA, LYMPHOBLASTIC**

LYMPHOMA, LYMPHOCYTIC see **LYMPHOMA, SMALL-CELL**

LYMPHOMA, LYMPHOCYTIC, DIFFUSE, WELL-DIFFERENTIATED see **LYMPHOMA, SMALL LYMPHOCYTIC**

LYMPHOMA, LYMPHOCYTIC, PLASMACYTOID see **LYMPHOMA, SMALL-CELL**

LYMPHOMA, LYMPHOCYTIC, WELL-DIFFERENTIATED see **LYMPHOMA, SMALL LYMPHOCYTIC**

LYMPHOMA, LYMPHOPLASMACYTOID, CLL see **LYMPHOMA, SMALL LYMPHOCYTIC**

LYMPHOMA, MALIGNANT see **LYMPHOMA**

LYMPHOMA, MUCOSA-ASSOCIATED LYMPHOID TISSUE

Mucosa-associated lymphoid tissue lymphomas. Thieblemont C, et al. **Curr Opin Oncol** 1995 Sep;7(5):415-20 (61 ref.)

Mucosa-associated lymphoid tissue (MALT) lymphoma. Mori N, et al. **Pathol Int** 1995 Aug;45(8):544-51 (63 ref.)

ETIOLOGY

Lymphoma in Sjögren's syndrome. From histopathology to molecular pathology. Jordan RC, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Mar;81(3):308-20 (70 ref.)

[Primary gastric lymphoma of the MALT type. The current knowledge on its etiology, therapy and prognosis] Fischbach W, et al. **Strahlenther Onkol** 1995 Oct; 171(10):549-53 (16 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Lymphomas of mucosa-associated lymphoid tissue and antigen drive [editorial; comment] Wright DH. **J Pathol** 1996 Feb;178(2):111-2 (14 ref.) Comment on: J Pathol 1996 Feb;178(2):122-7.

MICROBIOLOGY

Primary gastric lymphoma. Isaacson PG.
Br J Biomed Sci 1995 Dec;52(4):291–6 (40 ref.)

PATHOLOGY

Synchronous adenocarcinoma and low grade B-cell lymphoma of mucosa associated lymphoid tissue (MALT) of the stomach. Wotherspoon AC, et al. **Histopathology** 1995 Oct;27(4):325–31 (45 ref.)

Simultaneous gastric adenocarcinoma and MALT-type lymphoma in Helicobacter pylori infection. von Herbay A, et al. **Virchows Arch** 1995;427(4):445–50 (62 ref.)

[Primary non-Hodgkin lymphoma of the stomach--internal medicine aspects] Fischbach W.
Schweiz Rundsch Med Prax 1995 Nov 28;84(48):1427–31 (18 ref.) (Eng. Abstr.) **(Ger)**

[Pathology and pathogenesis of extranodal lymphomas in the gastrointestinal tract] Müller-Hermelink HK, et al.
Schweiz Rundsch Med Prax 1995 Nov 28;84(48):1416–22 (22 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Helicobacter pylori, gastric MALT and B-cell clonality. Sorrentino D, et al. **Clin Exp Rheumatol** 1996 Jan–Feb;14 Suppl 14:S51–4 (25 ref.)

LYMPHOMA, NON-HODGKIN'S

Non-Hodgkin's lymphoma in childhood. Sandlund JT, et al. **N Engl J Med** 1996 May 9;334(19):1238–48 (102 ref.)

[Intestinal non-Hodgkin's lymphoma] Heise W, et al.
Dtsch Med Wochenschr 1995 Oct 20;120(42):1447–51 (40 ref.) **(Ger)**

CHEMICALLY INDUCED

Organochlorine compounds: Risk of non-Hodgkin's lymphoma and breast cancer? Hoffman W.
Arch Environ Health 1996 May–Jun;51(3):189–92 (42 ref.)

CHEMISTRY

MDR1/P-glycoprotein in haematological neoplasms. Marie JP, et al. **Eur J Cancer** 1996 Jun;32A(6):1034–8 (81 ref.)

CLASSIFICATION

Clinical analysis of 670 cases in two trials of the European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group subtyped according to the Revised European-American Classification of Lymphoid Neoplasms: a comparison with the Working Formulation. Pittaluga S, et al. **Blood** 1996 May 15;87(10):4358–67 (24 ref.)

Revised European-American Lymphoma Classification. Pileri SA, et al. **Curr Opin Oncol** 1995 Sep;7(5):401–7 (75 ref.)

Classification of non-Hodgkin's lymphomas in children. Perkins SL, et al. **Semin Diagn Pathol** 1995 Nov; 12(4):303–13 (77 ref.)

COMPLICATIONS

AIDS-associated malignancies. Krown SE.
Cancer Chemother Biol Response Modif 1996;16:441–61 (141 ref.)

Intravascular malignant lymphomatosis: a cause of subacute dementia. Treves TA, et al. **Dementia** 1995 Sep–Oct; 6(5):286–93 (107 ref.)

Clinicopathological factors relating malignant lymphoma with Sjögren's syndrome. Anaya JM, et al.
Semin Arthritis Rheum 1996 Apr;25(5):337–46 (71 ref.)

[Hepatobiliary disease in malignant lymphoma, leukemia, and MDS] Ishikawa T. **Ryoikibetsu Shokogun Shirizu** 1995; (8):375–8 (21 ref.) **(Jpn)**

DIAGNOSIS

Non Hodgkin's lymphoma of the maxilla as a first clinical manifestation of HIV infection. Report of a case. Berberi A, et al. **Bull Group Int Rech Sci Stomatol Odontol** 1995 Sep–Oct;38(3–4):77–80 (11 ref.)

Primary brain lymphoma. A brief review of clinical aspects and management. Sharma K, et al. **Neurosurg Rev** 1995; 18(3):193–9 (43 ref.)

Testicular lymphoblastic leukemia/lymphoma. Gutjahr P, et al. **World J Urol** 1995;13(4):230–2 (5 ref.)

[Primary lymphoma of the sphenoid sinus. Report of a case and review of the literature] Ferrario F, et al.
Ann Otolaryngol Chir Cervicofac 1995;112(6):298–302 (44 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

Autologous bone marrow transplantation versus chemotherapy in relapsed/refractory non-Hodgkin's lymphoma: estimates of long-term survival from the recent literature. Meehan KR, et al. **Am J Hematol** 1995 Oct; 50(2):116–23 (52 ref.)

The management and outcome of stage IAE nonHodgkin's lymphoma of the testis. Zietman AL, et al. **J Urol** 1996 Mar;155(3):943–6 (21 ref.)

Ifosfamide in the treatment of lymphoma. Coiffier B.
Semin Oncol 1996 Jun;23(3 Suppl 7):2–7 (46 ref.)

Ifosfamide in the treatment of non-Hodgkin's lymphoma. Pohlman B. **Semin Oncol** 1996 Jun;23(3 Suppl 6):27–32 (24 ref.)

Dose-intensive ifosfamide for the treatment of non-Hodgkin's lymphoma. Vose JM. **Semin Oncol** 1996 Jun;23(3 Suppl 6):33–7 (20 ref.)

[Integrative concept on the treatment of highly malignant non-Hodgkin lymphomas] Havemann K, et al.
Schweiz Rundsch Med Prax 1996 Mar 19;85(12):353–6 (26 ref.) (Eng. Abstr.) **(Ger)**

[Non-Hodgkin lymphoma] Ogawa M.
Gan To Kagaku Ryoho 1996 Aug;23(9):1143–8 (25 ref.) (Eng. Abstr.) **(Jpn)**

[Can lymphoma be cured by antibiotics?] Gunvén P, et al.
Lakartidningen 1996 Feb 28;93(9):767–8 (7 ref.) **(Swe)**

ENZYMOLOGY

Rising serum lactate dehydrogenase often caused by granulocyte-or Granulocyte-macrophage colony stimulating factor and not tumor progression in patients with lymphoma or myeloma. Sarris AH, et al.
Leuk Lymphoma 1995 May;17(5–6):473–7 (25 ref.)

EPIDEMIOLOGY

Review of Hodgkin's disease and lung cancer following non-Hodgkin's lymphoma in Rhode Island and review of the literature. Dores GM, et al. **R I Med** 1995 Nov; 78(11):317–9 (20 ref.)

ETIOLOGY

Sinonasal non-Hodgkin's lymphoma in patients infected with human immunodeficiency virus: report of three cases and review. Pomilla PV, et al. **Clin Infect Dis** 1995 Jul; 21(1):137–49 (117 ref.)

[Sjögren's syndrome associated with non-Hodgkin's lymphoma] Nagai K. **Nippon Rinsho** 1995 Oct; 53(10):2574–9 (23 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Molecular pathogenesis of non-Hodgkin lymphoma: a clinical perspective. Gaidano G, et al. **Haematologica** 1995 Sep–Oct;80(5):454–72 (151 ref.)

Molecular biology and cytogenetics of non-Hodgkin's lymphoma in children. Williams SA, et al.
Semin Diagn Pathol 1995 Nov;12(4):335–41 (42 ref.)

Update: lymphoid neoplasms--molecular characterizations of non-Hodgkin's lymphomas: impact on patient management. Chappuis PO, et al. **Semin Hematol** 1995 Jul; 32(3):237–41 (27 ref.)

Identification of genetic imbalances in malignant lymphoma using comparative genomic hybridization. Bentz M, et al. **Stem Cells** 1995 Dec;13 Suppl 3:83–7 (19 ref.)

IMMUNOLOGY

CD30 expression in normal and neoplastic lymphoid tissue: biological aspects and clinical implications. de Bruin PC, et al. **Leukemia** 1995 Oct;9(10):1620–7 (166 ref.)

PATHOLOGY

Stage IE non-Hodgkin's lymphoma involving the dura: A clinicopathologic study of five cases. Miranda RN, et al. **Arch Pathol Lab Med** 1996 Mar;120(3):254–60 (20 ref.)

Primary non-Hodgkin's lymphoma of the prostate gland: case report and review of the literature. Bell CR, et al.
Clin Oncol (R Coll Radiol) 1995;7(6):409–10 (11 ref.)

Primary non-Hodgkin lymphoma of the gastric stump. Vanbockrijck M, et al. **Pathol Res Pract** 1995 Jul; 191(6):525–9 (18 ref.)

[Primary non-Hodgkin lymphoma of the stomach--internal medicine aspects] Fischbach W.
Schweiz Rundsch Med Prax 1995 Nov 28;84(48):1427–31 (18 ref.) (Eng. Abstr.) **(Ger)**

[Pathology and pathogenesis of extranodal lymphomas in the gastrointestinal tract] Müller-Hermelink HK, et al.
Schweiz Rundsch Med Prax 1995 Nov 28;84(48):1416–22 (22 ref.) (Eng. Abstr.) **(Ger)**

[Mediastinal large-cell lymphoma of B-cell (thymic?) type. An anatomo-clinical entity in development] Sanchez Fayos J, et al. **An Med Interna** 1996 Jan;13(1):37–9 (27 ref.) **(Spa)**

PHYSIOPATHOLOGY

[Gastric lymphoma: natural history and classification] Ducreux M, et al. **Gastroenterol Clin Biol** 1996;20(5 Pt 2):B105–112 (52 ref.) **(Fre)**

RADIOGRAPHY

Primary cranial vault lymphoma mimicking meningioma. Isla A, et al. **Neuroradiology** 1996 Apr;38(3):211–3 (18 ref.)

RADIONUCLIDE IMAGING

Somatostatin-receptor imaging in lymphoma. Goldsmith SJ, et al. **Semin Nucl Med** 1995 Jul;25(3):262–71 (13 ref.)

RADIOTHERAPY

Current role of radiotherapy in Hodgkin's and non-Hodgkin's lymphoma. Shulman LN, et al.
Curr Opin Oncol 1995 Sep;7(5):421–5 (12 ref.)

The management and outcome of stage IAE nonHodgkin's lymphoma of the testis. Zietman AL, et al. **J Urol** 1996 Mar;155(3):943–6 (21 ref.)

[Radiotherapy of primary non-Hodgkin lymphoma of the stomach] Hartmann A, et al.
Schweiz Rundsch Med Prax 1996 Jun 4;85(23):765–70 (45 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Surgical therapy of gastrointestinal non-Hodgkin's lymphomas. Ernst M, et al. **Eur J Surg Oncol** 1996 Apr; 22(2):177–81 (30 ref.)

[Role of surgery in gastrointestinal lymphomas] Tissot E. **Schweiz Med Wochenschr** 1996 May 11;126(19):836–40 (26 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Autologous bone marrow transplantation versus chemotherapy in relapsed/refractory non-Hodgkin's lymphoma: estimates of long-term survival from the recent literature. Meehan KR, et al. **Am J Hematol** 1995 Oct; 50(2):116–23 (52 ref.)

Reactivation toxoplasmic retinochoroiditis in patients undergoing bone marrow transplantation: is there a role for chemoprophylaxis? Peacock JE Jr, et al.
Bone Marrow Transplant 1995 Jun;15(6):983–7 (23 ref.)

Non-Hodgkin's lymphomas--current status of therapy and future perspectives [see comments] Hiddemann W.
Eur J Cancer 1995 Dec;31A(13–14):2141–5 (68 ref.)
Comment in: Eur J Cancer 1995 Dec;31A(13–14):2135–7.

Interferon in the treatment of multiple myeloma and non Hodgkins lymphoma. Smruti BK, et al.
J Assoc Physicians India 1995;Suppl 3:33–7 (27 ref.)

Coherent view of non-Hodgkin's lymphoma. Aisenberg AC.
J Clin Oncol 1995 Oct;13(10):2656–75 (196 ref.)

Primary central nervous system lymphoma. Freilich RJ, et al. **Neurol Clin** 1995 Nov;13(4):901–14 (75 ref.)

Update: lymphoid neoplasms--molecular characterizations of non-Hodgkin's lymphomas: impact on patient management. Chappuis PO, et al. **Semin Hematol** 1995 Jul; 32(3):237–41 (27 ref.)

[Management of a patient with gastric lymphoma] Ruskoné-Fourmestraux A. **Gastroenterol Clin Biol** 1996; 20(5 Pt 2):B113–9 (31 ref.) **(Fre)**

[Second malignant disease in patients under treatment for malignant lymphoma] Várady E, et al. **Orv Hetil** 1995 Oct 22;136(43):2323–8 (35 ref.) (Eng. Abstr.) **(Hun)**

[Treatment of gastrointestinal non-Hodgkin's lymphoma] Barone C, et al. **Riv Eur Sci Med Farmacol** 1994 Sep–Dec; 16 Suppl 1:89–100 (29 ref.) (Eng. Abstr.) **(Ita)**

[Pregnancy outcome in long-term survivors with adult acute leukemia, malignant lymphoma and breast cancer] Kawamura S, et al. **Gan To Kagaku Ryoho** 1996 Jun; 23(7):821–6 (30 ref.) (Eng. Abstr.) **(Jpn)**

ULTRASONOGRAPHY

Endoscopic ultrasonography in gastric lymphoma. Caletti GC, et al. **Schweiz Med Wochenschr** 1996 May 11; 126(19):819–25 (40 ref.)

[Gastrointestinal lymphomas: ultrasonic aspects] Stuckmann G, et al. **Schweiz Med Wochenschr** 1996 May 11; 126(19):813–8 (20 ref.) (Eng. Abstr.) **(Ger)**

VIROLOGY

HIV-related primary non-Hodgkin's lymphoma of the vulva. Kaplan EJ, et al. **Gynecol Oncol** 1996 Apr;61(1):131–8 (41 ref.)

LYMPHOMA, SMALL-CELL

[Mantle cell lymphoma of the liver] Itoh Y, et al.
Ryoikibetsu Shokogun Shirizu 1995;(7):299–301 (11 ref.) **(Jpn)**

LYMPHOMA, SMALL LYMPHOCYTIC

see related
LEUKEMIA, LYMPHOCYTIC, CHRONIC

[Pseudolymphoma of the liver] Hiroshige K, et al.
Ryoikibetsu Shokogun Shirizu 1995;(7):333–5 (20 ref.) **(Jpn)**

COMPLICATIONS

[Heart rupture at the right atrial level as the first manifestation of malignant lymphoma] Menotti A, et al. **Cardiologia** 1996 Jan;41(1):65–7 (10 ref.) (Eng. Abstr.) **(Ita)**

ETIOLOGY

[A case of Sjögren's syndrome with an eyelid tumor, a so-termed pseudolymphoma of the iacrimal gland] Takeshita S, et al. **Ryumachi** 1996 Feb;36(1):43–9 (17 ref.) (Eng. Abstr.) **(Jpn)**

RADIOGRAPHY

A case of pulmonary pseudolymphoma: five years' roentgenographic observation. Takeshita T, et al.
Radiat Med 1995 Sep–Oct;13(5):243–6 (9 ref.)

LYMPHOMA, SMALL LYMPHOCYTIC, PLASMACYTOID see **LYMPHOMA, SMALL LYMPHOCYTIC**

LYMPHOMA, T-CELL

CLASSIFICATION

Lymphomatoid papulosis: a low-grade T-cell lymphoma? Orchard GE. **Br J Biomed Sci** 1996 Jun;53(2):162–9 (33 ref.)

COMPLICATIONS

Hemophagocytic syndrome in Epstein-Barr virus-associated T-lymphoproliferative disorders: disease spectrum, pathogenesis, and management. Su IJ, et al. **Leuk Lymphoma** 1995 Nov;19(5–6):401–6 (407 ref.)

DIAGNOSIS

Angioimmunoblastic T-cell lymphoma: new insights, but the clinical challenge remains [editorial] Jaffe ES. **Ann Oncol** 1995 Sep;6(7):631–2 (21 ref.)

Primary T-cell lymphoma of the cerebellum. A case report. Kleopa K, et al. **J Neurooncol** 1996 Mar;27(3):225–30 (28 ref.)

Primary Ki-1-positive T-cell lymphoma of the brain—an aggressive subtype of lymphoma: case report and review of the literature. Goldbrunner R, et al. **Surg Neurol** 1996 Jul;46(1):37–41 (24 ref.)

[Angiocentric immunoproliferative lesions: the terminology and the clinical picture] Casas Vara A, et al. **An Med Interna** 1996 May;13(5):245–7 (19 ref.) (Eng. Abstr.) **(Spa)**

EPIDEMIOLOGY

Primary gastric T-cell lymphoma with cutaneous involvement. A case report and review of the literature. Naghavi R, et al. **J Clin Gastroenterol** 1995 Dec;21(4):312–6 (17 ref.)

ETIOLOGY

Intestinal lymphoma and enteropathy [editorial; comment] Isaacson PG. **J Pathol** 1995 Oct;177(2):111–3 (22 ref.) Comment on: J Pathol 1995 Oct;177(2):115–22.

[Lymphomatoid papulosis] Dreno B. **Presse Med** 1995 Jun 24;24(23):1084–7 (13 ref.) (Eng. Abstr.) **(Fre)**

[Abnormal T-cell differentiation and development of T-cell lymphomas in TL-transgenic mice] Obata Y, et al. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2054–61 (34 ref.) **(Jpn)**

IMMUNOLOGY

[Angiocentric T-cell lymphoma of the lung] Csanaky G, et al. **Orv Hetil** 1996 Mar 3;137(9):473–6 (28 ref.) (Eng. Abstr.) **(Hun)**

PATHOLOGY

Discordant CD3 expression in lymphomas when studied on frozen and paraffin sections. Chan JK, et al. **Hum Pathol** 1995 Oct;26(10):1139–43 (48 ref.)

Nasal T-cell lymphoma and the lethal midline granuloma syndrome. Hartig G, et al. **Otolaryngol Head Neck Surg** 1996 Apr;114(4):653–6 (16 ref.)

VIROLOGY

Epstein-Barr virus (EBV) in extranodal T-cell non-Hodgkin's lymphomas (T-NHL). Identification of nasal T-NHL as a distinct clinicopathological entity associated with EBV. Kanavaros P, et al. **Leuk Lymphoma** 1995 Jun;18(1–2):27–34 (86 ref.)

Epstein-Barr virus in T and natural killer (NK) cell non-Hodgkin's lymphomas. Kanavaros P, et al. **Leukemia** 1996 Jun;10 Suppl 2:s84–7 (44 ref.)

LYMPHOMA, T-CELL, CUTANEOUS

Epidemiology and clinical manifestations of cutaneous T-cell lymphoma. Koh HK, et al. **Hematol Oncol Clin North Am** 1995 Oct;9(5):943–60 (105 ref.)

Cutaneous T-cell lymphoma (mycosis fungoides) [see comments] Lorincz AL. **Lancet** 1996 Mar 30; 347(9005):871–6 (30 ref.) Comment in: Lancet 1996 Jul 13;348(9020):130–1.

COMPLICATIONS

Subcutaneous T-cell lymphoma with associated hemophagocytic syndrome and terminal leukemic transformation. Romero LS, et al. **J Am Acad Dermatol** 1996 May;34(5 Pt 2):904–10 (22 ref.)

DIAGNOSIS

Cutaneous T-cell lymphoma presenting as papuloerythroderma—a case and review of the literature. Shah M, et al. **Clin Exp Dermatol** 1995 Mar;20(2):161–3 (11 ref.)

Evaluation of cutaneous lymphomas. Breneman DL. **Compr Ther** 1996 Mar;22(3):169–74 (18 ref.)

DRUG THERAPY

Photopheresis for the treatment of cutaneous T-cell lymphoma. Lim HW, et al. **Hematol Oncol Clin North Am** 1995 Oct;9(5):1117–26 (25 ref.)

Topical treatment of early cutaneous T-cell lymphoma. Ramsay DL, et al. **Hematol Oncol Clin North Am** 1995 Oct;9(5):1031–56 (84 ref.)

EPIDEMIOLOGY

Primary gastric T-cell lymphoma with cutaneous involvement. A case report and review of the literature. Naghavi R, et al. **J Clin Gastroenterol** 1995 Dec;21(4):312–6 (17 ref.)

GENETICS

T-cell receptor gene analysis in cutaneous T-cell lymphomas. Whittaker S. **Clin Exp Dermatol** 1996 Mar;21(2):81–7 (67 ref.)

IMMUNOLOGY

Immunoregulatory events in the skin of patients with cutaneous T-cell lymphoma. Hansen ER. **Arch Dermatol** 1996 May;132(5):554–61 (107 ref.)

The immunopathogenesis of cutaneous T-cell lymphoma. Rook AH, et al. **Hematol Oncol Clin North Am** 1995 Oct; 9(5):997–1010 (51 ref.)

PATHOLOGY

Advances in the histologic diagnosis of cutaneous T-cell lymphoma. Shapiro PE. **Adv Dermatol** 1996;11:255–84; discussion 285 (53 ref.)

Rapidly progressive CD8-positive cutaneous T-cell lymphoma with tongue involvement. Quarterman MJ, et al. **Am J Dermatopathol** 1995 Jun;17(3):287–91 (31 ref.)

General lessons from cutaneous lymphoma [editorial] Slater DN. **Br J Hosp Med** 1995 Nov 1–14;54(9):426–8 (6 ref.)

Pathology of cutaneous T-cell lymphoma. Burg G, et al. **Hematol Oncol Clin North Am** 1995 Oct;9(5):961–95 (80 ref.)

Prognosis and staging of cutaneous T-cell lymphoma. Foss FM, et al. **Hematol Oncol Clin North Am** 1995 Oct; 9(5):1011–9 (22 ref.)

Granulomatous slack skin: a possible precursor of Hodgkin's disease. DeGregorio R, et al. **J Am Acad Dermatol** 1995 Dec;33(6):1044–7 (22 ref.)

Subcutaneous T-cell lymphoma with associated hemophagocytic syndrome and terminal leukemic transformation. Romero LS, et al. **J Am Acad Dermatol** 1996 May;34(5 Pt 2):904–10 (22 ref.)

RADIOTHERAPY

Ultraviolet radiation for treatment of cutaneous T-cell lymphoma. Herrmann JJ, et al. **Hematol Oncol Clin North Am** 1995 Oct;9(5):1077–88 (40 ref.)

Electron beam treatment for cutaneous T-cell lymphoma. Jones GW, et al. **Hematol Oncol Clin North Am** 1995 Oct; 9(5):1057–76 (44 ref.)

THERAPY

Experimental therapies in the treatment of cutaneous T-cell lymphoma. Foss FM, et al. **Hematol Oncol Clin North Am** 1995 Oct;9(5):1127–37 (47 ref.)

Interferon in the treatment of cutaneous T-cell lymphoma. Olsen EA, et al. **Hematol Oncol Clin North Am** 1995 Oct; 9(5):1089–107 (72 ref.)

Assessing clinical outcomes in cutaneous T-cell lymphoma. Zackheim HS, et al. **Hematol Oncol Clin North Am** 1995 Oct;9(5):1021–9 (9 ref.)

VIROLOGY

No detection of HTLV-I proviral DNA in lesional skin biopsies from Swiss and German patients with cutaneous T-cell lymphoma. Böni R, et al. **Br J Dermatol** 1996 Feb; 134(2):282–4 (20 ref.)

LYMPHOMA, T-CELL, PERIPHERAL

New insights into peripheral T-cell lymphomas. DeCoteau JF, et al. **Curr Opin Oncol** 1995 Sep;7(5):408–14 (51 ref.)

COMPLICATIONS

Subcutaneous T-cell lymphoma with associated hemophagocytic syndrome and terminal leukemic transformation. Romero LS, et al. **J Am Acad Dermatol** 1996 May;34(5 Pt 2):904–10 (22 ref.)

PATHOLOGY

Subcutaneous T-cell lymphoma with associated hemophagocytic syndrome and terminal leukemic transformation. Romero LS, et al. **J Am Acad Dermatol** 1996 May;34(5 Pt 2):904–10 (22 ref.)

Peripheral T-cell lymphomas in children. Agnarsson BA, et al. **Semin Diagn Pathol** 1995 Nov;12(4):314–24 (116 ref.)

[Pulmonary lymphomatoid granulomatosis—peripheral T cell lymphoma—pathomorphologic characteristics] Maryniak RK. **Pneumonol Alergol Pol** 1995;63(5–6):336–8 (19 ref.) **(Pol)**

LYMPHOMATOID GRANULOMATOSIS

COMPLICATIONS

Lyphomatoid granulomatosis causing central diabetes insipidus: case report and review of the literature. Bushunow PW, et al. **Cancer Invest** 1996;14(2):112–19 (42 ref.)

DIAGNOSIS

[Angiocentric immunoproliferative lesions: the terminology and the clinical picture] Casas Vara A, et al. **An Med Interna** 1996 May;13(5):245–7 (19 ref.) (Eng. Abstr.) **(Spa)**

PATHOLOGY

[Pulmonary lymphomatoid granulomatosis—peripheral T cell lymphoma—pathomorphologic characteristics] Maryniak RK. **Pneumonol Alergol Pol** 1995;63(5–6):336–8 (19 ref.) **(Pol)**

LYMPHOMATOID PAPULOSIS

Lymphomatoid papulosis in children. Zirbel GM, et al. **J Am Acad Dermatol** 1995 Nov;33(5 Pt 1):741–8 (24 ref.)

CLASSIFICATION

Lymphomatoid papulosis: a low-grade T-cell lymphoma? Orchard GE. **Br J Biomed Sci** 1996 Jun;53(2):162–9 (33 ref.)

COMPLICATIONS

[Lymphomatoid papulosis] Dreno B. **Presse Med** 1995 Jun 24;24(23):1084–7 (13 ref.) (Eng. Abstr.) **(Fre)**

LYMPHOPENIA

see related
LYMPHOCYTE DEPLETION

ETIOLOGY

Autoimmune mechanisms of depletion of CD4 cells in HIV infection. Dalgleish AG. **Br J Haematol** 1995 Nov; 91(3):525–34 (106 ref.)

LYMPHOPLASMACYTOID LYMPHOMA, CLL see **LYMPHOMA, SMALL LYMPHOCYTIC**

LYMPHOPOIETIN-1 see **INTERLEUKIN-7**

LYMPHOPROLIFERATIVE DISORDERS

The atypical lymphoproliferative disorders: tissue expression. Beltrami CA. **Clin Exp Rheumatol** 1996 Jan–Feb;14 Suppl 14:S15–9 (11 ref.)

X-linked lymphoproliferative disease: twenty-five years after the discovery. Seemayer TA, et al. **Pediatr Res** 1995 Oct; 38(4):471–8 (67 ref.)

CHEMICALLY INDUCED

Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. Salloum E, et al. **J Clin Oncol** 1996 Jun;14(6):1943–9 (56 ref.)

CLASSIFICATION

Hodgkin's disease: a monoclonal lymphoproliferative disorder? Delabie J, et al. **Histopathology** 1995 Jul; 27(1):93–6 (29 ref.)

COMPLICATIONS

Rheumatological manifestations of haematological diseases. Menon S, et al. **Ann Rheum Dis** 1995 Oct;54(10):787–95 (126 ref.)

Hemophagocytic syndrome in Epstein-Barr virus-associated T-lymphoproliferative disorders: disease spectrum, pathogenesis, and management. Su IJ, et al. **Leuk Lymphoma** 1995 Nov;19(5–6):401–6 (407 ref.)

DIAGNOSIS

Inflammatory pseudotumor of the spleen: a rare entity that may mimic hematopoietic malignancy. McHenry CR, et al. **Am Surg** 1995 Dec;61(12):1067–71 (23 ref.)

[Tumor markers in lymphoproliferative disorders] Ohtsu T. **Nippon Rinsho** 1996 Jun;54(6):1621–5 (16 ref.) (Eng. Abstr.) **(Jpn)**

[The principles of the differential diagnosis of mature-cell lymphatic tumors (editorial)] Vorob'ev AI, et al. **Ter Arkh** 1995;67(7):3–7 (21 ref.) **(Rus)**

DRUG THERAPY

2-Chloro-2'-deoxyadenosine [editorial] Delannoy A, et al. **Acta Clin Belg** 1995;50(4):193-6 (10 ref.)

[Fludarabine in the treatment of chronic lymphocytic leukemia and other lymphoproliferative disorders] Pawelski S. **Acta Haematol Pol** 1995;26(3):263-8 (32 ref.) (Eng. Abstr.) **(Pol)**

EPIDEMIOLOGY

Risk factors and pathogenesis of posttransplant lymphoproliferative disorders. Ho M. **Transplant Proc** 1995 Oct;27(5 Suppl 1):38-40 (36 ref.)

ETIOLOGY

Epstein-Barr virus-related localized hepatic lymphoproliferative disorders after liver transplantation. Raymond E, et al. **Cancer** 1995 Oct 15;76(8):1344-51 (36 ref.)

Posttransplantation lymphoproliferative disorders (PTLD): current perspectives. Nalesnik MA. **Semin Thorac Cardiovasc Surg** 1996 Apr;8(2):139-48 (75 ref.)

[Malignancy in autoimmune diseases] Sugai S. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Feb;19(1):1-14 (38 ref.) (Eng. Abstr.) **(Jpn)**

[Lymphoproliferative disorders in patients with Sjögren's syndrome--Vg gene rearrangement and expression of bcl-2 protein] Sugai S, et al. **Nippon Rinsho** 1995 Oct; 53(10):2580-6 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Lymphoproliferative disease and cancer in the transplant patient] Herreros J, et al. **Rev Esp Cardiol** 1995;48 Suppl 7:129-34 (44 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

B-cell lymphoproliferative disorder complicated by a natural killer cell lymphoproliferative disorder of granular lymphocytes associated with T-cell gene rearrangement: case report and review of the literature. Dunphy CH, et al. **Mod Pathol** 1995 Oct;8(8):803-10 (30 ref.)

IMMUNOLOGY

Monitoring clonal expansion in the laboratory. Sala P, et al. **Clin Exp Rheumatol** 1996 Jan-Feb;14 Suppl 14:S31-5 (44 ref.)

B-cell lymphoproliferation in primary Sjögren's syndrome. Tzioufas AG. **Clin Exp Rheumatol** 1996 Jan-Feb;14 Suppl 14:S65-70 (41 ref.)

PATHOLOGY

Lymphoproliferative disorders of natural killer cells. Oshimi K. **Int J Hematol** 1996 Jun;63(4):279-90 (108 ref.)

B-cell lymphoproliferative disorder complicated by a natural killer cell lymphoproliferative disorder of granular lymphocytes associated with T-cell gene rearrangement: case report and review of the literature. Dunphy CH, et al. **Mod Pathol** 1995 Oct;8(8):803-10 (30 ref.)

RADIOGRAPHY

Intrathoracic lymphoproliferative disorders and lymphoma. Murray KA, et al. **Curr Probl Diagn Radiol** 1996 May-Jun; 25(3):78-106 (133 ref.)

VIROLOGY

The new lymphotropic herpesviruses (HHV-6, HHV-7, HHV-8) and hepatitis C virus (HCV) in human lymphoproliferative diseases: an overview. Luppi M, et al. **Haematologica** 1996 May-Jun;81(3):265-81 (158 ref.)

Post-transplant lymphoproliferative disorder. Basgoz N, et al. **Infect Dis Clin North Am** 1995 Dec;9(4):901-23 (69 ref.)

LYMPHOSARCOMA, BOVINE see **ENZOOTIC BOVINE LEUKOSIS**

LYMPHOSARCOMA, LYMPHOBLASTIC, DIFFUSE see **LYMPHOMA, LYMPHOBLASTIC**

LYMPHOTOXIN

ANALYSIS

[Lymphotoxin (LT)] Kasakura S. **Nippon Rinsho** 1995 Mar; 53 Su Pt 2:835-8 (11 ref.) **(Jpn)**

GENETICS

Porcine TNF: a review. Pauli U. **Vet Immunol Immunopathol** 1995 Aug;47(3-4):187-201 (63 ref.)

PHYSIOLOGY

Mechanisms of action of the tumor necrosis factor and lymphotoxin ligand-receptor system. Warzocha K, et al. **Eur Cytokine Netw** 1995 Mar-Apr;6(2):83-96 (143 ref.)

T-LYMPHOTROPIC VIRUS TYPE III ANTIBODIES, HUMAN see **HIV ANTIBODIES**

T-LYMPHOTROPIC VIRUS TYPE III ANTIGENS, HUMAN see **HIV ANTIGENS**

T-LYMPHOTROPIC VIRUS TYPE III INFECTIONS, HUMAN see **HIV INFECTIONS**

T-LYMPHOTROPIC VIRUS, TYPE III, SIMIAN see **SIV**

LYNCH SYNDROME see **COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS**

LYOPHILIZATION see **FREEZE DRYING**

LYSERGIC ACID DIETHYLAMIDE

Recent changes in the etiology of hearing disorders: perinatal drug exposure. Gerber SE, et al. **J Am Acad Audiol** 1995 Sep;6(5):371-7 (50 ref.)

LYSERGIDE see **LYSERGIC ACID DIETHYLAMIDE**

LYSINE

BIOSYNTHESIS

Construction of L-lysine-, L-threonine-, and L-isoleucine-overproducing strains of Corynebacterium glutamicum. Sahm H, et al. **Ann N Y Acad Sci** 1996 May 15;782:25-39 (34 ref.)

DRUG EFFECTS

Protein kinases and phosphatases that act on histidine, lysine, or arginine residues in eukaryotic proteins: a possible regulator of the mitogen-activated protein kinase cascade. Matthews HR. **Pharmacol Ther** 1995;67(3):323-50 (154 ref.)

LYSOSOMAL ALPHA-GLUCOSIDASE see **GLUCAN 1,4-ALPHA-GLUCOSIDASE**

LYSOSOMAL ENZYME DISORDERS see **LYSOSOMAL STORAGE DISEASES**

LYSOSOMAL STORAGE DISEASES

[Galactosialidosis--protective protein and related enzymes] Hirasawa M. **Nippon Rinsho** 1995 Dec;53(12):2967-72 (22 ref.) (Eng. Abstr.) **(Jpn)**

[Schindler disease/Kanzaki disease] Kanzaki T. **Nippon Rinsho** 1995 Dec;53(12):2982-7 (18 ref.) (Eng. Abstr.) **(Jpn)**

[Lysosomal storage diseases with angiokeratoma corporis diffusum] Kanzaki T. **Nippon Rinsho** 1995 Dec; 53(12):3062-7 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Farber's lipogranulomatosis] Koga M. **Nippon Rinsho** 1995 Dec;53(12):3009-13 (21 ref.) (Eng. Abstr.) **(Jpn)**

[Lysosomal storage disease] Okada S. **Nippon Rinsho** 1995 Dec;53(12):2911-4 (7 ref.) (Eng. Abstr.) **(Jpn)**

[Mini review: animal model of human lysosomal storage disease] Sakiyama T. **Nippon Rinsho** 1995 Dec; 53(12):3105-11 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Lysosomal membrane transport disorders--cystinosis and sialic acid storage disorders (Salla disease, ISSD)] Yano T, et al. **Nippon Rinsho** 1995 Dec;53(12):3068-71 (5 ref.) (Eng. Abstr.) **(Jpn)**

[Disorders of glycoprotein degradation] Yoshida K, et al. **Nippon Rinsho** 1995 Dec;53(12):2973-81 (23 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

[Biochemical diagnosis and enzymic diagnosis of lysosomal diseases] Izumi T. **Nippon Rinsho** 1995 Dec;53(12):2915-20 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Prenatal diagnosis of lysosomal diseases] Owada M, et al. **Nippon Rinsho** 1995 Dec;53(12):2926-32 (22 ref.) **(Jpn)**

[Gene diagnosis of lysosomal diseases] Suzuki Y. **Nippon Rinsho** 1995 Dec;53(12):2921-5 (4 ref.) (Eng. Abstr.) **(Jpn)**

[Pseudodeficiency of lysosomal enzymes] Czartoryska B. **Pediatr Pol** 1995 Oct;70(10):857-63 (43 ref.) **(Pol)**

[Sialidosis type II, infantile form. Apropos a case] Menau Martin G, et al. **An Esp Pediatr** 1996 Jan;44(1):76-8 (8 ref.) **(Spa)**

DRUG THERAPY

[Medicinal therapy for lysosomal storage diseases] Sakuragawa N. **Nippon Rinsho** 1995 Dec;53(12):3072-6 (15 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

[Gene diagnosis of lysosomal diseases] Suzuki Y. **Nippon Rinsho** 1995 Dec;53(12):2921-5 (4 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

New insight into lysosomal protein storage disease: delayed catabolism of ATP synthase subunit c in Batten disease. Kominami E, et al. **Neurochem Res** 1995 Nov;20(11):1305-9 (26 ref.)

[Glycolipid analysis by confocal laser scanning microscopic system] Itoh K. **Nippon Rinsho** 1995 Dec;53(12):3095-101 (11 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Infantile sialic acid storage disease: a rare cause of cytoplasmic vacuolation in pediatric patients. Hale LP, et al. **Pediatr Pathol Lab Med** 1995 May-Jun;15(3):443-53 (18 ref.)

PREVENTION & CONTROL

[Screening methods for the diagnosis of lysosomal storage disease] Mutoh T, et al. **Nippon Rinsho** 1995 Dec; 53(12):2933-7 (9 ref.) (Eng. Abstr.) **(Jpn)**

THERAPY

Microglia: the effector cell for reconstitution of the central nervous system following bone marrow transplantation for lysosomal and peroxisomal storage diseases. Krivit W, et al. **Cell Transplant** 1995 Jul-Aug;4(4):385-92 (71 ref.)

[Bone marrow transplantation for lysosomal storage diseases] Imaizumi M. **Nippon Rinsho** 1995 Dec;53(12):3083-8 (21 ref.) (Eng. Abstr.) **(Jpn)**

[Enzyme replacement therapy of patients with lysosomal storage disease] Takada G, et al. **Nippon Rinsho** 1995 Dec; 53(12):3077-82 (22 ref.) (Eng. Abstr.) **(Jpn)**

LYSOSOMES

[Lysosomal enzymes, sphingolipid activator proteins, and protective protein] Suzuki Y. **Nippon Rinsho** 1995 Dec; 53(12):2887-91 (7 ref.) (Eng. Abstr.) **(Jpn)**

CHEMISTRY

Plant lysozymes. Beintema JJ, et al. **EXS** 1996;75:75-86 (52 ref.)

ENZYMOLOGY

Insulin-like growth factor II/cation-independent mannose 6-phosphate receptor and lysosomal enzyme recognition. Dahms NM. **Biochem Soc Trans** 1996 Feb;24(1):136-41 (46 ref.)

Function of the two mannose 6-phosphate receptors in lysosomal enzyme transport. Munier-Lehmann H, et al. **Biochem Soc Trans** 1996 Feb;24(1):133-6 (23 ref.)

Nutrition, lysosomal proteases, and protein breakdown [see comments] Andreu AL, et al. **Nutrition** 1995 Jul-Aug; 11(4):382-7 (66 ref.) Comment in: Nutrition 1995 Jul-Aug;11(4):398.

[Metabolic pathway of the degradation of macromolecules by lysosomal enzymes] Arai K, et al. **Nippon Rinsho** 1995 Dec;53(12):2904-10 (12 ref.) (Eng. Abstr.) **(Jpn)**

[Biosynthesis, processing, and lysosome targeting of acid phosphatase] Himeno M, et al. **Nippon Rinsho** 1995 Dec; 53(12):2898-903 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Lysosomal hydrolases have specific conformational domains for acquisition of mannose-6-phosphate] Himeno M, et al. **Nippon Rinsho** 1995 Dec;53(12):2892-7 (18 ref.) (Eng. Abstr.) **(Jpn)**

[Biochemical diagnosis and enzymic diagnosis of lysosomal diseases] Izumi T. **Nippon Rinsho** 1995 Dec;53(12):2915-20 (10 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Plant lysozymes. Beintema JJ, et al. **EXS** 1996;75:75-86 (52 ref.)

[Batten disease (Neuronal ceroid lipofuscinoses)--accumulation of ATP synthase subunit c caused by the delay of lysosomal degradation] Ezaki J, et al. **Nippon Rinsho** 1995 Dec;53(12):3055-61 (22 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Intracellular trafficking of lysosomal membrane proteins. Hunziker W, et al. **Bioessays** 1996 May;18(5):379-89 (88 ref.)

The endosomal-lysosomal system of neurons: new roles. Nixon RA, et al. **Trends Neurosci** 1995 Nov;18(11):489-96 (80 ref.)

SECRETION

The secretion of preformed granules by macrophages and neutrophils. Tapper H. **J Leukoc Biol** 1996 May; 59(5):613-22 (128 ref.)

LYSOZYME see **MURAMIDASE**

LYSSAVIRUS

CLASSIFICATION

[Lissaviruses] Pille ER. **Vopr Virusol** 1996 Jan-Feb;41(1):2-6 (30 ref.) **(Rus)**

LYSYL T RNA SYNTHETASE

METABOLISM

Lysyl-tRNA synthetase. Freist W, et al. **Biol Chem Hoppe Seyler** 1995 Aug;376(8):451-72 (251 ref.)

LYT 1 ANTIGEN see **ANTIGENS, LY**

M13 PHAGE

M13 PHAGE see **BACTERIOPHAGE M13**

M99 see **ETORPHINE**

M-CSF see **MACROPHAGE COLONY-STIMULATING FACTOR**

M PHASE see **MITOSIS**

M PHASE-PROMOTING FACTOR see **MATURATION-PROMOTING FACTOR**

MACACA

PHYSIOLOGY

Circuitry for color coding in the primate retina. Dacey DM. **Proc Natl Acad Sci U S A** 1996 Jan 23;93(2):582–8 (55 ref.)

Behind the optic nerve: an inside view of the primate visual system. Van Essen DC. **Trans Am Ophthalmol Soc** 1995; 93:123–33 (2 ref.)

PSYCHOLOGY

Observations on task-related behaviour of Macaca arctoides. Linnankoski I, et al. **Folia Primatol (Basel)** 1995;65(1):34–7 (7 ref.)

MACACA FASCICULARIS

IMMUNOLOGY

Determination of lymphocyte subsets and cytokine levels in cynomolgus monkeys. Verdier F, et al. **Toxicology** 1995 Dec 20;105(1):81–90 (27 ref.)

MACACA MULATTA

PHYSIOLOGY

Prevention of obesity in middle-aged monkeys: food intake during body weight clamp. Hansen BC, et al. **Obes Res** 1995 Sep;3 Suppl 2:199s–204s (26 ref.)

MACAQUE see **MACACA**

MACE see **OMEGA-CHLOROACETOPHENONE**

MACHADO-JOSEPH DISEASE

[Machado-Joseph disease] Yuasa T. **No To Shinkei** 1995 Oct; 47(10):939–45 (28 ref.) **(Jpn)**

GENETICS

[Gene hunting for Machado-Joseph disease] Kakizuka A. **No To Shinkei** 1996 Apr;48(4):329–32 (6 ref.) **(Jpn)**

PATHOLOGY

[Neuropathology of dentatorubral-pallidoluysian atrophy and Machado-Joseph disease] Takahashi H, et al. **No To Shinkei** 1995 Oct;47(10):947–53 (34 ref.) **(Jpn)**

MACROGLOBULINEMIA see **WALDENSTROM'S MACROGLOBULINEMIA**

MACROGLOSSIA

see related
BECKWITH-WIEDEMANN SYNDROME

ETIOLOGY

Posttraumatic macroglossia complicated by hyaluronidase injection. Dort JC. **Otolaryngol Head Neck Surg** 1996 Feb; 114(2):308–9 (9 ref.)

MACROGOLS see **POLYETHYLENE GLYCOLS**

MACROLIDE ANTIBIOTICS see **ANTIBIOTICS, MACROLIDE**

MACROLIDES

PHARMACOLOGY

[Macrolides and drug interactions: review of the literature] Lauby V, et al. **Therapie** 1996 Mar-Apr;51(2):177–84 (91 ref.) (Eng. Abstr.) **(Fre)**

THERAPEUTIC USE

Evaluation of penicillins, cephalosporins, and macrolides for therapy of streptococcal pharyngitis. Shulman ST. **Pediatrics** 1996 Jun;97(6 Pt 2):955–9 (34 ref.)

MACROMOLECULAR SYSTEMS

see related
POLYMERS

Measuring colloidal and macromolecular properties by FFF. Giddings JC. **Anal Chem** 1995 Oct 1;67(19):592A–598A (33 ref.)

Plasmodesmata: intercellular channels for macromolecular transport in plants. Lucas WJ. **Curr Opin Cell Biol** 1995 Oct;7(5):673–80 (48 ref.)

MACROPHAGE ACTIVATION

Regulation of macrophage activation and HIV replication. Montaner LJ, et al. **Adv Exp Med Biol** 1995;374:47–56 (69 ref.)

Activated liver macrophages in human liver diseases. Yamamoto K, et al. **J Gastroenterol Hepatol** 1995;10 Suppl 1:S72–6 (29 ref.)

Targeting lipoproteins to Fc gamma receptors with bispecific antibodies. Morganelli PM. **J Hematother** 1995 Oct; 4(5):457–61 (19 ref.)

On the relationship between activation and breakdown of macrophages in the pathogenesis of silicosis (an overview). Privalova LI, et al. **Med Lav** 1995 Nov-Dec;86(6):511–21 (28 ref.)

IMMUNOLOGY

Macrophages and transplant arteriosclerosis: known and novel molecules. Russell ME. **J Heart Lung Transplant** 1995 Nov-Dec;14(6 Pt 2):S111–5 (31 ref.)

PHYSIOLOGY

Intracytoplasmic sequences involved in the biological properties of low-affinity receptors for IgG expressed by murine macrophages. Daëron M. **Braz J Med Biol Res** 1995 Mar;28(3):263–74 (50 ref.)

MACROPHAGE CHEMOTACTIC FACTORS see **CHEMOTACTIC FACTORS, MACROPHAGE**

MACROPHAGE CHEMOTAXINS see **CHEMOTACTIC FACTORS, MACROPHAGE**

MACROPHAGE COLONY-STIMULATING FACTOR

BLOOD

[Macrophage colony-stimulating factor (M-CSF)] Motoyoshi K. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:803–5 (18 ref.) **(Jpn)**

PHYSIOLOGY

The heterogeneity of the osteopetroses reflects the diversity of cellular influences during skeletal development. Popoff SN, et al. **Bone** 1995 Nov;17(5):437–45 (131 ref.)

Modulation of osteoclast differentiation by local factors. Suda T, et al. **Bone** 1995 Aug;17(2 Suppl):87S–91S (30 ref.)

MACROPHAGE-GRANULOCYTE INDUCER see **COLONY-STIMULATING FACTORS**

MACROPHAGES

see related
PHAGOCYTOSIS

CYTOLOGY

Immune cell traffic from blood through the normal human skin to lymphatics. Olszewski WL, et al. **Clin Dermatol** 1995 Sep-Oct;13(5):473–83 (29 ref.)

The fetal macrophage: a review. Brighton VW, et al. **J Am Coll Surg** 1996 Mar;182(3):270–6 (50 ref.)

Development, differentiation, and phenotypic heterogeneity of murine tissue macrophages. Naito M, et al. **J Leukoc Biol** 1996 Feb;59(2):133–8 (79 ref.)

Role of yolk sac endodermal cells with special reference to the fetal macrophage differentiation. Yamashita A. **J Leukoc Biol** 1996 Feb;59(2):139–44 (26 ref.)

DRUG EFFECTS

Effects of mesalazine on lamina propria white cell functions. Verspaget HW. **Adv Exp Med Biol** 1995;371A:317–20 (20 ref.)

Examination of the role of MAP kinase in the response of macrophages to lipopolysaccharide. DeFranco AL, et al. **Prog Clin Biol Res** 1995;392:407–20 (30 ref.)

[Azithromycin and Mycobacterium avium infection] Perronne C. **Pathol Biol (Paris)** 1995 Jun;43(6):565–7 (12 ref.) (Eng. Abstr.) **(Fre)**

ENZYMOLOGY

On the expression of nitric oxide synthase by human macrophages. Why no NO? Albina JE. **J Leukoc Biol** 1995 Dec;58(6):643–9 (64 ref.)

Examination of the role of MAP kinase in the response of macrophages to lipopolysaccharide. DeFranco AL, et al. **Prog Clin Biol Res** 1995;392:407–20 (30 ref.)

IMMUNOLOGY

T-cell regulation of macrophage function. Doherty TM. **Curr Opin Immunol** 1995 Jun;7(3):400–4 (43 ref.)

In vitro interaction of Mycobacterium tuberculosis and macrophages: activation of anti-mycobacterial activity of macrophages and mechanisms of anti-mycobacterial activity. O'Brien L, et al. **Curr Top Microbiol Immunol** 1996;215:97–130 (206 ref.)

The role of macrophage subpopulations in autoimmune disease of the central nervous system. Bauer J, et al. **Histochem J** 1996 Feb;28(2):83–97 (104 ref.)

Costimulation and the regulation of antimicrobial immunity. Kaye PM. **Immunol Today** 1995 Sep;16(9):423–7 (45 ref.)

Bacterial stimulators of macrophages. Hauschildt S, et al. **Int Rev Cytol** 1995;161:263–331 (341 ref.)

The phagocytosis of mycoplasmas. Marshall AJ, et al. **J Med Microbiol** 1995 Oct;43(4):239–50 (163 ref.)

The macrophage-T-lymphocyte theory of schizophrenia: additional evidence. Smith RS, et al. **Med Hypotheses** 1995 Aug;45(2):135–41 (84 ref.)

Structure and function of the natural-resistance-associated macrophage protein (Nramp1), a candidate protein for infectious and autoimmune disease susceptibility. Blackwell JM. **Mol Med Today** 1996 May;2(5):205–11 (38 ref.)

[Comparative biology of Legionella species--with special reference to host-parasite relationships] Yoshida S, et al. **Nippon Saikingaku Zasshi** 1995 Jul;50(3):745–64 (139 ref.) **(Jpn)**

[Nonspecific host defense mechanism by macrophages--analysis by NF-IL6 deficient mice] Tanaka T. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2083–96 (32 ref.) **(Jpn)**

[Macrophages and lymphocytes in immune reactions during the course of tuberculosis] Dubaniewicz A, et al. **Pneumonol Alergol Pol** 1995;63(7-8):469–73 (29 ref.) **(Pol)**

METABOLISM

Substance P and stress-induced changes in macrophages. Chancellor-Freeland C, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:472–84 (39 ref.)

The stimulation of the cholesterol esterification pathway by atherogenic lipoproteins in macrophages. Tabas I. **Curr Opin Lipidol** 1995 Oct;6(5):260–8 (112 ref.)

The effect of NO/EDRF and monocytes/macrophages on LDL-oxidation. Leitinger N, et al. **J Physiol Pharmacol** 1995 Dec;46(4):385–408 (144 ref.)

On the relationship between activation and breakdown of macrophages in the pathogenesis of silicosis (an overview). Privalova LI, et al. **Med Lav** 1995 Nov-Dec;86(6):511–21 (28 ref.)

[Characteristic of nitric oxide production in macrophages] Takagi K, et al. **Seikagaku** 1995 Nov;67(11):1287–90 (17 ref.) **(Jpn)**

MICROBIOLOGY

Of microbes and macrophages: entry, survival and persistence. Russell DG. **Curr Opin Immunol** 1995 Aug; 7(4):479–84 (59 ref.)

PARASITOLOGY

Of microbes and macrophages: entry, survival and persistence. Russell DG. **Curr Opin Immunol** 1995 Aug; 7(4):479–84 (59 ref.)

[Leishmania-macrophage interactions: role of cytokines and molecules co-involved in killing] Faliero SM, et al. **Parassitologia** 1995 Apr;37(1):5–15 (126 ref.) (Eng. Abstr.) **(Ita)**

PATHOLOGY

Local macrophage proliferation in progressive renal injury. Lan HY, et al. **Contrib Nephrol** 1996;118:100–8 (22 ref.)

The experimental granuloma. A hypothesis to explain the persistence of the lesion. Mariano M. **Rev Inst Med Trop Sao Paulo** 1995 Mar-Apr;37(2):161–76 (115 ref.)

PHYSIOLOGY

The involvement of macrophages and lymphocytes in the apoptosis of enterocytes. Iwanaga T. **Arch Histol Cytol** 1995 Jun;58(2):151–9 (38 ref.)

Membrane molecules and macrophage endocytosis: scavenger receptor and macrosialin as markers of plasma-membrane and vacuolar functions. da Silva RP, et al. **Biochem Soc Trans** 1996 Feb;24(1):220–4 (17 ref.)

The macrophage. Gordon S. **Bioessays** 1995 Nov; 17(11):977–86 (30 ref.)

Role of macrophages in beta 2-microglobulin-related dialysis amyloidosis. Gejyo F, et al. **Contrib Nephrol** 1995; 112:97–104 (18 ref.)

Macrophages in host defense mechanisms. van Rooijen N, et al. **Curr Top Microbiol Immunol** 1996;210:159–65 (33 ref.)

The possible role of glutamine in some cells of the immune system and the possible consequence for the whole animal. Newsholme EA. **Experientia** 1996 May 15;52(5):455–9 (20 ref.)

Macrophages in the external muscle layers of mammalian intestines. Mikkelsen HB. **Histol Histopathol** 1995 Jul; 10(3):719–36 (92 ref.)

Immunopathology of tuberculosis: roles of macrophages and monocytes. Fenton MJ, et al. **Infect Immun** 1996 Mar; 64(3):683–90 (95 ref.)

Endotoxin signal transduction in macrophages. Sweet MJ, et al. **J Leukoc Biol** 1996 Jul;60(1):8–26 (304 ref.)

The secretion of preformed granules by macrophages and neutrophils. Tapper H. **J Leukoc Biol** 1996 May; 59(5):613–22 (128 ref.)

Sex steroid hormones and macrophage function. Miller L, et al. **Life Sci** 1996;59(1):1-14 (186 ref.)
Regulation of human immunodeficiency virus type 1 and cytokine gene expression in myeloid cells by NF-kappa B/Rel transcription factors. Roulston A, et al. **Microbiol Rev** 1995 Sep;59(3):481-505 (481 ref.)
Signaling events in monocytes and macrophages. Chow CW, et al. **New Horiz** 1995 May;3(2):342-51 (72 ref.)
Wound healing: the role of the macrophage and other immune cells. DiPietro LA. **Shock** 1995 Oct;4(4):233-40 (72 ref.)
[Interactions of neuromediators and neurohormones on dendritic cells, monocytes and macrophages (out of the central nervous system)] Misery L, et al. **Pathol Biol (Paris)** 1995 Dec;43(10):876-81 (66 ref.) (Eng. Abstr.) **(Fre)**
[Attempts to elucidate the reasons why mycobacterial infections are generally intractable] Tomioka H. **Nippon Saikingaku Zasshi** 1995 Jul;50(3):687-701 (50 ref.) **(Jpn)**

VIROLOGY

Role of macrophages in the pathogenesis of human immunodeficiency virus (HIV) infection. Crowe SM. **Aust N Z J Med** 1995 Dec;25(6):777-83 (54 ref.)
Cytomegalovirus persistence in macrophages and endothelial cells. Fish KN, et al. **Scand J Infect Dis Suppl** 1995;99:34-40 (54 ref.)

MACROPHAGES, ALVEOLAR

Pulmonary intravascular macrophages. Role in acute lung injury. Warner AE. **Clin Chest Med** 1996 Mar;17(1):125-35 (60 ref.)

DRUG EFFECTS

Review of azithromycin activity against Legionella spp. Edelstein PH. **Pathol Biol (Paris)** 1995 Jun;43(6):569-72 (18 ref.)

IMMUNOLOGY

[Clinical and immunobiological observations on the inflammatory activity of sarcoidosis] Müller-Quernheim J. **Pneumologie** 1996 Jan;50(1):40-8 (101 ref.) **(Ger)**

METABOLISM

Surfactant protein-D modulates interaction of Pneumocystis carinii with alveolar macrophages [see comments] Limper AH, et al. **J Lab Clin Med** 1995 Nov;126(5):416-22 (37 ref.) Comment in: J Lab Clin Med 1995 Nov;126(5):414-5.
Alveolar macrophages as a cell source of cytokine hyperproduction in HIV-related interstitial lung disease. Agostini C, et al. **J Leukoc Biol** 1995 Nov;58(5):495-500 (37 ref.)

PHYSIOLOGY

Pulmonary intravascular phagocytosis in liver disease. Chang SW, et al. **Clin Chest Med** 1996 Mar;17(1):137-50 (62 ref.)
The role of inflammation in the pathogenesis of bronchopulmonary dysplasia. Pierce MR, et al. **Pediatr Pulmonol** 1995 Jun;19(6):371-8 (89 ref.)

MACROPHAGES, PERITONEAL

SECRETION

Mechanisms regulating cytokine release from peritoneal macrophages during continuous ambulatory peritoneal dialysis. Fieren MW. **Blood Purif** 1996;14(2):179-87 (60 ref.)

MACROPHAGES, PULMONARY see **MACROPHAGES, ALVEOLAR**

MACROSOMIA, FETAL see **FETAL MACROSOMIA**

MACULA LUTEA

Congenital and childhood macular lesions. Drack AV. **Int Ophthalmol Clin** 1995 Fall;35(4):1-18 (34 ref.)
Tumors in the posterior pole. Edwards MG, et al. **Int Ophthalmol Clin** 1995 Fall;35(4):123-35 (48 ref.)
Advances in macular dystrophies. Saperstein DA. **Int Ophthalmol Clin** 1995 Fall;35(4):19-35 (65 ref.)

PATHOLOGY

Macular epiretinal membrane formation and treated retinal breaks. Saran BR, et al. **Am J Ophthalmol** 1995 Oct; 120(4):480-5 (27 ref.)
Genetic and molecular studies of macular dystrophies: recent developments. Zhang K, et al. **Surv Ophthalmol** 1995 Jul-Aug;40(1):51-61 (84 ref.)

SURGERY

Submacular surgery. Are randomized trials necessary? [editorial] Bressler NM. **Arch Ophthalmol** 1995 Dec; 113(12):1557-60 (31 ref.)
Submacular surgical procedures. Capone A Jr. **Int Ophthalmol Clin** 1995 Fall;35(4):83-93 (33 ref.)
[Microsurgery of the macula lutea] Chauvaud D. **Bull Acad Natl Med** 1996 Mar;180(3):625-32 (14 ref.) (Eng. Abstr.) **(Fre)**

MACULAR DEGENERATION

Epidemiology of age-related maculopathy. Vingerling JR, et al. **Epidemiol Rev** 1995;17(2):347-60 (146 ref.)

DIAGNOSIS

Indocyanine green angiography. Owens SL. **Br J Ophthalmol** 1996 Mar;80(3):263-6 (50 ref.)

ETIOLOGY

[Age-related macular degeneration. 1. Epidemiology, pathogenesis and differential diagnosis] Pauleikhoff D, et al. **Ophthalmologe** 1996 Jun;93(3):299-315 (31 ref.) **(Ger)**

GENETICS

Genetic and molecular studies of macular dystrophies: recent developments. Zhang K, et al. **Surv Ophthalmol** 1995 Jul-Aug;40(1):51-61 (84 ref.)

PREVENTION & CONTROL

Evidence for protection against age-related macular degeneration by carotenoids and antioxidant vitamins. Snodderly DM. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1448S-1461S (153 ref.)
Antioxidants and age-related eye disease. Current and future perspectives. Christen WG, et al. **Ann Epidemiol** 1996 Jan; 6(1):60-6 (79 ref.)

SURGERY

[Surgery of idiopathic macular holes] Hannouche D, et al. **J Fr Ophtalmol** 1995;18(8-9):559-63 (33 ref.) **(Fre)**

MACULAR HOLES see **RETINAL PERFORATIONS**

MACULOPATHY, AGE-RELATED see **MACULAR DEGENERATION**

MAD COW DISEASE see **ENCEPHALOPATHY, BOVINE SPONGIFORM**

MADURA FOOT see **MADUROMYCOSIS**

MADURELLA see **HYPHOMYCETES**

MADUROMYCOSIS

Pale grain eumycetomas in Madras. Venugopal PV, et al. **Australas J Dermatol** 1995 Aug;36(3):149-51 (20 ref.)
[Mycetomas in Africa] Develoux M, et al. **Sante** 1995 Jul-Aug;5(4):211-7 (25 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

Treatment of eumycetoma and actinomycetoma. Welsh O, et al. **Curr Top Med Mycol** 1995;6:47-71 (105 ref.)

MICROBIOLOGY

Pseudallescheria boydii in an immunocompromised host. Successful treatment with debridement and itraconazole. Ruxin TA, et al. **Arch Dermatol** 1996 Apr;132(4):382-4 (23 ref.)
Primary cutaneous nocardiosis caused by Nocardia otitidiscaviarum: two cases and a review of the literature. Freland C, et al. **J Trop Med Hyg** 1995 Dec;98(6):395-403 (26 ref.)

SURGERY

Treatment of eumycetoma and actinomycetoma. Welsh O, et al. **Curr Top Med Mycol** 1995;6:47-71 (105 ref.)

MAEDI VIRUS see **VISNA-MAEDI VIRUS**

MAEDI-VISNA VIRUS see **VISNA-MAEDI VIRUS**

MAFFUCCI SYNDROME see **ENCHONDROMATOSIS**

MAG PROTEIN see **MYELIN-ASSOCIATED GLYCOPROTEIN**

MAGGOT INFESTATIONS see **MYIASIS**

MAGIC

"Sucking with vampires". The medicine of unreason. Weissmann G. **Ann N Y Acad Sci** 1996 Jun 24;775:179-87 (26 ref.)

MAGNESIUM

ADMINISTRATION & DOSAGE

Magnesium status and health. Dreosti IE. **Nutr Rev** 1995 Sep; 53(9 Pt 2):S23-7 (37 ref.)
ISIS 4: clinical controversy regarding magnesium infusion, thrombolytic therapy, and acute myocardial infarction. Seelig MS. **Nutr Rev** 1995 Sep;53(9):261-4 (52 ref.)

BLOOD

Physiology and regulation. Ionized calcium, magnesium and lactate measurements in critical care settings. Toffaletti J. **Am J Clin Pathol** 1995 Oct;104(4 Suppl 1):S88-94 (20 ref.)
[Magnesium] Arakawa Y, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:762-8 (7 ref.) **(Jpn)**

CHEMISTRY

The importance of being modified: roles of modified nucleosides and Mg2+ in RNA structure and function. Agris PF. **Prog Nucleic Acid Res Mol Biol** 1996;53:79-129 (175 ref.)

METABOLISM

Isolated magnesium malabsorption in a 10-year-old boy. Romero R, et al. **Am J Gastroenterol** 1996 Mar;91(3):611-3 (12 ref.)
Impaired absorption of magnesium in the aetiology of grass tetany. Dua K, et al. **Br Vet J** 1995 Jul-Aug;151(4):413-26 (98 ref.)
Disorders of magnesium metabolism. Nadler JL, et al. **Endocrinol Metab Clin North Am** 1995 Sep;24(3):623-41 (118 ref.)

PHARMACOKINETICS

Recent data on the evaluation of magnesium bioavailability in humans. Benech H, et al. **Magnes Res** 1995 Sep; 8(3):277-84 (29 ref.)

PHARMACOLOGY

Complementary vascular-protective actions of magnesium and taurine: a rationale for magnesium taurate. McCarty MF. **Med Hypotheses** 1996 Feb;46(2):89-100 (136 ref.)

PHYSIOLOGY

Significance of magnesium in congestive heart failure. Douban S, et al. **Am Heart J** 1996 Sep;132(3):664-71 (103 ref.)
Integrin-ligand binding. Do integrins use a 'MIDAS touch' to grasp an Asp? Bergelson JM, et al. **Curr Biol** 1995 Jun 1;5(6):615-7 (15 ref.)
Calcium, magnesium and phosphorus in the nutrition of the newborn. Venkataraman PS, et al. **J Am Coll Nutr** 1995 Oct;14(5):439-47 (102 ref.)
[Magnesium and the transport system] Langmeier M. **Cesk Fysiol** 1995 Dec;44(4):191-4 (17 ref.) (Eng. Abstr.) **(Cze)**
[Indications for the use of magnesium in anesthesia and intensive care] Delhumeau A, et al. **Ann Fr Anesth Reanim** 1995;14(5):406-16 (113 ref.) (Eng. Abstr.) **(Fre)**

STANDARDS

Micronutrients (magnesium, zinc, and copper): are mineral supplements needed for athletes? Lukaski HC. **Int J Sport Nutr** 1995 Jun;5 Suppl:S74-83 (37 ref.)

THERAPEUTIC USE

Magnesium, myocardial infarction, meta-analysis and megatrials. **Drug Ther Bull** 1995 Apr;33(4):25-7 (18 ref.)
Efficacy of vitamin B6 and magnesium in the treatment of autism: a methodology review and summary of outcomes. Pfeiffer SI, et al. **J Autism Dev Disord** 1995 Oct; 25(5):481-93 (36 ref.)

MAGNESIUM ADP see **ADENOSINE DIPHOSPHATE**

MAGNESIUM ATP see **ADENOSINE TRIPHOSPHATE**

MAGNESIUM DEFICIENCY

Disorders of magnesium metabolism. Nadler JL, et al. **Endocrinol Metab Clin North Am** 1995 Sep;24(3):623-41 (118 ref.)
[Indications for the use of magnesium in anesthesia and intensive care] Delhumeau A, et al. **Ann Fr Anesth Reanim** 1995;14(5):406-16 (113 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

Hypomagnesemia and diabetes mellitus. A review of clinical implications. Tosiello L. **Arch Intern Med** 1996 Jun 10; 156(11):1143-8 (58 ref.)
Hypocalcaemia and chronic alcohol intoxication: transient hypoparathyroidism secondary to magnesium deficiency. Hermans C, et al. **Clin Rheumatol** 1996 Mar;15(2):193-6 (31 ref.)
Vitamin and mineral deficiencies which may predispose to glucose intolerance of pregnancy. Jovanovic-Peterson L, et al. **J Am Coll Nutr** 1996 Feb;15(1):14-20 (64 ref.)
Mitochondria, magnesium and migraine. Welch KM, et al. **J Neurol Sci** 1995 Dec;134(1-2):9-14 (62 ref.)

DIAGNOSIS

Isolated magnesium malabsorption in a 10-year-old boy. Romero R, et al. **Am J Gastroenterol** 1996 Mar;91(3):611-3 (12 ref.)

MAGNESIUM DEFICIENCY

ETIOLOGY

Thalasselis syndrome and genetic theories on keratoconus. Thalasselis A. **J Am Optom Assoc** 1995 Aug;66(8):495–9 (64 ref.)

METABOLISM

Effects of K+, Mg2+ deficiency and adrenal steroids on Na+, K(+)-pump concentration in skeletal muscle. Dørup I. **Acta Physiol Scand** 1996 Mar;156(3):305–11 (51 ref.)

White mineral and substance P. Weber KT. **Cardiovasc Res** 1996 May;31(5):675–82 (51 ref.)

PHYSIOPATHOLOGY

Hypothesis: the possible role of magnesium and copper deficiency in retinopathy of prematurity. Caddell JL. **Magnes Res** 1995 Sep;8(3):261–70 (81 ref.)

VETERINARY

Impaired absorption of magnesium in the aetiology of grass tetany. Dua K, et al. **Br Vet J** 1995 Jul–Aug;151(4):413–26 (98 ref.)

MAGNESIUM SULFATE

ADMINISTRATION & DOSAGE

Established role of magnesium sulfate as prophylactic anticonvulsive agent in preeclampsia/eclampsia. Skajaa K. **Acta Obstet Gynecol Scand** 1996 Apr;75(4):313–5 (18 ref.)

THERAPEUTIC USE

Magnesium in acute myocardial infarction: overview of available evidence. Antman EM. **Am Heart J** 1996 Aug; 132(2 Pt 2 Su):487–95; discussion 496–502 (53 ref.)

Is there a place for magnesium in the treatment of acute myocardial infarction? Seelig MS, et al. **Am Heart J** 1996 Aug;132(2 Pt 2 Su):471–7; discussion 496–502 (73 ref.)

The rationale of magnesium as alternative therapy for patients with acute myocardial infarction without thrombolytic therapy. Shechter M, et al. **Am Heart J** 1996 Aug;132(2 Pt 2 Su):483–6; discussion 496–502 (39 ref.)

Acute myocardial infarction, reperfusion injury, and intravenous magnesium therapy: basic concepts and clinical implications. Steurer G, et al. **Am Heart J** 1996 Aug;132(2 Pt 2 Su):478–82; discussion 496–502 (86 ref.)

Magnesium sulphate: the time of reckoning [see comments] Robson SC. **Br J Obstet Gynaecol** 1996 Feb;103(2):99–102 (30 ref.) Comment in: Br J Obstet Gynaecol 1996 Feb;103(2):vii–viii.

Magnesium sulfate. Gordon MC, et al. **Clin Obstet Gynecol** 1995 Dec;38(4):706–12 (25 ref.)

Use of magnesium sulfate in asthma in childhood. Monem GF, et al. **Pediatr Ann** 1996 Mar;25(3):136, 139–44 (52 ref.)

[Magnesium sulfate in acute myocardial infarction] Balli E, et al. **G Ital Cardiol** 1995 Nov;25(11):1425–32 (33 ref.) (Eng. Abstr.) **(Ita)**

MAGNETIC RESONANCE see **NUCLEAR MAGNETIC RESONANCE**

MAGNETIC RESONANCE ANGIOGRAPHY

Advances in vascular echoplanar imaging. Debatin JF, et al. **Cardiovasc Intervent Radiol** 1995 Sep–Oct;18(5):277–87 (41 ref.)

Coronary MR angiography. Duerinckx AJ. **Magn Reson Imaging Clin N Am** 1996 May;4(2):361–418 (222 ref.)

Magnetic resonance angiography and flow quantification of coronary arteries. Edelman RR, et al. **Magn Reson Imaging Clin N Am** 1993 Dec;1(2):339–47 (48 ref.)

Portal magnetic resonance angiography. Finn JP, et al. **Magn Reson Imaging Clin N Am** 1993 Dec;1(2):271–80 (31 ref.)

Magnetic resonance angiography of the aorta and renal arteries. Grist TM. **Magn Reson Imaging Clin N Am** 1993 Dec;1(2):253–69 (42 ref.)

Magnetic resonance angiography of systemic thoracic and abdominal veins. Hartnell GG. **Magn Reson Imaging Clin N Am** 1993 Dec;1(2):281–94 (49 ref.)

Magnetic resonance angiography of the thoracic aorta. Hartnell GG. **Magn Reson Imaging Clin N Am** 1993 Dec; 1(2):315–26 (47 ref.)

MR angiography in carotid stenosis. A clinical prospective. Lamparello PJ, et al. **Magn Reson Imaging Clin N Am** 1995 Aug;3(3):455–65 (33 ref.)

Vascular malformations. Marks MP. **Magn Reson Imaging Clin N Am** 1995 Aug;3(3):485–91 (25 ref.)

MR imaging and MR angiography in the diagnosis of dural arteriovenous fistulas. Panasci DJ, et al. **Magn Reson Imaging Clin N Am** 1995 Aug;3(3):493–508 (32 ref.)

Intracranial aneurysms. Puskar G, et al. **Magn Reson Imaging Clin N Am** 1995 Aug;3(3):467–83 (52 ref.)

Stroke and ischemia. Siewert B, et al. **Magn Reson Imaging Clin N Am** 1995 Aug;3(3):529–40 (90 ref.)

Venography of the extremities and pelvis. Spritzer CE. **Magn Reson Imaging Clin N Am** 1993 Dec;1(2):239–51 (28 ref.)

Pulmonary arteriography. Wielopolski PA. **Magn Reson Imaging Clin N Am** 1993 Dec;1(2):295–313 (51 ref.)

Phase-contrast magnetic resonance angiography in the abdomen and thorax. Yuasa Y. **Magn Reson Imaging Clin N Am** 1993 Dec;1(2):327–38 (25 ref.)

Magnetic resonance angiography of the peripheral arteries. Yucel EK. **Magn Reson Imaging Clin N Am** 1993 Dec; 1(2):229–38 (39 ref.)

Clinical applications of magnetic resonance angiography. Magalhães AC, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1995 Jul–Aug; 50(4):212–21 (62 ref.)

MR angiography of the coronary arteries. Duerinckx AJ. **Top Magn Reson Imaging** 1995 Fall;7(4):267–85 (103 ref.)

[Results of magnetic resonance imaging in the acute phase of cerebral infarction] Berry I, et al. **J Mal Vasc** 1995; 20(3):184–8 (31 ref.) (Eng. Abstr.) **(Fre)**

[Role of magnetic resonance imaging in cerebral venous thrombosis] Bousser MG. **J Mal Vasc** 1995;20(3):189–93 (21 ref.) (Eng. Abstr.) **(Fre)**

[Magnetic resonance imaging in vascular dementia] Leys D, et al. **J Mal Vasc** 1995;20(3):194–202 (73 ref.) (Eng. Abstr.) **(Fre)**

[Anatomy of the circle of Willis with 3D time of flight magnetic resonance angiography and analysis of partitions] Brunereau L, et al. **J Radiol** 1995 Sep;76(9):573–7 (19 ref.) (Eng. Abstr.) **(Fre)**

[The magnetic resonance assessment of craniofacial fibrous dysplasia. The completion of the study with gadolinium administration and magnetic resonance angiography] Di Girolamo M, et al. **Radiol Med (Torino)** 1996 Mar; 91(3):313–6 (10 ref.) **(Ita)**

[MR angiography (MRA)] Kumagai M, et al. **No To Shinkei** 1995 Aug;47(8):723–34 (25 ref.) **(Jpn)**

[Cerebral magnetic resonance angiography] Viaño J, et al. **Rev Neurol** 1995;23 Suppl 3:S300–6 (20 ref.) **(Spa)**

INSTRUMENTATION

Time-of-flight magnetic resonance angiography of aorta and renal arteries: state-of-the-art. Laissy JP, et al. **Eur J Radiol** 1996 Feb;21(3):201–11 (71 ref.)

Coronary artery imaging by magnetic resonance. Scheidegger MB, et al. **Herz** 1996 Apr;21(2):90–6 (20 ref.)

Coronary imaging using MRI. van Rossum AC, et al. **Herz** 1996 Apr;21(2):97–105 (38 ref.)

Clinical applications of functional MRI in neuropsychiatry. Levin JM, et al. **J Neuropsychiatry Clin Neurosci** 1995 Fall; 7(4):511–22 (98 ref.)

METHODS

MR flow quantification with cardiovascular applications: a short overview. Ståhlberg F, et al. **Acta Paediatr Suppl** 1995 Aug;410:49–56 (56 ref.)

MR angiography of abdominal and peripheral arteries. Techniques and clinical applications. Ekelund L, et al. **Acta Radiol** 1996 Jan;37(1):3–13 (109 ref.)

Diagnosis of coronary artery disease in women: roles of three dimensional imaging with magnetic resonance or positron emission tomography. Patterson RE, et al. **Am J Card Imaging** 1996 Jan;10(1):78–88 (86 ref.)

Time-of-flight techniques. Pulse sequences and clinical protocols. Anderson CM, et al. **Magn Reson Imaging Clin N Am** 1993 Dec;1(2):217–27 (27 ref.)

MR angiography of the central nervous system. Basic flow phenomena. Bradley WG. **Magn Reson Imaging Clin N Am** 1995 Aug;3(3):375–90 (25 ref.)

Echo-planar magnetic resonance angiography. Cohen MS. **Magn Reson Imaging Clin N Am** 1993 Dec;1(2):359–65 (29 ref.)

Phase contrast MR angiography techniques. Dumoulin CL. **Magn Reson Imaging Clin N Am** 1995 Aug;3(3):399–411 (34 ref.)

Black-blood and segmented k-space magnetic resonance angiography. Finn JP, et al. **Magn Reson Imaging Clin N Am** 1993 Dec;1(2):349–57 (25 ref.)

Contrast-enhanced MR imaging of the kidneys and adrenal glands. Huch Böni RA, et al. **Magn Reson Imaging Clin N Am** 1996 Feb;4(1):101–31 (61 ref.)

Venous disease and tumors. Knopp EA. **Magn Reson Imaging Clin N Am** 1995 Aug;3(3):509–28 (22 ref.)

Time-of-flight method of MR angiography. Laub GA. **Magn Reson Imaging Clin N Am** 1995 Aug;3(3):391–8 (16 ref.)

Magnetic resonance angiography of the body. Physical principles and technical challenges. Nishimura DG. **Magn Reson Imaging Clin N Am** 1993 Dec;1(2):203–15 (40 ref.)

Diffusion and perfusion imaging techniques. Patel MR, et al. **Magn Reson Imaging Clin N Am** 1995 Aug;3(3):425–38 (54 ref.)

Flow quantification and analysis methods. Pelc NJ. **Magn Reson Imaging Clin N Am** 1995 Aug;3(3):413–24 (56 ref.)

Body MR angiography with gadolinium contrast agents. Prince MR. **Magn Reson Imaging Clin N Am** 1996 Feb; 4(1):11–24 (28 ref.)

MR angiography of the hand and wrist. Rofsky NM. **Magn Reson Imaging Clin N Am** 1995 May;3(2):345–59 (31 ref.)

MR angiography of the extracranial carotid arteries. Rosovsky MA, et al. **Magn Reson Imaging Clin N Am** 1995 Aug;3(3):439–54 (43 ref.)

MR angiography flow analysis. Neurovascular applications. Turski PA, et al. **Magn Reson Imaging Clin N Am** 1995 Aug;3(3):541–55 (38 ref.)

MR angiography of congenital heart disease in adults. Hartnell GG, et al. **Radiographics** 1995 Jul;15(4):781–94 (24 ref.)

Principles of magnetic resonance angiography. Polachini Júnior I, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1995 Jul–Aug;50(4):205–11 (21 ref.)

[The evaluation of 3DFT time-of-flight MR-angiography versus angiography in the study of carotid atheromatous lesions with a review of the literature] Auffray-Calvier E, et al. **J Neuroradiol** 1995 Dec;22(4):272–87 (30 ref.) (Eng. Abstr.) **(Fre)**

MAGNETIC RESONANCE IMAGING

see related

NUCLEAR MAGNETIC RESONANCE

Crowned dens syndrome: a manifestation of hydroxy-apatite rheumatism. Malca SA, et al. **Acta Neurochir (Wien)** 1995; 135(3–4):126–30 (21 ref.)

Mycoplasma pneumoniae infection associated with an acute brainstem syndrome. Pellegrini M, et al. **Acta Neurol Scand** 1996 Feb–Mar;93(2–3):203–6 (10 ref.)

Meningioma of the optic nerve sheath. Ortiz O, et al. **AJNR Am J Neuroradiol** 1996 May;17(5):901–6 (13 ref.)

MR imaging of spinal nerve roots: techniques, enhancement patterns, and imaging findings. Georgy BA, et al. **AJR Am J Roentgenol** 1996 Jan;166(1):173–9 (36 ref.)

Magnetic resonance imaging in ischemic heart disease. Steffans JC, et al. **Am Heart J** 1996 Jul;132(1 Pt 1):156–73 (105 ref.)

Molecular and functional magnetic resonance neuroimaging for the study of dementia. Gilberto González R. **Ann N Y Acad Sci** 1996 Jan 17;777:37–48 (29 ref.)

Spatial resolution and spectral information content of proton NMR spectroscopic imaging of tumour metabolism. Bovée WM, et al. **Anticancer Res** 1996 May–Jun;16(3B):1515–20 (17 ref.)

Human cancers detected by proton MRS and chemical shift imaging ex vivo. Mountford CE, et al. **Anticancer Res** 1996 May–Jun;16(3B):1521–31 (38 ref.)

Normal caudate nucleus in obsessive–compulsive disorder assessed by quantitative neuroimaging. Aylward EH, et al. **Arch Gen Psychiatry** 1996 Jul;53(7):577–84 (48 ref.)

Extrapyramidal symptoms in a BMT recipient with hyperintense basal ganglia and elevated manganese. Fredstrom S, et al. **Bone Marrow Transplant** 1995 Jun; 15(6):989–92 (19 ref.)

Imaging pain in humans. Berman J. **Br J Anaesth** 1995 Aug; 75(2):209–16 (40 ref.)

Posterior pituitary ectopia and hypopituitarism--magnetic resonance appearances of four cases and a review of the literature. Denton ER, et al. **Br J Radiol** 1996 May; 69(821):402–6 (31 ref.)

Quantitative assessment of MRI lesion load in monitoring the evolution of multiple sclerosis. Filippi M, et al. **Brain** 1995 Dec;118 (Pt 6):1601–12 (98 ref.)

Congenital-infantile fibrosarcoma: magnetic resonance imaging findings. Lee MJ, et al. **Can Assoc Radiol J** 1996 Apr;47(2):121–5 (27 ref.)

Magnetic resonance imaging and histopathologic appearances of benign soft-tissue masses of the foot. Logan PM, et al. **Can Assoc Radiol J** 1996 Feb;47(1):36–43 (9 ref.)

Diffusion and perfusion MR imaging of cerebral ischemia. Hossmann KA, et al. **Cerebrovasc Brain Metab Rev** 1995 Fall;7(3):187–217 (150 ref.)

Magnetic resonance imaging in coronary artery disease. van der Wall EE, et al. **Circulation** 1995 Nov 1;92(9):2723–39 (198 ref.)

Diastematomyelia in adults. Modern imaging and operative treatment. Prasad VS, et al. **Clin Imaging** 1995 Oct–Dec; 19(4):270–4 (28 ref.)

Structural brain imaging in schizophrenia. Pfefferbaum A, et al. **Clin Neurosci** 1995;3(2):105–11 (82 ref.)

Magnetic resonance imaging of the musculoskeletal system. Part 4. The knee. Crotty JM, et al. **Clin Orthop** 1996 Sep; (330):288–303 (75 ref.)

Magnetic resonance imaging of the musculoskeletal system: Part 3. The elbow. Fritz RC, et al. **Clin Orthop** 1996 Mar; (324):321–39 (88 ref.)

Pictorial review: MR imaging of neuronal migration anomalies. Boardman P, et al. **Clin Radiol** 1996 Jan; 51(1):11–7 (17 ref.)

Cardiovascular magnetic resonance imaging goes beyond anatomy. Ganz W, et al. **Crit Rev Diagn Imaging** 1995; 36(6):479–503 (34 ref.)

Gadolinium-enhanced breast MRI. Kelcz F, et al.

Crit Rev Diagn Imaging 1995;36(4):287–338 (41 ref.)
Applications of magnetic resonance imaging in food science. Schmidt SJ, et al. **Crit Rev Food Sci Nutr** 1996 Apr; 36(4):357–85 (114 ref.)
Magnetic resonance imaging of the heart and its role in current cardiology. Seyad DE, et al. **Curr Opin Cardiol** 1995 Nov;10(6):640–9 (53 ref.)
MRI of the shoulder. Shankman S, et al. **Curr Probl Diagn Radiol** 1995 Nov–Dec;24(6):201–25 (46 ref.)
Magnetic resonance imaging in osteoporosis. Majumdar S, et al. **Eur J Radiol** 1995 Sep;20(3):193–7 (26 ref.)
Primary staging of urinary bladder carcinoma: the role of MRI and a comparison with CT. Barentsz JO, et al. **Eur Radiol** 1996;6(2):129–33 (49 ref.)
Advanced imaging techniques of the brachial plexus. Panasci DJ, et al. **Hand Clin** 1995 Nov;11(4):545–53 (17 ref.)
Tissutal imaging by nuclear magnetic resonance. Sbarbati A, et al. **Histol Histopathol** 1996 Jan;11(1):229–35 (81 ref.)
Role of magnetic resonance imaging in hypothalamic–pituitary disorders. Zucchini S, et al. **Horm Res** 1995;44 Suppl 3:8–14 (42 ref.)
Popliteal cysts and associated disorders of the knee. Critical review with MR imaging. Sansone V, et al. **Int Orthop** 1995;19(5):275–9 (20 ref.)
Brief report: neuroimaging in autism: the state of the science 1995. Filipek PA. **J Autism Dev Disord** 1996 Apr; 26(2):211–5 (21 ref.)
MR in the evaluation of gynecologic tumor. Barentsz J. **J Belge Radiol** 1995 Oct;78(5):305–7 (31 ref.)
Computer tomography and magnetic resonance imaging in the evaluation of bladder cancer. Husband JE. **J Belge Radiol** 1995 Dec;78(6):350–5 (33 ref.)
Magnetic resonance imaging of meniscal tears of the knee [editorial] Dixon AK. **J Bone Joint Surg Br** 1996 Mar; 78(2):174–6 (34 ref.)
MRI of giant cell tumor of the tendon sheath in the cervical spine. Bui–Mansfield LT, et al. **J Comput Assist Tomogr** 1996 Jan–Feb;20(1):113–5 (6 ref.)
From muscle properties to human performance, using magnetic resonance. Conley KE, et al. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:35–40 (30 ref.)
Early diagnosis and treatment of Ramsay Hunt syndrome: the role of magnetic resonance imaging. Kuo MJ, et al. **J Laryngol Otol** 1995 Aug;109(8):777–80 (28 ref.)
Imaging of ovarian cancer. Forstner R, et al. **J Magn Reson Imaging** 1995 Sep–Oct;5(5):606–13 (82 ref.)
Distinctive serial magnetic resonance changes in a young woman with rapidly evolved neurocysticercosis, with positron emission tomography results. Nagayama M, et al. **J Neuroimaging** 1996 Jul;6(3):198–201 (15 ref.)
Quantitative computed tomography and magnetic resonance imaging in aging and Alzheimer's disease. A review. Smith CD. **J Neuroimaging** 1996 Jan;6(1):44–53 (122 ref.)
Functional MRI of the brain principles, applications and limitations. Le Bihan D. **J Neuroradiol** 1996 Jun;23(1):1–5 (15 ref.)
MR imaging of knee ligaments. Pope TL Jr. **J South Orthop Assoc** 1996 Spring;5(1):46–62 (73 ref.)
Clinical correlations with hippocampal atrophy. Cascino GD. **Magn Reson Imaging** 1995;13(8):1133–6 (18 ref.)
Clinical correlations: MRI and EEG. Fish DR, et al. **Magn Reson Imaging** 1995;13(8):1113–7 (18 ref.)
Diffusion-weighted imaging in epilepsy. Helpern JA, et al. **Magn Reson Imaging** 1995;13(8):1227–31 (32 ref.)
MRI in cerebral developmental malformations and epilepsy. Kuzniecky RI. **Magn Reson Imaging** 1995;13(8):1137–45 (31 ref.)
Clinical applications: MRI, SPECT, and PET. Spencer SS, et al. **Magn Reson Imaging** 1995;13(8):1119–24 (34 ref.)
MRI hippocampal volume and neuropsychology in epilepsy surgery. Trenerry MR, et al. **Magn Reson Imaging** 1995; 13(8):1125–32 (47 ref.)
Anatomy of the medial temporal lobe. Van Hoesen GW. **Magn Reson Imaging** 1995;13(8):1047–55 (54 ref.)
MR imaging of soft-tissue infection. Beltran J. **Magn Reson Imaging Clin N Am** 1995 Nov;3(4):743–51 (18 ref.)
Magnetic resonance imaging of bone marrow disorders of the knee. Beltran J, et al. **Magn Reson Imaging Clin N Am** 1994 Aug;2(3):463–73 (41 ref.)
Magnetic resonance imaging manifestations of synovial lesions of the ankle and foot. Bergman AG. **Magn Reson Imaging Clin N Am** 1994 Feb;2(1):131–8 (33 ref.)
Contemporary magnetic resonance imaging of the knee. The orthopedic surgeon's perspective. Bonamo JJ, et al. **Magn Reson Imaging Clin N Am** 1994 Aug;2(3):481–95 (99 ref.)
MR imaging of congenital heart disease. Boxt LM. **Magn Reson Imaging Clin N Am** 1996 May;4(2):327–59 (62 ref.)
MR imaging of pulmonary hypertension and right ventricular dysfunction. Boxt LM. **Magn Reson Imaging Clin N Am** 1996 May;4(2):307–25 (94 ref.)
Breast MR imaging. An analysis of its role with respect to other imaging and interventional modalities. Brenner RJ. **Magn Reson Imaging Clin N Am** 1994 Nov;2(4):705–23 (84 ref.)
Achilles tendon and miscellaneous tendon lesions. Chandnani VP, et al. **Magn Reson Imaging Clin N Am** 1994 Feb; 2(1):89–96 (21 ref.)
Magnetic resonance imaging in pregnancy. Colletti PM, et al. **Magn Reson Imaging Clin N Am** 1994 May;2(2):291–307 (53 ref.)
Magnetic resonance imaging of impingement and rotator cuff disorders. A surgical perspective. Cuomo F, et al. **Magn Reson Imaging Clin N Am** 1993 Sep;1(1):65–76 (36 ref.)
MR imaging of the breast in the follow-up evaluation of conservative nonoperatively treated breast cancer. Dao TH, et al. **Magn Reson Imaging Clin N Am** 1994 Nov; 2(4):605–22 (46 ref.)
Magnetic resonance imaging of miscellaneous disorders of the shoulder. Deutsch AL, et al. **Magn Reson Imaging Clin N Am** 1993 Sep;1(1):171–83 (66 ref.)
Magnetic resonance imaging of arthritides affecting the shoulder. Ferraro FA, et al. **Magn Reson Imaging Clin N Am** 1993 Sep;1(1):157–70 (76 ref.)
MR imaging of the menisci. Fundamentals of anatomy and pathology. Firooznia H, et al. **Magn Reson Imaging Clin N Am** 1994 Aug;2(3):325–47 (46 ref.)
Magnetic resonance imaging of the meniscus. Advanced concepts. Fitzgerald SW. **Magn Reson Imaging Clin N Am** 1994 Aug;2(3):349–64 (49 ref.)
Muscle weakness and myalgia. MR imaging investigation. Fleckenstein JL. **Magn Reson Imaging Clin N Am** 1995 Nov;3(4):773–803 (43 ref.)
MR imaging of breast implants. Gorczyca DP. **Magn Reson Imaging Clin N Am** 1994 Nov;2(4):659–72 (29 ref.)
MR imaging of malignant soft-tissue tumors. Hanna SL, et al. **Magn Reson Imaging Clin N Am** 1995 Nov;3(4):629–50 (38 ref.)
Staging of breast cancer with MR imaging. Harms SE, et al. **Magn Reson Imaging Clin N Am** 1994 Nov;2(4):573–84 (41 ref.)
Magnetic resonance imaging of the postoperative shoulder. Haygood TM, et al. **Magn Reson Imaging Clin N Am** 1993 Sep;1(1):143–55 (26 ref.)
MR imaging versus alternative imaging techniques. Hodler J, et al. **Magn Reson Imaging Clin N Am** 1995 Nov; 3(4):591–608 (70 ref.)
Imaging techniques for breast MR imaging. Hylton NM, et al. **Magn Reson Imaging Clin N Am** 1994 Nov;2(4):511–25 (51 ref.)
Clinical significance of magnetic resonance imaging of the ankle and foot. Jahss MH. **Magn Reson Imaging Clin N Am** 1994 Feb;2(1):29–38 (10 ref.)
MR imaging of soft-tissue masses. Mass-like lesions that simulate neoplasms. Jelinek J, et al. **Magn Reson Imaging Clin N Am** 1995 Nov;3(4):727–41 (58 ref.)
Pregnancy and the safety of magnetic resonance imaging. Kanal E. **Magn Reson Imaging Clin N Am** 1994 May; 2(2):309–17 (74 ref.)
Magnetic resonance imaging of the knee. A senior musculoskeletal radiologist's perspective. Kaye JJ. **Magn Reson Imaging Clin N Am** 1994 Aug;2(3):497–500 (40 ref.)
Magnetic resonance imaging of the uterus. Kier R. **Magn Reson Imaging Clin N Am** 1994 May;2(2):189–210 (54 ref.)
Magnetic resonance imaging of plantar fasciitis and other causes of heel pain. Kier R. **Magn Reson Imaging Clin N Am** 1994 Feb;2(1):97–107 (35 ref.)
Normal magnetic resonance imaging anatomy of the ankle and foot. Kirsch MD, et al. **Magn Reson Imaging Clin N Am** 1994 Feb;2(1):1–21 (24 ref.)
MR mammography with pharmacokinetic mapping for monitoring of breast cancer treatment during neoadjuvant therapy. Knopp MV, et al. **Magn Reson Imaging Clin N Am** 1994 Nov;2(4):633–58 (42 ref.)
Magnetic resonance imaging of ankle ligaments. Emphasis on anatomy and injuries to lateral collateral ligaments. Mesgarzadeh M, et al. **Magn Reson Imaging Clin N Am** 1994 Feb;2(1):39–58 (48 ref.)
Magnetic resonance imaging applications in uterine cervical cancer. Mezrich R. **Magn Reson Imaging Clin N Am** 1994 May;2(2):211–43 (60 ref.)
Surgical considerations in a diagnostic imaging evaluation of musculoskeletal masses. Moreau G, et al. **Magn Reson Imaging Clin N Am** 1995 Nov;3(4):577–90 (30 ref.)
Magnetic resonance imaging techniques in the pelvis. Outwater EK, et al. **Magn Reson Imaging Clin N Am** 1994 May;2(2):161–88 (115 ref.)
Magnetic resonance imaging of the ovary. Outwater EK, et al. **Magn Reson Imaging Clin N Am** 1994 May; 2(2):245–74 (104 ref.)
MR imaging and MR angiography in the diagnosis of dural arteriovenous fistulas. Panasci DJ, et al. **Magn Reson Imaging Clin N Am** 1995 Aug;3(3):493–508 (32 ref.)
MR imaging of cardiomyopathy. Park JH, et al. **Magn Reson Imaging Clin N Am** 1996 May;4(2):269–86 (51 ref.)
Quantitative MR imaging of the heart. Peshock RM, et al. **Magn Reson Imaging Clin N Am** 1996 May;4(2):287–305 (130 ref.)
The specificity of contrast-enhanced breast MR imaging. Piccoli CW. **Magn Reson Imaging Clin N Am** 1994 Nov; 2(4):557–71 (75 ref.)
Normal anatomy of the hand and wrist. Prendergast N, et al. **Magn Reson Imaging Clin N Am** 1995 May;3(2):197–212 (33 ref.)
MR imaging of the patellofemoral compartment. Quinn SF, et al. **Magn Reson Imaging Clin N Am** 1994 Aug;2(3):425–40 (53 ref.)
Magnetic resonance imaging of glenohumeral instability. Rafii M, et al. **Magn Reson Imaging Clin N Am** 1993 Sep; 1(1):87–104 (68 ref.)
Magnetic resonance imaging of the brachial plexus. Reede DL. **Magn Reson Imaging Clin N Am** 1993 Sep;1(1):185–95 (16 ref.)
Clinical applications of MR imaging in hand and wrist surgery. Rettig ME, et al. **Magn Reson Imaging Clin N Am** 1995 May;3(2):361–8 (18 ref.)
Chronic rupture of the posterior tibial tendon. Rosenberg ZS. **Magn Reson Imaging Clin N Am** 1994 Feb;2(1):79–87 (36 ref.)
Medial and lateral supporting structures of the knee. Normal MR imaging anatomy and pathologic findings. Ruiz ME, et al. **Magn Reson Imaging Clin N Am** 1994 Aug;2(3):381–99 (18 ref.)
MR imaging of the breast. Imaging and tissue characterization without intravenous contrast. Santyr GE. **Magn Reson Imaging Clin N Am** 1994 Nov;2(4):673–90 (45 ref.)
Magnetic resonance imaging of pediatric disorders of the ankle and foot. Schoenberg NY, et al. **Magn Reson Imaging Clin N Am** 1994 Feb;2(1):109–22 (51 ref.)
Tumors of the ankle and foot. Shankman S, et al. **Magn Reson Imaging Clin N Am** 1994 Feb;2(1):139–53 (57 ref.)
Magnetic resonance imaging of the extensor mechanism. Sonin AH. **Magn Reson Imaging Clin N Am** 1994 Aug; 2(3):401–11 (30 ref.)
Magnetic resonance imaging of the diabetic foot. Spaeth HJ Jr, et al. **Magn Reson Imaging Clin N Am** 1994 Feb; 2(1):123–30 (28 ref.)
Magnetic resonance imaging of impingement and rotator cuff tears. Stoller DW, et al. **Magn Reson Imaging Clin N Am** 1993 Sep;1(1):47–63 (61 ref.)
MR imaging of benign soft-tissue masses. Sundaram M, et al. **Magn Reson Imaging Clin N Am** 1995 Nov;3(4):609–27 (62 ref.)
Magnetic resonance imaging of benign adnexal conditions. Thickman D, et al. **Magn Reson Imaging Clin N Am** 1994 May;2(2):275–89 (30 ref.)
Magnetic resonance arthrography of the shoulder. Tirman PF, et al. **Magn Reson Imaging Clin N Am** 1993 Sep; 1(1):125–42 (48 ref.)
Pathogenesis of rotator cuff disorders. Magnetic resonance imaging characteristics. Tyson LL, et al. **Magn Reson Imaging Clin N Am** 1993 Sep;1(1):37–46 (52 ref.)
MR imaging of anterior cruciate ligament injuries. Vahey TN, et al. **Magn Reson Imaging Clin N Am** 1994 Aug; 2(3):365–80 (58 ref.)
Magnetic resonance imaging of the biceps complex. van Leersum M, et al. **Magn Reson Imaging Clin N Am** 1993 Sep;1(1):77–86 (23 ref.)
MR imaging of periarticular soft-tissue lesions. Van Slyke MA, et al. **Magn Reson Imaging Clin N Am** 1995 Nov; 3(4):651–67 (49 ref.)
Soft-tissue sarcoma of the extremities. MR appearance of post-treatment changes and local recurrences. Varma DG, et al. **Magn Reson Imaging Clin N Am** 1995 Nov; 3(4):695–712 (59 ref.)
Magnetic resonance imaging of bone marrow and osteochondral injury. Vellet D. **Magn Reson Imaging Clin N Am** 1994 Aug;2(3):413–23 (22 ref.)
Benign and malignant masses. MR imaging differentiation. Weatherall PT. **Magn Reson Imaging Clin N Am** 1995 Nov; 3(4):669–94 (84 ref.)
Musculotendinous injury. Weatherall PT, et al. **Magn Reson Imaging Clin N Am** 1995 Nov;3(4):753–72 (73 ref.)
MR evaluation of the pericardium and cardiac malignancies. White CS. **Magn Reson Imaging Clin N Am** 1996 May; 4(2):237–51 (48 ref.)
Magnetic resonance imaging in synovial disorders and arthropathy of the knee. White EM. **Magn Reson Imaging Clin N Am** 1994 Aug;2(3):451–61 (11 ref.)
MR imaging of the breast after surgery for breast cancer. Whitehouse GH, et al. **Magn Reson Imaging Clin N Am** 1994 Nov;2(4):591–603 (59 ref.)
Magnetic resonance imaging in epilepsy. Jack CR Jr.

Mayo Clin Proc 1996 Jul;71(7):695–711 (70 ref.)

Magnetic resonance spectroscopy and imaging in radiology. Mahmood U, et al. **Med Phys** 1995 Nov;22(11 Pt 2):1935–41 (65 ref.)

The natural history of arachnoid cysts: endoscopic and cine-mode MRI evidence of a slit-valve mechanism. Santamarta D, et al. **Minim Invasive Neurosurg** 1995 Dec; 38(4):133–7 (28 ref.)

Temporal bone imaging. Casselman JW. **Neuroimaging Clin N Am** 1996 May;6(2):265–89 (51 ref.)

Imaging of the larynx. Castelijns JA, et al. **Neuroimaging Clin N Am** 1996 May;6(2):401–15 (68 ref.)

Magnetic resonance imaging. Neuroimaging and anatomy. Jack CR Jr. **Neuroimaging Clin N Am** 1995 Nov; 5(4):597–622 (94 ref.)

Interventional magnetic resonance imaging of the head and neck and new imaging techniques. Lambre H, et al. **Neuroimaging Clin N Am** 1996 May;6(2):461–72 (51 ref.)

Ocular and orbital imaging. Mafee MF, et al. **Neuroimaging Clin N Am** 1996 May;6(2):291–318 (84 ref.)

Oral cavity, oropharynx, and salivary glands. Sigal R. **Neuroimaging Clin N Am** 1996 May;6(2):379–400 (44 ref.)

Imaging of cervical lymphadenopathy. van den Brekel MW, et al. **Neuroimaging Clin N Am** 1996 May;6(2):417–34 (137 ref.)

Base of skull, nasopharynx, and parapharyngeal space. Vogl TJ, et al. **Neuroimaging Clin N Am** 1996 May;6(2):357–78 (25 ref.)

The role of computed tomography and magnetic resonance imaging in planning for conservation laryngeal surgery. Weinstein GS, et al. **Neuroimaging Clin N Am** 1996 May; 6(2):497–504 (25 ref.)

Temporomandibular joint and dental imaging. Westesson PL. **Neuroimaging Clin N Am** 1996 May;6(2):333–55 (31 ref.)

Atypical MRI findings in treatment-related leukoencephalopathy: case report. Ohmoto Y, et al. **Neuroradiology** 1996 Feb;38(2):128–33 (30 ref.)

Hyperhomocysteinaemia; with reference to its neuroradiological aspects. van den Berg M, et al. **Neuroradiology** 1995 Jul;37(5):403–11 (78 ref.)

Functional MRI: are we all moving towards artifactual conclusions? Or fMRI fact or fancy? Weisskoff RM. **NMR Biomed** 1995 May;8(3):101–3 (10 ref.)

Magnetic resonance imaging in the evaluation of Langerhans' cell histiocytosis of the temporal bone: case report. Angeli SI, et al. **Otolaryngol Head Neck Surg** 1996 Jan; 114(1):120–4 (25 ref.)

Ependymoblastoma: MR presentation. A case report and review of the literature. Dorsay TA, et al. **Pediatr Radiol** 1995;25(6):433–5 (13 ref.)

MRI and radiographic findings in Currarino's triad. Pfluger T, et al. **Pediatr Radiol** 1996;26(8):524–7 (21 ref.)

The relationship between symptoms and abnormal magnetic resonance images of lumbar intervertebral disks. Beattie P. **Phys Ther** 1996 Jun;76(6):601–8 (32 ref.)

Magnetic resonance imaging of the aging brain in Down syndrome. Emerson JF, et al. **Prog Clin Biol Res** 1995; 393:123–38 (28 ref.)

Behavioral and neuroimaging studies on schizophrenia in Japan. Shimazono Y, et al. **Psychiatry Clin Neurosci** 1995 Mar;49(1):3–11 (72 ref.)

Nuclear medicine techniques and magnetic resonance imaging in coronary artery disease. Pauwels E, et al. **Q J Nucl Med** 1996 Mar;40(1):132–41 (63 ref.)

MR imaging of nasal masses. Allbery SM, et al. **Radiographics** 1995 Nov;15(6):1311–27 (17 ref.)

Emerging applications of magnetic resonance imaging in the evaluation of articular cartilage. Peterfy CG, et al. **Radiol Clin North Am** 1996 Mar;34(2):195–213, ix (63 ref.)

Imaging of osteoarthritis. Preidler KW, et al. **Radiol Clin North Am** 1996 Mar;34(2):259–71, x (63 ref.)

The role of MR imaging in the evaluation of acquired cardiovascular disease. Carotti L, et al. **Radiol Med (Torino)** 1996 Jun;91(6):677–86 (87 ref.)

MRI's role in assessing and managing breast disease. Coons TA. **Radiol Technol** 1996 Mar-Apr;67(4):311–36; quiz 337–40 (80 ref.)

Pulmonary thromboembolism: recent developments in diagnosis with CT and MR imaging. Gefter WB, et al. **Radiology** 1995 Dec;197(3):561–74 (102 ref.)

Heart disease: functional evaluation with MR imaging. Higgins CB, et al. **Radiology** 1996 May;199(2):307–15 (85 ref.)

Abdominal iron deposition: metabolism, MR findings, and clinical importance. Siegelman ES, et al. **Radiology** 1996 Apr;199(1):13–22 (170 ref.)

Carcinoma of the pancreatic head area. Diagnostic imaging: magnetic resonance imaging. Kelekis NL, et al. **Rays** 1995 Jul-Sep;20(3):289–303 (35 ref.) **(Eng, Ita)**

In vivo magnetic resonance spectroscopy in HIV and HIV-related brain diseases. Chang L. **Rev Neurosci** 1995 Oct-Dec;6(4):365–78 (63 ref.)

Magnetic resonance imaging of the shoulder: review. Feller JF, et al. **Semin Roentgenol** 1995 Jul;30(3):224–40 (64 ref.)

Magnetic resonance imaging of focal liver lesions. Schnall M. **Semin Roentgenol** 1995 Oct;30(4):347–61 (34 ref.)

Magnetic resonance imaging of colorectal cancer. Zagoria RJ, et al. **Semin Roentgenol** 1996 Apr;31(2):162–5 (11 ref.)

Current concepts of imaging in patients with pituitary/hypothalamic dysfunction. Korogi Y, et al. **Semin Ultrasound CT MR** 1995 Aug;16(4):270–8 (36 ref.)

Oral cavity: anatomy and pathology. Laine FJ, et al. **Semin Ultrasound CT MR** 1995 Dec;16(6):527–45 (40 ref.)

Imaging of the temporomandibular joint. Rao VM. **Semin Ultrasound CT MR** 1995 Dec;16(6):513–26 (53 ref.)

Imaging of the salivary glands. Weissman JL. **Semin Ultrasound CT MR** 1995 Dec;16(6):546–68 (28 ref.)

MRI of posterior knee masses. Butler MG, et al. **Skeletal Radiol** 1996 May;25(4):309–17 (11 ref.)

CT/MRI of musculoskeletal complications of AIDS. Wyatt SH, et al. **Skeletal Radiol** 1995 Oct;24(7):481–8 (21 ref.)

Quantitative magnetic resonance imaging of the lumbar spine. Potential for investigations of water content and biochemical composition. Boos N, et al. **Spine** 1995 Nov 1;20(21):2358–65; discussion 2366 (83 ref.)

Magnetic resonance imaging. Use in patients with low back or radicular pain. Herzog RJ, et al. **Spine** 1995 Aug 15; 20(16):1834–8 (31 ref.)

MR evaluation of cardiac/juxtacardiac masses. Link KM, et al. **Top Magn Reson Imaging** 1995 Fall;7(4):232–45 (46 ref.)

MR evaluation of myocardial ischemia and infarction. Pattynama PM, et al. **Top Magn Reson Imaging** 1995 Fall; 7(4):218–31 (131 ref.)

MR evaluation of the pericardium. White CS. **Top Magn Reson Imaging** 1995 Fall;7(4):258–66 (32 ref.)

Magnetic resonance imaging of multiple sclerosis lesions. Measuring outcome in treatment trials [see comments] Simon JH. **West J Med** 1996 Jun;164(6):502–9 (71 ref.) Comment in: West J Med 1996 Jun;164(6):531–2.

[Magnetic resonance or computerized tomography for imaging of the brain?] Suoranta H, et al. **Duodecim** 1994; 110(16):1540–7 (9 ref.) **(Fin)**

[Exploration of the thoracic aorta, excluding the aortic valve] Douek P, et al. **Ann Cardiol Angeiol (Paris)** 1995 Dec; 44(10):552–60 (12 ref.) (Eng. Abstr.) **(Fre)**

[Magnetic resonance imaging in gynecology] Martin B, et al. **Contracept Fertil Sex** 1996 Feb;24(2):123–6 (0 ref.) **(Fre)**

[When is magnetic resonance imaging of liver diseases required?] Vilgrain V. **Gastroenterol Clin Biol** 1996;20(5 Pt 2):B134–9 (24 ref.) **(Fre)**

[Cerebral toxoplasmosis. Neuroradiologic diagnosis and prognostic monitoring] Martin-Duverneuil N, et al. **J Neuroradiol** 1995 Sep;22(3):196–203 (28 ref.) (Eng. Abstr.) **(Fre)**

[MRI aspects of progressive multifocal leukoencephalopathy] Sarrazin JL, et al. **J Neuroradiol** 1995 Sep;22(3):172–9 (16 ref.) (Eng. Abstr.) **(Fre)**

[Peritoneal mesothelioma. Contribution of MRI. Apropos of a case] Guzelian J, et al. **J Radiol** 1996 Jul;77(7):497–501 (15 ref.) (Eng. Abstr.) **(Fre)**

[Cat-scratch disease presenting as a pseudotumor. Imaging by x-ray computed tomography and MRI] Leblan I, et al. **J Radiol** 1995 Sep;76(9):601–4 (19 ref.) (Eng. Abstr.) **(Fre)**

[Results of endorectal MRI in local staging of prostatic cancer. Correlation with specimens from prostatectomy. Apropos of 47 cases] Chefchaouni MC, et al. **J Urol (Paris)** 1996;102(2):51–5 (18 ref.) (Eng. Abstr.) **(Fre)**

[Magnetic resonance imaging of the fetus. Contribution to antenatal diagnosis] Garel C, et al. **Presse Med** 1996 Mar 16;25(9):452–6 (23 ref.) (Eng. Abstr.) **(Fre)**

[MRI aspect and course of supra-tentorial sarcoidosic lesions] Caparros-lefebvre D, et al. **Rev Neurol (Paris)** 1996 Mar; 152(3):196–201 (45 ref.) (Eng. Abstr.) **(Fre)**

[Lhermitte-Duclos disease: is MRI diagnosis feasible?] Lemercier-Bertout C, et al. **Rev Neurol (Paris)** 1995 May; 151(5):327–31 (13 ref.) **(Fre)**

[MR tomography (MRT) of the skeleton, peripheral soft tissues and joints--current overview] Bohndorf K, et al. **Aktuelle Radiol** 1996 May;6(3):136–43 (47 ref.) (Eng. Abstr.) **(Ger)**

[MR-mammography: current status and perspectives] Funke M, et al. **Aktuelle Radiol** 1996 May;6(3):130–5 (47 ref.) (Eng. Abstr.) **(Ger)**

[The value of MRI in staging gynecologic tumors] Lorenzen M. **Aktuelle Radiol** 1996 Mar;6(2):63–8 (39 ref.) (Eng. Abstr.) **(Ger)**

[Patchy changes in white matter in cranial computerized and magnetic resonance tomography--significance for (differential) diagnosis of dementia of the Alzheimer type and vascular dementia] Stoppe G, et al. **Fortschr Neurol Psychiatr** 1995 Nov;63(11):425–40 (150 ref.) (Eng. Abstr.) **(Ger)**

[Applications of magnetic resonance tomography (MRT) in obstetrics] Wischnik A, et al. **Gynakologe** 1995 Oct; 28(5):321–8 (18 ref.) **(Ger)**

[Modern radiologic diagnosis for the ENT physician] Dammann F, et al. **HNO** 1995 Oct;43(10):590–5 (17 ref.) (Eng. Abstr.) **(Ger)**

[Modern neuroradiologic diagnosis and interventional strategies for the ENT physician] Hofmann E, et al. **HNO** 1995 Oct;43(10):584–9 (29 ref.) (Eng. Abstr.) **(Ger)**

[Neuroradiology in ophthalmology. 1] Müller-Forell W, et al. **Ophthalmologe** 1995 Aug;92(4):595–614 (0 ref.) **(Ger)**

[Primary non-Hodgkin's lymphoma of the skull in an 11-year-old girl. Follow-up and review of the literature] Daldrup HE, et al. **Radiologe** 1996 Apr;36(4):354–9 (31 ref.) (Eng. Abstr.) **(Ger)**

[Neuroradiologic findings in arterial cerebral ischemia] Jansen O, et al. **Radiologe** 1995 Nov;35(11):779–90 (33 ref.) (Eng. Abstr.) **(Ger)**

[Anatomy and pathology of the parotid gland. COrrelation with magnetic resonance tomography] Sartoretti-Schefer S, et al. **Radiologe** 1995 Nov;35(11):848–65 (70 ref.) (Eng. Abstr.) **(Ger)**

[Lymphedema-associated angiosarcoma (the Stewart-Treves syndrome) of the lower extremity: its MRT imaging] Gelmetti W, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Feb;164(2):168–70 (15 ref.) **(Ger)**

[The shoulder joint--diagnostic imaging] Imhof H, et al. **Wien Med Wochenschr** 1996;146(6-7):116–20 (24 ref.) (Eng. Abstr.) **(Ger)**

[Lymph node diagnosis with imaging methods. An overview with special reference to recent developments in the area of MR contrast media] Mohr U, et al. **Z Lymphol** 1996 Jun;20(1):15–20 (59 ref.) (Eng. Abstr.) **(Ger)**

[Cardiac magnetic resonance: the technical indications and a technical glossary] Molinari G, et al. **Cardiologia** 1995 Aug;40(8):541–50 (37 ref.) **(Ita)**

[Clinical use of endorectal coil MR in the study of prostatic pathology with special reference to hyperplasia and carcinoma] Gualdi GF, et al. **Clin Ter** 1996 Jan-Feb; 147(1-2):51–66 (29 ref.) (Eng. Abstr.) **(Ita)**

[Magnetic resonance in AIDS-related encephalopathy] Gualdi GF, et al. **Clin Ter** 1995 Dec;146(12):843–56 (42 ref.) (Eng. Abstr.) **(Ita)**

[Role of CT and MR in the assessment of lumbar degenerative disk disease] Gualdi GF, et al. **Clin Ter** 1995 Oct;146(10):635–48 (24 ref.) (Eng. Abstr.) **(Ita)**

[A comparison between magnetic resonance and other imaging technics in the study of cardiac pathology] Pirolli FM, et al. **Clin Ter** 1996 Apr;147(4):205–10 (20 ref.) (Eng. Abstr.) **(Ita)**

[Magnetic resonance imaging and hypothalamo-hypophyseal disorders in children: morpho-functional and etiologic aspects] Zucchini S, et al. **Pediatr Med Chir** 1995 Sep-Oct; 17(5):397–401 (33 ref.) (Eng. Abstr.) **(Ita)**

[Appendiceal mucocele: diagnosis by echography, spiral computed tomography and magnetic resonance] Bertolotto M, et al. **Radiol Med (Torino)** 1995 Dec;90(6):829–32 (6 ref.) **(Ita)**

[Elastofibroma dorsi. A report of a case diagnosed with magnetic resonance] Bianchi M, et al. **Radiol Med (Torino)** 1996 Jan-Feb;91(1-2):128–30 (16 ref.) **(Ita)**

[Hemospermia associated with a urogenital sinus cyst: diagnostic contribution of MRI. Report a case] Cinque T, et al. **Radiol Med (Torino)** 1995 Dec;90(6):840–2 (8 ref.) **(Ita)**

[Magnetic resonance in a case of lobular adenocarcinoma of the breast] Dalpiaz G, et al. **Radiol Med (Torino)** 1996 Apr;91(4):475–7 (12 ref.) **(Ita)**

[The magnetic resonance assessment of craniofacial fibrous dysplasia. The completion of the study with gadolinium administration and magnetic resonance angiography] Di Girolamo M, et al. **Radiol Med (Torino)** 1996 Mar; 91(3):313–6 (10 ref.) **(Ita)**

[The diagnosis of mediastinal hemangioma with magnetic resonance. A case report] Falaschi F, et al. **Radiol Med (Torino)** 1996 Jan-Feb;91(1-2):138–40 (11 ref.) **(Ita)**

[Giant intracranial aneurysms: a case history assessment of the correlation between etiopathogenetic hypothesis and magnetic resonance imaging] Manfrè L, et al. **Radiol Med (Torino)** 1995 Dec;90(6):822–5 (12 ref.) (Eng. Abstr.) **(Ita)**

[Magnetic resonance in delayed postanoxic encephalopathy following acute carbon monoxide poisoning. A case report] Pagnan L, et al. **Radiol Med (Torino)** 1996 Mar;91(3):309–11 (20 ref.) **(Ita)**

[Fast Spin Echo sequences in neuroradiology: technical features, semiology, and applications] Scarabino T, et al. **Radiol Med (Torino)** 1996 May;91(5):519–25 (36 ref.) **(Ita)**

[A pseudomass of the right atrium: an incidental echographic and magnetic resonance finding in a man over 100] Sessa M, et al. **Radiol Med (Torino)** 1996 Jan-Feb;91(1-2):135–7 (15 ref.) **(Ita)**

[Early diagnosis of hepatocellular carcinoma using computed tomography and magnetic resonance imaging] Moriyama N. **Nippon Naika Gakkai Zasshi** 1995 Dec 10; 84(12):1997–2002 (4 ref.) **(Jpn)**

[Neuroimaging and pathology of the spinal cord in compressive cervical myelopathy] Kameyama T, et al. **Rinsho Byori** 1995 Sep;43(9):886–90 (4 ref.) (Eng. Abstr.) **(Jpn)**

[Contrast media for computerized and magnetic resonance tomography. Basic principles] Rinck PA, et al. **Vestn Rentgenol Radiol** 1995 Nov-Dec;(6):52–9 (22 ref.) (Eng. Abstr.) **(Rus)**

[Magnetic resonance in familial central diabetes insipidus: a family study] Bastida Eizaguirre M, et al. **An Esp Pediatr** 1996 Jun;44(6):537–9 (16 ref.) (Eng. Abstr.) **(Spa)**

[Behr's syndrome. A report of 2 siblings studied by MR] Pascual-Castroviejo I, et al. **An Esp Pediatr** 1996 Jun; 44(6):593–5 (11 ref.) **(Spa)**

[Cranial NMR in the late diagnosis of congenital rubella] Ruiz Pérez JJ, et al. **An Esp Pediatr** 1996 Jun;44(6):585–7 (20 ref.) **(Spa)**

ADVERSE EFFECTS

[Safety aspects in MR imaging] Abart J, et al. **Aktuelle Radiol** 1995 Nov;5(6):376–84 (57 ref.) (Eng. Abstr.) **(Ger)**

ECONOMICS

Cost effectiveness of magnetic resonance imaging of the knee. Ruwe PA, et al. **Magn Reson Imaging Clin N Am** 1994 Aug;2(3):475–9 (25 ref.)

INSTRUMENTATION

MR cholangiopancreatography. Reinhold C, et al. **Abdom Imaging** 1996 Mar–Apr;21(2):105–16 (35 ref.)

Clinical applications of proton MR spectroscopy. Castillo M, et al. **AJNR Am J Neuroradiol** 1996 Jan;17(1):1–15 (64 ref.)

Coronary artery imaging by magnetic resonance. Scheidegger MB, et al. **Herz** 1996 Apr;21(2):90–6 (20 ref.)

Coronary imaging using MRI. van Rossum AC, et al. **Herz** 1996 Apr;21(2):97–105 (38 ref.)

Clinical applications of functional MRI in neuropsychiatry. Levin JM, et al. **J Neuropsychiatry Clin Neurosci** 1995 Fall; 7(4):511–22 (98 ref.)

Magnetic resonance imaging and epilepsy: neurosurgical decision making. Fried I. **Magn Reson Imaging** 1995; 13(8):1163–70 (47 ref.)

Application of spectroscopic imaging in epilepsy. Garcia PA, et al. **Magn Reson Imaging** 1995;13(8):1181–5 (28 ref.)

Application of high field spectroscopic imaging in the evaluation of temporal lobe epilepsy. Hetherington HP, et al. **Magn Reson Imaging** 1995;13(8):1175–80 (14 ref.)

New technical developments in magnetic resonance imaging of epilepsy. Riederer SJ, et al. **Magn Reson Imaging** 1995; 13(8):1095–8 (18 ref.)

Novel MR image contrast mechanisms in epilepsy. Tofts PS. **Magn Reson Imaging** 1995;13(8):1099–106 (67 ref.)

Image-guided spine surgery. Foley KT, et al. **Neurosurg Clin N Am** 1996 Apr;7(2):171–86 (7 ref.)

Image-guided surgery of epilepsy. Olivier A, et al. **Neurosurg Clin N Am** 1996 Apr;7(2):229–43 (23 ref.)

[Echo-planar imaging of the brain] Brüning R, et al. **Radiologe** 1995 Dec;35(12):902–10 (61 ref.) (Eng. Abstr.) **(Ger)**

[Fast and ultra-fast sequences in MRI of the pelvis and retroperitoneum] Heuck A, et al. **Radiologe** 1995 Dec; 35(12):936–44 (44 ref.) (Eng. Abstr.) **(Ger)**

[Fast and ultra-fast MRI of the brain] Schuierer G, et al. **Radiologe** 1995 Dec;35(12):894–901 (25 ref.) (Eng. Abstr.) **(Ger)**

[Fast and ultra-fast magnetic resonance tomography. Basic principles, pulse sequences and special properties] Stehling MK, et al. **Radiologe** 1995 Dec;35(12):879–93 (41 ref.) (Eng. Abstr.) **(Ger)**

[Fast and ultra-fast imaging of the musculoskeletal system] Vahlensieck M. **Radiologe** 1995 Dec;35(12):973–80 (34 ref.) (Eng. Abstr.) **(Ger)**

[Fast and ultra-fast MRI imaging of the heart] von Schulthess GK, et al. **Radiologe** 1995 Dec;35(12):952–63 (69 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Fast MR imaging: technical strategies. Petersein J, et al. **AJR Am J Roentgenol** 1995 Nov;165(5):1105–9 (47 ref.)

Diagnosis of coronary artery disease in women: roles of three dimensional imaging with magnetic resonance or positron emission tomography. Patterson RE, et al. **Am J Card Imaging** 1996 Jan;10(1):78–88 (86 ref.)

In vivo magnetic resonance spectroscopy. Applications in psychiatry. Maier M. **Br J Psychiatry** 1995 Sep; 167(3):299–306 (44 ref.)

The Mackenzie Davidson Memorial Lecture: detection of small changes to the brain with serial magnetic resonance imaging. Bydder GM. **Br J Radiol** 1995 Dec; 68(816):1271–95 (17 ref.)

Cardiac imaging techniques: which, when, and why. Thomas JD, et al. **Cleve Clin J Med** 1996 Jul–Aug;63(4):213–20 (35 ref.)

Magnetic resonance imaging of the musculoskeletal system. II. The hip. Hayes CW, et al. **Clin Orthop** 1996 Jan; (322):297–309 (45 ref.)

MR imaging of the female pelvis. Mayo-Smith WW, et al. **Clin Radiol** 1995 Oct;50(10):667–76 (57 ref.)

Contrast-enhanced MR imaging. Schima W, et al. **Clin Radiol** 1996 Apr;51(4):235–44 (108 ref.)

A conceptual overview and critique of functional neuroimaging techniques in humans: I. MRI/FMRI and PET. Aine CJ. **Crit Rev Neurobiol** 1995;9(2–3):229–309 (312 ref.)

Magnetic resonance imaging and spectroscopy in multiple sclerosis. Miller DH. **Curr Opin Neurol** 1995 Jun;8(3):210–5 (44 ref.)

Ultra-high-speed MR imaging. Davis CP, et al. **Eur Radiol** 1996;6(3):297–311 (94 ref.)

Mapping function in the human brain with magnetoencephalography, anatomical magnetic resonance imaging, and functional magnetic resonance imaging. George JS, et al. **J Clin Neurophysiol** 1995 Sep;12(5):406–31 (90 ref.)

Comparative assessment of sensorimotor function using functional magnetic resonance imaging and electrophysiological methods. Puce A. **J Clin Neurophysiol** 1995 Sep;12(5):450–9 (55 ref.)

New magnetic resonance imaging techniques for the evaluation of traumatic brain injury. Smith DH, et al. **J Neurotrauma** 1995 Aug;12(4):573–7 (34 ref.)

MRI-based hippocampal volumetrics: data acquisition, normal ranges, and optimal protocol. Jack CR Jr, et al. **Magn Reson Imaging** 1995;13(8):1057–64 (36 ref.)

The diagnosis of hippocampal sclerosis: other techniques. Jackson GD. **Magn Reson Imaging** 1995;13(8):1081–93 (21 ref.)

MRI of myocardial function: motion tracking techniques. McVeigh ER. **Magn Reson Imaging** 1996;14(2):137–50 (65 ref.)

Gastrointestinal contrast agents for MR imaging. Brown JJ. **Magn Reson Imaging Clin N Am** 1996 Feb;4(1):25–35 (43 ref.)

Kinematic magnetic resonance imaging of the knee. Brown SM, et al. **Magn Reson Imaging Clin N Am** 1994 Aug; 2(3):441–9 (24 ref.)

MR imaging techniques for soft-tissue lesions. Byers GE, et al. **Magn Reson Imaging Clin N Am** 1995 Nov;3(4):563–76 (53 ref.)

MR imaging of the thoracic aorta. Flamm SD, et al. **Magn Reson Imaging Clin N Am** 1996 May;4(2):217–35 (54 ref.)

Liver. III: Gadolinium-based hepatobiliary contrast agents (Gd-EOB-DTPA and Gd-BOPTA/Dimeg). Giovagnoni A, et al. **Magn Reson Imaging Clin N Am** 1996 Feb; 4(1):61–72 (34 ref.)

Targeted contrast agents in MR imaging. Gupta H, et al. **Magn Reson Imaging Clin N Am** 1996 Feb;4(1):171–84 (78 ref.)

Sensitivity of contrast-enhanced MR imaging of the breast. Heywang-Koebrunner SH, et al. **Magn Reson Imaging Clin N Am** 1994 Nov;2(4):527–38 (32 ref.)

Contrast-enhanced MR imaging of the kidneys and adrenal glands. Huch Böni RA, et al. **Magn Reson Imaging Clin N Am** 1996 Feb;4(1):101–31 (61 ref.)

Contrast-enhanced MR imaging of the pancreas. Kettritz U, et al. **Magn Reson Imaging Clin N Am** 1996 Feb;4(1):87–100 (62 ref.)

Technical considerations for magnetic resonance imaging of the ankle and foot. Kneeland JB. **Magn Reson Imaging Clin N Am** 1994 Feb;2(1):23–8 (7 ref.)

Carpal tunnel syndrome. MR imaging diagnosis. Mesgarzadeh M, et al. **Magn Reson Imaging Clin N Am** 1995 May;3(2):249–64 (45 ref.)

Imaging techniques, normal variations, and diagnostic pitfalls in shoulder magnetic resonance imaging. Mirowitz SA. **Magn Reson Imaging Clin N Am** 1993 Sep;1(1):19–36 (46 ref.)

Liver I: Currently available gadolinium chelates. Mitchell DG. **Magn Reson Imaging Clin N Am** 1996 Feb;4(1):37–51 (15 ref.)

Contrast-enhanced MR imaging of gynecologic disorders. Outwater EK. **Magn Reson Imaging Clin N Am** 1996 Feb; 4(1):133–51 (84 ref.)

Liver. II: Iron oxide-based reticuloendothelial contrast agents for MR imaging. Clinical review. Petersein J, et al. **Magn Reson Imaging Clin N Am** 1996 Feb;4(1):53–60 (38 ref.)

Mangafodipir trisodium injection (Mn-DPDP). A contrast agent for abdominal MR imaging. Rofsky NM, et al. **Magn Reson Imaging Clin N Am** 1996 Feb;4(1):73–85 (49 ref.)

Very fast cardiac imaging. Schwitter J, et al. **Magn Reson Imaging Clin N Am** 1996 May;4(2):419–32 (56 ref.)

Contrast-enhanced MR imaging of the bladder and prostate. Siegelman ES, et al. **Magn Reson Imaging Clin N Am** 1996 Feb;4(1):153–69 (61 ref.)

MR imaging of normal and injured wrist ligaments. Smith DK. **Magn Reson Imaging Clin N Am** 1995 May;3(2):229–48 (63 ref.)

MR imaging of the triangular fibrocartilage complex. Totterman SM, et al. **Magn Reson Imaging Clin N Am** 1995 May;3(2):213–28 (24 ref.)

Basic principles of MR contrast agents. Wolf GL, et al. **Magn Reson Imaging Clin N Am** 1996 Feb;4(1):1–10 (52 ref.)

Magnetic resonance of the heart and great vessels. de Roos A, et al. **Nat Med** 1995 Jul;1(7):711–3 (6 ref.)

Magnetic resonance elastography. Muthupillai R, et al. **Nat Med** 1996 May;2(5):601–3 (16 ref.)

Functional MR imaging in the evaluation of the patient with epilepsy. Functional localization. Latchaw RE, et al. **Neuroimaging Clin N Am** 1995 Nov;5(4):683–93 (20 ref.)

Diffusion weighted imaging for acute cerebral infarction. Schäbitz WR, et al. **Neurol Res** 1995 Aug;17(4):270–4 (53 ref.)

Diffusion MRI: precision, accuracy and flow effects. Conturo TE, et al. **NMR Biomed** 1995 Nov–Dec;8(7–8):307–32 (223 ref.)

Diffusion-weighted NMR imaging: application to experimental focal cerebral ischemia. Hoehn-Berlage M. **NMR Biomed** 1995 Nov–Dec;8(7–8):345–58 (103 ref.)

Magnetization transfer in magnetic resonance imaging. Thomas JD. **Radiol Technol** 1996 Mar–Apr;67(4):297–306 (26 ref.)

Statistical approaches to human brain mapping by functional magnetic resonance imaging. Lange N. **Stat Med** 1996 Feb 28;15(4):389–428 (93 ref.)

Magnetic resonance imaging of human brain function. Moseley ME, et al. **Surg Neurol** 1996 Apr;45(4):385–91 (12 ref.)

Magnetic resonance imaging of congenital heart disease. Gutierrez FR. **Top Magn Reson Imaging** 1995 Fall; 7(4):246–57 (36 ref.)

Cardiac MR imaging: principles and techniques. Haacke EM, et al. **Top Magn Reson Imaging** 1995 Fall;7(4):200–17 (59 ref.)

[Human brain function makes magnetic resonance imaging live] Hakumäki J, et al. **Duodecim** 1994;110(11):1068–75 (23 ref.) **(Fin)**

[Analysis of texture in medical imaging. Review of the literature] Rolland Y, et al. **Ann Radiol (Paris)** 1995; 38(6):315–47 (102 ref.) (Eng. Abstr.) **(Fre)**

[Magnetic resonance imaging for lumbar disk pathology. incidence of false negatives (editorial)] Berthelot JM, et al. **Presse Med** 1995 Oct 7;24(29):1329–31 (26 ref.) (Eng. Abstr.) **(Fre)**

[The endorem tolerance profile] Laniado M, et al. **Radiologe** 1995 Nov;35(11 Suppl 2):S266–70 (16 ref.) (Eng. Abstr.) **(Ger)**

[Detection of liver tumors] Rummeny EJ, et al. **Radiologe** 1995 Nov;35(11 Suppl 2):S252–8 (29 ref.) (Eng. Abstr.) **(Ger)**

[Value of MRI in diagnosis of focal liver lesions] Taupitz M, et al. **Radiologe** 1995 Nov;35(11 Suppl 2):S243–7 (39 ref.) (Eng. Abstr.) **(Ger)**

[Three-dimensional image diagnosis of neoplasms] Moriyama N. **Nippon Naika Gakkai Zasshi** 1996 Mar 10;85(3):333–6 (7 ref.) **(Jpn)**

[Fat measurement using MRI] Yamaguchi K, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:215–20 (9 ref.) **(Jpn)**

TRENDS

The development of magnetic resonance imaging in obstetrics. Duncan KR. **Br J Hosp Med** 1996 Feb 21–Mar 5;55(4):178–81 (20 ref.)

Advanced application of magnetic resonance imaging in human brain science. Caviness VS Jr, et al. **Brain Dev** 1995 Nov–Dec;17(6):399–408 (61 ref.)

Magnetic resonance imaging: present position and future prospects. Curati WL, et al. **Eur J Cancer** 1996 Apr; 32A(4):589–92 (31 ref.)

New magnetic resonance imaging techniques for the evaluation of traumatic brain injury. Smith DH, et al. **J Neurotrauma** 1995 Aug;12(4):573–7 (34 ref.)

Critical pathways for the future: MR imaging and digital mammography. Newstead GM, et al. **Radiographics** 1995 Jul;15(4):951–62 (40 ref.)

MR imaging of the breast for cancer evaluation. Current status and future directions. Stelling CB. **Radiol Clin North Am** 1995 Nov;33(6):1187–204 (60 ref.)

MAGNETIC RESONANCE IMAGING, CINE

Heart disease: functional evaluation with MR imaging. Higgins CB, et al. **Radiology** 1996 May;199(2):307–15 (85 ref.)

MAGNETIC RESONANCE IMAGING, ECHO-PLANAR see **ECHO-PLANAR IMAGING**

MAGNETIC RESONANCE SPECTROSCOPY see **NUCLEAR MAGNETIC RESONANCE**

MAGNETICS

Some positive effects of transcranial magnetic stimulation. Amassian VE, et al. **Adv Neurol** 1995;67:79–106 (62 ref.)

Transcranial magnetic stimulation. Negative effects. Hallett M. **Adv Neurol** 1995;67:107–13 (40 ref.)

A possible mechanism of action of repelling, molar distalizing magnets. Part I. Blechman AM, et al. **Am J Orthod Dentofacial Orthop** 1995 Oct;108(4):428–31 (18 ref.)

Magnetic stimulation in the assessment of peripheral nerve disorders. Benecke R. **Baillieres Clin Neurol** 1996 Mar; 5(1):115–28 (37 ref.)

Magnetoreception: why is conditioning so seldom successful? Wiltschko R, et al. **Naturwissenschaften** 1996 Jun; 83(6):241–7 (57 ref.)

A physical mechanism in the treatment of neurologic disorders with externally applied pico Tesla magnetic fields. Jacobson JI, et al. **Panminerva Med** 1995 Jun; 37(2):98–104 (22 ref.)

Magnetization transfer in magnetic resonance imaging. Thomas JD. **Radiol Technol** 1996 Mar–Apr;67(4):297–306 (26 ref.)

[The mechanism of action of a magnetic field on the living organism] Kirillov IuB, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1995 May–Jun; (3):43–5 (18 ref.) **(Rus)**

ADVERSE EFFECTS

Magnetic field effects on biomolecules, cells, and living organisms. Hong FT. **Biosystems** 1995;36(3):187–229 (150

ref.)
Health risk implications of magnetic field exposures. Wartenberg D. **Mt Sinai J Med** 1995 Oct;62(5):356–9 (12 ref.)

DIAGNOSTIC USE

Transcranial magnetic stimulation. Gates JR. **Neuroimaging Clin N Am** 1995 Nov;5(4):711–20 (51 ref.)

THERAPEUTIC USE

A magnetic approach to AIDS. Jacobson JI. **Panminerva Med** 1995 Mar;37(1):22–7 (21 ref.)
[Biotropic effects of electromagnetic fields: benefit or harm?] Agadzhanian NA, et al. **Aviakosm Ekolog Med** 1995; 29(4):9–12 (55 ref.) (Eng. Abstr.) **(Rus)**
[The use of permanent magnets in the orthodontic clinic] Persin LS, et al. **Stomatologiia (Mosk)** 1995;74(5):76–8 (26 ref.) (Eng. Abstr.) **(Rus)**

MAGNETIZATION TRANSFER CONTRAST IMAGING see **MAGNETIC RESONANCE IMAGING**

MAGNETOENCEPHALOGRAPHY

Imaging pain in humans. Berman J. **Br J Anaesth** 1995 Aug; 75(2):209–16 (40 ref.)
Generators of electrical and magnetic mismatch responses in humans. Näätänen R, et al. **Brain Topogr** 1995 Summer; 7(4):315–20 (63 ref.)
Spike and slow wave localization by magnetoencephalography. Lewine JD, et al. **Neuroimaging Clin N Am** 1995 Nov;5(4):575–96 (45 ref.)
Functional localization by magnetoencephalography. Rowley HA, et al. **Neuroimaging Clin N Am** 1995 Nov; 5(4):695–710 (92 ref.)
Magnetoencephalographic features in neurocysticercosis. Morioka T, et al. **Surg Neurol** 1996 Feb;45(2):176–81; discussion 181–2 (46 ref.)

METHODS

Mapping function in the human brain with magnetoencephalography, anatomical magnetic resonance imaging, and functional magnetic resonance imaging. George JS, et al. **J Clin Neurophysiol** 1995 Sep;12(5):406–31 (90 ref.)

MAGNETOMETRY see **MAGNETICS**

MAIC see **MYCOBACTERIUM AVIUM COMPLEX**

MAIDS see **MURINE ACQUIRED IMMUNODEFICIENCY SYNDROME**

MAINTENANCE

Service documentation and the biomedical engineer: results of a survey. Goffin K, et al. **Biomed Instrum Technol** 1996 May–Jun;30(3):223–35 (24 ref.)

MAINTENANCE AND ENGINEERING, HOSPITAL

Hospitals and plastics. Dioxin prevention and medical waste incinerators. Thornton J, et al. **Public Health Rep** 1996 Jul–Aug;111(4):299–313 (121 ref.)

MAIZE see **CORN**

MAJOR CORE PROTEIN see **VIRAL CORE PROTEINS**

MAJOR CORE PROTEINS, VIRAL see **VIRAL CORE PROTEINS**

MAJOR HISTOCOMPATIBILITY COMPLEX

see related
GENES, MHC CLASS I

The human leucocyte antigen complex: its role in colorectal cancer. Ngoi SS, et al. **Ann Acad Med Singapore** 1996 Jan; 25(1):11–6 (34 ref.)
Mechanisms of oral tolerance by MHC peptides. Sayegh MH, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:338–45 (30 ref.)
Antigen-presenting function of the mouse CD1 molecule. Tangri S, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:288–96 (21 ref.)
Predicting major histocompatibility complex-binding sequences within protein antigens. Sinigaglia F, et al. **Biochem Soc Trans** 1995 Aug;23(3):675–7 (18 ref.)
The search for IDDM susceptibility genes: the next generation. Owerbach D, et al. **Diabetes** 1996 May; 45(5):544–51 (79 ref.)
Advances in HLA genetics. Corzo D, et al. **Exp Clin Immunogenet** 1995;12(3):156–70 (89 ref.)
The major histocompatibility complex in man. Buc M. **Folia Biol (Praha)** 1995;41(3–4):119–22 (7 ref.)
The regulation of expression of histocompatibility antigens on the cell surface; molecular genetic basis. Petrányi GG. **Folia Biol (Praha)** 1995;41(3–4):163–77 (57 ref.)
Presentation of antigen and MHC-restricted unresponsiveness. Říhová B. **Folia Biol (Praha)** 1995; 41(3–4):140–62 (28 ref.)
The genetics of HLA. Schwartz DW, et al. **Folia Biol (Praha)** 1995;41(3–4):123–39 (19 ref.)
Genetic susceptibility to malaria and other infectious diseases: from the MHC to the whole genome. Hill AV. **Parasitology** 1996;112 Suppl:S75–84 (56 ref.)
The role of MHC- and non-MHC-associated genes in determining the human immune response to malaria antigens. Riley EM. **Parasitology** 1996;112 Suppl:S39–51 (78 ref.)
New molecular approaches to tissue typing. Wade JA. **Transplant Proc** 1996 Aug;28(4):2022–3 (9 ref.)
The HLA system and the analysis of multifactorial genetic disease. Tomlinson IP, et al. **Trends Genet** 1995 Dec; 11(12):493–8 (49 ref.)

GENETICS

MHC-encoded TAP genes in rheumatic diseases [editorial] Coakley G, et al. **Br J Rheumatol** 1996 Jun;35(6):501–3 (20 ref.)
Evolution and developmental regulation of the major histocompatibility complex. Salter-Cid L, et al. **Crit Rev Immunol** 1995;15(1):31–75 (389 ref.)
The evolution of major histocompatibility class I genes in primates. Watkins DI. **Crit Rev Immunol** 1995;15(1):1–29 (135 ref.)
Fish major histocompatibility complex genes: an expansion. Dixon B, et al. **Dev Comp Immunol** 1995 Mar–Apr; 19(2):109–33 (77 ref.)
A "minimal essential Mhc" and an "unrecognized Mhc": two extremes in selection for polymorphism. Kaufman J, et al. **Immunol Rev** 1995 Feb;143:63–88 (84 ref.)
MHC diversity and selection. Takahata N. **Immunol Rev** 1995 Feb;143:225–47 (43 ref.)
A genetic herd-immunity model for the maintenance of MHC polymorphism. Wills C, et al. **Immunol Rev** 1995 Feb;143:263–92 (70 ref.)
Evolution of the major histocompatibility complex: a current overview. Kasahara M, et al. **Transpl Immunol** 1995 Mar; 3(1):1–20 (224 ref.)
[Gene structure of the human MHC region] Mizuki N, et al. **Nippon Rinsho** 1996 Jun;54(6):1705–17 (29 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Immunoteratology: I. MHC involvement in the embryo response to teratogens in mice. Torchinsky A, et al. **Am J Reprod Immunol** 1995 Nov;34(5):288–98 (27 ref.)
T cell receptor usage in rheumatoid arthritis. Lanchbury JS, et al. **Br Med Bull** 1995 Apr;51(2):346–58 (62 ref.)
New methods to predict MHC-binding sequences within protein antigens. Hammer J. **Curr Opin Immunol** 1995 Apr; 7(2):263–9 (60 ref.)

PHYSIOLOGY

Interaction of antigenic peptides with MHC and TCR molecules. Sette A, et al. **Clin Immunol Immunopathol** 1995 Sep;76(3 Pt 2):S168–71 (7 ref.)
Biological meaning of the MHC. Ivanyi P. **Folia Biol (Praha)** 1995;41(3–4):178–89 (25 ref.)

MALABSORPTION SYNDROMES

Malabsorption in childhood. Talusan-Soriano K, et al. **Pediatr Rev** 1996 Apr;17(4):135–42 (10 ref.)
[Malabsorption syndrome] Hosoda S, et al. **Ryoikibetsu Shokogun Shiriza** 1995;(8):317–20 (17 ref.) **(Jpn)**

COMPLICATIONS

Small bowel intussusception and brown bowel syndrome in association with severe malnutrition. Drake WM, et al. **Am J Gastroenterol** 1996 Jul;91(7):1450–2 (20 ref.)
Intestinal lymphoma and enteropathy [editorial; comment] Isaacson PG. **J Pathol** 1995 Oct;177(2):111–3 (22 ref.) Comment on: J Pathol 1995 Oct;177(2):115–22.
[Intestinal malabsorption, celiac disease and associated lymphoma: from symptoms to diagnosis] Gasbarrini G, et al. **Riv Eur Sci Med Farmacol** 1994 Sep–Dec;16 Suppl 1:39–68 (115 ref.) (Eng. Abstr.) **(Ita)**

DIAGNOSIS

Isolated magnesium malabsorption in a 10-year-old boy. Romero R, et al. **Am J Gastroenterol** 1996 Mar;91(3):611–3 (12 ref.)
Solitary intestinal fibromatosis mimicking malabsorption syndromes. Türken A, et al. **J Pediatr Surg** 1995 Sep; 30(9):1387–9 (9 ref.)

DIET THERAPY

[Medical treatment of chronic radiation induced enteritis] Cosnes J. **Ann Chir** 1996;50(1):36–9 (23 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Chronic diarrhea and malabsorption. Branski D, et al. **Pediatr Clin North Am** 1996 Apr;43(2):307–31 (107 ref.)

PATHOLOGY

Mixed connective tissue disease complicated by pneumatosis cystoides intestinalis and malabsorption syndrome: case report and literature review. Wakamatsu M, et al. **Pathol Int** 1995 Nov;45(11):875–8 (18 ref.)

THERAPY

Chronic diarrhea and malabsorption. Branski D, et al. **Pediatr Clin North Am** 1996 Apr;43(2):307–31 (107 ref.)

VETERINARY

Impaired absorption of magnesium in the aetiology of grass tetany. Dua K, et al. **Br Vet J** 1995 Jul–Aug;151(4):413–26 (98 ref.)

MALACOPLAKIA

Cutaneous malacoplakia: a report of two cases and review of the literature. Lowitt MH, et al. **J Am Acad Dermatol** 1996 Feb;34(2 Pt 2):325–32 (37 ref.)
Malacoplakia of the epididymis. Report of a case and review of the literature. Dieckmann KP, et al. **Urol Int** 1995; 55(4):222–5 (23 ref.)

DIAGNOSIS

Malacoplakia. Two case reports and a comparison of treatment modalities based on a literature review. van der Voort HJ, et al. **Arch Intern Med** 1996 Mar 11; 156(5):577–83 (118 ref.)

PATHOLOGY

[Malacoplakia of the prostate and seminal vesicle. Ultrastructural study and review of the literature] Sánchez Chapado M, et al. **Arch Esp Urol** 1995 Oct;48(8):775–8 (34 ref.) (Eng. Abstr.) **(Spa)**
[Epididymal malacoplakia in a heart transplant recipient: clinico-pathologic study of a case] Soria Corón MR, et al. **Arch Esp Urol** 1996 Mar;49(2):172–6 (15 ref.) (Eng. Abstr.) **(Spa)**

MALARIA

see related
ANTIMALARIALS

Vitamin E and selenium: contrasting and interacting nutritional determinants of host resistance to parasitic and viral infections. Levander OA, et al. **Proc Nutr Soc** 1995 Jul;54(2):475–87 (73 ref.)

COMPLICATIONS

IGHG3 G and the pathogenesis of hyperreactive malarious splenomegaly. Kelly KM. **Med Hypotheses** 1996 Feb; 46(2):135–9 (48 ref.)

DIAGNOSIS

Malaria diagnosis: a review. Avila SL, et al. **Braz J Med Biol Res** 1996 Apr;29(4):431–43 (122 ref.)
ACP Broadsheet no 148. July 1996. Laboratory diagnosis of malaria. Warhurst DC, et al. **J Clin Pathol** 1996 Jul; 49(7):533–8 (16 ref.)
Comparison of acridine orange and giemsa stains for malaria diagnosis. Kong HH, et al. **Korean J Parasitol** 1995 Dec; 33(4):391–4 (18 ref.)

DRUG THERAPY

Clinical studies of iron chelators in malaria. Mabeza GF, et al. **Acta Haematol** 1996;95(1):78–86 (69 ref.)
Transport pathways in the malaria-infected erythrocyte: characterization and their use as potential targets for chemotherapy. Ginsburg H. **Mem Inst Oswaldo Cruz** 1994; 89 Suppl 2:99–109 (82 ref.)
Artemisinin and the antimalarial endoperoxides: from herbal remedy to targeted chemotherapy. Meshnick SR, et al. **Microbiol Rev** 1996 Jun;60(2):301–15 (189 ref.)
The treatment of malaria. White NJ. **N Engl J Med** 1996 Sep 12;335(11):800–6 (49 ref.)
Recent developments and rationale towards new strategies for malarial chemotherapy. Vial H. **Parasite** 1996 Mar; 3(1):3–23 (148 ref.)
[Malaria and drug resistance] Kager PA, et al. **Ned Tijdschr Geneeskd** 1996 Jan 20;140(3):151–5 (20 ref.) (Eng. Abstr.) **(Dut)**
[For new antimalarial drugs: the methods of fundamental research] Ambroise-Thomas P. **Med Trop (Mars)** 1995;55(4 Suppl):23–6 (11 ref.) (Eng. Abstr.) **(Fre)**
[Current perspectives in antimalarial therapy] Le Bras J. **Med Trop (Mars)** 1995;55(3 Suppl):13–7 (8 ref.) **(Fre)**
[Correct usage of amino alcohols] Touze JE. **Med Trop (Mars)** 1995;55(3 Suppl):24–5 (8 ref.) **(Fre)**
[Malaria resistant to chemotherapy] Născuțiu AM. **Bacteriol Virusol Parazitol Epidemiol** 1995 Jul–Dec; 40(3–4):271–6 (16 ref.) **(Rum)**

EPIDEMIOLOGY

Malaria, the submerged disease. Olliaro P, et al. **JAMA** 1996 Jan 17;275(3):230–3 (54 ref.)
[Role of genetic epidemiology in the study of infectious diseases. The example of malaria] Garcia A, et al.

Med Trop (Mars) 1995;55(4 Suppl):14–8 (39 ref.) (Eng. Abstr.) **(Fre)**

[Towards a vaccination against malaria] Ambroise-Thomas P. **Rev Med Interne** 1995;16(9):717–23 (48 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Genetic susceptibility to malaria and other infectious diseases: from the MHC to the whole genome. Hill AV. **Parasitology** 1996;112 Suppl:S75–84 (56 ref.)

The role of MHC- and non-MHC-associated genes in determining the human immune response to malaria antigens. Riley EM. **Parasitology** 1996;112 Suppl:S39–51 (78 ref.)

Host genetics and infectious disease. Weatherall DJ. **Parasitology** 1996;112 Suppl:S23–9 (30 ref.)

[Role of genetic epidemiology in the study of infectious diseases. The example of malaria] Garcia A, et al. **Med Trop (Mars)** 1995;55(4 Suppl):14–8 (39 ref.) (Eng. Abstr.) **(Fre)**

HISTORY

Malaria in prehistoric southeastern Asia. Poolsuwan S. **Southeast Asian J Trop Med Public Health** 1995 Mar; 26(1):3–22 (129 ref.)

IMMUNOLOGY

Malaria transmission-blocking immunity. Identification of epitopes and evaluation of immunogenicity. Kumar N, et al. **Adv Exp Med Biol** 1995;383:65–72 (18 ref.)

Genetic susceptibility to malaria and other infectious diseases: from the MHC to the whole genome. Hill AV. **Parasitology** 1996;112 Suppl:S75–84 (56 ref.)

The role of MHC- and non-MHC-associated genes in determining the human immune response to malaria antigens. Riley EM. **Parasitology** 1996;112 Suppl:S39–51 (78 ref.)

[Immunological interactions between malaria and pregnancy] Deloron P, et al. **Med Trop (Mars)** 1995;55(4 Suppl):67–8 (11 ref.) **(Fre)**

[Malaria--biological aspects of an infectious disease of importance to humans] Hildebrandt JP. **Naturwissenschaften** 1996 Aug;83(8):359–69 (86 ref.) (Eng. Abstr.) **(Ger)**

PARASITOLOGY

[Malaria and drug resistance] Kager PA, et al. **Ned Tijdschr Geneeskd** 1996 Jan 20;140(3):151–5 (20 ref.) (Eng. Abstr.) **(Dut)**

[The utilization of molecular biological tools in the study of malaria transmission: example of programs conducted in Senegal] Fontenille D, et al. **Med Trop (Mars)** 1995;55(4 Suppl):52–5 (15 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

[Physiopathology of symptoms of malaria. Role of cytokines, cytoadherence and premunition] Hommel M. **Presse Med** 1996 Jan 20;25(2):70–6 (54 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

Some operational aspects of the use of personal protection methods against malaria at individual and community level. Carnevale P, et al. **Ann Soc Belg Med Trop** 1995 Jun; 75(2):81–103 (92 ref.)

Economic aspects of the use of impregnated mosquito nets for malaria control. Brinkmann U, et al. **Bull World Health Organ** 1995;73(5):651–8 (23 ref.)

Control of parasitic diseases in China. Current status and prospects. Yu S. **Chin Med J (Engl)** 1996 Apr;109(4):259–65 (16 ref.)

Malaria vaccine trials: SPf66 and all that [editorial] Riley E. **Curr Opin Immunol** 1995 Oct;7(5):612–6 (16 ref.)

Some emerging issues on the malaria problem in Kenya. Oloo AJ, et al. **East Afr Med J** 1996 Jan;73(1):50–3 (48 ref.)

Malaria, the submerged disease. Olliaro P, et al. **JAMA** 1996 Jan 17;275(3):230–3 (54 ref.)

Rationale and approaches to constructing preerythrocytic malaria vaccines. Hoffman SL, et al. **Pharm Biotechnol** 1995;6:787–802 (152 ref.)

[Vector control, perspectives and realities] Carnevale P. **Med Trop (Mars)** 1995;55(4 Suppl):56–65 (89 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

The management of severe malaria in children: a review. Murphy S, et al. **East Afr Med J** 1995 Aug;72(8):536–9 (31 ref.)

TRANSMISSION

Malaria transmission-blocking immunity. Identification of epitopes and evaluation of immunogenicity. Kumar N, et al. **Adv Exp Med Biol** 1995;383:65–72 (18 ref.)

Some emerging issues on the malaria problem in Kenya. Oloo AJ, et al. **East Afr Med J** 1996 Jan;73(1):50–3 (48 ref.)

[The utilization of molecular biological tools in the study of malaria transmission: example of programs conducted in Senegal] Fontenille D, et al. **Med Trop (Mars)** 1995;55(4 Suppl):52–5 (15 ref.) (Eng. Abstr.) **(Fre)**

[Malaria--biological aspects of an infectious disease of importance to humans] Hildebrandt JP. **Naturwissenschaften** 1996 Aug;83(8):359–69 (86 ref.) (Eng. Abstr.) **(Ger)**

[Hazards of insect vectors of parasites: from theory to practice] Alvar Ezquerra JP. **An R Acad Nac Med (Madr)** 1995;112(3):617–45; discussion 646 (93 ref.) **(Spa)**

VETERINARY

Simian malaria at two sites in the Brazilian Amazon. I--The infection rates of Plasmodium brasilianum in non-human primates. Lourenço-de-Oliveira R, et al. **Mem Inst Oswaldo Cruz** 1995 May-Jun;90(3):331–9 (70 ref.)

MALARIA, CEREBRAL

[Cerebral malaria in children in Cameroon. Apropos of 11 cases] Simo-Moyo J, et al. **Cah Anesthesiol** 1995; 43(5):461–5 (31 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

An overview of pathophysiological theories in Plasmodium falciparum cerebral malaria with the special reference to the role of cytokines. Kotlowski A. **Bull Inst Marit Trop Med Gdynia** 1993–94;44–45(1–4):103–8 (37 ref.)

PATHOLOGY

[Neuromalaria: neuropathological study of 3 cases and review of the literature] Galatioto S. **Pathologica** 1995 Apr; 87(2):121–4 (13 ref.) (Eng. Abstr.) **(Ita)**

PHYSIOPATHOLOGY

[Physiopathology of cerebral malaria] Ringwald P. **Med Trop (Mars)** 1995;55(4 Suppl):19–22 (0 ref.) (Eng. Abstr.) **(Fre)**

MALARIA, FALCIPARUM

Falciparum malaria in children. Newton CR. **Curr Opin Pediatr** 1996 Feb;8(1):16–20 (30 ref.)

[Progresses in tropical medicine in China, 1995] He L. **Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):730–1 (0 ref.) **(Chi)**

BLOOD

Towards a vaccine against asexual blood stage infection by Plasmodium falciparum. Dubois P, et al. **Res Immunol** 1995 May-Jun;146(4–5):263–75 (64 ref.)

COMPLICATIONS

[Multiple organ failure in Plasmodium falciparum malaria] Botella de Maglia J, et al. **Rev Clin Esp** 1995 Oct; 195(10):688–92 (48 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Mechanisms of drug resistance in malaria. Cowman AF. **Aust N Z J Med** 1995 Dec;25(6):837–44 (89 ref.)

Artesunate. A review of its pharmacology and therapeutic efficacy in the treatment of malaria. Barradell LB, et al. **Drugs** 1995 Oct;50(4):714–41 (101 ref.)

Pharmacology and pharmacokinetics of new antimalarials. Watkins WM. **Med Trop (Mars)** 1995;55(4 Suppl):33–6 (31 ref.)

Artemisinin and the antimalarial endoperoxides: from herbal remedy to targeted chemotherapy. Meshnick SR, et al. **Microbiol Rev** 1996 Jun;60(2):301–15 (189 ref.)

[The role of qinghaosu derivatives in the treatment of malaria in 1995] Ambroise-Thomas P. **Med Trop (Mars)** 1995;55(3 Suppl):18–20 (7 ref.) **(Fre)**

[Decision making policies on the utilization of antimalarials in response to a modification of chloroquine efficacity. Applications to Africa] Baudon D. **Med Trop (Mars)** 1995; 55(4 Suppl):37–40 (5 ref.) (Eng. Abstr.) **(Fre)**

[Qinghao derivatives in the treatment of severe malaria (letter)] Danis M. **Med Trop (Mars)** 1995;55(4 Suppl):115 (8 ref.) **(Fre)**

[The status of malaria chemoresistance in Africa] Le Bras J. **Med Trop (Mars)** 1995;55(4 Suppl):9–13 (24 ref.) (Eng. Abstr.) **(Fre)**

[Role of modulators in Plasmodium falciparum resistance to antimalarials] Verdier F, et al. **Med Trop (Mars)** 1995;55(4 Suppl):27–32 (20 ref.) (Eng. Abstr.) **(Fre)**

EPIDEMIOLOGY

Malaria in South Africa--the past, the present and selected implications for the future. Sharp BL, et al. **S Afr Med J** 1996 Jan;86(1):83–9 (27 ref.)

HISTORY

Localized permanent epidemics: the genesis of chloroquine resistance in Plasmodium falciparum. Verdrager J. **Southeast Asian J Trop Med Public Health** 1995 Mar; 26(1):23–8 (18 ref.)

IMMUNOLOGY

An overview of pathophysiological theories in Plasmodium falciparum cerebral malaria with the special reference to the role of cytokines. Kotlowski A. **Bull Inst Marit Trop Med Gdynia** 1993–94;44–45(1–4):103–8 (37 ref.)

Immune mechanisms underlying the premunition against Plasmodium falciparum malaria. Pérignon JL, et al. **Mem Inst Oswaldo Cruz** 1994;89 Suppl 2:51–3 (13 ref.)

[Immunology of human Plasmodium falciparum malaria] Vanham G, et al. **Ann Soc Belg Med Trop** 1995 Sep; 75(3):159–78 (53 ref.) (Eng. Abstr.) **(Fre)**

[Are immunological therapies used in severe malaria?] Peyron F. **Med Trop (Mars)** 1995;55(3 Suppl):21–3 (11 ref.) **(Fre)**

PATHOLOGY

[Neuromalaria: neuropathological study of 3 cases and review of the literature] Galatioto S. **Pathologica** 1995 Apr; 87(2):121–4 (13 ref.) (Eng. Abstr.) **(Ita)**

PHYSIOPATHOLOGY

Dynamic interactions in malaria: host heterogeneity meets parasite polymorphism. Gupta S, et al. **Proc R Soc Lond B Biol Sci** 1995 Sep 22;261(1362):271–7 (39 ref.)

PREVENTION & CONTROL

Randomised trial of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania. Alonzo PL, et al. **Med Trop (Mars)** 1995;55(4 Suppl):41–6 (6 ref.)

Development of vaccines against falciparum malaria. Ramalingam S, et al. **Natl Med J India** 1996 May-Jun; 9(3):120–4 (71 ref.)

Towards a vaccine against asexual blood stage infection by Plasmodium falciparum. Dubois P, et al. **Res Immunol** 1995 May-Jun;146(4–5):263–75 (64 ref.)

Malaria vaccines--now and the future. Targett GA. **Trans R Soc Trop Med Hyg** 1995 Nov-Dec;89(6):585–7 (26 ref.)

[Malaria vaccines: why, who and how?] Hommel M. **Med Trop (Mars)** 1995;55(4 Suppl):47–51 (15 ref.) (Eng. Abstr.) **(Fre)**

[Antimalarial vaccination] Ambroise-Thomas P. **Sante** 1995 Nov-Dec;5(6):411–5 (19 ref.) (Eng. Abstr.) **(Fre)**

[The investigational vaccine SPf66 against Plasmodium falciparum: myth or reality?] Robert F, et al. **Sante** 1996 Jan-Feb;6(1):56–7 (11 ref.) **(Fre)**

THERAPY

[Are immunological therapies used in severe malaria?] Peyron F. **Med Trop (Mars)** 1995;55(3 Suppl):21–3 (11 ref.) **(Fre)**

TRANSMISSION

Early sporogonic development in local vectors of Plasmodium falciparum in rural Cameroon. Robert V, et al. **Mem Inst Oswaldo Cruz** 1994;89 Suppl 2:23–6 (10 ref.)

MALARIA VACCINES

Malaria transmission-blocking immunity. Identification of epitopes and evaluation of immunogenicity. Kumar N, et al. **Adv Exp Med Biol** 1995;383:65–72 (18 ref.)

Nucleic acid malaria vaccines. Current status and potential. Hoffman SL, et al. **Ann N Y Acad Sci** 1995 Nov 27; 772:88–94 (11 ref.)

Malaria vaccines [editorial] Moreno A, et al. **Curr Opin Immunol** 1995 Oct;7(5):607–11 (57 ref.)

Advances toward the development of an asexual blood stage MSP-1 vaccine of Plasmodium vivax. Levitus G, et al. **Mem Inst Oswaldo Cruz** 1994;89 Suppl 2:81–4 (13 ref.)

Development of vaccines against falciparum malaria. Ramalingam S, et al. **Natl Med J India** 1996 May-Jun; 9(3):120–4 (71 ref.)

Malaria vaccines--now and the future. Targett GA. **Trans R Soc Trop Med Hyg** 1995 Nov-Dec;89(6):585–7 (26 ref.)

[Towards a vaccination against malaria] Ambroise-Thomas P. **Rev Med Interne** 1995;16(9):717–23 (48 ref.) (Eng. Abstr.) **(Fre)**

ADMINISTRATION & DOSAGE

Malaria vaccine trials: SPf66 and all that [editorial] Riley E. **Curr Opin Immunol** 1995 Oct;7(5):612–6 (16 ref.)

Randomised trial of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania. Alonzo PL, et al. **Med Trop (Mars)** 1995;55(4 Suppl):41–6 (6 ref.)

[Malaria vaccines: why, who and how?] Hommel M. **Med Trop (Mars)** 1995;55(4 Suppl):47–51 (15 ref.) (Eng. Abstr.) **(Fre)**

CHEMICAL SYNTHESIS

Rationale and approaches to constructing preerythrocytic malaria vaccines. Hoffman SL, et al. **Pharm Biotechnol** 1995;6:787–802 (152 ref.)

IMMUNOLOGY

Towards a vaccine against asexual blood stage infection by

MALARIA VACCINES

Plasmodium falciparum. Dubois P, et al. **Res Immunol** 1995 May-Jun;146(4-5):263-75 (64 ref.)
[Antimalarial vaccination] Ambroise-Thomas P. **Sante** 1995 Nov-Dec;5(6):411-5 (19 ref.) (Eng. Abstr.) **(Fre)**
[The investigational vaccine SPf66 against Plasmodium falciparum: myth or reality?] Robert F, et al. **Sante** 1996 Jan-Feb;6(1):56-7 (11 ref.) **(Fre)**

MALARIA, VIVAX

PREVENTION & CONTROL

Advances toward the development of an asexual blood stage MSP-1 vaccine of Plasmodium vivax. Levitus G, et al. **Mem Inst Oswaldo Cruz** 1994;89 Suppl 2:81-4 (13 ref.)

MALASSEZIA

Seborrhoeic dermatitis and Pityrosporum yeasts. Bergbrant IM. **Curr Top Med Mycol** 1995;6:95-112 (130 ref.)

ISOLATION & PURIFICATION

Neonatal Malassezia furfur pustulosis. Rapelanoro R, et al. **Arch Dermatol** 1996 Feb;132(2):190-3 (30 ref.)

MALATE DEHYDROGENASE

BLOOD

[Malate dehydrogenase (MDH)] Takagi Y. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:376-9 (13 ref.) **(Jpn)**

MALD-MS see **SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION**

MALE BREAST NEOPLASMS see **BREAST NEOPLASMS, MALE**

MALE PATTERN BALDNESS see **ALOPECIA**

MALIGNANT CARCINOID SYNDROME

[Carcinoid syndrome] Li D, et al. **Chung Hua Wai Ko Tsa Chih** 1995 Apr;33(4):246-8 (22 ref.) **(Chi)**
[A functioning carcinoid tumor with liver involvement without the associated carcinoid syndrome] Sánchez A, et al. **Gastroenterol Hepatol** 1995 Nov;18(9):468-70 (7 ref.) (Eng. Abstr.) **(Spa)**

MALIGNANT HYPERPYREXIA see **MALIGNANT HYPERTHERMIA**

MALIGNANT HYPERTHERMIA

Variants of malignant hyperthermia. Special problems for the paediatric anaesthesiologist. Rosenberg H, et al. **Paediatr Anaesth** 1996;6(2):87-93 (37 ref.)
[Current view of malignant hyperthermia] Yuge O. **Masui** 1995;44 Suppl:S59-64 (15 ref.) **(Jpn)**
[Physiologic, biochemical and genetic aspects of malignant hyperthermia] Lahučký R, et al. **Cesk Fysiol** 1995 Dec; 44(4):195-9 (38 ref.) (Eng. Abstr.) **(Slo)**

EPIDEMIOLOGY

Investigation of malignant hyperthermia susceptibility in Denmark. Ording H. **Dan Med Bull** 1996 Apr;43(2):111-25 (98 ref.)

ETIOLOGY

[Chronic rhabdomyolysis disclosing mitochondriopathy and malignant hyperthermia susceptibility] Etcharry-Bouyx F, et al. **Rev Neurol (Paris)** 1995 Oct;151(10):589-92 (10 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Discordance between phenotype and genotype in malignant hyperthermia. MacLennan DH. **Curr Opin Neurol** 1995 Oct;8(5):397-401 (33 ref.)
[Molecular biological aspects for malignant hyperthermia] Otsu K. **Masui** 1995;44 Suppl:S108-12 (20 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Malignant hyperthermia: excitation-contraction coupling, Ca2+ release channel, and cell Ca2+ regulation defects. Mickelson JR, et al. **Physiol Rev** 1996 Apr;76(2):537-92 (433 ref.)

MALIGNANT MELANOMA see **MELANOMA**

MALINGERING

Malingering a challenge for the forensic examiner. Palermo GB, et al. **Med Law** 1996;15(1):143-60 (25 ref.)

COMPLICATIONS

Psychiatric aspects of chronic pain. Eisendrath SJ. **Neurology** 1995 Dec;45(12 Suppl 9):S26-34; discussion S35-6 (36 ref.)

DIAGNOSIS

Accident neurosis revisited [editorial] Mayou R. **Br J Psychiatry** 1996 Apr;168(4):399-403 (26 ref.)
The post-concussional syndrome: physiogenesis, psychogenesis and malingering. An integrative model. Jacobson RR. **J Psychosom Res** 1995 Aug;39(6):675-93 (119 ref.)
The detection of exaggerated or simulated memory disorder by neuropsychological methods. Leng NR, et al. **J Psychosom Res** 1995 Aug;39(6):767-76 (37 ref.)
Detecting the malingering of cognitive deficits: an update. Haines ME, et al. **Neuropsychol Rev** 1995 Jun;5(2):125-48 (82 ref.)

PSYCHOLOGY

'Functional overlay', and illness behaviour in chronic pain: distress or malingering? Conceptual difficulties in medico-legal assessment of personal injury claims. Main CJ, et al. **J Psychosom Res** 1995 Aug;39(6):737-53 (58 ref.)

MALNUTRITION see **NUTRITION DISORDERS**

MALOCCLUSION

see related
ORTHODONTICS, CORRECTIVE

DIAGNOSIS

Straight talk about extraction and nonextraction: a differential diagnostic decision. Vaden JL, et al. **Am J Orthod Dentofacial Orthop** 1996 Apr;109(4):445-52 (23 ref.)

ETIOLOGY

Progressive mandibular retrusion-idiopathic condylar resorption. Part II. Arnett GW, et al. **Am J Orthod Dentofacial Orthop** 1996 Aug;110(2):117-27 (109 ref.)
Mandibular resorption due to systemic sclerosis. Case report of surgical correction of a secondary open bite deformity. Haers PE, et al. **Int J Oral Maxillofac Surg** 1995 Aug; 24(4):261-7 (44 ref.)

SURGERY

The stability of facial osteotomies. 3. Chin advancement. Hoffman GR, et al. **Aust Dent J** 1995 Oct;40(5):289-95 (28 ref.)
Mandibular resorption due to systemic sclerosis. Case report of surgical correction of a secondary open bite deformity. Haers PE, et al. **Int J Oral Maxillofac Surg** 1995 Aug; 24(4):261-7 (44 ref.)
[Extraction in orthodontics: when and why?] Bousaba S, et al. **Rev Belge Med Dent** 1995;50(2):53-65 (32 ref.) (Eng. Abstr.) **(Fre)**
[Bimaxillary segmental osteotomies] Gattinger B, et al. **Fortschr Kiefer Gesichtschir** 1995;40:32-41 (39 ref.) **(Ger)**
[Surgical treatment of obstructive sleep apnea by maxillary and mandibular osteotomy] Hochban W, et al. **Fortschr Kiefer Gesichtschir** 1995;40:65-72 (28 ref.) **(Ger)**
[Indications, technique and results of bimaxillary surgery] Luhr HG, et al. **Fortschr Kiefer Gesichtschir** 1995;40:20-32 (125 ref.) **(Ger)**
[Complications in bimaxillary surgical interventions] Sailer HF, et al. **Fortschr Kiefer Gesichtschir** 1995;40:41-9 (65 ref.) **(Ger)**
[Orthodontic pre- and postoperative treatment in bimaxillary osteotomy] Scheuer H, et al. **Fortschr Kiefer Gesichtschir** 1995;40:11-20 (19 ref.) **(Ger)**
[Predictive soft tissue factors in bimaxillary operations] Steinhäuser EW, et al. **Fortschr Kiefer Gesichtschir** 1995; 40:50-7 (31 ref.) **(Ger)**

THERAPY

Orthodontic management of patients with hematologic malignancies. Sheller B, et al. **Am J Orthod Dentofacial Orthop** 1996 Jun;109(6):575-80 (11 ref.)
Straight talk about extraction and nonextraction: a differential diagnostic decision. Vaden JL, et al. **Am J Orthod Dentofacial Orthop** 1996 Apr;109(4):445-52 (23 ref.)
Lateral thinking: the management of missing upper lateral incisors. Millar BJ, et al. **Br Dent J** 1995 Aug 5; 179(3):99-106 (16 ref.)

MALOCCLUSION, ANGLE CLASS I

[Standard electromyographic and kinesiographic parameters in a sample of healthy population] Manni A, et al. **Minerva Stomatol** 1995 Sep;44(9):411-9 (29 ref.) (Eng. Abstr.) **(Ita)**

PATHOLOGY

Cephalometric analysis of Deutero-Malay Indonesians. Munandar S, et al. **Aust Dent J** 1995 Dec;40(6):381-8 (38 ref.)

MALOCCLUSION, ANGLE CLASS II

DIAGNOSIS

[Brodie's syndrome. A report of 2 atypical cases] Nocini PF, et al. **Minerva Stomatol** 1995 Jul-Aug;44(7-8):361-8 (10 ref.) (Eng. Abstr.) **(Ita)**

ETIOLOGY

Progressive mandibular retrusion--idiopathic condylar resorption. Part I. Arnett GW, et al. **Am J Orthod Dentofacial Orthop** 1996 Jul;110(1):8-15 (0 ref.)

MALOCCLUSION, ANGLE CLASS III

DIAGNOSIS

[Brodie's syndrome. A report of 2 atypical cases] Nocini PF, et al. **Minerva Stomatol** 1995 Jul-Aug;44(7-8):361-8 (10 ref.) (Eng. Abstr.) **(Ita)**

MALONALDEHYDE see **MALONDIALDEHYDE**

MALONDIALDEHYDE

IMMUNOLOGY

[Immunologic relevance of malonic dialdehyde] Chancerelle Y, et al. **Ann Pharm Fr** 1995;53(6):241-50 (54 ref.) (Eng. Abstr.) **(Fre)**

MALONYL COA see **MALONYL COENZYME A**

MALONYL COENZYME A

METABOLISM

Malonyl-CoA and carnitine palmitoyltransferase I: an expanding partnership. McGarry JD. **Biochem Soc Trans** 1995 Aug;23(3):481-5 (29 ref.)
Are the beta-cell signaling molecules malonyl-CoA and cystolic long-chain acyl-CoA implicated in multiple tissue defects of obesity and NIDDM? Prentki M, et al. **Diabetes** 1996 Mar;45(3):273-83 (163 ref.)

PHARMACOLOGY

Malonyl-CoA and carnitine palmitoyltransferase I: an expanding partnership. McGarry JD. **Biochem Soc Trans** 1995 Aug;23(3):481-5 (29 ref.)

MALPIGHIAN TUBULES

CYTOLOGY

Cell proliferation and development of the Malpighian tubules in Drosophila melanogaster. Skaer H. **Exp Nephrol** 1996 Mar-Apr;4(2):119-26 (30 ref.)

EMBRYOLOGY

Cell proliferation and development of the Malpighian tubules in Drosophila melanogaster. Skaer H. **Exp Nephrol** 1996 Mar-Apr;4(2):119-26 (30 ref.)

MALPRACTICE

see related
INSURANCE, LIABILITY
Implications of negligent selection and retention of physicians in the age of ERISA. Dorros TA, et al. **Am J Law Med** 1995;21(4):383-418 (346 ref.)

LEGISLATION & JURISPRUDENCE

Medical-legal issues in teleradiology [see comments] Berger SB, et al. **AJR Am J Roentgenol** 1996 Mar;166(3):505-10 (36 ref.) Comment in: AJR Am J Roentgenol 1996 Mar;166(3):511-2.
Adversarial medical and scientific testimony and lay jurors: a proposal for medical malpractice reform. Menon JW. **Am J Law Med** 1995;21(2-3):281-300 (141 ref.)
Liability for managed care decisions: the Employee Retirement Income Security Act (ERISA) and the uneven playing field. Mariner WK. **Am J Public Health** 1996 Jun; 86(6):863-9 (66 ref.)
APA resource document: legal sanctions for mental health professional-patient sexual misconduct. Hoge SK, et al. **Bull Am Acad Psychiatry Law** 1995;23(3):433-48 (56 ref.)
Regulating pastoral counseling practice: the problem of sexual misconduct. Young JL, et al. **Bull Am Acad Psychiatry Law** 1995;23(3):421-32 (32 ref.)
Medicolegal ramifications of electronic fetal monitoring during labor. Schifrin BS. **Clin Perinatol** 1995 Dec; 22(4):837-54 (42 ref.)
Emergency room follow-up care and malpractice liability. Morgan D. **J Leg Med** 1995 Sep;16(3):373-406 (143 ref.)
1994 Le Tourneau Award. An insurer's right to settle versus its duty to defend nonmeritorious medical malpractice claims. Thomas SS. **J Leg Med** 1995 Dec;16(4):545-83 (204

ref.)
Alternative dispute resolution for medical malpractice actions: an efficient approach to the law and health care. White WF. **Leg Med** 1995;:227-39 (47 ref.)
Formal complaints and disciplinary proceedings involving medical practitioners: recent developments in New South Wales, Australia. Buetow SA. **Med Law** 1995; 14(7-8):559-69 (33 ref.)
Credibility: the key to the successful physician witness. Marshall JC. **Surv Ophthalmol** 1995 Jul-Aug;40(1):69-72 (14 ref.)
[What are the medico-legal implications of induced labor?] Pierre F, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995; 24 Suppl 1:120-8 (0 ref.) **(Fre)**
[Endoscopic surgery and malpractice] Ulsenheimer K. **Arch Gynecol Obstet** 1995;257(1-4):29-36 (29 ref.) **(Ger)**
[Help or hinderniss? The effect of legal norms on the physician-patient relationship] Ulsenheimer K. **Geburtshilfe Frauenheilkd** 1995 Sep;55(9):M110-9 (113 ref.) **(Ger)**
[Closed claims analysis of anesthesia in Japan] Ito Y. **Masui** 1995;44 Suppl:S179-82 (7 ref.) **(Jpn)**

MALT see **CEREALS**

MALT LYMPHOMA see **LYMPHOMA, MUCOSA-ASSOCIATED LYMPHOID TISSUE**

MALTA FEVER see **BRUCELLOSIS**

MALTASES see **ALPHA-GLUCOSIDASES**

MALTOSE

ANALOGS & DERIVATIVES

Methods available to estimate the energy values of sugar alcohols. Ellwood KC. **Am J Clin Nutr** 1995 Nov;62(5 Suppl):1169S-1174S (38 ref.)

MAMBA see **ELAPIDAE**

MAMMAE

ABNORMALITIES

Happenstance, circumstance or enemy action: cyclin D1 in breast, eye and brain. Schmidt EV. **Bioessays** 1996 Jan; 18(1):6-8 (29 ref.)

CHEMISTRY

The epithelial mucin, MUC1, of milk, mammary gland and other tissues. Patton S, et al. **Biochim Biophys Acta** 1995 Dec 20;1241(3):407-23 (127 ref.)

CYTOLOGY

Signalling in extracellular-matrix-mediated control of epithelial cell phenotype. Edwards G, et al. **Biochem Soc Trans** 1995 Aug;23(3):464-8 (39 ref.)

GROWTH & DEVELOPMENT

A novel whey to study effects of insulin-like growth factor-I on mammary development [editorial; comment] Kleinberg DL. **Endocrinology** 1996 Jan;137(1):1-2 (20 ref.) Comment on: Endocrinology 1996 Jan;137(1):321-30.

METABOLISM

The mammary gland as a bioreactor: factors regulating the efficient expression of milk protein-based transgenes. Rosen JM, et al. **Am J Clin Nutr** 1996 Apr;63(4):627S-32S (53 ref.)
The role of estrogen in mammary carcinogenesis. Fishman J, et al. **Ann N Y Acad Sci** 1995 Sep 30;768:91-100 (31 ref.)
Prolactin-mediated gene activation in mammary epithelial cells. Groner B, et al. **Curr Opin Genet Dev** 1995 Oct; 5(5):587-94 (73 ref.)
New insights in the molecular mechanism of progestin-induced proliferation of mammary epithelium: induction of the local biosynthesis of growth hormone (GH) in the mammary glands of dogs, cats and humans. Mol JA, et al. **J Steroid Biochem Mol Biol** 1996 Jan; 57(1-2):67-71 (44 ref.)

PHYSIOLOGY

Structural remodelling of reproductive tissues. Luck MR, et al. **J Endocrinol** 1995 Aug;146(2):191-5 (61 ref.)
Substrate selection and oxygen uptake by the lactating mammary gland. Williamson DH, et al. **Proc Nutr Soc** 1995 Mar;54(1):165-75 (62 ref.)

PHYSIOPATHOLOGY

[Tissue regeneration processes in the bovine mammary gland] Michel G, et al. **Tierarztl Prax** 1996 Jun;24(3):223-7 (11 ref.) (Eng. Abstr.) **(Ger)**

MAMMALS

Progesterone receptors: expression and regulation in the mammalian ovary. Pinter JH, et al. **Clin Obstet Gynecol** 1996 Jun;39(2):424-35 (85 ref.)
mRNA stability in mammalian cells. Ross J. **Microbiol Rev** 1995 Sep;59(3):423-50 (395 ref.)
[The creation of genetic cryobanks and the use of the methods of developmental biology as a means for preserving rare animal species. I. The cryopreservation of the sperm of wild mammals] Rott NN. **Ontogenez** 1995 Jul-Aug;26(4):270-81 (59 ref.) (Eng. Abstr.) **(Rus)**

ANATOMY & HISTOLOGY

Structure and concentrating ability of the mammalian kidney: correlations with habitat. Beuchat CA. **Am J Physiol** 1996 Jul;271(1 Pt 2):R157-79 (179 ref.)
The harderian gland: a tercentennial review. Payne AP. **J Anat** 1994 Aug;185 (Pt 1):1-49 (263 ref.)
Homology in the evolution of the cerebral hemispheres. The case of reptilian dorsal ventricular ridge and its possible correspondence with mammalian neocortex. Aboitiz F. **J Hirnforsch** 1995;36(4):461-72 (84 ref.)

BLOOD

Diffusional water permeability of mammalian red blood cells. Benga G, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1995 Dec; 112(4):653-9 (54 ref.)

CLASSIFICATION

DNA "fossils" and phylogenetic analysis. Using L1 (LINE-1, long interspersed repeated) DNA to determine the evolutionary history of mammals. Furano AV, et al. **J Biol Chem** 1995 Oct 27;270(43):25301-4 (66 ref.)

EMBRYOLOGY

Epithelio-mesenchymal transformation during formation of the mesoderm in the mammalian embryo. Viebahn C. **Acta Anat (Basel)** 1995;154(1):79-97 (170 ref.)
The development of the genital peritoneum in domestic mammals. An analysis of the literature and nomenclature. Martin E. **Anat Histol Embryol** 1995 Dec;24(4):285-7 (18 ref.)
Contractile protein phenotypic variation during development. Murphy AM. **Cardiovasc Res** 1996 Feb;31 Spec No:E25-33 (106 ref.)
Fibroblast growth factors in mammalian development. Yamaguchi TP, et al. **Curr Opin Genet Dev** 1995 Aug; 5(4):485-91 (49 ref.)
Remodeling of the specialized intermediate filament network in mammalian eggs and embryos during development: regulation by protein kinase C and protein kinase M. Gallicano GI, et al. **Curr Top Dev Biol** 1995;31:277-320 (95 ref.)
Mammalian model systems for exploring cytoskeletal dynamics during fertilization. Navara CS, et al. **Curr Top Dev Biol** 1995;31:321-42 (54 ref.)
Role of chromatin structure in zygotic gene activation in the mammalian embryo. Schultz RM, et al. **Semin Cell Biol** 1995 Aug;6(4):201-8 (52 ref.)

GENETICS

Mapping of mammalian genomes with radiation (Goss and Harris) hybrids. Leach RJ, et al. **Adv Genet** 1995;33:63-99 (82 ref.)
Unusual evolution of 11beta- and 17beta-hydroxysteroid and retinol dehydrogenases. Baker ME. **Bioessays** 1996 Jan; 18(1):63-70 (47 ref.)
Comparative maps: the mammalian jigsaw puzzle. Eppig JT, et al. **Curr Opin Genet Dev** 1995 Dec;5(6):709-16 (52 ref.)
Multiple roles for DNA methylation in gametic imprinting. Neumann B, et al. **Curr Opin Genet Dev** 1996 Apr; 6(2):159-63 (45 ref.)
Chromosome painting in mammals as an approach to comparative genomics. Wienberg J, et al. **Curr Opin Genet Dev** 1995 Dec;5(6):792-7 (36 ref.)
Mechanistic and developmental aspects of genetic imprinting in mammals. Latham KE, et al. **Int Rev Cytol** 1995; 160:53-98 (185 ref.)
Metabolic regulation of gene transcription in mammals. Towle HC. **J Biol Chem** 1995 Oct 6;270(40):23235-8 (59 ref.)
The regulation of neuron-specific gene expression in the mammalian nervous system. Twyman RM, et al. **J Neurogenet** 1995 Nov;10(2):67-101 (190 ref.)
Evolution of longevity in mammals. Smith DW. **Mech Ageing Dev** 1995 Jun 30;81(1):51-60 (50 ref.)
Support for interordinal eutherian relationships with an emphasis on primates and their archontan relatives. Allard MW, et al. **Mol Phylogenet Evol** 1996 Feb;5(1):78-88 (74 ref.)
Evidence that mammalian cells possess homologous recombinational repair pathways. Thompson LH. **Mutat Res** 1996 Jun 12;363(2):77-88 (119 ref.)
Concerted evolution of repetitive DNA sequences in eukaryotes. Elder JF Jr, et al. **Q Rev Biol** 1995 Sep; 70(3):297-320 (146 ref.)
The molecular biology of SRY and its role in sex determination in mammals. Koopman P. **Reprod Fertil Dev** 1995;7(4):713-22 (63 ref.)
Genetic control of mitosis, meiosis and cellular differentiation during mammalian spermatogenesis. Wolgemuth DJ, et al. **Reprod Fertil Dev** 1995;7(4):669-83 (141 ref.)

METABOLISM

Structural basis for oxygen delivery: muscle capillaries and manifolds in tuna red muscle. Mathieu-Costello O, et al. **Comp Biochem Physiol A Physiol** 1996 Jan;113(1):25-31 (37 ref.)
gamma-Aminobutyric acid (GABA) metabolism in mammalian neural and nonneural tissues. Tillakaratne NJ, et al. **Comp Biochem Physiol A Physiol** 1995 Oct; 112(2):247-63 (162 ref.)
Mammalian aminoacyl-tRNA synthetases. Yang DC. **Curr Top Cell Regul** 1996;34:101-36 (192 ref.)
Metabolic regulation of gene transcription in mammals. Towle HC. **J Biol Chem** 1995 Oct 6;270(40):23235-8 (59 ref.)
Developmental expression and possible role of perinuclear theca proteins in mammalian spermatozoa. Oko RJ. **Reprod Fertil Dev** 1995;7(4):777-97 (26 ref.)

PHYSIOLOGY

Towards a molecular biology of the circadian clock and sleep of mammals. Shiromani PJ, et al. **Adv Neuroimmunol** 1995; 5(2):217-30 (89 ref.)
Structure and concentrating ability of the mammalian kidney: correlations with habitat. Beuchat CA. **Am J Physiol** 1996 Jul;271(1 Pt 2):R157-79 (179 ref.)
Phylogeny and the function of REM sleep. Siegel JM. **Behav Brain Res** 1995 Jul-Aug;69(1-2):29-34 (42 ref.)
Is sleep fundamentally different between mammalian species? Tobler I. **Behav Brain Res** 1995 Jul-Aug;69(1-2):35-41 (55 ref.)
Tubulin expression and axonal transport in injured and regenerating neurons in the adult mammalian central nervous system. Fournier AE, et al. **Biochem Cell Biol** 1995 Sep-Oct;73(9-10):659-64 (39 ref.)
Population cycles in northern small mammals. Norrdahl K. **Biol Rev Camb Philos Soc** 1995 Nov;70(4):621-37 (147 ref.)
The dorsal thalamus of jawed vertebrates: a comparative viewpoint. Butler AB. **Brain Behav Evol** 1995; 46(4-5):209-23 (115 ref.)
The thalamus of reptiles and mammals: similarities and differences. Pritz MB. **Brain Behav Evol** 1995; 46(4-5):197-208 (54 ref.)
Generation of respiratory rhythm and pattern in mammals: insights from developmental studies. Funk GD, et al. **Curr Opin Neurobiol** 1995 Dec;5(6):778-85 (53 ref.)
Reproductive effects in birds exposed to pesticides and industrial chemicals. Fry DM. **Environ Health Perspect** 1995 Oct;103 Suppl 7:165-71 (85 ref.)
Macrophages in the external muscle layers of mammalian intestines. Mikkelsen HB. **Histol Histopathol** 1995 Jul; 10(3):719-36 (92 ref.)
IGF-I: a mitogen also involved in differentiation processes in mammalian cells. Benito M, et al. **Int J Biochem Cell Biol** 1996 May;28(5):499-510 (95 ref.)
The effects of ageing on cutaneous wound healing in mammals. Ashcroft GS, et al. **J Anat** 1995 Aug;187 (Pt 1):1-26 (287 ref.)
Path integration in mammals and its interaction with visual landmarks. Etienne AS, et al. **J Exp Biol** 1996 Jan;199 (Pt 1):201-9 (49 ref.)
Computations on metric maps in mammals: getting oriented and choosing a multi-destination route. Gallistel CR, et al. **J Exp Biol** 1996 Jan;199 (Pt 1):211-7 (47 ref.)
Evidence that mammalian sex ratios at birth are partially controlled by parental hormone levels at the time of conception. James WH. **J Theor Biol** 1996 Jun 21; 180(4):271-86 (164 ref.)
Vanadium in mammalian physiology and nutrition. Nielsen FH. **Met Ions Biol Syst** 1995;31:543-73 (144 ref.)
Structural organization of the synaptic connections of the spinal cord motor neurons of mammals. Motorina MV. **Neurosci Behav Physiol** 1995 Jul-Aug;25(4):273-89 (134 ref.)
The sperm centrosome during fertilization in mammals: implications for fertility and reproduction. Navara CS, et al. **Reprod Fertil Dev** 1995;7(4):747-54 (30 ref.)
Long-term depression: a learning-related type of synaptic plasticity in the mammalian central nervous system. Zhuo M, et al. **Rev Neurosci** 1995 Jul-Sep;6(3):259-77 (142 ref.)
The organization of neocortex in mammals: are species differences really so different? Krubitzer L. **Trends Neurosci** 1995 Sep;18(9):408-17 (66 ref.)
The emergence and evolution of mammalian neocortex. Northcutt RG, et al. **Trends Neurosci** 1995 Sep;18(9):373-9 (51 ref.)
[Functional expression of vasopressin receptors V1a and V2 along the mammalian nephron] Imbert-Teboul M, et al. **C R Seances Soc Biol Fil** 1995;189(2):151-67 (50 ref.) (Eng. Abstr.) **(Fre)**

MAMMAPLASTY

Breast reconstruction. van Smitten K. **Acta Oncol** 1995; 34(5):685-8 (21 ref.)
Reconstruction after mastectomy. Osteen RT. **Cancer** 1995 Nov 15;76(10 Suppl):2070-4 (29 ref.)
Breast reconstruction--past achievements, current status and future goals. Wickman M. **Scand J Plast Reconstr Surg Hand Surg** 1995 Jun; 29(2):81-100 (124 ref.)
-Possibilities and limits of imaging for evaluating breast

MAMMAPLASTY

implants- Tristant H. **Arch Gynecol Obstet** 1995;256 Suppl:S135-47 (31 ref.) **(Fre)**

ADVERSE EFFECTS

Toxic shock syndrome as a complication of breast prostheses. Poblete JV, et al. **Plast Reconstr Surg** 1995 Dec; 96(7):1702-8 (54 ref.)

[Destructive paraffinoma of the breast and thoracic wall caused by paraffin injection for mammary increase. Apropos of 3 cases with review of the literature] Zekri A, et al. **Ann Chir Plast Esthet** 1996 Feb;41(1):90-3 (7 ref.) (Eng. Abstr.) **(Fre)**

METHODS

Primary and secondary breast reconstruction with special emphasis on the use of prostheses. Petit JY, et al. **Recent Results Cancer Res** 1996;140:169-75 (15 ref.)

Controversy in breast reconstruction. Corral CJ, et al. **Surg Clin North Am** 1996 Apr;76(2):309-26 (44 ref.)

TRENDS

The changing scene in breast surgery in a plastic surgery unit (1966-94). McGregor JC. **J R Coll Surg Edinb** 1995 Oct;40(5):279-89 (44 ref.)

MAMMARY CANCER VIRUS see **MAMMARY TUMOR VIRUSES, MOUSE**

MAMMARY DYSPLASIA see **FIBROCYSTIC DISEASE OF BREAST**

MAMMARY GLANDS see **BREAST**

MAMMARY GLANDS, ANIMAL see **MAMMAE**

MAMMARY NEOPLASMS

METABOLISM

Growth factors and their receptors in neoplastic mammary glands. Rudland PS, et al. **Biomed Pharmacother** 1995; 49(9):389-99 (95 ref.)

MAMMARY NEOPLASMS, EXPERIMENTAL

Animal models of breast cancer: their diversity and role in biomedical research. Clarke R. **Breast Cancer Res Treat** 1996;39(1):1-6 (27 ref.)

CHEMICALLY INDUCED

Experimentally induced mammary tumors in rats. Russo J, et al. **Breast Cancer Res Treat** 1996;39(1):7-20 (112 ref.)

Animal models for breast cancer. Sukumar S, et al. **Mutat Res** 1995 Dec;333(1-2):37-44 (51 ref.)

Transforming growth factor-beta s in mammary tumorigenesis: promoters or antipromoters? Wakefield LM, et al. **Prog Clin Biol Res** 1995;391:133-48 (56 ref.)

ETIOLOGY

Defining the steps in a multistep mouse model for mammary carcinogenesis. Varmus HE, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:491-9 (55 ref.)

Rodent models for the study of etiology, prevention and treatment of breast cancer. Gould MN. **Semin Cancer Biol** 1995 Jun;6(3):147-52 (32 ref.)

GENETICS

MMTV-induced mutations in mouse mammary tumors: their potential relevance to human breast cancer. Callahan R. **Breast Cancer Res Treat** 1996;39(1):33-44 (82 ref.)

ApcMin: a mouse model for intestinal and mammary tumorigenesis. Moser AR, et al. **Eur J Cancer** 1995 Jul-Aug;31A(7-8):1061-4 (30 ref.)

Animal models for breast cancer. Sukumar S, et al. **Mutat Res** 1995 Dec;333(1-2):37-44 (51 ref.)

Oncogene activation and oncogene cooperation in MMTV-induced mouse mammary cancer. van Leeuwen F, et al. **Semin Cancer Biol** 1995 Jun;6(3):127-33 (91 ref.)

[Transcription factors of the PEA3 group in mammary cancer] Monté D, et al. **Ann Endocrinol (Paris)** 1995; 56(5):547-51 (8 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Fish oil, lipid peroxidation and mammary tumor growth. Gonzalez MJ. **J Am Coll Nutr** 1995 Aug;14(4):325-35 (159 ref.)

PREVENTION & CONTROL

Indole-3-carbinol. A novel approach to breast cancer prevention. Bradlow HL, et al. **Ann N Y Acad Sci** 1995 Sep 30;768:180-200 (22 ref.)

Fish oil, lipid peroxidation and mammary tumor growth. Gonzalez MJ. **J Am Coll Nutr** 1995 Aug;14(4):325-35 (159 ref.)

THERAPY

Rodent models for the study of etiology, prevention and treatment of breast cancer. Gould MN. **Semin Cancer Biol** 1995 Jun;6(3):147-52 (32 ref.)

VIROLOGY

Mammary tumors induced by polyomavirus. Fluck MM, et al. **Breast Cancer Res Treat** 1996;39(1):45-56 (49 ref.)

Oncogene activation and oncogene cooperation in MMTV-induced mouse mammary cancer. van Leeuwen F, et al. **Semin Cancer Biol** 1995 Jun;6(3):127-33 (91 ref.)

MAMMARY TUMOR VIRUSES, MOUSE

GENETICS

MMTV-induced mutations in mouse mammary tumors: their potential relevance to human breast cancer. Callahan R. **Breast Cancer Res Treat** 1996;39(1):33-44 (82 ref.)

Transcriptional control by steroid hormones: the role of chromatin. Truss M, et al. **Ciba Found Symp** 1995;191:7-17; discussion 17-23 (45 ref.)

Oncogene activation and oncogene cooperation in MMTV-induced mouse mammary cancer. van Leeuwen F, et al. **Semin Cancer Biol** 1995 Jun;6(3):127-33 (91 ref.)

IMMUNOLOGY

Superantigenic characteristics of mouse mammary tumor viruses play a critical role in susceptibility to infection in mice. Pucillo CE, et al. **Immunol Res** 1995;14(1):58-68 (62 ref.)

MAMMOGRAPHY

Mammographic screening of women aged 40-49 years. Benefit, risk, and cost considerations. Feig SA. **Cancer** 1995 Nov 15;76(10 Suppl):2097-106 (54 ref.)

Mammographic diagnosis of breast cancer. Endo T. **Gan To Kagaku Ryoho** 1996 Mar;23 Suppl 1:8-13 (10 ref.)

Screening mammography in young women: a different perspective. Margolese R. **Lancet** 1996 Mar 30; 347(9005):881-2 (12 ref.)

Breast MR imaging. An analysis of its role with respect to other imaging and interventional modalities. Brenner RJ. **Magn Reson Imaging Clin N Am** 1994 Nov;2(4):705-23 (84 ref.)

Screening and diagnostic breast imaging procedures. A look at lesions through a radiologist's eyes. Schilling K, et al. **Postgrad Med** 1995 Oct;98(4):44-6, 51, 56 passim (7 ref.)

The mammographic spectrum of fat necrosis of the breast. Hogge JP, et al. **Radiographics** 1995 Nov;15(6):1347-56 (25 ref.)

Evaluation of the breast undergoing lumpectomy and radiation therapy. Dershaw DD. **Radiol Clin North Am** 1995 Nov;33(6):1147-60 (50 ref.)

Communication issues in breast imaging. D'Orsi CJ, et al. **Radiol Clin North Am** 1995 Nov;33(6):1231-45 (31 ref.)

Why question screening mammography for women in their forties? Fletcher SW. **Radiol Clin North Am** 1995 Nov; 33(6):1259-71 (62 ref.)

Mammography screening and the controversy concerning women aged 40 to 49. Kopans DB. **Radiol Clin North Am** 1995 Nov;33(6):1273-90 (51 ref.)

A critical review of screening for breast cancer. Del Turco MR. **Recent Results Cancer Res** 1996;140:123-30 (24 ref.)

[MR-mammography: current status and perspectives] Funke M, et al. **Aktuelle Radiol** 1996 May;6(3):130-5 (47 ref.) (Eng. Abstr.) **(Ger)**

[Morphometric analysis of mammographic images in clinical oncology] Campisi C, et al. **Clin Ter** 1995 Nov; 146(11):683-90 (46 ref.) (Eng. Abstr.) **(Ita)**

ADVERSE EFFECTS

Benefits versus risks from mammography: a critical reassessment [see comments] Mettler FA, et al. **Cancer** 1996 Mar 1;77(5):903-9 (49 ref.) Comment in: Cancer 1996 Mar 1;77(5):818-22.

METHODS

Critical pathways for the future: MR imaging and digital mammography. Newstead GM, et al. **Radiographics** 1995 Jul;15(4):951-62 (40 ref.)

[Gadolinium-DTPA (Magnevist) as contrast medium for galactography] Kaltenborn H, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1995 Nov;163(5):457-9 (14 ref.) **(Ger)**

TRENDS

[Recent improvement of mammographic diagnosis] Endo T. **Nippon Geka Gakkai Zasshi** 1996 May;97(5):333-7 (15 ref.) (Eng. Abstr.) **(Jpn)**

MAMMOGRAPHY, ULTRASONIC see **ULTRASONOGRAPHY, MAMMARY**

MAMMOTROPIC HORMONE, PITUITARY see **PROLACTIN**

MAMMOTROPIC HORMONE, PLACENTAL see **PLACENTAL LACTOGEN**

MAMMOTROPIN see **PROLACTIN**

MANAGED CARE PROGRAMS

Managed health care. Managing the risks of laboratory testing in an integrated delivery system. Cooney MM. **Am J Clin Pathol** 1995 Oct;104(4 Suppl 1):S50-3 (14 ref.)

The challenge of managing laboratory information in a managed care environment. Friedman BA. **Am J Clin Pathol** 1996 Apr;105(4 Suppl 1):S3-9 (23 ref.)

How should subspecialists be trained for clinical careers? McFadden D. **Am J Med** 1996 Jul;101(1):1-4 (12 ref.)

The effect of pharmaceutical benefits managers: is it being evaluated? Schulman KA, et al. **Ann Intern Med** 1996 May 15;124(10):906-13 (62 ref.)

The diagnosis and treatment of gastroesophageal reflux disease in a managed care environment. Suggested disease management guidelines. Fennerty MB, et al. **Arch Intern Med** 1996 Mar 11;156(5):477-84 (59 ref.)

Why is the laboratory an afterthought for managed care organizations? Forsman RW. **Clin Chem** 1996 May; 42(5):813-6 (5 ref.)

How to evaluate and implement new technologies in an era of managed care and cost containment. Koch DD. **Clin Chem** 1996 May;42(5):797-802 (34 ref.)

Medical ethics under managed care. Schwartz P. **Int J Fertil Menopausal Stud** 1996 Mar-Apr;41(2):124-8 (16 ref.)

A consideration of factors influencing the utilization of time-limited, short-term group therapy. Piper WE, et al. **Int J Group Psychother** 1996 Jul;46(3):311-28 (16 ref.)

Group psychotherapy and managed behavioral health care: current trends and future challenges. Steenbarger BN, et al. **Int J Group Psychother** 1996 Jul;46(3):297-309 (42 ref.)

Nutrition services in managed care: new paradigms for dietitians. Laramee SH. **J Am Diet Assoc** 1996 Apr; 96(4):335-6 (9 ref.)

Position of The American Dietetic Association: nutrition services in managed care. Laramee SH. **J Am Diet Assoc** 1996 Apr;96(4):391-5 (55 ref.)

Managed care and the treatment of asthma. O'Brien KP. **J Asthma** 1995;32(5):325-34 (46 ref.)

Economic and quality of life outcomes: managed care perspectives. Glandon GL, et al. **Oncology (Huntingt)** 1995 Nov;9(11 Suppl):111-9 (31 ref.)

ECONOMICS

Implications of current procompetitive approaches on EDs. Weil TP. **Am J Emerg Med** 1996 Jan;14(1):74-8 (24 ref.)

Strategic business planning for internal medicine. Ervin FR. **Am J Med** 1996 Jul;101(1):95-9 (22 ref.)

Surviving capitation. Dunham-Taylor J, et al. **Am J Nurs** 1996 Mar;96(3):26-9; quiz 30 (8 ref.)

The role of managed health care organizations in autopsy reimbursement. Chernof D. **Arch Pathol Lab Med** 1996 Aug;120(8):771-2 (0 ref.)

Federal reimbursement to laboratories. Logue J. **Clin Chem** 1996 May;42(5):817-21 (7 ref.)

States' embrace of managed mental health care. Essock SM, et al. **Health Aff (Millwood)** 1995 Fall;14(3):34-44; discussion 45-9 (10 ref.)

Estimating costs of mental health and substance abuse coverage. Frank RG, et al. **Health Aff (Millwood)** 1995 Fall;14(3):102-15 (17 ref.)

Care for depression in a changing environment. Wells KB, et al. **Health Aff (Millwood)** 1995 Fall;14(3):78-89 (15 ref.)

Can managed care plans control health care costs? Zwanziger J, et al. **Health Aff (Millwood)** 1996 Summer;15(2):185-99 (22 ref.)

Breakeven under capitation: pure and simple? Boles KE, et al. **Health Care Manage Rev** 1996 Winter;21(1):38-47 (15 ref.)

The patient as commodity: managed care and the question of ethics. Zoloth-Dorfman L, et al. **J Clin Ethics** 1995 Winter;6(4):339-57 (70 ref.)

Academic medical centers and the fight for survival in the new era of managed care. Nauert RC. **J Health Care Finance** 1995 Summer;21(4):47-59 (15 ref.)

Financing strategies for drug abuse treatment programs. Zarkin GA, et al. **J Subst Abuse Treat** 1995 Nov-Dec; 12(6):385-99 (26 ref.)

Clinical economics and noncoronary vascular disease. Schwartz JS. **J Vasc Interv Radiol** 1995 Nov-Dec;6(6 Pt 2 Su):116S-124S (16 ref.)

The managed care contract: implementation in radiation oncology. Bruner DW. **Oncol Nurs Forum** 1996 Apr; 23(3):451-4 (21 ref.)

The role of oncology clinical practice guidelines in the managed care era. Winn RJ. **Oncology (Huntingt)** 1995 Nov;9(11 Suppl):177-83 (28 ref.)

Profit-managed health care. Clements R. **Radiol Technol** 1996 May-Jun;67(5):377-8 (13 ref.)

LEGISLATION & JURISPRUDENCE

Implications of negligent selection and retention of physicians in the age of ERISA. Dorros TA, et al. **Am J Law Med** 1995;21(4):383-418 (346 ref.)

Medicaid physician participation: patients, poverty, and physician self-interest. Watson SD. **Am J Law Med** 1995; 21(2-3):191-220 (232 ref.)

Liability for managed care decisions: the Employee

Retirement Income Security Act (ERISA) and the uneven playing field. Mariner WK. **Am J Public Health** 1996 Jun; 86(6):863–9 (66 ref.)

Privacy and autonomy in the physician–patient relationship. Independent contracting under Medicare and implications for expansion into managed care. Coleman PG, et al. **J Leg Med** 1995 Dec;16(4):509–43 (197 ref.)

MANPOWER

Managed care and the role and training of psychiatrists. Meyer RE, et al. **Health Aff (Millwood)** 1995 Fall; 14(3):65–77 (23 ref.)

ORGANIZATION & ADMINISTRATION

Preserving the patient referral process in the managed care environment. Rosenthal TC, et al. **Am J Med** 1996 Mar; 100(3):338–43 (54 ref.)

Capitation for emergency physicians. Stapczynski JS. **Ann Emerg Med** 1996 Apr;27(4):501–5 (16 ref.)

Optimizing cardiothoracic surgery information for a managed care environment. Denton TA, et al. **Ann Thorac Surg** 1995 Nov;60(5):1522–5 (22 ref.)

Lifestyles of the risky and infamous. From managed care to managed lives. Morreim EH. **Hastings Cent Rep** 1995 Nov–Dec;25(6):5–12 (43 ref.)

Implementing TQM in the health care sector. Motwani J, et al. **Health Care Manage Rev** 1996 Winter;21(1):73–82 (44 ref.)

Managing mental health: whose responsibility? Rose SJ, et al. **Health Soc Work** 1996 Feb;21(1):76–80 (28 ref.)

MCOs and Medicaid: a good combination. Molina MM. **Hosp Pract (Off Ed)** 1996 Apr 15;31(4):111–4 (7 ref.)

The leadership dance. Ehrat KS, et al. **J Nurs Adm** 1996 Apr;26(4):13–5 (14 ref.)

Performance measurement: integrating quality management and activity-based cost management. McKeon T. **J Nurs Adm** 1996 Apr;26(4):45–51 (8 ref.)

Managed care: will the healthcare needs of rural citizens be met? Pierce SF, et al. **J Nurs Adm** 1996 Apr;26(4):28–32 (10 ref.)

Medical student education in managed care settings: beyond HMOs [see comments] Veloski J, et al. **JAMA** 1996 Sep 4;276(9):667–71 (58 ref.) Comment in: JAMA 1996 Sep 4;276(9):725–7.

Managed care at Eisenhower Army Medical Center: an initial experience. Reinhart SI, et al. **Mil Med** 1995 Aug; 160(8):384–8 (23 ref.)

Applications of QOL measurements: a managed care perspective. Peskin SR. **Oncology (Huntingt)** 1995 Nov;9(11 Suppl):127–8 (3 ref.)

STANDARDS

Standardizing care delivery for infants and children with common congenital cardiac lesions. Allen HD, et al. **Curr Opin Pediatr** 1995 Oct;7(5):601–5 (33 ref.)

Managed care in mental health: the ethical issues. Boyle PJ, et al. **Health Aff (Millwood)** 1995 Fall;14(3):7–22; discussion 23–33 (40 ref.)

Managed care: "new moves, moral uncertainty, and a radical attitude. Howe EG. **J Clin Ethics** 1995 Winter;6(4):290–305 (57 ref.)

Managed care and total quality management: a necessary integration. Phoon J, et al. **J Nurs Care Qual** 1996 Jan; 10(2):25–32 (22 ref.)

TRENDS

Managed care in the public mental health system. Cuffel BJ, et al. **Community Ment Health J** 1996 Apr;32(2):109–24 (42 ref.)

The future of consultation–liaison psychiatry and medical–psychiatric units in the era of managed care. Goldberg RJ, et al. **Gen Hosp Psychiatry** 1995 Jul; 17(4):268–77 (55 ref.)

Mergers, networking, and vertical integration: managed care and investor-owned hospitals. Brown M. **Health Care Manage Rev** 1996 Winter;21(1):29–37 (7 ref.)

Managed care: past, present, and future. Bischof RO, et al. **Med Clin North Am** 1996 Mar;80(2):225–44 (61 ref.)

MANAGED HEALTH CARE INSURANCE PLANS see **MANAGED CARE PROGRAMS**

MANAGEMENT INFORMATION SYSTEMS

Research practice and data management. van Es GA. **Neth J Med** 1996 Jan;48(1):38–44 (7 ref.)

MANAGEMENT SERVICE ORGANIZATIONS see **HOSPITAL–PHYSICIAN JOINT VENTURES**

MANDIBLE

see related
CHIN
TEMPOROMANDIBULAR JOINT

ANATOMY & HISTOLOGY

Relationship of muscular strength to jaw posture in sports dentistry. Gelb H, et al. **N Y State Dent J** 1995 Nov; 61(9):58–66 (0 ref.)

PATHOLOGY

Radiographic features of the mandible in neurofibromatosis: a report of 10 cases and review of the literature. Lee L, et al.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996 Mar;81(3):361–7 (37 ref.)

[Solitary plasmocytoma of the mandible. Report of one case and review of the literature] Ferrer Albiach C, et al. **An Otorrinolaringol Ibero Am** 1995;22(6):609–18 (16 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

[Diffuse sclerosing chronic osteomyelitis of the mandible] García Marín F, et al. **An Otorrinolaringol Ibero Am** 1996; 23(3):249–59 (32 ref.) (Eng. Abstr.) **(Spa)**

RADIOGRAPHY

Radiographic features of the mandible in neurofibromatosis: a report of 10 cases and review of the literature. Lee L, et al.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996 Mar;81(3):361–7 (37 ref.)

[The reliability of apical x-ray pictures in the diagnosis of mandibular bone lesions. A review of the literature and in-vitro study] Briseño Marroquin B, et al. **Schweiz Monatsschr Zahnmed** 1995;105(9):1142–8 (38 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

The stability of facial osteotomies. 3. Chin advancement. Hoffman GR, et al. **Aust Dent J** 1995 Oct;40(5):289–95 (28 ref.)

Lingual nerve damage during lower third molar removal: a comparison of two surgical methods. Robinson PP, et al. **Br Dent J** 1996 Jun 22;180(12):456–61 (29 ref.)

[Bone lengthening: application to the mandible. Review of the literature] Aldegheri A, et al. **Rev Stomatol Chir Maxillofac** 1995;96(5):335–41 (45 ref.) (Eng. Abstr.) **(Fre)**

[The surgical treatment of obstructive sleep apnea syndrome] Cimino A, et al. **Acta Otorhinolaryngol Ital** 1995 Apr;15(2 Suppl 47):3–14 (58 ref.) (Eng. Abstr.) **(Ita)**

MANDIBULAR CONDYLE

see related
TEMPOROMANDIBULAR JOINT

GROWTH & DEVELOPMENT

Basicranial synchondroses and the mandibular condyle in craniofacial growth. Rönning O. **Acta Odontol Scand** 1995 Jun;53(3):162–6 (42 ref.)

INJURIES

Intracranial reduction of an intact mandibular condyle displaced into the middle cranial fossa. Sandler NA, et al. **J Oral Maxillofac Surg** 1996 Apr;54(4):506–10 (17 ref.)

PATHOLOGY

Progressive mandibular retrusion--idiopathic condylar resorption. Part I. Arnett GW, et al.
Am J Orthod Dentofacial Orthop 1996 Jul;110(1):8–15 (0 ref.)

Progressive mandibular retrusion–idiopathic condylar resorption. Part II. Arnett GW, et al.
Am J Orthod Dentofacial Orthop 1996 Aug;110(2):117–27 (109 ref.)

Concurrent osteochondroma of the mandibular condyle and ipsilateral cranial base resulting in temperomandibular joint ankylosis: report of a case and review of the literature. Karras SC, et al. **J Oral Maxillofac Surg** 1996 May; 54(5):640–6 (27 ref.)

[Mandibular condyle hyperplasia. Therapeutic review] Gola R, et al. **Rev Stomatol Chir Maxillofac** 1996;97(3):145–60 (83 ref.) (Eng. Abstr.) **(Fre)**

MANDIBULAR DISEASES

CLASSIFICATION

Possible identity of diffuse sclerosing osteomyelitis and chronic recurrent multifocal osteomyelitis. One entity or two. Suei Y, et al.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995 Oct;80(4):401–8 (41 ref.)

COMPLICATIONS

Massive osteolysis of the mandible with subsequent obstructive sleep apnea syndrome: a case report. Kayada Y, et al. **J Oral Maxillofac Surg** 1995 Dec;53(12):1463–5 (14 ref.)

DIAGNOSIS

Tori mandibularis: a case report and review of the literature. Pynn BR, et al. **J Can Dent Assoc** 1995 Dec;61(12):1057–8, 1063–6 (29 ref.)

ETIOLOGY

Torus palatinus and torus mandibularis: a review of the literature. Seah YH. **Aust Dent J** 1995 Oct;40(5):318–21 (31 ref.)

Mandibular resorption due to systemic sclerosis. Case report of surgical correction of a secondary open bite deformity. Haers PE, et al. **Int J Oral Maxillofac Surg** 1995 Aug; 24(4):261–7 (44 ref.)

PATHOLOGY

Malignant and premalignant change in odontogenic cysts. Fanibunda K, et al. **J Oral Maxillofac Surg** 1995 Dec; 53(12):1469–72 (19 ref.)

p53-positive squamous cell carcinoma originating from an odontogenic cyst. McDonald AR, et al. **J Oral Maxillofac Surg** 1996 Feb;54(2):216–8 (9 ref.)

Synchronous central giant cell lesions of the jaws: report of a case and review of the literature. Miloro M, et al. **J Oral Maxillofac Surg** 1995 Nov;53(11):1350–5 (32 ref.)

Squamous cell carcinoma arising in association with an orthokeratinized odontogenic keratocyst. Report of a case. Yoshida H, et al. **J Oral Maxillofac Surg** 1996 May; 54(5):647–51 (25 ref.)

Radiographic features of the mandible in neurofibromatosis: a report of 10 cases and review of the literature. Lee L, et al.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996 Mar;81(3):361–7 (37 ref.)

[Aneurysmal bone cyst of the mandible. Apropos of a case and review of the literature] Kadiri F, et al. **Rev Stomatol Chir Maxillofac** 1995;96(6):356–9 (40 ref.) (Eng. Abstr.) **(Fre)**

[Salivary gland heterotopia in the bone tissue of the mandible] Afanas'ev VV, et al. **Stomatologiia (Mosk)** 1995;74(2):69–70 (8 ref.) (Eng. Abstr.) **(Rus)**

RADIOGRAPHY

Lesions of the jaws. DelBalso AM. **Semin Ultrasound CT MR** 1995 Dec;16(6):487–512 (42 ref.)

[The reliability of apical x-ray pictures in the diagnosis of mandibular bone lesions. A review of the literature and in-vitro study] Briseño Marroquin B, et al. **Schweiz Monatsschr Zahnmed** 1995;105(9):1142–8 (38 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Mandibular resorption due to systemic sclerosis. Case report of surgical correction of a secondary open bite deformity. Haers PE, et al. **Int J Oral Maxillofac Surg** 1995 Aug; 24(4):261–7 (44 ref.)

MANDIBULAR FRACTURES

COMPLICATIONS

Frey's syndrome following fracture of the mandibular condyle: case report and literature review. Mellor TK, et al. **Injury** 1996 Jun;27(5):359–60 (19 ref.)

DIAGNOSIS

Purtscher's retinopathy associated with mandibular fracture: a case report. Peled M, et al. **J Trauma** 1996 Jan;40(1):141–3 (11 ref.)

SURGERY

Treatment of comminuted mandibular fractures by open reduction and rigid internal fixation. Smith BR, et al. **J Oral Maxillofac Surg** 1996 Mar;54(3):328–31 (34 ref.)

THERAPY

Treatment of comminuted mandibular fractures by closed reduction. Finn RA. **J Oral Maxillofac Surg** 1996 Mar; 54(3):320–7 (85 ref.)

VETERINARY

Skull trauma and mandibular fractures. Smith MM, et al. **Vet Clin North Am Small Anim Pract** 1995 Sep; 25(5):1127–48 (47 ref.)

MANDIBULAR NEOPLASMS

COMPLICATIONS

Familial hyperparathyroidism associated with jaw fibroma: case report and literature review. Inoue H, et al. **Clin Endocrinol (Oxf)** 1995 Aug;43(2):225–9; discussion 230 (10 ref.)

Concurrent osteochondroma of the mandibular condyle and ipsilateral cranial base resulting in temperomandibular joint ankylosis: report of a case and review of the literature. Karras SC, et al. **J Oral Maxillofac Surg** 1996 May; 54(5):640–6 (27 ref.)

PATHOLOGY

Central hemangioma. Review and a case report. Mody RN, et al. **Ann Dent** 1995 Summer–Fall;54(1–2):22–4 (26 ref.)

Benign cementoblastoma. Case report. Mogi K, et al. **Aust Dent J** 1996 Feb;41(1):9–11 (11 ref.)

MANDIBULAR NEOPLASMS

Paget's sarcoma of the mandible. Gleich LL, et al. **Head Neck** 1995 Sep–Oct;17(5):425–30 (20 ref.)
Malignant and premalignant change in odontogenic cysts. Fanibunda K, et al. **J Oral Maxillofac Surg** 1995 Dec; 53(12):1469–72 (19 ref.)
Leiomyosarcoma of the mandible: report of a case and literature review. Karlis V, et al. **J Oral Maxillofac Surg** 1996 Sep;54(9):1127–30 (18 ref.)
Chondroblastic osteosarcoma of the mandible: report of a case. Kawasaki T, et al. **J Oral Maxillofac Surg** 1996 Sep; 54(9):1123–7 (11 ref.)
p53–positive squamous cell carcinoma originating from an odontogenic cyst. McDonald AR, et al. **J Oral Maxillofac Surg** 1996 Feb;54(2):216–8 (9 ref.)
Alveolar soft–part sarcoma of the oral cavity: report of a case and review of the literature. Marker P, et al. **J Oral Maxillofac Surg** 1995 Oct;53(10):1203–8 (22 ref.)
Squamous cell carcinoma arising in association with an orthokeratinized odontogenic keratocyst. Report of a case. Yoshida H, et al. **J Oral Maxillofac Surg** 1996 May; 54(5):647–51 (25 ref.)
Myofibroma of the mandible. Clinicopathologic study and review of the literature. Sugatani T, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1995 Sep;80(3):303–9 (22 ref.)
[Solitary plasmocytoma of the mandible. Report of one case and review of the literature] Ferrer Albiach C, et al. **An Otorrinolaringol Ibero Am** 1995;22(6):609–18 (16 ref.) (Eng. Abstr.) **(Spa)**

RADIOGRAPHY

Osteoma of the mandible. A case report. Piattelli A, et al. **Acta Stomatol Belg** 1995 Mar;92(1):13–6 (18 ref.)
Lesions of the jaws. DelBalso AM. **Semin Ultrasound CT MR** 1995 Dec;16(6):487–512 (42 ref.)
[Central odontogenic fibroma: apropos of a case] Darche V, et al. **Acta Stomatol Belg** 1995 Jun;92(2):53–6 (19 ref.) **(Fre)**
[Radiological criteria for laryngeal tumors and cervical metastases] Melchor Díaz MA, et al. **Acta Otorrinolaringol Esp** 1996 Jan–Feb;47(1):1–7 (17 ref.) (Eng. Abstr.) **(Spa)**

SECONDARY

[Radiological criteria for laryngeal tumors and cervical metastases] Melchor Díaz MA, et al. **Acta Otorrinolaringol Esp** 1996 Jan–Feb;47(1):1–7 (17 ref.) (Eng. Abstr.) **(Spa)**

SURGERY

Surgical management of ameloblastoma. Current status of the literature. Feinberg SE, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Apr;81(4):383–8 (31 ref.)
[The musculus pectoralis major rib flap. Personal experiences with 7 cases] Koch A, et al. **Chirurg** 1996 Mar;67(3):273–7 (26 ref.) (Eng. Abstr.) **(Ger)**

MANDIBULAR NERVE

ABNORMALITIES

Four common mandibular nerve anomalies that lead to local anesthesia failures. DeSantis JL, et al. **J Am Dent Assoc** 1996 Jul;127(7):1081–6 (25 ref.)

INJURIES

Surgical management of inferior alveolar nerve injuries (Part I): The case for early repair. Donoff RB. **J Oral Maxillofac Surg** 1995 Nov;53(11):1327–9 (10 ref.)
Surgical management of inferior alveolar nerve injuries (Part II): The case for delayed management. Gregg JM. **J Oral Maxillofac Surg** 1995 Nov;53(11):1330–3 (24 ref.)

SURGERY

Surgical management of inferior alveolar nerve injuries (Part I): The case for early repair. Donoff RB. **J Oral Maxillofac Surg** 1995 Nov;53(11):1327–9 (10 ref.)
Surgical management of inferior alveolar nerve injuries (Part II): The case for delayed management. Gregg JM. **J Oral Maxillofac Surg** 1995 Nov;53(11):1330–3 (24 ref.)

MANDIBULOFACIAL DYSOSTOSIS

Treacher Collins syndrome. Dixon MJ. **J Med Genet** 1995 Oct;32(10):806–8 (30 ref.)

PHYSIOPATHOLOGY

[Standard electromyographic and kinesiographic parameters in a sample of healthy population] Manni A, et al. **Minerva Stomatol** 1995 Sep;44(9):411–9 (29 ref.) (Eng. Abstr.) **(Ita)**

SURGERY

Treacher–Collins syndrome. Management of major and minor anomalies of the ear. Marres HA, et al. **Rev Laryngol Otol Rhinol (Bord)** 1995;116(2):105–8 (24 ref.)

ULTRASONOGRAPHY

Prenatal sonographic diagnosis of Treacher Collins syndrome: a case and review of the literature. Cohen J, et al. **Am J Perinatol** 1995 Nov;12(6):416–9 (23 ref.)

MANDUCA

PHYSIOLOGY

Regulation and consequences of cellular changes in the prothoracic glands of Manduca sexta during the last larval instar: a review. Smith WA. **Arch Insect Biochem Physiol** 1995;30(2–3):271–93 (75 ref.)
Short– and long–term modification of reflex function during learning and metamorphosis in Manduca. Weeks JC, et al. **Biol Bull** 1996 Aug;191(1):62–9 (34 ref.)

MANDUCA SEXTA see **MANDUCA**

MANGANESE

Specific DNA cleavage by manganese(III) complexes. Gravert DJ, et al. **Met Ions Biol Syst** 1996;33:515–36 (32 ref.)

ADVERSE EFFECTS

Extrapyramidal symptoms in a BMT recipient with hyperintense basal ganglia and elevated manganese. Fredstrom S, et al. **Bone Marrow Transplant** 1995 Jun; 15(6):989–92 (19 ref.)

ANALYSIS

[Manganese] Itokawa Y. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:839–42 (10 ref.) **(Jpn)**

DIAGNOSTIC USE

A toxicologic risk for using manganese complexes? A literature survey of existing data through several medical specialties. Misselwitz B, et al. **Invest Radiol** 1995 Oct; 30(10):611–20 (120 ref.)
Mangafodipir trisodium injection (Mn–DPDP). A contrast agent for abdominal MR imaging. Rofsky NM, et al. **Magn Reson Imaging Clin N Am** 1996 Feb;4(1):73–85 (49 ref.)

PHARMACOLOGY

Actions of manganese ions in contraction of smooth muscle. Nasu T. **Gen Pharmacol** 1995 Sep;26(5):945–53 (65 ref.)

TOXICITY

A toxicologic risk for using manganese complexes? A literature survey of existing data through several medical specialties. Misselwitz B, et al. **Invest Radiol** 1995 Oct; 30(10):611–20 (120 ref.)
Manganese toxicity, dopaminergic dysfunction and hepatic encephalopathy. Butterworth RF, et al. **Metab Brain Dis** 1995 Dec;10(4):259–67 (37 ref.)

MANGANESE COMPOUNDS

PHARMACOLOGY

[Lipid peroxidation in the presence of inorganic compounds. Relation to oxidative stress mechanisms] Fournier J, et al. **C R Seances Soc Biol Fil** 1995;189(3):429–42 (36 ref.) (Eng. Abstr.) **(Fre)**

MANGE see **MITE INFESTATIONS**

MANGE, SARCOPTIC see **SCABIES**

MANIA see **MANIC DISORDER**

MANIC–DEPRESSIVE PSYCHOSIS see **BIPOLAR DISORDER**

MANIC DISORDER

CHEMICALLY INDUCED

[Psychotropic effects of angiotensin–converting enzyme inhibitors: what are the arguments?] Mesure G, et al. **Encephale** 1995 Sep–Oct;21(5):609–14 (59 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Case study: mania associated with multiple sclerosis. Heilä H, et al. **J Am Acad Child Adolesc Psychiatry** 1995 Dec; 34(12):1591–5 (36 ref.)
[Dysphoric mania and mixed states] Bourgeois M, et al. **Encephale** 1995 Dec;21 Spec No 6:21–32 (39 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

Mania, psychosis, and antipsychotics. McElroy SL, et al. **J Clin Psychiatry** 1996;57 Suppl 3:14–26; discussion 47–9 (168 ref.)
[Value of old and new anticonvulsants in treatment of psychiatric diseases] Walden J, et al. **Fortschr Neurol Psychiatr** 1995 Aug;63(8):320–35 (185 ref.) (Eng. Abstr.) **(Ger)**

MANIC STATE see **MANIC DISORDER**

MANIHOT see **CASSAVA**

MANIOC see **CASSAVA**

MANIPULATION, CHIROPRACTIC see **CHIROPRACTIC**

MANIPULATION, ORTHOPEDIC

see related **CHIROPRACTIC**

Clubfoot controversies: complications and causes for failure. Crawford AH, et al. **Instr Course Lect** 1996;45:339–46 (65 ref.)

ADVERSE EFFECTS

Complications of spinal manipulation: a comprehensive review of the literature. Assendelft WJ, et al. **J Fam Pract** 1996 May;42(5):475–80 (41 ref.)

MANIPULATION THERAPY see **MANIPULATION, ORTHOPEDIC**

MANN–WHITNEY U TEST see **STATISTICS, NONPARAMETRIC**

MANNANS

ANALYSIS

Tools and trends in the detection of Aspergillus fumigatus. Latgé JP. **Curr Top Med Mycol** 1995;6:245–81 (137 ref.)

PHARMACOLOGY

Effect of konjac fibre (glucomannan) on glucose and lipids. Doi K. **Eur J Clin Nutr** 1995 Oct;49 Suppl 3:S190–7 (18 ref.)

MANNITOL

CHEMISTRY

Commentary: mannitol: molecule magnifique or a case of radical misinterpretation? Gillbe CE, et al. **Free Radic Res** 1996 Jan;24(1):1–7 (38 ref.)

THERAPEUTIC USE

Mannitol and other diuretics in severe neurotrauma. Bullock R. **New Horiz** 1995 Aug;3(3):448–52 (44 ref.)

MANNOSE

ANALYSIS

[Mannose] Kizaki Z, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:579–81 (12 ref.) **(Jpn)**

MANNOSE–6–PHOSPHATE RECEPTORS see **RECEPTORS, INSULIN–LIKE–GROWTH–FACTOR II**

MANNOSEPHOSPHATES

CHEMISTRY

[Lysosomal hydrolases have specific conformational domains for acquisition of mannose–6–phosphate] Himeno M, et al. **Nippon Rinsho** 1995 Dec;53(12):2892–7 (18 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Entry and egress of varicella–zoster virus: role of mannose 6–phosphate, heparan sulfate proteoglycan, and signal sequences in targeting virions and viral glycoproteins. Zhu Z, et al. **Neurology** 1995 Dec;45(12 Suppl 8):S15–7 (9 ref.)

MANNOSIDASES

METABOLISM

[Beta–D–mannosidase] Percheron F. **Bull Acad Natl Med** 1995 May;179(5):881–91; discussion 892 (25 ref.) (Eng. Abstr.) **(Fre)**

MANNOSYL–GLYCOPROTEIN ENDO–BETA–N–ACETYLGLUCOSAMINIDASE

METABOLISM

N–glycosylation/deglycosylation as a mechanism for the post–translational modification/remodification of proteins. Suzuki T, et al. **Glycoconj J** 1995 Jun;12(3):183–93 (141 ref.)

PHYSIOLOGY

Do de-N-glycosylation enzymes have an important role in plant cells? Berger S, et al. **Biochimie** 1995;77(9):751-60 (98 ref.)

MANOMETRY

Clinical applications of esophageal manometry and pH monitoring. Ergun GA, et al. **Am J Gastroenterol** 1996 Jun;91(6):1077-89 (92 ref.)

Ambulatory esophageal manometry in the evaluation of unexplained chest pain. Leite LP, et al. **Dig Dis** 1995 May-Jun;13(3):145-52 (15 ref.)

[Endoscopic manometry in suspected dysfunction of the sphincter of Oddi] Wehrmann T, et al. **Dtsch Med Wochenschr** 1996 Apr 19;121(16):509-16 (30 ref.) (Eng. Abstr.) **(Ger)**

[Anorectal manometry in hemorrhoidal disease] Girardi S, et al. **Ann Ital Chir** 1995 Nov-Dec;66(6):757-60 (17 ref.) (Eng. Abstr.) **(Ita)**

INSTRUMENTATION

[Current proctology--modern functional diagnosis] Feifel G, et al. **Chirurg** 1996 Mar;67(3):205-12 (33 ref.) (Eng. Abstr.) **(Ger)**

[Simultaneous video radiography and "solid state" intraluminal pharyngeal manometry during barium swallow; video manometry] Olsson R, et al. **Radiologe** 1995 Oct;35(10):753-8 (46 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Ambulatory manometry of the small bowel: indications and analysis. Wilmer A, et al. **Rev Esp Enferm Dig** 1996 Feb; 88(2):118-32 (45 ref.) **(Eng, Spa)**

[Rhinomanometry] Ghaem A. **Rev Mal Respir** 1996; 13(2):191-2 (8 ref.) **(Fre)**

MANUALS

The 1995 JCAHO mental health manual--an overview for dietetics professionals. Foiles RA. **J Am Diet Assoc** 1996 Apr;96(4):403-4 (6 ref.)

Applying the 1995 JCAHO standards to dietetics practice in home care. Westbrook NH. **J Am Diet Assoc** 1996 Apr; 96(4):404-6 (5 ref.)

MANURE

VIROLOGY

Inactivation of viruses in liquid manure. Haas B, et al. **Rev Sci Tech** 1995 Jun;14(2):435-45 (28 ref.)

MAO INHIBITORS see MONOAMINE OXIDASE INHIBITORS

MAP KINASES see CALMODULIN-DEPENDENT PROTEIN KINASES

MAPLE SYRUP URINE DISEASE

DIET THERAPY

[Methodology of care for children with phenylketonuria and maple-syrup urine disease] Jiménez Soto Z. **Arch Latinoam Nutr** 1993 Sep;43(3):204-10 (22 ref.) (Eng. Abstr.) **(Spa)**

MARASMUS see PROTEIN-ENERGY MALNUTRITION

MARBLE BONE DISEASE see OSTEOPETROSIS

MARBURG VIRUS DISEASE

EPIDEMIOLOGY

Threat of Marburg and Ebola viral haemorrhagic fevers in Africa. Tukei PM. **East Afr Med J** 1996 Jan;73(1):27-31 (15 ref.)

MARCHIAFAVA-MICHELI SYNDROME see HEMOGLOBINURIA, PAROXYSMAL

MAREK'S DISEASE

PREVENTION & CONTROL

Marek's disease and new approaches to its control. Zelník V. **Acta Virol** 1995 Feb;39(1):53-63 (101 ref.)

MARFAN SYNDROME

Congenital contractural arachnodactyly. Kulkarni ML, et al. **Indian Pediatr** 1995 Jan;32(1):82-7 (14 ref.)

Marfan syndrome. Gray JR, et al. **J Med Genet** 1996 May; 33(5):403-8 (50 ref.)

[Familial Marfan's syndrome. A critical review and presentation of a clinical case] Iannello S, et al. **Minerva Med** 1996 May;87(5):217-35 (174 ref.) (Eng. Abstr.) **(Ita)**

COMPLICATIONS

Is Marfan syndrome associated with symptomatic intracranial aneurysms? van den Berg JS, et al. **Stroke** 1996 Jan; 27(1):10-2 (35 ref.)

Epididymocutaneous fistula in a patient with the acquired immunodeficiency syndrome and Marfan's syndrome. Weiner DM, et al. **Urology** 1996 May;47(5):766-8 (14 ref.)

DIAGNOSIS

Aortic dissection in a 5-year old girl with Marfan's syndrome [letter] Ruiz ME, et al. **Arch Pediatr Adolesc Med** 1996 Apr;150(4):440-2 (14 ref.)

GENETICS

Mutations in the human gene for fibrillin-1 (FBN1) in the Marfan syndrome and related disorders. Dietz HC, et al. **Hum Mol Genet** 1995;4 Spec No:1799-809 (86 ref.)

Fibrillin-containing microfibrils: structure and function in health and disease. Kielty CM, et al. **Int J Biochem Cell Biol** 1995 Aug;27(8):747-60 (70 ref.)

PATHOLOGY

Patient with craniosynostosis and marfanoid phenotype (Shprintzen-Goldberg syndrome) and cloverleaf skull. Saal HM, et al. **Am J Med Genet** 1995 Jul 17;57(4):573-8 (16 ref.)

MARIE-BAMBERGER DISEASE see OSTEOARTHROPATHY, SECONDARY HYPERTROPHIC

MARIE-STRUEMPELL DISEASE see SPONDYLITIS, ANKYLOSING

MARIJUANA see CANNABIS

MARIJUANA SMOKING

ADVERSE EFFECTS

Successfully treated invasive pulmonary aspergillosis associated with smoking marijuana in a renal transplant recipient. Marks WH, et al. **Transplantation** 1996 Jun 27; 61(12):1771-4 (8 ref.)

MARINE BIOLOGY

see related
PLANKTON

Microbiology to 10,500 meters in the deep sea. Yayanos AA. **Annu Rev Microbiol** 1995;49:777-805 (170 ref.)

Marine natural products. Faulkner DJ. **Nat Prod Rep** 1996 Apr;13(2):75-125 (549 ref.)

MARINE TOXINS

POISONING

Scombroid poisoning. McInerney J, et al. **Ann Emerg Med** 1996 Aug;28(2):235-8 (9 ref.)

MARINESCO-SJOGREN SYNDROME see SPINOCEREBELLAR DEGENERATION

MARITAL RELATIONSHIP see MARRIAGE

MARITAL STATUS

Do socio-economic status, marital status and occupation influence the prevalence of Helicobacter pylori infection? Veldhuyzen van Zanten SJ. **Aliment Pharmacol Ther** 1995; 9 Suppl 2:41-4 (35 ref.)

MARITAL THERAPY

METHODS

Critical interaction therapy: couples therapy in combat-related posttraumatic stress disorder. Johnson DR, et al. **Fam Process** 1995 Dec;34(4):401-12 (16 ref.)

A self psychologist in couplesland: multisubjective approach to transference and countertransference-like phenomena in marital relationships. Livingston MS. **Fam Process** 1995 Dec;34(4):427-39 (26 ref.)

The couple and the psychotherapeutic group. Kretsch RA, et al. **Isr J Psychiatry Relat Sci** 1995;32(3):184-93 (18 ref.)

Behavioral treatment of depression in the context of marital discord. Beach SR, et al. **Prog Behav Modif** 1996;30:99-122 (110 ref.)

[Emotion-focused couples therapy--treatment approach--evaluating effectiveness and process research] Heekerens HP. **Z Klin Psychol Psychopathol Psychother** 1995;43(4):308-24 (50 ref.) (Eng. Abstr.) **(Ger)**

MARKER ANTIGENS see ANTIGENS, DIFFERENTIATION

MARKERS, BIOLOGICAL see BIOLOGICAL MARKERS

MARKERS, DNA see GENETIC MARKERS

MARKERS, GENETIC see GENETIC MARKERS

MARKERS, LABORATORY see BIOLOGICAL MARKERS

MARKERS, SERUM see BIOLOGICAL MARKERS

MARKERS, SURROGATE see BIOLOGICAL MARKERS

MARKERS, TUMOR see TUMOR MARKERS, BIOLOGICAL

MARKETING OF HEALTH SERVICES

Gender differences in career progress in nursing: towards a non-essentialist structural theory. Ratcliffe P. **J Adv Nurs** 1996 Feb;23(2):389-95 (48 ref.)

Market testing specialist health promotion services--a test case for an imaginative public health presence in purchasing. Whitelaw S, et al. **J Public Health Med** 1995 Jun;17(2):211-6 (22 ref.)

Promoting the nurse practitioner by using a marketing approach. Gallagher SM. **Nurse Pract** 1996 Mar;21(3):30, 36-7, 40 (21 ref.)

LEGISLATION & JURISPRUDENCE

Evaluating new refractive surgical procedures: free market madness versus regulatory rigor mortis [editorial] Waring GO 3rd. **J Refract Surg** 1995 Sep-Oct;11(5):335-9 (26 ref.)

ORGANIZATION & ADMINISTRATION

Promoting the nurse practitioner by using a marketing approach. Gallagher SM. **Nurse Pract** 1996 Mar;21(3):30, 36-7, 40 (21 ref.)

The development and dissemination of non-patentable therapies (NPTs). Root-Bernstein RS. **Perspect Biol Med** 1995 Autumn;39(1):110-7 (26 ref.)

MARMOSET, COMMON see CALLITHRIX

MARMOSET, SHORT-TUSKED see CALLITHRIX

MARMOSET VIRUS see SIMPLEXVIRUS

MARMOSETS see CALLITHRIX

MARMOTA

The woodchuck: an animal model for hepatitis B virus infection in man. Roggendorf M, et al. **Intervirology** 1995; 38(1-2):100-12 (111 ref.)

MARRIAGE

see related
SPOUSES

PSYCHOLOGY

The role of the father in parental postnatal mental health. Marks M, et al. **Br J Med Psychol** 1995 Jun;68 (Pt 2):157-68 (75 ref.)

Critical interaction therapy: couples therapy in combat-related posttraumatic stress disorder. Johnson DR, et al. **Fam Process** 1995 Dec;34(4):401-12 (16 ref.)

Behavioral treatment of depression in the context of marital discord. Beach SR, et al. **Prog Behav Modif** 1996;30:99-122 (110 ref.)

[Pregnancy, labor and partnership in a family with an IVF child] Pastor VS, et al. **Geburtshilfe Frauenheilkd** 1995 Aug; 55(8):M83-7 (45 ref.) **(Ger)**

[Marital problems in depressive patients: a review of the literature and own clinical investigations] Zięba A, et al. **Psychiatr Pol** 1996 May-Jun;30(3):511-20 (32 ref.) (Eng. Abstr.) **(Pol)**

MARRIAGE THERAPY see MARITAL THERAPY

MARRIED PERSONS see SPOUSES

MARROW see BONE MARROW

MARSUPIALIA

Eastern barred bandicoot recovery: the role of the veterinarian in the management of endangered species. Seebeck J, et al. **Aust Vet J** 1996 Mar;73(3):81-3 (21 ref.)

PHYSIOLOGY

Comparative aspects of oxytocin-like hormones in marsupials. Bathgate RA, et al. **Adv Exp Med Biol** 1995; 395:639-55 (99 ref.)

Selective retention of fluid digesta in the hindgut of bandicoots and other marsupial caecum fermenters. Hume ID, et al. **DTW Dtsch Tierarztl Wochenschr** 1995 Apr; 102(4):150-1 (14 ref.)

Monotreme and marsupial reproduction. Renfree MB. **Reprod Fertil Dev** 1995;7(5):1003-20 (133 ref.)

MARYLAND BRIDGE see DENTURE, PARTIAL, FIXED, RESIN-BONDED

MASKING, PERCEPTUAL

MASKING, PERCEPTUAL see PERCEPTUAL MASKING

MASKS

Noninvasive nasal mask positive pressure ventilation in a pediatric patient with acute hypoxic respiratory failure. Padman R, et al. **Pediatr Emerg Care** 1996 Feb;12(1):44–7 (63 ref.)

MASS FRAGMENTOGRAPHY

INSTRUMENTATION

Analytical instruments for stable isotopic tracers in mineral metabolism. Yergey AL. **J Nutr** 1996 Jan;126(1):355S–361S (59 ref.)

METHODS

The novel selected-ion flow tube approach to trace gas analysis of air and breath. Smith D, et al. **Rapid Commun Mass Spectrom** 1996;10(10):1183–98 (37 ref.)

MASS MEDIA

Pervasive media violence. Schooler C, et al. **Annu Rev Public Health** 1996;17:275–98 (216 ref.)

Public relations in disaster management and planning for emergency physicians. Friedman FD. **J Emerg Med** 1995 Sep–Oct;13(5):661–8 (25 ref.)

Media strategies for community health advocacy. Woodruff K. **Prim Care** 1995 Dec;22(4):805–15 (29 ref.)

MASS SCREENING

see related

SENSITIVITY AND SPECIFICITY

Screening high-risk groups for colorectal neoplasia. Hardcastle JD, et al. **Am J Gastroenterol** 1996 May; 91(5):850–2 (34 ref.)

Gastric premalignancy and cancer screening in high-risk patients. Yoshida S, et al. **Am J Gastroenterol** 1996 May; 91(5):839–43 (24 ref.)

Cholesterol screening in asymptomatic adults, revisited. Part 2 [see comments] Garber AM, et al. **Ann Intern Med** 1996 Mar 1;124(5):518–31 (121 ref.) Comment in: Ann Intern Med 1996 Mar 1;124(5):505–8. Comment in: Ann Intern Med 1996 Mar 1;124(5):513–4.

Breast cancer screening in premenopausal women: current recommendations and opportunities for research. Mettlin C, et al. **Ann Med** 1995 Aug;27(4):461–5 (15 ref.)

Screening for cancer, 1995: an update. La Vecchia C, et al. **Ann Oncol** 1995 Jul;6(6):537–41 (55 ref.)

Screening and treatment in the elderly to reduce osteoporotic fracture risk. Black DM. **Br J Obstet Gynaecol** 1996 May; 103 Suppl 13:2–7; discussion 7–8 (49 ref.)

Colorectal cancer and polyps: clinical decisions for screening, early diagnosis, and surveillance of high-risk groups. Bond JH. **Compr Ther** 1996 Feb;22(2):100–6 (47 ref.)

Screening for colorectal cancer. Mandel JS. **Curr Opin Gen Surg** 1994;:79–84 (27 ref.)

Fetal cardiology. Allan LD. **Curr Opin Obstet Gynecol** 1996 Apr;8(2):142–7 (28 ref.)

Intra-uterine growth retardation. Holmes RP, et al. **Curr Opin Obstet Gynecol** 1996 Apr;8(2):148–54 (51 ref.)

Cholesterol screening in children. Benuck I. **Curr Probl Pediatr** 1995 Sep;25(8):254–60 (45 ref.)

Screening for NIDDM in nonpregnant adults. A review of principles, screening tests, and recommendations. Engelgau MM, et al. **Diabetes Care** 1995 Dec;18(12):1606–18 (118 ref.)

Neuroblastoma mass screening: the arguments for and against. Treuner J, et al. **Eur J Cancer** 1995;31A(4):565–8 (18 ref.)

Strengths and weaknesses of screening programmes for oral malignancies and potentially malignant lesions. Warnakulasuriya KA, et al. **Eur J Cancer Prev** 1996 Apr; 5(2):93–8 (33 ref.)

Cytologic screening for cervix cancer: each year or each 3 years? Dubois G. **Eur J Obstet Gynecol Reprod Biol** 1996 Mar;65(1):57–9 (14 ref.)

Update on urology--prostate cancer. Screening for prostate cancer: an European view. de Silva FC. **Eur J Surg Oncol** 1996 Apr;22(2):189–91, 196 (9 ref.)

Abdominal aortic aneurysm screening: an epidemiological point of view. Hak E, et al. **Eur J Vasc Endovasc Surg** 1996 Apr;11(3):270–8 (115 ref.)

Screening and early detection of prostate cancer will decrease morbidity and mortality from prostate cancer: the argument for. Brawer MK. **Eur Urol** 1996;29 Suppl 2:19–23 (43 ref.)

Screening and early detection of prostate cancer will decrease morbidity and mortality from prostate cancer: the argument against. Hall RR. **Eur Urol** 1996;29 Suppl 2:24–6 (5 ref.)

Epidemiology, prevention and screening for prostate cancer. Pavone-Macaluso M. **Eur Urol** 1996;29 Suppl 2:49–53 (21 ref.)

A review of cervical cancer and cervical screening: implications for nursing practice. Ibbotson T, et al. **J Adv Nurs** 1995 Oct;22(4):745–52 (59 ref.)

Arguments in favor of screening for diabetes in cardiac rehabilitation. Maki KC, et al. **J Cardpulm Rehabil** 1995 Mar-Apr;15(2):97–102 (41 ref.)

Is cardiovascular screening in primary care worthwhile? Coope JR. **J Hum Hypertens** 1995 Oct;9(10):785–6 (20 ref.)

Colorectal cancer: the role of screening and surveillance. Westergaard H. **J Investig Med** 1996 Jun;44(5):216–27 (104 ref.)

Screening for neuroblastoma: a review of the evidence [see comments] Chamberlain J. **J Med Screen** 1994 Jul; 1(3):169–75 (37 ref.) Comment in: J Med Screen 1994 Jul;1(3):141–2.

Screening for melanoma and options for its evaluation [see comment] Elwood JM. **J Med Screen** 1994 Jan;1(1):22–38 (83 ref.) Comment on: J Med Screen 1994 Jan;1(1):2.

Common causes of short stature detectable by a height surveillance programme. Hyer W, et al. **J Med Screen** 1995; 2(3):150–3 (47 ref.)

Medical screening: from beginnings to benefits: a retrospective. Wilson JM. **J Med Screen** 1994 Apr; 1(2):121–3 (31 ref.)

Prospective characterization of pathological features of prostatic carcinomas detected via serum prostate specific antigen based screening [see comments] Humphrey PA, et al. **J Urol** 1996 Mar;155(3):816–20 (34 ref.) Comment in: J Urol 1996 Mar;155(3):827.

Screening mammography in young women: a different perspective. Margolese R. **Lancet** 1996 Mar 30; 347(9005):881–2 (12 ref.)

Screening for colorectal cancer, 1996 [see comments] Macrae FA. **Med J Aust** 1996 Jul 15;165(2):102–5 (42 ref.) Comment in: Med J Aust 1996 Jul 15;165(2):68–9.

Screening for diabetes in asymptomatic individuals. New Zealand Society for the Study of Diabetes. **N Z Med J** 1995 Nov 10;108(1011):464–5 (8 ref.)

Adult cancer detection screening by physical examination. **Nurse Pract** 1996 Mar;21(3):85–6, 89–90, 92–6 passim (0 ref.)

Screening and testing for gestational diabetes mellitus. Coustan DR. **Obstet Gynecol Clin North Am** 1996 Mar; 23(1):125–36 (51 ref.)

Screening for cervical cancer. Guidozzi F. **Obstet Gynecol Surv** 1996 Apr;51(4):247–52 (46 ref.)

Lues-lues: maternal and fetal considerations of syphilis. Ray JG. **Obstet Gynecol Surv** 1995 Dec;50(12):845–50 (30 ref.)

The current status of screening for vesicoureteral reflux. Noe HN. **Pediatr Nephrol** 1995 Oct;9(5):638–41 (16 ref.)

First trimester serum screening for Down's syndrome [see comments] Wald NJ, et al. **Prenat Diagn** 1995 Dec; 15(13):1227–40 (44 ref.) Comment in: Prenat Diagn 1995 Dec;15(3):1209–13.

Screening, health promotion, and prevention in women. Bowman MA, et al. **Prim Care** 1995 Dec;22(4):661–77 (98 ref.)

Prevention and screening in the nursing home. Gershman K, et al. **Prim Care** 1995 Dec;22(4):731–53 (106 ref.)

Screening, health promotion, and prevention in men. Horst T, et al. **Prim Care** 1995 Dec;22(4):679–95 (72 ref.)

Retrospective reviews of breast cancer screening: what do we really learn from them? [editorial; comment] Moskowitz M. **Radiology** 1996 Jun;199(3):615–20 (37 ref.) Comment on: Radiology 1996 Jun;199(3):811–7.

A critical review of screening for breast cancer. Del Turco MR. **Recent Results Cancer Res** 1996;140:123–30 (24 ref.)

Detection of latent prostate cancer from routine screening: comparison with breast cancer screening. Benoit RM, et al. **Urology** 1995 Oct;46(4):533–6; discussion 536–7 (43 ref.)

Impact of prostate-specific antigen screening on the natural history of prostate cancer. Rosen MA. **Urology** 1995 Dec; 46(6):757–68 (95 ref.)

-Screening for toxoplasmosis in pregnancy- Extermann P. **Arch Gynecol Obstet** 1995;256 Suppl:S170–2 (10 ref.) **(Fre)**

-Toxoplasmosis in pregnancy: arguments in favor of systematic screening in Switzerland- Hohlfeld P. **Arch Gynecol Obstet** 1995;256 Suppl:S165–9 (26 ref.) **(Fre)**

[Maternal serum screening for detection of fetal chromosome abnormalities] Holzgreve W, et al. **Gynakologe** 1995 Oct; 28(5):280–8 (44 ref.) **(Ger)**

[Prevention, standards and future developments in medical specialties--prevention] Vosteen KH. **Z Arztl Fortbild (Jena)** 1995 Dec;89(7):749–59 (0 ref.) **(Ger)**

[A case of genitourinary double cancers detected by health screening] Ito T, et al. **Hinyokika Kiyo** 1996 Jun; 42(6):461–4 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Mass screening of breast cancer] Dobashi K, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Aug; 47(8):885–93 (22 ref.) **(Jpn)**

[Echocardiographic examinations for mass-screening of cardiovascular abnormalities] Sato H, et al. **Rinsho Byori** 1995 Nov;43(11):1108–12 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Screening for cancer] Caicoya Gómez-Morán M. **Aten Primaria** 1995 Oct 31;16(7):441–4, 446–52 (56 ref.) **(Spa)**

ADVERSE EFFECTS

Prevention. How much harm? How much benefit? 3. Physical, psychological and social harm. Marshall KG. **Can Med Assoc J** 1996 Jul 15;155(2):169–76 (94 ref.)

ECONOMICS

Assessing value for money in medical screening. Cairns JA, et al. **J Med Screen** 1994 Jan;1(1):39–44 (31 ref.)

An overview cost-utility analysis of prostate cancer screening. Thompson IM, et al. **Oncology (Huntingt)** 1995 Nov;9(11 Suppl):141–5 (24 ref.)

Screening for colon cancer: economics and related considerations. Gelfand DW. **Semin Roentgenol** 1996 Apr; 31(2):170–6 (17 ref.)

Screening of average-risk individuals for colorectal cancer and postoperative evaluation of patients with colorectal cancer. Nelson RL. **Surg Clin North Am** 1996 Feb; 76(1):35–45 (36 ref.)

METHODS

Molecular genetic tumor markers in the early diagnosis and screening of non-small-cell lung cancer. Jacobson DR, et al. **Ann Oncol** 1995;6 Suppl 3:S3–8 (44 ref.)

Epidemiology and prevention of breast cancer. Kelsey JL, et al. **Annu Rev Public Health** 1996;17:47–67 (65 ref.)

Fecal occult blood screening for colorectal cancer. Van Dam J, et al. **Arch Intern Med** 1995 Dec 11-25;155(22):2389–402 (96 ref.)

The accuracy of a lead questionnaire in predicting elevated pediatric blood lead levels. France EK, et al. **Arch Pediatr Adolesc Med** 1996 Sep;150(9):958–63 (14 ref.)

Early detection of prostate cancer. Role of prostate-specific antigen. Prabhakaran VM. **Can Fam Physician** 1996 Apr; 42:709–12 (20 ref.)

Every woman with an abnormal cervical smear should be referred for treatment: debate. Flannelly G, et al. **Clin Obstet Gynecol** 1995 Sep;38(3):585–91 (20 ref.)

Cervical neoplasia: are adjunctive tests to cervical cytology worthwhile? Greenberg MD, et al. **Clin Obstet Gynecol** 1995 Sep;38(3):600–9 (24 ref.)

Routine voluntary antepartum HIV antibody counseling and testing: a sound public health prevention strategy. Lindsay MK. **Clin Obstet Gynecol** 1996 Jun;39(2):305–15 (59 ref.)

Every woman with an abnormal cervical smear should not be referred for colposcopy: debate. Prendiville W, et al. **Clin Obstet Gynecol** 1995 Sep;38(3):592–9 (16 ref.)

Assessing the effectiveness of cervical screening. Wilson S, et al. **Clin Obstet Gynecol** 1995 Sep;38(3):577–84 (36 ref.)

Antenatal Care. Bréart G. **Curr Opin Obstet Gynecol** 1995 Dec;7(6):417–9 (10 ref.)

Screening for Wilms tumor in high-risk individuals. Clericuzio CL, et al. **Hematol Oncol Clin North Am** 1995 Dec;9(6):1253–65 (43 ref.)

Screening for ovarian cancer: what are the optimal surrogate endpoints for clinical trials? Karlan BY. **J Cell Biochem Suppl** 1995;23:227–32 (40 ref.)

Office laparoscopy as a screening tool for early detection of ovarian cancer. Runowicz CD. **J Cell Biochem Suppl** 1995;23:238–42 (12 ref.)

Early detection and screening for ovarian cancer. Schwartz PE, et al. **J Cell Biochem Suppl** 1995;23:233–7 (20 ref.)

Screening infants for hearing impairment. Vohr BR, et al. **J Pediatr** 1996 May;128(5 Pt 1):710–4 (46 ref.)

Radiologic imaging in cancer. Ballinger JR. **Med Clin North Am** 1996 Jan;80(1):201–18 (55 ref.)

Skin cancer screening. Brandt TP. **Med Clin North Am** 1996 Jan;80(1):99–114 (39 ref.)

Colorectal cancer screening. Ferrante JM. **Med Clin North Am** 1996 Jan;80(1):27–43 (63 ref.)

Prostate cancer screening. Hostetler RM, et al. **Med Clin North Am** 1996 Jan;80(1):83–98 (70 ref.)

Principles of cancer screening. MacLean CD. **Med Clin North Am** 1996 Jan;80(1):1–14 (32 ref.)

Tumor markers. An update. Pamies RJ, et al. **Med Clin North Am** 1996 Jan;80(1):185–99 (81 ref.)

Breast cancer screening and compliance and evaluation of lesions. Schapira DV, et al. **Med Clin North Am** 1996 Jan; 80(1):15–26 (42 ref.)

Screening and early diagnosis of gynecologic cancers. Warner EA, et al. **Med Clin North Am** 1996 Jan;80(1):45–61 (80 ref.)

Early detection in lung cancer. Case finding and screening. Wolpaw DR. **Med Clin North Am** 1996 Jan;80(1):63–82 (74 ref.)

Adult screening for anemia and hemoglobinopathies. **Nurse Pract** 1995 Dec;20(12):48–51 (9 ref.)

Screening for primary open-angle glaucoma: a review. Harper R, et al. **Ophthalmic Physiol Opt** 1995 Sep;15 Suppl 2:S27–34 (49 ref.)

Ultrasound screening for fetal abnormalities [see comments] Chitty LS. **Prenat Diagn** 1995 Dec;15(13):1241–57 (74 ref.) Comment in: Prenat Diagn 1995 Dec;15(13):1209–13.

Prevention of colorectal cancer by screening flexible sigmoidoscopy: possible role of the primary care physician. Abbas Z, et al. **Scott Med J** 1995 Jun;40(3):67–9 (41 ref.)

Are T1c tumors different from incidental tumors found at autopsy? The risk and reality of overdetection. Belville WD. **Semin Urol Oncol** 1995 Aug;13(3):181–6 (22 ref.)

Screening for prostate cancer: opportunities for prevention. Thompson IM, et al. **Semin Urol Oncol** 1996 May;14(2 Suppl 2):4–10; discussion 10–1 (28 ref.)

Reducing risks in blood transfusion: process and outcome. McClelland DB, et al. **Transfus Med** 1996 Mar;6(1):1–10 (35 ref.)

[Improved prenatal diagnostic possibilities for congenital abnormalities and chromosomal disorders. Advantages and

disadvantages of screening and diagnostic methods] Nørgaard-Pedersen B, et al. **Ugeskr Laeger** 1996 Feb 26; 158(9):1201–7 (29 ref.) (Eng. Abstr.) **(Dan)**

[Tuberculosis in aged persons residing in Quebec facilities: are screening and chemoprophylaxis indicated? (see comments)] Marchand RS, et al. **Can J Public Health** 1995 Jul–Aug;86(4):238–42 (55 ref.) (Eng. Abstr.) Comment in: Can J Public Health 1995 Jul–Aug;86(4):221–3. **(Fre)**

[Reality of drug poisoning and screening tests] Kudo K. **Fukuoka Igaku Zasshi** 1995 Nov;86(11):399–404 (3 ref.) **(Jpn)**

[Screening methods for the diagnosis of lysosomal storage disease] Mutoh T, et al. **Nippon Rinsho** 1995 Dec; 53(12):2933–7 (9 ref.) (Eng. Abstr.) **(Jpn)**

[An analysis of the causes for the occurrence of Down's syndrome and the current approaches to its prevention at the stage of mass prenatal ultrasonic and immunobiochemical screening of pregnant women] Veropotvelian NP, et al. **Tsitol Genet** 1995 Sep–Oct; 29(5):82–92 (71 ref.) (Eng. Abstr.) **(Rus)**

ORGANIZATION & ADMINISTRATION

Multinational approaches to cervical cancer screening: a review. Lovejoy NC. **Cancer Nurs** 1996 Apr;19(2):126–34 (42 ref.)

The role of midlevel providers in cancer screening. Reed CA, et al. **Med Clin North Am** 1996 Jan;80(1):135–44 (34 ref.)

Reaching out to the African American community through innovative strategies. Robinson KD, et al. **Oncol Nurs Forum** 1995 Oct;22(9):1383–91 (28 ref.)

PSYCHOLOGY

Contrasting self-report screens for alcohol problems: a review. Maisto SA, et al. **Alcohol Clin Exp Res** 1995 Dec; 19(6):1510–6 (24 ref.)

Determinants of persistent compliance with screening for colorectal cancer. Neilson AR, et al. **Soc Sci Med** 1995 Aug;41(3):365–74 (36 ref.)

STANDARDS

Case-control studies of screening efficacy: the use of persons newly diagnosed with cancer who later sustain an unfavorable outcome. Weiss NS, et al. **Am J Epidemiol** 1996 Feb 15;143(4):319–22 (4 ref.)

Screening for cancer and pre-cancer. Mera SL. **Br J Biomed Sci** 1995 Jun;52(2):120–41 (94 ref.)

Prevention. How much harm? How much benefit? 2. Ten potential pitfalls in determining the clinical significance of benefits. Marshall KG. **Can Med Assoc J** 1996 Jun 15; 154(12):1837–43 (61 ref.)

Cervical cancer screening: are the 1989 recommendations still valid? National Workshop on Screening for Cancer of the Cervix [see comments] Parboosingh EJ, et al. **Can Med Assoc J** 1996 Jun 15;154(12):1847–53 (18 ref.) Comment in: Can Med Assoc J 1996 Jun 15;154(12):1867–9.

Screening for disease, cost-effectiveness, and guidelines. Meyer DL. **Prim Care** 1995 Dec;22(4):591–9 (18 ref.)

TRENDS

Screening. The next century. Richart RM. **Cancer** 1995 Nov 15;76(10 Suppl):1919–27 (36 ref.)

MASS SPECTROMETRY see **SPECTRUM ANALYSIS, MASS**

MASS SPECTROMETRY, FAST ATOM BOMBARDMENT see **SPECTROMETRY, MASS, FAST ATOM BOMBARDMENT**

MASS SPECTROMETRY, MATRIX-ASSISTED LASER DESORPTION-IONIZATION see **SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION**

MASS SPECTROSCOPY see **SPECTRUM ANALYSIS, MASS**

MASS SPECTROSCOPY, FAST ATOM BOMBARDMENT see **SPECTROMETRY, MASS, FAST ATOM BOMBARDMENT**

MASS SPECTROSCOPY, MATRIX-ASSISTED LASER DESORPTION-IONIZATION see **SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION**

MASS STORAGE DEVICES see **COMPUTER STORAGE DEVICES**

MASSAGE

METHODS

[Effectiveness, indications and contraindications of manual lymph drainage therapy in painful edema] Asdonk J. **Z Lymphol** 1995 Aug;19(1):16–22 (22 ref.) **(Ger)**

MASSETER MUSCLE

DRUG EFFECTS

[Masseter muscle spasm--approach to patient] Ben-Abraham R, et al. **Harefuah** 1995 Aug;129(3–4):135–8 (20 ref.) **(Heb)**

MAST-CELL COLONY-STIMULATING FACTOR see **INTERLEUKIN-3**

MAST-CELL DISEASE see **MASTOCYTOSIS**

MAST CELL GROWTH FACTOR see **STEM CELL FACTOR**

MAST CELL GROWTH FACTOR-2 see **INTERLEUKIN-4**

MAST-CELL LEUKEMIA see **LEUKEMIA, MAST-CELL**

MAST-CELL SARCOMA see **SARCOMA, MAST-CELL**

MAST CELLS

Human mast cell cytokines. Bradding P. **Clin Exp Allergy** 1996 Jan;26(1):13–9 (56 ref.)

CYTOLOGY

Cytokines involved in growth and differentiation of human basophils and mast cells. Valent P. **Exp Dermatol** 1995 Aug; 4(4 Pt 2):255–9 (40 ref.)

[New hypotheses in asthma: the mastocytes] Kassel O, et al. **Rev Pneumol Clin** 1996;52(2):59–63 (34 ref.) (Eng. Abstr.) **(Fre)**

DRUG EFFECTS

Effects of mesalazine on lamina propria white cell functions. Verspaget HW. **Adv Exp Med Biol** 1995;371A:317–20 (20 ref.)

Mast cells and basophils in adverse reactions to drugs used during general anesthesia. Stellato C, et al. **Chem Immunol** 1995;62:108–31 (94 ref.)

IMMUNOLOGY

Mast-cell-leukocyte cytokine cascades in allergic inflammation. Galli SJ, et al. **Allergy** 1995 Nov; 50(11):851–62 (129 ref.)

The role of mast cells and basophils in immunoregulation. Nolte H. **Allergy Asthma Proc** 1996 Jan–Feb;17(1):17–21 (13 ref.)

1995 Mack-Forster Award Lecture. Review. Mast cell differentiation antigens: expression in normal and malignant cells and use for diagnostic purposes. Valent P. **Eur J Clin Invest** 1995 Oct;25(10):715–20 (51 ref.)

Chemokines and the allergic response. Kaplan AP, et al. **Exp Dermatol** 1995 Aug;4(4 Pt 2):260–5 (36 ref.)

Immunological characterization and functional importance of human heart mast cells. Marone G, et al. **Immunopharmacology** 1995 Nov;31(1):1–18 (137 ref.)

METABOLISM

Mouse mast cell cytokine production: rôle in cutaneous inflammatory and immunological responses. Galli SJ, et al. **Exp Dermatol** 1995 Aug;4(4 Pt 2):240–9 (73 ref.)

Direct and indirect receptor-independent G-protein activation by cationic-amphiphilic substances. Studies with mast cells, HL-60 human leukemic cells and purified G-proteins. Klinker JF, et al. **Exp Dermatol** 1995 Aug;4(4 Pt 2):231–9 (53 ref.)

MICROBIOLOGY

Interaction of bacteria with mast cells. Malaviya R, et al. **Methods Enzymol** 1995;253:27–43 (47 ref.)

PHYSIOLOGY

The mast cell and inflammation. McNeil HP. **Aust N Z J Med** 1996 Apr;26(2):216–25 (67 ref.)

The mast cell revisited. Mota I. **Braz J Med Biol Res** 1995 Aug;28(8):895–901 (35 ref.)

Protein tyrosine phosphorylation as a mechanism of signalling in mast cells and basophils. Hamawy MM, et al. **Cell Signal** 1995 Aug;7(6):535–44 (90 ref.)

Role of mast cells in arthritis. Arnason JA, et al. **Chem Immunol** 1995;62:204–38 (279 ref.)

Role of basophils and mast cells in acute and late reactions in the skin. Charlesworth EN. **Chem Immunol** 1995; 62:84–107 (73 ref.)

Role of mast cells in atherosclerosis. Kovanen PT. **Chem Immunol** 1995;62:132–70 (120 ref.)

Mast cells and tumor-associated angiogenesis. Meininger CJ. **Chem Immunol** 1995;62:239–57 (135 ref.)

What are human heart mast cells for? Patella V, et al. **Chem Immunol** 1995;62:171–86 (89 ref.)

Role of mast cells and basophils in rhinitis. Peebles RS Jr, et al. **Chem Immunol** 1995;62:60–83 (113 ref.)

Role of mast cells and basophils in asthma. Redington AE, et al. **Chem Immunol** 1995;62:22–59 (293 ref.)

Role of mast cells and basophils in gastrointestinal inflammation. Wershil BK. **Chem Immunol** 1995;62:187–203 (83 ref.)

The Na+/K(+)-pump in rat peritoneal mast cells: some aspects of regulation of activity and cellular function. Knudsen T. **Dan Med Bull** 1995 Nov;42(5):441–54 (261 ref.)

Mast cells in the cytokine network: the what, where from and what for. Czarnetzki BM, et al. **Exp Dermatol** 1995 Aug;4(4 Pt 2):221–6 (43 ref.)

Cytokine treatment of mast-cell-mediated skin diseases. Luger TA. **Exp Dermatol** 1995 Aug;4(4 Pt 2):277–80 (39 ref.)

Mast cells as modulators of hair follicle cycling. Maurer M, et al. **Exp Dermatol** 1995 Aug;4(4 Pt 2):266–71 (99 ref.)

Mast cell ontogeny and apoptosis. Metcalfe DD, et al. **Exp Dermatol** 1995 Aug;4(4 Pt 2):227–30 (34 ref.)

PEI6, a new basic secretagogue in rat peritoneal mast cells: characteristics of polyethylenimine PEI6 resemble those of compound 48/80. Suzuki-Nishimura T, et al. **Gen Pharmacol** 1995 Oct;26(6):1171–8 (41 ref.)

Role of mast cells, basophils and their mediators in adverse reactions to general anesthetics and radiocontrast media. Genovese A, et al. **Int Arch Allergy Immunol** 1996 May; 110(1):13–22 (102 ref.)

Mast cells in the gastrointestinal tract. Barczyk M, et al. **Rocz Akad Med Bialymst** 1995;40(1):36–57 (108 ref.)

Mast cells in the brain: evidence and functional significance. Silver R, et al. **Trends Neurosci** 1996 Jan;19(1):25–31 (64 ref.)

[Mast cells and cytokines--a new insight on the participation of mast cells in inflammatory reactions] Kupryś I, et al. **Postepy Hig Med Dosw** 1996;50(1):43–63 (78 ref.) (Eng. Abstr.) **(Pol)**

SECRETION

Cytokine secretion by human mast cells. Krüger-Krasagakes S, et al. **Exp Dermatol** 1995 Aug;4(4 Pt 2):250–4 (26 ref.)

MASTECTOMY

Breast reconstruction. van Smitten K. **Acta Oncol** 1995; 34(5):685–8 (21 ref.)

Reconstruction after mastectomy. Osteen RT. **Cancer** 1995 Nov 15;76(10 Suppl):2070–4 (29 ref.)

Bilateral prophylactic mastectomy: issues and concerns. Stefanek ME. **J Natl Cancer Inst Monogr** 1995;(17):37–42 (31 ref.)

Surgical treatment of breast cancer relapse. Margolese RG. **Recent Results Cancer Res** 1996;140:159–67 (23 ref.)

The current role of prophylactic mastectomy. Lopez MJ, et al. **Surg Clin North Am** 1996 Apr;76(2):231–42 (51 ref.)

Arguments against routine contralateral mastectomy or undirected biopsy for invasive lobular breast cancer. Lee JS, et al. **Surgery** 1995 Oct;118(4):640–7; discussion 647–8 (22 ref.)

ADVERSE EFFECTS

Focused review: postmastectomy lymphedema. Brennan MJ, et al. **Arch Phys Med Rehabil** 1996 Mar;77(3 Suppl):S74–80 (55 ref.)

METHODS

More detailed documentation of operative procedures in breast conserving treatment: what good will it do us? Christiaens MR, et al. **Eur J Surg Oncol** 1996 Aug; 22(4):326–30 (44 ref.)

PSYCHOLOGY

Psychological intervention with couples after mastectomy. Baider L. **Support Care Cancer** 1995 Jul;3(4):239–43 (43 ref.)

REHABILITATION

Focused review: postmastectomy lymphedema. Brennan MJ, et al. **Arch Phys Med Rehabil** 1996 Mar;77(3 Suppl):S74–80 (55 ref.)

TRENDS

Breast cancer surgery: a century after Halsted. Veronesi U, et al. **J Cancer Res Clin Oncol** 1996;122(2):74–7 (20 ref.)

MASTECTOMY, RADICAL

Local and regional therapy for primary breast tumors. Answers to major questions. Porterfield LA, et al. **Postgrad Med** 1995 Oct;98(4):65–8, 73, 77 passim (16 ref.)

ADVERSE EFFECTS

Lymphangiosarcoma following mastectomy. Stewart NJ, et al. **Clin Orthop** 1995 Nov;(320):135–41 (15 ref.)

MASTECTOMY, SEGMENTAL

Postexcisional recurrence of carcinoma of the breast. Zavotsky J, et al. **J Am Coll Surg** 1996 Jan;182(1):71–7 (88 ref.)

Local control following breast-conserving surgery for invasive cancer: results of clinical trials. Morrow M, et al. **J Natl Cancer Inst** 1995 Nov 15;87(22):1669–73 (35 ref.)

Local and regional therapy for primary breast tumors. Answers to major questions. Porterfield LA, et al. **Postgrad Med** 1995 Oct;98(4):65–8, 73, 77 passim (16 ref.)

MASTECTOMY, SEGMENTAL

Evaluation of the breast undergoing lumpectomy and radiation therapy. Dershaw DD. **Radiol Clin North Am** 1995 Nov;33(6):1147–60 (50 ref.)

Three cases of breast angiosarcomas after breast-conserving treatment for carcinoma [letter] Weber B, et al. **Radiother Oncol** 1995 Dec;37(3):250–2 (21 ref.)

How to predict the risk of local relapse in the preserved breast. Kurtz JM. **Recent Results Cancer Res** 1996; 140:263–72 (26 ref.)

[Breast-preserving (conservative) therapy of breast cancer] Semiglazov VF, et al. **Vopr Onkol** 1996;42(3):26–9 (11 ref.) (Eng. Abstr.) **(Rus)**

METHODS

Lumpectomy versus quadrantectomy for breast conservation: a critical appraisal [editorial; comment] Fisher B. **Eur J Cancer** 1995 Sep;31A(10):1567–9 (9 ref.) Comment on: Eur J Cancer 1995 Sep;31A(10):1574–9.

Breast conservation therapy in the management of invasive and in situ carcinoma. Masko GB, et al. **R I Med** 1995 Sep;78(9):246–9 (18 ref.)

MASTICATION

A review of masticatory ability and efficiency. Boretti G, et al. **J Prosthet Dent** 1995 Oct;74(4):400–3 (30 ref.)

PHYSIOLOGY

Generation of masticatory rhythm in the brainstem. Nakamura Y, et al. **Neurosci Res** 1995 Aug;23(1):1–19 (171 ref.)

MASTICATORY FORCE see **BITE FORCE**

MASTICATORY MUSCLES

PHYSIOLOGY

Masticatory muscle influence on craniofacial growth. Kiliaridis S. **Acta Odontol Scand** 1995 Jun;53(3):196–202 (86 ref.)

[Standard electromyographic and kinesiographic parameters in a sample of healthy population] Manni A, et al. **Minerva Stomatol** 1995 Sep;44(9):411–9 (29 ref.) (Eng. Abstr.) **(Ita)**

MASTICATORY SYSTEM see **STOMATOGNATHIC SYSTEM**

MASTITIS

[Granulomatous mastitis] Lafont A, et al. **Rev Fr Gynecol Obstet** 1995 Dec;90(12):530–3 (11 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Cryptococcal infection of the breast. Goldman M, et al. **Clin Infect Dis** 1995 Nov;21(5):1166–9 (19 ref.)

MASTITIS, BOVINE

EPIDEMIOLOGY

Mastitis in dairy heifers: initial studies on prevalence and control. Nickerson SC, et al. **J Dairy Sci** 1995 Jul; 78(7):1607–18 (56 ref.)

PHYSIOPATHOLOGY

[Tissue regeneration processes in the bovine mammary gland] Michel G, et al. **Tierarztl Prax** 1996 Jun;24(3):223–7 (11 ref.) (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

Mastitis in dairy heifers: initial studies on prevalence and control. Nickerson SC, et al. **J Dairy Sci** 1995 Jul; 78(7):1607–18 (56 ref.)

Disinfection in the dairy parlour. Saran A. **Rev Sci Tech** 1995 Mar;14(1):207–24 (31 ref.)

MASTITIS, CYSTIC see **FIBROCYSTIC DISEASE OF BREAST**

MASTOCYTOMA, BENIGN see **MASTOCYTOSIS**

MASTOCYTOMA, MALIGNANT see **SARCOMA, MAST-CELL**

MASTOCYTOSIS

COMPLICATIONS

[Lymphocytic ascites revealing systemic mastocytosis] Essner C, et al. **Gastroenterol Clin Biol** 1995 Nov; 19(11):948–51 (23 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

[Systemic mastocytosis: a review of the literature and of the cases in Reggio Emilia from 1986 to 1994] D'Incà M, et al. **Ann Ital Med Int** 1996 Jan–Mar;11(1):52–8 (51 ref.) (Eng. Abstr.) **(Ita)**

ETIOLOGY

Biology, diagnosis and therapy of mastocytosis. Marone G, et al. **Chem Immunol** 1995;62:1–21 (100 ref.)

IMMUNOLOGY

1995 Mack-Forster Award Lecture. Review. Mast cell differentiation antigens: expression in normal and malignant cells and use for diagnostic purposes. Valent P. **Eur J Clin Invest** 1995 Oct;25(10):715–20 (51 ref.)

PATHOLOGY

Biology, classification and treatment of human mastocytosis. Valent P. **Wien Klin Wochenschr** 1996;108(13):385–97 (106 ref.)

[Inguinal mastocytosis with histiocytic infiltrate] Enginger V, et al. **Ann Dermatol Venereol** 1995;122(8):536–9 (14 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Clinical advances in mastocytosis. Genovese A, et al. **Int J Clin Lab Res** 1995;25(4):178–88 (117 ref.)

MASTOCYTOSIS, BULLOUS see **URTICARIA PIGMENTOSA**

MASTOCYTOSIS, DIFFUSE CUTANEOUS see **URTICARIA PIGMENTOSA**

MASTOID

PATHOLOGY

Cartinoid tumor of the middle ear and mastoid. Himi T, et al. **Auris Nasus Larynx** 1995;22(2):128–33 (21 ref.)

SURGERY

Mastoidectomy reconstruction: management of the high facial ridge using hydroxylapatite implants. Black B, et al. **Am J Otol** 1994 Nov;15(6):785–92 (78 ref.)

Pre-operative information in mastoidectomy: what about the facial nerve and hearing loss? Wormald PJ. **J Laryngol Otol** 1996 Jan;110(1):10–2 (8 ref.)

Mastoidectomy elimination. Black B. **Laryngoscope** 1995 Dec;105(12 Pt 2 Su 76):1–30 (197 ref.)

MASTOIDITIS

Acute and chronic mastoiditis: clinical presentation, diagnosis, and management. Nadol JB Jr, et al. **Curr Clin Top Infect Dis** 1995;15:204–29 (46 ref.)

COMPLICATIONS

Otogenic Fusobacterium necrophorum meningitis in children. Figueras G, et al. **Pediatr Infect Dis J** 1995 Jul; 14(7):627–8 (10 ref.)

Lateral sinus thrombosis associated with otitis media and mastoiditis in children. Garcia RD, et al. **Pediatr Infect Dis J** 1995 Jul;14(7):617–23 (35 ref.)

SURGERY

The use of the temporoparietal fascial flap in temporal bone reconstruction. Cheney ML, et al. **Am J Otol** 1996 Jan; 17(1):137–42 (11 ref.)

MATCHED CASE-CONTROL STUDIES see **CASE-CONTROL STUDIES**

MATCHED-PAIR ANALYSIS

Matching. Costanza MC. **Prev Med** 1995 Sep;24(5):425–33 (14 ref.)

MATERIA MEDICA

see related
MEDICINE, TRADITIONAL

MATERIALS TESTING

Several methods utilized for the assessment of biocompatibility of perfluorochemicals. Lutz J, et al. **Artif Cells Blood Substit Immobil Biotechnol** 1995; 23(3):407–15 (30 ref.)

Mechanical properties of implantable biomaterials. Meaney DF. **Clin Podiatr Med Surg** 1995 Jul;12(3):363–84 (6 ref.)

Sterilization and reprocessing of materials and medical devices--reusability. Jayabalan M. **J Biomater Appl** 1995 Jul;10(1):97–112 (39 ref.)

[Use of irradiation technique for obtaining and modifying biopolymers. Review.] Lewandowska-Szumiel M, et al. **Polim Med** 1995;25(1–2):57–67 (35 ref.) (Eng. Abstr.) **(Pol)**

METHODS

Dentin bonding system. Part II: Effect of crosshead speed. Oshida Y, et al. **Biomed Mater Eng** 1996;6(2):87–100 (106 ref.)

Mechanical testing of materials and the material-tissue interface. Ashry HR, et al. **Clin Podiatr Med Surg** 1995 Jul;12(3):385–401 (33 ref.)

MATERNAL AGE

Births by younger and older mothers in a population with late and regulated childbearing: Finland 1991. Hemminki E, et al. **Acta Obstet Gynecol Scand** 1996 Jan;75(1):19–27 (35 ref.)

The role of maternal age in assisted reproduction. Rosenwaks Z, et al. **Hum Reprod** 1995 Oct;10 Suppl 1:165–73 (36 ref.)

Fetal exomphalos and chromosomal defects: relationship to maternal age and gestation. Snijders RJ, et al. **Ultrasound Obstet Gynecol** 1995 Oct;6(4):250–5 (30 ref.)

MATERNAL AGE 35 AND OVER

see related
PREGNANCY, HIGH-RISK

Interpregnancy intervals, high maternal age and seasonal effects on the human sex ratio. James WH. **Hum Reprod** 1996 Jan;11(1):7–8 (14 ref.)

MATERNAL BEHAVIOR

PHYSIOLOGY

Regulation of pigeon cropmilk secretion and parental behaviors by prolactin. Horseman ND, et al. **Annu Rev Nutr** 1995;15:213–38 (130 ref.)

PSYCHOLOGY

Identification and care of problems associated with alcohol ingestion in pregnancy. Hankin JR, et al. **Semin Perinatol** 1995 Aug;19(4):286–92 (24 ref.)

MATERNAL-CHILD HEALTH CENTERS

[Parent and child care: medical efficacy] Verloove-Vanhorick SP. **Ned Tijdschr Geneeskd** 1996 Apr 20;140(16):874–8 (40 ref.) **(Dut)**

MATERNAL-CHILD NURSING

Use of ultrasonography in the home care of high-risk childbearing women. Stringer M. **Nurs Clin North Am** 1996 Jun;31(2):305–12 (17 ref.)

MATERNAL EXPOSURE

see related
MATERNAL-FETAL EXCHANGE
PATERNAL EXPOSURE

Effects of parental exposure to solvents on pregnancy outcome. Lindbohm ML. **J Occup Environ Med** 1995 Aug; 37(8):908–14 (48 ref.)

ADVERSE EFFECTS

Effects of parental occupational exposure to lead and other metals on spontaneous abortion. Anttila A, et al. **J Occup Environ Med** 1995 Aug;37(8):915–21 (36 ref.)

Maternal pesticide exposure and pregnancy outcome. Nurminen T. **J Occup Environ Med** 1995 Aug;37(8):935–40 (27 ref.)

MATERNAL-FETAL EXCHANGE

see related
ABNORMALITIES, DRUG-INDUCED

Comparative aspects of placental exchange functions. Schröder HJ. **Eur J Obstet Gynecol Reprod Biol** 1995 Nov; 63(1):81–90 (25 ref.)

Extrapulmonary effects of antenatally administered steroids. Padbury JF, et al. **J Pediatr** 1996 Feb;128(2):167–72 (61 ref.)

Pharmacokinetics and pharmacodynamics of maternal-fetal transport of drugs of abuse: a critical review. Melethil S. **NIDA Res Monogr** 1995;154:132–51 (48 ref.)

Transplacental hormonal carcinogenesis: diethylstilbestrol as an example. Newbold RR, et al. **Prog Clin Biol Res** 1996; 394:131–47 (37 ref.)

Drug delivery during pregnancy: evaluation in vitro of new drugs. Dancis J, et al. **Reprod Fertil Dev** 1995;7(6):1485–9 (33 ref.)

[Pregnancy and the child of a mother with phenylketonuria] Abadie V, et al. **Arch Pediatr** 1996 May;3(5):489–6 (38 ref.) (Eng. Abstr.) **(Fre)**

[Maternal corticotherapy . Pharmacology and effect on the fetus] Guillonneau M, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(2):160–7 (53 ref.) (Eng. Abstr.) **(Fre)**

[Measurement of drugs in neonatal hair--a window to fetal exposure] Koren G, et al. **Harefuah** 1995 Nov 1; 129(9):336–8 (15 ref.) **(Heb)**

GENETICS

HLA-G transgenic mice: a model for studying expression and function at the maternal/fetal interface. Schmidt CM, et al. **Immunol Rev** 1995 Oct;147:53–65 (32 ref.)

IMMUNOLOGY

Materno-fetal immunobiology in normal pregnancy and its possible failure in recurrent spontaneous abortion? Vince GS, et al. **Hum Reprod** 1995 Dec;10 Suppl 2:107-13 (50 ref.)
HLA-G transgenic mice: a model for studying expression and function at the maternal/fetal interface. Schmidt CM, et al. **Immunol Rev** 1995 Oct;147:53-65 (32 ref.)
Contribution of class I HLA-A2 antigen in immune reactions. Komios L, et al. **Med Hypotheses** 1995 Jul;45(1):54-8 (41 ref.)
[Trophoblastic interferons and embryonal immune tolerance] Martal J, et al. **Contracept Fertil Sex** 1995 Sep;23(9):562-72 (163 ref.) (Eng. Abstr.) **(Fre)**
[Diagnosis and therapy of fetal alloimmune thrombocytopenia] Marzusch K, et al. **Geburtshilfe Frauenheilkd** 1995 Oct;55(10):587-91 (29 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Not trophoblast alone: a review of the contribution of the fetal microvasculature to transplacental exchange. Firth JA, et al. **Placenta** 1996 Mar-Apr;17(2-3):89-96 (64 ref.)
[Importance of fetal sensorial capacity in the establishment of mother-child exchange during pregnancy] Relier JP. **Arch Pediatr** 1996 Mar;3(3):274-82 (16 ref.) (Eng. Abstr.) **(Fre)**
[Diagnostic and clinical value of Doppler ultrasound in obstetrics] Gonser M, et al. **Geburtshilfe Frauenheilkd** 1995 Nov;55(11):605-15 (127 ref.) (Eng. Abstr.) **(Ger)**
[Noninvasive prenatal diagnosis of fetal cells in maternal blood] Tutschek B, et al. **Gynakologe** 1995 Oct; 28(5):289-301 (74 ref.) **(Ger)**

MATERNAL HEALTH see **MATERNAL WELFARE**

MATERNAL PATTERNS OF CARE see **MATERNAL BEHAVIOR**

MATERNAL WELFARE

Maternal nutrition and obstetric outcome. Steegers-Theunissen BP. **Baillieres Clin Obstet Gynaecol** 1995 Sep;9(3):431-43 (65 ref.)
Pre-conception care of diabetes, congenital malformations, and spontaneous abortions. Kitzmiller JL, et al. **Diabetes Care** 1996 May;19(5):514-41 (324 ref.)
Maternal nutrition in relation to fetal and placental growth. Godfrey KM, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Jul;61(1):15-22 (62 ref.)
Nutrition and breast-feeding. Koppe JG. **Eur J Obstet Gynecol Reprod Biol** 1995 Jul;61(1):73-8 (11 ref.)

LEGISLATION & JURISPRUDENCE

Working conditions, maternity legislation, and preterm birth. Berkowitz GS, et al. **Semin Perinatol** 1995 Aug;19(4):272-8 (40 ref.)

MATERNALLY-ACQUIRED IMMUNITY see **IMMUNITY, MATERNALLY-ACQUIRED**

MATERNITY NURSING see **MATERNAL-CHILD NURSING**

MATHEMATICS

Graphic format for teaching long-term control of systemic arterial pressure. Faber JJ. **Am J Physiol** 1996 Jun;270(6 Pt 3):S40-9 (22 ref.)
Kinetic models in reverse micelles. Bru R, et al. **Biochem J** 1995 Sep 15;310 (Pt 3):721-39 (161 ref.)
Prediction of function in DNA sequence analysis. Gelfand MS. **J Comput Biol** 1995 Spring;2(1):87-115 (449 ref.)
Eye-movement models for arithmetic and reading performance. Suppes P. **Rev Oculomot Res** 1990;4:455-77 (53 ref.)
[Rare forms of reflex epilepsy--the epilepsy of calculation and the epilepsy of eating] Karlov VA, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995;95(3):13-6 (18 ref.) (Eng. Abstr.) **(Rus)**

MATING BEHAVIOR, ANIMAL see **SEX BEHAVIOR, ANIMAL**

MATING-TYPE GENES see **GENES, FUNGAL**

MATRIX-ASSISTED LASER DESORPTION-IONIZATION MASS SPECTROMETRY see **SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION**

MATRIX, EXTRACELLULAR see **EXTRACELLULAR MATRIX**

MATTRESSES see **BEDS**

MATURATION-PROMOTING FACTOR

see related
CYCLINS

Starfish maturation-promoting factor. Kishimoto T. **Trends Biochem Sci** 1996 Jan;21(1):35-7 (18 ref.)

MATURITY-ONSET DIABETES MELLITUS see **DIABETES MELLITUS, NON-INSULIN-DEPENDENT**

MAXILLA

see related
MAXILLOFACIAL DEVELOPMENT

SURGERY

Bilateral maxillectomy and midfacial reconstruction. Panje WR, et al. **Ann Otol Rhinol Laryngol** 1995 Nov; 104(11):845-9 (12 ref.)
Le Fort 1 downfracture approach for the treatment of a posterior maxillary ameloblastoma. Symington OG, et al. **J Can Dent Assoc** 1995 Dec;61(12):1048-52 (24 ref.)
[Antebrachial free flap with radial pedicle. II. Surgical technique] Iriarte Ortabe JI, et al. **Acta Stomatol Belg** 1995 Sep;92(3):105-23 (195 ref.) (Eng. Abstr.) **(Fre)**

MAXILLARY DISEASES

PATHOLOGY

Inflammatory pseudotumour of the mouth and maxilla. Shek AW, et al. **J Clin Pathol** 1996 Feb;49(2):164-7 (23 ref.)
Malignant and premalignant change in odontogenic cysts. Fanibunda K, et al. **J Oral Maxillofac Surg** 1995 Dec; 53(12):1469-72 (19 ref.)
Synchronous central giant cell lesions of the jaws: report of a case and review of the literature. Miloro M, et al. **J Oral Maxillofac Surg** 1995 Nov;53(11):1350-5 (32 ref.)

RADIOGRAPHY

Lesions of the jaws. DelBalso AM. **Semin Ultrasound CT MR** 1995 Dec;16(6):487-512 (42 ref.)

MAXILLARY NEOPLASMS

CLASSIFICATION

Maxillofacial fibro-osseous lesions: classification and differential diagnosis. Slootweg PJ. **Semin Diagn Pathol** 1996 May;13(2):104-12 (22 ref.)

DIAGNOSIS

Non Hodgkin's lymphoma of the maxilla as a first clinical manifestation of HIV infection. Report of a case. Berberi A, et al. **Bull Group Int Rech Sci Stomatol Odontol** 1995 Sep-Oct;38(3-4):77-80 (11 ref.)
Maxillofacial fibro-osseous lesions: classification and differential diagnosis. Slootweg PJ. **Semin Diagn Pathol** 1996 May;13(2):104-12 (22 ref.)

PATHOLOGY

Induction of osteodentin and abortive enamel in adenomatoid odontogenic tumor. Takeda Y. **Ann Dent** 1995 Summer-Fall;54(1-2):61-3 (13 ref.)
Odontogenic ghost cell carcinoma: report of a case and review of the literature. Alcalde RE, et al. **J Oral Maxillofac Surg** 1996 Jan;54(1):108-11 (9 ref.)
Malignant and premalignant change in odontogenic cysts. Fanibunda K, et al. **J Oral Maxillofac Surg** 1995 Dec; 53(12):1469-72 (19 ref.)
Primary leiomyosarcoma of the maxilla with regional lymph node metastasis. Report of a case and review of the literature. Izumi K, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1995 Sep;80(3):310-9 (56 ref.)

RADIOGRAPHY

Lesions of the jaws. DelBalso AM. **Semin Ultrasound CT MR** 1995 Dec;16(6):487-512 (42 ref.)
[Radiological criteria for laryngeal tumors and cervical metastases] Melchor Diaz MA, et al. **Acta Otorrinolaringol Esp** 1996 Jan-Feb;47(1):1-7 (17 ref.) (Eng. Abstr.) **(Spa)**

SECONDARY

[Radiological criteria for laryngeal tumors and cervical metastases] Melchor Diaz MA, et al. **Acta Otorrinolaringol Esp** 1996 Jan-Feb;47(1):1-7 (17 ref.) (Eng. Abstr.) **(Spa)**

SURGERY

Le Fort 1 downfracture approach for the treatment of a posterior maxillary ameloblastoma. Symington OG, et al. **J Can Dent Assoc** 1995 Dec;61(12):1048-52 (24 ref.)
Surgical management of ameloblastoma. Current status of the literature. Feinberg SE, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Apr;81(4):383-8 (31 ref.)
[The role of microsurgery in the reconstruction of loss of substance of soft tissue in the maxillofacial region] Iriarte Ortabe JI, et al. **Acta Stomatol Belg** 1995 Mar;92(1):17-29 (142 ref.) (Eng. Abstr.) **(Fre)**

MAXILLARY SINUSITIS

COMPLICATIONS

[Odontogenic sinusitis with cutaneous fistulization. A case report] Garbarino R, et al. **Minerva Stomatol** 1995 Jun; 44(6):319-23 (18 ref.) (Eng. Abstr.) **(Ita)**

ETIOLOGY

[Cystic fibrosis in adults] Durieu I, et al. **Presse Med** 1995 Dec 16-23;24(39):1882-7 (23 ref.) (Eng. Abstr.) **(Fre)**

MICROBIOLOGY

[Bacteriology of maxillary sinusitis among members of the 11th parachutist unit] Wéry G, et al. **Rev Laryngol Otol Rhinol (Bord)** 1995;116(3):187-9 (19 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

[Odontogenic diseases of the maxillary sinuses] Lambrecht JT. **Fortschr Kiefer Gesichtschir** 1995;40:106-13 (115 ref.) (Eng. Abstr.) **(Ger)**

MAXILLOFACIAL DEVELOPMENT

see related
CEPHALOMETRY

Abnormal craniofacial growth. Friede H. **Acta Odontol Scand** 1995 Jun;53(3):203-9 (53 ref.)
Craniocervical junction as a focus for craniofacial growth studies. Huggare J. **Acta Odontol Scand** 1995 Jun; 53(3):186-91 (36 ref.)
Masticatory muscle influence on craniofacial growth. Kiliaridis S. **Acta Odontol Scand** 1995 Jun;53(3):196-202 (86 ref.)
The role of sutures in normal and abnormal craniofacial growth. Persson M. **Acta Odontol Scand** 1995 Jun; 53(3):152-61 (87 ref.)
Endocrine regulation of craniofacial growth. Pirinen S. **Acta Odontol Scand** 1995 Jun;53(3):179-85 (62 ref.)
Basicranial synchondroses and the mandibular condyle in craniofacial growth. Rönning O. **Acta Odontol Scand** 1995 Jun;53(3):162-6 (42 ref.)
Basic mechanisms in craniofacial growth. Thilander B. **Acta Odontol Scand** 1995 Jun;53(3):144-51 (26 ref.)
Some aspects of bone formation and remodeling pertinent to craniofacial development and reconstructive treatment. Vargervik K. **Acta Odontol Scand** 1995 Jun;53(3):167-73 (16 ref.)
Habits affecting dental and maxillofacial growth and development. Josell SD. **Dent Clin North Am** 1995 Oct; 39(4):851-60 (32 ref.)
[Gnathologic concepts and their practical role in dentistry] Fazekas A, et al. **Fogorv Sz** 1996 Feb;89(2):39-49 (26 ref.) **(Hun)**

GENETICS

Homeobox genes and orofacial development. Sharpe PT. **Connect Tissue Res** 1995;32(1-4):17-25 (64 ref.)
Genetically engineered mice: tools to understand craniofacial development. Ignelzi MA Jr, et al. **Crit Rev Oral Biol Med** 1995;6(3):181-201 (118 ref.)
Genetics in oral-facial growth and diseases. Nakata M. **Int Dent J** 1995 Aug;45(4):227-44 (39 ref.)

PHYSIOLOGY

Homeobox genes and growth factors in regulation of craniofacial and tooth morphogenesis. Thesleff I. **Acta Odontol Scand** 1995 Jun;53(3):129-34 (38 ref.)

MAXILLOFACIAL INJURIES

COMPLICATIONS

Intracranial reduction of an intact mandibular condyle displaced into the middle cranial fossa. Sandler NA, et al. **J Oral Maxillofac Surg** 1996 Apr;54(4):506-10 (17 ref.)

SURGERY

Changing indications for tracheostomy in maxillofacial trauma. Taicher S, et al. **J Oral Maxillofac Surg** 1996 Mar; 54(3):292-5; discussion 295-6 (21 ref.)
Penetrating maxillofacial trauma--a case report. Arotiba TG. **West Afr J Med** 1995 Jul-Sep;14(3):186-8 (5 ref.)

MAXIMAL EXPIRATORY FLOW-VOLUME CURVES

Flow volume loops in the evaluation of upper airway obstruction. Lunn WW, et al. **Otolaryngol Clin North Am** 1995 Aug;28(4):721-9 (13 ref.)

MAXIMUM ALLOWABLE CONCENTRATION see **MAXIMUM PERMISSIBLE EXPOSURE LEVEL**

MAXIMUM LIKELIHOOD ESTIMATES

MAXIMUM LIKELIHOOD ESTIMATES see **LIKELIHOOD FUNCTIONS**

MAXIMUM PERMISSIBLE EXPOSURE LEVEL

Strategy of biological monitoring and setting of biological threshold limits (BAT values) in Germany [see comments] Lehnert G, et al. **Isr J Med Sci** 1995 Sep;31(9):549–57 (23 ref.) Comment in: Isr J Med Sci 1995 Sep;31(9):563–4.

MAZE LEARNING

PHYSIOLOGY

Simulation of spatial learning in the Morris water maze by a neural network model of the hippocampal formation and nucleus accumbens. Brown MA, et al. **Hippocampus** 1995; 5(3):171–88 (73 ref.)

MAZINDOL

THERAPEUTIC USE

Clinical studies with mazindol. Inoue S. **Obes Res** 1995 Nov; 3 Suppl 4:549S–552S (11 ref.)

[Therapy of obesity using appetite depressants] Ikeda Y. **Nippon Naika Gakkai Zasshi** 1995 Aug 10;84(8):1290–4 (4 ref.) **(Jpn)**

MCCUNE–ALBRIGHT SYNDROME see **FIBROUS DYSPLASIA, POLYOSTOTIC**

MCGILL PAIN QUESTIONNAIRE see **PAIN MEASUREMENT**

MCLS see **MUCOCUTANEOUS LYMPH NODE SYNDROME**

MCNAUGHTON RULE see **INSANITY DEFENSE**

MCP-1 see **MONOCYTE CHEMOATTRACTANT PROTEIN-1**

MDMA see **N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE**

MDR1 PROTEIN see **P-GLYCOPROTEIN**

MEALS ON WHEELS see **FOOD SERVICES**

MEALWORM see **TENEBRIO**

MEASLES

[Measles in here to stay] Sarig–Familia R, et al. **Harefuah** 1995 Jul;129(1–2):51–4 (28 ref.) **(Heb)**

[Yellow fever, measles, rubella] Yoshikawa Y. **Ryoikibetsu Shokogun Shirizu** 1995;(7):33–5 (9 ref.) **(Jpn)**

COMPLICATIONS

Measles & malnutrition. Bhaskaram P. **Indian J Med Res** 1995 Nov;102:195–9 (24 ref.)

[A case of an unusual course in measles] Brodov LE, et al. **Ter Arkh** 1995;67(11):23–4 (10 ref.) (Eng. Abstr.) **(Rus)**

DIAGNOSIS

Difficulties in clinical diagnosis of measles: proposal for modified clinical case definition. Ferson MJ, et al. **Med J Aust** 1995 Oct 2;163(7):364–6 (12 ref.)

Almost extinct diseases: measles, mumps, rubella, and pertussis. Gold E. **Pediatr Rev** 1996 Apr;17(4):120–7 (7 ref.)

EPIDEMIOLOGY

Guidelines for control of measles outbreaks in Canada (revised 1995). Advisory Committee on Epidemiology. **Can Med Assoc J** 1996 Apr 15;154(8):1197–1205 (3 ref.) **(Eng, Fre)**

Epidemiology and prevention of measles. Atkinson WL. **Dermatol Clin** 1995 Jul;13(3):553–9 (38 ref.)

Measles & malnutrition. Bhaskaram P. **Indian J Med Res** 1995 Nov;102:195–9 (24 ref.)

Measles outbreaks in the United States, 1987 through 1990. Hutchins S, et al. **Pediatr Infect Dis J** 1996 Jan;15(1):31–8 (40 ref.)

Space, persistence and dynamics of measles epidemics. Bolker B, et al. **Philos Trans R Soc Lond B Biol Sci** 1995 May 30;348(1325):309–20 (58 ref.)

IMMUNOLOGY

Overview: practical insights from comparative immunology and pathogenesis of AIDS, hepatitis B, and measles for developing an HIV vaccine. Hilleman MR. **Vaccine** 1995 Dec;13(18):1733–40 (41 ref.)

Pathogenetic aspects of measles virus infections. Schneider-Schaulies J, et al. **Vet Microbiol** 1995 May; 44(2–4):113–25 (44 ref.)

PATHOLOGY

[Pathogenesis of otosclerosis. "State of the art"] Arnold W, et al. **HNO** 1996 Mar;44(3):121–9 (61 ref.) (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

Guidelines for control of measles outbreaks in Canada (revised 1995). Advisory Committee on Epidemiology. **Can Commun Dis Rep** 1995 Nov 15;21(21):189–95 (2 ref.) **(Eng, Fre)**

Guidelines for control of measles outbreaks in Canada (revised 1995). Advisory Committee on Epidemiology. **Can Med Assoc J** 1996 Apr 15;154(8):1197–1205 (3 ref.) **(Eng, Fre)**

Epidemiology and prevention of measles. Atkinson WL. **Dermatol Clin** 1995 Jul;13(3):553–9 (38 ref.)

Measles elimination in the Americas. Evolving strategies [see comments] de Quadros CA, et al. **JAMA** 1996 Jan 17; 275(3):224–9 (47 ref.) Comment in: JAMA 1996 May 1;275(17):1311–2.

[Current status of the prevention and treatment of measles] Zi WL. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1996 Apr;17(2):111–2 (7 ref.) **(Chi)**

[History of purification, attenuation and testing a measles vaccine made from the strain "Leningrad–16" (L–16)] Smorodintsev AA, et al. **Tr Inst Im Pastera** 1992;67:86–95 (34 ref.) **(Rus)**

VIROLOGY

Pathogenetic aspects of measles virus infections. Schneider-Schaulies J, et al. **Vet Microbiol** 1995 May; 44(2–4):113–25 (44 ref.)

MEASLES, GERMAN see **RUBELLA**

MEASLES VACCINE

Measles elimination in the Americas. Evolving strategies [see comments] de Quadros CA, et al. **JAMA** 1996 Jan 17; 275(3):224–9 (47 ref.) Comment in: JAMA 1996 May 1;275(17):1311–2.

[Current status of the prevention and treatment of measles] Zi WL. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1996 Apr;17(2):111–2 (7 ref.) **(Chi)**

ADMINISTRATION & DOSAGE

[History of purification, attenuation and testing a measles vaccine made from the strain "Leningrad–16" (L–16)] Smorodintsev AA, et al. **Tr Inst Im Pastera** 1992;67:86–95 (34 ref.) **(Rus)**

ADVERSE EFFECTS

Case series analysis of adverse reactions to vaccines: a comparative evaluation. Farrington CP, et al. **Am J Epidemiol** 1996 Jun 1;143(11):1165–73 (18 ref.)

IMMUNOLOGY

[Measles virus and measles vaccine] Dai B. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1996 Apr; 17(2):108–10 (13 ref.) **(Chi)**

MEASLES VIRUS

GENETICS

[Measles virus and measles vaccine] Dai B. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1996 Apr; 17(2):108–10 (13 ref.) **(Chi)**

ISOLATION & PURIFICATION

[Pathogenesis of otosclerosis. "State of the art"] Arnold W, et al. **HNO** 1996 Mar;44(3):121–9 (61 ref.) (Eng. Abstr.) **(Ger)**

[History of purification, attenuation and testing a measles vaccine made from the strain "Leningrad–16" (L–16)] Smorodintsev AA, et al. **Tr Inst Im Pastera** 1992;67:86–95 (34 ref.) **(Rus)**

PATHOGENICITY

Measles virus infection of cerebral endothelial cells and effect on their adhesive properties. Cosby SL, et al. **Vet Microbiol** 1995 May;44(2–4):135–9 (21 ref.)

Pathogenetic aspects of measles virus infections. Schneider-Schaulies J, et al. **Vet Microbiol** 1995 May; 44(2–4):113–25 (44 ref.)

PHYSIOLOGY

CD46-mediated measles virus entry: a first key to host-range specificity. Gerlier D, et al. **Trends Microbiol** 1995 Sep; 3(9):338–45 (65 ref.)

MEAT

Hypercholesterolemia. Dietary advice for patients regarding meat [see comments] Keenan JM, et al. **Postgrad Med** 1995 Oct;98(4):113–4, 117–8, 120–1 passim (20 ref.) Comment in: Postgrad Med 1996 Feb;99(2):47–8.

ADVERSE EFFECTS

Chemical methods for assessing systemic exposure to dietary heterocyclic amines in man. Davies DS, et al. **Arch Toxicol Suppl** 1996;18:251–8 (29 ref.)

The medical costs attributable to meat consumption [see comments] Barnard ND, et al. **Prev Med** 1995 Nov; 24(6):646–55 (105 ref.) Comment in: Prev Med 1995 Nov;24(6):565–7.

MICROBIOLOGY

Strategies to accelerate the applicability of gene amplification protocols for pathogen detection in meat and meat products. Pillai SD, et al. **Crit Rev Microbiol** 1995; 21(4):239–61 (121 ref.)

Microbiology of fresh and restructured lamb meat: a review. al-Sheddy IA, et al. **Crit Rev Microbiol** 1995;21(1):31–52 (183 ref.)

[Contaminated fish and pork] Perret JL, et al. **Med Trop (Mars)** 1996;56(1):25–7 (0 ref.) **(Fre)**

PARASITOLOGY

[Contaminated fish and pork] Perret JL, et al. **Med Trop (Mars)** 1996;56(1):25–7 (0 ref.) **(Fre)**

POISONING

Scombroid poisoning. McInerney J, et al. **Ann Emerg Med** 1996 Aug;28(2):235–8 (9 ref.)

STANDARDS

Impact of composition manipulation on lean lamb production in the United States. Beermann DH, et al. **J Anim Sci** 1995 Aug;73(8):2493–502 (37 ref.)

Influence of dietary vitamin E on the oxidative stability and quality of pig meat. Buckley DJ, et al. **J Anim Sci** 1995 Oct;73(10):3122–30 (61 ref.)

A review of dietary vitamin E supplementation for improvement of beef quality. Liu Q, et al. **J Anim Sci** 1995 Oct;73(10):3131–40 (81 ref.)

Cleaning and disinfection practice in the meat industries of Europe. Salvat G, et al. **Rev Sci Tech** 1995 Jun;14(2):313–41 (19 ref.) **(Eng, Fre)**

TOXICITY

Preclinical drug metabolism programs for food-producing animals. Clement RP. **Toxicol Pathol** 1995 Mar–Apr; 23(2):209–16 (7 ref.)

MEAT PRODUCTS

Control of the dehydration process in production of intermediate-moisture meat products: a review. Chang SF, et al. **Adv Food Nutr Res** 1996;39:71–161 (222 ref.)

Carrageenans and their use in meat products. Trius A, et al. **Crit Rev Food Sci Nutr** 1996 Jan;36(1–2):69–85 (71 ref.)

MICROBIOLOGY

Strategies to accelerate the applicability of gene amplification protocols for pathogen detection in meat and meat products. Pillai SD, et al. **Crit Rev Microbiol** 1995; 21(4):239–61 (121 ref.)

Microbiology of fresh and restructured lamb meat: a review. al-Sheddy IA, et al. **Crit Rev Microbiol** 1995;21(1):31–52 (183 ref.)

MEBUBARBITAL see **PENTOBARBITAL**

MEBUMAL see **PENTOBARBITAL**

MECHANICAL VENTILATOR WEANING see **VENTILATOR WEANING**

MECHANORECEPTORS

see related **PROPRIOCEPTION**

[SA channels are mechanosensors of cells?] Sokabe M, et al. **Tanpakushitsu Kakusan Koso** 1996 Jan;41(1):2–13 (43 ref.) **(Jpn)**

PHYSIOLOGY

Genetic approaches to mechanosensory transduction. Kernan M, et al. **Curr Opin Neurobiol** 1995 Aug;5(4):443–8 (46 ref.)

Perspectives on the role of afferent signals in control of motor neuroprostheses. Johnson KO, et al. **Med Eng Phys** 1995 Oct;17(7):481–96 (99 ref.)

The differentiation and function of the touch receptor neurons of Caenorhabditis elegans. Chalfie M. **Prog Brain Res** 1995;105:179–82 (24 ref.)

[Regulation of food intake] Schusdziarra V. **Zentralbl Chir** 1996;121(5):354–7 (34 ref.) (Eng. Abstr.) **(Ger)**

[Blood flow modulates vascular endothelial gene expressions] Ando J. **Tanpakushitsu Kakusan Koso** 1996 Jan;41(1):26–33 (23 ref.) **(Jpn)**

[Mechanisms for flow-induced responses of vascular endothelial cells] Masuda M, et al. **Tanpakushitsu Kakusan Koso** 1996 Jan;41(1):34–46 (82 ref.) **(Jpn)**

[Mechano-electrical transduction in hair cells in the inner ear] Sugihara I. **Tanpakushitsu Kakusan Koso** 1996 Jan; 41(1):19–25 (31 ref.) **(Jpn)**

MECHLORETHAMINE

THERAPEUTIC USE

Innovative treatment approaches for rheumatoid arthritis. Cyclosporin, leflunomide and nitrogen mustard. Furst DE. **Baillieres Clin Rheumatol** 1995 Nov;9(4):711–29 (41 ref.)

Topical treatment of early cutaneous T-cell lymphoma. Ramsay DL, et al. **Hematol Oncol Clin North Am** 1995 Oct;9(5):1031–56 (84 ref.)

MECHLORETHAMINE OXIDE see **MECHLORETHAMINE**

MECKEL'S DIVERTICULUM

COMPLICATIONS

[An adult case of intussusception due to inverted Meckel's diverticulum accompanied by angiolipoma] Kaneko T, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Apr;93(4):260–5 (14 ref.) **(Jpn)**

DIAGNOSIS

Meckel's diverticulum: imaging diagnosis. Rossi P, et al. **AJR Am J Roentgenol** 1996 Mar;166(3):567–73 (55 ref.)

SURGERY

Current management of Meckel's diverticulum. Cullen JJ, et al. **Adv Surg** 1996;29:207–14 (23 ref.)

Laparoscopic treatment of Meckel's diverticulum. Obstruction and bleeding managed with minimal morbidity. Sanders LE. **Surg Endosc** 1995 Jun;9(6):724–7 (14 ref.)

Incidental Meckel's diverticulectomy in adults. Peoples JB, et al. **Surgery** 1995 Oct;118(4):649–52 (21 ref.)

[Atopic stomach polyp as the cause of invagination of Meckel's diverticulum] Schütter FW, et al. **Chirurg** 1995 Oct;66(10):1016–8 (24 ref.) (Eng. Abstr.) **(Ger)**

ULTRASONOGRAPHY

[Ultrasound morphologic spectrum of Meckel's diverticulitis—3 case reports and overview of the literature] Demharter J, et al. **Rontgenpraxis** 1996 Jun;49(6):145–8 (11 ref.) **(Ger)**

MECONIUM

Antenatal diagnosis and management of meconium peritonitis: a case report and review of the literature. Konje JC, et al. **Ultrasound Obstet Gynecol** 1995 Jul;6(1):66–9 (13 ref.)

MECONIUM ASPIRATION

PREVENTION & CONTROL

Meconium stained liquor: a view from a district hospital. Apers LM. **Trop Doct** 1996 Jan;26(1):14–7 (18 ref.)

MEDEX see **PHYSICIAN ASSISTANTS**

MEDIAL GENICULATE BODY see **GENICULATE BODIES**

MEDIAN EMINENCE

PHYSIOLOGY

The LHRH pulse generator: a mediobasal hypothalamic location. Maeda K, et al. **Neurosci Biobehav Rev** 1995 Fall; 19(3):427–37 (55 ref.)

MEDIAN NERVE

see related
CARPAL TUNNEL SYNDROME

Intraepineurial constriction of nerve fascicles in pronator syndrome and anterior interosseous nerve syndrome. Haussmann P, et al. **Orthop Clin North Am** 1996 Apr; 27(2):339–44 (13 ref.)

PHYSIOPATHOLOGY

Personal factors and blood volume movement in causation of median neuropathy at the carpal tunnel. A commentary. Radecki P. **Am J Phys Med Rehabil** 1996 May–Jun; 75(3):235–8 (27 ref.)

ULTRASONOGRAPHY

[Giant-cell tumor of the carpal tunnel, a color Doppler echographic study. A case report] Chiodi E, et al. **Radiol Med (Torino)** 1996 Jan–Feb;91(1–2):126–7 (9 ref.) **(Ita)**

MEDIASTINAL CYST

Cervical thymic cyst: case reports and review of the literature. Nguyen Q, et al. **Laryngoscope** 1996 Mar;106(3 Pt 1):247–52 (22 ref.)

MEDIASTINAL DISEASES

RADIOGRAPHY

[A mediastinal mass in a young man. Monostotic fibrous dysplasia] Sáez-Royuela A, et al. **Rev Clin Esp** 1995 Dec; 195(12):841–2 (8 ref.) **(Spa)**

MEDIASTINAL NEOPLASMS

Thymolipoma—a rare mediastinal tumour—report of two cases and review of literature. Sirpal YM, et al. **Indian J Cancer** 1995 Mar;32(1):23–6 (17 ref.)

BLOOD

Primary mediastinal malignant germ cell tumour. Single institution experience in Chinese patients and correlation with specific alpha-fetoprotein bends. Chan AT, et al. **Acta Oncol** 1996;35(2):221–7 (29 ref.)

COMPLICATIONS

Unusual cases of hyperparathyroidism [see comments] Vázquez-Quintana E, et al. **P R Health Sci J** 1995 Sep; 14(3):227–32 (8 ref.) Comment in: P R Health Sci J 1995 Sep;14(3):191–3.

[Mediastinal malignant schwannoma disclosed by pericardial tamponade in von Recklinghausen disease] Soulami S, et al. **Ann Cardiol Angeiol (Paris)** 1995 Oct;44(8):418–21 (11 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Extraosseous osteogenic sarcoma of the mediastinum occurring in a Chinese patient. Lin J, et al. **Clin Oncol (R Coll Radiol)** 1995;7(3):200–1 (10 ref.)

[The diagnosis of mediastinal lymphangioma in children] Hoeffel JC, et al. **Rev Mal Respir** 1996 Jul;13(3):287–93 (27 ref.) (Eng. Abstr.) **(Fre)**

[Cystic lymphangioma, lymphangiomatosis] Hutzelmann A, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1995 Oct;163(4):358–60 (11 ref.) **(Ger)**

[The diagnosis of mediastinal hemangioma with magnetic resonance. A case report] Faiaschi F, et al. **Radiol Med (Torino)** 1996 Jan–Feb;91(1–2):138–40 (11 ref.) **(Ita)**

EPIDEMIOLOGY

Extragonadal germ cell tumor: a clinical study. Bassetto MA, et al. **Anticancer Res** 1995 Nov–Dec;15(6B):2751–4 (17 ref.)

PATHOLOGY

[Surgical vein reconstruction in patients with tumor invasiveness of the superior caval system. Retrospective study of 7 cases] Jeanfaivre T, et al. **J Chir (Paris)** 1996 Apr;133(2):61–4 (19 ref.) (Eng. Abstr.) **(Fre)**

[Mediastinal large-cell lymphoma of B-cell (thymic?) type. An anatomo-clinical entity in development] Sanchez Fayos J, et al. **An Med Interna** 1996 Jan;13(1):37–9 (27 ref.) **(Spa)**

RADIOGRAPHY

Progressive mediastinal widening after therapy for Hodgkin's disease. Michel F, et al. **Acta Clin Belg** 1995;50(5):282–7 (36 ref.)

[Radiological criteria for laryngeal tumors and cervical metastases] Melchor Díaz MA, et al. **Acta Otorrinolaringol Esp** 1996 Jan–Feb;47(1):1–7 (17 ref.) (Eng. Abstr.) **(Spa)**

SECONDARY

Oncology imaging: nodal spread-intrathoracic nodes. Verschakelen JA, et al. **Eur Radiol** 1996;6(3):251–61 (76 ref.)

[Radiological criteria for laryngeal tumors and cervical metastases] Melchor Díaz MA, et al. **Acta Otorrinolaringol Esp** 1996 Jan–Feb;47(1):1–7 (17 ref.) (Eng. Abstr.) **(Spa)**

SURGERY

Immature mediastinal teratoma in a 2 1/2 year old Chinese girl. Yim AP, et al. **Aust N Z J Surg** 1996 Jun;66(6):420–2 (4 ref.)

Thoracoscopic management of posterior mediastinal tumors. Canvasser DA, et al. **Chest Surg Clin N Am** 1996 Feb; 6(1):53–67 (36 ref.)

Thoracoscopic resection of mediastinal tumors and the thymus. Kaiser LR. **Chest Surg Clin N Am** 1996 Feb; 6(1):41–52 (7 ref.)

Open approaches to posterior mediastinal tumors and the spine. Thurer RJ, et al. **Chest Surg Clin N Am** 1996 Feb; 6(1):117–38 (42 ref.)

Transverse sternothoracotomy. Wright C. **Chest Surg Clin N Am** 1996 Feb;6(1):149–56 (7 ref.)

Cystic neuroblastoma of infancy. Richards ML, et al. **J Pediatr Surg** 1995 Sep;30(9):1354–7 (16 ref.)

[New techniques in thoracic surgery. II] Andreassian B. **Presse Med** 1995 Jul 1–8;24(24):1127–32 (32 ref.) (Eng. Abstr.) **(Fre)**

[Malignant triton tumor of the posterior mediastinum treated by thoracoscopic approach. Apropos of a case] Pons F, et al. **Rev Pneumol Clin** 1995;51(6):338–42 (29 ref.) (Eng. Abstr.) **(Fre)**

[Mediastinal malignant tumor resection and superior vena cava revascularization. Resection of invasive thymoma with growth into the superior vena cava and right atrium using cardiopulmonary bypass] **Nippon Kyobu Geka Gakkai Zasshi** 1995 May;43(5):717–9 (4 ref.) **(Jpn)**

[Mediastinal schwannoma originating from the intrathoracic vagal nerve—a case report and review of the literature] Ohtaki A, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Sep;43(9):1675–9 (19 ref.) (Eng. Abstr.) **(Jpn)**

THERAPY

Primary mediastinal malignant germ cell tumour. Single institution experience in Chinese patients and correlation with specific alpha-fetoprotein bends. Chan AT, et al. **Acta Oncol** 1996;35(2):221–7 (29 ref.)

VETERINARY

Chylothorax and chylous ascites in a dog with mediastinal lymphangiosarcoma. Myers NC 3rd, et al. **J Am Anim Hosp Assoc** 1996 May–Jun;32(3):263–9 (32 ref.)

MEDIASTINITIS

COMPLICATIONS

[Primary acute osteomyelitis of the sternum associated with anterior mediastinitis] Tabib W, et al. **J Chir (Paris)** 1996 Jan;133(1):20–2 (10 ref.) (Eng. Abstr.) **(Fre)**

EPIDEMIOLOGY

Mediastinitis after coronary artery bypass graft surgery. Risk factors and long-term survival. Milano CA, et al. **Circulation** 1995 Oct 15;92(8):2245–51 (18 ref.)

ETIOLOGY

Postoperative mediastinitis: classification and management. El Oakley RM, et al. **Ann Thorac Surg** 1996 Mar; 61(3):1030–6 (80 ref.)

MICROBIOLOGY

Actinomyces odontolyticus thoracopulmonary infections. Two cases in lung and heart-lung transplant recipients and a review of the literature. Bassiri AG, et al. **Chest** 1996 Apr;109(4):1109–11 (10 ref.)

[A case report of mediastinitis due to methicillin resistant Staphylococcus aureus after total aortic arch replacement] Asano S, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Jun;44(6):814–9 (18 ref.) (Eng. Abstr.) **(Jpn)**

MEDIASTINOSCOPY

[Endosonography of the esophagus and mediastinum] Schüder G, et al. **Bildgebung** 1995 Oct;62 Suppl 2:29–34 (21 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Extended cervical mediastinoscopy. Ginsberg RJ. **Chest Surg Clin N Am** 1996 Feb;6(1):21–30 (12 ref.)

Cervical mediastinoscopy. Kirschner PA. **Chest Surg Clin N Am** 1996 Feb;6(1):1–20 (46 ref.)

MEDIASTINUM

see related
MEDIASTINOSCOPY

INJURIES

Cardiac and mediastinal trauma. Rosenthal MA, et al. **Emerg Med Clin North Am** 1995 Nov;13(4):887–902 (78 ref.)

PATHOLOGY

[Periaortic fibrosis with pericardial and perirenal involvement: apropos of a case] Cerisier A, et al. **Rev Med Interne** 1996;17(2):154–6 (11 ref.) (Eng. Abstr.) **(Fre)**

RADIATION EFFECTS

Pericardial angiosarcoma after mediastinal irradiation for seminoma. A case report and a review of the literature. Killion MJ, et al. **Cancer** 1996 Aug 15;78(4):912–7 (30 ref.)

SURGERY

Parasternal mediastinotomy (Chamberlain procedure). Olak J. **Chest Surg Clin N Am** 1996 Feb;6(1):31–40 (12 ref.)

MEDIATING see **NEGOTIATING**

MEDIATORS OF INFLAMMATION see **INFLAMMATION MEDIATORS**

MEDICAID

LEGISLATION & JURISPRUDENCE

Medicaid physician participation: patients, poverty, and physician self-interest. Watson SD. **Am J Law Med** 1995; 21(2-3):191-220 (232 ref.)

Prenatal care and public policy: lessons for promoting women's health. Hughes DC, et al. **J Am Med Wom Assoc** 1995 Sep-Oct;50(5):156-9, 163 (32 ref.)

ORGANIZATION & ADMINISTRATION

On the Oregon trail. Kitzhaber J, et al. **Br Med Bull** 1995 Oct;51(4):808-18 (0 ref.)

MCOs and Medicaid: a good combination. Molina MM. **Hosp Pract (Off Ed)** 1996 Apr 15;31(4):111-4 (7 ref.)

MEDICAL ASSISTANCE, TITLE 19 see **MEDICAID**

MEDICAL AUDIT

Endovascular stents in children under 1 year of age: acute impact and late results. Hatai Y, et al. **Br Heart J** 1995 Dec;74(6):689-95 (16 ref.)

A Scottish national audit of current patterns of management for patients with testicular non-seminomatous germ-cell tumours. The Scottish Radiological Society and the Scottish Committee of the Royal College of Radiologists. Howard GC, et al. **Br J Cancer** 1995 Nov;72(5):1303-6 (17 ref.)

METHODS

ABC of medical computing. Using computers in clinical audit. Kinn S, et al. **BMJ** 1995 Sep 16;311(7007):739-42 (0 ref.)

MEDICAL CARE COSTS see **HEALTH CARE COSTS**

MEDICAL CARE RESEARCH see **HEALTH SERVICES RESEARCH**

MEDICAL CARE TEAM see **PATIENT CARE TEAM**

MEDICAL CENTERS, ACADEMIC see **ACADEMIC MEDICAL CENTERS**

MEDICAL CENTERS, UNIVERSITY see **ACADEMIC MEDICAL CENTERS**

MEDICAL COMPUTER SCIENCE see **MEDICAL INFORMATICS**

MEDICAL DECISION MAKING, COMPUTER-ASSISTED see **DECISION MAKING, COMPUTER-ASSISTED**

MEDICAL DEVICE DESIGN see **EQUIPMENT DESIGN**

MEDICAL DEVICE SAFETY see **EQUIPMENT SAFETY**

MEDICAL DEVICES see **EQUIPMENT AND SUPPLIES**

MEDICAL DIRECTORS

ORGANIZATION & ADMINISTRATION

The medical director in the multi-level long-term care facility. Applebaum GE. **Clin Geriatr Med** 1995 Aug; 11(3):359-72 (4 ref.)

Omnibus Budget Reconciliation Act of 1987 and its implications for the medical director. Elon RD. **Clin Geriatr Med** 1995 Aug;11(3):419-32 (5 ref.)

The medical director in non-institutional long-term care programs. Finucane TE, et al. **Clin Geriatr Med** 1995 Aug; 11(3):391-402 (15 ref.)

The corporate medical director. Krein K. **Clin Geriatr Med** 1995 Aug;11(3):403-17 (10 ref.)

Policy and procedure development and implementation. Levenson SA. **Clin Geriatr Med** 1995 Aug;11(3):449-65 (8 ref.)

Current role of the medical director in community-based nursing facilities. Levinson MJ, et al. **Clin Geriatr Med** 1995 Aug;11(3):343-58 (10 ref.)

Total quality management and the medical director. Schnelle JF. **Clin Geriatr Med** 1995 Aug;11(3):433-48 (21 ref.)

The medical director in hospital-based transitional care units. Smith RL, et al. **Clin Geriatr Med** 1995 Aug;11(3):373-89 (11 ref.)

The future of long-term care and the role of the medical director. Willging P. **Clin Geriatr Med** 1995 Aug; 11(3):531-45 (10 ref.)

MEDICAL ECONOMICS see **ECONOMICS, MEDICAL**

MEDICAL EDUCATION see **EDUCATION, MEDICAL**

MEDICAL EDUCATION, CONTINUING see **EDUCATION, MEDICAL, CONTINUING**

MEDICAL EDUCATION, GRADUATE see **EDUCATION, MEDICAL, GRADUATE**

MEDICAL EDUCATION, UNDERGRADUATE see **EDUCATION, MEDICAL, UNDERGRADUATE**

MEDICAL EXAMINERS see **CORONERS AND MEDICAL EXAMINERS**

MEDICAL FUTILITY

see related

RESUSCITATION ORDERS

Foregoing renal dialysis: a case study and review of ethical issues. The End-Stage Renal Disease Group. Tobe SW, et al. **Am J Kidney Dis** 1996 Jul;28(1):147-53 (33 ref.)

Medical futility and implications for physician autonomy. Daar JF. **Am J Law Med** 1995;21(2-3):221-40 (117 ref.)

Medical futility: response to critiques [see comments] Schneiderman LJ, et al. **Ann Intern Med** 1996 Oct 15; 125(8):669-74 (64 ref.) Comment in: Ann Intern Med 1996 Oct 15;125(8):688-9.

Can healthcare providers obtain judicial intervention against surrogates who demand "medically inappropriate" life support for incompetent patients? [see comments] Cantor NL. **Crit Care Med** 1996 May;24(5):883-7 (28 ref.) Comment in: Crit Care Med 1996 May;24(5):730-2.

Futile care or caregiver frustration? A practical approach. Civetta JM. **Crit Care Med** 1996 Feb;24(2):346-51 (13 ref.)

Dworkin on dementia. Elegant theory, questionable policy. Dresser R. **Hastings Cent Rep** 1995 Nov-Dec;25(6):32-8 (17 ref.)

Medical futility and nursing. Taylor C. **Image J Nurs Sch** 1995 Winter;27(4):301-6 (37 ref.)

Restructuring the principle of medical futility. Smith GP 2nd. **J Palliat Care** 1995 Autumn;11(3):9-16 (40 ref.)

Ethical and legal barriers to futility policies. King NM. **N C Med J** 1995 Sep;56(9):444-8 (35 ref.)

The legislative role in defining medical futility. Warren DG. **N C Med J** 1995 Sep;56(9):453-5 (11 ref.)

MEDICAL HISTORY TAKING

see related

DATA COLLECTION

Refocusing on history-taking skills during internal medicine training. Schechter GP, et al. **Am J Med** 1996 Aug; 101(2):210-6 (54 ref.)

Family history of cancer. Lynch HT, et al. **Ann N Y Acad Sci** 1995 Sep 30;768:12-29 (33 ref.)

Guidelines for doctors on identifying and helping their patients who batter. Adams D. **J Am Med Womens Assoc** 1996 May-Jul;51(3):123-6 (22 ref.)

Occupational illness. Newman LS. **N Engl J Med** 1995 Oct 26;333(17):1128-34 (52 ref.)

[Respiratory allergies: some medical history elements are useful to the practitioner] Kaeser P, et al. **Rev Med Suisse Romande** 1996 Jun;116(6):415-21 (14 ref.) **(Fre)**

METHODS

Life histories in occupational therapy clinical practice. Frank G. **Am J Occup Ther** 1996 Apr;50(4):251-64 (121 ref.)

Woman abuse and pediatrics: expanding the web of detection. Barkan SE, et al. **J Am Med Womens Assoc** 1996 May-Jul; 51(3):96-100 (81 ref.)

STATISTICS & NUMERICAL DATA

Recall of psychiatric history in cross-sectional surveys: implications for epidemiologic research. Simon GE, et al. **Epidemiol Rev** 1995;17(1):221-7 (48 ref.)

MEDICAL ILLUSTRATION

A new representation of knowledge concerning human anatomy and function. Höhne KH, et al. **Nat Med** 1995 Jun;1(6):506-11 (33 ref.)

MEDICAL IMAGING see **DIAGNOSTIC IMAGING**

MEDICAL INDIGENCY

see related

MEDICALLY UNINSURED

Culture in treatment, culture as treatment. A critical appraisal of developments in addictions programs for indigenous North Americans and Australians. Brady M. **Soc Sci Med** 1995 Dec;41(11):1487-98 (78 ref.)

MEDICAL INFORMATICS

Nursing informatics: state of the science. Henry SB. **J Adv Nurs** 1995 Dec;22(6):1182-92 (83 ref.)

EDUCATION

Review of the state-of-the-art in education and training of health informatics in Europe. Hasman A, et al. **Comput Methods Programs Biomed** 1995 Sep-Oct; 48(1-2):183-8 (3 ref.)

Informing the nursing professions about IT. Barnett DE. **Medinfo** 1995;8 Pt 2:1316-20 (7 ref.)

TRENDS

Clinical informatics. Kazmierczak SC, et al. **Anal Chem** 1995 Jun 15;67(12):437R-441R (97 ref.)

Bridging theory and practice: cognitive science and medical informatics. Patel VL, et al. **Medinfo** 1995;8 Pt 2:1278-82 (26 ref.)

MEDICAL INFORMATICS APPLICATIONS

The challenge of managing laboratory information in a managed care environment. Friedman BA. **Am J Clin Pathol** 1996 Apr;105(4 Suppl 1):S3-9 (23 ref.)

Clinical computing: a view from the United Kingdom. Wyatt JC. **MD Comput** 1995 Sep-Oct;12(5):382-9 (57 ref.)

Medicine in virtual environments. Dumay AC. **Technol Health Care** 1995 Oct;3(2):75-89 (87 ref.)

[Informatics in the hospital] Melino C, et al. **Ann Ig** 1994 Jul-Dec;6(4-6):439-52 (39 ref.) (Eng. Abstr.) **(Ita)**

MEDICAL INFORMATION SCIENCE see **MEDICAL INFORMATICS**

MEDICAL JURISPRUDENCE see **JURISPRUDENCE**

MEDICAL ONCOLOGY

see related

NEOPLASMS

How to integrate serum tumor markers into clinical oncologic practice. van Dalen A. **Nutrition** 1995 Sep-Oct;11(5 Suppl):489-91 (21 ref.)

Why oncologists should get involved in practice guideline development. ASCO Health Services Committee Program. **Oncology (Huntingt)** 1995 May;9(5):412, 415 (0 ref.)

[Standards, options and recommendations for a successful practice in chemotherapy. National Federation of Centers for the Fight against Cancer] Heron JF, et al. **Bull Cancer (Paris)** 1995 Oct;82(10):823-34 (44 ref.) **(Fre)**

[Standards, options and recommendations for a successful practice in psycho-oncology. National Federation of Centers for the fight against cancer] Saltel P, et al. **Bull Cancer (Paris)** 1995 Oct;82(10):847-64 (55 ref.) **(Fre)**

ECONOMICS

The economics of reimbursement and technological change in cancer care [see comments] Kesteloot K. **Eur J Cancer** 1995;31A(9):1406-9 (22 ref.) Comment in: Eur J Cancer 1995;31A(9):1387.

European School of Oncology Advisory report to the Commission of the European Communities for the "Europe Against Cancer Programme" cost-effectiveness in cancer care [see comments] Williams C, et al. **Eur J Cancer** 1995; 31A(9):1410-24 (77 ref.) Comment in: Eur J Cancer 1995;31A(9):1387.

Current issues in oncology reimbursement. Bailes JS. **Oncology (Huntingt)** 1995 Nov;9(11 Suppl):185-9 (13 ref.)

The role of oncology clinical practice guidelines in the managed care era. Winn RJ. **Oncology (Huntingt)** 1995 Nov;9(11 Suppl):177-83 (28 ref.)

[Cancer and health economics] Koinuma N. **Gan To Kagaku Ryoho** 1996 Jan;23(1):1-7 (6 ref.) (Eng. Abstr.) **(Jpn)**

EDUCATION

Eat your cereal. Gardner B. **Ann Surg Oncol** 1996 Jan; 3(1):1-7 (13 ref.)

METHODS

The role of the occupational therapist in oncology. Penfold SL. **Cancer Treat Rev** 1996 Jan;22(1):75-81 (9 ref.)

European School of Oncology position paper. Gene therapy for the medical oncologist. Blaese M, et al. **Eur J Cancer** 1995;31A(9):1531-7 (17 ref.)

ORGANIZATION & ADMINISTRATION

The U.S.-Japan Cooperative Cancer Research Program: some highlights of seminars, interdisciplinary program area, 1981-1996. Miller RW. **Jpn J Cancer Res** 1996 Mar; 87(3):221-6 (20 ref.)

History and present organization of pediatric oncology in Germany. Hertl M. **Pediatr Hematol Oncol** 1995 Jul-Aug; 12(4):325-31 (10 ref.)

STANDARDS

Towards a high standard of surgical oncology throughout Europe. O'Higgins N. **Eur J Cancer** 1995;31A Suppl 6:S22-4 (4 ref.)

Clinical practice guidelines in oncology: pros and cons [editorial] Markman M. **J Cancer Res Clin Oncol** 1996; 122(7):381-2 (5 ref.)

STATISTICS & NUMERICAL DATA

The past and future of cancer in the young. Bleyer WA. **Pediatr Dent** 1995 Jul-Aug;17(4):285-90 (7 ref.)

TRENDS

What's new in surgical oncology. Norton JA. **J Am Coll Surg** 1996 Feb;182(2):122–9 (43 ref.)

[Therapy for the gastric cancer in the near future] Aoki T, et al. **Nippon Geka Gakkai Zasshi** 1996 Apr;97(4):317–22 (58 ref.) (Eng. Abstr.) **(Jpn)**

MEDICAL PSYCHOLOGY see **PSYCHOLOGY, MEDICAL**

MEDICAL RECORD LINKAGE

The hospital information system—integrated patient records. Scherrer JR. **Comput Methods Programs Biomed** 1995 Sep–Oct;48(1–2):1–6 (17 ref.)

DIALOG: co-ordination of the annual review process through a District Diabetes Register linked to the FHSA database. Vaughan NJ, et al. **Diabet Med** 1996 Feb; 13(2):182–8 (11 ref.)

The untapped potential of case registers and record-linkage studies in psychiatric epidemiology. Mortensen PB. **Epidemiol Rev** 1995;17(1):205–9 (36 ref.)

MEDICAL RECORDS

see related
FORMS AND RECORDS CONTROL
MEDICAL HISTORY TAKING

Case series analysis of adverse reactions to vaccines: a comparative evaluation. Farrington CP, et al. **Am J Epidemiol** 1996 Jun 1;143(11):1165–73 (18 ref.)

Patient data management systems in anaesthesia: an emerging technology. Weiss YG, et al. **Can J Anaesth** 1995 Oct; 42(10):914–21 (32 ref.)

A clinically useful diabetes electronic medical record: lessons from the past; pointers toward the future. Gorman C, et al. **Eur J Endocrinol** 1996 Jan;134(1):31–42 (39 ref.)

Privacy, confidentiality, and electronic medical records. Barrows RC Jr, et al. **J Am Med Inform Assoc** 1996 Mar–Apr;3(2):139–48 (42 ref.)

Using health care records as sources of data for research. vonKoss Krowchuk H, et al. **J Nurs Meas** 1995 Summer; 3(1):3–12 (21 ref.)

MRC quality of life studies using a daily diary card—practical lessons learned from cancer trials. Fayers P. **Qual Life Res** 1995 Aug;4(4):343–52 (42 ref.)

LEGISLATION & JURISPRUDENCE

Preserving confidentiality in occupational medical practice. McCunney RJ. **Am Fam Physician** 1996 Apr;53(5):1751–60 (19 ref.)

In camera inspections of privileged records in sexual assault trials: balancing defendants' rights and state interests under Massachusetts's Bishop Test. Crowley EM. **Am J Law Med** 1995;21(1):131–64 (313 ref.)

STANDARDS

Recommendations for the reporting of urinary bladder specimens containing bladder neoplasms. Association of Directors of Anatomic and Surgical Pathology. **Virchows Arch** 1996 Apr;428(1):1–3 (6 ref.)

MEDICAL RECORDS SYSTEMS, COMPUTERIZED

Modern image capture and data collection technology. Shafi MI, et al. **Clin Obstet Gynecol** 1995 Sep;38(3):640–3 (9 ref.)

Clinical decision support—how, when and for whom. Wigertz O. **Comput Methods Programs Biomed** 1995 Sep–Oct;48(1–2):15–20 (25 ref.)

DIALOG: co-ordination of the annual review process through a District Diabetes Register linked to the FHSA database. Vaughan NJ, et al. **Diabet Med** 1996 Feb; 13(2):182–8 (11 ref.)

A clinically useful diabetes electronic medical record: lessons from the past; pointers toward the future. Gorman C, et al. **Eur J Endocrinol** 1996 Jan;134(1):31–42 (39 ref.)

The computer-based patient record: the role of the hospital epidemiologist. Classen DC, et al. **Infect Control Hosp Epidemiol** 1995 Dec;16(12):729–36 (32 ref.)

Australian healthcare: a smart card for a clever country. Morris S, et al. **Int J Biomed Comput** 1995 Oct;40(2):101–5 (14 ref.)

AIDS nursing care and standardized nursing language: an application of the nursing intervention classification. Davis KA. **J Assoc Nurses AIDS Care** 1995 Nov–Dec;6(6):37–44 (17 ref.)

Clinical computing: a view from the United Kingdom. Wyatt JC. **MD Comput** 1995 Sep–Oct;12(5):382–9 (57 ref.)

Computerized patient record for a department of respiratory rehabilitation. Ballardini L, et al. **Monaldi Arch Chest Dis** 1996 Apr;51(2):153–8 (12 ref.)

Reporting and communications. Bauman RA. **Radiol Clin North Am** 1996 May;34(3):597–606 (54 ref.)

CLASSIFICATION

Exploring the functions of World Wide Web-based electronic medical record systems [see comments] Kohane IS. **MD Comput** 1996 Jul–Aug;13(4):339–46 (28 ref.) Comment in: MD Comput 1996 Jul–Aug;13(4):295–7.

ECONOMICS

Including oncology outcomes of care in the computer-based patient record. McCormick KA. **Oncology (Huntingt)** 1995 Nov;9(11 Suppl):161–7 (44 ref.)

INSTRUMENTATION

Application of computers in diabetes care—a review. I. Computers for data collection and interpretation. Lehmann ED, et al. **Med Inf (Lond)** 1995 Oct–Dec;20(4):281–302 (142 ref.)

LEGISLATION & JURISPRUDENCE

Confidentiality of HIV medical records: the computer age. Byrd CM, et al. **Prog Cardiovasc Nurs** 1995 Fall; 10(4):39–43, 45 (17 ref.)

ORGANIZATION & ADMINISTRATION

Exploring the functions of World Wide Web-based electronic medical record systems [see comments] Kohane IS. **MD Comput** 1996 Jul–Aug;13(4):339–46 (28 ref.) Comment in: MD Comput 1996 Jul–Aug;13(4):295–7.

MEDICAL RESEARCH see **RESEARCH**

MEDICAL SCHOOLS see **SCHOOLS, MEDICAL**

MEDICAL SOCIOLOGY see **SOCIOLOGY, MEDICAL**

MEDICAL STAFF, HOSPITAL

Management of asthma in the hospital emergency department. Beasley R, et al. **Br J Hosp Med** 1996 Mar 6–19;55(5):253–7 (18 ref.)

The leadership dance. Ehrat KS, et al. **J Nurs Adm** 1996 Apr;26(4):13–5 (14 ref.)

LEGISLATION & JURISPRUDENCE

[What can the hospital deliver? What must the hospital deliver?] Pannike A. **Unfallchirurgie** 1995 Aug;21(4):204–18 (68 ref.) **(Ger)**

ORGANIZATION & ADMINISTRATION

You are in charge of cost. Loop FD. **Ann Thorac Surg** 1995 Nov;60(5):1509–12 (3 ref.)

PSYCHOLOGY

The practice of anaesthesia—a stressor for the middle-aged? Seeley HF. **Anaesthesia** 1996 Jun;51(6):571–4 (16 ref.)

STANDARDS

Quality improvement and substance abuse: rethinking impaired provider policies. Corsino BV, et al. **Am J Med Qual** 1996 Summer;11(2):94–9 (21 ref.)

MEDICAL STAFF PRIVILEGES

Privileges, credentialing, and liability. Musallam LS. **Prim Care** 1995 Sep;22(3):491–8 (12 ref.)

Training and privileging for new procedures. Dent TL. **Surg Clin North Am** 1996 Jun;76(3):615–21 (28 ref.)

MEDICAL STAFF PRIVILEGES, NONPHYSICIAN see **MEDICAL STAFF PRIVILEGES**

MEDICAL TECHNOLOGY see **TECHNOLOGY, MEDICAL**

MEDICAL TRANSCRIPTION see **MEDICAL RECORDS**

MEDICAL WASTE

see related
BLOOD-BORNE PATHOGENS

Managing the infectious waste of the surgery unit and laboratory. Hoeltge GA. **Semin Dermatol** 1995 Sep; 14(3):247–51 (9 ref.)

MEDICAL WASTE DISPOSAL

METHODS

Hospitals and plastics. Dioxin prevention and medical waste incinerators. Thornton J, et al. **Public Health Rep** 1996 Jul–Aug;111(4):299–313 (121 ref.)

MEDICALLY ASSISTED SUICIDE see **SUICIDE, ASSISTED**

MEDICALLY UNDERINSURED see **MEDICALLY UNINSURED**

MEDICALLY UNDERSERVED AREA

see related
HEALTH SERVICES ACCESSIBILITY

The virtual health economy: telemedicine and the supply of primary care physicians in rural America. McCarthy D. **Am J Law Med** 1995;21(1):111–30 (176 ref.)

A research agenda for health education among underserved populations. Marin G, et al. **Health Educ Q** 1995 Aug; 22(3):346–63 (86 ref.)

De facto mental health services in the rural south. Fox J, et al. **J Health Care Poor Underserved** 1995;6(4):434–68 (190 ref.)

The development of Ontario's Home Care Program: a critical geographical analysis. Williams AM. **Soc Sci Med** 1996 Mar;42(6):937–48 (52 ref.)

MEDICALLY UNINSURED

LEGISLATION & JURISPRUDENCE

Prenatal care and public policy: lessons for promoting women's health. Hughes DC, et al. **J Am Med Wom Assoc** 1995 Sep–Oct;50(5):156–9, 163 (32 ref.)

MEDICARE

LEGISLATION & JURISPRUDENCE

Privacy and autonomy in the physician–patient relationship. Independent contracting under Medicare and implications for expansion into managed care. Coleman PG, et al. **J Leg Med** 1995 Dec;16(4):509–43 (197 ref.)

STANDARDS

Developing a quality improvement database using health insurance data: a guided tour with application to Medicare's National Claims History file. Parente ST, et al. **Am J Med Qual** 1995 Winter;10(4):162–76 (21 ref.)

Securing health care quality for Medicare. Palmer RH. **Health Aff (Millwood)** 1995 Winter;14(4):89–100 (31 ref.)

TRENDS

Entitlements and the federal budget: facts, folklore, and future. Gist JR. **Milbank Q** 1996;74(3):327–59 (42 ref.)

MEDICARE ASSIGNMENT

LEGISLATION & JURISPRUDENCE

Medicaid physician participation: patients, poverty, and physician self-interest. Watson SD. **Am J Law Med** 1995; 21(2–3):191–220 (232 ref.)

MEDICINAL HERBS see **PLANTS, MEDICINAL**

MEDICINE

see related
ECONOMICS, MEDICAL
EDUCATION, MEDICAL
HEALTH MANPOWER
LEGISLATION, MEDICAL

The medicalization of race: scientific legitimization of a flawed social construct [see comments] Witzig R. **Ann Intern Med** 1996 Oct 15;125(8):675–9 (57 ref.) Comment in: Ann Intern Med 1996 Oct 15;125(8):688–9.

Nudity in clinical photography: a literature review and the quest for standardization. Peres M, et al. **J Biol Photogr** 1996 Jan;64(1):3–13 (25 ref.)

Rituals and roles in medical practice. Elks ML. **Perspect Biol Med** 1996 Summer;39(4):601–9 (28 ref.)

[New horizons for medicine on the basis of genetic technology] Werner RG. **Arzneimittelforschung** 1995 Sep; 45(9):1040–7 (30 ref.) (Eng. Abstr.) **(Ger)**

MEDICINE, AFRICAN TRADITIONAL

[Myth reconstruction and health representations in a Southern Congolese therapeutic sect] Hagenbucher-Sacripanti F. **Sante** 1996 Jan–Feb;6(1):43–52 (6 ref.) **(Fre)**

MEDICINE, ALTERNATIVE see **ALTERNATIVE MEDICINE**

MEDICINE, AYURVEDIC

Ayurvedic herbal drugs with possible cytostatic activity. Smit HF, et al. **J Ethnopharmacol** 1995 Jul 7;47(2):75–84 (53 ref.)

MEDICINE, CHINESE TRADITIONAL

see related
DRUGS, CHINESE HERBAL

Medical applications of qigong. Sancier KM. **Altern Ther Health Med** 1996 Jan;2(1):40–6 (45 ref.)

Chinese Confucian culture and the medical ethical tradition. Guo Z. **J Med Ethics** 1995 Aug;21(4):239–46 (13 ref.)

Traditional Chinese herbal medicine. Zhu YP, et al. **Pharm World Sci** 1995 Jul 28;17(4):103–12 (49 ref.)

The language of acupuncture: should Western physicians learn it? Erickson JK. **Pharos** 1995 Fall;58(4):21–5 (14 ref.)

[The status quo and prospect of experimental study on channel tropism of Chinese herbal drugs] Liang A, et al. **Chung Kuo Chung Yao Tsa Chih** 1996 Jan;21(1):58–60,

MEDICINE, CHINESE TRADITIONAL

inside back cover (15 ref.) (Eng. Abstr.) **(Chi)**

MEDICINE, COMPLEMENTARY see **ALTERNATIVE MEDICINE**

MEDICINE, EMPORIATRIC see **TRAVEL**

MEDICINE, FOLK see **MEDICINE, TRADITIONAL**

MEDICINE, HERBAL

see related
DRUGS, CHINESE HERBAL
PLANTS, MEDICINAL

Pennyroyal toxicity: measurement of toxic metabolite levels in two cases and review of the literature. Anderson IB, et al. **Ann Intern Med** 1996 Apr 15;124(8):726–34 (46 ref.)
Recent advances in pharmacognosy research in China. Wang ZT, et al. **Gen Pharmacol** 1995 Oct;26(6):1211–24 (186 ref.)
Traditional Chinese herbal medicine. Zhu YP, et al. **Pharm World Sci** 1995 Jul 28;17(4):103–12 (49 ref.)
Balancing hot and cold—balancing power and weakness: social and cultural aspects of Malay jamu in Singapore. Tuschinsky C. **Soc Sci Med** 1995 Dec;41(11):1587–95 (18 ref.)
Phytotherapy in treatment of benign prostatic hyperplasia: a critical review. Lowe FC, et al. **Urology** 1996 Jul; 48(1):12–20 (55 ref.)

MEDICINE, HINDU see **MEDICINE, AYURVEDIC**

MEDICINE, INDIGENOUS see **MEDICINE, TRADITIONAL**

MEDICINE, ORIENTAL TRADITIONAL

Balancing hot and cold—balancing power and weakness: social and cultural aspects of Malay jamu in Singapore. Tuschinsky C. **Soc Sci Med** 1995 Dec;41(11):1587–95 (18 ref.)

MEDICINE, PRIMITIVE see **MEDICINE, TRADITIONAL**

MEDICINE, TRADITIONAL

see related
HEALTH SERVICES, INDIGENOUS

Interpreting culture and psychopathology: primitivist themes in cross-cultural debate. Lucas RH, et al. **Cult Med Psychiatry** 1995 Sep;19(3):287–326 (115 ref.)
Culture in treatment, culture as treatment. A critical appraisal of developments in addictions programs for indigenous North Americans and Australians. Brady M. **Soc Sci Med** 1995 Dec;41(11):1487–98 (78 ref.)
Therapeutic utility, constituents and toxicity of some medicinal plants: a review. Bakhiet AO, et al. **Vet Hum Toxicol** 1995 Jun;37(3):255–8 (76 ref.)
[Therapeutic effectiveness of Crataegus] Weihmayr T, et al. **Fortschr Med** 1996 Jan 20;114(1–2):27–9 (30 ref.) (Eng. Abstr.) **(Ger)**
[Traditional medicine: its influence on the concepts of health and disease] Ahmed AM, et al. **Ann Ig** 1995 May–Jun; 7(3):201–8 (34 ref.) (Eng. Abstr.) **(Ita)**

HISTORY

The ethnopharmacopoeia of Rotuma. McClatchey W. **J Ethnopharmacol** 1996 Mar;50(3):147–56 (9 ref.)
Psychoactive constituents of the genus Sceletium N.E.Br. and other Mesembryanthemaceae: a review. Smith MT, et al. **J Ethnopharmacol** 1996 Mar;50(3):119–30 (67 ref.)

MEDICINE, VETERINARY see **VETERINARY MEDICINE**

MEDITERRANEAN FEVER, FAMILIAL see **PERIODIC DISEASE**

MEDITERRANEAN FRUIT FLY see **DIPTERA**

MEDPHALAN see **MELPHALAN**

MEDROGESTONE

PHARMACOLOGY

The effects of estradiol valerate plus medroxyprogesterone acetate and conjugated estrogens plus medrogestone on climacteric symptoms and metabolic variables in perimenopausal women. Egarter C, et al. **Acta Obstet Gynecol Scand** 1996 Apr;75(4):386–93 (40 ref.)

MEDROXYPROGESTERONE

PHARMACOLOGY

The effects of estradiol valerate plus medroxyprogesterone acetate and conjugated estrogens plus medrogestone on climacteric symptoms and metabolic variables in perimenopausal women. Egarter C, et al. **Acta Obstet Gynecol Scand** 1996 Apr;75(4):386–93 (40 ref.)

MEDROXYPROGESTERONE 17-ACETATE

Use of depot medroxyprogesterone acetate contraception in adolescents. Davis AJ. **J Reprod Med** 1996 May;41(5 Suppl):407–13 (15 ref.)
Depot medroxyprogesterone acetate contraception in women with medical problems. Frederiksen MC. **J Reprod Med** 1996 May;41(5 Suppl):414–8 (32 ref.)

ADVERSE EFFECTS

Depot medroxyprogesterone acetate contraception and the risk of breast and gynecologic cancer. Kaunitz AM. **J Reprod Med** 1996 May;41(5 Suppl):419–27 (38 ref.)
Counseling issues and management of side effects for women using depot medroxyprogesterone acetate contraception. Nelson AL. **J Reprod Med** 1996 May;41(5 Suppl):391–400 (27 ref.)
Depot medroxyprogesterone acetate contraception. Metabolic parameters and mood changes. Westhoff C. **J Reprod Med** 1996 May;41(5 Suppl):401–6 (28 ref.)

PHARMACOKINETICS

Pharmacokinetics of depot medroxyprogesterone acetate contraception. Mishell DR Jr. **J Reprod Med** 1996 May; 41(5 Suppl):381–90 (11 ref.)

PHARMACOLOGY

The contraceptive use of depot medroxyprogesterone acetate. Hickey M, et al. **Clin Obstet Gynecol** 1995 Dec; 38(4):849–58 (20 ref.)
Continuous combined estrogen/progestin hormone replacement therapy. Andrews WC. **Clin Ther** 1995 Sep–Oct;17(5):812–26; discussion 811 (70 ref.)

THERAPEUTIC USE

Policing "perversions": Depo-Provera and John Money's new sexual order. Tsang DC. **J Homosex** 1995;28(3–4):397–426 (110 ref.)
Noncontraceptive benefits and therapeutic uses of depot medroxyprogesterone acetate. Cullins VE. **J Reprod Med** 1996 May;41(5 Suppl):428–33 (57 ref.)
[Recent problems on the endocrine and chemotherapy] Nishiya I, et al. **Hum Cell** 1995 Sep;8(3):107–14 (39 ref.) (Eng. Abstr.) **(Jpn)**

MEDULLA OBLONGATA

ANATOMY & HISTOLOGY

Two distinct descending inputs to the cricothyroid motoneuron in the medulla originating from the amygdala and the lateral hypothalamic area. Arita H, et al. **Adv Exp Med Biol** 1995;393:53–8 (10 ref.)

PATHOLOGY

Multiple neuroepithelial tumors of different cell types—case report. Akai T, et al. **Neurol Med Chir (Tokyo)** 1995 Dec; 35(12):901–4 (9 ref.)

PHYSIOLOGY

Pre-sympathetic neurones in the rostral ventrolateral medulla of the rat: electrophysiology, morphology and relationship to adjacent neuronal groups. Lipski J, et al. **Acta Neurobiol Exp (Warsz)** 1996;56(1):373–84 (44 ref.)
Retrotrapezoid nucleus (RTN) metabotropic glutamate receptors and long-term stimulation of ventilatory output. RTN glutamate receptors and breathing. Nattie EE, et al. **Adv Exp Med Biol** 1995;393:39–45 (27 ref.)
Relationship of rostral ventrolateral medullary neurons and angiotensin in the central control of blood pressure. Chan YS, et al. **Biol Signals** 1995 May–Jun;4(3):133–41 (42 ref.)

PHYSIOPATHOLOGY

From basal ganglia to motoneurons. Probable involvement of pathways relaying in the medulla. Delwaide PJ, et al. **Adv Neurol** 1996;69:111–6 (26 ref.)

MEDULLOBLASTOMA

CONGENITAL

Congenital CNS primitive neuroectodermal tumor: case report and review of the literature. Mitchell D, et al. **Pediatr Pathol Lab Med** 1995 Nov–Dec;15(6):949–56 (30 ref.)

DIAGNOSIS

Medulloblastoma in adults. Sheikh BY, et al. **J Neurosurg Sci** 1994 Dec;38(4):229–34 (21 ref.)

DRUG THERAPY

Cyclophosphamide therapy of medulloblastoma: from the laboratory to the clinic and back again (and again and again). Friedman HS, et al. **J Neurooncol** 1995;24(1):103–8 (21 ref.)

GENETICS

The cellular and molecular biology of medulloblastoma. Peringa J, et al. **Curr Opin Neurol** 1995 Dec;8(6):437–40 (20 ref.)

PATHOLOGY

Medullocytoma (lipidized medulloblastoma). A cerebellar neoplasm of adults with favorable prognosis. Giangaspero F, et al. **Am J Surg Pathol** 1996 Jun;20(6):656–64 (29 ref.)
Lipomatous medulloblastoma in adults. A distinct clinicopathological entity. Soylemezoglu F, et al. **Am J Surg Pathol** 1996 Apr;20(4):413–8 (33 ref.)

RADIOTHERAPY

An audit of craniospinal irradiation for medulloblastoma in Newcastle 1970–1992. Tinkler D, et al. **Clin Oncol (R Coll Radiol)** 1995;7(3):179–83 (21 ref.)
Radiation-induced meningioma in children: report of two cases and review of the literature. Starshak RJ. **Pediatr Radiol** 1996;26(8):537–41 (30 ref.)

MEDULLOMYOBLASTOMA see **MEDULLOBLASTOMA**

MEFLOQUINE

PHARMACOLOGY

Effects of mefloquine on Ca2+ uptake by crude microsomes of rabbit skeletal muscle. Go ML, et al. **Arch Int Pharmacodyn Ther** 1995 Mar–Apr;329(2):255–71 (29 ref.)

THERAPEUTIC USE

[Correct usage of amino alcohols] Touze JE. **Med Trop (Mars)** 1995;55(3 Suppl):24–5 (8 ref.) **(Fre)**

MEGACOLON, CONGENITAL see **HIRSCHSPRUNG DISEASE**

MEGACOLON, TOXIC

COMPLICATIONS

[Pseudomembranous colitis complicated with toxic megacolon. Report of a case] Fernández-Guisasola J, et al. **Rev Esp Anestesiol Reanim** 1995 Nov;42(9):389–91 (44 ref.) (Eng. Abstr.) **(Spa)**

MEGAESOPHAGUS see **ESOPHAGEAL ACHALASIA**

MEGAKARYOBLASTIC LEUKEMIA, ACUTE see **LEUKEMIA, MEGAKARYOCYTIC, ACUTE**

MEGAKARYOCYTES

TGF-beta and megakaryocytes in the pathogenesis of myelofibrosis in myeloproliferative disorders. Martyré MC. **Leuk Lymphoma** 1995 Dec;20(1–2):39–44 (58 ref.)

CYTOLOGY

Megakaryocytopoiesis: cellular aspects and regulation. Vainchenker W, et al. **Crit Rev Oncol Hematol** 1995 Aug; 20(1–2):165–92 (366 ref.)
Characteristic biological features of human megakaryoblastic leukaemia cell lines. Hassan HT, et al. **Leuk Res** 1995 Sep; 19(9):589–94 (60 ref.)
Thrombopoietin: biological and preclinical properties. Kaushansky K. **Leukemia** 1996 Apr;10 Suppl 1:S46–8 (20 ref.)
Preclinical biology of interleukin 11: a multifunctional hematopoietic cytokine with potent thrombopoietic activity. Goldman SJ. **Stem Cells (Dayt)** 1995 Sep; 13(5):462–71 (39 ref.)
Megakaryocytopoiesis: the state of the art. Gewirtz AM. **Thromb Haemost** 1995 Jul;74(1):204–9 (86 ref.)
Thrombopoietin: the primary regulator of megakaryocyte and platelet production. Kaushansky K. **Thromb Haemost** 1995 Jul;74(1):521–5 (43 ref.)
Regulation of gene transcription during the differentiation of megakaryocytes. Uzan G, et al. **Thromb Haemost** 1995 Jul;74(1):210–2 (20 ref.)
c-mpl, the thrombopoietin receptor. Vainchenker W, et al. **Thromb Haemost** 1995 Jul;74(1):526–8 (15 ref.)
[Megakaryocytopoiesis] Koloskov AV. **Gematol Transfuziol** 1995 Sep–Oct;40(5):29–33 (165 ref.) **(Rus)**

DRUG EFFECTS

Effect of interleukin 11 on normal and pathological thrombopoiesis. Teramura M, et al. **Cancer Chemother Pharmacol** 1996;38 Suppl:S99–102 (27 ref.)

ENZYMOLOGY

Phospholipase D in platelets and megakaryocytic cells. Halenda SP, et al. **Chem Phys Lipids** 1996 May 24; 80(1–2):21–6 (18 ref.)
Tyrosine kinases in megakaryocytopoiesis. Avraham H, et al. **Stem Cells (Dayt)** 1995 Jul;13(4):380–92 (141 ref.)

PHYSIOLOGY

[Cloning of thrombopoietin and its physiologic role in megakaryocytopoiesis and thrombopoiesis] Miyazaki H. **Rinsho Ketsueki** 1996 Jan;37(1):1–6 (19 ref.) **(Jpn)**

[Megakaryocytes as a component of bone marrow–blood barrier] Dzięcioł J. **Pol Arch Med Wewn** 1995 May; 93(5):433–8 (40 ref.) **(Pol)**

MEGAKARYOCYTIC LEUKEMIA see **LEUKEMIA, MEGAKARYOCYTIC, ACUTE**

MEGAKARYOCYTIC LEUKEMIA, ACUTE see **LEUKEMIA, MEGAKARYOCYTIC, ACUTE**

MEGAVITAMIN THERAPY see **ORTHOMOLECULAR THERAPY**

MEGAVOLT RADIOTHERAPY see **RADIOTHERAPY, HIGH-ENERGY**

MEGLUMINE

ANALOGS & DERIVATIVES

Liver. III: Gadolinium–based hepatobiliary contrast agents (Gd–EOB–DTPA and Gd–BOPTA/Dimeg). Giovagnoni A, et al. **Magn Reson Imaging Clin N Am** 1996 Feb; 4(1):61–72 (34 ref.)

MEIBOMIAN GLANDS

Meibomian gland dysfunction. Driver PJ, et al. **Surv Ophthalmol** 1996 Mar–Apr;40(5):343–67 (224 ref.)

ABNORMALITIES

Absent meibomian glands: a marker for EEC syndrome. Bonnar E, et al. **Eye** 1996;10 (Pt 3):355–61 (34 ref.)

PHYSIOPATHOLOGY

Chronic blepharitis: a review. Smith RE, et al. **CLAO J** 1995 Jul;21(3):200–7 (81 ref.)

MEIGS' SYNDROME

BLOOD

Meigs' syndrome with elevated serum CA 125 levels: two case reports and review of the literature. Timmerman D, et al. **Gynecol Oncol** 1995 Dec;59(3):405–8 (20 ref.)

SURGERY

[Meigs' syndrome. A case report] Vescio G, et al. **G Chir** 1996 Apr;17(4):178–80 (6 ref.) (Eng. Abstr.) **(Ita)**

MEIOSIS

see related
MATURATION–PROMOTING FACTOR

Meiotic sister chromatid recombination. Petes TD, et al. **Adv Genet** 1995;33:41–62 (68 ref.)

Meiotic recombination: a mechanism for tracking and eliminating mutations? McKee BD. **Bioessays** 1996 May; 18(5):411–9 (72 ref.)

Going mobile: microtubule motors and chromosome segregation. Barton NR, et al. **Proc Natl Acad Sci U S A** 1996 Mar 5;93(5):1735–42 (139 ref.)

Meiosis: how could it work? Kleckner N. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8167–74 (103 ref.)

Meiosis in Drosophila: seeing is believing. Orr–Weaver TL. **Proc Natl Acad Sci U S A** 1995 Nov 7;92(23):10443–9 (59 ref.)

Sex and the single cell: meiosis in yeast. Roeder GS. **Proc Natl Acad Sci U S A** 1995 Nov 7;92(23):10450–6 (93 ref.)

Chromosomal control of meiotic cell division. McKim KS, et al. **Science** 1995 Dec 8;270(5242):1595–601 (53 ref.)

Meiotic cycle checkpoints in mammalian oocytes. Fulka J Jr, et al. **Zygote** 1994 Nov;2(4):351–4 (19 ref.)

GENETICS

The bond between sisters [comment] Sekelsky JJ, et al. **Cell** 1995 Oct 20;83(2):157–60 (23 ref.) Comment on: Cell 1995 Oct 20;83(2):247–56.

Genetic control of mitosis, meiosis and cellular differentiation during mammalian spermatogenesis. Wolgemuth DJ, et al. **Reprod Fertil Dev** 1995;7(4):669–83 (141 ref.)

MEISSNER'S CORPUSCLE see **MECHANORECEPTORS**

MELANCHOLIA see **DEPRESSIVE DISORDER**

MELANCHOLIA, INVOLUTIONAL see **DEPRESSION, INVOLUTIONAL**

MELANINS

ANALYSIS

Neurotropic melanoma with prominent melanization. Barnhill RL, et al. **J Cutan Pathol** 1995 Oct;22(5):450–9 (44 ref.)

BIOSYNTHESIS

Tyrosinase and related proteins in mammalian pigmentation. del Marmol V, et al. **FEBS Lett** 1996 Mar 4;381(3):165–8 (48 ref.)

Longitudinal melanonychia induced by hydroxyurea: four case reports and review of the literature. Delmas–Marsalet B, et al. **Nouv Rev Fr Hematol** 1995;37(3):205–10 (17 ref.)

Free radical activity of melanins and related substances: biochemical and pathobiochemical aspects. Borovanský J. **Sb Lek** 1996;97(1):49–70 (146 ref.)

Metabolic interference of melanogenesis in pigment cells. Pavel S, et al. **Sb Lek** 1996;97(1):29–39 (51 ref.)

Melanogenic factors: regulation of gene expression. Vachtenheim J, et al. **Sb Lek** 1996;97(1):41–7 (39 ref.)

GENETICS

Melanogenic factors: regulation of gene expression. Vachtenheim J, et al. **Sb Lek** 1996;97(1):41–7 (39 ref.)

PHYSIOLOGY

Immune response in insects: the role of phenoloxidase in defense reactions in relation to melanization and sclerotization. Marmaras VJ, et al. **Arch Insect Biochem Physiol** 1996;31(2):119–33 (56 ref.)

On the functional of neuromelanin. Smythies J. **Proc R Soc Lond B Biol Sci** 1996 Apr 22;263(1369):487–9 (31 ref.)

MELANISM see **MELANOSIS**

MELANOCYTE–STIMULATING HORMONES see **MSH**

MELANOCYTES

Alterations in gene expression and signal transductions in human melanocytes and melanoma cells. Yamanishi DT, et al. **Crit Rev Oncog** 1994;5(5):429–50 (143 ref.)

PHYSIOLOGY

Melanocyte–stimulating hormone: a regulator of human melanocyte physiology. Hunt G. **Pathobiology** 1995; 63(1):12–21 (77 ref.)

MELANOMA

Alterations in gene expression and signal transductions in human melanocytes and melanoma cells. Yamanishi DT, et al. **Crit Rev Oncog** 1994;5(5):429–50 (143 ref.)

Lentigo maligna and lentigo maligna melanoma. Cohen LM. **J Am Acad Dermatol** 1995 Dec;33(6):923–36; quiz 937–40 (225 ref.)

Melanoma. Rivers JK. **Lancet** 1996 Mar 23;347(9004):803–6 (39 ref.)

Malignant melanomas—how many have you missed? Kelly JW. **Med J Aust** 1996 Apr 1;164(7):431–6 (25 ref.)

Malignant melanoma of the vulva: a review. Dunton CJ, et al. **Obstet Gynecol Surv** 1995 Oct;50(10):739–46 (43 ref.)

Malignant melanoma of the lacrimal sac. Owens RM, et al. **Otolaryngol Head Neck Surg** 1995 Nov;113(5):634–40 (27 ref.)

Vulvar melanoma. Panizzon RG. **Semin Dermatol** 1996 Mar; 15(1):67–70 (20 ref.)

Primary mucosal malignant melanoma of the larynx: case report and review of the literature. Mattavelli F, et al. **Tumori** 1995 Nov–Dec;81(6):460–3 (25 ref.)

[Malignant melanoma of the gallbladder] Saoshiro T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):240–2 (12 ref.) **(Jpn)**

BLOOD SUPPLY

[Incident light microscopic characterization of vascular patterns in skin tumors] Kreusch J, et al. **Hautarzt** 1996 Apr;47(4):264–72 (21 ref.) (Eng. Abstr.) **(Ger)**

CHEMICALLY INDUCED

[Levodopa and malignant melanoma—case report and review of the literature. A contribution to causal relationship between levodopa and the development of malignant melanoma] Kleinhans M, et al. **Hautarzt** 1996 Jun; 47(6):432–7 (29 ref.) (Eng. Abstr.) **(Ger)**

COMPLICATIONS

Congestive heart failure due to rapid right ventricular obliteration by metastatic malignant melanoma. Rusconi C, et al. **Minerva Cardioangiol** 1996 Mar;44(3):123–5 (8 ref.)

[Desmoplastic and neurotropic subungueal melanoma] Rongioletti F, et al. **Ann Dermatol Venereol** 1995; 122(10):707–10 (20 ref.) (Eng. Abstr.) **(Fre)**

[Paraneoplastic retinopathy associated with cutaneous melanoma. An update apropos of a case] Rougier MB, et al. **J Fr Ophtalmol** 1995;18(5):396–403 (16 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

The current status of melanoma early detection and screening. Koh HK, et al. **Dermatol Clin** 1995 Jul; 13(3):623–34 (80 ref.)

Management of stage I malignant melanoma. Greenstein DS, et al. **Dermatol Surg** 1995 Nov;21(11):927–37; quiz 938–9 (96 ref.)

Discordance in the histopathologic diagnosis of melanoma and melanocytic nevi between expert pathologists. Farmer ER, et al. **Hum Pathol** 1996 Jun;27(6):528–31 (22 ref.)

Hutchinson's sign: a reappraisal. Baran R, et al. **J Am Acad Dermatol** 1996 Jan;34(1):87–90 (21 ref.)

Malignant melanoma of soft parts involving the head and neck region: review of literature and case report. Hicks MJ, et al. **Ultrastruct Pathol** 1995 Sep–Oct;19(5):395–400 (28 ref.)

[After excision of primary melanoma should an initial evaluation be performed? Point of view of a French dermatologist] Bonerandi JJ. **Ann Dermatol Venereol** 1995; 122(5):289–91 (36 ref.) **(Fre)**

[Prognostic factors of stage I melanoma: non histological factors] Delaunay M. **Ann Dermatol Venereol** 1995; 122(5):267–75 (114 ref.) **(Fre)**

[Screening for and early diagnosis of cutaneous melanoma] Piérard GE, et al. **Rev Med Liege** 1995 Dec;50(12):525–9 (18 ref.) **(Fre)**

[Malignant melanoma of the skin] Simon JC, et al. **Fortschr Med** 1995 Oct 10;113(28):393–6 (18 ref.) (Eng. Abstr.) **(Ger)**

[The clinical and anatomicopathological aspects in malignant choroid melanoma] Stefan C. **Oftalmologia** 1996 Apr–Jun; 40(2):105–14 (64 ref.) (Eng. Abstr.) **(Rum)**

DRUG THERAPY

Combination chemotherapy for disseminated malignant melanoma. Abbott KL, et al. **Anticancer Drugs** 1995 Aug; 6(4):489–97 (74 ref.)

Treatment of metastatic malignant melanoma. Falkson CI. **Anticancer Drugs** 1995 Dec;6(6):709–16 (120 ref.)

Melanoma: chemotherapy. Lee SM, et al. **Br Med Bull** 1995 Jul;51(3):609–30 (151 ref.)

Adjuvant therapy for cutaneous melanoma. Nathan FE, et al. **Semin Oncol** 1995 Dec;22(6):647–61 (85 ref.)

[Interferons in the therapy of solid tumors] Tomao S, et al. **Clin Ter** 1995 Aug–Sep;146(8–9):491–502 (96 ref.) (Eng. Abstr.) **(Ita)**

ENZYMOLOGY

Induction of cytotoxicity in melanoma cells through inhibition of catechol–O–methyltransferase. Smit NP, et al. **Biochem Pharmacol** 1995 Dec 22;50(12):1955–62 (68 ref.)

EPIDEMIOLOGY

Cutaneous malignant melanoma and sun exposure. Recent developments in epidemiology. Katsambas A, et al. **Arch Dermatol** 1996 Apr;132(4):444–50 (62 ref.)

Epidemiology of malignant melanoma. Boyle P, et al. **Br Med Bull** 1995 Jul;51(3):523–47 (81 ref.)

Malignant melanoma: perspectives on incidence and its effects on awareness, diagnosis, and treatment [editorial] Rigel DS. **CA Cancer J Clin** 1996 Jul–Aug;46(4):195–8 (21 ref.)

Familial cutaneous melanoma. Lucchina LC, et al. **Melanoma Res** 1995 Dec;5(6):413–8 (29 ref.)

["Melanoma 92". epidemiological study of uveal melanoma in France] Vidal JL, et al. **J Fr Ophtalmol** 1995; 18(8–9):520–8 (39 ref.) (Eng. Abstr.) **(Fre)**

[Are skin tumors on the increase?] Böni R, et al. **Schweiz Med Wochenschr** 1995 Sep 2;125(35):1619–24 (50 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Prospectives for cutaneous malignant melanoma. Considerations of the precursor state and heritability. Clark WH, et al. **Br Med Bull** 1995 Jul;51(3):717–46 (104 ref.)

GENETICS

Activated ras. Yet another player in melanoma? [comment] Herlyn M, et al. **Am J Pathol** 1996 Sep;149(3):739–44 (47 ref.) Comment on: Am J Pathol 1996 Sep;149(3):883–93.

Recent advances in the molecular genetics of malignant melanoma. Haluska FG, et al. **Cancer Surv** 1995;25:277–92 (72 ref.)

Genetic epidemiology of familial melanoma. Goldstein AM, et al. **Dermatol Clin** 1995 Jul;13(3):605–12 (68 ref.)

Familial cutaneous melanoma. Lucchina LC, et al. **Melanoma Res** 1995 Dec;5(6):413–8 (29 ref.)

Somatic gene therapy of human melanoma: preclinical studies and early clinical trials. Parmiani G, et al. **Melanoma Res** 1995 Oct;5(5):295–301 (59 ref.)

Uveal melanoma and familial atypical mole and melanoma (FAM–M) syndrome. Singh AD, et al. **Ophthalmic Genet** 1995 Jun;16(2):53–61 (32 ref.)

[Multiple primary melanoma and familial melanoma. Risk evaluation and screening tests. How to evaluate the risk of developing a second melanoma? In what family? Should screening methods be implemented? Which ones and why?]

Grange F. **Ann Dermatol Venereol** 1995;122(5):365–71 (50 ref.) **(Fre)**

[Familial malignant melanoma] Takenouchi T, et al. **Nippon Rinsho** 1995 Nov;53(11):2754–8 (22 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Melanoma and vitiligo: immunology's Grecian urn. Berd D, et al. **Cancer Immunol Immunother** 1996 Jun;42(5):263–7 (56 ref.)

New tumor antigens recognized by T cells. Van den Eynde B, et al. **Curr Opin Immunol** 1995 Oct;7(5):674–81 (71 ref.)

Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Ferrone S, et al. **Immunol Today** 1995 Oct;16(10):487–94 (57 ref.)

Human melanoma antigens recognized by T lymphocytes. Kawakami Y, et al. **Keio J Med** 1996 Jun;45(2):100–8 (78 ref.)

New treatment options for patients with melanoma: review of melanoma-derived T-cell epitope-based peptide vaccines. Maeurer MJ, et al. **Melanoma Res** 1996 Feb; 6(1):11–24 (102 ref.)

[Future of malignant stage I melanoma. Immunology and immunotherapy] Nicolas JF, et al. **Ann Dermatol Venereol** 1995;122(5):324–35 (105 ref.) **(Fre)**

[Immunology of melanoma] Bröcker EB, et al. **Hautarzt** 1995 Nov;46(11):818–28 (20 ref.) **(Ger)**

[How do melanoma cells circumvent the immune response? Consequences for future therapy attempts and current biopsy processing] Dummer R, et al. **Schweiz Med Wochenschr** 1995 Sep 2;125(35):1638–41 (24 ref.) (Eng. Abstr.) **(Ger)**

METABOLISM

Melanoma formation in Xiphophorus: a model system for the role of receptor tyrosine kinases in tumorigenesis. Malitschek B, et al. **Bioessays** 1995 Dec;17(12):1017–23 (39 ref.)

Adhesion molecules in melanoma--more than just superglue? Mason MD, et al. **J R Soc Med** 1996 Jul;89(7):393–5 (13 ref.)

PATHOLOGY

Parenchymal–stromal interactions in neoplasia. Theoretical considerations and observations in melanocytic neoplasia. Clark WH Jr, et al. **Acta Oncol** 1995;34(6):749–57 (25 ref.)

Primary malignant melanoma of the esophagus. Ribeiro U Jr, et al. **Am J Gastroenterol** 1996 May;91(5):1048–9 (9 ref.)

Malignant melanoma of the gallbladder: report of a case and review of the literature. Velez AF, et al. **Am Surg** 1995 Dec;61(12):1095–8 (17 ref.)

Pathology of ocular melanomas. McCartney AC. **Br Med Bull** 1995 Jul;51(3):678–93 (56 ref.)

Cutaneous melanoma: pathology, relevant prognostic indicators and progression. Slominski A, et al. **Br Med Bull** 1995 Jul;51(3):548–69 (76 ref.)

Role of integrins as signal transducing cell adhesion molecules in human cutaneous melanoma. Danen EH, et al. **Cancer Surv** 1995;24:43–65 (130 ref.)

Malignant melanoma. Parker T, et al. **Dermatol Surg** 1996 Mar;22(3):234–40 (24 ref.)

Multiple malignant melanoma and squamous-cell carcinoma in a burn scar. Ikeda I, et al. **Dermatology** 1995; 191(4):328–32 (20 ref.)

Peritoneal implantation of meningeal melanosis via ventriculoperitoneal shunt: a case report and review of the literature. Gattuso P, et al. **Diagn Cytopathol** 1995 Oct; 13(3):257–9 (19 ref.)

Discordance in the histopathologic diagnosis of melanoma and melanocytic nevi between expert pathologists. Farmer ER, et al. **Hum Pathol** 1996 Jun;27(6):528–31 (22 ref.)

Neurotropic melanoma with prominent melanization. Barnhill RL, et al. **J Cutan Pathol** 1995 Oct;22(5):450–9 (44 ref.)

Approach to diagnostic image analysis of melanocytic tumors. Smolle J, et al. **J Cutan Pathol** 1995 Apr; 22(2):128–31 (25 ref.)

Desmoplastic melanoma of the hand: case reports and review of the literature. Chung KC, et al. **J Hand Surg [Am]** 1995 Sep;20(5):873–6 (10 ref.)

Simultaneous malignant melanoma and squamous cell carcinoma of the oral cavity: a case report. Nakahara H, et al. **J Oral Maxillofac Surg** 1995 Dec;53(12):1455–7 (12 ref.)

Sinonasal malignant melanoma--a clinicopathologic analysis of 18 cases. Crawford RI, et al. **Melanoma Res** 1995 Aug; 5(4):261–5 (34 ref.)

Malignant melanoma of the external auditory canal. Langman A, et al. **Otolaryngol Head Neck Surg** 1996 Apr; 114(4):645–8 (19 ref.)

[When, how and which patients should be screened for second melanoma?] Dreno B. **Ann Dermatol Venereol** 1995; 122(5):310–4 (42 ref.) **(Fre)**

[Detection methods of local, regional and distant recurrences of melanoma] Sigal R. **Ann Dermatol Venereol** 1995; 122(5):279–84 (46 ref.) **(Fre)**

[What are the methods for the detection of recurrent melanoma? What is their value? Should they be implemented? Which ones and how often?] Truchetet F, et al. **Ann Dermatol Venereol** 1995;122(5):360–4 (27 ref.) **(Fre)**

[Melanoma developped on nevus of Ota without ocular melanosis. Apropos of an anatomo-clinical case] Reichert S, et al. **J Fr Ophtalmol** 1996;19(5):389–94 (23 ref.) (Eng. Abstr.) **(Fre)**

[Desmoplastic malignant melanoma. Clinical and histopathologic results of a study in 34 patients] Rütten A, et al. **Hautarzt** 1996 Jun;47(6):447–53 (41 ref.) (Eng. Abstr.) **(Ger)**

[Colobomatous fossette of the optic papilla and juxtapapillary choroidal malignant melanoma] Chercota V, et al. **Oftalmologia** 1995 Oct–Dec;39(4):307–10 (9 ref.) (Eng. Abstr.) **(Rum)**

PHYSIOPATHOLOGY

Rel signalling pathway and the melanotic tumour phenotype of Drosophila. Govind S. **Biochem Soc Trans** 1996 Feb; 24(1):39–44 (44 ref.)

The paradoxical association of regression with a poor prognosis in melanoma contrasted with a good prognosis in keratoacanthoma. Prehn RT. **Cancer Res** 1996 Mar 1; 56(5):937–940 (43 ref.)

[Malignant melanoma and pregnancy] Rozen A, et al. **Harefuah** 1996 Apr 15;130(8):555–7 (17 ref.) **(Heb)**

PREVENTION & CONTROL

Prevention and early detection strategies for melanoma and skin cancer. Current status [editorial] Koh HK, et al. **Arch Dermatol** 1996 Apr;132(4):436–43 (88 ref.)

Melanoma prevention and early detection. MacKie RM. **Br Med Bull** 1995 Jul;51(3):570–83 (26 ref.)

Prevention and control of melanoma: the public health approach. Marks R. **CA Cancer J Clin** 1996 Jul–Aug; 46(4):199–216 (46 ref.)

Screening for melanoma and options for its evaluation [see comment] Elwood JM. **J Med Screen** 1994 Jan;1(1):22–38 (83 ref.) Comment on: J Med Screen 1994 Jan;1(1):2.

RADIOTHERAPY

Anorectal melanoma. Successful palliation in a 59-year-old woman. Mostafapour SP, et al. **West J Med** 1996 May; 164(5):448–50 (18 ref.)

SECONDARY

Complete resection of a right atrial intracavitary metastatic melanoma. Chen RH, et al. **Ann Thorac Surg** 1996 Apr; 61(4):1255–7 (8 ref.)

Treatment of metastatic malignant melanoma. Falkson CI. **Anticancer Drugs** 1995 Dec;6(6):709–16 (120 ref.)

Metastatic choroidal melanoma to the contralateral orbit 40 years after enucleation. Coupland SE, et al. **Arch Ophthalmol** 1996 Jun;114(6):751–6 (27 ref.)

The role of the integrin vitronectin receptor, alpha v beta 3 in melanoma metastasis. Nip J, et al. **Cancer Metastasis Rev** 1995 Sep;14(3):241–52 (101 ref.)

Different roles for plasminogen activators and metalloproteinases in melanoma metastasis. Mueller BM. **Curr Top Microbiol Immunol** 1996;213 (Pt 1):65–80 (80 ref.)

The role of clinical trials in assessing optimal treatment of cutaneous melanoma not extending beyond the regional nodes. Cascinelli N. **Eur J Surg Oncol** 1996 Apr;22(2):123–7 (49 ref.)

Favorable prognostic factors in recurrent and metastatic melanoma. Buzzell RA, et al. **J Am Acad Dermatol** 1996 May;34(5 Pt 1):798–803 (74 ref.)

Congestive heart failure due to rapid right ventricular obliteration by metastatic malignant melanoma. Rusconi C, et al. **Minerva Cardioangiol** 1996 Mar;44(3):123–5 (8 ref.)

[Cutaneous metastases of melanoma localized on the cicatrix at the site of flap taking] Salmon-Ehr V, et al. **Ann Dermatol Venereol** 1996;123(3):194–5 (16 ref.) (Eng. Abstr.) **(Fre)**

[Splenic metastases] Tiszlavicz L. **Orv Hetil** 1996 Feb 11; 137(6):295–8 (25 ref.) (Eng. Abstr.) **(Hun)**

[Metastatic malignant melanoma of the ovary] Tribbia G, et al. **Minerva Ginecol** 1996 Apr;48(4):159–62 (10 ref.) (Eng. Abstr.) **(Ita)**

SURGERY

Complete resection of a right atrial intracavitary metastatic melanoma. Chen RH, et al. **Ann Thorac Surg** 1996 Apr; 61(4):1255–7 (8 ref.)

Management of patients with intermediate-thickness melanoma. Urist MM. **Annu Rev Med** 1996;47:211–7 (25 ref.)

A factual, not arbitrary, basis for choice of resection margins in melanoma. Piepkorn M, et al. **Arch Dermatol** 1996 Jul; 132(7):811–4 (50 ref.)

Surgical management of malignant melanoma. Ball AS, et al. **Br Med Bull** 1995 Jul;51(3):584–608 (117 ref.)

Surgical management of primary cutaneous melanoma. Urist MM. **CA Cancer J Clin** 1996 Jul–Aug;46(4):217–24 (40 ref.)

Surgical oncology and tumor immunology [editorial] Bland KI, et al. **Curr Opin Gen Surg** 1993;:299–302 (16 ref.)

The case for minimal margins and delayed regional node dissection for high-risk cutaneous melanoma. Cascinelli N, et al. **Curr Opin Gen Surg** 1993;:310–5 (31 ref.)

The case for wide local excision and regional node dissection for high-risk cutaneous melanoma. Karakousis CP. **Curr Opin Gen Surg** 1993;:303–9 (40 ref.)

Recurrent melanoma of the hard palate treated by en bloc excision and reconstruction with an autologous palatal bone graft subjected to cryotherapy and a buccal mucosal flap. Rosales J, et al. **J Oral Maxillofac Surg** 1995 Oct; 53(10):1218–20 (16 ref.)

Surgical management of melanoma. Whooley BP, et al. **Surg Oncol** 1995 Aug;4(4):187–95 (75 ref.)

[In a patient, surgically treated for isolated primary melanoma, what is the risk of recurrence? How to evaluate this risk?] Gautier MS. **Ann Dermatol Venereol** 1995; 122(5):336–48 (53 ref.) **(Fre)**

[Anorectal malignant melanoma] Gramática L, et al. **Rev Fac Cien Med Univ Nac Cordoba** 1994;52(2):11–6 (26 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

No one knows the preferred management for choroidal melanoma [editorial] Fine SL. **Am J Ophthalmol** 1996 Jul; 122(1):106–8 (11 ref.)

Biological response modifiers in melanoma. Bridgewater JA, et al. **Br Med Bull** 1995 Jul;51(3):656–77 (88 ref.)

Targeted gene therapy. Hart IR, et al. **Br Med Bull** 1995 Jul;51(3):647–55 (26 ref.)

Management of ocular melanoma. Hungerford JL. **Br Med Bull** 1995 Jul;51(3):694–716 (67 ref.)

Active specific immunotherapy of melanoma. Mitchell MS. **Br Med Bull** 1995 Jul;51(3):631–46 (40 ref.)

Vaccine therapy for malignant melanoma. Morton DL, et al. **CA Cancer J Clin** 1996 Jul–Aug;46(4):225–44 (80 ref.)

The role of clinical trials in assessing optimal treatment of cutaneous melanoma not extending beyond the regional nodes. Cascinelli N. **Eur J Surg Oncol** 1996 Apr;22(2):123–7 (49 ref.)

Open trials in cutaneous malignant melanoma. Rudenstam CM. **Eur J Surg Oncol** 1996 Apr;22(2):128–30 (8 ref.)

Melanoma: questions for the future. Thomas JM. **Eur J Surg Oncol** 1996 Apr;22(2):130–3 (28 ref.)

Antiantiidiotypic response and clinical course of the disease in patients with malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2-23. Mittelman A, et al. **Hybridoma** 1995 Apr;14(2):175–81 (31 ref.)

Approaches to augmenting the immunogenicity of melanoma gangliosides: from whole melanoma cells to ganglioside–KLH conjugate vaccines. Livingston PO. **Immunol Rev** 1995 Jun;145:147–66 (68 ref.)

Favorable prognostic factors in recurrent and metastatic melanoma. Buzzell RA, et al. **J Am Acad Dermatol** 1996 May;34(5 Pt 1):798–803 (74 ref.)

The case for therapeutic vaccines. Dalgleish A. **Melanoma Res** 1996 Feb;6(1):5–10 (45 ref.)

New treatment options for patients with melanoma: review of melanoma-derived T-cell epitope-based peptide vaccines. Maeurer MJ, et al. **Melanoma Res** 1996 Feb; 6(1):11–24 (102 ref.)

Somatic gene therapy of human melanoma: preclinical studies and early clinical trials. Parmiani G, et al. **Melanoma Res** 1995 Oct;5(5):295–301 (59 ref.)

Systemic treatments for advanced cutaneous melanoma. Anderson CM, et al. **Oncology (Huntingt)** 1995 Nov; 9(11):1149–58; discussion 1163–4, 1167–8 (55 ref.)

[Consensus conference. Follow-up of patients surgically treated for stage I melanoma] **Ann Dermatol Venereol** 1995; 122(5):250–8 (13 ref.) **(Fre)**

[Consensus conference. Follow-up of patients surgically treated for stage I melanoma. Paris, France, 30 March 1995] **Ann Dermatol Venereol** 1995;122(5):250–391 (0 ref.) **(Fre)**

[Are there specific follow-up modalities recommended in the treatment of stage I melanoma?] Fortier-Beaulieu M. **Ann Dermatol Venereol** 1995;122(5):372–7 (52 ref.) **(Fre)**

[After excision of primary stage I cutaneous melanoma, is an initial evaluation necessary?] Richard-Lallemand MA. **Ann Dermatol Venereol** 1995;122(5):349–59 (63 ref.) **(Fre)**

[What are expected improvements in the follow-up and treatment of stage I melanoma?] Thomas L. **Ann Dermatol Venereol** 1995;122(5):378–88 (243 ref.) **(Fre)**

MELANOMA, AMELANOTIC

DIAGNOSIS

Amelanotic lentigo maligna melanoma: a diagnostic conundrum-- presentation of four new cases. Rahbari H, et al. **Cancer** 1996 May 15;77(10):2052–7 (15 ref.)

[Amelanotic nodular malignant melanoma of the vulva. Case report and review of the literature] Hofmann U, et al. **Hautarzt** 1995 Dec;46(12):850–3 (27 ref.) (Eng. Abstr.) **(Ger)**

MELANOMA, B16 see **MELANOMA, EXPERIMENTAL**

MELANOMA, CLOUDMAN S91 see **MELANOMA, EXPERIMENTAL**

MELANOMA, EXPERIMENTAL

IMMUNOLOGY

New tumor antigens recognized by T cells. Van den Eynde B, et al. **Curr Opin Immunol** 1995 Oct;7(5):674–81 (71 ref.)

MELANOMA, HARDING-PASSEY see **MELANOMA, EXPERIMENTAL**

MELANOMA, MALIGNANT, OF SOFT PARTS see **SARCOMA, CLEAR CELL**

MELANOSIS

[A case of melanosis duodeni] Nishimura Y, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Mar;93(3):185–90 (15 ref.) **(Jpn)**

DIAGNOSIS

[Neurocutaneous melanosis] Vernet AM. **Rev Neurol** 1996 Sep;24(133):1068–71 (23 ref.) **(Spa)**

DRUG THERAPY

Melanin hyperpigmentation of skin: melasma, topical treatment with azelaic acid, and other therapies. Breathnach AS. **Cutis** 1996 Jan;57(1 Suppl):36–45 (73 ref.)

ETIOLOGY

Melasma. Etiologic and therapeutic considerations. Grimes PE. **Arch Dermatol** 1995 Dec;131(12):1453–7 (41 ref.)

PATHOLOGY

Peritoneal implantation of meningeal melanosis via ventriculoperitoneal shunt: a case report and review of the literature. Gattuso P, et al. **Diagn Cytopathol** 1995 Oct; 13(3):257–9 (19 ref.)

Pigments of the gastrointestinal tract: a comparison of light microscopic and electron microscopic findings. Ghadially FN, et al. **Ultrastruct Pathol** 1995 Jul–Aug;19(4):213–9 (36 ref.)

PHYSIOPATHOLOGY

[Minor symptoms in family practice; chloasma or 'pregnancy mask' (see comments)] van Stralen–Bohlmann A, et al. **Ned Tijdschr Geneeskd** 1995 Sep 30;139(39):1971–4 (17 ref.) Comment in: Ned Tijdschr Geneeskd 1995 Dec 2;139(48):2513–4. Comment in: Ned Tijdschr Geneeskd 1995 Dec 23;139(51):2698. **(Dut)**

THERAPY

Melasma. Etiologic and therapeutic considerations. Grimes PE. **Arch Dermatol** 1995 Dec;131(12):1453–7 (41 ref.)

MELANOSOMES see **MELANOCYTES**

MELANOTROPIN see **MSH**

MELAS SYNDROME

MELAS syndrome. Koga SJ, et al. **West J Med** 1995 Oct; 163(4):379–81 (27 ref.)

COMPLICATIONS

[A case of mitochondrial encephalomyopathy (MELAS)] Suzuki T, et al. **Nippon Jinzo Gakkai Shi** 1996 Feb; 38(2):109–14 (25 ref.) (Eng. Abstr.) **(Jpn)**

[Mitochondrial diseases and cerebrovascular pathology] Vivancos J, et al. **Rev Neurol** 1995;23 Suppl 1:S106–12 (39 ref.) **(Spa)**

NURSING

MELAS: a mitochondrial encephalomyopathy syndrome. Hilton G. **J Neurosci Nurs** 1995 Oct;27(5):278–82 (33 ref.)

MELASMA see **MELANOSIS**

MELATONIN

ADMINISTRATION & DOSAGE

[Therapy of jet lag] Samel A, et al. **Wien Med Wochenschr** 1995;145(17–18):458–60 (21 ref.) (Eng. Abstr.) **(Ger)**

BIOSYNTHESIS

The melatonin hypothesis: electric power and breast cancer. Stevens RG, et al. **Environ Health Perspect** 1996 Mar;104 Suppl 1:135–40 (66 ref.)

Pineal gene expression: dawn in a dark matter. Stehle JH. **J Pineal Res** 1995 May;18(4):179–90 (90 ref.)

BLOOD

[Melatonin] Ikuyama S, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:759–63 (22 ref.) **(Jpn)**

[Pineal functioning (melatonin levels) in healthy children of different ages. An update and the value of pineal gland study in pediatrics] Molina Carballo A, et al. **An Esp Pediatr** 1996 Jul;45(1):33–44 (124 ref.) (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

The clinical neuroimmunotherapeutic role of melatonin in oncology. Conti A, et al. **J Pineal Res** 1995 Oct; 19(3):103–10 (38 ref.)

The influence of season, photoperiod, and pineal melatonin on immune function. Nelson RJ, et al. **J Pineal Res** 1995 Nov;19(4):149–65 (209 ref.)

METABOLISM

Melatonin in the context of the free radical theory of aging. Reiter RJ, et al. **Ann N Y Acad Sci** 1996 Jun 15;786:362–78 (73 ref.)

Oxygen free radicals, melatonin, and aging. Pierrefiche G, et al. **Exp Gerontol** 1995 May–Aug;30(3–4):213–27 (75 ref.)

Immunomodulatory role of melatonin: specific binding sites in human and rodent lymphoid cells. Calvo JR, et al. **J Pineal Res** 1995 Apr;18(3):119–26 (64 ref.)

The orphan receptor family RZR/ROR, melatonin and 5-lipoxygenase: an unexpected relationship. Carlberg C, et al. **J Pineal Res** 1995 May;18(4):171–8 (51 ref.)

PHARMACOLOGY

Melatonin as a chronobiotic: PROS and CONS. Steinlechner S. **Acta Neurobiol Exp (Warsz)** 1996;56(1):363–72 (64 ref.)

PHYSIOLOGY

The pineal gland and cancer. Ronco AL, et al. **Anticancer Res** 1996 Jul–Aug;16(4A):2033–9 (68 ref.)

Biorhythms and the biological clock involvement of melatonin and the pineal gland in life and disease. Nir I. **Biomed Environ Sci** 1995 Jun;8(2):90–105 (54 ref.)

Melatonin madness. Reppert SM, et al. **Cell** 1995 Dec 29; 83(7):1059–62 (19 ref.)

Functional aspects of the pineal hormone melatonin in combating cell and tissue damage induced by free radicals. Reiter RJ. **Eur J Endocrinol** 1996 Apr;134(4):412–20 (89 ref.)

Functional diversity of the pineal hormone melatonin: its role as an antioxidant. Reiter RJ. **Exp Clin Endocrinol Diabetes** 1996;104(1):10–6 (52 ref.)

The pineal gland and melatonin in relation to aging: a summary of the theories and of the data. Reiter RJ. **Exp Gerontol** 1995 May–Aug;30(3–4):199–212 (73 ref.)

Functional pleiotropy of the neurohormone melatonin: antioxidant protection and neuroendocrine regulation. Reiter RJ. **Front Neuroendocrinol** 1995 Oct;16(4):383–415 (133 ref.)

Reported biological consequences related to the suppression of melatonin by electric and magnetic field exposure. Reiter RJ. **Integr Physiol Behav Sci** 1995 Sep–Dec;30(4):314–30 (103 ref.)

Cell protective role of melatonin in the brain. Acuña-Castroviejo D, et al. **J Pineal Res** 1995 Sep; 19(2):57–63 (66 ref.)

Thirty years of human pineal research: do we know its clinical relevance? Garcia-Patterson A, et al. **J Pineal Res** 1996 Jan;20(1):1–6 (66 ref.)

The role of the neurohormone melatonin as a buffer against macromolecular oxidative damage. Reiter RJ. **Neurochem Int** 1995 Dec;27(6):453–60 (54 ref.)

[Melatonin—the hormone of darkness] Kancheva RL, et al. **Cas Lek Cesk** 1996 Apr 17;135(8):231–5 (43 ref.) (Eng. Abstr.) **(Cze)**

[Pineal gland and melatonin] Masuzawa T, et al. **No Shinkei Geka** 1995 Oct;23(10):857–68 (74 ref.) **(Jpn)**

THERAPEUTIC USE

Use of melatonin in circadian rhythm disorders and following phase shifts. Skene DJ, et al. **Acta Neurobiol Exp (Warsz)** 1996;56(1):359–62 (23 ref.)

Melatonin: implications at the oral level. Cutando A, et al. **Bull Group Int Rech Sci Stomatol Odontol** 1995 Sep–Oct; 38(3–4):81–6 (29 ref.)

Rationales to consider the use of melatonin as a chrono-oncotherapeutic drug. Bartsch C, et al. **In Vivo** 1995 Jul–Aug;9(4):305–9 (62 ref.)

[Melatonin: a fashion hormone for not very Cartesian reasons] Martin-Du Pan R, et al. **Rev Med Suisse Romande** 1996 Apr;116(4):299–303 (33 ref.) **(Fre)**

MELEDA DISEASE see **KERATODERMA, PALMOPLANTAR**

MELIOIDOSIS

Pulmonary melioidosis. Ip M, et al. **Chest** 1995 Nov; 108(5):1420–4 (32 ref.)

MELKERSSON-ROSENTHAL SYNDROME

Melkersson-Rosenthal syndrome and orofacial granulomatosis. Rogers RS 3rd. **Dermatol Clin** 1996 Apr; 14(2):371–9 (28 ref.)

Orofacial granulomatosis. Armstrong DK, et al. **Int J Dermatol** 1995 Dec;34(12):830–3 (17 ref.)

PATHOLOGY

Vulvitis granulomatosa: a cryptogenic chronic inflammatory hypertrophy of vulvar labia related to cheilitis granulomatosa and Crohn's disease. Guerrieri C, et al. **Int J Gynecol Pathol** 1995 Oct;14(4):352–9 (62 ref.)

MELNICK-NEEDLES SYNDROME see **OSTEOCHONDRODYSPLASIAS**

MELORHEOSTOSIS

RADIOGRAPHY

Melorheostosis of the foot: a case report and review of the literature. Mudge I, et al. **Nebr Med J** 1996 Jan;81(1):18–21 (6 ref.)

MELPHALAN

THERAPEUTIC USE

[Treatment of multiple myeloma—melphalan monotherapy after bone marrow transplantation] Hájek R, et al. **Vnitr Lek** 1996 Apr;42(4):278–84 (0 ref.) (Eng. Abstr.) **(Cze)**

MEMANTINE

THERAPEUTIC USE

[New therapeutic possibilities with low-affinity NMDA receptor antagonists] Kornhuber J, et al. **Nervenarzt** 1996 Jan;67(1):77–82 (22 ref.) (Eng. Abstr.) **(Ger)**

MEMBRANE ALANYL AMINOPEPTIDASE see **ANTIGENS, CD13**

MEMBRANE ATTACK COMPLEX see **COMPLEMENT MEMBRANE ATTACK COMPLEX**

MEMBRANE-BOUND IMMUNOGLOBULINS see **IMMUNOGLOBULINS, SURFACE**

MEMBRANE CHANNELS see **ION CHANNELS**

MEMBRANE FUSION

Membrane fusion in organelle biogenesis. Denesvre C, et al. **Curr Opin Cell Biol** 1996 Aug;8(4):519–23 (45 ref.)

Bending membranes to the task: structural intermediates in bilayer fusion. Chernomordik LV, et al. **Curr Opin Struct Biol** 1995 Aug;5(4):541–7 (67 ref.)

Lipids in biological membrane fusion. Chernomordik L, et al. **J Membr Biol** 1995 Jul;146(1):1–14 (143 ref.)

Instrumentation. Hofmann GA. **Methods Mol Biol** 1995; 47:27–45 (11 ref.)

The membrane fusion machine and neurotransmitter release. Fesce R, et al. **Neurochem Int** 1996 Jan;28(1):15–21 (44 ref.)

GENETICS

Molecular mechanisms of protein-mediated membrane fusion. Hughson FM. **Curr Opin Struct Biol** 1995 Aug; 5(4):507–13 (60 ref.)

PHYSIOLOGY

Enigma variations: protein mediators of membrane fusion. Mellman I. **Cell** 1995 Sep 22;82(6):869–72 (17 ref.)

Structure and function of fusion pores in exocytosis and ectoplasmic membrane fusion. Lindau M, et al. **Curr Opin Cell Biol** 1995 Aug;7(4):509–17 (64 ref.)

The fusion pore and mechanisms of biological membrane fusion. Monck JR, et al. **Curr Opin Cell Biol** 1996 Aug; 8(4):524–33 (79 ref.)

The neuronal exocytotic fusion machine: some new developments. Chapman ER, et al. **Neuropharmacology** 1995 Nov;34(11):1343–9 (64 ref.)

v- and t-SNAREs in neuronal exocytosis: a need for additional components to define sites of release. Galli T, et al. **Neuropharmacology** 1995 Nov;34(11):1351–60 (63 ref.)

MEMBRANE GLYCOPROTEINS

Cell-mediated cytotoxicity in perforin-less mice. Clark WR, et al. **Int Rev Immunol** 1995;13(1):1–14 (39 ref.)

[Telencephalon-specific cell adhesion molecule, telencephalin] Yoshihara Y, et al. **Tanpakushitsu Kakusan Koso** 1996 May;41(6):766–74 (36 ref.) **(Jpn)**

ANALYSIS

Molecular analysis of the pathological autoimmune antigens of Heymann nephritis [comment] Farquhar MG. **Am J Pathol** 1996 May;148(5):1331–7 (46 ref.) Comment on: Am J Pathol 1996 May;148(5):1613–24.

BIOSYNTHESIS

The modulation of thrombospondin and other naturally occurring inhibitors of angiogenesis during tumor progression. Volpert OV, et al. **Breast Cancer Res Treat** 1995;36(2):119–26 (56 ref.)

MEMBRANE GLYCOPROTEINS

Expression of thrombospondin-1 in cancer: a role in tumor progression. Qian X, et al. **Proc Soc Exp Biol Med** 1996 Jul;212(3):199–207 (96 ref.)

CHEMISTRY

Sialoadhesin and related cellular recognition molecules of the immunoglobulin superfamily. Crocker PR, et al. **Biochem Soc Trans** 1996 Feb;24(1):150–6 (50 ref.)

Nuclear pores and macromolecular assemblies involved in nucleocytoplasmic transport. Stewart M, et al. **Curr Opin Struct Biol** 1996 Apr;6(2):162–5 (43 ref.)

Altered glycoprotein sugar-chain structures as possible diagnostic and prognostic markers in malignant tumors. Yoshida K, et al. **Int J Urol** 1995 Nov;2(5):281–7 (53 ref.)

GENETICS

Mutations in the cartilage oligomeric matrix protein (COMP) gene in pseudoachondroplasia and multiple epiphyseal dysplasia. Cohn DH, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:188–94 (18 ref.)

Mutations in the X-linked and autosomal recessive forms of chronic granulomatous disease. Roos D, et al. **Blood** 1996 Mar 1;87(5):1663–81 (151 ref.)

Muscular dystrophies: diseases of the dystrophin-glycoprotein complex [comment] Worton R. **Science** 1995 Nov 3;270(5237):755–6 (15 ref.) Comment on: Science 1995 Nov 3;270(5237):819–22.

A family of murine NK cell receptors specific for target cell MHC class I molecules. Yokoyama WM, et al. **Semin Immunol** 1995 Apr;7(2):89–101 (93 ref.)

Urea transport and Kidd blood groups. Cartron JP, et al. **Transfus Clin Biol** 1995;2(4):309–15 (24 ref.)

Cf9 and Avr9, two major players in the gene-for-gene game. de Wit PJ. **Trends Microbiol** 1995 Jul;3(7):251–2 (15 ref.)

[New mucin core protein genes and their clinical application] Imai K. **Hokkaido Igaku Zasshi** 1996 Mar;71(2):139–43 (9 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Heterogeneity of microfibrils: role of thrombospondin-microfibrils in the thrombogenicity of the subendothelium. Fauvel-Lafève F, et al. **C R Acad Sci III** 1996 Apr;319(4):333–41 (41 ref.)

Die and let live: eliminating dangerous lymphocytes. Abbas AK. **Cell** 1996 Mar 8;84(5):655–7 (15 ref.)

CD40 and its ligand in host defense. Noelle RJ. **Immunity** 1996 May;4(5):415–9 (43 ref.)

Role of B7 signaling in the differentiation of naive CD4+ T cells to effector interleukin-4-producing T helper cells. Gause WC, et al. **Immunol Res** 1995;14(3):176–88 (84 ref.)

B7-mediated costimulation can either provoke or prevent clinical manifestations of experimental allergic encephalomyelitis. Perrin PJ, et al. **Immunol Res** 1995; 14(3):189–99 (47 ref.)

PELs and the perforin and granzyme independent mechanism of CTL-mediated lysis. Berke G. **Immunol Rev** 1995 Aug; 146:21–31 (52 ref.)

Perforin and lymphocyte-mediated cytolysis. Liu CC, et al. **Immunol Rev** 1995 Aug;146:145–75 (155 ref.)

The Heymann nephritis antigenic complex: megalin (gp330) and RAP [editorial] Farquhar MG, et al. **J Am Soc Nephrol** 1995 Jul;6(1):35–47 (70 ref.)

Therapeutic potential for blockade of the CD40 ligand, gp39. Buhlmann JE, et al. **J Clin Immunol** 1996 Mar;16(2):83–9 (56 ref.)

METABOLISM

Cytokine signal transduction through a homo- or heterodimer of gp130. Kishimoto T, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:224–34 (22 ref.)

Sialoadhesin and related cellular recognition molecules of the immunoglobulin superfamily. Crocker PR, et al. **Biochem Soc Trans** 1996 Feb;24(1):150–6 (50 ref.)

Association of TM4SF proteins with integrins: relevance to cancer. Hemler ME, et al. **Biochim Biophys Acta** 1996 Jun 7;1287(2-3):67–71 (58 ref.)

Intracellular trafficking of lysosomal membrane proteins. Hunziker W, et al. **Bioessays** 1996 May;18(5):379–89 (88 ref.)

CD40-CD40 ligand (CD40L) interactions and X-linked hyperIgM syndrome (HIGMX-1). Ramesh N, et al. **Clin Immunol Immunopathol** 1995 Sep;76(3 Pt 2):S208–13 (37 ref.)

Early events in neurotrophin signalling via Trk and p75 receptors. Greene LA, et al. **Curr Opin Neurobiol** 1995 Oct;5(5):579–87 (72 ref.)

Dystrophin-glycoprotein complex: molecular organization and critical roles in skeletal muscle. Sunada Y, et al. **Curr Opin Neurol** 1995 Oct;8(5):379–84 (40 ref.)

Sperm--egg recognition mechanisms in mammals. Wassarman PM, et al. **Curr Top Dev Biol** 1995;30:1–19 (70 ref.)

Dystrophin-associated proteins in muscular dystrophy. Ozawa E, et al. **Hum Mol Genet** 1995;4 Spec No:1711–6 (69 ref.)

Immunosuppression through blockade of CD28:B7-mediated costimulatory signals. Judge TA, et al. **Immunol Res** 1996; 15(1):38–49 (34 ref.)

Sperm-binding proteins. Foltz KR. **Int Rev Cytol** 1995; 163:249–303 (310 ref.)

Blocking CD28/B7 with soluble competitors: immunological phenotype of mCTLA4-H gamma 1 transgenic mice. Lane P. **Res Immunol** 1995 Mar-Apr;146(3):176–9 (30 ref.)

CD80 (B7-1) and CD86 (B7-2): potential targets for immunotherapy? van Gool SW, et al. **Res Immunol** 1995 Mar-Apr;146(3):183–96 (106 ref.)

CD46-mediated measles virus entry: a first key to host-range specificity. Gerlier D, et al. **Trends Microbiol** 1995 Sep; 3(9):338–45 (65 ref.)

p75 and Trk: a two-receptor system. Chao MV, et al. **Trends Neurosci** 1995 Jul;18(7):321–6 (61 ref.)

Is there a 'lock' for all agonist 'keys' in 7TM receptors? Schwartz TW, et al. **Trends Pharmacol Sci** 1996 Jun; 17(6):213–6 (37 ref.)

PHYSIOLOGY

Site directed mutagenesis of the murine coronavirus spike protein. Effects on fusion. Bos EC, et al. **Adv Exp Med Biol** 1995;380:283–6 (14 ref.)

Mammalian fertilization: egg and sperm (glyco)proteins that support gamete adhesion. Wassarman PM. **Am J Reprod Immunol** 1995 Mar;33(3):253–8 (48 ref.)

Target cell apoptosis induced by cytotoxic T cells and natural killer cells involves synergy between the pore-forming protein, perforin, and the serine protease, granzyme B. Trapani JA. **Aust N Z J Med** 1995 Dec;25(6):793–9 (63 ref.)

Membrane molecules and macrophage endocytosis: scavenger receptor and macrosialin as markers of plasma-membrane and vacuolar functions. da Silva RP, et al. **Biochem Soc Trans** 1996 Feb;24(1):220–4 (17 ref.)

The role of thrombospondin-1 in tumor progression and angiogenesis. Tuszynski GP, et al. **Bioessays** 1996 Jan; 18(1):71–6 (57 ref.)

The role of gp39 (CD40L) in immunity. Noelle RJ. **Clin Immunol Immunopathol** 1995 Sep;76(3 Pt 2):S203–7 (29 ref.)

Microvillus assembly. Not actin alone. Fath KR, et al. **Curr Biol** 1995 Jun 1;5(6):591–3 (22 ref.)

MUC18: A cell adhesion molecule with a potential role in tumor growth and tumor cell dissemination. Johnson JP, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 1):95–105 (25 ref.)

Role of laminin-nidogen complexes in basement membrane formation during embryonic development. Dziadek M. **Experientia** 1995 Sep 29;51(9–10):901–13 (136 ref.)

Syndecan family of cell surface proteoglycans: developmentally regulated receptors for extracellular effector molecules. Salmivirta M, et al. **Experientia** 1995 Sep 29;51(9–10):863–72 (118 ref.)

Regulation of tumor growth and metastasis by thrombospondin-1. Roberts DD. **FASEB J** 1996 Aug; 10(10):1183–91 (69 ref.)

Glycobiology of the cell surface: the emergence of sugars as an important feature of the cell periphery. Cook GM. **Glycobiology** 1995 Jul;5(5):449–58 (74 ref.)

Antigen-presenting function of the TL antigen and mouse CD1 molecules. Cheroutre H, et al. **Immunol Rev** 1995 Oct;147:31–52 (73 ref.)

Fas and FasL in the homeostatic regulation of immune responses. Lynch DH, et al. **Immunol Today** 1995 Dec; 16(12):569–74 (61 ref.)

ADAM, a novel family of membrane proteins containing A Disintegrin And Metalloprotease domain: multipotential functions in cell-cell and cell-matrix interactions. Wolfsberg TG, et al. **J Cell Biol** 1995 Oct;131(2):275–8 (22 ref.)

Gp130, a shared signal transducing receptor component for hematopoietic and neuropoietic cytokines. Taga T. **J Neurochem** 1996 Jul;67(1):1–10 (90 ref.)

Human regulator of complement activation (RCA) gene family proteins and their relationship to microbial infection. Seya T. **Microbiol Immunol** 1995;39(5):295–305 (82 ref.)

Angiogenesis inhibitors generated by tumors. Folkman J. **Mol Med** 1995 Jan;1(2):120–2 (23 ref.)

Unraveling immune privilege [comment] Streilein JW. **Science** 1995 Nov 17;270(5239):1158–9 (19 ref.) Comment on: Science 1995 Nov 17;270(5239):1189–92.

The molecular basis of platelet and endothelial cell interaction with neutrophils and monocytes: role of P-selectin and the P-selectin ligand, PSGL-1. Furie B, et al. **Thromb Haemost** 1995 Jul;74(1):224–7 (56 ref.)

MEMBRANE LIPIDS

ANALYSIS

Membrane phospholipid asymmetry: host response to the externalization of phosphatidylserine. Bruckheimer EM, et al. **J Leukoc Biol** 1996 Jun;59(6):784–8 (58 ref.)

CHEMISTRY

The morphology of lipid membranes. Lipowsky R. **Curr Opin Struct Biol** 1995 Aug;5(4):531–40 (103 ref.)

METABOLISM

Lipid vs protein theories of alcohol action in the nervous system. Peoples RW, et al. **Annu Rev Pharmacol Toxicol** 1996;36:185–201 (112 ref.)

Cell cycle regulation of membrane phospholipid metabolism. Jackowski S. **J Biol Chem** 1996 Aug 23;271(34):20219–22 (69 ref.)

Skeletal muscle membrane lipids and insulin resistance. Storlien LH, et al. **Lipids** 1996 Mar;31 Suppl:S261–5 (39 ref.)

Breakdown of membrane phospholipids in Alzheimer disease. Involvement of excitatory amino acid receptors. Farooqui AA, et al. **Mol Chem Neuropathol** 1995 Jun-Aug; 25(2-3):155–73 (94 ref.)

PHYSIOLOGY

Role of membrane lipids in temperature acclimatization of carp. Buda C, et al. **Arch Tierernahr** 1996;49(1):61–2 (7 ref.)

Lipids and membrane function in green algae. Thompson GA Jr. **Biochim Biophys Acta** 1996 Jul 12;1302(1):17–45 (183 ref.)

Lipids in biological membrane fusion. Chernomordik L, et al. **J Membr Biol** 1995 Jul;146(1):1–14 (143 ref.)

Membrane phospholipids and adrenergic receptor function. Williams S, et al. **Mol Cell Biochem** 1995 Aug-Sep; 149–150:217–21 (47 ref.)

MEMBRANE METALLO-ENDOPEPTIDASE

see related
LEUKEMIA, CALLA-POSITIVE

ANTAGONISTS & INHIBITORS

Dual inhibitors of enkephalin-degrading enzymes (neutral endopeptidase 24.11 and aminopeptidase N) as potential new medications in the management of pain and opioid addiction. Roques BP, et al. **NIDA Res Monogr** 1995; 147:104–45 (149 ref.)

BIOSYNTHESIS

Tissue-specific expression of rat neutral endopeptidase mRNAs. Li C, et al. **Ann N Y Acad Sci** 1996 Mar 22; 780:145–55 (10 ref.)

GENETICS

Tissue-specific expression of rat neutral endopeptidase mRNAs. Li C, et al. **Ann N Y Acad Sci** 1996 Mar 22; 780:145–55 (10 ref.)

PHARMACOLOGY

Dual inhibitors of enkephalin-degrading enzymes (neutral endopeptidase 24.11 and aminopeptidase N) as potential new medications in the management of pain and opioid addiction. Roques BP, et al. **NIDA Res Monogr** 1995; 147:104–45 (149 ref.)

PHYSIOLOGY

Enkephalinase (EC 3.4.24.11)--neutral endopeptidase (NEP)--characterization, distribution and role in the human gastrointestinal tract. Skrzydło-Radomańska B. **Ann Univ Mariae Curie Sklodowska [Med]** 1993;48:115–20 (37 ref.)

Tachykinin peptides, receptors, and peptidases in airway disease. Piedimonte G. **Exp Lung Res** 1995 Nov-Dec; 21(6):809–34 (154 ref.)

MEMBRANE POTENTIALS

Slow fluorescent indicators of membrane potential: a survey of different approaches to probe response analysis. Plášek J, et al. **J Photochem Photobiol B** 1996 Apr;33(2):101–24 (206 ref.)

GENETICS

Depolarization-transcription coupling in excitable cells. Schmidt J. **Rev Physiol Biochem Pharmacol** 1996; 127:251–79 (158 ref.)

PHYSIOLOGY

Intrinsic properties of motoneurons. Implications for muscle fatigue. Sawczuk A, et al. **Adv Exp Med Biol** 1995; 384:123–34 (86 ref.)

The resting membrane potential of cells are measures of electrical work, not of ionic currents. Veech RL, et al. **Integr Physiol Behav Sci** 1995 Sep-Dec;30(4):283–307 (46 ref.)

Utility of auditory P300 in detection of presenile dementia. Filipović SR, et al. **J Neurol Sci** 1995 Aug;131(2):150–5 (25 ref.)

Spatial organization of cardiac gap junctions can affect access resistance. Hall JE, et al. **Microsc Res Tech** 1995 Aug 1; 31(5):446–51 (30 ref.)

Basic concepts in cellular cardiac electrophysiology: Part I: Ion channels, membrane currents, and the action potential. Whalley DW, et al. **Pacing Clin Electrophysiol** 1995 Aug; 18(8):1556–74 (72 ref.)

Depolarization-transcription coupling in excitable cells. Schmidt J. **Rev Physiol Biochem Pharmacol** 1996; 127:251–79 (158 ref.)

MEMBRANE PROTEINS

ANALYSIS

Receptors for calcitonin, calcitonin gene related peptide, amylin, and adrenomedullin. Muff R, et al. **Can J Physiol Pharmacol** 1995 Jul;73(7):963–7 (54 ref.)

Glycosylphosphatidylinositol (GPI)–anchored membrane proteins in clinical pathophysiology of paroxysmal nocturnal hemoglobinuria (PNH). Shichishima T. **Fukushima J Med Sci** 1995 Jun;41(1):1–13 (45 ref.)

Identification of endothelial cell–surface proteins as targets for diagnosis and treatment of disease. Jacobson BS, et al. **Nat Med** 1996 Apr;2(4):482–4 (22 ref.)

v- and t-SNAREs in neuronal exocytosis: a need for additional components to define sites of release. Galli T, et al. **Neuropharmacology** 1995 Nov;34(11):1351–60 (63 ref.)

Biochemical approaches to the detection and characterization of membrane proteins carrying blood group determinants. Blanchard D. **Transfus Clin Biol** 1995;2(4):217–22 (19 ref.)

[Immunohistochemical observation of Fas in the liver with chronic hepatitis C] Takatani M, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:667–74 (23 ref.) **(Jpn)**

BIOSYNTHESIS

How glycosylphosphatidylinositol–anchored membrane proteins are made. Udenfriend S, et al. **Annu Rev Biochem** 1995;64:563–91 (129 ref.)

Molecular basis of cell integrity and morphogenesis in Saccharomyces cerevisiae. Cid VJ, et al. **Microbiol Rev** 1995 Sep;59(3):345–86 (463 ref.)

Overexpression of integral membrane proteins for structural studies. Grisshammer R, et al. **Q Rev Biophys** 1995 Aug; 28(3):315–422 (455 ref.)

CHEMISTRY

A comparison of the transmembrane domains of Golgi and plasma membrane proteins. Munro S. **Biochem Soc Trans** 1995 Aug;23(3):527–30 (28 ref.)

Biophysics of the membrane interface. Watts A. **Biochem Soc Trans** 1995 Nov;23(4):959–65 (27 ref.)

Reconstitution of membrane proteins into liposomes: application to energy-transducing membrane proteins. Rigaud JL, et al. **Biochim Biophys Acta** 1995 Oct 10; 1231(3):223–46 (128 ref.)

Engineering membrane proteins. Popot JL, et al. **Curr Opin Biotechnol** 1995 Aug;6(4):394–402 (90 ref.)

Molecular characterization of the epithelial Na–K–Cl cotransporter isoforms. Payne JA, et al. **Curr Opin Cell Biol** 1995 Aug;7(4):493–503 (73 ref.)

Protein folds in channel structure. Montal M. **Curr Opin Struct Biol** 1996 Aug;6(4):499–510 (111 ref.)

Characterization and modeling of membrane proteins using sequence analysis. Reithmeier RA. **Curr Opin Struct Biol** 1995 Aug;5(4):491–500 (79 ref.)

Porins: general to specific, native to engineered passive pores. Schulz GE. **Curr Opin Struct Biol** 1996 Aug;6(4):485–90 (61 ref.)

Transmembrane domains participate in functions of integral membrane proteins. Ramasarma T. **Indian J Biochem Biophys** 1996 Feb;33(1):20–9 (25 ref.)

Toward a molecular understanding of the structure and function of the nuclear pore complex. Panté N, et al. **Int Rev Cytol** 1995;162B:225–55 (103 ref.)

5-Lipoxygenase-activating protein (FLAP). Vickers PJ. **J Lipid Mediat Cell Signal** 1995 Oct;12(2–3):185–94 (46 ref.)

Computing the field in proteins and channels. Eisenberg RS. **J Membr Biol** 1996 Mar;150(1):1–25 (267 ref.)

Crystallization and structure analysis of membrane proteins. Newman R. **Methods Mol Biol** 1996;56:365–87 (109 ref.)

Structure and function of the natural-resistance-associated macrophage protein (Nramp1), a candidate protein for infectious and autoimmune disease susceptibility. Blackwell JM. **Mol Med Today** 1996 May;2(5):205–11 (38 ref.)

Membrane protein structure: the contribution and potential of novel solid state NMR approaches. Watts A, et al. **Mol Membr Biol** 1995 Jul–Sep;12(3):233–46 (118 ref.)

Overexpression of integral membrane proteins for structural studies. Grisshammer R, et al. **Q Rev Biophys** 1995 Aug; 28(3):315–422 (455 ref.)

Structure and function of bacterial light-harvesting complexes. Kühlbrandt W. **Structure** 1995 Jun 15;3(6):521–5 (17 ref.)

Molecular recognition between membrane-spanning polypeptides. Shai Y. **Trends Biochem Sci** 1995 Nov; 20(11):460–4 (42 ref.)

GENETICS

Schwannomin: new insights into this member of the band 4.1 superfamily. Belliveau MJ, et al. **Biochem Cell Biol** 1995 Sep–Oct;73(9–10):733–7 (44 ref.)

The molecular basis of paroxysmal nocturnal hemoglobinuria. Rosse WF, et al. **Blood** 1995 Nov 1;86(9):3277–86 (123 ref.)

Notch-related genes in animal development. Lardelli M, et al. **Int J Dev Biol** 1995 Oct;39(5):769–80 (106 ref.)

T cell development in CD3-zeta mutant mice. Huang MT. **Int Rev Immunol** 1995;13(1):29–41 (81 ref.)

Natural resistance to infection with intracellular parasites: molecular genetics identifies Nramp1 as the Bcg/Ity/Lsh locus. Vidal S, et al. **J Leukoc Biol** 1995 Oct;58(4):382–90 (61 ref.)

Over-production of proteins in Escherichia coli: mutant hosts that allow synthesis of some membrane proteins and globular proteins at high levels. Miroux B, et al. **J Mol Biol** 1996 Jul 19;260(3):289–98 (27 ref.)

Red cell membrane polypeptides under normal conditions and in genetic disorders. Delaunay J. **Transfus Clin Biol** 1995;2(4):207–16 (29 ref.)

Review: the dominant flocculation genes of Saccharomyces cerevisiae constitute a new subtelomeric gene family. Teunissen AW, et al. **Yeast** 1995 Sep 15;11(11):1001–13 (57 ref.)

IMMUNOLOGY

[Role of Fas system in apoptosis induced by hepatitis C virus infection] Mita E, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:198–202 (14 ref.) **(Jpn)**

ISOLATION & PURIFICATION

The purification of membranes by affinity partitioning. Persson A, et al. **FASEB J** 1995 Oct;9(13):1304–10 (48 ref.)

Strategies for crystallizing membrane proteins. Garavito RM, et al. **J Bioenerg Biomembr** 1996 Feb;28(1):13–27 (80 ref.)

Production of crystallizable fragments of membrane proteins. Hendrickson WA. **J Bioenerg Biomembr** 1996 Feb; 28(1):35–40 (40 ref.)

METABOLISM

COPs regulating membrane traffic. Kreis TE, et al. **Ann Rev Cell Dev Biol** 1995;11:677–706 (165 ref.)

Lipid vs protein theories of alcohol action in the nervous system. Peoples RW, et al. **Annu Rev Pharmacol Toxicol** 1996;36:185–201 (112 ref.)

Protein palmitoylation in membrane trafficking. Mundy DI. **Biochem Soc Trans** 1995 Aug;23(3):572–6 (43 ref.)

Isoprenylation/methylation of proteins enhances membrane association by a hydrophobic mechanism. Parish CA, et al. **Biochemistry** 1996 Jul 2;35(26):8473–7 (63 ref.)

Intracellular trafficking of lysosomal membrane proteins. Hunziker W, et al. **Bioessays** 1996 May;18(5):379–89 (88 ref.)

Molecular glue: kinase anchoring and scaffold proteins. Faux MC, et al. **Cell** 1996 Apr 5;85(1):9–12 (19 ref.)

Membrane traffic. Is the Golgi complex? Armstrong J. **Curr Biol** 1995 Sep 1;5(9):980–1 (10 ref.)

Calcium signalling. Cracking ICRAC in the eye. Bennett DL, et al. **Curr Biol** 1995 Nov 1;5(11):1225–8 (22 ref.)

Developmental signaling. Vertebrate ligands for Notch. Nye JS, et al. **Curr Biol** 1995 Sep 1;5(9):966–9 (25 ref.)

Aquaporin water channels: unanswered questions and unresolved controversies. Agre P, et al. **Curr Opin Cell Biol** 1995 Aug;7(4):472–83 (84 ref.)

Membrane fusion in organelle biogenesis. Denesvre C, et al. **Curr Opin Cell Biol** 1996 Aug;8(4):519–23 (45 ref.)

Recent advances in understanding signal transduction pathways in worms and flies. Duffy JB, et al. **Curr Opin Cell Biol** 1996 Apr;8(2):231–8 (44 ref.)

Membranes and sorting [editorial] Gruenberg J, et al. **Curr Opin Cell Biol** 1995 Aug;7(4):519–22 (14 ref.)

Membrane transport in the endocytic pathway. Gruenberg J, et al. **Curr Opin Cell Biol** 1995 Aug;7(4):552–63 (127 ref.)

Cell surface organization by the membrane skeleton. Kusumi A, et al. **Curr Opin Cell Biol** 1996 Aug;8(4):566–74 (76 ref.)

Caveolae and caveolins. Parton RG. **Curr Opin Cell Biol** 1996 Aug;8(4):542–8 (60 ref.)

Sorting and retrieval between the endoplasmic reticulum and Golgi apparatus. Pelham HR. **Curr Opin Cell Biol** 1995 Aug;7(4):530–5 (47 ref.)

New insights into membrane dynamics from the analysis of cell surface interactions by physical methods. Sheets ED, et al. **Curr Opin Cell Biol** 1995 Oct;7(5):707–14 (65 ref.)

5-Lipoxygenase-activating protein (FLAP). Vickers PJ. **J Lipid Mediat Cell Signal** 1995 Oct;12(2–3):185–94 (46 ref.)

Differing shapes of 1 alpha,25-dihydroxyvitamin D3 function as ligands for the D-binding protein, nuclear receptor and membrane receptor: a status report. Norman AW, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1–6 Spec No):13–22 (34 ref.)

Structural and molecular determinants of intercellular coupling in cardiac myocytes. Kanter HL, et al. **Microsc Res Tech** 1995 Aug 1;31(5):357–63 (32 ref.)

Colicin import and pore formation: a system for studying protein transport across membranes? Lazdunski CJ. **Mol Microbiol** 1995 Jun;16(6):1059–66 (84 ref.)

The SMR family: a novel family of multidrug efflux proteins involved with the efflux of lipophilic drugs. Paulsen IT, et al. **Mol Microbiol** 1996 Mar;19(6):1167–75 (64 ref.)

Notch and Wingless signals collide [see comments] Blair SS. **Science** 1996 Mar 29;271(5257):1822–3 (16 ref.) Comment in: Science 1996 Mar 29;271(5257):1826–32.

Phosphoinositides as regulators in membrane traffic. De Camilli P, et al. **Science** 1996 Mar 15;271(5255):1533–9 (74 ref.)

Molecular recognition between membrane-spanning polypeptides. Shai Y. **Trends Biochem Sci** 1995 Nov; 20(11):460–4 (42 ref.)

[Sidedness of biomembrane: asymmetrical distribution and flip-flop of phospholipids across lipid bilayer] Anzai K. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(16):2418–26 (93 ref.) **(Jpn)**

[Oligomeric assemblies of transport adenosine triphosphatases in a membrane bilayer] Boldyrev AA. **Zh Evol Biokhim Fiziol** 1995 Jul–Aug;31(4):375–86 (45 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Zonula occludens (ZO)-1 and ZO-2: membrane-associated guanylate kinase homologues (MAGuKs) of the tight junction. Anderson JM, et al. **Biochem Soc Trans** 1995 Aug; 23(3):470–5 (45 ref.)

Protein targeting to the plant vacuole—a historical perspective. Dombrowski JE, et al. **Braz J Med Biol Res** 1996 Apr;29(4):413–30 (221 ref.)

Clustering membrane proteins: It's all coming together with the PSD-95/SAP90 protein family. Gomperts SN. **Cell** 1996 Mar 8;84(5):659–62 (20 ref.)

Vesicle biogenesis: the coat connection [comment] Mallabiabarrena A, et al. **Cell** 1995 Dec 1;83(5):667–9 (21 ref.) Comment on: Cell 1995 Dec 1;83(5):703–13.

Enigma variations: protein mediators of membrane fusion. Mellman I. **Cell** 1995 Sep 22;82(6):869–72 (17 ref.)

Serpentine proteins slither into the wingless and hedgehog fields. Perrimon N. **Cell** 1996 Aug 23;86(4):513–6 (19 ref.)

Protein translocation across mitochondrial membranes: what a long, strange trip it is. Ryan KR, et al. **Cell** 1995 Nov 17;83(4):517–9 (15 ref.)

SNAREs and the specificity of transport vesicle targeting. Bennett MK. **Curr Opin Cell Biol** 1995 Aug;7(4):581–6 (52 ref.)

Protein tyrosine phosphatases as adhesion receptors. Brady-Kalnay SM, et al. **Curr Opin Cell Biol** 1995 Oct; 7(5):650–7 (58 ref.)

Molecular mechanisms of protein-mediated membrane fusion. Hughson FM. **Curr Opin Struct Biol** 1995 Aug; 5(4):507–13 (60 ref.)

Regulation of interaction between signaling protein CheY and flagellar motor during bacterial chemotaxis. Barak R, et al. **Curr Top Cell Regul** 1996;34:137–58 (156 ref.)

Peptides and gastrointestinal mucosal integrity. Playford RJ. **Gut** 1995 Nov;37(5):595–7 (24 ref.)

Transmembrane domains participate in functions of integral membrane proteins. Ramasarma T. **Indian J Biochem Biophys** 1996 Feb;33(1):20–9 (25 ref.)

Biology of flt3 ligand and receptor. Lyman SD. **Int J Hematol** 1995 Aug;62(2):63–73 (42 ref.)

Characterization of Pref-1 and its inhibitory role in adipocyte differentiation. Smas CM, et al. **Int J Obes Relat Metab Disord** 1996 Mar;20 Suppl 3:S65–72 (44 ref.)

ADAM, a novel family of membrane proteins containing A Disintegrin And Metalloprotease domain: multipotential functions in cell–cell and cell–matrix interactions. Wolfsberg TG, et al. **J Cell Biol** 1995 Oct;131(2):275–8 (22 ref.)

Regulation of voltage-dependent sodium channels. Cukierman S. **J Membr Biol** 1996 Jun;151(3):203–14 (64 ref.)

Plasma-membrane-bound macromolecules are dynamically aggregated to form non-random codistribution patterns of selected functional elements. Do pattern recognition processes govern antigen presentation and intercellular interactions? Vereb G, et al. **J Mol Recognit** 1995 Jul–Aug; 8(4):237–46 (78 ref.)

CD27–CD70 interaction: unravelling its implication in normal and neoplastic B-cell growth. Lens SM, et al. **Leuk Lymphoma** 1995 Jun;18(1–2):51–9 (78 ref.)

Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells. Drexler HG. **Leukemia** 1996 Apr; 10(4):588–99 (118 ref.)

The role of Notch in lateral inhibition and cell fate specification. Chitnis AB. **Mol Cell Neurosci** 1995 Aug; 6(4):311–21 (70 ref.)

Genetic mechanisms of early neurogenesis in Drosophila melanogaster. Campos-Ortega JA. **Mol Neurobiol** 1995 Apr–Jun;10(2–3):75–89 (97 ref.)

Is human patched the gatekeeper of common skin cancers? [news; comment] Sidransky D. **Nat Genet** 1996 Sep; 14(1):7–8 (11 ref.) Comment on: Nat Genet 1996 Sep;14(1):78–81.

Protein trafficking and polarity in kidney epithelium: from cell biology to physiology. Brown D, et al. **Physiol Rev** 1996 Jan;76(1):245–97 (357 ref.)

Synaptic vesicle proteins and regulated exocytosis. Elferink LA, et al. **Prog Brain Res** 1995;105:79–85 (42 ref.)

Nucleobase and nucleoside transport in mammalian cells. Kraupp M, et al. **Wien Klin Wochenschr** 1995; 107(22):677–80 (36 ref.)

An overview of membrane transport proteins in Saccharomyces cerevisiae. Andre B. **Yeast** 1995 Dec; 11(16):1575–611 (258 ref.)

[Flippases—phospholipid transporting proteins] Pulaski L. **Postepy Biochem** 1995;41(2):131–8 (78 ref.) **(Pol)**

[The Fas/APO-1 antigen—a molecule mediating apoptosis] Baryshnikov AIu, et al. **Gematol Transfuziol** 1995 Nov–Dec;40(6):35–8 (28 ref.) **(Rus)**

ULTRASTRUCTURE

Molecular dissection of the nuclear pore complex. Panté N, et al. **Crit Rev Biochem Mol Biol** 1996 Apr;31(2):153–99 (110 ref.)

Crystallization and structure analysis of membrane proteins.

MEMBRANE PROTEINS

Newman R. **Methods Mol Biol** 1996;56:365-87 (109 ref.)

MEMBRANE PROTEINS, VIRAL see **VIRAL MATRIX PROTEINS**

MEMBRANES

see related
CELL MEMBRANE
CELL WALL
INTRACELLULAR MEMBRANES
MEMBRANE LIPIDS
MEMBRANE PROTEINS
NUCLEAR MEMBRANE
SYNOVIAL MEMBRANE

CHEMISTRY

Visualizing life on biomembranes by atomic force microscopy. Oberleithner H, et al. **Kidney Int** 1995 Oct; 48(4):923-9 (27 ref.)

METABOLISM

Membranes and sorting [editorial] Gruenberg J, et al. **Curr Opin Cell Biol** 1995 Aug;7(4):519-22 (14 ref.)

ULTRASTRUCTURE

Visualizing life on biomembranes by atomic force microscopy. Oberleithner H, et al. **Kidney Int** 1995 Oct; 48(4):923-9 (27 ref.)

MEMBRANES, ARTIFICIAL

Hemodialyzer performance: biological indices. Holmes CJ. **Artif Organs** 1995 Nov;19(11):1126-35 (62 ref.)

Ultrafiltration and backfiltration during hemodialysis. Ofsthun NJ, et al. **Artif Organs** 1995 Nov;19(11):1143-61 (81 ref.)

Hemodialyzer performance: a review of the trends over the past two decades. Woffindin C, et al. **Artif Organs** 1995 Nov;19(11):1113-9 (14 ref.)

Prevention of dialysis-related amyloidosis using the polyacrylonitrile AN69 membrane. Chanard J. **Contrib Nephrol** 1995;112:137-44 (23 ref.)

Development of a PMMA membrane which can remove beta 2-microglobulin and its clinical significance. Kunitomo T, et al. **Contrib Nephrol** 1995;112:145-55 (22 ref.)

Membrane based ethanol separation process. Choudhury JP, et al. **Hindustan Antibiot Bull** 1994 Aug-Nov; 36(3-4):135-40 (32 ref.)

Ultrafiltration membranes in biotechnology. Ghose TK. **Hindustan Antibiot Bull** 1994 Aug-Nov;36(3-4):173-90 (26 ref.)

Membrane separations in biotechnology. Musale DA, et al. **Hindustan Antibiot Bull** 1994 Aug-Nov;36(3-4):157-63 (24 ref.)

Mass transfer limitations to the performance of membrane bioartificial liver support devices. Catapano G. **Int J Artif Organs** 1996 Jan;19(1):18-35 (70 ref.)

Acute renal failure and membranes. Some medical and ethical questions [editorial] Schaefer K, et al. **Int J Artif Organs** 1996 Mar;19(3):145-6 (4 ref.)

Biocompatibility: is it a relevant consideration for today's haemodialysis? [editorial] Shaldon S, et al. **Int J Artif Organs** 1996 Apr;19(4):201-14 (105 ref.)

Devices for dentoalveolar regeneration: an up-to-date literature review. Hardwick R, et al. **J Periodontol** 1995 Jun;66(6):495-505 (58 ref.)

Periodontal regenerative potential of space-providing expanded polytetrafluoroethylene membranes and recombinant human bone morphogenetic proteins. Sigurdsson TJ, et al. **J Periodontol** 1995 Jun;66(6):511-21 (37 ref.)

Membranes for dialysis. Klinkmann H, et al. **Nephrol Dial Transplant** 1995;10 Suppl 3:39-45 (43 ref.)

Biocompatible intermittent hemodialysis. Lang S, et al. **New Horiz** 1995 Nov;3(4):680-7 (56 ref.)

Supported membranes: scientific and practical applications. Sackmann E. **Science** 1996 Jan 5;271(5245):43-8 (40 ref.)

[The role of dialysis membranes in elimination of uremic toxins] Grzeszczak W, et al. **Przegl Lek** 1996;53(5):439-42 (27 ref.) **(Pol)**

MEMBRANES, INTRACELLULAR see **INTRACELLULAR MEMBRANES**

MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS see **GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE**

MEMBRANOUS GLOMERULOPATHY see **GLOMERULONEPHRITIS, MEMBRANOUS**

MEMORY

The MILD interview: evaluating complaints of memory loss. Meharg SS, et al. **Am Fam Physician** 1996 Jul;54(1):167-72 (20 ref.)

Treating the traumatic memories of patients with dissociative identity disorder. Kluft RP. **Am J Psychiatry** 1996 Jul;153(7 Suppl):103-10 (77 ref.)

Sleep stages, memory and learning. Dotto L. **Can Med Assoc J** 1996 Apr 15;154(8):1193-6 (12 ref.)

The functional anatomy of memory. Fletcher PC, et al. **Experientia** 1995 Dec 18;51(12):1197-207 (32 ref.)

Process dissociation, single-process theories, and recognition memory. Ratcliff R, et al. **J Exp Psychol Gen** 1995 Dec; 124(4):352-74 (41 ref.)

Minireview. Galanin-acetylcholine interactions: relevance to memory and Alzheimer's disease. Crawley JN. **Life Sci** 1996;58(24):2185-99 (112 ref.)

Memory for proper names: a review. Cohen G, et al. **Memory** 1993 Dec;1(4):249-63 (36 ref.)

Memory tools for the researcher and clinician. Gathercole SE, et al. **Memory** 1994 Jun;2(2):97-101 (14 ref.)

The generalisability of confidence-accuracy studies in eyewitnessing. Gruneberg MM, et al. **Memory** 1993 Sep; 1(3):185-9 (8 ref.)

Forgotten variables in memory theory and research. Mullin PA, et al. **Memory** 1993 Mar;1(1):43-64 (130 ref.)

Flies, genes, learning, and memory. Greenspan RJ. **Neuron** 1995 Oct;15(4):747-50 (29 ref.)

Separate digits tests: a brief history, a literature review, and a reexamination of the factor structure of the Test of Memory and Learning (TOMAL). Ramsay MC, et al. **Neuropsychol Rev** 1995 Sep;5(3):151-71 (58 ref.)

[Genes and the modulation of learning and memory] Xiong Y, et al. **Sheng Li Ke Hsueh Chin Chan** 1995 Oct; 26(4):293-8 (19 ref.) (Eng. Abstr.) **(Chi)**

[Neurobiology of learning and memory and anti-dementia drug] Ishikawa K. **Nippon Yakurigaku Zasshi** 1995 Aug; 106(2):67-76 (76 ref.) (Eng. Abstr.) **(Jpn)**

[Molecular mechanism of learning and memory with genetics] Yagi T. **Tanpakushitsu Kakusan Koso** 1995 Oct; 40(14):2175-80 (31 ref.) **(Jpn)**

CLASSIFICATION

Refining the taxonomy of memory [comment] Robbins TW. **Science** 1996 Sep 6;273(5280):1353-4 (11 ref.) Comment on: Science 1996 Sep 6;273(5280):1399-402.

DRUG EFFECTS

Addictive drugs as reinforcers: multiple partial actions on memory systems. White NM. **Addiction** 1996 Jul; 91(7):921-49; discussion 951-65 (304 ref.)

Learning during anaesthesia: a review. Andrade J. **Br J Psychol** 1995 Nov;86 (Pt 4):479-506 (110 ref.)

Effects of amylin on appetite regulation and memory. Morley JE, et al. **Can J Physiol Pharmacol** 1995 Jul;73(7):1042-6 (60 ref.)

[The assessment of drug effects on memory in animals] Hironaka N. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1995 Jun;15(3):211-22 (89 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Two components of long-term memory. Woźniak PA, et al. **Acta Neurobiol Exp (Warsz)** 1995;55(4):301-5 (21 ref.)

Human rehearsal processes and the frontal lobes: PET evidence. Awh E, et al. **Ann N Y Acad Sci** 1995 Dec 15; 769:97-117 (37 ref.)

Stress, aging, and memory. Involvement of peripheral catecholamines. Mabry TR, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:512-22 (53 ref.)

Neuronal actions of dehydroepiandrosterone. Possible roles in brain development, aging, memory, and affect. Majewska MD. **Ann N Y Acad Sci** 1995 Dec 29;774:111-20 (86 ref.)

Frontal lobes, memory, and aging. Moscovitch M, et al. **Ann N Y Acad Sci** 1995 Dec 15;769:119-50 (228 ref.)

Functional organization of the human frontal cortex for mnemonic processing. Evidence from neuroimaging studies. Petrides M. **Ann N Y Acad Sci** 1995 Dec 15; 769:85-96 (25 ref.)

Memory and the prefrontal cortex. Shimamura AP. **Ann N Y Acad Sci** 1995 Dec 15;769:151-9 (44 ref.)

Long-term potentiation and learning. Martinez JL Jr, et al. **Annu Rev Psychol** 1996;47:173-203 (150 ref.)

Aspects of the search for neural mechanisms of memory. Rosenzweig MR. **Annu Rev Psychol** 1996;47:1-32 (150 ref.)

The neuroethological development of food-storing memory: a case of use it, or lose it! Clayton NS. **Behav Brain Res** 1995 Sep;70(1):95-102 (54 ref.)

The sequential hypothesis of the function of sleep. Giuditta A, et al. **Behav Brain Res** 1995 Jul-Aug;69(1-2):157-66 (91 ref.)

Processing of learned information in paradoxical sleep: relevance for memory. Hennevin E, et al. **Behav Brain Res** 1995 Jul-Aug;69(1-2):125-35 (97 ref.)

Sleep states and memory processes. Smith C. **Behav Brain Res** 1995 Jul-Aug;69(1-2):137-45 (82 ref.)

Cognitive functions of the basal forebrain cholinergic system in monkeys: memory or attention? Voytko ML. **Behav Brain Res** 1996 Feb;75(1-2):13-25 (123 ref.)

A role for immediate-early transcription factors in learning and memory. Dragunow M. **Behav Genet** 1996 May; 26(3):293-9 (55 ref.)

The use of null mutant mice to study complex learning and memory processes. Wehner JM, et al. **Behav Genet** 1996 May;26(3):301-12 (75 ref.)

Flies, genes, and memory engineering. Gelperin A. **Biol Bull** 1996 Aug;191(1):139-43 (95 ref.)

Noun and verb retrieval by normal subjects. Studies with PET. Warburton E, et al. **Brain** 1996 Feb;119 (Pt 1):159-79 (85 ref.)

Exploring memory functions by means of brain electrical topography: a review. Rösler F, et al. **Brain Topogr** 1995 Summer;7(4):301-13 (45 ref.)

Development and plasticity of the neural circuitry underlying visual recognition memory. Webster MJ, et al. **Can J Physiol Pharmacol** 1995 Sep;73(9):1364-71 (37 ref.)

Oestrogens and the structural and functional plasticity of neurons: implications for memory, ageing and neurodegenerative processes. McEwen BS, et al. **Ciba Found Symp** 1995;191:52-66; discussion 66-73 (43 ref.)

Perception and memory: action and interaction. Eacott MJ, et al. **Crit Rev Neurobiol** 1995;9(4):311-20 (50 ref.)

Memory mechanisms. Photographic memory in flies. Goda Y. **Curr Biol** 1995 Aug 1;5(8):852-3 (11 ref.)

Neural networks. Sleep and memory. Sejnowski TJ. **Curr Biol** 1995 Aug 1;5(8):832-4 (14 ref.)

Building action repertoires: memory and learning functions of the basal ganglia. Graybiel AM. **Curr Opin Neurobiol** 1995 Dec;5(6):733-41 (89 ref.)

The role of the hippocampus in declarative memory: a comment on Zola-Morgan, Squire, and Ramus (1994) [letter; comment] Nadel L. **Hippocampus** 1995;5(3):232-9 (20 ref.) Comment on: Hippocampus 1994 Aug;4(4):483-95.

Configural association theory and the hippocampal formation: an appraisal and reconfiguration. Rudy JW, et al. **Hippocampus** 1995;5(5):375-89 (80 ref.)

Synaptic plasticity: stairway to memory. Jodar L, et al. **Jpn J Pharmacol** 1995 Aug;68(4):359-87 (285 ref.)

The biochemistry of learning and memory. Fagnou DD, et al. **Mol Cell Biochem** 1995 Aug-Sep;149-150:279-86 (84 ref.)

Involvement of LTP in memory: are we "searching under the street light"? Barnes CA. **Neuron** 1995 Oct;15(4):751-4 (21 ref.)

Molecular enhancement of memory formation. Carew TJ. **Neuron** 1996 Jan;16(1):5-8 (24 ref.)

The mental and the neural: psychological and neural studies of mental rotation and memory scanning. Georgopoulos AP, et al. **Neuropsychologia** 1995 Nov;33(11):1531-47 (25 ref.)

Long-term potentiation and N-methyl-D-aspartate receptors: foundations of memory and neurologic disease? Rison RA, et al. **Neurosci Biobehav Rev** 1995 Winter; 19(4):533-52 (223 ref.)

The gene knockout technology for the analysis of learning and memory, and neural development. Tonegawa S, et al. **Prog Brain Res** 1995;105:3-14 (43 ref.)

Synaptic mechanisms of olfactory recognition memory. Kaba H, et al. **Rev Neurosci** 1995 Apr-Jun;6(2):125-41 (128 ref.)

Functional brain imaging studies of cortical mechanisms for memory. Ungerleider LG. **Science** 1995 Nov 3; 270(5237):769-75 (94 ref.)

Cell-adhesion molecules, glucocorticoids and long-term-memory formation. Rose SP. **Trends Neurosci** 1995 Nov;18(11):502-6 (46 ref.)

[Paradoxical sleep and memory processes in humans] Guerrien A. **Acta Psychiatr Belg** 1994 Mar-Apr;94(2):75-87 (43 ref.) (Eng. Abstr.) **(Fre)**

[Memory and synaptic plasticity] Maitre M. **Ann Biol Clin (Paris)** 1996;54(2):49-66 (164 ref.) (Eng. Abstr.) **(Fre)**

[Genetic approaches to the study of memory in insects] Lopatina NG, et al. **Fiziol Zh Im I M Sechenova** 1995 Aug; 81(8):63-8 (12 ref.) (Eng. Abstr.) **(Rus)**

MEMORY DISORDERS

Aging and performance on implicit memory tasks: a brief review. Jelicic M. **Int J Neurosci** 1995 Jun;82(3-4):155-61 (46 ref.)

The False Memory Syndrome debate--will the victim please stand up? Choiniere M. **J Contemp Health Law Policy** 1996 Spring;12(2):675-700 (201 ref.)

DIAGNOSIS

Memory tools for the researcher and clinician. Gathercole SE, et al. **Memory** 1994 Jun;2(2):97-101 (14 ref.)

[Evaluation of memory in neuropsychological clinic] Benedet MJ. **Rev Neurol** 1996 Aug;24(132):914-20 (36 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

The nitric oxide pathway: potential implications for treatment of neuropsychiatric disorders. Karatinos J, et al. **Clin Neuropharmacol** 1995 Dec;18(6):482-99 (83 ref.)

ETIOLOGY

[Neuropsychiatric symptoms in vitamin B12 deficiency and microcarcinoidosis. The complications of chronic atrophic gastritis] Osege LM, et al. **Dtsch Med Wochenschr** 1996 Jun 7;121(23):758-62 (25 ref.) (Eng. Abstr.) **(Ger)**

[Neuropsychological description of memory impairment following cortical and subcortical brain injuries] Jodzio K. **Psychiatr Pol** 1995 Jul-Aug;29(4):491-501 (29 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOPATHOLOGY

Perception, learning and identification studied with reversible

suppression of cortical visual areas in monkeys. Horel JA. **Behav Brain Res** 1996 Apr;76(1-2):199-214 (90 ref.)

REHABILITATION

Rehabilitation and management of memory problems. Wilson BA. **Acta Neurol Belg** 1996 Mar;96(1):51-4 (19 ref.)

THERAPY

The efficacy of imagery mnemonics in memory remediation. Richardson JT. **Neuropsychologia** 1995 Nov;33(11):1345-57 (103 ref.)

MEMORY FOR DESIGNS TEST see **NEUROPSYCHOLOGICAL TESTS**

MEMORY, IMMEDIATE see **MEMORY, SHORT-TERM**

MEMORY, SHORT-TERM

Working memory and older adults: implications for occupational therapy. Andiel C, et al. **Am J Occup Ther** 1995 Jul-Aug;49(7):681-6 (42 ref.)

Interference in short-term memory: the magical number two (or three) in sentence processing. Lewis RL. **J Psycholinguist Res** 1996 Jan;25(1):93-115 (80 ref.)

PHYSIOLOGY

General and specific speed mediation of adult age differences in memory. Salthouse TA. **J Gerontol B Psychol Sci Soc Sci** 1996 Jan;51(1):P30-42 (32 ref.)

MEN 1 see **MULTIPLE ENDOCRINE NEOPLASIA TYPE 1**

MEN 2 see **MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A**

MEN 2A see **MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A**

MEN 2B see **MULTIPLE ENDOCRINE NEOPLASIA TYPE 2B**

MEN 3 see **MULTIPLE ENDOCRINE NEOPLASIA TYPE 2B**

MENADIONE see **VITAMIN K**

MENADIONE REDUCTASE see **NAD(P)H DEHYDROGENASE (QUINONE)**

MENAQUINONE see **VITAMIN K**

MENIERE'S DISEASE

COMPLICATIONS

Posturography--applications and limitations in the management of the dizzy patient. Harcourt JP. **Clin Otolaryngol** 1995 Aug;20(4):299-302 (24 ref.)

[Vestibular nerve section for medically uncontrollable vertigo with Menière's disease] Kohmura E, et al. **No Shinkei Geka** 1995 Sep;23(9):767-72 (18 ref.) **(Jpn)**

DIAGNOSIS

Neurotology. Baloh RW, et al. **Neurol Clin** 1996 Feb; 14(1):85-101 (22 ref.)

DRUG THERAPY

The pharmacological treatment of Menière's disease. Brookes GB. **Clin Otolaryngol** 1996 Feb;21(1):3-11 (78 ref.)

MENIERE'S SYNDROME see **MENIERE'S DISEASE**

MENINGEAL NEOPLASMS

Inflammatory meningiomas of the internal auditory canals. Doyle KJ, et al. **Otolaryngol Head Neck Surg** 1995 Nov; 113(5):617-20 (8 ref.)

COMPLICATIONS

[En-plaque meningioma as a rare cause of an osteosclerotic bone tumor of the frontal bone] Steidle B, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1995 Oct;163(4):350-2 (10 ref.) **(Ger)**

[Syringomyelia associated with tentorial meningioma] Sasaki J, et al. **No To Shinkei** 1995 Aug;47(8):795-8 (13 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Distinction of masses involving the sella and suprasellar space: specificity of imaging features. Donovan JL, et al. **AJR Am J Roentgenol** 1996 Sep;167(3):597-603 (69 ref.)

Radiation-induced meningioma in children: report of two cases and review of the literature. Starshak RJ. **Pediatr Radiol** 1996;26(8):537-41 (30 ref.)

[The diagnosis and treatment of meningeal carcinomatosis] Aparicio Urtasun J, et al. **Rev Clin Esp** 1995 Dec; 195(12):856-63 (71 ref.) **(Spa)**

DRUG THERAPY

Mifepristone: antineoplastic studies. Sartor O, et al. **Clin Obstet Gynecol** 1996 Jun;39(2):498-505 (28 ref.)

ETIOLOGY

Case report: late aggressive meningioma following prophylactic cranial irradiation for acute lymphoblastic leukaemia. Stein ME, et al. **Br J Radiol** 1995 Oct; 68(814):1123-5 (13 ref.)

PATHOLOGY

Meningioangiomatosis and oligodendroglioma in a 15-year-old boy. López JI, et al. **Arch Pathol Lab Med** 1996 Jun;120(6):587-90 (11 ref.)

Meningioangiomatosis. A clinicopathologic study including MIB1 immunoreactivity. Prayson RA. **Arch Pathol Lab Med** 1995 Nov;119(11):1061-4 (34 ref.)

Peritoneal implantation of meningeal melanosis via ventriculoperitoneal shunt: a case report and review of the literature. Gattuso P, et al. **Diagn Cytopathol** 1995 Oct; 13(3):257-9 (19 ref.)

Diffuse bone marrow metastases from glioblastoma multiforme: the role of dural invasion. Kleinschmidt-Demasters BK. **Hum Pathol** 1996 Feb; 27(2):197-201 (22 ref.)

RADIOTHERAPY

Radiotherapy for atypical or malignant intracranial meningioma. Milosevic MF, et al. **Int J Radiat Oncol Biol Phys** 1996 Mar 1;34(4):817-22 (29 ref.)

SECONDARY

Carcinomatous meningitis complicating cervical cancer: a clinicopathologic study and literature review. Aboulafia DM, et al. **Gynecol Oncol** 1996 Feb;60(2):313-8 (19 ref.)

Diffuse spinal leptomeningeal metastases from prostatic cancer. A case report. Matsui H, et al. **Int Orthop** 1995; 19(5):315-8 (18 ref.)

[Meningeal carcinomatosis from pulmonary adenocarcinoma: two clinical cases with review of the literature] Rostagno C, et al. **Ann Ital Med Int** 1995 Oct-Dec;10(4):253-6 (11 ref.) (Eng. Abstr.) **(Ita)**

SURGERY

Surgical and non-surgical treatment of symptomatic intracranial meningiomas. Davis C. **Br J Neurosurg** 1995; 9(3):295-302 (45 ref.)

The cavernous carotid artery: preservation is the best means of reconstruction. Bowles AP Jr, et al. **Clin Neurosurg** 1995; 42:154-70 (41 ref.)

Techniques of carotid reconstruction. Fukushima T. **Clin Neurosurg** 1995;42:119-34 (24 ref.)

Intracranial meningioma and astrocytoma in the same patient. Case report and review of the literature. Dario A, et al. **J Neurosurg Sci** 1995 Mar;39(1):27-35 (44 ref.)

Benign brain tumors. Meningiomas, pituitary tumors, and acoustic neuromas. Black PM. **Neurol Clin** 1995 Nov; 13(4):927-52 (115 ref.)

Resolution of chronic cluster headache after resection of a tentorial meningioma: case report [see comments] Taub E, et al. **Neurosurgery** 1995 Aug;37(2):319-21; discussion 321-2 (27 ref.) Comment in: Neurosurgery 1996 Apr;38(4):849-50.

[A case of thoracic meningioma presenting paraplegia at 4.5 years after removal of a falx meningioma] Suga T, et al. **No Shinkei Geka** 1996 Jun;24(6):567-72 (23 ref.) (Eng. Abstr.) **(Jpn)**

THERAPY

Advances in the treatment of meningeal cancers. Berg SL, et al. **Crit Rev Oncol Hematol** 1995 Aug;20(1-2):87-98 (135 ref.)

MENINGES

CHEMISTRY

Leptomeningeal amyloid and variant transthyretins [comment] Benson MD. **Am J Pathol** 1996 Feb; 148(2):351-4 (19 ref.) Comment on: Am J Pathol 1996 Feb;148(2):361-6.

PATHOLOGY

Xanthoma disseminatum with massive intracranial involvement. Hammond RR, et al. **Clin Neuropathol** 1995 Nov-Dec;14(6):314-21 (32 ref.)

MENINGIOMA

Inflammatory meningiomas of the internal auditory canals. Doyle KJ, et al. **Otolaryngol Head Neck Surg** 1995 Nov; 113(5):617-20 (8 ref.)

COMPLICATIONS

[En-plaque meningioma as a rare cause of an osteosclerotic bone tumor of the frontal bone] Steidle B, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1995 Oct;163(4):350-2 (10 ref.) **(Ger)**

[Syringomyelia associated with tentorial meningioma] Sasaki J, et al. **No To Shinkei** 1995 Aug;47(8):795-8 (13 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Meningioma of the optic nerve sheath. Ortiz O, et al. **AJNR Am J Neuroradiol** 1996 May;17(5):901-6 (13 ref.)

Distinction of masses involving the sella and suprasellar space: specificity of imaging features. Donovan JL, et al. **AJR Am J Roentgenol** 1996 Sep;167(3):597-603 (69 ref.)

Radiation-induced meningioma in children: report of two cases and review of the literature. Starshak RJ. **Pediatr Radiol** 1996;26(8):537-41 (30 ref.)

DRUG THERAPY

Mifepristone: antineoplastic studies. Sartor O, et al. **Clin Obstet Gynecol** 1996 Jun;39(2):498-505 (28 ref.)

[Endocrine treatment of meningiomas: a review] da Motta LA, et al. **Arq Neuropsiquiatr** 1995 Jun;53(2):324-32 (45 ref.) (Eng. Abstr.) **(Por)**

EPIDEMIOLOGY

Meningioma in children: a report of nine cases and a review of the literature. Sheikh BY, et al. **Surg Neurol** 1996 Apr; 45(4):328-35 (71 ref.)

ETIOLOGY

Case report: late aggressive meningioma following prophylactic cranial irradiation for acute lymphoblastic leukaemia. Stein ME, et al. **Br J Radiol** 1995 Oct; 68(814):1123-5 (13 ref.)

GENETICS

[A new tumor suppressor gene responsible for type 2 neurofibromatosis is inactivated in neurinoma and meningioma] Sanson M. **Rev Neurol (Paris)** 1996 Jan; 152(1):1-10 (74 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Meningioangiomatosis and oligodendroglioma in a 15-year-old boy. López JI, et al. **Arch Pathol Lab Med** 1996 Jun;120(6):587-90 (11 ref.)

Meningioangiomatosis. A clinicopathologic study including MIB1 immunoreactivity. Prayson RA. **Arch Pathol Lab Med** 1995 Nov;119(11):1061-4 (34 ref.)

Intracranial meningioma masquerading as a primary pleuropulmonary tumor. Hishima T, et al. **Pathol Int** 1995 Aug;45(8):617-21 (23 ref.)

RADIOGRAPHY

Primary cranial vault lymphoma mimicking meningioma. Isla A, et al. **Neuroradiology** 1996 Apr;38(3):211-3 (18 ref.)

RADIONUCLIDE IMAGING

[The use of SPECT with 201Tl in the evaluation of brain tumors] Prat-Acín R, et al. **Rev Neurol** 1996 Aug; 24(132):909-13 (34 ref.) (Eng. Abstr.) **(Spa)**

RADIOTHERAPY

Management of anterior cranial base and cavernous sinus neoplasms with conservative surgery alone or in combination with fractionated photon or stereotactic proton radiotherapy. Ojemann RG, et al. **Clin Neurosurg** 1995;42:71-98 (76 ref.)

Radiotherapy for atypical or malignant intracranial meningioma. Milosevic MF, et al. **Int J Radiat Oncol Biol Phys** 1996 Mar 1;34(4):817-22 (29 ref.)

SURGERY

Surgical and non-surgical treatment of symptomatic intracranial meningiomas. Davis C. **Br J Neurosurg** 1995; 9(3):295-302 (45 ref.)

The cavernous carotid artery: preservation is the best means of reconstruction. Bowles AP Jr, et al. **Clin Neurosurg** 1995; 42:154-70 (41 ref.)

Techniques of carotid reconstruction. Fukushima T. **Clin Neurosurg** 1995;42:119-34 (24 ref.)

Management of anterior cranial base and cavernous sinus neoplasms with conservative surgery alone or in combination with fractionated photon or stereotactic proton radiotherapy. Ojemann RG, et al. **Clin Neurosurg** 1995;42:71-98 (76 ref.)

Intracranial meningioma and astrocytoma in the same patient. Case report and review of the literature. Dario A, et al. **J Neurosurg Sci** 1995 Mar;39(1):27-35 (44 ref.)

Benign brain tumors. Meningiomas, pituitary tumors, and acoustic neuromas. Black PM. **Neurol Clin** 1995 Nov; 13(4):927-52 (115 ref.)

Resolution of chronic cluster headache after resection of a tentorial meningioma: case report [see comments] Taub E, et al. **Neurosurgery** 1995 Aug;37(2):319-21; discussion 321-2 (27 ref.) Comment in: Neurosurgery 1996 Apr;38(4):849-50.

[Long-term results of the surgical treatment of

MENINGIOMA

spheno-orbital osteomeningioma] Gaillard S, et al. **Neurochirurgie** 1995;41(6):391-7 (34 ref.) (Eng. Abstr.) **(Fre)**

[A case of thoracic meningioma presenting paraplegia at 4.5 years after removal of a falx meningioma] Suga T, et al. **No Shinkei Geka** 1996 Jun;24(6):567-72 (23 ref.) (Eng. Abstr.) **(Jpn)**

THERAPY

Advances in the treatment of meningeal cancers. Berg SL, et al. **Crit Rev Oncol Hematol** 1995 Aug;20(1-2):87-98 (135 ref.)

ULTRASTRUCTURE

Clear cell meningioma: report of a spinal case. Prinz M, et al. **Gen Diagn Pathol** 1996 Mar;141(3-4):261-7 (16 ref.)

MENINGIOMAS, MULTIPLE see **MENINGIOMA**

MENINGIOMATOSIS see **MENINGIOMA**

MENINGITIS

[Non-bacterial meningitis] Holguín J, et al. **Rev Neurol** 1995; 23 Suppl 3:S307-13 (61 ref.) **(Spa)**

CEREBROSPINAL FLUID

[The acid-base balance of cerebrospinal fluid] Kępa L. **Neurol Neurochir Pol** 1996 Jan-Feb;30(1):113-21 (27 ref.) (Eng. Abstr.) **(Pol)**

ETIOLOGY

Carcinomatous meningitis complicating cervical cancer: a clinicopathologic study and literature review. Aboulafia DM, et al. **Gynecol Oncol** 1996 Feb;60(2):313-8 (19 ref.)

Retroperitoneal pseudomeningocele complicated by meningitis following a lumbar burst fracture. A case report. Nairus JG, et al. **Spine** 1996 May 1;21(9):1090-3 (13 ref.)

VETERINARY

Neurobiology of simian and feline immunodeficiency virus infections. Gardner MB, et al. **Curr Top Microbiol Immunol** 1995;202:135-50 (62 ref.)

MENINGITIS, ASEPTIC

CEREBROSPINAL FLUID

[Aseptic meningitis. Demonstration of bacterial DNA in cerebrospinal fluid by gene amplification] Salord F, et al. **Ann Fr Anesth Reanim** 1995;14(4):320-5 (28 ref.) (Eng. Abstr.) **(Fre)**

CHEMICALLY INDUCED

Aseptic meningitis secondary to carbamazepine therapy. Dang CT, et al. **Clin Infect Dis** 1996 Apr;22(4):729-30 (4 ref.)

DIAGNOSIS

Neurologic complications of Bartonella henselae infection. Marra CM. **Curr Opin Neurol** 1995 Jun;8(3):164-9 (65 ref.)

MENINGITIS, BACTERIAL

Remediable recurrent meningitis. Rajeshwari K, et al. **Indian Pediatr** 1995 Apr;32(4):491-6 (28 ref.)

Actinobacillus ureae meningitis: case report and review of the literature. Kingsland RC, et al. **J Emerg Med** 1995 Sep-Oct;13(5):623-7 (37 ref.)

Acute bacterial meningitis [see comments] Tunkel AR, et al. **Lancet** 1995 Dec 23-30;346(8991-8992):1675-80 (60 ref.) Comment in: Lancet 1996 Feb 24;347(9000):536; discussion 538-9. Comment in: Lancet 1996 Feb 24;347(9000):536-7. Comment in: Lancet 1996 Feb 24;347(9000):537. Comment in: Lancet 1996 Feb 24;347(9000):537-8; discussion 538-9. Comment in: Lancet 1996 Feb 24;347(9000):538. Comment in: Lancet 1996 Feb 24;347(9000):539. Comment in: Lancet 1996 Mar 30;347(9005):903.

CEREBROSPINAL FLUID

Diffusion of 3-quaternary ammonium cephem antibiotics into cerebrospinal fluid of patients with bacterial meningitis. Modai J. **J Chemother** 1996 Feb;8 Suppl 2:83-90 (12 ref.)

COMPLICATIONS

Diffuse pneumocephalus due to meningitis: CT findings. Goyal M, et al. **Pediatr Radiol** 1996;26(4):278-9 (5 ref.)

[Hearing loss following bacterial meningitis] Hefer T, et al. **Harefuah** 1995 Aug;129(3-4):138-42 (38 ref.) **(Heb)**

[Cerebrovascular manifestations of infectious diseases] Martínez Vázquez F, et al. **Rev Neurol** 1995;23 Suppl 1:S11-21 (88 ref.) **(Spa)**

DIAGNOSIS

Mycoplasma pneumoniae infection associated with an acute brainstem syndrome. Pellegrini M, et al. **Acta Neurol Scand** 1996 Feb-Mar;93(2-3):203-6 (10 ref.)

[Bacterial brain abscess] Schielke E. **Nervenarzt** 1995 Oct; 66(10):745-53 (47 ref.) (Eng. Abstr.) **(Ger)**

[Meningitis due to streptococcus viridans] Alba D, et al. **Rev Neurol** 1995 May-Jun;23(121):656-60 (87 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

The use of adjunctive therapy to alter the pathophysiology of bacterial meningitis. Roos KL. **Clin Neuropharmacol** 1995 Apr;18(2):138-47 (25 ref.)

Acute bacterial meningitis in adults. Tunkel AR, et al. **Curr Clin Top Infect Dis** 1996;16:215-39 (115 ref.)

What is the role of corticosteroids in meningitis? Harvey DR, et al. **Drugs** 1995 Dec;50(6):945-50 (58 ref.)

Bacterial meningitis. Practical guidelines for management. Rockowitz J, et al. **Drugs** 1995 Nov;50(5):838-53 (98 ref.)

Antibacterial agents in infections of the central nervous system and eye. Papastamelos AG, et al. **Infect Dis Clin North Am** 1995 Sep;9(3):615-37 (81 ref.)

Partially treated meningitis in children--room for clinical judgement [editorial; comment] Ashkenazi S, et al. **Isr J Med Sci** 1995 Oct;31(10):638-9 (20 ref.) Comment on: Isr J Med Sci 1995 Oct;31(10):611-5.

Adjunctive dexamethasone therapy for pediatric bacterial meningitis. Bonadio WA. **J Emerg Med** 1996 Mar-Apr; 14(2):165-72 (40 ref.)

Adjunctive corticosteroid therapy in bacterial meningitis. Lauritsen A, et al. **Scand J Infect Dis** 1995;27(5):431-4 (25 ref.)

[Treatment of acute bacterial meningitis: present and future] Parras F. **Enferm Infecc Microbiol Clin** 1995 Aug-Sep; 13(7):411-8 (63 ref.) **(Spa)**

ETIOLOGY

Infections complicating tunneled intraspinal catheter systems used to treat chronic pain. Byers K, et al. **Clin Infect Dis** 1995 Aug;21(2):403-8 (30 ref.)

Air travel induced meningitis following vestibular schwannoma (acoustic neuroma) surgery. Callanan V, et al. **J Laryngol Otol** 1996 Mar;110(3):258-60 (18 ref.)

Clostridial meningitis as a result of craniocerebral arrow injury. Neal G, et al. **J Trauma** 1996 Mar;40(3):476-80 (23 ref.)

Otogenic Fusobacterium necrophorum meningitis in children. Figueras G, et al. **Pediatr Infect Dis J** 1995 Jul; 14(7):627-8 (10 ref.)

MICROBIOLOGY

Acute bacterial meningitis in adults. Tunkel AR, et al. **Curr Clin Top Infect Dis** 1996;16:215-39 (115 ref.)

Neurologic evaluation of the patient with acute bacterial meningitis. Ashwal S. **Neurol Clin** 1995 Aug;13(3):549-77 (105 ref.)

PHYSIOPATHOLOGY

The use of adjunctive therapy to alter the pathophysiology of bacterial meningitis. Roos KL. **Clin Neuropharmacol** 1995 Apr;18(2):138-47 (25 ref.)

In vitro models of the blood-brain barrier to study bacterial meningitis. Townsend GC, et al. **Trends Microbiol** 1995 Nov;3(11):441-5 (24 ref.)

MENINGITIS, CRYPTOCOCCAL

Cryptococcal meningitis. Jones GA, et al. **Br J Hosp Med** 1995 Nov 1-14;54(9):439-45 (38 ref.)

COMPLICATIONS

Recent advances in the management of cryptococcal meningitis in patients with AIDS. Powderly WG. **Clin Infect Dis** 1996 May;22 Suppl 2:S119-23 (32 ref.)

Cryptococcal meningitis and confusional psychosis. A case report and literature review. Sa'adah MA, et al. **Trop Geogr Med** 1995;47(5):224-6 (20 ref.)

DIAGNOSIS

Neurologic opportunistic infections. Clifford DB. **Curr Opin Neurol** 1995 Jun;8(3):175-8 (32 ref.)

DRUG THERAPY

Recent advances in the management of cryptococcal meningitis in patients with AIDS. Powderly WG. **Clin Infect Dis** 1996 May;22 Suppl 2:S119-23 (32 ref.)

MENINGITIS, FUNGAL

DRUG THERAPY

Therapy of fungal meningitis. Slavoski LA, et al. **Clin Neuropharmacol** 1995 Apr;18(2):95-112 (81 ref.)

MICROBIOLOGY

Meningitis caused by Candida species: an emerging problem in neurosurgical patients. Nguyen MH, et al. **Clin Infect Dis** 1995 Aug;21(2):323-7 (26 ref.)

MENINGITIS, HAEMOPHILUS

DRUG THERAPY

Cefotaxime use in pediatric infections. Dajani AS. **Diagn Microbiol Infect Dis** 1995 May-Jun;22(1-2):105-10 (19 ref.)

ETIOLOGY

Meningitis after adenoidectomy: an anatomic explanation. Isaacson G, et al. **Ann Otol Rhinol Laryngol** 1996 Sep; 105(9):684-8 (18 ref.)

MICROBIOLOGY

[Purulent meningitis with nonserotypable Haemophilus influenzae in infants and adults] Mihancea N, et al. **Bacteriol Virusol Parazitol Epidemiol** 1995 Apr-Jun; 40(2):149-51 (17 ref.) **(Rum)**

MENINGITIS, MENINGOCOCCAL

Meningococcal meningitis. Bhatt KM, et al. **East Afr Med J** 1996 Jan;73(1):35-9 (44 ref.)

ETIOLOGY

[Partial properdin deficiency revealed by a septicemia caused by Neisseria meningitidis] Frémeaux-Bacchi V, et al. **Presse Med** 1995 Sep 30;24(28):1305-7 (14 ref.) (Eng. Abstr.) **(Fre)**

MENINGITIS, PNEUMOCOCCAL

DRUG THERAPY

Management of meningitis caused by penicillin-resistant Streptococcus pneumoniae. París MM, et al. **Antimicrob Agents Chemother** 1995 Oct;39(10):2171-5 (64 ref.)

Cefotaxime use in pediatric infections. Dajani AS. **Diagn Microbiol Infect Dis** 1995 May-Jun;22(1-2):105-10 (19 ref.)

[What antibiotic combinations for pneumococcal meningitis in children in 1996? (editorial)] Bégué P. **Arch Pediatr** 1996 May;3(5):411-3 (16 ref.) **(Fre)**

ETIOLOGY

Meningitis after adenoidectomy: an anatomic explanation. Isaacson G, et al. **Ann Otol Rhinol Laryngol** 1996 Sep; 105(9):684-8 (18 ref.)

[Malformation of the internal ear and recurrent meningitis: radio-surgical correlations] Ruaux C, et al. **Ann Otolaryngol Chir Cervicofac** 1995;112(3):118-22 (21 ref.) (Eng. Abstr.) **(Fre)**

[Meningitis due to cefotaxime-resistant Streptococcus pneumoniae] Martín Fontelos P, et al. **An Esp Pediatr** 1996 Apr;44(4):395-6 (24 ref.) **(Spa)**

MICROBIOLOGY

Meningitis caused by Streptococcus pneumoniae showing high level resistance to penicillin. Wise KA, et al. **Pathology** 1995 Apr;27(2):165-7 (35 ref.)

MENINGITIS, TUBERCULOUS see **TUBERCULOSIS, MENINGEAL**

MENINGITIS, VIRAL

DIAGNOSIS

Acute viral infections. Jackson AC. **Curr Opin Neurol** 1995 Jun;8(3):170-4 (60 ref.)

MENINGOCELE

ETIOLOGY

Retroperitoneal pseudomeningocele complicated by meningitis following a lumbar burst fracture. A case report. Nairus JG, et al. **Spine** 1996 May 1;21(9):1090-3 (13 ref.)

[An intrathoracic meningocele in von Recklinghausen's disease. A case report] Fernández Guerra J, et al. **Arch Bronconeumol** 1995 Oct;31(8):418-20 (19 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

The Currarino syndrome--hereditary transmitted syndrome of anorectal, sacral and presacral anomalies. Case report and review of the literature. Köchling J, et al. **Eur J Pediatr Surg** 1996 Apr;6(2):114-9 (35 ref.)

SURGERY

Thoracic and lumbar meningocele in neurofibromatosis type 1. Report of two cases and review of the literature. Rainov NG, et al. **Neurosurg Rev** 1995;18(2):127-34 (47 ref.)

MENINGOCOCCAL INFECTIONS

Epidemiology and prevention of meningococcal disease. Riedo FX, et al. **Pediatr Infect Dis J** 1995 Aug;14(8):643-57 (163 ref.)

[Meningococcal arthritis] Mader R. **Harefuah** 1995 Sep; 129(5–6):214–6 (26 ref.) **(Heb)**

ETIOLOGY

Neisseria meningitidis peritonitis in a CAPD patient: first case report and review of the literature. Kleinpeter MA, et al. **Adv Perit Dial** 1995;11:168–71 (14 ref.)

METABOLISM

[Meningococcal infectious–toxic shock: pathogenetic features and biochemical signs] Roslyi IM. **Patol Fiziol Eksp Ter** 1996 Jan–Mar;(1):39–43 (71 ref.) **(Rus)**

MENINGOCOCCUS see **NEISSERIA MENINGITIDIS**

MENINGOENCEPHALITIS

CEREBROSPINAL FLUID

[The acid–base balance of cerebrospinal fluid] Kępa L. **Neurol Neurochir Pol** 1996 Jan–Feb;30(1):113–21 (27 ref.) (Eng. Abstr.) **(Pol)**

COMPLICATIONS

Hydrocephalus in mumps meningoencephalitis: case report. Oran B, et al. **Pediatr Infect Dis J** 1995 Aug;14(8):724–5 (10 ref.)

DIAGNOSIS

Balamuthia mandrillaris: a newly recognized agent for amebic meningoencephalitis. Rowen JL, et al. **Pediatr Infect Dis J** 1995 Aug;14(8):705–10 (30 ref.)

DRUG THERAPY

[Emergency drug therapy of meningoencephalitis] Kuzuhara S. **Nippon Naika Gakkai Zasshi** 1995 Nov 10;84(11):1837–42 (5 ref.) **(Jpn)**

ETIOLOGY

Neurological complications in psittacosis: a case report and literature review. Hughes P, et al. **Respir Med** 1995 Oct; 89(9):637–8 (15 ref.)

VETERINARY

Selected models of HIV-induced neurological disease. Narayan O, et al. **Curr Top Microbiol Immunol** 1995; 202:151–66 (61 ref.)

MENISCI, TIBIAL

INJURIES

Popliteal cysts and associated disorders of the knee. Critical review with MR imaging. Sansone V, et al. **Int Orthop** 1995;19(5):275–9 (20 ref.)

[Arthroscopy of the knee joint. Conclusions and recommendations] **Rev Chir Orthop Reparatrice Appar Mot** 1996;82(2):175–86 (0 ref.) **(Fre)**

PATHOLOGY

An intermeniscal fibrous band in a recreational runner. Butler JP, et al. **Arthroscopy** 1995 Dec;11(6):735–7 (16 ref.)

Cyst of the medial meniscus: observation of two cases. Tigani D, et al. **Chir Organi Mov** 1995 Oct–Dec;80(4):449–52 (14 ref.) **(Eng, Ita)**

Magnetic resonance imaging of meniscal tears of the knee [editorial] Dixon AK. **J Bone Joint Surg Br** 1996 Mar; 78(2):174–6 (34 ref.)

SURGERY

An intermeniscal fibrous band in a recreational runner. Butler JP, et al. **Arthroscopy** 1995 Dec;11(6):735–7 (16 ref.)

Meniscus repair: cases and review of the literature. Pellacci F, et al. **Chir Organi Mov** 1995 Jul–Aug;80(3):309–21 (80 ref.)

Discoid medial meniscus: report of a case treated by arthroscopy. Adriani E, et al. **Knee Surg Sports Traumatol Arthrosc** 1993;1(2):107–9 (27 ref.)

MENKES SYNDROME see **KINKY HAIR SYNDROME**

MENOPAUSE

see related
ESTROGEN REPLACEMENT THERAPY
OSTEOPOROSIS, POSTMENOPAUSAL
POSTMENOPAUSE
PREMENOPAUSE

Alternatives to hormone replacement for menopause. Soffa VM. **Altern Ther Health Med** 1996 Mar;2(2):34–9 (46 ref.)

What every woman should know about menopause. Wasaha S, et al. **Am J Nurs** 1996 Jan;96(1):24–32; quiz 33 (9 ref.)

Direction, misdirection and misconception in menopause research and management. Utian WH. **Br J Obstet Gynaecol** 1996 Aug;103(8):736–9 (11 ref.)

Continuous combined estrogen/progestin hormone replacement therapy. Andrews WC. **Clin Ther** 1995 Sep–Oct;17(5):812–26; discussion 811 (70 ref.)

Menopause: its epidemiology and potential association with chronic diseases. Sowers MR, et al. **Epidemiol Rev** 1995; 17(2):287–302 (208 ref.)

Advantages and disadvantages of estrogen treatment by transdermal or oral administration. Rozenbaum H. **Eur J Obstet Gynecol Reprod Biol** 1996 Mar;65(1):33–7 (28 ref.)

European consensus development conference on menopause. European Menopause Society. **Hum Reprod** 1996 May; 11(5):975–9 (0 ref.)

A practical guide to prescribing estrogen replacement therapy. Corson SL. **Int J Fertil Menopausal Stud** 1995 Sep–Oct;40(5):229–47 (140 ref.)

The menopause revisited. Samsioe G. **Int J Gynaecol Obstet** 1995 Oct;51(1):1–13 (35 ref.)

The demography of menopause. Hill K. **Maturitas** 1996 Mar; 23(2):113–27 (18 ref.)

Research on the menopause. Hulka BS, et al. **Maturitas** 1996 Mar;23(2):109–12 (17 ref.)

The normal menopause transition: an overview. McKinlay SM. **Maturitas** 1996 Mar;23(2):137–45 (29 ref.)

The perimenopause and contraception. Shaaban MM. **Maturitas** 1996 Mar;23(2):181–92 (77 ref.)

Menopause. Hargrove JT, et al. **Med Clin North Am** 1995 Nov;79(6):1337–56 (60 ref.)

Menopause and hormone replacement therapy: an overview. Hammond CB. **Obstet Gynecol** 1996 Feb;87(2 Suppl):2S–15S (97 ref.)

[Female sexuality after menopause] Rachev E, et al. **Akush Ginekol (Sofiia)** 1995;34(3):60–2 (10 ref.) **(Bul)**

[Treatment of uterine fibromas] Amiel C, et al. **Ann Chir** 1996;50(1):40–50 (79 ref.) (Eng. Abstr.) **(Fre)**

DRUG EFFECTS

The effects of estradiol valerate plus medroxyprogesterone acetate and conjugated estrogens plus medrogestone on climacteric symptoms and metabolic variables in perimenopausal women. Egarter C, et al. **Acta Obstet Gynecol Scand** 1996 Apr;75(4):386–93 (40 ref.)

The women's health agenda: evolution of hormone replacement therapy as treatment and prophylaxis for coronary artery disease. King KM, et al. **J Adv Nurs** 1996 May;23(5):984–91 (39 ref.)

A nurse's guide to hormone replacement therapy. Moore AA, et al. **J Obstet Gynecol Neonatal Nurs** 1996 Jan;25(1):24–31 (43 ref.)

Hormone therapy in the menopause and breast cancer risk—a review. Ewertz M. **Maturitas** 1996 Mar;23(2):241–6 (32 ref.)

[Hormone replacement therapy: practical management] Tamborini A. **Contracept Fertil Sex** 1996 Jun;24(6):444–51 (22 ref.) **(Fre)**

[Hormone replacement therapy in menopause and cancers] Cappelaere P. **Rev Med Interne** 1995;16(12):945–59 (76 ref.) (Eng. Abstr.) **(Fre)**

[Menopause, hormonal replacement therapy, and coronary disease] Gebara OC, et al. **Arq Bras Cardiol** 1995 Apr; 64(4):355–8 (40 ref.) **(Por)**

ETHNOLOGY

The social and cultural context of menopause. Kaufert PA. **Maturitas** 1996 Mar;23(2):169–80 (49 ref.)

METABOLISM

[How I explore... metabolic disorders in menopausal women] Scheen AJ. **Rev Med Liege** 1996 Mar;51(3):254–6 (15 ref.) **(Fre)**

PHYSIOLOGY

Symptoms related to the menopause and sex steroid treatments. Bäckström T. **Ciba Found Symp** 1995; 191:171–80; discussion 180–6 (55 ref.)

Influence of menopause on sexuality. Bachmann GA. **Int J Fertil Menopausal Stud** 1995;40 Suppl 1:16–22 (35 ref.)

Norethindrone—a review of therapeutic applications. Taitel HF, et al. **Int J Fertil Menopausal Stud** 1995 Jul–Aug; 40(4):207–23 (64 ref.)

Estrogen and cardiovascular function after menopause. Samaan SA, et al. **J Am Coll Cardiol** 1995 Nov 15; 26(6):1403–10 (77 ref.)

Sarcopenia in aging humans: the impact of menopause and disease. Poehlman ET, et al. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:73–7 (25 ref.)

Cross–cultural perspectives on menopause. Robinson G. **J Nerv Ment Dis** 1996 Aug;184(8):453–8 (23 ref.)

The menopause, hormone replacement, and cardiovascular disease: the epidemiologic evidence. Barrett–Connor E. **Maturitas** 1996 Mar;23(2):227–34 (57 ref.)

The endocrinology of the menopause. Burger HG. **Maturitas** 1996 Mar;23(2):129–36 (44 ref.)

Hormonal and non–hormonal interventions for menopausal symptoms. Coope J. **Maturitas** 1996 Mar;23(2):159–68 (73 ref.)

The menopause and hormone replacement therapy: lipids, lipoproteins, coagulation and fibrinolytic factors. Tikkanen MJ. **Maturitas** 1996 Mar;23(2):209–16 (66 ref.)

Pregnancy, lactation, and menopause: how physiology and gender affect the toxicity of chemicals. Roberts JS, et al. **Mt Sinai J Med** 1995 Oct;62(5):343–55 (66 ref.)

Menopause: the aging of multiple pacemakers. Wise PM, et al. **Science** 1996 Jul 5;273(5271):67–70 (67 ref.)

[The effect of menopause on risk factors for ischemic diseases] de Kleijn MJ, et al. **Ned Tijdschr Geneeskd** 1996 Mar 2;140(9):478–82 (45 ref.) **(Dut)**

[Vaginal environment. The vaginal climate and its variations] Nicoli JM, et al. **Rev Fr Gynecol Obstet** 1995 Nov; 90(11):471–80 (8 ref.) (Eng. Abstr.) **(Fre)**

[Sex hormone replacement following menopause—for all women? A plea for prevention using estrogens and gestagens] Nocke W. **Ther Umsch** 1995 Oct;52(10):693–704 (14 ref.) (Eng. Abstr.) **(Ger)**

PSYCHOLOGY

Cross–cultural perspectives on menopause. Robinson G. **J Nerv Ment Dis** 1996 Aug;184(8):453–8 (23 ref.)

Well–being, symptoms and the menopausal transition. Dennerstein L. **Maturitas** 1996 Mar;23(2):147–57 (51 ref.)

The social and cultural context of menopause. Kaufert PA. **Maturitas** 1996 Mar;23(2):169–80 (49 ref.)

[Difficulties in becoming a woman and staying a woman. On the problems of female identity in menopause] Hettlage–Varjas A, et al. **Psyche (Stuttg)** 1995 Sep–Oct; 49(9–10):903–37 (40 ref.) (Eng. Abstr.) **(Ger)**

[Psychiatric aspects of menopause] Becker D, et al. **Harefuah** 1996 Jan 1;130(1):33–7 (50 ref.) **(Heb)**

–Psychosomatic aspects around the period of menopause– Czubalski K. **Ginekol Pol** 1995 Dec;66(12):692–6 (22 ref.) **(Pol)**

MENOPAUSE, PREMATURE

DRUG EFFECTS

Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. Bines J, et al. **J Clin Oncol** 1996 May;14(5):1718–29 (91 ref.)

PHYSIOLOGY

[Physiopathologic anomalies in ovarian response] Christin–Maitre S, et al. **Contracept Fertil Sex** 1996 Feb; 24(2):105–10 (27 ref.) **(Fre)**

MENORRHAGIA

DRUG THERAPY

Levonorgestrel–releasing IUD as a method of contraception with therapeutic properties. Luukkainen T, et al. **Contraception** 1995 Nov;52(5):269–76 (41 ref.)

Assessing blood flow in practice. Foulkes J. **Practitioner** 1996 Apr;240(1561):234–43 (8 ref.)

PSYCHOLOGY

Psychological aspects of heavy periods: does endometrial ablation provide the answer? Wright JB, et al. **Br J Hosp Med** 1996 Mar 6–19;55(5):289–94 (77 ref.)

SURGERY

Hysteroscopic endometrial ablation. Goldrath MH. **Obstet Gynecol Clin North Am** 1995 Sep;22(3):559–72 (44 ref.)

Assessing blood flow in practice. Foulkes J. **Practitioner** 1996 Apr;240(1561):234–43 (8 ref.)

THERAPY

Treatment of menorrhagia due to dysfunctional uterine bleeding. Rosenfeld JA. **Am Fam Physician** 1996 Jan; 53(1):165–72 (24 ref.)

What is the role of hysteroscopy in the management of abnormal uterine bleeding? Brill AI. **Clin Obstet Gynecol** 1995 Jun;38(2):319–45 (107 ref.)

MENOTROPIN RECEPTORS see **RECEPTORS, GONADOTROPIN**

MENOTROPINS

see related
RECEPTORS, GONADOTROPIN

ADVERSE EFFECTS

Ovulation induction. Effects of ovulation induction with gonadotrophins on the ovary and uterus and their implications for assisted reproduction. Rojas FJ. **Hum Reprod** 1995 Sep;10(9):2219–24 (47 ref.)

[Feminization: a paradoxical effect of stimulation with hCG/hMG in the infertile male] Arango Toro O, et al. **Actas Urol Esp** 1995 May;19(5):376–82 (48 ref.) (Eng. Abstr.) **(Spa)**

THERAPEUTIC USE

Low– versus high–dose human menopausal gonadotropin in an in vitro fertilization–embryo transfer program. Levy T, et al. **J Assist Reprod Genet** 1995 Apr;12(4):235–8 (25 ref.)

The human menopausal gonadotropin (hMG) dose in in vitro

fertilization (IVF): what is the optimal dose? van Hooff MH. **J Assist Reprod Genet** 1995 Apr;12(4):233–5 (13 ref.)

MENSTRUAL CYCLE

Current and future roles of adjuvant endocrine therapy in the management of early carcinoma of the breast. Baum M, et al. **Recent Results Cancer Res** 1996;140:215–26 (30 ref.)

Menstrual cycle timing of breast cancer resection. Hrushesky WJ. **Recent Results Cancer Res** 1996;140:27–40 (38 ref.)

[Clinical study of ovulatory cervical mucus] Chrétien FC, et al. **Contracept Fertil Sex** 1996 May;24(5):359–67 (18 ref.) **(Fre)**

[Pulmonary endometriosis with recurrent catamenial hemoptysis] Ueno H, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Aug; 33(8):888–93 (19 ref.) (Eng. Abstr.) **(Jpn)**

DRUG EFFECTS

Mifepristone: clinical application in general gynecology. Morales AJ, et al. **Clin Obstet Gynecol** 1996 Jun; 39(2):451–60 (33 ref.)

Gestodene. A review of its pharmacology, efficacy and tolerability in combined contraceptive preparations. Wilde MI, et al. **Drugs** 1995 Aug;50(2):364–95 (128 ref.)

Hormone replacement therapy and vaginal bleeds. Theoretical aspects and clinical management. Samsioe G. **Zentralbl Gynakol** 1996;118(4):181–7 (28 ref.)

PHYSIOLOGY

Changes of neuroendocrine axes in patients with menstrual migraine. Fioroni L, et al. **Cephalalgia** 1995;15(4):297–300 (25 ref.)

Epidemiology of menstruation and its relevance to women's health. Harlow SD, et al. **Epidemiol Rev** 1995;17(2):265–86 (220 ref.)

Endometrial responses to corpus luteum products in cycles with induced ovulation: theoretical and practical considerations. Seppälä M, et al. **Hum Reprod** 1995 Dec; 10 Suppl 2:67–76 (101 ref.)

Blood vessel growth in the endometrium. Goodger AM, et al. **Microcirculation** 1995 Dec;2(4):329–43 (102 ref.)

Food intake and the menstrual cycle: a retrospective analysis, with implications for appetite research. Buffenstein R, et al. **Physiol Behav** 1995 Dec;58(6):1067–77 (142 ref.)

Menstrual synchrony: agenda for future research. Weller L, et al. **Psychoneuroendocrinology** 1995;20(4):377–83 (25 ref.)

The evolution of endometrial cycles and menstruation. Strassmann BI. **Q Rev Biol** 1996 Jun;71(2):181–220 (152 ref.)

Gonadotropin control of follicle and oocyte maturation: implications for ovulation induction. Brannian JD, et al. **S D J Med** 1995 Oct;48(10):335–9 (20 ref.)

PSYCHOLOGY

The menstrual cycle and the well being of women. Bancroft J. **Soc Sci Med** 1995 Sep;41(6):785–91 (29 ref.)

The menstrual cycle, science and femininity: assumptions underlying menstrual cycle research. Nicolson P. **Soc Sci Med** 1995 Sep;41(6):779–84 (64 ref.)

Theory and methodology in premenstrual syndrome research. Walker A. **Soc Sci Med** 1995 Sep;41(6):793–800 (56 ref.)

MENSTRUAL CYCLE, FOLLICULAR PHASE see **FOLLICULAR PHASE**

MENSTRUAL PROLIFERATIVE PHASE see **MENSTRUAL CYCLE**

MENSTRUAL SECRETORY PHASE see **MENSTRUAL CYCLE**

MENSTRUATION

see related
PREMENSTRUAL SYNDROME

The neuroendocrinology of menstrual cycle mood disorders. Rubinow DR, et al. **Ann N Y Acad Sci** 1995 Dec 29; 771:648–59 (51 ref.)

[Menstruation-associated (catamenial) pneumothorax and catamenial hemoptysis] Hamacher J, et al. **Schweiz Med Wochenschr** 1996 May 25;126(21):924–32 (100 ref.) (Eng. Abstr.) **(Ger)**

[Effect of menstrual cycle on the immune response to surgical stress] Lazzaretti MG, et al. **Minerva Ginecol** 1995 May; 47(5):197–205 (48 ref.) (Eng. Abstr.) **(Ita)**

[Therapeutic strategies in menstrual migraine] Targa C, et al. **Rev Neurol** 1995;23 Suppl 2:S226–31 (63 ref.) **(Spa)**

PHYSIOLOGY

A biological model for the regulation of peri-implantational hemostasis and menstruation. Lockwood CJ, et al. **J Soc Gynecol Investig** 1996 Jul–Aug;3(4):159–65 (79 ref.)

The control of prostaglandin production by the endometrium in relation to luteolysis and menstruation. Poyser NL. **Prostaglandins Leukot Essent Fatty Acids** 1995 Sep; 53(3):147–95 (500 ref.)

MENSTRUATION DISORDERS

BLOOD

African endocrine infertility: a review. Kuku SF. **Afr J Med Med Sci** 1995 Jun;24(2):111–23 (60 ref.)

CHEMICALLY INDUCED

Hormone replacement therapy: aspects of bleeding problems and compliance. Samsioe G. **Int J Fertil Menopausal Stud** 1996 Jan–Feb;41(1):11–5 (20 ref.)

Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. Bines J, et al. **J Clin Oncol** 1996 May;14(5):1718–29 (91 ref.)

Reproductive disorders due to chemical exposure among hairdressers. Kersemaekers WM, et al. **Scand J Work Environ Health** 1995 Oct;21(5):325–34 (85 ref.)

COMPLICATIONS

African endocrine infertility: a review. Kuku SF. **Afr J Med Med Sci** 1995 Jun;24(2):111–23 (60 ref.)

Three edemas. Williams AV Jr, et al. **J S C Med Assoc** 1996 Jul;92(7):306–10 (25 ref.)

EPIDEMIOLOGY

Epidemiology of menstruation and its relevance to women's health. Harlow SD, et al. **Epidemiol Rev** 1995;17(2):265–86 (220 ref.)

ETIOLOGY

Factors associated with menstrual irregularities and decreased bone mineral density in female athletes. Fruth SJ, et al. **J Orthop Sports Phys Ther** 1995 Jul;22(1):26–38 (54 ref.)

The interrelationships of body fat, exercise, and hormonal status and their impact on reproduction and bone health. Ramos RH, et al. **Semin Perinatol** 1995 Jun;19(3):163–70 (53 ref.)

[Gynecological diseases in obesity] Takahashi J, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:388–91 (5 ref.) **(Jpn)**

PATHOLOGY

Endometrial morphology and bleeding patterns as a function of progestogen supplementation. Sturdee DW. **Int J Fertil Menopausal Stud** 1996 Jan–Feb;41(1):22–8 (31 ref.)

PHYSIOPATHOLOGY

Menstrually related disorders: what we do know, what we only believe that we know, and what we know that we do not know. Halbreich U. **Crit Rev Neurobiol** 1995; 9(2–3):163–75 (133 ref.)

Epidemiology of menstruation and its relevance to women's health. Harlow SD, et al. **Epidemiol Rev** 1995;17(2):265–86 (220 ref.)

Endometrial morphology and bleeding patterns as a function of progestogen supplementation. Sturdee DW. **Int J Fertil Menopausal Stud** 1996 Jan–Feb;41(1):22–8 (31 ref.)

[Beta-endorphin--physiologic role and menstrual cycle disorders] Męczekalski B, et al. **Ginekol Pol** 1995 Oct; 66(10):586–95 (44 ref.) (Eng. Abstr.) **(Pol)**

SURGERY

[Indications for hysterectomy--a time for re-evaluation] Lerner A, et al. **Harefuah** 1996 Mar 15;130(6):400–3 (25 ref.) **(Heb)**

THERAPY

The need for systematic reviews in the treatment of menstrual disorders--another Cochrane collaborative review group is born. Farquhar CM. **Br J Obstet Gynaecol** 1996 Jun; 103(6):497–500 (20 ref.)

MENSTRUATION, FOLLICULAR PHASE see **FOLLICULAR PHASE**

MENSTRUATION, RETROGRADE see **MENSTRUATION DISORDERS**

MENTAL COMPETENCY

Ethical considerations of ensuring an informed and autonomous consent in research involving critically ill patients. Silverman HJ. **Am J Respir Crit Care Med** 1996 Sep;154(3 Pt 1):582–6 (34 ref.)

Decision-making capacity for informed consent in the older population. Christensen K, et al. **Bull Am Acad Psychiatry Law** 1995;23(3):353–65 (27 ref.)

Can healthcare providers obtain judicial intervention against surrogates who demand "medically inappropriate" life support for incompetent patients? [see comments] Cantor NL. **Crit Care Med** 1996 May;24(5):883–7 (28 ref.) Comment in: Crit Care Med 1996 May;24(5):730–2.

The constitutional case against permitting physician-assisted suicide for competent adults with "terminal conditions". Bopp J Jr, et al. **Issues Law Med** 1995 Winter;11(3):239–68 (130 ref.)

Breathing life into the right to die: Oregon's Death with Dignity Act. Bushong SK, et al. **Issues Law Med** 1995 Winter;11(3):269–82 (102 ref.)

Discussing cardiopulmonary resuscitation with patients and relatives. Stewart K. **Postgrad Med J** 1995 Oct; 71(840):585–9 (30 ref.)

Development of a functional capacity model for the elderly. Song M, et al. **Res Nurs Health** 1996 Jun;19(3):173–81 (631 ref.)

Mental competence and the question of beneficent intervention. Checkland D, et al. **Theor Med** 1996 Jun; 17(2):121–34 (43 ref.)

[Informed consent and mental competence of the elderly in medical-scientific studies] Olde Rikkert MG, et al. **Tijdschr Gerontol Geriatr** 1995 Aug;26(4):152–62 (40 ref.) (Eng. Abstr.) **(Dut)**

LEGISLATION & JURISPRUDENCE

Informed consent in chronic schizophrenia? [editorial] Jones GH. **Br J Psychiatry** 1995 Nov;167(5):565–8 (10 ref.)

Cult membership as a source of self-cohesion: forensic implications. Feldmann TB, et al. **Bull Am Acad Psychiatry Law** 1995;23(2):239–48 (46 ref.)

Denouement of an execution competency case: is Perry pyrrhic? Mossman D. **Bull Am Acad Psychiatry Law** 1995; 23(2):269–84 (113 ref.)

Malingering a challenge for the forensic examiner. Palermo GB, et al. **Med Law** 1996;15(1):143–60 (25 ref.)

MENTAL DEFICIENCY see **MENTAL RETARDATION**

MENTAL DISORDERS

Childhood behavior problems. Novak LL. **Am Fam Physician** 1996 Jan;53(1):257–62, 267–9 (08 ref.)

Psychosocial/cultural issues in medicine and psychiatry: treating African Americans. Carter JH. **J Natl Med Assoc** 1995 Dec;87(12):857–60 (18 ref.)

Primary care for women. Comprehensive assessment and management of common mental health problems. Weintraub TA, et al. **J Nurse Midwifery** 1996 Mar–Apr; 41(2):125–38 (53 ref.)

Legal status of the mentally disabled person in South African law. Oosthuizen H, et al. **Med Law** 1995;14(7–8):601–9 (9 ref.)

[Fragile X syndrome and mental disorders] Arinami T. **Seishin Shinkeigaku Zasshi** 1995;97(8):599–604 (41 ref.) **(Jpn)**

[International cooperative study on mental diseases] Nakane A. **Seishin Shinkeigaku Zasshi** 1995;97(7):471–84 (37 ref.) **(Jpn)**

BLOOD

Therapeutic drug monitoring for the treatment of psychiatric disorders. Clinical use and cost effectiveness. Eilers R. **Clin Pharmacokinet** 1995 Dec;29(6):442–50 (40 ref.)

CHEMICALLY INDUCED

Cognitive and behavioral effects of antiepileptic drugs. Devinsky O. **Epilepsia** 1995;36 Suppl 2:S46–65 (106 ref.)

[Anabolic steroid abuse and mental disorder] Nakatani Y, et al. **Arukoru Kenkyuto Yakubutsu Ison** 1995 Oct; 30(5):333–47 (45 ref.) (Eng. Abstr.) **(Jpn)**

CLASSIFICATION

Issues in the taxonomy of psychopathology in mental retardation. Einfeld SL, et al. **J Autism Dev Disord** 1995 Apr;25(2):143–67 (105 ref.)

Classification of child and adolescent psychopathology. Cantwell DP. **J Child Psychol Psychiatry** 1996 Jan; 37(1):3–12 (80 ref.)

Fundamental neuroscience and the classification of psychiatric disorders. Dubrovsky B. **Neurosci Biobehav Rev** 1995 Fall;19(3):511–8 (118 ref.)

A model for the classification and diagnosis of relational disorders. Committee on the Family, Group for the Advancement of Psychiatry. **Psychiatr Serv** 1995 Sep; 46(9):926–31 (61 ref.)

[Are current views of handling and classification of psychiatric problems discouraging?] Riikonen E, et al. **Duodecim** 1994;110(3):347–59 (54 ref.) **(Fin)**

[DSM IV and research. The problem of clinical trials] Boyer P. **Encephale** 1995 Dec;21 Spec No 5:41–6 (3 ref.) (Eng. Abstr.) **(Fre)**

[Classification and psychiatric practice] Ferreri M. **Encephale** 1995 Dec;21 Spec No 5:53–8 (10 ref.) (Eng. Abstr.) **(Fre)**

[The importance of classifications in psychiatry] Lempérière T. **Encephale** 1995 Dec;21 Spec No 5:3–7 (14 ref.) (Eng. Abstr.) **(Fre)**

[DSM-IV] Pull CB. **Encephale** 1995 Dec;21 Spec No 5:15–20 (17 ref.) (Eng. Abstr.) **(Fre)**

[Classification of mental disorders according to ICD 10] Sartorius N. **Encephale** 1995 Dec;21 Spec No 5:9–13 (7 ref.) (Eng. Abstr.) **(Fre)**

[Are the concepts of dementia according to DSM-4 and ICD-10 similar? Some theoretical aspects] Heinik J. **Harefuah** 1996 Mar 15;130(6):409–13 (32 ref.) **(Heb)**

COMPLICATIONS

Assessing substance use disorder in persons with severe mental illness. Drake RE, et al. **New Dir Ment Health Serv** 1996 Summer;(70):3–17 (75 ref.)

[Cocaine abuse and mental disease] Glyngdal P. **Ugeskr Laeger** 1996 Aug 12;158(33):4638–42 (39 ref.) (Eng. Abstr.) **(Dan)**

[Psychiatric diseases and ictus] Aguilar M, et al. **Rev Neurol** 1995;23 Suppl 1:S113–22 (128 ref.) **(Spa)**

DIAGNOSIS

A review of the usefulness of the standard EEG in psychiatry. Hughes JR. **Clin Electroencephalogr** 1996 Jan; 27(1):35–9 (0 ref.)

Review: DSM–IV and pain. King SA. **Clin J Pain** 1995 Sep; 11(3):171–6 (24 ref.)

Cultural challenges to the psychiatric enterprise. Fabrega H Jr. **Compr Psychiatry** 1995 Sep–Oct;36(5):377–83 (48 ref.)

The neo–Kraepelinian revolution in psychiatric diagnosis. Compton WM, et al. **Eur Arch Psychiatry Clin Neurosci** 1995;245(4–5):196–201 (29 ref.)

Compliance issues in primary care. Lieberman JA 3rd. **J Clin Psychiatry** 1996;57 Suppl 7:76–82; discussion 83–5 (20 ref.)

Clinical diagnoses and MCMI codetypes. Craig RJ. **J Clin Psychol** 1995 May;51(3):352–60 (75 ref.)

DSM–III–R and persons with dual diagnoses: conceptual issues and strategies for future research. Sturmey P. **J Intellect Disabil Res** 1995 Oct;39 (Pt 5):357–64 (42 ref.)

Artificial neural networks: a prospective tool for the analysis of psychiatric disorders. Galletly CA, et al. **J Psychiatry Neurosci** 1996 Jul;21(4):239–47 (45 ref.)

Stigma, labelling and psychiatric misdiagnosis: origins and outcomes. Witztum E, et al. **Med Law** 1995;14(7–8):659–69 (27 ref.)

Culture and psychiatric diagnosis. Impact on DSM–IV and ICD–10. Alarcon RD. **Psychiatr Clin North Am** 1995 Sep; 18(3):449–65 (80 ref.)

Assessing, diagnosing and treating culturally diverse individuals: a Hispanic perspective. Ruiz P. **Psychiatr Q** 1995 Winter;66(4):329–41 (34 ref.)

The Child and Adolescent Psychiatric Assessment (CAPA). Angold A, et al. **Psychol Med** 1995 Jul;25(4):739–53 (35 ref.)

Measuring social disabilities in mental health. Wiersma D. **Soc Psychiatry Psychiatr Epidemiol** 1996 Jun;31(3–4):101–8 (46 ref.)

[Prevalence of autistic states in a cohort of very young children followed up in home care] Drossart F, et al. **Acta Psychiatr Belg** 1995 May–Jun;95(3):122–38 (64 ref.) (Eng. Abstr.) **(Fre)**

[Compliance with psychiatric legal ordinance section 63 STGB. Legal principles––current status––treatment concepts––perspectives] Nedopil N, et al. **Nervenarzt** 1995 Nov;66(11):793–801 (38 ref.) (Eng. Abstr.) **(Ger)**

[Forensic practice between commonality, the law and psychiatry. 2] Hoffmann–Richter U, et al. **Psychiatr Prax** 1996 May;23(3):150–4 (16 ref.) **(Ger)**

[Subclinical neuro–psychobehavioral effects in occupational, environmental and community health: methodology and recent findings] Araki S, et al. **Nippon Eiseigaku Zasshi** 1995 Aug;50(3):713–29 (122 ref.) (Eng. Abstr.) **(Jpn)**

DRUG THERAPY

The nitric oxide pathway: potential implications for treatment of neuropsychiatric disorders. Karatinos J, et al. **Clin Neuropharmacol** 1995 Dec;18(6):482–99 (83 ref.)

The effects of flumazenil in neuropsychiatric disorders. Malizia AL, et al. **Clin Neuropharmacol** 1995 Jun; 18(3):215–32 (134 ref.)

Therapeutic drug monitoring for the treatment of psychiatric disorders. Clinical use and cost effectiveness. Eilers R. **Clin Pharmacokinet** 1995 Dec;29(6):442–50 (40 ref.)

Serotonin selective reuptake inhibitors in child and adolescent psychopharmacology: a review of published experience. DeVane CL, et al. **J Clin Psychiatry** 1996 Feb;57(2):55–66 (103 ref.)

Antipsychotic medications in children and adolescents. Findling RL, et al. **J Clin Psychiatry** 1996;57 Suppl 9:19–23 (33 ref.)

Modulation of NMDA and dopaminergic neurotransmissions by sigma ligands: possible implications for the treatment of psychiatric disorders. Debonnel G, et al. **Life Sci** 1996; 58(9):721–34 (179 ref.)

Emergency pharmacotherapy: the evolving role of medications in the emergency department. Ellison JM, et al. **New Dir Ment Health Serv** 1995 Fall;(67):87–98 (64 ref.)

Carbamazepine clinical pharmacology: a review. Albani F, et al. **Pharmacopsychiatry** 1995 Nov;28(6):235–44 (189 ref.)

Ethnicity and psychopharmacology. Bridging the gap. Lin KM, et al. **Psychiatr Clin North Am** 1995 Sep;18(3):635–47 (56 ref.)

Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors. Skop BP, et al. **Psychosomatics** 1996 Jan–Feb;37(1):12–6 (41 ref.)

Placebo effects. Issues for clinical practice in psychiatry and medicine. Straus JL, et al. **Psychosomatics** 1996 Jul–Aug; 37(4):315–26 (121 ref.)

[Experimental and clinical pharmacology of psychostimulants] Bourin M, et al. **Can J Psychiatry** 1995 Sep;40(7):401–10 (108 ref.) (Eng. Abstr.) **(Fre)**

[Research in psychiatry and legislative restrictions] Bougerol T. **Encephale** 1996 May;22 Spec No 1:63–8 (5 ref.) (Eng. Abstr.) **(Fre)**

[Clozapine in the treatment of mental manifestations of Parkinson disease] Diederich N, et al. **Rev Neurol (Paris)** 1995 Apr;151(4):251–7 (54 ref.) (Eng. Abstr.) **(Fre)**

[Possibilities of concomitant drug treatment of stuttering in childhood and adolescence] Marcus A, et al. **Z Kinder Jugendpsychiatr** 1995 Sep;23(3):182–94 (115 ref.) **(Ger)**

[Cholecystokinin receptors. A target for tomorrow's psychopharmaceuticals?] Zachrisson O, et al. **Lakartidningen** 1996 Mar 27;93(13):1225–7 (47 ref.) (Eng. Abstr.) **(Swe)**

EPIDEMIOLOGY

Co–occurring addictive and mental disorders among adolescents: prevalence research and future directions. Greenbaum PE, et al. **Am J Orthopsychiatry** 1996 Jan; 66(1):52–60 (33 ref.)

The epidemiology of psychiatric disorders and the de facto mental health care system. Norquist GS, et al. **Annu Rev Med** 1996;47:473–9 (29 ref.)

Mental health problems of homeless women and differences across subgroups. Robertson MJ, et al. **Annu Rev Public Health** 1996;17:311–36 (74 ref.)

Patterns of mental health service utilization. Howard KI, et al. **Arch Gen Psychiatry** 1996 Aug;53(8):696–703 (57 ref.)

Violence, crime, and mental illness. How strong a link? [editorial] Marzuk PM. **Arch Gen Psychiatry** 1996 Jun; 53(6):481–6 (51 ref.)

Workforce deployment: reconciling demands and resources. Andrews G. **Aust N Z J Psychiatry** 1995 Sep;29(3):394–402 (20 ref.)

Developmental epidemiology. Angold A, et al. **Epidemiol Rev** 1995;17(1):74–82 (126 ref.)

Epidemiology of mental disorders in middle age and late life: conceptual issues. Gallo JJ. **Epidemiol Rev** 1995;17(1):83–94 (171 ref.)

Epidemiology of mental disorders in primary care settings. Goldberg D. **Epidemiol Rev** 1995;17(1):182–90 (59 ref.)

Psychiatric illness and cardiovascular disease risk. Hayward C. **Epidemiol Rev** 1995;17(1):129–38 (138 ref.)

Advances in strategies for minimizing and adjusting for survey nonresponse. Kessler RC, et al. **Epidemiol Rev** 1995; 17(1):192–204 (67 ref.)

Work conditions as explanations for the relation between socioeconomic status, gender, and psychological disorders. Lennon MC. **Epidemiol Rev** 1995;17(1):120–7 (118 ref.)

Evidence bearing on mental illness as a possible cause of violent behavior. Link BG, et al. **Epidemiol Rev** 1995; 17(1):172–81 (51 ref.)

Psychiatric disorders and HIV infection: impact on one another. Lyketsos CG, et al. **Epidemiol Rev** 1995; 17(1):152–64 (82 ref.)

The untapped potential of case registers and record–linkage studies in psychiatric epidemiology. Mortensen PB. **Epidemiol Rev** 1995;17(1):205–9 (36 ref.)

Recall of psychiatric history in cross–sectional surveys: implications for epidemiologic research. Simon GE, et al. **Epidemiol Rev** 1995;17(1):221–7 (48 ref.)

Recent developments for diagnostic measures in psychiatry. Ustün TB, et al. **Epidemiol Rev** 1995;17(1):210–20 (87 ref.)

Psychiatric epidemiology in cross–cultural perspective: a review. Aderibigbe YA, et al. **Eur Arch Psychiatry Clin Neurosci** 1995;246(1):37–46 (78 ref.)

Co–morbidity and therapeutic community treatment. Jainchill N. **NIDA Res Monogr** 1994;144:209–31 (35 ref.)

A review of studies of heavy users of psychiatric services. Kent S, et al. **Psychiatr Serv** 1995 Dec;46(12):1247–53 (72 ref.)

Psychopathology among children placed in family foster care. Pilowsky D. **Psychiatr Serv** 1995 Sep;46(9):906–10 (32 ref.)

ETHNOLOGY

Is there a role for prevention in aboriginal mental health? Hunter E. **Aust J Public Health** 1995 Dec;19(6):573–9 (50 ref.)

ETIOLOGY

Helping the relatives of patients with cancer [editorial; comment] Fallowfield L. **Eur J Cancer** 1995 Oct; 31A(11):1731–2 (13 ref.) Comment on: Eur J Cancer 1995 Oct;31A(11):1736–40.

Neuropsychologic change after cardiac surgery: a critical review. Borowicz LM, et al. **J Cardiothorac Vasc Anesth** 1996 Jan;10(1):105–11; quiz 111–2 (61 ref.)

Neuropsychologic dysfunction after cardiac surgery: what is the problem? Gill R, et al. **J Cardiothorac Vasc Anesth** 1996 Jan;10(1):91–8 (62 ref.)

Gravitational effects of the period of high tides and the new moon on lunacy. Myers DE. **J Emerg Med** 1995 Jul–Aug; 13(4):529–32 (24 ref.)

Dementia: diagnosis and emergency behavioral complications. Tueth MJ. **J Emerg Med** 1995 Jul–Aug; 13(4):519–25 (38 ref.)

Psychiatric aspects of air pollution. Lundberg A. **Otolaryngol Head Neck Surg** 1996 Feb;114(2):227–31 (39 ref.)

Culture–bound syndromes. Levine RE, et al. **Psychiatr Clin North Am** 1995 Sep;18(3):523–36 (41 ref.)

[Mental dysfunction in Parkinson's disease] Ružička E. **Cas Lek Cesk** 1996 Apr 3;135(7):199–203 (37 ref.) (Eng. Abstr.) **(Cze)**

[Neuro–psychiatric involvement in primary Sjögren's syndrome] Sagawa A, et al. **Nippon Rinsho** 1995 Oct; 53(10):2563–7 (13 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Mapping genes for psychiatric disorders and behavioral traits. McInnes LA, et al. **Curr Opin Genet Dev** 1995 Jun; 5(3):376–81 (41 ref.)

Dopamine D2 receptor gene variants: association and linkage studies in impulsive–addictive–compulsive behaviour. Blum K, et al. **Pharmacogenetics** 1995 Jun;5(3):121–41 (122 ref.)

Searching for complex disease genes: can it be made any easier? Baron M. **Psychiatr Genet** 1995 Summer;5(2):89–91 (26 ref.)

[Genetic counseling in psychiatric diseases] Körner J, et al. **Nervenarzt** 1996 Jan;67(1):3–14 (58 ref.) (Eng. Abstr.) **(Ger)**

[Child psychiatry and genetics (editorial)] Poustka F. **Z Kinder Jugendpsychiatr** 1995 Dec;23(4):239–42 (12 ref.) **(Ger)**

METABOLISM

Postmortem and cerebrospinal fluid studies of corticotropin–releasing factor in humans. Hartline KM, et al. **Ann N Y Acad Sci** 1996 Mar 22;780:96–105 (44 ref.)

Monoamines, cytoskeletal elements and psychiatric disorders: a neurochemical fugue. Harris J, et al. **Prog Brain Res** 1995; 106:241–8 (54 ref.)

[Serotonin in neurology and psychiatry] van Kempen GM. **Ned Tijdschr Geneeskd** 1995 Oct 14;139(41):2084–8 (31 ref.) **(Dut)**

NURSING

The psychiatric model: a critical analysis of its undermining effects on nursing in chronic mental illness. Hall BA. **ANS Adv Nurs Sci** 1996 Mar;18(3):16–26 (28 ref.)

Special report: protection and advocacy: what nurses need to know. Schauer C. **Arch Psychiatr Nurs** 1995 Oct; 9(5):233–9 (15 ref.)

Mental health nurses working purposefully with people with serious and enduring mental illness––an international perspective. Gournay K. **Int J Nurs Stud** 1995 Aug; 32(4):341–52 (68 ref.)

Geropsychiatric public sector nursing: placement challenges. Fuller K, et al. **J Psychosoc Nurs Ment Health Serv** 1995 Aug;33(8):20–2 (6 ref.)

A discharge check list for psychiatric patients. Hochberger JM. **J Psychosoc Nurs Ment Health Serv** 1995 Dec; 33(12):35–8 (13 ref.)

PHYSIOPATHOLOGY

Reversing a history of unmet needs: approaches to care for persons with co–occurring addictive and mental disorders. Osher FC, et al. **Am J Orthopsychiatry** 1996 Jan;66(1):4–11 (40 ref.)

Biorhythms and the biological clock involvement of melatonin and the pineal gland in life and disease. Nir I. **Biomed Environ Sci** 1995 Jun;8(2):90–105 (54 ref.)

Failure at task–specific regional brain activation: new conceptualization of a disease entity. Wexler BE. **J Neuropsychiatry Clin Neurosci** 1991 Winter;3(1):94–8 (20 ref.)

Artificial neural networks: a prospective tool for the analysis of psychiatric disorders. Galletly CA, et al. **J Psychiatry Neurosci** 1996 Jul;21(4):239–47 (45 ref.)

Beyond specificity: effects of serotonin and serotonergic treatments on psychobiological dysfunction. Dubovsky SL, et al. **J Psychosom Res** 1995 May;39(4):429–44 (103 ref.)

Involvement of endogenous benzodiazepine receptor ligands in brain disorders: therapeutic potential for benzodiazepine antagonists? Polc P. **Med Hypotheses** 1995 Jun;44(6):439–46 (51 ref.)

Brain electrical activity in neurogerontology and psychogeriatric disorders. Franco–Maside A, et al. **Methods Find Exp Clin Pharmacol** 1995 Apr;17(3):207–24 (93 ref.)

Heart rate and blood pressure variability: implications for psychiatric research. Yeragani VK. **Neuropsychobiology** 1995;32(4):182–91 (80 ref.)

[Synaptic reorganization in early childhood experience and learning processes: relevance for the development of psychological diseases] Braun K. **Z Klin Psychol Psychopathol Psychother** 1996;44(3):253–66 (60 ref.) (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

Is there a role for prevention in aboriginal mental health? Hunter E. **Aust J Public Health** 1995 Dec;19(6):573–9 (50 ref.)

Difficult dementia: six steps to control problem behaviors. Banazak DA. **Geriatrics** 1996 Feb;51(2):36–42 (16 ref.)

[Health education as a method of treating psycho–emotional

disorders in patients with diabetes mellitus] Tatoń J, et al. **Pol Tyg Lek** 1996 Jan;51(1-5):46-9 (38 ref.) **(Pol)**

PSYCHOLOGY

Women with co-occurring addictive and mental disorders: an emerging profile of vulnerability. Alexander MJ. **Am J Orthopsychiatry** 1996 Jan;66(1):61-70 (86 ref.)

Heterogeneity of person and place: assessing co-occurring addictive and mental disorders. Lehman AF. **Am J Orthopsychiatry** 1996 Jan;66(1):32-41 (41 ref.)

A vision for the future: toward a service system responsive to those with co-occurring addictive and mental disorders. Osher FC. **Am J Orthopsychiatry** 1996 Jan;66(1):71-6 (16 ref.)

Basic behavioral science research for mental health. Vulnerability and resilience. Basic Behavioral Science Task Force of the National Advisory Mental Health Council. **Am Psychol** 1996 Jan;51(1):22-8 (7 ref.)

Methodological issues in psychopathology research. Sher KJ, et al. **Annu Rev Psychol** 1996;47:371-400 (225 ref.)

"Freedom's just another word": aboriginal youth and mental health. Hunter E. **Aust N Z J Psychiatry** 1995 Sep; 29(3):374-84 (64 ref.)

Fibromyalgia syndrome and psychiatric disorder. Dunne FJ, et al. **Br J Hosp Med** 1995 Sep 6-19;54(5):194-7 (23 ref.)

Psychiatric patients and HIV infection: a new population at risk? Stefan MD, et al. **Br J Psychiatry** 1995 Dec; 167(6):721-7 (32 ref.)

Interpreting culture and psychopathology: primitivist themes in cross-cultural debate. Lucas RH, et al. **Cult Med Psychiatry** 1995 Sep;19(3):287-326 (115 ref.)

Outcomes for youths with serious emotional disturbance in secondary school and early adulthood. Wagner MM. **Future Child** 1995 Summer-Fall;5(2):90-112 (37 ref.)

Mental health, work, and gender. Dennerstein L. **Int J Health Serv** 1995;25(3):503-9 (27 ref.)

Comment: the neglect of culture in psychiatric nosology: the case of culture bound syndromes. Aderibigbe YA, et al. **Int J Soc Psychiatry** 1995 Winter;41(4):235-41 (50 ref.)

Medical sociology and the study of severe mental illness: reflections on past accomplishments and directions for future research. Cook JA, et al. **J Health Soc Behav** 1995; Spec No:95-114 (170 ref.)

Insight in clinical psychiatry. A new model. Marková IS, et al. **J Nerv Ment Dis** 1995 Dec;183(12):743-51 (44 ref.)

Toward a more comprehensive medical anthropology: the case of adolescent psychopathology. Fabrega H Jr, et al. **Med Anthropol Q** 1995 Dec;9(4):431-61 (185 ref.)

Chronic psychiatric patients' use of caffeine: pharmacological effects and mechanisms. Kruger A. **Psychol Rep** 1996 Jun; 78(3 Pt 1):915-23 (50 ref.)

Risk factors for adolescent suicide and suicidal behavior: mental and substance abuse disorders, family environmental factors, and life stress. Brent DA. **Suicide Life Threat Behav** 1995;25 Suppl:52-63 (44 ref.)

[Psychiatric diseases and pregnancy] Fuchs U. **Gynakologe** 1995 Dec;28(6):440-5 (16 ref.) **(Ger)**

[Psychiatric emergencies and crises in gynecology] Gaebel W, et al. **Gynakologe** 1995 Dec;28(6):403-11 (19 ref.) **(Ger)**

[Violence--an element of the psychiatric profession] Cahn T. **Schweiz Arch Neurol Psychiatr** 1995;146(3):109-14 (25 ref.) (Eng. Abstr.) **(Ger)**

[Psychiatric aspects of menopause] Becker D, et al. **Harefuah** 1996 Jan 1;130(1):33-7 (50 ref.) **(Heb)**

[Mental disorders and obesity] Kodama K, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:392-7 (14 ref.) **(Jpn)**

[The understanding of psychopathology and the role of phenomenology. Contribution to a controversy] Ramos Gorostiza P, et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1995 Nov-Dec;23(6):281-6 (43 ref.) (Eng. Abstr.) **(Spa)**

RADIOGRAPHY

Some methodological issues in neuroradiological research in psychiatry. Becker T, et al. **J Neural Transm Gen Sect** 1995; 99(1-3):7-54 (292 ref.)

REHABILITATION

Coercion and commitment: understanding involuntary mental hospital admission. Monahan J, et al. **Int J Law Psychiatry** 1995 Summer;18(3):249-63 (75 ref.)

Family support for persons with dual disorders. Clark RE. **New Dir Ment Health Serv** 1996 Summer;(70):65-78 (54 ref.)

Housing for persons with co-occurring mental and addictive disorders. Osher FC, et al. **New Dir Ment Health Serv** 1996 Summer;(70):53-64 (37 ref.)

Refocusing the training of psychiatric rehabilitation staff. Corrigan PW, et al. **Psychiatr Serv** 1995 Nov;46(11):1172-7 (33 ref.)

Use of a token economy with seriously mentally ill patients: criticisms and misconceptions. Corrigan PW. **Psychiatr Serv** 1995 Dec;46(12):1258-63 (52 ref.)

Employment supports for people with mental illness. Marrone J, et al. **Psychiatr Serv** 1995 Jul;46(7):707-11 (40 ref.)

[Evaluation of autonomy in chronic mental patients. Problems, assessment tools, results] Leguay D. **Encephale** 1995 Nov-Dec;21(6):425-35 (98 ref.) (Eng. Abstr.) **(Fre)**

[Social legislative and structural deficits of ambulatory management of chronic psychiatric and handicapped patients] Rössler W, et al. **Nervenarzt** 1995 Nov; 66(11):802-10 (34 ref.) (Eng. Abstr.) **(Ger)**

[Psychoeducation--special reference to social skill training] Sarata Y. **Seishin Shinkeigaku Zasshi** 1995;97(7):522-8 (9 ref.) **(Jpn)**

[Social rehabilitation in psychiatric patients] Preradović M, et al. **Vojnosanit Pregl** 1994 Jan-Feb;51(1):54-9 (28 ref.) **(Scr)**

THERAPY

The course, treatment, and outcome of substance disorder in persons with severe mental illness. Drake RE, et al. **Am J Orthopsychiatry** 1996 Jan;66(1):42-51 (66 ref.)

Ideological singularity as a defense against clinical complexity. Schultz-Ross RA. **Am J Psychother** 1995 Fall; 49(4):540-7 (35 ref.)

What an old age psychiatrist does. Wattis J. **BMJ** 1996 Jul 13;313(7049):101-4 (6 ref.)

Psychotherapy assessment and treatment selection. Tillett R. **Br J Psychiatry** 1996 Jan;168(1):10-5 (59 ref.)

Current status of family-based outcome and process research. Diamond GS, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Jan;35(1):6-16 (120 ref.)

Compliance issues in primary care. Lieberman JA 3rd. **J Clin Psychiatry** 1996;57 Suppl 7:76-82; discussion 83-5 (20 ref.)

Does exercise help in the treatment of psychiatric disorders? Plante TG. **J Psychosoc Nurs Ment Health Serv** 1996 Mar; 34(3):38-43 (46 ref.)

Management of dementia-related behavioral disturbances: a nonpharmacologic approach. Carlson DL, et al. **Mayo Clin Proc** 1995 Nov;70(11):1108-15 (41 ref.)

Co-morbidity and therapeutic community treatment. Jainchill N. **NIDA Res Monogr** 1994;144:209-31 (35 ref.)

Cultural considerations in the assessment and treatment of religious and spiritual problems. Lukoff D, et al. **Psychiatr Clin North Am** 1995 Sep;18(3):467-85 (93 ref.)

Psychiatrists as treatment team leaders: pitfalls and rewards. Rodenhauser P. **Psychiatr Q** 1996 Spring;67(1):11-31 (100 ref.)

Estimated societal costs of assertive community mental health care. Wolff N, et al. **Psychiatr Serv** 1995 Sep;46(9):898-906 (29 ref.)

Beneficence re-examined: protective intervention in mental health. Murdach AD. **Soc Work** 1996 Jan;41(1):26-32 (43 ref.)

[Decision trees in psychiatric therapy] Dantchev N. **Encephale** 1996 May-Jun;22(3):205-14 (14 ref.) (Eng. Abstr.) **(Fre)**

[Surgical management of psychiatrically ill patients. Particular aspects of perioperative monitoring] Diefenbacher A, et al. **Gynakologe** 1995 Dec;28(6):412-9 (33 ref.) **(Ger)**

[Particular aspects of psychiatric management of mentally retarded patients with psychiatric disorders] Hennicke K, et al. **Psychiatr Prax** 1995 Nov;22(6):240-3 (27 ref.) (Eng. Abstr.) **(Ger)**

[The psychiatric emergency] Felber W. **Z Arztl Fortbild (Jena)** 1995 Dec;89(7):707-10 (2 ref.) (Eng. Abstr.) **(Ger)**

[The problem of the frequent hospitalizations of the mentally ill] Dolgov SA. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995;95(4):103-6 (73 ref.) **(Rus)**

VIROLOGY

HSV-1 brain infection by the olfactory nerve route and virus latency and reactivation may cause learning and behavioral deficiencies and violence in children and adults: a point of view. Becker Y. **Virus Genes** 1995;10(3):217-26 (58 ref.)

MENTAL DISORDERS, ORGANIC see **ORGANIC MENTAL DISORDERS**

MENTAL DISORDERS, ORGANIC, PSYCHOTIC see **ORGANIC MENTAL DISORDERS, PSYCHOTIC**

MENTAL DISORDERS, ORGANIC, SUBSTANCE-INDUCED see **ORGANIC MENTAL DISORDERS, SUBSTANCE-INDUCED**

MENTAL FATIGUE

The plasma level of some amino acids and physical and mental fatigue. Newsholme EA, et al. **Experientia** 1996 May 15;52(5):413-5 (14 ref.)

MENTAL HEALING

The healing energy of love. Green J, et al. **Altern Ther Health Med** 1996 May;2(3):46-56 (58 ref.)

How prayer heals: a theoretical model. Levin JS. **Altern Ther Health Med** 1996 Jan;2(1):66-73 (61 ref.)

"Sucking with vampires". The medicine of unreason. Weissmann G. **Ann N Y Acad Sci** 1996 Jun 24;775:179-87 (26 ref.)

The effectiveness of words: religion and healing among the Lubavitch of Stamford Hill. Littlewood R, et al. **Cult Med Psychiatry** 1995 Sep;19(3):339-83 (125 ref.)

MENTAL HEALTH

Interactive journals: an educational strategy to promote reflection. Tryssenaar J. **Am J Occup Ther** 1995 Jul-Aug; 49(7):695-702 (37 ref.)

Acute-phase mental health consequences of disasters: implications for triage and emergency medical services [see comments] Burkle FM Jr. **Ann Emerg Med** 1996 Aug; 28(2):119-28 (78 ref.) Comment in: Ann Emerg Med 1996 Aug;28(2):220-2.

Women's mental health: the new national focus. Blumenthal SJ. **Ann N Y Acad Sci** 1996 Jun 18;789:1-16 (55 ref.)

Women, work, and family: mental health issues. Denmark F, et al. **Ann N Y Acad Sci** 1996 Jun 18;789:101-17 (46 ref.)

Hispanic women and mental health. Gil RM. **Ann N Y Acad Sci** 1996 Jun 18;789:147-59 (53 ref.)

African-American women: considering diverse identities and societal barriers in psychotherapy. Greene B. **Ann N Y Acad Sci** 1996 Jun 18;789:191-209 (30 ref.)

Health and unemployment. Dooley D, et al. **Annu Rev Public Health** 1996;17:449-65 (112 ref.)

Exercise and mental health: a review. Glenister D. **J R Soc Health** 1996 Feb;116(1):7-13 (63 ref.)

Physical activity and psychological well-being: knowledge base, current issues, and caveats. Gauvin L, et al. **Nutr Rev** 1996 Apr;54(4 Pt 2):S53-65 (154 ref.)

The relationship between social support and physiological processes: a review with emphasis on underlying mechanisms and implications for health. Uchino BN, et al. **Psychol Bull** 1996 May;119(3):488-531 (276 ref.)

Measuring social disabilities in mental health. Wiersma D. **Soc Psychiatry Psychiatr Epidemiol** 1996 Jun;31(3-4):101-8 (46 ref.)

[The mental health of ethnic minorities in the United Kingdom] Picarda V, et al. **Cah Sociol Demogr Med** 1995 Jan-Mar;35(1):5-19 (59 ref.) (Eng. Abstr.) **(Fre)**

[Legislation related to mental health: a review of various international experiences] Bertolote JM. **Rev Saude Publica** 1995 Apr;29(2):152-6 (14 ref.) (Eng. Abstr.) **(Por)**

MENTAL HEALTH SERVICES

The essential elements of culturally sensitive psychiatric services. Bhui K, et al. **Int J Soc Psychiatry** 1995 Winter; 41(4):242-56 (83 ref.)

Outcomes of mental health care for children and adolescents: II. Literature review and application of a comprehensive model. Jensen PS, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Aug; 35(8):1064-77 (104 ref.)

[The Italian situation in psychiatry after fifteen years of the psychiatric reform: the mental health service in north Italy] Mizuno M. **Seishin Shinkeigaku Zasshi** 1996;98(1):27-40 (27 ref.) **(Jpn)**

ECONOMICS

States' embrace of managed mental health care. Essock SM, et al. **Health Aff (Millwood)** 1995 Fall;14(3):34-44; discussion 45-9 (10 ref.)

Estimating costs of mental health and substance abuse coverage. Frank RG, et al. **Health Aff (Millwood)** 1995 Fall;14(3):102-15 (17 ref.)

Care for depression in a changing environment. Wells KB, et al. **Health Aff (Millwood)** 1995 Fall;14(3):78-89 (15 ref.)

The economics of pain. Mental health care costs among minorities. Ruiz P, et al. **Psychiatr Clin North Am** 1995 Sep;18(3):659-70 (23 ref.)

MANPOWER

Managed care and the role and training of psychiatrists. Meyer RE, et al. **Health Aff (Millwood)** 1995 Fall; 14(3):65-77 (23 ref.)

ORGANIZATION & ADMINISTRATION

Is there a role for prevention in aboriginal mental health? Hunter E. **Aust J Public Health** 1995 Dec;19(6):573-9 (50 ref.)

Managing mental health: whose responsibility? Rose SJ, et al. **Health Soc Work** 1996 Feb;21(1):76-80 (28 ref.)

De facto mental health services in the rural south. Fox J, et al. **J Health Care Poor Underserved** 1995;6(4):434-68 (190 ref.)

Medical sociology and the study of severe mental illness: reflections on past accomplishments and directions for future research. Cook JA, et al. **J Health Soc Behav** 1995; Spec No:95-114 (170 ref.)

STANDARDS

The imperative of outcome assessment in psychiatry. Sederer LI, et al. **Am J Med Qual** 1995 Fall;10(3):127-32 (32 ref.)

Managed care in mental health: the ethical issues. Boyle PJ, et al. **Health Aff (Millwood)** 1995 Fall;14(3):7-22; discussion 23-33 (40 ref.)

Outcomes of mental health care for children and adolescents: II. Literature review and application of a comprehensive model. Jensen PS, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Aug;

35(8):1064–77 (104 ref.)
The 1995 JCAHO mental health manual—an overview for dietetics professionals. Foiles RA. **J Am Diet Assoc** 1996 Apr;96(4):403–4 (6 ref.)

UTILIZATION

The epidemiology of psychiatric disorders and the de facto mental health care system. Norquist GS, et al. **Annu Rev Med** 1996;47:473–9 (29 ref.)
Patterns of mental health service utilization. Howard KI, et al. **Arch Gen Psychiatry** 1996 Aug;53(8):696–703 (57 ref.)
Forming a consortium: a design for interagency collaboration in the delivery of service following the disclosure of incest. Peck JS, et al. **Fam Process** 1995 Sep;34(3):287–302 (53 ref.)
A review of studies of heavy users of psychiatric services. Kent S, et al. **Psychiatr Serv** 1995 Dec;46(12):1247–53 (72 ref.)

MENTAL HEALTH SERVICES, COMMUNITY see **COMMUNITY MENTAL HEALTH SERVICES**

MENTAL HOSPITALS see **HOSPITALS, PSYCHIATRIC**

MENTAL HYGIENE see **MENTAL HEALTH**

MENTAL HYGIENE SERVICES see **MENTAL HEALTH SERVICES**

MENTAL PROCESSES

Planning and script analysis following prefrontal lobe lesions. Sirigu A, et al. **Ann N Y Acad Sci** 1995 Dec 15;769:277–88 (18 ref.)
Chaotic analysis in psychology and psychoanalysis. Kincanon E, et al. **J Psychol** 1995 Sep;129(5):495–505 (14 ref.)
Constraint satisfaction as a theory of sentence processing. Frazier L. **J Psycholinguist Res** 1995 Nov;24(6):437–68 (59 ref.)
[Imagery and its neurological substrate] Decety J, et al. **Rev Neurol (Paris)** 1995 Aug–Sep;151(8–9):474–9 (50 ref.) (Eng. Abstr.) **(Fre)**

DRUG EFFECTS

Assessing the residual effects of hypnotics. Hindmarch I, et al. **Acta Psychiatr Belg** 1994 Mar–Apr;94(2):88–95 (24 ref.)
Meperidine associated mental status changes in a patient with chronic renal failure. Stock SL, et al. **J Fla Med Assoc** 1996 May;83(5):315–9 (16 ref.)
[Side effects of phenytoin and carbamazepine on cognitive functioning] Pulliainen V, et al. **Duodecim** 1994; 110(14):1320–8 (44 ref.) **(Fin)**
[Beta blockers, calcium channel blockers and psyche] Strandberg T, et al. **Duodecim** 1994;110(4):397–402 (29 ref.) **(Fin)**

PHYSIOLOGY

Hemispheric asymmetry for visual information processing. Hellige JB. **Acta Neurobiol Exp (Warsz)** 1996;56(1):485–97 (66 ref.)
Brain imaging and cognitive neuroscience. Toward strong inference in attributing function to structure. Sarter M, et al. **Am Psychol** 1996 Jan;51(1):13–21 (75 ref.)
A computer model of prefrontal cortex function. Levinson R. **Ann N Y Acad Sci** 1995 Dec 15;769:381–8 (9 ref.)
Processing of learned information in paradoxical sleep: relevance for memory. Hennevin E, et al. **Behav Brain Res** 1995 Jul–Aug;69(1–2):125–35 (97 ref.)
General and specific speed mediation of adult age differences in memory. Salthouse TA. **J Gerontol B Psychol Sci Soc Sci** 1996 Jan;51(1):P30–42 (32 ref.)
Current issues in the neuropsychology of image generation. Farah MJ. **Neuropsychologia** 1995 Nov;33(11):1455–71 (79 ref.)
Neuronal activities underlying the electroencephalogram and evoked potentials of sleeping and waking: implications for information processing. Coenen AM. **Neurosci Biobehav Rev** 1995 Fall;19(3):447–63 (75 ref.)
[Plasticity of brain structure and function as the neurobiological principle of psychotherapy] Bogerts B. **Z Klin Psychol Psychopathol Psychother** 1996;44(3):243–52 (22 ref.) (Eng. Abstr.) **(Ger)**
[Synaptic reorganization in early childhood experience and learning processes: relevance for the development of psychological diseases] Braun K. **Z Klin Psychol Psychopathol Psychother** 1996;44(3):253–66 (60 ref.) (Eng. Abstr.) **(Ger)**

MENTAL RETARDATION

see related
CRETINISM
EDUCATION OF MENTALLY RETARDED

"New" ectodermal dysplasia with mental retardation and syndactyly. Ilyina HG, et al. **Am J Med Genet** 1995 Sep 25;58(4):345–7 (15 ref.)

CLASSIFICATION

Another patient with an unusual syndrome of mental retardation and sparse hair? [letter] Krajewska-Walasek M, et al. **Clin Dysmorphol** 1996 Apr;5(2):183–6 (1 ref.)
Issues in the taxonomy of psychopathology in mental retardation. Einfeld SL, et al. **J Autism Dev Disord** 1995 Apr;25(2):143–67 (105 ref.)

COMPLICATIONS

Cutaneous findings in the mentally retarded. Schepis C, et al. **Int J Dermatol** 1996 May;35(5):317–22 (48 ref.)
[Depressive disorders in mentally retarded children. A review of selected literature. Part I] Rola J. **Psychiatr Pol** 1996 Mar–Apr;30(2):201–10 (20 ref.) (Eng. Abstr.) **(Pol)**
[Depressive disorders in mentally retarded children. A review of selected literature. Part II] Rola J. **Psychiatr Pol** 1996 Mar–Apr;30(2):211–9 (20 ref.) (Eng. Abstr.) **(Pol)**

DIAGNOSIS

DSM-III-R and persons with dual diagnoses: conceptual issues and strategies for future research. Sturmey P. **J Intellect Disabil Res** 1995 Oct;39 (Pt 5):357–64 (42 ref.)
[Behr's syndrome. A report of 2 siblings studied by MR] Pascual-Castroviejo I, et al. **An Esp Pediatr** 1996 Jun; 44(6):593–5 (11 ref.) **(Spa)**
[Epilepsy and psychomotor retardation in a child with aplasia cutis and brachydactyly (Adams-Oliver syndrome)] Verdú Pérez A, et al. **An Esp Pediatr** 1996 Mar;44(3):289–91 (15 ref.) **(Spa)**

DRUG THERAPY

Psychopharmacology in child and adolescent psychiatry: a review of the past seven years. Part I. Campbell M, et al. **J Am Acad Child Adolesc Psychiatry** 1995 Sep; 34(9):1124–32 (132 ref.)
Diagnostic-based pharmacological treatment of behavior disorders in persons with developmental disabilities: a review and a decision-making typology. Sturmey P. **Res Dev Disabil** 1995 Jul–Aug;16(4):235–52 (45 ref.)

ENZYMOLOGY

[Aspartylglucosaminuria: a point mutation as a cause of mental defect] Ikonen E, et al. **Duodecim** 1994; 110(7):667–73 (21 ref.) **(Fin)**

ETIOLOGY

[Fetal alcohol syndrome: an unrecognized cause of intellectual handicap and problem behavior in The Netherlands] van Balkom ID, et al. **Ned Tijdschr Geneeskd** 1996 Mar 16;140(11):592–5 (37 ref.) **(Dut)**
-Brain damage in infancy: mostly not intrapartum. On the etiology of mental and neurologic handicaps- Largo RH, et al. **Arch Gynecol Obstet** 1995;256 Suppl:S71–80 (18 ref.) **(Ger)**

GENETICS

Detection of a subtle rearrangement of chromosome 22 using molecular techniques. Biesecker LG, et al. **Am J Med Genet** 1995 Sep 25;58(4):389–94 (15 ref.)
Inversion duplication of the short arm of chromosome 8: clinical data on seven patients and review of the literature. de Die-Smulders CE, et al. **Am J Med Genet** 1995 Nov 20;59(3):369–74 (16 ref.)
Kabuki make-up (Niikawa-Kuroki) syndrome in five Spanish children. Galán-Gómez E, et al. **Am J Med Genet** 1995 Nov 20;59(3):276–82 (30 ref.)
Alopecia/mental retardation syndrome. Hannig VL, et al. **Am J Med Genet** 1995 Aug 28;58(2):123–4 (13 ref.)
Mirror image duplication of the hands and feet: report of a sporadic case with multiple congenital anomalies. Hersh JH, et al. **Am J Med Genet** 1995 Nov 20;59(3):341–5 (14 ref.)
Familial partial duplication (1)(p21p31). Hoechstetter L, et al. **Am J Med Genet** 1995 Nov 20;59(3):291–4 (8 ref.)
Neuroblastoma in a boy with MCA/MR syndrome, deletion 11q, and duplication 12q. Koiffmann CP, et al. **Am J Med Genet** 1995 Jul 31;58(1):46–9 (18 ref.)
Uniparental isodisomy of chromosome 14 in two cases: an abnormal child and a normal adult. Papenhausen PR, et al. **Am J Med Genet** 1995 Nov 20;59(3):271–5 (30 ref.)
Juberg-Marsidi syndrome: report of an additional case. Tsukahara M, et al. **Am J Med Genet** 1995 Sep 25; 58(4):353–5 (7 ref.)
Fryns syndrome survivors and neurologic outcome. Van Hove JL, et al. **Am J Med Genet** 1995 Nov 20;59(3):334–40 (39 ref.)
A distinct phenotype associated with partial trisomy 10q due to proximal direct duplication 10q11 --> q223? van Buggenhout G, et al. **Genet Couns** 1996;7(1):53–9 (14 ref.)
Zimmermann-Laband syndrome in a patient with severe mental retardation. Van Buggenhout GJ, et al. **Genet Couns** 1995;6(4):321–7 (15 ref.)
Syndromal mental retardation due to mutations in a regulator of gene expression. Gibbons RJ, et al. **Hum Mol Genet** 1995;4 Spec No:1705–9 (24 ref.)
Mental retardation: genetic findings, clinical implications and research agenda. Simonoff E, et al. **J Child Psychol Psychiatry** 1996 Mar;37(3):259–80 (252 ref.)
Filippi syndrome: a new case with skeletal abnormalities. Héron D, et al. **J Med Genet** 1995 Aug;32(8):659–61 (6 ref.)
Pfeiffer type cardiocranial syndrome: a third case report. Williamson-Kruse L, et al. **J Med Genet** 1995 Nov; 32(11):901–3 (5 ref.)
The alpha-thalassemia/mental retardation syndromes. Gibbons RJ, et al. **Medicine (Baltimore)** 1996 Mar; 75(2):45–52 (32 ref.)
Ophthalmic manifestations of Smith-Magenis syndrome. Chen RM, et al. **Ophthalmology** 1996 Jul;103(7):1084–91 (29 ref.)
Dynamic mutations and psychiatric genetics [editorial] O'Donovan MC, et al. **Psychol Med** 1996 Jan;26(1):1–6 (30 ref.)
The genetic basis for mental retardation. Raynham H, et al. **QJM** 1996 Mar;89(3):169–75 (51 ref.)
[Aspartylglucosaminuria: a point mutation as a cause of mental defect] Ikonen E, et al. **Duodecim** 1994; 110(7):667–73 (21 ref.) **(Fin)**

PHYSIOPATHOLOGY

Life-span intellectual development of people with mental retardation. Trower T, et al. **Dev Med Child Neurol** 1996 Jul;38(7):645–50 (25 ref.)

PSYCHOLOGY

Relationship between elderly carers and the older adult with learning disabilities: an overview of the literature. Maggs C, et al. **J Adv Nurs** 1996 Feb;23(2):243–51 (56 ref.)
Attachment and learning disability: a theoretical review informing three clinical interventions. Clegg JA, et al. **J Intellect Disabil Res** 1995 Aug;39 (Pt 4):295–305 (43 ref.)
Evaluation of the patient with idiopathic mental retardation. Bodensteiner JB, et al. **J Neuropsychiatry Clin Neurosci** 1995 Summer;7(3):361–70 (79 ref.)
African American families, religion, and disability: a conceptual framework. Rogers-Dulan J, et al. **Ment Retard** 1995 Aug;33(4):226–38 (65 ref.)
The parents of a severely dependent child. Keeley D, et al. **Practitioner** 1995 Sep;239(1554):505–8, 510, 512 (0 ref.)
Facial emotion recognition by persons with mental retardation: a review of the experimental literature. Rojahn J, et al. **Res Dev Disabil** 1995 Sep–Oct;16(5):393–414 (75 ref.)
[Depressive disorders in mentally retarded children. A review of selected literature. Part I] Rola J. **Psychiatr Pol** 1996 Mar–Apr;30(2):201–10 (20 ref.) (Eng. Abstr.) **(Pol)**
[Depressive disorders in mentally retarded children. A review of selected literature. Part II] Rola J. **Psychiatr Pol** 1996 Mar–Apr;30(2):211–9 (20 ref.) (Eng. Abstr.) **(Pol)**

REHABILITATION

Employment supports for people with mental illness. Marrone J, et al. **Psychiatr Serv** 1995 Jul;46(7):707–11 (40 ref.)
[Social legislative and structural deficits of ambulatory management of chronic psychiatric and handicapped patients] Rössler W, et al. **Nervenarzt** 1995 Nov; 66(11):802–10 (34 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Annotation: self-injurious behaviour in children with learning disabilities: recent advances in assessment and intervention. Oliver C. **J Child Psychol Psychiatry** 1995 Sep;36(6):909–27 (100 ref.)
Physical restraint procedures for managing challenging behaviours presented by mentally retarded adults and children. Harris J. **Res Dev Disabil** 1996 Mar–Apr; 17(2):99–134 (52 ref.)
Analog baselines: a critical review of the methodology. Sturmey P. **Res Dev Disabil** 1995 Jul–Aug;16(4):269–84 (54 ref.)
[Particular aspects of psychiatric management of mentally retarded patients with psychiatric disorders] Hennicke K, et al. **Psychiatr Prax** 1995 Nov;22(6):240–3 (27 ref.) (Eng. Abstr.) **(Ger)**

MENTAL STATUS SCHEDULE

Development of a functional capacity model for the elderly. Song M, et al. **Res Nurs Health** 1996 Jun;19(3):173–81 (631 ref.)

MENTAL TESTS see **INTELLIGENCE TESTS**

MENTALLY HANDICAPPED see **MENTAL RETARDATION**

MENTHOL

ANALOGS & DERIVATIVES

Pennyroyal toxicity: measurement of toxic metabolite levels in two cases and review of the literature. Anderson IB, et al. **Ann Intern Med** 1996 Apr 15;124(8):726–34 (46 ref.)

MEPERIDINE

ADVERSE EFFECTS

Meperidine associated mental status changes in a patient with chronic renal failure. Stock SL, et al. **J Fla Med Assoc** 1996 May;83(5):315–9 (16 ref.)

THERAPEUTIC USE

Meperidine: therapeutic use and toxicity. Clark RF, et al. **J Emerg Med** 1995 Nov–Dec;13(6):797–802 (62 ref.)

MERCAPTAMINE see CYSTEAMINE

MERCAPTO COMPOUNDS see SULFHYDRYL COMPOUNDS

2-MERCAPTOETHANESULFONATE see MESNA

6-MERCAPTOPURINE

ADMINISTRATION & DOSAGE

Sinus histiocytosis with massive lymphadenopathy (Rosai–Dorfman disease): response to methotrexate and mercaptopurine. Horneff G, et al. **Med Pediatr Oncol** 1996 Sep;27(3):187–92 (24 ref.)

THERAPEUTIC USE

A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Sandborn WJ. **Am J Gastroenterol** 1996 Mar;91(3):423–33 (65 ref.)

MERCAPTOVALINE see PENICILLAMINE

MERCAPTURIC ACID see ACETYLCYSTEINE

MERCURIC CHLORIDE

Mercury: god of Th2 cells? [editorial; comment] Mathieson PW. **Clin Exp Immunol** 1995 Nov;102(2):229–30 (26 ref.) Comment on: Clin Exp Immunol 1995 Nov;102(2):297–307.

TOXICITY

Comparison of neurite outgrowth with neurofilament protein subunit levels in neuroblastoma cells following mercuric oxide exposure. Abdulla EM, et al. **Clin Exp Pharmacol Physiol** 1995 May;22(5):362–3 (5 ref.)

MERCUROTHIOLATE see THIMEROSAL

MERCURY

ADMINISTRATION & DOSAGE

[Intravenous injection of metallic mercury—case report] Nalepa P, et al. **Pneumonol Alergol Pol** 1996;64(1–2):88–92 (12 ref.) (Eng. Abstr.) **(Pol)**

ADVERSE EFFECTS

Dental amalgam: toxicological evaluation and health risk assessment. Levy M. **J Can Dent Assoc** 1995 Aug; 61(8):667–8, 671–4 (46 ref.)

Elemental mercury–induced skin granuloma: a case report and review of the literature. Bradberry SM, et al. **J Toxicol Clin Toxicol** 1996;34(2):209–16 (38 ref.)

Health implications for Faroe islanders of heavy metals and PCBs from pilot whales. Weihe P, et al. **Sci Total Environ** 1996 Jul 16;186(1–2):141–8 (37 ref.)

[Exposure to mercury and population health. I. Immunotoxicity of mercury] Moszczyński P, et al. **Med Pr** 1995;46(4):385–93 (91 ref.) (Eng. Abstr.) **(Pol)**

ANALYSIS

[Mercury] Futatsuka M, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:850–3 (10 ref.) **(Jpn)**

IMMUNOLOGY

Investigation of the association between mercury sensitization and HLA-DR6. Sato K, et al. **Contact Dermatitis** 1996 Apr;34(4):295 (5 ref.)

TOXICITY

Comparison of neurite outgrowth with neurofilament protein subunit levels in neuroblastoma cells following mercuric oxide exposure. Abdulla EM, et al. **Clin Exp Pharmacol Physiol** 1995 May;22(5):362–3 (5 ref.)

Immunotoxicity of heavy metals in relation to Great Lakes. Bernier J, et al. **Environ Health Perspect** 1995 Dec;103 Suppl 9:23–34 (145 ref.)

Inorganic mercury. Von Burg R. **J Appl Toxicol** 1995 Nov–Dec;15(6):483–93 (135 ref.)

[Amalgam and the toxicological risks of mercury. A review of the argument] Marchi A, et al. **Minerva Stomatol** 1995 Jun;44(6):311–8 (44 ref.) (Eng. Abstr.) **(Ita)**

[The biomedical aspects of mercury neurotoxicity (a review)] Chukhlovina ML. **Gig Sanit** 1995 Nov–Dec;(6):39–41 (45 ref.) **(Rus)**

MERCURY COMPOUNDS

TOXICITY

Inorganic mercury. Von Burg R. **J Appl Toxicol** 1995 Nov–Dec;15(6):483–93 (135 ref.)

MERCURY DICHLORIDE see MERCURIC CHLORIDE

MERCURY POISONING

DIAGNOSIS

[Intravenous injection of metallic mercury—case report] Nalepa P, et al. **Pneumonol Alergol Pol** 1996;64(1–2):88–92 (12 ref.) (Eng. Abstr.) **(Pol)**

[Subclinical mercury poisoning (editorial; comment)] López-Alburquerque T. **An Med Interna** 1996 May; 13(5):209–10 (12 ref.) Comment on: An Med Interna 1996 May;13(5):211–6. **(Spa)**

ETIOLOGY

[Amalgam allergy and amalgam controversy] Lübbe J, et al. **Schweiz Med Wochenschr** 1996 Apr 20;126(16):661–5 (48 ref.) (Eng. Abstr.) **(Ger)**

MERCY KILLING see EUTHANASIA

MERGER, HEALTH FACILITY see HEALTH FACILITY MERGER

MERIONES see GERBILLINAE

MERISTEM

CYTOLOGY

Chemically induced mitotic synchrony in root apical meristems. Prewett B, et al. **Methods Cell Biol** 1995; 49:355–65 (10 ref.)

Cellular and molecular events in a newly organizing lateral root meristem. Sussex IM, et al. **Philos Trans R Soc Lond B Biol Sci** 1995 Oct 30; 350(1331):39–43 (14 ref.)

EMBRYOLOGY

Cellular and molecular events in a newly organizing lateral root meristem. Sussex IM, et al. **Philos Trans R Soc Lond B Biol Sci** 1995 Oct 30; 350(1331):39–43 (14 ref.)

GENETICS

Homeobox genes in the functioning of plant meristems. Hake S, et al. **Philos Trans R Soc Lond B Biol Sci** 1995 Oct 30;350(1331):45–51 (32 ref.)

MERKEL CELL TUMOR see CARCINOMA, MERKEL CELL

MERKEL CELLS

see related
CARCINOMA, MERKEL CELL

PHYSIOLOGY

The Merkel cell: recent findings and unresolved problems. Tachibana T. **Arch Histol Cytol** 1995 Oct;58(4):379–96 (158 ref.)

MERKEL'S RECEPTOR see MERKEL CELLS

MEROMYOSIN SUBFRAGMENTS see MYOSIN SUBFRAGMENTS

MERPHALAN see MELPHALAN

MERRF SYNDROME

COMPLICATIONS

[Mitochondrial diseases and cerebrovascular pathology] Vivancos J, et al. **Rev Neurol** 1995;23 Suppl 1:S106–12 (39 ref.) **(Spa)**

MESANGIOCAPILLARY GLOMERULONEPHRITIS see GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE

MESANGIUM, GLOMERULAR see GLOMERULAR MESANGIUM

MESENCEPHALIC CENTRAL GRAY see PERIAQUEDUCTAL GRAY

MESENCEPHALON

CYTOLOGY

Morphological study of microglia in human mesencephalon during the development and aging. Wierzba-Bobrowicz T, et al. **Folia Neuropathol** 1995;33(2):77–83 (46 ref.)

EMBRYOLOGY

Determination events in the nervous system of the vertebrate embryo. Bally-Cuif L, et al. **Curr Opin Genet Dev** 1995 Aug;5(4):450–8 (70 ref.)

PATHOLOGY

Vertical gaze paralysis and intermittent unresponsiveness in a patient with a thalamomesencephalic stroke. Beversdorf DQ, et al. **J Neuroophthalmol** 1995 Dec;15(4):230–5 (21 ref.)

PHYSIOLOGY

Morphological study of microglia in human mesencephalon during the development and aging. Wierzba-Bobrowicz T, et al. **Folia Neuropathol** 1995;33(2):77–83 (46 ref.)

Neural control of vocalization: respiratory and emotional influences. Davis PJ, et al. **J Voice** 1996 Mar;10(1):23–38 (107 ref.)

Functional characteristics of the midbrain periaqueductal gray. Behbehani MM. **Prog Neurobiol** 1995 Aug; 46(6):575–605 (325 ref.)

The pedunculopontine tegmental nucleus: where the striatum meets the reticular formation. Inglis WL, et al. **Prog Neurobiol** 1995 Sep;47(1):1–29 (205 ref.)

TRANSPLANTATION

Radical directions in Parkinson's disease [comment] Fisher LJ, et al. **Nat Med** 1995 Mar;1(3):201–3 (20 ref.) Comment on: Nat Med 1995 Mar;1(3):226–31.

Tempting fate and commitment in the developing forebrain. Barbe MF. **Neuron** 1996 Jan;16(1):1–4 (16 ref.)

[Neuronal transplantation in animal models of Parkinson disease: in vivo voltammetry, tissue cryopreservation and immunology] Sautter J, et al. **Zentralbl Neurochir** 1995; 56(4):161–7 (28 ref.) (Eng. Abstr.) **(Ger)**

MESENCHYME see MESODERM

MESENCHYMOMA

COMPLICATIONS

Tumor-induced osteomalacia. Schapira D, et al. **Semin Arthritis Rheum** 1995 Aug;25(1):35–46 (79 ref.)

PATHOLOGY

Intraoral benign mesenchymomas. Yencha MW Jr, et al. **Otolaryngol Head Neck Surg** 1995 Dec;113(6):816–9 (15 ref.)

Malignant mesenchymoma of the pleura. Sheffield M, et al. **South Med J** 1996 May;89(5):526–8 (7 ref.)

Myolipoma of the round ligament: report of a case with a review of the English literature. Sonobe H, et al. **Virchows Arch** 1995;427(4):455–8 (24 ref.)

[Low malignancy myxofibrosarcoma versus low malignancy fibromyxoid sarcoma. Distinct entities with similar names but different clinical course] Mentzel T, et al. **Pathologe** 1996 Mar;17(2):116–21 (19 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Technique of sacral hernia repair. Kaplan LJ, et al. **Am Surg** 1996 Sep;62(9):762–4 (4 ref.)

MESENTERIC CIRCULATION see SPLANCHNIC CIRCULATION

MESENTERIC CYST

DIAGNOSIS

[Appearance forms of mesenteric cyst. A case report] Gissler HM, et al. **Radiologe** 1996 Jun;36(6):503–7 (30 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

A complication of mesenteric lymphangioma: case report and brief review of literature. Takkal M, et al. **Acta Chir Belg** 1996 Jun;96(3):130–2 (12 ref.)

MESENTERIC PANNICULITIS see PANNICULITIS, PERITONEAL

MESENTERIC VASCULAR OCCLUSION

ETIOLOGY

Portal and mesenteric thrombosis in protein S (pS) deficiency. Zigrossi P, et al. **Am J Gastroenterol** 1996 Jan;91(1):163–5 (11 ref.)

Conservative management strategy for pancreatitis-associated mesenteric venous thrombosis. Krummen DM, et al. **Am Surg** 1996 Jun;62(6):432–4 (12 ref.)

Superior mesenteric artery thrombosis in a patient with the antiphospholipid syndrome. England RJ, et al. **Eur J Vasc Endovasc Surg** 1995 Oct;10(3):372–3 (4 ref.)

[Thrombosis of the superior mesenteric artery and Behçet's syndrome] Mercié P, et al. **Rev Med Interne** 1996;

17(6):470-3 (16 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Angioplasty for the treatment of visceral ischemia. Hallisey MJ, et al. **J Vasc Interv Radiol** 1995 Sep-Oct;6(5):785-91 (26 ref.)

MESENTERIC VEINS

[Fissured aneurysm of the superior mesenteric vein. Report of a case] Catalano O. **Radiol Med (Torino)** 1995 Jul-Aug; 90(1-2):148-9 (19 ref.) **(Ita)**

ABNORMALITIES

Congenital absence of portal venous system associated with a large inferior mesenteric-caval shunt: a case report. Komatsu S, et al. **Hepatogastroenterology** 1995 Jul; 42(3):286-90 (17 ref.)

PATHOLOGY

Conservative management strategy for pancreatitis-associated mesenteric venous thrombosis. Krummen DM, et al. **Am Surg** 1996 Jun;62(6):432-4 (12 ref.)

Venous hemangioma of the mesoappendix: report of a case and a brief review of the Japanese literature. Hanatate F, et al. **Surg Today** 1995;25(11):962-4 (8 ref.)

MESENTERY

Sequential treatment of recurrent mesenteric desmoid tumor. Bauernhofer T, et al. **Cancer** 1996 Mar 15;77(6):1061-5 (44 ref.)

Cavitation of mesenteric lymph nodes: a rare complication of coeliac disease, associated with a poor outcome. Howat AJ, et al. **Histopathology** 1995 Oct;27(4):349-54 (8 ref.)

[Mesenteric lipodystrophy] Obelar Bernal L, et al. **Rev Esp Enferm Dig** 1995 Sep;87(9):658-64 (82 ref.) (Eng. Abstr.) **(Spa)**

BLOOD SUPPLY

Non-occlusive mesenteric ischemia. Lock G, et al. **Hepatogastroenterology** 1995 Jul;42(3):234-9 (36 ref.)

PATHOLOGY

Pheocromocytoma and gastrointestinal bleeding. Vázquez-Quintana E, et al. **Am Surg** 1995 Nov; 61(11):937-9 (12 ref.)

RADIOGRAPHY

Anatomic CT demonstration of the peritoneal spaces, ligaments, and mesenteries: normal and pathologic processes. DeMeo JH, et al. **Radiographics** 1995 Jul; 15(4):755-70 (18 ref.)

CT scan of mesentery-omentum peritoneum. Sivit CJ. **Radiol Clin North Am** 1996 Jul;34(4):863-84 (58 ref.)

MESMERISM see **HYPNOSIS**

MESNA

THERAPEUTIC USE

Efficacy of mesna for prevention of hemorrhagic cystitis after high-dose cyclophosphamide therapy. Haselberger MB, et al. **Ann Pharmacother** 1995 Sep;29(9):918-21 (21 ref.)

Oral administration of mesna with ifosfamide. Goren MP. **Semin Oncol** 1996 Jun;23(3 Suppl 6):91-6 (51 ref.)

MESODERM

Micromass cultures of limb and other mesenchyme. Daniels K, et al. **Methods Cell Biol** 1996;51:237-47 (24 ref.)

Somite strips: an embryo fillet preparation. Tosney KW, et al. **Methods Cell Biol** 1996;51:93-108 (10 ref.)

CYTOLOGY

Cell-cell adhesion molecules in epithelial-mesenchymal transformations. Prieto AL, et al. **Acta Anat (Basel)** 1995; 154(1):21-33 (176 ref.)

Transformations between epithelium and mesenchyme: normal, pathological, and experimentally induced. Hay ED, et al. **Am J Kidney Dis** 1995 Oct;26(4):678-90 (103 ref.)

A new turn (or two) for twist [comment] Michelson AM. **Science** 1996 Jun 7;272(5267):1449-50 (15 ref.) Comment on: Science 1996 Jun 7;272(5267):1476-80. Comment on: Science 1996 Jun 7;272(5267):1481-4.

Regulation of differentiation pathway of skeletal mesenchymal cells in cell lines by transforming growth factor-beta superfamily. Yamaguchi A. **Semin Cell Biol** 1995 Jun;6(3):165-73 (53 ref.)

PHYSIOLOGY

Epithelium-mesenchyme transition during neural crest development. Duband JL, et al. **Acta Anat (Basel)** 1995; 154(1):63-78 (107 ref.)

An overview of epithelio-mesenchymal transformation. Hay ED. **Acta Anat (Basel)** 1995;154(1):8-20 (101 ref.)

Cell-cell adhesion molecules in epithelial-mesenchymal transformations. Prieto AL, et al. **Acta Anat (Basel)** 1995; 154(1):21-33 (176 ref.)

Epithelio-mesenchymal transformation during formation of the mesoderm in the mammalian embryo. Viebahn C. **Acta Anat (Basel)** 1995;154(1):79-97 (170 ref.)

A new subclass of helix-loop-helix transcription factors expressed in paraxial mesoderm and chondrogenic cell lineages. Olson EN, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:108-18 (30 ref.)

Vasculogenesis. Risau W, et al. **Ann Rev Cell Dev Biol** 1995; 11:73-91 (122 ref.)

Signals for mesoderm induction. Roles of fibroblast growth factor (FGF)/mitogen-activated protein kinase (MAPK) pathway. Gotoh Y, et al. **Biochim Biophys Acta** 1996 Aug 8;1288(1):F1-7 (121 ref.)

How many signals does it take? Venkatesh TV, et al. **Bioessays** 1995 Sep;17(9):754-7 (31 ref.)

Regulation of cardiac gene expression during development. Robbins J. **Cardiovasc Res** 1996 Feb;31 Spec No:E2-16 (168 ref.)

Epithelial-mesenchymal signaling during tooth development. Thesleff I, et al. **Connect Tissue Res** 1995;32(1-4):9-15 (53 ref.)

Somite differentiation. Sonic signals somites. Bumcrot DA, et al. **Curr Biol** 1995 Jun 1;5(6):612-4 (13 ref.)

Mesoderm-inducing factors and mesodermal patterning. Smith JC. **Curr Opin Cell Biol** 1995 Dec;7(6):856-61 (61 ref.)

Inductive interactions between the mesenchyme and the ureteric bud. Davies JA, et al. **Exp Nephrol** 1996 Mar-Apr; 4(2):77-85 (82 ref.)

Epithelial-mesenchymal transitions in development and tumor progression. Birchmeier W, et al. **EXS** 1995;74:1-15 (93 ref.)

Angiogenesis as a component of epithelial-mesenchymal interactions. Grant DS, et al. **EXS** 1995;74:235-48 (36 ref.)

Keratinocyte growth factor as a cytokine that mediates mesenchymal-epithelial interaction. Rubin JS, et al. **EXS** 1995;74:191-214 (90 ref.)

MESONEPHROMA

PATHOLOGY

Malignant mesonephric neoplasms of the uterine cervix. A report of eight cases, including four with a malignant spindle cell component. Clement PB, et al. **Am J Surg Pathol** 1995 Oct;19(10):1158-71 (43 ref.)

MESOTHELIOMA

Malignant pleural mesothelioma: newer aspects of carcinogenesis, molecular genetics, and prospects for future therapies. Donington JS, et al. **Surg Oncol** 1995 Aug; 4(4):175-85 (45 ref.)

CHEMICALLY INDUCED

[Malignant peritoneal mesothelioma: its relation to asbestos] Pentimone F, et al. **Minerva Med** 1995 Oct;86(10):439-43 (38 ref.) (Eng. Abstr.) **(Ita)**

COMPLICATIONS

[Peritoneal mesothelioma as a rare case of acute abdomen. Review of the literature] Cipollone G, et al. **Chir Ital** 1994; 46(6):73-9 (86 ref.) (Eng. Abstr.) **(Ita)**

DIAGNOSIS

Methods to improve the diagnostic accuracy of malignant mesothelioma. Dejmek A. **Respir Med** 1996 Apr; 90(4):191-9 (129 ref.)

[Peritoneal mesothelioma. Contribution of MRI. Apropos of a case] Guzelian J, et al. **J Radiol** 1996 Jul;77(7):497-501 (15 ref.) (Eng. Abstr.) **(Fre)**

[Pseudomesotheliomatous carcinoma in HIV infection] Brunner-La Rocca HP, et al. **Dtsch Med Wochenschr** 1995 Sep 29;120(39):1312-7 (38 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Bronchoesophagopleural fistula after photodynamic therapy for malignant mesothelioma. Luketich JD, et al. **Ann Thorac Surg** 1996 Jul;62(1):283-4 (7 ref.)

Chemotherapy in malignant pleural mesothelioma. A review. Ong ST, et al. **J Clin Oncol** 1996 Mar;14(3):1007-17 (79 ref.)

ETHNOLOGY

Malignant mesothelioma in Pilbara Aborigines. Musk AW, et al. **Aust J Public Health** 1995 Oct;19(5):520-2 (10 ref.)

ETIOLOGY

Malignant peritoneal mesothelioma. Case report and review of the literature. Watteeuw G, et al. **Acta Clin Belg** 1995; 50(4):222-6 (18 ref.)

Airborne fibre concentrations and lung burden compared to the tumour response in rats and humans exposed to asbestos. Rödelsperger K, et al. **Ann Occup Hyg** 1995 Oct; 39(5):715-25 (27 ref.)

Mechanisms of carcinogenesis and clinical features of asbestos-associated cancers. Mossman BT, et al. **Cancer Invest** 1996;14(5):466-80 (126 ref.)

GENETICS

Genetic factors in the aetiology of malignant mesothelioma. Huncharek M. **Eur J Cancer** 1995 Oct;31A(11):1741-7 (66 ref.)

Asbestos and mesothelioma: genetic lessons from a tragedy [comment] Knudson A. **Proc Natl Acad Sci U S A** 1995 Nov 21;92(24):10819-20 (21 ref.) Comment on: Proc Natl Acad Sci U S A 1995 Nov 21;92(24):10854-8.

IMMUNOLOGY

Molecular pathobiology and immunology of malignant mesothelioma. Bielefeldt-Ohmann H, et al. **J Pathol** 1996 Apr;178(4):369-78 (76 ref.)

PATHOLOGY

Malignant pleural mesothelioma. A proposed new staging system [editorial; comment] Jett JR. **Chest** 1995 Oct; 108(4):895-7 (18 ref.) Comment on: Chest 1995 Oct;108(4):1122-8.

Smooth muscle tumours of the pleura. Gibbs AR. **Histopathology** 1995 Sep;27(3):295-6 (17 ref.)

Molecular pathobiology and immunology of malignant mesothelioma. Bielefeldt-Ohmann H, et al. **J Pathol** 1996 Apr;178(4):369-78 (76 ref.)

[Peritoneal mesothelioma and abdominal hernias] Mirabella F. **Minerva Med** 1996 Jan-Feb;87(1-2):21-4 (51 ref.) (Eng. Abstr.) **(Ita)**

PHYSIOPATHOLOGY

Clinical features and current treatment of diffuse malignant pleural mesothelioma. Rusch VW. **Lung Cancer** 1995 Jun; 12 Suppl 2:S127-46 (81 ref.)

SURGERY

[Benign pleural mesothelioma. Report of 2 cases] Ruff S, et al. **Langenbecks Arch Chir** 1995;380(6):345-9 (12 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Clinical features and current treatment of diffuse malignant pleural mesothelioma. Rusch VW. **Lung Cancer** 1995 Jun; 12 Suppl 2:S127-46 (81 ref.)

Malignant mesothelioma: new insights into tumour biology and immunology as a basis for new treatment approaches. Upham JW, et al. **Thorax** 1995 Aug;50(8):887-93 (74 ref.)

MESOTHELIOMA, CYSTIC

SURGERY

Peritoneal cystic mesothelioma treated with minimally invasive approach. Navarra G, et al. **Surg Endosc** 1996 Jan; 10(1):60-1 (23 ref.)

MESOTHELIUM see **EPITHELIUM**

MESOZOA see **INVERTEBRATES**

MESSENGER RNA see **RNA, MESSENGER**

MESSENGER RNA, POLYADENYLATED see **RNA, MESSENGER**

MESULAM SYNDROME see **APHASIA, PRIMARY PROGRESSIVE**

META-ANALYSIS

see related
PUBLICATION BIAS
REVIEW LITERATURE

Understanding research synthesis (meta-analysis). Mosteller F, et al. **Annu Rev Public Health** 1996;17:1-23 (91 ref.)

Meta-analyses and overviews of randomised trials. Richards SM. **Blood Rev** 1995 Jun;9(2):85-91 (16 ref.)

Meta-analysis: a method for synthesizing research. D'Agostino RB, et al. **Clin Pharmacol Ther** 1995 Dec; 58(6):605-16 (30 ref.)

Meta-analysis: an introduction and point of view. Friedman HP, et al. **Hepatology** 1996 Apr;23(4):917-28 (60 ref.)

Meta-analyses to evaluate analgesic interventions: a systematic qualitative review of their methodology. Jadad AR, et al. **J Clin Epidemiol** 1996 Feb;49(2):235-43 (100 ref.)

Meta-analysis: an update. Sacks HS, et al. **Mt Sinai J Med** 1996 May-Sep;63(3-4):216-24 (47 ref.)

What is metanalysis? Haines SJ, et al. **Surg Neurol** 1995 Dec; 44(6):581-2 (7 ref.)

Critical reading of the meta-analysis of clinical trials. Nony P, et al. **Therapie** 1995 Jul-Aug;50(4):339-51 (67 ref.)

[Introduction to meta-analytic methodology] Nony P, et al. **Rev Med Interne** 1995;16(7):536-46 (68 ref.) (Eng. Abstr.) **(Fre)**

[Inclusion of research quality in meta-analyses] Delgado-Rodriguez M, et al. **Gac Sanit** 1995 Jul-Aug; 9(49):265-72 (50 ref.) (Eng. Abstr.) **(Spa)**

METABOLIC ACTIVATION see **BIOTRANSFORMATION**

METABOLIC DETOXICATION, DRUG

Variability in glutathione-dependent detoxication in vivo and its relevance to detoxication of chemical mixtures. Jones DP, et al. **Toxicology** 1995 Dec 28;105(2-3):267-74 (40 ref.)
[Molecular pharmacological and toxicological studies of drug-metabolizing enzymes] Kato R. **Yakugaku Zasshi** 1995 Sep;115(9):661-80 (94 ref.) (Eng. Abstr.) **(Jpn)**

METABOLIC DISEASES

Pediatric gastroenterology. Update on metabolic liver disease. Schwarzenberg SJ, et al.
Pediatr Clin North Am 1996 Feb;43(1):27-56 (166 ref.)

COMPLICATIONS

Metabolic and endocrine disease and arthritis. Matteucci BM. **Curr Opin Rheumatol** 1995 Jul;7(4):356-8 (8 ref.)
Metabolic etiologies of cyclic or recurrent vomiting. Korson M. **J Pediatr Gastroenterol Nutr** 1995;21 Suppl 1:S15-9 (11 ref.)
Recurrence of the original disease. Does this influence renal graft failure? Michielsen P. **Kidney Int Suppl** 1995 Dec; 52:S79-84 (68 ref.)
[Metabolic changes and cerebrovascular disease] Dávalos A. **Rev Neurol** 1995;23 Suppl 1:S128-30 (30 ref.) **(Spa)**

DIAGNOSIS

Diagnosis of inherited metabolic disorders affecting the nervous system. Swanson PD.
J Neurol Neurosurg Psychiatry 1995 Nov;59(5):460-70 (123 ref.)

DRUG THERAPY

Drug management of noninfective complications of cystic fibrosis. Sanchez I, et al. **Drugs** 1995 Oct;50(4):626-35 (40 ref.)
[The treatment of hypertension in patients with a metabolic disorder] Dal Palù C, et al. **Ann Ital Med Int** 1995 Oct; 10 Suppl:130S-132S (21 ref.) (Eng. Abstr.) **(Ita)**

ETIOLOGY

Drug management of noninfective complications of cystic fibrosis. Sanchez I, et al. **Drugs** 1995 Oct;50(4):626-35 (40 ref.)
Nutrition and metabolic eye disease. Haddad HM.
Metab Pediatr Syst Ophthalmol 1994;17(1-4):41-4 (11 ref.)
Medical emergencies in oncology. Advani SH, et al.
Natl Med J India 1995 Nov-Dec;8(6):273-6 (0 ref.)

GENETICS

Diagnosis of inherited metabolic disorders affecting the nervous system. Swanson PD.
J Neurol Neurosurg Psychiatry 1995 Nov;59(5):460-70 (123 ref.)

METABOLISM

Metabolic disorders and neurotoxicology [editorial] Beal MF. **Curr Opin Neurol** 1995 Dec;8(6):467-8 (10 ref.)

PHYSIOPATHOLOGY

[The role of muscle, adipose tissue and liver in development of metabolic syndrome] Krotkiewski M. **Pol Tyg Lek** 1996 Jan;51(1-5):40-5 (55 ref.) **(Pol)**

PREVENTION & CONTROL

[Physical activity and prevention and treatment of metabolic syndrome] Eriksson J, et al. **Duodecim** 1994;110(12):1193-9 (46 ref.) **(Fin)**

THERAPY

Bone marrow transplantation for metabolic diseases. Parkman R, et al. **Cancer Treat Res** 1995;76:87-96 (33 ref.)
What's new in critical care and metabolism. Rice CL.
J Am Coll Surg 1996 Feb;182(2):93-9 (69 ref.)
Liver-directed gene transfer and application to therapy. Sandig V, et al. **J Mol Med** 1996 Apr;74(4):205-12 (89 ref.)

METABOLIC PUMP see **BIOLOGICAL TRANSPORT, ACTIVE**

METABOLISM

Physiological control of metabolic flux: the requirement for multisite modulation. Fell DA, et al. **Biochem J** 1995 Oct 1;311 (Pt 1):35-9 (48 ref.)
Metabolic control and metabolic capacity: two aspects of creatine kinase functioning in the cells. Saks VA, et al. **Biochim Biophys Acta** 1996 Jun 13;1274(3):81-8 (57 ref.)
Metabolic regulation: a control analytic perspective. Hofmeyr JH. **J Bioenerg Biomembr** 1995 Oct;27(5):479-90 (30 ref.)
Elusive control. Westerhoff HV, et al.
J Bioenerg Biomembr 1995 Oct;27(5):491-7 (54 ref.)
Depot medroxyprogesterone acetate contraception. Metabolic parameters and mood changes. Westhoff C.
J Reprod Med 1996 May;41(5 Suppl):401-6 (28 ref.)
Physical inactivity and metabolic factors as predictors of weight gain. Saris WH. **Nutr Rev** 1996 Apr;54(4 Pt 2):S110-5 (28 ref.)

DRUG EFFECTS

Metabolic effects of insulin-like growth factor-I: a focus on insulin sensitivity. Hussain MA, et al. **Metabolism** 1995 Oct; 44(10 Suppl 4):108-12 (48 ref.)
Metabolic effects of growth hormone in children. Wollmann HA, et al. **Metabolism** 1995 Oct;44(10 Suppl 4):97-102 (84 ref.)

PHYSIOLOGY

Upper limits to mass-specific metabolic rates. Suarez RK. **Annu Rev Physiol** 1996;58:583-605 (146 ref.)
General integration and regulation of metabolism at the organ level. Elia M. **Proc Nutr Soc** 1995 Mar;54(1):213-32 (84 ref.)
Carbon dioxide formation and elimination in man. Recent theories and possible consequences. Wiklund L.
Ups J Med Sci 1996;101(1):35-67 (71 ref.)

RADIATION EFFECTS

[Effect of low-intensity laser radiation on the metabolic and restorative processes of the body] Briskin BS, et al.
Klin Med (Mosk) 1996;74(1):54-5 (08 ref.) **(Rus)**

METABOLISM AND ENDOCRINOLOGY (SPECIALTY) see **ENDOCRINOLOGY**

METABOLISM, BASAL see **BASAL METABOLISM**

METABOLISM, INBORN ERRORS

see related
MENTAL RETARDATION
Defects in the synthesis and metabolism of vitamin D. Holick MF. **Exp Clin Endocrinol Diabetes** 1995;103(4):219-27 (49 ref.)

COMPLICATIONS

Recent pulmonary observations in alpha 1-antitrypsin deficiency, primary biliary cirrhosis, chronic hepatitis C, and other hepatic problems. Krowka MJ.
Clin Chest Med 1996 Mar;17(1):67-82 (90 ref.)
Metabolic and infectious disorders associated with emesis in infants. Cohen R. **Semin Pediatr Surg** 1995 Aug;4(3):136-46 (46 ref.)
[Congenital metabolic disorder] Uchiyama M.
Nippon Rinsho 1995 Aug;53(8):2001-6 (17 ref.) (Eng. Abstr.) **(Jpn)**
[Progressive neuronal degeneration and childhood cirrhosis] Kumada S, et al. **Ryoikibetsu Shokogun Shirizu** 1995; (8):442-5 (15 ref.) **(Jpn)**
[Liver cirrhosis associated with metabolic disorders] Ono M, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):191-6 (26 ref.) **(Jpn)**

DIAGNOSIS

Medical aspects of ketone body metabolism. Mitchell GA, et al. **Clin Invest Med** 1995 Jun;18(3):193-216 (168 ref.)
Respiratory-chain and pyruvate metabolism defects: Italian collaborative survey on 72 patients. Caruso U, et al.
J Inherit Metab Dis 1996;19(2):143-8 (6 ref.)

EMBRYOLOGY

In utero transplantation of fetal liver stem cells into human fetuses. Touraine JL. **J Hematother** 1996 Apr;5(2):195-9 (15 ref.)

ENZYMOLOGY

The promiscuous receptor: a case for the guardian enzyme. Weber KT, et al. **Cardiovasc Res** 1995 Aug;30(2):176-80 (34 ref.)

ETHNOLOGY

The Finnish disease heritage: a personal look. Perheentupa J. **Acta Paediatr** 1995 Oct;84(10):1094-9 (26 ref.)

GENETICS

Molecular defects in the chondrodysplasias. Rimoin DL.
Am J Med Genet 1996 May 3;63(1):106-10 (35 ref.)
Investigation of mitochondrial disease. Poulton J, et al.
Arch Dis Child 1995 Aug;73(2):94-7 (26 ref.)
Inherited errors of cobalamin metabolism and their management. Linnell JC, et al. **Baillieres Clin Haematol** 1995 Sep;8(3):567-601 (154 ref.)
Congenital errors of folate metabolism. Zittoun J.
Baillieres Clin Haematol 1995 Sep;8(3):603-16 (51 ref.)
Red cell enzymopathies as a model of inborn errors of metabolism. Miwa S, et al.
Southeast Asian J Trop Med Public Health 1995;26 Suppl 1:112-9 (39 ref.)
[Hyperornithinemia and gyrate atrophy: ornithine aminotransferase gene error causing a Finnish disease] Sipilä I, et al. **Duodecim** 1994;110(7):681-6 (18 ref.) **(Fin)**

METABOLISM

L-Carnitine. Walter JH. **Arch Dis Child** 1996 Jun;74(6):475-8 (99 ref.)

THERAPY

[Gene therapy approaches in metabolic diseases] Ameis D, et al. **Internist (Berl)** 1996 Apr;37(4):360-8 (88 ref.) **(Ger)**

URINE

Organic aciduria and related abnormalities. Lehotay DC, et al. **Crit Rev Clin Lab Sci** 1995;32(4):377-429 (262 ref.)

METABOLITE MARKERS, NEOPLASM see **TUMOR MARKERS, BIOLOGICAL**

METABOTROPIC GLUTAMATE RECEPTORS see **RECEPTORS, METABOTROPIC GLUTAMATE**

METACARPOPHALANGEAL JOINT

Knuckle pads--a forgotten skin condition: report of a case and review of the literature. Guberman D, et al. **Cutis** 1996 Apr;57(4):241-2 (20 ref.)
Acute injuries of the extensor tendons proximal to the metacarpophalangeal joints. Aulicino PL. **Hand Clin** 1995 Aug;11(3):403-10 (33 ref.)

INJURIES

Dislocation of the distal interphalangeal and the metacarpophalangeal joints in the same finger: a case report. Andersen MB, et al. **J Hand Surg [Am]** 1995 Jul; 20(4):574-5 (4 ref.)
Open dorsal dislocations of the index, long, ring, and small finger metacarpophalangeal joints. Fraser KE, et al.
J Hand Surg [Am] 1995 Jul;20(4):576-7 (4 ref.)

PATHOLOGY

MR imaging of the metacarpophalangeal joints. Masson JA, et al. **Magn Reson Imaging Clin N Am** 1995 May; 3(2):313-25 (54 ref.)

METACARPUS

[Metacarpal aneurysmal cysts. Report of two cases and review of the literature] Duteille F, et al.
Ann Chir Main Memb Super 1995;14(4-5):229-34 (35 ref.) (Eng. Abstr.) **(Fre)**

INJURIES

Metacarpal and metatarsal fractures in cattle. Tulleners EP.
Vet Clin North Am Food Anim Pract 1996 Mar; 12(1):199-209 (13 ref.)

PATHOLOGY

Giant cell tumour of metacarpal with pulmonary and skeletal metastases. Sanjay BK, et al. **J Hand Surg [Br]** 1996 Feb; 21(1):126-32 (22 ref.)

SURGERY

Chondromyxoid fibroma of a metacarpal: a case report and review of the literature. Strauch RJ, et al.
J Hand Surg [Am] 1996 Mar;21(2):293-5 (6 ref.)
[Therapy of osteomyelitis in the metacarpal region with local pedicle m. interosseus dorsalis II and III-flap-plasty. Anatomic principles and case report] Giunta R, et al.
Handchir Mikrochir Plast Chir 1996 Mar;28(2):64-9 (28 ref.) (Eng. Abstr.) **(Ger)**

METAETHICS see **ETHICS**

METAGONIMIASIS see **TREMATODE INFECTIONS**

METAL ANTAGONISTS see **CHELATING AGENTS**

METAL CERAMIC ALLOYS

Designs of bond strength tests for metal-ceramic complexes: review of the literature. Hammad IA, et al.
J Prosthet Dent 1996 Jun;75(6):602-8 (44 ref.)

METAL CERAMIC RESTORATIONS see **METAL CERAMIC ALLOYS**

METALLO-CERAMIC ALLOYS see **METAL CERAMIC ALLOYS**

METALLO-ORGANIC COMPOUNDS see **ORGANOMETALLIC COMPOUNDS**

METALLOPORPHYRINS

CHEMISTRY

Porphyrin and metalloporphyrin interactions with nucleic acids. Pasternack RF, et al. **Met Ions Biol Syst** 1996; 33:367-97 (114 ref.)
Selective DNA cleavage by metalloporphyrin derivatives. Pratviel G, et al. **Met Ions Biol Syst** 1996;33:399-426 (96

ref.)

METALLOPROTEASES see METALLOPROTEINASES

METALLOPROTEINASES

[Bacterial metalloproteases] Okabe A, et al. **Nippon Saikingaku Zasshi** 1995 Oct;50(4):971–89 (126 ref.) **(Jpn)**

ANALYSIS

ADAM, a novel family of membrane proteins containing A Disintegrin And Metalloprotease domain: multipotential functions in cell–cell and cell–matrix interactions. Wolfsberg TG, et al. **J Cell Biol** 1995 Oct;131(2):275–8 (22 ref.)

ANTAGONISTS & INHIBITORS

Matrix metalloproteinase inhibition: a review of anti–tumour activity. Brown PD, et al. **Ann Oncol** 1995 Dec; 6(10):967–74 (48 ref.)

Induction of tissue inhibitor of metalloproteinase and its mitogenic response to endothelial cells in human atherosclerotic and restenotic lesions. Tyagi SC, et al. **Can J Cardiol** 1996 Apr;12(4):353–62 (42 ref.)

Chronic renal disease: do metalloproteinase inhibitors have a demonstrable role in extracellular matrix accumulation? Baricos WH. **Curr Opin Nephrol Hypertens** 1995 Jul; 4(4):365–8 (24 ref.)

BIOSYNTHESIS

Matrix metalloproteinases and tumor invasion: from correlation and causality to the clinic. Stetler–Stevenson WG, et al. **Semin Cancer Biol** 1996 Jun;7(3):147–54 (58 ref.)

CEREBROSPINAL FLUID

Neuropeptide converting and processing enzymes in the spinal cord and cerebrospinal fluid. Persson S, et al. **Prog Brain Res** 1995;104:111–30 (195 ref.)

CHEMISTRY

Structural features of a superfamily of zinc–endopeptidases: the metzincins. Stöcker W, et al. **Curr Opin Struct Biol** 1995 Jun;5(3):383–90 (47 ref.)

The bifunctional cytochrome c reductase/processing peptidase complex from plant mitochondria. Braun HP, et al. **J Bioenerg Biomembr** 1995 Aug;27(4):423–36 (110 ref.)

GENETICS

[Genetic diagnosis of colorectal cancer] Itoh F, et al. **Hokkaido Igaku Zasshi** 1996 Jan;71(1):9–14 (18 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Matrix metalloproteinases in immunity. Goetzl EJ, et al. **J Immunol** 1996 Jan 1;156(1):1–4 (32 ref.)

METABOLISM

Matrix metalloproteinases and their inhibitors. Murphy G. **Acta Orthop Scand Suppl** 1995 Oct;266:55–60 (53 ref.)

Regulation of matrix metalloproteinases during extracellular matrix turnover. Corcoran ML, et al. **Adv Exp Med Biol** 1995;385:151–9; discussion 179–84 (53 ref.)

Two novel metallopeptidases with a specificity for basic residues: functional properties, structure and cellular distribution. Foulon T, et al. **Ann N Y Acad Sci** 1996 Mar 22;780:106–20 (49 ref.)

Molecular pharmacology of endothelin converting enzymes. Turner AJ, et al. **Biochem Pharmacol** 1996 Jan 26; 51(2):91–102 (127 ref.)

Cytokine regulation of matrix metalloproteinase activity and its regulatory dysfunction in disease. Ries C, et al. **Biol Chem Hoppe Seyler** 1995 Jun;376(6):345–55 (100 ref.)

Utilization of transgenic mice in the study of matrix degrading proteinases and their inhibitors. Khokha R, et al. **Cancer Metastasis Rev** 1995 Jun;14(2):97–111 (109 ref.)

Matrix metalloproteinases and cardiovascular disease. Dollery CM, et al. **Circ Res** 1995 Nov;77(5):863–8 (49 ref.)

Proteolytic remodeling of extracellular matrix. Birkedal–Hansen H. **Curr Opin Cell Biol** 1995 Oct; 7(5):728–35 (61 ref.)

Intracellular targets and metalloprotease activity of tetanus and botulism neurotoxins. Schiavo G, et al. **Curr Top Microbiol Immunol** 1995;195:257–74 (90 ref.)

The bifunctional cytochrome c reductase/processing peptidase complex from plant mitochondria. Braun HP, et al. **J Bioenerg Biomembr** 1995 Aug;27(4):423–36 (110 ref.)

Role of Ito cells in the degradation of matrix in liver. Arthur MJ. **J Gastroenterol Hepatol** 1995;10 Suppl 1:S57–62 (61 ref.)

Matrix metalloproteinases in brain injury. Rosenberg GA. **J Neurotrauma** 1995 Oct;12(5):833–42 (69 ref.)

The metallo–proteinase activity of tetanus and botulism neurotoxins. Rossetto O, et al. **J Physiol Paris** 1995; 89(1):43–50 (60 ref.)

PHARMACOLOGY

Staphylokinase: fibrinolytic properties and current experience in patients with occlusive arterial thrombosis. Collen D, et al. **Verh K Acad Geneeskd Belg** 1995;57(3):183–96; discussion 196–8 (40 ref.)

Mechanism of action and thrombolytic potential of staphylokinase. Lijnen HR. **Verh K Acad Geneeskd Belg** 1995;57(4):303–14 (32 ref.)

PHYSIOLOGY

BMP–1 and the astacin family of metalloproteinases: a potential link between the extracellular matrix, growth factors and pattern formation. Sarras MP Jr. **Bioessays** 1996 Jun;18(6):439–42 (26 ref.)

Enterotoxigenic Bacteroides fragilis. Sears CL, et al. **Clin Infect Dis** 1995 Jun;20 Suppl 2:S142–8 (33 ref.)

Different roles for plasminogen activators and metalloproteinases in melanoma metastasis. Mueller BM. **Curr Top Microbiol Immunol** 1996;213 (Pt 1):65–80 (80 ref.)

Complex roles of matrix metalloproteinases in tumor progression. Powell WC, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 1):1–21 (46 ref.)

Membrane type–matrix metalloproteinase and tumor invasion. Seiki M. **Curr Top Microbiol Immunol** 1996;213 (Pt 1):23–32 (44 ref.)

Matrilysin: an epithelial matrix metalloproteinase with potentially novel functions. Wilson CL, et al. **Int J Biochem Cell Biol** 1996 Feb;28(2):123–36 (64 ref.)

ADAM, a novel family of membrane proteins containing A Disintegrin And Metalloprotease domain: multipotential functions in cell–cell and cell–matrix interactions. Wolfsberg TG, et al. **J Cell Biol** 1995 Oct;131(2):275–8 (22 ref.)

THERAPEUTIC USE

Fibrin–selective thrombolytic therapy for acute myocardial infarction. Collen D. **Circulation** 1996 Mar 1;93(5):857–65 (90 ref.)

METALLOPROTEINS

Synthetic metallopeptides as probes of protein–DNA interactions. Long EC, et al. **Met Ions Biol Syst** 1996; 33:427–52 (65 ref.)

ANALYSIS

Anabolic and catabolic markers of proteoglycan metabolism in osteoarthritis. Caterson B, et al. **Acta Orthop Scand Suppl** 1995 Oct;266:121–4 (32 ref.)

CHEMISTRY

Depletion and replacement of protein metal ligands. Barrick D. **Curr Opin Biotechnol** 1995 Aug;6(4):411–8 (59 ref.)

Metalloprotein design. Hellinga HW. **Curr Opin Biotechnol** 1996 Aug;7(4):437–41 (56 ref.)

Energised (entatic) states of groups and of secondary structures in proteins and metalloproteins. Williams RJ. **Eur J Biochem** 1995 Dec 1;234(2):363–81 (76 ref.)

Zinc metallochemistry in biochemistry. Vallee BL, et al. **EXS** 1995;73:259–77 (66 ref.)

Phytochelatins and related peptides. Structure, biosynthesis, and function. Rauser WE. **Plant Physiol** 1995 Dec; 109(4):1141–9 (36 ref.)

Metal–carbon bonds in nature [comment] Kovacs JA, et al. **Science** 1995 Oct 27;270(5236):587–8 (22 ref.) Comment on: Science 1995 Oct 27;270(5236):628–30.

METABOLISM

CO dehydrogenase. Ferry JG. **Annu Rev Microbiol** 1995; 49:305–33 (132 ref.)

Nitrogenase structure and function: a biochemical–genetic perspective. Peters JW, et al. **Annu Rev Microbiol** 1995; 49:335–66 (92 ref.)

Metalloprotein design. Hellinga HW. **Curr Opin Biotechnol** 1996 Aug;7(4):437–41 (56 ref.)

Zinc metallochemistry in biochemistry. Vallee BL, et al. **EXS** 1995;73:259–77 (66 ref.)

[Metalloproteins, cellular targets of nitric oxide: a concise review] Henry Y, et al. **C R Seances Soc Biol Fil** 1995; 189(6):1039–57 (110 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Phytochelatins and related peptides. Structure, biosynthesis, and function. Rauser WE. **Plant Physiol** 1995 Dec; 109(4):1141–9 (36 ref.)

METALLOTHIONEIN

BIOSYNTHESIS

Metal–responsive gene regulation and the zinc metalloregulatory model. Suhy DA, et al. **Met Ions Biol Syst** 1996;32:557–78 (49 ref.)

CHEMISTRY

[Structure and function of metallothionein] Suzuki KT. **Nippon Rinsho** 1996 Jan;54(1):33–9 (11 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

[Role of trace elements on metallothionein gene expression] Ohta H. **Nippon Rinsho** 1996 Jan;54(1):40–5 (23 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Metallothionein research in terrestrial invertebrates: synopsis and perspectives. Dallinger R. **Comp Biochem Physiol C Pharmacol Toxicol Endocrinol** 1996 Feb;113(2):125–33 (48 ref.)

PHYSIOLOGY

The functional significance of brain metallothioneins. Aschner M. **FASEB J** 1996 Aug;10(10):1129–36 (70 ref.)

Disordered copper metabolism in LEC rats, an animal model of Wilson disease: roles of metallothionein. Suzuki KT. **Res Commun Mol Pathol Pharmacol** 1995 Aug;89(2):221–40 (69 ref.)

[Physiological roles of metallothionein as possible scavenger and promoter for active oxygen species] Sakurai H. **Nippon Rinsho** 1996 Jan;54(1):2–4 (5 ref.) **(Jpn)**

[Structure and function of metallothionein] Suzuki KT. **Nippon Rinsho** 1996 Jan;54(1):33–9 (11 ref.) (Eng. Abstr.) **(Jpn)**

METALLURGY

The yellowed archives of yellowcake. Silver K. **Public Health Rep** 1996 Mar–Apr;111(2):116–27 (55 ref.)

METALS

see related
ORGANOMETALLIC COMPOUNDS

Metal on metal bearings in hip arthroplasty. Amstutz HC, et al. **Clin Orthop** 1996 Aug;(329 Suppl):S11–34 (101 ref.)

Metal versus polyethylene wear particles in total hip replacements. A review. Doorn PF, et al. **Clin Orthop** 1996 Aug;(329 Suppl):S206–16 (64 ref.)

Systems view of optimizing metal on metal bearings. Schey JA. **Clin Orthop** 1996 Aug;(329 Suppl):S115–27 (53 ref.)

Metal ion interactions with DNA: considerations on structure, stability, and effects from metal ion binding. Bregadze VG. **Met Ions Biol Syst** 1996;32:419–51 (44 ref.)

Effect of metal ions on the fluorescence of dyes bound to DNA. Bregadze VG, et al. **Met Ions Biol Syst** 1996; 33:253–67 (20 ref.)

Molecular modeling of transition metal complexes with nucleic acids and their constituents. Kozelka J. **Met Ions Biol Syst** 1996;33:1–28 (91 ref.)

Metallocene interactions with DNA and DNA–processing enzymes. Kuo LY, et al. **Met Ions Biol Syst** 1996;33:53–85 (113 ref.)

Effect of metal ions on the hydrolytic reactions of nucleosides and their phosphoesters. Kuusela S, et al. **Met Ions Biol Syst** 1996;32:271–300 (107 ref.)

Hydrolytic cleavage of RNA catalyzed by metal ion complexes. Morrow JR. **Met Ions Biol Syst** 1996;33:561–92 (116 ref.)

Metallobleomycin–DNA interactions: structures and reactions related to bleomycin–induced DNA damage. Petering DH, et al. **Met Ions Biol Syst** 1996;33:619–48 (92 ref.)

Metal ions in multiple–stranded DNA. Sabat M, et al. **Met Ions Biol Syst** 1996;33:143–76 (148 ref.)

Metal replacement in DNA–binding zinc finger proteins and its relevance to mutagenicity and carcinogenicity through free radical generation. Sarkar B. **Nutrition** 1995 Sep–Oct; 11(5 Suppl):646–9 (17 ref.)

Catalytic metals, ascorbate and free radicals: combinations to avoid. Buettner GR, et al. **Radiat Res** 1996 May; 145(5):532–41 (79 ref.)

[Plastic prostheses or self–expanding stents—is there an ideal drainage? Pro metal] Hochberger J, et al. **Bildgebung** 1995 Oct;62 Suppl 2:59–63 (22 ref.) **(Ger)**

[Metal dermatoses I] Schwarz T, et al. **Hautarzt** 1996 Apr; 47(4):316–28; quiz 327–8 (10 ref.) **(Ger)**

[Stereochemistry of highly selective transition metal or Lewis acid–catalyzed asymmetric reactions] Hiroi K. **Yakugaku Zasshi** 1995 Aug;115(8):553–69 (63 ref.) (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Interactions of essential and/or toxic metals and metalloid regarding interindividual differences in susceptibility to various toxicants and chronic diseases in man. Telišman S. **Arh Hig Rada Toksikol** 1995 Dec;46(4):459–76 (47 ref.)

Effects of parental occupational exposure to lead and other metals on spontaneous abortion. Anttila A, et al. **J Occup Environ Med** 1995 Aug;37(8):915–21 (36 ref.)

Metals and school learning: a review of investigative techniques. Ittenbach RF, et al. **Percept Mot Skills** 1995 Dec;81(3 Pt 2):1079–90 (48 ref.)

The role of metals in ischemia/reperfusion injury of the liver. Arora AS, et al. **Semin Liver Dis** 1996 Feb;16(1):31–8 (65 ref.)

Metal–induced hepatotoxicity. Britton RS. **Semin Liver Dis** 1996 Feb;16(1):3–12 (105 ref.)

Metals, oxidative stress, and hepatic fibrogenesis. Pietrangelo A. **Semin Liver Dis** 1996 Feb;16(1):13–30 (117 ref.)

METALS

Antioxidant defenses in metal-induced liver damage. Sokol RJ. **Semin Liver Dis** 1996 Feb;16(1):39–46 (40 ref.)
[Vitamins and metals: possible hazards for humans] Ballmer PE. **Schweiz Med Wochenschr** 1996 Apr 13;126(15):607–11 (16 ref.) (Eng. Abstr.) **(Ger)**
[Toxicity of chemical elements] Olibet G, et al. **Ann Ist Super Sanita** 1995;31(2):283–8 (30 ref.) (Eng. Abstr.) **(Ita)**
[The first case of severe pneumopathy due to hard metals successfully undergoing a lung transplant] Tomasini M, et al. **Med Lav** 1995 Jul–Aug;86(4):325–31 (6 ref.) (Eng. Abstr.) **(Ita)**
[Relationship between exposure to environmental toxins and motor neuron disease: a case report] Vanacore N, et al. **Med Lav** 1995 Nov–Dec;86(6):522–33 (50 ref.) (Eng. Abstr.) **(Ita)**

ANALYSIS

Plants and animals as biomonitors of heavy metal level in the aquatic ecosystem of the river Danube. Oertel N. **Arch Toxicol Suppl** 1996;18:404–16 (23 ref.)

CHEMISTRY

Photolytic covalent binding of metal complexes to DNA. Billadeau MA, et al. **Met Ions Biol Syst** 1996;33:269–96 (73 ref.)
Interactions of metallopharmaceuticals with DNA. Clarke MJ, et al. **Met Ions Biol Syst** 1996;32:727–80 (235 ref.)
Electron transfer reactions through the DNA double helix. Meade TJ. **Met Ions Biol Syst** 1996;32:453–78 (85 ref.)
DNA interactions with substitution-inert transition metal ion complexes. Nordén B, et al. **Met Ions Biol Syst** 1996; 33:177–252 (210 ref.)
NMR studies of oligonucleotide–metal ion interactions. Sletten E, et al. **Met Ions Biol Syst** 1996;32:397–418 (56 ref.)
Electron transfer between metal complexes bound to DNA: is DNA a wire? Stemp ED, et al. **Met Ions Biol Syst** 1996; 33:325–65 (75 ref.)

IMMUNOLOGY

Metal ion induced autoimmunity. Griem P, et al. **Curr Opin Immunol** 1995 Dec;7(6):831–8 (57 ref.)

ISOLATION & PURIFICATION

Microbial mobilization and immobilization of heavy metals. Unz RF, et al. **Curr Opin Biotechnol** 1996 Jun;7(3):307–10 (35 ref.)

METABOLISM

Depletion and replacement of protein metal ligands. Barrick D. **Curr Opin Biotechnol** 1995 Aug;6(4):411–8 (59 ref.)
Interfacial metal-binding site design. Matthews DJ. **Curr Opin Biotechnol** 1995 Aug;6(4):419–24 (49 ref.)
Role of metal ions in ribozymes. Pyle AM. **Met Ions Biol Syst** 1996;32:479–520 (136 ref.)
Ternary metal ion–nucleic acid base–protein complexes. Sabat M. **Met Ions Biol Syst** 1996;32:521–55 (153 ref.)
Biological relevance and consequences of chemical- or metal-induced DNA cross-linking. Paustenbach DJ, et al. **Proc Soc Exp Biol Med** 1996 Mar;211(3):211–7 (62 ref.)

PHARMACOKINETICS

Microbial mobilization and immobilization of heavy metals. Unz RF, et al. **Curr Opin Biotechnol** 1996 Jun;7(3):307–10 (35 ref.)
Dermal exposure to environmental contaminants in the Great Lakes. Moody RP, et al. **Environ Health Perspect** 1995 Dec;103 Suppl 9:103–14 (88 ref.)

PHARMACOLOGY

The chemistry of lipid alkoxyl radicals and their role in metal-amplified lipid peroxidation. Marnett LJ, et al. **Biochem Soc Symp** 1995;61:65–72 (34 ref.)
Physiological and toxicological changes in the skin resulting from the action and interaction of metal ions. Lansdown AB. **Crit Rev Toxicol** 1995;25(5):397–462 (720 ref.)
Metal-responsive gene regulation and the zinc metalloregulatory model. Suhy DA, et al. **Met Ions Biol Syst** 1996;32:557–78 (49 ref.)

POISONING

Shellfish-borne illnesses. A Hong Kong perspective. Chan TY. **Trop Geogr Med** 1995;47(6):305–7 (17 ref.)

THERAPEUTIC USE

Radiation protection and radiation recovery with essential metalloelement chelates. Sorenson JR, et al. **Proc Soc Exp Biol Med** 1995 Dec;210(3):191–204 (97 ref.)

TOXICITY

Metal carcinogenesis in total joint arthroplasty. Animal models. Lewis CG, et al. **Clin Orthop** 1996 Aug;(329 Suppl):S264–8 (37 ref.)
Cancer risk after metal on metal and polyethylene on metal total hip arthroplasty. Visuri T, et al. **Clin Orthop** 1996 Aug;(329 Suppl):S280–9 (51 ref.)
Physiological and toxicological changes in the skin resulting from the action and interaction of metal ions. Lansdown AB. **Crit Rev Toxicol** 1995;25(5):397–462 (720 ref.)
[Evaluation of pulmonary toxicity of heavy metal compounds] Hirano S. **Nippon Eiseigaku Zasshi** 1996 Feb; 50(6):1013–25 (70 ref.) (Eng. Abstr.) **(Jpn)**

METALS, ACTINOID

PHARMACOKINETICS

Biokinetics and absorption of actinides in human volunteers: a review. Popplewell DS. **Appl Radiat Isot** 1995 May; 46(5):279–86 (36 ref.)

METALS, RARE EARTH

TOXICITY

Exposure, metabolism, and toxicity of rare earths and related compounds. Hirano S, et al. **Environ Health Perspect** 1996 Mar;104 Suppl 1:85–95 (139 ref.)

METAMIZOLE see **DIPYRONE**

METAMORPHOSIS, BIOLOGICAL

Nineteenth century research on naturally occurring cell death and related phenomena. Clarke PG, et al. **Anat Embryol (Berl)** 1996 Feb;193(2):81–99 (143 ref.)
Tadpole competence and tissue-specific temporal regulation of amphibian metamorphosis: roles of thyroid hormone and its receptors. Shi YB, et al. **Bioessays** 1996 May;18(5):391–9 (63 ref.)
Metamorphosis in Drosophila: from molecular biology to mutants. Bender M. **Trends Genet** 1995 Sep;11(9):335–6 (21 ref.)

GENETICS

Overview of the regulation of metamorphosis-associated genes in Trichoplusia ni. Jones G, et al. **Arch Insect Biochem Physiol** 1996;32(3–4):429–37 (18 ref.)

PHYSIOLOGY

Short- and long-term modification of reflex function during learning and metamorphosis in Manduca. Weeks JC, et al. **Biol Bull** 1996 Aug;191(1):62–9 (34 ref.)
From embryogenesis to metamorphosis: the regulation and function of Drosophila nuclear receptor superfamily members. Thummel CS. **Cell** 1995 Dec 15;83(6):871–7 (56 ref.)
Apoptosis of larval cells during amphibian metamorphosis. Ishizuya-Oka A. **Microsc Res Tech** 1996 Jun 15; 34(3):228–35 (73 ref.)
[Results and conclusions from 328 radical operations of rectal carcinoma by one surgeon. Comparative anatomic studies with Brachydanio rerio and Latimeria chalumnae] Stelzner F. **Chirurg** 1995 Dec;66(12):1230–8 (22 ref.) (Eng. Abstr.) **(Ger)**

METANEPHRINE

ANALYSIS

[Metanephrine (M) and normetanephrine (NM)] Sasaki M, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:511–5 (11 ref.) **(Jpn)**

METAPLASIA

see related
MYELOID METAPLASIA

METASTASIS see **NEOPLASM METASTASIS**

METATARSAL BONES

INJURIES

Lisfranc's fracture–dislocation. A literature review and case presentations of tarsometatarsal joint injuries. Felder-Johnson KL, et al. **Clin Podiatr Med Surg** 1995 Oct;12(4):565–602 (61 ref.)
First metatarsal fractures. Saraiya MJ. **Clin Podiatr Med Surg** 1995 Oct;12(4):749–58 (20 ref.)
Fractures of the central metatarsals. Urteaga AJ, et al. **Clin Podiatr Med Surg** 1995 Oct;12(4):759–72 (51 ref.)
Fifth metatarsal fractures. Biomechanics, classification, and treatment. Vogler HW, et al. **Clin Podiatr Med Surg** 1995 Oct;12(4):725–47 (33 ref.)

SURGERY

Complications of distal first metatarsal osteotomies. Laughlin TJ. **J Foot Ankle Surg** 1995 Nov–Dec;34(6):524–31; discussion 593–4 (46 ref.)
Surgical considerations for hematogenous osteomyelitis. Loder BG, et al. **J Foot Ankle Surg** 1995 Jul–Aug; 34(4):347–53 (58 ref.)

METATARSAL DEFORMITY see **FOOT DEFORMITIES**

METATARSALS see **METATARSAL BONES**

METATARSOPHALANGEAL JOINT

INJURIES

Irreducible dorsal dislocation of the great toe interphalangeal joint: case report and literature review. Crosby LA, et al. **Foot Ankle Int** 1995 Sep;16(9):559–61 (7 ref.)

PHYSIOPATHOLOGY

The dose effect of continuous passive motion in postoperative rehabilitation of the first metatarsophalangeal joint. Lawrence BR. **J Foot Ankle Surg** 1996 Mar–Apr; 35(2):155–61; discussion 190–1 (73 ref.)

SURGERY

Irreducible dorsal dislocation of the great toe interphalangeal joint: case report and literature review. Crosby LA, et al. **Foot Ankle Int** 1995 Sep;16(9):559–61 (7 ref.)
[Arthrodesis of the metatarsophalangeal joint of the large toe] Wülker N. **Orthopade** 1996 Apr;25(2):187–93 (28 ref.) (Eng. Abstr.) **(Ger)**

METATARSUS

see related
METATARSAL BONES

INJURIES

Metacarpal and metatarsal fractures in cattle. Tulleners EP. **Vet Clin North Am Food Anim Pract** 1996 Mar; 12(1):199–209 (13 ref.)

PHYSIOLOGY

[Form and structure of the metatarsal head arch in adults. Ultrasonographic and podometric studies] Hermann B. **Z Orthop Ihre Grenzgeb** 1995 Jul–Aug;133(4):335–40 (55 ref.) (Eng. Abstr.) **(Ger)**

METAVANADATE see **VANADATES**

METENCEPHALON see **PONS**

METFORMIN

PHARMACOKINETICS

Clinical pharmacokinetics of metformin. Scheen AJ. **Clin Pharmacokinet** 1996 May;30(5):359–71 (74 ref.)

PHARMACOLOGY

Metformin and intestinal glucose handling. Bailey CJ. **Diabetes Metab Rev** 1995 Sep;11 Suppl 1:S23–32 (47 ref.)
Metformin and free fatty acid metabolism. Del Prato S, et al. **Diabetes Metab Rev** 1995 Sep;11 Suppl 1:S33–41 (56 ref.)
Mechanisms of metformin action in non-insulin-dependent diabetes mellitus. Perriello G. **Diabetes Metab Rev** 1995 Sep;11 Suppl 1:S51–6 (62 ref.)
Effect of metformin on liver insulin metabolism and regional blood flow. Signore A, et al. **Diabetes Metab Rev** 1995 Sep;11 Suppl 1:S13–21 (48 ref.)
Metformin–insulin interactions: from organ to cell. Wiernsperger N, et al. **Diabetes Metab Rev** 1995 Sep;11 Suppl 1:S3–12 (56 ref.)

THERAPEUTIC USE

Role of metformin in type II diabetes. Epstein S. **Cleve Clin J Med** 1995 Sep–Oct;62(5):278–9 (4 ref.)
The insulin-sparing effect of metformin in insulin-treated diabetic patients. Golay A, et al. **Diabetes Metab Rev** 1995 Sep;11 Suppl 1:S63–7 (34 ref.)
The effects of metformin on cardiovascular risk factors. Grant PJ. **Diabetes Metab Rev** 1995 Sep;11 Suppl 1:S43–50 (56 ref.)
Effects of metformin in obese patients with impaired glucose tolerance. Scheen AJ, et al. **Diabetes Metab Rev** 1995 Sep; 11 Suppl 1:S69–80 (75 ref.)
Metformin: a new treatment option for non-insulin-dependent diabetes mellitus. Goo AK, et al. **J Fam Pract** 1996 Jun;42(6):612–8 (52 ref.)
Metformin. Bailey CJ, et al. **N Engl J Med** 1996 Feb 29; 334(9):574–9 (66 ref.)
Metformin in noninsulin-dependent diabetes mellitus. Lee AJ. **Pharmacotherapy** 1996 May–Jun;16(3):327–51 (114 ref.)

METHADONE

THERAPEUTIC USE

Regulating controversial programs for unpopular people: methadone maintenance and syringe exchange programs [see comments] Des Jarlais DC, et al. **Am J Public Health** 1995 Nov;85(11):1577–84 (39 ref.) Comment in: Am J Public Health 1995 Nov;85(11):1490–1.
The demedicalization of methadone maintenance. Rosenbaum M. **J Psychoactive Drugs** 1995 Apr–Jun; 27(2):145–9 (43 ref.)

METHADYL ACETATE

THERAPEUTIC USE

Levo-alpha-acetylmethadol (LAAM): clinical, research, and policy issues of a new pharmacotherapy for opioid addiction. Prendergast ML, et al. **J Psychoactive Drugs** 1995 Jul-Sep;27(3):239-47 (57 ref.)

METHALAMIC ACID see **IOTHALAMIC ACID**

METHAMPHETAMINE

Methamphetamine and driving impairment. Logan BK. **J Forensic Sci** 1996 May;41(3):457-64 (37 ref.)

Qualitative research considerations and other issues in the study of methamphetamine use among men who have sex with other men. Gorman EM, et al. **NIDA Res Monogr** 1995;157:156-81 (77 ref.)

Going nowhere fast: methamphetamine use and HIV infection. Rotheram-Borus MJ, et al. **NIDA Res Monogr** 1994;143:155-82 (33 ref.)

TOXICITY

Neurotoxicity, drugs and abuse, and the CuZn-superoxide dismutase transgenic mice. Cadet JL, et al. **Mol Neurobiol** 1995 Aug-Dec;11(1-3):155-63 (49 ref.)

Ontogeny of methamphetamine-induced neurotoxicity in the rat model. Vorhees CV, et al. **NIDA Res Monogr** 1995; 158:149-71 (46 ref.)

METHAMPYRONE see **DIPYRONE**

METHANE

METABOLISM

The regulation of methane oxidation in soil. Mancinelli RL. **Annu Rev Microbiol** 1995;49:581-605 (216 ref.)

Bacterial growth with chlorinated methanes. Leisinger T, et al. **Environ Health Perspect** 1995 Jun;103 Suppl 5:33-6 (13 ref.)

Methanotrophic bacteria. Hanson RS, et al. **Microbiol Rev** 1996 Jun;60(2):439-71 (436 ref.)

METHANE-OXIDIZING BACTERIA see **METHYLOCOCCACEAE**

METHANOCOCCUS

GROWTH & DEVELOPMENT

High pressure influences on gene and protein expression. Bartlett DH, et al. **Res Microbiol** 1995 Oct;146(8):697-706 (63 ref.)

METHANOL see **ALCOHOL, METHYL**

METHANOMONADACEAE see **METHYLOCOCCACEAE**

METHEMOGLOBINEMIA

CHEMICALLY INDUCED

Extreme methaemoglobinaemia secondary to recreational use of amyl nitrite. Edwards RJ, et al. **J Accid Emerg Med** 1995 Jun;12(2):138-42 (41 ref.)

Health implications of nitrate and nitrite in drinking water: an update on methemoglobinemia occurrence and reproductive and developmental toxicity. Fan AM, et al. **Regul Toxicol Pharmacol** 1996 Feb;23(1 Pt 1):35-43 (54 ref.)

CLASSIFICATION

Dapsone toxicity: some current perspectives. Coleman MD. **Gen Pharmacol** 1995 Nov;26(7):1461-7 (51 ref.)

ETIOLOGY

Methemoglobinemia in an infant: case report and review of the literature. Jolly BT, et al. **Pediatr Emerg Care** 1995 Oct;11(5):294-7 (22 ref.)

[Methemoglobinemia, acidemia and diarrhea induced by hypersensitivity to cow's milk proteins] Catalán Muñoz M, et al. **An Esp Pediatr** 1996 Mar;44(3):295-6 (6 ref.) **(Spa)**

METHICILLIN

see related
METHICILLIN RESISTANCE

METHICILLIN RESISTANCE

Strategies for controlling methicillin-resistant Staphylococcus aureus in hospitals. Boyce JM. **J Chemother** 1995 Jul;7 Suppl 3:81-5 (24 ref.)

Aspects of the epidemiology of MRSA in Europe. Cookson B. **J Chemother** 1995 Jul;7 Suppl 3:93-8 (15 ref.)

The epidemiology of methicillin-resistant Staphylococcus aureus colonisation and infection. Doebbeling BN. **J Chemother** 1995 Jul;7 Suppl 3:99-103 (35 ref.)

[Methicillin-resistant Staphylococcus epidermidis] Vandenbroucke-Grauls CM. **Ned Tijdschr Geneeskd** 1996 Jan 20;140(3):138-41 (25 ref.) (Eng. Abstr.) **(Dut)**

[A case report of mediastinitis due to methicillin resistant Staphylococcus aureus after total aortic arch replacement] Asano S, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Jun;44(6):814-9 (18 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Molecular evolution of MRSA. Hiramatsu K. **Microbiol Immunol** 1995;39(8):531-43 (68 ref.)

PHYSIOLOGY

Antimicrobial resistance patterns in long term geriatric care. Implications for drug therapy. Mao CA, et al. **Drugs Aging** 1996 Mar;8(3):162-70 (66 ref.)

[Methicillin-resistant Staphylococci] Sidorenko SV. **Antibiot Khimioter** 1995 Nov-Dec;40(11-12):57-69 (79 ref.) **(Rus)**

METHIMAZOLE

ADVERSE EFFECTS

Aplasia cutis congenita after exposure to methimazole: a causal relationship? Vogt T, et al. **Br J Dermatol** 1995 Dec; 133(6):994-6 (23 ref.)

METHIONINE

PHYSIOLOGY

New views on the pathogenesis of kwashiorkor: methionine and other amino acids. Roediger WE. **J Pediatr Gastroenterol Nutr** 1995 Aug;21(2):130-6 (75 ref.)

METHODOLOGY RESEARCH, NURSING see **NURSING METHODOLOGY RESEARCH**

D-METHORPHAN see **DEXTROMETHORPHAN**

METHOTREXATE

ADMINISTRATION & DOSAGE

High-dose methotrexate in the treatment of adult acute lymphoblastic leukemia. Gökbuget N, et al. **Ann Hematol** 1996 Apr;72(4):194-201 (58 ref.)

Acute febrile toxic reaction in patients with refractory rheumatoid arthritis who are receiving combined therapy with methotrexate and azathioprine. Blanco R, et al. **Arthritis Rheum** 1996 Jun;39(6):1016-20 (19 ref.)

Complete remission of multicentric reticulohistiocytosis with combination therapy of steroid, cyclophosphamide, and low-dose pulse methotrexate. Case report, review of the literature, and proposal for treatment. Liang GC, et al. **Arthritis Rheum** 1996 Jan;39(1):171-4 (15 ref.)

Concepts in use of high-dose methotrexate therapy. Treon SP, et al. **Clin Chem** 1996 Aug;42(8 Pt 2):1322-9 (66 ref.)

Combination therapy with cyclosporin in rheumatoid arthritis. Yocum DE. **Drugs** 1995;50 Suppl 1:37-40 (20 ref.)

Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): response to methotrexate and mercaptopurine. Horneff G, et al. **Med Pediatr Oncol** 1996 Sep;27(3):187-92 (24 ref.)

Errors involving pediatric patients receiving chemotherapy: a literature review. Trinkle R, et al. **Med Pediatr Oncol** 1996 May;26(5):344-51 (47 ref.)

[Chemo-endocrine therapy including mitomycin C and medroxyprogesterone acetate in doxorubicin-refractory advanced breast cancer] Nomura Y, et al. **Gan To Kagaku Ryoho** 1996 Mar;23(4):439-45 (11 ref.) (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Hazards of low dose methotrexate [editorial] Conaghan PG, et al. **Aust N Z J Med** 1995 Dec;25(6):670-3 (30 ref.)

Methotrexate hepatotoxicity and the role of routine liver biopsy: a collective opinion [letter] Sinclair RD, et al. **Australas J Dermatol** 1995 Nov;36(4):228-9 (5 ref.)

Folate supplementation and methotrexate. Dijkmans BA. **Br J Rheumatol** 1995 Dec;34(12):1172-4 (22 ref.)

Adverse events in methotrexate-treated rheumatoid arthritis patients. Sandoval DM, et al. **Br J Rheumatol** 1995 Nov; 34 Suppl 2:49-56 (76 ref.)

Methotrexate in rheumatoid arthritis: toxicity issues [editorial] Weinblatt ME. **Br J Rheumatol** 1996 May; 35(5):403-5 (27 ref.)

Anaphylactoid reactions to methotrexate. Alkins SA, et al. **Cancer** 1996 May 15;77(10):2123-6 (13 ref.)

Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. Salloum E, et al. **J Clin Oncol** 1996 Jun;14(6):1943-9 (56 ref.)

Fatal pulmonary fibrosis complicating low dose methotrexate therapy for rheumatoid arthritis. van der Veen MJ, et al. **J Rheumatol** 1995 Sep;22(9):1766-8 (20 ref.)

Atypical MRI findings in treatment-related leukoencephalopathy: case report. Ohmoto Y, et al. **Neuroradiology** 1996 Feb;38(2):128-33 (30 ref.)

Pancytopenia and severe cytopenia induced by low-dose methotrexate. Eight case-reports and a review of one hundred cases from the literature (with twenty-four deaths) [see comments] Berthelot JM, et al. **Rev Rhum Engl Ed** 1995 Jul-Sep;62(7-8):477-86 (108 ref.) Comment in: Rev Rhum Engl Ed 1995 Jul-Sep;62(7-8):471-3.

[Cutaneous pseudolymphoma during treatment of rheumatoid polyarthritis with low-dose methotrexate] Delaporte E, et al. **Ann Dermatol Venereol** 1995;122(8):521-5 (33 ref.) (Eng. Abstr.) **(Fre)**

[Emergency therapy of collagen diseases and their complications] Ichikawa Y, et al. **Nippon Naika Gakkai Zasshi** 1995 Nov 10;84(11):1865-9 (5 ref.) **(Jpn)**

[A case of rheumatoid arthritis with malignant lymphoma taking methotrexate] Hayakawa M, et al. **Ryumachi** 1995 Aug;35(4):678-82 (23 ref.) (Eng. Abstr.) **(Jpn)**

[Pneumocystis carinii pneumonia associated with low dose methotrexate treatment for malignant rheumatoid arthritis] Okuda Y, et al. **Ryumachi** 1995 Aug;35(4):699-704 (18 ref.) (Eng. Abstr.) **(Jpn)**

BLOOD

[Methotrexate (MTX)] Yamada M. **Nippon Rinsho** 1995 Feb; 53 Su Pt 1:1053-5 (8 ref.) **(Jpn)**

PHARMACOKINETICS

Practical clinical pharmacology and drug interactions of low-dose methotrexate therapy in rheumatoid arthritis. Furst DE. **Br J Rheumatol** 1995 Nov;34 Suppl 2:20-5 (50 ref.)

PHARMACOLOGY

The antirheumatic agents sulphasalazine and methotrexate share an anti-inflammatory mechanism. Cronstein BN. **Br J Rheumatol** 1995 Nov;34 Suppl 2:30-2 (20 ref.)

Possible mechanisms of action of methotrexate in patients with rheumatoid arthritis. Kremer JM. **Br J Rheumatol** 1995 Nov;34 Suppl 2:26-9 (37 ref.)

Methotrexate for inflammatory bowel disease: pharmacology and preliminary results [see comments] Egan LJ, et al. **Mayo Clin Proc** 1996 Jan;71(1):69-80 (98 ref.) Comment in: Mayo Clin Proc 1996 Jan;71(1):104-5.

THERAPEUTIC USE

A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Sandborn WJ. **Am J Gastroenterol** 1996 Mar;91(3):423-33 (65 ref.)

Combining sulphasalazine and methotrexate in rheumatoid arthritis: early clinical impressions. Haagsma CJ, et al. **Br J Rheumatol** 1995 Nov;34 Suppl 2:104-8 (30 ref.)

Efficacy of methotrexate in rheumatoid arthritis. Weinblatt ME. **Br J Rheumatol** 1995 Nov;34 Suppl 2:43-8 (49 ref.)

Methotrexate in rheumatoid arthritis: when NSAIDs fail. Flynn JA, et al. **Cleve Clin J Med** 1995 Nov-Dec; 62(6):351-9 (92 ref.)

Medical management should be routinely used as primary therapy for ectopic pregnancy. Stovall TG. **Clin Obstet Gynecol** 1995 Jun;38(2):346-52 (28 ref.)

Methotrexate and other chemotherapeutic agents used to treat psoriasis. Jeffes EW III, et al. **Dermatol Clin** 1995 Oct;13(4):875-90 (128 ref.)

Low-dose methotrexate as an adjunctive therapy with surgery for ectropion complicating dermatomyositis. Abernethy ML, et al. **Dermatology** 1996;192(2):153-5 (14 ref.)

Methotrexate for rheumatoid arthritis. **Drug Ther Bull** 1995 Mar;33(3):17-9 (31 ref.)

Disease-modifying antirheumatic drugs. Potential effects in older patients. Gardner G, et al. **Drugs Aging** 1995 Dec; 7(6):420-37 (43 ref.)

Conservative management options for cervical pregnancy; case reports and literature review. Creinin MD, et al. **Int J Fertil Menopausal Stud** 1995 Jul-Aug;40(4):175-86 (67 ref.)

Methotrexate for nonsurgical treatment of ectopic pregnancy: nursing implications. Maiolatesi CR, et al. **J Obstet Gynecol Neonatal Nurs** 1996 Mar-Apr;25(3):205-8 (16 ref.)

Methotrexate in the treatment of systemic glucocorticoid-dependent severe persistent asthma: a word of caution. Fabbri L, et al. **Monaldi Arch Chest Dis** 1996 Apr;51(2):130-7 (118 ref.)

Intrinsic and acquired resistance to methotrexate in acute leukemia. Gorlick R, et al. **N Engl J Med** 1996 Oct 3; 335(14):1041-8 (59 ref.)

The changing face of therapy for rheumatoid arthritis. Kremer JM. **Rheum Dis Clin North Am** 1995 Aug; 21(3):845-52 (34 ref.)

[Role of conservative therapy and medical treatment in ectopic pregnancy: literature review and clinical trial comparing medical treatment and conservative laparoscopic treatment] Fernandez H, et al. **Contracept Fertil Sex** 1996 Apr;24(4):297-302 (36 ref.) (Eng. Abstr.) **(Fre)**

[Current indications for medical treatment of ectopic pregnancy] Darai E, et al. **Rev Fr Gynecol Obstet** 1995 Dec;90(12):552-7 (41 ref.) (Eng. Abstr.) **(Fre)**

[Use of methotrexate in spondylarthropathies. Review of the literature] Toussirot E, et al. **Rev Med Interne** 1996; 17(4):333-9 (40 ref.) (Eng. Abstr.) **(Fre)**

METHOTREXATE

[Methotrexate in rheumatology: a therapeutic revolution] Kaye O, et al. **Rev Med Liege** 1995 Nov;50(11):453–7 (10 ref.) **(Fre)**

[Methotrexate treatment of rheumatoid arthritis] Beyeler C. **Schweiz Med Wochenschr** 1996 Apr 27;126(17):703–12 (61 ref.) (Eng. Abstr.) **(Ger)**

METHOXYHYDROXYMANDELIC ACID see **VANILMANDELIC ACID**

METHOXYHYDROXYPHENYLGLYCOL

ANALYSIS

[3-Methoxy-4-hydroxyphenylglycol (MHPG)] Shigetomi S, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:534–6 (12 ref.) **(Jpn)**

12-METHOXYIBOGAMINE see **IBOGAINE**

N-METHYL-D-ASPARTATE RECEPTORS see **RECEPTORS, N-METHYL-D-ASPARTATE**

METHYL ETHERS

METABOLISM

Disposition, metabolism, and toxicity of methyl tertiary butyl ether, an oxygenate for reformulated gasoline. Hutcheon DE, et al. **J Toxicol Environ Health** 1996 Apr 5; 47(5):453–64 (40 ref.)

TOXICITY

Disposition, metabolism, and toxicity of methyl tertiary butyl ether, an oxygenate for reformulated gasoline. Hutcheon DE, et al. **J Toxicol Environ Health** 1996 Apr 5; 47(5):453–64 (40 ref.)

METHYL MERCURY COMPOUNDS see **METHYLMERCURY COMPOUNDS**

METHYL VIOLOGEN see **PARAQUAT**

METHYLADENINE RECEPTORS see **RECEPTORS, PURINERGIC**

METHYLAMINES

THERAPEUTIC USE

Pharmacologic treatment of recurrent pediatric headache. Graf WD, et al. **Pediatr Ann** 1995 Sep;24(9):477–84 (27 ref.)

N-METHYLASPARTATE

see related
RECEPTORS, N-METHYL-D-ASPARTATE

ANTAGONISTS & INHIBITORS

NMDA antagonists: antiepileptic-neuroprotective drugs with diversified neuropharmacological profiles. Sagratella S. **Pharmacol Res** 1995 Jul-Aug;32(1-2):1–13 (124 ref.)

PHARMACOLOGY

Enhanced N-methyl-D-aspartate (NMDA)-induced activity following morphine: sensitivity to sigma and PCP ligands. Larson AA, et al. **NIDA Res Monogr** 1995;147:146–60 (20 ref.)

PHYSIOLOGY

Modulation of NMDA and dopaminergic neurotransmissions by sigma ligands: possible implications for the treatment of psychiatric disorders. Debonnel G, et al. **Life Sci** 1996; 58(9):721–34 (179 ref.)

N-METHYL-D-ASPARTATE see **N-METHYLASPARTATE**

METHYLDOPA

ADVERSE EFFECTS

[A case of SLE-like syndrome and severe hemolytic anemia caused by methyldopa] Sakurai Y, et al. **Nippon Naika Gakkai Zasshi** 1995 Dec 10;84(12):2069–71 (9 ref.) **(Jpn)**

POISONING

Poisoning with anti-hypertensive drugs: methyldopa and clonidine. Zarifis J, et al. **J Hum Hypertens** 1995 Oct; 9(10):787–90 (31 ref.)

METHYLDOPATE see **METHYLDOPA**

METHYLENE BICHLORIDE see **METHYLENE CHLORIDE**

METHYLENE BLUE

ADVERSE EFFECTS

Methylene blue-induced phototoxicity: an unrecognized complication. Porat R, et al. **Pediatrics** 1996 May; 97(5):717–21 (19 ref.)

THERAPEUTIC USE

Nitric oxide inhibition in the treatment of septic shock [editorial; comment] Hata JS, et al. **Crit Care Med** 1995 Oct;23(10):1621–4 (26 ref.) Comment on: Crit Care Med 1995 Oct;23(10):1711–21.

METHYLENE CHLORIDE

METABOLISM

Bacterial growth with chlorinated methanes. Leisinger T, et al. **Environ Health Perspect** 1995 Jun;103 Suppl 5:33–6 (13 ref.)

PHARMACOKINETICS

Incorporating biological information in quantitative risk assessment: an example with methylene chloride. Clewell HJ 3rd. **Toxicology** 1995 Sep 1;102(1-2):83–94 (33 ref.)

Use of quantitative modelling in methylene chloride risk assessment. Rhomberg L. **Toxicology** 1995 Sep 1; 102(1-2):95–114 (58 ref.)

TOXICITY

Methylene chloride. Dhillon S, et al. **J Appl Toxicol** 1995 Jul-Aug;15(4):329–35 (67 ref.)

Incorporating biological information in quantitative risk assessment: an example with methylene chloride. Clewell HJ 3rd. **Toxicology** 1995 Sep 1;102(1-2):83–94 (33 ref.)

METHYLENE DICHLORIDE see **METHYLENE CHLORIDE**

METHYLENEDIOXYMETHAMPHETAMINE see **N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE**

METHYLERGOBASIN see **METHYLERGONOVINE**

METHYLERGOMETRIN see **METHYLERGONOVINE**

METHYLERGONOVINE

ADVERSE EFFECTS

Accidental administration of an ergot alkaloid to a neonate. Baum CR, et al. **Pediatrics** 1996 Sep;98(3 Pt 1):457–8 (8 ref.)

DIAGNOSTIC USE

[Reflections of an expert committee of the French Society of Cardiology on the use of methylergometrine maleate (Methergin) for the detection of abnormal coronary vasomotricity] Lablanche JM, et al. **Arch Mal Coeur Vaiss** 1995 Feb;88(2):247–53 (53 ref.) **(Fre)**

THERAPEUTIC USE

[Postpartum hemorrhage. Current management] Bertault D, et al. **Presse Med** 1995 Oct 14;24(30):1397–9 (15 ref.) (Eng. Abstr.) **(Fre)**

METHYLGLUCAMINE see **MEGLUMINE**

METHYLGLYOXAL see **PYRUVALDEHYDE**

METHYLGLYOXALASE see **LACTOYL GLUTATHIONE LYASE**

METHYLHISTIDINES

URINE

[Methylhistidine] Koda M, et al. **Nippon Rinsho** 1995 Feb; 53 Su Pt 1:493–5 (10 ref.) **(Jpn)**

METHYLHYDROXYPROGESTERONE see **MEDROXYPROGESTERONE**

METHYLMALONIC ACID

ANALYSIS

[Methylmalonic acid] Tanaka A, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:600–2 (14 ref.) **(Jpn)**

BLOOD

[P-methylmalonate and P-homocysteine: metabolic markers of vitamin deficiencies. Background, validity and applications] Rasmussen K. **Ugeskr Laeger** 1996 Jul 1; 158(27):3913–8 (40 ref.) (Eng. Abstr.) **(Dan)**

[Bilateral necrosis of the basal ganglia in methylmalonic acidemia] Vázquez López M, et al. **An Esp Pediatr** 1996 Mar;44(3):273–6 (29 ref.) **(Spa)**

METABOLISM

The management and outcome of propionic and methylmalonic acidaemia. Leonard JV. **J Inherit Metab Dis** 1995;18(4):430–4 (29 ref.)

METHYLMERCURY COMPOUNDS

ADVERSE EFFECTS

Neurotoxicity of lead, methylmercury, and PCBs in relation to the Great Lakes. Rice DC. **Environ Health Perspect** 1995 Dec;103 Suppl 9:71–87 (221 ref.)

POISONING

Neurobehavioral effects of developmental methylmercury exposure. Gilbert SG, et al. **Environ Health Perspect** 1995 Sep;103 Suppl 6:135–42 (107 ref.)

Comparison of four human studies of perinatal exposure to methylmercury for use in risk assessment. Cicmanec JL. **Toxicology** 1996 Jul 17;111(1-3):157–62 (11 ref.)

TOXICITY

[Early manifestation of harmful effects of methylmercury on organism] Lin X, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1995 Jul;29(4):240–1 (7 ref.) **(Chi)**

METHYLMETHACRYLATES

Development of a PMMA membrane which can remove beta 2-microglobulin and its clinical significance. Kunitomo T, et al. **Contrib Nephrol** 1995;112:145–55 (22 ref.)

Use of antimicrobial-impregnated polymethyl methacrylate. Tobias KM, et al. **J Am Vet Med Assoc** 1996 Mar 15; 208(6):841–5 (50 ref.)

THERAPEUTIC USE

[Use of mini-septopal in trauma surgery of the hand. Experimental and clinical studies] Zimmer K. **Polim Med** 1996;26(1-2):3–57 (136 ref.) (Eng. Abstr.) **(Pol)**

N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE

[MDMA—"ecstasy"] Keup W. **Med Monatsschr Pharm** 1996 Jan;19(1):2–5 (27 ref.) **(Ger)**

PHARMACOKINETICS

The use of toxicokinetics for the safety assessment of drugs acting in the brain. Campbell DB. **Mol Neurobiol** 1995 Aug-Dec;11(1-3):193–216 (125 ref.)

POISONING

Ecstasy intoxication: an overlap between serotonin syndrome and neuroleptic malignant syndrome. Demirkiran M, et al. **Clin Neuropharmacol** 1996 Apr;19(2):157–64 (43 ref.)

TOXICITY

The use of toxicokinetics for the safety assessment of drugs acting in the brain. Campbell DB. **Mol Neurobiol** 1995 Aug-Dec;11(1-3):193–216 (125 ref.)

METHYLMETHYLERGONOVINE see **METHYSERGIDE**

METHYLOCOCCACEAE

METABOLISM

Methanotrophic bacteria. Hanson RS, et al. **Microbiol Rev** 1996 Jun;60(2):439–71 (436 ref.)

METHYLOMONADACEAE see **METHYLOCOCCACEAE**

METHYLPHENIDATE

THERAPEUTIC USE

The run on Ritalin. Attention deficit disorder and stimulant treatment in the 1990s. Diller LH. **Hastings Cent Rep** 1996 Mar-Apr;26(2):12–8 (45 ref.)

Neuroendocrine responses to methylphenidate and d-amphetamine: applications to attention-deficit disorder. Lurie S, et al. **J Neuropsychiatry Clin Neurosci** 1991 Winter; 3(1):41–50 (70 ref.)

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE

METABOLISM

The colorful past and bright future of monoamine oxidase research. Singer TP. **Prog Brain Res** 1995;106:1–22 (86 ref.)

[Metabolic enzymes of neurotoxin: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and Parkinson's disease] Wu RF, et al. **Seikagaku** 1995 Nov;

67(11):1307–11 (15 ref.) **(Jpn)**

PHARMACOLOGY

Effects of chronic MPTP and 3-nitropropionic acid in nonhuman primates. Brouillet E, et al. **Curr Opin Neurol** 1995 Dec;8(6):469–73 (44 ref.)

TOXICITY

Excitatory amino acids and MPTP toxicity. Fornai F, et al. **Adv Neurol** 1996;69:167–76 (52 ref.)

Neurotoxicity, drugs and abuse, and the CuZn-superoxide dismutase transgenic mice. Cadet JL, et al. **Mol Neurobiol** 1995 Aug-Dec;11(1-3):155–63 (49 ref.)

METHYLPREDNISOLONE

ADMINISTRATION & DOSAGE

[Chronic recurrent subileus due to Strongyloides stercoralis infection under immunosuppressive therapy] Birck R, et al. **Dtsch Med Wochenschr** 1996 May 31;121(22):723–6 (17 ref.) (Eng. Abstr.) **(Ger)**

[A case of acute eosinophilic pneumonia: bronchoalveolar lavage findings before and after steroid treatment] Kawaguchi H, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Jul;33(7):738–44 (21 ref.) (Eng. Abstr.) **(Jpn)**

[Emergency therapy of collagen diseases and their complications] Ichikawa Y, et al. **Nippon Naika Gakkai Zasshi** 1995 Nov 10;84(11):1865–9 (5 ref.) **(Jpn)**

[Recurrent amiodarone lung toxicity after withdrawal of the drug and treatment with corticoids] Donado Uña JR, et al. **Arch Bronconeumol** 1995 Oct;31(8):426–8 (13 ref.) (Eng. Abstr.) **(Spa)**

THERAPEUTIC USE

[Essential bone cysts in children. Value of systematic cystography. Apropos of a series of 42 cysts] Journeau P, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1995; 81(3):248–56 (26 ref.) (Eng. Abstr.) **(Fre)**

[A case of lupus cystitis successfully treated with corticosteroid accompanied by gastrointestinal symptoms] Sato M, et al. **Ryumachi** 1995 Oct;35(5):814–20 (38 ref.) (Eng. Abstr.) **(Jpn)**

METHYLTHIONINE CHLORIDE see **METHYLENE BLUE**

METHYLTRANSFERASES

METABOLISM

[Repair of O6-methylguanine-DNA] Sledziewska-Gójska EW. **Postepy Biochem** 1996;42(1):21–30 (132 ref.) **(Pol)**

PHYSIOLOGY

Phosphatidylethanolamine methylation and hepatoma cell growth. Vance DE, et al. **Anticancer Res** 1996 May-Jun; 16(3B):1413–6 (17 ref.)

DNA-repair methyltransferase as a molecular device for preventing mutation and cancer. Sekiguchi M, et al. **J Cancer Res Clin Oncol** 1996;122(4):199–206 (64 ref.)

METHYMAZOL see **METHIMAZOLE**

METHYSERGIDE

THERAPEUTIC USE

[Prophylactic treatment of episodic forms of cluster headache] Liaño H, et al. **Rev Neurol** 1995;23 Suppl 4:S525–9 (29 ref.) **(Spa)**

METINDAMIDE see **INDAPAMIDE**

METOCLOPRAMIDE

PHARMACOLOGY

Progress in identifying clinical relevance of inhibition, stimulation and measurements of poly ADP-ribosylation. Pero RW, et al. **Biochimie** 1995;77(5):385–93 (45 ref.)

THERAPEUTIC USE

Progress in identifying clinical relevance of inhibition, stimulation and measurements of poly ADP-ribosylation. Pero RW, et al. **Biochimie** 1995;77(5):385–93 (45 ref.)

Pharmacologic treatment of recurrent pediatric headache. Graf WD, et al. **Pediatr Ann** 1995 Sep;24(9):477–84 (27 ref.)

METOPROLOL

PHARMACOLOGY

Approaches to meeting the criteria for fixed dose antihypertensive combinations. Focus on metoprolol. Kendall MJ. **Drugs** 1995 Sep;50(3):454–64 (51 ref.)

THERAPEUTIC USE

Approaches to meeting the criteria for fixed dose antihypertensive combinations. Focus on metoprolol. Kendall MJ. **Drugs** 1995 Sep;50(3):454–64 (51 ref.)

A felodipine-metoprolol extended-release tablet: its properties and clinical development. Dahlöf B, et al. **J Hum Hypertens** 1995 Jul;9 Suppl 2:S43–7 (17 ref.)

Improving the therapeutic balance between efficacy and tolerability in antihypertensive drugs—the rationale and benefits of combining felodipine and metoprolol. Trenkwalder P, et al. **J Hum Hypertens** 1995 Jul;9 Suppl 2:S37–42 (17 ref.)

METRONIDAZOLE

ANALOGS & DERIVATIVES

Secnidazole. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic use in the management of protozoal infections and bacterial vaginosis. Gillis JC, et al. **Drugs** 1996 Apr;51(4):621–38 (56 ref.)

THERAPEUTIC USE

Is there any reason to continue treating Blastocystis infections? [editorial; comment] Markell EK. **Clin Infect Dis** 1995 Jul;21(1):104–5 (11 ref.) Comment on: Clin Infect Dis 1995 Jul;21(1):97–101.

Cephalosporin–metronidazole combinations in the management of intra-abdominal infections. Nicolau DP, et al. **Diagn Microbiol Infect Dis** 1995 May-Jun; 22(1-2):189–94 (28 ref.)

Cure of a solitary brainstem abscess with antibiotic therapy: case report. Fulgham JR, et al. **Neurology** 1996 May; 46(5):1451–4 (10 ref.)

Metronidazole: utilization in the obstetric and gynecologic patient. Schwebke JR. **Sex Transm Dis** 1995 Nov-Dec; 22(6):370–6 (84 ref.)

[Influence of colloidal bismuth subcitrate, metronidazole, and amoxycillin on Helicobacter pylori and gastroduodenal ulcer healing] Quintero M, et al. **G E N** 1995 Apr-Jun; 49(2):116–22 (21 ref.) (Eng. Abstr.) **(Spa)**

MEVALONIC ACID

ANTAGONISTS & INHIBITORS

Inhibition of the mevalonate pathway: benefits beyond cholesterol reduction? [see comments] Massy ZA, et al. **Lancet** 1996 Jan 13;347(8994):102–3 (18 ref.) Comment in: Lancet 1996 Feb 24;347(9000):551.

METABOLISM

The mevalonate pathway in parasitic protozoa and helminths. Coppens I, et al. **Exp Parasitol** 1996 Jan;82(1):76–85 (60 ref.)

Inhibition of the mevalonate pathway: benefits beyond cholesterol reduction? [see comments] Massy ZA, et al. **Lancet** 1996 Jan 13;347(8994):102–3 (18 ref.) Comment in: Lancet 1996 Feb 24;347(9000):551.

MEVINOLIN see **LOVASTATIN**

MEVINPHOS

ADVERSE EFFECTS

Risks from occupational and dietary exposure to mevinphos. Cochran RC, et al. **Rev Environ Contam Toxicol** 1996; 146:1–24 (76 ref.)

MEXICAN AMERICANS

Drug prevention research with Hispanic populations: theoretical and methodological issues and a generic structural model. Castro FG, et al. **NIDA Res Monogr** 1994; 139:203–33 (51 ref.)

MEXILETINE

BLOOD

[Disopyramide, mexiletine, aprindine] Suzuki M. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:989–93 (25 ref.) **(Jpn)**

MGADP see **ADENOSINE DIPHOSPHATE**

MGATP see **ADENOSINE TRIPHOSPHATE**

MGI-1 see **COLONY-STIMULATING FACTORS**

MGI-2 see **INTERLEUKIN-6**

MGN see **GLOMERULONEPHRITIS, MEMBRANOUS**

MHC CLASS I GENES see **GENES, MHC CLASS I**

MHC CLASS II GENES see **GENES, MHC CLASS II**

MHPG see **METHOXYHYDROXYPHENYLGLYCOL**

MIANSERIN

ANALOGS & DERIVATIVES

The pharmacologic profile of mirtazapine. de Boer T. **J Clin Psychiatry** 1996;57 Suppl 4:19–25 (48 ref.)

MIBELLI POROKERATOSIS see **POROKERATOSIS**

MICE

Genetics of liver tumor susceptibility in mice. Dragani TA, et al. **Toxicol Lett** 1995 Dec;82–83:613–9 (36 ref.)

[Mouse hepatitis virus] Homberger FR. **Schweiz Arch Tierheilkd** 1996;138(4):183–8 (10 ref.) (Eng. Abstr.) **(Ger)**

[Procedures for health monitoring in a breeding facility for specific pathogen free mice and rats] Wyss-Spillmann SK, et al. **Schweiz Arch Tierheilkd** 1995;137(11):505–14 (39 ref.) (Eng. Abstr.) **(Ger)**

[Mouse model for familial adenomatous polyposis coli and APC gene] Ito M, et al. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2035–44 (22 ref.) **(Jpn)**

EMBRYOLOGY

Galectins in mouse embryogenesis. Colnot C, et al. **Biochem Soc Trans** 1996 Feb;24(1):141–6 (41 ref.)

Retinoblastoma gene in mouse neural development. Slack RS, et al. **Dev Genet** 1996;18(1):81–91 (155 ref.)

What can be learned from intermediate filament gene regulation in the mouse embryo. Duprey P, et al. **Int J Dev Biol** 1995 Jun;39(3):443–57 (150 ref.)

Role of gap junctions in the development of the preimplantation mouse embryo. Becker DL, et al. **Microsc Res Tech** 1995 Aug 1;31(5):364–74 (31 ref.)

Mouse embryonic hematopoiesis. Dzierzak E, et al. **Trends Genet** 1995 Sep;11(9):359–66 (65 ref.)

Retinoids and mouse embryonic development. Underhill TM, et al. **Vitam Horm** 1995;51:403–57 (263 ref.)

GENETICS

Genomic imprinting in mice: its function and mechanism. Leighton PA, et al. **Biol Reprod** 1996 Feb;54(2):273–8 (56 ref.)

Linkage homology for bronchial hyperresponsiveness between DNA markers on human chromosome 5q31–q33 and mouse chromosome 13. Levitt RC, et al. **Clin Exp Allergy** 1995 Nov;25 Suppl 2:61–3 (21 ref.)

Knockouts. Targeting the mouse genome: a compendium of knockouts (Part I). Brandon EP, et al. **Curr Biol** 1995 Jun 1;5(6):625–34 (207 ref.)

Retinoblastoma gene in mouse neural development. Slack RS, et al. **Dev Genet** 1996;18(1):81–91 (155 ref.)

Human/mouse homology relationships. DeBry RW, et al. **Genomics** 1996 May 1;33(3):337–51 (46 ref.)

Genome engineering: the new mouse genetics. Rossant J, et al. **Nat Med** 1995 Jun;1(6):592–4 (11 ref.)

The genetics of brain development: conserved programs in flies and mice. Thor S. **Neuron** 1995 Nov;15(5):975–7 (18 ref.)

Mapping the mouse genome: current status and future prospects. Dietrich WF, et al. **Proc Natl Acad Sci U S A** 1995 Nov 21;92(24):10849–53 (68 ref.)

Taking stock of complex trait genetics in mice. Frankel WN. **Trends Genet** 1995 Dec;11(12):471–7 (51 ref.)

[Application of PCR technique to mouse genetics] Kominami R, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):623–8 (21 ref.) **(Jpn)**

IMMUNOLOGY

Development of the mouse B-cell repertoire. Martin F, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:207–21 (56 ref.)

Mouse NK1+ T cells. Bendelac A. **Curr Opin Immunol** 1995 Jun;7(3):367–74 (54 ref.)

PARASITOLOGY

Mouse-parasite interactions: from gene to population. Moulia C, et al. **Adv Parasitol** 1996;38:119–67 (195 ref.)

PHYSIOLOGY

Uptake of foreign DNA by mammalian cells via the gastrointestinal tract in mice: methylation of foreign DNA—a cellular defense mechanism. Doerfler W. **Curr Top Microbiol Immunol** 1995;197:209–24 (73 ref.)

A miracle enough: the power of mice. Paigen K. **Nat Med** 1995 Mar;1(3):215–20 (8 ref.)

MICE, DEER see **PEROMYSCUS**

MICE, HOUSE see **MICE**

MICE, INBRED BALB C

METABOLISM

Induction and repair of benzo[a]pyrene-DNA adducts in C57BL/6 and BALB/c mice: association with aging and longevity. Boerrigter ME, et al. **Mech Ageing Dev** 1995 Jul 28;82(1):31–50 (50 ref.)

MICE, INBRED C57BL

METABOLISM

Induction and repair of benzo[a]pyrene-DNA adducts in C57BL/6 and BALB/c mice: association with aging and longevity. Boerrigter ME, et al. **Mech Ageing Dev** 1995 Jul 28;82(1):31-50 (50 ref.)

MICE, INBRED MDX

METABOLISM

How does dystrophin deficiency lead to muscle degeneration?--evidence from the mdx mouse. McArdle A, et al. **Neuromuscul Disord** 1995 Nov;5(6):445-56 (78 ref.)

MICE, INBRED NOD

GENETICS

The genetics of the NOD mouse. Baxter AG, et al. **Diabetes Metab Rev** 1995 Dec;11(4):315-35 (102 ref.)

MICE, INBRED NZB

GENETICS

Genetic contributions to lupus-like disease in (NZB x NZW)F1 mice. Drake CG, et al. **Immunol Rev** 1995 Apr; 144:51-74 (59 ref.)

MICE, INBRED STRAINS

GENETICS

Mouse mutations as animal models and biomedical tools for dermatological research. Sundberg JP, et al. **J Invest Dermatol** 1996 Feb;106(2):368-76 (170 ref.)

MICE, KNOCKOUT

Production of corticotropin-releasing hormone-deficient mice by targeted mutation in embryonic stem cells. Muglia L, et al. **Ann N Y Acad Sci** 1996 Mar 22;780:49-59 (36 ref.)

Transgenic and gene knockout mice in cancer research. Viney JL. **Cancer Metastasis Rev** 1995 Jun;14(2):77-90 (81 ref.)

P-selectin knockout: a mouse model for various human diseases. Wagner DD. **Ciba Found Symp** 1995;189:2-10; discussion 10-16, 77-8 (43 ref.)

Knockouts. Targeting the mouse genome: a compendium of knockouts (Part I). Brandon EP, et al. **Curr Biol** 1995 Jun 1;5(6):625-34 (207 ref.)

Transgenic/knockout mice--tools to study autoimmunity. Mueller R, et al. **Curr Opin Immunol** 1995 Dec;7(6):799-803 (53 ref.)

Genetic knockouts in mice: an update. Shastry BS. **Experientia** 1995 Nov 15;51(11):1028-39 (159 ref.)

Strategies for studying cardiovascular phenotypes in genetically manipulated mice. Becker KD, et al. **Hypertension** 1996 Mar;27(3 Pt 2):495-501 (66 ref.)

Use of genetically engineered mice as models for understanding human neurodegenerative disease. Andersen JK, et al. **J Am Geriatr Soc** 1996 Jun;44(6):717-22 (34 ref.)

Transgenic and knockout mice in the study of neurodegenerative diseases. Aguzzi A, et al. **J Mol Med** 1996 Mar;74(3):111-26 (149 ref.)

Knockout mice. Majzoub JA, et al. **N Engl J Med** 1996 Apr 4;334(14):904-7 (8 ref.)

EMBRYOLOGY

[The roles of Wnt genes during mouse development] Takada S. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2162-74 (66 ref.) **(Jpn)**

GENETICS

Use of transgenics, null mutants, and antisense approaches to study ethanol's actions. Wehner JM, et al. **Alcohol Clin Exp Res** 1995 Aug;19(4):811-20 (79 ref.)

The use of null mutant mice to study complex learning and memory processes. Wehner JM, et al. **Behav Genet** 1996 May;26(3):301-12 (75 ref.)

Interleukin-10 gene knock-out mice: a model of chronic inflammation. Rennick D, et al. **Clin Immunol Immunopathol** 1995 Sep;76(3 Pt 2):S174-8 (33 ref.)

Targeting the mouse genome: a compendium of knockouts (Part II). Brandon EP, et al. **Curr Biol** 1995 Jul 1; 5(7):758-65 (189 ref.)

The role of transgenic knockout models in defining the pathogenesis of viral heart disease. Liu P, et al. **Eur Heart J** 1995 Dec;16 Suppl O:25-7 (28 ref.)

Cytokine knockout mice: possible application in toxicological research. Ryffel B. **Toxicology** 1995 Dec 20;105(1):69-80 (55 ref.)

[Preparation and application of knock-out mice] Noguchi S. **Nippon Rinsho** 1995 Aug;53(8):2079-85 (22 ref.) (Eng. Abstr.) **(Jpn)**

[The roles of Wnt genes during mouse development] Takada S. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2162-74 (66 ref.) **(Jpn)**

IMMUNOLOGY

Animal models of human disease. Transgenic and knockout models of autoimmunity: Building a better disease? [see comments] Lo D. **Clin Immunol Immunopathol** 1996 May; 79(2):96-104 (60 ref.) Comment in: Clin Immunol Immunopathol 1996 May;79(2):93-4.

Analysis of lymphocyte costimulation in vivo using transgenic and 'knockout' mice. Sharpe AH. **Curr Opin Immunol** 1995 Jun;7(3):389-95 (55 ref.)

Lymphocyte development in genetically manipulated mice. Killeen N, et al. **Ther Immunol** 1994 Apr;1(2):123-33 (140 ref.)

METABOLISM

Multidrug resistance and the role of P-glycoprotein knockout mice. Schinkel AH, et al. **Eur J Cancer** 1995 Jul-Aug; 31A(7-8):1295-8 (30 ref.)

PHYSIOLOGY

Genes and physiology: molecular physiology in genetically engineered animals. Chien KR. **J Clin Invest** 1996 Feb 15; 97(4):901-9 (66 ref.)

MICE, LABORATORY see MICE

MICE, MUTANT STRAINS

Creation and characterization of E-selectin- and VCAM-1-deficient mice. Kwee L, et al. **Ciba Found Symp** 1995;189:17-28; discussion 28-34, 77-8 (26 ref.)

Biological insights through genomics: mouse to man. Rubin EM, et al. **J Clin Invest** 1996 Jan 15;97(2):275-80 (82 ref.)

[Genetic screening for novel genes by insertional mutagenesis with gene trap method in ES cells] Araki K, et al. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2017-24 (17 ref.) **(Jpn)**

EMBRYOLOGY

[The mouse embryogenesis of jumonji mutant obtained by gene-trap method] Motoyama J, et al. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2152-61 (24 ref.) **(Jpn)**

GENETICS

Mouse mutants and cardiac development: new molecular insights into cardiogenesis. Rossant J. **Circ Res** 1996 Mar; 78(3):349-53 (60 ref.)

Lessons from the p53 mutant mouse. Jacks T. **J Cancer Res Clin Oncol** 1996;122(6):319-27 (79 ref.)

Mouse mutations as animal models and biomedical tools for dermatological research. Sundberg JP, et al. **J Invest Dermatol** 1996 Feb;106(2):368-76 (170 ref.)

[Targeted ablation of transcription factor genes] Kondoh H. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2126-33 (30 ref.) **(Jpn)**

[The mouse embryogenesis of jumonji mutant obtained by gene-trap method] Motoyama J, et al. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2152-61 (24 ref.) **(Jpn)**

MICE, NEUROLOGIC MUTANTS

Deaf and dizzy mice with mutated myosin motors. Gillespie PG. **Nat Med** 1996 Jan;2(1):27-9 (13 ref.)

GENETICS

The use of null mutant mice to study complex learning and memory processes. Wehner JM, et al. **Behav Genet** 1996 May;26(3):301-12 (75 ref.)

MICE, OBESE

Beta-adrenergic receptors and G-proteins in the ob/ob mouse. Bégin-Heick N. **Int J Obes Relat Metab Disord** 1996 Mar;20 Suppl 3:S32-5 (21 ref.)

[The hormone leptin reduces body weight. A mutant gene makes the mouse obese] Meister B, et al. **Lakartidningen** 1996 Jan 24;93(4):247-51 (18 ref.) (Eng. Abstr.) **(Swe)**

MICE, RED-BACKED see MICROTINAE

MICE, SCID

HIV-1-associated pathology in hemato-lymphoid organs and the experimental evaluation in the SCID-hu mouse. Kaneshima H. **Int J Hematol** 1996 Jun;63(4):253-64 (89 ref.)

IMMUNOLOGY

The human immune system in hu-PBL-SCID mice. Tary-Lehmann M, et al. **Immunol Today** 1995 Nov; 16(11):529-33 (34 ref.)

PHYSIOLOGY

Severe combined immunodeficient mouse models of human leukemia. Uckun FM. **Blood** 1996 Aug 15;88(4):1135-46 (47 ref.)

MICE, TRANSGENIC

Transgenic insertional mutagenesis. Applications to inner-ear genetics. Friedman RA. **Arch Otolaryngol Head Neck Surg** 1996 Mar;122(3):252-7 (55 ref.)

Transgenic mouse models of breast cancer. Amundadottir LT, et al. **Breast Cancer Res Treat** 1996;39(1):119-35 (133 ref.)

Transgenic mice and squamous multistage skin carcinogenesis. Brown K, et al. **Cancer Metastasis Rev** 1995 Jun;14(2):113-24 (112 ref.)

Murine models of neoplasia: functional analysis of the tumour suppressor genes Rb-1 and p53. Clarke AR. **Cancer Metastasis Rev** 1995 Jun;14(2):125-48 (107 ref.)

Utilization of transgenic mice in the study of matrix degrading proteinases and their inhibitors. Khokha R, et al. **Cancer Metastasis Rev** 1995 Jun;14(2):97-111 (109 ref.)

Assessing new anti-tumour agents and strategies in oncogene transgenic mice. Thomas H, et al. **Cancer Metastasis Rev** 1995 Jun;14(2):91-5 (18 ref.)

Transgenic and gene knockout mice in cancer research. Viney JL. **Cancer Metastasis Rev** 1995 Jun;14(2):77-90 (81 ref.)

Role of transgenic mice in identification and characterization of tumour suppressor genes. Sharan SK, et al. **Cancer Surv** 1995;25:143-59 (103 ref.)

Genetically engineered mice: tools to understand craniofacial development. Ignelzi MA Jr, et al. **Crit Rev Oral Biol Med** 1995;6(3):181-201 (118 ref.)

Transgenic/knockout mice--tools to study autoimmunity. Mueller R, et al. **Curr Opin Immunol** 1995 Dec;7(6):799-803 (53 ref.)

New models of lymphoma in transgenic mice. Seldin DC. **Curr Opin Immunol** 1995 Oct;7(5):665-73 (53 ref.)

Liver regeneration 7. Prometheus' myth revisited: transgenic mice as a powerful tool to study liver regeneration. Pistoi S, et al. **FASEB J** 1996 Jun;10(8):819-28 (68 ref.)

Hepatitis B virus transgenic mice: insights into the virus and the disease. Chisari FV. **Hepatology** 1995 Oct;22(4 Pt 1):1316-25 (60 ref.)

Strategies for studying cardiovascular phenotypes in genetically manipulated mice. Becker KD, et al. **Hypertension** 1996 Mar;27(3 Pt 2):495-501 (66 ref.)

Use of genetically engineered mice as models for understanding human neurodegenerative disease. Andersen JK, et al. **J Am Geriatr Soc** 1996 Jun;44(6):717-22 (34 ref.)

Biological insights through genomics: mouse to man. Rubin EM, et al. **J Clin Invest** 1996 Jan 15;97(2):275-80 (82 ref.)

Transgenic and knockout mice in the study of neurodegenerative diseases. Aguzzi A, et al. **J Mol Med** 1996 Mar;74(3):111-26 (149 ref.)

Plasmid-based transgenic mouse model for studying in vivo mutations. Boerrigter ME, et al. **Nature** 1995 Oct 19; 377(6550):657-9 (16 ref.)

Transgenic models for eye malformations. Götz W. **Ophthalmic Genet** 1995 Sep;16(3):85-104 (160 ref.)

Insights into cellular energy metabolism from transgenic mice. Koretsky AP. **Physiol Rev** 1995 Oct;75(4):667-88 (130 ref.)

Multistage skin carcinogenesis in transgenic mice. Greenhalgh DA, et al. **Proc Assoc Am Physicians** 1995 Jul;107(2):258-75 (112 ref.)

Transgenic models to study the roles of inhibins and activins in reproduction, oncogenesis, and development. Matzuk MM, et al. **Recent Prog Horm Res** 1996;51:123-54; discussion 155-7 (107 ref.)

[Establishment of immortalized cell lines with differentiation phenotypes from the transgenic mice harboring temperature-sensitive SV40 T-antigen gene] Obinata M. **Seikagaku** 1995 Dec;67(12):1391-6 (11 ref.) **(Jpn)**

[On transgenic mouse systems] Katsuki M. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2001-7 (16 ref.) **(Jpn)**

[Analysis of regulatory mechanism for humoral immunity using transgenic mice of rearranged immunoglobulin genes] Shimizu A. **Tanpakushitsu Kakusan Koso** 1995 Oct; 40(14):2107-17 (21 ref.) **(Jpn)**

EMBRYOLOGY

[The roles of Wnt genes during mouse development] Takada S. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2162-74 (66 ref.) **(Jpn)**

GENETICS

Use of transgenics, null mutants, and antisense approaches to study ethanol's actions. Wehner JM, et al. **Alcohol Clin Exp Res** 1995 Aug;19(4):811-20 (79 ref.)

YAC transgenics and the study of genetics and human disease. Lamb BT, et al. **Curr Opin Genet Dev** 1995 Jun; 5(3):342-8 (54 ref.)

Transgenic systems in studying myelin gene expression. Ikenaka K, et al. **Dev Neurosci** 1995;17(3):127-36 (76 ref.)

Use of transgenic mouse models for studying somatic mutations in aging. Martus HJ, et al. **Mutat Res** 1995 Oct; 338(1-6):203-13 (46 ref.)

Germ line transmission of yeast artificial chromosomes in transgenic mice. Montoliu L, et al. **Reprod Fertil Dev** 1994;

6(5):577–84 (44 ref.)
[Transgenic mice as models for skin diseases (see comments)] Sellheyer K. **Hautarzt** 1995 Nov;46(11):755–61 (30 ref.) (Eng. Abstr.) Comment in: Hautarzt 1996 Jun;47(6):475–6. **(Ger)**
[The roles of Wnt genes during mouse development] Takada S. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2162–74 (66 ref.) **(Jpn)**

IMMUNOLOGY

Animal models of human disease. Transgenic and knockout models of autoimmunity: Building a better disease? [see comments] Lo D. **Clin Immunol Immunopathol** 1996 May; 79(2):96–104 (60 ref.) Comment in: Clin Immunol Immunopathol 1996 May;79(2):93–4.
Production of fully human antibodies by transgenic mice. Jakobovits A. **Curr Opin Biotechnol** 1995 Oct;6(5):561–6 (24 ref.)
Analysis of lymphocyte costimulation in vivo using transgenic and 'knockout' mice. Sharpe AH. **Curr Opin Immunol** 1995 Jun;7(3):389–95 (55 ref.)
Human antibodies from transgenic mice. Lonberg N, et al. **Int Rev Immunol** 1995;13(1):65–93 (102 ref.)

METABOLISM

Transgenic systems in studying myelin gene expression. Ikenaka K, et al. **Dev Neurosci** 1995;17(3):127–36 (76 ref.)

PHYSIOLOGY

Genes and physiology: molecular physiology in genetically engineered animals. Chien KR. **J Clin Invest** 1996 Feb 15; 97(4):901–9 (66 ref.)

VIROLOGY

Safety requirements for maintenance and distribution of transgenic mice susceptible to human viruses: the example of poliovirus-susceptible transgenic mice. Ghendon Y, et al. **Curr Top Microbiol Immunol** 1996;206:327–40 (31 ref.)

MICE, WHITE-FOOTED see **PEROMYSCUS**

MICELLES

Thermodynamics of micellar systems: comparison of mass action and phase equilibrium models for the calculation of standard Gibbs energies of micelle formation. Blandamer MJ, et al. **Adv Colloid Interface Sci** 1995 Jul 12; 58(2–3):171–209 (34 ref.)
Kinetic models in reverse micelles. Bru R, et al. **Biochem J** 1995 Sep 15;310 (Pt 3):721–39 (161 ref.)
Phospholipid vesicles and other cholesterol carriers in bile. Gilat T, et al. **Biochim Biophys Acta** 1996 Jun 10; 1286(2):95–115 (108 ref.)

MICROANGIOPATHY, DIABETIC see **DIABETIC ANGIOPATHIES**

MICROBIAL ANTAGONISM see **ANTIBIOSIS**

MICROBIAL SENSITIVITY TESTS

see related
DRUG RESISTANCE, MICROBIAL
In vitro testing of antimicrobial agents. Woods GL. **Infect Dis Clin North Am** 1995 Sep;9(3):463–81 (60 ref.)

METHODS

Is antifungal susceptibility testing useful in guiding fluconazole therapy? Ghannoum MA. **Clin Infect Dis** 1996 May;22 Suppl 2:S161–5 (25 ref.)
E test: a novel technique for antimicrobial susceptibility testing. Sader HS, et al. **Rev Paul Med** 1994 Oct–Dec; 112(4):635–8 (15 ref.)
[Modern methods and means for the rapid determination of the sensitivity of the causative agents of dangerous infectious diseases to antibiotics and chemical preparations] D'iakov SI, et al. **Voen Med Zh** 1996 Mar;317(3):44–7 (17 ref.) **(Rus)**

MICROBIAL SUPERINVASION see **SUPERINFECTION**

MICROBIOLOGICAL TECHNIQUES

Review: methods of monitoring for process micro-organisms in biotechnology. Crook B. **Ann Occup Hyg** 1996 Jun; 40(3):245–60 (23 ref.)
Nucleic acid amplification and related techniques in microbiological diagnostics and epidemiology. Van Belkum A, et al. **Cell Mol Biol (Noisy-le-grand)** 1995 Jul; 41(5):615–23 (48 ref.)
General principles of specimen collection and transport. Wilson ML. **Clin Infect Dis** 1996 May;22(5):766–77 (59 ref.)
Basic microbiologic support for hospital epidemiology. McGowan JEJr, et al. **Infect Control Hosp Epidemiol** 1996 May;17(5):298–303 (30 ref.)
Scanning probe microscopy in microbiology. Firtel M, et al. **Microsc Res Tech** 1995;26(4):347–62 (110 ref.)
[Revolution in diagnostic microbiology. Needs, driving forces and consequences] Bukholm G, et al. **Tidsskr Nor Laegeforen** 1995 Nov 10;115(27):3387–9 (3 ref.) (Eng. Abstr.) **(Nor)**

MICROBIOLOGY

see related
BACTERIA
FUNGI
PROTOZOA
VIRUSES
Microbiological research at the Centre for Tropical Veterinary Medicine (CTVM). Scott GR. **Trop Anim Health Prod** 1996 Feb;28(1):40–8 (24 ref.)
[Progresses in microbiology and immunology in China, 1995] Wen Y. **Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):781 (0 ref.) **(Chi)**
[Hospital management and the role of clinical microbiology laboratory for preventing nosocomial infection] Ichiyama S. **Rinsho Byori** 1995 Oct;43(10):1005–9 (4 ref.) (Eng. Abstr.) **(Jpn)**

TRENDS

The impact of recent advances in microbiology and immunology on perinatal and women's health care. Munro CL. **J Obstet Gynecol Neonatal Nurs** 1995 Jul–Aug; 24(6):525–31 (32 ref.)
[Revolution in diagnostic microbiology. Needs, driving forces and consequences] Bukholm G, et al. **Tidsskr Nor Laegeforen** 1995 Nov 10;115(27):3387–9 (3 ref.) (Eng. Abstr.) **(Nor)**

MICROBODIES

DRUG EFFECTS

Does DHEAS restore immune competence in aged animals through its capacity to function as a natural modulator of peroxisome activities? Spencer NF, et al. **Ann N Y Acad Sci** 1995 Dec 29;774:200–16 (129 ref.)
Role of oxidative stress in non-genotoxic carcinogenesis with special reference to liver tumors induced by peroxisome proliferators. Sai-Kato K, et al. **Biomed Environ Sci** 1995 Sep;8(3):269–79 (64 ref.)
PPAR: a mediator of peroxisome proliferator action. Green S. **Mutat Res** 1995 Dec;333(1–2):101–9 (65 ref.)
Peroxisome proliferators: potential role of altered hepatocyte growth and differentiation in tumor development. Cattley RC, et al. **Prog Clin Biol Res** 1995;391:295–303 (55 ref.)
Peroxisome proliferation: current mechanisms relating to nongenotoxic carcinogenesis. Lake BG. **Toxicol Lett** 1995 Dec;82–83:673–81 (33 ref.)
[Peroxisome proliferators and hepatocarcinogenesis] Tamura H. **Seikagaku** 1995 Aug;67(8):1044–7 (15 ref.) **(Jpn)**

METABOLISM

The role of peroxisomes in intermediary metabolism. Chandoga J. **Bratisl Lek Listy** 1995 Sep;96(9):465–86 (166 ref.) **(Eng, Slo)**
How proteins penetrate peroxisomes. Rachubinski RA, et al. **Cell** 1995 Nov 17;83(4):525–8 (14 ref.)
Convergence of model systems for peroxisome biogenesis. Subramani S. **Curr Opin Cell Biol** 1996 Aug;8(4):513–8 (52 ref.)
On the role of the peroxisome in ontogeny, ageing and degenerative disease. Masters CJ, et al. **Mech Ageing Dev** 1995 May 12;80(2):69–83 (31 ref.)
Glycerolipid biosynthesis in peroxisomes (microbodies). Hajra AK. **Prog Lipid Res** 1995;34(4):343–64 (208 ref.)

PHYSIOLOGY

Recent developments in peroxisome biology. Masters C, et al. **Endeavour** 1996;20(2):68–73 (25 ref.)

ULTRASTRUCTURE

Molecular organization of hepatocyte peroxisomes. Makita T. **Int Rev Cytol** 1995;160:303–52 (220 ref.)

MICROCAPSULES see **CAPSULES**

MICROCEPHALY

Microcephaly, characteristic facies, joint abnormalities, and deficient leucocyte chemotaxis: a further case of the syndrome of Say et al. Perandones C, et al. **J Med Genet** 1996 Mar;33(3):227–9 (7 ref.)

DIAGNOSIS

[The MMT syndrome (microcephaly, mesobrachyphalangy and tracheoesophageal fistula). The first case described in Spain and a review of the literature] Martínez-Frías ML, et al. **An Esp Pediatr** 1996 Jul;45(1):87–9 (7 ref.) **(Spa)**

GENETICS

Microdontia with severe microcephaly and short stature in two brothers: osteodysplastic primordial dwarfism with dental findings. Lin HJ, et al. **Am J Med Genet** 1995 Aug 28;58(2):136–42 (4 ref.)
A distinct phenotype associated with partial trisomy 10q due to proximal direct duplication 10q11 --> q22? van Buggenhout G, et al. **Genet Couns** 1996;7(1):53–9 (14 ref.)
A nine-month-old boy with microcephaly, cataracts, intracerebral calcifications and dysmorphic signs: an additional observation of an autosomal recessive congenital infection-like syndrome? Wieczorek D, et al. **Genet Couns** 1995;6(4):297–302 (18 ref.)
Filippi syndrome: a new case with skeletal abnormalities. Héron D, et al. **J Med Genet** 1995 Aug;32(8):659–61 (6 ref.)
The Aicardi-Goutières syndrome (familial, early onset encephalopathy with calcifications of the basal ganglia and chronic cerebrospinal fluid lymphocytosis). Tolmie JL, et al. **J Med Genet** 1995 Nov;32(11):881–4 (26 ref.)

MICROCIRCULATION

Is stunned myocardium ischemic on a microvascular level? Becker LC. **Basic Res Cardiol** 1995 Jul–Aug;90(4):282–4 (11 ref.)
Temporal chaos in the microcirculation. Griffith TM. **Cardiovasc Res** 1996 Mar;31(3):342–58 (108 ref.)
[Progresses in microcirculation in China, 1995] Zeng S. **Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):779–80 (0 ref.) **(Chi)**
[The blood-brain barrier: a specialty of cerebral microcirculation systems] Wolf S, et al. **Naturwissenschaften** 1996 Jul;83(7):302–11 (41 ref.) **(Ger)**
[State of microcirculation in the bulbar conjunctiva in retinal thrombosis of patients with hypertension and diabetes mellitus] Polunin GS, et al. **Vestn Oftalmol** 1996 Jan–Mar; 112(1):51–3 (60 ref.) **(Rus)**

IMMUNOLOGY

Role of microcirculation in seasonal allergic rhinitis [editorial] Rajakulasingam K. **Clin Exp Allergy** 1995 Oct; 25(10):910–1 (12 ref.)

METABOLISM

Influence of microvascular architecture on oxygen exchange in skeletal muscle. Pittman RN. **Microcirculation** 1995 May; 2(1):1–18 (67 ref.)

PATHOLOGY

Intravital capillaroscopy in patients with chronic venous insufficiency and lymphoedema: relevance to Daflon 500 mg. Bollinger A, et al. **Int J Microcirc Clin Exp** 1995;15 Suppl 1:41–4 (24 ref.)

PHYSIOLOGY

Simulation of intraluminal gas transport processes in the microcirculation. Hellums JD, et al. **Ann Biomed Eng** 1996 Jan–Feb;24(1):1–24 (97 ref.)
Microcirculation of the islets of Langerhans. Long Beach Veterans Administration Regional Medical Education Center Symposium. Brunicardi FC, et al. **Diabetes** 1996 Apr;45(4):385–92 (84 ref.)
Nitric oxide affects microvascular permeability in the intact and inflamed vasculature. Kubes P. **Microcirculation** 1995 Sep;2(3):235–44 (46 ref.)
Microcirculatory homeostasis 1930–1990: insight into microcirculatory readjustments provided by studies on the peripheral circulatory insufficiency of the shock syndrome. Zweifach BW. **Microcirculation** 1995 Sep;2(3):245–51 (44 ref.)
Initial interaction of leukocytes within the microvasculature: deformability, adhesion, and transmigration. Downey GP, et al. **New Horiz** 1995 May;3(2):219–28 (79 ref.)
Mechanics of blood flow in the microcirculation. Secomb TW. **Symp Soc Exp Biol** 1995;49:305–21 (41 ref.)
[Successes and debatable problems in the study of the microcirculation] Ivanov KP. **Fiziol Zh Im I M Sechenova** 1995 Jun;81(6):1–18 (51 ref.) **(Rus)**
[The concept of the structuring of the blood flow in microvessels] Mchedlishvili GI. **Fiziol Zh Im I M Sechenova** 1995 Jun;81(6):48–53 (8 ref.) **(Rus)**

PHYSIOPATHOLOGY

Assessment of the microcirculation in cardiovascular disease. Struijker-Boudier HA, et al. **Clin Sci (Colch)** 1996 Aug; 91(2):131–9 (75 ref.)
Sepsis/septic shock: participation of the microcirculation: an abbreviated review [see comments] Hinshaw LB. **Crit Care Med** 1996 Jun;24(6):1072–8 (75 ref.) Comment in: Crit Care Med 1996 Jun;24(6):918.
The use of non-invasive vascular assessment in diabetic patients with foot lesions. Takolander R, et al. **Diabet Med** 1996;13 Suppl 1:S39–42 (30 ref.)
Microvascular aspects of diabetic foot disease. Tooke JE, et al. **Diabet Med** 1996;13 Suppl 1:S26–9 (14 ref.)
Advances in microcirculation network evaluation: an update. Fagrell B. **Int J Microcirc Clin Exp** 1995;15 Suppl 1:34–40 (61 ref.)
Microcirculatory models of ischaemia-reperfusion in skin and striated muscle. Nolte D, et al. **Int J Microcirc Clin Exp** 1995;15 Suppl 1:9–16 (67 ref.)
Microcirculatory disturbances secondary to ischemia-reperfusion. Menger MD. **Transplant Proc** 1995 Oct;27(5):2863–5 (20 ref.)
The role of the microcirculation in multiple organ dysfunction syndrome (MODS): a review and perspective.

MICROCIRCULATION

Kirkpatrick CJ, et al. **Virchows Arch** 1996 Feb; 427(5):461–76 (209 ref.)
[Endothelial function and coronary microcirculation in arterial hypertension] Salvetti A. **Cardiologia** 1996 Apr; 41(4):319–25 (41 ref.) **(Ita)**

ULTRASTRUCTURE

Microvascular architecture and exchange in synovial joints. Levick JR. **Microcirculation** 1995 Sep;2(3):217–33 (92 ref.)

MICROCOCCAL NUCLEASE

METABOLISM

Thermodynamics of denaturation of staphylococcal nuclease mutants: an intermediate state in protein folding. Carra JH, et al. **FASEB J** 1996 Jan;10(1):67–74 (52 ref.)

MICROCOCCUS DENITRIFICANS see **PARACOCCUS DENITRIFICANS**

MICROCOMPUTERS

DNA on a chip. Ross DW. **Arch Pathol Lab Med** 1996 Jun; 120(6):604–5 (4 ref.)
[Sensible utilization of modern hearing aid technique. II: Multiple channel compression] Steffens T. **HNO** 1996 May; 44(5):273–85 (24 ref.) **(Ger)**
[PC applications in routine practice, science and teaching. What computer peripherals are useful?] Knopp MV, et al. **Radiologe** 1995 Sep;35(9):620–4 (3 ref.) (Eng. Abstr.) **(Ger)**

MICROCYTOTOXICITY TESTS see **CYTOTOXICITY TESTS, IMMUNOLOGIC**

MICRODIALYSIS

Brain microdialysis and its application for the study of animal behaviour. Westerink BH. **Behav Brain Res** 1995 Oct; 70(2):103–24 (153 ref.)
Microdialysis in human skin [editorial] Church MK, et al. **Clin Exp Allergy** 1995 Nov;25(11):1027–9 (19 ref.)
[Intracerebral microdialysis and its application in neurosciences] Yin PB, et al.
Sheng Li Ko Hsueh Chin Chan 1995 Jul;26(3):223–9 (20 ref.) (Eng. Abstr.) **(Chi)**

METHODS

Microdialysis sampling for pharmacological studies: HPLC and CE analysis. Lunte SM, et al. **Adv Chromatogr** 1996; 36:383–432 (73 ref.)

MICROELECTRODES

Microelectrode monitoring of cortical and subcortical structures during stereotactic surgery. Lozano AM, et al. **Acta Neurochir Suppl (Wien)** 1995;64:30–4 (19 ref.)

MICROENCAPSULATION see **DRUG COMPOUNDING**

MICROFILAMENT PROTEINS

Actin-binding proteins. 1: Spectrin super family. Hartwig JH. **Protein Profile** 1995;2(7):703–800 (1448 ref.)

ANALYSIS

Fibrillin-containing microfibrils: structure and function in health and disease. Kielty CM, et al.
Int J Biochem Cell Biol 1995 Aug;27(8):747–60 (70 ref.)

CHEMISTRY

Actin-binding proteins 1: spectrin superfamily. Hartwig JH. **Protein Profile** 1994;1(7):706–78 (479 ref.)

GENETICS

Mutations in the human gene for fibrillin-1 (FBN1) in the Marfan syndrome and related disorders. Dietz HC, et al. **Hum Mol Genet** 1995;4 Spec No:1799–809 (86 ref.)

METABOLISM

Control of actin assembly at filament ends. Schafer DA, et al. **Ann Rev Cell Dev Biol** 1995;11:497–518 (143 ref.)
Heterogeneity of microfibrils: role of thrombospondin-microfibrils in the thrombogenicity of the subendothelium. Fauvel-Lafève F, et al.
C R Acad Sci III 1996 Apr;319(4):333–41 (41 ref.)

PHYSIOLOGY

Fascins, a family of actin bundling proteins. Edwards RA, et al. **Cell Motil Cytoskeleton** 1995;32(1):1–9 (48 ref.)
The structure and function of fibrillin. Reinhardt DP, et al. **Ciba Found Symp** 1995;192:128–43; discussion 143–7 (47 ref.)
Microvillus assembly. Not actin alone. Fath KR, et al. **Curr Biol** 1995 Jun 1;5(6):591–3 (22 ref.)

MICROFILAMENTS

METABOLISM

Microfilament dynamics: regulation of actin polymerization by actin-fragmin kinase and phosphatases. Waelkens E, et al. **Adv Enzyme Regul** 1995;35:199–227 (60 ref.)
Troponin C – troponin I interactions and molecular signalling in cardiac myofilaments. Solaro RJ. **Adv Exp Med Biol** 1995;382:109–15 (24 ref.)
Stunned myocardium: a disease of the myofilaments? Marban E, et al. **Basic Res Cardiol** 1995 Jul-Aug;90(4):269–72 (21 ref.)
Microvillus assembly. Not actin alone. Fath KR, et al. **Curr Biol** 1995 Jun 1;5(6):591–3 (22 ref.)
Altered interactions among thin filament proteins modulate cardiac function. Solaro RJ, et al. **J Mol Cell Cardiol** 1996 Feb;28(2):217–30 (105 ref.)

PATHOLOGY

[Microfilament dysfunction (severe familial cholestasis in North American Indian children)] Terazawa S.
Ryoikibetsu Shokogun Shirizu 1995;(7):535–8 (12 ref.) **(Jpn)**

PHYSIOLOGY

The ADF/cofilin proteins: stimulus-responsive modulators of actin dynamics. Moon A, et al. **Mol Biol Cell** 1995 Nov; 6(11):1423–31 (84 ref.)

ULTRASTRUCTURE

Microfilament organization and wound repair in retinal pigment epithelium. Kalnins VI, et al.
Biochem Cell Biol 1995 Sep-Oct;73(9–10):709–22 (97 ref.)

MICROFLUOROMETRY, FLOW see **FLOW CYTOMETRY**

MICROGLIA

CYTOLOGY

Microglia: the effector cell for reconstitution of the central nervous system following bone marrow transplantation for lysosomal and peroxisomal storage diseases. Krivit W, et al. **Cell Transplant** 1995 Jul-Aug;4(4):385–92 (71 ref.)
Morphological study of microglia in human mesencephalon during the development and aging. Wierzba-Bobrowicz T, et al. **Folia Neuropathol** 1995;33(2):77–83 (46 ref.)

DRUG EFFECTS

Astrocytes and microglia as potential targets for calcitonin gene related peptide in the central nervous system. Reddington M, et al. **Can J Physiol Pharmacol** 1995 Jul; 73(7):1047–9 (18 ref.)
Microglia as a unique cellular target in the treatment of stroke: potential neurotoxic mediators produced by activated microglia. Wood PL. **Neurol Res** 1995 Aug; 17(4):242–8 (104 ref.)

IMMUNOLOGY

Microglia: intrinsic immuneffector cell of the brain. Gehrmann J, et al. **Brain Res Brain Res Rev** 1995 Mar; 20(3):269–87 (122 ref.)

PHYSIOLOGY

Morphological study of microglia in human mesencephalon during the development and aging. Wierzba-Bobrowicz T, et al. **Folia Neuropathol** 1995;33(2):77–83 (46 ref.)
The microglial cell. A historical review. Barron KD.
J Neurol Sci 1995 Dec;134 Suppl:57–68 (88 ref.)
Reactive microglia in cerebral ischaemia: an early mediator of tissue damage? Gehrmann J, et al.
Neuropathol Appl Neurobiol 1995 Aug;21(4):277–89 (104 ref.)

VIROLOGY

HIV interactions with cells of the nervous system. Dubois-Dalcq M, et al. **Curr Opin Neurobiol** 1995 Oct; 5(5):647–55 (65 ref.)

MICROGNATHISM

DIAGNOSIS

[The cerebrocostomandibular syndrome] Casas Gómez J, et al. **An Esp Pediatr** 1996 Apr;44(4):369–72 (25 ref.) **(Spa)**

MICROGRAPHIC SURGERY, MOHS see **MOHS SURGERY**

MICROINJECTIONS

Micromanipulative assisted fertilization – still clinical research. Bui TH, et al. **Hum Reprod** 1996 May;11(5):925–6 (21 ref.)
Genetic anomaly and ICSI. Chandley AC, et al.
Hum Reprod 1996 May;11(5):930–2 (26 ref.)
Intracytoplasmic sperm injection—what kind of reproduction is being assisted? De Jonge CJ, et al. **Hum Reprod** 1995 Oct;10(10):2518–20 (11 ref.)
The risk of chromosomal abnormalities following ICSI. Martin RH. **Hum Reprod** 1996 May;11(5):924–5 (12 ref.)
Intracytoplasmic sperm injection—is there a need for an animal model, especially in assessing the genetic risks involved? Ng SC, et al. **Hum Reprod** 1995 Oct; 10(10):2523–5 (26 ref.)
Intracytoplasmic sperm injection (ICSI): potential genetic concerns. Patrizio P. **Hum Reprod** 1995 Oct;10(10):2520–3 (26 ref.)
Is ICSI associated with risks of genetic disease? Implications for counselling, practice and research. Persson JW, et al. **Hum Reprod** 1996 May;11(5):921–4 (30 ref.)
Micro-assisted fertilization and sperm chromosome abnormalities. Rosenbusch B, et al. **Hum Reprod** 1996 May; 11(5):928–30 (29 ref.)
Intracytoplasmic sperm injection three years after the birth of the first ICSI child. Van Steirteghem A, et al.
Hum Reprod 1995 Oct;10(10):2527–8 (16 ref.)
Is an animal model needed for intracytoplasmic sperm injection (ICSI) and other assisted reproduction technologies? Yanagimachi R. **Hum Reprod** 1995 Oct; 10(10):2525–6 (11 ref.)
The potential of intracytoplasmic sperm injection (ICSI) to transmit genetic defects causing male infertility. de Kretser DM. **Reprod Fertil Dev** 1995;7(2):137–41; discussion 141–2 (36 ref.)
Cell cycle factors in the human oocyte and the intracytoplasmic injection of spermatozoa. Edwards RG. **Reprod Fertil Dev** 1995;7(2):143–53 (86 ref.)

INSTRUMENTATION

Intracytoplasmic sperm injection: instrumentation and injection technique. Payne D. **Reprod Fertil Dev** 1995; 7(2):185–96 (22 ref.)

METHODS

Intracytoplasmic sperm injection: instrumentation and injection technique. Payne D. **Reprod Fertil Dev** 1995; 7(2):185–96 (22 ref.)

MICROMANIPULATION

Concerns and recommendations for intracytoplasmic sperm injection (ICSI) treatment. Cummins JM, et al.
Hum Reprod 1995 Oct;10 Suppl 1:138–43 (47 ref.)
Recent developments in assisted fertilization. Gordts S, et al. **Hum Reprod** 1995 Oct;10 Suppl 1:107–14 (45 ref.)

METHODS

Micro-assisted fertilization. Payne D. **Reprod Fertil Dev** 1995; 7(4):831–9 (55 ref.)

MICRONUCLEUS ASSAYS see **MICRONUCLEUS TESTS**

MICRONUCLEUS TESTS

The micronucleus test: its value as a predictor of rodent carcinogens versus its value in risk assessment. Gocke E. **Mutat Res** 1996 Jun 10;352(1–2):189–90 (7 ref.)
Achievements by CSGMT/JEMS.MMS: the Collaborative Study Group for the Micronucleus Test in the Mammalian Mutagenesis Study Group of the Environmental Mutagen Society of Japan. Sutou S. **Mutat Res** 1996 Jun; 340(2–3):151–74 (129 ref.)

METHODS

The micronucleus test and NTP rodent carcinogens: not so many false negatives. Galloway SM. **Mutat Res** 1996 Jun 10;352(1–2):185–8 (5 ref.)

MICRONUTRIENTS

see related
TRACE ELEMENTS

Lowered energy intake and dietary macronutrient balance: potential consequences for micronutrient status. Whitehead RG. **Nutr Rev** 1995 Sep;53(9 Pt 2):S2–8 (6 ref.)
[Food fortification with emphasis on the addition of micronutrients to wheat flour] Arroyave G.
Arch Latinoam Nutr 1993 Sep;43(3):186–90 (16 ref.) (Eng. Abstr.) **(Spa)**

STANDARDS

Strategies for control of micronutrient malnutrition. Vijayaraghavan K. **Indian J Med Res** 1995 Nov;102:216–22 (33 ref.)
Intake of sugars in relation to fatness and micronutrient adequacy. Bolton-Smith C.
Int J Obes Relat Metab Disord 1996 Mar;20 Suppl 2:S31–3 (35 ref.)
Micronutrient status and aging. Tucker K. **Nutr Rev** 1995 Sep;53(9 Pt 2):S9–15 (47 ref.)

MICROPHTHALMOS

GENETICS

Familial arhinia, choanal atresia, and microphthalmia. Thiele H, et al. **Am J Med Genet** 1996 May 3;63(1):310–3 (7 ref.)

Insight into the microphthalmia gene. Moore KJ. **Trends Genet** 1995 Nov;11(11):442–8 (41 ref.)

MICROPROCESSORS see **MICROCOMPUTERS**

MICROPUNCTURES see **PUNCTURES**

MICROSATELLITE MARKERS see **MICROSATELLITE REPEATS**

MICROSATELLITE REPEATS

Detection of a subtle rearrangement of chromosome 22 using molecular techniques. Biesecker LG, et al. **Am J Med Genet** 1995 Sep 25;58(4):389–94 (15 ref.)
Mechanisms of DNA expansion. McMurray CT. **Chromosoma** 1995 Oct;104(1):2–13 (103 ref.)
Mutation processes at human minisatellites. Jeffreys AJ, et al. **Electrophoresis** 1995 Sep;16(9):1577–85 (49 ref.)
Biological significance of minisatellites. Singh L. **Electrophoresis** 1995 Sep;16(9):1586–95 (76 ref.)
Microsatellites and PCR genomic analysis. Koreth J, et al. **J Pathol** 1996 Mar;178(3):239–48 (152 ref.)
Microsatellite instability and DNA mismatch repair in human cancer. Karran P. **Semin Cancer Biol** 1996 Feb;7(1):15–24 (72 ref.)
[Analysis of STS (sequence tagged site): microsatellite marker] Miki T, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):618–22 (13 ref.) **(Jpn)**

MICROSCOPY

Image analysis of tissue sections. Ong SH, et al. **Comput Biol Med** 1996 May;26(3):269–79 (68 ref.)
Role of microscopy in elucidating the mechanism and regulation of the osteoclast resorptive apparatus. Gay CV. **Microsc Res Tech** 1996 Feb 1;33(2):165–70 (74 ref.)
[Structural analysis of nucleic acids by the use of Raman microscope] Ueda T, et al. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1540–7 (19 ref.) **(Jpn)**

INSTRUMENTATION

High-resolution light microscopy for interpretation of renal biopsies. Hoffmann EO. **Pediatr Nephrol** 1995 Dec; 9(6):763–9 (81 ref.)
[Incident light microscopic characterization of vascular patterns in skin tumors] Kreusch J, et al. **Hautarzt** 1996 Apr;47(4):264–72 (21 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Robert Feulgen Prize Lecture 1995. Electronic light microscopy: present capabilities and future prospects. Shotton DM. **Histochem Cell Biol** 1995 Aug;104(2):97–137 (150 ref.)
Indirect fundus biomicroscopy. Flanagan JG, et al. **Ophthalmic Physiol Opt** 1995 Sep;15 Suppl 2:S38–41 (3 ref.)
Fractals in pathology: are they really useful? Losa GA. **Pathologica** 1995 Jun;87(3):310–7 (74 ref.)
The potential and limitations of neutrons, electrons and X-rays for atomic resolution microscopy of unstained biological molecules. Henderson R. **Q Rev Biophys** 1995 May;28(2):171–93 (42 ref.)
[Microsensory systems in cell biology basic research and medical diagnostics] Brischwein M, et al. **Naturwissenschaften** 1996 May;83(5):193–200 (28 ref.) (Eng. Abstr.) **(Ger)**

MICROSCOPY, ATOMIC FORCE

see related
MICROSCOPY, SCANNING TUNNELING

Biological atomic force microscopy: from microns to nanometers and beyond. Shao Z, et al. **Ann Rev Cell Dev Biol** 1995;11:241–65 (134 ref.)
Scanning probe microscopy in microbiology. Firtel M, et al. **Micron** 1995;26(4):347–62 (110 ref.)
Scanning force microscopy of chromatin. Fritzsche W, et al. **Scanning Microsc** 1995 Sep;9(3):729–37; discussion 738–9 (66 ref.)
Atomic force microscopy of nucleoprotein complexes. Lyubchenko YL, et al. **Scanning Microsc** 1995 Sep; 9(3):705–24; discussion 724–7 (118 ref.)

METHODS

Visualizing life on biomembranes by atomic force microscopy. Oberleithner H, et al. **Kidney Int** 1995 Oct; 48(4):923–9 (27 ref.)
Progress in high resolution atomic force microscopy in biology. Shao Z, et al. **Q Rev Biophys** 1995 May; 28(2):195–251 (255 ref.)

MICROSCOPY, CONFOCAL

Confocal laser scanning microscopy: a new optical microscopic technique for applications in pathology and dermatology. Fink-Puches R, et al. **J Cutan Pathol** 1995 Jun;22(3):252–9 (27 ref.)
[Glycolipid analysis by confocal laser scanning microscopic system] Itoh K. **Nippon Rinsho** 1995 Dec;53(12):3095–101 (11 ref.) (Eng. Abstr.) **(Jpn)**
[Analysis of calcium ion concentration in cells by confocal microscopy] Hisaba K. **Nippon Seirigaku Zasshi** 1996; 58(3):115–24 (10 ref.) **(Jpn)**

INSTRUMENTATION

[Instruments used for measurement of intracellular calcium ions] Miyakawa A. **Nippon Seirigaku Zasshi** 1995; 57(10):401–17 (18 ref.) **(Jpn)**

METHODS

Confocal epipolarization microscopy of gold probes in plant cells and protoplasts. Griffing LR, et al. **Methods Cell Biol** 1995;49:109–21 (40 ref.)

MICROSCOPY, CONFOCAL, LASER SCANNING see **MICROSCOPY, CONFOCAL**

MICROSCOPY, ELECTRON

Canalicular cholestasis due to amiodarone toxicity. A definite diagnosis obtained by electron microscopy. Macarri G, et al. **Ital J Gastroenterol** 1995 Oct-Nov;27(8):436–8 (18 ref.)
Advances in computational image processing for microscopy. Carragher B, et al. **J Struct Biol** 1996 Jan-Feb;116(1):2–8 (35 ref.)
MRC image processing programs. Crowther RA, et al. **J Struct Biol** 1996 Jan-Feb;116(1):9–16 (31 ref.)
The micrograph data processing program. Smith PR, et al. **J Struct Biol** 1996 Jan-Feb;116(1):35–40 (28 ref.)
A new generation of the IMAGIC image processing system. van Heel M, et al. **J Struct Biol** 1996 Jan-Feb;116(1):17–24 (58 ref.)
Gap junctions revealed by freeze-fracture electron microscopy. Shivers RR, et al. **Microsc Res Tech** 1995 Aug 1;31(5):437–45 (44 ref.)
Electron microscopy--tool to diagnostic pathology. Horváth M. **Vet Med (Praha)** 1996 Jun;41(6):191–5 (40 ref.)

METHODS

Practical aspects of electron microscopy in cheese research. Kaláb M. **Adv Exp Med Biol** 1995;367:247–76 (136 ref.)
Electron microscopy as a tool to diagnose neuropathies. Vallat JM. **Baillieres Clin Neurol** 1996 Mar;5(1):143–56 (8 ref.)
Recent advances in molecular histochemical techniques: in situ hybridization and southwestern histochemistry. Koji T, et al. **J Electron Microsc (Tokyo)** 1996 Apr;45(2):119–27 (71 ref.)
Electron microscopy and three-dimensional image reconstruction. Hall DH. **Methods Cell Biol** 1995; 48:395–436 (49 ref.)

MICROSCOPY, ELECTRON, SCANNING

Scanning electron microscopy of bone: instrument, specimen, and issues. Boyde A, et al. **Microsc Res Tech** 1996 Feb 1;33(2):92–120 (131 ref.)
Bone surface morphology reflects local skeletal metabolism. Marks SC Jr, et al. **Microsc Res Tech** 1996 Feb 1; 33(2):121–7 (23 ref.)

METHODS

Microvasculature of the ocular anterior segment. Morrison JC, et al. **Microsc Res Tech** 1996 Apr 15;33(6):480–9 (18 ref.)

MICROSCOPY, ELECTRON, TRANSMISSION see **MICROSCOPY, ELECTRON**

MICROSCOPY, ELECTRON, X-RAY MICROANALYSIS see **ELECTRON PROBE MICROANALYSIS**

MICROSCOPY, FLUORESCENCE

INSTRUMENTATION

[Comparative genomic hybridization in pathology. A new molecular cytogenetic method] Störkel S, et al. **Pathologe** 1996 May;17(3):189–94 (19 ref.) (Eng. Abstr.) **(Ger)**
[Instruments used for measurement of intracellular calcium ions] Miyakawa A. **Nippon Seirigaku Zasshi** 1995; 57(10):401–17 (18 ref.) **(Jpn)**

METHODS

Immunofluorescence microscopy. Miller DM, et al. **Methods Cell Biol** 1995;48:365–94 (75 ref.)

MICROSCOPY, IMMUNOELECTRON

METHODS

Immunolocalization and microstructure of milk proteins and fat mimetics in reduced fat cheese. Armbruster BL, et al. **Adv Exp Med Biol** 1995;367:277–94 (47 ref.)
Advances in immunoelectron microscopy. Moore PJ. **Methods Cell Biol** 1995;49:45–56 (21 ref.)

MICROSCOPY, IMMUNOFLUORESCENCE see **MICROSCOPY, FLUORESCENCE**

MICROSCOPY, SCANNING TUNNELING

see related
MICROSCOPY, ATOMIC FORCE

Scanning probe microscopy in microbiology. Firtel M, et al. **Micron** 1995;26(4):347–62 (110 ref.)

MICROSCOPY, VIDEO

Colour thresholding in video imaging. Fermin CD, et al. **J Anat** 1995 Jun;186 (Pt 3):469–81 (21 ref.)

INSTRUMENTATION

NeoPath, Inc. NeoPath AutoPap 300 Automatic Pap Screener System. Patten SF Jr, et al. **Acta Cytol** 1996 Jan-Feb;40(1):45–52 (12 ref.)

MICROSOMES

DRUG EFFECTS

Effects of mefloquine on Ca2+ uptake by crude microsomes of rabbit skeletal muscle. Go ML, et al. **Arch Int Pharmacodyn Ther** 1995 Mar-Apr;329(2):255–71 (29 ref.)

ENZYMOLOGY

The mechanism of microsomal azoreduction: predictions based on electronic aspects of structure-activity relationships. Zbaida S. **Drug Metab Rev** 1995; 27(3):497–516 (112 ref.)

IMMUNOLOGY

[Microsomal antibodies] Kobayashi I. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:414–7 (10 ref.) **(Jpn)**

MICROSOMES, LIVER

ENZYMOLOGY

Microsomal carnitine acyltransferases. Broadway NM, et al. **Biochem Soc Trans** 1995 Aug;23(3):490–4 (49 ref.)
NADPH-P-450 reductase: structural and functional comparisons of the eukaryotic and prokaryotic isoforms. Sevrioukova IF, et al. **Biochimie** 1995;77(7–8):562–72 (59 ref.)
11 beta-Hydroxysteroid dehydrogenase: implications for clinical medicine. Stewart PM. **Clin Endocrinol (Oxf)** 1996 May;44(5):493–9 (55 ref.)

METABOLISM

Optimization of the Salmonella/mammalian microsome assay for urine mutagenesis by experimental designs. De Méo M, et al. **Mutat Res** 1996 Jun;340(2–3):51–65 (50 ref.)

MICROSPHERES

see related
ENZYMES, IMMOBILIZED

Biodegradable microspheres in drug delivery. Okada H, et al. **Crit Rev Ther Drug Carrier Syst** 1995;12(1):1–99 (475 ref.)
Polymer microspheres for vaccine delivery. Hanes J, et al. **Pharm Biotechnol** 1995;6:389–412 (76 ref.)
Nanoparticles as adjuvants for vaccines. Kreuter J. **Pharm Biotechnol** 1995;6:463–72 (32 ref.)

MICROSPORA INFECTIONS

[Update on microsporidiosis in humans] Atías A. **Rev Med Chil** 1995 Jun;123(6):762–72 (40 ref.) (Eng. Abstr.) **(Spa)**

PARASITOLOGY

Multiorgan microsporidiosis: report of five cases and review. Gunnarsson G, et al. **Clin Infect Dis** 1995 Jul;21(1):37–44 (46 ref.)
[Microsporidia--biology and clinical relevance] Franzen C, et al. **Med Klin** 1996 May 15;91(5):284–94 (106 ref.) **(Ger)**
[Microsporidia: an animal parasite of growing interest in human pathology] Gutiérrez J, et al. **Enferm Infecc Microbiol Clin** 1995 Aug-Sep;13(7):419–21 (15 ref.) **(Spa)**

PREVENTION & CONTROL

Microsporidiosis as an AIDS-related opportunistic infection. Bryan RT. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S62–5 (57 ref.)

MICROSPORIDA

Pathology of microsporidiosis: emerging parasitic infections in patients with acquired immunodeficiency syndrome. Schwartz DA, et al. **Arch Pathol Lab Med** 1996 Feb; 120(2):173–88 (72 ref.)
Microsporidiosis as an AIDS-related opportunistic infection. Bryan RT. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S62–5 (57 ref.)

MICROSPORIDA

Microsporidium in AIDS patients: a perspective. Chukwuma C Sr. **East Afr Med J** 1996 Jan;73(1):72–5 (35 ref.)
Human microsporidioses and AIDS: recent advances. Desportes-Livage I. **Parasite** 1996 Jun;3(2):107–13 (12 ref.)
[Microsporidia: an animal parasite of growing interest in human pathology] Gutiérrez J, et al.
Enferm Infecc Microbiol Clin 1995 Aug–Sep;13(7):419–21 (15 ref.) **(Spa)**
[Update on microsporidiosis in humans] Atías A.
Rev Med Chil 1995 Jun;123(6):762–72 (40 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

[Microsporidia—biology and clinical relevance] Franzen C, et al. **Med Klin** 1996 May 15;91(5):284–94 (106 ref.) **(Ger)**

MICROSURGERY

Culture and microsurgical manipulation of the early avian embryo. Selleck MA. **Methods Cell Biol** 1996;51:1–21 (55 ref.)
Gamete microsurgery for assisted fertilization. Sparks AE. **Microsurgery** 1995;16(5):345–8 (25 ref.)
Microsurgical anatomy of the posterior choroidal arteries. Vinas FC, et al. **Neurol Res** 1995 Oct;17(5):334–44 (34 ref.)
Recurrence of hemifacial spasm after microvascular decompression. Payner TD, et al. **Neurosurgery** 1996 Apr; 38(4):686–90; discussion 690–1 (28 ref.)
[Progresses in microsurgery in China, 1995] Zhu S.
Chung Hua I Hsueh Tsa Chih 1995 Dec;75(12):740–2 (0 ref.) **(Chi)**
[Microsurgery of the macula lutea] Chauvaud D.
Bull Acad Natl Med 1996 Mar;180(3):625–32 (14 ref.) (Eng. Abstr.) **(Fre)**
[The modern aspects of the microsurgical anatomy of the pancreas] Zheleznov LM. **Morfologiia** 1995;108(2):76–80 (79 ref.) **(Rus)**

ADVERSE EFFECTS

Complications of free flap donor sites. Mahoney J.
Microsurgery 1995;16(7):437–44 (78 ref.)
[Complications of endonasal microsurgery] Stoll D, et al.
Rev Laryngol Otol Rhinol (Bord) 1995;116(3):191–4 (23 ref.) (Eng. Abstr.) **(Fre)**

INSTRUMENTATION

Anterior decompressive microsurgery and osteosynthesis for the treatment of multi-segmental cervical spondylosis. Pathophysiological considerations, surgical indication, results and complications: a survey. Seifert V.
Acta Neurochir (Wien) 1995;135(3–4):105–21 (108 ref.)
[Pro and contra: pelviscopy and microsurgery of the fallopian tube] Semm K. **Arch Gynecol Obstet** 1995;257(1–4):302–10 (14 ref.) **(Ger)**

METHODS

Microsurgical reconstruction of sensory skin. Brunelli GA, et al. **Ann Acad Med Singapore** 1995 Jul;24(4 Suppl):108–12 (14 ref.)
The role of microsurgery and free tissue transfer in the reconstruction of the paediatric upper extremity. Kay S, et al. **Ann Acad Med Singapore** 1995 Jul;24(4 Suppl):113–23 (50 ref.)
Microsurgery for cranial base tumors. Thomson JG, et al. **Clin Plast Surg** 1995 Jul;22(3):563–72 (74 ref.)
Local surgical treatment of rectal cancer. Buess GF.
Eur J Cancer 1995 Jul–Aug;31A(7–8):1233–7 (20 ref.)
Microscopic vasovasostomy: current practice and future trends. Donovan JF Jr. **Microsurgery** 1995;16(5):325–32 (63 ref.)
Nerve wound healing. An overview. Wong BJ, et al.
Otolaryngol Clin North Am 1995 Oct;28(5):881–95 (130 ref.)
[Antebrachial free flap with radial pedicle. II. Surgical technique] Iriarte Ortabe JI, et al. **Acta Stomatol Belg** 1995 Sep;92(3):105–23 (195 ref.) (Eng. Abstr.) **(Fre)**
[The role of microsurgery in the reconstruction of loss of substance of soft tissue in the maxillofacial region] Iriarte Ortabe JI, et al. **Acta Stomatol Belg** 1995 Mar;92(1):17–29 (142 ref.) (Eng. Abstr.) **(Fre)**
[Hypospadias—results of correction] Beintker M.
Urologe A 1996 Mar;35(2):104–10 (31 ref.) (Eng. Abstr.) **(Ger)**

MICROSURGERY, LASER see **LASER SURGERY**

MICROSURGICAL REVASCULARIZATION, CEREBRAL see **CEREBRAL REVASCULARIZATION**

MICROTINAE

PHYSIOLOGY

Sexually dimorphic spatial learning in meadow voles Microtus pennsylvanicus and deer mice Peromyscus maniculatus. Galea LA, et al. **J Exp Biol** 1996 Jan;199 (Pt 1):195–200 (29 ref.)

MICROTINES see **MICROTINAE**

MICROTOMY

3D reconstruction and quantitation of pathological tissues. Whimster WF, et al. **Pathologica** 1995 Jun;87(3):279–85 (40 ref.)

METHODS

Precision-cut tissue slices: applications in pharmacology and toxicology. Parrish AR, et al. **Life Sci** 1995;57(21):1887–901 (151 ref.)

MICROTRABECULAR LATTICE see **CYTOSKELETON**

MICROTUBULE-ASSOCIATED PROTEIN KINASES see **CALMODULIN-DEPENDENT PROTEIN KINASES**

MICROTUBULE-ASSOCIATED PROTEINS

GENETICS

Identification of a new exon of the brain microtubule-associated protein 2. Guilleminot J, et al.
C R Acad Sci III 1995 Sep;318(9):959–64 (21 ref.)

PHYSIOLOGY

Role of microtubule-associated proteins in the control of microtubule assembly. Maccioni RB, et al. **Physiol Rev** 1995 Oct;75(4):835–64 (348 ref.)
Going mobile: microtubule motors and chromosome segregation. Barton NR, et al.
Proc Natl Acad Sci U S A 1996 Mar 5;93(5):1735–42 (139 ref.)

ULTRASTRUCTURE

Confocal immunofluorescence microscopy of microtubules, microtubule-associated proteins, and microtubule-organizing centers during amphibian oogenesis and early development. Gard DL, et al.
Curr Top Dev Biol 1995;31:383–431 (137 ref.)

MICROTUBULE-ORGANIZING CENTER see **CENTROSOME**

MICROTUBULE PROTEINS

ANALYSIS

Flagellar assembly in two hundred and fifty easy-to-follow steps. Dutcher SK. **Trends Genet** 1995 Oct;11(10):398–404 (62 ref.)

METABOLISM

Microtubules and microtubule motors: mechanisms of regulation. Thaler CD, et al. **Int Rev Cytol** 1996; 164:269–327 (340 ref.)
Microtubule-based motor proteins: new targets for enhancing drug delivery? Hamm-Alvarez SF. **Pharm Res** 1996 Apr; 13(4):489–96 (48 ref.)
[Biosynthesis and microbial transformation of griseofulvin and carcinogenesis and prevention of cancer by estrogens] Sato Y. **Yakugaku Zasshi** 1995 Nov;115(11):892–908 (80 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Functional organization of tau proteins during neuronal differentiation and development. Maccioni RB, et al.
Braz J Med Biol Res 1995 Aug;28(8):827–41 (78 ref.)

MICROTUBULES

CHEMISTRY

On the structure of microtubules, tau, and paired helical filaments. Mandelkow E, et al. **Neurobiol Aging** 1995 May-Jun;16(3):347–54 (57 ref.)
Tau domains, phosphorylation, and interactions with microtubules. Mandelkow EM, et al. **Neurobiol Aging** 1995 May-Jun;16(3):355–62; discussion 362–3 (57 ref.)

METABOLISM

The movement of kinesin along microtubules. Howard J. **Annu Rev Physiol** 1996;58:703–29 (77 ref.)
Biochemical and functional diversity of microtubule motors in the nervous system. Brady ST, et al.
Curr Opin Neurobiol 1995 Oct;5(5):551–8 (65 ref.)
Microtubules and microtubule motors: mechanisms of regulation. Thaler CD, et al. **Int Rev Cytol** 1996; 164:269–327 (340 ref.)
Mechanisms of neuronal polarity. Cid-Arregui A, et al.
Neurobiol Aging 1995 May-Jun;16(3):239–43; discussion 243–6 (61 ref.)
[Biosynthesis and microbial transformation of griseofulvin and carcinogenesis and prevention of cancer by estrogens] Sato Y. **Yakugaku Zasshi** 1995 Nov;115(11):892–908 (80 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Morphological, biochemical, and genetic support for an apolipoprotein E effect on microtubular metabolism. Roses AD, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:146–57 (35 ref.)
Roles for microtubules and kinesin in membrane traffic between the endoplasmic reticulum and the Golgi complex. Lippincott-Schwartz J, et al. **Biochem Soc Trans** 1995 Aug; 23(3):544–8 (24 ref.)
The role of microtubules in apical and basolateral endocytosis in epithelial Madin-Darby canine kidney (MDCK) cells. Prydz K, et al. **Biochem Soc Trans** 1995 Aug;23(3):535–8 (30 ref.)
Morphogenetic properties of microtubules and mitotic spindle assembly. Hyman AA, et al. **Cell** 1996 Feb 9; 84(3):401–10 (70 ref.)
Cell-cell signaling, microtubules, and the loss of symmetry in the Drosophila oocyte. Lehmann R. **Cell** 1995 Nov 3; 83(3):353–6 (15 ref.)
Regulation of dynein-driven microtubule sliding by an axonemal kinase and phosphatase in Chlamydomonas flagella. Habermacher G, et al. **Cell Motil Cytoskeleton** 1995;32(2):106–9 (23 ref.)
Microtubule dynamics. Kinetochores get a grip. Hyman AA.
Curr Biol 1995 May 1;5(5):483–4 (15 ref.)
Force generation by microtubule assembly/disassembly in mitosis and related movements. Inoué S, et al.
Mol Biol Cell 1995 Dec;6(12):1619–40 (188 ref.)
Role of microtubule-associated proteins in the control of microtubule assembly. Maccioni RB, et al. **Physiol Rev** 1995 Oct;75(4):835–64 (348 ref.)
Going mobile: microtubule motors and chromosome segregation. Barton NR, et al.
Proc Natl Acad Sci U S A 1996 Mar 5;93(5):1735–42 (139 ref.)
Targeting of motor proteins. Vallee RB, et al. **Science** 1996 Mar 15;271(5255):1539–44 (108 ref.)

ULTRASTRUCTURE

Confocal immunofluorescence microscopy of microtubules, microtubule-associated proteins, and microtubule-organizing centers during amphibian oogenesis and early development. Gard DL, et al.
Curr Top Dev Biol 1995;31:383–431 (137 ref.)
Cytoskeleton and ctenophore development. Houliston E, et al. **Curr Top Dev Biol** 1995;31:41–63 (401 ref.)
Sea urchin microtubules. Suprenant KA, et al.
Curr Top Dev Biol 1995;31:65–99 (206 ref.)
Force generation by microtubule assembly/disassembly in mitosis and related movements. Inoué S, et al.
Mol Biol Cell 1995 Dec;6(12):1619–40 (188 ref.)
On the structure of microtubules, tau, and paired helical filaments. Mandelkow E, et al. **Neurobiol Aging** 1995 May-Jun;16(3):347–54 (57 ref.)
Role of microtubule-associated proteins in the control of microtubule assembly. Maccioni RB, et al. **Physiol Rev** 1995 Oct;75(4):835–64 (348 ref.)

MICROTUS see **MICROTINAE**

MICROVASCULAR PERMEABILITY see **CAPILLARY PERMEABILITY**

MICROVILLI

METABOLISM

Microvillus assembly. Not actin alone. Fath KR, et al.
Curr Biol 1995 Jun 1;5(6):591–3 (22 ref.)

MICROWAVES

see related
DIATHERMY

Handling of large brain specimens: the use of microwaves. A review. Marani E, et al. **Eur J Morphol** 1995 Apr; 33(2):158–64 (33 ref.)
[The mechanism of the action of electromagnetic radiation in the nano- and millimeter ranges] Bogdanov NN, et al.
Vopr Kurortol Fizioter Lech Fiz Kult 1995 Nov–Dec;(6):7–9 (28 ref.) (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Transurethral microwave thermotherapy: an evolving technology in the treatment of benign prostatic enlargement [see comments] de Wildt MJ, et al.
Br J Urol 1995 Nov;76(5):531–8 (47 ref.) Comment in: Br J Urol 1996 May;77(5):764.
[Microwave coagulation therapy of hepatocellular carcinoma] Seki T, et al. **Nippon Naika Gakkai Zasshi** 1995 Dec 10;84(12):2024–7 (5 ref.) **(Jpn)**

MICRURUS see **ELAPIDAE**

MIDAZOLAM

ADMINISTRATION & DOSAGE

Flumazenil and midazolam in anaesthesia. Whitwam JG.
Acta Anaesthesiol Scand Suppl 1995;108:15–22 (67 ref.)
The management of opioid and benzodiazepine dependence in infants, children, and adolescents. Yaster M, et al.
Pediatrics 1996 Jul;98(1):135–40 (41 ref.)

MIDBRAIN see **MESENCEPHALON**

MIDBRAIN CENTRAL GRAY see **PERIAQUEDUCTAL GRAY**

MIDDLE EAR CHOLESTEATOMA see **CHOLESTEATOMA, MIDDLE EAR**

MIDDLE EAR IMPLANT see **OSSICULAR REPLACEMENT PROSTHESIS**

MIDDLE EAR VENTILATION

ADVERSE EFFECTS

Chronic otitis media after tympanostomy tube placement caused by Mycobacterium abscessus: a new clinical entity? Franklin DJ, et al. **Am J Otol** 1994 May;15(3):313–20 (21 ref.)

Implications of middle ear hyperoxia induced by ventilation tubes in otitis media with effusion. Ovesen T. **APMIS Suppl** 1995;54:1–36 (233 ref.)

MIDDLE LOBE SYNDROME

Middle lobe syndrome. Gudmundsson G, et al. **Am Fam Physician** 1996 Jun;53(8):2547–50 (08 ref.)

MIDDLE PROMOTERS see **PROMOTER REGIONS (GENETICS)**

MIDGES, BITING see **CERATOPOGONIDAE**

MIDWIFERY

see related
HOME CHILDBIRTH
NURSE MIDWIVES

MIFEPRISTONE

Mifepristone and first trimester abortion. Murray S, et al. **Clin Obstet Gynecol** 1996 Jun;39(2):474–85 (59 ref.)

The combined use of prostaglandin and antiprogestin in human fertility control. Baulieu EE. **Eur J Obstet Gynecol Reprod Biol** 1996 Mar;65(1):115–9 (42 ref.)

Acceptability of medical abortion in early pregnancy. Winikoff B. **Fam Plann Perspect** 1995 Jul–Aug;27(4):142–8, 185 (36 ref.)

[Advances in the study of mifepristone] Wong L. **Chung Hua Fu Chan Ko Tsa Chih** 1995 Sep;30(9):565–8 (22 ref.) **(Chi)**

[Mifepristone and misoprostol in therapeutic abortions] Jannet D, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996; 25(3):277–82 (24 ref.) (Eng. Abstr.) **(Fre)**

[Induced labor by pharmacological methods. Advantages and disadvantages] Rotten D. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24 Suppl 1:13–27 (42 ref.) **(Fre)**

ADMINISTRATION & DOSAGE

Mifepristone: clinical application in general gynecology. Morales AJ, et al. **Clin Obstet Gynecol** 1996 Jun; 39(2):451–60 (33 ref.)

PHARMACOLOGY

Mifepristone and ovarian function. Curry TE Jr, et al. **Clin Obstet Gynecol** 1996 Jun;39(2):486–97 (64 ref.)

Mifepristone: a potential contraceptive. Heikinheimo O, et al. **Clin Obstet Gynecol** 1996 Jun;39(2):461–8 (20 ref.)

Clinical applications of the antiprogestins. Kettel LM. **Clin Obstet Gynecol** 1995 Dec;38(4):921–34 (56 ref.)

Mifepristone: clinical pharmacology. Robbins A, et al. **Clin Obstet Gynecol** 1996 Jun;39(2):436–50 (21 ref.)

THERAPEUTIC USE

Mifepristone: treatment of Cushing's syndrome. Sartor O, et al. **Clin Obstet Gynecol** 1996 Jun;39(2):506–10 (12 ref.)

Mifepristone: antineoplastic studies. Sartor O, et al. **Clin Obstet Gynecol** 1996 Jun;39(2):498–505 (28 ref.)

[Multiple usages for antiprogestins] Heikinheimo O. **Duodecim** 1994;110(10):1001–8 (39 ref.) **(Fin)**

[Endocrine treatment of meningiomas: a review] da Motta LA, et al. **Arq Neuropsiquiatr** 1995 Jun;53(2):324–32 (45 ref.) (Eng. Abstr.) **(Por)**

MIGRAINE

Diagnosis and management of migraine. Goadsby PJ, et al. **BMJ** 1996 May 18;312(7041):1279–83 (20 ref.)

Migraine: definitions, mechanisms, and treatment. Noack H, et al. **South Med J** 1996 Aug;89(8):762–9 (78 ref.)

BLOOD

[Current views on pathophysiology of migraine. Part III: Biochemical hypothesis. The role of blood platelets] Prusiński A, et al. **Neurol Neurochir Pol** 1995 Nov–Dec; 29(6):867–76 (26 ref.) (Eng. Abstr.) **(Pol)**

COMPLICATIONS

Migraine and other causes of headache. Spence J. **Ann Emerg Med** 1996 Apr;27(4):448–50 (25 ref.)

Ophthalmoplegic migraine. Troost BT. **Biomed Pharmacother** 1996;50(2):49–51 (24 ref.)

Migraine and angina pectoris by coronary artery spasm. Lafitte C, et al. **Headache** 1996 May;36(5):332–4 (14 ref.)

Abdominal migraine as a cause of vomiting in children: a clinician's view. Bentley D, et al. **J Pediatr Gastroenterol Nutr** 1995;21 Suppl 1:S49–51 (15 ref.)

The relationship between cyclic vomiting syndrome and abdominal migraine. Symon DN, et al. **J Pediatr Gastroenterol Nutr** 1995;21 Suppl 1:S42–3 (18 ref.)

[Migraine and cerebrovascular accidents] Nater B. **Rev Med Suisse Romande** 1996 Aug;116(8):587–9 (14 ref.) **(Fre)**

[Migraine and epilepsy] Hernández Gallego J. **Rev Neurol** 1995;23 Suppl 2:S240–2 (27 ref.) **(Spa)**

[Prevention of migrainous infarction] Leira R. **Rev Neurol** 1995;23 Suppl 2:S219–25 (109 ref.) **(Spa)**

DIAGNOSIS

Migraine impact and functional disability. Lipton RB, et al. **Cephalalgia** 1995 Oct;15 Suppl 15:4–9 (33 ref.)

Symptomatology and pathogenesis of migraine. Spierings EL. **J Pediatr Gastroenterol Nutr** 1995;21 Suppl 1:S37–41 (13 ref.)

[Diagnosis and treatment of headache in childhood] Hämäläinen M, et al. **Duodecim** 1994;110(11):1096–101 (10 ref.) **(Fin)**

[The clinical picture of migraine] Noya M, et al. **Rev Clin Esp** 1995 Sep;195(2 Spec No):20–3 (40 ref.) **(Spa)**

DRUG THERAPY

Behavioral management of migraine. Andrasik F. **Biomed Pharmacother** 1996;50(2):52–7 (69 ref.)

Recent developments in tachykinin NK1 receptor antagonists: prospects for the treatment of migraine headache. Beattie DT, et al. **Can J Physiol Pharmacol** 1995 Jul;73(7):871–7 (53 ref.)

Analgesics and NSAIDs in the treatment of the acute migraine attack. Pfaffenrath V, et al. **Cephalalgia** 1995 Oct; 15 Suppl 15:14–20 (53 ref.)

Early-phase clinical trials in migraine: efficacy, safety and dose-finding. Pilgrim AJ. **Cephalalgia** 1995 Oct;15 Suppl 15:10–3 (13 ref.)

Prophylactic treatment of migraine: evaluation of clinical trials and choice among drugs. Tfelt-Hansen P. **Cephalalgia** 1995 Oct;15 Suppl 15:29–32 (15 ref.)

Migraine and cluster headache—their management with sumatriptan: a critical review of the current clinical experience. Wilkinson M, et al. **Cephalalgia** 1995 Oct; 15(5):337–57 (166 ref.)

Acute treatment of migraine attacks. Ferrari MD, et al. **Curr Opin Neurol** 1995 Jun;8(3):237–42 (34 ref.)

Transnasal butorphanol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute pain management. Gillis JC, et al. **Drugs** 1995 Jul; 50(1):157–75 (47 ref.)

Approach to the patient with migraine. Raskin NH, et al. **Hosp Pract (Off Ed)** 1996 Feb 15;31(2):93–6, 101–4 (14 ref.)

Pharmacologic treatment of recurrent pediatric headache. Graf WD, et al. **Pediatr Ann** 1995 Sep;24(9):477–84 (27 ref.)

Treatment of migraine during pregnancy and lactation. Miles CB. **S D J Med** 1995 Nov;48(11):373–7 (24 ref.)

[Understanding the treatment of migraine] De Léan J. **Union Med Can** 1995 Nov;124(3):40–8 (5 ref.) **(Fre)**

[Migraine: dihydroergotamine nasal spray—an alternative] Beubler E. **Wien Med Wochenschr** 1995;145(14):326–31 (18 ref.) (Eng. Abstr.) **(Ger)**

[Drug treatment of migraine attacks. Pharmacological considerations] Salvesen R. **Tidsskr Nor Laegeforen** 1996 Aug 10;116(18):2176–9 (41 ref.) (Eng. Abstr.) **(Nor)**

[The treatment of migraine] Badalian LO, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995;95(4):87–93 (54 ref.) **(Rus)**

[Migraine: the therapeutic approach] Diez Tejedor E, et al. **Rev Clin Esp** 1995 Sep;195(2 Spec No):24–30 (42 ref.) **(Spa)**

[Pharmacological treatment of migraine: other treatments] Gómez Aranda F, et al. **Rev Neurol** 1995;23 Suppl 2:S198–200 (43 ref.) **(Spa)**

[Analgesics and non-steroidal anti-inflammatory agents in the treatment of migraine] Iglesias F, et al. **Rev Neurol** 1995;23 Suppl 2:S157–61 (20 ref.) **(Spa)**

[Sumatriptan ++ in the treatment of migraine and cluster headache] Láinez JM, et al. **Rev Neurol** 1995;23 Suppl 2:S166–78 (127 ref.) **(Spa)**

[Calcium antagonists in the prophylaxis of migraine] Lara M, et al. **Rev Neurol** 1995;23 Suppl 2:S179–84 (32 ref.) **(Spa)**

[Antidepressants and migraine] Legarda I. **Rev Neurol** 1995; 23 Suppl 2:S193–7 (47 ref.) **(Spa)**

[Prophylaxis of migraine] Liaño H. **Rev Neurol** 1995;23 Suppl 2:S212–8 (21 ref.) **(Spa)**

[Therapeutic strategies in mixed or combined headache] Morales F. **Rev Neurol** 1995;23 Suppl 2:S238–9 (7 ref.) **(Spa)**

[Treatment of the acute migraine attack] Titus F. **Rev Neurol** 1995;23 Suppl 2:S203–7 (49 ref.) **(Spa)**

EPIDEMIOLOGY

Epidemiology of migraine. Rasmussen BK. **Biomed Pharmacother** 1995;49(10):452–5 (42 ref.)

Headache epidemiology. Emphasis on migraine. Silberstein SD, et al. **Neurol Clin** 1996 May;14(2):421–34 (75 ref.)

[Epidemiology of migraine] Galiano L, et al. **Rev Neurol** 1995 Jul–Aug;23(122):819–25 (59 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

Headache as a symptom of organic diseases. Edmeads JG. **Curr Opin Neurol** 1995 Jun;8(3):233–6 (32 ref.)

Symptomatology and pathogenesis of migraine. Spierings EL. **J Pediatr Gastroenterol Nutr** 1995;21 Suppl 1:S37–41 (13 ref.)

Behavioral treatment of pediatric headache. McGrath PJ, et al. **Pediatr Ann** 1995 Sep;24(9):486–91 (22 ref.)

Psychosocial factors in recurrent pediatric headache. Martin SE, et al. **Pediatr Ann** 1995 Sep;24(9):464–74 (23 ref.)

[Migraine and mitochondrial dysfunction] Lantéri-Minet M, et al. **Rev Neurol (Paris)** 1996 Apr;152(4):234–8 (55 ref.) (Eng. Abstr.) **(Fre)**

[Current views on pathophysiology of migraine. Part IV: autonomic disturbances. Central neural hypothesis. Conclusions] Prusiński A. **Neurol Neurochir Pol** 1995 Nov–Dec;29(6):877–88 (20 ref.) (Eng. Abstr.) **(Pol)**

[Current views on pathophysiology of migraine. Part II: Further development and current status of the vascular theory. Migraine and allergy] Prusiński A, et al. **Neurol Neurochir Pol** 1995 Nov–Dec;29(6):857–66 (28 ref.) (Eng. Abstr.) **(Pol)**

[Stress as a precipitating factor in migraine] Galiano L, et al. **Rev Neurol** 1995 Jul–Aug;23(122):830–2 (10 ref.) (Eng. Abstr.) **(Spa)**

[Diet and migraine] Leira R, et al. **Rev Neurol** 1996 May; 24(129):534–8 (46 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

[Current views on pathophysiology of migraine: Part I. Genetics of migraine. Genesis of the vascular theory] Prusiński A. **Neurol Neurochir Pol** 1995 Nov–Dec; 29(6):845–55 (27 ref.) (Eng. Abstr.) **(Pol)**

[Genetics of migraine] Pardo J, et al. **Rev Neurol** 1995 Jul–Aug;23(122):795–9 (57 ref.) **(Spa)**

IMMUNOLOGY

Immunological aspects of migraine. Pradalier A, et al. **Biomed Pharmacother** 1996;50(2):64–70 (52 ref.)

METABOLISM

Interrelationships of neurochemicals, estrogen, and recurring headache. Marcus DA. **Pain** 1995 Aug;62(2):129–39 (136 ref.)

PHYSIOPATHOLOGY

Deficient habituation of evoked cortical potentials in migraine: a link between brain biology, behavior and trigeminovascular activation? Schoenen J. **Biomed Pharmacother** 1996;50(2):71–8 (78 ref.)

Changes of neuroendocrine axes in patients with menstrual migraine. Fioroni L, et al. **Cephalalgia** 1995;15(4):297–300 (25 ref.)

The autonomic nervous system and the regulation of arterial tone in migraine. Thomsen LL, et al. **Clin Auton Res** 1995 Oct;5(5):243–50 (111 ref.)

Mitochondria, magnesium and migraine. Welch KM, et al. **J Neurol Sci** 1995 Dec;134(1–2):9–14 (62 ref.)

Migraine aura and prodrome. Silberstein SD, et al. **Semin Neurol** 1995 Jun;15(2):175–82 (55 ref.)

[Current views on pathophysiology of migraine. Part II: Further development and current status of the vascular theory. Migraine and allergy] Prusiński A, et al. **Neurol Neurochir Pol** 1995 Nov–Dec;29(6):857–66 (28 ref.) (Eng. Abstr.) **(Pol)**

[Current views on pathophysiology of migraine. Part IV: autonomic disturbances. Central neural hypothesis. Conclusions] Prusiński A. **Neurol Neurochir Pol** 1995 Nov–Dec;29(6):877–88 (20 ref.) (Eng. Abstr.) **(Pol)**

[The physiopathology of migraine] Leira R, et al. **Rev Clin Esp** 1995 Sep;195(2 Spec No):16–9 (58 ref.) **(Spa)**

[Status migrainosus] Alberca R, et al. **Rev Neurol** 1995;23 Suppl 2:S208–11 (13 ref.) **(Spa)**

[Quality of life and migraine] Asensio M, et al. **Rev Neurol** 1996 Aug;24(132):926–9 (26 ref.) (Eng. Abstr.) **(Spa)**

[Factors brought on by migraine] Galiano L, et al. **Rev Neurol** 1995 Jul–Aug;23(122):826–9 (38 ref.) (Eng. Abstr.) **(Spa)**

[Basic mechanisms of the migraine physiopathology] Martínez F, et al. **Rev Neurol** 1995 Jul–Aug;23(122):800–18 (205 ref.) **(Spa)**

[Migraine in childhood] Mederer S. **Rev Neurol** 1995;23 Suppl 2:S232–7 (55 ref.) **(Spa)**

[Therapeutic strategies in menstrual migraine] Targa C, et al. **Rev Neurol** 1995;23 Suppl 2:S226–31 (63 ref.) **(Spa)**

MIGRAINE

PREVENTION & CONTROL

Medications used to prevent migraine headaches and their potential ocular adverse effects. Doughty MJ, et al. **Optom Vis Sci** 1995 Dec;72(12):879–91 (176 ref.)
[Prevention of migrainous infarction] Leira R. **Rev Neurol** 1995;23 Suppl 2:S219–25 (109 ref.) **(Spa)**
[Prophylaxis of migraine] Liaño H. **Rev Neurol** 1995;23 Suppl 2:S212–8 (21 ref.) **(Spa)**

PSYCHOLOGY

Psychological treatments for migraine. Reid GJ, et al. **Biomed Pharmacother** 1996;50(2):58–63 (55 ref.)
Migraine: association with personality characteristics and psychopathology. Silberstein SD, et al. **Cephalalgia** 1995 Oct;15(5):358–69; discussion 336 (64 ref.)
Association between psychopathology and headache syndromes. Merikangas KR. **Curr Opin Neurol** 1995 Jun; 8(3):248–51 (19 ref.)

THERAPY

Psychological treatments for migraine. Reid GJ, et al. **Biomed Pharmacother** 1996;50(2):58–63 (55 ref.)
The management of migraine and cluster headaches. Diamond S. **Compr Ther** 1995 Sep;21(9):492–8 (27 ref.)
Treatment of cluster headache and its variants. Stovner LJ, et al. **Curr Opin Neurol** 1995 Jun;8(3):243–7 (44 ref.)
Behavioral treatment of pediatric headache. McGrath PJ, et al. **Pediatr Ann** 1995 Sep;24(9):486–91 (22 ref.)
[Value of acupuncture in treatment of migraine] Chrubasik S, et al. **Anaesthesiol Reanim** 1995;20(6):150–2 (25 ref.) (Eng. Abstr.) **(Ger)**

MIGRATING MOTOR COMPLEX see **MYOELECTRIC COMPLEX, MIGRATING**

MIGRATION, CELL see **CELL MOVEMENT**

MIKAMYCIN see **VIRGINIAMYCIN**

MILITARY MEDICINE

Review of modified hemoglobin research at Letterman: attempts to delineate the toxicity of cell-free tetrameric hemoglobin. Hess JR.
Artif Cells Blood Substit Immobil Biotechnol 1995; 23(3):277–89 (30 ref.)
Environmental health issues in prisoner of war camps. Korte DV, et al. **Mil Med** 1995 Oct;160(10):483–6 (24 ref.)

ECONOMICS

Defence Costs Study 15 [editorial] Macmillan AH.
J R Army Med Corps 1996 Feb;142(1):3–8 (10 ref.)

METHODS

[Methods for DNA diagnosis in military medicine] Belokhvostov AS. **Voen Med Zh** 1995 Sep;(9):39–44, 80 (24 ref.) (Eng. Abstr.) **(Rus)**

ORGANIZATION & ADMINISTRATION

Increased flight surgeon role in military aeromedical evacuation. Lyons TJ, et al. **Aviat Space Environ Med** 1995 Oct;66(10):927–9 (16 ref.)
Operational medicine in disasters. Yeskey KS, et al.
Emerg Med Clin North Am 1996 May;14(2):429–38 (24 ref.)

MILITARY PERSONNEL

see related
VETERANS

The Army Medical Museum/Armed Forces Institute of Pathology and Emerging Infections: from camp fevers and diarrhea during the American Civil War in the 1860's to global molecular epidemiology and pathology in the 1990s. Nelson AM, et al. **Arch Pathol Lab Med** 1996 Feb; 120(2):129–33 (21 ref.)
Injuries due to antipersonnel land mines in Sri Lanka. Goonetilleke G. **Ceylon Med J** 1995 Dec;40(4):141–5 (8 ref.)
The impact of infectious diseases on the health of U.S. troops deployed to the Persian Gulf during operations Desert Shield and Desert Storm. Hyams KC, et al.
Clin Infect Dis 1995 Jun;20(6):1497–504 (69 ref.)
Heat illness—a review of military experience (Part 2). Bricknell MC. **J R Army Med Corps** 1996 Feb;142(1):34–42 (31 ref.)
Metastatic squamous cell carcinoma of the hand and review of the literature. Foley SJ, et al. **J R Army Med Corps** 1995 Jun;141(2):102–4 (8 ref.)
Noise induced hearing loss in military helicopter aircrew—a review of the evidence. Owen JP.
J R Army Med Corps 1995 Jun;141(2):98–101 (19 ref.)
Hantaviruses are likely threat to NATO forces in Bosnia and Herzegovina and Croatia. Markotić A, et al. **Nat Med** 1996 Mar;2(3):269–70 (18 ref.)
Medical care of women deployed during Desert Storm. Lyon DS. **South Med J** 1996 Feb;89(2):172–6 (6 ref.)
[Stress fractures in athletes and military recruits. An overview] Orava S, et al. **Orthopade** 1995 Sep;24(5):457–66 (51 ref.) (Eng. Abstr.) **(Ger)**
[Bilateral coronary fistula: a case report and review] Vanselow B, et al. **Z Kardiol** 1996 Mar;85(3):214–20 (45 ref.) (Eng. Abstr.) **(Ger)**
[Acute viral hepatitides] Khazanov AI. **Voen Med Zh** 1996 Feb;317(2):45–50, 79 (23 ref.) (Eng. Abstr.) **(Rus)**
[The importance of the human factor in the medical support for flight safety] Lapa VV, et al. **Voen Med Zh** 1996 Apr; 317(4):41–4, 79 (16 ref.) (Eng. Abstr.) **(Rus)**
[The problem of cytomegalovirus infection in military blood transfusions] Shevchenko IuL, et al. **Voen Med Zh** 1995 Nov;(11):27–31, 80 (18 ref.) (Eng. Abstr.) **(Rus)**

HISTORY

Heat illness—a review of military experience (Part 1). Bricknell MC. **J R Army Med Corps** 1995 Oct; 141(3):157–66 (47 ref.)

PSYCHOLOGY

Military shoplifting. Lande G. **Mil Med** 1995 Aug; 160(8):404–7 (28 ref.)
[Stress-protective role of the opioidergic system under conditions of military operations] Shanin VIu.
Fiziol Cheloveka 1996 Mar–Apr;22(2):43–6 (11 ref.) **(Rus)**
[The addictive behavior of servicemen under combat conditions] Litvintsev SV, et al. **Voen Med Zh** 1995 Nov; (11):39–43, 80 (29 ref.) (Eng. Abstr.) **(Rus)**

MILITARY SCIENCE

Program development in military toxicology laboratories. Mattie DR, et al. **Toxicol Lett** 1995 Sep;79(1–3):291–5 (1 ref.)

MILK

see related
LACTATION

Chemical species in cheese and their origin in milk components. Hill AR. **Adv Exp Med Biol** 1995;367:43–58 (75 ref.)
Contribution of lactic acid bacteria to cheese ripening. Steele JL. **Adv Exp Med Biol** 1995;367:209–20 (43 ref.)
Should we use milk fluoridation? A review. Mariño R.
Bull Pan Am Health Organ 1995 Dec;29(4):287–98 (71 ref.)
Early infant diets and insulin-dependent diabetes. Ellis TM, et al. **Lancet** 1996 May 25;347(9013):1464–5 (20 ref.)
The production of pharmaceutical proteins from the milk of transgenic animals. Houdebine LM. **Reprod Nutr Dev** 1995;35(6):609–17 (64 ref.)
[Biomedical aspects of the use of milk whey in nutrition (review)] Lind AR, et al. **Vopr Pitan** 1995;(6):29–33 (45 ref.) (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

The relationship between cow's milk exposure and type 1 diabetes. Gerstein HC, et al. **Diabet Med** 1996 Jan; 13(1):23–9 (89 ref.)
Milk and type I diabetes. Scott FW, et al. **Diabetes Care** 1996 Apr;19(4):379–83 (51 ref.)

CHEMISTRY

Whey proteins in cheese—an overview. Lelièvre J.
Adv Exp Med Biol 1995;367:359–65 (34 ref.)
The epithelial mucin, MUC1, of milk, mammary gland and other tissues. Patton S, et al. **Biochim Biophys Acta** 1995 Dec 20;1241(3):407–23 (127 ref.)
Antibacterial and immunostimulating casein-derived substances from milk: casecidin, isracidin peptides. Lahov E, et al. **Food Chem Toxicol** 1996 Jan;34(1):131–45 (49 ref.)
Novel products and new technologies for use of a familiar carbohydrate, milk lactose. Yang ST, et al. **J Dairy Sci** 1995 Nov;78(11):2541–62 (128 ref.)

ENZYMOLOGY

Contribution of milk-clotting enzymes and plasmin to cheese ripening. Farkye NY. **Adv Exp Med Biol** 1995;367:195–207 (64 ref.)

METABOLISM

Strategies for production of pharmaceutical proteins in milk. Wilmut I, et al. **Reprod Fertil Dev** 1994;6(5):625–30 (51 ref.)

STANDARDS

Disinfection in the dairy parlour. Saran A. **Rev Sci Tech** 1995 Mar;14(1):207–24 (31 ref.)

MILK-ALKALI SYNDROME see **HYPERCALCEMIA**

MILK EJECTION

PHYSIOLOGY

Influence of reproductive state and ovarian steroids on facilitation of the milk-ejection reflex by central oxytocin. Wakerley JB, et al. **Adv Exp Med Biol** 1995;395:117–32 (56 ref.)

MILK FACTOR see **MAMMARY TUMOR VIRUSES, MOUSE**

MILK, HUMAN

see related
BREAST FEEDING
LACTATION

Early infant diets and insulin-dependent diabetes. Ellis TM, et al. **Lancet** 1996 May 25;347(9013):1464–5 (20 ref.)

CHEMISTRY

Recombinant human milk proteins - an opportunity and a challenge. Lönnerdal B. **Am J Clin Nutr** 1996 Apr; 63(4):622S–6S (63 ref.)
Pollutants in breast milk. Rogan WJ.
Arch Pediatr Adolesc Med 1996 Sep;150(9):981–90 (102 ref.)
Breast-milk vitamin A as an indicator of the vitamin A status of women and infants. Stoltzfus RJ, et al.
Bull World Health Organ 1995;73(5):703–11 (44 ref.)
Chemical contaminants in human milk: an overview. Sonawane BR. **Environ Health Perspect** 1995 Sep;103 Suppl 6:197–205 (80 ref.)
[Structural and functional aspects of oligosaccharides in human milk] Kunz C, et al. **Z Ernahrungswiss** 1996 Mar; 35(1):22–31 (51 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

What is the role of preterm breast milk supplementation in the host defenses of preterm infants? Science vs. fiction. Groër M, et al. **Adv Pediatr** 1996;43:335–58 (99 ref.)
Human milk and intestinal host defense in newborns: an update. Xanthou M, et al. **Adv Pediatr** 1995;42:171–208 (169 ref.)
The immunologic significance of breast milk. Orlando S.
J Obstet Gynecol Neonatal Nurs 1995 Sep;24(7):678–83 (30 ref.)

METABOLISM

Selenium in human lactation. Sanz Alaejos M, et al.
Nutr Rev 1995 Jun;53(6):159–66 (101 ref.)

PHYSIOLOGY

Human milk and premature infants. Martinez FE, et al.
World Rev Nutr Diet 1995;78:55–73 (93 ref.)

MILK HYPERSENSITIVITY

see related
LACTOSE INTOLERANCE

The cow milk allergy complex: overlapping disease profiles in infancy. Hill DJ, et al. **Eur J Clin Nutr** 1995 Sep;49 Suppl 1:S1–12 (38 ref.)

COMPLICATIONS

[Type I hypersensitivity reactions and etiopathogenesis of hemorrhagic rectocolitis] Leprince E, et al. **Presse Med** 1995 Dec 16–23;24(39):1902–6 (58 ref.) (Eng. Abstr.) **(Fre)**
[Methemoglobinemia, acidemia and diarrhea induced by hypersensitivity to cow's milk proteins] Catalán Muñoz M, et al. **An Esp Pediatr** 1996 Mar;44(3):295–6 (6 ref.) **(Spa)**

DIET THERAPY

Which formula in cow's milk protein intolerance? The dietitian's dilemma. MacDonald A. **Eur J Clin Nutr** 1995 Sep;49 Suppl 1:S56–63 (66 ref.)
The use of hydrolysates in allergy prevention programmes. Vandenplas Y. **Eur J Clin Nutr** 1995 Sep;49 Suppl 1:S84–91 (52 ref.)

IMMUNOLOGY

The natural history of cow's milk protein allergy/intolerance. Høst A. et al. **Eur J Clin Nutr** 1995 Sep;49 Suppl 1:S13–8 (27 ref.)

PREVENTION & CONTROL

Strategies for prevention. Vandenplas Y.
Clin Rev Allergy Immunol 1995 Winter;13(4):361–71 (67 ref.)

THERAPY

The treatment of cow's milk allergy. Isolauri E.
Eur J Clin Nutr 1995 Sep;49 Suppl 1:S49–55 (26 ref.)

MILK PROTEINS

Whey proteins in cheese—an overview. Lelièvre J.
Adv Exp Med Biol 1995;367:359–65 (34 ref.)
Functional properties and applications of edible films made of milk proteins. Chen H. **J Dairy Sci** 1995 Nov; 78(11):2563–83 (94 ref.)

ADVERSE EFFECTS

Strategies for prevention. Vandenplas Y.
Clin Rev Allergy Immunol 1995 Winter;13(4):361–71 (67 ref.)
[Methemoglobinemia, acidemia and diarrhea induced by

hypersensitivity to cow's milk proteins] Catalán Muñoz M, et al. **An Esp Pediatr** 1996 Mar;44(3):295–6 (6 ref.) **(Spa)**

BIOSYNTHESIS

Production of proteins in the milk of transgenic livestock: problems, solutions, and successes. Colman A. **Am J Clin Nutr** 1996 Apr;63(4):639S–45S (30 ref.)

The mammary gland as a bioreactor: factors regulating the efficient expression of milk proteins–based transgenes. Rosen JM, et al. **Am J Clin Nutr** 1996 Apr;63(4):627S–32S (53 ref.)

Prolactin–mediated gene activation in mammary epithelial cells. Groner B, et al. **Curr Opin Genet Dev** 1995 Oct; 5(5):587–94 (73 ref.)

GENETICS

Genetic modification of milk proteins. Clark AJ. **Am J Clin Nutr** 1996 Apr;63(4):633S–8S (48 ref.)

Recombinant human milk proteins – an opportunity and a challenge. Lönnerdal B. **Am J Clin Nutr** 1996 Apr; 63(4):622S–6S (63 ref.)

The mammary gland as a bioreactor: factors regulating the efficient expression of milk protein–based transgenes. Rosen JM, et al. **Am J Clin Nutr** 1996 Apr;63(4):627S–32S (53 ref.)

[Expression and regulation of milk protein gene in mammalia] Yue JM, et al. **Sheng Li Ko Hsueh Chin Chan** 1995 Oct; 26(4):299–304 (16 ref.) (Eng. Abstr.) **(Chi)**

STANDARDS

Recombinant human milk proteins – an opportunity and a challenge. Lönnerdal B. **Am J Clin Nutr** 1996 Apr; 63(4):622S–6S (63 ref.)

ULTRASTRUCTURE

Immunolocalization and microstructure of milk proteins and fat mimetics in reduced fat cheese. Armbruster BL, et al. **Adv Exp Med Biol** 1995;367:277–94 (47 ref.)

MILROY'S DISEASE see **LYMPHEDEMA**

MIMA see **ACINETOBACTER**

MIMAE INFECTIONS see **ACINETOBACTER INFECTIONS**

MIMETIC MUSCLES see **FACIAL MUSCLES**

MIMICRY, MOLECULAR see **MOLECULAR MIMICRY**

MINAMATA DISEASE see **MERCURY POISONING**

MIND–BODY RELATIONS see **PSYCHOPHYSIOLOGY**

MINERAL FIBERS

see related
PNEUMOCONIOSIS

Deposition of inhaled asbestos and man–made mineral fibres in the respiratory tract. Morgan A. **Ann Occup Hyg** 1995 Oct;39(5):747–58 (40 ref.)

ADVERSE EFFECTS

[Cellular reactions of the lung to mineral fibers] Gillissen A, et al. **Pneumologie** 1996 Jan;50(1):5–17 (137 ref.) **(Ger)**

[Oxidative stress as a basic mechanism of the carcinogenic effect of man made mineral fibers on the human body] Lutz W, et al. **Med Pr** 1995;46(3):275–84 (18 ref.) (Eng. Abstr.) **(Pol)**

ANALYSIS

[Refractory ceramic fibers, kinds, health effects after exposure, TLVs] Woźniak H, et al. **Med Pr** 1996; 47(4):393–9 (17 ref.) (Eng. Abstr.) **(Pol)**

TOXICITY

Respiratory health effects of man–made vitreous (mineral) fibres. De Vuyst P, et al. **Eur Respir J** 1995 Dec; 8(12):2149–73 (169 ref.)

Role of iron in the reactivity of mineral fibers. Fubini B, et al. **Toxicol Lett** 1995 Dec;82–83:951–60 (57 ref.)

MINERAL OIL

TOXICITY

A toxicological review of topical exposure to white mineral oils. Nash JF, et al. **Food Chem Toxicol** 1996 Feb; 34(2):213–25 (46 ref.)

Variable responses of species and strains to white mineral oils and paraffin waxes. Miller MJ, et al. **Regul Toxicol Pharmacol** 1996 Feb;23(1 Pt 1):55–68 (78 ref.)

MINERAL WATERS

[Ecology and thermal parks in the context of the environment. Psychological and possible therapeutic aspects: trends in medicine] Grossi F, et al. **Clin Ter** 1995 Dec;146(12):781–92 (32 ref.) (Eng. Abstr.) **(Ita)**

MINERALOCORTICOID RECEPTORS see **RECEPTORS, MINERALOCORTICOID**

MINERALOCORTICOIDS

BLOOD

Apparent mineralocorticoid excess. Funder JW. **Endocrinol Metab Clin North Am** 1995 Sep;24(3):613–21 (41 ref.)

METABOLISM

11 beta–Hydroxysteroid dehydrogenase: implications for clinical medicine. Stewart PM. **Clin Endocrinol (Oxf)** 1996 May;44(5):493–9 (55 ref.)

PHYSIOLOGY

Apparent mineralocorticoid excess. Funder JW. **Endocrinol Metab Clin North Am** 1995 Sep;24(3):613–21 (41 ref.)

Cortisol as mineralocorticoid [editorial] Ulick S. **J Clin Endocrinol Metab** 1996 Apr;81(4):1307–8 (21 ref.)

Mineralocorticoid receptors in the central nervous system. Funder JW. **J Steroid Biochem Mol Biol** 1996 Jan;56(1–6 Spec No):179–83 (44 ref.)

MINERALS

ADMINISTRATION & DOSAGE

Position of the American Dietetic Association: vitamin and mineral supplementation. **J Am Diet Assoc** 1996 Jan; 96(1):73–7 (53 ref.)

Vitamin and mineral supplements as nutritional aids to exercise performance and health. Armstrong LE, et al. **Nutr Rev** 1996 Apr;54(4 Pt 2):S149–58 (126 ref.)

ANALYSIS

Analysis and interpretation of inorganic mineral particles in "lung" tissues. Gibbs AR, et al. **Thorax** 1996 Mar; 51(3):327–34 (60 ref.)

BLOOD

Indicators of vitamin and mineral status in athletes' blood: a review. Fogelholm M. **Int J Sport Nutr** 1995 Dec; 5(4):267–84 (91 ref.)

METABOLISM

Analytical instruments for stable isotopic tracers in mineral metabolism. Yergey AL. **J Nutr** 1996 Jan;126(1):355S–361S (59 ref.)

Bone and mineral metabolism in childhood end–stage renal disease. Salusky IB. **Pediatr Clin North Am** 1995 Dec; 42(6):1531–50 (103 ref.)

TOXICITY

Mineral fiber–induced oxidative stress in phagocytes. Savolainen KM, et al. **Arch Toxicol Suppl** 1996;18:236–47 (53 ref.)

MINIMAL BRAIN DYSFUNCTION see **ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY**

MINIMAL RESIDUAL DISEASE see **NEOPLASM, RESIDUAL**

MINIMALLY INVASIVE SURGERY see **SURGERY, MINIMALLY INVASIVE**

MINING

Airborne fibre concentrations and lung burden compared to the tumour response in rats and humans exposed to asbestos. Rödelsperger K, et al. **Ann Occup Hyg** 1995 Oct; 39(5):715–25 (27 ref.)

ICRP recommendations applicable to the mining and minerals processing industries and to natural sources. International Commission on Radiological Protection. Clarke RH. **Health Phys** 1995 Oct;69(4):454–60 (18 ref.)

Dental problems in the offshore oil and gas industry: a review. Duffy B. **Occup Med (Oxf)** 1996 Feb;46(1):79–83 (8 ref.)

MINK ENCEPHALOPATHY VIRUS see **PRIONS**

MINOCYCLINE

ADVERSE EFFECTS

Serious adverse reactions induced by minocycline. Report of 13 patients and review of the literature. Knowles SR, et al. **Arch Dermatol** 1996 Aug;132(8):934–9 (38 ref.)

THERAPEUTIC USE

Minocycline in rheumatoid arthritis. Langevitz P, et al. **Isr J Med Sci** 1996 May;32(5):327–30 (33 ref.)

Antibiotic therapy for rheumatoid arthritis. Scientific and anecdotal appraisals. Trentham DE, et al. **Rheum Dis Clin North Am** 1995 Aug;21(3):817–34 (58 ref.)

MINOR HISTOCOMPATIBILITY ANTIGENS

IMMUNOLOGY

The role of human minor histocompatibility antigens in graft failure: a mini–review. Goulmy E, et al. **Eye** 1995;9 (Pt 2):180–4 (33 ref.)

MINOR HISTOCOMPATIBILITY PEPTIDES see **MINOR HISTOCOMPATIBILITY ANTIGENS**

MINORITY GROUPS

Meeting the needs of minority ethnic communities. Webb E. **Arch Dis Child** 1996 Mar;74(3):264–7 (49 ref.)

Cervical cancer screening: meeting the needs of minority ethnic women. Luke K. **Br J Cancer** 1996 Sep;74 Suppl 29:S47–50 (11 ref.)

Smoking cessation programmes targeted at black and minority ethnic communities. Farren C, et al. **Br J Cancer Suppl** 1996 Sep;29:S78–80 (17 ref.)

Cancer among special populations: women, ethnic minorities, and the poor. Haynes A. **Environ Health Perspect** 1995 Nov;103 Suppl 8:319–20 (10 ref.)

A research agenda for health education among underserved populations. Marín G, et al. **Health Educ Q** 1995 Aug; 22(3):346–63 (86 ref.)

Epidemiology of minority health. Flack JM, et al. **Health Psychol** 1995 Dec;14(7):592–600 (50 ref.)

Macrosocial and environmental influences on minority health. Johnson KW, et al. **Health Psychol** 1995 Dec; 14(7):601–12 (115 ref.)

Behavioral risk factors related to chronic diseases in ethnic minorities. Myers HF, et al. **Health Psychol** 1995 Dec; 14(7):613–21 (65 ref.)

Ethnic minorities, health care systems, and behavior. Penn NE, et al. **Health Psychol** 1995 Dec;14(7):641–6 (40 ref.)

Risk–taking and abusive behaviors among ethnic minorities. Yee BW, et al. **Health Psychol** 1995 Dec;14(7):622–31 (100 ref.)

Nutrition in minority elders: current problems and future directions. Buchowski MS, et al. **J Health Care Poor Underserved** 1996 Aug;7(3):184–209 (158 ref.)

Recruiting minorities into clinical trials: toward a participant–friendly system [see comments] Swanson GM, et al. **J Natl Cancer Inst** 1995 Dec 6;87(23):1747–59 (107 ref.) Comment in: J Natl Cancer Inst 1996 Mar 20;88(6):377.

Minority inclusion in clinical trials issues and potential strategies. Brawley OW, et al. **J Natl Cancer Inst Monogr** 1995;(17):55–7 (18 ref.)

A research development program for minority honors students. Inouye J. **J Nurs Educ** 1995 Sep;34(6):268–71 (35 ref.)

Ectopic pregnancy: a nursing approach to excess risk among minority women. Bernstein J. **J Obstet Gynecol Neonatal Nurs** 1995 Nov–Dec; 24(9):803–10 (71 ref.)

PSYCHOLOGY

The economics of pain. Mental health care costs among minorities. Ruiz P, et al. **Psychiatr Clin North Am** 1995 Sep;18(3):659–70 (23 ref.)

STATISTICS & NUMERICAL DATA

Cancer and ethnic minorities—the Department of Health's perspective. Bahl V. **Br J Cancer** 1996 Sep;74 Suppl 29:S2–10 (28 ref.)

Cancer in minority ethnic populations: priorities from epidemiological data. Bhopal RS, et al. **Br J Cancer** 1996 Sep;74 Suppl 29:S22–32 (15 ref.)

Cancer in minority ethnic populations: priorities from epidemiological data. Bhopal RS, et al. **Br J Cancer Suppl** 1996 Sep;29:S22–32 (15 ref.)

MINUTE VIRUS OF MICE

GROWTH & DEVELOPMENT

Minute virus of mice cis–acting sequences required for genome replication and the role of the trans–acting viral protein, NS–1. Astell CR, et al. **Prog Nucleic Acid Res Mol Biol** 1996;55:245–85 (116 ref.)

MIOPITHECUS TALAPOIN see **CERCOPITHECIDAE**

MIOSIS

Spasm of the near reflex: a spectrum of anomalies. Goldstein JH, et al. **Surv Ophthalmol** 1996 Jan–Feb;40(4):269–78 (50 ref.)

MIOTICS

see related
CHOLINESTERASE INHIBITORS
MUSCARINIC AGONISTS
PARASYMPATHOMIMETICS
SYMPATHOLYTICS

MIREX

ADVERSE EFFECTS

ATSDR evaluation of health effects of chemicals. II. Mirex and chlordecone: health effects, toxicokinetics, human exposure, and environmental fate. Faroon O, et al. **Toxicol Ind Health** 1995;11(6):1-203 (681 ref.)

MIRROR WRITING see **DOMINANCE, CEREBRAL**

MISARTICULATION see **ARTICULATION DISORDERS**

MISCARRIAGE see **ABORTION**

MISOPROSTOL

[Mifepristone and misoprostol in therapeutic abortions] Jannet D, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996; 25(3):277-82 (24 ref.) (Eng. Abstr.) **(Fre)**

ADVERSE EFFECTS

Review of Arthrotec clinical data. McKenna F. **Eur J Rheumatol Inflamm** 1994;14(3 Suppl):25-9 (9 ref.)

THERAPEUTIC USE

Misoprostol for tinnitus. Crinnion CL, et al. **Ann Pharmacother** 1995 Jul-Aug;29(7-8):782-4 (13 ref.)
Diclofenac/misoprostol. A review of its pharmacology and therapeutic efficacy in painful inflammatory conditions. Davis R, et al. **Drugs Aging** 1995 Nov;7(5):372-93 (76 ref.)
Use of misoprostol in the elderly: is the expense justified? Stucki G, et al. **Drugs Aging** 1996 Feb;8(2):84-8 (24 ref.)
Review of Arthrotec clinical data. McKenna F. **Eur J Rheumatol Inflamm** 1994;14(3 Suppl):25-9 (9 ref.)

MISUSE OF HEALTH SERVICES see **HEALTH SERVICES MISUSE**

MITE CONTROL see **TICK CONTROL**

MITE INFESTATIONS

DIAGNOSIS

Rosacea-like demodicosis in an HIV-positive child. Barrio J, et al. **Dermatology** 1996;192(2):143-5 (23 ref.)

VETERINARY

Sarcoptic mange and production performance of swine: a review of the literature and studies of associations between mite infestation, growth rate and measures of mange severity in growing pigs. Davies PR. **Vet Parasitol** 1995 Dec;60(3-4):249-64 (51 ref.)

MITES

Specific immunotherapy in house dust mite allergy. Bousquet J, et al. **Clin Rev Allergy Immunol** 1995 Summer;13(2):151-9 (57 ref.)
Atopic dermatitis and delayed hypersensitivity to dust mites. Castelain M. **Clin Rev Allergy Immunol** 1995 Summer; 13(2):161-72 (53 ref.)
Introduction. House dust mite allergy. Guérin B. **Clin Rev Allergy Immunol** 1995 Summer;13(2):107-13 (57 ref.)
[Allergy to house dust mites] Horak B. **Wiad Parazytol** 1995; 41(3):355-68 (47 ref.) (Eng. Abstr.) **(Pol)**

IMMUNOLOGY

Modulation of immune responses to allergens of house dust mite. Hawrylowicz C, et al. **Biochem Soc Trans** 1995 Aug; 23(3):660-4 (29 ref.)
Dermatophagoides siboney and Blomia tropicalis--dust mites of subtropical and tropical areas [editorial] van Hage-Hamsten M. **Clin Exp Allergy** 1995 Oct;25(10):905-7 (25 ref.)
Dust mite allergens. Stewart GA. **Clin Rev Allergy Immunol** 1995 Summer;13(2):135-50 (65 ref.)

PHYSIOLOGY

The biology of allergenic domestic mites. An update. Hart BJ. **Clin Rev Allergy Immunol** 1995 Summer;13(2):115-33 (134 ref.)

MITOCHONDRIA

Molecular and functional properties of mitochondrial benzodiazepine receptors. Krueger KE. **Biochim Biophys Acta** 1995 Dec 20;1241(3):453-70 (189 ref.)
Mitochondrial medicine. Luft R, et al. **J Intern Med** 1995 Nov;238(5):405-21 (119 ref.)

CHEMISTRY

Structural and functional aspects of the phosphate carrier from mitochondria. Krämer R. **Kidney Int** 1996 Apr; 49(4):947-52 (55 ref.)

DRUG EFFECTS

How do Ca2+ and 5-aminolevulinic acid-derived oxyradicals promote injury to isolated mitochondria? Hermes-Lima M. **Free Radic Biol Med** 1995 Sep; 19(3):381-90 (87 ref.)
Mitochondrial toxicity of antiviral drugs. Lewis W, et al. **Nat Med** 1995 May;1(5):417-22 (66 ref.)

ENZYMOLOGY

A compilation of mutations located in the cytochrome b subunit of the bacterial and mitochondrial bc1 complex. Brasseur G, et al. **Biochim Biophys Acta** 1996 Jul 18; 1275(1-2):61-9 (45 ref.)
The bifunctional cytochrome c reductase/processing peptidase complex from plant mitochondria. Braun HP, et al. **J Bioenerg Biomembr** 1995 Aug;27(4):423-36 (110 ref.)
Regulation of alternative oxidase activity in higher plants. Day DA, et al. **J Bioenerg Biomembr** 1995 Aug; 27(4):379-85 (41 ref.)
Structure-function relationships of the alternative oxidase of plant mitochondria: a model of the active site. Moore AL, et al. **J Bioenerg Biomembr** 1995 Aug;27(4):367-77 (70 ref.)
Functional molecular aspects of the NADH dehydrogenases of plant mitochondria. Soole KL, et al. **J Bioenerg Biomembr** 1995 Aug;27(4):397-406 (64 ref.)
Mechanisms of active transport in the FOF1 ATP synthase. Nakamoto RK. **J Membr Biol** 1996 May;151(2):101-11 (123 ref.)
[Ketoacidotic coma in an infant as the form of onset of a mitochondrial 2-methylacetoacetyl-CoA thiolase deficiency] Yeste Fernández D, et al. **An Esp Pediatr** 1996 Jun;44(6):620-2 (9 ref.) **(Spa)**

GENETICS

Investigation of mitochondrial disease. Poulton J, et al. **Arch Dis Child** 1995 Aug;73(2):94-7 (26 ref.)
Compilation and classification of higher plant mitochondrial tRNA genes. Veronico P, et al. **Nucleic Acids Res** 1996 Jun 15;24(12):2199-203 (27 ref.)
Uniparental inheritance of mitochondrial and chloroplast genes: mechanisms and evolution. Birky CW Jr. **Proc Natl Acad Sci U S A** 1995 Dec 5;92(25):11331-8 (96 ref.)
[Mitochondria gene mutation and diabetes] Kadowaki T. **Nippon Naika Gakkai Zasshi** 1996 Apr 10;85(4):573-7 (5 ref.) **(Jpn)**

IMMUNOLOGY

[Joint and systemic manifestations related to type 2 anti-mitochondrial antibodies] Dhôte R, et al. **Ann Med Interne (Paris)** 1995;146(8):536-40 (31 ref.) (Eng. Abstr.) **(Fre)**
[Primary biliary cirrhosis--antimitochondrial antibody and the reactive antigens] Ishibashi H. **Fukuoka Igaku Zasshi** 1995 Oct;86(10):385-8 (4 ref.) **(Jpn)**
[Antimitochondrial antibody negative primary biliary cirrhosis] Aizawa Y, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):527-30 (12 ref.) **(Jpn)**

METABOLISM

The ATPase module and the process of cellular immortalization. Krpoll J. **Ann N Y Acad Sci** 1996 Jun 15;786:57-61 (36 ref.)
Critical evaluation of the free radical theory of aging. A proposal for the oxidative stress hypothesis. Yu BP, et al. **Ann N Y Acad Sci** 1996 Jun 15;786:1-11 (44 ref.)
Intracellular trafficking of phospholipids: import of phosphatidylserine into mitochondria. Vance JE, et al. **Anticancer Res** 1996 May-Jun;16(3B):1333-9 (48 ref.)
The permeability transition pore. Control points of a cyclosporin A-sensitive mitochondrial channel involved in cell death. Bernardi P. **Biochim Biophys Acta** 1996 Jul 18; 1275(1-2):5-9 (43 ref.)
Mitochondrial metabolite transporters. Palmieri F, et al. **Biochim Biophys Acta** 1996 Jul 18;1275(1-2):127-32 (25 ref.)
Protein translocation across mitochondrial membranes: what a long, strange trip it is. Ryan KR, et al. **Cell** 1995 Nov 17;83(4):517-9 (15 ref.)
Mitochondrial water loss and aging of cells. von Zglinicki T, et al. **Cell Biochem Funct** 1995 Sep;13(3):181-7 (48 ref.)
Genetic and biochemical dissection of the mitochondrial protein-import machinery. Kübrich M, et al. **Curr Genet** 1995 Apr;27(5):393-403 (110 ref.)
Mitochondrial transcription initiation: promoter structures and RNA polymerases. Tracy RL, et al. **Curr Genet** 1995 Aug;28(3):205-16 (103 ref.)
Biogenesis of mitochondrial proteins. Lill R, et al. **Curr Opin Cell Biol** 1996 Aug;8(4):505-12 (62 ref.)
Mitochondrial defects in basal ganglia diseases. Shoffner JM. **Curr Opin Neurol** 1995 Dec;8(6):474-9 (81 ref.)
Routes and regulation of NADPH production in steroidogenic mitochondria. Hanukoglu I, et al. **Endocr Res** 1995 Feb-May;21(1-2):231-41 (46 ref.)
The contribution of mitochondria to energetic metabolism in photosynthetic cells. Gardeström P, et al. **J Bioenerg Biomembr** 1995 Aug;27(4):415-21 (53 ref.)
High-level bacterial expression of mitochondrial transport proteins. Kaplan RS. **J Bioenerg Biomembr** 1996 Feb; 28(1):41-7 (23 ref.)
Kinetic and regulatory aspects of the function of the alternative oxidase in plant respiration. Krab K. **J Bioenerg Biomembr** 1995 Aug;27(4):387-96 (47 ref.)
URF13, a ligand-gated, pore-forming receptor for T-toxin in the inner membrane of cms-T mitochondria. Rhoads DM, et al. **J Bioenerg Biomembr** 1995 Aug;27(4):437-45 (52 ref.)
Design of the oxygen and substrate pathways. VII. Different structural limits for oxygen and substrate supply to muscle mitochondria. Weibel ER, et al. **J Exp Biol** 1996 Aug;199 (Pt 8):1699-709 (18 ref.)
Disorders of mitochondrial long-chain fatty acid oxidation. Pollitt RJ. **J Inherit Metab Dis** 1995;18(4):473-90 (78 ref.)
Cytosolic and mitochondrial calcium in synaptosomes during aging. Satrústegui J, et al. **Life Sci** 1996;59(5-6):429-34 (33 ref.)
Fuel selection at the level of mitochondria in mammalian tissues. Denton RM, et al. **Proc Nutr Soc** 1995 Mar; 54(1):11-22 (39 ref.)
Update in molecular genetics: mitochondrial energy transduction disorders. Marzuki S, et al. **Southeast Asian J Trop Med Public Health** 1995;26 Suppl 1:155-61 (37 ref.)

PATHOLOGY

Mitochondrial disorders. Methods and specimen selection for diagnostic molecular pathology. Kiechle FL, et al. **Arch Pathol Lab Med** 1996 Jun;120(6):597-603 (89 ref.)
Renal involvement in mitochondrial cytopathies [editorial] Grünfeld JP, et al. **Nephrol Dial Transplant** 1996 May; 11(5):760-1 (16 ref.)

PHYSIOLOGY

Mitochondrial dysfunction in ischaemia-reperfusion. Saris NE, et al. **Acta Anaesthesiol Scand Suppl** 1995;107:171-6 (75 ref.)
Mitochondrial damage as a source of diseases and aging: a strategy of how to fight these. Zorov DB. **Biochim Biophys Acta** 1996 Jul 18;1275(1-2):10-5 (48 ref.)
Aspects of oxidative metabolism in schizophrenia [editorial] Marchbanks RM, et al. **Br J Psychiatry** 1995 Sep; 167(3):293-8 (24 ref.)
Sexuality of mitochondria: fusion, recombination, and plasmids. Kawano S, et al. **Int Rev Cytol** 1995;161:49-110 (179 ref.)
How do alterations in plant mitochondrial genomes disrupt pollen development? Conley CA, et al. **J Bioenerg Biomembr** 1995 Aug;27(4):447-57 (78 ref.)
Mitochondria, magnesium and migraine. Welch KM, et al. **J Neurol Sci** 1995 Dec;134(1-2):9-14 (62 ref.)
[Migraine and mitochondrial dysfunction] Lantéri-Minet M, et al. **Rev Neurol (Paris)** 1996 Apr;152(4):234-8 (55 ref.) (Eng. Abstr.) **(Fre)**

ULTRASTRUCTURE

The apical mitochondria-rich cells of the mammalian epididymis. Martínez-García F, et al. **Andrologia** 1995 Jul-Aug;27(4):195-206 (83 ref.)
Design of the oxygen and substrate pathways. VII. Different structural limits for oxygen and substrate supply to muscle mitochondria. Weibel ER, et al. **J Exp Biol** 1996 Aug;199 (Pt 8):1699-709 (18 ref.)

MITOCHONDRIA, HEART

ENZYMOLOGY

Functional implications of the structure of the 'Rieske' iron-sulfur protein of bovine heart mitochondrial cytochrome bc1 complex. Link TA, et al. **Biochim Biophys Acta** 1996 Jul 18;1275(1-2):54-60 (45 ref.)
Crystallization and preliminary structure of beef heart mitochondrial cytochrome-bc1 complex. Yu CA, et al. **Biochim Biophys Acta** 1996 Jul 18;1275(1-2):47-53 (52 ref.)
ATPase activity, IF1 content, and proton conductivity of ESMP from control and ischemic slow and fast heart-rate hearts. Rousiin W, et al. **J Bioenerg Biomembr** 1995 Aug; 27(4):459-66 (30 ref.)

MITOCHONDRIA, LIVER

DRUG EFFECTS

Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration. Guillaume MP, et al. **Am J Gastroenterol** 1996 Jan;91(1):165-8 (14 ref.)
Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity. Fromenty B, et al. **Pharmacol Ther** 1995; 67(1):101-54 (520 ref.)

ENZYMOLOGY

Site directed mutagenesis to probe for active site components of liver mitochondrial aldehyde dehydrogenase. Weiner H, et al. **Adv Exp Med Biol** 1995;372:1-7 (17 ref.)

Regulation of mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase gene expression in liver and intestine from the rat. Hegardt FG. **Biochem Soc Trans** 1995 Aug;23(3):486-90 (23 ref.)

[Hepatic mitochondrial fatty acid oxidation disorders] Matsubara Y. **Ryoikibetsu Shokogun Shirizu** 1995;(8):312-6 (21 ref.) **(Jpn)**

IMMUNOLOGY

Mitochondrial antigen/antibody systems in primary biliary cirrhosis: revisited. Berg PA, et al. **Liver** 1995 Dec; 15(6):281-92 (73 ref.)

MITOCHONDRIA, MUSCLE

see related
MITOCHONDRIAL ENCEPHALOMYOPATHIES
MITOCHONDRIAL MYOPATHIES

ENZYMOLOGY

Variations of muscle mitochondrial creatine kinase activity in mitochondrial diseases. Bouzidi MF, et al. **Biochim Biophys Acta** 1996 Jun 7;1316(2):61-70 (45 ref.)

PHYSIOLOGY

Contractile activity-induced mitochondrial biogenesis in skeletal muscle. Essig DA. **Exerc Sport Sci Rev** 1996; 24:289-319 (94 ref.)

MITOCHONDRIAL DNA see DNA, MITOCHONDRIAL

MITOCHONDRIAL ENCEPHALOMYOPATHIES

COMPLICATIONS

The therapy of respiratory chain encephalomyopathy: a critical review of the past and current perspective. Walker UA, et al. **Acta Neurol Scand** 1995 Oct;92(4):273-80 (77 ref.)

[Mitochondrial diseases and cerebrovascular pathology] Vivancos J, et al. **Rev Neurol** 1995;23 Suppl 1:S106-12 (39 ref.) **(Spa)**

DRUG THERAPY

The therapy of respiratory chain encephalomyopathy: a critical review of the past and current perspective. Walker UA, et al. **Acta Neurol Scand** 1995 Oct;92(4):273-80 (77 ref.)

GENETICS

Clinical presentations and laboratory investigations in respiratory chain deficiency. Munnich A, et al. **Eur J Pediatr** 1996 Apr;155(4):262-74 (28 ref.)

METABOLISM

Further evidence for multitopological localization of mammalian porin (VDAC) in the plasmalemma forming part of a chloride channel complex affected in cystic fibrosis and encephalomyopathy. Reymann S, et al. **Biochem Mol Med** 1995 Apr;54(2):75-87 (74 ref.)

THERAPY

The therapy of respiratory chain encephalomyopathy: a critical review of the past and current perspective. Walker UA, et al. **Acta Neurol Scand** 1995 Oct;92(4):273-80 (77 ref.)

MITOCHONDRIAL MYOPATHIES

COMPLICATIONS

[Chronic rhabdomyolysis disclosing mitochondriopathy and malignant hyperthermia susceptibility] Etcharry-Bouyx F, et al. **Rev Neurol (Paris)** 1995 Oct;151(10):589-92 (10 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

[Mitochondrial diseases. Part I — general review] Mierzewska H. **Neurol Neurochir Pol** 1996 Mar-Apr; 30(2):265-78 (22 ref.) (Eng. Abstr.) **(Pol)**

[Mitochondrial diseases. Part II — diagnosis and detailed review] Mierzewska H. **Neurol Neurochir Pol** 1996 Mar-Apr;30(2):279-92 (22 ref.) (Eng. Abstr.) **(Pol)**

ENZYMOLOGY

Variations of muscle mitochondrial creatine kinase activity in mitochondrial diseases. Bouzidi MF, et al. **Biochim Biophys Acta** 1996 Jun 7;1316(2):61-70 (45 ref.)

GENETICS

The genetic basis of paediatric heart disease. Johnson MC, et al. **Ann Med** 1995 Jun;27(3):289-300 (126 ref.)

Investigation of mitochondrial disease. Poulton J, et al. **Arch Dis Child** 1995 Aug;73(2):94-7 (26 ref.)

Clinical presentations and laboratory investigations in respiratory chain deficiency. Munnich A, et al. **Eur J Pediatr** 1996 Apr;155(4):262-74 (28 ref.)

THERAPY

Germ-line therapy to cure mitochondrial disease: protocol and ethics of in vitro ovum nuclear transplantation. Rubenstein DS, et al. **Camb Q Healthc Ethics** 1995 Summer; 4(3):316-39 (101 ref.)

MITOGENIC FACTORS, LYMPHOCYTE see INTERLEUKIN-2

MITOGENS

PHARMACOLOGY

The 70 kDa S6 kinase: regulation of a kinase with multiple roles in mitogenic signalling. Chou MM, et al. **Curr Opin Cell Biol** 1995 Dec;7(6):806-14 (72 ref.)

Mitogen and stress response pathways: MAP kinase cascades and phosphatase regulation in mammals and yeast. Waskiewicz AJ, et al. **Curr Opin Cell Biol** 1995 Dec; 7(6):798-805 (79 ref.)

Positive regulation of the nuclear activator CREM by the mitogen-induced p70 S6 kinase. de Groot RP, et al. **Immunobiology** 1995 Jul;193(2-4):155-60 (9 ref.)

The NF-jun transcription factor in the hematopoietic response to mitogenic signals. Sott C, et al. **Immunobiology** 1995 Jul;193(2-4):149-54 (16 ref.)

Transforming growth factor-beta-3 is mitogenic for rat retinal progenitor cells in vitro. Anchan RM, et al. **J Neurobiol** 1995 Oct;28(2):133-45 (50 ref.)

PHYSIOLOGY

Mitogen-responsive nuclear factors that mediate growth control signals in vascular myocytes. Gorski DH, et al. **Cardiovasc Res** 1995 Oct;30(4):585-92 (114 ref.)

IGF-I: a mitogen also involved in differentiation processes in mammalian cells. Benito M, et al. **Int J Biochem Cell Biol** 1996 May;28(5):499-510 (95 ref.)

MITOGENS, ENDOGENOUS see GROWTH SUBSTANCES

MITOMYCIN C

ADMINISTRATION & DOSAGE

Bolus mitomycin C and 5-FU with sequential radiation for poor-prognosis locally advanced cervical cancer. Denehy TR, et al. **Gynecol Oncol** 1996 Jan;60(1):64-71 (21 ref.)

[Chemo-endocrine therapy including mitomycin C and medroxyprogesterone acetate in doxorubicin-refractory advanced breast cancer] Nomura Y, et al. **Gan To Kagaku Ryoho** 1996 Mar;23(4):439-45 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Prophylaxis and treatment of peritoneal metastasis from gastric cancer] Kaibara N. **Nippon Geka Gakkai Zasshi** 1996 Apr;97(4):308-11 (10 ref.) (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

[Bladder retraction, a complication of chemoprophylaxis of superficial bladder cancer using intravesical mitomycin C. Apropos of a case and review of the literature] Punga-Maole ML, et al. **Prog Urol** 1995 Sep;5(4):580-5 (39 ref.) (Eng. Abstr.) **(Fre)**

PHARMACOLOGY

Re-evaluation of the molecular pharmacology of mitomycin C. Cummings J, et al. **Eur J Cancer** 1995 Nov; 31A(12):1928-33 (61 ref.)

THERAPEUTIC USE

Mitomycins. Verweij J. **Cancer Chemother Biol Response Modif** 1996;16:48-56 (43 ref.)

MITOMYCINS

ADVERSE EFFECTS

[Complications of intravesical mitomycin chemotherapy, apropos of 2 clinical case reports] Pouya M, et al. **Acta Urol Belg** 1996 Mar;64(1):47-53 (24 ref.) (Eng. Abstr.) **(Fre)**

THERAPEUTIC USE

Mitomycins. Verweij J. **Cancer Chemother Biol Response Modif** 1996;16:48-56 (43 ref.)

MITOSIS

see related
MATURATION-PROMOTING FACTOR
MITOGENS

Mitosis and genome partition in trypanosomes. Solari AJ. **Biocell** 1995 Aug;19(2):65-84 (77 ref.)

Phosphoinositide-specific phospholipase C and mitogenic signaling. Noh DY, et al. **Biochim Biophys Acta** 1995 Dec 18;1242(2):99-113 (143 ref.)

The SMC proteins and the coming of age of the chromosome scaffold hypothesis. Saitoh N, et al. **Bioessays** 1995 Sep; 17(9):759-66 (54 ref.)

Cell cycle. The only way out of mitosis. Glotzer M. **Curr Biol** 1995 Sep 1;5(9):970-2 (26 ref.)

Chemically induced mitotic synchrony in root apical meristems. Prewett B, et al. **Methods Cell Biol** 1995; 49:355-65 (10 ref.)

Force generation by microtubule assembly/disassembly in mitosis and related movements. Inoué S, et al. **Mol Biol Cell** 1995 Dec;6(12):1619-40 (188 ref.)

Going mobile: microtubule motors and chromosome segregation. Barton NR, et al. **Proc Natl Acad Sci U S A** 1996 Mar 5;93(5):1735-42 (139 ref.)

The centromere: hub of chromosomal activities. Pluta AF, et al. **Science** 1995 Dec 8;270(5242):1591-4 (83 ref.)

Biochemical and genetic dissection of mitotic chromosome condensation. Hirano T. **Trends Biochem Sci** 1995 Sep; 20(9):357-61 (32 ref.)

GENETICS

The last mitoses of the human fibroblast proliferative life span, physiopathologic implications. Macieira-Coelho A. **Mech Ageing Dev** 1995 Aug 8;82(2-3):91-104 (22 ref.)

Genetic control of mitosis, meiosis and cellular differentiation during mammalian spermatogenesis. Wolgemuth DJ, et al. **Reprod Fertil Dev** 1995;7(4):669-83 (141 ref.)

PHYSIOLOGY

Cell cycle. The NIMA kinase joins forces with Cdc2. Fry AM, et al. **Curr Biol** 1995 Oct 1;5(10):1122-5 (16 ref.)

Molecular mechanisms in the disassembly and reassembly of the mammalian Golgi apparatus during M-phase. Misteli T. **FEBS Lett** 1996 Jun 24;389(1):66-9 (44 ref.)

Circasemiseptan (about-half-weekly) and/or circaseptan (about-weekly) pattern in human mitotic activity? Blank M, et al. **In Vivo** 1995 Jul-Aug;9(4):391-4 (49 ref.)

Protein kinases in the control of mitosis: focus on nucleocytoplasmic trafficking. Gallant P, et al. **J Cell Sci Suppl** 1995;19:21-8 (86 ref.)

Role of the time factor in signaling specificity: application to mitogenic and metabolic signaling by the insulin and insulin-like growth factor-I receptor tyrosine kinases. De Meyts P, et al. **Metabolism** 1995 Oct;44(10 Suppl 4):2-11 (88 ref.)

The role of protein phosphatase type-2A in the Xenopus cell cycle: initiation of the G2/M transition. Lee TH. **Semin Cancer Biol** 1995 Aug;6(4):203-9 (39 ref.)

[The role of incomplete terminal repair of chromosomal DNA in the aging of neurons and postmitotic organisms] Olovnikov AM. **Izv Akad Nauk Ser Biol** 1995 Jul-Aug; (4):504-7 (12 ref.) (Eng. Abstr.) **(Rus)**

MITOSIS-PROMOTING FACTOR see MATURATION-PROMOTING FACTOR

MITOTIC SPINDLE APPARATUS

see related
CENTROMERE
CENTROSOME
KINETOCHORES
MICROTUBULES

Nuclear matrix proteins as structural and functional components of the mitotic apparatus. He D, et al. **Int Rev Cytol** 1995;162B:1-74 (283 ref.)

CHEMISTRY

Kinesin-related proteins at mitotic spindle poles: function and regulation. Walczak CE, et al. **Cell** 1996 Jun 28; 85(7):943-6 (18 ref.)

Kinesin-II, a membrane traffic motor in axons, axonemes, and spindles. Scholey JM. **J Cell Biol** 1996 Apr;133(1):1-4 (29 ref.)

DRUG EFFECTS

Genetic toxicology of mitotic spindle inhibitors used as anticancer drugs. Kirsch-Volders M, et al. **Mutat Res** 1996 Aug 17;355(1-2):103-28 (220 ref.)

PHYSIOLOGY

Chromosomes take an active role in spindle assembly. Waters JC, et al. **Bioessays** 1995 Nov;17(11):911-4 (32 ref.)

Spindle orientation and asymmetric localization in Drosophila: both inscuteable? Doe CQ. **Cell** 1996 Sep 6; 86(5):695-7 (16 ref.)

Morphogenetic properties of microtubules and mitotic spindle assembly. Hyman AA, et al. **Cell** 1996 Feb 9; 84(3):401-10 (70 ref.)

Going mobile: microtubule motors and chromosome segregation. Barton NR, et al. **Proc Natl Acad Sci U S A** 1996 Mar 5;93(5):1735-42 (139 ref.)

MITRAL CLICK-MURMUR SYNDROME see MITRAL

MITRAL CLICK-MURMUR SYNDROME

VALVE PROLAPSE

MITRAL INCOMPETENCE see MITRAL VALVE INSUFFICIENCY

MITRAL REGURGITATION see MITRAL VALVE INSUFFICIENCY

MITRAL VALVE

Prosthetic valve thrombosis: a case report and review of the literature. Goh PP, et al. **Ann Acad Med Singapore** 1996 Jan;25(1):147–51 (28 ref.)

How should we describe forward flow through replacement mitral valves using echocardiography? Chambers JB. **J Heart Valve Dis** 1995 Jul;4 Suppl 1:S55–8 (17 ref.)

Salmonella prosthetic valve endocarditis. Fukushima N, et al. **J Thorac Cardiovasc Surg** 1996 Sep;112(3):840–2 (5 ref.)

Papillary fibroelastoma of the mitral valve. A rare cause of embolic events. Colucci V, et al. **Tex Heart Inst J** 1995; 22(4):327–31 (31 ref.)

[Morphological study by transesophageal echocardiography and clinical aspects of ruptured chordae tendineae in the elderly] Benhalima B, et al. **Arch Mal Coeur Vaiss** 1995 Mar;88(3):345–52 (29 ref.) (Eng. Abstr.) **(Fre)**

[Myxoma of the mitral valve; apropos of 2 surgically treated cases. Review of the literature] Leude E, et al. **Arch Mal Coeur Vaiss** 1995 Sep;88(9):1345–8 (18 ref.) (Eng. Abstr.) **(Fre)**

[Mitral subvalvular aneurysm of probable chagasic etiology] García Hernández N, et al. **Arch Inst Cardiol Mex** 1995 May–Jun;65(3):265–9 (20 ref.) (Eng. Abstr.) **(Spa)**

ABNORMALITIES

[Mitral valve replacement for congenital parachute mitral valve] Sasahashi N, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Jul;43(7):1092–6 (13 ref.) (Eng. Abstr.) **(Jpn)**

EMBRYOLOGY

[The embryogenesis of the atrioventricular valves] Berishvili II, et al. **Morfologiia** 1996;109(1):106–9 (34 ref.) **(Rus)**

INJURIES

Mitral valve injury after blunt chest trauma. McDonald ML, et al. **Ann Thorac Surg** 1996 Mar;61(3):1024–9 (43 ref.)

[Acute mitral valve insufficiency] Acar J. **Ann Cardiol Angeiol (Paris)** 1995 Dec;44(10):561–6 (22 ref.) (Eng. Abstr.) **(Fre)**

[Posttraumatic pericardial laceration and cleft of the anterior mitral leaflet] Venturini E, et al. **G Ital Cardiol** 1995 Aug; 25(8):1037–41 (11 ref.) (Eng. Abstr.) **(Ita)**

MICROBIOLOGY

Nonfebrile mitral valve endocarditis due to Neisseria subflava. Amsel BJ, et al. **Chest** 1996 Jan;109(1):280–2 (16 ref.)

PATHOLOGY

Interruption of aortic arch and hypoplastic left heart syndrome. Devloo–Blancquaert A, et al. **Pediatr Cardiol** 1995 Nov–Dec;16(6):304–8 (10 ref.)

SURGERY

Mitral valve myxoma: a case report and brief review of the literature. Kulshrestha P, et al. **J Heart Valve Dis** 1995 Mar;4(2):196–8 (7 ref.)

Operative therapy for mitral insufficiency from coronary artery disease. Galloway AC, et al. **Semin Thorac Cardiovasc Surg** 1995 Oct;7(4):227–32 (33 ref.)

ULTRASONOGRAPHY

[Correlation between transthoracic and transesophageal echocardiography and surgery in mitral stenosis] Khatouri A, et al. **Ann Cardiol Angeiol (Paris)** 1995 Nov;44(9):501–6 (18 ref.) (Eng. Abstr.) **(Fre)**

MITRAL VALVE INCOMPETENCE see MITRAL VALVE INSUFFICIENCY

MITRAL VALVE INSUFFICIENCY

DRUG THERAPY

Medical treatment of chronic valvular regurgitation. Schön HR. **J Heart Valve Dis** 1995 Oct;4 Suppl 2:S170–4 (26 ref.)

ETIOLOGY

Pathogenesis of mitral regurgitation in acute myocardial infarction: importance of changes in left ventricular shape and regional function. Van Dantzig JM, et al. **Am Heart J** 1996 May;131(5):865–71 (36 ref.)

Operative therapy for mitral insufficiency from coronary artery disease. Galloway AC, et al. **Semin Thorac Cardiovasc Surg** 1995 Oct;7(4):227–32 (33 ref.)

[Acute mitral valve insufficiency] Acar J. **Ann Cardiol Angeiol (Paris)** 1995 Dec;44(10):561–6 (22 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Left ventricular function in mitral valve disease. Oakley CM. **J Heart Valve Dis** 1995 Oct;4 Suppl 2:S236–40; discussion S240–1 (28 ref.)

SURGERY

Mitral valve repair in lupus valvulitis—report of a case and review of the literature. Kalangos A, et al. **J Heart Valve Dis** 1995 Mar;4(2):202–7 (29 ref.)

Operative therapy for mitral insufficiency from coronary artery disease. Galloway AC, et al. **Semin Thorac Cardiovasc Surg** 1995 Oct;7(4):227–32 (33 ref.)

[Mitral valve insufficiency in asymptomatic patients: when to think about reparative surgical intervention, when to decide about replacement] La Canna G, et al. **G Ital Cardiol** 1996 Apr;26(4):463–75 (72 ref.) **(Ita)**

[Left ventricular rupture following aortic and mitral valve replacement in a patient with osteogenesis imperfecta: a case report] Ichikawa H, et al. **Kyobu Geka** 1996 Apr; 49(4):294–6 (13 ref.) (Eng. Abstr.) **(Jpn)**

[A case report of mitral valve plasty for traumatic mitral regurgitation] Shimokawa T, et al. **Kyobu Geka** 1996 Mar; 49(3):228–30 (9 ref.) (Eng. Abstr.) **(Jpn)**

[Report of a case with re-mitral valve replacement for Björk–Shiley Delrin disc valve prosthesis—disc wear of the Delrin disc 20 years after implantation] Abe M, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Apr;44(4):545–7 (11 ref.) (Eng. Abstr.) **(Jpn)**

THERAPY

[Mitral valvuloplasty using the Inoue balloon] Hellmüller B, et al. **Schweiz Med Wochenschr** 1995 Nov 4;125(44):2122–30 (36 ref.) (Eng. Abstr.) **(Ger)**

ULTRASONOGRAPHY

Current status of flow convergence for clinical applications: is it a leaning tower of "PISA"? Simpson IA, et al. **J Am Coll Cardiol** 1996 Feb;27(2):504–9 (51 ref.)

Intraoperative transesophageal echocardiographic evaluation of mitral regurgitation. Ammar T, et al. **J Cardiothorac Vasc Anesth** 1996 Apr;10(3):397–405 (44 ref.)

[The quantification of valvular regurgitation. What new does echocardiography offer?] Mele D. **G Ital Cardiol** 1995 Sep; 25(9):1195–203 (54 ref.) **(Ita)**

MITRAL VALVE PROLAPSE

PHYSIOPATHOLOGY

Mitral valve prolapse. Hanson EW, et al. **Anesthesiology** 1996 Jul;85(1):178–95 (176 ref.)

ULTRASONOGRAPHY

[Morphological study by transesophageal echocardiography and clinical aspects of ruptured chordae tendineae in the elderly] Benhalima B, et al. **Arch Mal Coeur Vaiss** 1995 Mar;88(3):345–52 (29 ref.) (Eng. Abstr.) **(Fre)**

MITRAL VALVE STENOSIS

COMPLICATIONS

Serial changes of left atrial thrombus in mitral stenosis: transesophageal echocardiographic studies in candidates for balloon mitral commissurotomy. Hase M, et al. **Can J Cardiol** 1996 Mar;12(3):278–84 (28 ref.)

[Sneddon syndrome and mitral valve disease] Puisieux F, et al. **Ann Cardiol Angeiol (Paris)** 1996 Feb;45(2):64–7 (19 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

[Principals of clinical examinations of mitral stenosis prior to invasive treatment] Hula J. **Vnitr Lek** 1995 Dec; 41(12):842–5 (18 ref.) (Eng. Abstr.) **(Cze)**

ETIOLOGY

[A case of SLE associated with antiphospholipid syndrome and mitral stenosis] Takahashi M, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Feb;18(1):90–7 (28 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

Left ventricular function in mitral valve disease. Oakley CM. **J Heart Valve Dis** 1995 Oct;4 Suppl 2:S236–40; discussion S240–1 (28 ref.)

SURGERY

Indications for valve surgery in asymptomatic patients with aortic and mitral stenosis. Carabello BA. **Chest** 1995 Dec; 108(6):1678–82 (30 ref.)

[Mitral valve replacement for congenital parachute mitral valve] Sasahashi N, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Jul;43(7):1092–6 (13 ref.) (Eng. Abstr.) **(Jpn)**

THERAPY

[Complications of percutaneous mitral commissurotomy. Personal experience and review of the literature] Ben Farhat M, et al. **Arch Mal Coeur Vaiss** 1996 Apr; 89(4):417–23 (30 ref.) (Eng. Abstr.) **(Fre)**

[Cardiology update—II] Trappe HJ. **Med Klin** 1995 Oct 15; 90(10):567–78 (139 ref.) **(Ger)**

[Mitral valvuloplasty using the Inoue balloon] Hellmüller B, et al. **Schweiz Med Wochenschr** 1995 Nov 4;125(44):2122–30 (36 ref.) (Eng. Abstr.) **(Ger)**

[Percutaneous balloon mitral valvoplasty. Immediate results, complications and hospital outcome] Peixoto EC, et al. **Arq Bras Cardiol** 1995 Feb;64(2):109–16 (86 ref.) (Eng. Abstr.) **(Por)**

[Percutaneous mitral commissurotomy with an Inoue catheter in congenital mitral stenosis] Ledesma Velasco M, et al. **Arch Inst Cardiol Mex** 1995 May–Jun;65(3):261–3 (13 ref.) (Eng. Abstr.) **(Spa)**

ULTRASONOGRAPHY

Stenotic lesions. Wranne B, et al. **Heart** 1996 Jun;75(6 Suppl 2):36–42 (42 ref.)

[Correlation between transthoracic and transesophageal echocardiography and surgery in mitral stenosis] Khatouri A, et al. **Ann Cardiol Angeiol (Paris)** 1995 Nov;44(9):501–6 (18 ref.) (Eng. Abstr.) **(Fre)**

MIXED CONNECTIVE TISSUE DISEASE

ETIOLOGY

Mixed connective tissue disease: fact or fiction? Citera G, et al. **Lupus** 1995 Aug;4(4):255–7 (36 ref.)

PATHOLOGY

Mixed connective tissue disease complicated by pneumatosis cystoides intestinalis and malabsorption syndrome: case report and literature review. Wakamatsu M, et al. **Pathol Int** 1995 Nov;45(11):875–8 (18 ref.)

THERAPY

[Treatment of mixed connective tissue disease] Kasukawa R. **Nippon Naika Gakkai Zasshi** 1995 Sep 10;84(9):1538–44 (13 ref.) **(Jpn)**

MIXED GONADAL DYSGENESIS see GONADAL DYSGENESIS, MIXED

MIXED LYMPHOCYTE CULTURE TEST see LYMPHOCYTE CULTURE TEST, MIXED

MIXED LYMPHOCYTE REACTION see LYMPHOCYTE CULTURE TEST, MIXED

MIXED SALIVARY GLAND TUMOR see ADENOMA, PLEOMORPHIC

MIXED TUMOR, MALIGNANT

[Malignant mixed tumor of the liver] Kubo Y. **Ryoikibetsu Shokogun Shirizu** 1995;(7):345–8 (3 ref.) **(Jpn)**

PATHOLOGY

Malignant mixed müllerian tumor of the extraovarian secondary müllerian system. Report of two cases and review of the English literature. Mira JL, et al. **Arch Pathol Lab Med** 1995 Nov;119(11):1044–9 (31 ref.)

Two cases of pheochromocytoma diagnosed histopathologically as mixed neuroendocrine–neural tumor. Watanabe T, et al. **Intern Med** 1995 Jul;34(7):683–7 (47 ref.)

MIXED TUMOR, MULLERIAN

DIAGNOSIS

Diagnosis and clinical management in malignant Müllerian tumors of the fallopian tube. A report of four cases and review of recent literature. Horn LC, et al. **Arch Gynecol Obstet** 1996;258(1):47–53 (23 ref.)

PATHOLOGY

Malignant mixed müllerian tumor of the extraovarian secondary müllerian system. Report of two cases and review of the English literature. Mira JL, et al. **Arch Pathol Lab Med** 1995 Nov;119(11):1044–9 (31 ref.)

Two unusual presentations of müllerian adenosarcoma: case reports, literature review, and treatment considerations. Gollard R, et al. **Gynecol Oncol** 1995 Dec;59(3):412–22 (26 ref.)

Müllerian adenosarcoma of the cervix: differential diagnosis, histogenesis and review of the literature. García–Rostán y P erez GM, et al. **Pathol Int** 1995 Nov;45(11):890–4 (30 ref.)

SURGERY

[Heterologous adenosarcoma of the Müllerian ducts in

adolescence. Presentation of clinical case and review of the literature] Juárez Azpilcueta A, et al. **Ginecol Obstet Mex** 1995 Sep;63:398–400 (15 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

Diagnosis and clinical management in malignant Müllerian tumors of the fallopian tube. A report of four cases and review of recent literature. Horn LC, et al. **Arch Gynecol Obstet** 1996;258(1):47–53 (23 ref.)

MK-421 see **ENALAPRIL**

MK-422 see **ENALAPRILAT**

MK-801 see **DIZOCILPINE MALEATE**

MN SIALOGLYCOPROTEIN see **GLYCOPHORIN**

MNSS BLOOD-GROUP SYSTEM

GENETICS

Molecular genetics of the glycophorin gene family, the antigens for MNSs blood groups: multiple gene rearrangements and modulation of splice site usage result in extensive diversification. Blumenfeld OO, et al. **Hum Mutat** 1995;6(3):199–209 (52 ref.)

MNSs and major glycophorins of human erythrocytes. Cartron JP, et al. **Transfus Clin Biol** 1995;2(4):251–8 (12 ref.)

MOBILE EMERGENCY UNITS see **AMBULANCES**

MOBILE GENETIC ELEMENTS see **DNA INSERTION ELEMENTS**

MODELS, ANATOMIC

The social body and the biomechanical body: can they coexist in nurse education? Brown C, et al. **J Adv Nurs** 1996 Apr; 23(4):651–6 (36 ref.)

Computer simulation of the upper extremities. Buford WL Jr, et al. **J Hand Ther** 1995 Apr–Jun;8(2):167–74 (33 ref.)

A new representation of knowledge concerning human anatomy and function. Höhne KH, et al. **Nat Med** 1995 Jun;1(6):506–11 (33 ref.)

MODELS, BIOLOGICAL

see related
DISEASE MODELS, ANIMAL

New computational models of the respiratory oscillator in mammals. Smith JC. **Adv Exp Med Biol** 1995;393:7–13 (10 ref.)

Control of intermittent ventilation in lower vertebrates. A computer dynamic model. Topor ZL, et al. **Adv Exp Med Biol** 1995;393:21–2 (4 ref.)

Is the slow component of exercise VO2 a respiratory adaptation to anaerobiosis? Wasserman K, et al. **Adv Exp Med Biol** 1995;393:187–94 (11 ref.)

Towards a molecular biology of the circadian clock and sleep of mammals. Shiromani PJ, et al. **Adv Neuroimmunol** 1995; 5(2):217–30 (89 ref.)

Dialysate-based kinetic modeling. Garred LJ. **Adv Ren Replace Ther** 1995 Oct;2(4):305–18 (35 ref.)

Solute disequilibrium and multicompartment modeling. Kaufman AM, et al. **Adv Ren Replace Ther** 1995 Oct; 2(4):319–29 (39 ref.)

New model for the regulation of energy balance and adiposity by the central nervous system. Kaiyala KJ, et al. **Am J Clin Nutr** 1995 Nov;62(5 Suppl):1123S–1134S (130 ref.)

Metabolizable energy of macronutrients. Livesey G. **Am J Clin Nutr** 1995 Nov;62(5 Suppl):1135S–1142S (35 ref.)

Euclidean distance matrix analysis: confidence intervals for form and growth differences. Lele S, et al. **Am J Phys Anthropol** 1995 Sep;98(1):73–86 (28 ref.)

Prediction of body composition in elderly men over 75 years of age. Fuller NJ, et al. **Ann Hum Biol** 1996 Mar–Apr; 23(2):127–47 (64 ref.)

Neuronal models of prefrontal cortical functions. Dehaene S, et al. **Ann N Y Acad Sci** 1995 Dec 15;769:305–19 (37 ref.)

Analogical transfer in sequence learning. Human and neural-network models of frontostriatal function. Dominey PF, et al. **Ann N Y Acad Sci** 1995 Dec 15;769:369–73 (5 ref.)

Toward a cognitive account of frontal lobe function: simulating frontal lobe deficits in normal subjects. Dunbar K, et al. **Ann N Y Acad Sci** 1995 Dec 15;769:289–304 (34 ref.)

A model of the dynamics of prefrontal cortico–thalamo–basal ganglionic loops in verbal response selection tasks. Gullapalli V, et al. **Ann N Y Acad Sci** 1995 Dec 15; 769:375–80 (22 ref.)

A computer model of prefrontal cortex function. Levinson R. **Ann N Y Acad Sci** 1995 Dec 15;769:381–8 (9 ref.)

The bidirectional paradigm of transplant immunology. Starzl TE, et al. **Ann N Y Acad Sci** 1995 Dec 29;770:165–76 (32 ref.)

Energy partitioning and modeling in animal nutrition. Baldwin RL, et al. **Annu Rev Nutr** 1995;15:191–211 (56 ref.)

The nature of the ponderostat: Hervey's hypothesis revived. Cabanac M, et al. **Appetite** 1996 Feb;26(1):45–54 (77 ref.)

Is the intracellular pH threshold an anaerobic threshold from the view point of intracellular events?: a brief review. Iwanaga K, et al. **Appl Human Sci** 1996 Mar;15(2):59–65 (53 ref.)

Convective mass transfer in hemodialysis. Jaffrin MY. **Artif Organs** 1995 Nov;19(11):1162–71 (12 ref.)

Mechanoreception at the cellular level: the detection, interpretation, and diversity of responses to mechanical signals. Banes AJ, et al. **Biochem Cell Biol** 1995 Jul–Aug; 73(7–8):349–65 (130 ref.)

Physiological control of metabolic flux: the requirement for multisite modulation. Fell DA, et al. **Biochem J** 1995 Oct 1;311 (Pt 1):35–9 (48 ref.)

Escherichia coli as a model for the regulation of dissociable (type II) fatty acid biosynthesis. Rock CO, et al. **Biochim Biophys Acta** 1996 Jul 12;1302(1):1–16 (143 ref.)

Multi-dynein hypothesis. Asai DJ. **Cell Motil Cytoskeleton** 1995;32(2):129–32 (36 ref.)

Biophysical aspects and modelling of ciliary motility. Holwill ME, et al. **Cell Motil Cytoskeleton** 1995;32(2):114–20 (31 ref.)

The molecular basis of pneumococcal infection: a hypothesis. Cundell D, et al. **Clin Infect Dis** 1995 Dec;21 Suppl 3:S204–11 (114 ref.)

Mechanical properties of implantable biomaterials. Meaney DF. **Clin Podiatr Med Surg** 1995 Jul;12(3):363–84 (6 ref.)

Barrett's esophagus: a model of human neoplastic progression. Neshat K, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:577–83 (58 ref.)

The biopsychosocial paradigm and the future of psychiatry. Freedman AM. **Compr Psychiatry** 1995 Nov–Dec; 36(6):397–406 (44 ref.)

Homeostatic control of plasma calcium concentration. Hurwitz S. **Crit Rev Biochem Mol Biol** 1996 Feb; 31(1):41–100 (500 ref.)

Microbial modeling in foods. Whiting RC. **Crit Rev Food Sci Nutr** 1995 Nov;35(6):464–94 (217 ref.)

Doubly labelled water measurement of total energy expenditure. Ritz P, et al. **Diabete Metab** 1995 Oct; 21(4):241–51 (68 ref.)

Empirical and biologically based models for cancer risk assessment. Zielinski JM, et al. **Drug Metab Rev** 1996 Feb–May;28(1–2):53–75 (29 ref.)

Morphology and mechanics of muscle: two or one? Huyghe JM. **Eur J Morphol** 1996;34(1):3–4 (8 ref.)

Does the kidney express redundant or important molecules during nephrogenesis? Sariola H. **Exp Nephrol** 1996 Mar–Apr;4(2):70–6 (43 ref.)

A mechanism for beta-amyloid overproduction in Alzheimer's disease: precursor-independent generation of beta-amyloid via antisense RNA-primed mRNA synthesis. Volloch V. **FEBS Lett** 1996 Jul 22;390(2):124–8 (31 ref.)

The cascade mechanism to explain ozone toxicity: the role of lipid ozonation products. Pryor WA, et al. **Free Radic Biol Med** 1995 Dec;19(6):935–41 (42 ref.)

The role of follicle-stimulating hormone in the selection of follicles in human ovaries: a survey of the literature and a proposed model. Scheele F, et al. **Gynecol Endocrinol** 1996 Feb;10(1):55–66 (108 ref.)

Putative neuroimmunological mechanisms in cluster headache. An integrated hypothesis. Martelletti P, et al. **Headache** 1996 May;36(5):312–5 (44 ref.)

Why is there a peak of human chorionic gonadotrophin (HCG) in early pregnancy? Chard T, et al. **Hum Reprod** 1995 Jul;10(7):1837–40 (61 ref.)

A role for glycoconjugates in human development: the human feto–embryonic defence system hypothesis. Clark GF, et al. **Hum Reprod** 1996 Mar;11(3):467–73 (62 ref.)

The origin of CD4–CD8–TCR alpha beta+ thymocytes: a model based on T-cell receptor avidity. Budd RC, et al. **Immunol Today** 1995 Sep;16(9):428–31 (27 ref.)

Physical chemistry and the biologic week in the perspective of chrono–oncology. Ulmer W, et al. **In Vivo** 1995 Jul–Aug; 9(4):363–74 (96 ref.)

Radiation-induced apoptosis: relevance to radiotherapy. Dewey WC, et al. **Int J Radiat Oncol Biol Phys** 1995 Nov 1;33(4):781–96 (78 ref.)

AIDS pathogenesis: from models to viral dynamics in patients. Nowak MA. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995;10 Suppl 1:S1–5 (14 ref.)

Prediction of ruminal volatile fatty acids and pH within the net carbohydrate and protein system. Pitt RE, et al. **J Anim Sci** 1996 Jan;74(1):226–44 (126 ref.)

Scaling, normalizing, and per ratio standards: an allometric modeling approach. Nevill AM, et al. **J Appl Physiol** 1995 Sep;79(3):1027–31 (28 ref.)

Functional role of glycosphingolipids in cell recognition and signaling. Hakomori S, et al. **J Biochem (Tokyo)** 1995 Dec; 118(6):1091–103 (123 ref.)

Regulation and control of compartmentalized glycolysis in bloodstream form Trypanosoma brucei. Bakker BM, et al. **J Bioenerg Biomembr** 1995 Oct;27(5):513–25 (63 ref.)

Metabolic regulation: a control analytic perspective. Hofmeyr JH. **J Bioenerg Biomembr** 1995 Oct;27(5):479–90 (30 ref.)

Kinetic and regulatory aspects of the function of the alternative oxidase in plant respiration. Krab K. **J Bioenerg Biomembr** 1995 Aug;27(4):387–96 (47 ref.)

Elusive control. Westerhoff HV, et al. **J Bioenerg Biomembr** 1995 Oct;27(5):491–7 (54 ref.)

Design of the oxygen and substrate pathways. I. Model and strategy to test symmorphosis in a network structure. Taylor CR, et al. **J Exp Biol** 1996 Aug;199 (Pt 8):1643–9 (25 ref.)

Looking beyond the dogma of genomic steroid action: insights and facts of the 1990s. Wehling M. **J Mol Med** 1995 Sep;73(9):439–47 (88 ref.)

An imaging-based computational and experimental study of skull fracture: finite element model development. Bandak FA, et al. **J Neurotrauma** 1995 Aug;12(4):679–88 (31 ref.)

Perspectives in pharmacokinetics. Physiologically based pharmacokinetic modeling as a tool for drug development [see comments] Charnick SB, et al. **J Pharmacokinet Biopharm** 1995 Apr;23(2):217–29 (70 ref.) Comment in: J Pharmacokinet Biopharm 1995 Apr;23(2):231–5.

A biological model for the regulation of peri-implantational hemostasis and menstruation. Lockwood CJ, et al. **J Soc Gynecol Investig** 1996 Jul–Aug;3(4):159–65 (79 ref.)

Evolution of control system models of ocular accommodation, vergence and their interaction. Eadie AS, et al. **Med Biol Eng Comput** 1995 Jul;33(4):517–24 (84 ref.)

A radical view of gallstone aetiogenesis. Braganza JM, et al. **Med Hypotheses** 1995 Nov;45(5):510–6 (62 ref.)

Fibrosis causes progressive kidney failure. Cohen EP. **Med Hypotheses** 1995 Nov;45(5):459–62 (35 ref.)

Neuroendocrine dysrhythmias. Elks ML. **Med Hypotheses** 1995 May;44(5):319–24 (43 ref.)

Hair growth and the fluid factor. Foote SI. **Med Hypotheses** 1995 Jun;44(6):475–8 (18 ref.)

Opioid involvement in feeding behaviour and the pathogenesis of certain eating disorders. Johnson RD. **Med Hypotheses** 1995 Nov;45(5):491–7 (48 ref.)

Pre-eclampsia, autoimmune diseases and breast cancer etiology. Polednak AP. **Med Hypotheses** 1995 May; 44(5):414–8 (46 ref.)

An enzyme/brain-barrier theory of psychiatric pathogenesis: unifying observations on phenylketonuria, autism, schizophrenia and postpartum psychosis. Seim AR, et al. **Med Hypotheses** 1995 Nov;45(5):498–502 (36 ref.)

Preovulatory overripeness of the oocyte as a cause of ovarian dysfunction in the human female. Smits LJ, et al. **Med Hypotheses** 1995 Nov;45(5):441–8 (116 ref.)

The hypothetical epidemic of coronary heart disease and atherosclerosis. Stehbens WE. **Med Hypotheses** 1995 Nov; 45(5):449–54 (55 ref.)

Force generation by microtubule assembly/disassembly in mitosis and related movements. Inoué S, et al. **Mol Biol Cell** 1995 Dec;6(12):1619–40 (188 ref.)

State-dependent life histories. McNamara JM, et al. **Nature** 1996 Mar 21;380(6571):215–21 (73 ref.)

Orientation in visual cortex: a simple mechanism emerges. Das A. **Neuron** 1996 Mar;16(3):477–80 (23 ref.)

Diffusion-weighted imaging in tissues: theoretical models. Szafer A, et al. **NMR Biomed** 1995 Nov–Dec;8(7–8):289–96 (45 ref.)

Disease heterogeneity: does it impact our ability to detect dietary associations with breast cancer? Slattery ML, et al. **Nutr Cancer** 1995;24(3):213–20 (72 ref.)

Hypothesis: vascular compromise is the central pathogenic mechanism for acute hemorrhagic pancreatitis. Blackstone MO. **Perspect Biol Med** 1995 Autumn;39(1):56–63 (23 ref.)

Changing patterns of communicable disease: who is turning the kaleidoscope? Waltner-Toews D. **Perspect Biol Med** 1995 Autumn;39(1):43–55 (22 ref.)

Hox genes and the evolution of diverse body plans. Akam M. **Philos Trans R Soc Lond B Biol Sci** 1995 Sep 29; 349(1329):313–9 (52 ref.)

GTPases: a family of molecular switches and clocks. Bourne HR. **Philos Trans R Soc Lond B Biol Sci** 1995 Sep 29; 349(1329):283–9 (32 ref.)

The neurotrophic hypothesis: where does it stand? Davies AM. **Philos Trans R Soc Lond B Biol Sci** 1996 Mar 29; 351(1338):389–94 (51 ref.)

Evolution of a dynamic cytoskeleton. Mitchison TJ. **Philos Trans R Soc Lond B Biol Sci** 1995 Sep 29; 349(1329):299–304 (18 ref.)

The pathogenesis of emphysema: the elastase:antielastase hypothesis 30 years later. Shapiro SD. **Proc Assoc Am Physicians** 1995 Oct;107(3):346–52 (40 ref.)

How food preferences are learned: laboratory animal models. Sclafani A. **Proc Nutr Soc** 1995 Jul;54(2):419–27 (63 ref.)

How do long-chain free fatty acids cross cell membranes? [comment] Berk PD. **Proc Soc Exp Biol Med** 1996 May; 212(1):1–4 (33 ref.) Comment on: Proc Soc Exp Biol Med 1996 May;212(1):5–14. Comment on: Proc Soc Exp Biol Med 1996 May;212(1):15–23.

To cell from environment. Palmlund I. **Prog Clin Biol Res** 1996;394:425–45 (95 ref.)

Principles underlying dose selection for, and extrapolation from, the carcinogen bioassay: dose influences mechanism. Counts JL, et al. **Regul Toxicol Pharmacol** 1995 Jun; 21(3):418–21 (39 ref.)

Cyclosporine-induced apoptosis in CD4+ T lymphocytes and computer-simulated analysis: modeling a treatment scenario for HIV infection. Huss R, et al. **Res Immunol** 1995 Feb;146(2):101–8 (32 ref.)

Eye-movement models for arithmetic and reading

performance. Suppes P. **Rev Oculomot Res** 1990;4:455–77 (53 ref.)
Validation of a methodology for modelling PCDD and PCDF intake via the foodchain. Eduljee GH, et al. **Sci Total Environ** 1996 Sep 9;187(3):211–29 (36 ref.)
Physiological and pathophysiological aspects of the immune system contributing to a biomathematical model of lymphocytes. Wuestermann PR, et al. **Stem Cells (Dayt)** 1995 May;13 Suppl 1:268–75 (59 ref.)
Functional significance of cytochrome c oxidase structure. Scott RA. **Structure** 1995 Oct 15;3(10):981–6 (26 ref.)
Physiologically-based pharmacokinetic modeling and bioactivation of xenobiotics. Clewell HJ 3rd, et al. **Toxicol Ind Health** 1994 Jan–Apr;10(1–2):1–24 (55 ref.)
Summary and recommendations for session B: activity classification and structure–activity relationship modeling for human health risk assessment of toxic substances. Bristol DW. **Toxicol Lett** 1995 Sep;79(1–3):265–80 (10 ref.)
The application of physiologically based pharmacokinetic modeling in human health risk assessment of hazardous substances. Clewell HJ 3rd. **Toxicol Lett** 1995 Sep; 79(1–3):207–17 (79 ref.)
Extrapolation of physiological parameters for physiologically based simulation models. Fiserova–Bergerova V. **Toxicol Lett** 1995 Sep;79(1–3):77–86 (39 ref.)
Summary of panel discussion on the 'advantages/limitations/uncertainties in the use of physiologically based pharmacokinetic and pharmacodynamic models in hazard identification and risk assessment of toxic substances'. Frederick CB. **Toxicol Lett** 1995 Sep;79(1–3):201–6 (4 ref.)
Physiologically based pharmacokinetic models: mathematical fundamentals and simulation implementations. Hoang K. **Toxicol Lett** 1995 Sep;79(1–3):99–106 (20 ref.)
The application of dosimetry models to identify key processes and parameters for default dose–response assessment approaches. Jarabek AM. **Toxicol Lett** 1995 Sep; 79(1–3):171–84 (26 ref.)
Achieving credibility in risk assessment models. Kohn MC. **Toxicol Lett** 1995 Sep;79(1–3):107–14 (19 ref.)
The application of physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) modeling to understanding the mechanism of action of hazardous substances. Medinsky MA. **Toxicol Lett** 1995 Sep; 79(1–3):185–91 (16 ref.)
Extrapolating the future: research trends in modeling. Menzel DB. **Toxicol Lett** 1995 Sep;79(1–3):299–303 (8 ref.)
The application of physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) modeling for exploring risk assessment approaches of chemical mixtures. Yang RS, et al. **Toxicol Lett** 1995 Sep; 79(1–3):193–200 (37 ref.)
Negative selection in hepatic tumor promotion in relation to cancer risk assessment. Andersen ME, et al. **Toxicology** 1995 Sep 1;102(1–2):223–37 (82 ref.)
Biologically-based models of dioxin pharmacokinetics. Buckley LA. **Toxicology** 1995 Sep 1;102(1–2):125–31 (26 ref.)
Incorporating biological information in quantitative risk assessment: an example with methylene chloride. Clewell HJ 3rd. **Toxicology** 1995 Sep 1;102(1–2):83–94 (33 ref.)
Use of physiologically based pharmacokinetic modeling to investigate individual versus population risk. Clewell HJ 3rd, et al. **Toxicology** 1996 Jul 17;111(1–3):315–29 (107 ref.)
Cell proliferation in the bladder and implications for cancer risk assessment. Cohen SM. **Toxicology** 1995 Sep 1; 102(1–2):149–59 (24 ref.)
Cancer and non-cancer risk assessment: not so different if you consider mechanisms. Conolly RB. **Toxicology** 1995 Sep 1;102(1–2):179–88 (31 ref.)
Comparison of experimental and theoretical parameters of the Moolgavkar–Venzon–Knudson incidence function for the stages of initiation and promotion in rat hepatocarcinogenesis. Dragan YP, et al. **Toxicology** 1995 Sep 1;102(1–2):161–75 (65 ref.)
The future of mechanistic research in risk assessment: where are we going and can we get there from here? Goddard MJ, et al. **Toxicology** 1995 Sep 1;102(1–2):53–70 (84 ref.)
Toxicity prediction from metabolic pathway modelling. Jackson RC. **Toxicology** 1995 Sep 1;102(1–2):197–205 (23 ref.)
Pharmacokinetics and receptor–mediated pharmacodynamics of corticosteroids. Jusko WJ. **Toxicology** 1995 Sep 1; 102(1–2):189–96 (28 ref.)
Biochemical mechanisms and cancer risk assessment models for dioxin. Kohn MC. **Toxicology** 1995 Sep 1; 102(1–2):133–8 (31 ref.)
Use of quantitative modelling in methylene chloride risk assessment. Rhomberg L. **Toxicology** 1995 Sep 1; 102(1–2):95–114 (58 ref.)
Research to strengthen the scientific basis for health risk assessment: a survey of the context and rationale for mechanistically based methods and models. Sexton K, et al. **Toxicology** 1995 Sep 1;102(1–2):3–20 (62 ref.)
Biological modeling of 5-fluorouracil developmental toxicity. Shuey DL, et al. **Toxicology** 1995 Sep 1;102(1–2):207–13 (23 ref.)
Transfusion and the immune system: a paradigm shift in progress? Blumberg N, et al. **Transfusion** 1995 Oct; 35(10):879–83 (55 ref.)
[How to calculate the growth rate of a neoplasm?] Rissanen K. **Duodecim** 1994;110(9):878–81 (7 ref.) **(Fin)**
[Comments on the suitability of swine skin as a biological model for human skin] Meyer W. **Hautarzt** 1996 Mar; 47(3):178–82 (65 ref.) (Eng. Abstr.) **(Ger)**
[The functional state of denatured proteins: the principles of modelling and the first results] Bychkova VE, et al. **Tsitologiia** 1995;37(12):1238–50 (48 ref.) (Eng. Abstr.) **(Rus)**
[A model of the spatial organization of double-row (pseudostratified) epithelium (a topical article)] Savost'ianov GA. **Zh Evol Biokhim Fiziol** 1994 Sep–Oct; 30(5):625–31 (23 ref.) **(Rus)**

MODELS, CARDIOVASCULAR

Simulation of intraluminal gas transport processes in the microcirculation. Hellums JD, et al. **Ann Biomed Eng** 1996 Jan–Feb;24(1):1–24 (97 ref.)
Energetic and spatial constraints of arterial networks. Rossitti S. **Arq Neuropsiquiatr** 1995 Jun;53(2):333–41 (48 ref.)
An alternative perspective on ischemic preconditioning derived from mathematical modeling. Whittaker P. **Basic Res Cardiol** 1996 Jan–Feb;91(1):47–9 (9 ref.)
Cardiac efficiency. Gibbs CL, et al. **Cardiovasc Res** 1995 Nov; 30(5):627–34 (67 ref.)
Mechanoelectric feedback (transduction) in heart: concepts and implications. Lab MJ. **Cardiovasc Res** 1996 Jul; 32(1):3–14 (146 ref.)
Linear and non-linear analyses of heart rate variability: a minireview. Mansier P, et al. **Cardiovasc Res** 1996 Mar; 31(3):371–9 (64 ref.)
Mechano–electric feedback in the human heart. Taggart P. **Cardiovasc Res** 1996 Jul;32(1):38–43 (41 ref.)
Artificial neural networks: current status in cardiovascular medicine. Itchhaporia D, et al. **J Am Coll Cardiol** 1996 Aug;28(2):515–21 (39 ref.)
The influence of optimization target selection on the structure of arterial tree models generated by constrained constructive optimization. Schreiner W, et al. **J Gen Physiol** 1995 Oct;106(4):583–99 (34 ref.)
Limiting factors in the control of BP: why is there a gap between theory and practice? Ménard J, et al. **J Hum Hypertens** 1995 Jul;9 Suppl 2:S19–23 (17 ref.)
Endothelium, fibrinolysis, cardiac risk factors, and prostaglandins: a unified model of atherogenesis. Kadish J. **Med Hypotheses** 1995 Aug;45(2):205–13 (106 ref.)
Bioenergetics in the pathogenesis, progression and treatment of cardiovascular disorders. Tanner HA. **Med Hypotheses** 1995 May;44(5):347–58 (82 ref.)

MODELS, CHEMICAL

Selected new developments in computational chemistry. Darden TA, et al. **Environ Health Perspect** 1996 Mar;104 Suppl 1:69–74 (56 ref.)
Pharmacokinetic modelling—a prelude to therapeutic drug monitoring for all cancer patients? [editorial; comment] Judson IR. **Eur J Cancer** 1995 Oct;31A(11):1733–5 (24 ref.) Comment on: Eur J Cancer 1995 Oct;31A(11):1794–8. Comment on: Eur J Cancer 1995 Oct;31A(11):1804–10.
Thermodynamics of denaturation of staphylococcal nuclease mutants: an intermediate state in protein folding. Carra JH, et al. **FASEB J** 1996 Jan;10(1):67–74 (52 ref.)
Protein folding by a biased Monte Carlo procedure in the dihedral angle space. Lee B, et al. **FASEB J** 1996 Jan; 10(1):119–25 (43 ref.)
Lipophilicity in molecular modeling. Testa B, et al. **Pharm Res** 1996 Mar;13(3):335–43 (43 ref.)
The search for synergy: a critical review from a response surface perspective. Greco WR, et al. **Pharmacol Rev** 1995 Jun;47(2):331–85 (161 ref.)
A simple model for deuterium cross-polarization magic-angle spinning nuclear magnetic resonance at the interphases of amorphous materials. Zumbulyadis N. **Solid State Nucl Magn Reson** 1995 Oct;5(1):3–7 (11 ref.)
Use of graph theoretic parameters in risk assessment of chemicals. Basak SC, et al. **Toxicol Lett** 1995 Sep; 79(1–3):239–50 (55 ref.)
Structure–activity relationships and computer-assisted analysis of respiratory sensitization potential. Karol MH, et al. **Toxicol Lett** 1996 Aug;86(2–3):187–91 (10 ref.)

MODELS, COMPUTER see **COMPUTER SIMULATION**

MODELS, DECISION SUPPORT see **DECISION SUPPORT TECHNIQUES**

MODELS, ECONOMETRIC

Spain: an explanatory model of supply and utilization of human resources of the health care system. Alfonso Sanchez JL, et al. **Cah Sociol Demogr Med** 1995 Oct–Dec; 35(3–4):227–61 (79 ref.)
Sensitivity analysis in economic evaluation: a review of published studies. Briggs A, et al. **Health Econ** 1995 Sep–Oct;4(5):355–71 (109 ref.)
Health status index models for use in resource allocation decisions. A critical review in the light of observed preferences for social choice. Nord E. **Int J Technol Assess Health Care** 1996 Winter;12(1):31–44 (47 ref.)

MODELS, ECONOMIC

Breakeven under capitation: pure and simple? Boles KE, et al. **Health Care Manage Rev** 1996 Winter;21(1):38–47 (15 ref.)
Gender differences in career progress in nursing: towards a non-essentialist structural theory. Ratcliffe P. **J Adv Nurs** 1996 Feb;23(2):389–95 (48 ref.)
[QALYS or not QALYS: that is the question?] Moatti JP, et al. **Rev Epidemiol Sante Publique** 1995 Dec;43(6):573–83 (27 ref.) (Eng. Abstr.) **(Fre)**

MODELS, EDUCATIONAL

Can educational accreditation drive interdisciplinary learning in the health professions? Gelmon SB. **Jt Comm J Qual Improv** 1996 Mar;22(3):213–22 (27 ref.)
Accepting the Galvin challenge: increasing efficiency and productivity in health professions education. Neuhauser D, et al. **Jt Comm J Qual Improv** 1996 Mar;22(3):223–27 (1 ref.)
Refocusing the training of psychiatric rehabilitation staff. Corrigan PW, et al. **Psychiatr Serv** 1995 Nov;46(11):1172–7 (33 ref.)
Postpositivist methodology and clinical education. Baird M. **Radiol Technol** 1995 Sep–Oct;67(1):15–23 (86 ref.)

MODELS, GENETIC

Gene hypothesis of autoimmunity, and autoimmune disease. Storch WB. **Adv Exp Med Biol** 1995;371B:1213–5 (22 ref.)
Use of transgenics, null mutants, and antisense approaches to study ethanol's actions. Wehner JM, et al. **Alcohol Clin Exp Res** 1995 Aug;19(4):811–20 (79 ref.)
Proenkephalin gene regulation in the neuroendocrine hypothalamus: a model of gene regulation in the CNS. Borsook D, et al. **Am J Physiol** 1995 Sep;269(3 Pt 1):E393–408 (203 ref.)
Conjugative transposition. Scott JR, et al. **Annu Rev Microbiol** 1995;49:367–97 (108 ref.)
Multiple steps in the regulation of transcription–factor level and activity. Calkhoven CF, et al. **Biochem J** 1996 Jul 15; 317 (Pt 2):329–42 (269 ref.)
Meiotic recombination: a mechanism for tracking and eliminating mutations? McKee BD. **Bioessays** 1996 May; 18(5):411–9 (72 ref.)
Control of mating and development in Ustilago maydis. Kahmann R, et al. **Curr Opin Genet Dev** 1995 Oct; 5(5):559–64 (31 ref.)
Model systems for studying the effects of adenovirus E3 genes on virulence in vivo. Horwitz MS, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 3):195–211 (63 ref.)
Gene silencing in transgenic plants: a heuristic autoregulation model. Meins F Jr, et al. **Curr Top Microbiol Immunol** 1995; 197:105–20 (55 ref.)
Paramutation in maize and related allelic interactions. Patterson GI, et al. **Curr Top Microbiol Immunol** 1995; 197:121–41 (94 ref.)
Genetic knockouts in mice: an update. Shastry BS. **Experientia** 1995 Nov 15;51(11):1028–39 (159 ref.)
A polygenic model of inherited predisposition to cancer. Dragani TA, et al. **FASEB J** 1996 Jun;10(8):865–70 (56 ref.)
The emergence of major cellular processes in evolution. Ouzounis C, et al. **FEBS Lett** 1996 Jul 22;390(2):119–23 (35 ref.)
The genetic basis of murine and human sex determination: a review. McElreavey K, et al. **Heredity** 1995 Dec;75 (Pt 6):599–611 (82 ref.)
HLA–G transgenic mice: a model for studying expression and function at the maternal/fetal interface. Schmidt CM, et al. **Immunol Rev** 1995 Oct;147:53–65 (32 ref.)
A genetic herd–immunity model for the maintenance of MHC polymorphism. Wills C, et al. **Immunol Rev** 1995 Feb;143:263–92 (70 ref.)
A chromomeric model for nuclear and chromosome structure. Cook PR. **J Cell Sci** 1995 Sep;108 (Pt 9):2927–35 (71 ref.)
Prediction of function in DNA sequence analysis. Gelfand MS. **J Comput Biol** 1995 Spring;2(1):87–115 (449 ref.)
Is the synaptonemal complex a disjunction machine? Maguire MP. **J Hered** 1995 Sep–Oct;86(5):330–40 (91 ref.)
Hypomelanosis of Ito and X;autosome translocations: a unifying hypothesis. Hatchwell E. **J Med Genet** 1996 Mar; 33(3):177–83 (61 ref.)
Collapse and repair of replication forks in Escherichia coli. Kuzminov A. **Mol Microbiol** 1995 May;16(3):373–84 (102 ref.)
Genetic analysis of ageing: role of oxidative damage and environmental stresses. Martin GM, et al. **Nat Genet** 1996 May;13(1):25–34 (151 ref.)
Plasmid–based transgenic mouse model for studying in vivo mutations. Boerrigter ME, et al. **Nature** 1995 Oct 19; 377(6550):657–9 (16 ref.)
Controversies about the genetic model of colorectal tumorigenesis. Waliszewski P. **Pol J Pathol** 1995; 46(4):239–43 (48 ref.)
The genetics of pain and pain inhibition. Mogil JS, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2;93(7):3048–55 (141 ref.)
Analysis of the mechanism of DNA recombination using

tangles. Sumners DW, et al. **Q Rev Biophys** 1995 Aug; 28(3):253–313 (85 ref.)
Transgenic livestock as genetic models of human disease. Petters RM. **Reprod Fertil Dev** 1994;6(5):643–5 (24 ref.)
The base excision repair pathway. Seeberg E, et al. **Trends Biochem Sci** 1995 Oct;20(10):391–7 (50 ref.)
Homologous recombination and the roles of double-strand breaks. Shinohara A, et al. **Trends Biochem Sci** 1995 Oct; 20(10):387–91 (32 ref.)
Human and rodent DNA sequence comparisons: a mosaic model of genomic evolution. Koop BF. **Trends Genet** 1995 Sep;11(9):367–71 (25 ref.)
Polygenic disease: methods for mapping complex disease traits. Weeks DE, et al. **Trends Genet** 1995 Dec; 11(12):513–9 (110 ref.)
[Genetics of Crohn disease: a complex model] Colombel JF, et al. **Gastroenterol Clin Biol** 1996;20(5 Pt 2):B15–20 (45 ref.) **(Fre)**
[Application of genetic principles to the causal assessment of atherosclerosis] Miserez AR, et al. **Ther Umsch** 1995 Dec;52(12):835–43 (48 ref.) (Eng. Abstr.) **(Ger)**

MODELS, IMMUNOLOGICAL

Immunophysiology: the immune system as a multifunctional physiological unit. Deschaux P, et al. **Cell Mol Biol Res** 1995;41(1):1–10 (89 ref.)
Synovium and epithelia: barriers between self and non-self? Berthelot JM, et al. **Clin Exp Rheumatol** 1995 Jul–Aug; 13(4):517–9 (40 ref.)
A theory of follicular dendritic cell origin. Szakal AK, et al. **Curr Top Microbiol Immunol** 1995;201:1–13 (39 ref.)
A genetic herd-immunity model for the maintenance of MHC polymorphism. Wills C, et al. **Immunol Rev** 1995 Feb;143:263–92 (70 ref.)
Th1 and Th2 subsets: paradigms lost? Kelso A. **Immunol Today** 1995 Aug;16(8):374–9 (41 ref.)
The ontogeny of class-regulation of CD4+ T lymphocyte populations. Carneiro J, et al. **Int Immunol** 1995 Aug; 7(8):1265–77 (37 ref.)
Fas and the art of lymphocyte maintenance [comment] Lenardo MJ. **J Exp Med** 1996 Mar 1;183(3):721–4 (31 ref.) Comment on: J Exp Med 1996 Mar 1;183(3):1071–82.
CD4/CD8 lineage commitment: back to instruction? von Boehmer H. **J Exp Med** 1996 Mar 1;183(3):713–5 (22 ref.)
"The good, the bad, and the ugly." The role of chemokines in models of human disease. Strieter RM, et al. **J Immunol** 1996 May 15;156(10):3583–6 (33 ref.)
The two-signal model and 'self'-reactivity: are they really compatible? A reply to Faro & Carneiro. Cohn M. **Scand J Immunol** 1996 Jan;43(1):1–5; discussion 6–8 (8 ref.)
The role of the thymus during T-lymphocyte development in vitro. Anderson G, et al. **Semin Immunol** 1995 Jun; 7(3):177–83 (49 ref.)
In-vitro models of B-lineage commitment. Kee BL, et al. **Semin Immunol** 1995 Jun;7(3):143–54 (115 ref.)
In-vitro models of stroma-dependent lymphopoiesis. Péault B. **Semin Immunol** 1995 Jun;7(3):169–75 (76 ref.)
In-vitro analyses of mechanisms of B-cell development. Rolink A, et al. **Semin Immunol** 1995 Jun;7(3):155–67 (72 ref.)
Missing self recognition by natural killer cells in MHC class I transgenic mice. A 'receptor calibration' model for how effector cells adapt to self. Sentman CL, et al. **Semin Immunol** 1995 Apr;7(2):109–19 (45 ref.)
Making the in-vitro model closer to actual B lymphopoiesis in the bone marrow. Yasunaga M, et al. **Semin Immunol** 1995 Jun;7(3):185–96 (59 ref.)
Modelling HIV vaccination. McLean AR, et al. **Trends Microbiol** 1995 Dec;3(12):458–62 (18 ref.)

MODELS, LINEAR see **LINEAR MODELS**

MODELS, LOGISTIC see **LOGISTIC MODELS**

MODELS, MOLECULAR

A functional classification scheme for beta-lactamases and its correlation with molecular structure. Bush K, et al. **Antimicrob Agents Chemother** 1995 Jun;39(6):1211–33 (338 ref.)
Peptide models for membrane channels. Marsh D. **Biochem J** 1996 Apr 15;315 (Pt 2):345–61 (143 ref.)
Model of a sub-main transition in phospholipid bilayers. Nielsen M, et al. **Biochim Biophys Acta** 1996 Sep 4; 1283(2):170–6 (20 ref.)
Local sequence-structure correlations in proteins. Bystroff C, et al. **Curr Opin Biotechnol** 1996 Aug;7(4):417–21 (37 ref.)
The current state of the art in protein structure prediction. Moult J. **Curr Opin Biotechnol** 1996 Aug;7(4):422–7 (36 ref.)
Pitfalls of protein sequence analysis. Rost B, et al. **Curr Opin Biotechnol** 1996 Aug;7(4):457–61 (12 ref.)
Modeling mutations and homologous proteins. Sali A. **Curr Opin Biotechnol** 1995 Aug;6(4):437–51 (222 ref.)
Modeling protein-ligand complexes. Bamborough P, et al. **Curr Opin Struct Biol** 1996 Apr;6(2):236–41 (54 ref.)
Novel methods for molecular dynamics simulations. Elber R. **Curr Opin Struct Biol** 1996 Apr;6(2):232–5 (29 ref.)
Structure-derived potentials and protein simulations. Jernigan RL, et al. **Curr Opin Struct Biol** 1996 Apr; 6(2):195–209 (92 ref.)
Mean-field minimization methods for biological macromolecules. Koehl P, et al. **Curr Opin Struct Biol** 1996 Apr;6(2):222–6 (36 ref.)
Simulating DNA at low resolution. Olson WK. **Curr Opin Struct Biol** 1996 Apr;6(2):242–56 (76 ref.)
Modeling side-chain conformation. Vásquez M. **Curr Opin Struct Biol** 1996 Apr;6(2):217–21 (53 ref.)
A useful role for "static" models in elucidating the behaviour of DNA in solution. Calladine CR, et al. **J Mol Biol** 1996 Apr 5;257(3):479–85 (36 ref.)
How to make my blood boil [comment] Goldman A. **Structure** 1995 Dec 15;3(12):1277–9 (18 ref.) Comment on: Structure 1995 Dec 15;3(12):1295–306.
Where freedom is given, liberties are taken. Kleywegt GJ, et al. **Structure** 1995 Jun 15;3(6):535–40 (34 ref.)
Homeodomains: together again for the first time. Tullius T. **Structure** 1995 Nov 15;3(11):1143–5 (15 ref.)

MODELS, NEURAL NETWORK see **NEURAL NETWORKS (COMPUTER)**

MODELS, NEUROLOGICAL

see related
KINDLING (NEUROLOGY)
A spinal circuitry simulator as a teaching tool for neuromuscular physiology. Maw S, et al. **Am J Physiol** 1996 Jun;270(6 Pt 3):S50–68 (25 ref.)
Neural Mechanisms in dissociative amnesia for childhood abuse: relevance to the current controversy surrounding the "false memory syndrome". Bremner JD, et al. **Am J Psychiatry** 1996 Jul;153(7 Suppl):71–82 (124 ref.)
Similarities and distinctions among current models of prefrontal cortical functions. Grafman J. **Ann N Y Acad Sci** 1995 Dec 15;769:337–68 (116 ref.)
Molecular neurobiology and pharmacology of the vasopressin/oxytocin receptor family. Peter J, et al. **Cell Mol Neurobiol** 1995 Oct;15(5):573–95 (100 ref.)
Theory in motion. Marder E, et al. **Curr Opin Neurobiol** 1995 Dec;5(6):832–40 (80 ref.)
Binding in models of perception and brain function. von der Malsburg C. **Curr Opin Neurobiol** 1995 Aug;5(4):520–6 (70 ref.)
Causes and mechanisms of primary headaches: toward a bio-behavioral model. Buzzi MG, et al. **Ital J Neurol Sci** 1995 Nov;16(8 Suppl):15–9 (32 ref.)
Models of delayed recovery. Leviton A, et al. **J Child Neurol** 1995 Sep;10(5):385–91 (55 ref.)
Transfer of coded information from sensory to motor networks. Salinas E, et al. **J Neurosci** 1995 Oct; 15(10):6461–74 (80 ref.)
On the mechanics of impact neurotrauma: a review and critical synthesis. Bandak FA. **J Neurotrauma** 1995 Aug; 12(4):635–49 (28 ref.)
Neuropoiesis: proposal for a connectionistic neurobiology. Jobe TH, et al. **Med Hypotheses** 1995 Aug;45(2):147–63 (145 ref.)
Physiological relevance and functional potential of central nervous system-derived cell lines. Whittemore SR, et al. **Mol Neurobiol** 1996 Feb;12(1):13–38 (165 ref.)
A computational model of cholinergic disruption of septohippocampal activity in classical eyeblink conditioning. Myers CE, et al. **Neurobiol Learn Mem** 1996 Jul;66(1):51–66 (90 ref.)
Molecular enhancement of memory formation. Carew TJ. **Neuron** 1996 Jan;16(1):5–8 (24 ref.)
Multineuronal codes in retinal signaling. Meister M. **Proc Natl Acad Sci U S A** 1996 Jan 23;93(2):609–14 (32 ref.)
Radial versus tangential migration of neuronal clones in the developing cerebral cortex [comment] Rakic P. **Proc Natl Acad Sci U S A** 1995 Dec 5;92(25):11323–7 (61 ref.) Comment on: Proc Natl Acad Sci U S A 1995 Dec 5;92(25):11676–80.
Neurotoxicity modeling for risk assessment. Kodell RL, et al. **Regul Toxicol Pharmacol** 1995 Aug;22(1):24–9 (10 ref.)
Cracking the neuronal code. Ferster D, et al. **Science** 1995 Nov 3;270(5237):756–7 (20 ref.)
Effects of local connectivity on striatal function: stimulation and analysis of a model. Wickens JR, et al. **Synapse** 1995 Aug;20(4):281–98 (84 ref.)
Sensitization induced by kindling and kindling-related phenomena as a model for multiple chemical sensitivity. Rossi J 3rd. **Toxicology** 1996 Jul 17;111(1–3):87–100 (93 ref.)

MODELS, NONLINEAR see **NONLINEAR DYNAMICS**

MODELS, NURSING

Evaluation of the Interaction Model of Client Health Behavior through the first decade of research. Carter KF, et al. **ANS Adv Nurs Sci** 1995 Sep;18(1):62–73 (47 ref.)
The psychiatric model: a critical analysis of its undermining effects on nursing in chronic mental illness. Hall BA. **ANS Adv Nurs Sci** 1996 Mar;18(3):16–26 (28 ref.)
Defining nursing interventions. Snyder M, et al. **Image J Nurs Sch** 1996 Summer;28(2):137–41 (31 ref.)
Intervention model for substance-using women. Tiedje LB, et al. **Image J Nurs Sch** 1996 Summer;28(2):113–8 (69 ref.)
Kitwood's approach to dementia and dementia care: a critical but appreciative review. Adams T. **J Adv Nurs** 1996 May; 23(5):948–53 (32 ref.)
Processes in the creation and diffusion of nursing knowledge: an examination of the developing concept of family-centred care. Bradley SF. **J Adv Nurs** 1996 Apr; 23(4):722–7 (33 ref.)
The social body and the biomechanical body: can they coexist in nurse education? Brown C, et al. **J Adv Nurs** 1996 Apr; 23(4):651–6 (36 ref.)
Parent participation: a concept analysis. Coyne IT. **J Adv Nurs** 1996 Apr;23(4):733–40 (78 ref.)
Is the professional code still the cornerstone of clinical nursing practice? Esterhuizen P. **J Adv Nurs** 1996 Jan; 23(1):25–31 (39 ref.)
The nursing process re-examined: enrollment and translation. Latimer J. **J Adv Nurs** 1995 Aug;22(2):213–20 (35 ref.)
Health-promoting nursing practice: the demise of the nursing process? Lindsey E, et al. **J Adv Nurs** 1996 Jan;23(1):106–12 (24 ref.)
Intuition and expertise: comments on the Benner debate. Paley J. **J Adv Nurs** 1996 Apr;23(4):665–71 (38 ref.)
A nursing perspective on the interrelationships between theory, research and practice. Pryjmachuk S. **J Adv Nurs** 1996 Apr;23(4):679–84 (19 ref.)
The changing profile of acute childhood illness: a need for the development of family nursing knowledge. Rennick JE. **J Adv Nurs** 1995 Aug;22(2):258–66 (57 ref.)
An analysis of the concept of empowerment. Rodwell CM. **J Adv Nurs** 1996 Feb;23(2):305–13 (74 ref.)
Disparagement of the nursing process: the new dogma? Varcoe C. **J Adv Nurs** 1996 Jan;23(1):120–5 (41 ref.)
Caring, curing, coping: towards an integrated model. Webb C. **J Adv Nurs** 1996 May;23(5):960–8 (44 ref.)
Psychoneuroimmunology: an emerging framework for nursing research. Zeller JM, et al. **J Adv Nurs** 1996 Apr; 23(4):657–64 (63 ref.)
A model of family adaptation to new-onset childhood epilepsy. Austin JK. **J Neurosci Nurs** 1996 Apr;28(2):82–92 (55 ref.)
Patient satisfaction with nursing care: concept clarification. Eriksen LR. **J Nurs Meas** 1995 Summer;3(1):59–76 (50 ref.)
A model of home care for high-risk childbearing families. Women with diabetes in pregnancy. Persily CA, et al. **Nurs Clin North Am** 1996 Jun;31(2):327–32 (11 ref.)
Latex allergy precautions. A research-based protocol. Steelman VM. **Nurs Clin North Am** 1995 Sep;30(3):475–93 (85 ref.)
Models and processes of research utilization. White JM, et al. **Nurs Clin North Am** 1995 Sep;30(3):409–20 (27 ref.)
Nurse practitioners in a teaching hospital. Genet CA, et al. **Nurse Pract** 1995 Sep;20(9):47–52, 54 (33 ref.)

MODELS, ORGANIZATIONAL

Effective emergency management: reconsidering the bureaucratic approach. Neal DM, et al. **Disasters** 1995 Dec; 19(4):327–37 (48 ref.)
Information systems and strategic management. Austin CJ, et al. **Health Care Manage Rev** 1995 Summer;20(3):26–33; discussion 34–42 (17 ref.)
The problematic fit of diagnosis and strategy for medical group stakeholders—including IDS/Ns. Blair JD, et al. **Health Care Manage Rev** 1996 Winter;21(1):7–28 (21 ref.)
Owned vertical integration and health care: promise and performance. Walston SL, et al. **Health Care Manage Rev** 1996 Winter;21(1):83–92 (59 ref.)
Towards a conceptual model of 'quality care'. Attree M. **Int J Nurs Stud** 1996 Feb;33(1):13–28 (38 ref.)
From research to practice: one organizational model for promoting research-based practice. Kitson A, et al. **J Adv Nurs** 1996 Mar;23(3):430–40 (53 ref.)
Eating disorders in adolescents: a model for broadening our perspective. Rees JM. **J Am Diet Assoc** 1996 Jan;96(1):22–3 (4 ref.)
Community medicine: an urban model. Deuschle KW, et al. **J Community Health** 1995 Dec;20(6):459–72 (37 ref.)
Allocating health care: cost-utility analysis, informed democratic decision making, or the veil of ignorance? Goold SD. **J Health Polit Policy Law** 1996 Spring; 21(1):69–98 (41 ref.)
Alcohol-problem prevention research policy: the need for a phases research model. Holder H, et al. **J Public Health Policy** 1995;16(3):324–46 (43 ref.)
Promises and limitations of the Patient Outcome Research Teams: the low-back pain example. Deyo RA. **Proc Assoc Am Physicians** 1995 Oct;107(3):324–8 (22 ref.)
Families of young technology-dependent children and the social worker. Bradley RH, et al. **Soc Work Health Care** 1995;21(1):23–37 (41 ref.)

MODELS, PSYCHOLOGICAL

The classification of disability. Hutchison T. **Arch Dis Child** 1995 Aug;73(2):91–3; discussion 94 (5 ref.)
The biopsychosocial paradigm and the future of psychiatry. Freedman AM. **Compr Psychiatry** 1995 Nov–Dec; 36(6):397–406 (44 ref.)
Animal models of cognitive function. Decker MW. **Crit Rev Neurobiol** 1995;9(4):321–43 (244 ref.)
Training to think culturally: a multidimensional comparative framework. Falicov CJ. **Fam Process** 1995 Dec; 34(4):373–88 (56 ref.)

MODELS, PSYCHOLOGICAL

The effects of poverty environments on elders' subjective well-being: a conceptual model. Brown V. **Gerontologist** 1995 Aug;35(4):541–8 (48 ref.)
The sense of coherence: an historical and future perspective. McCubbin HI, et al. **Isr J Med Sci** 1996 Mar–Apr; 32(3–4):170–8 (19 ref.)
Causes and mechanisms of primary headaches: toward a bio–behavioral model. Buzzi MG, et al. **Ital J Neurol Sci** 1995 Nov;16(8 Suppl):15–9 (32 ref.)
Kitwood's approach to dementia and dementia care: a critical but appreciative review. Adams T. **J Adv Nurs** 1996 May; 23(5):948–53 (32 ref.)
Process dissociation, single–process theories, and recognition memory. Ratcliff R, et al. **J Exp Psychol Gen** 1995 Dec; 124(4):352–74 (41 ref.)
A model of family adaptation to new–onset childhood epilepsy. Austin JK. **J Neurosci Nurs** 1996 Apr;28(2):82–92 (55 ref.)
Adolescent condom use, the health belief model, and the prevention of sexually transmitted disease. Hiltabiddle SJ. **J Obstet Gynecol Neonatal Nurs** 1996 Jan;25(1):61–6 (36 ref.)
The SolCos model: facilitating reminiscence therapy. Soltys FG, et al. **J Psychosoc Nurs Ment Health Serv** 1995 Nov; 33(11):21–6 (27 ref.)
Expressed emotion and a hypothetical model of relapse in schizophrenia. Eva FJ, et al. **Med Hypotheses** 1995 Jul; 45(1):99–105 (65 ref.)
Memory for proper names: a review. Cohen G, et al. **Memory** 1993 Dec;1(4):249–63 (36 ref.)
The therapeutic community: toward a general theory and model. De Leon G. **NIDA Res Monogr** 1994;144:16–53 (24 ref.)
A review of the validity and variability of the elevated plus–maze as an animal model of anxiety. Hogg S. **Pharmacol Biochem Behav** 1996 May;54(1):21–30 (56 ref.)

MODELS, STATISTICAL

see related
META-ANALYSIS
Predicting clinical states in individual patients. Braitman LE, et al. **Ann Intern Med** 1996 Sep 1;125(5):406–12 (28 ref.)
Statistical considerations and modeling of clinical utility of tumor markers. George SL. **Hematol Oncol Clin North Am** 1994 Jun;8(3):457–70 (45 ref.)
Outcomes monitoring: adjusting for risk factors, severity of illness, and complexity of care. Petryshen P, et al. **J Am Med Inform Assoc** 1995 Jul–Aug;2(4):243–9 (40 ref.)
Models of delayed recovery. Leviton A, et al. **J Child Neurol** 1995 Sep;10(5):385–91 (55 ref.)
A population–based exposure model for benzene. MacIntosh DL, et al. **J Expo Anal Environ Epidemiol** 1995 Jul–Sep; 5(3):375–403 (73 ref.)
Drug prevention research with Hispanic populations: theoretical and methodological issues and a generic structural model. Castro FG, et al. **NIDA Res Monogr** 1994; 139:203–33 (51 ref.)
Some design, measurement, and analysis pitfalls in drug abuse prevention research and how to avoid them: let your model be your guide. Collins LM. **NIDA Res Monogr** 1994; 139:95–114 (26 ref.)
Hypothesis formulation and testing in substance use prevention research. Hansen WB. **NIDA Res Monogr** 1994; 139:59–74 (23 ref.)
Model selection techniques for the covariance matrix for incomplete longitudinal data. Grady JJ, et al. **Stat Med** 1995 Jul 15;14(13):1397–416 (20 ref.)
Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Harrell FE Jr, et al. **Stat Med** 1996 Feb 28;15(4):361–87 (72 ref.)
[Evaluation of the proliferative potential of residual tumor. Verification of parametric methods by computer simulation] Ivankov AA, et al. **Vopr Onkol** 1996;42(1):34–9 (14 ref.) **(Rus)**

MODELS, THEORETICAL

How prayer heals: a theoretical model. Levin JS. **Altern Ther Health Med** 1996 Jan;2(1):66–73 (61 ref.)
Kinetic models in reverse micelles. Bru R, et al. **Biochem J** 1995 Sep 15;310 (Pt 3):721–39 (161 ref.)
Situational disease. Gannik DE. **Fam Pract** 1995 Jun; 12(2):202–6 (14 ref.)
Technology assessment. Old, new, and needs–based. Tugwell P, et al. **Int J Technol Assess Health Care** 1995 Fall; 11(4):650–62 (39 ref.)
Domestic violence: changing theory, changing practice. Warshaw C. **J Am Med Womens Assoc** 1996 May–Jul; 51(3):87–91, 100 (70 ref.)
Mathematical and computer models in epidemiology. Massad E. **MD Comput** 1996 Mar–Apr;13(2):147–54 (31 ref.)
Electroporation theory. Concepts and mechanisms. Weaver JC. **Methods Mol Biol** 1995;47:1–26 (64 ref.)
A computational model of cholinergic disruption of septohippocampal activity in classical eyeblink conditioning. Myers CE, et al. **Neurobiol Learn Mem** 1996 Jul;66(1):51–66 (90 ref.)
Testing theory through developmental epidemiologically based prevention research. Kellam SG. **NIDA Res Monogr** 1994;139:37–57 (33 ref.)
Using prediction models and cost–effectiveness analysis to improve clinical decisions: emergency department patients with acute chest pain. Goldman L. **Proc Assoc Am Physicians** 1995 Oct;107(3):329–33 (22 ref.)
McCay's hypothesis: undernutrition and longevity. Masoro EJ. **Proc Nutr Soc** 1996 Nov;54(3):657–64 (39 ref.)
Models used in Australia in risk assessments for veterinary biologicals. Doyle KA. **Rev Sci Tech** 1995 Dec; 14(4):1021–42 (27 ref.)
[3D echocardiography. Mathematical principles and technical realization] Wollschläger H. **Herz** 1995 Aug; 20(4):225–35 (15 ref.) (Eng. Abstr.) **(Ger)**

MODELS, WEIGHTLESSNESS see **WEIGHTLESSNESS SIMULATION**

MODY see **DIABETES MELLITUS, NON-INSULIN-DEPENDENT**

MOERSCH-WOLTMANN SYNDROME see **STIFF-MAN SYNDROME**

MOHR SYNDROME see **OROFACIODIGITAL SYNDROMES**

MOHS SURGERY

Intraoperative radiation therapy and Mohs micrographic surgery on an outpatient basis. Siegle RJ, et al. **Dermatol Surg** 1995 Nov;21(11):975–8 (16 ref.)
A comparison between Mohs micrographic surgery and wide surgical excision for the treatment of dermatofibrosarcoma protuberans. Gloster HM Jr, et al. **J Am Acad Dermatol** 1996 Jul;35(1):82–7 (37 ref.)
Infection control precautions for surgical personnel in the surgery unit and for laboratory personnel in the Mohs surgery unit laboratory areas. Hruza GJ. **Semin Dermatol** 1995 Sep;14(3):228–34 (47 ref.)

METHODS
[Micrographic surgery. A current methodological assessment] Kopke LF, et al. **Hautarzt** 1995 Sep; 46(9):607–14 (52 ref.) (Eng. Abstr.) **(Ger)**

MOLAR

A clinical report for distalizing maxillary molars by using super–elastic wires. Basdra EK, et al. **Fortschr Kieferorthop** 1996 Apr;57(2):118–23 (6 ref.) **(Eng, Ger)**

GROWTH & DEVELOPMENT
Cementogenesis reviewed: a comparison between human premolars and rodent molars. Bosshardt DD, et al. **Anat Rec** 1996 Jun;245(2):267–92 (141 ref.)

PATHOLOGY
A clinical and histopathological study of radicular cysts associated with primary molars. Mass E, et al. **J Oral Pathol Med** 1995 Nov;24(10):458–61 (9 ref.)
Pre–eruptive resorption of dentin in the primary and permanent dentitions: case reports and literature review. Seow WK, et al. **Pediatr Dent** 1996 Jan–Feb;18(1):67–71 (24 ref.)

MOLAR, FOURTH see **TOOTH, SUPERNUMERARY**

MOLAR, THIRD

SURGERY
Lingual nerve damage during lower third molar removal: a comparison of two surgical methods. Robinson PP, et al. **Br Dent J** 1996 Jun 22;180(12):456–61 (29 ref.)
Use of intravenous sedation for wisdom tooth surgery on aircraft carriers. Hooley JR, et al. **Mil Med** 1995 Aug; 160(8):398–400 (17 ref.)
[Should we or should we not extract impacted teeth?] Lechien P. **Rev Belge Med Dent** 1995;50(2):29–39 (16 ref.) (Eng. Abstr.) **(Fre)**
[Severe complications after surgical removal of wisdom teeth] Locher MC, et al. **Fortschr Kiefer Gesichtschir** 1995; 40:123–8 (55 ref.) (Eng. Abstr.) **(Ger)**

MOLECULAR BIOLOGY

Molecular biology as a tool for taxonomy. Wilson KH. **Clin Infect Dis** 1995 Jun;20 Suppl 2:S117–21 (20 ref.)
Molecular biology and physiology at the single–cell level. Monyer H, et al. **Curr Opin Neurobiol** 1995 Jun;5(3):382–7 (21 ref.)
The Leon Golberg Memorial Lecture. Structural molecular biology and drug discovery. Blundell TL. **Food Chem Toxicol** 1995 Nov;33(11):979–85 (33 ref.)
Current techniques in cell and molecular biology. Downey GP, et al. **J Crit Care** 1995 Sep;10(3):136–49 (22 ref.)
The role of molecular techniques in the understanding of emerging infections. Sable CA, et al. **Mol Med Today** 1996 Mar;2(3):120–8 (43 ref.)
Introduction to modern molecular biology: fundamental concepts and techniques. Daley MD, et al. **New Horiz** 1995 May;3(2):146–60 (38 ref.)
Molecular and cell biology of acute renal failure: new therapeutic strategies. Wagener OE, et al. **New Horiz** 1995 Nov;3(4):634–49 (164 ref.)
[Molecular biology of thyroid diseases] Nagy E, et al. **Orv Hetil** 1996 Mar 17;137(11):563–8 (44 ref.) (Eng. Abstr.) **(Hun)**
[From the Smart alpha 2–macroglobulin to single molecule biochemistry] Ikai A. **Seikagaku** 1996 Mar;68(3):179–95 (47 ref.) **(Jpn)**
[Molecular biology in medicine. I. Molecular structure of the gene] Moreno G, et al. **Rev Invest Clin** 1996 Jan–Feb; 48(1):81–4 (5 ref.) **(Spa)**
[Future drugs against aging? New research on molecular background of aging] Nordstedt C, et al. **Lakartidningen** 1995 Oct 18;92(42):3881–4 (20 ref.) **(Swe)**

INSTRUMENTATION
Conducting polymers and the bioanalytical sciences: new tools for biomolecular communication. A review. Adeloju SB, et al. **Analyst** 1996 Jun;121(6):699–703 (46 ref.)
Future prospects for the analysis of complex biological systems using micro–column liquid chromatography–electrospray tandem mass spectrometry. Yates JR 3rd, et al. **Analyst** 1996 Jul;121(7):65R–76R (66 ref.)

METHODS
Molecular diagnostics in the clinical laboratory: a plea for prudence! [editorial] Ieven M, et al. **Acta Clin Belg** 1995; 50(5):255–9 (33 ref.)
Molecular bases for the construction of artificial immunogens and vaccines based on synthetic polyions. Khaitov RM. **Allergy Proc** 1995 Sep–Oct;16(5):255–60 (14 ref.)
Molecular biology techniques. Skogerboe KJ. **Anal Chem** 1995 Jun 15;67(12):449R–454R (134 ref.)
Molecular biology in ophthalmology. A review of principles and recent advances. Della NG. **Arch Ophthalmol** 1996 Apr;114(4):457–63 (63 ref.)
Specimen collection and storage for diagnostic molecular pathology investigation. Farkas DH, et al. **Arch Pathol Lab Med** 1996 Jun;120(6):591–6 (50 ref.)
Mitochondrial disorders. Methods and specimen selection for diagnostic molecular pathology. Kiechle FL, et al. **Arch Pathol Lab Med** 1996 Jun;120(6):597–603 (89 ref.)
Quantitative molecular methods in virology. Clementi M, et al. **Arch Virol** 1995;140(9):1523–39 (107 ref.)
The applications of the polymerase chain reaction in the life sciences. Lenstra JA. **Cell Mol Biol (Noisy-le-grand)** 1995 Jul;41(5):603–14 (89 ref.)
Tutorial. Molecular biology for the clinician. Part II. Tools of molecular biology. Shore EM, et al. **Clin Orthop** 1995 Nov;(320):247–78 (7 ref.)
Molecular biology and its application in paediatric endocrinology. Mullis PE, et al. **Eur J Pediatr** 1995;154(9 Suppl 4):S30–9 (34 ref.)
Molecular biological studies on teeth, and inquests. Yamamoto K. **Forensic Sci Int** 1996 Jun 28;80(1–2):79–87 (21 ref.)
Molecular biology in the intensive care unit: a framework for interpretation. Buchman TG, et al. **New Horiz** 1995 May;3(2):139–45 (24 ref.)
The use of molecular biology techniques for diagnostic microbiology and hospital epidemiology. Low DE, et al. **New Horiz** 1995 May;3(2):161–9 (84 ref.)

TRENDS
[Revolution in diagnostic microbiology. Needs, driving forces and consequences] Bukholm G, et al. **Tidsskr Nor Laegeforen** 1995 Nov 10;115(27):3387–9 (3 ref.) (Eng. Abstr.) **(Nor)**

MOLECULAR CHAPERONES

see related
HEAT-SHOCK PROTEINS
[Calnexin is involved in the quality–control mechanism of the ER] Wada I. **Seikagaku** 1995 Sep;67(9):1133–7 (26 ref.) **(Jpn)**

METABOLISM
The Merck Frosst Award Lecture 1994/La conference Merck Frosst 1994. Calnexin: a molecular chaperone with a taste for carbohydrate. Williams DB. **Biochem Cell Biol** 1995 Mar–Apr;73(3–4):123–32 (50 ref.)
The 67 kDa spliced variant of beta–galactosidase serves as a reusable protective chaperone for tropoelastin. Hinek A. **Ciba Found Symp** 1995;192:185–91; discussion 191–6 (30 ref.)
Chromatin. Nucleosome assembly during DNA replication. Krude T. **Curr Biol** 1995 Nov 1;5(11):1232–4 (17 ref.)
Protein biogenesis: chaperones for nascent polypeptides. Rassow J, et al. **Curr Biol** 1996 Feb 1;6(2):115–8 (29 ref.)
Supervising the fold: functional principles of molecular chaperones. Buchner J. **FASEB J** 1996 Jan;10(1):10–9 (73 ref.)
The "bio" in biochemistry: protein folding inside and outside the cell [comment] Ellis RJ. **Science** 1996 Jun 7; 272(5267):1448–9 (10 ref.) Comment on: Science 1996 Jun

7;272(5267):1497–502.
Hsp47: a collagen-specific molecular chaperone. Nagata K. **Trends Biochem Sci** 1996 Jan;21(1):22–6 (29 ref.)
Prepilin-like molecules in type 4 pilus biogenesis: minor subunits, chaperones or mediators of organelle translocation? Koomey M. **Trends Microbiol** 1995 Nov; 3(11):409–10; discussion 411–3 (49 ref.)

PHYSIOLOGY

Molecular chaperones. Resurrection or destruction? Horwich AL. **Curr Biol** 1995 May 1;5(5):455–8 (26 ref.)
Molecular chaperones in protein folding and translocation. Clarke AR. **Curr Opin Struct Biol** 1996 Feb;6(1):43–50 (73 ref.)
The role of molecular chaperones in protein folding. Hendrick JP, et al. **FASEB J** 1995 Dec;9(15):1559–69 (76 ref.)
Molecular chaperones and disease. Henderson B, et al. **Inflamm Res** 1996 Apr;45(4):155–8 (51 ref.)
Roles of molecular chaperones in protein degradation. Hayes SA, et al. **J Cell Biol** 1996 Feb;132(3):255–8 (24 ref.)

MOLECULAR CLONING see **CLONING, MOLECULAR**

MOLECULAR CONFIGURATION see **MOLECULAR CONFORMATION**

MOLECULAR CONFORMATION

Telomere structure and function. Rhodes D, et al. **Curr Opin Struct Biol** 1995 Jun;5(3):311–22 (83 ref.)
Differing shapes of 1 alpha,25-dihydroxyvitamin D3 function as ligands for the D-binding protein, nuclear receptor and membrane receptor: a status report. Norman AW, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1–6 Spec No):13–22 (34 ref.)
Recent developments for crystallographic refinement of macromolecules. Brünger AT. **Methods Mol Biol** 1996; 56:245–66 (81 ref.)
Molecular replacement using known structural information. Tickle IJ, et al. **Methods Mol Biol** 1996;56:173–203 (92 ref.)

MOLECULAR EPIDEMIOLOGY see **EPIDEMIOLOGY, MOLECULAR**

MOLECULAR EVOLUTION see **EVOLUTION, MOLECULAR**

MOLECULAR EVOLUTION, DIRECTED see **DIRECTED MOLECULAR EVOLUTION**

MOLECULAR GENETICS see **GENETICS, BIOCHEMICAL**

MOLECULAR MIMICRY

Molecular mimicry in channel-protein structure. Montal M. **Curr Opin Struct Biol** 1995 Aug;5(4):501–6 (69 ref.)
Auto-anti-idiotypy, autoimmunity and some thoughts on the structure of internal images. Erlanger BF. **Int Rev Immunol** 1989;5(2):131–7 (29 ref.)
[Molecular mimicry between LKM 1-autoantigen and HCV-polyproteins] Miyakawa H, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:885–91 (20 ref.) **(Jpn)**

MOLECULAR MODELS see **MODELS, MOLECULAR**

MOLECULAR NEUROBIOLOGY see **NEUROBIOLOGY**

MOLECULAR PROBE TECHNIQUES

Molecular site assessment and process monitoring in bioremediation and natural attenuation. off Sayler GS, et al. **Appl Biochem Biotechnol** 1995 Jul-Sep;54(1–3):277–90 (25 ref.)
The digoxigenin (DIG) system for non-radioactive labelling and detection of nucleic acids--an overview. Höltke HJ, et al. **Cell Mol Biol (Noisy-le-grand)** 1995 Nov; 41(7):883–905 (48 ref.)
Nonradioactive probes. Isaac PG, et al. **Mol Biotechnol** 1995 Jun;3(3):259–65 (24 ref.)

MOLECULAR PROBES

Peptides as active probes. Undén A, et al. **EXS** 1995; 73:229–55 (82 ref.)
Use of molecular probes and PCR for detection and typing of Leishmania--a mini-review. Degrave W, et al. **Mem Inst Oswaldo Cruz** 1994 Jul-Sep;89(3):463–9 (31 ref.)

IMMUNOLOGY

Single T cell probes for antigen/MHC expression. Shastri N. **Curr Opin Immunol** 1995 Apr;7(2):258–62 (33 ref.)
Monoclonal anti-TNF alpha antibody as a probe of pathogenesis and therapy of rheumatoid disease. Maini RN, et al. **Immunol Rev** 1995 Apr;144:195–223 (112 ref.)

MOLECULAR STEREOCHEMISTRY see **MOLECULAR CONFORMATION**

MOLECULAR STRUCTURE

see related
MODELS, MOLECULAR

Molecular pharmacology of V1a vasopressin receptors. Howl J, et al. **Gen Pharmacol** 1995 Oct;26(6):1143–52 (72 ref.)
Structure and function of the NMDA receptor channel. Mori H, et al. **Neuropharmacology** 1995 Oct;34(10):1219–37 (142 ref.)

MOLECULAR VACCINES see **VACCINES, SYNTHETIC**

MOLESTATION, SEXUAL, CHILD see **CHILD ABUSE, SEXUAL**

MOLLUSCA

see related
SHELLFISH

MOLTING

see related
ECDYSONE
ECDYSTERONE

MOLTING HORMONE see **ECDYSONE**

MONGOLISM see **DOWN SYNDROME**

MONGOLOID RACE

Molecular changes of colorectal cancer in Singapore. Goh HS, et al. **Ann Acad Med Singapore** 1996 Jan;25(1):3–10 (93 ref.)
Cephalometric analysis of Deutero-Malay Indonesians. Munandar S, et al. **Aust Dent J** 1995 Dec;40(6):381–8 (38 ref.)

GENETICS

HLA-B27 and its subtypes in world populations [editorial] Khan MA. **Curr Opin Rheumatol** 1995 Jul;7(4):263–9 (94 ref.)

MONILIA see **CANDIDA**

MONILIALES see **HYPHOMYCETES**

MONILIASIS see **CANDIDIASIS**

MONILIASIS, CUTANEOUS see **CANDIDIASIS, CUTANEOUS**

MONILIASIS, ORAL see **CANDIDIASIS, ORAL**

MONILIASIS, VULVOVAGINAL see **CANDIDIASIS, VULVOVAGINAL**

MONITORING, AMBULATORY

Ambulatory urodynamic monitoring [see comments] Heslington K, et al. **Br J Obstet Gynaecol** 1996 May; 103(5):393–9 (49 ref.) Comment in: Br J Obstet Gynaecol 1996 May;103(5):xxi.
Ambulatory urodynamics. Bristow SE, et al. **Br J Urol** 1996 Mar;77(3):333–8 (30 ref.)
Current status of home uterine activity monitoring. Iams JD. **Clin Obstet Gynecol** 1995 Dec;38(4):771–9 (35 ref.)
Ambulatory urodynamics. van Waalwijk van Doorn ES, et al. **Curr Opin Obstet Gynecol** 1995 Oct;7(5):378–81 (14 ref.)
Ambulatory esophageal manometry in the evaluation of unexplained chest pain. Leite LP, et al. **Dig Dis** 1995 May-Jun;13(3):145–52 (15 ref.)
Ambulatory manometry of the small bowel: indications and analysis. Wilmer A, et al. **Rev Esp Enferm Dig** 1996 Feb; 88(2):118–32 (45 ref.) **(Eng, Spa)**
Ambulatory urodynamics: extramural testing of the lower and upper urinary tract by Holter monitoring of cystometrogram, uroflowmetry, and renal pelvic pressures. van Waalwijk van Doorn ES, et al. **Urol Clin North Am** 1996 Aug;23(3):345–71 (32 ref.)
[Continuous ambulatory measurement of left ventricular function by an isotopic method] Millaire A. **Arch Mal Coeur Vaiss** 1995 Oct;88(10):1453–63 (30 ref.) (Eng. Abstr.) **(Fre)**

METHODS

Twenty-four hour esophageal pH monitoring: technique and application. Trimble KC, et al. **Gastroenterologist** 1995 Sep; 3(3):187–98 (97 ref.)

MONITORING, AMBULATORY BLOOD PRESSURE see **BLOOD PRESSURE MONITORING, AMBULATORY**

MONITORING, AMBULATORY ELECTROCARDIOGRAPHIC see **ELECTROCARDIOGRAPHY, AMBULATORY**

MONITORING, DRUG see **DRUG MONITORING**

MONITORING, ENVIRONMENTAL see **ENVIRONMENTAL MONITORING**

MONITORING, FETAL see **FETAL MONITORING**

MONITORING, HOLTER see **ELECTROCARDIOGRAPHY, AMBULATORY**

MONITORING, HOME BLOOD GLUCOSE see **BLOOD GLUCOSE SELF-MONITORING**

MONITORING, IMMUNE see **MONITORING, IMMUNOLOGIC**

MONITORING, IMMUNOLOGIC

Cytokines and immunological monitoring. Kopp WC, et al. **Cancer Chemother Biol Response Modif** 1996;16:189–238 (203 ref.)

MONITORING, INTRAOPERATIVE see **INTRAOPERATIVE MONITORING**

MONITORING, PHYSIOLOGIC

see related
SIGNAL PROCESSING, COMPUTER-ASSISTED

Clinical and economic performance criteria for intraarterial and extraarterial blood gas monitors, with comparison with in vitro testing. Shapiro BA. **Am J Clin Pathol** 1995 Oct; 104(4 Suppl 1):S100–6 (39 ref.)
Prehospital monitoring of trauma patients: experience of a helicopter emergency medical service. Morley AP. **Br J Anaesth** 1996 May;76(5):726–30 (56 ref.)
Monitoring tissue perfusion. Vincent JL. **Can J Anaesth** 1996 May;43(5 Pt 2):R55–60 (16 ref.) **(Eng, Fre)**
Intrapartum use of fetal heart rate monitoring, contraction monitoring, and amnioinfusion. Cusick W, et al. **Clin Perinatol** 1995 Dec;22(4):875–906 (130 ref.)
Technology assessment status evaluation: monitoring equipment for endoscopy. American Society for Gastrointestinal Endoscopy. Kimmey MB, et al. **Gastrointest Endosc** 1995 Dec;42(6):615–7 (13 ref.)
Monitoring and management of raised intracranial pressure (ICP) in the intensive care unit with an analysis of one year of intracranial pressure monitoring. Kapadia F, et al. **J Assoc Physicians India** 1995 Nov;43(11):783–90 (16 ref.)
Near-infrared spectroscopy: theory and applications. Wahr JA, et al. **J Cardiothorac Vasc Anesth** 1996 Apr; 10(3):406–18 (96 ref.)
Electrophysiological monitoring and mild hypothermia. Kochs E. **J Neurosurg Anesthesiol** 1995 Jul;7(3):222–8 (56 ref.)
Monitoring of O2 transport and tissue oxygenation in paediatric critical care. Hüttemann E, et al. **Paediatr Anaesth** 1995;5(5):281–6 (54 ref.)
[VO2 and DO2 during cardiogenic shock and infection] Beale R. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May;31(1 Suppl):S22–5 (19 ref.) **(Ger)**
[Function-controlled neurosurgery. Neurophysiologic and neuropsychological monitoring during surgery of the nervous system] Schmid UD, et al. **Nervenarzt** 1995 Aug; 66(8):582–95 (84 ref.) (Eng. Abstr.) **(Ger)**

INSTRUMENTATION

Emerging technology in critical care: continuous intra-arterial blood gas monitoring. Szaflarski NL. **Am J Crit Care** 1996 Jan;5(1):55–65 (45 ref.)
Standards of evidence for the safety and effectiveness of critical care monitoring devices and related interventions. Coalition for Critical Care Excellence: Consensus Conference on Physiologic Monitoring Devices. **Crit Care Med** 1995 Oct;23(10):1756–63 (12 ref.)
A physiologic method for monitoring premature infants. Ludington-Hoe S, et al. **J Nurs Meas** 1995 Summer; 3(1):13–29 (16 ref.)
Complications of Swan-Ganz catheterization for hemodynamic monitoring in patients with subarachnoid hemorrhage. Rosenwasser RH, et al. **Neurosurgery** 1995 Nov;37(5):872–5; discussion 875–6 (21 ref.)
Review of monitors and monitoring during sedation with emphasis on clinical applications. Wilson S. **Pediatr Dent** 1995 Nov-Dec;17(7):413–8 (14 ref.)
[Methods of microcirculatory monitoring (laser Doppler flowmetry, photoplethysmography and computer-assisted venous occlusion plethysmography)] Christ F. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May; 31(1 Suppl):S37–43 (77 ref.) **(Ger)**
[Continuous monitoring of minute cardiac volume] Jansen JR. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May;31(1 Suppl):S30–4 (26 ref.) **(Ger)**
[Pulmonary artery catheter. Theory and practice] Versprille A. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May;31(1 Suppl):S9–16 (22 ref.) **(Ger)**

METHODS

Simplified approaches to calculate Kt/V. It's time for agreement. Movilli E. **Nephrol Dial Transplant** 1996 Jan; 11(1):24–7 (31 ref.)
On-line monitoring. Santoro A. **Nephrol Dial Transplant** 1995;10(5):615–8 (17 ref.)
Review of monitors and monitoring during sedation with

emphasis on clinical applications. Wilson S. **Pediatr Dent** 1995 Nov–Dec;17(7):413–8 (14 ref.)
["Home monitoring" does not prevent crib death. Managing possibilities and results of new technology (see comments)] Rognum TO. **Tidsskr Nor Laegeforen** 1995 Sep 20; 115(22):2790–3 (21 ref.) (Eng. Abstr.) Comment in: Tidsskr Nor Laegeforen 1995 Nov 10;115(27):3419–20. **(Nor)**

STATISTICS & NUMERICAL DATA

Spectral analysis of clinical signals: an interface between medical statisticians and medical engineers. Campbell MJ. **Stat Methods Med Res** 1996 Mar;5(1):51–66 (54 ref.)

TRENDS

The current and future status of critical care testing and patient monitoring. Kost GJ, et al. **Am J Clin Pathol** 1995 Oct;104(4 Suppl 1):S2–17 (202 ref.)

MONITORING, RADIOIMMUNOLOGIC see **MONITORING, IMMUNOLOGIC**

MONITORING, SLEEP see **POLYSOMNOGRAPHY**

MONITORS, BLOOD PRESSURE see **BLOOD PRESSURE MONITORS**

MONKEY, CRAB-EATING see **MACACA FASCICULARIS**

MONKEY, CYNOMOLGUS see **MACACA FASCICULARIS**

MONKEY DISEASES

PARASITOLOGY

Simian malaria at two sites in the Brazilian Amazon. I—The infection rates of Plasmodium brasilianum in non-human primates. Lourenço-de-Oliveira R, et al. **Mem Inst Oswaldo Cruz** 1995 May–Jun;90(3):331–9 (70 ref.)

MONKEY HEMORRHAGIC DISEASE VIRUS see **ARTERIVIRUS**

MONKEY, JAPANESE see **MACACA**

MONKEY, RHESUS see **MACACA MULATTA**

MONKEY, SPIDER see **CEBIDAE**

MONKEY, TALAPOIN see **CERCOPITHECIDAE**

MONKEY, WOOLLY see **CEBIDAE**

MONKEYS see **HAPLORHINI**

MONKEYS, NEW WORLD see **CEBIDAE**

MONKEYS, OLD WORLD see **CERCOPITHECIDAE**

MONOACYLGLYCEROLS see **GLYCERIDES**

MONO-ADP-RIBOSYLTRANSFERASE see **NAD(P)(+)-ARGININE ADP-RIBOSYLTRANSFERASE**

MONOAMINE OXIDASE

[Metabolic enzymes of neurotoxin: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and Parkinson's disease] Wu RF, et al. **Seikagaku** 1995 Nov; 67(11):1307–11 (15 ref.) **(Jpn)**

BLOOD

The correlation between platelet MAO activity and personality: short review of findings and a discussion on possible mechanisms. Oreland L, et al. **Prog Brain Res** 1995; 106:77–84 (52 ref.)
[Monoamine oxidase] Nakano H, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:288–91 (7 ref.) **(Jpn)**

CHEMISTRY

Radical thoughts about the life of MAO. Silverman RB. **Prog Brain Res** 1995;106:23–31 (25 ref.)
The colorful past and bright future of monoamine oxidase research. Singer TP. **Prog Brain Res** 1995;106:1–22 (86 ref.)

GENETICS

Norrie disease and MAO genes: nearest neighbors. Chen ZY, et al. **Hum Mol Genet** 1995;4 Spec No:1729–37 (100 ref.)
Analysis of MAOA mutations in humans. Hsu YP, et al. **Prog Brain Res** 1995;106:67–75 (54 ref.)
Expression of human monoamine oxidase (MAO) A gene controlled by transcription factor Sp1. Shih JC, et al. **Prog Brain Res** 1995;106:49–56 (36 ref.)

METABOLISM

Substrate-specificity of mammalian tissue-bound semicarbazide-sensitive amine oxidase. Lyles GA. **Prog Brain Res** 1995;106:293–303 (82 ref.)
Monoamine oxidase: distribution in the cat brain studied by enzyme- and immunohistochemistry: recent progress. Kitahama K, et al. **Prog Neurobiol** 1994 Jan;42(1):53–78 (189 ref.)
Aminium cation radical mechanism proposed for monoamine oxidase B catalysis: are there alternatives? Edmondson DE. **Xenobiotica** 1995 Jul;25(7):735–53 (53 ref.)

PHYSIOLOGY

The role of monoamine oxidase and catechol O-methyltransferase in dopaminergic neurotransmission. Napolitano A, et al. **J Neural Transm Suppl** 1995;45:35–45 (60 ref.)

MONOAMINE OXIDASE INHIBITORS

see related
ANTIDEPRESSIVE AGENTS

ADVERSE EFFECTS

Clinical implications of antidepressant drug effects on sexual function. Harvey KV, et al. **Ann Clin Psychiatry** 1995 Dec; 7(4):189–201 (107 ref.)
The making of a user friendly MAOI diet. Gardner DM, et al. **J Clin Psychiatry** 1996 Mar;57(3):99–104 (53 ref.)
The behavioral toxicity of reversible inhibitors of monoamine oxidase A: laboratory and clinical investigations. Fairweather DB, et al. **J Clin Psychopharmacol** 1995 Aug; 15(4 Suppl 2):68S–75S (43 ref.)

PHARMACOKINETICS

Clinical pharmacokinetics of the monoamine oxidase-A inhibitor moclobemide. Mayersohn M, et al. **Clin Pharmacokinet** 1995 Nov;29(5):292–332 (132 ref.)

PHARMACOLOGY

Monoamine oxidase inhibitors. An update on drug interactions. Livingston MG, et al. **Drug Saf** 1996 Apr; 14(4):219–27 (53 ref.)
Selective inhibitors of monoamine oxidase (MAO-A and MAO-B) as probes of its catalytic site and mechanism. Kalgutkar AS, et al. **Med Res Rev** 1995 Jul;15(4):325–88 (229 ref.)
Neurochemical, neuroprotective and neurorescue effects of aliphatic N-methylpropargylamines; new MAO-B inhibitors without amphetamine-like properties. Yu PH, et al. **Prog Brain Res** 1995;106:113–21 (54 ref.)
[Monoamine oxidase inhibitors and food precautions. A comparison of utilization in Belgian psychiatric education institutes and current findings in the literature] Mallet L, et al. **Acta Psychiatr Belg** 1996 Mar–Apr;96(2):74–100 (52 ref.) (Eng. Abstr.) **(Fre)**

THERAPEUTIC USE

Clinical implications of antidepressant drug effects on sexual function. Harvey KV, et al. **Ann Clin Psychiatry** 1995 Dec; 7(4):189–201 (107 ref.)
Recent clinical development with reversible and selective amine oxidase inhibitors: a valuable addition to the armamentarium. Chairman's introduction. Priest RG. **J Clin Psychopharmacol** 1995 Aug;15(4 Suppl 2):1S–3S (18 ref.)
[Prediction of therapeutic response in depressive states] Radat F, et al. **Ann Med Psychol (Paris)** 1996 May;154(2):89–102 (53 ref.) (Eng. Abstr.) **(Fre)**
[The role of enzymatic systems in pathophysiology and pharmacotherapy of Parkinson's disease] Kuran W. **Neurol Neurochir Pol** 1995 Jul–Aug;29(4):561–8 (30 ref.) (Eng. Abstr.) **(Pol)**

MONOAMINES, BIOGENIC see **BIOGENIC MONOAMINES**

MONOBACTAMS

THERAPEUTIC USE

The newer cephalosporins. Aztreonam and imipenem. Ennis DM, et al. **Infect Dis Clin North Am** 1995 Sep;9(3):687–713 (123 ref.)

MONOBLASTIC LEUKEMIA, ACUTE see **LEUKEMIA, MONOCYTIC, ACUTE**

MONOCLONAL ANTIBODIES see **ANTIBODIES, MONOCLONAL**

MONOCLONAL ANTIBODY OKT3 see **MUROMONAB-CD3**

MONOCLONAL GAMMOPATHIES see **PARAPROTEINEMIAS**

MONOCLONAL GAMMOPATHIES, BENIGN

METABOLISM

Monoclonal gammopathy of undetermined significance (MGUS). Kyle RA. **Baillieres Clin Haematol** 1995 Dec; 8(4):761–81 (92 ref.)

MONOCULAR VISION see **VISION, MONOCULAR**

MONOCYCLIC BETA-LACTAMS see **MONOBACTAMS**

MONOCYTE CHEMOATTRACTANT PROTEIN-1

ANALYSIS

[Macrophage chemotactic factor (MCF)] Takahashi M, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:819–21 (9 ref.) **(Jpn)**

IMMUNOLOGY

Monocyte chemoattractant protein 1: a potential regulator of monocyte recruitment in inflammatory disease. Rollins BJ. **Mol Med Today** 1996 May;2(5):198–204 (35 ref.)

MONOCYTE CHEMOTACTIC PROTEIN-1 see **MONOCYTE CHEMOATTRACTANT PROTEIN-1**

MONOCYTES

DRUG EFFECTS

The effect of granulocyte-macrophage colony-stimulating factor on myeloid cells and its clinical applications. Hill AD, et al. **J Leukoc Biol** 1995 Dec;58(6):634–42 (103 ref.)

IMMUNOLOGY

Monocyte chemoattractant protein 1: a potential regulator of monocyte recruitment in inflammatory disease. Rollins BJ. **Mol Med Today** 1996 May;2(5):198–204 (35 ref.)

METABOLISM

Regulation of IL-1 beta expression by cyclic AMP in myeloid cells. Hurme M. **Immunobiology** 1995 Jul; 193(2–4):224–8 (18 ref.)
Nitric oxide production by human monocytes: evidence for a role of CD23. Dugas B, et al. **Immunol Today** 1995 Dec; 16(12):574–80 (54 ref.)
Pentoxifylline: a potential treatment for thrombosis associated with abnormal tissue factor expression by monocytes and endothelial cells. de Prost D. **J Cardiovasc Pharmacol** 1995; 25 Suppl 2:S114–8 (41 ref.)
The effect of NO/EDRF and monocytes/macrophages on LDL-oxidation. Leitinger N, et al. **J Physiol Pharmacol** 1995 Dec;46(4):385–408 (144 ref.)
Interleukin-1 and interleukin-1 receptor antagonist production during haemodialysis: which cytokine is a surrogate marker for dialysis-related complications? Dinarello CA. **Nephrol Dial Transplant** 1995;10 Suppl 3:25–8 (32 ref.)

PHYSIOLOGY

Immunopathology of tuberculosis: roles of macrophages and monocytes. Fenton MJ, et al. **Infect Immun** 1996 Mar; 64(3):683–90 (95 ref.)
Signaling events in monocytes and macrophages. Chow CW, et al. **New Horiz** 1995 May;3(2):342–51 (72 ref.)
Alpha 4-integrin-dependent emigration of monocytes. Chuluyan HE, et al. **Springer Semin Immunopathol** 1995; 16(4):391–404 (82 ref.)
The molecular basis of platelet and endothelial cell interaction with neutrophils and monocytes: role of P-selectin and the P-selectin ligand, PSGL-1. Furie B, et al. **Thromb Haemost** 1995 Jul;74(1):224–7 (56 ref.)
[Interactions of neuromediators and neurohormones on dendritic cells, monocytes and macrophages (out of the central nervous system)] Misery L, et al. **Pathol Biol (Paris)** 1995 Dec;43(10):876–81 (66 ref.) (Eng. Abstr.) **(Fre)**

TRANSPLANTATION

Assessment of engraftment and function of human tonsillar and blood mononuclear cells in immunodeficient mice. Albini B, et al. **Adv Exp Med Biol** 1995;371A:85–9 (28 ref.)

VIROLOGY

Influence of redox status of lymphocytes and monocytes on HIV transcription and replication. Gougerot-Pocidalo MA, et al. **Immunobiology** 1995 Jul;193(2–4):204–9 (27 ref.)

MONOCYTES, ACTIVATED KILLER

see related
IMMUNOTHERAPY, ADOPTIVE

MONOCYTIC LEUKEMIA, ACUTE see **LEUKEMIA, MONOCYTIC, ACUTE**

MONOKINES

PHYSIOLOGY

Cytokine regulation of monocyte recruitment. Mantovani A, et al. **Arch Immunol Ther Exp (Warsz)** 1995;43(2):149–52 (21 ref.)
The role of MIP-1 alpha in inflammation and hematopoiesis.

Cook DN. **J Leukoc Biol** 1996 Jan;59(1):61–6 (40 ref.)

MONONUCLEAR LEUKOCYTES see **LEUKOCYTES, MONONUCLEAR**

MONOPHENOL MONOOXYGENASE

METABOLISM

Immune response in insects: the role of phenoloxidase in defense reactions in relation to melanization and sclerotization. Marmaras VJ, et al. **Arch Insect Biochem Physiol** 1996;31(2):119–33 (56 ref.)

Tyrosinase and related proteins in mammalian pigmentation. del Marmol V, et al. **FEBS Lett** 1996 Mar 4;381(3):165–8 (48 ref.)

MONOSACCHARIDE TRANSPORT PROTEINS

GENETICS

Glucose transporter gene expression: regulation of transcription and mRNA stability. McGowan KM, et al. **Pharmacol Ther** 1995 Jun;66(3):465–505 (287 ref.)

METABOLISM

Facilitative glucose transport proteins and sodium–glucose co–transporters in the kidney. Hoffman BB, et al. **Curr Opin Nephrol Hypertens** 1995 Sep;4(5):406–11 (52 ref.)

Insulin–induced redistribution of GLUT4 glucose carriers in the muscle fiber. In search of GLUT4 trafficking pathways. Zorzano A, et al. **Diabetes** 1996 Jan;45 Suppl 1:S70–81 (120 ref.)

PHYSIOLOGY

Insulin resistance, hypertension and the insulin–responsive glucose transporter, GLUT4 [editorial] Livingstone C, et al. **Clin Sci (Colch)** 1995 Aug;89(2):109–16 (61 ref.)

Glucose transporters and insulin receptors in skeletal muscle. Physiology and pathophysiology. Handberg A. **Dan Med Bull** 1995 Jun;42(3):211–26 (173 ref.)

Adaptation to life at micromolar nutrient levels: the regulation of Escherichia coli glucose transport by endoinduction and cAMP. Ferenci T. **FEMS Microbiol Rev** 1996 Jul;18(4):301–17 (92 ref.)

MONOSACCHARIDES

ANALYSIS

[Structural and functional aspects of oligosaccharides in human milk] Kunz C, et al. **Z Ernahrungswiss** 1996 Mar; 35(1):22–31 (51 ref.) (Eng. Abstr.) **(Ger)**

MONOSIALOSYL TETRAGLYCOSYL CERAMIDE see **G(M1) GANGLIOSIDE**

MONOSOMY

Monosomy 21q: two cases of del(21q) and review of the literature. Huret JL, et al. **Clin Genet** 1995 Sep;48(3):140–7 (60 ref.)

[Hereditary hematopoietic malignancy with emphasis of juvenile chronic myelogenous leukemia and 7 monosomy syndrome] Hayashi Y. **Nippon Rinsho** 1995 Nov; 53(11):2737–41 (21 ref.) (Eng. Abstr.) **(Jpn)**

MONOSOMY, PARTIAL see **CHROMOSOME DELETION**

MONOSPORIUM APIOSPERMUM see **PSEUDALLESCHERIA**

MONOTREMATA

PHYSIOLOGY

Monotreme and marsupial reproduction. Renfree MB. **Reprod Fertil Dev** 1995;7(5):1003–20 (133 ref.)

MONTE CARLO METHOD

Protein folding by a biased Monte Carlo procedure in the dihedral angle space. Lee B, et al. **FASEB J** 1996 Jan; 10(1):119–25 (43 ref.)

MOOD see **AFFECT**

MOOD DISORDERS, NON-PSYCHOTIC see **AFFECTIVE DISORDERS**

MOOD DISORDERS, PSYCHOTIC see **AFFECTIVE DISORDERS, PSYCHOTIC**

MOON

Gravitational effects of the period of high tides and the new moon on lunacy. Myers DE. **J Emerg Med** 1995 Jul–Aug; 13(4):529–32 (24 ref.)

MOPEDS see **MOTORCYCLES**

MOPEG see **METHOXYHYDROXYPHENYLGLYCOL**

MORALS

see related
CONFLICT OF INTEREST

Moral competency. Cassidy VR. **Annu Rev Nurs Res** 1996; 14:181–204 (94 ref.)

Is there a moral obligation not to infect others? Harris J, et al. **BMJ** 1995 Nov 4;311(7014):1215–7 (9 ref.)

Measurement of moral development in medicine. Self DJ, et al. **Camb Q Healthc Ethics** 1996 Spring;5(2):269–77 (70 ref.)

The debate on assisted suicide—redefining morally appropriate care for people with intractable suffering. Reitman JS. **Issues Law Med** 1995 Winter;11(3):299–329 (118 ref.)

Professional caring: the moral dimension. Fealy GM. **J Adv Nurs** 1995 Dec;22(6):1135–40 (18 ref.)

MORAXELLA (BRANHAMELLA) CATARRHALIS

Spectrum and significance of bacteremia due to Moraxella catarrhalis. Ioannidis JP, et al. **Clin Infect Dis** 1995 Aug; 21(2):390–7 (45 ref.)

Lower respiratory tract infection therapy—the role of ciprofloxacin. Ball AP, et al. **J Int Med Res** 1995 Sep–Oct; 23(5):315–27 (55 ref.)

ENZYMOLOGY

[beta–Lactamases of Branhamella catarrhalis and their phenotypic implications] Chaibi EB, et al. **Res Microbiol** 1995 Nov–Dec;146(9):761–71 (40 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Branhamella catarrhalis: epidemiology, surface antigenic structure, and immune response. Murphy TF. **Microbiol Rev** 1996 Jun;60(2):267–79 (186 ref.)

MORAXELLA CATARRHALIS see **MORAXELLA (BRANHAMELLA) CATARRHALIS**

MORBID OBESITY see **OBESITY, MORBID**

MORBIDITY

Capture–recapture and multiple–record systems estimation II: Applications in human diseases. International Working Group for Disease Monitoring and Forecasting. **Am J Epidemiol** 1995 Nov 15;142(10):1059–68 (87 ref.)

Physical activity, the compression of morbidity, and the health of the elderly. Fries JF. **J R Soc Med** 1996 Feb; 89(2):64–8 (36 ref.)

Coitally—related morbidities in the non–pregnant female. Babarinsa IA, et al. **West Afr J Med** 1995 Jul–Sep; 14(3):141–6 (63 ref.)

Linkage failures in ecological studies. Nurminen M. **World Health Stat Q** 1995;48(2):78–84 (20 ref.)

[Who is ill and what are the diseases in Finland?] Huttunen JK, et al. **Duodecim** 1995;111(1):17–25 (27 ref.) **(Fin)**

TRENDS

Addressing the epidemiologic transition in the former Soviet Union: strategies for health system and public health reform in Russia [see comments] Tulchinsky TH, et al. **Am J Public Health** 1996 Mar;86(3):313–20 (46 ref.) Comment in: Am J Public Health 1996 Mar;86(3):321–3.

MORBILLIVIRUS

ISOLATION & PURIFICATION

Morbilliviruses and morbillivirus diseases of marine mammals. de Swart RL, et al. **Infect Agents Dis** 1995 Sep; 4(3):125–30 (61 ref.)

MORBILLIVIRUS INFECTIONS

VETERINARY

Morbilliviruses and morbillivirus diseases of marine mammals. de Swart RL, et al. **Infect Agents Dis** 1995 Sep; 4(3):125–30 (61 ref.)

MORMYRID see **ELECTRIC FISH**

MORNING-AFTER PILL see **CONTRACEPTIVES, POSTCOITAL**

MORPHEA see **SCLERODERMA, CIRCUMSCRIBED**

MORPHINE

see related
RECEPTORS, OPIOID

ADMINISTRATION & DOSAGE

A review of anatomical and immunological links between epidural morphine and herpes simplex labialis in obstetric patients. Boyle RK. **Anaesth Intensive Care** 1995 Aug; 23(4):425–32 (41 ref.)

Morphine in cancer pain: modes of administration. Expert Working Group of the European Association for Palliative Care. **BMJ** 1996 Mar 30;312(7034):823–6 (39 ref.)

Intracerebroventricular administration of morphine for control of irreducible cancer pain. Lazorthes YR, et al. **Neurosurgery** 1995 Sep;37(3):422–8; discussion 428–9 (26 ref.)

The management of opioid and benzodiazepine dependence in infants, children, and adolescents. Yaster M, et al. **Pediatrics** 1996 Jul;98(1):135–40 (41 ref.)

ADVERSE EFFECTS

Recurrence of herpes simplex virus blepharitis after cesarean section and epidural morphine. James CF. **Anesth Analg** 1996 May;82(5):1094–6 (17 ref.)

The role of the locus coeruleus and N–methyl–D–aspartic acid (NMDA) and AMPA receptors in opiate withdrawal. Rasmussen K. **Neuropsychopharmacology** 1995 Dec; 13(4):295–300 (165 ref.)

METABOLISM

Endogenous morphine. Hosztafi S, et al. **Pharmacol Res** 1995 Jul–Aug;32(1–2):15–20 (51 ref.)

PHARMACOLOGY

Addictive drugs as reinforcers: multiple partial actions on memory systems. White NM. **Addiction** 1996 Jul; 91(7):921–49; discussion 951–65 (304 ref.)

Nitric oxide synthase inhibitors. Preclinical studies of potential use for treatment of opioid withdrawal. Vaupel DB, et al. **Neuropsychopharmacology** 1995 Dec; 13(4):315–22 (27 ref.)

Dopamine, a common substrate for the rewarding effects of brain stimulation reward, cocaine, and morphine. Kornetsky C, et al. **NIDA Res Monogr** 1994;145:19–39 (66 ref.)

Enhanced N–methyl–D–aspartate (NMDA)–induced activity following morphine: sensitivity to sigma and PCP ligands. Larson AA, et al. **NIDA Res Monogr** 1995;147:146–60 (20 ref.)

The association of neuropathic pain, morphine tolerance and dependence, and the translocation of protein kinase C. Mayer DJ, et al. **NIDA Res Monogr** 1995;147:269–98 (111 ref.)

Effects of morphine and cocaine on breathing control in neonatal animals: a minireview. Olsen GD, et al. **NIDA Res Monogr** 1995;158:22–39 (106 ref.)

Effects of prenatal morphine and cocaine on postnatal behaviors and brain neurotransmitters. Vathy I. **NIDA Res Monogr** 1995;158:88–114 (118 ref.)

1994 John J. Bonica Lecture. The clinical effects of morphine pharmacology. Mather LE. **Reg Anesth** 1995 Jul–Aug; 20(4):263–82 (95 ref.)

[Analgesic effect of morphine and its metabolites administered by an intracerebroventricular route] Serrié A. **Bull Acad Natl Med** 1995 Jun;179(6):1237–52; discussion 1252–3 (20 ref.) (Eng. Abstr.) **(Fre)**

THERAPEUTIC USE

Sublingual and oral morphine administration. Review and new findings. Robison JM, et al. **Nurs Clin North Am** 1995 Dec;30(4):725–43 (51 ref.)

Mechanisms of hyperalgesia and morphine tolerance: a current view of their possible interactions. Mao J, et al. **Pain** 1995 Sep;62(3):259–74 (150 ref.)

1994 John J. Bonica Lecture. The clinical effects of morphine pharmacology. Mather LE. **Reg Anesth** 1995 Jul–Aug; 20(4):263–82 (95 ref.)

MORPHINE DEPENDENCE

The association of neuropathic pain, morphine tolerance and dependence, and the translocation of protein kinase C. Mayer DJ, et al. **NIDA Res Monogr** 1995;147:269–98 (111 ref.)

DRUG THERAPY

Inhibitors of nitric oxide synthase and the opioid withdrawal syndrome. London ED, et al. **NIDA Res Monogr** 1995; 147:170–81 (26 ref.)

THERAPY

The management of opioid and benzodiazepine dependence in infants, children, and adolescents. Yaster M, et al. **Pediatrics** 1996 Jul;98(1):135–40 (41 ref.)

MORPHINE DERIVATIVES

PHARMACOLOGY

[Analgesic effect of morphine and its metabolites administered by an intracerebroventricular route] Serrié A. **Bull Acad Natl Med** 1995 Jun;179(6):1237–52; discussion 1252–3 (20 ref.) (Eng. Abstr.) **(Fre)**

MORPHINE DERIVATIVES

THERAPEUTIC USE

Methoclocinnamox: a mu partial agonist with pharmacotherapeutic potential for heroin abuse. Woods JH, et al. **NIDA Res Monogr** 1995;147:195–219 (29 ref.)

[Optimal use of the administration of morphine derivatives] Langlade A. **Cah Anesthesiol** 1995;43(3):251–7 (66 ref.) (Eng. Abstr.) **(Fre)**

MORPHINE RECEPTORS see **RECEPTORS, OPIOID, MU**

MORPHOGENESIS

Plant morphogenesis. Life on a different plane. Lloyd C. **Curr Biol** 1995 Oct 1;5(10):1085–7 (9 ref.)

Gap junction communication and cell adhesion in development. DeHaan RL. **Zygote** 1994 Aug;2(3):183–8 (71 ref.)

[Molecular mechanisms of the neural induction and morphogenesis] Okamoto H, et al. **Tanpakushitsu Kakusan Koso** 1996 May;41(6):746–57 (25 ref.) **(Jpn)**

GENETICS

Inductive signals. Revolving vertebrates. Jones CM, et al. **Curr Biol** 1995 Jun 1;5(6):574–6 (16 ref.)

From morphogenes to morphogenesis. Harold FM. **Microbiology** 1995 Nov;141 (Pt 11):2765–78 (102 ref.)

PHYSIOLOGY

Cell adhesion: the molecular basis of tissue architecture and morphogenesis. Gumbiner BM. **Cell** 1996 Feb 9; 84(3):345–57 (72 ref.)

Morphogenetic properties of microtubules and mitotic spindle assembly. Hyman AA, et al. **Cell** 1996 Feb 9; 84(3):401–10 (70 ref.)

Somite differentiation. Sonic signals somites. Bumcrot DA, et al. **Curr Biol** 1995 Jun 1;5(6):612–4 (13 ref.)

Morphogenetic signalling. Responses to hedgehog. Kalderon D. **Curr Biol** 1995 Jun 1;5(6):580–2 (15 ref.)

Control of signal transduction and morphogenesis by Ras. Hughes DA. **Semin Cell Biol** 1995 Apr;6(2):89–94 (49 ref.)

MORPHOLINES

THERAPEUTIC USE

Treatment of Gaucher disease with an enzyme inhibitor. Radin NS. **Glycoconj J** 1996 Apr;13(2):153–7 (22 ref.)

MORQUIO'S DISEASE see **MUCOPOLYSACCHARIDOSIS IV**

MORTALITY

Particulate air pollution and mortality: the Philadelphia story [editorial; comment] [see comments] Samet JM. **Epidemiology** 1995 Sep;6(5):471–3 (14 ref.) Comment on: Epidemiology 1995 Sep;6(5):476–84. Comment in: Epidemiology 1995 Nov;6(6):629–32.

The fetal and infant origins of disease. Barker DJ. **Eur J Clin Invest** 1995 Jul;25(7):457–63 (51 ref.)

Do physical activity and physical fitness avert premature mortality? Lee IM, et al. **Exerc Sport Sci Rev** 1996; 24:135–71 (113 ref.)

Mortality crossovers and selective survival in human and nonhuman populations. New developments in mortality. Olshansky SJ. **Gerontologist** 1995 Oct;35(5):583–7 (31 ref.)

Air pollution and mortality: issues and uncertainties. Lipfert FW, et al. **J Air Waste Manag Assoc** 1995 Dec; 45(12):949–66 (54 ref.)

"Weight cycling" and mortality: how do the epidemiologists explain the role of intentional weight loss? Williamson DF. **J Am Coll Nutr** 1996 Feb;15(1):6–13 (23 ref.)

Cohort analysis of mortality rates as an historical or narrative technique [see comments] Case RA. **J Epidemiol Community Health** 1996 Apr;50(2):114–24 (34 ref.) Comment in: J Epidemiol Community Health 1996 Apr;50(2):125–6.

A critical review of PM10–mortality time–series studies. Thurston GD. **J Expo Anal Environ Epidemiol** 1996 Jan–Mar;6(1):3–21 (33 ref.)

Is weight loss hazardous? Lee IM, et al. **Nutr Rev** 1996 Apr; 54(4 Pt 2):S116–24 (51 ref.)

A review of post transport mortality among younger calves. Knowles TG. **Vet Rec** 1995 Oct 14;137(16):406–7 (17 ref.)

[Association of air pollution and mortality: a review of recent epidemiological studies] Ballester Diez F, et al. **Rev Esp Salud Publica** 1995 Mar–Apr;69(2):177–88 (38 ref.) (Eng. Abstr.) **(Spa)**

MORTALITY, HOSPITAL see **HOSPITAL MORTALITY**

MOSAIC VIRUSES

PHYSIOLOGY

[Mosaic proteins] Zak I. **Postepy Biochem** 1995;41(2):120–30 (81 ref.) **(Pol)**

MOSAICISM

see related
MICE, TRANSGENIC

Transient leukemia with trisomy 21: description of a case and review of the literature. Bhatt S, et al. **Am J Med Genet** 1995 Sep 25;58(4):310–4 (23 ref.)

Mosaic vs. nonmosaic trisomy 9: report of a liveborn infant evaluated by fluorescence in situ hybridization and review of the literature. Cantú ES, et al. **Am J Med Genet** 1996 Apr 24;62(4):330–5 (39 ref.)

Risk of fetal mosaicism when placental mosaicism is diagnosed by chorionic villus sampling. Phillips OP, et al. **Am J Obstet Gynecol** 1996 Mar;174(3):850–5 (24 ref.)

Mosaic "tetrasomy" 8p: case report and review of the literature. Winters J, et al. **Clin Genet** 1995 Oct;48(4):195–8 (9 ref.)

Hypomelanosis of Ito and X;autosome translocations: a unifying hypothesis. Hatchwell E. **J Med Genet** 1996 Mar; 33(3):177–83 (61 ref.)

GENETICS

Cutaneous mosaicism. Savin JA. **QJM** 1996 Jul;89(7):489–91 (18 ref.)

Ambiguous genitalia in an elderly woman with a mosaic 45,X/46,X,dic(Y)(Q11.2) karyotype. Smith YR, et al. **Urology** 1996 Feb;47(2):259–62 (13 ref.)

MOSCHKOWITZ DISEASE see **PURPURA, THROMBOTIC THROMBOCYTOPENIC**

MOSQUITO CONTROL

see related
INSECTICIDE RESISTANCE
PEST CONTROL, BIOLOGICAL

Computer models: killing mosquitoes with information. Roberts FC. **J Am Mosq Control Assoc** 1995 Jun;11(2 Pt 2):284–9 (10 ref.)

Global distribution and continuing spread of Aedes albopictus. Knudsen AB. **Parassitologia** 1995 Dec; 37(2–3):91–7 (44 ref.)

[War on several front–lines against mosquitoes. Over 20,000 different agents against 2,000 different species] Tunón H, et al. **Lakartidningen** 1996 Jul 10;93(28–29):2593–6 (18 ref.) **(Swe)**

ECONOMICS

Economic aspects of the use of impregnated mosquito nets for malaria control. Brinkmann U, et al. **Bull World Health Organ** 1995;73(5):651–8 (23 ref.)

From efficacy to effectiveness: insecticide–treated bednets in Africa. Lengeler C, et al. **Bull World Health Organ** 1996; 74(3):325–32 (40 ref.)

METHODS

Community involvement in the control of Aedes aegypti. Gubler DJ, et al. **Acta Trop** 1996 Apr;61(2):169–79 (21 ref.)

Some operational aspects of the use of personal protection methods against malaria at individual and community level. Carnevale P, et al. **Ann Soc Belg Med Trop** 1995 Jun; 75(2):81–103 (92 ref.)

Economic aspects of the use of impregnated mosquito nets for malaria control. Brinkmann U, et al. **Bull World Health Organ** 1995;73(5):651–8 (23 ref.)

Some emerging issues on the malaria problem in Kenya. Oloo AJ, et al. **East Afr Med J** 1996 Jan;73(1):50–3 (48 ref.)

Can we control mosquitoes without pesticides? A summary. Service MW. **J Am Mosq Control Assoc** 1995 Jun;11(2 Pt 2):290–3 (24 ref.)

Some environmental and biological factors influencing the activity of entomopathogenic Bacillus on mosquito larvae in Brazil. Consoli RA, et al. **Mem Inst Oswaldo Cruz** 1995 Jan–Feb;90(1):121–4 (55 ref.)

Transfer of toxin genes to alternate bacterial hosts for mosquito control. Orduz S, et al. **Mem Inst Oswaldo Cruz** 1995 Jan–Feb;90(1):97–107 (88 ref.)

Control of Aedes albopictus from the perspective of North America. Nasci RS. **Parassitologia** 1995 Dec;37(2–3):123–7 (6 ref.)

[Vector control, perspectives and realities] Carnevale P. **Med Trop (Mars)** 1995;55(4 Suppl):56–65 (89 ref.) (Eng. Abstr.) **(Fre)**

ORGANIZATION & ADMINISTRATION

A North American model to contain the spread of Aedes albopictus through tire legislation. Novak RJ. **Parassitologia** 1995 Dec;37(2–3):129–39 (17 ref.)

MOSQUITO FISH see **CYPRINODONTIFORMES**

MOSQUITOES see **CULICIDAE**

MOTHER CELLS see **STEM CELLS**

MOTHER–CHILD RELATIONS

Reinventing the mother–daughter relationship. van Mens–Verhulst J. **Am J Psychother** 1995 Fall;49(4):526–39 (49 ref.)

Parents as partners: including mothers and fathers in the treatment of children who stutter. Kelly EM. **J Commun Disord** 1995 Jun;28(2):93–105 (50 ref.)

Challenges in moving from a traditional therapeutic community to a women and children's TC model. Brown VB, et al. **J Psychoactive Drugs** 1996 Jan–Mar;28(1):39–46 (16 ref.)

The social life of bonding theory. Crouch M, et al. **Soc Sci Med** 1995 Sep;41(6):837–44 (88 ref.)

Breastfeeding for optimal mental development. The alpha and the omega in human milk. de Andraca I, et al. **World Rev Nutr Diet** 1995;78:1–27 (74 ref.)

MOTHERS

see related
MATERNAL BEHAVIOR

Postpartum care. Stover AM, et al. **Am Fam Physician** 1995 Oct;52(5):1465–72 (32 ref.)

Problems associated with early discharge of newborn infants. Early discharge of newborns and mothers: a critical review of the literature. Braveman P, et al. **Pediatrics** 1995 Oct; 96(4 Pt 1):716–26 (74 ref.)

Potential interventions for preventing pneumonia among young children in developing countries: promoting maternal education. van Ginneken JK, et al. **Trop Med Int Health** 1996 Jun;1(3):283–94 (34 ref.)

At mother's mercy: the nightmare of Munchausen syndrome by proxy. Lesaca TG. **W V Med J** 1995 Nov–Dec; 91(7):318–9 (16 ref.)

[European study of working mothers and congenital malformations] Candela S, et al. **Epidemiol Prev** 1996 Apr–Sep;20(2–3):183–5 (17 ref.) **(Ita)**

EDUCATION

Should breast–feeding by women with silicone implants be recommended? [letter] Jordan ME, et al. **Arch Pediatr Adolesc Med** 1996 Aug;150(8):880–1 (27 ref.)

PSYCHOLOGY

Mendacious moms or devious dads? Some perplexing issues in child custody/sexual abuse allegation disputes. Penfold PS. **Can J Psychiatry** 1995 Aug;40(6):337–41 (38 ref.)

Treatment needs of drug–addicted mothers. Integrated parenting psychotherapy interventions. Luthar SS, et al. **J Subst Abuse Treat** 1995 Sep–Oct;12(5):341–8 (64 ref.)

MOTHS

PHYSIOLOGY

Proteins that smell: pheromone recognition and signal transduction. Prestwich GD. **Bioorg Med Chem** 1996 Mar; 4(3):505–13 (55 ref.)

MOTILIN

see related
GASTROINTESTINAL AGENTS

AGONISTS

[Treatment of radiotherapy–induced gastroparesis with erythromycin] Sturm A, et al. **Dtsch Med Wochenschr** 1996 Mar 29;121(13):402–5 (16 ref.) (Eng. Abstr.) **(Ger)**

BLOOD

[Motilin] Ueda H, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:640–3 (18 ref.) **(Jpn)**

MOTILITY, CELL see **CELL MOVEMENT**

MOTION

see related
MOVEMENT

MOTION PERCEPTION

Functional MRI: are we all moving towards artifactual conclusions? Or fMRI fact or fancy? Weisskoff RM. **NMR Biomed** 1995 May;8(3):101–3 (10 ref.)

PHYSIOLOGY

Cortical mechanisms for visual perception of object motion and position in space. Battaglini PP, et al. **Behav Brain Res** 1996 Apr;76(1–2):143–54 (57 ref.)

The role of eye movements in the perception of motion and shape. Wallach H. **Rev Oculomot Res** 1990;4:289–305 (24 ref.)

MOTION PICTURES

see related
CINERADIOGRAPHY

DRUG THERAPY

Motion sickness. Noel P, et al. **J La State Med Soc** 1996 Jan;148(1):7–11 (14 ref.)

MOTION THERAPY, CONTINUOUS PASSIVE

History of rest and motion and the scientific basis for early continuous passive motion. Salter RB. **Hand Clin** 1996 Feb; 12(1):1–11 (66 ref.)

The dose effect of continuous passive motion in postoperative rehabilitation of the first metatarsophalangeal joint. Lawrence BR. **J Foot Ankle Surg** 1996 Mar–Apr; 35(2):155–61; discussion 190–1 (73 ref.)

INSTRUMENTATION

Continuous passive motion use in hand therapy. Adams KM, et al. **Hand Clin** 1996 Feb;12(1):109–27 (22 ref.)

MOTIVATION

see related
COGNITIVE DISSONANCE
LIBIDO

The motivation of addiction. Bell DS. **Acta Neurochir (Wien)** 1995;132(4):185–91 (27 ref.)

Acamprosate in alcohol dependence: how does it work? Littleton J. **Addiction** 1995 Sep;90(9):1179–88 (42 ref.)

Behaviour change in practice: targeting individuals. Rollnick S. **Int J Obes Relat Metab Disord** 1996 Feb;20 Suppl 1:S22–6 (19 ref.)

The behavioral neurochemistry of motivation: methodological and conceptual issues in studies of the dynamic activity of nucleus accumbens dopamine. Salamone JD. **J Neurosci Methods** 1996 Feb;64(2):137–49 (152 ref.)

Hope: implications for neuroscience nursing. Fowler SB. **J Neurosci Nurs** 1995 Oct;27(5):298–304 (47 ref.)

Self-with-other representations and a taxonomy of motives: two approaches to studying persons. Ogilvie DM, et al. **J Pers** 1995 Sep;63(3):643–79 (80 ref.)

Psychological needs and the facilitation of integrative processes. Ryan RM. **J Pers** 1995 Sep;63(3):397–427 (115 ref.)

Alcoholism: the role of different motivational systems. Pihl RO, et al. **J Psychiatry Neurosci** 1995 Nov;20(5):372–96 (205 ref.)

Role for the mesocortical dopamine system in the motivating effects of cocaine. Koob GF, et al. **NIDA Res Monogr** 1994;145:1–18 (44 ref.)

Neurobiological mechanisms underlying the acquisition and expression of incentive motivation by cocaine-associated stimuli: relationship to craving. Pert A. **NIDA Res Monogr** 1994;145:163–90 (70 ref.)

Motivating change in health behavior. Implications for health promotion and disease prevention. Botelho RJ, et al. **Prim Care** 1995 Dec;22(4):565–89 (52 ref.)

Contingency detection and the contingent organization of behavior in interactions: implications for socioemotional development in infancy. Tarabulsy GM, et al. **Psychol Bull** 1996 Jul;120(1):25–41 (110 ref.)

Monitoring and control processes in the strategic regulation of memory accuracy. Koriat A, et al. **Psychol Rev** 1996 Jul;103(3):490–517 (140 ref.)

Intrapersonal and interpersonal factors in athletic performance. Iso-Ahola SE. **Scand J Med Sci Sports** 1995 Aug;5(4):191–9 (20 ref.)

[Activity and motivational disorders in neurology: proposal for an evaluation scale] Habib M. **Encephale** 1995 Sep–Oct; 21(5):563–70 (21 ref.) (Eng. Abstr.) **(Fre)**

[Craving—an adequately defined concept?] Wetterling T, et al. **Fortschr Neurol Psychiatr** 1996 Apr;64(4):142–52 (136 ref.) (Eng. Abstr.) **(Ger)**

[Perspectives and time as relevant phenomena in the psychopathology of obsessive-compulsive neuroses] Kraus MR, et al. **Z Klin Psychol Psychopathol Psychother** 1995; 43(4):348–54 (33 ref.) (Eng. Abstr.) **(Ger)**

[Motivation and reinforcement in the systemic mechanisms of behavior: the dynamic engrams of reinforcement] Sudakov KV. **Zh Vyssh Nerv Deist Im I P Pavlova** 1995 Jul–Aug;45(4):627–37 (40 ref.) (Eng. Abstr.) **(Rus)**

MOTOR ACTIVITY

see related
HYPERKINESIS

The clinical differentiation of nervous and muscular locomotor disorders of sheep in Australia. Bourke CA. **Aust Vet J** 1995 Jun;72(6):228–34 (40 ref.)

Penetrating gunshots to the head and lack of immediate incapacitation. II. Review of case reports. Karger B. **Int J Legal Med** 1995;108(3):117–26 (75 ref.)

Complex motor behavior arising during the sleep period: forensic science implications. Mahowald MW, et al. **Sleep** 1995 Nov;18(9):724–7 (26 ref.)

[Activity and motivational disorders in neurology: proposal for an evaluation scale] Habib M. **Encephale** 1995 Sep–Oct; 21(5):563–70 (21 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Locomotor activity and non-photic influences on circadian clocks. Mrosovsky N. **Biol Rev Camb Philos Soc** 1996 Aug; 71(3):343–72 (128 ref.)

Physical motion in dreams: one measure of three theories. Porte HS, et al. **J Abnorm Psychol** 1996 Aug;105(3):329–35 (45 ref.)

Clinical neurophysiology of cortical sensorimotor function: yesterday, today, and tomorrow. Aminoff MJ. **J Clin Neurophysiol** 1996 May;13(3):219–26 (60 ref.)

Transfer of coded information from sensory to motor networks. Salinas E, et al. **J Neurosci** 1995 Oct; 15(10):6461–74 (80 ref.)

Principles of rhythmic motor pattern generation. Marder E, et al. **Physiol Rev** 1996 Jul;76(3):687–717 (327 ref.)

Eye movements in visual search: cognitive, perceptual and motor control aspects. Viviani P. **Rev Oculomot Res** 1990; 4:353–93 (235 ref.)

Ensemble activity and behavior: what's the code? Deadwyler SA, et al. **Science** 1995 Nov 24;270(5240):1316–8 (24 ref.)

Current issues in directional motor control [see comments] Georgopoulos AP. **Trends Neurosci** 1995 Nov; 18(11):506–10 (63 ref.) Comment in: Trends Neurosci 1996 Apr;19(4):137–8.

MOTOR CORTEX

ANATOMY & HISTOLOGY

Invasive investigation and surgery of the supplementary motor area. The Cleveland Clinic experience. Comair YG, et al. **Adv Neurol** 1996;70:369–78 (12 ref.)

Functional organization of the human supplementary motor area and dorsolateral premotor cortex. Freund HJ. **Adv Neurol** 1996;70:263–9 (52 ref.)

Functional magnetic resonance imaging and the supplementary sensorimotor area. Gadian DG, et al. **Adv Neurol** 1996;70:161–5 (20 ref.)

The classic supplementary motor area is formed by two independent areas. Rizzolatti G, et al. **Adv Neurol** 1996; 70:45–56 (76 ref.)

Anatomy and transmitter receptors of the supplementary motor areas in the human and nonhuman primate brain. Zilles K, et al. **Adv Neurol** 1996;70:29–43 (90 ref.)

Motor areas of the medial wall: a review of their location and functional activation. Picard N, et al. **Cereb Cortex** 1996 May–Jun;6(3):342–53 (110 ref.)

INJURIES

Lesions of the supplementary motor area. Brust JC. **Adv Neurol** 1996;70:237–48 (120 ref.)

Neurocognitive studies in patients with supplementary sensorimotor area lesions. Burton DB, et al. **Adv Neurol** 1996;70:249–61 (58 ref.)

METABOLISM

Anatomy and transmitter receptors of the supplementary motor areas in the human and nonhuman primate brain. Zilles K, et al. **Adv Neurol** 1996;70:29–43 (90 ref.)

PATHOLOGY

Magnetic resonance imaging and supplementary motor area epilepsy. Fish DR. **Adv Neurol** 1996;70:341–51 (25 ref.)

PHYSIOLOGY

Long-term potentiation and long-term depression of horizontal connections in rat motor cortex. Hess G, et al. **Acta Neurobiol Exp (Warsz)** 1996;56(1):397–405 (32 ref.)

Lesions of the supplementary motor area. Brust JC. **Adv Neurol** 1996;70:237–48 (120 ref.)

Generation of movement-related potentials and fields in the supplementary sensorimotor area and the primary motor area. Deecke L, et al. **Adv Neurol** 1996;70:127–46 (50 ref.)

Historical overview. Freund HJ. **Adv Neurol** 1996;70:17–27 (70 ref.)

Functional organization of the human supplementary motor area and dorsolateral premotor cortex. Freund HJ. **Adv Neurol** 1996;70:263–9 (52 ref.)

Electrical stimulation of the supplementary sensorimotor area. Fried I. **Adv Neurol** 1996;70:177–85 (52 ref.)

Generation of movement-related potentials in the supplementary sensorimotor area. Hallett M, et al. **Adv Neurol** 1996;70:147–52 (20 ref.)

Generation of contingent negative variation in the supplementary sensorimotor area. Ikeda A, et al. **Adv Neurol** 1996;70:153–9 (44 ref.)

Cortical stimulation of the supplementary sensorimotor area. Lim SH, et al. **Adv Neurol** 1996;70:187–97 (56 ref.)

The supplementary sensorimotor area. An overview. Lüders HO. **Adv Neurol** 1996;70:1–16 (21 ref.)

Cortical electrical stimulation in humans. The negative motor areas. Lüders HO, et al. **Adv Neurol** 1995;67:115–29 (66 ref.)

Anatomy and neurotransmitters of brainstem motor systems. Newman DB. **Adv Neurol** 1995;67:219–44 (138 ref.)

Functional specialization of the supplementary motor area in monkeys and humans. Passingham RE. **Adv Neurol** 1996; 70:105–16 (42 ref.)

The classic supplementary motor area is formed by two independent areas. Rizzolatti G, et al. **Adv Neurol** 1996; 70:45–56 (76 ref.)

Neurophysiology of the human supplementary motor area. Positron emission tomography. Seitz RJ, et al. **Adv Neurol** 1996;70:167–75 (53 ref.)

Generation of movement-related potentials in the supplementary sensorimotor area. Shibasaki H, et al. **Adv Neurol** 1996;70:117–25 (45 ref.)

Electrical stimulation of the supplementary sensorimotor area. Sutherling WW, et al. **Adv Neurol** 1996;70:211–5 (17 ref.)

Contrast of neuronal activity between the supplemental motor area and other cortical motor areas. Tanji J, et al. **Adv Neurol** 1996;70:95–103 (44 ref.)

Is the supplementary motor area a bilaterally organized system? Wiesendanger M, et al. **Adv Neurol** 1996;70:85–93 (32 ref.)

Corticospinal efferents of the supplementary sensorimotor area in relation to the primary motor area. Wise SP. **Adv Neurol** 1996;70:57–69 (62 ref.)

Evolutionary and comparative neurobiology of the supplementary sensorimotor area. Wise SP. **Adv Neurol** 1996;70:71–83 (133 ref.)

Motor areas of the medial wall: a review of their location and functional activation. Picard N, et al. **Cereb Cortex** 1996 May–Jun;6(3):342–53 (110 ref.)

Plasticity of adult sensorimotor representations. Donoghue JP. **Curr Opin Neurobiol** 1995 Dec;5(6):749–54 (54 ref.)

Current issues in directional motor control [see comments] Georgopoulos AP. **Trends Neurosci** 1995 Nov; 18(11):506–10 (63 ref.) Comment in: Trends Neurosci 1996 Apr;19(4):137–8.

[The doctrine of brain localization and its development in the 20th century] Wiesendanger M. **Schweiz Rundsch Med Prax** 1995 Dec 5;84(49):1448–58 (39 ref.) (Eng. Abstr.) **(Ger)**

[Role of cortical motor areas in voluntary movements] Kurata K. **No To Shinkei** 1995 Dec;47(12):1135–42 (35 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Supplementary sensorimotor area epilepsy in adults. Bleasel AF, et al. **Adv Neurol** 1996;70:271–84 (54 ref.)

Dystonia and the supplementary sensorimotor area. Hallett M, et al. **Adv Neurol** 1996;70:471–6 (31 ref.)

Psychogenic seizures and the supplementary sensorimotor area. Kanner AM. **Adv Neurol** 1996;70:461–6 (42 ref.)

Supplementary sensorimotor area epilepsy in adults. King DW, et al. **Adv Neurol** 1996;70:285–91 (31 ref.)

Unusual features of supplementary sensorimotor area epilepsy: cyclic pattern, unusual sensory aura, startle sensitivity, anoxic encephalopathy, and spontaneous remission. Reutens DC, et al. **Adv Neurol** 1996;70:293–300 (22 ref.)

Invasive electroencephalography in the evaluation of supplementary motor area seizures. Van Ness PC. **Adv Neurol** 1996;70:319–40 (35 ref.)

[Tics: clinical spectrum] Calderón R. **Rev Neurol** 1995;23 Suppl 3:S355–8 (17 ref.) **(Spa)**

SURGERY

Invasive investigation and surgery of the supplementary motor area. The Cleveland Clinic experience. Comair YG, et al. **Adv Neurol** 1996;70:369–78 (12 ref.)

Space-occupying lesions of the sensori-motor region. Ebeling U, et al. **Adv Tech Stand Neurosurg** 1995;22:137–81 (106 ref.)

MOTOR NEURON DISEASE

Multifocal motor neuropathy and chronic inflammatory demyelinating polyradiculoneuropathy. Léger JM. **Curr Opin Neurol** 1995 Oct;8(5):359–63 (23 ref.)

Neuroepidemiology of amyotrophic lateral sclerosis: clues to aetiology and pathogenesis. Román GC. **J Neurol Neurosurg Psychiatry** 1996 Aug;61(2):131–7 (87 ref.)

BLOOD

Multifocal motor neuropathy [editorial] Nobile-Orazio E. **J Neurol Neurosurg Psychiatry** 1996 Jun;60(6):599–603 (67 ref.)

CEREBROSPINAL FLUID

Multifocal motor neuropathy [editorial] Nobile-Orazio E. **J Neurol Neurosurg Psychiatry** 1996 Jun;60(6):599–603 (67 ref.)

CHEMICALLY INDUCED

[Relationship between exposure to environmental toxins and motor neuron disease: a case report] Vanacore N, et al. **Med Lav** 1995 Nov–Dec;86(6):522–33 (50 ref.) (Eng. Abstr.) **(Ita)**

DIAGNOSIS

Clues to the diagnosis of amyotrophic lateral sclerosis. Cambier J, et al. **Adv Neurol** 1995;68:161–2 (12 ref.)

Megaslope, natural course, and historical controls in amyotrophic lateral sclerosis trials. Conradi S, et al. **Adv Neurol** 1995;68:219–24 (7 ref.)

Natural history of amyotrophic lateral sclerosis. Observations

with the Charing Cross Amyotrophic Lateral Sclerosis Rating Scales. Guiloff RJ, et al. **Adv Neurol** 1995;68:185–98 (28 ref.)
Natural history of amyotrophic lateral sclerosis. A discussion. Meininger V, et al. **Adv Neurol** 1995;68:199–207 (18 ref.)
The diagnosis of amyotrophic lateral sclerosis. Pouget J, et al. **Adv Neurol** 1995;68:143–52 (82 ref.)
The diagnosis of amyotrophic lateral sclerosis. A discussion. Swash M. **Adv Neurol** 1995;68:157–60 (21 ref.)
Chronic motor neuropathies and lower motor neurone syndromes. Kornberg AJ, et al. **Baillieres Clin Neurol** 1995 Nov;4(3):427–41 (98 ref.)
Atypical motor neuron disease with severe ophthalmoplegia: a report of two cases [letter; comment] Yuki N, et al. **J Neurol** 1995 Aug;242(8):541–6 (16 ref.) Comment on: J Neurol 1994 Oct;241(10):592–6.

DRUG THERAPY

Neurotrophic factors as therapeutic agents in amyotrophic lateral sclerosis. Potential and pitfalls. Henderson CE. **Adv Neurol** 1995;68:235–40 (22 ref.)
Use of growth factors in the treatment of motor neuron diseases. Windebank AJ. **Adv Neurol** 1995;68:229–34 (22 ref.)

ETIOLOGY

Autoimmunity as an etiological factor in sporadic amyotrophic lateral sclerosis. Appel SH, et al. **Adv Neurol** 1995;68:47–57 (88 ref.)

GENETICS

Defects of androgen receptor function: from sex reversal to motor neurone disease. MacLean HE, et al. **Mol Cell Endocrinol** 1995 Aug 11;112(2):133–41 (104 ref.)
X-linked recessive bulbospinal neuronopathy (SBMA). Sobue G. **Nagoya J Med Sci** 1995 Dec;58(3–4):95–106 (41 ref.)
The expanded trinucleotide repeat in Kennedy's disease. Fischbeck KH. **Proc Assoc Am Physicians** 1995 Jul; 107(2):228–30 (9 ref.)

METABOLISM

Amyotrophic lateral sclerosis with paraproteins and autoantibodies. Rowland LP. **Adv Neurol** 1995;68:93–105; discussion 107–11 (136 ref.)

PATHOLOGY

Motor neuron disease with involvement of the pallido-luysio-nigral system and mesencephalic tegmentum. Kato S, et al. **Clin Neuropathol** 1995 Jul–Aug; 14(4):241–4 (15 ref.)

PHYSIOPATHOLOGY

Megalope, natural course, and historical controls in amyotrophic lateral sclerosis trials. Conradi S, et al. **Adv Neurol** 1995;68:219–24 (7 ref.)
Peripherally induced EMG silent periods. Normal physiology and disorders of motor control. Ford B, et al. **Adv Neurol** 1995;67:321–8 (47 ref.)
Natural history of amyotrophic lateral sclerosis. Observations with the Charing Cross Amyotrophic Lateral Sclerosis Rating Scales. Guiloff RJ, et al. **Adv Neurol** 1995;68:185–98 (28 ref.)
Chronic motor neuropathies. Kornberg AJ, et al. **Adv Neurol** 1995;68:113–9 (52 ref.)
Natural history of amyotrophic lateral sclerosis. A discussion. Meininger V, et al. **Adv Neurol** 1995;68:199–207 (18 ref.)
Animal models of amyotrophic lateral sclerosis. Mitsumoto H, et al. **Adv Neurol** 1995;68:73–87; discussion 89–91 (80 ref.)
Single-joint rapid arm movements in normal subjects and in patients with motor disorders. Berardelli A, et al. **Brain** 1996 Apr;119 (Pt 2):661–74 (78 ref.)
Some aspects of higher motor disorders and their relationship to movement disorders associated with disease of subcortical nuclei [editorial] Thompson PD, et al. **Curr Opin Neurol** 1995 Aug;8(4):303–5 (6 ref.)

THERAPY

The design of clinical trials in amyotrophic lateral sclerosis. Azulay JP. **Adv Neurol** 1995;68:225–7 (13 ref.)
Megaslope, natural course, and historical controls in amyotrophic lateral sclerosis trials. Conradi S, et al. **Adv Neurol** 1995;68:219–24 (7 ref.)
Chronic motor neuropathies. Kornberg AJ, et al. **Adv Neurol** 1995;68:113–9 (52 ref.)
Issues in amyotrophic lateral sclerosis clinical trial design. Munsat TL. **Adv Neurol** 1995;68:209–18 (33 ref.)

VIROLOGY

The viral hypothesis. Gastaut JL. **Adv Neurol** 1995;68:135–7 (33 ref.)

MOTOR NEURONS

see related
NEUROMUSCULAR JUNCTION

CHEMISTRY

The peptidergic innervation of spinal motoneurons via the bulbospinal 5-hydroxytryptamine pathway. Cullheim S, et al. **Prog Brain Res** 1995;104:21–40 (115 ref.)
Peptides in motoneurons. Raivich G, et al. **Prog Brain Res** 1995;104:3–20 (185 ref.)

DRUG EFFECTS

Neurotrophic factors and amyotrophic lateral sclerosis. Askanas V. **Adv Neurol** 1995;68:241–4 (14 ref.)

METABOLISM

Potassium currents in motoneurones. McLarnon JG. **Prog Neurobiol** 1995 Dec;47(6):513–31 (82 ref.)

PHYSIOLOGY

Two distinct descending inputs to the cricothyroid motoneuron in the medulla originating from the amygdala and the lateral hypothalamic area. Arita H, et al. **Adv Exp Med Biol** 1995;393:53–8 (10 ref.)
Variable-frequency stimulation patterns for the optimization of force during muscle fatigue. Muscle wisdom and the catch-like property. Binder-Macleod SA. **Adv Exp Med Biol** 1995;384:227–40 (67 ref.)
Task-dependent nature of fatigue in single motor units. Botterman BR. **Adv Exp Med Biol** 1995;384:351–60 (54 ref.)
Central fatigue. Critical issues, quantification and practical implications. Gandevia SC, et al. **Adv Exp Med Biol** 1995; 384:281–94 (79 ref.)
Role of muscle afferents in the inhibition of motoneurons during fatigue. Garland SJ, et al. **Adv Exp Med Biol** 1995; 384:271–8 (50 ref.)
Neuromuscular frequency-coding and fatigue. Kernell D. **Adv Exp Med Biol** 1995;384:135–45 (54 ref.)
Fatigue of jaw muscles and speech mechanisms. Miles TS, et al. **Adv Exp Med Biol** 1995;384:415–26 (55 ref.)
The significance of motor unit variability in sustaining mechanical output of muscle. Sargeant AJ, et al. **Adv Exp Med Biol** 1995;384:323–38 (68 ref.)
Intrinsic properties of motoneurons. Implications for muscle fatigue. Sawczuk A, et al. **Adv Exp Med Biol** 1995; 384:123–34 (86 ref.)
Human motor units studied by spike-triggered averaging and intraneural motor axon stimulation. Thomas CK. **Adv Exp Med Biol** 1995;384:147–60 (75 ref.)
Overview: potential role of segmental motor circuitry in muscle fatigue. Windhorst U, et al. **Adv Exp Med Biol** 1995; 384:241–58 (70 ref.)
Some spinal mechanisms of negative motor phenomena in humans. Ashby P. **Adv Neurol** 1995;67:305–20 (60 ref.)
From basal ganglia to motoneurons. Probable involvement of pathways relaying in the medulla. Delwaide PJ, et al. **Adv Neurol** 1996;69:111–6 (26 ref.)
Peripherally induced EMG silent periods. Normal physiology and disorders of motor control. Ford B, et al. **Adv Neurol** 1995;67:321–8 (47 ref.)
Neuroanatomical and neurophysiological bases of postural control. Mori S, et al. **Adv Neurol** 1995;67:289–303 (59 ref.)
Neural development. A 'LIM code' for motor neurons? Lumsden A. **Curr Biol** 1995 May 1;5(5):491–5 (26 ref.)
Intrinsic and extrinsic neuromodulation of motor circuits. Katz PS. **Curr Opin Neurobiol** 1995 Dec;5(6):799–808 (83 ref.)
Correlated firing in sensory-motor systems. König P, et al. **Curr Opin Neurobiol** 1995 Aug;5(4):511–9 (94 ref.)
From motor unit to whole muscle properties during locomotor movements. Heckman CJ, et al. **Exerc Sport Sci Rev** 1996;24:109–33 (68 ref.)
Strength and power training: physiological mechanisms of adaptation. Kraemer WJ, et al. **Exerc Sport Sci Rev** 1996; 24:363–97 (158 ref.)
Molecular mechanisms and neural pathways mediating the influence of interleukin-1 on the activity of neuroendocrine CRF motoneurons in the rat. Rivest S. **Int J Dev Neurosci** 1995 Jun–Jul;13(3–4):135–46 (96 ref.)
Presynaptic excitability. Jackson MB. **Int Rev Neurobiol** 1995; 38:201–51 (296 ref.)
Morphological features and activation patterns of motor units. Enoka RM. **J Clin Neurophysiol** 1995 Nov; 12(6):538–59 (252 ref.)
Neurotrophic survival molecules for motoneurons: an embarrassment of riches. Oppenheim RW. **Neuron** 1996 Aug;17(2):195–7 (22 ref.)
Structural organization of the synaptic connections of the spinal cord motor neurons of mammals. Motorina MV. **Neurosci Behav Physiol** 1995 Jul–Aug;25(4):273–89 (134 ref.)
Neural networks that co-ordinate locomotion and body orientation in lamprey. Grillner S, et al. **Trends Neurosci** 1995 Jun;18(6):270–9 (64 ref.)
[Motor units hyperactivity syndromes] Vilchez JJ. **Rev Neurol** 1995 Jan–Feb;23(119):28–9 (37 ref.) **(Spa)**

MOTOR NEURONS, GAMMA

see related
MUSCLE SPINDLES

PHYSIOLOGY

The fusimotor system. Its role in fatigue. Hagbarth KE, et al. **Adv Exp Med Biol** 1995;384:259–70 (68 ref.)

MOTOR SKILLS

Developmental dyslexia: a motor-articulatory feedback hypothesis. Heilman KM, et al. **Ann Neurol** 1996 Mar; 39(3):407–12 (35 ref.)

PHYSIOLOGY

The evolution of research on motor development: new approaches bringing new insights. Whitall J. **Exerc Sport Sci Rev** 1995;23:243–73 (116 ref.)

MOTOR VEHICLES

see related
ACCIDENTS, TRAFFIC

STANDARDS

Disinfection of trucks and trailers. Mateost Poumian A. **Rev Sci Tech** 1995 Mar;14(1):165–76 (4 ref.) **(Eng, Spa)**

MOTORCYCLES

Motor-scooter handlebar syndrome: blunt traumatic injury of the femoral artery. Baker WE, et al. **J Trauma** 1996 Jun;40(6):1017–20 (18 ref.)
Intra-abdominal injury with handlebar hernia: case report and literature review. Yarbrough DR 3rd. **J Trauma** 1996 Jan;40(1):116–8 (21 ref.)

MOTTLED ENAMEL

ETIOLOGY

Consideration of possible biologic mechanisms of fluorosis. Bawden JW, et al. **J Dent Res** 1995 Jul;74(7):1349–52 (52 ref.)

MOULAGES see **MODELS, ANATOMIC**

MOUNIER-KUHN SYNDROME see **TRACHEOBRONCHOMEGALY**

MOUNTAINEERING

see related
ALTITUDE

A trek to the top: a review of acute mountain sickness. Porcelli MJ, et al. **J Am Osteopath Assoc** 1995 Dec; 95(12):718–20 (15 ref.)

PHYSIOLOGY

Optimum gradient of mountain paths. Minetti AE. **J Appl Physiol** 1995 Nov;79(5):1698–703 (11 ref.)
Age, altitude, and arrhythmia. Alexander JK. **Tex Heart Inst J** 1995;22(4):308–16 (69 ref.)

MOURNING see **GRIEF**

MOUSE HEPATITIS VIRUS see **GASTROENTERITIS VIRUS, MURINE**

MOUSE LEUKEMIA VIRUSES see **LEUKEMIA VIRUSES, MURINE**

MOUSE MAMMARY TUMOR VIRUS see **MAMMARY TUMOR VIRUSES, MOUSE**

MOUSE POLIOVIRUSES see **POLIOVIRUSES, MURINE**

MOUSE THYMIC VIRUS see **HERPESVIRIDAE**

MOUTH

see related
SURGERY, ORAL

Orofacial manifestations of child abuse and neglect. Jessee SA. **Am Fam Physician** 1995 Nov 1;52(6):1829–34 (38 ref.)

ANATOMY & HISTOLOGY

Imaging of the oropharynx and oral cavity. Part I: Normal anatomy. Hermans R, et al. **Eur Radiol** 1996;6(3):362–8 (9 ref.)

INJURIES

A review of orthodontic face-bow injuries and safety equipment. Samuels RH. **Am J Orthod Dentofacial Orthop** 1996 Sep;110(3):269–72 (13 ref.)
Electrical burns of the mouth: still searching for an answer. Thomas SS. **Burns** 1996 Mar;22(2):137–40 (15 ref.)

MICROBIOLOGY

Transmission of Helicobacter pylori: faecal-oral versus oral-oral route. Mégraud F. **Aliment Pharmacol Ther** 1995; 9 Suppl 2:85–91 (54 ref.)
Antimicrobial actions of fluoride for oral bacteria. Marquis RE. **Can J Microbiol** 1995 Nov;41(11):955–64 (92 ref.)
The biochemical milieu of the host in the selection of

anaerobic species in the oral cavity. Shah HN, et al. **Clin Infect Dis** 1995 Jun;20 Suppl 2:S291-300 (59 ref.)
Role of adhesion in microbial colonization of host tissues: a contribution of oral microbiology. Gibbons RJ. **J Dent Res** 1996 Mar;75(3):866-70 (34 ref.)
Adhesion of oral bacteria to soft tissue. Meyer DH, et al. **Methods Enzymol** 1995;253:373-85 (44 ref.)

PHYSIOLOGY

Oral motor function in the neonate. Lau C, et al. **Clin Perinatol** 1996 Jun;23(2):161-78 (65 ref.)
Mechanisms of oral sensation. Capra NF. **Dysphagia** 1995 Fall;10(4):235-47 (72 ref.)

SURGERY

Economic analysis and its application to oral and maxillofacial surgery. Sandler NA, et al. **J Oral Maxillofac Surg** 1996 May;54(5):622-6 (12 ref.)
[The use of tongue flaps for oral tissue repair] Robben C, et al. **Acta Stomatol Belg** 1995 Dec;92(4):171-84 (28 ref.) (Eng. Abstr.) **(Dut)**
[General ambulatory anesthesia in oral medicine and maxillofacial surgery] Boufflers E, et al. **Rev Stomatol Chir Maxillofac** 1995;96(4):247-58 (22 ref.) **(Fre)**
[The use of hydroxyapatite for the surgical preparation of the oral cavity for prosthesis] Zuev VP, et al. **Stomatologiia (Mosk)** 1996;75(1):71-4 (69 ref.) **(Rus)**

VIROLOGY

[Fecal-oral transmission of viral hepatitis] Buisson Y, et al. **Med Trop (Mars)** 1995;55(4):305-11 (0 ref.) **(Fre)**

MOUTH ABNORMALITIES

GENETICS

Molecular biology experimental strategies for craniofacial-oral-dental dysmorphology. Slavkin HC. **Connect Tissue Res** 1995;32(1-4):233-9 (62 ref.)

MOUTH DISEASES

see related
DIAGNOSIS, ORAL
HALITOSIS
ORAL HEALTH

HIV-associated lesions. Greenberg MS. **Dermatol Clin** 1996 Apr;14(2):319-26 (39 ref.)
Oral manifestations of selected sexually related conditions. Terezhalmy GT, et al. **Dermatol Clin** 1996 Apr; 14(2):303-17 (163 ref.)
Vesiculobullous disease of the oral cavity. Zunt SL. **Dermatol Clin** 1996 Apr;14(2):291-302 (50 ref.)
Eosinophilic ulcer of the oral mucosa. Mezei MM, et al. **J Am Acad Dermatol** 1995 Nov;33(5 Pt 1):734-40 (47 ref.)
Dental practice parameters. Parameters for 12 oral health conditions. Adopted by the American Dental Association House of Delegates. October 1995. **J Am Dent Assoc** 1996 Jan;Suppl:iS-iiS, 1S-36S (0 ref.)
Pediatric HIV infection and its oral manifestations: a review. Chigurupati R, et al. **Pediatr Dent** 1996 Mar-Apr; 18(2):106-13 (68 ref.)

CHEMICALLY INDUCED

Lesions associated with drug reactions. Parks ET. **Dermatol Clin** 1996 Apr;14(2):327-37 (47 ref.)
[Inhibition of saliva secretion caused by antidepressive drugs; a risk for oral health] Peeters FP, et al. **Ned Tijdschr Geneeskd** 1996 Mar 9;140(10):533-6 (25 ref.) **(Dut)**
[Health hazards when using snuff] Steen T. **Tidsskr Nor Laegeforen** 1996 Feb 20;116(5):625-7 (41 ref.) (Eng. Abstr.) **(Nor)**

COMPLICATIONS

Mucocutaneous histoplasmosis in AIDS. Souza Filho FJ, et al. **Br J Dermatol** 1995 Sep;133(3):472-4 (26 ref.)

CONGENITAL

Hyalinosis cutis et mucosae. Review with a case report. Chaudhary SJ, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1995 Aug;80(2):168-71 (33 ref.)

DIAGNOSIS

Common oral conditions. Kretzschmar JL, et al. **Am Fam Physician** 1996 Jul;54(1):225-34 (16 ref.)
Swellings of the oral cavity. Van Dis ML. **Dermatol Clin** 1996 Apr;14(2):355-70 (25 ref.)
Differential diagnosis of oral enlargements in children. Flaitz CM, et al. **Pediatr Dent** 1995 Jul-Aug;17(4):294-300 (12 ref.)
Oral cavity: anatomy and pathology. Laine FJ, et al. **Semin Ultrasound CT MR** 1995 Dec;16(6):527-45 (40 ref.)
[The diagnosis and therapy of acquired factor-VIII inhibitors in combination with lupus anticoagulants] Grossmann R, et al. **Dtsch Med Wochenschr** 1996 Jul 12;121(28-29):906-10 (14 ref.) (Eng. Abstr.) **(Ger)**
[Clinical differential diagnosis of the mouth and oropharynx] Grevers G. **Radiologe** 1996 Mar;36(3):181-7 (26 ref.) (Eng. Abstr.) **(Ger)**
[The recognition and treatment of mouth mucosal diseases (II). Hyperkeratosis, leukoplakia, erythroplakia, lichenoid changes and erosions of the mouth mucosa] Pajarola GF, et al. **Schweiz Monatsschr Zahnmed** 1995;105(11):1446-56 (45 ref.) **(Ger, Fre)**

DRUG THERAPY

Melatonin: implications at the oral level. Cutando A, et al. **Bull Group Int Rech Sci Stomatol Odontol** 1995 Sep-Oct; 38(3-4):81-6 (29 ref.)

ETIOLOGY

Oral manifestations of HIV infection. Weinert M, et al. **Ann Intern Med** 1996 Sep 15;125(6):485-96 (89 ref.)
Oral complications of cancer therapies: prevention and management. Singh N, et al. **Clin Oncol (R Coll Radiol)** 1996;8(1):15-24 (158 ref.)
Oral complications of local and systemic cancer treatment. Carl W. **Curr Opin Oncol** 1995 Jul;7(4):320-4 (28 ref.)
The role of the dentist in the era of AIDS. Glick M. **Dent Clin North Am** 1996 Apr;40(2):343-57 (52 ref.)
Oral verruca vulgaris in a bone marrow transplant patient: a case report and review of literature. Barasch A, et al. **Eur J Cancer B Oral Oncol** 1996 Mar;32B(2):137-9 (13 ref.)
HIV-related oral disease. Greenspan D, et al. **Lancet** 1996 Sep 14;348(9029):729-33 (38 ref.)
Managing HIV. Part 5: Treating secondary outcomes. 5.2 HIV and oral disease. Foltyn P, et al. **Med J Aust** 1996 Mar 18;164(6):357-9 (6 ref.)
Minimizing oral complications of cancer treatment. Toth BB, et al. **Oncology (Huntingt)** 1995 Sep;9(9):851-8; discussion 858, 863-6 (53 ref.)
Oral manifestations of bulimia nervosa. Zachariasen RD. **Women Health** 1995;22(4):67-76 (39 ref.)
[Oro-dental manifestations of leukemia in children] Nikoui M, et al. **J Can Dent Assoc** 1996 May;62(5):443-6, 449-50 (41 ref.) (Eng. Abstr.) **(Fre)**
[Latent anaerobic infection in the development of pathological processes in the oral cavity] Ivashkevich LG. **Vrach Delo** 1995 Jan-Feb;(1-2):16-9 (32 ref.) **(Rus)**

GENETICS

Genetics in oral-facial growth and diseases. Nakata M. **Int Dent J** 1995 Aug;45(4):227-44 (39 ref.)

IMMUNOLOGY

[Allergies to dental prostheses and to amalgam: various data from the literature] Dejobert Y, et al. **Rev Stomatol Chir Maxillofac** 1995;96(4):243-6 (16 ref.) **(Fre)**

MICROBIOLOGY

Oral manifestations of infectious diseases. Laskaris G. **Dent Clin North Am** 1996 Apr;40(2):395-423 (145 ref.)
Syphilis and gonorrhea. Siegel MA. **Dent Clin North Am** 1996 Apr;40(2):369-83 (34 ref.)
Oral manifestation of disseminated Mycobacterium kansasii infection in a patient with AIDS. Nüesch R, et al. **Dermatology** 1996;192(2):183-4 (10 ref.)

PATHOLOGY

Oral fasciitis [letter; comment] Mighell A. **Eur J Cancer B Oral Oncol** 1995 May;31B(3):207-8 (39 ref.) Comment on: Eur J Cancer B Oral Oncol 1994 May;30B(3):221-2.
Inflammatory pseudotumour of the mouth and maxilla. Shek AW, et al. **J Clin Pathol** 1996 Feb;49(2):164-7 (23 ref.)
Verruciform xanthoma. Case report and literature review. Huang JS, et al. **J Periodontol** 1996 Feb;67(2):162-5 (13 ref.)
Intraoral juvenile xanthogranuloma. A case report and literature review. Kwan CY, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Apr;81(4):450-3 (19 ref.)
Granulomatous disorders of the oral mucosa. Eveson JW. **Semin Diagn Pathol** 1996 May;13(2):118-27 (46 ref.)

PSYCHOLOGY

[Oral disease epidemiologic illness indices and oral health measures--traditional concepts are supplemented by new socio-dental indicators] Strippel H. **Gesundheitswesen** 1996 Mar;58(3):162-8 (50 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Palatal mucoperiosteal expansion as an adjunct to palatal fistula repair: case report and review of the literature. Van Damme PA, et al. **Cleft Palate Craniofac J** 1996 May; 33(3):255-7 (10 ref.)
[The use of tongue flaps for oral tissue repair] Robben C, et al. **Acta Stomatol Belg** 1995 Dec;92(4):171-84 (28 ref.) (Eng. Abstr.) **(Dut)**

VIROLOGY

Oral manifestations of infectious diseases. Laskaris G. **Dent Clin North Am** 1996 Apr;40(2):395-423 (145 ref.)
Oral manifestiations of pediatric human immunodeficincy virus infection: a review of the literature. Kline MW. **Pediatrics** 1996 Mar;97(3):380-8 (67 ref.)

MOUTH DRYNESS see **XEROSTOMIA**

MOUTH, EDENTULOUS

see related
DENTURE, COMPLETE
SURGERY, ORAL, PREPROSTHETIC

REHABILITATION

[Dental implants--indications and long-term outcome] Kniha H, et al. **Fortschr Med** 1996 Mar 30;114(9):99-103 (8 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Preprosthetic surgery for the edentulous patients. Costello BJ, et al. **Dent Clin North Am** 1996 Jan;40(1):19-38 (46 ref.)

MOUTH FLOOR

PATHOLOGY

Congenital teratoid cyst of the floor of the mouth--a case report. Harada H, et al. **Int J Oral Maxillofac Surg** 1995 Oct;24(5):361-2 (6 ref.)
Malignant hemangiopericytoma of the floor of the mouth: report of a case and review of the literature. Lin JC, et al. **J Oral Maxillofac Surg** 1996 Aug;54(8):1020-3 (15 ref.)
Focal myositis of the floor of mouth: report of two cases and review of the literature. McCluggage WG, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 May;81(5):573-5 (22 ref.)

MOUTH MUCOSA

Intraoral sebaceous carcinoma. Abuzeid M, et al. **J Laryngol Otol** 1996 May;110(5):500-2 (27 ref.)

CYTOLOGY

Oral mucosal Langerhans' cells. Barrett AW, et al. **Crit Rev Oral Biol Med** 1996;7(1):36-58 (180 ref.)

DRUG EFFECTS

Adverse effects of mouthwash use. A review. Gagari E, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1995 Oct;80(4):432-9 (60 ref.)

IMMUNOLOGY

The use of oral tolerance as a therapy for ocular autoimmunity. Rizzo LV. **Braz J Med Biol Res** 1995 Aug; 28(8):931-6 (23 ref.)
Oral mucosal Langerhans' cells. Barrett AW, et al. **Crit Rev Oral Biol Med** 1996;7(1):36-58 (180 ref.)
The hamster cheek pouch: an immunologically privileged site suitable to the study of granulomatous infections. de Arruda MS, et al. **Rev Inst Med Trop Sao Paulo** 1995 Jul-Aug;37(4):303-9 (46 ref.)

PATHOLOGY

Recurrent sialadenoma papilliferum of the buccal mucosa. Pimentel MT, et al. **J Laryngol Otol** 1995 Aug; 109(8):787-90 (29 ref.)
Granulomatous disorders of the oral mucosa. Eveson JW. **Semin Diagn Pathol** 1996 May;13(2):118-27 (46 ref.)

RADIATION EFFECTS

Oral complications of local and systemic cancer treatment. Carl W. **Curr Opin Oncol** 1995 Jul;7(4):320-4 (28 ref.)

TRANSPLANTATION

Buccal mucosa grafts in hypospadias surgery. Baskin LS, et al. **Br J Urol** 1995 Dec;76 Suppl 3:23-30 (40 ref.)
Recurrent melanoma of the hard palate treated by en bloc excision and reconstruction with an autologous palatal bone graft subjected to cryotherapy and a buccal mucosal flap. Rosales J, et al. **J Oral Maxillofac Surg** 1995 Oct; 53(10):1218-20 (16 ref.)

MOUTH NEOPLASMS

Verrucous carcinoma of the mouth. Jordan RC. **J Can Dent Assoc** 1995 Sep;61(9):797-801 (34 ref.)

CONGENITAL

Congenital teratoid cyst of the floor of the mouth--a case report. Harada H, et al. **Int J Oral Maxillofac Surg** 1995 Oct;24(5):361-2 (6 ref.)
[Ultrasound diagnosis of epignathus in the 17th week of pregnancy. Case report and review of the literature] Brühwiler H, et al. **Ultraschall Med** 1995 Oct;16(5):238-40 (18 ref.) (Eng. Abstr.) **(Ger)**

MOUTH NEOPLASMS

DIAGNOSIS

Early diagnosis of asymptomatic oral and oropharyngeal squamous cancers. Mashberg A, et al. **CA Cancer J Clin** 1995 Nov-Dec;45(6):328-51 (58 ref.)

Imaging of the oropharynx and oral cavity. Part II: Pathology. Lenz M, et al. **Eur Radiol** 1996;6(4):536-49 (28 ref.)

Oral cavity, oropharynx, and salivary glands. Sigal R. **Neuroimaging Clin N Am** 1996 May;6(2):379-400 (44 ref.)

Differential diagnosis of oral enlargements in children. Flaitz CM, et al. **Pediatr Dent** 1995 Jul-Aug;17(4):294-300 (12 ref.)

Oral cavity: anatomy and pathology. Laine FJ, et al. **Semin Ultrasound CT MR** 1995 Dec;16(6):527-45 (40 ref.)

[Bucco-sinusal site of primary leiomyosarcoma] Le Toux G, et al. **Ann Otolaryngol Chir Cervicofac** 1995;112(5):244-7 (26 ref.) (Eng. Abstr.) **(Fre)**

[Clinical differential diagnosis of the mouth and oropharynx] Grevers G. **Radiologe** 1996 Mar;36(3):181-7 (26 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

The role of photodynamic therapy in the management of oral cancer and precancer. Hopper C. **Eur J Cancer B Oral Oncol** 1996 Mar;32B(2):71-2 (7 ref.)

EPIDEMIOLOGY

Epidemiology of cancer by tobacco products and the significance of TSNA. Gupta PC, et al. **Crit Rev Toxicol** 1996;26(2):183-98 (81 ref.)

Hereditary and environmental risk factors; clinical and laboratory risk matters for head and neck, especially oral, cancer and precancer. Johnson NW, et al. **Eur J Cancer Prev** 1996 Feb;5(1):5-17 (139 ref.)

Oral cancer and precancer related to betel and miang chewing in Thailand: a review. Reichart PA. **J Oral Pathol Med** 1995 Jul;24(6):241-3 (17 ref.)

Tobacco use and cancer. A reappraisal. Vigneswaran N, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1995 Aug;80(2):178-82 (62 ref.)

ETIOLOGY

Tobacco use and cancer. A reappraisal. Vigneswaran N, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1995 Aug;80(2):178-82 (62 ref.)

[Oral lesions in Kaposi sarcoma: clinical and radiotherapeutic considerations] Barberis M, et al. **Minerva Stomatol** 1996 Jan-Feb;45(1-2):17-27 (62 ref.) (Eng. Abstr.) **(Ita)**

GENETICS

Molecular changes in oral cancer may reflect aetiology and ethnic origin. Paterson IC, et al. **Eur J Cancer B Oral Oncol** 1996 May;32B(3):150-3 (60 ref.)

Hereditary and environmental risk factors; clinical and laboratory risk matters for head and neck, especially oral, cancer and precancer. Johnson NW, et al. **Eur J Cancer Prev** 1996 Feb;5(1):5-17 (139 ref.)

PATHOLOGY

Intraoral spindle-cell lipoma: report of a case and literature review. Khoo SP, et al. **Ann Dent** 1995 Summer-Fall; 54(1-2):53-5 (14 ref.)

Exfoliative cytology in clinical oral pathology. Sugerman PB, et al. **Aust Dent J** 1996 Apr;41(2):71-4 (29 ref.)

Precancerous and cancerous lesions of the oral cavity. Summerlin DJ. **Dermatol Clin** 1996 Apr;14(2):205-23 (22 ref.)

Spindle cell lipoma of the oral cavity. Tosios K, et al. **Int J Oral Maxillofac Surg** 1995 Oct;24(5):363-4 (10 ref.)

Angiolipoma of the cheek: report of a case. Ali MH, et al. **J Oral Maxillofac Surg** 1996 Feb;54(2):213-5 (17 ref.)

Malignant hemangiopericytoma of the floor of the mouth: report of a case and review of the literature. Lin JC, et al. **J Oral Maxillofac Surg** 1996 Aug;54(8):1020-3 (15 ref.)

Simultaneous malignant melanoma and squamous cell carcinoma of the oral cavity: a case report. Nakahara H, et al. **J Oral Maxillofac Surg** 1995 Dec;53(12):1455-7 (12 ref.)

Oral white lesions with special reference to precancerous and tobacco- related lesions: conclusions of an international symposium held in Uppsala, Sweden, May 18-21 1994. International Collaborative Group on Oral White Lesions. Axéll T, et al. **J Oral Pathol Med** 1996 Feb;25(2):49-54 (3 ref.)

Ancient schwannoma of the oral floor and ventricular portion of the tongue: a case report and review of the literature. Nakayama H, et al. **Jpn J Clin Oncol** 1996 Jun;26(3):185-8 (15 ref.)

Intraoral benign mesenchymomas. Yencha MW Jr, et al. **Otolaryngol Head Neck Surg** 1995 Dec;113(6):816-9 (15 ref.)

Primary intraoral epithelioid hemangioendothelioma presenting in childhood: review of the literature and case report. Flaitz CM, et al. **Ultrastruct Pathol** 1995 Jul-Aug; 19(4):275-9 (8 ref.)

[The malignant transformation of leukoplakia of the oral cavity. A review of the literature and clinical case reports] Colella G, et al. **Minerva Stomatol** 1995 Jun;44(6):291-300 (62 ref.) (Eng. Abstr.) **(Ita)**

[Granular-cell tumor of the oral cavity (a case report and statistical notes)] Sica GS, et al. **Minerva Stomatol** 1995 May;44(5):257-61 (18 ref.) (Eng. Abstr.) **(Ita)**

PREVENTION & CONTROL

Antioxidants in oral cancer prevention. Garewal H. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1410S-1416S (54 ref.)

Strengths and weaknesses of screening programmes for oral malignancies and potentially malignant lesions. Warnakulasuriya KA, et al. **Eur J Cancer Prev** 1996 Apr; 5(2):93-8 (33 ref.)

Preparing for the mouth cancer epidemic. Langdon J. **Practitioner** 1996 Jan;240(1558):58-60 (8 ref.)

RADIOGRAPHY

[Computerized tomography of malignancies of the oral cavity, the oropharynx and hypopharynx and invasiveness] Helmberger R, et al. **Radiologe** 1996 Mar;36(3):193-8 (19 ref.) (Eng. Abstr.) **(Ger)**

RADIOTHERAPY

[ORL brachytherapy. Salvage brachytherapy in ORL cancers (oral cavity, oropharynx, nasopharynx)] Ardiet JM, et al. **Bull Cancer Radiother** 1995;82(2):199-202 (27 ref.) **(Fre)**

[ORL brachytherapy. Brachytherapy of epidermoid carcinoma of the oral cavity] Haie-Meder C, et al. **Bull Cancer Radiother** 1995;82(2):186-90 (42 ref.) **(Fre)**

[ORL brachytherapy. Focus on brachytherapy for squamous cell carcinoma of the oral cavity and pharynx] Mazeron JJ. **Bull Cancer Radiother** 1995;82(2):179-85 (68 ref.) **(Fre)**

SECONDARY

Prolactin-secreting pituitary carcinoma with implants in the cheek pouch and metastases to the ovaries. A case report and literature review. Gollard R, et al. **Cancer** 1995 Nov 15;76(10):1814-20 (43 ref.)

Metastatic tumours to the oral region. An overview. Hirshberg A, et al. **Eur J Cancer B Oral Oncol** 1995 Nov; 31B(6):355-60 (69 ref.)

Recurrent intrapulmonary malignant small cell tumor of the thoracopulmonary region with metastasis to the oral cavity: review of literature and case report. Hicks MJ, et al. **Ultrastruct Pathol** 1995 Jul-Aug;19(4):297-303 (21 ref.)

SURGERY

Management of oral cancer. Brown AE, et al. **Ann R Coll Surg Engl** 1995 Nov;77(6):404-8 (29 ref.)

VIROLOGY

[Progresses in orodentofacial surgery in China, 1995] Qiu W. **Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):759-60 (0 ref.) **(Chi)**

MOUTH PROTECTORS

Relationship of muscular strength to jaw posture in sports dentistry. Gelb H, et al. **N Y State Dent J** 1995 Nov; 61(9):58-66 (0 ref.)

MOUTH-TO-MOUTH RESUSCITATION see **CARDIOPULMONARY RESUSCITATION**

MOUTHPIECES see **MOUTH PROTECTORS**

MOUTHWASHES

see related
DENTIFRICES

ADVERSE EFFECTS

Adverse effects of mouthwash use. A review. Gagari E, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1995 Oct;80(4):432-9 (60 ref.)

MOVEMENT

see related
IMMOBILIZATION

Changes in movement capabilities with aging. Grabiner MD, et al. **Exerc Sport Sci Rev** 1995;23:65-104 (230 ref.)

Thumb movements, motions, and moments. Hollister A, et al. **J Hand Ther** 1995 Apr-Jun;8(2):106-14 (8 ref.)

Mobility and balance in the elderly: a guide to bedside assessment. MacKnight C, et al. **Postgrad Med** 1996 Mar; 99(3):269-71, 275-6 (19 ref.)

DRUG EFFECTS

Apomorphine continuous stimulation in Parkinson's disease: receptor desensitization as a possible mechanism of reduced motor response. Maggio R, et al. **J Neural Transm Suppl** 1995;45:133-6 (22 ref.)

PHYSIOLOGY

Monosynaptic Ia pathways and motor behaviour of the cat distal forelimb. Illert M. **Acta Neurobiol Exp (Warsz)** 1996; 56(1):423-34 (29 ref.)

The performance of rapid arm movements in Parkinson's disease. A review. Agostino R, et al. **Adv Neurol** 1996; 69:135-46 (61 ref.)

Basal ganglia function during normal and parkinsonian movement. PET activation studies. Brooks DJ. **Adv Neurol** 1996;69:433-41 (38 ref.)

Generation of movement-related potentials and fields in the supplementary sensorimotor area and the primary motor area. Deecke L, et al. **Adv Neurol** 1996;70:127-46 (50 ref.)

Generation of movement-related potentials in the supplementary sensorimotor area. Hallett M, et al. **Adv Neurol** 1996;70:147-52 (20 ref.)

Generation of movement-related potentials in the supplementary sensorimotor area. Shibasaki H, et al. **Adv Neurol** 1996;70:117-25 (45 ref.)

Frontal lobe mechanisms subserving vision-for-action versus vision-for-perception. Boussaoud D, et al. **Behav Brain Res** 1995 Dec 14;72(1-2):1-15 (145 ref.)

Single-joint rapid arm movements in normal subjects and in patients with motor disorders. Berardelli A, et al. **Brain** 1996 Apr;119 (Pt 2):661-74 (78 ref.)

Encoding of intention and spatial location in the posterior parietal cortex. Andersen RA. **Cereb Cortex** 1995 Sep-Oct; 5(5):457-69 (58 ref.)

Oscillation in motor pattern-generating networks. Calabrese RL. **Curr Opin Neurobiol** 1995 Dec;5(6):816-23 (55 ref.)

Mental motor imagery: a window into the representational stages of action. Jeannerod M, et al. **Curr Opin Neurobiol** 1995 Dec;5(6):727-32 (49 ref.)

Theory in motion. Marder E, et al. **Curr Opin Neurobiol** 1995 Dec;5(6):832-40 (80 ref.)

Role of the cerebellum in movement control and adaptation. Robinson FR. **Curr Opin Neurobiol** 1995 Dec;5(6):755-62 (49 ref.)

Psychophysical approaches to motor control. Soechting JF, et al. **Curr Opin Neurobiol** 1995 Dec;5(6):742-8 (80 ref.)

Localization of functional regions of human mesial cortex by somatosensory evoked potential recording and by cortical stimulation. Allison T, et al. **Electroencephalogr Clin Neurophysiol** 1996 Mar; 100(2):126-40 (62 ref.)

Muscle compliance: implications for the control of movement. Gottlieb GL. **Exerc Sport Sci Rev** 1996;24:1-34 (50 ref.)

From motor unit to whole muscle properties during locomotor movements. Heckman CJ, et al. **Exerc Sport Sci Rev** 1996;24:109-33 (68 ref.)

Deciphering the hippocampal polyglot: the hippocampus as a path integration system. McNaughton BL, et al. **J Exp Biol** 1996 Jan;199 (Pt 1):173-85 (56 ref.)

Technology assessment: dynamic electromyography in gait and motion analysis. Rechtien JJ, et al. **Muscle Nerve** 1996 Mar;19(3):396-402 (110 ref.)

Motor imagery: perception or action? Annett J. **Neuropsychologia** 1995 Nov;33(11):1395-417 (101 ref.)

Mental imagery in the motor context. Jeannerod M. **Neuropsychologia** 1995 Nov;33(11):1419-32 (66 ref.)

The role of the cerebello-thalamo-cortical pathway in skilled movement. Horne MK, et al. **Prog Neurobiol** 1995 Jun; 46(2-3):199-213 (150 ref.)

Exercise performance of lower-extremity amputees. Ward KH, et al. **Sports Med** 1995 Oct;20(4):207-14 (50 ref.)

Grasping objects: the cortical mechanisms of visuomotor transformation. Jeannerod M, et al. **Trends Neurosci** 1995 Jul;18(7):314-20 (43 ref.)

[Role of cortical motor areas in voluntary movements] Kurata K. **No To Shinkei** 1995 Dec;47(12):1135-42 (35 ref.) **(Jpn)**

MOVEMENT, CELL see **CELL MOVEMENT**

MOVEMENT DISORDER AGENTS see **ANTI-DYSKINESIA AGENTS**

MOVEMENT DISORDERS

see related
PSYCHOMOTOR DISORDERS

Update on pediatric movement disorders. Pranzatelli MR. **Adv Pediatr** 1995;42:415-63 (201 ref.)

DIAGNOSIS

The freezing phenomenon in parkinsonism. Fahn S. **Adv Neurol** 1995;67:53-63 (49 ref.)

Clinical aspects and features of cataplexy. Guilleminault C, et al. **Adv Neurol** 1995;67:65-77 (47 ref.)

Gait disorders in older adults. Alexander NB. **J Am Geriatr Soc** 1996 Apr;44(4):434-51 (311 ref.)

Movement disorders in multiple sclerosis. Tranchant C, et al. **Mov Disord** 1995 Jul;10(4):418-23 (75 ref.)

Diagnostic testing in movement disorders. Anouti A, et al. **Neurol Clin** 1996 Feb;14(1):169-82 (61 ref.)

Testing cognition may contribute to the diagnosis of movement disorders. Pillon B, et al. **Neurology** 1996 Feb; 46(2):329-34 (75 ref.)

The child who has a limp. Renshaw TS. **Pediatr Rev** 1995 Dec;16(12):458-65 (15 ref.)

DRUG THERAPY

Botulinum toxin therapy, immunologic resistance, and problems with available materials. Borodic G, et al. **Neurology** 1996 Jan;46(1):26–9 (20 ref.)

ETIOLOGY

New opinions of pathomechanisms of involuntary movements. Iłżecka J. **Ann Univ Mariae Curie Sklodowska [Med]** 1994;49:99–104 (16 ref.)

Tardive syndromes and other drug-induced movement disorders. Jankovic J. **Clin Neuropharmacol** 1995 Jun; 18(3):197–214 (124 ref.)

Pathogenesis, prevention, and treatment of neuroleptic-induced movement disorders. Ebadi M, et al. **Pharmacol Rev** 1995 Dec;47(4):575–604 (395 ref.)

Involuntary movement disorders following lightning and electrical injuries. O'Brien CF. **Semin Neurol** 1995 Sep; 15(3):263–7 (18 ref.)

PHYSIOPATHOLOGY

Contribution of dopaminergic and glutamatergic mechanisms to the pathogenesis of motor response complications in Parkinson's disease. Chase TN, et al. **Adv Neurol** 1996; 69:497–501 (30 ref.)

Clinical aspects and features of cataplexy. Guilleminault C, et al. **Adv Neurol** 1995;67:65–77 (47 ref.)

Is striatal dopaminergic receptor imbalance responsible for levodopa-induced dyskinesia? Blanchet PJ, et al. **Fundam Clin Pharmacol** 1995;9(5):434–42 (103 ref.)

The cardiopulmonary system and movement dysfunction. Peel C. **Phys Ther** 1996 May;76(5):448–55 (34 ref.)

Paroxysmal movement disorders. Shulman LM, et al. **Semin Neurol** 1995 Jun;15(2):188–93 (53 ref.)

THERAPY

Pathogenesis, prevention, and treatment of neuroleptic-induced movement disorders. Ebadi M, et al. **Pharmacol Rev** 1995 Dec;47(4):575–604 (395 ref.)

MOXIBUSTION

Recent progress in the studies on weight reduction by acupuncture and moxibustion. Liu Z, et al. **J Tradit Chin Med** 1995 Sep;15(3):224–30 (42 ref.)

MOYAMOYA DISEASE

COMPLICATIONS

Treatment of ruptured cerebral aneurysm in moyamoya disease. Kodama N, et al. **Surg Neurol** 1996 Jul;46(1):62–6 (12 ref.)

[Surgical treatment of aneurysms at basilar artery and posterior cerebral artery associated with moyamoya disease: a case report] Kawaguti T, et al. **No Shinkei Geka** 1995 Sep;23(9):807–11 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Neurofibromatosis associated with multiple intracranial vascular lesions: stenosis of the internal carotid artery and peripheral aneurysm of the Heubner's artery; report of a case] Sasaki J, et al. **No Shinkei Geka** 1995 Sep;23(9):813–7 (22 ref.) (Eng. Abstr.) **(Jpn)**

ETIOLOGY

[Moyamoya associated with Down syndrome] Soto-Ares G, et al. **J Radiol** 1996 Jun;77(6):441–4 (14 ref.) (Eng. Abstr.) **(Fre)**

[The moyamoya syndrome secondary to fibromuscular dysplasia of the middle cerebral artery] Verdú Pérez A, et al. **An Esp Pediatr** 1996 Jul;45(1):99–100 (12 ref.) **(Spa)**

PHYSIOPATHOLOGY

Evaluation of cerebral blood flow and hemodynamic reserve in symptomatic moyamoya disease using stable Xenon-CT blood flow. Horowitz M, et al. **Surg Neurol** 1995 Sep; 44(3):251–61; discussion 262 (75 ref.)

RADIOGRAPHY

Evaluation of cerebral blood flow and hemodynamic reserve in symptomatic moyamoya disease using stable Xenon-CT blood flow. Horowitz M, et al. **Surg Neurol** 1995 Sep; 44(3):251–61; discussion 262 (75 ref.)

MPGN see **GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE**

MPTP see **1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE**

MR SPECTROSCOPY see **NUCLEAR MAGNETIC RESONANCE**

MR TOMOGRAPHY see **MAGNETIC RESONANCE IMAGING**

MR TOMOGRAPHY, ECHO-PLANAR see **ECHO-PLANAR IMAGING**

MRI ANGIOGRAPHY see **MAGNETIC RESONANCE ANGIOGRAPHY**

MRI SCANS see **MAGNETIC RESONANCE IMAGING**

MRNA see **RNA, MESSENGER**

MRNA, NON-POLYADENYLATED see **RNA, MESSENGER**

MRNA, POLYADENYLATED see **RNA, MESSENGER**

MSH

BLOOD

[Lipotropin (LPH) and melanocyte-stimulating hormone (MSH)] Tanaka K. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:315–8 (13 ref.) **(Jpn)**

PHYSIOLOGY

Melanocyte-stimulating hormone: a regulator of human melanocyte physiology. Hunt G. **Pathobiology** 1995; 63(1):12–21 (77 ref.)

ACTH-related peptides: receptors and signal transduction systems involved in their neurotrophic and neuroprotective actions. Hol EM, et al. **Peptides** 1995;16(5):979–93 (150 ref.)

MSH, ALPHA see **ALPHA-MSH**

MTDNA see **DNA, MITOCHONDRIAL**

MU-CHAIN DISEASE see **HEAVY CHAIN DISEASE**

MU PHAGE see **BACTERIOPHAGE MU**

MU RECEPTORS see **RECEPTORS, OPIOID, MU**

MUCINOSES

DIAGNOSIS

Fever, convulsions and coma in scleromyxedema: a "dermato-neuro syndrome". River Y, et al. **Neurology** 1996 Jun;46(6):1778–9 (7 ref.)

[Cutaneous mucinoses] Rongioletti F, et al. **Presse Med** 1996 Apr 13;25(13):631–6 (18 ref.) (Eng. Abstr.) **(Fre)**

MUCINS

ANALYSIS

A simple mucus test for cancer screening. Shamsuddin AM. **Anticancer Res** 1996 Jul-Aug;16(4B):2193–9 (57 ref.)

BIOSYNTHESIS

Biosynthesis and molecular architecture of gel-forming mucins: implications from an amphibian model system. Hoffmann W, et al. **Biochem Soc Trans** 1995 Nov; 23(4):805–10 (50 ref.)

Biosynthesis of intestinal mucins: MUC1, MUC2, MUC3 and more. Van Klinken BJ, et al. **Biochem Soc Trans** 1995 Nov; 23(4):814–8 (42 ref.)

CHEMISTRY

Glycosylation patterns of mucins in colonic disease. Corfield AP, et al. **Biochem Soc Trans** 1995 Nov;23(4):840–5 (42 ref.)

Biosynthesis and molecular architecture of gel-forming mucins: implications from an amphibian model system. Hoffmann W, et al. **Biochem Soc Trans** 1995 Nov; 23(4):805–10 (50 ref.)

Oviductins possess chitinase- and mucin-like domains: a lead in the search for the biological function of these oviduct-specific ZP-associating glycoproteins. Malette B, et al. **Mol Reprod Dev** 1995 Jul;41(3):384–97 (145 ref.)

GENETICS

Mucin gene structure and expression: protection vs. adhesion. Van Klinken BJ, et al. **Am J Physiol** 1995 Nov;269(5 Pt 1):G613–27 (125 ref.)

[New mucin core protein genes and their clinical application] Imai K. **Hokkaido Igaku Zasshi** 1996 Mar;71(2):139–43 (9 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

MUC-1 epithelial tumor mucin-based immunity and cancer vaccines. Finn OJ, et al. **Immunol Rev** 1995 Jun;145:61–89 (112 ref.)

Development of active specific immunotherapeutic agents based on cancer-associated mucins. Samuel J, et al. **Pharm Biotechnol** 1995;6:875–90 (145 ref.)

[Mucin antigen gene and host immune response] Imai K. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Feb;19(1):109–13 (12 ref.) **(Jpn)**

METABOLISM

Interactions between human respiratory mucins and pathogens. Scharfman A, et al. **Biochem Soc Trans** 1995 Nov;23(4):836–9 (45 ref.)

PHYSIOLOGY

Salivary mucins: protective functions in relation to their diversity. Amerongen AV, et al. **Glycobiology** 1995 Dec; 5(8):733–40 (100 ref.)

[Functions of mucin molecules in gastrointestinal cancer] Imai K, et al. **Nippon Geka Gakkai Zasshi** 1996 Feb; 97(2):152–9 (34 ref.) (Eng. Abstr.) **(Jpn)**

SECRETION

Mucin-producing neoplasms of the pancreas. Intraductal papillary and mucinous cystic neoplasms. Shyr YM, et al. **Ann Surg** 1996 Feb;223(2):141–6 (27 ref.)

Regulation of mucin exocytosis from intestinal goblet cells. Laboisse C, et al. **Biochem Soc Trans** 1995 Nov;23(4):810–3 (20 ref.)

MUCOCELE

see related
RANULA

COMPLICATIONS

Respiratory distress in the neonate. Sequela of a congenital dacryocystocele. Hepler KM, et al. **Arch Otolaryngol Head Neck Surg** 1995 Dec;121(12):1423–5 (16 ref.)

CONGENITAL

Congenital lacrimal sac mucoceles with intranasal extension. Hulka GF, et al. **Otolaryngol Head Neck Surg** 1995 Nov; 113(5):651–5 (22 ref.)

DIAGNOSIS

[Appendiceal mucocele: diagnosis by echography, spiral computed tomography and magnetic resonance] Bertolotto M, et al. **Radiol Med (Torino)** 1995 Dec;90(6):829–32 (6 ref.) **(Ita)**

[Current possibilities in the diagnosis and treatment of appendiceal mucocele] Fedorov VD, et al. **Khirurgiia (Mosk)** 1996;(1):27–8 (10 ref.) (Eng. Abstr.) **(Rus)**

ETIOLOGY

External abdominal hernia of mucocele of the appendix in drain-tube removal site. Bacchin P, et al. **Radiol Med (Torino)** 1995 Dec;90(6):827–9 (13 ref.)

MUCOCILIARY CLEARANCE

[Disorders of clearance of pollutants from the lung] Mustajbegović J, et al. **Lijec Vjesn** 1996 Jan-Feb; 118(1-2):39–43 (88 ref.) (Eng. Abstr.) **(Scr)**

PHYSIOLOGY

[The clearance function of the bronchial epithelium] Kobylianskii VI. **Tsitologiia** 1995;37(3):179–86 (81 ref.) (Eng. Abstr.) **(Rus)**

MUCOCILIARY TRANSPORT see **MUCOCILIARY CLEARANCE**

MUCOCUTANEOUS LYMPH NODE SYNDROME

Kawasaki disease. Kawasaki T. **Acta Paediatr** 1995 Jul; 84(7):713–5 (20 ref.)

Kawasaki disease. Shulman ST, et al. **Pediatr Clin North Am** 1995 Oct;42(5):1205–22 (52 ref.)

COMPLICATIONS

Sequelae of Kawasaki disease in adolescents and young adults. Burns JC, et al. **J Am Coll Cardiol** 1996 Jul; 28(1):253–7 (76 ref.)

DIAGNOSIS

Kawasaki syndrome. Polkowska G. **Ann Univ Mariae Curie Sklodowska [Med]** 1994;49:145–50 (17 ref.)

Kawasaki disease. Samuel J, et al. **Br J Hosp Med** 1996 Jan 17-Feb 6;55(1-2):9–14 (22 ref.)

[Hydrocele in Kawasaki disease] Sacco MC, et al. **Pediatr Med Chir** 1995 May-Jun;17(3):279–80 (10 ref.) (Eng. Abstr.) **(Ita)**

[Is there Kawasaki disease (syndrome) in our country?] Kuznetsov VG. **Zh Mikrobiol Epidemiol Immunobiol** 1995 Nov-Dec;(6):90–5 (60 ref.) **(Rus)**

ETIOLOGY

Kawasaki syndrome. Meissner HC, et al. **Curr Opin Rheumatol** 1995 Sep;7(5):455–8 (26 ref.)

IMMUNOLOGY

Superantigens in Kawasaki syndrome. Leung DY, et al. **Clin Immunol Immunopathol** 1995 Nov;77(2):119–26 (48 ref.)

MUCOCUTANEOUS LYMPH NODE SYNDROME

PATHOLOGY

[Youthful sudden cardiac death and the Kawasaki syndrome. An anatomopathological case report] Nappo A, et al. **Minerva Cardioangiol** 1996 Mar;44(3):127–32 (14 ref.) (Eng. Abstr.) **(Ita)**

THERAPY

Kawasaki syndrome: immunomodulatory benefit and potential toxin neutralization by intravenous immune globulin. Leung DY. **Clin Exp Immunol** 1996 May;104 Suppl 1:49–54 (41 ref.)

Kawasaki syndrome. Meissner HC, et al. **Curr Opin Rheumatol** 1995 Sep;7(5):455–8 (26 ref.)

The immunologic effects of IVIG in Kawasaki disease. Leung DY. **Int Rev Immunol** 1989;5(2):197–202 (24 ref.)

MUCOLIPIDOSIS

[I-cell disease and pseudo-Hurler polydystrophy] Owada M. **Nippon Rinsho** 1995 Dec;53(12):3028–34 (20 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

[Disorders of glycoprotein metabolism] Inui K. **Ryoikibetsu Shokogun Shirizu** 1995;(8):392–5 (3 ref.) **(Jpn)**

MUCOLYTIC AGENTS see **EXPECTORANTS**

MUCOPEPTIDE AMIDOHYDROLASE see **N-ACETYLMURAMOYL-L-ALANINE AMIDASE**

MUCOPOLYSACCHARIDES see **GLYCOSAMINOGLYCANS**

MUCOPOLYSACCHARIDOSES

[Mucopolysaccharidoses] Fukuda S, et al. **Nippon Rinsho** 1995 Dec;53(12):3019–24 (18 ref.) (Eng. Abstr.) **(Jpn)**

[Mucopolysaccharidoses] Tsukamoto H. **Ryoikibetsu Shokogun Shirizu** 1995;(8):414–8 (8 ref.) **(Jpn)**

GENETICS

[Mucopolysaccharidoses—current aspects of diagnosis and therapy] Fang-Kircher S. **Wien Klin Wochenschr** 1995; 107(22):698–701 (7 ref.) (Eng. Abstr.) **(Ger)**

[Mutation analysis in Hunter patients] Villani GR, et al. **Pediatr Med Chir** 1996 Jan–Feb;18(1):71–83 (46 ref.) (Eng. Abstr.) **(Ita)**

PSYCHOLOGY

Neuropsychological outcomes of several storage diseases with and without bone marrow transplantation. Shapiro EG, et al. **J Inherit Metab Dis** 1995;18(4):413–29 (29 ref.)

SURGERY

Neuropsychological outcomes of several storage diseases with and without bone marrow transplantation. Shapiro EG, et al. **J Inherit Metab Dis** 1995;18(4):413–29 (29 ref.)

THERAPY

Bone marrow transplantation for metabolic diseases. Parkman R, et al. **Cancer Treat Res** 1995;76:87–96 (33 ref.)

MUCOPOLYSACCHARIDOSIS I

GENETICS

Molecular genetics of mucopolysaccharidosis type I: diagnostic, clinical, and biological implications. Scott HS, et al. **Hum Mutat** 1995;6(4):288–302 (66 ref.)

PSYCHOLOGY

Neuropsychological outcomes of several storage diseases with and without bone marrow transplantation. Shapiro EG, et al. **J Inherit Metab Dis** 1995;18(4):413–29 (29 ref.)

SURGERY

The future for treatment by bone marrow transplantation for adrenoleukodystrophy, metachromatic leukodystrophy, globoid cell leukodystrophy and Hurler syndrome. Krivit W, et al. **J Inherit Metab Dis** 1995;18(4):398–412 (23 ref.)

Neuropsychological outcomes of several storage diseases with and without bone marrow transplantation. Shapiro EG, et al. **J Inherit Metab Dis** 1995;18(4):413–29 (29 ref.)

MUCOPOLYSACCHARIDOSIS II

THERAPY

Bone marrow transplantation in Hunter syndrome (mucopolysaccharidosis type II): two-year follow-up of the first Italian patient and review of the literature. Coppa GV, et al. **Pediatr Med Chir** 1995 May–Jun;17(3):227–35 (56 ref.)

MUCOPOLYSACCHARIDOSIS IV

[beta-galactosidosis—GM1 gangliosidosis and Morquio B disease] Yoshida K, et al. **Nippon Rinsho** 1995 Dec; 53(12):2960–6 (23 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Craniovertebral junction anomalies in inherited disorders: part of the syndrome or caused by the disorder? Crockard HA, et al. **Eur J Pediatr** 1995 Jul;154(7):504–12 (48 ref.)

MUCOPOLYSACCHARIDOSIS V see **MUCOPOLYSACCHARIDOSIS I**

MUCOPROTEINS

CHEMISTRY

Human mucin glycoproteins: varied structures predict diverse properties and specific functions. Gum JR Jr. **Biochem Soc Trans** 1995 Nov;23(4):795–9 (40 ref.)

METABOLISM

Human mucin glycoproteins: varied structures predict diverse properties and specific functions. Gum JR Jr. **Biochem Soc Trans** 1995 Nov;23(4):795–9 (40 ref.)

PHYSIOLOGY

The physiologic and pathologic roles of Tamm–Horsfall glycoprotein in urinary system. Yu CL, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1995 Sep; 11(9):481–95 (88 ref.)

Arabinogalactan proteins and plant differentiation. Kreuger M, et al. **Plant Mol Biol** 1996 Mar;30(6):1077–86 (66 ref.)

URINE

[Urinary Tamm–Horsfall protein (THP)] Katayama Y, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:154–6 (11 ref.) **(Jpn)**

MUCORMYCOSIS

Isolated renal mucormycosis: case report and review. Levy E, et al. **J Am Soc Nephrol** 1995 Jun;5(12):2014–9 (25 ref.)

COMPLICATIONS

Zygomycosis (mucormycosis) and HIV infection: report of three cases and review. Nagy-Agren SE, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995 Dec 1;10(4):441–9 (27 ref.)

Systemic mucormycosis complicating acute renal failure: case report and review of the literature. Melnick JZ, et al. **Ren Fail** 1995 Sep;17(5):619–27 (31 ref.)

DIAGNOSIS

Mucormycosis of the sphenoid sinus in an otherwise healthy patient. Case report and literature review. Del Valle Zapico A, et al. **J Laryngol Otol** 1996 May;110(5):471–3 (19 ref.)

DRUG THERAPY

Rhinocerebral mucormycosis. Therapy with amphotericin B lipid complex. Strasser MD, et al. **Arch Intern Med** 1996 Feb 12;156(3):337–9 (21 ref.)

ETIOLOGY

Mucormycosis after bone marrow transplantation: report of four cases in thalassemia and review of the literature. Gaziev D, et al. **Bone Marrow Transplant** 1996 Mar; 17(3):409–14 (34 ref.)

MUCOSAL DISEASE VIRUS see **DIARRHEA VIRUS, BOVINE VIRAL**

MUCOSAL IMMUNITY see **IMMUNITY, MUCOSAL**

MUCOUS MEMBRANE

IMMUNOLOGY

[Mucosal immunity with implications for use in developing a new generation of vaccines] Osek J, et al. **Postepy Hig Med Dosw** 1995;49(4):469–86 (62 ref.) (Eng. Abstr.) **(Pol)**

PATHOLOGY

Specific mucosal erosions in hypereosinophilic syndrome. Evidence for eosinophil protein deposition [see comments] Aractingi S, et al. **Arch Dermatol** 1996 May;132(5):535–41 (37 ref.) Comment in: Arch Dermatol 1996 May;132(5):583–5.

MUCOVISCIDOSIS see **CYSTIC FIBROSIS**

MUCUS

IMMUNOLOGY

Epithelial cytokine responses and mucosal cytokine networks. Hedges SR, et al. **Trends Microbiol** 1995 Jul; 3(7):266–70 (69 ref.)

METABOLISM

Gut mucosa reconditioning with species-specific lactobacilli, surfactants, pseudomucus, and fibers—an invited review. Bengmark S, et al. **Biotechnol Ther** 1994–95;5(3–4):171–94 (149 ref.)

PHYSIOLOGY

Barrier function of the gastric mucus gel. Engel E, et al. **Am J Physiol** 1995 Dec;269(6 Pt 1):G994–9 (33 ref.)

SECRETION

A case of pancreatic carcinoma causing massive bronchial fluid production and electrolyte abnormalities. Lembo T, et al. **Chest** 1995 Oct;108(4):1161–3 (8 ref.)

[Bronchial mucolytic agents] Leuenberger P. **Rev Med Suisse Romande** 1996 May;116(5):335–9 (16 ref.) **(Fre)**

[Mucinous cholangiocarcinoma, mucus producing carcinoma] Sakamoto H, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):414–6 (17 ref.) **(Jpn)**

MUERTO CANYON VIRUS see **HANTAVIRUS**

MULLERIAN DUCTS

[Anti-Mullerian hormone. Structure and role in sexual differentiation] Jarmińska-Jackowiak T, et al. **Ginekol Pol** 1995 Jan;66(1):51–8 (35 ref.) (Eng. Abstr.) **(Pol)**

ABNORMALITIES

Hernia uteri (correction of: uterus) inguinale associated with unilateral renal agenesis. Keating JP, et al. **Aust N Z J Surg** 1995 Sep;65(9):688–90 (10 ref.)

MULTICENTER STUDIES

see related
CLINICAL TRIALS, PHASE III

The methodological problems of multinational epidemiological studies with particular reference to carbon black studies. Gardiner K. **Occup Med (Oxf)** 1995 Oct; 45(5):247–55 (39 ref.)

[Early clinical trials in ECTG. Early Clinical Trial Group] Ogawa M. **Gan To Kagaku Ryoho** 1996 Jan;23(2):238–41 (13 ref.) (Eng. Abstr.) **(Jpn)**

METHODS

New developments in the conduct and management of multi-center trials: an international review of clinical trial units. Gluud C, et al. **Fundam Clin Pharmacol** 1995; 9(3):284–9 (16 ref.)

MULTICENTER TRIALS see **MULTICENTER STUDIES**

MULTICULTURALISM see **CULTURAL DIVERSITY**

MULTIDISCIPLINARY PAIN CENTERS see **PAIN CLINICS**

MULTIDRUG RESISTANCE see **DRUG RESISTANCE, MULTIPLE**

MULTIDRUG TRANSPORTER see **P-GLYCOPROTEIN**

MULTIENZYME COMPLEXES

[Lactacystin: a tool for elucidation of proteasome functions] Omura S, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr; 41(4):327–36 (57 ref.) **(Jpn)**

ANTAGONISTS & INHIBITORS

Inhibition of citrate lyase may aid aerobic endurance. McCarty MF. **Med Hypotheses** 1995 Sep;45(3):247–54 (77 ref.)

BIOSYNTHESIS

Necessary but not sufficient: the role of glucocorticoids in the acidosis-induced increase in levels of mRNAs encoding proteins of the ATP-dependent proteolytic pathway in rat muscle. Price SR, et al. **Miner Electrolyte Metab** 1996; 22(1–3):72–5 (14 ref.)

CHEMISTRY

Biosynthesis of riboflavin: structure and mechanism of lumazine synthase. Bacher A, et al. **Biochem Soc Trans** 1996 Feb;24(1):89–94 (28 ref.)

Proteasome: from structure to function. Stock D, et al. **Curr Opin Biotechnol** 1996 Aug;7(4):376–85 (75 ref.)

A structural model for the membrane-integral domain of succinate: quinone oxidoreductases. Hägerhäll C, et al. **FEBS Lett** 1996 Jun 24;389(1):25–31 (59 ref.)

Molecular biology of proteasomes. Tanaka K. **Mol Biol Rep** 1995;21(1):21–6 (54 ref.)

[Structure-activity relationships in multienzyme complexes] Gol'dshtein BN, et al. **Mol Biol (Mosk)** 1995 May–Jun;

29(3):603–11 (35 ref.) (Eng. Abstr.) **(Rus)**

DEFICIENCY

[Congenital disorders of the bile acid metabolism (3 beta-hydroxy-delta 5-steroid dehydrogenase/isomerase deficiency, delta 4–3-oxosteroid 5 beta-reductase deficiency, cerebrotendinous xanthomatosis, and peroxisomal disorders] Kondo KH, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):362–6 (23 ref.) **(Jpn)**

GENETICS

Polyketide synthase gene manipulation: a structure-function approach in engineering novel antibiotics. Hutchinson CR, et al. **Annu Rev Microbiol** 1995;49:201–38 (144 ref.)

Avermectins. MacNeil DJ. **Biotechnology** 1995;28:421–42 (59 ref.)

METABOLISM

CO dehydrogenase. Ferry JG. **Annu Rev Microbiol** 1995; 49:305–33 (132 ref.)

Biosynthesis of riboflavin: structure and mechanism of lumazine synthase. Bacher A, et al. **Biochem Soc Trans** 1996 Feb;24(1):89–94 (28 ref.)

Macrolides. Katz L, et al. **Biotechnology** 1995;28:385–420 (136 ref.)

Proteolysis. The proteasome: a protein-degrading organelle? Rubin DM, et al. **Curr Biol** 1995 Aug 1;5(8):854–8 (32 ref.)

A hypothetical holoenzyme involved in the replication of the murein sacculus of Escherichia coli. Höltje JV. **Microbiology** 1996 Aug;142 (Pt 8):1911–8 (45 ref.)

The 20S/26S proteasomal pathway of protein degradation in muscle tissue. Dahlmann B, et al. **Mol Biol Rep** 1995; 21(1):57–62 (88 ref.)

Catalytic components of proteasomes and the regulation of proteinase activity. Rivett AJ, et al. **Mol Biol Rep** 1995; 21(1):35–41 (55 ref.)

Multicatalytic proteinase in fish muscle. Sánchez JJ, et al. **Mol Biol Rep** 1995;21(1):63–9 (31 ref.)

Relationships between proteasomes and RNA. Schmid HP, et al. **Mol Biol Rep** 1995;21(1):43–7 (46 ref.)

Proteolytic activity of proteasome on myofibrillar structures. Taylor RG, et al. **Mol Biol Rep** 1995;21(1):71–3 (19 ref.)

Covalent control of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase: insights into autoregulation of a bifunctional enzyme. Kurland IJ, et al. **Protein Sci** 1995 Jun;4(6):1023–37 (70 ref.)

[Fatty acid synthases--strategic functions of multienzymes] Schweizer E. **Naturwissenschaften** 1996 Aug;83(8):347–58 (52 ref.) (Eng. Abstr.) **(Ger)**

[Batten disease (Neuronal ceroid lipofuscinoses)--accumulation of ATP synthase subunit c caused by the delay of lysosomal degradation] Ezaki J, et al. **Nippon Rinsho** 1995 Dec;53(12):3055–61 (22 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Selective protein degradation: a journey's end within the proteasome. Jentsch S, et al. **Cell** 1995 Sep 22;82(6):881–4 (22 ref.)

Proteasome: from structure to function. Stock D, et al. **Curr Opin Biotechnol** 1996 Aug;7(4):376–85 (75 ref.)

Regulatory features of multicatalytic and 26S proteases. Hoffman L, et al. **Curr Top Cell Regul** 1996;34:1–32 (192 ref.)

Mechanistic aspects of NF-kappa B regulation: the emerging role of phosphorylation and proteolysis. Finco TS, et al. **Immunity** 1995 Sep;3(3):263–72 (100 ref.)

Proteasome and class I antigen processing and presentation. Belich MP, et al. **Mol Biol Rep** 1995;21(1):53–6 (39 ref.)

Proteasomes of the yeast S. cerevisiae: genes, structure and functions. Hilt W, et al. **Mol Biol Rep** 1995;21(1):3–10 (74 ref.)

Roles of proteasomes in cell growth. Ichihara A, et al. **Mol Biol Rep** 1995;21(1):49–52 (46 ref.)

MULTIFACTORIAL CAUSALITY see **CAUSALITY**

MULTIFUNCTIONAL ENZYMES see **MULTIENZYME COMPLEXES**

MULTIGENE FAMILY see **GENES, REITERATED**

MULTI-HOSPITAL INFORMATION SYSTEMS see **HOSPITAL INFORMATION SYSTEMS**

MULTI-HOSPITAL SYSTEMS see **MULTI-INSTITUTIONAL SYSTEMS**

MULTI-INFARCT DEMENTIA see **DEMENTIA, MULTI-INFARCT**

MULTI-INSTITUTIONAL SYSTEMS

ORGANIZATION & ADMINISTRATION

The corporate medical director. Krein K. **Clin Geriatr Med** 1995 Aug;11(3):403–17 (10 ref.)

Local markets and systems: hospital consolidations in metropolitan areas. Luke RD, et al. **Health Serv Res** 1995 Oct;30(4):555–75 (23 ref.)

MULTINUCLEATED GIANT CELLS see **GIANT CELLS**

MULTIPLE CARBOXYLASE DEFICIENCY

DIAGNOSIS

[Biotinidase deficiency. Its form of presentation and response to treatment] Campistol J, et al. **An Esp Pediatr** 1996 Apr; 44(4):389–92 (22 ref.) **(Spa)**

MULTIPLE CAUSATION see **CAUSALITY**

MULTIPLE CHEMICAL SENSITIVITY

see related
PERSIAN GULF SYNDROME

Neuropsychiatric and somatic characteristics of young adults with and without self-reported chemical odor intolerance and chemical sensitivity. Bell IR, et al. **Arch Environ Health** 1996 Jan–Feb;51(1):9–21 (114 ref.)

Multiple chemical sensitivities--fact or myth [editorial] Brautbar N, et al. **Toxicol Ind Health** 1992 Nov–Dec; 8(6):v–xiii (9 ref.)

ETIOLOGY

Clinically relevant EEG studies and psychophysiological findings: possible neural mechanisms for multiple chemical sensitivity. Bell IR. **Toxicology** 1996 Jul 17;111(1–3):101–17 (122 ref.)

Chemical sensitivity: symptom, syndrome or mechanism for disease? Miller CS. **Toxicology** 1996 Jul 17;111(1–3):69–86 (36 ref.)

Potential animal model of multiple chemical sensitivity with cholinergic supersensitivity. Overstreet DH, et al. **Toxicology** 1996 Jul 17;111(1–3):119–34 (101 ref.)

Sensitization induced by kindling and kindling-related phenomena as a model for multiple chemical sensitivity. Rossi J 3rd. **Toxicology** 1996 Jul 17;111(1–3):87–100 (93 ref.)

PHYSIOPATHOLOGY

Clinically relevant EEG studies and psychophysiological findings: possible neural mechanisms for multiple chemical sensitivity. Bell IR. **Toxicology** 1996 Jul 17;111(1–3):101–17 (122 ref.)

Chemical sensitivity: symptom, syndrome or mechanism for disease? Miller CS. **Toxicology** 1996 Jul 17;111(1–3):69–86 (36 ref.)

Sensitization induced by kindling and kindling-related phenomena as a model for multiple chemical sensitivity. Rossi J 3rd. **Toxicology** 1996 Jul 17;111(1–3):87–100 (93 ref.)

MULTIPLE ENDOCRINE NEOPLASIA

DIAGNOSIS

Endocrine tumors of the gastrointestinal tract. Perry RR, et al. **Annu Rev Med** 1996;47:57–68 (33 ref.)

[Peptide hormone] Ohnami S, et al. **Nippon Rinsho** 1996 Jun; 54(6):1510–4 (15 ref.) (Eng. Abstr.) **(Jpn)**

MULTIPLE ENDOCRINE NEOPLASIA TYPE 1

Multiple endocrine neoplasia type I: clinical syndrome to molecular genetics. Teh BT, et al. **Aust N Z J Surg** 1995 Oct;65(10):708–13 (62 ref.)

DIAGNOSIS

[Pancreatic somatostatinoma and MEN 1. Apropos of a case. Review of the literature] Roy J, et al. **Ann Endocrinol (Paris)** 1996;57(1):71–6 (26 ref.) (Eng. Abstr.) **(Fre)**

[Endocrine pancreatic tumors] Goretzki PE, et al. **Ther Umsch** 1996 May;53(5):408–12 (18 ref.) (Eng. Abstr.) **(Ger)**

GENETICS

Genetic aspects of multiple endocrine neoplasia types 1 and 2. Sandelin K, et al. **Curr Opin Gen Surg** 1994;:60–8 (68 ref.)

[Multiple endocrine neoplasia type I] Kawa S, et al. **Nippon Rinsho** 1995 Nov;53(11):2702–7 (17 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Pituitary lesions in multiple endocrine neoplasia syndrome (MENS) type 1. Capella C, et al. **Pathol Res Pract** 1995 May;191(4):345–7 (27 ref.)

MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A

[Multiple endocrine neoplasia type 2a and 2b] Vestergaard P. **Ugeskr Laeger** 1996 Jan 29;158(5):590–3 (38 ref.) (Eng. Abstr.) **(Dan)**

GENETICS

RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma. Cote GJ, et al. **Baillieres Clin Endocrinol Metab** 1995 Jul; 9(3):609–30 (64 ref.)

Putting the bits and pieces of the RET proto-oncogene puzzle together. Gagel RF. **Bone** 1995 Aug;17(2 Suppl):13S–16S (30 ref.)

Mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2. Ponder BA. **Cancer Surv** 1995;25:195–205 (31 ref.)

Genetic aspects of multiple endocrine neoplasia types 1 and 2. Sandelin K, et al. **Curr Opin Gen Surg** 1994;:60–8 (68 ref.)

RET gene and its implications for cancer. Goodfellow PJ, et al. **J Natl Cancer Inst** 1995 Oct 18;87(20):1515–23 (71 ref.)

Seminars in medicine of the Beth Israel Hospital, Boston. The RET proto-oncogene in multiple endocrine neoplasia type 2 and Hirschsprung's disease. Eng C. **N Engl J Med** 1996 Sep 26;335(13):943–51 (89 ref.)

[The direct gene test in familial medullary thyroid gland carcinoma and in MEN syndromes. Detection of mutations in the ret proto-oncogene saves screening studies] Stuhrmann M. **Fortschr Med** 1995 Dec 20;113(35–36):503–6 (23 ref.) (Eng. Abstr.) **(Ger)**

[Detection of RET-proto-oncogene mutations in the diagnosis of Type 2 endocrine neoplasia (MEN 2)] Komminoth P, et al. **Schweiz Med Wochenschr** 1996 Aug 6;126(31–32):1329–38 (57 ref.) (Eng. Abstr.) **(Ger)**

[Multiple endocrine neoplasia type 2A, type 2B and familial medullary thyroid carcinoma syndrome] Obara T, et al. **Nippon Rinsho** 1995 Nov;53(11):2708–15 (19 ref.) (Eng. Abstr.) **(Jpn)**

[Ret proto-oncogene mutations associated with type 2 multiple endocrine neoplasms (MEN 2). Clinical implications] Bugalho MJ, et al. **Acta Med Port** 1995 Jul–Aug;8(7–8):419–24 (66 ref.) (Eng. Abstr.) **(Por)**

MULTIPLE ENDOCRINE NEOPLASIA TYPE 2B

[Multiple endocrine neoplasia type 2a and 2b] Vestergaard P. **Ugeskr Laeger** 1996 Jan 29;158(5):590–3 (38 ref.) (Eng. Abstr.) **(Dan)**

GENETICS

RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma. Cote GJ, et al. **Baillieres Clin Endocrinol Metab** 1995 Jul; 9(3):609–30 (64 ref.)

Putting the bits and pieces of the RET proto-oncogene puzzle together. Gagel RF. **Bone** 1995 Aug;17(2 Suppl):13S–16S (30 ref.)

RET gene and its implications for cancer. Goodfellow PJ, et al. **J Natl Cancer Inst** 1995 Oct 18;87(20):1515–23 (71 ref.)

Seminars in medicine of the Beth Israel Hospital, Boston. The RET proto-oncogene in multiple endocrine neoplasia type 2 and Hirschsprung's disease. Eng C. **N Engl J Med** 1996 Sep 26;335(13):943–51 (89 ref.)

[The direct gene test in familial medullary thyroid gland carcinoma and in MEN syndromes. Detection of mutations in the ret proto-oncogene saves screening studies] Stuhrmann M. **Fortschr Med** 1995 Dec 20;113(35–36):503–6 (23 ref.) (Eng. Abstr.) **(Ger)**

[Multiple endocrine neoplasia type 2A, type 2B and familial medullary thyroid carcinoma syndrome] Obara T, et al. **Nippon Rinsho** 1995 Nov;53(11):2708–15 (19 ref.) (Eng. Abstr.) **(Jpn)**

MULTIPLE EPIPHYSEAL DYSPLASIA see **OSTEOCHONDRODYSPLASIAS**

MULTIPLE HAMARTOMA SYNDROME see **HAMARTOMA SYNDROME, MULTIPLE**

MULTIPLE MYELOMA

see related
MYELOMA PROTEINS

Biologic and clinical advances in multiple myeloma. Varterasian ML. **Oncology (Huntingt)** 1995 May; 9(5):417–24; discussion 429–30 (57 ref.)

Multiple myeloma. Sheridan CA. **Semin Oncol Nurs** 1996 Feb;12(1):59–69 (71 ref.)

[Progresses in hematology in China, 1995] Shan Y, et al. **Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):720–1 (0 ref.) **(Chi)**

BLOOD

Effects of alpha-interferon on serum beta-2-microglobulin. Remes K, et al. **Leuk Lymphoma** 1996 Apr;21(3–4):233–8 (57 ref.)

[Hyperviscosity syndrome in patients with immunoproliferative disorder] Hashimoto T. **Nippon Naika Gakkai Zasshi** 1995 Jul 10;84(7):1096–9 (5

ref.) **(Jpn)**

CHEMICALLY INDUCED

[Multiple myeloma associated with phenytoin (diphenylhydantoin) therapy] Kanoh T, et al. **Rinsho Ketsueki** 1996 Mar;37(3):239–43 (15 ref.) **(Eng. Abstr.)** **(Jpn)**

COMPLICATIONS

Complications and supportive therapy of multiple myeloma. Dimopoulos MA, et al. **Baillieres Clin Haematol** 1995 Dec; 8(4):845–52 (35 ref.)

Improvement of scleredema associated with IgA multiple myeloma after chemotherapy. Pujol JA, et al. **Clin Exp Dermatol** 1995 Mar;20(2):149–52 (19 ref.)

Cutis laxa acquisita associated with multiple myeloma: a case report and review of the literature. McCarty MJ, et al. **Cutis** 1996 Apr;57(4):267–70 (30 ref.)

Primary hyperparathyroidism associated with multiple myeloma. Goto S, et al. **Intern Med** 1995 Oct;34(10):988–91 (20 ref.)

Acute myeloma kidney. Winearls CG. **Kidney Int** 1995 Oct; 48(4):1347–61 (65 ref.)

Erythropoiesis and erythropoietin in multiple myeloma. Beguin Y. **Leuk Lymphoma** 1995 Aug;18(5–6):413–21 (135 ref.)

Multiple myeloma following essential thrombocythemia. Cobo F, et al. **Leuk Lymphoma** 1995 Dec;20(1–2):177–9 (16 ref.)

Bence Jones proteinuria and myeloma kidney [editorial] Chauveau D, et al. **Nephrol Dial Transplant** 1996 Mar; 11(3):413–5 (7 ref.)

[Isolated oculomotor palsy disclosing multiple myeloma] Feletti A, et al. **J Fr Ophtalmol** 1995;18(12):771–6 (30 ref.) (Eng. Abstr.) **(Fre)**

[Renal involvement in multiple myeloma. Physiopathology and therapy] Fiorini F, et al. **Minerva Urol Nefrol** 1995 Sep;47(3):125–31 (41 ref.) (Eng. Abstr.) **(Ita)**

[Anemia and hemostasis dysfunction in patients with immunoproliferative disorders] Suehiro A, et al. **Nippon Naika Gakkai Zasshi** 1995 Jul 10;84(7):1091–5 (5 ref.) **(Jpn)**

[Bone lesions in patients with multiple myeloma] Umeda M, et al. **Nippon Naika Gakkai Zasshi** 1995 Jul 10;84(7):1070–4 (5 ref.) **(Jpn)**

[Kidney involvement in multiple myeloma] Gordovskaia NB. **Klin Med (Mosk)** 1995;73(3):71–7 (78 ref.) **(Rus)**

DIAGNOSIS

Oncocytic nonsecretory multiple myeloma. A clinicopathologic study of a case and review of the literature. Bosman C, et al. **Acta Haematol** 1996;96(1):50–6 (36 ref.)

[Multiple myeloma] Peest D. **Ther Umsch** 1996 Feb; 53(2):147–51 (17 ref.) (Eng. Abstr.) **(Ger)**

[Pleural effusion of non-neoplastic etiology in a patient with a rare form of myeloma] Alvares E, et al. **Acta Med Port** 1995 Oct;8(10):579–84 (10 ref.) (Eng. Abstr.) **(Por)**

DRUG THERAPY

The role of biotherapies (interleukins, interferons and erythropoietin) in multiple myeloma. Avvisati G, et al. **Baillieres Clin Haematol** 1995 Dec;8(4):815–29 (76 ref.)

The role of chemotherapy in the treatment of multiple myeloma. Bergsagel DE. **Baillieres Clin Haematol** 1995 Dec;8(4):783–94 (38 ref.)

Modulation of multidrug resistance in multiple myeloma. Sonneveld P. **Baillieres Clin Haematol** 1995 Dec; 8(4):831–44 (107 ref.)

Bisphosphonates in multiple myeloma: current status; future perspectives. Jantunen E, et al. **Br J Haematol** 1996 Jun 1;93(3):501–6 (58 ref.)

Refractory multiple myeloma: recent advances in therapy. Giles FJ. **Hematol Pathol** 1995;9(3–4):121–40 (170 ref.)

Use of clodronate in multiple myeloma. Jantunen E, et al. **Leuk Lymphoma** 1995 Oct;19(3–4):207–11 (29 ref.)

Intrinsic expression of the multidrug transporter, P-glycoprotein 170, in multiple myeloma: implications for treatment. Pilarski LM, et al. **Leuk Lymphoma** 1995 May; 17(5–6):367–74 (70 ref.)

Chemoresistance and multiple myeloma: from biological to clinical aspects. Rossi JF. **Stem Cells (Dayt)** 1995 Aug;13 Suppl 2:64–71 (30 ref.)

ENZYMOLOGY

Rising serum lactate dehydrogenase often caused by granulocyte-or Granulocyte-macrophage colony stimulating factor and not tumor progression in patients with lymphoma or myeloma. Sarris AH, et al. **Leuk Lymphoma** 1995 May;17(5–6):473–7 (25 ref.)

EPIDEMIOLOGY

Multiple myeloma in patients younger than 30 years. Report of 10 cases and review of the literature. Bladé J, et al. **Arch Intern Med** 1996 Jul 8;156(13):1463–8 (31 ref.)

Incidence and time trends for lymphomas, leukemias and myelomas: hypothesis generation. Working Group on the Epidemiology of Hematolymphopoietic Malignancies in Italy. Vineis P. **Leuk Res** 1996 Apr;20(4):285–90 (39 ref.)

The incidence and epidemiology of plasma cell neoplasms. Bergsagel D. **Stem Cells (Dayt)** 1995 Aug;13 Suppl 2:1–9 (56 ref.)

ETIOLOGY

Pathogenetic relation between monoclonal gammopathies of undetermined significance and multiple myeloma. Greipp PR, et al. **Stem Cells (Dayt)** 1995 Aug;13 Suppl 2:10–21 (82 ref.)

Prognostic factors in multiple myeloma. Kyle RA. **Stem Cells (Dayt)** 1995 Aug;13 Suppl 2:56–63 (63 ref.)

Homing mechanisms in the etiopathogenesis of multiple myeloma. Van Riet I, et al. **Stem Cells (Dayt)** 1995 Aug; 13 Suppl 2:22–7 (32 ref.)

[A case of rheumatoid arthritis associated with multiple myeloma] Inoue F, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Feb;19(1):94–9 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Immunoglobulin producing mechanism and their abnormalities] Hamano T. **Nippon Naika Gakkai Zasshi** 1995 Jul 10;84(7):1050–4 (8 ref.) **(Jpn)**

[IgD (lambda) multiple myeloma associated with myelofibrosis: an isolated case of nuclear physicist] Kanoh T, et al. **Rinsho Ketsueki** 1996 Mar;37(3):244–8 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Multiple myeloma--the biology of malignant plasma cells] Paluszewska M. **Pol Arch Med Wewn** 1996 Jan;95(1):67–72 (33 ref.) **(Pol)**

GENETICS

Multiple myeloma: almost all patients are cytogenetically abnormal. Zandecki M, et al. **Br J Haematol** 1996 Aug; 94(2):217–27 (86 ref.)

Abnormalities of retinoblastoma gene expression in hematological malignancies. Zhu YM, et al. **Leuk Lymphoma** 1995 Jun;18(1–2):61–7 (80 ref.)

Familial multiple myeloma. Report of a case in a father and daughter. Review of the literature. Crozes-Bony P, et al. **Rev Rhum Engl Ed** 1995 Jun;62(6):439–45 (71 ref.)

IMMUNOLOGY

Molecular anatomy and the pathological expression of antibody light chains [comment] Schiffer M. **Am J Pathol** 1996 May;148(5):1339–44 (31 ref.) Comment on: Am J Pathol 1996 May;148(5):1397–406.

Tumor-directed cytotoxicity in multiple myeloma--the basis for an experimental treatment approach with interleukin 2. Peest D, et al. **Stem Cells (Dayt)** 1995 Aug;13 Suppl 2:72–6 (20 ref.)

METABOLISM

Intrinsic expression of the multidrug transporter, P-glycoprotein 170, in multiple myeloma: implications for treatment. Pilarski LM, et al. **Leuk Lymphoma** 1995 May; 17(5–6):367–74 (70 ref.)

MORTALITY

IgD myeloma: clinical characteristics and a new staging system based on analysis of Japanese patients. Shimamoto Y. **Cancer Detect Prev** 1995;19(5):426–35 (148 ref.)

PATHOLOGY

Stromal abnormalities in neoplastic bone marrow diseases. Dührsen U, et al. **Ann Hematol** 1996 Aug;73(2):53–70 (222 ref.)

Biological aspects of multiple myeloma. Epstein J, et al. **Baillieres Clin Haematol** 1995 Dec;8(4):721–34 (71 ref.)

Immunophenotype and DNA cell content in multiple myeloma. San Miguel JF, et al. **Baillieres Clin Haematol** 1995 Dec;8(4):735–59 (102 ref.)

Osteoclast function in Paget's disease and multiple myeloma. Roodman GD. **Bone** 1995 Aug;17(2 Suppl):57S–61S (30 ref.)

The clonogenic precursor cell in multiple myeloma. Bakkus MH, et al. **Leuk Lymphoma** 1995 Jul;18(3–4):221–9 (79 ref.)

Multiple myeloma: new evidence and insights from the immunoglobulin heavy chain gene and phenotypes. Takishita M, et al. **Leuk Lymphoma** 1995 Nov; 19(5–6):395–400 (36 ref.)

Angiogenesis in B cell lymphoproliferative diseases. Biological and clinical studies. Vacca A, et al. **Leuk Lymphoma** 1995 Dec;20(1–2):27–38 (61 ref.)

Therapeutic strategies for inhibition of interleukin-6 mediated multiple myeloma cell growth. Ogata A, et al. **Leuk Res** 1996 Apr;20(4):303–7 (60 ref.)

[Cell division mechanism of multiple myeloma] Shimizu S. **Nippon Naika Gakkai Zasshi** 1995 Jul 10;84(7):1055–60 (7 ref.) **(Jpn)**

[Myeloma cell growth and interleukin 6] Takahashi T. **Nippon Naika Gakkai Zasshi** 1995 Jul 10;84(7):1122–6 (5 ref.) **(Jpn)**

RADIOTHERAPY

Refractory multiple myeloma: recent advances in therapy. Giles FJ. **Hematol Pathol** 1995;9(3–4):121–40 (170 ref.)

THERAPY

The role of haematopoietic stem cell-supported myeloablative therapy for the management of multiple myeloma. Cavo M, et al. **Baillieres Clin Haematol** 1995 Dec;8(4):795–813 (58 ref.)

Complications and supportive therapy of multiple myeloma. Dimopoulos MA, et al. **Baillieres Clin Haematol** 1995 Dec; 8(4):845–52 (35 ref.)

Comparison of autologous bone marrow transplantation and peripheral blood stem cell transplantation after first remission induction treatment in multiple myeloma. Harousseau JL, et al. **Bone Marrow Transplant** 1995 Jun; 15(6):963–9 (35 ref.)

Haematopoietic stem-cell transplantation in multiple myeloma. Handelsman H. **Cancer Treat Rev** 1996 Mar; 22(2):119–25 (41 ref.)

Interferon in multiple myeloma--does it pay? [editorial; comment] Kedar I, et al. **Isr J Med Sci** 1995 Oct; 31(10):635–7 (30 ref.) Comment on: Isr J Med Sci 1995 Oct;31(10):604–10.

Interferon in the treatment of multiple myeloma and non Hodgkins lymphoma. Smruti BK, et al. **J Assoc Physicians India** 1995;Suppl 3:33–7 (27 ref.)

Interferon-gamma in multiple myeloma. Palumbo A, et al. **Leuk Lymphoma** 1995 Jul;18(3–4):215–9 (35 ref.)

Effects of alpha-interferon on serum beta-2-microglobulin. Remes K, et al. **Leuk Lymphoma** 1996 Apr;21(3–4):233–8 (57 ref.)

Interferon and multiple myeloma. Lauta VM. **Med Oncol** 1995 Mar;12(1):63–9 (31 ref.)

Is alpha-interferon treatment in multiple myeloma worthwhile? Avvisati G, et al. **Stem Cells (Dayt)** 1995 Aug; 13 Suppl 2:106–13 (44 ref.)

Allogeneic bone marrow transplantation for the treatment of multiple myeloma. An overview of published reports. Cavo M, et al. **Stem Cells (Dayt)** 1995 Aug;13 Suppl 2:126–31 (25 ref.)

Current therapy of refractory multiple myeloma. Giles FJ. **Stem Cells (Dayt)** 1995 Aug;13 Suppl 2:88–105 (170 ref.)

Tumor-directed cytotoxicity in multiple myeloma--the basis for an experimental treatment approach with interleukin 2. Peest D, et al. **Stem Cells (Dayt)** 1995 Aug;13 Suppl 2:72–6 (20 ref.)

[Treatment of multiple myeloma] Hájek R, et al. **Vnitr Lek** 1996 May;42(5):345–50 (54 ref.) (Eng. Abstr.) **(Cze)**

[Treatment of multiple myeloma--melphalan monotherapy after bone marrow transplantation] Hájek R, et al. **Vnitr Lek** 1996 Apr;42(4):278–84 (0 ref.) (Eng. Abstr.) **(Cze)**

[Use of interferon alpha in multiple myeloma] Harousseau JL, et al. **Rev Med Interne** 1996;17(6):488–95 (53 ref.) (Eng. Abstr.) **(Fre)**

[Interferon-alpha in therapy of malignant hemoblastoses] Schuler M, et al. **Internist (Berl)** 1995 Dec;36(12):1133–8 (36 ref.) **(Ger)**

[Multiple myeloma] Peest D. **Ther Umsch** 1996 Feb; 53(2):147–51 (17 ref.) (Eng. Abstr.) **(Ger)**

[Hematopoietic stem cell transplantation in multiple myeloma] Okamoto S. **Nippon Naika Gakkai Zasshi** 1995 Jul 10;84(7):1127–31 (4 ref.) **(Jpn)**

[Treatment of multiple myeloma] Tokumine H, et al. **Nippon Naika Gakkai Zasshi** 1995 Jul 10;84(7):1100–6 (8 ref.) **(Jpn)**

MULTIPLE ORGAN FAILURE

Infection, the gut and the development of the multiple organ dysfunction syndrome. Nieuwenhuijzen GA, et al. **Eur J Surg** 1996 Apr;162(4):259–73 (185 ref.)

Pathogenesis and treatment of multiorgan failure dysfunction syndrome in shock. Ciesielski L, et al. **Rocz Akad Med Bialymst** 1995;40(1):13–24 (50 ref.)

BLOOD

Disturbance of leucocyte circulation and adhesion to the endothelium as factors in circulatory pathology. Adams DH, et al. **Br J Anaesth** 1996 Jul;77(1):17–31 (114 ref.)

Plasma concentrations of cytokines, their soluble receptors, and antioxidant vitamins can predict the development of multiple organ failure in patients at risk. Borrelli E, et al. **Crit Care Med** 1996 Mar;24(3):392–7 (38 ref.)

CLASSIFICATION

Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome [see comments] Marshall JC, et al. **Crit Care Med** 1995 Oct;23(10):1638–52 (40 ref.) Comment in: Crit Care Med 1995 Oct;23(10):1619–20. Comment in: Crit Care Med 1996 Jul;24(7):1272–3.

Severity stratification and outcome prediction for multisystem organ failure and dysfunction. Zimmerman JE, et al. **World J Surg** 1996 May;20(4):401–5 (15 ref.)

COMPLICATIONS

[The pathogenesis and treatment of the adult respiratory distress syndrome in patients with multiple organ failure] Iakovleva II, et al. **Anesteziol Reanimatol** 1996 Jan–Feb; (1):75–81 (184 ref.) **(Rus)**

ETIOLOGY

Splanchnic ischaemia/reperfusion and multiple organ failure. Biffl WL, et al. **Br J Anaesth** 1996 Jul;77(1):59–70 (136

ref.)
Involvement of bacteria/endotoxin translocation in the development of multiple organ failure. Bahrami S, et al. **Curr Top Microbiol Immunol** 1996;216:239–58 (111 ref.)
Multiple organ failure in septic shock. Thijs LG, et al. **Curr Top Microbiol Immunol** 1996;216:209–37 (220 ref.)
The role of endothelial cells in the systemic inflammatory response syndrome and multiple system organ failure. Wang X, et al. **Eur J Surg** 1995 Oct;161(10):703–13 (141 ref.)
Sepsis, SIRS, and MODS: what's in a name? Nathens AB, et al. **World J Surg** 1996 May;20(4):386–91 (46 ref.)
[Multiple organ failure in Plasmodium falciparum malaria] Botella de Maglia J, et al. **Rev Clin Esp** 1995 Oct; 195(10):688–92 (48 ref.) (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

Immunologic dissonance: a continuing evolution in our understanding of the systemic inflammatory response syndrome (SIRS) and the multiple organ dysfunction syndrome (MODS) [see comments] Bone RC. **Ann Intern Med** 1996 Oct 15;125(8):680–7 (101 ref.) Comment in: Ann Intern Med 1996 Oct 15;125(8):690–1.
The immuno-inflammatory cascade. Galley HF, et al. **Br J Anaesth** 1996 Jul;77(1):11–6 (24 ref.)
Gut-derived mediators of multiple organ failure: platelet-activating factor and interleukin-6. Biffl WL, et al. **Br J Hosp Med** 1995 Aug 16–Sep 5;54(4):134–8 (21 ref.)
Update on the mechanisms of immune suppression of injury and immune modulation. Faist E, et al. **World J Surg** 1996 May;20(4):454–9 (32 ref.)

MICROBIOLOGY

Trauma and bacterial transiocation [see comments] Saadia R. **Br J Surg** 1995 Sep;82(9):1243–4 (18 ref.) Comment in: Br J Surg 1996 Feb;83(2):282–3. Comment in: Br J Surg 1996 Feb;83(2):283.

MORTALITY

Prognostic importance of vital organ dysfunction in sepsis. Suter PM, et al. **Contrib Nephrol** 1995;116:16–21 (36 ref.)

PATHOLOGY

Mechanisms of cell injury and death. Cobb JP, et al. **Br J Anaesth** 1996 Jul;77(1):3–10 (36 ref.)

PHYSIOPATHOLOGY

Splanchnic ischemia and gut mucosal injury in sepsis and the multiple organ dysfunction syndrome. Pastores SM, et al. **Am J Gastroenterol** 1996 Sep;91(9):1697–710 (145 ref.)
Determinants of splanchnic blood flow. Takala J. **Br J Anaesth** 1996 Jul;77(1):50–8 (78 ref.)
Gut-derived mediators of multiple organ failure: platelet-activating factor and interleukin-6. Biffl WL, et al. **Br J Hosp Med** 1995 Aug 16–Sep 5;54(4):134–8 (21 ref.)
Lung-liver interactions in sepsis and multiple organ failure syndrome. Matuschak GM. **Clin Chest Med** 1996 Mar; 17(1):83–98 (191 ref.)
Pathobiology of the endothelium in multiple organ dysfunction syndrome. Kirkpatrick CJ, et al. **Contrib Nephrol** 1995;116:1–9 (39 ref.)
Uncoupling of biological oscillators: a complementary hypothesis concerning the pathogenesis of multiple organ dysfunction syndrome. Godin PJ, et al. **Crit Care Med** 1996 Jul;24(7):1107–16 (79 ref.)
Sepsis and multiple organ dysfunction syndrome: a clinical-mechanistic overview. Livingston DH, et al. **New Horiz** 1995 May;3(2):257–66 (93 ref.)
Pathophysiology and therapy of end-organ failure in critical illness. Pinsky MR. **Proc Assoc Am Physicians** 1995 Oct; 107(3):353–60 (63 ref.)
The role of the microcirculation in multiple organ dysfunction syndrome (MODS): a review and perspective. Kirkpatrick CJ, et al. **Virchows Arch** 1996 Feb; 427(5):461–76 (209 ref.)
MODS/SIRS: result of an overwhelming inflammatory response? Goris RJ. **World J Surg** 1996 May;20(4):418–21 (24 ref.)
Biologic control of injury and inflammation: much more than too little or too late. Guirao X, et al. **World J Surg** 1996 May;20(4):437–46 (135 ref.)
Ingredients of organ dysfunction or failure. Gullo A, et al. **World J Surg** 1996 May;20(4):430–6 (97 ref.)
Metabolism of sepsis and multiple organ failure. Michie HR. **World J Surg** 1996 May;20(4):460–4 (31 ref.)
Early risk factors for postinjury multiple organ failure. Sauaia A, et al. **World J Surg** 1996 May;20(4):392–400 (88 ref.)
Mediators of injury and inflammation. Schlag G, et al. **World J Surg** 1996 May;20(4):406–10 (45 ref.)
Role of the gut in multiple organ failure: bacterial translocation and permeability changes. Swank GM, et al. **World J Surg** 1996 May;20(4):411–7 (65 ref.)
[Microcirculation and oxygen supply to the liver in hemorrhagic shock and sepsis] Vollmar B. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Oct; 30 Suppl 1:S52–4 (21 ref.) **(Ger)**

PREVENTION & CONTROL

Nutrition and immunonutrition. O'Leary MJ, et al. **Br J Anaesth** 1996 Jul;77(1):118–27 (102 ref.)

THERAPY

Nutritional aspects in patients with acute renal failure/multiorgan failure. Alvestrand A. **Blood Purif** 1996; 14(1):109–14 (31 ref.)
Extracorporeal blood purification in the treatment of acute renal failure with multiorgan involvement. Kaplan AA. **Blood Purif** 1996;14(1):86–93 (45 ref.)
Mediators in continuous extracorporeal treatment of multiple organ dysfunction syndrome. Sunder-Plassmann G, et al. **Contrib Nephrol** 1995;116:10–5 (46 ref.)
Nutritional management and the multisystem organ failure/systemic inflammatory response syndrome in critically ill preterm neonates. Adan D, et al. **Crit Care Clin** 1995 Jul;11(3):751–84 (162 ref.)
Multiple organ failure. Buchman TG. **Curr Opin Gen Surg** 1993;:26–31 (30 ref.)
Pathophysiology and therapy of end-organ failure in critical illness. Pinsky MR. **Proc Assoc Am Physicians** 1995 Oct; 107(3):353–60 (63 ref.)
Hypertonic volume therapy: feasibility in the prevention and treatment of multiple organ failure and sepsis. Monteiro Pacheco A Jr, et al. **Rev Paul Med** 1995 Nov-Dec; 113(6):1053–60 (53 ref.)
Clinical trials of new and novel therapeutic agents. Baue AE, et al. **World J Surg** 1996 May;20(4):493–8 (42 ref.)
Nutritional support to prevent and treat multiple organ failure. Bengmark S, et al. **World J Surg** 1996 May; 20(4):474–81 (90 ref.)
Potential strategies for inflammatory mediator manipulation: retrospect and prospect. Fisher CJ Jr, et al. **World J Surg** 1996 May;20(4):447–53 (89 ref.)
Blood purification for prevention and treatment of multiple organ failure. Hirasawa H, et al. **World J Surg** 1996 May; 20(4):482–6 (15 ref.)
Animal models as the basis of pharmacologic intervention in trauma and sepsis patients. Redl H, et al. **World J Surg** 1996 May;20(4):487–92 (81 ref.)
Prevention and therapy of multiple organ failure. Vincent JL. **World J Surg** 1996 May;20(4):465–70 (29 ref.)

MULTIPLE-PERSONALITY DISORDER

CLASSIFICATION

The characterological basis of multiple personality. Brenner I. **Am J Psychother** 1996 Spring;50(2):154–66 (30 ref.)

PSYCHOLOGY

The characterological basis of multiple personality. Brenner I. **Am J Psychother** 1996 Spring;50(2):154–66 (30 ref.)
The sociocognitive model of dissociative identity disorder: a reexamination of the evidence. Gleaves DH. **Psychol Bull** 1996 Jul;120(1):42–59 (150 ref.)

MULTIPLE SCLEROSIS

Recent advances in the understanding, diagnosis and management of multiple sclerosis. Pender MP. **Aust N Z J Med** 1996 Apr;26(2):157–61 (34 ref.)
Childhood multiple sclerosis—the long view from Scotland. Brett E. **Dev Med Child Neurol** 1995 Nov;37(11):1027–30 (15 ref.)
Multiple sclerosis. Lynch SG, et al. **Dis Mon** 1996 Jan; 42(1):1–55 (146 ref.)
Two models for multiple sclerosis: experimental allergic encephalomyelitis and Theiler's murine encephalomyelitis virus. Tsunoda I, et al. **J Neuropathol Exp Neurol** 1996 Jun;55(6):673–86 (136 ref.)
Magnetic resonance imaging of multiple sclerosis lesions. Measuring outcome in treatment trials [see comments] Simon JH. **West J Med** 1996 Jun;164(6):502–9 (71 ref.) Comment in: West J Med 1996 Jun;164(6):531–2.
[Multiple sclerosis--a new approach to pathophysiology, diagnosis and therapy] Dordević D, et al. **Vojnosanit Pregl** 1995 Jul–Aug;52(4):377–87 (95 ref.) **(Scr)**

COMPLICATIONS

Depression associated with multiple sclerosis: an etiological conundrum. Feinstein A. **Can J Psychiatry** 1995 Dec; 40(10):573–6 (30 ref.)
Severe occlusive retinal periphlebitis with vitreous hemorrhage in multiple sclerosis. Ronzani M, et al. **Ger J Ophthalmol** 1995 Nov;4(6):328–31 (15 ref.)
[Optic neuritis. A common first manifestation of multiple sclerosis] Frederiksen JL. **Ugeskr Laeger** 1996 Mar 4; 158(10):1353–7 (35 ref.) (Eng. Abstr.) **(Dan)**
[Bladder and sphincter disorders in multiple sclerosis. Clinical, urodynamic and neurophysiological study of 225 cases] Amarenco G, et al. **Rev Neurol (Paris)** 1995 Dec; 151(12):722–30 (34 ref.) (Eng. Abstr.) **(Fre)**
[Treatment of micturition disorders in multiple sclerosis] Bagunyà-Durich J. **Neurologia** 1996 May;11(5):182–91 (30 ref.) **(Spa)**
[Treatment of erectile dysfunction in multiple sclerosis] Fernández O. **Rev Neurol** 1995 Mar-Apr;23(120):320–1 (16 ref.) **(Spa)**

DIAGNOSIS

Multiple sclerosis: clinical presentation, diagnosis and treatment. Brod SA, et al. **Am Fam Physician** 1996 Sep 15;54(4):1301–6, 1309–11 (40 ref.)
Quantitative assessment of MRI lesion load in monitoring the evolution of multiple sclerosis. Filippi M, et al. **Brain** 1995 Dec;118 (Pt 6):1601–12 (98 ref.)
Magnetic resonance imaging and spectroscopy in multiple sclerosis. Miller DH. **Curr Opin Neurol** 1995 Jun;8(3):210–5 (44 ref.)
Neuropsychology of multiple sclerosis. Rao SM. **Curr Opin Neurol** 1995 Jun;8(3):216–20 (44 ref.)
Case study: mania associated with multiple sclerosis. Heilä H, et al. **J Am Acad Child Adolesc Psychiatry** 1995 Dec; 34(12):1591–5 (36 ref.)
Movement disorders in multiple sclerosis. Tranchant C, et al. **Mov Disord** 1995 Jul;10(4):418–23 (75 ref.)
The diagnosis of multiple sclerosis. Rolak LA. **Neurol Clin** 1996 Feb;14(1):27–43 (34 ref.)
[Psychoses in multiple sclerosis--a reevaluation] Schifferdecker M, et al. **Fortschr Neurol Psychiatr** 1995 Aug;63(8):310–9 (85 ref.) (Eng. Abstr.) **(Ger)**
[Course of illness and prognosis of multiple sclerosis. 1: The natural illness course] Flachenecker P, et al. **Nervenarzt** 1996 Jun;67(6):435–43 (62 ref.) (Eng. Abstr.) **(Ger)**
[Course of illness and prognosis of multiple sclerosis. 2: Predictive value of clinical and paraclinical factors] Flachenecker P, et al. **Nervenarzt** 1996 Jun;67(6):444–51 (45 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

The role of interferons in the treatment of multiple sclerosis. Kelley CL. **J Neurosci Nurs** 1996 Apr;28(2):114–20 (21 ref.)
[Pulse-dose cyclophosphamide therapy for steroid-refractory autoimmune neurological diseases] Watanabe T, et al. **Rinsho Shinkeigaku** 1995 Jun;35(6):611–6 (30 ref.) (Eng. Abstr.) **(Jpn)**
[Has it been indicated already to use beta-interferon in patients with multiple sclerosis?] Fernández O. **Rev Neurol** 1995 Sep-Oct;23(123):986–90 (54 ref.) **(Spa)**
[New treatments for multiple sclerosis] Masdeu JC. **Rev Neurol** 1996 Jun;24(130):708–11 (38 ref.) **(Spa)**

EPIDEMIOLOGY

Multiple sclerosis: it epidemiological, genetic, and health care impact. Williams R, et al. **J Epidemiol Community Health** 1995 Dec;49(6):563–9 (99 ref.)
Notes on the epidemiology of multiple sclerosis. Poser CM. **J Formos Med Assoc** 1995 Jun;94(6):300–8 (66 ref.)
Review of the contribution of twin studies in the search for non-genetic causes of multiple sclerosis. James WH. **Neuroepidemiology** 1996;15(3):132–41 (35 ref.)
Epidemiology of multiple sclerosis. Weinshenker BG. **Neurol Clin** 1996 May;14(2):291–308 (108 ref.)

ETIOLOGY

Virus-induced autoimmune disease: transgenic approach to mimic insulin-dependent diabetes mellitus and multiple sclerosis. Oldstone MB, et al. **Curr Top Microbiol Immunol** 1996;206:67–83 (34 ref.)
Multiple sclerosis: sunlight, diet, immunology and aetiology. Hutter CD, et al. **Med Hypotheses** 1996 Feb;46(2):67–74 (77 ref.)

GENETICS

Multiple sclerosis: it epidemiological, genetic, and health care impact. Williams R, et al. **J Epidemiol Community Health** 1995 Dec;49(6):563–9 (99 ref.)
Review of the contribution of twin studies in the search for non-genetic causes of multiple sclerosis. James WH. **Neuroepidemiology** 1996;15(3):132–41 (35 ref.)
Heat shock protein 70 gene polymorphisms and multiple sclerosis. Ramachandran S, et al. **Tissue Antigens** 1995 Aug; 46(2):140–1 (18 ref.)
[Genes and multiple sclerosis] Tienari P, et al. **Duodecim** 1994;110(7):741–8 (47 ref.) **(Fin)**
[Influence of genetic factors on multiple sclerosis] Sommer N, et al. **Nervenarzt** 1996 Jun;67(6):457–64 (67 ref.) (Eng. Abstr.) **(Ger)**
[Susceptibility to multiple sclerosis and T-lymphocyte receptor genes. A synthetic review] Bongioanni P, et al. **Minerva Med** 1995 Dec;86(12):543–9 (57 ref.) (Eng. Abstr.) **(Ita)**
[Multiple sclerosis: molecular and cellular mechanisms] Boĭko AN, et al. **Mol Biol (Mosk)** 1995 Jul–Aug;29(4):727–49 (218 ref.) (Eng. Abstr.) **(Rus)**
[Genetic factors predisposing to multiple sclerosis: association with HLA system] Caminero AB, et al. **Rev Neurol** 1995 Mar–Apr;23(120):326–33 (125 ref.) **(Spa)**

IMMUNOLOGY

Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system. Steinman L. **Cell** 1996 May 3;85(3):299–302 (31 ref.)
Pathogenesis of inflammatory demyelination: implications for therapy [editorial] Hartung HP. **Curr Opin Neurol** 1995 Jun;8(3):191–9 (49 ref.)

MULTIPLE SCLEROSIS

Immunologic mechanisms and therapy in multiple sclerosis. Hafler DA, et al. **Immunol Rev** 1995 Apr;144:75–107 (130 ref.)

Evolution of the T-cell repertoire during the course of experimental immune-mediated demyelinating diseases. Miller SD, et al. **Immunol Rev** 1995 Apr;144:225–44 (66 ref.)

Critical influences of the cytokine orchestration on the outcome of myelin antigen-specific T-cell autoimmunity in experimental autoimmune encephalomyelitis and multiple sclerosis. Olsson T. **Immunol Rev** 1995 Apr; 144:245–68 (169 ref.)

Multiple sclerosis: TNF revisited, with promise [comment] Raine CS. **Nat Med** 1995 Mar;1(3):211–4 (28 ref.) Comment on: Nat Med 1995 Mar;1(3):244–8.

Heat shock proteins and the immunopathogenesis of multiple sclerosis. Linington C. **Neuropathol Appl Neurobiol** 1995 Dec;21(6):483–6 (31 ref.)

Multiple sclerosis: a unique immunopathological syndrome of the central nervous system. Hunter SF, et al. **Springer Semin Immunopathol** 1995;17(1):89–105 (105 ref.)

Are current immunological concepts of multiple sclerosis reflected by the immunopathology of its lesions? Lassmann H, et al. **Springer Semin Immunopathol** 1995;17(1):77–87 (64 ref.)

METABOLISM

Cytokines in Alzheimer's disease and multiple sclerosis. Patterson PH. **Curr Opin Neurobiol** 1995 Oct;5(5):642–6 (44 ref.)

Heat shock proteins and multiple sclerosis: a review. Brosnan CF, et al. **J Neuropathol Exp Neurol** 1996 Apr; 55(4):389–402 (77 ref.)

Stress proteins: their role in the normal central nervous system and in disease states, especially multiple sclerosis. Birnbaum G. **Springer Semin Immunopathol** 1995; 17(1):107–18 (75 ref.)

PATHOLOGY

Two models of multiple sclerosis: experimental allergic encephalomyelitis (EAE) and Theiler's murine encephalomyelitis virus (TMEV) infection. A pathological and immunological comparison. Dal Canto MC, et al. **Microsc Res Tech** 1995 Oct 15;32(3):215–29 (74 ref.)

Spontaneous and induced remyelination in multiple sclerosis and the Theiler's virus model of central nervous system demyelination. Miller DJ, et al. **Microsc Res Tech** 1995 Oct 15;32(3):230–45 (119 ref.)

Multiple sclerosis: a unique immunopathological syndrome of the central nervous system. Hunter SF, et al. **Springer Semin Immunopathol** 1995;17(1):89–105 (105 ref.)

Are current immunological concepts of multiple sclerosis reflected by the immunopathology of its lesions? Lassmann H, et al. **Springer Semin Immunopathol** 1995;17(1):77–87 (64 ref.)

[Multiple sclerosis: molecular and cellular mechanisms] Boiko AN, et al. **Mol Biol (Mosk)** 1995 Jul–Aug;29(4):727–49 (218 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Chronic relapsing multiple sclerosis: a case of rapid recovery by application of weak electromagnetic fields. Sandyk R. **Int J Neurosci** 1995 Jun;82(3–4):223–42 (160 ref.)

Experimental strategies to promote central nervous system remyelination in multiple sclerosis: insights gained from the Theiler's virus model system. Miller DJ, et al. **J Neurosci Res** 1995 Jun 15;41(3):291–6 (40 ref.)

Heat shock proteins and the immunopathogenesis of multiple sclerosis. Linington C. **Neuropathol Appl Neurobiol** 1995 Dec;21(6):483–6 (31 ref.)

Urodynamics and multiple sclerosis. Hinson JL, et al. **Urol Clin North Am** 1996 Aug;23(3):475–81 (46 ref.)

REHABILITATION

Hypnosis for pain and neuromuscular rehabilitation with multiple sclerosis: case summary, literature review, and analysis of outcomes. Dane JR. **Int J Clin Exp Hypn** 1996 Jul;44(3):208–31 (60 ref.)

THERAPY

Multiple sclerosis: clinical presentation, diagnosis and treatment. Brod SA, et al. **Am Fam Physician** 1996 Sep 15;54(4):1301–6, 1309–11 (40 ref.)

Immunotherapy in multiple sclerosis, Part 1. Becker CC, et al. **Am J Health Syst Pharm** 1995 Sep 15;52(18):1985–2000 (197 ref.)

Immunotherapy in multiple sclerosis, Part 2. Becker CC, et al. **Am J Health Syst Pharm** 1995 Oct 1;52(19):2105–20; quiz 2132–4 (357 ref.)

Bone marrow transplantation for multiple sclerosis [editorial] Burt RK, et al. **Bone Marrow Transplant** 1995 Jul;16(1):1–6 (74 ref.)

The treatment of multiple sclerosis: current and future. Polman CH, et al. **Curr Opin Neurol** 1995 Jun;8(3):200–9 (87 ref.)

Immunologic mechanisms and therapy in multiple sclerosis. Hafler DA, et al. **Immunol Rev** 1995 Apr;144:75–107 (130 ref.)

Chronic relapsing multiple sclerosis: a case of rapid recovery by application of weak electromagnetic fields. Sandyk R. **Int J Neurosci** 1995 Jun;82(3–4):223–42 (160 ref.)

More immunotherapy for multiple sclerosis [editorial; comment] Hughes RA, et al. **J Neurol Neurosurg Psychiatry** 1996 Sep;61(3):239–41 (44 ref.) Comment on: J Neurol Neurosurg Psychiatry 1996 Sep;61(3):251–8.

Multiple sclerosis: a review of existing therapy and future prospects. Khan OA. **JPMA J Pak Med Assoc** 1996 Jan; 46(1):20–4 (45 ref.)

Melanin, melatonin, melanocyte-stimulating hormone, and the susceptibility to autoimmune demyelination: a rationale for light therapy in multiple sclerosis. Constantinescu CS. **Med Hypotheses** 1995 Nov;45(5):455–8 (38 ref.)

Immune-based therapy of multiple sclerosis. Kaufman MD. **N C Med J** 1995 Aug;56(8):379–84 (24 ref.)

Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conference. Lublin FD, et al. **Neurology** 1996 Jan;46(1):12–8 (18 ref.)

[[Therapeutic perspectives in multiple sclerosis (editorial)] Lubetzki C, et al. **Presse Med** 1996 Jun 15;25(21):964–6 (10 ref.) (Eng. Abstr.) **(Fre)**

[Active vaccinations in multiple sclerosis] Flachenecker P, et al. **Dtsch Med Wochenschr** 1995 Nov 3;120(44):1513–6 (40 ref.) **(Ger)**

[Bladder dysfunctions in encephalomyelitis disseminata—drug and interventional therapeutic options] Zwergel U, et al. **Fortschr Neurol Psychiatr** 1995 Dec; 63(12):495–503 (125 ref.) (Eng. Abstr.) **(Ger)**

[Therapy of multiple sclerosis with interferon-beta-1b. Educating the patient and managing side-effects] Walther EU, et al. **Nervenarzt** 1996 Jun;67(6):452–6 (16 ref.) (Eng. Abstr.) **(Ger)**

[Drug treatment in multiple sclerosis—1995] Achiron A. **Harefuah** 1995 Dec 15;129(12):579–83 (41 ref.) **(Heb)**

[Intensifying the care of MS-patients] Fredrikson S, et al. **Lakartidningen** 1996 Mar 13;93(11):1015–20 (47 ref.) **(Swe)**

MULTIPLE TRAUMA

Measurement of disability after multiple injuries: the functional independence measure. Clinical review. Hetherington H, et al. **Eur J Surg** 1995 Aug;161(8):549–55 (60 ref.)

The effect of associated injuries, blood loss, and oxygen debt on death and disability in blunt traumatic brain injury: the need for early physiologic predictors of severity. Siegel JH. **J Neurotrauma** 1995 Aug;12(4):579–90 (18 ref.)

COMPLICATIONS

Rapidly progressive portal hypertension 23 years after post-traumatic arterioportal fistula of the liver. Kayser S, et al. **Am J Gastroenterol** 1996 Jul;91(7):1442–6 (30 ref.)

Resuscitation from severe hemorrhage. Shoemaker WC, et al. **Crit Care Med** 1996 Feb;24(2 Suppl):S12–23 (76 ref.)

Neuroleptic malignant syndrome in a trauma patient [see comments] Burke C, et al. **J Trauma** 1995 Oct;39(4):796–8 (11 ref.) Comment in: J Trauma 1996 Apr;40(4):673.

Intravascular stenting of traumatic abdominal aortic dissection. Marty-Ané CH, et al. **J Vasc Surg** 1996 Jan; 23(1):156–61 (13 ref.)

[Post-traumatic dissection of the aortic isthmus with favorable outcome without surgical treatment. Value of transesophageal echocardiography] Bourgeois M, et al. **Ann Fr Anesth Reanim** 1995;14(2):218–21 (16 ref.) (Eng. Abstr.) **(Fre)**

[Aneurysms of the left ventricle without atheromatous coronary artery disease. Apropos of 2 cases] Obadia JF, et al. **Arch Mal Coeur Vaiss** 1996 Jun;89(6):755–9 (10 ref.) (Eng. Abstr.) **(Fre)**

[Traumatic aortic valve insufficiency] Nascimento J, et al. **Rev Port Cardiol** 1996 Feb;15(2):147–52, 101 (17 ref.) (Eng. Abstr.) **(Por)**

DIAGNOSIS

New diagnostic techniques in trauma. Livingston DH. **Curr Opin Gen Surg** 1994;:35–40 (38 ref.)

ECONOMICS

Cost effectiveness in trauma care. Elliott DC, et al. **Surg Clin North Am** 1996 Feb;76(1):47–62 (101 ref.)

IMMUNOLOGY

Update on the mechanisms of immune suppression of injury and immune modulation. Faist E, et al. **World J Surg** 1996 May;20(4):454–9 (32 ref.)

NURSING

Meeting the challenge of the older trauma patient [published erratum appears in Am J Nurs 1996 Jun;96(6):17] Stamatos CA, et al. **Am J Nurs** 1996 May;96(5):40–7; quiz 48 (7 ref.)

PHYSIOPATHOLOGY

Management of nutrition in the critically ill patient. Kudsk KA, et al. **Curr Opin Gen Surg** 1994;:24–9 (15 ref.)

Biologic control of injury and inflammation: much more than too little or too late. Guirao X, et al. **World J Surg** 1996 May;20(4):437–46 (135 ref.)

Early risk factors for postinjury multiple organ failure. Sauaia A, et al. **World J Surg** 1996 May;20(4):392–400 (88 ref.)

PSYCHOLOGY

Psychosocial aspects of accidental injuries—an overview [see comments] Schnyder U, et al. **Langenbecks Arch Chir** 1996; 381(3):125–31 (67 ref.) Comment in: Langenbecks Arch Chir 1996;381(3):123–4.

SURGERY

Peripheral vascular injury. Flynn TC. **Curr Opin Gen Surg** 1994;:30–4 (41 ref.)

Advances in the treatment of pediatric trauma. Moront ML, et al. **Curr Opin Gen Surg** 1994;:41–9 (70 ref.)

Traumatic injury to the azygous vein: case report. Butler DA, et al. **J Trauma** 1995 Oct;39(4):761–2 (10 ref.)

[Anesthesiologic problems in polytrauma patients] Radke J. **Anaesthesiol Reanim** 1995;20(2):32–6 (6 ref.) (Eng. Abstr.) **(Ger)**

[Intramedullary nailing in multiple trauma] Nast-Kolb D, et al. **Orthopade** 1996 Jun;25(3):266–73 (32 ref.) (Eng. Abstr.) **(Ger)**

[Management of ipsilateral fractures of the femur shaft and proximal femur—therapy overview and current management] Haas NP, et al. **Zentralbl Chir** 1995; 120(11):856–61 (19 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Meeting the challenge of the older trauma patient [published erratum appears in Am J Nurs 1996 Jun;96(6):17] Stamatos CA, et al. **Am J Nurs** 1996 May;96(5):40–7; quiz 48 (7 ref.)

Therapy of alcohol withdrawal syndrome in intensive care unit patients following trauma: results of a prospective, randomized trial. Spies CD, et al. **Crit Care Med** 1996 Mar; 24(3):414–22 (64 ref.)

Animal models as the basis of pharmacologic intervention in trauma and sepsis patients. Redl H, et al. **World J Surg** 1996 May;20(4):487–92 (81 ref.)

[Pre-hospital care for patients with multiple injuries] Kivioja A. **Duodecim** 1995;111(9):866–72 (23 ref.) **(Fin)**

[Resuscitation in multiple trauma] Berger K, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Apr; 31(3):187–90 (23 ref.) (Eng. Abstr.) **(Ger)**

MULTIPLICATION-STIMULATING ACTIVITY see **INSULIN-LIKE GROWTH FACTOR II**

MULTIPOTENTIAL COLONY-STIMULATING FACTOR see **INTERLEUKIN-3**

MULTIVARIATE ANALYSIS

Use of multivariate mathematical methods for the evaluation of retention data matrices. Cserháti T, et al. **Adv Chromatogr** 1996;36:1–63 (118 ref.)

Multivariate statistical analysis for pathologist. Part I, The logistic model. Vollmer RT. **Am J Clin Pathol** 1996 Jan; 105(1):115–26 (16 ref.)

MUMPS

COMPLICATIONS

Hydrocephalus in mumps meningoencephalitis: case report. Oran B, et al. **Pediatr Infect Dis J** 1995 Aug;14(8):724–5 (10 ref.)

[Gianotti-Crosti syndrome due to a mixed infection produced by the mumps virus and the parainfluenza virus type 2] Hergueta Lendínez R, et al. **An Esp Pediatr** 1996 Jan; 44(1):65–6 (17 ref.) **(Spa)**

DIAGNOSIS

Almost extinct diseases: measles, mumps, rubella, and pertussis. Gold E. **Pediatr Rev** 1996 Apr;17(4):120–7 (7 ref.)

MUMPS VACCINE

ADVERSE EFFECTS

Case series analysis of adverse reactions to vaccines: a comparative evaluation. Farrington CP, et al. **Am J Epidemiol** 1996 Jun 1;143(11):1165–73 (18 ref.)

MUNCHAUSEN SYNDROME

[Infantile Munchausen syndrome. Etiology, diagnostic criteria, and treatment] Morales-Franco B, et al. **Gac Med Mex** 1995 May–Jun;131(3):323–8 (22 ref.) (Eng. Abstr.) **(Spa)**

MUNCHAUSEN SYNDROME BY PROXY

Munchausen syndrome by proxy: a review. Skau K, et al. **Acta Paediatr** 1995 Sep;84(9):977–82 (43 ref.)

At mother's mercy: the nightmare of Munchausen syndrome by proxy. Lesaca TG. **W V Med J** 1995 Nov–Dec; 91(7):318–9 (16 ref.)

DIAGNOSIS

Munchausen syndrome by proxy. Child abuse in the medical system. Donald T, et al. **Arch Pediatr Adolesc Med** 1996 Jul;150(7):753–8 (22 ref.)

NURSING

Nursing interventions in Münchausen syndrome by proxy. Volz AG. **J Psychosoc Nurs Ment Health Serv** 1995 Sep; 33(9):51–8 (13 ref.)

MUPIROCIN

PHARMACOLOGY

Update on mupirocin resistance. Poupard JA. **J Chemother** 1995 Jul;7 Suppl 3:71–4 (14 ref.)

MUR-NAC-L-ALA-D-ISOGLN see ACETYLMURAMYL-ALANYL-ISOGLUTAMINE

MURAMIDASE

ANALYSIS

[Lysozyme (muramidase)] Kamakura M. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:361–4 (18 ref.) **(Jpn)**

CHEMISTRY

Phage lysozymes. Fastrez J. **EXS** 1996;75:35–64 (146 ref.)
Folding of lysozyme. Fischer B. **EXS** 1996;75:143–61 (59 ref.)
Engineering of lysozyme. Imoto T. **EXS** 1996;75:163–81 (80 ref.)
Molecular evolution of ruminant lysozymes. Irwin DM. **EXS** 1996;75:347–61 (42 ref.)
Simulations of lysozyme: internal motions and the reaction mechanism. Karplus M, et al. **EXS** 1996;75:111–41 (82 ref.)
alpha-Lactalbumins and lysozymes. McKenzie HA. **EXS** 1996;75:365–409 (215 ref.)
Adaptive evolution of lysozyme: changes in amino acid sequence, regulation of expression and gene number. Prager EM. **EXS** 1996;75:323–45 (75 ref.)
Animal lysozymes c and g: an overview. Prager EM, et al. **EXS** 1996;75:9–31 (62 ref.)
Lysozyme: a model enzyme in protein crystallography. Strynadka NC, et al. **EXS** 1996;75:185–222 (100 ref.)
Chitinases, chitosanases, and lysozymes can be divided into procaryotic and eucaryotic families sharing a conserved core. Monzingo AF, et al. **Nat Struct Biol** 1996 Feb; 3(2):133–40 (27 ref.)
Interactions of protein antigens with antibodies. Davies DR, et al. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):7–12 (69 ref.)

GENETICS

Isolation and characterization of vertebrate lysozyme genes. Irwin DM, et al. **EXS** 1996;75:225–41 (71 ref.)
Molecular evolution of ruminant lysozymes. Irwin DM. **EXS** 1996;75:347–61 (42 ref.)
Adaptive evolution of lysozyme: changes in amino acid sequence, regulation of expression and gene number. Prager EM. **EXS** 1996;75:323–45 (75 ref.)
Lysozyme gene expression and regulation. Short ML, et al. **EXS** 1996;75:243–57 (52 ref.)

IMMUNOLOGY

The crystal structures of complexes formed between lysozyme and antibody fragments. Bentley GA. **EXS** 1996; 75:301–19 (42 ref.)
Polyclonal antisera elicited by lysozymes: insights into antigenic structure and evolution. Prager EM. **EXS** 1996; 75:261–76 (57 ref.)
Molecular recognition of lysozyme by monoclonal antibodies. Smith-Gill SJ. **EXS** 1996;75:277–300 (59 ref.)

METABOLISM

Evidence for lysozyme-type mechanism of hydrolysis in xylanases. Dupont C, et al. **EXS** 1996;75:411–23 (32 ref.)
Bacterial lysozymes. Höltje JV. **EXS** 1996;75:65–74 (48 ref.)
Lysozyme substrates. Höltje JV. **EXS** 1996;75:105–10 (34 ref.)
Insect lysozymes. Hultmark D. **EXS** 1996;75:87–102 (83 ref.)
Engineering of lysozyme. Imoto T. **EXS** 1996;75:163–81 (80 ref.)
Simulations of lysozyme: internal motions and the reaction mechanism. Karplus M, et al. **EXS** 1996;75:111–41 (82 ref.)
alpha-Lactalbumins and lysozymes. McKenzie HA. **EXS** 1996;75:365–409 (215 ref.)
Structural and genetic analysis of the folding and function of T4 lysozyme. Matthews BW. **FASEB J** 1996 Jan; 10(1):35–41 (29 ref.)

PHARMACOLOGY

Pharmacological aspects and therapeutic applications of lysozymes. Sava G. **EXS** 1996;75:433–49 (79 ref.)

THERAPEUTIC USE

Pharmacological aspects and therapeutic applications of lysozymes. Sava G. **EXS** 1996;75:433–49 (79 ref.)

MURAMOYLPENTAPEPTIDE CARBOXYPEPTIDASE see CARBOXYPEPTIDASE TRANSPEPTIDASE

MURAMYL DIPEPTIDE see ACETYLMURAMYL-ALANYL-ISOGLUTAMINE

MURDER see HOMICIDE

MUREIN see PEPTIDOGLYCAN

MURINE ACQUIRED IMMUNODEFICIENCY SYNDROME

ETIOLOGY

Cells and cytokines in the pathogenesis of MAIDS, a retrovirus-induced immunodeficiency syndrome of mice. Morse HC 3rd, et al. **Springer Semin Immunopathol** 1995; 17(2–3):231–45 (66 ref.)

IMMUNOLOGY

Cells and cytokines in the pathogenesis of MAIDS, a retrovirus-induced immunodeficiency syndrome of mice. Morse HC 3rd, et al. **Springer Semin Immunopathol** 1995; 17(2–3):231–45 (66 ref.)

MURINE AIDS see MURINE ACQUIRED IMMUNODEFICIENCY SYNDROME

MURINE GASTROENTERITIS VIRUS see GASTROENTERITIS VIRUS, MURINE

MURINE LEUKEMIA VIRUSES see LEUKEMIA VIRUSES, MURINE

MUROMONAB-CD3

ADVERSE EFFECTS

Side-effects of a monoclonal antibody, muromonab CD3/orthoclone OKT3: bibliographic review. Sgro C. **Toxicology** 1995 Dec 20;105(1):23–9 (45 ref.)

PHARMACOLOGY

Mechanisms of immunosuppression induced by antithymocyte globulins and OKT3. Bonnefoy-Berard N, et al. **J Heart Lung Transplant** 1996 May;15(5):435–42 (52 ref.)
Mechanisms of action and overview of OKT3. Norman DJ. **Ther Drug Monit** 1995 Dec;17(6):615–20 (72 ref.)

THERAPEUTIC USE

Performance of CD3xCD19 bispecific monoclonal antibodies in B cell malignancy. Haagen IA. **Leuk Lymphoma** 1995 Nov;19(5–6):381–93 (160 ref.)

MURRAY VALLEY ENCEPHALITIS VIRUS see ENCEPHALITIS VIRUS, MURRAY VALLEY

MUS MUSCULUS see MICE

MUSCARINE

METABOLISM

G protein regulation of cardiac muscarinic potassium channel. Kurachi Y. **Am J Physiol** 1995 Oct;269(4 Pt 1):C821–30 (80 ref.)
[Biologic characteristics and physiological significances of M current] Zheng JQ, et al. **Sheng Li Ko Hsueh Chin Chan** 1995 Oct;26(4):344–6 (9 ref.) **(Chi)**

MUSCARINIC ACETYLCHOLINE RECEPTORS see RECEPTORS, MUSCARINIC

MUSCARINIC AGENTS see CHOLINERGIC AGENTS

MUSCARINIC AGONISTS

PHARMACOLOGY

Pentatomic cyclic agonists and muscarinic receptors: a 20 years review. Angeli P. **Farmaco** 1995 Sep;50(9):565–77 (70 ref.)

THERAPEUTIC USE

M1 agonists for the treatment of Alzheimer's disease. Novel properties and clinical update. Fisher A, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:189–96 (21 ref.)

MUSCARINIC ANTAGONISTS

ADMINISTRATION & DOSAGE

New potential uses for transdermal scopolamine (hyoscine). La Rovere MT, et al. **Drugs** 1995 Nov;50(5):769–76 (49 ref.)

PHARMACOLOGY

The interaction of 4-DAMP mustard with subtypes of the muscarinic receptor. Ehlert FJ. **Life Sci** 1996;58(22):1971–8 (39 ref.)

THERAPEUTIC USE

Anticholinergic antimuscarinic agents in the treatment of airways bronchoconstriction in children. Martinati LC, et al. **Allergy** 1996 Jan;51(1):2–7 (33 ref.)
An international perspective on anticholinergic therapy. Chapman KR. **Am J Med** 1996 Jan 29;100(1A):2S–4S (19 ref.)
Use of anticholinergic bronchodilation in children. Rubin BK, et al. **Am J Med** 1996 Jan 29;100(1A):49S–53S (40 ref.)
New potential uses for transdermal scopolamine (hyoscine). La Rovere MT, et al. **Drugs** 1995 Nov;50(5):769–76 (49 ref.)

MUSCARINIC RECEPTORS see RECEPTORS, MUSCARINIC

MUSCIMOL

see related
RECEPTORS, GABA-A

MUSCLE CONTRACTION

see related
MUSCLE FATIGUE
MUSCLE RELAXATION

Developmental aspects of excitation contraction coupling in urinary bladder smooth muscle. Zderic SA, et al. **Adv Exp Med Biol** 1995;385:105–15; discussion 131–9 (39 ref.)
Eccentric activation and muscle damage: biomechanical and physiological considerations during downhill running. Eston RG, et al. **Br J Sports Med** 1995 Jun;29(2):89–94 (53 ref.)
Concentric and eccentric knee extension strength in older and younger men and women. Porter MM, et al. **Can J Appl Physiol** 1995 Dec;20(4):429–39 (38 ref.)
Significance of insulin for glucose metabolism in skeletal muscle during contractions. Hespel P, et al. **Diabetes** 1996 Jan;45 Suppl 1:S99–104 (61 ref.)
Muscle atrophy and weakness with aging: contraction-induced injury as an underlying mechanism. Faulkner JA, et al. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:124–9 (36 ref.)
Relationship of muscular strength to jaw posture in sports dentistry. Gelb H, et al. **N Y State Dent J** 1995 Nov; 61(9):58–66 (0 ref.)
Malignant hyperthermia: excitation-contraction coupling, Ca2+ release channel, and cell Ca2+ regulation defects. Mickelson JR, et al. **Physiol Rev** 1996 Apr;76(2):537–92 (433 ref.)
Protein-protein interactions in the rigor actomyosin complex. Milligan RA. **Proc Natl Acad Sci U S A** 1996 Jan 9; 93(1):21–6 (31 ref.)
Regulation of skeletal muscle blood flow during contractions. Lash JM. **Proc Soc Exp Biol Med** 1996 Mar;211(3):218–35 (151 ref.)
[Second messenger system and regulation of smooth muscle contractile activity in digestive tract] Zheng GH, et al. **Sheng Li Ko Hsueh Chin Chan** 1995 Oct;26(4):359–62 (7 ref.) **(Chi)**
[Study of muscular strength in clinical practice] van der Ploeg RJ, et al. **Ned Tijdschr Geneeskd** 1995 Oct 7; 139(40):2028–32 (20 ref.) **(Dut)**
[The contractile properties of uterine smooth muscle from physiological viewpoint] Ochiai K. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Aug;47(8):791–6 (26 ref.) **(Jpn)**
[Excitation-contraction uncoupling and muscular degeneration lacking functional skeletal muscle ryanodine-receptor gene] Nishi M. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2181–7 (18 ref.) **(Jpn)**
[Some new perspectives on V. I. Deshcherevskiy's kinetic theory of muscle contraction] Sidorenko NP. **Biofizika** 1996 Jan-Feb;41(1):33–9 (33 ref.) (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

Towards the development of ryanoid insecticides with low mammalian toxicity. Usherwood PN, et al. **Toxicol Lett** 1995 Dec;82–83:247–54 (13 ref.)
[Phallotoxins as modifiers in the study of muscles] Bukatina AE. **Biofizika** 1996 Jan-Feb;41(1):95–102 (38 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Fatigue vs. shortening-induced deactivation in striated muscle. Edman KA. **Acta Physiol Scand** 1996 Mar; 156(3):183–92 (43 ref.)
Effect of intracellular and extracellular ion changes on E-C coupling and skeletal muscle fatigue. Fitts RH, et al. **Acta Physiol Scand** 1996 Mar;156(3):169–81 (91 ref.)
Ion gradients and contractility in skeletal muscle: the role of active Na+, K+ transport. Nielsen OB, et al. **Acta Physiol Scand** 1996 Mar;156(3):247–56 (70 ref.)
Modulation of muscle contractility during fatigue and recovery by ATP sensitive potassium channel. Renaud JM, et al. **Acta Physiol Scand** 1996 Mar;156(3):203–12 (50 ref.)
Mechanisms underlying changes of tetanic [Ca2+]i and force in skeletal muscle. Westerblad H, et al. **Acta Physiol Scand** 1996 Mar;156(3):407–16 (68 ref.)
Task-dependent factors in fatigue of human voluntary

MUSCLE CONTRACTION

contractions. Bigland-Ritchie B, et al. **Adv Exp Med Biol** 1995;384:361-80 (92 ref.)

Task-dependent nature of fatigue in single motor units. Botterman BR. **Adv Exp Med Biol** 1995;384:351-60 (54 ref.)

An integrative view of limitations to muscular performance. Dempsey JA, et al. **Adv Exp Med Biol** 1995;384:393-9 (17 ref.)

Myofibrillar fatigue versus failure of activation. Edman KA. **Adv Exp Med Biol** 1995;384:29-43 (54 ref.)

Fatigue in adapted systems. Overuse and underuse paradigms. Gordon T. **Adv Exp Med Biol** 1995;384:429-56 (202 ref.)

Intramuscular pressures for monitoring different tasks and muscle conditions. Sejersted OM, et al. **Adv Exp Med Biol** 1995;384:339-50 (56 ref.)

Mechanisms of excitation-contraction coupling relevant to skeletal muscle fatigue. Stephenson DG, et al. **Adv Exp Med Biol** 1995;384:45-56 (75 ref.)

A personal view of muscle and motility mechanisms. Huxley HE. **Annu Rev Physiol** 1996;58:1-19 (50 ref.)

Structure-function relationships in smooth muscle: the missing links. Small JV. **Bioessays** 1995 Sep;17(9):785-92 (86 ref.)

Phase transitions and the molecular mechanism of contraction. Pollack GH. **Biophys Chem** 1996 Apr 16; 59(3):315-28 (119 ref.)

Regulation of contraction by calcium binding myosins. Szent-Györgyi AG. **Biophys Chem** 1996 Apr 16; 59(3):357-63 (29 ref.)

Origins of [H+] changes in exercising skeletal muscle. Lindinger MI. **Can J Appl Physiol** 1995 Sep;20(3):357-68 (38 ref.)

Intracellular mechanisms involved in the regulation of vascular smooth muscle tone. Walsh MP, et al. **Can J Physiol Pharmacol** 1995 May;73(5):565-73 (53 ref.)

Contractile activity-induced mitochondrial biogenesis in skeletal muscle. Essig DA. **Exerc Sport Sci Rev** 1996; 24:289-319 (94 ref.)

Age, gender, and muscular strength. Hurley BF. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:41-4 (50 ref.)

Theories of muscle contraction. Jontes JD. **J Struct Biol** 1995 Sep-Oct;115(2):119-43 (175 ref.)

Geometry, kinetics and plasticity of release and clearance of ATP and noradrenaline as sympathetic cotransmitters: roles for the neurogenic contraction. Stjärne L, et al. **Prog Neurobiol** 1995 Sep;47(1):45-94 (145 ref.)

[The mechanism of muscle contraction: along the path carved by Academician G.M Frank] Pollack GH. **Biofizika** 1996 Jan-Feb;41(1):7-21 (134 ref.) (Eng. Abstr.) **(Rus)**

MUSCLE CRAMP

DRUG THERAPY

Quinine for nocturnal leg cramps? **Drug Ther Bull** 1996 Jan; 34(1):7-8 (15 ref.)

Benign nocturnal leg cramps. Current controversies over use of quinine. Leclerc KM, et al. **Postgrad Med** 1996 Feb; 99(2):177-8, 181-4 (13 ref.)

ETIOLOGY

Leg cramps: differential diagnosis and management [see comments] Riley JD, et al. **Am Fam Physician** 1995 Nov 1;52(6):1794-8 (25 ref.) Comment in: Am Fam Physician 1996 May 15;53(7):2284.

Black widow spider bite in a child. Reeves JA, et al. **Am J Emerg Med** 1996 Sep;14(5):469-71 (17 ref.)

THERAPY

Leg cramps: differential diagnosis and management [see comments] Riley JD, et al. **Am Fam Physician** 1995 Nov 1;52(6):1794-8 (25 ref.) Comment in: Am Fam Physician 1996 May 15;53(7):2284.

MUSCLE DENERVATION

Functional reorganization of the partially denervated hindlimb extensor and flexor muscle in rat. Sławińska U, et al. **Acta Neurobiol Exp (Warsz)** 1996;56(1):441-7 (27 ref.)

MUSCLE DYSTONIA see **DYSTONIA**

MUSCLE FATIGUE

Historical perspective: a framework for interpreting pathobiological ideas on human muscle fatigue. Edwards RH, et al. **Adv Exp Med Biol** 1995;384:481-94 (59 ref.)

PHYSIOLOGY

Fatigue vs. shortening-induced deactivation in striated muscle. Edman KA. **Acta Physiol Scand** 1996 Mar; 156(3):183-92 (43 ref.)

Effect of intracellular and extracellular ion changes on E-C coupling and skeletal muscle fatigue. Fitts RH, et al. **Acta Physiol Scand** 1996 Mar;156(3):169-81 (91 ref.)

High-and low-frequency fatigue revisited. Jones DA. **Acta Physiol Scand** 1996 Mar;156(3):265-70 (22 ref.)

Slow recovery of force in single skeletal muscle fibres. Lännergren J, et al. **Acta Physiol Scand** 1996 Mar; 156(3):193-202 (59 ref.)

Modulation of muscle contractility during fatigue and recovery by ATP sensitive potassium channel. Renaud JM, et al. **Acta Physiol Scand** 1996 Mar;156(3):203-12 (50 ref.)

Potassium and fatigue: the pros and cons. Sjøgaard G. **Acta Physiol Scand** 1996 Mar;156(3):257-64 (58 ref.)

The role of intracellular acidosis in muscle fatigue. Allen DG, et al. **Adv Exp Med Biol** 1995;384:57-68 (54 ref.)

Emerging opportunities with NMR. Bertocci LA. **Adv Exp Med Biol** 1995;384:211-23 (39 ref.)

Task-dependent factors in fatigue of human voluntary contractions. Bigland-Ritchie B, et al. **Adv Exp Med Biol** 1995;384:361-80 (92 ref.)

Variable-frequency stimulation patterns for the optimization of force during muscle fatigue. Muscle wisdom and the catch-like property. Binder-Macleod SA. **Adv Exp Med Biol** 1995;384:227-40 (67 ref.)

Task-dependent nature of fatigue in single motor units. Botterman BR. **Adv Exp Med Biol** 1995;384:351-60 (54 ref.)

Associations between muscle soreness, damage, and fatigue. Clarkson PM, et al. **Adv Exp Med Biol** 1995;384:457-69 (63 ref.)

An integrative view of limitations to muscular performance. Dempsey JA, et al. **Adv Exp Med Biol** 1995;384:393-9 (17 ref.)

Myofibrillar fatigue versus failure of activation. Edman KA. **Adv Exp Med Biol** 1995;384:29-43 (54 ref.)

Muscle fatigue in old animals. Unique aspects of fatigue in elderly humans. Faulkner JA, et al. **Adv Exp Med Biol** 1995;384:471-80 (35 ref.)

The role of the sarcolemma action potential in fatigue. Fuglevand AJ. **Adv Exp Med Biol** 1995;384:101-8 (56 ref.)

Central fatigue. Critical issues, quantification and practical implications. Gandevia SC, et al. **Adv Exp Med Biol** 1995; 384:281-94 (79 ref.)

Neurobiology of muscle fatigue. Advances and issues. Gandevia SC, et al. **Adv Exp Med Biol** 1995;384:515-25 (31 ref.)

Role of muscle afferents in the inhibition of motoneurons during fatigue. Garland SJ, et al. **Adv Exp Med Biol** 1995; 384:271-8 (50 ref.)

Fatigue in adapted systems. Overuse and underuse paradigms. Gordon T. **Adv Exp Med Biol** 1995;384:429-56 (202 ref.)

The fusimotor system. Its role in fatigue. Hagbarth KE, et al. **Adv Exp Med Biol** 1995;384:259-70 (68 ref.)

The senses of effort and force during fatiguing contractions. Jones LA. **Adv Exp Med Biol** 1995;384:305-13 (38 ref.)

Neuromuscular frequency-coding and fatigue. Kernell D. **Adv Exp Med Biol** 1995;384:135-45 (54 ref.)

Fatigue and the design of the respiratory system. Lindstedt SL, et al. **Adv Exp Med Biol** 1995;384:383-91 (20 ref.)

Fatigue brought on by malfunction of the central and peripheral nervous systems. McComas AJ, et al. **Adv Exp Med Biol** 1995;384:495-512 (59 ref.)

Respiratory muscle fatigue. McKenzie DK, et al. **Adv Exp Med Biol** 1995;384:401-14 (74 ref.)

Fatigue of jaw muscles and speech mechanisms. Miles TS, et al. **Adv Exp Med Biol** 1995;384:415-26 (55 ref.)

Mechanisms of human muscle fatigue. Quantitating the contribution of metabolic factors and activation impairment. Miller RG, et al. **Adv Exp Med Biol** 1995; 384:195-210 (38 ref.)

Tryptophan, 5-hydroxytryptamine and a possible explanation for central fatigue. Newsholme EA, et al. **Adv Exp Med Biol** 1995;384:315-20 (16 ref.)

Single-trial readiness potentials and fatigue. Popivanov D, et al. **Adv Exp Med Biol** 1995;384:295-304 (26 ref.)

The significance of motor unit variability in sustaining mechanical output of muscle. Sargeant AJ, et al. **Adv Exp Med Biol** 1995;384:323-38 (68 ref.)

Intrinsic properties of motoneurons. Implications for muscle fatigue. Sawczuk A, et al. **Adv Exp Med Biol** 1995; 384:123-34 (86 ref.)

Fatigue at the neuromuscular junction. Branch point vs. presynaptic vs. postsynaptic mechanisms. Sieck GC, et al. **Adv Exp Med Biol** 1995;384:83-100 (90 ref.)

Role of interstitial potassium. Sjøgaard G, et al. **Adv Exp Med Biol** 1995;384:69-80 (81 ref.)

Mechanisms of excitation-contraction coupling relevant to skeletal muscle fatigue. Stephenson DG, et al. **Adv Exp Med Biol** 1995;384:45-56 (75 ref.)

Human motor units studied by spike-triggered averaging and intraneural motor axon stimulation. Thomas CK. **Adv Exp Med Biol** 1995;384:147-60 (75 ref.)

The scientific contributions of Brenda Bigland-Ritchie. Thomas CK, et al. **Adv Exp Med Biol** 1995;384:11-25 (103 ref.)

Metabolic correlates of fatigue from different types of exercise in man. Vøllestad NK. **Adv Exp Med Biol** 1995; 384:185-94 (37 ref.)

Overview: potential role of segmental motor circuitry in muscle fatigue. Windhorst U, et al. **Adv Exp Med Biol** 1995; 384:241-58 (70 ref.)

Muscle cell function during prolonged activity: cellular mechanisms of fatigue. Allen DG, et al. **Exp Physiol** 1995 Jul;80(4):497-527 (140 ref.)

Behaviour of zinc in physical exercise: a special reference to immunity and fatigue. Cordova A, et al. **Neurosci Biobehav Rev** 1995 Fall;19(3):439-45 (101 ref.)

MUSCLE FIBERS

Functional morphology and motor control of series-fibered muscles. Trotter JA, et al. **Exerc Sport Sci Rev** 1995; 23:167-213 (155 ref.)

DRUG EFFECTS

Effects of myotoxins on skeletal muscle fibers. Khan MA. **Prog Neurobiol** 1995 Aug;46(5):541-60 (230 ref.)

METABOLISM

Fuel selection, muscle fibre. Hultman E. **Proc Nutr Soc** 1995 Mar;54(1):107-21 (51 ref.)

PHYSIOLOGY

Slow recovery of force in single skeletal muscle fibres. Lännergren J, et al. **Acta Physiol Scand** 1996 Mar; 156(3):193-202 (59 ref.)

Myofibrillar fatigue versus failure of activation. Edman KA. **Adv Exp Med Biol** 1995;384:29-43 (54 ref.)

Single-trial readiness potentials and fatigue. Popivanov D, et al. **Adv Exp Med Biol** 1995;384:295-304 (26 ref.)

The significance of motor unit variability in sustaining mechanical output of muscle. Sargeant AJ, et al. **Adv Exp Med Biol** 1995;384:323-38 (68 ref.)

Single fiber electromyography in studies of neuromuscular function. Trontelj JV, et al. **Adv Exp Med Biol** 1995; 384:109-19 (31 ref.)

Motor units: remodeling in aged animals. Larsson L. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:91-5 (15 ref.)

ULTRASTRUCTURE

Human aging, muscle mass, and fiber type composition. Lexell J. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:11-6 (55 ref.)

MUSCLE FIBERS, FAST-TWITCH

PHYSIOLOGY

The role of intracellular pH in the control of adenosine output from red skeletal muscle. Ballard HJ. **Biol Signals** 1995 May-Jun;4(3):168-73 (21 ref.)

MUSCLE FIBERS, RED see **MUSCLE FIBERS, FAST-TWITCH**

MUSCLE FIBERS, TYPE II see **MUSCLE FIBERS, FAST-TWITCH**

MUSCLE FIBERS, WHITE see **MUSCLE FIBERS, FAST-TWITCH**

MUSCLE FLACCIDITY see **MUSCLE HYPOTONIA**

MUSCLE HYPOTONIA

CONGENITAL

[Cerebral congenital hypotonia] Papazian O, et al. **Rev Neurol** 1995;23 Suppl 3:S289-99 (50 ref.) **(Spa)**

GENETICS

Detection of a subtle rearrangement of chromosome 22 using molecular techniques. Biesecker LG, et al. **Am J Med Genet** 1995 Sep 25;58(4):389-94 (15 ref.)

Inversion duplication of the short arm of chromosome 8: clinical data on seven patients and review of the literature. de Die-Smulders CE, et al. **Am J Med Genet** 1995 Nov 20;59(3):369-74 (16 ref.)

PHYSIOPATHOLOGY

[Cerebral congenital hypotonia] Papazian O, et al. **Rev Neurol** 1995;23 Suppl 3:S289-99 (50 ref.) **(Spa)**

RADIONUCLIDE IMAGING

Hemiatrophy, juvenile-onset exertional alternating leg paresis, hypotonia, and hemidystonia and adult-onset hemiparkinsonism: the spectrum of hemiparkinsonism-hemiatrophy syndrome. Lang AE. **Mov Disord** 1995 Jul;10(4):489-95 (32 ref.)

MUSCLE, INVOLUNTARY see **MUSCLE, SMOOTH**

MUSCLE NEOPLASMS

Chondroid syringoma of the abdominal wall. A case report and review of the literature. Sliwa-Hähnle K, et al. **S Afr J Surg** 1996 Feb;34(1):46-8 (15 ref.)

DIAGNOSIS

Unusual problems of the athlete's elbow, forearm, and wrist. Shaffer B, et al. **Clin Sports Med** 1996 Apr;15(2):425-38 (11 ref.)

MR imaging of musculoskeletal tumors of the hand and wrist. Kransdorf MJ, et al. **Magn Reson Imaging Clin N Am** 1995 May;3(2):327-44 (105 ref.)

Surgical considerations in a diagnostic imaging evaluation of musculoskeletal masses. Moreau G, et al. **Magn Reson Imaging Clin N Am** 1995 Nov;3(4):577-90 (30 ref.)

MR spectroscopy of musculoskeletal soft-tissue tumors.

Negendank WG. **Magn Reson Imaging Clin N Am** 1995 Nov;3(4):713–25 (53 ref.)
Benign and malignant masses. MR imaging differentiation. Weatherall PT. **Magn Reson Imaging Clin N Am** 1995 Nov; 3(4):669–94 (84 ref.)
From the archives of the AFIP. Musculoskeletal angiomatous lesions: radiologic–pathologic correlation. Murphey MD, et al. **Radiographics** 1995 Jul;15(4):893–917 (84 ref.)
[Musculoskeletal tumors: epidemiology, clinical aspects and diagnostic requirements] Rechl H, et al. **Rontgenpraxis** 1995 Aug;48(8):217–22 (32 ref.) **(Ger)**

DRUG THERAPY

The evolution of chemotherapeutic agents for the treatment of pediatric musculoskeletal malignancies. Velez-Yanguas MC, et al. **Orthop Clin North Am** 1996 Jul;27(3):545–9 (48 ref.)

GENETICS

Chromosomal aberrations in musculoskeletal tumours: clinical importance. Rydholm A. **J Bone Joint Surg Br** 1996 May;78(3):501–6 (7 ref.)

PATHOLOGY

Postradiation malignant triton tumor. A case report and review of the literature. Yakulis R, et al. **Arch Pathol Lab Med** 1996 Jun;120(6):541–8 (59 ref.)
Successful treatment for solitary brain metastasis from alveolar soft part sarcoma. Wang CH, et al. **J Neurooncol** 1995;25(2):161–6 (31 ref.)
Hemangioma of the temporalis muscle: a case report and review of the literature. Lopez-Cedrun JL, et al. **J Oral Maxillofac Surg** 1996 Sep;54(9):1130–2 (15 ref.)
Chordoid tumor: a light, electron microscopic, and immunohistochemical study. Carstens PH. **Ultrastruct Pathol** 1995 Jul–Aug;19(4):291–5 (22 ref.)

SECONDARY

Solitary contralateral psoas metastasis 14 years after radical nephrectomy for organ confined renal cell carcinoma. Linn JF, et al. **J Urol** 1996 Jul;156(1):173 (2 ref.)
[Adenocarcinoma of the appendix. A propos of a case complicated by double local and parietal recurrence] de Souza N, et al. **J Chir (Paris)** 1996 Jun;133(4):159–61 (10 ref.) (Eng. Abstr.) **(Fre)**
[Muscular metastasis of cancer of the pancreas. A propos of a case] Wafflart E, et al. **J Chir (Paris)** 1996 Jun; 133(4):167–70 (16 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Successful treatment for solitary brain metastasis from alveolar soft part sarcoma. Wang CH, et al. **J Neurooncol** 1995;25(2):161–6 (31 ref.)
Surgical considerations in a diagnostic imaging evaluation of musculoskeletal masses. Moreau G, et al. **Magn Reson Imaging Clin N Am** 1995 Nov;3(4):577–90 (30 ref.)
The staging and surgery of musculoskeletal neoplasms. Wolf RE, et al. **Orthop Clin North Am** 1996 Jul;27(3):473–81 (21 ref.)

MUSCLE PROTEINS

Calponin. Winder SJ, et al. **Curr Top Cell Regul** 1996;34:33–61 (70 ref.)

BIOSYNTHESIS

Protein synthesis in the heart in vivo, its measurement and patho-physiological alterations. Preedy VR, et al. **Int J Cardiol** 1995 Jun 30;50(2):95–106 (48 ref.)

CHEMISTRY

Phase transitions and the molecular mechanism of contraction. Pollack GH. **Biophys Chem** 1996 Apr 16; 59(3):315–28 (119 ref.)
Kinesin-II, a membrane traffic motor in axons, axonemes, and spindles. Scholey JM. **J Cell Biol** 1996 Apr;133(1):1–4 (29 ref.)
Molecular structure and tissue distribution of ryanodine receptors calcium channels. Giannini G, et al. **Med Res Rev** 1995 Jul;15(4):313–23 (73 ref.)

GENETICS

Molecular and clinical aspects of inherited cardiomyopathies. Durand JB, et al. **Ann Med** 1995 Jun;27(3):311–7 (38 ref.)
Mutational analysis of motor proteins. Sweeney HL, et al. **Annu Rev Physiol** 1996;58:751–92 (251 ref.)
Towards unravelling the Igf2/H19 imprinted domain. Viville S, et al. **Bioessays** 1995 Oct;17(10):835–8 (23 ref.)
Molecular diversity of myofibrillar proteins: gene regulation and functional significance. Schiaffino S, et al. **Physiol Rev** 1996 Apr;76(2):371–423 (585 ref.)
[Excitation–contraction uncoupling and muscular degeneration lacking functional skeletal muscle ryanodine-receptor gene] Nishi M. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2181–7 (18 ref.) **(Jpn)**

METABOLISM

Regulation of protein synthesis and degradation in adult ventricular cardiomyocytes. Schlüter KD, et al. **Am J Physiol** 1995 Dec;269(6 Pt 1):C1347–55 (76 ref.)
Muscle protein metabolism during sepsis. Hasselgren PO. **Biochem Soc Trans** 1995 Nov;23(4):1019–25 (46 ref.)
Muscle protein turnover: methodological issues and the effect of aging. Nair KS. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:107–12 (26 ref.)
Altered interactions among thin filament proteins modulate cardiac function. Solaro RJ, et al. **J Mol Cell Cardiol** 1996 Feb;28(2):217–30 (105 ref.)
Molecular structure and tissue distribution of ryanodine receptors calcium channels. Giannini G, et al. **Med Res Rev** 1995 Jul;15(4):313–23 (73 ref.)
The 20S/26S proteasomal pathway of protein degradation in muscle tissue. Dahlmann B, et al. **Mol Biol Rep** 1995; 21(1):57–62 (88 ref.)
The ubiquitin-dependent proteolytic pathway in skeletal muscle: its role in pathological states. Argilés JM, et al. **Trends Pharmacol Sci** 1996 Jun;17(6):223–6 (40 ref.)
Cyclic ADP-ribose, the ryanodine receptor and Ca2+ release. Sitsapesan R, et al. **Trends Pharmacol Sci** 1995 Nov; 16(11):386–91 (50 ref.)
[Mechanisms of mobilization of intracellular stored calcium] Li HW, et al. **Sheng Li Ko Hsueh Chin Chan** 1995 Jul; 26(3):209–12 (17 ref.) (Eng. Abstr.) **(Chi)**
[Ryanodine receptors in the central nervous system] Ogawa Y, et al. **Nippon Yakurigaku Zasshi** 1995 Jun;105(6):423–30 (50 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

The ryanodine receptor family of intracellular calcium release channels. Sorrentino V. **Adv Pharmacol** 1995; 33:67–90 (119 ref.)
Structure-function relationships in smooth muscle: the missing links. Small JV. **Bioessays** 1995 Sep;17(9):785–92 (86 ref.)
Phase transitions and the molecular mechanism of contraction. Pollack GH. **Biophys Chem** 1996 Apr 16; 59(3):315–28 (119 ref.)
Kinesin-related proteins at mitotic spindle poles: function and regulation. Walczak CE, et al. **Cell** 1996 Jun 28; 85(7):943–6 (18 ref.)
Fatty acid binding protein in locust and mammalian muscle. Comparison of structure, function and regulation. Haunerland NH. **Comp Biochem Physiol B Biochem Mol Biol** 1994 Oct–Nov; 109(2–3):199–208 (49 ref.)
Transcription factor families: muscling in on the myogenic program. Ludolph DC, et al. **FASEB J** 1995 Dec; 9(15):1595–604 (65 ref.)
Kinesin-II, a membrane traffic motor in axons, axonemes, and spindles. Scholey JM. **J Cell Biol** 1996 Apr;133(1):1–4 (29 ref.)
Calcium and inositol trisphosphate receptors. Taylor CW, et al. **J Membr Biol** 1995 May;145(2):109–18 (108 ref.)
The anatomy of a molecular giant: how the sarcomere cytoskeleton is assembled from immunoglobulin superfamily molecules. Fürst DO, et al. **J Mol Cell Cardiol** 1995 Apr;27(4):951–9 (76 ref.)
Molecular diversity of myofibrillar proteins: gene regulation and functional significance. Schiaffino S, et al. **Physiol Rev** 1996 Apr;76(2):371–423 (585 ref.)

MUSCLE RELAXANTS, CENTRAL

ADVERSE EFFECTS

Five-year multicenter retrospective review of cyclobenzaprine toxicity. Spiller HA, et al. **J Emerg Med** 1995 Nov–Dec;13(6):781–5 (14 ref.)

THERAPEUTIC USE

Management of suspected neuroleptic malignant syndrome. Velamoor VR, et al. **Can J Psychiatry** 1995 Nov; 40(9):545–50 (33 ref.)
Quinine for nocturnal leg cramps? **Drug Ther Bull** 1996 Jan; 34(1):7–8 (15 ref.)
[The neuroleptic malignant syndrome in an adolescent. Its treatment with dantrolene, bromocryptin and diazepam] Real Rodríguez B, et al. **An Esp Pediatr** 1996 Jan;44(1):60–2 (20 ref.) **(Spa)**

MUSCLE RELAXANTS, DEPOLARIZING see **NEUROMUSCULAR DEPOLARIZING AGENTS**

MUSCLE RELAXANTS, NON-DEPOLARIZING see **NEUROMUSCULAR NONDEPOLARIZING AGENTS**

MUSCLE RELAXATION

Calcium sparks in vascular smooth muscle: relaxation regulators [comment] Fay FS. **Science** 1995 Oct 27; 270(5236):588–9 (15 ref.) Comment on: Science 1995 Oct 27;270(5236):633–7.
[Hyperpolarization-relaxation coupling in vascular smooth muscle] Yanagisawa T. **Nippon Yakurigaku Zasshi** 1995 Sep;106(3):157–69 (57 ref.) (Eng. Abstr.) **(Jpn)**

DRUG EFFECTS

Pharmacological basis for duration of effect: formoterol and salmeterol versus short-acting beta 2-adrenoceptor agonists. Lindén A, et al. **Lung** 1996;174(1):1–22 (52 ref.)
Airway smooth muscle relaxation. Knox AJ, et al. **Thorax** 1995 Aug;50(8):894–901 (115 ref.)

PHYSIOLOGY

Molecular mechanisms of beta-adrenergic relaxation of airway smooth muscle. Kotlikoff MI, et al. **Annu Rev Physiol** 1996;58:115–41 (164 ref.)

MUSCLE, SKELETAL

Integration of the physiological factors determining endurance performance ability. Coyle EF. **Exerc Sport Sci Rev** 1995;23:25–63 (67 ref.)
Human skeletal muscle metabolism in health and disease: utility of magnetic resonance spectroscopy. Kent-Braun JA, et al. **Exerc Sport Sci Rev** 1995;23:305–47 (177 ref.)
Muscle-based gene therapy: realistic possibilities for the future. Svensson EC, et al. **Mol Med Today** 1996 Apr; 2(4):166–72 (40 ref.)
Muscle-mediated gene therapy. Blau HM, et al. **N Engl J Med** 1995 Dec 7;333(23):1554–6 (0 ref.)
[Injected fat for correction of soft tissue defects] Shoshani O, et al. **Harefuah** 1995 Dec 1;129(11):489–93 (40 ref.) **(Heb)**
[Excitation–contraction uncoupling and muscular degeneration lacking functional skeletal muscle ryanodine-receptor gene] Nishi M. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2181–7 (18 ref.) **(Jpn)**

ABNORMALITIES

Anomalous flexor digitorum superficialis presenting as a painful palmar mass: a case report. Grant SD, et al. **Clin Anat** 1995;8(6):432–3 (6 ref.)
Accessory soleus presenting as a posterior ankle mass: a case report and literature review. Travis MT, et al. **Foot Ankle Int** 1995 Oct;16(10):651–4 (14 ref.)
Ulnar nerve compression at the elbow caused by a prominent medial head of the triceps and an anconeus epitrochlearis muscle. O'Hara JJ, et al. **J Hand Surg [Br]** 1996 Feb; 21(1):133–5 (5 ref.)

ANATOMY & HISTOLOGY

Two cases of the superficial dorsalis pedis artery observed in man. Chiba S. **Anat Anz** 1996 Apr;178(2):183–9 (41 ref.)
Anatomy of the extensor mechanism of the hand and wrist. Wehbé MA. **Hand Clin** 1995 Aug;11(3):361–6 (13 ref.)
Factors influencing the repair and adaptation of muscles in aged individuals: satellite cells and innervation. Carlson BM. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:96–100 (34 ref.)
Muscle biopsy as a tool in the study of aging. Coggan AR. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:30–4 (38 ref.)
From muscle properties to human performance, using magnetic resonance. Conley KE, et al. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:35–40 (30 ref.)
Muscle performance and structure in the elderly as studied cross-sectionally and longitudinally. Grimby G. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:17–22 (22 ref.)
Measurement of skeletal muscle: laboratory and epidemiological methods. Heymsfield SB, et al. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:23–9 (30 ref.)
Human aging, muscle mass, and fiber type composition. Lexell J. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:11–6 (55 ref.)

BLOOD SUPPLY

Structural basis for oxygen delivery: muscle capillaries and manifolds in tuna red muscle. Mathieu-Costello O, et al. **Comp Biochem Physiol A Physiol** 1996 Jan;113(1):25–31 (37 ref.)
Microcirculatory models of ischaemia–reperfusion in skin and striated muscle. Nolte D, et al. **Int J Microcirc Clin Exp** 1995;15 Suppl 1:9–16 (67 ref.)
The application of blood flow measurements to the study of aging muscle. McCully KK, et al. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:130–6 (80 ref.)
Effects of exercise training on endothelium-dependent peripheral vascular responsiveness. Delp MD. **Med Sci Sports Exerc** 1995 Aug;27(8):1152–7 (38 ref.)
Contribution of endothelium-derived nitric oxide (EDNO) to the skeletal muscle blood flow response to exercise. McAllister RM, et al. **Med Sci Sports Exerc** 1995 Aug; 27(8):1145–51 (49 ref.)
Coordination of blood flow control in the resistance vasculature of skeletal muscle. Segal SS, et al. **Med Sci Sports Exerc** 1995 Aug;27(8):1158–64 (65 ref.)
Influence of microvascular architecture on oxygen exchange in skeletal muscle. Pittman RN. **Microcirculation** 1995 May; 2(1):1–18 (67 ref.)
Regulation of skeletal muscle blood flow during contractions.

Lash JM. **Proc Soc Exp Biol Med** 1996 Mar;211(3):218–35 (151 ref.)

CHEMISTRY

Thermal unfolding of Acanthamoeba myosin II and skeletal muscle myosin. Zolkiewski M, et al. **Biophys Chem** 1996 Apr 16;59(3):365–71 (45 ref.)

[Histological and immunohistochemical analysis of dystrophin++ in muscular dystrophy of Duchenne and Becker type] Cabello A. **Rev Neurol** 1995;23 Suppl 3:S395–9 (31 ref.) **(Spa)**

CYTOLOGY

Regulation of muscle differentiation by the MEF2 family of MADS box transcription factors. Olson EN, et al. **Dev Biol** 1995 Nov;172(1):2–14 (102 ref.)

Extrinsic regulation of domestic animal-derived satellite cells. Dodson MV, et al. **Domest Anim Endocrinol** 1996 Mar;13(2):107–26 (130 ref.)

[The cytoskeleton of muscle cells] Dąbrowska R, et al. **Postepy Biochem** 1995;41(3):165–74 (156 ref.) **(Pol)**

DRUG EFFECTS

Investigations into the toxic effects of alcohol on skeletal muscle. Reilly ME, et al. **Adverse Drug React Toxicol Rev** 1995 Summer;14(2):117–50 (141 ref.)

Effects of mefloquine on Ca2+ uptake by crude microsomes of rabbit skeletal muscle. Go ML, et al. **Arch Int Pharmacodyn Ther** 1995 Mar–Apr;329(2):255–71 (29 ref.)

Trophic factor supplementation: effect on the age–associated changes in body composition. Schwartz RS. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:151–6 (53 ref.)

Effects of myotoxins on skeletal muscle fibers. Khan MA. **Prog Neurobiol** 1995 Aug;46(5):541–60 (230 ref.)

EMBRYOLOGY

Determination versus differentiation and the MyoD family of transcription factors. Megeney LA, et al. **Biochem Cell Biol** 1995 Sep–Oct;73(9–10):723–32 (100 ref.)

Transcription factor families: muscling in on the myogenic program. Ludolph DC, et al. **FASEB J** 1995 Dec; 9(15):1595–604 (65 ref.)

Combinatorial control of muscle development by basic helix–loop–helix and MADS-box transcription factors. Molkentin JD, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9366–73 (108 ref.)

An intrinsic genetic program for autonomous differentiation of muscle cells in the ascidian embryo. Satoh N, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9315–21 (48 ref.)

Functional development of fetal limb muscles: a review of the roles of activity, nerves and hormones. Walker DW, et al. **Reprod Fertil Dev** 1995;7(3):391–8 (27 ref.)

ENZYMOLOGY

The 20S/26S proteasomal pathway of protein degradation in muscle tissue. Dahlmann B, et al. **Mol Biol Rep** 1995; 21(1):57–62 (88 ref.)

Multicatalytic proteinase in fish muscle. Sánchez JJ, et al. **Mol Biol Rep** 1995;21(1):63–9 (31 ref.)

GROWTH & DEVELOPMENT

Developmental regulation of cation pumps in skeletal and cardiac muscle. Dauncey MJ, et al. **Acta Physiol Scand** 1996 Mar;156(3):313–23 (75 ref.)

Fibroblast growth factor signalling and myogenic development. Swain JL. **Trans Am Clin Climatol Assoc** 1994;106:109–12; discussion 112–3 (0 ref.)

INJURIES

Biomechanics of iliotibial band friction syndrome in runners. Orchard JW, et al. **Am J Sports Med** 1996 May–Jun; 24(3):375–9 (26 ref.)

Muscle–tendon injuries in young athletes. Best TM. **Clin Sports Med** 1995 Jul;14(3):669–86 (75 ref.)

Advances in the management of musculoskeletal trauma. Lazarus MD, et al. **Curr Opin Gen Surg** 1993;:46–54 (26 ref.)

Magnetic resonance imaging of the extensor mechanism. Sonin AH. **Magn Reson Imaging Clin N Am** 1994 Aug; 2(3):401–11 (30 ref.)

Musculotendinous injury. Weatherall PT, et al. **Magn Reson Imaging Clin N Am** 1995 Nov;3(4):753–72 (73 ref.)

Inflammatory cell response to acute muscle injury. Tidball JG. **Med Sci Sports Exerc** 1995 Jul;27(7):1022–32 (118 ref.)

Hyperbaric oxygen reduces ischemia–induced skeletal muscle injury. Haapaniemi T, et al. **Plast Reconstr Surg** 1996 Mar; 97(3):602–7; discussion 608–9 (42 ref.)

INNERVATION

Variety of muscle responses to tactile stimuli. Czarkowska–Bauch J. **Acta Neurobiol Exp (Warsz)** 1996; 56(1):435–9 (13 ref.)

Functional reorganization of the partially denervated hindlimb extensor and flexor muscle in rat. Sławińska U, et al. **Acta Neurobiol Exp (Warsz)** 1996;56(1):441–7 (27 ref.)

Functional development of fetal limb muscles: a review of the roles of activity, nerves and hormones. Walker DW, et al. **Reprod Fertil Dev** 1995;7(3):391–8 (27 ref.)

Modular organization of motor behavior in the frog's spinal cord. Bizzi E, et al. **Trends Neurosci** 1995 Oct;18(10):442–6 (30 ref.)

[Anterior interosseus syndrome from the surgical viewpoint] Axmann HD, et al. **Nervenarzt** 1995 Aug;66(8):610–3 (44 ref.) (Eng. Abstr.) **(Ger)**

[Metabolic changes in denervated skeletal muscles] Boćkowski L, et al. **Postepy Hig Med Dosw** 1996; 50(2):191–204 (75 ref.) (Eng. Abstr.) **(Pol)**

METABOLISM

Developmental regulation of cation pumps in skeletal and cardiac muscle. Dauncey MJ, et al. **Acta Physiol Scand** 1996 Mar;156(3):313–23 (75 ref.)

Calcium uptake and release modulated by counter–ion conductances in the sarcoplasmic reticulum of skeletal muscle. Fink RH, et al. **Acta Physiol Scand** 1996 Mar; 156(3):387–96 (65 ref.)

Effect of intracellular and extracellular ion changes on E–C coupling and skeletal muscle fatigue. Fitts RH, et al. **Acta Physiol Scand** 1996 Mar;156(3):169–81 (91 ref.)

Lactate/proton co–transport in skeletal muscle: regulation and importance for pHi homeostasis. Juel C. **Acta Physiol Scand** 1996 Mar;156(3):369–74 (29 ref.)

Stimulation of Na+, K(+)–pump activity in skeletal muscle by methylxanthines: evidence and proposed mechanisms. Lindinger MI, et al. **Acta Physiol Scand** 1996 Mar; 156(3):347–53 (45 ref.)

Role of skeletal muscle sodium pumps in the adaptation to potassium deprivation. McDonough AA, et al. **Acta Physiol Scand** 1996 Mar;156(3):295–304 (77 ref.)

Fuzzy space and control of Na+, K(+)–pump rate in heart and skeletal muscle. Semb SO, et al. **Acta Physiol Scand** 1996 Mar;156(3):213–25 (79 ref.)

Mechanisms underlying changes of tetanic [Ca2+]i and force in skeletal muscle. Westerblad H, et al. **Acta Physiol Scand** 1996 Mar;156(3):407–16 (68 ref.)

In vitro studies of human skeletal muscle: hormonal and metabolic regulation of glucose transport. Zierath JR. **Acta Physiol Scand Suppl** 1995;626:1–96 (435 ref.)

Fatigue in adapted systems. Overuse and underuse paradigms. Gordon T. **Adv Exp Med Biol** 1995;384:429–56 (202 ref.)

Na–Ca exchange studies in sarcolemmal skeletal muscle. Gonzalez–Serratos H, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:556–60 (11 ref.)

Extreme derangements of acid–base balance in exercise: advantages and limitations of the Stewart analysis. Fedde MR, et al. **Can J Appl Physiol** 1995 Sep;20(3):369–79 (10 ref.)

A quantitative approach to acid–base chemistry. Heigenhauser GJ. **Can J Appl Physiol** 1995 Sep; 20(3):333–40 (20 ref.)

Acid–base balance: origin of plasma [H+] during exercise. Kowalchuk JM, et al. **Can J Appl Physiol** 1995 Sep; 20(3):341–56 (33 ref.)

Origins of [H+] changes in exercising skeletal muscle. Lindinger MI. **Can J Appl Physiol** 1995 Sep;20(3):357–68 (38 ref.)

Getting rid of carbon dioxide during exercise [editorial] Jones NL, et al. **Clin Sci (Colch)** 1996 May;90(5):323–35 (92 ref.)

Structural basis for oxygen delivery: muscle capillaries and manifolds in tuna red muscle. Mathieu–Costello O, et al. **Comp Biochem Physiol A Physiol** 1996 Jan;113(1):25–31 (37 ref.)

Inherited disorders of contractile proteins in skeletal and cardiac muscle. Laing NG. **Curr Opin Neurol** 1995 Oct; 8(5):391–6 (50 ref.)

Exercise and oxidative stress: role of the cellular antioxidant systems. Ji LL. **Exerc Sport Sci Rev** 1995;23:135–66 (140 ref.)

Effects of acute and chronic exercise on fat metabolism. Martin WH 3rd. **Exerc Sport Sci Rev** 1996;24:203–31 (84 ref.)

Control of adenine nucleotide metabolism and glycolysis in vertebrate skeletal muscle during exercise. Krause U, et al. **Experientia** 1996 May 15;52(5):396–403 (51 ref.)

Skeletal muscle as a target for gene therapy [editorial] Partridge T. **Gene Ther** 1994 Mar;1(2):77–9 (31 ref.)

A review of dietary vitamin E supplementation for improvement of beef quality. Liu Q, et al. **J Anim Sci** 1995 Oct;73(10):3131–40 (81 ref.)

Oxidants and antioxidants in exercise. Sen CK. **J Appl Physiol** 1995 Sep;79(3):675–86 (100 ref.)

Potassium regulation during exercise and recovery in humans: implications for skeletal and cardiac muscle. Lindinger MI. **J Mol Cell Cardiol** 1995 Apr;27(4):1011–22 (83 ref.)

Glutamine metabolism and transport in skeletal muscle and heart and their clinical relevance. Rennie MJ, et al. **J Nutr** 1996 Apr;126(4 Suppl):1142S–9S (33 ref.)

Skeletal muscle membrane lipids and insulin resistance. Storlien LH, et al. **Lipids** 1996 Mar;31 Suppl:S261–5 (39 ref.)

Necessary but not sufficient: the role of glucocorticoids in the acidosis–induced increase in levels of mRNAs encoding proteins of the ATP–dependent proteolytic pathway in rat muscle. Price SR, et al. **Miner Electrolyte Metab** 1996; 22(1–3):72–5 (14 ref.)

How does dystrophin deficiency lead to muscle degeneration?—evidence from the mdx mouse. McArdle A, et al. **Neuromuscul Disord** 1995 Nov;5(6):445–56 (78 ref.)

Muscle fuel selection: effect of exercise and training. Henriksson J. **Proc Nutr Soc** 1995 Mar;54(1):125–38 (100 ref.)

Fuel selection, muscle fibre. Hultman E. **Proc Nutr Soc** 1995 Mar;54(1):107–21 (51 ref.)

Factors limiting adenosine triphosphatase function during high intensity exercise. Thermodynamic and regulatory considerations. Korge P. **Sports Med** 1995 Oct;20(4):215–25 (31 ref.)

The ubiquitin–dependent proteolytic pathway in skeletal muscle: its role in pathological states. Argilés JM, et al. **Trends Pharmacol Sci** 1996 Jun;17(6):223–6 (40 ref.)

[Metabolic changes in denervated skeletal muscles] Boćkowski L, et al. **Postepy Hig Med Dosw** 1996; 50(2):191–204 (75 ref.) (Eng. Abstr.) **(Pol)**

PATHOLOGY

Techniques of assessing muscle mass and function (sarcopenia) for epidemiological studies of the elderly. Chumlea WC, et al. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:45–51 (48 ref.)

Loss of skeletal muscle mass with aging: effect on glucose tolerance. Kohrt WM, et al. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:68–72 (43 ref.)

Relationship of age–related decreases in muscle mass and strength to skeletal status. Marcus R. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:86–7 (12 ref.)

Magnetic resonance imaging of the biceps complex. van Leersum M, et al. **Magn Reson Imaging Clin N Am** 1993 Sep;1(1):77–86 (23 ref.)

Phospholipase A2 myotoxins from Bothrops snake venoms. Gutiérrez JM, et al. **Toxicon** 1995 Nov;33(11):1405–24 (129 ref.)

PHYSIOLOGY

The Na+, K+ pump in skeletal muscle: quantification, regulation and functional significance. Clausen T. **Acta Physiol Scand** 1996 Mar;156(3):227–35 (81 ref.)

Effects of K+, Mg2+ deficiency and adrenal steroids on Na+, K(+)–pump concentration in skeletal muscle. Dørup I. **Acta Physiol Scand** 1996 Mar;156(3):305–11 (51 ref.)

Effects of thyroid hormones on contractility and cation transport in skeletal muscle. Everts ME. **Acta Physiol Scand** 1996 Mar;156(3):325–33 (65 ref.)

Effect of intracellular and extracellular ion changes on E–C coupling and skeletal muscle fatigue. Fitts RH, et al. **Acta Physiol Scand** 1996 Mar;156(3):169–81 (91 ref.)

High–and low–frequency fatigue revisited. Jones DA. **Acta Physiol Scand** 1996 Mar;156(3):265–70 (22 ref.)

Slow recovery of force in single skeletal muscle fibres. Lännergren J, et al. **Acta Physiol Scand** 1996 Mar; 156(3):193–202 (59 ref.)

Effects of training on potassium, calcium and hydrogen ion regulation in skeletal muscle and blood during exercise. McKenna MJ, et al. **Acta Physiol Scand** 1996 Mar; 156(3):335–46 (68 ref.)

Ion gradients and contractility in skeletal muscle: the role of active Na+, K+ transport. Nielsen OB, et al. **Acta Physiol Scand** 1996 Mar;156(3):247–56 (70 ref.)

Muscle fatigue in old animals. Unique aspects of fatigue in elderly humans. Faulkner JA, et al. **Adv Exp Med Biol** 1995;384:471–80 (35 ref.)

Mechanisms of excitation–contraction coupling relevant to skeletal muscle fatigue. Stephenson DG, et al. **Adv Exp Med Biol** 1995;384:45–56 (75 ref.)

The scientific contributions of Brenda Bigland–Ritchie. Thomas CK, et al. **Adv Exp Med Biol** 1995;384:11–25 (103 ref.)

Is the intracellular pH threshold an anaerobic threshold from the view point of intracellular events?: a brief review. Iwanaga K, et al. **Appl Human Sci** 1996 Mar;15(2):59–65 (53 ref.)

Skeletal muscle ventricles: frontiers in 1995. Isoda S, et al. **Artif Organs** 1996 Feb;20(2):114–9 (33 ref.)

The role of intracellular pH in the control of adenosine output from red skeletal muscle. Ballard HJ. **Biol Signals** 1995 May–Jun;4(3):168–73 (21 ref.)

Eccentric activation and muscle damage: biomechanical and physiological considerations during downhill running. Eston RG, et al. **Br J Sports Med** 1995 Jun;29(2):89–94 (53 ref.)

Concentric and eccentric knee extension strength in older and younger men and women. Porter MM, et al. **Can J Appl Physiol** 1995 Dec;20(4):429–39 (38 ref.)

Glenohumeral joint stability. Selective cutting studies on the static capsular restraints. Curl LA, et al. **Clin Orthop** 1996 Sep;(330):54–65 (36 ref.)

Glucose transporters and insulin receptors in skeletal muscle. Physiology and pathophysiology. Handberg A. **Dan Med Bull** 1995 Jun;42(3):211–26 (173 ref.)

Regulation of muscle differentiation by the MEF2 family of MADS box transcription factors. Olson EN, et al. **Dev Biol** 1995 Nov;172(1):2–14 (102 ref.)

A review of the role of the agonist/antagonist muscle pairs ratio in rehabilitation. Calmels P, et al. **Disabil Rehabil** 1995 Aug–Sep;17(6):265–76 (54 ref.)

Thyroid hormone: modulation of muscle structure, function,

and adaptive responses to mechanical loading. Caiozzo VJ, et al. **Exerc Sport Sci Rev** 1996;24:321–61 (159 ref.)
Magnetic resonance imaging and spectroscopy in studying exercise in children. Cooper DM, et al.
Exerc Sport Sci Rev 1996;24:475–99 (78 ref.)
Contractile activity–induced mitochondrial biogenesis in skeletal muscle. Essig DA. **Exerc Sport Sci Rev** 1996; 24:289–319 (94 ref.)
Muscle mechanics: adaptations with exercise–training. Fitts RH, et al. **Exerc Sport Sci Rev** 1996;24:427–73 (139 ref.)
Changes in movement capabilities with aging. Grabiner MD, et al. **Exerc Sport Sci Rev** 1995;23:65–104 (230 ref.)
From motor unit to whole muscle properties during locomotor movements. Heckman CJ, et al.
Exerc Sport Sci Rev 1996;24:109–33 (68 ref.)
Force–sharing among synergistic muscles: theoretical considerations and experimental approaches. Herzog W. **Exerc Sport Sci Rev** 1996;24:173–202 (118 ref.)
Strength and power training: physiological mechanisms of adaptation. Kraemer WJ, et al. **Exerc Sport Sci Rev** 1996; 24:363–97 (158 ref.)
Response of the neuromuscular unit to spaceflight: what has been learned from the rat model. Roy RR, et al.
Exerc Sport Sci Rev 1996;24:399–425 (72 ref.)
The role of the skeletal muscle myosin light chains N–terminal fragments. Stępkowski D. **FEBS Lett** 1995 Oct 23;374(1):6–11 (52 ref.)
Extensor physiology in the hand and wrist. Thompson ST, et al. **Hand Clin** 1995 Aug;11(3):367–71 (16 ref.)
Adaptation of human skeletal muscle to exercise–training. Simoneau JA. **Int J Obes Relat Metab Disord** 1995 Oct; 19 Suppl 4:S9–13 (47 ref.)
Variability in metabolic rate: biological sites of regulation. Tataranni PA, et al. **Int J Obes Relat Metab Disord** 1995 Oct;19 Suppl 4:S102–6 (27 ref.)
Cytokines in aging and muscle homeostasis. Cannon JG.
J Gerontol A Biol Sci Med Sci 1995 Nov;50 Spec No:120–3 (39 ref.)
Factors influencing the repair and adaptation of muscles in aged individuals: satellite cells and innervation. Carlson BM. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:96–100 (34 ref.)
What insights into age–related changes in skeletal muscle are provided by animal models? Cartee GD.
J Gerontol A Biol Sci Med Sci 1995 Nov;50 Spec No:137–41 (43 ref.)
From muscle properties to human performance, using magnetic resonance. Conley KE, et al.
J Gerontol A Biol Sci Med Sci 1995 Nov;50 Spec No:35–40 (30 ref.)
Effects of exercise on body composition and functional capacity of the elderly. Evans WJ.
J Gerontol A Biol Sci Med Sci 1995 Nov;50 Spec No:147–50 (23 ref.)
Muscle performance and structure in the elderly as studied cross–sectionally and longitudinally. Grimby G.
J Gerontol A Biol Sci Med Sci 1995 Nov;50 Spec No:17–22 (22 ref.)
Age, gender, and muscular strength. Hurley BF.
J Gerontol A Biol Sci Med Sci 1995 Nov;50 Spec No:41–4 (50 ref.)
Muscle function and mobility biomechanics in the elderly: an overview of some recent research. Schultz AB.
J Gerontol A Biol Sci Med Sci 1995 Nov;50 Spec No:60–3 (29 ref.)
Trophic factor supplementation: effect on the age–associated changes in body composition. Schwartz RS.
J Gerontol A Biol Sci Med Sci 1995 Nov;50 Spec No:151–6 (53 ref.)
Strength and aerobic training attenuate muscle wasting and improve resistance to the development of disability with aging. Tseng BS, et al. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:113–9 (49 ref.)
Relationship of muscular strength to jaw posture in sports dentistry. Gelb H, et al. **N Y State Dent J** 1995 Nov; 61(9):58–66 (0 ref.)
The significance of smooth and striated muscles in the sphincter function of the urethra in healthy women. Thind P. **Neurourol Urodyn** 1995;14(6):585–618 (289 ref.)
The influence of subject and test design on dynamometric measurements of extremity muscles. Keating JL, et al.
Phys Ther 1996 Aug;76(8):866–89 (224 ref.)
Dynamics of nerve–muscle interaction in developing and mature neuromuscular junctions. Grinnell AD.
Physiol Rev 1995 Oct;75(4):789–834 (619 ref.)
Effects of exercise training in the elderly: impact of progressive– resistance training on skeletal muscle and whole–body protein metabolism. Fielding RA.
Proc Nutr Soc 1996 Nov;54(3):665–75 (58 ref.)
Muscle fuel selection: effect of exercise and training. Henriksson J. **Proc Nutr Soc** 1995 Mar;54(1):125–38 (100 ref.)
Aging of human muscle: structure, function and adaptability [see comments] Porter MM, et al.
Scand J Med Sci Sports 1995 Jun;5(3):129–42 (122 ref.)
Comment in: Scand J Med Sci Sports 1995 Jun;5(3):127–8.
The role of quadriceps exercise in the treatment of patellofemoral pain syndrome. Callaghan MJ, et al.
Sports Med 1996 May;21(5):384–91 (55 ref.)
[The role of muscle, adipose tissue and liver in development of metabolic syndrome] Krotkiewski M. **Pol Tyg Lek** 1996 Jan;51(1–5):40–5 (55 ref.) **(Pol)**

PHYSIOPATHOLOGY

Na+, K(+)-pump activity and skeletal muscle contractile deficits in the spontaneously hypertensive rat. Carlsen RC, et al. **Acta Physiol Scand** 1996 Mar;156(3):237–45 (24 ref.)
Role of skeletal muscle sodium pumps in the adaptation to potassium deprivation. McDonough AA, et al.
Acta Physiol Scand 1996 Mar;156(3):295–304 (77 ref.)
Exercise–induced muscle damage and inflammation: a review. Pyne DB. **Aust J Sci Med Sport** 1994 Sep–Dec; 26(3–4):49–58 (133 ref.)
A carrier of Duchenne muscular dystrophy with dilated cardiomyopathy but no skeletal muscle symptom. Kinoshita H, et al. **Brain Dev** 1995 May–Jun;17(3):202–5 (11 ref.)
Muscle compliance: implications for the control of movement. Gottlieb GL. **Exerc Sport Sci Rev** 1996;24:1–34 (50 ref.)
Reversing sarcopenia: how weight training can build strength and vitality. Evans WJ. **Geriatrics** 1996 May;51(5):46–7, 51–3; quiz 54 (18 ref.)
What is sarcopenia? Evans WJ.
J Gerontol A Biol Sci Med Sci 1995 Nov;50 Spec No:5–8 (36 ref.)
Muscle atrophy and weakness with aging:
contraction–induced injury as an underlying mechanism. Faulkner JA, et al. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:124–9 (36 ref.)
Functional consequences of sarcopenia: effects on thermoregulation. Kenney WL, et al.
J Gerontol A Biol Sci Med Sci 1995 Nov;50 Spec No:78–85 (73 ref.)
Sarcopenia in aging humans: the impact of menopause and disease. Poehlman ET, et al.
J Gerontol A Biol Sci Med Sci 1995 Nov;50 Spec No:73–7 (25 ref.)
Interventions based on the possibility that oxidative stress contributes to sarcopenia. Weindruch R.
J Gerontol A Biol Sci Med Sci 1995 Nov;50 Spec No:157–61 (54 ref.)
Inflammatory cell response to acute muscle injury. Tidball JG. **Med Sci Sports Exerc** 1995 Jul;27(7):1022–32 (118 ref.)
How does dystrophin deficiency lead to muscle degeneration?--evidence from the mdx mouse. McArdle A, et al. **Neuromuscul Disord** 1995 Nov;5(6):445–56 (78 ref.)
Electromyography and biomechanics of a dynamic knee brace for anterior cruciate ligament deficiency. Acierno SP, et al. **Orthopedics** 1995 Nov;18(11):1101–7 (33 ref.)
Malignant hyperthermia: excitation–contraction coupling, Ca2+ release channel, and cell Ca2+ regulation defects. Mickelson JR, et al. **Physiol Rev** 1996 Apr;76(2):537–92 (433 ref.)
Rhabdomyolysis following electrical injury. Brumback RA, et al. **Semin Neurol** 1995 Dec;15(4):329–34 (22 ref.)

RADIOGRAPHY

Iliopsoas compartment: normal anatomy and pathologic processes. Torres GM, et al. **Radiographics** 1995 Nov; 15(6):1285–97 (12 ref.)

TRANSPLANTATION

Commentary on the present state of knowledge for myoblast transfer therapy [comment] Grounds MD.
Cell Transplant 1996 May–Jun;5(3):431–3 (14 ref.)
Comment on: Cell Transplant 1996 May–Jun;5(3):421–9.
Skeletal muscle as a myocardial substitute. Greer KA, et al.
Proc Soc Exp Biol Med 1996 Apr;211(4):297–305 (36 ref.)

ULTRASTRUCTURE

Design of the oxygen and substrate pathways. VII. Different structural limits for oxygen and substrate supply to muscle mitochondria. Weibel ER, et al. **J Exp Biol** 1996 Aug;199 (Pt 8):1699–709 (18 ref.)
Evolution of myosin filament arrangements in vertebrate skeletal muscle. Luther PK, et al. **J Morphol** 1996 Sep; 229(3):325–35 (28 ref.)

MUSCLE, SMOOTH

Smooth muscle tumours of the pleura. Gibbs AR.
Histopathology 1995 Sep;27(3):295–6 (17 ref.)

ANATOMY & HISTOLOGY

Functional anatomy of the organs of micturition. Elbadawi A. **Urol Clin North Am** 1996 May;23(2):177–210 (255 ref.)

BLOOD SUPPLY

The penis as a vascular organ. The importance of corporal smooth muscle tone in the control of erection. Christ GJ. **Urol Clin North Am** 1995 Nov;22(4):727–45 (77 ref.)

CHEMISTRY

[Collagens in intestinal smooth muscles] Le Blay G, et al. **Gastroenterol Clin Biol** 1996 Mar;20(2):185–92 (49 ref.) **(Fre)**

CYTOLOGY

A case for interstitial cells of Cajal as pacemakers and mediators of neurotransmission in the gastrointestinal tract. Sanders KM. **Gastroenterology** 1996 Aug;111(2):492–515 (154 ref.)
Macrophages in the external muscle layers of mammalian intestines. Mikkelsen HB. **Histol Histopathol** 1995 Jul; 10(3):719–36 (92 ref.)
[Application of antisense oligodeoxynucleotides on smooth muscle cells and endothelial cells] Yang HP, et al.
Sheng Li Ko Hsueh Chin Chan 1995 Jul;26(3):259–62 (9 ref.) **(Chi)**
[The cytoskeleton of muscle cells] Dąbrowska R, et al.
Postepy Biochem 1995;41(3):165–74 (156 ref.) **(Pol)**

DRUG EFFECTS

Effects of sex hormones on oncogene expression in the vagina and on development of sexual dimorphism of the pelvis and anococcygeus muscle in the mouse. Iguchi T, et al. **Environ Health Perspect** 1995 Oct;103 Suppl 7:79–82 (34 ref.)
Actions of manganese ions in contraction of smooth muscle. Nasu T. **Gen Pharmacol** 1995 Sep;26(5):945–53 (65 ref.)
Pharmacological basis for duration of effect: formoterol and salmeterol versus short–acting beta 2–adrenoceptor agonists. Lindén A, et al. **Lung** 1996;174(1):1–22 (52 ref.)
Effects of experimental diabetes and insulin on smooth muscle functions. Oztürk Y, et al. **Pharmacol Rev** 1996 Mar; 48(1):69–112 (728 ref.)

ENZYMOLOGY

[The structure of smooth muscle myosin phosphatase] Ito M, et al. **Seikagaku** 1996 Feb;68(2):147–51 (15 ref.) **(Jpn)**

INNERVATION

[The control of smooth muscle tissues by nonadrenergic noncholinergic (NANC) nerve fibres in the autonomic nervous system] Itoh H, et al. **J Smooth Muscle Res** 1995 Jun;31(3):67–78 (41 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Metabolism of detrusor smooth muscle in normal and obstructed urinary bladder. Uvelius B, et al.
Adv Exp Med Biol 1995;385:29–39; discussion 75–9 (42 ref.)
Inositolpolyphosphate binding sites and their likely role in calcium regulation in smooth muscle. Zhang L, et al.
Int J Biochem Cell Biol 1995 Dec;27(12):1231–48 (135 ref.)
Calcium homeostasis in smooth muscle cells. Smith JB.
New Horiz 1996 Feb;4(1):2–18 (137 ref.)
Cross talk between cyclic AMP and the polyphosphoinositide signaling cascade in iris sphincter and other nonvascular smooth muscle. Abdel–Latif AA.
Proc Soc Exp Biol Med 1996 Feb;211(2):163–77 (126 ref.)

PHYSIOLOGY

Developmental aspects of excitation contraction coupling in urinary bladder smooth muscle. Zderic SA, et al.
Adv Exp Med Biol 1995;385:105–15; discussion 131–9 (39 ref.)
The molecular biology of the Na(+)–Ca2+ exchanger and its functional roles in heart, smooth muscle cells, neurons, glia, lymphocytes, and nonexcitable cells. Lederer WJ, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:7–17 (60 ref.)
Molecular mechanisms of beta–adrenergic relaxation of airway smooth muscle. Kotlikoff MI, et al.
Annu Rev Physiol 1996;58:115–41 (164 ref.)
Structure–function relationships in smooth muscle: the missing links. Small JV. **Bioessays** 1995 Sep;17(9):785–92 (86 ref.)
Tyrosine kinase–mediated signal transduction pathways and the actions of polypeptide growth factors and G–protein–coupled agonists in smooth muscle. Hollenberg MD. **Mol Cell Biochem** 1995 Aug–Sep;149–150:77–85 (77 ref.)
The significance of smooth and striated muscles in the sphincter function of the urethra in healthy women. Thind P. **Neurourol Urodyn** 1995;14(6):585–618 (289 ref.)
Geometry, kinetics and plasticity of release and clearance of ATP and noradrenaline as sympathetic cotransmitters: roles for the neurogenic contraction. Stjärne L, et al.
Prog Neurobiol 1995 Sep;47(1):45–94 (145 ref.)
Airway smooth muscle relaxation. Knox AJ, et al.
Thorax 1995 Aug;50(8):894–901 (115 ref.)
Smooth–muscle physiology. Zimmern PE, et al.
Urol Clin North Am 1996 May;23(2):211–9 (45 ref.)
[Second messenger system and regulation of smooth muscle contractile activity in digestive tract] Zheng GH, et al.
Sheng Li Ko Hsueh Chin Chan 1995 Oct;26(4):359–62 (7 ref.) **(Chi)**
[The muscarinic system of the gastrointestinal smooth muscle] Cuq P. **Gastroenterol Clin Biol** 1995 Aug–Sep; 19(8–9):675–84 (101 ref.) **(Fre)**
[The contractile properties of uterine smooth muscle from physiological viewpoint] Ochiai K.
Nippon Sanka Fujinka Gakkai Zasshi 1995 Aug;47(8):791–6 (26 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Role of airway smooth muscle. Black JL.
Am J Respir Crit Care Med 1996 Jun;153(6 Pt 2):S2–4 (39 ref.)

MUSCLE, SMOOTH, VASCULAR

Cell calcium and arterial blood pressure. Gonzalez JM, et al. **Semin Nephrol** 1995 Nov;15(6):564–8 (56 ref.)

CHEMISTRY

Localization of the Na(+)–Ca2+ exchanger in vascular smooth muscle, and in neurons and astrocytes. Juhaszova M, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:318–35 (31 ref.)

CYTOLOGY

Unique growth properties of neonatal pulmonary vascular cells: importance of time- and site-specific responses, cell-cell interaction, and synergy. Dempsey EC, et al. **J Perinatol** 1996 Mar–Apr;16(2 Pt 2 Su):S2–11 (67 ref.)

[Agents inducing cell death of the vascular wall] Munsch B, et al. **Ann Biol Clin (Paris)** 1995;53(9):473–80 (88 ref.) (Eng. Abstr.) **(Fre)**

[Phenotypic change of the smooth muscle cell and atherosclerosis] Mori S, et al. **Nippon Yakurigaku Zasshi** 1996 Mar;107(3):161–70 (50 ref.) (Eng. Abstr.) **(Jpn)**

DRUG EFFECTS

New insights into mechanisms underlying nitrate tolerance. Münzel T, et al. **Am J Cardiol** 1996 May 30;77(13):24C–30C (41 ref.)

Non-genomic effects of estrogen and the vessel wall. Farhat MY, et al. **Biochem Pharmacol** 1996 Mar 8;51(5):571–6 (78 ref.)

Endothelin-1 and the regulation of vascular tone. La M, et al. **Clin Exp Pharmacol Physiol** 1995 May;22(5):315–23 (85 ref.)

The vascular protective effects of estrogen. Farhat MY, et al. **FASEB J** 1996 Apr;10(5):615–24 (123 ref.)

Comparison of the effect of dopamine in primate arteries and veins. Okamura T, et al. **Hypertens Res** 1995 Jun;18 Suppl 1:S35–7 (19 ref.)

Glucose-induced vascular smooth muscle dysfunction: the role of protein kinase C. Williams B. **J Hypertens** 1995 May;13(5):477–86 (96 ref.)

Pharmacological and physiological significance of ion channels and factors that modulate them in vascular tissues. Kuriyama H, et al. **Pharmacol Rev** 1995 Sep;47(3):387–573 (3527 ref.)

Vascular actions of the calcium-regulating hormones. Bukoski RD, et al. **Semin Nephrol** 1995 Nov;15(6):536–49 (154 ref.)

Mechanisms of calcium's effects on blood pressure. Hatton DC, et al. **Semin Nephrol** 1995 Nov;15(6):593–602 (111 ref.)

ENZYMOLOGY

Cyclic nucleotide phosphodiesterases and vascular smooth muscle. Polson JB, et al. **Annu Rev Pharmacol Toxicol** 1996; 36:403–27 (87 ref.)

GROWTH & DEVELOPMENT

Mitogen-responsive nuclear factors that mediate growth control signals in vascular myocytes. Gorski DH, et al. **Cardiovasc Res** 1995 Oct;30(4):585–92 (114 ref.)

INNERVATION

Regulation of blood pressure by nitroxidergic nerve. Toda N. **J Diabetes Complications** 1995 Oct–Dec;9(4):200–2 (21 ref.)

METABOLISM

Angiotensin II signal transduction and the mitogen-activated protein kinase pathway. Duff JL, et al. **Cardiovasc Res** 1995 Oct;30(4):511–7 (102 ref.)

Ion channels, oxygen sensation and signal transduction in pulmonary arterial smooth muscle. Kozlowski RZ. **Cardiovasc Res** 1995 Sep;30(3):318–25 (73 ref.)

Insight into atherosclerosis: a review of c-myc and the vascular smooth muscle cell. Golja AM, et al. **Cell Mol Biol Res** 1995;41(6):487–99 (74 ref.)

Modulation of Ca2+ channels by alpha 1A- and alpha 2A-adrenoceptors in vascular myocytes: involvement of different transduction pathways. Mironneau J, et al. **Cell Signal** 1995 Jul;7(5):471–9 (29 ref.)

Stretch-induced parathyroid hormone-related peptide gene expression: implication in the regulation of myogenic tone. Noda M, et al. **Curr Opin Nephrol Hypertens** 1995 Sep; 4(5):383–7 (23 ref.)

Parathyroid hormone-related peptide and models of vascular disease: its expression and action in vascular smooth muscle cells. Nishizawa Y, et al. **Miner Electrolyte Metab** 1995; 21(1–3):152–6 (36 ref.)

[Role of glycosoaminoglycans in venous disease. Mode of action of some flavonoid drugs] Drubaix I, et al. **Pathol Biol (Paris)** 1995 May;43(5):461–70 (37 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Mechanisms and prevention of restenosis: from experimental models to clinical practice. Bauters C, et al. **Cardiovasc Res** 1996 Jun;31(6):835–46 (181 ref.)

The pathogenesis of graft vascular disease: implications of vascular remodeling. Gibbons GH. **J Heart Lung Transplant** 1995 Nov–Dec;14(6 Pt 2):S149–58 (59 ref.)

Vascular structure, smooth muscle cell phenotype and growth in hypertension. Lindop GB, et al. **J Hum Hypertens** 1995 Jun;9(6):475–8 (44 ref.)

Is vascular smooth muscle cell proliferation beneficial? Weissberg PL, et al. **Lancet** 1996 Feb 3;347(8997):305–7 (22 ref.)

Inhibition of intravascular thrombosis and vascular smooth muscle cell proliferation by gene therapy. Flugelman MY. **Thromb Haemost** 1995 Jul;74(1):406–10 (35 ref.)

[Arterial wall texture after uncomplicated endarterectomy] Bürrig KF, et al. **Pathologe** 1995 Sep;16(5):336–41 (49 ref.) (Eng. Abstr.) **(Ger)**

[Experimental approaches for gene therapy modification of vascular remodeling] von der Leyen HE, et al. **Z Kardiol** 1995 Oct;84(10):791–7 (62 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Scatter factor and angiogenesis. Rosen EM, et al. **Adv Cancer Res** 1995;67:257–79 (93 ref.)

New concepts of regulation of retinal vessel tone. Brown SM, et al. **Arch Ophthalmol** 1996 Feb;114(2):199–204 (58 ref.)

Angiotensin II-mediated signal transduction events in vascular smooth muscle cells: kinases and phosphatases. Duff JL, et al. **Blood Press Suppl** 1995;2:55–60 (68 ref.)

Gene expression and vascular smooth muscle cell phenotype. Weissberg PL, et al. **Blood Press Suppl** 1995;2:68–73 (19 ref.)

Vascular alpha-adrenoceptors: from the gene to the human. Bylund DB, et al. **Can J Physiol Pharmacol** 1995 May; 73(5):533–43 (87 ref.)

Regulation of vascular tone: cross-talk between sarcoplasmic reticulum and plasmalemma. Daniel EE, et al. **Can J Physiol Pharmacol** 1995 May;73(5):551–7 (46 ref.)

Regulation of vascular tone. Rossitti S, et al. **Can J Physiol Pharmacol** 1995 May;73(5):544–50 (43 ref.)

Intracellular mechanisms involved in the regulation of vascular smooth muscle tone. Walsh MP, et al. **Can J Physiol Pharmacol** 1995 May;73(5):565–73 (53 ref.)

Signalling mechanisms in the regulation of vascular cell migration. Abedi H, et al. **Cardiovasc Res** 1995 Oct; 30(4):544–56 (145 ref.)

Thrombin and proliferation of vascular smooth muscle cells. Fager G. **Circ Res** 1995 Oct;77(4):645–50 (73 ref.)

Age-related changes in vascular smooth muscle and endothelium. Dohi Y, et al. **Drugs Aging** 1995 Oct; 7(4):278–91 (141 ref.)

Hypoxic and metabolic regulation of voltage-gated K+ channels in rat pulmonary artery smooth muscle cells. Yuan XJ, et al. **Exp Physiol** 1995 Sep;80(5):803–13 (24 ref.)

Superoxide anion and endothelial regulation of arterial tone. Katusic ZS. **Free Radic Biol Med** 1996;20(3):443–8 (52 ref.)

Vascular smooth muscle polyploidy in genetic hypertension: the role of angiotensin II. Devlin AM, et al. **J Hum Hypertens** 1995 Jun;9(6):497–500 (16 ref.)

Diversity of phenotype and function of vascular smooth muscle cells. Archer SL. **J Lab Clin Med** 1996 Jun; 127(6):524–9 (43 ref.)

Alterations in extracellular matrix protein expression in neonatal pulmonary hypertension: implications for vascular function. Durmowicz AG, et al. **J Perinatol** 1996 Mar–Apr; 16(2 Pt 2 Su):S11–8 (39 ref.)

Calcium channels in vascular smooth muscle cells. Hughes AD. **J Vasc Res** 1995 Nov–Dec;32(6):353–70 (294 ref.)

Mechanotransduction by vascular smooth muscle. Osol G. **J Vasc Res** 1995 Sep–Oct;32(5):275–92 (163 ref.)

The insulin-like growth factor system in vascular smooth muscle: interaction with insulin and growth factors. Arnqvist HJ, et al. **Metabolism** 1995 Oct;44(10 Suppl 4):58–66 (102 ref.)

Paracrine functions of the coronary vascular endothelium. Fleming I, et al. **Mol Cell Biochem** 1996 Apr 12–26; 157(1–2):137–45 (49 ref.)

Effects of oxidized low-density lipoprotein on vascular contraction and relaxation: clinical and pharmacological implications in atherosclerosis. Cox DA, et al. **Pharmacol Rev** 1996 Mar;48(1):3–19 (182 ref.)

Pharmacological and physiological significance of ion channels and factors that modulate them in vascular tissues. Kuriyama H, et al. **Pharmacol Rev** 1995 Sep;47(3):387–573 (3527 ref.)

Calcium sparks in vascular smooth muscle: relaxation regulators [comment] Fay FS. **Science** 1995 Oct 27; 270(5236):588–9 (15 ref.) Comment on: Science 1995 Oct 27;270(5236):633–7.

[Hyperpolarization-relaxation coupling in vascular smooth muscle] Yanagisawa T. **Nippon Yakurigaku Zasshi** 1995 Sep;106(3):157–69 (57 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

Pathophysiology of smooth muscle in hypertension. Lee RM, et al. **Can J Physiol Pharmacol** 1995 May;73(5):574–84 (103 ref.)

Smooth muscle cells and atherosclerosis. Stein O, et al. **Curr Opin Lipidol** 1995 Oct;6(5):269–74 (54 ref.)

Mechanisms of abnormal vasoreactivity in persistent pulmonary hypertension of the newborn infant. Abman SH, et al. **J Perinatol** 1996 Mar–Apr;16(2 Pt 2 Su):S18–23 (44 ref.)

[Cerebral vasospasm following subarachnoid hemorrhage as studied from the mechanism of physiological smooth muscle contraction] Sakaki S, et al. **No Shinkei Geka** 1996 Jan;24(1):19–28 (34 ref.) **(Jpn)**

MUSCLE SPASTICITY

see related
SPASM

DIAGNOSIS

[Chronic progressive spinobulbar spasticity (primary lateral sclerosis)] Heene R, et al. **Fortschr Neurol Psychiatr** 1996 May;64(5):192–203 (42 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Progressive kyphosis and neurologic compromise complicating spondylothoracic dysplasia in infancy (Jarcho-Levin syndrome). Mooney JF 3rd, et al. **Spine** 1995 Sep 1;20(17):1938–42 (8 ref.)

PHYSIOPATHOLOGY

Mechanical and electromyographic stretch responses in spastic and healthy subjects. Toft E. **Acta Neurol Scand Suppl** 1995;163:1–24 (103 ref.)

MUSCLE SPINDLES

see related
REFLEX, STRETCH

PHYSIOLOGY

The fusimotor system. Its role in fatigue. Hagbarth KE, et al. **Adv Exp Med Biol** 1995;384:259–70 (68 ref.)

ULTRASTRUCTURE

[Cytoskeleton and differentiation. Genetic regulation of intermediate filaments in the neuromuscular system] Li Z, et al. **Arch Inst Pasteur Tunis** 1994 Jul–Oct;71(3–4):419–30 (48 ref.) **(Fre)**

MUSCLE STRETCH RECEPTORS see **MUSCLE SPINDLES**

MUSCLE, STRIATED see **MUSCLE, SKELETAL**

MUSCLE TONUS

see related
DYSTONIA
MUSCLE HYPOTONIA

PHYSIOLOGY

Intracellular mechanisms involved in the regulation of vascular smooth muscle tone. Walsh MP, et al. **Can J Physiol Pharmacol** 1995 May;73(5):565–73 (53 ref.)

Stretch-induced parathyroid hormone-related peptide gene expression: implication in the regulation of myogenic tone. Noda M, et al. **Curr Opin Nephrol Hypertens** 1995 Sep; 4(5):383–7 (23 ref.)

Superoxide anion and endothelial regulation of arterial tone. Katusic ZS. **Free Radic Biol Med** 1996;20(3):443–8 (52 ref.)

The penis as a vascular organ. The importance of corporal smooth muscle tone in the control of erection. Christ GJ. **Urol Clin North Am** 1995 Nov;22(4):727–45 (77 ref.)

MUSCLE, VOLUNTARY see **MUSCLE, SKELETAL**

MUSCLE WEAKNESS

Clues to the diagnosis of amyotrophic lateral sclerosis. Cambier J, et al. **Adv Neurol** 1995;68:161–2 (12 ref.)

Fatigue and weakness in cancer patients: the symptoms experience. Nail LM, et al. **Semin Oncol Nurs** 1995 Nov; 11(4):272–8 (42 ref.)

[Post-polio syndrome; the limit of neuromuscular adaptation?] Nollet F, et al. **Ned Tijdschr Geneeskd** 1996 Jun 1;140(22):1169–73 (39 ref.) **(Dut)**

DIAGNOSIS

Muscle weakness and myalgia. MR imaging investigation. Fleckenstein JL. **Magn Reson Imaging Clin N Am** 1995 Nov;3(4):773–803 (43 ref.)

Measurement of respiratory muscle strength [editorial] Polkey MI, et al. **Thorax** 1995 Nov;50(11):1131–5 (67 ref.)

DIET THERAPY

Exercise, nutrition, and aging. Evans WJ. **Clin Geriatr Med** 1995 Nov;11(4):725–34 (49 ref.)

DRUG THERAPY

Effect of anabolic hormones and insulin-like growth factor-I on muscle mass and strength in elderly persons. Carter WJ. **Clin Geriatr Med** 1995 Nov;11(4):735–48 (63 ref.)

ETIOLOGY

Neurologic complications in critically ill patients. Wijdicks EF. **Anesth Analg** 1996 Aug;83(2):411–9 (60 ref.)
Progressive kyphosis and neurologic compromise complicating spondylothoracic dysplasia in infancy (Jarcho–Levin syndrome). Mooney JF 3rd, et al. **Spine** 1995 Sep 1;20(17):1938–42 (8 ref.)

PHYSIOPATHOLOGY

Postpoliomyelitis syndrome problems of knee function: a review. Grant AD, et al. **Bull Hosp Jt Dis** 1993–95; 53(4):27–9 (16 ref.)
Muscle atrophy and weakness with aging: contraction–induced injury as an underlying mechanism. Faulkner JA, et al. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:124–9 (36 ref.)
Neuromuscular complications in the ICU: the spectrum of critical illness–related conditions causing muscular weakness and weaning failure. Hund EF. **J Neurol Sci** 1996 Mar;136(1–2):10–6 (75 ref.)
[Current viewpoints in the pathophysiology and treatment of muscle weakness in elderly men] Lamberts SW. **Ned Tijdschr Geneeskd** 1996 Jan 13;140(2):68–72 (51 ref.) **(Dut)**

PREVENTION & CONTROL

Exercise, nutrition, and aging. Evans WJ. **Clin Geriatr Med** 1995 Nov;11(4):725–34 (49 ref.)

MUSCLES

see related
SARCOLEMMA
SARCOPLASMIC RETICULUM

Functional morphology and motor control of series–fibered muscles. Trotter JA, et al. **Exerc Sport Sci Rev** 1995; 23:167–213 (155 ref.)

ANATOMY & HISTOLOGY

[Structure and functional significance of the thick filament] Skubiszak L. **Biofizika** 1996 Jan–Feb;41(1):40–57 (65 ref.) (Eng. Abstr.) **(Rus)**

BLOOD SUPPLY

The coupling of glucose metabolism and perfusion in human skeletal muscle. The potential role of endothelium–derived nitric oxide. Baron AD. **Diabetes** 1996 Jan;45 Suppl 1:S105–9 (43 ref.)

CHEMISTRY

Phase transitions and the molecular mechanism of contraction. Pollack GH. **Biophys Chem** 1996 Apr 16; 59(3):315–28 (119 ref.)
Dystrophin–glycoprotein complex: molecular organization and critical roles in skeletal muscle. Sunada Y, et al. **Curr Opin Neurol** 1995 Oct;8(5):379–84 (40 ref.)

CYTOLOGY

A new turn (or two) for twist [comment] Michelson AM. **Science** 1996 Jun 7;272(5267):1449–50 (15 ref.) Comment on: Science 1996 Jun 7;272(5267):1476–80. Comment on: Science 1996 Jun 7;272(5267):1481–4.

DRUG EFFECTS

Avian muscle cells as targets for the secosteroid hormone 1,25–dihydroxy–vitamin D3. Boland R, et al. **Mol Cell Endocrinol** 1995 Oct 30;114(1–2):1–8 (91 ref.)

EMBRYOLOGY

Muscle development. Making Drosophila muscle. Taylor MV. **Curr Biol** 1995 Jul 1;5(7):740–2 (14 ref.)
Cell division and differentiation in avian embryos: techniques for study of early neurogenesis and myogenesis. Sechrist J, et al. **Methods Cell Biol** 1996;51:301–29 (57 ref.)

ENZYMOLOGY

Mutations in muscle phosphofructokinase gene. Raben N, et al. **Hum Mutat** 1995;6(1):1–6 (37 ref.)
In vivo regulation of muscle glycogen synthase and the control of glycogen synthesis. Shulman RG, et al. **Proc Natl Acad Sci U S A** 1995 Sep 12;92(19):8535–42 (64 ref.)

GROWTH & DEVELOPMENT

Regulatory role of ATP at developing neuromuscular junctions. Fu WM. **Prog Neurobiol** 1995 Sep;47(1):31–44 (101 ref.)

INNERVATION

Paradoxical clinical consequences of peripheral nerve injury: a review of anatomical, neurophysiological and psychological mechanisms. McAllister RM, et al. **Br J Plast Surg** 1995 Sep;48(6):384–95 (159 ref.)
Regulatory role of ATP at developing neuromuscular junctions. Fu WM. **Prog Neurobiol** 1995 Sep;47(1):31–44 (101 ref.)
[Exteroceptive suppression of voluntary muscular activity: a new method of studying central nociceptive mechanisms] Danilov AB, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995;95(3):90–5 (59 ref.) **(Rus)**

METABOLISM

Ion channels in the sarcoplasmic reticulum of striated muscle. Dulhunty AF, et al. **Acta Physiol Scand** 1996 Mar; 156(3):375–85 (48 ref.)
Membrane abnormalities and Ca homeostasis in muscles of the mdx mouse, an animal model of the Duchenne muscular dystrophy: a review. Gillis JM. **Acta Physiol Scand** 1996 Mar;156(3):397–406 (57 ref.)
An integrative view of limitations to muscular performance. Dempsey JA, et al. **Adv Exp Med Biol** 1995;384:393–9 (17 ref.)
Fatigue and the design of the respiratory system. Lindstedt SL, et al. **Adv Exp Med Biol** 1995;384:383–91 (20 ref.)
Mechanisms of human muscle fatigue. Quantitating the contribution of metabolic factors and activation impairment. Miller RG, et al. **Adv Exp Med Biol** 1995; 384:195–210 (38 ref.)
Tryptophan, 5–hydroxytryptamine and a possible explanation for central fatigue. Newsholme EA, et al. **Adv Exp Med Biol** 1995;384:315–20 (16 ref.)
Metabolic correlates of fatigue from different types of exercise in man. Vøllestad NK. **Adv Exp Med Biol** 1995; 384:185–94 (37 ref.)
The coupling of glucose metabolism and perfusion in human skeletal muscle. The potential role of endothelium–derived nitric oxide. Baron AD. **Diabetes** 1996 Jan;45 Suppl 1:S105–9 (43 ref.)
Potential role of bradykinin in forearm muscle metabolism in humans. Dietze GJ, et al. **Diabetes** 1996 Jan;45 Suppl 1:S110–4 (43 ref.)
Significance of insulin for glucose metabolism in skeletal muscle during contractions. Hespel P, et al. **Diabetes** 1996 Jan;45 Suppl 1:S99–104 (61 ref.)
Skeletal muscle kallikrein. Potential role in metabolic regulation. Mayfield RK, et al. **Diabetes** 1996 Jan;45 Suppl 1:S20–3 (34 ref.)
Nuclear magnetic resonance studies of muscle and applications to exercise and diabetes. Shulman RG, et al. **Diabetes** 1996 Jan;45 Suppl 1:S93–8 (20 ref.)
Insulin–induced redistribution of GLUT4 glucose carriers in the muscle fiber. In search of GLUT4 trafficking pathways. Zorzano A, et al. **Diabetes** 1996 Jan;45 Suppl 1:S70–81 (120 ref.)
Avian muscle cells as targets for the secosteroid hormone 1,25–dihydroxy–vitamin D3. Boland R, et al. **Mol Cell Endocrinol** 1995 Oct 30;114(1–2):1–8 (91 ref.)

PATHOLOGY

[Neurogenic muscle hypertrophy: 3 cases] Deffond D, et al. **Rev Neurol (Paris)** 1996 Apr;152(4):272–8 (45 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Mechanical and electromyographic stretch responses in spastic and healthy subjects. Toft E. **Acta Neurol Scand Suppl** 1995;163:1–24 (103 ref.)
Fatigue vs. shortening–induced deactivation in striated muscle. Edman KA. **Acta Physiol Scand** 1996 Mar; 156(3):183–92 (43 ref.)
Muscular function, metabolism and electrolyte shifts during prolonged repetitive exercise in humans. Vøollestad NK, et al. **Acta Physiol Scand** 1996 Mar;156(3):271–8 (38 ref.)
Bioenergetics and muscle cell types. Kushmerick MJ. **Adv Exp Med Biol** 1995;384:175–84 (55 ref.)
Intramuscular pressures for monitoring different tasks and muscle conditions. Sejersted OM, et al. **Adv Exp Med Biol** 1995;384:339–50 (56 ref.)
The kinetic cycles of myosin, kinesin, and dynein. Hackney DD. **Annu Rev Physiol** 1996;58:731–50 (126 ref.)
A personal view of muscle and motility mechanisms. Huxley HE. **Annu Rev Physiol** 1996;58:1–19 (50 ref.)
Phase transitions and the molecular mechanism of contraction. Pollack GH. **Biophys Chem** 1996 Apr 16; 59(3):315–28 (119 ref.)
Morphology and mechanics of muscle: two or one? Huyghe JM. **Eur J Morphol** 1996;34(1):3–4 (8 ref.)
Muscle cell function during prolonged activity: cellular mechanisms of fatigue. Allen DG, et al. **Exp Physiol** 1995 Jul;80(4):497–527 (140 ref.)
The utility of isokinetic dynamometry in the assessment of human muscle function. Gleeson NP, et al. **Sports Med** 1996 Jan;21(1):18–34 (86 ref.)
Applied physiology of water–skiing. Leggett SH, et al. **Sports Med** 1996 Apr;21(4):262–76 (30 ref.)
Use of exercise for treatment of chronic fatigue syndrome. McCully KK, et al. **Sports Med** 1996 Jan;21(1):35–48 (78 ref.)
Insect sound production: transduction mechanisms and impedance matching. Bennet–Clark HC. **Symp Soc Exp Biol** 1995;49:199–218 (33 ref.)
[Structure and functional significance of the thick filament] Skubiszak L. **Biofizika** 1996 Jan–Feb;41(1):40–57 (65 ref.) (Eng. Abstr.) **(Rus)**
[The perception of muscle loading and the role of locomotor and respiratory sensation] Breslav IS. **Fiziol Zh Im I M Sechenova** 1994 Dec;80(12):10–20 (69 ref.) **(Rus)**
[Exteroceptive suppression of voluntary muscular activity: a new method of studying central nociceptive mechanisms] Danilov AB, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995;95(3):90–5 (59 ref.) **(Rus)**

PHYSIOPATHOLOGY

Muscular function in chronic renal failure. Laville M, et al. **Adv Nephrol Necker Hosp** 1995;24:245–69 (120 ref.)

TRANSPLANTATION

Transmission of disease through transplantation of musculoskeletal allografts. Tomford WW. **J Bone Joint Surg Am** 1995 Nov;77(11):1742–54 (164 ref.)

ULTRASTRUCTURE

Ultrastructure of invertebrate muscle cell types. Paniagua R, et al. **Histol Histopathol** 1996 Jan;11(1):181–201 (151 ref.)

MUSCULAR ATROPHY

[Diagnosis and therapy of juvenile muscular atrophy of distal upper extremity] Hirayama K. **Nippon Naika Gakkai Zasshi** 1996 Mar 10;85(3):393–8 (8 ref.) **(Jpn)**

ETIOLOGY

[Neuralgic shoulder amyotrophy] Cranovsky C. **Schweiz Med Wochenschr** 1996 Jan 27;126(4):111–9 (40 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Muscle atrophy and weakness with aging: contraction–induced injury as an underlying mechanism. Faulkner JA, et al. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:124–9 (36 ref.)

PREVENTION & CONTROL

Reversing sarcopenia: how weight training can build strength and vitality. Evans WJ. **Geriatrics** 1996 May;51(5):46–7, 51–3; quiz 54 (18 ref.)

RADIONUCLIDE IMAGING

Hemiatrophy, juvenile–onset exertional alternating leg paresis, hypotonia, and hemidystonia and adult–onset hemiparkinsonism: the spectrum of hemiparkinsonism–hemiatrophy syndrome. Lang AE. **Mov Disord** 1995 Jul;10(4):489–95 (32 ref.)

MUSCULAR ATROPHY, POSTPOLIOMYELITIS see **POSTPOLIOMYELITIS SYNDROME**

MUSCULAR ATROPHY, SPINAL

COMPLICATIONS

[Cardiac involvement in Kugelberg–Welander disease. A prospective study of 8 cases] Elkohen M, et al. **Arch Mal Coeur Vaiss** 1996 May;89(5):611–7 (26 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

[Hiramaya disease: disease or syndrome?] Billé–Turc F, et al. **Rev Neurol (Paris)** 1996 Jan;152(1):20–6 (12 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

X–linked recessive bulbospinal neuronopathy (SBMA). Sobue G. **Nagoya J Med Sci** 1995 Dec;58(3–4):95–106 (41 ref.)
From enigmatic to problematic: the new molecular genetics of childhood spinal muscular atrophy. Crawford TO. **Neurology** 1996 Feb;46(2):335–40 (54 ref.)
The expanded trinucleotide repeat in Kennedy's disease. Fischbeck KH. **Proc Assoc Am Physicians** 1995 Jul; 107(2):228–30 (9 ref.)
Spinal and bulbar muscular atrophy: a trinucleotide–repeat expansion neurodegenerative disease. Brooks BP, et al. **Trends Neurosci** 1995 Oct;18(10):459–61 (25 ref.)
[Molecular genetic diagnosis and deletion analysis in Type I–III spinal muscular atrophy] Spiegel R, et al. **Schweiz Med Wochenschr** 1996 May 25;126(21):907–14 (30 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

From enigmatic to problematic: the new molecular genetics of childhood spinal muscular atrophy. Crawford TO. **Neurology** 1996 Feb;46(2):335–40 (54 ref.)
Spinal and bulbar muscular atrophy: a trinucleotide–repeat expansion neurodegenerative disease. Brooks BP, et al. **Trends Neurosci** 1995 Oct;18(10):459–61 (25 ref.)

THERAPY

Possible strategies for treatment of SMA patients: a neurobiologist's view. Greensmith L, et al. **Neuromuscul Disord** 1995 Sep;5(5):359–69 (85 ref.)

MUSCULAR ATROPHY, SPINAL, INFANTILE see **WERDNIG-HOFFMANN DISEASE**

MUSCULAR DISEASES

CHEMICALLY INDUCED

Investigations into the toxic effects of alcohol on skeletal muscle. Reilly ME, et al. **Adverse Drug React Toxicol Rev** 1995 Summer;14(2):117–50 (141 ref.)

[Present status of cortisone myopathy] Bielefeld P. **Rev Med Interne** 1996;17(3):255–61 (29 ref.) (Eng. Abstr.) **(Fre)**

[Toxic myopathies related to the administration of hypolipidemic agents: are the drugs the only things responsible?] Galiana J, et al. **Rev Clin Esp** 1995 Sep; 195(9):620–2 (28 ref.) (Eng. Abstr.) **(Spa)**

COMPLICATIONS

[Femoral neuropathy due to a spontaneous hematoma of the iliopsoas muscle during therapy with heparin–calcium] Casoni P, et al. **Acta Biomed Ateneo Parmense** 1994; 65(5–6):289–96 (5 ref.) (Eng. Abstr.) **(Ita)**

[Cardiac sarcoidosis with myopathy and advanced A–V nodal block in a woman with a previous diagnosis of sarcoidosis] Sugo A, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Oct; 33(10):1111–8 (33 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Pseudotumor of infancy and congenital muscular torticollis. Porter SB, et al. **Am Fam Physician** 1995 Nov 1; 52(6):1731–6 (19 ref.)

Muscle biopsy. O'Rourke KS, et al. **Curr Opin Rheumatol** 1995 Nov;7(6):462–8 (31 ref.)

Investigation of muscle disease. Mastaglia FL, et al. **J Neurol Neurosurg Psychiatry** 1996 Mar;60(3):256–74 (182 ref.)

Muscle weakness and myalgia. MR imaging investigation. Fleckenstein JL. **Magn Reson Imaging Clin N Am** 1995 Nov;3(4):773–803 (43 ref.)

MR imaging of soft-tissue masses. Mass-like lesions that simulate neoplasms. Jelinek J, et al. **Magn Reson Imaging Clin N Am** 1995 Nov;3(4):727–41 (58 ref.)

[Echinococcosis of the paravertebral space. Report of a case] Calderoni PP, et al. **Radiol Med (Torino)** 1995 Dec; 90(6):820–1 (11 ref.) (Eng. Abstr.) **(Ita)**

ENZYMOLOGY

Enzyme and muscle diseases. Panteghini M. **Curr Opin Rheumatol** 1995 Nov;7(6):469–74 (49 ref.)

ETIOLOGY

Calcific myonecrosis following compartment syndrome: report of two cases, review of the literature, and recommendations for treatment. Snyder BJ, et al. **J Trauma** 1995 Oct;39(4):792–5 (6 ref.)

[Muscular involvement in HIV infection] Gherardi R, et al. **Rev Neurol (Paris)** 1995 Nov;151(11):603–7 (44 ref.) (Eng. Abstr.) **(Fre)**

[Paraneoplastic syndromes of the nervous system and muscles during the course of small cell lung carcinoma] Joachimowicz-Jaśkowiak E. **Pneumonol Pol** 1990 Nov–Dec;58(11–12):647–50 (21 ref.) **(Pol)**

GENETICS

The genetic basis of paediatric heart disease. Johnson MC, et al. **Ann Med** 1995 Jun;27(3):289–300 (126 ref.)

Recent advances in muscular dystrophies and myopathies. Anderson JR. **J Clin Pathol** 1995 Jul;48(7):597–601 (33 ref.)

The myotubular myopathies: differential diagnosis of the X linked recessive, autosomal dominant, and autosomal recessive forms and present state of DNA studies. Wallgren-Pettersson C, et al. **J Med Genet** 1995 Sep; 32(9):673–9 (56 ref.)

Molecular genetics of ion channel diseases. George AL Jr. **Kidney Int** 1995 Oct;48(4):1180–90 (97 ref.)

[Molecular basis of inherited muscular diseases] Takeda S. **No To Shinkei** 1995 Aug;47(8):735–48 (87 ref.) **(Jpn)**

METABOLISM

Molecular genetics of ion channel diseases. George AL Jr. **Kidney Int** 1995 Oct;48(4):1180–90 (97 ref.)

The ubiquitin-dependent proteolytic pathway in skeletal muscle: its role in pathological states. Argilés JM, et al. **Trends Pharmacol Sci** 1996 Jun;17(6):223–6 (40 ref.)

PHYSIOPATHOLOGY

Associations between muscle soreness, damage, and fatigue. Clarkson PM, et al. **Adv Exp Med Biol** 1995;384:457–69 (63 ref.)

Muscles of a different 'color': the unusual properties of the extraocular muscles may predispose or protect them in neurogenic and myogenic disease. Porter JD, et al. **Neurology** 1996 Jan;46(1):30–7 (61 ref.)

RADIOGRAPHY

Iliopsoas compartment: normal anatomy and pathologic processes. Torres GM, et al. **Radiographics** 1995 Nov; 15(6):1285–97 (12 ref.)

SURGERY

Arthroscopic treatment of rotator cuff disease. Gartsman GM. **J Shoulder Elbow Surg** 1995 May–Jun;4(3):228–41 (27 ref.)

VETERINARY

The clinical differentiation of nervous and muscular locomotor disorders of sheep in Australia. Bourke CA. **Aust Vet J** 1995 Jun;72(6):228–34 (40 ref.)

VIROLOGY

Myopathy and HIV infection. Chariot P, et al. **Curr Opin Rheumatol** 1995 Nov;7(6):497–502 (72 ref.)

MUSCULAR DYSTROPHY

see related
MICE, INBRED MDX

[Recent advances in Fukuyama type congenital muscular dystrophy] Saito K. **No To Hattatsu** 1995 Nov;27(6):447–54 (40 ref.) (Eng. Abstr.) **(Jpn)**

[Animal models for muscle research and muscle diseases] Nabeshima Y. **Tanpakushitsu Kakusan Koso** 1995 Oct; 40(14):2197–203 (29 ref.) **(Jpn)**

CLASSIFICATION

Structure and function of basement membranes. Engvall E. **Int J Dev Biol** 1995 Oct;39(5):781–7 (71 ref.)

COMPLICATIONS

Acute gastric dilatation in Duchenne muscular dystrophy: a case report and review of the literature. Bensen ES, et al. **Arch Phys Med Rehabil** 1996 May;77(5):512–4 (19 ref.)

Use of suxamethonium in children [editorial] [see comments] Hopkins PM. **Br J Anaesth** 1995 Dec;75(6):675–7 (23 ref.) Comment in: Br J Anaesth 1996 Jun;76(6):883; discussion 884. Comment in: Br J Anaesth 1996 Jun;76(6):883–4; discussion 884.

Dystrophinopathies: clarification and complication. Samaha FJ, et al. **J Child Neurol** 1996 Jan;11(1):13–20 (63 ref.)

DIAGNOSIS

Imaging of the cobblestone lissencephalies [comment] Barkovich AJ. **AJNR Am J Neuroradiol** 1996 Apr; 17(4):615–8 (56 ref.) Comment on: AJNR Am J Neuroradiol 1996 Apr;17(4):605–13.

An unusual association: celiac disease and Becker muscular dystrophy. Meini A, et al. **Am J Gastroenterol** 1996 Jul; 91(7):1459–60 (11 ref.)

Dystrophinopathies: clarification and complication. Samaha FJ, et al. **J Child Neurol** 1996 Jan;11(1):13–20 (63 ref.)

[Clinical and genetic heterogeneity of limb-girdle muscular dystrophy] Kozłowska M. **Neurol Neurochir Pol** 1995 Jul–Aug;29(4):569–75 (19 ref.) (Eng. Abstr.) **(Pol)**

[Histological and immunohistochemical analysis of dystrophin + + in muscular dystrophy of Duchenne and Becker type] Cabello A. **Rev Neurol** 1995;23 Suppl 3:S395–9 (31 ref.) **(Spa)**

[Western blotting in the diagnosis of dystrophinopathies] Navarro C. **Rev Neurol** 1995;23 Suppl 3:S401–3 (26 ref.) **(Spa)**

DRUG THERAPY

[For the present Duchenne' disease should not be treated with prednisone] Jennekens FG, et al. **Ned Tijdschr Geneeskd** 1996 May 25;140(21):1109–11 (21 ref.) **(Dut)**

EPIDEMIOLOGY

Early onset distal muscular dystrophy. Kinoshita H, et al. **Brain Dev** 1995 May–Jun;17(3):206–9 (13 ref.)

ETIOLOGY

Etiology and pathogenesis of the muscular dystrophies. Van den Bergh PY, et al. **Acta Neurol Belg** 1995;95(3):123–41 (191 ref.)

[Dystrophin, dystrophin-associated protein and dystrophinopathy] Ozawa E. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1995 Jun; 15(3):289–93 (15 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Infantile autosomal dominant distal myopathy. Scoppetta C, et al. **Acta Neurol Scand** 1995 Aug;92(2):122–6 (21 ref.)

Dystrophin, its gene, and the dystrophinopathies. Roberts RG. **Adv Genet** 1995;33:177–231 (263 ref.)

Molecular diagnosis of Duchenne muscular dystrophy in Singapore. Low PS, et al. **Ann Acad Med Singapore** 1996 Jan;25(1):84–9 (18 ref.)

Chromosome 12-linked autosomal dominant scapuloperoneal muscular dystrophy. Wilhelmsen KC, et al. **Ann Neurol** 1996 Apr;39(4):507–20 (75 ref.)

A carrier of Duchenne muscular dystrophy with dilated cardiomyopathy but no skeletal muscle symptom. Kinoshita H, et al. **Brain Dev** 1995 May–Jun;17(3):202–5 (11 ref.)

Recent advances in muscular dystrophies and myopathies. Anderson JR. **J Clin Pathol** 1995 Jul;48(7):597–601 (33 ref.)

Congenital muscular dystrophies: clinical review and proposed classification. Parano E, et al. **Pediatr Neurol** 1995 Sep;13(2):97–103 (26 ref.)

Muscular dystrophies: diseases of the dystrophin–glycoprotein complex [comment] Worton R. **Science** 1995 Nov 3;270(5237):755–6 (15 ref.) Comment on: Science 1995 Nov 3;270(5237):819–22.

Duchenne muscular dystrophy. Matsuo M. **Southeast Asian J Trop Med Public Health** 1995;26 Suppl 1:166–71 (31 ref.)

[Reflexions apropos of recent progresses in molecular genetics of myopathies (editorial)] Kaplan JC. **Arch Pediatr** 1995 Aug;2(8):715–8 (13 ref.) **(Fre)**

[Gene hunting of facioscapulohumeral muscular dystrophy] Song MD, et al. **No To Shinkei** 1996 Apr;48(4):307–13 (50 ref.) **(Jpn)**

[Gene hunting for Fukuyama type congenital muscular dystrophy] Toda T. **No To Shinkei** 1996 Apr;48(4):315–22 (22 ref.) **(Jpn)**

[Positional cloning of the genes for progeroid syndromes] Miki T, et al. **Tanpakushitsu Kakusan Koso** 1996 Mar; 41(3):245–54 (41 ref.) **(Jpn)**

[Clinical and genetic heterogeneity of limb-girdle muscular dystrophy] Kozłowska M. **Neurol Neurochir Pol** 1995 Jul–Aug;29(4):569–75 (19 ref.) (Eng. Abstr.) **(Pol)**

[Molecular genetic research on Duchenne–Becker myodystrophy. The correlation of the severity of the disease with the type of deletion] Badalian LO, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995;95(6):90–2 (35 ref.) **(Rus)**

[Autosomal recessive limb-girdle muscular dystrophy probably linked to chromosome 15] Noguera Moya A, et al. **An Esp Pediatr** 1996 Mar;44(3):267–9 (17 ref.) **(Spa)**

METABOLISM

Free radicals, programmed cell death and muscular dystrophy [editorial] Brown RH. **Curr Opin Neurol** 1995 Oct;8(5):373–8 (43 ref.)

Dystrophin-glycoprotein complex: molecular organization and critical roles in skeletal muscle. Sunada Y, et al. **Curr Opin Neurol** 1995 Oct;8(5):379–84 (40 ref.)

Dystrophinopathies and related disorders. Cherin P. **Curr Opin Rheumatol** 1995 Nov;7(6):475–85 (85 ref.)

Dystrophin-associated proteins in muscular dystrophy. Ozawa E, et al. **Hum Mol Genet** 1995;4 Spec No:1711–6 (69 ref.)

PATHOLOGY

Congenital muscular dystrophies. Arahata K, et al. **Curr Opin Neurol** 1995 Oct;8(5):385–90 (43 ref.)

PHYSIOPATHOLOGY

Agrin: toward a molecular understanding of synapse regeneration. Deyst KA, et al. **Neurosurgery** 1995 Jul; 37(1):71–7 (81 ref.)

SURGERY

Commentary on the present state of knowledge for myoblast transfer therapy [comment] Grounds MD. **Cell Transplant** 1996 May–Jun;5(3):431–3 (14 ref.) Comment on: Cell Transplant 1996 May–Jun;5(3):421–9.

THERAPY

Muscle-based gene therapy: realistic possibilities for the future. Svensson EC, et al. **Mol Med Today** 1996 Apr; 2(4):166–72 (40 ref.)

[Gene therapy in muscular dystrophy] Takeda S, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2765–71 (32 ref.) **(Jpn)**

[Duchenne muscular dystrophy: clinical analysis and prospects of genetic therapy] Mateos F. **Rev Neurol** 1995; 23 Suppl 3:S404–7 (32 ref.) **(Spa)**

MUSCULAR DYSTROPHY, ANIMAL

METABOLISM

Membrane abnormalities and Ca homeostasis in muscles of the mdx mouse, an animal model of the Duchenne muscular dystrophy: a review. Gillis JM. **Acta Physiol Scand** 1996 Mar;156(3):397–406 (57 ref.)

How does dystrophin deficiency lead to muscle degeneration?—evidence from the mdx mouse. McArdle A, et al. **Neuromuscul Disord** 1995 Nov;5(6):445–56 (78 ref.)

PHYSIOPATHOLOGY

How does dystrophin deficiency lead to muscle degeneration?—evidence from the mdx mouse. McArdle A, et al. **Neuromuscul Disord** 1995 Nov;5(6):445–56 (78 ref.)

MUSCULOSKELETAL DISEASES

CLASSIFICATION

Classification systems of soft tissue disorders of the neck and

upper limb: do they satisfy methodological guidelines? Buchbinder R, et al. **J Clin Epidemiol** 1996 Feb;49(2):141–9 (76 ref.)

DIAGNOSIS

Adolescent chest pain. Anzai AK, et al. **Am Fam Physician** 1996 Apr;53(5):1682–90 (16 ref.)

Additional methods of diagnosis in the histopathology of the musculoskeletal system. Gamberi G, et al. **Chir Organi Mov** 1995 Oct–Dec;80(4):417–26 (47 ref.) **(Eng, Ita)**

Magnetic resonance imaging of the musculoskeletal system. II. The hip. Hayes CW, et al. **Clin Orthop** 1996 Jan; (322):297–309 (45 ref.)

Classification systems of soft tissue disorders of the neck and upper limb: do they satisfy methodological guidelines? Buchbinder R, et al. **J Clin Epidemiol** 1996 Feb;49(2):141–9 (76 ref.)

CT/MRI of musculoskeletal complications of AIDS. Wyatt SH, et al. **Skeletal Radiol** 1995 Oct;24(7):481–8 (21 ref.)

[MR tomography (MRT) of the skeleton, peripheral soft tissues and joints—current overview] Bohndorf K, et al. **Aktuelle Radiol** 1996 May;6(3):136–43 (47 ref.) (Eng. Abstr.) **(Ger)**

[Fast and ultra-fast imaging of the musculoskeletal system] Vahlensieck M. **Radiologe** 1995 Dec;35(12):973–80 (34 ref.) (Eng. Abstr.) **(Ger)**

[Unclear pathomechanism behind neck-shoulder pain. Problem with insurance claim] Zetterberg C. **Lakartidningen** 1996 Feb 28;93(9):793–6 (68 ref.) **(Swe)**

DRUG THERAPY

Treating musculoskeletal disease with NSAIDs. Practitioner's guide. Bellamy N. **Can Fam Physician** 1996 Mar;42:482–6, 489–92 (38 ref.)

An evidence-based approach to prescribing NSAIDs in musculoskeletal disease: a Canadian consensus. Canadian NSAID Consensus Participants. Tannenbaum H, et al. **Can Med Assoc J** 1996 Jul 1;155(1):77–88 (99 ref.)

ECONOMICS

The economic cost and social and psychological impact of musculoskeletal conditions. National Arthritis Data Work Groups. Yelin E, et al. **Arthritis Rheum** 1995 Oct; 38(10):1351–62 (68 ref.)

EPIDEMIOLOGY

Collection of domestic waste. Review of occupational health problems and their possible causes. Poulsen OM, et al. **Sci Total Environ** 1995 Aug 18;170(1–2):1–19 (83 ref.)

ETIOLOGY

ABC of work related disorders. Neck and arm disorders. Hagberg M. **BMJ** 1996 Aug 17;313(7054):419–22 (0 ref.)

[The involvement of the locomotor system in Lyme borreliosis] Lesniak OM. **Klin Med (Mosk)** 1995;73(3):28–30 (44 ref.) **(Rus)**

GENETICS

Nonrheumatic conditions in children including infectious diseases and syndromes. Tucker LB. **Curr Opin Rheumatol** 1995 Sep;7(5):419–24 (31 ref.)

MICROBIOLOGY

Mycobacterial and fungal infections of bone and joints. Meier JL, et al. **Curr Opin Rheumatol** 1995 Jul;7(4):329–36 (75 ref.)

Nonrheumatic conditions in children including infectious diseases and syndromes. Tucker LB. **Curr Opin Rheumatol** 1995 Sep;7(5):419–24 (31 ref.)

PREVENTION & CONTROL

Prevention of occupational musculo-skeletal injuries. Labour Inspectorate investigation. Kemmlert K. **Scand J Rehabil Med Suppl** 1996;35:1–34 (124 ref.)

[Physical activity and musculoskeletal functioning] Alaranta H, et al. **Duodecim** 1994;110(12):1200–5 (38 ref.) **(Fin)**

PSYCHOLOGY

Musculoskeletal pain syndromes that affect adolescents. Szer IS. **Arch Pediatr Adolesc Med** 1996 Jul;150(7):740–7 (23 ref.)

The economic cost and social and psychological impact of musculoskeletal conditions. National Arthritis Data Work Groups. Yelin E, et al. **Arthritis Rheum** 1995 Oct; 38(10):1351–62 (68 ref.)

REHABILITATION

Effects of early motion on healing of musculoskeletal tissues. Buckwalter JA. **Hand Clin** 1996 Feb;12(1):13–24 (81 ref.)

[How to facilitate the rehabilitation of patients with musculoskeletal symptoms] Alaranta H, et al. **Duodecim** 1994;110(15):1431–8 (40 ref.) **(Fin)**

THERAPY

Primary care for women. Management of common musculoskeletal disorders. Benetti MC, et al. **J Nurse Midwifery** 1996 Mar–Apr;41(2):173–87 (40 ref.)

MUSCULOSKELETAL SYSTEM

INJURIES

Lower extremity musculoskeletal problems in dancers. Schon LC, et al. **Curr Opin Rheumatol** 1996 Mar;8(2):130–42 (43 ref.)

Prevention of occupational musculo-skeletal injuries. Labour Inspectorate investigation. Kemmlert K. **Scand J Rehabil Med Suppl** 1996;35:1–34 (124 ref.)

PATHOLOGY

[MR tomography (MRT) of the skeleton, peripheral soft tissues and joints—current overview] Bohndorf K, et al. **Aktuelle Radiol** 1996 May;6(3):136–43 (47 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Cytokines and skeletal physiology. Goldring SR, et al. **Clin Orthop** 1996 Mar;(324):13–23 (67 ref.)

MUSEUMS

The Army Medical Museum/Armed Forces Institute of Pathology and Emerging Infections: from camp fevers and diarrhea during the American Civil War in the 1860's to global molecular epidemiology and pathology in the 1990s. Nelson AM, et al. **Arch Pathol Lab Med** 1996 Feb; 120(2):129–33 (21 ref.)

MUSHROOM POISONING

see related
MYCOTOXINS

COMPLICATIONS

Hepatotoxicity of herbal remedies and mushrooms. Larrey D, et al. **Semin Liver Dis** 1995 Aug;15(3):183–8 (63 ref.)

[Acute kidney failure due to Corinarius orellanus (letter)] Romanillos T, et al. **Med Clin (Barc)** 1995 Oct 7;105(11):437 (10 ref.) **(Spa)**

DIAGNOSIS

A fatal Sunday brunch: Amanita mushroom poisoning in a Gulf Coast family. O'Brien BL, et al. **Am J Gastroenterol** 1996 Mar;91(3):581–3 (21 ref.)

ETIOLOGY

[An outbreak of poisoning by mushrooms of the genus Omphalotus (letter)] Alguacil Garcia GF, et al. **Med Clin (Barc)** 1996 Jun 8;107(2):75 (8 ref.) **(Spa)**

MUSHROOMS see **BASIDIOMYCETES**

MUSIC

Musculoskeletal and neuromuscular conditions of instrumental musicians. Bejjani FJ, et al. **Arch Phys Med Rehabil** 1996 Apr;77(4):406–13 (108 ref.)

Potential risk of hearing damage associated with exposure to highly amplified music. Hétu R, et al. **J Am Acad Audiol** 1995 Sep;6(5):378–86 (43 ref.)

Expression of emotion in voice and music. Scherer KR. **J Voice** 1995 Sep;9(3):235–48 (89 ref.)

[Neuropsychology of musical identification] Lechevalier B, et al. **Rev Neurol (Paris)** 1995 Aug–Sep;151(8–9):505–10 (32 ref.) (Eng. Abstr.) **(Fre)**

[When to stop the music (editorial)] Ohry A, et al. **Harefuah** 1995 Dec 1;129(11):472–4 (31 ref.) **(Heb)**

PSYCHOLOGY

Music, noise, and the human voice in the nurse-patient environment. Pope DS. **Image J Nurs Sch** 1995 Winter; 27(4):291–6 (51 ref.)

MUSKRATS see **MICROTINAE**

MUSSELS

CHEMISTRY

Wresting the muscle from mussel beards: research and applications. Rzepecki LM, et al. **Mol Mar Biol Biotechnol** 1995 Dec;4(4):313–22 (45 ref.)

MUSTARD GAS

POISONING

[Percutaneous poisoning with sulphur mustard. Prevention, decontamination and therapy] Knežević DL, et al. **Vojnosanit Pregl** 1995 Mar–Apr;52(2):163–72 (95 ref.) **(Scr)**

MUSTINE see **MECHLORETHAMINE**

MUTAGEN SCREENING see **MUTAGENICITY TESTS**

MUTAGENESIS

see related
ANTIMUTAGENIC AGENTS
MUTAGENS

The spectrum of mutations at the p53 locus. Evidence for tissue-specific mutagenesis, selection of mutant alleles, and a "gain of function" phenotype. Levine AJ, et al. **Ann N Y Acad Sci** 1995 Sep 30;768:111–28 (55 ref.)

The zebrafish: heritable disorders in transparent embryos. Driever W, et al. **J Clin Invest** 1996 Apr 15;97(8):1788–94 (67 ref.)

Mutagenesis. Anderson P. **Methods Cell Biol** 1995;48:31–58 (102 ref.)

Reverse genetics: from gene sequence to mutant worm. Plasterk RH. **Methods Cell Biol** 1995;48:59–80 (26 ref.)

Transdominant negative mutations. Shamah SM, et al. **Methods Enzymol** 1995;254:565–76 (58 ref.)

Antioxidant defences against reactive oxygen species causing genetic and other damage. Anderson D. **Mutat Res** 1996 Feb 19;350(1):103–8 (46 ref.)

Rodent mutation assay data presentation and statistical assessment. Ashby J. **Mutat Res** 1995 Oct;331(2):233–5 (7 ref.)

Role of induced genetic instability in the mutagenic effects of chemicals and radiation. Murnane JP. **Mutat Res** 1996 Jan;367(1):11–23 (160 ref.)

DNA damage and mutagenesis by radiomimetic DNA-cleaving agents: bleomycin, neocarzinostatin and other enediynes. Povirk LF. **Mutat Res** 1996 Aug 17; 355(1–2):71–89 (125 ref.)

Of mice and mutants: target size and sensitivity. Skopek TR. **Mutat Res** 1995 Oct;331(2):225–8 (7 ref.)

Nucleic acid fingerprinting by PCR-based methods: applications to problems in aging and mutagenesis. Welsh J, et al. **Mutat Res** 1995 Oct;338(1–6):215–29 (72 ref.)

SOS-regulated proteins in translesion DNA synthesis and mutagenesis. Walker GC. **Trends Biochem Sci** 1995 Oct; 20(10):416–20 (50 ref.)

[Mechanisms of nucleoside-analog mutagenesis] Negishi K, et al. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1564–70 (55 ref.) **(Jpn)**

GENETICS

TSH receptor and LH receptor, 1995. Kosugi S, et al. **Endocr J** 1995 Oct;42(5):587–606 (95 ref.)

Health effects associated with global climate changes: a role for environmental mutagens? Rosenkranz HS. **Environ Mol Mutagen** 1996;27(2):81–3 (39 ref.)

Somatic mutagenesis and antimutagenesis in aging research. Martin GM. **Mutat Res** 1996 Feb 19;350(1):35–41 (55 ref.)

PHYSIOLOGY

Dopamine-induced, genotoxic activation of programmed cell death. A role in nigrostriatal neuronal degeneration in Parkinson's disease? Ziv I, et al. **Adv Neurol** 1996;69:229–33 (26 ref.)

Potential sources of multiple mutations in human cancers. Christians FC, et al. **Prev Med** 1995 Jul;24(4):329–32 (37 ref.)

RADIATION EFFECTS

Genetic, cytogenetic, and carcinogenic effects of radon: a review. Jostes RF. **Mutat Res** 1996 Jun;340(2–3):125–39 (87 ref.)

MUTAGENESIS, CASSETTE see **MUTAGENESIS, INSERTIONAL**

MUTAGENESIS, INSERTIONAL

Retroviral insertional mutagenesis as a strategy to identify cancer genes. Jonkers J, et al. **Biochim Biophys Acta** 1996 May 16;1287(1):29–57 (410 ref.)

The emerging role of insertions and deletions in protein engineering. Shortle D, et al. **Curr Opin Biotechnol** 1995 Aug;6(4):387–93 (40 ref.)

Retroviral insertional mutagenesis in murine promonocytic leukemias: c-myb and Mml1. Wolff L, et al. **Curr Top Microbiol Immunol** 1996;211:191–9 (33 ref.)

[Genetic screening for novel genes by insertional mutagenesis with gene trap method in ES cells] Araki K, et al. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2017–24 (17 ref.) **(Jpn)**

GENETICS

MMTV-induced mutations in mouse mammary tumors: their potential relevance to human breast cancer. Callahan R. **Breast Cancer Res Treat** 1996;39(1):33–44 (82 ref.)

METHODS

Transgenic insertional mutagenesis. Applications to inner-ear genetics. Friedman RA. **Arch Otolaryngol Head Neck Surg** 1996 Mar;122(3):252–7 (55 ref.)

MUTAGENESIS, OLIGONUCLEOTIDE-DIRECTED see **MUTAGENESIS, SITE-DIRECTED**

MUTAGENESIS, SITE-DIRECTED

Site directed mutagenesis to probe for active site components of liver mitochondrial aldehyde dehydrogenase. Weiner H, et al. **Adv Exp Med Biol** 1995;372:1-7 (17 ref.)

Mutagenesis studies of the cardiac Na(+)-Ca2+ exchanger. Nicoll DA, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:86-92 (14 ref.)

Biological electron transfer: structural and mechanistic studies. Canters GW, et al. **Biochimie** 1995;77(7-8):506-15 (87 ref.)

Genetic heterogeneity in mammalian specific-locus mutation systems. Malling HV. **Environ Mol Mutagen** 1995; 26(3):187-8 (8 ref.)

Exploring the nucleotide-binding site in proteins by affinity labeling and site-directed mutagenesis. Fukui T. **J Biochem (Tokyo)** 1995 Jun;117(6):1139-44 (45 ref.)

[Site-directed mutagenesis by PCR] Yamashita T, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):534-8 (13 ref.) **(Jpn)**

MUTAGENESIS, SITE-SPECIFIC see **MUTAGENESIS, SITE-DIRECTED**

MUTAGENICITY TESTS

see related
CARCINOGENICITY TESTS

Validation of the SOS/umu test using test results of 486 chemicals and comparison with the Ames test and carcinogenicity data. Reifferscheid G, et al. **Mutat Res** 1996 Aug 12;369(3-4):129-45 (120 ref.)

METHODS

Treatment protocols for transgenic mutation assays in vivo. Heddle JA, et al. **Mutagenesis** 1995 Nov;10(6):467-70 (17 ref.)

Optimization of the Salmonella/mammalian microsome assay for urine mutagenesis by experimental designs. De Méo M, et al. **Mutat Res** 1996 Jun;340(2-3):51-65 (50 ref.)

Genetic toxicology of four commonly used benzodiazepines: a review. Giri AK, et al. **Mutat Res** 1996 Jun; 340(2-3):93-108 (100 ref.)

Cytogenetic damage measured in human sperm following cancer chemotherapy. Robbins WA. **Mutat Res** 1996 Aug 17;355(1-2):235-52 (109 ref.)

Development and validation of alternative metabolic systems for mutagenicity testing in short-term assays. Rueff J, et al. **Mutat Res** 1996 Jun 12;353(1-2):151-76 (132 ref.)

Of mice and mutants: target size and sensitivity. Skopek TR. **Mutat Res** 1995 Oct;331(2):225-8 (7 ref.)

STATISTICS & NUMERICAL DATA

Rodent mutation assay data presentation and statistical assessment. Ashby J. **Mutat Res** 1995 Oct;331(2):233-5 (7 ref.)

MUTAGENS

see related
ALKYLATING AGENTS
DNA ADDUCTS
MUTAGENESIS

Role of induced genetic instability in the mutagenic effects of chemicals and radiation. Murnane JP. **Mutat Res** 1996 Jan;367(1):11-23 (160 ref.)

Achievements by CSGMT/JEMS.MMS: the Collaborative Study Group for the Micronucleus Test in the Mammalian Mutagenesis Study Group of the Environmental Mutagen Society of Japan. Sutou S. **Mutat Res** 1996 Jun; 340(2-3):151-74 (129 ref.)

Metal replacement in DNA-binding zinc finger proteins and its relevance to mutagenicity and carcinogenicity through free radical generation. Sarkar B. **Nutrition** 1995 Sep-Oct; 11(5 Suppl):646-9 (17 ref.)

ADVERSE EFFECTS

Chemical methods for assessing systemic exposure to dietary heterocyclic amines in man. Davies DS, et al. **Arch Toxicol Suppl** 1996;18:251-8 (29 ref.)

Variability in DNA repair and individual susceptibility to genotoxins. Kyrtopoulos SA. **Clin Chem** 1995 Dec;41(12 Pt 2):1848-53 (51 ref.)

Health effects associated with global climate changes: a role for environmental mutagens? Rosenkranz HS. **Environ Mol Mutagen** 1996;27(2):81-3 (39 ref.)

Dietary contribution to genotoxic risk and its control. Lindsay DG. **Food Chem Toxicol** 1996 Apr;34(4):423-31 (61 ref.)

Mutagenic damage to mammalian cells by therapeutic alkylating agents. Sanderson BJ, et al. **Mutat Res** 1996 Aug 17;355(1-2):41-57 (118 ref.)

Mutagenic and carcinogenic properties of platinum-based anticancer drugs. Sanderson BJ, et al. **Mutat Res** 1996 Aug 17;355(1-2):59-70 (59 ref.)

ANALYSIS

[Reference values in biological monitoring of occupational exposure to mutagens and carcinogens] Clonfero E, et al. **G Ital Med Lav** 1994 Jan-Nov;16(1-6):25-9 (43 ref.) (Eng. Abstr.) **(Ita)**

CHEMISTRY

Quantitative structure--activity relationship (QSAR) studies of mutagens and carcinogens. Benigni R, et al. **Med Res Rev** 1996 May;16(3):267-84 (85 ref.)

Trenimon: structure and reactivity of a versatile chemical agent. Rademacher P, et al. **Mutat Res** 1995 Nov; 340(1):37-49 (76 ref.)

METABOLISM

Formation and processing of reactive metabolites of the heterocyclic amines. Alexander J. **Arch Toxicol Suppl** 1996; 18:275-85 (52 ref.)

Enzymic and interindividual differences in the human metabolism of heterocyclic amines. Boobis AR, et al. **Arch Toxicol Suppl** 1996;18:286-302 (65 ref.)

Biological relevance and consequences of chemical- or metal-induced DNA cross-linking. Paustenbach DJ, et al. **Proc Soc Exp Biol Med** 1996 Mar;211(3):211-7 (62 ref.)

TOXICITY

Extrapolation of heterocyclic amine carcinogenesis data from rodents and nonhuman primates to humans. Adamson RH, et al. **Arch Toxicol Suppl** 1996;18:303-18 (56 ref.)

Synthesis report of the step project detection of germ cell mutagens. Adler ID, et al. **Mutat Res** 1996 Jun 12; 353(1-2):65-84 (76 ref.)

Series: current issues in mutagenesis and carcinogenesis, No. 65. The genotoxicity and carcinogenicity of paracetamol: a regulatory (re)view. Bergman K, et al. **Mutat Res** 1996 Feb 1;349(2):263-88 (103 ref.)

Genotoxic potential of beta-carbolines: a review. de Meester C. **Mutat Res** 1995 Oct;339(3):139-53 (93 ref.)

Genetic toxicology of trichloroethylene (TCE). Fahrig R, et al. **Mutat Res** 1995 Nov;340(1):1-36 (126 ref.)

Mutagenicity of anticancer drugs that inhibit topoisomerase enzymes. Ferguson LR, et al. **Mutat Res** 1996 Aug 17; 355(1-2):91-101 (81 ref.)

Genetic toxicology of four commonly used benzodiazepines: a review. Giri AK, et al. **Mutat Res** 1996 Jun; 340(2-3):93-108 (100 ref.)

Genetic toxicology of mitotic spindle inhibitors used as anticancer drugs. Kirsch-Volders M, et al. **Mutat Res** 1996 Aug 17;355(1-2):103-28 (220 ref.)

Inhibitors of thymine nucleotide biosynthesis: antimetabolites that provoke genetic change via primary non-DNA targets. Kunz BA. **Mutat Res** 1996 Aug 17;355(1-2):129-40 (135 ref.)

The detection and evaluation of aneugenic chemicals. Parry JM, et al. **Mutat Res** 1996 Jun 12;353(1-2):11-46 (90 ref.)

DNA damage and mutagenesis by radiomimetic DNA-cleaving agents: bleomycin, neocarzinostatin and other enediynes. Povirk LF. **Mutat Res** 1996 Aug 17; 355(1-2):71-89 (125 ref.)

Mutagenic nitroarenes, diesel emissions, particulate-induced mutations and cancer: an essay on cancer-causation by a moving target. Rosenkranz HS. **Mutat Res** 1996 Feb; 367(2):65-72 (85 ref.)

The mutagenic properties of DNA minor-groove binding ligands. Turner PR, et al. **Mutat Res** 1996 Aug 17; 355(1-2):141-69 (116 ref.)

DNA damage and repair in mutagenesis and carcinogenesis: implications of structure-activity relationships for cross-species extrapolation. Vogel EW, et al. **Mutat Res** 1996 Jun 12;353(1-2):177-218 (125 ref.)

Mutagenicity of anticancer drugs in mammalian germ cells. Witt KL, et al. **Mutat Res** 1996 Aug 17;355(1-2):209-34 (207 ref.)

Nongenotoxic carcinogens: development of detection methods based on mechanisms: a European project. Yamasaki H, et al. **Mutat Res** 1996 Jun 12;353(1-2):47-63 (74 ref.)

Use of graph theoretic parameters in risk assessment of chemicals. Basak SC, et al. **Toxicol Lett** 1995 Sep; 79(1-3):239-50 (55 ref.)

Cell proliferation as a determining factor for the carcinogenicity of chemicals: studies with mutagenic carcinogens and mutagenic noncarcinogens. Cunningham ML, et al. **Toxicol Lett** 1995 Dec;82-83:9-14 (25 ref.)

[Genotoxic properties of 5-nitrofuran compounds] Szczypka M. **Rocz Panstw Zakl Hig** 1995;46(4):389-95 (45 ref.) (Eng. Abstr.) **(Pol)**

MUTATION

see related
ANTIMUTAGENIC AGENTS
MUTAGENESIS
MUTAGENS
SUPPRESSION, GENETIC

Genetics of murine lung tumors. Dragani TA, et al. **Adv Cancer Res** 1995;67:83-112 (181 ref.)

Mutation and cancer: a personal odyssey. Knudson AG Jr. **Adv Cancer Res** 1995;67:1-23 (144 ref.)

The clinical significance of hepatitis B mutations [editorial; comment] Kim LS, et al. **Am J Gastroenterol** 1996 Jul; 91(7):1297-8 (8 ref.) Comment on: Am J Gastroenterol 1996 Jul;91(7):1312-7.

Mutations in fibroblast growth factor receptors: phenotypic consequences during eukaryotic development [editorial] Park WJ, et al. **Am J Hum Genet** 1995 Oct;57(4):748-54 (45 ref.)

Mitochondrial genome mutations and kidney disease. Singh PJ, et al. **Am J Kidney Dis** 1996 Jul;28(1):140-6 (47 ref.)

Mutations in PAX3 that cause Waardenburg syndrome type I: ten new mutations and review of the literature. Baldwin CT, et al. **Am J Med Genet** 1995 Aug 28;58(2):115-22 (16 ref.)

A chondrodysplasia family produced by mutations in the diastrophic dysplasia sulfate transporter gene: genotype/phenotype correlations. Superti-Furga A, et al. **Am J Med Genet** 1996 May 3;63(1):144-7 (28 ref.)

Hypochondroplasia: molecular analysis of the fibroblast growth factor receptor 3 gene. Bellus GA, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:182-7 (25 ref.)

Transport mutants and transport genes of Corynebacterium glutamicum. Eggeling L, et al. **Ann N Y Acad Sci** 1996 May 15;782:191-201 (32 ref.)

Progress in human chondrodysplasias: molecular genetics. Horton WA. **Ann N Y Acad Sci** 1996 Jun 8;785:150-9 (44 ref.)

Somatic mutation of human immunoglobulin V genes: bias, rate, and regulation. Insel RA, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:158-69 (46 ref.)

The spectrum of mutations at the p53 locus. Evidence for tissue-specific mutagenesis, selection of mutant alleles, and a "gain of function" phenotype. Levine AJ, et al. **Ann N Y Acad Sci** 1995 Sep 30;768:111-28 (55 ref.)

Fibroblast growth factor receptor-2 mutations in craniosynostosis. Malcolm S, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:164-70 (29 ref.)

Campomelic dysplasia with XY sex reversal: diverse phenotypes resulting from mutations in a single gene. Schafer AJ, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:137-49 (46 ref.)

A family of chondrodysplasias caused by mutations in the diastrophic dysplasia sulfate transporter gene and associated with impaired sulfation of proteoglycans. Superti-Furga A, et al. **Ann N Y Acad Sci** 1996 Jun 8; 785:195-201 (26 ref.)

Two novel molecular defects in the LCAT gene are associated with fish eye disease. Kuivenhoven JA, et al. **Arterioscler Thromb Vasc Biol** 1996 Feb;16(2):294-303 (33 ref.)

The genetic determinants of plasma cholesterol and response to diet. Humphries SE, et al. **Baillieres Clin Endocrinol Metab** 1995 Oct;9(4):797-823 (148 ref.)

Mutant insulin receptors in syndromes of insulin resistance. Krook A, et al. **Baillieres Clin Endocrinol Metab** 1996 Jan; 10(1):97-122 (163 ref.)

Endocrine disorders associated with mutations in guanine nucleotide binding proteins. Milligan G. **Baillieres Clin Endocrinol Metab** 1996 Jan;10(1):177-87 (60 ref.)

Effects of p53 mutation on tumor progression: recent insights from mouse tumor models. Donehower LA. **Biochim Biophys Acta** 1996 Mar 18;1242(3):171-6 (66 ref.)

Recombination, mutation and the origin of species. Cox EC. **Bioessays** 1995 Sep;17(9):747-9 (23 ref.)

Meiotic recombination: a mechanism for tracking and eliminating mutations? McKee BD. **Bioessays** 1996 May; 18(5):411-9 (72 ref.)

Genetic counselling and testing for susceptibility to breast, ovarian and colon cancer: where are we today? Cole DE, et al. **Can Med Assoc J** 1996 Jan 15;154(2):149-55 (56 ref.)

The genetic epidemiology of cancer. Claus EB. **Cancer Surv** 1995;25:13-26 (62 ref.)

Germline mutations in the TP53 gene. Eeles RA. **Cancer Surv** 1995;25:101-24 (106 ref.)

Molecular genetics of lung cancer. Greenblatt MS, et al. **Cancer Surv** 1995;25:293-313 (141 ref.)

Mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2. Ponder BA. **Cancer Surv** 1995;25:195-205 (31 ref.)

Von Hippel-Lindau disease and sporadic renal cell carcinoma. Zbar B. **Cancer Surv** 1995;25:219-32 (32 ref.)

The role of adduct site-specific mutagenesis in understanding how carcinogen-DNA adducts cause mutations: perspective, prospects and problems. Loechler EL. **Carcinogenesis** 1996 May;17(5):895-902 (70 ref.)

Somatic hypermutation: how many mechanisms diversify V region sequences? Maizels N. **Cell** 1995 Oct 6;83(1):9-12 (26 ref.)

Mechanisms of DNA expansion. McMurray CT. **Chromosoma** 1995 Oct;104(1):2-13 (103 ref.)

Mouse mutants and cardiac development: new molecular insights into cardiogenesis. Rossant J. **Circ Res** 1996 Mar; 78(3):349-53 (60 ref.)

The role of lipids in cardiovascular disease: lessons from rare mutations and special populations. Hegele RA. **Clin Invest Med** 1996 Jun;19(3):161-70 (42 ref.)

Molecular genetic aspects of hyperhomocysteinemia and its relation to folic acid. Rozen R. **Clin Invest Med** 1996 Jun; 19(3):171-8 (18 ref.)

Defects in replication fidelity of simple repeated sequences reveal a new mutator mechanism for oncogenesis. Perucho M, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:339-48 (63 ref.)

Mutations in type IV collagen genes and Alport phenotypes. Tryggvason K. **Contrib Nephrol** 1996;117:154-71 (58 ref.)

Modeling mutations and homologous proteins. Sali A.

Curr Opin Biotechnol 1995 Aug;6(4):437–51 (222 ref.)
Viral mutations, TCR antagonism and escape from the immune response. Franco A, et al. **Curr Opin Immunol** 1995 Aug;7(4):524–31 (62 ref.)
Somatic hypermutation. Neuberger MS, et al. **Curr Opin Immunol** 1995 Apr;7(2):248–54 (69 ref.)
Paramutation in maize and related allelic interactions. Patterson GI, et al. **Curr Top Microbiol Immunol** 1995; 197:121–41 (94 ref.)
Detection of mismatched bases in double stranded DNA by gel electrophoresis. Ganguly A, et al. **Electrophoresis** 1995 Oct;16(10):1830–5 (49 ref.)
Mutation processes at human minisatellites. Jeffreys AJ, et al. **Electrophoresis** 1995 Sep;16(9):1577–85 (49 ref.)
Genetic heterogeneity in mammalian specific-locus mutation systems. Malling HV. **Environ Mol Mutagen** 1995; 26(3):187–8 (8 ref.)
DNA-replication fidelity, mismatch repair and genome instability in cancer cells. Umar A, et al. **Eur J Biochem** 1996 Jun 1;238(2):297–307 (81 ref.)
Luteinizing hormone receptor mutations and sex differentiation. Themmen AP, et al. **Eur J Endocrinol** 1996 May;134(5):533–40 (60 ref.)
CRASH syndrome: clinical spectrum of corpus callosum hypoplasia, retardation, adducted thumbs, spastic paraparesis and hydrocephalus due to mutations in one single gene, L1. Fransen E, et al. **Eur J Hum Genet** 1995; 3(5):273–84 (49 ref.)
Molecular analysis of mutations in thyroid tumors with TGGE. Simon D, et al. **Exp Clin Endocrinol Diabetes** 1995; 103(5):275–9 (36 ref.)
Spontaneous mutation as a risk factor. Crow JF. **Exp Clin Immunogenet** 1995;12(3):121–8 (24 ref.)
Degeneration of human oncogenes and mitochondrial genes occurs in cells that exhibit age-related pathology. Cortopassi G, et al. **Exp Gerontol** 1996 Jan–Apr; 31(1–2):253–65 (43 ref.)
Mitochondrial DNA mutations associated with aging and degenerative diseases. Ozawa T. **Exp Gerontol** 1995 May–Aug;30(3–4):269–90 (55 ref.)
Mismatch repair as an important source of new mutations in non-dividing cells. MacPhee DG. **Experientia** 1996 Apr 15;52(4):357–63 (30 ref.)
Genetic markers: the key to early diagnosis and improved survival in pancreatic cancer? [editorial; comment] [see comments] Urrutia R, et al. **Gastroenterology** 1996 Jan; 110(1):306–10 (57 ref.) Comment on: Gastroenterology 1996 Jan;110(1):221–6. Comment on: Gastroenterology 1996 Jan;110(1):227–31. Comment in: Gastroenterology 1996 Aug;111(2):566–7.
The amber mutants of phage T4. Stahl FW. **Genetics** 1995 Oct;141(2):439–42 (24 ref.)
Mutations of the fibroblast growth factor receptor-3 gene in achondroplasia. Rousseau F, et al. **Horm Res** 1996; 45(1–2):108–10 (18 ref.)
Novel FGFR2 mutations in Crouzon and Jackson-Weiss syndromes show allelic heterogeneity and phenotypic variability. Park WJ, et al. **Hum Mol Genet** 1995 Jul; 4(7):1229–33 (18 ref.)
Mutations in pyruvate kinase. Beutler E, et al. **Hum Mutat** 1996;7(1):1–6 (40 ref.)
Applications of heteroduplex analysis for mutation detection in disease genes. Glavac D, et al. **Hum Mutat** 1995; 6(4):281–7 (75 ref.)
Molecular genetics of human antithrombin deficiency. Perry DJ, et al. **Hum Mutat** 1996;7(1):7–22 (119 ref.)
Mutations in muscle phosphofructokinase gene. Raben N, et al. **Hum Mutat** 1995;6(1):1–6 (37 ref.)
Molecular genetics of mucopolysaccharidosis type I: diagnostic, clinical, and biological implications. Scott HS, et al. **Hum Mutat** 1995;6(4):288–302 (66 ref.)
CDKN2A (p16INK4A) somatic and germline mutations. Smith-Sørensen B, et al. **Hum Mutat** 1996;7(4):294–303 (81 ref.)
Antagonists or altruists: do viral mutants modulate T-cell responses? Davenport MP. **Immunol Today** 1995 Sep; 16(9):432–6 (30 ref.)
Identification of DNA mismatch repair gene mutations in hereditary nonpolyposis colon cancer patients. Luce MC, et al. **Int J Cancer** 1996 Feb 20;69(1):50–2 (25 ref.)
K-ras mutation and pancreatic adenocarcinoma. Caldas C, et al. **Int J Pancreatol** 1995 Aug;18(1):1–6 (66 ref.)
Implications of delayed reproductive cell death (lethal mutations/genomic instability) for the interpretation of tissue responses. Hendry JH, et al. **Int J Radiat Biol** 1995 Oct;68(4):363–7 (32 ref.)
Lessons from the p53 mutant mouse. Jacks T. **J Cancer Res Clin Oncol** 1996;122(6):319–27 (79 ref.)
Recent advances in understanding the molecular mechanisms of the long QT syndrome. Roden DM, et al. **J Cardiovasc Electrophysiol** 1995 Nov;6(11):1023–31 (49 ref.)
Calcium-sensing receptor mutations: insights into a structurally and functionally novel receptor [editorial; comment] Pearce SH, et al. **J Clin Endocrinol Metab** 1996 Apr;81(4):1309–11 (16 ref.) Comment on: J Clin Endocrinol Metab 1996 Apr;81(4):1312–7.
Mutations in G proteins and G protein-coupled receptors in endocrine disease. Spiegel AM. **J Clin Endocrinol Metab** 1996 Jul;81(7):2434–42 (71 ref.)
Free-radical-induced mutation vs redox regulation: costs and benefits of genes in organelles. Allen JF, et al. **J Mol Evol** 1996 May;42(5):482–92 (76 ref.)
RET gene and its implications for cancer. Goodfellow PJ, et al. **J Natl Cancer Inst** 1995 Oct 18;87(20):1515–23 (71 ref.)
The structure of hepatitis B envelope and molecular variants of hepatitis B virus. Howard CR. **J Viral Hepat** 1995; 2(4):165–70 (21 ref.)
P53 and induction of apoptosis as a target for anticancer therapy. Neubauer A, et al. **Leukemia** 1996 Jul;10 Suppl 3:S2–S4 (46 ref.)
Molecular events in lung cancer. Roth JA. **Lung Cancer** 1995 Jun;12 Suppl 2:S3–15 (51 ref.)
Molecular methods for isolation of signal transduction pathway mutants. Chory J, et al. **Methods Cell Biol** 1995; 49:441–54 (16 ref.)
Diagnostic detection of mutant ras genes in minor cell populations. Kahn SM, et al. **Methods Enzymol** 1995; 255:452–64 (47 ref.)
Transdominant negative mutations. Shamah SM, et al. **Methods Enzymol** 1995;254:565–76 (58 ref.)
Myelin mutants: new models and new observations. Lunn KF, et al. **Microsc Res Tech** 1995 Oct 15;32(3):183–203 (113 ref.)
Defects of androgen receptor function: from sex reversal to motor neurone disease. MacLean HE, et al. **Mol Cell Endocrinol** 1995 Aug 11;112(2):133–41 (104 ref.)
Treatment protocols for transgenic mutation assays in vivo. Heddle JA, et al. **Mutagenesis** 1995 Nov;10(6):467–70 (17 ref.)
Genotypic selection of mitochondrial and oncogenic mutations in human tissue suggests mechanisms of age-related pathophysiology. Cortopassi G, et al. **Mutat Res** 1995 Oct;338(1–6):151–9 (43 ref.)
Mutation and mutagenesis in inherited and acquired human disease. The first EEMS Frits Sobels Prize Lecture, Noordwijkerhout, The Netherlands, June 1995. Evans HJ. **Mutat Res** 1996 Apr 13;351(2):89–103 (120 ref.)
Mutagenic nitroarenes, diesel emissions, particulate-induced mutations and cancer: an essay on cancer-causation by a moving target. Rosenkranz HS. **Mutat Res** 1996 Feb; 367(2):65–72 (85 ref.)
Molecular dosimetry of chemical mutagens. Relationship between DNA adduct formation and genetic changes analyzed at the molecular level. van Zeeland AA. **Mutat Res** 1996 Jun 12;353(1–2):123–50 (96 ref.)
Transcription-factor mutations and disease. Latchman DS. **N Engl J Med** 1996 Jan 4;334(1):28–33 (43 ref.)
Genetic analysis of ageing: role of oxidative damage and environmental stresses. Martin GM, et al. **Nat Genet** 1996 May;13(1):25–34 (151 ref.)
Deaf and dizzy mice with mutated myosin motors. Gillespie PG. **Nat Med** 1996 Jan;2(1):27–9 (13 ref.)
Plasmid-based transgenic mouse model for studying in vivo mutations. Boerrigter ME, et al. **Nature** 1995 Oct 19; 377(6550):657–9 (16 ref.)
When more is less: pathogenesis of glutamine repeat neurodegenerative diseases. Ross CA. **Neuron** 1995 Sep; 15(3):493–6 (35 ref.)
Microsatellite instability in human cancer. Speicher MR. **Oncol Res** 1995;7(6):267–75 (87 ref.)
Genetic variation of CNS receptors--a new perspective for pharmacogenetics. Propping P, et al. **Pharmacogenetics** 1995 Oct;5(5):318–25 (75 ref.)
p53 gene mutations and photocarcinogenesis. Nataraj AJ, et al. **Photochem Photobiol** 1995 Aug;62(2):218–30 (140 ref.)
Physiology and biochemistry of Drosophila learning mutants. Davis RL. **Physiol Rev** 1996 Apr;76(2):299–317 (97 ref.)
Premature termination codon mutations in the type VII collagen gene (COL7A1) underlie severe recessive dystrophic epidermolysis bullosa. Uitto J, et al. **Proc Assoc Am Physicians** 1995 Jul;107(2):245–52 (30 ref.)
Protein minimization: downsizing through mutation. DeGrado WF, et al. **Proc Natl Acad Sci U S A** 1996 Jun 11;93(12):5680–1 (19 ref.)
Analysis of MAOA mutations in humans. Hsu YP, et al. **Prog Brain Res** 1995;106:67–75 (54 ref.)
Estrogen receptor gene disruption: molecular characterization and experimental and clinical phenotypes. Korach KS, et al. **Recent Prog Horm Res** 1996;51:159–86; discussion 186–8 (50 ref.)
Resistance to thyrotropin and other abnormalities of the thyrotropin receptor. Refetoff S, et al. **Recent Prog Horm Res** 1996;51:97–120; discussion 120–2 (67 ref.)
Mutations of the BRCA1 gene in human cancer. Xu CF, et al. **Semin Cancer Biol** 1996 Feb;7(1):33–40 (63 ref.)
The targeting of somatic hypermutation. Jolly CJ, et al. **Semin Immunol** 1996 Jun;8(3):159–68 (53 ref.)
Sequential triggering of apoptosis, somatic mutation and isotype switch during germinal center development. Liu YJ, et al. **Semin Immunol** 1996 Jun;8(3):169–77 (51 ref.)
Gene conversion and homologous recombination in murine B cells. Selsing E, et al. **Semin Immunol** 1996 Jun;8(3):151–8 (39 ref.)
The mechanism of somatic hypermutation studied with transgenic and transfected target genes. Storb U, et al. **Semin Immunol** 1996 Jun;8(3):131–40 (55 ref.)
Characterization of the cis-acting elements required for somatic hypermutation of murine antibody V genes using conventional transgenic and transgene homologous recombination approaches. Tumas-Brundage K, et al. **Semin Immunol** 1996 Jun;8(3):141–50 (68 ref.)
Molecular biology of colon polyps and colon cancer. Allen JI. **Semin Surg Oncol** 1995 Nov–Dec;11(6):399–405 (22 ref.)
Fragile X syndrome and other dynamic mutation diseases. Sutherland GR, et al. **Southeast Asian J Trop Med Public Health** 1995;26 Suppl 1:77–85 (41 ref.)
Multistep carcinogenesis in colorectal cancers. Takami K, et al. **Southeast Asian J Trop Med Public Health** 1995;26 Suppl 1:190–6 (28 ref.)
A review of mutations causing deficiencies of antithrombin, protein C and protein S. Aiach M, et al. **Thromb Haemost** 1995 Jul;74(1):81–9 (120 ref.)
Protein C deficiency: a database of mutations, 1995 update. On behalf of the Subcommittee on Plasma Coagulation Inhibitors of the Scientific and Standardization Committee of the ISTH. Reitsma PH, et al. **Thromb Haemost** 1995 May;73(5):876–89 (112 ref.)
Analysis of mutation at the hprt locus in human T lymphocytes. Lambert B, et al. **Toxicol Lett** 1995 Dec; 82–83:323–33 (54 ref.)
Transgenic models for detection of mutations in tumors and normal tissues of rodents. Mirsalis JC. **Toxicol Lett** 1995 Dec;82–83:131–4 (12 ref.)
The genetic basis of quantitative variation: numbers of sensory bristles of Drosophila melanogaster as a model system. Mackay TF. **Trends Genet** 1995 Dec;11(12):464–70 (35 ref.)
Fibroblast-growth-factor receptor mutations in human skeletal disorders. Muenke M, et al. **Trends Genet** 1995 Aug; 11(8):308–13 (50 ref.)
Molecular genetics of hereditary non-polyposis colorectal cancer (HNPCC). Cama A, et al. **Tumori** 1996 Mar–Apr; 82(2):122–35 (107 ref.)
[Biochemical, molecular and social aspects of carrier screening for Tay-Sachs disease] Peleg L, et al. **Harefuah** 1995 Dec 1;129(11):475–80 (43 ref.) **(Heb)**
[Genetic abnormalities in lung cancer and their prognostic implications] Mitsudomi T, et al. **Gan To Kagaku Ryoho** 1996 Jul;23(8):990–6 (54 ref.) (Eng. Abstr.) **(Jpn)**
[Prognostic factors of colon cancer from a molecular biology standpoint] Mori M, et al. **Gan To Kagaku Ryoho** 1996 Jul;23(8):982–9 (51 ref.) (Eng. Abstr.) **(Jpn)**
[Genetic alterations in stomach cancer] Tahara E, et al. **Nippon Geka Gakkai Zasshi** 1996 Apr;97(4):252–6 (23 ref.) (Eng. Abstr.) **(Jpn)**
[Mitochondria gene mutation and diabetes] Kadowaki T. **Nippon Naika Gakkai Zasshi** 1996 Apr 10;85(4):573–7 (5 ref.) **(Jpn)**
[Mutations in precore and core nucleotide sequence of hepatitis B virus correlated with fulminant and severe hepatitis] Ehata T, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:457–62 (10 ref.) **(Jpn)**
[Precore/core mutation and clinical course of chronic hepatitis B virus infection from the view point of asymptomatic carriers] Fujiwara K, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:401–5 (20 ref.) **(Jpn)**
[Virological diagnosis--HBV mutant, HBV subtype, etc.] Ito Y, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:492–7 (12 ref.) **(Jpn)**
[Probable implication of mutations of the X open reading frame in the onset of fulminant hepatitis B] Kaneko M, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:463–6 (14 ref.) **(Jpn)**
[Nucleotide mutations in the precore and core region of hepatitis B virus] Karasawa T, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:52–7 (20 ref.) **(Jpn)**
[Analysis of hepatitis C virus quasispecies populations using PCR-SSCP method] Kurosaki M, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:339–45 (16 ref.) **(Jpn)**
[Cloning of the holocarboxylase synthetase cDNA and identification of mutations prevalent in Japanese HCS-deficient patients] Narisawa K, et al. **Nippon Rinsho** 1996 Jan;54(1):259–67 (14 ref.) (Eng. Abstr.) **(Jpn)**
[Detection of HBV precore mutation by PCR-RFLP] Niitsuma H, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:316–20 (7 ref.) **(Jpn)**
[Mutant of the pre-S and S region of HBV] Nishikawa M, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:47–51 (15 ref.) **(Jpn)**
[Mutation site-specific assay (MSSA) for the detection of hepatitis B virus precore defective mutant in hepatitis B infection] Tsubota A. **Nippon Rinsho** 1995 Oct;53 Suppl:321–4 (6 ref.) **(Jpn)**
[Mutagenesis study of pharmacological receptors: approach to their structure-function relationships] Sakamoto A, et al. **Nippon Yakurigaku Zasshi** 1995 Nov;106(5):321–6 (16 ref.) (Eng. Abstr.) **(Jpn)**
[p53 gene mutations in brain tumors] Koga H, et al. **No To Shinkei** 1995 Sep;47(9):845–55 (108 ref.) **(Jpn)**
[Diabetogenes; which cause type II diabetes mellitus] Murakami T, et al. **Rinsho Byori** 1995 Aug;43(8):781–5 (0 ref.) (Eng. Abstr.) **(Jpn)**
[A family with X-linked hydrocephalus resulting from mutations in the neural cell adhesion molecule L1] Maruta K, et al. **Rinsho Shinkeigaku** 1996 Mar;36(3):462–6 (16 ref.) (Eng. Abstr.) **(Jpn)**
[8-Oxoguanine repair system and its role in mitochondria] Kang D, et al. **Seikagaku** 1996 Apr;68(4):289–95 (22 ref.) **(Jpn)**
[Representational difference analysis: identification of the

differences between genomes] Aburatani H, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):573–9 (11 ref.) **(Jpn)**

[DNA lesions produced by active oxygen and their induced mutations] Kamiya H, et al. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1571–7 (36 ref.) **(Jpn)**

[Mice carrying null mutations of the homeotic genes Hoxa10 and Msx1] Satokata I, et al. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2134–43 (50 ref.) **(Jpn)**

[A new mechanism of mutation in man: expansion of trinucleotide repeats] Illarioshkin SN, et al. **Genetika** 1995 Nov;31(11):1478–89 (108 ref.) (Eng. Abstr.) **(Rus)**

[The problem of systemic mutation] Stegnii VN. **Genetika** 1996 Jan;32(1):14–22 (43 ref.) (Eng. Abstr.) **(Rus)**

[Dynamic mutations—a newly detected category of mutations which is the basis for certain neurologic diseases] Mardelić D. **Lijec Vjesn** 1995 Jul–Aug;117(7–8):184–8 (23 ref.) (Eng. Abstr.) **(Scr)**

DRUG EFFECTS

Variability in gene expression and tumor formation within genetically homogeneous animal populations in bioassays. Wolff GL. **Fundam Appl Toxicol** 1996 Feb;29(2):176–84 (30 ref.)

DNA damage: chemistry, repair, and mutagenic potential. Singer B. **Regul Toxicol Pharmacol** 1996 Feb;23(1 Pt 1):2–13 (43 ref.)

GENETICS

K-ras mutation in a tubular adenoma originating at an ileostomy in a familial adenomatous polyposis patient. Herring JA, et al. **Am J Gastroenterol** 1996 Mar; 91(3):587–91 (38 ref.)

Trinucleotide instability: a repeating theme in human inherited disorders. Gusella JF, et al. **Annu Rev Med** 1996; 47:201–9 (18 ref.)

Mutations in collagen genes resulting in metaphyseal and epiphyseal dysplasias. Olsen BR. **Bone** 1995 Aug;17(2 Suppl):45S–49S (30 ref.)

Genetics of aniridia and anterior segment dysgenesis. Churchill A, et al. **Br J Ophthalmol** 1996 Jul;80(7):669–73 (53 ref.)

The spectrum of mutations in Btk that cause X-linked agammaglobulinemia. Conley ME, et al. **Clin Immunol Immunopathol** 1995 Sep;76(3 Pt 2):S192–7 (33 ref.)

Antimicrobial agent resistance in mycobacteria: molecular genetic insights. Musser JM. **Clin Microbiol Rev** 1995 Oct; 8(4):496–514 (181 ref.)

Understanding enamel formation from mutations causing X-linked amelogenesis imperfecta. Lagerström-Fermér M, et al. **Connect Tissue Res** 1995;32(1–4):241–6 (40 ref.)

Mutations in Alport syndrome associated with diffuse esophageal leiomyomatosis. Antignac C, et al. **Contrib Nephrol** 1996;117:172–82 (37 ref.)

P53-mediated radioresistance does not correlate with metastatic potential in tumorigenic rat embryo cell lines following oncogene transfection. Bristow RG, et al. **Int J Radiat Oncol Biol Phys** 1996 Jan 15;34(2):341–55 (81 ref.)

Appearance of HBV mutants during chronic infection. Santantonio T, et al. **Ital J Gastroenterol** 1995 Jun; 27(5):265–9 (43 ref.)

Mutations, malformations and mortality. Suthers G. **J Paediatr Child Health** 1996 Feb;32(1):10–5 (67 ref.)

Somatic mutations in the brain: relationship to aging? Evans DA, et al. **Mutat Res** 1995 Oct;338(1–6):173–82 (47 ref.)

Use of transgenic mouse models for studying somatic mutations in aging. Martus HJ, et al. **Mutat Res** 1995 Oct; 338(1–6):203–13 (46 ref.)

The somatic mutation theory of ageing. Morley AA. **Mutat Res** 1995 Oct;338(1–6):19–23 (49 ref.)

Mechanisms of mutant genes in spina bifida: a review of implications from animal models. George TM, et al. **Pediatr Neurosurg** 1995;23(5):236–45 (62 ref.)

Pseudomonas aeruginosa, mucoidy and the chronic infection phenotype in cystic fibrosis. Deretic V, et al. **Trends Microbiol** 1995 Sep;3(9):351–6 (59 ref.)

Genetic alterations associated with the evolution and progression of astrocytic brain tumours. Ohgaki H, et al. **Virchows Arch** 1995;427(2):113–8 (44 ref.)

[Mutation of G proteins] Trüeb RM. **Hautarzt** 1995 Sep; 46(9):603–6 (15 ref.) (Eng. Abstr.) **(Ger)**

[The mouse embryogenesis of jumonji mutant obtained by gene-trap method] Motoyama J, et al. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2152–61 (24 ref.) **(Jpn)**

IMMUNOLOGY

Potential targets for autosomal SCID mutations. Taccioli GE, et al. **Curr Opin Immunol** 1995 Aug;7(4):436–40 (50 ref.)

PHYSIOLOGY

Glucokinase mutations, insulin secretion, and diabetes mellitus. Bell GI, et al. **Annu Rev Physiol** 1996;58:171–86 (63 ref.)

MUTATION, FRAMESHIFT see **FRAMESHIFT MUTATION**

MUTATION, GERM-LINE see **GERM-LINE MUTATION**

MUTATION, POINT see **POINT MUTATION**

MUTATIONAL ANALYSIS, DNA see **DNA MUTATIONAL ANALYSIS**

MUTISM

[Elective mutism in children: literature review] Kołakowski A, et al. **Psychiatr Pol** 1996 Mar–Apr;30(2):233–46 (27 ref.) (Eng. Abstr.) **(Pol)**

ETIOLOGY

Cerebellar mutism: report of seven cases and review of the literature. Erşahin Y, et al. **Neurosurgery** 1996 Jan; 38(1):60–5;discussion 66 (30 ref.)

PHYSIOPATHOLOGY

Mutism and pseudobulbar symptoms after resection of posterior fossa tumors in children: incidence and pathophysiology. Pollack IF, et al. **Neurosurgery** 1995 Nov; 37(5):885–93 (39 ref.)

Transient cerebellar mutism after posterior fossa surgery in children. Van Calenbergh F, et al. **Neurosurgery** 1995 Nov; 37(5):894–8 (32 ref.)

MUTISM, AKINETIC see **AKINETIC MUTISM**

MYASTHENIA GRAVIS

Myasthenia gravis. Sen S, et al. **J Assoc Physicians India** 1995 Jul;43(7):487–93 (7 ref.)

[Myasthenia and pregnancy. Two case reports] Lucot JP, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996; 25(2):179–85 (19 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

Nephrotic syndrome, malignant thymoma, and myasthenia gravis. Case report and review of the literature. Jayasena SD, et al. **Am J Nephrol** 1995;15(4):361–3 (8 ref.)

Myasthenia gravis presenting with stridor. Hanson JA, et al. **Thorax** 1996 Jan;51(1):108–9 (8 ref.)

[A case of thymoma in an elderly patient associated with myasthenia gravis] Mukaida T, et al. **Kyobu Geka** 1996 Apr; 49(4):274–7 (12 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

[Differential diagnosis of disorders of neuromuscular transmission: myasthenia gravis and myasthenic syndrome] Martić V, et al. **Vojnosanit Pregl** 1994 May–Jun; 51(3):237–41 (55 ref.) **(Scr)**

DRUG THERAPY

[Intravenous immunoglobulins in the treatment of neurologic diseases] Illa I, et al. **Neurologia** 1996 Jun–Jul;11(6):220–8 (56 ref.) **(Spa)**

ETIOLOGY

The thymus and the pathogenesis of myasthenia gravis. Levinson AI, et al. **Clin Immunol Immunopathol** 1996 Jan; 78(1):1–5 (46 ref.)

[Pathophysiology on the disorder of neuromuscular transmission defects] Sahashi K, et al. **Rinsho Byori** 1995 Sep;43(9):902–9 (15 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Establishment of a mouse model of myasthenia gravis which mimics human myasthenia gravis pathogenesis for immune intervention. Christadoss P, et al. **Adv Exp Med Biol** 1995; 383:195–9 (16 ref.)

Oral tolerance in myasthenia gravis. Drachman DB, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:258–72 (58 ref.)

NURSING

Myasthenia gravis: pathophysiology, diagnosis and collaborative care. Kernich CA, et al. **J Neurosci Nurs** 1995 Aug;27(4):207–15; quiz 216–8 (18 ref.)

PATHOLOGY

The thymus and the pathogenesis of myasthenia gravis. Levinson AI, et al. **Clin Immunol Immunopathol** 1996 Jan; 78(1):1–5 (46 ref.)

SURGERY

Long-term outcome and quality of life after thymectomy for myasthenia gravis. Busch C, et al. **Ann Surg** 1996 Aug; 224(2):225–32 (22 ref.)

Transcervical thymectomy. Ferguson MK. **Chest Surg Clin N Am** 1996 Feb;6(1):105–15 (24 ref.)

Extended transsternal thymectomy. Mulder DG. **Chest Surg Clin N Am** 1996 Feb;6(1):95–105 (7 ref.)

The effect of thymectomy on myasthenia gravis, thrombocytopenia, and granulocytopenia associated with thymoma: report of a case. Kobayashi M, et al. **Surg Today** 1995;25(12):1061–5 (14 ref.)

THERAPY

Oral tolerance in myasthenia gravis. Drachman DB, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:258–72 (58 ref.)

[Myasthenic crisis during pregnancy: case report and literature survey] Kwieciński H, et al. **Pol Tyg Lek** 1995 Oct;50(40–44):50–2 (14 ref.) (Eng. Abstr.) **(Pol)**

MYB GENES see **ONCOGENES**

MYC GENES see **GENES, MYC**

MYC PROTO-ONCOGENE PROTEINS see **PROTO-ONCOGENE PROTEINS C-MYC**

MYCETOMA see **MADUROMYCOSIS**

MYCOBACTERIUM

Microbiology and classification of mycobacteria. Eisenstadt J, et al. **Clin Dermatol** 1995 May–Jun;13(3):197–206 (59 ref.)

CHEMISTRY

The variable surface glycolipids of mycobacteria: structures, synthesis of epitopes, and biological properties. Aspinall GO, et al. **Adv Carbohydr Chem Biochem** 1995;51:169–242 (226 ref.)

The envelope of mycobacteria. Brennan PJ, et al. **Annu Rev Biochem** 1995;64:29–63 (153 ref.)

CLASSIFICATION

Current techniques in mycobacterial detection and speciation. Herold CD, et al. **Crit Rev Clin Lab Sci** 1996 Apr; 33(2):83–138 (145 ref.)

Feline tuberculosis: a literature review and discussion of 19 cases caused by an unusual mycobacterial variant. Gunn-Moore DA, et al. **Vet Rec** 1996 Jan 20;138(3):53–8 (38 ref.)

DRUG EFFECTS

Antimicrobial agent resistance in mycobacteria: molecular genetic insights. Musser JM. **Clin Microbiol Rev** 1995 Oct; 8(4):496–514 (181 ref.)

Activity of quinolones against mycobacteria. Jacobs MR. **Drugs** 1995;49 Suppl 2:67–75 (29 ref.)

Resistance to quinolones in mycobacteria. Cambau E, et al. **Res Microbiol** 1996 Jan–Feb;147(1–2):52–9 (41 ref.)

Rifamycin resistance in mycobacteria. Cole ST. **Res Microbiol** 1996 Jan–Feb;147(1–2):48–52 (43 ref.)

GENETICS

Techniques for genetic engineering in mycobacteria. Alternative host strains, DNA-transfer systems and vectors. Hermans J, et al. **Antonie Van Leeuwenhoek** 1996 Apr;69(3):243–56 (100 ref.)

[Rapid detection and identification of mycobacteria by the PCR assay based on the co-amplification of the gene IS6110 and groEL] Fusegawa H, et al. **Rinsho Byori** 1995 Oct;43(10):1051–6 (18 ref.) (Eng. Abstr.) **(Jpn)**

[Current status of research on molecular genetics of mycobacteria] Gizatulina NM. **Probl Tuberk** 1996;(2):58–62 (62 ref.) **(Rus)**

IMMUNOLOGY

T-cell recognition of mycobacterial antigens. Vordermeier HM. **Eur Respir J Suppl** 1995 Sep;20:657s–667s (121 ref.)

[The role of some cellular components of bacterial parasites in determining the incidence of tuberculosis: studies on mycobacterial antigens, with special reference to mycobacterial immunoreactive ribosomal and secreted proteins] Yamada T, et al. **Kekkaku** 1995 Nov; 70(11):639–44 (40 ref.) (Eng. Abstr.) **(Jpn)**

ISOLATION & PURIFICATION

Chronic otitis media after tympanostomy tube placement caused by Mycobacterium abscessus: a new clinical entity? Franklin DJ, et al. **Am J Otol** 1994 May;15(3):313–20 (21 ref.)

Mycobacterial disease of the head and neck: current perspective. Cleary KR, et al. **Ann Otol Rhinol Laryngol** 1995 Oct;104(10 Pt 1):830–3 (22 ref.)

Current techniques in mycobacterial detection and speciation. Herold CD, et al. **Crit Rev Clin Lab Sci** 1996 Apr; 33(2):83–138 (145 ref.)

[Current developments in Mycobacteria diagnosis] Bodmer T, et al. **Schweiz Med Wochenschr** 1995 Sep 16; 125(37):1726–34 (65 ref.) (Eng. Abstr.) **(Ger)**

MYCOBACTERIUM, ATYPICAL

GENETICS

Mobile genetic elements in mycobacteria. Dale JW. **Eur Respir J Suppl** 1995 Sep;20:633s–648s (100 ref.)

Molecular diagnosis of tuberculosis. Richeldi L, et al. **Eur Respir J Suppl** 1995 Sep;20:689s–700s (95 ref.)

GROWTH & DEVELOPMENT

Cutaneous infections with rapidly growing mycobacteria. Sastry V, et al. **Clin Dermatol** 1995 May-Jun;13(3):266-71 (55 ref.)

ISOLATION & PURIFICATION

Mycobacterium marinum. Gluckman SJ. **Clin Dermatol** 1995 May-Jun;13(3):273-6 (40 ref.)

Mycocutaneous atypical mycobacterial infections in acquired immunodeficiency syndrome. Zanelli G, et al. **Clin Dermatol** 1995 May-Jun;13(3):281-8 (68 ref.)

Clinical manifestations and implications of coinfection with Mycobacterium kansasii and human immunodeficiency virus type 1. Witzig RS, et al. **Clin Infect Dis** 1995 Jul; 21(1):77-85 (69 ref.)

Oral manifestation of disseminated Mycobacterium kansasii infection in a patient with AIDS. Nüesch R, et al. **Dermatology** 1996;192(2):183-4 (10 ref.)

Mycobacterium marinum infection of the finger. Phillips SA, et al. **J Hand Surg [Br]** 1995 Dec;20(6):801-2 (8 ref.)

VIROLOGY

Human immunodeficiency virus-associated atypical mycobacterial skeletal infections. Hirsch R, et al. **Semin Arthritis Rheum** 1996 Apr;25(5):347-56 (46 ref.)

MYCOBACTERIUM AVIUM

DRUG EFFECTS

Antimycobacterial quinolones: a comparative analysis of structure-activity and structure-cytotoxicity relationships. Klopman G, et al. **Res Microbiol** 1996 Jan-Feb; 147(1-2):86-96 (32 ref.)

GENETICS

Mobile genetic elements in mycobacteria. Dale JW. **Eur Respir J Suppl** 1995 Sep;20:633s-648s (100 ref.)

MYCOBACTERIUM AVIUM COMPLEX

[Attempts to elucidate the reasons why mycobacterial infections are generally intractable] Tomioka H. **Nippon Saikingaku Zasshi** 1995 Jul;50(3):687-701 (50 ref.) **(Jpn)**

DRUG EFFECTS

Glycosyltransferases as targets for inhibition of cell wall synthesis in M. tuberculosis and M. avium. Maddry JA, et al. **Res Microbiol** 1996 Jan-Feb;147(1-2):106-12 (25 ref.)

The genetics of multiple drug resistance in Mycobacterium tuberculosis and the Mycobacterium avium complex. Morris SL, et al. **Res Microbiol** 1996 Jan-Feb; 147(1-2):68-73 (40 ref.)

Identification of new drug targets in Mycobacterium avium and Mycobacterium tuberculosis. Rastogi N, et al. **Res Microbiol** 1996 Jan-Feb;147(1-2):97-105 (36 ref.)

Ribosomal drug resistance in mycobacteria. Sander P, et al. **Res Microbiol** 1996 Jan-Feb;147(1-2):59-67 (73 ref.)

[Azithromycin and Mycobacterium avium infection] Perronne C. **Pathol Biol (Paris)** 1995 Jun;43(6):565-7 (12 ref.) (Eng. Abstr.) **(Fre)**

ISOLATION & PURIFICATION

Clinical and epidemiologic implications of polyclonal infection due to Mycobacterium avium complex. von Reyn CF, et al. **Res Microbiol** 1996 Jan-Feb;147(1-2):24-30 (46 ref.)

MYCOBACTERIUM AVIUM-INTRACELLULARE see **MYCOBACTERIUM AVIUM COMPLEX**

MYCOBACTERIUM AVIUM-INTRACELLULARE COMPLEX see **MYCOBACTERIUM AVIUM COMPLEX**

MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION

Localized soft-tissue infections with Mycobacterium avium/Mycobacterium intracellulare complex in immunocompetent patients: granulomatous tenosynovitis of the hand or wrist. Hellinger WC, et al. **Clin Infect Dis** 1995 Jul;21(1):65-9 (25 ref.)

Mycobacterium avium complex infection in AIDS: clinical features, treatment, and prevention. Eccles E, et al. **J Assoc Nurses AIDS Care** 1995 Sep-Oct;6(5):37-47; quiz 48-9 (23 ref.)

Mycobacterium avium intracellulare infection in children with AIDS. Gershon AA. **Pediatr Pulmonol Suppl** 1995; 11:7-9 (14 ref.)

[Clinical comparison of pulmonary tuberculosis with pulmonary M. avium complex disease] Suzuki K. **Kekkaku** 1995 Nov;70(11):659-63 (4 ref.) (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

[Liver, biliary tracts and human immunodeficiency virus infection. 2: hepatobiliary complications of AIDS] Vuitton DA, et al. **Gastroenterol Clin Biol** 1996;20(3):281-93 (146 ref.) **(Fre)**

DIAGNOSIS

[Clinical aspects and therapy of ubiquitous mycobacterioses] Fätkenheuer G, et al. **Internist (Berl)** 1995 Oct; 36(10):987-94 (52 ref.) **(Ger)**

[Molecular biological methods in the mycobacteriological laboratory--was 1995 a year of progress, problems or both?] Böttger EC, et al. **Pneumologie** 1995 Dec; 49(12):664-6 (19 ref.) **(Ger)**

DRUG THERAPY

Rifabutin in the treatment of Mycobacterium avium complex infection: experience in Europe. Dautzenberg B. **Clin Infect Dis** 1996 Apr;22 Suppl 1:S33-6 (22 ref.)

Mycobacterium avium complex infection, rifabutin, and uveitis--is there a connection? Nichols CW. **Clin Infect Dis** 1996 Apr;22 Suppl 1:S43-7; discussion S47-9 (21 ref.)

Rifabutin prophylaxis for Mycobacterium avium complex infection in patients with AIDS. Siegal FP. **Clin Infect Dis** 1996 Apr;22 Suppl 1:S23-30; discussion S30-2 (38 ref.)

Rifabutin therapy for disseminated Mycobacterium avium complex infection. Sullam PM. **Clin Infect Dis** 1996 Apr; 22 Suppl 1:S37-41; discussion S41-2 (41 ref.)

Treatment and prophylaxis of Mycobacterium avium complex. Young LS. **Int J STD AIDS** 1996;7 Suppl 1:23-7 (15 ref.)

Managing HIV. Part 5: Treating secondary outcomes. 5.15 HIV and non-tuberculous mycobacterial infection. Hoy JF, et al. **Med J Aust** 1996 May 6;164(9):543-5 (29 ref.)

Treatment of disseminated Mycobacterium avium complex disease: a clinician's perspective. Benson CA. **Res Microbiol** 1996 Jan-Feb;147(1-2):16-24 (43 ref.)

Solving the dilemma of antimycobacterial chemotherapy. Rastogi N, et al. **Res Microbiol** 1996 Jan-Feb;147(1-2):7-10 (30 ref.)

Clarithromycin against Mycobacterium avium complex infections. Heifets LB. **Tuber Lung Dis** 1996 Feb; 77(1):19-26 (105 ref.)

[Azithromycin and Mycobacterium avium infection] Perronne C. **Pathol Biol (Paris)** 1995 Jun;43(6):565-7 (12 ref.) (Eng. Abstr.) **(Fre)**

[Treatment of non-tuberculous mycobacterial infections] Dautzenberg B. **Rev Mal Respir** 1996;13(1):81-3 (17 ref.) **(Fre)**

EPIDEMIOLOGY

Clinical and epidemiologic implications of polyclonal infection due to Mycobacterium avium complex. von Reyn CF, et al. **Res Microbiol** 1996 Jan-Feb;147(1-2):24-30 (46 ref.)

ETIOLOGY

Mycobacterium avium complex infection in AIDS. Kemper CA, et al. **AIDS Clin Rev** 1995-96;:153-228 (271 ref.)

MICROBIOLOGY

Beige mouse model for Mycobacterium avium complex disease. Gangadharam PR. **Antimicrob Agents Chemother** 1995 Aug;39(8):1647-54 (101 ref.)

PREVENTION & CONTROL

Preventing disseminated Mycobacterium avium complex disease in patients infected with human immunodeficiency virus. Ostroff SM, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S72-6 (27 ref.)

MYCOBACTERIUM BOVIS

Epidemiology of Mycobacterium bovis infection in animals and humans, with particular reference to Africa. Cosivi O, et al. **Rev Sci Tech** 1995 Sep;14(3):733-46 (63 ref.)

The zoonotic importance of Mycobacterium bovis. Moda G, et al. **Tuber Lung Dis** 1996 Apr;77(2):103-8 (33 ref.)

The epidemiology of Mycobacterium bovis infections in animals and man: a review. O'Reilly LM, et al. **Tuber Lung Dis** 1995 Aug;76 Suppl 1:1-46 (362 ref.)

[Diagnosis of a retroperitoneal BCG abscess in an infant. Case report and review of the literature] Stegmann J. **Ultraschall Med** 1996 Feb;17(1):27-30 (21 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

T cells and cytokines in intracellular bacterial infections: experiences with Mycobacterium bovis BCG. Kaufmann SH, et al. **Ciba Found Symp** 1995;195:123-32; discussion 132-6 (33 ref.)

[Application and development of immunity of childhood vaccines] Yang Y. **Chung Hua I Hsueh Tsa Chih** 1996 Apr; 76(4):318-9 (21 ref.) **(Chi)**

MYCOBACTERIUM CHELONAE

[A case of a patient with post-operative empyema due to Mycobacterium chelonae] Takemoto N, et al. **Kyobu Geka** 1996 Apr;49(4):301-5 (12 ref.) (Eng. Abstr.) **(Jpn)**

ISOLATION & PURIFICATION

[A case of keratitis due to Mycobacterium chelonae] Duchesne B, et al. **Bull Soc Belge Ophtalmol** 1994;254:59-62 (10 ref.) (Eng. Abstr.) **(Fre)**

MYCOBACTERIUM CHELONEI see **MYCOBACTERIUM CHELONAE**

MYCOBACTERIUM INFECTIONS

[Non-tuberculous mycobacterium pulmonary infection in children] Albertini M, et al. **Rev Pneumol Clin** 1996; 52(3):171-4 (26 ref.) **(Fre)**

[Infection and cytokine] Onozaki K. **Nippon Rai Gakkai Zasshi** 1995 Nov;64(3):149-62 (76 ref.) **(Jpn)**

DIAGNOSIS

[Mycobacteriosis--diagnosis and treatment] Krasucka-Kluzniak A. **Pneumonol Pol** 1990 Nov-Dec; 58(11-12):639-46 (50 ref.) **(Pol)**

DRUG THERAPY

Toxic effects and drug interactions of antimycobacterial therapy. Chan-Tompkins NH. **Clin Dermatol** 1995 May-Jun;13(3):223-33 (99 ref.)

EPIDEMIOLOGY

Epidemiology of mycobacterial diseases. Portaels F. **Clin Dermatol** 1995 May-Jun;13(3):207-22 (117 ref.)

ETIOLOGY

Mycobacterial infections: are the observed enigmas and paradoxes explained by immunosuppression and immunodeficiency? Maes HH, et al. **Med Hypotheses** 1996 Feb;46(2):163-71 (86 ref.)

IMMUNOLOGY

Functions of T-cell subsets and cytokines in mycobacterial infections. Munk ME, et al. **Eur Respir J Suppl** 1995 Sep; 20:668s-675s (91 ref.)

Mycobacterial infections: are the observed enigmas and paradoxes explained by immunosuppression and immunodeficiency? Maes HH, et al. **Med Hypotheses** 1996 Feb;46(2):163-71 (86 ref.)

MICROBIOLOGY

Mycobacterial and fungal infections of bone and joints. Meier JL, et al. **Curr Opin Rheumatol** 1995 Jul;7(4):329-36 (75 ref.)

[Current developments in Mycobacteria diagnosis] Bodmer T, et al. **Schweiz Med Wochenschr** 1995 Sep 16; 125(37):1726-34 (65 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

Penile mass caused by the newly described organism Mycobacterium celatum. Dahl DM, et al. **Urology** 1996 Feb;47(2):266-8 (13 ref.)

PREVENTION & CONTROL

Prospects for new interventions in the treatment and prevention of mycobacterial disease. Young DB, et al. **Annu Rev Microbiol** 1995;49:641-73 (163 ref.)

Variation in protection by BCG: implications of and for heterologous immunity [see comments] Fine PE. **Lancet** 1995 Nov 18;346(8986):1339-45 (73 ref.) Comment in: Lancet 1996 Feb 3;347(8997):333-4. Comment in: Lancet 1996 Feb 3;347(8997):334.

THERAPY

Prospects for new interventions in the treatment and prevention of mycobacterial disease. Young DB, et al. **Annu Rev Microbiol** 1995;49:641-73 (163 ref.)

[Mycobacteriosis--diagnosis and treatment] Krasucka-Kluzniak A. **Pneumonol Pol** 1990 Nov-Dec; 58(11-12):639-46 (50 ref.) **(Pol)**

VETERINARY

Mycobacterial infections of animals: pathology and pathogenesis. Hines ME 2nd, et al. **Lab Anim Sci** 1995 Aug; 45(4):334-51 (142 ref.)

VIROLOGY

Human immunodeficiency virus-associated atypical mycobacterial skeletal infections. Hirsch R, et al. **Semin Arthritis Rheum** 1996 Apr;25(5):347-56 (46 ref.)

MYCOBACTERIUM INFECTIONS, ATYPICAL

Mycobacterium marinum. Gluckman SJ. **Clin Dermatol** 1995 May-Jun;13(3):273-6 (40 ref.)

Unusual cutaneous mycobacterial diseases. Groves R. **Clin Dermatol** 1995 May-Jun;13(3):257-63 (82 ref.)

Diseases caused by Mycobacterium scrofulaceum. Hautmann G, et al. **Clin Dermatol** 1995 May-Jun;13(3):277-80 (25 ref.)

Cutaneous infections with rapidly growing mycobacteria. Sastry V, et al. **Clin Dermatol** 1995 May-Jun;13(3):266-71 (55 ref.)

Mycocutaneous atypical mycobacterial infections in acquired immunodeficiency syndrome. Zanelli G, et al. **Clin Dermatol** 1995 May-Jun;13(3):281-8 (68 ref.)

The changing spectrum of pulmonary infections due to nontuberculous mycobacteria. Boggs DS. **J Okla State Med Assoc** 1995 Sep;88(9):373-82 (52 ref.)

[Mycobacterium gordonae infections in human immunodeficiency virus infection] Maslo C, et al. **Presse Med** 1995 Sep 2-9;24(25):1157-60 (15 ref.) (Eng. Abstr.) **(Fre)**

[A case report of Mycobacterium chelonei keratitis] Sasagawa T, et al. **Nippon Ganka Gakkai Zasshi** 1996 Jun; 100(6):464-70 (30 ref.) (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

Clinical manifestations and implications of coinfection with Mycobacterium kansasii and human immunodeficiency virus type 1. Witzig RS, et al. **Clin Infect Dis** 1995 Jul; 21(1):77-85 (69 ref.)

[Pulmonary infection due to Mycobacterium szulgai associated with multiple bullous disease of the lung] Mori K, et al. **Kekkaku** 1995 Sep;70(9):511-6 (12 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Mycobacterium ulcerans infection in Australian children: report of eight cases and review. Goutzamanis JJ, et al. **Clin Infect Dis** 1995 Nov;21(5):1186-92 (55 ref.)

Cutaneous Mycobacterium chelonei presenting in an immunocompetent host: case report and review of the literature. Kelley LC, et al. **Cutis** 1995 Nov;56(5):293-5 (10 ref.)

Oral manifestation of disseminated Mycobacterium kansasii infection in a patient with AIDS. Nüesch R, et al. **Dermatology** 1996;192(2):183-4 (10 ref.)

Mycobacterium marinum infection of the finger. Phillips SA, et al. **J Hand Surg [Br]** 1995 Dec;20(6):801-2 (8 ref.)

[Clinical aspects and therapy of ubiquitous mycobacterioses] Fätkenheuer G, et al. **Internist (Berl)** 1995 Oct; 36(10):987-94 (52 ref.) **(Ger)**

[Diagnosis of tuberculosis] Rüsch-Gerdes S. **Internist (Berl)** 1995 Oct;36(10):957-60 (20 ref.) **(Ger)**

[Mycobacteria and mycobacterioses] Böttger EC. **Pneumologie** 1995 Dec;49 Suppl 3:636-42 (18 ref.) (Eng. Abstr.) **(Ger)**

[New developments in non-tuberculoid mycobacterioses. I: Diseases in patients without HIV infection] Schönfeld N, et al. **Pneumologie** 1996 Apr;50(4):313-22 (116 ref.) **(Ger)**

DRUG THERAPY

Treatment of infections caused by rapidly growing mycobacteria in the era of the newer macrolides. Wallace RJ Jr. **Res Microbiol** 1996 Jan-Feb;147(1-2):30-5 (34 ref.)

[Treatment of non-tuberculous mycobacterial infections] Dautzenberg B. **Rev Mal Respir** 1996;13(1):81-3 (17 ref.) **(Fre)**

[Therapeutic approaches in diseases caused by mycobacteria] Urbanczik R. **Pneumologie** 1995 Dec;49 Suppl 3:649-52 (32 ref.) (Eng. Abstr.) **(Ger)**

MICROBIOLOGY

[A case of keratitis due to Mycobacterium chelonae] Duchesne B, et al. **Bull Soc Belge Ophtalmol** 1994;254:59-62 (10 ref.) (Eng. Abstr.) **(Fre)**

[Mycobacterium ulcerans cutaneous infections: Buruli ulcers] Josse R, et al. **Med Trop (Mars)** 1995;55(4):363-73 (114 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

[A case of a patient with post-operative empyema due to Mycobacterium chelonae] Takemoto N, et al. **Kyobu Geka** 1996 Apr;49(4):301-5 (12 ref.) (Eng. Abstr.) **(Jpn)**

TRANSMISSION

Mycobactericidal testing of disinfectants: an update. Sattar SA, et al. **J Hosp Infect** 1995 Jun;30 Suppl:372-82 (37 ref.)

MYCOBACTERIUM INTRACELLULARE see **MYCOBACTERIUM AVIUM COMPLEX**

MYCOBACTERIUM INTRACELLULARE INFECTION see **MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION**

MYCOBACTERIUM LEPRAE

see related

LEPROSTATIC AGENTS

Host parasite response in nerve in leprosy. Turk JL. **Indian J Lepr** 1996 Jan-Mar;68(1):113-7 (15 ref.)

DRUG EFFECTS

Rifamycin resistance in mycobacteria. Cole ST. **Res Microbiol** 1996 Jan-Feb;147(1-2):48-52 (43 ref.)

GENETICS

[Present and future in leprosy research] Saito H, et al. **Nippon Rai Gakkai Zasshi** 1995 Nov;64(3):200-13 (74 ref.) **(Jpn)**

IMMUNOLOGY

The immunology of leprosy; unravelling an enigma [editorial] Choudhuri K. **Int J Lepr Other Mycobact Dis** 1995 Sep; 63(3):430-47 (62 ref.)

Cytokine responses in leprosy lesions. Modlin RL. **Nippon Rai Gakkai Zasshi** 1995 Jul;64(2):85-8 (14 ref.)

[Recent development in immunology of leprosy: roles of immunoregulatory cytokines in the establishment of immuno-unresponsiveness to M. leprae in leprosy patients] Tomioka H. **Nippon Rai Gakkai Zasshi** 1995 Jul;64(2):69-84 (37 ref.) **(Jpn)**

MYCOBACTERIUM SCROFULACEUM

ISOLATION & PURIFICATION

Diseases caused by Mycobacterium scrofulaceum. Hautmann G, et al. **Clin Dermatol** 1995 May-Jun;13(3):277-80 (25 ref.)

MYCOBACTERIUM TUBERCULOSIS

see related

ANTITUBERCULAR AGENTS

Soft tissue tuberculosis: a series of 11 cases. Puttick MP, et al. **J Rheumatol** 1995 Jul;22(7):1321-5 (33 ref.)

[Attempts to elucidate the reasons why mycobacterial infections are generally intractable] Tomioka H. **Nippon Saikingaku Zasshi** 1995 Jul;50(3):687-701 (50 ref.) **(Jpn)**

CHEMISTRY

Mycobacterium tuberculosis cell envelope. Lee RE, et al. **Curr Top Microbiol Immunol** 1996;215:1-27 (68 ref.)

CLASSIFICATION

Diagnostic mycobacteriology laboratory practices. Shinnick TM, et al. **Clin Infect Dis** 1995 Aug;21(2):291-9 (56 ref.)

DRUG EFFECTS

Mechanisms of drug resistance in Mycobacterium tuberculosis. Heym B, et al. **Curr Top Microbiol Immunol** 1996;215:49-69 (133 ref.)

Drug resistance in Mycobacterium tuberculosis. Cole ST, et al. **Eur Respir J Suppl** 1995 Sep;20:701s-713s (116 ref.)

Resistance to quinolones in mycobacteria. Cambau E, et al. **Res Microbiol** 1996 Jan-Feb;147(1-2):52-9 (41 ref.)

Rifamycin resistance in mycobacteria. Cole ST. **Res Microbiol** 1996 Jan-Feb;147(1-2):48-52 (43 ref.)

Rapid measurement of antimycobacterial drug activity. Gordon S, et al. **Res Microbiol** 1996 Jan-Feb; 147(1-2):79-86 (31 ref.)

Glycosyltransferases as targets for inhibition of cell wall synthesis in M. tuberculosis and M. avium. Maddry JA, et al. **Res Microbiol** 1996 Jan-Feb;147(1-2):106-12 (25 ref.)

The genetics of multiple drug resistance in Mycobacterium tuberculosis and the Mycobacterium avium complex. Morris SL, et al. **Res Microbiol** 1996 Jan-Feb; 147(1-2):68-73 (40 ref.)

Identification of new drug targets in Mycobacterium avium and Mycobacterium tuberculosis. Rastogi N, et al. **Res Microbiol** 1996 Jan-Feb;147(1-2):97-105 (36 ref.)

The structure and function of the isoniazid target in M. tuberculosis. Sacchettini JC, et al. **Res Microbiol** 1996 Jan-Feb;147(1-2):36-43 (29 ref.)

Ribosomal drug resistance in mycobacteria. Sander P, et al. **Res Microbiol** 1996 Jan-Feb;147(1-2):59-67 (73 ref.)

Novel strategies for the detection of drug resistance in Mycobacterium tuberculosis. Telenti A, et al. **Res Microbiol** 1996 Jan-Feb;147(1-2):73-9 (34 ref.)

GENETICS

The molecular genetics of Mycobacterium tuberculosis. Hatfull GF. **Curr Top Microbiol Immunol** 1996;215:29-47 (54 ref.)

Mobile genetic elements in mycobacteria. Dale JW. **Eur Respir J Suppl** 1995 Sep;20:633s-648s (100 ref.)

Molecular diagnosis of tuberculosis. Richeldi L, et al. **Eur Respir J Suppl** 1995 Sep;20:689s-700s (95 ref.)

Epidemiology of tuberculosis by DNA fingerprinting. van Soolingen D, et al. **Eur Respir J Suppl** 1995 Sep; 20:649s-656s (58 ref.)

Restriction fragment length polymorphism typing of Mycobacterium tuberculosis. Hayward AC. **Thorax** 1995 Nov;50(11):1211-8 (66 ref.)

[The mode of infection of tuberculosis--analysis using molecular epidemiologic methods] Abe C. **Kekkaku** 1995 Nov;70(11):645-50 (32 ref.) (Eng. Abstr.) **(Jpn)**

[The application of molecular biology to the diagnosis of mycobacteriosis] Koga H. **Kekkaku** 1995 Oct;70(10):601-6 (10 ref.) (Eng. Abstr.) **(Jpn)**

GROWTH & DEVELOPMENT

Mycobacterial dormancy [editorial] Gangadharam PR. **Tuber Lung Dis** 1995 Dec;76(6):477-9 (24 ref.)

IMMUNOLOGY

The protective immune response to Mycobacterium tuberculosis. Cooper AM, et al. **Curr Opin Immunol** 1995 Aug;7(4):512-6 (53 ref.)

Human cellular immune responses to Mycobacterium tuberculosis. Barnes PF, et al. **Curr Top Microbiol Immunol** 1996;215:197-219 (156 ref.)

In vitro interaction of Mycobacterium tuberculosis and macrophages: activation of anti-mycobacterial activity of macrophages and mechanisms of anti-mycobacterial activity. O'Brien L, et al. **Curr Top Microbiol Immunol** 1996;215:97-130 (206 ref.)

Entry of Mycobacterium tuberculosis into mononuclear phagocytes. Schlesinger LS. **Curr Top Microbiol Immunol** 1996;215:71-96 (150 ref.)

Serological diagnosis of tuberculosis. Bothamley GH. **Eur Respir J Suppl** 1995 Sep;20:676s-688s (114 ref.)

Functions of T-cell subsets and cytokines in mycobacterial infections. Munk ME, et al. **Eur Respir J Suppl** 1995 Sep; 20:668s-675s (91 ref.)

Pulmonary immune response to Mycobacterium tuberculosis and human immunodeficiency virus. Rich EA. **Infect Agents Dis** 1996 Mar;5(2):108-18 (61 ref.)

Regulation of the human immune response in tuberculosis. Tsuyuguchi I. **Infect Agents Dis** 1996 Mar;5(2):82-97 (57 ref.)

New approaches to identification of antigens of Mycobacterium tuberculosis. Wallis RS. **Infect Agents Dis** 1996 Mar;5(2):119-25 (70 ref.)

Human host response to Mycobacterium tuberculosis. Rom WN, et al. **Schweiz Med Wochenschr** 1995 Nov 11; 125(45):2178-85 (46 ref.)

Perspectives for the control of tuberculosis. Rosen H, et al. **Ther Immunol** 1995 Apr;2(2):105-13 (74 ref.)

Prospects for new vaccines against tuberculosis. Orme IM. **Trends Microbiol** 1995 Oct;3(10):401-4 (27 ref.)

ISOLATION & PURIFICATION

Molecular biology in medicine: laboratory diagnosis of tuberculosis. Ling ML. **Ann Acad Med Singapore** 1996 Jan; 25(1):94-7 (26 ref.)

Mycobacterial disease of the head and neck: current perspective. Cleary KR, et al. **Ann Otol Rhinol Laryngol** 1995 Oct;104(10 Pt 1):830-3 (22 ref.)

Detection of mycobacterial DNA in the skin. Etiologic insights and diagnostic perspectives. Degitz K. **Arch Dermatol** 1996 Jan;132(1):71-5 (58 ref.)

Prosthetic joint infection due to Mycobacterium tuberculosis: report of three cases. Tokumoto JI, et al. **Clin Infect Dis** 1995 Jul;21(1):134-6 (14 ref.)

[Current status and diagnostic value of nucleic acid amplification and conventional methods in laboratory diagnosis of tuberculosis] Küchler R. **Pneumologie** 1996 Apr;50(4):323-6 (19 ref.) **(Ger)**

PATHOGENICITY

Virulence determinants of Mycobacterium tuberculosis. Quinn FD, et al. **Curr Top Microbiol Immunol** 1996; 215:131-56 (133 ref.)

PHYSIOLOGY

Role of mononuclear phagocytes in M tuberculosis pathogenesis. Schlesinger LS. **J Investig Med** 1996 Aug; 44(6):312-23 (161 ref.)

Tuberculosis research--the way forward [editorial] Beyers AD, et al. **S Afr Med J** 1996 Jan;86(1):30-3 (24 ref.)

MYCOLOGICAL TYPING TECHNIQUES

Epidemiology of fungal infections: the promise of molecular typing. Pfaller MA. **Clin Infect Dis** 1995 Jun;20(6):1535-9 (61 ref.)

Molecular typing of Aspergillus species. Birch M, et al. **J Hosp Infect** 1995 Jun;30 Suppl:339-51 (43 ref.)

MYCOPHENOLIC ACID

ANALOGS & DERIVATIVES

Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF). Allison AC, et al. **Clin Transplant** 1996 Feb;10(1 Pt 2):77-84 (33 ref.)

Mycophenolate mofetil (MMF) in heart transplantation: rejection prevention and treatment. Renlund DG, et al. **Clin Transplant** 1996 Feb;10(1 Pt 2):136-9 (29 ref.)

From mice to man: the preclinical history of mycophenolate

mofetil. Sollinger HW. **Clin Transplant** 1996 Feb;10(1 Pt 2):85–92 (46 ref.)
Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation. Fulton B, et al. **Drugs** 1996 Feb; 51(2):278–98 (78 ref.)
Mycophenolate mofetil in renal transplantation: results from the U.S. randomized trials. Danovitch GM. **Kidney Int Suppl** 1995 Dec;52:S93–6 (19 ref.)
Mycophenolate mofetil. Sollinger HW. **Kidney Int Suppl** 1995 Dec;52:S14–7 (23 ref.)
Mycophenolate mofetil (RS 61443): nothing new under the sun or an important break-through in the field of transplantation? [editorial] van der Woude FJ. **Nephrol Dial Transplant** 1995;10(7):1112–5 (10 ref.)
Mechanism of action of mycophenolate mofetil. Ransom JT. **Ther Drug Monit** 1995 Dec;17(6):681–4 (14 ref.)
Mycophenolate mofetil: a report of the consensus panel. Shaw LM, et al. **Ther Drug Monit** 1995 Dec;17(6):690–9 (27 ref.)
Pharmacokinetics of mycophenolate mofetil (RS61443): a short review. Bullingham RE, et al. **Transplant Proc** 1996 Apr;28(2):925–9 (0 ref.)

BLOOD

Mycophenolic acid: measurement and relationship to pharmacologic effects. Shaw LM, et al. **Ther Drug Monit** 1995 Dec;17(6):685–9 (22 ref.)

PHARMACOLOGY

Mycophenolic acid: measurement and relationship to pharmacologic effects. Shaw LM, et al. **Ther Drug Monit** 1995 Dec;17(6):685–9 (22 ref.)

MYCOPLASMA

GENETICS

[Information from complete bacterial genome sequences] Ogasawara N. **Tanpakushitsu Kakusan Koso** 1996 Apr; 41(4):366–70 (12 ref.) **(Jpn)**

IMMUNOLOGY

The phagocytosis of mycoplasmas. Marshall AJ, et al. **J Med Microbiol** 1995 Oct;43(4):239–50 (163 ref.)

ISOLATION & PURIFICATION

Advances in PCR-based detection of mycoplasmas contaminating cell cultures. Rawadi G, et al. **PCR Methods Appl** 1995 Feb;4(4):199–208 (70 ref.)
[Simple detection of the contamination in animal cell cultures] Harasawa R, et al. **Tanpakushitsu Kakusan Koso** 1995 Nov;40(15):2361–8 (15 ref.) **(Jpn)**

MYCOPLASMA INFECTIONS

[Mycoplasma infections] Silva S, et al. **Rev Chil Obstet Ginecol** 1994;59(6):485–91 (25 ref.) **(Spa)**

ETIOLOGY

Mycoplasma hominis infections occurring in cardiovascular surgical patients. Sielaff TD, et al. **Ann Thorac Surg** 1996 Jan;61(1):99–103 (21 ref.)

GENETICS

[Mycoplasma infections as a possible factor in genetic changes in the cells of higher eukaryotes] Chernov VM, et al. **Tsitologiia** 1996;38(2):107–14 (59 ref.) (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

The phagocytosis of mycoplasmas. Marshall AJ, et al. **J Med Microbiol** 1995 Oct;43(4):239–50 (163 ref.)

MYCOPLASMA MYCOIDES

Mycoplasma mycoides subspecies mycoides (small colony variant): the agent of contagious bovine pleuropneumonia and member of the "Mycoplasma mycoides cluster". Nicholas RA, et al. **J Comp Pathol** 1995 Jul;113(1):1–27 (122 ref.)

IMMUNOLOGY

Uses of serology for the diagnosis of contagious bovine pleuropneumonia. Rurangirwa FR. **Rev Sci Tech** 1995 Sep; 14(3):603–9 (30 ref.)
Contagious bovine pleuropneumonia vaccines: the need for improvements. Rweyemamu MM, et al. **Rev Sci Tech** 1995 Sep;14(3):593–601 (14 ref.)

MYCOPLASMA PNEUMONIA see **PNEUMONIA, MYCOPLASMA**

MYCOPLASMA PNEUMONIAE

ISOLATION & PURIFICATION

[Detection of Mycoplasma pneumoniae by using polymerase chain reaction and nonradioactive DNA probes] Yamashita K, et al. **Rinsho Byori** 1995 Dec;43(12):1251–5 (17 ref.) (Eng. Abstr.) **(Jpn)**

PATHOGENICITY

Acute pharyngitis: etiology and diagnosis. Bisno AL. **Pediatrics** 1996 Jun;97(6 Pt 2):949–54 (76 ref.)

MYCOSES

see related

ANTIFUNGAL AGENTS

Targeting fungi: a challenge. Meunier F. **Am J Med** 1995 Dec 29;99(6A):60S–67S (77 ref.)
Fungal sinusitis: an update. Morpeth JF, et al. **Ann Allergy Asthma Immunol** 1996 Feb;76(2):128–39; quiz 139–40 (64 ref.)
Emerging and reemerging microbial threats. Nosocomial fungal infections. Henderson VJ, et al. **Arch Surg** 1996 Mar; 131(3):330–7 (57 ref.)
Clinical management of fungal infections. Speed B. **Aust Fam Physician** 1996 Jun;25(6):903–5 (12 ref.)
Infection with Penicillium marneffei. Wortman PD. **Int J Dermatol** 1996 Jun;35(6):393–9 (35 ref.)
Fungal sinusitis. Spring PM, et al. **J La State Med Soc** 1995 Sep;147(9):395–8 (10 ref.)
Bacterial and fungal infections in the neonate. Askin DF. **J Obstet Gynecol Neonatal Nurs** 1995 Sep;24(7):635–43 (40 ref.)
Mycotic infections in pediatric surgical patients. Hilfiker ML, et al. **Semin Pediatr Surg** 1995 Nov;4(4):239–44 (16 ref.)
[Hepatic mycosis, mycotic liver abscess] Ito A. **Ryoikibetsu Shokogun Shirizu** 1995;(7):87–9 (12 ref.) **(Jpn)**

CLASSIFICATION

Nomenclature of fungal diseases. Odds FC, et al. **Curr Top Med Mycol** 1995;6:33–46 (12 ref.)
Overview and classification of spinal infections. Calderone RR, et al. **Orthop Clin North Am** 1996 Jan;27(1):1–8 (38 ref.)

COMPLICATIONS

Systemic fungal infections: major problems in cancer patients. Powles RL, et al. **Indian J Cancer** 1994 Sep;31(3):180–4 (14 ref.)
Management of mycoses associated with HIV disease. Coker RJ, et al. **Int J STD AIDS** 1995 Nov–Dec;6(6):408–12 (17 ref.)
Opportunistic mycotic infections of the upper limb. A review. al-Qattan MM. **J Hand Surg [Br]** 1996 Apr;21(2):148–50 (21 ref.)

DIAGNOSIS

Diagnosis of systemic mycoses by specific immunohistochemical tests. Jensen HE, et al. **APMIS** 1996 Apr;104(4):241–58 (85 ref.)
Use of molecular biological techniques in the diagnostic laboratory for detecting and differentiating fungi. Hopfer RL. **Arch Med Res** 1995 Autumn;26(3):287–92 (22 ref.)
Molecular genetics and the diagnostic mycology laboratory. Kobayashi GS. **Arch Med Res** 1995 Autumn;26(3):293–6 (20 ref.)
Diagnostic imaging of fungal sinusitis: eleven new cases and literature review. Roithmann R, et al. **Rhinology** 1995 Jun; 33(2):104–10 (20 ref.)
[The problems in the laboratory diagnosis of deep mycoses (a review)] Lipnitskiĭ AV, et al. **Med Parazitol (Mosk)** 1995 Oct–Dec;(4):53–6 (42 ref.) **(Rus)**

DRUG THERAPY

Peritoneal dialysis complicated by Bipolaris hawaiiensis peritonitis: successful therapy with catheter removal and oral itraconazol without the use of amphotericin-B. Gadallah MF, et al. **Am J Nephrol** 1995;15(4):348–52 (19 ref.)
Fungal infection in surgical patients. Dean DA, et al. **Am J Surg** 1996 Mar;171(3):374–82 (100 ref.)
Use of amphotericin B with azole antifungal drugs: what are we doing? Sugar AM. **Antimicrob Agents Chemother** 1995 Sep;39(9):1907–12 (46 ref.)
New antifungal compounds and strategies for treatment of invasive fungal infections in patients with neoplastic diseases. Walsh TJ, et al. **Cancer Treat Res** 1995;79:113–48 (268 ref.)
Amphotericin B: a commentary on its role as an antifungal agent and as a comparative agent in clinical trials. Gallis HA. **Clin Infect Dis** 1996 May;22 Suppl 2:S145–7 (18 ref.)
The future of antifungal therapy. Graybill JR. **Clin Infect Dis** 1996 May;22 Suppl 2:S166–78 (147 ref.)
Role of azoles in antifungal therapy. Kauffman CA. **Clin Infect Dis** 1996 May;22 Suppl 2:S148–53 (72 ref.)
New and emerging yeast pathogens. Hazen KC. **Clin Microbiol Rev** 1995 Oct;8(4):462–78 (168 ref.)
Itraconazole and therapy of fungal infections. Van Cutsem J. **Curr Probl Dermatol** 1996;24:194–202 (29 ref.)
Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients. Goa KL, et al. **Drugs** 1995 Oct;50(4):658–90 (204 ref.)
Itraconazole. A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections. Haria M, et al. **Drugs** 1996 Apr;51(4):585–620 (245 ref.)
Fungal urinary tract infections in the elderly: treatment guidelines. Jacobs LG. **Drugs Aging** 1996 Feb;8(2):89–96 (32 ref.)
Current drug therapy of systemic mycoses: a review. Yonga G. **East Afr Med J** 1995 Jun;72(6):394–8 (59 ref.)
Therapy for opportunistic fungal infections: past, present and future. Stevens DA. **Indian J Cancer** 1995 Mar;32(1):1–9 (15 ref.)
The use of lipid formulations of amphotericin B for systemic fungal infections. Leenders AC, et al. **Leukemia** 1996 Oct; 10(10):1570–5 (55 ref.)
P450 inhibitors of use in medical treatment: focus on mechanisms of action. Vanden Bossche H, et al. **Pharmacol Ther** 1995;67(1):79–100 (155 ref.)
Prevention and therapy of fungal infections in cancer patients. A review of recently published information [see comments] Klastersky J. **Support Care Cancer** 1995 Nov; 3(6):393–401 (42 ref.) Comment in: Support Care Cancer 1995 Nov;3(6):385–6.
New challenges to the therapy of systemic fungal infections. Medoff G. **Trans Am Clin Climatol Assoc** 1995;107:146–57; discussion 157–8 (24 ref.)
[Rational use of antimycotics against yeast infections] Hof H, et al. **Immun Infekt** 1995 Dec;23(6):209–15 (29 ref.) (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Jarvis WR. **Clin Infect Dis** 1995 Jun; 20(6):1526–30 (21 ref.)
Epidemiology of fungal infections: the promise of molecular typing. Pfaller MA. **Clin Infect Dis** 1995 Jun;20(6):1535–9 (61 ref.)
The changing epidemiology of fungal infections: are the lipid-forms of amphotericin B an advance? Herbrecht R. **Eur J Haematol Suppl** 1996;57:12–7 (24 ref.)
Endemic mycosis complicating human immunodeficiency virus infection. Sarosi GA, et al. **West J Med** 1996 Apr; 164(4):335–40 (43 ref.)

ETIOLOGY

Corneal phaeohyphomycosis due to Exserohilum rostratum. A case report and brief review. Kanungo R, et al. **Acta Ophthalmol Scand** 1996 Apr;74(2):197–9 (21 ref.)
Paecilomyces varioti peritonitis in patients on continuous ambulatory peritoneal dialysis. Chan TH, et al. **Am J Kidney Dis** 1996 Jan;27(1):138–42 (24 ref.)
Identification of dematiaceous fungi and their role in human disease. Fothergill AW. **Clin Infect Dis** 1996 May;22 Suppl 2:S179–84 (10 ref.)
Deep tissue infections caused by Scopulariopsis brevicaulis: report of a case of prosthetic valve endocarditis and review. Migrino RQ, et al. **Clin Infect Dis** 1995 Sep;21(3):672–4 (16 ref.)
The new fungal opportunists are coming. Perfect JR, et al. **Clin Infect Dis** 1996 May;22 Suppl 2:S112–8 (18 ref.)
Opportunistic fusarial infections in humans. Guarro J, et al. **Eur J Clin Microbiol Infect Dis** 1995 Sep;14(9):741–54 (131 ref.)
Fungal infections in solid organ transplant recipients. Hadley S, et al. **Infect Dis Clin North Am** 1995 Dec;9(4):1045–74 (249 ref.)
Infection in the bone marrow transplant recipient. Walter EA, et al. **Infect Dis Clin North Am** 1995 Dec;9(4):823–47 (133 ref.)
Fatal, disseminated Acremonium strictum infection in a neutropenic host. Schell WA, et al. **J Clin Microbiol** 1996 May;34(5):1333–6 (27 ref.)
Zygomycosis in HIV-positive patients: a review of the literature. Van den Saffele JK, et al. **Mycoses** 1996 Mar–Apr;39(3–4):77–84 (51 ref.)
Fusarium peritonitis in a child on peritoneal dialysis: case report and review of the literature. Flynn JT, et al. **Perit Dial Int** 1996 Jan–Feb;16(1):52–7 (45 ref.)
[Infections in diabetes mellitus] Schubert S, et al. **Immun Infekt** 1995 Dec;23(6):200–4 (57 ref.) (Eng. Abstr.) **(Ger)**
[The etiology and pathogenesis of intrauterine infection] Durova AA, et al. **Akush Ginekol (Mosk)** 1995;(6):9–12 (59 ref.) **(Rus)**

IMMUNOLOGY

Activation of the complement system by pathogenic fungi. Kozel TR. **Clin Microbiol Rev** 1996 Jan;9(1):34–46 (109 ref.)
Mechanisms of resistance to fungal infections. Romani L, et al. **Curr Opin Immunol** 1995 Aug;7(4):517–23 (74 ref.)
Immunology of fungal infection. Hospenthal DR, et al. **Curr Top Med Mycol** 1995;6:127–88 (495 ref.)
Fluconazole. An update of its pharmacodynamic and

pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients. Goa KL, et al. **Drugs** 1995 Oct;50(4):658–90 (204 ref.)

Antibody immunity and invasive fungal infections. Casadevall A. **Infect Immun** 1995 Nov;63(11):4211–8 (133 ref.)

Fungal infections: a growing threat. Dixon DM, et al. **Public Health Rep** 1996 May–Jun;111(3):226–35 (70 ref.)

[Fungi and autoimmune conditions] George J, et al. **Harefuah** 1996 Mar 15;130(6):388–90 (24 ref.) **(Heb)**

MICROBIOLOGY

New and emerging yeast pathogens. Hazen KC. **Clin Microbiol Rev** 1995 Oct;8(4):462–78 (168 ref.)

Mycobacterial and fungal infections of bone and joints. Meier JL, et al. **Curr Opin Rheumatol** 1995 Jul;7(4):329–36 (75 ref.)

Cell surface hydrophobicity and medically important fungi. Hazen KC, et al. **Curr Top Med Mycol** 1995;6:1–31 (157 ref.)

Phaeohyphomycosis caused by Dactylaria (human dactylariosis): report of a case with review of the literature. Kralovic SM, et al. **J Infect** 1995 Sep;31(2):107–13 (54 ref.)

Mixed intranasal infection caused by Fusarium solani and a zygomycete in a leukaemic patient. Lopes JO, et al. **Mycoses** 1995 Jul–Aug;38(7–8):281–4 (26 ref.)

Microbiology and antimicrobial therapy of spinal infections. Sapico FL. **Orthop Clin North Am** 1996 Jan;27(1):9–13 (22 ref.)

PATHOLOGY

Diagnosis of systemic mycoses by specific immunohistochemical tests. Jensen HE, et al. **APMIS** 1996 Apr;104(4):241–58 (85 ref.)

PHYSIOPATHOLOGY

Evidence for disruption of sphingolipid metabolism as a contributing factor in the toxicity and carcinogenicity of fumonisins. Riley RT, et al. **Nat Toxins** 1996;4(1):3–15 (77 ref.)

PREVENTION & CONTROL

Antifungal prophylaxis in bone marrow transplant. Lam HH, et al. **Ann Pharmacother** 1995 Sep;29(9):921–4 (12 ref.)

Chemoprophylaxis for the prevention of bacterial and fungal infections. Donnelly JP. **Cancer Treat Res** 1995;79:45–81 (276 ref.)

[Mycotic pollution prevention in the indoor environments] Petyx M, et al. **Ann Ig** 1996 Mar–Apr;8(2):305–15 (53 ref.) (Eng. Abstr.) **(Ita)**

[Current status of antifungal prophylaxis in opportunistic mycoses] Torres-Rodríguez JM. **Enferm Infecc Microbiol Clin** 1996 Jan;14(1):44–53 (73 ref.) **(Spa)**

THERAPY

Invasive fungal infections in children: recent advances in diagnosis and treatment. Walsh TJ, et al. **Adv Pediatr Infect Dis** 1996;11:187–290 (418 ref.)

Management of mycoses associated with HIV disease. Coker RJ, et al. **Int J STD AIDS** 1995 Nov–Dec;6(6):408–12 (17 ref.)

Clinical perspectives of granulocyte transfusions: efficacy to date. Strauss RG. **J Clin Apheresis** 1995;10(3):114–8 (23 ref.)

VETERINARY

Fungal infections of the feline lower urinary tract. Lulich JP, et al. **Vet Clin North Am Small Anim Pract** 1996 Mar; 26(2):309–15 (10 ref.)

MYCOSIS FUNGOIDES

Cutaneous T-cell lymphoma (mycosis fungoides) [see comments] Lorincz AL. **Lancet** 1996 Mar 30; 347(9005):871–6 (30 ref.) Comment in: Lancet 1996 Jul 13;348(9020):130–1.

COMPLICATIONS

Hypopigmented mycosis fungoides in a white female. Amichai B, et al. **J Dermatol** 1996 Jun;23(6):425–6 (9 ref.)

[Association of mycosis fungoides and Hodgkin disease] Duhault P, et al. **Ann Med Interne (Paris)** 1995; 146(6):427–30 (17 ref.) **(Fre)**

[Mycosis fungoides and Hodgkin disease. Apropos of 2 cases] Modiano P, et al. **Ann Med Interne (Paris)** 1995; 146(6):424–7 (30 ref.) **(Fre)**

DRUG THERAPY

Chemotherapy for mycosis fungoides and the Sézary syndrome. Rosen ST, et al. **Hematol Oncol Clin North Am** 1995 Oct;9(5):1109–16 (18 ref.)

ETIOLOGY

[Lymphomatoid papulosis] Dreno B. **Presse Med** 1995 Jun 24;24(23):1084–7 (13 ref.) (Eng. Abstr.) **(Fre)**

MYCOSIS, OCULAR see **EYE INFECTIONS, FUNGAL**

MYCOTIC ANEURYSM see **ANEURYSM, INFECTED**

MYCOTIC INFECTIONS, OCULAR see **EYE INFECTIONS, FUNGAL**

MYCOTOXICOSIS

Mycotoxicosis--humankind's greatest affliction? Campbell GD. **Nutr Health** 1996;10(4):323–9 (13 ref.)

VETERINARY

Plant poisonings and mycotoxicoses as constraints in livestock production in east Africa: the southern African experience. Naudé TW, et al. **J S Afr Vet Assoc** 1996 Mar; 67(1):8–11 (18 ref.)

MYCOTOXINS

ADVERSE EFFECTS

Mycotoxicosis--humankind's greatest affliction? Campbell GD. **Nutr Health** 1996;10(4):323–9 (13 ref.)

ANALYSIS

BCR- and M&T-activities in the area of mycotoxin analysis in food and feedstuffs. Boenke A. **Nat Toxins** 1995; 3(4):243–7; discussion 280 (10 ref.)

Keeping the mycotoxins out: experience gathered by an international food company. Pittet A. **Nat Toxins** 1995; 3(4):281–7; discussion 317 (26 ref.)

CHEMISTRY

Mycotoxins, general view, chemistry and structure. Steyn PS. **Toxicol Lett** 1995 Dec;82–83:843–51 (49 ref.)

METABOLISM

URF13, a ligand-gated, pore-forming receptor for T-toxin in the inner membrane of cms-T mitochondria. Rhoads DM, et al. **J Bioenerg Biomembr** 1995 Aug;27(4):437–45 (52 ref.)

Fumonisin generation [editorial] ApSimon JW, et al. **Nat Toxins** 1996;4(1):1–2 (16 ref.)

Genetic implications in the metabolism and toxicity of mycotoxins. Neal GE. **Toxicol Lett** 1995 Dec;82–83:861–7 (25 ref.)

TOXICITY

IARC activities in mycotoxin research. Castegnaro M, et al. **Nat Toxins** 1995;3(4):327–31; discussion 341 (29 ref.)

Economic losses and decontamination. Charmley LL, et al. **Nat Toxins** 1995;3(4):199–203; discussion 221 (36 ref.)

Fumonisins: their implications for human and animal health. Marasas WF. **Nat Toxins** 1995;3(4):193–8; discussion 221 (65 ref.)

Evidence for disruption of sphingolipid metabolism as a contributing factor in the toxicity and carcinogenicity of fumonisins. Riley RT, et al. **Nat Toxins** 1996;4(1):3–15 (77 ref.)

Role of mycotoxins in human and animal nutrition and health. Smith JE, et al. **Nat Toxins** 1995;3(4):187–92; discussion 221 (19 ref.)

Prevention of nephrotoxicity of ochratoxin A, a food contaminant. Creppy EE, et al. **Toxicol Lett** 1995 Dec; 82–83:869–77 (54 ref.)

Mycotoxins: risk assessment and legislation. Kuiper-Goodman T. **Toxicol Lett** 1995 Dec;82–83:853–9 (21 ref.)

MYDRIASIS

ETIOLOGY

Traumatic superior orbital fissure syndrome: report of two cases. Bun RJ, et al. **J Oral Maxillofac Surg** 1996 Jun; 54(6):758–61 (16 ref.)

[Unilateral benign episodic mydriasis] Manai R, et al. **Rev Neurol (Paris)** 1995 May;151(5):344–6 (14 ref.) (Eng. Abstr.) **(Fre)**

MYELENCEPHALON see **MEDULLA OBLONGATA**

MYELIN-ASSOCIATED GLYCOPROTEIN

GENETICS

Chromatin structure and transcriptional activity of MAG gene. Konat GW. **Acta Neurobiol Exp (Warsz)** 1996; 56(1):281–5 (25 ref.)

PHYSIOLOGY

Myelin-associated glycoprotein: a role in myelination and in the inhibition of axonal regeneration? Filbin MT. **Curr Opin Neurobiol** 1995 Oct;5(5):588–95 (58 ref.)

MYELIN BASIC PROTEINS

ADMINISTRATION & DOSAGE

Oral tolerance in experimental autoimmune encephalomyelitis. Whitacre CC, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:217–27 (17 ref.)

GENETICS

[Usefulness of myelin basic protein gene promoter for the gene therapy of malignant glioma] Miyao Y, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2618–23 (13 ref.) **(Jpn)**

IMMUNOLOGY

Experimental autoimmune encephalomyelitis in rodents as a model for human demyelinating disease [see comments] Swanborg RH. **Clin Immunol Immunopathol** 1995 Oct; 77(1):4–13 (99 ref.) Comment in: Clin Immunol Immunopathol 1995 Oct;77(1):3.

Critical influences of the cytokine orchestration on the outcome of myelin antigen-specific T-cell autoimmunity in experimental autoimmune encephalomyelitis and multiple sclerosis. Olsson T. **Immunol Rev** 1995 Apr; 144:245–68 (169 ref.)

PHYSIOLOGY

Membrane adhesion and other functions for the myelin basic proteins. Staugaitis SM, et al. **Bioessays** 1996 Jan;18(1):13–8 (45 ref.)

MYELIN P2 PROTEIN

IMMUNOLOGY

Comparison of purified 12 kDa and recombinant 15 kDa Fasciola hepatica antigens related to a Schistosoma mansoni fatty acid binding protein. Hillyer GV. **Mem Inst Oswaldo Cruz** 1995 Mar–Apr;90(2):249–53 (17 ref.)

PHYSIOLOGY

Fatty acid binding protein in locust and mammalian muscle. Comparison of structure, function and regulation. Haunerland NH. **Comp Biochem Physiol B Biochem Mol Biol** 1994 Oct–Nov; 109(2–3):199–208 (49 ref.)

Fatty acid transport and fatty acid-binding proteins. Veerkamp JH. **Proc Nutr Soc** 1995 Mar;54(1):23–37 (75 ref.)

MYELIN PROTEINS

BIOSYNTHESIS

Transgenic systems in studying myelin gene expression. Ikenaka K, et al. **Dev Neurosci** 1995;17(3):127–36 (76 ref.)

CHEMISTRY

Structure and function of peripheral nerve myelin proteins. Uyemura K, et al. **Prog Brain Res** 1995;105:311–8 (27 ref.)

GENETICS

Transgenic systems in studying myelin gene expression. Ikenaka K, et al. **Dev Neurosci** 1995;17(3):127–36 (76 ref.)

PHYSIOLOGY

Molecular anatomy and genetics of myelin proteins in the peripheral nervous system. Snipes GJ, et al. **J Anat** 1995 Jun;186 (Pt 3):483–94 (120 ref.)

MYELIN PROTEOLIPID PROTEIN

IMMUNOLOGY

Experimental autoimmune encephalomyelitis in rodents as a model for human demyelinating disease [see comments] Swanborg RH. **Clin Immunol Immunopathol** 1995 Oct; 77(1):4–13 (99 ref.) Comment in: Clin Immunol Immunopathol 1995 Oct;77(1):3.

MYELIN SHEATH

see related
DEMYELINATING DISEASES
MYELIN PROTEINS

CHEMISTRY

Molecular anatomy and genetics of myelin proteins in the peripheral nervous system. Snipes GJ, et al. **J Anat** 1995 Jun;186 (Pt 3):483–94 (120 ref.)

IMMUNOLOGY

Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system. Steinman L. **Cell** 1996 May 3;85(3):299–302 (31 ref.)

METABOLISM

Transgenic systems in studying myelin gene expression. Ikenaka K, et al. **Dev Neurosci** 1995;17(3):127–36 (76 ref.)

PATHOLOGY

Myelin mutants: new models and new observations. Lunn KF, et al. **Microsc Res Tech** 1995 Oct 15;32(3):183–203 (113 ref.)

PHYSIOLOGY

Myelin-associated glycoprotein: a role in myelination and in the inhibition of axonal regeneration? Filbin MT. **Curr Opin Neurobiol** 1995 Oct;5(5):588–95 (58 ref.)

Effects of growth hormone on cerebral development: morphological studies. Noguchi T. **Horm Res** 1996; 45(1–2):5–17 (41 ref.)

Experimental strategies to promote central nervous system remyelination in multiple sclerosis: insights gained from the Theiler's virus model system. Miller DJ, et al. **J Neurosci Res** 1995 Jun 15;41(3):291–6 (40 ref.)

Spontaneous and induced remyelination in multiple sclerosis and the Theiler's virus model of central nervous system demyelination. Miller DJ, et al. **Microsc Res Tech** 1995 Oct 15;32(3):230–45 (119 ref.)

Glial cell transplantation and remyelination of the central nervous system. Duncan ID. **Neuropathol Appl Neurobiol** 1996 Apr;22(2):87–100 (100 ref.)

Molecular genetic analyses of myelin deficiency and cerebellar ataxia. Mikoshiba K, et al. **Prog Brain Res** 1995; 105:23–41 (89 ref.)

Regeneration of oligodendrocytes and myelin. Dubois-Dalcq M. **Trends Neurosci** 1995 Jul;18(7):289–91 (39 ref.)

[Phylogeny of myelin and myelin forming cells] Zalc B. **C R Seances Soc Biol Fil** 1995;189(2):239–44 (11 ref.) (Eng. Abstr.) **(Fre)**

MYELITIS

DIAGNOSIS

[Varicella-zoster-virus myelitis without herpes. An important differential diagnosis of the radicular syndrome] Jacobs A, et al. **Dtsch Med Wochenschr** 1996 Mar 15; 121(11):331–5 (25 ref.) (Eng. Abstr.) **(Ger)**

VETERINARY

Neurobiology of simian and feline immunodeficiency virus infections. Gardner MB, et al. **Curr Top Microbiol Immunol** 1995;202:135–50 (62 ref.)

MYELITIS, TRANSVERSE

COMPLICATIONS

Acute transverse myelopathy and cutaneous vasculopathy in primary Sjögren's syndrome. Lyu RK, et al. **Eur Neurol** 1995;35(6):359–62 (24 ref.)

ETIOLOGY

[Transverse myelitis caused by Mycoplasma pneumoniae infection] Albucher JF, et al. **Rev Neurol (Paris)** 1995 May; 151(5):350–3 (10 ref.) (Eng. Abstr.) **(Fre)**

MYELOBLASTIC LEUKEMIA, ACUTE see **LEUKEMIA, MYELOCYTIC, ACUTE**

MYELOBLASTOSIS VIRUS, AVIAN

GENETICS

Gene regulation by NF-M and Myb during differentiation and leukemic transformation. Kowenz-Leutz E, et al. **Immunobiology** 1995 Jul;193(2–4):356–62 (15 ref.)

PATHOGENICITY

Contribution of MAV-1-induced nephroblastoma to the study of genes involved in human Wilms' tumor development. Perbal B. **Crit Rev Oncog** 1994;5(6):589–613 (107 ref.)

Pathogenic potential of myeloblastosis-associated viruses. Perbal B. **Infect Agents Dis** 1995 Dec;4(4):212–27 (69 ref.)

MYELOCYTIC LEUKEMIA see **LEUKEMIA, MYELOID**

MYELOCYTIC LEUKEMIA, ACUTE see **LEUKEMIA, MYELOCYTIC, ACUTE**

MYELOCYTIC LEUKEMIA, CHRONIC see **LEUKEMIA, MYELOID, CHRONIC**

MYELODYSPLASIA see **NEURAL TUBE DEFECTS**

MYELODYSPLASTIC SYNDROMES

Myelodysplastic syndromes. Utley SM. **Semin Oncol Nurs** 1996 Feb;12(1):51–8 (56 ref.)

CHEMICALLY INDUCED

[Two cases of therapy-related myelodysplastic syndrome] Takahashi A, et al. **Rinsho Ketsueki** 1996 Jan;37(1):53–9 (16 ref.) (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

[Lymphocytic ascites revealing systemic mastocytosis] Essner C, et al. **Gastroenterol Clin Biol** 1995 Nov; 19(11):948–51 (23 ref.) (Eng. Abstr.) **(Fre)**

[Systemic diseases in myelodysplastic syndromes] Hebbar M, et al. **Rev Med Interne** 1995;16(12):897–904 (63 ref.) (Eng. Abstr.) **(Fre)**

[Hepatobiliary disease in malignant lymphoma, leukemia, and MDS] Ishikawa T. **Ryoikibetsu Shokogun Shirizu** 1995; (8):375–8 (21 ref.) **(Jpn)**

DIAGNOSIS

Cytogenetics and its prognostic value in myelodysplastic syndromes. Verhoef GE, et al. **Acta Haematol** 1996; 95(2):95–101 (55 ref.)

[Myeloproliferative syndromes] Ganser A. **Ther Umsch** 1996 Feb;53(2):97–102 (27 ref.) (Eng. Abstr.) **(Ger)**

[Procedure of diagnosis and therapy of myelodysplastic syndrome] Yoshida Y. **Nippon Naika Gakkai Zasshi** 1996 Mar 10;85(3):459–63 (8 ref.) **(Jpn)**

[Secondary myelodysplastic syndromes] Zduńczyk A. **Pol Arch Med Wewn** 1995 Apr;93(4):351–60 (45 ref.) **(Pol)**

[Intense neutropenia of 14 years duration as the only manifestation of a myelodysplastic syndrome] Las Heras G, et al. **Med Clin (Barc)** 1995 Nov 11;105(16):619–21 (12 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Treatment of acute myeloid leukemia with antecedent myelodysplastic syndrome. Larson RA. **Leukemia** 1996 Apr;10 Suppl 1:S23–5 (7 ref.)

ETIOLOGY

Therapy-related myeloid leukemia. Thirman MJ, et al. **Hematol Oncol Clin North Am** 1996 Apr;10(2):293–320 (139 ref.)

GENETICS

Isodicentric (X)(q13) in haematological malignancies: presentation of five new cases, application of fluorescence in situ hybridization (FISH) and review of the literature. Dierlamm J, et al. **Br J Haematol** 1995 Dec;91(4):885–91 (23 ref.)

Dicentric (1;15) in myeloid disorders. Michaux L, et al. **Cancer Genet Cytogenet** 1996 May;88(1):86–9 (10 ref.)

der(1;15)(q10;10): a nonrandom chromosomal abnormality of myeloid neoplasia. Wong KF, et al. **Cancer Genet Cytogenet** 1995 Sep;83(2):144–7 (12 ref.)

Myelodysplastic syndrome with t(5;12)(q31;p12–p13) and eosinophilia: a pediatric case with review of literature. Pellier I, et al. **J Pediatr Hematol Oncol** 1996 Aug; 18(3):285–8 (19 ref.)

Molecular cytogenetics and the myelodysplastic syndromes [comment] Anastasi J. **Leuk Res** 1996 Jul;20(7):559–62 (38 ref.) Comment on: Leuk Res 1996 Jul;20(7):551–7.

[Myelodysplastic syndrome; current insights in pathogenesis and treatment] Soepenberg O, et al. **Ned Tijdschr Geneeskd** 1995 Oct 21;139(42):2130–5 (57 ref.) **(Dut)**

[Significance, diagnosis and prognosis in the cytogenetic analysis in acute leukemias and myelodysplastic syndromes] Jotterand Bellomo M. **Ther Umsch** 1996 Feb;53(2):103–10 (23 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

[Immunohematologic study in 112 patients with myelodysplastic syndromes: 10-year analysis] Arriaga F, et al. **Sangre (Barc)** 1995 Jun;40(3):177–80 (17 ref.) (Eng. Abstr.) **(Spa)**

PATHOLOGY

Stromal abnormalities in neoplastic bone marrow diseases. Dührsen U, et al. **Ann Hematol** 1996 Aug;73(2):53–70 (222 ref.)

The SKM-1 leukemic cell line established from a patient with progression to myelomonocytic leukemia in myelodysplastic syndrome (MDS)–contribution to better understanding of MDS. Nakagawa T, et al. **Leuk Lymphoma** 1995 Apr;17(3–4):335–9 (63 ref.)

Apoptosis in myelodysplasia: a paradox or paradigm. Yoshida Y, et al. **Leuk Res** 1995 Dec;19(12):887–91 (31 ref.)

A paradigm shift in myelodysplastic syndromes. Raza A, et al. **Leukemia** 1996 Oct;10(10):1648–52 (59 ref.)

PHYSIOPATHOLOGY

Novel insights into the biology of myelodysplastic syndromes: excessive apoptosis and the role of cytokines. Raza A, et al. **Int J Hematol** 1996 Jun;63(4):265–78 (52 ref.)

THERAPY

Successful allogeneic bone marrow transplantation in a case with myelodysplastic syndrome which developed following Fanconi anemia. Ikushima S, et al. **Bone Marrow Transplant** 1995 Oct;16(4):621–4 (21 ref.)

The role of bone marrow transplantation in the treatment of myelodysplastic syndromes. Schultz AB, et al. **J Hematother** 1995 Aug;4(4):323–34 (92 ref.)

Interleukin-2 therapy for myelodysplastic syndrome: does it work? Ogata K, et al. **Leuk Lymphoma** 1995 May; 17(5–6):411–5 (44 ref.)

Myelodysplastic syndromes in the elderly: the role of growth factors in management. Saba HI. **Leuk Res** 1996 Mar; 20(3):203–19 (136 ref.)

[Current developments in the therapy of the myelodysplastic syndrome] de Witte T, et al. **Ned Tijdschr Geneeskd** 1995 Oct 21;139(42):2135–9 (39 ref.) **(Dut)**

[Current approaches of treatment for myelodysplastic syndrome (MDS)] Lewandowski K, et al. **Acta Haematol Pol** 1995;26(4):333–41 (49 ref.) (Eng. Abstr.) **(Pol)**

MYELOFIBROSIS

[Chronic myeloproliferative diseases. New knowledge about well known diseases] Aulitzky WE, et al. **Dtsch Med Wochenschr** 1996 May 3;121(18):600–4 (42 ref.) (Eng. Abstr.) **(Ger)**

[Idiopathic myelofibrosis. Main pathogenetic, prognostic and therapeutic aspects] Barulli S, et al. **Recenti Prog Med** 1995 Jul–Aug;86(7–8):312–9 (27 ref.) (Eng. Abstr.) **(Ita)**

COMPLICATIONS

Leukemia with megakaryocytic differentiation following essential thrombocythemia and myelofibrosis. Case report and review of the literature. Patiño-Sarcinelli F, et al. **Acta Haematol** 1996;95(2):122–8 (53 ref.)

ETIOLOGY

Evans' syndrome, myelofibrosis and systemic lupus erythematosus: role of procollagens in myelofibrosis. Ramakrishna R, et al. **Pathology** 1995 Jul;27(3):255–9 (23 ref.)

[IgD (lambda) multiple myeloma associated with myelofibrosis: an isolated case of nuclear physicist] Kanoh T, et al. **Rinsho Ketsueki** 1996 Mar;37(3):244–8 (14 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Translocation (Y;1)(q12;q12) in hematologic malignancies. Report on two new cases, FISH characterization, and review of the literature. Michaux L, et al. **Cancer Genet Cytogenet** 1996 Jan;86(1):35–8 (13 ref.)

METABOLISM

Platelet derived growth factor expression, myelofibrosis and chronic myelogenous leukemia. Kimura A, et al. **Leuk Lymphoma** 1995 Jul;18(3–4):237–42 (47 ref.)

PATHOLOGY

Acute myelofibrosis terminating in acute lymphoblastic leukemia: case report and review of the literature. Dunphy CH, et al. **Am J Hematol** 1996 Jan;51(1):85–9 (21 ref.)

PHYSIOPATHOLOGY

TGF-beta and megakaryocytes in the pathogenesis of myelofibrosis in myeloproliferative disorders. Martyré MC. **Leuk Lymphoma** 1995 Dec;20(1–2):39–44 (58 ref.)

THERAPY

The role of alpha-interferon in essential thrombocythaemia, polycythaemia vera and myelofibrosis with myeloid metaplasia (MMM): a concise update. Sacchi S. **Leuk Lymphoma** 1995 Sep;19(1–2):13–20 (86 ref.)

MYELOGENOUS LEUKEMIA see **LEUKEMIA, MYELOID**

MYELOGENOUS LEUKEMIA, ACUTE see **LEUKEMIA, MYELOCYTIC, ACUTE**

MYELOGENOUS LEUKEMIA, CHRONIC see **LEUKEMIA, MYELOID, CHRONIC**

MYELOGENOUS LEUKEMIA, CHRONIC, CHRONIC-PHASE see **LEUKEMIA, MYELOID, CHRONIC-PHASE**

MYELOGENOUS LEUKEMIA, PH1-NEGATIVE see **LEUKEMIA, MYELOID, PHILADELPHIA-NEGATIVE**

MYELOGENOUS LEUKEMIA, PH1-POSITIVE see **LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE**

MYELOGRAPHY

Computed tomography and myelography in the evaluation of cervical degenerative disease. Russell EJ. **Neuroimaging Clin N Am** 1995 Aug;5(3):329–48 (83 ref.)

ADVERSE EFFECTS

Adverse reactions in myelography. Maly P, et al. **Acta Radiol Suppl** 1995;399:230–7 (61 ref.)

MYELOGRAPHY

Case report: Pontine haemorrhage following iohexol lumbar myelography. Yeh YF, et al. **Br J Radiol** 1996 Apr; 69(820):368–70 (28 ref.)

Postmyelography headache: a review. Peterman SB. **Radiology** 1996 Sep;200(3):765–70 (39 ref.)

[Postmyelographic headache] Fries J. **Ugeskr Laeger** 1995 Nov 6;157(45):6249–52 (35 ref.) (Eng. Abstr.) **(Dan)**

MYELOID DIFFERENTIATION-INDUCING PROTEIN see **INTERLEUKIN-6**

MYELOID LEUKEMIA see **LEUKEMIA, MYELOID**

MYELOID LEUKEMIA, ACUTE, M1 see **LEUKEMIA, MYELOCYTIC, ACUTE**

MYELOID LEUKEMIA, ACUTE, M2 see **LEUKEMIA, MYELOCYTIC, ACUTE**

MYELOID LEUKEMIA, ACUTE, M3 see **LEUKEMIA, PROMYELOCYTIC, ACUTE**

MYELOID LEUKEMIA, ACUTE, M4 see **LEUKEMIA, MYELOMONOCYTIC, ACUTE**

MYELOID LEUKEMIA, ACUTE, M5 see **LEUKEMIA, MONOCYTIC, ACUTE**

MYELOID LEUKEMIA, ACUTE, M6 see **LEUKEMIA, ERYTHROBLASTIC, ACUTE**

MYELOID LEUKEMIA, ACUTE, M7 see **LEUKEMIA, MEGAKARYOCYTIC, ACUTE**

MYELOID LEUKEMIA, CHRONIC see **LEUKEMIA, MYELOID, CHRONIC**

MYELOID LEUKEMIA, CHRONIC, CHRONIC-PHASE see **LEUKEMIA, MYELOID, CHRONIC-PHASE**

MYELOID LEUKEMIA, CHRONIC, STABLE-PHASE see **LEUKEMIA, MYELOID, CHRONIC-PHASE**

MYELOID LEUKEMIA, NAEGELI-TYPE see **LEUKEMIA, MYELOMONOCYTIC, ACUTE**

MYELOID LEUKEMIA, PH1-NEGATIVE see **LEUKEMIA, MYELOID, PHILADELPHIA-NEGATIVE**

MYELOID LEUKEMIA, PH1-POSITIVE see **LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE**

MYELOID LEUKEMIA, PHILADELPHIA-NEGATIVE see **LEUKEMIA, MYELOID, PHILADELPHIA-NEGATIVE**

MYELOID LEUKEMIA, PHILADELPHIA-POSITIVE see **LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE**

MYELOID LEUKEMIA, SCHILLING-TYPE see **LEUKEMIA, MONOCYTIC, ACUTE**

MYELOID METAPLASIA

THERAPY

The role of alpha-interferon in essential thrombocythaemia, polycythaemia vera and myelofibrosis with myeloid metaplasia (MMM): a concise update. Sacchi S. **Leuk Lymphoma** 1995 Sep;19(1–2):13–20 (86 ref.)

MYELOLIPOMA

[Lipomatous tumors (lipoma, angiomyolipoma, myelolipoma, focal fatty change) in the liver] Imaoka S, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):288–91 (24 ref.) **(Jpn)**

[Adrenal myelolipoma. Report of a case and review of the literature] Bordallo Cortina A, et al. **Arch Esp Urol** 1996 Mar;49(2):184–7 (18 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

[Adrenal myelolipoma: apropos a case with urologic symptomatology. A review of the literature] Pérez Arbej JA, et al. **Actas Urol Esp** 1995 Mar;19(3):243–6 (27 ref.) (Eng. Abstr.) **(Spa)**

RADIOGRAPHY

[Giant myelolipoma of the adrenals. A report of 3 cases studied by CT and a review of the literature] Catalano O, et al. **Radiol Med (Torino)** 1995 Dec;90(6):842–6 (53 ref.) **(Ita)**

ULTRASONOGRAPHY

Presacral myelolipoma: sonographic appearance. Adetiloye VA, et al. **Pediatr Radiol** 1996;26(4):271–2 (5 ref.)

MYELOMA, PLASMA CELL see **MULTIPLE MYELOMA**

MYELOMA PROTEINS

GENETICS

Multiple myeloma: new evidence and insights from the immunoglobulin heavy chain gene and phenotypes. Takishita M, et al. **Leuk Lymphoma** 1995 Nov; 19(5–6):395–400 (36 ref.)

MYELOMONOCYTIC DIFFERENTIATION ANTIGENS see **ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC**

MYELOMONOCYTIC LEUKEMIA, ACUTE see **LEUKEMIA, MYELOMONOCYTIC, ACUTE**

MYELOMONOCYTIC LEUKEMIA, CHRONIC see **LEUKEMIA, MYELOMONOCYTIC, CHRONIC**

MYELOPATHIC MUSCULAR ATROPHY see **MUSCULAR ATROPHY, SPINAL**

MYELOPEROXIDASE see **PEROXIDASE**

MYELOPROLIFERATIVE DISORDERS

see related
LEUKEMIA

BLOOD

Effects of alpha-interferon on serum beta-2-microglobulin. Remes K, et al. **Leuk Lymphoma** 1996 Apr;21(3–4):233–8 (57 ref.)

COMPLICATIONS

Bleeding and thrombosis in myeloproliferative disorders: mechanisms and treatment. Landolfi R, et al. **Crit Rev Oncol Hematol** 1995 Oct;20(3):203–22 (200 ref.)

Transient abnormal myelopoiesis accompanied by hepatic fibrosis in two infants with Down syndrome. Yagihashi N, et al. **J Clin Pathol** 1995 Oct;48(10):973–5 (10 ref.)

DIAGNOSIS

[Thrombosis in the small branches of the superior mesenteric artery in the early stages of essential thrombocythemia] Adorján T, et al. **Orv Hetil** 1996 Mar 10;137(10):527–9 (28 ref.) (Eng. Abstr.) **(Hun)**

GENETICS

A new myeloproliferative disorder associated with chromosomal translocations involving 8p11: a review [see comments] Macdonald D, et al. **Leukemia** 1995 Oct; 9(10):1628–30 (30 ref.) Comment in: Leukemia 1996 Jul;10(7):1252–3.

The molecular biology of myeloproliferative disorders as revealed by chromosomal abnormalities. Zeleznik-Le NJ, et al. **Semin Hematol** 1995 Jul;32(3):201–19 (137 ref.)

[Positional cloning of the putative gene responsible for transient abnormal myelopoiesis and that for multiple cartilaginous exostoses] Niikawa N. **Rinsho Byori** 1996 Jan; 44(1):13–8 (6 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

TGF-beta and megakaryocytes in the pathogenesis of myelofibrosis in myeloproliferative disorders. Martyré MC. **Leuk Lymphoma** 1995 Dec;20(1–2):39–44 (58 ref.)

THERAPY

Bleeding and thrombosis in myeloproliferative disorders: mechanisms and treatment. Landolfi R, et al. **Crit Rev Oncol Hematol** 1995 Oct;20(3):203–22 (200 ref.)

Effects of alpha-interferon on serum beta-2-microglobulin. Remes K, et al. **Leuk Lymphoma** 1996 Apr;21(3–4):233–8 (57 ref.)

MYELOSCLEROSIS see **MYELOFIBROSIS**

MYELOSIS, NONLEUKEMIC see **MYELOID METAPLASIA**

MYERS-BRIGGS TYPE INDICATOR see **PERSONALITY INVENTORY**

MYIASIS

[Human external ophthalmomyiasis: a bibliographic review apropos of cases in the Republic of Djibouti] Dorchies P, et al. **Bull Soc Pathol Exot** 1995;88(3):86–9 (40 ref.) (Eng. Abstr.) **(Fre)**

[Human myiases] Năstoiu I. **Bacteriol Virusol Parazitol Epidemiol** 1995 Apr-Jun; 40(2):77–83 (38 ref.) (Eng. Abstr.) **(Rum)**

DIAGNOSIS

Oral myiasis: report of case and review of management. Felices RR, et al. **J Oral Maxillofac Surg** 1996 Feb; 54(2):219–20 (8 ref.)

PARASITOLOGY

[Human furunculoid cutaneous myiasis caused by Dermatobia hominis (L.) diagnosed in Belgium (Diptera: Cuterebridae)] Leclerco M. **Rev Med Liege** 1996 Jun;51(6):434–8 (32 ref.) **(Fre)**

[2 cases of ocular infestation by Oestrus ovis (letter)] Boquet E, et al. **Enferm Infecc Microbiol Clin** 1995 Aug-Sep; 13(7):442–4 (9 ref.) **(Spa)**

PREVENTION & CONTROL

Trapping the flies that cause myiasis: their responses to host-stimuli. Hall MJ. **Ann Trop Med Parasitol** 1995 Aug; 89(4):333–57 (162 ref.)

MYO-INOSITOL 1,4,5-TRISPHOSPHATE see **INOSITOL 1,4,5-TRISPHOSPHATE**

MYOBLASTOMA see **NEOPLASMS, MUSCLE TISSUE**

MYOBLASTOMA, GRANULAR CELL see **GRANULAR CELL TUMOR**

MYOCARDIAL CONTRACTION

see related
CARDIOTONIC AGENTS
MYOCARDIAL STUNNING

The elusive difference between hibernation and stunning in patients. Ambrosio G. **Basic Res Cardiol** 1995 Jul-Aug; 90(4):297–9 (14 ref.)

Signal transduction in the cardiac k-receptor. Wong TM, et al. **Biol Signals** 1995 May-Jun;4(3):174–8 (18 ref.)

Cellular mechanisms of contractile dysfunction in human heart failure. Davies CH, et al. **Eur Heart J** 1996 Feb; 17(2):189–98 (137 ref.)

Comparative pharmacology of nitric oxide and nitric oxide generators on cardiac contractility in mammalian species. Lefer AM, et al. **Int J Cardiol** 1995 Jul;50(3):239–42 (7 ref.)

Positive inotropic effect of nitric oxide in myocardium. Mohan P, et al. **Int J Cardiol** 1995 Jul;50(3):233–7 (25 ref.)

The influence of endothelium-derived nitric oxide on myocardial contractile function. Shah AM, et al. **Int J Cardiol** 1995 Jul;50(3):225–31 (39 ref.)

Repolarization gradients derived by subtraction of monophasic action potential recordings in the human heart. Studies incorporating altered mechanical loading and ischemia. Taggart P, et al. **J Electrocardiol** 1995;28 Suppl:156–61 (25 ref.)

Cross-bridge-dependent changes in the intracellular Ca2+ concentration in mammalian cardiac muscles. Kurihara S, et al. **Jpn Heart J** 1996 Mar;37(2):143–52 (33 ref.)

MRI of myocardial function: motion tracking techniques. McVeigh ER. **Magn Reson Imaging** 1996;14(2):137–50 (65 ref.)

DRUG EFFECTS

Improvement in cardiac myocyte function by biological effects of medical therapy: a new concept in the treatment of heart failure. Bristow MR, et al. **Eur Heart J** 1995 Jul; 16 Suppl F:20–31 (93 ref.)

Phosphodiesterase inhibition and Ca2+ sensitization. Ravens U, et al. **Mol Cell Biochem** 1996 Apr 12–26;157(1–2):245–9 (21 ref.)

Myocardial contractile response and IP3, cAMP and cGMP interrelationships. Martinussen HJ. **Ups J Med Sci** 1996; 101(1):1–33 (142 ref.)

[Recent development in experimental research of single Chinese medicinal herb with positive inotropic action] Zhao W. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Jul;15(7):443–5 (25 ref.) **(Chi)**

GENETICS

Prospects for genetic manipulation of cardiac excitability. Lawrence JH, et al. **Adv Exp Med Biol** 1995;382:41–8 (44 ref.)

PHYSIOLOGY

Na+, K(+)-ATPase and heart excitability. Lichtstein D. **Adv Exp Med Biol** 1995;382:23–30 (51 ref.)

Na-Ca exchange and Ca fluxes during contraction and relaxation in mammalian ventricular muscle. Bers DM, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:430–42 (31 ref.)

Evidence that reverse Na-Ca exchange can trigger SR calcium release. Litwin S, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:451–63 (20 ref.)

Thin filament-mediated regulation of cardiac contraction. Tobacman LS. **Annu Rev Physiol** 1996;58:447–81 (207 ref.)

Preconditioning-induced protection against post-ischemic contractile dysfunction: inhibitory effect of tissue washout. Cave AC, et al. **Basic Res Cardiol** 1996 Jan-Feb;91(1):16–9 (14 ref.)

Is contractility depressed in the failing human heart? Gwathmey JK, et al. **Cardiovasc Drugs Ther** 1995 Aug; 9(4):581–7 (40 ref.)

Signal transduction mechanisms controlling cardiac contractility and their alterations in chronic heart failure. Brodde OE, et al. **Cardiovasc Res** 1995 Oct;30(4):570–84 (214 ref.)

Stretch-induced modifications of myocardial performance:

from ventricular function to cellular and molecular mechanisms. Crozatier B. **Cardiovasc Res** 1996 Jul; 32(1):25–37 (143 ref.)
Mechano–electrical feedback in ventricular myocardium. Franz MR. **Cardiovasc Res** 1996 Jul;32(1):15–24 (40 ref.)
Cardiac efficiency. Gibbs CL, et al. **Cardiovasc Res** 1995 Nov; 30(5):627–34 (67 ref.)
Mechanosensitive connective tissue: potential influence on heart rhythm. Kohl P, et al. **Cardiovasc Res** 1996 Jul; 32(1):62–8 (63 ref.)
Mechanoelectric feedback (transduction) in heart: concepts and implications. Lab MJ. **Cardiovasc Res** 1996 Jul; 32(1):3–14 (146 ref.)
Regulation of intracellular calcium concentration in the developing heart. Mahony L. **Cardiovasc Res** 1996 Feb;31 Spec No:E61–7 (83 ref.)
Sarcoplasmic reticulum function during myocardial ischaemia and reperfusion. Mubagwa K. **Cardiovasc Res** 1995 Aug;30(2):166–75 (114 ref.)
Contractile protein phenotypic variation during development. Murphy AM. **Cardiovasc Res** 1996 Feb;31 Spec No:E25–33 (106 ref.)
Mechanoelectric feedback and atrial arrhythmias. Nazir SA, et al. **Cardiovasc Res** 1996 Jul;32(1):52–61 (92 ref.)
Effects of mechano–electrical feedback: potential arrhythmogenic influence in patients with congestive heart failure. Reiter MJ. **Cardiovasc Res** 1996 Jul;32(1):44–51 (44 ref.)
Paracrine modulation of heart cell function by endothelial cells. Shah AM. **Cardiovasc Res** 1996 Jun;31(6):847–67 (224 ref.)
Mechano–electric feedback in the human heart. Taggart P. **Cardiovasc Res** 1996 Jul;32(1):38–43 (41 ref.)
Cell swelling and ion transport pathways in cardiac myocytes. Vandenberg JI, et al. **Cardiovasc Res** 1996 Jul; 32(1):85–97 (94 ref.)
Developmental cardiac electrophysiology recent advances in cellular physiology. Wetzel GT, et al. **Cardiovasc Res** 1996 Feb;31 Spec No:E52–60 (76 ref.)
Inward rectification and implications for cardiac excitability. Nichols CG, et al. **Circ Res** 1996 Jan;78(1):1–7 (52 ref.)
Adrenergic control of the force–frequency relation. Ross J Jr, et al. **Circulation** 1995 Oct 15;92(8):2327–32 (48 ref.)
Effects of edema on systolic and diastolic function in vivo. Spotnitz HM. **J Card Surg** 1995 Jul;10(4 Suppl):454–9 (27 ref.)
Torsional deformation of the left ventricle. Yun KL, et al. **J Heart Valve Dis** 1995 Oct;4 Suppl 2:S214–20; discussion S220–2 (42 ref.)
Preconditioning induced protection against post–ischaemic contractile dysfunction: characteristics and mechanisms. Cave AC. **J Mol Cell Cardiol** 1995 Apr;27(4):969–79 (48 ref.)
Carnosine: a novel peptide regulator of intracellular calcium and contractility in cardiac muscle. Zaloga GP, et al. **New Horiz** 1996 Feb;4(1):26–35 (92 ref.)
[Isotope methods of determination of myocardial viability] Merlet P, et al. **Ann Cardiol Angeiol (Paris)** 1995 Dec; 44(10):587–96 (58 ref.) (Eng. Abstr.) **(Fre)**
[Pathophysiology of the "hibernating" myocardium] Schulz R, et al. **Z Kardiol** 1995;84 Suppl 4:91–100 (40 ref.) (Eng. Abstr.) **(Ger)**
[Evaluation of systolic and diastolic left ventricular function by echocardiography] Haertel JC. **Arq Bras Cardiol** 1995 Apr;64(4):391–400 (45 ref.) **(Por)**
[Noninvasive evaluation of ischemia and viability after acute myocardial infarction] Reis G, et al. **Arq Bras Cardiol** 1995 Apr;64(4):367–72 (74 ref.) **(Por)**

MYOCARDIAL DEPRESSANTS see
ANTI-ARRHYTHMIA AGENTS

MYOCARDIAL DISEASES

Recent advances in the etiology, diagnosis, and treatment of myocarditis and cardiomyopathies in children. Gajarski RJ, et al. **Curr Opin Pediatr** 1995 Oct;7(5):587–94 (79 ref.)
[Progresses in endemiology in China, 1995] Wang Z, et al. **Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):764–5 (0 ref.) **(Chi)**
[Myocardial diverticulum of the left ventricle. Review of the literature apropos of a case] Roche R, et al. **Ann Cardiol Angeiol (Paris)** 1996 Feb;45(2):68–70 (14 ref.) (Eng. Abstr.) **(Fre)**
[Myocardial diseases: lessons from the past and future prospects] Zarco P, et al. **Rev Esp Cardiol** 1995 Sep; 48(9):616–27 (103 ref.) (Eng. Abstr.) **(Spa)**

CHEMICALLY INDUCED

Combination therapy with probucol prevents adriamycin–induced cardiomyopathy. Singal PK, et al. **J Mol Cell Cardiol** 1995 Apr;27(4):1055–63 (80 ref.)
Structural and biochemical remodelling in catecholamine–induced cardiomyopathy: comparative and ontogenetic aspects. Oštádal B, et al. **Mol Cell Biochem** 1995 Jun 7–21;147(1–2):83–8 (49 ref.)
[Pediatric aspects of anthracycline cardiotoxicity and practical implications for prevention] Pein F, et al. **Arch Pediatr** 1995 Oct;2(10):988–99 (75 ref.) (Eng. Abstr.) **(Fre)**

CLASSIFICATION

[New criteria for the classification of cardiomyopathies (editorial)] Mariani M. **Cardiologia** 1995 Sep;40(9):631–4 (27 ref.) **(Ita)**

COMPLICATIONS

[Arrhythmogenic right ventricle: dysplasia or cardiomyopathy? Value of left ventricle ejection fraction] Fontaine G, et al. **Ann Cardiol Angeiol (Paris)** 1995 Sep; 44(7):321–31 (37 ref.) (Eng. Abstr.) **(Fre)**
[Cardiac sarcoidosis with myopathy and advanced A–V nodal block in a woman with a previous diagnosis of sarcoidosis] Sugo A, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Oct; 33(10):1111–8 (33 ref.) (Eng. Abstr.) **(Jpn)**
[Ventricular tachycardia in non–ischemic heart disease] Murin J, et al. **Vnitr Lek** 1995 Jul;41(7):476–9 (17 ref.) (Eng. Abstr.) **(Slo)**

DIAGNOSIS

MR imaging of cardiomyopathy. Park JH, et al. **Magn Reson Imaging Clin N Am** 1996 May;4(2):269–86 (51 ref.)
[Cardiac amyloidosis] Meierhenrich R, et al. **Med Klin** 1995 Oct 15;90(10):599–605 (53 ref.) **(Ger)**
[Myocardial lipofuscinosis of unknown etiology in a young asymptomatic woman] Dolara A, et al. **Cardiologia** 1996 Mar;41(3):275–7 (17 ref.) (Eng. Abstr.) **(Ita)**

DRUG THERAPY

Successful treatment of supraventricular tachycardia–induced cardiomyopathy with amiodarone: case report and review of literature. Chen RP, et al. **Can J Cardiol** 1995 Nov;11(10):918–22 (20 ref.)

ETIOLOGY

Successful treatment of supraventricular tachycardia–induced cardiomyopathy with amiodarone: case report and review of literature. Chen RP, et al. **Can J Cardiol** 1995 Nov;11(10):918–22 (20 ref.)
Acute reversal of pheochromocytoma–induced catecholamine cardiomyopathy. Nanda AS, et al. **Clin Cardiol** 1995 Jul;18(7):421–3 (8 ref.)
Diabetic cardiomyopathy. A unique entity or a complication of coronary artery disease? Bell DS. **Diabetes Care** 1995 May;18(5):708–14 (79 ref.)
Cirrhotic cardiomyopathy: getting to the heart of the matter. Ma Z, et al. **Hepatology** 1996 Aug;24(2):451–9 (115 ref.)
Coronary ventricular fistula as a complication of PTCA: a case report and literature review. el–Omar MM, et al. **Int J Cardiol** 1995 Sep;51(2):113–6 (10 ref.)
[Cardiac involvement in Kugelberg–Welander disease. A prospective study of 8 cases] Elkohen M, et al. **Arch Mal Coeur Vaiss** 1996 May;89(5):611–7 (26 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Molecular genetic insights into cardiovascular disease. Keating MT, et al. **Science** 1996 May 3;272(5262):681–5 (33 ref.)

METABOLISM

Cardiomyopathy: a role for nitric oxide? de Belder A, et al. **Int J Cardiol** 1995 Jul;50(3):263–8 (51 ref.)

PATHOLOGY

Endomyocardial biopsy in arrhythmogenic right ventricular cardiomyopathy [editorial] Angelini A, et al. **Am Heart J** 1996 Jul;132(1 Pt 1):203–6 (35 ref.)
Necrobiotic xanthogranuloma with cardiac involvement. Umbert I, et al. **Br J Dermatol** 1995 Sep;133(3):438–43 (37 ref.)
[A case of oxalosis with heart and lung involvement] Magnani G, et al. **Cardiologia** 1992 Jul;37(7):507–11 (10 ref.) (Eng. Abstr.) **(Ita)**

RADIONUCLIDE IMAGING

Cardiac studies with metaiodobenzylguanidine: a critique of methods and interpretation of results. Glowniak JV. **J Nucl Med** 1995 Nov;36(11):2133–7 (41 ref.)

ULTRASONOGRAPHY

New technology in echocardiography II: imaging techniques. McDicken WN, et al. **Heart** 1996 Jun;75(6 Suppl 2):9–16 (59 ref.)

MYOCARDIAL DISEASES, PRIMARY see
MYOCARDIAL DISEASES

MYOCARDIAL DISEASES, SECONDARY see
MYOCARDIAL DISEASES

MYOCARDIAL INFARCTION

see related
HEART RUPTURE, POST-INFARCTION

Myocardial infarction: the first 24 hours. Gavagan T, et al. **Am Fam Physician** 1996 Sep 1;54(3):921–31, 934 (51 ref.)
Acute myocardial infarction during pregnancy and puerperium: a review. Badui E, et al. **Angiology** 1996 Aug; 47(8):739–56 (128 ref.)
Arterial thrombosis for the clinician. Pathobiology and emerging concepts. Becker RC. **Cardiol Clin** 1995 Aug; 13(3):295–310 (168 ref.)
Myocardial infarction in women. Mendelson MA, et al. **Cardiology** 1995;86(4):272–85 (138 ref.)
"Hibernating" myocardium: asleep or part dead? [editorial] Armstrong WF. **J Am Coll Cardiol** 1996 Aug;28(2):530–5 (43 ref.)

BLOOD

Platelets and platelet inhibitors in acute myocardial infarction. Kamat SG, et al. **Cardiol Clin** 1995 Aug; 13(3):435–47 (139 ref.)
Thrombin generation in myocardial infarction and hypercholesterolemia: effects of aspirin. Szczeklik A. **Thromb Haemost** 1995 Jul;74(1):77–80 (34 ref.)
[Troponin––current possibility for the diagnosis of myocardial infarction (editorial)] Partanen J. **Duodecim** 1994;110(18):1673–5 (16 ref.) **(Fin)**

CHEMICALLY INDUCED

Recurrent non–Q–wave myocardial infarction associated with toluene abuse. Hussain TF, et al. **Am Heart J** 1996 Mar;131(3):615–6 (6 ref.)
Cocaine–associated myocardial infarction. Hollander JE. **J R Soc Med** 1996 Aug;89(8):443–7 (69 ref.)
The management of cocaine–associated myocardial ischemia [see comments] Hollander JE. **N Engl J Med** 1995 Nov 9;333(19):1267–72 (66 ref.) Comment in: N Engl J Med 1996 Feb 22;334(8):535; discussion 536–7. Comment in: N Engl J Med 1996 Feb 22;334(8):535–6; discussion 536–7. Comment in: N Engl J Med 1996 Feb 22;334(8):536; discussion 536–7.
[Calcium antagonists––much noise about nothing?] Oberpichler–Schwenk H. **Med Monatsschr Pharm** 1995 Dec;18(12):344–9 (14 ref.) **(Ger)**

COMPLICATIONS

Is it safe to prescribe digoxin after acute myocardial infarction? Update on continued controversy [editorial] Leor J, et al. **Am Heart J** 1995 Dec;130(6):1322–6 (47 ref.)
Pathogenesis of mitral regurgitation in acute myocardial infarction: importance of changes in left ventricular shape and regional function. Van Dantzig JM, et al. **Am Heart J** 1996 May;131(5):865–71 (36 ref.)
The revolution and evolution of prehospital cardiac care. Eisenberg MS, et al. **Arch Intern Med** 1996 Aug 12–26; 156(15):1611–9 (43 ref.)
Improving outcome after acute myocardial infarction: what is the role of ACE inhibitors? [see comments] Purcell H, et al. **Br J Clin Pract** 1995 Jul–Aug;49(4):195–9 (59 ref.) Comment in: Br J Clin Pract 1995 Jul–Aug;49(4):171.
Assessment of arrhythmias after myocardial infarction in the post–CAST era. Camm AJ, et al. **Can J Cardiol** 1996 Apr; 12 Suppl B:9B–19B; discussion 27B–28B (106 ref.)
Hemorrhagic complications of thrombolytic therapy in the treatment of myocardial infarction and venous thromboembolism. Levine MN, et al. **Chest** 1995 Oct;108(4 Suppl):291S–301S (86 ref.)
Postinfarction ventricular aneurysms. Friedman BM, et al. **Clin Cardiol** 1995 Sep;18(9):505–11 (80 ref.)
Left ventricular remodelling after acute myocardial infarction––solved and unsolved issues. Bassand JP. **Eur Heart J** 1995 Aug;16 Suppl I:58–63 (53 ref.)
Should post–infarction asymptomatic ventricular arrhythmias be treated? Campbell RW. **Eur Heart J** 1995 Jul;16 Suppl E:46–8 (37 ref.)
Should post–infarction asymptomatic ventricular arrhythmias be treated? The need for caution. Sleight P. **Eur Heart J** 1995 Jul;16 Suppl E:49 (29 ref.)
Management strategies in patients at high risk of sudden cardiac death following myocardial infarction. Sra J, et al. **Indian Heart J** 1995 Mar–Apr;47(2):158–62 (37 ref.)
Ventricular tachycardia after myocardial infarction: from arrhythmia surgery to catheter ablation. Stevenson WG. **J Cardiovasc Electrophysiol** 1995 Oct;6(10 Pt 2):942–50 (52 ref.)
[Endoscopy for digestive system after acute myocardial infarction] Yi X. **Chung Hua Nei Ko Tsa Chih** 1995 Jul; 34(7):487–90 (20 ref.) **(Chi)**
[Surgical treatment of aneurysms of the left ventricle. Immediate and long–term results. Apropos of a consecutive series of 121 cases] Valla J, et al. **Ann Chir** 1995; 49(9):816–23 (52 ref.) (Eng. Abstr.) **(Fre)**
[Post–infarction, myocardial ischemia: clinical importance and risk factor] Jespersen C. **Arch Mal Coeur Vaiss** 1995 Sep;88 Spec No 4:17–27 (86 ref.) (Eng. Abstr.) **(Fre)**
[Detection of multivessel lesions after myocardial infarction. Improvement of the predictive value of early exercise stress test by discriminant analysis] Leroy F, et al. **Arch Mal Coeur Vaiss** 1996 Feb;89(2):193–200 (31 ref.) (Eng. Abstr.) **(Fre)**
[Post–infarction myocardial viability. Role of scintigraphic evaluation] Faraggi M, et al. **Presse Med** 1995 Dec 9; 24(38):1795–9 (24 ref.) (Eng. Abstr.) **(Fre)**
[Stratification of arrhythmia risk and therapeutic options in survivors of acute myocardial infarction] Arós Borau F, et al. **Rev Esp Cardiol** 1996 Mar;49(3):157–65 (85 ref.) (Eng.

Abstr.) **(Spa)**

DIAGNOSIS

Myocardial markers of injury. Evolution and insights. Keffer JH. **Am J Clin Pathol** 1996 Mar;105(3):305–20 (221 ref.)

Evaluation of the patient with 'rule out myocardial infarction'. Lewis WR, et al. **Arch Intern Med** 1996 Jan 8;156(1):41–5 (21 ref.)

Rapid diagnosis of acute myocardial infarction. Guest TM, et al. **Cardiol Clin** 1995 Aug;13(3):283–94 (60 ref.)

Prediction of myocardium at risk. Clinical significance during acute infarction and in evaluating subsequent prognosis. Mahmarian JJ. **Cardiol Clin** 1995 Aug;13(3):355–78 (127 ref.)

New biochemical markers for myocardial cell injury. Hamm CW, et al. **Curr Opin Cardiol** 1995 Jul;10(4):355–60 (42 ref.)

Advances in the use of ancillary diagnostic testing in the emergency department evaluation of chest pain. Stack LB, et al. **Emerg Med Clin North Am** 1995 Nov;13(4):713–33 (75 ref.)

Management after a first myocardial infarction. Flapan AD. **Hosp Pract (Off Ed)** 1996 May 15;31(5):133–7, 141–6 (11 ref.)

The role of CK-MB in chest pain decision-making. Hedges JR. **J Accid Emerg Med** 1995 Jun;12(2):101–6 (39 ref.)

Advances in the early diagnosis and management of acute myocardial infarction. Vincent R. **J Accid Emerg Med** 1996 Mar;13(2):74–9 (36 ref.)

MR evaluation of myocardial ischemia and infarction. Pattynama PM, et al. **Top Magn Reson Imaging** 1995 Fall; 7(4):218–31 (131 ref.)

[Prognostic stratification after acute myocardial infarction: evaluation of ischemic risk] Penco M. **Cardiologia** 1995 Jun; 40(6):413–8 (75 ref.) **(Ita)**

[Primary antiphospholipid syndrome with a familial element and myocardial infarct in an adolescent] Gaeta G, et al. **G Ital Cardiol** 1995 Aug;25(8):1025–30 (35 ref.) (Eng. Abstr.) **(Ita)**

[Human myoglobin (hMb) and its diagnostic value] Szewczuk A, et al. **Postepy Hig Med Dosw** 1995;49(3):343–52 (51 ref.) (Eng. Abstr.) **(Pol)**

[Acute juvenile myocardial infarct. A clinical case and review of the literature] Gouveia D, et al. **Rev Port Cardiol** 1995 Sep;14(9):645–52 (32 ref.) (Eng. Abstr.) **(Por)**

[Acute myocardial infarct: apropos a clinical case] Rosário L, et al. **Rev Port Cardiol** 1995 Dec;14(12):1041–8, 989 (31 ref.) (Eng. Abstr.) **(Por)**

DRUG THERAPY

ACE inhibitors: myocardial infarction and congestive heart failure. Cody RJ. **Am Fam Physician** 1995 Nov 1; 52(6):1801–6 (18 ref.)

Magnesium in acute myocardial infarction: overview of available evidence. Antman EM. **Am Heart J** 1996 Aug; 132(2 Pt 2 Su):487–95; discussion 496–502 (53 ref.)

Who should be treated with angiotensin-converting enzyme inhibitors after myocardial infarction? Ball SG, et al. **Am Heart J** 1996 Jul;132(1 Pt 2 Su):244–50 (22 ref.)

Relation between systemic anticoagulation as determined by activated partial thromboplastin time and heparin measurements and in-hospital clinical events in unstable angina and non-Q wave myocardiaL infarction. Thrombolysis in Myocardial Ischemia III B Investigators. Becker RC, et al. **Am Heart J** 1996 Mar;131(3):421–33 (66 ref.)

Management of acute myocardial infarction: evaluating the past, practicing in the present, elaborating the future. Glogar D, et al. **Am Heart J** 1996 Aug;132(2 Pt 2 Su):465–70; discussion 496–502 (68 ref.)

Is there a place for magnesium in the treatment of acute myocardial infarction? Seelig MS, et al. **Am Heart J** 1996 Aug;132(2 Pt 2 Su):471–7; discussion 496–502 (73 ref.)

The rationale of magnesium as alternative therapy for patients with acute myocardial infarction without thrombolytic therapy. Shechter M, et al. **Am Heart J** 1996 Aug;132(2 Pt 2 Su):483–6; discussion 496–502 (39 ref.)

Acute myocardial infarction, reperfusion injury, and intravenous magnesium therapy: basic concepts and clinical implications. Steurer G, et al. **Am Heart J** 1996 Aug;132(2 Pt 2 Su):478–82; discussion 496–502 (86 ref.)

Prognosis of patients with unstable angina or acute myocardial infarction treated with calcium channel antagonists. Ferrari R. **Am J Cardiol** 1996 Jun 20; 77(16):22D–25D (44 ref.)

Effect of nitrates on myocardial remodeling after acute myocardial infarction. Jugdutt BI. **Am J Cardiol** 1996 May 30;77(13):17C–23C (90 ref.)

Clinical science review: current aspects of thrombolytic therapy in women with acute myocardial infarction. Hussain KM, et al. **Angiology** 1996 Jan;47(1):23–33 (83 ref.)

Clinical applications of new antithrombotic agents. Beijering RJ, et al. **Ann Hematol** 1996 Apr;72(4):177–83 (52 ref.)

Prehospital administration of aspirin in patients with unstable angina and acute myocardial infarction. Eisenberg MJ, et al. **Arch Intern Med** 1996 Jul 22;156(14):1506–10 (34 ref.)

Adjunctive therapy for myocardial infarction. Avezum A Jr, et al. **Arq Bras Cardiol** 1995 Jul;65(1):97–110 (92 ref.)

Thrombolytic therapy of acute myocardial infarction. de Bono DP. **Baillieres Clin Haematol** 1995 Jun;8(2):403–12 (36 ref.)

Acute care of myocardial infarction [see comments] Gutman MB, et al. **Can Fam Physician** 1996 Jul;42:1330–9 (30 ref.) Comment in: Can Fam Physician 1996 Jul;42:1269–70, 1278–9.

Thrombin inhibitors in acute myocardial infarction. Cannon CP. **Cardiol Clin** 1995 Aug;13(3):421–33 (73 ref.)

Platelets and platelet inhibitors in acute myocardial infarction. Kamat SG, et al. **Cardiol Clin** 1995 Aug; 13(3):435–47 (139 ref.)

Risk-benefit of thrombolysis. Simoons ML. **Cardiol Clin** 1995 Aug;13(3):339–45 (28 ref.)

Selecting a thrombolytic agent. White HD. **Cardiol Clin** 1995 Aug;13(3):347–54 (54 ref.)

Angiotensin-converting enzyme inhibitors post-myocardial infarction. Young JB. **Cardiol Clin** 1995 Aug;13(3):379–90 (56 ref.)

Myocardial infarction: when and how should we initiate treatment with ACE inhibitors? GISSI-3 Investigators. Latini R, et al. **Cardiology** 1996;87 Suppl 1:16–22 (22 ref.)

Treatment for survivors of acute myocardial infarction: what have we learned from large intervention trials? Julian DG. **Cardiovasc Drugs Ther** 1995 Aug;9 Suppl 3:495–502 (35 ref.)

Thrombolytic intervention of acute myocardial infarction in the 1990s. Hu D. **Chin Med J (Engl)** 1996 Feb;109(2):107–8 (0 ref.)

Fibrin-selective thrombolytic therapy for acute myocardial infarction. Collen D. **Circulation** 1996 Mar 1;93(5):857–65 (90 ref.)

ACE inhibitor use in patients with myocardial infarction. Summary of evidence from clinical trials. Latini R, et al. **Circulation** 1995 Nov 15;92(10):3132–7 (35 ref.)

Antiplatelet and anticoagulant use after myocardial infarction. Almony GT, et al. **Clin Cardiol** 1996 May; 19(5):357–65 (109 ref.)

Left ventricular function following thrombolytic therapy for myocardial infarction. French JK, et al. **Clin Exp Pharmacol Physiol** 1995 Mar;22(3):173–9 (46 ref.)

The use of angiotensin converting enzyme inhibitors in asymptomatic patients with left ventricular dysfunction after myocardial infarction. Bazunga M. **Conn Med** 1995 Nov;59(11):663–6 (39 ref.)

Inhibitors of platelet glycoprotein IIb/IIIa as augmenters of thrombolysis. Eccleston D, et al. **Coron Artery Dis** 1995 Dec;6(12):947–55 (67 ref.)

Aspirin augmentation of the efficacy of thrombolysis. O'Donnell CJ, et al. **Coron Artery Dis** 1995 Dec;6(12):936–9 (23 ref.)

The actions of talinolol, a beta 1-selective beta blocker, in cardiac arrhythmia and acute myocardial infarction. Assmann I. **Curr Med Res Opin** 1995;13(6):325–42 (43 ref.)

The role of coronary angiography after thrombolysis. Aguirre FV, et al. **Curr Opin Cardiol** 1995 Jul;10(4):381–8 (58 ref.)

Thrombolysis in the era of the randomized trials. Zahger D, et al. **Curr Opin Cardiol** 1995 Jul;10(4):372–80 (84 ref.)

Magnesium, myocardial infarction, meta-analysis and megatrials. **Drug Ther Bull** 1995 Apr;33(4):25–7 (18 ref.)

Alteplase. A reappraisal of its pharmacological properties and therapeutic use in acute myocardial infarction. Gillis JC, et al. **Drugs** 1995 Jul;50(1):102–36 (154 ref.)

Guidelines for general practitioners administering thrombolytics. Rawles J. **Drugs** 1995 Oct;50(4):615–25 (45 ref.)

Calcium antagonists during and after myocardial infarction. Sleight P. **Drugs** 1996 Feb;51(2):216–25 (41 ref.)

Pharmacological properties of hirudin and its derivatives. Potential clinical advantages over heparin. Monreal M, et al. **Drugs Aging** 1996 Mar;8(3):171–82 (52 ref.)

Captopril. A review of its pharmacology and therapeutic efficacy after myocardial infarction and in ischaemic heart disease. Plosker GL, et al. **Drugs Aging** 1995 Sep; 7(3):226–53 (171 ref.)

Optimising thrombolytic therapy in elderly patients with acute myocardial infarction. Verstraete M, et al. **Drugs Aging** 1996 Jan;8(1):17–22 (32 ref.)

Current and future perspectives on antithrombotic therapy of acute myocardial infarction. Hennekens CH, et al. **Eur Heart J** 1995 Jul;16 Suppl D:2–9 (42 ref.)

Anti-ischaemic intervention with verapamil in patients recovering from acute myocardial infarction. Jespersen CM. **Eur Heart J** 1995 Aug;16 Suppl H:13–7 (24 ref.)

Should ACE inhibitors be administered to all patients after acute myocardial infarction? A (cautious) negative response. Julian DG. **Eur Heart J** 1995 Jul;16 Suppl E:44–5 (7 ref.)

Should ACE inhibitors be administered to all patients with acute myocardial infarction? Prashad R, et al. **Eur Heart J** 1995 Jul;16 Suppl E:41–3 (26 ref.)

Heparin as adjunctive therapy to coronary thrombolysis in acute myocardial infarction. Bowlby H, et al. **Heart Lung** 1995 Jul-Aug;24(4):292–304; quiz 304–6 (112 ref.)

Pharmacological treatment for myocardial infarction Part 2: Implications of clinical trials of other adjunctive therapies. Avezum A Jr, et al. **Indian Heart J** 1995 Mar-Apr; 47(2):95–105 (60 ref.)

Should angiotensin converting enzyme inhibitors be routinely used in patients with acute myocardial infarction? Chatterjee K. **Indian Heart J** 1995 May-Jun;47(3):275–8 (17 ref.)

Thrombolytic and antithrombotic treatment in myocardial infarction: main achievements and future perspectives. Agnelli G. **Int J Cardiol** 1995 Aug;49 Suppl:S77–87 (60 ref.)

Time as a factor in thrombolytic therapy. Julian DG. **Int J Cardiol** 1995 Aug;49 Suppl:S17–9 (15 ref.)

From the experimental myocardial infarction to the clinical acute myocardial infarction: limitations of thrombolytic therapy. Marzilli M. **Int J Cardiol** 1995 Aug;49 Suppl:S71–5 (30 ref.)

Advances in the early diagnosis and management of acute myocardial infarction. Vincent R. **J Accid Emerg Med** 1996 Mar;13(2):74–9 (36 ref.)

Reocclusion: the flip side of coronary thrombolysis. Verheugt FW, et al. **J Am Coll Cardiol** 1996 Mar 15;27(4):766–73 (62 ref.)

Third generation plasminogen activators in the treatment of acute myocardial infarction. Talley JD. **J Ark Med Soc** 1996 Apr;92(11):587–8 (6 ref.)

Effects of ACE inhibitors on mortality when started in the early phase of myocardial infarction: evidence from the larger randomized controlled trials. Flather MD, et al. **J Cardiovasc Risk** 1995 Oct;2(5):423–8 (27 ref.)

Clinical background to the use of ACE inhibitor therapy after myocardial infarction. Hall AS, et al. **J Cardiovasc Risk** 1995 Oct;2(5):396–405 (66 ref.)

Circadian rhythms and the onset of myocardial infarction: clinical implications. Purcell H, et al. **J Cardiovasc Risk** 1995 Dec;2(6):510–4 (34 ref.)

Prevention of congestive heart failure by ACE inhibition in patients with acute myocardial infarction. Sigurdsson A, et al. **J Cardiovasc Risk** 1995 Oct;2(5):406–12 (44 ref.)

Practical issues for the use of ACE inhibitors in acute myocardial infarction. Testa M, et al. **J Cardiovasc Risk** 1995 Oct;2(5):429–33 (27 ref.)

Drug differences between ACE inhibitors in experimental settings and clinical practice. Voors AA, et al. **J Cardiovasc Risk** 1995 Oct;2(5):413–22 (105 ref.)

Update on the use of angiotensin converting enzyme inhibitors and calcium antagonists in postinfarction patients. Persson S. **J Hypertens Suppl** 1995 Aug;13(2):S57–63 (33 ref.)

Clinical and economic lessons from studies of coronary thrombolysis. Mark DB. **J Vasc Interv Radiol** 1995 Nov-Dec;6(6 Pt 2 Su):94S–101S (27 ref.)

Comparison of "accelerated" tissue plasminogen activator with streptokinase for treatment of suspected myocardial infarction [see comments] Kellett J, et al. **Med Decis Making** 1995 Oct-Dec;15(4):297–310 (145 ref.) Comment in: Med Decis Making 1995 Oct-Dec;15(4):395–6.

Acute myocardial infarction. A guide for North Carolina doctors. Williams ML, et al. **N C Med J** 1995 Aug; 56(8):390–7 (39 ref.)

ISIS 4: clinical controversy regarding magnesium infusion, thrombolytic therapy, and acute myocardial infarction. Seelig MS. **Nutr Rev** 1995 Sep;53(9):261–4 (52 ref.)

Thrombolytic therapy in acute myocardial infarction. Huber K, et al. **Semin Thromb Hemost** 1996;22(1):15–26 (115 ref.)

Thrombolytic therapy: overview of results in major vascular occlusions. Marder VJ. **Thromb Haemost** 1995 Jul; 74(1):101–5 (60 ref.)

[Thrombolysis after 75 years of age: benefits, risks, indications] Tabone X, et al. **Arch Mal Coeur Vaiss** 1995 Feb;88(2):255–60 (21 ref.) (Eng. Abstr.) **(Fre)**

[Thrombolytic therapy of acute myocardial infarction] Verstraete M. **Arch Mal Coeur Vaiss** 1995 Dec; 88(12):1883–9 (58 ref.) (Eng. Abstr.) **(Fre)**

[The value of preclinical thrombolysis in acute myocardial infarct] Arntz HR. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Aug; 30(5):299–302 (25 ref.) **(Ger)**

[Use of nitrates in coronary heart disease including acute myocardial infarct] Auch-Schwelk W. **Herz** 1996 Jun;21 Suppl 1:31–4 (34 ref.) (Eng. Abstr.) **(Ger)**

[ACE inhibitor after myocardial infarct: are there differences?] Jahrmärker H. **Herz** 1995 Aug;20(4):293–6 (15 ref.) **(Ger)**

[Thrombolysis in acute myocardial infarct] Heintzen MP, et al. **Internist (Berl)** 1996 Jun;37(6):585–96 (80 ref.) **(Ger)**

[Thrombolysis of myocardial infarction--state of the art] Erne P. **Schweiz Rundsch Med Prax** 1995 Oct 17; 84(42):1194–201 (72 ref.) (Eng. Abstr.) **(Ger)**

[ACE-inhibitors in acute heart infarct] Genoni M, et al. **Schweiz Rundsch Med Prax** 1996 Apr 23;85(17):548–53 (20 ref.) (Eng. Abstr.) **(Ger)**

[ACE inhibitors in the treatment of patients with acute myocardial infarct] Borghi C, et al. **Ann Ital Med Int** 1995 Jul-Sep;10(3):175–87 (75 ref.) (Eng. Abstr.) **(Ita)**

[Magnesium sulfate in acute myocardial infarction] Balli E, et al. **G Ital Cardiol** 1995 Nov;25(11):1425–32 (33 ref.) (Eng. Abstr.) **(Ita)**

[Thrombolysis (Consensus about post-myocardial infarction treatment)] **Arq Bras Cardiol** 1995 Mar;64(3):271–80 (65 ref.) **(Por)**

[Prophylactic use of lidocaine in the acute period of myocardial infarction] Fomichev VI, et al. **Klin Med (Mosk)** 1995;73(4):17–20 (26 ref.) **(Rus)**

[Evaluation of a standard electrocardiogram in acute myocardial infarct and therapy with thrombolysis] Kuchárová L, et al. **Vnitr Lek** 1995 Dec;41(12):836–41 (43 ref.) (Eng. Abstr.) **(Slo)**

[Thrombolytic treatment in acute myocardial infarction in

the aged: arguments in favor] Alonso-Orcajo N, et al. **Rev Esp Cardiol** 1995 Sep;48(9):589-93 (43 ref.) **(Spa)**

[Thrombolytic treatment in acute myocardial infarction in the aged: arguments against] Pabón Osuna P, et al. **Rev Esp Cardiol** 1995 Sep;48(9):581-8 (36 ref.) **(Spa)**

ENZYMOLOGY

Involvement of inducible nitric oxide synthase in the inflammatory process of myocardial infarction. Wildhirt SM, et al. **Int J Cardiol** 1995 Jul;50(3):253-61 (72 ref.)

EPIDEMIOLOGY

Epidemiologic aspects of circadian patterns of cardiovascular disease and triggers of acute cardiac events. Goldberg RJ. **Cardiol Clin** 1996 May;14(2):175-84 (40 ref.)

[Progresses in clinical epidemiology in China, 1995] Wang J. **Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):766-8 (0 ref.) **(Chi)**

ETIOLOGY

Implications of the links between hypertension and myocardial infarction for choice of drug therapy in patients with hypertension. Meredith PA. **Am Heart J** 1996 Jul; 132(1 Pt 2 Su):222-8 (29 ref.)

Links between hypertension and myocardial infarction. Rakugi H, et al. **Am Heart J** 1996 Jul;132(1 Pt 2 Su):213-21 (67 ref.)

Physical exertion as a trigger of myocardial infarction and sudden cardiac death. Mittleman MA, et al. **Cardiol Clin** 1996 May;14(2):263-70 (47 ref.)

New concepts regarding events that lead to myocardial infarction. Opie LH. **Cardiovasc Drugs Ther** 1995 Aug;9 Suppl 3:479-87 (77 ref.)

Myocardial infarction with normal coronary artery after carbon monoxide exposure: a case report. Lee D, et al. **Chung Hua I Hsueh Tsa Chih (Taipei)** 1996 May;57(5):355-9 (21 ref.)

Morphological and functional significance of findings in unstable atherothrombotic plaque underlying acute coronary syndromes: a review. Baroldi G. **Int J Cardiol** 1995 Aug;49 Suppl:S3-9 (18 ref.)

Cigarette smoking and health of the heart. Leone A. **J R Soc Health** 1995 Dec;115(6):354-5 (13 ref.)

[Acute myocardial infarction in young age and drug dependence. Review of the literature and personal experience] Massari FM, et al. **G Ital Cardiol** 1995 Oct; 25(10):1273-83 (44 ref.) (Eng. Abstr.) **(Ita)**

[Myocardial infarction as a work-related occurrence] Szozda R, et al. **Med Pr** 1995;46(3):285-8 (19 ref.) (Eng. Abstr.) **(Pol)**

[The pathogenesis of myocardial infarct in young people] Lemkina SM. **Vrach Delo** 1995 Jan-Feb;(1-2):6-12 (51 ref.) **(Rus)**

GENETICS

[Cardiac gene expression after brief coronary occlusion] Zimmermann R, et al. **Z Kardiol** 1995;84 Suppl 4:159-65 (23 ref.) (Eng. Abstr.) **(Ger)**

METABOLISM

Myocardial gap junction organization in ischemia and infarction. Peters NS. **Microsc Res Tech** 1995 Aug 1; 31(5):375-86 (95 ref.)

MORTALITY

Patterns of aspirin use in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study. Shahar E, et al. **Am Heart J** 1996 May;131(5):915-22 (37 ref.)

Sudden cardiac death. How to reduce the number of victims? Wellens HJ, et al. **Eur Heart J** 1995 Aug;16 Suppl G:7-9 (30 ref.)

[Which patients at risk of sudden death after myocardial infarction? Critical study of prognostic factors] Aliot E, et al. **Arch Mal Coeur Vaiss** 1995 Aug;88 Spec No 3:37-44 (51 ref.) (Eng. Abstr.) **(Fre)**

[Mortality and morbidity in the acute phase of myocardial infarction. Comparison of 3 patient cohorts admitted to hospital over 10 years] Maheu B, et al. **Arch Mal Coeur Vaiss** 1996 Feb;89(2):187-92 (14 ref.) (Eng. Abstr.) **(Fre)**

[Risk stratification following myocardial infarct] Buser PT, et al. **Schweiz Med Wochenschr** 1996 Jun 8;126(23):1011-22 (57 ref.) (Eng. Abstr.) **(Ger)**

[Prognostic value of neuroendocrine activation after acute myocardial infarction] Omland T. **Tidsskr Nor Laegeforen** 1995 Sep 10;115(21):2641-5 (45 ref.) (Eng. Abstr.) **(Nor)**

NURSING

Risk profile screening. Froelicher ES, et al. **J Cardiovasc Nurs** 1995 Oct;10(1):30-50 (89 ref.)

Assessing social support in patients with cardiac disease. McCauley KM. **J Cardiovasc Nurs** 1995 Oct;10(1):73-80 (28 ref.)

Drug profiles: maximizing therapeutic effectiveness. Porter LA, et al. **J Cardiovasc Nurs** 1995 Oct;10(1):64-72 (29 ref.)

PATHOLOGY

Role of plaque size and degree of stenosis in acute myocardial infarction. Little WC, et al. **Cardiol Clin** 1996 May; 14(2):221-8 (58 ref.)

Cellular basis of ventricular remodeling after myocardial infarction in rats. Olivetti G, et al. **Cardioscience** 1995 Jun; 6(2):101-6 (29 ref.)

Intracardiac thrombi: frequency, location, etiology, and complications: a morphologic review--Part II. Waller BF, et al. **Clin Cardiol** 1995 Sep;18(9):530-4 (29 ref.)

Does ACE inhibition limit structural changes in the heart following myocardial infarction? Smits JF, et al. **Eur Heart J** 1995 Dec;16 Suppl N:46-51 (48 ref.)

[Interstitial collagen matrix and its relationship with expansion of acute myocardial infarction] Matsubara BB, et al. **Arq Bras Cardiol** 1995 Jun;64(6):559-63 (39 ref.) **(Por)**

[Cardiac thrombosis in myocardial infarct] Perdigão C. **Rev Port Cardiol** 1996 Mar;15(3):233-51 (93 ref.) **(Por)**

PHYSIOPATHOLOGY

Incomplete, delayed functional recovery late after reperfusion following acute myocardial infarction: "maimed myocardium" [editorial] Boden WE, et al. **Am Heart J** 1995 Oct;130(4):922-32 (60 ref.)

The role of neurohormonal activation in chronic heart failure and postmyocardial infarction. Sigurdsson A, et al. **Am Heart J** 1996 Jul;132(1 Pt 2 Su):229-34 (50 ref.)

The renin-angiotensin system in left ventricular remodeling. Blaufarb IS, et al. **Am J Cardiol** 1996 May 30; 77(13):8C-16C (121 ref.)

The pathophysiology of the onset of morning cardiovascular events. Johnstone MT, et al. **Am J Hypertens** 1996 Apr; 9(4 Pt 3):22S-28S (45 ref.)

Epidemiologic aspects of circadian patterns of cardiovascular disease and triggers of acute cardiac events. Goldberg RJ. **Cardiol Clin** 1996 May;14(2):175-84 (40 ref.)

Right-to-left flow through a patent foramen ovale in acute right ventricular infarction. Two case reports and a proposal for management. Amsel BJ, et al. **Chest** 1995 Nov; 108(5):1468-71 (23 ref.)

Autonomic markers of prognosis after myocardial infarction. La Rovere MT. **Clin Sci (Colch)** 1996;91 Suppl:133-5 (30 ref.)

Prognosis and risk stratification after myocardial infarction. Breithardt G, et al. **Eur Heart J** 1995 Aug;16 Suppl G:10-9 (85 ref.)

Post-infarction myocardial remodelling: why does it happen? Francis GS, et al. **Eur Heart J** 1995 Dec;16 Suppl N:31-6 (41 ref.)

The changing late prognosis of acute myocardial infarction. Implications and mechanisms. Gersh BJ. **Eur Heart J** 1995 Jul;16 Suppl E:50-3 (29 ref.)

Has the long-term prognosis of acute myocardial infarction improved with the new treatments? The negative outlook. Gorgels AP, et al. **Eur Heart J** 1995 Jul;16 Suppl E:54-6 (6 ref.)

Myocardial contrast echocardiography in acute myocardial infarction. Pathophysiological background and clinical applications. Iliceto S, et al. **Eur Heart J** 1996 Mar; 17(3):344-53 (68 ref.)

Detection of viability after myocardial infarction: available techniques and clinical relevance--a review. Huitink JM, et al. **Int J Cardiol** 1995 Oct;51(3):253-66 (110 ref.)

Polymorphous ventricular tachycardia in the early stages of an evolving myocardial infarction. Birnbaum Y, et al. **J Basic Clin Physiol Pharmacol** 1993 Oct-Dec;4(4):347-56 (68 ref.)

Pathophysiological aspects of the renin-angiotensin-aldosterone system in acute myocardial infarction. Dargie HJ, et al. **J Cardiovasc Risk** 1995 Oct; 2(5):389-95 (48 ref.)

Diurnal physiologic processes and circadian variation of acute myocardial infarction. Feng DL, et al. **J Cardiovasc Risk** 1995 Dec;2(6):494-8 (43 ref.)

Triggering of acute myocardial infarction. Kondo NI, et al. **J Cardiovasc Risk** 1995 Dec;2(6):499-504 (66 ref.)

Circadian rhythms and the onset of myocardial infarction: clinical implications. Purcell H, et al. **J Cardiovasc Risk** 1995 Dec;2(6):510-4 (34 ref.)

Circadian rhythms and the onset of acute myocardial infarction. Thompson DR, et al. **J Cardiovasc Risk** 1995 Dec;2(6):491-3 (12 ref.)

Prevention of remodeling of the heart after myocardial infarction. Gorlin R. **Mt Sinai J Med** 1995 Sep;62(4):287-92 (32 ref.)

Women and heart attacks: prevention, diagnosis, and care. Arnstein PM, et al. **Nurse Pract** 1996 May;21(5):57-8, 61-4, 67-9; quiz 70-1 (67 ref.)

Assessing myocardial viability to help select patients for revascularization to improve left ventricular dysfunction due to coronary artery disease. Patterson RE, et al. **Semin Thorac Cardiovasc Surg** 1995 Oct;7(4):214-26 (61 ref.)

[Left ventricular remodeling and its role following myocardial infarction (editorial)] Uusimaa P, et al. **Duodecim** 1994;110(23-24):2179, 2181-2 (17 ref.) **(Fin)**

[Correlation between the persistence of ST elevation and left ventricular aneurysm in the post-infarction period] Hamani A, et al. **Ann Cardiol Angeiol (Paris)** 1995 Sep;44(7):361-4 (22 ref.) (Eng. Abstr.) **(Fre)**

[Study of myocardial viability after recent infarction by echocardiography under dobutamine. Evidence of stunned myocardium] Guéret P, et al. **Arch Mal Coeur Vaiss** 1995 Aug;88 Spec No 3:13-7 (19 ref.) (Eng. Abstr.) **(Fre)**

[Influence of post-infarction myocardial revascularization on the prevalence of delayed potentials] Lomama E, et al. **Arch Mal Coeur Vaiss** 1995 Sep;88(9):1267-72 (29 ref.) (Eng. Abstr.) **(Fre)**

[Development of late potentials in ventricular activation in myocardial infarction (1)] Gobin E, et al. **Rev Med Liege** 1996 Mar;51(3):230-40 (64 ref.) **(Fre)**

-Myocardial protection by preconditioning. Experimental and clinical significance- Strasser R, et al. **Z Kardiol** 1996 Feb;85(2):79-89 (108 ref.) (Eng. Abstr.) **(Ger)**

[Myocardial infarction and nitric oxide] Bing RJ, et al. **G Ital Cardiol** 1995 Dec;25(12):1621-6 (35 ref.) **(Ita)**

[Polymorphonuclear leukocytes as a potential source of oxygen free radicals in myocardial infarction] Wysocka J. **Postepy Hig Med Dosw** 1995;49(2):297-304 (42 ref.) (Eng. Abstr.) **(Pol)**

PREVENTION & CONTROL

Some issues concerning treatment in patients after myocardial infarction. Poole-Wilson PA. **Arch Mal Coeur Vaiss** 1995 Aug;88 Spec No 3:9-11 (22 ref.)

Delayed myocardial protection following ischaemic preconditioning. Baxter GF, et al. **Basic Res Cardiol** 1996 Jan-Feb;91(1):53-6 (19 ref.)

Three questions about preconditioning. Connaughton M, et al. **Basic Res Cardiol** 1996 Jan-Feb;91(1):12-5 (17 ref.)

Preconditioning: markers vs. epiphenomena. Downey JM, et al. **Basic Res Cardiol** 1996 Jan-Feb;91(1):35-7 (14 ref.)

Criteria for a mediator or effector of myocardial preconditioning: do KATP channels meet the requirements? Gross GJ, et al. **Basic Res Cardiol** 1996 Jan-Feb;91(1):31-4 (12 ref.)

Preconditioning--a reappraisal of protection. King LM, et al. **Basic Res Cardiol** 1996 Jan-Feb;91(1):5-7 (12 ref.)

Activation of ecto-5'-nucleotidase and cardioprotection by ischemic preconditioning. Kitakaze M, et al. **Basic Res Cardiol** 1996 Jan-Feb;91(1):23-6 (8 ref.)

Adenosine and bradykinin: are they independent triggers of preconditioning? Miura T. **Basic Res Cardiol** 1996 Jan-Feb; 91(1):20-2 (14 ref.)

Role of protein kinase C in ischemic preconditioning: in search of the "pure and simple truth". Przyklenk K, et al. **Basic Res Cardiol** 1996 Jan-Feb;91(1):41-3 (11 ref.)

Ischemic preconditioning and myocardial hibernation: is there a common mechanism? Schulz R, et al. **Basic Res Cardiol** 1996 Jan-Feb;91(1):50-2 (11 ref.)

Limitation of infarct size by myocardial ischemic preconditioning. Van Winkle DM. **Basic Res Cardiol** 1996 Jan-Feb;91(1):38-40 (13 ref.)

Cardioprotection by organs in stress or distress. Verdouw PD, et al. **Basic Res Cardiol** 1996 Jan-Feb;91(1):44-6 (20 ref.)

An alternative perspective on ischemic preconditioning derived from mathematical modeling. Whittaker P. **Basic Res Cardiol** 1996 Jan-Feb;91(1):47-9 (9 ref.)

New directions in anticoagulant and antiplatelet treatment [editorial] Simoons ML, et al. **Br Heart J** 1995 Oct; 74(4):337-40 (33 ref.)

Activation of ATP-sensitive potassium channels: a novel pharmacological approach to myocardial protection? Hearse DJ. **Cardiovasc Res** 1995 Jul;30(1):1-17 (94 ref.)

Primary and secondary prevention of myocardial infarction. Borghi C, et al. **Clin Exp Hypertens** 1996 Apr-May; 18(3-4):547-58 (22 ref.)

Management of postmyocardial infarction in the elderly patient. Forman R, et al. **Clin Geriatr Med** 1996 Feb; 12(1):169-80 (57 ref.)

Preoperative cardiac risk assessment and management. Abrams J. **Curr Opin Gen Surg** 1993;:13-8 (30 ref.)

Are antianginal drugs effective in secondary prevention after myocardial infarction? Julian DG. **Eur Heart J** 1995 Jul; 16 Suppl E:38-40 (13 ref.)

Are antianginal drugs effective in post-myocardial infarction secondary prevention? Sleight P. **Eur Heart J** 1995 Jul;16 Suppl E:36-7 (11 ref.)

Ischaemic preconditioning: is it clinically relevant? Verdouw PD, et al. **Eur Heart J** 1995 Sep;16(9):1169-76 (69 ref.)

Ischemic preconditioning and myocardial protection [editorial] Gambhir DS, et al. **Indian Heart J** 1995 Jul-Aug; 47(4):319-21 (37 ref.)

alpha-Linolenic acid: a preventive in secondary coronary events? Hartman IS. **Nutr Rev** 1995 Jul;53(7):194-7 (13 ref.)

Aspirin in ischemic cerebrovascular disease. How strong is the case for a different dosing regimen? [see comments] Patrono C, et al. **Stroke** 1996 Apr;27(4):756-60 (36 ref.) Comment in: Stroke 1996 Apr;27(4):585-7. Comment in: Stroke 1996 Apr;27(4):588-92.

[Impact of controlling risk factors after myocardial infarction] Guize L, et al. **Arch Mal Coeur Vaiss** 1995 Aug; 88 Spec No 3:51-7 (71 ref.) (Eng. Abstr.) **(Fre)**

[The high risk cardiac patient in anesthesia] Francke A. **Anaesthesiol Reanim** 1996;21(2):32-42 (89 ref.) (Eng. Abstr.) **(Ger)**

[Risk predictors and secondary prevention after PTCA and bypass operations] Gulba DC, et al. **Internist (Berl)** 1995 Sep;36(9):891-901 (82 ref.) **(Ger)**

[Risk predictors and secondary prevention in angina pectoris and after myocardial infarct] Huber K, et al.

Internist (Berl) 1995 Sep;36(9):883–90 (74 ref.) **(Ger)**
[Introduction to ischemic preconditioning of the heart] Della Bella D. **Cardiologia** 1996 Apr;41(4):331–42 (77 ref.) **(Ita)**
[Value of prophylactic use of lidocaine in acute myocardial infarction] Zawadzka-Byśko M, et al. **Pol Arch Med Wewn** 1995 Jun;93(6):515–9 (47 ref.) **(Pol)**

RADIOGRAPHY

Role of angiography. Anderson HV. **Cardiol Clin** 1995 Aug; 13(3):407–19 (57 ref.)

RADIONUCLIDE IMAGING

[Progresses in nuclear medicine in China, 1995] Lin X. **Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):771–2 (0 ref.) **(Chi)**
[Indium III monoclonal antimyosin antibody scintigraphy for the detection of chronic myocardial infarction apart from the acute phase] Adrie C, et al. **Arch Mal Coeur Vaiss** 1995 Dec;88(12):1863–8 (33 ref.) (Eng. Abstr.) **(Fre)**
[Post-infarction myocardial viability. Role of scintigraphic evaluation] Faraggi M, et al. **Presse Med** 1995 Dec 9; 24(38):1795–9 (24 ref.) (Eng. Abstr.) **(Fre)**

REHABILITATION

Cardiac rehabilitation and secondary prevention after a myocardial event. Cundey PE 3rd, et al. **Clin Cardiol** 1995 Oct;18(10):547–53 (35 ref.)
Cardiac rehabilitation: how can it be improved? [editorial] Thompson DR. **J Psychosom Res** 1995 Jul;39(5):519–23 (20 ref.)
Rehabilitation in the patient after myocardial infarction with or without surgical management. Pashkow FJ. **Semin Thorac Cardiovasc Surg** 1995 Oct;7(4):240–7 (93 ref.)
[Benefits and risks of physical activity in patient with coronary heart disease] Gohlke H. **Wien Klin Wochenschr** 1995;107(24):760–5 (29 ref.) (Eng. Abstr.) **(Ger)**
[Organization of cardiologic rehabilitation in central Europe: retrospect, present, future outlook] Halhuber MJ. **Wien Klin Wochenschr** 1995;107(24):756–9 (6 ref.) (Eng. Abstr.) **(Ger)**
[Rehabilitation after acute myocardial infarction (Consensus about post-myocardial infarction treatment)] **Arq Bras Cardiol** 1995 Mar;64(3):289–96 (29 ref.) **(Por)**

SURGERY

Cardiac surgical procedures following myocardial infarction. Sekela ME. **Cardiol Clin** 1995 Aug;13(3):449–57 (55 ref.)
Myocardial protection for coronary artery bypass in patients with acute myocardial infarction: resuscitation of ischemic myocardium. Brown WM 3rd, et al. **Semin Thorac Cardiovasc Surg** 1995 Oct;7(4):191–7 (84 ref.)
Surgical intervention in acute myocardial infarction: an historical perspective [see comments] Coleman WS, et al. **Semin Thorac Cardiovasc Surg** 1995 Oct;7(4):176–83 (45 ref.) Comment in: Semin Thorac Cardiovasc Surg 1995 Oct;7(4):174–5.
Surgical treatment of acute myocardial infarct: clinical considerations. Gott JP, et al. **Semin Thorac Cardiovasc Surg** 1995 Oct;7(4):198–207 (64 ref.)
Treatment of acute myocardial infarction by invasive cardiology techniques. Morris DC. **Semin Thorac Cardiovasc Surg** 1995 Oct;7(4):184–90 (42 ref.)
Assessing myocardial viability to help select patients for revascularization to improve left ventricular dysfunction due to coronary artery disease. Patterson RE, et al. **Semin Thorac Cardiovasc Surg** 1995 Oct;7(4):214–26 (61 ref.)
[Heart surgery in acute heart infarct. Indications and results] Genoni M, et al. **Schweiz Med Wochenschr** 1996 Apr 20; 126(16):682–7 (36 ref.) (Eng. Abstr.) **(Ger)**
[Quality of life after an episode of myocardial infarct] Borrello G, et al. **Minerva Cardioangiol** 1995 Jul–Aug; 43(7–8):315–27 (39 ref.) (Eng. Abstr.) **(Ita)**

THERAPY

Reperfusion in acute inferior myocardial infarction: could tailored therapy be based on precordial ST depression? [editorial] Wong CK, et al. **Am Heart J** 1996 Jun; 131(6):1240–7 (61 ref.)
Thrombolysis of primary angioplasty? An ongoing controversy in the management of acute myocardial infarction. Futterman LG, et al. **Am J Crit Care** 1996 Mar; 5(2):160–66 (20 ref.)
Myocardial preconditioning promises to be a novel approach to the treatment of ischemic heart disease. Cohen MV, et al. **Annu Rev Med** 1996;47:21–9 (52 ref.)
Direct angioplasty in acute myocardial infarction. State of the art and current controversies. Horrigan MC, et al. **Cardiol Clin** 1995 Aug;13(3):321–38 (108 ref.)
Aggressive interventional treatment of acute myocardial infarction. Lessons from the animal laboratory applied to the catheterization suite. Feld S, et al. **Cardiology** 1995; 86(5):365–73 (65 ref.)
Management of acute myocardial infarction. Shen W. **Chin Med J (Engl)** 1996 Feb;109(2):102–4 (0 ref.)
Therapy for acute myocardial infarction. Rich MW. **Clin Geriatr Med** 1996 Feb;12(1):141–68 (148 ref.)
The importance of early patency after acute myocardial infarction. Grover A, et al. **Curr Opin Cardiol** 1995 Jul; 10(4):361–6 (29 ref.)
Direct angioplasty for acute myocardial infarction. Stewart RE, et al. **Curr Opin Cardiol** 1995 Jul;10(4):367–71 (32 ref.)
Intracoronary stents. Wong SC, et al. **Curr Opin Cardiol** 1995 Jul;10(4):404–11 (37 ref.)
Acute myocardial infarction and congestive heart failure. Howell JM. **Emerg Med Clin North Am** 1996 Feb; 14(1):83–91 (36 ref.)
Acute myocardial infarction. Sirois JG. **Emerg Med Clin North Am** 1995 Nov;13(4):759–69 (94 ref.)
Tiarombolytic therapy. Young GP, et al. **Emerg Med Clin North Am** 1995 Nov;13(4):735–58 (124 ref.)
Acute myocardial infarction: pre-hospital and in-hospital management. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. **Eur Heart J** 1996 Jan;17(1):43–63 (127 ref.)
The open artery hypothesis: to open, or not to open, that is the question. Marber MS, et al. **Eur Heart J** 1996 Apr; 17(4):505–9 (47 ref.)
Management after a first myocardial infarction. Flapan AD. **Hosp Pract (Off Ed)** 1996 May 15;31(5):133–7, 141–6 (11 ref.)
Primary angioplasty and thrombolysis for acute myocardial infarction: an evidence summary [see comments] Lieu TA, et al. **J Am Coll Cardiol** 1996 Mar 1;27(3):737–50 (76 ref.) Comment in: J Am Coll Cardiol 1996 Mar 1;27(3):736.
Preconditioning in man: progress and prospects. Lawson CS. **J Mol Cell Cardiol** 1995 Apr;27(4):961–7 (46 ref.)
Acute myocardial infarction: enhancing the results of reperfusion therapy. Reeder GS. **Mayo Clin Proc** 1995 Dec; 70(12):1185–90 (31 ref.)
The management of acute myocardial infarction. Saltissi S, et al. **Postgrad Med J** 1995 Sep;71(839):534–41 (28 ref.)
Angioplasty or thrombolysis for acute infarction? Reeder GS. **Z Kardiol** 1995;84 Suppl 2:1–4 (14 ref.)
[Therapeutic strategies in acute myocardial infarction. Results of STIM 93 registry] Monassier JP, et al. **Arch Mal Coeur Vaiss** 1996 Mar;89(3):281–9 (35 ref.) (Eng. Abstr.) **(Fre)**
[Is coronary angioplasty the best treatment of acute myocardial infarction?] Himbert D, et al. **Presse Med** 1995 Dec 9;24(38):1831–5 (32 ref.) (Eng. Abstr.) **(Fre)**
[Myocardial infarction and revascularization. Current indications] Grollier G, et al. **Rev Med Interne** 1995; 16(9):673–83 (62 ref.) (Eng. Abstr.) **(Fre)**
[Immediate PTCA in acute myocardial infarct—results and indications] Deutsch HJ, et al. **Herz** 1996 Jun;21(3):201–6 (30 ref.) **(Ger)**
[Cardiology update—II] Trappe HJ. **Med Klin** 1995 Oct 15; 90(10):567–78 (139 ref.) **(Ger)**
[Therapeutic measures following acute myocardial infarct: differential use of PTCA, surgery and drugs] Noll G, et al. **Schweiz Med Wochenschr** 1996 Feb 3;126(5):164–76 (81 ref.) (Eng. Abstr.) **(Ger)**
[Management of the patient with infarction after hospital discharge (Consensus about post-myocardial infarction treatment)] **Arq Bras Cardiol** 1995 Mar;64(3):281–8 (38 ref.) **(Por)**
[Stratification of arrhythmia risk and therapeutic options in survivors of acute myocardial infarction] Arós Borau F, et al. **Rev Esp Cardiol** 1996 Mar;49(3):157–65 (85 ref.) (Eng. Abstr.) **(Spa)**
[Reperfusion in myocardial infarction: a two-edged sword] Emanuelsson H, et al. **Lakartidningen** 1996 Mar 20; 93(12):1112–5 (20 ref.) **(Swe)**

ULTRASONOGRAPHY

Perfusion imaging with contract echocardiography: assessment of the no-reflow phenomenon. Winkelmann JW, et al. **Coron Artery Dis** 1995 Aug;6(8):619–24 (73 ref.)
Myocardial contrast echocardiography in acute myocardial infarction. Pathophysiological background and clinical applications. Iliceto S, et al. **Eur Heart J** 1996 Mar; 17(3):344–53 (68 ref.)
Echocardiography in acute myocardial infarction: today and tomorrow. Firoozan S, et al. **Indian Heart J** 1996 Jan–Feb; 48(1):23–32 (63 ref.)
[The prognostic importance of echocardiography in myocardial infarct] Gazarian GA, et al. **Ter Arkh** 1995; 67(9):83–6 (53 ref.) **(Rus)**

MYOCARDIAL ISCHEMIA

see related
MYOCARDIAL INFARCTION
MYOCARDIAL REPERFUSION
MYOCARDIAL REVASCULARIZATION

Delayed myocardial protection following ischaemic preconditioning. Baxter GF, et al. **Basic Res Cardiol** 1996 Jan–Feb;91(1):53–6 (19 ref.)
The early and late phases of preconditioning against myocardial stunning and the essential role of oxyradicals in the late phase: an overview. Bolli R. **Basic Res Cardiol** 1996 Jan–Feb;91(1):57–63 (15 ref.)
Three questions about preconditioning. Connaughton M, et al. **Basic Res Cardiol** 1996 Jan–Feb;91(1):12–5 (17 ref.)
Preconditioning—a reappraisal of protection. King LM, et al. **Basic Res Cardiol** 1996 Jan–Feb;91(1):5–7 (12 ref.)
Cardioprotection by organs in stress or distress. Verdouw PD, et al. **Basic Res Cardiol** 1996 Jan–Feb;91(1):44–6 (20 ref.)
An alternative perspective on ischemic preconditioning derived from mathematical modeling. Whittaker P. **Basic Res Cardiol** 1996 Jan–Feb;91(1):47–9 (9 ref.)
New insights into myocardial arrhythmogenesis: distribution of gap-junctional coupling in normal, ischaemic and hypertrophied human hearts. Peters NS. **Clin Sci (Colch)** 1996 Jun;90(6):447–52 (56 ref.)
Role of exercise in the cause and prevention of cardiac dysfunction. Starnes JW, et al. **Exerc Sport Sci Rev** 1995; 23:349–73 (107 ref.)
"Hibernating" myocardium: asleep or part dead? [editorial] Armstrong WF. **J Am Coll Cardiol** 1996 Aug;28(2):530–5 (43 ref.)
[Myocardial ischemia and anesthesia] Lehot JJ, et al. **Ann Fr Anesth Reanim** 1995;14(2):176–97 (210 ref.) (Eng. Abstr.) **(Fre)**
[Silent myocardial ischemia. Physiopathologic, clinical, and therapeutic considerations and review of the literature] D'Amore F, et al. **Clin Ter** 1995 Oct;146(10):611–6 (15 ref.) (Eng. Abstr.) **(Ita)**
[Recent trend on study of therapy and pathophysiology of ischemic heart diseases] Maruyama Y. **Nippon Naika Gakkai Zasshi** 1996 Mar 10;85(3):432–7 (4 ref.) **(Jpn)**

BLOOD

The case for cardiac troponin T: marker for effective risk stratification of patients with acute cardiac ischemia. Alonsozana GL, et al. **Clin Chem** 1996 May;42(5):803–8 (51 ref.)

CHEMICALLY INDUCED

Case report: paclitaxel-induced myocardial ischemia. Soe MS, et al. **Md Med J** 1996 Jan;45(1):41–3 (4 ref.)

COMPLICATIONS

Thrombosis in ischemic heart disease. Ambrose JA, et al. **Arch Intern Med** 1996 Jul 8;156(13):1382–94 (166 ref.)
Ventricular tachyarrhythmias, myocardial ischemia, and sudden cardiac death in patients with hypertensive heart disease. Zehender M, et al. **Clin Cardiol** 1995 Jul; 18(7):377–83 (84 ref.)
Microvascular angina in patients with normal coronary arteries and with other ischaemic syndromes. Cianflone D, et al. **Eur Heart J** 1995 Aug;16 Suppl I:96–103 (77 ref.)
Ventricular tachycardia in ischaemic heart disease: insights into the mechanisms from cardiac mapping and implications for patient management. Doig JC, et al. **Eur Heart J** 1995 Aug;16(8):1027–35 (71 ref.)

DIAGNOSIS

Magnetic resonance imaging in ischemic heart disease. Steffans JC, et al. **Am Heart J** 1996 Jul;132(1 Pt 1):156–73 (105 ref.)
Myocardial markers of injury. Evolution and insights. Keffer JH. **Am J Clin Pathol** 1996 Mar;105(3):305–20 (221 ref.)
Clinical assessment of regional function: strengths and limitations. Quiñones MA. **Coron Artery Dis** 1995 Aug; 6(8):625–8 (7 ref.)
Preoperative assessment and perioperative management of cardiac ischemic risk in noncardiac surgery. Coley CM, et al. **Curr Probl Cardiol** 1996 May;21(5):289–382 (325 ref.)
Myocardial viability. Hendel RC, et al. **Curr Probl Cardiol** 1996 Mar;21(3):145–221 (260 ref.)
Detection of myocardial ischemia. Jain A, et al. **Curr Probl Cardiol** 1995 Nov;20(11):773–824 (112 ref.)
Advances in the use of ancillary diagnostic testing in the emergency department evaluation of chest pain. Stack LB, et al. **Emerg Med Clin North Am** 1995 Nov;13(4):713–33 (75 ref.)
Acute outpatient care and comprehensive management of acute myocardial ischemia in chest pain emergency departments. Bahr RD. **Md Med J** 1995 Sep;44(9):691–3 (9 ref.)
Stable ischemic heart disease. Using stress and imaging procedures to direct therapy. Lavie CJ, et al. **Postgrad Med** 1996 Feb;99(2):63–6, 73–4, 77–81 passim (23 ref.)
Coronary artery disease in the geriatric population. Keller NM, et al. **Prog Cardiovasc Dis** 1996 Mar–Apr;38(5):407–18 (92 ref.)
MR evaluation of myocardial ischemia and infarction. Pattynama PM, et al. **Top Magn Reson Imaging** 1995 Fall; 7(4):218–31 (131 ref.)
[Isotope methods of determination of myocardial viability] Merlet P, et al. **Ann Cardiol Angeiol (Paris)** 1995 Dec; 44(10):587–96 (58 ref.) (Eng. Abstr.) **(Fre)**
[The utility of electrocardiography in the age of exercise echocardiography] Boccardi L, et al. **Cardiologia** 1995 Nov; 40(11):807–12 (20 ref.) **(Ita)**

DRUG THERAPY

Relation between systemic anticoagulation as determined by activated partial thromboplastin time and heparin measurements and in-hospital clinical events in unstable angina and non-Q wave myocardiaL infarction.

Thrombolysis in Myocardial Ischemia III B Investigators. Becker RC, et al. **Am Heart J** 1996 Mar;131(3):421–33 (66 ref.)

Novel antiplatelet therapies for treatment of patients with ischemic heart disease: inhibitors of the platelet glycoprotein IIb/IIIa integrin receptor. Frishman WH, et al. **Am Heart J** 1995 Oct;130(4):877–92 (69 ref.)

Clentiazem and diltiazem preserve endothelium–dependent relaxation following global rat heart ischemia. Dagenais F, et al. **Can J Cardiol** 1995 Oct;11(9):816–22 (45 ref.)

Anti–ischemic properties of ACE–inhibitors. Deedwania PC. **Cardiologia** 1996 Mar;41(3):209–15 (30 ref.)

The clinical role of platelet glycoprotein IIb/IIIa receptor inhibitors in ischemic heart disease. Lefkovits J, et al. **Cleve Clin J Med** 1996 May–Jun;63(3):181–9 (32 ref.)

Platelet glycoprotein IIb/IIIa receptor inhibitors in ischemic heart disease. Lefkovits J, et al. **Curr Opin Cardiol** 1995 Jul;10(4):420–6 (53 ref.)

Captopril. A review of its pharmacology and therapeutic efficacy after myocardial infarction and in ischaemic heart disease. Plosker GL, et al. **Drugs Aging** 1995 Sep; 7(3):226–53 (171 ref.)

The role of calcium antagonists in ischaemic heart disease. Pepine CJ. **Eur Heart J** 1995 Aug;16 Suppl H:19–24 (36 ref.)

Anti–ischaemic effects of converting enzyme inhibitors: underlying mechanisms and future prospects. Remme WJ, et al. **Eur Heart J** 1995 Aug;16 Suppl I:87–95 (51 ref.)

Possibilities for the pharmacological exploitation of ischaemic preconditioning. Parratt JR. **J Mol Cell Cardiol** 1995 Apr; 27(4):991–1000 (81 ref.)

Antiarrhythmic and anti–ischemic properties of calcium–channel antagonists. Apostolakos MJ, et al. **New Horiz** 1996 Feb;4(1):45–57 (94 ref.)

Current trends in cardiovascular pharmacology. Ciccone CD. **Phys Ther** 1996 May;76(5):481–97 (184 ref.)

Stable ischemic heart disease. Using stress and imaging procedures to direct therapy. Lavie CJ, et al. **Postgrad Med** 1996 Feb;99(2):63–6, 73–4, 77–81 passim (23 ref.)

[The effect of cardiovascular agents on the hemostatic system in myocardial ischemia] Denisova SV, et al. **Eksp Klin Farmakol** 1995 Jul–Aug;58(4):63–8 (82 ref.) **(Rus)**

ENZYMOLOGY

Role of protein kinase C in ischemic preconditioning: in search of the "pure and simple truth". Przyklenk K, et al. **Basic Res Cardiol** 1996 Jan–Feb;91(1):41–3 (11 ref.)

EPIDEMIOLOGY

Hyperlipidemia, hypertension and atherosclerosis in women. Reality and perspectives. Bugliosi R, et al. **Clin Ter** 1995 Aug–Sep;146(8–9):503–18 (66 ref.)

A brief review of epidemiological studies on ischemic heart disease in Japan. Tanaka H, et al. **J Epidemiol** 1996 Aug; 6(3 Suppl):S49–59 (28 ref.)

[Fetal environment and coronary ischemia risk: review of the literature with particular reference to syndrome X] Lehingue Y. **Rev Epidemiol Sante Publique** 1996 Jun; 44(3):262–77 (57 ref.) (Eng. Abstr.) **(Fre)**

[The relationship between the incidence of ischemic heart disease and the degree of obesity] Kobayashi N, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:281–5 (20 ref.) **(Jpn)**

[The epidemiology and risk factors of ischemic cardiopathy] de Velasco Rami JA. **Rev Esp Cardiol** 1995;48 Suppl 5:3–12 (89 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

Mental stress as a trigger of myocardial ischemia and infarction. Krantz DS, et al. **Cardiol Clin** 1996 May; 14(2):271–87 (75 ref.)

Myocardial ischemia after cardiopulmonary bypass. Jain U. **J Card Surg** 1995 Jul;10(4 Suppl):520–6 (97 ref.)

Reduced cardiac ischaemia tolerance in uraemia – what is the role of structural abnormalities of the heart? [editorial] Amann K, et al. **Nephrol Dial Transplant** 1996 Jul; 11(7):1238–41 (24 ref.)

[Post–infarction, myocardial ischemia: clinical importance and risk factor] Jespersen C. **Arch Mal Coeur Vaiss** 1995 Sep;88 Spec No 4:17–27 (86 ref.) (Eng. Abstr.) **(Fre)**

[Fetal environment and coronary ischemia risk: review of the literature with particular reference to syndrome X] Lehingue Y. **Rev Epidemiol Sante Publique** 1996 Jun; 44(3):262–77 (57 ref.) (Eng. Abstr.) **(Fre)**

[Prognostic stratification after acute myocardial infarction: evaluation of ischemic risk] Penco M. **Cardiologia** 1995 Jun; 40(6):413–8 (75 ref.) **(Ita)**

[Cardiac hypertrophy and ischemic heart disease in obesity] Ohta M, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:332–7 (20 ref.) **(Jpn)**

[Is heavy physical work a risk factor for ischemic heart disease?] Makowiec–Dąbrowska T. **Med Pr** 1995; 46(3):263–74 (42 ref.) (Eng. Abstr.) **(Pol)**

[Congestive heart failure associated with ischemic cardiopathy] da Silva MA. **Arq Bras Cardiol** 1995 Apr; 64(4):347–54 (42 ref.) **(Por)**

[Ischemic heart disease and occupational exposure to chemical substances. Review of the literature] Waissmann W, et al. **Arq Bras Cardiol** 1995 May;64(5):477–82 (87 ref.) **(Por)**

[Ischemic cardiopathy in women: the role of estrogens in the coronary vascular wall and in syndrome X] Gaxiola E, et al. **Arch Inst Cardiol Mex** 1995 Sep–Oct;65(5):461–7 (61 ref.) **(Spa)**

GENETICS

Heat shock proteins in myocardial stress. Dillmann WH, et al. **Z Kardiol** 1995;84 Suppl 4:87–90 (10 ref.)

METABOLISM

Preconditioning: markers vs. epiphenomena. Downey JM, et al. **Basic Res Cardiol** 1996 Jan–Feb;91(1):35–7 (14 ref.)

Criteria for a mediator or effector of myocardial preconditioning: do KATP channels meet the requirements? Gross GJ, et al. **Basic Res Cardiol** 1996 Jan–Feb;91(1):31–4 (12 ref.)

Activation of ecto–5'–nucleotidase and cardioprotection by ischemic preconditioning. Kitakaze M, et al. **Basic Res Cardiol** 1996 Jan–Feb;91(1):23–6 (8 ref.)

Adenosine and bradykinin: are they independent triggers of preconditioning? Miura T. **Basic Res Cardiol** 1996 Jan–Feb; 91(1):20–2 (14 ref.)

Endothelial cells, nitric oxide and ischaemic preconditioning. Parratt JR, et al. **Basic Res Cardiol** 1996 Jan–Feb; 91(1):27–30 (14 ref.)

Limitation of infarct size by myocardial ischemic preconditioning. Van Winkle DM. **Basic Res Cardiol** 1996 Jan–Feb;91(1):38–40 (13 ref.)

Sarcoplasmic reticulum function during myocardial ischaemia and reperfusion. Mubagwa K. **Cardiovasc Res** 1995 Aug;30(2):166–75 (114 ref.)

Myocardial phospholipase A2. Gross RW. **J Lipid Mediat Cell Signal** 1995 Oct;12(2–3):131–7 (25 ref.)

Preconditioning induced protection against post–ischaemic contractile dysfunction: characteristics and mechanisms. Cave AC. **J Mol Cell Cardiol** 1995 Apr;27(4):969–79 (48 ref.)

Harnessing an endogenous cardioprotective mechanism: cellular sources and sites of action of adenosine. Mullane K, et al. **J Mol Cell Cardiol** 1995 Apr;27(4):1041–54 (145 ref.)

Myocardial gap junction organization in ischemia and infarction. Peters NS. **Microsc Res Tech** 1995 Aug 1; 31(5):375–86 (95 ref.)

PATHOLOGY

Ventricular remodeling in global ischemia. Anversa P, et al. **Cardioscience** 1995 Jun;6(2):89–100 (59 ref.)

Cell swelling and ion transport pathways in cardiac myocytes. Vandenberg JI, et al. **Cardiovasc Res** 1996 Jul; 32(1):85–97 (94 ref.)

Abnormalities of the myocytes in ischaemic cardiomyopathy. Harding SE, et al. **Eur Heart J** 1995 Aug;16 Suppl I:74–81 (82 ref.)

Reduced cardiac ischaemia tolerance in uraemia – what is the role of structural abnormalities of the heart? [editorial] Amann K, et al. **Nephrol Dial Transplant** 1996 Jul; 11(7):1238–41 (24 ref.)

How vessels narrow. Schwartz SM. **Z Kardiol** 1995;84 Suppl 4:129–35 (58 ref.)

PHYSIOPATHOLOGY

Integrative models and responses in cardiac ischemia. Horner S, et al. **Adv Exp Med Biol** 1995;382:49–60 (52 ref.)

Preconditioning–induced protection against post–ischemic contractile dysfunction: inhibitory effect of tissue washout. Cave AC, et al. **Basic Res Cardiol** 1996 Jan–Feb;91(1):16–9 (14 ref.)

Ischemic preconditioning: a brief review. Reimer KA, et al. **Basic Res Cardiol** 1996 Jan–Feb;91(1):1–4 (24 ref.)

Ischemic preconditioning, remembrances of things past and future. Schaper W. **Basic Res Cardiol** 1996 Jan–Feb; 91(1):8–11 (23 ref.)

Ischemic preconditioning and myocardial hibernation: is there a common mechanism? Schulz R, et al. **Basic Res Cardiol** 1996 Jan–Feb;91(1):50–2 (11 ref.)

On the mechanism and possible therapeutic application of delayed cardiac adaptation to stress. Szekeres L. **Can J Cardiol** 1996 Feb;12(2):177–85 (49 ref.)

Diastolic dysfunction. Tardif JC, et al. **Can J Cardiol** 1996 Apr;12(4):389–98 (73 ref.)

Bradykinin as an endogenous myocardial protective substance with particular reference to ischemic preconditioning--a brief review of the evidence. Parratt JR, et al. **Can J Physiol Pharmacol** 1995 Jul;73(7):837–42 (36 ref.)

Hemodynamic variability and myocardial ischemia. Deedwania PC. **Cardiol Clin** 1995 Nov;13(4):491–500 (37 ref.)

Role of protein kinase C in ischemic preconditioning: player or spectator? [editorial] Brooks G, et al. **Circ Res** 1996 Sep;79(3):627–30 (32 ref.)

Ionic mechanisms of ischemia–related ventricular arrhythmias. Ducceschi V, et al. **Clin Cardiol** 1996 Apr; 19(4):325–31 (106 ref.)

Role of kinins in the pathophysiology of myocardial ischemia. In vitro and in vivo studies. Linz W, et al. **Diabetes** 1996 Jan;45 Suppl 1:S51–8 (62 ref.)

Ischaemic preconditioning: is it clinically relevant? Verdouw PD, et al. **Eur Heart J** 1995 Sep;16(9):1169–76 (69 ref.)

Ischemic preconditioning and myocardial protection [editorial] Gambhir DS, et al. **Indian Heart J** 1995 Jul–Aug; 47(4):319–21 (37 ref.)

ATPase activity, IF1 content, and proton conductivity of ESMP from control and ischemic slow and fast heart–rate hearts. Rouslin W, et al. **J Bioenerg Biomembr** 1995 Aug; 27(4):459–66 (30 ref.)

Myocardial preconditioning: a model or a phenomenon? Abd–Elfattah AS, et al. **J Card Surg** 1995 Jul;10(4 Suppl):381–8 (54 ref.)

The role of ATP sensitive potassium channels in myocardial protection. Cason BA, et al. **J Card Surg** 1995 Jul;10(4 Suppl):441–4 (32 ref.)

Biological perspective on "myocardial preconditioning". Chiu RC, et al. **J Card Surg** 1995 Jul;10(4 Suppl):376–80 (36 ref.)

The electrophysiology of ischemia and cardioplegia: implications for myocardial protection. Damiano RJ Jr. **J Card Surg** 1995 Jul;10(4 Suppl):445–53 (61 ref.)

Myocardial ischemia after cardiopulmonary bypass. Jain U. **J Card Surg** 1995 Jul;10(4 Suppl):520–6 (97 ref.)

Clinical aspects of preconditioning and implications for the cardiac surgeon. Kloner RA, et al. **J Card Surg** 1995 Jul; 10(4 Suppl):369–75 (38 ref.)

Electrophysiologic changes in ischemic ventricular myocardium: I. Influence of ionic, metabolic, and energetic changes. Cascio WE, et al. **J Cardiovasc Electrophysiol** 1995 Nov;6(11):1039–62 (165 ref.)

A circadian perspective on myocardial ischaemia. Gnecchi–Ruscone T, et al. **J Cardiovasc Risk** 1995 Dec; 2(6):505–9 (73 ref.)

Repolarization gradients derived by subtraction of monophasic action potential recordings in the human heart. Studies incorporating altered mechanical loading and ischemia. Taggart P, et al. **J Electrocardiol** 1995;28 Suppl:156–61 (25 ref.)

Increased protection of the ischemic myocardium by decreased aortic pressure. Nakamura Y, et al. **Jpn Heart J** 1995 Nov;36(6):689–97 (34 ref.)

Intermittent ischemia of the heart. Flameng W. **Transplant Proc** 1995 Oct;27(5):2791–2 (12 ref.)

Delayed protection of the heart against ischaemia. Parratt JR, et al. **Trends Pharmacol Sci** 1995 Oct;16(10):351–5 (52 ref.)

Signal transduction in ischemic preconditioning. Downey JM, et al. **Z Kardiol** 1995;84 Suppl 4:77–86 (68 ref.)

[Myocardial adaptation to ischemia. A study during repeated prolonged coronary occlusions in angioplasty] Tron C, et al. **Arch Mal Coeur Vaiss** 1996 Apr;89(4):399–406 (27 ref.) (Eng. Abstr.) **(Fre)**

[Asymptomatic ischemia--an important part of the spectrum of coronary disease] Rutishauser W, et al. **Schweiz Rundsch Med Prax** 1995 Oct 17;84(42):1181–5 (28 ref.) (Eng. Abstr.) **(Fre)**

-Myocardial protection by preconditioning. Experimental and clinical significance- Strasser R, et al. **Z Kardiol** 1996 Feb;85(2):79–89 (108 ref.) (Eng. Abstr.) **(Ger)**

[Introduction to ischemic preconditioning of the heart] Della Bella D. **Cardiologia** 1996 Apr;41(4):331–42 (77 ref.) **(Ita)**

[Nervous mechanisms and ischemic cardiopathy (editorial)] Malliani A. **Cardiologia** 1996 Jan;41(1):9–17 (54 ref.) **(Ita)**

[The role of coronary vasomotoricity in ischemic cardiopathy: fluctuating preconceptions (editorial)] Maseri A, et al. **Cardiologia** 1996 Jan;41(1):19–30 (132 ref.) **(Ita)**

[Preconditioning of the ischemic myocardium] Tedesco MA, et al. **Cardiologia** 1995 Jan;40(1):51–9 (95 ref.) **(Ita)**

[Molecular mechanisms for protecting the heart] Andres J. **Folia Med Cracov** 1994;35(1–4):22–30 (39 ref.) (Eng. Abstr.) **(Pol)**

[Biochemical aspects of cardiomyocyte damage during ischemia and reperfusion] Skłodowska M. **Postepy Hig Med Dosw** 1995;49(2):287–96 (50 ref.) (Eng. Abstr.) **(Pol)**

[Noninvasive evaluation of ischemia and viability after acute myocardial infarction] Reis G, et al. **Arq Bras Cardiol** 1995 Apr;64(4):367–72 (74 ref.) **(Por)**

PREVENTION & CONTROL

Anti–ischemic intervention as prognosis improvement in patients with coronary artery disease, with special focus on verapamil. Jespersen CM. **Am J Cardiol** 1996 Jun 20; 77(16):32D–36D (64 ref.)

Optimal myocardial preservation: cooling, cardioplegia, and conditioning. Cleveland JC Jr, et al. **Ann Thorac Surg** 1996 Feb;61(2):760–8 (75 ref.)

Anticoagulant therapy in ischaemic heart disease in seafarers. Częstochowska E. **Bull Inst Marit Trop Med Gdynia** 1993–94;44–45(1–4):13–5 (10 ref.)

Myocardial protection with calcium–channel blockers during ischaemia and reperfusion by PTCA. Chouairi S, et al. **Eur Heart J** 1995 Aug;16 Suppl H:3–8 (42 ref.)

Anti–ischaemic intervention with verapamil in patients recovering from acute myocardial infarction. Jespersen CM. **Eur Heart J** 1995 Aug;16 Suppl H:13–7 (24 ref.)

The role of oxygen free radicals in preconditioning. Ambrosio G, et al. **J Mol Cell Cardiol** 1995 Apr; 27(4):1035–9 (49 ref.)

A "second window of protection" or delayed preconditioning phenomenon: future horizons for myocardial protection?

Yellon DM, et al. **J Mol Cell Cardiol** 1995 Apr; 27(4):1023–34 (65 ref.)

Ought low alcohol intake to be promoted for health reasons? Holman CD, et al. **J R Soc Med** 1996 Mar;89(3):123–9 (36 ref.)

[Postmenopausal estrogen replacement therapy—does it reduce morbidity and mortality from ischemic heart disease?] Zyssman I, et al. **Harefuah** 1996 Feb 1; 130(3):200–3 (34 ref.) **(Heb)**

[Secondary prevention of ischemic cardiopathy] Caruzzo E, et al. **Cardiologia** 1995 May;40(5):347–53 (31 ref.) **(Ita)**

[Contemporary views on estrogen replacement therapy. II. Hormonal therapy in women with imminent ischemic heart disease] Krasomski G. **Ginekol Pol** 1995 Feb;66(2):93–6 (27 ref.) (Eng. Abstr.) **(Pol)**

RADIOGRAPHY

Our preoccupation with coronary luminology. The dissociation between clinical and angiographic findings in ischemic heart disease. Topol EJ, et al. **Circulation** 1995 Oct 15;92(8):2333–42 (85 ref.)

RADIONUCLIDE IMAGING

The role of scintigraphic perfusion imaging for predicting ischemic cardiac events in noncardiac surgery. Gojer B, et al. **Am J Card Imaging** 1995 Jul;9(3):213–25 (78 ref.)

[Scintigraphic evaluation of the ischemically damaged myocardium in patients with reduced left ventricular function. From clinical aspects to the cell] Schwaiger M, et al. **Z Kardiol** 1995;84 Suppl 4:115–23 (65 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Arterial switch operation: myocardial ischemia reversed by internal mammary artery graft. Merlo M, et al. **Ann Thorac Surg** 1996 Aug;62(2):586–8 (12 ref.)

[Direct revascularization of ischemic myocardium by laser] Wang G, et al. **Chung Hua Wai Ko Tsa Chih** 1995 Apr; 33(4):243–5 (20 ref.) **(Chi)**

[Transmyocardial laser revascularization. A new possible method for treatment of ischemic heart disease] Andreasen JJ. **Ugeskr Laeger** 1996 Jun 24;158(26):3764–7 (29 ref.) (Eng. Abstr.) **(Dan)**

[Indication and clinical results of heart transplantation in the terminal stage of ischemic cardiomyopathy] Kyo S, et al. **Nippon Geka Gakkai Zasshi** 1996 Mar;97(3):240–4 (9 ref.) (Eng. Abstr.) **(Jpn)**

[Current status and 21 century in the laser transmyocardial revascularization (LTMR)] Okada M. **Nippon Geka Gakkai Zasshi** 1996 Mar;97(3):234–9 (5 ref.) (Eng. Abstr.) **(Jpn)**

THERAPY

Myocardial preconditioning promises to be a novel approach to the treatment of ischemic heart disease. Cohen MV, et al. **Annu Rev Med** 1996;47:21–9 (52 ref.)

Acute outpatient care and comprehensive management of acute myocardial ischemia in chest pain emergency departments. Bahr RD. **Md Med J** 1995 Sep;44(9):691–3 (9 ref.)

[Silent myocardial ischemia. Arguments in favor of treatment] Lezaun R, et al. **Rev Esp Cardiol** 1996 Jan; 49(1):1–5 (45 ref.) **(Spa)**

[Silent myocardial ischemia. Arguments against treatment] Rayo Llerena I, et al. **Rev Esp Cardiol** 1996 Jan;49(1):6–12 (45 ref.) **(Spa)**

ULTRASONOGRAPHY

Stress echocardiography. Burn S, et al. **QJM** 1995 Nov; 88(11):755–61 (68 ref.)

[Importance of ischemic heart disease in patients with carotid arteriosclerosis and lower extremity arteriopathy. Results of a prospective study] Racco F, et al. **Minerva Cardioangiol** 1995 Sep;43(9):345–54 (32 ref.) (Eng. Abstr.) **(Ita)**

MYOCARDIAL MITOCHONDRIA see **MITOCHONDRIA, HEART**

MYOCARDIAL PREINFARCTION SYNDROME see **ANGINA, UNSTABLE**

MYOCARDIAL REPERFUSION

see related
MYOCARDIAL STUNNING

Reperfusion in acute inferior myocardial infarction: could tailored therapy be based on precordial ST depression? [editorial] Wong CK, et al. **Am Heart J** 1996 Jun; 131(6):1240–7 (61 ref.)

Preconditioning: an endogenous defense against the insult of myocardial ischemia. Martin HB, et al. **Anesth Analg** 1996 Sep;83(3):639–45 (53 ref.)

Aggressive interventional treatment of acute myocardial infarction. Lessons from the animal laboratory applied to the catheterization suite. Feld S, et al. **Cardiology** 1995; 86(5):365–73 (65 ref.)

Role of protein kinase C in ischemic preconditioning: player or spectator? [editorial] Brooks G, et al. **Circ Res** 1996 Sep;79(3):627–30 (32 ref.)

Adjunctive therapy in coronary thrombolysis: prostaglandins, nitrates and calcium antagonists. Fitzgerald D. **Coron Artery Dis** 1995 Dec;6(12):940–6 (69 ref.)

Myocardial protection with calcium-channel blockers during ischaemia and reperfusion by PTCA. Chouairi S, et al. **Eur Heart J** 1995 Aug;16 Suppl H:3–8 (42 ref.)

The open artery hypothesis: to open, or not to open, that is the question. Marber MS, et al. **Eur Heart J** 1996 Apr; 17(4):505–9 (47 ref.)

Ischaemic preconditioning: is it clinically relevant? Verdouw PD, et al. **Eur Heart J** 1995 Sep;16(9):1169–76 (69 ref.)

Ischemic preconditioning and myocardial protection [editorial] Gambhir DS, et al. **Indian Heart J** 1995 Jul–Aug; 47(4):319–21 (37 ref.)

Surgical treatment of acute myocardial infarct: clinical considerations. Gott JP, et al. **Semin Thorac Cardiovasc Surg** 1995 Oct;7(4):198–207 (64 ref.)

[Introduction to ischemic preconditioning of the heart] Della Bella D. **Cardiologia** 1996 Apr;41(4):331–42 (77 ref.) **(Ita)**

[Preconditioning of the ischemic myocardium] Tedesco MA, et al. **Cardiologia** 1995 Jan;40(1):51–9 (95 ref.) **(Ita)**

METHODS

The scientific basis for hypocalcemic cardioplegia and reperfusion in cardiac surgery. Chen RH. **Ann Thorac Surg** 1996 Sep;62(3):910–4 (57 ref.)

Acute myocardial infarction: enhancing the results of reperfusion therapy. Reeder GS. **Mayo Clin Proc** 1995 Dec; 70(12):1185–90 (31 ref.)

The management of acute myocardial infarction. Saltissi S, et al. **Postgrad Med J** 1995 Sep;71(839):534–41 (28 ref.)

Myocardial protection for coronary artery bypass in patients with acute myocardial infarction: resuscitation of ischemic myocardium. Brown WM 3rd, et al. **Semin Thorac Cardiovasc Surg** 1995 Oct;7(4):191–7 (84 ref.)

[Use of contrast echocardiography in coronary insufficiency] Morcerf FA. **Arq Bras Cardiol** 1995 Apr;64(4):373–82 (66 ref.) **(Por)**

REHABILITATION

Myocardial protection in the occlusion/reperfusion dog model: the role of ischemic necrosis vs reperfusion injury. Chagas AC, et al. **Braz J Med Biol Res** 1995 Sep; 28(9):951–9 (40 ref.)

MYOCARDIAL REPERFUSION INJURY

see related
MYOCARDIAL STUNNING

Incomplete, delayed functional recovery late after reperfusion following acute myocardial infarction: "maimed myocardium" [editorial] Boden WE, et al. **Am Heart J** 1995 Oct;130(4):922–32 (60 ref.)

Myocardial reperfusion injury: experimental evidence and clinical relevance. Hansen PR. **Eur Heart J** 1995 Jun; 16(6):734–40 (130 ref.)

[Preconditioning of the ischemic myocardium] Tedesco MA, et al. **Cardiologia** 1995 Jan;40(1):51–9 (95 ref.) **(Ita)**

ETIOLOGY

[Reperfusion in myocardial infarction: a two-edged sword] Emanuelsson H, et al. **Lakartidningen** 1996 Mar 20; 93(12):1112–5 (20 ref.) **(Swe)**

GENETICS

[Cardiac gene expression after brief coronary occlusion] Zimmermann R, et al. **Z Kardiol** 1995;84 Suppl 4:159–65 (23 ref.) (Eng. Abstr.) **(Ger)**

METABOLISM

Studies of hypoxemic/reoxygenation injury: I. Linkage between cardiac function and oxidant damage. Buckberg GD. **J Thorac Cardiovasc Surg** 1995 Oct;110(4 Pt 2):1164–70 (47 ref.)

[The biochemical and cellular bases of myocardial ischemia-reperfusion damage] Téllez F, et al. **Arch Inst Cardiol Mex** 1996 Mar–Apr;66(2):162–81 (105 ref.) (Eng. Abstr.) **(Spa)**

PATHOLOGY

Cardiac allograft vasculopathy: the central pathogenetic role of ischemia-induced endothelial cell injury. Day JD, et al. **J Heart Lung Transplant** 1995 Nov–Dec;14(6 Pt 2):S142–9 (84 ref.)

Cell biology of restenosis post-angioplasty. Badimon L, et al. **Z Kardiol** 1995;84 Suppl 4:145–9 (25 ref.)

Metabolic aspects of hibernating myocardium. Pantely GA, et al. **Z Kardiol** 1995;84 Suppl 4:101–5 (25 ref.)

PHYSIOPATHOLOGY

Acute myocardial infarction, reperfusion injury, and intravenous magnesium therapy: basic concepts and clinical implications. Steurer G, et al. **Am Heart J** 1996 Aug;132(2 Pt 2 Su):478–82; discussion 496–502 (86 ref.)

Preconditioning: an endogenous defense against the insult of myocardial ischemia. Martin HB, et al. **Anesth Analg** 1996 Sep;83(3):639–45 (53 ref.)

Tissue protection by anti-ischemic drugs. Nolte D, et al. **Minerva Cardioangiol** 1995 Nov–Dec;43(11–12):485–91 (59 ref.)

Myocardial protection during reperfusion. Piper HM, et al. **Thorac Cardiovasc Surg** 1996 Feb;44(1):15–9 (19 ref.)

[Pathophysiology of the "hibernating" myocardium] Schulz R, et al. **Z Kardiol** 1995;84 Suppl 4:91–100 (40 ref.) (Eng. Abstr.) **(Ger)**

-Myocardial protection by preconditioning. Experimental and clinical significance- Strasser R, et al. **Z Kardiol** 1996 Feb;85(2):79–89 (108 ref.) (Eng. Abstr.) **(Ger)**

[Molecular mechanisms for protecting the heart] Andres J. **Folia Med Cracov** 1994;35(1–4):22–30 (39 ref.) (Eng. Abstr.) **(Pol)**

[Free oxygen radicals in the pathogenesis of ischemic-reperfusion heart damage and possibilities of its pharmacologic control] Jadroňová O, et al. **Ceska Slov Farm** 1995 Oct;44(5):268–72 (28 ref.) (Eng. Abstr.) **(Slo)**

PREVENTION & CONTROL

Physiological and cellular mechanisms of myocardial protection. Krukenkamp IB, et al. **Am J Surg** 1996 Jul; 172(1):79–84 (21 ref.)

Preconditioning: an endogenous defense against the insult of myocardial ischemia. Martin HB, et al. **Anesth Analg** 1996 Sep;83(3):639–45 (53 ref.)

Myocardial protection in the occlusion/reperfusion dog model: the role of ischemic necrosis vs reperfusion injury. Chagas AC, et al. **Braz J Med Biol Res** 1995 Sep; 28(9):951–9 (40 ref.)

New strategies for intraoperative myocardial protection. Flameng W. **Curr Opin Cardiol** 1995 Nov;10(6):577–83 (37 ref.)

The role of nitric oxide and NO-donor agents in myocardial protection from surgical ischemic-reperfusion injury. Vinten-Johansen J, et al. **Int J Cardiol** 1995 Jul; 50(3):273–81 (47 ref.)

Preconditioning and its potential role in myocardial protection during cardiac surgery. Lasley RD, et al. **J Card Surg** 1995 Jul;10(4 Pt 1):349–53 (33 ref.)

Possibilities for the pharmacological exploitation of ischaemic preconditioning. Parratt JR. **J Mol Cell Cardiol** 1995 Apr; 27(4):991–1000 (81 ref.)

Tissue protection by anti-ischemic drugs. Nolte D, et al. **Minerva Cardioangiol** 1995 Nov–Dec;43(11–12):485–91 (59 ref.)

Myocardial protection for coronary artery bypass in patients with acute myocardial infarction: resuscitation of ischemic myocardium. Brown WM 3rd, et al. **Semin Thorac Cardiovasc Surg** 1995 Oct;7(4):191–7 (84 ref.)

[Progress on research in preventing and treating the myocardial ischemia/reperfussion injury with Chinese herb medicine] Yi HZ, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Aug; 15(8):509–11 (25 ref.) **(Chi)**

RADIONUCLIDE IMAGING

[Scintigraphic evaluation of the ischemically damaged myocardium in patients with reduced left ventricular function. From clinical aspects to the cell] Schwaiger M, et al. **Z Kardiol** 1995;84 Suppl 4:115–23 (65 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Myocardial preconditioning promises to be a novel approach to the treatment of ischemic heart disease. Cohen MV, et al. **Annu Rev Med** 1996;47:21–9 (52 ref.)

MYOCARDIAL REVASCULARIZATION

Flow reserve capacity of left internal thoracic artery 23 years after Vineberg procedure. Nasu M, et al. **Ann Thorac Surg** 1996 Apr;61(4):1242–4 (5 ref.)

Percutaneous revascularization strategies. Usefulness in ischemic coronary artery disease. Garratt KN. **Postgrad Med** 1996 Feb;99(2):125–6, 129–31, 135–7 (30 ref.)

Assessing myocardial viability to help select patients for revascularization to improve left ventricular dysfunction due to coronary artery disease. Patterson RE, et al. **Semin Thorac Cardiovasc Surg** 1995 Oct;7(4):214–26 (61 ref.)

[Direct revascularization of ischemic myocardium by laser] Wang G, et al. **Chung Hua Wai Ko Tsa Chih** 1995 Apr; 33(4):243–5 (20 ref.) **(Chi)**

[Coronary artery disease in octogenarians: contribution of coronary angiography and evaluation of therapeutic possibilities] Elbaz M, et al. **Arch Mal Coeur Vaiss** 1995 Oct;88(10):1391–8 (27 ref.) (Eng. Abstr.) **(Fre)**

[Influence of post-infarction myocardial revascularization on the prevalence of delayed potentials] Lomama E, et al. **Arch Mal Coeur Vaiss** 1995 Sep;88(9):1267–72 (29 ref.) (Eng. Abstr.) **(Fre)**

[Myocardial infarction and revascularization. Current indications] Grollier G, et al. **Rev Med Interne** 1995; 16(9):673–83 (62 ref.) (Eng. Abstr.) **(Fre)**

[Quality of life after an episode of myocardial infarct] Borrello G, et al. **Minerva Cardioangiol** 1995 Jul–Aug;

43(7-8):315-27 (39 ref.) (Eng. Abstr.) **(Ita)**
[Angioplasty, surgical, or clinical treatment. Therapeutic options for obstructive coronary artery disease (editorial)] Hueb WA, et al. **Arq Bras Cardiol** 1995 Jul;65(1):7-10 (28 ref.) **(Por)**

METHODS

Roles of percutaneous transluminal coronary angioplasty and bypass graft surgery for the treatment of coronary artery disease. Cishek MB, et al. **Am Heart J** 1996 May; 131(5):1012-7 (58 ref.)
Use of calcium channel antagonists in myocardial revascularization procedures. Califf RM, et al. **Am J Cardiol** 1996 Jun 20;77(16):26D-31D (28 ref.)
The lima success story--whither other arterial grafts--are vein grafts obsolete? Cooper GJ, et al. **Br J Clin Pract** 1996 Apr-May;50(3):144-50 (131 ref.)
Restenosis--an open file. Gottsauner-Wolf M, et al. **Clin Cardiol** 1996 May;19(5):347-56 (118 ref.)
Current status of the inferior epigastric artery. Buche M, et al. **Semin Thorac Cardiovasc Surg** 1996 Jan;8(1):10-4 (19 ref.)
Complete revascularization with internal thoracic artery grafts. Tector AJ, et al. **Semin Thorac Cardiovasc Surg** 1996 Jan;8(1):29-41 (67 ref.)
[Transmyocardial laser revascularization. A new possible method for treatment of ischemic heart disease] Andreasen JJ. **Ugeskr Laeger** 1996 Jun 24;158(26):3764-7 (29 ref.) (Eng. Abstr.) **(Dan)**
[Isotope methods of determination of myocardial viability] Merlet P, et al. **Ann Cardiol Angeiol (Paris)** 1995 Dec; 44(10):587-96 (58 ref.) (Eng. Abstr.) **(Fre)**
[Heart surgery in acute heart infarct. Indications and results] Genoni M, et al. **Schweiz Med Wochenschr** 1996 Apr 20; 126(16):682-7 (36 ref.) (Eng. Abstr.) **(Ger)**

TRENDS

[Current status and 21 century in the laser transmyocardial revascularization (LTMR)] Okada M. **Nippon Geka Gakkai Zasshi** 1996 Mar;97(3):234-9 (5 ref.) (Eng. Abstr.) **(Jpn)**

MYOCARDIAL STIMULANTS see **CARDIOTONIC AGENTS**

MYOCARDIAL STUNNING

Ubiquity of myocardial stunning. Vatner SF, et al. **Basic Res Cardiol** 1995 Jul-Aug;90(4):253-6 (12 ref.)
"Hibernating" myocardium: asleep or part dead? [editorial] Armstrong WF. **J Am Coll Cardiol** 1996 Aug;28(2):530-5 (43 ref.)
[Stunned myocardium or hibernating myocardium? Apropos of a case] Levy A, et al. **Rev Med Interne** 1996;17(1):61-5 (25 ref.) (Eng. Abstr.) **(Fre)**
[Myocardial stunning during coronary angioplasty: significance and clinical relevance] Trevi G, et al. **Cardiologia** 1996 May;41(5):427-33 (70 ref.) **(Ita)**

DIAGNOSIS

Commentary on myocardial stunning and its clinical relevance. Ferrari R. **Basic Res Cardiol** 1995 Jul-Aug; 90(4):300-2 (10 ref.)

DRUG THERAPY

Therapy for myocardial stunning. Birnbaum Y, et al. **Basic Res Cardiol** 1995 Jul-Aug;90(4):291-3 (11 ref.)
Stunned myocardium: inotropic reserve and pharmacological attenuation. Schulz R, et al. **Basic Res Cardiol** 1995 Jul-Aug;90(4):294-6 (11 ref.)

ETIOLOGY

Common methodological problems and artifacts associated with studies of myocardial stunning in vivo. Bolli R. **Basic Res Cardiol** 1995 Jul-Aug;90(4):257-62 (13 ref.)
Stunning: three questions and concerns. Hearse DJ. **Basic Res Cardiol** 1995 Jul-Aug;90(4):263-5 (5 ref.)
Clinical aspects of myocardial stunning. Birnbaum Y, et al. **Coron Artery Dis** 1995 Aug;6(8):606-12 (91 ref.)

METABOLISM

Myocardial stunning: the role of oxidative substrate metabolism. Lerch R. **Basic Res Cardiol** 1995 Jul-Aug; 90(4):276-8 (10 ref.)
Stunned myocardium: a disease of the myofilaments? Marban E, et al. **Basic Res Cardiol** 1995 Jul-Aug;90(4):269-72 (21 ref.)
Adjustments in competitive substrate utilization in stunned myocardium during early reperfusion. Renstrom B, et al. **Basic Res Cardiol** 1995 Jul-Aug;90(4):279-81 (12 ref.)

PHYSIOPATHOLOGY

The elusive difference between hibernation and stunning in patients. Ambrosio G. **Basic Res Cardiol** 1995 Jul-Aug; 90(4):297-9 (14 ref.)
Is stunned myocardium ischemic on a microvascular level? Becker LC. **Basic Res Cardiol** 1995 Jul-Aug;90(4):282-4 (11 ref.)
Common methodological problems and artifacts associated with studies of myocardial stunning in vivo. Bolli R. **Basic Res Cardiol** 1995 Jul-Aug;90(4):257-62 (13 ref.)
Do ATP-sensitive potassium channels play a role in myocardial stunning? Gross GJ. **Basic Res Cardiol** 1995 Jul-Aug;90(4):266-8 (10 ref.)
Coronary vasomotion of the stunned myocardium. Mandinov L, et al. **Basic Res Cardiol** 1995 Jul-Aug;90(4):288-90 (11 ref.)
Chronic stunning: the new switch in thought. Opie LH. **Basic Res Cardiol** 1995 Jul-Aug;90(4):303-4 (12 ref.)
Stunned myocardium, an opinionated review. Schaper W. **Basic Res Cardiol** 1995 Jul-Aug;90(4):273-5 (15 ref.)
[Molecular mechanisms for protecting the heart] Andres J. **Folia Med Cracov** 1994;35(1-4):22-30 (39 ref.) (Eng. Abstr.) **(Pol)**
[Certain biochemical aspects of pathogenesis in stunned myocardium] Moczarska A. **Postepy Biochem** 1995; 41(3):158-64 (62 ref.) **(Pol)**

PREVENTION & CONTROL

The early and late phases of preconditioning against myocardial stunning and the essential role of oxyradicals in the late phase: an overview. Bolli R. **Basic Res Cardiol** 1996 Jan-Feb;91(1):57-63 (15 ref.)

RADIONUCLIDE IMAGING

FDG uptake within regionally stunned myocardium. McFalls EO, et al. **Am J Card Imaging** 1995 Oct;9(4):269-74 (30 ref.)

ULTRASONOGRAPHY

Diagnosis of myocardial stunning: a new use for myocardial contrast and dobutamine echocardiography. Cheirif J. **Am J Card Imaging** 1995 Oct;9(4):261-8 (51 ref.)
[Study of myocardial viability after recent infarction by echocardiography under dobutamine. Evidence of stunned myocardium] Guéret P, et al. **Arch Mal Coeur Vaiss** 1995 Aug;88 Spec No 3:13-7 (19 ref.) (Eng. Abstr.) **(Fre)**

MYOCARDIOPATHIES see **MYOCARDIAL DISEASES**

MYOCARDITIS

Recent advances in the etiology, diagnosis, and treatment of myocarditis and cardiomyopathies in children. Gajarski RJ, et al. **Curr Opin Pediatr** 1995 Oct;7(5):587-94 (79 ref.)

DIAGNOSIS

[Myocarditis] Decoodt P. **Rev Med Brux** 1995 Jul-Aug; 16(4):191-3 (6 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

Treatment of viral myocarditis with focus on captopril [editorial] Rezkalla SH, et al. **Am J Cardiol** 1996 Mar 15; 77(8):634-7 (41 ref.)
Immunosuppressive treatment for myocarditis and dilated cardiomyopathy. Maisch B, et al. **Eur Heart J** 1995 Dec; 16 Suppl O:153-61 (81 ref.)

EPIDEMIOLOGY

The epidemiology of infectious myocarditis, lymphocytic myocarditis and dilated cardiomyopathy. Friman G, et al. **Eur Heart J** 1995 Dec;16 Suppl O:36-41 (85 ref.)
Infectious and lymphocytic myocarditis: epidemiology and factors relevant to sports medicine. Friman G, et al. **Scand J Med Sci Sports** 1995 Oct;5(5):269-78 (97 ref.)

ETIOLOGY

Cardiac manifestations of Lyme disease: a review. Nagi KS, et al. **Can J Cardiol** 1996 May;12(5):503-6 (38 ref.)
The pathogenesis of postinfectious myocarditis. Rose NR, et al. **Clin Immunol Immunopathol** 1996 Sep;80(3 Pt 2):S92-9 (51 ref.)
[Cardiac involvement in fetal parvovirus B19 infection] Soulié JC. **Pathol Biol (Paris)** 1995 May;43(5):416-9 (22 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Viral myocarditis: are we dealing with an autoimmune phenomenon? Finkelstein Y, et al. **Ann Med Interne (Paris)** 1995;146(5):322-4 (28 ref.)

PATHOLOGY

[Advances in pathology of 5 endemic diseases in China] Wang F, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1995 Aug;24(4):252-4 (20 ref.) **(Chi)**

RADIONUCLIDE IMAGING

Non-invasive detection of myocyte necrosis in myocarditis and dilated cardiomyopathy with radiolabelled antimyosin. Khaw BA, et al. **Eur Heart J** 1995 Dec;16 Suppl O:119-23 (16 ref.)

THERAPY

Immunomodulating agents for the management of heart failure with myocarditis and cardiomyopathy--lessons from animal experiments. Matsumori A, et al. **Eur Heart J** 1995 Dec;16 Suppl O:140-3 (10 ref.)
[Therapy of myocarditis] Frigerio M, et al. **G Ital Cardiol** 1995 Dec;25(12):1669-73 (26 ref.) **(Ita)**

VIROLOGY

The pathogenesis of postinfectious myocarditis. Rose NR, et al. **Clin Immunol Immunopathol** 1996 Sep;80(3 Pt 2):S92-9 (51 ref.)
The role of transgenic knockout models in defining the pathogenesis of viral heart disease. Liu P, et al. **Eur Heart J** 1995 Dec;16 Suppl O:25-7 (28 ref.)
Genetics of coxsackievirus B cardiovirulence and inflammatory heart muscle disease. Tracy S, et al. **Trends Microbiol** 1996 May;4(5):175-9 (38 ref.)

MYOCARDIUM

Myocardial imaging of sympathetic nervous function by radiolabelled metaiodobenzylguanidine [editorial; comment] Nakagawa M. **Intern Med** 1996 Feb;35(2):85-6 (7 ref.) Comment on: Intern Med 1996 Feb;35(2):94-9.

CHEMISTRY

The cardiac Na-Ca exchanger in giant membrane patches. Hilgemann DW. **Ann N Y Acad Sci** 1996 Apr 15;779:136-58 (28 ref.)
A new splicing variant in the frog heart sarcolemmal Na-Ca exchanger creates a putative ATP-binding site. Iwata T, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:37-45 (34 ref.)
Molecular biological studies of the cardiac sodium-calcium exchanger. Kraev A, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:103-9 (20 ref.)
Mutagenesis studies of the cardiac Na(+)-Ca2+ exchanger. Nicoll DA, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:86-92 (14 ref.)
Transgenic manipulation of myocardial G protein-coupled receptors and receptor kinases. Koch WJ, et al. **Circ Res** 1996 Apr;78(4):511-6 (29 ref.)
The case for cardiac troponin T: marker for effective risk stratification of patients with acute cardiac ischemia. Alonsozana GL, et al. **Clin Chem** 1996 May;42(5):803-8 (51 ref.)
New insights into myocardial arrhythmogenesis: distribution of gap-junctional coupling in normal, ischaemic and hypertrophied human hearts. Peters NS. **Clin Sci (Colch)** 1996 Jun;90(6):447-52 (56 ref.)

CYTOLOGY

The polyclonal origin of myocyte lineages. Mikawa T, et al. **Annu Rev Physiol** 1996;58:509-21 (76 ref.)
Cardiac intercellular communication: consequences of connexin distribution and diversity. Beyer EC, et al. **Braz J Med Biol Res** 1995 Apr;28(4):415-25 (62 ref.)
What are human heart mast cells for? Patella V, et al. **Chem Immunol** 1995;62:171-86 (89 ref.)
Cellular mechanisms of contractile dysfunction in human heart failure. Davies CH, et al. **Eur Heart J** 1996 Feb; 17(2):189-98 (137 ref.)
Immunological characterization and functional importance of human heart mast cells. Marone G, et al. **Immunopharmacology** 1995 Nov;31(1):1-18 (137 ref.)
Determination of impulse conduction characteristics at a microscopic scale in patterned growth heart cell cultures using multiple site optical recording of transmembrane voltage. Rohr S. **J Cardiovasc Electrophysiol** 1995 Jul; 6(7):551-68 (84 ref.)
[Hypertrophic responses to mechanical stretch in cardiac myocytes] Yamazaki T, et al. **Tanpakushitsu Kakusan Koso** 1996 Jan;41(1):14-8 (8 ref.) **(Jpn)**
[Polyploidy in the myocardium. Compensatory reserve of the heart] Brodskiĭ VIa. **Biull Eksp Biol Med** 1995 May; 119(5):454-9 (49 ref.) **(Rus)**

ENZYMOLOGY

Multiple roles of carbonic anhydrase in cellular transport and metabolism. Henry RP. **Annu Rev Physiol** 1996; 58:523-38 (108 ref.)
Intracellular signalling through protein kinases in the heart. Sugden PH, et al. **Cardiovasc Res** 1995 Oct;30(4):478-92 (206 ref.)
Anatomic distribution of nitric oxide synthase in the heart. Ursell PC, et al. **Int J Cardiol** 1995 Jul;50(3):217-23 (15 ref.)
Involvement of inducible nitric oxide synthase in the inflammatory process of myocardial infarction. Wildhirt SM, et al. **Int J Cardiol** 1995 Jul;50(3):253-61 (72 ref.)
Myocardial phospholipase A2. Gross RW. **J Lipid Mediat Cell Signal** 1995 Oct;12(2-3):131-7 (25 ref.)
Polyunsaturated fatty acids and signalling via phospholipase C-beta and A2 in myocardium. de Jonge HW, et al. **Mol Cell Biochem** 1996 Apr 12-26;157(1-2):199-210 (79 ref.)
Regulation and functional significance of phospholipase D in myocardium. Eskildsen-Helmond YE, et al. **Mol Cell Biochem** 1996 Apr 12-26;157(1-2):39-48 (72 ref.)
Mitogen-activated protein kinase (MAPK) in cardiac tissues. Page C, et al. **Mol Cell Biochem** 1996 Apr 12-26; 157(1-2):49-57 (39 ref.)
Signalling by protein kinase C isoforms in the heart. Pucéat

M, et al. **Mol Cell Biochem** 1996 Apr 12-26;157(1-2):65-72 (72 ref.)

IMMUNOLOGY

Immunological characterization and functional importance of human heart mast cells. Marone G, et al. **Immunopharmacology** 1995 Nov;31(1):1-18 (137 ref.)

METABOLISM

Developmental regulation of cation pumps in skeletal and cardiac muscle. Dauncey MJ, et al. **Acta Physiol Scand** 1996 Mar;156(3):313-23 (75 ref.)

Fuzzy space and control of Na+, K(+)-pump rate in heart and skeletal muscle. Semb SO, et al. **Acta Physiol Scand** 1996 Mar;156(3):213-25 (79 ref.)

Troponin C - troponin I interactions and molecular signalling in cardiac myofilaments. Solaro RJ. **Adv Exp Med Biol** 1995;382:109-15 (24 ref.)

Role of angiotensin II and prostaglandin E2 in regulating cardiac fibroblast collagen turnover. Brilla CG, et al. **Am J Cardiol** 1995 Nov 2;76(13):8D-13D (42 ref.)

Chymase-dependent angiotensin II forming systems in humans. Urata H, et al. **Am J Hypertens** 1996 Mar; 9(3):277-84 (63 ref.)

Dynamics of matrix turnover during pathologic remodeling of the extracellular matrix [comment] Stetler-Stevenson WG. **Am J Pathol** 1996 May;148(5):1345-50 (34 ref.) Comment on: Am J Pathol 1996 May;148(5):1639-48.

G protein regulation of cardiac muscarinic potassium channel. Kurachi Y. **Am J Physiol** 1995 Oct;269(4 Pt 1):C821-30 (80 ref.)

Regulation of protein synthesis and degradation in adult ventricular cardiomyocytes. Schlüter KD, et al. **Am J Physiol** 1995 Dec;269(6 Pt 1):C1347-55 (76 ref.)

Cardiac ATP-sensitive K+ channels: regulation by intracellular nucleotides and K+ channel-opening drugs. Terzic A, et al. **Am J Physiol** 1995 Sep;269(3 Pt 1):C525-45 (196 ref.)

Na-Ca exchange and Ca fluxes during contraction and relaxation in mammalian ventricular muscle. Bers DM, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:430-42 (31 ref.)

Regulation of sodium-calcium exchange in intact myocytes by ATP and calcium. Haworth RA, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:464-79 (42 ref.)

Kinetics and mechanism: modulation of ion transport in the cardiac sarcolemma sodium-calcium exchanger by protons, monovalent, ions, and temperature. Khananshvili D, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:217-35 (37 ref.)

Calcium in the cardiac diadic cleft. Implications for sodium-calcium exchange. Langer GA, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:408-16 (24 ref.)

Adjustments in competitive substrate utilization in stunned myocardium during early reperfusion. Renstrom B, et al. **Basic Res Cardiol** 1995 Jul-Aug;90(4):279-81 (12 ref.)

Signal transduction in the cardiac k-receptor. Wong TM, et al. **Biol Signals** 1995 May-Jun;4(3):174-8 (18 ref.)

Stretch-induced modifications of myocardial performance: from ventricular function to cellular and molecular mechanisms. Crozatier B. **Cardiovasc Res** 1996 Jul; 32(1):25-37 (143 ref.)

Cardiac efficiency. Gibbs CL, et al. **Cardiovasc Res** 1995 Nov; 30(5):627-34 (67 ref.)

The role of Na-Ca exchange current in the cardiac action potential. Janvier NC, et al. **Cardiovasc Res** 1996 Jul; 32(1):69-84 (74 ref.)

Phospholipase-A2-dependent signalling in the heart. Van Bilsen M, et al. **Cardiovasc Res** 1995 Oct;30(4):518-29 (125 ref.)

Calcium signalling in cardiac muscle cells. Wier WG, et al. **Ciba Found Symp** 1995;188:146-60; discussion 160-4 (41 ref.)

Novel delivery of antiarrhythmic agents. Labhasetwar V, et al. **Clin Pharmacokinet** 1995 Jul;29(1):1-5 (24 ref.)

Inherited disorders of contractile proteins in skeletal and cardiac muscle. Laing NG. **Curr Opin Neurol** 1995 Oct; 8(5):391-6 (50 ref.)

Role of kinins in the pathophysiology of myocardial ischemia. In vitro and in vivo studies. Linz W, et al. **Diabetes** 1996 Jan;45 Suppl 1:S51-8 (62 ref.)

Substrate metabolism, hormone interaction, and angiotensin-converting enzyme inhibitors in left ventricular hypertrophy. Zhu YC, et al. **Diabetes** 1996 Jan;45 Suppl 1:S59-65 (85 ref.)

Collagen turnover and its regulation in the normal and hypertrophying heart. Bishop JE, et al. **Eur Heart J** 1995 May;16 Suppl C:38-44 (43 ref.)

Myocardial phenotypic changes in Na+, K+ ATPase in left ventricular hypertrophy: pharmacological consequences. Charlemagne D, et al. **Eur Heart J** 1995 May;16 Suppl C:20-3 (16 ref.)

Sodium-calcium balance in coronary angiography and experimental experience with iodixanol. Jynge P. **Eur Radiol** 1996;6 Suppl 2:S8-12 (19 ref.)

Influence of etomoxir on the expression of several genes in liver, testis and heart. Hegardt FG, et al. **Gen Pharmacol** 1995 Sep;26(5):897-904 (33 ref.)

Positive inotropic effect of nitric oxide in myocardium. Mohan P, et al. **Int J Cardiol** 1995 Jul;50(3):233-7 (25 ref.)

Protein synthesis in the heart in vivo, its measurement and patho-physiological alterations. Preedy VR, et al. **Int J Cardiol** 1995 Jun 30;50(2):95-106 (48 ref.)

Fibronectin expression during physiological and pathological cardiac growth. Farhadian F, et al. **J Mol Cell Cardiol** 1995 Apr;27(4):981-90 (57 ref.)

Preconditioning in man: progress and prospects. Lawson CS. **J Mol Cell Cardiol** 1995 Apr;27(4):961-7 (46 ref.)

Potassium regulation during exercise and recovery in humans: implications for skeletal and cardiac muscle. Lindinger MI. **J Mol Cell Cardiol** 1995 Apr;27(4):1011-22 (83 ref.)

Altered interactions among thin filament proteins modulate cardiac function. Solaro RJ, et al. **J Mol Cell Cardiol** 1996 Feb;28(2):217-30 (105 ref.)

A "second window of protection" or delayed preconditioning phenomenon: future horizons for myocardial protection? Yellon DM, et al. **J Mol Cell Cardiol** 1995 Apr; 27(4):1023-34 (65 ref.)

Calcium transport proteins in the nonfailing and failing heart: gene expression and function. Wankerl M, et al. **J Mol Med** 1995 Oct;73(10):487-96 (92 ref.)

Inositol phosphates in the heart: controversy and consensus. Woodcock EA. **J Mol Med** 1995 Jun;73(6):313-23 (110 ref.)

Glutamine metabolism and transport in skeletal muscle and heart and their clinical relevance. Rennie MJ, et al. **J Nutr** 1996 Apr;126(4 Suppl):1142S-9S (33 ref.)

Studies of hypoxemic/reoxygenation injury: I. Linkage between cardiac function and oxidant damage. Buckberg GD. **J Thorac Cardiovasc Surg** 1995 Oct;110(4 Pt 2):1164-70 (47 ref.)

Intracellular calcium modulators for cardiac muscle in pathological conditions. Ishide N. **Jpn Heart J** 1996 Jan; 37(1):1-17 (80 ref.)

Cross-bridge-dependent changes in the intracellular Ca2+ concentration in mammalian cardiac muscles. Kurihara S, et al. **Jpn Heart J** 1996 Mar;37(2):143-52 (33 ref.)

Crossbridge dynamics under various inotropic states in cardiac muscle: evaluation by perturbation analyses. Saeki Y. **Jpn J Physiol** 1995;45(5):687-705 (101 ref.)

Spatial organization of cardiac gap junctions can affect access resistance. Hall JE, et al. **Microsc Res Tech** 1995 Aug 1; 31(5):446-51 (30 ref.)

Structural and molecular determinants of intercellular coupling in cardiac myocytes. Kanter HL, et al. **Microsc Res Tech** 1995 Aug 1;31(5):357-63 (32 ref.)

Myocardial gap junction organization in ischemia and infarction. Peters NS. **Microsc Res Tech** 1995 Aug 1; 31(5):375-86 (95 ref.)

Alterations of beta-adrenoceptor-G-protein-regulated adenylyl cyclase in heart failure. Böhm M. **Mol Cell Biochem** 1995 Jun 7-21;147(1-2):147-60 (84 ref.)

Regulation of expression of cardiac sarcoplasmic reticulum proteins under pathophysiological conditions. Dillmann WH. **Mol Cell Biochem** 1996 Apr 12-26;157(1-2):125-8 (14 ref.)

The role of catecholamines on intercellular coupling, myocardial cell synchronization and self ventricular defibrillation. Manoach M, et al. **Mol Cell Biochem** 1995 Jun 7-21;147(1-2):181-5 (63 ref.)

Regulation of G protein function: implications for heart disease. Meij JT. **Mol Cell Biochem** 1996 Apr 12-26; 157(1-2):31-8 (43 ref.)

Structural and biochemical remodelling in catecholamine-induced cardiomyopathy: comparative and ontogenetic aspects. Oitádal B, et al. **Mol Cell Biochem** 1995 Jun 7-21;147(1-2):83-8 (49 ref.)

Signal transduction: regulation of cAMP concentration in cardiac muscle by calmodulin-dependent cyclic nucleotide phosphodiesterase. Sharma RK. **Mol Cell Biochem** 1995 Aug-Sep;149-150:241-7 (23 ref.)

Oxidative stress and heart failure. Singh N, et al. **Mol Cell Biochem** 1995 Jun 7-21;147(1-2):77-81 (36 ref.)

Regulation of phospholamban and troponin-I phosphorylation in the intact rat cardiomyocytes by adrenergic and cholinergic stimuli: roles of cyclic nucleotides, calcium, protein kinases and phosphatases and depolarization. Sulakhe PV, et al. **Mol Cell Biochem** 1995 Aug-Sep;149-150:103-26 (96 ref.)

Phosphoinositide-generated messengers in cardiac signal transduction. van Heugten HA, et al. **Mol Cell Biochem** 1996 Apr 12-26;157(1-2):5-14 (88 ref.)

Measurement of calcium transport in heart using modern approaches. Bers DM. **New Horiz** 1996 Feb;4(1):36-44 (29 ref.)

Molecular physiology of cardiac potassium channels. Deal KK, et al. **Physiol Rev** 1996 Jan;76(1):49-67 (186 ref.)

Structure and function of voltage-dependent sodium channels: comparison of brain II and cardiac isoforms. Fozzard HA, et al. **Physiol Rev** 1996 Jul;76(3):887-926 (258 ref.)

Myocardial protection during reperfusion. Piper HM, et al. **Thorac Cardiovasc Surg** 1996 Feb;44(1):15-9 (19 ref.)

Myocardial contractile response and IP3, cAMP and cGMP interrelationships. Martinussen HJ. **Ups J Med Sci** 1996; 101(1):1-33 (142 ref.)

[Regulation of intracellular pH in cardiac myocytes] Sun B, et al. **Sheng Li Ko Hsueh Chin Chan** 1995 Jul;26(3):253-5 (10 ref.) **(Chi)**

[Nuclear cardiology: techniques of metabolic evaluation] Parodi O, et al. **G Ital Cardiol** 1995 Dec;25(12):1675-8 (10 ref.) **(Ita)**

[Biochemical aspects of cardiomyocyte damage during ischemia and reperfusion] Skłodowska M. **Postepy Hig Med Dosw** 1995;49(2):287-96 (50 ref.) (Eng. Abstr.) **(Pol)**

PATHOLOGY

Ventricular remodeling in heart failure: the role of myocardial collagen. Janicki JS, et al. **Adv Exp Med Biol** 1995;382:239-45 (27 ref.)

Endomyocardial biopsy in arrhythmogenic right ventricular cardiomyopathy [editorial] Angelini A, et al. **Am Heart J** 1996 Jul;132(1 Pt 1):203-6 (35 ref.)

Structural changes in cardiovascular disease. Cohn JN. **Am J Cardiol** 1995 Nov 24;76(15):34E-37E (36 ref.)

Dynamics of matrix turnover during pathologic remodeling of the extracellular matrix [comment] Stetler-Stevenson WG. **Am J Pathol** 1996 May;148(5):1345-50 (34 ref.) Comment on: Am J Pathol 1996 May;148(5):1639-48.

The athlete's heart: is big beautiful? Shephard RJ. **Br J Sports Med** 1996 Mar;30(1):5-10 (75 ref.)

Cell swelling and ion transport pathways in cardiac myocytes. Vandenberg JI, et al. **Cardiovasc Res** 1996 Jul; 32(1):85-97 (94 ref.)

Stretching the evidence in the case of cardiac growth. Weber KT. **Cardiovasc Res** 1996 Apr;31(4):492-8 (45 ref.)

Intracardiac thrombi: frequency, location, etiology, and complications: a morphologic review—Part II. Waller BF, et al. **Clin Cardiol** 1995 Sep;18(9):530-4 (29 ref.)

The renin-angiotensin-aldosterone system and myocardial collagen matrix remodelling in congestive heart failure. Brilla CG, et al. **Eur Heart J** 1995 Dec;16 Suppl O:107-9 (24 ref.)

Abnormalities of the myocytes in ischaemic cardiomyopathy. Harding SE, et al. **Eur Heart J** 1995 Aug;16 Suppl I:74-81 (82 ref.)

Structural remodelling of the heart by fibrous tissue: role of circulating hormones and locally produced peptides. Weber KT, et al. **Eur Heart J** 1995 Dec;16 Suppl N:12-8 (83 ref.)

Myocardial fibrosis in hypertensive heart disease: an overview of potential regulatory mechanisms. Weber KT, et al. **Eur Heart J** 1995 May;16 Suppl C:24-8 (49 ref.)

Role of M cells in acquired long QT syndrome, U waves, and torsade de pointes. Antzelevitch C, et al. **J Electrocardiol** 1995;28 Suppl:131-8 (44 ref.)

Intracellular calcium modulators for cardiac muscle in pathological conditions. Ishide N. **Jpn Heart J** 1996 Jan; 37(1):1-17 (80 ref.)

Angiopeptin: experimental and clinical studies of inhibition of myointimal proliferation. Foegh ML, et al. **Kidney Int Suppl** 1995 Dec;52:S18-22 (47 ref.)

MR imaging of pulmonary hypertension and right ventricular dysfunction. Boxt LM. **Magn Reson Imaging Clin N Am** 1996 May;4(2):307-25 (94 ref.)

Angiotensin converting enzyme inhibitors, left ventricular hypertrophy and fibrosis. Linz W, et al. **Mol Cell Biochem** 1995 Jun 7-21;147(1-2):89-97 (73 ref.)

Magnetic resonance of the heart and great vessels. de Roos A, et al. **Nat Med** 1995 Jul;1(7):711-3 (6 ref.)

Heart disease: functional evaluation with MR imaging. Higgins CB, et al. **Radiology** 1996 May;199(2):307-15 (85 ref.)

Metabolic aspects of hibernating myocardium. Pantely GA, et al. **Z Kardiol** 1995;84 Suppl 4:101-5 (25 ref.)

[Advances in the pathology of human cardiac transplantation] Zhao H, et al. **Chung Hua I Hsueh Tsa Chih** 1995 Jul; 75(7):440-3 (30 ref.) **(Chi)**

[Significance of lymphoplasmocytic infiltration in arrhythmogenic right ventricular dysplasia. Apropos of 3 own cases and review of the literature] Fontaliran F, et al. **Arch Mal Coeur Vaiss** 1995 Jul;88(7):1021-8 (32 ref.) (Eng. Abstr.) **(Fre)**

[Angiotensin receptors--organ and subtype specific regulation in cardiovascular diseases by modulation of the renin-angiotensin system. Studies of the rat model and in human myocardium] Regitz-Zagrosek V, et al. **Z Kardiol** 1995;84 Suppl 4:61-9 (34 ref.) (Eng. Abstr.) **(Ger)**

[Cardiac magnetic resonance: the technical indications and a technical glossary] Molinari G, et al. **Cardiologia** 1995 Aug;40(8):541-50 (57 ref.) **(Ita)**

[Endomyocardial biopsy in pediatric cardiovascular pathology (editorial)] Gallo P. **G Ital Cardiol** 1995 Nov; 25(11):1499-512 (97 ref.) **(Ita)**

[Basic forms of acute injury to cardiomyocytes determined by polarized microscopy of myofibrils] Nepomniashchikh LM. **Biull Eksp Biol Med** 1996 Jan;121(1):4-13 (49 ref.) **(Rus)**

[A critical review of the role of endomyocardial biopsy in heart transplantation] Vázquez de Prada JA. **Rev Esp Cardiol** 1995;48 Suppl 7:86-91 (25 ref.) (Eng. Abstr.) **(Spa)**

ULTRASTRUCTURE

Calcium in the cardiac diadic cleft. Implications for sodium-calcium exchange. Langer GA, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:408-16 (24 ref.)

Ultrastructural and functional features of the developing mammalian heart: a brief overview. Smolich JJ. **Reprod Fertil Dev** 1995;7(3):451-61 (73 ref.)

MYOCLONIC EPILEPSY, PROGRESSIVE see **EPILEPSY, MYOCLONIC**

MYOCLONIC JERKING see EPILEPSY, MYOCLONIC

MYOCLONIC JERKING, MASSIVE see SPASMS, INFANTILE

MYOCLONUS

Myoclonus. Caviness JN. **Mayo Clin Proc** 1996 Jul; 71(7):679–88 (77 ref.)

CHEMICALLY INDUCED

[The serotonin syndrome: review of the literature and description of an original study] Lejoyeux M, et al. **Encephale** 1995 Sep–Oct;21(5):537–43 (45 ref.) (Eng. Abstr.) **(Fre)**

CLASSIFICATION

Pathophysiology of negative myoclonus and asterixis. Shibasaki H. **Adv Neurol** 1995;67:199–209 (34 ref.)

[The semiology and classification of myoclonias] Almeida R, et al. **Acta Med Port** 1995 Sep;8(9):523–7 (31 ref.) (Eng. Abstr.) **(Por)**

COMPLICATIONS

Progressive myoclonic ataxia associated with coeliac disease. The myoclonus is of cortical origin, but the pathology is in the cerebellum. Bhatia KP, et al. **Brain** 1995 Oct;118 (Pt 5):1087–93 (14 ref.)

DIAGNOSIS

Atonic phenomena and partial seizures. A reappraisal. So NK. **Adv Neurol** 1995;67:29–39 (33 ref.)

[The semiology and classification of myoclonias] Almeida R, et al. **Acta Med Port** 1995 Sep;8(9):523–7 (31 ref.) (Eng. Abstr.) **(Por)**

[Sialidosis type II, infantile form. Apropos a case] Menau Martin G, et al. **An Esp Pediatr** 1996 Jan;44(1):76–8 (8 ref.) **(Spa)**

GENETICS

Essential myoclonus and myoclonic dystonia. Quinn NP. **Mov Disord** 1996 Mar;11(2):119–24 (51 ref.)

PHYSIOPATHOLOGY

Pathophysiology of negative myoclonus and asterixis. Shibasaki H. **Adv Neurol** 1995;67:199–209 (34 ref.)

Physiology of negative myoclonus. Toro C, et al. **Adv Neurol** 1995;67:211–7 (16 ref.)

MYOD PROTEIN

GENETICS

Transdifferentiation induced by gene transfer. Boukamp P. **Semin Cell Biol** 1995 Jun;6(3):157–63 (35 ref.)

PHYSIOLOGY

Determination versus differentiation and the MyoD family of transcription factors. Megeney LA, et al. **Biochem Cell Biol** 1995 Sep–Oct;73(9–10):723–32 (100 ref.)

MYODYSTROPHIA FETALIS DEFORMANS see ARTHROGRYPOSIS

MYOELECTRIC COMPLEX, MIGRATING

Clinical significance of gastric myoelectrical dysrhythmias. Chen JD, et al. **Dig Dis** 1995 Sep–Oct;13(5):275–90 (103 ref.)

MYOEPITHELIAL TUMOR see MYOEPITHELIOMA

MYOEPITHELIOMA

DIAGNOSIS

Myoepithelioma: definitions and diagnostic criteria. Dardick I. **Ultrastruct Pathol** 1995 Sep–Oct;19(5):335–45 (42 ref.)

PATHOLOGY

Malignant myoepithelioma of the parotid gland: case report and review of the literature. Klumpp TR, et al. **J Laryngol Otol** 1995 Oct;109(10):995–8 (27 ref.)

MYOFASCIAL PAIN DYSFUNCTION SYNDROME, TEMPOROMANDIBULAR JOINT see TEMPOROMANDIBULAR JOINT SYNDROME

MYOFASCIAL PAIN SYNDROMES

DIAGNOSIS

Tender points/fibromyalgia vs. trigger points/myofascial pain syndrome: a need for clarity in terminology and differential diagnosis. Schneider MJ. **J Manipulative Physiol Ther** 1995 Jul–Aug;18(6):398–406 (43 ref.)

Problems with myofascial pain syndrome and fibromyalgia syndrome [editorial] Bohr T. **Neurology** 1996 Mar; 46(3):593–7 (46 ref.)

EPIDEMIOLOGY

Fibromyalgia, chronic fatigue syndrome, and myofascial pain. Goldenberg DL. **Curr Opin Rheumatol** 1996 Mar; 8(2):113–23 (95 ref.)

PHYSIOPATHOLOGY

[Highlights in the subject of low frequency–high intensity TENS (review)] Galletti SP, et al. **Minerva Stomatol** 1995 Sep;44(9):421–9 (41 ref.) (Eng. Abstr.) **(Ita)**

MYOFIBRILS

see related
MUSCLE CONTRACTION

METABOLISM

Proteolytic activity of proteasome on myofibrillar structures. Taylor RG, et al. **Mol Biol Rep** 1995;21(1):71–3 (19 ref.)

Molecular diversity of myofibrillar proteins: gene regulation and functional significance. Schiaffino S, et al. **Physiol Rev** 1996 Apr;76(2):371–423 (585 ref.)

PATHOLOGY

[Basic forms of acute injury to cardiomyocytes determined by polarized microscopy of myofibrils] Nepomniashchikh LM. **Biull Eksp Biol Med** 1996 Jan;121(1):4–13 (49 ref.) **(Rus)**

ULTRASTRUCTURE

The cardiac mutant gene c in axolotls: cellular, developmental, and molecular studies. Lemanski LF, et al. **Cell Mol Biol Res** 1995;41(4):293–305 (28 ref.)

MYOFIBROBLASTOMA see NEOPLASMS, MUSCLE TISSUE

MYOFIBROMA see LEIOMYOMA

MYOFIBROMATOSIS

PATHOLOGY

Solitary infantile and adult myofibromatosis of the nasal cavity: a report of two cases. Walsh RM, et al. **J Laryngol Otol** 1996 Jun;110(6):574–7 (15 ref.)

MYOFILAMENTS see MICROFILAMENTS

MYOGENIC REGULATORY FACTORS

GENETICS

Know your neighbors: three phenotypes in null mutants of the myogenic bHLH gene MRF4. Olson EN, et al. **Cell** 1996 Apr 5;85(1):1–4 (20 ref.)

METABOLISM

Combinatorial control of muscle development by basic helix–loop–helix and MADS-box transcription factors. Molkentin JD, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9366–73 (108 ref.)

MYOGLOBIN

ANALYSIS

[Myoglobin] Haraoka S, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:240–2 (8 ref.) **(Jpn)**

[Human myoglobin (hMb) and its diagnostic value] Szewczuk A, et al. **Postepy Hig Med Dosw** 1995;49(3):343–52 (51 ref.) (Eng. Abstr.) **(Pol)**

BLOOD

New biochemical markers for myocardial cell injury. Hamm CW, et al. **Curr Opin Cardiol** 1995 Jul;10(4):355–60 (42 ref.)

METABOLISM

Kinetic pathways and barriers for ligand binding to myoglobin. Olson JS, et al. **J Biol Chem** 1996 Jul 26; 271(30):17593–6 (28 ref.)

MYOGLOBINURIA

COMPLICATIONS

Carnitine palmitoyltransferase deficiency in a college athlete: a case report and literature review. Faigel HC. **J Am Coll Health** 1995 Sep;44(2):51–4 (40 ref.)

ETIOLOGY

Case report: polymyositis–induced myoglobinuric acute renal failure. Thakur V, et al. **Am J Med Sci** 1996 Aug; 312(2):85–7 (11 ref.)

[Recurrent myoglobinuria in a girl due to carnitine palmitoyltransferase deficiency] Carrasco Marina LL, et al. **An Esp Pediatr** 1996 Jan;44(1):67–9 (15 ref.) **(Spa)**

MYOINOSITOL see INOSITOL

MYOKYMIA see FASCICULATION

MYOMETRIUM

METABOLISM

Mechanisms regulating oxytocin receptor coupling to phospholipase C in rat and human myometrium. Sanborn BM, et al. **Adv Exp Med Biol** 1995;395:469–79 (54 ref.)

PATHOLOGY

Myometrial and stromal lesions of the uterus. Smoot JS, et al. **Clin Lab Med** 1995 Sep;15(3):545–73 (66 ref.)

PHYSIOLOGY

Regulation of the switch from myometrial contractures to contractions in late pregnancy: studies in the pregnant sheep and monkey. Nathanielsz PW, et al. **Reprod Fertil Dev** 1995;7(3):595–602 (42 ref.)

MYONEURAL JUNCTION see NEUROMUSCULAR JUNCTION

MYOPIA

[Progresses in ophthalmology in China, 1995] Zhang S. **Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):755–7 (0 ref.) **(Chi)**

[The problem of myopia in pilots (causes and characteristics of development and comprehensive correction)] Ovechkin IG, et al. **Vestn Oftalmol** 1995 Oct–Dec;111(4):38–40 (45 ref.) **(Rus)**

ETIOLOGY

Retinal-image mediated ocular growth as a mechanism for juvenile onset myopia and for emmetropization. A literature review. Goss DA, et al. **Doc Ophthalmol** 1995; 90(4):341–75 (182 ref.)

Myopia. The nature versus nurture debate goes on. Mutti DO, et al. **Invest Ophthalmol Vis Sci** 1996 May;37(6):952–7 (20 ref.)

PHYSIOPATHOLOGY

Retinal-image mediated ocular growth as a mechanism for juvenile onset myopia and for emmetropization. A literature review. Goss DA, et al. **Doc Ophthalmol** 1995; 90(4):341–75 (182 ref.)

Animal models of emmetropization: matching axial length to the focal plane. Norton TT, et al. **J Am Optom Assoc** 1995 Jul;66(7):405–14 (87 ref.)

SURGERY

Do topical corticosteroids have a role following excimer laser photorefractive keratectomy? [see comments] Corbett MC, et al. **J Refract Surg** 1995 Sep–Oct;11(5):380–7 (64 ref.) Comment in: J Refract Surg 1995 Sep–Oct;11(5):339–40.

Photorefractive keratectomy for myopia. Wu HK, et al. **Ophthalmic Surg Lasers** 1996 Jan;27(1):29–44 (96 ref.)

Automated lamellar keratoplasty. American Academy of Ophthalmology [see comments] **Ophthalmology** 1996 May; 103(5):852–61 (15 ref.) Comment in: Ophthalmology 1996 May;103(5):703–4.

How predictable are the results of excimer laser photorefractive keratectomy? A review. Grosvenor T. **Optom Vis Sci** 1995 Oct;72(10):698–712 (55 ref.)

Excimer laser photorefractive keratectomy. Seiler T, et al. **Surv Ophthalmol** 1995 Sep–Oct;40(2):89–118 (210 ref.)

[Clinical progress in the therapy of myopia with excimer laser keratotomy] Zhu RY, et al. **Chung Hua Yen Ko Tsa Chih** 1995 May;31(3):221–5 (31 ref.) **(Chi)**

[Critical thoughts on current laser surgery of the cornea] Gloor B, et al. **Ophthalmologe** 1995 Aug;92(4):389–96 (42 ref.) (Eng. Abstr.) **(Ger)**

[Current evaluation of myopia correction with the excimer laser] Seiler T. **Ophthalmologe** 1995 Aug;92(4):379–84 (18 ref.) (Eng. Abstr.) **(Ger)**

MYOSIN

Motor proteins 2: myosin. Sellers JR, et al. **Protein Profile** 1995;2(12):1323–1423 (2354 ref.)

BIOSYNTHESIS

Regulation of class I and class II myosins by heavy chain phosphorylation. Brzeska H, et al. **J Biol Chem** 1996 Jul 19;271(29):16983–6 (64 ref.)

CHEMISTRY

Unconventional myosins. Mooseker MS, et al. **Ann Rev Cell Dev Biol** 1995;11:633–75 (159 ref.)

Thermal unfolding of Acanthamoeba myosin II and skeletal muscle myosin. Zolkiewski M, et al. **Biophys Chem** 1996 Apr 16;59(3):365–71 (45 ref.)

Vertebrate unconventional myosins. Hasson T, et al. **J Biol Chem** 1996 Jul 12;271(28):16431–4 (51 ref.)

Protein–protein interactions in the rigor actomyosin complex.

MYOSIN

Milligan RA. **Proc Natl Acad Sci U S A** 1996 Jan 9; 93(1):21–6 (31 ref.)

GENETICS

Unconventional myosins. Mooseker MS, et al. **Ann Rev Cell Dev Biol** 1995;11:633–75 (159 ref.)

The myosin superfamily in Drosophila melanogaster. Morgan NS. **J Exp Zool** 1995 Oct 1;273(2):104–17 (89 ref.)

Deaf and dizzy mice with mutated myosin motors. Gillespie PG. **Nat Med** 1996 Jan;2(1):27–9 (13 ref.)

IMMUNOLOGY

Non-invasive detection of myocyte necrosis in myocarditis and dilated cardiomyopathy with radiolabelled antimyosin. Khaw BA, et al. **Eur Heart J** 1995 Dec;16 Suppl O:119–23 (16 ref.)

Autoimmunity in Chagas' heart disease. Cunha-Neto E, et al. **Rev Paul Med** 1995 Mar-Apr;113(2):757–66 (39 ref.)

[Indium III monoclonal antimyosin antibody scintigraphy for the detection of chronic myocardial infarction apart from the acute phase] Adrie C, et al. **Arch Mal Coeur Vaiss** 1995 Dec;88(12):1863–8 (33 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

The active site of myosin. Rayment I, et al. **Annu Rev Physiol** 1996;58:671–702 (146 ref.)

PHYSIOLOGY

The kinetic cycles of myosin, kinesin, and dynein. Hackney DD. **Annu Rev Physiol** 1996;58:731–50 (126 ref.)

Regulation of contraction by calcium binding myosins. Szent-Györgyi AG. **Biophys Chem** 1996 Apr 16; 59(3):357–63 (29 ref.)

TEDS rule: a molecular rationale for differential regulation of myosins by phosphorylation of the heavy chain head. Bement WM, et al. **Cell Motil Cytoskeleton** 1995; 31(2):87–92 (38 ref.)

Molecular motors, membrane movements and physiology: emerging roles for myosins. Hasson T, et al. **Curr Opin Cell Biol** 1995 Aug;7(4):587–94 (49 ref.)

Myosin minireview series [comment] Stull JT. **J Biol Chem** 1996 Jul 5;271(27):15849 (21 ref.) Comment on: J Biol Chem 1996 Jul 5;271(27):15850–3.

Overlapping functions of myosin-I isoforms? [comment] Ostap EM, et al. **J Cell Biol** 1996 Apr;133(2):221–4 (40 ref.) Comment on: J Cell Biol 1996 Apr;133(2):305–23.

ULTRASTRUCTURE

Evolution of myosin filament arrangements in vertebrate skeletal muscle. Luther PK, et al. **J Morphol** 1996 Sep; 229(3):325–35 (28 ref.)

MYOSIN ADENOSINETRIPHOSPHATASE see MYOSIN ATPASE

MYOSIN ALKALI LIGHT CHAINS see MYOSIN LIGHT CHAINS

MYOSIN ATPASE

CHEMISTRY

The structural basis of the myosin ATPase activity [see comments] Rayment I. **J Biol Chem** 1996 Jul 5; 271(27):15850–3 (44 ref.) Comment in: J Biol Chem 1996 Jul 5;271(27):15849.

METABOLISM

The structural basis of the myosin ATPase activity [see comments] Rayment I. **J Biol Chem** 1996 Jul 5; 271(27):15850–3 (44 ref.) Comment in: J Biol Chem 1996 Jul 5;271(27):15849.

Myosin minireview series [comment] Stull JT. **J Biol Chem** 1996 Jul 5;271(27):15849 (21 ref.) Comment on: J Biol Chem 1996 Jul 5;271(27):15850–3.

MYOSIN HEAVY CHAINS

METABOLISM

TEDS rule: a molecular rationale for differential regulation of myosins by phosphorylation of the heavy chain head. Bement WM, et al. **Cell Motil Cytoskeleton** 1995; 31(2):87–92 (38 ref.)

Regulation of class I and class II myosins by heavy chain phosphorylation. Brzeska H, et al. **J Biol Chem** 1996 Jul 19;271(29):16983–6 (64 ref.)

MYOSIN ISOENZYMES see MYOSIN ATPASE

MYOSIN ISOZYMES see MYOSIN ATPASE

MYOSIN LIGHT CHAINS

BLOOD

[Myosin light chain] Nishimura H, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:243–5 (4 ref.) **(Jpn)**

PHYSIOLOGY

The role of the skeletal muscle myosin light chains N-terminal fragments. Stępkowski D. **FEBS Lett** 1995 Oct 23;374(1):6–11 (52 ref.)

MYOSIN ROD see MYOSIN SUBFRAGMENTS

MYOSIN S-1 see MYOSIN SUBFRAGMENTS

MYOSIN S-2 see MYOSIN SUBFRAGMENTS

MYOSIN SUBFRAGMENTS

see related
MYOSIN ATPASE

CHEMISTRY

[Calorimetric study of stable complexes of myosin subfragment I with adenosine diphosphate and phosphate analogs] Levitskiĭ DI, et al. **Biofizika** 1996 Jan-Feb; 41(1):64–72 (29 ref.) (Eng. Abstr.) **(Rus)**

MYOSITIS

Inflammatory myopathies. Oddis CV, et al. **Baillieres Clin Rheumatol** 1995 Aug;9(3):497–514 (57 ref.)

Infectious myositis. A tropical disease steals out of its zone. O'Neill DS, et al. **Postgrad Med** 1996 Aug;100(2):193–4, 199–200 (10 ref.)

COMPLICATIONS

Pyomyositis as the sole manifestation of disseminated gonococcal infection: case report and review. Haugh PJ, et al. **Clin Infect Dis** 1996 May;22(5):861–3 (7 ref.)

DIAGNOSIS

Pyomyositis as the sole manifestation of disseminated gonococcal infection: case report and review. Haugh PJ, et al. **Clin Infect Dis** 1996 May;22(5):861–3 (7 ref.)

[Pseudophlebitis disclosing nodular and focal myositis (letter)] Cardon T, et al. **Rev Med Interne** 1996;17(1):91–2 (17 ref.) **(Fre)**

[Clinical investigation for polymyositis and related disorders] Matsubara S. **Rinsho Byori** 1995 Sep;43(9):877–85 (9 ref.) (Eng. Abstr.) **(Jpn)**

ETIOLOGY

Pyomyositis in intravenous drug abusers: report of a unique case and review of the literature. Hsueh PR, et al. **Clin Infect Dis** 1996 May;22(5):858–60 (10 ref.)

IMMUNOLOGY

Clinical benefits and immunopathological correlates of intravenous immune globulin in the treatment of inflammatory myopathies. Dalakas MC. **Clin Exp Immunol** 1996 May;104 Suppl 1:55–60 (35 ref.)

T cell-mediated immune mechanisms in myositis. O'Hanlon TP, et al. **Curr Opin Rheumatol** 1995 Nov;7(6):503–9 (51 ref.)

MICROBIOLOGY

Pneumococcal pyomyositis. Case report, review of the literature, and comparison with classic pyomyositis caused by other bacteria. Collazos J, et al. **Arch Intern Med** 1996 Jul 8;156(13):1470–4 (40 ref.)

PATHOLOGY

Focal myositis of the floor of mouth: report of two cases and review of the literature. McCluggage WG, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 May;81(5):573–5 (22 ref.)

PHYSIOPATHOLOGY

Exercise-induced muscle damage and inflammation: a review. Pyne DB. **Aust J Sci Med Sport** 1994 Sep-Dec; 26(3–4):49–58 (133 ref.)

RADIOGRAPHY

Inflammatory myopathies: radiologic evaluation. Fleckenstein JL, et al. **Radiol Clin North Am** 1996 Mar; 34(2):427–39, xii (92 ref.)

CT evaluation of soft tissue and muscle infection and inflammation: a systematic compartmental approach. Beauchamp NJ Jr, et al. **Skeletal Radiol** 1995 Jul; 24(5):317–24 (8 ref.)

THERAPY

Clinical benefits and immunopathological correlates of intravenous immune globulin in the treatment of inflammatory myopathies. Dalakas MC. **Clin Exp Immunol** 1996 May;104 Suppl 1:55–60 (35 ref.)

Treatment of inflammatory myopathy with intravenous gamma globulin. Sussman GL, et al. **Curr Opin Rheumatol** 1995 Nov;7(6):510–5 (57 ref.)

MYOSITIS, INCLUSION BODY

Inclusion body myositis [editorial] Garlepp MJ, et al. **J Neurol Neurosurg Psychiatry** 1996 Mar;60(3):251–5 (73 ref.)

COMPLICATIONS

[Inclusion body myositis] Serratrice G. **Presse Med** 1996 Jun 15;25(21):985–8 (23 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

New advances in the understanding of sporadic inclusion-body myositis and hereditary inclusion-body myopathies. Askanas V, et al. **Curr Opin Rheumatol** 1995 Nov;7(6):486–96 (75 ref.)

PATHOLOGY

Inclusion body myositis and myopathies. Griggs RC, et al. **Ann Neurol** 1995 Nov;38(5):705–13 (58 ref.)

MYOSITIS, MULTIPLE see POLYMYOSITIS

MYOSITIS, ORBITAL see GRANULOMA, PLASMA CELL, ORBITAL

MYOSITIS OSSIFICANS

Fibrodysplasia ossificans progressiva: still turning into wood after 300 years? Buyse G, et al. **Eur J Pediatr** 1995 Sep; 154(9):694–9 (29 ref.)

ETIOLOGY

[Traumatic myositis ossificans. Posttraumatic non-neoplastic heterotopic ossification] Jacobsen S. **Ugeskr Laeger** 1995 Sep 25;157(39):5385–8 (35 ref.) (Eng. Abstr.) **(Dan)**

MYOTONIA

DIAGNOSIS

Ocular neuromyotonia. Ezra E, et al. **Br J Ophthalmol** 1996 Apr;80(4):350–5 (27 ref.)

GENETICS

The myotonias: their diagnosis and treatment. Moxley RT 3rd. **Compr Ther** 1996 Jan;22(1):8–21 (55 ref.)

Hereditary nondystrophic myotonias and periodic paralyses. Lehmann-Horn F, et al. **Curr Opin Neurol** 1995 Oct; 8(5):402–10 (62 ref.)

PHYSIOPATHOLOGY

Ion-channel defects and aberrant excitability in myotonia and periodic paralysis. Cannon SC. **Trends Neurosci** 1996 Jan; 19(1):3–10 (59 ref.)

MYOTONIA ATROPHICA

DIAGNOSIS

Single-cell analysis of unstable genes. Daniels R, et al. **J Assist Reprod Genet** 1996 Feb;13(2):163–9 (28 ref.)

[DNA diagnosis in myotonic dystrophy] Tachi N. **Hokkaido Igaku Zasshi** 1996 Jan;71(1):3–8 (38 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

The myotonias: their diagnosis and treatment. Moxley RT 3rd. **Compr Ther** 1996 Jan;22(1):8–21 (55 ref.)

PHYSIOPATHOLOGY

Proximal myotonic myopathy: mini-review of a recently delineated clinical disorder. MOxley RT 3rd. **Neuromuscul Disord** 1996 Mar;6(2):87–93 (27 ref.)

MYOTONIA CONGENITA

GENETICS

The myotonias: their diagnosis and treatment. Moxley RT 3rd. **Compr Ther** 1996 Jan;22(1):8–21 (55 ref.)

MYOTONIA DYSTROPHICA see MYOTONIA ATROPHICA

MYOTONIC DYSTROPHY see MYOTONIA ATROPHICA

MYOXIDAE see RODENTIA

MYRINGOPLASTY

see related
TYMPANOPLASTY

Tympanic membrane wound healing. An overview. Gladstone HB, et al. **Otolaryngol Clin North Am** 1995 Oct; 28(5):913–32 (111 ref.)

MYRISTIC ACIDS

CHEMISTRY

Portrait of a myristoyl switch protein. Ames JB, et al.

Curr Opin Struct Biol 1996 Aug;6(4):432–8 (47 ref.)

METABOLISM

The MARCKS family of protein kinase-C substrates. Aderem A. **Biochem Soc Trans** 1995 Aug;23(3):587–91 (31 ref.)

Viral lipoproteins: the role of myristoylation. Harper DR, et al. **Biochem Soc Trans** 1995 Aug;23(3):553–7 (49 ref.)

Detergent binding to unmyristylated protein kinase A—structural implications for the role of myristate. Sowadski JM, et al. **J Bioenerg Biomembr** 1996 Feb; 28(1):7–12 (27 ref.)

MYTHOLOGY

The mythology of modern medicine—IV. HIV: heuristically important virus. AIDS: advances induced deficiency syndromes. Kothari MV, et al. **J Postgrad Med** 1994 Jan–Mar;40(1):42–5 (31 ref.)

Barraquer Lecture. Refractive surgery: myth versus reality. Salz J. **J Refract Surg** 1995 Jul–Aug;11(4):284–300 (46 ref.)

Myth, metaphor and hypothesis: how anthropomorphism defeats science. Sullivan LG.
Philos Trans R Soc Lond B Biol Sci 1995 Aug 29; 349(1328):215–8; discussion 219–24 (9 ref.)

[Myth reconstruction and health representations in a Southern Congolese therapeutic sect]
Hagenbucher-Sacripanti F. **Sante** 1996 Jan–Feb;6(1):43–52 (6 ref.) **(Fre)**

MYTILUS see **MUSSELS**

MYXEDEMA

see related
CRETINISM

Myxedema coma in the elderly [published erratum appears in J Am Board Fam Pract 1995 Nov–Dec;8(6):502] Olsen CG. **J Am Board Fam Pract** 1995 Sep–Oct;8(5):376–83 (51 ref.)

PHYSIOPATHOLOGY

[Pathophysiology and clinical aspects of myxedema] Reisert PM. **Z Lymphol** 1996 Jun;20(1):6–10, 12–4 (27 ref.) (Eng. Abstr.) **(Ger)**

MYXOBACTERALES see **MYXOCOCCALES**

MYXOCOCCALES

PHYSIOLOGY

The social behavior of myxobacteria. Muñoz-Dorado J, et al. **Microbiologia** 1995 Dec;11(4):429–38 (61 ref.)

MYXOCOCCUS XANTHUS

CYTOLOGY

A Myxococcus xanthus cell density-sensing system required for multicellular development. Kaplan HB, et al.
FEMS Microbiol Lett 1996 Jun 1;139(2–3):89–95 (28 ref.)

GROWTH & DEVELOPMENT

Genetics of gliding motility and development in Myxococcus xanthus. Hartzell PL, et al. **Arch Microbiol** 1995 Nov; 164(5):309–23 (117 ref.)

A Myxococcus xanthus cell density-sensing system required for multicellular development. Kaplan HB, et al.
FEMS Microbiol Lett 1996 Jun 1;139(2–3):89–95 (28 ref.)

Branched-chain fatty acids: the case for a novel form of cell-cell signalling during Myxococcus xanthus development. Downard J, et al. **Mol Microbiol** 1995 Apr; 16(2):171–5 (18 ref.)

MYXOFIBROMA see **FIBROMA**

MYXOID CYST see **SYNOVIAL CYST**

MYXOMA

[Leiomyoma, lipoma, myxoma, and fibroma of the gallbladder] Furukawa H. **Ryoikibetsu Shokogun Shirizu** 1996;(9):333–4 (8 ref.) **(Jpn)**

DIAGNOSIS

Don't confuse dental soft tissues with odontogenic tumors. Suarez PA, et al. **Ann Otol Rhinol Laryngol** 1996 Jun; 105(6):490–4 (9 ref.)

Cardiac myxomas [see comments] Reynen K.
N Engl J Med 1995 Dec 14;333(24):1610–7 (128 ref.) Comment in: N Engl J Med 1996 May 23;334(21):1407–8; discussion 1408–9. Comment in: N Engl J Med 1996 May 23;334(21):1408; discussion 1408–9.

A case of juxta-articular myxoma of the knee. Daluiski A, et al. **Skeletal Radiol** 1995 Jul;24(5):389–91 (23 ref.)

[The diagnostic problem of cardiac myxoma (editorial)] Zghaib Abad A, et al. **Arch Inst Cardiol Mex** 1995 May–Jun;65(3):193–5 (19 ref.) **(Spa)**

PATHOLOGY

Erythematous papules in a patient with cardiac myxoma: a case report and review of the literature. Misago N, et al. **J Dermatol** 1995 Aug;22(8):600–5 (22 ref.)

Aggressive angiomyxoma of the pelvis and perineum. A case report. Fishman A, et al. **J Reprod Med** 1995 Sep; 40(9):665–9 (16 ref.)

SURGERY

Mitral valve myxoma: a case report and brief review of the literature. Kulshrestha P, et al. **J Heart Valve Dis** 1995 Mar;4(2):196–8 (7 ref.)

[Myxoma of the mitral valve; apropos of 2 surgically treated cases. Review of the literature] Leude E, et al.
Arch Mal Coeur Vaiss 1995 Sep;88(9):1345–8 (18 ref.) (Eng. Abstr.) **(Fre)**

MYXOMA, NERVE SHEATH see **NEUROTHEKEOMA**

MYXOVIRUS INFLUENZAE-A HOMINIS see **ORTHOMYXOVIRUS TYPE A, HUMAN**

MYXOVIRUS PESTIS GALLI see **ORTHOMYXOVIRUS TYPE A, AVIAN**

MYXOVIRUSES see **ORTHOMYXOVIRIDAE**

N-CADHERINS see **CADHERINS**

N-MYC GENES see **GENES, MYC**

N-MYC PROTEINS see **PROTO-ONCOGENE PROTEINS C-MYC**

N-RAS GENES see **GENES, RAS**

NA(+)-H(+)-ANTIPORTER see **SODIUM-HYDROGEN ANTIPORTER**

NA(+)-H(+)-EXCHANGER see **SODIUM-HYDROGEN ANTIPORTER**

NA(+)-K(+)-EXCHANGING ATPASE

ANTAGONISTS & INHIBITORS

Koch's postulates and the digitalis-like factor. Hollenberg NK, et al. **Hypertens Res** 1995 Mar;18(1):1–6 (32 ref.)

Natriuretic hormones II. Benaksas EJ, et al.
Prog Drug Res 1995;45:245–88 (109 ref.)

Endogenous sodium pump inhibition: current status and therapeutic opportunities. Hollenberg NK, et al.
Prog Drug Res 1996;46:9–42 (116 ref.)

[Endogenous digitalis-like substance. I. Basic characteristics] Martinka E. **Vnitr Lek** 1995 Sep;41(9):637–43 (31 ref.) (Eng. Abstr.) **(Slo)**

DRUG EFFECTS

Stimulation of Na+, K(+)-pump activity in skeletal muscle by methylxanthines: evidence and proposed mechanisms. Lindinger MI, et al. **Acta Physiol Scand** 1996 Mar; 156(3):347–53 (45 ref.)

METABOLISM

Role of skeletal muscle sodium pumps in the adaptation to potassium deprivation. McDonough AA, et al.
Acta Physiol Scand 1996 Mar;156(3):295–304 (77 ref.)

Structure-function relationships in the Ca(2+)-ATPase of sarcoplasmic reticulum studied by use of the substrate analogue CrATP and site-directed mutagenesis. Comparison with the Na+,K(+)-ATPase. Vilsen B.
Acta Physiol Scand Suppl 1995;624:1–146 (255 ref.)

Myocardial phenotypic changes in Na+, K+ ATPase in left ventricular hypertrophy: pharmacological consequences. Charlemagne D, et al. **Eur Heart J** 1995 May;16 Suppl C:20–3 (16 ref.)

Significance of sodium pump isoforms in digitalis therapy. McDonough AA, et al. **J Mol Cell Cardiol** 1995 Apr; 27(4):1001–9 (65 ref.)

PHYSIOLOGY

Na+, K(+)-pump activity and skeletal muscle contractile deficits in the spontaneously hypertensive rat. Carlsen RC, et al. **Acta Physiol Scand** 1996 Mar;156(3):237–45 (24 ref.)

The Na+, K+ pump in skeletal muscle: quantification, regulation and functional significance. Clausen T.
Acta Physiol Scand 1996 Mar;156(3):227–35 (81 ref.)

Effects of K+, Mg2+ deficiency and adrenal steroids on Na+, K(+)-pump concentration in skeletal muscle. Dørup I. **Acta Physiol Scand** 1996 Mar;156(3):305–11 (51 ref.)

Ion gradients and contractility in skeletal muscle: the role of active Na+, K+ transport. Nielsen OB, et al.
Acta Physiol Scand 1996 Mar;156(3):247–56 (70 ref.)

Fuzzy space and control of Na+, K(+)-pump rate in heart and skeletal muscle. Semb SO, et al.
Acta Physiol Scand 1996 Mar;156(3):213–25 (79 ref.)

Na+, K(+)-ATPase and heart excitability. Lichtstein D. **Adv Exp Med Biol** 1995;382:23–30 (51 ref.)

The Na+/K(+)-pump in rat peritoneal mast cells: some aspects of regulation of activity and cellular function. Knudsen T. **Dan Med Bull** 1995 Nov;42(5):441–54 (261 ref.)

Endogenous sodium pump inhibition: current status and therapeutic opportunities. Hollenberg NK, et al.
Prog Drug Res 1996;46:9–42 (116 ref.)

NA(+)-K(+)-TRANSPORTING ATPASE see **NA(+)-K(+)-EXCHANGING ATPASE**

NA-872 see **AMBROXOL**

NAD

METABOLISM

NAD and poly(ADP-ribose) regulation of proteins involved in response to cellular stress and DNA damage. Berger NA, et al. **Biochimie** 1995;77(5):364–7 (16 ref.)

Evaluating the role of niacin in human carcinogenesis. Jacobson EL, et al. **Biochimie** 1995;77(5):394–8 (22 ref.)

NAD glycohydrolases and the metabolism of cyclic ADP-ribose. Jacobson MK, et al. **Biochimie** 1995; 77(5):341–4 (15 ref.)

A proposed mechanism of ADP-ribosylation catalyzed by the pertussis toxin S1 subunit. Locht C, et al. **Biochimie** 1995;77(5):333–40 (56 ref.)

New aspects of the physiological significance of NAD, poly ADP-ribose and cyclic ADP-ribose. Okamoto H, et al. **Biochimie** 1995;77(5):356–63 (41 ref.)

Characterization of mammalian ADP-ribosylation cycles. Okazaki IJ, et al. **Biochimie** 1995;77(5):319–25 (43 ref.)

ADP-ribosylation reactions. Shall S. **Biochimie** 1995; 77(5):313–8 (21 ref.)

PHYSIOLOGY

[Role of nicotinic acid and its derivatives in disorders of nervous system function] Parkhomets PK, et al.
Ukr Biokhim Zh 1995 Jul–Aug;67(4):3–11 (91 ref.) (Eng. Abstr.) **(Rus)**

NAD+ ADP-RIBOSYLTRANSFERASE

ANTAGONISTS & INHIBITORS

The role of inhibitors of poly(ADP-ribose) polymerase as resistance-modifying agents in cancer therapy. Griffin RJ, et al. **Biochimie** 1995;77(6):408–22 (84 ref.)

CHEMISTRY

ADP-ribosylation reactions in plants. O'Farrell M.
Biochimie 1995;77(6):486–91 (54 ref.)

DEFICIENCY

Depletion of nuclear poly(ADP-ribose) polymerase by antisense RNA expression: influence on genomic stability, chromatin organization, DNA repair, and DNA replication. Simbulan-Rosenthal CM, et al.
Prog Nucleic Acid Res Mol Biol 1996;55:135–56 (68 ref.)

DRUG EFFECTS

Nitric oxide synthase, immunophilins and poly(ADP-ribose) synthetase: novel targets for the development of neuroprotective drugs. Zhang J, et al. **Neurol Res** 1995 Aug;17(4):285–8 (37 ref.)

GENETICS

Genetic analysis of exoenzyme S expression by Pseudomonas aeruginosa. Goranson J, et al. **FEMS Microbiol Lett** 1996 Jan 15;135(2–3):149–55 (39 ref.)

Post-translational modification of poly(ADP-ribose) polymerase induced by DNA strand breaks. Lindahl T, et al. **Trends Biochem Sci** 1995 Oct;20(10):405–11 (46 ref.)

METABOLISM

Progress in identifying clinical relevance of inhibition, stimulation and measurements of poly ADP-ribosylation. Pero RW, et al. **Biochimie** 1995;77(5):385–93 (45 ref.)

ADP-ribosylation reactions. Shall S. **Biochimie** 1995; 77(5):313–8 (21 ref.)

PHYSIOLOGY

Role of poly(ADP-ribose) polymerase in cell-cycle checkpoint mechanisms following gamma-irradiation. Masutani M, et al. **Biochimie** 1995;77(6):462–5 (24 ref.)

Analysis of biological function of poly(ADP-ribosyl)ation in Drosophila melanogaster. Miwa M, et al. **Biochimie** 1995; 77(6):466–71 (32 ref.)

ADP-ribosylation reactions in plants. O'Farrell M.
Biochimie 1995;77(6):486–91 (54 ref.)

Poly(ADP-ribosyl)ation as a fail-safe, transcription-independent, suicide mechanism in acutely DNA-damaged cells: a hypothesis. Nagele A.
Radiat Environ Biophys 1995 Nov;34(4):251–4 (36 ref.)

NAD-ARGININE ADP-RIBOSYLTRANSFERASE see **NAD(P)(+)-ARGININE ADP-RIBOSYLTRANSFERASE**

NAD ISOCITRATE DEHYDROGENASE see **ISOCITRATE DEHYDROGENASE**

NAD+ NUCLEOSIDASE

METABOLISM

NAD glycohydrolases and the metabolism of cyclic ADP-ribose. Jacobson MK, et al. **Biochimie** 1995; 77(5):341–4 (15 ref.)

PHYSIOLOGY

[Novel NAD(+)-cleavage enzymes possibly involved in signal transduction system] Katada T, et al. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(13):1900–11 (76 ref.) **(Jpn)**

NAD(P)H DEHYDROGENASE (QUINONE)

ANTAGONISTS & INHIBITORS

Recent advances in Annonaceous acetogenins. Zeng L, et al. **Nat Prod Rep** 1996 Aug;13(4):275–306 (177 ref.)

METABOLISM

Functional molecular aspects of the NADH dehydrogenases of plant mitochondria. Soole KL, et al. **J Bioenerg Biomembr** 1995 Aug;27(4):397–406 (64 ref.)

NAD-PROTEIN ADP-RIBOSYLTRANSFERASE see NAD(P)(+)-ARGININE ADP-RIBOSYLTRANSFERASE

NADASE see NAD+ NUCLEOSIDASE

NADH CYTOCHROME C REDUCTASE see NADH DEHYDROGENASE

NADH DEHYDROGENASE

CHEMISTRY

The bifunctional cytochrome c reductase/processing peptidase complex from plant mitochondria. Braun HP, et al. **J Bioenerg Biomembr** 1995 Aug;27(4):423–36 (110 ref.)

METABOLISM

The bifunctional cytochrome c reductase/processing peptidase complex from plant mitochondria. Braun HP, et al. **J Bioenerg Biomembr** 1995 Aug;27(4):423–36 (110 ref.)

Functional molecular aspects of the NADH dehydrogenases of plant mitochondria. Soole KL, et al. **J Bioenerg Biomembr** 1995 Aug;27(4):397–406 (64 ref.)

NADH, NADPH OXIDOREDUCTASES

NADPH oxidase of neutrophils. Henderson LM, et al. **Biochim Biophys Acta** 1996 Feb 15;1273(2):87–107 (216 ref.)

BLOOD

Small G proteins and the neutrophil NADPH oxidase. Dagher MC, et al. **Biochimie** 1995;77(7–8):651–60 (94 ref.)

CHEMISTRY

Protein engineering of domains in flavoprotein disulphide oxidoreductases: contributions to folding and assembly. Perham RN, et al. **Biochem Soc Trans** 1996 Feb;24(1):61–6 (45 ref.)

Predicted structure and possible ionmotive mechanism of the sodium-linked NADH-ubiquinone oxidoreductase of Vibrio alginolyticus. Rich PR, et al. **FEBS Lett** 1995 Nov 13;375(1–2):5–10 (42 ref.)

DEFICIENCY

Mutations in the X-linked and autosomal recessive forms of chronic granulomatous disease. Roos D, et al. **Blood** 1996 Mar 1;87(5):1663–81 (151 ref.)

METABOLISM

Intracellular regulation. Rac and Bcr regulate phagocytic phoxes. Ridley AJ. **Curr Biol** 1995 Jul 1;5(7):710–2 (19 ref.)

The mechanism of microsomal azoreduction: predictions based on electronic aspects of structure-activity relationships. Zbaida S. **Drug Metab Rev** 1995; 27(3):497–516 (112 ref.)

Predicted structure and possible ionmotive mechanism of the sodium-linked NADH-ubiquinone oxidoreductase of Vibrio alginolyticus. Rich PR, et al. **FEBS Lett** 1995 Nov 13;375(1–2):5–10 (42 ref.)

The NADPH oxidase complex of phagocytic leukocytes: a biochemical and cytochemical view. Robinson JM, et al. **Histochem Cell Biol** 1995 Mar;103(3):163–80 (197 ref.)

The NADPH oxidase and chronic granulomatous disease. Segal AW. **Mol Med Today** 1996 Mar;2(3):129–35 (31 ref.)

PHYSIOLOGY

Phagocytic NADPH oxidase and its role in chronic granulomatous disease. Pallister CJ, et al. **Br J Biomed Sci** 1995 Jun;52(2):149–56 (91 ref.)

NADIDE see NAD

NADP

BIOSYNTHESIS

Routes and regulation of NADPH production in steroidogenic mitochondria. Hanukoglu I, et al. **Endocr Res** 1995 Feb–May;21(1–2):231–41 (46 ref.)

METABOLISM

Reoxidation of the NADPH produced by the pentose phosphate pathway is necessary for the utilization of glucose by Kluyveromyces lactis rag2 mutants. González Siso MI, et al. **FEBS Lett** 1996 May 27;387(1):7–10 (27 ref.)

NADP-ARGININE ADP-RIBOSYLTRANSFERASE see NAD(P)(+)-ARGININE ADP-RIBOSYLTRANSFERASE

NAD(P)(+)-ARGININE ADP-RIBOSYLTRANSFERASE

CHEMISTRY

Studies on the active-site structure of C3-like exoenzymes: involvement of glutamic acid in catalysis of ADP-ribosylation. Aktories K, et al. **Biochimie** 1995; 77(5):326–32 (62 ref.)

METABOLISM

Studies on the active-site structure of C3-like exoenzymes: involvement of glutamic acid in catalysis of ADP-ribosylation. Aktories K, et al. **Biochimie** 1995; 77(5):326–32 (62 ref.)

Characterization of mammalian ADP-ribosylation cycles. Okazaki IJ, et al. **Biochimie** 1995;77(5):319–25 (43 ref.)

ADP-ribosylation reactions. Shall S. **Biochimie** 1995; 77(5):313–8 (21 ref.)

NADP DEHYDROGENASE see NADPH DEHYDROGENASE

NADP DIAPHORASE see NADPH DEHYDROGENASE

NADP TRANSHYDROGENASE

PHYSIOLOGY

Nicotinamide nucleotide transhydrogenase: a model for utilization of substrate binding energy for proton translocation. Hatefi Y, et al. **FASEB J** 1996 Mar; 10(4):444–52 (49 ref.)

NADPH CYTOCHROME C REDUCTASE see NADPH-FERRIHEMOPROTEIN REDUCTASE

NADPH CYTOCHROME P-450 OXIDOREDUCTASE see NADPH-FERRIHEMOPROTEIN REDUCTASE

NADPH CYTOCHROME P-450 REDUCTASE see NADPH-FERRIHEMOPROTEIN REDUCTASE

NADPH DEHYDROGENASE

GENETICS

Mutations in the X-linked and autosomal recessive forms of chronic granulomatous disease. Roos D, et al. **Blood** 1996 Mar 1;87(5):1663–81 (151 ref.)

PHYSIOLOGY

Flavoprotein structure and mechanism. 8. Structure-function relations for old yellow enzyme. Karplus PA, et al. **FASEB J** 1995 Dec;9(15):1518–26 (39 ref.)

NADPH DIAPHORASE see NADPH DEHYDROGENASE

NADPH-FERRIHEMOPROTEIN REDUCTASE

CHEMISTRY

NADPH-P-450 reductase: structural and functional comparisons of the eukaryotic and prokaryotic isoforms. Sevrioukova IF, et al. **Biochimie** 1995;77(7–8):562–72 (59 ref.)

Artificial P450/reductase fusion enzymes: what can we learn from their structures? Yabusaki Y. **Biochimie** 1995; 77(7–8):594–603 (51 ref.)

NAFCILLIN

ADVERSE EFFECTS

Nafcillin-associated hepatotoxicity. Report of a case and review of the literature. Presti ME, et al. **Dig Dis Sci** 1996 Jan;41(1):180–4 (24 ref.)

THERAPEUTIC USE

Cure of a solitary brainstem abscess with antibiotic therapy: case report. Fulgham JR, et al. **Neurology** 1996 May; 46(5):1451–4 (10 ref.)

NAGANA see TRYPANOSOMIASIS, AFRICAN

NAIL DISEASES

CHEMICALLY INDUCED

Adverse contact reactions to sculptured acrylic nails: 4 case reports and a literature review. Freeman S, et al. **Contact Dermatitis** 1995 Dec;33(6):381–5 (48 ref.)

Longitudinal melanonychia induced by hydroxyurea: four case reports and review of the literature. Delmas-Marsalet B, et al. **Nouv Rev Fr Hematol** 1995;37(3):205–10 (17 ref.)

CONGENITAL

Gastrointestinal problems in a child with dyskeratosis congenita. Berezin S, et al. **Am J Gastroenterol** 1996 Jun; 91(6):1271–2 (6 ref.)

DIAGNOSIS

Onychomatricoma. Haneke E, et al. **Dermatol Surg** 1995 Nov; 21(11):984–7 (19 ref.)

ETIOLOGY

Psoriatic onycho-pachydermo-periostitis. A variant of psoriatic distal interphalangeal arthritis? Boisseau-Garsaud AM, et al. **Arch Dermatol** 1996 Feb;132(2):176–80 (22 ref.)

Sea urchin granuloma of the nail apparatus: report of 2 cases. Haneke E, et al. **Dermatology** 1996;192(2):140–2 (9 ref.)

[Desmoplastic and neurotropic subungueal melanoma] Rongioletti F, et al. **Ann Dermatol Venereol** 1995; 122(10):707–10 (20 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Dyskeratosis congenita: an inherited bone marrow failure syndrome. Dokal I. **Br J Haematol** 1996 Mar;92(4):775–9 (52 ref.)

PATHOLOGY

Problem sites: scalp, palm and sole, and nail. Larko O. **Dermatol Clin** 1995 Oct;13(4):771–7 (91 ref.)

Sea urchin granuloma of the nail apparatus: report of 2 cases. Haneke E, et al. **Dermatology** 1996;192(2):140–2 (9 ref.)

Hutchinson's sign: a reappraisal. Baran R, et al. **J Am Acad Dermatol** 1996 Jan;34(1):87–90 (21 ref.)

NAILING, INTRAMEDULLARY see FRACTURE FIXATION, INTRAMEDULLARY

NAILS

Adverse contact reactions to sculptured acrylic nails: 4 case reports and a literature review. Freeman S, et al. **Contact Dermatitis** 1995 Dec;33(6):381–5 (48 ref.)

Congenital subungual nevus in a black infant. Libow LF, et al. **Cutis** 1995 Sep;56(3):154–6 (17 ref.)

ANATOMY & HISTOLOGY

The lunula. Cohen PR. **J Am Acad Dermatol** 1996 Jun; 34(6):943–53; quiz 954–6 (131 ref.)

NALOXONE

ADVERSE EFFECTS

Antidotes: benefits and risks. Proudfoot AT. **Toxicol Lett** 1995 Dec;82–83:779–83 (20 ref.)

PHARMACOLOGY

The opioid receptor antagonist naloxone influences the pathophysiology of spinal cord injury. Olsson Y, et al. **Prog Brain Res** 1995;104:381–99 (96 ref.)

NALTREXONE

THERAPEUTIC USE

Medical management of alcohol dependence: clinical use and limitations of naltrexone treatment. Volpicelli JR, et al. **Alcohol Alcohol** 1995 Nov;30(6):789–98 (42 ref.)

[Clinical use of naltrexone] Manzanares J. **Rev Med Univ Navarra** 1995 Apr-Jun;40(2):78–84 (22 ref.) (Eng. Abstr.) **(Spa)**

NAMES

Terms of address: implications for nursing. Bowie I. **J Adv Nurs** 1996 Jan;23(1):113–9 (17 ref.)

The difficulty with recalling people's names: the plausible phonology hypothesis. Brennen T. **Memory** 1993 Dec; 1(4):409–31 (45 ref.)

Naming faces and naming names: exploring an interactive activation model of person recognition. Burton AM, et al. **Memory** 1993 Dec;1(4):457–80 (26 ref.)

Memory for proper names: a review. Cohen G, et al.

Memory 1993 Dec;1(4):249–63 (36 ref.)
Proper names and how they are learned. La Palme Reyes M, et al. **Memory** 1993 Dec;1(4):433–55 (32 ref.)

NANDROLONE

ANALOGS & DERIVATIVES

Nandrolone decanoate: pharmacological properties and therapeutic use in osteoporosis. Geusens P. **Clin Rheumatol** 1995 Sep;14 Suppl 3:32–9 (52 ref.)

NANISM see **DWARFISM**

NAPHTHALENEDIONES see **NAPHTHOQUINONES**

NAPHTHALENES

PHARMACOLOGY

Pharmacology and structure--activity relationships of the nonpeptide bradykinin receptor antagonist WIN 64338. Sawutz DG, et al. **Can J Physiol Pharmacol** 1995 Jul; 73(7):805–11 (32 ref.)

THERAPEUTIC USE

[Tolrestat in the therapy of diabetic peripheral neuropathy: is this drug really useful?] Daniele E, et al. **Clin Ter** 1995 Dec;146(12):793–99 (31 ref.) (Eng. Abstr.) **(Ita)**

NAPHTHAMIDOPENICILLIN see **NAFCILLIN**

NAPHTHOLS

[Prostacyclin mimetics with non-prostanoid structures] Kondo K, et al. **Nippon Yakurigaku Zasshi** 1995 Sep; 106(3):181–91 (21 ref.) (Eng. Abstr.) **(Jpn)**

NAPHTHOQUINONES

CHEMICAL SYNTHESIS

[Synthesis of lactone ring-containing bioactive natural products. Cardiotonic steroids, naphthoquinone antibiotics, and tetronic acid ionophore antibiotics] Yoshii E. **Yakugaku Zasshi** 1996 Jan;116(1):1–20 (45 ref.) (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

Atovaquone. A review of its pharmacological properties and therapeutic efficacy in opportunistic infections. Spencer CM, et al. **Drugs** 1995 Jul;50(1):176–96 (64 ref.)

NAPHTHYLAMIDASES see **AMINO ACID NAPHTHYLAMIDASES**

1-NAPHTHYLAMINE

ANALOGS & DERIVATIVES

Discontinuation reactions following sertraline. Leiter FL, et al. **Biol Psychiatry** 1995 Nov 15;38(10):694–5 (7 ref.)
Sertraline 50 mg daily: the optimal dose in the treatment of depression. Preskorn SH, et al. **Int Clin Psychopharmacol** 1995 Sep;10(3):129–41 (55 ref.)
Does intolerance or lack of response with fluoxetine predict the same will happen with sertraline? Zarate CA, et al. **J Clin Psychiatry** 1996 Feb;57(2):67–71 (23 ref.)

NAPHURIDE see **SURAMIN**

NARCOLEPSY

DIAGNOSIS

Sleep disorders. Yousaf F, et al. **Br J Hosp Med** 1996 Mar 20–Apr 2;55(6):353–8 (21 ref.)

PSYCHOLOGY

Sleep-related spells associated with parasomnias and narcolepsy. Aldrich MS. **Semin Neurol** 1995 Jun; 15(2):194–202 (37 ref.)

NARCOTIC ANALGESICS see **ANALGESICS, OPIOID**

NARCOTIC ANTAGONISTS

PHARMACOLOGY

The opioid receptor antagonist naloxone influences the pathophysiology of spinal cord injury. Olsson Y, et al. **Prog Brain Res** 1995;104:381–99 (96 ref.)

THERAPEUTIC USE

Medical management of alcohol dependence: clinical use and limitations of naltrexone treatment. Volpicelli JR, et al. **Alcohol Alcohol** 1995 Nov;30(6):789–98 (42 ref.)
The use of opiate antagonists for recurrent self-injurious behavior. Buzan RD, et al. **J Neuropsychiatry Clin Neurosci** 1995 Fall;7(4):437–44 (86 ref.)
Methoclocinnamox: a mu partial agonist with pharmacotherapeutic potential for heroin abuse. Woods JH, et al. **NIDA Res Monogr** 1995;147:195–219 (29 ref.)
[Drug treatment of obesity] Yoshida T. **Nippon Rinsho** 1995 Jun;53 Suppl:481–6 (20 ref.) **(Jpn)**

NARCOTIC CONTROL see **DRUG AND NARCOTIC CONTROL**

NARCOTIC DEPENDENCE

DRUG THERAPY

N-methyl-D-aspartate (NMDA) receptors, mu and kappa opioid tolerance, and perspectives on new analgesic drug development. Elliott K, et al. **Neuropsychopharmacology** 1995 Dec;13(4):347–56 (58 ref.)
The effects of NMDA receptor antagonists and nitric oxide synthase inhibitors on opioid tolerance and withdrawal. Medication development issues for opiate addiction. Herman BH, et al. **Neuropsychopharmacology** 1995 Dec; 13(4):269–93 (165 ref.)
Perspectives on the N-methyl-D-aspartate/nitric oxide cascade and opioid tolerance. Pasternak GW, et al. **Neuropsychopharmacology** 1995 Dec;13(4):309–13 (24 ref.)
Effects of noncompetitive N-methyl-D-aspartate receptor antagonists on opiate tolerance and physical dependence. Trujillo KA. **Neuropsychopharmacology** 1995 Dec; 13(4):301–7 (38 ref.)
Nitric oxide synthase inhibitors. Preclinical studies of potential use for treatment of opioid withdrawal. Vaupel DB, et al. **Neuropsychopharmacology** 1995 Dec; 13(4):315–22 (27 ref.)
Drugs that modify opioid tolerance, physical dependence, and abstinence symptoms: preclinical and clinical studies. Bhargava HN. **NIDA Res Monogr** 1995;147:53–83 (127 ref.)
Etorphine elicits unique inhibitory-agonist and excitatory-antagonist actions at opioid receptors on sensory neurons: new rationale for improved clinical analgesia and treatment of opiate addiction. Crain SM, et al. **NIDA Res Monogr** 1995;147:234–68 (67 ref.)
Dual inhibitors of enkephalin-degrading enzymes (neutral endopeptidase 24.11 and aminopeptidase N) as potential new medications in the management of pain and opioid addiction. Roques BP, et al. **NIDA Res Monogr** 1995; 147:104–45 (149 ref.)
[Clinical use of naltrexone] Manzanares J. **Rev Med Univ Navarra** 1995 Apr-Jun;40(2):78–84 (22 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

Shaking out the cause of addiction [comment] Hyman SE. **Science** 1996 Aug 2;273(5275):611–2 (5 ref.) Comment on: Science 1996 Aug 2;273(5275):657–9.

PHYSIOPATHOLOGY

In vivo analysis of the role of dopamine in stimulant and opiate self-administration. Gratton A. **J Psychiatry Neurosci** 1996 Jul;21(4):264–79 (120 ref.)

PSYCHOLOGY

Drugs that modify opioid tolerance, physical dependence, and abstinence symptoms: preclinical and clinical studies. Bhargava HN. **NIDA Res Monogr** 1995;147:53–83 (127 ref.)

REHABILITATION

Dealing with drug misuse. Gabbay MB. **J R Soc Health** 1995 Dec;115(6):391–4 (14 ref.)

THERAPY

[Progress in the treatment of opiate dependence] Wu LZ, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Sep;15(9):569–73 (38 ref.) **(Chi)**

NARCOTIC LAWS see **LEGISLATION, DRUG**

NARCOTIC RECEPTORS see **RECEPTORS, OPIOID**

NARCOTICS

see related
ANALGESICS, OPIOID
COCAINE
NARCOTIC DEPENDENCE
RECEPTORS, OPIOID

Optimal intravenous dosing strategies for sedatives and analgesics in the intensive care unit. Barr J, et al. **Crit Care Clin** 1995 Oct;11(4):827–47 (64 ref.)
Opioids and benzodiazepines. Murray MJ, et al. **Crit Care Clin** 1995 Oct;11(4):849–73 (91 ref.)
Species-, gender-, and pregnancy-related differences in the pharmacokinetics and pharmacodynamics of cocaine. Morishima HO, et al. **NIDA Res Monogr** 1995;158:2–21 (52 ref.)

ADMINISTRATION & DOSAGE

Side effects of intrathecal and epidural opioids. Chaney MA. **Can J Anaesth** 1995 Oct;42(10):891–903 (187 ref.)
Intrathecal narcotics: new approach for labor analgesia. Manning J. **J Obstet Gynecol Neonatal Nurs** 1996 Mar–Apr; 25(3):221–4 (9 ref.)
Shaking out the cause of addiction [comment] Hyman SE. **Science** 1996 Aug 2;273(5275):611–2 (5 ref.) Comment on: Science 1996 Aug 2;273(5275):657–9.

ADVERSE EFFECTS

Side effects of intrathecal and epidural opioids. Chaney MA. **Can J Anaesth** 1995 Oct;42(10):891–903 (187 ref.)
The effects of NMDA receptor antagonists and nitric oxide synthase inhibitors on opioid tolerance and withdrawal. Medication development issues for opiate addiction. Herman BH, et al. **Neuropsychopharmacology** 1995 Dec; 13(4):269–93 (165 ref.)
Perspectives on the N-methyl-D-aspartate/nitric oxide cascade and opioid tolerance. Pasternak GW, et al. **Neuropsychopharmacology** 1995 Dec;13(4):309–13 (24 ref.)
The role of the locus coeruleus and N-methyl-D-aspartic acid (NMDA) and AMPA receptors in opiate withdrawal. Rasmussen K. **Neuropsychopharmacology** 1995 Dec; 13(4):295–300 (165 ref.)
Effects of noncompetitive N-methyl-D-aspartate receptor antagonists on opiate tolerance and physical dependence. Trujillo KA. **Neuropsychopharmacology** 1995 Dec; 13(4):301–7 (38 ref.)
Nitric oxide synthase inhibitors. Preclinical studies of potential use for treatment of opioid withdrawal. Vaupel DB, et al. **Neuropsychopharmacology** 1995 Dec; 13(4):315–22 (27 ref.)
Treatment options for drug-exposed infants. Kandall SR. **NIDA Res Monogr** 1995;149:78–99 (37 ref.)
Overview of the effects of abuse and drugs on pregnancy and offspring. Zuckerman B, et al. **NIDA Res Monogr** 1995; 149:16–38 (89 ref.)

PHARMACOLOGY

Opioid mechanisms controlling renal function. Kapusta DR. **Clin Exp Pharmacol Physiol** 1995 Dec;22(12):891–902 (95 ref.)
Opioid and anti-opioid peptides. Cesselin F. **Fundam Clin Pharmacol** 1995;9(5):409–33 (316 ref.)
Exogenous and endogenous opioids as biological response modifiers. Carr DJJ, et al. **Immunopharmacology** 1995 Nov; 31(1):59–71 (118 ref.)
Spinal opioid systems in inflammation. Stanfa L, et al. **Inflamm Res** 1995 Jun;44(6):231–41 (119 ref.)
Under siege: The brain on opiates. Nestler EJ. **Neuron** 1996 May;16(5):897–900 (26 ref.)
Prenatal cocaine produces biochemical and functional changes in brain serotonin systems in rat progeny. Battaglia G, et al. **NIDA Res Monogr** 1995;158:115–48 (56 ref.)
Drugs that modify opioid tolerance, physical dependence, and abstinence symptoms: preclinical and clinical studies. Bhargava HN. **NIDA Res Monogr** 1995;147:53–83 (127 ref.)
Effects of cocaine on fetal brain metabolism and behavioral state in the sheep model. Burchfield DJ. **NIDA Res Monogr** 1995;158:58–66 (30 ref.)
Neurobehavioral pharmacology of cocaine: role for serotonin in its locomotor and discriminative stimulus effects. Cunningham KA, et al. **NIDA Res Monogr** 1994;145:40–66 (95 ref.)
Dopamine, a common substrate for the rewarding effects of brain stimulation reward, cocaine, and morphine. Kornetsky C, et al. **NIDA Res Monogr** 1994;145:19–39 (66 ref.)
Action of opioid drugs on the brain-reward system. Kornetsky C. **NIDA Res Monogr** 1995;147:33–52 (47 ref.)
Effects of morphine and cocaine on breathing control in neonatal animals: a minireview. Olsen GD, et al. **NIDA Res Monogr** 1995;158:22–39 (106 ref.)
Nitric oxide and opioid tolerance. Pasternak GW. **NIDA Res Monogr** 1995;147:182–94 (49 ref.)
A review of the effects of dopaminergic agents in humans: implications for medication development. Rothman RB. **NIDA Res Monogr** 1994;145:67–87 (73 ref.)
Fetal cerebral vascular effects of cocaine exposure. Schreiber MD. **NIDA Res Monogr** 1995;158:67–87 (50 ref.)
Effects of prenatal morphine and cocaine on postnatal behaviors and brain neurotransmitters. Vathy I. **NIDA Res Monogr** 1995;158:88–114 (118 ref.)
Drug discrimination: no evidence for tolerance to opiates. Colpaert FC. **Pharmacol Rev** 1995 Dec;47(4):605–29 (133 ref.)

THERAPEUTIC USE

Opioids and pain. Kanjhan R. **Clin Exp Pharmacol Physiol** 1995 Jun–Jul;22(6–7):397–403 (72 ref.)
Effective pain management in terminal care. Dahl JL. **Clin Geriatr Med** 1996 May;12(2):279–300 (92 ref.)
Pharmacology of neuropathic pain. Ollat H, et al. **Clin Neuropharmacol** 1995 Oct;18(5):391–404 (62 ref.)
Recent developments in analgesia during labour. Kan RE, et al. **Drugs** 1995 Sep;50(3):417–22 (41 ref.)
Opioid use in HIV patients with neurological changes. Paice JA, et al. **J Assoc Nurses AIDS Care** 1995 Jul–Aug; 6(4):28–36 (27 ref.)
Levo-alpha-acetylmethadol (LAAM): clinical, research, and policy issues of a new pharmacotherapy for opioid addiction. Prendergast ML, et al. **J Psychoactive Drugs** 1995 Jul–Sep;27(3):239–47 (57 ref.)

NASAL BONE

see related
RHINOPLASTY

NASAL CAVITY

Solitary infantile and adult myofibromatosis of the nasal cavity: a report of two cases. Walsh RM, et al. **J Laryngol Otol** 1996 Jun;110(6):574–7 (15 ref.)

Mixed intranasal infection caused by Fusarium solani and a zygomycete in a leukaemic patient. Lopes JO, et al. **Mycoses** 1995 Jul–Aug;38(7–8):281–4 (26 ref.)

Central nervous system metastases from esthesioneuroblastoma. Shaari CM, et al. **Otolaryngol Head Neck Surg** 1996 Jun;114(6):808–12 (20 ref.)

PHYSIOLOGY

Rhinomanometric study in China. Li X, et al. **Chin Med J (Engl)** 1995 Jul;108(7):557–60 (15 ref.)

SURGERY

Treatment of olfactory neuroblastoma. A report of 11 cases. Jekunen AP, et al. **Am J Clin Oncol** 1996 Aug;19(4):375–8 (21 ref.)

Tension pneumocephalus following craniofacial resection. Wanamaker JR, et al. **Head Neck** 1995 Mar–Apr; 17(2):152–6 (22 ref.)

VIROLOGY

Spread of MHV-JHM from nasal cavity to white matter of spinal cord. Transneuronal movement and involvement of astrocytes. Perlman S, et al. **Adv Exp Med Biol** 1995; 380:73–8 (21 ref.)

NASAL DECONGESTANTS

ADVERSE EFFECTS

Rhinitis medicamentosa [editorial] Scadding GK. **Clin Exp Allergy** 1995 May;25(5):391–4 (37 ref.)

[Daily administration of nose drops can cause chronic nasal congestion] Graf P, et al. **Lakartidningen** 1996 Jan 24; 93(4):259–62 (17 ref.) **(Swe)**

POISONING

[Digital necrosis associated with fenoxazoline poisoning. Apropos of a case and review of the literature] Hauet T, et al. **Rev Med Interne** 1996;17(1):66–9 (19 ref.) (Eng. Abstr.) **(Fre)**

THERAPEUTIC USE

A rationale for the selection of nasal decongestants in lacrimal drainage surgery. Hosal BM, et al. **Ophthal Plast Reconstr Surg** 1995 Sep;11(3):215–20 (29 ref.)

NASAL MUCOSA

[Nasal localization of a cicatricial pemphigoid: apropos of a case] Stoll D, et al. **Rev Laryngol Otol Rhinol (Bord)** 1995;116(5):341–5 (13 ref.) (Eng. Abstr.) **(Fre)**

BLOOD SUPPLY

The role of the autonomic nerves in the control of nasal circulation. Lung MA. **Biol Signals** 1995 May–Jun; 4(3):179–85 (33 ref.)

CYTOLOGY

The kinetics of the cytologic and rhinomanometric changes in the nose after challenge with allergen. Bernheim N, et al. **Acta Otorhinolaryngol Belg** 1995;49(3):229–33 (20 ref.)

PATHOLOGY

Nasal polyps—a model of chronic respiratory mucosal inflammation [editorial] Djukanović R. **Clin Exp Allergy** 1995 Jul;25(7):582–5 (35 ref.)

PHYSIOLOGY

A role for the nasal cycle in respiratory defence. Eccles R. **Eur Respir J** 1996 Feb;9(2):371–6 (58 ref.)

[Neuropeptides and nasal mucosa: a general review and update] Duroux S, et al. **Rev Laryngol Otol Rhinol (Bord)** 1996;117(1):3–7 (38 ref.) (Eng. Abstr.) **(Fre)**

SECRETION

Neurokinin receptors subserving airways secretion. Rogers DF. **Can J Physiol Pharmacol** 1995 Jul;73(7):932–9 (80 ref.)

NASAL OBSTRUCTION

COMPLICATIONS

Respiratory distress in the neonate. Sequela of a congenital dacryocystocele. Hepler KM, et al. **Arch Otolaryngol Head Neck Surg** 1995 Dec;121(12):1423–5 (16 ref.)

[Trigemino-vegetative physiopathology in the central dysnociceptive biorhythms in primary headache] Passàli D, et al. **Ital J Neurol Sci** 1995 Nov;16(8 Suppl):41–5 (14 ref.) (Eng. Abstr.) **(Ita)**

DIAGNOSIS

[Rhinomanometry] Ghaem A. **Rev Mal Respir** 1996; 13(2):191–2 (8 ref.) **(Fre)**

ETIOLOGY

Intranasal tooth in a patient with a cleft lip and alveolus. Yeung KH, et al. **Cleft Palate Craniofac J** 1996 Mar; 33(2):157–9 (30 ref.)

[Nasal localization of a cicatricial pemphigoid: apropos of a case] Stoll D, et al. **Rev Laryngol Otol Rhinol (Bord)** 1995;116(5):341–5 (13 ref.) (Eng. Abstr.) **(Fre)**

NASAL POLYPS

Diagnosis and treatment of nasal polyps. Lund VJ. **BMJ** 1995 Nov 25;311(7017):1411–4 (22 ref.)

COMPLICATIONS

[Frontal cerebral abscess, a rare complication of nasosinusal polyposis. Apropos of a case] Abgrall S, et al. **Neurochirurgie** 1995;41(5):367–71 (13 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Management of nasal polyps: is objective assessment possible? Lund VJ. **Acta Otorhinolaryngol Belg** 1995;49(3):219–24 (20 ref.)

[Churg–Strauss syndrome. A differential diagnosis in chronic polypoid sinusitis] Trittel C, et al. **Laryngorhinootologie** 1995 Sep;74(9):577–80 (23 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Cystic fibrosis and the sinonasal tract. Batsakis JG, et al. **Ann Otol Rhinol Laryngol** 1996 Apr;105(4):329–30 (9 ref.)

Role of allergy in nasal polyposis: a review. Bernstein JM, et al. **Otolaryngol Head Neck Surg** 1995 Dec;113(6):724–32 (30 ref.)

GENETICS

Multiple polysomies in nasal polyps in children. Speleman F, et al. **Cancer Genet Cytogenet** 1996 Aug;90(1):86–7 (13 ref.)

PATHOLOGY

Nasal polyps—a model of chronic respiratory mucosal inflammation [editorial] Djukanović R. **Clin Exp Allergy** 1995 Jul;25(7):582–5 (35 ref.)

SURGERY

[Endonasal ethmoidectomy in naso-sinusal polyposis. Results in 110 surgically treated patients] Simon D, et al. **Ann Otolaryngol Chir Cervicofac** 1995;112(8):359–66 (35 ref.) (Eng. Abstr.) **(Fre)**

NASAL PROVOCATION TESTS

[Nasal provocation tests] Mastalerz L, et al. **Pneumonol Alergol Pol** 1996;64(3–4):229–34 (33 ref.) **(Pol)**

NASAL SEPTUM

ANATOMY & HISTOLOGY

[The vomeronasal organ—a rediscovered sensory organ] Trotier D, et al. **Tidsskr Nor Laegeforen** 1996 Jan 10; 116(1):47–51 (35 ref.) (Eng. Abstr.) **(Nor)**

PATHOLOGY

Pathology in focus. Spindle-cell carcinoma of the nasal septum. Ahluwalia H, et al. **J Laryngol Otol** 1996 Mar; 110(3):284–7 (26 ref.)

Leiomyoma of the nasal septum: report of a case and review of the literature. Llorente JL, et al. **J Laryngol Otol** 1996 Jan;110(1):65–8 (18 ref.)

SURGERY

[Decompressive neurovascular nose and skull-base surgery in primary headache with a rhinogenic trigger] Bonaccorsi P. **Ital J Neurol Sci** 1995 Nov;16(8 Suppl):69–100 (104 ref.) (Eng. Abstr.) **(Ita)**

NASAL SINUSES see **PARANASAL SINUSES**

NASOLACRIMAL DUCT

DRUG EFFECTS

Punctal and canalicular stenosis associated with systemic fluorouracil therapy. Report of five cases and review of the literature. Brink HM, et al. **Doc Ophthalmol** 1995; 90(1):1–6 (23 ref.)

NASOPHARYNGEAL NEOPLASMS

CONGENITAL

Perinatal management of nasopharyngeal teratoma. Marras T, et al. **J Otolaryngol** 1995 Oct;24(5):310–2 (10 ref.)

DIAGNOSIS

Molecular diagnosis of nasopharyngeal carcinoma: a review. Gan YY, et al. **Ann Acad Med Singapore** 1996 Jan; 25(1):71–4 (32 ref.)

Base of skull, nasopharynx, and parapharyngeal space. Vogl TJ, et al. **Neuroimaging Clin N Am** 1996 May;6(2):357–78 (25 ref.)

EPIDEMIOLOGY

[Screening of undifferentiated carcinoma of the nasopharynx] Sasco AJ. **Bull Cancer (Paris)** 1996 May;83(5):344–51 (70 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Recent advances in the study of the pathogenesis of nasopharyngeal carcinoma (NPC). Yao K. **Chin Med J (Engl)** 1995 Aug;108(8):566–8 (4 ref.)

IMMUNOLOGY

[Value of anti-Epstein-Barr antibody detection in the diagnosis and management of undifferentiated carcinoma of the nasopharynx] Mazeron MC. **Bull Cancer Radiother** 1996;83(1):3–7 (29 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Nasopharyngeal lipoma—a rare clinico-pathological entity. Fagan JJ, et al. **J Laryngol Otol** 1996 Mar;110(3):275–6 (12 ref.)

RADIOGRAPHY

Pneumocephalus due to nasopharyngeal carcinoma: case report. Kiu MC, et al. **Neuroradiology** 1996 Jan;38(1):70–2 (24 ref.)

RADIOTHERAPY

Effects of cranial irradiation on hearing acuity: a review of the literature. Sataloff RT, et al. **Am J Otol** 1994 Nov; 15(6):772–80 (28 ref.)

[ORL brachytherapy. Salvage brachytherapy in ORL cancers (oral cavity, oropharynx, nasopharynx)] Ardiet JM, et al. **Bull Cancer Radiother** 1995;82(2):199–202 (27 ref.) **(Fre)**

THERAPY

Perinatal management of nasopharyngeal teratoma. Marras T, et al. **J Otolaryngol** 1995 Oct;24(5):310–2 (10 ref.)

Retropharyngeal abscess after radiation therapy and cis-platinum, 5-fluorouracil treatment for nasopharyngeal carcinoma with collagen disease: report of two patients and a review of the literature. Hareyama M, et al. **Jpn J Clin Oncol** 1996 Jun;26(3):189–93 (15 ref.)

VIROLOGY

Viruses in human tumors—reminiscences and perspectives. zur Hausen H. **Adv Cancer Res** 1996;68:1–22 (119 ref.)

Role of Epstein-Barr virus gene latent membrane protein in nasopharyngeal carcinoma. Nicholson LJ, et al. **Trends Microbiol** 1996 Apr;4(4):132–3 (21 ref.)

NASOPHARYNX

PATHOLOGY

Effects of cranial irradiation on hearing acuity: a review of the literature. Sataloff RT, et al. **Am J Otol** 1994 Nov; 15(6):772–80 (28 ref.)

NATIONAL COUNCIL ON HEALTH PLANNING AND DEVELOPMENT see **HEALTH PLANNING COUNCILS**

NATIONAL FORMULARY see **PHARMACOPOEIAS**

NATIONAL HEALTH INSURANCE, NON-U.S. see **NATIONAL HEALTH PROGRAMS**

NATIONAL HEALTH PLANNING AND RESOURCES DEVELOPMENT ACT OF 1974 see **HEALTH PLANNING**

NATIONAL HEALTH POLICY see **HEALTH POLICY**

NATIONAL HEALTH PROGRAMS

Universal health care and high-tech medicine. Chiu RC. **J Formos Med Assoc** 1995 Jun;94(6):293–7; discussion 298–9 (11 ref.)

Childhood diarrhea and malnutrition in Pakistan, Part III: Social policy issues. David S, et al. **J Pediatr Nurs** 1995 Aug;10(4):273–8 (35 ref.)

[Background and prospects of the Community Health Act] Aoyama H. **Nippon Eiseigaku Zasshi** 1996 Feb;

50(6):1026–35 (14 ref.) (Eng. Abstr.) **(Jpn)**

ECONOMICS

Re-minding our Ps and Qs: medical cost controls in Canada. Barer ML, et al. **Health Aff (Millwood)** 1996 Summer; 15(2):216–34 (34 ref.)

LEGISLATION & JURISPRUDENCE

Conflicts of interest in Canadian health care law. Dickens BM. **Am J Law Med** 1995;21(2–3):259–80 (152 ref.)

ORGANIZATION & ADMINISTRATION

Cervical cancer screening: are the 1989 recommendations still valid? National Workshop on Screening for Cancer of the Cervix [see comments] Parboosingh EJ, et al. **Can Med Assoc J** 1996 Jun 15;154(12):1847–53 (18 ref.) Comment in: Can Med Assoc J 1996 Jun 15;154(12):1867–9.

NATIONAL HEALTH SERVICE CORPS see **MEDICALLY UNDERSERVED AREA**

NATIONAL HEALTH SERVICE, BRITISH see **STATE MEDICINE**

NATIONAL INSTITUTES OF HEALTH (U.S.)

Taking a bite out of CRISP. Strategies on using and conducting searches in the Computer Retrieval of Information on Scientific Projects database. Bair AH, et al. **Comput Nurs** 1996 Jul–Aug;14(4):218–24; quiz 225–6 (10 ref.)

The Weight-Control Information Network: a project of the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health. **Nutr Rev** 1995 Aug;53(8):232–3 (0 ref.)

The stress response—a radiation study section workshop. **Radiat Res** 1996 Jan;145(1):107–17 (97 ref.)

NIEHS perspectives on collaboration among government, academia, and industry. Olden K. **Toxicol Lett** 1995 Sep; 79(1–3):287–9 (0 ref.)

Use of mechanistic and pharmacokinetic data for risk assessment at the National Institute of Environmental Health Sciences (NIEHS). Schwetz BA. **Toxicol Lett** 1995 Sep;79(1–3):29–32 (0 ref.)

NATIONALITY see **ETHNIC GROUPS**

NATIVE AMERICANS see **INDIANS, NORTH AMERICAN**

NATRIURESIS

1994 Homer W. Smith Award. From flies to physiology—accidental findings along the trail of renal NaCl transport. Aronson PS. **J Am Soc Nephrol** 1995 Jun; 5(12):2001–13 (104 ref.)

PHYSIOLOGY

Salt and water homeostasis: uroguanylin is a circulating peptide hormone with natriuretic activity. Forte LR, et al. **Am J Kidney Dis** 1996 Aug;28(2):296–304 (35 ref.)

Pressure natriuresis and long-term blood pressure control. Anderson WP, et al. **J Cardiovasc Pharmacol** 1995;26 Suppl 2:S17–23 (44 ref.)

NATRIURETIC FACTOR see **NATRIURETIC HORMONE**

NATRIURETIC HORMONE

PHARMACOLOGY

Natriuretic hormones II. Benaksas EJ, et al. **Prog Drug Res** 1995;45:245–88 (109 ref.)

PHYSIOLOGY

Natriuretic hormones. Espiner EA, et al. **Endocrinol Metab Clin North Am** 1995 Sep;24(3):481–509 (126 ref.)

NATRIURETIC PEPTIDES, ATRIAL see **ATRIAL NATRIURETIC FACTOR**

NATURAL DISASTERS

Infectious disease emergencies in disasters. Howard MJ, et al. **Emerg Med Clin North Am** 1996 May;14(2):413–28 (87 ref.)

A medical disaster response to reduce immediate mortality after an earthquake [see comments] Schultz CH, et al. **N Engl J Med** 1996 Feb 15;334(7):438–44 (53 ref.) Comment in: N Engl J Med 1996 Jun 27;334(26):1746; discussion 1747. Comment in: N Engl J Med 1996 Jun 27;334(26):1746–7.

NATURAL KILLER CELL STIMULATORY FACTOR see **INTERLEUKIN-12**

NATURAL KILLER CELLS see **KILLER CELLS, NATURAL**

NATURAL RESOURCES see **CONSERVATION OF NATURAL RESOURCES**

NATURAL SELECTION see **SELECTION (GENETICS)**

NAUSEA

see related
ANTIEMETICS

Nausea, vomiting, and retching: the management of the symptom experience. Rhodes VA, et al. **Semin Oncol Nurs** 1995 Nov;11(4):256–65 (32 ref.)

CHEMICALLY INDUCED

Mechanisms and management of nausea and emesis [editorial] Dicato M. **Oncology** 1996 Jun;53 Suppl 1:1–3 (16 ref.)

Management of other non-cisplatin-induced emesis. Schmoll HJ, et al. **Oncology** 1996 Jun;53 Suppl 1:51–5 (24 ref.)

DIAGNOSIS

[A diabetic woman with a picture of temporospatial disorientation, nausea and vomiting] Urbano García J, et al. **Rev Clin Esp** 1996 May;196(5):333–4, 338 (6 ref.) **(Spa)**

DRUG THERAPY

Progress in reducing nausea and emesis. Comparisons of ondansetron (Zofran), granisetron (Kytril), and tropisetron (Navoban). Morrow GR, et al. **Cancer** 1995 Aug 1; 76(3):343–57 (121 ref.)

Ondansetron. Thavaraj V, et al. **Indian Pediatr** 1995 Aug; 32(8):898–901 (12 ref.)

Management of acute emesis. Singhal S, et al. **J Assoc Physicians India** 1995 Aug;43(8):560–2 (6 ref.)

Economic impact of antiemesis. Grunberg SM. **Oncology (Huntingt)** 1995 Nov;9(11 Suppl):155–60 (16 ref.)

[Prevention and treatment of postoperative nausea and vomiting with 5-HT3-receptor blockers] Alon E, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May; 31(4):200–4 (47 ref.) (Eng. Abstr.) **(Ger)**

NURSING

Management of nausea and vomiting in children. Keller VE. **J Pediatr Nurs** 1995 Oct;10(5):280–6 (30 ref.)

PREVENTION & CONTROL

Mechanisms and management of nausea and emesis [editorial] Dicato M. **Oncology** 1996 Jun;53 Suppl 1:1–3 (16 ref.)

Management of other non-cisplatin-induced emesis. Schmoll HJ, et al. **Oncology** 1996 Jun;53 Suppl 1:51–5 (24 ref.)

Preventing chemotherapy-induced nausea and vomiting: an update and a review of emesis. Ettinger DS. **Semin Oncol** 1995 Aug;22(4 Suppl 10):6–18 (109 ref.)

[Efficacy of ondansetron in acute and delayed cisplatin-induced nausea and vomiting] Depierre A. **Bull Cancer (Paris)** 1996 Feb;83(2):147–53 (29 ref.) (Eng. Abstr.) **(Fre)**

[Optimal control by ondansetron of acute and prolonged emesis induced by chemotherapy without cisplatin] Harousseau JL. **Bull Cancer (Paris)** 1996 Jan;83(1):71–76 (27 ref.) (Eng. Abstr.) **(Fre)**

PSYCHOLOGY

Models, mechanisms and management of anticipatory nausea and emesis. Morrow GR, et al. **Oncology** 1996 Jun;53 Suppl 1:4–7 (12 ref.)

THERAPY

Can acupuncture have specific effects on health? A systematic review of acupuncture antiemesis trials. Vickers AJ. **J R Soc Med** 1996 Jun;89(6):303–11 (49 ref.)

Models, mechanisms and management of anticipatory nausea and emesis. Morrow GR, et al. **Oncology** 1996 Jun;53 Suppl 1:4–7 (12 ref.)

NAUTICAL MEDICINE see **NAVAL MEDICINE**

NAVAL MEDICINE

see related
DIVING
SHIPS

[Naval medicine] Lu H. **Chung Hua I Hsueh Tsa Chih** 1996 Jan;76(1):73–5 (0 ref.) **(Chi)**

NAVAL SCIENCE see **MILITARY SCIENCE**

NCAM

[Morphological analysis of NCAM-180 deficient mouse brain—polysialic acid moiety and neuronal migration] Ono K. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2188–96 (44 ref.) **(Jpn)**

[Telencephalon-specific cell adhesion molecule, telencephalin] Yoshihara Y, et al. **Tanpakushitsu Kakusan Koso** 1996 May;41(6):766–74 (36 ref.) **(Jpn)**

GENETICS

The deleted in colorectal cancer (DCC) gene: a candidate tumour suppressor gene encoding a cell surface protein with similarity to neural cell adhesion molecules. Fearon ER, et al. **Cancer Surv** 1995;24:3–17 (58 ref.)

CRASH syndrome: clinical spectrum of corpus callosum hypoplasia, retardation, adducted thumbs, spastic paraparesis and hydrocephalus due to mutations in one single gene, L1. Fransen E, et al. **Eur J Hum Genet** 1995; 3(5):273–84 (49 ref.)

[A family with X-linked hydrocephalus resulting from mutations in the neural cell adhesion molecule L1] Maruta K, et al. **Rinsho Shinkeigaku** 1996 Mar;36(3):462–6 (16 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

The leucocyte protein L1 (calprotectin): a putative nonspecific defence factor at epithelial surfaces. Brandtzaeg P, et al. **Adv Exp Med Biol** 1995;371A:201–6 (30 ref.)

NEAMIN see **NEOMYCIN**

NEAR-DEATH EXPERIENCE see **DEATH**

NEAR DROWNING

THERAPY

Effective interventions for nearly drowned children. Macnab AJ. **Can Fam Physician** 1995 Sep;41:1545–8, 1551–2, 1555–6 (32 ref.)

[History of respiratory intensive care with reference to first aid for nearly-drowned persons] Leveau P. **Ann Fr Anesth Reanim** 1996;15(1):86–100 (57 ref.) (Eng. Abstr.) **(Fre)**

NEAR EAST EQUINE ENCEPHALOMYELITIS VIRUS see **BORNA DISEASE VIRUS**

NEARSIGHTEDNESS see **MYOPIA**

NEBRAMYCIN FACTOR 6 see **TOBRAMYCIN**

NEBULIZERS AND VAPORIZERS

Guidelines for the use of nebulizers in the home and at domiciliary sites. Report of a consensus conference. National Association for Medical Direction of Respiratory Care (NAMDRC) Consensus Group. O'Donohue WJ Jr. **Chest** 1996 Mar;109(3):814–20 (32 ref.)

Bronchodilator delivery with metered-dose inhalers in mechanically-ventilated patients. Dhand R, et al. **Eur Respir J** 1996 Mar;9(3):585–95 (69 ref.)

Intravenous drug delivery systems: toward an intravenous "vaporizer". Egan TD. **J Clin Anesth** 1996 May;8(3 Suppl):8S–14S (38 ref.)

Nebulizers in cystic fibrosis. Hambleton G, et al. **J R Soc Med** 1996;89 Suppl 27:14–8 (4 ref.)

Inhalers and nebulizers: which to choose and why. Pedersen S. **Respir Med** 1996 Feb;90(2):69–77 (65 ref.)

[Asthma therapy with topically active steroids] Matthys H. **Internist (Berl)** 1995 Oct;36(10):1005–9 (21 ref.) **(Ger)**

STANDARDS

Home nebuliser-compressors. Ariyananda PL, et al. **Br J Hosp Med** 1995 Nov 15–Dec 12;54(10):489–93 (22 ref.)

The delivery of aerosolized steroids from MDIs with nozzle extensions: quantitative laboratory evaluation of a method to improve aerosol delivery to intubated patients. Hess D, et al. **Intensive Care Med** 1995 Nov;21(11):945–51 (36 ref.)

NECK

see related
CERVICAL VERTEBRAE

Characteristics of patients successfully treated for cervicogenic headache by surgical decompression of the second cervical root. Pikus HJ, et al. **Headache** 1995 Nov-Dec;35(10):621–9 (39 ref.)

Classification systems of soft tissue disorders of the neck and upper limb: do they satisfy methodological guidelines? Buchbinder R, et al. **J Clin Epidemiol** 1996 Feb;49(2):141–9 (76 ref.)

Diagnostic tests for the evaluation of back and neck pain. Haldeman S. **Neurol Clin** 1996 Feb;14(1):103–17 (52 ref.)

Cervical Radiculopathy. Ahlgren BD, et al. **Orthop Clin North Am** 1996 Apr;27(2):253–63 (30 ref.)

ABNORMALITIES

[Mento-sternal fistulae. Review of the literature. Apropos of 4 cases] Sfeir R, et al. **Ann Chir Plast Esthet** 1995 Apr; 40(2):176–81 (19 ref.) (Eng. Abstr.) **(Fre)**

INJURIES

Thoracic duct injury in penetrating neck trauma. Whiteford MH, et al. **Am Surg** 1995 Dec;61(12):1072–5 (63 ref.)

Carotid artery pseudoaneurysm and pellet embolism to the middle cerebral artery following a shotgun wound of the neck. Cogbill TH, et al. **J Trauma** 1995 Oct;39(4):763–7

NECK

(16 ref.)
Complex problems in penetrating neck trauma. Demetriades D, et al. **Surg Clin North Am** 1996 Aug;76(4):661–83 (96 ref.)

MICROBIOLOGY

Necrotizing fasciitis originating from pinna perichondritis. Skorina J, et al. **Otolaryngol Head Neck Surg** 1995 Oct; 113(4):467–73 (33 ref.)

PATHOLOGY

Molecular alterations in head and neck squamous cell carcinoma. Bron L, et al. **Clin Otolaryngol** 1995 Aug; 20(4):291–8 (86 ref.)

SURGERY

Lasers in otorhinolaryngology-head and neck surgery. Rebeiz EE. **J Med Liban** 1994;42(4):242–9 (21 ref.)
Head and neck reconstruction. Deschler DG, et al. **Neuroimaging Clin N Am** 1996 May;6(2):505–14 (38 ref.)

ULTRASONOGRAPHY

Definite distinction between thyroidal inflammatory conditions and other soft tissue inflammations of the neck using ultrasound. Klima G, et al. **Acta Med Austriaca** 1996; 23(1–2):80–2 (9 ref.)

NECK MUSCLES

[Unclear pathomechanism behind neck-shoulder pain. Problem with insurance claim] Zetterberg C. **Lakartidningen** 1996 Feb 28;93(9):793–6 (68 ref.) **(Swe)**

ABNORMALITIES

The double omohyoid muscle in humans: report of one case and review of the literature. Miura M, et al. **Okajimas Folia Anat Jpn** 1995 Aug;72(2–3):81–97 (37 ref.)

PATHOLOGY

Pseudotumor of infancy and congenital muscular torticollis. Porter SB, et al. **Am Fam Physician** 1995 Nov 1; 52(6):1731–6 (19 ref.)
Focal myositis of the floor of mouth: report of two cases and review of the literature. McCluggage WG, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 May;81(5):573–5 (22 ref.)

NECK NEOPLASMS see **HEAD AND NECK NEOPLASMS**

NECROBACILLOSIS see **FUSOBACTERIUM INFECTIONS**

NECROBIOTIC DISORDERS

DIAGNOSIS

Unusual clinical manifestation of a disfiguring necrobiotic granulomatous disease. Willemsen M, et al. **J Am Acad Dermatol** 1995 Nov;33(5 Pt 2):887–90 (13 ref.)

NECROSIS

see related
TUMOR NECROSIS FACTOR
The Gerhard Zbinden Memorial Lecture. Alteration of cell signalling in chemical toxicity. Nicotera P. **Arch Toxicol Suppl** 1996;18:3–11 (46 ref.)

PATHOLOGY

A toxicologic pathologist's view of apoptosis or I used to call it necrobiosis, but now I'm singing the apoptosis blues [see comments] Levin S. **Toxicol Pathol** 1995 Jul–Aug; 23(4):533–9 (34 ref.) Comment in: Toxicol Pathol 1995 Sep–Oct;23(5):617–21.

SURGERY

[Management of pancreatic necrosis] Csáky G, et al. **Orv Hetil** 1995 Sep 24;136(39):2105–11 (50 ref.) (Eng. Abstr.) **(Hun)**

NECROSIS, ASEPTIC, OF BONE see **OSTEONECROSIS**

NECROSIS, AVASCULAR, OF BONE see **OSTEONECROSIS**

NECROTIZING ARTERITIS see **POLYARTERITIS NODOSA**

NECROTIZING SCLERITIS see **SCLERITIS**

NECROTIZING SIALOMETAPLASIA see **SIALOMETAPLASIA, NECROTIZING**

NEDOCROMIL

PHARMACOLOGY

Clinical implications of the pharmacological profile of Tilarin. Davies RJ. **Allergy** 1996;51(28 Suppl):8–13 (26 ref.)

THERAPEUTIC USE

Asthma mechanisms, determinants of severity and treatment: the role of nedocromil sodium. Report of a workshop held in Whistler, British Columbia, Canada, 18–19 May 1995. Barnes PJ, et al. **Clin Exp Allergy** 1995 Aug;25(8):771–87 (146 ref.)
The efficacy and therapeutic position of nedocromil sodium. Holgate ST. **Respir Med** 1996 Aug;90(7):391–4 (32 ref.)

NEEDLE-EXCHANGE PROGRAMS

ECONOMICS

Economic analysis of needle exchange [editorial] Kaplan EH. **AIDS** 1995 Oct;9(10):1113–9 (20 ref.)

LEGISLATION & JURISPRUDENCE

The legal strategies used in operating syringe exchange programs in the United States [see comments] Burris S, et al. **Am J Public Health** 1996 Aug;86(8 Pt 1):1161–6 (57 ref.) Comment in: Am J Public Health 1996 Aug;86(8 Pt 1):1077–8.
Regulating controversial programs for unpopular people: methadone maintenance and syringe exchange programs [see comments] Des Jarlais DC, et al. **Am J Public Health** 1995 Nov;85(11):1577–84 (39 ref.) Comment in: Am J Public Health 1995 Nov;85(11):1490–1.

TRENDS

Syringe exchange: HIV prevention, key findings, and future directions. Paone D, et al. **Int J Addict** 1995;30(12):1647–83 (320 ref.)

NEEDLE SHARING

see related
NEEDLE-EXCHANGE PROGRAMS

STATISTICS & NUMERICAL DATA

Syringe-mediated drug sharing among injecting drug users: patterns, social context and implications for transmission of blood-borne pathogens. Grund JP, et al. **Soc Sci Med** 1996 Mar;42(5):691–703 (89 ref.)

NEEDLES

Needle arthroscopy: a new frontier in rheumatology. Panchal P, et al. **Compr Ther** 1996 Jan;22(1):44–7 (14 ref.)

NEEDLESTICK INJURIES

EPIDEMIOLOGY

Epidemiology of injuries by needles and other sharp instruments. Minimizing sharp injuries in gynecologic and obstetric operations. Lewis FR Jr, et al. **Surg Clin North Am** 1995 Dec;75(6):1105–21 (34 ref.)

PREVENTION & CONTROL

Injury prevention in anesthesiology. Berry AJ. **Surg Clin North Am** 1995 Dec;75(6):1123–32 (21 ref.)

NEFA see **FATTY ACIDS, NONESTERIFIED**

NEGATIVE REINFORCEMENT see **REINFORCEMENT (PSYCHOLOGY)**

NEGATRONS see **ELECTRONS**

NEGLIGENCE, PROFESSIONAL see **MALPRACTICE**

NEGOTIATING

Alternative dispute resolution for medical malpractice actions: an efficient approach to the law and health care. White WF. **Leg Med** 1995;:227–39 (47 ref.)

PSYCHOLOGY

Gender-power relations and safer sex negotiation. Taylor BM. **J Adv Nurs** 1995 Oct;22(4):687–93 (46 ref.)

NEGROES see **BLACKS**

NEGROID RACE

see related
BLACKS
Epidemiology of hypertension in African American women. Gillum RF. **Am Heart J** 1996 Feb;131(2):385–95 (72 ref.)
Hypertension in minorities: blacks. Saunders E. **Am J Hypertens** 1995 Dec;8(12 Pt 2):115s–119s (19 ref.)
Racial differences in the pathogenesis of hypertension. Calhoun DA, et al. **Am J Med Sci** 1995 Dec;310 Suppl 1:S86–90 (29 ref.)
Racial differences in health: not just black and white, but shades of gray. Lillie-Blanton M, et al. **Annu Rev Public Health** 1996;17:411–48 (52 ref.)
Immunization among African American children: implications for social work. Copeland VC. **Health Soc Work** 1996 May;21(2):105–14 (70 ref.)
Role of dietary salt in hypertension. Haddy FJ, et al. **J Am Coll Nutr** 1995 Oct;14(5):428–38 (147 ref.)
Controversy in the pharmacologic treatment of hypertension in African Americans [see comments] Lockette W. **J Assoc Acad Minor Phys** 1995;6(4):125–9 (32 ref.) Comment in: J Assoc Acad Minor Phys 1995;6(4):124.
Racial disparities in preterm births. The role of urogenital infections [see comments] Fiscella K. **Public Health Rep** 1996 Mar–Apr;111(2):104–13 (15 ref.) Comment in: Public Health Rep 1996 Mar–Apr;111(2):114–5.
Possible mediators in hypertension: renal factors. Bergman SM, et al. **Semin Nephrol** 1996 Mar;16(2):134–9 (36 ref.)
The role of cardiovascular reactivity as a mediator of hypertension in African Americans. Falkner B. **Semin Nephrol** 1996 Mar;16(2):117–25 (52 ref.)
Epidemiology of hypertension in African Americans. Lackland DT, et al. **Semin Nephrol** 1996 Mar;16(2):63–70 (51 ref.)
Renovasculopathies of hypertension and the rise of blood pressure with age in blacks and whites. Tracy RE. **Semin Nephrol** 1996 Mar;16(2):126–33 (21 ref.)
Hypertension in African Americans: the role of sodium chloride and extracellular fluid volume. Weinberger MH. **Semin Nephrol** 1996 Mar;16(2):110–6 (49 ref.)
Hypertension in African Americans: a paradigm of metabolic disarray. Weir MR, et al. **Semin Nephrol** 1996 Mar; 16(2):102–9 (78 ref.)
[Disseminated Histoplasma capsulatum histoplasmosis in African AIDS patients (3 cases)] Imbert P, et al. **Med Trop (Mars)** 1995;55(2):151–3 (12 ref.) (Eng. Abstr.) **(Fre)**
[Vascularization of the sinus node in the Black African] Yangni-Angate H, et al. **West Afr J Med** 1995 Jul–Sep; 14(3):181–3 (6 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Hereditary iron overload and African Americans [editorial; comment] Baer D. **Am J Med** 1996 Jul;101(1):5–8 (46 ref.) Comment on: Am J Med 1996 Jul;101(1):9–18.
HLA-B27 and its subtypes in world populations [editorial] Khan MA. **Curr Opin Rheumatol** 1995 Jul;7(4):263–9 (94 ref.)
Does keloid pathogenesis hold the key to understanding black/white differences in hypertension severity? [clinical conference] Dustan HP. **Hypertension** 1995 Dec;26(6 Pt 1):858–62 (40 ref.)
Blood pressure variation in blacks: genetic factors. Grim CE, et al. **Semin Nephrol** 1996 Mar;16(2):83–93 (49 ref.)

NEISSERIA

Nonfebrile mitral valve endocarditis due to Neisseria subflava. Amsel BJ, et al. **Chest** 1996 Jan;109(1):280–2 (16 ref.)

ENZYMOLOGY

Antigenic and genetic heterogeneity among Haemophilus influenzae and Neisseria IgA1 proteases. Lomholt H, et al. **Adv Exp Med Biol** 1995;371A:599–603 (18 ref.)

IMMUNOLOGY

Molecular mechanisms and implications for infection of lipopolysaccharide variation in Neisseria. van Putten JP, et al. **Mol Microbiol** 1995 Jun;16(5):847–53 (53 ref.)

METABOLISM

Iron acquisition in the pathogenic Neisseria. Genco CA, et al. **Trends Microbiol** 1996 May;4(5):179–84 (47 ref.)

PATHOGENICITY

Molecular mechanisms and implications for infection of lipopolysaccharide variation in Neisseria. van Putten JP, et al. **Mol Microbiol** 1995 Jun;16(5):847–53 (53 ref.)
Bacterial transferrin and lactoferrin receptors. Gray-Owen SD, et al. **Trends Microbiol** 1996 May;4(5):185–91 (49 ref.)

NEISSERIA GONORRHOEAE

CLASSIFICATION

Uses and limitations of gonococcal serotyping [editorial] Ross JD. **Int J STD AIDS** 1996 Jan–Feb;7(1):14–8 (68 ref.)

PATHOGENICITY

Interaction of pathogenic neisseriae with nonphagocytic cells. Nassif X, et al. **Clin Microbiol Rev** 1995 Jul; 8(3):376–88 (148 ref.)

NEISSERIA MENINGITIDIS

Neisseria meningitidis peritonitis in a CAPD patient: first case report and review of the literature. Kleinpeter MA, et al. **Adv Perit Dial** 1995;11:168–71 (14 ref.)

IMMUNOLOGY

Transferrin receptors of Neisseria meningitidis: promising candidates for a broadly cross-protective vaccine.

Ala'Aldeen DA. **J Med Microbiol** 1996 Apr;44(4):237–43 (40 ref.)

ISOLATION & PURIFICATION

[Partial properdin deficiency revealed by a septicemia caused by Neisseria meningitidis] Frémeaux-Bacchi V, et al. **Presse Med** 1995 Sep 30;24(28):1305–7 (14 ref.) (Eng. Abstr.) **(Fre)**

PATHOGENICITY

Interaction of pathogenic neisseriae with nonphagocytic cells. Nassif X, et al. **Clin Microbiol Rev** 1995 Jul; 8(3):376–88 (148 ref.)

NEISSERIACEAE INFECTIONS

Branhamella catarrhalis: epidemiology, surface antigenic structure, and immune response. Murphy TF. **Microbiol Rev** 1996 Jun;60(2):267–79 (186 ref.)

[Neisseria mucosa endocarditis: apropos of a case and review of the literature (letter)] Lechowski L, et al. **Ann Med Interne (Paris)** 1995;146(8):592–3 (17 ref.) **(Fre)**

COMPLICATIONS

Spectrum and significance of bacteremia due to Moraxella catarrhalis. Ioannidis JP, et al. **Clin Infect Dis** 1995 Aug; 21(2):390–7 (45 ref.)

DIAGNOSIS

Nonfebrile mitral valve endocarditis due to Neisseria subflava. Amsel BJ, et al. **Chest** 1996 Jan;109(1):280–2 (16 ref.)

DRUG THERAPY

Lower respiratory tract infection therapy—the role of ciprofloxacin. Ball AP, et al. **J Int Med Res** 1995 Sep–Oct; 23(5):315–27 (55 ref.)

NEMATOCIDES see **ANTINEMATODAL AGENTS**

NEMATODA

see related
ANTINEMATODAL AGENTS

DRUG EFFECTS

The prevalence of anthelmintic resistance in nematode parasites of sheep in southern Latin America: general overview. Waller PJ, et al. **Vet Parasitol** 1996 Apr; 62(3–4):181–7 (20 ref.)

[Anthelmintics resistance in gastrointestinal nematodes in domestic animals] Geerts S. **Verh K Acad Geneeskd Belg** 1995;57(5):351–69; discussion 369–70 (45 ref.) (Eng. Abstr.) **(Dut)**

GROWTH & DEVELOPMENT

Evolution of nematode vulval fate patterning. Sommer RJ, et al. **Dev Biol** 1996 Feb 1;173(2):396–407 (62 ref.)

PHYSIOLOGY

The pharmacology of FMRFamide-related neuropeptides in nematodes: new opportunities for rational anthelmintic discovery? Geary TG, et al. **Int J Parasitol** 1995 Nov; 25(11):1273–80 (42 ref.)

NEMATODE INFECTIONS

see related
ANTINEMATODAL AGENTS

DRUG THERAPY

Chemotherapy of human nematodes: learning from the problems in sheep. Coles GC. **J R Soc Med** 1995 Nov; 88(11):649P–651P (10 ref.)

ETIOLOGY

Nematode infections in children. Kanesa-thasan N, et al. **Adv Pediatr Infect Dis** 1996;11:291–331 (137 ref.)

IMMUNOLOGY

T cell and cytokine basis of host variability in response to intestinal nematode infections. Grencis RK. **Parasitology** 1996;112 Suppl:S31–7 (45 ref.)

TRANSMISSION

[The interrelationships of ixodid ticks (Ixodidae) with the causative agents of transmissible vertebrate infections] Balashov IuS. **Parazitologiia** 1995 Sep–Oct;29(5):337–52 (90 ref.) (Eng. Abstr.) **(Rus)**

VETERINARY

Chemotherapy of human nematodes: learning from the problems in sheep. Coles GC. **J R Soc Med** 1995 Nov; 88(11):649P–651P (10 ref.)

Effect of chemoprophylaxis on immunity to gastrointestinal nematodes in cattle. Vercruysse J, et al. **Verh K Acad Geneeskd Belg** 1996;58(1):51–60 (18 ref.)

The prevalence of anthelmintic resistance in nematode parasites of sheep in southern Latin America: general overview. Waller PJ, et al. **Vet Parasitol** 1996 Apr; 62(3–4):181–7 (20 ref.)

[Anthelmintics resistance in gastrointestinal nematodes in domestic animals] Geerts S. **Verh K Acad Geneeskd Belg** 1995;57(5):351–69; discussion 369–70 (45 ref.) (Eng. Abstr.) **(Dut)**

NEMATOMORPHA see **HELMINTHS**

NEMATOMORPHA INFECTIONS see **HELMINTHIASIS**

NEOCARZINOSTATIN see **ZINOSTATIN**

NEOLIGNANS see **LIGNANS**

NEOMYCIN

ADVERSE EFFECTS

Ototoxicity of ear drops: a clinical perspective. Linder TE, et al. **Am J Otol** 1995 Sep;16(5):653–7 (23 ref.)

Chronic finger dermatitis after trauma. Diagnosis: posttraumatic eczema with allergic contact dermatitis to neomycin, bacitracin, and topical corticosteroids. Sherertz EF. **Arch Dermatol** 1996 Apr;132(4):461, 464 (11 ref.)

NEOMYCIN A see **NEOMYCIN**

NEOMYCIN B see **FRAMYCETIN**

NEONATAL ABSTINENCE SYNDROME

DRUG THERAPY

Treatment options for drug-exposed infants. Kandall SR. **NIDA Res Monogr** 1995;149:78–99 (37 ref.)

NEONATAL CALF DIARRHEA VIRUS see **ROTAVIRUS**

NEONATAL IMMUNITY, MATERNALLY-ACQUIRED see **IMMUNITY, MATERNALLY-ACQUIRED**

NEONATAL INTENSIVE CARE see **INTENSIVE CARE, NEONATAL**

NEONATAL INTENSIVE CARE UNITS see **INTENSIVE CARE UNITS, NEONATAL**

NEONATAL MORTALITY see **INFANT MORTALITY**

NEONATAL NURSING

Neonatal nutritional requirements and formula composition: a review. Darby MK, et al. **J Obstet Gynecol Neonatal Nurs** 1996 Mar–Apr; 25(3):209–17 (49 ref.)

Advanced ventilation in the neonate. Antunes MJ, et al. **Nurs Clin North Am** 1996 Jun;31(2):405–22 (123 ref.)

METHODS

Nursing management of the infant with a congenital malignancy. Thompson DG, et al. **J Obstet Gynecol Neonatal Nurs** 1996 Jan;25(1):32–8 (23 ref.)

ORGANIZATION & ADMINISTRATION

The role of the perinatal nurse in open adoption. Fister S, et al. **MCN Am J Matern Child Nurs** 1995 Jan–Feb; 20(1):9–12 (11 ref.)

Integrating family-centered developmental assessment and intervention into routine care in the neonatal intensive care unit. McGrath JM, et al. **Nurs Clin North Am** 1996 Jun; 31(2):367–86 (104 ref.)

TRENDS

The evolving nature of perinatal nursing. Arnold L, et al. **Nurs Clin North Am** 1996 Jun;31(2):259–67 (25 ref.)

NEONATAL SCREENING

Neonatal screening for sickle cell disorders: what about the carrier infants? Laird L, et al. **BMJ** 1996 Aug 17; 313(7054):407–11 (51 ref.)

[Screening for hepatitis B in pregnancy and sequelae for the newborn infant] Albrecht K. **Z Geburtshilfe Neonatol** 1995 Nov–Dec;199(6):253–6 (24 ref.) **(Ger)**

METHODS

Prediction and non-invasive assessment of neonatal jaundice in the term healthy newborn infant. Knudsen A. **Acta Paediatr** 1996 Apr;85(4):393–7 (32 ref.)

Newborn screening: principles and practice. Allen DB, et al. **Adv Pediatr** 1996;43:231–70 (85 ref.)

STANDARDS

[Outcome of cystic fibrosis children screened at birth] Brouard J, et al. **Rev Mal Respir** 1996;13(1):79–80 (21 ref.) **(Fre)**

NEONATE see **INFANT, NEWBORN**

NEONATOLOGY

see related
INFANT, NEWBORN

METHODS

[The "kangaroo mother" method (editorial)] Mosseri R, et al. **Harefuah** 1996 Jan 15;130(2):95–7 (15 ref.) **(Heb)**

STANDARDS

The impact of early obstetric discharge on newborn health care. Lee KS, et al. **Curr Opin Pediatr** 1996 Apr;8(2):96–101 (42 ref.)

NEOPLASIA, PROSTATIC INTRAEPITHELIAL see **PROSTATIC INTRAEPITHELIAL NEOPLASIA**

NEOPLASIA, CERVICAL INTRAEPITHELIAL see **CERVICAL INTRAEPITHELIAL NEOPLASIA**

NEOPLASIA, MULTIPLE ENDOCRINE see **MULTIPLE ENDOCRINE NEOPLASIA**

NEOPLASIA, MULTIPLE ENDOCRINE TYPE 1 see **MULTIPLE ENDOCRINE NEOPLASIA TYPE 1**

NEOPLASIA, MULTIPLE ENDOCRINE TYPE 2A see **MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A**

NEOPLASIA, MULTIPLE ENDOCRINE, TYPE 2B see **MULTIPLE ENDOCRINE NEOPLASIA TYPE 2B**

NEOPLASM ANTIBODIES see **ANTIBODIES, NEOPLASM**

NEOPLASM ANTIGENS see **ANTIGENS, NEOPLASM**

NEOPLASM CIRCULATING CELLS

Intraportal tumor thrombus of gallbladder carcinoma: detection with intravascular ultrasonography. Kaneko T, et al. **Am J Gastroenterol** 1996 Jun;91(6):1268–9 (8 ref.)

Tumor embolism to LAD during pneumonectomy. A case report. Shah R, et al. **J Cardiovasc Surg (Torino)** 1996 Jun; 37(3):319–21 (13 ref.)

Sudden death caused by testicular germ cell tumour. Dada MA, et al. **Med Sci Law** 1995 Oct;35(4):357–9 (12 ref.)

[Principles of lymphogenic and hematogenous metastasis and metastasis classification] Wittekind C. **Zentralbl Chir** 1996; 121(6):435–41 (16 ref.) (Eng. Abstr.) **(Ger)**

[Renal adenocarcinoma with venous tumor extension to the right atrium: diagnostic and therapeutic considerations] Herranz Amo F, et al. **Arch Esp Urol** 1996 Jan–Feb; 49(1):17–25 (61 ref.) (Eng. Abstr.) **(Spa)**

PATHOLOGY

Polymerase chain reaction in the detection of micrometastases and circulating tumor cells [see comments] Ghossein RA, et al. **Cancer** 1996 Jul 1;78(1):10–6 (41 ref.) Comment in: Cancer 1996 Jul 1;78(1):1–3.

Erythematous papules in a patient with cardiac myxoma: a case report and review of the literature. Misago N, et al. **J Dermatol** 1995 Aug;22(8):600–5 (22 ref.)

NEOPLASM DNA see **DNA, NEOPLASM**

NEOPLASM INVASIVENESS

see related
LEUKEMIC INFILTRATION

The urokinase/urokinase-receptor system and cancer invasion. Conese M, et al. **Baillieres Clin Haematol** 1995 Jun;8(2):365–89 (237 ref.)

E-cadherin and its associated protein catenins, cancer invasion and metastasis. Jiang WG. **Br J Surg** 1996 Apr; 83(4):437–46 (138 ref.)

Cancer metastasis: negative regulation by an invasion-suppressor complex. Mareel M, et al. **Cancer Detect Prev** 1995;19(5):451–64 (105 ref.)

Desmosomes and cancer. Garrod DR. **Cancer Surv** 1995; 24:97–111 (51 ref.)

E-cadherin as an invasion suppressor. Birchmeier W, et al. **Ciba Found Symp** 1995;189:124–36; discussion 136–41, 174–6 (66 ref.)

The E-cadherin/catenin complex in invasion and metastasis. Bracke ME, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 1):123–61 (350 ref.)

The 67-kDa laminin receptor and tumor progression. Montuori N, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 1):205–14 (60 ref.)

Does soluble CD44 reflect the clinical behavior of human cancer? Ristamäki R, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 3):155–66 (53 ref.)

Maspin: a tumor suppressing serpin. Sager R, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 1):51–64 (14

ref.)
Stimulation and regulation of tumor cell motility in invasion and metastasis. Levine MD, et al. **EXS** 1995;74:157–79 (135 ref.)
Cell adhesion and regulatory molecules involved in tumor formation, hemostasis, and wound healing. Van Waes C. **Head Neck** 1995 Mar–Apr;17(2):140–7 (18 ref.)
Urokinase–type plasminogen activator (uPA) and its receptor (CD87): a new target in tumor invasion and metastasis. Schmitt M, et al. **J Obstet Gynaecol** 1995 Apr;21(2):151–65 (60 ref.)

PATHOLOGY

Microinvasion in low malignant potential tumors of the ovary. Nayar R, et al. **Hum Pathol** 1996 Jun;27(6):521–7 (17 ref.)
Biology of tumor cell invasion: interplay of cell adhesion and matrix degradation. Heino J. **Int J Cancer** 1996 Mar 15;65(6):717–22 (66 ref.)
Pandora's box or Ariadne's thread? Definition and prognostic significance of microinvasion in the uterine cervix. Squamous lesions. Ostör AG. **Pathol Annu** 1995;30 Pt 2:103–36 (129 ref.)

PHYSIOPATHOLOGY

Complex roles of matrix metalloproteinases in tumor progression. Powell WC, et al.
Curr Top Microbiol Immunol 1996;213 (Pt 1):1–21 (46 ref.)
Membrane type–matrix metalloproteinase and tumor invasion. Seiki M. **Curr Top Microbiol Immunol** 1996;213 (Pt 1):23–32 (44 ref.)

PREVENTION & CONTROL

Fish oil may impede tumour angiogenesis and invasiveness by down–regulating protein kinase C and modulating eicosanoid production. McCarty MF. **Med Hypotheses** 1996 Feb;46(2):107–15 (120 ref.)

NEOPLASM METASTASIS

Treatment principles in advanced colorectal cancer. Zalcberg JR, et al. **Aust N Z J Surg** 1996 Apr;66(4):202–5 (30 ref.)
E–cadherin and its associated protein catenins, cancer invasion and metastasis. Jiang WG. **Br J Surg** 1996 Apr; 83(4):437–46 (138 ref.)
Desmosomes and cancer. Garrod DR. **Cancer Surv** 1995; 24:97–111 (51 ref.)
Model systems of carcinoma cell dispersion. Boyer B, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 1):179–94 (85 ref.)
The E–cadherin/catenin complex in invasion and metastasis. Bracke ME, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 1):123–61 (350 ref.)
Curing metastases? Gene and peptide therapy. Eisenbach L. **Curr Top Microbiol Immunol** 1996;213 (Pt 3):85–100 (150 ref.)
CD44 in malignant disorders. Günthert U.
Curr Top Microbiol Immunol 1996;213 (Pt 1):271–85 (93 ref.)
Involvement of alpha 6 and alpha v integrins in metastasis. Imhof BA, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 1):195–203 (36 ref.)
Immunotherapy of metastases. Schirrmacher V, et al.
Curr Top Microbiol Immunol 1996;213 (Pt 3):189–216 (112 ref.)
The CD44 proteins in embryonic development and in cancer. Sherman L, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 1):249–69 (123 ref.)
Joint features of metastasis formation and lymphocyte maturation and activation. Zöller M.
Curr Top Microbiol Immunol 1996;213 (Pt 1):215–47 (330 ref.)
Metastasis. A primer for dermatologists. Brodland DG.
Dermatol Surg 1996 Mar;22(3):228–33 (47 ref.)
The potential roles of nm23 in cancer metastasis and cellular differentiation. MacDonald NJ, et al. **Eur J Cancer** 1995 Jul–Aug;31A(7–8):1096–100 (30 ref.)
Molecular mechanisms for organ–specific colon carcinoma metastasis. Radinsky R. **Eur J Cancer** 1995 Jul–Aug; 31A(7–8):1091–5 (28 ref.)
Stimulation and regulation of tumor cell motility in invasion and metastasis. Levine MD, et al. **EXS** 1995;74:157–79 (135 ref.)
Tumor cell interactions with the vascular endothelium and their role in cancer metastasis. Nicolson GL. **EXS** 1995; 74:123–36 (189 ref.)
Stromal–epithelial interaction in type IV collagenase expression and activation: The role in cancer metastasis. Shi YE, et al. **EXS** 1995;74:215–34 (98 ref.)
Regulation of tumor growth and metastasis by thrombospondin–1. Roberts DD. **FASEB J** 1996 Aug; 10(10):1183–91 (69 ref.)
Cell adhesion and regulatory molecules involved in tumor formation, hemostasis, and wound healing. Van Waes C. **Head Neck** 1995 Mar–Apr;17(2):140–7 (18 ref.)
Modulation of the organ microenvironment for treatment of cancer metastasis. Fidler IJ. **J Natl Cancer Inst** 1995 Nov 1;87(21):1588–92 (63 ref.)
Involvement of CD44 and its variant isoforms in membrane–cytoskeleton interaction, cell adhesion and tumor metastasis. Bourrguignon LY, et al. **J Neurooncol** 1995 Dec;26(3):201–8 (44 ref.)
Hyaluronan: RHAMM mediated cell locomotion and signaling in tumorigenesis. Hall CL, et al. **J Neurooncol** 1995 Dec;26(3):221–9 (84 ref.)
Urokinase–type plasminogen activator (uPA) and its receptor (CD87): a new target in tumor invasion and metastasis. Schmitt M, et al. **J Obstet Gynaecol** 1995 Apr;21(2):151–65 (60 ref.)
Metastases of unknown primary site. Lembersky BC, et al. **Med Clin North Am** 1996 Jan;80(1):153–71 (76 ref.)
Angiogenesis in cancer, vascular, rheumatoid and other disease. Folkman J. **Nat Med** 1995 Jan;1(1):27–31 (72 ref.)
How cancer spreads. Ruoslahti E. **Sci Am** 1996 Sep; 275(3):72–7 (0 ref.)
[Clinical implication of tumor marker expressions suggesting biological characters of malignancies] Ariyoshi Y, et al. **Nippon Rinsho** 1996 Jun;54(6):1568–73 (17 ref.) (Eng. Abstr.) **(Jpn)**
[Cancer metastasis] Berner A, et al. **Tidsskr Nor Laegeforen** 1996 Mar 20;116(8):952–7 (47 ref.) (Eng. Abstr.) **(Nor)**
[Radiological criteria for laryngeal tumors and cervical metastases] Melchor Díaz MA, et al.
Acta Otorrinolaringol Esp 1996 Jan–Feb;47(1):1–7 (17 ref.) (Eng. Abstr.) **(Spa)**
[Angiogenesis—a marker for metastases] Sköldenberg E, et al. **Lakartidningen** 1996 May 8;93(19):1853–5 (24 ref.) **(Swe)**

DIAGNOSIS

Molecular and immunological detection of circulating tumor cells and micrometastases from solid tumors. Pelkey TJ, et al. **Clin Chem** 1996 Sep;42(9):1369–81 (163 ref.)
Micrometastasis detection and treatment with monoclonal antibodies. Pantel K, et al.
Curr Top Microbiol Immunol 1996;213 (Pt 3):1–18 (88 ref.)

GENETICS

Genetic alterations associated with metastatic dissemination and chemoresistance in neuroblastoma. Bénard J.
Eur J Cancer 1995;31A(4):560–4 (59 ref.)
CD44: physiological expression of distinct isoforms as evidence for organ–specific metastasis formation. Zöller M. **J Mol Med** 1995 Sep;73(9):425–38 (265 ref.)

IMMUNOLOGY

The role of CD44 splice variants in human metastatic cancer. Sleeman J, et al. **Ciba Found Symp** 1995;189:142–51; discussion 151–6, 174–6 (43 ref.)

PATHOLOGY

[Pathogenesis of tumor metastases] Ruiter DJ, et al.
Ned Tijdschr Geneeskd 1995 Nov 4;139(44):2240–6 (53 ref.) **(Dut)**
[The development of metastases and their classification] Wittekind C, et al. **Strahlenther Onkol** 1996 Jun; 172(6):287–94 (37 ref.) (Eng. Abstr.) **(Ger)**
[Principles of lymphogenic and hematogenous metastasis and metastasis classification] Wittekind C. **Zentralbl Chir** 1996; 121(6):435–41 (16 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Tumor–host interaction in non–random metastatic pattern distribution. Alonso–Varona A, et al.
Bull Cancer (Paris) 1996 Jan;83(1):27–38 (92 ref.)
Early metastasis of human solid tumours: expression of cell adhesion molecules. Pantel K, et al. **Ciba Found Symp** 1995; 189:157–70; discussion 170–3, 174–6 (62 ref.)
Angiogenesis and cancer metastases: therapeutic approaches. Teicher BA. **Crit Rev Oncol Hematol** 1995 Aug; 20(1–2):9–39 (407 ref.)
MUC18: A cell adhesion molecule with a potential role in tumor growth and tumor cell dissemination. Johnson JP, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 1):95–105 (25 ref.)
Complex roles of matrix metalloproteinases in tumor progression. Powell WC, et al.
Curr Top Microbiol Immunol 1996;213 (Pt 1):1–21 (46 ref.)
Interactions between CD44 and hyaluronic acid: their role in tumor growth and metastasis. Sy MS, et al.
Curr Top Microbiol Immunol 1996;213 (Pt 3):129–53 (150 ref.)
Significance of angiogenesis in tumour progression and metastasis. Bikfalvi A. **Eur J Cancer** 1995 Jul–Aug; 31A(7–8):1101–4 (30 ref.)
Role of platelets, thrombin, integrin IIb–IIIa, fibronectin and von Willebrand factor on tumor adhesion in vitro and metastasis in vivo. Nierodzik ML, et al.
Thromb Haemost 1995 Jul;74(1):282–90 (67 ref.)
[Mechanism of neoplasm metastasis and treatment strategy] Takahashi T. **Nippon Geka Gakkai Zasshi** 1995 Aug; 96(8):539–46 (40 ref.) **(Jpn)**

PREVENTION & CONTROL

Cancer metastasis: negative regulation by an invasion–suppressor complex. Mareel M, et al.
Cancer Detect Prev 1995;19(5):451–64 (105 ref.)
Antitumor and antimetastatic activity of interleukin–12. Hendrzak JA, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 3):65–83 (131 ref.)
Effect of antisense inhibition of Urokinase receptor on malignancy. Ossowski L. **Curr Top Microbiol Immunol** 1996;213 (Pt 3):101–12 (71 ref.)
Influence of local cytokines on tumor metastasis: using cytokine gene–transfected tumor cells as experimental models. Qin Z, et al. **Curr Top Microbiol Immunol** 1996; 213 (Pt 3):55–64 (27 ref.)
Prevention of manifest metastasis with monoclonal antibodies: a novel approach to immunotherapy of solid tumours. Schneider–Gädicke E, et al. **Eur J Cancer** 1995 Jul–Aug;31A(7–8):1326–30 (51 ref.)
Activation of nitric oxide synthase gene for inhibition of cancer metastasis. Xie K, et al. **J Leukoc Biol** 1996 Jun; 59(6):797–803 (107 ref.)

NEOPLASM METASTASIS, UNKNOWN PRIMARY see **NEOPLASMS, UNKNOWN PRIMARY**

NEOPLASM PROTEINS

ANALYSIS

Meningioangiomatosis. A clinicopathologic study including MIB1 immunoreactivity. Prayson RA.
Arch Pathol Lab Med 1995 Nov;119(11):1061–4 (34 ref.)
How to probe clinical tumour samples for P–glycoprotein and multidrug resistance–associated protein. Broxterman HJ, et al. **Eur J Cancer** 1996 Jun;32A(6):1024–33 (86 ref.)
MDR1/P–glycoprotein in haematological neoplasms. Marie JP, et al. **Eur J Cancer** 1996 Jun;32A(6):1034–8 (81 ref.)
Carbohydrate–based measurements on alpha–fetoprotein in the early diagnosis of hepatocellular carcinoma. Aoyagi Y. **Glycoconj J** 1995 Jun;12(3):194–9 (66 ref.)
Correlation between pS2 protein positivity, steroid receptor status and other prognostic factors in breast cancer. Racca S, et al. **Int J Biol Markers** 1995 Apr–Jun;10(2):87–93 (35 ref.)
[Future of malignant stage I melanoma. Immunology and immunotherapy] Nicolas JF, et al.
Ann Dermatol Venereol 1995;122(5):324–35 (105 ref.) **(Fre)**
[Primary angiosarcoma of the thyroid. Presentation of a case (epithelioid type) and nosological problems] Bisceglia M, et al. **Pathologica** 1995 Apr;87(2):154–61 (49 ref.) (Eng. Abstr.) **(Ita)**

ANTAGONISTS & INHIBITORS

Effect of antisense inhibition of Urokinase receptor on malignancy. Ossowski L. **Curr Top Microbiol Immunol** 1996;213 (Pt 3):101–12 (71 ref.)
Intervention in receptor tyrosine kinase–mediated pathways: recombinant antibody fusion proteins targeted to ErbB2. Wels W, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 3):113–28 (47 ref.)
Clinical trials of P–glycoprotein reversal in solid tumours. Ferry DR, et al. **Eur J Cancer** 1996 Jun;32A(6):1070–81 (119 ref.)
P450–dependent enzymes as targets for prostate cancer therapy. De Coster R, et al.
J Steroid Biochem Mol Biol 1996 Jan;56(1–6 Spec No):133–43 (101 ref.)

BIOSYNTHESIS

The humoral hypercalcemia of benignancy. A newly appreciated syndrome [see comments] Knecht TP, et al. **Am J Clin Pathol** 1996 Apr;105(4):487–92 (42 ref.)
Comment in: Am J Clin Pathol 1996 Apr;105(4):377–9.
Progesterone receptor A and B protein expression in human breast cancer. Graham JD, et al.
J Steroid Biochem Mol Biol 1996 Jan;56(1–6 Spec No):93–8 (33 ref.)
A case of acute lymphoblastic leukemia accompanied with the production of parathyroid hormone–related protein. Harutsumi M, et al. **Miner Electrolyte Metab** 1995; 21(1–3):171–6 (24 ref.)
Parathyroid hormone–related peptide in hypercalcemia associated with adult T cell leukemia/lymphoma: molecular and cellular mechanism of parathyroid hormone–related peptide overexpression in HTLV–I–infected T cells. Ikeda K, et al.
Miner Electrolyte Metab 1995;21(1–3):166–70 (36 ref.)

CHEMISTRY

Glycoforms of serum alpha 1–acid glycoprotein as markers of inflammation and cancer. Mackiewicz A, et al.
Glycoconj J 1995 Jun;12(3):241–7 (43 ref.)

DRUG EFFECTS

Androgen receptor mediated growth control of breast cancer and endometrial cancer modulated by antiandrogen– and androgen–like steroids. Hackenberg R, et al.
J Steroid Biochem Mol Biol 1996 Jan;56(1–6 Spec No):113–7 (56 ref.)

GENETICS

Schwannomin: new insights into this member of the band 4.1 superfamily. Belliveau MJ, et al. **Biochem Cell Biol** 1995 Sep–Oct;73(9–10):733–7 (44 ref.)
BRCA1, a gene involved in inherited predisposition to breast

and ovarian cancer. Feunteun J, et al. **Biochim Biophys Acta** 1996 Mar 18;1242(3):177–80 (42 ref.)

DNA topoisomerase II mutations and resistance to anti-tumor drugs. Vassetzky YS, et al. **Bioessays** 1995 Sep; 17(9):767–74 (66 ref.)

The mycN/max protein complex in neuroblastoma. Short review. Wenzel A, et al. **Eur J Cancer** 1995;31A(4):516–9 (40 ref.)

Inherited breast and ovarian cancer. Szabo CI, et al. **Hum Mol Genet** 1995;4 Spec No:1811–7 (64 ref.)

Human tumor rejection antigens MAGE. Itoh K, et al. **J Biochem (Tokyo)** 1996 Mar;119(3):385–90 (33 ref.)

Alternative splicing of the estrogen receptor primary transcript normally occurs in estrogen receptor positive tissues and cell lines. Pfeffer U, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1–6 Spec No):99–105 (37 ref.)

The molecular biology of chronic myeloid leukaemia. Melo JV. **Leukemia** 1996 May;10(5):751–6 (58 ref.)

Molecular biology of breast cancer: integration of cellular and molecular concepts into therapeutic strategies. Konstadoulakis MM, et al. **R I Med** 1995 Sep;78(9):257–60 (67 ref.)

Mutations of the BRCA1 gene in human cancer. Xu CF, et al. **Semin Cancer Biol** 1996 Feb;7(1):33–40 (63 ref.)

[Prognostic factors for esophageal cancer--from the viewpoint of molecular biology] Shimada Y, et al. **Gan To Kagaku Ryoho** 1996 Jul;23(8):972–81 (98 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Antiantiidiotypic response and clinical course of the disease in patients with malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2–23. Mittelman A, et al. **Hybridoma** 1995 Apr;14(2):175–81 (31 ref.)

G-CSF-stimulated PMN in immunotherapy of breast cancer with a bispecific antibody to Fc gamma RI and to HER-2/neu (MDX-210). Repp R, et al. **J Hematother** 1995 Oct;4(5):415–21 (26 ref.)

Human melanoma antigens recognized by T lymphocytes. Kawakami Y, et al. **Keio J Med** 1996 Jun;45(2):100–8 (78 ref.)

METABOLISM

Protein tyrosine phosphorylation and estradiol action. Auricchio F, et al. **Ann N Y Acad Sci** 1996 Apr 30; 784:149–72 (41 ref.)

Effects of taxol on the polymerization and posttranslational modification of class III beta-tubulin in P19 embryonal carcinoma cells. Laferrière NB, et al. **Biochem Cell Biol** 1995 Sep–Oct;73(9–10):687–94 (36 ref.)

Multidrug resistance proteins and other drug transport-related resistance to natural product agents. Broxterman HJ, et al. **Curr Opin Oncol** 1995 Nov; 7(6):532–40 (78 ref.)

Lu-ECAM-1 and DPP IV in lung metastasis. Elble RC, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 1):107–22 (77 ref.)

Transcriptional regulation by the t(8;21) fusion protein, AML-1/ETO. Hiebert SW, et al. **Curr Top Microbiol Immunol** 1996;211:253–8 (19 ref.)

Interactions between CD44 and hyaluronic acid: their role in tumor growth and metastasis. Sy MS, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 3):129–53 (150 ref.)

MDR1 gene expression in solid tumours. Goldstein LJ. **Eur J Cancer** 1996 Jun;32A(6):1039–50 (84 ref.)

MDR1/P-glycoprotein expression in colorectal cancer. Linn SC, et al. **Eur J Cancer** 1995 Jul–Aug;31A(7–8):1291–4 (30 ref.)

Nuclear p53 overexpression is an independent prognostic parameter in node-negative non-small cell lung carcinoma. Dalquen P, et al. **J Pathol** 1996 Jan;178(1):53–8 (41 ref.)

PHYSIOLOGY

Cell proliferation-associated nuclear antigen defined by antibody Ki-67: a new kind of cell cycle-maintaining proteins. Duchrow M, et al. **Arch Immunol Ther Exp (Warsz)** 1995;43(2):117–21 (30 ref.)

The role of thrombospondin-1 in tumor progression and angiogenesis. Tuszynski GP, et al. **Bioessays** 1996 Jan; 18(1):71–6 (57 ref.)

Molecular and pharmacologic targeting of angiogenesis factors--the example of pleiotrophin. Czubayko F, et al. **Breast Cancer Res Treat** 1995;36(2):157–68 (68 ref.)

CD44 in malignant disorders. Günthert U. **Curr Top Microbiol Immunol** 1996;213 (Pt 1):271–85 (93 ref.)

Involvement of alpha 6 and alpha v integrins in metastasis. Imhof BA, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 1):195–203 (36 ref.)

MUC18: A cell adhesion molecule with a potential role in tumor growth and tumor cell dissemination. Johnson JP, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 1):95–105 (25 ref.)

Plasminogen activators and angiogenesis. Mignatti P, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 1):33–50 (137 ref.)

The 67-kDa laminin receptor and tumor progression. Montuori N, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 1):205–14 (60 ref.)

Different roles for plasminogen activators and metalloproteinases in melanoma metastasis. Mueller BM. **Curr Top Microbiol Immunol** 1996;213 (Pt 1):65–80 (80 ref.)

Complex roles of matrix metalloproteinases in tumor progression. Powell WC, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 1):1–21 (46 ref.)

SPARC and the extracellular matrix: implications for cancer and wound repair. Reed MJ, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 1):81–94 (66 ref.)

Does soluble CD44 reflect the clinical behavior of human cancer? Ristamäki R, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 3):155–66 (53 ref.)

Membrane type-matrix metalloproteinase and tumor invasion. Seiki M. **Curr Top Microbiol Immunol** 1996;213 (Pt 1):23–32 (44 ref.)

The CD44 proteins in embryonic development and in cancer. Sherman L, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 1):249–69 (123 ref.)

Function of PU.1 (Spi-1), C/EBP, and AML1 in early myelopoiesis: regulation of multiple myeloid CSF receptor promoters. Zhang DE, et al. **Curr Top Microbiol Immunol** 1996;211:137–47 (61 ref.)

Major vault protein LRP-related multidrug resistance. Izquierdo MA, et al. **Eur J Cancer** 1996 Jun;32A(6):979–84 (40 ref.)

The potential roles of nm23 in cancer metastasis and cellular differentiation. MacDonald NJ, et al. **Eur J Cancer** 1995 Jul–Aug;31A(7–8):1096–100 (30 ref.)

The control and biological importance of intratumoural aromatase in breast cancer. Dowsett M, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1–6 Spec No):145–50 (22 ref.)

The role of the estrogen receptor in tumor progression. Lemieux P, et al. **J Steroid Biochem Mol Biol** 1996 Jan; 56(1–6 Spec No):87–91 (21 ref.)

NEOPLASM RECURRENCE, LOCAL

Local recurrence after breast-conserving surgery for breast cancer. Macmillan RD, et al. **Br J Surg** 1996 Feb; 83(2):149–55 (52 ref.)

Recurrent placental site trophoblastic tumor of the uterus: clinical, pathologic, ultrastructural, and DNA fingerprint study. Kodama S, et al. **Gynecol Oncol** 1996 Jan;60(1):89–93 (20 ref.)

Analysis of local recurrence rates after surgery alone for rectal cancer. McCall JL, et al. **Int J Colorectal Dis** 1995; 10(3):126–32 (105 ref.)

Long-term survival in refractory recurrent neuroblastoma. Pierce ST. **J Pediatr Hematol Oncol** 1996 May;18(2):202–5 (34 ref.)

Recurrent intrapulmonary malignant small cell tumor of the thoracopulmonary region with metastasis to the oral cavity: review of literature and case report. Hicks MJ, et al. **Ultrastruct Pathol** 1995 Jul–Aug;19(4):297–303 (21 ref.)

[Detection methods of local, regional and distant recurrences of melanoma] Sigal R. **Ann Dermatol Venereol** 1995; 122(5):279–84 (46 ref.) **(Fre)**

[What are the methods for the detection of recurrent melanoma? What is their value? Should they be implemented? Which ones and how often?] Truchetet F, et al. **Ann Dermatol Venereol** 1995;122(5):360–4 (27 ref.) **(Fre)**

[Adenocarcinoma of the appendix. A propos of a case complicated by double local and parietal recurrence] de Souza N, et al. **J Chir (Paris)** 1996 Jun;133(4):159–61 (10 ref.) (Eng. Abstr.) **(Fre)**

[Role of the anterior resection in the surgical treatment of rectal cancer. Review of the literature] Santini L, et al. **Minerva Gastroenterol Dietol** 1995 Dec;41(4):283–7 (37 ref.) (Eng. Abstr.) **(Ita)**

BLOOD

The use of prognostic markers in surgery for colorectal cancer. Northover J. **Eur J Cancer** 1995 Jul–Aug; 31A(7–8):1207–9 (36 ref.)

CHEMICALLY INDUCED

Hormonal therapy and genital tract cancer. Wren B. **Curr Opin Obstet Gynecol** 1996 Feb;8(1):38–41 (31 ref.)

Hormone replacement therapy in women with breast cancer. Do the risks outweigh the benefits? Roy JA, et al. **J Clin Oncol** 1996 Mar;14(3):997–1006 (85 ref.)

DIAGNOSIS

Detection of breast cancer local recurrences. Ciatto S. **Ann Oncol** 1995;6 Suppl 2:23–6 (6 ref.)

Postexcisional recurrence of carcinoma of the breast. Zavotsky J, et al. **J Am Coll Surg** 1996 Jan;182(1):71–7 (88 ref.)

Soft-tissue sarcoma of the extremities. MR appearance of post-treatment changes and local recurrences. Varma DG, et al. **Magn Reson Imaging Clin N Am** 1995 Nov; 3(4):695–712 (59 ref.)

Prediction of recurrence for advanced breast cancer. Traditional and contemporary pathologic and molecular markers. Masood S. **Surg Oncol Clin N Am** 1995 Oct; 4(4):601–32 (213 ref.)

[MR-mammography: current status and perspectives] Funke M, et al. **Aktuelle Radiol** 1996 May;6(3):130–5 (47 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Supportive care is not the only option in prostate cancer patients resistant to hormone therapy: the argument for. Scher HI. **Eur Urol** 1996;29 Suppl 2:40–4 (36 ref.)

Neoadjuvant chemotherapy of locally advanced non-small cell lung cancer. Pujol JL, et al. **Lung Cancer** 1995 Apr; 12 Suppl 1:S107–18 (46 ref.)

[Carboplatin and etoposide combination for the treatment of recurrent epithelial ovarian cancer] Chauvergne J, et al. **Bull Cancer (Paris)** 1996 Apr;83(4):315–23 (52 ref.) (Eng. Abstr.) **(Fre)**

[Chemotherapy for recurrent ovarian cancer] Nishimura H, et al. **Gan To Kagaku Ryoho** 1996 Aug;23(9):1124–8 (22 ref.) (Eng. Abstr.) **(Jpn)**

ETIOLOGY

Role of cytokines and growth factors in promoting the local recurrence of breast cancer. Reid SE, et al. **Br J Surg** 1996 Mar;83(3):313–20 (97 ref.)

How to predict the risk of local relapse in the preserved breast. Kurtz JM. **Recent Results Cancer Res** 1996; 140:263–72 (26 ref.)

PATHOLOGY

Treatment of vaginal recurrence in endometrial cancer. A review. Møller LA, et al. **Acta Obstet Gynecol Scand** 1996 Jan;75(1):1–7 (45 ref.)

The tumor burden of locally recurrent breast cancer is a neglected prognostic factor. Evans RA. **Am J Surg** 1996 Apr;171(4):445–8 (47 ref.)

Tubular carcinoma of the breast. Predicting axillary nodal metastases and recurrence. Winchester DJ, et al. **Ann Surg** 1996 Mar;223(3):342–7 (20 ref.)

Liposarcoma of the base of tongue and tonsillar fossa: A possibly underdiagnosed neoplasm. Saddik M, et al. **Arch Pathol Lab Med** 1996 Mar;120(3):292–5 (23 ref.)

Transanal electroresection of small rectal cancer: a sole treatment? Faivre J, et al. **Dis Colon Rectum** 1996 Mar; 39(3):270–8 (39 ref.)

Recurrent squamous cell carcinoma in a rectus abdominis neovagina. Carlson JW, et al. **Gynecol Oncol** 1995 Oct; 59(1):159–61 (17 ref.)

Recurring digital fibroma of childhood. Burgert S, et al. **J Hand Surg [Br]** 1996 Jun;21(3):400–2 (15 ref.)

Mucinous adenocarcinoma of the prostate: a report of a case of long-term survival. Olivas TP, et al. **Urology** 1996 Feb; 47(2):256–8 (7 ref.)

[Prolactin producing hypophyseal carcinoma. Case report of an extremely rare metastatic tumor] Saeger W, et al. **Pathologe** 1995 Sep;16(5):354–8 (19 ref.) (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

Surgical technique and colorectal cancer: impaction on local recurrence and survival. Averbach AM, et al. **Tumori** 1995 May–Jun;81(3 Suppl):65–71 (75 ref.)

RADIOGRAPHY

Pneumocephalus due to nasopharyngeal carcinoma: case report. Kiu MC, et al. **Neuroradiology** 1996 Jan;38(1):70–2 (24 ref.)

RADIOTHERAPY

Operation and permanent low activity 125I brachytheraphy for recurrent high-grade astrocytomas. Halligan JB, et al. **Int J Radiat Oncol Biol Phys** 1996 Jun 1;35(3):541–7 (24 ref.)

SURGERY

Pelvic exenteration for recurrent rectal cancer. Avradopoulos KA, et al. **Adv Surg** 1996;29:215–33 (71 ref.)

Technique of sacral hernia repair. Kaplan LJ, et al. **Am Surg** 1996 Sep;62(9):762–4 (4 ref.)

Surgical management of locally recurrent rectal cancer. Sagar PM, et al. **Br J Surg** 1996 Mar;83(3):293–304 (159 ref.)

Repeated hepatic resections for recurrent metastasis of colorectal cancer. Gazzaniga GM, et al. **Hepatogastroenterology** 1995 Jul–Aug;42(4):383–6 (19 ref.)

Operation and permanent low activity 125I brachytheraphy for recurrent high-grade astrocytomas. Halligan JB, et al. **Int J Radiat Oncol Biol Phys** 1996 Jun 1;35(3):541–7 (24 ref.)

Trocar site tumor recurrence after laparoscopic-assisted colectomy. Fodera M, et al. **J Laparoendosc Surg** 1995 Aug; 5(4):259–62 (12 ref.)

Recurrent melanoma of the hard palate treated by en bloc excision and reconstruction with an autologous palatal bone graft subjected to cryotherapy and a buccal mucosal flap. Rosales J, et al. **J Oral Maxillofac Surg** 1995 Oct; 53(10):1218–20 (16 ref.)

Intramedullary spinal cord germinoma: case report and review of the literature. Itoh Y, et al. **Neurosurgery** 1996 Jan;38(1):187–90; discussion 190–1 (17 ref.)

NEOPLASM RECURRENCE, LOCAL

Expanding intracerebral hematoma from pituitary adenoma: case report. Wakai S, et al. **Neurosurgery** 1995 Oct; 37(4):807–8; discussion 808–9 (2 ref.)
Surgical treatment of breast cancer relapse. Margolese RG. **Recent Results Cancer Res** 1996;140:139–67 (23 ref.)
Radioimmunoguided Surgery system improves survival for patients with recurrent colorectal cancer. Bertsch DJ, et al. **Surgery** 1995 Oct;118(4):634–8; discussion 638–9 (9 ref.)
Local recurrences from rectal cancer: impact of previous surgery. Bozzetti F, et al. **Tumori** 1995 May–Jun;81(3 Suppl):135–40 (84 ref.)

THERAPY

Thermoradiotherapy for brain tumors. Three cases of recurrent malignant astrocytoma and review of clinical experience. Seegenschmiedt MH, et al.
Am J Clin Oncol 1995 Dec;18(6):510–8 (53 ref.)
Isolated incisional recurrence after curative resection for primary lung cancer. Yokoi K, et al. **Ann Thorac Surg** 1996 Apr;61(4):1236–7 (9 ref.)
The management of relapsed Wilms tumor. Miser JS, et al. **Hematol Oncol Clin North Am** 1995 Dec;9(6):1287–302 (51 ref.)
Favorable prognostic factors in recurrent and metastatic melanoma. Buzzell RA, et al. **J Am Acad Dermatol** 1996 May;34(5 Pt 1):798–803 (74 ref.)
Intensive therapy and autologous stem cell transplantation for Hodgkin's disease in first relapse after combination chemotherapy. Reece DE, et al. **Leuk Lymphoma** 1996 Apr; 21(3–4):245–53 (55 ref.)
Impact of chemotherapy on survival in locally advanced non-small cell lung cancer: the Gustave-Roussy experience. Le Cesne A, et al. **Lung Cancer** 1995 Apr;12 Suppl 1:S79–85 (25 ref.)
The management of locally recurrent invasive bladder cancer following radical cystectomy. Pisters LL, et al.
Semin Urol Oncol 1996 May;14(2):112–9 (25 ref.)
Surgical and medical management of local–regional treatment failures in advanced primary breast cancer. Singletary SE, et al. **Surg Oncol Clin N Am** 1995 Oct; 4(4):671–84 (27 ref.)
[Sense and nonsense in after-care of colorectal carcinoma] Schölmerich J. **Med Klin** 1996 Jun 15;91(6):420–7 (53 ref.) **(Ger)**

ULTRASONOGRAPHY

Detection of anastomotic recurrence by endoscopic ultrasonography. Lightdale CJ.
Gastrointest Endosc Clin N Am 1995 Jul;5(3):595–600 (20 ref.)

NEOPLASM REGRESSION, SPONTANEOUS

A case of microscopic testicular tumour. Shoji N, et al.
Int Urol Nephrol 1995;27(2):189–91 (5 ref.)
[Spontaneous regression of primary cerebral lymphoma] Heinzlef O, et al. **Rev Neurol (Paris)** 1996 Feb;152(2):135–8 (10 ref.) (Eng. Abstr.) **(Fre)**
[The regression of a hepatocellular adenoma after the withdrawal of hormonal contraception] Daldrup HE, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1995 Nov;163(5):449–51 (12 ref.) **(Ger)**

NEOPLASM REMISSION, SPONTANEOUS see **NEOPLASM REGRESSION, SPONTANEOUS**

NEOPLASM, RESIDUAL

DIAGNOSIS

Detection of minimal residual disease in hematopoietic tissues. Sharp JG, et al. **Ann N Y Acad Sci** 1995 Dec 29; 770:242–61 (89 ref.)
Detection of minimal residual disease. Gribben J, et al.
Cancer Treat Res 1995;76:249–70 (94 ref.)
Postexcisional recurrence of carcinoma of the breast. Zavotsky J, et al. **J Am Coll Surg** 1996 Jan;182(1):71–7 (88 ref.)
Techniques for detection of minimal residual disease. Carlo-Stella C, et al. **Leuk Lymphoma** 1995;18 Suppl 1:75–80 (29 ref.)
The clinical significance of residual disease in childhood acute lymphoblastic leukemia as detected by polymerase chain reaction amplification by antigen-receptor gene sequences. Roberts WM, et al. **Leuk Lymphoma** 1996 Jan; 20(3–4):181–97 (50 ref.)

PATHOLOGY

Polymerase chain resction in the detection of micrometastases and circulating tumor cells [see comments] Ghossein RA, et al. **Cancer** 1996 Jul 1;78(1):10–6 (41 ref.) Comment in: Cancer 1996 Jul 1;78(1):1–3.
Culture methods for the detection of minimal tumor contamination of hematopoietic harvests: a review. Sharp JG, et al. **J Hematother** 1995 Jun;4(3):141–8 (53 ref.)
[Evaluation of the proliferative potential of residual tumor. Verification of parametric methods by computer simulation] Ivankov AA, et al. **Vopr Onkol** 1996;42(1):34–9 (14 ref.) **(Rus)**

NEOPLASM RNA see **RNA, NEOPLASM**

NEOPLASM SEEDING

Exfoliated tumour cells and locally recurrent colorectal cancer. Basha G, et al. **Acta Chir Belg** 1996 Apr;96(2):66–70 (41 ref.)
Abdominal wall metastasis and peritoneal carcinomatosis after laparoscopic-assisted colectomy for colon cancer. Jacquet P, et al. **Eur J Surg Oncol** 1995 Oct;21(5):568–70 (25 ref.)
Port site metastasis. An unresolved problem in laparoscopic surgery. A review. Martinez J, et al. **Int Surg** 1995 Oct–Dec;80(4):315–21 (106 ref.)
Port site recurrences after laparoscopic and thoracoscopic procedures in malignancy. Johnstone PA, et al.
J Clin Oncol 1996 Jun;14(6):1950–6 (38 ref.)
Abdominal wall metastasis following percutaneous endoscopic gastrostomy. Becker G, et al.
Support Care Cancer 1995 Sep;3(5):313–6 (18 ref.)
[Seed metastases following laparoscopic surgery for gastrointestinal malignancies] Nieveen van Dijkum EJ, et al. **Ned Tijdschr Geneeskd** 1996 Jul 6;140(27):1391–4 (50 ref.) **(Dut)**
[Tumor implantation in cicatrization sites following surgery for digestive cancers] Jacquet P, et al. **J Chir (Paris)** 1996 Jun;133(4):175–82 (63 ref.) (Eng. Abstr.) **(Fre)**
[Implantation metastases following laparoscopic cholecystectomy in gallbladder carcinoma] Buhr J, et al. **Dtsch Med Wochenschr** 1996 Jan 19;121(3):57–61; discussion 61–2 (36 ref.) (Eng. Abstr.) **(Ger)**

NEOPLASM STAGING

The TNM classification of prostate cancer: a discussion of the 1992 classification. The British Association of Urological Surgeons TNM Subcommittee. **Br J Urol** 1995 Sep;76(3):279–85 (22 ref.)
Clinical symptoms and comorbidity: significance for the prognostic classification of cancer. Piccirillo JF, et al.
Cancer 1996 Mar 1;77(5):834–42 (50 ref.)
Prognosis and staging of cutaneous T-cell lymphoma. Foss FM, et al. **Hematol Oncol Clin North Am** 1995 Oct; 9(5):1011–9 (22 ref.)
Inclusion of comorbidity in a staging system for head and neck cancer. Piccirillo JF. **Oncology (Huntingt)** 1995 Sep; 9(9):831–6; discussion 841, 845–8 (47 ref.)
[Stage I and II endometrial cancer: should lymphadenectomy still be done?] Descamps P, et al.
J Gynecol Obstet Biol Reprod (Paris) 1995;24(8):794–801 (48 ref.) (Eng. Abstr.) **(Fre)**

METHODS

Pathologic staging of prostate carcinoma. What are the issues? Grignon DJ, et al. **Cancer** 1996 Jul 15;78(2):337–40 (29 ref.)
Staging concepts for gastrointestinal malignancies: the importance of preoperative locoregional T- and N-staging. Hölscher AH, et al. **Gastrointest Endosc Clin N Am** 1995 Jul;5(3):529–36 (24 ref.)
Restaging after radiotherapy and chemotherapy: value of endoscopic ultrasonography. Hordijk ML.
Gastrointest Endosc Clin N Am 1995 Jul;5(3):601–8 (30 ref.)
Interobserver variation in tumor staging. Palazzo L, et al.
Gastrointest Endosc Clin N Am 1995 Jul;5(3):559–67 (28 ref.)
Endosonographic staging of esophageal cancer: a review of literature results. Rösch T.
Gastrointest Endosc Clin N Am 1995 Jul;5(3):537–47 (50 ref.)
Endosonographic staging of gastric cancer: a review of literature results. Rösch T.
Gastrointest Endosc Clin N Am 1995 Jul;5(3):549–57 (54 ref.)
Laparoscopic surgical staging of ovarian cancer. Childers JM, et al. **Gynecol Oncol** 1995 Oct;59(1):25–33 (30 ref.)
Optimal staging procedures, including imaging, to define prognosis of bladder cancer. Paulson D, et al.
Int J Urol 1995 Jun;2 Suppl 2:1–7 (8 ref.)
Molecular staging of genitourinary malignancies. Katz AE, et al. **Urology** 1996 Jun;47(6):948–58 (86 ref.)
[Tumor staging and follow-up care in rectosigmoid carcinoma: colonoscopic endosonography compared to CT, MRI and endorectal MRI] Meyenberger C, et al.
Schweiz Rundsch Med Prax 1996 May 7;85(19):622–31 (44 ref.) (Eng. Abstr.) **(Ger)**

NEOPLASM STEM CELL ASSAY see **TUMOR STEM CELL ASSAY**

NEOPLASM STRUCTURAL GENES see **GENES, STRUCTURAL, NEOPLASM**

NEOPLASM TRANSPLANTATION

Human breast cancer cell line xenografts as models of breast cancer. The immunobiologies of recipient mice and the characteristics of several tumorigenic cell lines. Clarke R. **Breast Cancer Res Treat** 1996;39(1):69–86 (147 ref.)
Influence of local cytokines on tumor metastasis: using cytokine gene-transfected tumor cells as experimental models. Qin Z, et al. **Curr Top Microbiol Immunol** 1996; 213 (Pt 3):55–64 (27 ref.)
Neoplasia: an example of plasticity of the immune response. Penn I. **Transplant Proc** 1996 Aug;28(4):2089–93 (29 ref.)
[Insulin producing cells as therapy in diabetes mellitus] Schnedl WJ, et al. **Naturwissenschaften** 1996 Jan;83(1):1–5 (41 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

A standardized flow cytometry protocol for mobilized peripheral CD34+ cells estimation and collection for autotransplantation in cancer patients. Brando B, et al.
Eur J Histochem 1994;38 Suppl 1:21–6 (12 ref.)

NEOPLASMS

see related
ANTIBODIES, NEOPLASM
ANTICARCINOGENIC AGENTS
ANTIGENS, NEOPLASM
ANTINEOPLASTIC AGENTS
CARCINOGENS
DNA, NEOPLASM
GENES, SUPPRESSOR, TUMOR
ONCOGENIC VIRUSES
PLEURAL EFFUSION, MALIGNANT
PRECANCEROUS CONDITIONS
RNA, NEOPLASM

ABC of work related disorders. Occupational cancers. Veys CA. **BMJ** 1996 Sep 7;313(7057):615–9 (0 ref.)
The effects of overfeeding and moderate dietary restriction on Sprague–Dawley rat survival, pathology, carcinogenicity, and the toxicity of pharmaceutical agents. Keenan KP, et al. **Exp Toxicol Pathol** 1996 Feb; 48(2–3):139–44 (24 ref.)
Tumor heterogeneity and immunotherapy of cancer. Fleuren GJ, et al. **Immunol Rev** 1995 Jun;145:91–122 (181 ref.)
Transgenic models to study the roles of inhibins and activins in reproduction, oncogenesis, and development. Matzuk MM, et al. **Recent Prog Horm Res** 1996;51:123–54; discussion 155–7 (107 ref.)
Symptom experience. McDaniel RW, et al.
Semin Oncol Nurs 1995 Nov;11(4):232–4 (21 ref.)

BLOOD

Proton nuclear magnetic resonance spectroscopy of plasma lipoprotein: technical problems and potential interest in cancer disease. de Certaines JD, et al. **Anticancer Res** 1996 May–Jun;16(3B):1451–60 (46 ref.)
Magnetic resonance spectroscopy of blood plasma lipoproteins in malignant disease: methodological aspects and clinical relevance. Engan T. **Anticancer Res** 1996 May–Jun;16(3B):1461–71 (85 ref.)
How to integrate serum tumor markers into clinical oncologic practice. van Dalen A. **Nutrition** 1995 Sep–Oct;11(5 Suppl):489–91 (21 ref.)

BLOOD SUPPLY

How tumors become angiogenic. Bouck N, et al.
Adv Cancer Res 1996;69:135–74 (376 ref.)
Scatter factor and angiogenesis. Rosen EM, et al.
Adv Cancer Res 1995;67:257–79 (93 ref.)
Role of VEGF-flt receptor system in normal and tumor angiogenesis. Shibuya M. **Adv Cancer Res** 1995;67:281–316 (141 ref.)
Tumor oxygenation: a matter of supply and demand. Gulledge CJ, et al. **Anticancer Res** 1996 Mar–Apr; 16(2):741–9 (68 ref.)
The clinical experience with antiangiogenic agents. Marshall JL, et al. **Breast Cancer Res Treat** 1995;36(2):253–61 (48 ref.)
Antibody-directed targeting of the vasculature of solid tumors. Thorpe PE, et al. **Breast Cancer Res Treat** 1995; 36(2):237–51 (55 ref.)
Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Weidner N. **Breast Cancer Res Treat** 1995; 36(2):169–80 (66 ref.)
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Hanahan D, et al. **Cell** 1996 Aug 9;86(3):353–64 (80 ref.)
Mast cells and tumor-associated angiogenesis. Meininger CJ. **Chem Immunol** 1995;62:239–57 (135 ref.)
Angiogenesis and cancer metastases: therapeutic approaches. Teicher BA. **Crit Rev Oncol Hematol** 1995 Aug; 20(1–2):9–39 (407 ref.)
Significance of angiogenesis in tumour progression and metastasis. Bikfalvi A. **Eur J Cancer** 1995 Jul–Aug; 31A(7–8):1101–4 (30 ref.)
Angiogenesis as a component of epithelial–mesenchymal interactions. Grant DS, et al. **EXS** 1995;74:235–48 (36 ref.)
Tumor cell interactions with the vascular endothelium and their role in cancer metastasis. Nicolson GL. **EXS** 1995; 74:123–56 (189 ref.)
The role of scatter factor and the c-met proto-oncogene in angiogenic responses. Polverini PJ, et al. **EXS** 1995; 74:51–67 (82 ref.)
Antiangiogenesis as a novel therapeutic concept in pediatric oncology. Schweigerer L. **J Mol Med** 1995 Oct; 73(10):497–508 (146 ref.)
Tumour angiogenesis. Fox SB, et al. **J Pathol** 1996 Jul; 179(3):232–7 (123 ref.)

Fish oil may impede tumour angiogenesis and invasiveness by down-regulating protein kinase C and modulating eicosanoid production. McCarty MF. **Med Hypotheses** 1996 Feb;46(2):107–15 (120 ref.)

Angiogenesis inhibitors generated by tumors. Folkman J. **Mol Med** 1995 Jan;1(2):120–2 (23 ref.)

Tumour angiogenesis: pathophysiology and clinical significance. Lichtenbeld HH, et al. **Neth J Med** 1996 Jul; 49(1):42–51 (126 ref.)

Fighting cancer by attacking its blood supply. Folkman J. **Sci Am** 1996 Sep;275(3):150–4 (0 ref.)

[Does the c-ets 1 oncogene participate in the regulation of tumor angiogenesis?] Vandenbunder B, et al. **Arch Inst Pasteur Tunis** 1994 Jul–Oct;71(3–4):493–509 (56 ref.) (Eng. Abstr.) **(Fre)**

[Anti-angiogenesis: a new concept in therapy of solid malignancies?] Schweigerer L. **Med Klin** 1995 Dec 15; 90(12):709–12 (52 ref.) **(Ger)**

[Angiogenesis--a marker for metastases] Sköldenberg E, et al. **Lakartidningen** 1996 May 8;93(19):1853–5 (24 ref.) **(Swe)**

CHEMICALLY INDUCED

The questionable link between alcohol intake and cancer. Rubin E. **Clin Chim Acta** 1996 Mar 15;246(1–2):143–8 (14 ref.)

Cancer risk after metal on metal and polyethylene on metal total hip arthroplasty. Visuri T, et al. **Clin Orthop** 1996 Aug;(329 Suppl):S280–9 (51 ref.)

Oral contraceptives and cancer. A review of the evidence. La Vecchia C, et al. **Drug Saf** 1996 Apr;14(4):260–72 (100 ref.)

Implications for risk assessment of suggested nongenotoxic mechanisms of chemical carcinogenesis. Melnick RL, et al. **Environ Health Perspect** 1996 Mar;104 Suppl 1:123–34 (122 ref.)

Drinking water and cancer. Morris RD. **Environ Health Perspect** 1995 Nov;103 Suppl 8:225–31 (47 ref.)

Can laboratory animal carcinogenicity studies predict cancer in exposed children? Rall DP. **Environ Health Perspect** 1995 Sep;103 Suppl 6:173–5 (17 ref.)

Nonhormonal drugs and cancer. Stolley PD, et al. **Environ Health Perspect** 1995 Nov;103 Suppl 8:191–6 (114 ref.)

Age-specific carcinogenesis: environmental exposure and susceptibility. Thomas RD. **Environ Health Perspect** 1995 Sep;103 Suppl 6:45–8 (47 ref.)

Childhood cancer: overview of incidence trends and environmental carcinogens. Zahm SH, et al. **Environ Health Perspect** 1995 Sep;103 Suppl 6:177–84 (143 ref.)

Is ingested inorganic arsenic a "threshold" carcinogen? Abernathy CO, et al. **Fundam Appl Toxicol** 1996 Feb; 29(2):168–75 (59 ref.)

Formaldehyde. **IARC Monogr Eval Carcinog Risks Hum** 1995;62:217–375 (479 ref.)

Occupational cancer in developed and developing countries. Vineis P, et al. **Int J Cancer** 1995 Sep 15;62(6):655–60 (32 ref.)

Do antidepressants cause, promote, or inhibit cancers? Steingart AB, et al. **J Clin Epidemiol** 1995 Nov; 48(11):1407–12 (43 ref.)

Hemoglobin adducts for in vivo dose monitoring and cancer risk estimation. Törnqvist M, et al. **J Occup Environ Med** 1995 Sep;37(9):1077–85 (41 ref.)

Carcinogenicity of lipid-lowering drugs [see comments] Newman TB, et al. **JAMA** 1996 Jan 3;275(1):55–60 (54 ref.) Comment in: JAMA 1996 Jan 3;275(1):67–9. Comment in: JAMA 1996 May 15;275(19):1479; discussion 1481–2. Comment in: JAMA 1996 May 15;275(19):1479–80; discussion 1481–2. Comment in: JAMA 1996 May 15;275(19):1480; discussion 1481–2. Comment in: JAMA 1996 May 15;275(19):1480–1; discussion 1481–2. Comment in: JAMA 1996 May 15;275(19):1481–2.

Enhancement of tumor growth by drugs with some common molecular actions. LaBella FS, et al. **Mol Carcinog** 1996 Jun;16(2):68–76 (91 ref.)

Antioxidant defences against reactive oxygen species causing genetic and other damage. Anderson D. **Mutat Res** 1996 Feb 19;350(1):103–8 (46 ref.)

Mechanisms for species differences in receptor-mediated carcinogenesis. Barrett JC. **Mutat Res** 1995 Dec; 333(1–2):189–202 (111 ref.)

DNA adducts in human carcinogenesis: etiological relevance and structure-activity relationship. Bartsch H. **Mutat Res** 1996 Jun;340(2–3):67–79 (67 ref.)

Receptor-mediated mechanisms in carcinogenesis: an overview. Capen CC, et al. **Mutat Res** 1995 Dec; 333(1–2):215–24 (15 ref.)

Membrane bound receptor tyrosine kinases and chemical carcinogenesis. Shawver LK, et al. **Mutat Res** 1995 Dec; 333(1–2):23–8 (27 ref.)

IARC activities in mycotoxin research. Castegnaro M, et al. **Nat Toxins** 1995;3(4):327–31; discussion 341 (29 ref.)

Trans fatty acids and cancer. Ip C, et al. **Nutr Rev** 1996 May; 54(5):138–45 (35 ref.)

Scientific challenges in environmental carcinogenesis. Hoffmann D, et al. **Prev Med** 1996 Jan–Feb;25(1):14–22 (85 ref.)

Mechanisms of estrogen-associated carcinogenesis. Barrett JC, et al. **Prog Clin Biol Res** 1996;394:105–11 (38 ref.)

Receptor-mediated carcinogenesis: the role of biological effect modeling for risk assessment of dioxin and tamoxifen. Demby KB, et al. **Prog Clin Biol Res** 1996;394:113–29 (57 ref.)

Chemically induced cancers in hormonal organs of laboratory animals and of humans. Huff J. **Prog Clin Biol Res** 1996; 394:77–102 (96 ref.)

Transplacental hormonal carcinogenesis: diethylstilbestrol as an example. Newbold RR, et al. **Prog Clin Biol Res** 1996; 394:131–47 (37 ref.)

The instability of tumor promotion in relation to human cancer risk. Pitot HC, et al. **Prog Clin Biol Res** 1995; 391:21–38 (120 ref.)

Measures of cell replication in risk/safety assessment of xenobiotic-induced, nongenotoxic carcinogenesis. Jones HB, et al. **Regul Toxicol Pharmacol** 1996 Apr;23(2):117–27 (103 ref.)

The role of regenerative cell proliferation in chloroform-induced cancer. Butterworth BE, et al. **Toxicol Lett** 1995 Dec;82–83:23–6 (27 ref.)

Cancer and non-cancer risk assessment: not so different if you consider mechanisms. Conolly RB. **Toxicology** 1995 Sep 1;102(1–2):179–88 (31 ref.)

[Hormone replacement therapy in menopause and cancers] Cappelaere P. **Rev Med Interne** 1995;16(12):945–59 (76 ref.) (Eng. Abstr.) **(Fre)**

[Occupational medicine aspects related to carcinogenic hazardous substances] Letzel S. **Dtsch Med Wochenschr** 1996 Jan 26;121(4):104–9 (11 ref.) **(Ger)**

[Biosynthesis and microbial transformation of griseofulvin and carcinogenesis and prevention of cancer by estrogens] Sato Y. **Yakugaku Zasshi** 1995 Nov;115(11):892–908 (80 ref.) (Eng. Abstr.) **(Jpn)**

[The role of genetically determined acetylation of drugs and xenobiotics in pathogenesis of neoplastic diseases] Niewiński P, et al. **Postepy Hig Med Dosw** 1996; 50(2):131–43 (50 ref.) (Eng. Abstr.) **(Pol)**

CHEMISTRY

Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Beck WT, et al. **Cancer Res** 1996 Jul 1;56(13):3010–20 (66 ref.)

Are CD44 variant isoforms involved in human tumour progression? Günthert U, et al. **Cancer Surv** 1995;24:19–42 (116 ref.)

How to probe clinical tumour samples for P-glycoprotein and multidrug resistance-associated protein. Broxterman HJ, et al. **Eur J Cancer** 1996 Jun;32A(6):1024–33 (86 ref.)

Diagnosis and reversal of multidrug resistance in paediatric cancers. Chan HS, et al. **Eur J Cancer** 1996 Jun; 32A(6):1051–61 (153 ref.)

Altered glycoprotein sugar-chain structures as possible diagnostic and prognostic markers in malignant tumors. Yoshida K, et al. **Int J Urol** 1995 Nov;2(5):281–7 (53 ref.)

[VLA and alpha6, beta4 integrins. Expression in normal and neoplastic human tissues] Hofman P, et al. **Arch Anat Cytol Pathol** 1995;43(5–6):309–24 (112 ref.) (Eng. Abstr.) **(Fre)**

[The clinical prospects for the study of epidermal growth factor receptors in human tumors] Kushpinskiĭ NE, et al. **Klin Lab Diagn** 1996 Jan–Feb;(1):9–12 (20 ref.) **(Rus)**

CLASSIFICATION

Clinical symptoms and comorbidity: significance for the prognostic classification of cancer. Piccirillo JF, et al. **Cancer** 1996 Mar 1;77(5):834–42 (50 ref.)

Classification and differential diagnosis of clear and basal cell tumors of the salivary glands. Seifert G. **Semin Diagn Pathol** 1996 May;13(2):95–103 (47 ref.)

COMPLICATIONS

Erythropoietin and the anemia of cancer. Beguin Y. **Acta Clin Belg** 1996;51(1):36–52 (104 ref.)

Clodronate and other bisphosphonates as supportive therapy in osteolysis due to malignancy. Elomaa I, et al. **Acta Oncol** 1995;34(5):629–36 (81 ref.)

Cutaneous paraneoplastic syndromes in solid tumors. Kurzrock R, et al. **Am J Med** 1995 Dec;99(6):662–71 (70 ref.)

Acute management of cancer-related hypercalcemia. Chisholm MA, et al. **Ann Pharmacother** 1996 May; 30(5):507–13 (58 ref.)

Paraneoplastic peripheral neuropathy. Smitt PS, et al. **Baillieres Clin Neurol** 1995 Nov;4(3):443–68 (120 ref.)

Phlegmasia caerulea dolens and venous gangrene. Perkins JM, et al. **Br J Surg** 1996 Jan;83(1):19–23 (62 ref.)

Pulmonary complications in cancer patients. Stover DE, et al. **CA Cancer J Clin** 1996 Sep–Oct;46(5):303–20 (58 ref.)

Diagnosis of cancer-associated vascular disorders. Naschitz JE, et al. **Cancer** 1996 May 1;77(9):1759–67 (110 ref.)

Mechanisms mediating cancer cachexia. Toomey D, et al. **Cancer** 1995 Dec 15;76(12):2418–26 (75 ref.)

Malignancy-related pericardial effusion. 127 cases from the Roswell Park Cancer Institute. Wilkes JD, et al. **Cancer** 1995 Oct 15;76(8):1377–87 (91 ref.)

Pathogenesis and management of cancer associated hypercalcaemia. Ralston SH. **Cancer Surv** 1994;21:179–96 (104 ref.)

Current approaches to the management of constipation. Sykes NP. **Cancer Surv** 1994;21:137–46 (52 ref.)

Anorexia and cachexia in advanced cancer patients. Vigano A, et al. **Cancer Surv** 1994;21:99–115 (76 ref.)

Chemoprophylaxis for the prevention of bacterial and fungal infections. Donnelly JP. **Cancer Treat Res** 1995;79:45–81 (276 ref.)

Signs and symptoms of infections and differential diagnosis from noninfectious conditions. Hemmer R. **Cancer Treat Res** 1995;79:31–44 (77 ref.)

Empiric therapy for bacterial infections in neutropenic patients. Klastersky J. **Cancer Treat Res** 1995;79:101–12 (34 ref.)

Intravascular device-related infections in cancer patients. Raad II, et al. **Cancer Treat Res** 1995;79:211–31 (149 ref.)

Factors predisposing cancer patients to infection. Viscoli C, et al. **Cancer Treat Res** 1995;79:1–30 (150 ref.)

Pneumonia in cancer patients. Whimbey E, et al. **Cancer Treat Res** 1995;79:185–210 (144 ref.)

New and unusual infections in neutropenic patients. Zinner SH. **Cancer Treat Res** 1995;79:173–84 (53 ref.)

Hemolytic anemia and cancer. Diehl LF, et al. **Cancer Treat Rev** 1996 Jan;22(1):33–73 (298 ref.)

Effective pain management in terminal care. Dahl JL. **Clin Geriatr Med** 1996 May;12(2):279–300 (92 ref.)

Management of diarrhea induced by tumors or cancer therapy. Cascinu S. **Curr Opin Oncol** 1995 Jul;7(4):325–9 (63 ref.)

Management of chemotherapy-induced anemia. Eguchi K. **Curr Opin Oncol** 1995 Jul;7(4):316–9 (33 ref.)

Human papillomavirus-associated malignancies in HIV-positive men and women. Palefsky J. **Curr Opin Oncol** 1995 Sep;7(5):437–41 (46 ref.)

Malignancies in pediatric AIDS. Mueller BU, et al. **Curr Opin Pediatr** 1996 Feb;8(1):45–9 (42 ref.)

The use of quinolones as therapy in granulocytopenic cancer patients. Comparison with other antimicrobials. Krcméry V Jr. **Drugs** 1995;49 Suppl 2:139–43 (30 ref.)

An approach to the design and implementation of clinical trials of empirical antibiotic therapy in febrile and neutropenic cancer patients. Viscoli C, et al. **Eur J Cancer** 1995 Nov;31A(12):2013–22 (60 ref.)

Coagulation disorders in cancer. Goad KE, et al. **Hematol Oncol Clin North Am** 1996 Apr;10(2):457–84 (308 ref.)

Hypercoagulability in cancer. Green KB, et al. **Hematol Oncol Clin North Am** 1996 Apr;10(2):499–530 (144 ref.)

The thrombocytopenia of cancer. Prospects for effective cytokine therapy. Kaushansky K. **Hematol Oncol Clin North Am** 1996 Apr;10(2):431–55 (167 ref.)

Anemia of cancer. Moliterno AR, et al. **Hematol Oncol Clin North Am** 1996 Apr;10(2):345–63 (78 ref.)

Hemolytic disorders associated with cancer. Rytting M, et al. **Hematol Oncol Clin North Am** 1996 Apr;10(2):365–76 (87 ref.)

Dyspnoea: a study of measurement instruments for the assessment of dyspnoea and their application for patients with advanced cancer. van der Molen B. **J Adv Nurs** 1995 Nov;22(5):948–56 (49 ref.)

Infection prevention strategies for children with cancer and AIDS: contrasting dilemmas. Chanock SJ, et al. **J Hosp Infect** 1995 Jun;30 Suppl:197–208 (69 ref.)

France: status of cancer pain and palliative care. Larue F, et al. **J Pain Symptom Manage** 1996 Aug;12(2):106–8 (11 ref.)

The Philippines: status of cancer pain and palliative care. Laudico AV. **J Pain Symptom Manage** 1996 Aug; 12(2):133–5 (10 ref.)

Development of the World Health Organization Guidelines on Cancer Pain Relief and Palliative Care in Children. McGrath PA. **J Pain Symptom Manage** 1996 Aug; 12(2):87–92 (12 ref.)

The World Health Organization Cancer Pain and Palliative Care Program. Past, present, and future. Stjernswärd J, et al. **J Pain Symptom Manage** 1996 Aug;12(2):65–72 (31 ref.)

The Netherlands: status of cancer pain and palliative care. Zylicz Z. **J Pain Symptom Manage** 1996 Aug;12(2):136–8 (13 ref.)

Quality improvement guidelines for the treatment of acute pain and cancer pain. American Pain Society Quality of Care Committee [see comments] **JAMA** 1995 Dec 20; 274(23):1874–80 (67 ref.) Comment in: JAMA 1995 Dec 20;274(23):1881–2.

The WHO analgesic ladder for cancer pain management. Stepping up the quality of its evaluation [see comments] Jadad AR, et al. **JAMA** 1995 Dec 20;274(23):1870–3 (40 ref.) Comment in: JAMA 1995 Dec 20;274(23):1881–2. Comment in: JAMA 1996 Mar 20;275(11):835; discussion 836. Comment in: JAMA 1996 Mar 20;275(11):835–6.

Cancer pain. O'Neill WM. **Middle East J Anesthesiol** 1996 Feb;13(4):373–8 (7 ref.)

Pharmacologic treatment of cancer pain. Levy MH. **N Engl J Med** 1996 Oct 10;335(15):1124–32 (101 ref.)

Medical emergencies in oncology. Advani SH, et al. **Natl Med J India** 1995 Nov–Dec;8(6):273–6 (0 ref.)

From laboratory to bedside: new strategies in the treatment of malnutrition in cancer patients. Laviano A, et al. **Nutrition** 1996 Feb;12(2):112–22 (139 ref.)

Patient-induced dehydration--can it ever be therapeutic? Smith SA. **Oncol Nurs Forum** 1995 Nov–Dec;

22(10):1487–91 (20 ref.)
Serotonin mechanisms in chemotherapy-induced emesis in cancer patients. Cubeddu LX. **Oncology** 1996 Jun;53 Suppl 1:18–25 (34 ref.)
The outpatient management of febrile neutropenia in cancer patients. Freifeld AG, et al. **Oncology (Huntingt)** 1996 Apr; 10(4):599–606, 611–2; discussion 615–6 (31 ref.)
Diagnosis and management of brachial plexus lesions in cancer patients. Kori SH. **Oncology (Huntingt)** 1995 Aug; 9(8):756–60; discussion 765 (31 ref.)
Interventional radiology in a palliative care setting. Jones SN. **Palliat Med** 1995 Oct;9(4):319–26 (23 ref.)
Use of nonsteroidal anti-inflammatory drugs in cancer. Pace V. **Palliat Med** 1995 Oct;9(4):273–86 (105 ref.)
Secretory diarrhea in children: newly recognized toxins and hormone-secreting tumors. Udall JN Jr. **Pediatr Clin North Am** 1996 Apr;43(2):333–53 (78 ref.)
Controlling the pain of cancer. Foley KM. **Sci Am** 1996 Sep; 275(3):164–5 (0 ref.)
Tumor-induced osteomalacia. Schapira D, et al. **Semin Arthritis Rheum** 1995 Aug;25(1):35–46 (79 ref.)
Symptom management: loss of concentration. Cimprich B. **Semin Oncol Nurs** 1995 Nov;11(4):279–88 (80 ref.)
The symptom experience of mucositis, stomatitis, and xerostomia. Dose AM. **Semin Oncol Nurs** 1995 Nov; 11(4):248–55 (59 ref.)
Management of cutaneous symptoms. Gallagher J. **Semin Oncol Nurs** 1995 Nov;11(4):239–47 (63 ref.)
Anorexia, cachexia, and dysphagia: the symptom experience. Grant MM, et al. **Semin Oncol Nurs** 1995 Nov;11(4):266–71 (32 ref.)
Fatigue and weakness in cancer patients: the symptoms experience. Nail LM, et al. **Semin Oncol Nurs** 1995 Nov; 11(4):272–8 (42 ref.)
The symptom experience of alopecia. Pickard-Holley S. **Semin Oncol Nurs** 1995 Nov;11(4):235–8 (16 ref.)
Nausea, vomiting, and retching: the management of the symptom experience. Rhodes VA, et al. **Semin Oncol Nurs** 1995 Nov;11(4):256–65 (32 ref.)
Constipation and diarrhea: the neglected symptoms. Wright PS, et al. **Semin Oncol Nurs** 1995 Nov;11(4):289–97 (87 ref.)
Opportunistic infections in immunocompromised patients. Chaignaud BE, et al. **Semin Pediatr Surg** 1995 Nov; 4(4):245–51 (91 ref.)
Management of cancer pain. Conroy JM, et al. **South Med J** 1996 Aug;89(8):744–60; quiz 761 (153 ref.)
Herpes zoster and internal malignancy. Smith JB, et al. **South Med J** 1995 Nov;88(11):1089–92 (25 ref.)
Prevention and therapy of fungal infections in cancer patients. A review of recently published information [see comments] Klastersky J. **Support Care Cancer** 1995 Nov; 3(6):393–401 (42 ref.) Comment in: Support Care Cancer 1995 Nov;3(6):385–6.
Malignant obstructive jaundice. Evaluation and management. Rossi RL, et al. **Surg Clin North Am** 1996 Feb;76(1):63–70 (18 ref.)
Malignancy, mortality, and medicosurgical management of Clostridium septicum infection. Larson CM, et al. **Surgery** 1995 Oct;118(4):592–7; discussion 597–8 (13 ref.)
Cancer and thrombosis: from Phlegmasia alba dolens to transgenic mice. Donati MB. **Thromb Haemost** 1995 Jul; 74(1):278–81 (32 ref.)
[Treatment of anemia in patients with tumors] Tesařová P, et al. **Cas Lek Cesk** 1995 Oct 18;134(20):647–50 (29 ref.) (Eng. Abstr.) **(Cze)**
[Erythropoietin in oncology. II. Evaluation of the effectiveness of erythropoietin in hematologic and oncologic diseases] Adam Z, et al. **Vnitr Lek** 1996 May; 42(5):351–8 (82 ref.) (Eng. Abstr.) **(Cze)**
[Mental confusion syndromes in oncology] Reich MG, et al. **Bull Cancer (Paris)** 1996 Feb;83(2):115–28 (73 ref.) (Eng. Abstr.) **(Fre)**
[Pain management in cancer patients] Willenbrink HJ, et al. **Dtsch Med Wochenschr** 1995 Oct 6;120(40):1363–6 (13 ref.) **(Ger)**
[Malignancy associated with hypercalcemia] Eto S. **Nippon Naika Gakkai Zasshi** 1996 Mar 10;85(3):371–6 (10 ref.) **(Jpn)**
[Hematologic disturbances in patients with nonhematologic neoplasms. I. Anemias] Kwiatkowski A, et al. **Przegl Lek** 1995;52(8):407–9 (11 ref.) **(Pol)**
[Hematologic disturbances in patients with nonhematologic neoplasms. II. Thrombosis, bleedings and leukemoid reaction] Kwiatkowski A, et al. **Przegl Lek** 1995; 52(8):410–2 (11 ref.) **(Pol)**
[Cerebrovascular complications in patients with cancer] Casado JL, et al. **Rev Neurol** 1995;23 Suppl 1:S70–8 (75 ref.) **(Spa)**
[Childhood cancer and chickenpox. Principles of management] Lidin-Janson G, et al. **Lakartidningen** 1996 Jun 19;93(25):2434–6 (19 ref.) **(Swe)**

CONGENITAL

Nursing management of the infant with a congenital malignancy. Thompson DG, et al. **J Obstet Gynecol Neonatal Nurs** 1996 Jan;25(1):32–8 (23 ref.)

DIAGNOSIS

Case-control studies of screening efficacy: the use of persons newly diagnosed with cancer who later sustain an unfavorable outcome. Weiss NS, et al. **Am J Epidemiol** 1996 Feb 15;143(4):319–22 (4 ref.)
Dynamic use of tumor markers, rationale-clinical applications and pitfalls. Gion M, et al. **Anticancer Res** 1996 Jul-Aug;16(4B):2279–84 (61 ref.)
Novel approaches to tumor detection and therapy using a combination of monoclonal antibody and cytokine. Greiner JW, et al. **Anticancer Res** 1996 Jul-Aug;16(4B):2129–33 (23 ref.)
Human cancers detected by proton MRS and chemical shift imaging ex vivo. Mountford CE, et al. **Anticancer Res** 1996 May-Jun;16(3B):1521–31 (38 ref.)
Tumor markers as targets for selective diagnostic and therapeutic procedures. Roselli M, et al. **Anticancer Res** 1996 Jul-Aug;16(4B):2187–92 (59 ref.)
Tumour markers: from laboratory to clinical use. Torre GC, et al. **Anticancer Res** 1996 Jul-Aug;16(4B):2215–9 (16 ref.)
College of American Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors. Summary. Members of the Cancer Committee. Henson DE, et al. **Arch Pathol Lab Med** 1995 Dec;119(12):1109–12 (10 ref.)
Growth factors: potential for the management of solid epithelial tumours. Jankowski JA. **Baillieres Clin Gastroenterol** 1996 Mar;10(1):165–79 (64 ref.)
Can molecular markers now be used for early diagnosis of malignancy? Duffy MJ. **Clin Chem** 1995 Oct;41(10):1410–3 (38 ref.)
Recent progress in the use of monoclonal antibodies for imaging and therapy. Monson JR. **Curr Opin Gen Surg** 1993;:334–9 (24 ref.)
Bromodeoxyuridine: a diagnostic tool in biology and medicine, Part II: Oncology, chemotherapy and carcinogenesis. Dolbeare F. **Histochem J** 1995 Dec; 27(12):923–64 (468 ref.)
Interference by human antibodies with tumor marker assays. Reinsberg J. **Hybridoma** 1995 Apr;14(2):205–8 (30 ref.)
Altered glycoprotein sugar-chain structures as possible diagnostic and prognostic markers in malignant tumors. Yoshida K, et al. **Int J Urol** 1995 Nov;2(5):281–7 (53 ref.)
Imaging of pedal soft tissue neoplasms. Levey DS, et al. **J Foot Ankle Surg** 1995 Jul-Aug;34(4):411–8 (23 ref.)
The spectrum of non-AIDS-defining neoplastic disease in HIV infection. Remick SC. **J Investig Med** 1996 Jun; 44(5):205–15 (183 ref.)
Tumors of the ankle and foot. Shankman S, et al. **Magn Reson Imaging Clin N Am** 1994 Feb;2(1):139–53 (57 ref.)
The disclosure of the diagnosis of cancer. Carnes JW, et al. **Med Clin North Am** 1996 Jan;80(1):145–51 (10 ref.)
Applications of fluorescent in situ hybridization (FISH) to genetic analysis of human tumors. Wolman SR. **Pathol Annu** 1995;30 Pt 2:227–43 (50 ref.)
Discussing the diagnosis and prognosis with cancer patients. Bennett M, et al. **Postgrad Med J** 1996 Jan;72(843):25–9 (14 ref.)
Advances in tumor imaging. Giger ML, et al. **Sci Am** 1996 Sep;275(3):110–2 (0 ref.)
Advances in cancer detection. Sidransky D. **Sci Am** 1996 Sep;275(3):104–9 (0 ref.)
Classification and differential diagnosis of clear and basal cell tumors of the salivary glands. Seifert G. **Semin Diagn Pathol** 1996 May;13(2):95–103 (47 ref.)
Monoclonal antibodies: innovations in diagnosis and therapy. Baquiran DC, et al. **Semin Oncol Nurs** 1996 May; 12(2):130–41 (71 ref.)
The 1993 ISOBM Abbott Award Lecture. Isozymes, tumor markers and oncodevelopmental biology. Fishman WH. **Tumour Biol** 1995;16(6):394–402 (58 ref.)
[The cytological screening problems in cancer of the cervix uteri] Khristova L. **Akush Ginekol (Sofiia)** 1994;33(2):39–40 (14 ref.) **(Bul)**
[Monoclonal antibodies for diagnosis and therapy in oncological patients] Boven E, et al. **Ned Tijdschr Geneeskd** 1995 Dec 9;139(49):2552–8 (31 ref.) **(Dut)**
[When should a child be suspected of having a malignancy?] Saarinen U. **Duodecim** 1995;111(5):466–70 (5 ref.) **(Fin)**
[Tumor diagnosis, therapy and drug targeting with magnetic fluids] Günther D. **Pharm Unserer Zeit** 1996 May; 25(3):130–4 (10 ref.) **(Ger)**
[Paraneoplastic syndromes] Kaboth U, et al. **Urologe A** 1995 Sep;34(5):431–6 (0 ref.) **(Ger)**
[Three-dimensional image diagnosis of neoplasms] Moriyama N. **Nippon Naika Gakkai Zasshi** 1996 Mar 10;85(3):333–6 (7 ref.) **(Jpn)**
[Role of tumor marker in the presymptomatic diagnosis of hereditary malignant tumors] Baba S, et al. **Nippon Rinsho** 1996 Jun;54(6):1597–603 (13 ref.) (Eng. Abstr.) **(Jpn)**
[Expression of EGF receptor subfamily in tumor] Gamou S, et al. **Nippon Rinsho** 1996 Jun;54(6):1521–8 (29 ref.) (Eng. Abstr.) **(Jpn)**
[Intermediate filaments] Hirasawa T, et al. **Nippon Rinsho** 1996 Jun;54(6):1542–50 (28 ref.) (Eng. Abstr.) **(Jpn)**
[Current advancement of assay of tumor markers and the perspective in future] Kawamura T. **Nippon Rinsho** 1996 Jun;54(6):1642–8 (17 ref.) (Eng. Abstr.) **(Jpn)**
[Sensitivity and specificity of tumor markers in cancer diagnosis] Motoo Y, et al. **Nippon Rinsho** 1996 Jun; 54(6):1587–91 (14 ref.) (Eng. Abstr.) **(Jpn)**
[Amines and pteridines] Shimpo K, et al. **Nippon Rinsho** 1996 Jun;54(6):1515–20 (22 ref.) (Eng. Abstr.) **(Jpn)**
[Organ specificity of tumor markers and its application for clinical diagnosis] Watanabe N. **Nippon Rinsho** 1996 Jun; 54(6):1592–6 (6 ref.) (Eng. Abstr.) **(Jpn)**
[AP-PCR genomic fingerprinting] Kohno T, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):629–32 (3 ref.) **(Jpn)**
[Molecular diagnosis of cancer by non-radioisotopic PCR/SSCP analysis] Sugano K. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):638–42 (8 ref.) **(Jpn)**

DIET THERAPY

Nutritional pharmacology and malignant disease: a therapeutic modality in patients with cancer. Heys SD, et al. **Br J Surg** 1996 May;83(5):608–19 (135 ref.)
beta-carotene and cancer chemoprevention. Buring JE, et al. **J Cell Biochem Suppl** 1995;22:226–30 (37 ref.)

DRUG THERAPY

Role of deferoxamine in tumor therapy. Donfrancesco A, et al. **Acta Haematol** 1996;95(1):66–9 (16 ref.)
Present research trends in cancer chemotherapy. Eckhardt S. **Acta Med Hung** 1994;50(3–4):133–40 (14 ref.)
The use of porphyrins and non-ionizing radiation for treatment of cancer. Evensen JF. **Acta Oncol** 1995; 34(8):1103–10 (79 ref.)
Development of antiemetic therapy in cancer patients. Herrstedt J. **Acta Oncol** 1995;34(5):637–40 (42 ref.)
Selenium: a quest for better understanding. Badmaev V, et al. **Altern Ther Health Med** 1996 Jul;2(4):59–62, 65–7 (87 ref.)
Will increases in dose intensity improve outcome: con [comment] Souhami RL. **Am J Med** 1995 Dec 29; 99(6A):71S–76S (39 ref.) Comment on: Am J Med 1995 Dec 29;99(6A):69S–70S.
High-dose chemotherapy of solid tumours. Crown J. **Ann Oncol** 1995;6 Suppl 1:11–4; discussion 14–5 (57 ref.)
Potential uses of interferon alpha 2 as adjuvant therapy in cancer. Agarwala SS, et al. **Ann Surg Oncol** 1995 Jul; 2(4):365–71 (44 ref.)
Safety profile of gemcitabine. Tonato M, et al. **Anticancer Drugs** 1995 Dec;6 Suppl 6:27–32 (11 ref.)
Review of current clinical experience with prolonged (oral) etoposide in cancer treatment. de Jong RS, et al. **Anticancer Res** 1995 Sep-Oct;15(5B):2319–30 (120 ref.)
Induction (neo-adjuvant) chemotherapy: systemic and arterial delivery techniques and their clinical applications. Stephens FO. **Aust N Z J Surg** 1995 Oct;65(10):699–707 (57 ref.)
Current perspectives on camptothecins in cancer treatment [editorial] Dancey J, et al. **Br J Cancer** 1996 Aug; 74(3):327–38 (146 ref.)
The clinical experience with antiangiogenic agents. Marshall JL, et al. **Breast Cancer Res Treat** 1995;36(2):253–61 (48 ref.)
Homoharringtonine: an effective new natural product in cancer chemotherapy. Zhou DC, et al. **Bull Cancer (Paris)** 1995 Dec;82(12):987–95 (83 ref.)
Cisplatin. Dabholkar M, et al. **Cancer Chemother Biol Response Modif** 1996;16:88–110 (101 ref.)
Cytokines and immunological monitoring. Kopp WC, et al. **Cancer Chemother Biol Response Modif** 1996;16:189–238 (203 ref.)
Hematopoietic growth factors in cancer chemotherapy. Morstyn G, et al. **Cancer Chemother Biol Response Modif** 1996;16:295–314 (99 ref.)
Mitomycins. Verweij J. **Cancer Chemother Biol Response Modif** 1996;16:48–56 (43 ref.)
Is interleukin 3 active in anticancer drug-induced thrombocytopenia? Newland AC. **Cancer Chemother Pharmacol** 1996;38 Suppl:S83–8 (46 ref.)
Progress in preclinical and clinical studies for the development of new anticancer drugs in Japan, with emphasis on taxanes. Saijo N, et al. **Cancer Chemother Pharmacol** 1996;38 Suppl:S11–5 (21 ref.)
New promising anticancer agents in development: what comes next? Verweij J. **Cancer Chemother Pharmacol** 1996; 38 Suppl:S3–10 (69 ref.)
Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Beck WT, et al. **Cancer Res** 1996 Jul 1;56(13):3010–20 (66 ref.)
The reversal of multidrug resistance. Fisher GA, et al. **Cancer Treat Res** 1995;78:45–70 (138 ref.)
Drug interaction and pharmacological considerations during anti-infective therapy in cancer patients. Petitjean O, et al. **Cancer Treat Res** 1995;79:255–80 (223 ref.)
Potential for protein kinase C inhibitors in cancer therapy. Philip PA, et al. **Cancer Treat Res** 1995;78:3–27 (156 ref.)
Use of hydroxyurea to alter drug resistance of human tumor cells. Van den Berg C, et al. **Cancer Treat Res** 1995; 78:95–114 (123 ref.)
The comparative clinical pharmacology of vincristine and vindesine: does vindesine offer any advantage in clinical use? Joel S. **Cancer Treat Rev** 1996 Nov;21(6):513–25 (75 ref.)

Docetaxel (Taxotere): single agent activity, development of combination treatment and reducing side-effects. Pronk LC, et al. **Cancer Treat Rev** 1995 Sep;21(5):463–78 (93 ref.)
Photodynamic therapy. Stables GI, et al. **Cancer Treat Rev** 1995 Jul;21(4):311–23 (98 ref.)
Concepts in use of high-dose methotrexate therapy. Treon SP, et al. **Clin Chem** 1996 Aug;42(8 Pt 2):1322–9 (66 ref.)
Economic evaluation of new treatments: haematopoietic growth factors. Johnson NJ, et al. **Clin Oncol (R Coll Radiol)** 1996;8(1):43–7 (29 ref.)
Multicellular resistance: a new paradigm to explain aspects of acquired drug resistance of solid tumors. Kerbel RS, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:661–72 (79 ref.)
High-dose chemotherapy for malignancies: a review. Roman-Unfer S, et al. **Compr Ther** 1996 Feb;22(2):107–20 (128 ref.)
Hormone resistance in cancer: the role of abnormal steroid receptors. Sluyser M. **Crit Rev Oncog** 1994;5(6):539–54 (122 ref.)
Angiogenesis and cancer metastases: therapeutic approaches. Teicher BA. **Crit Rev Oncol Hematol** 1995 Aug; 20(1–2):9–39 (407 ref.)
Therapeutic strategies for cytokines. Dutcher JP. **Curr Opin Oncol** 1995 Nov;7(6):566–71 (76 ref.)
Cardiotoxicity and cardioprotection during chemotherapy. Hochster H, et al. **Curr Opin Oncol** 1995 Jul;7(4):304–9 (37 ref.)
Strategies to prevent nephrotoxicity of anticancer drugs. Skinner R. **Curr Opin Oncol** 1995 Jul;7(4):310–5 (38 ref.)
Potential of antineoplastons in diseases of old age. Burzynski SR. **Drugs Aging** 1995 Sep;7(3):157–67 (175 ref.)
The role of the immune system in anti-tumour responses. Potential for drug therapy. Dermime S, et al. **Drugs Aging** 1995 Oct;7(4):266–77 (152 ref.)
Early clinical studies with docetaxel. Docetaxel Investigators Group. Aapro M, et al. **Eur J Cancer** 1995;31A Suppl 4:S7–10 (13 ref.)
Clinical trials of P-glycoprotein reversal in solid tumours. Ferry DR, et al. **Eur J Cancer** 1996 Jun;32A(6):1070–81 (119 ref.)
Pharmacological considerations in the modulation of multidrug resistance. Fisher GA, et al. **Eur J Cancer** 1996 Jun;32A(6):1082–8 (69 ref.)
Haemopoietic growth factors and childhood cancer. Hann IM. **Eur J Cancer** 1995;31A(9):1476–8 (27 ref.)
Chemotherapeutic tumour targeting using clostridial spores. Minton NP, et al. **FEMS Microbiol Rev** 1995 Oct; 17(3):357–64 (40 ref.)
Rationales to consider the use of melatonin as a chrono-oncotherapeutic drug. Bartsch C, et al. **In Vivo** 1995 Jul–Aug;9(4):305–9 (62 ref.)
Marker rhythms for cancer chronotherapy. From laboratory animals to human beings. Focan C. **In Vivo** 1995 Jul–Aug; 9(4):283–98 (113 ref.)
Regional chemotherapy: revisited [editorial] Markman M. **J Cancer Res Clin Oncol** 1996;122(1):1–2 (11 ref.)
Current concepts of treatment in medical oncology: new anticancer drugs. Unger C. **J Cancer Res Clin Oncol** 1996; 122(4):189–98 (29 ref.)
Docetaxel. Cortes JE, et al. **J Clin Oncol** 1995 Oct; 13(10):2643–55 (104 ref.)
Current concepts for chronochemotherapy of cancer. Laerum OD, et al. **J Infus Chemother** 1995;5(3 Suppl 1):159–70 (189 ref.)
DNA repair: enzymatic mechanisms and relevance to drug response. Chaney SG, et al. **J Natl Cancer Inst** 1996 Oct 2;88(19):1346–60 (253 ref.)
The secondary leukemias: challenges and research directions. Smith MA, et al. **J Natl Cancer Inst** 1996 Apr 3; 88(7):407–18 (199 ref.)
Pediatric phase I drug tolerance: a review and comparison of recent adult and pediatric phase I trials. Carlson L, et al. **J Pediatr Hematol Oncol** 1996 Aug;18(3):250–6 (83 ref.)
Endocrine treatment of cancer. Gulliford T, et al. **J R Soc Med** 1996 Aug;89(8):448–53 (37 ref.)
Vitamin D3 as a possible chemopreventive and therapeutic agent of cancers. DeLuca HF. **Jpn J Cancer Res** 1996 Apr; 87(4):inside front cover (10 ref.)
Successful cancer therapy with promethazine: the rationale. Jones GR. **Med Hypotheses** 1996 Jan;46(1):25–9 (28 ref.)
Fish oil may impede tumour angiogenesis and invasiveness by down-regulating protein kinase C and modulating eicosanoid production. McCarty MF. **Med Hypotheses** 1996 Feb;46(2):107–15 (120 ref.)
Modulation of 5-fluorouracil by interferon: a review of potential cellular targets. Horowitz R, et al. **Med Oncol** 1995 Mar;12(1):3–8 (48 ref.)
Octreotide. Lamberts SW, et al. **N Engl J Med** 1996 Jan 25;334(4):246–54 (76 ref.)
New anticancer agents in clinical development. Eckardt J, et al. **Oncology (Huntingt)** 1995 Dec;9(12):1321–8; 1331; discussion 1332–4 (147 ref.)
Economic outcomes associated with the use of hematopoietic growth factors. Glaspy JA. **Oncology (Huntingt)** 1995 Nov; 9(11 Suppl):93–105 (45 ref.)
Circadian rhythms and cancer chemotherapy. Focan C. **Pharmacol Ther** 1995;67(1):1–52 (289 ref.)
Molecular, cellular, and clinical aspects of the pharmacology of 20(S)camptothecin and its derivatives. Rivory LP, et al. **Pharmacol Ther** 1995;68(2):269–96 (170 ref.)
Fighting cancer by attacking its blood supply. Folkman J. **Sci Am** 1996 Sep;275(3):150–4 (0 ref.)
The performance of e23(Fv)PEs, recombinant toxins targeting the erbB-2 protein. King CR, et al. **Semin Cancer Biol** 1996 Apr;7(2):79–86 (48 ref.)
Future development of amifostine in cancer treatment. Alberts DS, et al. **Semin Oncol** 1996 Aug;23(4 Suppl 8):90–9 (61 ref.)
CPT-11: clinical experience in phase I studies. Armand JP. **Semin Oncol** 1996 Feb;23(1 Suppl 3):27–33 (22 ref.)
Amifostine and chemotherapy-related thrombocytopenia. Budd GT. **Semin Oncol** 1996 Aug;23(4 Suppl 8):49–52 (31 ref.)
Amifostine: the preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies. Capizzi R. **Semin Oncol** 1996 Aug;23(4 Suppl 8):2–17 (99 ref.)
Ongoing clinical studies of ifosfamide for pediatric cancer in the United States. Pratt CB. **Semin Oncol** 1996 Jun;23(3 Suppl 6):84–90 (51 ref.)
CPT-11: an original spectrum of clinical activity. Rothenberg ML. **Semin Oncol** 1996 Feb;23(1 Suppl 3):21–6 (38 ref.)
Amifostine and radiation therapy: past, present, and future. Tannehill SP, et al. **Semin Oncol** 1996 Aug;23(4 Suppl 8):69–77 (40 ref.)
Arterial, peritoneal, and intraventricular access devices. Almadrones L, et al. **Semin Oncol Nurs** 1995 Aug; 11(3):194–202 (23 ref.)
Ambulatory infusion pumps: application to oncology. Rapsilber LM, et al. **Semin Oncol Nurs** 1995 Aug; 11(3):213–20 (46 ref.)
Laser photochemotherapy: a less invasive approach for treatment of cancer. Saxton RE, et al. **Semin Surg Oncol** 1995 Jul–Aug;11(4):283–9 (76 ref.)
Prodrugs in cancer chemotherapy. Connors TA, et al. **Stem Cells (Dayt)** 1995 Sep;13(5):501–11 (76 ref.)
Bcl-2 family proteins: regulators of chemoresistance in cancer. Reed JC. **Toxicol Lett** 1995 Dec;82–83:155–8 (21 ref.)
Cisplatin and DNA repair in cancer chemotherapy. Zamble DB, et al. **Trends Biochem Sci** 1995 Oct;20(10):435–9 (33 ref.)
[Photobiologic effects of porphyrins and their use in therapy of tumors] Hrkal Z, et al. **Cas Lek Cesk** 1996 Apr 17; 135(8):236–8 (20 ref.) (Eng. Abstr.) **(Cze)**
[Photodynamic therapy of malignant tumors] Jirsa M. **Sb Lek** 1996;97(1):115–34 (98 ref.) **(Cze)**
[Role of bisphosphonates in the treatment of tumoral osteolysis] Claudepierre P, et al. **Ann Med Interne (Paris)** 1995;146(5):325–7 (38 ref.) **(Fre)**
[Topoisomerase I inhibitors. Review of phase II trials with irinotecan (CPT-11) and topotecan] Bonneterre J. **Bull Cancer (Paris)** 1995 Aug;82(8):623–8 (52 ref.) (Eng. Abstr.) **(Fre)**
[Dose optimization in clinical oncology: pharmacokinetic-pharmacodynamic relationship] Canal P, et al. **Bull Cancer (Paris)** 1996 Apr;83(4):256–65 (65 ref.) (Eng. Abstr.) **(Fre)**
[Efficacy of ondansetron in acute and delayed cisplatin-induced nausea and vomiting] Depierre A. **Bull Cancer (Paris)** 1996 Feb;83(2):147–53 (29 ref.) (Eng. Abstr.) **(Fre)**
[Cytotoxic chemotherapy in elderly patients: present and future] Freyer G, et al. **Bull Cancer (Paris)** 1995 Jul; 82(7):531–40 (66 ref.) (Eng. Abstr.) **(Fre)**
[Paclitaxel (Taxol) and docetaxel (Taxotere): results of phase II trials in monochemotherapy] Fumoleau P, et al. **Bull Cancer (Paris)** 1995 Aug;82(8):629–36 (58 ref.) (Eng. Abstr.) **(Fre)**
[Standards, options and recommendations for a successful practice in chemotherapy. National Federation of Centers for the Fight against Cancer] Heron JF, et al. **Bull Cancer (Paris)** 1995 Oct;82(10):823–34 (44 ref.) **(Fre)**
[Etoposide: specificity of prolonged oral administration] Munck JN. **Bull Cancer (Paris)** 1996 May;83(5):352–60 (66 ref.) (Eng. Abstr.) **(Fre)**
[Synthetic progestational hormones in the treatment of neoplastic cachexia] Freyer G, et al. **Rev Med Interne** 1996; 17(1):79–84 (21 ref.) (Eng. Abstr.) **(Fre)**
[Clinical phase I studies in oncology and hematology. Concepts, implementation and ethical considerations] Hanauske AR. **Med Klin** 1996 Apr 12;91 Suppl 3:68–70 (28 ref.) **(Ger)**
[Value of corticoids in hematology/oncology in adulthood] Schlimok G, et al. **Med Klin** 1995 Oct 15;90(10):579–84 (23 ref.) **(Ger)**
[Anti-angiogenesis: a new concept in therapy of solid malignancies?] Schweigerer L. **Med Klin** 1995 Dec 15; 90(12):709–12 (52 ref.) **(Ger)**
[Methods for optimizing cytostatic drug therapy] Lipp HP. **Med Monatsschr Pharm** 1995 Oct;18(10):282–91 (63 ref.) **(Ger)**
[Protein-carbohydrate recognition. Foundation and medical application with illustrations of tumor lectin studies] Gabius HJ, et al. **Naturwissenschaften** 1995 Dec;82(12):533–43 (162 ref.) (Eng. Abstr.) **(Ger)**
[Tumor diagnosis, therapy and drug targeting with magnetic fluids] Günther D. **Pharm Unserer Zeit** 1996 May; 25(3):130–4 (10 ref.) **(Ger)**
[Use of taxol in the management of malignant tumors] Eckhardt S. **Orv Hetil** 1995 Sep 10;136(37):1987–93 (85 ref.) (Eng. Abstr.) **(Hun)**
[Platinum-based antineoplastic agents: biomedical applications and therapeutic aspects] Dominici C, et al. **Ann Ist Super Sanita** 1995;31(2):289–94 (52 ref.) (Eng. Abstr.) **(Ita)**
[Interferons in the therapy of solid tumors] Tomao S, et al. **Clin Ter** 1995 Aug–Sep;146(8–9):491–502 (96 ref.) (Eng. Abstr.) **(Ita)**
[Current status and problems in clinical trial for new anticancer drug in Japan] Fukuoka M. **Gan To Kagaku Ryoho** 1996 Jan;23(2):141–5 (5 ref.) (Eng. Abstr.) **(Jpn)**
[Novel targets for cancer chemotherapy] Inoue S. **Gan To Kagaku Ryoho** 1996 Jan;23(2):191–201 (31 ref.) (Eng. Abstr.) **(Jpn)**
[History of photodynamic therapy--past, present and future] Kato H. **Gan To Kagaku Ryoho** 1996 Jan;23(1):8–15 (31 ref.) (Eng. Abstr.) **(Jpn)**
[Combination phase I trials] Masuda N. **Gan To Kagaku Ryoho** 1996 Jan;23(2):219–25 (13 ref.) (Eng. Abstr.) **(Jpn)**
[Current problems in development of new anticancer agents for new molecular targets] Nishii K. **Gan To Kagaku Ryoho** 1996 Jan;23(2):211–8 (12 ref.) (Eng. Abstr.) **(Jpn)**
[Mechanism of photodynamic therapy] Takemura T, et al. **Gan To Kagaku Ryoho** 1996 Jan;23(1):16–21 (6 ref.) (Eng. Abstr.) **(Jpn)**
[Chemotherapy of solid tumor] Ogawa M. **Nippon Naika Gakkai Zasshi** 1996 Mar 10;85(3):342–6 (28 ref.) **(Jpn)**
[Assessment of response to chemotherapy by tumor marker in solid neoplasms] Yoshimoto M, et al. **Nippon Rinsho** 1996 Jun;54(6):1685–9 (12 ref.) (Eng. Abstr.) **(Jpn)**
[The molecular mechanisms of the multiple drug resistance of tumors] Leont'eva OV. **Antibiot Khimioter** 1995 May; 40(5):48–60 (84 ref.) **(Rus)**
[New approaches to antitumor therapy: the use of preparations acting on processes regulated by epidermal and/or alpha-transforming growth factors] Kushlinskii NE, et al. **Eksp Klin Farmakol** 1996 Jan–Feb;59(1):74–80 (64 ref.) **(Rus)**
[Factors of the therapeutic effectiveness of 5-fluorouracil] Manziuk LV, et al. **Vopr Onkol** 1996;42(2):31–6 (33 ref.) **(Rus)**
[The experimental chemotherapy of malignant tumors today] Syrkin AB, et al. **Vopr Onkol** 1995;41(2):41–5 (23 ref.) **(Rus)**

ECONOMICS

Economic and quality of life outcomes: managed care perspectives. Glandon GL, et al. **Oncology (Huntingt)** 1995 Nov;9(11 Suppl):111–9 (31 ref.)
Applications of QOL measurements: a managed care perspective. Peskin SR. **Oncology (Huntingt)** 1995 Nov;9(11 Suppl):127–8 (3 ref.)
Economic and quality of life outcomes in oncology: the regulatory perspective. Turner S. **Oncology (Huntingt)** 1995 Nov;9(11 Suppl):121–5 (0 ref.)
[Cancer and health economics] Koinuma N. **Gan To Kagaku Ryoho** 1996 Jan;23(1):1–7 (6 ref.) (Eng. Abstr.) **(Jpn)**

ENZYMOLOGY

Telomeres, telomerase and cancer: is the magic bullet real? Sharma HW, et al. **Anticancer Res** 1996 Jan–Feb; 16(1):511–5 (32 ref.)
Some tumor cell protein kinases activated by receptors as markers, including elastin receptors. Parsons DF. **Cancer Invest** 1995;13(6):629–36 (61 ref.)
Advances in glyoxalase research. Glyoxalase expression in malignancy, anti-proliferative effects of methylglyoxal, glyoxalase I inhibitor diesters and S-D-lactoylglutathione, and methylglyoxal-modified protein binding and endocytosis by the advanced glycation endproduct receptor. Thornalley PJ. **Crit Rev Oncol Hematol** 1995 Aug;20(1–2):99–128 (225 ref.)
Antitopoisomerase drug action and resistance. Nitiss JL, et al. **Eur J Cancer** 1996 Jun;32A(6):958–66 (115 ref.)
DNA-repair methyltransferase as a molecular device for preventing mutation and cancer. Sekiguchi M, et al. **J Cancer Res Clin Oncol** 1996;122(4):199–206 (64 ref.)
Telomere dynamics and telomerase activation in tumor progression: prospects for prognosis and therapy. Healy KC. **Oncol Res** 1995;7(3–4):121–30 (84 ref.)

EPIDEMIOLOGY

Biomarkers: a molecular approach to cancer epidemiology. Shi CY, et al. **Ann Acad Med Singapore** 1996 Jan; 25(1):49–54 (41 ref.)
Psychosocial and ethical implications of defining genetic risk for cancers. Kash KM. **Ann N Y Acad Sci** 1995 Sep 30; 768:41–52 (26 ref.)
The contributions of molecular biology to cancer epidemiology. Weinstein IB. **Ann N Y Acad Sci** 1995 Sep 30;768:30–40 (26 ref.)
Cancer research in Mexico. An overview. Benítez-Bribiesca L, et al. **Arch Med Res** 1995;26 Spec No:S153–6 (50 ref.)
Cancer and ethnic minorities--the Department of Health's perspective. Bahl V. **Br J Cancer** 1996 Sep;74 Suppl 29:S2–10 (28 ref.)

Cancer in minority ethnic populations: priorities from epidemiological data. Bhopal RS, et al. **Br J Cancer** 1996 Sep;74 Suppl 29:S22–32 (15 ref.)
Epidemiology of cancer in ethnic groups. Muir CS. **Br J Cancer** 1996 Sep;74 Suppl 29:S12–6 (32 ref.)
Cancer in minority ethnic populations: priorities from epidemiological data. Bhopal RS, et al. **Br J Cancer Suppl** 1996 Sep;29:S22–32 (15 ref.)
Epidemiology of cancer in ethnic groups. Muir CS. **Br J Cancer Suppl** 1996 Sep;29:S12–6 (32 ref.)
The genetic epidemiology of cancer. Claus EB. **Cancer Surv** 1995;25:13–26 (62 ref.)
Epidemiologic data on alcoholic beverage consumption and risk of cancer. Longnecker MP, et al. **Clin Chim Acta** 1996 Mar 15;246(1–2):121–41 (130 ref.)
Diet, aging, and cancer. Goodwin JS, et al. **Clin Geriatr Med** 1995 Nov;11(4):577–89 (45 ref.)
The role of cancer registries [editorial] Bell CM, et al. **Clin Oncol (R Coll Radiol)** 1995;7(3):143–4 (17 ref.)
Human drug–metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer. Nebert DW, et al. **DNA Cell Biol** 1996 Apr;15(4):273–80 (96 ref.)
Risk estimation—an overview: disease risk estimation based upon animal bioassays. Gaylor DW. **Drug Metab Rev** 1996 Feb–May;28(1–2):9–27 (39 ref.)
Bioassay designs for validating biologically based mathematical models of carcinogenesis for risk assessment. Kodell RL. **Drug Metab Rev** 1996 Feb–May;28(1–2):219–23 (6 ref.)
A toxicologist's view of cancer risk assessment. Rozman KK, et al. **Drug Metab Rev** 1996 Feb–May;28(1–2):29–52 (27 ref.)
Empirical and biologically based models for cancer risk assessment. Zielinski JM, et al. **Drug Metab Rev** 1996 Feb–May;28(1–2):53–75 (29 ref.)
Agricultural exposures and cancer. Blair A, et al. **Environ Health Perspect** 1995 Nov;103 Suppl 8:205–8 (39 ref.)
Cancer among special populations: women, ethnic minorities, and the poor. Haynes A. **Environ Health Perspect** 1995 Nov;103 Suppl 8:319–20 (10 ref.)
Differences in cancer incidence, mortality, and survival between African Americans and whites. Walker B, et al. **Environ Health Perspect** 1995 Nov;103 Suppl 8:275–81 (64 ref.)
Racial, ethnic, and gender variations in cancer risk: considerations for future epidemiologic research. Zahm SH, et al. **Environ Health Perspect** 1995 Nov;103 Suppl 8:283–6 (48 ref.)
Childhood cancer: overview of incidence trends and environmental carcinogens. Zahm SH, et al. **Environ Health Perspect** 1995 Sep;103 Suppl 6:177–84 (143 ref.)
Exposure to extremely low frequency electromagnetic fields and the risk of malignant diseases—an evaluation of epidemiological and experimental findings. Hardell L, et al. **Eur J Cancer Prev** 1995 Sep;4 Suppl 1:3–107 (314 ref.)
Cancer consequences of the Chernobyl accident in Europe outside the former USSR: a review. Sali D, et al. **Int J Cancer** 1996 Jul 29;67(3):343–52 (33 ref.)
Causal thinking, biomarkers, and mechanisms of carcinogenesis. Vineis P, et al. **J Clin Epidemiol** 1996 Sep; 49(9):951–6 (44 ref.)
Some evidences of molecular epidemiology in cancer research. Nakachi K, et al. **J Epidemiol** 1996 Aug;6(3 Suppl):S125–9 (22 ref.)
Research activities of cancer epidemiology in Japan. Watanabe S, et al. **J Epidemiol** 1996 Aug;6(3 Suppl):S19–29 (113 ref.)
Epidemiology of cancer among Hispanics in the United States. Trapido EJ, et al. **J Natl Cancer Inst Monogr** 1995; (18):17–28 (65 ref.)
Epidemiological aspects of cancer risk associated with exposure in the occupational environment. Simonato L, et al. **Med Lav** 1996 Jan–Feb;87(1):5–15 (24 ref.)
Cancer in relation to occupational exposure to trichloroethylene. Weiss NS. **Occup Environ Med** 1996 Jan; 53(1):1–5 (27 ref.)
Twelve major cancers. **Sci Am** 1996 Sep;275(3):126–32 (0 ref.)
Limitations and inconsistencies in the approaches to cancer prevention. Tomatis L. **Teratog Carcinog Mutagen** 1995–96; 15(6):277–82 (37 ref.)
[Epidemiology and prevention of cancer: reflections on the ethics of public health measures] Sasco AJ. **Bull Acad Natl Med** 1995 May;179(5):987–1004; discussion 1005–7 (23 ref.) (Eng. Abstr.) **(Fre)**
[Role of cancer registries] Schaffer P. **Bull Acad Natl Med** 1995 May;179(5):951–62; discussion 962–3 (24 ref.) (Eng. Abstr.) **(Fre)**
[Current status and future estimation of patients with cancers in Japan] Tominaga S. **Nippon Naika Gakkai Zasshi** 1996 Mar 10;85(3):322–7 (8 ref.) **(Jpn)**

ETHNOLOGY

Social theory, social action, and intervention research: implications for cancer prevention among Latinos. Flores ET, et al. **J Natl Cancer Inst Monogr** 1995;(18):101–8 (53 ref.)
Cancer in Hispanics: issues of concern. Modiano MR, et al. **J Natl Cancer Inst Monogr** 1995;(18):35–9 (48 ref.)

ETIOLOGY

The NF-kappaB transcription factor in oncogenesis. Sharma HW, et al. **Anticancer Res** 1996 Mar–Apr;16(2):589–96 (74 ref.)
Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer. Wiseman H, et al. **Biochem J** 1996 Jan 1;313 (Pt 1):17–29 (213 ref.)
Depression, stressful events and the risk of cancer [editorial] Mathé G. **Biomed Pharmacother** 1996;50(1):1–2 (22 ref.)
Cancers weakly related to smoking. Doll R. **Br Med Bull** 1996 Jan;52(1):35–49 (63 ref.)
Nutritional aspects of changes in disease patterns in the Western Pacific region. Cavalli-Sforza LT, et al. **Bull World Health Organ** 1996;74(3):307–18 (51 ref.)
Electromagnetic field exposure and cancer: a review of epidemiologic evidence. Heath CW Jr. **CA Cancer J Clin** 1996 Jan–Feb;46(1):29–44 (55 ref.)
Apoptosis: inhibitor or instigator of carcinogenesis? Manning FC, et al. **Cancer Invest** 1996;14(5):455–65 (130 ref.)
Integrin mediated signal transduction in oncogenesis: an overview. Dedhar S. **Cancer Metastasis Rev** 1995 Sep; 14(3):165–72 (59 ref.)
Transforming growth factor beta and cancer. Nørgaard P, et al. **Cancer Treat Rev** 1995 Jul;21(4):367–403 (313 ref.)
Cellular senescence and cancer. Barrett JC, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:411–8 (67 ref.)
Telomerase, cell immortality, and cancer. Harley CB, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:307–15 (72 ref.)
Cell cycle checkpoints, genomic integrity, and cancer. Hartwell L, et al. **Cold Spring Harb Symp Quant Biol** 1994; 59:259–63 (30 ref.)
Lymphocyte-specific genetic instability and cancer. Kirsch IR, et al. **Cold Spring Harb Symp Quant Biol** 1994; 59:287–95 (77 ref.)
Defects in replication fidelity of simple repeated sequences reveal a new mutator mechanism for oncogenesis. Perucho M, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:339–48 (63 ref.)
Assessment of environmental and genetic factors in the etiology of childhood cancers: the Childrens Cancer Group epidemiology program. Robison LL, et al. **Environ Health Perspect** 1995 Sep;103 Suppl 6:111–6 (29 ref.)
Using biomarkers of genetic susceptibility to enhance the study of cancer etiology. Rothman N, et al. **Environ Health Perspect** 1995 Nov;103 Suppl 8:291–5 (74 ref.)
Diet and cancer: future etiologic research. Schatzkin A, et al. **Environ Health Perspect** 1995 Nov;103 Suppl 8:171–5 (55 ref.)
The effect of over- and undernutrition on cancer. Kritchevsky D. **Eur J Cancer Prev** 1995 Dec;4(6):445–51 (70 ref.)
The role of iron in cancer. Weinberg ED. **Eur J Cancer Prev** 1996 Feb;5(1):19–36 (204 ref.)
Etiology of cancer in humans and animals. Wild CP, et al. **Exp Toxicol Pathol** 1996 Feb;48(2–3):95–100 (43 ref.)
bcl-2: role in epithelial differentiation and oncogenesis. Lu QL, et al. **Hum Pathol** 1996 Feb;27(2):102–10 (85 ref.)
Wood dust. **IARC Monogr Eval Carcinog Risks Hum** 1995; 62:35–215 (383 ref.)
Molecular epidemiology: insights into cancer susceptibility, risk assessment, and prevention. Perera FP. **J Natl Cancer Inst** 1996 Apr 17;88(8):496–509 (189 ref.)
Cancer risk in patients with cystic fibrosis: the European data. CF/CSG Group. Schöni MH, et al. **J R Soc Med** 1996; 89 Suppl 27:38–43 (4 ref.)
HIV infection and neoplasia. Schulz TF, et al. **Lancet** 1996 Aug 31;348(9027):587–91 (50 ref.)
Cancer and stress. Cholst S. **Med Hypotheses** 1996 Feb; 46(2):101–6 (14 ref.)
Role of gangliosides in tumour progression: a molecular target for cancer therapy? Fish RG. **Med Hypotheses** 1996 Feb;46(2):140–4 (45 ref.)
The estrogen connection: the etiological relationship between diabetes, cancer, rheumatoid arthritis and psychiatric disorders. Holden RJ. **Med Hypotheses** 1995 Aug; 45(2):169–89 (162 ref.)
Mutation and mutagenesis in inherited and acquired human disease. The first EEMS Frits Sobels Prize Lecture, Noordwijkerhout, The Netherlands, June 1995. Evans HJ. **Mutat Res** 1996 Apr 13;351(2):89–103 (120 ref.)
Genetic, cytogenetic, and carcinogenic effects of radon: a review. Jostes RF. **Mutat Res** 1996 Jun;340(2–3):125–39 (87 ref.)
The role of receptors in multistage carcinogenesis. Pitot HC. **Mutat Res** 1995 Dec;333(1–2):3–14 (87 ref.)
Somatic recombination, gene amplification and cancer. Ramel C, et al. **Mutat Res** 1996 Jun 12;353(1–2):85–107 (34 ref.)
Mutagenic nitroarenes, diesel emissions, particulate-induced mutations and cancer: an essay on cancer-causation by a moving target. Rosenkranz HS. **Mutat Res** 1996 Feb; 367(2):65–72 (85 ref.)
Intercellular communication and carcinogenesis. Yamasaki H, et al. **Mutat Res** 1995 Dec;333(1–2):181–8 (49 ref.)
Molecular foundations of cancer: new targets for intervention. Karp JE, et al. **Nat Med** 1995 Apr;1(4):309–20 (121 ref.)
Low-frequency magnetic fields and cancer. What you should know and what to tell your patients. Salvatore JR. **Postgrad Med** 1996 Aug;100(2):183–8, 190 (21 ref.)
Perspectives in hormonal carcinogenesis: animal models to human disease. Li JJ. **Prog Clin Biol Res** 1996;394:447–54 (48 ref.)
To cell from environment. Palmlund I. **Prog Clin Biol Res** 1996;394:425–45 (95 ref.)
What causes cancer? Trichopoulos D, et al. **Sci Am** 1996 Sep;275(3):80–7 (0 ref.)
How cancer arises. Weinberg RA. **Sci Am** 1996 Sep; 275(3):62–70 (0 ref.)
Do electromagnetic fields cause brain tumors and other cancers? Deutsch S. **Semin Neurol** 1995 Sep;15(3):304–10 (13 ref.)
Pathophysiological aspects of tumor development. Möller P. **Stem Cells (Dayt)** 1995 May;13 Suppl 1:240–7 (86 ref.)
Beware of a new carcinogenic risk: promotion of promoters. Bounias M, et al. **Toxicol Lett** 1995 Oct;80(1–3):19–24 (61 ref.)
1995 Deichmann Lecture—p53 tumor suppressor gene: at the crossroads of molecular carcinogenesis, molecular epidemiology and cancer risk assessment. Harris CC. **Toxicol Lett** 1995 Dec;82–83:1–7 (43 ref.)
Role of blocked gap junctional intercellular communication in non-genotoxic carcinogenesis. Mesnil M, et al. **Toxicol Lett** 1995 Dec;82–83:701–6 (27 ref.)
Role of active cell death (apoptosis) in multi-stage carcinogenesis. Schulte-Hermann R, et al. **Toxicol Lett** 1995 Dec;82–83:143–8 (20 ref.)
Neoplasia: an example of plasticity of the immune response. Penn I. **Transplant Proc** 1996 Aug;28(4):2089–93 (29 ref.)
[Erythropoietin in hematology and oncology. I. Chronic anemia in malignant disease and the pharmacology of erythropoietin] Adam Z, et al. **Vnitr Lek** 1996 Apr; 42(4):285–9 (39 ref.) (Eng. Abstr.) **(Cze)**
[Effect of smoking on the fetus and the child during pregnancy] Gueguen C, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(8):853–9 (63 ref.) (Eng. Abstr.) **(Fre)**
[Environment and oncology] Frentzel-Beyme R. **Arch Gynecol Obstet** 1995;257(1–4):228–39 (14 ref.) **(Ger)**
[Nutrition and cancer] Schusdziarra V. **Internist (Berl)** 1995 Nov;36(11):1046–51 (74 ref.) **(Ger)**
[Tumors as sequelae of smoking] Drings P. **Z Arztl Fortbild (Jena)** 1995 Oct;89(5):447–58 (69 ref.) (Eng. Abstr.) **(Ger)**
[Mechanical trauma as a cause of cancer—a continuing dispute] Cohen AD, et al. **Harefuah** 1995 Jun 1; 128(11):715–8 (36 ref.) **(Heb)**
[The use of computerized image analysis of tissue specimens and cell cultures in the early identification and the understanding of the pathogenesis of malignant tumors] Goshen R, et al. **Harefuah** 1995 Nov 1;129(9):329–36 (31 ref.) **(Heb)**
[Diet and cancer: review of the epidemiologic evidence] Del Prete U, et al. **Ann Ig** 1996 Mar–Apr;8(2):213–28 (127 ref.) (Eng. Abstr.) **(Ita)**
[The evolution of etiological research on tumors (editorial)] Tomatis L. **Epidemiol Prev** 1995 Sep;19:229–34 (39 ref.) **(Ita)**
[Malignancy in autoimmune diseases] Sugai S. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Feb;19(1):1–14 (38 ref.) (Eng. Abstr.) **(Jpn)**
[Human papillomavirus type 16-gene functions relevant to molecular human carcinogenesis] Yasumoto S. **Nippon Rinsho** 1995 Nov;53(11):2858–67 (20 ref.) (Eng. Abstr.) **(Jpn)**
[Epstein-Barr virus oncogenesis: immortalization by a human ubiquitous virus and neoplastic conversion by risk factors] Osato T, et al. **Tanpakushitsu Kakusan Koso** 1995 Sep; 40(12):1822–34 (46 ref.) **(Jpn)**
[Cellular senescence, cancer and telomerase] Suzuki M, et al. **Tanpakushitsu Kakusan Koso** 1996 Mar;41(3):220–7 (24 ref.) **(Jpn)**
[Folate deficiency, cancer and congenital abnormalities. Is there a connection?] Christensen B. **Tidsskr Nor Laegeforen** 1996 Jan 20;116(2):250–4 (45 ref.) (Eng. Abstr.) **(Nor)**
[Combined biological effect of electromagnetic fields and chemical substances (toxic)] Kamedula M, et al. **Med Pr** 1996;47(3):285–92 (20 ref.) (Eng. Abstr.) **(Pol)**
[Oxidative stress as a basic mechanism of the carcinogenic effect of man made mineral fibers on the human body] Lutz W, et al. **Med Pr** 1995;46(3):275–84 (18 ref.) (Eng. Abstr.) **(Pol)**
[Antisense strategies in studies on the role of sugar chains in phenotype expression of neoplasms] Ugorski M. **Postepy Hig Med Dosw** 1995;49(1):77–84 (22 ref.) (Eng. Abstr.) **(Pol)**
[Lymphoproliferative disease and cancer in the transplant patient] Herreros J, et al. **Rev Esp Cardiol** 1995;48 Suppl 7:129–34 (44 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

HLA class I antigens in human tumors. Garrido F, et al. **Adv Cancer Res** 1995;67:155–95 (287 ref.)
Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Hall M, et al. **Adv Cancer Res** 1996;68:67–108 (219 ref.)
Mutation and cancer: a personal odyssey. Knudson AG Jr. **Adv Cancer Res** 1995;67:1–23 (144 ref.)
PAX and HOX in neoplasia. Stuart ET, et al. **Adv Genet**

1995;33:255–74 (92 ref.)
Biomarkers: a molecular approach to cancer epidemiology. Shi CY, et al. **Ann Acad Med Singapore** 1996 Jan; 25(1):49–54 (41 ref.)
Psychosocial and ethical implications of defining genetic risk for cancers. Kash KM. **Ann N Y Acad Sci** 1995 Sep 30; 768:41–52 (26 ref.)
The spectrum of mutations at the p53 locus. Evidence for tissue-specific mutagenesis, selection of mutant alleles, and a "gain of function" phenotype. Levine AJ, et al. **Ann N Y Acad Sci** 1995 Sep 30;768:111–28 (55 ref.)
Family history of cancer. Lynch HT, et al. **Ann N Y Acad Sci** 1995 Sep 30;768:12–29 (33 ref.)
The contributions of molecular biology to cancer epidemiology. Weinstein IB. **Ann N Y Acad Sci** 1995 Sep 30;768:30–40 (26 ref.)
Tumour heterogeneity and clonality—an old theme revisited. Fey MF, et al. **Ann Oncol** 1996 Feb;7(2):121–8 (88 ref.)
Clinical implications of the p53 gene. Sidransky D, et al. **Annu Rev Med** 1996;47:285–301 (89 ref.)
Telomeres, telomerase and cancer: is the magic bullet real? Sharma HW, et al. **Anticancer Res** 1996 Jan–Feb; 16(1):511–5 (32 ref.)
Linkage of an American pedigree with palmoplantar keratoderma and malignancy (palmoplantar ectodermal dysplasia type III) to 17q24. Literature survey and proposed updated classification of the keratodermas. Stevens HP, et al. **Arch Dermatol** 1996 Jun;132(6):640–51 (143 ref.)
Myc oncogenes: the enigmatic family. Ryan KM, et al. **Biochem J** 1996 Mar 15;314 (Pt 3):713–21 (113 ref.)
The 1995 Walter Hubert Lecture—molecular epidemiology of human cancer: insights from the mutational analysis of the p53 tumour-suppressor gene. Harris CC. **Br J Cancer** 1996 Feb;73(3):261–9 (89 ref.)
Aspects of the neoplasms observed in patients with constitutional autosomal trisomy. Satge D, et al. **Cancer Genet Cytogenet** 1996 Mar;87(1):63–70 (164 ref.)
Genetics of chromosome 11: loci for pediatric and adult malignancies, developmental disorders, and other diseases. Nowak NJ, et al. **Cancer Invest** 1995;13(6):646–59 (78 ref.)
Apoptosis, cancer and the p53 tumour suppressor gene. Lee JM, et al. **Cancer Metastasis Rev** 1995 Jun;14(2):149–61 (113 ref.)
Transgenic and gene knockout mice in cancer research. Viney JL. **Cancer Metastasis Rev** 1995 Jun;14(2):77–90 (81 ref.)
DNA methylation errors and cancer. Jones PA. **Cancer Res** 1996 Jun 1;56(11):2463–7 (60 ref.)
Genomic imprinting and cancer. Brenton JD, et al. **Cancer Surv** 1995;25:161–71 (68 ref.)
The genetic epidemiology of cancer. Claus EB. **Cancer Surv** 1995;25:13–26 (62 ref.)
Nucleotide excision repair: variations associated with cancer development and speciation. Cleaver JE, et al. **Cancer Surv** 1995;25:125–42 (76 ref.)
Germline mutations in the TP53 gene. Eeles RA. **Cancer Surv** 1995;25:101–24 (106 ref.)
Ethical, social and counselling issues in hereditary cancer susceptibility. Garber JE, et al. **Cancer Surv** 1995;25:381–97 (54 ref.)
Molecular genetics of prostate cancer. Isaacs WB. **Cancer Surv** 1995;25:357–79 (133 ref.)
The neurofibromatosis 2 (NF2) tumour suppressor gene: implications beyond the hereditary tumour syndrome? Kley N, et al. **Cancer Surv** 1995;25:207–18 (45 ref.)
Metabolic polymorphisms and cancer susceptibility. Smith G, et al. **Cancer Surv** 1995;25:27–65 (249 ref.)
Prospects for cancer genetics. Weinberg RA. **Cancer Surv** 1995;25:3–12 (20 ref.)
Can molecular markers now be used for early diagnosis of malignancy? Duffy MJ. **Clin Chem** 1995 Oct;41(10):1410–3 (38 ref.)
Fluorescence in situ hybridization: powerful molecular tool for cancer prognosis. Fox JL, et al. **Clin Chem** 1995 Nov; 41(11):1554–9 (11 ref.)
The molecular genetic basis of childhood neoplasia. Mott MG. **Clin Oncol (R Coll Radiol)** 1995;7(5):279–86 (87 ref.)
Cell cycle checkpoints, genomic integrity, and cancer. Hartwell L, et al. **Cold Spring Harb Symp Quant Biol** 1994; 59:259–63 (30 ref.)
Role of a cell cycle regulator in hereditary and sporadic cancer. Kamb A. **Cold Spring Harb Symp Quant Biol** 1994; 59:39–47 (58 ref.)
Lymphocyte-specific genetic instability and cancer. Kirsch IR, et al. **Cold Spring Harb Symp Quant Biol** 1994; 59:287–95 (77 ref.)
Genomic integrity and the genetics of cancer. Tlsty TD, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:265–75 (53 ref.)
The hepatocyte nuclear factor-3/forkhead transcription regulatory family in development, inflammation, and neoplasia. Hromas R, et al. **Crit Rev Oncol Hematol** 1995 Aug;20(1–2):129–40 (64 ref.)
Cancer. Exploring the bowels of DNA methylation. Balmain A. **Curr Biol** 1995 Sep 1;5(9):1013–6 (33 ref.)
Molecular biology and clinical applications to cancer. Lotze MT. **Curr Opin Gen Surg** 1994;:245–54 (70 ref.)
Identification of mismatch repair genes and their role in the development of cancer. Fishel R, et al. **Curr Opin Genet Dev** 1995 Jun;5(3):382–95 (158 ref.)
Cancer therapy and p53. Lowe SW. **Curr Opin Oncol** 1995 Nov;7(6):547–53 (61 ref.)
Genetic and phenotypic heterogeneity of human malignancies: finding order in chaos. Shackney SE, et al. **Cytometry** 1995 Sep 1;21(1):2–5 (21 ref.)
Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer. Nebert DW, et al. **DNA Cell Biol** 1996 Apr;15(4):273–80 (96 ref.)
Identification and management of inherited cancer susceptibility. Li FP. **Environ Health Perspect** 1995 Nov; 103 Suppl 8:297–300 (26 ref.)
Age-specific oncogenesis: the genetics of cancer susceptibility. Malkin D. **Environ Health Perspect** 1995 Sep; 103 Suppl 6:37–9 (10 ref.)
Assessment of environmental and genetic factors in the etiology of childhood cancers: the Childrens Cancer Group epidemiology program. Robison LL, et al. **Environ Health Perspect** 1995 Sep;103 Suppl 6:111–6 (29 ref.)
DNA-replication fidelity, mismatch repair and genome instability in cancer cells. Umar A, et al. **Eur J Biochem** 1996 Jun 1;238(2):297–307 (81 ref.)
A polygenic model of inherited predisposition to cancer. Dragani TA, et al. **FASEB J** 1996 Jun;10(8):865–70 (56 ref.)
DNA mismatch repair and cancer. Chung DC, et al. **Gastroenterology** 1995 Nov;109(5):1685–99 (109 ref.)
Markers of risk for human malignancies. Garber JE. **Hematol Oncol Clin North Am** 1994 Jun;8(3):471–83 (59 ref.)
DNA methylation and polyamines in embryonic development and cancer. Heby O. **Int J Dev Biol** 1995 Oct;39(5):737–57 (169 ref.)
Normal development and neoplasia: the imprinting connection. Ohlsson R, et al. **Int J Dev Biol** 1995 Oct; 39(5):869–76 (54 ref.)
Gene replacement strategies for cancer. Roth JA. **Isr J Med Sci** 1996 Feb;32(2):89–94 (12 ref.)
Progress against cancer. Broder S, et al. **J Cancer Res Clin Oncol** 1995;121(11):633–47 (134 ref.)
Hereditary cancer: two hits revisited. Knudson AG. **J Cancer Res Clin Oncol** 1996;122(3):135–40 (62 ref.)
Genetics of tumour necrosis factor-alpha in autoimmune, infectious, and neoplastic diseases. Wilson AG, et al. **J Inflamm** 1995;45(1):1–12 (114 ref.)
Genomic imprinting, DNA methylation, and cancer. Feinberg AP, et al. **J Natl Cancer Inst Monogr** 1995; (17):21–6 (83 ref.)
Genetic testing for cancer predisposition: behavioral science issues. Lerman C, et al. **J Natl Cancer Inst Monogr** 1995; (17):63–6 (27 ref.)
Molecular markers in cancer diagnosis. Sidransky D. **J Natl Cancer Inst Monogr** 1995;(17):27–9 (26 ref.)
Evaluating children and adolescents for heritable cancer risk. Strong LC, et al. **J Natl Cancer Inst Monogr** 1995; (17):111–3 (18 ref.)
The p53 tumour suppressor gene and tumour prognosis: is there a relationship? [editorial] Dowell SP, et al. **J Pathol** 1995 Nov;177(3):221–4 (40 ref.)
Clinical relevance of drug resistance genes in malignant disease. Filipits M, et al. **Leukemia** 1996 Jul;10 Suppl 3:S10–S17 (131 ref.)
P53 and induction of apoptosis as a target for anticancer therapy. Neubauer A, et al. **Leukemia** 1996 Jul;10 Suppl 3:S2–S4 (46 ref.)
Gene competition and the possible evolutionary role of tumours. Kozlov AP. **Med Hypotheses** 1996 Feb;46(2):81–4 (33 ref.)
Genetic susceptibility and occupational cancer. Hayes RB. **Med Lav** 1995 May–Jun;86(3):206–13 (51 ref.)
p53 tumor suppressor gene: implications for iatrogenic cancer and cancer therapy. De Benedetti V, et al. **Med Pediatr Oncol Suppl** 1996;1:2–11 (129 ref.)
A possible role in chemical carcinogenesis for epigenetic, heritable changes in gene expression. MacLeod MC. **Mol Carcinog** 1996 Apr;15(4):241–50 (58 ref.)
DNA adducts in human carcinogenesis: etiological relevance and structure-activity relationship. Bartsch H. **Mutat Res** 1996 Jun;340(2–3):67–79 (67 ref.)
Genetic, cytogenetic, and carcinogenic effects of radon: a review. Jostes RF. **Mutat Res** 1996 Jun;340(2–3):125–39 (87 ref.)
Transcription-factor mutations and disease. Latchman DS. **N Engl J Med** 1996 Jan 4;334(1):28–33 (43 ref.)
Microsatellite instability in human cancer. Speicher MR. **Oncol Res** 1995;7(6):267–75 (87 ref.)
Applications of fluorescent in situ hybridization (FISH) to genetic analysis of human tumors. Wolman SR. **Pathol Annu** 1995;30 Pt 2:227–43 (50 ref.)
The CYP2A gene subfamily: species differences, regulation, catalytic activities and role in chemical carcinogenesis. Fernandez-Salguero P, et al. **Pharmacogenetics** 1995;5 Spec No:S123–8 (56 ref.)
Assessment of cancer susceptibility in humans by use of genetic polymorphisms in carcinogen metabolism. Ikawa S, et al. **Pharmacogenetics** 1995;5 Spec No:S154–60 (42 ref.)
Metabolic polymorphisms and carcinogen-DNA adduct formation in human populations. Kaderlik KR, et al. **Pharmacogenetics** 1995;5 Spec No:S108–17 (112 ref.)
Potential sources of multiple mutations in human cancers. Christians FC, et al. **Prev Med** 1995 Jul;24(4):329–32 (37 ref.)
Tumor suppressor genes: at the crossroads of molecular carcinogenesis, molecular epidemiology, and human risk assessment. Harris CC. **Prev Med** 1996 Jan–Feb;25(1):10–2 (33 ref.)
Significance of DNA adducts at low dose: shortening the time to spontaneous tumor occurrence. Lutz WK, et al. **Regul Toxicol Pharmacol** 1996 Feb;23(1 Pt 1):29–34 (40 ref.)
Cytogenetics and molecular genetics of human solid tumours. Sahlin P, et al. **Scand J Plast Reconstr Surg Hand Surg** 1995 Jun;29(2):101–10 (80 ref.)
New molecular targets for cancer therapy. Oliff A, et al. **Sci Am** 1996 Sep;275(3):144–9 (0 ref.)
Advances in cancer detection. Sidransky D. **Sci Am** 1996 Sep;275(3):104–9 (0 ref.)
How cancer arises. Weinberg RA. **Sci Am** 1996 Sep; 275(3):62–70 (0 ref.)
The bcl-2 gene family. Craig RW. **Semin Cancer Biol** 1995 Feb;6(1):35–43 (71 ref.)
Microsatellite instability and DNA mismatch repair in human cancer. Karran P. **Semin Cancer Biol** 1996 Feb;7(1):15–24 (72 ref.)
Genetic predisposition to cancer—issues to consider. Malkin D, et al. **Semin Cancer Biol** 1996 Feb;7(1):49–53 (24 ref.)
Clinical applications of genetic rearrangements in cancer. Sheer D, et al. **Semin Cancer Biol** 1996 Feb;7(1):25–32 (34 ref.)
Gene fusions encoding chimaeric transcription factors in solid tumours. Sorensen PH, et al. **Semin Cancer Biol** 1996 Feb; 7(1):3–14 (100 ref.)
Genomic imprinting in tumours. Squire J, et al. **Semin Cancer Biol** 1996 Feb;7(1):41–7 (52 ref.)
Detection of specific genetic alterations in cancer cells. Huebner K, et al. **Semin Oncol** 1996 Feb;23(1):22–30 (25 ref.)
Mismatch repair: mechanisms and relationship to cancer susceptibility. Kolodner RD. **Trends Biochem Sci** 1995 Oct; 20(10):397–401 (49 ref.)
The clinical significance of p53 aberrations in human tumours. Bosari S, et al. **Virchows Arch** 1995;427(3):229–41 (158 ref.)
Molecular cytogenetics: unraveling of the genetic composition of individual cells by fluorescence in situ hybridization and digital imaging microscopy. Tanke HJ, et al. **World J Urol** 1995;13(3):138–42 (19 ref.)
[Correlation of c-met activation with human carcinogrenesis] Gao CF, et al. **Sheng Li Ko Hsueh Chin Chan** 1995 Jul; 26(3):243–5 (8 ref.) **(Chi)**
[Oncogenes and the malignancy process] Mareš J, et al. **Cas Lek Cesk** 1996 May 29;135(11):335–9 (39 ref.) (Eng. Abstr.) **(Cze)**
[Brakes of the cell cycle—new inhibitor genes? (editorial)] Laiho M. **Duodecim** 1994;110(16):1502–4 (12 ref.) **(Fin)**
[Ataxia telangiectasia and genetic predisposition to cancer] Bay JO, et al. **Bull Cancer (Paris)** 1996 Mar;83(3):171–5 (31 ref.) (Eng. Abstr.) **(Fre)**
[P53 protein: a new tool for the clinician? (editorial)] Laurent-Puig P. **Gastroenterol Clin Biol** 1995 May; 19(5):463–4 (8 ref.) **(Fre)**
[Genetic predisposition to cancer] Janin N. **Rev Med Interne** 1995;16(7):500–17 (52 ref.) (Eng. Abstr.) **(Fre)**
[Tumor suppressor gene p53. Theoretical principles and their significance for pathology] Poremba C, et al. **Pathologe** 1996 May;17(3):181–8 (62 ref.) (Eng. Abstr.) **(Ger)**
[Molecular cancer epidemiology—the present status and future possibilities] Sakai T. **Nippon Eiseigaku Zasshi** 1996 Feb;50(6):1036–46 (46 ref.) (Eng. Abstr.) **(Jpn)**
[Study of cancers as genetic diseases] Kuroki T. **Nippon Naika Gakkai Zasshi** 1996 Mar 10;85(3):318–21 (2 ref.) **(Jpn)**
[Inherited cancer—concept and classification] Abe T, et al. **Nippon Rinsho** 1995 Nov;53(11):2627–33 (9 ref.) (Eng. Abstr.) **(Jpn)**
[Role of tumor marker in the presymptomatic diagnosis of hereditary malignant tumors] Baba S, et al. **Nippon Rinsho** 1996 Jun;54(6):1597–603 (13 ref.) (Eng. Abstr.) **(Jpn)**
[Linkage analysis of hereditary cancer syndrome] Nakamura Y. **Nippon Rinsho** 1995 Nov;53(11):2640–6 (4 ref.) (Eng. Abstr.) **(Jpn)**
[Mechanisms of hereditary tumorigenesis] Takebe H. **Nippon Rinsho** 1995 Nov;53(11):2634–9 (12 ref.) (Eng. Abstr.) **(Jpn)**
[Strategies for the detection and the identification of tumor suppressor genes] Takimoto M, et al. **Nippon Rinsho** 1995 Nov;53(11):2666–71 (22 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

HLA class I antigens in human tumors. Garrido F, et al. **Adv Cancer Res** 1995;67:155–95 (287 ref.)
Vaccine therapy for cancer. Linehan DC, et al. **Ann Surg Oncol** 1996 Mar;3(2):219–28 (47 ref.)
C-type lectins of natural killer cells: carbohydrate ligands and role in tumour cell lysis. Bezouška K. **Biochem Soc Trans** 1996 Feb;24(1):156–61 (24 ref.)
Insulin and prostaglandins as signals between tumor and the host immune system. Curi R, et al. **Braz J Med Biol Res** 1995 Jul;28(7):773–9 (46 ref.)
Natural killer cells and cancer. Brittenden J, et al. **Cancer** 1996 Apr 1;77(7):1226–43 (266 ref.)
Costimulation of T-cell-mediated tumor immunity. Hellström KE, et al. **Cancer Chemother Pharmacol** 1996;

38 Suppl:S40–1 (30 ref.)
Indications for intensive care in the management of infections in cancer patients. Sculier JP. **Cancer Treat Res** 1995; 79:233–44 (60 ref.)
Herpesvirus infections in immunocompromised patients. Snoeck R, et al. **Cancer Treat Res** 1995;79:149–71 (172 ref.)
New antifungal compounds and strategies for treatment of invasive fungal infections in patients with neoplastic diseases. Walsh TJ, et al. **Cancer Treat Res** 1995;79:113–48 (268 ref.)
Infection control for oncology. Wiblin RT, et al. **Cancer Treat Res** 1995;79:83–100 (115 ref.)
Immunologic status of the cancer patient and the effects of blood transfusion on antitumor responses. Browell DA, et al. **Curr Opin Gen Surg** 1993;:325–33 (110 ref.)
The role of natural killer cells in immune surveillance of cancer. Whiteside TL, et al. **Curr Opin Immunol** 1995 Oct; 7(5):704–10 (57 ref.)
The role of the immune system in anti-tumour responses. Potential for drug therapy. Dermime S, et al. **Drugs Aging** 1995 Oct;7(4):266–77 (152 ref.)
The role of CD4+ tumor-infiltrating lymphocytes in human solid tumors. Goedegebuure PS, et al. **Immunol Res** 1995; 14(2):119–31 (56 ref.)
Human tumor antigens recognized by T lymphocytes. Boon T, et al. **J Exp Med** 1996 Mar 1;183(3):725–9 (60 ref.)
Managing HIV. Part 3: Mechanisms of disease. 3.6 How HIV promotes malignancies. Boyle MJ, et al. **Med J Aust** 1996 Feb 19;164(4):230–2 (21 ref.)
Development of active specific immunotherapeutic agents based on cancer-associated mucins. Samuel J, et al. **Pharm Biotechnol** 1995;6:875–90 (145 ref.)
Synthetic hormone/growth factor subunit vaccine with application to antifertility and cancer. Snyder LL, et al. **Pharm Biotechnol** 1995;6:907–30 (145 ref.)
Mutant ras epitopes as targets for cancer vaccines. Abrams SI, et al. **Semin Oncol** 1996 Feb;23(1):118–34 (79 ref.)
In situ cytokine gene transfection using vaccinia virus vectors. Lattime EC, et al. **Semin Oncol** 1996 Feb; 23(1):88–100 (98 ref.)
The immune system. Post-White J. **Semin Oncol Nurs** 1996 May;12(2):89–96 (34 ref.)
The interferons. Skalla K. **Semin Oncol Nurs** 1996 May; 12(2):97–105 (56 ref.)
Antigens recognized on human tumors by cytolytic T lymphocytes: towards vaccination? Coulie PG. **Stem Cells (Dayt)** 1995 Jul;13(4):393–403 (65 ref.)
[Dendritic cells and immune function in cancer] Chaux P. **Pathol Biol (Paris)** 1995 Dec;43(10):897–903 (53 ref.) (Eng. Abstr.) **(Fre)**
[Carbohydrate antigens as tumor marker] Ohkura H. **Nippon Geka Gakkai Zasshi** 1996 Feb;97(2):145–51 (16 ref.) (Eng. Abstr.) **(Jpn)**
[Recent studies on tumor immunity and prospects for therapy of neoplasms] Aoki Y, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Aug; 47(8):863–71 (27 ref.) **(Jpn)**
[Characteristics of cells in inflammation and neoplastic processes] Bogunia-Kubik K. **Postepy Hig Med Dosw** 1995; 49(1):117–23 (9 ref.) (Eng. Abstr.) **(Pol)**
[Molecular bases of cancer immunology] Barrera-Rodríguez R, et al. **Salud Publica Mex** 1995 Jul–Aug;37(4):344–53 (62 ref.) (Eng. Abstr.) **(Spa)**

METABOLISM

Tumor-associated hyaluronan. Providing an extracellular matrix that facilitates invasion [comment] Knudson W. **Am J Pathol** 1996 Jun;148(6):1721–6 (36 ref.) Comment on: Am J Pathol 1996 Jun;148(6):1861–9.
Spatial resolution and spectral information content of proton NMR spectroscopic imaging of tumour metabolism. Bovée WM, et al. **Anticancer Res** 1996 May–Jun;16(3B):1515–20 (17 ref.)
Neutral lipids production, transport, utilization. Cantafora A, et al. **Anticancer Res** 1996 May–Jun;16(3B):1441–9 (54 ref.)
High resolution nuclear magnetic resonance spectroscopy in clinical biology: application in oncology. de Certaines JD. **Anticancer Res** 1996 May–Jun;16(3B):1325–31 (37 ref.)
Tumor oxygenation: a matter of supply and demand. Gulledge CJ, et al. **Anticancer Res** 1996 Mar–Apr; 16(2):741–9 (68 ref.)
Introduction to in vivo MRS of cancer: new perspectives and open problems. Leach MO. **Anticancer Res** 1996 May–Jun;16(3B):1503–14 (104 ref.)
Phospholipid metabolites in 1H-decoupled 31P MRS in vivo in human cancer: implications for experimental models and clinical studies. Negendank W, et al. **Anticancer Res** 1996 May–Jun;16(3B):1539–44 (32 ref.)
Magnetic resonance spectroscopy in cancer: phospholipid, neutral lipid and lipoprotein metabolism and function. Podo F, et al. **Anticancer Res** 1996 May–Jun;16(3B):1305–15 (57 ref.)
Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer. Wiseman H, et al. **Biochem J** 1996 Jan 1;313 (Pt 1):17–29 (213 ref.)
Integrin-mediated signaling in normal and malignant cells: a role of protein tyrosine kinases. Malik RK, et al. **Biochim Biophys Acta** 1996 Jun 7;1287(2–3):73–6 (61 ref.)
The role of thrombospondin-1 in tumor progression and angiogenesis. Tuszynski GP, et al. **Bioessays** 1996 Jan; 18(1):71–6 (57 ref.)
Fluoropyrimidine catabolism. Diasio RB, et al. **Cancer Treat Res** 1995;78:71–93 (103 ref.)
Aspects of one-carbon folate cycling related to fluoropyrimidine and antifolate therapy. Spears CP, et al. **Cancer Treat Res** 1995;78:115–34 (128 ref.)
Interaction of tumour cells with elastin and the metastatic phenotype. Timár J, et al. **Ciba Found Symp** 1995; 192:321–35; discussion 335–7 (44 ref.)
Transforming growth factor beta: relevance to radiotherapy. Parker CC, et al. **Clin Oncol (R Coll Radiol)** 1995;7(3):160–1 (19 ref.)
Cyclins, cyclin-dependent kinases and cdk inhibitors: implications in cell cycle control and cancer. MacLachlan TK, et al. **Crit Rev Eukaryot Gene Expr** 1995;5(2):127–56 (235 ref.)
MDR1 gene expression in solid tumours. Goldstein LJ. **Eur J Cancer** 1996 Jun;32A(6):1039–50 (84 ref.)
Major vault protein LRP-related multidrug resistance. Izquierdo MA, et al. **Eur J Cancer** 1996 Jun;32A(6):979–84 (40 ref.)
Pharmacokinetic modelling—a prelude to therapeutic drug monitoring for all cancer patients? [editorial; comment] Judson IR. **Eur J Cancer** 1995 Oct;31A(11):1733–5 (24 ref.) Comment on: Eur J Cancer 1995 Oct;31A(11):1794–8. Comment on: Eur J Cancer 1995 Oct;31A(11):1804–10.
Glutathione and related enzymes in multidrug resistance. O'Brien ML, et al. **Eur J Cancer** 1996 Jun;32A(6):967–78 (147 ref.)
Multidrug resistance reversal in childhood malignancies—potential for a real step forward? Pinkerton CR. **Eur J Cancer** 1996 Apr;32A(4):641–4 (37 ref.)
Accumulation of purine catabolites in solid tumors exposed to therapeutic hyperthermia. Busse M, et al. **Experientia** 1996 May 15;52(5):469–73 (26 ref.)
Histochemical demonstration and analysis of poly-N-acetyllactosamine structures in normal and malignant human tissues. Ito N, et al. **Histol Histopathol** 1996 Jan;11(1):203–14 (110 ref.)
Physical chemistry and the biologic week in the perspective of chrono-oncology. Ulmer W, et al. **In Vivo** 1995 Jul–Aug; 9(4):363–74 (96 ref.)
The focal adhesion kinase. Schaller MD. **J Endocrinol** 1996 Jul;150(1):1–7 (88 ref.)
Nuclear structure and the lamins [editorial; comment] Bosman FT. **J Pathol** 1996 Jan;178(1):3–4 (14 ref.) Comment on: J Pathol 1996 Jan;178(1):21–9.
Role of gangliosides in tumour progression: a molecular target for cancer therapy? Fish RG. **Med Hypotheses** 1996 Feb;46(2):140–4 (45 ref.)
Tumor suppressor genes in the TGF-beta signaling pathway? Serra R, et al. **Nat Med** 1996 Apr;2(4):390–1 (15 ref.)
Tumor-induced changes in host metabolism: a possible marker of neoplastic disease. Rossi Fanelli F, et al. **Nutrition** 1995 Sep–Oct;11(5 Suppl):595–600 (56 ref.)
Expression of thrombospondin-1 in cancer: a role in tumor progression. Qian X, et al. **Proc Soc Exp Biol Med** 1996 Jul;212(3):199–207 (96 ref.)
Nutrition in cancer patients [see comments] Mercadante S. **Support Care Cancer** 1996 Jan;4(1):10–20 (67 ref.) Comment in: Support Care Cancer 1996 Jan;4(1):1–3.
Tissue factor expression in human leukocytes and tumor cells. Rickles FR, et al. **Thromb Haemost** 1995 Jul;74(1):391–5 (45 ref.)
The clinical significance of p53 aberrations in human tumours. Bosari S, et al. **Virchows Arch** 1995;427(3):229–41 (158 ref.)
[Cancer-associated alterations of glycoconjugates—special reference to glycosphingolipids] Taki T. **Nippon Geka Gakkai Zasshi** 1996 Feb;97(2):123–30 (44 ref.) (Eng. Abstr.) **(Jpn)**
[Ectopic cytokine syndrome] Yamaguchi K, et al. **Nippon Naika Gakkai Zasshi** 1996 Mar 10;85(3):328–32 (15 ref.) **(Jpn)**
[Mechanism of resistance to antitumor agents—its involvement in blood-brain barrier] Tsuruo T. **Yakugaku Zasshi** 1995 Jul;115(7):513–22 (36 ref.) (Eng. Abstr.) **(Jpn)**

MICROBIOLOGY

Recovery of uncommon bacteria from blood: association with neoplastic disease. Beebe JL, et al. **Clin Microbiol Rev** 1995 Jul;8(3):336–56 (332 ref.)
Bacterial infection as a cause of cancer. Parsonnet J. **Environ Health Perspect** 1995 Nov;103 Suppl 8:263–8 (93 ref.)

MORTALITY

Chronic and degenerative disease: major causes of morbidity and death. Doll R. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1301S–1305S (15 ref.)
The conquest of cancer. Berlin NI. **Cancer Invest** 1995; 13(5):540–50 (30 ref.)
Reality versus extrapolation: an academic perspective of cancer risk regulation. Waddell WJ. **Drug Metab Rev** 1996 Feb–May;28(1–2):181–95 (32 ref.)
Tobacco use and its contribution to early cancer mortality with a special emphasis on cigarette smoking. Shopland DR. **Environ Health Perspect** 1995 Nov;103 Suppl 8:131–42 (77 ref.)
Estimating length of survival in end-stage cancer: a review of the literature. den Daas N. **J Pain Symptom Manage** 1995 Oct;10(7):548–55 (39 ref.)
The war on cancer. Sporn MB. **Lancet** 1996 May 18; 347(9012):1377–81 (48 ref.)
Measurement of utilities and quality-adjusted survival. Weeks J. **Oncology (Huntingt)** 1995 Nov;9(11 Suppl):67–70 (10 ref.)
The changing face of paediatric oncology. Foot AB. **Palliat Med** 1995 Jul;9(3):193–9 (19 ref.)
The past and future of cancer in the young. Bleyer WA. **Pediatr Dent** 1995 Jul–Aug;17(4):285–90 (7 ref.)

NURSING

Caring, curing, coping: towards an integrated model. Webb C. **J Adv Nurs** 1996 May;23(5):960–8 (44 ref.)
Informed consent: process and clinical issues. Berry DL, et al. **Oncol Nurs Forum** 1996 Apr;23(3):507–12 (19 ref.)
Believing and dreaming to improve cancer care. Given BA. **Oncol Nurs Forum** 1995 Jul;22(6):929–40 (36 ref.)
Biotherapy and the oncology nurse. Farrell MM. **Semin Oncol Nurs** 1996 May;12(2):82–8 (31 ref.)
Nursing management of patients receiving biological therapy. Sandstrom SK. **Semin Oncol Nurs** 1996 May;12(2):152–62 (34 ref.)

PATHOLOGY

Tumor-associated hyaluronan. Providing an extracellular matrix that facilitates invasion [comment] Knudson W. **Am J Pathol** 1996 Jun;148(6):1721–6 (36 ref.) Comment on: Am J Pathol 1996 Jun;148(6):1861–9.
The cell cycle and regulation of cancer cell growth. Leake R. **Ann N Y Acad Sci** 1996 Apr 30;784:252–62 (25 ref.)
The role of the insulin-like growth factor-I receptor in cancer. LeRoith D, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:402–8 (30 ref.)
The effects of cytokine gene transfer into tumors on host cell infiltration and regression. McBride WH, et al. **Anticancer Res** 1996 May–Jun;16(3A):1139–43 (32 ref.)
p53 in growth control and neoplasia. Gottlieb TM, et al. **Biochim Biophys Acta** 1996 Jun 7;1287(2–3):77–102 (357 ref.)
Clinical symptoms and comorbidity: significance for the prognostic classification of cancer. Piccirillo JF, et al. **Cancer** 1996 Mar 1;77(5):834–42 (50 ref.)
E-cadherin mediated adhesion system in cancer cells. Shiozaki H, et al. **Cancer** 1996 Apr 15;77(8 Suppl):1605–13 (88 ref.)
Fibronectin and integrins in invasion and metastasis. Akiyama SK, et al. **Cancer Metastasis Rev** 1995 Sep;14(3):173–89 (117 ref.)
Adherens junction proteins in tumour progression. Birchmeier W, et al. **Cancer Surv** 1995;24:129–40 (68 ref.)
Integrins in tumour development and spread. Pignatelli M, et al. **Cancer Surv** 1995;24:113–27 (85 ref.)
E-cadherin as an invasion suppressor. Birchmeier W, et al. **Ciba Found Symp** 1995;189:124–36; discussion 136–41, 174–6 (66 ref.)
The cancer cell and the cell cycle clock. Hatakeyama M, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:1–10 (79 ref.)
The killer and the executioner: how apoptosis controls malignancy. Green DR, et al. **Curr Opin Immunol** 1995 Oct;7(5):694–703 (102 ref.)
Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance. Reed JC. **Curr Opin Oncol** 1995 Nov;7(6):541–6 (57 ref.)
MUC18: A cell adhesion molecule with a potential role in tumor growth and tumor cell dissemination. Johnson JP, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 1):95–105 (25 ref.)
Does soluble CD44 reflect the clinical behavior of human cancer? Ristamäki R, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 3):155–66 (53 ref.)
Epithelial-mesenchymal transitions in development and tumor progression. Birchmeier W, et al. **EXS** 1995;74:1–15 (93 ref.)
Angiogenesis as a component of epithelial-mesenchymal interactions. Grant DS, et al. **EXS** 1995;74:235–48 (36 ref.)
Stimulation and regulation of tumor cell motility in invasion and metastasis. Levine MD, et al. **EXS** 1995;74:157–79 (135 ref.)
Tumor cell interactions with the vascular endothelium and their role in cancer metastasis. Nicolson GL. **EXS** 1995; 74:123–56 (189 ref.)
Fibroblast subpopulations as accelerators of tumor progression: the role of migration stimulating factor. Schor SL. **EXS** 1995;74:273–96 (80 ref.)
Stromal-epithelial interaction in type IV collagenase expression and activation: The role in cancer metastasis. Shi YE, et al. **EXS** 1995;74:215–34 (98 ref.)
Regulation of tumor growth and metastasis by thrombospondin-1. Roberts DD. **FASEB J** 1996 Aug; 10(10):1183–91 (69 ref.)
New entities, concepts, and questions in childhood tumor pathology. Harms D. **Gen Diagn Pathol** 1995 May; 141(1):1–14 (32 ref.)
Elimination of transformed cells by normal cells: a novel concept for the control of carcinogenesis. Bauer G. **Histol Histopathol** 1996 Jan;11(1):237–55 (152 ref.)
In vitro drug response assays for entry into the rational era cancer chemotherapy. Hoffman RM. **Hum Cell** 1995 Dec; 8(4):131–48 (208 ref.)

CD44: physiological expression of distinct isoforms as evidence for organ-specific metastasis formation. Zöller M. **J Mol Med** 1995 Sep;73(9):425–38 (265 ref.)
Modulation of the organ microenvironment for treatment of cancer metastasis. Fidler IJ. **J Natl Cancer Inst** 1995 Nov 1;87(21):1588–92 (63 ref.)
Rates of growth of human solid neoplasms: Part I. Spratt JS, et al. **J Surg Oncol** 1995 Oct;60(2):137–46 (45 ref.)
Can virus therapy of human cancer be improved by apoptosis induction? [published erratum appears in Med Hypotheses 1995 Sep;45(3):316] Sinkovics JG, et al. **Med Hypotheses** 1995 May;44(5):359–68 (72 ref.)
Enhancement of tumor growth by drugs with some common molecular actions. LaBella FS, et al. **Mol Carcinog** 1996 Jun;16(2):68–76 (91 ref.)
Telomere dynamics and telomerase activation in tumor progression: prospects for prognosis and therapy. Healy KC. **Oncol Res** 1995;7(3–4):121–30 (84 ref.)
Implications of apoptotic cell death regulation in cancer therapy. McDonnell TJ, et al. **Semin Cancer Biol** 1995 Feb; 6(1):53–60 (80 ref.)
Better dead than red. Evan IG. **Ther Immunol** 1994 Dec; 1(6):343–8 (80 ref.)
Role of platelets, thrombin, integrin IIb–IIIa, fibronectin and von Willebrand factor on tumor adhesion in vitro and metastasis in vivo. Nierodzik ML, et al. **Thromb Haemost** 1995 Jul;74(1):282–90 (67 ref.)
[How to calculate the growth rate of a neoplasm?] Rissanen K. **Duodecim** 1994;110(9):878–81 (7 ref.) **(Fin)**
[Morphology of basement membrane and associated matrix proteins in normal and pathological tissues] Nerlich A. **Veroff Pathol** 1995;145:1–139 (336 ref.) (Eng. Abstr.) **(Ger)**
[Cytokines and growth of cancers] Tachibana M. **Hum Cell** 1995 Dec;8(4):215–6 (18 ref.) **(Jpn)**
[Clinical implication of tumor marker expressions suggesting biological characters of malignancies] Ariyoshi Y, et al. **Nippon Rinsho** 1996 Jun;54(6):1568–73 (17 ref.) (Eng. Abstr.) **(Jpn)**
[Anticancer agents and apoptosis] Fukuoka K, et al. **Nippon Rinsho** 1996 Jan;54(1):250–8 (33 ref.) (Eng. Abstr.) **(Jpn)**
[The cell cycle and the tumor suppressor genes] Kobayashi H. **Rinsho Byori** 1996 Jan;44(1):3–11 (35 ref.) (Eng. Abstr.) **(Jpn)**
[On the novel differentiation-apoptosis inducers in tumor cells] Nakaya K. **Tanpakushitsu Kakusan Koso** 1996 Feb; 41(2):119–26 (38 ref.) **(Jpn)**
[Evaluation of tumor response through of morphometric measurements. Quantification of apoptosis] Vargas F, et al. **G E N** 1995 Apr–Jun;49(2):161–4 (42 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

CT-guided pain procedures for intractable pain in malignancy. Kanpolat Y, et al. **Acta Neurochir Suppl (Wien)** 1995;64:88–91 (24 ref.)
The role of the insulin-like growth factor system in human cancer. Werner H, et al. **Adv Cancer Res** 1996;68:183–223 (184 ref.)
The role of the insulin-like growth factor-I receptor in cancer. LeRoith D, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:402–8 (30 ref.)
The pineal gland and cancer. Ronco AL, et al. **Anticancer Res** 1996 Jul–Aug;16(4A):2033–9 (68 ref.)
Association of TM4SF proteins with integrins: relevance to cancer. Hemler ME, et al. **Biochim Biophys Acta** 1996 Jun 7;1287(2–3):67–71 (58 ref.)
Morphine in cancer pain: modes of administration. Expert Working Group of the European Association for Palliative Care. **BMJ** 1996 Mar 30;312(7034):823–6 (39 ref.)
Measuring symptomatic benefit and quality of life in paediatric oncology [editorial] Eiser C, et al. **Br J Cancer** 1996 Jun;73(11):1313–6 (35 ref.)
Angiogenesis as a new target for cancer treatment. Ono M, et al. **Cancer Chemother Pharmacol** 1996;38 Suppl:S78–82 (38 ref.)
Pain and symptom control in paediatric palliative care. Stevens MM, et al. **Cancer Surv** 1994;21:211–31 (47 ref.)
SPARC and the extracellular matrix: implications for cancer and wound repair. Reed MJ, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 1):81–94 (66 ref.)
Cancer cachexia: pathophysiological mechanisms. Gough DB, et al. **Eur J Surg Oncol** 1996 Apr;22(2):192–6 (63 ref.)
Epithelial–mesenchymal transitions in development and tumor progression. Birchmeier W, et al. **EXS** 1995;74:1–15 (93 ref.)
Stimulation and regulation of tumor cell motility in invasion and metastasis. Levine MD, et al. **EXS** 1995;74:157–79 (135 ref.)
Regulation of scatter factor (hepatocyte growth factor) production by tumor–stroma interaction. Rosen EM, et al. **EXS** 1995;74:17–31 (51 ref.)
Fibroblast subpopulations as accelerators of tumor progression: the role of migration stimulating factor. Schor SL. **EXS** 1995;74:273–96 (80 ref.)
Stromal–epithelial interaction in type IV collagenase expression and activation: The role in cancer metastasis. Shi YE, et al. **EXS** 1995;74:215–34 (98 ref.)
Cancer pain management and the role of social work: barriers and interventions. Glajchen M, et al. **Health Soc Work** 1995 Aug;20(3):200–6 (35 ref.)
Feedback inhibitors in normal and tumor tissues. Marshall E, et al. **Int Rev Cytol** 1996;167:185–261 (299 ref.)
The role of mdr2 P-glycoprotein in biliary lipid secretion. Cross-talk between cancer research and biliary physiology. Oude Elferink RP, et al. **J Hepatol** 1995 Nov;23(5):617–25 (62 ref.)
DNA repair: enzymatic mechanisms and relevance to drug response. Chaney SG, et al. **J Natl Cancer Inst** 1996 Oct 2;88(19):1346–60 (253 ref.)
Modulation of the organ microenvironment for treatment of cancer metastasis. Fidler IJ. **J Natl Cancer Inst** 1995 Nov 1;87(21):1588–92 (63 ref.)
Involvement of CD44 and its variant isoforms in membrane–cytoskeleton interaction, cell adhesion and tumor metastasis. Bourrguignon LY, et al. **J Neurooncol** 1995 Dec;26(3):201–8 (44 ref.)
The clinical significance of malfunction of the CD44 locus in malignancy. Tarin D, et al. **J Neurooncol** 1995 Dec; 26(3):209–19 (59 ref.)
Managing cancer pain: basic principles and invasive treatments. Marshall KA. **Mayo Clin Proc** 1996 May; 71(5):472–7 (10 ref.)
Up-regulation of intracellular signalling pathways may play a central pathogenic role in hypertension, atherogenesis, insulin resistance, and cancer promotion—the 'PKC syndrome'. McCarty MF. **Med Hypotheses** 1996 Mar; 46(3):191–221 (402 ref.)
Angiogenesis inhibitors generated by tumors. Folkman J. **Mol Med** 1995 Jan;1(2):120–2 (23 ref.)
Calories lost—another mediator of cancer cachexia? Nabel GJ, et al. **Nat Med** 1996 Apr;2(4):397–8 (16 ref.)
Intracerebroventricular administration of morphine for control of irreducible cancer pain. Lazorthes YR, et al. **Neurosurgery** 1995 Sep;37(3):422–8; discussion 428–9 (26 ref.)
Multiple meanings of pain and complexities of pain management. Benoliel JQ. **Nurs Clin North Am** 1995 Dec; 30(4):583–96 (91 ref.)
Outcomes that provide evidence of change in cancer pain management. Dalton JA. **Nurs Clin North Am** 1995 Dec; 30(4):683–95 (53 ref.)
The impact of pain on quality of life. A decade of research. Ferrell BR. **Nurs Clin North Am** 1995 Dec;30(4):609–24 (29 ref.)
The importance of nursing research design and methods in cancer pain management. Enhancing care. Gaston-Johansson F, et al. **Nurs Clin North Am** 1995 Dec; 30(4):597–607 (90 ref.)
An algorithmic approach to cancer pain management. Hudzinski DM. **Nurs Clin North Am** 1995 Dec;30(4):711–23 (11 ref.)
Pharmacologic management of cancer pain. Niles R. **Nurs Clin North Am** 1995 Dec;30(4):745–63 (83 ref.)
Sublingual and oral morphine administration. Review and new findings. Robison JM, et al. **Nurs Clin North Am** 1995 Dec;30(4):725–43 (51 ref.)
Prostaglandins, their inhibitors and cancer. Lupulescu A. **Prostaglandins Leukot Essent Fatty Acids** 1996 Feb; 54(2):83–94 (109 ref.)
Concerns about analgesics among patients and family caregivers in a hospice setting. Ward SE, et al. **Res Nurs Health** 1996 Jun;19(3):205–11 (31 ref.)
The use of access devices in cancer pain control. Brant JM. **Semin Oncol Nurs** 1995 Aug;11(3):203–12 (44 ref.)
Pathophysiological aspects of tumor development. Möller P. **Stem Cells (Dayt)** 1995 May;13 Suppl 1:240–7 (86 ref.)
The 1993 ISOBM Abbott Award Lecture. Isozymes, tumor markers and oncodevelopmental biology. Fishman WH. **Tumour Biol** 1995;16(6):394–402 (58 ref.)
[Drug treatment of tumor pain] Larsen B, et al. **Internist (Berl)** 1996 Apr;37(4):425–40 (10 ref.) **(Ger)**
[Protein-carbohydrate recognition. Foundation and medical application with illustrations of tumor lectin studies] Gabius HJ, et al. **Naturwissenschaften** 1995 Dec;82(12):533–43 (162 ref.) (Eng. Abstr.) **(Ger)**
[Ambulatory pain treatment in tumor patients] Keseberg A. **Z Gerontol Geriatr** 1995 Sep–Oct;28(5):328–34 (0 ref.) (Eng. Abstr.) **(Ger)**
[Continuous spinal analgesia in home care of oncologic pain] Ricci V, et al. **Minerva Med** 1995 Oct;86(10):409–14 (30 ref.) (Eng. Abstr.) **(Ita)**
[Cancer patient care—management of intractable pain in patients with cancers] Takeda F. **Nippon Naika Gakkai Zasshi** 1996 Mar 10;85(3):360–4 (5 ref.) **(Jpn)**
[Role of heparin in neoplastic angiogenesis] Sikora J, et al. **Pneumonol Alergol Pol** 1995;63(5–6):344–8 (28 ref.) (Eng. Abstr.) **(Pol)**
[Status of pathophysiologic research in the field of oncology] Tereshchenko IP, et al. **Patol Fiziol Eksp Ter** 1995 Jul–Sep; (3):10–5 (41 ref.) (Eng. Abstr.) **(Rus)**

PREVENTION & CONTROL

4-Hydroxyphenylretinamide in the chemoprevention of cancer. Naik HR, et al. **Adv Pharmacol** 1995;33:315–47 (98 ref.)
Evidence from cancer intervention and biomarker studies and the development of biochemical markers. Bowen PE, et al. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1403S–1409S (54 ref.)
Epidemiologic evidence for beta-carotene and cancer prevention. van Poppel G, et al. **Am J Clin Nutr** 1995 Dec; 62(6 Suppl):1393S–1402S (127 ref.)
What accounts for the association of vegetables and fruits with lower incidence of cancers and coronary heart disease? [editorial; comment] Omenn GS. **Ann Epidemiol** 1995 Jul;5(4):333–5 (12 ref.) Comment on: Ann Epidemiol 1995 Jul;5(4):255–60. Comment on: Ann Epidemiol 1995 Jul;5(4):261–9.
Preventive clinical trials. An overview. Greenwald P. **Ann N Y Acad Sci** 1995 Sep 30;768:129–40 (41 ref.)
How can carcinogenesis be inhibited? Smith TJ, et al. **Ann N Y Acad Sci** 1995 Sep 30;768:82–90 (67 ref.)
What are the critical attributes for cancer chemopreventive agents? Wattenberg LW. **Ann N Y Acad Sci** 1995 Sep 30; 768:73–81 (35 ref.)
Screening for cancer, 1995: an update. La Vecchia C, et al. **Ann Oncol** 1995 Jul;6(6):537–41 (55 ref.)
Vitamins in the maintenance of optimum immune functions and in the prevention of phagocyte-mediated tissue damage and carcinogenesis. Anderson R, et al. **Bibl Nutr Dieta** 1995;(52):66–74 (34 ref.)
Cardiovascular disease and vitamins. Concurrent correction of 'suboptimal' plasma antioxidant levels may, as important part of 'optimal' nutrition, help to prevent early stages of cardiovascular disease and cancer, respectively. Gey KF. **Bibl Nutr Dieta** 1995;(52):75–91 (58 ref.)
Micronutrients, antioxidants and risk of cancer. Schorah CJ. **Bibl Nutr Dieta** 1995;(52):92–107 (101 ref.)
Screening for cancer and pre-cancer. Mera SL. **Br J Biomed Sci** 1995 Jun;52(2):120–41 (94 ref.)
Cancer and the workplace [see comments] Stellman JM, et al. **CA Cancer J Clin** 1996 Mar–Apr;46(2):70–92 (64 ref.) Comment in: CA Cancer J Clin 1996 Jul–Aug;46(4):255–6.
Apoptosis: inhibitor or instigator of carcinogenesis? Manning FC, et al. **Cancer Invest** 1996;14(5):455–65 (130 ref.)
Nature and nurture: possibilities for cancer control. Doll R. **Carcinogenesis** 1996 Feb;17(2):177–84 (36 ref.)
Taking the path of combining traditional Chinese medicine with Western medicine in cancer research and control. Yu R. **Chin Med J (Engl)** 1995 Oct;108(10):732–3 (0 ref.)
Screening for cancer in high risk families. Narod SA. **Clin Biochem** 1995 Aug;28(4):367–72 (30 ref.)
Diet, aging, and cancer. Goodwin JS, et al. **Clin Geriatr Med** 1995 Nov;11(4):577–89 (45 ref.)
Exercise and cancer: linkages with obesity? Shephard RJ. **Crit Rev Food Sci Nutr** 1996 Apr;36(4):321–39 (108 ref.)
Hydrogen ion-dependent oncogenesis and parallel new avenues to cancer prevention and treatment using a H(+)-mediated unifying approach: pH-related and pH-unrelated mechanisms. Harguindey S, et al. **Crit Rev Oncog** 1995;6(1):1–33 (303 ref.)
Phytoestrogens: epidemiology and a possible role in cancer protection. Adlercreutz H. **Environ Health Perspect** 1995 Oct;103 Suppl 7:103–12 (133 ref.)
Viruses and human cancers: challenges for preventive strategies. de The G. **Environ Health Perspect** 1995 Nov; 103 Suppl 8:269–73 (22 ref.)
Dietary modifiers of carcinogenesis. Kohlmeier L, et al. **Environ Health Perspect** 1995 Nov;103 Suppl 8:177–84 (78 ref.)
Molecular epidemiology and prevention of cancer. Perera FP. **Environ Health Perspect** 1995 Nov;103 Suppl 8:233–6 (33 ref.)
Overview of preventable industrial causes of occupational cancer. Ward E. **Environ Health Perspect** 1995 Nov;103 Suppl 8:197–203 (44 ref.)
Retinoids in cancer chemoprevention. Lotan R. **FASEB J** 1996 Jul;10(9):1031–9 (47 ref.)
Dietary contribution to genotoxic risk and its control. Lindsay DG. **Food Chem Toxicol** 1996 Apr;34(4):423–31 (61 ref.)
Diet, nutrition & cancer—the Indian scenario. Krishnaswamy K, et al. **Indian J Med Res** 1995 Nov;102:200–9 (70 ref.)
Exercise and cancer: linkages with obesity? Shephard RJ. **Int J Obes Relat Metab Disord** 1995 Oct;19 Suppl 4:S62–8 (107 ref.)
Intermediate cancer biomarkers and their use in beta-carotene studies in humans. Gerster H. **Int J Vitam Nutr Res** 1996;66(1):3–18 (83 ref.)
Epidemiologic studies of antioxidants and cancer in humans. Flagg EW, et al. **J Am Coll Nutr** 1995 Oct;14(5):419–27 (88 ref.)
Role of the pathologist in biomarker studies. Wilkinson EJ, et al. **J Cell Biochem Suppl** 1995;23:10–8 (29 ref.)
Do antidepressants cause, promote, or inhibit cancers? Steingart AB, et al. **J Clin Epidemiol** 1995 Nov; 48(11):1407–12 (43 ref.)
Social theory, social action, and intervention research: implications for cancer prevention among Latinos. Flores ET, et al. **J Natl Cancer Inst Monogr** 1995;(18):101–8 (53 ref.)
Cancer chemoprevention. Hong WK, et al. **J Natl Cancer Inst Monogr** 1995;(17):49–53 (29 ref.)
The emerging Hispanic population: a foundation for cancer prevention and control. Ramirez AG, et al. **J Natl Cancer Inst Monogr** 1995;(18):1–9 (32 ref.)
The dual roles of nutrients as antioxidants and prooxidants: their effects on tumor cell growth. Schwartz JL. **J Nutr** 1996 Apr;126(4 Suppl):1221S–7S (42 ref.)
Vitamin D3 as a possible chemopreventive and therapeutic agent of cancers. DeLuca HF. **Jpn J Cancer Res** 1996 Apr; 87(4):inside front cover (10 ref.)

The war on cancer. Sporn MB. **Lancet** 1996 May 18; 347(9012):1377–81 (48 ref.)
Phytoestrogens—a short review. Knight DC, et al. **Maturitas** 1995 Nov;22(3):167–75 (89 ref.)
Radiologic imaging in cancer. Ballinger JR. **Med Clin North Am** 1996 Jan;80(1):201–18 (55 ref.)
Principles of cancer screening. MacLean CD. **Med Clin North Am** 1996 Jan;80(1):1–14 (32 ref.)
Tumor markers. An update. Pamies RJ, et al. **Med Clin North Am** 1996 Jan;80(1):185–99 (81 ref.)
The role of midlevel providers in cancer screening. Reed CA, et al. **Med Clin North Am** 1996 Jan;80(1):135–44 (34 ref.)
Barriers to cancer screening. Womeodu RJ, et al. **Med Clin North Am** 1996 Jan;80(1):115–33 (81 ref.)
Folic acid as a cancer-preventing agent. Jennings E. **Med Hypotheses** 1995 Sep;45(3):297–303 (60 ref.)
Cancer prevention strategies for the future: risk identification and preventive intervention. Colditz GA, et al. **Milbank Q** 1995;73(4):621–51 (104 ref.)
Adult cancer detection screening by physical examination. **Nurse Pract** 1996 Mar;21(3):85–6, 89–90, 92–6 passim (0 ref.)
Whole grain intake and cancer: a review of the literature. Jacobs DR Jr, et al. **Nutr Cancer** 1995;24(3):221–9 (35 ref.)
Reaching out to the African American community through innovative strategies. Robinson KD, et al. **Oncol Nurs Forum** 1995 Oct;22(9):1383–91 (28 ref.)
The mechanistic rationale in support of dietary cancer prevention. Rose DP. **Prev Med** 1996 Jan–Feb;25(1):34–7 (36 ref.)
Chemoprevention of cancer. Wattenberg LW. **Prev Med** 1996 Jan–Feb;25(1):44–5 (11 ref.)
Chemoprevention of cancer. Greenwald P. **Sci Am** 1996 Sep; 275(3):96–9 (0 ref.)
Making headway against cancer. Rennie J, et al. **Sci Am** 1996 Sep;275(3):56–9 (0 ref.)
How cancer spreads. Ruoslahti E. **Sci Am** 1996 Sep; 275(3):72–7 (0 ref.)
Strategies for minimizing cancer risk. Willett WC, et al. **Sci Am** 1996 Sep;275(3):88–91, 94–5 (0 ref.)
Educating African-Americans about cancer prevention and detection: a review of the literature. Lowe JI, et al. **Soc Work Health Care** 1995;21(4):17–36 (36 ref.)
Limitations and inconsistencies in the approaches to cancer prevention. Tomatis L. **Teratog Carcinog Mutagen** 1995–96; 15(6):277–82 (37 ref.)
Chemoprotection against cancer by phase 2 enzyme induction. Talalay P, et al. **Toxicol Lett** 1995 Dec; 82–83:173–9 (36 ref.)
[European codex against cancer] Boyle P, et al. **Med Klin** 1996 May 15;91(5):262–7 (49 ref.) **(Ger)**
[Trace elements: mechanistic aspects of anticarcinogenic action] Koyama H. **Nippon Rinsho** 1996 Jan;54(1):52–8 (22 ref.) (Eng. Abstr.) **(Jpn)**
[The role of antioxidants in the prevention of tumors] Ginter E. **Bratisl Lek Listy** 1995 Apr;96(4):195–209 (32 ref.) (Eng. Abstr.) **(Slo)**
[The pediatrician and cancer prevention. Dietetic factors and smoking] Ferrís i Tortajada J, et al. **An Esp Pediatr** 1996 Jul;45(1):6–13 (51 ref.) (Eng. Abstr.) **(Spa)**
[Screening for cancer] Caicoya Gómez-Morán M. **Aten Primaria** 1995 Oct 31;16(7):441–4, 446–52 (56 ref.) **(Spa)**

PSYCHOLOGY

Measuring symptomatic benefit and quality of life in paediatric oncology [editorial] Eiser C, et al. **Br J Cancer** 1996 Jun;73(11):1313–6 (35 ref.)
Ethnicity and health beliefs with respect to cancer: a critical review of methodology. Pfeffer N, et al. **Br J Cancer** 1996 Sep;74 Suppl 29:S66–72 (112 ref.)
Ethnicity and health beliefs with respect to cancer: a critical review of methodology. Pfeffer N, et al. **Br J Cancer Suppl** 1996 Sep;29:S66–72 (112 ref.)
Self-esteem and cancer: theory and research. Katz MR, et al. **Can J Psychiatry** 1995 Dec;40(10):608–15 (120 ref.)
Monitoring versus blunting styles of coping with cancer influence the information patients want and need about their disease. Implications for cancer screening and management. Miller SM. **Cancer** 1995 Jul 15;76(2):167–77 (93 ref.)
Hope and quality of life, two central issues for cancer patients: a theoretical analysis. Rustøen T. **Cancer Nurs** 1995 Oct;18(5):355–61 (60 ref.)
Helping the relatives of patients with cancer [editorial; comment] Fallowfield L. **Eur J Cancer** 1995 Oct; 31A(11):1731–2 (13 ref.) Comment on: Eur J Cancer 1995 Oct;31A(11):1736–40.
The psychiatrist's perspective on quality of life and quality of care in oncology: concepts, symptom management, communication issues. Razavi D, et al. **Eur J Cancer** 1995; 31A Suppl 6:S25–9 (41 ref.)
Social support and adjustment to cancer: reconciling descriptive, correlational, and intervention research. Helgeson VS, et al. **Health Psychol** 1996 Mar;15(2):135–48 (80 ref.)
Group psychological therapy for cancer patients: a point of view, and discussion of the hierarchy of options. Cunningham AJ, et al. **Int J Psychiatry Med** 1996; 26(1):51–82 (82 ref.)
Social support and the patient with cancer: a consideration of the literature. Krishnasamy M. **J Adv Nurs** 1996 Apr; 23(4):757–62 (29 ref.)
Quality-of-life research in the Pediatric Oncology Group: 1991–1995. Bradlyn AS, et al. **J Natl Cancer Inst Monogr** 1996;(20):49–53 (21 ref.)
Trial-related quality of life: using quality-of-life assessment to distinguish among cancer therapies. Gotay CC. **J Natl Cancer Inst Monogr** 1996;(20):1–6 (44 ref.)
Communication with cancer patients: does it matter? Butow PN, et al. **J Palliat Care** 1995 Winter;11(4):34–8 (50 ref.)
The disclosure of the diagnosis of cancer. Carnes JW, et al. **Med Clin North Am** 1996 Jan;80(1):145–51 (10 ref.)
Cancer fatalism among African-Americans: a review of the literature. Powe BD. **Nurs Outlook** 1996 Jan–Feb; 44(1):18–21 (25 ref.)
Definition and measurement of quality of life in oncology nursing research: review and theoretical implications. Mast ME. **Oncol Nurs Forum** 1995 Jul;22(6):957–64 (66 ref.)
Measuring quality of life: 1995 update. Cella DF, et al. **Oncology (Huntingt)** 1995 Nov;9(11 Suppl):47–60 (97 ref.)
MRC quality of life studies using a daily diary card—practical lessons learned from cancer trials. Fayers P. **Qual Life Res** 1995 Aug;4(4):343–52 (42 ref.)
Cancer's psychological challenges. Holland JC. **Sci Am** 1996 Sep;275(3):158–61 (0 ref.)
Group psychological therapy for cancer patients. A brief discussion of indications for its use, and the range of interventions available. Cunningham AJ. **Support Care Cancer** 1995 Jul;3(4):244–7 (29 ref.)
Some problems and some solutions in research on psychotherapeutic intervention in cancer. Fox BH. **Support Care Cancer** 1995 Jul;3(4):257–63 (19 ref.)
Improving quality of life: adjuvant psychological therapy for patients with cancer. Greer S. **Support Care Cancer** 1995 Jul;3(4):248–51 (8 ref.)
Essentials of psychotherapeutic intervention for cancer patients. Spiegel D. **Support Care Cancer** 1995 Jul; 3(4):252–6 (49 ref.)
[Quality of life in the evaluation of cancer therapy] Sprangers MA, et al. **Ned Tijdschr Geneeskd** 1996 Mar 23; 140(12):646–9 (34 ref.) **(Dut)**
[Systemic approach to families dealing with cancer diagnosis, its treatment and its prognosis] Bodart A, et al. **Acta Psychiatr Belg** 1996 Jan–Feb;96(1):30–57 (73 ref.) (Eng. Abstr.) **(Fre)**
[Mental confusion syndromes in oncology] Reich MG, et al. **Bull Cancer (Paris)** 1996 Feb;83(2):115–28 (73 ref.) (Eng. Abstr.) **(Fre)**
[Standards, options and recommendations for a successful practice in psycho-oncology. National Federation of Centers for the fight against cancer] Saltel P, et al. **Bull Cancer (Paris)** 1995 Oct;82(10):847–64 (55 ref.) **(Fre)**
[Recommendations for patient education in poor prognosis. Australian Consensus Document] Bornkessel B. **Med Monatsschr Pharm** 1996 May;19(5):143–5 (0 ref.) **(Ger)**
[The impact of psychological factors on the treatment of somatic diseases. The situation today, as exemplified by cardiovascular disorders and cancer] Blomhoff S, et al. **Tidsskr Nor Laegeforen** 1995 Sep 30;115(23):2893–5 (31 ref.) (Eng. Abstr.) **(Nor)**
[Does social support have an impact on the prognosis in cancer?] Jacobsen EM, et al. **Tidsskr Nor Laegeforen** 1995 Oct 10;115(24):3022–5 (31 ref.) (Eng. Abstr.) **(Nor)**
[Psychooncology: anxiety] Matias J, et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1995 Nov–Dec;23(6):305–9 (26 ref.) (Eng. Abstr.) **(Spa)**
[Conceptualization and measurement of the quality of life of cancer patients] Lara-Muñoz MC, et al. **Rev Invest Clin** 1995 Jul–Aug;47(4):315–27 (108 ref.) (Eng. Abstr.) **(Spa)**

RADIOGRAPHY

The current state of the art in three dimensional oncologic imaging: an overview. Kuszyk BS, et al. **Int J Radiat Oncol Biol Phys** 1995 Dec 1;33(5):1029–39 (79 ref.)
Radiologic imaging in cancer. Ballinger JR. **Med Clin North Am** 1996 Jan;80(1):201–18 (55 ref.)

RADIONUCLIDE IMAGING

Generation of human monoclonal antibodies against ganglioside antigens and their applications in the diagnosis and therapy of cancer. Alfonso M, et al. **Acta Oncol** 1996; 35(3):287–95 (67 ref.)
Immunoscintigraphy: Importance for researchers and patients. Britton KE, et al. **Acta Oncol** 1996;35(3):313–7 (35 ref.)
Secondary antibodies as tools to improve tumor to non tumor ratio at radioimmunolocalisation and radioimmunotherapy. Ullén A, et al. **Acta Oncol** 1996;35(3):281–5 (37 ref.)
Improving the balance between treatment and diagnosis: a role for radioimmunodetection. Larson SM. **Cancer Res** 1995 Dec 1;55(23 Suppl):5756s–5758s (7 ref.)
Positron emission tomography: a new investigational area for cancer research. Wells P, et al. **Clin Oncol (R Coll Radiol)** 1996;8(1):7–14 (48 ref.)
The current status of clinical PET imaging. Cook GJ, et al. **Clin Radiol** 1996 Sep;51(9):603–13 (108 ref.)
Can positron emission tomography (PET) be used to detect subclinical response to cancer therapy? The EC PET Oncology Concerted Action and the EORTC PET Study Group. Price P, et al. **Eur J Cancer** 1995 Nov; 31A(12):1924–7 (14 ref.)
The diagnostic utility of somatostatin receptor scintigraphy in oncology. Valkema R, et al. **J Cancer Res Clin Oncol** 1996;122(9):513–32 (152 ref.)
Neuropeptide receptors in health and disease: the molecular basis for in vivo imaging. Reubi JC. **J Nucl Med** 1995 Oct; 36(10):1825–35 (61 ref.)
Applications of 99mTc-sestamibi in oncology. Maffioli L, et al. **Tumori** 1996 Jan–Feb;82(1):12–21 (59 ref.)
[Positron-emission tomography: role of 18F-fluorodeoxyglucose (18FDG) imaging in oncology] Lagrange JL, et al. **Bull Cancer (Paris)** 1995 Aug; 82(8):611–22 (118 ref.) (Eng. Abstr.) **(Fre)**
[Immunoscintigraphy in oncology] Vuillez JP. **Rev Med Interne** 1995;16(11):833–42 (70 ref.) (Eng. Abstr.) **(Fre)**
[Current status of nuclear oncology in Japan] Endo K. **Kaku Igaku** 1995 Oct;32(10):1125–30 (6 ref.) (Eng. Abstr.) **(Jpn)**
[Cancer diagnosis with positron emission tomography (PET)] Kubota K. **Kaku Igaku** 1996 Feb;33(2):207–12 (22 ref.) (Eng. Abstr.) **(Jpn)**

RADIOTHERAPY

Generation of human monoclonal antibodies against ganglioside antigens and their applications in the diagnosis and therapy of cancer. Alfonso M, et al. **Acta Oncol** 1996; 35(3):287–95 (67 ref.)
Cancer therapy with radiolabeled antibodies. An overview. Bruland OS. **Acta Oncol** 1995;34(8):1085–94 (115 ref.)
Nicotinamide and other benzamide analogs as agents for overcoming hypoxic cell radiation resistance in tumours. A review. Horsman MR. **Acta Oncol** 1995;34(5):571–87 (158 ref.)
Radioimmunotherapy of solid cancers: A review. Kairemo KJ. **Acta Oncol** 1996;35(3):343–55 (92 ref.)
Secondary antibodies as tools to improve tumor to non tumor ratio at radioimmunolocalisation and radioimmunotherapy. Ullén A, et al. **Acta Oncol** 1996;35(3):281–5 (37 ref.)
Invited review: intrinsic radiosensitivity as a predictor of patient response to radiotherapy. West CM. **Br J Radiol** 1995 Aug;68(812):827–37 (87 ref.)
Normal tissue radiosensitivity—how important is it? Burnet NG, et al. **Clin Oncol (R Coll Radiol)** 1996;8(1):25–34 (88 ref.)
Transforming growth factor beta: relevance to radiotherapy. Parker CC, et al. **Clin Oncol (R Coll Radiol)** 1995;7(3):160–1 (19 ref.)
Remote controlled high dose rate brachytherapy. Nag S, et al. **Crit Rev Oncol Hematol** 1996 Mar;22(2):127–50 (115 ref.)
Eicosanoids and radiation. Milas L, et al. **Eur J Cancer** 1995 Sep;31A(10):1580–5 (57 ref.)
Hematologic side effects of radiolabeled immunoglobulin therapy. Vriesendorp HM, et al. **Exp Hematol** 1996 Aug; 24(10):1183–90 (52 ref.)
Imaging: the basis for effective therapy. Chen GT, et al. **Front Radiat Ther Oncol** 1996;29:31–42 (34 ref.)
Clinical interpretation of dose-volume histograms: the basis for normal tissue preservation and tumor dose escalation. Lawrence TS, et al. **Front Radiat Ther Oncol** 1996;29:57–66 (12 ref.)
Assessment of the impact of local control on clinical outcome. Suit H. **Front Radiat Ther Oncol** 1996;29:17–23 (14 ref.)
Safety of growth hormone after treatment of a childhood malignancy. Ogilvy-Stuart AL. **Horm Res** 1995;44 Suppl 3:73–9 (39 ref.)
Roentgen Centennial Lecture: discovering the past, inventing the future. Hellman S. **Int J Radiat Oncol Biol Phys** 1996 Apr 1;35(1):15–20 (30 ref.)
Radioimmunotherapy: recent results and future directions. Wilder RB, et al. **J Clin Oncol** 1996 Apr;14(4):1383–400 (209 ref.)
Radiation protection issues associated with nuclear medicine out-patients [see comments] Thomson WH, et al. **Nucl Med Commun** 1995 Nov;16(11):879–92 (43 ref.) Comment in: Nucl Med Commun 1995 Nov;16(11):877–8.
Optimising the radioimmunotherapy of malignant disease: the broadening choice of carrier and effector moieties. Schubiger PA, et al. **Pharm Acta Helv** 1995 Sep; 70(3):203–17 (67 ref.)
Applications of proton beam therapy. Nicholson J, et al. **Radiol Technol** 1996 May-Jun;67(5):439–41 (9 ref.)
Relationship between DNA damage, rejoining and cell killing by radiation in mammalian cells. Núñez MI, et al. **Radiother Oncol** 1996 May;39(2):155–65 (102 ref.)
The use of radioimmunotherapy in combination with bioreductive agents. Langmuir VK. **Recent Results Cancer Res** 1996;141:137–43 (40 ref.)
Optimal therapeutic strategies for radioimmunotherapy. O'Donoghue JA. **Recent Results Cancer Res** 1996; 141:77–99 (26 ref.)
Two approaches for enhancing radioimmunotherapy: alpha emitters and hyperthermia. Zalutsky MR, et al. **Recent Results Cancer Res** 1996;141:101–22 (41 ref.)
Amifostine and radiation therapy: past, present, and future. Tannehill SP, et al. **Semin Oncol** 1996 Aug;23(4 Suppl 8):69–77 (40 ref.)

Palliative radiation therapy. Thrall DE, et al. **Semin Vet Med Surg (Small Anim)** 1995 Aug;10(3):205–8 (14 ref.)

[Standards, options and recommendations for the practice of external radiotherapy and brachytherapy in oncology. National Federation of Centers for the fight against Cancer] Bey P, et al. **Bull Cancer (Paris)** 1995 Oct;82(10):811–22 (81 ref.) **(Fre)**

[Gene transfer and radiotherapy] Bourhis J, et al. **Bull Cancer (Paris)** 1996 Feb;83(2):107–13 (43 ref.) (Eng. Abstr.) **(Fre)**

[Predictive tests of radiocurability: towards a custom-made radiotherapy?] Cosset JM, et al. **Bull Cancer Radiother** 1990;77(2):83–94 (54 ref.) (Eng. Abstr.) **(Fre)**

[Neutron capturing irradiation: principle, current results and perspectives] Pignol JP, et al. **Bull Cancer Radiother** 1995; 82(3):283–97 (145 ref.) (Eng. Abstr.) **(Fre)**

[The present and future of heavy charged particle therapy] Tsujii H. **Nippon Rinsho** 1996 Jan;54(1):268–73 (13 ref.) (Eng. Abstr.) **(Jpn)**

REHABILITATION

Cardiovascular, pulmonary, and cancer rehabilitation. 3. Cancer rehabilitation. Brennan MJ, et al. **Arch Phys Med Rehabil** 1996 Mar;77(3 Suppl):S52–8 (38 ref.)

[Rehabilitation of cancer patients] Vertio H. **Duodecim** 1994; 110(15):1446–51 (19 ref.) **(Fin)**

[Oncologic after-care—a patient-oriented concept. Basic diagnostic plan for pediatric oncology patients] Duffner U, et al. **Klin Padiatr** 1995 Jul–Aug;207(4):193–203 (55 ref.) (Eng. Abstr.) **(Ger)**

SECRETION

A peptide hormone causing abnormal hair-growth associated with malignancy. Pilszek FH. **Med Hypotheses** 1995 Sep; 45(3):223–4 (6 ref.)

SURGERY

Eat your cereal. Gardner B. **Ann Surg Oncol** 1996 Jan; 3(1):1–7 (13 ref.)

The physical, biologic, and clinical basis of radiosurgery. Mehta MP. **Curr Probl Cancer** 1995 Sep–Oct;19(5):265–329 (163 ref.)

Towards a high standard of surgical oncology throughout Europe. O'Higgins N. **Eur J Cancer** 1995;31A Suppl 6:S22–4 (4 ref.)

[Anticancer therapy and anesthetic implications] Nishino T. **Masui** 1995;44 Suppl:S40–4 (16 ref.) **(Jpn)**

THERAPY

Cytokines in the treatment of malignancies. Jákó J, et al. **Acta Med Hung** 1994;50(3–4):257–73 (50 ref.)

Vaccines in the treatment of cancer. Baltz JK. **Am J Health Syst Pharm** 1995 Nov 15;52(22):2574–85; quiz 2594–5 (37 ref.)

Present status of biological response modifiers in cancer. Parkinson DR. **Am J Med** 1995 Dec 29;99(6A):54S–56S (9 ref.)

Combination of BRMs with chemotherapy. Tursz T. **Am J Med** 1995 Dec 29;99(6A):56S–58S (7 ref.)

Immunotherapy of human cancers. Hui KM, et al. **Ann Acad Med Singapore** 1996 Jan;25(1):113–9 (19 ref.)

The multidrug-resistance gene in gene therapy of cancer and hematopoietic disorders. Licht T, et al. **Ann Hematol** 1996 Apr;72(4):184–93 (118 ref.)

Antitumor activity of syngeneic/autologous graft-versus-host disease. Hess AD, et al. **Ann N Y Acad Sci** 1995 Dec 29;770:189–202 (59 ref.)

Direct gene transfer for treatment of human cancer. Nabel GJ, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:227–31 (40 ref.)

Neoplasia in childhood—25 years of progress. Mott MG. **Ann Oncol** 1995;6 Suppl 1:3–8; discussion 8–9 (42 ref.)

Practical applications for peripheral blood progenitor cells in the treatment of lymphomas and solid tumours. Pettengell R. **Ann Oncol** 1995;6 Suppl 4:9–12 (11 ref.)

Palliative and supportive care: at the frontier of medical omnipotence. Stiefel F, et al. **Ann Oncol** 1996 Feb; 7(2):135–8 (24 ref.)

Vaccine therapy for cancer. Linehan DC, et al. **Ann Surg Oncol** 1996 Mar;3(2):219–28 (47 ref.)

The immunotherapy of solid cancers based on cloning the genes encoding tumor-rejection antigens. Rosenberg SA. **Annu Rev Med** 1996;47:481–91 (38 ref.)

Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies. Bodey B, et al. **Anticancer Res** 1996 Mar–Apr;16(2):661–74 (172 ref.)

The effects of cytokine gene transfer into tumors on host cell infiltration and regression. McBride WH, et al. **Anticancer Res** 1996 May–Jun;16(3A):1139–43 (32 ref.)

An overview on oxygen carriers in cancer therapy. Teicher BA. **Artif Cells Blood Substit Immobil Biotechnol** 1995; 23(3):395–405 (60 ref.)

Cytotoxic lymphocyte-mediated immunotherapy. Smyth MJ, et al. **Aust N Z J Med** 1995 Dec;25(6):852–8 (57 ref.)

The role of inhibitors of poly(ADP-ribose) polymerase as resistance-modifying agents in cancer therapy. Griffin RJ, et al. **Biochimie** 1995;77(6):408–22 (84 ref.)

Assessing the health needs for cancer services for people from ethnic groups. Rawaf S. **Br J Cancer** 1996 Sep;74 Suppl 29:S35–7 (28 ref.)

High-dose chemotherapy with stem cell rescue for solid tumours. Protheroe AS, et al. **Br J Hosp Med** 1996 Apr 3–16;55(7):437–41 (29 ref.)

Review article: high intensity focused ultrasound—potential for cancer treatment. Hill CR, et al. **Br J Radiol** 1995 Dec; 68(816):1296–1303 (44 ref.)

Ethical issues in cancer treatment. Penson RT, et al. **Br J Urol** 1995 Nov;76 Suppl 2:37–40 (18 ref.)

The use of bone marrow and peripheral blood stem cell transplantation in the treatment of cancer [see comments] Appelbaum FR. **CA Cancer J Clin** 1996 May–Jun; 46(3):142–64 (181 ref.) Comment in: CA Cancer J Clin 1996 May–Jun;46(3):131–6.

Hematopoietic growth factors [see comments] Bociek RG, et al. **CA Cancer J Clin** 1996 May–Jun;46(3):165–84 (138 ref.) Comment in: CA Cancer J Clin 1996 May–Jun;46(3):131–6.

Alternative and complementary cancer therapies. Cassileth BR, et al. **Cancer** 1996 Mar 15;77(6):1026–34 (61 ref.)

Whole body hyperthermia as a potential therapeutic option. Shecterle LM, et al. **Cancer Biother** 1995 Winter; 10(4):253–6 (31 ref.)

Biological response modifiers. Clark JW. **Cancer Chemother Biol Response Modif** 1996;16:239–73 (296 ref.)

Adoptive immunotherapy. Curti BD. **Cancer Chemother Biol Response Modif** 1996;16:274–84 (48 ref.)

Monoclonal antibody therapy of cancer. Jurcic JG, et al. **Cancer Chemother Biol Response Modif** 1996;16:168–88 (124 ref.)

Supportive care. Markman M. **Cancer Chemother Biol Response Modif** 1996;16:644–54 (56 ref.)

Gene therapy of cancer. Mullen CA, et al. **Cancer Chemother Biol Response Modif** 1996;16:285–94 (74 ref.)

Biology and clinical potential of stem-cell factor. Glaspy J, et al. **Cancer Chemother Pharmacol** 1996;38 Suppl:S53–7 (33 ref.)

Immunoconjugates and immunotoxins for therapy of solid tumors. Hellström I, et al. **Cancer Chemother Pharmacol** 1996;38 Suppl:S35–6 (13 ref.)

Vectors in cancer therapy: how will they deliver? Blaese M, et al. **Cancer Gene Ther** 1995 Dec;2(4):291–7 (33 ref.)

Strategies to accomplish gene delivery via the receptor-mediated endocytosis pathway. Cristiano RJ, et al. **Cancer Gene Ther** 1996 Jan–Feb;3(1):49–57 (60 ref.)

Application of ribozymes to cancer gene therapy. Kashani-Sabet M, et al. **Cancer Gene Ther** 1995 Sep; 2(3):213–23 (102 ref.)

Tumor cells engineered to produce cytokines or cofactors as cellular vaccines: do animal studies really support clinical trials? Colombo MP, et al. **Cancer Immunol Immunother** 1995 Nov;41(5):265–70 (66 ref.)

The cell cycle as therapeutic target. Broxmeyer H. **Cancer Invest** 1995;13(6):617–24 (38 ref.)

Alternative cancer medicine: a ten-year update. Cassileth BR, et al. **Cancer Invest** 1996;14(4):396–404 (46 ref.)

The potential applications of gene transfer in the treatment of patients with cancer: a concise review. Hussein AM. **Cancer Invest** 1996;14(4):343–52 (150 ref.)

Growth following therapy for childhood cancer. Sklar CA. **Cancer Invest** 1995;13(5):511–6 (40 ref.)

Assessing new anti-tumour agents and strategies in oncogene transgenic mice. Thomas H, et al. **Cancer Metastasis Rev** 1995 Jun;14(2):91–5 (18 ref.)

Improving the balance between treatment and diagnosis: a role for radioimmunodetection. Larson SM. **Cancer Res** 1995 Dec 1;55(23 Suppl):5756s–5758s (7 ref.)

Neurophysiology of opioid poorly responsive pain. Dickenson AH. **Cancer Surv** 1994;21:5–16 (49 ref.)

Peripheral blood stem cell transplantation. Bensinger W. **Cancer Treat Res** 1995;76:169–93 (114 ref.)

High-dose chemotherapy with peripheral blood progenitor autografting. Crown JP, et al. **Cancer Treat Res** 1995; 78:209–26 (115 ref.)

Detection of minimal residual disease. Gribben J, et al. **Cancer Treat Res** 1995;76:249–70 (94 ref.)

Cellular adoptive immunotherapy after bone marrow transplantation. Riddell SR, et al. **Cancer Treat Res** 1995; 76:337–69 (192 ref.)

Interleukin-2 in bone marrow transplantation. Verma UN, et al. **Cancer Treat Res** 1995;76:315–36 (99 ref.)

Patient assessment in palliative cancer care. Bruera E. **Cancer Treat Rev** 1996 Jan;22 Suppl A:3–12 (15 ref.)

Assessment of values, utilities and preferences in cancer patients. de Haes JC, et al. **Cancer Treat Rev** 1996 Jan;22 Suppl A:13–26 (21 ref.)

Dimensions of quality control in oncology. Franklin JL, et al. **Cancer Treat Rev** 1996 Jan;22 Suppl A:27–32 (14 ref.)

The role of the occupational therapist in oncology. Penfold SL. **Cancer Treat Rev** 1996 Jan;22(1):75–81 (9 ref.)

Late effects of treatment in long-term survivors of cancer. Schwartz CL. **Cancer Treat Rev** 1995 Jul;21(4):355–66 (45 ref.)

Taking the path of combining traditional Chinese medicine with Western medicine in cancer research and control. Yu R. **Chin Med J (Engl)** 1995 Oct;108(10):732–3 (0 ref.)

Complementary cancer treatments: hope or hazard? Ernst E. **Clin Oncol (R Coll Radiol)** 1995;7(4):259–63 (34 ref.)

Oral complications of cancer therapies: prevention and management. Singh N, et al. **Clin Oncol (R Coll Radiol)** 1996;8(1):15–24 (158 ref.)

Hyperthermia: an update [editorial] Vernon CC. **Clin Oncol (R Coll Radiol)** 1995;7(6):345–6 (11 ref.)

Long-term effects of treatment of childhood malignancy. Malpas JS. **Clin Radiol** 1996 Jul;51(7):466–74 (65 ref.)

Management of cancer in the aged. Balducci L, et al. **Compr Ther** 1996 Feb;22(2):88–93 (28 ref.)

Hydrogen ion-dependent oncogenesis and parallel new avenues to cancer prevention and treatment using a H(+)-mediated unifying approach: pH-related and pH-unrelated mechanisms. Harguindey S, et al. **Crit Rev Oncog** 1995;6(1):1–33 (303 ref.)

Vaccination for treatment of tumors: a critical comment. Sedlacek HH. **Crit Rev Oncog** 1994;5(6):555–87 (275 ref.)

Cellular immunotherapy of cancer. Yang JC. **Curr Opin Gen Surg** 1994;:238–44 (31 ref.)

Manipulation of costimulatory signals to enhance antitumor T-cell responses. Allison JP, et al. **Curr Opin Immunol** 1995 Oct;7(5):682–6 (34 ref.)

Hematopoietic stem cell transplantation for cancer therapy. Reisner Y, et al. **Curr Opin Immunol** 1995 Oct;7(5):687–93 (69 ref.)

Oral complications of local and systemic cancer treatment. Carl W. **Curr Opin Oncol** 1995 Jul;7(4):320–4 (28 ref.)

Cancer therapy and p53. Lowe SW. **Curr Opin Oncol** 1995 Nov;7(6):547–53 (61 ref.)

Interferons: laboratory to clinic investigations. Platanias LC. **Curr Opin Oncol** 1995 Nov;7(6):560–5 (73 ref.)

Biologic treatment of human cancer. Clark JI, et al. **Curr Probl Cancer** 1995 Jul–Aug;19(4):185–262 (315 ref.)

The role of total parenteral nutrition in the patient with cancer. Harrison LE, et al. **Curr Probl Surg** 1995 Oct; 32(10):833–917 (225 ref.)

Signal transduction as a therapeutic target. Alessandro R, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 3):167–88 (123 ref.)

Transcriptionally targeted gene therapy. Hart IR. **Curr Top Microbiol Immunol** 1996;213 (Pt 3):19–25 (28 ref.)

Antitumor and antimetastatic activity of interleukin-12. Hendrzak JA, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 3):65–83 (131 ref.)

Effect of antisense inhibition of Urokinase receptor on malignancy. Ossowski L. **Curr Top Microbiol Immunol** 1996;213 (Pt 3):101–12 (71 ref.)

Recombinant antibody fusion proteins for cancer immunotherapy. Reisfeld RA, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 3):27–53 (67 ref.)

Intervention in receptor tyrosine kinase-mediated pathways: recombinant antibody fusion proteins targeted to ErbB2. Wels W, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 3):113–28 (47 ref.)

Physiological aspects of aging. Implications for the treatment of cancer. Lichtman SM. **Drugs Aging** 1995 Sep;7(3):212–25 (173 ref.)

The impact of cytokines on high dose chemotherapy followed by transplantation of purified and ex vivo expanded peripheral blood stem cells: achieving a state of minimal residual disease for tumor immunotherapy with cytokine gene transfected cells [editorial] Mertelsmann R. **Eur Cytokine Netw** 1995 Mar–Apr;6(2):79–82 (12 ref.)

Randomised consent designs in cancer clinical trials. Altman DG, et al. **Eur J Cancer** 1995 Nov;31A(12):1934–44 (53 ref.)

European School of Oncology position paper. Gene therapy for the medical oncologist. Blaese M, et al. **Eur J Cancer** 1995;31A(9):1531–7 (17 ref.)

Multidisciplinarity and multimedia in quality of care—education. Heyrman J. **Eur J Cancer** 1995;31A Suppl 6:S11–4 (6 ref.)

Using quality of life assessment methods in patients with advanced cancer: a clinical perspective. Kaasa S. **Eur J Cancer** 1995;31A Suppl 6:S15–7 (16 ref.)

A proposed matrix for organisational changes to improve quality of life in oncology. MacDonald N. **Eur J Cancer** 1995;31A Suppl 6:S18–21 (30 ref.)

Can positron emission tomography (PET) be used to detect subclinical response to cancer therapy? The EC PET Oncology Concerted Action and the EORTC PET Study Group. Price P, et al. **Eur J Cancer** 1995 Nov; 31A(12):1924–7 (14 ref.)

Accumulation of purine catabolites in solid tumors exposed to therapeutic hyperthermia. Busse M, et al. **Experientia** 1996 May 15;52(5):469–73 (26 ref.)

The role of IL-2 in gene therapy. Dalgleish AG. **Gene Ther** 1994 Mar;1(2):83–7 (51 ref.)

Genetic delivery of enzymes for cancer therapy. Deonarain MP, et al. **Gene Ther** 1995 Jun;2(4):235–44 (76 ref.)

Genetic approaches to cancer therapy [editorial] Sikora K. **Gene Ther** 1994 May;1(3):149–51 (15 ref.)

Gene transfer technologies for the gene therapy of cancer. Vile R, et al. **Gene Ther** 1994 Mar;1(2):88–98 (88 ref.)

Immunotoxin therapy of hematological malignancies. Pasqualucci L, et al. **Haematologica** 1995 Nov–Dec; 80(6):546–56 (47 ref.)

Transfusion and stem cell support in cancer treatment. Wuest DL. **Hematol Oncol Clin North Am** 1996 Apr;10(2):397–429

(223 ref.)
The impact of gene therapy on T cell function in cancer. Zier KS, et al. **Hum Gene Ther** 1995 Oct;6(10):1259–64 (45 ref.)
Tumor vaccination. Mallmann P. **Hybridoma** 1995 Apr; 14(2):187–90 (19 ref.)
Tumor therapy by immune recruitment with bispecific antibodies. Renner C, et al. **Immunol Rev** 1995 Jun; 145:179–209 (153 ref.)
Preventing abnormalities in signal transduction of T cells in cancer: the promise of cytokine gene therapy. Zier K, et al. **Immunol Today** 1996 Jan;17(1):39–45 (62 ref.)
The week in phylogeny and ontogeny: opportunities for oncology. Halberg F. **In Vivo** 1995 Jul–Aug;9(4):269–78 (92 ref.)
Systemic fungal infections: major problems in cancer patients. Powles RL, et al. **Indian J Cancer** 1994 Sep;31(3):180–4 (14 ref.)
Tumor vaccine design: concepts, mechanisms, and efficacy testing. Schirrmacher V. **Int Arch Allergy Immunol** 1995 Dec;108(4):340–4 (25 ref.)
Gene replacement strategies for cancer. Roth JA. **Isr J Med Sci** 1996 Feb;32(2):89–94 (12 ref.)
Interferons in solid tumors. Parikh PM, et al. **J Assoc Physicians India** 1995;Suppl 3:38–43 (63 ref.)
The future of antihormone therapy: innovations based on an established principle. Parczyk K, et al. **J Cancer Res Clin Oncol** 1996;122(7):383–96 (82 ref.)
Cytokines and bone marrow transplantation. Takaku F. **J Cancer Res Clin Oncol** 1995;121(12):701–9 (88 ref.)
Antibody–interleukin 2 fusion proteins: a new approach to cancer therapy. Reisfeld RA, et al. **J Clin Lab Anal** 1996; 10(3):160–6 (34 ref.)
Reducing patient eligibility criteria in cancer clinical trials. George SL. **J Clin Oncol** 1996 Apr;14(4):1364–70 (24 ref.)
Inhibitors of cyclin–dependent kinase and cancer. Biggs JR, et al. **J Mol Med** 1995 Oct;73(10):509–14 (58 ref.)
Strategies for cancer gene therapy using adenoviral vectors. Descamps V, et al. **J Mol Med** 1996 Apr;74(4):183–9 (80 ref.)
IL–2 gene therapy of solid tumors: an approach for the prevention of signal transduction defects in T cells. Zier KS, et al. **J Mol Med** 1996 Mar;74(3):127–34 (78 ref.)
Quality–of–life research in the Pediatric Oncology Group: 1991–1995. Bradlyn AS, et al. **J Natl Cancer Inst Monogr** 1996;(20):49–53 (21 ref.)
Trial–related quality of life: using quality–of–life assessment to distinguish among cancer therapies. Gotay CC. **J Natl Cancer Inst Monogr** 1996;(20):1–6 (44 ref.)
Urokinase–type plasminogen activator (uPA) and its receptor (CD87): a new target in tumor invasion and metastasis. Schmitt M, et al. **J Obstet Gynaecol** 1995 Apr;21(2):151–65 (60 ref.)
Nursing management of the infant with a congenital malignancy. Thompson DG, et al. **J Obstet Gynecol Neonatal Nurs** 1996 Jan;25(1):32–8 (23 ref.)
The clinical neuroimmunotherapeutic role of melatonin in oncology. Conti A, et al. **J Pineal Res** 1995 Oct; 19(3):103–10 (38 ref.)
Benefits from specialised cancer care. Selby P, et al. **Lancet** 1996 Aug 3;348(9023):313–8 (52 ref.)
Human umbilical cord blood for hematopoietic progenitor cells transplantation. Varadi G, et al. **Leuk Lymphoma** 1995 Dec;20(1–2):51–8 (54 ref.)
MDR1 reversal: criteria for clinical trials designed to overcome the multidrug resistance phenotype. Hegewisch–Becker S. **Leukemia** 1996 Jul;10 Suppl 3:S32–S38 (53 ref.)
P53 and induction of apoptosis as a target for anticancer therapy. Neubauer A, et al. **Leukemia** 1996 Jul;10 Suppl 3:S2–S4 (46 ref.)
Can virus therapy of human cancer be improved by apoptosis induction? [published erratum appears in Med Hypotheses 1995 Sep;45(3):316] Sinkovics JG, et al. **Med Hypotheses** 1995 May;44(5):359–68 (72 ref.)
Alpha interferon as an immunomodulator in the treatment of patients with tumors. Alvarez–Mon M, et al. **Med Oncol** 1995 Mar;12(1):15–21 (45 ref.)
Alpha interferon: new associations in haematology/oncology. The Montpellier experience. Rossi JF. **Med Oncol** 1995 Mar;12(1):59–61 (23 ref.)
Gene therapy against cancer and HIV infection using the gene encoding herpes simplex virus thymidine kinase. Caruso M. **Mol Med Today** 1996 May;2(5):212–7 (37 ref.)
Site–specific delivery of cytokines in cancer. Klingemann HG, et al. **Mol Med Today** 1996 Apr;2(4):154–9 (38 ref.)
Introduction to clinical economics: assessment of cancer therapies. Schulman KA, et al. **Monogr Natl Cancer Inst** 1995;(19):1–9 (59 ref.)
Radiotherapy for genes that cause cancer. McBride WH, et al. **Nat Med** 1995 Nov;1(11):1215–7 (29 ref.)
Gene therapy for cancer (present status). Altaner C. **Neoplasma** 1995;42(5):209–13 (43 ref.)
DNA–mediated gene transfer into mammalian cells and cancer. Sláviková K, et al. **Neoplasma** 1995;42(6):293–7 (33 ref.)
Reproductive issues for men with cancer: technology and nursing management. Sweet V, et al. **Oncol Nurs Forum** 1996 Jan–Feb;23(1):51–8 (53 ref.)
Economic analysis during phase III clinical trials: who, what, when, where, and why? Bennett CL, et al. **Oncology (Huntingt)** 1995 Nov;9(11 Suppl):169–75 (17 ref.)
Impact of quality of life outcomes on clinical practice. Ganz PA. **Oncology (Huntingt)** 1995 Nov;9(11 Suppl):61–5 (37 ref.)
Issues in the economic analysis of therapies for cancer pain. Portenoy RK. **Oncology (Huntingt)** 1995 Nov;9(11 Suppl):71–8 (36 ref.)
The costs of cancer care in the United States: implications for action. Schuette HL, et al. **Oncology (Huntingt)** 1995 Nov;9(11 Suppl):19–22 (18 ref.)
Costs and benefits of nutrition support in cancer. Tchekmedyian NS. **Oncology (Huntingt)** 1995 Nov;9(11 Suppl):79–84 (45 ref.)
Minimizing oral complications of cancer treatment. Toth BB, et al. **Oncology (Huntingt)** 1995 Sep;9(9):851–8; discussion 858, 863–6 (53 ref.)
The changing face of paediatric oncology. Foot AB. **Palliat Med** 1995 Jul;9(3):193–9 (19 ref.)
Late effects of cancer treatment in children. Ried H, et al. **Pediatr Dent** 1995 Jul–Aug;17(4):273–84 (117 ref.)
Design and testing of peptide–based cytotoxic T–cell–mediated immunotherapeutics to treat infectious diseases and cancer. Chesnut RW, et al. **Pharm Biotechnol** 1995;6:847–74 (170 ref.)
Development of active specific immunotherapeutic agents based on cancer–associated mucins. Samuel J, et al. **Pharm Biotechnol** 1995;6:875–90 (145 ref.)
Therapeutic applications of ribozymes. Kijima H, et al. **Pharmacol Ther** 1995;68(2):247–67 (200 ref.)
Monoclonal antibodies in tumor therapy. Matzku S. **Recent Results Cancer Res** 1996;141:1–8 (31 ref.)
Sucralfate: prophylaxis of mucosal damage during cancer therapy. Henriksson R, et al. **Scand J Gastroenterol Suppl** 1995;210:45–7 (29 ref.)
When are bone marrow transplants considered? Antman K. **Sci Am** 1996 Sep;275(3):124–5 (0 ref.)
Alternative cancer treatments. Aulas JJ. **Sci Am** 1996 Sep; 275(3):162–3 (0 ref.)
Advancing current treatments for cancer. Hellman S, et al. **Sci Am** 1996 Sep;275(3):118–23 (0 ref.)
Immunotherapy for cancer. Old LJ. **Sci Am** 1996 Sep; 275(3):136–43 (0 ref.)
New molecular targets for cancer therapy. Oliff A, et al. **Sci Am** 1996 Sep;275(3):144–9 (0 ref.)
Making headway against cancer. Rennie J, et al. **Sci Am** 1996 Sep;275(3):56–9 (0 ref.)
Clinical trials of targeted toxins. Frankel AE, et al. **Semin Cancer Biol** 1995 Oct;6(5):307–17 (78 ref.)
Tumor targeting through fibroblast growth factor receptors. Lappi DA. **Semin Cancer Biol** 1995 Oct;6(5):279–88 (78 ref.)
Implications of apoptotic cell death regulation in cancer therapy. McDonnell TJ, et al. **Semin Cancer Biol** 1995 Feb; 6(1):53–60 (80 ref.)
Genetic approaches to adoptive cellular therapy of malignancy. Arca MJ, et al. **Semin Oncol** 1996 Feb; 23(1):108–17 (62 ref.)
Novel genetic immunotoxins and intracellular antibodies for cancer therapy. Chen SY, et al. **Semin Oncol** 1996 Feb; 23(1):148–53 (55 ref.)
Polynucleotide–mediated immunization therapy of cancer. Conry RM, et al. **Semin Oncol** 1996 Feb;23(1):135–47 (79 ref.)
Noninfectious gene transfer and expression systems for cancer gene therapy. Cooper MJ. **Semin Oncol** 1996 Feb; 23(1):172–87 (176 ref.)
In situ use of suicide genes for cancer therapy. Freeman SM, et al. **Semin Oncol** 1996 Feb;23(1):31–45 (120 ref.)
Immunotherapy of cancer with genetically modified tumor vaccines. Gilboa E. **Semin Oncol** 1996 Feb;23(1):101–7 (53 ref.)
Tissue specific promoters in targeting systemically delivered gene therapy. Hart IR. **Semin Oncol** 1996 Feb;23(1):154–8 (33 ref.)
Genomic targeting and genetic conversion in cancer therapy. Kmiec EB. **Semin Oncol** 1996 Feb;23(1):188–93 (17 ref.)
Transfer of drug resistance genes into hematopoietic progenitors to improve chemotherapy tolerance. Koç ON, et al. **Semin Oncol** 1996 Feb;23(1):46–65 (196 ref.)
In situ cytokine gene transfection using vaccinia virus vectors. Lattime EC, et al. **Semin Oncol** 1996 Feb; 23(1):88–100 (98 ref.)
Gene therapy for human cancer: an essay for clinicians. Mastrangelo MJ, et al. **Semin Oncol** 1996 Feb;23(1):4–21 (104 ref.)
Parvoviral vectors for the gene therapy of cancer. Shaughnessy E, et al. **Semin Oncol** 1996 Feb;23(1):159–71 (116 ref.)
Monoclonal antibodies: innovations in diagnosis and therapy. Baquiran DC, et al. **Semin Oncol Nurs** 1996 May; 12(2):130–41 (71 ref.)
Hematopoietic growth factors in clinical practice. Pitler LR. **Semin Oncol Nurs** 1996 May;12(2):115–29 (115 ref.)
Future projections in biotherapy. Rieger PT. **Semin Oncol Nurs** 1996 May;12(2):163–71 (49 ref.)
Gene therapy of cancer. Robinson KD, et al. **Semin Oncol Nurs** 1996 May;12(2):142–51 (52 ref.)
Interleukins: the search for an anticancer therapy. Wheeler VS. **Semin Oncol Nurs** 1996 May;12(2):106–14 (39 ref.)
Blood stem cell transplantation and gene therapy of cancer. Körbling M. **Stem Cells** 1995 Dec;13 Suppl 3:106–13 (55 ref.)
The contribution of marker gene studies to hemopoietic stem cell therapies. Brenner MK. **Stem Cells (Dayt)** 1995 Sep; 13(5):453–61 (44 ref.)
Antigens recognized on human tumors by cytolytic T lymphocytes: towards vaccination? Coulie PG. **Stem Cells (Dayt)** 1995 Jul;13(4):393–403 (65 ref.)
Perspective of rhGM–CSF in the treatment of neutropenic infections and aggressive lymphomas. Gerhartz HH. **Stem Cells (Dayt)** 1995 Sep;13(5):472–6 (27 ref.)
Platelet transfusion and alternatives to transfusion in patients with malignancy. Vaickus L, et al. **Stem Cells (Dayt)** 1995 Nov;13(6):588–96 (86 ref.)
Supportive palliative treatment, psychological care and the hospice movement in Hungary. Muszbek K, et al. **Support Care Cancer** 1996 Jan;4(1):7–9 (10 ref.)
Basic principles associated with gene therapy of cancer. Geraghty PJ, et al. **Surg Oncol** 1995 Jun;4(3):125–37 (90 ref.)
Vascular catheter related infections in cancer patients. Farr BM. **Surg Oncol Clin N Am** 1995 Jul;4(3):493–503 (83 ref.)
Current indications for intravenous nutritional support in oncology patients. Hill AD, et al. **Surg Oncol Clin N Am** 1995 Jul;4(3):549–63 (78 ref.)
Immunotherapy and gene transfer in the treatment of the oncology patient: role of transfusion medicine. Hillyer CD, et al. **Transfus Med Rev** 1996 Jan;10(1):1–14 (111 ref.)
Unproven (questionable) cancer therapies. Brigden ML. **West J Med** 1995 Nov;163(5):463–9 (39 ref.)
[High–dose chemotherapy and autologous bone marrow transplantation in solid tumors. A review] Handberg J, et al. **Ugeskr Laeger** 1996 Jul 15;158(29):4175–80 (40 ref.) (Eng. Abstr.) **(Dan)**
[Monoclonal antibodies for diagnosis and therapy in oncological patients] Boven E, et al. **Ned Tijdschr Geneeskd** 1995 Dec 9;139(49):2552–8 (31 ref.) **(Dut)**
[Quality of life in the evaluation of cancer therapy] Sprangers MA, et al. **Ned Tijdschr Geneeskd** 1996 Mar 23; 140(12):646–9 (34 ref.) **(Dut)**
[Cancer vaccines: scientific bases and clinical developments] Bellet D. **Bull Cancer (Paris)** 1995 Nov;82(11):899–909 (49 ref.) (Eng. Abstr.) **(Fre)**
[Late complications of chemoradiotherapeutic combinations: fundamental aspects and clinical experience] Balosso J, et al. **Bull Cancer Radiother** 1995;82(2):101–12 (37 ref.) **(Fre)**
[Hyperthermia: principles, techniques. Current role in the treatment of cancer] Dubois JB. **Bull Cancer Radiother** 1995;82(2):207–24 (91 ref.) **(Fre)**
[Dendritic cells and tumor cell therapy] Pioche C, et al. **Pathol Biol (Paris)** 1995 Dec;43(10):904–9 (43 ref.) (Eng. Abstr.) **(Fre)**
[Blood transfusions in cancer patients] Elias D, et al. **Presse Med** 1996 Feb 17;25(6):255–8 (30 ref.) (Eng. Abstr.) **(Fre)**
[Strategy of treatment of cancer pain in children] Pichard–Léandri E, et al. **Rev Med Interne** 1995; 16(9):708–16 (28 ref.) (Eng. Abstr.) **(Fre)**
[Principles and strategies of gene therapy] Brach MA, et al. **Internist (Berl)** 1996 Apr;37(4):343–9 (35 ref.) **(Ger)**
[Immunotherapy with genetically modified tumor cells] Topf N, et al. **Internist (Berl)** 1996 Apr;37(4):374–81 (55 ref.) **(Ger)**
[Using the thymidine kinase gene in therapy of solid tumors] Wicke I, et al. **Internist (Berl)** 1996 Apr;37(4):369–73 (15 ref.) **(Ger)**
['94 oncology update] Pfreundschuh M. **Med Klin** 1996 Apr 1;91 Suppl 1:7–22 (244 ref.) **(Ger)**
[Tumor therapy and family planning] Theile U, et al. **Med Klin** 1996 Jun 15;91(6):402–9 (43 ref.) **(Ger)**
[Clinical studies on combination of ifosfamide, carboplatin and etoposide (ICE) with whole body hyperthermia] Wiedemann GJ, et al. **Med Klin** 1996 May 15;91(5):279–83 (59 ref.) **(Ger)**
[Immunotherapy of hemato–oncologic diseases] Winkler U, et al. **Med Klin** 1996 Apr 10;91(4):226–33 (49 ref.) **(Ger)**
[Alternative treatment methods in cancer] Jungi WF, et al. **Med Monatsschr Pharm** 1996 Jan;19(1):6–16 (8 ref.) **(Ger)**
[Myeloablative chemotherapy with autologous bone marrow and/or peripheral blood stem cell transplantation in children with high–risk solid tumor] Endo M, et al. **Gan To Kagaku Ryoho** 1995 Oct;22(12):1762–70 (32 ref.) (Eng. Abstr.) **(Jpn)**
[Cancer and health economics] Koinuma N. **Gan To Kagaku Ryoho** 1996 Jan;23(1):1–7 (6 ref.) (Eng. Abstr.) **(Jpn)**
[Problems in conducting clinical trials for cancer patients] Kondo M. **Gan To Kagaku Ryoho** 1996 Jan;23(2):151–5 (6 ref.) (Eng. Abstr.) **(Jpn)**
[The guideline for clinical trials proposed by Japan Society for Cancer Therapy (JSCT)] Kurihara M. **Gan To Kagaku Ryoho** 1996 Jan;23(2):156–65 (10 ref.) (Eng. Abstr.) **(Jpn)**
[Tumor rejection antigen and cancer immunotherapy] Matsutake T, et al. **Gan To Kagaku Ryoho** 1995 Nov; 22(13):1871–7 (37 ref.) (Eng. Abstr.) **(Jpn)**
[Getting informed consent in clinical trials on Japanese cancer patients] Sasako M. **Gan To Kagaku Ryoho** 1996 Jan;23(2):146–50 (3 ref.) (Eng. Abstr.) **(Jpn)**
[Gene therapy for cancer] Sakamaki S, et al. **Hokkaido Igaku Zasshi** 1996 Jan;71(1):15–20 (8 ref.) (Eng.

Abstr.) (Jpn)
[The study of the biological activation induced by the lymphocyte transfusion--the induction of the bio-reproducing protein (BRP)] Sato I. **Hum Cell** 1995 Sep; 8(3):77-84 (18 ref.) (Eng. Abstr.) (Jpn)
[Cancer patient care--informed consent and disease notification] Eguchi K. **Nippon Naika Gakkai Zasshi** 1996 Mar 10;85(3):356-9 (25 ref.) (Jpn)
[Present status of peripheral hematopoietic stem cell transplantation] Harada M. **Nippon Naika Gakkai Zasshi** 1996 Mar 10;85(3):454-8 (17 ref.) (Jpn)
[Palliative care of patients with neoplasm] Shima Y. **Nippon Naika Gakkai Zasshi** 1996 Mar 10;85(3):365-8 (5 ref.) (Jpn)
[Progress on the treatment of tumors--present status and future of bonemarrow and peripheral hematopoietic stem cell transplantation] Takaue Y. **Nippon Naika Gakkai Zasshi** 1996 Mar 10;85(3):347-50 (5 ref.) (Jpn)
[Present status of gene therapy in cancer] Yoshida T. **Nippon Naika Gakkai Zasshi** 1996 Mar 10;85(3):351-5 (6 ref.) (Jpn)
[Application of tumor marker for immunotargeting therapy of cancer] Yamaguchi T, et al. **Nippon Rinsho** 1996 Jun; 54(6):1674-9 (17 ref.) (Eng. Abstr.) (Jpn)
[Recent studies on tumor immunity and prospects for therapy of neoplasms] Aoki Y, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Aug; 47(8):863-71 (27 ref.) (Jpn)
[Autologous bone marrow transplantation] Fujimori Y, et al. **Rinsho Byori** 1995 Jul;Suppl 99:9-14 (9 ref.) (Jpn)
[Gene delivery by immunogene and its application to cancer gene therapy] Gamou S, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2562-9 (22 ref.) (Jpn)
[Immunogene therapy of cancer using cytokine genes] Hanada K, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec; 40(17):2688-93 (23 ref.) (Jpn)
[Inducible regulatable promoter--ionizing radiation-inducible promoter EGR-1] Ohno T. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2624-30 (25 ref.) (Jpn)
[Gene therapy of cancer using TNF gene] Sato Y, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2694-9 (30 ref.) (Jpn)
[Suicide genes for gene therapy] Suzuki S, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2720-6 (24 ref.) (Jpn)
[Cancer gene therapy by IFN gene transfer] Watanabe Y. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2700-8 (46 ref.) (Jpn)
[Tumor-infiltrating lymphocytes (TIL)] Matysiak W. **Pol Arch Med Wewn** 1995 Jul;94(1):76-83 (47 ref.) (Pol)
[Lung toxicity of cancer treatment] de Castro Carpeño J, et al. **Med Clin (Barc)** 1995 Nov 18;105(17):661-8 (76 ref.) (Spa)

ULTRASONOGRAPHY

[Duplex sonography in tumor diagnosis] Karasch T, et al. **Dtsch Med Wochenschr** 1996 Jul 5;121(27):876-84 (51 ref.) (Ger)

ULTRASTRUCTURE

The role of the MDR protein in altered drug translocation across tumor cell membranes. Roepe PD. **Biochim Biophys Acta** 1995 Dec 20;1241(3):385-405 (135 ref.)
Some tumor cell protein kinases activated by receptors as markers, including elastin receptors. Parsons DF. **Cancer Invest** 1995;13(6):629-36 (61 ref.)
Adhesive receptors expressed by tumor cells and platelets: novel targets for therapeutic anti-metastatic strategies. Oleksowicz L, et al. **Med Oncol** 1995 Jun;12(2):95-102 (161 ref.)
[Nuclear bodies--their structure and function in the correction of malignant differentiation in neoplastic cells] Hod I. **Harefuah** 1996 Apr 15;130(8):527-31 (26 ref.) (Heb)

VETERINARY

Tumor physiology and cell kinetics. Dewhirst MW, et al. **Semin Vet Med Surg (Small Anim)** 1995 Aug;10(3):148-57 (47 ref.)
Principles of radiation therapy. Gillette EL, et al. **Semin Vet Med Surg (Small Anim)** 1995 Aug;10(3):129-34 (14 ref.)
Normal tissue tolerance and management of radiation injury. Gillette EL, et al. **Semin Vet Med Surg (Small Anim)** 1995 Aug;10(3):209-13 (12 ref.)
Combining radiation therapy with other treatment modalities. LaRue SM, et al. **Semin Vet Med Surg (Small Anim)** 1995 Aug;10(3):197-204 (14 ref.)
Tumor diagnosis, grading, and staging. Powers BE, et al. **Semin Vet Med Surg (Small Anim)** 1995 Aug;10(3):158-67 (45 ref.)
Physics and treatment planning. Thrall DE, et al. **Semin Vet Med Surg (Small Anim)** 1995 Aug;10(3):135-47 (8 ref.)
The role of blood component therapy in the management of canine and feline patients with cancer. Rudloff E. **Vet Clin North Am Small Anim Pract** 1995 Nov; 25(6):1403-16 (72 ref.)
Cytostatic treatment in veterinary medicine. Rutteman GR, et al. **Vet Q** 1995 Apr;17 Suppl 1:S25-7 (4 ref.)
[Diagnosis of tumors by needle aspiration cytology] Kessler M. **Tierarztl Prax** 1995 Dec;23(6):534-41 (27 ref.) (Eng. Abstr.) (Ger)

VIROLOGY

Viruses in human tumors--reminiscences and perspectives. zur Hausen H. **Adv Cancer Res** 1996;68:1-22 (119 ref.)
Viruses and human cancers: challenges for preventive strategies. de The G. **Environ Health Perspect** 1995 Nov; 103 Suppl 8:269-73 (22 ref.)
Overview: viral agents and cancer. Mueller N. **Environ Health Perspect** 1995 Nov;103 Suppl 8:259-61 (18 ref.)
Managing HIV. Part 3: Mechanisms of disease. 3.6 How HIV promotes malignancies. Boyle MJ, et al. **Med J Aust** 1996 Feb 19;164(4):230-2 (21 ref.)

NEOPLASMS, BASAL CELL

CLASSIFICATION

Classification and differential diagnosis of clear and basal cell tumors of the salivary glands. Seifert G. **Semin Diagn Pathol** 1996 May;13(2):95-103 (47 ref.)

DIAGNOSIS

Classification and differential diagnosis of clear and basal cell tumors of the salivary glands. Seifert G. **Semin Diagn Pathol** 1996 May;13(2):95-103 (47 ref.)

NEOPLASMS, BREAST, MALE see **BREAST NEOPLASMS, MALE**

NEOPLASMS, CONNECTIVE TISSUE

see related
SOFT TISSUE NEOPLASMS

NEOPLASMS, DENTAL TISSUE see **ODONTOGENIC TUMORS**

NEOPLASMS, EMBRYONAL AND MIXED see **NEOPLASMS, GERM CELL AND EMBRYONAL**

NEOPLASMS, EXPERIMENTAL

see related
NEOPLASM TRANSPLANTATION
TUMOR VIRUS INFECTIONS

[General aspects and progress of the etiological survey in experimental oncology] Gao J. **Chung Hua Ping Li Hsueh Tsa Chih** 1995 Aug;24(4):205-6 (10 ref.) (Chi)

BLOOD SUPPLY

VEGF-mediated tumour angiogenesis: a new target for cancer therapy. Martiny-Baron G, et al. **Curr Opin Biotechnol** 1995 Dec;6(6):675-80 (40 ref.)

CHEMICALLY INDUCED

Can laboratory animal carcinogenicity studies predict cancer in exposed children? Rall DP. **Environ Health Perspect** 1995 Sep;103 Suppl 6:173-5 (17 ref.)
Epigenetic carcinogens: evaluation and risk assessment. Williams GM, et al. **Exp Toxicol Pathol** 1996 Feb; 48(2-3):189-95 (55 ref.)
The maximum tolerated dose for inhalation bioassays: toxicity vs overload. Morrow PE, et al. **Fundam Appl Toxicol** 1996 Feb;29(2):155-67 (69 ref.)
Experimental models for carcinogenesis in the house musk shrew, Suncus murinus, Insectivora. Tsubura A, et al. **Histol Histopathol** 1995 Oct;10(4):1047-55 (69 ref.)
Trans fatty acids and cancer. Ip C, et al. **Nutr Rev** 1996 May; 54(5):138-45 (35 ref.)
International safety assessment of pesticides: dithiocarbamate pesticides, ETU, and PTU--a review and update. Vettorazzi G, et al. **Teratog Carcinog Mutagen** 1995-96; 15(6):313-37 (88 ref.)
Quantitative cancer assessment for vinyl chloride: indications of early-life sensitivity. Cogliano VJ, et al. **Toxicology** 1996 Jul 17;111(1-3):21-8 (11 ref.)
Risk assessment and biological mechanisms: lessons learned, future opportunities. McClellan RO. **Toxicology** 1995 Sep 1;102(1-2):239-58 (48 ref.)

CHEMISTRY

Proliferation markers. Iatropoulos MJ, et al. **Exp Toxicol Pathol** 1996 Feb;48(2-3):175-81 (31 ref.)

DRUG THERAPY

The Rac and Rho pathways as a source of drug targets for Ras-mediated malignancies. Symons M. **Curr Opin Biotechnol** 1995 Dec;6(6):668-74 (63 ref.)
[Combined effect of Paclitaxel and ionizing radiation. Experimental data of in-vitro and in-vivo models] Rübe C, et al. **Strahlenther Onkol** 1996 May;172 Suppl 1:2-5 (30 ref.) (Ger)
[The molecular mechanisms of the multiple drug resistance of tumors] Leont'eva OV. **Antibiot Khimioter** 1995 May; 40(5):48-60 (84 ref.) (Rus)
[New approaches to antitumor therapy: the use of preparations acting on processes regulated by epidermal and/or alpha-transforming growth factors] Kushlinskii NE, et al. **Eksp Klin Farmakol** 1996 Jan-Feb;59(1):74-80 (64 ref.) (Rus)

ENZYMOLOGY

[Cytochrome P-450 in tumors and during carcinogenesis] Kobliakov VA. **Biokhimiia** 1995 Nov;60(11):1747-64 (122 ref.) (Eng. Abstr.) (Rus)

EPIDEMIOLOGY

Estimating the probability of occurrence of tumor for a rare cancer with zero occurrence in a sample. Basu AP, et al. **Regul Toxicol Pharmacol** 1996 Apr;23(2):139-44 (13 ref.)

ETIOLOGY

Enhanced cell survival and tumorigenesis. Cory S, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:365-75 (82 ref.)
Etiology of cancer in humans and animals. Wild CP, et al. **Exp Toxicol Pathol** 1996 Feb;48(2-3):95-100 (43 ref.)

GENETICS

Effects of p53 mutation on tumor progression: recent insights from mouse tumor models. Donehower LA. **Biochim Biophys Acta** 1996 Mar 18;1242(3):171-6 (66 ref.)
Murine models of neoplasia: functional analysis of the tumour suppressor genes Rb-1 and p53. Clarke AR. **Cancer Metastasis Rev** 1995 Jun;14(2):125-48 (107 ref.)
Variability in gene expression and tumor formation within genetically homogeneous animal populations in bioassays. Wolff GL. **Fundam Appl Toxicol** 1996 Feb;29(2):176-84 (30 ref.)
Genomic imprinting, DNA methylation, and cancer. Feinberg AP, et al. **J Natl Cancer Inst Monogr** 1995; (17):21-6 (83 ref.)

PATHOLOGY

Proliferation markers. Iatropoulos MJ, et al. **Exp Toxicol Pathol** 1996 Feb;48(2-3):175-81 (31 ref.)

PHYSIOPATHOLOGY

The role of mdr2 P-glycoprotein in biliary lipid secretion. Cross-talk between cancer research and biliary physiology. Oude Elferink RP, et al. **J Hepatol** 1995 Nov;23(5):617-25 (62 ref.)

PREVENTION & CONTROL

Mechanism of cancer preventive action of DHEA. Role of glucose-6-phosphate dehydrogenase. Schwartz AG, et al. **Ann N Y Acad Sci** 1995 Dec 29;774:180-6 (57 ref.)
How can carcinogenesis be inhibited? Smith TJ, et al. **Ann N Y Acad Sci** 1995 Sep 30;768:82-90 (67 ref.)

RADIOTHERAPY

Experimental approaches to increase radiolabeled antibody localization in tumors. Buchsbaum DJ. **Cancer Res** 1995 Dec 1;55(23 Suppl):5729s-5732s (65 ref.)
Preclinical animal studies with radioiododeoxyuridine. Kassis AI, et al. **J Nucl Med** 1996 Apr;37(4 Suppl):10S-12S (25 ref.)
[Gene transfer and radiotherapy] Bourhis J, et al. **Bull Cancer (Paris)** 1996 Feb;83(2):107-13 (43 ref.) (Eng. Abstr.) (Fre)
[Combined effect of Paclitaxel and ionizing radiation. Experimental data of in-vitro and in-vivo models] Rübe C, et al. **Strahlenther Onkol** 1996 May;172 Suppl 1:2-5 (30 ref.) (Ger)

THERAPY

Tissue distribution and tumor localization of effector cells in adoptive immunotherapy of cancer. Basse PH. **APMIS Suppl** 1995;55:1-28 (107 ref.)
Monoclonal antibody therapy of cancer. Jurcic JG, et al. **Cancer Chemother Biol Response Modif** 1996;16:168-88 (124 ref.)
Gene therapy of cancer. Mullen CA, et al. **Cancer Chemother Biol Response Modif** 1996;16:285-94 (74 ref.)
Antitumor activity of interleukin 12 in preclinical models. Brunda MJ, et al. **Cancer Chemother Pharmacol** 1996;38 Suppl:S16-21 (51 ref.)
Transgenic models and cancer treatment. Coletta PL, et al. **Cancer Treat Rev** 1996 Nov;21(6):565-76 (79 ref.)
VEGF-mediated tumour angiogenesis: a new target for cancer therapy. Martiny-Baron G, et al. **Curr Opin Biotechnol** 1995 Dec;6(6):675-80 (40 ref.)
Can co-stimulated tumor immunity be therapeutically efficacious? Hellström KE, et al. **Immunol Rev** 1995 Jun; 145:123-45 (110 ref.)
T-cell immunotherapy of tumors by adoptive transfer of cytotoxic T lymphocytes and by vaccination with minimal essential epitopes. Melief CJ, et al. **Immunol Rev** 1995 Jun; 145:167-77 (42 ref.)
Preventing abnormalities in signal transduction of T cells in

cancer: the promise of cytokine gene therapy. Zier K, et al. **Immunol Today** 1996 Jan;17(1):39–45 (62 ref.)

Antisense oncogene and tumor suppressor gene therapy of cancer. Zhang WW. **J Mol Med** 1996 Apr;74(4):191–204 (137 ref.)

Targeted therapy of carcinomas using BR96 sFv–PE40, a single-chain immunotoxin that binds to the Le(y) antigen. Siegall CB. **Semin Cancer Biol** 1995 Oct;6(5):289–95 (44 ref.)

[The potential of interleukin-12 for use in cancer therapy] Gately MK, et al. **Gan To Kagaku Ryoho** 1996 Jul; 23(8):961–71 (74 ref.) (Eng. Abstr.) **(Jpn)**

[Strategies for studies on mechanism of action of antineoplastic agents] Kuśnierczyk H. **Postepy Hig Med Dosw** 1995;49(1):85–96 (20 ref.) (Eng. Abstr.) **(Pol)**

NEOPLASMS, GERM CELL AND EMBRYONAL

COMPLICATIONS

[Association between testicular germinal tumor and Hodgkin disease] Al-Aukla N, et al. **Bull Cancer (Paris)** 1995 Dec; 82(12):1072–5 (28 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

The use of tumor markers in germ cell malignancies. Bosl GJ, et al. **Hematol Oncol Clin North Am** 1994 Jun; 8(3):573–87 (86 ref.)

DRUG THERAPY

Experience with dose and schedule variations in germ cell tumors. De Mulder PH, et al. **Anticancer Drugs** 1995 Oct; 6 Suppl 5:43–52 (57 ref.)

GENETICS

Reviews of chromosome studies in urological tumors. III. Cytogenetics and genes in testicular tumors. Sandberg AA, et al. **J Urol** 1996 May;155(5):1531–56 (254 ref.)

PATHOLOGY

Torsion of intraabdominal testicular tumors. A case report. Hutcheson JC, et al. **Cancer** 1996 Jan 15;77(2):339–43 (40 ref.)

New developments in sex cord–stromal and germ cell tumors of the ovary. Gordon MD, et al. **Clin Lab Med** 1995 Sep; 15(3):595–610 (50 ref.)

Undifferentiated embryonal sarcoma of the liver in childhood. Mistry RC, et al. **Indian J Cancer** 1995 Dec; 32(4):175–8 (11 ref.)

SURGERY

[Malignant tumors in infancy and childhood] Daum R. **Chirurg** 1996 Jun;67(6):584–92 (18 ref.) (Eng. Abstr.) **(Ger)**

[Results of fertility preserving operations in malignant ovarian tumors] Kleine W. **Zentralbl Gynakol** 1996; 118(6):317–21 (21 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Diagnosis and treatment of urological malignancy: the testes. Wilkins M, et al. **Br J Hosp Med** 1996 Feb 21–Mar 5; 55(4):199–203 (23 ref.)

[Therapy of germ cell tumors. Model for interdisciplinary treatment approach] Schmoll HJ. **Med Klin** 1996 Apr 12; 91 Suppl 3:80–4 (41 ref.) **(Ger)**

[Pathogenesis, diagnosis and therapy of testicular tumors] Weissbach I, et al. **Urologe A** 1996 Mar;35(2):163–72 (11 ref.) **(Ger)**

NEOPLASMS, GLANDULAR AND EPITHELIAL

COMPLICATIONS

Co-occurrence of plasma cell orificial mucositis and plasmoacanthoma. Report of a case and review of the literature. van de Kerkhof PC, et al. **Dermatology** 1995; 191(1):53–5 (21 ref.)

DIAGNOSIS

Early detection and screening for ovarian cancer. Schwartz PE, et al. **J Cell Biochem Suppl** 1995;23:233–7 (20 ref.)

Minimal residual epithelial cancer: diagnostic approaches and prognostic relevance. Pantel K, et al. **Prog Histochem Cytochem** 1996;30(3):1–60 (186 ref.)

DRUG THERAPY

The importance of dose and schedule in cancer chemotherapy: epithelial ovarian cancer. Mainwaring PN, et al. **Anticancer Drugs** 1995 Oct;6 Suppl 5:29–41 (116 ref.)

PATHOLOGY

Sebomatricoma: a unifying term that encompasses all benign neoplasms with sebaceous differentiation. Sáchez Yus E, et al. **Am J Dermatopathol** 1995 Jun;17(3):213–21 (22 ref.)

Epithelial neoplasms of the ovary. An update on current concepts. Gordon MD, et al. **Clin Lab Med** 1995 Sep; 15(3):575–93 (46 ref.)

Epithelial tumours of the lower urinary tract in humans and rodents. Oyasu R. **Food Chem Toxicol** 1995 Sep; 33(9):747–55 (64 ref.)

Angiosarcoma-like neoplasms of epithelial organs: true endothelial tumors or variants of carcinoma? Ritter JH, et al. **Semin Diagn Pathol** 1995 Aug;12(3):270–82 (74 ref.)

The role of ultrastructural pathology in the diagnosis of epithelial and unusual renal tumors. Herrera GA, et al. **Ultrastruct Pathol** 1996 Jan–Feb;20(1):7–26 (68 ref.)

PREVENTION & CONTROL

Potential criteria for cohort selection in chemoprevention trials of epithelial ovarian cancer. Baker VV. **J Cell Biochem Suppl** 1995;23:243–6 (19 ref.)

Molecular approaches to prevention and detection of epithelial ovarian cancer. Bast RC Jr, et al. **J Cell Biochem Suppl** 1995;23:219–22 (21 ref.)

THERAPY

[Epithelial ovarian cancer: what is the consensus in 1995?] Chevallier B, et al. **Bull Cancer (Paris)** 1995 Nov; 82(11):923–8 (26 ref.) (Eng. Abstr.) **(Fre)**

ULTRASTRUCTURE

The role of ultrastructural pathology in the diagnosis of epithelial and unusual renal tumors. Herrera GA, et al. **Ultrastruct Pathol** 1996 Jan–Feb;20(1):7–26 (68 ref.)

NEOPLASMS, HORMONE-DEPENDENT

see related
ANTINEOPLASTIC AGENTS, HORMONAL

The effect of tamoxifen on the endometrium. Barakat RR. **Oncology (Huntingt)** 1995 Feb;9(2):129–34; discussion 139–40, 142 (27 ref.)

CHEMICALLY INDUCED

Chemically induced cancers in hormonal organs of laboratory animals and of humans. Huff J. **Prog Clin Biol Res** 1996; 394:77–102 (96 ref.)

DRUG THERAPY

Aromatase inhibitors: current status. Ibrahim NK, et al. **Am J Clin Oncol** 1995 Oct;18(5):407–17 (142 ref.)

Recent advances in hormonal therapy for cancer. Traynor A. **Curr Opin Oncol** 1995 Nov;7(6):572–81 (75 ref.)

Adjuvant treatment of breast cancer. Akerley WL 3rd. **R I Med** 1995 Sep;78(9):250–3 (12 ref.)

[New strategies of drugs for treatment of hormone-related tumors] von Angerer E. **Pharm Unserer Zeit** 1996 Apr; 25(2):74–84 (42 ref.) **(Ger)**

[Strategy of drug development for hormone-dependent tumor] Kudoh M. **Gan To Kagaku Ryoho** 1996 May; 23(6):668–72 (16 ref.) (Eng. Abstr.) **(Jpn)**

ENZYMOLOGY

The control and biological importance of intratumoural aromatase in breast cancer. Dowsett M, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1–6 Spec No):145–50 (22 ref.)

EPIDEMIOLOGY

Time trends in hormone-dependent cancer. Muir CS, et al. **Prog Clin Biol Res** 1996;394:25–40 (22 ref.)

ETIOLOGY

Organochlorine compounds and estrogen-related cancers in women. Adami HO, et al. **Cancer Causes Control** 1995 Nov; 6(6):551–66 (105 ref.)

Phytoestrogens, body composition, and breast cancer. Horn-Ross PL. **Cancer Causes Control** 1995 Nov; 6(6):567–73 (59 ref.)

Hormonal carcinogenesis and environmental influences: background and overview. Huff J, et al. **Prog Clin Biol Res** 1996;394:3–23 (110 ref.)

Modulating effects of hormones on carcinogenesis. Lijinsky W. **Prog Clin Biol Res** 1996;394:57–76 (09 ref.)

GENETICS

Alternative splicing of the estrogen receptor primary transcript normally occurs in estrogen receptor positive tissues and cell lines. Pfeffer U, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1–6 Spec No):99–105 (37 ref.)

Molecular biology of breast cancer: integration of cellular and molecular concepts into therapeutic strategies. Konstadoulakis MM, et al. **R I Med** 1995 Sep;78(9):257–60 (67 ref.)

METABOLISM

[Progesterone receptor in breast cancer: fundamental data and clinical applications] Ojasoo T. **Bull Cancer (Paris)** 1996;83 Suppl 1:1–5 (53 ref.) **(Fre)**

PATHOLOGY

Apoptosis in prostate cancer. Molecular basis to study hormone refractory mechanisms. Colombel M, et al. **Ann N Y Acad Sci** 1996 Apr 30;784:63–9 (20 ref.)

Sex steroid binding protein is a negative modulator of estrogen-induced breast cancer cell growth. Frairia R, et al. **Ann N Y Acad Sci** 1996 Apr 30;784:362–9 (18 ref.)

Role of growth factors, steroid and peptide hormones in the regulation of human prostatic tumor growth. Motta M, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1–6 Spec No):107–11 (36 ref.)

PHYSIOPATHOLOGY

Influence of diet on tumors of hormonal tissues. Rao GN. **Prog Clin Biol Res** 1996;394:41–56 (92 ref.)

THERAPY

Progress toward hormonal therapy of gastrointestinal cancer [see comments] Bold RJ, et al. **Ann Surg** 1996 Jan; 223(1):4–11 (36 ref.) Comment in: Ann Surg 1996 Jan;223(1):12–3.

The future of antihormone therapy: innovations based on an established principle. Parczyk K, et al. **J Cancer Res Clin Oncol** 1996;122(7):383–96 (82 ref.)

Current status of endocrine therapy for metastatic breast cancer. Kimmick G, et al. **Oncology (Huntingt)** 1995 Sep; 9(9):877–86, 889–90; discussion 892–4 (129 ref.)

[Sex hormone substitution in hormone-dependent neoplasms—oil into the fire?] Kleeberg UR. **Med Klin** 1996 Apr 10;91(4):234–7 (38 ref.) **(Ger)**

[Theoretical considerations and initial clinical results of intermittent hormone treatment of patients with advanced prostatic carcinoma] Bruchovsky N, et al. **Urologe A** 1995 Sep;34(5):389–92 (8 ref.) (Eng. Abstr.) **(Ger)**

[Recent multicenter study protocols in the USA for patients with metastatic prostatic carcinoma] DeAntoni E, et al. **Urologe A** 1995 Sep;34(5):382–8 (14 ref.) (Eng. Abstr.) **(Ger)**

[Renaissance of estrogen therapy in advanced prostate carcinoma?] Smith PH, et al. **Urologe A** 1995 Sep; 34(5):393–7 (17 ref.) (Eng. Abstr.) **(Ger)**

[Intramuscular depot estrogens (Estradurin) in treatment of patients with prostate carcinoma. Historical aspects, mechanism of action, results and current clinical status] Stege R, et al. **Urologe A** 1995 Sep;34(5):398–403 (52 ref.) (Eng. Abstr.) **(Ger)**

[Advanced prostatic carcinoma—which hormone therapy when?] Studer UE. **Urologe A** 1995 Sep;34(5):361–6 (34 ref.) **(Ger)**

NEOPLASMS, METACHRONOUS see **NEOPLASMS, SECOND PRIMARY**

NEOPLASMS, METACHRONOUS SECOND PRIMARY see **NEOPLASMS, SECOND PRIMARY**

NEOPLASMS, MULTIPLE ENDOCRINE see **MULTIPLE ENDOCRINE NEOPLASIA**

NEOPLASMS, MULTIPLE ENDOCRINE TYPE 1 see **MULTIPLE ENDOCRINE NEOPLASIA TYPE 1**

NEOPLASMS, MULTIPLE ENDOCRINE TYPE 2A see **MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A**

NEOPLASMS, MULTIPLE ENDOCRINE, TYPE 2B see **MULTIPLE ENDOCRINE NEOPLASIA TYPE 2B**

NEOPLASMS, MULTIPLE PRIMARY

see related
NEOPLASMS, SECOND PRIMARY

Second primary malignancies in the head and neck cancer patient. Sturgis EM, et al. **Ann Otol Rhinol Laryngol** 1995 Dec;104(12):946–54 (97 ref.)

Extrahepatic biliary cystadenomas and cystadenocarcinoma. Report of seven cases and review of the literature. Davies W, et al. **Ann Surg** 1995 Nov;222(5):619–25 (20 ref.)

Mixed adenocarcinoma and neuroendocrine carcinoma arising in the urachus. A case report and review of the literature. Munichor M, et al. **Eur Urol** 1995;28(4):345–7 (22 ref.)

Congenital glomangioma: case report and review of the world literature. Glick SA, et al. **Pediatr Dermatol** 1995 Sep;12(3):242–4 (11 ref.)

[Double localization of intracranial germinoma. Apropos of a case] Alifdal M, et al. **Neurochirurgie** 1995;41(6):424–8 (23 ref.) (Eng. Abstr.) **(Fre)**

[Urachal adenocarcinoma associated with urothelial tumor of the bladder. Report of a case] Payen E, et al. **Prog Urol** 1996 Apr;6(2):288–91 (13 ref.) (Eng. Abstr.) **(Fre)**

[Appearance in 2 brothers of double primary neoplasms: right renal carcinoma and gastric adenocarcinoma] Casetta G, et al. **Minerva Urol Nefrol** 1995 Mar;47(1):49–51 (11 ref.) (Eng. Abstr.) **(Ita)**

[Double cancers of renal cell carcinoma and testicular seminoma: a case report] Nozawa M, et al. **Hinyokika Kiyo** 1995 Dec;41(12):999–1002 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Double-primary cancer of the lung and trachea] Kishiro

I, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Feb; 34(2):216–9 (13 ref.) (Eng. Abstr.) **(Jpn)**

[Carcinoma in adenoma of the gallbladder] Itoi T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):311–3 (6 ref.) **(Jpn)**

[Combined hepatocellular and cholangiocarcinoma] Omagari K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):473–5 (14 ref.) **(Jpn)**

COMPLICATIONS

Clinical characteristics of synchronous multiple lung cancer associated with idiopathic pulmonary fibrosis. A review of Japanese cases [see comments] Mizushima Y, et al. **Chest** 1995 Nov;108(5):1272–7 (37 ref.) Comment in: Chest 1995 Nov;108(5):1193–4.

DIAGNOSIS

Multicentric primary adenocarcinomas of the midgut: the first case report. Liu KJ, et al. **Am J Gastroenterol** 1996 Jun;91(6):1239–43 (48 ref.)

Symptomatic spinal hemangiomas in association with cutaneous hemangiomas. A case report. Asumu TO, et al. **Spine** 1996 May 1;21(9):1082–4 (7 ref.)

[A case of genitourinary double cancers detected by health screening] Ito T, et al. **Hinyokika Kiyo** 1996 Jun; 42(6):461–4 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Primary malignant neoplasms of the female genitalia] Saraiva J, et al. **Acta Med Port** 1995 Oct;8(10):585–8 (11 ref.) (Eng. Abstr.) **(Por)**

DRUG THERAPY

[Photodynamic therapy for multiple primary lung cancer] Konaka C, et al. **Gan To Kagaku Ryoho** 1996 Jan;23(1):31–5 (8 ref.) (Eng. Abstr.) **(Jpn)**

EPIDEMIOLOGY

Triple primary malignant neoplasms including a malignant brain tumor: report of two cases and review of the literature. Nagane M, et al. **Surg Neurol** 1996 Mar; 45(3):219–29 (44 ref.)

Arguments against routine contralateral mastectomy or undirected biopsy for invasive lobular breast cancer. Lee JS, et al. **Surgery** 1995 Oct;118(4):640–7; discussion 647–8 (22 ref.)

[Multiple primary neoplasia in a urologic setting. Clinical review and tentative etiopathogenetic profile] Marino G, et al. **Minerva Urol Nefrol** 1995 Jun;47(2):71–6 (18 ref.) (Eng. Abstr.) **(Ita)**

GENETICS

Hereditary multiple glomus tumors involving the glans penis. A case report and review of the literature. Kiyosawa T, et al. **Dermatol Surg** 1995 Oct;21(10):895–9 (36 ref.)

[Multiple primary melanoma and familial melanoma. Risk evaluation and screening tests. How to evaluate the risk of developing a second melanoma? In what family? Should screening methods be implemented? Which ones and why?] Grange F. **Ann Dermatol Venereol** 1995;122(5):365–71 (50 ref.) **(Fre)**

MORTALITY

Synchronous colon primaries have the same prognosis as solitary colon cancers. Passman MA, et al. **Dis Colon Rectum** 1996 Mar;39(3):329–34 (42 ref.)

PATHOLOGY

Meningioangiomatosis and oligodendroglioma in a 15-year-old boy. López JI, et al. **Arch Pathol Lab Med** 1996 Jun;120(6):587–90 (11 ref.)

Multiple cutaneous plexiform schwannomas. Report of a case and review of the literature with particular reference to the association with types 1 and 2 neurofibromatosis and schwannomatosis. Reith JD, et al. **Arch Pathol Lab Med** 1996 Apr;120(4):399–401 (22 ref.)

Thyroid carcinoma originating in a teratoma of the ovary. Ferrer J, et al. **Eur J Gynaecol Oncol** 1995;16(5):396–402 (24 ref.)

Adequacy of conization margins in adenocarcinoma in situ of the cervix as a predictor of residual disease. Im DD, et al. **Gynecol Oncol** 1995 Nov;59(2):179–82 (20 ref.)

Synchronous adenocarcinoma and low grade B-cell lymphoma of mucosa associated lymphoid tissue (MALT) of the stomach. Wotherspoon AC, et al. **Histopathology** 1995 Oct;27(4):325–31 (45 ref.)

Multiple tumors of the follicular infundibulum. Kolenik SA 3rd, et al. **Int J Dermatol** 1996 Apr;35(4):282–4 (11 ref.)

Widespread eruptive dermal and atypical melanocytic nevi in association with chronic myelocytic leukemia: case report and review of the literature. Richert S, et al. **J Am Acad Dermatol** 1996 Aug;35(2 Pt 2):326–9 (25 ref.)

Mucin-producing adenoma associated with pancreas divisum and hepatic hilar carcinoma: an autopsy case. Origuchi N, et al. **J Gastroenterol** 1996 Jun;31(3):455–9 (40 ref.)

Increased incidence of second primary malignancy in patients with carcinoid tumors: case report and literature review. Rivadeneira DE, et al. **J Natl Med Assoc** 1996 May; 88(5):310–2 (12 ref.)

Simultaneous malignant melanoma and squamous cell carcinoma of the oral cavity: a case report. Nakahara H, et al. **J Oral Maxillofac Surg** 1995 Dec;53(12):1455–7 (12 ref.)

Coexistence of nipple duct adenoma and breast carcinoma: a clinicopathologic study of five cases and review of the literature. Jones MW, et al. **Mod Pathol** 1995 Aug; 8(6):633–6 (13 ref.)

Simultaneous multifocal polymorphous low-grade adenocarcinoma. Report of two cases. Clayton JR, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1995 Jul;80(1):71–7 (31 ref.)

Adrenal gland leiomyoma in a child with acquired immunodeficiency syndrome. Jimenez-Heffernan JA, et al. **Pediatr Pathol Lab Med** 1995 Nov-Dec;15(6):923–9 (22 ref.)

Simultaneous gastric adenocarcinoma and MALT-type lymphoma in Helicobacter pylori infection. von Herbay A, et al. **Virchows Arch** 1995;427(4):445–50 (62 ref.)

[Synchronous bilateral renal oncocytoma] Sánchez-Chapado M, et al. **Arch Esp Urol** 1995 Nov;48(9):909–13 (35 ref.) (Eng. Abstr.) **(Spa)**

SURGERY

Concurrent papillary and squamous carcinoma in a thyroglossal duct cyst: a case report [see comments] Kwan WB, et al. **Can J Surg** 1996 Aug;39(4):328–32 (20 ref.) Comment in: Can J Surg 1996 Aug;39(4):263–4. Comment in: Can J Surg 1996 Aug;39(4):340.

Synchronous colon primaries have the same prognosis as solitary colon cancers. Passman MA, et al. **Dis Colon Rectum** 1996 Mar;39(3):329–34 (42 ref.)

[A simultaneous operation for esophageal and cholangiocellular carcinomas--a case of report] Kudo T, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Oct; 92(10):1789–93 (12 ref.) **(Jpn)**

THERAPY

The management of relapsed Wilms tumor. Miser JS, et al. **Hematol Oncol Clin North Am** 1995 Dec;9(6):1287–302 (51 ref.)

The management of synchronous bilateral Wilms tumor. Ritchey ML, et al. **Hematol Oncol Clin North Am** 1995 Dec;9(6):1303–15 (68 ref.)

Multimodal management of diffuse neonatal hemangiomatosis. Stratte EG, et al. **J Am Acad Dermatol** 1996 Feb;34(2 Pt 2):337–42 (36 ref.)

VIROLOGY

Bilateral primary ovarian squamous cell carcinoma associated with human papilloma virus infection and vulvar and cervical intraepithelial neoplasia. A case report with review of the literature. Mai KT, et al. **Am J Surg Pathol** 1996 Jun;20(6):767–72 (23 ref.)

Do human papillomaviruses have a role in the pathogenesis of bladder carcinoma? Mvula M, et al. **J Urol** 1996 Feb; 155(2):471–4 (24 ref.)

NEOPLASMS, MUSCLE TISSUE

PATHOLOGY

Ethmoidal myofibroblastoma. Samuel D, et al. **J Otolaryngol** 1995 Oct;24(5):313–6 (18 ref.)

Intranodal myofibroblastoma: report of a case. Eyden BP, et al. **Ultrastruct Pathol** 1996 Jan-Feb;20(1):79–88 (35 ref.)

ULTRASTRUCTURE

Intranodal myofibroblastoma: report of a case. Eyden BP, et al. **Ultrastruct Pathol** 1996 Jan-Feb;20(1):79–88 (35 ref.)

NEOPLASMS, NEUROEPITHELIAL

DIAGNOSIS

Central nervous system medulloepithelioma: a series of eight cases including two arising in the pons. Molloy PT, et al. **J Neurosurg** 1996 Mar;84(3):430–6 (45 ref.)

NEOPLASMS, OCCULT PRIMARY see **NEOPLASMS, UNKNOWN PRIMARY**

NEOPLASMS, RADIATION-INDUCED

see related
LEUKEMIA, RADIATION-INDUCED
NEOPLASMS, SECOND PRIMARY

Low-grade dermal angiosarcoma of the breast following radiotherapy. Bolin DJ, et al. **Am Surg** 1996 Aug; 62(8):668–72 (19 ref.)

Radiation-associated angiosarcoma: diagnostic and therapeutic implications--two case reports and a review of the literature. Cafiero F, et al. **Cancer** 1996 Jun 15; 77(12):2496–502 (46 ref.)

Role of low-level ionizing radiation in multi-step carcinogenic process. Trosko JE. **Health Phys** 1996 Jun; 70(6):812–22 (112 ref.)

Radiation-induced sarcoma of the breast. Mason RW, et al. **J Am Osteopath Assoc** 1996 Jun;96(6):368–70 (15 ref.)

Management of papillary thyroid cancer. Vassilopoulou-Sellin R. **Oncology (Huntingt)** 1995 Feb; 9(2):145–51; discussion 151–2, 154, 157 (50 ref.)

DIAGNOSIS

Nonmelanoma skin cancer. Epstein JH. **Compr Ther** 1996 Mar;22(3):179–82 (17 ref.)

Metastatic squamous cell carcinoma of the hand and review of the literature. Foley SJ, et al. **J R Army Med Corps** 1995 Jun;141(2):102–4 (8 ref.)

Radiation-induced meningioma in children: report of two cases and review of the literature. Starshak RJ. **Pediatr Radiol** 1996;26(8):537–41 (30 ref.)

EPIDEMIOLOGY

Breast cancer and environmental risk factors: epidemiological and experimental findings. Wolff MS, et al. **Annu Rev Pharmacol Toxicol** 1996;36:573–96 (116 ref.)

Cutaneous malignant melanoma and sun exposure. Recent developments in epidemiology. Katsambas A, et al. **Arch Dermatol** 1996 Apr;132(4):444–50 (62 ref.)

Childhood cancer: overview of incidence trends and environmental carcinogens. Zahm SH, et al. **Environ Health Perspect** 1995 Sep;103 Suppl 6:177–84 (143 ref.)

Radioepidemiology of the A-bomb survivors. Schull WJ. **Health Phys** 1996 Jun;70(6):798–803 (14 ref.)

Cancer consequences of the Chernobyl accident in Europe outside the former USSR: a review. Sali D, et al. **Int J Cancer** 1996 Jul 29;67(3):343–52 (33 ref.)

[Cancer epidemiology of radiation workers] Hosoda Y, et al. **Sangyo Eiseigaku Zasshi** 1996 May;38(3):107–18 (83 ref.) (Eng. Abstr.) **(Jpn)**

ETIOLOGY

Breast cancer following treatment for Hodgkin's disease: the need for screening in a young population. Australasian Radiation Oncology Lymphoma Group (AROLG) [see comments] O'Brien PC, et al. **Australas Radiol** 1995 Aug; 39(3):271–6 (30 ref.) Comment in: Australas Radiol 1995 Aug;39(3):207.

Case report: late aggressive meningioma following prophylactic cranial irradiation for acute lymphoblastic leukaemia. Stein ME, et al. **Br J Radiol** 1995 Oct; 68(814):1123–5 (13 ref.)

Pericardial angiosarcoma after mediastinal irradiation for seminoma. A case report and a review of the literature. Killion MJ, et al. **Cancer** 1996 Aug 15;78(4):912–7 (30 ref.)

Benefits versus risks from mammography: a critical reassessment [see comments] Mettler FA, et al. **Cancer** 1996 Mar 1;77(5):903–9 (49 ref.) Comment in: Cancer 1996 Mar 1;77(5):818–22.

The risk of childhood cancer from intrauterine and preconceptional exposure to ionizing radiation. Wakeford R. **Environ Health Perspect** 1995 Nov;103(11):1018–25 (84 ref.)

Effects of low doses of radiation. Fry RJ. **Health Phys** 1996 Jun;70(6):823–7 (24 ref.)

Cancer following irradiation in childhood and adolescence. Boice JD Jr. **Med Pediatr Oncol Suppl** 1996;1:29–34 (42 ref.)

Alternative sources of risk estimates for cancer effects of radiation. Stewart A. **Mt Sinai J Med** 1995 Oct;62(5):380–5 (31 ref.)

Effects in society of ionizing radiation. Yalow RS. **Mt Sinai J Med** 1995 Oct;62(5):339–42 (15 ref.)

Nonionizing electromagnetic fields and cancer: a review. Salvatore JR, et al. **Oncology (Huntingt)** 1996 Apr; 10(4):563–70; discussion 573–4, 577–8 (71 ref.)

Radiation-induced carcinogenesis: individual sensitivity and genomic instability. Sabatier L, et al. **Radiat Environ Biophys** 1995 Nov;34(4):229–32 (19 ref.)

Three cases of breast angiosarcomas after breast-conserving treatment for carcinoma [letter] Weber B, et al. **Radiother Oncol** 1995 Dec;37(3):250–2 (21 ref.)

How dangerous is low level radiation? Cohen BL. **Risk Anal** 1995 Dec;15(6):645–53 (30 ref.)

Basal cell carcinoma due to radiotherapy for carcinoma of the cervix. Copas P, et al. **South Med J** 1995 Nov; 88(11):1161–2 (12 ref.)

Cancer risks and biomarker studies in the atomic bomb survivors. Preston D. **Stem Cells (Dayt)** 1995 May;13 Suppl 1:40–8 (24 ref.)

[Ozone depletion--does the incidence of skin cancer increase? (editorial)] Jokela K, et al. **Duodecim** 1994; 110(19):1756–9 (20 ref.) **(Fin)**

GENETICS

p53 gene mutations and photocarcinogenesis. Nataraj AJ, et al. **Photochem Photobiol** 1995 Aug;62(2):218–30 (140 ref.)

[Cutaneous photocarcinogenesis] Césarini JP. **Rev Med Interne** 1995;16 Suppl 3:344s–347s (28 ref.) **(Fre)**

MORTALITY

[From Hiroshima to Chernobyl. Increasing number of late fatal cases of cancer] Drottz-Sjöberg BM, et al. **Lakartidningen** 1995 Nov 1;92(44):4100–2, 4105 (18 ref.) **(Swe)**

PATHOLOGY

Postradiation malignant triton tumor. A case report and review of the literature. Yakulis R, et al.

NEOPLASMS, RADIATION-INDUCED

Arch Pathol Lab Med 1996 Jun;120(6):541-8 (59 ref.)
Pericardial angiosarcoma after mediastinal irradiation for seminoma. A case report and a review of the literature. Killion MJ, et al. **Cancer** 1996 Aug 15;78(4):912-7 (30 ref.)
Cutaneous angiosarcoma arising in the radiation site of a congenital hemangioma. Caldwell JB, et al. **J Am Acad Dermatol** 1995 Nov;33(5 Pt 2):865-70 (50 ref.)

PHYSIOPATHOLOGY

Enhanced risks of cancer from protracted exposures to X- or gamma-rays: a radiobiological model of radiation-induced breast cancer [editorial] Elkind MM. **Br J Cancer** 1996 Jan;73(2):133-8 (54 ref.)

PREVENTION & CONTROL

DNA repair and cytokines in antimutagenesis and anticarcinogenesis. Yarosh DB, et al. **Mutat Res** 1996 Feb 19;350(1):255-60 (28 ref.)
[Cancers of the skin, relations to ultraviolet rays] Robert C, et al. **Presse Med** 1995 Nov 11;24(34):1610-6 (33 ref.) (Eng. Abstr.) **(Fre)**

NEOPLASMS, SECOND PRIMARY

see related
NEOPLASMS, MULTIPLE PRIMARY

Hodgkin's disease developing after spontaneous remission of chronic lymphocytic leukemia. Schmidt HH, et al. **Ann Hematol** 1995 Nov;71(5):247-52 (46 ref.)
Second primary malignancies in the head and neck cancer patient. Sturgis EM, et al. **Ann Otol Rhinol Laryngol** 1995 Dec;104(12):946-54 (97 ref.)
[Detection methods of local, regional and distant recurrences of melanoma] Sigal R. **Ann Dermatol Venereol** 1995; 122(5):279-84 (46 ref.) **(Fre)**
[Primary leiomyosarcoma of the liver 37 years after successful treatment of hereditary retinoblastoma] Abdelli N, et al. **Gastroenterol Clin Biol** 1996;20(5):502-5 (31 ref.) (Eng. Abstr.) **(Fre)**
[Second tumors in pediatric oncologic patients. Report of 5 cases] Jiménez M, et al. **Rev Med Univ Navarra** 1995 Apr-Jun;40(2):72-7 (23 ref.) (Eng. Abstr.) **(Spa)**

CHEMICALLY INDUCED

Uterine neoplasms in patients treated with tamoxifen. Silva EG, et al. **J Cell Biochem Suppl** 1995;23:179-83 (22 ref.)
[A case of secondary leukemia in anaplastic seminoma patient treated with long-term chemotherapy] Kamai T, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 May;87(5):875-9 (12 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Postexcisional recurrence of carcinoma of the breast. Zavotsky J, et al. **J Am Coll Surg** 1996 Jan;182(1):71-7 (88 ref.)
[When, how and which patients should be screened for second melanoma?] Dreno B. **Ann Dermatol Venereol** 1995; 122(5):310-4 (42 ref.) **(Fre)**

DRUG THERAPY

[II. Leukemia in the elderly, secondary, recurrent and refractory leukemia, chloroma] Jehn U, et al. **Internist (Berl)** 1996 Jun;37(6):669-77 (18 ref.) **(Ger)**

EPIDEMIOLOGY

Review of Hodgkin's disease and lung cancer following non-Hodgkin's lymphoma in Rhode Island and review of the literature. Dores GM, et al. **R I Med** 1995 Nov; 78(11):317-9 (20 ref.)
[Incidence and risk factors of second primary cancers in patients treated for primary pharyngeal cancer] Brochet F, et al. **Bull Cancer Radiother** 1996;83(1):8-11 (34 ref.) (Eng. Abstr.) **(Fre)**
[Multiple primary neoplasia in a urologic setting. Clinical review and tentative etiopathogenetic profile] Marino G, et al. **Minerva Urol Nefrol** 1995 Jun;47(2):71-6 (18 ref.) (Eng. Abstr.) **(Ita)**

ETIOLOGY

Therapy-related acute promyelocytic leukemia with t(15;17)(q22;q12) following chemotherapy with drugs targeting DNA topoisomerase II. A report of two cases and a review of the literature [see comments] Hoffmann L, et al. **Ann Oncol** 1995 Oct;6(8):781-8 (32 ref.) Comment in: Ann Oncol 1995 Oct;6(8):751-3.
Breast cancer following treatment for Hodgkin's disease: the need for screening in a young population. Australasian Radiation Oncology Lymphoma Group (AROLG) [see comments] O'Brien PC, et al. **Australas Radiol** 1995 Aug; 39(3):271-6 (30 ref.) Comment in: Australas Radiol 1995 Aug;39(3):207.
Lymphangiosarcoma following mastectomy. Stewart NJ, et al. **Clin Orthop** 1995 Nov;(320):135-41 (15 ref.)
Therapy-related myeloid leukemia. Thirman MJ, et al. **Hematol Oncol Clin North Am** 1996 Apr;10(2):293-320 (139 ref.)
The secondary leukemias: challenges and research directions. Smith MA, et al. **J Natl Cancer Inst** 1996 Apr 3; 88(7):407-18 (199 ref.)
Acute promyelocytic leukemia after treatment of malignant glioma in a patient with von Recklinghausen's disease: case report and review of the literature. Wiernik PH, et al. **Leukemia** 1996 Jan;10(1):178-82 (49 ref.)
Three cases of breast angiosarcomas after breast-conserving treatment for carcinoma [letter] Weber B, et al. **Radiother Oncol** 1995 Dec;37(3):250-2 (21 ref.)

GENETICS

Therapy-related acute leukemia associated with t(11q23) after primary acute myeloid leukemia with t(8;21): a report of two cases [letter] Roulston D, et al. **Blood** 1995 Nov 1;86(9):3613-4 (7 ref.)
p53 tumor suppressor gene: implications for iatrogenic cancer and cancer therapy. De Benedetti V, et al. **Med Pediatr Oncol Suppl** 1996;1:2-11 (129 ref.)

PATHOLOGY

Multiple malignant melanoma and squamous-cell carcinoma in a burn scar. Ikeda I, et al. **Dermatology** 1995; 191(4):328-32 (20 ref.)
Squamous cell carcinoma arising from mature cystic teratoma: a report of three cases. Bontis J, et al. **Eur J Gynaecol Oncol** 1996;17(1):49-52 (20 ref.)
Cutaneous angiosarcoma arising in the radiation site of a congenital hemangioma. Caldwell JB, et al. **J Am Acad Dermatol** 1995 Nov;33(5 Pt 2):865-70 (50 ref.)
Laryngeal carcinoma ex-papilloma in a non-irradiated, non-smoking patient: a clinical record and review of the literature. Hasan S, et al. **J Laryngol Otol** 1995 Aug; 109(8):762-6 (33 ref.)
Familial adenomatous polyposis and lung cancer. Wong RP, et al. **J Surg Oncol** 1995 Nov;60(3):213-4 (11 ref.)
Carcinoma of the tongue in a long-term survivor of clear cell sarcoma of the kidney. Ferbend P, et al. **Pedistr Pathol Lab Med** 1995 Mar-Apr;15(2):327-32 (22 ref.)
[Melanoma developped on nevus of Ota without ocular melanosis. Apropos of an anatomo-clinical case] Reichert S, et al. **J Fr Ophtalmol** 1996;19(5):389-94 (23 ref.) (Eng. Abstr.) **(Fre)**
[Transitional cell carcinoma of the ureter and cyclophosphamide: apropos of a case] Ponsot Y, et al. **Prog Urol** 1995 Sep;5(4):578-9 (8 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

Arguments against routine contralateral mastectomy or undirected biopsy for invasive lobular breast cancer. Lee JS, et al. **Surgery** 1995 Oct;118(4):640-7; discussion 647-8 (22 ref.)
[Prevention of second primary cancer with vitamin supplementation in patients treated for head and neck cancers] Bairati I, et al. **Bull Cancer Radiother** 1996; 83(1):12-6 (37 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Surgical treatment of breast cancer relapse. Margolese RG. **Recent Results Cancer Res** 1996;140:159-67 (23 ref.)
[A case of thoracic meningioma presenting paraplegia at 4.5 years after removal of a falx meningioma] Suga T, et al. **No Shinkei Geka** 1996 Jun;24(6):567-72 (23 ref.) (Eng. Abstr.) **(Jpn)**

THERAPY

[Second malignant disease in patients under treatment for malignant lymphoma] Várady E, et al. **Orv Hetil** 1995 Oct 22;136(43):2323-8 (35 ref.) (Eng. Abstr.) **(Hun)**

VIROLOGY

Recurrent laryngeal papillomatosis developing into laryngeal carcinoma with human papilloma virus (HPV) type 18: a case report. Sakakura A, et al. **J Laryngol Otol** 1996 Jan; 110(1):75-7 (18 ref.)

NEOPLASMS, SYNCHRONOUS see **NEOPLASMS, MULTIPLE PRIMARY**

NEOPLASMS, SYNCHRONOUS MULTIPLE PRIMARY see **NEOPLASMS, MULTIPLE PRIMARY**

NEOPLASMS, THERAPY-RELATED see **NEOPLASMS, SECOND PRIMARY**

NEOPLASMS, TREATMENT-RELATED see **NEOPLASMS, SECOND PRIMARY**

NEOPLASMS, UNKNOWN PRIMARY

Metastases of unknown primary site. Lembersky BC, et al. **Med Clin North Am** 1996 Jan;80(1):153-71 (76 ref.)

DIAGNOSIS

Strategy for identifying primary malignancies with inaugural bone metastases. Alcalay M, et al. **Rev Rhum Engl Ed** 1995 Nov;62(10):632-42 (70 ref.)
[Serum tumor markers in the diagnosis of cancer of unknown primary site] Cohen AD, et al. **Harefuah** 1995 Oct; 129(7-8):279-82 (31 ref.) **(Heb)**

THERAPY

Unknown primary of the head and neck. Talmi YP, et al. **J Laryngol Otol** 1996 Apr;110(4):353-6 (12 ref.)

NEOPLASMS, VASCULAR TISSUE

DIAGNOSIS

Multifocal vascular lesions of bone: imaging characteristics. Lomasney LM, et al. **Skeletal Radiol** 1996 Apr;25(3):255-61 (31 ref.)

PATHOLOGY

Neoplastic vascular tumors of the central nervous system. Papierz W, et al. **Folia Neuropathol** 1995;33(4):215-20 (42 ref.)
Vascular tumors: an update with emphasis on the diagnosis of angiosarcoma and borderline vascular neoplasms. Fletcher CD. **Monogr Pathol** 1996;38:181-206 (42 ref.)

NEOPLASTIC CELLS, CULTURED see **TUMOR CELLS, CULTURED**

NEOPLASTIC ENDOCRINE-LIKE SYNDROMES

see related
ACTH SYNDROME, ECTOPIC

[Ectopic cytokine syndrome] Yamaguchi K, et al. **Nippon Naika Gakkai Zasshi** 1996 Mar 10;85(3):328-32 (15 ref.) **(Jpn)**

DIAGNOSIS

Thyrotropin-secreting pituitary tumors in hyper- and hypothyroidism. Beck-Peccoz P, et al. **Acta Med Austriaca** 1996;23(1-2):41-6 (45 ref.)
Diagnosis and management of nonfunctioning pituitary tumors. Greenman Y, et al. **Annu Rev Med** 1996;47:95-106 (51 ref.)

ETIOLOGY

A peptide hormone causing abnormal hair-growth associated with malignancy. Pilszczek FH. **Med Hypotheses** 1995 Sep; 45(3):223-4 (6 ref.)

GENETICS

The classification and molecular biology of pituitary adenomas. Thapar K, et al. **Adv Tech Stand Neurosurg** 1995; 22:3-53 (130 ref.)
The value of cytometric DNA analysis as a prognostic tool in neuroendocrine neoplastic diseases. Falkmer UG, et al. **Pathol Res Pract** 1995 May;191(4):281-303 (121 ref.)

PATHOLOGY

Histologic, flow cytometric, and genetic criteria in endocrine surgery. Flynn SD, et al. **Curr Opin Gen Surg** 1993;:115-20 (45 ref.)

PHYSIOPATHOLOGY

[Endocrinology update--I] Allolio B, et al. **Med Klin** 1996 Apr 1;91 Suppl 1:24-32 (112 ref.) **(Ger)**

RADIOGRAPHY

Incidentally discovered adrenal tumors. Saxe A. **Curr Opin Gen Surg** 1993;:121-9 (50 ref.)

SURGERY

Endocrine tumors of the pancreas. Meko JB, et al. **Curr Opin Gen Surg** 1994;:186-94 (75 ref.)

NEOPLASTIC GENE EXPRESSION REGULATION see **GENE EXPRESSION REGULATION, NEOPLASTIC**

NEOPLASTIC SYNDROMES, HEREDITARY

Inherited syndromes of colon polyps. Box JC, et al. **Semin Surg Oncol** 1995 Nov-Dec;11(6):394-8 (24 ref.)

DIAGNOSIS

The emerging role of the physician in genetic counselling and testing for heritable breast, ovarian and colon cancer. Taylor KM, et al. **Can Med Assoc J** 1996 Apr 15; 154(8):1155-8 (23 ref.)

GENETICS

Molecular genetics of familial breast-ovarian cancer. van Rensburg EJ, et al. **J Clin Pathol** 1995 Sep;48(9):789-95 (64 ref.)
Microsatellite instability and hereditary non-polyposis colon cancer [editorial] Peltomäki P. **J Pathol** 1995 Aug; 176(4):329-30 (26 ref.)
A tale of four syndromes: familial adenomatous polyposis, Gardner syndrome, attenuated APC and Turcot syndrome. Foulkes WD. **QJM** 1995 Dec;88(12):853-63 (58 ref.)
[Genetic predisposition to cancer] Janin N. **Rev Med Interne** 1995;16(7):500-17 (52 ref.) (Eng. Abstr.)

(Fre)

[Genetic predisposition for breast carcinoma: overview of molecular genetic principles from long familiar epidemiologic observation] Krainer M, et al. **Geburtshilfe Frauenheilkd** 1995 Jul;55(7):M73–6 (10 ref.) (Ger)

NEOPLASTIC TRANSFORMATION, CELL see CELL TRANSFORMATION, NEOPLASTIC

NEORICKETTSIA see RICKETTSIACEAE

NEOSTRIATUM

CYTOLOGY

Striatal interneurones: chemical, physiological and morphological characterization. Kawaguchi Y, et al. **Trends Neurosci** 1995 Dec;18(12):527–35 (107 ref.)

EMBRYOLOGY

Development of the human striatum: implications for fetal striatal transplantation in the treatment of Huntington's disease. Freeman TB, et al. **Cell Transplant** 1995 Nov–Dec; 4(6):539–45 (61 ref.)

PATHOLOGY

Dopamine–induced, genotoxic activation of programmed cell death. A role in nigrostriatal neuronal degeneration in Parkinson's disease? Ziv I, et al. **Adv Neurol** 1996;69:229–33 (26 ref.)

PHYSIOLOGY

The pedunculopontine tegmental nucleus: where the striatum meets the reticular formation. Inglis WL, et al. **Prog Neurobiol** 1995 Sep;47(1):1–29 (205 ref.)

RADIONUCLIDE IMAGING

Functional positron emission tomographic studies of striatal dopaminergic activity. Changes induced by drugs and nigrostriatal degeneration. Tedroff J, et al. **Adv Neurol** 1996;69:443–8 (31 ref.)

TRANSPLANTATION

Neural transplantation for Huntington's disease: experimental rationale and recommendations for clinical trials. Shannon KM, et al. **Cell Transplant** 1996 Mar–Apr;5(2):339–52 (107 ref.)

Rationale for intrastriatal grafting of striatal neuroblasts in patients with Huntington's disease. Peschanski M, et al. **Neuroscience** 1995 Sep;68(2):273–85 (159 ref.)

NEOVASCULARIZATION, PATHOLOGIC

How tumors become angiogenic. Bouck N, et al. **Adv Cancer Res** 1996;69:135–74 (376 ref.)

Scatter factor and angiogenesis. Rosen EM, et al. **Adv Cancer Res** 1995;67:257–79 (93 ref.)

Apoptosis and angiogenesis: two promising tumor markers in breast cancer (review). Wu J. **Anticancer Res** 1996 Jul–Aug;16(4B):2233–9 (80 ref.)

Angiogenesis in urological malignancy. O'Brien TS, et al. **Br J Urol** 1995 Dec;76(6):675–82 (42 ref.)

The vascularity of colorectal liver metastases. Shankar A, et al. **Eur J Surg Oncol** 1996 Aug;22(4):389–96 (88 ref.)

Angiogenesis in malignant gliomas. Plate KH, et al. **Glia** 1995 Nov;15(3):339–47 (78 ref.)

Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects. Battegay EJ. **J Mol Med** 1995 Jul; 73(7):333–46 (178 ref.)

Angiogenesis in B cell lymphoproliferative diseases. Biological and clinical studies. Vacca A, et al. **Leuk Lymphoma** 1995 Dec;20(1–2):27–38 (61 ref.)

Angiogenesis in cancer, vascular, rheumatoid and other disease. Folkman J. **Nat Med** 1995 Jan;1(1):27–31 (72 ref.)

[Endothelial cell function and angiogenesis] Kanayasu–Toyoda T, et al. **Nippon Yakurigaku Zasshi** 1996 Mar;107(3):99–107 (54 ref.) (Eng. Abstr.) (Jpn)

[Regulators of angiogenesis] Sato Y. **Nippon Yakurigaku Zasshi** 1996 Mar;107(3):109–17 (51 ref.) (Eng. Abstr.) (Jpn)

[Angiogenesis—a marker for metastases] Sköldenberg E, et al. **Lakartidningen** 1996 May 8;93(19):1853–5 (24 ref.) (Swe)

DRUG THERAPY

The clinical experience with antiangiogenic agents. Marshall JL, et al. **Breast Cancer Res Treat** 1995;36(2):253–61 (48 ref.)

Antibody–directed targeting of the vasculature of solid tumors. Thorpe PE, et al. **Breast Cancer Res Treat** 1995; 36(2):237–51 (55 ref.)

Clinical implications of tumor–associated neovascularization and current antiangiogenic strategies for the treatment of malignancies of pancreas. Pluda JM, et al. **Cancer** 1996 Aug 1;78(3 Suppl):680–7 (88 ref.)

Angiogenesis and cancer metastases: therapeutic approaches. Teicher BA. **Crit Rev Oncol Hematol** 1995 Aug; 20(1–2):9–39 (407 ref.)

[Anti–angiogenesis: a new concept in therapy of solid malignancies?] Schweigerer L. **Med Klin** 1995 Dec 15; 90(12):709–12 (52 ref.) (Ger)

ENZYMOLOGY

[Angiogenesis and enzymatic activity of thymidine phosphorylase] Haraguchi M, et al. **Seikagaku** 1996 Feb; 68(2):143–7 (21 ref.) (Jpn)

ETIOLOGY

Mast cells and tumor–associated angiogenesis. Meininger CJ. **Chem Immunol** 1995;62:239–57 (135 ref.)

Normal and pathological mechanisms in retinal vascular development. Gariano RF, et al. **Surv Ophthalmol** 1996 May–Jun;40(6):481–90 (147 ref.)

GENETICS

[Does the c–ets 1 oncogene participate in the regulation of tumor angiogenesis?] Vandenbunder B, et al. **Arch Inst Pasteur Tunis** 1994 Jul–Oct;71(3–4):493–509 (56 ref.) (Eng. Abstr.) (Fre)

METABOLISM

Regulation of the expression of the VEGF/VPS and its receptors: role in tumor angiogenesis. Kolch W, et al. **Breast Cancer Res Treat** 1995;36(2):139–55 (156 ref.)

The modulation of thrombospondin and other naturally occurring inhibitors of angiogenesis during tumor progression. Volpert OV, et al. **Breast Cancer Res Treat** 1995;36(2):119–26 (56 ref.)

CD 105 and angiogenesis [editorial] Kumar P, et al. **J Pathol** 1996 Apr;178(4):363–6 (42 ref.)

PATHOLOGY

Molecular and pharmacologic targeting of angiogenesis factors—the example of pleiotrophin. Czubayko F, et al. **Breast Cancer Res Treat** 1995;36(2):157–68 (68 ref.)

Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Weidner N. **Breast Cancer Res Treat** 1995; 36(2):169–80 (66 ref.)

Clinical implications of tumor–associated neovascularization and current antiangiogenic strategies for the treatment of malignancies of pancreas. Pluda JM, et al. **Cancer** 1996 Aug 1;78(3 Suppl):680–7 (88 ref.)

Vascular morphology and angiogenesis in glial tumors. Plate KH, et al. **Exp Toxicol Pathol** 1995 May;47(2–3):89–94 (62 ref.)

Angiogenesis and the skin: a primer. Arbiser JL. **J Am Acad Dermatol** 1996 Mar;34(3):486–97 (116 ref.)

[Breast cancer angiogenesis] Toi M, et al. **Gan To Kagaku Ryoho** 1996 May;23(6):659–66 (50 ref.) (Eng. Abstr.) (Jpn)

[The importance of tumor angiogenesis as a prognostic indicator in primary breast cancer] Saji S, et al. **Nippon Geka Gakkai Zasshi** 1996 May;97(5):368–74 (50 ref.) (Eng. Abstr.) (Jpn)

[Invasion, metastasis and angiogenesis of renal cell carcinoma] Tsukamoto T. **Nippon Hinyokika Gakkai Zasshi** 1996 Jan;87(1):1–12 (82 ref.) (Jpn)

PHYSIOPATHOLOGY

Role of VEGF–flt receptor system in normal and tumor angiogenesis. Shibuya M. **Adv Cancer Res** 1995;67:281–316 (141 ref.)

The role of thrombospondin–1 in tumor progression and angiogenesis. Tuszynski GP, et al. **Bioessays** 1996 Jan; 18(1):71–6 (57 ref.)

The role of vascular endothelial growth factor in pathological angiogenesis. Ferrara N. **Breast Cancer Res Treat** 1995; 36(2):127–37 (91 ref.)

The influence of angiogenesis research on management of patients with breast cancer. Folkman J. **Breast Cancer Res Treat** 1995;36(2):109–18 (78 ref.)

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Hanahan D, et al. **Cell** 1996 Aug 9;86(3):353–64 (80 ref.)

The pathophysiology of angiogenesis. Polverini PJ. **Crit Rev Oral Biol Med** 1995;6(3):230–47 (151 ref.)

Plasminogen activators and angiogenesis. Mignatti P, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 1):33–50 (137 ref.)

Vascular endothelial growth factor and retinal neovascularisation: a new therapeutic approach for diabetic retinopathy. Favard C, et al. **Diabetes Metab** 1996 Jul; 22(4):268–73 (67 ref.)

Significance of angiogenesis in tumour progression and metastasis. Bikfalvi A. **Eur J Cancer** 1995 Jul–Aug; 31A(7–8):1101–4 (30 ref.)

Angiogenesis as a component of epithelial–mesenchymal interactions. Grant DS, et al. **EXS** 1995;74:235–48 (36 ref.)

The role of scatter factor and the c–met proto–oncogene in angiogenic responses. Polverini PJ, et al. **EXS** 1995; 74:51–67 (82 ref.)

Hypothetical roles of angiogenesis, osmotic swelling, and ischemia in high–altitude cerebral edema. Severinghaus JW. **J Appl Physiol** 1995 Aug;79(2):375–9 (68 ref.)

Angiogenesis. Swerlick RA. **J Dermatol** 1995 Nov; 22(11):845–52 (69 ref.)

Tumour angiogenesis. Fox SB, et al. **J Pathol** 1996 Jul; 179(3):232–7 (123 ref.)

Tumour angiogenesis: pathophysiology and clinical significance. Lichtenbeld HH, et al. **Neth J Med** 1996 Jul; 49(1):42–51 (126 ref.)

[Role of heparin in neoplastic angiogenesis] Sikora J, et al. **Pneumonol Alergol Pol** 1995;63(5–6):344–8 (28 ref.) (Eng. Abstr.) (Pol)

PREVENTION & CONTROL

Angiogenesis as a new target for cancer treatment. Ono M, et al. **Cancer Chemother Pharmacol** 1996;38 Suppl:S78–82 (38 ref.)

Fish oil may impede tumour angiogenesis and invasiveness by down–regulating protein kinase C and modulating eicosanoid production. McCarty MF. **Med Hypotheses** 1996 Feb;46(2):107–15 (120 ref.)

Angiogenesis inhibitors generated by tumors. Folkman J. **Mol Med** 1995 Jan;1(2):120–2 (23 ref.)

SURGERY

Indocyanine green angiography. Can it help preserve the vision of our patients? [editorial; comment] Bressler NM, et al. **Arch Ophthalmol** 1996 Jun;114(6):747–9 (30 ref.) Comment on: Arch Ophthalmol 1996 Jun;114(6):693–7.

Submacular surgery. Are randomized trials necessary? [editorial] Bressler NM. **Arch Ophthalmol** 1995 Dec; 113(12):1557–60 (31 ref.)

Treatment of choroidal neovascularization: updated information from recent macular photocoagulation study group reports. Zimmer–Galler IE, et al. **Int Ophthalmol Clin** 1995 Fall;35(4):37–57 (13 ref.)

[Effective mechanisms of laser photocoagulation for neovascularization in diabetic retinopathy] Funatsu H, et al. **Nippon Ganka Gakkai Zasshi** 1996 May;100(5):339–49 (64 ref.) (Eng. Abstr.) (Jpn)

THERAPY

VEGF–mediated tumour angiogenesis: a new target for cancer therapy. Martiny–Baron G, et al. **Curr Opin Biotechnol** 1995 Dec;6(6):675–80 (40 ref.)

Antiangiogenesis as a novel therapeutic concept in pediatric oncology. Schweigerer L. **J Mol Med** 1995 Oct; 73(10):497–508 (146 ref.)

Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis [see comments] Folkman J. **N Engl J Med** 1995 Dec 28; 333(26):1757–63 (50 ref.) Comment in: N Engl J Med 1996 Apr 4;334(14):920–1; discussion 921. Comment in: N Engl J Med 1996 Apr 4;334(14):921.

Novel biologic therapies for malignant gliomas. Antiangiogenesis, immunotherapy, and gene therapy. Fine HA. **Neurol Clin** 1995 Nov;13(4):827–46 (128 ref.)

NEOVASCULARIZATION, PHYSIOLOGIC

Scatter factor and angiogenesis. Rosen EM, et al. **Adv Cancer Res** 1995;67:257–79 (93 ref.)

Between molecules and morphology. Extracellular matrix and creation of vascular form. Vernon RB, et al. **Am J Pathol** 1995 Oct;147(4):873–83 (77 ref.)

Vasculogenesis. Risau W, et al. **Ann Rev Cell Dev Biol** 1995; 11:73–91 (122 ref.)

The interstitium, the connective tissue environment of the lymphatic, and angiogenesis in human skin. Ryan TJ, et al. **Clin Dermatol** 1995 Sep–Oct;13(5):451–8 (54 ref.)

Control of coronary angiogenesis. Schaper W. **Eur Heart J** 1995 May;16 Suppl C:66–8 (16 ref.)

Angiogenesis [editorial] Ziche M, et al. **Exp Nephrol** 1996 Jan–Feb;4(1):1–14 (177 ref.)

Vascular endothelial growth factor, a potent and selective angiogenic agent. Thomas KA. **J Biol Chem** 1996 Jan 12; 271(2):603–6 (51 ref.)

Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects. Battegay EJ. **J Mol Med** 1995 Jul; 73(7):333–46 (178 ref.)

Blood vessel growth in the endometrium. Goodger AM, et al. **Microcirculation** 1995 Dec;2(4):329–43 (102 ref.)

Embryonic angiogenesis: a review. Wilting J, et al. **Naturwissenschaften** 1996 Apr;83(4):153–64 (168 ref.)

Angiogenesis in the human female reproductive tract. Gordon JD, et al. **Obstet Gynecol Surv** 1995 Sep; 50(9):688–97 (126 ref.)

The role of CXC chemokines as regulators of angiogenesis. Strieter RM, et al. **Shock** 1995 Sep;4(3):155–60 (87 ref.)

Normal and pathological mechanisms in retinal vascular development. Gariano RF, et al. **Surv Ophthalmol** 1996 May–Jun;40(6):481–90 (147 ref.)

[Shear stress and vascular formation] Ando J. **Nippon Yakurigaku Zasshi** 1996 Mar;107(3):141–52 (50 ref.) (Eng. Abstr.) (Jpn)

[Extracellular matrix components and angiogenesis] Imamura M. **Nippon Yakurigaku Zasshi** 1996 Mar;107(3):153–60 (30 ref.) (Eng. Abstr.) (Jpn)

[Regulators of angiogenesis] Sato Y. **Nippon Yakurigaku Zasshi** 1996 Mar;107(3):109–17 (51 ref.) (Eng. Abstr.) (Jpn)

NEOVASCULARIZATION, PHYSIOLOGIC

DRUG EFFECTS

Cellular adhesion molecules. Newly identified mediators of angiogenesis. Polverini PJ. **Am J Pathol** 1996 Apr; 148(4):1023–9 (83 ref.)

PHYSIOLOGY

Role of VEGF–flt receptor system in normal and tumor angiogenesis. Shibuya M. **Adv Cancer Res** 1995;67:281–316 (141 ref.)

The role of thrombospondin–1 in tumor progression and angiogenesis. Tuszynski GP, et al. **Bioessays** 1996 Jan; 18(1):71–6 (57 ref.)

The role of scatter factor and the c–met proto–oncogene in angiogenic responses. Polverini PJ, et al. **EXS** 1995; 74:51–67 (82 ref.)

The vascularization of the developing human brain. Dąmbska M. **Folia Neuropathol** 1995;33(4):189–93 (29 ref.)

CD 105 and angiogenesis [editorial] Kumar P, et al. **J Pathol** 1996 Apr;178(4):363–6 (42 ref.)

Regulation of angiogenesis by SPARC and angiostatin: implications for tumor cell biology. Jendraschak E, et al. **Semin Cancer Biol** 1996 Jun;7(3):139–46 (68 ref.)

NEPHELOMETRY AND TURBIDIMETRY

[Thymol turbidity test (TTT)] Monna T, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:163–6 (11 ref.) **(Jpn)**

METHODS

[Zinc sulfate turbidity test (ZTT)] Monna T, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:167–70 (7 ref.) **(Jpn)**

NEPHRECTOMY

Nephrectomy for metastatic renal cell carcinoma and surgery for distant metastases. Van Poppel H, et al. **Acta Urol Belg** 1996 May;64(2):11–7 (45 ref.)

Malignant vascular disease of the kidney: nature of the lesions, mediators of disease progression, and the case for bilateral nephrectomy. Ruggenenti P, et al. **Am J Kidney Dis** 1996 Apr;27(4):459–75 (123 ref.)

Splenectomy complicating left nephrectomy [see comments] Cooper CS, et al. **J Urol** 1996 Jan;155(1):30–6 (46 ref.) Comment in: J Urol 1996 Jan;155(1):37.

ADVERSE EFFECTS

Preservation of renal function and the risk of hyperfiltration nephropathy. Goldfarb DA. **Semin Urol Oncol** 1995 Nov; 13(4):292–5 (24 ref.)

METHODS

Laparoscopic extirpation of renal cell cancer: feasibility, questions, and concerns. Nakada SY, et al. **Semin Surg Oncol** 1996 Mar–Apr;12(2):100–12 (34 ref.)

Surgical technique and morbidity of elective partial nephrectomy. Campbell SC, et al. **Semin Urol Oncol** 1995 Nov;13(4):281–7 (27 ref.)

Rationale for total nephrectomy for suspected renal cell carcinoma. Marsh CL, et al. **Semin Urol Oncol** 1995 Nov; 13(4):273–80 (65 ref.)

Clinical experience with nephron–sparing surgery in the presence of a normal contralateral kidney. Steinbach F, et al. **Semin Urol Oncol** 1995 Nov;13(4):288–91 (18 ref.)

[Conservative surgery in cancer of the kidney] Ferrière JM, et al. **Presse Med** 1995 Oct 28;24(32):1507–8 (10 ref.) (Eng. Abstr.) **(Fre)**

[Cadaver donor nephrectomy. Surgical technique in the context of multi–organ donation] Benoit G, et al. **Prog Urol** 1996 Feb;6(1):114–22 (48 ref.) (Eng. Abstr.) **(Fre)**

[Laparoscopic nephrectomy in a patient with a parenchymatous form of nephrogenic hypertension] Troitskiĭ OA, et al. **Urol Nefrol (Mosk)** 1996 Mar–Apr; (2):8–11 (9 ref.) (Eng. Abstr.) **(Rus)**

NEPHRITIS

IMMUNOLOGY

The role of T–cells in inflammatory kidney disease. Main IW, et al. **Curr Opin Nephrol Hypertens** 1995 Jul;4(4):354–8 (41 ref.)

Host immune deficiency in immune complex nephritis [editorial] Ooi BS, et al. **J Am Soc Nephrol** 1995 Nov; 6(5):1342–6 (57 ref.)

[Nephritogenic immune response] Koyama A. **Nippon Jinzo Gakkai Shi** 1995 Oct;37(10):529–33 (45 ref.) **(Jpn)**

NEPHRITIS, FAMILIAL see **NEPHRITIS, HEREDITARY**

NEPHRITIS, HEREDITARY

Alport syndrome—clinical phenotypes, incidence, and pathology. Gregory MC, et al. **Contrib Nephrol** 1996; 117:1–28 (140 ref.)

DIAGNOSIS

Goodpasture's disease and Alport's syndromes. Turner AN, et al. **Annu Rev Med** 1996;47:377–86 (34 ref.)

Application of linked markers for genetic diagnosis of Alport syndrome. Barker DF, et al. **Contrib Nephrol** 1996; 117:29–45 (33 ref.)

New approaches to the DNA diagnosis of Alport syndrome. Renieri A, et al. **Contrib Nephrol** 1996;117:183–97 (50 ref.)

Clinical and molecular diagnosis of Alport syndrome. Kashtan CE. **Proc Assoc Am Physicians** 1995 Oct; 107(3):306–13 (61 ref.)

GENETICS

Mutations in Alport syndrome associated with diffuse esophageal leiomyomatosis. Antignac C, et al. **Contrib Nephrol** 1996;117:172–82 (37 ref.)

Application of linked markers for genetic diagnosis of Alport syndrome. Barker DF, et al. **Contrib Nephrol** 1996; 117:29–45 (33 ref.)

Alport syndrome—clinical phenotypes, incidence, and pathology. Gregory MC, et al. **Contrib Nephrol** 1996; 117:1–28 (140 ref.)

New approaches to the DNA diagnosis of Alport syndrome. Renieri A, et al. **Contrib Nephrol** 1996;117:183–97 (50 ref.)

Mutations in type IV collagen genes and Alport phenotypes. Tryggvason K. **Contrib Nephrol** 1996;117:154–71 (58 ref.)

METABOLISM

Immunohistologic findings in Alport syndrome. Kashtan CE, et al. **Contrib Nephrol** 1996;117:142–53 (58 ref.)

NEPHRITIS, INTERSTITIAL

[Hereditary tubulo–interstitial nephropathy] Horie S. **Nippon Rinsho** 1995 Aug;53(8):2064–7 (7 ref.) (Eng. Abstr.) **(Jpn)**

[Idiopathic chronic tubulointerstitial nephritis] Kumagai H, et al. **Nippon Rinsho** 1995 Aug;53(8):2057–63 (20 ref.) (Eng. Abstr.) **(Jpn)**

CHEMICALLY INDUCED

[Clinical aspects of drug–induced tubulo–interstitial nephropathy] Shibasaki T. **Nippon Rinsho** 1995 Aug; 53(8):2047–51 (7 ref.) (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

Do glomerular atherosclerosis and lipid–mediated tubulo–interstitial disease cause progressive renal failure in man? Moorhead JF, et al. **Blood Purif** 1996;14(1):58–66 (69 ref.)

DIAGNOSIS

Pan–nephritis (glomerulonephritis, arteriolitis, and tubulointerstitial nephritis) associated with predominant mesangial C1q deposition and hypocomplementemia: a variant type of C1q nephropathy? Imai H, et al. **Am J Kidney Dis** 1996 Apr;27(4):583–7 (15 ref.)

[Renal biopsy for diagnosis of interstitial nephritis] Kimura K. **Nippon Rinsho** 1995 Aug;53(8):1931–8 (6 ref.) (Eng. Abstr.) **(Jpn)**

[General examination and renal function test for tubulointerstitial nephropathy] Tajima A, et al. **Nippon Rinsho** 1995 Aug;53(8):1925–30 (16 ref.) (Eng. Abstr.) **(Jpn)**

ETIOLOGY

Reshaping the interstitium by platelet–derived growth factor. Implications for progressive renal disease. Nath KA. **Am J Pathol** 1996 Apr;148(4):1031–6 (63 ref.)

Tumor necrosis factor in renal injury. Baud L, et al. **Miner Electrolyte Metab** 1995;21(4–5):336–41 (55 ref.)

The pathogenesis of tubulointerstitial disease associated with glomerulonephritis: the glomerular cytokine theory. Pichler R, et al. **Miner Electrolyte Metab** 1995; 21(4–5):317–27 (140 ref.)

[Renal involvement in Sjögren's syndrome—interstitial nephritis and glomerulonephritis] Fujimoto T, et al. **Nippon Rinsho** 1995 Oct;53(10):2495–502 (29 ref.) (Eng. Abstr.) **(Jpn)**

[Interstitial nephropathy due to chronic bacterial pyelonephritis] Hirose T. **Nippon Rinsho** 1995 Aug; 53(8):1963–8 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Tubulointerstitial injuries in heavy metal intoxications] Kaizu K, et al. **Nippon Rinsho** 1995 Aug;53(8):2052–6 (19 ref.) (Eng. Abstr.) **(Jpn)**

[Renal arterial disease–induced tubulo–interstitial lesions] Kida H, et al. **Nippon Rinsho** 1995 Aug;53(8):2034–9 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Tubulointerstitial changes in some hematological disorders] Morita H, et al. **Nippon Rinsho** 1995 Aug;53(8):2007–12 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Tubulo–interstitial lesions in human renal allograft] Morozumi K, et al. **Nippon Rinsho** 1995 Aug;53(8):2040–6 (16 ref.) (Eng. Abstr.) **(Jpn)**

[T cell receptor repertoire of infiltrating T cells in the interstitial nephritis of patients with Sjögren's syndrome] Murata H, et al. **Nippon Rinsho** 1995 Oct;53(10):2510–5 (19 ref.) (Eng. Abstr.) **(Jpn)**

[Recent advances of studies on interstitial nephritis—definition and pathogenesis] Sakai O. **Nippon Rinsho** 1995 Aug;53(8):1908–12 (7 ref.) (Eng. Abstr.) **(Jpn)**

[Symptoms in patients with tubulo–interstitial nephritis] Tomino Y, et al. **Nippon Rinsho** 1995 Aug;53(8):1919–24 (13 ref.) (Eng. Abstr.) **(Jpn)**

[Nephropathy associated with electrolyte disorders] Tsuchiya K, et al. **Nippon Rinsho** 1995 Aug;53(8):1995–2000 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Congenital metabolic disorder] Uchiyama M. **Nippon Rinsho** 1995 Aug;53(8):2001–6 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Tubulointerstitial nephropathy secondary to collagen–vascular diseases] Yamada A. **Nippon Rinsho** 1995 Aug;53(8):1969–73 (19 ref.) (Eng. Abstr.) **(Jpn)**

[Immunological and non–immunological mechanisms of tubulo–interstitial nephropathies] Yoshioka K. **Nippon Rinsho** 1995 Aug;53(8):1913–8 (13 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

[Immune reactions that mediate tubulointerstitial nephritis] Ueda S. **Nippon Rinsho** 1995 Aug;53(8):1886–93 (24 ref.) (Eng. Abstr.) **(Jpn)**

MICROBIOLOGY

[Acute tubulointerstitial nephritis in acute infection] Kobayashi Y. **Nippon Rinsho** 1995 Aug;53(8):1954–61 (41 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Predominant tubulointerstitial lupus nephritis. Singh AK, et al. **Am J Kidney Dis** 1996 Feb;27(2):273–8 (21 ref.)

Reshaping the interstitium by platelet–derived growth factor. Implications for progressive renal disease. Nath KA. **Am J Pathol** 1996 Apr;148(4):1031–6 (63 ref.)

[Interstitial nephritis with acute renal failure in Ascaris lumbricoides infection] Meister P, et al. **Pathologe** 1995 Nov;16(6):434–8 (16 ref.) (Eng. Abstr.) **(Ger)**

[Immunohistochemical identification of infiltrating mononuclear cells in tubulointerstitial nephritis associated with Sjögren's syndrome] Matsumura R, et al. **Nippon Rinsho** 1995 Oct;53(10):2503–9 (11 ref.) (Eng. Abstr.) **(Jpn)**

RADIONUCLIDE IMAGING

[Tubulointerstitial nephropathy—radionuclide imaging diagnosis] Kawamura J, et al. **Nippon Rinsho** 1995 Aug; 53(8):1944–53 (9 ref.) (Eng. Abstr.) **(Jpn)**

NEPHRITIS, LUPUS see **LUPUS NEPHRITIS**

NEPHRITIS, TUBULOINTERSTITIAL see **NEPHRITIS, INTERSTITIAL**

NEPHROBLASTOMA

see related
GENES, WILMS' TUMOR

Wilms tumor. Green DM, et al. **CA Cancer J Clin** 1996 Jan–Feb;46(1):46–63 (108 ref.)

[Progresses in pediatric surgery in China, 1995] Jin B. **Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):753–4 (0 ref.) **(Chi)**

[Hereditary renal tumors: Wilms' tumor—congenital anomalies' syndrome] Tsuchida Y, et al. **Nippon Rinsho** 1995 Nov;53(11):2742–8 (20 ref.) (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

Varicocele as a presenting feature of Wilms' tumor. Monroe K, et al. **Pediatr Emerg Care** 1995 Oct;11(5):300–1 (7 ref.)

DIAGNOSIS

Imaging patients with Wilms tumor. Babyn P, et al. **Hematol Oncol Clin North Am** 1995 Dec;9(6):1217–52 (117 ref.)

Screening for Wilms tumor in high–risk individuals. Clericuzio CL, et al. **Hematol Oncol Clin North Am** 1995 Dec;9(6):1253–65 (43 ref.)

EPIDEMIOLOGY

Epidemiologic features of Wilms tumor. Birch JM, et al. **Hematol Oncol Clin North Am** 1995 Dec;9(6):1157–78 (84 ref.)

ETIOLOGY

Etiology of Wilms' tumor. Sharpe CR, et al. **Epidemiol Rev** 1995;17(2):415–32 (108 ref.)

GENETICS

Genetics of embryonal tumours of childhood: retinoblastoma, Wilms' tumour and neuroblastoma. Brodeur GM. **Cancer Surv** 1995;25:67–99 (209 ref.)

Contribution of MAV–1–induced nephroblastoma to the study of genes involved in human Wilms' tumor development. Perbal B. **Crit Rev Oncog** 1994;5(6):589–613 (107 ref.)

RNA processing. Wilms' tumour—the splicing connection?

Lamond AI. **Curr Biol** 1995 Aug 1;5(8):862–5 (10 ref.)
Molecular genetics of Wilms' tumour. Tay JS. **J Paediatr Child Health** 1995 Oct;31(5):379–83 (64 ref.)

PATHOLOGY

Focal versus diffuse anaplasia in Wilms tumor--new definitions with prognostic significance: a report from the National Wilms Tumor Study Group. Faria P, et al. **Am J Surg Pathol** 1996 Aug;20(8):909–20 (14 ref.)
Adult extrarenal Wilms' tumor. A case report. Gürsoy R, et al. **Gynecol Obstet Invest** 1995;40(2):141–4 (7 ref.)
Extrarenal Wilms' tumour--a case report and review of literature. Waingankar VS, et al. **Indian J Cancer** 1995 Sep; 32(3):135–40 (33 ref.)

RADIOTHERAPY

Damage to the urinary tract secondary to irradiation. Fichtner J, et al. **World J Urol** 1995;13(4):240–2 (23 ref.)

SURGERY

[Malignant tumors in infancy and childhood] Daum R. **Chirurg** 1996 Jun;67(6):584–92 (18 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

The path to progress in medical science: a Wilms tumor conspectus. Coppes MJ, et al. **Hematol Oncol Clin North Am** 1995 Dec;9(6):xiii–xviii (27 ref.)
Preoperative strategies in the management of Wilms tumor. de Kraker J, et al. **Hematol Oncol Clin North Am** 1995 Dec;9(6):1275–85 (12 ref.)
The treatment of Wilms tumor. Results of the National Wilms Tumor Studies. Green DM, et al. **Hematol Oncol Clin North Am** 1995 Dec;9(6):1267–74 (13 ref.)
Late effects of treatment for Wilms tumor. Green DM, et al. **Hematol Oncol Clin North Am** 1995 Dec;9(6):1317–27 (83 ref.)
Future directions in clinical research in Wilms tumor. Green DM, et al. **Hematol Oncol Clin North Am** 1995 Dec; 9(6):1329–39 (57 ref.)
The management of relapsed Wilms tumor. Miser JS, et al. **Hematol Oncol Clin North Am** 1995 Dec;9(6):1287–302 (51 ref.)
The management of synchronous bilateral Wilms tumor. Ritchey ML, et al. **Hematol Oncol Clin North Am** 1995 Dec;9(6):1303–15 (68 ref.)
Progress and controversies in modern treatment of Wilms' tumors. Gutjahr P. **World J Urol** 1995;13(4):209–12 (8 ref.)
[Wilms' tumor] Graf N. **Schweiz Rundsch Med Prax** 1996 Jun 4;85(23):753–61 (48 ref.) (Eng. Abstr.) **(Ger)**

NEPHROCALCINOSIS

PREVENTION & CONTROL

Urinary kidney stone inhibitors. Where are we? [editorial] Dussol B, et al. **Nephrol Dial Transplant** 1996 Jul; 11(7):1222–4 (14 ref.)

NEPHROLITHOTOMY, PERCUTANEOUS see **NEPHROSTOMY, PERCUTANEOUS**

NEPHROLOGY

see related
KIDNEY DISEASES

NEPHROMA, MESOBLASTIC

COMPLICATIONS

The presence of hydrops fetalis in a fetus with congenital mesoblastic nephroma. Liu YC, et al. **Prenat Diagn** 1996 Apr;16(4):363–5 (8 ref.)

NEPHRONS

METABOLISM

Renal chloride–bicarbonate exchangers. Godinich MJ, et al. **Curr Opin Nephrol Hypertens** 1995 Sep;4(5):398–401 (34 ref.)
[Molecular structure of luminal diuretic receptors] Gamba G. **Rev Invest Clin** 1995 May–Jun;47(3):231–49 (131 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

Multihormonal regulation of nephron epithelia: achieved through combinational mode? De Rouffignac C. **Am J Physiol** 1995 Oct;269(4 Pt 2):R739–48 (59 ref.)
[Functional expression of vasopressin receptors V1a and V2 along the mammalian nephron] Imbert–Teboul M, et al. **C R Seances Soc Biol Fil** 1995;189(2):151–67 (50 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

The hyperfiltration theory: progression of chronic renal failure and the effects of diet in dogs. Gonin–Jmaa D, et al. **J Am Vet Med Assoc** 1995 Dec 1;207(11):1411–5 (54 ref.)

SURGERY

Initial experience with retroperitoneoscopic nephroureterectomy: use of a double–balloon technique. Gill IS, et al. **Urology** 1995 Nov;46(5):747–50 (22 ref.)
Current controversies in nephron–sparing surgery for renal–cell carcinoma. Steinbach F, et al. **World J Urol** 1995; 13(3):163–5 (29 ref.)

NEPHROPATHIA EPIDEMICA see **HANTAVIRUS INFECTIONS**

NEPHROPATHY, IGA see **GLOMERULONEPHRITIS, IGA**

NEPHROPATHY, MEMBRANOUS see **GLOMERULONEPHRITIS, MEMBRANOUS**

NEPHROPATHY, MINIMAL CHANGE see **NEPHROSIS, LIPOID**

NEPHROSCLEROSIS

COMPLICATIONS

[Renal arterial disease–induced tubulo–interstitial lesions] Kida H, et al. **Nippon Rinsho** 1995 Aug;53(8):2034–9 (10 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Can we accurately diagnose nephrosclerosis? Zucchelli P, et al. **Nephrol Dial Transplant** 1995;10 Suppl 6:2–5 (32 ref.)

PATHOLOGY

Renovasculopathies of hypertension and the rise of blood pressure with age in blacks and whites. Tracy RE. **Semin Nephrol** 1996 Mar;16(2):126–33 (21 ref.)

NEPHROSIS

DRUG THERAPY

Cyclosporine in the treatment of idiopathic nephrosis. Niaudet P. **Indian Pediatr** 1995 Dec;32(12):1317–21 (17 ref.)

NEPHROSIS, LIPOID

COMPLICATIONS

Kimura's disease and minimal–change nephrotic syndrome. Sud K, et al. **Nephrol Dial Transplant** 1996 Jul; 11(7):1349–51 (13 ref.)

NEPHROSTOMY, PERCUTANEOUS

[Percutaneous surgical interventions and extracorporeal lithotripsy in the treatment of the urological complications after a kidney transplant] Urenkov SB, et al. **Urol Nefrol (Mosk)** 1995 Jul–Aug;(4):45–9 (122 ref.) **(Rus)**

ECONOMICS

Percutaneous nephrostomy using hospital modified catheters for cost containment. Ahmed I, et al. **East Afr Med J** 1995 Jun;72(6):391–3 (17 ref.)

INSTRUMENTATION

Percutaneous nephrostomy using hospital modified catheters for cost containment. Ahmed I, et al. **East Afr Med J** 1995 Jun;72(6):391–3 (17 ref.)
[Current status of percutaneous calculus therapy] Kaldenbach U, et al. **Wien Med Wochenschr** 1995;145(11–12):260–7 (62 ref.) (Eng. Abstr.) **(Ger)**
[Current strategies in patients with urinary diversion, 2: Upper urinary tract] Moll F. **Z Arztl Fortbild (Jena)** 1996 May;90(3):241–8 (22 ref.) (Eng. Abstr.) **(Ger)**

NEPHROTIC SYNDROME

Primary nephrotic syndrome of childhood. Schnaper HW. **Curr Opin Pediatr** 1996 Apr;8(2):141–7 (62 ref.)
The primary glomerulopathies. Glassock RJ, et al. **Dis Mon** 1996 Jun;42(6):329–83 (182 ref.)
Nephrosis in childhood. Salcedo JR, et al. **Nephron** 1995; 71(4):373–85 (82 ref.)

BLOOD

Hypercoagulability, intraglomerular coagulation, and thromboembolism in nephrotic syndrome [editorial] Sagripanti A, et al. **Nephron** 1995;70(3):271–81 (118 ref.)

CHEMICALLY INDUCED

[Nephrotic syndrome complicating treatment with interferon alpha] Dhib M, et al. **Presse Med** 1996 Jun 29;25(23):1066–8 (18 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

Three edemas. Williams AV Jr, et al. **J S C Med Assoc** 1996 Jul;92(7):306–10 (25 ref.)
Spontaneous arterial thrombosis associated with nephrotic syndrome: case report and review of the literature. Khatri VP, et al. **Nephron** 1995;71(1):95–7 (11 ref.)
Hypercoagulability, intraglomerular coagulation, and thromboembolism in nephrotic syndrome [editorial] Sagripanti A, et al. **Nephron** 1995;70(3):271–81 (118 ref.)
Is there any reason to lower proteinuria in a child with nephrotic–range proteinuria who is not clinically edematous? Kees–Folts D. **Pediatr Nephrol** 1996 Apr; 10(2):180 (17 ref.)

DRUG THERAPY

Treatment of anemia of nephrotic syndrome with recombinant erythropoietin. Gansevoort RT, et al. **Am J Kidney Dis** 1996 Aug;28(2):274–7 (14 ref.)
Use of cyclosporin in the treatment of idiopathic nephrotic syndrome in adults. Meyrier A. **Contrib Nephrol** 1995; 114:28–48 (47 ref.)
Cyclosporin in steroid–resistant idiopathic nephrotic syndrome. Tejani A, et al. **Contrib Nephrol** 1995;114:73–7 (32 ref.)
Does it make sense to administer albumin to the patient with nephrotic oedema? [editorial] Dorhout Mees EJ. **Nephrol Dial Transplant** 1996 Jul;11(7):1224–6 (17 ref.)
Management of the difficult nephrotic patient. Mendoza SA, et al. **Pediatr Clin North Am** 1995 Dec;42(6):1459–68 (24 ref.)

ETIOLOGY

Nephrotic syndrome, malignant thymoma, and myasthenia gravis. Case report and review of the literature. Jayasena SD, et al. **Am J Nephrol** 1995;15(4):361–3 (8 ref.)
Regression of the nephrotic syndrome in rheumatoid arthritis and amyloidosis treated with azathioprine. A case report. Shapiro DL, et al. **Arthritis Rheum** 1995 Dec;38(12):1851–4 (24 ref.)

IMMUNOLOGY

Current concepts of pathogenesis of nephrotic syndrome. Tejani A, et al. **Contrib Nephrol** 1995;114:1–5 (23 ref.)

PHYSIOPATHOLOGY

Phosphodiesterase activity as a mediator of renal resistance to ANP in pathological salt retention. Lee EY, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):F3–6 (27 ref.)

NEPHROTIC SYNDROME, MINIMAL CHANGE see **NEPHROSIS, LIPOID**

NERVE BLOCK

Thoracic paravertebral analgesia [see comments] Richardson J, et al. **Acta Anaesthesiol Scand** 1995 Nov;39(8):1005–15 (94 ref.) Comment in: Acta Anaesthesiol Scand 1995 Nov;39(8):1003–4.
Rocuronium: the newest aminosteroid neuromuscular blocking drug [editorial] Hunter JM. **Br J Anaesth** 1996 Apr;76(4):481–3 (30 ref.)
[Optimal use of peripheral nerve blocks] Bruelle P, et al. **Can Anesthesiol** 1995;43(3):259–66 (80 ref.) (Eng. Abstr.) **(Fre)**
[Clinical usefulness of neuromuscular monitor] Amaki Y. **Masui** 1995;44 Suppl:S100–5 (9 ref.) **(Jpn)**

ADVERSE EFFECTS

Retroperitoneal hematoma as a complication of pudendal block. Diagnosis made by computed tomography. Kurzel RB, et al. **West J Med** 1996 Jun;164(6):523–5 (15 ref.)

NERVE CELLS see **NEURONS**

NERVE COMPRESSION SYNDROMES

Anatomy, function, and pathophysiology of peripheral nerves and nerve compression. Lundborg G, et al. **Hand Clin** 1996 May;12(2):185–93 (77 ref.)
Intraepineurial constriction of nerve fascicles in pronator syndrome and anterior interosseous nerve syndrome. Haussmann P, et al. **Orthop Clin North Am** 1996 Apr; 27(2):339–44 (13 ref.)
Radial nerve entrapment. Kleinert JM, et al. **Orthop Clin North Am** 1996 Apr;27(2):305–15 (18 ref.)
Unusual compressive neuropathies of the upper limb. Osterman AL, et al. **Orthop Clin North Am** 1996 Apr; 27(2):389–408 (116 ref.)

COMPLICATIONS

Multiple compression neuropathies and the double–crush syndrome. Simpson RL, et al. **Orthop Clin North Am** 1996 Apr;27(2):381–8 (59 ref.)
[Cyclic sciatica and extrauterine endometriosis] Jelk W, et al. **Schweiz Rundsch Med Prax** 1995 Nov 14;84(46):1349–55 (29 ref.) (Eng. Abstr.) **(Ger)**

DIAGNOSIS

Compressive neuropathies and tendinopathies in the athletic

elbow and wrist. Plancher KD, et al. **Clin Sports Med** 1996 Apr;15(2):331–71 (142 ref.)
Cervical radiculopathy. Ruggieri PM. **Neuroimaging Clin N Am** 1995 Aug;5(3):349–66 (63 ref.)
Cervical Radiculopathy. Ahlgren BD, et al. **Orthop Clin North Am** 1996 Apr;27(2):253–63 (30 ref.)
Clinical diagnosis of peripheral nerve compression in the upper extremity. Anto C, et al. **Orthop Clin North Am** 1996 Apr;27(2):227–36 (31 ref.)
Electrodiagnosis in compression neuropathies of the upper extremities. de Araujo MP. **Orthop Clin North Am** 1996 Apr;27(2):237–44 (50 ref.)
Persistence of symptoms after surgical release of compressive neuropathies and subsequent management. Idler RS. **Orthop Clin North Am** 1996 Apr;27(2):409–16 (21 ref.)
Differential diagnosis and pitfalls in electrodiagnostic studies and special tests for diagnosing compressive neuropathies. Kaufman MA. **Orthop Clin North Am** 1996 Apr; 27(2):245–52 (32 ref.)
Multiple compression neuropathies and the double-crush syndrome. Simpson RL, et al. **Orthop Clin North Am** 1996 Apr;27(2):381–8 (59 ref.)
[Meralgia paresthetica. A rare differential diagnosis of circumscribed alopecia] Nabavi DG, et al. **Dtsch Med Wochenschr** 1996 Jun 21;121(25–26):834–8 (25 ref.) (Eng. Abstr.) **(Ger)**
[Atypical entrapment syndrome of the distal suprascapular nerve of the incisura scapulae. Case report and overview of the literature] Röhrich E, et al. **Nervenarzt** 1995 Aug; 66(8):638–42 (28 ref.) (Eng. Abstr.) **(Ger)**
[Significance of the radial compression syndrome for the diagnosis and surgical therapy of so-called epicondylitis humeri radialis (Epic. hum. rad.)] Totkas D, et al. **Z Orthop Ihre Grenzgeb** 1995 Jul–Aug;133(4):317–22 (73 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Suprascapular nerve entrapment by ganglion cysts: a report of six cases with arthroscopic findings and review of the literature. Fehrman DA, et al. **Arthroscopy** 1995 Dec; 11(6):727–34 (47 ref.)
Complications of spinal manipulation: a comprehensive review of the literature. Assendelft WJ, et al. **J Fam Pract** 1996 May;42(5):475–80 (41 ref.)
Axillary neuropathy in volleyball players: report of two cases and literature review. Paladini D, et al. **J Neurol Neurosurg Psychiatry** 1996 Mar;60(3):345–7 (14 ref.)
Cauda equina compression by epidural lipomatosis in obesity. Effectiveness of weight reduction. Pouchot J, et al. **J Rheumatol** 1995 Sep;22(9):1771–5 (20 ref.)
Dynamics and pathophysiology of nerve compression in the upper extremity. Delfiner JS. **Orthop Clin North Am** 1996 Apr;27(2):219–26 (25 ref.)
[Femoral neuropathy due to a spontaneous hematoma of the iliopsoas muscle during therapy with heparin-calcium] Casoni P, et al. **Acta Biomed Ateneo Parmense** 1994; 65(5–6):289–96 (5 ref.) (Eng. Abstr.) **(Ita)**

PATHOLOGY

Anatomic considerations of the peripheral nerve in compressive neuropathies of the upper extremity. George V, et al. **Orthop Clin North Am** 1996 Apr;27(2):211–8 (22 ref.)

PHYSIOPATHOLOGY

Dynamics and pathophysiology of nerve compression in the upper extremity. Delfiner JS. **Orthop Clin North Am** 1996 Apr;27(2):219–26 (25 ref.)

SURGERY

Neurophysiological monitoring of cranial nerves during posterior fossa surgery. Broggi G, et al. **Acta Neurochir Suppl (Wien)** 1995;64:35–9 (16 ref.)
Characteristics of patients successfully treated for cervicogenic headache by surgical decompression of the second cervical root. Pikus HJ, et al. **Headache** 1995 Nov–Dec;35(10):621–9 (39 ref.)
Posterior tibial neurovascular decompression for restoration of plantar sweating and sensibility. Oommen PK. **Indian J Lepr** 1996 Jan–Mar;68(1):75–82 (35 ref.)
Recurrence of hemifacial spasm after microvascular decompression. Payner TD, et al. **Neurosurgery** 1996 Apr; 38(4):686–90; discussion 690–1 (28 ref.)
Persistence of symptoms after surgical release of compressive neuropathies and subsequent management. Idler RS. **Orthop Clin North Am** 1996 Apr;27(2):409–16 (21 ref.)
[Decompressive neurovascular nose and skull-base surgery in primary headache with a rhinogenic trigger] Bonaccorsi P. **Ital J Neurol Sci** 1995 Nov;16(8 Suppl):69–100 (104 ref.) (Eng. Abstr.) **(Ita)**
[Nerve compression syndrome—present status of microvascular decompression] Matsushima T. **Fukuoka Igaku Zasshi** 1996 Apr;87(4):87–91 (6 ref.) **(Jpn)**
[Microvascular decompression] Vinogradova IN. **Zh Vopr Neirokhir Im N N Burdenko** 1995 Jul–Sep;(3):35–7 (53 ref.) **(Rus)**

THERAPY

Cervical Radiculopathy. Ahlgren BD, et al. **Orthop Clin North Am** 1996 Apr;27(2):253–63 (30 ref.)

NERVE CONDUCTION see **NEURAL CONDUCTION**

NERVE CROSSOVER see **NERVE TRANSFER**

NERVE DEGENERATION

Molecular mechanism of Alzheimer's neurofibrillary degeneration and therapeutic intervention. Iqbal K, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:132–8 (22 ref.)
Metabolic disorders and neurotoxicology [editorial] Beal MF. **Curr Opin Neurol** 1995 Dec;8(6):467–8 (10 ref.)
Excitotoxicity and neurodegenerative diseases. Ikonomidou C, et al. **Curr Opin Neurol** 1995 Dec;8(6):487–97 (182 ref.)
Role of nitric oxide in neurodegenerative diseases. Schulz JB, et al. **Curr Opin Neurol** 1995 Dec;8(6):480–6 (42 ref.)
Human prion diseases and neurodegeneration. Prusiner SB. **Curr Top Microbiol Immunol** 1996;207:1–17 (118 ref.)
Glial inclusions in CNS degenerative diseases. Chin SS, et al. **J Neuropathol Exp Neurol** 1996 May;55(5):499–508 (78 ref.)
Mechanisms of neuronal degeneration in Alzheimer's disease. Yankner BA. **Neuron** 1996 May;16(5):921–32 (172 ref.)
Degeneration and regeneration of axons in the lesioned spinal cord. Schwab ME, et al. **Physiol Rev** 1996 Apr;76(2):319–70 (774 ref.)
Nitric oxide in neuronal degeneration. Dawson VL, et al. **Proc Soc Exp Biol Med** 1996 Jan;211(1):33–40 (86 ref.)
Excitatory amino acid receptors and neurodegeneration. Doble A. **Therapie** 1995 Jul–Aug;50(4):319–37 (175 ref.)
[Pathogenesis and neuroprotective therapy trial in chronic degenerative diseases. Status of antioxidants] Gerlach M, et al. **Med Klin** 1996 Mar 15;91(3):163–70 (69 ref.) **(Ger)**
[Corticobasal degeneration: clinical features] Ueno E. **No To Shinkei** 1996 Jun;48(6):505–12 (42 ref.) **(Jpn)**
[Neuropathology of corticobasal degeneration] Wakabayashi K, et al. **No To Shinkei** 1996 Jun;48(6):521–32 (88 ref.) **(Jpn)**

DRUG EFFECTS

The inhibition of peroxide formation as a possible substrate for the neuroprotective action of dihydroergocryptine. Favit A, et al. **J Neural Transm Suppl** 1995;45:297–305 (30 ref.)
The pharmacotherapy of Alzheimer's disease based on the cholinergic hypothesis: an update. Weinstock M. **Neurodegeneration** 1995 Dec;4(4):349–56 (82 ref.)
Calpain as a novel target for treating acute neurodegenerative disorders. Bartus RT, et al. **Neurol Res** 1995 Aug; 17(4):249–58 (40 ref.)

GENETICS

Genetically engineered animal models of human neurodegenerative diseases. Higgins LS, et al. **Neurodegeneration** 1995 Jun;4(2):117–29 (49 ref.)
Association of infantile neuroaxonal dystrophy and osteopetrosis: a rare autosomal recessive disorder. Rees H, et al. **Pediatr Neurosurg** 1995;22(6):321–7 (36 ref.)

PHYSIOLOGY

Is dopaminergic cell death accompanied by concomitant nerve plasticity? Anglade P, et al. **Adv Neurol** 1996; 69:195–208 (96 ref.)
Molecular mechanisms for neurodegeneration. Synergism between reactive oxygen species, calcium, and excitotoxic amino acids. Gerlach M, et al. **Adv Neurol** 1996;69:177–94 (119 ref.)
Adenosine: a prototherapeutic concept in neurodegeneration. von Lubitz DK, et al. **Ann N Y Acad Sci** 1995 Sep 15; 765:163–78; discussion 196–7 (123 ref.)
Oxidative stress in neurodegenerative diseases. Simonian NA, et al. **Annu Rev Pharmacol Toxicol** 1996;36:83–106 (177 ref.)
Glial cell transplants: experimental therapies of myelin diseases. Duncan ID, et al. **Brain Pathol** 1995 Jul; 5(3):301–10 (77 ref.)
Oestrogens and the structural and functional plasticity of neurons: implications for memory, ageing and neurodegenerative processes. McEwen BS, et al. **Ciba Found Symp** 1995;191:52–66; discussion 66–73 (43 ref.)
Motor neuron disease with involvement of the pallido-luysio-nigral system and mesencephalic tegmentum. Kato S, et al. **Clin Neuropathol** 1995 Jul–Aug; 14(4):241–4 (15 ref.)
Multiple system atrophy. Quinn N, et al. **Curr Opin Neurol** 1995 Aug;8(4):323–6 (28 ref.)
Cytokines in neurodegeneration and repair. Rothwell NJ, et al. **Int J Dev Neurosci** 1995 Jun–Jul;13(3–4):179–85 (52 ref.)
Can the neurotrophic hypothesis explain degeneration and loss of plasticity in mature and ageing autonomic nerves? Gavazzi I, et al. **J Auton Nerv Syst** 1996 Apr 20; 58(1–2):1–10 (79 ref.)
The cell biology of myelin degeneration and regeneration in the peripheral nervous system. Goodrum JF, et al. **J Neuropathol Exp Neurol** 1996 Sep;55(9):943–53 (47 ref.)
Degenerative and protective signaling mechanisms in the neurofibrillary pathology of AD. Mattson MP. **Neurobiol Aging** 1995 May–Jun;16(3):447–57; discussion 458–63 (99 ref.)
Canine pituitary-dependent hyperadrenocorticism: a spontaneous animal model for neurodegenerative disorders and their treatment with l-deprenyl. Bruyette DS, et al. **Prog Brain Res** 1995;106:207–15 (30 ref.)
Spinal and bulbar muscular atrophy: a trinucleotide-repeat expansion neurodegenerative disease. Brooks BP, et al. **Trends Neurosci** 1995 Oct;18(10):459–61 (25 ref.)
Selective neuronal vulnerability in the hippocampus--a role for gene expression? Schreiber SS, et al. **Trends Neurosci** 1995 Oct;18(10):446–51 (93 ref.)
[Degeneration of catecholaminergic neurons (editorial)] Chatellard-Causse C, et al. **Pathol Biol (Paris)** 1995 Sep; 43(7):577–80 (13 ref.) **(Fre)**

NERVE ENDINGS

see related
PRESYNAPTIC TERMINALS

IMMUNOLOGY

Cholinergic-specific glycoconjugates. Whittaker VP, et al. **Neurochem Res** 1995 Nov;20(11):1377–87 (47 ref.)

METABOLISM

A unifying hypothesis for acetylcholine release. Israël M, et al. **Neurochem Int** 1996 Jan;28(1):1–9 (88 ref.)

PHYSIOPATHOLOGY

Neural mechanisms of lumbar pain. Cavanaugh JM. **Spine** 1995 Aug 15;20(16):1804–9 (44 ref.)

NERVE ENDINGS, PRESYNAPTIC see **PRESYNAPTIC TERMINALS**

NERVE ENDINGS, SENSORY see **RECEPTORS, SENSORY**

NERVE FIBERS

DRUG EFFECTS

Peptidergic afferents: physiological aspects. Urban L, et al. **Prog Brain Res** 1995;104:255–69 (71 ref.)

PATHOLOGY

Retinal nerve fiber layer [editorial; comment] Sommer A. **Am J Ophthalmol** 1995 Nov;120(5):665–7 (20 ref.) Comment on: Am J Ophthalmol 1995 Nov;120(5):577–86.
Evaluation of the retinal nerve fiber layer. Jonas JB, et al. **Surv Ophthalmol** 1996 Mar–Apr;40(5):369–78 (107 ref.)
[Ophthalmoscopic study of the retinal nerve fiber layer] Jonas JB, et al. **Klin Monatsbl Augenheilkd** 1996 Feb;208(2):aA3–9 (0 ref.) **(Ger)**

PHYSIOLOGY

Update on the concepts and probable role of peptidergic nerves in dentine sensitivity and pain mechanisms. Ngassapa DN. **East Afr Med J** 1996 Apr;73(4):268–70 (29 ref.)
Comparison of functional characteristics of intradental A- and C-nerve fibres in dental pain. Ngassapa DN. **East Afr Med J** 1996 Mar;73(3):207–9 (30 ref.)

TRANSPLANTATION

Chromaffin cell survival and host dopaminergic fiber recovery in a patient with Parkinson's disease treated by cografts of adrenal medulla and pretransected peripheral nerve. Case report. Date I, et al. **J Neurosurg** 1996 Apr; 84(4):685–9 (33 ref.)

NERVE FIBERS, MYELINATED

PHYSIOLOGY

Comparison of functional characteristics of intradental A- and C-nerve fibres in dental pain. Ngassapa DN. **East Afr Med J** 1996 Mar;73(3):207–9 (30 ref.)
Update on the concepts and probable role of peptidergic nerves in dentine sensitivity and pain mechanisms. Ngassapa DN. **East Afr Med J** 1996 Apr;73(4):268–70 (29 ref.)
[Phylogeny of myelin and myelin forming cells] Zalc B. **C R Seances Soc Biol Fil** 1995;189(2):239–44 (11 ref.) (Eng. Abstr.) **(Fre)**
[Degeneration of catecholaminergic neurons (editorial)] Chatellard-Causse C, et al. **Pathol Biol (Paris)** 1995 Sep; 43(7):577–80 (13 ref.) **(Fre)**

NERVE GROWTH FACTOR RECEPTORS see **RECEPTORS, NERVE GROWTH FACTOR**

NERVE GROWTH FACTORS

see related
RECEPTORS, NERVE GROWTH FACTOR

[Biochemical studies on functional proteins in the brain nervous system. Neurobiochemical studies on nerve growth factor] Hayashi K. **Yakugaku Zasshi** 1996 Apr;

116(4):286–308 (120 ref.) (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Neurotrophic factors as therapeutic agents in amyotrophic lateral sclerosis. Potential and pitfalls. Henderson CE. **Adv Neurol** 1995;68:235–40 (22 ref.)

BIOSYNTHESIS

Neurotrophins and their receptors in chicken neuronal development. Hallböök F, et al. **Int J Dev Biol** 1995 Oct; 39(5):855–68 (115 ref.)

Cytoskeletal derangements following central nervous system injury: modulation by neurotrophic gene transfection. Hayes RL, et al. **J Neurotrauma** 1995 Oct;12(5):933–41 (58 ref.)

CHEMISTRY

[Biochemical studies on functional proteins in the brain nervous system. Neurobiochemical studies on nerve growth factor] Hayashi K. **Yakugaku Zasshi** 1996 Apr; 116(4):286–308 (120 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Cytoskeletal derangements following central nervous system injury: modulation by neurotrophic gene transfection. Hayes RL, et al. **J Neurotrauma** 1995 Oct;12(5):933–41 (58 ref.)

METABOLISM

Neuropeptides, nerve growth factor and eczema. Giannetti A. **Australas J Dermatol** 1996 May;37 Suppl 1:S1–3 (47 ref.)

Neurotrophic factors in central nervous system trauma. Mocchetti I, et al. **J Neurotrauma** 1995 Oct;12(5):853–70 (186 ref.)

Neurotrophins and Alzheimer's disease: beyond the cholinergic neurons. Knusel B, et al. **Life Sci** 1996; 58(22):2019–27 (38 ref.)

Neurotrophic factors and their receptors. Ip NY, et al. **Prog Brain Res** 1995;105:189–95 (30 ref.)

PHARMACOLOGY

Neurotrophic factors and amyotrophic lateral sclerosis. Askanas V. **Adv Neurol** 1995;68:241–4 (14 ref.)

Neurosteroids: synthesis and functions in the central and peripheral nervous systems. Schumacher M, et al. **Ciba Found Symp** 1995;191:90–106; discussion 106–12 (50 ref.)

Prospects for the treatment of spinal cord and peripheral nerve injury [editorial] Hems TE, et al. **J Bone Joint Surg Br** 1996 Mar;78(2):176–7 (18 ref.)

Growth factors in the CNS and their effects on oligodendroglia. Kahn MA, et al. **Prog Brain Res** 1995; 105:145–69 (152 ref.)

How neurotrophic factors protect brain against excitotoxicity. Cuevas Sanchez P. **Surg Neurol** 1996 Aug; 46(2):152–3 (15 ref.)

PHYSIOLOGY

The neuronal response to bladder outlet obstruction, a role for NGF. Dupont MC, et al. **Adv Exp Med Biol** 1995; 385:41–54; discussion 75–9 (85 ref.)

Neurotrophic factors as therapeutic agents in amyotrophic lateral sclerosis. Potential and pitfalls. Henderson CE. **Adv Neurol** 1995;68:235–40 (22 ref.)

Structural and functional properties of the TRK family of neurotrophin receptors. Barbacid M. **Ann N Y Acad Sci** 1995 Sep 7;766:442–58 (67 ref.)

Nerve growth factor regulates nociception in human health and disease. Anand P. **Br J Anaesth** 1995 Aug;75(2):201–8 (64 ref.)

Visceral pain. McMahon SB, et al. **Br J Anaesth** 1995 Aug; 75(2):132–44 (114 ref.)

Plasticity following neonatal visual cortex damage in cats. Spear PD. **Can J Physiol Pharmacol** 1995 Sep;73(9):1389–97 (40 ref.)

Developmental signalling. Hendry IA, et al. **Clin Exp Pharmacol Physiol** 1995 Aug;22(8):563–8 (21 ref.)

Trophic factors for the gastrointestinal tract. Carver JD, et al. **Clin Perinatol** 1996 Jun;23(2):265–85 (174 ref.)

Neurotrophic factors. Neurotrophin autocrine loops. Davies AM, et al. **Curr Biol** 1995 Jul 1;5(7):723–6 (15 ref.)

Peripheral neuropathies and neurotrophic factors: animal models and clinical perspectives. McMahon SB, et al. **Curr Opin Neurobiol** 1995 Oct;5(5):616–24 (77 ref.)

Silencing is golden: negative regulation in the control of neuronal gene transcription. Schoenherr CJ, et al. **Curr Opin Neurobiol** 1995 Oct;5(5):566–71 (48 ref.)

Can the neurotrophic hypothesis explain degeneration and loss of plasticity in mature and ageing autonomic nerves? Gavazzi I, et al. **J Auton Nerv Syst** 1996 Apr 20; 58(1–2):1–10 (79 ref.)

Is IL–6 both a cytokine and a neurotrophic factor? [comment] Wagner JA. **J Exp Med** 1996 Jun 1;183(6):2417–9 (28 ref.) Comment on: J Exp Med 1996 Jun 1;183(6):2627–34.

Update of the NGF saga. Levi-Montalcini R, et al. **J Neurol Sci** 1995 Jun;130(2):119–27 (113 ref.)

Mechanisms of estrogen action during neural development: mediation by interactions with the neurotrophins and their receptors? Toran-Allerand CD. **J Steroid Biochem Mol Biol** 1996 Jan;56(1–6 Spec No):169–78 (77 ref.)

Regulation of neuropeptide expression in the brain by neurotrophins. Potential role in vivo. Carnahan J, et al. **Mol Neurobiol** 1995 Apr–Jun;10(2–3):135–49 (107 ref.)

Neurotrophin-3 as an essential signal for the developing nervous system. Chalazonitis A. **Mol Neurobiol** 1996 Feb; 12(1):39–53 (90 ref.)

Maintaining the neuronal phenotype after injury in the adult CNS. Neurotrophic factors, axonal growth substrates, and gene therapy. Tuszynski MH, et al. **Mol Neurobiol** 1995 Apr–Jun;10(2–3):151–67 (107 ref.)

Neurotrophic factors and synaptic plasticity. Lo DC. **Neuron** 1995 Nov;15(5):979–81 (31 ref.)

Neurotrophic survival molecules for motoneurons: an embarrassment of riches. Oppenheim RW. **Neuron** 1996 Aug;17(2):195–7 (22 ref.)

NGF regulatory role in stress and coping of rodents and humans. Alleva E, et al. **Pharmacol Biochem Behav** 1996 May;54(1):65–72 (110 ref.)

Non target-derived roles of the neurotrophins. Acheson A, et al. **Philos Trans R Soc Lond B Biol Sci** 1996 Mar 29; 351(1338):417–22 (62 ref.)

Neurotrophins and peripheral neuropathy. Anand P. **Philos Trans R Soc Lond B Biol Sci** 1996 Mar 29; 351(1338):449–54 (55 ref.)

The neurotrophic hypothesis: where does it stand? Davies AM. **Philos Trans R Soc Lond B Biol Sci** 1996 Mar 29; 351(1338):389–94 (51 ref.)

The role of neurotrophins in development of neural-crest cells that become sensory ganglia. Kalcheim C. **Philos Trans R Soc Lond B Biol Sci** 1996 Mar 29; 351(1338):375–81 (45 ref.)

Neurotrophins and the specification of neuronal phenotype. Lewin GR. **Philos Trans R Soc Lond B Biol Sci** 1996 Mar 29;351(1338):405–11 (44 ref.)

Role of neurotrophins and trk receptors in the development and maintenance of sensory neurons: an overview. Lindsay RM. **Philos Trans R Soc Lond B Biol Sci** 1996 Mar 29; 351(1338):365–73 (53 ref.)

NGF as a mediator of inflammatory pain. McMahon SB. **Philos Trans R Soc Lond B Biol Sci** 1996 Mar 29; 351(1338):431–40 (86 ref.)

Neurotrophins and peripheral neuropathy. Tomlinson DR, et al. **Philos Trans R Soc Lond B Biol Sci** 1996 Mar 29; 351(1338):455–62 (47 ref.)

Neurotrophins and nerve injury in the adult. Verge VM, et al. **Philos Trans R Soc Lond B Biol Sci** 1996 Mar 29; 351(1338):423–30 (57 ref.)

Phenotypic modification of primary sensory neurons: the role of nerve growth factor in the production of persistent pain. Woolf CJ. **Philos Trans R Soc Lond B Biol Sci** 1996 Mar 29;351(1338):441–8 (34 ref.)

Involvement of nerve growth factor in visual cortex plasticity. Gu Q. **Rev Neurosci** 1995 Oct–Dec;6(4):329–51 (259 ref.)

Neurotrophins and neuronal plasticity. Thoenen H. **Science** 1995 Oct 27;270(5236):593–8 (64 ref.)

[Expression of neurotrophin proteins in the brain, and its physiological significance] Furukawa S. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1995 Oct; 15(5):405–10 (17 ref.) **(Jpn)**

[Nerve growth factor strategy and preparation of animal model for Alzheimer-type senile dementia] Nabeshima T. **Yakugaku Zasshi** 1995 Jul;115(7):499–512 (59 ref.) (Eng. Abstr.) **(Jpn)**

[The factors supporting peripheral nerve regeneration] Chelyshev IuA. **Usp Fiziol Nauk** 1995 Jul–Sep;26(3):57–77 (220 ref.) (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Neurotrophic factors as therapeutic agents in amyotrophic lateral sclerosis. Potential and pitfalls. Henderson CE. **Adv Neurol** 1995;68:235–40 (22 ref.)

Use of growth factors in the treatment of motor neuron diseases. Windebank AJ. **Adv Neurol** 1995;68:229–34 (22 ref.)

Molecular biology of neurotrophic factors. Sendtner M. **Baillieres Clin Neurol** 1995 Nov;4(3):575–91 (100 ref.)

Trophic factor supplementation: effect on the age-associated changes in body composition. Schwartz RS. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:151–6 (53 ref.)

How neurotrophic factors protect brain against excitotoxicity. Cuevas Sanchez P. **Surg Neurol** 1996 Aug; 46(2):152–3 (15 ref.)

Neurotrophic factors: ready to go? Schätzl HM. **Trends Neurosci** 1995 Nov;18(11):463–4 (19 ref.)

NERVE NET

BLOOD SUPPLY

Regional cerebral blood flow in schizophrenia and the local circuit neurons hypothesis. Bachneff SA. **Schizophr Bull** 1996;22(1):163–82 (160 ref.)

EMBRYOLOGY

[Molecular mechanisms for the formation of crossed and uncrossed projections in the brain] Murakami F, et al. **Tanpakushitsu Kakusan Koso** 1996 May;41(6):775–84 (27 ref.) **(Jpn)**

GROWTH & DEVELOPMENT

Neuronal target recognition. Garrity PA, et al. **Cell** 1995 Oct 20;83(2):177–85 (70 ref.)

PHYSIOLOGY

Layer I of primary sensory neocortex: where top-down converges upon bottom-up. Cauller L. **Behav Brain Res** 1995 Nov;71(1–2):163–70 (52 ref.)

REM sleep and neural nets. Crick F, et al. **Behav Brain Res** 1995 Jul–Aug;69(1–2):147–55 (17 ref.)

Large-scale cortical networks and cognition. Bressler SL. **Brain Res Brain Res Rev** 1995 Mar;20(3):288–304 (191 ref.)

Temporal structure in spatially organized neuronal ensembles: a role for interneuronal networks. Buzsáki G, et al. **Curr Opin Neurobiol** 1995 Aug;5(4):504–10 (61 ref.)

Oscillation in motor pattern-generating networks. Calabrese RL. **Curr Opin Neurobiol** 1995 Dec;5(6):816–23 (55 ref.)

Interactions among neural networks for behavior. Dickinson PS. **Curr Opin Neurobiol** 1995 Dec;5(6):792–8 (48 ref.)

Synthesizing animal and human behavior research via neural network learning theory. Tryon WW. **J Behav Ther Exp Psychiatry** 1995 Dec;26(4):303–12 (98 ref.)

Transfer of coded information from sensory to motor networks. Salinas E, et al. **J Neurosci** 1995 Oct; 15(10):6461–74 (80 ref.)

Neuropoiesis: proposal for a connectionistic neurobiology. Jobe TH, et al. **Med Hypotheses** 1995 Aug;45(2):147–63 (145 ref.)

Functional alterations in neural circuits in Alzheimer's disease. Simonian NA, et al. **Neurobiol Aging** 1995 May–Jun;16(3):305–9 (38 ref.)

Networks of neurons, networks of genes. Berkowitz A. **Neuron** 1996 Aug;17(2):199–202 (25 ref.)

Circuitry for color coding in the primate retina. Dacey DM. **Proc Natl Acad Sci U S A** 1996 Jan 23;93(2):582–8 (55 ref.)

Hebb's concept of cell assemblies and the psychophysiology of word processing. Pulvermüller F. **Psychophysiology** 1996 Jul;33(4):317–33 (145 ref.)

Ensemble activity and behavior: what's the code? Deadwyler SA, et al. **Science** 1995 Nov 24;270(5240):1316–8 (24 ref.)

Cracking the neuronal code. Ferster D, et al. **Science** 1995 Nov 3;270(5237):756–7 (20 ref.)

[Progress in research on the central mechanism of feeding behavior—neuronal network] Oomura Y, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:585–96 (20 ref.) **(Jpn)**

[The network mechanisms of physiological regulation] Terekhin AT, et al. **Usp Fiziol Nauk** 1995 Oct–Dec; 26(4):75–97 (34 ref.) (Eng. Abstr.) **(Rus)**

NERVE REGENERATION

Axonal regeneration. Brecknell JE, et al. **Biol Rev Camb Philos Soc** 1996 May;71(2):227–55 (260 ref.)

Agrin: toward a molecular understanding of synapse regeneration. Deyst KA, et al. **Neurosurgery** 1995 Jul; 37(1):71–7 (81 ref.)

Periapical neural changes after pulpectomy. Holland GR. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1995 Dec;80(6):726–34 (55 ref.)

Degeneration and regeneration of axons in the lesioned spinal cord. Schwab ME, et al. **Physiol Rev** 1996 Apr;76(2):319–70 (774 ref.)

[Recovery processes in interrupted peripheral nerves] Jennekens FG, et al. **Ned Tijdschr Geneeskd** 1996 Feb 17; 140(7):348–52 (23 ref.) **(Dut)**

[Nerve transplantation in the central nervous system: a strategy for inducing nerve fiber regeneration in lesions of the brain and spinal cord] Gauthier P, et al. **Rev Neurol (Paris)** 1996 Feb;152(2):106–15 (62 ref.) (Eng. Abstr.) **(Fre)**

[Degeneration and regeneration of the peripheral nervous system with aging] Verdú E, et al. **Rev Neurol** 1995 May–Jun;23(121):648–55 (98 ref.) (Eng. Abstr.) **(Spa)**

DRUG EFFECTS

Prospects for the treatment of spinal cord and peripheral nerve injury [editorial] Hems TE, et al. **J Bone Joint Surg Br** 1996 Mar;78(2):176–7 (18 ref.)

PHYSIOLOGY

Tubulin expression and axonal transport in injured and regenerating neurons in the adult mammalian central nervous system. Fournier AE, et al. **Biochem Cell Biol** 1995 Sep–Oct;73(9–10):659–64 (39 ref.)

Neural injury repair: hope for the future as barriers to effective CNS regeneration become clearer. Jackowski A. **Br J Neurosurg** 1995;9(3):303–17 (149 ref.)

Regeneration in the adult mammalian CNS: guided by development. Aubert I, et al. **Curr Opin Neurobiol** 1995 Oct;5(5):625–35 (118 ref.)

Myelin-associated glycoprotein: a role in myelination and in the inhibition of axonal regeneration? Filbin MT. **Curr Opin Neurobiol** 1995 Oct;5(5):588–95 (58 ref.)

Nerve regeneration. Pollock M. **Curr Opin Neurol** 1995 Oct; 8(5):354–8 (33 ref.)

NERVE REGENERATION

Peripheral nerve injury and regeneration. Terenghi G. **Histol Histopathol** 1995 Jul;10(3):709–18 (71 ref.)
Cytokines in neurodegeneration and repair. Rothwell NJ, et al. **Int J Dev Neurosci** 1995 Jun–Jul;13(3–4):179–85 (52 ref.)
Models of delayed recovery. Leviton A, et al. **J Child Neurol** 1995 Sep;10(5):385–91 (55 ref.)
Role of proteoglycans in neural development, regeneration, and the aging brain. Small DH, et al. **J Neurochem** 1996 Sep;67(3):889–99 (140 ref.)
The cell biology of myelin degeneration and regeneration in the peripheral nervous system. Goodrum JF, et al. **J Neuropathol Exp Neurol** 1996 Sep;55(9):943–53 (47 ref.)
Neuropeptide messenger plasticity in the CNS neurons following axotomy. Palkovits M. **Mol Neurobiol** 1995 Apr–Jun;10(2–3):91–103 (48 ref.)
Nerve wound healing. An overview. Wong BJ, et al. **Otolaryngol Clin North Am** 1995 Oct;28(5):881–95 (130 ref.)
Neural regeneration in gastropod molluscs. Moffett SB. **Prog Neurobiol** 1995 Jun;46(2–3):289–330 (275 ref.)
Regeneration of oligodendrocytes and myelin. Dubois–Dalcq M. **Trends Neurosci** 1995 Jul;18(7):289–91 (39 ref.)
[The factors supporting peripheral nerve regeneration] Chelyshev IuA. **Usp Fiziol Nauk** 1995 Jul–Sep;26(3):57–77 (220 ref.) (Eng. Abstr.) **(Rus)**

NERVE SHEATH TUMORS

CHEMISTRY

Peripheral nerve sheath neoplasms. Clinicopathologic and immunochemical observations. Swanson PE, et al. **Pathol Annu** 1995;30 Pt 2:1–82 (500 ref.)

PATHOLOGY

Pathology of the major peripheral nerve sheath neoplasms. Woodruff JM. **Monogr Pathol** 1996;38:129–61 (67 ref.)
Peripheral nerve sheath neoplasms. Clinicopathologic and immunochemical observations. Swanson PE, et al. **Pathol Annu** 1995;30 Pt 2:1–82 (500 ref.)

NERVE TISSUE

CHEMISTRY

Analysis of trace elements in the central nerve tissues with inductively coupled plasma–mass spectrometry. Ejima A, et al. **Tohoku J Exp Med** 1996 Jan;178(1):1–10 (14 ref.)

GROWTH & DEVELOPMENT

Implications of the subtilisin/kexin–like precursor convertases in the development and function of nervous tissues. Marcinkiewicz M, et al. **Acta Neurobiol Exp (Warsz)** 1996;56(1):287–98 (60 ref.)

IMMUNOLOGY

Nerve tissue culture as an approach towards the study of onset of reactions in the nerve in leprosy—observations and hypothesis. Mistry NF, et al. **Indian J Lepr** 1996 Jan–Mar;68(1):67–73 (18 ref.)

METABOLISM

gamma–Aminobutyric acid (GABA) metabolism in mammalian neural and nonneural tissues. Tillakaratne NJ, et al. **Comp Biochem Physiol A Physiol** 1995 Oct; 112(2):247–63 (162 ref.)

PHYSIOLOGY

Electrical stimulation of neural tissue to evoke behavioral responses. Tehovnik EJ. **J Neurosci Methods** 1996 Mar; 65(1):1–17 (144 ref.)

NERVE TISSUE PROTEIN S 100

PHYSIOLOGY

The S–100: a protein family in search of a function. Fanò G, et al. **Prog Neurobiol** 1995 May;46(1):71–82 (141 ref.)
The S100 family of EF–hand calcium–binding proteins: functions and pathology. Schäfer BW, et al. **Trends Biochem Sci** 1996 Apr;21(4):134–40 (29 ref.)

NERVE TISSUE PROTEINS

[Brain natriuretic peptide] La Villa G, et al. **Ann Ital Med Int** 1995 Oct–Dec;10(4):233–41 (73 ref.) (Eng. Abstr.) **(Ita)**
[Histocytochemical and functional aspects on the "brain–vascular peptides"] Yamada H, et al. **Kaibogaku Zasshi** 1995 Oct;70(5):422–35 (108 ref.) (Eng. Abstr.) **(Jpn)**
[Telencephalon–specific cell adhesion molecule, telencephalin] Yoshihara Y, et al. **Tanpakushitsu Kakusan Koso** 1996 May;41(6):766–74 (36 ref.) **(Jpn)**

ANALYSIS

A collection of cortical crescents: asymmetric protein localization in CNS precursor cells. Doe CQ, et al. **Neuron** 1995 Nov;15(5):991–5 (31 ref.)
v– and t–SNAREs in neuronal exocytosis: a need for additional components to define sites of release. Galli T, et al. **Neuropharmacology** 1995 Nov;34(11):1351–60 (63 ref.)

BLOOD

[Atrial natriuretic factor and brain natriuretic peptide. Variations in elderly subjects with heart failure] Tissandier O, et al. **Presse Med** 1995 Dec 9;24(38):1837–41 (27 ref.) (Eng. Abstr.) **(Fre)**
[Human atrial natriuretic peptide (hANP), human brain natriuretic peptide (hBNP)] Tsujino M, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:737–40 (8 ref.) **(Jpn)**

CHEMISTRY

The ADF/cofilin proteins: stimulus–responsive modulators of actin dynamics. Moon A, et al. **Mol Biol Cell** 1995 Nov; 6(11):1423–31 (84 ref.)

GENETICS

Use of transgenics, null mutants, and antisense approaches to study ethanol's actions. Wehner JM, et al. **Alcohol Clin Exp Res** 1995 Aug;19(4):811–20 (79 ref.)
Reelin: a novel extracellular matrix protein involved in brain lamination. Rugarli EI, et al. **Bioessays** 1995 Oct; 17(10):832–4 (32 ref.)
E2F and cell proliferation: a world turned upside down. Weinberg RA. **Cell** 1996 May 17;85(4):457–9 (10 ref.)
FMR1 triplet arrays: paying the price for perfection. Hirst MC. **J Med Genet** 1995 Oct;32(10):761–3 (16 ref.)
Analysis of the CAG repeat and gene product in spinocerebellar ataxia type 1. Zoghbi HY. **Proc Assoc Am Physicians** 1995 Jul;107(2):231–6 (21 ref.)
[Structure and function of FMR] Huang T, et al. **Sheng Li Ko Hsueh Chin Chan** 1995 Jul;26(3):218–22 (18 ref.) (Eng. Abstr.) **(Chi)**

METABOLISM

Phosphorylation of paired helical filament tau in Alzheimer's disease neurofibrillary lesions: focusing on phosphatases. Trojanowski JQ, et al. **FASEB J** 1995 Dec;9(15):1570–6 (77 ref.)
Effects of testosterone and its metabolites on aromatase–immunoreactive cells in the quail brain: relationship with the activation of male reproductive behavior. Balthazart J, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1–6 Spec No):185–200 (125 ref.)
Mineralocorticoid receptors in the central nervous system. Funder JW. **J Steroid Biochem Mol Biol** 1996 Jan;56(1–6 Spec No):179–83 (44 ref.)
A unifying hypothesis for acetylcholine release. Israël M, et al. **Neurochem Int** 1996 Jan;28(1):1–9 (88 ref.)
[The mechanisms of synaptic plasticity: the role of synaptic protein phosphorylation and gene expression] Godukhin OV, et al. **Usp Fiziol Nauk** 1995 Jul–Sep;26(3):41–56 (98 ref.) (Eng. Abstr.) **(Rus)**
[Protein phosphorylation in the normal nervous system and in Alzheimer's disease] Burbaeva GSh, et al. **Vestn Ross Akad Med Nauk** 1996;(4):13–8 (43 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Multifunctional calcium and calmodulin–dependent kinase II in neuronal function and disease. Churn SB. **Adv Neuroimmunol** 1995;5(3):241–59 (141 ref.)
Deciphering neuronal secretion: tools of the trade. Linial M, et al. **Biochim Biophys Acta** 1996 Jun 10;1286(2):117–52 (395 ref.)
Clustering membrane proteins: It's all coming together with the PSD–95/SAP90 protein family. Gomperts SN. **Cell** 1996 Mar 8;84(5):659–62 (20 ref.)
The postsynaptic density: a subcellular anchor for signal transduction enzymes. Klauck TM, et al. **Cell Signal** 1995 Nov;7(8):747–57 (114 ref.)
Trophic factors for the gastrointestinal tract. Carver JD, et al. **Clin Perinatol** 1996 Jun;23(2):265–85 (174 ref.)
Neural development. Spinning skin into neurons. Anderson DJ. **Curr Biol** 1995 Nov 1;5(11):1235–8 (16 ref.)
Neurotrophic factors. Neurotrophin autocrine loops. Davies AM, et al. **Curr Biol** 1995 Jul 1;5(7):723–6 (15 ref.)
SNAREs and the specificity of transport vesicle targeting. Bennett MK. **Curr Opin Cell Biol** 1995 Aug;7(4):581–6 (52 ref.)
Natriuretic peptides and hypertension. Prins BA, et al. **Curr Opin Nephrol Hypertens** 1996 Mar;5(2):170–3 (29 ref.)
TNF–alpha– and IFN–gamma–mediated signal transduction pathways: effects on glial cell gene expression and function. Benveniste EN, et al. **FASEB J** 1995 Dec;9(15):1577–84 (68 ref.)
Inducible nitric oxide synthase in the central nervous system. Sparrow JR. **J Mol Neurosci** 1994–95;5(4):219–29 (95 ref.)
Mediatophore and other presynaptic proteins. A cybernetic linking at the active zone. Dunant Y, et al. **J Physiol Paris** 1995;89(3):147–56 (68 ref.)
Cysteine string proteins and presynaptic function. Umbach JA, et al. **J Physiol Paris** 1995;89(2):95–101 (25 ref.)
Regulation of sex–specific formation of oestrogen in brain development: endogenous inhibitors of aromatase. Hutchison JB, et al. **J Steroid Biochem Mol Biol** 1996 Jan; 56(1–6 Spec No):201–7 (37 ref.)
The ADF/cofilin proteins: stimulus–responsive modulators of actin dynamics. Moon A, et al. **Mol Biol Cell** 1995 Nov; 6(11):1423–31 (84 ref.)
Regulatory properties of neuronal cdc2–like kinase. Qi Z, et al. **Mol Cell Biochem** 1995 Aug–Sep;149–150:35–9 (38 ref.)
Regulation of neuropeptide expression in the brain by neurotrophins. Potential role in vivo. Carnahan J, et al. **Mol Neurobiol** 1995 Apr–Jun;10(2–3):135–49 (107 ref.)
Molecular enhancement of memory formation. Carew TJ. **Neuron** 1996 Jan;16(1):5–8 (24 ref.)
PY in the fly receptor–like tyrosine phosphatases in axonal pathfinding. Chien CB. **Neuron** 1996 Jun;16(6):1065–8 (17 ref.)
The neuronal exocytotic fusion machine: some new developments. Chapman ER, et al. **Neuropharmacology** 1995 Nov;34(11):1343–9 (64 ref.)
Synaptic vesicle proteins and regulated exocytosis. Elferink LA, et al. **Prog Brain Res** 1995;105:79–85 (42 ref.)
Neurotrophins and neuronal plasticity. Thoenen H. **Science** 1995 Oct 27;270(5236):593–8 (64 ref.)
[Neurospecific protein–hormonal complexes] Srapionian RM. **Usp Fiziol Nauk** 1996 Jan–Mar;27(1):21–31 (38 ref.) (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Trophic factor supplementation: effect on the age–associated changes in body composition. Schwartz RS. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:151–6 (53 ref.)
Toward trophic treatment in parkinsonism: a primate step. Olson L. **Nat Med** 1996 Apr;2(4):400–1 (18 ref.)

NERVE TRANSFER

see related
NERVE REGENERATION

METHODS

Microsurgical reconstruction of sensory skin. Brunelli GA, et al. **Ann Acad Med Singapore** 1995 Jul;24(4 Suppl):108–12 (14 ref.)

NERVE TRANSMITTER SUBSTANCES see **NEUROTRANSMITTERS**

NERVOUS MICE see **MICE, NEUROLOGIC MUTANTS**

NERVOUS SYSTEM

Quantitative RT–PCR for neuroendocrine studies. A minireview. Zamorano PL, et al. **Neuroendocrinology** 1996 May;63(5):397–407 (39 ref.)
[Imagery and its neurological substrate] Decety J, et al. **Rev Neurol (Paris)** 1995 Aug–Sep;151(8–9):474–9 (50 ref.) (Eng. Abstr.) **(Fre)**

ANATOMY & HISTOLOGY

Roles of steroid hormones and their receptors in structural organization in the nervous system. Kawata M. **Neurosci Res** 1995 Dec;24(1):1–46 (655 ref.)

CYTOLOGY

Development and function of embryonic central nervous system glial cells in Drosophila. Klämbt C, et al. **Dev Genet** 1996;18(1):40–9 (87 ref.)
Cell fate specification and differentiation in the nervous system of Caenorhabditis elegans. Sengupta P, et al. **Dev Genet** 1996;18(1):73–80 (65 ref.)

DRUG EFFECTS

Neurotoxicity of water–soluble contrast media. Torvik A, et al. **Acta Radiol Suppl** 1995;399:221–9 (101 ref.)
The concern for developmental neurotoxicology: is it justified and what is being done about it? Tilson HA. **Environ Health Perspect** 1995 Sep;103 Suppl 6:147–51 (31 ref.)
Neuropsychological consequences of antihypertensive medication use. Muldoon MF, et al. **Exp Aging Res** 1995 Oct–Dec;21(4):353–68 (68 ref.)
Neuropsychopathological changes by organophosphorus compounds—a review. Eyer P. **Hum Exp Toxicol** 1995 Nov;14(11):857–64 (76 ref.)
Ontogeny of methamphetamine–induced neurotoxicity in the rat model. Vorhees CV, et al. **NIDA Res Monogr** 1995; 158:149–71 (46 ref.)
A review of nonpesticide phosphate ester–induced neurotoxicity in cattle. Coppock RW, et al. **Vet Hum Toxicol** 1995 Dec;37(6):576–9 (20 ref.)
[Neurotoxicity of nerve agents] Morita H. **No To Shinkei** 1995 Dec;47(12):1129–34 (20 ref.) **(Jpn)**
[The biomedical aspects of mercury neurotoxicity (a review)] Chukhlovina ML. **Gig Sanit** 1995 Nov–Dec;(6):39–41 (45 ref.) **(Rus)**

EMBRYOLOGY

Reelin: a novel extracellular matrix protein involved in brain lamination. Rugarli EI, et al. **Bioessays** 1995 Oct; 17(10):832–4 (32 ref.)
Tag team specification of a neural precursor in the

Drosophila embryonic central nervous system. Skeath JB. **Bioessays** 1995 Oct;17(10):829–31 (18 ref.)

Hierarchical guidance cues in the developing nervous system of C. elegans. Wadsworth WG, et al. **Bioessays** 1996 May; 18(5):355–62 (47 ref.)

Basic FGF as an inducer of anteroposterior neural pattern. Doniach T. **Cell** 1995 Dec 29;83(7):1067–70 (19 ref.)

Regulation of mammalian neural development by helix–loop–helix transcription factors. Kageyama R, et al. **Crit Rev Neurobiol** 1995;9(2–3):177–88 (84 ref.)

The role of the notochord and floor plate in inductive interactions. Placzek M. **Curr Opin Genet Dev** 1995 Aug; 5(4):499–506 (74 ref.)

Lateral specification of cell fate during vertebrate development. Raible DW, et al. **Curr Opin Genet Dev** 1995 Aug;5(4):444–9 (54 ref.)

Regulatory interactions during early neurogenesis in Drosophila. Hassan B, et al. **Dev Genet** 1996;18(1):18–27 (88 ref.)

Development and function of embryonic central nervous system glial cells in Drosophila. Klämbt C, et al. **Dev Genet** 1996;18(1):40–9 (87 ref.)

Invertebrate versus vertebrate neurogenesis: variations on the same theme? Salzberg A, et al. **Dev Genet** 1996;18(1):1–10 (128 ref.)

Cell fate specification and differentiation in the nervous system of Caenorhabditis elegans. Sengupta P, et al. **Dev Genet** 1996;18(1):73–80 (65 ref.)

Retinoblastoma gene in mouse neural development. Slack RS, et al. **Dev Genet** 1996;18(1):81–91 (155 ref.)

Sonic hedgehog: a common signal for ventral patterning along the rostrocaudal axis of the neural tube. Ericson J, et al. **Int J Dev Biol** 1995 Oct;39(5):809–16 (45 ref.)

Cell division and differentiation in avian embryos: techniques for study of early neurogenesis and myogenesis. Sechrist J, et al. **Methods Cell Biol** 1996;51:301–29 (57 ref.)

VIP as a cell–growth and differentiation neuromodulator role in neurodevelopment. Muller JM, et al. **Mol Neurobiol** 1995 Apr–Jun;10(2–3):115–34 (126 ref.)

Wiring by fly: the neuromuscular system of the Drosophila embryo. Bate M, et al. **Neuron** 1995 Sep;15(3):513–25 (108 ref.)

Neural induction and neurogenesis in amphibian embryos. Chitnis A, et al. **Perspect Dev Neurobiol** 1995;3(1):3–15 (63 ref.)

Evolution of regional identity in the vertebrate nervous system. Holland PW, et al. **Perspect Dev Neurobiol** 1995; 3(1):17–27 (48 ref.)

Hepatocyte growth factor/scatter factor (HGF/SF) in early development: evidence for a role in neural induction. Bronner–Fraser M. **Trends Genet** 1995 Nov;11(11):423–5 (18 ref.)

[Midkine in relation to development and pathological status of the nervous system] Muramatsu T. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1995 Jun; 15(3):275–9 (26 ref.) (Eng. Abstr.) **(Jpn)**

[Molecular mechanisms of the neural induction and morphogenesis] Okamoto H, et al. **Tanpakushitsu Kakusan Koso** 1996 May;41(6):746–57 (25 ref.) **(Jpn)**

ENZYMOLOGY

Histochemistry of nitric oxide synthase in the nervous system. Blottner D, et al. **Histochem J** 1995 Oct;27(10):785–811 (271 ref.)

GROWTH & DEVELOPMENT

Axon guidance molecules. Keynes R, et al. **Cell** 1995 Oct 20;83(2):161–9 (60 ref.)

Making the connection: cytoskeletal rearrangements during growth cone guidance. Tanaka E, et al. **Cell** 1995 Oct 20; 83(2):171–6 (40 ref.)

Positive and negative regulators of neural fate. Simpson P. **Neuron** 1995 Oct;15(4):739–42 (20 ref.)

IMMUNOLOGY

Functions of the L2/HNK–1 carbohydrate in the nervous system. Schachner M, et al. **Prog Brain Res** 1995;105:183–8 (39 ref.)

INJURIES

Mediators of injury in neurotrauma: intracellular signal transduction and gene expression. Bazan NG, et al. **J Neurotrauma** 1995 Oct;12(5):791–814 (249 ref.)

Lightning and electrical injuries: neuro–ophthalmologic aspects. Grover S, et al. **Semin Neurol** 1995 Dec; 15(4):335–41 (37 ref.)

Neuropathology of lightning–strike injuries. Kleinschmidt–DeMasters BK. **Semin Neurol** 1995 Dec; 15(4):323–8 (34 ref.)

Management of complicated neurologic injuries. Gruen JP, et al. **Surg Clin North Am** 1996 Aug;76(4):905–22 (29 ref.)

METABOLISM

The regulation of neuron–specific gene expression in the mammalian nervous system. Twyman RM, et al. **J Neurogenet** 1995 Nov;10(2):67–101 (190 ref.)

Ceramide: a potential second messenger in the nervous system. Chao MV. **Mol Cell Neurosci** 1995 Apr;6(2):91–6 (55 ref.)

Immediate early genes (IEGs) encoding for inducible transcription factors (ITFs) and neuropeptides in the nervous system: functional network for long–term plasticity and pain. Herdegen T, et al. **Prog Brain Res** 1995; 104:299–321 (184 ref.)

[Protein phosphorylation in the normal nervous system and in Alzheimer's disease] Burbaeva GSh, et al. **Vestn Ross Akad Med Nauk** 1996;(4):13–8 (43 ref.) (Eng. Abstr.) **(Rus)**

PATHOLOGY

Neuropathology of thiamine deficiency: an update on the comparative analysis of human disorders and experimental models. Langlais PJ, et al. **Metab Brain Dis** 1996 Mar; 11(1):19–37 (88 ref.)

Immortalized neural stem cells: insights into development; prospects for gene therapy and repair. Snyder EY. **Proc Assoc Am Physicians** 1995 Jul;107(2):195–204 (58 ref.)

[Neuropathology of dentatorubral–pallidoluysian atrophy and Machado–Joseph disease] Takahashi H, et al. **No To Shinkei** 1995 Oct;47(10):947–53 (34 ref.) **(Jpn)**

PHYSIOLOGY

The molecular biology of the Na(+)–Ca2+ exchanger and its functional roles in heart, smooth muscle cells, neurons, glia, lymphocytes, and nonexcitable cells. Lederer WJ, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:7–17 (60 ref.)

Nitric oxide: a neural messenger. Jaffrey SR, et al. **Ann Rev Cell Dev Biol** 1995;11:417–40 (167 ref.)

Apoptosis in the nervous system: morphological features, methods, pathology, and prevention. Lo AC, et al. **Arch Histol Cytol** 1995 Jun;58(2):139–49 (107 ref.)

Neural mechanisms for stimulus selection in cortical areas of the macaque subserving object vision. Chelazzi L. **Behav Brain Res** 1995 Nov;71(1–2):125–34 (84 ref.)

The problem of animal consciousness in relation to neuropsychology. Weiskrantz L. **Behav Brain Res** 1995 Nov;71(1–2):171–5 (17 ref.)

A VIP hybrid antagonist: from developmental neurobiology to clinical applications. Gozes I, et al. **Cell Mol Neurobiol** 1995 Dec;15(6):675–87 (74 ref.)

Neurodevelopmental variation in school–aged children. Tanner JL. **Compr Ther** 1995 Sep;21(9):499–506 (17 ref.)

Biochemical and functional diversity of microtubule motors in the nervous system. Brady ST, et al. **Curr Opin Neurobiol** 1995 Oct;5(5):551–8 (65 ref.)

The GAL4 system as a tool for unravelling the mysteries of the Drosophila nervous system. Brand AH, et al. **Curr Opin Neurobiol** 1995 Oct;5(5):572–8 (60 ref.)

Silencing is golden: negative regulation in the control of neuronal gene transcription. Schoenherr CJ, et al. **Curr Opin Neurobiol** 1995 Oct;5(5):566–71 (48 ref.)

Transforming growth factor–beta 1: a lesion–associated cytokine of the nervous system. Kiefer R, et al. **Int J Dev Neurosci** 1995 Jun–Jul;13(3–4):331–9 (54 ref.)

Neural functions of the transforming growth factors beta. Krieglstein K, et al. **Int J Dev Neurosci** 1995 Jun–Jul; 13(3–4):301–15 (126 ref.)

Neurotrophins and cytokines—intermediaries between the immune and nervous systems. Otten U, et al. **Int J Dev Neurosci** 1995 Jun–Jul;13(3–4):147–51 (48 ref.)

Neural regulation of the endocrine pancreas. Brunicardi FC, et al. **Int J Pancreatol** 1995 Dec;18(3):177–95 (185 ref.)

Temporal encoding in nervous systems: a rigorous definition. Theunissen F, et al. **J Comput Neurosci** 1995 Jun; 2(2):149–62 (33 ref.)

Skin–nervous system interactions. Ansel JC, et al. **J Invest Dermatol** 1996 Jan;106(1):198–204 (188 ref.)

Role of phospholipase D activation in nervous system physiology and pathophysiology. Klein J, et al. **J Neurochem** 1995 Oct;65(4):1445–55 (83 ref.)

Role of essential fatty acids in the function of the developing nervous system. Uauy R, et al. **Lipids** 1996 Mar;31 Suppl:S167–76 (84 ref.)

Neurotrophin–3 as an essential signal for the developing nervous system. Chalazonitis A. **Mol Neurobiol** 1996 Feb; 12(1):39–53 (90 ref.)

Immunophilins and the nervous system. Snyder SH, et al. **Nat Med** 1995 Jan;1(1):32–7 (82 ref.)

Regulatory mechanism of stress response in mammalian nervous system during cerebral ischaemia or after heat shock. Higashi T, et al. **Neuropathol Appl Neurobiol** 1995 Dec;21(6):480–3 (19 ref.)

The cognitive neuroscience of mental imagery. Kosslyn SM, et al. **Neuropsychologia** 1995 Nov;33(11):1335–44 (21 ref.)

Fundamental neuroscience and the classification of psychiatric disorders. Dubrovsky B. **Neurosci Biobehav Rev** 1995 Fall;19(3):511–8 (118 ref.)

Roles of steroid hormones and their receptors in structural organization in the nervous system. Kawata M. **Neurosci Res** 1995 Dec;24(1):1–46 (655 ref.)

Arachidonic acid as a neurotoxic and neurotrophic substance. Katsuki H, et al. **Prog Neurobiol** 1995 Aug;46(6):607–36 (345 ref.)

Neural component placement. Cherniak C. **Trends Neurosci** 1995 Dec;18(12):522–7 (41 ref.)

Application of focused ultrasound for the stimulation of neural structures. Gavrilov LR, et al. **Ultrasound Med Biol** 1996;22(2):179–92 (50 ref.)

Neural regulation of swallowing in the dog. Venker–van Haagen AJ. **Vet Q** 1995 Apr;17 Suppl 1:S7 (1 ref.)

[Is the animal in hibernal sleep awake?] Canguilhem B, et al. **Neurophysiol Clin** 1996;26(1):1–7 (20 ref.) (Eng. Abstr.) **(Fre)**

[Biological role of carbon monoxide in nervous system function] Borowicz KK, et al. **Postepy Hig Med Dosw** 1996; 50(1):81–94 (79 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOPATHOLOGY

What is the role of nerves in chronic asthma and symptoms? Barnes PJ. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 2):S5–8 (58 ref.)

Match and mismatch: identifying the neuronal determinants of pain [comment] [see comments] Casey KL. **Ann Intern Med** 1996 Jun 1;124(11):995–8 (35 ref.) Comment on: Ann Intern Med 1996 Jun 1;124(11):939–49. Comment on: Ann Intern Med 1996 Jun 1;124(11):950–8. Comment on: Ann Intern Med 1996 Jun 1;124(11):959–69. Comment on: Ann Intern Med 1996 Jun 1;124(11):1006–8. Comment on: Ann Intern Med 1996 Jun 1;124(11):1008–1011. Comment in: Ann Intern Med 1996 Jun 1;124(11):939–49. Comment in: Ann Intern Med 1996 Jun 1;124(11):950–8. Comment in: Ann Intern Med 1996 Jun 1;124(11):959–8.

Selective nonoperative management of liver and spleen injuries in neurologically impaired adult patients. Archer LP, et al. **Arch Surg** 1996 Mar;131(3):309–15 (57 ref.)

Neuropsychiatry of obsessive–compulsive disorder in children and adolescents. March JS, et al. **Compr Ther** 1995 Sep;21(9):507–12 (71 ref.)

The neural mechanisms and progressive nature of symptoms of Parkinson's disease—based on clinical, neurophysiological and morphological studies. Narabayashi H. **J Neural Transm Park Dis Dement Sect** 1995;10(1):63–75 (26 ref.)

Role of phospholipase D activation in nervous system physiology and pathophysiology. Klein J, et al. **J Neurochem** 1995 Oct;65(4):1445–55 (83 ref.)

Neurobehavioral outcome of closed head injury: implications for clinical trials. Levin HS. **J Neurotrauma** 1995 Aug; 12(4):601–10 (60 ref.)

[Clinical aspects of immunoneuroendocrine alterations in HIV infection] Rondanelli M, et al. **Minerva Endocrinol** 1995 Jun;20(2):113–26 (78 ref.) (Eng. Abstr.) **(Ita)**

[The phenomenon of hypoglycemia unawareness—definition, frequency, pathogenesis and clinical forms] Mokáň M. **Bratisl Lek Listy** 1995 Aug;96(8):413–9 (39 ref.) (Eng. Abstr.) **(Slo)**

ULTRASTRUCTURE

P2 purinergic receptors for diadenosine polyphosphates in the nervous system. Pintor J, et al. **Gen Pharmacol** 1995 Mar;26(2):229–35 (49 ref.)

VIROLOGY

HSV as a gene transfer vector for the nervous system. Glorioso JC, et al. **Mol Biotechnol** 1995 Aug;4(1):87–99 (61 ref.)

NERVOUS SYSTEM DISEASES

Neuronal intestinal dysplasia: a role for surgery? Lugo–Vicente HL. **Bol Asoc Med P R** 1995 Mar–Apr; 87(3–4):60–3 (29 ref.)

Transgenic and knockout mice in the study of neurodegenerative diseases. Aguzzi A, et al. **J Mol Med** 1996 Mar;74(3):111–26 (149 ref.)

Neurological complications of HIV infection. Price RW. **Lancet** 1996 Aug 17;348(9025):445–52 (50 ref.)

CHEMICALLY INDUCED

Long term neurotoxic effects of organophosphate compounds. Jamal GA. **Adverse Drug React Toxicol Rev** 1995 Summer;14(2):85–99 (81 ref.)

Biomarker research in neurotoxicology: the role of mechanistic studies to bridge the gap between the laboratory and epidemiological investigations. Costa LG. **Environ Health Perspect** 1996 Mar;104 Suppl 1:55–67 (187 ref.)

Neurotoxicity of lead, methylmercury, and PCBs in relation to the Great Lakes. Rice DC. **Environ Health Perspect** 1995 Dec;103 Suppl 9:71–87 (221 ref.)

Neuropsychopathological changes by organophosphorus compounds—a review. Eyer P. **Hum Exp Toxicol** 1995 Nov;14(11):857–64 (76 ref.)

Neuropathogenic actions of cytokines assessed in transgenic mice. Campbell IL. **Int J Dev Neurosci** 1995 Jun–Jul; 13(3–4):275–84 (68 ref.)

Defining neurotoxicity in a decision–making context. Tilson HA, et al. **Neurotoxicology** 1995 Summer;16(2):363–75 (49 ref.)

[Drug–induced neurological complications in a hospital cohort] Vuadens P, et al. **Schweiz Med Wochenschr** 1995 Sep 2;125(35):1625–33 (42 ref.) (Eng. Abstr.) **(Fre)**

[After vaccination for tick–borne encephalitis must onset of neurologic disorders be expected?] Hofmann H. **Wien Klin Wochenschr** 1995;107(17):509–15 (17 ref.) (Eng. Abstr.) **(Ger)**

[A review of studies of the delayed neurotoxicity induced by organophosphorus esters] Katoh K.

Sangyo Eiseigaku Zasshi 1995 Sep;37(5):309–19 (121 ref.) (Eng. Abstr.) **(Jpn)**

[Cocaine-induced neurological complications] García Castaño J, et al. **An Med Interna** 1996 Apr;13(4):198–201 (33 ref.) (Eng. Abstr.) **(Spa)**

COMPLICATIONS

New opinions of pathomechanisms of involuntary movements. Iłżecka J.
Ann Univ Mariae Curie Sklodowska [Med] 1994;49:99–104 (16 ref.)

Neurological and psychiatric adverse effects of anaesthetics: epidemiology and treatment. Klafta JM, et al. **Drug Saf** 1995 Nov;13(5):281–95 (137 ref.)

Neurologic antecedents to patient falls. Benson C, et al. **J Neurosci Nurs** 1995 Dec;27(6):331–7 (25 ref.)

Managing HIV. Part 5: Treating secondary outcomes. 5.4 HIV-induced neurological disease. Wright EJ, et al. **Med J Aust** 1996 Apr 1;164(7):414–7 (31 ref.)

Clinical neuromythology XV. Feinting science: Neurocardiogenic syncope and collateral vasovagal confusion. Landau WM, et al. **Neurology** 1996 Mar; 46(3):609–18 (77 ref.)

Sleep-related breathing disorders. 7. Sleep and breathing problems in general medicine. Calverley PM. **Thorax** 1995 Dec;50(12):1311–6 (98 ref.)

[Hypothermia and the nervous system. Review of the literature apropos of 4 cases] Mouton P, et al.
Ann Med Interne (Paris) 1996;147(2):107–14 (69 ref.) (Eng. Abstr.) **(Fre)**

[Sleep disorders in neurologic diseases] Schilling F.
Z Arztl Fortbild (Jena) 1996 Apr;90(2):131–7 (46 ref.) (Eng. Abstr.) **(Ger)**

DIAGNOSIS

Instrumental diagnosis of multiple system atrophy. Stocchi F, et al. **Adv Neurol** 1996;69:421–4 (6 ref.)

Indirect DNA/gene diagnoses via electrophoresis--an obsolete principle? Epplen JT, et al. **Electrophoresis** 1995 May;16(5):683–90 (53 ref.)

Diagnostic reasoning in neurology. Gifford DR, et al. **Neurol Clin** 1996 Feb;14(1):223–38 (59 ref.)

[Paraneoplastic neurologic syndromes. Classification and diagnosis] Grisold W, et al. **Nervenarzt** 1995 Oct; 66(10):736–44 (107 ref.) (Eng. Abstr.) **(Ger)**

[Diagnostic methods in the assessment of anosmia in neurologic diseases] Kobal G, et al. **Nervenarzt** 1995 Dec; 66(12):869–84 (54 ref.) (Eng. Abstr.) **(Ger)**

[Subclinical neuro-psychobehavioral effects in occupational, environmental and community health: methodology and recent findings] Araki S, et al. **Nippon Eiseigaku Zasshi** 1995 Aug;50(3):713–29 (122 ref.) (Eng. Abstr.) **(Jpn)**

[Biomarkers of neurotoxic effects induced by environmental chemicals] Indulski JA, et al. **Med Pr** 1996;47(4):383–91 (32 ref.) (Eng. Abstr.) **(Pol)**

[Clinical picture of vibration syndrome and diagnostic principles] Iżycki J. **Med Pr** 1996;47(3):277–83 (17 ref.) (Eng. Abstr.) **(Pol)**

[Dermatitis and neurological changes] Benítez León MD, et al. **Rev Clin Esp** 1995 Oct;195(10):717–8 (15 ref.) **(Spa)**

DRUG THERAPY

Sedation for the critically ill neurologic patient. Mirski MA, et al. **Crit Care Med** 1995 Dec;23(12):2038–53 (124 ref.)

Neurotrophic factors: ready to go? Schätzl HM.
Trends Neurosci 1995 Nov;18(11):463–4 (19 ref.)

EPIDEMIOLOGY

Epidemiology of disabling neurological disease: how and why does disability occur? Wade DT.
J Neurol Neurosurg Psychiatry 1996 Sep;61(3):242–9 (77 ref.)

Neuroepidemiology of HIV infection. Dal Pan GJ, et al. **Neurol Clin** 1996 May;14(2):359–82 (133 ref.)

Changing demographics and neurologic disease in the elderly. Riggs JE. **Neurol Clin** 1996 May;14(2):477–86 (41 ref.)

ETIOLOGY

Neurological complications of central nerve blocks [editorial; comment] Renck H. **Acta Anaesthesiol Scand** 1995 Oct; 39(7):859–68 (93 ref.) Comment on: Acta Anaesthesiol Scand 1995 Oct;39(7):872–80.

Neurological complications of celiac disease: a rare but continuing problem. Muller AF, et al.
Am J Gastroenterol 1996 Jul;91(7):1430–5 (28 ref.)

Neurological complications of acquired cobalamin deficiency: clinical aspects. Savage DG, et al.
Baillieres Clin Haematol 1995 Sep;8(3):657–78 (114 ref.)

Maternal sequelae of childbirth [editorial] Reynolds F.
Br J Anaesth 1995 Nov;75(5):515–7 (26 ref.)

Opioid use in HIV patients with neurological changes. Paice JA, et al. **J Assoc Nurses AIDS Care** 1995 Jul-Aug; 6(4):28–36 (27 ref.)

Neuro-ophthalmology and systemic disease--Part I. An annual review (1994). Newman NJ. **J Neuroophthalmol** 1995 Jun;15(2):109–21 (136 ref.)

Neuro-ophthalmology and systemic disease--Part II. An annual review (1994). Newman NJ. **J Neuroophthalmol** 1995 Dec;15(4):241–53 (134 ref.)

Bioenergetic and oxidative stress in neurodegenerative diseases. Bowling AC, et al. **Life Sci** 1995;56(14):1151–71 (257 ref.)

Onconeural antigens and the paraneoplastic neurologic disorders: at the intersection of cancer, immunity, and the brain. Darnell RB. **Proc Natl Acad Sci U S A** 1996 May 14;93(10):4529–36 (107 ref.)

Nitric oxide in neuronal degeneration. Dawson VL, et al. **Proc Soc Exp Biol Med** 1996 Jan;211(1):33–40 (86 ref.)

Nervous system lupus: pathogenesis and rationale for therapy. Denburg JA, et al. **Scand J Rheumatol** 1995;24(5):263–73 (155 ref.)

Systemic lupus erythematosus: immunopathogenesis of neurologic dysfunction. Moore PM, et al.
Springer Semin Immunopathol 1995;17(1):43–60 (123 ref.)

[Neurologic complications of infectious endocarditis] Gergaud JM, et al. **Ann Med Interne (Paris)** 1995; 146(6):413–8 (34 ref.) (Eng. Abstr.) **(Fre)**

[Management of neurologic manifestations after obstetrical epidural anesthesia] Frangié S, et al. **Cah Anesthesiol** 1995; 43(5):455–60 (43 ref.) (Eng. Abstr.) **(Fre)**

[What are the complications likely to lead to medicolegal problems? How to manage them?] Samii K, et al.
Cah Anesthesiol 1995;43(6):521–4 (20 ref.) **(Fre)**

[Neurologic manifestations of Lyme disease. Apropos of 25 cases] Ragnaud JM, et al. **Rev Med Interne** 1995; 16(7):487–94 (54 ref.) (Eng. Abstr.) **(Fre)**

[Role of glutamate and excitotoxicity in neurologic diseases] Hugon J, et al. **Rev Neurol (Paris)** 1996 Apr;152(4):239–48 (115 ref.) (Eng. Abstr.) **(Fre)**

[Neuropsychiatric symptoms in vitamin B12 deficiency and microcarcinoidosis. The complications of chronic atrophic gastritis] Ossege LM, et al. **Dtsch Med Wochenschr** 1996 Jun 7;121(23):758–62 (25 ref.) (Eng. Abstr.) **(Ger)**

[Neurological symptoms after an infection by the sandfly fever virus] Pauli C, et al. **Dtsch Med Wochenschr** 1995 Oct 27;120(43):1468–72 (22 ref.) (Eng. Abstr.) **(Ger)**

[Nerve lesions in patients with immunoproliferative disorders] Ito H, et al. **Nippon Naika Gakkai Zasshi** 1995 Jul 10;84(7):1075–80 (6 ref.) **(Jpn)**

[Triplet repeat disorders] Yamada M.
Tanpakushitsu Kakusan Koso 1996 Apr;41(5):643–51 (54 ref.) **(Jpn)**

[Paraneoplastic syndromes of the nervous system and muscles during the course of small cell lung carcinoma] Joachimowicz-Jaśkowiak E. **Pneumonol Pol** 1990 Nov-Dec;58(11-12):647–50 (21 ref.) **(Pol)**

[The role of the delta sleep-inducing peptide in the formation of neuropathological syndromes] Shandra AA, et al.
Fiziol Zh Im I M Sechenova 1995 Sep;81(9):13–24 (56 ref.) (Eng. Abstr.) **(Rus)**

[Neurologic manifestations of Whipple disease] Alba D, et al. **An Med Interna** 1995 Oct;12(10):508–12 (92 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

Diagnosis of inherited metabolic disorders affecting the nervous system. Swanson PD.
J Neurol Neurosurg Psychiatry 1995 Nov;59(5):460–70 (123 ref.)

From genes to mechanisms to therapies: lessons to be learned from neurological disorders [see comments] Roses AD. **Nat Med** 1996 Mar;2(3):267–9 (17 ref.) Comment in: Nat Med 1996 Jun;2(6):609–10.

Identification of the weaver mouse mutation: the end of the beginning. Hess EJ. **Neuron** 1996 Jun;16(6):1073–6 (19 ref.)

When more is less: pathogenesis of glutamine repeat neurodegenerative diseases. Ross CA. **Neuron** 1995 Sep; 15(3):493–6 (35 ref.)

Neurogenetics: now and the future. Martin JB.
Trans Am Clin Climatol Assoc 1994;106:114–22; discussion 122–3 (16 ref.)

[Schimmelpenning-Feuerstein-Mims syndrome and its neurologic manifestations. 6 personal cases and review of the literature] Fritzsch C, et al. **Klin Padiatr** 1995 Sep-Oct; 207(5):288–97 (40 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Immune-mediated cell death in neurodegenerative disease. Appel SH, et al. **Adv Neurol** 1996;69:153–9 (55 ref.)

Autoantibodies, neurotoxins and the nervous system. Vincent A, et al. **J Physiol Paris** 1995;89(3):129–36 (75 ref.)

The Hughlings Jackson Lecture: autoimmunity and the nervous system. Newsom-Davis J. **J R Soc Med** 1995 Nov; 88(11):639P–643P (20 ref.)

Neurological and obstetric manifestations of the antiphospholipid syndrome. Gatenby PA. **Lupus** 1996 Apr; 5(2):170–2 (13 ref.)

Managing HIV. Part 3: Mechanisms of diseases. 3.7 How HIV leads to neurological disease. Brew BJ, et al.
Med J Aust 1996 Feb 19;164(4):233–4 (19 ref.)

Systemic lupus erythematosus: immunopathogenesis of neurologic dysfunction. Moore PM, et al.
Springer Semin Immunopathol 1995;17(1):43–60 (123 ref.)

[Neurologic paraneoplastic syndromes and anti-neuronal antibodies] Mygland A. **Tidsskr Nor Laegeforen** 1996 Jan 30;116(3):361–5 (44 ref.) (Eng. Abstr.) **(Nor)**

METABOLISM

Postmortem and cerebrospinal fluid studies of corticotropin-releasing factor in humans. Hartline KM, et al. **Ann N Y Acad Sci** 1996 Mar 22;780:96–105 (44 ref.)

Excitotoxicity and neurodegenerative diseases. Ikonomidou C, et al. **Curr Opin Neurol** 1995 Dec;8(6):487–97 (182 ref.)

Role of nitric oxide in neurodegenerative diseases. Schulz JB, et al. **Curr Opin Neurol** 1995 Dec;8(6):480–6 (42 ref.)

The calcium hypothesis of brain aging and neurodegenerative disorders: significance in diabetic neuropathy. Biessels G, et al. **Life Sci** 1996;59(5–6):379–87 (67 ref.)

From genes to mechanisms to therapies: lessons to be learned from neurological disorders [see comments] Roses AD. **Nat Med** 1996 Mar;2(3):267–9 (17 ref.) Comment in: Nat Med 1996 Jun;2(6):609–10.

NURSING

Hope: implications for neuroscience nursing. Fowler SB.
J Neurosci Nurs 1995 Oct;27(5):298–304 (47 ref.)

PATHOLOGY

Immune-mediated cell death in neurodegenerative disease. Appel SH, et al. **Adv Neurol** 1996;69:153–9 (55 ref.)

Alterations of intermediate filaments in various histopathological conditions. Cadrin M, et al.
Biochem Cell Biol 1995 Sep-Oct;73(9–10):627–34 (103 ref.)

Genetic markers and animal models of neurocristopathy. Nakamura T. **Histol Histopathol** 1995 Jul;10(3):747–59 (155 ref.)

Host parasite response in nerve in leprosy. Turk JL.
Indian J Lepr 1996 Jan-Mar;68(1):113–7 (15 ref.)

Magnetic resonance imaging of brain iron in health and disease. Vymazal J, et al. **J Neurol Sci** 1995 Dec;134 Suppl:19–26 (55 ref.)

PHYSIOPATHOLOGY

Molecular biology of brain aging and neurodegenerative disorders. Wisniewski T, et al.
Acta Neurobiol Exp (Warsz) 1996;56(1):267–79 (93 ref.)

Is dopaminergic cell death accompanied by concomitant nerve plasticity? Anglade P, et al. **Adv Neurol** 1996; 69:195–208 (96 ref.)

Molecular mechanisms for neurodegeneration. Synergism between reactive oxygen species, calcium, and excitotoxic amino acids. Gerlach M, et al. **Adv Neurol** 1996;69:177–94 (119 ref.)

Multiple system atrophy. Quinn NP, et al. **Adv Neurol** 1996; 69:413–9 (39 ref.)

Inflammation in the nervous system. Perry VH, et al.
Curr Opin Neurobiol 1995 Oct;5(5):636–41 (52 ref.)

Long-term hippocampal slices: a model system for investigating synaptic mechanisms and pathologic processes. Bahr BA. **J Neurosci Res** 1995 Oct 15; 42(3):294–305 (96 ref.)

Muscles of a different 'color': the unusual properties of the extraocular muscles may predispose or protect them in neurogenic and myogenic disease. Porter JD, et al.
Neurology 1996 Jan;46(1):30–7 (61 ref.)

Long-term potentiation and N-methyl-D-aspartate receptors: foundations of memory and neurologic disease? Rison RA, et al. **Neurosci Biobehav Rev** 1995 Winter; 19(4):533–52 (223 ref.)

Arachidonic acid as a neurotoxic and neurotrophic substance. Katsuki H, et al. **Prog Neurobiol** 1995 Aug;46(6):607–36 (345 ref.)

Paroxysmal nonepileptic disorders in children and adolescents. Bleasel A, et al. **Semin Neurol** 1995 Jun; 15(2):203–17 (83 ref.)

Neurological manifestations of acute posterior multifocal placoid pigment epitheliopathy. Comu S, et al. **Stroke** 1996 May;27(5):996–1001 (38 ref.)

[Amyloidosis, protein conformation dynamics and neurologic diseases] Tranchant C, et al. **Rev Neurol (Paris)** 1996 Mar; 152(3):153–7 (26 ref.) (Eng. Abstr.) **(Fre)**

[Role of nicotinic acid and its derivatives in disorders of nervous system function] Parkhomets PK, et al.
Ukr Biokhim Zh 1995 Jul-Aug;67(4):3–11 (91 ref.) (Eng. Abstr.) **(Rus)**

PSYCHOLOGY

Funny spells in neuroendocrine disorders. Pleet AB.
Semin Neurol 1995 Jun;15(2):133–50 (473 ref.)

[Neuropsychology of musical identification] Lechevalier B, et al. **Rev Neurol (Paris)** 1995 Aug-Sep;151(8–9):505–10 (32 ref.) (Eng. Abstr.) **(Fre)**

RADIONUCLIDE IMAGING

[Neurological applications of single photon emission tomoscintigraphy] Stievenart JL, et al.
Rev Neurol (Paris) 1995 Nov;151(11):619–33 (139 ref.) (Eng. Abstr.) **(Fre)**

REHABILITATION

Neurorehabilitation of lightning and electrical injuries. Yarnell PR, et al. **Semin Neurol** 1995 Dec;15(4):391–6 (51 ref.)

THERAPY

Intravenous immunoglobulin treatment in neurological diseases [editorial] Otten A, et al.
J Neurol Neurosurg Psychiatry 1996 Apr;60(4):359–61 (44 ref.)

A physical mechanism in the treatment of neurologic disorders with externally applied pico Tesla magnetic fields. Jacobson JI, et al. **Panminerva Med** 1995 Jun; 37(2):98–104 (22 ref.)

Nervous system lupus: pathogenesis and rationale for therapy. Denburg JA, et al. **Scand J Rheumatol** 1995;24(5):263–73 (155 ref.)

[Plasmapheresis as a method of intensive care in neurology] Piradov MA. **Anesteziol Reanimatol** 1996 Mar–Apr; (2):92–4 (3 ref.) **(Rus)**

VETERINARY

The clinical differentiation of nervous and muscular locomotor disorders of sheep in Australia. Bourke CA. **Aust Vet J** 1995 Jun;72(6):228–34 (40 ref.)

VIROLOGY

Managing HIV. Part 3: Mechanisms of diseases. 3.7 How HIV leads to neurological disease. Brew BJ, et al. **Med J Aust** 1996 Feb 19;164(4):233–4 (19 ref.)

NERVOUS SYSTEM NEOPLASMS

GENETICS

Transgenic and gene disruption techniques in the study of neurocarcinogenesis. Aguzzi A, et al. **Glia** 1995 Nov; 15(3):348–64 (151 ref.)

PATHOLOGY

Genetic markers and animal models of neurocristopathy. Nakamura T. **Histol Histopathol** 1995 Jul;10(3):747–59 (155 ref.)

SURGERY

[Tumor of the gastrointestinal autonomic nervous system (GAN-tumor or plexus sarcoma)] Flückiger R, et al. **Chirurg** 1996 Apr;67(4):371–9 (20 ref.) (Eng. Abstr.) **(Ger)**

NESIDIOBLASTOMA see **ADENOMA, ISLET CELL**

NESIDIOBLASTOSIS see **PANCREATIC DISEASES**

NESIDIOBLASTS see **ISLETS OF LANGERHANS**

NESTED CASE-CONTROL STUDIES see **CASE-CONTROL STUDIES**

NESTED PCR see **POLYMERASE CHAIN REACTION**

NETWORK COMMUNICATION PROTOCOLS see **COMPUTER COMMUNICATION NETWORKS**

NEU PROTO-ONCOGENE PROTEINS see **PROTO-ONCOGENE PROTEINS C-ERBB-2**

NEU RECEPTORS see **PROTO-ONCOGENE PROTEINS C-ERBB-2**

NEURAL ANALYZERS

ANATOMY & HISTOLOGY

Anatomical substrates for early stages in cortical processing of visual information in the macaque monkey. Levitt JB, et al. **Behav Brain Res** 1996 Apr;76(1–2):5–19 (119 ref.)

On the specificity of neurons and visual areas. Schiller PH. **Behav Brain Res** 1996 Apr;76(1–2):21–35 (83 ref.)

PHYSIOLOGY

On the specificity of neurons and visual areas. Schiller PH. **Behav Brain Res** 1996 Apr;76(1–2):21–35 (83 ref.)

[The epiphysis in the visual analyzer system] Arushanian EB, et al. **Usp Fiziol Nauk** 1995 Jul–Sep;26(3):25–40 (98 ref.) (Eng. Abstr.) **(Rus)**

NEURAL CELL ADHESION MOLECULE see **NCAM**

NEURAL CONDUCTION

see related
NEURAL INHIBITION

[Conduction blocks and peripheral neuropathies] Kuntzer T, et al. **Rev Neurol (Paris)** 1995 Jun–Jul;151(6–7):368–82 (163 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Developmental neurotransmitters. Signals for shaping neuronal circuitry. Redburn DA, et al. **Invest Ophthalmol Vis Sci** 1996 Jul;37(8):1479–82 (16 ref.)

Nitric oxide synthase and the lower urinary tract: possible implications for physiology and pathophysiology. Andersson KE, et al. **Scand J Urol Nephrol Suppl** 1995; 175:43–53 (102 ref.)

NEURAL CREST

CYTOLOGY

Manipulations of neural crest cells or their migratory pathways. Bronner-Fraser M. **Methods Cell Biol** 1996; 51:61–79 (17 ref.)

EMBRYOLOGY

Epithelium–mesenchyme transition during neural crest development. Duband JL, et al. **Acta Anat (Basel)** 1995; 154(1):63–78 (107 ref.)

Visual understanding of cardiac development: the neural crest's contribution. Leatherbury L, et al. **Cell Mol Biol Res** 1995;41(4):279–91 (27 ref.)

The genesis of avian neural crest cells: a classic embryonic induction. Selleck MA, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9352–7 (67 ref.)

Origin of the avian neural crest. Bronner-Fraser M. **Stem Cells (Dayt)** 1995 Nov;13(6):640–6 (22 ref.)

GROWTH & DEVELOPMENT

Patterning of the vertebrate neural crest. Bronner-Fraser M. **Perspect Dev Neurobiol** 1995;3(1):53–62 (47 ref.)

The role of neurotrophins in development of neural-crest cells that become sensory ganglia. Kalcheim C. **Philos Trans R Soc Lond B Biol Sci** 1996 Mar 29; 351(1338):375–81 (45 ref.)

PATHOLOGY

Genetic markers and animal models of neurocristopathy. Nakamura T. **Histol Histopathol** 1995 Jul;10(3):747–59 (155 ref.)

PHYSIOLOGY

Neural crest development. Do developing enteric neurons need endothelins? Gershon MD. **Curr Biol** 1995 Jun 1; 5(6):601–4 (23 ref.)

Role of environmental signals and transcriptional regulators in neural crest development. Groves AK, et al. **Dev Genet** 1996;18(1):64–72 (82 ref.)

NEURAL INHIBITION

[Conduction blocks and peripheral neuropathies] Kuntzer T, et al. **Rev Neurol (Paris)** 1995 Jun–Jul;151(6–7):368–82 (163 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

The role of Notch in lateral inhibition and cell fate specification. Chitnis AB. **Mol Cell Neurosci** 1995 Aug; 6(4):311–21 (70 ref.)

Endogenous control of epilepsy: the nigral inhibitory system. Depaulis A, et al. **Prog Neurobiol** 1994 Jan;42(1):33–52 (186 ref.)

Long-term depression: a learning-related type of synaptic plasticity in the mammalian central nervous system. Zhuo M, et al. **Rev Neurosci** 1995 Jul–Sep;6(3):259–77 (142 ref.)

[The participation of enteral mechanisms in the sympathetic-adrenal inhibition of gastric secretion] Trefilov AB. **Usp Fiziol Nauk** 1995 Jan–Mar;26(1):76–92 (79 ref.) (Eng. Abstr.) **(Rus)**

[Exteroceptive suppression of voluntary muscular activity: a new method of studying central nociceptive mechanisms] Danilov AB, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995;95(3):90–5 (59 ref.) **(Rus)**

[The simultaneous activation of excitatory and inhibitory inputs as a condition for the induction of homo-, hetero- and associative long-term excitation depression] Sil'kis IG. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1995 Nov–Dec; 45(6):1151–66 (58 ref.) (Eng. Abstr.) **(Rus)**

NEURAL INTERCONNECTIONS see **NEURAL PATHWAYS**

NEURAL NETWORK MODELS see **NEURAL NETWORKS (COMPUTER)**

NEURAL NETWORKS (ANATOMIC) see **NERVE NET**

NEURAL NETWORKS (COMPUTER)

Neuromedical Systems, Inc. Mango LJ. **Acta Cytol** 1996 Jan–Feb;40(1):53–9 (25 ref.)

Artificial neural networks for decision support in clinical medicine. Forsström JJ, et al. **Ann Med** 1995 Oct; 27(5):509–17 (72 ref.)

Analogical transfer in sequence learning. Human and neural-network models of frontostriatal function. Dominey PF, et al. **Ann N Y Acad Sci** 1995 Dec 15;769:369–73 (5 ref.)

The backpropagation neural network—a Bayesian classifier. Introduction and applicability to pharmacokinetics. Erb RJ. **Clin Pharmacokinet** 1995 Aug;29(2):69–79 (50 ref.)

Knowledge-based systems, artificial neural networks and pattern recognition: applications to biotechnological processes. Kamimura R, et al. **Curr Opin Biotechnol** 1996 Apr;7(2):231–4 (18 ref.)

Simulation of spatial learning in the Morris water maze by a neural network model of the hippocampal formation and nucleus accumbens. Brown MA, et al. **Hippocampus** 1995; 5(3):171–88 (73 ref.)

Artificial neural networks: current status in cardiovascular medicine. Itchhaporia D, et al. **J Am Coll Cardiol** 1996 Aug;28(2):515–21 (39 ref.)

What do connectionism and social psychology offer each other? Smith ER. **J Pers Soc Psychol** 1996 May; 70(5):893–912 (132 ref.)

Artificial neural networks: a prospective tool for the analysis of psychiatric disorders. Galletly CA, et al. **J Psychiatry Neurosci** 1996 Jul;21(4):239–47 (45 ref.)

Application of artificial neural networks to clinical medicine [see comments] Baxt WG. **Lancet** 1995 Oct 28; 346(8983):1135–8 (61 ref.) Comment in: Lancet 1995 Dec 2;346(8988):1501. Comment in: Lancet 1995 Dec 23–30;346(8991–8992):1712.

Artificial neural networks in pathology and medical laboratories [see comments] Dybowski R, et al. **Lancet** 1995 Nov 4;346(8984):1203–7 (34 ref.) Comment in: Lancet 1995 Nov 4;346(8984):1175–7. Comment in: Lancet 1995 Dec 23–30;346(8991–8992):1712.

Hints. Abu-Mostafa YS. **Neural Comput** 1995 Jul;7(4):639–71 (34 ref.)

Methods for combining experts' probability assessments. Jacobs RA. **Neural Comput** 1995 Sep;7(5):867–88 (51 ref.)

Consciousness: perspectives from symbolic and connectionist AI. Bechtel W. **Neuropsychologia** 1995 Sep;33(9):1075–86 (37 ref.)

Applications of neural networks in histopathology. Becker RL JR. **Pathologica** 1995 Jun;87(3):246–54 (82 ref.)

Clinical applications of Bayesian belief networks in pathology. Hamilton PW, et al. **Pathologica** 1995 Jun; 87(3):237–45 (11 ref.)

Cognitive dissonance reduction as constraint satisfaction. Shultz TR, et al. **Psychol Rev** 1996 Apr;103(2):219–40 (64 ref.)

Implementation of the three-dimensional-pattern search problem on Hopfield-like neural networks. Feuilleaubois E, et al. **SAR QSAR Environ Res** 1993;1(2–3):97–114 (29 ref.)

Neural networks that co-ordinate locomotion and body orientation in lamprey. Grillner S, et al. **Trends Neurosci** 1995 Jun;18(6):270–9 (64 ref.)

NEURAL PATHWAYS

ANATOMY & HISTOLOGY

Two distinct descending inputs to the cricothyroid motoneuron in the medulla originating from the amygdala and the lateral hypothalamic area. Arita H, et al. **Adv Exp Med Biol** 1995;393:53–8 (10 ref.)

Identifiable Achatina giant neurones: their localizations in ganglia, axonal pathways and pharmacological features. Takeuchi H, et al. **Gen Pharmacol** 1996 Jan;27(1):3–32 (220 ref.)

PY in the fly receptor-like tyrosine phosphatases in axonal pathfinding. Chien CB. **Neuron** 1996 Jun;16(6):1065–8 (17 ref.)

Neuronal chain gangs: homotypic contacts support migration into the olfactory bulb. O'Rourke NA. **Neuron** 1996 Jun; 16(6):1061–4 (15 ref.)

[Descending pathways of the basal ganglia] Takada M. **Kaibogaku Zasshi** 1995 Aug;70(4):289–93 (10 ref.) **(Jpn)**

DRUG EFFECTS

Identifiable Achatina giant neurones: their localizations in ganglia, axonal pathways and pharmacological features. Takeuchi H, et al. **Gen Pharmacol** 1996 Jan;27(1):3–32 (220 ref.)

PHYSIOLOGY

Long-term potentiation and long-term depression of horizontal connections in rat motor cortex. Hess G, et al. **Acta Neurobiol Exp (Warsz)** 1996;56(1):397–405 (32 ref.)

Two distinct descending inputs to the cricothyroid motoneuron in the medulla originating from the amygdala and the lateral hypothalamic area. Arita H, et al. **Adv Exp Med Biol** 1995;393:53–8 (10 ref.)

Some spinal mechanisms of negative motor phenomena in humans. Ashby P. **Adv Neurol** 1995;67:305–20 (60 ref.)

Neuroanatomical and neurophysiological bases of postural control. Mori S, et al. **Adv Neurol** 1995;67:289–303 (59 ref.)

Anatomy and neurotransmitters of brainstem motor systems. Newman DB. **Adv Neurol** 1995;67:219–44 (138 ref.)

New model for the regulation of energy balance and adiposity by the central nervous system. Kaiyala KJ, et al. **Am J Clin Nutr** 1995 Nov;62(5 Suppl):1123S–1134S (130 ref.)

Molecular mechanisms and neural pathways mediating the influence of interleukin-1 on the activity of neuroendocrine CRF motoneurons in the rat. Rivest S. **Int J Dev Neurosci** 1995 Jun–Jul;13(3–4):135–46 (96 ref.)

Anatomical evidence concerning the role of the thalamus in corticocortical communication: a brief review. Guillery RW. **J Anat** 1995 Dec;187 (Pt 3):583–92 (69 ref.)

Bulbospinal catecholamine neurones and sympathetic pattern generation. Coote JH, et al. **J Physiol Pharmacol** 1995 Sep; 46(3):259–71 (50 ref.)

NEURAL PATHWAYS

The concept of trophic units in the central nervous system. Agnati LF, et al. **Prog Neurobiol** 1995 Aug;46(6):561–74 (140 ref.)
Development and plasticity of cortical processing architectures. Singer W. **Science** 1995 Nov 3; 270(5237):758–64 (66 ref.)

NEURAL TRANSMISSION see **SYNAPTIC TRANSMISSION**

NEURAL TUBE DEFECTS

Orthopedic aspects of myelodysplasia in children. Locke MD, et al. **Curr Opin Pediatr** 1996 Feb;8(1):65–7 (15 ref.)

BLOOD

Blood folic acid and vitamin B12 in relation to neural tube defects. Wald NJ, et al. **Br J Obstet Gynaecol** 1996 Apr; 103(4):319–24 (16 ref.)

CHEMICALLY INDUCED

Role of arsenic as a reproductive toxin with particular attention to neural tube defects. Shalat SL, et al. **J Toxicol Environ Health** 1996 Jun 28;48(3):253–72 (130 ref.)

DIAGNOSIS

MRI and radiographic findings in Currarino's triad. Pfluger T, et al. **Pediatr Radiol** 1996;26(8):524–7 (21 ref.)

ETIOLOGY

Nutritional ecogenetics: homocysteine-related arteriosclerotic vascular disease, neural tube defects, and folic acid [editorial; comment] Motulsky AG. **Am J Hum Genet** 1996 Jan;58(1):17–20 (28 ref.) Comment on: Am J Hum Genet 1996 Jan;58(1):35–41.
Looking for causes of neural tube defects: where does the environment fit in? Sever LE. **Environ Health Perspect** 1995 Sep;103 Suppl 6:165–71 (57 ref.)
Folate metabolism and neural tube defects: a review. Steegers-Theunissen RP. **Eur J Obstet Gynecol Reprod Biol** 1995 Jul;61(1):39–48 (65 ref.)
Homocysteine and neural tube defects. Mills JL, et al. **J Nutr** 1996 Mar;126(3):756S–760S (28 ref.)
Is an elevated circulating maternal homocysteine concentration a risk factor for neural tube defects? Ubbink JB. **Nutr Rev** 1995 Jun;53(6):173–5 (14 ref.)

METABOLISM

Folate metabolism and neural tube defects. Gordon N. **Brain Dev** 1995 Sep–Oct;17(5):307–11 (44 ref.)

PREVENTION & CONTROL

Folic acid and the prevention of neural tube defects: the need for public health action. Wald NJ. **Bibl Nutr Dieta** 1995; (52):56–65 (14 ref.)
Periconceptional folic acid and neural tube defects: public health issues. Pérez-Escamilla R. **Bull Pan Am Health Organ** 1995 Sep;29(3):250–63 (70 ref.)
Vitamin B12 deficiency and the fortification of food with folic acid. Bower C, et al. **Eur J Clin Nutr** 1995 Nov; 49(11):787–93 (34 ref.)
Periconceptional vitamin supplementation to prevent neural tube defects: how can we do it? Mills JL, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Jul;61(1):49–55 (21 ref.)
Periconceptional folate intake and neural tube defects. Rayburn WF, et al. **J Am Coll Nutr** 1996 Apr;15(2):121–5 (32 ref.)
What practitioners need to know about folic acid. Hine RJ. **J Am Diet Assoc** 1996 May;96(5):451–2 (15 ref.)
Fortification of the food supply with folic acid to prevent neural tube defects is not yet warranted. Gaull GE, et al. **J Nutr** 1996 Mar;126(3):773S–780S (48 ref.)
Folate and neural tube defects. Bower C. **Nutr Rev** 1995 Sep;53(9 Pt 2):S33–8 (39 ref.)
Periconceptional folic acid supplementation as a social intervention. Rose NC, et al. **Semin Perinatol** 1995 Aug; 19(4):243–54 (61 ref.)
[Prevention of neural tube defects by preconception administration of folic acid. Presentation of the current status of research] Hages M, et al. **Geburtshilfe Frauenheilkd** 1996 May;56(5):M59–65 (57 ref.) **(Ger)**
[Folic acid in the prevention of neural tube defects] Tönz O, et al. **Schweiz Med Wochenschr** 1996 Feb 3;126(5):177–87 (60 ref.) (Eng. Abstr.) **(Ger)**

NEURALGIA

COMPLICATIONS

[Neuralgic shoulder amyotrophy] Cranovsky C. **Schweiz Med Wochenschr** 1996 Jan 27;126(4):111–9 (40 ref.) (Eng. Abstr.) **(Ger)**

DIAGNOSIS

Occipital neuralgia manifesting as orofacial pain. Sulfaro MA, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1995 Dec;80(6):751–5 (22 ref.)

DRUG THERAPY

Topical capsaicin. A review of its pharmacological properties and therapeutic potential in post-herpetic neuralgia, diabetic neuropathy and osteoarthritis. Rains C, et al. **Drugs Aging** 1995 Oct;7(4):317–28 (52 ref.)
Neuropathic pain of peripheral origin: advances in pharmacologic treatment. Galer BS. **Neurology** 1995 Dec; 45(12 Suppl 9):S17–25; discussion S35–6 (53 ref.)
The treatment of postherpetic neuralgia. Watson CP. **Neurology** 1995 Dec;45(12 Suppl 8):S58–60 (15 ref.)

ETIOLOGY

Neuralgia-like symptoms in a patient with an airgun pellet in the ethmoid sinus: a case report. Donald PJ, et al. **J Laryngol Otol** 1995 Jul;109(7):646–9 (19 ref.)

PHYSIOPATHOLOGY

Pathophysiology of postherpetic neuralgia: towards a rational treatment. Bowsher D. **Neurology** 1995 Dec;45(12 Suppl 8):S56–7 (12 ref.)
Clinical features and pathophysiologic mechanisms of postherpetic neuralgia. Nurmikko T. **Neurology** 1995 Dec; 45(12 Suppl 8):S54–5 (19 ref.)
Opioid receptors in the superficial layers of the rat spinal cord: functional implications in pain processing. Lombard MC, et al. **Prog Brain Res** 1995;104:77–92 (79 ref.)

PREVENTION & CONTROL

Does sympathetic ganglionic block prevent postherpetic neuralgia? Literature review. Ali NM. **Reg Anesth** 1995 May–Jun;20(3):227–33 (44 ref.)

THERAPY

Postherpetic neuralgia--pathogenesis, treatment, and prevention. Kost RG, et al. **N Engl J Med** 1996 Jul 4; 335(1):32–42 (110 ref.)

NEURALGIA, GENICULATE see **HERPES ZOSTER OTICUS**

NEURAMINIC ACIDS

BLOOD

[Neuraminic acid] Murata K. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:571–4 (12 ref.) **(Jpn)**

NEURAMINIDASE

CHEMISTRY

Interactions of protein antigens with antibodies. Davies DR, et al. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):7–12 (69 ref.)

DEFICIENCY

[Galactosialidosis--protective protein and related enzymes] Hirasawa M. **Nippon Rinsho** 1995 Dec;53(12):2967–72 (22 ref.) (Eng. Abstr.) **(Jpn)**
[Sialidosis type II, infantile form. Apropos a case] Menau Martín G, et al. **An Esp Pediatr** 1996 Jan;44(1):76–8 (8 ref.) **(Spa)**

NEURASTHENIA

see related
FATIGUE SYNDROME, CHRONIC

NEURENTERIC CYST see **SPINA BIFIDA OCCULTA**

NEURILEMMOMA

Neurinoma of the trigeminal root and atypical trigeminal neuralgia: case report and review of the literature. Tancioni F, et al. **Surg Neurol** 1995 Jul;44(1):36–42 (29 ref.)
[Neurofibroma of the liver, schwannoma of the liver] Nakajima M. **Ryoikibetsu Shokogun Shirizu** 1995;(7):381–3 (14 ref.) **(Jpn)**

COMPLICATIONS

Hypophosphatemic osteomalacia with plantar neurilemoma. A review of the literature (100 cases). Crouzet J, et al. **Rev Rhum Engl Ed** 1995 Jun;62(6):463–6 (34 ref.)
[Mediastinal malignant schwannoma disclosed by pericardial tamponade in von Recklinghausen disease] Soulami S, et al. **Ann Cardiol Angiol (Paris)** 1995 Oct;44(8):418–21 (11 ref.) (Eng. Abstr.) **(Fre)**
[Giant schwannoma in the pelvic cavity presenting as renal failure: a case report] Gotoh T, et al. **Hinyokika Kiyo** 1995 Aug;41(8):621–4 (10 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

A case report of rectal schwannoma. Murakami N, et al. **Kurume Med J** 1996;43(1):101–6 (12 ref.)
Benign schwannoma of the liver: a case report. Yoshida M, et al. **Nippon Geka Hokan** 1994 Nov 1;63(6):208–14 (13 ref.)
Neurilemoma of the kidney. Singer AJ, et al. **Urology** 1996 Apr;47(4):575–81 (18 ref.)
[Benign schwannoma of the celiac tripod simulating a pancreatic neoplasm] Cedolini C, et al. **Minerva Chir** 1996 Jan–Feb;51(1–2):47–9 (15 ref.) (Eng. Abstr.) **(Ita)**

GENETICS

[A new tumor suppressor gene responsible for type 2 neurofibromatosis is inactivated in neurinoma and meningioma] Sanson M. **Rev Neurol (Paris)** 1996 Jan; 152(1):1–10 (74 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Schwann cell tumors express characteristic patterns of CD44 splice variants. Sherman L, et al. **J Neurooncol** 1995 Dec; 26(3):171–84 (57 ref.)

PATHOLOGY

Multiple cutaneous plexiform schwannomas. Report of a case and review of the literature with particular reference to the association with types 1 and 2 neurofibromatosis and schwannomatosis. Reith JD, et al. **Arch Pathol Lab Med** 1996 Apr;120(4):399–401 (22 ref.)
Postradiation malignant triton tumor. A case report and review of the literature. Yakulis R, et al. **Arch Pathol Lab Med** 1996 Jun;120(6):541–8 (59 ref.)
Primary diaphragmatic schwannoma with a typical target appearance: correlation of CT and MR imagings and histologic findings. Koyama S, et al. **J Gastroenterol** 1996 Apr;31(2):268–72 (11 ref.)
Schwannoma of the posterior pharyngeal wall: a case report. Haraguchi H, et al. **J Laryngol Otol** 1996 Feb;110(2):170–1 (3 ref.)
Schwannoma of the larynx: a case report. Ingels K, et al. **J Laryngol Otol** 1996 Mar;110(3):294–6 (12 ref.)
Ancient schwannoma of the oral floor and ventricular portion of the tongue: a case report and review of the literature. Nakayama H, et al. **Jpn J Clin Oncol** 1996 Jun;26(3):185–8 (15 ref.)
Purely epithelioid schwannoma. Two case reports and a review of the literature. Artico M, et al. **Neurochirurgie** 1996;42(1):61–5 (20 ref.)
Schwannoma of the breast. Gultekin SH, et al. **South Med J** 1996 Feb;89(2):238–9 (18 ref.)
[A case of schwannoma in the transverse colon] Hoshi S. **Nippon Shokakibyo Gakkai Zasshi** 1995 Sep;92(9):1289–92 (10 ref.) **(Jpn)**

RADIOGRAPHY

Intraosseous neurilemmoma of the lower third of the fibula [letter] Chevalier X, et al. **AJR Am J Roentgenol** 1995 Dec; 165(6):1555–6 (4 ref.)
Primary diaphragmatic schwannoma with a typical target appearance: correlation of CT and MR imagings and histologic findings. Koyama S, et al. **J Gastroenterol** 1996 Apr;31(2):268–72 (11 ref.)

SURGERY

Vestibular schwannoma and the only hearing ear. Bhatia S, et al. **J Laryngol Otol** 1996 Apr;110(4):366–9 (18 ref.)
[Malignant triton tumor of the posterior mediastinum treated by thoracoscopic approach. Apropos of a case] Pons F, et al. **Rev Pneumol Clin** 1995;51(6):338–42 (29 ref.) (Eng. Abstr.) **(Fre)**
[Mediastinal schwannoma originating from the intrathoracic vagal nerve--a case report and review of the literature] Ohtaki A, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Sep;43(9):1675–9 (19 ref.) (Eng. Abstr.) **(Jpn)**
[A case of bronchial neurinoma] Yodonawa S, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Jun;44(6):820–5 (18 ref.) (Eng. Abstr.) **(Jpn)**

NEURILEMMOMA, ACOUSTIC see **NEUROMA, ACOUSTIC**

NEURINOMA see **NEURILEMMOMA**

NEURINOMA, ACOUSTIC see **NEUROMA, ACOUSTIC**

NEURITE OUTGROWTH FACTOR see **NERVE GROWTH FACTORS**

NEURITES

see related
NERVE GROWTH FACTORS

DRUG EFFECTS

Comparison of neurite outgrowth with neurofilament protein subunit levels in neuroblastoma cells following mercuric oxide exposure. Abdulla EM, et al. **Clin Exp Pharmacol Physiol** 1995 May;22(5):362–3 (5 ref.)
Mechanisms of estrogen action during neural development: mediation by interactions with the neurotrophins and their receptors? Toran-Allerand CD. **J Steroid Biochem Mol Biol** 1996 Jan;56(1–6 Spec No):169–78 (77 ref.)

PHYSIOLOGY

The economics of neurite outgrowth--the addition of new membrane to growing axons. Futerman AH, et al. **Trends Neurosci** 1996 Apr;19(4):144-9 (55 ref.)

The Rho's progress: a potential role during neuritogenesis for the Rho family of GTPases. Mackay DJ, et al. **Trends Neurosci** 1995 Nov;18(11):496-501 (43 ref.)

NEURITIS

COMPLICATIONS

T-cell-mediated ganglionitis associated with acute sensory neuronopathy. Hainfellner JA, et al. **Ann Neurol** 1996 Apr; 39(4):543-7 (20 ref.)

DRUG THERAPY

Mononeuritis multiplex in systemic lupus erythematosus: response to pulse intravenous cyclophosphamide. Martinez-Taboada VM, et al. **Lupus** 1996 Feb;5(1):74-6 (21 ref.)

ETIOLOGY

Mononeuritis multiplex in systemic lupus erythematosus: response to pulse intravenous cyclophosphamide. Martinez-Taboada VM, et al. **Lupus** 1996 Feb;5(1):74-6 (21 ref.)

NEURITIS, EXPERIMENTAL ALLERGIC

see related
MYELIN P2 PROTEIN

NEUROANATOMY

METHODS

Handling of large brain specimens: the use of microwaves. A review. Marani E, et al. **Eur J Morphol** 1995 Apr; 33(2):158-64 (33 ref.)

NEUROBIOLOGY

Possible strategies for treatment of SMA patients: a neurobiologist's view. Greensmith L, et al. **Neuromuscul Disord** 1995 Sep;5(5):359-69 (85 ref.)

METHODS

Molecular biology of CNS injury. Yakovlev AG, et al. **J Neurotrauma** 1995 Oct;12(5):767-77 (83 ref.)

NEUROBLASTOMA

Paediatric surgical oncology. 6--Neuroblastoma. Powis MR, et al. **Eur J Surg Oncol** 1995 Dec;21(6):669-78 (57 ref.)

Long-term survival in refractory recurrent neuroblastoma. Pierce ST. **J Pediatr Hematol Oncol** 1996 May;18(2):202-5 (34 ref.)

Neuroblastoma and brain tumors in childhood. Ater JL. **Pediatr Dent** 1995 Jul-Aug;17(4):268-72 (19 ref.)

[Neurofibroma of the liver, schwannoma of the liver] Nakajima M. **Ryoikibetsu Shokogun Shirizu** 1995;(7):381-3 (14 ref.) **(Jpn)**

COMPLICATIONS

Neuroblastoma and congenital cardiovascular malformations. Rosti L, et al. **Pediatrics** 1996 Feb;97(2):258-61 (24 ref.)

CONGENITAL

Monozygotic twins concordant for congenital neuroblastoma: case report and review of the literature. Boyd TK, et al. **Pediatr Pathol Lab Med** 1995 Nov-Dec; 15(6):931-40 (16 ref.)

Neuroblastoma and congenital cardiovascular malformations. Rosti L, et al. **Pediatrics** 1996 Feb;97(2):258-61 (24 ref.)

DIAGNOSIS

Neuroblastoma presenting as acute monoblastic leukemia. Boyd JE, et al. **J Pediatr Hematol Oncol** 1996 May; 18(2):206-12 (37 ref.)

Neuroblastoma. Humpl T. **World J Urol** 1995;13(4):233-9 (16 ref.)

GENETICS

Neuroblastoma in a boy with MCA/MR syndrome, deletion 11q, and duplication 12q. Koiffmann CP, et al. **Am J Med Genet** 1995 Jul 31;58(1):46-9 (18 ref.)

Genetics of embryonal tumours of childhood: retinoblastoma, Wilms' tumour and neuroblastoma. Brodeur GM. **Cancer Surv** 1995;25:67-99 (209 ref.)

Genetic alterations associated with metastatic dissemination and chemoresistance in neuroblastoma. Bénard J. **Eur J Cancer** 1995;31A(4):560-4 (59 ref.)

Molecular basis for heterogeneity in human neuroblastomas. Brodeur GM. **Eur J Cancer** 1995;31A(4):505-10 (90 ref.)

Gene expression and neuroblastoma cell differentiation in response to retinoic acid: differential effects of 9-cis and all-trans retinoic acid. Redfern CP, et al. **Eur J Cancer** 1995;31A(4):486-94 (73 ref.)

1p36: every subband a suppressor? Versteeg R, et al. **Eur J Cancer** 1995;31A(4):538-41 (27 ref.)

The mycN/max protein complex in neuroblastoma. Short review. Wenzel A, et al. **Eur J Cancer** 1995;31A(4):516-9 (40 ref.)

The molecular pathology of small round-cell tumours--relevance to diagnosis, prognosis, and classification. McManus AP, et al. **J Pathol** 1996 Feb; 178(2):116-21 (80 ref.)

Genetic clinical markers of human neuroblastoma with special reference to N-myc oncogene: amplified or not amplified?--An overview. Tsuchida Y, et al. **Tumour Biol** 1996;17(2):65-74 (78 ref.)

[Identification of the breakpoint-flanking markers on chromosomes 1 and 17 of a constitutional translocation T(1;17)(P36;Q12-21) in a patient with neuroblastoma] Laureys GG. **Verh K Acad Geneeskd Belg** 1995; 57(5):389-422 (65 ref.) (Eng. Abstr.) **(Dut)**

[Familial neuroblastoma] Nakamura M, et al. **Nippon Rinsho** 1995 Nov;53(11):2684-7 (12 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Differentiation and prognosis of neuroblastoma in correlation to the expression of CD44s. Terpe HJ, et al. **Eur J Cancer** 1995;31A(4):549-52 (60 ref.)

METABOLISM

Differentiation and survival influences of growth factors in human neuroblastoma. Påhlman S, et al. **Eur J Cancer** 1995; 31A(4):453-8 (49 ref.)

The use of the human neuroblastoma SH-SY5Y to study the effect of second messengers on noradrenaline release. Vaughan PF, et al. **Gen Pharmacol** 1995 Oct;26(6):1191-201 (62 ref.)

Neuropeptides in neuroblastomas and ganglioneuromas. Kogner P. **Prog Brain Res** 1995;104:325-38 (99 ref.)

PATHOLOGY

Schwann cells in neuroblastoma. Ambros IM, et al. **Eur J Cancer** 1995;31A(4):429-34 (80 ref.)

Two cases of pheochromocytoma diagnosed histopathologically as mixed neuroendocrine-neural tumor. Watanabe T, et al. **Intern Med** 1995 Jul;34(7):683-7 (47 ref.)

International neuroblastoma staging system stage 1 neuroblastoma: a prospective study and literature review. Kushner BH, et al. **J Clin Oncol** 1996 Jul;14(7):2174-80 (55 ref.)

Monozygotic twins concordant for congenital neuroblastoma: case report and review of the literature. Boyd TK, et al. **Pediatr Pathol Lab Med** 1995 Nov-Dec; 15(6):931-40 (16 ref.)

Genetic clinical markers of human neuroblastoma with special reference to N-myc oncogene: amplified or not amplified?--An overview. Tsuchida Y, et al. **Tumour Biol** 1996;17(2):65-74 (78 ref.)

PHYSIOPATHOLOGY

Overexpression of choline acetyltransferase reconstitutes discrete acetylcholine release in some but not all synapse formation-defective neuroblastoma cells. Zhong ZG, et al. **J Physiol Paris** 1995;89(3):137-45 (40 ref.)

PREVENTION & CONTROL

Neuroblastoma mass screening: the arguments for and against. Treuner J, et al. **Eur J Cancer** 1995;31A(4):565-8 (18 ref.)

Screening for neuroblastoma: a review of the evidence [see comments] Chamberlain J. **J Med Screen** 1994 Jul; 1(3):169-75 (37 ref.) Comment in: J Med Screen 1994 Jul;1(3):141-2.

RADIOTHERAPY

Radiolabelled mIBG in the treatment of neuroblastoma. Gaze MN, et al. **Eur J Cancer** 1996 Jan;32A(1):93-6 (33 ref.)

SURGERY

Autotransplants for neuroblastoma [editorial] Kamani NR. **Bone Marrow Transplant** 1996 Mar;17(3):301-4 (27 ref.)

Cystic neuroblastoma of infancy. Richards ML, et al. **J Pediatr Surg** 1995 Sep;30(9):1354-7 (16 ref.)

[Malignant tumors in infancy and childhood] Daum R. **Chirurg** 1996 Jun;67(6):584-92 (18 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Clinical strategies for the treatment of neuroblastoma. Niethammer D, et al. **Eur J Cancer** 1995;31A(4):568-71 (38 ref.)

[Prognostic factors in neuroblastoma in children] Izbicki T, et al. **Pediatr Pol** 1995 Nov;70(11):949-53 (0 ref.) (Eng. Abstr.) **(Pol)**

NEUROBLASTOMA, OLFACTORY see **ESTHESIONEUROBLASTOMA**

NEUROCIRCULATORY ASTHENIA

DIAGNOSIS

[The psychosomatics and psychotherapy of the cardiac anxiety syndrome] Csef H. **Dtsch Med Wochenschr** 1996 Jun 7;121(23):771-6 (53 ref.) **(Ger)**

PHYSIOPATHOLOGY

An appraisal of Thomas Lewis's effort syndrome. Nixon PG. **QJM** 1995 Oct;88(10):741-7 (59 ref.)

PSYCHOLOGY

Psychological aspects of non-cardiac chest pain. Serlie AW, et al. **Psychother Psychosom** 1995;64(2):62-73 (57 ref.)

THERAPY

[The psychosomatics and psychotherapy of the cardiac anxiety syndrome] Csef H. **Dtsch Med Wochenschr** 1996 Jun 7;121(23):771-6 (53 ref.) **(Ger)**

NEUROCYTOMA

DIAGNOSIS

Intraventricular neurocytoma. Ng P, et al. **Australas Radiol** 1996 May;40(2):125-33 (27 ref.)

PATHOLOGY

Central neurocytoma: clinico-pathological study of 5 cases and review of the literature. Maiuri F, et al. **Clin Neurol Neurosurg** 1995 Aug;97(3):219-28 (39 ref.)

Intraventricular neurocytoma: a report of two cases. Radhakrishnan VV, et al. **Indian J Cancer** 1994 Sep; 31(3):198-202 (11 ref.)

SURGERY

Giant central neurocytoma with tetraventricular and extra-axial extension. Case report. Roche PH, et al. **Acta Neurochir (Wien)** 1995;133(1-2):95-100 (33 ref.)

NEURODERMATITIS, ATOPIC see **DERMATITIS, ATOPIC**

NEURODERMATITIS, DISSEMINATED see **DERMATITIS, ATOPIC**

NEUROECTODERMAL TUMOR, PERIPHERAL

DIAGNOSIS

Ewing's sarcoma and extracranial peripheral neuroectodermal tumors. Granowetter L. **Curr Opin Oncol** 1995 Jul;7(4):355-60 (43 ref.)

[A peripheral neuroectodermal tumor of the vulva] Paredes E, et al. **Acta Med Port** 1995 Mar;8(3):161-3 (17 ref.) (Eng. Abstr.) **(Por)**

NEUROECTODERMAL TUMOR, PRIMITIVE

PATHOLOGY

Primitive neuroectodermal tumour of the orbit: a case report. Bansal RK, et al. **Indian J Ophthalmol** 1995 Mar; 43(1):29-31 (10 ref.)

RADIOGRAPHY

Primitive neuroectodermal tumour of the chest wall (Askin tumour): CT and roentgenographic findings in a 51-year-old male. Miller JA, et al. **Respir Med** 1995 Nov; 89(10):705-8 (7 ref.)

NEUROECTODERMAL TUMORS

COMPLICATIONS

Hydrocephalus and shunts in children with brain tumors. Ryan JA, et al. **J Pediatr Oncol Nurs** 1995 Oct;12(4):223-9 (19 ref.)

DIAGNOSIS

Pediatric brain tumors: diagnosis and management. Shiminski-Maher T, et al. **J Pediatr Oncol Nurs** 1995 Oct; 12(4):188-98; quiz 199-202 (25 ref.)

THERAPY

Pediatric brain tumors: diagnosis and management. Shiminski-Maher T, et al. **J Pediatr Oncol Nurs** 1995 Oct; 12(4):188-98; quiz 199-202 (25 ref.)

NEUROENDOCRINE SYSTEM see **NEUROSECRETORY SYSTEMS**

NEUROENDOCRINE TUMORS

DIAGNOSIS

Radiopharmaceutical diagnosis and therapy of sympatho-medullary disorders. Shapiro B. **Ann Nucl Med** 1996 Feb;10(1):9-12 (34 ref.)

Imaging of gastrointestinal neuroendocrine tumors. Gorman B, et al. **Semin Ultrasound CT MR** 1995 Aug;16(4):331-41 (46 ref.)

[Imaging of endocrine tumors of the pancreas] Thérasse E, et al. **Ann Endocrinol (Paris)** 1995;56(5):509-10 (4 ref.) **(Fre)**

METABOLISM

Somatostatin receptors: clinical implications for endocrinology and oncology. Lamberts SW, et al. **Ciba Found Symp** 1995;190:222-36; discussion 236-9 (48 ref.)

PATHOLOGY

Neuroendocrine differentiation in prostatic malignancy. di Sant'Agnese PA, et al. **Cancer** 1996 Jul 15;78(2):357-61 (32 ref.)

Endocrine tumors of the small and large intestine. Solcia E, et al. **Pathol Res Pract** 1995 May;191(4):366-72 (56 ref.)

PHYSIOPATHOLOGY

Neuroendocrine disorders of the gut [see comments] Yee LF, et al. **West J Med** 1995 Nov;163(5):454-62 (45 ref.) Comment in: West J Med 1995 Nov;163(5):485-6.

RADIOGRAPHY

[Ossified bronchial neuroendocrine tumors: 3 cases] Debourdeau P, et al. **Rev Pneumol Clin** 1995;51(6):325-9 (27 ref.) (Eng. Abstr.) **(Fre)**

RADIONUCLIDE IMAGING

Somatostatin receptor imaging of neuroendocrine tumors with indium-111 pentetreotide (Octreoscan). Olsen JO, et al. **Semin Nucl Med** 1995 Jul;25(3):251-61 (25 ref.)

[Detection of endocrine tumors of the digestive tract. Value and limitations of scintigraphy of somatostatin receptors] Le Guludec D, et al. **Presse Med** 1996 Apr 20;25(14):677-82 (27 ref.) (Eng. Abstr.) **(Fre)**

RADIOTHERAPY

Radiopharmaceutical diagnosis and therapy of sympatho-medullary disorders. Shapiro B. **Ann Nucl Med** 1996 Feb;10(1):9-12 (34 ref.)

Therapy of neuroendocrine tumors with radiolabeled MIBG and somatostatin analogues. Wiseman GA, et al. **Semin Nucl Med** 1995 Jul;25(3):272-8 (39 ref.)

NEUROENDOCRINOLOGY

HISTORY

The history of neuropeptides 1. Klavdieva MM. **Front Neuroendocrinol** 1995 Oct;16(4):293-321 (176 ref.)

NEUROEPITHELIOMA

DIAGNOSIS

[Dysembryoplastic neuroepithelial tumor] Vajtai I, et al. **Orv Hetil** 1995 Nov 26;136(48):2623-7 (38 ref.) (Eng. Abstr.) **(Hun)**

NEUROFIBRILLARY TANGLES

see related
NEUROFILAMENT PROTEINS

METABOLISM

Phosphorylation of paired helical filament tau in Alzheimer's disease neurofibrillary lesions: focusing on phosphatases. Trojanowski JQ, et al. **FASEB J** 1995 Dec;9(15):1570-6 (77 ref.)

Hyperphosphorylation of tau in PHF. Morishima-Kawashima M, et al. **Neurobiol Aging** 1995 May-Jun;16(3):365-71; discussion 371-80 (56 ref.)

PATHOLOGY

Tau protein and the neurofibrillary pathology of Alzheimer's disease. Goedert M. **Ann N Y Acad Sci** 1996 Jan 17; 777:121-31 (26 ref.)

Neurofibrillary pathology and aluminum in Alzheimer's disease. Shin RW, et al. **Histol Histopathol** 1995 Oct; 10(4):969-78 (168 ref.)

Glial inclusions in CNS degenerative diseases. Chin SS, et al. **J Neuropathol Exp Neurol** 1996 May;55(5):499-508 (78 ref.)

Staging of Alzheimer's disease-related neurofibrillary changes. Braak H, et al. **Neurobiol Aging** 1995 May-Jun; 16(3):271-8; discussion 278-84 (45 ref.)

Degenerative and protective signaling mechanisms in the neurofibrillary pathology of AD. Mattson MP. **Neurobiol Aging** 1995 May-Jun;16(3):447-57; discussion 458-63 (99 ref.)

Relationship between plaques, tangles, and dystrophic processes in Alzheimer's disease. Trojanowski JQ, et al. **Neurobiol Aging** 1995 May-Jun;16(3):335-40; discussion 341-5 (47 ref.)

Alzheimer neurofibrillary lesions: molecular nature and potential roles of different components. Yen SH, et al. **Neurobiol Aging** 1995 May-Jun;16(3):381-7 (92 ref.)

[An autopsy case of "diffuse neurofibrillary tangles with calcification", multiple infarctions and hyaline arteriosclerosis] Arai T, et al. **No To Shinkei** 1996 Jan; 48(1):69-76 (26 ref.) (Eng. Abstr.) **(Jpn)**

NEUROFIBRILS

see related
AMYLOID BETA-PROTEIN

CHEMISTRY

Molecular dissection of the paired helical filament. Goedert M, et al. **Neurobiol Aging** 1995 May-Jun;16(3):325-34 (72 ref.)

On the structure of microtubules, tau, and paired helical filaments. Mandelkow E, et al. **Neurobiol Aging** 1995 May-Jun;16(3):347-54 (57 ref.)

METABOLISM

Hyperphosphorylation of tau in PHF. Morishima-Kawashima M, et al. **Neurobiol Aging** 1995 May-Jun;16(3):365-71; discussion 371-80 (56 ref.)

PATHOLOGY

Molecular mechanism of Alzheimer's neurofibrillary degeneration and therapeutic intervention. Iqbal K, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:132-8 (22 ref.)

ULTRASTRUCTURE

Molecular dissection of the paired helical filament. Goedert M, et al. **Neurobiol Aging** 1995 May-Jun;16(3):325-34 (72 ref.)

On the structure of microtubules, tau, and paired helical filaments. Mandelkow E, et al. **Neurobiol Aging** 1995 May-Jun;16(3):347-54 (57 ref.)

NEUROFIBROMA

DIAGNOSIS

Giant neurofibroma of the tongue. Sahota JS, et al. **Int J Pediatr Otorhinolaryngol** 1996 Jan;34(1-2):153-7 (10 ref.)

PATHOLOGY

Bilateral ventricular neurofibroma of the larynx. Koc C, et al. **J Laryngol Otol** 1996 Apr;110(4):385-6 (18 ref.)

SURGERY

Laser vestibulectomy for endolaryngeal neurofibroma. Hisa Y, et al. **Otolaryngol Head Neck Surg** 1995 Oct; 113(4):459-61 (19 ref.)

NEUROFIBROMA, PLEXIFORM

DIAGNOSIS

Diffuse ganglioneuromatosis with plexiform neurofibromas limited to the gastrointestinal tract involving a large segment of small intestine. Hirata K, et al. **J Gastroenterol** 1996 Apr;31(2):263-7 (15 ref.)

EPIDEMIOLOGY

Laryngeal involvement in pediatric neurofibromatosis: a case report and review of the literature. Masip MJ, et al. **Pediatr Radiol** 1996 Jul;26(7):488-92 (22 ref.)

PATHOLOGY

Plexiform neurofibromatosis of the liver: case report and review of the literature. Ghalib R, et al. **Hepatology** 1995 Oct;22(4 Pt 1):1154-7 (25 ref.)

NEUROFIBROMATOSIS

Neurofibromatosis. Goldberg NS. **Adv Dermatol** 1996; 11:179-97; discussion 198 (60 ref.)

COMPLICATIONS

Clinical significance of neurofibromatosis in pregnancy. Hadi HA. **Am J Perinatol** 1995 Nov;12(6):459-61 (11 ref.)

[Neurofibromatosis (von Recklinghausen disease) and carcinoid tumor in Vater's ampulla] Simon L, et al. **Orv Hetil** 1995 Oct 15;136(42):2287-92 (34 ref.) (Eng. Abstr.) **(Hun)**

[Digestive hemorrhage in a patient with multiple neurofibromatosis] Vagni V, et al. **G Chir** 1995 Aug-Sep; 16(8-9):357-9 (14 ref.) (Eng. Abstr.) **(Ita)**

DIAGNOSIS

Neurofibromatosis with involvement of the prostate gland. Chung AK, et al. **Urology** 1996 Mar;47(3):448-51 (34 ref.)

GENETICS

Genetic and epigenetic mechanisms in the pathogenesis of neurofibromatosis type I. Metheny LJ, et al. **J Neuropathol Exp Neurol** 1995 Nov;54(6):753-60 (58 ref.)

PATHOLOGY

Multiple cutaneous plexiform schwannomas. Report of a case and review of the literature with particular reference to the association with types 1 and 2 neurofibromatosis and schwannomatosis. Reith JD, et al. **Arch Pathol Lab Med** 1996 Apr;120(4):399-401 (22 ref.)

Genetic and epigenetic mechanisms in the pathogenesis of neurofibromatosis type I. Metheny LJ, et al. **J Neuropathol Exp Neurol** 1995 Nov;54(6):753-60 (58 ref.)

RADIOGRAPHY

Radiographic features of the mandible in neurofibromatosis: a report of 10 cases and review of the literature. Lee L, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Mar;81(3):361-7 (37 ref.)

SURGERY

Neurofibromatosis of the skull base. Jackson IT. **Clin Plast Surg** 1995 Jul;22(3):513-30 (26 ref.)

NEUROFIBROMATOSIS 1

see related
GENES, NEUROFIBROMATOSIS 1

COMPLICATIONS

Case report: angiosarcoma in a patient with von Recklinghausen's disease. Png MA, et al. **Clin Radiol** 1996 Jul;51(7):521-3 (8 ref.)

Acute promyelocytic leukemia after treatment of malignant glioma in a patient with von Recklinghausen's disease: case report and review of the literature. Wiernik PH, et al. **Leukemia** 1996 Jan;10(1):178-82 (49 ref.)

Rapid growth of an optic nerve ganglioglioma in a patient with neurofibromatosis 1. Sadun F, et al. **Ophthalmology** 1996 May;103(5):794-9 (41 ref.)

[Mediastinal malignant schwannoma disclosed by pericardial tamponade in von Recklinghausen disease] Soulami S, et al. **Ann Cardiol Angeiol (Paris)** 1995 Oct;44(8):418-21 (11 ref.) (Eng. Abstr.) **(Fre)**

[Neurofibromatosis associated with multiple intracranial vascular lesions: stenosis of the internal carotid artery and peripheral aneurysm of the Heubner's artery; report of a case] Sasaki J, et al. **No Shinkei Geka** 1995 Sep;23(9):813-7 (22 ref.) (Eng. Abstr.) **(Jpn)**

[An intrathoracic meningocele in von Recklinghausen's disease. A case report] Fernández Guerra J, et al. **Arch Bronconeumol** 1995 Oct;31(8):418-20 (19 ref.) (Eng. Abstr.) **(Spa)**

[Neurofibromatosis type 1 (NF1): peculiarities and complications] Pascual-Castroviejo I. **Rev Neurol** 1996 Sep; 24(133):1051-5 (22 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

[Neurocutaneous disorders. Diagnostic criteria and follow-up protocols: introduction] Nieto M. **Rev Neurol** 1996 Sep;24(133):1049-50 (21 ref.) **(Spa)**

[Neurofibromatosis type 1 (NF1): peculiarities and complications] Pascual-Castroviejo I. **Rev Neurol** 1996 Sep; 24(133):1051-5 (22 ref.) (Eng. Abstr.) **(Spa)**

[Natural evolution of neurocutaneous syndrome in adults] Pou Serradell A. **Rev Neurol** 1996 Sep;24(133):1085-127 (104 ref.) (Eng. Abstr.) **(Spa)**

EPIDEMIOLOGY

Laryngeal involvement in pediatric neurofibromatosis: a case report and review of the literature. Masip MJ, et al. **Pediatr Radiol** 1996 Jul;26(7):488-92 (22 ref.)

GENETICS

[von Recklinghausen's disease and its pathogenesis] Sakai A, et al. **Nippon Rinsho** 1995 Nov;53(11):2688-90 (5 ref.) (Eng. Abstr.) **(Jpn)**

[Neurofibromatosis] Bauer MS. **Rev Neurol** 1995;23 Suppl 3:S322-4 (18 ref.) **(Spa)**

PATHOLOGY

Plexiform neurofibromatosis of the liver: case report and review of the literature. Ghalib R, et al. **Hepatology** 1995 Oct;22(4 Pt 1):1154-7 (25 ref.)

PHYSIOPATHOLOGY

[Natural evolution of neurocutaneous syndrome in adults] Pou Serradell A. **Rev Neurol** 1996 Sep;24(133):1085-127 (104 ref.) (Eng. Abstr.) **(Spa)**

SURGERY

Thoracic and lumbar meningocele in neurofibromatosis type 1. Report of two cases and review of the literature. Rainov

NG, et al. **Neurosurg Rev** 1995;18(2):127-34 (47 ref.)

THERAPY

The management of brainstem gliomas in patients with neurofibromatosis 1. Pollack IF, et al. **Neurology** 1996 Jun; 46(6):1652-60 (48 ref.)

NEUROFIBROMATOSIS 1 GENES see **GENES, NEUROFIBROMATOSIS 1**

NEUROFIBROMATOSIS 2

see related
GENES, NEUROFIBROMATOSIS 2

GENETICS

CNS Young Investigator Award Lecture: molecular analysis of the neurofibromatosis 2 tumor suppressor. MacCollin M. **Brain Dev** 1995 Jul-Aug;17(4):231-8 (64 ref.)

The neurofibromatosis 2 (NF2) tumour suppressor gene: implications beyond the hereditary tumour syndrome? Kley N, et al. **Cancer Surv** 1995;25:207-18 (45 ref.)

Neurofibromatosis type 2 and von Hippel-Lindau disease: from gene cloning to function. Kley N, et al. **Glia** 1995 Nov;15(3):297-307 (75 ref.)

METABOLISM

CNS Young Investigator Award Lecture: molecular analysis of the neurofibromatosis 2 tumor suppressor. MacCollin M. **Brain Dev** 1995 Jul-Aug;17(4):231-8 (64 ref.)

SURGERY

Preservation of auditory and vestibular function after surgical removal of bilateral vestibular schwannomas in a patient with neurofibromatosis type 2. Black FO, et al. **Am J Otol** 1995 Jul;16(4):431-43 (51 ref.)

Complications of the gamma knife. Wiet RJ, et al. **Arch Otolaryngol Head Neck Surg** 1996 Apr;122(4):414-6 (13 ref.)

Hearing preservation in bilateral acoustic neurinomas. Samii M. **Br J Neurosurg** 1995;9(3):413-24 (16 ref.)

NEUROFIBROMATOSIS 2 GENES see **GENES, NEUROFIBROMATOSIS 2**

NEUROFIBROMATOSIS, ACOUSTIC, BILATERAL see **NEUROFIBROMATOSIS 2**

NEUROFIBROMATOSIS, CENTRAL, NF2 see **NEUROFIBROMATOSIS 2**

NEUROFIBROMATOSIS, PERIPHERAL, NF1 see **NEUROFIBROMATOSIS 1**

NEUROFILAMENT PROTEINS

METABOLISM

Neurofilament phosphorylation. Pant HC, et al. **Biochem Cell Biol** 1995 Sep-Oct;73(9-10):575-92 (84 ref.)

Comparison of neurite outgrowth with neurofilament protein subunit levels in neuroblastoma cells following mercuric oxide exposure. Abdulla EM, et al. **Clin Exp Pharmacol Physiol** 1995 May;22(5):362-3 (5 ref.)

PHYSIOLOGY

A role for neurofilaments in the pathogenesis of amyotrophic lateral sclerosis. Julien JP. **Biochem Cell Biol** 1995 Sep-Oct; 73(9-10):593-7 (45 ref.)

Gene regulation by NF-M and Myb during differentiation and leukemic transformation. Kowenz-Leutz E, et al. **Immunobiology** 1995 Jul;193(2-4):356-62 (15 ref.)

NEUROGLIA

CYTOLOGY

Development and function of embryonic central nervous system glial cells in Drosophila. Klämbt C, et al. **Dev Genet** 1996;18(1):40-9 (87 ref.)

Olfactory bulb ensheathing glia: a unique cell type with axonal growth-promoting properties. Ramón-Cueto A, et al. **Glia** 1995 Jul;14(3):163-73 (145 ref.)

[Specification of glial lineage in invertebrates] Vincent S, et al. **C R Seances Soc Biol Fil** 1995;189(2):245-52 (27 ref.) (Eng. Abstr.) **(Fre)**

DRUG EFFECTS

Trophic actions of extracellular nucleotides and nucleosides on glial and neuronal cells. Neary JT, et al. **Trends Neurosci** 1996 Jan;19(1):13-8 (84 ref.)

IMMUNOLOGY

Neuro-glial-immune interactions. An experimental, neural transplant and lesion study. Finsen B. **Dan Med Bull** 1995 Sep;42(4):323-41 (192 ref.)

METABOLISM

A study on tumor necrosis factor, tumor necrosis factor receptors, and nitric oxide in human fetal glial cultures. St. Pierre BA, et al. **Adv Pharmacol** 1995;34:415-38 (94 ref.)

Neurotransmitters. NMDA receptors: do glia hold the key? Cull-Candy S. **Curr Biol** 1995 Aug 1;5(8):841-3 (25 ref.)

Metabolic coupling between glia and neurons. Tascopoulos M, et al. **J Neurosci** 1996 Feb 1;16(3):877-85 (98 ref.)

Excitatory amino acid receptors in glia: different subtypes for distinct functions? Gallo V, et al. **J Neurosci Res** 1995 Sep 1;42(1):1-8 (69 ref.)

PATHOLOGY

Glial inclusions in CNS degenerative diseases. Chin SS, et al. **J Neuropathol Exp Neurol** 1996 May;55(5):499-508 (78 ref.)

PHYSIOLOGY

What the fly's glia tell the fly's brain. Pfrieger FW, et al. **Cell** 1995 Dec 1;83(5):671-4 (19 ref.)

Glia, cytokines, and neurotoxicity. Chao CC, et al. **Crit Rev Neurobiol** 1995;9(2-3):189-205 (249 ref.)

Regeneration in the adult mammalian CNS: guided by development. Aubert I, et al. **Curr Opin Neurobiol** 1995 Oct;5(5):625-35 (118 ref.)

Development and function of embryonic central nervous system glial cells in Drosophila. Klämbt C, et al. **Dev Genet** 1996;18(1):40-9 (87 ref.)

Signal transduction mechanisms in glial cells. Bhat NR. **Dev Neurosci** 1995;17(5-6):267-84 (162 ref.)

TNF-alpha- and IFN-gamma-mediated signal transduction pathways: effects on glial cell gene expression and function. Benveniste EN, et al. **FASEB J** 1995 Dec;9(15):1577-84 (68 ref.)

Endocrine glia: roles of glial cells in the brain actions of steroid and thyroid hormones and in the regulation of hormone secretion. Garcia-Segura LM, et al. **Front Neuroendocrinol** 1996 Apr;17(2):180-211 (253 ref.)

Physiology of transformed glial cells. Brismar T. **Glia** 1995 Nov;15(3):231-43 (136 ref.)

Physiology of Bergmann glial cells. Müller T, et al. **Int Rev Neurobiol** 1995;38:341-59 (76 ref.)

Neurons and glial cells of the enteric nervous system: studies in tissue culture. Hanani M. **J Basic Clin Physiol Pharmacol** 1993 Jul-Sep;4(3):157-79 (72 ref.)

A molecular switch for the neuron-glia developmental decision. Anderson DJ. **Neuron** 1995 Dec;15(6):1219-22 (25 ref.)

Glial cell transplantation and remyelination of the central nervous system. Duncan ID. **Neuropathol Appl Neurobiol** 1996 Apr;22(2):87-100 (100 ref.)

pH regulation and proton signalling by glial cells. Deitmer JW, et al. **Prog Neurobiol** 1996 Feb;48(2):73-103 (265 ref.)

TRANSPLANTATION

Glial cell transplants: experimental therapies of myelin diseases. Duncan ID, et al. **Brain Pathol** 1995 Jul; 5(3):301-10 (77 ref.)

Glial transplants: an in vivo analysis of extrinsic and intrinsic determinants of dysmyelination in genetic variants. Lachapelle F. **Brain Pathol** 1995 Jul;5(3):289-99 (103 ref.)

NEUROHEMAL ORGAN see **NEUROSECRETORY SYSTEMS**

NEUROHUMOR RECEPTORS see **RECEPTORS, NEUROTRANSMITTER**

NEUROHUMORS see **NEUROTRANSMITTERS**

NEUROHYPOPHYSIS see **PITUITARY GLAND, POSTERIOR**

NEUROIMMUNE PROCESSES see **NEUROIMMUNOMODULATION**

NEUROIMMUNOMODULATION

Mechanisms of conditioned immunomodulation. Lysle DT, et al. **Int J Immunopharmacol** 1995 Aug;17(8):641-7 (54 ref.)

[Interactions between the immune and neuroendocrine system] Bojić I. **Vojnosanit Pregl** 1994 Sep-Oct; 51(5):417-22 (28 ref.) **(Scr)**

IMMUNOLOGY

Immune-neuroendocrine interactions. Savino W, et al. **Immunol Today** 1995 Jul;16(7):318-22 (27 ref.)

PHYSIOLOGY

Neuroimmunomodulation: classical and non-classical cellular activation. Agro A, et al. **Adv Neuroimmunol** 1995; 5(3):311-9 (57 ref.)

Immunoendocrine reshaping with age. Panerai AE, et al. **Int Rev Immunol** 1995;12(1):75-84 (73 ref.)

The role of the growth and lactogenic hormone family in immune function. Berczi I. **Neuroimmunomodulation** 1994 Jul-Aug;1(4):201-16 (182 ref.)

The neuropeptide alpha-melanocyte-stimulating hormone: a key component of neuroimmunomodulation. Catania A, et al. **Neuroimmunomodulation** 1994 Mar-Apr;1(2):93-9 (65 ref.)

Hypothalamic-pituitary-thyroid axis and the immune system. Pawlikowski M, et al. **Neuroimmunomodulation** 1994 May-Jun;1(3):149-52 (56 ref.)

Cytokines in the central nervous system: regulatory roles in neuronal function, cell death and repair. Sei Y, et al. **Neuroimmunomodulation** 1995 May-Jun;2(3):121-33 (159 ref.)

Neuronal factors modulating immunity. Stanisz AM. **Neuroimmunomodulation** 1994 Jul-Aug;1(4):217-30 (196 ref.)

Neuropeptides as native immune modulators. Singh VK. **Prog Drug Res** 1995;45:9-31 (101 ref.)

[Current concepts of the interactions of regulating systems: nervous, endocrine and immune] Akmaev IG. **Usp Fiziol Nauk** 1996 Jan-Mar;27(1):3-20 (129 ref.) (Eng. Abstr.) **(Rus)**

RADIATION EFFECTS

Visible light induced changes in the immune response through an eye-brain mechanism (photoneuroimmunology). Roberts JE. **J Photochem Photobiol B** 1995 Jul;29(1):3-15 (86 ref.)

NEUROKININ A

see related
RECEPTORS, NEUROKININ-2

NEUROKININ A RECEPTORS see **RECEPTORS, NEUROKININ-2**

NEUROKININ B RECEPTORS see **RECEPTORS, NEUROKININ-3**

NEUROKININ K

see related
RECEPTORS, NEUROKININ-3

NEUROKININ-1 RECEPTORS see **RECEPTORS, NEUROKININ-1**

NEUROKININ-2 RECEPTORS see **RECEPTORS, NEUROKININ-2**

NEUROKININ-3 RECEPTORS see **RECEPTORS, NEUROKININ-3**

NEUROLEPTANALGESIA

[Balanced anesthesia--historical aspect] Dohi S. **Masui** 1995; 44 Suppl:S141-3; discussion S147-8 (10 ref.) **(Jpn)**

[Balanced anesthesia (NLA) in the past] Koga Y. **Masui** 1995; 44 Suppl:S144-6; discussion S147-8 (6 ref.) **(Jpn)**

NEUROLEPTIC MALIGNANT SYNDROME

[Neuroleptic malignant syndrome] Amar M, et al. **Rev Assoc Med Bras** 1995 May-Jun;41(3):239-42 (25 ref.) **(Por)**

COMPLICATIONS

Epidemiology and pathoetiology of neurological syndromes with hyperthermia. Di Rosa AE, et al. **Funct Neurol** 1995 May-Jun;10(3):111-9 (49 ref.)

Pathogenesis, prevention, and treatment of neuroleptic-induced movement disorders. Ebadi M, et al. **Pharmacol Rev** 1995 Dec;47(4):575-604 (395 ref.)

DIAGNOSIS

Neuroleptic malignant syndrome and catatonia: one entity or two? [editorial] Fink M. **Biol Psychiatry** 1996 Jan 1; 39(1):1-4 (30 ref.)

Neuroleptic malignant syndrome. Bristow MF, et al. **Br J Hosp Med** 1996 Apr 17-30;55(8):517-20 (18 ref.)

[The neuroleptic malignant syndrome] Dammers S, et al. **Dtsch Med Wochenschr** 1995 Dec 15;120(50):1739-42 (17 ref.) (Eng. Abstr.) **(Ger)**

[The neuroleptic malignant syndrome (NMS). A report of a clinical case with a protracted and recurrent course. A review of the literature] Marelli A, et al. **Minerva Med** 1996 Jan-Feb;87(1-2):45-51 (30 ref.) (Eng. Abstr.) **(Ita)**

DRUG THERAPY

Management of suspected neuroleptic malignant syndrome. Velamoor VR, et al. **Can J Psychiatry** 1995 Nov; 40(9):545-50 (33 ref.)

[The neuroleptic malignant syndrome in an adolescent. Its treatment with dantrolene, bromocryptin and diazepam] Real Rodríguez B, et al. **An Esp Pediatr** 1996 Jan;44(1):60-2 (20 ref.) **(Spa)**

ETIOLOGY

Cocaine-associated agitated delirium and the neuroleptic malignant syndrome. Wetli CV, et al. **Am J Emerg Med** 1996 Jul;14(4):425-8 (18 ref.)

NEUROLEPTIC MALIGNANT SYNDROME

Clozapine-induced neuroleptic malignant syndrome: review and report of new cases. Sachdev P, et al. **J Clin Psychopharmacol** 1995 Oct;15(5):365-71 (29 ref.)
Neuroleptic malignant syndrome in a trauma patient [see comments] Burke C, et al. **J Trauma** 1995 Oct;39(4):796-8 (11 ref.) Comment in: J Trauma 1996 Apr;40(4):673.
[Neuroleptic malignant syndrome: a review of literature] Crespo Facorro B, et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1995 Sep-Oct;23(5):273-8 (57 ref.) (Eng. Abstr.) **(Spa)**

PSYCHOLOGY

Ecstasy intoxication: an overlap between serotonin syndrome and neuroleptic malignant syndrome. Demirkiran M, et al. **Clin Neuropharmacol** 1996 Apr;19(2):157-64 (43 ref.)

THERAPY

Pathogenesis, prevention, and treatment of neuroleptic-induced movement disorders. Ebadi M, et al. **Pharmacol Rev** 1995 Dec;47(4):575-604 (395 ref.)

NEUROLEPTICS see **ANTIPSYCHOTIC AGENTS**

NEUROLOGIC EXAMINATION

Diagnostic tests in neuro-ophthalmology. Galetta SL, et al. **Neurol Clin** 1996 Feb;14(1):201-22 (114 ref.)
Diagnostic testing of seizure disorders. Gilliam F, et al. **Neurol Clin** 1996 Feb;14(1):61-84 (119 ref.)
Assessment: neurological evaluation of male sexual dysfunction. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. **Neurology** 1995 Dec;45(12):2287-92 (77 ref.)
Assessment: Clinical autonomic testing report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. **Neurology** 1996 Mar;46(3):873-80 (101 ref.)
[Clinical aspects and neurologic expert assessment in sequelae of whiplash injury to the cervical spine] Jenzer G. **Nervenarzt** 1995 Oct;66(10):730-5 (30 ref.) (Eng. Abstr.) **(Ger)**

DRUG EFFECTS

[Clinical aspects and conservative therapy of Parkinson disease] Dengler R. **Zentralbl Neurochir** 1995;56(4):148-52 (5 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Use of evoked potentials in preterm neonates. Taylor MJ, et al. **Arch Dis Child Fetal Neonatal Ed** 1996 Jan; 74(1):F70-6 (74 ref.)
Diagnostic testing in movement disorders. Anouti A, et al. **Neurol Clin** 1996 Feb;14(1):169-82 (61 ref.)
Diagnostic testing for the evaluation of headaches. Evans RW. **Neurol Clin** 1996 Feb;14(1):1-26 (159 ref.)
Laboratory testing in peripheral nerve disease. Griffin JW, et al. **Neurol Clin** 1996 Feb;14(1):119-33 (58 ref.)
Diagnostic tests for the evaluation of back and neck pain. Haldeman S. **Neurol Clin** 1996 Feb;14(1):103-17 (52 ref.)
The diagnosis of multiple sclerosis. Rolak LA. **Neurol Clin** 1996 Feb;14(1):27-43 (34 ref.)
Diagnosis in neuromuscular diseases. Younger DS, et al. **Neurol Clin** 1996 Feb;14(1):135-68 (305 ref.)

NEUROLOGIC MODELS see **MODELS, NEUROLOGICAL**

NEUROLOGY

see related
NERVOUS SYSTEM DISEASES

An introduction to neuroepidemiology. Kurtzke JF. **Neurol Clin** 1996 May;14(2):255-72 (26 ref.)
Neurologic intensive care unit management and economic issues. Sundrani S. **Neurol Clin** 1995 Aug;13(3):679-93 (57 ref.)
Assessment: Clinical autonomic testing report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. **Neurology** 1996 Mar;46(3):873-80 (101 ref.)
Fundamental neuroscience and the classification of psychiatric disorders. Dubrovsky B. **Neurosci Biobehav Rev** 1995 Fall;19(3):511-8 (118 ref.)
A neurologist's reflections on boxing. I: Impact mechanics in boxing and injuries other than central nervous system damage. Unterharnscheidt F. **Rev Neurol** 1995 May-Jun; 23(121):661-74 (63 ref.)

ECONOMICS

Cost-effectiveness analysis: what is it and how will it influence neurology. Holloway RG. **Ann Neurol** 1996 Jun; 39(6):818-23 (32 ref.)

HISTORY

Historical overview. Freund HJ. **Adv Neurol** 1996;70:17-27 (70 ref.)
The evolution of ideas concerning the function of the neocortex. Mountcastle V. **Cereb Cortex** 1995 Jul-Aug; 5(4):289-95 (19 ref.)

INSTRUMENTATION

Biomagnetic neurosensors. Rechnitz GA, et al. **Curr Opin Biotechnol** 1996 Feb;7(1):55-9 (56 ref.)
Nuclear magnetic resonance spectroscopy: a review of neuropsychiatric applications. Passe TJ, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1995 Jul; 19(4):541-63 (155 ref.)

MANPOWER

A neurologist's reflections on boxing. V. Conclude remarks. Unterharnscheidt F. **Rev Neurol** 1995 Sep-Oct; 23(123):1027-32 (19 ref.)
A neurologist's reflections on boxing. II. Acute and chronic clinical findings secondary to central nervous system damage. Unterharnscheidt F. **Rev Neurol** 1995 Jul-Aug; 23(122):833-46 (92 ref.)
A neurologist's reflections on boxing. III. Vascular injuries. Unterharnscheidt F. **Rev Neurol** 1995 Jul-Aug; 23(122):847-55 (27 ref.)
[Mad cows: neurologists in their place] Polo JM, et al. **Neurologia** 1996 Jun-Jul;11(6):201-4 (64 ref.) **(Spa)**

METHODS

Methodologic issues in studying glucocorticoid-induced damage to neurons. Sapolsky R, et al. **J Neurosci Methods** 1995 May;58(1-2):1-15 (73 ref.)
Clinical research in neurology. From observation to experimentation. Marshall FJ, et al. **Neurol Clin** 1996 May; 14(2):451-66 (61 ref.)
[The use of the contingent negative wave in neurology and psychiatry] Vein AM, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995; 95(4):99-102 (79 ref.) **(Rus)**

ORGANIZATION & ADMINISTRATION

[How is new selective neuropsychiatry being structured?] Barraquer-Bordas LI. **Rev Neurol** 1996 Aug; 24(132):999-1007 (104 ref.) **(Spa)**

TRENDS

The understanding of epilepsy across three millennia. Eadie MJ. **Clin Exp Neurol** 1994;31:1-12 (16 ref.)
Neuropsychiatry and society. Cummings JL. **J Neuropsychiatry Clin Neurosci** 1996 Winter;8(1):104-9 (40 ref.)

NEUROLYMPHOMATOSIS see **MAREK'S DISEASE**

NEUROMA

Intratemporal facial nerve perineurioma. Li D, et al. **Laryngoscope** 1996 Mar;106(3 Pt 1):328-33 (39 ref.)
[Neuroma of the extrahepatic bile duct, amputation neuroma of the bile duct] Yamauchi H, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):37-9 (13 ref.) **(Jpn)**

SURGERY

Intra-operative monitoring is not essential. Malis LI. **Clin Neurosurg** 1995;42:203-13 (8 ref.)
Morton's interdigital neuroma: a clinical review of its etiology, treatment, and results. Wu KK. **J Foot Ankle Surg** 1996 Mar-Apr;35(2):112-9; discussion 187-8 (41 ref.)
Postsurgical development of dural arteriovenous malformations after transpetrosal and transtentorial operations: case report. Sasaki T, et al. **Neurosurgery** 1995 Oct;37(4):820-4; discussion 824-5 (14 ref.)

NEUROMA, ACOUSTIC

DIAGNOSIS

When to suspect an acoustic neuroma. Spoelhof GD. **Am Fam Physician** 1995 Nov 1;52(6):1768-74 (16 ref.)

SURGERY

Management of acoustic neuroma [see comments] Wright A, et al. **BMJ** 1995 Oct 28;311(7013):1141-4 (11 ref.) Comment in: BMJ 1996 Feb 24;312(7029):511.
The continuing challenge of acoustic neurinomas (1949-1993). Ramamurthi B. **Br J Neurosurg** 1995; 9(3):361-6 (6 ref.)
Air travel induced meningitis following vestibular schwannoma (acoustic neuroma) surgery. Callanan V, et al. **J Laryngol Otol** 1996 Mar;110(3):258-60 (18 ref.)
Benign brain tumors. Meningiomas, pituitary tumors, and acoustic neuromas. Black PM. **Neurol Clin** 1995 Nov; 13(4):927-52 (115 ref.)
Staged removal of acoustic tumors: techniques and lessons learned from a series of 83 patients. Comey CH, et al. **Neurosurgery** 1995 Nov;37(5):915-20; discussion 920-1 (25 ref.)
The choice of approach in surgery for acoustic neuromas (vestibular schwannomas). Thomsen J, et al. **Tokai J Exp Clin Med** 1994 Dec;19(3-6):93-101 (18 ref.)
[Establishment of the criteria to evaluate intraoperative changes of brainstem auditory evoked potentials during microvascular decompression and acoustic neurinoma excision] Sekiya T, et al. **No Shinkei Geka** 1996 May; 24(5):431-6 (55 ref.) (Eng. Abstr.) **(Jpn)**

NEUROMA, ACOUSTIC, BILATERAL see **NEUROFIBROMATOSIS 2**

NEUROMA, ACOUSTIC, UNILATERAL see **NEUROMA, ACOUSTIC**

NEUROMEDIATOR RECEPTORS see **RECEPTORS, NEUROTRANSMITTER**

NEUROMEDIN B RECEPTORS see **RECEPTORS, BOMBESIN**

NEUROMODULATOR RECEPTORS see **RECEPTORS, NEUROTRANSMITTER**

NEUROMODULATORS see **NEUROTRANSMITTERS**

NEUROMUSCULAR AGENTS

Complications associated with sedative and neuromuscular blocking drugs in critically ill patients. Prielipp RC, et al. **Crit Care Clin** 1995 Oct;11(4):983-1003 (79 ref.)

PHARMACOKINETICS

Clinical pharmacokinetics in patients with burns. Jaehde U, et al. **Clin Pharmacokinet** 1995 Jul;29(1):15-28 (75 ref.)

THERAPEUTIC USE

The insulin-like growth factor signaling system and ALS neurotrophic factor treatment strategies. Festoff BW, et al. **J Neurol Sci** 1995 May;129 Suppl:114-21 (60 ref.)

NEUROMUSCULAR BLOCKING AGENTS

Use of neuromuscular blocking drugs in the critically ill patient. Coursin DB, et al. **Crit Care Clin** 1995 Oct; 11(4):957-81 (94 ref.)

ADMINISTRATION & DOSAGE

Con: The choice of muscle relaxants is not important in cardiac surgery [comment] Fleming N. **J Cardiothorac Vasc Anesth** 1995 Dec;9(6):772-4 (20 ref.) Comment on: J Cardiothorac Vasc Anesth 1995 Dec;9(6):786-71.
Pro: The choice of muscle relaxants is important in cardiac surgery. Hudson RJ, et al. **J Cardiothorac Vasc Anesth** 1995 Dec;9(6):768-71 (38 ref.)

ADVERSE EFFECTS

Muscle relaxants and histamine release. Moss J. **Acta Anaesthesiol Scand Suppl** 1995;106:7-12 (30 ref.)

ECONOMICS

The cost of sedating and paralyzing the critically ill patient. Cheng EY. **Crit Care Clin** 1995 Oct;11(4):1005-19 (29 ref.)

PHARMACOLOGY

Molecular mechanisms of neuromuscular blocking agents: is the increased understanding of importance to the practising anaesthetist? Aglan MY, et al. **Pharmacol Ther** 1995; 68(3):365-83 (76 ref.)

THERAPEUTIC USE

Sedative and neuromuscular blocking drug use in critically ill patients with head injuries. Prielipp RC, et al. **New Horiz** 1995 Aug;3(3):456-68 (102 ref.)

NEUROMUSCULAR BLOCKING AGENTS, COMPETITIVE see **NEUROMUSCULAR NONDEPOLARIZING AGENTS**

NEUROMUSCULAR DEPOLARIZING AGENTS

ADVERSE EFFECTS

Variants of malignant hyperthermia. Special problems for the paediatric anaesthesiologist. Rosenberg H, et al. **Paediatr Anaesth** 1996;6(2):87-93 (37 ref.)
[Heart arrest in children after intravenous injection of succinylcholine in the ENT operating room (see comments)] Schulte-Sasse U. **HNO** 1995 Nov;43(11):676-9 (29 ref.) (Eng. Abstr.) Comment in: Hosp Formul 1995 Nov;43(11):640-1. **(Ger)**

CONTRAINDICATIONS

Use of suxamethonium in children [editorial] [see comments] Hopkins PM. **Br J Anaesth** 1995 Dec;75(6):675-7 (23 ref.) Comment in: Br J Anaesth 1996 Jun;76(6):883; discussion 884. Comment in: Br J Anaesth 1996 Jun;76(6):883-4; discussion 884.

PHARMACOLOGY

[The effect of suxamethonium on intracranial pressure]

Handberg G, et al. **Ugeskr Laeger** 1996 Apr 22; 158(17):2381–3 (17 ref.) (Eng. Abstr.) **(Dan)**

THERAPEUTIC USE

Neuromuscular blocking agents in the emergency department. Rubin MA, et al. **J Emerg Med** 1996 Mar–Apr; 14(2):193–9 (67 ref.)

NEUROMUSCULAR DISEASES

Musculoskeletal and neuromuscular conditions of instrumental musicians. Bejjani FJ, et al. **Arch Phys Med Rehabil** 1996 Apr;77(4):406–13 (108 ref.)

The young athlete with chronic disease. Small E, et al. **Clin Sports Med** 1995 Jul;14(3):709–26 (144 ref.)

COMPLICATIONS

Respiratory function in children with neuromuscular disease. Allen JL. **Monaldi Arch Chest Dis** 1996 Jun;51(3):230–5 (51 ref.)

Neuropathies associated with monoclonal gammopathies. Kissel JT, et al. **Neuromuscul Disord** 1996 Jan;6(1):3–18 (95 ref.)

Intestinal motility during ontogeny and intestinal pseudo-obstruction in children. Milla PJ. **Pediatr Clin North Am** 1996 Apr;43(2):511–32 (72 ref.)

DIAGNOSIS

Role of exercise in the assessment and management of neuromuscular disease in children. Bar-Or O. **Med Sci Sports Exerc** 1996 Apr;28(4):421–7 (63 ref.)

Technology assessment: the use of surface EMG in the diagnosis and treatment of nerve and muscle disorders. Haig AJ, et al. **Muscle Nerve** 1996 Mar;19(3):392–5 (21 ref.)

Diagnosis in neuromuscular diseases. Younger DS, et al. **Neurol Clin** 1996 Feb;14(1):135–68 (305 ref.)

ETIOLOGY

Sepsis and the systemic inflammatory response syndrome: neuromuscular manifestations. Bolton CF. **Crit Care Med** 1996 Aug;24(8):1408–16 (82 ref.)

[Neuromuscular involvement and cerebrovascular accidents] Kuntzer T, et al. **Rev Med Suisse Romande** 1996 Aug; 116(8):605–9 (31 ref.) **(Fre)**

GENETICS

Inherited disorders of contractile proteins in skeletal and cardiac muscle. Laing NG. **Curr Opin Neurol** 1995 Oct; 8(5):391–6 (50 ref.)

Use of genetically engineered mice as models for understanding human neurodegenerative disease. Andersen JK, et al. **J Am Geriatr Soc** 1996 Jun;44(6):717–22 (34 ref.)

METABOLISM

Inherited disorders of contractile proteins in skeletal and cardiac muscle. Laing NG. **Curr Opin Neurol** 1995 Oct; 8(5):391–6 (50 ref.)

PHYSIOPATHOLOGY

Fatigue brought on by malfunction of the central and peripheral nervous systems. McComas AJ, et al. **Adv Exp Med Biol** 1995;384:495–512 (59 ref.)

Neuromuscular complications of sepsis in children. Sheth RD, et al. **J Child Neurol** 1995 Sep;10(5):346–52 (73 ref.)

Neuromuscular complications in the ICU: the spectrum of critical illness-related conditions causing muscular weakness and weaning failure. Hund EF. **J Neurol Sci** 1996 Mar;136(1–2):10–6 (75 ref.)

Desmin-related neuromuscular disorders. Goebel HH. **Muscle Nerve** 1995 Nov;18(11):1306–20 (104 ref.)

Inspiratory muscle training in the patient with neuromuscular disease. McCool FD, et al. **Phys Ther** 1995 Nov; 75(11):1006–14 (45 ref.)

RADIOGRAPHY

[Radiologic differential diagnosis of neurologically-induced deglutition disorders] Wuttge-Hanning A, et al. **Radiologe** 1995 Oct;35(10):733–40 (16 ref.) (Eng. Abstr.) **(Ger)**

REHABILITATION

Inspiratory muscle training in the patient with neuromuscular disease. McCool FD, et al. **Phys Ther** 1995 Nov; 75(11):1006–14 (45 ref.)

THERAPY

Role of exercise in the assessment and management of neuromuscular disease in children. Bar-Or O. **Med Sci Sports Exerc** 1996 Apr;28(4):421–7 (63 ref.)

NEUROMUSCULAR JUNCTION

see related
NEUROMUSCULAR BLOCKING AGENTS
NEUROMUSCULAR DEPOLARIZING AGENTS
RECEPTORS, CHOLINERGIC

CHEMISTRY

Testing the agrin hypothesis. Kleiman RJ, et al. **Cell** 1996 May 17;85(4):461–4 (16 ref.)

DRUG EFFECTS

Spontaneous recovery or evoked reversal of neuromuscular block. Mirakhur RK. **Acta Anaesthesiol Scand Suppl** 1995; 106:62–5 (25 ref.)

Regulation of postsynaptic responses by calcitonin gene related peptide and ATP at developing neuromuscular junctions. Lu B, et al. **Can J Physiol Pharmacol** 1995 Jul; 73(7):1050–6 (42 ref.)

Molecular mechanisms of neuromuscular blocking agents: is the increased understanding of importance to the practising anaesthetist? Aglan MY, et al. **Pharmacol Ther** 1995; 68(3):365–83 (76 ref.)

EMBRYOLOGY

Wiring by fly: the neuromuscular system of the Drosophila embryo. Bate M, et al. **Neuron** 1995 Sep;15(3):513–25 (108 ref.)

GROWTH & DEVELOPMENT

Peptides in motoneurons. Raivich G, et al. **Prog Brain Res** 1995;104:3–20 (185 ref.)

METABOLISM

Tyrosine phosphorylation and synapse formation at the neuromuscular junction. Mei L, et al. **Life Sci** 1995; 57(16):1459–66 (114 ref.)

PHYSIOLOGY

Neuromuscular frequency-coding and fatigue. Kernell D. **Adv Exp Med Biol** 1995;384:135–45 (54 ref.)

Fatigue at the neuromuscular junction. Branch point vs. presynaptic vs. postsynaptic mechanisms. Sieck GC, et al. **Adv Exp Med Biol** 1995;384:83–100 (90 ref.)

A spinal circuitry simulator as a teaching tool for neuromuscular physiology. Maw S, et al. **Am J Physiol** 1996 Jun;270(6 Pt 3):S50–68 (25 ref.)

The basement membrane at the neuromuscular junction: a synaptic mediatrix. Carbonetto S, et al. **Curr Opin Neurobiol** 1995 Oct;5(5):596–605 (64 ref.)

Response of the neuromuscular unit to spaceflight: what has been learned from the rat model. Roy RR, et al. **Exerc Sport Sci Rev** 1996;24:399–425 (72 ref.)

Dynamics of nerve-muscle interaction in developing and mature neuromuscular junctions. Grinnell AD. **Physiol Rev** 1995 Oct;75(4):789–834 (619 ref.)

Involvement of nitric oxide in neuromuscular transmission in canine proximal colon. Shuttleworth CW, et al. **Proc Soc Exp Biol Med** 1996 Jan;211(1):16–23 (50 ref.)

Plasticity of developing neuromuscular synapses. Dan Y, et al. **Prog Brain Res** 1995;105:211–5 (13 ref.)

Regulatory role of ATP at developing neuromuscular junctions. Fu WM. **Prog Neurobiol** 1995 Sep;47(1):31–44 (101 ref.)

PHYSIOPATHOLOGY

Single fiber electromyography in studies of neuromuscular function. Trontelj JV, et al. **Adv Exp Med Biol** 1995; 384:109–19 (31 ref.)

[Clinical usefulness of neuromuscular monitor] Amaki Y. **Masui** 1995;44 Suppl:S100–5 (9 ref.) **(Jpn)**

[Pathophysiology on the disorder of neuromuscular transmission defects] Sahashi K, et al. **Rinsho Byori** 1995 Sep;43(9):902–9 (15 ref.) (Eng. Abstr.) **(Jpn)**

NEUROMUSCULAR NONDEPOLARIZING AGENTS

see related
NICOTINIC ANTAGONISTS

Mivacurium chloride--a comparative profile. Diffenbach C, et al. **Acta Anaesthesiol Scand Suppl** 1995;106:23–5 (10 ref.)

Rocuronium: the newest aminosteroid neuromuscular blocking drug [editorial] Hunter JM. **Br J Anaesth** 1996 Apr;76(4):481–3 (30 ref.)

Onset time and evaluation of intubating conditions: rocuronium in perspective. Agoston S. **Eur J Anaesthesiol Suppl** 1995 Sep;11:31–7 (14 ref.)

ADMINISTRATION & DOSAGE

The use of neuromuscular blocking drugs in intensive care practice. Elliot JM, et al. **Acta Anaesthesiol Scand Suppl** 1995;106:70–82 (166 ref.)

Mivacurium in special patient groups. Jones RM. **Acta Anaesthesiol Scand Suppl** 1995;106:47–54 (57 ref.)

[Neuromuscular relaxants in the recovery room (see comments)] de la Cruz CA, et al. **Rev Esp Anestesiol Reanim** 1995 Oct;42(8):344–8 (25 ref.) Comment in: Rev Esp Anestesiol Reanim 1995 Oct;42(8):301–2. **(Spa)**

ANTAGONISTS & INHIBITORS

Spontaneous recovery or evoked reversal of neuromuscular block. Mirakhur RK. **Acta Anaesthesiol Scand Suppl** 1995; 106:62–5 (25 ref.)

METABOLISM

Spontaneous recovery or evoked reversal of neuromuscular block. Mirakhur RK. **Acta Anaesthesiol Scand Suppl** 1995; 106:62–5 (25 ref.)

PHARMACOKINETICS

Pharmacokinetics and pharmacodynamics of the benzylisoquinolinium muscle relaxants. Hull CJ. **Acta Anaesthesiol Scand Suppl** 1995;106:13–7 (19 ref.)

The pharmacokinetics of rocuronium bromide in hepatic cirrhosis. Hunter JM. **Eur J Anaesthesiol Suppl** 1995 Sep; 11:39–41 (6 ref.)

PHARMACOLOGY

Pharmacokinetics and pharmacodynamics of the benzylisoquinolinium muscle relaxants. Hull CJ. **Acta Anaesthesiol Scand Suppl** 1995;106:13–7 (19 ref.)

The clinical and basic pharmacology of mivacurium: a short-acting nondepolarizing benzylisoquinolinium diester neuromuscular blocking drug. Savarese JJ, et al. **Acta Anaesthesiol Scand Suppl** 1995;106:18–22 (16 ref.)

Ventilatory responses to hypoxia and hypercapnia during inhalation anaesthesia and subparalytical muscle relaxation in humans [see comments] Lindahl SG. **Acta Anaesthesiol Sin** 1995 Dec;33(4):223–6 (13 ref.) Comment in: Acta Anaesthesiol Sin 1995 Dec;33(4):i–ii.

Research and development of aminosteroid neuromuscular blocking agents: past and future. Marshall RJ, et al. **Eur J Anaesthesiol Suppl** 1995 Sep;11:5–10 (19 ref.)

THERAPEUTIC USE

Neuromuscular blocking agents in the emergency department. Rubin MA, et al. **J Emerg Med** 1996 Mar–Apr; 14(2):193–9 (67 ref.)

NEUROMUSCULAR SPINDLES see MUSCLE SPINDLES

NEURON DEGENERATION see NERVE DEGENERATION

NEURONAL CELL ADHESION MOLECULES see CELL ADHESION MOLECULES, NEURONAL

NEURONAL CEROID-LIPOFUSCINOSIS

The neuronal ceroid-lipofuscinoses. Goebel HH. **J Child Neurol** 1995 Nov;10(6):424–37 (125 ref.)

[Neuronal ceroid lipofuscinosis. An unknown overload disease] Echaniz-Laguna A, et al. **Presse Med** 1996 May 25;25(18):853–6 (17 ref.) (Eng. Abstr.) **(Fre)**

[Batten disease (Neuronal ceroid lipofuscinoses)--accumulation of ATP synthase subunit c caused by the delay of lysosomal degradation] Ezaki J, et al. **Nippon Rinsho** 1995 Dec;53(12):3055–61 (22 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

[Myocardial lipofuscinosis of unknown etiology in a young asymptomatic woman] Dolara A, et al. **Cardiologia** 1996 Mar;41(3):275–7 (17 ref.) (Eng. Abstr.) **(Ita)**

[Late infantile neuronal ceroid-lipofuscinosis: clinical symptoms and investigations] Kmieć T. **Pediatr Pol** 1995 Jun;70(6):501–6 (32 ref.) (Eng. Abstr.) **(Pol)**

METABOLISM

New insight into lysosomal protein storage disease: delayed catabolism of ATP synthase subunit c in Batten disease. Kominami E, et al. **Neurochem Res** 1995 Nov;20(11):1305–9 (26 ref.)

NEURONAL PLASTICITY

c-Fos expression as a tool to search for the neurobiological base of the sexual behaviour of males. Biały M, et al. **Acta Neurobiol Exp (Warsz)** 1996;56(2):567–77 (52 ref.)

Extracellular ATP as a neurotransmitter: its role in synaptic plasticity in the hippocampus. Wieraszko A. **Acta Neurobiol Exp (Warsz)** 1996;56(2):637–48 (85 ref.)

Plasticity of calcitonin gene related peptide neurotransmission in the spinal cord during peripheral inflammation. Seybold VS, et al. **Can J Physiol Pharmacol** 1995 Jul;73(7):1007–14 (51 ref.)

Ionotropic glutamate receptors. Their possible role in the expression of hippocampal synaptic plasticity. Asztély F, et al. **Mol Neurobiol** 1996 Feb;12(1):1–11 (122 ref.)

Neurotrophic factors and synaptic plasticity. Lo DC. **Neuron** 1995 Nov;15(5):979–81 (31 ref.)

Development and plasticity of cortical processing architectures. Singer W. **Science** 1995 Nov 3; 270(5237):758–64 (66 ref.)

Neurotrophins and neuronal plasticity. Thoenen H. **Science** 1995 Oct 27;270(5236):593–8 (64 ref.)

[Mechanisms of neuroplasticity] Pokorný J. **Cesk Fysiol** 1996 Mar;45(1):21–8 (48 ref.) (Eng. Abstr.) **(Cze)**

GENETICS

Protein phosphorylation in neuronal plasticity and gene expression. Schulman H. **Curr Opin Neurobiol** 1995 Jun;

5(3):375–81 (47 ref.)

PHYSIOLOGY

Long-term potentiation and long-term depression of horizontal connections in rat motor cortex. Hess G, et al. **Acta Neurobiol Exp (Warsz)** 1996;56(1):397–405 (32 ref.)

Is dopaminergic cell death accompanied by concomitant nerve plasticity? Anglade P, et al. **Adv Neurol** 1996; 69:195–208 (96 ref.)

Apolipoprotein E, synaptic plasticity and Alzheimer's disease. Poirier J, et al. **Ann Med** 1995 Dec;27(6):663–70 (89 ref.)

Aspects of the search for neural mechanisms of memory. Rosenzweig MR. **Annu Rev Psychol** 1996;47:1–32 (150 ref.)

Plasticity following neonatal visual cortex damage in cats. Spear PD. **Can J Physiol Pharmacol** 1995 Sep;73(9):1389–97 (40 ref.)

Emotion: systems, cells, synaptic plasticity. Rogan MT, et al. **Cell** 1996 May 17;85(4):469–75 (40 ref.)

Oestrogens and the structural and functional plasticity of neurons: implications for memory, ageing and neurodegenerative processes. McEwen BS, et al. **Ciba Found Symp** 1995;191:52–66; discussion 66–73 (43 ref.)

Plasticity of adult sensorimotor representations. Donoghue JP. **Curr Opin Neurobiol** 1995 Dec;5(6):749–54 (54 ref.)

Molecular basis of neuronal plasticity to gonadal steroids. Matsumoto A, et al. **Funct Neurol** 1995 Mar–Apr; 10(2):59–76 (137 ref.)

Can the neurotrophic hypothesis explain degeneration and loss of plasticity in mature and ageing autonomic nerves? Gavazzi I, et al. **J Auton Nerv Syst** 1996 Apr 20; 58(1–2):1–10 (79 ref.)

Update of the NGF saga. Levi-Montalcini R, et al. **J Neurol Sci** 1995 Jun;130(2):119–27 (113 ref.)

Long-term regulation of short-term plasticity: a postsynaptic influence on presynaptic transmitter release. Davis GW. **J Physiol Paris** 1995;89(1):33–41 (39 ref.)

Synaptic plasticity: stairway to memory. Jodar L, et al. **Jpn J Pharmacol** 1995 Aug;68(4):359–87 (285 ref.)

Alzheimer's disease: maladaptive synaptoplasticity hypothesis. Neill D. **Neurodegeneration** 1995 Jun; 4(2):217–32 (250 ref.)

Activation by GABAb, reduction of the intracellular concentration of Ca++, and inhibition of protein kinases are possible mechanisms of the long-term posttetanic modification of the efficiency of inhibitory transmission in the new cortex. Silkis IG. **Neurosci Behav Physiol** 1996 Jan–Feb;26(1):88–97 (41 ref.)

Anatomy, development and lesion-induced plasticity of rodent corticospinal tract. Terashima T. **Neurosci Res** 1995 May;22(2):139–61 (180 ref.)

Induction of non-catalytic TrkB neurotrophin receptors during lesion-induced synaptic rearrangement in the adult rat hippocampus. Beck KD, et al. **Prog Brain Res** 1995; 105:197–210 (80 ref.)

Plasticity of developing neuromuscular synapses. Dan Y, et al. **Prog Brain Res** 1995;105:211–5 (13 ref.)

Mechanisms of neuronal plasticity as analyzed at the single cell level. Eberwine J, et al. **Prog Brain Res** 1995; 105:117–26 (18 ref.)

Immediate early genes (IEGs) encoding for inducible transcription factors (ITFs) and neuropeptides in the nervous system: functional network for long-term plasticity and pain. Herdegen T, et al. **Prog Brain Res** 1995; 104:299–321 (184 ref.)

Plasticity and commitment in the developing cerebral cortex. McConnell SK. **Prog Brain Res** 1995;105:129–43 (107 ref.)

'Vestibular compensation': neural plasticity and its relations to functional recovery after labyrinthine lesions in frogs and other vertebrates. Dieringer N. **Prog Neurobiol** 1995 Jun;46(2–3):97–129 (225 ref.)

Plasticity of cutaneous primary afferent projections to the spinal dorsal horn. Wilson P, et al. **Prog Neurobiol** 1996 Feb;48(2):105–29 (240 ref.)

Involvement of nerve growth factor in visual cortex plasticity. Gu Q. **Rev Neurosci** 1995 Oct–Dec;6(4):329–51 (259 ref.)

Long-term depression: a learning-related type of synaptic plasticity in the mammalian central nervous system. Zhuo M, et al. **Rev Neurosci** 1995 Jul–Sep;6(3):259–77 (142 ref.)

Metaplasticity: the plasticity of synaptic plasticity. Abraham WC, et al. **Trends Neurosci** 1996 Apr;19(4):126–30 (53 ref.)

The corticostriatal projection: from synaptic plasticity to dysfunctions of the basal ganglia. Calabresi P, et al. **Trends Neurosci** 1996 Jan;19(1):19–24 (58 ref.)

Cerebellar long-term depression might normalize excitation of Purkinje cells: a hypothesis. De Schutter E. **Trends Neurosci** 1995 Jul;18(7):291–5 (79 ref.)

A role for hippocampal opioids in long-term functional plasticity. Morris BJ, et al. **Trends Neurosci** 1995 Aug; 18(8):350–5 (59 ref.)

NMDA receptor redox sites: are they targets for selective neuronal protection? [see comments] Gozlan H, et al. **Trends Pharmacol Sci** 1995 Nov;16(11):368–74 (80 ref.) Comment in: Trends Pharmacol Sci 1996 May;17(5):186–7; discussion 187–9.

[Memory and synaptic plasticity] Maitre M. **Ann Biol Clin (Paris)** 1996;54(2):49–66 (164 ref.) (Eng. Abstr.) **(Fre)**

[Plasticity of brain structure and function as the neurobiological principle of psychotherapy] Bogerts B. **Z Klin Psychol Psychopathol Psychother** 1996;44(3):243–52 (22 ref.) (Eng. Abstr.) **(Ger)**

[Synaptic reorganization in early childhood experience and learning processes: relevance for the development of psychological diseases] Braun K. **Z Klin Psychol Psychopathol Psychother** 1996;44(3):253–66 (60 ref.) (Eng. Abstr.) **(Ger)**

[Psychological stress and neuronal plasticity. An expanded model of the stress reaction process as the basis for understand central nervous system adaptation processes] Huether G, et al. **Z Psychosom Med Psychoanal** 1996; 42(2):107–27 (70 ref.) (Eng. Abstr.) **(Ger)**

[The mechanisms of synaptic plasticity: the role of synaptic protein phosphorylation and gene expression] Godukhin OV, et al. **Usp Fiziol Nauk** 1995 Jul–Sep;26(3):41–56 (98 ref.) (Eng. Abstr.) **(Rus)**

[The plasticity of systemic brain mechanisms] Sudakov KV. **Usp Fiziol Nauk** 1996 Apr–Jun;27(2):3–27 (91 ref.) (Eng. Abstr.) **(Rus)**

NEURONS

see related

NEURAL CONDUCTION

Autonomic and sensory neuron cultures. Nishi R. **Methods Cell Biol** 1996;51:249–63 (11 ref.)

Neuronal polarity: giving neurons heads and tails. Prochiantz A. **Neuron** 1995 Oct;15(4):743–6 (26 ref.)

[The excito-toxicity theory of glaucomatous neuropathy. General review] Bonne C, et al. **J Fr Ophtalmol** 1996; 19(1):69–74 (46 ref.) **(Fre)**

CHEMISTRY

Localization of the Na(+)–Ca2+ exchanger in vascular smooth muscle, and in neurons and astrocytes. Juhaszova M, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:318–35 (31 ref.)

Peptidergic neurons in the vertebrate spinal cord: evolutionary trends. Brodin L, et al. **Prog Brain Res** 1995; 104:61–74 (119 ref.)

Organization of peptidergic neurons in the dorsal horn of the spinal cord: anatomical and functional correlates. Ribeiro-da-Silva A, et al. **Prog Brain Res** 1995;104:41–59 (77 ref.)

Influence of dynorphin A antibodies on the formation of edema and cell changes in spinal cord trauma. Sharma HS, et al. **Prog Brain Res** 1995;104:401–16 (95 ref.)

CYTOLOGY

In vitro models for the effects of sex hormones on neurons. Lustig RH. **Ann N Y Acad Sci** 1996 Apr 30;784:370–80 (72 ref.)

Definition of signals for neuronal differentiation. Obermeier A, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:1–17 (55 ref.)

Neural apoptosis. Bredesen DE. **Ann Neurol** 1995 Dec; 38(6):839–51 (143 ref.)

c-fos expression as a marker of central cardiovascular neurons. Dun NJ, et al. **Biol Signals** 1995 May–Jun; 4(3):117–23 (25 ref.)

Neuronal growth and death: order and disorder in the axoplasm. Cleveland DW. **Cell** 1996 Mar 8;84(5):663–6 (17 ref.)

Neural development. Spinning skin into neurons. Anderson DJ. **Curr Biol** 1995 Nov 1;5(11):1235–8 (16 ref.)

Influence of growth factors on neuronal differentiation. Birling MC, et al. **Curr Opin Cell Biol** 1995 Dec;7(6):878–84 (66 ref.)

Role of environmental signals and transcriptional regulators in neural crest development. Groves AK, et al. **Dev Genet** 1996;18(1):64–72 (82 ref.)

Cell fate specification and differentiation in the nervous system of Caenorhabditis elegans. Sengupta P, et al. **Dev Genet** 1996;18(1):73–80 (65 ref.)

Role of the subplate neurons in specification of neocortical areas. Woźniak W. **Folia Morphol (Warsz)** 1995;54(3):141–5 (26 ref.)

Methods for determining numbers of cells and synapses: a case for more uniform standards of review. Coggeshall RE, et al. **J Comp Neurol** 1996 Jan 1;364(1):6–15 (30 ref.)

Strategies for the generation of neuronal diversity in the developing central nervous system. McConnell SK. **J Neurosci** 1995 Nov;15(11):6987–98 (126 ref.)

VIP as a cell–growth and differentiation neuromodulator role in neurodevelopment. Muller JM, et al. **Mol Neurobiol** 1995 Apr–Jun;10(2–3):115–34 (126 ref.)

Constructing the cerebral cortex: neurogenesis and fate determination. McConnell SK. **Neuron** 1995 Oct; 15(4):761–8 (70 ref.)

The economics of neurite outgrowth—the addition of new membrane to growing axons. Futerman AH, et al. **Trends Neurosci** 1996 Apr;19(4):144–9 (55 ref.)

Neurones from stem cells? Svendsen CN, et al. **Trends Neurosci** 1995 Nov;18(11):465–7 (33 ref.)

[Regulation of neural differentiation by HES helix-loop-helix transcription factors] Kageyama R. **Seikagaku** 1995 Sep; 67(9):1093–114 (71 ref.) **(Jpn)**

DRUG EFFECTS

How does trimethyltin affect the brain: facts and hypotheses. Koczyk D. **Acta Neurobiol Exp (Warsz)** 1996;56(2):587–96 (85 ref.)

Neuroprotective properties of the uncompetitive NMDA receptor antagonist remacemide hydrochloride. Palmer GC, et al. **Ann N Y Acad Sci** 1995 Sep 15;765:236–47; discussion 248 (38 ref.)

Quantitative histological evaluation of neuroprotective compounds. Scallet AC. **Ann N Y Acad Sci** 1995 Sep 15; 765:47–58; discussion 59–61 (39 ref.)

Pathophysiological basis of vulnerability to drug abuse: role of an interaction between stress, glucocorticoids, and dopaminergic neurons. Piazza PV, et al. **Annu Rev Pharmacol Toxicol** 1996;36:359–78 (117 ref.)

Pharmacology of sodium and calcium channel modulation in neurons: implications for neuroprotection. Spedding M, et al. **Biochem Soc Trans** 1995 Aug;23(3):633–6 (50 ref.)

Steroid hormone effects on neurons subserving behavior. Weeks JC, et al. **Curr Opin Neurobiol** 1995 Dec;5(6):809–15 (57 ref.)

Effects of aluminum on neuronal signal transduction: mechanisms underlying disruption of phosphoinositide hydrolysis. Shafer TJ, et al. **Gen Pharmacol** 1995 Sep; 26(5):889–95 (46 ref.)

The inhibition of peroxide formation as a possible substrate for the neuroprotective action of dihydroergocryptine. Favit A, et al. **J Neural Transm Suppl** 1995;45:297–305 (30 ref.)

Methodologic issues in studying glucocorticoid-induced damage to neurons. Sapolsky R, et al. **J Neurosci Methods** 1995 May;58(1–2):1–15 (73 ref.)

Microglia as a unique cellular target in the treatment of stroke: potential neurotoxic mediators produced by activated microglia. Wood PL. **Neurol Res** 1995 Aug; 17(4):242–8 (104 ref.)

Serotonin uptake inhibitors: uses in clinical therapy and in laboratory research. Fuller RW. **Prog Drug Res** 1995; 45:167–204 (280 ref.)

Targeting toxins to neural antigens and receptors. Wiley RG. **Semin Cancer Biol** 1996 Apr;7(2):71–7 (96 ref.)

Trophic actions of extracellular nucleotides and nucleosides on glial and neuronal cells. Neary JT, et al. **Trends Neurosci** 1996 Jan;19(1):13–8 (84 ref.)

[Neurotoxicity of excitatory amino acids and the central nervous system] Martos JM, et al. **Rev Clin Esp** 1996 Feb; 196(2):113–8 (102 ref.) **(Spa)**

ENZYMOLOGY

Multifunctional calcium and calmodulin–dependent kinase II in neuronal function and disease. Churn SB. **Adv Neuroimmunol** 1995;5(3):241–59 (141 ref.)

The postsynaptic density: a subcellular anchor for signal transduction enzymes. Klauck TM, et al. **Cell Signal** 1995 Nov;7(8):747–57 (114 ref.)

Neuronal nitric oxide synthase, a modular enzyme formed by convergent evolution: structure studies of a cysteine thiolate–liganded heme protein that hydroxylates L–arginine to produce NO. as a cellular signal. Masters BS, et al. **FASEB J** 1996 Apr;10(5):552–8 (70 ref.)

Regulatory properties of neuronal cdc2–like kinase. Qi Z, et al. **Mol Cell Biochem** 1995 Aug–Sep;149–150:35–9 (38 ref.)

The involvement of PKC and multifunctional CaM kinase II of the postsynaptic neuron in induction and maintenance of long–term potentiation. Feng TP. **Prog Brain Res** 1995; 105:55–63 (27 ref.)

IMMUNOLOGY

[Pure cerebellar syndrome associated with anti–Hu antibodies] Pradat PF, et al. **Rev Neurol (Paris)** 1995 May; 151(5):341–3 (12 ref.) (Eng. Abstr.) **(Fre)**

[Neurologic paraneoplastic syndromes and anti–neuronal antibodies] Mygland A. **Tidsskr Nor Laegeforen** 1996 Jan 30;116(3):361–5 (44 ref.) (Eng. Abstr.) **(Nor)**

METABOLISM

Calcium transients in brain ischemia: role in neuronal injury. Lazarewicz JW. **Acta Neurobiol Exp (Warsz)** 1996; 56(1):299–311 (113 ref.)

Strategies for cell biological studies in oxytocinergic neurons. Gainer H, et al. **Adv Exp Med Biol** 1995;395:1–8 (58 ref.)

Control of electron transfer in neuronal nitric oxide synthase by calmodulin, substrate, substrate analogs, and nitric oxide. Stuehr DJ, et al. **Adv Pharmacol** 1995;34:207–13 (15 ref.)

Parkinson's disease and free radicals. Mechanism of neurodegeneration and neuroprotection. Kondo T. **Ann N Y Acad Sci** 1996 Jun 15;786:206–16 (35 ref.)

The sodium–calcium exchanger and glutamate–induced calcium loads in aged hippocampal neurons in vitro. Mills LR. **Ann N Y Acad Sci** 1996 Apr 15;779:379–90 (39 ref.)

Persistent sodium current in mammalian central neurons. Crill WE. **Annu Rev Physiol** 1996;58:349–62 (77 ref.)

Low–threshold calcium currents in central nervous system neurons. Huguenard JR. **Annu Rev Physiol** 1996;58:329–48 (111 ref.)

Queer current and pacemaker: the hyperpolarization–activated cation current in neurons. Pape HC. **Annu Rev Physiol** 1996;58:299–327 (142 ref.)

Regulation of calcium homoeostasis in neurons: the role of calcium–binding proteins. Miller RJ. **Biochem Soc Trans** 1995 Aug;23(3):629–32 (21 ref.)

Pharmacology of sodium and calcium channel modulation in neurons: implications for neuroprotection. Spedding M, et al. **Biochem Soc Trans** 1995 Aug;23(3):633–6 (50 ref.)

With platelets, as with T lymphocytes, the blood cell system

behaves as a neuron [editorial] Mathé G. **Biomed Pharmacother** 1995;49(10):433–4 (25 ref.)
Calcium–induced calcium release in neurones. Verkhratsky A, et al. **Cell Calcium** 1996 Jan;19(1):1–14 (107 ref.)
Calcium oscillations in neurons. Friel DD. **Ciba Found Symp** 1995;188:210–23; discussion 223–34 (36 ref.)
Neurospecific binding, internalization, and retrograde axonal transport. Halpern JL, et al. **Curr Top Microbiol Immunol** 1995;195:221–41 (147 ref.)
Metabolic trafficking between neurons and astrocytes: the glutamate/glutamine cycle revisited. Westergaard N, et al. **Dev Neurosci** 1995;17(4):203–11 (97 ref.)
The regulation of neuron–specific gene expression in the mammalian nervous system. Twyman RM, et al. **J Neurogenet** 1995 Nov;10(2):67–101 (190 ref.)
Metabolic coupling between glia and neurons. Tascopoulos M, et al. **J Neurosci** 1996 Feb 1;16(3):877–85 (98 ref.)
Soluble beta–amyloid induces Alzheimer's disease features in human fibroblasts and in neuronal tissues. Etcheberrigaray R, et al. **Life Sci** 1996;59(5–6):491–8 (42 ref.)
Regulation of neuropeptide expression in the brain by neurotrophins. Potential role in vivo. Carnahan J, et al. **Mol Neurobiol** 1995 Apr–Jun;10(2–3):135–49 (107 ref.)
Neuropeptide messenger plasticity in the CNS neurons following axotomy. Palkovits M. **Mol Neurobiol** 1995 Apr–Jun;10(2–3):91–103 (48 ref.)
Positive and negative regulators of neural fate. Simpson P. **Neuron** 1995 Oct;15(4):739–42 (20 ref.)
Hypothalamic neuronal histamine modulates adaptive behavior and thermogenesis in response to endogenous pyrogen. Sakata T, et al. **Obes Res** 1995 Dec;3 Suppl 5:707S–712S (26 ref.)
Aspects of calcium–activated chloride currents: a neuronal perspective. Scott RH, et al. **Pharmacol Ther** 1995 Jun; 66(3):535–65 (178 ref.)
Gene expression of serotonergic neurons in the central nervous system: molecular and developmental analysis. Joh TH, et al. **Prog Brain Res** 1995;105:43–52 (31 ref.)
Interaction of neuropeptides and excitatory amino acids in the rat superficial spinal dorsal horn. Randić M, et al. **Prog Brain Res** 1995;104:225–53 (306 ref.)
Neuronal Ca2+ stores: activation and function. Simpson PB, et al. **Trends Neurosci** 1995 Jul;18(7):299–306 (63 ref.)
[Parkinson disease and the neuronal dopamine uptake complex] Costentin J. **Ann Pharm Fr** 1995;53(4):145–54 (87 ref.) (Eng. Abstr.) **(Fre)**
[Clinical trials on ganglioside effectiveness] Horga JF, et al. **Rev Neurol** 1995 Jul–Aug;23(122):889–95 (90 ref.) **(Spa)**

PATHOLOGY

Noradrenergic locus coeruleus neurons [letter] Halliday G, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1):191–2 (15 ref.)
Neuronal death after perinatal asphyxia. de Haan HH, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Aug;61(2):123–7 (46 ref.)
Central neuronal tumors in childhood: relationship to dysplasia. Becker LE. **J Neurooncol** 1995;24(1):13–9 (32 ref.)
Calcium, energy metabolism and the development of selective neuronal loss following short–term cerebral ischemia. Sims NR. **Metab Brain Dis** 1995 Sep; 10(3):191–217 (168 ref.)
Ischemic stroke and incomplete infarction. Garcia JH, et al. **Stroke** 1996 Apr;27(4):761–5 (48 ref.)

PHYSIOLOGY

Pre–sympathetic neurones in the rostral ventrolateral medulla of the rat: electrophysiology, morphology and relationship to adjacent neuronal groups. Lipski J, et al. **Acta Neurobiol Exp (Warsz)** 1996;56(1):373–84 (44 ref.)
Carnitine—a known compound, a novel function in neural cells. Nałęcz KA, et al. **Acta Neurobiol Exp (Warsz)** 1996; 56(2):597–609 (86 ref.)
The neuronal response to bladder outlet obstruction, a role for NGF. Dupont MC, et al. **Adv Exp Med Biol** 1995; 385:41–54; discussion 75–9 (85 ref.)
Molecular biology of catecholamine neurons in relation to Parkinson's disease. Nagatsu T, et al. **Adv Neurol** 1996; 69:147–52 (22 ref.)
Contrast of neuronal activity between the supplemental motor area and other cortical motor areas. Tanji J, et al. **Adv Neurol** 1996;70:95–103 (44 ref.)
Neuronal models of prefrontal cortical functions. Dehaene S, et al. **Ann N Y Acad Sci** 1995 Dec 15;769:305–19 (37 ref.)
Mechanisms and functions of serotonin neuronal systems: opportunities for neuropeptide interactions. Fuller RW. **Ann N Y Acad Sci** 1996 Mar 22;780:176–84 (61 ref.)
Cellular signaling pathways and cytoskeletal organization. Kosik KS, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:114–20 (28 ref.)
Definition of signals for neuronal differentiation. Obermeier A, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:1–17 (55 ref.)
Nitric oxide: a neural messenger. Jaffrey SR, et al. **Ann Rev Cell Dev Biol** 1995;11:417–40 (167 ref.)
Sleep as neuronal detoxification and restitution. Inoué S, et al. **Behav Brain Res** 1995 Jul–Aug;69(1–2):91–6 (64 ref.)
Neuroprotection and selective vulnerability of neurons within the nucleus basalis magnocellularis. Wenk GL. **Behav Brain Res** 1995 Dec 14;72(1–2):17–24 (87 ref.)
Neural mechanisms and axon reflexes in asthma. Where are we? Verleden GM. **Biochem Pharmacol** 1996 May 17; 51(10):1247–57 (176 ref.)
Relationship of rostral ventrolateral medullary neurons and angiotensin in the central control of blood pressure. Chan YS, et al. **Biol Signals** 1995 May–Jun;4(3):133–41 (42 ref.)
Hemodynamic mechanisms of neurogenic pulmonary edema. Chen HI. **Biol Signals** 1995 May–Jun;4(3):186–92 (40 ref.)
Cardiovascular function of the paraventricular nucleus of the hypothalamus. Coote JH. **Biol Signals** 1995 May–Jun; 4(3):142–9 (31 ref.)
The role of inducible transcription factors in apoptotic nerve cell death. Dragunow M, et al. **Brain Res Brain Res Rev** 1995 Jul;21(1):1–28 (374 ref.)
The ratio of pre– to postganglionic neurons and related issues in the autonomic nervous system. Wang FB, et al. **Brain Res Brain Res Rev** 1995 Jul;21(1):93–115 (260 ref.)
Functional organization of tau proteins during neuronal differentiation and development. Maccioni RB, et al. **Braz J Med Biol Res** 1995 Aug;28(8):827–41 (78 ref.)
Neuronal growth and death: order and disorder in the axoplasm. Cleveland DW. **Cell** 1996 Mar 8;84(5):663–6 (17 ref.)
Neuronal target recognition. Garrity PA, et al. **Cell** 1995 Oct 20;83(2):177–85 (70 ref.)
Making the connection: cytoskeletal rearrangements during growth cone guidance. Tanaka E, et al. **Cell** 1995 Oct 20; 83(2):171–6 (40 ref.)
Regulation of neural precursor differentiation in the embryonic and adult forebrain. Bartlett PF, et al. **Clin Exp Pharmacol Physiol** 1995 Aug;22(8):559–62 (21 ref.)
Cytokines and neuronal differentiation. Mehler MF, et al. **Crit Rev Neurobiol** 1995;9(4):419–46 (291 ref.)
Neurotrophic factors. Neurotrophin autocrine loops. Davies AM, et al. **Curr Biol** 1995 Jul 1;5(7):723–6 (15 ref.)
Neural modulation: following your own rhythm. Marder E. **Curr Biol** 1996 Feb 1;6(2):119–21 (10 ref.)
Biomagnetic neurosensors. Rechnitz GA, et al. **Curr Opin Biotechnol** 1996 Feb;7(1):55–9 (56 ref.)
Temporal structure in spatially organized neuronal ensembles: a role for interneuronal networks. Buzsáki G, et al. **Curr Opin Neurobiol** 1995 Aug;5(4):504–10 (61 ref.)
Oscillation in motor pattern–generating networks. Calabrese RL. **Curr Opin Neurobiol** 1995 Dec;5(6):816–23 (55 ref.)
Neureglins and their receptors. Carraway KL 3rd, et al. **Curr Opin Neurobiol** 1995 Oct;5(5):606–12 (54 ref.)
Calcium regulation of gene expression in neurons: the mode of entry matters. Gallin WJ, et al. **Curr Opin Neurobiol** 1995 Jun;5(3):367–74 (61 ref.)
Trophic factor response to neuronal stimuli or injury. Isackson PJ. **Curr Opin Neurobiol** 1995 Jun;5(3):350–7 (75 ref.)
Theory in motion. Marder E, et al. **Curr Opin Neurobiol** 1995 Dec;5(6):832–40 (80 ref.)
Neuronal circuitry controlling the near response. Mays LE, et al. **Curr Opin Neurobiol** 1995 Dec;5(6):763–8 (29 ref.)
Molecular biology and physiology at the single–cell level. Monyer H, et al. **Curr Opin Neurobiol** 1995 Jun;5(3):382–7 (21 ref.)
Binding in models of perception and brain function. von der Malsburg C. **Curr Opin Neurobiol** 1995 Aug;5(4):520–6 (70 ref.)
Steroid hormone effects on neurons subserving behavior. Weeks JC, et al. **Curr Opin Neurobiol** 1995 Dec;5(6):809–15 (57 ref.)
Neuroexocytosis. Benfenati F, et al. **Curr Top Microbiol Immunol** 1995;195:195–219 (132 ref.)
Role of environmental signals and transcriptional regulators in neural crest development. Groves AK, et al. **Dev Genet** 1996;18(1):64–72 (82 ref.)
Invertebrate versus vertebrate neurogenesis: variations on the same theme? Salzberg A, et al. **Dev Genet** 1996;18(1):1–10 (128 ref.)
Cell fate specification and differentiation in the nervous system of Caenorhabditis elegans. Sengupta P, et al. **Dev Genet** 1996;18(1):73–80 (65 ref.)
Retinoblastoma gene in mouse neural development. Slack RS, et al. **Dev Genet** 1996;18(1):81–91 (155 ref.)
Cadherin expression in the developing vertebrate CNS: from neuromeres to brain nuclei and neural circuits. Redies C. **Exp Cell Res** 1995 Oct;220(2):243–56 (187 ref.)
Neurotrophins and their receptors in chicken neuronal development. Hallböök F, et al. **Int J Dev Biol** 1995 Oct; 39(5):855–68 (115 ref.)
Developmental neurotransmitters. Signals for shaping neuronal circuitry. Redburn DA, et al. **Invest Ophthalmol Vis Sci** 1996 Jul;37(8):1479–82 (16 ref.)
Neurons and glial cells of the enteric nervous system: studies in tissue culture. Hanani M. **J Basic Clin Physiol Pharmacol** 1993 Jul–Sep;4(3):157–79 (72 ref.)
Mitochondria, magnesium and migraine. Welch KM, et al. **J Neurol Sci** 1995 Dec;134(1–2):9–14 (62 ref.)
Cytoskeletal derangements following central nervous system injury: modulation by neurotrophic gene transfection. Hayes RL, et al. **J Neurotrauma** 1995 Oct;12(5):933–41 (58 ref.)
Neuronal apoptosis: current understanding of molecular mechanisms and potential role in ischemic brain injury. Johnson EM JR, et al. **J Neurotrauma** 1995 Oct; 12(5):843–52 (102 ref.)
Signalling synapse formation between identified neurons. Drapeau P, et al. **J Physiol Paris** 1995;89(3):115–23 (52 ref.)
Bulbospinal catecholamine neurones and sympathetic pattern generation. Coote JH, et al. **J Physiol Pharmacol** 1995 Sep; 46(3):259–71 (50 ref.)
Neural control of vocalization: respiratory and emotional influences. Davis PJ, et al. **J Voice** 1996 Mar;10(1):23–38 (107 ref.)
Neuropoiesis: proposal for a connectionistic neurobiology. Jobe TH, et al. **Med Hypotheses** 1995 Aug;45(2):147–63 (145 ref.)
The nitric oxide/ascorbate cycle: how neurones may control their own oxygen supply. Millar J. **Med Hypotheses** 1995 Jul;45(1):21–6 (65 ref.)
Involvement of endogenous benzodiazepine receptor ligands in brain disorders: therapeutic potential for benzodiazepine antagonists? Polc P. **Med Hypotheses** 1995 Jun;44(6):439–46 (51 ref.)
Excitatory amino acid receptor–mediated neuronal signal transduction: modulation by polyamines and calcium. Iqbal Z. **Mol Cell Biochem** 1995 Aug–Sep;149–150:233–40 (61 ref.)
Glutamate and Parkinson's disease. Blandini F, et al. **Mol Neurobiol** 1996 Feb;12(1):73–94 (165 ref.)
Neurotrophin–3 as an essential signal for the developing nervous system. Chalazonitis A. **Mol Neurobiol** 1996 Feb; 12(1):39–53 (90 ref.)
Maintaining the neuronal phenotype after injury in the adult CNS. Neurotrophic factors, axonal growth substrates, and gene therapy. Tuszynski MH, et al. **Mol Neurobiol** 1995 Apr–Jun;10(2–3):151–67 (107 ref.)
Physiological relevance and functional potential of central nervous system–derived cell lines. Whittemore SR, et al. **Mol Neurobiol** 1996 Feb;12(1):13–38 (165 ref.)
Making the connections in nerve regeneration. Nash J, et al. **Nat Med** 1996 Jan;2(1):25–6 (19 ref.)
Mechanisms of neuronal polarity. Cid–Arregui A, et al. **Neurobiol Aging** 1995 May–Jun;16(3):239–43; discussion 243–6 (61 ref.)
Roles of cytokines in the neural–immune interactions: modulation of NMDA responses by IFN–alpha. Katafuchi T, et al. **Neurobiology (Bp)** 1995;3(3–4):319–27 (39 ref.)
A molecular switch for the neuron–glia developmental decision. Anderson DJ. **Neuron** 1995 Dec;15(6):1219–22 (25 ref.)
Networks of neurons, networks of genes. Berkowitz A. **Neuron** 1996 Aug;17(2):199–202 (25 ref.)
Neuronal chain gangs: homotypic contacts support migration into the olfactory bulb. O'Rourke NA. **Neuron** 1996 Jun; 16(6):1061–4 (15 ref.)
Cell stress genes and neuronal protection. Latchman DS. **Neuropathol Appl Neurobiol** 1995 Dec;21(6):475–7 (24 ref.)
Neuronal activities underlying the electroencephalogram and evoked potentials of sleeping and waking: implications for information processing. Coenen AM. **Neurosci Biobehav Rev** 1995 Fall;19(3):447–63 (75 ref.)
Intercellular communication in the brain: wiring versus volume transmission. Agnati LF, et al. **Neuroscience** 1995 Dec;69(3):711–26 (159 ref.)
Rationale for intrastriatal grafting of striatal neuroblasts in patients with Huntington's disease. Peschanski M, et al. **Neuroscience** 1995 Sep;68(2):273–85 (159 ref.)
Agrin: toward a molecular understanding of synapse regeneration. Deyst KA, et al. **Neurosurgery** 1995 Jul; 37(1):71–7 (81 ref.)
Neurotrophins and the specification of neuronal phenotype. Lewin GR. **Philos Trans R Soc Lond B Biol Sci** 1996 Mar 29;351(1338):405–11 (44 ref.)
Nonsynaptic modulation of neuronal activity in the brain: electric currents and extracellular ions. Jefferys JG. **Physiol Rev** 1995 Oct;75(4):689–723 (404 ref.)
Radial versus tangential migration of neuronal clones in the developing cerebral cortex [comment] Rakic P. **Proc Natl Acad Sci U S A** 1995 Dec 5;92(25):11323–7 (61 ref.) Comment on: Proc Natl Acad Sci U S A 1995 Dec 5;92(25):11676–80.
The differentiation and function of the touch receptor neurons of Caenorhabditis elegans. Chalfie M. **Prog Brain Res** 1995;105:179–82 (24 ref.)
Neuronal calcium channels encoded by the alpha 1A subunit and their contribution to excitatory synaptic transmission in the CNS. Wheeler DB, et al. **Prog Brain Res** 1995; 105:65–78 (51 ref.)
Ensemble activity and behavior: what's the code? Deadwyler SA, et al. **Science** 1995 Nov 24;270(5240):1316–8 (24 ref.)
Cracking the neuronal code. Ferster D, et al. **Science** 1995 Nov 3;270(5237):756–7 (20 ref.)
Development and plasticity of cortical processing architectures. Singer W. **Science** 1995 Nov 3; 270(5237):758–64 (66 ref.)
Neurotrophins and neuronal plasticity. Thoenen H. **Science** 1995 Oct 27;270(5236):593–8 (64 ref.)
The Bcl–2 family of proteins, and the regulation of neuronal survival. Davies AM. **Trends Neurosci** 1995 Aug; 18(8):355–8 (49 ref.)
Theory meets experiment: correlated neural activity helps determine ocular dominance column periodicity. Goodhill GJ, et al. **Trends Neurosci** 1995 Oct;18(10):437–9 (38 ref.)
Integrator or coincidence detector? The role of the cortical neuron revisited. König P, et al. **Trends Neurosci** 1996 Apr; 19(4):130–7 (45 ref.)

Adenylate cyclases: critical foci in neuronal signaling. Mons N, et al. **Trends Neurosci** 1995 Dec;18(12):536–42 (60 ref.)
Second-order neurones and receptor mechanisms in visual- and olfactory-information processing. Nakanishi S. **Trends Neurosci** 1995 Aug;18(8):359–64 (50 ref.)
The endosomal-lysosomal system of neurons: new roles. Nixon RA, et al. **Trends Neurosci** 1995 Nov;18(11):489–96 (80 ref.)
A small step for the cell, a giant leap for mankind: a hypothesis of neocortical expansion during evolution. Rakic P. **Trends Neurosci** 1995 Sep;18(9):383–8 (59 ref.)
Ca(2+)-activated K+ currents in neurones: types, physiological roles and modulation. Sah P. **Trends Neurosci** 1996 Apr;19(4):150–4 (66 ref.)
Selective neuronal vulnerability in the hippocampus—a role for gene expression? Schreiber SS, et al. **Trends Neurosci** 1995 Oct;18(10):446–51 (93 ref.)
Dendritic spines for neuroprotection: a hypothesis. Segal M. **Trends Neurosci** 1995 Nov;18(11):468–71 (33 ref.)
Neuronal Ca2+ stores: activation and function. Simpson PB, et al. **Trends Neurosci** 1995 Jul;18(7):299–306 (63 ref.)
[Programmed neural cell death?] Langmeier M. **Cesk Fysiol** 1995 Dec;44(4):188–90 (26 ref.) (Eng. Abstr.) **(Cze)**
[Current information on nitric oxide as a neuronal messenger] Haulică I, et al. **Rom J Physiol** 1994 Jan–Dec;31(1–4):3–12 (28 ref.) **(Fre)**
[Cellular mechanisms of circadian clocks] Roenneberg T, et al. **Wien Med Wochenschr** 1995;145(17–18):385–9 (74 ref.) (Eng. Abstr.) **(Ger)**
[The role of incomplete terminal repair of chromosomal DNA in the aging of neurons and postmitotic organisms] Olovnikov AM. **Izv Akad Nauk Ser Biol** 1995 Jul–Aug;(4):504–7 (12 ref.) (Eng. Abstr.) **(Rus)**
[The regulation of calcium homeostasis in nerve cells] Kozlovskiĭ VL. **Usp Fiziol Nauk** 1995 Jul–Sep;26(3):14–24 (105 ref.) (Eng. Abstr.) **(Rus)**

SECRETION

Deciphering neuronal secretion: tools of the trade. Linial M, et al. **Biochim Biophys Acta** 1996 Jun 10;1286(2):117–52 (395 ref.)

TRANSPLANTATION

Grafting of genetically manipulated cells into adult brain: toward graft-gene therapy. Uchida K, et al. **Keio J Med** 1996 Jun;45(2):81–9 (40 ref.)
[Cell and gene transfers for therapeutic use into the central nervous system] Peschanski M. **Ann Endocrinol (Paris)** 1995;56(6):375–7 (17 ref.) (Eng. Abstr.) **(Fre)**
[Retinal grafts: biological problems and clinical stakes] Sahel JA, et al. **Bull Acad Natl Med** 1996 Mar;180(3):633–43; discussion 643–4 (24 ref.) (Eng. Abstr.) **(Fre)**

ULTRASTRUCTURE

The Golgi apparatus and the pathogenesis of Alzheimer's disease [comment] Dal Canto MC. **Am J Pathol** 1996 Feb; 148(2):355–60 (40 ref.) Comment on: Am J Pathol 1996 Feb;148(2):415–26.
Dendritic integration in mammalian neurons, a century after Cajal. Yuste R, et al. **Neuron** 1996 Apr;16(4):701–16 (208 ref.)

VIROLOGY

Spread of MHV-JHM from nasal cavity to white matter of spinal cord. Transneuronal movement and involvement of astrocytes. Perlman S, et al. **Adv Exp Med Biol** 1995; 380:73–8 (21 ref.)
Virus–neuron–cytotoxic T lymphocyte interactions. Rall GF, et al. **Curr Top Microbiol Immunol** 1995;202:261–73 (33 ref.)

NEURONS, AFFERENT

see related
RECEPTORS, SENSORY

Autonomic and sensory neuron cultures. Nishi R. **Methods Cell Biol** 1996;51:249–63 (11 ref.)

CHEMISTRY

Functions of ionotropic and metabotropic glutamate receptors in sensory transmission in the mammalian thalamus. Salt TE, et al. **Prog Neurobiol** 1996 Jan; 48(1):55–72 (220 ref.)

DRUG EFFECTS

Etorphine elicits unique inhibitory-agonist and excitatory-antagonist actions at opioid receptors on sensory neurons: new rationale for improved clinical analgesia and treatment of opiate addiction. Crain SM, et al. **NIDA Res Monogr** 1995;147:234–68 (67 ref.)
Peptidergic afferents: physiological aspects. Urban L, et al. **Prog Brain Res** 1995;104:255–69 (71 ref.)

PHYSIOLOGY

The role of mesolimbic dopaminergic and retrohippocampal afferents to the nucleus accumbens in latent inhibition: implications for schizophrenia. Gray JA, et al. **Behav Brain Res** 1995 Nov;71(1–2):19–31 (80 ref.)
Tachykinins, sensory nerves, and asthma—an overview. Lundberg JM. **Can J Physiol Pharmacol** 1995 Jul; 73(7):908–14 (99 ref.)
Oculocentric spatial representation in parietal cortex. Colby CL, et al. **Cereb Cortex** 1995 Sep–Oct;5(5):470–81 (38 ref.)
Functional mapping of odor-activated neurons in the olfactory bulb. Guthrie KM, et al. **Chem Senses** 1995 Apr; 20(2):271–82 (44 ref.)
Correlated firing in sensory-motor systems. König P, et al. **Curr Opin Neurobiol** 1995 Aug;5(4):511–9 (94 ref.)
Relation of chemical structure to specificity of response in olfactory glomeruli. Mori K. **Curr Opin Neurobiol** 1995 Aug;5(4):467–74 (50 ref.)
Neuropathogenesis and neuropharmacology of psoriasis. Raychaudhuri SP, et al. **Int J Dermatol** 1995 Oct; 34(10):685–93 (114 ref.)
Presynaptic facilitation revisited: state and time dependence. Byrne JH, et al. **J Neurosci** 1996 Jan 15;16(2):425–35 (132 ref.)
Perspectives on the role of afferent signals in control of motor neuroprostheses. Johnson KO, et al. **Med Eng Phys** 1995 Oct;17(7):481–96 (99 ref.)
Role of neurotrophins and trk receptors in the development and maintenance of sensory neurons: an overview. Lindsay RM. **Philos Trans R Soc Lond B Biol Sci** 1996 Mar 29; 351(1338):365–73 (53 ref.)
Phenotypic modification of primary sensory neurons: the role of nerve growth factor in the production of persistent pain. Woolf CJ. **Philos Trans R Soc Lond B Biol Sci** 1996 Mar 29;351(1338):441–8 (34 ref.)
Neuropeptides in morphologically and functionally identified primary afferent neurons in dorsal root ganglia: substance P, CGRP and somatostatin. Lawson SN. **Prog Brain Res** 1995;104:161–73 (56 ref.)
Electrophysiology of neuropeptides in the sensory spinal cord. Radhakrishnan V, et al. **Prog Brain Res** 1995; 104:175–95 (176 ref.)
Plasticity of cutaneous primary afferent projections to the spinal dorsal horn. Wilson P, et al. **Prog Neurobiol** 1996 Feb;48(2):105–29 (240 ref.)
Receptive-field dynamics in the central visual pathways. DeAngelis GC, et al. **Trends Neurosci** 1995 Oct; 18(10):451–8 (60 ref.)
[From nociception to pain: to feel or not to feel (editorial)] Konttinen YT, et al. **Duodecim** 1994;110(6):545–8 (15 ref.) **(Fin)**

NEURONS, EFFERENT

PHYSIOLOGY

Capsaicin-sensitive sensory-motor neurotransmission in the peripheral control of cardiovascular function. Rubino A, et al. **Cardiovasc Res** 1996 Apr;31(4):467–79 (160 ref.)

NEURONS, FUSIMOTOR see **MOTOR NEURONS, GAMMA**

NEURONS, GAMMA MOTOR see **MOTOR NEURONS, GAMMA**

NEURONS, MOTOR see **MOTOR NEURONS**

NEURONS, OLFACTORY RECEPTOR see **OLFACTORY RECEPTOR NEURONS**

NEURONS, SENSORY see **NEURONS, AFFERENT**

NEUROPATHIES, AMYLOID see **AMYLOID NEUROPATHIES**

NEUROPATHIES, HEREDITARY MOTOR AND SENSORY

GENETICS

[Hereditary motor and sensory neuropathies. Clinical and molecular genetic aspects] Lechner-Scott JS, et al. **Schweiz Arch Neurol Psychiatr** 1995;146(4):157–67 (55 ref.) (Eng. Abstr.) **(Ger)**

NEUROPATHY, HEREDITARY MOTOR AND SENSORY TYPE IV see **REFSUM DISEASE**

NEUROPATHY, TYPE I HEREDITARY MOTOR AND SENSORY see **CHARCOT-MARIE DISEASE**

NEUROPEPTIDE RECEPTORS see **RECEPTORS, NEUROPEPTIDE**

NEUROPEPTIDE Y

BIOSYNTHESIS

Neuropeptide Y, the hypothalamus, and diabetes: insights into the central control of metabolism. Frankish HM, et al. **Peptides** 1995;16(4):757–71 (154 ref.)

GENETICS

Evolution of neuropeptide Y, peptide YY and pancreatic polypeptide. Larhammar D. **Regul Pept** 1996 Apr 9; 62(1):1–11 (104 ref.)
[Second messenger-mediated transcriptional regulation of neural genes and possible drug action sites] Higuchi H, et al. **Nippon Yakurigaku Zasshi** 1995 Dec;106(6):365–78 (50 ref.) (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

Roles of peptides and other substances in cotransmission from vascular autonomic and sensory neurons. Morris JL, et al. **Can J Physiol Pharmacol** 1995 May;73(5):521–32 (123 ref.)

PHYSIOLOGY

Neuropeptide Y. A novel sympathetic stress hormone and more. Zukowska-Grojec Z. **Ann N Y Acad Sci** 1995 Dec 29;771:219–33 (42 ref.)
Neurobiology and clinical aspects of neuropeptide Y. Heilig M, et al. **Crit Rev Neurobiol** 1995;9(2–3):115–36 (252 ref.)
Exercise and the neurobiological control of food intake and energy expenditure. Richard D. **Int J Obes Relat Metab Disord** 1995 Oct;19 Suppl 4:S73–9 (78 ref.)
Photic information coded by vasoactive intestinal polypeptide and neuropeptide Y. Shinohara K, et al. **Neurosci Biobehav Rev** 1995 Fall;19(3):349–52 (16 ref.)
Brain peptides and obesity: pharmacologic treatment. Leibowitz SF. **Obes Res** 1995 Nov;3 Suppl 4:573S–589S (196 ref.)
[Effect of brain peptides on feeding and body weight regulation] Inui A, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:49–57 (20 ref.) **(Jpn)**

SECRETION

Central insulin may up-regulate thyroid activity by suppressing neuropeptide Y release in the paraventricular nucleus. McCarty MF. **Med Hypotheses** 1995 Aug; 45(2):193–9 (114 ref.)

NEUROPEPTIDE Y-LIKE IMMUNOREACTIVE PEPTIDE see **NEUROPEPTIDE Y**

NEUROPEPTIDES

see related
RECEPTORS, NEUROPEPTIDE

Peptides in the nervous systems of cnidarians: structure, function, and biosynthesis. Grimmelikhuijzen CJ, et al. **Int Rev Cytol** 1996;167:37–89 (124 ref.)

ANALYSIS

The chemical neuroanatomy of the mammalian pineal gland: neuropeptides. Møller M, et al. **Neurochem Int** 1996 Jan; 28(1):23–33 (72 ref.)
Peptidergic neurons in the vertebrate spinal cord: evolutionary trends. Brodin L, et al. **Prog Brain Res** 1995; 104:61–74 (119 ref.)
Peptides in motoneurons. Raivich G, et al. **Prog Brain Res** 1995;104:3–20 (185 ref.)

BIOSYNTHESIS

Proenkephalin-processing enzymes in chromaffin granules: model for neuropeptide biosynthesis. Hook VY, et al. **Ann N Y Acad Sci** 1996 Mar 22;780:121–33 (22 ref.)
Proteolytic processing mechanisms in the biosynthesis of neuroendocrine peptides: the subtilisin-like proprotein convertases. Rouillé Y, et al. **Front Neuroendocrinol** 1995 Oct;16(4):322–61 (202 ref.)
Peptidergic transmission: from morphological correlates to functional implications. Zupanc GK. **Micron** 1996 Feb; 27(1):35–91 (630 ref.)
Regulation of neuropeptide expression in the brain by neurotrophins. Potential role in vivo. Carnahan J, et al. **Mol Neurobiol** 1995 Apr–Jun;10(2–3):135–49 (107 ref.)
Secretogranin II: molecular properties, regulation of biosynthesis and processing to the neuropeptide secretoneurin. Fischer-Colbrie R, et al. **Prog Neurobiol** 1995 May;46(1):49–70 (209 ref.)

CHEMISTRY

Mass spectrometry, high performance liquid chromatography, and brain peptides. Desiderio DM. **Biopolymers** 1996;40(3):257–64 (45 ref.)
Molecular biology of neurohormone precursors in the eyestalk of Crustacea. De Kleijn DP, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1995 Dec; 112(4):573–9 (32 ref.)

GENETICS

Neuropeptide messenger plasticity in the CNS neurons following axotomy. Palkovits M. **Mol Neurobiol** 1995 Apr–Jun;10(2–3):91–103 (48 ref.)
Transgenic targeting of neuroendocrine peptide genes in the hypothalamic-pituitary axis. Waschek JA. **Mol Neurobiol** 1995 Apr–Jun;10(2–3):205–17 (50 ref.)
Immediate early genes (IEGs) encoding for inducible transcription factors (ITFs) and neuropeptides in the nervous system: functional network for long-term plasticity and pain. Herdegen T, et al. **Prog Brain Res** 1995; 104:299–321 (184 ref.)
Regulation of spinal neuropeptide genes in a rat model of peripheral inflammation and hyperalgesia. Ruda MA, et al. **Prog Brain Res** 1995;104:349–65 (121 ref.)

Neuronal calcium channels encoded by the alpha 1A subunit and their contribution to excitatory synaptic transmission in the CNS. Wheeler DB, et al. **Prog Brain Res** 1995; 105:65–78 (51 ref.)

HISTORY

The history of neuropeptides 1. Klavdieva MM. **Front Neuroendocrinol** 1995 Oct;16(4):293–321 (176 ref.)

IMMUNOLOGY

The role of cytokines and neuroendocrine hormones in cutaneous immunity and inflammation. Luger TA, et al. **Allergy** 1995 Apr;50(4):292–302 (119 ref.)

Endocrine peptides 'moonlighting' as immune modulators: roles for somatostatin and GH-releasing factor. Campbell RM, et al. **J Endocrinol** 1995 Dec;147(3):383–96 (120 ref.)

METABOLISM

Neuropeptides, nerve growth factor and eczema. Giannetti A. **Australas J Dermatol** 1996 May;37 Suppl 1:S1–3 (47 ref.)

Neuroendocrine changes in heart failure and their clinical relevance. Parmley WW. **Clin Cardiol** 1995 Aug; 18(8):440–5 (27 ref.)

Peptidergic transmission: from morphological correlates to functional implications. Zupanc GK. **Micron** 1996 Feb; 27(1):35–91 (630 ref.)

Antipsychotics and neuropeptides: the atypical profile of CI-943 and its relationship to neurotensin. Liégeois JF, et al. **Neurosci Biobehav Rev** 1995 Winter;19(4):519–31 (101 ref.)

Inactivation of neuropeptides. Csuhai E, et al. **Prog Brain Res** 1995;104:131–42 (122 ref.)

Release of neuropeptides in the spinal cord. Duggan AW. **Prog Brain Res** 1995;104:197–223 (162 ref.)

Neuropeptides in neuroblastomas and ganglioneuromas. Kogner P. **Prog Brain Res** 1995;104:325–38 (99 ref.)

Neuropeptide converting and processing enzymes in the spinal cord and cerebrospinal fluid. Persson S, et al. **Prog Brain Res** 1995;104:111–30 (195 ref.)

Interaction of neuropeptides and excitatory amino acids in the rat superficial spinal dorsal horn. Randić M, et al. **Prog Brain Res** 1995;104:225–53 (306 ref.)

Prostaglandin-induced neuropeptide release from spinal cord. Vasko MR. **Prog Brain Res** 1995;104:367–80 (80 ref.)

Neuropeptide changes in cortical and deep gray structures in Alzheimer's disease. Roeske LC, et al. **Rev Neurosci** 1995 Oct–Dec;6(4):317–28 (156 ref.)

[Proteolytic enzymes and regulation of the level of active neuropeptides] Vernigora AN, et al. **Biokhimiia** 1995 Oct; 60(10):1575–9 (46 ref.) (Eng. Abstr.) **(Rus)**

[Mechanisms of regulation and the biological role of carboxypeptidase H--a neuropeptide-processing enzyme] Vernigora AN, et al. **Biokhimiia** 1995 Dec;60(12):1953–63 (124 ref.) (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

Convergent signalling in the action of integrins, neuropeptides, growth factors and oncogenes. Rozengurt E. **Cancer Surv** 1995;24:81–96 (49 ref.)

Neuropeptides in the adrenal gland: distribution, localization of receptors, and effects on steroid hormone synthesis. Tóth IE, et al. **Endocr Res** 1995 Feb–May;21(1–2):39–51 (135 ref.)

Central noradrenergic neurones and stress. Stanford SC. **Pharmacol Ther** 1995;68(2):297–42 (360 ref.)

Peptidergic afferents: physiological aspects. Urban L, et al. **Prog Brain Res** 1995;104:255–69 (71 ref.)

PHYSIOLOGY

Neuropeptides in anxiety disorders. Effects of lactation. Altemus M. **Ann N Y Acad Sci** 1995 Dec 29;771:697–707 (80 ref.)

Mechanisms and functions of serotonin neuronal systems: opportunities for neuropeptide interactions. Fuller RW. **Ann N Y Acad Sci** 1996 Mar 22;780:176–84 (61 ref.)

Interactions and coexistence of neuropeptides and serotonin in spinal autonomic systems. Helke CJ, et al. **Ann N Y Acad Sci** 1996 Mar 22;780:185–92 (49 ref.)

The history of neuropeptide research: version 5.a. Kastin AJ, et al. **Ann N Y Acad Sci** 1996 Mar 22;780:1–18 (138 ref.)

Role of allatostatins in the regulation of juvenile hormone synthesis. Stay B, et al. **Arch Insect Biochem Physiol** 1996; 32(3–4):287–97 (39 ref.)

Peptides as neurotransmitters in vascular autonomic neurons. Morris JL. **Clin Exp Pharmacol Physiol** 1995 Nov; 22(11):792–802 (119 ref.)

Pituitary adenylate cyclase-activating polypeptide (PACAP) and PACAP/vasoactive intestinal polypeptide receptors: actions on the anterior pituitary gland. Rawlings SR, et al. **Endocr Rev** 1996 Feb;17(1):4–29 (170 ref.)

Neuropeptides in the human brain. Takahashi K, et al. **Funct Neurol** 1996 Mar–Jun;11(2–3):65–98 (266 ref.)

Neuropeptides. Koblenzer CS. **Int J Dermatol** 1995 Oct; 34(10):694–5 (13 ref.)

Neuropathogenesis and neuropharmacology of psoriasis. Raychaudhuri SP, et al. **Int J Dermatol** 1995 Oct; 34(10):685–93 (114 ref.)

The pharmacology of FMRFamide-related neuropeptides in nematodes: new opportunities for rational anthelmintic discovery? Geary TG, et al. **Int J Parasitol** 1995 Nov; 25(11):1273–80 (42 ref.)

Platyhelminth FMRFamide-related peptides. Shaw C, et al. **Int J Parasitol** 1996 Apr;26(4):335–45 (59 ref.)

Neuropeptides implicated in the control of diuresis in insects. Coast GM. **Peptides** 1996;17(2):327–36 (61 ref.)

ACTH-related peptides: receptors and signal transduction systems involved in their neurotrophic and neuroprotective actions. Hol EM, et al. **Peptides** 1995;16(5):979–93 (150 ref.)

Pheromone biosynthesis activating neuropeptides: functions and chemistry. Teal PE, et al. **Peptides** 1996;17(2):337–44 (69 ref.)

The peptidergic innervation of spinal motoneurons via the bulbospinal 5-hydroxytryptamine pathway. Cullheim S, et al. **Prog Brain Res** 1995;104:21–40 (115 ref.)

Electrophysiology of neuropeptides in the sensory spinal cord. Radhakrishnan V, et al. **Prog Brain Res** 1995; 104:175–95 (176 ref.)

Organization of peptidergic neurons in the dorsal horn of the spinal cord: anatomical and functional correlates. Ribeiro-da-Silva A, et al. **Prog Brain Res** 1995;104:41–59 (77 ref.)

Neuropeptides and spinal cord reflexes. Wiesenfeld-Hallin Z. **Prog Brain Res** 1995;104:271–82 (104 ref.)

Neuropeptides as native immune modulators. Singh VK. **Prog Drug Res** 1995;45:9–31 (101 ref.)

The opioid/anti-opioid balance in shock: a new target for therapy in resuscitation. Bertolini A. **Resuscitation** 1995 Aug;30(1):29–42 (177 ref.)

[Neuropeptides and nasal mucosa: a general review and update] Duroux S, et al. **Rev Laryngol Otol Rhinol (Bord)** 1996;117(1):3–7 (38 ref.) (Eng. Abstr.) **(Fre)**

[Effect of gut peptides on feeding and body weight regulation] Inui A, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:40–8 (15 ref.) **(Jpn)**

[The vasomotor effects of neuropeptides] Polenov SA, et al. **Fiziol Zh Im I M Sechenova** 1995 Jun;81(6):29–47 (84 ref.) **(Rus)**

SECRETION

Evaluation of the role of mammalian thyroid parafollicular cells. Sawicki B. **Acta Histochem** 1995 Oct;97(4):389–99 (74 ref.)

NEUROPHYSINS

BLOOD

[Neurophysin] Terano T, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:351–5 (17 ref.) **(Jpn)**

PHYSIOLOGY

Development and evolutionary aspects of thymic T cell education to neuroendocrine self. Geenen V, et al. **Acta Haematol** 1996;95(3–4):263–7 (27 ref.)

NEUROPHYSIOLOGY

see related

SENSATION

Natural history of amyotrophic lateral sclerosis. Quantification of symptoms, signs, strength, and function. Brooks BR, et al. **Adv Neurol** 1995;68:163–84 (27 ref.)

Neurophysiologic monitoring during cranial base surgery: is it necessary? Sekhar LN, et al. **Clin Neurosurg** 1995; 42:180–202 (37 ref.)

The psychoanalytical concept from a neurophysiological perspective. Derevenco P. **Rom J Physiol** 1994 Jan–Dec; 31(1–4):13–8 (35 ref.)

METHODS

[A research tool for autonomic nervous function: methodology and application of microneurography] Mano T. **Masui** 1995;44 Suppl:S17–25 (41 ref.) **(Jpn)**

TRENDS

Clinical neurophysiology of cortical sensorimotor function: yesterday, today, and tomorrow. Aminoff MJ. **J Clin Neurophysiol** 1996 May;13(3):219–26 (60 ref.)

NEUROPROTECTIVE AGENTS

PHARMACOKINETICS

Clinical pharmacokinetics of drugs for Alzheimer's disease. Parnetti L. **Clin Pharmacokinet** 1995 Aug;29(2):110–29 (111 ref.)

PHARMACOLOGY

Neuroprotective use-dependent blockers of Na+ and Ca2+ channels controlling presynaptic release of glutamate. Goldin SM, et al. **Ann N Y Acad Sci** 1995 Sep 15;765:210–29 (59 ref.)

Neuroprotective properties of the uncompetitive NMDA receptor antagonist remacemide hydrochloride. Palmer GC, et al. **Ann N Y Acad Sci** 1995 Sep 15;765:236–47; discussion 248 (38 ref.)

Quantitative histological evaluation of neuroprotective compounds. Scallet AC. **Ann N Y Acad Sci** 1995 Sep 15; 765:47–58; discussion 59–61 (39 ref.)

Neuroprotective effects of free radical scavengers and energy repletion in animal models of neurodegenerative disease. Schulz JB, et al. **Ann N Y Acad Sci** 1995 Sep 15;765:100–10; discussion 116–8 (56 ref.)

Adenosine: a prototherapeutic concept in neurodegeneration. von Lubitz DK, et al. **Ann N Y Acad Sci** 1995 Sep 15; 765:163–78; discussion 196–7 (123 ref.)

The neuroprotective properties of the Ginkgo biloba leaf: a review of the possible relationship to platelet-activating factor (PAF). Smith PF, et al. **J Ethnopharmacol** 1996 Mar; 50(3):131–9 (62 ref.)

The inhibition of peroxide formation as a possible substrate for the neuroprotective action of dihydroergocryptine. Favit A, et al. **J Neural Transm Suppl** 1995;45:297–305 (30 ref.)

Nitric oxide synthase, immunophilins and poly(ADP-ribose) synthetase: novel targets for the development of neuroprotective drugs. Zhang J, et al. **Neurol Res** 1995 Aug;17(4):285–8 (37 ref.)

New pharmacologic approaches to acute spinal cord injury. Rhoney DH, et al. **Pharmacotherapy** 1996 May–Jun; 16(3):382–92 (82 ref.)

Na+ channels as targets for neuroprotective drugs. Taylor CP, et al. **Trends Pharmacol Sci** 1995 Sep;16(9):309–16 (74 ref.)

THERAPEUTIC USE

Possible neuroprotective therapy for Parkinson's disease. Ogawa N. **Acta Med Okayama** 1995 Aug;49(4):179–85 (70 ref.)

Strategies for neuroprotection with glutamate antagonists. Extrapolating from evidence taken from the first stroke and head injury studies. Bullock R. **Ann N Y Acad Sci** 1995 Sep 15;765:272–8; discussion 298 (11 ref.)

Prophylactic pharmacologic neuroprotection against focal cerebral ischemia. Jonas S. **Ann N Y Acad Sci** 1995 Sep 15;765:21–5; discussion 26–7 (9 ref.)

The rationale for glutamate antagonists in the treatment of traumatic brain injury. Myseros JS, et al. **Ann N Y Acad Sci** 1995 Sep 15;765:262–71; discussion 298 (44 ref.)

Clinical potential for the use of neuroprotective agents. A brief overview. Trembly B. **Ann N Y Acad Sci** 1995 Sep 15;765:1–20; discussion 26–7 (87 ref.)

Dexamethasone and the prevention of neonatal hypoxic-ischemic brain damage. Tuor UI. **Ann N Y Acad Sci** 1995 Sep 15;765:179–95; discussion 196–7 (97 ref.)

Clinical pharmacokinetics of drugs for Alzheimer's disease. Parnetti L. **Clin Pharmacokinet** 1995 Aug;29(2):110–29 (111 ref.)

Pathophysiology of postischemic hypoxia and cerebral protection: implications of the almitrine and raubasine combination. Chan P. **Eur Neurol** 1995;35 Suppl 1:23–7 (41 ref.)

Pharmacological strategies in the treatment of cerebral ischemia. O'Neill M, et al. **Eur Neurol** 1995;35 Suppl 1:28–36 (88 ref.)

Quantitative electroencephalography in aging brain and cerebrovascular disease: the effects of almitrine-raubasine. Sebban C. **Eur Neurol** 1995;35 Suppl 1:37–42 (16 ref.)

Cardiopulmonary bypass and the central nervous system: potential for cerebral protection. Newman MF, et al. **J Clin Anesth** 1996 May;8(3 Suppl):53S–60S (70 ref.)

Dihydroergocryptine in the treatment of Parkinson's disease. Bonuccelli U, et al. **J Neural Transm Suppl** 1995;45:239–45 (33 ref.)

Pergolide mesylate in Parkinson's disease treatment. Pezzoli G, et al. **J Neural Transm Suppl** 1995;45:203–12 (48 ref.)

Development of HU-211 as a neuroprotectant for ischemic brain damage. Biegon A, et al. **Neurol Res** 1995 Aug; 17(4):275–80 (27 ref.)

Neuroprotective properties of calcium-channel blockers. Zornow MH, et al. **New Horiz** 1996 Feb;4(1):107–14 (58 ref.)

NMDA antagonists: antiepileptic-neuroprotective drugs with diversified neuropharmacological profiles. Sagratella S. **Pharmacol Res** 1995 Jul–Aug;32(1–2):1–13 (124 ref.)

Pharmacological modulation of voltage-gated Na+ channels: a rational and effective strategy against ischemic brain damage. Urenjak J, et al. **Pharmacol Rev** 1996 Mar; 48(1):21–67 (670 ref.)

Noncompetitive NMDA receptor antagonists with fast open-channel blocking kinetics and strong voltage-dependency as potential therapeutic agents for Alzheimer's dementia. Müller WE, et al. **Pharmacopsychiatry** 1995 Jul;28(4):113–24 (90 ref.)

Moderate Parkinson's disease. Strategies for maximizing treatment. Silverstein PM. **Postgrad Med** 1996 Jan; 99(1):52–4, 61–3, 67–8, passim (21 ref.)

Possibilities of brain protection with tirilazad after cardiac arrest. Sterz F, et al. **Semin Thromb Hemost** 1996; 22(1):105–12 (37 ref.)

[Thrombolytic therapy in ischemic cerebrovascular accidents] Hommel M, et al. **Schweiz Rundsch Med Prax** 1995 Sep 19;84(38):1025–31 (59 ref.) (Eng. Abstr.) **(Fre)**

[Pathogenesis and neuroprotective therapy trial in chronic degenerative diseases. Status of antioxidants] Gerlach M, et al. **Med Klin** 1996 Mar 15;91(3):163–70 (69 ref.) **(Ger)**

NEUROPROTECTIVE AGENTS

TOXICITY

Risk assessment strategies for neuroprotective agents. Slikker W Jr, et al. **Ann N Y Acad Sci** 1995 Sep 15;765:198–208; discussion 209 (18 ref.)

NEUROPSYCHOLOGICAL TESTS

What are the functional consequences of neurocognitive deficits in schizophrenia? Green MF. **Am J Psychiatry** 1996 Mar;153(3):321–30 (73 ref.)

Defining neuropsychological dysfunction after coronary artery bypass grafting [see comments] Mahanna EP, et al. **Ann Thorac Surg** 1996 May;61(5):1342–7 (41 ref.) Comment in: Ann Thorac Surg 1996 May;61(5):1295–6.

Vascular cognitive impairment: a new approach to vascular dementia. Bowler JV, et al. **Baillieres Clin Neurol** 1995 Aug;4(2):357–76 (75 ref.)

Is face recognition 'special'? Evidence from neuropsychology. Farah MJ. **Behav Brain Res** 1996 Apr; 76(1–2):181–9 (18 ref.)

A multi-factor account of disability after brain injury: implications for neuropsychological counselling. Montgomery GK. **Brain Inj** 1995 Jul;9(5):453–69 (45 ref.)

The time course of syntactic activation during language processing: a model based on neuropsychological and neurophysiological data. Friederici AD. **Brain Lang** 1995 Sep;50(3):259–81 (61 ref.)

Neuropsychology of multiple sclerosis. Rao SM. **Curr Opin Neurol** 1995 Jun;8(3):216–20 (44 ref.)

The neuropsychiatric aspects of boxing. Mendez MF. **Int J Psychiatry Med** 1995;25(3):249–62 (74 ref.)

Brief report: neuropsychology of autism: a report on the state of the science. Dawson G. **J Autism Dev Disord** 1996 Apr; 26(2):179–84 (38 ref.)

Autism: towards an integration of clinical, genetic, neuropsychological, and neurobiological perspectives. Bailey A, et al. **J Child Psychol Psychiatry** 1996 Jan; 37(1):89–126 (280 ref.)

Neuropsychiatric manifestations of diffuse Lewy body disease. Beck BJ. **J Geriatr Psychiatry Neurol** 1995 Jul; 8(3):189–96 (70 ref.)

Neuropsychological outcomes of several storage diseases with and without bone marrow transplantation. Shapiro EG, et al. **J Inherit Metab Dis** 1995;18(4):413–29 (29 ref.)

Cognitive status as a predictor of right hemisphere stroke outcomes. Sisson RA. **J Neurosci Nurs** 1995 Jun; 27(3):152–6 (19 ref.)

The detection of exaggerated or simulated memory disorder by neuropsychological methods. Leng NR, et al. **J Psychosom Res** 1995 Aug;39(6):767–76 (37 ref.)

MRI hippocampal volume and neuropsychology in epilepsy surgery. Trenerry MR, et al. **Magn Reson Imaging** 1995; 13(8):1125–32 (47 ref.)

Memory tools for the researcher and clinician. Gathercole SE, et al. **Memory** 1994 Jun;2(2):97–101 (14 ref.)

The Autobiographical Memory Interview (AMI) in organic and psychogenic amnesia. Kopelman MD. **Memory** 1994 Jun;2(2):211–35 (66 ref.)

Diagnostic testing and dementia. Sandson TA, et al. **Neurol Clin** 1996 Feb;14(1):45–59 (145 ref.)

Testing cognition may contribute to the diagnosis of movement disorders. Pillon B, et al. **Neurology** 1996 Feb; 46(2):329–34 (75 ref.)

The neuropsychology of depression and its implications for cognitive therapy. Crews WD Jr, et al. **Neuropsychol Rev** 1995 Jun;5(2):81–123 (156 ref.)

The California Verbal Learning Test: psychometric characteristics and clinical application. Elwood RW. **Neuropsychol Rev** 1995 Sep;5(3):173–201 (122 ref.)

Issues associated with repeated neuropsychological assessments. McCaffrey RJ, et al. **Neuropsychol Rev** 1995 Sep;5(3):203–21 (55 ref.)

Separate digits tests: a brief history, a literature review, and a reexamination of the factor structure of the Test of Memory and Learning (TOMAL). Ramsay MC, et al. **Neuropsychol Rev** 1995 Sep;5(3):151–71 (58 ref.)

The nurosociology of schizophrenia: vulnerability and functional disability. Carter M, et al. **Psychiatry** 1995 Aug; 58(3):209–24 (55 ref.)

The neuropsychology of schizophrenia: relations with clinical and neurobiological dimensions. Elliott R, et al. **Psychol Med** 1995 May;25(3):581–94 (85 ref.)

Assessing cognitive function in schizophrenics and patients with Alzheimer's disease. Mohs RC. **Schizophr Res** 1995 Sep;17(1):115–21 (65 ref.)

Neuropsychological and olfactory dysfunction in schizophrenia: relationship of frontal syndromes to syndromes of schizophrenia. Pantelis C, et al. **Schizophr Res** 1995 Sep;17(1):35–45 (75 ref.)

[Cognition disorders in obsessive disorder] Amado-Boccara I, et al. **Encephale** 1989 May-Jun;15(3):319–23 (22 ref.) (Eng. Abstr.) **(Fre)**

[Function-controlled neurosurgery. Neurophysiologic and neuropsychological monitoring during surgery of the nervous system] Schmid UD, et al. **Nervenarzt** 1995 Aug; 66(8):582–95 (84 ref.) (Eng. Abstr.) **(Ger)**

[Neuropsychological analysis of schizophrenia-induced attention deficits—attempt at an overview] Gebauer W, et al. **Rehabilitation (Stuttg)** 1995 Aug;34(3):128–38 (85 ref.) (Eng. Abstr.) **(Ger)**

[Psychological aspects of neurotransplantation] Ellgring H. **Zentralbl Neurochir** 1995;56(4):168–72 (11 ref.) (Eng. Abstr.) **(Ger)**

[Subclinical neuro-psychobehavioral effects in occupational, environmental and community health: methodology and recent findings] Araki S, et al. **Nippon Eiseigaku Zasshi** 1995 Aug;50(3):713–29 (122 ref.) (Eng. Abstr.) **(Jpn)**

[Psychopathy and neuropsychology of the prefrontal cortex] Jurado MA, et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1996 May-Jun;24(3):148–55 (49 ref.) (Eng. Abstr.) **(Spa)**

[Evaluation of memory in neuropsychological clinic] Benedet MJ. **Rev Neurol** 1996 Aug;24(132):914–20 (36 ref.) (Eng. Abstr.) **(Spa)**

STATISTICS & NUMERICAL DATA

Is there a sex difference in human laterality? II. An exhaustive survey of visual laterality studies from six neuropsychology journals. Hiscock M, et al. **J Clin Exp Neuropsychol** 1995 Aug;17(4):590–610 (60 ref.)

[Activity and motivational disorders in neurology: proposal for an evaluation scale] Habib M. **Encephale** 1995 Sep–Oct; 21(5):563–70 (21 ref.) (Eng. Abstr.) **(Fre)**

NEUROPSYCHOLOGY

Cognitive deficit associated with rheumatic diseases: neuropsychological perspectives. Carbotte RM, et al. **Arthritis Rheum** 1995 Oct;38(10):1363–74 (92 ref.)

The neuropsychology of aging. Zec RF. **Exp Gerontol** 1995 May–Aug;30(3–4):431–42 (79 ref.)

N-acetylaspartate in neuropsychiatric disorders. Tsai G, et al. **Prog Neurobiol** 1995 Aug;46(5):531–40 (178 ref.)

NEURORADIOGRAPHY

Acute neuroradiology: methods, indications and timing. Fagerlund MK. **Ann Med** 1995 Dec;27(6):657–62 (53 ref.)

[Quality assurance in neuroradiology] Huk WJ. **Aktuelle Radiol** 1995 Nov;5(6):343–5 (4 ref.) (Eng. Abstr.) **(Ger)**

TRENDS

Interventional neuroradiology [see comments] Taylor W, et al. **BMJ** 1995 Sep 23;311(7008):789–92 (42 ref.) Comment in: BMJ 1995 Dec 9;311(7019):1575.

NEURORECEPTORS see **RECEPTORS, SENSORY**

NEUROREGULATOR RECEPTORS see **RECEPTORS, NEUROTRANSMITTER**

NEUROREGULATORS see **NEUROTRANSMITTERS**

NEUROSCIENCES

Clinical-experimental interactions in the development of neuroscience. A primer for nonspecialists and lessons for young scientists. Miller NE. **Am Psychol** 1995 Nov; 50(11):901–11 (46 ref.)

Careers and recruitment. Flexibility the key for neuroscientists. Horton B. **Nature** 1996 May 23; 381(6580):347–9 (0 ref.)

The view from Europe. Schermeier Q. **Nature** 1996 May 23;381(6580):349–50 (0 ref.)

TRENDS

On the specificity of neurons and visual areas. Schiller PH. **Behav Brain Res** 1996 Apr;76(1–2):21–35 (83 ref.)

NEUROSECRETION

see related
PITUITARY HORMONE-RELEASING HORMONES

NEUROSECRETORY SYSTEMS

see related
NEUROIMMUNOMODULATION

CYTOLOGY

The neuroendocrine system in hibernating mammals: present knowledge and open questions. Nürnberger F. **Cell Tissue Res** 1995 Sep;281(3):391–412 (145 ref.)

Neuroendocrine differentiation and hormone-refractory prostate cancer. Abrahamsson PA. **Prostate Suppl** 1996; 6:3–8 (26 ref.)

Transcriptional control of cell phenotypes in the neuroendocrine system. Rosenfeld MG, et al. **Recent Prog Horm Res** 1996;51:217–38; discussion 238–9 (98 ref.)

DRUG EFFECTS

Beta-blockade in the management of chronic heart failure. Another step in the conceptual evolution of a neurohormonal model of the disease. Packer M. **Eur Heart J** 1996 Apr;17 Suppl B:21–3 (23 ref.)

Antisense oligonucleotides in the study of neuroendocrine systems. Morris M, et al. **J Neuroendocrinol** 1995 Jul; 7(7):493–500 (64 ref.)

Neuroendocrine responses to methylphenidate and d-amphetamine: applications to attention-deficit disorder. Lurie S, et al. **J Neuropsychiatry Clin Neurosci** 1991 Winter; 3(1):41–50 (70 ref.)

ENZYMOLOGY

Proteolytic processing mechanisms in the biosynthesis of neuroendocrine peptides: the subtilisin-like proprotein convertases. Rouillé Y, et al. **Front Neuroendocrinol** 1995 Oct;16(4):322–61 (202 ref.)

IMMUNOLOGY

Development and evolutionary aspects of thymic T cell education to neuroendocrine self. Geenen V, et al. **Acta Haematol** 1996;95(3–4):263–7 (27 ref.)

Immune-neuroendocrine interactions. Savino W, et al. **Immunol Today** 1995 Jul;16(7):318–22 (27 ref.)

Immunoendocrine reshaping with age. Panerai AE, et al. **Int Rev Immunol** 1995;12(1):75–84 (73 ref.)

Cryptocrine signaling in the thymus network and T cell education to neuroendocrine self-antigens. Geenen V, et al. **J Mol Med** 1995 Sep;73(9):449–55 (49 ref.)

PATHOLOGY

Neuroendocrine differentiation in prostatic malignancy. di Sant'Agnese PA, et al. **Cancer** 1996 Jul 15;78(2):357–61 (32 ref.)

PHYSIOLOGY

Neuroendocrine control of reproduction. Steger RW, et al. **Adv Exp Med Biol** 1995;377:15–32 (131 ref.)

Proenkephalin gene regulation in the neuroendocrine hypothalamus: a model of gene regulation in the CNS. Borsook D, et al. **Am J Physiol** 1995 Sep;269(3 Pt 1):E393–408 (203 ref.)

Luteinizing hormone-releasing hormone (LHRH) receptors in the neuroendocrine-immune network. Biochemical bases and implications for reproductive physiopathology. Marchetti B, et al. **Ann N Y Acad Sci** 1996 Apr 30; 784:209–36 (117 ref.)

Fifteenth Gaddum Memorial Lecture December 1994. Stress and the neuroendocrine-immune axis: the pivotal role of glucocorticoids and lipocortin 1. Buckingham JC. **Br J Pharmacol** 1996 May;118(1):1–19 (138 ref.)

The neuroendocrine system in hibernating mammals: present knowledge and open questions. Nürnberger F. **Cell Tissue Res** 1995 Sep;281(3):391–412 (145 ref.)

Anteroventral wall of the third ventricle and dorsal lamina terminalis: headquarters for control of body fluid homeostasis? McKinley MJ, et al. **Clin Exp Pharmacol Physiol** 1996 Apr;23(4):271–81 (96 ref.)

Neuroendocrine regulation of sodium and volume following subarachnoid hemorrhage. Diringer MN. **Clin Neuropharmacol** 1995 Apr;18(2):114–26 (64 ref.)

Immune-neuro-endocrine interactions: facts and hypotheses. Besedovsky HO, et al. **Endocr Rev** 1996 Feb;17(1):64–102 (578 ref.)

The neurohypophysial endocrine regulatory cascade: precursors, mediators, receptors, and effectors. Acher R, et al. **Front Neuroendocrinol** 1995 Jul;16(3):237–89 (236 ref.)

Functional pleiotropy of the neurohormone melatonin: antioxidant protection and neuroendocrine regulation. Reiter RJ. **Front Neuroendocrinol** 1995 Oct;16(4):383–415 (133 ref.)

Cytochrome P450 in the brain: neuroendocrine functions. Warner M, et al. **Front Neuroendocrinol** 1995 Jul; 16(3):224–36 (50 ref.)

Sex steroids, growth hormone, insulin-like growth factor-1: neuroendocrine and metabolic regulation in puberty. Mauras N, et al. **Horm Res** 1996;45(1–2):74–80 (41 ref.)

Molecular mechanisms and neural pathways mediating the influence of interleukin-1 on the activity of neuroendocrine CRF motoneurons in the rat. Rivest S. **Int J Dev Neurosci** 1995 Jun-Jul;13(3–4):135–46 (96 ref.)

A neuroendocrine reappraisal of the dual-centre hypothesis: its implications for obesity and insulin resistance. Rohner-Jeanrenaud F. **Int J Obes Relat Metab Disord** 1995 Aug;19(8):517–34 (312 ref.)

Gaseous transmitters as new agents in neuroendocrine regulation. Costa A, et al. **J Endocrinol** 1996 May; 149(2):199–207 (80 ref.)

Neuroendocrine ageing. Björntorp P. **J Intern Med** 1995 Nov;238(5):401–4 (19 ref.)

Neuroendocrine dysrhythmias. Elks ML. **Med Hypotheses** 1995 May;44(5):319–24 (43 ref.)

Neuroendocrine involvement in aging: evidence from studies of reproductive aging and caloric restriction. Nelson JF, et al. **Neurobiol Aging** 1995 Sep–Oct;16(5):837–43; discussion 855–6 (50 ref.)

Use of caloric restriction to investigate neuroendocrine involvement in aging. Weindruch R, et al. **Neurobiol Aging** 1995 Sep–Oct;16(5):845–7; discussion 855–6 (30 ref.)

Synaptic like microvesicles: do they participate in regulated exocytosis? Llona I. **Neurochem Int** 1995 Sep;27(3):219–26 (82 ref.)

Neuroendocrine regulation of growth hormone secretion. Thorner MO, et al. **Neurosci Biobehav Rev** 1995 Fall; 19(3):465–8 (41 ref.)

Neuroimmunomodulation and psychoneuroendocrinology: recent findings in adults and aged. Tricerri A, et al. **Panminerva Med** 1995 Jun;37(2):77–83 (70 ref.)

Synaptic mechanisms of olfactory recognition memory. **Kaba H, et al. Rev Neurosci** 1995 Apr-Jun;6(2):125-41 (128 ref.)
[Pulsatile hormone secretion for control of target organs] **Schöfl C, et al. Wien Med Wochenschr** 1995; 145(17-18):431-5 (23 ref.) (Eng. Abstr.) **(Ger)**
[Neuroendocrine mechanisms in the shaping of adaptive behavior] **Shaliapina VG, et al. Fiziol Zh Im I M Sechenova** 1995 Aug;81(8):94-100 (25 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Neuroendocrine mechanisms during reversible hypovolaemic shock in humans with emphasis on the histaminergic and serotonergic system. **Matzen SH. Acta Physiol Scand Suppl** 1995;628:1-31 (208 ref.)
The role of neurohormonal activation in chronic heart failure and postmyocardial infarction. **Sigurdsson A, et al. Am Heart J** 1996 Jul;132(1 Pt 2 Su):229-34 (50 ref.)
Nitric oxide synthase: role as a transmitter/mediator in the brain and endocrine system. **Dawson TM, et al. Annu Rev Med** 1996;47:219-27 (40 ref.)
Neuroendocrine changes in heart failure and their clinical relevance. **Parmley WW. Clin Cardiol** 1995 Aug; 18(8):440-5 (27 ref.)
Insulin resistance: the consequence of a neuroendocrine disturbance? **Björntorp P. Int J Obes Relat Metab Disord** 1995 May;19 Suppl 1:S6-10 (27 ref.)
Funny spells in neuroendocrine disorders. **Pleet AB. Semin Neurol** 1995 Jun;15(2):133-50 (473 ref.)
Neuroendocrine disorders of the gut [see comments] **Yee LF, et al. West J Med** 1995 Nov;163(5):454-62 (45 ref.) Comment in: West J Med 1995 Nov;163(5):485-6.

ULTRASTRUCTURE

[A morphofunctional analysis of the nuclear apparatus of the nonapeptidergic neurosecretory cells in the vertebrate hypothalamus] **Polenov AL, et al. Tsitologiia** 1996; 38(1):28-38 (55 ref.) (Eng. Abstr.) **(Rus)**

NEUROSES see **NEUROTIC DISORDERS**

NEUROSES, ANXIETY see **ANXIETY DISORDERS**

NEUROSES, PHOBIC see **PHOBIC DISORDERS**

NEUROSES, POST-TRAUMATIC see **STRESS DISORDERS, POST-TRAUMATIC**

NEUROSES, WAR see **COMBAT DISORDERS**

NEUROSIS, DEPRESSIVE see **DEPRESSIVE DISORDER**

NEUROSIS, HYPOCHONDRIACAL see **HYPOCHONDRIASIS**

NEUROSIS, OBSESSIVE-COMPULSIVE see **OBSESSIVE-COMPULSIVE DISORDER**

NEUROSPORA CRASSA

GENETICS

Genetic and epigenetic inactivation of repetitive sequences in Neurospora crassa: RIP, DNA methylation, and quelling. **Singer MJ, et al. Curr Top Microbiol Immunol** 1995; 197:165-77 (54 ref.)

NEUROSURGERY

Surgical management of patients with severe head injuries. **Pieper DR, et al. AORN J** 1996 May;63(5):854-64, 867 (29 ref.)
Intra-operative neurophysiologic monitoring in neurosurgery: benefits, efficacy, and cost-effectiveness. **Møller AR. Clin Neurosurg** 1995;42:171-9 (8 ref.)
Health reform: past, present, and future. **Smits HL. Clin Neurosurg** 1995;42:30-6 (0 ref.)
Medicine in transition: strategies for change. **Vogel DE. Clin Neurosurg** 1995;42:23-9 (0 ref.)
[Progresses in neurosurgery in China, 1995] **Zhao Y. Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):736-8 (0 ref.) **(Chi)**
[Air embolism in neurosurgical interventions] **Lubnin AIu, et al. Zh Vopr Neirokhir Im N N Burdenko** 1995 Oct-Dec; (4):33-8 (80 ref.) **(Rus)**

METHODS

Minimally invasive neurosurgery. **Rosenfeld JV. Aust N Z J Surg** 1996 Aug;66(8):553-9 (75 ref.)
Transoral surgery: some lessons learned. **Crockard HA. Br J Neurosurg** 1995;9(3):283-93 (26 ref.)
Techniques of carotid reconstruction. **Fukushima T. Clin Neurosurg** 1995;42:119-34 (24 ref.)
Radical resection of anterior skull base tumors. **Lawton MT, et al. Clin Neurosurg** 1995;42:43-70 (62 ref.)
Neurosurgical considerations of cranial base surgery. **Chenelle AG, et al. Clin Plast Surg** 1995 Jul;22(3):451-60 (13 ref.)
Endovascular surgical approach to intracranial vascular diseases. **Higashida RT, et al. J Endovasc Surg** 1996 May; 3(2):146-57 (57 ref.)
Aneurysmal subarachnoid hemorrhage in a patient with bilateral A1 fenestrations associated with an azygos anterior cerebral artery. Case report and literature review. **Friedlander RM, et al. J Neurosurg** 1996 Apr;84(4):681-4 (33 ref.)
Frameless neuronavigation in modern neurosurgery. **Spetzger U, et al. Minim Invasive Neurosurg** 1995 Dec;38(4):163-6 (31 ref.)

TRENDS

Neurosurgery in China. **Wang Z. Chin Med J (Engl)** 1995 Oct;108(10):727-8 (11 ref.)
What's new in neurological surgery. **Camins MB. J Am Coll Surg** 1996 Feb;182(2):115-21 (39 ref.)

NEUROTENSIN

see related
RECEPTORS, NEUROTENSIN

BLOOD

[Neurotensin] **Shimosegawa T, et al. Nippon Rinsho** 1995 Mar;53 Su Pt 2:319-23 (60 ref.) **(Jpn)**

METABOLISM

Antipsychotics and neuropeptides: the atypical profile of CI-943 and its relationship to neurotensin. **Liégeois JF, et al. Neurosci Biobehav Rev** 1995 Winter;19(4):519-31 (101 ref.)
Functional consequences of retrograde axonal transport of receptor-bound neurotensin. **Laduron PM. Trends Pharmacol Sci** 1995 Oct;16(10):338-43 (55 ref.)

NEUROTENSIN RECEPTORS see **RECEPTORS, NEUROTENSIN**

NEUROTHEKEOMA

PATHOLOGY

Cellular neurothekeoma. **Tomasini C, et al. Dermatology** 1996;192(2):160-3 (15 ref.)
Nerve-sheath myxoma (neurothekeoma) of the oral cavity: a case report and review of the literature. **Katsourakis M, et al. J Oral Maxillofac Surg** 1996 Jul;54(7):904-6 (17 ref.)

NEUROTIC DISORDERS

COMPLICATIONS

Psychiatric aspects of chronic pain. **Eisendrath SJ. Neurology** 1995 Dec;45(12 Suppl 9):S26-34; discussion S35-6 (36 ref.)

DIAGNOSIS

Accident neurosis revisited [editorial] **Mayou R. Br J Psychiatry** 1996 Apr;168(4):399-403 (26 ref.)
[Diagnosis and management of neurotic occupational disorders (before pension application)] **Stevens A, et al. Nervenarzt** 1995 Nov;66(11):811-9 (42 ref.) (Eng. Abstr.) **(Ger)**

GENETICS

Clinical relevance of defects in signalling pathways. **Kraus JE, et al. Curr Opin Neurobiol** 1995 Jun;5(3):358-66 (66 ref.)

THERAPY

Unconscious fantasy in psychotherapy. **Levin K. Am J Psychother** 1996 Spring;50(2):137-53 (54 ref.)

NEUROTIZATION see **NERVE TRANSFER**

NEUROTOXINS

Excitotoxic blocking strategies in amyotrophic lateral sclerosis. **Hugon J. Adv Neurol** 1995;68:245-52; discussion 253-8 (56 ref.)
Animal models of amyotrophic lateral sclerosis. **Mitsumoto H, et al. Adv Neurol** 1995;68:73-87; discussion 89-91 (80 ref.)
Ion channel hypothesis for Alzheimer amyloid peptide neurotoxicity. **Pollard HB, et al. Cell Mol Neurobiol** 1995 Oct;15(5):513-26 (67 ref.)
kdr-Type resistance in insects with special reference to the German cockroach, Blattella germanica. **Scott JG, et al. Comp Biochem Physiol B Biochem Mol Biol** 1994 Oct-Nov; 109(2-3):191-8 (68 ref.)
Glutamate and Parkinson's disease. **Blandini F, et al. Mol Neurobiol** 1996 Feb;12(1):73-94 (165 ref.)
How neurotrophic factors protect brain against excitotoxicity. **Cuevas Sanchez P. Surg Neurol** 1996 Aug; 46(2):152-3 (15 ref.)

ADVERSE EFFECTS

Toxic neuropathies and their treatment. **Ludolph AC, et al. Baillieres Clin Neurol** 1995 Nov;4(3):505-27 (75 ref.)
Markers of neurotoxicity: from behavior to autoantibodies against brain proteins. **Evans HL. Clin Chem** 1995 Dec; 41(12 Pt 2):1874-81 (116 ref.)
Evolution and current status of neurotoxicity risk assessment. **Tilson HA. Drug Metab Rev** 1996 Feb-May;28(1-2):121-39 (47 ref.)
[Biomarkers of neurotoxic effects induced by environmental chemicals] **Indulski JA, et al. Med Pr** 1996;47(4):383-91 (32 ref.) (Eng. Abstr.) **(Pol)**

ANALYSIS

The metallo-proteinase activity of tetanus and botulism neurotoxins. **Rossetto O, et al. J Physiol Paris** 1995; 89(1):43-50 (60 ref.)

BIOSYNTHESIS

Expression of a large, nontoxic fragment of botulinum neurotoxin serotype A and its use as an immunogen. **LaPenotiere HF, et al. Toxicon** 1995 Oct;33(10):1383-6 (8 ref.)

IMMUNOLOGY

Autoantibodies, neurotoxins and the nervous system. **Vincent A, et al. J Physiol Paris** 1995;89(3):129-36 (75 ref.)

METABOLISM

Excitotoxic mechanisms in the pathogenesis of amyotrophic lateral sclerosis. **Rothstein JD. Adv Neurol** 1995;68:7-20; discussion 21-7 (80 ref.)
Current concepts of excitotoxicity. **Whetsell WO Jr. J Neuropathol Exp Neurol** 1996 Jan;55(1):1-13 (127 ref.)
[Nitric oxide: implication in excitotoxicity and cerebral ischemia] **Demerlé-Pallardy C, et al. C R Seances Soc Biol Fil** 1995;189(6):1059-68 (49 ref.) (Eng. Abstr.) **(Fre)**

PHARMACOLOGY

Glia, cytokines, and neurotoxicity. **Chao CC, et al. Crit Rev Neurobiol** 1995;9(2-3):189-205 (249 ref.)
Actions of neurotoxins (bungarotoxins, neosurugatoxin and lophotoxins) on insect and nematode nicotinic acetylcholine receptors. **Tornøe C, et al. Toxicon** 1995 Apr;33(4):411-24 (61 ref.)

THERAPEUTIC USE

Botulinum neurotoxin A in ophthalmology. **Bentley C. Ophthalmic Physiol Opt** 1996 Mar;16 Suppl 1:S9-14 (43 ref.)

TOXICITY

How does trimethyltin affect the brain: facts and hypotheses. **Koczyk D. Acta Neurobiol Exp (Warsz)** 1996;56(2):587-96 (85 ref.)
The dopamine transporter. The cloned target site of parkinsonism-inducing toxins and of drugs of abuse. **Pifl C, et al. Adv Neurol** 1996;69:235-8 (9 ref.)
Excitotoxic mechanisms in the pathogenesis of amyotrophic lateral sclerosis. **Rothstein JD. Adv Neurol** 1995;68:7-20; discussion 21-7 (80 ref.)
Neurotoxicity and the mechanisms of cell death in Parkinson's disease. **Schapira AH. Adv Neurol** 1996; 69:161-5 (33 ref.)
Risk assessment strategies for neuroprotective agents. **Slikker W Jr, et al. Ann N Y Acad Sci** 1995 Sep 15;765:198-208; discussion 209 (18 ref.)
The mechanism of action of tetanus and botulinum neurotoxins. **Montecucco C, et al. Arch Toxicol Suppl** 1996; 18:342-54 (66 ref.)
Involvement of cytoskeletal proteins in the mechanisms of organophosphorus ester-induced delayed neurotoxicity. **Abou-Donia MB. Clin Exp Pharmacol Physiol** 1995 May; 22(5):358-9 (5 ref.)
Examination of developmental neurotoxicity by the use of tissue culture model systems. **Heller A, et al. Clin Exp Pharmacol Physiol** 1995 May;22(5):375-8 (29 ref.)
The AF64A model of cholinergic hypofunction: an update. **Hanin I. Life Sci** 1996;58(22):1955-64 (66 ref.)
Neurotoxicity, drugs and abuse, and the CuZn-superoxide dismutase transgenic mice. **Cadet JL, et al. Mol Neurobiol** 1995 Aug-Dec;11(1-3):155-63 (49 ref.)

NEUROTRANSMITTER UPTAKE INHIBITORS

PHARMACOLOGY

A review of the preclinical pharmacology of tiagabine: a potent and selective anticonvulsant GABA uptake inhibitor. **Suzdak PD, et al. Epilepsia** 1995 Jun;36(6):612-26 (81 ref.)

NEUROTRANSMITTERS

see related
AUTACOIDS
NEUROIMMUNOMODULATION
RECEPTORS, NEUROTRANSMITTER
Nitric oxide: a neural messenger. **Jaffrey SR, et al. Ann Rev Cell Dev Biol** 1995;11:417-40 (167 ref.)

NEUROTRANSMITTERS

AGONISTS

Gn-RH agonists in the treatment of prostatic carcinoma. Vacher P. **Biomed Pharmacother** 1995;49(7-8):325-31 (60 ref.)

ANALYSIS

[Belching, flatus, breath. Measurements of airborne nitric oxide in the non-invasive diagnosis of inflammation] Lundberg J, et al. **Lakartidningen** 1996 May 15; 93(20):1945-8 (22 ref.) (Eng. Abstr.) **(Swe)**

ANTAGONISTS & INHIBITORS

Neurohormonal modulation in heart failure: ACE inhibition and beyond. Remme WJ. **Eur Heart J** 1995 Dec;16 Suppl N:73-8 (36 ref.)

BIOSYNTHESIS

[Interactions of neuromediators and neurohormones on dendritic cells, monocytes and macrophages (out of the central nervous system)] Misery L, et al. **Pathol Biol (Paris)** 1995 Dec;43(10):876-81 (66 ref.) (Eng. Abstr.) **(Fre)**

BLOOD

Neurohormonal activation and congestive heart failure: today's experience with ACE inhibitors and rationale for their use. Sigurdsson A, et al. **Eur Heart J** 1995 Dec;16 Suppl N:65-72 (53 ref.)

[Humoral aspects of sleep deprivation] Ebert D, et al. **Fortschr Neurol Psychiatr** 1995 Nov;63(11):441-50 (60 ref.) (Eng. Abstr.) **(Ger)**

GENETICS

Genetic dissection of the molecular mechanisms of transmitter vesicle release during synaptic transmission. Broadie KS. **J Physiol Paris** 1995;89(2):59-70 (55 ref.)

METABOLISM

Synaptic vesicles and release of transmitters: new insights at the molecular level. Fried G. **Acta Physiol Scand** 1995 May;154(1):1-15 (80 ref.)

Anatomy and neurotransmitters of brainstem motor systems. Newman DB. **Adv Neurol** 1995;67:219-44 (138 ref.)

Second messenger pathways in the modulation of neurotransmitter release. Majewski HK, et al. **Aust N Z J Med** 1995 Dec;25(6):817-21 (28 ref.)

Psychopharmacology of Alzheimer's disease. Procter AW. **Br J Hosp Med** 1996 Feb 21-Mar 5;55(4):191-4 (20 ref.)

Neurotransmitters in the retina. Pourcho RG. **Curr Eye Res** 1996 Jul;15(7):797-803 (81 ref.)

Quantal neurotransmitter release and the clostridial neurotoxins' targets. Poulain B, et al. **Curr Top Microbiol Immunol** 1995;195:243-55 (77 ref.)

Neurotransmitter transporters: molecular biology, function, and regulation. Borowsky B, et al. **Int Rev Neurobiol** 1995; 38:139-99 (250 ref.)

Neurotransmitter systems in schizophrenia. Reynolds GP. **Int Rev Neurobiol** 1995;38:305-39 (144 ref.)

Monoamine neurotransmitters in invertebrates and vertebrates: an examination of the diverse enzymatic pathways utilized to synthesize and inactivate biogenic amines. Sloley BD, et al. **Int Rev Neurobiol** 1995;38:253-303 (490 ref.)

Genetic dissection of the molecular mechanisms of transmitter vesicle release during synaptic transmission. Broadie KS. **J Physiol Paris** 1995;89(2):59-70 (55 ref.)

Calcium binding sites of the transmitter release mechanism: clues from short-term facilitation. Liu Y, et al. **J Physiol Paris** 1995;89(3):163-6 (28 ref.)

The membrane fusion machine and neurotransmitter release. Fesce R, et al. **Neurochem Int** 1996 Jan;28(1):15-21 (44 ref.)

Effects of prenatal morphine and cocaine on postnatal behaviors and brain neurotransmitters. Vathy I. **NIDA Res Monogr** 1995;158:88-114 (118 ref.)

Interrelationships of neurochemicals, estrogen, and recurring headache. Marcus DA. **Pain** 1995 Aug;62(2):129-39 (136 ref.)

Purinergic inhibition of neurotransmitter release in the central nervous system. Ribeiro JA. **Pharmacol Toxicol** 1995 Nov; 77(5):299-305 (68 ref.)

Exercise and brain neurotransmission. Meeusen R, et al. **Sports Med** 1995 Sep;20(3):160-88 (117 ref.)

[Therapy-oriented assessment of heart failure in the hospital and clinical practice] Mohacsi P, et al. **Schweiz Rundsch Med Prax** 1996 Feb 20;85(8):245-55 (110 ref.) (Eng. Abstr.) **(Ger)**

PHARMACOLOGY

Human substantia nigra in vitro as a bioassay for neurotrophic molecules of clinical significance. Silani V, et al. **Adv Neurol** 1996;69:253-62 (31 ref.)

An anesthetic-sensitive superfamily of neurotransmitter-gated ion channels. Franks NP, et al. **J Clin Anesth** 1996 May;8(3 Suppl):3S-7S (32 ref.)

Pharmacological modulators of the inositol 1,4,5-trisphosphate receptor. Michelangeli F, et al. **Neuropharmacology** 1995 Sep;34(9):1111-22 (108 ref.)

Pharmacology of cotransmission in the autonomic nervous system: integrative aspects on amines, neuropeptides, adenosine triphosphate, amino acids and nitric oxide. Lundberg JM. **Pharmacol Rev** 1996 Mar;48(1):113-78 (975 ref.)

PHYSIOLOGY

Extracellular ATP as a neurotransmitter: its role in synaptic plasticity in the hippocampus. Wieraszko A. **Acta Neurobiol Exp (Warsz)** 1996;56(2):637-48 (85 ref.)

Sleep regulation: interactions among cytokines and classical neurotransmitters. Grazia de Simoni M, et al. **Adv Neuroimmunol** 1995;5(2):189-200 (61 ref.)

Neurotoxicity and the mechanisms of cell death in Parkinson's disease. Schapira AH. **Adv Neurol** 1996; 69:161-5 (33 ref.)

Neural receptors and asthma. Baraniuk JN. **Allergy Proc** 1995 Sep-Oct;16(5):227-33 (76 ref.)

Neurotransmitter regulation of the hypothalamic corticotropin-releasing hormone neuron. Calogero AE. **Ann N Y Acad Sci** 1995 Dec 29;771:31-40 (68 ref.)

Nitric oxide synthase: role as a transmitter/mediator in the brain and endocrine system. Dawson TM, et al. **Annu Rev Med** 1996;47:219-27 (40 ref.)

Brain microdialysis and its application for the study of animal behaviour. Westerink BH. **Behav Brain Res** 1995 Oct; 70(2):103-24 (153 ref.)

Hormonal and neurotransmitter regulation of GnRH gene expression and related reproductive behaviors. Sagrillo CA, et al. **Behav Genet** 1996 May;26(3):241-77 (360 ref.)

Descending control of pain. Stamford JA. **Br J Anaesth** 1995 Aug;75(2):217-27 (133 ref.)

Neurotransmitter organization and connectivity of the basal ganglia in vertebrates: implications for the evolution of basal ganglia. Medina L, et al. **Brain Behav Evol** 1995; 46(4-5):235-58 (214 ref.)

Calcitonin gene related peptide as inhibitory neurotransmitter in the ureter. Maggi CA, et al. **Can J Physiol Pharmacol** 1995 Jul;73(7):986-90 (21 ref.)

Capsaicin-sensitive sensory-motor neurotransmission in the peripheral control of cardiovascular function. Rubino A, et al. **Cardiovasc Res** 1996 Apr;31(4):467-79 (160 ref.)

Neurogenic control of the cerebral circulation. Branston NM. **Cerebrovasc Brain Metab Rev** 1995 Winter;7(4):338-49 (61 ref.)

Neurosteroids: biosynthesis and function. Robel P, et al. **Crit Rev Neurobiol** 1995;9(4):383-94 (52 ref.)

Trophic factor response to neuronal stimuli or injury. Isackson PJ. **Curr Opin Neurobiol** 1995 Jun;5(3):350-7 (75 ref.)

Changes in neurohumoral systems during the development of congestive heart failure: impact on cardiovascular and renal function. Elsner D. **Eur Heart J** 1995 Dec;16 Suppl N:52-8 (37 ref.)

Evolution of the neurohormonal hypothesis to explain the progression of chronic heart failure. Packer M. **Eur Heart J** 1995 Jul;16 Suppl F:4-6 (40 ref.)

Changes in tissue responsiveness to hormones and neurotransmitters during aging. Roth GS. **Exp Gerontol** 1995 May-Aug;30(3-4):361-8 (30 ref.)

On the physiology of metazoa. Ameen AR. **Experientia** 1996 Mar 15;52(3):189-211 (205 ref.)

Substance P: a neurotransmitter of amacrine and ganglion cells in the vertebrate retina. Kolb H, et al. **Histol Histopathol** 1995 Oct;10(4):947-68 (127 ref.)

Is there a third peripheral catecholaminergic system? Endogenous dopamine as an autocrine/paracrine substance derived from plasma DOPA and inactivated by conjugation. Goldstein DS, et al. **Hypertens Res** 1995 Jun; 18 Suppl 1:S93-9 (76 ref.)

Neurotrophins and cytokines--intermediaries between the immune and nervous systems. Otten U, et al. **Int J Dev Neurosci** 1995 Jun-Jul;13(3-4):147-51 (48 ref.)

Platyhelminth FMRFamide-related peptides. Shaw C, et al. **Int J Parasitol** 1996 Apr;26(4):335-45 (59 ref.)

Neurotransmitter transporters: molecular biology, function, and regulation. Borowsky B, et al. **Int Rev Neurobiol** 1995; 38:139-99 (250 ref.)

Developmental neurotransmitters. Signals for shaping neuronal circuitry. Redburn DA, et al. **Invest Ophthalmol Vis Sci** 1996 Jul;37(8):1479-82 (16 ref.)

Brief report: pathophysiology of autism: neurochemistry. Cook EH Jr. **J Autism Dev Disord** 1996 Apr;26(2):221-5 (11 ref.)

New concepts in the pathophysiology of heart failure: beneficial and deleterious interaction of endogenous haemodynamic and neurohormonal mechanisms. Packer M. **J Intern Med** 1996 Apr;239(4):327-33 (28 ref.)

Long-term regulation of short-term plasticity: a postsynaptic influence on presynaptic transmitter release. Davis GW. **J Physiol Paris** 1995;89(1):33-41 (39 ref.)

Noradrenaline and ATP: cotransmitters and neuromodulators. Burnstock G. **J Physiol Pharmacol** 1995 Dec;46(4):365-84 (195 ref.)

Psychophysiological aspects of autistic disorders: overview. Murray JB. **J Psychol** 1996 Mar;130(2):145-58 (95 ref.)

Neurosteroids: molecular mechanisms of action and psychopharmacological significance. Rupprecht R, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1-6 Spec No):163-8 (50 ref.)

Optimal physical performance in athletes: key roles of dopamine in a specific neurotransmitter/hormonal mechanism. Gilbert C. **Mech Ageing Dev** 1995 Oct 13; 84(2):83-102 (85 ref.)

Glutamate and Parkinson's disease. Blandini F, et al. **Mol Neurobiol** 1996 Feb;12(1):73-94 (165 ref.)

Neuronal nicotinic receptors: molecular organization and regulations. Galzi JL, et al. **Neuropharmacology** 1995 Jun; 34(6):563-82 (215 ref.)

The transport of neurotransmitters into synaptic vesicles. Peter D, et al. **Prog Brain Res** 1995;105:273-81 (30 ref.)

Organization of peptidergic neurons in the dorsal horn of the spinal cord: anatomical and functional correlates. Ribeiro-da-Silva A, et al. **Prog Brain Res** 1995;104:41-59 (77 ref.)

Neurotransmitters involved in the central regulation of the cardiovascular system. McCall RB. **Prog Drug Res** 1996; 46:43-113 (484 ref.)

Geometry, kinetics and plasticity of release and clearance of ATP and noradrenaline as sympathetic cotransmitters: roles for the neurogenic contraction. Stjärne L, et al. **Prog Neurobiol** 1995 Sep;47(1):45-94 (145 ref.)

Nitric oxide: a radical neurotransmitter in the central nervous system. Vincent SR. **Prog Neurobiol** 1994 Jan;42(1):129-60 (485 ref.)

The neurobiology of anxiety disorders. Johnson MR, et al. **Psychiatr Clin North Am** 1995 Dec;18(4):681-725 (152 ref.)

Neurotransmitters in the CNS control of breathing. Bonham AC. **Respir Physiol** 1995 Sep;101(3):219-30 (40 ref.)

Mast cells in the brain: evidence and functional significance. Silver R, et al. **Trends Neurosci** 1996 Jan;19(1):25-31 (64 ref.)

[The role of mediator-metabolic factors in the development of brain edema-swelling] Novikov VE, et al. **Usp Fiziol Nauk** 1996 Apr-Jun;27(2):78-89 (118 ref.) (Eng. Abstr.) **(Rus)**

[The chemical structure of the peripheral autonomic (visceral) reflex] Nozdrachev AD. **Usp Fiziol Nauk** 1996 Apr-Jun;27(2):28-60 (74 ref.) (Eng. Abstr.) **(Rus)**

[Neurohumoral regulation of Fallopian tube motility] Janković SM, et al. **Med Pregl** 1995;48(11-12):395-8 (34 ref.) (Eng. Abstr.) **(Scr)**

[Neurotransmitters and cerebral development: physiologic and physiopathologic aspects] Legido A. **Rev Neurol** 1995; 23 Suppl 3:S269-77 (100 ref.) **(Spa)**

[The role of neurohumoral factors and hemodynamic disorders in the development of primary juvenile arterial hypertension] Byhar VP. **Lik Sprava** 1995 May-Jun; (5-6):51-5 (50 ref.) **(Ukr)**

SECRETION

Deciphering neuronal secretion: tools of the trade. Linial M, et al. **Biochim Biophys Acta** 1996 Jun 10;1286(2):117-52 (395 ref.)

How do we study autonomic function in humans? Macdonald IA. **Fundam Clin Pharmacol** 1995;9(5):443-9 (25 ref.)

Role of nitric oxide in central synaptic transmission: effects on neurotransmitter release. Kuriyama K, et al. **Jpn J Pharmacol** 1995 Sep;69(1):1-8 (50 ref.)

[Hypothalamic-pituitary stress hormones and serotonergic system in the brain] Yan J, et al. **Sheng Li Ko Hsueh Chin Chan** 1995 Oct;26(4):337-40 (8 ref.) **(Chi)**

[Molecular mechanism of neurotransmitter release] Abe T. **Seikagaku** 1995 Oct;67(10):1227-32 (22 ref.) **(Jpn)**

THERAPEUTIC USE

Gn-RH agonists in the treatment of prostatic carcinoma. Vacher P. **Biomed Pharmacother** 1995;49(7-8):325-31 (60 ref.)

NEUROTRANSMITTERS, AMINO ACID see **AMINO ACID NEUROTRANSMITTERS**

NEUROTRANSMITTERS, BIOGENIC AMINE see **BIOGENIC AMINE NEUROTRANSMITTERS**

NEUTRALIZATION TESTS

Neutralising epitopes of simian immunodeficiency virus envelope glycoprotein. Kent KA. **J Med Primatol** 1995 May;24(3):145-9 (41 ref.)

NEUTRON ACTIVATION ANALYSIS

[Neutron activation analysis of biological samples] Ohta A, et al. **Nippon Rinsho** 1996 Jan;54(1):207-14 (7 ref.) (Eng. Abstr.) **(Jpn)**

METHODS

[Potential and limitations of neutron activation analysis methods for measuring elements of toxicological and environmental interest] Gallorini M. **Ann Ist Super Sanita** 1995;31(2):239-44 (10 ref.) (Eng. Abstr.) **(Ita)**

NEUTRONS

THERAPEUTIC USE

Neutron therapy for pancreatic cancer: thirty years of unrealized promise [editorial; comment] Donahue BR, et al. **Radiology** 1996 Sep;200(3):608-9 (13 ref.) Comment on: Radiology 1996 Sep;200(3):627-30.

NEUTROPENIA

Pathophysiology and treatment of severe chronic neutropenia. Welte K, et al. **Ann Hematol** 1996 Apr; 72(4):158–65 (30 ref.)
Neutropenia in the neonate. al-Mulla ZS, et al. **Clin Perinatol** 1995 Sep;22(3):711–39 (157 ref.)
Leukocyte disorders: quantitative and qualitative disorders of the neutrophil, Part 1. Boxer LA, et al. **Pediatr Rev** 1996 Jan;17(1):19–28 (7 ref.)

CHEMICALLY INDUCED

Chemotherapy and neutropenia. Kim SK, et al. **Hematol Oncol Clin North Am** 1996 Apr;10(2):377–95 (123 ref.)

COMPLICATIONS

Empiric therapy for bacterial infections in neutropenic patients. Klastersky J. **Cancer Treat Res** 1995;79:101–12 (34 ref.)
New antifungal compounds and strategies for treatment of invasive fungal infections in patients with neoplastic diseases. Walsh TJ, et al. **Cancer Treat Res** 1995;79:113–48 (268 ref.)
New and unusual infections in neutropenic patients. Zinner SH. **Cancer Treat Res** 1995;79:173–84 (53 ref.)
Anti-infective strategies in neutropenia. Boogaerts MA. **J Antimicrob Chemother** 1995 Jul;36 Suppl A:167–78 (54 ref.)
Neutropenic infections: strategies for empirical therapy. Kibbler CC. **J Antimicrob Chemother** 1995 Oct;36 Suppl B:107–17 (65 ref.)
Clinical perspectives of granulocyte transfusions: efficacy to date. Strauss RG. **J Clin Apheresis** 1995;10(3):114–8 (23 ref.)
Fatal, disseminated Acremonium strictum infection in a neutropenic host. Schell WA, et al. **J Clin Microbiol** 1996 May;34(5):1333–6 (27 ref.)
[Rational use of antibiotics in the neutropenic patient with fever] de Pauw BE, et al. **Ned Tijdschr Geneeskd** 1995 Aug 26;139(34):1725–9 (26 ref.) **(Dut)**
[2 cases of neutropenic enteropathy and bone marrow hypoplasia. An association not reported in Mexico] Gamboa-Domínguez A, et al. **Rev Invest Clin** 1995 Jul-Aug;47(4):303–9 (25 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Diagnosis and management of chronic neutropenia during childhood. Bernini JC. **Pediatr Clin North Am** 1996 Jun; 43(3):773–92 (126 ref.)
[Intense neutropenia of 14 years duration as the only manifestation of a myelodysplastic syndrome] Las Heras G, et al. **Med Clin (Barc)** 1995 Nov 11;105(16):619–21 (12 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Filgrastim (r-metHuG-CSF): the first 10 years. Welte K, et al. **Blood** 1996 Sep 15;88(6):1907–29 (176 ref.)
Colony-stimulating factors: current applications and perspectives. Bron D, et al. **Cancer Treat Res** 1995; 79:245–54 (63 ref.)
An approach to the design and implementation of clinical trials of empirical antibiotic therapy in febrile and neutropenic cancer patients. Viscoli C, et al. **Eur J Cancer** 1995 Nov;31A(12):2013–22 (60 ref.)
Resolution of the neutropenia of Felty's syndrome by longterm administration of recombinant granulocyte colony stimulating factor. Krishnaswamy G, et al. **J Rheumatol** 1996 Apr;23(4):763–5 (18 ref.)
The use of aminoglycosides in neutropenic patients. Cometta A, et al. **Schweiz Med Wochenschr Suppl** 1996;76:21S–27S (10 ref.)
[Treatment of neutropenia in HIV infection with hematopoietic growth factors] Moreno García M, et al. **Rev Clin Esp** 1996 Apr;196(4):248–54 (121 ref.) **(Spa)**

EPIDEMIOLOGY

Combined autoimmune cytopenias. Martino R, et al. **Haematologica** 1995 Jul-Aug;80(4):305–10 (25 ref.)

ETIOLOGY

Medical emergencies in oncology. Advani SH, et al. **Natl Med J India** 1995 Nov-Dec;8(6):273–6 (0 ref.)
Leukocyte—endothelial cell interactions in haemodialysis-induced neutropenia. Muñoz de Bustillo E, et al. **Nephrol Dial Transplant** 1996 Apr;11(4):572–4 (23 ref.)
[Congenital and acquired neutropenia in children] Donadieu J. **Presse Med** 1996 Feb 24;25(7):293–8 (22 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

[Alloimmune neonatal neutropenia due to anti-NA1 antibodies] Buznego Sánchez R, et al. **An Esp Pediatr** 1996 Feb;44(2):176–8 (11 ref.) **(Spa)**

PREVENTION & CONTROL

Should hematopoietic growth factors routinely be given concurrently with cytotoxic chemotherapy? Croockewit AJ, et al. **Clin Pharmacol Ther** 1996 Jan;59(1):1–6 (31 ref.)

THERAPY

Haemopoietic growth factors and childhood cancer. Hann IM. **Eur J Cancer** 1995;31A(9):1476–8 (27 ref.)
The outpatient management of febrile neutropenia in cancer patients. Freifeld AG, et al. **Oncology (Huntingt)** 1996 Apr; 10(4):599–606, 611–2; discussion 615–6 (31 ref.)
Perspective of rhGM-CSF in the treatment of neutropenic infections and aggressive lymphomas. Gerhartz HH. **Stem Cells (Dayt)** 1995 Sep;13(5):472–6 (27 ref.)

VIROLOGY

Glomerulonephritis, thrombocytopenia, and autoimmune neutropenia probably induced by a virus-like illness: case report and review of the literature. Mackey JR, et al. **Nephron** 1995;71(4):454–8 (33 ref.)

NEUTROPHIL-ACTIVATING PEPTIDE, LYMPHOCYTE-DERIVED see **INTERLEUKIN-8**

NEUTROPHIL-ACTIVATING PEPTIDE, MONOCYTE-DERIVED see **INTERLEUKIN-8**

NEUTROPHIL-ACTIVATING PEPTIDES, FIBROBLAST-DERIVED see **INTERLEUKIN-8**

NEUTROPHIL ACTIVATION

The activated neutrophil—formidable forces unleashed. Anderson R. **S Afr Med J** 1995 Oct;85(10):1024–8 (37 ref.)

PHYSIOLOGY

Regulation of endothelial permeability by second messengers. Siflinger-Birnboim A, et al. **New Horiz** 1996 Feb;4(1):87–98 (86 ref.)

NEUTROPHIL-DERIVED RELAXANT FACTOR see **ENDOTHELIUM-DERIVED RELAXING FACTOR**

NEUTROPHILIC DERMATOSIS, ACUTE FEBRILE see **SWEET'S SYNDROME**

NEUTROPHILIC LEUKEMIA, CHRONIC see **LEUKEMIA, NEUTROPHILIC, CHRONIC**

NEUTROPHILS

Complement receptors in neutrophils. Sengeløv H. **Crit Rev Immunol** 1995;15(2):107–31 (223 ref.)
Leukocyte disorders: quantitative and qualitative disorders of the neutrophil, Part 1. Boxer LA, et al. **Pediatr Rev** 1996 Jan;17(1):19–28 (7 ref.)
[Neutrophilic leukocytes, thrombotic risk factors in vascular diseases] Berti F. **Cardiologia** 1996 Feb;41(2):107–16 (95 ref.) **(Ita)**

CHEMISTRY

Cell signalling by integrins and immunoglobulin receptors in primed neutrophils. Edwards SW. **Trends Biochem Sci** 1995 Sep;20(9):362–7 (34 ref.)

CYTOLOGY

Shape oscillations of human neutrophil leukocytes: characterization and relationship to cell motility. Ehrengruber MU, et al. **J Exp Biol** 1996 Apr;199 (Pt 4):741–7 (46 ref.)

DRUG EFFECTS

G-CSF-stimulated PMN in immunotherapy of breast cancer with a bispecific antibody to Fc gamma RI and to HER-2/neu (MDX-210). Repp R, et al. **J Hematother** 1995 Oct;4(5):415–21 (26 ref.)
The effect of granulocyte-macrophage colony-stimulating factor on myeloid cells and its clinical applications. Hill AD, et al. **J Leukoc Biol** 1995 Dec;58(6):634–42 (103 ref.)
Bacterial infections during immunosuppression - immunosuppressive agents interfere not only with immune response, but also with polymorphonuclear cell function. [editorial] Schmaldienst S, et al. **Nephrol Dial Transplant** 1996 Jul;11(7):1243–5 (26 ref.)

ENZYMOLOGY

NADPH oxidase of neutrophils. Henderson LM, et al. **Biochim Biophys Acta** 1996 Feb 15;1273(2):87–107 (216 ref.)
Small G proteins and the neutrophil NADPH oxidase. Dagher MC, et al. **Biochimie** 1995;77(7–8):651–60 (94 ref.)
Phagocytic NADPH oxidase and its role in chronic granulomatous disease. Pallister CJ, et al. **Br J Biomed Sci** 1995 Jun;52(2):149–56 (91 ref.)
Biochemistry and cell biology of phospholipase D in human neutrophils. Olson SC, et al. **Chem Phys Lipids** 1996 May 24;80(1-2):3–19 (124 ref.)
A role for neutrophil elastase in solar elastosis. Starcher B, et al. **Ciba Found Symp** 1995;192:338–46; discussion 346–7 (6 ref.)
Neutrophil-mediated platelet activation: a key role for serine proteinases. Renesto P, et al. **Gen Pharmacol** 1995 Sep; 26(5):905–10 (54 ref.)
[Neutrophil alkaline phosphatase (NAP) score] Aoyagi M, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:221–4 (17 ref.) **(Jpn)**
[Human neutrophil elastase] Ishizaki T, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:262–4 (17 ref.) **(Jpn)**

IMMUNOLOGY

Adhesion molecules in host defense. Etzioni A. **Clin Diagn Lab Immunol** 1994 Jan;1(1):1–4 (41 ref.)
Anti-neutrophil cytoplasmic antibodies in generalized autoimmune diseases. Schnabel A, et al. **Int Arch Allergy Immunol** 1996 Mar;109(3):201–6 (32 ref.)
The phagocytosis of mycoplasmas. Marshall AJ, et al. **J Med Microbiol** 1995 Oct;43(4):239–50 (163 ref.)
Resolution of the neutropenia of Felty's syndrome by longterm administration of recombinant granulocyte colony stimulating factor. Krishnaswamy G, et al. **J Rheumatol** 1996 Apr;23(4):763–5 (18 ref.)
Bacterial infections during immunosuppression - immunosuppressive agents interfere not only with immune response, but also with polymorphonuclear cell function. [editorial] Schmaldienst S, et al. **Nephrol Dial Transplant** 1996 Jul;11(7):1243–5 (26 ref.)
[Significance of antineutrophil cytoplasmic antibodies (ANCA) in diagnosis and immunopathogenesis of chronic inflammatory liver diseases] Mayet WJ, et al. **Med Klin** 1996 Jun 15;91(6):384–8 (33 ref.) **(Ger)**
[Autoantibodies against neutrophil cytoplasm and their significance in the classification of systemic vasculitis] Fijalkowska-Morawska J, et al. **Przegl Lek** 1995; 52(6):318–22 (20 ref.) (Eng. Abstr.) **(Pol)**
[Alloimmune neonatal neutropenia due to anti-NA1 antibodies] Buznego Sánchez R, et al. **An Esp Pediatr** 1996 Feb;44(2):176–8 (11 ref.) **(Spa)**

METABOLISM

Investigations on the mechanism of adipocere formation and its relation to other biochemical reactions. Takatori T. **Forensic Sci Int** 1996 Jun 28;80(1-2):49–61 (25 ref.)
Circulating neutrophils from patients with ulcerative colitis have a normal respiratory burst. Haydek JM, et al. **Inflammation** 1995 Dec;19(6):701–15 (42 ref.)
Lymphocytes and neutrophils as peripheral models to study the effect of beta-amyloid on cellular calcium signalling in Alzheimer's disease. Eckert A, et al. **Life Sci** 1996; 59(5–6):499–510 (47 ref.)

PHYSIOLOGY

Possible modes of action of nimesulide in controlling neutrophilic inflammation. Dallegri F, et al. **Arzneimittelforschung** 1995 Oct;45(10):1114–7 (36 ref.)
Disorders of neutrophil function. Bogomolski-Yahalom V, et al. **Blood Rev** 1995 Sep;9(3):183–90 (71 ref.)
Coordinate regulation of neutrophil secondary granule protein gene expression. Khanna-Gupta A, et al. **Curr Top Microbiol Immunol** 1996;211:165–71 (20 ref.)
Antibiotic proteins of polymorphonuclear leukocytes. Levy O. **Eur J Haematol** 1996 May;56(5):263–77 (177 ref.)
Cathelicidins: a novel protein family with a common proregion and a variable C-terminal antimicrobial domain. Zanetti M, et al. **FEBS Lett** 1995 Oct 23;374(1):1–5 (55 ref.)
Neutrophil-mediated platelet activation: a key role for serine proteinases. Renesto P, et al. **Gen Pharmacol** 1995 Sep; 26(5):905–10 (54 ref.)
Regulation of apoptosis in neutrophils—Fas track to death? Liles WC, et al. **J Immunol** 1995 Oct 1;155(7):3289–91 (71 ref.)
Review: granulocyte colony-stimulating factor—role and relationships in infectious diseases. Dale DC, et al. **J Infect Dis** 1995 Oct;172(4):1061–75 (204 ref.)
Acute lung injury: the role of cytokines in the elicitation of neutrophils [published erratum appears in J Investig Med 1995 Apr;43(2):204] Strieter RM, et al. **J Investig Med** 1994 Dec;42(4):640–51 (109 ref.)
The secretion of preformed granules by macrophages and neutrophils. Tapper H. **J Leukoc Biol** 1996 May; 59(5):613–22 (128 ref.)
Impaired activation of phospholipase D in polycythaemia vera-implications for the pathogenesis of the disease? Samuelsson J. **Leuk Lymphoma** 1995 Sep;19(1–2):21–6 (60 ref.)
Prevention of late lumen loss after coronary angioplasty by photodynamic therapy: role of activated neutrophils. Sluiter W, et al. **Mol Cell Biochem** 1996 Apr 12–26; 157(1–2):233–8 (44 ref.)
Leukocyte—endothelial cell interactions in haemodialysis-induced neutropenia. Muñoz de Bustillo E, et al. **Nephrol Dial Transplant** 1996 Apr;11(4):572–4 (23 ref.)
Initial interaction of leukocytes within the microvasculature: deformability, adhesion, and transmigration. Downey GP, et al. **New Horiz** 1995 May;3(2):219–28 (79 ref.)
New insights into directed cell migration: characteristics and mechanisms. Gruler H. **Nouv Rev Fr Hematol** 1995; 37(5):255–65 (43 ref.)
Eicosanoids, fatty acids and neutrophils: their relevance to the pathophysiology of disease. Bates EJ. **Prostaglandins Leukot Essent Fatty Acids** 1995 Aug; 53(2):75–86 (213 ref.)

NEUTROPHILS

The neutrophil in rheumatoid arthritis. Pillinger MH, et al. **Rheum Dis Clin North Am** 1995 Aug;21(3):691–714 (135 ref.)
The activated neutrophil—formidable forces unleashed. Anderson R. **S Afr Med J** 1995 Oct;85(10):1024–8 (37 ref.)
Dysfunction of polymorphonuclear leukocytes in uremia. Haag-Weber M, et al. **Semin Nephrol** 1996 May; 16(3):192–201 (123 ref.)
Polymorphonuclear leukocytes: their role as central cellular elements in shock pathogenesis. Simms HH. **Shock** 1995 Sep;4(3):225–31 (92 ref.)
The adhesion cascade and anti-adhesion therapy: an overview. Sharar SR, et al. **Springer Semin Immunopathol** 1995;16(4):359–78 (139 ref.)
Polymorphonuclear leucocyte traffic in lung inflammation [editorial] Hogg JC, et al. **Thorax** 1995 Aug;50(8):819–20 (24 ref.)
Platelet activation by polymorphonuclear leukocytes: role of cathepsin G and P-selectin. Cerletti C, et al. **Thromb Haemost** 1995 Jul;74(1):218–23 (82 ref.)
The molecular basis of platelet and endothelial cell interaction with neutrophils and monocytes: role of P-selectin and the P-selectin ligand, PSGL-1. Furie B, et al. **Thromb Haemost** 1995 Jul;74(1):224–7 (56 ref.)
[Cellular biology of neutrophil granulocytes] Borregaard N. **Ugeskr Laeger** 1996 Jul 1;158(27):3908–12 (7 ref.) **(Dan)**
[The role of polymorphonuclear neutrophilic leukocytes in the pathogenesis of acute respiratory distress syndrome (ARDS)] Thiel M, et al. **Anaesthesist** 1996 Feb;45(2):113–30 (88 ref.) (Eng. Abstr.) **(Ger)**
[Reactive oxygen species and arachidonic acid metabolites of polymorphonuclear leukocytes] Döring G, et al. **Immun Infekt** 1995 Oct;23(5):148–57 (163 ref.) (Eng. Abstr.) **(Ger)**
[Polymorphonuclear leukocytes as a potential source of oxygen free radicals in myocardial infarction] Wysocka J. **Postepy Hig Med Dosw** 1995;49(2):297–304 (42 ref.) (Eng. Abstr.) **(Pol)**

TRANSPLANTATION

Blood center perspective of granulocyte transfusions: future applications. Price TH. **J Clin Apheresis** 1995;10(3):119–23 (34 ref.)
Clinical perspectives of granulocyte transfusions: efficacy to date. Strauss RG. **J Clin Apheresis** 1995;10(3):114–8 (23 ref.)

ULTRASTRUCTURE

Secretory vesicles of human neutrophils. Sengeløv H. **Eur J Haematol Suppl** 1996;58:1–24 (136 ref.)

NEVOID BASAL CELL CARCINOMA SYNDROME see **BASAL CELL NEVUS SYNDROME**

NEVOXANTHOENDOTHELIOMA see **XANTHOGRANULOMA, JUVENILE**

NEVUS

The significance of birthmarks. Rogers M. **Med J Aust** 1996 May 20;164(10):618–23 (24 ref.)

BLOOD SUPPLY

[Incident light microscopic characterization of vascular patterns in skin tumors] Kreusch J, et al. **Hautarzt** 1996 Apr;47(4):264–72 (21 ref.) (Eng. Abstr.) **(Ger)**

CLASSIFICATION

What is a nevus? A proposed definition of a common medical term. Happle R. **Dermatology** 1995;191(1):1–5 (38 ref.)

COMPLICATIONS

The clinical spectrum of naevus anaemicus and its association with port wine stains: report of 15 cases and a review of the literature. Katugampola GA, et al. **Br J Dermatol** 1996 Feb;134(2):292–5 (19 ref.)

GENETICS

The CHILD nevus: a distinct skin disorder. Happle R, et al. **Dermatology** 1995;191(3):210–6 (64 ref.)
Cutaneous mosaicism. Savin JA. **QJM** 1996 Jul;89(7):489–91 (18 ref.)

PATHOLOGY

[Epithelial-cystic nevus of the conjunctiva (Parinaud's dermo-epithelioma)] Cernea P, et al. **Oftalmologia** 1996 Jan-Mar;40(1):58–62 (8 ref.) (Eng. Abstr.) **(Rum)**
[Neurocutaneous syndromes with predominant vascular anomalies] Rodriguez-Barrionuevo AC. **Rev Neurol** 1996 Sep;24(133):1072–84 (121 ref.) **(Spa)**

NEVUS, BLUE

DIAGNOSIS

[Malignant infiltrating blue nevus of the plaque type. Case report and literature review] Wlotzke U, et al. **Hautarzt** 1995 Dec;46(12):860–4 (30 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

Acquired multiple blue nevi on an extremity. Suchniak JM, et al. **J Am Acad Dermatol** 1995 Dec;33(6):1051–2 (10 ref.)
[Blue nevus of the endocervix] Di Renzi F, et al. **Minerva Ginecol** 1995 Jul-Aug;47(7–8):331–4 (23 ref.) (Eng. Abstr.) **(Ita)**

NEVUS, DYSPLASTIC see **DYSPLASTIC NEVUS SYNDROME**

NEVUS, HALO see **NEVUS, PIGMENTED**

NEVUS, MELANOCYTIC see **NEVUS, PIGMENTED**

NEVUS OF OTA

PATHOLOGY

[Melanoma developped on nevus of Ota without ocular melanosis. Apropos of an anatomo-clinical case] Reichert S, et al. **J Fr Ophtalmol** 1996;19(5):389–94 (23 ref.) (Eng. Abstr.) **(Fre)**

NEVUS, PIGMENTED

CONGENITAL

Congenital subungual nevus in a black infant. Libow LF, et al. **Cutis** 1995 Sep;56(3):154–6 (17 ref.)
Congenital nevi. Schleicher SM, et al. **Int J Dermatol** 1995 Dec;34(12):825–9 (34 ref.)

DIAGNOSIS

Discordance in the histopathologic diagnosis of melanoma and melanocytic nevi between expert pathologists. Farmer ER, et al. **Hum Pathol** 1996 Jun;27(6):528–31 (22 ref.)

EPIDEMIOLOGY

The epidemiology of acquired melanocytic nevi. A brief review. Gallagher RP, et al. **Dermatol Clin** 1995 Jul; 13(3):595–603 (49 ref.)

ETIOLOGY

[Eruptive nevus in the course of Lyell syndrome] Jullien D, et al. **Ann Dermatol Venereol** 1995;122(8):540–2 (14 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Parenchymal-stromal interactions in neoplasia. Theoretical considerations and observations in melanocytic neoplasia. Clark WH Jr, et al. **Acta Oncol** 1995;34(6):749–57 (25 ref.)
Discordance in the histopathologic diagnosis of melanoma and melanocytic nevi between expert pathologists. Farmer ER, et al. **Hum Pathol** 1996 Jun;27(6):528–31 (22 ref.)
Widespread eruptive dermal and atypical melanocytic nevi in association with chronic myelocytic leukemia: case report and review of the literature. Richert S, et al. **J Am Acad Dermatol** 1996 Aug;35(2 Pt 2):326–9 (25 ref.)

NEVUS SYNDROME, BASAL CELL see **BASAL CELL NEVUS SYNDROME**

NEVUS SYNDROME, DYSPLASTIC see **DYSPLASTIC NEVUS SYNDROME**

NEW DEVICE APPROVAL see **DEVICE APPROVAL**

NEW DRUG APPROVAL see **DRUG APPROVAL**

NEWBORN INFANT SCREENING see **NEONATAL SCREENING**

NEWBORN INTENSIVE CARE UNITS see **INTENSIVE CARE UNITS, NEONATAL**

NEWCASTLE DISEASE

EPIDEMIOLOGY

Australian studies on Newcastle disease virus. The French heritage. Spradbrow PB, et al. **Vet Microbiol** 1995 Sep; 46(1–3):15–9, 1–2 (14 ref.)

NEWCASTLE DISEASE VIRUS

Australian studies on Newcastle disease virus. The French heritage. Spradbrow PB, et al. **Vet Microbiol** 1995 Sep; 46(1–3):15–9, 1–2 (14 ref.)

NEWSLETTERS see **PERIODICALS**

NF-KAPPA B

BIOSYNTHESIS

TNF-induced activation of NF-kappa B. Schütze S, et al. **Immunobiology** 1995 Jul;193(2–4):193–203 (52 ref.)

GENETICS

Activation of NF-kappa B by the Tax protein of HTLV-1. Munoz E, et al. **Immunobiology** 1995 Jul;193(2–4):128–36 (54 ref.)
Multi-step activation of NF-kappa B/Rel transcription factors. Schmitz ML, et al. **Immunobiology** 1995 Jul; 193(2–4):116–27 (72 ref.)

METABOLISM

Antioxidant and redox regulation of gene transcription. Sen CK, et al. **FASEB J** 1996 May;10(7):709–20 (94 ref.)
Rel/NF-kappa B/I kappa B family: intimate tales of association and dissociation. Verma IM, et al. **Genes Dev** 1995 Nov 15;9(22):2723–35 (114 ref.)
Regulation of the DNA binding activity of NF-kappa B. Matthews JR, et al. **Int J Biochem Cell Biol** 1995 Sep; 27(9):865–79 (130 ref.)
Molecular interactions between HTLV-1 Tax protein and the NF-kappa B/kappa B transcription complex. Hiscott J, et al. **Virology** 1995 Dec 1;214(1):3–11 (77 ref.)

PHYSIOLOGY

The NF-kappaB transcription factor in oncogenesis. Sharma HW, et al. **Anticancer Res** 1996 Mar-Apr;16(2):589–96 (74 ref.)
Redox signalling by transcription factors NF-kappa B and AP-1 in lymphocytes. Schulze-Osthoff K, et al. **Biochem Pharmacol** 1995 Sep 7;50(6):735–41 (69 ref.)
Lymphopoiesis. Transcription factors controlling B-cell development. Desiderio S. **Curr Biol** 1995 Jun 1;5(6):605–8 (20 ref.)
Mechanistic aspects of NF-kappa B regulation: the emerging role of phosphorylation and proteolysis. Finco TS, et al. **Immunity** 1995 Sep;3(3):263–72 (100 ref.)
Novel insight into molecular mechanism of endotoxin shock: biochemical analysis of LPS receptor signaling in a cell-free system targeting NF-kappaB and regulation of cytokine production/action through beta2 integrin in vivo. Mukaida N, et al. **J Leukoc Biol** 1996 Feb;59(2):145–51 (42 ref.)
Defects in signal transduction pathways in chronic B lymphocytic leukemia cells. Jabbar SA, et al. **Leuk Lymphoma** 1995 Jun;18(1–2):163–70 (52 ref.)
Regulation of human immunodeficiency virus type 1 and cytokine gene expression in myeloid cells by NF-kappa B/Rel transcription factors. Roulston A, et al. **Microbiol Rev** 1995 Sep;59(3):481–505 (481 ref.)
Function and activation of the transcription factor NF-kappa B in the response to toxins and pathogens. Schmitz ML. **Toxicol Lett** 1995 Dec;82–83:407–11 (19 ref.)

NF1 GENES see **GENES, NEUROFIBROMATOSIS 1**

NF2 GENES see **GENES, NEUROFIBROMATOSIS 2**

NGF RECEPTORS see **RECEPTORS, NERVE GROWTH FACTOR**

NIACIN

BLOOD

[Nicotinic acid] Hashizume N. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:731–3 (6 ref.) **(Jpn)**

METABOLISM

Evaluating the role of niacin in human carcinogenesis. Jacobson EL, et al. **Biochimie** 1995;77(5):394–8 (22 ref.)

PHYSIOLOGY

[Role of nicotinic acid and its derivatives in disorders of nervous system function] Parkhomets PK, et al. **Ukr Biokhim Zh** 1995 Jul-Aug;67(4):3–11 (91 ref.) (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Evaluating the role of niacin in human carcinogenesis. Jacobson EL, et al. **Biochimie** 1995;77(5):394–8 (22 ref.)

NIACINAMIDE

ANALOGS & DERIVATIVES

Nicorandil for angina. **Drug Ther Bull** 1995 Dec;33(12):89–92 (26 ref.)

PHYSIOLOGY

[Role of nicotinic acid and its derivatives in disorders of nervous system function] Parkhomets PK, et al. **Ukr Biokhim Zh** 1995 Jul-Aug;67(4):3–11 (91 ref.) (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Nicotinamide and other benzamide analogs as agents for overcoming hypoxic cell radiation resistance in tumours. A review. Horsman MR. **Acta Oncol** 1995;34(5):571–87 (158 ref.)

NICARDIPINE

Nicardipine: applications in anesthesia practice. Tobias JD.

J Clin Anesth 1995 Sep;7(6):525-33 (56 ref.)

NICKEL

Nickel complexes as probes of guanine sites in nucleic acid folding. Burrows CJ, et al. **Met Ions Biol Syst** 1996; 33:537-60 (41 ref.)

ADVERSE EFFECTS

The immunology of nickel-induced allergic contact dermatitis. Sosroseno W. **Asian Pac J Allergy Immunol** 1995 Dec;13(2):173-81 (95 ref.)

ANALYSIS

[Nickel (Ni)] Karita K, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:843-5 (19 ref.) **(Jpn)**

CHEMISTRY

Nickel-catalyzed oxidations: from hydrocarbons to DNA. Burrows CJ, et al. **Acta Chem Scand** 1996 Apr;50(4):337-44 (35 ref.)

NICKEL-CHROMIUM ALLOYS see **CHROMIUM ALLOYS**

NICOTIANA see **TOBACCO**

NICOTINAMIDE see **NIACINAMIDE**

NICOTINAMIDE-ADENINE DINUCLEOTIDE see **NAD**

NICOTINAMIDE-ADENINE DINUCLEOTIDE PHOSPHATE see **NADP**

NICOTINE

Practice guideline for the treatment of patients with nicotine dependence. American Psychiatric Association. **Am J Psychiatry** 1996 Oct;153(10 Suppl):1-31 (219 ref.)

Molecular and cellular aspects of nicotine abuse. Dani JA, et al. **Neuron** 1996 May;16(5):905-8 (25 ref.)

ADMINISTRATION & DOSAGE

Dose-related actions of nicotine on behavior and physiology: review and implications for replacement therapy for nicotine dependence. Henningfield JE, et al. **J Subst Abuse** 1989;1(3):301-17 (50 ref.)

[Smoking cessation with the nicotine patch] Batra A, et al. **Z Arztl Fortbild (Jena)** 1995 Oct;89(5):505-9 (28 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Nicotine addiction and treatment. Rose JE. **Annu Rev Med** 1996;47:493-507 (111 ref.)

Pharmacology of nicotine: addiction and therapeutics. Benowitz NL. **Annu Rev Pharmacol Toxicol** 1996; 36:597-613 (93 ref.)

[Neuroleptics and nicotine] Erdmann R. **Psychiatr Prax** 1995 Nov;22(6):223-7 (34 ref.) (Eng. Abstr.) **(Ger)**

PHARMACOLOGY

Addictive drugs as reinforcers: multiple partial actions on memory systems. White NM. **Addiction** 1996 Jul; 91(7):921-49; discussion 951-65 (304 ref.)

Sites, mechanisms, and structural characteristics of the brain's nicotine receptor. Abood LG, et al. **J Subst Abuse** 1989; 1(3):259-71 (50 ref.)

Differential effect of chronic nicotine treatment on nicotinic receptor numbers in various brain regions of mice. Collins AC, et al. **J Subst Abuse** 1989;1(3):273-86 (43 ref.)

[Connection between smoking and reduced risk of ulcerative colitis. Does nicotine mediate a protective effect?] Nilsson A. **Lakartidningen** 1995 Dec 13;92(50):4788-92 (20 ref.) **(Swe)**

THERAPEUTIC USE

Nicotine medications for smoking cessation. Henningfield JE. **N Engl J Med** 1995 Nov 2;333(18):1196-203 (101 ref.)

NICOTINIC ACETYLCHOLINE RECEPTORS see **RECEPTORS, NICOTINIC**

NICOTINIC ACID see **NIACIN**

NICOTINIC AGENTS see **CHOLINERGIC AGENTS**

NICOTINIC ANTAGONISTS

[Desensitization of the nicotinic acetylcholine receptor] Quiñonez M, et al. **Acta Cient Venez** 1994;45(1):13-22 (78 ref.) (Eng. Abstr.) **(Spa)**

PHARMACOLOGY

Agonist self-inhibitory binding site of the nicotinic acetylcholine receptor. Arias HR. **J Neurosci Res** 1996 Apr 15;44(2):97-105 (72 ref.)

[Epibatidine--a nicotine-related, analgesic alkaloid from poison-dart frogs] Müller CE. **Pharm Unserer Zeit** 1996 Apr;25(2):85-92 (27 ref.) **(Ger)**

NICOTINIC RECEPTORS see **RECEPTORS, NICOTINIC**

NIDATION see **OVUM IMPLANTATION**

NIDDM see **DIABETES MELLITUS, NON-INSULIN-DEPENDENT**

NIEMANN-PICK DISEASE

Niemann-Pick disease type C. From bench to bedside. Schiffmann R. **JAMA** 1996 Aug 21;276(7):561-4 (23 ref.)

[Niemann-Pick disease type C] Akaboshi S, et al. **Nippon Rinsho** 1995 Dec;53(12):3036-40 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Niemann-Pick disease types A and B] Ohno K. **Nippon Rinsho** 1995 Dec;53(12):3014-8 (7 ref.) (Eng. Abstr.) **(Jpn)**

NIFEDIPINE

ADVERSE EFFECTS

Nifedipine gastrointestinal therapeutic system (GITS). A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in hypertension and angina pectoris. Brogden RN, et al. **Drugs** 1995 Sep; 50(3):495-512 (82 ref.)

PHARMACOKINETICS

The nifedipine gastrointestinal therapeutic system (GITS). Evaluation of pharmaceutical, pharmacokinetic and pharmacological properties. Grundy JS, et al. **Clin Pharmacokinet** 1996 Jan;30(1):28-51 (131 ref.)

PHARMACOLOGY

The nifedipine gastrointestinal therapeutic system (GITS). Evaluation of pharmaceutical, pharmacokinetic and pharmacological properties. Grundy JS, et al. **Clin Pharmacokinet** 1996 Jan;30(1):28-51 (131 ref.)

Nifedipine gastrointestinal therapeutic system (GITS). A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in hypertension and angina pectoris. Brogden RN, et al. **Drugs** 1995 Sep; 50(3):495-512 (82 ref.)

THERAPEUTIC USE

Blood pressure-lowering effect of adding grapefruit juice to nifedipine and terazosin in a patient with severe renovascular hypertension. Pisarik P. **Arch Fam Med** 1996 Jul-Aug;5(7):413-6 (17 ref.)

Calcium channel blockers. Ray D, et al. **Clin Obstet Gynecol** 1995 Dec;38(4):713-21 (40 ref.)

Nifedipine gastrointestinal therapeutic system (GITS). A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in hypertension and angina pectoris. Brogden RN, et al. **Drugs** 1995 Sep; 50(3):495-512 (82 ref.)

[Selected passages from the clinical trials of Cordaflex] Somogyi M, et al. **Acta Pharm Hung** 1996 Jan;66(1):47-51 (16 ref.) (Eng. Abstr.) **(Hun)**

TOXICITY

Pathogenesis of drug-induced gingival overgrowth. A review of studies in the rat model. Nishikawa S, et al. **J Periodontol** 1996 May;67(5):463-71 (94 ref.)

NIGHT TERRORS see **SLEEP DISORDERS**

NIGHTMARES see **DREAMS**

NIH 3T3 CELLS see **3T3 CELLS**

NIMODIPINE

PHARMACOLOGY

Potential interactions between nimodipine and adrenal hormones. Isaacson RL, et al. **Ann N Y Acad Sci** 1995 Sep 15;765:134-42; discussion 160-2 (29 ref.)

NIPECOTIC ACIDS

PHARMACOLOGY

Tiagabine pharmacology in profile. Brodie MJ. **Epilepsia** 1995;36 Suppl 6:S7-S9 (18 ref.)

A review of the preclinical pharmacology of tiagabine: a potent and selective anticonvulsant GABA uptake inhibitor. Suzdak PD, et al. **Epilepsia** 1995 Jun;36(6):612-26 (81 ref.)

NIPPLES

Retroareolar leiomyoma [letter] Way JC. **Can J Surg** 1996 Aug;39(4):339 (7 ref.)

Coexistence of nipple duct adenoma and breast carcinoma: a clinicopathologic study of five cases and review of the literature. Jones MW, et al. **Mod Pathol** 1995 Aug; 8(6):633-6 (13 ref.)

[The differential diagnosis of tumors of the nipple and areola] Schulz B, et al. **Dtsch Med Wochenschr** 1996 Jan 5; 121(1-2):23-7 (19 ref.) **(Ger)**

[Cytologic and biochemical characteristics of breast fluid obtained through the nipple of non-lactating women] Vizoso F. **Med Clin (Barc)** 1995 Sep 23;105(9):349-56 (137 ref.) **(Spa)**

PATHOLOGY

Superficial papillary adenomatosis of the nipple: a case report and review of the literature. Montemarano AD, et al. **J Am Acad Dermatol** 1995 Nov;33(5 Pt 2):871-5 (24 ref.)

NISIN

METABOLISM

Maturation pathway of nisin and other lantibiotics: post-translationally modified antimicrobial peptides exported by gram-positive bacteria. de Vos WM, et al. **Mol Microbiol** 1995 Aug;17(3):427-37 (73 ref.)

NISSEN OPERATION see **FUNDOPLICATION**

NITRATES

ADMINISTRATION & DOSAGE

[Controlled clinical studies of tolerance development and dosing problems in nitrate therapy] Abshagen U. **Herz** 1996 Jun;21 Suppl 1:23-30 (18 ref.) (Eng. Abstr.) **(Ger)**

[Use of nitrates in coronary heart disease including acute myocardial infarct] Auch-Schwelk W. **Herz** 1996 Jun;21 Suppl 1:31-4 (34 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Health implications of nitrate and nitrite in drinking water: an update on methemoglobinemia occurrence and reproductive and developmental toxicity. Fan AM, et al. **Regul Toxicol Pharmacol** 1996 Feb;23(1 Pt 1):35-43 (54 ref.)

BLOOD

[Drug of nitrate and nitrite] Iida K. **Nippon Rinsho** 1995 Feb; 53 Su Pt 1:986-8 (17 ref.) **(Jpn)**

PHARMACOLOGY

Oral nitrate preparations: an update. Bomber JW, et al. **Am Fam Physician** 1995 Dec;52(8):2331-7 (28 ref.)

[Pharmacology of nitrates and other NO donors] Dendorfer A. **Herz** 1996 Jun;21 Suppl 1:38-49 (54 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Reactions between nitric oxide, superoxide, and peroxynitrite: footprints of peroxynitrite in vivo. Crow JP, et al. **Adv Pharmacol** 1995;34:17-43 (74 ref.)

THERAPEUTIC USE

Beneficial actions of nitrates in cardiovascular disease. Abrams J. **Am J Cardiol** 1996 May 30;77(13):31C-7C (29 ref.)

Nitrates in the treatment of congestive heart failure. Elkayam U. **Am J Cardiol** 1996 May 30;77(13):41C-51C (56 ref.)

Effect of nitrates on myocardial remodeling after acute myocardial infarction. Jugdutt BI. **Am J Cardiol** 1996 May 30;77(13):17C-23C (90 ref.)

Nitric oxide and nitrovasodilators: similarities, differences, and interactions. Kelly RA, et al. **Am J Cardiol** 1996 May 30;77(13):2C-7C (70 ref.)

Organic nitrates: new formulations and their clinical advantages. Parker JA. **Am J Cardiol** 1996 May 30; 77(13):38C-40C (23 ref.)

Thiol compounds and organic nitrates. Boesgaard S. **Dan Med Bull** 1995 Nov;42(5):473-84 (117 ref.)

[Treatment of Angina pectoris using nitrates] van Wijngaarden J, et al. **Ned Tijdschr Geneeskd** 1996 Apr 13; 140(15):819-22 (25 ref.) **(Dut)**

[Characteristics of angina pectoris therapy with nitrates] Silber S. **Herz** 1996 Jun;21 Suppl 1:4-22 (331 ref.) (Eng. Abstr.) **(Ger)**

[The role of nitrates in therapy of heart failure] Strasser RH. **Herz** 1996 Jun;21 Suppl 1:35-7 (36 ref.) (Eng. Abstr.) **(Ger)**

TOXICITY

[Causes and mechanisms of nitrate and nitrite poisoning (review of the literature)] Gozhenko AI, et al. **Med Tr Prom Ekol** 1996;(4):15-21 (42 ref.) **(Rus)**

NITRAZEPAM

BLOOD

[Clonazepam, nitrazepam, diazepam] Yasuda K. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:911-4 (19 ref.) **(Jpn)**

POISONING

Two cases of lethal nitrazepam poisoning. Brødsgaard I, et al. **Am J Forensic Med Pathol** 1995 Jun;16(2):151-3 (7 ref.)

NITRIC OXIDE

see related

ENDOTHELIUM-DERIVED RELAXING FACTOR

Clinical applications of nitric oxide. Mizutani T, et al. **Chest** 1996 Aug;110(2):506–24 (217 ref.)

Respiratory effects of air pollutants: experimental studies in humans [see comments] Sandström T. **Eur Respir J** 1995 Jun;8(6):976–95 (221 ref.) Comment in: Eur Respir J 1995 Jun;8(6):883–4.

[Nitric oxide: an ubiquitous mediator] Sabry S, et al. **Arch Pediatr** 1996;3 Suppl 1:275s–277s (10 ref.) **(Fre)**

ADMINISTRATION & DOSAGE

Inhaled nitric oxide therapy of pulmonary hypertension and respiratory failure in premature and term neonates. Abman SH, et al. **Adv Pharmacol** 1995;34:457–74 (71 ref.)

Inhaled nitric oxide, clinical rationale and applications. Frostell CG, et al. **Adv Pharmacol** 1995;34:439–56 (106 ref.)

Clinical applications of inhaled nitric oxide in children with pulmonary hypertension. Wessel DL, et al. **Adv Pharmacol** 1995;34:475–504 (136 ref.)

Nitric oxide inhalation in infants and children: physiologic and clinical implications. Craig J, et al. **Am J Crit Care** 1995 Nov;4(6):443–50; quiz 451–2 (47 ref.)

Inhalational nitric oxide in pulmonary parenchymal and vascular disease. Cornfield DN, et al. **J Lab Clin Med** 1996 Jun;127(6):530–9 (64 ref.)

Advanced ventilation in the neonate. Antunes MJ, et al. **Nurs Clin North Am** 1996 Jun;31(2):405–22 (123 ref.)

Inhaled nitric oxide for persistent pulmonary hypertension of the newborn: the physiology matters! [comment] [see comments] Abman SH, et al. **Pediatrics** 1995 Dec; 96(6):1153–5 (14 ref.) Comment on: Pediatrics 1995 Dec;96(6):1147–51. Comment in: Pediatrics 1996 Mar;97(3):438–9.

Inhaled nitric oxide for persistent pulmonary hypertension of the newborn: implications and strategy for future "high-tech" neonatal clinical trials [see comments] Stark AR, et al. **Pediatrics** 1995 Dec;96(6):1147–51 (19 ref.) Comment in: Pediatrics 1995 Dec;96(6):1153–5.

Inhaled vasodilator therapy in acute lung injury: first, do NO harm? [editorial] Brett SJ, et al. **Thorax** 1995 Aug; 50(8):821–3 (4 ref.)

[The usefulness of inhaled nitric oxide in the treatment of pulmonary hypertension in the postoperative period of cardiac surgery in infancy] de Lucas García N, et al. **An Esp Pediatr** 1996 Apr;44(4):373–6 (27 ref.) **(Spa)**

[The immediate response to the administration of inhaled nitric oxide in a newborn infant with congenital diaphragmatic hernia and pulmonary hypertension] Figueras Aloy J, et al. **An Esp Pediatr** 1996 Jan;44(1):70–2 (24 ref.) **(Spa)**

ANALYSIS

Free radicals (nitric oxide). Kostka P. **Anal Chem** 1995 Jun 15;67(12):411R–416R (118 ref.)

Exhaled nitric oxide: a new lung function test [editorial] Barnes PJ, et al. **Thorax** 1996 Mar;51(3):233–7 (73 ref.)

[Distribution and localization of nitric oxide containing neural elements in the digestive tract] Altdorfer K, et al. **Orv Hetil** 1996 Apr 21;137(16):857–60 (32 ref.) (Eng. Abstr.) **(Hun)**

[Techniques for measurement of nitric oxide in biological systems: principles and practice] Yamamura T. **Nippon Yakurigaku Zasshi** 1996 Apr;107(4):173–82 (41 ref.) (Eng. Abstr.) **(Jpn)**

[Belching, flatus, breath. Measurements of airborne nitric oxide in the non-invasive diagnosis of inflammation] Lundberg J, et al. **Lakartidningen** 1996 May 15; 93(20):1945–8 (22 ref.) (Eng. Abstr.) **(Swe)**

ANTAGONISTS & INHIBITORS

Nitric oxide inhibition in the treatment of septic shock [editorial; comment] Hata JS, et al. **Crit Care Med** 1995 Oct;23(10):1621–4 (26 ref.) Comment on: Crit Care Med 1995 Oct;23(10):1711–21.

BIOSYNTHESIS

Control and consequences of endothelial nitric oxide formation. Fleming I, et al. **Adv Pharmacol** 1995;34:187–206 (118 ref.)

Why tetrahydrobiopterin? Mayer B, et al. **Adv Pharmacol** 1995;34:251–61 (50 ref.)

Regulation of nitric oxide synthase: role of oxygen radicals and cations in nitric oxide formation. Mittal CK, et al. **Adv Pharmacol** 1995;34:235–50 (50 ref.)

On the mechanism of nitric oxide formation upon oxidative cleavage of C = N(OH) bonds by NO-synthases and cytochromes P450. Mansuy D, et al. **Biochimie** 1995; 77(7–8):661–7 (28 ref.)

Nitric oxide and cerebral blood flow: an update. Watkins LD. **Cerebrovasc Brain Metab Rev** 1995 Winter; 7(4):324–337 (99 ref.)

Nitric oxide production by human monocytes: evidence for a role of CD23. Dugas B, et al. **Immunol Today** 1995 Dec; 16(12):574–80 (54 ref.)

Role of nitric oxide in anaphylactic shock. Mitsuhata H, et al. **J Clin Immunol** 1995 Nov;15(6):277–83 (63 ref.)

On the expression of nitric oxide synthase by human macrophages. Why no NO? Albina JE. **J Leukoc Biol** 1995 Dec;58(6):643–9 (64 ref.)

Nitric oxide production and NO synthase gene expression contribute to vascular regulation during exercise. Shen W, et al. **Med Sci Sports Exerc** 1995 Aug;27(8):1125–34 (75 ref.)

Biosynthesis of nitric oxide: dependence on pteridine metabolism. Werner ER, et al. **Rev Physiol Biochem Pharmacol** 1996;127:97–135 (280 ref.)

The L-arginine/nitric oxide pathway--biological properties and therapeutic applications. Neilly PJ, et al. **Ulster Med J** 1994 Oct;63(2):193–200 (67 ref.)

[Nitric oxide. Current findings on the synthesis and genetics of nitric oxide synthases, regulation of hypothalamic and vascular function] Dioh A, et al. **Rev Med Liege** 1995 Nov; 50(11):480–6 (50 ref.) **(Fre)**

[The role of vascular nitric oxide (NO) in the pathomechanism of pre-eclampsia] Visontai ZZ, et al. **Orv Hetil** 1995 Nov 19;136(47):2547–51 (50 ref.) (Eng. Abstr.) **(Hun)**

[Characteristic of nitric oxide production in macrophages] Takagi K, et al. **Seikagaku** 1995 Nov;67(11):1287–90 (17 ref.) **(Jpn)**

[Ethanol mechanism(s) of action on LHRH secretion] Canteros MG, et al. **Acta Physiol Pharmacol Ther Latinoam** 1995;45(1):55–63 (18 ref.) **(Spa)**

CHEMISTRY

Chemistry of nitric oxide: biologically relevant aspects. Fukuto JM. **Adv Pharmacol** 1995;34:1–15 (36 ref.)

IMMUNOLOGY

The role of nitric oxide in inflammation. Lyons CR. **Adv Immunol** 1995;60:323–71 (340 ref.)

Natural resistance and nitric oxide. Nathan C. **Cell** 1995 Sep 22;82(6):873–6 (30 ref.)

METABOLISM

Gases as chemical messengers in the carotid body. Role of nitric oxide and carbon monoxide in chemoreception. Prabhakar NR. **Adv Exp Med Biol** 1995;393:309–12 (14 ref.)

Oxygen radical-nitric oxide reactions in vascular diseases. Freeman BA, et al. **Adv Pharmacol** 1995;34:45–69 (81 ref.)

Nitric oxide donors: a continuing opportunity in drug design. Hanson SR, et al. **Adv Pharmacol** 1995;34:383–98 (28 ref.)

A study on tumor necrosis factor, tumor necrosis factor receptors, and nitric oxide in human fetal glial cultures. St. Pierre BA, et al. **Adv Pharmacol** 1995;34:415–38 (94 ref.)

Cognitive enhancement. New strategies for stimulating cholinergic, glutamatergic, and nitric oxide systems. Ingram DK, et al. **Ann N Y Acad Sci** 1996 Jun 15; 786:348–61 (80 ref.)

Endothelial cells, nitric oxide and ischaemic preconditioning. Parratt JR, et al. **Basic Res Cardiol** 1996 Jan–Feb; 91(1):27–30 (14 ref.)

Inducible nitric oxide synthase and its product nitric oxide, a small molecule with complex biological activities. Kröncke KD, et al. **Biol Chem Hoppe Seyler** 1995 Jun; 376(6):327–43 (163 ref.)

The nitric oxide pathway in glomerulonephritis. Cattell V, et al. **Curr Opin Nephrol Hypertens** 1995 Jul;4(4):359–64 (52 ref.)

Role of nitric oxide in neurodegenerative diseases. Schulz JB, et al. **Curr Opin Neurol** 1995 Dec;8(6):480–6 (42 ref.)

Light-mediated conversion of nitrogen dioxide to nitric oxide by carotenoids. Cooney RV, et al. **Environ Health Perspect** 1994 May;102(5):460–2 (33 ref.)

Neuronal nitric oxide synthase, a modular enzyme formed by convergent evolution: structure studies of a cysteine thiolate-liganded heme protein that hydroxylates L-arginine to produce NO. as a cellular signal. Masters BS, et al. **FASEB J** 1996 Apr;10(5):552–8 (70 ref.)

Nitric oxide and liver disease. Abrams GA, et al. **Gastroenterologist** 1995 Sep;3(3):220–33 (187 ref.)

Kinetic pathways and barriers for ligand binding to myoglobin. Olson JS, et al. **J Biol Chem** 1996 Jul 26; 271(30):17593–6 (28 ref.)

Calcium supplementation prevents pregnancy-induced hypertension by increasing the production of vascular nitric oxide. López-Jaramillo P, et al. **Med Hypotheses** 1995 Jul; 45(1):68–72 (73 ref.)

The nitric oxide/ascorbate cycle: how neurones may control their own oxygen supply. Millar J. **Med Hypotheses** 1995 Jul;45(1):21–6 (65 ref.)

NO honey, I don't remember. Hawkins RD. **Neuron** 1996 Mar;16(3):465–7 (18 ref.)

Molecular control of vertebrate iron metabolism: mRNA-based regulatory circuits operated by iron, nitric oxide, and oxidative stress. Hentze MW, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8175–82 (151 ref.)

Placental nitric oxide metabolism. Sooranna SR, et al. **Reprod Fertil Dev** 1995;7(6):1525–31 (38 ref.)

[Biochemistry and medical value of NO. Physiology and physiopathology of nitric oxide] Keipes M. **Bull Soc Sci Med Grand Duche Luxemb** 1995;132(3):27–32 (25 ref.) (Eng. Abstr.) **(Fre)**

[Nitric oxide: implication in excitotoxicity and cerebral ischemia] Demerlé-Pallardy C, et al. **C R Seances Soc Biol Fil** 1995;189(6):1059–68 (49 ref.) (Eng. Abstr.) **(Fre)**

[NO, ambivalent effector of non-specific immunity and of inflammation] Drapier JC. **C R Seances Soc Biol Fil** 1995; 189(6):1081–96 (104 ref.) (Eng. Abstr.) **(Fre)**

[Metalloproteins, cellular targets of nitric oxide: a concise review] Henry Y, et al. **C R Seances Soc Biol Fil** 1995; 189(6):1039–57 (110 ref.) (Eng. Abstr.) **(Fre)**

[Does nitric oxide stress exist?] Torreilles J, et al. **C R Seances Soc Biol Fil** 1995;189(3):389–400 (42 ref.) (Eng. Abstr.) **(Fre)**

[The L-arginine/nitric oxide metabolic pathway. Its physiopathology and clinical implications] Mengozzi G, et al. **Ann Ital Med Int** 1996 Jan–Mar;11(1):46–51 (48 ref.) (Eng. Abstr.) **(Ita)**

[Nitric oxide and oxidative metabolism: heads or tails in inflammatory gastric disease] Esteban Carretero J, et al. **Rev Esp Enferm Dig** 1996 Jun;88(6):423–30 (90 ref.) **(Spa)**

PHARMACOLOGY

Inhaled nitric oxide, clinical rationale and applications. Frostell CG, et al. **Adv Pharmacol** 1995;34:439–56 (106 ref.)

Negative modulation of nitric oxide synthase by nitric oxide and nitroso compounds. Griscavage JM, et al. **Adv Pharmacol** 1995;34:215–34 (56 ref.)

Nitric oxide: physiology and pharmacology. Schroeder RA, et al. **Anesth Analg** 1995 Nov;81(5):1052–9 (91 ref.)

The nitric oxide pathway: potential implications for treatment of neuropsychiatric disorders. Karatinos J, et al. **Clin Neuropharmacol** 1995 Dec;18(6):482–99 (83 ref.)

Role of nitric oxide in central synaptic transmission: effects on neurotransmitter release. Kuriyama K, et al. **Jpn J Pharmacol** 1995 Sep;69(1):1–8 (50 ref.)

Impact of the L-arginine/nitric oxide system in pregnancy. Neri I, et al. **Obstet Gynecol Surv** 1995 Dec;50(12):851–8 (64 ref.)

PHYSIOLOGY

Role of nitric oxide in glomerular physiology and pathophysiology. Gabbai FB, et al. **Adv Nephrol Necker Hosp** 1995;24:3–18 (72 ref.)

Interactions between cytokines and nitric oxide. Liew FY. **Adv Neuroimmunol** 1995;5(2):201–9 (49 ref.)

Nitric oxide in the developing lung. Shaul PW. **Adv Pediatr** 1995;42:367–414 (182 ref.)

Nitric oxide donors: biochemical pharmacology and therapeutics. Bauer JA, et al. **Adv Pharmacol** 1995; 34:361–81 (88 ref.)

Glyceraldehyde-3-phosphate dehydrogenase: a target for nitric oxide signaling. Brüne B, et al. **Adv Pharmacol** 1995; 34:351–60 (30 ref.)

Reactions between nitric oxide, superoxide, and peroxynitrite: footprints of peroxynitrite in vivo. Crow JP, et al. **Adv Pharmacol** 1995;34:17–43 (74 ref.)

Physiological and toxicological actions of nitric oxide in the central nervous system. Dawson VL, et al. **Adv Pharmacol** 1995;34:323–42 (73 ref.)

Control and consequences of endothelial nitric oxide formation. Fleming I, et al. **Adv Pharmacol** 1995;34:187–206 (118 ref.)

Chemistry of nitric oxide: biologically relevant aspects. Fukuto JM. **Adv Pharmacol** 1995;34:1–15 (36 ref.)

Nitric oxide and intracellular heme. Kim YM, et al. **Adv Pharmacol** 1995;34:277–91 (84 ref.)

Nitric oxide and cGMP signaling. McDonald LJ, et al. **Adv Pharmacol** 1995;34:263–75 (49 ref.)

Control of electron transfer in neuronal nitric oxide synthase by calmodulin, substrate, substrate analogs, and nitric oxide. Stuehr DJ, et al. **Adv Pharmacol** 1995;34:207–13 (15 ref.)

S-nitrosothiols: chemistry, biochemistry, and biological actions. Upchurch GR Jr, et al. **Adv Pharmacol** 1995; 34:343–9 (30 ref.)

Nitric oxide: physiology and pharmacology. Schroeder RA, et al. **Anesth Analg** 1995 Nov;81(5):1052–9 (91 ref.)

Nitric oxide and airway disease. Barnes PJ. **Ann Med** 1995 Jun;27(3):389–93 (56 ref.)

Regulation and functional consequences of endothelial nitric oxide formation. Busse R, et al. **Ann Med** 1995 Jun; 27(3):331–40 (128 ref.)

Endogenous nitric oxide in cardiovascular disease and transplantation. Dusting GJ, et al. **Ann Med** 1995 Jun; 27(3):395–406 (123 ref.)

Interactions between endothelial secretogogues. Gryglewski RJ. **Ann Med** 1995 Jun;27(3):421–7 (80 ref.)

Nitric oxide in inflammation and immune response. Moilanen E, et al. **Ann Med** 1995 Jun;27(3):359–67 (119 ref.)

Nitric oxide in cardiovascular diseases. Nava E, et al. **Ann Med** 1995 Jun;27(3):343–51 (82 ref.)

Nitric oxide in the central nervous system. Paakkari I, et al. **Ann Med** 1995 Jun;27(3):369–77 (96 ref.)

Nitric oxide-based possibilities for pharmacotherapy. Pörsti I, et al. **Ann Med** 1995 Jun;27(3):407–20 (232 ref.)

Nitric oxide: biological mediator, modulator and effector. Radomski MW. **Ann Med** 1995 Jun;27(3):321–9 (121 ref.)

Nitric oxide in hypertension and renal diseases. Tikkanen I, et al. **Ann Med** 1995 Jun;27(3):353–7 (48 ref.)

Nitric oxide: a neural messenger. Jaffrey SR, et al. **Ann Rev Cell Dev Biol** 1995;11:417–40 (167 ref.)

Nitric oxide. Farrell AJ, et al. **Ann Rheum Dis** 1996 Jan; 55(1):7–20 (261 ref.)

The vascular biology of nitric oxide and its role in atherogenesis. Lloyd-Jones DM, et al. **Annu Rev Med** 1996; 47:365–75 (52 ref.)
Nitric oxide and reactive oxygen species in vascular injury. Rubbo H, et al. **Biochem Soc Symp** 1995;61:33–45 (59 ref.)
Role of nitric oxide in the vascular dysfunction of septic shock. Rees DD. **Biochem Soc Trans** 1995 Nov; 23(4):1025–9 (38 ref.)
The role of nitric oxide in carotid chemoreception. Wang ZZ, et al. **Biol Signals** 1995 May–Jun;4(3):109–16 (28 ref.)
Nitric oxide, the endothelium, pregnancy and pre-eclampsia. Morris NH, et al. **Br J Obstet Gynaecol** 1996 Jan; 103(1):4–15 (152 ref.)
Clinical biology of nitric oxide. Davies MG, et al. **Br J Surg** 1995 Dec;82(12):1598–610 (187 ref.)
Diverse interactions of calcitonin gene related peptide and nitric oxide in the gastric and cutaneous microcirculation. Holzer P, et al. **Can J Physiol Pharmacol** 1995 Jul; 73(7):991–4 (37 ref.)
Paracrine modulation of heart cell function by endothelial cells. Shah AM. **Cardiovasc Res** 1996 Jun;31(6):847–67 (224 ref.)
Do nitric oxide and cGMP play a role in calcium cycling? Milbourne EA, et al. **Cell Calcium** 1995 Sep;18(3):207–13 (43 ref.)
Does nitric oxide play a role in liver function? Milbourne EA, et al. **Cell Signal** 1995 May;7(4):313–8 (35 ref.)
Nitric oxide and cerebral blood flow: an update. Watkins LD. **Cerebrovasc Brain Metab Rev** 1995 Winter; 7(4):324–337 (99 ref.)
Nitric oxide in infectious and autoimmune diseases. Liew FY. **Ciba Found Symp** 1995;195:234–9; discussion 239–44 (26 ref.)
Nitric oxide and cardiac function. Kelly RA, et al. **Circ Res** 1996 Sep;79(3):363–80 (232 ref.)
Modulation of vasoconstriction by endothelium-derived nitric oxide: the influence of vascular disease. Woodman OL. **Clin Exp Pharmacol Physiol** 1995 Sep;22(9):585–93 (97 ref.)
NO inhibitions: antimicrobial properties of nitric oxide. De Groote MA, et al. **Clin Infect Dis** 1995 Oct;21 Suppl 2:S162–5 (55 ref.)
Nitric oxide and infection: another view. Schoedon G, et al. **Clin Infect Dis** 1995 Oct;21 Suppl 2:S152–7 (30 ref.)
Regulation of lymphocyte functions by nitric oxide. Liew FY. **Curr Opin Immunol** 1995 Jun;7(3):396–9 (43 ref.)
Nitric oxide and hypertension in 1995. Dominiczak AF, et al. **Curr Opin Nephrol Hypertens** 1996 Mar;5(2):174–80 (64 ref.)
Chemical biology of nitric oxide: regulation and protective and toxic mechanisms. Wink DA, et al. **Curr Top Cell Regul** 1996;34:159–87 (121 ref.)
Mediators: nitric oxide and other toxic oxygen species. Evans TJ, et al. **Curr Top Microbiol Immunol** 1996;216:189–207 (97 ref.)
The coupling of glucose metabolism and perfusion in human skeletal muscle. The potential role of endothelium-derived nitric oxide. Baron AD. **Diabetes** 1996 Jan;45 Suppl 1:S105–9 (43 ref.)
Local regulation of the coronary circulation in health and disease: role of nitric oxide and endothelin. Lüscher TF, et al. **Eur Heart J** 1995 May;16 Suppl C:51–8 (120 ref.)
Lung disease and pulmonary endothelial nitric oxide. Higenbottam T. **Exp Physiol** 1995 Sep;80(5):855–64 (29 ref.)
Molecular mechanisms and therapeutic strategies related to nitric oxide. Moncada S, et al. **FASEB J** 1995 Oct; 9(13):1319–30 (126 ref.)
Superoxide anion and endothelial regulation of arterial tone. Katusic ZS. **Free Radic Biol Med** 1996;20(3):443–8 (52 ref.)
Nitric oxide and the control of renin secretion. Reid IA, et al. **Fundam Clin Pharmacol** 1995;9(4):309–23 (118 ref.)
Inducible nitric oxide synthase in inflammation. Cattell V, et al. **Histochem J** 1995 Oct;27(10):777–84 (52 ref.)
Emerging roles of nitric oxide in inflammation. Lyons CR. **Hosp Pract (Off Ed)** 1996 Jul 15;31(7):69–73, 77–80, 85–6 (0 ref.)
Nitroxidergic nerves and hypertension. Toda N. **Hypertens Res** 1995 Mar;18(1):19–26 (68 ref.)
The role of nitric oxide in the development of asthma. Curran AD. **Int Arch Allergy Immunol** 1996 Sep;111(1):1–4 (34 ref.)
Nitric oxide, myocardial failure and septic shock. Brady AJ. **Int J Cardiol** 1995 Jul;50(3):269–72 (32 ref.)
Cardiomyopathy: a role for nitric oxide? de Belder A, et al. **Int J Cardiol** 1995 Jul;50(3):263–8 (51 ref.)
Comparative pharmacology of nitric oxide and nitric oxide generators on cardiac contractility in mammalian species. Lefer AM, et al. **Int J Cardiol** 1995 Jul;50(3):239–42 (7 ref.)
Positive inotropic effect of nitric oxide in myocardium. Mohan P, et al. **Int J Cardiol** 1995 Jul;50(3):233–7 (25 ref.)
The role of nitric oxide and NO-donor agents in myocardial protection from surgical ischemic-reperfusion injury. Vinten-Johansen J, et al. **Int J Cardiol** 1995 Jul; 50(3):273–81 (47 ref.)
Nitric oxide, oxygen-derived free radicals and vascular endothelium. Marin J, et al. **J Auton Pharmacol** 1995 Aug; 15(4):279–307 (223 ref.)
Regulation of blood pressure by nitroxidergic nerve. Toda N. **J Diabetes Complications** 1995 Oct–Dec;9(4):200–2 (21 ref.)
Gaseous transmitters as new agents in neuroendocrine regulation. Costa A, et al. **J Endocrinol** 1996 May; 149(2):199–207 (80 ref.)
The role of nitric oxide in the hyperdynamic circulatory syndrome associated with portal hypertension. Sogni P, et al. **J Hepatol** 1995 Aug;23(2):218–24 (78 ref.)
Nitroxidergic nerve: regulation of vascular tone and blood flow in the brain. Toda N, et al. **J Hypertens** 1996 Apr; 14(4):423–34 (127 ref.)
Endothelium-derived vasoactive factors in hypertension: nitric oxide and endothelin. Nava E, et al. **J Hypertens Suppl** 1995 Aug;13(2):S39–48 (97 ref.)
Regulation of cytokine gene expression by reactive oxygen and reactive nitrogen intermediates. Remick DG, et al. **J Leukoc Biol** 1996 Apr;59(4):471–5 (34 ref.)
Nitric oxide: a new paradigm for second messengers. Kerwin JF Jr, et al. **J Med Chem** 1995 Oct 27;38(22):4343–62 (192 ref.)
Clinical pathophysiology of persistent pulmonary hypertension of the newborn and the role of inhaled nitric oxide therapy. Kinsella JP, et al. **J Perinatol** 1996 Mar–Apr; 16(2 Pt 2 Su):S24–7 (28 ref.)
The effect of NO/EDRF and monocytes/macrophages on LDL-oxidation. Leitinger N, et al. **J Physiol Pharmacol** 1995 Dec;46(4):385–408 (144 ref.)
Nitric oxide, sepsis, and arginine metabolism. Kelly E, et al. **JPEN J Parenter Enteral Nutr** 1995 May–Jun; 19(3):234–8 (52 ref.)
Glomerular actions of nitric oxide [editorial] Raij L, et al. **Kidney Int** 1995 Jul;48(1):20–32 (216 ref.)
Does nitric oxide, an inflammatory mediator of glomerular mesangial cells, have a role in diabetic nephropathy? Pfeilschifter J. **Kidney Int Suppl** 1995 Sep;51:S50–60 (114 ref.)
Nitric oxide: its identity and role in blood pressure control. Das S, et al. **Life Sci** 1995;57(17):1547–56 (66 ref.)
Contribution of endothelium-derived nitric oxide (EDNO) to the skeletal muscle blood flow response to exercise. McAllister RM, et al. **Med Sci Sports Exerc** 1995 Aug; 27(8):1145–51 (49 ref.)
Role of nitric oxide in parasitic infections. James SL. **Microbiol Rev** 1995 Dec;59(4):533–47 (204 ref.)
Nitric oxide affects microvascular permeability in the intact and inflamed vasculature. Kubes P. **Microcirculation** 1995 Sep;2(3):235–44 (46 ref.)
Paracrine functions of the coronary vascular endothelium. Fleming I, et al. **Mol Cell Biochem** 1996 Apr 12–26; 157(1–2):137–45 (49 ref.)
Oxygen-radical/nitric oxide mediate calcium-dependent hormone action on cyclic GMP system: a novel concept in signal transduction mechanisms. Mittal CK. **Mol Cell Biochem** 1995 Aug–Sep;149–150:257–62 (37 ref.)
Nitric oxide in the regulation of renal blood flow. Ito S, et al. **New Horiz** 1995 Nov;3(4):615–23 (68 ref.)
Nitric oxide in the gut. Salzman AL. **New Horiz** 1995 May; 3(2):352–64 (145 ref.)
Nitric oxide and opioid tolerance. Pasternak GW. **NIDA Res Monogr** 1995;147:182–94 (49 ref.)
The dark side of nitric oxide: mediator of cell injury. Andreoli SP. **Pediatr Nephrol** 1995 Dec;9(6):779–82 (13 ref.)
Targeting nitric oxide to its targets. Bredt DS. **Proc Soc Exp Biol Med** 1996 Jan;211(1):41–8 (60 ref.)
Nitric oxide: a novel mediator of inflammation. Clancy RM, et al. **Proc Soc Exp Biol Med** 1995 Nov;210(2):93–101 (98 ref.)
Nitric oxide in neuronal degeneration. Dawson VL, et al. **Proc Soc Exp Biol Med** 1996 Jan;211(1):33–40 (86 ref.)
The role of nitric oxide in reproduction. McCann SM, et al. **Proc Soc Exp Biol Med** 1996 Jan;211(1):7–15 (51 ref.)
Cytokines and nitric oxide in islet inflammation and diabetes. McDaniel ML, et al. **Proc Soc Exp Biol Med** 1996 Jan; 211(1):24–32 (41 ref.)
Nitric oxide and cyclic GMP signaling. McDonald LJ, et al. **Proc Soc Exp Biol Med** 1996 Jan;211(1):1–6 (42 ref.)
Involvement of nitric oxide in neuromuscular transmission in canine proximal colon. Shuttleworth CW, et al. **Proc Soc Exp Biol Med** 1996 Jan;211(1):16–23 (50 ref.)
The role of nitric oxide and other endothelium-derived vasoactive substances in vascular disease. Cohen RA. **Prog Cardiovasc Dis** 1995 Sep–Oct;38(2):105–28 (294 ref.)
Role of nitric oxide in the regulation of myocardial function. Hare JM, et al. **Prog Cardiovasc Dis** 1995 Sep–Oct; 38(2):155–66 (70 ref.)
Nitric oxide and its role in the cardiovascular system. Loscalzo J, et al. **Prog Cardiovasc Dis** 1995 Sep–Oct; 38(2):87–104 (171 ref.)
Nitric oxide: a radical neurotransmitter in the central nervous system. Vincent SR. **Prog Neurobiol** 1994 Jan;42(1):129–60 (485 ref.)
Regulation of human placental fetal vessel tone: role of nitric oxide. King RG, et al. **Reprod Fertil Dev** 1995;7(6):1407–11 (56 ref.)
NO in the lung. Adnot S, et al. **Respir Physiol** 1995 Aug; 101(2):109–20 (32 ref.)
Protein thiol modification and apoptotic cell death as cGMP-independent nitric oxide (NO) signaling pathways. Brüne B, et al. **Rev Physiol Biochem Pharmacol** 1996; 127:1–30 (105 ref.)
Activities of nitric oxide in normal physiology and uremia. Blantz RC, et al. **Semin Nephrol** 1996 May;16(3):144–50 (38 ref.)
Nitric oxide and the renal hemodynamic response to proteins. King AJ. **Semin Nephrol** 1995 Sep;15(5):405–14 (88 ref.)
NO or no NO in asthma? Barnes PJ. **Thorax** 1996 Feb; 51(2):218–20 (12 ref.)
The role of nitric oxide in cell injury. Brüne B, et al. **Toxicol Lett** 1995 Dec;82–83:233–7 (20 ref.)
Inhibition of biotransformation by nitric oxide (NO) overproduction and toxic consequences. Stadler J, et al. **Toxicol Lett** 1995 Dec;82–83:215–9 (26 ref.)
Nitric oxide (NO) protects against cellular damage by reactive oxygen species. Wink DA, et al. **Toxicol Lett** 1995 Dec;82–83:221–6 (25 ref.)
Role of nitric oxide in progression and regression of atherosclerosis. Cooke JP. **West J Med** 1996 May; 164(5):419–24 (52 ref.)
[The role of nitric oxide in the pathogenesis of pregnancy induced hypertension] Li A, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1996 Jan;31(1):52–4 (17 ref.) **(Chi)**
[Nitric oxide and hyperdynamic circulation in liver cirrhosis] Wang Y, et al. **Chung Hua Nei Ko Tsa Chih** 1995 Nov; 34(11):779–81 (19 ref.) **(Chi)**
[Nitric oxide, the non-adrenergic non-cholinergic system and digestive motility] de Laet MH, et al. **Arch Pediatr** 1996; 3 Suppl 1:287s–291s (32 ref.) **(Fre)**
[Nitric oxide and regulation of fetal and neonatal pulmonary circulation. Group Français Pédiatrique d'étude du NO inhalé] Mercier JC, et al. **Arch Pediatr** 1996;3 Suppl 1:280s–283s (15 ref.) **(Fre)**
[Nitric oxide and the kidney during the development] Simeoni U, et al. **Arch Pediatr** 1996;3 Suppl 1:284s–286s (16 ref.) **(Fre)**
[Nitric oxide: new horizons in gynecology and obstetrics] Ohl J, et al. **Contracept Fertil Sex** 1995 Nov;23(11):645–50 (51 ref.) **(Fre)**
[Current information on nitric oxide as a neuronal messenger] Haulică I, et al. **Rom J Physiol** 1994 Jan–Dec;31(1–4):3–12 (28 ref.) **(Fre)**
[Pharmacology of nitrates and other NO donors] Dendorfer A. **Herz** 1996 Jun;21 Suppl 1:38–49 (54 ref.) (Eng. Abstr.) **(Ger)**
[Nitric oxide: the endogenous nitrate in the cardiovascular system] Tschudi MR, et al. **Herz** 1996 Jun;21 Suppl 1:50–60 (104 ref.) (Eng. Abstr.) **(Ger)**
[Myocardial infarction and nitric oxide] Bing RJ, et al. **G Ital Cardiol** 1995 Dec;25(12):1621–6 (35 ref.) **(Ita)**
[Leishmania–macrophage interactions: role of cytokines and molecules co-involved in killing] Faliero SM, et al. **Parassitologia** 1995 Apr;37(1):5–15 (126 ref.) (Eng. Abstr.) **(Ita)**
[Role of nitric oxide (no) in urology] Yoshida M, et al. **Nippon Hinyokika Gakkai Zasshi** 1995 Dec; 86(12):1691–710 (140 ref.) **(Jpn)**
[Importance of nitric oxide in physiological states and pathology] Jędrusik P. **Pol Arch Med Wewn** 1995 Apr; 93(4):340–5 (89 ref.) **(Pol)**
[The role of free radicals in pathogenesis of insulin dependent diabetes mellitus] Komosińska K, et al. **Postepy Hig Med Dosw** 1995;49(6):733–46 (64 ref.) (Eng. Abstr.) **(Pol)**
[The bioregulatory system L-arginine—nitric oxide] Markov KhM. **Patol Fiziol Eksp Ter** 1996 Jan–Mar;(1):34–9 (76 ref.) **(Rus)**
[The role of nitric oxide in physiologic functions and pathologic conditions] Jovičić A, et al. **Vojnosanit Pregl** 1994 Mar–Apr;51(2):126–31 (38 ref.) **(Scr)**
[Nitric oxide in the lower respiratory tract] García Salgado MJ, et al. **An Med Interna** 1995 Jul;12(7):349–54 (53 ref.) (Eng. Abstr.) **(Spa)**
[Role of nitric oxide in the reproductive function in mammals] Villalpando Ramos G, et al. **Ginecol Obstet Mex** 1995 Dec;63:518–23 (28 ref.) (Eng. Abstr.) **(Spa)**
[Nitric oxide in gastroenterology] Merino Ugarte C. **Rev Gastroenterol Peru** 1995;15 Suppl 1:S101–4 (21 ref.) (Eng. Abstr.) **(Spa)**
[Nitric oxide in the mechanism of the action of cardiovascular agents] Chekman IS, et al. **Lik Sprava** 1995 May–Jun; (5–6):36–40 (40 ref.) **(Ukr)**

THERAPEUTIC USE

Inhaled nitric oxide therapy for persistent pulmonary hypertension of the newborn. Fineman JR, et al. **Acta Paediatr Jpn** 1995 Aug;37(4):425–30 (41 ref.)
Inhaled nitric oxide therapy of pulmonary hypertension and respiratory failure in premature and term neonates. Abman SH, et al. **Adv Pharmacol** 1995;34:457–74 (71 ref.)
Nitric oxide and nitrovasodilators: similarities, differences, and interactions. Kelly RA, et al. **Am J Cardiol** 1996 May 30;77(13):2C–7C (70 ref.)
Inhaled nitric oxide: therapeutic applications in cardiothoracic surgery. Fullerton DA, et al. **Ann Thorac Surg** 1996 Jun;61(6):1856–64 (56 ref.)
Nitric oxide: physiological roles and therapeutic implications in the lung. Brett SJ, et al. **Br J Hosp Med** 1996 Apr 17–30; 55(8):487–90 (20 ref.)
The nitric oxide pathway: potential implications for treatment of neuropsychiatric disorders. Karatinos J, et al. **Clin Neuropharmacol** 1995 Dec;18(6):482–99 (83 ref.)
Inhaled nitric oxide in the management of congenital heart disease. Kulik TJ. **Curr Opin Cardiol** 1996 Jan;11(1):75–80 (29 ref.)
The role of nitric oxide in the treatment of neonatal

pulmonary hypertension. Mariani G, et al. **Curr Opin Pediatr** 1996 Apr;8(2):118–25 (80 ref.)

Treatment of ARDS with nitric oxide and ECMO. Pappert D, et al. **Int J Artif Organs** 1995 Oct;18(10):611–9 (40 ref.)

Nitric oxide: delivery, measurement, and clinical application. Body SC, et al. **J Cardiothorac Vasc Anesth** 1995 Dec; 9(6):748–63 (158 ref.)

Inhalational nitric oxide in pulmonary parenchymal and vascular disease. Cornfield DN, et al. **J Lab Clin Med** 1996 Jun;127(6):530–9 (64 ref.)

[Nitric oxide: new horizons in gynecology and obstetrics] Ohl J, et al. **Contracept Fertil Sex** 1995 Nov;23(11):645–50 (51 ref.) **(Fre)**

[Can nitrogen monoxide replace aspirin in the prevention of preeclampsia?] Ohl J, et al. **Contracept Fertil Sex** 1996 Apr;24(4):259–61 (16 ref.) **(Fre)**

TOXICITY

Physiological and toxicological actions of nitric oxide in the central nervous system. Dawson VL, et al. **Adv Pharmacol** 1995;34:323–42 (73 ref.)

NITRIC OXIDE, ENDOTHELIUM-DERIVED see **ENDOTHELIUM-DERIVED RELAXING FACTOR**

NITRIC-OXIDE SYNTHASE

ANALYSIS

Histochemical methods for detecting nitric oxide synthase. Beesley JE. **Histochem J** 1995 Oct;27(10):757–69 (69 ref.)

ANTAGONISTS & INHIBITORS

Negative modulation of nitric oxide synthase by nitric oxide and nitroso compounds. Griscavage JM, et al. **Adv Pharmacol** 1995;34:215–34 (56 ref.)

Nitric oxide–based possibilities for pharmacotherapy. Pörsti I, et al. **Ann Med** 1995 Jun;27(3):407–20 (232 ref.)

Selective pharmacological inhibition of distinct nitric oxide synthase isoforms. Southan GJ, et al. **Biochem Pharmacol** 1996 Feb 23;51(4):383–94 (131 ref.)

Prospects for management of peripheral vascular failure in septic shock [editorial; comment] Allen JD, et al. **Br J Anaesth** 1996 Feb;76(2):177–8 (29 ref.) Comment on: Br J Anaesth 1996 Feb;76(2):251–7.

Regulation of blood pressure by nitroxidergic nerve. Toda N. **J Diabetes Complications** 1995 Oct–Dec;9(4):200–2 (21 ref.)

Nitric oxide synthase, immunophilins and poly(ADP-ribose) synthetase: novel targets for the development of neuroprotective drugs. Zhang J, et al. **Neurol Res** 1995 Aug;17(4):285–8 (37 ref.)

The effects of NMDA receptor antagonists and nitric oxide synthase inhibitors on opioid tolerance and withdrawal. Medication development issues for opiate addiction. Herman BH, et al. **Neuropsychopharmacology** 1995 Dec; 13(4):269–93 (165 ref.)

Perspectives on the N-methyl-D-aspartate/nitric oxide cascade and opioid tolerance. Pasternak GW, et al. **Neuropsychopharmacology** 1995 Dec;13(4):309–13 (24 ref.)

Nitric oxide synthase inhibitors. Preclinical studies of potential use for treatment of opioid withdrawal. Vaupel DB, et al. **Neuropsychopharmacology** 1995 Dec; 13(4):315–22 (27 ref.)

Inhibitors of nitric oxide synthase and the opioid withdrawal syndrome. London ED, et al. **NIDA Res Monogr** 1995; 147:170–81 (26 ref.)

Selective inhibition of the activity of inducible nitric oxide synthase in septic shock. Thiemermann C. **Prog Clin Biol Res** 1995;392:383–92 (26 ref.)

BIOSYNTHESIS

Expression and expressional control of nitric oxide synthases in various cell types. Förstermann U, et al. **Adv Pharmacol** 1995;34:171–86 (102 ref.)

Regulation of the expression of the inducible isoform of nitric oxide synthase. Szabó C, et al. **Adv Pharmacol** 1995; 34:113–53 (265 ref.)

Regulation and function of inducible nitric oxide synthase during sepsis and acute inflammation. Wong JM, et al. **Adv Pharmacol** 1995;34:155–70 (68 ref.)

Transcription of the human neuronal nitric oxide synthase gene in the central nervous system is mediated by multiple promoters. Young AP, et al. **Adv Pharmacol** 1995;34:91–112 (51 ref.)

Hepatic inducible nitric oxide synthase: regulation and function. de Vera ME, et al. **Biochem Soc Trans** 1995 Nov; 23(4):1008–13 (51 ref.)

Intraislet expression of inducible nitric oxide synthase and islet cell death. Kolb-Bachofen V. **Biochem Soc Trans** 1996 Feb;24(1):233–4 (14 ref.)

Inducible nitric oxide synthase and its product nitric oxide, a small molecule with complex biological activities. Krömcke KD, et al. **Biol Chem Hoppe Seyler** 1995 Jun; 376(6):327–43 (163 ref.)

Inducible nitric oxide synthase in inflammation. Cattell V, et al. **Histochem J** 1995 Oct;27(10):777–84 (52 ref.)

On the expression of nitric oxide synthase by human macrophages. Why no NO? Albina JE. **J Leukoc Biol** 1995 Dec;58(6):643–9 (64 ref.)

Nitric oxide: a radical neurotransmitter in the central nervous system. Vincent SR. **Prog Neurobiol** 1994 Jan;42(1):129–60 (485 ref.)

CHEMISTRY

Neuronal nitric oxide synthase, a modular enzyme formed by convergent evolution: structure studies of a cysteine thiolate-liganded heme protein that hydroxylates L-arginine to produce NO. as a cellular signal. Masters BS, et al. **FASEB J** 1996 Apr;10(5):552–8 (70 ref.)

DRUG EFFECTS

NO honey, I don't remember. Hawkins RD. **Neuron** 1996 Mar;16(3):465–7 (18 ref.)

GENETICS

Regulation of the expression of the inducible isoform of nitric oxide synthase. Szabó C, et al. **Adv Pharmacol** 1995; 34:113–53 (265 ref.)

Nitric oxide synthases: gene structure and regulation. Wang Y, et al. **Adv Pharmacol** 1995;34:71–90 (99 ref.)

Transcription of the human neuronal nitric oxide synthase gene in the central nervous system is mediated by multiple promoters. Young AP, et al. **Adv Pharmacol** 1995;34:91–112 (51 ref.)

Activation of nitric oxide synthase gene for inhibition of cancer metastasis. Xie K, et al. **J Leukoc Biol** 1996 Jun; 59(6):797–803 (107 ref.)

Nitric oxide production and NO synthase gene expression contribute to vascular regulation during exercise. Shen W, et al. **Med Sci Sports Exerc** 1995 Aug;27(8):1125–34 (75 ref.)

Nitric oxide synthase: expression and expressional control of the three isoforms. Förstermann U, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Oct; 352(4):351–64 (166 ref.)

[Molecular biology and genetics of NO synthases] Nadaud S, et al. **C R Seances Soc Biol Fil** 1995;189(6):1025–38 (70 ref.) (Eng. Abstr.) **(Fre)**

[Nitric oxide. Current findings on the synthesis and genetics of nitric oxide synthases, regulation of hypothalamic and vascular function] Dioh A, et al. **Rev Med Liege** 1995 Nov; 50(11):480–6 (50 ref.) **(Fre)**

IMMUNOLOGY

Nitric oxide synthase isozymes antibodies. Pollock JS, et al. **Histochem J** 1995 Oct;27(10):738–44 (61 ref.)

METABOLISM

Control and consequences of endothelial nitric oxide formation. Fleming I, et al. **Adv Pharmacol** 1995;34:187–206 (118 ref.)

Why tetrahydrobiopterin? Mayer B, et al. **Adv Pharmacol** 1995;34:251–61 (50 ref.)

Regulation of nitric oxide synthase: role of oxygen radicals and cations in nitric oxide formation. Mittal CK, et al. **Adv Pharmacol** 1995;34:235–50 (50 ref.)

Control of electron transfer in neuronal nitric oxide synthase by calmodulin, substrate, substrate analogs, and nitric oxide. Stuehr DJ, et al. **Adv Pharmacol** 1995;34:207–13 (15 ref.)

Inducible cyclooxygenase and nitric oxide synthase. Wu KK. **Adv Pharmacol** 1995;33:179–207 (148 ref.)

Nitric oxide in the central nervous system. Paakkari I, et al. **Ann Med** 1995 Jun;27(3):369–77 (96 ref.)

Nitric oxide: a neural messenger. Jaffrey SR, et al. **Ann Rev Cell Dev Biol** 1995;11:417–40 (167 ref.)

Isoforms of nitric oxide synthase. Properties, cellular distribution and expressional control. Förstermann U, et al. **Biochem Pharmacol** 1995 Oct 26;50(9):1321–32 (134 ref.)

On the mechanism of nitric oxide formation upon oxidative cleavage of C = N(OH) bonds by NO-synthases and cytochromes P450. Mansuy D, et al. **Biochimie** 1995; 77(7–8):661–7 (28 ref.)

The role of nitric oxide in carotid chemoreception. Wang ZZ, et al. **Biol Signals** 1995 May–Jun;4(3):109–16 (28 ref.)

Histochemistry of nitric oxide synthase in the nervous system. Blottner D, et al. **Histochem J** 1995 Oct;27(10):785–811 (271 ref.)

Nitric oxide synthase in invertebrates. Martínez A. **Histochem J** 1995 Oct;27(10):770–6 (55 ref.)

Studies on the localization and expression of nitric oxide synthase using histochemical techniques. Norris PJ, et al. **Histochem J** 1995 Oct;27(10):745–56 (28 ref.)

Anatomic distribution of nitric oxide synthase in the heart. Ursell PC, et al. **Int J Cardiol** 1995 Jul;50(3):217–23 (15 ref.)

Targeting nitric oxide to its targets. Bredt DS. **Proc Soc Exp Biol Med** 1996 Jan;211(1):41–8 (60 ref.)

Nitric oxide: a novel mediator of inflammation. Clancy RM, et al. **Proc Soc Exp Biol Med** 1995 Nov;210(2):93–101 (98 ref.)

[Endothelial NO synthase] Boulanger CM. **C R Seances Soc Biol Fil** 1995;189(6):1069–79 (49 ref.) (Eng. Abstr.) **(Fre)**

[Molecular biology and genetics of NO synthases] Nadaud S, et al. **C R Seances Soc Biol Fil** 1995;189(6):1025–38 (70 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Regulation and function of inducible nitric oxide synthase during sepsis and acute inflammation. Wong JM, et al. **Adv Pharmacol** 1995;34:155–70 (68 ref.)

Nitric oxide synthase: role as a transmitter/mediator in the brain and endocrine system. Dawson TM, et al. **Annu Rev Med** 1996;47:219–27 (40 ref.)

Molecular mechanisms and therapeutic strategies related to nitric oxide. Moncada S, et al. **FASEB J** 1995 Oct; 9(13):1319–30 (126 ref.)

Nitric oxide in physiology and pathology. Whittle BJ. **Histochem J** 1995 Oct;27(10):727–37 (61 ref.)

Involvement of inducible nitric oxide synthase in the inflammatory process of myocardial infarction. Wildhirt SM, et al. **Int J Cardiol** 1995 Jul;50(3):253–61 (72 ref.)

Inducible nitric oxide synthase in the central nervous system. Sparrow JR. **J Mol Neurosci** 1994–95;5(4):219–29 (95 ref.)

Nitric oxide synthases: regulation in disease. Wong GK, et al. **Nephrol Dial Transplant** 1996 Jan;11(1):215–20 (62 ref.)

Nitric oxide synthase and the lower urinary tract: possible implications for physiology and pathophysiology. Andersson KE, et al. **Scand J Urol Nephrol Suppl** 1995; 175:43–53 (102 ref.)

NITRILES

see related
CYANIDES

NITRITES

ADVERSE EFFECTS

Health implications of nitrate and nitrite in drinking water: an update on methemoglobinemia occurrence and reproductive and developmental toxicity. Fan AM, et al. **Regul Toxicol Pharmacol** 1996 Feb;23(1 Pt 1):35–43 (54 ref.)

BLOOD

[Drug of nitrate and nitrite] Iida K. **Nippon Rinsho** 1995 Feb; 53 Su Pt 1:986–8 (17 ref.) **(Jpn)**

TOXICITY

[Causes and mechanisms of nitrate and nitrite poisoning (review of the literature)] Gozhenko AI, et al. **Med Tr Prom Ekol** 1996;(4):15–21 (42 ref.) **(Rus)**

NITRO COMPOUNDS

METABOLISM

Biodegradation of nitroaromatic compounds. Spain JC. **Annu Rev Microbiol** 1995;49:523–55 (136 ref.)

NITRODIAZEPAM see **NITRAZEPAM**

NITROFURANS

TOXICITY

[Genotoxic properties of 5-nitrofuran compounds] Szczypka M. **Rocz Panstw Zakl Hig** 1995;46(4):389–95 (45 ref.) (Eng. Abstr.) **(Pol)**

NITROGEN

BLOOD

[Blood urea nitrogen, non-protein nitrogen] Orita Y, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:473–7 (10 ref.) **(Jpn)**

METABOLISM

The significance of protein intake and catabolism. Flanigan MJ, et al. **Adv Ren Replace Ther** 1995 Oct;2(4):330–40 (62 ref.)

Protein requirements of elderly people. Campbell WW, et al. **Eur J Clin Nutr** 1996 Feb;50 Suppl 1:S180–3; discussion S183–5 (8 ref.)

Reactive oxygen and nitrogen metabolites as mediators of secretory diarrhea. Gaginella TS, et al. **Gastroenterology** 1995 Dec;109(6):2019–28 (147 ref.)

Effect of rumen protozoa on nitrogen utilization by ruminants. Jouany JP. **J Nutr** 1996 Apr;126(4 Suppl):1335S–46S (127 ref.)

Nitrogen control in bacteria. Merrick MJ, et al. **Microbiol Rev** 1995 Dec;59(4):604–22 (275 ref.)

Salvage of urea-nitrogen and protein requirements. Jackson AA. **Proc Nutr Soc** 1995 Jul;54(2):535–47 (38 ref.)

NITROGEN DIOXIDE

METABOLISM

Light-mediated conversion of nitrogen dioxide to nitric oxide by carotenoids. Cooney RV, et al. **Environ Health Perspect** 1994 May;102(5):460–2 (33 ref.)

TOXICITY

Oxidative damage by ozone and nitrogen dioxide: synergistic toxicity in vivo but no evidence of synergistic oxidative damage in an extracellular fluid. O'Neill CA, et al.

Biochem Soc Symp 1995;61:139–52 (49 ref.)
Effect of oxidant air pollutants on the respiratory system: insights from experimental animal research. Chitano P, et al. **Eur Respir J** 1995 Aug;8(8):1357–71 (182 ref.)
Interaction of air pollutants and pulmonary allergic responses in experimental animals. Gilmour MI. **Toxicology** 1995 Dec 28;105(2–3):335–42 (48 ref.)

NITROGEN FIXATION

Nitrogenase structure and function: a biochemical–genetic perspective. Peters JW, et al. **Annu Rev Microbiol** 1995; 49:335–66 (92 ref.)
What makes nodulation signals host-plant specific? Schultze M, et al. **Trends Microbiol** 1995 Oct;3(10):370–2 (24 ref.)

NITROGEN MUSTARD see **MECHLORETHAMINE**

NITROGEN MUSTARD N-OXIDE see **MECHLORETHAMINE**

NITROGEN OXIDES

ADVERSE EFFECTS

Health effects of outdoor air pollution. Part 2. Committee of the Environmental and Occupational Health Assembly of the American Thoracic Society.
Am J Respir Crit Care Med 1996 Feb;153(2):477–98 (226 ref.)

METABOLISM

Enzymes and associated electron transport systems that catalyse the respiratory reduction of nitrogen oxides and oxyanions. Berks BC, et al. **Biochim Biophys Acta** 1995 Dec 12;1232(3):97–173 (625 ref.)

TOXICITY

Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer. Wiseman H, et al. **Biochem J** 1996 Jan 1;313 (Pt 1):17–29 (213 ref.)

NITROGENASE

Vanadium nitrogenases of Azotobacter. Eady RR.
Met Ions Biol Syst 1995;31:363–405 (106 ref.)

METABOLISM

Nitrogenase structure and function: a biochemical–genetic perspective. Peters JW, et al. **Annu Rev Microbiol** 1995; 49:335–66 (92 ref.)

NITROGLYCERIN

ADMINISTRATION & DOSAGE

Organic nitrates: new formulations and their clinical advantages. Parker JA. **Am J Cardiol** 1996 May 30; 77(13):38C–40C (23 ref.)
Intermittent or continuous transdermal nitroglycerin: still an issue, or is the case closed? Klemsdal TO, et al.
Cardiovasc Drugs Ther 1996 Mar;10(1):5–10 (61 ref.)

PHARMACOLOGY

New insights into mechanisms underlying nitrate tolerance. Münzel T, et al. **Am J Cardiol** 1996 May 30;77(13):24C–30C (41 ref.)
Glyceryl trinitrate enhances the adenosine-induced inhibition of platelet responses: a mechanism potentially involved in the in vivo anti-aggregating effects of organic nitrates. Anfossi G, et al. **Clin Exp Pharmacol Physiol** 1995 Nov; 22(11):803–11 (57 ref.)

THERAPEUTIC USE

Racing horses, nitroglycerin and exercise induced pulmonary haemorrhage (EIPH) [editorial; comment] Harkins JD, et al. **Equine Vet J** 1995 Jul;27(4):240–1 (12 ref.) Comment on: Equine Vet J 1995 Jul;27(4):275–9.

NITROIMIDAZOLES

THERAPEUTIC USE

Etiological treatment of acute and chronic Chagas' heart disease. Fragata Filho AA, et al. **Rev Paul Med** 1995 Mar–Apr;113(2):867–72 (11 ref.)

NITROREDUCTASES

GENETICS

Chemotherapeutic tumour targeting using clostridial spores. Minton NP, et al. **FEMS Microbiol Rev** 1995 Oct; 17(3):357–64 (40 ref.)

NITROSAMINES

Nitrosamines and vitamins. Reed PI. **Bibl Nutr Dieta** 1995; (52):30–42 (63 ref.)

ADVERSE EFFECTS

Epidemiology of cancer by tobacco products and the significance of TSNA. Gupta PC, et al.
Crit Rev Toxicol 1996;26(2):183–98 (81 ref.)

ANALYSIS

Formation and analysis of tobacco-specific N-nitrosamines. Brunnemann KD, et al. **Crit Rev Toxicol** 1996;26(2):121–37 (43 ref.)

METABOLISM

Recent studies on mechanisms of bioactivation and detoxification of
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), a tobacco-specific lung carcinogen. Hecht SS.
Crit Rev Toxicol 1996;26(2):163–81 (83 ref.)
Endogenous formation of nitrosamines and oxidative DNA-damaging agents in tobacco users. Nair J, et al.
Crit Rev Toxicol 1996;26(2):149–61 (55 ref.)

TOXICITY

Synthesis of tobacco-specific N-nitrosamines and their metabolites and results of related bioassays. Amin S, et al.
Crit Rev Toxicol 1996;26(2):139–47 (32 ref.)
The biological significance of tobacco-specific N-nitrosamines: smoking and adenocarcinoma of the lung. Hoffmann D, et al. **Crit Rev Toxicol** 1996;26(2):199–211 (76 ref.)

NITROSO COMPOUNDS

PHARMACOLOGY

Negative modulation of nitric oxide synthase by nitric oxide and nitroso compounds. Griscavage JM, et al.
Adv Pharmacol 1995;34:215–34 (56 ref.)
S-nitrosothiols: chemistry, biochemistry, and biological actions. Upchurch GR Jr, et al. **Adv Pharmacol** 1995; 34:343–9 (30 ref.)

NITROUS OXIDE

[Clinical potency of nitrous oxide—is MAC the gold standard?] Schwilden H, et al.
Anasthesiol Intensivmed Notfallmed Schmerzther 1995 Oct; 30(6):337–40 (23 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Severe neurologic deficit after nitrous oxide anesthesia. Hadzic A, et al. **Anesthesiology** 1995 Oct;83(4):863–6 (14 ref.)

NK CELLS see **KILLER CELLS, NATURAL**

NK-1 RECEPTORS see **RECEPTORS, NEUROKININ-1**

NK-2 RECEPTORS see **RECEPTORS, NEUROKININ-2**

NK-3 RECEPTORS see **RECEPTORS, NEUROKININ-3**

NMDA see **N-METHYLASPARTATE**

NMDA RECEPTOR-IONOPHORE COMPLEX see **RECEPTORS, N-METHYL-D-ASPARTATE**

NMDA RECEPTORS see **RECEPTORS, N-METHYL-D-ASPARTATE**

NMR IMAGING see **MAGNETIC RESONANCE IMAGING**

NMR TOMOGRAPHY see **MAGNETIC RESONANCE IMAGING**

NO-FAULT INSURANCE see **INSURANCE, LIABILITY**

NO-OBSERVED-ADVERSE-EFFECT LEVEL

Utilizing uncertainty factors in minimal risk levels derivation. Pohl HR, et al. **Regul Toxicol Pharmacol** 1995 Oct; 22(2):180–8 (52 ref.)

NO-OBSERVED-EFFECT LEVEL see **NO-OBSERVED-ADVERSE-EFFECT LEVEL**

NO SYNTHASE see **NITRIC-OXIDE SYNTHASE**

NOAEL see **NO-OBSERVED-ADVERSE-EFFECT LEVEL**

NOBEL PRIZE

The Drosophila Stock Centers and their implications for developmental biology. Rasmuson-Lestander A.
Int J Dev Biol 1995 Oct;39(5):765–8 (29 ref.)

NOCARDIA

Treatment of eumycetoma and actinomycetoma. Welsh O, et al. **Curr Top Med Mycol** 1995;6:47–71 (105 ref.)

METABOLISM

Rifamycin SV and related ansamycins. Chiao JS, et al.
Biotechnology 1995;28:477–98 (110 ref.)

NOCARDIA INFECTIONS

MICROBIOLOGY

Primary cutaneous nocardiosis caused by Nocardia otitidiscaviarum: two cases and a review of the literature. Freland C, et al. **J Trop Med Hyg** 1995 Dec;98(6):395–403 (26 ref.)
Lymphocutaneous Nocardia brasiliensis infection: a case report and review. Seddon M, et al. **N Z Med J** 1995 Sep 22;108(1008):385–6 (08 ref.)

NOCICEPTION TESTS see **PAIN MEASUREMENT**

NOCICEPTORS

DRUG EFFECTS

A review of the pharmacology, pharmacokinetics, and regulatory control in the US of local anaesthetics in the horse. Harkins JD, et al. **J Vet Pharmacol Ther** 1995 Dec; 18(6):397–406 (56 ref.)

PHYSIOLOGY

Nerve growth factor regulates nociception in human health and disease. Anand P. **Br J Anaesth** 1995 Aug;75(2):201–8 (64 ref.)
Inflammatory mediators of pain. Dray A. **Br J Anaesth** 1995 Aug;75(2):125–31 (60 ref.)
Pain mechanisms and management: an update. Siddall PJ, et al. **Clin Exp Pharmacol Physiol** 1995 Oct;22(10):679–88 (91 ref.)
[The roles of thalamic nucleus submedius in nociception and pain modulation] Tang JS, et al.
Sheng Li Ko Hsueh Chin Chan 1995 Oct;26(4):312–6 (20 ref.) (Eng. Abstr.) **(Chi)**
[Exteroceptive suppression of voluntary muscular activity: a new method of studying central nociceptive mechanisms] Danilov AB, et al.
Zh Nevropatol Psikhiatr Im S S Korsakova 1995;95(3):90–5 (59 ref.) **(Rus)**

PHYSIOPATHOLOGY

[From nociception to pain: to feel or not to feel (editorial)] Konttinen YT, et al. **Duodecim** 1994;110(6):545–8 (15 ref.) **(Fin)**
[The nociceptive flexor reflex: a method for studying the brain mechanisms of pain control] Danilov AB, et al.
Zh Nevropatol Psikhiatr Im S S Korsakova 1996; 96(1):107–11 (63 ref.) **(Rus)**

NOCTURIA see **URINATION DISORDERS**

NODDING SPASM see **SPASMS, INFANTILE**

NODULAR ELASTOIDOSIS see **FAVRE-RACOUCHOT SYNDROME**

NOEL see **NO-OBSERVED-ADVERSE-EFFECT LEVEL**

NOISE

see related
ACOUSTIC STIMULATION
HEARING LOSS, NOISE-INDUCED
Encoding with bursting, subthreshold oscillations, and noise in mammalian cold receptors. Longtin A, et al.
Neural Comput 1996 Feb 15;8(2):215–55 (75 ref.)

ADVERSE EFFECTS

Human response to environmental noise. Psychological research and public policy. Staples SL. **Am Psychol** 1996 Feb;51(2):143–50 (95 ref.)
Music, noise, and the human voice in the nurse-patient environment. Pope DS. **Image J Nurs Sch** 1995 Winter; 27(4):291–6 (51 ref.)
Sources and effects of low-frequency noise. Berglund B, et al. **J Acoust Soc Am** 1996 May;99(5):2985–3002 (207 ref.)
Hearing conservation programs for nonserved occupations and populations. Axelsson A, et al. **Occup Med** 1995 Jul–Aug;10(3):657–62 (11 ref.)
Effects of noise and age on the auditory system. Boettcher FA, et al. **Occup Med** 1995 Jul–Aug;10(3):577–91 (41 ref.)
Use of animal models in the study of the effects of noise on hearing. Dancer AL. **Occup Med** 1995 Jul–Aug; 10(3):535–44 (28 ref.)
Combined effects of noise and chemicals. Fechter LD. **Occup Med** 1995 Jul–Aug;10(3):609–21 (51 ref.)
Noise, impulse noise, and other physical factors: combined effects on hearing. Pekkarinen J. **Occup Med** 1995 Jul–Aug; 10(3):545–59 (152 ref.)
Endogenous factors related to susceptibility to damage from noise. Ward WD. **Occup Med** 1995 Jul–Aug;10(3):561–75 (138 ref.)

NOISE, OCCUPATIONAL

Technology advancements in hearing protection circa 1995: active noise reduction, frequency/amplitude-sensitivity, and uniform attenuation. Casali JG, et al. **Am Ind Hyg Assoc J** 1996 Feb;57(2):175–85 (31 ref.)

ADVERSE EFFECTS

Female noise exposure, shift work, and reproduction. Nurminen T. **J Occup Environ Med** 1995 Aug;37(8):945–50 (31 ref.)

Economic compensation for hearing loss. Dobie RA. **Occup Med** 1995 Jul–Aug;10(3):663–8 (22 ref.)

Impact of occupational hearing loss on the lives of workers. Hétu R, et al. **Occup Med** 1995 Jul–Aug;10(3):495–512 (55 ref.)

Effects of industrial solvents on hearing. Johnson AC, et al. **Occup Med** 1995 Jul–Aug;10(3):623–40 (87 ref.)

Historical assessment and future directions in the prevention of occupational hearing loss. Merry CJ, et al. **Occup Med** 1995 Jul–Aug;10(3):669–81 (39 ref.)

Epidemiologic considerations in the evaluation of occupational hearing loss. Morata TC, et al. **Occup Med** 1995 Jul–Aug;10(3):641–56 (67 ref.)

Presbycusis and occupational hearing loss. Rosenhall U, et al. **Occup Med** 1995 Jul–Aug;10(3):593–607 (73 ref.)

NOISE, TRANSPORTATION

ADVERSE EFFECTS

Effects of traffic noise on sleep: a review. Kawada T. **Nippon Eiseigaku Zasshi** 1995 Dec;50(5):932–8 (44 ref.)

NOMA

EPIDEMIOLOGY

Noma: a neglected scourge of children in sub-Saharan Africa. Enwonwu CO. **Bull World Health Organ** 1995;73(4):541–5 (47 ref.)

ETIOLOGY

[Noma or cancrum oris: etiopathogenic and nosologic aspects] Costini B, et al. **Med Trop (Mars)** 1995;55(3):263–73 (77 ref.) (Eng. Abstr.) **(Fre)**

NOMENCLATURE

Premalignant and early malignant lesions in the gastrointestinal tract: definitions, terminology, and problems. Riddell RH. **Am J Gastroenterol** 1996 May; 91(5):864–72 (69 ref.)

Developmental dyspraxia by any other name: are they all just clumsy children? Missiuna C, et al. **Am J Occup Ther** 1995 Jul–Aug;49(7):619–27 (71 ref.)

The development of the genital peritoneum in domestic mammals. An analysis of the literature and nomenclature. Martin E. **Anat Histol Embryol** 1995 Dec;24(4):285–7 (18 ref.)

Developmental lesions of the head and neck: terminology and biologic behavior. Ferlito A, et al. **Ann Otol Rhinol Laryngol** 1995 Nov;104(11):913–8 (39 ref.)

The classification of disability. Hutchison T. **Arch Dis Child** 1995 Aug;73(2):91–3; discussion 94 (5 ref.)

Reference databases of cytokine structure and function. Casciari JJ, et al. **Cancer Chemother Biol Response Modif** 1996;16:315–46 (103 ref.)

Solving nomenclature problems in cardiology. I. Updating terminology in electrocardiography. Constant J. **Cardiology** 1995;86(5):357–60 (9 ref.)

Solving nomenclature problems in cardiology. II. Updating terminology in clinical cardiology. Constant J. **Cardiology** 1995;86(5):361–4 (9 ref.)

The definition and classification of Koro. Chowdhury AN. **Cult Med Psychiatry** 1996 Mar;20(1):41–65 (147 ref.)

Nomenclature of fungal diseases. Odds FC, et al. **Curr Top Med Mycol** 1995;6:33–46 (12 ref.)

What is a nevus? A proposed definition of a common medical term. Happle R. **Dermatology** 1995;191(1):1–5 (38 ref.)

Multiple tumours of the salivary glands—terminology and nomenclature. Seifert G, et al. **Eur J Cancer B Oral Oncol** 1996 Jan;32B(1):3–7 (105 ref.)

Defining nursing interventions. Snyder M, et al. **Image J Nurs Sch** 1996 Summer;28(2):137–41 (31 ref.)

Human T-cell receptor variable gene segment families. Arden B, et al. **Immunogenetics** 1995;42(6):455–500 (151 ref.)

Mouse T-cell receptor variable gene segment families. Arden B, et al. **Immunogenetics** 1995;42(6):501–30 (118 ref.)

AIDS nursing care and standardized nursing language: an application of the nursing intervention classification. Davis KA. **J Assoc Nurses AIDS Care** 1995 Nov–Dec;6(6):37–44 (17 ref.)

The definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. **J Auton Nerv Syst** 1996 Apr 20;58(1–2):123–4 (1 ref.)

Histopathological diagnosis and terminology of chronic hepatitis. Ludwig J. **J Hepatol** 1995;23 Suppl 1:49–53 (26 ref.)

Tender points/fibromyalgia vs. trigger points/myofascial pain syndrome: a need for clarity in terminology and differential diagnosis. Schneider MJ. **J Manipulative Physiol Ther** 1995 Jul–Aug;18(6):398–406 (43 ref.)

New definition for relating occlusion to varying conditions of the temporomandibular joint. Dawson PE. **J Prosthet Dent** 1995 Dec;74(6):619–27 (39 ref.)

Male rape: the impact of a legal definition on the clinical area. Rogers P. **Med Sci Law** 1995 Oct;35(4):303–6 (14 ref.)

What is rurality? Rousseau N. **Occas Pap R Coll Gen Pract** 1995 Sep;(71):1–4 (39 ref.)

Titling for advanced practice nurses. Hawkins JW, et al. **Oncol Nurs Forum** 1995 Sep;22(8 Suppl):5–9 (47 ref.)

Possible identity of diffuse sclerosing osteomyelitis and chronic recurrent multifocal osteomyelitis. One entity or two. Suei Y, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1995 Oct;80(4):401–8 (41 ref.)

Tuberculosis: why "the white plague"? Weisse AB. **Perspect Biol Med** 1995 Autumn;39(1):132–8 (15 ref.)

International Union of Pharmacology. X. Recommendation for nomenclature of alpha 1-adrenoceptors: consensus update. Hieble JP, et al. **Pharmacol Rev** 1995 Jun; 47(2):267–70 (41 ref.)

International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. IX. Recommendations on terms and symbols in quantitative pharmacology. Jenkinson DH, et al. **Pharmacol Rev** 1995 Jun;47(2):255–66 (14 ref.)

What's in a name? Names, definitions, descriptions, and diagnostic criteria of diseases, with emphasis on chronic obstructive pulmonary disease. Snider GL. **Respiration** 1995;62(6):297–301 (19 ref.)

A toxicologic pathologist's view of apoptosis or I used to call it necrobiosis, but now I'm singing the apoptosis blues [see comments] Levin S. **Toxicol Pathol** 1995 Jul–Aug; 23(4):533–9 (34 ref.) Comment in: Toxicol Pathol 1995 Sep–Oct;23(5):617–21.

[Motor deficiencies in children: for a nosologic clarification in epidemiological studies] Cans C, et al. **Arch Pediatr** 1996 Jan;3(1):75–80 (20 ref.) (Eng. Abstr.) **(Fre)**

[Cardiac magnetic resonance: the technical indications and a technical glossary] Molinari G, et al. **Cardiologia** 1995 Aug;40(8):541–50 (57 ref.) **(Ita)**

[Validly published pathogenic bacterial names and new biosafety level of National Institute of Health] Ezaki T, et al. **Nippon Saikingaku Zasshi** 1995 Jul;50(3):803–38 (11 ref.) **(Jpn)**

[Angiocentric immunoproliferative lesions: the terminology and the clinical picture] Casas Vara A, et al. **An Med Interna** 1996 May;13(5):245–7 (19 ref.) (Eng. Abstr.) **(Spa)**

[Organic hyperactivity] Yelin B. **Rev Neurol** 1995;23 Suppl 3:S314–7 (36 ref.) **(Spa)**

NON-HODGKIN'S LYMPHOMA see **LYMPHOMA, NON-HODGKIN'S**

NON-OBESE DIABETIC MICE see **MICE, INBRED NOD**

NONAGENARIANS see **AGED, 80 AND OVER**

NON-HISTONE CHROMOSOMAL PROTEINS see **CHROMOSOMAL PROTEINS, NON-HISTONE**

NONINVASIVE LITHOLAPAXY see **LITHOTRIPSY**

NONLINEAR DYNAMICS

see related
FRACTALS

Chaos and complexity. Can it help us to understand mood and behavior? Ehlers CL. **Arch Gen Psychiatry** 1995 Nov; 52(11):960–4 (57 ref.)

Temporal chaos in the microcirculation. Griffith TM. **Cardiovasc Res** 1996 Mar;31(3):342–58 (108 ref.)

Linear and non-linear analyses of heart rate variability: a minireview. Mansier P, et al. **Cardiovasc Res** 1996 Mar; 31(3):371–9 (64 ref.)

General principles of chaotic dynamics. Persson PB, et al. **Cardiovasc Res** 1996 Mar;31(3):332–41 (40 ref.)

Chaos in blood pressure control. Wagner CD, et al. **Cardiovasc Res** 1996 Mar;31(3):380–7 (68 ref.)

Chaos and non-linear phenomena in renal vascular control. Yip KP, et al. **Cardiovasc Res** 1996 Mar;31(3):359–70 (87 ref.)

Linear genetics, non-linear epigenetics: complementary approaches to understanding complex diseases. Strohman RC. **Integr Physiol Behav Sci** 1995 Sep–Dec;30(4):273–82 (24 ref.)

Nonlinear forecasting and the dynamics of cardiac rhythm. Lippman N, et al. **J Electrocardiol** 1995;28 Suppl:65–70 (15 ref.)

Chaotic analysis in psychology and psychoanalysis. Kincanon E, et al. **J Psychol** 1995 Sep;129(5):495–505 (14 ref.)

Spatial heterogeneity, nonlinear dynamics and chaos in infectious diseases. Grenfell BT, et al. **Stat Methods Med Res** 1995 Jun;4(2):160–83 (82 ref.)

NONLYMPHOBLASTIC LEUKEMIA, ACUTE see **LEUKEMIA, NONLYMPHOCYTIC, ACUTE**

NONLYMPHOCYTIC LEUKEMIA, ACUTE see **LEUKEMIA, NONLYMPHOCYTIC, ACUTE**

NONOPIOID ANALGESICS see **ANALGESICS, NON-NARCOTIC**

NONPROFIT ORGANIZATIONS see **ORGANIZATIONS, NONPROFIT**

NONSENSE CODON see **CODON, NONSENSE**

NON-SMALL-CELL LUNG CARCINOMA see **CARCINOMA, NON-SMALL-CELL LUNG**

NON-STEROIDAL ANTI-INFLAMMATORY AGENTS see **ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL**

NONSTRUCTURAL PROTEINS, VIRAL see **VIRAL NONSTRUCTURAL PROTEINS**

NONVERBAL COMMUNICATION

Long-term retention of memory for preverbal experience: evidence and implications. Nelson K. **Memory** 1994 Dec; 2(4):467–75 (5 ref.)

NOONAN SYNDROME

PATHOLOGY

Cherubism in a patient with Noonan's syndrome. Addante RR, et al. **J Oral Maxillofac Surg** 1996 Feb;54(2):210–3 (15 ref.)

NOOTROPIC AGENTS

PHARMACOKINETICS

Clinical pharmacokinetics of drugs for Alzheimer's disease. Parnetti L. **Clin Pharmacokinet** 1995 Aug;29(2):110–29 (111 ref.)

PHARMACOLOGY

On the possible role of nootropica in geriatric prevention and therapy. Nagy IZ. **Ann N Y Acad Sci** 1996 Jun 15; 786:444–52 (45 ref.)

CDP-choline: pharmacological and clinical review. Secades JJ, et al. **Methods Find Exp Clin Pharmacol** 1995 Oct;17 Suppl B:2–54 (239 ref.)

THERAPEUTIC USE

Clinical pharmacokinetics of drugs for Alzheimer's disease. Parnetti L. **Clin Pharmacokinet** 1995 Aug;29(2):110–29 (111 ref.)

Therapeutic trials in Alzheimer's disease. Whitehouse PJ, et al. **Curr Opin Neurol** 1995 Aug;8(4):275–8 (25 ref.)

CDP-choline: pharmacological and clinical review. Secades JJ, et al. **Methods Find Exp Clin Pharmacol** 1995 Oct;17 Suppl B:2–54 (239 ref.)

Cognitive impairment as a target for pharmacological treatment in schizophrenia. Davidson M, et al. **Schizophr Res** 1995 Sep;17(1):123–9 (55 ref.)

[Possibilities and limits of therapy of cognition disorders in the elderly] Hoyer S. **Z Gerontol Geriatr** 1995 Nov–Dec; 28(6):457–62 (56 ref.) (Eng. Abstr.) **(Ger)**

[Dementias: present situation and future perspectives (III). Neurological, therapeutic, psychosocial aspects and patient care] Espert R, et al. **Rev Neurol** 1995 Jan–Feb; 23(119):86–95 (138 ref.) (Eng. Abstr.) **(Spa)**

[Pharmacological treatment of Alzheimer's disease: present situation and perspectives] Jané F. **Rev Neurol** 1995 Jan–Feb;23(119):103–7 (43 ref.) (Eng. Abstr.) **(Spa)**

NORADRENALINE see **NOREPINEPHRINE**

NORAMIDOPYRINE METHANESULFONATE see **DIPYRONE**

NORANDROSTENOLONE see **NANDROLONE**

NOREPINEPHRINE

see related
RECEPTORS, ADRENERGIC

ANALYSIS

Innervation of cerebral arteries by nerves containing 5-hydroxytryptamine and noradrenaline. Lincoln J. **Pharmacol Ther** 1995;68(3):473–501 (256 ref.)

METABOLISM

Noradrenergic locus coeruleus neurons [letter] Halliday G, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1):191–2 (15 ref.)

Clinical assessment of sympathetic responses to stress. Goldstein DS. **Ann N Y Acad Sci** 1995 Dec 29;771:570–93 (144 ref.)

Anterior hypothalamic norepinephrine, atrial natriuretic peptide, and hypertension. Oparil S, et al. **Front Neuroendocrinol** 1996 Apr;17(2):212–46 (122 ref.)

Central noradrenergic neurones and stress. Stanford SC.

Pharmacol Ther 1995;68(2):297–42 (360 ref.)
Norepinephrine metabolism and psychoactive drugs in the endogenous depressions. 1968 [classical article] Schildkraut JJ, et al. **Pharmacopsychiatry** 1995 Sep;28 Suppl 1:24–37 (58 ref.)

PHARMACOLOGY

The contribution of alpha 2–noradrenergic mechanisms of prefrontal cortical cognitive function. Potential significance for attention–deficit hyperactivity disorder. Arnsten AF, et al. **Arch Gen Psychiatry** 1996 May;53(5):448–55 (130 ref.)
Signal transduction in brown adipose tissue recruitment: noradrenaline and beyond. Cannon B, et al.
Int J Obes Relat Metab Disord 1996 Mar;20 Suppl 3:S36–42 (37 ref.)

PHYSIOLOGY

Norepinephrine as a morphogen?: its unique interaction with brown adipose tissue. Nedergaard J, et al.
Int J Dev Biol 1995 Oct;39(5):827–37 (55 ref.)
Noradrenergic and serotonergic abnormalities in depression: stress–induced dysfunction? Dinan TG.
J Clin Psychiatry 1996;57 Suppl 4:14–8 (43 ref.)
Biologic markers and neurochemical correlates of agitation and psychosis in dementia. Kirby M, et al.
J Geriatr Psychiatry Neurol 1995 Oct;8 Suppl 1:S2–7 (63 ref.)
Noradrenaline and ATP: cotransmitters and neuromodulators. Burnstock G. **J Physiol Pharmacol** 1995 Dec;46(4):365–84 (195 ref.)
Pharmacology of descending noradrenergic systems in relation to motor function. Ono H, et al.
Pharmacol Ther 1995;68(1):105–12 (61 ref.)
Geometry, kinetics and plasticity of release and clearance of ATP and noradrenaline as sympathetic cotransmitters: roles for the neurogenic contraction. Stjärne L, et al.
Prog Neurobiol 1995 Sep;47(1):45–94 (145 ref.)
[Deficit schizophrenia: from pharmacology to clinical practice] Tassin JP. **Encephale** 1996 Jun;22 Spec No 2:9–12 (20 ref.) (Eng. Abstr.) **(Fre)**

SECRETION

The use of the human neuroblastoma SH-SY5Y to study the effect of second messengers on noradrenaline release. Vaughan PF, et al. **Gen Pharmacol** 1995 Oct;26(6):1191–201 (62 ref.)
Biochemical assessment of sympathetic activity and prejunctional modulation of noradrenaline release in humans [editorial] Hjemdahl P, et al. **J Hypertens** 1996 Feb;14(2):147–50 (28 ref.)

NORETHINDRONE

ANALOGS & DERIVATIVES

Accumulated knowledge of Kliogest safety aspects. Ulrich LG. **Br J Obstet Gynaecol** 1996 May;103 Suppl 13:99–102; discussion 102–3 (14 ref.)

BLOOD

[Synthetic steroids] Miyazaki S. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:1036–9 (19 ref.) **(Jpn)**

THERAPEUTIC USE

Norethindrone—a review of therapeutic applications. Taitel HF, et al. **Int J Fertil Menopausal Stud** 1995 Jul–Aug; 40(4):207–23 (64 ref.)

NORETHISTERONE see **NORETHINDRONE**

NORGESTREL

ADMINISTRATION & DOSAGE

The effectiveness of the Yuzpe regimen of emergency contraception. Trussell J, et al. **Fam Plann Perspect** 1996 Mar–Apr;28(2):58–64, 87 (30 ref.)

ANALOGS & DERIVATIVES

Desogestrel, norgestimate, and gestodene: the newer progestins. Kaplan B. **Ann Pharmacother** 1995 Jul–Aug; 29(7–8):736–42 (51 ref.)
Norgestimate. Corson SL. **Clin Obstet Gynecol** 1995 Dec; 38(4):841–8 (25 ref.)

L-NORGESTREL see **LEVONORGESTREL**

NORMAL DISTRIBUTION

The origin of Gaussian distributions of synaptic potentials. Bennett MR. **Prog Neurobiol** 1995 Jul;46(4):331–50 (81 ref.)

NORMAL SERUM GLOBULIN THERAPY see **IMMUNIZATION, PASSIVE**

NORMETANEPHRINE

ANALYSIS

[Metanephrine (M) and normetanephrine (NM)] Sasaki M, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:511–5 (11 ref.) **(Jpn)**

NORPREGNENES

Desogestrel, norgestimate, and gestodene: the newer progestins. Kaplan B. **Ann Pharmacother** 1995 Jul–Aug; 29(7–8):736–42 (51 ref.)

PHARMACOLOGY

Gestodene–containing contraceptives. Kuhl H, et al.
Clin Obstet Gynecol 1995 Dec;38(4):829–40 (32 ref.)
Gestodene. A review of its pharmacology, efficacy and tolerability in combined contraceptive preparations. Wilde MI, et al. **Drugs** 1995 Aug;50(2):364–95 (128 ref.)

NORPREGNENINOLONE see **NORETHINDRONE**

NORSYNEPHRINE see **OCTOPAMINE**

NORTESTOSTERONE see **NANDROLONE**

NORTHERN BLOTTING see **BLOTTING, NORTHERN**

NOSE

see related
RHINOPLASTY

ABNORMALITIES

Familial arhinia, choanal atresia, and microphthalmia. Thiele H, et al. **Am J Med Genet** 1996 May 3;63(1):310–3 (7 ref.)
Oculoauriculofrontonasal syndrome: report of another case and review of differential diagnosis. Toriello HV, et al. **Clin Dysmorphol** 1995 Oct;4(4):338–46 (25 ref.)
The residual cleft lip nasal deformity. An anatomic approach. Rifley W, et al. **Clin Plast Surg** 1996 Jan;23(1):81–92 (67 ref.)
Frontonasal dysplasia: analysis of 21 cases and literature review. Guion–Almeida ML, et al.
Int J Oral Maxillofac Surg 1996 Apr;25(2):91–7 (62 ref.)

ANATOMY & HISTOLOGY

Surgical anatomy of the nose. Oneal RM, et al.
Clin Plast Surg 1996 Apr;23(2):195–222 (72 ref.)

BLOOD SUPPLY

[Decompressive neurovascular nose and skull–base surgery in primary headache with a rhinogenic trigger] Bonaccorsi P. **Ital J Neurol Sci** 1995 Nov;16(8 Suppl):69–100 (104 ref.) (Eng. Abstr.) **(Ita)**

MICROBIOLOGY

Postoperative wound infections: risk factors and role of Staphylococcus aureus nasal carriage. Perl TM, et al.
J Chemother 1995 Jul;7 Suppl 3:29–35 (51 ref.)
The significance of nasal carriage of Staphylococcus aureus and the incidence of postoperative wound infection. Wenzel RP, et al. **J Hosp Infect** 1995 Sep;31(1):13–24 (52 ref.)

PHYSIOLOGY

The kinetics of the cytologic and rhinomanometric changes in the nose after challenge with allergen. Bernheim N, et al. **Acta Otorhinolaryngol Belg** 1995;49(3):229–33 (20 ref.)
Effect of partial middle turbinectomy on nasal airflow and resistance. Cook PR, et al.
Otolaryngol Head Neck Surg 1995 Oct;113(4):413–9 (32 ref.)

PHYSIOPATHOLOGY

[Pneumologists and the nose (editorial)] Picado C.
Arch Bronconeumol 1995 Aug–Sep;31(7):314–6 (11 ref.) **(Spa)**

SURGERY

Development of an instrument for endoscopic nasal surgery. Hochberg J, et al. **Clin Plast Surg** 1995 Oct;22(4):781–4 (4 ref.)
Rethinking the logic and techniques of primary tip rhinoplasty. A perspective of the evolution of surgery of the nasal tip. Tebbetts JB. **Clin Plast Surg** 1996 Apr; 23(2):245–53 (11 ref.)

NOSE BLEED see **EPISTAXIS**

NOSE DEFORMITIES, ACQUIRED

ETIOLOGY

Treatment of over–reduction of the nose and subsequent deformities. Aiach G, et al. **Br J Oral Maxillofac Surg** 1995 Aug;33(4):250–61 (6 ref.)

SURGERY

Treatment of over–reduction of the nose and subsequent deformities. Aiach G, et al. **Br J Oral Maxillofac Surg** 1995 Aug;33(4):250–61 (6 ref.)

NOSE DISEASES

COMPLICATIONS

[Centro–peripheral etiopathogenesis of primary headache triggered nasally] Ottaviani F. **Ital J Neurol Sci** 1995 Nov; 16(8 Suppl):35–9 (18 ref.) (Eng. Abstr.) **(Ita)**

CONGENITAL

[Clinical and surgical aspects of cysts and fistulae of the nose in children. Apropos of 37 cases] Ducroz V, et al.
Ann Otolaryngol Chir Cervicofac 1995;112(5):218–24 (33 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

The nasal tooth. Case report. Nastri AL, et al.
Aust Dent J 1996 Jun;41(3):176–7 (7 ref.)
Laser technology in research, diagnosis and therapy in rhinology. Soh KB. **Clin Otolaryngol** 1996 Apr;21(2):102–5 (34 ref.)
MR imaging of nasal masses. Allbery SM, et al.
Radiographics 1995 Nov;15(6):1311–27 (17 ref.)

MICROBIOLOGY

Mixed intranasal infection caused by Fusarium solani and a zygomycete in a leukaemic patient. Lopes JO, et al.
Mycoses 1995 Jul–Aug;38(7–8):281–4 (26 ref.)

SURGERY

Palatal mucoperiosteal expansion as an adjunct to palatal fistula repair: case report and review of the literature. Van Damme PA, et al. **Cleft Palate Craniofac J** 1996 May; 33(3):255–7 (10 ref.)
[Complications of endonasal microsurgery] Stoll D, et al.
Rev Laryngol Otol Rhinol (Bord) 1995;116(3):191–4 (23 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Laser technology in research, diagnosis and therapy in rhinology. Soh KB. **Clin Otolaryngol** 1996 Apr;21(2):102–5 (34 ref.)

NOSE NEOPLASMS

EPIDEMIOLOGY

Malignant tumors of the nasal cavity: review of a 60–case series. Haraguchi H, et al. **Jpn J Clin Oncol** 1995 Oct; 25(5):188–94 (18 ref.)

PATHOLOGY

Microcystic adnexal carcinoma. Case report and review of the literature. Billingsley EM, et al.
Arch Otolaryngol Head Neck Surg 1996 Feb;122(2):179–82 (20 ref.)
Pathology in focus. Spindle–cell carcinoma of the nasal septum. Ahluwalia H, et al. **J Laryngol Otol** 1996 Mar; 110(3):284–7 (26 ref.)
Leiomyoma of the nasal septum: report of a case and review of the literature. Llorente JL, et al. **J Laryngol Otol** 1996 Jan;110(1):65–8 (18 ref.)
Solitary infantile and adult myofibromatosis of the nasal cavity: a report of two cases. Walsh RM, et al.
J Laryngol Otol 1996 Jun;110(6):574–7 (15 ref.)
Dermoid cyst of the nose: a case report and review of the literature. Nocini PF, et al. **J Oral Maxillofac Surg** 1996 Mar;54(3):357–62 (21 ref.)
Nasal T–cell lymphoma and the lethal midline granuloma syndrome. Hartig G, et al.
Otolaryngol Head Neck Surg 1996 Apr;114(4):653–6 (16 ref.)
Central nervous system metastases from esthesioneuroblastoma. Shaari CM, et al.
Otolaryngol Head Neck Surg 1996 Jun;114(6):808–12 (20 ref.)
Benign mucosal tumors of the nose and paranasal sinuses. Michaels L. **Semin Diagn Pathol** 1996 May;13(2):113–7 (15 ref.)
[Oncocytoma of the nose. A case report and review of the literature] Förster C, et al. **Pathologe** 1995 Nov;16(6):431–3 (12 ref.) (Eng. Abstr.) **(Ger)**

RADIOTHERAPY

Management of anterior cranial base and cavernous sinus neoplasms with conservative surgery alone or in combination with fractionated photon or stereotactic proton radiotherapy. Ojemann RG, et al.
Clin Neurosurg 1995;42:71–98 (76 ref.)

SURGERY

Treatment of olfactory neuroblastoma. A report of 11 cases. Jekunen AP, et al. **Am J Clin Oncol** 1996 Aug;19(4):375–8 (21 ref.)
Management of anterior cranial base and cavernous sinus neoplasms with conservative surgery alone or in combination with fractionated photon or stereotactic proton radiotherapy. Ojemann RG, et al.
Clin Neurosurg 1995;42:71–98 (76 ref.)

NOSE NEOPLASMS

VIROLOGY

Epstein-Barr virus (EBV) in extranodal T-cell non-Hodgkin's lymphomas (T-NHL). Identification of nasal T-NHL as a distinct clinicopathological entity associated with EBV. Kanavaros P, et al. **Leuk Lymphoma** 1995 Jun;18(1-2):27-34 (86 ref.)

Epstein-Barr virus in T and natural killer (NK) cell non-Hodgkin's lymphomas. Kanavaros P, et al. **Leukemia** 1996 Jun;10 Suppl 2:s84-7 (44 ref.)

NOSEBLEED see EPISTAXIS

NOSOCOMIAL INFECTIONS see CROSS INFECTION

NOTIFICATION, DISEASE see DISEASE NOTIFICATION

NOTIFICATION, PARTNER see CONTACT TRACING

NOTOCHORD

Chasing tails in ascidians: developmental insights into the origin and evolution of chordates. Satoh N, et al. **Trends Genet** 1995 Sep;11(9):354-9 (44 ref.)

PHYSIOLOGY

The role of the notochord and floor plate in inductive interactions. Placzek M. **Curr Opin Genet Dev** 1995 Aug; 5(4):499-506 (74 ref.)

NOVELTY-SEEKING BEHAVIOR see EXPLORATORY BEHAVIOR

NUCLEAR ACCIDENTS see ACCIDENTS, RADIATION

NUCLEAR AND CYTOPLASMIC RECEPTORS see RECEPTORS, CYTOPLASMIC AND NUCLEAR

NUCLEAR ENERGY

see related
RADIATION PROTECTION
RADIOACTIVE WASTE

NUCLEAR ENVELOPE see NUCLEAR MEMBRANE

NUCLEAR FACTOR KAPPA B see NF-KAPPA B

NUCLEAR FAMILY

[Modern family and adolescence] Takikawa K. **Seishin Shinkeigaku Zasshi** 1995;97(8):586-98 (7 ref.) **(Jpn)**

NUCLEAR MAGNETIC RESONANCE

see related
MAGNETIC RESONANCE IMAGING

Vigabatrin: effect on brain GABA levels measured by nuclear magnetic resonance spectroscopy. Mattson RH, et al. **Acta Neurol Scand Suppl** 1995;162:27-30 (16 ref.)

The development and application of coupled HPLC-NMR spectroscopy. Lindon JC, et al. **Adv Chromatogr** 1996; 36:315-82 (70 ref.)

Nuclear magnetic resonance spectroscopy. Smith IC, et al. **Anal Chem** 1995 Jun 15;67(12):509R-518R (115 ref.)

Heteronuclear NMR pulse sequences applied to biomolecules. Pelton JG, et al. **Annu Rev Phys Chem** 1995; 46:139-67 (120 ref.)

High resolution nuclear magnetic resonance spectroscopy in clinical biology: application in oncology. de Certaines JD. **Anticancer Res** 1996 May-Jun;16(3B):1325-31 (37 ref.)

Proton nuclear magnetic resonance spectroscopy of plasma lipoprotein: technical problems and potential interest in cancer disease. de Certaines JD, et al. **Anticancer Res** 1996 May-Jun;16(3B):1451-60 (46 ref.)

Introduction to in vivo MRS of cancer: new perspectives and open problems. Leach MO. **Anticancer Res** 1996 May-Jun;16(3B):1503-14 (104 ref.)

An introduction to the potential of 1H-, 31P- and 13C-NMR-spectroscopy. Leibfritz D. **Anticancer Res** 1996 May-Jun;16(3B):1317-24 (39 ref.)

Human cancers detected by proton MRS and chemical shift imaging ex vivo. Mountford CE, et al. **Anticancer Res** 1996 May-Jun;16(3B):1521-31 (38 ref.)

Characterization of hydrogels using nuclear magnetic resonance spectroscopy. Mathur AM, et al. **Biomaterials** 1996 Mar;17(6):547-57 (80 ref.)

Structural analysis of non-native states of proteins by NMR methods. Shortle DR. **Curr Opin Struct Biol** 1996 Feb; 6(1):24-30 (58 ref.)

Evaluation of cardiac 31P magnetic resonance spectroscopy: reviewing NMR principles. Hoffenberg EF, et al. **J Surg Res** 1996 Apr;62(1):135-43 (38 ref.)

NMR studies of brain 13C-glucose uptake and metabolism: present status. van Zijl PC, et al. **Magn Reson Imaging** 1995;13(8):1213-21 (44 ref.)

Magnetic resonance spectroscopy and imaging in radiology. Mahmood U, et al. **Med Phys** 1995 Nov;22(11 Pt 2):1935-41 (65 ref.)

Use of vanadate-induced photocleavage for detecting phosphate binding sites in proteins. Muhlrad A, et al. **Mol Ions Biol Syst** 1995;31:211-30 (65 ref.)

Membrane protein structure: the contribution and potential of novel solid state NMR approaches. Watts A, et al. **Mol Membr Biol** 1995 Jul-Sep;12(3):233-46 (118 ref.)

Diffusion-weighted imaging in tissues: theoretical models. Szafer A, et al. **NMR Biomed** 1995 Nov-Dec;8(7-8):289-96 (45 ref.)

Nuclear magnetic resonance spectroscopy: a review of neuropsychiatric applications. Passe TJ, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1995 Jul; 19(4):541-63 (155 ref.)

Nuclear magnetic resonance investigation of the structures of phosphate and phosphate-containing glasses: a review. Kirkpatrick RJ, et al. **Solid State Nucl Magn Reson** 1995 Oct;5(1):9-21 (51 ref.)

[Nuclear magnetic resonance spectroscopy: methodology and applications to the study of asphyxia neonatorum] Barantin L, et al. **Neurophysiol Clin** 1995;25(3):115-29 (56 ref.) (Eng. Abstr.) **(Fre)**

[Stable isotopic labeling and NMR analyses of nucleic acids] Kawai G. **Tanpakushitsu Kakusan Koso** 1994 Jul; 40(10):1502-8 (47 ref.) **(Jpn)**

DIAGNOSTIC USE

MRS and NIRS for muscle disease evaluation. Olsen NJ, et al. **Bull Rheum Dis** 1995 Aug;44(5):4-7 (10 ref.)

Magnetic resonance spectroscopy. Duncan JS. **Epilepsia** 1996 Jul;37(7):598-605 (37 ref.)

MR spectroscopy of the breast. Merchant TE. **Magn Reson Imaging Clin N Am** 1994 Nov;2(4):691-703 (38 ref.)

MR spectroscopy of musculoskeletal soft-tissue tumors. Negendank WG. **Magn Reson Imaging Clin N Am** 1995 Nov;3(4):713-25 (53 ref.)

Magnetic resonance spectroscopy. Garcia PA, et al. **Neuroimaging Clin N Am** 1995 Nov;5(4):675-82 (40 ref.)

[Magnetic resonance spectroscopy: a new technique for the exploration of brain metabolism in pediatrics] Chabrol B, et al. **Arch Pediatr** 1995 Aug;2(8):783-92 (39 ref.) (Eng. Abstr.) **(Fre)**

[N-acetyl-aspartate abnormalities in internal-temporal epileptic foci using proton magnetic resonance spectroscopy] Giroud M, et al. **Rev Neurol (Paris)** 1995 Jun-Jul;151(6-7):404-9 (28 ref.) (Eng. Abstr.) **(Fre)**

INSTRUMENTATION

Clinical applications of proton MR spectroscopy. Castillo M, et al. **AJNR Am J Neuroradiol** 1996 Jan;17(1):1-15 (64 ref.)

Application of spectroscopic imaging in epilepsy. Garcia PA, et al. **Magn Reson Imaging** 1995;13(8):1181-5 (28 ref.)

Application of high field spectroscopic imaging in the evaluation of temporal lobe epilepsy. Hetherington HP, et al. **Magn Reson Imaging** 1995;13(8):1175-80 (14 ref.)

METHODS

Reaction engineering methods to study intracellular metabolite concentrations. Weuster-Botz D, et al. **Adv Biochem Eng Biotechnol** 1996;54:75-108 (62 ref.)

Emerging opportunities with NMR. Bertocci LA. **Adv Exp Med Biol** 1995;384:211-23 (39 ref.)

Magnetic resonance spectroscopy of blood plasma lipoproteins in malignant disease: methodological aspects and clinical relevance. Engan T. **Anticancer Res** 1996 May-Jun;16(3B):1461-71 (85 ref.)

In vivo magnetic resonance spectroscopy. Applications in psychiatry. Maier M. **Br J Psychiatry** 1995 Sep; 167(3):299-306 (44 ref.)

Structures of protein complexes by multidimensional heteronuclear magnetic resonance spectroscopy. Gronenborn AM, et al. **Crit Rev Biochem Mol Biol** 1995; 30(5):351-85 (156 ref.)

Protein complexes studied by NMR spectroscopy. Wand AJ, et al. **Curr Opin Biotechnol** 1996 Aug;7(4):403-8 (100 ref.)

Magnetic resonance imaging and spectroscopy in multiple sclerosis. Miller DH. **Curr Opin Neurol** 1995 Jun;8(3):210-5 (44 ref.)

Field gradient techniques in NMR spectroscopy. Kay LE. **Curr Opin Struct Biol** 1995 Oct;5(5):674-81 (58 ref.)

Automated analysis of nuclear magnetic resonance assignments for proteins. Zimmerman DE, et al. **Curr Opin Struct Biol** 1995 Oct;5(5):664-73 (65 ref.)

In vivo 13C nuclear magnetic resonance: applications and current limitations for noninvasive assessment of fatty acid status. Cunnane SC, et al. **Lipids** 1996 Mar;31 Suppl:S127-30 (15 ref.)

Overview--the role of NMR spectroscopy in epilepsy. Novotny EJ Jr. **Magn Reson Imaging** 1995;13(8):1171-3 (17 ref.)

Inferring microstructural features and the physiological state of tissues from diffusion-weighted images. Basser PJ. **NMR Biomed** 1995 Nov-Dec;8(7-8):333-44 (60 ref.)

In vivo quantitation of metabolite concentrations in the brain by means of proton MRS. Henriksen O. **NMR Biomed** 1995 Jun;8(4):139-48 (76 ref.)

Diffusion-weighted NMR imaging: application to experimental focal cerebral ischemia. Hoehn-Berlage M. **NMR Biomed** 1995 Nov-Dec;8(7-8):345-58 (103 ref.)

Molecular diffusion, tissue microdynamics and microstructure. Le Bihan D. **NMR Biomed** 1995 Nov-Dec; 8(7-8):375-86 (95 ref.)

In vivo diffusion spectroscopy. An overview. Nicolay K, et al. **NMR Biomed** 1995 Nov-Dec;8(7-8):365-74 (52 ref.)

Interpretation of DW-NMR data: dependence on experimental conditions. Norris DG, et al. **NMR Biomed** 1995 Nov-Dec;8(7-8):280-8 (56 ref.)

Two-, three-, and four-dimensional nuclear magnetic resonance spectroscopy of protein pharmaceuticals. Vander Velde DG, et al. **Pharm Biotechnol** 1995;7:179-218 (186 ref.)

Pulsed field gradient multi-dimensional NMR methods for the study of protein structure and dynamics in solution. Kay LE. **Prog Biophys Mol Biol** 1995;63(3):277-99 (80 ref.)

A simple model for deuterium cross-polarization magic-angle spinning nuclear magnetic resonance at the interphases of amorphous materials. Zumbulyadis N. **Solid State Nucl Magn Reson** 1995 Oct;5(1):3-7 (11 ref.)

[Preparation of stable isotope labeled DNA oligomers: applications to the structural analysis of nucleic acids by heteronuclear multidimensional NMR spectroscopy] Ono A, et al. **Tanpakushitsu Kakusan Koso** 1994 Jul; 40(10):1509-17 (21 ref.) **(Jpn)**

NUCLEAR MATRIX

Nuclear matrix and the cell cycle. Loidl P, et al. **Int Rev Cytol** 1995;162B:377-403 (125 ref.)

[Biological significance of nuclear matrix attachment regions (MAR) and tissue specific MAR-DNA binding proteins] Kohwi Y, et al. **Seikagaku** 1995 Sep;67(9):1115-27 (28 ref.) **(Jpn)**

CHEMISTRY

Chromatin domains and prediction of MAR sequences. Boulikas T. **Int Rev Cytol** 1995;162A:279-388 (478 ref.)

Origins of replication and the nuclear matrix: the DHFR domain as a paradigm. Dijkwel PA, et al. **Int Rev Cytol** 1995;162A:455-84 (180 ref.)

Nuclear matrix acceptor binding sites for steroid hormone receptors: a candidate nuclear matrix acceptor protein. Lauber AH, et al. **Int Rev Cytol** 1995;162B:337-76 (178 ref.)

DRUG EFFECTS

The nuclear matrix as a site of anticancer drug action. Fernandes DJ, et al. **Int Rev Cytol** 1995;162A:539-76 (260 ref.)

ENZYMOLOGY

Nuclear domains and the nuclear matrix. van Driel R, et al. **Int Rev Cytol** 1995;162A:151-89 (440 ref.)

METABOLISM

Specificity and functional significance of DNA interaction with the nuclear matrix: new approaches to clarify the old questions. Razin SV, et al. **Int Rev Cytol** 1995;162B:405-48 (142 ref.)

Nuclear structure and the lamins [editorial; comment] Bosman FT. **J Pathol** 1996 Jan;178(1):3-4 (14 ref.) Comment on: J Pathol 1996 Jan;178(1):21-9.

A nuclear matrix acceptor site for the progesterone receptor in the avian c-myc gene promoter. Spelsberg TC, et al. **Recent Prog Horm Res** 1996;51:63-96 (121 ref.)

PHYSIOLOGY

The nuclear matrix: a structural milieu for genomic function. Berezney R, et al. **Int Rev Cytol** 1995;162A:1-65 (270 ref.)

The nuclear matrix and the regulation of chromatin organization and function. Davie JR. **Int Rev Cytol** 1995; 162A:191-250 (353 ref.)

The nuclear matrix and virus function. Deppert W, et al. **Int Rev Cytol** 1995;162A:485-537 (92 ref.)

ULTRASTRUCTURE

The nuclear matrix and the regulation of chromatin organization and function. Davie JR. **Int Rev Cytol** 1995; 162A:191-250 (353 ref.)

Nuclear matrix isolated from plant cells. Moreno Díaz de la Espina SM. **Int Rev Cytol** 1995;162B:75-139 (172 ref.)

Nuclear domains and the nuclear matrix. van Driel R, et al. **Int Rev Cytol** 1995;162A:151-89 (440 ref.)

NUCLEAR MEDICINE

see related
RADIOISOTOPES

The clinical challenge of nuclear medicine in gastroenterology. Notghi A, et al. **Br J Hosp Med** 1995 Jul 12-Aug 15;54(2-3):80-6 (23 ref.)

METHODS

Parametric imaging in nuclear medicine. Lassen NA, et al. **Ann Nucl Med** 1995 Nov;9(4):167-70 (8 ref.)

TRENDS

Is there life after technetium: what is the potential for developing new broad-based radionuclides? Srivastava SC. **Semin Nucl Med** 1996 Apr;26(2):119-31 (78 ref.)

[Future prospects for nuclear medicine] Senda K, et al.

Nippon Igaku Hoshasen Gakkai Zasshi 1995 Oct; 55(13):508–16 (0 ref.) (Eng. Abstr.) **(Jpn)**

NUCLEAR MEMBRANE

CHEMISTRY

Nuclear pores and macromolecular assemblies involved in nucleocytoplasmic transport. Stewart M, et al. **Curr Opin Struct Biol** 1996 Apr;6(2):162–5 (43 ref.)

Nuclear pore complex proteins. Bastos R, et al. **Int Rev Cytol** 1995;162B:257–302 (156 ref.)

Toward a molecular understanding of the structure and function of the nuclear pore complex. Panté N, et al. **Int Rev Cytol** 1995;162B:225–55 (103 ref.)

METABOLISM

The nuclear pore complex. Davis LI. **Annu Rev Biochem** 1995;64:865–96 (188 ref.)

Signalling and transport through the nuclear membrane. Csermely P, et al. **Biochim Biophys Acta** 1995 Dec 20; 1241(3):425–51 (512 ref.)

Importins/karyopherins meet nucleoporins. Hurt EC. **Cell** 1996 Feb 23;84(4):509–15 (44 ref.)

ULTRASTRUCTURE

Molecular dissection of the nuclear pore complex. Panté N, et al. **Crit Rev Biochem Mol Biol** 1996 Apr;31(2):153–99 (110 ref.)

Toward a molecular understanding of the structure and function of the nuclear pore complex. Panté N, et al. **Int Rev Cytol** 1995;162B:225–55 (103 ref.)

Exploring nuclear pore complex structure and function in molecular detail. Panté N, et al. **J Cell Sci Suppl** 1995; 19:1–11 (60 ref.)

NUCLEAR PHYSICS

[IgD (lambda) multiple myeloma associated with myelofibrosis: an isolated case of nuclear physicist] Kanoh T, et al. **Rinsho Ketsueki** 1996 Mar;37(3):244–8 (14 ref.) (Eng. Abstr.) **(Jpn)**

NUCLEAR POLYHEDROSIS VIRUS

Baculovirus bounty. Volkman LE. **Science** 1995 Sep 29; 269(5232):1834 (12 ref.)

NUCLEAR PORE see **NUCLEAR MEMBRANE**

NUCLEAR POWER PLANTS see **POWER PLANTS**

NUCLEAR PROTEINS

The C/EBP family of transcription factors. Wedel A, et al. **Immunobiology** 1995 Jul;193(2–4):171–85 (100 ref.)

Nuclear pore complex proteins. Bastos R, et al. **Int Rev Cytol** 1995;162B:257–302 (156 ref.)

Nuclear matrix proteins as structural and functional components of the mitotic apparatus. He D, et al. **Int Rev Cytol** 1995;162B:1–74 (283 ref.)

Nucleoid proteins. Hayat MA, et al. **Micron** 1995; 26(5):461–80 (220 ref.)

MYC family ties [news; comment] Schmidt EV. **Nat Genet** 1996 Sep;14(1):8–10 (25 ref.) Comment on: Nat Genet 1996 Sep;14(1):69–77.

[HN7–3/fork head (winged–helix) transcription factor family in dorso–ventral pattern formation of vertebrate embryos] Sasaki H. **Seikagaku** 1995 Oct;67(10):1218–21 (15 ref.) **(Jpn)**

ANALYSIS

Meningioangiomatosis. A clinicopathologic study including MIB1 immunoreactivity. Prayson RA. **Arch Pathol Lab Med** 1995 Nov;119(11):1061–4 (34 ref.)

CHEMISTRY

Nuclear pores and macromolecular assemblies involved in nucleocytoplasmic transport. Stewart M, et al. **Curr Opin Struct Biol** 1996 Apr;6(2):162–5 (43 ref.)

Targeting and association of proteins with functional domains in the nucleus: the insoluble solution. Leonhardt H, et al. **Int Rev Cytol** 1995;162B:303–35 (161 ref.)

Toward a molecular understanding of the structure and function of the nuclear pore complex. Panté N, et al. **Int Rev Cytol** 1995;162B:225–55 (103 ref.)

Exploring nuclear pore complex structure and function in molecular detail. Panté N, et al. **J Cell Sci Suppl** 1995; 19:1–11 (60 ref.)

GENETICS

The hepatocyte nuclear factor-3/forkhead transcription regulatory family in development, inflammation, and neoplasia. Hromas R, et al. **Crit Rev Oncol Hematol** 1995 Aug;20(1–2):129–40 (64 ref.)

MYC family ties [news; comment] Schmidt EV. **Nat Genet** 1996 Sep;14(1):8–10 (25 ref.) Comment on: Nat Genet 1996 Sep;14(1):69–77.

period and timeless tango: a dance of two clock genes. Reppert SM, et al. **Neuron** 1995 Nov;15(5):983–6 (23 ref.)

Analysis of the CAG repeat and gene product in spinocerebellar ataxia type 1. Zoghbi HY. **Proc Assoc Am Physicians** 1995 Jul;107(2):231–6 (21 ref.)

The superfamily of arginine/serine–rich splicing factors. Fu XD. **RNA** 1995 Sep;1(7):663–80 (160 ref.)

Infertility treatment: a nuclear restorer gene in maize [comment] Levings CS 3rd. **Science** 1996 May 31; 272(5266):1279–80 (16 ref.) Comment on: Science 1996 May 31;272(5266):1334–6.

IMMUNOLOGY

The Ku autoantigen: cast in a new light. Robinson A. **Can Med Assoc J** 1996 Jun 15;154(12):1871–3 (8 ref.)

METABOLISM

The regulation of protein transport to the nucleus by phosphorylation. Jans DA. **Biochem J** 1995 Nov 1;311 (Pt 3):705–16 (169 ref.)

The signal transduction pathway leading from the toll receptor to nuclear localization of dorsal transcription factor. Gay NJ, et al. **Biochem Soc Trans** 1996 Feb; 24(1):35–8 (26 ref.)

Mitogen–responsive nuclear factors that mediate growth control signals in vascular myocytes. Gorski DH, et al. **Cardiovasc Res** 1995 Oct;30(4):585–92 (114 ref.)

Importins/karyopherins meet nucleoporins. Hurt EC. **Cell** 1996 Feb 23;84(4):509–15 (44 ref.)

The role of BSAP (Pax–5) in B–cell development. Busslinger M, et al. **Curr Opin Genet Dev** 1995 Oct;5(5):595–601 (53 ref.)

C/EBP alpha: a critical regulator of genes governing integrative metabolic processes. Darlington GJ, et al. **Curr Opin Genet Dev** 1995 Oct;5(5):565–70 (37 ref.)

Genomic simple repetitive DNAs are targets for differential binding of nuclear proteins. Epplen JT, et al. **FEBS Lett** 1996 Jun 24;389(1):92–5 (40 ref.)

Nuclear matrix acceptor binding sites for steroid hormone receptors: a candidate nuclear matrix acceptor protein. Lauber AH, et al. **Int Rev Cytol** 1995;162B:337–76 (178 ref.)

Targeting and association of proteins with functional domains in the nucleus: the insoluble solution. Leonhardt H, et al. **Int Rev Cytol** 1995;162B:303–35 (161 ref.)

B cell lineage–specific activator protein (BSAP). A player at multiple stages of B cell development. Michaelson JS, et al. **J Immunol** 1996 Apr 1;156(7):2349–51 (50 ref.)

Nuclear structure and the lamins [editorial; comment] Bosman FT. **J Pathol** 1996 Jan;178(1):3–4 (14 ref.) Comment on: J Pathol 1996 Jan;178(1):21–9.

Differing shapes of 1 alpha,25–dihydroxyvitamin D3 function as ligands for the D–binding protein, nuclear receptor and membrane receptor: a status report. Norman AW, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1–6 Spec No):13–22 (34 ref.)

A model for circadian oscillations in the Drosophila period protein (PER). Goldbeter A. **Proc R Soc Lond B Biol Sci** 1995 Sep 22;261(1362):319–24 (46 ref.)

PHYSIOLOGY

Cell proliferation–associated nuclear antigen defined by antibody Ki–67: a new kind of cell cycle–maintaining proteins. Duchrow M, et al. **Arch Immunol Ther Exp (Warsz)** 1995;43(2):117–21 (30 ref.)

Lymphopoiesis. Transcription factors controlling B–cell development. Desiderio S. **Curr Biol** 1995 Jun 1;5(6):605–8 (20 ref.)

Boundary and insulator elements in chromosomes. Gerasimova TI, et al. **Curr Opin Genet Dev** 1996 Apr; 6(2):185–92 (42 ref.)

Function of PU.1 (Spi–1), C/EBP, and AML1 in early myelopoiesis: regulation of multiple myeloid CSF receptor promoters. Zhang DE, et al. **Curr Top Microbiol Immunol** 1996;211:137–47 (61 ref.)

SR proteins and splicing control. Manley JL, et al. **Genes Dev** 1996 Jul 1;10(13):1569–79 (93 ref.)

The NF–jun transcription factor in the hematopoietic response to mitogenic signals. Sott C, et al. **Immunobiology** 1995 Jul;193(2–4):149–54 (16 ref.)

BSAP: a key regulator of B–cell development and differentiation. Neurath MF, et al. **Immunol Today** 1995 Dec;16(12):564–9 (22 ref.)

Control of adipocyte differentiation by CCAAT/enhancer binding protein alpha (C/EBP alpha). Lane MD, et al. **Int J Obes Relat Metab Disord** 1996 Mar;20 Suppl 3:S91–6 (16 ref.)

The dynamic properties and possible functions of nuclear lamins. Moir RD, et al. **Int Rev Cytol** 1995;162B:141–82 (190 ref.)

Exploring nuclear pore complex structure and function in molecular detail. Panté N, et al. **J Cell Sci Suppl** 1995; 19:1–11 (60 ref.)

Enhancement of nuclear receptor transcriptional signalling. Renkawitz R, et al. **J Steroid Biochem Mol Biol** 1996 Jan; 56(1–6 Spec No):39–45 (29 ref.)

Identification and characterization of transcriptional regulatory elements of the human aromatase cytochrome P450 gene (CYP19). Toda K, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1–6 Spec No):151–9 (22 ref.)

Prothymosin alpha: in search of a function. Smith MR. **Leuk Lymphoma** 1995 Jul;18(3–4):209–14 (41 ref.)

Regulation of protein transport to the nucleus: central role of phosphorylation. Jans DA, et al. **Physiol Rev** 1996 Jul; 76(3):651–85 (400 ref.)

A new turn (or two) for twist [comment] Michelson AM. **Science** 1996 Jun 7;272(5267):1449–50 (15 ref.) Comment on: Science 1996 Jun 7;272(5267):1476–80. Comment on: Science 1996 Jun 7;272(5267):1481–4.

ULTRASTRUCTURE

Molecular dissection of the nuclear pore complex. Panté N, et al. **Crit Rev Biochem Mol Biol** 1996 Apr;31(2):153–99 (110 ref.)

NUCLEAR RADIOLOGY see **NUCLEAR MEDICINE**

NUCLEAR REACTOR ACCIDENTS see **ACCIDENTS, RADIATION**

NUCLEAR REACTORS

see related
ACCIDENTS, RADIATION

[Is the risk of leukemia increased for children near nuclear installations?] Auvinen A. **Duodecim** 1994;110(5):479–86 (39 ref.) **(Fin)**

[The sequelae of the Kyshtym and Chernobyl accidents for hydrobionts] Polikarpov GG, et al. **Radiats Biol Radioecol** 1995 Jul–Aug;35(4):536–49 (79 ref.) (Eng. Abstr.) **(Rus)**

[From Hiroshima to Chernobyl. Increasing number of late fatal cases of cancer] Drottz–Sjöberg BM, et al. **Lakartidningen** 1995 Nov 1;92(44):4100–2, 4105 (18 ref.) **(Swe)**

NUCLEAR RNA see **RNA, NUCLEAR**

NUCLEAR TRACK DETECTION see **RADIOMETRY**

NUCLEAR TRANS–ACTING FACTOR see **TRANS–ACTIVATORS**

NUCLEAR WARFARE

Radioepidemiology of the A–bomb survivors. Schull WJ. **Health Phys** 1996 Jun;70(6):798–803 (14 ref.)

Late effects of radiation on the human immune system: an overview of immune response among the atomic–bomb survivors. Akiyama M. **Int J Radiat Biol** 1995 Nov; 68(5):497–508 (79 ref.)

Cancer risks and biomarker studies in the atomic bomb survivors. Preston D. **Stem Cells (Dayt)** 1995 May;13 Suppl 1:40–8 (24 ref.)

NUCLEAR WASTE see **RADIOACTIVE WASTE**

NUCLEASES, DNA see **DEOXYRIBONUCLEASES**

NUCLEASES, RNA see **RIBONUCLEASES**

NUCLEIC ACID CONFORMATION

see related
POLYMORPHISM, SINGLE–STRANDED CONFORMATIONAL

Multi–helical DNA–binding domains: their structures and modes of DNA–binding. Suzuki M, et al. **Adv Biophys** 1996; 32:31–52 (88 ref.)

DNA conformation and its changes upon binding transcription factors. Suzuki M, et al. **Adv Biophys** 1996; 32:53–72 (47 ref.)

Mutational analysis of 16S ribosomal RNA structure and function in Escherichia coli. Triman KL. **Adv Genet** 1995; 33:1–39 (144 ref.)

Triplex DNA structures. Frank–Kamenetskii MD, et al. **Annu Rev Biochem** 1995;64:65–95 (212 ref.)

Force field development and conformational search strategy in the simulation of biomolecular recognition processes. Tenette C, et al. **Biochem Soc Trans** 1996 Feb;24(1):268–74 (43 ref.)

Ribosomal 5S RNA: tertiary structure and interactions with proteins. Barciszewska MZ, et al. **Biol Rev Camb Philos Soc** 1996 Feb;71(1):1–25 (135 ref.)

Secondary structure conservation of the U3 small nucleolar RNA introns in Saccharomyces. Brulé F, et al. **C R Acad Sci III** 1995 Dec;318(12):1197–206 (48 ref.)

The TATA box binding protein. Burley SK. **Curr Opin Struct Biol** 1996 Feb;6(1):69–75 (38 ref.)

Mean–field minimization methods for biological macromolecules. Koehl P, et al. **Curr Opin Struct Biol** 1996 Apr;6(2):222–6 (36 ref.)

RNA–protein complexes. Nagai K. **Curr Opin Struct Biol** 1996 Feb;6(1):53–61 (60 ref.)

Simulating DNA at low resolution. Olson WK. **Curr Opin Struct Biol** 1996 Apr;6(2):242–56 (76 ref.)

RNA folding. Pyle AM, et al. **Curr Opin Struct Biol** 1995 Jun;5(3):303–10 (53 ref.)

The design and engineering of nucleic acid nanoscale assemblies. Seeman NC. **Curr Opin Struct Biol** 1996 Aug; 6(4):519–26 (52 ref.)

Aggregated DNA in ethanol solution. Pilkur J, et al. **FEBS Lett** 1995 Nov 20;375(3):174–8 (38 ref.)

NUCLEIC ACID CONFORMATION

The RuvABC proteins and Holliday junction processing in Escherichia coli. West SC. **J Bacteriol** 1996 Mar; 178(5):1237–41 (59 ref.)
Alignment of 3 (but not 4) DNA strands within a RecA protein filament. Cox MM. **J Biol Chem** 1995 Nov 3; 270(44):26021–4 (68 ref.)
The biology of left-handed Z-DNA. Herbert A, et al. **J Biol Chem** 1996 May 17;271(20):11595–8 (76 ref.)
What is the orientation of DNA polymerases on their templates? Hughes SH, et al. **J Virol** 1996 May; 70(5):2679–83 (34 ref.)
RNA recognition and cleavage by iron(II)–bleomycin. Battigello JM, et al. **Met Ions Biol Syst** 1996;33:593–617 (98 ref.)
Evidences for a catalytic activity of the DNA double helix in the reaction between DNA, platinum(II), and intercalators. Boudvillain M, et al. **Met Ions Biol Syst** 1996; 33:87–104 (44 ref.)
Nickel complexes as probes of guanine sites in nucleic acid folding. Burrows CJ, et al. **Met Ions Biol Syst** 1996; 33:537–60 (41 ref.)
Targeting of nucleic acids by iron complexes. Draganescu A, et al. **Met Ions Biol Syst** 1996;33:453–84 (92 ref.)
Molecular modeling of transition metal complexes with nucleic acids and their constituents. Kozelka J. **Met Ions Biol Syst** 1996;33:1–28 (91 ref.)
Trans-diammineplatinum(II): what makes it different from cis-DDP? Coordination chemistry of a neglected relative of cisplatin and its interaction with nucleic acids. Lippert B. **Met Ions Biol Syst** 1996;33:105–41 (153 ref.)
Synthetic metallopeptides as probes of protein–DNA interactions. Long EC, et al. **Met Ions Biol Syst** 1996; 33:427–52 (65 ref.)
Electron transfer reactions through the DNA double helix. Meade TJ. **Met Ions Biol Syst** 1996;32:453–78 (85 ref.)
DNA interactions with substitution-inert transition metal ion complexes. Nordén B, et al. **Met Ions Biol Syst** 1996; 33:177–252 (210 ref.)
Porphyrin and metalloporphyrin interactions with nucleic acids. Pasternack RF, et al. **Met Ions Biol Syst** 1996; 33:367–97 (114 ref.)
Metallobleomycin–DNA interactions: structures and reactions related to bleomycin-induced DNA damage. Petering DH, et al. **Met Ions Biol Syst** 1996;33:619–48 (92 ref.)
Metal ions in multiple-stranded DNA. Sabat M, et al. **Met Ions Biol Syst** 1996;33:143–76 (148 ref.)
Ternary metal ion–nucleic acid base–protein complexes. Sabat M. **Met Ions Biol Syst** 1996;32:521–55 (153 ref.)
Nucleic acid chemistry of the cuprous complexes of 1,10-phenanthroline and derivatives. Sigman DS, et al. **Met Ions Biol Syst** 1996;33:485–513 (60 ref.)
Electron transfer between metal complexes bound to DNA: is DNA a wire? Stemp ED, et al. **Met Ions Biol Syst** 1996; 33:325–65 (75 ref.)
The crystallization and structure analysis of oligonucleotide sequences. Neidle S. **Methods Mol Biol** 1996;56:267–92 (82 ref.)
Refinement of protein and nucleic acid structures. Westhof E, et al. **Methods Mol Biol** 1996;56:227–44 (39 ref.)
Relaxing and unwinding on Holliday: DNA helicase–mediated branch migration. Adams DE, et al. **Mutat Res** 1995 Nov;337(3):149–59 (70 ref.)
Conformational properties of oligonucleotides. Gold L. **Nucleic Acids Symp Ser** 1995;(33):20–2 (9 ref.)
Eukaryotic nuclear RNase P: structures and functions. Chamberlain JR, et al. **Prog Nucleic Acid Res Mol Biol** 1996;55:87–119 (145 ref.)
S1-nuclease-sensitive DNA structures contribute to transcriptional regulation of the human PDGF A-chain. Wang ZY, et al. **Prog Nucleic Acid Res Mol Biol** 1996; 55:227–44 (110 ref.)
Analysis of the mechanism of DNA recombination using tangles. Sumners DW, et al. **Q Rev Biophys** 1995 Aug; 28(3):253–313 (85 ref.)
Intercalation, DNA kinking, and the control of transcription. Werner MH, et al. **Science** 1996 Feb 9;271(5250):778–84 (54 ref.)
Hammerhead ribozyme structure: U-turn for RNA structural biology. Doudna JA. **Structure** 1995 Aug 15;3(8):747–50 (20 ref.)
Counting the calories to stay in the groove. Ladbury JE. **Structure** 1995 Jul 15;3(7):635–9 (21 ref.)
Unraveling transposition: gamma delta resolvase in complex with DNA. Mondragón A. **Structure** 1995 Aug 15; 3(8):755–8 (16 ref.)
Action at a distance: DNA-looping and initiation of transcription. Rippe K, et al. **Trends Biochem Sci** 1995 Dec; 20(12):500–6 (39 ref.)
[Structural analysis of nucleic acids by the use of Raman microscope] Ueda T, et al. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1540–7 (19 ref.) **(Jpn)**
[A cracked state of the double-helical DNA] Volkov SN. **Mol Biol (Mosk)** 1995 Sep–Oct;29(5):1086–94 (29 ref.) **(Rus)**

NUCLEIC ACID DENATURATION

Aggregated DNA in ethanol solution. Pilkur J, et al. **FEBS Lett** 1995 Nov 20;375(3):174–8 (38 ref.)

NUCLEIC ACID HETERODUPLEXES

ANALYSIS

Applications of heteroduplex analysis for mutation detection in disease genes. Glavac D, et al. **Hum Mutat** 1995; 6(4):281–7 (75 ref.)

NUCLEIC ACID HYBRIDIZATION

see related
BLOTTING, SOUTHERN

[Dot hybridization] Shimada M. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):483–5 (3 ref.) **(Jpn)**

GENETICS

[Comparative genomic hybridization in pathology. A new molecular cytogenetic method] Störkel S, et al. **Pathologe** 1996 May;17(3):189–94 (19 ref.) (Eng. Abstr.) **(Ger)**

NUCLEIC ACID PROBES

see related
NUCLEIC ACID HYBRIDIZATION

[Detection of gene expression using digoxigenin-labeled probes] Kubota S, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):486–90 (14 ref.) **(Jpn)**

DIAGNOSTIC USE

[Current status and diagnostic value of nucleic acid amplification and conventional methods in laboratory diagnosis of tuberculosis] Küchler R. **Pneumologie** 1996 Apr;50(4):323–6 (19 ref.) **(Ger)**

NUCLEIC ACID REGULATORY SEQUENCES see **REGULATORY SEQUENCES, NUCLEIC ACID**

NUCLEIC ACID REPETITIVE SEQUENCES see **REPETITIVE SEQUENCES, NUCLEIC ACID**

NUCLEIC ACIDS

ANALYSIS

The digoxigenin (DIG) system for non-radioactive labelling and detection of nucleic acids--an overview. Höltke HJ, et al. **Cell Mol Biol (Noisy-le-grand)** 1995 Nov; 41(7):883–905 (48 ref.)
Robert Feulgen Prize Lecture 1995. New approaches to in situ detection of nucleic acids. Thiry M. **Histochem Cell Biol** 1995 Aug;104(2):81–95 (81 ref.)

CHEMISTRY

Salt–nucleic acid interactions. Anderson CF, et al. **Annu Rev Phys Chem** 1995;46:657–700 (63 ref.)
Peptide nucleic acids (PNA): synthesis, properties and potential applications. Hyrup B, et al. **Bioorg Med Chem** 1996 Jan;4(1):5–23 (66 ref.)
Backbone modifications in oligonucleotides and peptide nucleic acid systems. De Mesmaeker A, et al. **Curr Opin Struct Biol** 1995 Jun;5(3):343–55 (92 ref.)
Hydration and solution structure of nucleic acids. Kochoyan M, et al. **Curr Opin Struct Biol** 1995 Jun;5(3):329–33 (59 ref.)
Salt effects on nucleic acids. Sharp KA, et al. **Curr Opin Struct Biol** 1995 Jun;5(3):323–8 (35 ref.)
New crystal structures of nucleic acids and their complexes. Wahl MC, et al. **Curr Opin Struct Biol** 1995 Jun;5(3):282–95 (77 ref.)
Molecular modeling of transition metal complexes with nucleic acids and their constituents. Kozelka J. **Met Ions Biol Syst** 1996;33:1–28 (91 ref.)
[Nucleic acid chemistry and protein engineering] Ikehara M. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1660–2 (0 ref.) **(Jpn)**
[Stable isotopic labeling and NMR analyses of nucleic acids] Kawai G. **Tanpakushitsu Kakusan Koso** 1994 Jul; 40(10):1502–8 (47 ref.) **(Jpn)**
[Preparation of stable isotope labeled DNA oligomers: applications to the structural analysis of nucleic acids by heteronuclear multidimensional NMR spectroscopy] Ono A, et al. **Tanpakushitsu Kakusan Koso** 1994 Jul; 40(10):1509–17 (21 ref.) **(Jpn)**

GENETICS

Nucleic acid amplification and related techniques in microbiological diagnostics and epidemiology. Van Belkum A, et al. **Cell Mol Biol (Noisy-le-grand)** 1995 Jul; 41(5):615–23 (48 ref.)
RT-PCR and alternative methods to PCR for in vitro amplification of nucleic acids. Hagen-Mann K, et al. **Exp Clin Endocrinol Diabetes** 1995;103(3):150–5 (22 ref.)
[The noncanonical base pairings in crystal structure] Fujii S. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1518–26 (38 ref.) **(Jpn)**

ISOLATION & PURIFICATION

Nucleic acids in the environment. Trevors JT. **Curr Opin Biotechnol** 1996 Jun;7(3):331–6 (33 ref.)

PHARMACOLOGY

Peptide nucleic acids (PNA): synthesis, properties and potential applications. Hyrup B, et al. **Bioorg Med Chem** 1996 Jan;4(1):5–23 (66 ref.)

NUCLEOLAR PROTEINS see **NUCLEAR PROTEINS**

NUCLEOLYSIS, INTERVERTEBRAL DISK see **INTERVERTEBRAL DISK CHEMOLYSIS**

NUCLEOPROTEINS

ANALYSIS

Atomic force microscopy of nucleoprotein complexes. Lyubchenko YL, et al. **Scanning Microsc** 1995 Sep; 9(3):705–24; discussion 724–7 (118 ref.)

GENETICS

Nucleoprotein architecture of the albumin transcriptional enhancer. Zaret KS. **Semin Cell Biol** 1995 Aug;6(4):209–18 (56 ref.)

IMMUNOLOGY

[Pure cerebellar syndrome associated with anti-Hu antibodies] Pradat PF, et al. **Rev Neurol (Paris)** 1995 May; 151(5):341–3 (12 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Recombination. Pieces of the site-specific recombination puzzle. Oram M, et al. **Curr Biol** 1995 Oct 1;5(10):1106–9 (20 ref.)

NUCLEOSIDASES

IMMUNOLOGY

Murine CD38: an immunoregulatory ectoenzyme. Lund F, et al. **Immunol Today** 1995 Oct;16(10):469–73 (46 ref.)

METABOLISM

New aspects of the physiological significance of NAD, poly ADP-ribose and cyclic ADP-ribose. Okamoto H, et al. **Biochimie** 1995;77(5):356–63 (41 ref.)
Enzyme structures. DNA repair flips out. Demple B. **Curr Biol** 1995 Jul 1;5(7):719–21 (11 ref.)

NUCLEOSIDE-PHOSPHATE KINASE

PHYSIOLOGY

Zonula occludens (ZO)-1 and ZO-2: membrane-associated guanylate kinase homologues (MAGuKs) of the tight junction. Anderson JM, et al. **Biochem Soc Trans** 1995 Aug; 23(3):470–5 (45 ref.)
Tight junctions, membrane-associated guanylate kinases and cell signaling. Kim SK. **Curr Opin Cell Biol** 1995 Oct; 7(5):641–9 (71 ref.)

NUCLEOSIDES

Radiosensitizing nucleosides. McGinn CJ, et al. **J Natl Cancer Inst** 1996 Sep 4;88(17):1193–203 (107 ref.)
Effect of metal ions on the hydrolytic reactions of nucleosides and their phosphoesters. Kuusela S, et al. **Met Ions Biol Syst** 1996;32:271–300 (107 ref.)
Mechanistic insight from kinetic studies on the interaction of model palladium (II) complexes with nucleic acid components. Rau T, et al. **Met Ions Biol Syst** 1996; 32:339–78 (95 ref.)
[Mechanisms of nucleoside–analog mutagenesis] Negishi K, et al. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1564–70 (55 ref.) **(Jpn)**
[Modified nucleosides of tRNA in decoding] Ueda T, et al. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1465–73 (17 ref.) **(Jpn)**

CHEMICAL SYNTHESIS

[New and large scale syntheses of nucleoside polyphosphates] Ishikawa M, et al. **Tanpakushitsu Kakusan Koso** 1994 Jul; 40(10):1333–41 (22 ref.) **(Jpn)**
[Synthesis of novel nucleosides: carbocyclic nucleosides] Katagiri N, et al. **Tanpakushitsu Kakusan Koso** 1994 Jul; 40(10):1219–31 (54 ref.) **(Jpn)**
[Advance in synthesis of sugar-modified nucleosides] Ohrui H. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1195–210 (76 ref.) **(Jpn)**

CHEMISTRY

The importance of being modified: roles of modified nucleosides and Mg2+ in RNA structure and function. Agris PF. **Prog Nucleic Acid Res Mol Biol** 1996;53:79–129 (175 ref.)
[Mechanism of anti-leishmanial drugs on the basis of the nucleoside structures] Shin I, et al. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1293–8 (28 ref.) **(Jpn)**

METABOLISM

Hepatic purine and pyrimidine metabolism: implications for antiviral chemotherapy of viral hepatitis. Shaw T, et al. **Liver** 1995 Aug;15(4):169–84 (117 ref.)
Nucleobase and nucleoside transport in mammalian cells. Kraupp M, et al. **Wien Klin Wochenschr** 1995; 107(22):677–80 (36 ref.)

PHARMACOKINETICS

Passive and facilitative transport of nucleobases, nucleosides, and oligonucleotides—application to antiviral and other therapies. Brewster ME, et al. **NIDA Res Monogr** 1995; 154:61–85 (62 ref.)

PHARMACOLOGY

Trophic actions of extracellular nucleotides and nucleosides on glial and neuronal cells. Neary JT, et al. **Trends Neurosci** 1996 Jan;19(1):13–8 (84 ref.)
[Inhibitors of inosine monophosphate dehydrogenase and their biological activities] Minakawa N, et al. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1299–305 (32 ref.) **(Jpn)**
[Mechanism of anti-leishmanial drugs on the basis of the nucleoside structures] Shin I, et al. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1293–8 (28 ref.) **(Jpn)**
[Nucleosides and related compounds which act as inhibitors against replication of HIV-1] Tanaka H, et al. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1250–60 (27 ref.) **(Jpn)**

THERAPEUTIC USE

[Nucleoside analogues as anti-herpes agents and their mode of action] Maruyama T. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1242–9 (22 ref.) **(Jpn)**

NUCLEOSOMES

CHEMISTRY

Trinucleotide models for DNA bending propensity: comparison of models based on DNaseI digestion and nucleosome packaging data. Brukner I, et al. **J Biomol Struct Dyn** 1995 Oct;13(2):309–17 (28 ref.)
The histone fold: evolutionary questions. Ramakrishnan V. **Proc Natl Acad Sci U S A** 1995 Dec 5;92(25):11328–30 (30 ref.)

GENETICS

Interplay between nucleosomes and transcription factors at the yeast PHO5 promoter. Svaren J, et al. **Semin Cell Biol** 1995 Aug;6(4):177–83 (52 ref.)

IMMUNOLOGY

Apoptosis, nucleosomes, and nephritis in systemic lupus erythematosus [editorial] Tax WJ, et al. **Kidney Int** 1995 Sep;48(3):666–73 (88 ref.)
Central role for nucleosomes in lupus [editorial] van Bruggen MC, et al. **Nephrol Dial Transplant** 1996 Jul;11(7):1219–22 (22 ref.)

PHYSIOLOGY

Chromatin. Nucleosome assembly during DNA replication. Krude T. **Curr Biol** 1995 Nov 1;5(11):1232–4 (17 ref.)
Regulation of gene expression by nucleosomes. Svaren J, et al. **Curr Opin Genet Dev** 1996 Apr;6(2):164–70 (63 ref.)

5'-NUCLEOTIDASE

BLOOD

[5'-Nucleotidase] Shibata H. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:329–32 (26 ref.) **(Jpn)**

METABOLISM

Activation of ecto-5'-nucleotidase and cardioprotection by ischemic preconditioning. Kitakaze M, et al. **Basic Res Cardiol** 1996 Jan–Feb;91(1):23–6 (8 ref.)
Mammalian deoxyribonucleoside kinases. Arnér ES, et al. **Pharmacol Ther** 1995;67(2):155–86 (241 ref.)

NUCLEOTIDE SEQUENCE see **BASE SEQUENCE**

NUCLEOTIDES

see related
BASE SEQUENCE

Minireview: nucleotide prodrugs. Jones RJ, et al. **Antiviral Res** 1995 May;27(1–2):1–17 (119 ref.)
Effect of metal ions on the hydrolytic reactions of nucleosides and their phosphoesters. Kuusela S, et al. **Met Ions Biol Syst** 1996;32:271–300 (107 ref.)
Mechanistic insight from kinetic studies on the interaction of model palladium (II) complexes with nucleic acid components. Rau T, et al. **Met Ions Biol Syst** 1996; 32:339–78 (95 ref.)
[RNase T1-nucleotide interaction] Hakoshima T. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1627–34 (32 ref.) **(Jpn)**

BIOSYNTHESIS

Enzymes of nucleotide biosynthesis: differences between intact and lysed cells as well as between species and tissues can be important. Simmonds HA. **Biochem Soc Trans** 1995 Nov;23(4):877–9 (11 ref.)

METABOLISM

Membrane transport of nucleobases: interaction with inhibitors. Kraupp M, et al. **Gen Pharmacol** 1995 Oct; 26(6):1185–90 (29 ref.)
Exploring the nucleotide-binding site in proteins by affinity labeling and site-directed mutagenesis. Fukui T. **J Biochem (Tokyo)** 1995 Jun;117(6):1139–44 (45 ref.)
Role of renal handling of extracellular nucleotides in modulation of phosphate transport. Friedlander G, et al. **Kidney Int** 1996 Apr;49(4):1019–22 (43 ref.)
The role of glutamine, short-chain fatty acids, and nucleotides in intestinal adaptation to gastrointestinal disease. LeLeiko NS, et al. **Pediatr Clin North Am** 1996 Apr;43(2):451–70 (98 ref.)

PHARMACOLOGY

Trophic actions of extracellular nucleotides and nucleosides on glial and neuronal cells. Neary JT, et al. **Trends Neurosci** 1996 Jan;19(1):13–8 (84 ref.)

PHYSIOLOGY

Cardiac ATP-sensitive K+ channels: regulation by intracellular nucleotides and K+ channel-opening drugs. Terzic A, et al. **Am J Physiol** 1995 Sep;269(3 Pt 1):C525–45 (196 ref.)

NUCLEOTIDES, CYCLIC

METABOLISM

Molecular characterization of voltage and cyclic nucleotide-gated potassium channels in kidney. Desir GV. **Kidney Int** 1995 Oct;48(4):1031–5 (57 ref.)

PHYSIOLOGY

Cyclic nucleotide gated channels. Zimmerman AL. **Curr Opin Neurobiol** 1995 Jun;5(3):296–303 (62 ref.)
Regulation of phospholamban and troponin-I phosphorylation in the intact rat cardiomyocytes by adrenergic and cholinergic stimuli: roles of cyclic nucleotides, calcium, protein kinases and phosphatases and depolarization. Sulakhe PV, et al. **Mol Cell Biochem** 1995 Aug–Sep;149–150:103–26 (96 ref.)

NUCLEOTIDYLTRANSFERASES

CHEMISTRY

Unraveling transposition: gamma delta resolvase in complex with DNA. Mondragón A. **Structure** 1995 Aug 15; 3(8):755–8 (16 ref.)

GENETICS

The Tc1/mariner transposon family. Plasterk RH. **Curr Top Microbiol Immunol** 1996;204:125–43 (98 ref.)
RNA capping enzyme and DNA ligase: a superfamily of covalent nucleotidyl transferases. Shuman S, et al. **Mol Microbiol** 1995 Aug;17(3):405–10 (36 ref.)

METABOLISM

Unraveling transposition: gamma delta resolvase in complex with DNA. Mondragón A. **Structure** 1995 Aug 15; 3(8):755–8 (16 ref.)

NUCLEUS ACCUMBENS

PHYSIOLOGY

The role of mesolimbic dopaminergic and retrohippocampal afferents to the nucleus accumbens in latent inhibition: implications for schizophrenia. Gray JA, et al. **Behav Brain Res** 1995 Nov;71(1–2):19–31 (80 ref.)
Simulation of spatial learning in the Morris water maze by a neural network model of the hippocampal formation and nucleus accumbens. Brown MA, et al. **Hippocampus** 1995; 5(3):171–88 (73 ref.)
The behavioral neurochemistry of motivation: methodological and conceptual issues in studies of the dynamic activity of nucleus accumbens dopamine. Salamone JD. **J Neurosci Methods** 1996 Feb;64(2):137–49 (152 ref.)

PHYSIOPATHOLOGY

Dopamine release in the nucleus accumbens: the perspective from aberrations of consciousness in schizophrenia. Gray JA. **Neuropsychologia** 1995 Sep;33(9):1143–53 (53 ref.)

NUCLEUS DENTATUS see **CEREBELLAR NUCLEI**

NUCLEUS SOLITARIUS see **SOLITARY NUCLEUS**

NURSE ADMINISTRATORS

Healthcare violence. A nursing administration perspective. Claravall L. **J Nurs Adm** 1996 Feb;26(2):41–6 (29 ref.)
Managed care and total quality management: a necessary integration. Phoon J, et al. **J Nurs Care Qual** 1996 Jan; 10(2):25–32 (22 ref.)
Nurse-managed primary care center. Newland JA, et al. **Nurs Clin North Am** 1996 Sep;31(3):471–86 (20 ref.)

ORGANIZATION & ADMINISTRATION

Improving nursing practice, education, and research. Fagin CM. **J Nurs Adm** 1996 Mar;26(3):30–7 (12 ref.)

PSYCHOLOGY

Management of conflict: do nurses/women handle it differently? Valentine PE. **J Adv Nurs** 1995 Jul;22(1):142–9 (77 ref.)

NURSE ANESTHETISTS

Clinical aspects of nurse anesthesia practice. Sedation and monitored anesthesia care. Booth M. **Nurs Clin North Am** 1996 Sep;31(3):667–82 (14 ref.)

NURSE CLINICIANS

The clinical nurse specialist: a way forward? Miller S. **J Adv Nurs** 1995 Sep;22(3):494–501 (24 ref.)
A model of home care for high-risk childbearing families. Women with diabetes in pregnancy. Persily CA, et al. **Nurs Clin North Am** 1996 Jun;31(2):327–32 (11 ref.)
Titling for advanced practice nurses. Hawkins JW, et al. **Oncol Nurs Forum** 1995 Sep;22(8 Suppl):5–9 (47 ref.)
The specialist nurse in HIV/AIDS medicine. Whitehead CM. **Postgrad Med J** 1996 Apr;72(846):211–3 (6 ref.)

EDUCATION

Education of the advanced practice nurse in oncology. Belcher A, et al. **Oncol Nurs Forum** 1995 Sep;22(8 Suppl):19–24 (31 ref.)
Regulation of advanced nursing practice: Part One—Second licensure. Greco KE. **Oncol Nurs Forum** 1995 Sep;22(8 Suppl):35–8 (7 ref.)
Regulation of advanced nursing practice: Part Two—Certification. Spencer-Cisek P, et al. **Oncol Nurs Forum** 1995 Sep;22(8 Suppl):39–42 (12 ref.)

ORGANIZATION & ADMINISTRATION

The future of the clinical nurse specialist in the USA. Briody ME. **Int Nurs Rev** 1996 Jan–Feb;43(1):17–20, 31 (25 ref.)
Documentation and outcomes of advanced nursing practice. Boyle DM. **Oncol Nurs Forum** 1995 Sep;22(8 Suppl):11–7 (57 ref.)
Reimbursement issues for advanced practice. Camp-Sorrell D, et al. **Oncol Nurs Forum** 1995 Sep;22(8 Suppl):31–4 (11 ref.)
Prescriptive authority for advanced practice nurses: current and future perspectives. McDermott KC. **Oncol Nurs Forum** 1995 Sep;22(8 Suppl):25–30 (33 ref.)

PSYCHOLOGY

Empowerment of graduate nursing students: a dialogue toward change. Roberts SJ, et al. **J Prof Nurs** 1996 Jul–Aug;12(4):233–9 (25 ref.)

NURSE MIDWIVES

The diagnosis of foetal distress: a challenge to midwives. Mead M. **J Adv Nurs** 1996 May;23(5):975–83 (73 ref.)
Primary care for women. Assessment and management of headache. Barrett E. **J Nurse Midwifery** 1996 Mar–Apr; 41(2):117–24 (23 ref.)
Primary care for women. Management of common musculoskeletal disorders. Benetti MC, et al. **J Nurse Midwifery** 1996 Mar–Apr;41(2):173–87 (40 ref.)
Home birth with certified nurse-midwife attendants in the United States. An overview. Jackson ME, et al. **J Nurse Midwifery** 1995 Nov–Dec;40(6):493–507 (118 ref.)
Primary care for women. Management of common respiratory problems. Mays M, et al. **J Nurse Midwifery** 1996 Mar–Apr;41(2):139–54 (50 ref.)
In pursuit of excellence: quality assurance, documentation, and peer review by home birth CNMs. Morales ME, et al. **J Nurse Midwifery** 1995 Nov–Dec;40(6):555–69 (56 ref.)
Primary care for women. Management of common problems of the head and neck. Phillips LP, et al. **J Nurse Midwifery** 1996 Mar–Apr;41(2):101–16 (55 ref.)
Delayed reporting of sexual assault. Implications for counseling. Plumbo MA. **J Nurse Midwifery** 1995 Sep–Oct; 40(5):424–7 (9 ref.)
Primary care for women. Management and treatment of gastrointestinal disorders. Shaw B. **J Nurse Midwifery** 1996 Mar–Apr;41(2):155–72 (20 ref.)
Informed consent and home birth. Spindel PG, et al. **J Nurse Midwifery** 1995 Nov–Dec;40(6):541–69 (56 ref.)
Neonatal considerations when birth occurs at home. Toepke ML, et al. **J Nurse Midwifery** 1995 Nov–Dec;40(6):529–33 (29 ref.)
Primary care for women. Comprehensive assessment and

management of common mental health problems. Weintraub TA, et al. **J Nurse Midwifery** 1996 Mar–Apr; 41(2):125–38 (53 ref.)

The role of midlevel providers in cancer screening. Reed CA, et al. **Med Clin North Am** 1996 Jan;80(1):135–44 (34 ref.)

Nurse midwifery. Advanced practice nursing? Burkhardt P. **Nurs Clin North Am** 1996 Sep;31(3):439–48 (23 ref.)

[Advantages and disadvantages of induced labor without medical indications: the viewpoint of the midwife] Kovacs C. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24 Suppl 1:89–93 (22 ref.) **(Fre)**

ORGANIZATION & ADMINISTRATION

Bridging the gap between hospital and home for premature infants in Malawi. Mbweza E. **Int Nurs Rev** 1996 Mar–Apr; 43(2):53–7 (19 ref.)

Certified nurse midwives: over twenty years of military service. Davis LJ. **Mil Med** 1995 Aug;160(8):401–4 (20 ref.)

STANDARDS

Care of the at–risk neonate born at home. A model for nurse–midwife/physician collaboration. Sullivan NH, et al. **J Nurse Midwifery** 1995 Nov–Dec;40(6):534–40 (16 ref.)

NURSE–PATIENT RELATIONS

"Methodological notes on empathy": further considerations. Bennett JA. **ANS Adv Nurs Sci** 1995 Sep;18(1):36–50 (57 ref.)

Evaluation of the Interaction Model of Client Health Behavior through the first decade of research. Carter KF, et al. **ANS Adv Nurs Sci** 1995 Sep;18(1):62–73 (47 ref.)

Advocacy and empowerment: dichotomous or synchronous concepts? Rafael AR. **ANS Adv Nurs Sci** 1995 Dec; 18(2):25–32 (56 ref.)

Schema model of the self–concept. Stein KF. **Image J Nurs Sch** 1995 Fall;27(3):187–93 (60 ref.)

Reformulation of deviance and labeling theory for nursing. Trexler JC. **Image J Nurs Sch** 1996 Summer;28(2):131–5 (39 ref.)

Towards an individualized client's care: implication for education. The transcultural approach. Abdullah SN. **J Adv Nurs** 1995 Oct;22(4):715–20 (36 ref.)

Terms of address: implications for nursing. Bowie I. **J Adv Nurs** 1996 Jan;23(1):113–9 (17 ref.)

Professional caring: the moral dimension. Fealy GM. **J Adv Nurs** 1995 Dec;22(6):1135–40 (18 ref.)

A selective review of the literature on nurse–patient communication: has the patient's contribution been neglected? Jarrett N, et al. **J Adv Nurs** 1995 Jul;22(1):72–8 (51 ref.)

Social support: some pragmatic implications for health care professionals. Keeling DI, et al. **J Adv Nurs** 1996 Jan; 23(1):76–81 (36 ref.)

Nursing, humanism and transcultural theory: the 'bracketing–out' of reality. Mulholland J. **J Adv Nurs** 1995 Sep;22(3):442–9 (43 ref.)

An analysis of the concept of empowerment. Rodwell CM. **J Adv Nurs** 1996 Feb;23(2):305–13 (74 ref.)

Theoretical and practical considerations on the use of reassurance in the nursing management of anxious patients. Teasdale K. **J Adv Nurs** 1995 Jul;22(1):79–86 (61 ref.)

Hope: implications for neuroscience nursing. Fowler SB. **J Neurosci Nurs** 1995 Oct;27(5):298–304 (47 ref.)

Cultural diversity: a nursing concept not yet reliably defined. Habayeb GL. **Nurs Outlook** 1995 Sep–Oct;43(5):224–7 (45 ref.)

Informed consent: process and clinical issues. Berry DL, et al. **Oncol Nurs Forum** 1996 Apr;23(3):507–12 (19 ref.)

Psychoneuroimmunology and innovative behavioral interventions in patients with leukemia. Caudell KA. **Oncol Nurs Forum** 1996 Apr;23(3):493–502 (60 ref.)

NURSE PRACTITIONERS

Professionalization of nurse practitioners. Bullough B. **Annu Rev Nurs Res** 1995;13:239–65 (106 ref.)

The role of midlevel providers in cancer screening. Reed CA, et al. **Med Clin North Am** 1996 Jan;80(1):135–44 (34 ref.)

The role of the psychiatric nurse practitioner. Caverly SE. **Nurs Clin North Am** 1996 Sep;31(3):449–63 (36 ref.)

Planning for pediatric laceration repairs. Brokaw A, et al. **Nurse Pract** 1996 Mar;21(3):42, 45, 49 (3 ref.)

Promoting the nurse practitioner by using a marketing approach. Gallagher SM. **Nurse Pract** 1996 Mar;21(3):30, 36–7, 40 (21 ref.)

Recurrent aphthous stomatitis: primary care management. Petersen MJ, et al. **Nurse Pract** 1996 May;21(5):36–40, 42, 47 (32 ref.)

Titling for advanced practice nurses. Hawkins JW, et al. **Oncol Nurs Forum** 1995 Sep;22(8 Suppl):5–9 (47 ref.)

EDUCATION

The future of graduate education in nursing: scholarship, the health of communities, and health care reform. Hall JM, et al. **J Prof Nurs** 1995 Nov–Dec;11(6):332–8 (22 ref.)

The preparation of advanced practice nurses. Current issues. O'Flynn AI. **Nurs Clin North Am** 1996 Sep;31(3):429–38 (20 ref.)

Education of the advanced practice nurse in oncology. Belcher A, et al. **Oncol Nurs Forum** 1995 Sep;22(8 Suppl):19–24 (31 ref.)

Regulation of advanced nursing practice: Part One—Second licensure. Greco KE. **Oncol Nurs Forum** 1995 Sep;22(8 Suppl):35–8 (7 ref.)

Regulation of advanced nursing practice: Part Two—Certification. Spencer–Cisek P, et al. **Oncol Nurs Forum** 1995 Sep;22(8 Suppl):39–42 (12 ref.)

ORGANIZATION & ADMINISTRATION

The future of the clinical nurse specialist in the USA. Briody ME. **Int Nurs Rev** 1996 Jan–Feb;43(1):17–20, 31 (25 ref.)

Nurse practitioners in a teaching hospital. Genet CA, et al. **Nurse Pract** 1995 Sep;20(9):47–52, 54 (33 ref.)

Documentation and outcomes of advanced nursing practice. Boyle DM. **Oncol Nurs Forum** 1995 Sep;22(8 Suppl):11–7 (57 ref.)

Reimbursement issues for advanced practice. Camp–Sorrell D, et al. **Oncol Nurs Forum** 1995 Sep;22(8 Suppl):31–4 (11 ref.)

Prescriptive authority for advanced practice nurses: current and future perspectives. McDermott KC. **Oncol Nurs Forum** 1995 Sep;22(8 Suppl):25–30 (33 ref.)

PSYCHOLOGY

Empowerment of graduate nursing students: a dialogue toward change. Roberts SJ, et al. **J Prof Nurs** 1996 Jul–Aug;12(4):233–9 (25 ref.)

NURSERIES

see related
CHILD DAY CARE CENTERS

NURSES

Roles of nurses and health workers in cardiovascular health promotion. Hill MN, et al. **Am J Med Sci** 1995 Dec;310 Suppl 1:S123–6 (16 ref.)

Nurse–physician collaboration: a poststructuralist view. Henneman EA. **J Adv Nurs** 1995 Aug;22(2):359–63 (15 ref.)

Nurses: at special risk. Jackson MM, et al. **J Obstet Gynecol Neonatal Nurs** 1995 Jul–Aug;24(6):533–40 (37 ref.)

ORGANIZATION & ADMINISTRATION

Women's health. The role of advanced practice nurses in the 21st century. Spatz DL. **Nurs Clin North Am** 1996 Jun; 31(2):269–77 (16 ref.)

PSYCHOLOGY

Anger in nurses: don't lose it, use it. Droppleman PG, et al. **Am J Nurs** 1996 Apr;96(4):26–31; quiz 32 (11 ref.)

The nurse–doctor relationship: a selective literature review. Sweet SJ, et al. **J Adv Nurs** 1995 Jul;22(1):165–70 (41 ref.)

Nurses' attitudes about acquired immunodeficiency syndrome care: what research tells us. Bennett JA. **J Prof Nurs** 1995 Nov–Dec;11(6):339–50 (67 ref.)

Perinatally transmitted HIV infection. Supporting the helpers. Burr CK. **Nurs Clin North Am** 1996 Mar; 31(1):243–51 (21 ref.)

STANDARDS

Past–present–future messages for nursing leadership. Kelley LS. **J Prof Nurs** 1996 Mar–Apr;12(2):76–85 (33 ref.)

NURSES' AIDES

ORGANIZATION & ADMINISTRATION

The impact of multiskilling on quality of care. Holzemer WL. **Int Nurs Rev** 1996 Jan–Feb;43(1):21–5 (32 ref.)

NURSES, HEAD see **NURSING, SUPERVISORY**

NURSES, MALE

Gender differences in career progress in nursing: towards a non–essentialist structural theory. Ratcliffe P. **J Adv Nurs** 1996 Feb;23(2):389–95 (48 ref.)

NURSES PERFORMANCE EVALUATION see **EMPLOYEE PERFORMANCE APPRAISAL**

NURSING

see related
EDUCATION, NURSING
LEGISLATION, NURSING

Creating a nursing home page on the World Wide Web. Shellenbarger T, et al. **Comput Nurs** 1996 Jul–Aug; 14(4):239–45 (15 ref.)

Nursing informatics: state of the science. Henry SB. **J Adv Nurs** 1995 Dec;22(6):1182–92 (83 ref.)

The role of nursing journals in the advancement of professional nursing. Smith JP. **J Adv Nurs** 1996 Jan; 23(1):12–6 (7 ref.)

Health care rationing: nursing perspectives. Wells JS. **J Adv Nurs** 1995 Oct;22(4):738–44 (59 ref.)

MANPOWER

Transformation of the nursing workforce. Aiken LH. **Nurs Outlook** 1995 Sep–Oct;43(5):201–9 (36 ref.)

ORGANIZATION & ADMINISTRATION

Feminism and nursing. Chinn PL. **Annu Rev Nurs Res** 1995; 13:267–89 (110 ref.)

Challenging old notions of professionalism: how can nurses work with paraprofessional ethnic health workers? Fuller J. **J Adv Nurs** 1995 Sep;22(3):465–72 (44 ref.)

Joint nursing appointments: a vehicle for influencing health care change. Tamlyn D, et al. **J Adv Nurs** 1995 Sep; 22(3):490–3 (18 ref.)

TRENDS

Technology, deskilling, and nurses: the impact of the technologically changing environment. Rinard RG. **ANS Adv Nurs Sci** 1996 Jun;18(4):60–9 (49 ref.)

NURSING ADMINISTRATION RESEARCH

Case management. Lamb GS. **Annu Rev Nurs Res** 1995; 13:117–36 (46 ref.)

Technology and home care. Smith CE. **Annu Rev Nurs Res** 1995;13:137–67 (234 ref.)

STATISTICS & NUMERICAL DATA

The nature of nursing administration research. Knowledge building or fire stomping? Lynn MR, et al. **J Nurs Adm** 1996 May;26(5):9–14 (11 ref.)

NURSING ASSESSMENT

Identifying chronic peripheral arterial disease. Cantwell–Gab K. **Am J Nurs** 1996 Jul;96(7):40–6; quiz 47 (11 ref.)

Performing foot screening for diabetic patients. Dorgan MB, et al. **Am J Nurs** 1995 Nov;95(11):32–6; quiz 37 (12 ref.)

Managing vascular leg ulcers. Part 1: Assessment [see comments] Harris AH, et al. **Am J Nurs** 1996 Jan; 96(1):38–43; quiz 44 (5 ref.) Comment in: Am J Nurs 1996 Jun;96(6):17.

Assessing fluid and electrolyte balance in elders. O'Donnell ME. **Am J Nurs** 1995 Nov;95(11):40–5; quiz 46 (11 ref.)

Cognitive effects of electroconvulsive therapy: a clinical review for nurses. Durr AL, et al. **Convuls Ther** 1995 Sep; 11(3):192–201 (33 ref.)

The cognitive component of nursing assessment: an analysis. Crow RA, et al. **J Adv Nurs** 1995 Aug;22(2):206–12 (44 ref.)

Assessment of the cardiovascular effects of stress. Engler MB, et al. **J Cardiovasc Nurs** 1995 Oct;10(1):51–63 (85 ref.)

Diagnostic and functional exercise testing: test selection and interpretation. Franklin BA. **J Cardiovasc Nurs** 1995 Oct; 10(1):8–29 (57 ref.)

Risk profile screening. Froelicher ES, et al. **J Cardiovasc Nurs** 1995 Oct;10(1):30–50 (89 ref.)

Assessment of quality of life in recovery settings. Kinney MR. **J Cardiovasc Nurs** 1995 Oct;10(1):88–96 (41 ref.)

Assessing social support in patients with cardiac disease. McCauley KM. **J Cardiovasc Nurs** 1995 Oct;10(1):73–80 (28 ref.)

Drug profiles: maximizing therapeutic effectiveness. Porter LA, et al. **J Cardiovasc Nurs** 1995 Oct;10(1):64–72 (29 ref.)

Nursing assessment and management strategies for urinary incontinence. Ravalli R, et al. **J Endourol** 1996 Jun; 10(3):297–300 (14 ref.)

A discharge check list for psychiatric patients. Hochberger JM. **J Psychosoc Nurs Ment Health Serv** 1995 Dec; 33(12):35–8 (13 ref.)

Integrating family–centered developmental assessment and intervention into routine care in the neonatal intensive care unit. McGrath JM, et al. **Nurs Clin North Am** 1996 Jun; 31(2):367–86 (104 ref.)

Nursing management of patients receiving biological therapy. Sandstrom SK. **Semin Oncol Nurs** 1996 May;12(2):152–62 (34 ref.)

Selection of vascular access devices and nursing care. Winslow MN, et al. **Semin Oncol Nurs** 1995 Aug; 11(3):167–73 (37 ref.)

METHODS

Symbiosis of nurse and machine through fuzzy logic: improved specificity of a neonatal pulse oximeter alarm. Bosque EM. **ANS Adv Nurs Sci** 1995 Dec;18(2):67–75 (60 ref.)

Dyspnoea: a study of measurement instruments for the assessment of dyspnoea and their application for patients with advanced cancer. van der Molen B. **J Adv Nurs** 1995 Nov;22(5):948–56 (49 ref.)

Interviewing the young child sexual abuse victim. Lewin L. **J Psychosoc Nurs Ment Health Serv** 1995 Jul;33(7):5–10 (26 ref.)

Guidelines for assessing HIV in women. Sipes C. **MCN Am J Matern Child Nurs** 1995 Jan–Feb;20(1):29–33 (28 ref.)

NURSING CARE

What every woman should know about menopause. Wasaha

S, et al. **Am J Nurs** 1996 Jan;96(1):24–32; quiz 33 (9 ref.)
Advance directives and opportunities for nurses. Johns JL. **Image J Nurs Sch** 1996 Summer;28(2):149–53 (52 ref.)
The proper focus of nursing: a critique of the "caring" ideology. Barker PJ, et al. **Int J Nurs Stud** 1995 Aug; 32(4):386–97 (44 ref.)
A nursing perspective on the interrelationships between theory, research and practice. Pryjmachuk S. **J Adv Nurs** 1996 Apr;23(4):679–84 (19 ref.)
The theory/practice "gap": taking issue with the issue. Rafferty AM, et al. **J Adv Nurs** 1996 Apr;23(4):685–91 (44 ref.)
Barriers and facilitators of research utilization. An integrative review. Funk SG, et al. **Nurs Clin North Am** 1995 Sep; 30(3):395–407 (79 ref.)
Caring advanced nursing practice [letter] Martin SR. **Nurse Pract** 1995 Nov;20(11 Pt 1):16, 21, 23 (29 ref.)
The contrary ideals of individualism and nursing value of care. Katims I. **Sch Inq Nurs Pract** 1995 Fall;9(3):231–40; discussion 241–4 (30 ref.)

METHODS

Positioning your patient properly. Metzler DJ, et al. **Am J Nurs** 1996 Mar;96(3):33–7 (21 ref.)
Reflective practice: reviewing the issues and refocusing the debate. Clarke B, et al. **Int J Nurs Stud** 1996 Apr; 33(2):171–80 (24 ref.)
A classical view of the theory–practice gap in nursing. Allmark P. **J Adv Nurs** 1995 Jul;22(1):18–23 (23 ref.)
Helping the vulnerable or condoning control within the family: where is nursing? Cody A. **J Adv Nurs** 1996 May; 23(5):882–6 (51 ref.)
Theoretical and practical considerations on the use of reassurance in the nursing management of anxious patients. Teasdale K. **J Adv Nurs** 1995 Jul;22(1):79–86 (61 ref.)
Nursing theory: everything the artist spits is art? Timpson J. **J Adv Nurs** 1996 May;23(5):1030–6 (65 ref.)
Try to remember ... reminiscence as a nursing intervention. Nugent E. **J Psychosoc Nurs Ment Health Serv** 1995 Nov; 33(11):7–11 (16 ref.)

ORGANIZATION & ADMINISTRATION

Organizational redesign: effect on institutional and consumer outcomes. Ingersoll GL. **Annu Rev Nurs Res** 1996; 14:121–43 (52 ref.)
Organizational culture. Mark BA. **Annu Rev Nurs Res** 1996; 14:145–63 (32 ref.)
Nursing information management and processing: a framework and definition for systems analysis, design and evaluation. Goossen WT. **Int J Biomed Comput** 1996 Jan; 40(3):187–95 (34 ref.)
Primary health care progress in nursing citations. MacIntosh J, et al. **Int Nurs Rev** 1995 Jul–Aug;42(4):115–20 (13 ref.)
A view from somewhere: the presence and function of religious commitment in nursing practice. Cusveller BS. **J Adv Nurs** 1995 Nov;22(5):973–8 (15 ref.)
Is the professional code still the cornerstone of clinical nursing practice? Esterhuizen P. **J Adv Nurs** 1996 Jan; 23(1):25–31 (39 ref.)
Health care and nursing in Romania. Lakey CK, et al. **J Adv Nurs** 1996 May;23(5):1045–9 (20 ref.)
The clinical nurse specialist: a way forward? Miller S. **J Adv Nurs** 1995 Sep;22(3):494–501 (24 ref.)
Improving nursing practice, education, and research. Fagin CM. **J Nurs Adm** 1996 Mar;26(3):30–7 (12 ref.)
Outcomes that provide evidence of change in cancer pain management. Dalton JA. **Nurs Clin North Am** 1995 Dec; 30(4):683–95 (53 ref.)

PSYCHOLOGY

Measuring patients' satisfaction with nursing: 1990–1994. Thomas LH, et al. **J Adv Nurs** 1996 Apr;23(4):747–56 (48 ref.)
Patient satisfaction with nursing care: concept clarification. Eriksen LR. **J Nurs Meas** 1995 Summer;3(1):59–76 (50 ref.)

STANDARDS

Promoting nursing practice through nursing research. Baumgart AJ. **Int Nurs Rev** 1996 Mar–Apr;43(2):45–8, 57 (7 ref.)
How nursing research makes a difference. Holzemer W, et al. **Int Nurs Rev** 1996 Mar–Apr;43(2):49–52, 58 (38 ref.)
Neglected conflicts in the discipline of nursing: perceptions of the importance and value of practical skill. Bjørk IT. **J Adv Nurs** 1995 Jul;22(1):6–12 (44 ref.)
Clinical guidelines: an introduction to their development and implementation. Duff LA, et al. **J Adv Nurs** 1996 May; 23(5):887–95 (35 ref.)
An explanation of the differences between expert and novice performance in the administration of an intramuscular injection of an analgesic agent to a patient in pain. Noyes J. **J Adv Nurs** 1995 Oct;22(4):800–7 (61 ref.)
Measuring patients' satisfaction with nursing: 1990–1994. Thomas LH, et al. **J Adv Nurs** 1996 Apr;23(4):747–56 (48 ref.)
Patient satisfaction and normative decision theory. Brennan PF. **J Am Med Inform Assoc** 1995 Jul–Aug;2(4):250–9 (34 ref.)
Patient satisfaction with nursing care as an outcome variable: dilemmas for nursing evaluation researchers. Lin CC. **J Prof Nurs** 1996 Jul–Aug;12(4):207–16 (47 ref.)

NURSING CARE PLANS see **PATIENT CARE PLANNING**

NURSING DIAGNOSIS

Nursing diagnosis: a critical analysis of underlying assumptions. Lützén K, et al. **Int J Nurs Stud** 1996 Apr; 33(2):190–200 (37 ref.)
Differential diagnosis of common causes of pediatric pharyngitis. Ruppert SD. **Nurse Pract** 1996 Apr; 21(4):38–42, 44, 47–8 (21 ref.)

NURSING EDUCATION see **EDUCATION, NURSING**

NURSING EDUCATION, BACCALAUREATE see **EDUCATION, NURSING, BACCALAUREATE**

NURSING EDUCATION, CONTINUING see **EDUCATION, NURSING, CONTINUING**

NURSING EDUCATION, GRADUATE see **EDUCATION, NURSING, GRADUATE**

NURSING EDUCATION RESEARCH

Faculty practice: interest, issues, and impact. Walker PH. **Annu Rev Nurs Res** 1995;13:217–36 (33 ref.)

NURSING ETHICS see **ETHICS, NURSING**

NURSING EVALUATION RESEARCH

Towards a conceptual model of 'quality care'. Attree M. **Int J Nurs Stud** 1996 Feb;33(1):13–28 (38 ref.)
Nursing development units: an opportunity for evaluation. Draper J. **J Adv Nurs** 1996 Feb;23(2):267–71 (24 ref.)

METHODS

Approaches to community needs assessment: a literature review. Billings JR, et al. **J Adv Nurs** 1995 Oct;22(4):721–30 (100 ref.)
Measuring patients' satisfaction with nursing: 1990–1994. Thomas LH, et al. **J Adv Nurs** 1996 Apr;23(4):747–56 (48 ref.)
Patient satisfaction with nursing care as an outcome variable: dilemmas for nursing evaluation researchers. Lin CC. **J Prof Nurs** 1996 Jul–Aug;12(4):207–16 (47 ref.)

NURSING FACULTY see **FACULTY, NURSING**

NURSING FACULTY PRACTICE

ORGANIZATION & ADMINISTRATION

Faculty practice: interest, issues, and impact. Walker PH. **Annu Rev Nurs Res** 1995;13:217–36 (33 ref.)

NURSING, HOLISTIC see **HOLISTIC NURSING**

NURSING, HOME see **HOME NURSING**

NURSING HOMES

Pain evaluation and management in the nursing home. Ferrell BA. **Ann Intern Med** 1995 Nov 1;123(9):681–7 (75 ref.)
Nutritional issues in nursing home care. Morley JE, et al. **Ann Intern Med** 1995 Dec 1;123(11):850–9 (90 ref.)
Infections and antibiotic resistance in nursing homes. Nicolle LE, et al. **Clin Microbiol Rev** 1996 Jan;9(1):1–17 (188 ref.)
Epidemiology of adverse drug events in the nursing home setting. Monette J, et al. **Drugs Aging** 1995 Sep;7(3):203–11 (57 ref.)
The effect of living in a nursing home on socialization in elderly people. Jacelon CS. **J Adv Nurs** 1995 Sep; 22(3):539–46 (25 ref.)
Utility of clysis for hydration in nursing home residents. Hussain NA, et al. **J Am Geriatr Soc** 1996 Aug;44(8):969–73 (20 ref.)
Approach to fever and infection in the nursing home. Yoshikawa TT, et al. **J Am Geriatr Soc** 1996 Jan; 44(1):74–82 (87 ref.)
Prevention and screening in the nursing home. Gershman K, et al. **Prim Care** 1995 Dec;22(4):731–53 (106 ref.)
Urologic care in long-term facilities. Pranikoff K. **Urol Clin North Am** 1996 Feb;23(1):137–46 (111 ref.)
[Nursing home medicine, a new medical specialism] de Pijper NF, et al. **Ned Tijdschr Geneeskd** 1995 Sep 9;139(36):1820–3 (41 ref.) **(Dut)**

ECONOMICS

Long-term care reimbursement issues. Stone D, et al. **Clin Geriatr Med** 1995 Aug;11(3):517–29 (19 ref.)
An economic evaluation of schizophrenia--1991. Wyatt RJ, et al. **Soc Psychiatry Psychiatr Epidemiol** 1995 Aug; 30(5):196–205 (49 ref.)

LEGISLATION & JURISPRUDENCE

Barriers to forgoing nutrition and hydration in nursing homes. Meisel A. **Am J Law Med** 1995;21(4):335–82 (274 ref.)

ORGANIZATION & ADMINISTRATION

Omnibus Budget Reconciliation Act of 1987 and its implications for the medical director. Elon RD. **Clin Geriatr Med** 1995 Aug;11(3):419–32 (5 ref.)
Academics and the nursing home. Katz PR, et al. **Clin Geriatr Med** 1995 Aug;11(3):503–16 (36 ref.)
The corporate medical director. Krein K. **Clin Geriatr Med** 1995 Aug;11(3):403–17 (10 ref.)
Policy and procedure development and implementation. Levenson SA. **Clin Geriatr Med** 1995 Aug;11(3):449–65 (8 ref.)
Current role of the medical director in community-based nursing facilities. Levinson MJ, et al. **Clin Geriatr Med** 1995 Aug;11(3):343–58 (10 ref.)
Total quality management and the medical director. Schnelle JF. **Clin Geriatr Med** 1995 Aug;11(3):433–48 (21 ref.)
The future of long-term care and the role of the medical director. Willging P. **Clin Geriatr Med** 1995 Aug; 11(3):531–45 (10 ref.)
Infection control in long-term care. Yoshikawa TT, et al. **Clin Geriatr Med** 1995 Aug;11(3):467–80 (65 ref.)
Nursing homes: what you need to know for quality patient care. Cefalu CA. **Geriatrics** 1995 Dec;50(12):37–40, 49–50 (22 ref.)
Geropsychiatric public sector nursing: placement challenges. Fuller K, et al. **J Psychosoc Nurs Ment Health Serv** 1995 Aug;33(8):20–2 (6 ref.)

STANDARDS

Ethical and legal issues in nursing home care. Hayley DC, et al. **Arch Intern Med** 1996 Feb 12;156(3):249–56 (65 ref.)

NURSING, MATERNAL-CHILD see **MATERNAL-CHILD NURSING**

NURSING METHODOLOGY RESEARCH

The phenomenological movement: implications for nursing research. Walters AJ. **J Adv Nurs** 1995 Oct;22(4):791–9 (23 ref.)
Definition and measurement of quality of life in oncology nursing research: review and theoretical implications. Mast ME. **Oncol Nurs Forum** 1995 Jul;22(6):957–64 (66 ref.)

METHODS

Focus on qualitative methods: Using qualitative methods in intervention studies. Sandelowski M. **Res Nurs Health** 1996 Aug;19(4):359–64 (39 ref.)

ORGANIZATION & ADMINISTRATION

Hermeneutic phenomenology: philosophical perspectives and current use in nursing research. Annells M. **J Adv Nurs** 1996 Apr;23(4):705–13 (52 ref.)

NURSING MODELS see **MODELS, NURSING**

NURSING, ONCOLOGIC see **ONCOLOGIC NURSING**

NURSING PROCESS

Nursing minimum data set. Ryan P, et al. **Annu Rev Nurs Res** 1995;13:169–94 (70 ref.)
Dialectical analysis concerning the rational aspect of the art of nursing. Johnson JL. **Image J Nurs Sch** 1996 Summer; 28(2):169–75 (106 ref.)
Health-promoting nursing practice: the demise of the nursing process? Lindsey E, et al. **J Adv Nurs** 1996 Jan;23(1):106–12 (24 ref.)
Critical thinking and intuitive nursing practice. Paul RW, et al. **J Adv Nurs** 1995 Jul;22(1):40–7 (5 ref.)
Disparagement of the nursing process: the new dogma? Varcoe C. **J Adv Nurs** 1996 Jan;23(1):120–5 (41 ref.)
Technology and the lifeworld of critical care nursing. Walters AJ. **J Adv Nurs** 1995 Aug;22(2):338–46 (26 ref.)
Parallels and contradictions in the theory and practice of action research and nursing. Waterman H, et al. **J Adv Nurs** 1995 Oct;22(4):779–84 (35 ref.)

CLASSIFICATION

Defining nursing interventions. Snyder M, et al. **Image J Nurs Sch** 1996 Summer;28(2):137–41 (31 ref.)

ORGANIZATION & ADMINISTRATION

The nursing process re-examined: enrollment and translation. Latimer J. **J Adv Nurs** 1995 Aug;22(2):213–20 (35 ref.)

NURSING PROGRAM EVALUATION see **NURSING EVALUATION RESEARCH**

NURSING PROTOCOLS see **NURSING ASSESSMENT**

NURSING RECORDS

see related
FORMS AND RECORDS CONTROL

Nursing minimum data set. Ryan P, et al. **Annu Rev Nurs Res** 1995;13:169–94 (70 ref.)
Linguistic entrapment: medico–nursing biographies as

fictions. Crawford P, et al. **J Adv Nurs** 1995 Dec; 22(6):1141–8 (52 ref.)
AIDS nursing care and standardized nursing language: an application of the nursing intervention classification. Davis KA. **J Assoc Nurses AIDS Care** 1995 Nov–Dec;6(6):37–44 (17 ref.)
Using health care records as sources of data for research. vonKoss Krowchuk H, et al. **J Nurs Meas** 1995 Summer; 3(1):3–12 (21 ref.)

NURSING RESEARCH

Professionalization of nurse practitioners. Bullough B. **Annu Rev Nurs Res** 1995;13:239–65 (106 ref.)
Feminism and nursing. Chinn PL. **Annu Rev Nurs Res** 1995; 13:267–89 (110 ref.)
Quality of life and the spectrum of HIV infection. Holzemer WL, et al. **Annu Rev Nurs Res** 1995;13:3–29 (99 ref.)
Child sexual abuse: initial effects. Kelley SJ. **Annu Rev Nurs Res** 1995;13:63–85 (65 ref.)
Physical health of homeless adults. Lindsey AM. **Annu Rev Nurs Res** 1995;13:31–61 (112 ref.)
Pediatric hospice nursing. Martinson IM. **Annu Rev Nurs Res** 1995;13:195–214 (66 ref.)
Nursing minimum data set. Ryan P, et al. **Annu Rev Nurs Res** 1995;13:169–94 (70 ref.)
Health risk behaviors for Hispanic women. Torres S, et al. **Annu Rev Nurs Res** 1995;13:293–319 (94 ref.)
Neuro-behavioral effects of childhood lead exposure. vonKoss Krowchuk H. **Annu Rev Nurs Res** 1995;13:87–114 (108 ref.)
Agitation: measurement, management, and intervention research. Weinrich S, et al. **Arch Psychiatr Nurs** 1995 Oct; 9(5):251–60 (112 ref.)
Processes in the creation and diffusion of nursing knowledge: an examination of the developing concept of family–centred care. Bradley SF. **J Adv Nurs** 1996 Apr; 23(4):722–7 (33 ref.)
From research to practice: one organizational model for promoting research–based practice. Kitson A, et al. **J Adv Nurs** 1996 Mar;23(3):430–40 (53 ref.)
A nursing perspective on the interrelationships between theory, research and practice. Pryjmachuk S. **J Adv Nurs** 1996 Apr;23(4):679–84 (19 ref.)
The theory/practice 'gap': taking issue with the issue. Rafferty AM, et al. **J Adv Nurs** 1996 Apr;23(4):685–91 (44 ref.)
Psychoneuroimmunology: an emerging framework for nursing research. Zeller JM, et al. **J Adv Nurs** 1996 Apr; 23(4):657–64 (63 ref.)
Barriers and facilitators of research utilization. An integrative review. Funk SG, et al. **Nurs Clin North Am** 1995 Sep; 30(3):395–407 (79 ref.)
Cultural diversity: a nursing concept not yet reliably defined. Habayeb GL. **Nurs Outlook** 1995 Sep–Oct;43(5):224–7 (45 ref.)

CLASSIFICATION

Making sense of action research through the use of a typology. Hart E, et al. **J Adv Nurs** 1996 Jan;23(1):152–9 (14 ref.)

EDUCATION

A research development program for minority honors students. Inouye J. **J Nurs Educ** 1995 Sep;34(6):268–71 (35 ref.)

METHODS

"Methodological notes on empathy": further considerations. Bennett JA. **ANS Adv Nurs Sci** 1995 Sep;18(1):36–50 (57 ref.)
Coming to voice: the power of emancipatory community interventions. Drevdahl D. **ANS Adv Nurs Sci** 1995 Dec; 18(2):13–24 (50 ref.)
Stories and numbers: coexistence without compromise. Ford–Gilboe M, et al. **ANS Adv Nurs Sci** 1995 Sep; 18(1):14–26 (41 ref.)
Quantitative methods in nursing research. Abrams KR, et al. **J Adv Nurs** 1996 May;23(5):1008–15 (26 ref.)
The use of different research methodologies to evaluate the effectiveness of programmes to improve the care of patients in postoperative pain. Allcock N. **J Adv Nurs** 1996 Jan; 23(1):32–8 (34 ref.)
The use of the Nominal Group Technique in research with community nurses. Carney O, et al. **J Adv Nurs** 1996 May; 23(5):1024–9 (13 ref.)
An in–depth study of triangulation. Dootson S. **J Adv Nurs** 1995 Jul;22(1):183–7 (27 ref.)
Action research as a professionalizing strategy: issues and dilemmas. Hart E, et al. **J Adv Nurs** 1996 Mar;23(3):454–61 (58 ref.)
A selective review of the literature on nurse–patient communication: has the patient's contribution been neglected? Jarrett N, et al. **J Adv Nurs** 1995 Jul;22(1):72–8 (51 ref.)
Grounded theory as feminist research methodology. Keddy B, et al. **J Adv Nurs** 1996 Mar;23(3):448–53 (30 ref.)
Parallels and contradictions in the theory and practice of action research and nursing. Waterman H, et al. **J Adv Nurs** 1995 Oct;22(4):779–84 (35 ref.)
Feminist research. Torkelson DJ. **J Neurosci Nurs** 1996 Apr; 28(2):121–4 (31 ref.)
Using health care records as sources of data for research. vonKoss Krowchuk H, et al. **J Nurs Meas** 1995 Summer; 3(1):3–12 (21 ref.)
The importance of nursing research design and methods in cancer pain management. Enhancing care. Gaston–Johansson F, et al. **Nurs Clin North Am** 1995 Dec; 30(4):597–607 (90 ref.)
Triangles and crystals: on the geometry of qualitative research. Sandelowski M. **Res Nurs Health** 1995 Dec; 18(6):569–74 (43 ref.)
Tools of the trade: analyzing technology as object in nursing. Sandelowski M. **Sch Inq Nurs Pract** 1996 Spring;10(1):5–16; discussion 17–21 (79 ref.)

ORGANIZATION & ADMINISTRATION

Nursing research in Israel. Golander H, et al. **Annu Rev Nurs Res** 1996;14:207–24 (41 ref.)
The evolution of nursing research in Brazil. Mendes IA, et al. **Annu Rev Nurs Res** 1996;14:225–42 (68 ref.)
Member responsibilities on a nursing research committee. Martin PA. **Appl Nurs Res** 1996 Aug;9(3):154–7 (15 ref.)
Promoting nursing practice through nursing research. Baumgart AJ. **Int Nurs Rev** 1996 Mar–Apr;43(2):45–8, 57 (7 ref.)
How nursing research makes a difference. Holzemer W, et al. **Int Nurs Rev** 1996 Mar–Apr;43(2):49–52, 58 (38 ref.)
Agency and research team co–operation: an exploration of human territoriality. Ervin NE, et al. **J Adv Nurs** 1996 Apr;23(4):728–32 (11 ref.)
Making sense of action research through the use of a typology. Hart E, et al. **J Adv Nurs** 1996 Jan;23(1):152–9 (14 ref.)
Improving nursing practice, education, and research. Fagin CM. **J Nurs Adm** 1996 Mar;26(3):30–7 (12 ref.)
Looking toward the twenty–first century. The role of nursing research in care of children and families affected by HIV. Sherwen LN, et al. **Nurs Clin North Am** 1996 Mar; 31(1):165–78 (35 ref.)

NURSING RESEARCH, ADMINISTRATIVE see **NURSING ADMINISTRATION RESEARCH**

NURSING RESEARCH, CLINICAL see **CLINICAL NURSING RESEARCH**

NURSING RESEARCH, EDUCATIONAL see **NURSING EDUCATION RESEARCH**

NURSING SCHOOLS see **SCHOOLS, NURSING**

NURSING SERVICE, HOSPITAL

ECONOMICS

Surviving capitation. Dunham–Taylor J, et al. **Am J Nurs** 1996 Mar;96(3):26–9; quiz 30 (8 ref.)

ORGANIZATION & ADMINISTRATION

Healthcare violence. A nursing administration perspective. Claravall L. **J Nurs Adm** 1996 Feb;26(2):41–6 (29 ref.)

STANDARDS

Physical restraint use in the hospital setting: unresolved issues and directions for research. Mion LC, et al. **Milbank Q** 1996;74(3):411–33 (80 ref.)

TRENDS

The impact of the technological care environment on the nursing role. Pelletier D, et al. **Int J Technol Assess Health Care** 1996 Spring;12(2):358–66 (81 ref.)

NURSING SERVICES

ORGANIZATION & ADMINISTRATION

Organizational culture. Mark BA. **Annu Rev Nurs Res** 1996; 14:145–63 (32 ref.)

NURSING STAFF

EDUCATION

Neglected conflicts in the discipline of nursing: perceptions of the importance and value of practical skill. Bjørk IT. **J Adv Nurs** 1995 Jul;22(1):6–12 (44 ref.)

ORGANIZATION & ADMINISTRATION

The organization of clinical supervision within the nursing profession: a review of the literature. Fowler J. **J Adv Nurs** 1996 Mar;23(3):471–8 (44 ref.)

PSYCHOLOGY

Neglected conflicts in the discipline of nursing: perceptions of the importance and value of practical skill. Bjørk IT. **J Adv Nurs** 1995 Jul;22(1):6–12 (44 ref.)
Agency and research team co–operation: an exploration of human territoriality. Ervin NE, et al. **J Adv Nurs** 1996 Apr;23(4):728–32 (11 ref.)
Management of conflict: do nurses/women handle it differently? Valentine PE. **J Adv Nurs** 1995 Jul;22(1):142–9 (77 ref.)

NURSING STAFF, HOSPITAL

EDUCATION

The role of the nurse in patient–focused care: models of competence and implications for education and training. Burchell H, et al. **Int J Nurs Stud** 1996 Feb;33(1):67–75 (42 ref.)

ORGANIZATION & ADMINISTRATION

Integration of emerging designs for the practice and management of nursing. Blouin AS, et al. **J Nurs Adm** 1996 Mar;26(3):38–46 (54 ref.)
The role of the consultation–liaison nurse. Caring for patients with AIDS dementia complex. Price N. **J Psychosoc Nurs Ment Health Serv** 1995 Dec;33(12):31–4 (14 ref.)

PSYCHOLOGY

Burnout. Why do we blame the nurse? Cullen A. **Am J Nurs** 1995 Nov;95(11):22–7; quiz 28 (11 ref.)
Work group culture, stress, and hostility. Correlations with organizational outcomes. Seago JA. **J Nurs Adm** 1996 Jun; 26(6):39–47 (56 ref.)

NURSING, SUPERVISORY

ORGANIZATION & ADMINISTRATION

The organization of clinical supervision within the nursing profession: a review of the literature. Fowler J. **J Adv Nurs** 1996 Mar;23(3):471–8 (44 ref.)
Integration of emerging designs for the practice and management of nursing. Blouin AS, et al. **J Nurs Adm** 1996 Mar;26(3):38–46 (54 ref.)

NURSING THEORY

see related
MODELS, NURSING

The Pinwheel Model of Bereavement. Solari–Twadell PA, et al. **Image J Nurs Sch** 1995 Winter;27(4):323–6 (21 ref.)
Reformulation of deviance and labeling theory for nursing. Trexler JC. **Image J Nurs Sch** 1996 Summer;28(2):131–5 (39 ref.)
Reflective practice: reviewing the issues and refocusing the debate. Clarke B, et al. **Int J Nurs Stud** 1996 Apr; 33(2):171–80 (24 ref.)
A classical view of the theory–practice gap in nursing. Allmark P. **J Adv Nurs** 1995 Jul;22(1):18–23 (23 ref.)
A view from somewhere: the presence and function of religious commitment in nursing practice. Cusveller BS. **J Adv Nurs** 1995 Nov;22(5):973–8 (15 ref.)
Grounded theory as feminist research methodology. Keddy B, et al. **J Adv Nurs** 1996 Mar;23(3):448–53 (30 ref.)
Nursing, humanism and transcultural theory: the 'bracketing–out' of reality. Mulholland J. **J Adv Nurs** 1995 Sep;22(3):442–9 (43 ref.)
An explanation of the differences between expert and novice performance in the administration of an intramuscular injection of an analgesic agent to a patient in pain. Noyes J. **J Adv Nurs** 1995 Oct;22(4):800–7 (61 ref.)
A critical analysis of nursing: meeting the spiritual needs of patients. Oldnall A. **J Adv Nurs** 1996 Jan;23(1):138–44 (43 ref.)
Humanism and positivism in nursing: contradictions and conflicts. Playle JF. **J Adv Nurs** 1995 Nov;22(5):979–84 (46 ref.)
A nursing perspective on the interrelationships between theory, research and practice. Pryjmachuk S. **J Adv Nurs** 1996 Apr;23(4):679–84 (19 ref.)
The theory/practice 'gap': taking issue with the issue. Rafferty AM, et al. **J Adv Nurs** 1996 Apr;23(4):685–91 (44 ref.)
Theoretical and practical considerations on the use of reassurance in the nursing management of anxious patients. Teasdale K. **J Adv Nurs** 1995 Jul;22(1):79–86 (61 ref.)
Nursing theory: everything the artist spits is art? Timpson J. **J Adv Nurs** 1996 May;23(5):1030–6 (65 ref.)
Disparagement of the nursing process: the new dogma? Varcoe C. **J Adv Nurs** 1996 Jan;23(1):120–5 (41 ref.)
Parallels and contradictions in the theory and practice of action research and nursing. Waterman H, et al. **J Adv Nurs** 1995 Oct;22(4):779–84 (35 ref.)
The comfort and discomfort of infertility. Schoener CJ, et al. **J Obstet Gynecol Neonatal Nurs** 1996 Feb;25(2):167–72 (18 ref.)
Life–threatening situations: supporting the child survivor and the family. Davenport LB, et al. **J Pediatr Nurs** 1995 Aug; 10(4):219–23 (7 ref.)
Believing and dreaming to improve cancer care. Given BA. **Oncol Nurs Forum** 1995 Jul;22(6):929–40 (36 ref.)

NURSING, TRANSCULTURAL see **TRANSCULTURAL NURSING**

NUTCRACKER ESOPHAGUS see **ESOPHAGEAL**

MOTILITY DISORDERS

NUTMEG see SPICES

NUTRITION

see related
DIET
FOOD

The role of nutrition in the development of normal cognition. Kretchmer N, et al. **Am J Clin Nutr** 1996 Jun; 63(6):997S–1001S (52 ref.)

Copper biochemistry and molecular biology. Linder MC, et al. **Am J Clin Nutr** 1996 May;63(5):797S–811S (109 ref.)

Nutritional ecogenetics: homocysteine-related arteriosclerotic vascular disease, neural tube defects, and folic acid [editorial; comment] Motulsky AG. **Am J Hum Genet** 1996 Jan;58(1):17–20 (28 ref.) Comment on: Am J Hum Genet 1996 Jan;58(1):35–41.

Nutritional management of the continuous ambulatory peritoneal dialysis patient. Wolfson M. **Am J Kidney Dis** 1996 May;27(5):744–9 (49 ref.)

Nutritional issues in nursing home care. Morley JE, et al. **Ann Intern Med** 1995 Dec 1;123(11):850–9 (90 ref.)

The importance of menaquinones in human nutrition. Suttie JW. **Annu Rev Nutr** 1995;15:399–417 (80 ref.)

Nutritional treatment of hemodialysis and peritoneal dialysis patients. Schmicker R. **Artif Organs** 1995 Aug;19(8):837–41 (34 ref.)

Nutritional aspects of changes in disease patterns in the Western Pacific region. Cavalli-Sforza LT, et al. **Bull World Health Organ** 1996;74(3):307–18 (51 ref.)

Breast-milk vitamin A as an indicator of the vitamin A status of women and infants. Stoltzfus RJ, et al. **Bull World Health Organ** 1995;73(5):703–11 (44 ref.)

Omega-3 fatty acids--nutritional aspects. Drevon CA, et al. **Can J Cardiol** 1995 Oct;11 Suppl G:47G–54G (47 ref.)

Antioxidants in the Mediterranean diet. Mancini M, et al. **Can J Cardiol** 1995 Oct;11 Suppl G:105G–109G (20 ref.)

Controlling coronary risk through nutrition. Nestel PJ. **Can J Cardiol** 1995 Oct;11 Suppl G:9G–14G (19 ref.)

Nutritional regulation of lipoprotein lipase. Olivecrona T, et al. **Can J Cardiol** 1995 Oct;11 Suppl G:73G–78G (31 ref.)

Exercise, nutrition, and aging. Evans WJ. **Clin Geriatr Med** 1995 Nov;11(4):725–34 (49 ref.)

Phytic acid in health and disease. Zhou JR, et al. **Crit Rev Food Sci Nutr** 1995 Nov;35(6):495–508 (171 ref.)

Nutrition principles and diabetes. A role for "lente carbohydrate"? Jenkins DJ, et al. **Diabetes Care** 1995 Nov; 18(11):1491–8 (78 ref.)

The role of nutrition in mitigating environmental insults: policy and ethical issues. Hu H, et al. **Environ Health Perspect** 1995 Sep;103 Suppl 6:185–90 (56 ref.)

Nutrition and lead: strategies for public health. Mahaffey KR. **Environ Health Perspect** 1995 Sep;103 Suppl 6:191–6 (60 ref.)

Early human nutrition. Exalto N. **Eur J Obstet Gynecol Reprod Biol** 1995 Jul;61(1):3–6 (15 ref.)

Maternal nutrition in relation to fetal and placental growth. Godfrey KM, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Jul;61(1):15–22 (62 ref.)

Nutrition and breast-feeding. Koppe JG. **Eur J Obstet Gynecol Reprod Biol** 1995 Jul;61(1):73–8 (11 ref.)

Nutrition and its relationship to aging. Casper RC. **Exp Gerontol** 1995 May-Aug;30(3–4):299–314 (93 ref.)

Nutritional determinants of the insulin resistance syndrome. Tremblay A. **Int J Obes Relat Metab Disord** 1995 May; 19 Suppl 1:S60–8 (72 ref.)

The role of progressive resistance training and nutrition in the preservation of lean body mass in the elderly. Fielding RA. **J Am Coll Nutr** 1995 Dec;14(6):587–94 (51 ref.)

Position of the American Dietetic Association: oral health and nutrition. **J Am Diet Assoc** 1996 Feb;96(2):184–9 (55 ref.)

Nutrition and HIV infection. A continuum of care. Elbein RC. **J Am Podiatr Med Assoc** 1995 Aug;85(8):434–8 (10 ref.)

Clustering of cardiovascular risk factors in Australian adolescents: association with dietary excesses and deficiencies. Milligan RA, et al. **J Cardiovasc Risk** 1995 Dec;2(6):515–23 (50 ref.)

Nutrient antioxidants in the pathogenesis and prevention of cervical dysplasias and cancer. Romney SL, et al. **J Cell Biochem Suppl** 1995;23:96–103 (45 ref.)

Nutrition in minority elders: current problems and future directions. Buchowski MS, et al. **J Health Care Poor Underserved** 1996 Aug;7(3):184–209 (158 ref.)

Nutritional management of the child with mild to moderate chronic renal failure. Sedman A, et al. **J Pediatr** 1996 Aug; 129(2):s13–8 (26 ref.)

Nutrition and metabolic eye disease. Haddad HM. **Metab Pediatr Syst Ophthalmol** 1994;17(1–4):41–4 (11 ref.)

Nutrition in the head-injured patient. Roberts PR. **New Horiz** 1995 Aug;3(3):506–17 (96 ref.)

Interactions between nutrients and the immune system. Grimble RF. **Nutr Health** 1995;10(3):191–200 (15 ref.)

Communicating emerging scientific information. **Nutr Rev** 1996 May;54(5):153–7 (2 ref.)

The Weight-Control Information Network: a project of the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health. **Nutr Rev** 1995 Aug;53(8):232–3 (0 ref.)

Vitamin and mineral supplements as nutritional aids to exercise performance and health. Armstrong LE, et al. **Nutr Rev** 1996 Apr;54(4 Pt 2):S149–58 (126 ref.)

Nutritional determinants of puberty. Cameron JL. **Nutr Rev** 1996 Feb;54(2 Pt 2):S17–22 (70 ref.)

An eastern perspective on nutrition and performance. Chen JD. **Nutr Rev** 1996 Apr;54(4 Pt 2):S176–81 (28 ref.)

The role of stereospecific saturated fatty acid positions on lipid nutrition. Decker EA. **Nutr Rev** 1996 Apr;54(4 Pt 1):108–10 (18 ref.)

Bone mass, nutrition, and other lifestyle factors. Heaney RP. **Nutr Rev** 1996 Apr;54(4 Pt 2):S3–10 (56 ref.)

Exercise, physical activity, nutrition, and the brain. Hollmann W, et al. **Nutr Rev** 1996 Apr;54(4 Pt 2):S37–43 (42 ref.)

The role of nutrition in economic development. Martorell R. **Nutr Rev** 1996 Apr;54(4 Pt 2):S66–71 (35 ref.)

Total nutrient intake and ready-to-eat cereal consumption of children and young adults in the Bogalusa Heart Study. Nicklas TA, et al. **Nutr Rev** 1995 Sep;53(9 Pt 2):S39–45 (41 ref.)

Nutritional and hormonal regulation of fatty acid synthase. Wolf G. **Nutr Rev** 1996 Apr;54(4 Pt 1):122–3 (9 ref.)

Nutrition, lysosomal proteases, and protein breakdown [see comments] Andreu AL, et al. **Nutrition** 1995 Jul–Aug; 11(4):382–7 (66 ref.) Comment in: Nutrition 1995 Jul–Aug;11(4):398.

Nutritional effect of continuous hemodiafiltration. Frankenfield DC, et al. **Nutrition** 1995 Jul–Aug; 11(4):388–93 (15 ref.)

Beta-agonists as antiobesity, antidiabetic and nutrient partitioning agents. Yen TT. **Obes Res** 1995 Nov;3 Suppl 4:531S–536S (57 ref.)

Ontogenic changes in the nutritive function of the placenta. Schneider H. **Placenta** 1996 Jan;17(1):15–26 (135 ref.)

Copper and zinc metabolism in health and disease: speciation and interactions. Bremner I, et al. **Proc Nutr Soc** 1995 Jul; 54(2):489–99 (60 ref.)

Nutritional influences on pancreatic development and potential links with non-insulin-dependent diabetes. Dahri S, et al. **Proc Nutr Soc** 1995 Jul;54(2):345–56 (32 ref.)

Priorities for nutrition interventions in reproductive health: a bilateral agency perspective. Davidson FR. **Proc Nutr Soc** 1995 Jul;54(2):361–6 (19 ref.)

Iron-zinc and calcium-Fe interactions in relation to Zn and Fe absorption. Fairweather-Tait SJ. **Proc Nutr Soc** 1995 Jul;54(2):465–73 (41 ref.)

Effects of exercise training in the elderly: impact of progressive- resistance training on skeletal muscle and whole-body protein metabolism. Fielding RA. **Proc Nutr Soc** 1996 Nov;54(3):665–75 (58 ref.)

The effects of dietary change on serum cholesterol. Haq IU, et al. **Proc Nutr Soc** 1996 Nov;54(3):601–16 (80 ref.)

Maternal nutrition and the regulation of milk synthesis. Hartmann P, et al. **Proc Nutr Soc** 1995 Jul;54(2):379–89 (45 ref.)

Investing in nutrition at the national level: an African perspective. Kavishe FP. **Proc Nutr Soc** 1995 Jul; 54(2):367–78 (19 ref.)

Nutrition in overseas aid: the investors' perspective. Lambert J. **Proc Nutr Soc** 1995 Jul;54(2):357–60 (3 ref.)

Vitamin E and selenium: contrasting and interacting nutritional determinants of host resistance to parasitic and viral infections. Levander OA, et al. **Proc Nutr Soc** 1995 Jul;54(2):475–87 (73 ref.)

Understanding fat preference and consumption: applications of behavioural sciences to a nutritional problem. Mela DJ. **Proc Nutr Soc** 1995 Jul;54(2):453–64 (77 ref.)

The Nutrition Society 1994 Silver Medal Lecture. Pregnancy, parturition and neonatal development: interactions between nutrition and thyroid hormones. Symonds ME. **Proc Nutr Soc** 1995 Jul;54(2):329–43 (97 ref.)

Nutrition and fetal growth. Harding JE, et al. **Reprod Fertil Dev** 1995;7(3):539–47 (54 ref.)

Nutritional risk factors among low-income pregnant US women: the Centers for Disease Control and Prevention (CDC) Pregnancy Nutrition Surveillance System, 1979 through 1993. Perry GS, et al. **Semin Perinatol** 1995 Jun; 19(3):211–21 (46 ref.)

Nutrition in cancer patients [see comments] Mercadante S. **Support Care Cancer** 1996 Jan;4(1):10–20 (67 ref.) Comment in: Support Care Cancer 1996 Jan;4(1):1–3.

Nutrition and ageing at the population level. Kesteloot H. **Verh K Acad Geneeskd Belg** 1996;58(2):117–38; discussion 138–9 (24 ref.)

[Treatment of Crohn disease in children] Cezard JP, et al. **Gastroenterol Clin Biol** 1996;20(5 Pt 2):B50–55 (55 ref.) **(Fre)**

[Eating, nutrition and drugs] Noirfalise A. **J Pharm Belg** 1996 Mar–Apr;51(2):87–91 (23 ref.) **(Fre)**

[Mucoviscidosis and nutrition] Munck A. **Rev Pneumol Clin** 1995;51(3):145–50 (28 ref.) (Eng. Abstr.) **(Fre)**

[Neurohormonal control of gallbladder motility by intra-ileal and intracolonic nutrients--a review] Niebergall-Roth E, et al. **Berl Munch Tierarztl Wochenschr** 1996 Mar; 109(3):87–94 (110 ref.) (Eng. Abstr.) **(Ger)**

[Zinc--update of an essential trace element] Rimbach G, et al. **Z Ernahrungswiss** 1996 Jun;35(2):123–42 (211 ref.) (Eng. Abstr.) **(Ger)**

[The role of nutrition in the development of circulatory system diseases] Szponar L, et al. **Wiad Lek** 1994 Oct; 47(19–20):771–8 (50 ref.) (Eng. Abstr.) **(Pol)**

[Biomedical aspects of the use of milk whey in nutrition (review)] Lind AR, et al. **Vopr Pitan** 1995;(6):29–33 (45 ref.) (Eng. Abstr.) **(Rus)**

[Role of soybean proteins in human nutrition (review)] Vysotskil VG, et al. **Vopr Pitan** 1995;(5):20–7 (45 ref.) (Eng. Abstr.) **(Rus)**

EDUCATION

Assessment of nutrition and physical activity education programmes in children. Burke V, et al. **Clin Exp Pharmacol Physiol** 1995 Mar;22(3):212–6 (33 ref.)

[Nutrition-related prevention studies in children and adolescents on a population level--concepts, methods, outcome] Kersting M, et al. **Z Arztl Fortbild (Jena)** 1996 Feb;90(1):25–31 (34 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Nutrition-physiology link. Need to increase basic research. De Angelis RC. **Arq Gastroenterol** 1995 Jan–Mar; 32(1):35–9 (13 ref.)

Nutrition and immunonutrition. O'Leary MJ, et al. **Br J Anaesth** 1996 Jul;77(1):118–27 (102 ref.)

Interaction between nutrients, pro-inflammatory cytokines and inflammation [editorial] Grimble RF. **Clin Sci (Colch)** 1996 Aug;91(2):121–30 (102 ref.)

Nutritional regulation of insulin-like growth factor-I. Ketelslegers JM, et al. **Metabolism** 1995 Oct;44(10 Suppl 4):50–7 (75 ref.)

Postprandial triacylglycerolaemia--nutritional implications. Roche HM, et al. **Prog Lipid Res** 1995;34(3):249–66 (110 ref.)

[Sports and nutrition] Mannhart C. **Schweiz Rundsch Med Prax** 1995 Sep 5;84(36):963–9 (45 ref.) (Eng. Abstr.) **(Ger)**

[Growth hormone secretion and nutrition] de Lemos Silva GM, et al. **Arq Gastroenterol** 1994 Oct–Dec;31(4):159–72 (115 ref.) (Eng. Abstr.) **(Por)**

[A shift in types of nutrition and digestion in ontogeny] Arshavskiĭ IA, et al. **Usp Fiziol Nauk** 1996 Jan–Mar; 27(1):109–29 (95 ref.) (Eng. Abstr.) **(Rus)**

NUTRITION ASSESSMENT

Assessment of nutritional status in dialysis patients. Wolfson M, et al. **Adv Ren Replace Ther** 1996 Apr;3(2):174–9 (24 ref.)

Nutrition and the dialysis prescription. Chertow GM, et al. **Am J Nephrol** 1996;16(1):79–89 (85 ref.)

Nutrition assessment practical approaches. Barrocas A, et al. **Clin Geriatr Med** 1995 Nov;11(4):675–713 (32 ref.)

Nutritional assessment in the critically ill. Manning EM, et al. **Crit Care Clin** 1995 Jul;11(3):603–34 (110 ref.)

Methods to assess glucose metabolism in humans in relation to carbohydrate and fibre in the diet. Bornet FR, et al. **Eur J Clin Nutr** 1995 Oct;49 Suppl 3:S97–104 (60 ref.)

Zinc status of Indian children. Bhaskaram P, et al. **Indian J Med Res** 1995 Nov;102:210–5 (13 ref.)

Indexes of overall diet quality: a review. Kant AK. **J Am Diet Assoc** 1996 Aug;96(8):785–91 (69 ref.)

Recent advances in methods of assessing dietary amino acid requirements for adult humans. Zello GA, et al. **J Nutr** 1995 Dec;125(12):2907–15 (64 ref.)

Portion sizes in dietary assessment: issues and policy implications. Young LR, et al. **Nutr Rev** 1995 Jun; 53(6):149–58 (100 ref.)

Nutritional status in children receiving chronic peritoneal dialysis. Canepa A, et al. **Perit Dial Int** 1996;16 Suppl 1:S526–31 (37 ref.)

NUTRITION DISORDERS

Malnutrition: incidence, diagnosis, causes, effects and indications for nutritional support. Bettany GE, et al. **Eur J Gastroenterol Hepatol** 1995 Jun;7(6):494–500 (34 ref.)

Nutritional disorders in the elderly. Wahlqvist ML, et al. **Med J Aust** 1995 Oct 2;163(7):376–81 (19 ref.)

COMPLICATIONS

Small bowel intussusception and brown bowel syndrome in association with severe malnutrition. Drake WM, et al. **Am J Gastroenterol** 1996 Jul;91(7):1450–2 (20 ref.)

The effect of over- and undernutrition on cancer. Kritchevsky D. **Eur J Cancer Prev** 1995 Dec;4(6):445–51 (70 ref.)

Measles & malnutrition. Bhaskaram P. **Indian J Med Res** 1995 Nov;102:195–9 (24 ref.)

Diarrhea and malnutrition: a challenge for pediatricians. Gracey M. **J Pediatr Gastroenterol Nutr** 1996 Jan; 22(1):6–16 (120 ref.)

Timing and vulnerability in research on malnutrition and cognition. Pollitt E. **Nutr Rev** 1996 Feb;54(2 Pt 2):S49–55 (15 ref.)

[Prevention and therapy of nutrition-induced diseases and disease-induced nutrition disorders by internists. Deficiencies and future developments] Ollenschläger G. **Med Klin** 1995 Aug 15;90(8):486–9 (16 ref.) **(Ger)**

NUTRITION DISORDERS

DIAGNOSIS

Review article: artificial nutritional support for improved patient care. Pennington CR, et al. **Aliment Pharmacol Ther** 1995 Oct;9(5):471–81 (79 ref.)

DIET THERAPY

[Nutritional management in chronic hemodialysis] Ishigai T, et al. **Nippon Naika Gakkai Zasshi** 1995 Oct 10; 84(10):1648–52 (5 ref.) **(Jpn)**

EPIDEMIOLOGY

Measles & malnutrition. Bhaskaram P. **Indian J Med Res** 1995 Nov;102:195–9 (24 ref.)

Neurobiological plausibility of prenatal nutritional deprivation as a risk factor for schizophrenia. Brown AS, et al. **J Nerv Ment Dis** 1996 Feb;184(2):71–85 (98 ref.)

ETIOLOGY

Herman Award Lecture, 1995: infection-induced malnutrition—from cholera to cytokines. Beisel WR. **Am J Clin Nutr** 1995 Oct;62(4):813–9 (91 ref.)

Age-associated problems in nutrition. Sone Y. **Appl Human Sci** 1995 Sep;14(5):201–10 (85 ref.)

Nutrition and mortality in hemodialysis [editorial] Bergström J. **J Am Soc Nephrol** 1995 Nov;6(5):1329–41 (146 ref.)

Malnutrition in cirrhosis. Müller MJ. **J Hepatol** 1995;23 Suppl 1:31–5 (36 ref.)

From laboratory to bedside: new strategies in the treatment of malnutrition in cancer patients. Laviano A, et al. **Nutrition** 1996 Feb;12(2):112–22 (139 ref.)

Growth hormone and malnutrition in dialysis patients. Blake PG. **Perit Dial Int** 1995 Jul–Sep;15(6):210–6 (49 ref.)

Malnutrition in peritoneal dialysis patients: etiologic factors and treatment options. Ikizler TA, et al. **Perit Dial Int** 1995; 15(5 Suppl):S63–6 (28 ref.)

Nutrition and dialysis adequacy. Schreiber MJ Jr. **Perit Dial Int** 1995;15(5 Suppl):S39–49 (81 ref.)

Malnutrition in the elderly. Is it simply a matter of not eating enough? Zawada ET Jr. **Postgrad Med** 1996 Jul; 100(1):207–8, 211–4, 220–2 passim (9 ref.)

[Malnutrition in chronic obstructive bronchopulmonary diseases] Horáček J, et al. **Vnitr Lek** 1995 Jul;41(7):493–7 (35 ref.) (Eng. Abstr.) **(Cze)**

IMMUNOLOGY

Total parenteral nutrition and immune system activity: a review [see comments] Gogos CA, et al. **Nutrition** 1995 Jul–Aug;11(4):339–44 (74 ref.) Comment in: Nutrition 1995 Jul–Aug;11(4):394–5.

[Immune disorders in patients with nutrition disorders and renal insufficiency] Gajdosz R, et al. **Folia Med Cracov** 1994;35(1–4):87–90 (15 ref.) **(Pol)**

PHYSIOPATHOLOGY

Nutritional aspects of hip fractures. Bonjour JP, et al. **Bone** 1996 Mar;18(3 Suppl):139S–144S (87 ref.)

Nutritional status in the patient with spinal infection. Klein JD, et al. **Orthop Clin North Am** 1996 Jan;27(1):33–6 (30 ref.)

New strategies in clinical nutrition. Fürst P. **Perit Dial Int** 1996;16 Suppl 1:S28–35 (25 ref.)

McCay's hypothesis: undernutrition and longevity. Masoro EJ. **Proc Nutr Soc** 1996 Nov;54(3):657–64 (39 ref.)

PREVENTION & CONTROL

Approaches to the nutritional support of the older patient. Lipschitz DA. **Clin Geriatr Med** 1995 Nov;11(4):715–24 (11 ref.)

The role of total parenteral nutrition in the patient with cancer. Harrison LE, et al. **Curr Probl Surg** 1995 Oct; 32(10):833–917 (225 ref.)

Strategies for control of micronutrient malnutrition. Vijayaraghavan K. **Indian J Med Res** 1995 Nov;102:216–22 (33 ref.)

Childhood diarrhea and malnutrition in Pakistan, Part III: Social policy issues. David S, et al. **J Pediatr Nurs** 1995 Aug;10(4):273–8 (35 ref.)

Nutrition and dialysis adequacy. Schreiber MJ Jr. **Perit Dial Int** 1995;15(5 Suppl):S39–49 (81 ref.)

Royal Society of Tropical Medicine and Hygiene Meeting at Manson House, London, 16 February 1995. Aspects of Helicobacter pylori infection in the developing and developed world. Helicobacter pylori infection, nutrition and growth of West African infants. Weaver LT. **Trans R Soc Trop Med Hyg** 1995 Jul–Aug;89(4):347–50 (24 ref.)

THERAPY

Review article: artificial nutritional support for improved patient care. Pennington CR, et al. **Aliment Pharmacol Ther** 1995 Oct;9(5):471–81 (79 ref.)

Nutrition and the dialysis prescription. Chertow GM, et al. **Am J Nephrol** 1996;16(1):79–89 (85 ref.)

A practical approach to nutritional support in liver disease. Levinson MJ. **Gastroenterologist** 1995 Sep;3(3):234–40 (38 ref.)

Malnutrition and clinical outcomes: the case for medical nutrition therapy. Gallagher-Allred CR, et al. **J Am Diet Assoc** 1996 Apr;96(4):361–6, 369; quiz 367–8 (107 ref.)

From laboratory to bedside: new strategies in the treatment of malnutrition in cancer patients. Laviano A, et al. **Nutrition** 1996 Feb;12(2):112–22 (139 ref.)

[Cyclic enteral nutrition] Hébuterne X, et al. **Presse Med** 1996 Feb 10;25(5):202–6 (30 ref.) (Eng. Abstr.) **(Fre)**

VETERINARY

Veterinary nutritional management of amphibians and reptiles. Donoghue S. **J Am Vet Med Assoc** 1996 Jun 1; 208(11):1816–20 (22 ref.)

NUTRITION DISORDERS, CHILD see **CHILD NUTRITION DISORDERS**

NUTRITION DISORDERS, INFANT see **INFANT NUTRITION DISORDERS**

NUTRITION, ENTERAL see **ENTERAL NUTRITION**

NUTRITION, HOME PARENTERAL see **PARENTERAL NUTRITION, HOME**

NUTRITION LABELING see **FOOD LABELING**

NUTRITION, PARENTERAL see **PARENTERAL NUTRITION**

NUTRITION POLICY

Position paper on trans fatty acids. ASCN/AIN Task Force on Trans Fatty Acids. American Society for Clinical Nutrition and American Institute of Nutrition. **Am J Clin Nutr** 1996 May;63(5):663–70 (32 ref.)

Fatty acid-related functions. Dupont J, et al. **Am J Clin Nutr** 1996 Jun;63(6):991S–993S (10 ref.)

Discussions in the United States about recommended daily dietary allowances in the future. Lachance PA. **Bibl Nutr Dieta** 1995;(52):158–67 (35 ref.)

Criteria and scientific basis for RDA (PRI). Philip W, et al. **Bibl Nutr Dieta** 1995;(52):146–57 (20 ref.)

Strategies for control of micronutrient malnutrition. Vijayaraghavan K. **Indian J Med Res** 1995 Nov;102:216–22 (33 ref.)

Are dietary recommendations for dietary fat reduction achievable? Drummond S, et al. **Int J Food Sci Nutr** 1996 May;47(3):221–6 (37 ref.)

What practitioners need to know about folic acid. Hine RJ. **J Am Diet Assoc** 1996 May;96(5):451–2 (15 ref.)

Putting things in perspective: building on our experience. Shank FR, et al. **J Nutr** 1996 Mar;126(3):781S–787S (18 ref.)

The politics of nutrition in North America. Levenstein HA. **Neurosci Biobehav Rev** 1996;20(1):75–8 (14 ref.)

Complex carbohydrates: the science and the label. **Nutr Rev** 1995 Jul;53(7):186–93 (8 ref.)

On-line food and nutrition information resources. Institute of Food Science and Technology. **Nutr Rev** 1996 May; 54(5):158 (0 ref.)

Nutrition recommendations update: dietary fats and children. **Nutr Rev** 1995 Dec;53(12):367–75 (55 ref.)

Risk assessment of essential trace elements: new approaches to setting recommended dietary allowances and safety limits. Mertz W. **Nutr Rev** 1995 Jul;53(7):179–85 (38 ref.)

Portion sizes in dietary assessment: issues and policy implications. Young LR, et al. **Nutr Rev** 1995 Jun; 53(6):149–58 (100 ref.)

Optimal calcium intake. Sponsored by National Institutes of Health Continuing Medical Education. **Nutrition** 1995 Sep–Oct;11(5):409–17 (0 ref.)

LEGISLATION & JURISPRUDENCE

Salt and public health—policies for dietary salt in the Nordic countries. Närhinen M, et al. **Scand J Prim Health Care** 1995 Dec;13(4):300–6 (18 ref.)

NUTRITION SURVEYS

Diet, nutrition & cancer—the Indian scenario. Krishnaswamy K, et al. **Indian J Med Res** 1995 Nov;102:200–9 (70 ref.)

Fats in Indian diets and their nutritional and health implications. Ghafoorunissa. **Lipids** 1996 Mar;31 Suppl:S287–91 (29 ref.)

Characteristics of fats in Japanese diets and current recommendations. Sugano M. **Lipids** 1996 Mar;31 Suppl:S283–6 (13 ref.)

What we eat in America [news] **Nutr Rev** 1996 May; 54(5):159–60 (0 ref.)

Results of surveys to assess iron status in Europe. Hallberg L. **Nutr Rev** 1995 Nov;53(11):314–22 (46 ref.)

Methods to assess iron status in various NHANES surveys. Looker AC, et al. **Nutr Rev** 1995 Sep;53(9):246–54 (46 ref.)

[Nutrition behavior in Germany] Pudel V, et al. **Internist (Berl)** 1995 Nov;36(11):1032–9 (22 ref.) **(Ger)**

NUTRITION, TOTAL PARENTERAL see **PARENTERAL NUTRITION, TOTAL**

NUTRITIONAL AVAILABILITY see **NUTRITIVE VALUE**

NUTRITIONAL REQUIREMENTS

Essential nutrients and immunologic functions. Kelley DS, et al. **Am J Clin Nutr** 1996 Jun;63(6):994S–996S (32 ref.)

The need to consider functional endpoints in defining nutrient requirements. King J. **Am J Clin Nutr** 1996 Jun; 63(6):983S–984S (10 ref.)

The potential of pasture to supply the nutritional requirements of grazing horses. Gallagher JR. **Aust Vet J** 1996 Feb;73(2):67–8 (19 ref.)

The requirement for vitamins in aging and age-associated degenerative conditions. Blumberg J. **Bibl Nutr Dieta** 1995; (52):108–15 (44 ref.)

Folate requirements for health in different population groups. McNulty H. **Br J Biomed Sci** 1995 Jun;52(2):110–9 (75 ref.)

Effects of age on nutrient requirements. Chernoff R. **Clin Geriatr Med** 1995 Nov;11(4):641–51 (81 ref.)

Energy requirements of infants. Butte NF. **Eur J Clin Nutr** 1996 Feb;50 Suppl 1:S24–36 (54 ref.)

Protein requirements of elderly people. Campbell WW, et al. **Eur J Clin Nutr** 1996 Feb;50 Suppl 1:S180–3; discussion S183–5 (8 ref.)

Protein requirements of infants and children. Dewey KG, et al. **Eur J Clin Nutr** 1996 Feb;50 Suppl 1:S119–47; discussion S147–50 (140 ref.)

Energy requirements: general principles. Durnin JV. **Eur J Clin Nutr** 1996 Feb;50 Suppl 1:S2–9; discussion 9–10 (26 ref.)

Energy requirements of pregnant and lactating women. Prentice AM, et al. **Eur J Clin Nutr** 1996 Feb;50 Suppl 1:S82–110; discussion S10–1 (114 ref.)

Energy requirements of older individuals. Roberts SB. **Eur J Clin Nutr** 1996 Feb;50 Suppl 1:S112–7; discussion S117–8 (20 ref.)

Energy requirements of adults: an update on basal metabolic rates (BMRs) and physical activity levels (PALs). Shetty PS, et al. **Eur J Clin Nutr** 1996 Feb;50 Suppl 1:S11–23 (77 ref.)

Energy requirements and dietary energy recommendations for children and adolescents 1 to 18 years old. Torun B, et al. **Eur J Clin Nutr** 1996 Feb;50 Suppl 1:S37–80; discussion S80–1 (164 ref.)

The requirements of adult man for indispensable amino acids. Waterlow JC. **Eur J Clin Nutr** 1996 Feb;50 Suppl 1:S151–76; discussion S176–9 (160 ref.)

Energy requirements of pregnancy for healthy Dutch women. van Raaij JM. **Eur J Obstet Gynecol Reprod Biol** 1995 Jul;61(1):7–13 (12 ref.)

Human requirements of iodine & safe use of iodised salt. Ranganathan S, et al. **Indian J Med Res** 1995 Nov; 102:227–32 (21 ref.)

Vitamin C and human health—a review of recent data relevant to human requirements. Weber P, et al. **Int J Vitam Nutr Res** 1996;66(1):19–30 (107 ref.)

An evolutionary perspective enhances understanding of human nutritional requirements. Eaton SB, et al. **J Nutr** 1996 Jun;126(6):1732–40 (92 ref.)

Pattern of amino acid requirements in humans: an interspecies comparison using published amino acid requirement recommendations. McLarney MJ, et al. **J Nutr** 1996 Jul; 126(7):1871–82 (55 ref.)

Calcium and phosphorus nutrition in infants. Demarini S, et al. **J Pediatr Gastroenterol Nutr** 1995 Nov;21(4):367–73 (85 ref.)

Zinc and human health. Aggett PJ, et al. **Nutr Rev** 1995 Sep;53(9 Pt 2):S16–22 (39 ref.)

Magnesium status and health. Dreosti IE. **Nutr Rev** 1995 Sep; 53(9 Pt 2):S23–7 (37 ref.)

Is increased dietary protein necessary or beneficial for individuals with a physically active lifestyle? Lemon PW. **Nutr Rev** 1996 Apr;54(4 Pt 2):S169–75 (79 ref.)

Salvage of urea-nitrogen and protein requirements. Jackson AA. **Proc Nutr Soc** 1995 Jul;54(2):535–47 (38 ref.)

Breast-feeding: matching supply with demand in human lactation. Wilde CJ, et al. **Proc Nutr Soc** 1995 Jul; 54(2):401–6 (20 ref.)

The nutritional requirements of ornamental fish. Earle KE. **Vet Q** 1995 Apr;17 Suppl 1:S53–5 (5 ref.)

[Role of vitamin E and C, carotenoids, ubiquinone and selenium in the antioxidative defense system] Alho H, et al. **Duodecim** 1994;110(17):1621–8 (49 ref.) **(Fin)**

NUTRITIONAL STATUS

Growth hormone/insulin-like growth factor I axis in children treated for brain tumours: relationship to chemotherapy and nutrition. Rappaport R, et al. **Acta Paediatr Suppl** 1995 Sep;411:37–9; discussion 40 (19 ref.)

Review article: artificial nutritional support for improved patient care. Pennington CR, et al. **Aliment Pharmacol Ther** 1995 Oct;9(5):471–81 (79 ref.)

Nutritional assessment (protein nutriture). Spiekerman AM. **Anal Chem** 1995 Jun 15;67(12):429R–436R (80 ref.)

Maternal nutrition and obstetric outcome. Steegers-Theunissen RP. **Baillieres Clin Obstet Gynaecol** 1995 Sep;9(3):431–43 (65 ref.)

Endogenous and nutritional factors affecting bone. Marcus R. **Bone** 1996 Jan;18(1 Suppl):11S–13S (21 ref.)

Breast-milk vitamin A as an indicator of the vitamin A status of women and infants. Stoltzfus RJ, et al.

Bull World Health Organ 1995;73(5):703–11 (44 ref.)
Indicators of vitamin and mineral status in athletes' blood: a review. Fogelholm M. **Int J Sport Nutr** 1995 Dec; 5(4):267–84 (91 ref.)
Nutritional status outcomes for children: ethnic, cultural, and environmental contexts. Bronner YL. **J Am Diet Assoc** 1996 Sep;96(9):891–903 (88 ref.)
Methods to assess iron status in various NHANES surveys. Looker AC, et al. **Nutr Rev** 1995 Sep;53(9):246–54 (46 ref.)
Measuring nutrition status, physical activity, and fitness, with special emphasis on populations at nutritional risk. Rodrigues Matsudo VK. **Nutr Rev** 1996 Apr;54(4 Pt 2):S79–96 (171 ref.)
Drug–nutrient interactions. Thomas JA. **Nutr Rev** 1995 Oct; 53(10):271–82 (54 ref.)
Answers to all your questions about peritoneal urea clearance and nutrition in CAPD patients [editorial] Blake PG, et al. **Perit Dial Int** 1996 May–Jun;16(3):248–51 (25 ref.)
Effect of peritoneal dialysis prescription and peritoneal membrane transport characteristics on nutritional status. Burkart JM. **Perit Dial Int** 1995;15(5 Suppl):S20–35 (94 ref.)
Nutrition and dialysis adequacy. Schreiber MJ Jr. **Perit Dial Int** 1995;15(5 Suppl):S39–49 (81 ref.)
Bioelectrical impedance analysis and dual energy x-ray absorptiometry to monitor nutritional status. Stall S, et al. **Perit Dial Int** 1995;15(5 Suppl):S59–62 (31 ref.)
Functional ability and nutritional status of free–living elderly people. Manandhar MC. **Proc Nutr Soc** 1996 Nov; 54(3):677–91 (99 ref.)
[Growth hormone (GH) and insulin–like growth factor 1 (IGF–1) in nutritional status] Chevenne D, et al. **Ann Biol Clin (Paris)** 1995;53(10–11):527–38 (115 ref.) (Eng. Abstr.) **(Fre)**
[Assessment of the nutritional status of the surgical patient] Dionigi P. **Chir Ital** 1994;46(6):7–10 (28 ref.) (Eng. Abstr.) **(Ita)**
[Bioelectric profiles and nutritional status in pregnancy: protocol of a multicentric project to measure bioimpedance in pregnancy] Mele MC, et al. **Minerva Ginecol** 1996 Jan–Feb;48(1–2):25–33 (23 ref.) (Eng. Abstr.) **(Ita)**

PHYSIOLOGY

Exercise and macronutrient balance. Hill JO, et al. **Int J Obes Relat Metab Disord** 1995 Oct;19 Suppl 4:S88–92 (39 ref.)
Nutrition and mortality in hemodialysis [editorial] Bergström J. **J Am Soc Nephrol** 1995 Nov;6(5):1329–41 (146 ref.)
Nutritional status in the patient with spinal infection. Klein JD, et al. **Orthop Clin North Am** 1996 Jan;27(1):33–6 (30 ref.)

NUTRITIONAL SUPPORT

Nutritional aspects in patients with acute renal failure/multiorgan failure. Alvestrand A. **Blood Purif** 1996; 14(1):109–14 (31 ref.)
Approaches to the nutritional support of the older patient. Lipschitz DA. **Clin Geriatr Med** 1995 Nov;11(4):715–24 (11 ref.)
Nutritional support in inflammatory bowel disease. Zurita VF, et al. **Dig Dis** 1995 Mar–Apr;13(2):92–107 (91 ref.)
Malnutrition: incidence, diagnosis, causes, effects and indications for nutritional support. Bettany GE, et al. **Eur J Gastroenterol Hepatol** 1995 Jun;7(6):494–500 (34 ref.)
Inflammatory bowel disease. Bowling TE. **Eur J Gastroenterol Hepatol** 1995 Jun;7(6):521–7 (45 ref.)
Nutritional support in liver disease. Cabré E, et al. **Eur J Gastroenterol Hepatol** 1995 Jun;7(6):528–32 (42 ref.)
A practical approach to nutritional support in liver disease. Levinson MJ. **Gastroenterologist** 1995 Sep;3(3):234–40 (38 ref.)
Nutrition support teams: an integral part of developing a gastroenterology service. Reynolds N, et al. **Gut** 1995 Dec; 37(6):740–2 (19 ref.)
Malnutrition and clinical outcomes: the case for medical nutrition therapy. Gallagher–Allred CR, et al. **J Am Diet Assoc** 1996 Apr;96(4):361–6, 369; quiz 367–8 (107 ref.)
Nutritional support in Crohn's disease: current status and future directions. O'Morain C, et al. **J Gastroenterol** 1995 Nov;30 Suppl 8:102–7 (32 ref.)
The nutrition management of the patient with acute renal failure. Kopple JD. **JPEN J Parenter Enteral Nutr** 1996 Jan–Feb;20(1):3–12 (70 ref.)
From laboratory to bedside: new strategies in the treatment of malnutrition in cancer patients. Laviano A, et al. **Nutrition** 1996 Feb;12(2):112–22 (139 ref.)
Malnutrition in peritoneal dialysis patients: etiologic factors and treatment options. Ikizler TA, et al. **Perit Dial Int** 1995; 15(5 Suppl):S63–6 (28 ref.)
[Perioperative artificial nutrition in planned surgery in adults. Consensus development conference. Saint–Mande, France, 16 December 1994] **Ann Fr Anesth Reanim** 1995;14 Suppl 2:1–136 (0 ref.) **(Fre)**
[Mucoviscidosis and nutrition] Munck A. **Rev Pneumol Clin** 1995;51(3):145–50 (28 ref.) (Eng. Abstr.) **(Fre)**
[Immunologic aspects of artificial nutrition] Braga M, et al. **Chir Ital** 1994;46(6):11–9 (75 ref.) (Eng. Abstr.) **(Ita)**
[Nutritional support in acute pancreatitis] Dionigi P, et al. **Chir Ital** 1995;47(2):9–13 (55 ref.) (Eng. Abstr.) **(Ita)**
[Artificial nutrition in the injured patient] Enrichens F, et al. **Chir Ital** 1994;46(6):49–53 (22 ref.) (Eng. Abstr.) **(Ita)**
[Hormones, growth factors, and drugs in metabolism and nutrition] García de Lorenzo A, et al. **Nutr Hosp** 1995 Sep–Oct;10(5):297–305 (91 ref.) (Eng. Abstr.) **(Spa)**

ECONOMICS

Costs and benefits of nutrition support in cancer. Tchekmedyian NS. **Oncology (Huntingt)** 1995 Nov;9(11 Suppl):79–84 (45 ref.)

METHODS

Nutritional management and the multisystem organ failure/systemic inflammatory response syndrome in critically ill preterm neonates. Adan D, et al. **Crit Care Clin** 1995 Jul;11(3):751–84 (162 ref.)
Nutritional support of the burn patient. Deitch EA. **Crit Care Clin** 1995 Jul;11(3):735–50 (54 ref.)
Micronutrients in critical illness. Demling RH, et al. **Crit Care Clin** 1995 Jul;11(3):651–73 (40 ref.)
Nutritional support during liver failure. Gecelter GR, et al. **Crit Care Clin** 1995 Jul;11(3):675–83 (52 ref.)
Protein and amino acids in nutritional support. McNurlan MA, et al. **Crit Care Clin** 1995 Jul;11(3):635–50 (114 ref.)
Nutritional support in the patient with renal failure. Molina MF, et al. **Crit Care Clin** 1995 Jul;11(3):685–704 (83 ref.)
Nutritional support during pulmonary failure. Pinard B, et al. **Crit Care Clin** 1995 Jul;11(3):705–15 (33 ref.)
Nutritional support of the septic patient. Wojnar MM, et al. **Crit Care Clin** 1995 Jul;11(3):717–33 (59 ref.)
The nutritional management of acute renal failure in the intensive care unit. Kierdorf HP. **New Horiz** 1995 Nov; 3(4):699–707 (101 ref.)
[Perioperative artificial nutrition programmed for the adult surgical patient. Saint–Mandé, December 16, 1994: The Francophone Society of Enteral and Parenteral Nutrition and the French Society of Anesthesia and Resuscitation] **Ann Gastroenterol Hepatol (Paris)** 1995 Oct;31(5):310–9 (0 ref.) **(Fre)**
[Chronic inflammatory bowel diseases and nutrition] Meier R. **Schweiz Med Wochenschr Suppl** 1996;79:14S–24S (101 ref.) (Eng. Abstr.) **(Ger)**
[Intestinal adaptation in the short and ultrashort bowel syndrome. Nutritional support] Galiano Segovia MJ, et al. **An Esp Pediatr** 1996 Jun;44(6):605–8 (16 ref.) **(Spa)**

STANDARDS

Review article: artificial nutritional support for improved patient care. Pennington CR, et al. **Aliment Pharmacol Ther** 1995 Oct;9(5):471–81 (79 ref.)
Nutritional and metabolic considerations of the adult liver transplant candidate and organ donor. Driscoll DF, et al. **Nutrition** 1995 May–Jun;11(3):255–63 (85 ref.)

NUTRITIVE VALUE

Nutritional aspects of reduced–fat cheese. Holsinger VH. **Adv Exp Med Biol** 1995;367:339–44 (12 ref.)
Cheese: physical, biochemical, and nutritional aspects. Fox PF, et al. **Adv Food Nutr Res** 1996;39:163–328 (712 ref.)
Food preferences in farm animals: why don't they always choose wisely? Forbes JM, et al. **Proc Nutr Soc** 1995 Jul; 54(2):429–40 (45 ref.)

NYCTIPHANES see CRUSTACEA

NYCTOHEMERAL RHYTHM see CIRCADIAN RHYTHM

NYCTURIA see URINATION DISORDERS

NYSTAGMUS

see related
ELECTRONYSTAGMOGRAPHY

COMPLICATIONS

Benign paroxysmal positional vertigo. Gordon N. **Br J Clin Pract** 1996 Jun;50(4):208–10 (17 ref.)
On infantile esotropia with nystagmus in abduction. Ciancia AO. **J Pediatr Ophthalmol Strabismus** 1995 Sep–Oct; 32(5):280–8 (62 ref.)

DIAGNOSIS

Assessment: electronystagmography. Report of the Therapeutics and Technology Assessment Subcommittee. **Neurology** 1996 Jun;46(6):1763–6 (9 ref.)

ETIOLOGY

[See–saw nystagmus. Clinical aspects, diagnosis, pathophysiology: observations in 2 patients] Endres M, et al. **Nervenarzt** 1996 Jun;67(6):484–9 (41 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

[Special ocular movements in the neonate and Bell's phenomenon] Kuperman AA, et al. **Harefuah** 1996 Mar 1;130(5):333–6 (33 ref.) **(Heb)**
[Mechanisms of interactions between different types of nystagmus] Neverov VP, et al. **Vesta Otorinolaringol** 1995 Sep–Oct;(5):29–33 (39 ref.) (Eng. Abstr.) **(Rus)**
[Nystagmus and other anomalous movements of the eye] Prats Viñas JM. **Rev Neurol** 1995;23 Suppl 3:S359–62 (25 ref.) **(Spa)**

NYSTAGMUS, BARANY'S see NYSTAGMUS, PHYSIOLOGIC

NYSTAGMUS, CALORIC see NYSTAGMUS, PHYSIOLOGIC

NYSTAGMUS, PHYSIOLOGIC

see related
ELECTRONYSTAGMOGRAPHY

PHYSIOLOGY

Adaptation in the oculomotor response to caloric irrigation and the merits of bithermal stimulation [see comments] Barnes G. **Br J Audiol** 1995 Apr;29(2):93–106 (22 ref.) Comment in: Br J Audiol 1995 Apr;29(2):83–6.
Comparison of assessment of caloric nystagmus by observation of duration and by electronystagmographic measurement of slow–phase velocity [see comments] Luxon L. **Br J Audiol** 1995 Apr;29(2):107–15 (29 ref.) Comment in: Br J Audiol 1995 Apr;29(2):83–6.

NYSTAGMUS, THERMAL see NYSTAGMUS, PHYSIOLOGIC

NYSTATIN

THERAPEUTIC USE

Nystatin prophylaxis in immunocompromised children. Taylor TL. **Ann Pharmacother** 1996 May;30(5):534–5 (8 ref.)

O ANTIGENS

CHEMISTRY

[Structure and properties of the common polysaccharide antigen of Pseudomonas aeruginosa bacteria (review)] Knirel' IuA, et al. **Biokhimiia** 1995 Dec;60(12):1964–76 (53 ref.) (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

Role of O–antigen variation in the immune response. Reeves P. **Trends Microbiol** 1995 Oct;3(10):381–6 (49 ref.)

O–SPECIFIC POLYSACCHARIDES see O ANTIGENS

OBESE MICE see MICE, OBESE

OBESITY

see related
APPETITE DEPRESSANTS
DIET, REDUCING
LIPECTOMY
SKINFOLD THICKNESS

Current views on obesity. Stunkard AJ. **Am J Med** 1996 Feb;100(2):230–6 (82 ref.)
Absolving a deadly sin: a medical and legal argument for including obesity as a disability under the Americans with Disabilities Act. Kuss CL. **J Contemp Health Law Policy** 1996 Spring;12(2):563–605 (335 ref.)
Brain serotonin, carbohydrate–craving, obesity and depression. Wurtman RJ, et al. **Obes Res** 1995 Nov;3 Suppl 4:477S–480S (34 ref.)
[Definition, classification and judgement of obesity, and clinical diagnosis of obesity as disease] Ikeda Y, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:229–36 (8 ref.) **(Jpn)**
[Experimental animal models of obesity] Katoh J, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:599–603 (24 ref.) **(Jpn)**
[Bulimia nervosa and obesity] Kuboki T. **Nippon Rinsho** 1995 Jun;53 Suppl:561–6 (17 ref.) **(Jpn)**
[Obesity in the elderly] Nakano H, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:537–42 (18 ref.) **(Jpn)**
[Visceral fat obesity] Tokunaga K. **Nippon Rinsho** 1995 Jun; 53 Suppl:257–61 (20 ref.) **(Jpn)**
[Obesity in pregnancy and delivery] Yamamoto T, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:553–8 (21 ref.) **(Jpn)**
[Toward the treatment of obesity: role of PPAR gamma in adipogenesis] Motojima K. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(13):1936–41 (32 ref.) **(Jpn)**

BLOOD

Hypercortisolism and obesity. Peeke PM, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:665–76 (57 ref.)
[Abnormality of coagulation and fibrinolysis in obesity] Terada H. **Nippon Rinsho** 1995 Jun;53 Suppl:365–70 (21 ref.) **(Jpn)**
[Hyperuric acidemia and obesity] Yamanouchi T, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:310–5 (13 ref.) **(Jpn)**

OBESITY

CHEMICALLY INDUCED

[Drug induced obesity] Murakami T, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:425–9 (16 ref.) **(Jpn)**

COMPLICATIONS

Non-insulin-dependent diabetes mellitus in children and adolescents. Glaser N, et al. **Adv Pediatr** 1996;43:359–96 (264 ref.)

Overweight and health: communications challenges and opportunities. Rippe JM. **Am J Clin Nutr** 1996 Mar;63(3 Suppl):470S–473S (32 ref.)

The importance of body fat distribution in early life. Freedman DS. **Am J Med Sci** 1995 Dec;310 Suppl 1:S72–6 (47 ref.)

A perspective on obesity. Gidding SS. **Am J Med Sci** 1995 Dec;310 Suppl 1:S68–71 (35 ref.)

Obesity studies in Bogalusa. Webber LS, et al. **Am J Med Sci** 1995 Dec;310 Suppl 1:S53–61 (35 ref.)

Exercise and cancer: linkages with obesity? Shephard RJ. **Crit Rev Food Sci Nutr** 1996 Apr;36(4):321–39 (108 ref.)

Effects of metformin in obese patients with impaired glucose tolerance. Scheen AJ, et al. **Diabetes Metab Rev** 1995 Sep; 11 Suppl 1:S69–80 (75 ref.)

Evolution of the understanding of the role of exercise in obesity and its complications. Björntorp P. **Int J Obes Relat Metab Disord** 1995 Oct;19 Suppl 4:S1–4 (15 ref.)

The insulin resistance-dyslipidemic syndrome: contribution of visceral obesity and therapeutic implications. Després JP, et al. **Int J Obes Relat Metab Disord** 1995 May;19 Suppl 1:S76–86 (72 ref.)

Obesity and breast cancer. Stoll BA. **Int J Obes Relat Metab Disord** 1996 May;20(5):389–92 (43 ref.)

Liver disturbances in obesity and diabetes mellitus. Van Steenbergen W, et al. **Int J Obes Relat Metab Disord** 1995 Sep;19 Suppl 3:S27–36 (80 ref.)

Binge eating among the overweight population: a serious and prevalent problem. Bruce B, et al. **J Am Diet Assoc** 1996 Jan;96(1):58–61 (30 ref.)

Cauda equina compression by epidural lipomatosis in obesity. Effectiveness of weight reduction. Pouchot J, et al. **J Rheumatol** 1995 Sep;22(9):1771–5 (20 ref.)

Maternal obesity increases congenital malformations. Prentice A, et al. **Nutr Rev** 1996 May;54(5):146–50 (19 ref.)

Obesity-related hypertension and the insulin resistance syndrome. Landsberg L. **Trans Am Clin Climatol Assoc** 1994;106:69–75; discussion 75–6 (32 ref.)

[Lipedema] Herpertz U. **Z Lymphol** 1995 Aug;19(1):1–11 (5 ref.) (Eng. Abstr.) **(Ger)**

[Obesity and the related diseases: gout] Akaoka Y, et al. **Nippon Naika Gakkai Zasshi** 1995 Aug 10;84(8):1262–6 (6 ref.) **(Jpn)**

[Obesity and the related diseases: diabetes mellitus] Kobayashi M. **Nippon Naika Gakkai Zasshi** 1995 Aug 10; 84(8):1251–5 (5 ref.) **(Jpn)**

[Obesity and the related diseases: hyperlipidemia] Koizumi J, et al. **Nippon Naika Gakkai Zasshi** 1995 Aug 10; 84(8):1256–61 (5 ref.) **(Jpn)**

[Obesity and vascular diseases] Oikawa S, et al. **Nippon Naika Gakkai Zasshi** 1995 Aug 10;84(8):1246–50 (5 ref.) **(Jpn)**

[Obesity and the related diseases: hypertension] Ouchi Y, et al. **Nippon Naika Gakkai Zasshi** 1995 Aug 10;84(8):1241–5 (6 ref.) **(Jpn)**

[Obesity as a risk factor of diabetes mellitus (prospective study)] Amemiya T. **Nippon Rinsho** 1995 Jun;53 Suppl:265–70 (19 ref.) **(Jpn)**

[Obesity and hyperlipidemia] Funahashi T, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:304–9 (34 ref.) **(Jpn)**

[Obesity as a risk factor of endometrial cancer of the uterus] Hori S, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:290–5 (23 ref.) **(Jpn)**

[The relationship between the incidence of ischemic heart disease and the degree of obesity] Kobayashi N, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:281–5 (20 ref.) **(Jpn)**

[Orthopaedic disorders and problems related to obesity] Koshino T. **Nippon Rinsho** 1995 Jun;53 Suppl:382–7 (20 ref.) **(Jpn)**

[Obesity and syndrome X] Mukaida H, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:577–81 (15 ref.) **(Jpn)**

[Obesity as a risk factor of ischemic brain disease (prospective study] Ogawa M. **Nippon Rinsho** 1995 Jun;53 Suppl:276–80 (15 ref.) **(Jpn)**

[Cardiac hypertrophy and ischemic heart disease in obesity] Ohta M, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:332–7 (20 ref.) **(Jpn)**

[Obesity associated with distorted function of autonomic nervous system] Ookuma K, et al. **Nippon Rinsho** 1995 Jun; 53 Suppl:371–6 (13 ref.) **(Jpn)**

[Obesity as a risk factor of breast cancer (prospective study)] Sakamoto G. **Nippon Rinsho** 1995 Jun;53 Suppl:286–9 (10 ref.) **(Jpn)**

[Respiratory function disturbance in obesity.] Taguchi O. **Nippon Rinsho** 1995 Jun;53 Suppl:343–8 (20 ref.) **(Jpn)**

[Gynecological diseases in obesity] Takahashi J, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:388–91 (5 ref.) **(Jpn)**

[Diseases of the biliary system in obesity] Takikawa H, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:349–53 (21 ref.) **(Jpn)**

[Liver injuries in obese patients] Toshima K, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:354–8 (30 ref.) **(Jpn)**

[Complication of childhood obesity] Yamazaki K, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:524–8 (17 ref.) **(Jpn)**

[Fatty liver in obesity] Ishii M, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):32–4 (18 ref.) **(Jpn)**

[Obesity] Saito Y. **Ryoikibetsu Shokogun Shirizu** 1995; (8):407–9 (6 ref.) **(Jpn)**

[Obesity and hypertension] Gus M, et al. **Arq Bras Cardiol** 1995 Jun;64(6):565–70 (53 ref.) **(Por)**

DIAGNOSIS

[Etiology and physiopathology of obesity: childhood obesity] Murata M. **Nippon Naika Gakkai Zasshi** 1995 Aug 10; 84(8):1236–40 (13 ref.) **(Jpn)**

[Obesity type and the diagnostic criteria] Saito Y. **Nippon Naika Gakkai Zasshi** 1995 Aug 10;84(8):1217–20 (4 ref.) **(Jpn)**

[Guidelines for body weight in adults] Kataoka K. **Nippon Rinsho** 1995 Jun;53 Suppl:141–6 (19 ref.) **(Jpn)**

[Indices of obesity derived from body weight and height] Kataoka K. **Nippon Rinsho** 1995 Jun;53 Suppl:147–53 (30 ref.) **(Jpn)**

[Techniques of measurement of human body fat mass: overview] Kataoka K. **Nippon Rinsho** 1995 Jun;53 Suppl:157–64 (42 ref.) **(Jpn)**

[Diagnosis of childhood obesity] Murata M. **Nippon Rinsho** 1995 Jun;53 Suppl:517–23 (5 ref.) **(Jpn)**

DIET THERAPY

New perspectives on dietary and behavioural treatments for obesity. Fairburn CG, et al. **Int J Obes Relat Metab Disord** 1996 Feb;20 Suppl 1:S9–13 (63 ref.)

Behaviour change in practice: group approaches. Hayaki J, et al. **Int J Obes Relat Metab Disord** 1996 Feb;20 Suppl 1:S27–30 (18 ref.)

Behaviour change in practice: targeting individuals. Rollnick S. **Int J Obes Relat Metab Disord** 1996 Feb;20 Suppl 1:S22–6 (19 ref.)

Behaviour change in practice: population strategies. Wiseman MJ. **Int J Obes Relat Metab Disord** 1996 Feb;20 Suppl 1:S31–3 (14 ref.)

The role of dietary fiber in the development and treatment of childhood obesity. Kimm SY. **Pediatrics** 1995 Nov;96(5 Pt 2):1010–4 (51 ref.)

[Diet therapy of obesity] Nakamura T. **Nippon Naika Gakkai Zasshi** 1995 Aug 10;84(8):1273–8 (12 ref.) **(Jpn)**

[Diet therapy in obesity] Nakamura T, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:449–54 (12 ref.) **(Jpn)**

[Very low calorie diets for obesity] Tanaka S. **Nippon Rinsho** 1995 Jun;53 Suppl:495–8 (13 ref.) **(Jpn)**

DRUG THERAPY

Prospects for beta 3-adrenoceptor agonists in the treatment of obesity and diabetes. Arch JR, et al. **Int J Obes Relat Metab Disord** 1996 Mar;20(3):191–9 (90 ref.)

Pharmacological aspects of obesity treatment: towards the 21st century. Blundell JE, et al. **Int J Obes Relat Metab Disord** 1995 Sep;19 Suppl 3:S51–5 (34 ref.)

Appetite suppressants as adjuncts in the treatment of obesity. Elks ML. **J Fam Pract** 1996 Mar;42(3):287–92 (57 ref.)

Pharmacological and clinical studies of ephedrine and other thermogenic agonists. Astrup A, et al. **Obes Res** 1995 Nov; 3 Suppl 4:537S–540S (12 ref.)

Combined drug treatment of obesity. Atkinson RL, et al. **Obes Res** 1995 Nov;3 Suppl 4:497S–500S (32 ref.)

Evaluation of drugs for treating obesity. Bray GA. **Obes Res** 1995 Nov;3 Suppl 4:425S–434S (52 ref.)

Multiple serotonin receptors: opportunities for new treatments for obesity? Dourish CT. **Obes Res** 1995 Nov; 3 Suppl 4:449S–462S (108 ref.)

First clinical studies with orlistat: a short review. Drent ML, et al. **Obes Res** 1995 Nov;3 Suppl 4:623S–625S (6 ref.)

Clinical studies with dexfenfluramine: from past to future. Guy-Grand B. **Obes Res** 1995 Nov;3 Suppl 4:491S–496S (34 ref.)

Clinical studies with mazindol. Inoue S. **Obes Res** 1995 Nov; 3 Suppl 4:549S–552S (11 ref.)

Sibutramine: a novel new agent for obesity treatment. Ryan DH, et al. **Obes Res** 1995 Nov;3 Suppl 4:553S–559S (29 ref.)

Beta-agonists as antiobesity, antidiabetic and nutrient partitioning agents. Yen TT. **Obes Res** 1995 Nov;3 Suppl 4:531S–536S (57 ref.)

[Drug treatment of obesity] Meinders AE, et al. **Ned Tijdschr Geneeskd** 1996 Aug 10;140(32):1632–4 (22 ref.) **(Dut)**

[Therapy of obesity using appetite depressants] Ikeda Y. **Nippon Naika Gakkai Zasshi** 1995 Aug 10;84(8):1290–4 (4 ref.) **(Jpn)**

[Drug treatment of obesity] Yoshida T. **Nippon Rinsho** 1995 Jun;53 Suppl:481–6 (20 ref.) **(Jpn)**

ECONOMICS

Social and economic effects of body weight in the United States. Wolf AM, et al. **Am J Clin Nutr** 1996 Mar;63(3 Suppl):466S–469S (19 ref.)

The impact of obesity on health status: some implications for health care costs. Seidell JC. **Int J Obes Relat Metab Disord** 1995 Nov;19 Suppl 6:S13–6 (9 ref.)

Costs and benefits when treating obesity. Sjöström L, et al. **Int J Obes Relat Metab Disord** 1995 Nov;19 Suppl 6:S9–12 (10 ref.)

EPIDEMIOLOGY

Morbidity and mortality associated with elevated body weight in children and adolescents. Must A. **Am J Clin Nutr** 1996 Mar;63(3 Suppl):445S–447S (27 ref.)

Carbohydrate and obesity. Astrup A, et al. **Int J Obes Relat Metab Disord** 1995 Nov;19 Suppl 5:S27–37 (121 ref.)

Epidemiology of obesity in relation to nutrient intake. Gibney MJ. **Int J Obes Relat Metab Disord** 1995 Nov;19 Suppl 5:S1–3 (25 ref.)

Familial trends of obesity through three generations: the Belgian-Luxembourg child study. Guillaume M, et al. **Int J Obes Relat Metab Disord** 1995 Sep;19 Suppl 3:S5–9 (31 ref.)

A public health approach to the problem of obesity. James WP. **Int J Obes Relat Metab Disord** 1995 Sep;19 Suppl 3:S37–45 (40 ref.)

Obesity in Europe: scaling an epidemic. Seidell JC. **Int J Obes Relat Metab Disord** 1995 Sep;19 Suppl 3:S1–4 (20 ref.)

Socio-economic aspects of obesity: causes or effects? Sørensen TI. **Int J Obes Relat Metab Disord** 1995 Nov; 19 Suppl 6:S6–8 (16 ref.)

Behaviour change in practice: population strategies. Wiseman MJ. **Int J Obes Relat Metab Disord** 1996 Feb;20 Suppl 1:S31–3 (14 ref.)

Trends in body weight and overweight in the U.S. population. Flegal KM. **Nutr Rev** 1996 Apr;54(4 Pt 2):S97–100 (13 ref.)

Susceptibility to development of central adiposity among populations. Fujimoto WY, et al. **Obes Res** 1995 Sep;3 Suppl 2:179S–186S (28 ref.)

A review of dietary and environmental correlates of obesity with emphasis on developing countries. Popkin BM, et al. **Obes Res** 1995 Sep;3 Suppl 2:145s–153s (69 ref.)

Pregnancy as a risk factor for obesity: lessons from the Stockholm Pregnancy and Weight Development Study. Rössner S, et al. **Obes Res** 1995 Sep;3 Suppl 2:267s–275s (22 ref.)

Obesity in Europe. Seidell JC. **Obes Res** 1995 Sep;3 Suppl 2:89s–93s (9 ref.)

[Nutrition and metabolic syndrome] Hauner H. **Internist (Berl)** 1995 Nov;36(11):1040–5 (37 ref.) **(Ger)**

[Nutrition behavior in Germany] Pudel V, et al. **Internist (Berl)** 1995 Nov;36(11):1032–9 (22 ref.) **(Ger)**

[Epidemiologic study on factors related to obesity] Hara M. **Nippon Rinsho** 1995 Jun;53 Suppl:249–54 (11 ref.) **(Jpn)**

[Obesity as a risk factor of hypertension (prospective study)] Yoshikawa A, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:271–5 (18 ref.) **(Jpn)**

ETHNOLOGY

Ethnicity and energy stores. Conway JM. **Am J Clin Nutr** 1995 Nov;62(5 Suppl):1067S–1071S (35 ref.)

ETIOLOGY

Body composition, respiratory quotient, and weight maintenance. Flatt JP. **Am J Clin Nutr** 1995 Nov;62(5 Suppl):1107S–1117S (72 ref.)

Television viewing as a cause of increasing obesity among children in the United States, 1986–1990. Gortmaker SL, et al. **Arch Pediatr Adolesc Med** 1996 Apr;150(4):356–62 (40 ref.)

Glycogen levels and obesity. Flatt JP. **Int J Obes Relat Metab Disord** 1996 Mar;20 Suppl 2:S1–11 (48 ref.)

A neuroendocrine reappraisal of the dual-centre hypothesis: its implications for obesity and insulin resistance. Rohner-Jeanrenaud F. **Int J Obes Relat Metab Disord** 1995 Aug;19(8):517–34 (312 ref.)

Obesity and behaviour change: matching problems to practice. Wardle J. **Int J Obes Relat Metab Disord** 1996 Feb;20 Suppl 1:S1–8 (90 ref.)

Fat and obesity. Weststrate JA. **Int J Obes Relat Metab Disord** 1995 Nov;19 Suppl 5:S38–43 (43 ref.)

Brain peptides and obesity: pharmacologic treatment. Leibowitz SF. **Obes Res** 1995 Nov;3 Suppl 4:573S–589S (196 ref.)

Pathophysiology and pathogenesis of visceral fat obesity. Matsuzawa Y, et al. **Obes Res** 1995 Sep;3 Suppl 2:187S–194S (14 ref.)

A review of dietary and environmental correlates of obesity with emphasis on developing countries. Popkin BM, et al. **Obes Res** 1995 Sep;3 Suppl 2:145s–153s (69 ref.)

Abnormalities of energy expenditure and the development of obesity. Roberts SB. **Obes Res** 1995 Sep;3 Suppl 2:155s–163s (50 ref.)

The role of dietary fiber in the development and treatment of childhood obesity. Kimm SY. **Pediatrics** 1995 Nov;96(5 Pt 2):1010–4 (51 ref.)

Is obesity an eating disorder? Jebb SA, et al. **Proc Nutr Soc** 1996 Nov;54(3):721–8 (22 ref.)

[Etiology and physiopathology of obesity: eating behaviors and their disorders] Fukudo S, et al. **Nippon Naika Gakkai Zasshi** 1995 Aug 10;84(8):1226–30 (11 ref.) **(Jpn)**

[Etiology and physiopathology of obesity: mechanism of appetite control] Inokuchi T. **Nippon Naika Gakkai Zasshi** 1995 Aug 10;84(8):1221–5 (5 ref.) **(Jpn)**

[Etiology and physiopathology of obesity: obesity due to hypothalamic lesions] Tokunga K, et al. **Nippon Naika Gakkai Zasshi** 1995 Aug 10;84(8):1231–5 (5 ref.) **(Jpn)**

[Etiology of obesity] Goto Y. **Nippon Rinsho** 1995 Jun;53 Suppl:239–46 (10 ref.) **(Jpn)**

[Endocrine obesity] Inoue S, et al. **Nippon Rinsho** 1995 Jun; 53 Suppl:419–24 (16 ref.) **(Jpn)**

[Feeding behavior: its deviation in obese subjects] Kurokawa M. **Nippon Rinsho** 1995 Jun;53 Suppl:398–404 (12 ref.) **(Jpn)**

[Obesity due to alcohol intake] Nakamura H, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:430–5 (8 ref.) **(Jpn)**

[Obesity due to central nervous system diseases] Sakuragawa N. **Nippon Rinsho** 1995 Jun;53 Suppl:415–8 (16 ref.) **(Jpn)**

[Molecular biology of obesity] Suzuki H, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:569–73 (18 ref.) **(Jpn)**

[Genetic syndrome with obesity] Tsuda K, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:436–40 (19 ref.) **(Jpn)**

[TV and sedentary life result in more overweight people] Sjöström L. **Lakartidningen** 1996 Jan 17;93(3):167–70 (37 ref.) **(Swe)**

GENETICS

The use of discordant sibling pairs for finding genetic loci linked to obesity: practical considerations. Allison DB. **Int J Obes Relat Metab Disord** 1996 Jun;20(6):553–60 (54 ref.)

Genetics of obesity: an update on molecular markers. Bouchard C. **Int J Obes Relat Metab Disord** 1995 Sep;19 Suppl 3:S10–3 (34 ref.)

Current status of the human obesity gene map. Bouchard C, et al. **Obes Res** 1996 Jan;4(1):81–90 (56 ref.)

[Molecular biology of adipocyte metabolism and obese gene] Kagawa Y. **Nippon Rinsho** 1995 Jun;53 Suppl:93–9 (16 ref.) **(Jpn)**

IMMUNOLOGY

[Obesity and the related diseases: obesity and the immunology] Tanaka S. **Nippon Naika Gakkai Zasshi** 1995 Aug 10;84(8):1267–72 (5 ref.) **(Jpn)**

[Impaired immunity in obesity] Tanaka S. **Nippon Rinsho** 1995 Jun;53 Suppl:377–81 (20 ref.) **(Jpn)**

METABOLISM

beta-cell stimulus – secretion coupling defects in rodent models of obesity. Chan CB. **Can J Physiol Pharmacol** 1995 Oct;73(10):1414–24 (138 ref.)

Glucose metabolism in obese subjects: lessons from OGTT, IVGTT and clamp studies. Scheen AJ, et al. **Int J Obes Relat Metab Disord** 1995 Sep;19 Suppl 3:S14–20 (45 ref.)

Human obesity: from lipid abnormalities to lipid oxidation. Van Gaal LF, et al. **Int J Obes Relat Metab Disord** 1995 Sep;19 Suppl 3:S21–6 (40 ref.)

Arachidonic acid maldistribution in obesity. Phinney SD. **Lipids** 1996 Mar;31 Suppl:S271–4 (14 ref.)

Homeostatic maintenance regulated by hypothalamic neuronal histamine. Sakata T, et al. **Methods Find Exp Clin Pharmacol** 1995 Nov;17 Suppl C:51–6 (39 ref.)

Endocrine aspects of obesity. Drent ML, et al. **Neth J Med** 1995 Sep;47(3):127–36 (98 ref.)

[Brain neurochemical systems which control appetite] Pesonen U, et al. **Duodecim** 1994;110(13):1241–50 (26 ref.) **(Fin)**

[Physiopathology of lipid metabolism and liver changes in obesity] Cotrozzi G, et al. **Clin Ter** 1995 Aug–Sep; 146(8–9):483–90 (53 ref.) (Eng. Abstr.) **(Ita)**

[Abnormal glucose metabolism and insulin resistance in obesity] Inoue Y, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:299–303 (22 ref.) **(Jpn)**

[Steroid hormone receptors in the CNS from animal models with fatty syndrome] Takeda R. **Nippon Rinsho** 1995 Jun; 53 Suppl:70–4 (13 ref.) **(Jpn)**

[Hormonal aspects of obesity] Męczekalski B, et al. **Ginekol Pol** 1995 Oct;66(10):600–4 (30 ref.) (Eng. Abstr.) **(Pol)**

MORTALITY

Morbidity and mortality associated with elevated body weight in children and adolescents. Must A. **Am J Clin Nutr** 1996 Mar;63(3 Suppl):445S–447S (27 ref.)

PHYSIOPATHOLOGY

Insulin resistance and obesity. The role of fat distribution pattern. Abate N. **Diabetes Care** 1996 Mar;19(3):292–4 (25 ref.)

Changes in autonomic nervous system activity and consecutive hyperinsulinaemia: respective roles in the development of obesity in rodents. Pénicaud L, et al. **Diabetes Metab** 1996 Feb;22(1):15–24 (67 ref.)

Insulin, corticosterone and the autonomic nervous system in animal obesities: a viewpoint. Jeanrenaud B. **Diabetologia** 1995 Aug;38(8):998–1002 (61 ref.)

Physical fitness, mortality and obesity. Barlow CE, et al. **Int J Obes Relat Metab Disord** 1995 Oct;19 Suppl 4:S41–4 (14 ref.)

Evolution of the understanding of the role of exercise in obesity and its complications. Björntorp P. **Int J Obes Relat Metab Disord** 1995 Oct;19 Suppl 4:S1–4 (15 ref.)

Intake of sugars in relation to fatness and micronutrient adequacy. Bolton-Smith C. **Int J Obes Relat Metab Disord** 1996 Mar;20 Suppl 2:S31–3 (35 ref.)

The acylation stimulating protein–adipsin system. Cianflone K, et al. **Int J Obes Relat Metab Disord** 1995 May;19 Suppl 1:S34–8 (57 ref.)

Epidemiology of obesity in relation to nutrient intake. Gibney MJ. **Int J Obes Relat Metab Disord** 1995 Nov;19 Suppl 5:S1–3 (25 ref.)

Energy density of diets and obesity. Poppitt SD. **Int J Obes Relat Metab Disord** 1995 Nov;19 Suppl 5:S20–6 (55 ref.)

Alcohol and obesity. Prentice AM. **Int J Obes Relat Metab Disord** 1995 Nov;19 Suppl 5:S44–50 (31 ref.)

Manipulating carbohydrate content and sources in obesity prone subjects: effect on energy expenditure and macronutrient balance. Raben A, et al. **Int J Obes Relat Metab Disord** 1996 Mar;20 Suppl 2:S24–30 (81 ref.)

A neuroendocrine reappraisal of the dual–centre hypothesis: its implications for obesity and insulin resistance. Rohner-Jeanrenaud F. **Int J Obes Relat Metab Disord** 1995 Aug;19(8):517–34 (312 ref.)

Exercise and thermogenesis in obesity. Segal KR. **Int J Obes Relat Metab Disord** 1995 Oct;19 Suppl 4:S80–7 (25 ref.)

The impact of obesity on health status: some implications for health care costs. Seidell JC. **Int J Obes Relat Metab Disord** 1995 Nov;19 Suppl 6:S13–6 (9 ref.)

Obesity and behaviour change: matching problems to practice. Wardle J. **Int J Obes Relat Metab Disord** 1996 Feb;20 Suppl 1:S1–8 (90 ref.)

Influence of altered body weight on energy expenditure. Kinney JM. **Nutr Rev** 1995 Sep;53(9):265–8 (14 ref.)

The hypothalamic–pituitary–adrenal axis in obesity. Chalew S, et al. **Obes Res** 1995 Jul;3(4):371–82 (136 ref.)

Prevention of obesity in middle–aged monkeys: food intake during body weight clamp. Hansen BC, et al. **Obes Res** 1995 Sep;3 Suppl 2:199s–204s (26 ref.)

Community programs for obesity prevention: the Minnesota Heart Health Program. Jeffery RW. **Obes Res** 1995 Sep; 3 Suppl 2:283s–288s (21 ref.)

Pathophysiology and pathogenesis of visceral fat obesity. Matsuzawa Y, et al. **Obes Res** 1995 Sep;3 Suppl 2:187S–194S (14 ref.)

Insulin resistance in obesity and its molecular control. Noguchi T, et al. **Obes Res** 1995 Sep;3 Suppl 2:195S–198S (20 ref.)

Abnormalities of energy expenditure and the development of obesity. Roberts SB. **Obes Res** 1995 Sep;3 Suppl 2:155s–163s (50 ref.)

Pregnancy as a risk factor for obesity: lessons from the Stockholm Pregnancy and Weight Development Study. Rössner S, et al. **Obes Res** 1995 Sep;3 Suppl 2:267s–275s (22 ref.)

Energy homeostasis, autonomic activity and obesity. Scheurink AJ, et al. **Obes Res** 1995 Dec;3 Suppl 5:721S–727S (54 ref.)

Abnormalities of fuel utilization as predisposing to the development of obesity in humans. Schutz Y. **Obes Res** 1995 Sep;3 Suppl 2:173S–178S (27 ref.)

[Renal alterations in obesity] Kato A, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:359–64 (20 ref.) **(Jpn)**

[Effect of obesity on gonadal function in men] Minowada S. **Nippon Rinsho** 1995 Jun;53 Suppl:320–4 (14 ref.) **(Jpn)**

[Cerebral circulatory disorder, ischemic cerebrovascular disease in obesity] Nagatsuka K. **Nippon Rinsho** 1995 Jun; 53 Suppl:338–42 (12 ref.) **(Jpn)**

[Endocrine function (pituitary, thyroid, adrenal gland) of obesity] Ogino Y, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:316–9 (13 ref.) **(Jpn)**

[Hemodynamics in obesity] Sugimoto T, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:325–31 (9 ref.) **(Jpn)**

PREVENTION & CONTROL

Carbohydrate and obesity. Astrup A, et al. **Int J Obes Relat Metab Disord** 1995 Nov;19 Suppl 5:S27–37 (121 ref.)

Exercise and cancer: linkages with obesity? Shephard RJ. **Int J Obes Relat Metab Disord** 1995 Oct;19 Suppl 4:S62–8 (107 ref.)

Internal regulation and the evolution of normal growth as the basis for prevention of obesity in children. Satter EM. **J Am Diet Assoc** 1996 Sep;96(9):860–4 (35 ref.)

Can obesity be prevented? Bouchard C. **Nutr Rev** 1996 Apr; 54(4 Pt 2):S125–30 (32 ref.)

Toward comprehensive obesity prevention programs in Native American communities. Broussard BA, et al. **Obes Res** 1995 Sep;3 Suppl 2:289s–297s (50 ref.)

Prevention of obesity in middle–aged monkeys: food intake during body weight clamp. Hansen BC, et al. **Obes Res** 1995 Sep;3 Suppl 2:199s–204s (26 ref.)

Community programs for obesity prevention: the Minnesota Heart Health Program. Jeffery RW. **Obes Res** 1995 Sep; 3 Suppl 2:283s–288s (21 ref.)

A very-low-calorie conventional Japanese diet: its implications for prevention of obesity. Sakata T. **Obes Res** 1995 Sep;3 Suppl 2:233s–239s (21 ref.)

Changing diet and exercise behaviors in individuals at risk for weight gain. Wing RR. **Obes Res** 1995 Sep;3 Suppl 2:277s–282s (28 ref.)

[Leptin—a new way to diet?] Holst JJ. **Ugeskr Laeger** 1996 Aug 5;158(32):4505–8 (25 ref.) (Eng. Abstr.) **(Dan)**

[Hypertension and coronary heart disease. Global risk moderation through control of body weight] Suter PM, et al. **Schweiz Rundsch Med Prax** 1996 Jan 30;85(5):113–6 (18 ref.) (Eng. Abstr.) **(Ger)**

PSYCHOLOGY

Psychosocial consequences of weight reduction: how much weight loss is enough? Wadden TA, et al. **Am J Clin Nutr** 1996 Mar;63(3 Suppl):461S–465S (48 ref.)

Exercise and obesity treatment: psychological aspects. Brownell KD. **Int J Obes Relat Metab Disord** 1995 Oct; 19 Suppl 4:S122–5 (24 ref.)

New perspectives on dietary and behavioural treatments for obesity. Fairburn CG, et al. **Int J Obes Relat Metab Disord** 1996 Feb;20 Suppl 1:S9–13 (63 ref.)

Behaviour change in practice: group approaches. Hayaki J, et al. **Int J Obes Relat Metab Disord** 1996 Feb;20 Suppl 1:S27–30 (18 ref.)

Behaviour change in practice: targeting individuals. Rollnick S. **Int J Obes Relat Metab Disord** 1996 Feb;20 Suppl 1:S22–6 (19 ref.)

Psychosocial factors and quality of life in obesity. Sarlio-Lähteenkorva S, et al. **Int J Obes Relat Metab Disord** 1995 Nov;19 Suppl 6:S1–5 (49 ref.)

Self–esteem and obesity in children and adolescents: a literature review. French SA, et al. **Obes Res** 1995 Sep; 3(5):479–90 (74 ref.)

The dyslipophobias: a view of the psychopathologies involved and the hazards of construing anorexia nervosa and bulimia nervosa as 'eating disorders'. Crisp AH. **Proc Nutr Soc** 1996 Nov;54(3):701–9 (10 ref.)

[Mental disorders and obesity] Kodama K, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:392–7 (14 ref.) **(Jpn)**

[Features of eating behaviour and their psychological background in simple obesity patients] Takeda N, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:407–11 (8 ref.) **(Jpn)**

SURGERY

A "bicycle–handlebar" type of incision for primary and secondary abdominoplasty. Baroudi R, et al. **Aesthetic Plast Surg** 1995 Jul–Aug;19(4):307–20 (27 ref.)

[Operative complications of obese patients and its countermeasure] Kawamura I. **Nippon Rinsho** 1995 Jun;53 Suppl:545–9 (16 ref.) **(Jpn)**

[Prevention of wound infection in surgical treatment of alimentary–constitutional obesity] Okoemov MN, et al. **Khirurgiia (Mosk)** 1995;(6):47–50 (77 ref.) **(Rus)**

THERAPY

Psychosocial consequences of weight reduction: how much weight loss is enough? Wadden TA, et al. **Am J Clin Nutr** 1996 Mar;63(3 Suppl):461S–465S (48 ref.)

Exercise in the treatment of childhood obesity. Epstein LH. **Int J Obes Relat Metab Disord** 1995 Oct;19 Suppl 4:S117–21 (32 ref.)

Exercise in the treatment of obesity: a marginal contribution. Garrow JS. **Int J Obes Relat Metab Disord** 1995 Oct;19 Suppl 4:S126–9 (36 ref.)

Exercise with or without dietary restriction and obesity treatment. Saris WH. **Int J Obes Relat Metab Disord** 1995 Oct;19 Suppl 4:S113–6 (31 ref.)

Costs and benefits when treating obesity. Sjöström L, et al. **Int J Obes Relat Metab Disord** 1995 Nov;19 Suppl 6:S9–12 (10 ref.)

Exercise for weight loss: what are the facts? Zelasko CJ. **J Am Diet Assoc** 1995 Dec;95(12):1414–7 (22 ref.)

Recent progress in the studies on weight reduction by acupuncture and moxibustion. Liu Z, et al. **J Tradit Chin Med** 1995 Sep;15(3):224–30 (42 ref.)

Exercise in treating obesity in children and adolescents. Epstein LH, et al. **Med Sci Sports Exerc** 1996 Apr; 28(4):428–35 (52 ref.)

The case for randomized clinical trials on the treatment of obesity. Stern MP. **Obes Res** 1995 Sep;3 Suppl 2:299s–306s (25 ref.)

Preventing relapse in weight control: a discussion of cognitive and behavioral strategies. Turner LW, et al. **Psychol Rep** 1995 Oct;77(2):651–6 (25 ref.)

[Therapy of obesity] Wechsler JG. **Internist (Berl)** 1995 Nov; 36(11):1063–9 (23 ref.) **(Ger)**

[Group treatment programs for obese subjects] Melcarne R,

et al. **Minerva Gastroenterol Dietol** 1996 Mar;42(1):27-38 (75 ref.) (Eng. Abstr.) **(Ita)**

[Exercise therapy of obesity] Abe R. **Nippon Naika Gakkai Zasshi** 1995 Aug 10;84(8):1279-83 (3 ref.) **(Jpn)**

[Behavior therapy of obesity] Sakata T. **Nippon Naika Gakkai Zasshi** 1995 Aug 10;84(8):1284-9 (5 ref.) **(Jpn)**

[Cognitive-behavioral therapy for obesity--with special reference to binge eating disorder] Komaki G. **Nippon Rinsho** 1995 Jun;53 Suppl:468-74 (14 ref.) **(Jpn)**

[Psychotherapy for obesity] Noda S, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:475-80 (19 ref.) **(Jpn)**

[Effects of one-week inpatient weight reduction program for obese persons] Ogawa K, et al. **Nippon Rinsho** 1995 Jun; 53 Suppl:501-8 (11 ref.) **(Jpn)**

[Behavioural modification for therapy of obesity] Ohno M, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:460-7 (15 ref.) **(Jpn)**

[General aspects of the management for obesity] Sato T, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:443-8 (20 ref.) **(Jpn)**

[Physical exercise and obesity] Sato Y, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:455-9 (20 ref.) **(Jpn)**

[Childhood obesity: treatment and prognosis] Yamazaki K, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:529-33 (12 ref.) **(Jpn)**

[Old principles for th treatment of obesity are still valid. Diet and exercise are still the most important factors] Rössner S. **Lakartidningen** 1996 Mar 20;93(12):1117-20 (12 ref.) **(Swe)**

ULTRASONOGRAPHY

[Ultrasonic diagnosis of visceral type obesity] Murano S, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:203-8 (10 ref.) **(Jpn)**

OBESITY IN DIABETES

[Obesity and diabetes mellitus] Funahashi T, et al. **Nippon Naika Gakkai Zasshi** 1996 Apr 10;85(4):578-82 (0 ref.) **(Jpn)**

METABOLISM

Are the beta-cell signaling molecules malonyl-CoA and cystolic long-chain acyl-CoA implicated in multiple tissue defects of obesity and NIDDM? Prentki M, et al. **Diabetes** 1996 Mar;45(3):273-83 (163 ref.)

PHYSIOPATHOLOGY

Understanding the pathogenesis of type 2 diabetes: can we get off the metabolic merry-go-rounds? Proietto J, et al. **Aust N Z J Med** 1995 Dec;25(6):870-5 (33 ref.)

Insulin secretion in obese and non-obese NIDDM. Cerasi E, et al. **Diabetes Res Clin Pract** 1995 Aug;28 Suppl:S27-37 (62 ref.)

URINE

[Microalbuminuria and non-insulin-dependent diabetes: practical interpretation and therapeutic consequences] Bouhanick B, et al. **Diabete Metab** 1995 Oct;21(4):295-8 (20 ref.) **(Fre)**

OBESITY, MORBID

see related
GASTRIC BYPASS
JEJUNOILEAL BYPASS

Obesity: an anaesthetic challenge. Oberg B, et al. **Acta Anaesthesiol Scand** 1996 Feb;40(2):191-200 (88 ref.)

[Morbid obesity] Koh N, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:511-4 (20 ref.) **(Jpn)**

ETIOLOGY

Unravelling the nature of massive obesity: the research of Daniel AK Roncari. Hamilton BS. **Int J Obes Relat Metab Disord** 1996 Mar;20 Suppl 3:S73-6 (37 ref.)

METABOLISM

[Physiopathology of lipid metabolism and liver changes in obesity] Cotrozzi G, et al. **Clin Ter** 1995 Aug-Sep; 146(8-9):483-90 (53 ref.) (Eng. Abstr.) **(Ita)**

SURGERY

The surgical treatment of morbid obesity. Pories WJ, et al. **Curr Opin Gen Surg** 1993;:195-205 (22 ref.)

[Therapy of morbid obesity--is the surgeon consulted? (editorial)] Husemann B. **Zentralbl Chir** 1996;121(5):349-53 (36 ref.) (Eng. Abstr.) **(Ger)**

[Is there still a place for biliointestinal bypass in the treatment of super obesity? (editorial)] Benhamou G, et al. **G Chir** 1996 Apr;17(4):149-53 (16 ref.) **(Ita)**

[Surgical treatment of obesity] Kawamura I. **Nippon Naika Gakkai Zasshi** 1995 Aug 10;84(8):1295-9 (5 ref.) **(Jpn)**

[Surgical treatment of morbid obesity] Isono K, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:487-92 (11 ref.) **(Jpn)**

[Pathogenesis of chronic diarrhoea after surgery for extreme obesity] Lemieszewski A. **Pol Tyg Lek** 1996 Jan; 51(1-5):37-9 (32 ref.) **(Pol)**

[Morbid obesity. Reflections on a surgical protocol (I). A clinical and peroperative protocol] Alastrué A, et al. **Nutr Hosp** 1995 Nov-Dec;10(6):307-20 (80 ref.) (Eng. Abstr.) **(Spa)**

[Morbid obesity. Reflections on a surgical protocol (II). The experience accumulated over 5 years] Alastrué A, et al. **Nutr Hosp** 1995 Nov-Dec;10(6):321-30 (61 ref.) (Eng. Abstr.) **(Spa)**

[Obese patients on the operating table. A laparoscopic technique is under way] Näslund I. **Lakartidningen** 1996 Feb 7;93(6):485-8 (15 ref.) **(Swe)**

OBJECT ATTACHMENT

Factors in the etiology and pathogenesis of panic disorder: revisiting the attachment-separation paradigm. Shear MK. **Am J Psychiatry** 1996 Jul;153(7 Suppl):125-36 (64 ref.)

Spousal abuse and violence against women: the significance of understanding attachment. Vazquez CI. **Ann N Y Acad Sci** 1996 Jun 18;789:119-28 (26 ref.)

Attachment and separation in young children. Field T. **Annu Rev Psychol** 1996;47:541-61 (45 ref.)

Object relations and nursing care of persons experiencing psychosis. Connick Jamison S, et al. **Arch Psychiatr Nurs** 1996 Jun;10(3):129-35 (18 ref.)

Transpersonal processes: a bridge between object relations and attachment theory in normal and psychopathological development. Muir RC. **Br J Med Psychol** 1995 Sep;68 (Pt 3):243-57 (85 ref.)

Orphans of the Real: II. The future of object relations theory in the treatment of the psychoses and other primitive mental disorders. Grotstein JS. **Bull Menninger Clin** 1995 Summer;59(3):312-32 (75 ref.)

Object relations units and the ego. Hamilton NG. **Bull Menninger Clin** 1995 Fall;59(4):416-26 (25 ref.)

A representational perspective of child abuse and prevention: internal working models of attachment and caregiving. George C. **Child Abuse Negl** 1996 May;20(5):411-24 (62 ref.)

Human development in the context of aging and chronic illness: the role of attachment in Alzheimer's disease and stroke. Wright LK, et al. **Int J Aging Hum Dev** 1995; 41(2):133-50 (82 ref.)

Termination in group psychotherapy from the perspectives of contemporary object relations theory and self psychology. Schermer VL, et al. **Int J Group Psychother** 1996 Jan;46(1):99-115 (38 ref.)

Attachment and risk for psychopathology: the early years. Crittenden PM. **J Dev Behav Pediatr** 1995 Jun;16(3 Suppl):S12-6 (16 ref.)

Attachment and learning disability: a theoretical review informing three clinical interventions. Clegg JA, et al. **J Intellect Disabil Res** 1995 Aug;39 (Pt 4):295-305 (43 ref.)

The social life of bonding theory. Crouch M, et al. **Soc Sci Med** 1995 Sep;41(6):837-44 (88 ref.)

[Quality of attachment representation, social integration and use of social network resources in advanced age] Wensauer M, et al. **Z Gerontol Geriatr** 1995 Nov-Dec;28(6):444-56 (89 ref.) (Eng. Abstr.) **(Ger)**

OBJECT RELATIONS see **OBJECT ATTACHMENT**

OBLIGATION, SOCIAL see **SOCIAL RESPONSIBILITY**

OBSESSIVE-COMPULSIVE DISORDER

[Obsessive-compulsive disorder in children and adolescents. Epidemiological and clinical aspects] Thomsen PH. **Ugeskr Laeger** 1996 Aug 19;158(34):4737-40 (29 ref.) (Eng. Abstr.) **(Dan)**

[Obsessive-compulsive disorder in children and adolescents. Etiology and treatment--a literature review] Thomsen PH. **Ugeskr Laeger** 1996 Aug 19;158(34):4741-5 (40 ref.) (Eng. Abstr.) **(Dan)**

COMPLICATIONS

Eating disorder and obsessive-compulsive disorder: neurochemical and phenomenological commonalities. Jarry JL, et al. **J Psychiatry Neurosci** 1996 Jan;21(1):36-48 (125 ref.)

The physiological threat of compulsive syndromes. Cohn LG. **J R Soc Health** 1995 Oct;115(5):320-2 (16 ref.)

[Depression and obsessive-compulsive disorder cor-morbidity] Barcia D. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1996 Mar-Apr;24(2):91-6 (29 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Normal caudate nucleus in obsessive-compulsive disorder assessed by quantitative neuroimaging. Aylward EH, et al. **Arch Gen Psychiatry** 1996 Jul;53(7):577-84 (48 ref.)

The assessment of unwanted intrusive thoughts: a review and critique of the literature. Clark DA, et al. **Behav Res Ther** 1995 Nov;33(8):967-76 (60 ref.)

Annotation: developmental issues in obsessive-compulsive disorder. Bolton D. **J Child Psychol Psychiatry** 1996 Feb; 37(2):131-7 (68 ref.)

Obsessive-compulsive spectrum disorders in primary care: the possibilities and the pitfalls. Higgins ES. **J Clin Psychiatry** 1996;57 Suppl 8:7-9; discussion 9-10 (14 ref.)

Functional neuroanatomy of obsessive-compulsive disorder. Trivedi MH. **J Clin Psychiatry** 1996;57 Suppl 8:26-35; discussion 36 (69 ref.)

[Cognition disorders in obsessive disorder] Amado-Boccara I, et al. **Encephale** 1989 May-Jun;15(3):319-23 (22 ref.) (Eng. Abstr.) **(Fre)**

[Psychometric evaluation of obsessive compulsive disorder. Recent diagnostic scales] Buisson G, et al. **Encephale** 1989 May-Jun;15(3):359-67 (33 ref.) (Eng. Abstr.) **(Fre)**

[Obsessive compulsive disorder. Clinical and epidemiologic studies] Hantouche E, et al. **Encephale** 1989 May-Jun; 15(3):309-18 (54 ref.) (Eng. Abstr.) **(Fre)**

[Anorexia nervosa. A frequent antecedent of obsessive compulsive disorder] Zribi S, et al. **Encephale** 1989 May-Jun;15(3):355-8 (19 ref.) (Eng. Abstr.) **(Fre)**

[Follow-up of obsessive-compulsive disorders in childhood and adolescence--a review of the literature] Neudörfl A, et al. **Z Kinder Jugendpsychiatr** 1996 Jun;24(2):105-16 (45 ref.) **(Ger)**

DRUG THERAPY

The pathogenesis and treatment of obsessive-compulsive disorder. Dolberg OT, et al. **Clin Neuropharmacol** 1996 Apr;19(2):129-47 (112 ref.)

Selective serotonin reuptake inhibitors in obsessive-compulsive disorder. **Drug Ther Bull** 1995 Jun; 33(6):47-8 (21 ref.)

Obsessive-compulsive disorder in elderly patients. Jackson CW. **Drugs Aging** 1995 Dec;7(6):438-48 (108 ref.)

OCD: where the serotonin selectivity story begins. Pigott TA. **J Clin Psychiatry** 1996;57 Suppl 6:11-20 (91 ref.)

[Critical analysis of controlled pharmacologic studies in obsessive compulsive disorder] Brochier T, et al. **Encephale** 1989 May-Jun;15(3):325-33 (51 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Obsessive-compulsive disorder after closed head injury: review of literature and report of four cases. Kant R, et al. **Brain Inj** 1996 Jan;10(1):55-63 (37 ref.)

Frontal abnormalities in a patient with obsessive-compulsive disorder: the role of structural lesions in obsessive-compulsive behavior. Swoboda KJ, et al. **Neurology** 1995 Dec;45(12):2130-4 (25 ref.)

PHYSIOPATHOLOGY

Neuropeptides in anxiety disorders. Effects of lactation. Altemus M. **Ann N Y Acad Sci** 1995 Dec 29;771:697-707 (80 ref.)

The pathogenesis and treatment of obsessive-compulsive disorder. Dolberg OT, et al. **Clin Neuropharmacol** 1996 Apr;19(2):129-47 (112 ref.)

Neuropsychiatry of obsessive-compulsive disorder in children and adolescents. March JS, et al. **Compr Ther** 1995 Sep;21(9):507-12 (71 ref.)

Serotonin dysfunction disorders: a behavioral neurochemistry perspective. Petty F, et al. **J Clin Psychiatry** 1996;57 Suppl 8:11-6 (24 ref.)

OCD: where the serotonin selectivity story begins. Pigott TA. **J Clin Psychiatry** 1996;57 Suppl 6:11-20 (91 ref.)

[Neuroimaging and neurobiology of obsessive compulsive disorder: review of recent developments in research] Huguelet P, et al. **Encephale** 1996 Jan-Feb;22(1):41-5 (29 ref.) (Eng. Abstr.) **(Fre)**

[Neurobiological and psychodynamic correlations in obsessive-compulsive disorders and bulimia nervosa] Csef H. **Z Klin Psychol Psychopathol Psychother** 1996; 44(3):267-79 (70 ref.) (Eng. Abstr.) **(Ger)**

PSYCHOLOGY

Symptom subtypes of obsessive-compulsive disorder in behavioral treatment studies: a quantitative review. Ball SG, et al. **Behav Res Ther** 1996 Jan;34(1):47-51 (73 ref.)

[Perspectives and time as relevant phenomena in the psychopathology of obsessive-compulsive neuroses] Kraus MR, et al. **Z Klin Psychol Psychopathol Psychother** 1995; 43(4):348-54 (33 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Symptom subtypes of obsessive-compulsive disorder in behavioral treatment studies: a quantitative review. Ball SG, et al. **Behav Res Ther** 1996 Jan;34(1):47-51 (73 ref.)

Correcting faulty appraisals of obsessional thoughts. Freeston MH, et al. **Behav Res Ther** 1996 May-Jun;34(5-6):433-46 (52 ref.)

Obsessive-compulsive disorder. Diagnosis and management. Ladouceur R, et al. **Can Fam Physician** 1996 Jun; 42:1169-72, 1175-8 (23 ref.)

Behavior therapy: endogenous serotonin therapy? Baer L. **J Clin Psychiatry** 1996;57 Suppl 6:33-5 (12 ref.)

Management of obsessive compulsive disorder. Yap HL. **Singapore Med J** 1995 Feb;36(1):77-9 (23 ref.)

[Behavior therapy of obsessive compulsive disorders] Légeron P, et al. **Encephale** 1989 May-Jun;15(3):343-50 (75 ref.) (Eng. Abstr.) **(Fre)**

OBSTETRICAL ANALGESIA see **ANALGESIA, OBSTETRICAL**

OBSTETRICAL FORCEPS

Forcep deliveries. Thompson JP. **Clin Perinatol** 1995 Dec; 22(4):953–72 (14 ref.)

ADVERSE EFFECTS

Choice and instrumental delivery. Drife JO.
Br J Obstet Gynaecol 1996 Jul;103(7):608–11 (38 ref.)

OBSTETRICAL NURSING

METHODS

Helping survivors of sexual abuse through labor. Burian J. **MCN Am J Matern Child Nurs** 1995 Sep–Oct;20(5):252–6 (14 ref.)

OBSTETRICS

see related
PREGNANCY COMPLICATIONS

The current status of Doppler sonography in obstetrics. Alfirevic Z, et al. **Curr Opin Obstet Gynecol** 1996 Apr; 8(2):114–8 (38 ref.)

Preventive care in obstetrics: toxoplasmosis, cytomegalovirus, and hepatitis B. Ledger WJ.
J Matern Fetal Med 1996 May–Jun;5(3):100–5 (26 ref.)

What is obstetric ethics? Chervenak FA, et al.
J Perinat Med 1995;23(5):331–41 (52 ref.)

Epidemiology of injuries by needles and other sharp instruments. Minimizing sharp injuries in gynecologic and obstetric operations. Lewis FR Jr, et al.
Surg Clin North Am 1995 Dec;75(6):1105–21 (34 ref.)

The art of ultrasound in obstetrics: from abstraction to hyper-realism [editorial] Achiron R.
Ultrasound Obstet Gynecol 1995 Jul;6(1):1–3 (9 ref.)

[Advantages and disadvantages of induced labor without medical indication: the viewpoint of obstetricians in private practice] Peter J. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24 Suppl 1:78–88 (40 ref.) **(Fre)**

[Application of molecular biological techniques for obstetric and gynecologic field] Suganuma N.
Nippon Sanka Fujinka Gakkai Zasshi 1995 Aug; 47(8):785–90 (19 ref.) **(Jpn)**

EDUCATION

Training in the management of critical obstetric problems: trainee's view. Mikkelsen B, et al.
Eur J Obstet Gynecol Reprod Biol 1996 Mar;65(1):149–51 (9 ref.)

Training in the management of critical problems: teacher's view. van Geijn HP, et al.
Eur J Obstet Gynecol Reprod Biol 1996 Mar;65(1):145–8 (10 ref.)

LEGISLATION & JURISPRUDENCE

Medicolegal ramifications of electronic fetal monitoring during labor. Schifrin BS. **Clin Perinatol** 1995 Dec; 22(4):837–54 (42 ref.)

Interhospital transfers of obstetric patients under the Emergency Medical Treatment and Active Labor Act. Cardwell MS. **J Leg Med** 1995 Sep;16(3):357–72 (98 ref.)

[What are the medico-legal implications of induced labor?] Pierre F, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995; 24 Suppl 1:120–8 (0 ref.) **(Fre)**

STANDARDS

The origins of cerebral palsy. Australian and New Zealand Perinatal Societies. **J Paediatr Child Health** 1995 Aug; 31(4):284–9 (39 ref.)

Problems associated with early discharge of newborn infants. Early discharge of newborns and mothers: a critical review of the literature. Braveman P, et al. **Pediatrics** 1995 Oct; 96(4 Pt 1):716–26 (74 ref.)

TRENDS

Recent advances. Obstetrics [see comments] Steer P.
BMJ 1995 Nov 4;311(7014):1209–12 (57 ref.) Comment in: BMJ 1996 Feb 10;312(7027):379. Comment in: BMJ 1996 Feb 10;312(7027):379–80. Comment in: BMJ 1996 Apr 13;312(7036):974–5.

What's new in gynecology and obstetrics. Kammerer-Doak DN, et al. **J Am Coll Surg** 1996 Feb;182(2):107–14 (52 ref.)

OBSTETRICS AND GYNECOLOGY DEPARTMENT, HOSPITAL

ORGANIZATION & ADMINISTRATION

[Advantages and disadvantages of induced labor without medical indications: the viewpoint of the obstetrician in hospital practice] Maria B.
J Gynecol Obstet Biol Reprod (Paris) 1995;24 Suppl 1:67–77 (52 ref.) **(Fre)**

OBTURATOR HERNIA see **HERNIA, OBTURATOR**

OBTURATORS, PALATAL see **PALATAL OBTURATORS**

OCCIPITAL BONE

INJURIES

Fracture of the occipital condyle: case report and review of the literature. Emery E, et al. **Eur Spine J** 1995; 4(3):191–3 (17 ref.)

OCCIPITAL LOBE

ANATOMY & HISTOLOGY

Task dependency of visual processing in the human visual system. Orban GA, et al. **Behav Brain Res** 1996 Apr; 76(1–2):215–23 (41 ref.)

PHYSIOLOGY

Task dependency of visual processing in the human visual system. Orban GA, et al. **Behav Brain Res** 1996 Apr; 76(1–2):215–23 (41 ref.)

RADIOGRAPHY

Early onset bilateral calcifications and epilepsy. Nunes ML, et al. **Pediatr Neurol** 1995 Jul;13(1):80–2 (11 ref.)

OCCLUDING JUNCTIONS see **TIGHT JUNCTIONS**

OCCLUSAL FORCE see **BITE FORCE**

OCCLUSIVE DRESSINGS

Toxic epidermal necrolysis: a review and report of the successful use of Biobrane for early wound coverage. Bradley T, et al. **Ann Plast Surg** 1995 Aug;35(2):124–32 (45 ref.)

The use of gauze versus transparent dressings for peripheral intravenous catheter sites. Pettit DM, et al.
Nurs Clin North Am 1995 Sep;30(3):495–506 (15 ref.)

[Treatment of ulcus cruris. What is the role of wound dressings?] Sedlarik KM. **Med Monatsschr Pharm** 1995 Dec;18(12):358–62 (21 ref.) **(Ger)**

OCCULT BLOOD

Fecal occult blood screening for colorectal cancer. Van Dam J, et al. **Arch Intern Med** 1995 Dec 11–25;155(22):2389–402 (96 ref.)

Screening for colon cancer: a review of current and future strategies. Weinberg DS, et al. **Semin Oncol** 1995 Oct; 22(5):433–47 (138 ref.)

[Test for occult blood in feces: a method for reducing the mortality from colorectal cancer? (editorial)] Faivre J, et al. **Gastroenterol Clin Biol** 1996;20(3):225–7 (15 ref.) **(Fre)**

OCCULT PRIMARY NEOPLASMS see **NEOPLASMS, UNKNOWN PRIMARY**

OCCULT SPINA BIFIDA see **SPINA BIFIDA OCCULTA**

OCCULT SPINAL DYSRAPHISM see **SPINA BIFIDA OCCULTA**

OCCUPATIONAL DERMATITIS see **DERMATITIS, OCCUPATIONAL**

OCCUPATIONAL AIR POLLUTANTS see **AIR POLLUTANTS, OCCUPATIONAL**

OCCUPATIONAL DISEASES

see related
ACCIDENTS, OCCUPATIONAL

Rhabdomyolysis secondary to keyboard overuse: occupational hazard of the computer age. Jolly BT, et al.
Am J Emerg Med 1995 Nov;13(6):644–6 (18 ref.)

Can Dupuytren's contracture be work-related?: review of the evidence. Liss GM, et al. **Am J Ind Med** 1996 May; 29(5):521–32 (56 ref.)

Musculoskeletal and neuromuscular conditions of instrumental musicians. Bejjani FJ, et al.
Arch Phys Med Rehabil 1996 Apr;77(4):406–13 (108 ref.)

ABC of work related disorders. Building related illnesses. Appleby PH. **BMJ** 1996 Sep 14;313(7058):674–7 (0 ref.)

ABC of work related disorders. Back pain. Jayson MI.
BMJ 1996 Aug 10;313(7053):355–8 (0 ref.)

ABC of work related disorders. Occupational hearing loss and vibration induced disorders. Jones CM. **BMJ** 1996 Jul 27;313(7051):223–6 (0 ref.)

ABC of work related disorders. Hazards of work. Snashall D. **BMJ** 1996 Jul 20;313(7050):161–3 (0 ref.)

ABC of work related disorders. Occupational cancers. Veys CA. **BMJ** 1996 Sep 7;313(7057):615–9 (0 ref.)

Hepatitis C virus infection. Molinari JA.
Dent Clin North Am 1996 Apr;40(2):309–25 (77 ref.)

Tuberculosis. Phelan JA, et al. **Dent Clin North Am** 1996 Apr;40(2):327–41 (35 ref.)

Skin hazards of the marine aquarium industry. Tong DW.
Int J Dermatol 1996 Mar;35(3):153–8 (43 ref.)

Upper extremity disorders: a literature review to determine work-relatedness. Vender MI, et al. **J Hand Surg [Am]** 1995 Jul;20(4):534–41 (79 ref.)

Nurses: at special risk. Jackson MM, et al.
J Obstet Gynecol Neonatal Nurs 1995 Jul–Aug;24(6):533–40 (37 ref.)

Repetitive strain injury (RSI) or cumulative trauma disorder (CTD) as legal and clinical entities. The need for a total reappraisal of this concept as being occupationally caused and therefore compensatable. Lam SJ. **Med Sci Law** 1995 Oct;35(4):279–86 (10 ref.)

Overview of diisocyanate occupational asthma. Bernstein JA. **Toxicology** 1996 Jul 17;111(1–3):181–9 (24 ref.)

[Progress in occupational diseases in China, 1995] Ren Y, et al. **Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):765–6 (0 ref.) **(Chi)**

[When to stop the music (editorial)] Ohry A, et al.
Harefuah 1995 Dec 1;129(11):472–4 (31 ref.) **(Heb)**

CHEMICALLY INDUCED

Review of occupational lung carcinogens. Steenland K, et al. **Am J Ind Med** 1996 May;29(5):474–90 (167 ref.)

Organochlorine compounds: Risk of non-Hodgkin's lymphoma and breast cancer? Hoffman W.
Arch Environ Health 1996 May–Jun;51(3):189–92 (42 ref.)

Reactive airways dysfunction syndrome. Alberts WM, et al.
Chest 1996 Jun;109(6):1618–26 (72 ref.)

Occupational renal diseases. de Broe ME, et al.
Curr Opin Nephrol Hypertens 1996 Mar;5(2):114–21 (68 ref.)

Diesel engine exhaust and lung cancer: an unproven association. Muscat JE, et al. **Environ Health Perspect** 1995 Sep;103(9):812–8 (77 ref.)

Occupational asthma caused by natural rubber latex. Vandenplas O. **Eur Respir J** 1995 Nov;8(11):1957–65 (80 ref.)

Formaldehyde. **IARC Monogr Eval Carcinog Risks Hum** 1995;62:217–375 (479 ref.)

Occupational cancer in developed and developing countries. Vineis P, et al. **Int J Cancer** 1995 Sep 15;62(6):655–60 (32 ref.)

Hemoglobin adducts for in vivo dose monitoring and cancer risk estimation. Törnqvist M, et al.
J Occup Environ Med 1995 Sep;37(9):1077–85 (41 ref.)

Hepatitis, rash and eosinophilia following trichloroethylene exposure: a case report and speculation on mechanistic similarity to halothane induced hepatitis. Bond GR.
J Toxicol Clin Toxicol 1996;34(4):461–6 (11 ref.)

Occupational asthma due to isocyanates. Baur X. **Lung** 1996; 174(1):23–30 (50 ref.)

Measurements of environmental lead contamination and human exposure. Flegal AR, et al.
Rev Environ Contam Toxicol 1995;143:1–45 (231 ref.)

Epidemiology of atrazine. Loosli R.
Rev Environ Contam Toxicol 1995;143:47–57 (31 ref.)

Reproductive disorders due to chemical exposure among hairdressers. Kersemaekers WM, et al.
Scand J Work Environ Health 1995 Oct;21(5):325–34 (85 ref.)

Respiratory irritants encountered at work. Taylor AJ.
Thorax 1996 May;51(5):541–5 (17 ref.)

Respiratory effects of organic solvent exposure. Schenker MB, et al. **Tuber Lung Dis** 1996 Feb;77(1):4–18 (92 ref.)

[Occupational medicine aspects related to carcinogenic hazardous substances] Letzel S. **Dtsch Med Wochenschr** 1996 Jan 26;121(4):104–9 (11 ref.) **(Ger)**

[Do employees in the rubber industry have an increased risk of laryngeal cancer?] Tisch M, et al. **HNO** 1995 Nov; 43(11):649–53 (24 ref.) (Eng. Abstr.) **(Ger)**

[The first case of severe pneumopathy due to hard metals successfully undergoing a lung transplant] Tomasini M, et al. **Med Lav** 1995 Jul–Aug;86(4):325–31 (6 ref.) (Eng. Abstr.) **(Ita)**

[Relationship between exposure to environmental toxins and motor neuron disease: a case report] Vanacore N, et al. **Med Lav** 1995 Nov–Dec;86(6):522–33 (50 ref.) (Eng. Abstr.) **(Ita)**

[Pneumonitis secondary to the inhalation of isocyanates. An analysis of 2 cases] Haro M, et al. **Arch Bronconeumol** 1995 Aug–Sep;31(7):365–7 (18 ref.) (Eng. Abstr.) **(Spa)**

COMPLICATIONS

Mixed urinary incontinence secondary to lead poisoning. Crewalk JA, et al. **J Urol** 1996 Jun;155(6):2029 (3 ref.)

Cadmium-associated renal disease. Savolainen H. **Ren Fail** 1995 Sep;17(5):483–7 (30 ref.)

DIAGNOSIS

Assessment of asthma in the workplace. ACCP consensus statement. American College of Chest Physicians. Chan-Yeung M. **Chest** 1995 Oct;108(4):1084–117 (159 ref.)

Occupational asthma. Diagnosis, management, and prevention. Newman LS. **Clin Chest Med** 1995 Dec; 16(4):621–36 (187 ref.)

Occupational stress and the law: some current issues for employers. Howard G. **J Psychosom Res** 1995 Aug; 39(6):707–19 (27 ref.)

Metastatic squamous cell carcinoma of the hand and review of the literature. Foley SJ, et al. **J R Army Med Corps** 1995 Jun;141(2):102–4 (8 ref.)

Occupational illness. Newman LS. **N Engl J Med** 1995 Oct 26;333(17):1128–34 (52 ref.)

OCCUPATIONAL DISEASES

Occupational lung disease. 8. The diagnosis of occupational asthma from serial measurements of lung function at and away from work. Bright P, et al. **Thorax** 1996 Aug; 51(8):857–63 (49 ref.)

Bartender's hand an unusual form of occupational cumulative trauma disorder. David AM, et al. **West J Med** 1996 Apr; 164(4):353–4 (6 ref.)

[Burn–out syndrome] Klieser E, et al. **Med Monatsschr Pharm** 1996 Jan;19(1):17–20 (6 ref.) **(Ger)**

[Diagnosis and management of neurotic occupational disorders (before pension application)] Stevens A, et al. **Nervenarzt** 1995 Nov;66(11):811–9 (42 ref.) (Eng. Abstr.) **(Ger)**

[Principles for assessment and diagnosis of work–related pulmonary and pleural diseases] Aasen TB, et al. **Tidsskr Nor Laegeforen** 1996 Feb 28;116(6):739–41 (23 ref.) (Eng. Abstr.) **(Nor)**

[Clinical picture of vibration syndrome and diagnostic principles] Iżycki J. **Med Pr** 1996;47(3):277–83 (17 ref.) (Eng. Abstr.) **(Pol)**

[Subclinical mercury poisoning (editorial; comment)] López–Alburquerque T. **An Med Interna** 1996 May; 13(5):209–10 (12 ref.) Comment on: An Med Interna 1996 May;13(5):211–6. **(Spa)**

[Unclear pathomechanism behind neck–shoulder pain. Problem with insurance claim] Zetterberg C. **Lakartidningen** 1996 Feb 28;93(9):793–6 (68 ref.) **(Swe)**

EPIDEMIOLOGY

Epidemiologic methods for the study of occupational asthma. Current problems and solutions. Cullen MR. **Chest** 1996 Mar;109(3 Suppl):51S–54S (28 ref.)

The integration of epidemiology and fundamental biology in occupational lung disease. Thomas A. Neff Lecture. Weill H. **Chest** 1996 Mar;109(3 Suppl):2S–5S (14 ref.)

Work conditions as explanations for the relation between socioeconomic status, gender, and psychological disorders. Lennon MC. **Epidemiol Rev** 1995;17(1):120–7 (118 ref.)

Occupational health. Yoshimura T. **J Epidemiol** 1996 Aug; 6(3 Suppl):S115–20 (68 ref.)

Epidemiological aspects of cancer risk associated with exposure in the occupational environment. Simonato L, et al. **Med Lav** 1996 Jan–Feb;87(1):5–15 (24 ref.)

Cancer in relation to occupational exposure to trichloroethylene. Weiss NS. **Occup Environ Med** 1996 Jan; 53(1):1–5 (27 ref.)

The yellowed archives of yellowcake. Silver K. **Public Health Rep** 1996 Mar–Apr;111(2):116–27 (55 ref.)

Collection of domestic waste. Review of occupational health problems and their possible causes. Poulsen OM, et al. **Sci Total Environ** 1995 Aug 18;170(1–2):1–19 (83 ref.)

Occupational risk of infection with human immunodeficiency virus. Chamberland ME, et al. **Surg Clin North Am** 1995 Dec;75(6):1057–70 (36 ref.)

Occupational risk of infection with hepatitis B and hepatitis C virus. Shapiro CN. **Surg Clin North Am** 1995 Dec; 75(6):1047–56 (51 ref.)

[Extrinsic allergic alveolitis of occupational origin] Toubas D, et al. **Presse Med** 1995 Oct 14;24(30):1391–6 (42 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Is occupational asthma a relevant model? Fabbri LM. **Am J Respir Crit Care Med** 1996 Jun;153(6 Pt 2):S26 (21 ref.)

Airborne fibre concentrations and lung burden compared to the tumour response in rats and humans exposed to asbestos. Rödelsperger K, et al. **Ann Occup Hyg** 1995 Oct; 39(5):715–25 (27 ref.)

ABC of work related disorders. Neck and arm disorders. Hagberg M. **BMJ** 1996 Aug 17;313(7054):419–22 (0 ref.)

ABC of work related disorders. Occupational asthma and other respiratory diseases. Madan I. **BMJ** 1996 Aug 3; 313(7052):291–4 (0 ref.)

ABC of work related disorders. Occupational infections. Snashall D. **BMJ** 1996 Aug 31;313(7056):551–4 (0 ref.)

Hepatitis C virus (HCV)—an occupational risk to dentists? Porter SR, et al. **Br Dent J** 1996 Jun 22;180(12):473–4 (21 ref.)

Occupational hazards for the male reproductive system. Tas S, et al. **Crit Rev Toxicol** 1996 May;26(3):261–307 (460 ref.)

Occupational asthma. Chan–Yeung M. **Environ Health Perspect** 1995 Sep;103 Suppl 6:249–52 (40 ref.)

Wood dust. **IARC Monogr Eval Carcinog Risks Hum** 1995; 62:35–215 (383 ref.)

Clinical–epidemiologic study of alopecia areata. Roselino AM, et al. **Int J Dermatol** 1996 Mar;35(3):181–4 (8 ref.)

Occupational exposure to dusts containing asbestos and chronic airways disease. Zejda JE. **Int J Occup Med Environ Health** 1996;9(2):117–25 (50 ref.)

Human bites to the hand. Carr MM. **J Can Dent Assoc** 1995 Sep;61(9):782–4 (32 ref.)

What occupations have been associated with brain cancer, and, more specifically, what is the connection between brain cancer and electric utility work? **J Occup Environ Med** 1995 Sep;37(9):1067–9 (46 ref.)

Noise induced hearing loss in military helicopter aircrew—a review of the evidence. Owen JP. **J R Army Med Corps** 1995 Jun;141(2):98–101 (19 ref.)

Occupationally induced airways obstruction. Garshick E, et al. **Med Clin North Am** 1996 Jul;80(4):851–78 (132 ref.)

Nonsensitizing causes of occupational asthma. Lemière C, et al. **Med Clin North Am** 1996 Jul;80(4):749–74 (67 ref.)

Exposure to crystalline silica and risk of lung cancer: the epidemiological evidence. Weill H, et al. **Thorax** 1996 Jan; 51(1):97–102 (48 ref.)

Occupational asthma. Brooks SM. **Toxicol Lett** 1995 Dec; 82–83:39–45 (32 ref.)

[Occupational asthma in an agricultural setting] Bessot JC, et al. **Rev Mal Respir** 1996 Jul;13(3):205–15 (103 ref.) (Eng. Abstr.) **(Fre)**

[A syndrome caused by separating rags in textile industry: a new clinical entity?] Fioravanti A, et al. **Minerva Med** 1995 Nov;86(11):467–4 (25 ref.) (Eng. Abstr.) **(Ita)**

[Occupational asthma] Shiro T. **Arerugi** 1995 Sep; 44(9):1105–10 (37 ref.) **(Jpn)**

[Hepatitis B virus infection in health care settings] Sodeyama T. **Nippon Rinsho** 1995 Oct;53 Suppl:362–70 (15 ref.) **(Jpn)**

[Is heavy physical work a risk factor for ischemic heart disease?] Makowiec–Dąbrowska T. **Med Pr** 1995; 46(3):263–74 (42 ref.) (Eng. Abstr.) **(Pol)**

[Myocardial infarction as a work–related occurrence] Szozda R, et al. **Med Pr** 1995;46(3):285–8 (19 ref.) (Eng. Abstr.) **(Pol)**

[Arachnids as risk factors in occupational exposure] Dutkiewicz J. **Wiad Parazytol** 1995;41(3):253–66 (48 ref.) (Eng. Abstr.) **(Pol)**

GENETICS

Genetic susceptibility and occupational cancer. Hayes RB. **Med Lav** 1995 May–Jun;86(3):206–13 (51 ref.)

IMMUNOLOGY

Dental health care workers at risk. Garfunkel AA, et al. **Dent Clin North Am** 1996 Apr;40(2):277–91 (44 ref.)

METABOLISM

Use of biomarkers to investigate occupational and environmental lung disorders. Schulte PA. **Chest** 1996 Mar; 109(3 Suppl):9S–12S (26 ref.)

Analysis and interpretation of inorganic mineral particles in "lung" tissues. Gibbs AR, et al. **Thorax** 1996 Mar; 51(3):327–34 (60 ref.)

MORTALITY

Occupational mortality among firefighters: assessing the association. Guidotti TL. **J Occup Environ Med** 1995 Dec; 37(12):1348–56 (35 ref.)

PHYSIOPATHOLOGY

The integration of epidemiology and fundamental biology in occupational lung disease. Thomas A. Neff Lecture. Weill H. **Chest** 1996 Mar;109(3 Suppl):2S–5S (14 ref.)

[Occupational asthma: medical and social prognosis] Pauli G, et al. **Rev Pneumol Clin** 1996;52(2):104–9 (25 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

Occupational stress intervention. Hurrell JJ Jr, et al. **Am J Ind Med** 1996 Apr;29(4):338–41 (23 ref.)

Qualitative methods for intervention research. Needleman C, et al. **Am J Ind Med** 1996 Apr;29(4):329–37 (77 ref.)

Regional harmonization of occupational health rules: the European example. Raworth P. **Am J Law Med** 1995; 21(1):7–44 (339 ref.)

Review: methods of monitoring for process micro–organisms in biotechnology. Crook B. **Ann Occup Hyg** 1996 Jun; 40(3):245–60 (23 ref.)

Tuberculosis: a re–emerging problem for health care workers. Bagg J. **Br Dent J** 1996 May 25;180(10):376–81 (47 ref.)

Cancer and the workplace [see comments] Stellman JM, et al. **CA Cancer J Clin** 1996 Mar–Apr;46(2):70–92 (64 ref.) Comment in: CA Cancer J Clin 1996 Jul–Aug;46(4):255–6.

A national consensus on guidelines for establishment of a post–exposure notification protocol for emergency responders. Laboratory Centre for Disease Control, Health Protection Branch, Health Canada. **Can Commun Dis Rep** 1995 Oct 15;21(19):169–80 (5 ref.) **(Eng, Fre)**

Common infectious diseases. Bagg J. **Dent Clin North Am** 1996 Apr;40(2):385–93 (33 ref.)

Hepatitis B virus infection. Current status in dentistry. Cottone JA, et al. **Dent Clin North Am** 1996 Apr; 40(2):293–307 (62 ref.)

Occupational health and safety emergencies. Goupil MT. **Dent Clin North Am** 1995 Jul;39(3):637–47 (69 ref.)

Syphilis and gonorrhea. Siegel MA. **Dent Clin North Am** 1996 Apr;40(2):369–83 (34 ref.)

Postexposure protocol. Younai FS. **Dent Clin North Am** 1996 Apr;40(2):457–86 (118 ref.)

Overview of preventable industrial causes of occupational cancer. Ward E. **Environ Health Perspect** 1995 Nov;103 Suppl 8:197–203 (44 ref.)

The integrated model: implications for worksite health promotion and occupational health and safety practice. Baker E, et al. **Health Educ Q** 1996 May;23(2):175–90 (61 ref.)

Worksite health programs: working together to advance employee health. Heaney CA, et al. **Health Educ Q** 1996 May;23(2):133–6 (18 ref.)

The ecology of work and health: research and policy directions for the promotion of employee health. Stokols D, et al. **Health Educ Q** 1996 May;23(2):137–58 (162 ref.)

Use of back belts in occupational settings. Minor SD. **Phys Ther** 1996 Apr;76(4):403–8 (21 ref.)

Prevention of occupational musculo–skeletal injuries. Labour Inspectorate investigation. Kemmlert K. **Scand J Rehabil Med Suppl** 1996;35:1–34 (124 ref.)

HIV infection in healthcare workers: risk for infection and methods of prevention. Beekmann SE, et al. **Semin Dermatol** 1995 Sep;14(3):212–8 (39 ref.)

Postexposure prophylaxis for occupational exposures to hepatitis B, hepatitis C, and human immunodeficiency virus. Henderson DK. **Surg Clin North Am** 1995 Dec; 75(6):1175–87 (51 ref.)

[For whom is the hepatitis A vaccination in 1995? (editorial)] Buisson Y. **Gastroenterol Clin Biol** 1995 Oct;19(10):745–6 (18 ref.) **(Fre)**

[Preventing transmission of infection in endoscopy: hygienic maintainance of flexible endoscopes and measures for personal protection] Leiss O, et al. **Leber Magen Darm** 1995 Dec;25(6):251–7 (25 ref.) (Eng. Abstr.) **(Ger)**

[Stress management: individual differences and determination of situations (review of studies)] Makowska Z. **Med Pr** 1995;46(4):395–406 (31 ref.) (Eng. Abstr.) **(Pol)**

[Indications for psychological examination in diagnosis, certification and prevention of occupational diseases] Waszkowska M. **Med Pr** 1995;46(5):505–8 (14 ref.) (Eng. Abstr.) **(Pol)**

PSYCHOLOGY

The practice of anaesthesia—a stressor for the middle–aged? Seeley HF. **Anaesthesia** 1996 Jun;51(6):571–4 (16 ref.)

Mental health, work, and gender. Dennerstein L. **Int J Health Serv** 1995;25(3):503–9 (27 ref.)

Work group culture, stress, and hostility. Correlations with organizational outcomes. Seago JA. **J Nurs Adm** 1996 Jun; 26(6):39–47 (56 ref.)

RADIOGRAPHY

[Is the bronchial provocation test justified in occupational respiratory disease?] Pauli G, et al. **Rev Pneumol Clin** 1996; 52(2):97–102 (20 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

[The first case of severe pneumopathy due to hard metals successfully undergoing a lung transplant] Tomasini M, et al. **Med Lav** 1995 Jul–Aug;86(4):325–31 (6 ref.) (Eng. Abstr.) **(Ita)**

THERAPY

Medical problems of professional voice users. Mitchell SA. **Compr Ther** 1996 Apr;22(4):231–8 (40 ref.)

The use of chelating agents in occupational lead poisoning. Porru S, et al. **Occup Med (Oxf)** 1996 Feb;46(1):41–8 (34 ref.)

[Therapeutic approaches of hematopoietic syndrome following accidental total whole body irradiation] Thierry D, et al. **Bull Cancer (Paris)** 1996 May;83(5):361–70 (40 ref.) (Eng. Abstr.) **(Fre)**

VIROLOGY

Hazards to the orthopaedic trauma surgeon: occupational exposure to HIV and viral hepatitis (a review article). Chou L, et al. **J Orthop Trauma** 1996;10(4):289–96 (46 ref.)

OCCUPATIONAL EXPOSURE

see related
AIR POLLUTANTS, OCCUPATIONAL
MULTIPLE CHEMICAL SENSITIVITY

Do socio–economic status, marital status and occupation influence the prevalence of Helicobacter pylori infection? Veldhuyzen van Zanten SJ. **Aliment Pharmacol Ther** 1995; 9 Suppl 2:41–4 (35 ref.)

Occupational exposure to chrysotile asbestos and cancer risk: a review of the amphibole hypothesis. Stayner LT, et al. **Am J Public Health** 1996 Feb;86(2):179–86 (72 ref.)

Prophylaxis for occupational exposure to HIV. Gerberding JL. **Ann Intern Med** 1996 Sep 15;125(6):497–501 (31 ref.)

Genetic predisposition in occupational toxicology. Bolt HM. **Arch Toxicol Suppl** 1996;18:362–6 (32 ref.)

Specific factors leading to interindividual variability in response to occupational toxicants. Goergens HW. **Arch Toxicol Suppl** 1996;18:357–61 (28 ref.)

Individual susceptibility to occupational toxicants: practical consequences for risk management. Norseth T. **Arch Toxicol Suppl** 1996;18:367–78 (37 ref.)

Occupational hazards for the male reproductive system. Tas S, et al. **Crit Rev Toxicol** 1996 May;26(3):261–307 (460 ref.)

Postexposure protocol. Younai FS. **Dent Clin North Am** 1996 Apr;40(2):457–86 (118 ref.)

Hazard evaluation in risk assessment: whatever happened to sound scientific judgment and weight of evidence? Doull J, et al. **Drug Metab Rev** 1996 Feb–May;28(1–2):285–99 (9 ref.)

Biological markers and risk assessment. Goldstein BD. **Drug Metab Rev** 1996 Feb-May;28(1-2):225-33 (12 ref.)
ICRP recommendations applicable to the mining and minerals processing industries and to natural sources. International Commission on Radiological Protection. Clarke RH. **Health Phys** 1995 Oct;69(4):454-60 (18 ref.)
Wood dust. **IARC Monogr Eval Carcinog Risks Hum** 1995; 62:35-215 (383 ref.)
Formaldehyde. **IARC Monogr Eval Carcinog Risks Hum** 1995;62:217-375 (479 ref.)
Fundamentals and possibilities of classification of occupational substances as developmental toxicants. Hofmann A. **Int Arch Occup Environ Health** 1995; 67(3):139-45 (45 ref.)
Occupational exposure to dusts containing asbestos and chronic airways disease. Zejda JE. **Int J Occup Med Environ Health** 1996;9(2):117-25 (50 ref.)
Effects of parental exposure to solvents on pregnancy outcome. Lindbohm ML. **J Occup Environ Med** 1995 Aug; 37(8):908-14 (48 ref.)
Asbestos exposure and asbestosis: clarifying terminology and avoiding confusion [see comments] Woodard PK, et al. **J R Soc Med** 1995 Dec;88(12):669-71 (19 ref.) Comment in: J R Soc Med 1996 Apr;89(4):240.
Monitoring of occupational exposure to cytostatic anticancer agents. Sorsa M, et al. **Mutat Res** 1996 Aug 17; 355(1-2):253-61 (58 ref.)
Risks from occupational and dietary exposure to mevinphos. Cochran RC, et al. **Rev Environ Contam Toxicol** 1996; 146:1-24 (76 ref.)
Management of occupational exposure to HIV. Critchley SE, et al. **Semin Dermatol** 1995 Sep;14(3):235-9 (36 ref.)
Electrical safety measures for physicians using electromedical equipment. Laks MM, et al. **Semin Neurol** 1995 Sep; 15(3):311-6 (24 ref.)
Occupational lung disease. 8. The diagnosis of occupational asthma from serial measurements of lung function at and away from work. Bright P, et al. **Thorax** 1996 Aug; 51(8):857-63 (49 ref.)
Strategies for use of biological markers of exposure. Henderson RF. **Toxicol Lett** 1995 Dec;82-83:379-83 (9 ref.)
Case studies of the use of biomarkers to assess exposures. Needham LL, et al. **Toxicol Lett** 1995 Dec;82-83:373-8 (14 ref.)
[Occupational environment in veterinary clinics] Jensen BS, et al. **Ugeskr Laeger** 1996 Jan 15;158(3):265-9 (28 ref.) (Eng. Abstr.) **(Dan)**
[Exposure to solvents in scleroderma: disseminated circumscribed scleroderma (morphea) in a painter exposed to perchloroethylene] Hinnen U, et al. **Schweiz Med Wochenschr** 1995 Dec 16;125(50):2433-7 (13 ref.) (Eng. Abstr.) **(Ger)**
[The work environment and the health risk for women in Italy: the results and prospects of epidemiological research] Pirastu R, et al. **Epidemiol Prev** 1996 Apr-Sep; 20(2-3):180-2 (10 ref.) **(Ita)**
[Multiple occupational exposure to solvents] Alessio L, et al. **G Ital Med Lav** 1994 Jan-Nov;16(1-6):37-42 (26 ref.) (Eng. Abstr.) **(Ita)**
[Persistent reactive airway dysfunction syndrome after exposure to chromate] Nagasaka Y, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Jul;33(7):759-64 (16 ref.) (Eng. Abstr.) **(Jpn)**
[IgD (lambda) multiple myeloma associated with myelofibrosis: an isolated case of nuclear physicist] Kanoh T, et al. **Rinsho Ketsueki** 1996 Mar;37(3):244-8 (14 ref.) (Eng. Abstr.) **(Jpn)**
[Cancer epidemiology of radiation workers] Hosoda Y, et al. **Sangyo Eiseigaku Zasshi** 1996 May;38(3):107-18 (83 ref.) (Eng. Abstr.) **(Jpn)**
[The effect of painful dazzle on the perception process] Janosik E. **Med Pr** 1996;47(2):175-81 (16 ref.) (Eng. Abstr.) **(Pol)**
[Ischemic heart disease and occupational exposure to chemical substances. Review of the literature] Waissmann W, et al. **Arq Bras Cardiol** 1995 May;64(5):477-82 (87 ref.) **(Por)**

ADVERSE EFFECTS

Silica exposure and autoimmune diseases. Steenland K, et al. **Am J Ind Med** 1995 Nov;28(5):603-8 (24 ref.)
Biomarkers as tools in human health risk assessment. Greim H, et al. **Clin Chem** 1995 Dec;41(12 Pt 2):1804-8 (13 ref.)
Agricultural exposures and cancer. Blair A, et al. **Environ Health Perspect** 1995 Nov;103 Suppl 8:205-8 (39 ref.)
Pesticide-induced immunotoxicity: are Great Lakes residents at risk? Thomas PT. **Environ Health Perspect** 1995 Dec; 103 Suppl 9:55-61 (78 ref.)
Occupational phosgene poisoning: a case report and review. Wyatt JP, et al. **J Accid Emerg Med** 1995 Sep;12(3):212-3 (11 ref.)
Effects of parental occupational exposure to lead and other metals on spontaneous abortion. Anttila A, et al. **J Occup Environ Med** 1995 Aug;37(8):915-21 (36 ref.)
Occupational mortality among firefighters: assessing the association. Guidotti TL. **J Occup Environ Med** 1995 Dec; 37(12):1348-56 (35 ref.)
Occupation- and exposure-related studies on human sperm. Lähdetie J. **J Occup Environ Med** 1995 Aug;37(8):922-30 (92 ref.)
Magnetic fields of video display terminals and pregnancy outcome. Lindbohm ML, et al. **J Occup Environ Med** 1995 Aug;37(8):952-6 (30 ref.)
Maternal pesticide exposure and pregnancy outcome. Nurminen T. **J Occup Environ Med** 1995 Aug;37(8):935-40 (27 ref.)
Hemoglobin adducts for in vivo dose monitoring and cancer risk estimation. Törnqvist M, et al. **J Occup Environ Med** 1995 Sep;37(9):1077-85 (41 ref.)
Arsine toxicity: chemical and mechanistic implications. Klimecki WT, et al. **J Toxicol Environ Health** 1995 Dec; 46(4):399-409 (49 ref.)
Occupational asthma due to isocyanates. Baur X. **Lung** 1996; 174(1):23-30 (50 ref.)
Combined effects of noise and chemicals. Fechter LD. **Occup Med** 1995 Jul-Aug;10(3):609-21 (51 ref.)
Effects of industrial solvents on hearing. Johnson AC, et al. **Occup Med** 1995 Jul-Aug;10(3):623-40 (87 ref.)
Epidemiologic considerations in the evaluation of occupational hearing loss. Morata TC, et al. **Occup Med** 1995 Jul-Aug;10(3):641-56 (67 ref.)
Reproductive disorders due to chemical exposure among hairdressers. Kersemaekers WM, et al. **Scand J Work Environ Health** 1995 Oct;21(5):325-34 (85 ref.)
Exposure to crystalline silica and risk of lung cancer: the epidemiological evidence. Weill H, et al. **Thorax** 1996 Jan; 51(1):97-102 (48 ref.)
[Occupational asthma: definition--epidemiology--etiologic substances--prognosis--prevention--diagnosis--expert assessment aspects] Merget R, et al. **Pneumologie** 1996 May; 50(5):356-63 (83 ref.) **(Ger)**
[European study of working mothers and congenital malformations] Candela S, et al. **Epidemiol Prev** 1996 Apr-Sep;20(2-3):183-5 (17 ref.) **(Ita)**
[The prevention of work risks deriving from the use of chemotherapeutic antineoplastics in the health environment: the consensus document (November 1995)] **Med Lav** 1996 Jan-Feb;87(1):78-86 (0 ref.) **(Ita)**
[Occupational asthma] Fujimura N. **Nippon Naika Gakkai Zasshi** 1996 Feb 10;85(2):234-9 (8 ref.) **(Jpn)**

ANALYSIS

Development and application of non-invasive biomarkers for carcinogen-DNA adduct analysis in occupationally exposed populations. Talaska G, et al. **Toxicology** 1996 Jul 17;111(1-3):207-12 (17 ref.)
[Studies on the evaluation of exposure to industrial chemicals] Sakai T. **Sangyo Eiseigaku Zasshi** 1996 May;38(3):119-37 (151 ref.) (Eng. Abstr.) **(Jpn)**

LEGISLATION & JURISPRUDENCE

A national consensus on guidelines for establishment of a post-exposure notification protocol for emergency responders. Laboratory Centre for Disease Control, Health Protection Branch, Health Canada. **Can Commun Dis Rep** 1995 Oct 15;21(19):169-80 (5 ref.) **(Eng, Fre)**
The origin and development of the asbestos Threshold Limit Value: scientific indifference and corporate influence. Egilman DS, et al. **Int J Health Serv** 1995;25(4):667-96 (98 ref.)

PREVENTION & CONTROL

Review: methods of monitoring for process micro-organisms in biotechnology. Crook B. **Ann Occup Hyg** 1996 Jun; 40(3):245-60 (23 ref.)
A basic framework of working environment control for occupational health in Japan. Koshi S. **Ind Health** 1996; 34(3):149-65 (5 ref.)
[The prevention of work risks deriving from the use of chemotherapeutic antineoplastics in the health environment: the consensus document (November 1995)] **Med Lav** 1996 Jan-Feb;87(1):78-86 (0 ref.) **(Ita)**

STANDARDS

The development of occupational exposure limits for chemical substances in China. Liang YX, et al. **Regul Toxicol Pharmacol** 1995 Oct;22(2):162-71 (25 ref.)
[Reference values in biological monitoring of occupational exposure to mutagens and carcinogens] Clonfero E, et al. **G Ital Med Lav** 1994 Jan-Nov;16(1-6):25-9 (43 ref.) (Eng. Abstr.) **(Ita)**

STATISTICS & NUMERICAL DATA

The yellowed archives of yellowcake. Silver K. **Public Health Rep** 1996 Mar-Apr;111(2):116-27 (55 ref.)

OCCUPATIONAL HEALTH

Policy evaluation: better living through research. Boden LI. **Am J Ind Med** 1996 Apr;29(4):346-52 (40 ref.)
Methodological issues for intervention research in occupational health and safety. Goldenhar LM, et al. **Am J Ind Med** 1996 Apr;29(4):289-94 (52 ref.)
Qualitative methods for intervention research. Needleman C, et al. **Am J Ind Med** 1996 Apr;29(4):329-37 (77 ref.)
Approaches for assessing the efficacy of occupational health and safety standards. Stayner L, et al. **Am J Ind Med** 1996 Apr;29(4):353-7 (12 ref.)
How safe is your ED? Keep NB, et al. **Am J Nurs** 1995 Sep;95(9):44-50; quiz 51 (5 ref.)
Health effects of outdoor air pollution. Committee of the Environmental and Occupational Health Assembly of the American Thoracic Society. **Am J Respir Crit Care Med** 1996 Jan;153(1):3-50 (578 ref.)
Violence in the health care environment. Gregg CM, et al. **Arch Otolaryngol Head Neck Surg** 1996 Jan;122(1):11-6 (19 ref.)
Occupational health in surgery: risks extend beyond the operating room. Patz JA, et al. **Aust N Z J Surg** 1995 Sep; 65(9):627-9 (27 ref.)
A basic framework of working environment control for occupational health in Japan. Koshi S. **Ind Health** 1996; 34(3):149-65 (5 ref.)
Playing chicken with people: the occupational safety and health consequences of throughput über alles. Linder M. **Int J Health Serv** 1995;25(4):633-66 (184 ref.)
Employment-related physical activity and pregnancy outcome. Berkowitz GS. **J Am Med Wom Assoc** 1995 Sep-Oct;50(5):167-9, 174 (33 ref.)
Occupational health. Yoshimura T. **J Epidemiol** 1996 Aug; 6(3 Suppl):S115-20 (68 ref.)
Improving workplace environments and working conditions at worksites providing school lunch service in Japan. Koda S, et al. **J Hum Ergol (Tokyo)** 1995 Jun;24(1):93-101 (26 ref.)
Healthcare violence. A nursing administration perspective. Claravall L. **J Nurs Adm** 1996 Feb;26(2):41-6 (29 ref.)
The impact of violence in the health care setting upon nursing education. Whitley GG, et al. **J Nurs Educ** 1996 May; 35(5):211-8 (46 ref.)
Participatory approaches in occupational health research: a review. Loewenson R, et al. **Med Lav** 1995 May-Jun; 86(3):263-71 (13 ref.)
Hearing conservation programs for nonserved occupations and populations. Axelsson A, et al. **Occup Med** 1995 Jul-Aug;10(3):657-62 (11 ref.)
Historical assessment and future directions in the prevention of occupational hearing loss. Merry CJ, et al. **Occup Med** 1995 Jul-Aug;10(3):669-81 (39 ref.)
Electrical safety measures for physicians using electromedical equipment. Laks MM, et al. **Semin Neurol** 1995 Sep; 15(3):311-6 (24 ref.)
[Advances in the study of industrial women's hygiene in China] Bao Y, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1995 Sep;29(5):301-2 (20 ref.) **(Chi)**
[When to stop the music (editorial)] Ohry A, et al. **Harefuah** 1995 Dec 1;129(11):472-4 (31 ref.) **(Heb)**
[Protection from ionizing radiation for pregnant workers] Campos Venuti G, et al. **Epidemiol Prev** 1996 Apr-Sep; 20(2-3):194-6 (15 ref.) **(Ita)**

LEGISLATION & JURISPRUDENCE

Regional harmonization of occupational health rules: the European example. Raworth P. **Am J Law Med** 1995; 21(1):7-44 (339 ref.)
Maryland restricts workplace smoking. Patrick E. **Md Med J** 1995 Oct;44(10):800-4 (32 ref.)
[Occupational medicine aspects related to carcinogenic hazardous substances] Letzel S. **Dtsch Med Wochenschr** 1996 Jan 26;121(4):104-9 (11 ref.) **(Ger)**

STATISTICS & NUMERICAL DATA

Aggression against doctors: a review. Hobbs FD, et al. **J R Soc Med** 1996 Feb;89(2):69-72 (38 ref.)

OCCUPATIONAL HEALTH SERVICES

ORGANIZATION & ADMINISTRATION

Perinatally transmitted HIV infection. Supporting the helpers. Burr CK. **Nurs Clin North Am** 1996 Mar; 31(1):243-51 (21 ref.)
The development and state of health and safety in the workplace in west Africa: perspectives from Nigeria. Asuzu MC. **West Afr J Med** 1996 Jan-Mar;15(1):36-44 (19 ref.)
[Occupational health services in Sweden. II. Internal control of the working environment] Zielińska-Jankiewicz K, et al. **Med Pr** 1996;47(2):189-93 (3 ref.) (Eng. Abstr.) **(Pol)**

STANDARDS

[Quality assurance in occupational health services] Michalak J. **Med Pr** 1996;47(3):267-75 (15 ref.) (Eng. Abstr.) **(Pol)**

OCCUPATIONAL MEDICINE

see related
OCCUPATIONAL DISEASES
OCCUPATIONAL HEALTH SERVICES
PROTECTIVE DEVICES

Alternative medicine in the workplace. Lippin RA. **Altern Ther Health Med** 1996 Jan;2(1):47-51 (28 ref.)
Occupational and environmental medicine in Norway. Langård S, et al. **Int Arch Occup Environ Health** 1995; 67(4):219-24 (16 ref.)
[Use of computer base MEDIP in retrieving information on

occupational medicine and hygiene] Przyluska J. **Med Pr** 1996;47(2):183–8 (5 ref.) (Eng. Abstr.) **(Pol)**

EDUCATION

[On the need for analysis of the occupational health education system] Boczkowski A, et al. **Med Pr** 1995;46(4):415–26 (23 ref.) (Eng. Abstr.) **(Pol)**

LEGISLATION & JURISPRUDENCE

Preserving confidentiality in occupational medical practice. McCunney RJ. **Am Fam Physician** 1996 Apr;53(5):1751–60 (19 ref.)

METHODS

Strategy of biological monitoring and setting of biological threshold limits (BAT values) in Germany [see comments] Lehnert G, et al. **Isr J Med Sci** 1995 Sep;31(9):549–57 (23 ref.) Comment in: Isr J Med Sci 1995 Sep;31(9):563–4.

[Indications for psychological examination in diagnosis, certification and prevention of occupational diseases] Waszkowska M. **Med Pr** 1995;46(5):505–8 (14 ref.) (Eng. Abstr.) **(Pol)**

ORGANIZATION & ADMINISTRATION

[Computer systems in medical practice. I. The aims, difficulties and implementation of computerization in health care organizations] Michalak J. **Med Pr** 1995;46(5):509–16 (12 ref.) (Eng. Abstr.) **(Pol)**

STANDARDS

[Quality control for trace elements in occupational and environmental medicine] Morisi G, et al. **Ann Ist Super Sanita** 1995;31(2):245–54 (8 ref.) (Eng. Abstr.) **(Ita)**

OCCUPATIONAL NOISE see **NOISE, OCCUPATIONAL**

OCCUPATIONAL SAFETY see **OCCUPATIONAL HEALTH**

OCCUPATIONAL SAFETY AND HEALTH ADMINISTRATION (U.S.) see **UNITED STATES OCCUPATIONAL SAFETY AND HEALTH ADMINISTRATION**

OCCUPATIONAL THERAPY

Working memory and older adults: implications for occupational therapy. Andiel C, et al. **Am J Occup Ther** 1995 Jul–Aug;49(7):681–6 (42 ref.)

Understanding cortical visual impairment in children. Baker-Nobles L, et al. **Am J Occup Ther** 1995 Oct; 49(9):899–903 (12 ref.)

A study of the development of traits of entry-level occupational therapy students. Donohue MV. **Am J Occup Ther** 1995 Jul–Aug;49(7):703–9 (22 ref.)

Nationally speaking. Life history and narrative research: generating a humanistic knowledge base for occupational therapy. Larson EA, et al. **Am J Occup Ther** 1996 Apr; 50(4):247–50 (27 ref.)

The role of the occupational therapist in oncology. Penfold SL. **Cancer Treat Rev** 1996 Jan;22(1):75–81 (9 ref.)

Use of back belts in occupational settings. Minor SD. **Phys Ther** 1996 Apr;76(4):403–8 (21 ref.)

EDUCATION

Interactive journals: an educational strategy to promote reflection. Tryssenaar J. **Am J Occup Ther** 1995 Jul–Aug; 49(7):695–702 (37 ref.)

METHODS

Occupational therapy and the person with diabetes and vision impairment. Cate Y, et al. **Am J Occup Ther** 1995 Oct; 49(9):905–11 (31 ref.)

Life histories in occupational therapy clinical practice. Frank G. **Am J Occup Ther** 1996 Apr;50(4):251–64 (121 ref.)

PSYCHOLOGY

Transformative narratives: from victimic to agentic life plots. Polkinghorne DE. **Am J Occup Ther** 1996 Apr; 50(4):299–305 (34 ref.)

OCCUPATIONS

see related
HEALTH OCCUPATIONS
WORKPLACE

Occupational conditions and workers' sense of community: variations by gender and race. Lambert SJ, et al. **Am J Community Psychol** 1995 Apr;23(2):151–79 (78 ref.)

Occupational risk factors for female breast cancer: a review. Goldberg MS, et al. **Occup Environ Med** 1996 Mar; 53(3):145–56 (194 ref.)

A minibus driver with amnesia. Gray P, et al. **Practitioner** 1995 Oct;239(1555):567–72 (0 ref.)

OCEANOGRAPHY

see related
MARINE BIOLOGY

OCHRATOXINS

TOXICITY

Prevention of nephrotoxicity of ochratoxin A, a food contaminant. Creppy EE, et al. **Toxicol Lett** 1995 Dec; 82–83:869–77 (54 ref.)

OCHRONOSIS

COMPLICATIONS

Ochronosis and alkaptonuria. Case report and literature review. Kneebone TS, et al. **J Am Podiatr Med Assoc** 1995 Oct;85(10):554–5 (7 ref.)

DIAGNOSIS

The clinical manifestations of ochronosis: a review. Van Offel JF, et al. **Acta Clin Belg** 1995;50(6):358–62 (27 ref.)

OCKELBO VIRUS see **ALPHAVIRUS**

OCTADECENOIC ACIDS see **OLEIC ACIDS**

OCTODON see **RODENTIA**

OCTOGENARIANS see **AGED, 80 AND OVER**

OCTOPAMINE

PHARMACOLOGY

Pharmacology and molecular biology of octopamine receptors from different insect species. Roeder T, et al. **Prog Brain Res** 1995;106:249–58 (32 ref.)

P-OCTOPAMINE see **OCTOPAMINE**

OCTOPUS

PHYSIOLOGY

A review of simultaneous visual discrimination as a method of training octopuses. Boal JG. **Biol Rev Camb Philos Soc** 1996 May;71(2):157–90 (66 ref.)

OCTREOTIDE

ANALOGS & DERIVATIVES

Imaging and staging of small-cell lung cancer: is there a future role for octreotide scintigraphy? Stokkel MP, et al. **Br J Clin Pract** 1995 Sep–Oct;49(5):235–8 (41 ref.)

Somatostatin-receptor imaging in lymphoma. Goldsmith SJ, et al. **Semin Nucl Med** 1995 Jul;25(3):262–71 (13 ref.)

Somatostatin receptor imaging of neuroendocrine tumors with indium-111 pentetreotide (Octreoscan). Olsen JO, et al. **Semin Nucl Med** 1995 Jul;25(3):251–61 (25 ref.)

THERAPEUTIC USE

Octreotide treatment of carcinoid syndrome: analysis of published dose–titration data. Harris AG, et al. **Aliment Pharmacol Ther** 1995 Aug;9(4):387–94 (83 ref.)

Review article: the relative effectiveness of somatostatin and octreotide therapy in pancreatic disease [see comments] Jenkins SA, et al. **Aliment Pharmacol Ther** 1995 Aug; 9(4):349–61 (91 ref.) Comment in: Aliment Pharmacol Ther 1995 Oct;9(5):581–3.

Somatostatin receptors: clinical implications for endocrinology and oncology. Lamberts SW, et al. **Ciba Found Symp** 1995;190:222–36; discussion 236–9 (48 ref.)

Octreotide. Lamberts SW, et al. **N Engl J Med** 1996 Jan 25;334(4):246–54 (76 ref.)

[Emergency medical treatment of portal hypertension] Heresbach D, et al. **Presse Med** 1995 Sep 30;24(28):1311–4 (26 ref.) (Eng. Abstr.) **(Fre)**

[Metastasizing pancreatic vipoma. Its diagnosis and therapy with the somatostatin analog octreotide] Scheffold N, et al. **Dtsch Med Wochenschr** 1995 Oct 27;120(43):1463–7 (21 ref.) (Eng. Abstr.) **(Ger)**

[The potentials for using sandostatin in gastroenterology (a review)] Lopatkina TN. **Ter Arkh** 1995;67(7):66–8 (62 ref.) **(Rus)**

[Gastrointestinal fistulas. Treatment with a somatostatin analogue (SMS 201-995)] Gerardo Pérez D, et al. **G E N** 1994 Oct–Dec;48(4):209–18 (51 ref.) (Eng. Abstr.) **(Spa)**

[Somatostatin and its analogs in the treatment of gastrointestinal and liver diseases] Feu F, et al. **Gastroenterol Hepatol** 1996 Feb;19(2):68–77 (102 ref.) **(Spa)**

OCULAR FIXATION see **FIXATION, OCULAR**

OCULAR HERPES ZOSTER VIRUS see **HERPESVIRUS 3, HUMAN**

OCULAR HYPERTENSION

DRUG THERAPY

Will latanoprost be the 'wonder' drug of the '90s for the treatment of glaucoma? [editorial; comment] Higginbotham EJ. **Arch Ophthalmol** 1996 Aug;114(8):998–9 (16 ref.) Comment on: Arch Ophthalmol 1996 Aug;114(8):929–32.

OCULAR INFECTIONS see **EYE INFECTIONS**

OCULAR INFECTIONS, BACTERIAL see **EYE INFECTIONS, BACTERIAL**

OCULAR INFECTIONS, FUNGAL see **EYE INFECTIONS, FUNGAL**

OCULAR INFECTIONS, PARASITIC see **EYE INFECTIONS, PARASITIC**

OCULAR INFECTIONS, VIRAL see **EYE INFECTIONS, VIRAL**

OCULAR LARVA MIGRANS see **LARVA MIGRANS**

OCULAR MOTILITY DISORDERS

DIAGNOSIS

Ocular neuromyotonia. Ezra E, et al. **Br J Ophthalmol** 1996 Apr;80(4):350–5 (27 ref.)

Diagnostic tests in neuro-ophthalmology. Galetta SL, et al. **Neurol Clin** 1996 Feb;14(1):201–22 (114 ref.)

DRUG THERAPY

[Clinical application of botulinum toxin] Grandas F. **Neurologia** 1995 Jun–Jul;10(6):224–33 (141 ref.) **(Spa)**

ETIOLOGY

Vertical gaze paralysis and intermittent unresponsiveness in a patient with a thalamomesencephalic stroke. Beversdorf DQ, et al. **J Neuroophthalmol** 1995 Dec;15(4):230–5 (21 ref.)

[Mechanically-induced eye movement disorders] Esser J. **Ophthalmologe** 1995 Dec;92(6):877–900 (71 ref.) **(Ger)**

PHYSIOPATHOLOGY

Ocular motor systems. Part 2: Nuclear and supranuclear systems. Skarf B. **J Neuroophthalmol** 1995 Sep; 15(3):191–201 (74 ref.)

[Nystagmus and other anomalous movements of the eye] Prats Viñas JM. **Rev Neurol** 1995;23 Suppl 3:S359–62 (25 ref.) **(Spa)**

VIROLOGY

Acquired immunodeficiency syndrome (AIDS) and the eye. Armstrong RA. **Ophthalmic Physiol Opt** 1995 Sep;15 Suppl 2:S42–8 (25 ref.)

OCULAR REFRACTION see **REFRACTION, OCULAR**

OCULAR TENSION see **INTRAOCULAR PRESSURE**

OCULAR TORTICOLLIS see **OCULAR MOTILITY DISORDERS**

OCULAR TOXOPLASMOSIS see **TOXOPLASMOSIS, OCULAR**

OCULAR TUBERCULOSIS see **TUBERCULOSIS, OCULAR**

OCULOAURICULOVERTEBRAL SYNDROME see **GOLDENHAR SYNDROME**

OCULOMOTOR MUSCLES

PHYSIOLOGY

A review of the role of efference copy in sensory and oculomotor control systems. Bridgeman B. **Ann Biomed Eng** 1995 Jul–Aug;23(4):409–22 (82 ref.)

Egocentric visual target position and velocity coding: role of ocular muscle proprioception. Gauthier GM, et al. **Ann Biomed Eng** 1995 Jul–Aug;23(4):423–35 (34 ref.)

Adaptation in the oculomotor response to caloric irrigation and the merits of bithermal stimulation [see comments] Barnes G. **Br J Audiol** 1995 Apr;29(2):95–106 (22 ref.) Comment in: Br J Audiol 1995 Apr;29(2):83–6.

Ocular motor systems. Part 2: Nuclear and supranuclear systems. Skarf B. **J Neuroophthalmol** 1995 Sep; 15(3):191–201 (74 ref.)

Muscles of a different 'color': the unusual properties of the extraocular muscles may predispose or protect them in neurogenic and myogenic disease. Porter JD, et al. **Neurology** 1996 Jan;46(1):30–7 (61 ref.)

Predictive control of eye movement. Pavel M. **Rev Oculomot Res** 1990;4:71–114 (84 ref.)

SURGERY

Surgical treatment of myogenic blepharoptosis. De Wilde F, et al. **Bull Soc Belge Ophtalmol** 1995;255:139–46 (9 ref.)

OCULOMOTOR NERVE

Simultaneous, multiple cranial neuropathies in diabetes mellitus. Eshbaugh CG, et al. **J Neuroophthalmol** 1995 Dec; 15(4):219–24 (23 ref.)

Pineal germinoma with cranial nerve metastasis. Incesu L, et al. **Radiol Med (Torino)** 1996 Apr;91(4):471–2 (11 ref.)

OCULOMOTOR NERVE PALSY see **OCULOMOTOR NERVE PARALYSIS**

OCULOMOTOR NERVE PARALYSIS

ETIOLOGY

[Isolated oculomotor palsy disclosing multiple myeloma] Feletti A, et al. **J Fr Ophtalmol** 1995;18(12):771–6 (30 ref.) (Eng. Abstr.) **(Fre)**

OCULOMOTOR PARALYSIS see **OPHTHALMOPLEGIA**

OCULOMYCOSIS see **EYE INFECTIONS, FUNGAL**

OCYTOCIN see **OXYTOCIN**

ODDI'S SPHINCTER

see related
CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE
SPHINCTEROTOMY, ENDOSCOPIC

Sphincter of Oddi. Toouli J. **Gastroenterologist** 1996 Mar; 4(1):44–53 (44 ref.)

[Biliary dyskinesia, sphincter of Oddi dysfunction] Makino I, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):183–6 (10 ref.) **(Jpn)**

PHYSIOLOGY

Motility of Oddi's sphincter: recent developments and clinical applications. Coelho JC, et al. **Am J Surg** 1996 Jul; 172(1):48–51 (34 ref.)

PHYSIOPATHOLOGY

[Endoscopic manometry in suspected dysfunction of the sphincter of Oddi] Wehrmann T, et al. **Dtsch Med Wochenschr** 1996 Apr 19;121(16):509–16 (30 ref.) (Eng. Abstr.) **(Ger)**

[Sphincter of Oddi dysfunction] Jonas Y, et al. **Harefuah** 1996 Apr 1;130(7):486–90 (34 ref.) **(Heb)**

ODONTOBLASTS

METABOLISM

Dentin mineralization and the role of odontoblasts in calcium transport. Linde A. **Connect Tissue Res** 1995;33(1–3):163–70 (46 ref.)

ULTRASTRUCTURE

Structure and organization of odontoblasts. Sasaki T, et al. **Anat Rec** 1996 Jun;245(2):235–49 (98 ref.)

ODONTOCLASTS see **OSTEOCLASTS**

ODONTOGENESIS

Tooth crown morphogenesis and cytodifferentiations: candid questions and critical comments. Ruch JV. **Connect Tissue Res** 1995;32(1–4):1–8 (84 ref.)

Epithelial–mesenchymal signaling during tooth development. Thesleff I, et al. **Connect Tissue Res** 1995;32(1–4):9–15 (53 ref.)

GENETICS

Molecular mechanisms of cell and tissue interactions during early tooth development. Thesleff I, et al. **Anat Rec** 1996 Jun;245(2):151–61 (68 ref.)

PHYSIOLOGY

Homeobox genes and growth factors in regulation of craniofacial and tooth morphogenesis. Thesleff I. **Acta Odontol Scand** 1995 Jun;53(3):129–34 (38 ref.)

Application of immunocytochemistry for detection of proliferating cell populations during tooth development. Casasco A. **Anat Rec** 1996 Jun;245(2):162–73 (146 ref.)

ODONTOGENIC CYST, CALCIFYING

PATHOLOGY

Calcifying odontogenic cyst associated with compound odontoma: a study on undemineralized material. Piattelli A, et al. **Bull Group Int Rech Sci Stomatol Odontol** 1995 Sep–Oct;38(3–4):105–9 (18 ref.)

Odontogenic ghost cell carcinoma: report of a case and review of the literature. Alcalde RE, et al. **J Oral Maxillofac Surg** 1996 Jan;54(1):108–11 (9 ref.)

ODONTOGENIC CYSTS

PATHOLOGY

An immunohistochemical study of the lining epithelium of odontogenic keratocyst. Siar CH, et al. **J Nihon Univ Sch Dent** 1995 Sep;37(3):163–9 (26 ref.)

Malignant and premalignant change in odontogenic cysts. Fanibunda K, et al. **J Oral Maxillofac Surg** 1995 Dec; 53(12):1469–72 (19 ref.)

p53–positive squamous cell carcinoma originating from an odontogenic cyst. McDonald AR, et al. **J Oral Maxillofac Surg** 1996 Feb;54(2):216–8 (9 ref.)

Squamous cell carcinoma arising in association with an orthokeratinized odontogenic keratocyst. Report of a case. Yoshida H, et al. **J Oral Maxillofac Surg** 1996 May; 54(5):647–51 (25 ref.)

ODONTOGENIC TUMOR, SQUAMOUS see **AMELOBLASTOMA**

ODONTOGENIC TUMORS

COMPLICATIONS

Familial hyperparathyroidism associated with jaw fibroma: case report and literature review. Inoue H, et al. **Clin Endocrinol (Oxf)** 1995 Aug;43(2):225–9; discussion 230 (10 ref.)

DIAGNOSIS

Don't confuse dental soft tissues with odontogenic tumors. Suarez PA, et al. **Ann Otol Rhinol Laryngol** 1996 Jun; 105(6):490–4 (9 ref.)

PATHOLOGY

Induction of osteodentin and abortive enamel in adenomatoid odontogenic tumor. Takeda Y. **Ann Dent** 1995 Summer–Fall;54(1–2):61–3 (13 ref.)

Benign cementoblastoma. Case report. Mogi K, et al. **Aust Dent J** 1996 Feb;41(1):9–11 (11 ref.)

Adenomatoid odontogenic tumours in Ibadan, Nigeria. Arotiba JT, et al. **East Afr Med J** 1995 Dec;72(12):783–6 (21 ref.)

RADIOGRAPHY

[Central odontogenic fibroma: apropos of a case] Darche V, et al. **Acta Stomatol Belg** 1995 Jun;92(2):53–6 (19 ref.) **(Fre)**

ODONTOID PROCESS

INJURIES

Fractures of the odontoid process in small children: biomechanical analysis and report of three cases. Blauth M, et al. **Eur Spine J** 1996;5(1):63–70 (27 ref.)

Odontoid fracture and C1–C2 subluxation in psoriatic cervical spondyloarthropathy. A case report. Sosner J, et al. **Spine** 1996 Feb 15;21(4):519–21 (6 ref.)

PATHOLOGY

Crowned dens syndrome: a manifestation of hydroxy–apatite rheumatism. Malca SA, et al. **Acta Neurochir (Wien)** 1995; 135(3–4):126–30 (21 ref.)

ODONTOMA

PATHOLOGY

Calcifying odontogenic cyst associated with compound odontoma: a study on undemineralized material. Piattelli A, et al. **Bull Group Int Rech Sci Stomatol Odontol** 1995 Sep–Oct;38(3–4):105–9 (18 ref.)

ODONTOMA, COMPOUND see **ODONTOMA**

ODORANT RECEPTORS see **RECEPTORS, ODORANT**

ODORS

see related
SMELL

Time–temperature effects on microbial, chemical and sensory changes during cooling and aging of cheddar cheese. Torres JA, et al. **Adv Exp Med Biol** 1995;367:123–59 (95 ref.)

Neuropsychiatric and somatic characteristics of young adults with and without self–reported chemical odor intolerance and chemical sensitivity. Bell IR, et al. **Arch Environ Health** 1996 Jan–Feb;51(1):9–21 (114 ref.)

The role of attention in learning about odorants. Smith BH. **Biol Bull** 1996 Aug;191(1):76–83 (54 ref.)

Functional mapping of odor–activated neurons in the olfactory bulb. Guthrie KM, et al. **Chem Senses** 1995 Apr; 20(2):271–82 (44 ref.)

Contribution of activity coefficients of methylene homologues to odor and flavor detection thresholds. Yamanaka T. **Chem Senses** 1995 Aug;20(4):471–5 (19 ref.)

Fish flavor. Kawai T. **Crit Rev Food Sci Nutr** 1996 Feb; 36(3):257–98 (127 ref.)

What is the role of the immune system in determining individually distinct body odours? Brown RE. **Int J Immunopharmacol** 1995 Aug;17(8):655–61 (58 ref.)

Olfactory control of behavior in moths: central processing of odor information and the functional significance of olfactory glomeruli. Hildebrand JG. **J Comp Physiol [A]** 1996 Jan;178(1):5–19 (123 ref.)

Odor images and tunes. Laurent G. **Neuron** 1996 Mar; 16(3):473–6 (25 ref.)

The fish–odor syndrome. Mitchell SC. **Perspect Biol Med** 1996 Summer;39(4):514–26 (75 ref.)

[The power of odors—pathogenic or unpleasant] Glück U. **Schweiz Med Wochenschr** 1996 Jun 1;126(22):958–66 (55 ref.) (Eng. Abstr.) **(Ger)**

OFFICE AUTOMATION

The computer–based patient record: the role of the hospital epidemiologist. Classen DC, et al. **Infect Control Hosp Epidemiol** 1995 Dec;16(12):729–36 (32 ref.)

Clinical computing: a view from the United Kingdom. Wyatt JC. **MD Comput** 1995 Sep–Oct;12(5):382–9 (57 ref.)

[PC applications in routine practice, science and teaching. What computer peripherals are useful?] Knopp MV, et al. **Radiologe** 1995 Sep;35(9):620–4 (3 ref.) (Eng. Abstr.) **(Ger)**

OFFICE SURGERY see **AMBULATORY SURGERY**

OFFICE VISITS

Reducing demand for physician visits through public education: a look at the pilot cold–and–flu campaign in London, Ontario. Brown EM, et al. **Can Med Assoc J** 1996 Mar 15;154(6):835–40 (21 ref.)

Updates in pediatric emergency medicine for the office practitioner. Carlson DW, et al. **Curr Opin Pediatr** 1995 Oct;7(5):523–8 (37 ref.)

STATISTICS & NUMERICAL DATA

Evaluation of 2–week doctor visit reporting in the national health interview survey. Edwards WS, et al. **Vital Health Stat 2** 1996 Aug;(122):1–46 (17 ref.)

OFFSPRING OF IMPAIRED PARENTS see **CHILD OF IMPAIRED PARENTS**

OGILVIE DISEASE see **COLONIC PSEUDO–OBSTRUCTION**

OIL, IODIZED see **IODIZED OIL**

OILS, PLANT see **PLANT OILS**

OILS, VEGETABLE see **PLANT OILS**

OK–432 see **PICIBANIL**

OKM5 ANTIGEN see **ANTIGENS, CD36**

OLD AGE HOMES see **HOMES FOR THE AGED**

OLD YELLOW ENZYME see **NADPH DEHYDROGENASE**

OLDEST OLD see **AGED, 80 AND OVER**

OLEANOL see **OLEANOLIC ACID**

OLEANOLIC ACID

PHARMACOLOGY

Pharmacology of oleanolic acid and ursolic acid. Liu J. **J Ethnopharmacol** 1995 Dec 1;49(2):57–68 (91 ref.)

OLEIC ACIDS

BIOSYNTHESIS

Investigations on the mechanism of adipocere formation and its relation to other biochemical reactions. Takatori T. **Forensic Sci Int** 1996 Jun 28;80(1–2):49–61 (25 ref.)

OLFACTION see **SMELL**

OLFACTORY BULB

CYTOLOGY

Olfactory bulb ensheathing glia: a unique cell type with axonal growth–promoting properties. Ramón–Cueto A, et al. **Glia** 1995 Jul;14(3):163–73 (145 ref.)

[Morphological analysis of NCAM–180 deficient mouse brain—polysialic acid moiety and neuronal migration] Ono K. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2188–96 (44 ref.) **(Jpn)**

OLFACTORY BULB

PHYSIOLOGY

Functional mapping of odor-activated neurons in the olfactory bulb. Guthrie KM, et al. **Chem Senses** 1995 Apr; 20(2):271-82 (44 ref.)

Cyclic nucleotide gated channels. Zimmerman AL. **Curr Opin Neurobiol** 1995 Jun;5(3):296-303 (62 ref.)

Odor images and tunes. Laurent G. **Neuron** 1996 Mar; 16(3):473-6 (25 ref.)

Neuronal chain gangs: homotypic contacts support migration into the olfactory bulb. O'Rourke NA. **Neuron** 1996 Jun; 16(6):1061-4 (15 ref.)

OLFACTORY CORTEX see **OLFACTORY PATHWAYS**

OLFACTORY MUCOSA

CHEMISTRY

Freeze-fracture, deep-etch, and freeze-substitution studies of olfactory epithelia, with special emphasis on immunocytochemical variables. Menco BP. **Microsc Res Tech** 1995 Nov 1;32(4):337-56 (132 ref.)

INNERVATION

Relation of chemical structure to specificity of response in olfactory glomeruli. Mori K. **Curr Opin Neurobiol** 1995 Aug;5(4):467-74 (50 ref.)

OLFACTORY PATHWAYS

[The conscious and the unconscious olfactory perception] Fredholm BB. **Lakartidningen** 1995 Dec 20; 92(51-52):4873-6 (12 ref.) **(Swe)**

PHYSIOLOGY

The olfactory system as a model for the analysis of the contribution of gene expression to programmed cell death. Hayward MD, et al. **Chem Senses** 1995 Apr;20(2):261-9 (100 ref.)

Spatial patterning and information coding in the olfactory system. Sullivan SL, et al. **Curr Opin Genet Dev** 1995 Aug; 5(4):516-23 (66 ref.)

Olfactory control of behavior in moths: central processing of odor information and the functional significance of olfactory glomeruli. Hildebrand JG. **J Comp Physiol [A]** 1996 Jan;178(1):5-19 (123 ref.)

Synaptic mechanisms of olfactory recognition memory. Kaba H, et al. **Rev Neurosci** 1995 Apr-Jun;6(2):125-41 (128 ref.)

The molecular logic of smell. Axel R. **Sci Am** 1995 Oct; 273(4):154-9 (5 ref.)

PHYSIOPATHOLOGY

Neuropsychological and olfactory dysfunction in schizophrenia: relationship of frontal syndromes to syndromes of schizophrenia. Pantelis C, et al. **Schizophr Res** 1995 Sep;17(1):35-45 (75 ref.)

OLFACTORY RECEPTOR NEURONS

see related
RECEPTORS, ODORANT

PHYSIOLOGY

[Hypothesis on the function of olfactory receptor cells (see comments)] Smirnov AA. **Biofizika** 1995 Mar-Apr; 40(2):459-75 (55 ref.) (Eng. Abstr.) Comment in: Biofizika 1995 Mar-Apr;40(2):476-7. **(Rus)**

OLFACTORY RECEPTOR PROTEINS see **RECEPTORS, ODORANT**

OLFACTORY TRACT see **OLFACTORY PATHWAYS**

OLFACTORY TUBERCLE see **OLFACTORY PATHWAYS**

2',5'-OLIGOADENYLATE POLYMERASE see **2',5'-OLIGOADENYLATE SYNTHETASE**

2',5'-OLIGOADENYLATE SYNTHETASE

BLOOD

[Changes of serum 2',5'-oligoadenylate synthetase activity and neopterin during interferon treatment for chronic hepatitis C] Daito K, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:981-5 (16 ref.) **(Jpn)**

[2-5 Oligoadenylate synthetase] Koura T, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:202-5 (16 ref.) **(Jpn)**

OLIGOCHAETA

EMBRYOLOGY

Role of the cytoskeleton in the generation of spatial patterns in Tubifex eggs. Shimizu T. **Curr Top Dev Biol** 1995; 31:197-235 (57 ref.)

OLIGODENDROBLASTOMA see **OLIGODENDROGLIOMA**

OLIGODENDROCYTES see **OLIGODENDROGLIA**

OLIGODENDROGLIA

CYTOLOGY

From rodent glial precursor cell to human glial neoplasia in the oligodendrocyte-type-2 astrocyte lineage. Noble M, et al. **Glia** 1995 Nov;15(3):222-30 (63 ref.)

[Oligodendrocyte lineage] Cochard P, et al. **C R Seances Soc Biol Fil** 1995;189(2):263-9 (28 ref.) (Eng. Abstr.) **(Fre)**

DRUG EFFECTS

Growth factors in the CNS and their effects on oligodendroglia. Kahn MA, et al. **Prog Brain Res** 1995; 105:145-69 (152 ref.)

METABOLISM

Dysmyelination in class I MHC transgenic mice. Turnley AM, et al. **Microsc Res Tech** 1995 Nov 1;32(4):286-94 (64 ref.)

PHYSIOLOGY

Signal transduction pathways in oligodendrocytes: role of tumor necrosis factor-alpha. Soliven B, et al. **Int J Dev Neurosci** 1995 Jun-Jul;13(3-4):351-67 (143 ref.)

Regeneration of oligodendrocytes and myelin. Dubois-Dalcq M. **Trends Neurosci** 1995 Jul;18(7):289-91 (39 ref.)

OLIGODENDROGLIOMA

DIAGNOSIS

Oligodendrogliomas: clinicopathological correlations. Kros JM. **J Neurooncol** 1995;24(1):29-31 (26 ref.)

[Oligodendroglioma in childhood: a case report (letter)] del Val Río MR, et al. **An Esp Pediatr** 1996 Jan;44(1):80-2 (10 ref.) **(Spa)**

PATHOLOGY

Meningioangiomatosis and oligodendroglioma in a 15-year-old boy. López JI, et al. **Arch Pathol Lab Med** 1996 Jun;120(6):587-90 (11 ref.)

THERAPY

Oligodendroglioma [see comments] Peterson K, et al. **Cancer Invest** 1996;14(3):243-51 (59 ref.) Comment in: Cancer Invest 1996;14(3):288-9.

New therapies of primary CNS lymphomas and oligodendrogliomas. Macdonald DR. **J Neurooncol** 1995; 24(1):97-101 (26 ref.)

Oligodendrogliomas. Peterson K, et al. **Neurol Clin** 1995 Nov;13(4):861-73 (65 ref.)

OLIGODEOXYRIBONUCLEOTIDE PRIMERS see **DNA PRIMERS**

OLIGODEOXYRIBONUCLEOTIDE PROBES see **OLIGONUCLEOTIDE PROBES**

OLIGODEOXYRIBONUCLEOTIDES

CHEMICAL SYNTHESIS

Principles and methods for the analysis and purification of synthetic deoxyribonucleotides by high-performance liquid chromatography. Warren WJ, et al. **Mol Biotechnol** 1995 Oct;4(2):179-99 (24 ref.)

CHEMISTRY

What is the basis of sequence-directed curvature in DNAs containing A tracts? Harvey SC, et al. **J Biomol Struct Dyn** 1995 Oct;13(2):301-7 (55 ref.)

Cisplatin and derived anticancer drugs: mechanism and current status of DNA binding. Bloemink MJ, et al. **Met Ions Biol Syst** 1996;32:641-85 (191 ref.)

Specific DNA cleavage by manganese(III) complexes. Gravert DJ, et al. **Met Ions Biol Syst** 1996;33:515-36 (32 ref.)

Molecular modeling of transition metal complexes with nucleic acids and their constituents. Kozelka J. **Met Ions Biol Syst** 1996;33:1-28 (91 ref.)

Metallocene interactions with DNA and DNA-processing enzymes. Kuo LY, et al. **Met Ions Biol Syst** 1996;33:53-85 (113 ref.)

Trans-diammineplatinum(II): what makes it different from cis-DDP? Coordination chemistry of a neglected relative of cisplatin and its interaction with nucleic acids. Lippert B. **Met Ions Biol Syst** 1996;33:105-41 (153 ref.)

Selective DNA cleavage by metalloporphyrin derivatives. Pratviel G, et al. **Met Ions Biol Syst** 1996;33:399-426 (96 ref.)

Metal ions in multiple-stranded DNA. Sabat M, et al. **Met Ions Biol Syst** 1996;33:143-76 (148 ref.)

NMR studies of oligonucleotide-metal ion interactions. Sletten E, et al. **Met Ions Biol Syst** 1996;32:397-418 (56 ref.)

The crystallization and structure analysis of oligonucleotide sequences. Neidle S. **Methods Mol Biol** 1996;56:267-92 (82 ref.)

ISOLATION & PURIFICATION

The crystallization and structure analysis of oligonucleotide sequences. Neidle S. **Methods Mol Biol** 1996;56:267-92 (82 ref.)

Principles and methods for the analysis and purification of synthetic deoxyribonucleotides by high-performance liquid chromatography. Warren WJ, et al. **Mol Biotechnol** 1995 Oct;4(2):179-99 (24 ref.)

PHARMACOLOGY

Oligonucleotide-mediated modulation of mammalian gene expression. Scanlon KJ, et al. **FASEB J** 1995 Oct; 9(13):1288-96 (68 ref.)

OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE see **OLIGONUCLEOTIDES, ANTISENSE**

OLIGOHYDRAMNIOS

MORTALITY

Cytogenetic evaluation of cystic hygroma associated with hydrops fetalis, oligohydramnios or intrauterine fetal death: the roles of amniocentesis, postmortem chorionic villus sampling and cystic hygroma paracentesis. Chen CP, et al. **Acta Obstet Gynecol Scand** 1996 May;75(5):454-8 (29 ref.)

PHYSIOPATHOLOGY

[Oligohydramnios] Pekhlivanov B, et al. **Akush Ginekol (Sofiia)** 1995;34(1):24-7 (24 ref.) **(Bul)**

OLIGONUCLEOTIDE-DIRECTED MUTAGENESIS see **MUTAGENESIS, SITE-DIRECTED**

OLIGONUCLEOTIDE PRIMERS see **DNA PRIMERS**

OLIGONUCLEOTIDE PROBES

see related
NUCLEIC ACID HYBRIDIZATION

Using oligonucleotide probe arrays to access genetic diversity. Lipshutz RJ, et al. **Biotechniques** 1995 Sep; 19(3):442-7 (16 ref.)

[PCR-SSOP (sequence specific oligonucleotide probe) method] Yasunaga S, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):553-5 (3 ref.) **(Jpn)**

OLIGONUCLEOTIDES

[Molecular design of oligonucleotide porphyrin derivatives] Shimidzu T. **Tanpakushitsu Kakusan Koso** 1994 Jul; 40(10):1357-63 (18 ref.) **(Jpn)**

[Isolation of mRNA 5'-end using oigo-capping] Suzuki Y, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):603-7 (0 ref.) **(Jpn)**

[Directed molecular evolution of oligonucleotides] Terabe M. **Tanpakushitsu Kakusan Koso** 1996 Feb;41(2):166-9 (16 ref.) **(Jpn)**

CHEMICAL SYNTHESIS

Large-scale oligonucleotide synthesizers. I. Basic principles and system design. Anderson NG, et al. **Appl Biochem Biotechnol** 1995 Jul-Sep;54(1-3):19-42 (7 ref.)

[Synthesis of oligonucleotide analogues by the post-elongation modification methods] Ono A, et al. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1391-9 (20 ref.) **(Jpn)**

[Chemical synthesis of nucleopeptide] Ueno Y, et al. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1342-8 (20 ref.) **(Jpn)**

[Synthesis and properties of Oligonucleotides with modified sugar fragment] Yamana K. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1349-56 (12 ref.) **(Jpn)**

CHEMISTRY

Backbone modifications in oligonucleotides and peptide nucleic acid systems. De Mesmaeker A, et al. **Curr Opin Struct Biol** 1995 Jun;5(3):343-55 (92 ref.)

DNA fingerprinting by hybridisation to oligonucleotide arrays. Southern EM. **Electrophoresis** 1995 Sep; 16(9):1539-42 (14 ref.)

Trinucleotide models for DNA bending propensity: comparison of models based on DNaseI digestion and nucleosome packaging data. Brukner I, et al. **J Biomol Struct Dyn** 1995 Oct;13(2):309-17 (28 ref.)

Oligonucleotide diversity and drug discovery. Trotta PP, et al. **Med Res Rev** 1995 Jul;15(4):277-98 (88 ref.)

Conformational properties of oligonucleotides. Gold L. **Nucleic Acids Symp Ser** 1995;(33):20-2 (9 ref.)

GENETICS

Origins and evolution of Huntington disease chromosomes.

Andrew SE, et al. **Neurodegeneration** 1995 Sep;4(3):239–44 (50 ref.)

METABOLISM

Diversity of oligonucleotide functions. Gold L, et al. **Annu Rev Biochem** 1995;64:763–97 (138 ref.)

PHARMACOKINETICS

Passive and facilitative transport of nucleobases, nucleosides, and oligonucleotides—application to antiviral and other therapies. Brewster ME, et al. **NIDA Res Monogr** 1995; 154:61–85 (62 ref.)

PHARMACOLOGY

Oligonucleotide diversity and drug discovery. Trotta PP, et al. **Med Res Rev** 1995 Jul;15(4):277–98 (88 ref.)

THERAPEUTIC USE

Pharmacological intervention in antibody mediated disease. Coutts SM, et al. **Lupus** 1996 Apr;5(2):158–9 (13 ref.)

OLIGONUCLEOTIDES, ANTISENSE

Mapping of opioid receptors using antisense oligodeoxynucleotides: correlating their molecular biology and pharmacology. Pasternak GW, et al. **Trends Pharmacol Sci** 1995 Oct;16(10):344–50 (57 ref.)

[Application of antisense oligodeoxynucleotides on smooth muscle cells and endothelial cells] Yang HP, et al. **Sheng Li Ko Hsueh Chin Chan** 1995 Jul;26(3):259–62 (9 ref.) **(Chi)**

[Recent developments in the field of antigene oligonucleotides] Inoue H. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1383–90 (53 ref.) **(Jpn)**

[Molecular design of antisense oligonucleotide] Murakami A. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1364–70 (37 ref.) **(Jpn)**

ADMINISTRATION & DOSAGE

Facilitating oligonucleotide delivery: helping antisense deliver on its promise. Gewirtz AM, et al. **Proc Natl Acad Sci U S A** 1996 Apr 16;93(8):3161–3 (33 ref.)

ANALYSIS

Emerging technologies for sequencing antisense oligonucleotides: capillary electrophoresis and mass spectrometry. Cohen AS, et al. **Adv Chromatogr** 1996; 36:127–62 (115 ref.)

Capillary gel electrophoresis and antisense therapeutics. Analysis of DNA analogs. DeDionisio LA, et al. **J Chromatogr A** 1996 May 31;735(1–2):191–208 (32 ref.)

CHEMICAL SYNTHESIS

[Synthesis of oligodeoxyribonucleotides with modified internucleotide phosphate residues] Hayakawa Y, et al. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1306–14 (33 ref.) **(Jpn)**

GENETICS

Facilitating oligonucleotide delivery: helping antisense deliver on its promise. Gewirtz AM, et al. **Proc Natl Acad Sci U S A** 1996 Apr 16;93(8):3161–3 (33 ref.)

PHARMACOKINETICS

Animal models of antisense oligonucleotides: lessons for use in humans. Plenat F. **Mol Med Today** 1996 Jun;2(6):250–7 (37 ref.)

[Labeling for the studies on dynamic properties of antisense molecules] Makino K, et al. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1371–7 (12 ref.) **(Jpn)**

PHARMACOLOGY

Antisense oligodeoxynucleotides directed against the Na–Ca exchanger mRNA. Promising tools for studies on the cellular and molecular level. Niggli E, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:93–102 (33 ref.)

To cleave or not to cleave: ribozymes and antisense. Woolf TM. **Antisense Res Dev** 1995 Fall;5(3):227–32 (34 ref.)

Prospects for the therapeutic use of antigene oligonucleotides. Maher LJ 3rd. **Cancer Invest** 1996; 14(1):66–82 (165 ref.)

Antisense oligodeoxynucleotides as clinical therapeutic agents. Tonkinson JL, et al. **Cancer Invest** 1996;14(1):54–65 (103 ref.)

The effect of c-raf antisense oligonucleotides on growth factor–induced proliferation of hematopoietic cells. Keller JR, et al. **Curr Top Microbiol Immunol** 1996;211:43–53 (25 ref.)

Oligonucleotide modulation of multidrug resistance. Bouffard DY, et al. **Eur J Cancer** 1996 Jun;32A(6):1010–8 (111 ref.)

Oligonucleotide-mediated modulation of mammalian gene expression. Scanlon KJ, et al. **FASEB J** 1995 Oct; 9(13):1288–96 (68 ref.)

Antitumor effects of antisense phosphorothioate c-myc oligodeoxynucleotides: a question of mechanism [editorial; comment] Stein C.A.. **J Natl Cancer Inst** 1996 Apr 3; 88(7):391–3 (9 ref.) Comment on: J Natl Cancer Inst 1996 Apr 3;88(7):419–29.

Brief overview of control of genetic expression by antisense oligonucleotides and in vivo applications. Prospects for neurobiology. Zon G. **Mol Neurobiol** 1995 Apr–Jun; 10(2–3):219–29 (69 ref.)

In vivo antisense approaches to the role of immediate early gene expression in the brain. Cirelli C, et al. **Regul Pept** 1995 Oct 20;59(2):151–62 (48 ref.)

Antisense oligonucleotides in in vivo regulatory peptide research [editorial] Phillips MI. **Regul Pept** 1995 Oct 20; 59(2):iii–v (13 ref.)

In vivo applications of antisense oligonucleotides for peptide research. [editorial] Phillips MI, et al. **Regul Pept** 1995 Oct 20;59(2):131–41 (56 ref.)

[Anti-sense in medicine and central nervous system disorders] Cohen H, et al. **Harefuah** 1996 Apr 1;130(7):500–2 (14 ref.) **(Heb)**

[Inhibition of HBx gene expression by antisense oligonucleotide] Moriya K, et al. **Nippon Rinsho** 1995 Oct; 53 Suppl:111–4 (9 ref.) **(Jpn)**

THERAPEUTIC USE

Progress in antisense oiigonucleotide therapeutics. Crooke ST, et al. **Annu Rev Pharmacol Toxicol** 1996;36:107–29 (185 ref.)

Immunologic consequences of nucleic acid therapy. Pisetsky DS. **Antisense Res Dev** 1995 Fall;5(3):219–25 (53 ref.)

The therapeutic potential of antisense oligonucleotides. Sharma HW, et al. **Bioessays** 1995 Dec;17(12):1055–63 (72 ref.)

Application of antisense oligodeoxynucleotides (ODNs) for the intervention of kidney disease. Antisense ODNs for transforming growth factor-beta-suppressed glomerulosclerosis in experimental glomerulonephritis. Imai E, et al. **Contrib Nephrol** 1996;118:86–93 (17 ref.)

Effect of antisense inhibition of Urokinase receptor on malignancy. Ossowski L. **Curr Top Microbiol Immunol** 1996;213 (Pt 3):101–12 (71 ref.)

Progress in antisense therapeutics. Crooke ST. **Hematol Pathol** 1995;9(2):59–72 (69 ref.)

Therapy of hepadnavirus infection using antisense oligonucleotides. Offensperger WB, et al. **Intervirology** 1995;38(1–2):113–9 (84 ref.)

Antisense oligonucleotides in the study of neuroendocrine systems. Morris M, et al. **J Neuroendocrinol** 1995 Jul; 7(7):493–500 (64 ref.)

Antisense approach to restenosis. Simons M. **Jpn Circ J** 1996 Jan;60(1):1–9 (50 ref.)

The repression of apoptosis by activated abl oncogenes in chronic myelogenous leukaemia. Fernandes RS, et al. **Leukemia** 1996 Jun;10 Suppl 2:s17–21 (39 ref.)

Antisense-oligonucleotide therapy. Askari FK, et al. **N Engl J Med** 1996 Feb 1;334(5):316–8 (0 ref.)

Antisense strategies in the treatment of leukemias. Calabretta B, et al. **Semin Oncol** 1996 Feb;23(1):78–87 (47 ref.)

[Anti-sense in medicine and central nervous system disorders] Cohen H, et al. **Harefuah** 1996 Apr 1;130(7):500–2 (14 ref.) **(Heb)**

[Approach to human glioma cells using antisense molecules] Yoshida S, et al. **No To Shinkei** 1995 Sep;47(9):823–8 (24 ref.) **(Jpn)**

TOXICITY

Antisense phosphorothioate oligodeoxynucleotides: introductory concepts and possible molecular mechanisms of toxicity. Zon G. **Toxicol Lett** 1995 Dec;82–83:419–24 (23 ref.)

OLIGOPEPTIDES

Antithrombotic agents: from RGD to peptide mimetics. Ojima I, et al. **Bioorg Med Chem** 1995 Apr;3(4):337–60 (142 ref.)

BLOOD

[APC (activated protein C) resistance and oral contraceptives] Kreis I, et al. **Geburtshilfe Frauenheilkd** 1996 May;56(5):231–3 (21 ref.) (Eng. Abstr.) **(Ger)**

CHEMICAL SYNTHESIS

Design and synthesis of substrate-based peptidomimetic human immunodeficiency virus protease inhibitors containing the hydroxymethylcarbonyl isostere. Kiso Y. **Biopolymers** 1996;40(2):235–44 (27 ref.)

Solid-phase combinatorial chemistry and novel tagging methods for identifying leads. Chabala JC. **Curr Opin Biotechnol** 1995 Dec;6(6):632–9 (24 ref.)

CHEMISTRY

Synthetic metallopeptides as probes of protein–DNA interactions. Long EC, et al. **Met Ions Biol Syst** 1996; 33:427–52 (65 ref.)

GENETICS

Filamentous phage display of oligopeptide libraries. Burritt JB, et al. **Anal Biochem** 1996 Jun 15;238(1):1–13 (102 ref.)

IMMUNOLOGY

New treatment options for patients with melanoma: review of melanoma-derived T-cell epitope-based peptide vaccines. Maeurer MJ, et al. **Melanoma Res** 1996 Feb; 6(1):11–24 (102 ref.)

METABOLISM

Interactions of connective tissue cells with the extracellular matrix. Horton MA. **Bone** 1995 Aug;17(2 Suppl):51S–53S (20 ref.)

Intestinal oligopeptide transport. Boyd CA. **Proc Nutr Soc** 1995 Jul;54(2):519–23 (18 ref.)

A new receptor for growth hormone-release peptide [comment] Conn PM, et al. **Science** 1996 Aug 16; 273(5277):923 (13 ref.) Comment on: Science 1996 Aug 16;273(5277):974–7.

PHARMACOLOGY

Opioid infidelity: novel opioid peptides with dual high affinity for delta- and mu-receptors. Lazarus LH, et al. **Trends Neurosci** 1996 Jan;19(1):31–5 (64 ref.)

[Antimicrobial oligopeptides—an important factor in non-specific defense against infection] Haegele B, et al. **Immun Infekt** 1995 Dec;23(6):205–8 (27 ref.) (Eng. Abstr.) **(Ger)**

[Anti-adhesive and anti-thrombotic effects of integrin-inhibiting tripeptides (Arg-Gly-Asp)] Udvardy M. **Orv Hetil** 1995 Oct 1;136(40):2155–9 (42 ref.) (Eng. Abstr.) **(Hun)**

THERAPEUTIC USE

Growth hormone secretagogues. Clinical experience and therapeutic potential. Laron Z. **Drugs** 1995 Oct; 50(4):595–601 (48 ref.)

Pathophysiology of renal tubular obstruction: therapeutic role of synthetic RGD peptides in acute renal failure. Noiri E, et al. **Kidney Int** 1995 Nov;48(5):1375–85 (91 ref.)

Angiopeptin: experimental and clinical studies of inhibition of myointimal proliferation. Foegh ML, et al. **Kidney Int Suppl** 1995 Dec;52:S18–22 (47 ref.)

[APC resistance: pathogenesis, diagnosis, prevalence and importance of a new thrombosis risk factor] Wankmüller H, et al. **Med Klin** 1996 May 15;91(5):308–12, 324 (49 ref.) **(Ger)**

OLIGORIBONUCLEOTIDE PROBES see **OLIGONUCLEOTIDE PROBES**

OLIGORIBONUCLEOTIDES

CHEMICAL SYNTHESIS

[Synthesis and properties of 2'-phosphorylated oligoribonucleotides] Sekine M. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1315–22 (52 ref.) **(Jpn)**

OLIGORIBONUCLEOTIDES, ANTISENSE see **OLIGONUCLEOTIDES, ANTISENSE**

OLIGOSACCHARIDES

Oligosaccharide anti-infective agents. Zopf D, et al. **Lancet** 1996 Apr 13;347(9007):1017–21 (28 ref.)

ANALYSIS

On the presence of inulin and oligofructose as natural ingredients in the western diet. van Loo J, et al. **Crit Rev Food Sci Nutr** 1995 Nov;35(6):525–52 (102 ref.)

Matrix-assisted laser desorption/ionisation mass spectrometry of oligosaccharides and glycoconjugates. Harvey DJ. **J Chromatogr A** 1996 Jan 12;720(1–2):429–46 (64 ref.)

High-performance liquid chromatographic analysis of glycosaminoglycan-derived oligosaccharides. Imanari T, et al. **J Chromatogr A** 1996 Jan 12;720(1–2):275–93 (134 ref.)

Analysis of glycoproteins, glycopeptides and glycoprotein-derived oligosaccharides by high-performance capillary electrophoresis. Kakehi K, et al. **J Chromatogr A** 1996 Jan 12;720(1–2):377–93 (48 ref.)

Enzymatic release of oligosaccharides from glycoproteins for chromatographic and electrophoretic analysis. O'Neill RA. **J Chromatogr A** 1996 Jan 12;720(1–2):201–15 (101 ref.)

Fluorophore-assisted carbohydrate electrophoresis in the separation, analysis, and sequencing of carbohydrates. Starr CM, et al. **J Chromatogr A** 1996 Jan 12;720(1–2):295–321 (42 ref.)

BIOSYNTHESIS

Mechanisms in the glucansucrase synthesis of polysaccharides and oligosaccharides from sucrose. Robyt JF. **Adv Carbohydr Chem Biochem** 1995;51:133–68 (146 ref.)

Control and function of complex-type oligosaccharide synthesis. Novel variants of the lacNAc pathway. Van den Eijnden DH, et al. **Adv Exp Med Biol** 1995;376:47–52 (26 ref.)

[Dolichol-coupled biosynthesis of an oligosaccharide precursor for N-glycosylated proteins in the rough endoplasmic reticulum] Shpakov AO. **Ukr Biokhim Zh**

1995 Mar-Apr;67(2):3-17 (87 ref.) (Eng. Abstr.) **(Rus)**

BLOOD

Abnormalities in the glycosylation of IgG and its clinical utility. Isenberg D. **Adv Exp Med Biol** 1995;376:179-83 (16 ref.)

CHEMICAL SYNTHESIS

Synthesis and biological activity of oligosaccharide libraries. Ding Y, et al. **Adv Exp Med Biol** 1995;376:261-9 (18 ref.)

CHEMISTRY

Chemometrics of oligosaccharide analysis. Parameterization of HPLC of PA-oligosaccharides. Lee YC, et al. **Adv Exp Med Biol** 1995;376:27-35 (16 ref.)

In vivo targeting function of N-linked oligosaccharides. Pharmacokinetic and biodistribution of N-linked oligosaccharides. Rice KG, et al. **Adv Exp Med Biol** 1995; 376:271-82 (24 ref.)

Characterization of protein glycosylation by mass spectrometry. Burlingame AL. **Curr Opin Biotechnol** 1996 Feb;7(1):4-10 (78 ref.)

Three-dimensional structures of oligosaccharides. Woods RJ. **Curr Opin Struct Biol** 1995 Oct;5(5):591-8 (94 ref.)

Oligosaccharide sequencing based on exo- and endoglycosidase digestion and liquid chromatographic analysis of the products. Prime S, et al. **J Chromatogr A** 1996 Jan 12;720(1-2):263-74 (92 ref.)

Three-dimensional mapping of N-linked oligosaccharides using anion-exchange, hydrophobic and hydrophilic interaction modes of high-performance liquid chromatography. Takahashi N. **J Chromatogr A** 1996 Jan 12;720(1-2):217-25 (20 ref.)

[Structural and functional aspects of oligosaccharides in human milk] Kunz C, et al. **Z Ernahrungswiss** 1996 Mar; 35(1):22-31 (51 ref.) (Eng. Abstr.) **(Ger)**

GENETICS

The genetic regulation of sialyl-Lewisx expression in haemopoietic cells. Watkins WM, et al. **Adv Exp Med Biol** 1995;376:83-93 (64 ref.)

ISOLATION & PURIFICATION

Fractionation of glycoprotein-derived oligosaccharides by affinity chromatography using immobilized lectin columns. Endo T. **J Chromatogr A** 1996 Jan 12;720(1-2):251-61 (66 ref.)

Preparative purification of tyrosinamide N-linked oligosaccharides. Rice KG, et al. **J Chromatogr A** 1996 Jan 12;720(1-2):235-49 (34 ref.)

METABOLISM

IgA glycosylation and disease. Dueymes M, et al. **Adv Exp Med Biol** 1995;376:217-20 (18 ref.)

C-type lectins of natural killer cells: carbohydrate ligands and role in tumour cell lysis. Bezouška K. **Biochem Soc Trans** 1996 Feb;24(1):156-61 (24 ref.)

Sialoadhesin and related cellular recognition molecules of the immunoglobulin superfamily. Crocker PR, et al. **Biochem Soc Trans** 1996 Feb;24(1):150-6 (50 ref.)

Evidence that molecules on the surface of one cell can adhere to the oligosaccharide portion of gangliosides on the surface of another cell. Schengrund CL. **Biol Signals** 1995 Jan-Feb;4(1):1-13 (85 ref.)

Lysozyme substrates. Höltje JV. **EXS** 1996;75:105-10 (34 ref.)

Oligosaccharides containing beta 1,4-linked N-acetylgalactosamine, a paradigm for protein-specific glycosylation. Manzella SM, et al. **J Biol Chem** 1996 May 24;271(21):12117-20 (54 ref.)

PHARMACOKINETICS

In vivo targeting function of N-linked oligosaccharides. Pharmacokinetic and biodistribution of N-linked oligosaccharides. Rice KG, et al. **Adv Exp Med Biol** 1995; 376:271-82 (24 ref.)

PHARMACOLOGY

Synthesis and biological activity of oligosaccharide libraries. Ding Y, et al. **Adv Exp Med Biol** 1995;376:261-9 (18 ref.)

OLIGOSPERMIA

BLOOD

Increased follicle stimulating hormone in infertile men. Is increased plasma FSH always due to damaged germinal epithelium? Martin-du-Pan RC, et al. **Hum Reprod** 1995 Aug;10(8):1940-5 (82 ref.)

CHEMICALLY INDUCED

Hormonal male contraception: progress and prospects for the 21st century. Handelsman DJ. **Aust N Z J Med** 1995 Dec;25(6):808-16 (54 ref.)

DRUG THERAPY

[Evaluation of hormonal treatments for idiopathic oligospermia] Buvat J. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(3):223-32 (76 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

The azoospermia factor (AZF) of the human Y chromosome in Yq11: function and analysis in spermatogenesis. Vogt PH, et al. **Reprod Fertil Dev** 1995;7(4):685-93 (56 ref.)

PATHOLOGY

Whither the investigation of male infertility? Is FSH measurement redundant and should all azoospermic patients have testicular biopsy? Wu FC. **Hum Reprod** 1995 Aug;10(8):1945-7 (25 ref.)

THERAPY

Functional motion changes during sperm transit to the site of fertilization and in-vitro applications: a review. Mbizvo MT. **Int J Androl** 1995 Jun;18 Suppl 1:1-6 (59 ref.)

[Treatment of obstructive azoospermia] Hovatta O, et al. **Duodecim** 1994;110(8):802-7 (28 ref.) **(Fin)**

OLIVOPONTOCEREBELLAR ATROPHY

CLASSIFICATION

The relationship of multiple system atrophy to sporadic olivopontocerebellar atrophy and other forms of idiopathic late-onset cerebellar atrophy. Gilman S, et al. **Neurology** 1996 May;46(5):1197-9 (40 ref.)

DIAGNOSIS

Multiple system atrophy. Quinn N, et al. **Curr Opin Neurol** 1995 Aug;8(4):323-6 (28 ref.)

OLIVOPONTOCEREBELLAR DEGENERATION see **OLIVOPONTOCEREBELLAR ATROPHY**

OLLIER'S DISEASE see **ENCHONDROMATOSIS**

OMEGA-CHLOROACETOPHENONE

POISONING

Delayed pulmonary edema and bronchospasm after accidental lacrimator exposure. Vaca FE, et al. **Am J Emerg Med** 1996 Jul;14(4):402-5 (32 ref.)

OMEGA-3 FATTY ACIDS see **FATTY ACIDS, OMEGA-3**

OMEGA PROTEIN see **DNA TOPOISOMERASE**

OMENTUM

[The greater omentum. Its role in reconstructive plastic surgery] Micheau P. **Ann Chir Plast Esthet** 1995 Apr; 40(2):192-207 (65 ref.) (Eng. Abstr.) **(Fre)**

[Torsion of the greater omentum. A case report] Grassi R, et al. **Radiol Med (Torino)** 1996 Jan-Feb;91(1-2):141-2 (15 ref.) **(Ita)**

RADIOGRAPHY

CT scan of mesentery-omentum peritoneum. Sivit CJ. **Radiol Clin North Am** 1996 Jul;34(4):863-84 (58 ref.)

Epiploic appendicitis: ultrasound and CT characteristics. Rutten MJ, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Mar;164(3):264-5 (6 ref.)

SURGERY

Endoscopic harvest of the omental and jejunal free flaps. Saltz R. **Clin Plast Surg** 1995 Oct;22(4):747-54 (24 ref.)

ULTRASONOGRAPHY

Epiploic appendicitis: ultrasound and CT characteristics. Rutten MJ, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Mar;164(3):264-5 (6 ref.)

OMEPRAZOLE

ADVERSE EFFECTS

Hyponatremia with consciousness disturbance caused by omeprazole administration. A case report and literature review. Shiba S, et al. **Dig Dis Sci** 1996 Aug;41(8):1615-7 (5 ref.)

ANALOGS & DERIVATIVES

Drug therapy of peptic ulcer disease. Ching CK, et al. **Br J Hosp Med** 1995 Jul 12-Aug 15;54(2-3):101-6 (39 ref.)

Similarities and differences in the properties of substituted benzimidazoles: a comparison between pantoprazole and related compounds. Kromer W. **Digestion** 1995; 56(6):443-54 (90 ref.)

Lansoprazole--another proton pump inhibitor. **Drug Ther Bull** 1995 May;33(5):36-7 (14 ref.)

PHARMACOLOGY

Similarities and differences in the properties of substituted benzimidazoles: a comparison between pantoprazole and related compounds. Kromer W. **Digestion** 1995; 56(6):443-54 (90 ref.)

THERAPEUTIC USE

Comparative role of omeprazole in the treatment of gastroesophageal reflux disease. Skoutakis VA, et al. **Ann Pharmacother** 1995 Dec;29(12):1252-62 (64 ref.)

Drug therapy of peptic ulcer disease. Ching CK, et al. **Br J Hosp Med** 1995 Jul 12-Aug 15;54(2-3):101-6 (39 ref.)

The medical management of gastro-oesophageal reflux. **Drug Ther Bull** 1996 Jan;34(1):1-4 (38 ref.)

Strategies for Helicobacter pylori eradication in 1995: a review of international and Belgian experience. Deltenre M, et al. **J Physiol Pharmacol** 1996 Mar;47(1):59-69 (66 ref.)

[How to eradicate Helicobacter pylori in 1995? Critical review of available treatments] Deltenre M, et al. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S44-S52 (122 ref.) **(Fre)**

[Losek (omeprazole), a new therapeutic agent in the treatment of peptic ulcer and hyperacidity states] Bulgakov SA. **Klin Med (Mosk)** 1995;73(5):11-6 (77 ref.) **(Rus)**

[Omeprazole and amoxycillin in the eradicating treatment of Helicobacter pylori] Gisbert JP, et al. **Rev Clin Esp** 1995 Nov;195(11):787-91 (74 ref.) **(Spa)**

OMP PROTEINS see **BACTERIAL OUTER MEMBRANE PROTEINS**

OMPHALOCELE see **HERNIA, UMBILICAL**

ON-LINE SYSTEMS see **ONLINE SYSTEMS**

ONCOGENE PRODUCTS see **ONCOGENE PROTEINS**

ONCOGENE PROTEIN P21(RAS)

METABOLISM

Ras effectors. Marshall CJ. **Curr Opin Cell Biol** 1996 Apr; 8(2):197-204 (64 ref.)

PHYSIOLOGY

p21ras: an oncoprotein functioning in growth factor-induced signal transduction. Bos JL. **Eur J Cancer** 1995 Jul-Aug; 31A(7-8):1051-4 (29 ref.)

ONCOGENE PROTEIN P55(V-FOS) see **ONCOGENE PROTEINS V-FOS**

ONCOGENE PROTEIN P65(GAG-JUN)

PHYSIOLOGY

The glucocorticoid receptor synergizes with Jun homodimers to activate AP-1-regulated promoters lacking GR binding sites. Teurich S, et al. **Chem Senses** 1995 Apr;20(2):251-5 (17 ref.)

ONCOGENE PROTEIN P75(GAG-FOS-FOX) see **ONCOGENE PROTEINS V-FOS**

ONCOGENE PROTEIN P190(BCR-ABL) see **FUSION PROTEINS, BCR-ABL**

ONCOGENE PROTEIN P210(BCR-ABL) see **FUSION PROTEINS, BCR-ABL**

ONCOGENE PROTEIN V-JUN see **ONCOGENE PROTEIN P65(GAG-JUN)**

ONCOGENE PROTEINS

[Cyclin D1 in oncogenesis] Hosokawa Y. **Seikagaku** 1996 Mar;68(3):201-5 (15 ref.) **(Jpn)**

[Specific DNA recognition by Myb protein] Ogata K, et al. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1592-7 (24 ref.) **(Jpn)**

ANALYSIS

Oncogene products and other diagnostic markers in human breast cancer patients. Treatment effects and their significance. Dowsett M, et al. **Ann N Y Acad Sci** 1996 Apr 30;784:403-11 (11 ref.)

GENETICS

Tumors antigens encoded by oncogenes and the impact of oncogenes upon the immune responses. Appleman LJ, et al. **Cell Immunol** 1996 May 25;170(1):1-10 (129 ref.)

The cyclin D1/PRAD1 oncogene in human neoplasia. Arnold A. **J Investig Med** 1995 Dec;43(6):543-9 (44 ref.)

IMMUNOLOGY

Novel genetic immunotoxins and intracellular antibodies for cancer therapy. Chen SY, et al. **Semin Oncol** 1996 Feb; 23(1):148-53 (55 ref.)

METABOLISM

Intracellular regulation. Rac and Bcr regulate phagocytic phoxes. Ridley AJ. **Curr Biol** 1995 Jul 1;5(7):710–2 (19 ref.)
Value of cancer-related oncoprotein expression as prognostic factors in breast-cancer with one to three axillary lymph nodes positive. Zhang G, et al. **Gan To Kagaku Ryoho** 1996 Mar;23 Suppl 1:66–74 (22 ref.)

PHYSIOLOGY

Happenstance, circumstance or enemy action: cyclin D1 in breast, eye and brain. Schmidt EV. **Bioessays** 1996 Jan; 18(1):6–8 (29 ref.)
One billion years of Myb. Lipsick JS. **Oncogene** 1996 Jul 18;13(2):223–35 (175 ref.)

ONCOGENE PROTEINS, FUSION

GENETICS

Transforming properties of the leukemic inv(16) fusion gene CBFB-MYH11. Hajra A, et al.
Curr Top Microbiol Immunol 1996;211:289–98 (23 ref.)

ONCOGENE PROTEINS V-ERBA

PHYSIOLOGY

Enhancement of nuclear receptor transcriptional signalling. Renkawitz R, et al. **J Steroid Biochem Mol Biol** 1996 Jan; 56(1–6 Spec No):39–45 (29 ref.)

ONCOGENE PROTEINS V-FOS

PHYSIOLOGY

The glucocorticoid receptor synergizes with Jun homodimers to activate AP-1-regulated promoters lacking GR binding sites. Teurich S, et al. **Chem Senses** 1995 Apr;20(2):251–5 (17 ref.)

ONCOGENE PROTEINS, VIRAL

METABOLISM

Human papillomavirus E6 and E7: proteins which deregulate the cell cycle. Tommasino M, et al. **Bioessays** 1995 Jun; 17(6):509–18 (62 ref.)

PHYSIOLOGY

Role of Epstein-Barr virus gene latent membrane protein in nasopharyngeal carcinoma. Nicholson LJ, et al.
Trends Microbiol 1996 Apr;4(4):132–3 (21 ref.)
[The significance of tumor suppressor genes and viral oncoproteins in the onset of malignant cell transformation] Bojić I, et al. **Vojnosanit Pregl** 1995 Jul–Aug;52(4):371–6 (42 ref.) **(Scr)**

ONCOGENES

Mutation and cancer: a personal odyssey. Knudson AG Jr. **Adv Cancer Res** 1995;67:1–23 (144 ref.)
Oncogenic role of "master" transcription factors in human leukemias and sarcomas: a developmental model. Look AT. **Adv Cancer Res** 1995;67:25–57 (162 ref.)
PAX and HOX in neoplasia. Stuart ET, et al. **Adv Genet** 1995;33:255–74 (92 ref.)
Retroviral insertional mutagenesis as a strategy to identify cancer genes. Jonkers J, et al. **Biochim Biophys Acta** 1996 May 16;1287(1):29–57 (410 ref.)
Molecular thanatopsis: a discourse on the BCL2 family and cell death. Yang E, et al. **Blood** 1996 Jul 15;88(2):386–401 (150 ref.)
Genetic characteristics of prostate cancer. Huncharek M, et al. **Cancer Epidemiol Biomarkers Prev** 1995 Sep;4(6):681–7 (65 ref.)
Assessing new anti-tumour agents and strategies in oncogene transgenic mice. Thomas H, et al.
Cancer Metastasis Rev 1995 Jun;14(2):91–5 (18 ref.)
The genetic epidemiology of cancer. Claus EB.
Cancer Surv 1995;25:13–26 (62 ref.)
Molecular genetics of prostate cancer. Isaacs WB.
Cancer Surv 1995;25:357–79 (133 ref.)
Convergent signalling in the action of integrins, neuropeptides, growth factors and oncogenes. Rozengurt E. **Cancer Surv** 1995;24:81–96 (49 ref.)
Prospects for cancer genetics. Weinberg RA. **Cancer Surv** 1995;25:3–12 (20 ref.)
Dominant oncogenes, tumor suppressors, and radiosensitivity. Chiarugi V, et al. **Cell Mol Biol Res** 1995; 41(3):161–6 (63 ref.)
Bcl-2 gene family and the regulation of programmed cell death. Yin XM, et al.
Cold Spring Harb Symp Quant Biol 1994;59:387–93 (46 ref.)
Biological characteristics of micrometastatic carcinoma cells in bone marrow. Braun S, et al.
Curr Top Microbiol Immunol 1996;213 (Pt 1):163–77 (55 ref.)
The c-myb negative regulatory domain. Gonda TJ, et al.
Curr Top Microbiol Immunol 1996;211:99–109 (43 ref.)
Structure and function of the proteins encoded by the myb gene family. Kanei-Ishii C, et al.
Curr Top Microbiol Immunol 1996;211:89–98 (51 ref.)
Molecular analysis of Evi1, a zinc finger oncogene involved in myeloid leukemia. Lopingco MC, et al.
Curr Top Microbiol Immunol 1996;211:211–22 (63 ref.)
Molecular control of development in normal and leukemic myeloid cells by cytokines, tumor suppressor and oncogenes. Sachs L. **Curr Top Microbiol Immunol** 1996; 211:3–5 (18 ref.)
Degeneration of human oncogenes and mitochondrial genes occurs in cells that exhibit age-related pathology. Cortopassi G, et al. **Exp Gerontol** 1996 Jan–Apr; 31(1–2):253–65 (43 ref.)
The helix-loop-helix gene SCL: implicated in T-cell acute lymphoblastic leukaemia and in normal haematopoietic development. Robb L, et al. **Int J Biochem Cell Biol** 1996 Jun;28(6):609–18 (84 ref.)
Antisense oncogene and tumor suppressor gene therapy of cancer. Zhang WW. **J Mol Med** 1996 Apr;74(4):191–204 (137 ref.)
Detection of chromosomal translocations in leukemia-lymphoma cells by polymerase chain reaction. Drexler HG, et al. **Leuk Lymphoma** 1995 Nov; 19(5–6):359–80 (278 ref.)
Molecular events in lung cancer. Roth JA. **Lung Cancer** 1995 Jun;12 Suppl 2:S3–15 (51 ref.)
Radiotherapy for genes that cause cancer. McBride WH, et al. **Nat Med** 1995 Nov;1(11):1215–7 (29 ref.)
One billion years of Myb. Lipsick JS. **Oncogene** 1996 Jul 18;13(2):223–35 (175 ref.)
Hepatocarcinogenesis in transgenic mice. Sandgren EP, et al. **Prog Clin Biol Res** 1995;391:213–22 (35 ref.)
Oncogene activation and oncogene cooperation in MMTV-induced mouse mammary cancer. van Leeuwen F, et al. **Semin Cancer Biol** 1995 Jun;6(3):127–33 (91 ref.)
Multistep carcinogenesis in colorectal cancers. Takami K, et al. **Southeast Asian J Trop Med Public Health** 1995;26 Suppl 1:190–6 (28 ref.)
Winner of the Theodore E. Woodward Award: c-Myb and the coordinate regulation of thymic genes. Hutton JJ, et al. **Trans Am Clin Climatol Assoc** 1995;107:115–24 (39 ref.)
[Viruses and cancer: molecular pathologic mechanisms of viral carcinogenesis] Butz K, et al. **Immun Infekt** 1995 Oct; 23(5):179–84 (65 ref.) (Eng. Abstr.) **(Ger)**
[Study of cancers as genetic diseases] Kuroki T.
Nippon Naika Gakkai Zasshi 1996 Mar 10;85(3):318–21 (2 ref.) **(Jpn)**
[Molecular biology of lung neoplasms--progress of the basic understandings of solid tumors in general and the application to clinical study] Nukiwa T.
Nippon Naika Gakkai Zasshi 1996 Mar 10;85(3):443–8 (8 ref.) **(Jpn)**
[Role of tumor marker in the presymptomatic diagnosis of hereditary malignant tumors] Baba S, et al.
Nippon Rinsho 1996 Jun;54(6):1597–603 (13 ref.) (Eng. Abstr.) **(Jpn)**
[Clinical application of oncogene and antioncogene as a tumor marker] Kondo H, et al. **Nippon Rinsho** 1996 Jun; 54(6):1494–8 (7 ref.) (Eng. Abstr.) **(Jpn)**
[Cyclin D1 in oncogenesis] Hosokawa Y. **Seikagaku** 1996 Mar;68(3):201–5 (15 ref.) **(Jpn)**
[Mechanism of DNA recognition by a protooncogene product, Myb] Ogata K, et al. **Seikagaku** 1996 Feb; 68(2):111–28 (24 ref.) **(Jpn)**
[P53 protein and human papillomavirus oncogenes in carcinogenesis of the uterine cervix] Toledo-Cuevas EM, et al. **Rev Invest Clin** 1996 Jan–Feb;48(1):59–68 (42 ref.) (Eng. Abstr.) **(Spa)**

DRUG EFFECTS

Effects of sex hormones on oncogene expression in the vagina and on development of sexual dimorphism of the pelvis and anococcygeus muscle in the mouse. Iguchi T, et al. **Environ Health Perspect** 1995 Oct;103 Suppl 7:79–82 (34 ref.)

GENETICS

Molecular and genetic events in schistosomiasis-associated human bladder cancer: role of oncogenes and tumor suppressor genes. Badawi AF. **Cancer Lett** 1996 Aug 2; 105(2):123–38 (111 ref.)
Oncogenes and antioncogenes in lung tumorigenesis. Giaccone G. **Chest** 1996 May;109(5 Suppl):130S–134S (46 ref.)
Molecular defects in thyroid carcinomas: role of the RET oncogene in thyroid neoplastic transformation. Santoro M, et al. **Eur J Endocrinol** 1995 Nov;133(5):513–22 (114 ref.)
Genotypic selection of mitochondrial and oncogenic mutations in human tissue suggests mechanisms of age-related pathophysiology. Cortopassi G, et al.
Mutat Res 1995 Oct;338(1–6):151–9 (43 ref.)
[Positional cloning of the putative gene responsible for transient abnormal myelopoiesis and that for multiple cartilaginous exostoses] Niikawa N. **Rinsho Byori** 1996 Jan; 44(1):13–8 (6 ref.) (Eng. Abstr.) **(Jpn)**
[Oncogenes and suppressor genes: apoptosis mechanisms] Mezquita C. **Med Clin (Barc)** 1995 Sep 30;105(10):389–95 (53 ref.) **(Spa)**

IMMUNOLOGY

Tumors antigens encoded by oncogenes and the impact of oncogenes upon the immune responses. Appleman LJ, et al. **Cell Immunol** 1996 May 25;170(1):1–10 (129 ref.)

PHYSIOLOGY

Oncogenes and other growth factors in gynaecological neoplasms. Cheung AN. **Curr Opin Obstet Gynecol** 1996 Feb;8(1):46–51 (47 ref.)
Control of apoptosis in hematopoiesis and leukemia by cytokines, tumor suppressor and oncogenes. Lotem J, et al. **Leukemia** 1996 Jun;10(6):925–31 (131 ref.)
Phenotype modulation of human adult fibroblasts by oncogenes. Kopelovich L, et al. **Mol Carcinog** 1996 Mar; 15(3):163–6 (60 ref.)
Oncogenes in rheumatoid arthritis. Müller-Ladner U, et al. **Rheum Dis Clin North Am** 1995 Aug;21(3):675–90 (97 ref.)
Induction of apoptosis by tumor suppressor genes and oncogenes. Canman CE, et al. **Semin Cancer Biol** 1995 Feb; 6(1):17–25 (90 ref.)
[Oncogenes and the malignancy process] Mareš J, et al.
Cas Lek Cesk 1996 May 29;135(11):335–9 (39 ref.) (Eng. Abstr.) **(Cze)**

ONCOGENIC VIRUSES

see related
TUMOR VIRUS INFECTIONS

[Virus as an etiological factor of cancer in human beings] Dalen A. **Tidsskr Nor Laegeforen** 1995 Oct 30; 115(26):3263–5 (27 ref.) (Eng. Abstr.) **(Nor)**

IMMUNOLOGY

Selective mechanisms utilized by persistent and oncogenic viruses to interfere with antigen processing and presentation. Ehrlich R. **Immunol Res** 1995;14(2):77–97 (165 ref.)

PATHOGENICITY

[Viruses and cancer: molecular pathologic mechanisms of viral carcinogenesis] Butz K, et al. **Immun Infekt** 1995 Oct; 23(5):179–84 (65 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Regulation of viral and cellular gene expression by E1A proteins encoded by the oncogenic adenovirus type 12. Brockmann D, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 3):81–112 (221 ref.)
Assessing the role of E1A in the differential oncogenicity of group A and group C human adenoviruses. Williams J, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 3):149–75 (134 ref.)
[Human oncogenic viruses. New findings] Pavan JV, et al. **Rev Fac Cien Med Univ Nac Cordoba** 1995;53(1):37–44 (35 ref.) **(Spa)**

ONCOGENS see **CARCINOGENS**

ONCOLOGIC NURSING

Clinical trials and quality of life assessment: the nurses' viewpoint. Molin C, et al. **Eur J Cancer** 1995;31A Suppl 6:S8–10 (25 ref.)
Documentation and outcomes of advanced nursing practice. Boyle DM. **Oncol Nurs Forum** 1995 Sep;22(8 Suppl):11–7 (57 ref.)
Reimbursement issues for advanced practice. Camp-Sorrell D, et al. **Oncol Nurs Forum** 1995 Sep;22(8 Suppl):31–4 (11 ref.)
Titling for advanced practice nurses. Hawkins JW, et al. **Oncol Nurs Forum** 1995 Sep;22(8 Suppl):5–9 (47 ref.)
Definition and measurement of quality of life in oncology nursing research: review and theoretical implications. Mast ME. **Oncol Nurs Forum** 1995 Jul;22(6):957–64 (66 ref.)

ECONOMICS

The managed care contract: implementation in radiation oncology. Bruner DW. **Oncol Nurs Forum** 1996 Apr; 23(3):451–4 (21 ref.)

EDUCATION

Oncology nursing education. Workman ML.
Annu Rev Nurs Res 1996;14:167–78 (52 ref.)
Education of the advanced practice nurse in oncology. Belcher A, et al. **Oncol Nurs Forum** 1995 Sep;22(8 Suppl):19–24 (31 ref.)
Regulation of advanced nursing practice: Part One--Second licensure. Greco KE. **Oncol Nurs Forum** 1995 Sep;22(8 Suppl):35–8 (7 ref.)
Regulation of advanced nursing practice: Part Two--Certification. Spencer-Cisek P, et al.
Oncol Nurs Forum 1995 Sep;22(8 Suppl):39–42 (12 ref.)

ONCOLOGY, MEDICAL see **MEDICAL ONCOLOGY**

ONCOLOGY, RADIATION see **RADIATION ONCOLOGY**

ONCOLYTIC VIRUSES see **VIRUSES**

ONCOPROTEINS see **ONCOGENE PROTEINS**

ONCORHYNCHUS MYKISS

Fish models for environmental carcinogenesis: the rainbow trout. Bailey GS, et al. **Environ Health Perspect** 1996 Mar; 104 Suppl 1:5–21 (174 ref.)

PARASITOLOGY

A checklist of metazoan parasites from rainbow trout (Oncorhynchus mykiss). Buchmann K, et al. **Acta Vet Scand** 1995;36(3):299–318 (161 ref.)

ONCORNAVIRUSES see **RETROVIRIDAE**

ONCOVIRINAE see **RETROVIRIDAE**

ONCOVIRUSES see **RETROVIRIDAE**

ONCOVIRUSES, TYPE C see **RETROVIRIDAE**

ONDANSETRON

Ondansetron. Thavaraj V, et al. **Indian Pediatr** 1995 Aug; 32(8):898–901 (12 ref.)

PHARMACOKINETICS

Ondansetron clinical pharmacokinetics. Roila F, et al. **Clin Pharmacokinet** 1995 Aug;29(2):95–109 (40 ref.)

THERAPEUTIC USE

Ondansetron use for smoking cessation. Cropp CD, et al. **Ann Pharmacother** 1995 Oct;29(10):1041–2 (9 ref.)

Assessing the comparative clinical value of tropisetron. Olver IN. **Aust N Z J Med** 1995 Oct;25(5):523–7 (31 ref.)

[Efficacy of ondansetron in acute and delayed cisplatin-induced nausea and vomiting] Depierre A. **Bull Cancer (Paris)** 1996 Feb;83(2):147–53 (29 ref.) (Eng. Abstr.) **(Fre)**

[Optimal control by ondansetron of acute and prolonged emesis induced by chemotherapy without cisplatin] Harousseau JL. **Bull Cancer (Paris)** 1996 Jan;83(1):71–76 (27 ref.) (Eng. Abstr.) **(Fre)**

ONDATRA see **MICROTINAE**

ONDINE'S CURSE see **SLEEP APNEA SYNDROMES**

ONLINE SYSTEMS

Medical resources and the internet. Making the connection. Kramer JM, et al. **Arch Intern Med** 1996 Apr 22; 156(8):833–42 (13 ref.)

On-line resources for pediatricians. Spooner SA. **Arch Pediatr Adolesc Med** 1995 Oct;149(10):1160–8 (23 ref.)

On-line portal imaging: contributions and limitations in clinical practice. Shalev S. **Front Radiat Ther Oncol** 1996; 29:156–67 (37 ref.)

On-line monitoring. Santoro A. **Nephrol Dial Transplant** 1995;10(5):615–8 (17 ref.)

ORGANIZATION & ADMINISTRATION

Creating a nursing home page on the World Wide Web. Shellenbarger T, et al. **Comput Nurs** 1996 Jul–Aug; 14(4):239–45 (15 ref.)

ONYCHOMYCOSIS

Onychomycosis. Schwartz RA, et al. **Cutis** 1996 Feb; 57(2):67–74, 80–1 (137 ref.)

DIAGNOSIS

Present and potential diagnostic techniques in onychomycosis. Piérard GE, et al. **J Am Acad Dermatol** 1996 Feb;34(2 Pt 1):273–7 (24 ref.)

Diagnosing and treating onychomycosis. Zaias N, et al. **J Fam Pract** 1996 May;42(5):513–8 (20 ref.)

DRUG THERAPY

Diagnosing and treating onychomycosis. Zaias N, et al. **J Fam Pract** 1996 May;42(5):513–8 (20 ref.)

MICROBIOLOGY

Evolving role of nondermatophytes in onychomycosis. Greer DL. **Int J Dermatol** 1995 Aug;34(8):521–4 (36 ref.)

THERAPY

Fungal nail disease: a guide to good practice (report of a Working Group of the British Society for Medical Mycology). Denning DW, et al. **BMJ** 1995 Nov 11; 311(7015):1277–81 (19 ref.)

OOCYTE DONATION

Exploring the mechanism(s) of endometriosis-related infertility: an analysis of embryo development and implantation in assisted reproduction. Pellicer A, et al. **Hum Reprod** 1995 Dec;10 Suppl 2:91–7 (33 ref.)

LEGISLATION & JURISPRUDENCE

Age and assisted reproduction. Pennings G. **Med Law** 1995; 14(7–8):531–41 (20 ref.)

OOCYTES

Clinical approaches to increasing uterine receptivity during human implantation. Edwards RG. **Hum Reprod** 1995 Dec; 10 Suppl 2:60–6 (26 ref.)

Cell cycle factors in the human oocyte and the intracytoplasmic injection of spermatozoa. Edwards RG. **Reprod Fertil Dev** 1995;7(2):143–53 (86 ref.)

[Analysis of receptor-ion channel functions in Xenopus oocyte translation system] Kaneko S. **Nippon Yakurigaku Zasshi** 1995 Oct;106(4):243–53 (50 ref.) (Eng. Abstr.) **(Jpn)**

CHEMISTRY

RNA localization and the cytoskeleton in Drosophila oocytes. Pokrywka NJ. **Curr Top Dev Biol** 1995;31:139–66 (49 ref.)

CYTOLOGY

The influence of intrinsic and extrinsic factors on the developmental potential and chromosomal normality of the human oocyte. Van Blerkom J. **J Soc Gynecol Investig** 1996 Jan–Feb;3(1):3–11 (38 ref.)

Second messenger signalling during hormone-induced Xenopus oocyte maturation. Cork RJ, et al. **Zygote** 1994 Nov;2(4):289–99 (101 ref.)

Meiotic cycle checkpoints in mammalian oocytes. Fulka J Jr, et al. **Zygote** 1994 Nov;2(4):351–4 (19 ref.)

DRUG EFFECTS

Assessment of follicle destruction in chemical-induced ovarian toxicity. Hoyer PB, et al. **Annu Rev Pharmacol Toxicol** 1996;36:307–31 (122 ref.)

Important biological variables that can influence the degree of chemical-induced aneuploidy in mammalian oocyte and zygotes. Mailhes JB. **Mutat Res** 1995 Oct;339(3):155–76 (144 ref.)

GROWTH & DEVELOPMENT

Regulation of oocyte growth and maturation in fish. Nagahama Y, et al. **Curr Top Dev Biol** 1995;30:103–45 (134 ref.)

Preovulatory overripeness of the oocyte as a cause of ovarian dysfunction in the human female. Smits LJ, et al. **Med Hypotheses** 1995 Nov;45(5):441–8 (116 ref.)

METABOLISM

The inositol trisphosphate receptor of Xenopus oocytes. Parys JB, et al. **Cell Calcium** 1995 Nov;18(5):353–63 (89 ref.)

Calcium puffs in Xenopus oocytes. Parker I, et al. **Ciba Found Symp** 1995;188:50–60; discussion 60–5 (30 ref.)

Activation mechanism and function of the MAP kinase cascade. Gotoh Y, et al. **Mol Reprod Dev** 1995 Dec; 42(4):486–92 (48 ref.)

[Anesthetics and the glutamate receptor channels expressed in Xenopus oocytes] Yamakura T, et al. **Masui** 1995;44 Suppl:S121–4 (14 ref.) **(Jpn)**

PHYSIOLOGY

Cell–cell signaling, microtubules, and the loss of symmetry in the Drosophila oocyte. Lehmann R. **Cell** 1995 Nov 3; 83(3):353–6 (15 ref.)

Of oocytes and runny noses [editorial; comment] Rosen MR. **Circulation** 1996 Aug 15;94(4):607–9 (20 ref.) Comment on: Circulation 1996 Aug 15;94(4):817–23.

Pattern formation. Gurken meets torpedo for the first time. Gavis ER. **Curr Biol** 1995 Nov 1;5(11):1252–4 (14 ref.)

The influence of intrinsic and extrinsic factors on the developmental potential and chromosomal normality of the human oocyte. Van Blerkom J. **J Soc Gynecol Investig** 1996 Jan–Feb;3(1):3–11 (38 ref.)

Cell–cell interactions and oocyte growth. Canipari R. **Zygote** 1994 Nov;2(4):343–5 (31 ref.)

Second messenger signalling during hormone-induced Xenopus oocyte maturation. Cork RJ, et al. **Zygote** 1994 Nov;2(4):289–99 (101 ref.)

Oocyte activation in invertebrates and humans. Dale B. **Zygote** 1994 Nov;2(4):373–7 (38 ref.)

Oocyte reaction to penetrating sperm. Galeati G. **Zygote** 1994 Nov;2(4):355–8 (38 ref.)

Transduction mechanisms for gonadotrophin-induced oocyte maturation in mammals. Mattioli M. **Zygote** 1994 Nov; 2(4):347–9 (10 ref.)

ULTRASTRUCTURE

Cortical cytoskeleton of the Xenopus oocyte, egg, and early embryo. Larabell CA. **Curr Top Dev Biol** 1995;31:433–53 (72 ref.)

[The morphological criteria and proposed mechanisms of cortical contractility in oocytes of the clawed toad] Riabova LV, et al. **Ontogenez** 1996 May–Jun;27(3):165–72 (14 ref.) (Eng. Abstr.) **(Rus)**

OOECYAN see **BILIVERDINE**

OOGENESIS

Intercellular signaling and the polarization of body axes during Drosophila oogenesis. Ray RP, et al. **Genes Dev** 1996 Jul 15;10(14):1711–23 (80 ref.)

[The formation of the karyosphere in the oogenesis of insects and amphibians] Gruzova MN, et al. **Tsitologiia** 1995; 37(8):744–69 (156 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Confocal immunofluorescence microscopy of microtubules, microtubule-associated proteins, and microtubule-organizing centers during amphibian oogenesis and early development. Gard DL, et al. **Curr Top Dev Biol** 1995;31:383–431 (137 ref.)

Axis formation during amphibian oogenesis: reevaluating the role of the cytoskeleton. Gard DL. **Curr Top Dev Biol** 1995; 30:215–52 (122 ref.)

Cortical cytoskeleton of the Xenopus oocyte, egg, and early embryo. Larabell CA. **Curr Top Dev Biol** 1995;31:433–53 (72 ref.)

OOPHORECTOMY see **OVARIECTOMY**

OPEN-ANGLE GLAUCOMA see **GLAUCOMA, OPEN-ANGLE**

OPEN READING FRAMES

Selenium and cellular immunity. Evidence that selenoproteins may be encoded in the +1 reading frame overlapping the human CD4, CD8, and HLA-DR genes. Taylor EW. **Biol Trace Elem Res** 1995 Aug–Sep;49(2–3):85–95 (37 ref.)

Varicella-zoster virus gene regulation. Piette J, et al. **Neurology** 1995 Dec;45(12 Suppl 8):S23–7 (37 ref.)

Effects of the ferritin open reading frame on translational induction by iron. Mascotti DP, et al. **Prog Nucleic Acid Res Mol Biol** 1996;55:121–34 (82 ref.)

GENETICS

[Probable implication of mutations of the X open reading frame in the onset of fulminant hepatitis B] Kaneko M, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:463–6 (14 ref.) **(Jpn)**

OPERATING ROOM NURSING

METHODS

Patient preparation and monitoring for carotid stenting: the operating room nurse's perspective. Plat S, et al. **J Endovasc Surg** 1996 May;3(2):224–7 (6 ref.)

OPERATING ROOMS

Occupational health in surgery: risks extend beyond the operating room. Patz JA, et al. **Aust N Z J Surg** 1995 Sep; 65(9):627–9 (27 ref.)

Are universal precautions realistic? Gerberding JL, et al. **Surg Clin North Am** 1995 Dec;75(6):1091–104 (23 ref.)

OPERATIONS RESEARCH

see related
DECISION THEORY
INFORMATION THEORY

OPERON

Regulation and organization of the groE and dnaK operons in Eubacteria. Segal R, et al. **FEMS Microbiol Lett** 1996 Apr 15;138(1):1–10 (32 ref.)

OPHTHALMIA see **ENDOPHTHALMITIS**

OPHTHALMIA, SYMPATHETIC

ETIOLOGY

Sympathetic ophthalmia. Towler HM, et al. **Int Ophthalmol Clin** 1995 Spring;35(2):31–42 (23 ref.)

OPHTHALMIC ARTERY

SURGERY

[The surgical treatment of an aneurysm with a carotid-ophthalmic location] Krylov VV, et al. **Zh Vopr Neirokhir Im N N Burdenko** 1995 Jul–Sep;(3):31–2 (24 ref.) **(Rus)**

OPHTHALMIC SOLUTIONS

ADVERSE EFFECTS

Chloramphenicol eye drops: a dangerous drug? Diamond J, et al. **Practitioner** 1995 Oct;239(1555):608–11 (15 ref.)

THERAPEUTIC USE

[Current medical treatment of dry eye] Roncin S, et al. **J Fr Ophtalmol** 1995;18(11):708–13, 715–30 (105 ref.) **(Fre)**

OPHTHALMOLOGY

see related
EYE DISEASES
VISION

Molecular biology in ophthalmology. A review of principles and recent advances. Della NG. **Arch Ophthalmol** 1996 Apr;114(4):457–63 (63 ref.)

AIDS and the contact lens practice. Slonim CB. **CLAO J** 1995 Oct;21(4):233–5 (19 ref.)

Epidemiological aspects, development and management of prevention in ophthalmology in relation to different ages. Nuzzi R, et al. **Panminerva Med** 1995 Mar;37(1):28–37 (19 ref.)

[Drug side-effects of the eye—a contribution to quality assurance in ophthalmology] Dangelmaier S, et al. **Klin Monatsbl Augenheilkd** 1996 May;208(5):385–8 (4 ref.) (Eng. Abstr.) **(Ger)**

[Cytokines in ophthalmology] Yamashita H. **Nippon Ganka Gakkai Zasshi** 1995 Oct;99(10):1109–10 (5 ref.) **(Jpn)**

HISTORY

The Bowman Lecture. Naumann GO. **Eye** 1995;9 (Pt 4):395–421 (227 ref.)

LEGISLATION & JURISPRUDENCE

Credibility: the key to the successful physician witness. Marshall JC. **Surv Ophthalmol** 1995 Jul–Aug;40(1):69–72 (14 ref.)

METHODS

Evaluating new refractive surgical procedures: free market madness versus regulatory rigor mortis [editorial] Waring GO 3rd. **J Refract Surg** 1995 Sep–Oct;11(5):335–9 (26 ref.)

TRENDS

Ophthalmology [see comments] Towler HM, et al. **BMJ** 1996 Apr 6;312(7035):889–92 (30 ref.) Comment in: BMJ 1996 Jul 20;313(7050):169.

What's new in ophthalmic surgery. Weinstein GW. **J Am Coll Surg** 1996 Feb;182(2):130–2 (17 ref.)

OPHTHALMOPLEGIA

COMPLICATIONS

Ophthalmoplegic migraine. Troost BT. **Biomed Pharmacother** 1996;50(2):49–51 (24 ref.)

[Tolosa Hunt syndrome and autoimmune polyglandular syndrome. A rare case report] Cesareo R, et al. **Minerva Endocrinol** 1995 Jun;20(2):149–52 (13 ref.) (Eng. Abstr.) **(Ita)**

[Guillain-Barré syndrome associated with external ophthalmoplegia, consciousness disturbance, and extensor plantar responses: an overlap between Guillain-Barré syndrome and Bickerstaff's brainstem encephalitis] Kitazawa K, et al. **Rinsho Shinkeigaku** 1995 Jun; 35(6):626–32 (30 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

[Sellar metastases simulating the Tolosa-Hunt syndrome] Aprile I, et al. **Radiol Med (Torino)** 1996 Mar;91(3):311–3 (9 ref.) **(Ita)**

ETIOLOGY

Simultaneous, multiple cranial neuropathies in diabetes mellitus. Eshbaugh CG, et al. **J Neuroophthalmol** 1995 Dec; 15(4):219–24 (23 ref.)

Traumatic superior orbital fissure syndrome: report of two cases. Bun RJ, et al. **J Oral Maxillofac Surg** 1996 Jun; 54(6):758–61 (16 ref.)

[Campylobacter jejuni and autoimmune-mediated neurologic diseases: pathogenesis of Guillain-Barré syndrome and Fisher's syndrome] Yuki N. **Nippon Saikingaku Zasshi** 1995 Oct;50(4):991–1003 (41 ref.) **(Jpn)**

OPHTHALMOPLEGIA, CHRONIC PROGRESSIVE EXTERNAL

ETIOLOGY

Atypical motor neuron disease with severe ophthalmoloplegia: a report of two cases [letter; comment] Yuki N, et al. **J Neurol** 1995 Aug;242(8):541–6 (16 ref.) Comment on: J Neurol 1994 Oct;241(10):592–6.

OPHTHALMOSCOPY

[Ophthalmoscopic study of the retinal nerve fiber layer] Jonas JB, et al. **Klin Monatsbl Augenheilkd** 1996 Feb;208(2):aA3–9 (0 ref.) **(Ger)**

INSTRUMENTATION

Laser photocoagulation using binocular indirect ophthalmoscope laser delivery systems. Friberg TR. **Ophthalmic Surg Lasers** 1995 Nov–Dec;26(6):549–59 (18 ref.)

OPIATE DEPENDENCE see **NARCOTIC DEPENDENCE**

OPIATES see **NARCOTICS**

OPIATES, ENDOGENOUS see **OPIOID PEPTIDES**

OPIOID ANALGESICS see **ANALGESICS, OPIOID**

OPIOID ANTAGONISTS see **NARCOTIC ANTAGONISTS**

OPIOID PEPTIDES

see related
RECEPTORS, OPIOID

CHEMISTRY

Structural studies of opioid peptides: a review of recent progress in x-ray diffraction studies. Deschamps JR, et al. **Biopolymers** 1996;40(1):121–39 (59 ref.)

METABOLISM

Endogenous morphine. Hosztafi S, et al. **Pharmacol Res** 1995 Jul–Aug;32(1–2):15–20 (51 ref.)

PHARMACOKINETICS

Vector-mediated delivery of opioid peptides to the brain. Bickel U, et al. **NIDA Res Monogr** 1995;154:28–46 (39 ref.)

PHARMACOLOGY

Opioid and anti-opioid peptides. Cesselin F. **Fundam Clin Pharmacol** 1995;9(5):409–33 (316 ref.)

Drugs that modify opioid tolerance, physical dependence, and abstinence symptoms: preclinical and clinical studies. Bhargava HN. **NIDA Res Monogr** 1995;147:53–83 (127 ref.)

Dynorphin A: a rectifying peptide. Lee NM. **NIDA Res Monogr** 1995;147:161–9 (22 ref.)

PHYSIOLOGY

Exogenous and endogenous opioids as biological response modifiers. Carr DJJ, et al. **Immunopharmacology** 1995 Nov; 31(1):59–71 (118 ref.)

Spinal opioid systems in inflammation. Stanfa L, et al. **Inflamm Res** 1995 Jun;44(6):231–41 (119 ref.)

Opioid involvement in feeding behaviour and the pathogenesis of certain eating disorders. Johnson RD. **Med Hypotheses** 1995 Nov;45(5):491–7 (48 ref.)

Endogenous opiates: 1994. Olson GA, et al. **Peptides** 1995; 16(8):1517–55 (538 ref.)

The opioid receptor antagonist naloxone influences the pathophysiology of spinal cord injury. Olsson Y, et al. **Prog Brain Res** 1995;104:381–99 (96 ref.)

The opioid/anti-opioid balance in shock: a new target for therapy in resuscitation. Bertolini A. **Resuscitation** 1995 Aug;30(1):29–42 (177 ref.)

[Trigemino-vegetative physiopathology in the central dysnociceptive biorhythms in primary headache] Passàli D, et al. **Ital J Neurol Sci** 1995 Nov;16(8 Suppl):41–5 (14 ref.) (Eng. Abstr.) **(Ita)**

[Effect of brain peptides on feeding and body weight regulation] Inui A, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:49–57 (20 ref.) **(Jpn)**

[Function of endogenous opioid peptides and sex steroids at the level of the central nervous system] Bidzińska B, et al. **Postepy Hig Med Dosw** 1995;49(4):523–30 (44 ref.) (Eng. Abstr.) **(Pol)**

OPIOID RECEPTORS see **RECEPTORS, OPIOID**

OPIOID RECEPTORS, DELTA see **RECEPTORS, OPIOID, DELTA**

OPIOID RECEPTORS, KAPPA see **RECEPTORS, OPIOID, KAPPA**

OPIOID RECEPTORS, MU see **RECEPTORS, OPIOID, MU**

OPIOID RECEPTORS, SIGMA see **RECEPTORS, SIGMA**

OPIOIDS see **NARCOTICS**

OPPENHEIM-ZIEHEN DISEASE see **DYSTONIA MUSCULORUM DEFORMANS**

OPPORTUNISTIC INFECTIONS

Human herpesvirus-6 in transplantation: an emerging pathogen. Singh N, et al. **Ann Intern Med** 1996 Jun 15; 124(12):1065–71 (58 ref.)

Opportunistic infections in immunocompromised patients. Chaignaud BE, et al. **Semin Pediatr Surg** 1995 Nov; 4(4):245–51 (91 ref.)

COMPLICATIONS

Visceral leishmaniasis emerging as an important opportunistic infection in HIV-infected persons living in areas nonendemic for Leishmania donovani. Albrecht H, et al. **Arch Pathol Lab Med** 1996 Feb;120(2):189–98 (53 ref.)

Cystic fibrosis and the pseudomonads. Wright KC. **Br J Biomed Sci** 1996 Jun;53(2):140–5 (51 ref.)

Factors predisposing cancer patients to infection. Viscoli C, et al. **Cancer Treat Res** 1995;79:1–30 (150 ref.)

Pneumonia in cancer patients. Whimbey E, et al. **Cancer Treat Res** 1995;79:185–210 (144 ref.)

Systemic fungal infections: major problems in cancer patients. Powles RL, et al. **Indian J Cancer** 1994 Sep;31(3):180–4 (14 ref.)

Opportunistic mycotic infections of the upper limb. A review. al-Qattan MM. **J Hand Surg [Br]** 1996 Apr;21(2):148–50 (21 ref.)

Pulmonary acremonium abscesses and gastrointestinal tuberculosis manifested as massive upper gastrointestinal bleeding. Miró O, et al. **Nephrol Dial Transplant** 1995; 10(8):1444–6 (17 ref.)

Systemic mucormycosis complicating acute renal failure: case report and review of the literature. Melnick JZ, et al. **Ren Fail** 1995 Sep;17(5):619–27 (31 ref.)

DIAGNOSIS

The laboratory evaluation of opportunistic pulmonary infections. Shelhamer JH, et al. **Ann Intern Med** 1996 Mar 15;124(6):585–99 (94 ref.)

Signs and symptoms of infections and differential diagnosis from noninfectious conditions. Hemmer R. **Cancer Treat Res** 1995;79:31–44 (77 ref.)

Lower extremity manifestations of Vibrio vulnificus infection. Laughlin TJ, et al. **J Foot Ankle Surg** 1995 Jul–Aug;34(4):354–7 (19 ref.)

[Current methods for the laboratory diagnosis of infections caused by asporogenous anaerobic bacteria] Vorob'ev AA, et al. **Klin Lab Diagn** 1996 Jan–Feb;(1):14–6 (16 ref.) (Eng. Abstr.) **(Rus)**

DRUG THERAPY

Antimicrobial prophylaxis in patients undergoing solid organ transplantation. Basgoz N, et al. **Curr Clin Top Infect Dis** 1995;15:344–64 (79 ref.)

Therapy for opportunistic fungal infections: past, present and future. Stevens DA. **Indian J Cancer** 1995 Mar;32(1):1–9 (15 ref.)

New drug developments for opportunistic infections in immunosuppressed patients: Pneumocystis carinii. Queener SF. **J Med Chem** 1995 Nov 24;38(24):4739–59 (158 ref.)

ETIOLOGY

Reactivation toxoplasmic retinochoroiditis in patients undergoing bone marrow transplantation: is there a role for chemoprophylaxis? Peacock JE Jr, et al. **Bone Marrow Transplant** 1995 Jun;15(6):983–7 (23 ref.)

Intravascular device-related infections in cancer patients. Raad II, et al. **Cancer Treat Res** 1995;79:211–31 (149 ref.)

The new fungal opportunists are coming. Perfect JR, et al. **Clin Infect Dis** 1996 May;22 Suppl 2:S112–8 (18 ref.)

Opportunistic fusarial infections in humans. Guarro J, et al. **Eur J Clin Microbiol Infect Dis** 1995 Sep;14(9):741–54 (131 ref.)

Cytomegalovirus infection in organ transplant recipients. Hibberd PL, et al. **Infect Dis Clin North Am** 1995 Dec; 9(4):863–77 (87 ref.)

Infection in the organ transplant recipient. An overview. Kontoyiannis DP, et al. **Infect Dis Clin North Am** 1995 Dec;9(4):811–22 (13 ref.)

Fatal, disseminated Acremonium strictum infection in a neutropenic host. Schell WA, et al. **J Clin Microbiol** 1996 May;34(5):1333–6 (27 ref.)

IMMUNOLOGY

Fungal infections: a growing threat. Dixon DM, et al. **Public Health Rep** 1996 May–Jun;111(3):226–35 (70 ref.)

MICROBIOLOGY

Epidemiology of mycobacterial diseases. Portaels F. **Clin Dermatol** 1995 May–Jun;13(3):207–22 (117 ref.)

Fungal sinusitis. Spring PM, et al. **J La State Med Soc** 1995 Sep;147(9):395–8 (10 ref.)

Molecular genetic approaches to identification, epidemiology and taxonomy of non-albicans Candida species. Sullivan DJ, et al. **J Med Microbiol** 1996 Jun;44(6):399–408 (109 ref.)

[Pathogenic opportunistic microorganisms] Buiuc D. **Bacteriol Virusol Parazitol Epidemiol** 1995 Jan–Mar; 40(1):3–7 (4 ref.) **(Rum)**

PATHOLOGY

[Subcutaneous phaeohyphomycosis in the state of Pará: a report of 3 cases] Arnaud MV, et al. **Rev Soc Bras Med Trop** 1996 May–Jun;29(3):271–4 (20 ref.) (Eng. Abstr.) **(Por)**

PREVENTION & CONTROL

Colony-stimulating factors: current applications and perspectives. Bron D, et al. **Cancer Treat Res** 1995; 79:245–54 (63 ref.)

New and unusual infections in neutropenic patients. Zinner SH. **Cancer Treat Res** 1995;79:173–84 (53 ref.)

Should hematopoietic growth factors routinely be given concurrently with cytotoxic chemotherapy? Croockewit AJ, et al. **Clin Pharmacol Ther** 1996 Jan;59(1):1–6 (31 ref.)

Cytomegalovirus infection in the bone marrow transplant

OPPORTUNISTIC INFECTIONS

recipient. Zaia JA, et al. **Infect Dis Clin North Am** 1995 Dec;9(4):879-900 (95 ref.)

Infection prevention strategies for children with cancer and AIDS: contrasting dilemmas. Chanock SJ, et al. **J Hosp Infect** 1995 Jun;30 Suppl:197-208 (69 ref.)

Problems and priorities for controlling opportunistic pathogens with new antimicrobial strategies; an overview of current literature. Araneo BA, et al. **Zentralbl Bakteriol** 1996 Apr;283(4):431-65 (202 ref.)

[Current status of antifungal prophylaxis in opportunistic mycoses] Torres-Rodríguez JM. **Enferm Infecc Microbiol Clin** 1996 Jan;14(1):44-53 (73 ref.) **(Spa)**

THERAPY

Indications for intensive care in the management of infections in cancer patients. Sculier JP. **Cancer Treat Res** 1995; 79:233-44 (60 ref.)

Management of the transplant recipient with pulmonary infection. Houston SH, et al. **Infect Dis Clin North Am** 1995 Dec;9(4):965-85 (113 ref.)

OPPORTUNISTIC INFECTIONS, AIDS-RELATED see **AIDS-RELATED OPPORTUNISTIC INFECTIONS**

OPPORTUNISTIC INFECTIONS, HIV-RELATED see **AIDS-RELATED OPPORTUNISTIC INFECTIONS**

OPSIN

GENETICS

Colour vision. Dalton's eyes and monkey genes. Tovée MJ. **Curr Biol** 1995 Jun 1;5(6):583-6 (16 ref.)

OPSOCLONUS see **OCULAR MOTILITY DISORDERS**

OPSONINS

see related
PHAGOCYTOSIS

OPTIC ATROPHY

CHEMICALLY INDUCED

Carbohydrate tolerance in patients with tropical ataxic neuropathy--A human model of chronic cyanide intoxication. Famuyiwa OO, et al. **Afr J Med Med Sci** 1995 Jun;24(2):151-7 (28 ref.)

DIAGNOSIS

[Ophthalmoscopic study of the retinal nerve fiber layer] Jonas JB, et al. **Klin Monatsbl Augenheilkd** 1996 Feb;208(2):aA3-9 (0 ref.) **(Ger)**

GENETICS

GAPO syndrome: a new case. Sandgren G. **Am J Med Genet** 1995 Jul 31;58(1):87-90 (16 ref.)

OPTIC ATROPHY, HEREDITARY

DIAGNOSIS

[Behr's syndrome. A report of 2 siblings studied by MR] Pascual-Castroviejo I, et al. **An Esp Pediatr** 1996 Jun; 44(6):593-5 (11 ref.) **(Spa)**

OPTIC CHIASM

Neoplasms of the optic-chiasmatic region. Bozzao A, et al. **Rays** 1996 Jan-Mar;21(1):50-69 (24 ref.) **(Eng, Ita)**

PATHOLOGY

Chiasmal syndrome. Trevino R. **J Am Optom Assoc** 1995 Sep;66(9):559-75 (87 ref.)

SURGERY

Cavernous malformations of the optic chiasma. Shibuya M, et al. **Acta Neurochir (Wien)** 1995;136(1-2):29-36 (26 ref.)

OPTIC DISK

[A family with glaucomatous excavation but without glaucoma] Radian AB, et al. **Oftalmologia** 1996 Jan-Mar; 40(1):16-7 (6 ref.) (Eng. Abstr.) **(Rum)**

ABNORMALITIES

Midline craniofacial defects and morning glory disc anomaly. A distinct clinical entity. Leitch RJ, et al. **Acta Ophthalmol Scand Suppl** 1996;(219):16-9 (13 ref.)

[Dragged disk syndrome. Review of etiologies. Apropos of a case] Barreau E, et al. **J Fr Ophtalmol** 1996;19(1):58-63 (16 ref.) (Eng. Abstr.) **(Fre)**

[Colobomatous fossette of the optic papilla and juxtapapillary choroidal malignant melanoma] Chercota V, et al. **Oftalmologia** 1995 Oct-Dec;39(4):307-10 (9 ref.) (Eng. Abstr.) **(Rum)**

BLOOD SUPPLY

The 1994 Von Sallman Lecture. The optic nerve head circulation in health and disease. Hayreh SS. **Exp Eye Res** 1995 Sep;61(3):259-72 (97 ref.)

PATHOLOGY

[Accuracy in the measurements of the glaucomatous papilla] Radian AB, et al. **Oftalmologia** 1996 Jan-Mar;40(1):48-50 (6 ref.) (Eng. Abstr.) **(Rum)**

OPTIC NERVE

ABNORMALITIES

Basal encephaloceles with morning glory syndrome, and progressive hormonal and visual disturbances: case report and review of the literature. Morioka M, et al. **Brain Dev** 1995 May-Jun;17(3):196-201 (27 ref.)

Glaucoma and findings simulating glaucoma in the Rubinstein-Taybi syndrome. Brei TJ, et al. **J Pediatr Ophthalmol Strabismus** 1995 Jul-Aug; 32(4):248-52 (56 ref.)

BLOOD SUPPLY

Na(+)-Ca2+ exchange in anoxic/ischemic injury of CNS myelinated axons. Stys PK, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:366-78 (41 ref.)

PATHOLOGY

Retinal nerve fiber layer [editorial; comment] Sommer A. **Am J Ophthalmol** 1995 Nov;120(5):665-7 (20 ref.) Comment on: Am J Ophthalmol 1995 Nov;120(5):577-86.

Evaluation of the retinal nerve fiber layer. Jonas JB, et al. **Surv Ophthalmol** 1996 Mar-Apr;40(5):369-78 (107 ref.)

PHYSIOLOGY

Behind the optic nerve: an inside view of the primate visual system. Van Essen DC. **Trans Am Ophthalmol Soc** 1995; 93:123-33 (2 ref.)

PHYSIOPATHOLOGY

Glaucoma: current thinking. Hitchings RA. **Br J Hosp Med** 1996 Mar 20-Apr 2;55(6):312-4 (21 ref.)

ULTRASTRUCTURE

Na(+)-Ca2+ exchange in anoxic/ischemic injury of CNS myelinated axons. Stys PK, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:366-78 (41 ref.)

OPTIC NERVE DISEASES

COMPLICATIONS

[Vision disorders in retrochiasmatic lesions of the visual pathways] Huber A. **Ther Umsch** 1996 Jan;53(1):31-6 (15 ref.) (Eng. Abstr.) **(Ger)**

DIAGNOSIS

Meningioma of the optic nerve sheath. Ortiz O, et al. **AJNR Am J Neuroradiol** 1996 May;17(5):901-6 (13 ref.)

Diagnostic tests in neuro-ophthalmology. Galetta SL, et al. **Neurol Clin** 1996 Feb;14(1):201-22 (114 ref.)

Evaluation of the retinal nerve fiber layer. Jonas JB, et al. **Surv Ophthalmol** 1996 Mar-Apr;40(5):369-78 (107 ref.)

EPIDEMIOLOGY

An epidemic of optic neuropathy and painful sensory neuropathy in Cuba: clinical aspects. Thomas PK, et al. **J Neurol** 1995 Oct;242(10):629-38 (53 ref.)

ETIOLOGY

Chiasmal syndrome. Trevino R. **J Am Optom Assoc** 1995 Sep;66(9):559-75 (87 ref.)

[Toxic lesions of the optic nerve] Mozherenkov VP, et al. **Vestn Oftalmol** 1996 Jan-Mar;112(1):54-5 (32 ref.) **(Rus)**

PATHOLOGY

Rapid growth of an optic nerve ganglioglioma in a patient with neurofibromatosis 1. Sadun F, et al. **Ophthalmology** 1996 May;103(5):794-9 (41 ref.)

PHYSIOPATHOLOGY

Optic neuropathy. Newman NJ. **Neurology** 1996 Feb; 46(2):315-22 (144 ref.)

SURGERY

Cavernous malformations of the optic chiasma. Shibuya M, et al. **Acta Neurochir (Wien)** 1995;136(1-2):29-36 (26 ref.)

THERAPY

Management of thyroid optic neuropathy. Lucarelli MJ, et al. **Int Ophthalmol Clin** 1996 Winter;36(1):179-93 (56 ref.)

OPTIC NEURITIS

DIAGNOSIS

[Retrobulbar neuritis--diagnosis and differential diagnosis] Killer HE, et al. **Schweiz Rundsch Med Prax** 1996 Apr 23;85(17):554-8 (35 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

[Optic neuritis. A common first manifestation of multiple sclerosis] Frederiksen JL. **Ugeskr Laeger** 1996 Mar 4; 158(10):1353-7 (35 ref.) (Eng. Abstr.) **(Dan)**

OPTIC NEUROPATHY, ISCHEMIC

ETIOLOGY

Posterior ischemic optic neuropathy following bilateral radical neck dissection. Schobel GA, et al. **Int J Oral Maxillofac Surg** 1995 Aug;24(4):283-7 (22 ref.)

PREVENTION & CONTROL

[Neuro-ophthalmological problems in the diabetic patient] Boschi A. **Bull Soc Belge Ophtalmol** 1995;256:145-50 (19 ref.) (Eng. Abstr.) **(Fre)**

OPTIC PAPILLA see **OPTIC DISK**

OPTIC TECTUM see **SUPERIOR COLLICULUS**

OPTICAL READERS see **AUTOMATIC DATA PROCESSING**

OPTICAL STORAGE DEVICES

ABC of medical computing. CD ROMS, multimedia, and optical storage systems. Millman A, et al. **BMJ** 1995 Sep 9;311(7006):675-8 (0 ref.)

[The Quick Return Service of electroencephalogram] Shimazaki A, et al. **Rinsho Byori** 1995 Oct;43(10):1044-50 (4 ref.) (Eng. Abstr.) **(Jpn)**

OPTICS

see related
VISION

Optical immunosensors. Rabbany SY, et al. **Crit Rev Biomed Eng** 1994;22(5-6):307-46 (117 ref.)

Optical methods to measure membrane transport processes. Verkman AS. **J Membr Biol** 1995 Nov;148(2):99-110 (87 ref.)

Intraocular lens power calculation for eyes after refractive keratotomy. Hoffer KJ. **J Refract Surg** 1995 Nov-Dec; 11(6):490-3 (4 ref.)

OPTOMETRY

EDUCATION

Design elements of professional ethics courses. Spafford MM, et al. **Optom Vis Sci** 1995 Oct;72(10):741-52 (59 ref.)

METHODS

[Measuring the level of tonic accomodation as a function of wavelength] Dechriste S, et al. **J Fr Ophtalmol** 1995; 18(6-7):439-46 (26 ref.) (Eng. Abstr.) **(Fre)**

TRENDS

Integrating lasers into clinical practice. Rounds RS, et al. **Optom Clin** 1995;4(4):125-40 (10 ref.)

ORAL HEALTH

see related
DENTAL HEALTH SURVEYS
DIAGNOSIS, ORAL
MOUTH DISEASES

Does variability in salivary protein concentrations influence oral microbial ecology and oral health? Rudney JD. **Crit Rev Oral Biol Med** 1995;6(4):343-67 (249 ref.)

Measuring oral health: an historical view and details of a contemporary oral health index (OHX). Burke FJ, et al. **Int Dent J** 1995 Dec;45(6):358-70 (53 ref.)

Oral health and dental care in Hong Kong. Schwarz E, et al. **Int Dent J** 1995 Jun;45(3):169-76 (20 ref.)

Dental practice parameters. Parameters for 12 oral health conditions. Adopted by the American Dental Association House of Delegates. October 1995. **J Am Dent Assoc** 1996 Jan;Suppl:iS-iiS, 1S-36S (0 ref.)

Position of the American Dietetic Association: oral health and nutrition. **J Am Diet Assoc** 1996 Feb;96(2):184-9 (55 ref.)

Geriatric oral health and its impact on eating. Ship JA, et al. **J Am Geriatr Soc** 1996 Apr;44(4):456-64 (105 ref.)

An overview of self-reported outcome assessment in dental research. Reisine S. **J Dent Educ** 1996 Jun;60(6):488-93 (25 ref.)

Research issues related to the oral health status of aging veterans. Gibson G, et al. **Med Care** 1995 Nov;33(11 Suppl):NS45-56 (46 ref.)

Oral health, health, and health-related quality of life. Gift

HC, et al. **Med Care** 1995 Nov;33(11 Suppl):NS57-77 (95 ref.)
Dental problems in the offshore oil and gas industry: a review. Duffy B. **Occup Med (Oxf)** 1996 Feb;46(1):79-83 (8 ref.)

ORAL HYGIENE

see related
TOOTHBRUSHING

Benzo[c]phenanthridine alkaloids sanguinarine and chelerythrine: biological activities and dental care applications. Walterová D, et al.
Acta Univ Palacki Olomuc Fac Med 1995;139:7-16 (110 ref.)
The symptom experience of mucositis, stomatitis, and xerostomia. Dose AM. **Semin Oncol Nurs** 1995 Nov; 11(4):248-55 (59 ref.)
[Decreased saliva secretion. A pharmacologic effect with sequelae for oral health] Foth H.
Med Monatsschr Pharm 1995 Dec;18(12):350-7 (8 ref.) **(Ger)**

ORAL HYGIENE INDEX

[Oral disease epidemiologic illness indices and oral health measures—traditional concepts are supplemented by new socio-dental indicators] Strippel H. **Gesundheitswesen** 1996 Mar;58(3):162-8 (50 ref.) (Eng. Abstr.) **(Ger)**

ORAL MEDICINE see **DENTISTRY**

ORAL MUCOSA see **MOUTH MUCOSA**

ORAL REHYDRATION THERAPY see **FLUID THERAPY**

ORAL TOBACCO see **TOBACCO, SMOKELESS**

ORBICULARIS OCULI REFLEX see **BLINKING**

ORBIT

ABNORMALITIES

[Cerebro-oculofacial dysplasia associated with vertebral changes] Munteanu G, et al. **Oftalmologia** 1995 Oct-Dec; 39(4):316-21 (10 ref.) (Eng. Abstr.) **(Rum)**

BLOOD SUPPLY

Color Doppler ultrasound imaging of the eye and orbit. Williamson TH, et al. **Surv Ophthalmol** 1996 Jan-Feb; 40(4):255-67 (69 ref.)

GROWTH & DEVELOPMENT

Hypertelorism: interorbital growth, measurements, and pathogenetic considerations. Cohen MM Jr, et al.
Int J Oral Maxillofac Surg 1995 Dec;24(6):387-95 (60 ref.)

INJURIES

Traumatic superior orbital fissure syndrome: report of two cases. Bun RJ, et al. **J Oral Maxillofac Surg** 1996 Jun; 54(6):758-61 (16 ref.)

PATHOLOGY

Involvement of the orbital fibroblast and TSH receptor in the pathogenesis of Graves' ophthalmopathy. Heufelder AE. **Thyroid** 1995 Aug;5(4):331-40 (84 ref.)

SURGERY

Adverse effects of bone wax in surgery of the orbit. Katz SE, et al. **Ophthal Plast Reconstr Surg** 1996 Jun;12(2):121-6 (15 ref.)
Use of demineralized bone implants in orbital and craniofacial reconstruction and a review of the literature. Neigel JM, et al. **Ophthal Plast Reconstr Surg** 1996 Jun;12(2):108-20 (63 ref.)
Rehabilitation of a child with partial unilateral cryptophthalmos and multiple congenital anomalies. Konrad H, et al. **Trans Am Ophthalmol Soc** 1995;93:219-40; discussion 241-4 (121 ref.)

ULTRASONOGRAPHY

Color Doppler ultrasound imaging of the eye and orbit. Williamson TH, et al. **Surv Ophthalmol** 1996 Jan-Feb; 40(4):255-67 (69 ref.)

ORBITAL DISEASES

CHEMICALLY INDUCED

Adverse effects of bone wax in surgery of the orbit. Katz SE, et al. **Ophthal Plast Reconstr Surg** 1996 Jun;12(2):121-6 (15 ref.)

DIAGNOSIS

Streptococcal gangrene of the eyelids and orbit. Shayegani A, et al. **Am J Ophthalmol** 1995 Dec;120(6):784-92 (49 ref.)
Intraocular retinoblastoma presenting as ocular and orbital inflammation. Foster BS, et al. **Int Ophthalmol Clin** 1996 Winter;36(1):153-60 (23 ref.)
Ocular and orbital imaging. Mafee MF, et al.
Neuroimaging Clin N Am 1996 May;6(2):291-318 (84 ref.)
Fundus manifestations of orbital disease and treatment of orbital disease. De La Paz MA, et al. **Surv Ophthalmol** 1995 Jul-Aug;40(1):3-21 (271 ref.)
[Neuroradiology in ophthalmology. 2] Müller-Forell W, et al. **Ophthalmologe** 1995 Oct;92(5):757-84 (26 ref.) **(Ger)**
[Retrobulbar orbital dirofilariasis. A case report] Eligi C, et al. **Radiol Med (Torino)** 1995 Sep;90(3):334-5 (8 ref.) **(Ita)**

THERAPY

Fundus manifestations of orbital disease and treatment of orbital disease. De La Paz MA, et al. **Surv Ophthalmol** 1995 Jul-Aug;40(1):3-21 (271 ref.)

ORBITAL FRACTURES

[Zygomatic-orbito-malar fractures. Apropos of 85 cases] Ait Benhamou C, et al. **Rev Laryngol Otol Rhinol (Bord)** 1996; 117(1):15-7 (18 ref.) (Eng. Abstr.) **(Fre)**

ORBITAL GRANULOMA, PLASMA CELL see **GRANULOMA, PLASMA CELL, ORBITAL**

ORBITAL MYOSITIS see **GRANULOMA, PLASMA CELL, ORBITAL**

ORBITAL NEOPLASMS

see related
EYE NEOPLASMS

PATHOLOGY

Invasive periorbital squamous cell carcinoma [letter] Lopez-Avila A, et al. **Clin Exp Dermatol** 1995 Jul; 20(4):358-9 (4 ref.)
Primitive neuroectodermal tumour of the orbit: a case report. Bansal RK, et al. **Indian J Ophthalmol** 1995 Mar; 43(1):29-31 (10 ref.)
[Melanoma developped on nevus of Ota without ocular melanosis. Apropos of an anatomo-clinical case] Reichert S, et al. **J Fr Ophtalmol** 1996;19(5):389-94 (23 ref.) (Eng. Abstr.) **(Fre)**

SECONDARY

Metastatic choroidal melanoma to the contralateral orbit 40 years after enucleation. Coupland SE, et al.
Arch Ophthalmol 1996 Jun;114(6):751-6 (27 ref.)

SURGERY

Transorbital approaches to the cranial base. Bumpous J, et al. **Clin Plast Surg** 1995 Jul;22(3):461-81 (47 ref.)
[Long-term results of the surgical treatment of spheno-orbital osteomeningioma] Gaillard S, et al.
Neurochirurgie 1995;41(6):391-7 (34 ref.) (Eng. Abstr.) **(Fre)**

ORBIVIRUS

PHYSIOLOGY

Orbivirus structure and assembly. Roy P. **Virology** 1996 Feb 1;216(1):1-11 (60 ref.)

ULTRASTRUCTURE

Orbivirus structure and assembly. Roy P. **Virology** 1996 Feb 1;216(1):1-11 (60 ref.)

ORCHIDECTOMY see **ORCHIECTOMY**

ORCHIECTOMY

Compliance with hormonal treatment for prostate cancer. Kaisary AV. **Br J Hosp Med** 1996 Mar 20-Apr 2; 55(6):359-66 (59 ref.)
Combined androgen blockade. Crawford ED. **Eur Urol** 1996; 29 Suppl 2:54-61 (28 ref.)
Combined androgen blockade is the treatment of choice for patients with advanced prostate cancer: the argument for. Debruyne FM. **Eur Urol** 1996;29 Suppl 2:34-6 (8 ref.)
Advances and trends in hormonal therapy for advanced prostate cancer. Debruyne FM, et al. **Eur Urol** 1995; 28(3):177-88 (98 ref.)
Combined androgen blockade is the treatment of choice for patients with advanced prostate cancer: the argument against. Fitzpatrick JM. **Eur Urol** 1996;29 Suppl 2:37-9 (7 ref.)
Combined androgen blockade for the treatment of metastatic cancer of the prostate. Schellhammer PF. **Urology** 1996 May;47(5):622-8 (46 ref.)
[Hot flushes in men after surgical or pharmacologic castration] Aubert J, et al. **Prog Urol** 1995 Sep;5(4):507-9 (13 ref.) (Eng. Abstr.) **(Fre)**

ORGAN CULTURE

see related
CELLS, CULTURED
TISSUE CULTURE

ORGAN DONORS see **TISSUE DONORS**

ORGAN FAILURE, MULTIPLE see **MULTIPLE ORGAN FAILURE**

ORGAN PRESERVATION

Lung preservation: the importance of endothelial and alveolar type II cell integrity. Novick RJ, et al.
Ann Thorac Surg 1996 Jul;62(1):302-14 (141 ref.)
Cardiac allograft vasculopathy: the central pathogenetic role of ischemia-induced endothelial cell injury. Day JD, et al. **J Heart Lung Transplant** 1995 Nov-Dec;14(6 Pt 2):S142-9 (84 ref.)
[Penetrating keratoplasty after graft preservation in organ culture at +37 degrees centigrade. 1-year results] Borderie V, et al. **J Fr Ophtalmol** 1995;18(10):570-7 (27 ref.) (Eng. Abstr.) **(Fre)**
[Effect of organ preservation conditions on reperfusion after liver transplantation] Walcher F, et al.
Anasthesiol Intensivmed Notfallmed Schmerzther 1995 Oct; 30 Suppl 1:S55-7 (27 ref.) **(Ger)**
[The role of reperfusion damage] Post S, et al. **Chirurg** 1996 Apr;67(4):318-23 (38 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Optimal myocardial preservation: cooling, cardioplegia, and conditioning. Cleveland JC Jr, et al. **Ann Thorac Surg** 1996 Feb;61(2):760-8 (75 ref.)
A review of methods for storage of corneas for keratoplasty. Basu PK. **Indian J Ophthalmol** 1995 Jun;43(2):55-8 (30 ref.)
Physiology of cell survival and cell death: implications for organ conservation. Lang F, et al.
Nephrol Dial Transplant 1995;10(9):1551-5 (62 ref.)
The role of calcium-channel antagonists in solid organ transplantation. Huntress JD, et al. **New Horiz** 1996 Feb; 4(1):129-33 (30 ref.)
The vascular biology of heart and lung preservation for transplantation. Pinsky DJ. **Thromb Haemost** 1995 Jul; 74(1):58-65 (50 ref.)

TRENDS

[New frontiers in myocardial preservation] Juffe Stein A. **Rev Esp Cardiol** 1995;48 Suppl 7:24-8 (29 ref.) (Eng. Abstr.) **(Spa)**

ORGAN PROCUREMENT

see related
TISSUE DONORS

Nonheart-beating donors: the Maastricht experience. Daemen JW, et al. **Clin Transpl** 1994;:303-16 (59 ref.)
The procurement of vital organs: a synopsis of policy from various nations and the ethical implications of policy options. Chelminski PR. **Ren Fail** 1996 Mar;18(2):151-72 (178 ref.)
[Answers to human organ procurement: donations, research, and prevention] Garrafa V. **Rev Assoc Med Bras** 1995 Jan-Feb;41(1):67-76 (59 ref.) **(Por)**

LEGISLATION & JURISPRUDENCE

Who are the donors in organ donation? The family's perspective in mandated choice. Klassen AC, et al.
Ann Intern Med 1996 Jul 1;125(1):70-3 (14 ref.)
Mandated choice for organ donation: time to give it a try. Spital A. **Ann Intern Med** 1996 Jul 1;125(1):66-9 (33 ref.)
Organ donation consanguinity or universality. Kishore RR. **Med Law** 1996;15(1):93-104 (15 ref.)

METHODS

Presumed consent: the solution to the critical organ donor shortage? Futterman LG. **Am J Crit Care** 1995 Sep; 4(5):383-8 (78 ref.)
Nonheart-beating donors: the Maastricht experience. Daemen JW, et al. **Clin Transpl** 1994;:303-16 (59 ref.)
Outcome following organ removal from poisoned donors in brain death status: a report of 12 cases and review of the literature. Hantson P, et al. **J Toxicol Clin Toxicol** 1995; 33(6):709-12 (8 ref.)
[Cadaver donor nephrectomy. Surgical technique in the context of multi-organ donation] Benoit G, et al.
Prog Urol 1996 Feb;6(1):114-22 (48 ref.) (Eng. Abstr.) **(Fre)**

ORGANIZATION & ADMINISTRATION

Nonheart-beating donors: the Maastricht experience. Daemen JW, et al. **Clin Transpl** 1994;:303-16 (59 ref.)
The factors influencing organ donation: a review of the research. Gibson V. **J Adv Nurs** 1996 Feb;23(2):353-6 (26 ref.)

STANDARDS

Expanding the donor pool: use of marginal donors for solid organ transplantation. Alexander JW, et al.
Clin Transplant 1996 Feb;10(1 Pt 1):1-19 (113 ref.)
Ethical and legal aspects, and the history of organ transplantation in Turkey. Haberal M, et al.
Transplant Proc 1996 Feb;28(1):382-3 (12 ref.)

ORGAN PROCUREMENT

STATISTICS & NUMERICAL DATA

The UNOS OPTN waiting list: 1988 to 1994. United Network for Organ Sharing. Organ Procurement and Transplantation Network. Guo TJ, et al. **Clin Transpl** 1994; :69–86 (6 ref.)

ORGAN PROCUREMENT FOUNDATIONS see **ORGAN PROCUREMENT**

ORGAN PROCUREMENT SYSTEMS see **ORGAN PROCUREMENT**

ORGAN RETRIEVAL see **ORGAN PROCUREMENT**

ORGAN SPECIFICITY

IMMUNOLOGY

Organ–specific autoimmunity. Bach JF. **Immunol Today** 1995 Jul;16(7):353–5 (15 ref.)

The role of IL–12 in the induction of organ–specific autoimmune diseases. Trembleau S, et al. **Immunol Today** 1995 Aug;16(8):383–6 (51 ref.)

ORGAN TEMPERATURE see **BODY TEMPERATURE**

ORGAN TRANSPLANTATION

see related
TRANSPLANTATION IMMUNOLOGY

The dichotomous functions of passenger leukocytes in solid–organ transplantation. Demetris AJ, et al. **Adv Nephrol Necker Hosp** 1995;24:341–54 (66 ref.)

Endothelin in organ transplantation. Watschinger B, et al. **Am J Kidney Dis** 1996 Jan;27(1):151–61 (127 ref.)

The pleural space and organ transplantation. Judson MA, et al. **Am J Respir Crit Care Med** 1996 Mar;153(3):1153–65 (182 ref.)

Solid–organ transplantation. Lott JA. **Anal Chem** 1995 Jun 15;67(12):417R–424R (127 ref.)

Anaesthesia and the transplanted patient. Sharpe MD. **Can J Anaesth** 1996 May;43(5 Pt 2):R89–98 (9 ref.) **(Eng, Fre)**

Drug interactions in transplantation. Seifeldin R. **Clin Ther** 1995 Nov–Dec;17(6):1043–61 (102 ref.)

Transplantation 1994: the year in review. Browne BJ, et al. **Clin Transpl** 1994;:317–40 (265 ref.)

Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF). Allison AC, et al. **Clin Transplant** 1996 Feb;10(1 Pt 2):77–84 (33 ref.)

Costimulation and its role in organ transplantation. Bluestone JA. **Clin Transplant** 1996 Feb;10(1 Pt 2):104–9 (23 ref.)

Antimicrobial prophylaxis in patients undergoing solid organ transplantation. Basgoz N, et al. **Curr Clin Top Infect Dis** 1995;15:344–64 (79 ref.)

IL–10 immunosuppression in transplantation. Bromberg JS. **Curr Opin Immunol** 1995 Oct;7(5):639–43 (51 ref.)

Cytokines and transplantation: Th1/Th2 regulation of the immune response to solid organ transplants in the adult. Dallman MJ. **Curr Opin Immunol** 1995 Oct;7(5):632–8 (54 ref.)

Hepatitis B and transplantation. Davis CL, et al. **Infect Dis Clin North Am** 1995 Dec;9(4):925–41 (102 ref.)

Pneumocystis carinii and parasitic infections in transplantation. Fishman JA. **Infect Dis Clin North Am** 1995 Dec;9(4):1005–44 (128 ref.)

Hepatitis C infection in the transplant recipient. Terrault NA, et al. **Infect Dis Clin North Am** 1995 Dec;9(4):943–64 (111 ref.)

Dual roles of HMG–CoA reductase inhibitors in solid organ transplantation: lipid lowering and immunosuppression. Katznelson S, et al. **Kidney Int Suppl** 1995 Dec;52:S112–5 (30 ref.)

The role of calcium–channel antagonists in solid organ transplantation. Huntress JD, et al. **New Horiz** 1996 Feb; 4(1):129–33 (30 ref.)

Opportunistic infections in immunocompromised patients. Chaignaud BE, et al. **Semin Pediatr Surg** 1995 Nov; 4(4):245–51 (91 ref.)

FK506 in solid organ transplantation. Fung JJ, et al. **Ther Drug Monit** 1995 Dec;17(6):592–5 (33 ref.)

Therapeutic drug monitoring of tacrolimus in clinical transplantation. McMaster P, et al. **Ther Drug Monit** 1995 Dec;17(6):602–5 (8 ref.)

Lake Louise Consensus Conference on cyclosporin monitoring in organ transplantation: report of the consensus panel. Oellerich M, et al. **Ther Drug Monit** 1995 Dec; 17(6):642–54 (47 ref.)

Comparative study of the role of professional versus semiprofessional or nonprofessional antigen presenting cells in the rejection of vascularized organ allografts. Sundstrom JB, et al. **Transpl Immunol** 1995 Dec;3(4):273–89 (147 ref.)

[Progresses in organ transplantation in China, 1995] Qiu F, et al. **Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):744–5 (0 ref.) **(Chi)**

[Advances in transplantation biology and transplantation of vital organs in the era of immunosuppression with cyclosporin A] Hökl J, et al. **Cas Lek Cesk** 1995 Dec 13; 134(24):775–8 (21 ref.) (Eng. Abstr.) **(Cze)**

[Perspectives of immunosuppressive therapy] Meuer S, et al. **Chirurg** 1996 Apr;67(4):310–7 (53 ref.) (Eng. Abstr.) **(Ger)**

[Sense and nonsense in infection prevention following organ transplantation] Schaad HJ, et al. **Ther Umsch** 1995 Sep; 52(9):608–16 (74 ref.) (Eng. Abstr.) **(Ger)**

[Multiple organ transplants] Téllez de Peralta G, et al. **Rev Esp Cardiol** 1995;48 Suppl 7:46–50 (12 ref.) (Eng. Abstr.) **(Spa)**

[Tacrolimus (FK 506): an immunosuppression alternative in solid organ transplantation. (Part 2)] Díaz M, et al. **Rev Med Univ Navarra** 1995 Apr–Jun;40(2):93–108 (170 ref.) **(Spa)**

ADVERSE EFFECTS

Prophylaxis and treatment of CMV infections in transplantation. Zaia JA. **Adv Exp Med Biol** 1996; 394:117–34 (72 ref.)

Approaches to the treatment of hyperlipidemia in the solid organ transplant recipient. Kirk JK, et al. **Ann Pharmacother** 1995 Sep;29(9):879–91 (98 ref.)

Post–transplant lymphoproliferative disorder. Basgoz N, et al. **Infect Dis Clin North Am** 1995 Dec;9(4):901–23 (69 ref.)

Fever in the solid organ transplant patient. Fischer SA, et al. **Infect Dis Clin North Am** 1996 Mar;10(1):167–84 (115 ref.)

Fungal infections in solid organ transplant recipients. Hadley S, et al. **Infect Dis Clin North Am** 1995 Dec;9(4):1045–74 (249 ref.)

Cytomegalovirus infection in organ transplant recipients. Hibberd PL, et al. **Infect Dis Clin North Am** 1995 Dec; 9(4):863–77 (87 ref.)

Management of the transplant recipient with pulmonary infection. Houston SH, et al. **Infect Dis Clin North Am** 1995 Dec;9(4):965–85 (113 ref.)

Infection in the organ transplant recipient. An overview. Kontoyiannis DP, et al. **Infect Dis Clin North Am** 1995 Dec;9(4):811–22 (13 ref.)

Orthomyxoviral and paramyxoviral infections in transplant patients. Sable CA, et al. **Infect Dis Clin North Am** 1995 Dec;9(4):987–1003 (70 ref.)

Posttransplantation lymphoproliferative disorders (PTLD): current perspectives. Nalesnik MA. **Semin Thorac Cardiovasc Surg** 1996 Apr;8(2):139–48 (75 ref.)

Hemolytic uremic syndrome in solid–organ transplant recipients. Singh N, et al. **Transpl Int** 1996;9(1):68–75 (45 ref.)

Sarcomas in organ allograft recipients. Penn I. **Transplantation** 1995 Dec 27;60(12):1485–91 (48 ref.)

[What are the non transfusional modes of transmission of hepatitis C virus?] Serfaty L, et al. **Gastroenterol Clin Biol** 1995 May;19(5):525–33 (110 ref.) **(Fre)**

[The pathogenesis, diagnosis and therapy of posttransplantation osteoporosis] Hofbauer LC, et al. **Dtsch Med Wochenschr** 1996 Jul 26;121(30):953–7 (45 ref.) **(Ger)**

[Chronic transplant damages: unsatisfactory long–term results of organ transplantation] Tullius SG, et al. **Dtsch Med Wochenschr** 1995 Dec 22;120(51–52):1791–6 (60 ref.) **(Ger)**

LEGISLATION & JURISPRUDENCE

Legal & ethical safeguards: protection of society's most vulnerable participants in a commercialized organ transplantation system. Banks GJ. **Am J Law Med** 1995; 21(1):45–110 (505 ref.)

METHODS

Multiple bone marrow infusions to enhance acceptance of allografts from the same donor. Ricordi C, et al. **Ann N Y Acad Sci** 1995 Dec 29;770:345–50 (23 ref.)

PHYSIOLOGY

[The role of reperfusion damage] Post S, et al. **Chirurg** 1996 Apr;67(4):318–23 (38 ref.) (Eng. Abstr.) **(Ger)**

PSYCHOLOGY

The future of organ transplant psychiatry. Freeman AM 3rd, et al. **Psychosomatics** 1995 Sep–Oct;36(5):429–37 (68 ref.)

[Psychological factors associated with organ transplantation] Kronqvist K, et al. **Duodecim** 1994;110(19):1771–5 (13 ref.) **(Fin)**

STANDARDS

Infectious disease transmission through cell, tissue, and organ transplantation: reducing the risk through donor selection. Eastlund T. **Cell Transplant** 1995 Sep–Oct;4(5):455–77 (223 ref.)

Current ethical issues in organ transplantation. McGeown MG. **Ulster Med J** 1994 Apr;63(1):32–43 (21 ref.)

STATISTICS & NUMERICAL DATA

The UNOS OPTN waiting list: 1988 to 1994. United Network for Organ Sharing. Organ Procurement and Transplantation Network. Guo TJ, et al. **Clin Transpl** 1994; :69–86 (6 ref.)

The factors influencing organ donation: a review of the research. Gibson V. **J Adv Nurs** 1996 Feb;23(2):353–6 (26 ref.)

TRENDS

The changing immunology of organ transplantation. Starzl TE, et al. **Hosp Pract (Off Ed)** 1995 Oct 15;30(10):31–4, 37–42 (11 ref.)

The emergence of xenotransplantation. Fryer JP, et al. **Transpl Immunol** 1995 Mar;3(1):21–31 (98 ref.)

ORGAN TRANSPLANTS see **ORGAN TRANSPLANTATION**

ORGAN WEIGHT

PHYSIOLOGY

Considerations of quantitative data on organ sizes and cell numbers and sizes in Down syndrome. Landing BH, et al. **Prog Clin Biol Res** 1995;393:177–91 (36 ref.)

ORGANELLES

ENZYMOLOGY

The postsynaptic density: a subcellular anchor for signal transduction enzymes. Klauck TM, et al. **Cell Signal** 1995 Nov;7(8):747–57 (114 ref.)

[Organelle specificity of yeast cell polyphosphatases] Kulaev IS, et al. **Biokhimiia** 1995 Sep;60(9):1396–402 (34 ref.) (Eng. Abstr.) **(Rus)**

GENETICS

Free–radical–induced mutation vs redox regulation: costs and benefits of genes in organelles. Allen JF, et al. **J Mol Evol** 1996 May;42(5):482–92 (76 ref.)

METABOLISM

Proteolysis. The proteasome: a protein–degrading organelle? Rubin DM, et al. **Curr Biol** 1995 Aug 1;5(8):854–8 (32 ref.)

Chloride channels of intracellular organelles. al–Awqati Q. **Curr Opin Cell Biol** 1995 Aug;7(4):504–8 (50 ref.)

Membrane fusion in organelle biogenesis. Denesvre C, et al. **Curr Opin Cell Biol** 1996 Aug;8(4):519–23 (45 ref.)

Plasmodesmata: intercellular channels for macromolecular transport in plants. Lucas WJ. **Curr Opin Cell Biol** 1995 Oct;7(5):673–80 (48 ref.)

Major vault protein LRP–related multidrug resistance. Izquierdo MA, et al. **Eur J Cancer** 1996 Jun;32A(6):979–84 (40 ref.)

Regulation and control of compartmentalized glycolysis in bloodstream form Trypanosoma brucei. Bakker BM, et al. **J Bioenerg Biomembr** 1995 Oct;27(5):513–25 (63 ref.)

The fates of proteins in cells. Bohley P. **Naturwissenschaften** 1995 Dec;82(12):544–50 (112 ref.)

beta–oxidation of fatty acids in mitochondria, peroxisomes, and bacteria: a century of continued progress. Kunau WH, et al. **Prog Lipid Res** 1995;34(4):267–342 (951 ref.)

Protein sorting by transport vesicles. Rothman JE, et al. **Science** 1996 Apr 12;272(5259):227–34 (86 ref.)

Coat proteins and vesicle budding. Schekman R, et al. **Science** 1996 Mar 15;271(5255):1526–33 (83 ref.)

Targeting of motor proteins. Vallee RB, et al. **Science** 1996 Mar 15;271(5255):1539–44 (108 ref.)

Plasmodesmata: plant channels for molecules on the move [see comments] Zambryski P. **Science** 1995 Dec 22; 270(5244):1943–4 (15 ref.) Comment in: Science 1995 Dec 22;270(5244):1980–3. Comment in: Science 1995 Dec 22;270(5244):1983–5.

PHYSIOLOGY

Role of endocrine cell microvesicles in intercellular chemical transduction. Moriyama Y, et al. **Biol Chem Hoppe Seyler** 1996 Mar;377(3):155–65 (108 ref.)

Regulation of organelle biogenesis. Nunnari J, et al. **Cell** 1996 Feb 9;84(3):389–94 (73 ref.)

Organelle inheritance. Warren G, et al. **Cell** 1996 Feb 9; 84(3):395–400 (75 ref.)

And still they are moving.... dynamic properties of caveolae. Kurzchalia TV, et al. **FEBS Lett** 1996 Jun 24;389(1):52–4 (41 ref.)

Integration of intermediate filaments into cellular organelles. Georgatos SD, et al. **Int Rev Cytol** 1996;164:91–138 (293 ref.)

Synaptic like microvesicles: do they participate in regulated exocytosis? Llona I. **Neurochem Int** 1995 Sep;27(3):219–26 (82 ref.)

ULTRASTRUCTURE

Biological atomic force microscopy: from microns to nanometers and beyond. Shao Z, et al. **Ann Rev Cell Dev Biol** 1995;11:241–65 (134 ref.)

Glycosomes—the organelles of glycogen metabolism. Rybicka KK. **Tissue Cell** 1996 Jun;28(3):253–65 (63 ref.)

Ribosome–lamella complexes in sinus histiocytes [letter] Eyden BP, et al. **Ultrastruct Pathol** 1995 Nov–Dec; 19(6):511–5 (65 ref.)

ORGANIC BRAIN SYNDROME, NONPSYCHOTIC see **ORGANIC MENTAL DISORDERS**

ORGANIC BRAIN SYNDROME, PSYCHOTIC see **ORGANIC MENTAL DISORDERS, PSYCHOTIC**

ORGANIC BRAIN SYNDROME, SUBSTANCE-INDUCED see **ORGANIC MENTAL DISORDERS, SUBSTANCE-INDUCED**

ORGANIC HALLUCINOSIS see **ORGANIC MENTAL DISORDERS, PSYCHOTIC**

ORGANIC MENTAL DISORDERS

COMPLICATIONS

Neurologic antecedents to patient falls. Benson C, et al. **J Neurosci Nurs** 1995 Dec;27(6):331-7 (25 ref.)

DIAGNOSIS

A review of the usefulness of the standard EEG in psychiatry. Hughes JR. **Clin Electroencephalogr** 1996 Jan; 27(1):35-9 (0 ref.)

Neuropsychology of multiple sclerosis. Rao SM. **Curr Opin Neurol** 1995 Jun;8(3):216-20 (44 ref.)

Neuroimaging in child and adolescent neuropsychiatric disorders. Peterson BS. **J Am Acad Child Adolesc Psychiatry** 1995 Dec; 34(12):1560-76 (115 ref.)

The post-concussional syndrome: physiogenesis, psychogenesis and malingering. An integrative model. Jacobson RR. **J Psychosom Res** 1995 Aug;39(6):675-93 (119 ref.)

[Confusional states in the elderly--an underdiagnosed syndrome with a poor prognosis] Pitkälä K. **Nord Med** 1996 Jun;111(6):184-8 (15 ref.) (Eng. Abstr.) **(Swe)**

DRUG THERAPY

[Biological factors and resistance to antidepressive agents] Puech AJ, et al. **Encephale** 1995 Mar;21 Spec No 2:17-21 (25 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Obsessive-compulsive disorder after closed head injury: review of literature and report of four cases. Kant R, et al. **Brain Inj** 1996 Jan;10(1):55-63 (37 ref.)

Depression associated with multiple sclerosis: an etiological conundrum. Feinstein A. **Can J Psychiatry** 1995 Dec; 40(10):573-6 (30 ref.)

Cryptococcal meningitis and confusional psychosis. A case report and literature review. Sa'adah MA, et al. **Trop Geogr Med** 1995;47(5):224-6 (20 ref.)

[Organic mental disorders and AIDS] Kasparas GG. **Acta Psiquiatr Psicol Am Lat** 1994 Dec;40(4):330-4 (14 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

Dynamic mutations and psychiatric genetics [editorial] O'Donovan MC, et al. **Psychol Med** 1996 Jan;26(1):1-6 (30 ref.)

PHYSIOPATHOLOGY

Hormones and behaviour. Fahlbusch R, et al. **Acta Neurochir (Wien)** 1995;132(4):169-77 (75 ref.)

Clinical applications of functional MRI in neuropsychiatry. Levin JM, et al. **J Neuropsychiatry Clin Neurosci** 1995 Fall; 7(4):511-22 (98 ref.)

[Neuroimaging and neurobiology of obsessive compulsive disorder: review of recent developments in research] Huguelet P, et al. **Encephale** 1996 Jan-Feb;22(1):41-5 (29 ref.) (Eng. Abstr.) **(Fre)**

PSYCHOLOGY

Violence: the scientific medical perspective. Pincus JH. **Isr J Med Sci** 1996 Jul;32(7):511-4 (24 ref.)

RADIONUCLIDE IMAGING

Brain SPECT imaging of neuropsychiatric disorders. Krausz Y, et al. **Eur J Radiol** 1996 Feb;21(3):183-7 (39 ref.)

REHABILITATION

Treatment methodology. Guiding of behaviour through redirection in brain injury rehabilitation. Yuen HK, et al. **Brain Inj** 1996 Mar;10(3):229-38 (15 ref.)

THERAPY

[Surgical management of psychiatrically ill patients. Particular aspects of perioperative monitoring] Diefenbacher A, et al. **Gynakologe** 1995 Dec;28(6):412-9 (33 ref.) **(Ger)**

ORGANIC MENTAL DISORDERS, DRUG-INDUCED see **ORGANIC MENTAL DISORDERS, SUBSTANCE-INDUCED**

ORGANIC MENTAL DISORDERS, PSYCHOTIC

DIAGNOSIS

The neuropsychiatric aspects of boxing. Mendez MF. **Int J Psychiatry Med** 1995;25(3):249-62 (74 ref.)

Case study: mania associated with multiple sclerosis. Heilä H, et al. **J Am Acad Child Adolesc Psychiatry** 1995 Dec; 34(12):1591-5 (36 ref.)

Neuroimaging in child and adolescent neuropsychiatric disorders. Peterson BS. **J Am Acad Child Adolesc Psychiatry** 1995 Dec; 34(12):1560-76 (115 ref.)

The neuropsychology of schizophrenia: relations with clinical and neurobiological dimensions. Elliott R, et al. **Psychol Med** 1995 May;25(3):581-94 (85 ref.)

[Psychoses in multiple sclerosis--a reevaluation] Schifferdecker M, et al. **Fortschr Neurol Psychiatr** 1995 Aug;63(8):310-9 (85 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Perinatal risk factors and schizophrenia: selective review and methodological concerns. McNeil TF. **Epidemiol Rev** 1995; 17(1):107-12 (46 ref.)

PHYSIOPATHOLOGY

The psychobiology of first-episode schizophrenia. Waring EM. **Can J Psychiatry** 1995 Sep;40(7 Suppl 2):S33-7 (51 ref.)

[The dopamine transporter: characterization and physiopathologic implications] Thibaut F, et al. **Encephale** 1995 Nov-Dec;21(6):445-51 (35 ref.) (Eng. Abstr.) **(Fre)**

[Neurobiology of schizophrenia] Henn FA. **Schweiz Arch Neurol Psychiatr** 1995;146(5):224-9 (25 ref.) (Eng. Abstr.) **(Ger)**

PSYCHOLOGY

The neurosociology of schizophrenia: vulnerability and functional disability. Carter M, et al. **Psychiatry** 1995 Aug; 58(3):209-24 (55 ref.)

REHABILITATION

[Neuropsychological analysis of schizophrenia-induced attention deficits--attempt at an overview] Gebauer W, et al. **Rehabilitation (Stuttg)** 1995 Aug;34(3):128-38 (85 ref.) (Eng. Abstr.) **(Ger)**

ORGANIC MENTAL DISORDERS, SUBSTANCE-INDUCED

DIAGNOSIS

A review of the usefulness of the standard EEG in psychiatry. Hughes JR. **Clin Electroencephalogr** 1996 Jan; 27(1):35-9 (0 ref.)

ETIOLOGY

[Psychiatrically relevant side effects of non-psychopharmacological pharmacotherapy] Kasper S, et al. **Nervenarzt** 1995 Sep;66(9):649-61 (95 ref.) (Eng. Abstr.) **(Ger)**

ORGANIZATION AND ADMINISTRATION, HOSPITAL see **HOSPITAL ADMINISTRATION**

ORGANIZATIONAL CHANGE see **ORGANIZATIONAL INNOVATION**

ORGANIZATIONAL CULTURE

Organizational culture. Mark BA. **Annu Rev Nurs Res** 1996; 14:145-63 (32 ref.)

Work group culture, stress, and hostility. Correlations with organizational outcomes. Seago JA. **J Nurs Adm** 1996 Jun; 26(6):39-47 (56 ref.)

Rethinking organization stability as a determinant for innovation adoption and diffusion. Glassman AM. **NIDA Res Monogr** 1995;155:132-46 (40 ref.)

Socialization into the therapeutic community culture. Szalay L. **NIDA Res Monogr** 1994;144:54-79 (21 ref.)

Constructing the symbolic complainant: police subculture and the nonenforcement of protection orders for battered women. Rigakos GS. **Violence Vict** 1995 Fall;10(3):227-47 (50 ref.)

ORGANIZATIONAL DECISION MAKING see **DECISION MAKING, ORGANIZATIONAL**

ORGANIZATIONAL EFFICIENCY see **EFFICIENCY, ORGANIZATIONAL**

ORGANIZATIONAL INNOVATION

Implementing TQM in the health care sector. Motwani J, et al. **Health Care Manage Rev** 1996 Winter;21(1):73-82 (44 ref.)

Through the lenses of organizational sociology: the role of organizational theory and research in conceptualizing and examining our health care system. Flood AB, et al. **J Health Soc Behav** 1995;Spec No:154-69 (95 ref.)

Participatory ergonomics that builds on local solutions. Kogi K. **J Hum Ergol (Tokyo)** 1995 Jun;24(1):37-45 (17 ref.)

Defence Costs Study 15 [editorial] Macmillan AH. **J R Army Med Corps** 1996 Feb;142(1):3-8 (10 ref.)

Synthesis of behavioral science learnings about technology transfer. Backer TE, et al. **NIDA Res Monogr** 1995; 155:262-79 (2 ref.)

Reducing impediments to technology transfer in drug abuse programming. Brown BS. **NIDA Res Monogr** 1995; 155:169-85 (38 ref.)

Organizational change as human process, not technique. Diamond MA. **NIDA Res Monogr** 1995;155:119-31 (10 ref.)

Rethinking organization stability as a determinant for innovation adoption and diffusion. Glassman AM. **NIDA Res Monogr** 1995;155:132-46 (40 ref.)

ORGANIZATIONAL MODELS see **MODELS, ORGANIZATIONAL**

ORGANIZATIONAL OBJECTIVES

NCA-IRM desk record. Kniffen D. **Vet Clin North Am Food Anim Pract** 1995 Jul;11(2):215-78 (0 ref.)

ORGANIZATIONAL POLICY

Quality improvement and substance abuse: rethinking impaired provider policies. Corsino BV, et al. **Am J Med Qual** 1996 Summer;11(2):94-9 (21 ref.)

Policy issues for improving institutional response to domestic violence. Langford DR. **J Nurs Adm** 1996 Jan;26(1):39-45 (29 ref.)

The evolution of American Medical Association policies concerning health care of veterans. Kendall JW. **Mil Med** 1995 Oct;160(10):518-21 (10 ref.)

Ethical and legal barriers to futility policies. King NM. **N C Med J** 1995 Sep;56(9):444-8 (35 ref.)

ORGANIZATIONS

see related
SOCIETIES

Prevention of birth defects: a task for a world alliance. Wertelecki W, et al. **Acta Paediatr Sin** 1996 May-Jun; 37(3):168-72 (57 ref.)

ORGANIZATIONS, NONPROFIT

LEGISLATION & JURISPRUDENCE

Accreditation of those who arrange adoptions under the Hague Convention on intercountry adoption as a means of protecting, through private international law, the rights of children. Pierce WL. **J Contemp Health Law Policy** 1996 Spring;12(2):535-61 (31 ref.)

ORGANOCHLORINE INSECTICIDES see **INSECTICIDES, ORGANOCHLORINE**

ORGANOGENESIS see **FETAL DEVELOPMENT**

ORGANOMETALLIC COMPOUNDS

The suitability of a monofunctional reagent of an undecagold cluster for phasing data collected from the large ribosomal subunits from Bacillus stearothermophilus. Bartels H, et al. **Biopolymers** 1995;37(6):411-9 (19 ref.)

CHEMISTRY

Interactions of metallopharmaceuticals with DNA. Clarke MJ, et al. **Met Ions Biol Syst** 1996;32:727-80 (235 ref.)

DIAGNOSTIC USE

Gadolinium-enhanced breast MRI. Kelcz F, et al. **Crit Rev Diagn Imaging** 1995;36(4):287-338 (41 ref.)

Liver. III: Gadolinium-based hepatobiliary contrast agents (Gd-EOB-DTPA and Gd-BOPTA/Dimeg). Giovagnoni A, et al. **Magn Reson Imaging Clin N Am** 1996 Feb; 4(1):61-72 (34 ref.)

[Gadolinium-DTPA (Magnevist) as contrast medium for galactography] Kaltenborn H, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1995 Nov;163(5):457-9 (14 ref.) **(Ger)**

[The magnetic resonance assessment of craniofacial fibrous dysplasia. The completion of the study with gadolinium administration and magnetic resonance angiography] Di Girolamo M, et al. **Radiol Med (Torino)** 1996 Mar; 91(3):313-6 (10 ref.) **(Ita)**

[Image diagnosis of heart diseases using new radioisotope compounds] Nishimural T. **Nippon Naika Gakkai Zasshi** 1995 Sep 10;84(9):1564-8 (8 ref.) **(Jpn)**

PHARMACOLOGY

Light scattering of human skin: a comparison between zinc (II)-phthalocyanine and photofrin II. Ochsner M. **J Photochem Photobiol B** 1996 Jan;32(1-2):3-9 (23 ref.)

THERAPEUTIC USE

[Influence of colloidal bismuth subcitrate, metronidazole, and amoxycillin on Helicobacter pylori and gastroduodenal ulcer healing] Quintero M, et al. **G E N** 1995 Apr-Jun; 49(2):116-22 (21 ref.) (Eng. Abstr.) **(Spa)**

ORGANOPHOSPHATE INSECTICIDES see **INSECTICIDES, ORGANOPHOSPHATE**

ORGANOPHOSPHORUS COMPOUNDS

see related
CHOLINESTERASE INHIBITORS
INSECTICIDES, ORGANOPHOSPHATE

ADVERSE EFFECTS

Cholinesterase inhibition: complexities in interpretation. Lotti M. **Clin Chem** 1995 Dec;41(12 Pt 2):1814–8 (22 ref.)
[A review of studies of the delayed neurotoxicity induced by organophosphorus esters] Katoh K. **Sangyo Eiseigaku Zasshi** 1995 Sep;37(5):309–19 (121 ref.) (Eng. Abstr.) **(Jpn)**

CHEMISTRY

Water-soluble phosphazene polymers for parenteral and mucosal vaccine delivery. Payne LG, et al. **Pharm Biotechnol** 1995;6:473–93 (15 ref.)

METABOLISM

Bialaphos. Thompson CJ, et al. **Biotechnology** 1995; 28:197–222 (68 ref.)

PHARMACOLOGY

A preclinical and clinical overview of the nucleotide-based antiviral agent cidofovir (HPMPC). Lalezari JP, et al. **Adv Exp Med Biol** 1996;394:105–15 (26 ref.)
Pharmacology and structure–activity relationships of the nonpeptide bradykinin receptor antagonist WIN 64338. Sawutz DG, et al. **Can J Physiol Pharmacol** 1995 Jul; 73(7):805–11 (32 ref.)

POISONING

A review of nonpesticide phosphate ester-induced neurotoxicity in cattle. Coppock RW, et al. **Vet Hum Toxicol** 1995 Dec;37(6):576–9 (20 ref.)
[Neurotoxicity of nerve agents] Morita H. **No To Shinkei** 1995 Dec;47(12):1129–34 (20 ref.) **(Jpn)**

TOXICITY

Long term neurotoxic effects of organophosphate compounds. Jamal GA. **Adverse Drug React Toxicol Rev** 1995 Summer;14(2):85–99 (81 ref.)
Involvement of cytoskeletal proteins in the mechanisms of organophosphorus ester-induced delayed neurotoxicity. Abou-Donia MB. **Clin Exp Pharmacol Physiol** 1995 May; 22(5):358–9 (5 ref.)
Neuropathy target esterase (NTE) and organophosphorus-induced delayed polyneuropathy (OPIDP): recent advances. Johnson MK, et al. **Toxicol Lett** 1995 Dec;82–83:459–63 (24 ref.)

ORGANOPLATINUM COMPOUNDS

ADVERSE EFFECTS

Mutagenic and carcinogenic properties of platinum-based anticancer drugs. Sanderson BJ, et al. **Mutat Res** 1996 Aug 17;355(1–2):59–70 (59 ref.)

THERAPEUTIC USE

[Platinum-based antineoplastic agents: biomedical applications and therapeutic aspects] Dominici C, et al. **Ann Ist Super Sanita** 1995;31(2):289–94 (52 ref.) (Eng. Abstr.) **(Ita)**
[Nedaplatin] Ota K. **Gan To Kagaku Ryoho** 1996 Feb; 23(3):379–87 (13 ref.) (Eng. Abstr.) **(Jpn)**

ORGANOSELENIUM COMPOUNDS

METABOLISM

Ebselen. Sies H. **Methods Enzymol** 1995;252:341–2 (18 ref.)

PHARMACOLOGY

Molecular actions of ebselen—an antiinflammatory antioxidant. Schewe T. **Gen Pharmacol** 1995 Oct; 26(6):1153–69 (91 ref.)

THERAPEUTIC USE

Chemoprevention of cancer by organoselenium compounds. el-Bayoumy K, et al. **J Cell Biochem Suppl** 1995;22:92–100 (34 ref.)

ORGANOTECHNETIUM COMPOUNDS

DIAGNOSTIC USE

Imaging infection and inflammation in veterinary practice [editorial; comment] Peters AM. **Equine Vet J** 1995 Jul; 27(4):242–4 (20 ref.) Comment on: Equine Vet J 1995 Jul;27(4):313–5.
A review of renal scarring in children. MacKenzie JR. **Nucl Med Commun** 1996 Mar;17(3):176–90 (44 ref.)
Detection of myocardial viability with 99mTc-labelled myocardial perfusion agents. Bisi G, et al. **Q J Nucl Med** 1996 Mar;40(1):68–75 (60 ref.)
[Frontal type dementia and amyotrophic lateral sclerosis. 3 cases with (HmPAO Tc99m) single-photon emission tomography study] Vercelletto M, et al. **Rev Neurol (Paris)** 1995 Nov;151(11):640–7 (43 ref.) (Eng. Abstr.) **(Fre)**

ORGANOTHIOPHOSPHATE INSECTICIDES see **INSECTICIDES, ORGANOTHIOPHOSPHATE**

ORGANOTHIOPHOSPHORUS COMPOUNDS

see related
CHOLINESTERASE INHIBITORS
INSECTICIDES, ORGANOTHIOPHOSPHATE

[General characteristic and toxicity of VX] Inoue N, et al. **Fukuoka Igaku Zasshi** 1995 Nov;86(11):405–10 (10 ref.) **(Jpn)**

PHARMACOLOGY

[Radiation-protective action of microbial substances] Andrushchenko VN, et al. **Radiats Biol Radioecol** 1996 Mar–Apr;36(2):195–208 (95 ref.) (Eng. Abstr.) **(Rus)**

ORGASM

DRUG EFFECTS

Antidepressant-induced orgasm disorder. Segraves RT. **J Sex Marital Ther** 1995 Fall;21(3):192–201 (81 ref.)

PHYSIOLOGY

[Pro: a critical contribution to better understanding of possible functional disorders of the genital, bladder and pelvic floor system] Schüssler B. **Arch Gynecol Obstet** 1995; 257(1–4):359–62 (14 ref.) **(Ger)**

ORI REGION see **REPLICATION ORIGIN**

ORIENTAL MEDICINE, TRADITIONAL see **MEDICINE, ORIENTAL TRADITIONAL**

ORIENTAL SORE see **LEISHMANIASIS, CUTANEOUS**

ORIENTATION

Origins and early development of perception, action, and representation. Bertenthal BI. **Annu Rev Psychol** 1996; 47:431–59 (150 ref.)
Orientation in visual cortex: a simple mechanism emerges. Das A. **Neuron** 1996 Mar;16(3):477–80 (23 ref.)
Goodness of visual regularities: a nontransformational approach. van der Helm PA, et al. **Psychol Rev** 1996 Jul; 103(3):429–56 (95 ref.)

PHYSIOLOGY

New diagnostic tests for the function of utricles, saccules and somatic graviceptors. Mittelstaedt H. **Acta Otolaryngol Suppl (Stockh)** 1995;520 Pt 1:188–93 (5 ref.)
Covert orienting to non-informative cues: reaction time studies. Tassinari G, et al. **Behav Brain Res** 1995 Nov; 71(1–2):101–12 (58 ref.)
Computations on metric maps in mammals: getting oriented and choosing a multi-destination route. Gallistel CR, et al. **J Exp Biol** 1996 Jan;199 (Pt 1):211–7 (47 ref.)

ORIENTATION PROGRAMS, EMPLOYEE see **INSERVICE TRAINING**

ORIGIN OF LIFE see **BIOGENESIS**

ORIGIN OF REPLICATION see **REPLICATION ORIGIN**

ORMOND'S DISEASE see **RETROPERITONEAL FIBROSIS**

ORNITHINE

METABOLISM

Transcriptional regulation of genes for ornithine cycle enzymes. Takiguchi M, et al. **Biochem J** 1995 Dec 15;312 (Pt 3):649–59 (272 ref.)
[Hyperornithinemia and gyrate atrophy: ornithine aminotransferase gene error causing a Finnish disease] Sipilä I, et al. **Duodecim** 1994;110(7):681–6 (18 ref.) **(Fin)**

ORNITHINE AMINOTRANSFERASE

DEFICIENCY

[Hyperornithinemia and gyrate atrophy: ornithine aminotransferase gene error causing a Finnish disease] Sipilä I, et al. **Duodecim** 1994;110(7):681–6 (18 ref.) **(Fin)**

ORNITHINE CARBAMOYLTRANSFERASE

BLOOD

[Ornithine carbamoyl transferase (OCT)] Maekawa M. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:350–3 (11 ref.) **(Jpn)**

DEFICIENCY

Gene therapy for ornithine transcarbamylase deficiency. Kiwaki K, et al. **Acta Paediatr Jpn** 1996 Apr;38(2):189–92 (31 ref.)
[Gene therapy for ornithine transcarbamylase deficiency] Matsuda I, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec; 40(17):2759–64 (19 ref.) **(Jpn)**
[Gene therapy for ornithine transcarbamylase (OTC) deficient mice] Shimada T, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2674–8 (24 ref.) **(Jpn)**

GENETICS

[Gene therapy for ornithine transcarbamylase deficiency] Matsuda I, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec; 40(17):2759–64 (19 ref.) **(Jpn)**
[Promoter and enhancer of the ornithine transcarbamylase gene] Nishiyori A, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2606–12 (26 ref.) **(Jpn)**
[Gene therapy for ornithine transcarbamylase (OTC) deficient mice] Shimada T, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2674–8 (24 ref.) **(Jpn)**

ORNITHINE CARBOXY-LYASE see **ORNITHINE DECARBOXYLASE**

ORNITHINE DECARBOXYLASE

ANTAGONISTS & INHIBITORS

Ornithine decarboxylase as a target for chemoprevention. Pegg AE, et al. **J Cell Biochem Suppl** 1995;22:132–8 (41 ref.)
Ornithine decarboxylase antizyme: a novel type of regulatory protein. Hayashi S, et al. **Trends Biochem Sci** 1996 Jan; 21(1):27–30 (47 ref.)

URINE

[Polyamine and ornithine decarboxylase] Kubota S. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:501–5 (20 ref.) **(Jpn)**

ORNITHINE TRANSAMINASE see **ORNITHINE AMINOTRANSFERASE**

ORNITHOSIS

Chlamydia psittaci infections: a review with emphasis on avian chlamydiosis. Vanrompay D, et al. **Vet Microbiol** 1995 Jul;45(2–3):93–119 (237 ref.)

COMPLICATIONS

Neurological complications in psittacosis: a case report and literature review. Hughes P, et al. **Respir Med** 1995 Oct; 89(9):637–8 (15 ref.)

DIAGNOSIS

[A case of fulminant psittacosis necessitating mechanical ventilation diagnosed by chlamydial isolation form BALF] Taniguchi H, et al. **Kansenshogaku Zasshi** 1995 Dec; 69(12):1396–401 (9 ref.) (Eng. Abstr.) **(Jpn)**

OROFACIODIGITAL SYNDROMES

Orofaciodigital syndrome type I in a patient with severe CNS defects. Leão MJ, et al. **Pediatr Neurol** 1995 Oct; 13(3):247–51 (34 ref.)

OROPHARYNGEAL NEOPLASMS

DIAGNOSIS

Early diagnosis of asymptomatic oral and oropharyngeal squamous cancers. Mashberg A, et al. **CA Cancer J Clin** 1995 Nov–Dec;45(6):328–51 (58 ref.)
Imaging of the oropharynx and oral cavity. Part II: Pathology. Lenz M, et al. **Eur Radiol** 1996;6(4):536–49 (28 ref.)
Oral cavity, oropharynx, and salivary glands. Sigal R. **Neuroimaging Clin N Am** 1996 May;6(2):379–400 (44 ref.)
Oral cavity: anatomy and pathology. Laine FJ, et al. **Semin Ultrasound CT MR** 1995 Dec;16(6):527–45 (40 ref.)
[Clinical differential diagnosis of the mouth and oropharynx] Grevers G. **Radiologe** 1996 Mar;36(3):181–7 (26 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

[Concomitant radiochemotherapy with cisplatin (CDDP), 5-fluorouracil (5-FU) and mitomycin C (MMC) in locally advanced carcinoma of the oropharynx. Results of a phase

II trial] Berger C, et al. **Bull Cancer (Paris)** 1995 Dec; 82(12):1044–51 (38 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

Preparing for the mouth cancer epidemic. Langdon J. **Practitioner** 1996 Jan;240(1558):58–60 (8 ref.)

RADIOGRAPHY

[Computerized tomography of malignancies of the oral cavity, the oropharynx and hypopharynx and invasiveness] Helmberger R, et al. **Radiologe** 1996 Mar;36(3):193–8 (19 ref.) (Eng. Abstr.) **(Ger)**

RADIOTHERAPY

[Concomitant radiochemotherapy with cisplatin (CDDP), 5-fluorouracil (5-FU) and mitomycin C (MMC) in locally advanced carcinoma of the oropharynx. Results of a phase II trial] Berger C, et al. **Bull Cancer (Paris)** 1995 Dec; 82(12):1044–51 (38 ref.) (Eng. Abstr.) **(Fre)**

[ORL brachytherapy. Salvage brachytherapy in ORL cancers (oral cavity, oropharynx, nasopharynx)] Ardiet JM, et al. **Bull Cancer Radiother** 1995;82(2):199–202 (27 ref.) **(Fre)**

[ORL brachytherapy. Brachytherapy of squamous cell carcinoma of the oropharynx] Hoffstetter S. **Bull Cancer Radiother** 1995;82(2):191–8 (53 ref.) **(Fre)**

[ORL brachytherapy. Focus on brachytherapy for squamous cell carcinoma of the oral cavity and pharynx] Mazeron JJ. **Bull Cancer Radiother** 1995;82(2):179–85 (68 ref.) **(Fre)**

THERAPY

[Retrospective study of 136 cases of epidermoid carcinoma of the base of the tongue treated at the Alexis Vautrin Centre 1978–1992] Hoffstetter S, et al. **Bull Cancer Radiother** 1996;83(2):90–6 (11 ref.) (Eng. Abstr.) **(Fre)**

OROPHARYNX

ABNORMALITIES

Giant hamartoma of the oropharynx. Santana-Hernandez DJ, et al. **J Laryngol Otol** 1996 May;110(5):480–2 (20 ref.)

ANATOMY & HISTOLOGY

Imaging of the oropharynx and oral cavity. Part I: Normal anatomy. Hermans R, et al. **Eur Radiol** 1996;6(3):362–8 (9 ref.)

PHYSIOPATHOLOGY

Oropharyngeal dysphagia due to iatrogenic neurological dysfunction. Buchholz DW. **Dysphagia** 1995 Fall; 10(4):248–54 (51 ref.)

Cricopharyngeal myotomy may be effective treatment for selected patients with neurogenic oropharyngeal dysphagia. Buchholz DW. **Dysphagia** 1995 Fall;10(4):255–8 (20 ref.)

OROSOMUCOID

ANALYSIS

[alpha 1-Acid glycoprotein] Watanabe F. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:203–6 (13 ref.) **(Jpn)**

CHEMISTRY

Glycoforms of serum alpha 1-acid glycoprotein as markers of inflammation and cancer. Mackiewicz A, et al. **Glycoconj J** 1995 Jun;12(3):241–7 (43 ref.)

PHYSIOLOGY

alpha 1-Acid glycoprotein. A natural occurring anti-inflammatory molecule? van Dijk W. **Adv Exp Med Biol** 1995;376:223–9 (25 ref.)

Alpha 1-acid glycoprotein (orosomucoid): pathophysiological changes in glycosylation in relation to its function. van Dijk W, et al. **Glycoconj J** 1995 Jun; 12(3):227–33 (90 ref.)

OROTIC ACID

METABOLISM

Uracil metabolism--UMP synthesis from orotic acid or uridine and conversion of uracil to beta-alanine: enzymes and cDNAs. Traut TW, et al. **Prog Nucleic Acid Res Mol Biol** 1996;53:1–78 (273 ref.)

OROYA FEVER see **BARTONELLA INFECTIONS**

ORTHO-AMINOBENZOIC ACIDS see **ANTHRANILIC ACIDS**

ORTHODONTIC APPLIANCE DESIGN

The effects of loops on the torsional stiffnesses of rectangular wires: an in vitro study. Odegaard J, et al. **Am J Orthod Dentofacial Orthop** 1996 May;109(5):496–505 (11 ref.)

A review of orthodontic face-bow injuries and safety equipment. Samuels RH. **Am J Orthod Dentofacial Orthop** 1996 Sep;110(3):269–72 (13 ref.)

ORTHODONTIC APPLIANCES

see related
DENTAL BONDING

Oral appliances for the treatment of snoring and obstructive sleep apnea: a review. Schmidt-Nowara W, et al. **Sleep** 1995 Jul;18(6):501–10 (61 ref.)

[Indications, technique and results of bimaxillary surgery] Luhr HG, et al. **Fortschr Kiefer Gesichtschir** 1995;40:20–32 (125 ref.) **(Ger)**

[The use of permanent magnets in the orthodontic clinic] Persin LS, et al. **Stomatologiia (Mosk)** 1995;74(5):76–8 (26 ref.) (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

Periodontal and microbiological changes associated with the placement of orthodontic appliances. A review. Atack NE, et al. **J Periodontol** 1996 Feb;67(2):78–85 (61 ref.)

ORTHODONTIC BRACKETS

Effect of varying etching times on the bond strength of ceramic brackets. Olsen ME, et al. **Am J Orthod Dentofacial Orthop** 1996 Apr;109(4):403–9 (49 ref.)

ORTHODONTIC RETAINERS

Orthodontic retention. Mamandras AH, et al. **J Can Dent Assoc** 1996 May;62(5):412–4, 417 (39 ref.)

ORTHODONTIC WIRES

The effects of loops on the torsional stiffnesses of rectangular wires: an in vitro study. Odegaard J, et al. **Am J Orthod Dentofacial Orthop** 1996 May;109(5):496–505 (11 ref.)

A clinical report for distalizing maxillary molars by using super-elastic wires. Basdra EK, et al. **Fortschr Kieferorthop** 1996 Apr;57(2):118–23 (6 ref.) **(Eng, Ger)**

STANDARDS

[Scanning electron microscopic study of the surface finish of the round sections of preformed arches of NiTi (orthodontic wires made of nickel/titanium] Nardi E, et al. **Minerva Stomatol** 1995 Oct;44(10):449–53 (23 ref.) (Eng. Abstr.) **(Ita)**

ORTHODONTICS

Effects of information-giving and communication during orthodontic consultation and treatment. Part 3: Optimized orthodontist-patient communication. Witt E, et al. **Fortschr Kieferorthop** 1996 Jun;57(3):154–67 (55 ref.) **(Eng, Ger)**

INSTRUMENTATION

[Jaw position, head position, body posture: development of an integrated system of examination, Part I] Takigawa T, et al. **Kokubyo Gakkai Zasshi** 1995 Sep;62(3):441–50 (23 ref.) (Eng. Abstr.) **(Jpn)**

METHODS

[Orthodontic pre- and postoperative treatment in bimaxillary osteotomy] Scheuer H, et al. **Fortschr Kiefer Gesichtschir** 1995;40:11–20 (19 ref.) **(Ger)**

[The use of permanent magnets in the orthodontic clinic] Persin LS, et al. **Stomatologiia (Mosk)** 1995;74(5):76–8 (26 ref.) (Eng. Abstr.) **(Rus)**

ORTHODONTICS, CORRECTIVE

Adult orthodontics--a review. Nattrass C, et al. **Br J Orthod** 1995 Nov;22(4):331–7 (40 ref.)

INSTRUMENTATION

Orthodontic retention. Mamandras AH, et al. **J Can Dent Assoc** 1996 May;62(5):412–4, 417 (39 ref.)

[Scanning electron microscopic study of the surface finish of the round sections of preformed arches of NiTi (orthodontic wires made of nickel/titanium] Nardi E, et al. **Minerva Stomatol** 1995 Oct;44(10):449–53 (23 ref.) (Eng. Abstr.) **(Ita)**

METHODS

One-phase versus two-phase treatment [see comments] Gianelly AA. **Am J Orthod Dentofacial Orthop** 1995 Nov; 108(5):556–9 (32 ref.) Comment in: Am J Orthod Dentofacial Orthop 1996 Feb;109(2):17A. Comment in: Am J Orthod Dentofacial Orthop 1996 Jul;110(1):14A–15A.

[The decision to extract in orthodontics] Limme M. **Rev Belge Med Dent** 1995;50(2):40–52 (10 ref.) (Eng. Abstr.) **(Fre)**

ORTHODONTICS, INTERCEPTIVE

METHODS

[The GTR technic within the framework of combined periodontal-orthodontic treatments. A case report] Stelzel M, et al. **Fortschr Kieferorthop** 1995 Nov;56(6):347–52 (28 ref.) (Eng. Abstr.) **(Ger)**

ORTHOMOLECULAR THERAPY

Efficacy of vitamin B6 and magnesium in the treatment of autism: a methodology review and summary of outcomes. Pfeiffer SI, et al. **J Autism Dev Disord** 1995 Oct; 25(5):481–93 (36 ref.)

ORTHOMYXOVIRIDAE

CLASSIFICATION

The next pandemic influenza virus? Shortridge KF. **Lancet** 1995 Nov 4;346(8984):1210–2 (10 ref.)

ENZYMOLOGY

Influenza viruses, cell enzymes, and pathogenicity. Rott R, et al. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 2):S16–9 (45 ref.)

IMMUNOLOGY

Interferons, Mx genes, and resistance to influenza virus. Horisberger MA. **Am J Respir Crit Care Med** 1995 Oct; 152(4 Pt 2):S67–71 (56 ref.)

PATHOGENICITY

Influenza viruses, cell enzymes, and pathogenicity. Rott R, et al. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 2):S16–9 (45 ref.)

Influenza viruses and cell membranes. Skehel JJ, et al. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 2):S13–5 (20 ref.)

[Dynamics of influenza virus pathogenicity] Kawaoka Y. **Uirusu** 1995 Jun;45(1):80–4 (19 ref.) **(Jpn)**

PHYSIOLOGY

Influenza viruses and cell membranes. Skehel JJ, et al. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 2):S13–5 (20 ref.)

ORTHOMYXOVIRIDAE INFECTIONS

THERAPY

[Essential properties of the group O virus with direct medical importance] Siennicka J. **Postepy Hig Med Dosw** 1995; 49(5):599–608 (78 ref.) (Eng. Abstr.) **(Pol)**

ORTHOMYXOVIRUS INFECTIONS see **ORTHOMYXOVIRIDAE INFECTIONS**

ORTHOMYXOVIRUS TYPE A, AVIAN

Interspecies transmission of influenza viruses. Webster RG, et al. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 2):S25–30 (27 ref.)

ORTHOMYXOVIRUS TYPE A, HUMAN

GENETICS

A review of attenuation of influenza viruses by genetic manipulation. Belshe RB. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 2):S72–5 (26 ref.)

IMMUNOLOGY

Stimulation of human anti-viral CD8+ cytolytic T lymphocytes by dendritic cells. Bhardwaj N, et al. **Adv Exp Med Biol** 1995;378:375–9 (35 ref.)

Influenza vaccines. Brede HD. **Int Arch Allergy Immunol** 1995 Dec;108(4):318–20 (2 ref.)

ORTHOMYXOVIRUSES TYPE A

CLASSIFICATION

[The nature of pandemic strains of the influenza virus] Golubev DB. **Tr Inst Im Pastera** 1992;67:65–73 (52 ref.) **(Rus)**

GENETICS

Influenza virus vectors. García-Sastre A, et al. **Biologicals** 1995 Jun;23(2):171–8 (40 ref.)

ORTHOMYXOVIRUSES TYPE B

CLASSIFICATION

[The nature of pandemic strains of the influenza virus]

ORTHOMYXOVIRUSES TYPE B

Golubev DB. **Tr Inst Im Pastera** 1992;67:65–73 (52 ref.) **(Rus)**

GENETICS

A review of attenuation of influenza viruses by genetic manipulation. Belshe RB. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 2):S72–5 (26 ref.)

IMMUNOLOGY

Influenza vaccines. Brede HD. **Int Arch Allergy Immunol** 1995 Dec;108(4):318–20 (2 ref.)

ORTHOPANTOMOGRAPHY see **RADIOGRAPHY, PANORAMIC**

ORTHOPEDIC EQUIPMENT

ADVERSE EFFECTS

[Cutaneous reactions to external orthopedic materials] Vigan M, et al. **Ann Dermatol Venereol** 1995;122(8):548–50 (23 ref.) **(Fre)**

ORTHOPEDIC FIXATION DEVICES

Arthroscopic rotator cuff repairs using suture anchors. Farrall LA. **AORN J** 1995 Nov;62(5):739–46, 748, 750; quiz 754, 756–8 (18 ref.)

Appropriate methods for bone fixation [editorial] Reinherz RP. **J Foot Ankle Surg** 1996 Mar–Apr;35(2):93 (29 ref.)

STANDARDS

Orientruded polylactide based body-absorbable osteosynthesis devices: a short review. Tunc DC. **J Biomater Sci Polym Ed** 1995;7(4):375–80 (9 ref.)

ORTHOPEDIC MANIPULATION see **MANIPULATION, ORTHOPEDIC**

ORTHOPEDIC SURGERY see **ORTHOPEDICS**

ORTHOPEDICS

Blood transfusion in orthopaedic operations. Lemos MJ, et al. **J Bone Joint Surg Am** 1996 Aug;78(8):1260–70 (128 ref.)

Hazards to the orthopaedic trauma surgeon: occupational exposure to HIV and viral hepatitis (a review article). Chou L, et al. **J Orthop Trauma** 1996;10(4):289–96 (46 ref.)

The potential use of human recombinant erythropoietin in orthopedic surgery. Bose WJ. **Orthopedics** 1996 Apr; 19(4):325–8 (24 ref.)

[Progresses in orthopedics in China, 1995] Chen Z, et al. **Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):734–5 (0 ref.) **(Chi)**

[Role of conservative orthopedic surgery in the treatment of the diabetic foot] Ha Van G, et al. **Diabetes Metab** 1996 Feb;22(1):80–6 (31 ref.) **(Fre)**

[New paradigm of medical science] Hirotani H. **Nippon Seikeigeka Gakkai Zasshi** 1996 Apr;70(4):169–78 (50 ref.) **(Jpn)**

[Interview of the orthopaedics] Takayama A. **Nippon Seikeigeka Gakkai Zasshi** 1996 Apr;70(4):159–68 (25 ref.) **(Jpn)**

LEGISLATION & JURISPRUDENCE

A surgeon's perspective of medical device regulation. Brantigan JW. **J Spinal Disord** 1995 Oct;8(5):396–412 (74 ref.)

METHODS

Surgical management of primary bone sarcomas. Yasko AW, et al. **Hematol Oncol Clin North Am** 1995 Aug;9(4):719–31 (31 ref.)

STANDARDS

Outcomes measurement in orthopaedic trauma surgery. Swiontkowski MF. **Injury** 1995 Dec;26(10):653–7 (33 ref.)

TRENDS

Changes in practice and knowledge in orthopaedic surgery. Nade S. **Aust N Z J Surg** 1995 Nov;65(11):822–30 (38 ref.)

Sterilization, toxicity, biocompatibility and clinical applications of polylactic acid/polyglycolic acid copolymers. Athanasiou KA, et al. **Biomaterials** 1996 Jan; 17(2):93–102 (100 ref.)

What's new in orthopedic surgery. Rosenthal RE. **J Am Coll Surg** 1996 Feb;182(2):133–8 (28 ref.)

VETERINARY

External skeletal fixation in ruminants. Anderson DE, et al. **Vet Clin North Am Food Anim Pract** 1996 Mar;12(1):117–52 (139 ref.)

Decision making in ruminant orthopedics. Fessler JF, et al. **Vet Clin North Am Food Anim Pract** 1996 Mar;12(1):1–18 (58 ref.)

Fractures of the humerus. Rakestraw PC. **Vet Clin North Am Food Anim Pract** 1996 Mar;12(1):153–68 (31 ref.)

Fracture biology, biomechanics, and internal fixation. Trostle SS, et al. **Vet Clin North Am Food Anim Pract** 1996 Mar; 12(1):19–46 (52 ref.)

Client counseling in orthopedic emergencies. Brackenridge SS, et al. **Vet Clin North Am Small Anim Pract** 1995 Sep; 25(5):1047–58 (7 ref.)

Fracture management decisions. Roush JK. **Vet Clin North Am Small Anim Pract** 1995 Sep; 25(5):1059–72 (19 ref.)

ORTHOPOXVIRUS

GENETICS

[Orthopoxvirus genome] Shchelkunlov SN. **Mol Biol (Mosk)** 1996 Jan–Feb;30(1):5–32 (263 ref.) **(Rus)**

ORTHOPSYCHIATRY

see related
MENTAL HEALTH

ORTHOVANADATE see **VANADATES**

ORYCTES VIRUSES see **BACULOVIRIDAE**

ORYZA see **RICE**

OS TRIGONUM see **TALUS**

OSCILLATORS, ENDOGENOUS see **BIOLOGICAL CLOCKS**

OSGOOD-SCHLATTER DISEASE see **OSTEOCHONDRITIS**

OSLER-RENDU DISEASE see **TELANGIECTASIA, HEREDITARY HEMORRHAGIC**

OSLER-VAQUEZ DISEASE see **POLYCYTHEMIA VERA**

OSMOLALITY see **OSMOLAR CONCENTRATION**

OSMOLAR CONCENTRATION

[Osmolality] Shimizu K, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:776–81 (13 ref.) **(Jpn)**

OSMOLARITY see **OSMOLAR CONCENTRATION**

OSMOREGULATION see **WATER-ELECTROLYTE BALANCE**

OSMOSIS

Micro-osmosis in gels, cells and enzymes. Wiggins PM. **Cell Biochem Funct** 1995 Sep;13(3):165–72 (54 ref.)

PHYSIOLOGY

Role of hepatic receptors in controlling body fluid homeostasis. Morita H, et al. **Jpn J Physiol** 1995; 45(3):355–68 (47 ref.)

OSMOTIC DIURETICS see **DIURETICS, OSMOTIC**

OSSEOINTEGRATED DENTAL IMPLANTATION see **DENTAL IMPLANTATION, ENDOSSEOUS**

OSSEOINTEGRATION

see related
ARTHROPLASTY
BONE SUBSTITUTES
DENTAL IMPLANTATION, ENDOSSEOUS
HIP PROSTHESIS

Osteoinductive agents. Basic science and clinical applications. Kale AA, et al. **Am J Orthop** 1995 Oct;24(10):752–61 (92 ref.)

Biologic incorporation of allograft anterior cruciate ligament replacements. Jackson DW, et al. **Clin Orthop** 1996 Mar; (324):126–33 (26 ref.)

Osseointegrated implants: a review of the literature. Shearer BH. **Int Dent J** 1995 Aug;45(4):261–6 (25 ref.)

The reverse-torque test: a clinical report. Sullivan DY, et al. **Int J Oral Maxillofac Implants** 1996 Mar–Apr; 11(2):179–85 (15 ref.)

Consolidation of massive bone allografts in limb-preserving operations for bone tumours. San Julian Aranguren M, et al. **Int Orthop** 1995;19(6):377–82 (53 ref.)

[Endoprosthesis and bone reaction] Kohn D, et al. **Orthopade** 1995 Sep;24(5):409–15 (52 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

In vitro modeling of the bone/implant interface. Davies JE. **Anat Rec** 1996 Jun;245(2):426–45 (94 ref.)

Soft and hard tissue response to endosseous dental implants. Listgarten MA. **Anat Rec** 1996 Jun;245(2):410–25 (154 ref.)

OSSICULAR REPLACEMENT PROSTHESIS

The lessons of middle-ear function in non-mammals: improving columellar prostheses [editorial] Manley GA. **J R Soc Med** 1995 Jul;88(7):367–8 (8 ref.)

OSSIFICATION, HETEROTOPIC

see related
SYNOSTOSIS

[Traumatic myositis ossificans. Posttraumatic non-neoplastic heterotopic ossification] Jacobsen S. **Ugeskr Laeger** 1995 Sep 25;157(39):5385–8 (35 ref.) (Eng. Abstr.) **(Dan)**

[Heterotopic bone formation] Kiyomatsu K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):462–3 (9 ref.) **(Jpn)**

COMPLICATIONS

[Fracture of an ossified Achilles tendon] Krause K, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Feb;164(2):171–2 (9 ref.) **(Ger)**

PATHOLOGY

Osseous choristoma of the tongue. Wei Cheong Ngeow, et al. **J Nihon Univ Sch Dent** 1996 Mar;38(1):49–51 (3 ref.)

Congenital constriction band syndrome. Perdue PS, et al. **J South Orthop Assoc** 1996 Spring;5(1):71–5 (12 ref.)

Progressive osseous heteroplasia, uncommon cause of soft tissue ossification: a case report and review of the literature. Rodriguez-Jurado R, et al. **Pediatr Pathol Lab Med** 1995 Sep–Oct;15(5):813–27 (15 ref.)

Ossifying renal tumor of infancy: a clinicopathologic study of nine cases. Sotelo-Avila C, et al. **Pediatr Pathol Lab Med** 1995 Sep–Oct;15(5):745–62 (9 ref.)

RADIOGRAPHY

An unusual location for heterotopic ossification: lumbar anterior longitudinal ligament. Czyrny JJ, et al. **J Spinal Cord Med** 1995 Jul;18(3):194–9 (32 ref.)

SURGERY

A retrospective comparison of endoscopic plantar fasciotomy to open plantar fasciotomy with heel spur resection for chronic plantar fasciitis/heel spur syndrome. Tomczak RL, et al. **J Foot Ankle Surg** 1995 May–Jun;34(3):305–11 (41 ref.)

OSSIFICATION, PATHOLOGIC see **OSSIFICATION, HETEROTOPIC**

OSSIFICATION, PHYSIOLOGIC see **OSTEOGENESIS**

OSTEITIS

Why the "SAPHO" syndrome? [editorial] Kahn MF. **J Rheumatol** 1995 Nov;22(11):2017–9 (20 ref.)

ETIOLOGY

[Osteitis secondary to toxic dermatitis caused by hydroxyurea. Apropos ofa case, review of the literature (letter)] Mounier N, et al. **Ann Med Interne (Paris)** 1995; 146(8):590–1 (14 ref.) **(Fre)**

RADIOGRAPHY

Osteitis condensans of the clavicle: does fibrocartilage play a role? A report of two cases with spontaneous clinical and roentgenographic resolution. Berthelot JM, et al. **Rev Rhum Engl Ed** 1995 Jul–Sep;62(7–8):501–6 (54 ref.)

[Pubalgia in sportsmen] Zeitoun F, et al. **Ann Radiol (Paris)** 1995;38(5):244–54 (31 ref.) (Eng. Abstr.) **(Fre)**

OSTEITIS DEFORMANS

Paget's disease of bone: diagnosis and management [see comments] Hosking D, et al. **BMJ** 1996 Feb 24; 312(7029):491–4 (33 ref.) Comment in: BMJ 1996 Jun 8;312(7044):1476–7.

COMPLICATIONS

Paget sarcoma of the cervical vertebrae: an autopsy case report and review of the literature. Matsukuma S, et al. **Pathol Int** 1995 Nov;45(11):885–9 (27 ref.)

DIAGNOSIS

[Vertebral localizations of Paget disease] Chrétien J. **Ann Radiol (Paris)** 1995;38(4):169–76 (7 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

Skeletal safety of tiludronate. Neer RM. **Bone** 1995 Nov;17(5 Suppl):501S–503S (27 ref.)

Efficacy and safety of drugs for Paget's disease of bone. Reginster JY, et al. **Bone** 1995 Nov;17(5 Suppl):485S–488S (49 ref.)

Comparative clinical pharmacology and therapeutic use of bisphosphonates in metabolic bone diseases. Rosen CJ, et

al. **Drugs** 1996 Apr;51(4):537–51 (80 ref.)

PATHOLOGY

Osteoclast function in Paget's disease and multiple myeloma. Roodman GD. **Bone** 1995 Aug;17(2 Suppl):57S–61S (30 ref.)

Paget sarcoma of the cervical vertebrae: an autopsy case report and review of the literature. Matsukuma S, et al. **Pathol Int** 1995 Nov;45(11):885–9 (27 ref.)

VIROLOGY

[Viral origin of Paget's disease of bone?] Basle MF, et al. **Presse Med** 1996 Jan 27;25(3):113–8 (25 ref.) (Eng. Abstr.) **(Fre)**

OSTEITIS FIBROSA DISSEMINATA see **FIBROUS DYSPLASIA OF BONE**

OSTEOARTHRITIS

Osteoarthrosis—the orthopedic surgeon's perspective. Radin EL. **Acta Orthop Scand Suppl** 1995 Oct;266:6–9 (18 ref.)

Weight and osteoarthritis. Felson DT. **Am J Clin Nutr** 1996 Mar;63(3 Suppl):430S–432S (10 ref.)

New perspectives on osteoarthritis. Oddis CV. **Am J Med** 1996 Feb 26;100(2A):10S–15S (39 ref.)

New insights into osteoarthritis. Brooks PM, et al. **Med J Aust** 1995 Oct 2;163(7):367–9 (33 ref.)

Osteoarthritis. A continuing challenge. Sack KE. **West J Med** 1995 Dec;163(6):579–86 (149 ref.)

CHEMICALLY INDUCED

Indomethacin hastens large joint osteoarthritis in humans—how strong is the evidence? [editorial] Doherty M, et al. **J Rheumatol** 1995 Nov;22(11):2013–6 (32 ref.)

DIAGNOSIS

Validating markers in osteoarthritis. Felson DT. **Acta Orthop Scand Suppl** 1995 Oct;266:205–7 (1 ref.)

The role of molecular markers to monitor disease, intervention and cartilage breakdown in osteoarthritis. Lohmander LS, et al. **Acta Orthop Scand Suppl** 1995 Oct; 266:84–7 (32 ref.)

Needle arthroscopy: a new frontier in rheumatology. Panchal P, et al. **Compr Ther** 1996 Jan;22(1):44–7 (14 ref.)

Joint failure in erosive osteoarthritis of the hands. Rovetta G, et al. **Int J Tissue React** 1995;17(1):33–42 (36 ref.)

The case for a simple method of grading osteoarthritis severity at arthroscopy [editorial; comment] Marshall KW. **J Rheumatol** 1996 Apr;23(4):582–5 (24 ref.) Comment on: J Rheumatol 1996 Apr;23(4):698–706.

Imaging of osteoarthritis. Preidler KW, et al. **Radiol Clin North Am** 1996 Mar;34(2):259–71, x (63 ref.)

[Clinical relevance of the early detection of arthrosis] Willauschus W, et al. **Z Orthop Ihre Grenzgeb** 1995 Nov–Dec;133(6):507–13 (49 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Management of osteoarthritis and rheumatoid arthritis: prospects and possibilities. Blackburn WD. **Am J Med** 1996 Feb 26;100(2A):24S–30S (47 ref.)

Clinical trials in osteoarthritis [editorial] March LM, et al. **Ann Rheum Dis** 1996 Aug;55(8):491–3 (27 ref.)

Practical management of osteoarthritis. Integration of pharmacologic and nonpharmacologic measures. Griffin MR, et al. **Arch Fam Med** 1995 Dec;4(12):1049–55 (102 ref.)

Assessment outcomes of clinical drug trials in osteoarthritis. Sangha O, et al. **Curr Opin Rheumatol** 1995 Jul;7(4):352–5 (24 ref.)

Topical capsaicin. A review of its pharmacological properties and therapeutic potential in post-herpetic neuralgia, diabetic neuropathy and osteoarthritis. Rains C, et al. **Drugs Aging** 1995 Oct;7(4):317–28 (52 ref.)

Neurogenic influences in arthritis: potential modification by capsaicin [editorial] Matucci Cerinic M, et al. **J Rheumatol** 1995 Aug;22(8):1447–9 (27 ref.)

Methodology of clinical trials in hand osteoarthritis. Issues and proposals. Maheu E, et al. **Rev Rhum Engl Ed** 1995 Jun;62(6 Suppl 1):55S–62S (22 ref.)

Review of clinical trials and benefit/risk ratio of meloxicam. Barner A. **Scand J Rheumatol Suppl** 1996;102:29–37 (15 ref.)

EPIDEMIOLOGY

The epidemiology of osteoarthritis of the hand [see comments] Cicuttini FM, et al. **Rev Rhum Engl Ed** 1995 Jun;62(6 Suppl 1):3S–8S (45 ref.) Comment in: Rev Rhum Engl Ed 1995 Jun;62(6 Suppl 1):1S–2S.

["State of the art" in epidemiology of arthroses. An overview of important studies of etiology and sequelae] Kriegel W, et al. **Z Rheumatol** 1995 Jul–Aug;54(4):223–40 (90 ref.) (Eng. Abstr.) **(Ger)**

[Why I do not grease up my axles... (editorial; comment)] Tena Marsà X. **Med Clin (Barc)** 1996 Apr 27;106(16):617–8 (21 ref.) Comment on: Med Clin (Barc) 1996 Apr 27;106(16):601–6. **(Spa)**

ETIOLOGY

Osteoarthritis and molecular markers. A rheumatologist's perspective. Dieppe P. **Acta Orthop Scand Suppl** 1995 Oct; 266:1–5 (25 ref.)

Pathogenesis of degenerative joint disease in the human temporomandibular joint. Haskin CL, et al. **Crit Rev Oral Biol Med** 1995;6(3):248–77 (359 ref.)

Etiologic factors in finger osteoarthritis [see comments] Verrouil E, et al. **Rev Rhum Engl Ed** 1995 Jun;62(6 Suppl 1):9S–13S (39 ref.) Comment in: Rev Rhum Engl Ed 1995 Jun;62(6 Suppl 1):1S–2S.

[Orthopaedic disorders and problems related to obesity] Koshino T. **Nippon Rinsho** 1995 Jun;53 Suppl:382–7 (20 ref.) **(Jpn)**

METABOLISM

Anabolic and catabolic markers of proteoglycan metabolism in osteoarthritis. Caterson B, et al. **Acta Orthop Scand Suppl** 1995 Oct;266:121–4 (32 ref.)

Aggrecan degradation in osteoarthritis and rheumatoid arthritis. Lark MW, et al. **Acta Orthop Scand Suppl** 1995 Oct;266:92–7 (31 ref.)

The structure, biochemistry, and metabolism of osteoarthritic cartilage: a review of the literature. Dijkgraaf LC, et al. **J Oral Maxillofac Surg** 1995 Oct;53(10):1182–92 (36 ref.)

Acute-phase proteins in osteoarthritis. Sipe JD. **Semin Arthritis Rheum** 1995 Oct;25(2):75–86 (115 ref.)

PATHOLOGY

The structure, biochemistry, and metabolism of osteoarthritic cartilage: a review of the literature. Dijkgraaf LC, et al. **J Oral Maxillofac Surg** 1995 Oct;53(10):1182–92 (36 ref.)

Methodology of clinical trials in hand osteoarthritis. Issues and proposals. Maheu E, et al. **Rev Rhum Engl Ed** 1995 Jun;62(6 Suppl 1):55S–62S (22 ref.)

Etiologic factors in finger osteoarthritis [see comments] Verrouil E, et al. **Rev Rhum Engl Ed** 1995 Jun;62(6 Suppl 1):9S–13S (39 ref.) Comment in: Rev Rhum Engl Ed 1995 Jun;62(6 Suppl 1):1S–2S.

[Advances in pathology of 5 endemic diseases in China] Wang F, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1995 Aug;24(4):252–4 (20 ref.) **(Chi)**

[Biophysical bases of the effects of holmium laser on articular cartilage and their impact on clinical application technics] Gerber BE, et al. **Orthopade** 1996 Feb;25(1):21–9 (37 ref.) (Eng. Abstr.) **(Ger)**

[Comparative histomorphometry of subchondral bone density and articular cartilage thickness in the tibial head in early human arthritis] Böhringer ME, et al. **Z Orthop Ihre Grenzgeb** 1995 Jul–Aug;133(4):291–302 (61 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Differential release of molecular markers in joint disease. Saxne T. **Acta Orthop Scand Suppl** 1995 Oct;266:80–3 (29 ref.)

Recommended methodology for assessing the progression of osteoarthritis of the hip and knee joints. Dieppe PA. **Osteoarthritis Cartilage** 1995 Jun;3(2):73–7 (27 ref.)

PSYCHOLOGY

Mechanisms related to psychological well-being in older women with chronic illnesses: age and disease comparisons. Heidrich SM. **Res Nurs Health** 1996 Jun;19(3):225–35 (47 ref.)

[Pain and pain perception in the elderly from the viewpoint of rheumatology] Nehen HG. **Z Gerontol Geriatr** 1995 Sep–Oct;28(5):335–8 (10 ref.) (Eng. Abstr.) **(Ger)**

RADIOGRAPHY

Recommended methodology for assessing the progression of osteoarthritis of the hip and knee joints. Dieppe PA. **Osteoarthritis Cartilage** 1995 Jun;3(2):73–7 (27 ref.)

[Vertebral vacuum phenomena] Hamzé B, et al. **Ann Radiol (Paris)** 1995;38(4):186–91 (17 ref.) (Eng. Abstr.) **(Fre)**

[Computed tomography of the sacroiliac joints] Miquel A, et al. **Ann Radiol (Paris)** 1995;38(4):177–85 (28 ref.) **(Fre)**

[Pubalgia in sportsmen] Zeitoun F, et al. **Ann Radiol (Paris)** 1995;38(5):244–54 (31 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Medial compartment arthrosis of the knee. Dearborn JT, et al. **Am J Orthop** 1996 Jan;25(1):18–26 (64 ref.)

Surgical treatment for osteoarthritis at the base of the thumb. Kuschner SH, et al. **Am J Orthop** 1996 Feb;25(2):91–100 (73 ref.)

Should total prosthetization of the patella be used in knee surgery? A review of the literature and personal experience. Murena PF, et al. **Chir Organi Mov** 1995 Jul–Aug; 80(3):323–8 (30 ref.)

Total hip and knee replacement treatment programs: a report using consensus. Enloe LJ, et al. **J Orthop Sports Phys Ther** 1996 Jan;23(1):3–11 (20 ref.)

Isolated patellofemoral arthritis. Dennis DA. **Orthopedics** 1995 Sep;18(9):893–5 (33 ref.)

[Arthrodesis of the wrist in arthritis] Knopp W, et al. **Orthopade** 1996 Apr;25(2):121–5 (23 ref.) (Eng. Abstr.) **(Ger)**

[Progression of arthrosis after alloplasty—what factors play a role?] Küllmer K, et al. **Unfallchirurgie** 1996 Jun; 22(3):130–8 (36 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Nonsurgical management of osteoarthritis, with an emphasis on nonpharmacologic measures. Brandt KD. **Arch Fam Med** 1995 Dec;4(12):1057–64 (73 ref.)

Workshop on chronic pain, pain control, and patient outcomes in rheumatoid arthritis and osteoarthritis. Bellamy N, et al. **Arthritis Rheum** 1996 Mar;39(3):357–62 (26 ref.)

What can be done about osteoarthritis? **Drug Ther Bull** 1996 May;34(5):33–5 (21 ref.)

Osteoarthritis in older patients. Optimum treatment. Bagge E, et al. **Drugs Aging** 1995 Sep;7(3):176–83 (47 ref.)

Challenges for clinical decision making in the management of osteoarthritis of the knee [editorial; comment] Williams MH. **J Rheumatol** 1996 Apr;23(4):586–9 (63 ref.) Comment on: J Rheumatol 1996 Apr;23(4):730–8.

VETERINARY

Treatment of canine hip dysplasia: a review. Remedios AM, et al. **Can Vet J** 1995 Aug;36(8):503–9 (73 ref.)

Canine cemented total hip replacements: state of the art. Olmstead ML. **J Small Anim Pract** 1995 Sep;36(9):395–9 (13 ref.)

Knee joint function, meniscal disease, and osteoarthritis. Bellenger CR. **Vet Q** 1995 Apr;17 Suppl 1:S5–6 (6 ref.)

OSTEOARTHRITIS, HIP

DIAGNOSIS

[Clinical relevance of the early detection of arthrosis] Willauschus W, et al. **Z Orthop Ihre Grenzgeb** 1995 Nov–Dec;133(6):507–13 (49 ref.) (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

The epidemiology of hip osteoarthritis and rheumatoid arthritis in the Orient. Lau EM, et al. **Clin Orthop** 1996 Feb;(323):81–90 (67 ref.)

PREVENTION & CONTROL

Osteotomies about the hip for the prevention and treatment of osteoarthrosis. Millis MB, et al. **Instr Course Lect** 1996; 45:209–26 (86 ref.)

SURGERY

Spontaneous fracture of the ceramic ball in a ceramic–polyethylene total hip arthroplasty. Michaud RJ, et al. **J Arthroplasty** 1995 Dec;10(6):863–7 (27 ref.)

THERAPY

Management of hip osteoarthritis. Dieppe P. **BMJ** 1995 Sep 30;311(7009):853–7 (23 ref.)

OSTEOARTHROPATHY, PRIMARY HYPERTROPHIC

ETIOLOGY

Psoriatic onycho–pachydermo–periostitis. A variant of psoriatic distal interphalangeal arthritis? Boisseau-Garsaud AM, et al. **Arch Dermatol** 1996 Feb;132(2):176–80 (22 ref.)

OSTEOARTHROPATHY, SECONDARY HYPERTROPHIC

ETIOLOGY

Hypertrophic pulmonary osteoarthropathy: is there a role for radiotherapy to symptomatic sites? Case report and literature review. Roos DE. **Acta Oncol** 1996;35(1):101–3 (16 ref.)

RADIOTHERAPY

Hypertrophic pulmonary osteoarthropathy: is there a role for radiotherapy to symptomatic sites? Case report and literature review. Roos DE. **Acta Oncol** 1996;35(1):101–3 (16 ref.)

OSTEOARTHROSIS see **OSTEOARTHRITIS**

OSTEOARTHROSIS DEFORMANS see **OSTEOARTHRITIS**

OSTEOBLASTOMA

DIAGNOSIS

CT and MR imaging of vertebral osteoblastoma. A report of two cases. Ozkal E, et al. **Clin Imaging** 1996 Jan–Mar; 20(1):37–41 (13 ref.)

Clinicopathologic features and treatment of osteoid osteoma and osteoblastoma in children and adolescents. Frassica FJ, et al. **Orthop Clin North Am** 1996 Jul;27(3):559–74 (66 ref.)

OSTEOBLASTS

CYTOLOGY

Expression and role of epidermal growth factor receptors during differentiation of cementoblasts, osteoblasts, and periodontal ligament fibroblasts in the rat. Cho MI, et al. **Anat Rec** 1996 Jun;245(2):342–60 (69 ref.)

Role of material surfaces in regulating bone and cartilage cell response. Boyan BD, et al. **Biomaterials** 1996 Jan; 17(2):137–46 (94 ref.)

Osteoblast and chondroblast differentiation. Aubin JE, et al. **Bone** 1995 Aug;17(2 Suppl):77S–83S (56 ref.)

Modulation of osteoclast differentiation by local factors. Suda T, et al. **Bone** 1995 Aug;17(2 Suppl):87S–91S (30 ref.)

Transcriptional control of osteoblast growth and differentiation. Stein GS, et al. **Physiol Rev** 1996 Apr; 76(2):593–629 (461 ref.)

DRUG EFFECTS

Anabolic effects of insulin on bone suggest a role for chromium picolinate in preservation of bone density. McCarty MF. **Med Hypotheses** 1995 Sep;45(3):241–6 (69 ref.)

PTH-mediated osteoblast retraction: possible participation of the calpain pathway. Murray EJ, et al. **Miner Electrolyte Metab** 1995;21(1–3):184–8 (20 ref.)

IMMUNOLOGY

Monoclonal antibodies as tools for studying the osteoblast lineage. Aubin JE, et al. **Microsc Res Tech** 1996 Feb 1; 33(2):128–40 (119 ref.)

METABOLISM

The mechanism of uptake of ascorbic acid into osteoblasts and leukocytes. Wolf G. **Nutr Rev** 1996 May;54(5):150–2 (12 ref.)

PHYSIOLOGY

Mechano–reception in osteoblast–like cells. Jones D, et al. **Biochem Cell Biol** 1995 Jul–Aug;73(7–8):525–34 (80 ref.)

The insulin–like growth factor system and the coupling of formation to resorption. Hayden JM, et al. **Bone** 1995 Aug; 17(2 Suppl):93S–98S (32 ref.)

The effects of cytokines and growth factors on osteoblastic cells. Mundy GR, et al. **Bone** 1995 Aug;17(2 Suppl):71S–75S (41 ref.)

Regulation of bone cells by 1,25(OH)2D3. Ljunghall S, et al. **Nephrol Dial Transplant** 1995;10 Suppl 4:11–3; discussion 37–43 (17 ref.)

OSTEOCALCIN

BLOOD

[Osteocalcin] Hino F, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:745–8 (10 ref.) **(Jpn)**

OSTEOCHONDRITIS

DIAGNOSIS

Avascular necrosis of carpal bones. Golimbu CN, et al. **Magn Reson Imaging Clin N Am** 1995 May;3(2):281–303 (74 ref.)

VETERINARY

Arthroscopy in food animal practice. Gaughan EM. **Vet Clin North Am Food Anim Pract** 1996 Mar;12(1):233–47 (11 ref.)

OSTEOCHONDRITIS DISSECANS

Osteochondritis dissecans. Schenck RC Jr, et al. **J Bone Joint Surg Am** 1996 Mar;78(3):439–56 (163 ref.)

OSTEOCHONDRODYSPLASIAS

CLASSIFICATION

Evolution of the bone dysplasia family [editorial] Horton WA. **Am J Med Genet** 1996 May 3;63(1):4–6 (22 ref.)

COMPLICATIONS

Double patella syndrome with a form of multiple epiphyseal dysplasia. Yochum TR, et al. **J Manipulative Physiol Ther** 1995 Jul–Aug;18(6):407–10 (11 ref.)

DIAGNOSIS

Sponastrime dysplasia: five new cases and review of nine previously published cases. Langer LO Jr, et al. **Am J Med Genet** 1996 May 3;63(1):20–7 (6 ref.)

Melnick Needles syndrome. Kothari V, et al. **Indian Pediatr** 1995 Apr;32(4):471–5 (8 ref.)

Tracheobronchopathia osteochondroplastica. Report of a young man with severe disease and retrospective review of 18 cases. Vilkman S, et al. **Respiration** 1995;62(3):151–4 (13 ref.)

EPIDEMIOLOGY

Osteochondrodysplasias in South Africa. Beighton P. **Am J Med Genet** 1996 May 3;63(1):7–11 (45 ref.)

GENETICS

Osteochondrodysplasias in South Africa. Beighton P. **Am J Med Genet** 1996 May 3;63(1):7–11 (45 ref.)

Evolution of the bone dysplasia family [editorial] Horton WA. **Am J Med Genet** 1996 May 3;63(1):4–6 (22 ref.)

Cardiac malformation in two infants with hypochondrogenesis. Potocki L, et al. **Am J Med Genet** 1995 Nov 20;59(3):295–9 (17 ref.)

Molecular defects in the chondrodysplasias. Rimoin DL. **Am J Med Genet** 1996 May 3;63(1):106–10 (35 ref.)

A chondrodysplasia family produced by mutations in the diastrophic dysplasia sulfate transporter gene: genotype/phenotype correlations. Superti–Furga A, et al. **Am J Med Genet** 1996 May 3;63(1):144–7 (28 ref.)

Autosomal recessive omodysplasia. Stoll C, et al. **Ann Genet** 1995;38(2):97–101 (8 ref.)

Hypochondroplasia: molecular analysis of the fibroblast growth factor receptor 3 gene. Bellus GA, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:182–7 (25 ref.)

Mutations in the cartilage oligomeric matrix protein (COMP) gene in pseudoachondroplasia and multiple epiphyseal dysplasia. Cohn DH, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:188–94 (18 ref.)

Sulfate transport in chondrodysplasia. Hästbacka J, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:131–6 (29 ref.)

Progress in human chondrodysplasias: molecular genetics. Horton WA. **Ann N Y Acad Sci** 1996 Jun 8;785:150–9 (44 ref.)

Campomelic dysplasia with XY sex reversal: diverse phenotypes resulting from mutations in a single gene. Schafer AJ, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:137–49 (46 ref.)

A family of chondrodysplasias caused by mutations in the diastrophic dysplasia sulfate transporter gene and associated with impaired sulfation of proteoglycans. Superti–Furga A, et al. **Ann N Y Acad Sci** 1996 Jun 8; 785:195–201 (26 ref.)

Dutch variant of Bellini metaphyseal dysplasia: report of two siblings. Kozlowski K, et al. **Australas Radiol** 1995 Aug; 39(3):282–6 (6 ref.)

Mutations in collagen genes resulting in metaphyseal and epiphyseal dysplasias. Olsen BR. **Bone** 1995 Aug;17(2 Suppl):45S–49S (30 ref.)

METABOLISM

Sulfate transport in chondrodysplasia. Hästbacka J, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:131–6 (29 ref.)

PATHOLOGY

Opsismodyaplasia: another case and literature review. Santos HG, et al. **Clin Dysmorphol** 1995 Jul;4(3):222–6 (7 ref.)

OSTEOCHONDROMA

COMPLICATIONS

Osteochondroma: an unusual cause of vascular disease in young adults. Eschelman DJ, et al. **J Vasc Interv Radiol** 1995 Jul–Aug;6(4):605–13 (54 ref.)

OSTEOCHONDROMAS, MULTIPLE see **EXOSTOSES, MULTIPLE HEREDITARY**

OSTEOCHONDROMATOSIS

COMPLICATIONS

Concurrent osteochondroma of the mandibular condyle and ipsilateral cranial base resulting in temperomandibular joint ankylosis: report of a case and review of the literature. Karras SC, et al. **J Oral Maxillofac Surg** 1996 May; 54(5):640–6 (27 ref.)

OSTEOCHONDROMATOSIS, SYNOVIAL see **CHONDROMATOSIS, SYNOVIAL**

OSTEOCHONDROSIS see **OSTEOCHONDRITIS**

OSTEOCLASTIC BONE LOSS see **BONE RESORPTION**

OSTEOCLASTS

Cellular biology of bone–resorbing cells. Athanasou NA. **J Bone Joint Surg Am** 1996 Jul;78(7):1096–112 (170 ref.)

[Recent progress of the investigation of osteoclast] Nakamura T. **Nippon Geka Hokan** 1995 Jan 1;64(1):1–2 (9 ref.) **(Jpn)**

CHEMISTRY

Toward a more complete molecular description of the osteoclast. Horne WC. **Bone** 1995 Aug;17(2):107–9 (14 ref.)

CYTOLOGY

Modulation of osteoclast differentiation by local factors. Suda T, et al. **Bone** 1995 Aug;17(2 Suppl):87S–91S (30 ref.)

The osteoclast clear zone is a specialized cell–extracellular matrix adhesion structure. Väänänen HK, et al. **J Cell Sci** 1995 Aug;108 (Pt 8):2729–32 (39 ref.)

Cytoskeletal changes in osteoclasts during the resorption cycle. Lakkakorpi PT, et al. **Microsc Res Tech** 1996 Feb 1;33(2):171–81 (90 ref.)

DRUG EFFECTS

Anabolic effects of insulin on bone suggest a role for chromium picolinate in preservation of bone density. McCarty MF. **Med Hypotheses** 1995 Sep;45(3):241–6 (69 ref.)

Signal transduction mechanisms of parathyroid hormone– and parathyroid hormone–related–peptide–stimulated osteoclast–like cell formation from hemopoietic blast cells. Sugimoto T, et al. **Miner Electrolyte Metab** 1995; 21(1–3):161–5 (22 ref.)

ENZYMOLOGY

The tartrate–resistant purple acid phosphatase of bone osteoclasts—a protein phosphatase with multivalent substrate specificity and regulation. Andersson G, et al. **Acta Orthop Scand Suppl** 1995 Oct;266:189–94 (28 ref.)

METABOLISM

Role of microscopy in elucidating the mechanism and regulation of the osteoclast resorptive apparatus. Gay CV. **Microsc Res Tech** 1996 Feb 1;33(2):165–70 (74 ref.)

PATHOLOGY

Osteoclast function in Paget's disease and multiple myeloma. Roodman GD. **Bone** 1995 Aug;17(2 Suppl):57S–61S (30 ref.)

Cellular and molecular mechanisms of bone resorption. Teitelbaum SL, et al. **Miner Electrolyte Metab** 1995; 21(1–3):193–6 (18 ref.)

[Transitional–cell sarcomatoid carcinoma of the renal pelvis with osteoclast–type giant cells. Review of the literature] Meseguer García P, et al. **Actas Urol Esp** 1996 Jan; 20(1):63–7 (26 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

The osteoclast clear zone is a specialized cell–extracellular matrix adhesion structure. Väänänen HK, et al. **J Cell Sci** 1995 Aug;108 (Pt 8):2729–32 (39 ref.)

Regulation of bone cells by 1,25(OH)2D3. Ljunghall S, et al. **Nephrol Dial Transplant** 1995;10 Suppl 4:11–3; discussion 37–43 (17 ref.)

[Osteoclast activating factor (OAF)] Kamihagi K, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:756–8 (14 ref.) **(Jpn)**

OSTEOGENESIS

Osteopontin at mineralized tissue interfaces in bone, teeth, and osseointegrated implants: ultrastructural distribution and implications for mineralized tissue formation, turnover, and repair. McKee MD, et al. **Microsc Res Tech** 1996 Feb 1;33(2):141–64 (112 ref.)

[Advances in the understanding of the etiopathogenesis of non syndromic craniostenoses and therapeutic approaches] Czorny A, et al. **Ann Chir Plast Esthet** 1995 Dec; 40(6):657–65 (22 ref.) (Eng. Abstr.) **(Fre)**

[Fundamental aspects of osteoinductive activity of bone tissue and potential clinical application] Aldinger G, et al. **Z Orthop Ihre Grenzgeb** 1996 May–Jun;134(3):205–9 (22 ref.) (Eng. Abstr.) **(Ger)**

DRUG EFFECTS

Growth factors: possible new clinical tools. A review. Lind M. **Acta Orthop Scand** 1996 Aug;67(4):407–17 (111 ref.)

[Metastatic bone lesions in solid tumors and possible use of clodronate (Bonephos) in clinical oncology] Moiseenko VM, et al. **Vopr Onkol** 1996;42(2):17–30 (93 ref.) **(Rus)**

PHYSIOLOGY

The insulin–like growth factor system and the coupling of formation to resorption. Hayden JM, et al. **Bone** 1995 Aug; 17(2 Suppl):93S–98S (32 ref.)

Characteristics and regulation of Pi transport in osteogenic cells for bone metabolism. Caverzasio J, et al. **Kidney Int** 1996 Apr;49(4):975–80 (24 ref.)

OSTEOGENESIS IMPERFECTA

see related
DENTINOGENESIS IMPERFECTA

COMPLICATIONS

Osteogenesis imperfecta and hearing loss. Verstreken M, et al. **Acta Otorhinolaryngol Belg** 1996;50(2):91–8 (47 ref.)

Combined valve replacement and coronary bypass grafting in osteogenesis imperfecta [see comments] Almassi GH, et al. **Ann Thorac Surg** 1995 Nov;60(5):1395–7 (15 ref.) Comment in: Ann Thorac Surg 1996 Apr;61(4):1294.

Acute aortic dissection in a patient with osteogenesis imperfecta [see comments] Moriyama Y, et al. **Ann Thorac Surg** 1995 Nov;60(5):1397–9 (8 ref.) Comment in: Ann Thorac Surg 1996 Apr;61(4):1294.

Osteogenesis imperfecta and cardiovascular diseases [see

comments] Wong RS, et al. **Ann Thorac Surg** 1995 Nov; 60(5):1439–43 (36 ref.) Comment in: Ann Thorac Surg 1996 Apr;61(4):1294.

[Severe 5-fluorouracil toxicity in a woman treated for breast cancer with concurrent osteogenesis imperfecta and dehydrogenase deficiency] Beuzeboc P, et al. **Bull Cancer (Paris)** 1996 Apr;83(4):324–7 (24 ref.) (Eng. Abstr.) **(Fre)**

[Left ventricular rupture following aortic and mitral valve replacement in a patient with osteogenesis imperfecta: a case report] Ichikawa H, et al. **Kyobu Geka** 1996 Apr; 49(4):294–6 (13 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Deficient expression of the small proteoglycan decorin in a case of severe/lethal osteogenesis imperfecta. Dyne KM, et al. **Am J Med Genet** 1996 May 3;63(1):161–6 (34 ref.)

OSTEOLYSIS

DRUG THERAPY

Clodronate and other bisphosphonates as supportive therapy in osteolysis due to malignancy. Elomaa I, et al. **Acta Oncol** 1995;34(5):629–36 (81 ref.)

[Role of bisphosphonates in the treatment of tumoral osteolysis] Claudepierre P, et al. **Ann Med Interne (Paris)** 1995;146(5):325–7 (38 ref.) **(Fre)**

ETIOLOGY

Clodronate and other bisphosphonates as supportive therapy in osteolysis due to malignancy. Elomaa I, et al. **Acta Oncol** 1995;34(5):629–36 (81 ref.)

Posttraumatic spinal osteolysis in ankylosing spondylitis as part of pseudoarthrosis. A case report. Albertsen AM, et al. **Acta Radiol** 1996 Jan;37(1):98–100 (10 ref.)

Pyoderma gangrenosum and cranial osteolysis: case report and review of the paediatric literature. Samlaska CP, et al. **Br J Dermatol** 1995 Dec;133(6):972–7 (61 ref.)

The role of polyethylene properties in osteolysis after total hip replacement. Gómez-Barrena E, et al. **Instr Course Lect** 1996;45:187–97 (80 ref.)

Multifocal osteolysis following limb-sparing procedures: imaging findings and a review of the literature. Kaste SC, et al. **Pediatr Radiol** 1996;26(2):158–61 (17 ref.)

[The assessment of solitary osteolytic bone lesions in breast carcinoma. A special case report] Mose S, et al. **Strahlenther Onkol** 1996 Jan;172(1):43–6 (16 ref.) (Eng. Abstr.) **(Ger)**

[Bone lesions in patients with multiple myeloma] Umeda M, et al. **Nippon Naika Gakkai Zasshi** 1995 Jul 10;84(7):1070–4 (5 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Periprosthetic osteolysis in total hip arthroplasty: the role of particulate wear debris. Maloney WJ, et al. **Instr Course Lect** 1996;45:171–82 (85 ref.)

PREVENTION & CONTROL

Bone cement as a seal protecting the femur from the ingress of particulate debris and femoral osteolysis. Harris WH, et al. **Instr Course Lect** 1996;45:183–5 (23 ref.)

OSTEOLYSIS, ESSENTIAL

Gorham's disease: a literature review and case reports. Green HD, et al. **J Foot Ankle Surg** 1995 Sep–Oct;34(5):435–41 (17 ref.)

COMPLICATIONS

Massive osteolysis of the mandible with subsequent obstructive sleep apnea syndrome: a case report. Kayada Y, et al. **J Oral Maxillofac Surg** 1995 Dec;53(12):1463–5 (14 ref.)

RADIOGRAPHY

Idiopathic osteolysis of the acetabulum: a case report. Nemec B, et al. **J Bone Joint Surg Br** 1996 Jul;78(4):666–7 (8 ref.)

OSTEOLYSIS, IDIOPATHIC MULTICENTRIC see **OSTEOLYSIS, ESSENTIAL**

OSTEOLYSIS, MASSIVE see **OSTEOLYSIS, ESSENTIAL**

OSTEOMA

COMPLICATIONS

[Pneumocephalus complicating osteoma of the frontal sinus] Attane F, et al. **Rev Neurol (Paris)** 1996 Apr;152(4):279–82 (13 ref.) (Eng. Abstr.) **(Fre)**

RADIOGRAPHY

Osteoma of the mandible. A case report. Piattelli A, et al. **Acta Stomatol Belg** 1995 Mar;92(1):13–6 (18 ref.)

Imaging quiz case 2. Bilateral osteomas of the petrous temporal bones. Hamilton MM, et al. **Arch Otolaryngol Head Neck Surg** 1996 Jul;122(7):793, 795 (9 ref.)

Osteoma of the internal auditory canal: case report. Coakley DJ, et al. **J Laryngol Otol** 1996 Feb;110(2):158–60 (10 ref.)

OSTEOMA, GIANT OSTEOID see **OSTEOBLASTOMA**

OSTEOMA, OSTEOID

DIAGNOSIS

Clinicopathologic features and treatment of osteoid osteoma and osteoblastoma in children and adolescents. Frassica FJ, et al. **Orthop Clin North Am** 1996 Jul;27(3):559–74 (66 ref.)

PATHOLOGY

Painless osteoid osteoma of the rib in an adult. A case report and a review of the literature. McDermott MB, et al. **Cancer** 1996 Apr 15;77(8):1442–9 (62 ref.)

THERAPY

Osteoma of the long bones and the spine. A study of eleven patients and a review of the literature. Peyser AB, et al. **J Bone Joint Surg Am** 1996 Aug;78(8):1172–80 (20 ref.)

OSTEOMALACIA

COMPLICATIONS

Osteomalacia associated with adult Fanconi's syndrome: clinical and diagnostic features. Clarke BL, et al. **Clin Endocrinol (Oxf)** 1995 Oct;43(4):479–90 (62 ref.)

Hypophosphatemic osteomalacia with plantar neurilemoma. A review of the literature (100 cases). Crouzet J, et al. **Rev Rhum Engl Ed** 1995 Jun;62(6):463–6 (34 ref.)

ETIOLOGY

Osteomalacia as a presenting manifestation of Sjögren's syndrome. Hajjaj-Hassouni N, et al. **Rev Rhum Engl Ed** 1995 Jul–Sep;62(7–8):529–32 (30 ref.)

Tumor-induced osteomalacia. Schapira D, et al. **Semin Arthritis Rheum** 1995 Aug;25(1):35–46 (79 ref.)

OSTEOMYELITIS

CLASSIFICATION

Possible identity of diffuse sclerosing osteomyelitis and chronic recurrent multifocal osteomyelitis. One entity or two. Suei Y, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1995 Oct;80(4):401–8 (41 ref.)

COMPLICATIONS

Vertebral bone destruction in sickle cell disease: infection, infarction or both. Kooy A, et al. **Neth J Med** 1996 Jun; 48(6):227–31 (11 ref.)

[Primary acute osteomyelitis of the sternum associated with anterior mediastinitis] Tabib W, et al. **J Chir (Paris)** 1996 Jan;133(1):20–2 (10 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Osteomyelitis. Laughlin RT, et al. **Curr Opin Rheumatol** 1995 Jul;7(4):315–21 (44 ref.)

Multimodality imaging of osteomyelitis. Elgazzar AH, et al. **Eur J Nucl Med** 1995 Sep;22(9):1043–63 (142 ref.)

Chronic recurrent multifocal osteomyelitis (CRMO). Schuster T, et al. **Eur J Pediatr Surg** 1996 Feb;6(1):45–51 (32 ref.)

Pediatric bone and joint infections. Diagnosis and antimicrobial management. Sonnen GM, et al. **Pediatr Clin North Am** 1996 Aug;43(4):933–47 (30 ref.)

Primary sternal osteomyelitis. Heaton PA, et al. **Pediatr Infect Dis J** 1995 Aug;14(8):722–3 (6 ref.)

Osteomyelitis. Roy DR. **Pediatr Rev** 1995 Oct;16(10):380–4; quiz 385 (17 ref.)

Neonatal group B streptococcal vertebral osteomyelitis. Barton LL, et al. **Pediatrics** 1996 Sep;98(3 Pt 1):459–61 (9 ref.)

[Diffuse sclerosing chronic osteomyelitis of the mandible] García Marín F, et al. **An Otorrinolaringol Ibero Am** 1996; 23(3):249–59 (32 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Local antibacterial therapy for the management of orthopaedic infections. Pharmacokinetic considerations. Henry SL, et al. **Clin Pharmacokinet** 1995 Jul;29(1):36–45 (88 ref.)

Quinolones and osteomyelitis: state-of-the-art. Lew DP, et al. **Drugs** 1995;49 Suppl 2:100–11 (48 ref.)

Hematogenous osteomyelitis of the calcaneus in children: surgical treatment and use of implanted antibiotic beads. Kelsey R, et al. **J Foot Ankle Surg** 1995 Nov–Dec; 34(6):547–55; discussion 594 (26 ref.)

Pediatric bone and joint infections. Diagnosis and antimicrobial management. Sonnen GM, et al. **Pediatr Clin North Am** 1996 Aug;43(4):933–47 (30 ref.)

EPIDEMIOLOGY

[Osteoarticular infections by Salmonella non-typhi] Ramos JM, et al. **Enferm Infecc Microbiol Clin** 1995 Aug–Sep; 13(7):406–10 (30 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

Uncommon complications of odontogenic infections. Ferrera PC, et al. **Am J Emerg Med** 1996 May;14(3):317–22 (49 ref.)

Atlanto-axial subluxation and cervical osteomyelitis: two unusual complications of adenoidectomy. Baker LL, et al. **Ann Otol Rhinol Laryngol** 1996 Apr;105(4):295–9 (12 ref.)

Propionibacterium acnes vertebral osteomyelitis following lumbar puncture: case report and review [letter] Abolnik IZ, et al. **Clin Infect Dis** 1995 Sep;21(3):694–5 (10 ref.)

MICROBIOLOGY

Skull osteomyelitis due to Salmonella species: two case reports and review. Kamarulzaman A, et al. **Clin Infect Dis** 1996 Apr;22(4):638–41 (27 ref.)

Salmonella panama osteomyelitis in an otherwise healthy patient. A case report. van Cappelle HG, et al. **Clin Orthop** 1995 Dec;(321):235–8 (19 ref.)

Microbiology and antimicrobial therapy of spinal infections. Sapico FL. **Orthop Clin North Am** 1996 Jan;27(1):9–13 (22 ref.)

Human immunodeficiency virus-associated atypical mycobacterial skeletal infections. Hirsch R, et al. **Semin Arthritis Rheum** 1996 Apr;25(5):347–56 (46 ref.)

Torulopsis glabrata spinal osteomyelitis involving two contiguous vertebrae. A case report. Curran MP, et al. **Spine** 1996 Apr 1;21(7):866–70 (8 ref.)

PHYSIOPATHOLOGY

[Diffuse sclerosing chronic osteomyelitis of the mandible] García Marín F, et al. **An Otorrinolaringol Ibero Am** 1996; 23(3):249–59 (32 ref.) (Eng. Abstr.) **(Spa)**

RADIOGRAPHY

Primary subacute osteomyelitis of the wrist in children. De Smet L, et al. **Acta Orthop Belg** 1995;61(4):282–5 (16 ref.)

SURGERY

Osteomyelitis. Laughlin RT, et al. **Curr Opin Rheumatol** 1995 Jul;7(4):315–21 (44 ref.)

Update on management of chronic osteomyelitis: report of four cases. Fasika OM, et al. **East Afr Med J** 1995 Sep; 72(9):611–2 (9 ref.)

Hematogenous osteomyelitis of the calcaneus in children: surgical treatment and use of implanted antibiotic beads. Kelsey R, et al. **J Foot Ankle Surg** 1995 Nov–Dec; 34(6):547–55; discussion 594 (26 ref.)

Surgical considerations for hematogenous osteomyelitis. Loder BG, et al. **J Foot Ankle Surg** 1995 Jul–Aug; 34(4):347–53 (58 ref.)

[Therapy of osteomyelitis in the metacarpal region with local pedicle m. interosseus dorsalis II and III-flap-plasty. Anatomic principles and case report] Giunta R, et al. **Handchir Mikrochir Plast Chir** 1996 Mar;28(2):64–9 (28 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Pyogenic vertebral osteomyelitis and postsurgical disc space infections. Ozuna RM, et al. **Orthop Clin North Am** 1996 Jan;27(1):87–94 (59 ref.)

VIROLOGY

Human immunodeficiency virus-associated atypical mycobacterial skeletal infections. Hirsch R, et al. **Semin Arthritis Rheum** 1996 Apr;25(5):347–56 (46 ref.)

OSTEONECROSIS

The issue of vascularity in fractures and non-union of the scaphoid. Büchler U, et al. **J Hand Surg [Br]** 1995 Dec; 20(6):726–35 (86 ref.)

Idiopathic avascular necrosis of the scaphoid in a child. Jensen CH, et al. **Scand J Plast Reconstr Surg Hand Surg** 1995 Dec; 29(4):359–60 (6 ref.)

COMPLICATIONS

Enterococcal arthritis with avascular necrosis in a lupus patient. Markov G, et al. **Br J Rheumatol** 1996 Jun; 35(6):595–7 (11 ref.)

DIAGNOSIS

Avascular necrosis of carpal bones. Golimbu CN, et al. **Magn Reson Imaging Clin N Am** 1995 May;3(2):281–303 (74 ref.)

Osteonecrosis, transient osteoporosis, and transient bone marrow edema: current concepts. Froberg PK, et al. **Radiol Clin North Am** 1996 Mar;34(2):273–91, x (63 ref.)

SURGERY

Avascular necrosis of the hallucial sesamoids. Fleischli J, et al. **J Foot Ankle Surg** 1995 Jul–Aug;34(4):358–65 (34 ref.)

OSTEONECTIN

OSTEONECTIN

PHYSIOLOGY

SPARC and the extracellular matrix: implications for cancer and wound repair. Reed MJ, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 1):81-94 (66 ref.)

OSTEOPATHIC MANIPULATION see **MANIPULATION, ORTHOPEDIC**

OSTEOPENIA see **BONE DISEASES, METABOLIC**

OSTEOPETROSIS

GENETICS

Association of infantile neuroaxonal dystrophy and osteopetrosis: a rare autosomal recessive disorder. Rees H, et al. **Pediatr Neurosurg** 1995;22(6):321-7 (36 ref.)

PHYSIOPATHOLOGY

The heterogeneity of the osteopetroses reflects the diversity of cellular influences during skeletal development. Popoff SN, et al. **Bone** 1995 Nov;17(5):437-45 (131 ref.)

Recent developments in the understanding of the pathophysiology of osteopetrosis. Felix R, et al. **Eur J Endocrinol** 1996 Feb;134(2):143-56 (142 ref.)

THERAPY

[Bone marrow transplantation in primary immunodeficiency syndrome and in osteopetrosis] Fasth A. **Nord Med** 1995; 110(12):316-7 (15 ref.) (Eng. Abstr.) **(Swe)**

VIROLOGY

Retroviruses and bone diseases. Labat ML. **Clin Orthop** 1996 May;(326):287-309 (109 ref.)

OSTEOPHYTOSIS, SPINAL see **SPINAL OSTEOPHYTOSIS**

OSTEOPOROSIS

Putting body weight and osteoporosis into perspective. Wardlaw GM. **Am J Clin Nutr** 1996 Mar;63(3 Suppl):433S-436S (43 ref.)

Osteoporosis. Cooper C, et al. **Baillieres Clin Rheumatol** 1995 Aug;9(3):555-64 (40 ref.)

Perspectives on osteoporosis research: its focus and some insights from a new paradigm [editorial] Ferretti JL, et al. **Calcif Tissue Int** 1995 Dec;57(6):399-404 (75 ref.)

Advances in osteoporosis: better identification of risk factors can reduce morbidity and mortality. Johnell O. **J Intern Med** 1996 Apr;239(4):299-304 (24 ref.)

Osteoporotic fractures: background and prevention strategies. Wark JD. **Maturitas** 1996 Mar;23(2):193-207 (140 ref.)

[Osteoporosis. 1] Fojtik Z, et al. **Vnitr Lek** 1995 Nov; 41(11):796-801 (20 ref.) (Eng. Abstr.) **(Cze)**

[Male osteoporosis] Dolev E, et al. **Harefuah** 1995 Dec 15; 129(12):573-5 (25 ref.) **(Heb)**

CHEMICALLY INDUCED

Prevention and management of glucocorticoid-induced osteoporosis. Lane NE, et al. **Bull Rheum Dis** 1995 Aug; 44(5):1-4 (23 ref.)

COMPLICATIONS

Senile (type II) osteoporosis: pathogenesis and prevention of estrogen deficiency-related bone loss at the proximal femur. Boonen S. **Acta Clin Belg** 1995;50(4):214-21 (54 ref.)

Late consequences of a low peak bone mass. Ribot C, et al. **Acta Paediatr Suppl** 1995 Sep;411:31-5; discussion 36 (39 ref.)

The osteoporotic spine. Lee YL, et al. **Clin Orthop** 1996 Feb; (323):91-7 (37 ref.)

[Recurrent rheumatism and idiopathic osteoporosis in young adults. Coincidence or association?] Giordano N, et al. **Clin Ter** 1995 Dec;146(12):811-7 (16 ref.) (Eng. Abstr.) **(Ita)**

DIAGNOSIS

Role of biochemical markers in assessment of osteoporosis. Riggs BL, et al. **Acta Orthop Scand Suppl** 1995 Oct; 266:14-8 (24 ref.)

Osteoporosis: diagnosis and management today and tomorrow. Christiansen C. **Bone** 1995 Nov;17(5 Suppl):513S-516S (17 ref.)

Investigation of osteoporosis. Smith R. **Clin Endocrinol (Oxf)** 1996 Apr;44(4):371-4 (9 ref.)

Magnetic resonance imaging in osteoporosis. Majumdar S, et al. **Eur J Radiol** 1995 Sep;20(3):193-7 (26 ref.)

Osteoporosis: using 'bone markers' for diagnosis and monitoring. Arnaud CD. **Geriatrics** 1996 Apr;51(4):24-30 (25 ref.)

Osteoporosis: diagnosis and treatment. Lane JM, et al. **J Bone Joint Surg Am** 1996 Apr;78(4):618-32 (141 ref.)

Osteonecrosis, transient osteoporosis, and transient bone marrow edema: current concepts. Froberg PK, et al. **Radiol Clin North Am** 1996 Mar;34(2):273-91, x (63 ref.)

[Transient osteoporosis of the hip. Presentation of a case and literature review] Leyes Vence M, et al. **Acta Orthop Belg** 1996 Mar;62(1):56-9 (6 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

Osteoporosis prevention and treatment. Bellantoni MF. **Am Fam Physician** 1996 Sep 1;54(3):986-92, 995-6 (31 ref.)

Approach to discovering novel therapeutic agents for osteoporosis based on integrin receptor blockade. Chorev M, et al. **Biopolymers** 1995;37(6):367-75 (44 ref.)

Maintenance therapy for added bone mass or how to keep the profit after withdrawal of therapy of osteopenia. Jee WS, et al. **Bone** 1995 Oct;17(4 Suppl):309S-319S (49 ref.)

Prevention of hip fractures: drug therapy. Lips P. **Bone** 1996 Mar;18(3 Suppl):159S-163S (46 ref.)

Assessing bone quality--animal models in preclinical osteoporosis research. Mosekilde L. **Bone** 1995 Oct;17(4 Suppl):343S-352S (35 ref.)

Osteoporosis into the year 2010. Mundy GR. **Br J Obstet Gynaecol** 1996 May;103 Suppl 13:32-7; discussion 37-8 (46 ref.)

Nandrolone decanoate: pharmacological properties and therapeutic use in osteoporosis. Geusens P. **Clin Rheumatol** 1995 Sep;14 Suppl 3:32-9 (52 ref.)

Transcription factors as drug targets: opportunities for therapeutic selectivity. Butt TR, et al. **Gene Expr** 1995; 4(6):319-36 (137 ref.)

Osteoporosis: diagnosis and treatment. Lane JM, et al. **J Bone Joint Surg Am** 1996 Apr;78(4):618-32 (141 ref.)

Some aspects of the anabolic action of parathyroid hormone. Martin TJ, et al. **Miner Electrolyte Metab** 1995; 21(1-3):87-90 (25 ref.)

Vitamin D in the treatment of osteoporosis revisited. Fujita T. **Proc Soc Exp Biol Med** 1996 Jun;212(2):110-5 (76 ref.)

Recent developments in the chemotherapy of osteoporosis. Dwivedy I, et al. **Prog Drug Res** 1995;45:289-338 (326 ref.)

[Administration of vitamin D3 and its active metabolites in the prevention and treatment of osteoporosis] Lips P. **Ned Tijdschr Geneeskd** 1996 Jan 13;140(2):65-8 (34 ref.) **(Dut)**

[Estrogen agonists, especially raloxifene, in the treatment of osteoporosis] Lips P, et al. **Ned Tijdschr Geneeskd** 1996 Jun 8;140(23):1215-7 (31 ref.) **(Dut)**

[Place of ipriflavone in the therapy of osteoporosis] Zsuzsanna B. **Acta Pharm Hung** 1995 Nov;65(6):229-32 (32 ref.) (Eng. Abstr.) **(Hun)**

[Rational bases for the treatment of osteoporosis] Adami S, et al. **Ann Ital Med Int** 1995 Oct;10 Suppl:18S-21S (29 ref.) (Eng. Abstr.) **(Ita)**

[Agonists-antagonists of estrogens, their potential use in prophylaxis and treatment of osteoporosis] Hoszowski K. **Pol Tyg Lek** 1995 Nov;50(44-47):41-2 (16 ref.) (Eng. Abstr.) **(Pol)**

[Use of bisphosphates in treatment of primary and secondary osteoporosis] Olszyński WP. **Pol Tyg Lek** 1995 Nov; 50(44-47):56-8 (6 ref.) (Eng. Abstr.) **(Pol)**

ECONOMICS

Social and economic impact of osteoporosis. A review of the literature. Schütte HE. **Eur J Radiol** 1995 Sep; 20(3):165-9 (18 ref.)

EPIDEMIOLOGY

Osteoporosis. Frequency, consequences, and risk factors. Ross PD. **Arch Intern Med** 1996 Jul 8;156(13):1399-411 (214 ref.)

Epidemiology of hip fractures: implications of the exponential increase with age. Melton LJ 3rd. **Bone** 1996 Mar;18(3 Suppl):121S-125S (53 ref.)

The worldwide problem of osteoporosis: insights afforded by epidemiology. Riggs BL, et al. **Bone** 1995 Nov;17(5 Suppl):505S-511S (47 ref.)

The epidemiology of osteoporosis. Dennison E, et al. **Br J Clin Pract** 1996 Jan-Feb;50(1):33-6 (24 ref.)

The epidemiology of osteoporosis. The oriental perspective in a world context. Lau EM, et al. **Clin Orthop** 1996 Feb; (323):65-74 (76 ref.)

ETIOLOGY

Pathogenesis of osteoporosis. Johnston CC Jr, et al. **Bone** 1995 Aug;17(2 Suppl):19S-22S (30 ref.)

Osteoporosis in rheumatoid arthritis. Dequeker J, et al. **Clin Exp Rheumatol** 1995 Sep-Oct;13 Suppl 12:S21-6 (60 ref.)

Biophysical parameters affecting osteoporosis. Behari J. **Crit Rev Biomed Eng** 1994;22(2):69-137 (637 ref.)

The impact of bone loss in women with endometriosis. Stevenson JC. **Int J Gynaecol Obstet** 1995 Sep;50 Suppl 1:S11-5 (26 ref.)

Clinical review 76: The nature of osteoporosis. Marcus R. **J Clin Endocrinol Metab** 1996 Jan;81(1):1-5 (36 ref.)

Fracturing osteoporosis after kidney transplantation--what are the options? Coen G. **Nephrol Dial Transplant** 1996 Apr;11(4):567-9 (17 ref.)

Cytokines and osteoporosis [editorial] Cohen-Solal M, et al. **Rev Rhum Engl Ed** 1996 Feb;63(2):83-6 (19 ref.)

[Bone disorders in intestinal cryptogenetic inflammatory diseases] Abitbol V, et al. **Gastroenterol Clin Biol** 1995 Oct; 19(10):826-32 (54 ref.) **(Fre)**

[Sports, bones and hormones. Multiple interactions (editorial)] Maugars Y, et al. **Presse Med** 1995 Sep 30; 24(28):1284-6 (15 ref.) (Eng. Abstr.) **(Fre)**

[Osteoporosis in ankylosing spondylitis] Toussirot E, et al. **Presse Med** 1996 Apr 27;25(15):720-4 (32 ref.) (Eng. Abstr.) **(Fre)**

[The pathogenesis, diagnosis and therapy of posttransplantation osteoporosis] Hofbauer LC, et al. **Dtsch Med Wochenschr** 1996 Jul 26;121(30):953-7 (45 ref.) **(Ger)**

[Osteoporosis following heart transplantation. Pathogenesis and therapy] Stempfle HU. **Dtsch Med Wochenschr** 1996 Sep 6;121(36):1103-7 (44 ref.) **(Ger)**

[The bones and their diseases. VI. The origin of "secondary" osteoporosis] Ziegler R. **Dtsch Med Wochenschr** 1995 Oct 20;120(42):1445-6 (0 ref.) **(Ger)**

[Generalized osteoporosis in chronic polyarthritis--pathomechanisms and treatment approaches] Ringe JD. **Z Rheumatol** 1996 May-Jun;55(3):149-57 (49 ref.) (Eng. Abstr.) **(Ger)**

[Effects of essential trace elements on bone turnover--in relation to the osteoporosis] Okano T. **Nippon Rinsho** 1996 Jan;54(1):148-54 (20 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Is osteoporosis a genetically determined disease? Kelly PJ. **Br J Obstet Gynaecol** 1996 May;103 Suppl 13:20-6; discussion 26-7 (50 ref.)

Vitamin D receptor gene alleles and osteoporosis: an affirmative view [editorial] Eisman JA. **J Bone Miner Res** 1995 Sep;10(9):1289-93 (43 ref.)

METABOLISM

The skeleton as an ion exchange system: implications for the role of acid-base imbalance in the genesis of osteoporosis. Barzel US. **J Bone Miner Res** 1995 Oct;10(10):1431-6 (31 ref.)

[Vitamin D and osteoporosis] Ljunghall S, et al. **Nord Med** 1995;110(10):253-7 (11 ref.) (Eng. Abstr.) **(Swe)**

NURSING

Patient care of osteoporosis. Recker RR, et al. **Clin Geriatr Med** 1995 Nov;11(4):625-40 (29 ref.)

PHYSIOPATHOLOGY

The epidemiology of peripheral fractures. Baron JA, et al. **Bone** 1996 Mar;18(3 Suppl):209S-213S (29 ref.)

Nutritional aspects of hip fractures. Bonjour JP, et al. **Bone** 1996 Mar;18(3 Suppl):139S-144S (87 ref.)

The natural history of osteoporosis. Ballard PA, et al. **Br J Hosp Med** 1996 Apr 17-30;55(8):503-7 (24 ref.)

Sex steroids, cytokines and the bone marrow: new concepts on the pathogenesis of osteoporosis. Manolagas SC, et al. **Ciba Found Symp** 1995;191:187-96; discussion 197-202 (45 ref.)

SLE and osteoporosis: dependence and/or independence on glucocorticoids. Sels F, et al. **Lupus** 1996 Apr;5(2):89-92 (23 ref.)

The interrelationships of body fat, exercise, and hormonal status and their impact on reproduction and bone health. Ramos RH, et al. **Semin Perinatol** 1995 Jun;19(3):163-70 (53 ref.)

[Bone structure and mechanical resistance of the bone tissue] Benhamou CL, et al. **Presse Med** 1996 Feb 17;25(6):249-54 (43 ref.) (Eng. Abstr.) **(Fre)**

[Bones and bone diseases. Part V: Pathogenesis of type-II osteoporosis] Ziegler R. **Dtsch Med Wochenschr** 1995 Oct 6;120(40):1367-8 (00 ref.) **(Ger)**

[Pregnancy-associated osteoporosis] Ohana N, et al. **Harefuah** 1996 Mar 1;130(5):344-6 (32 ref.) **(Heb)**

[The physiopathology of osteoporosis: the role of local factors] Girasole G, et al. **Ann Ital Med Int** 1995 Oct;10 Suppl:9S-17S (70 ref.) (Eng. Abstr.) **(Ita)**

[Vitamin D and osteoporosis] Hoszowski K. **Pol Tyg Lek** 1995 Nov;50(44-47):53-5 (29 ref.) (Eng. Abstr.) **(Pol)**

[Physiologic principles of osteoporosis] Otfinowski J, et al. **Przegl Lek** 1996;53(1):26-8 (17 ref.) (Eng. Abstr.) **(Pol)**

PREVENTION & CONTROL

Osteoporosis prevention and treatment. Bellantoni MF. **Am Fam Physician** 1996 Sep 1;54(3):986-92, 995-6 (31 ref.)

Osteoporosis and exercise. Mosekilde L. **Bone** 1995 Sep; 17(3):193-5 (42 ref.)

The role of bisphosphonates in the prevention and treatment of osteoporosis. Reginster JY. **Clin Rheumatol** 1995 Sep;14 Suppl 3:22-5 (25 ref.)

Current and future nonhormonal approaches to the treatment of osteoporosis. Bilezikian JP. **Int J Fertil Menopausal Stud** 1996 Mar-Apr;41(2):148-55 (45 ref.)

Strategies for the prevention of senile (type II) osteoporosis: an update. Boonen S, et al. **J Intern Med** 1996 May; 239(5):383-91 (107 ref.)

Calcium, why and how much? Palmieri GM. **Miner Electrolyte Metab** 1995;21(1-3):236-41 (44 ref.)

[Prevention of osteoporosis--why? Who? How?] Siggelkow H, et al. **Med Klin** 1995 Nov 15;90(11):639-44 (43 ref.) **(Ger)**

[Overview of clinical studies with ipriflavone] Attila BK. **Acta Pharm Hung** 1995 Nov;65(6):223–8 (20 ref.) (Eng. Abstr.) **(Hun)**
[The ipriflavone story] György L, et al. **Acta Pharm Hung** 1995 Nov;65(6):191–4 (20 ref.) (Eng. Abstr.) **(Hun)**
[Place of ipriflavone in the therapy of osteoporosis] Zsuzsanna B. **Acta Pharm Hung** 1995 Nov;65(6):229–32 (32 ref.) (Eng. Abstr.) **(Hun)**

PSYCHOLOGY

Social and economic impact of osteoporosis. A review of the literature. Schütte HE. **Eur J Radiol** 1995 Sep; 20(3):165–9 (18 ref.)

RADIOGRAPHY

Bone densitometry: patients with end-stage renal disease. Erlichman M, et al. **Health Technol Assess** 1996 Mar; (8):1–27 (174 ref.)

REHABILITATION

[Rehabilitation tactics in osteoporosis] Lesiak A, et al. **Pol Tyg Lek** 1995 Nov;50(44–47):66–7 (12 ref.) **(Pol)**

SURGERY

Osteoporosis—a modifying factor of surgical treatment. Perlaky G, et al. **Acta Med Hung** 1994;50(3–4):245–56 (8 ref.)

THERAPY

Present and future of osteoporosis therapy. Seeman E, et al. **Bone** 1995 Aug;17(2 Suppl):23S–29S (47 ref.)
Patient care of osteoporosis. Recker RR, et al. **Clin Geriatr Med** 1995 Nov;11(4):625–40 (29 ref.)
Office management of osteoporosis: a guide for the primary care provider. Daly PA. **Compr Ther** 1995 Oct; 21(10):565–74 (57 ref.)
Biophysical parameters affecting osteoporosis. Behari J. **Crit Rev Biomed Eng** 1994;22(2):69–137 (637 ref.)
Managing osteoporosis. **Drug Ther Bull** 1996 Jun;34(6):45–8 (34 ref.)
[Recent progress in treatment of osteoporosis] Hosoi T. **Nippon Ronen Igakkai Zasshi** 1996 Apr;33(4):240–4 (16 ref.) (Eng. Abstr.) **(Jpn)**
[Can parathormone be used to treat osteoporosis?] Hoppe A. **Pol Tyg Lek** 1995 Nov;50(44–47):59–61 (36 ref.) **(Pol)**

ULTRASONOGRAPHY

Ultrasound measurement of bone. van Daele PL, et al. **Clin Endocrinol (Oxf)** 1996 Apr;44(4):363–9 (52 ref.)
On measuring bone to predict osteoporotic fracture: moving beyond statistical inference [editorial; comment] Beck TJ. **Radiology** 1996 Jun;199(3):612–4 (25 ref.) Comment on: Radiology 1996 Jun;199(3):725–32.

OSTEOPOROSIS, AGE-RELATED see **OSTEOPOROSIS**

OSTEOPOROSIS, POST-TRAUMATIC see **REFLEX SYMPATHETIC DYSTROPHY**

OSTEOPOROSIS, POSTMENOPAUSAL

Osteoporosis. It steals more than bone. Galsworthy TD, et al. **Am J Nurs** 1996 Jun;96(6):26–33; quiz 34 (10 ref.)
Osteoporosis: taking a fresh look. Barzel US. **Hosp Pract (Off Ed)** 1996 May 15;31(5):59–64, 67–8 (6 ref.)
Osteoporosis as a model for the long-term clinical consequences of the menopause. Kleerekoper M, et al. **Prog Cardiovasc Dis** 1995 Nov-Dec;38(3):181–8 (36 ref.)

COMPLICATIONS

Insufficiency fractures of the sacrum and os pubis. Peh WC, et al. **Br J Hosp Med** 1995 Jun 21-Jul 11;54(1):15–9 (20 ref.)

DRUG THERAPY

Prevention and treatment of osteoporosis [see comments] Chapuy MC, et al. **Aging (Milano)** 1995 Aug;7(4):164–73 (93 ref.) Comment in: Aging (Milano) 1995 Aug;7(4):161–3.
Safe play for osteoporosis? [editorial; comment] Sartori L. **Aging (Milano)** 1995 Aug;7(4):161–3 (15 ref.) Comment on: Aging (Milano) 1995 Aug;7(4):164–73.
An overview of the results of clinical trials with alendronate, a promising treatment of osteoporosis in postmenopausal women. Hirsch LJ, et al. **Ann Ital Med Int** 1995 Oct;10 Suppl:22S–28S (41 ref.)
Tiludronate: development as an osteoporosis therapy. Chesnut CH 3rd. **Bone** 1995 Nov;17(5 Suppl):517S–519S (16 ref.)
Treatable and untreatable risk factors for hip fracture. Cummings SR. **Bone** 1996 Mar;18(3 Suppl):165S–167S (20 ref.)
Prevention of hip fractures: drug therapy. Lips P. **Bone** 1996 Mar;18(3 Suppl):159S–163S (46 ref.)
Critical drug appraisal: etidronate intermittent cyclic therapy for postmenopausal osteoporosis. Miller PD. **Br J Clin Pract** 1996 Jan-Feb;50(1):23–31 (71 ref.)
Hormone replacement therapy and diabetes mellitus. Dunne FP, et al. **Clin Endocrinol (Oxf)** 1996 Jun;44(6):615–20 (48 ref.)
Fluoride therapy of type I osteoporosis. Devogelaer JP, et al. **Clin Rheumatol** 1995 Sep;14 Suppl 3:26–31 (57 ref.)
Comparative clinical pharmacology and therapeutic use of bisphosphonates in metabolic bone diseases. Rosen CJ, et al. **Drugs** 1996 Apr;51(4):537–51 (80 ref.)
Treatment options for osteoporosis. Khosla S, et al. **Mayo Clin Proc** 1995 Oct;70(10):978–82 (17 ref.)
Small bone-building fragments of parathyroid hormone: new therapeutic agents for osteoporosis. Whitfield JF, et al. **Trends Pharmacol Sci** 1995 Nov;16(11):382–6 (47 ref.)
[Progestins and osteoporosis. Does progestin contribute to the effectiveness of estrogen replacement therapy in menopause?] Lopes P. **Rev Fr Gynecol Obstet** 1995 May-Jun;90(5–6):307–8 (17 ref.) **(Fre)**

EPIDEMIOLOGY

Osteoporosis. Frequency, consequences, and risk factors. Ross PD. **Arch Intern Med** 1996 Jul 8;156(13):1399–411 (214 ref.)
The worldwide problem of osteoporosis: insights afforded by epidemiology. Riggs BL, et al. **Bone** 1995 Nov;17(5 Suppl):505S–511S (47 ref.)

ETIOLOGY

Pathogenesis of osteoporosis. Johnston CC Jr, et al. **Bone** 1995 Aug;17(2 Suppl):19S–22S (30 ref.)
Evolution of the pathogenesis of postmenopausal bone loss. Kalu DN. **Bone** 1995 Oct;17(4 Suppl):135S–144S (60 ref.)

METABOLISM

The role of bone turnover in the pathophysiology of osteoporosis. Riis BJ. **Br J Obstet Gynaecol** 1996 May;103 Suppl 13:9–14; discussion 14–5 (18 ref.)

PHYSIOPATHOLOGY

Drug therapy for vertebral fractures in osteoporosis: evidence that decreases in bone turnover and increases in bone mass both determine antifracture efficacy. Riggs BL, et al. **Bone** 1996 Mar;18(3 Suppl):197S–201S (26 ref.)
Vertebral fracture epidemiology. Wasnich RD. **Bone** 1996 Mar;18(3 Suppl):179S–183S (24 ref.)

PREVENTION & CONTROL

Prevention and treatment of osteoporosis [see comments] Chapuy MC, et al. **Aging (Milano)** 1995 Aug;7(4):164–73 (93 ref.) Comment in: Aging (Milano) 1995 Aug;7(4):161–3.
Safe play for osteoporosis? [editorial; comment] Sartori L. **Aging (Milano)** 1995 Aug;7(4):161–3 (15 ref.) Comment on: Aging (Milano) 1995 Aug;7(4):164–73.
Bone-sparing properties of oral contraceptives. DeCherney A. **Am J Obstet Gynecol** 1996 Jan;174(1 Pt 1):15–20 (25 ref.)
Using functional loading to influence bone mass and architecture: objectives, mechanisms, and relationship with estrogen of the mechanically adaptive process in bone. Lanyon LE. **Bone** 1996 Jan;18(1 Suppl):37S–43S (74 ref.)
HRT, a general practice approach: how to reach the most vulnerable. Coope JK, et al. **Br J Clin Pract** 1996 Jan-Feb; 50(1):38–43 (67 ref.)
Comment: preventive strategies: is current clinical practice effective for bones? Rowe R. **Br J Clin Pract** 1996 Jan-Feb; 50(1):47–9 (8 ref.)
Prevention of both osteoporosis and coronary heart disease in primary care. Waine C. **Br J Clin Pract** 1996 Jan-Feb; 50(1):44–6 (12 ref.)
Screening and treatment in the elderly to reduce osteoporotic fracture risk. Black DM. **Br J Obstet Gynaecol** 1996 May; 103 Suppl 13:2–7; discussion 7–8 (49 ref.)
The role of vitamin D and calcium supplementation in the prevention of osteoporotic fractures in the elderly. Compston JE. **Clin Endocrinol (Oxf)** 1995 Oct; 43(4):393–405 (146 ref.)
Calcitonin for prevention and treatment of postmenopausal osteoporosis. Body JJ. **Clin Rheumatol** 1995 Sep;14 Suppl 3:18–21 (22 ref.)
Role of calcium and vitamin D in the prevention and the treatment of postmenopausal osteoporosis: an overview. Kaufman JM. **Clin Rheumatol** 1995 Sep;14 Suppl 3:9–13 (46 ref.)
The case for postmenopausal hormone therapy. Speroff L. **Hosp Pract (Off Ed)** 1996 Feb 15;31(2):75–89 (13 ref.)
Estrogen therapy for postmenopausal symptoms and prevention of osteoporosis. Sagraves R. **J Clin Pharmacol** 1995 Sep;35(9 Suppl):2S–10S (46 ref.)
Phytoestrogens—a short review. Knight DC, et al. **Maturitas** 1995 Nov;22(3):167–75 (89 ref.)
Anabolic effects of insulin on bone suggest a role for chromium picolinate in preservation of bone density. McCarty MF. **Med Hypotheses** 1995 Sep;45(3):241–6 (69 ref.)
Preventing and treating osteoporosis. Woolf A. **Practitioner** 1996 Apr;240(1561):244–6 (6 ref.)
Practical aspects of hormone replacement therapy. Thorneycroft IH. **Prog Cardiovasc Dis** 1995 Nov-Dec; 38(3):243–54 (83 ref.)
Postmenopausal estrogen replacement therapy in the patient with breast carcinoma. Cyr MG. **R I Med** 1995 Sep; 78(9):261–3 (23 ref.)
Estrogen replacement therapy in the elderly. Paganini-Hill A. **Zentralbl Gynakol** 1996;118(5):255–61 (41 ref.)
[Hormone replacement therapy in menopausal women previously treated for breast cancer (editorial)] This P. **Presse Med** 1996 Feb 3;25(4):141–4 (25 ref.) (Eng. Abstr.) **(Fre)**
[Estrogen-gestagen substitution in geriatric gynecology. Long-term prevention for the third segment of life after menopause] Lauritzen C. **Fortschr Med** 1996 May 30; 114(15):187–90 (0 ref.) (Eng. Abstr.) **(Ger)**
[Estrogens in menopause—therapy and prevention. II. Estrogens and osteoporosis] Hüfner M. **Internist (Berl)** 1996 Apr;37(4):405–9 (50 ref.) **(Ger)**
[Prevention of osteoporosis—why? Who? How?] Siggelkow H, et al. **Med Klin** 1995 Nov 15;90(11):639–44 (43 ref.) **(Ger)**
[Value of transdermal hormone substitution for postmenopausal osteoporosis] Felsenberg D. **Zentralbl Gynakol** 1995;117(10):516–23 (47 ref.) (Eng. Abstr.) **(Ger)**

PSYCHOLOGY

The clinical impact of vertebral fractures: quality of life in women with osteoporosis. Gold DT. **Bone** 1996 Mar;18(3 Suppl):185S–189S (29 ref.)

THERAPY

Osteoporosis prevention and treatment with sex hormone replacement therapy. Rozenberg S, et al. **Clin Rheumatol** 1995 Sep;14 Suppl 3:14–7 (28 ref.)
Office management of osteoporosis: a guide for the primary care provider. Daly PA. **Compr Ther** 1995 Oct; 21(10):565–74 (57 ref.)
[Osteoporosis. 2] Fojtík Z, et al. **Vnitr Lek** 1995 Dec; 41(12):851–7 (43 ref.) (Eng. Abstr.) **(Cze)**

OSTEOPOROSIS, SENILE see **OSTEOPOROSIS**

OSTEORADIONECROSIS

THERAPY

Irradiated bone and its management. Costantino PD, et al. **Otolaryngol Clin North Am** 1995 Oct;28(5):1021–38 (29 ref.)

OSTEOSARCOMA

Osteosarcoma and its variants. Vander Griend RA. **Orthop Clin North Am** 1996 Jul;27(3):575–81 (30 ref.)
Cancer of bone in children. Jaffe N. **Pediatr Dent** 1995 Jul-Aug;17(4):263–7 (56 ref.)
Primary renal osteosarcoma. Case report and review of the literature. Messen S, et al. **Urol Int** 1995;55(3):158–61 (17 ref.)
[Osteosarcoma of the liver] Itoh A, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):360–2 (19 ref.) **(Jpn)**

COMPLICATIONS

Osteogenic sarcoma in a child with transfusion-dependent Diamond-Blackfan anemia. Aquino VM, et al. **J Pediatr Hematol Oncol** 1996 May;18(2):230–2 (17 ref.)
Osteogenic sarcoma in the Rothmund-Thomson syndrome. Leonard A, et al. **Med Pediatr Oncol** 1996 Apr;26(4):249–53 (22 ref.)

DIAGNOSIS

Extraosseous osteogenic sarcoma of the mediastinum occurring in a Chinese patient. Lin J, et al. **Clin Oncol (R Coll Radiol)** 1995;7(3):200–1 (10 ref.)
Intracortical low grade osteosarcoma. A unique case and review of the literature on intracortical osteosarcoma. Blasius S, et al. **Gen Diagn Pathol** 1996 Mar;141(3–4):273–8 (22 ref.)
Giant bone island of femur. Case report, literature review, and its distinction from low grade osteosarcoma. Brien EW, et al. **Skeletal Radiol** 1995 Oct;24(7):546–50 (15 ref.)
High-grade surface osteosarcoma of the humerus. Okada K, et al. **Skeletal Radiol** 1995 Oct;24(7):531–4 (15 ref.)
[Vertebral osteosarcoma. Review of the literature apropos of a case] Peyrade F, et al. **Bull Cancer (Paris)** 1995 Jul; 82(7):551–6 (31 ref.) (Eng. Abstr.) **(Fre)**
[Transitional-cell sarcomatoid carcinoma of the renal pelvis with osteoclast-type giant cells. Review of the literature] Meseguer García P, et al. **Actas Urol Esp** 1996 Jan; 20(1):63–7 (26 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Anaphylactoid reactions to methotrexate. Alkins SA, et al. **Cancer** 1996 May 15;77(10):2123–6 (13 ref.)
The role of chemotherapy in osteogenic sarcoma. Bramwell VH. **Crit Rev Oncol Hematol** 1995 Aug;20(1–2):61–85 (187 ref.)
Chemotherapy in osteosarcoma. Basis for application and antagonism to implementation; early controversies surrounding its implementation. Jaffe N, et al. **Hematol Oncol Clin North Am** 1995 Aug;9(4):825–40 (79 ref.)

OSTEOSARCOMA

Can amputation be avoided in local recurrence after limb salvage for high grade osteosarcoma? A case report and a review of the literature. Babin SR, et al. **Int Orthop** 1995; 19(6):374–6 (10 ref.)
Tumor size and prognosis in aggressively treated osteosarcoma. Bieling P, et al. **J Clin Oncol** 1996 Mar; 14(3):848–58 (38 ref.)
[Chemotherapy of osteogenic sarcomas] Brain E, et al. **Chirurgie** 1994–95;120(13):193–8 (70 ref.) **(Fre)**
[Role of chemotherapy in treatment of osteosarcoma] Perek D, et al. **Pediatr Pol** 1995 Nov;70(11):939–47 (39 ref.) (Eng. Abstr.) **(Pol)**

ETIOLOGY

Paget sarcoma of the cervical vertebrae: an autopsy case report and review of the literature. Matsukuma S, et al. **Pathol Int** 1995 Nov;45(11):885–9 (27 ref.)

GENETICS

Osteosarcoma and other tumors of bone. Mertens WC, et al. **Curr Opin Oncol** 1995 Jul;7(4):349–54 (40 ref.)
[Osteosarcoma in 2 siblings. A case report] Danckwerth F, et al. **Klin Padiatr** 1995 Sep–Oct;207(5):298–301 (41 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

BK virus–induced osteosarcoma (Os515) as a model of human osteosarcoma. Sekiguchi M, et al. **Anticancer Res** 1996 Jul–Aug;16(4A):1835–42 (40 ref.)
Paget's sarcoma of the mandible. Gleich LL, et al. **Head Neck** 1995 Sep–Oct;17(5):425–30 (20 ref.)
Osteosarcoma. Specimen management following primary chemotherapy. Raymond AK, et al. **Hematol Oncol Clin North Am** 1995 Aug;9(4):841–67 (70 ref.)
Tumor size and prognosis in aggressively treated osteosarcoma. Bieling P, et al. **J Clin Oncol** 1996 Mar; 14(3):848–58 (38 ref.)
Chondroblastic osteosarcoma of the mandible: report of a case. Kawasaki T, et al. **J Oral Maxillofac Surg** 1996 Sep; 54(9):1123–7 (11 ref.)
Paget sarcoma of the cervical vertebrae: an autopsy case report and review of the literature. Matsukuma S, et al. **Pathol Int** 1995 Nov;45(11):885–9 (27 ref.)
Osteogenic sarcoma of the tongue. Case report and review of the literature. Loyzaga JM, et al. **Pathol Res Pract** 1996 Jan;192(1):75–8; discussion 79–80 (9 ref.)
Malignant bone tumors of childhood. Himelstein BP, et al. **Pediatr Clin North Am** 1996 Aug;43(4):967–84 (38 ref.)

RADIOGRAPHY

Pictorial review: Imaging of primary osteosarcoma of the spine. Green R, et al. **Clin Radiol** 1996 May;51(5):325–9 (22 ref.)

SECONDARY

Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide. Kleinerman ES. **Hematol Oncol Clin North Am** 1995 Aug;9(4):927–38 (37 ref.)

SURGERY

Can amputation be avoided in local recurrence after limb salvage for high grade osteosarcoma? A case report and a review of the literature. Babin SR, et al. **Int Orthop** 1995; 19(6):374–6 (10 ref.)
Consolidation of massive bone allografts in limb-preserving operations for bone tumours. San Julian Aranguren M, et al. **Int Orthop** 1995;19(6):377–82 (53 ref.)
Multifocal osteolysis following limb-sparing procedures: imaging findings and a review of the literature. Kaste SC, et al. **Pediatr Radiol** 1996;26(2):158–61 (17 ref.)
Limb salvage procedures in osteosarcomas around the knee joint. Rodrigu.z Merchán EC, et al. **Rev Paul Med** 1994 Oct–Dec;112(4):661–7 (42 ref.)

THERAPY

New aspects in the treatment of bone sarcomas. Szendröi M. **Acta Med Hung** 1994;50(3–4):237–44 (14 ref.)
Osteosarcoma and other tumors of bone. Mertens WC, et al. **Curr Opin Oncol** 1995 Jul;7(4):349–54 (40 ref.)
Osteoma of the long bones and the spine. A study of eleven patients and a review of the literature. Peyser AB, et al. **J Bone Joint Surg Am** 1996 Aug;78(8):1172–80 (20 ref.)
Current combined treatment of high-grade osteosarcomas. Damron TA, et al. **Oncology (Huntingt)** 1995 Apr; 9(4):327–43; discussion 343–4, 347–50 (54 ref.)

OSTEOSCLEROSIS

ETIOLOGY

[En-plaque meningioma as a rare cause of an osteosclerotic bone tumor of the frontal bone] Steidle B, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1995 Oct;163(4):350–2 (10 ref.) **(Ger)**

RADIOGRAPHY

[Imaging of osteosclerotic metastases] Feydy A, et al. **J Radiol** 1995 Sep;76(9):561–72 (61 ref.) (Eng. Abstr.) **(Fre)**

OSTEOSCLEROSIS FRAGILIS see **OSTEOPETROSIS**

OSTEOSYNTHESIS, FRACTURE see **FRACTURE FIXATION, INTERNAL**

OSTEOSYNTHESIS, FRACTURE, INTRAMEDULLARY see **FRACTURE FIXATION, INTRAMEDULLARY**

OSTEOTOMY

Traumatic plastic deformity of an adult forearm: case report and literature review. Simonian PT, et al. **J Orthop Trauma** 1996;10(3):213–5 (12 ref.)

ADVERSE EFFECTS

Complications of distal first metatarsal osteotomies. Laughlin TJ. **J Foot Ankle Surg** 1995 Nov–Dec;34(6):524–31; discussion 593–4 (46 ref.)

METHODS

Congenital radioulnar synostosis. Surgical correction by derotational osteotomy. Castelló JR, et al. **Ann Chir Main Memb Super** 1996;15(1):11–7 (8 ref.)
The stability of facial osteotomies. Part 6. Chin setback. Hoffman GR, et al. **Aust Dent J** 1996 Jun;41(3):178–83 (21 ref.)
The stability of facial osteotomies. 3. Chin advancement. Hoffman GR, et al. **Aust Dent J** 1995 Oct;40(5):289–95 (28 ref.)
Radiographic course after acetabuloplasty and femoral osteotomy in hip dysplasia. Fritsch EW, et al. **Clin Orthop** 1996 Feb;(323):215–25 (52 ref.)
Osteotomies about the hip for the prevention and treatment of osteoarthrosis. Millis MB, et al. **Instr Course Lect** 1996; 45:209–26 (86 ref.)
Le Fort 1 downfracture approach for the treatment of a posterior maxillary ameloblastoma. Symington OG, et al. **J Can Dent Assoc** 1995 Dec;61(12):1048–52 (24 ref.)
Cuneiform and cuboid wedge osteotomies for correction of residual metatarsus adductus: a surgical review. Brink DS, et al. **J Foot Ankle Surg** 1995 Jul–Aug;34(4):371–8 (26 ref.)
Transfibular osteotomy in the correction of ankle joint incongruity. Davis JL, et al. **J Foot Ankle Surg** 1995 Jul–Aug;34(4):389–99 (23 ref.)
[Bimaxillary segmental osteotomies] Gattinger B, et al. **Fortschr Kiefer Gesichtschir** 1995;40:32–41 (39 ref.) **(Ger)**
[Surgical treatment of obstructive sleep apnea by maxillary and mandibular osteotomy] Hochban W, et al. **Fortschr Kiefer Gesichtschir** 1995;40:65–72 (28 ref.) **(Ger)**
[Complications in bimaxillary surgical interventions] Sailer HF, et al. **Fortschr Kiefer Gesichtschir** 1995;40:41–9 (65 ref.) **(Ger)**
[Predictive soft tissue factors in bimaxillary operations] Steinhäuser EW, et al. **Fortschr Kiefer Gesichtschir** 1995; 40:50–7 (31 ref.) **(Ger)**
[Stabilization of interligamentous valgus procedure in tibial head osteotomy using staples] Zügel N, et al. **Z Orthop Ihre Grenzgeb** 1995 Sep–Oct;133(5):437–41 (31 ref.) (Eng. Abstr.) **(Ger)**

OTALGIA see **EARACHE**

OTA'S NEVUS see **NEVUS OF OTA**

OTC DRUGS see **DRUGS, NON-PRESCRIPTION**

OTITIS EXTERNA

Otitis externa. Management in the primary care office. Mirza N. **Postgrad Med** 1996 May;99(5):153–4, 157–8 (9 ref.)

OTITIS MEDIA

COMPLICATIONS

Lateral sinus thrombosis associated with otitis media and mastoiditis in children. Garcia RD, et al. **Pediatr Infect Dis J** 1995 Jul;14(7):617–23 (35 ref.)

DIAGNOSIS

Acute otitis media: making an accurate diagnosis. Weiss JC, et al. **Am Fam Physician** 1996 Mar;53(4):1200–6 (24 ref.)
Concise review for primary-care physicians. Swanson JA, et al. **Mayo Clin Proc** 1996 Feb;71(2):179–83 (12 ref.)

DRUG THERAPY

Ototoxicity of ear drops: a clinical perspective. Linder TE, et al. **Am J Otol** 1995 Sep;16(5):653–7 (23 ref.)
Management of otitis media. A review. Liston TE. **Clin Pediatr (Phila)** 1995 Oct;34(10):542–8 (53 ref.)
Management of acute otitis media and glue ear. **Drug Ther Bull** 1995 Feb;33(2):12–5 (52 ref.)
Concise review for primary-care physicians. Swanson JA, et al. **Mayo Clin Proc** 1996 Feb;71(2):179–83 (12 ref.)

SURGERY

Chronic otitis media after tympanostomy tube placement caused by Mycobacterium abscessus: a new clinical entity? Franklin DJ, et al. **Am J Otol** 1994 May;15(3):313–20 (21 ref.)
Epitympanic compartment surgical considerations: reevaluation. Palva T, et al. **Am J Otol** 1995 Jul; 16(4):505–13 (24 ref.)
Tympanic membrane wound healing. An overview. Gladstone HB, et al. **Otolaryngol Clin North Am** 1995 Oct; 28(5):913–32 (111 ref.)
[Audiometric results of 81 ossiculoplasties after tympanoplasty with closed technique in chronic cholesteatomatous otitis] Caprio D, et al. **Ann Otolaryngol Chir Cervicofac** 1995;112(3):107–17 (16 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Management of acute and chronic otitis media in pediatric practice. Berman S. **Curr Opin Pediatr** 1995 Oct; 7(5):513–22 (62 ref.)
What to expect from medical treatment of otitis media. Rosenfeld RM. **Pediatr Infect Dis J** 1995 Sep;14(9):731–7; quiz 738 (27 ref.)
Options for treating otitis media. McLay K. **Practitioner** 1996 Jan;240(1558):42–7 (10 ref.)

OTITIS MEDIA, PURULENT see **OTITIS MEDIA, SUPPURATIVE**

OTITIS MEDIA, SECRETORY see **OTITIS MEDIA WITH EFFUSION**

OTITIS MEDIA, SEROUS see **OTITIS MEDIA WITH EFFUSION**

OTITIS MEDIA, SUPPURATIVE

MICROBIOLOGY

Alcaligenes xylosoxidans subsp xylosoxidans in children with chronic otorrhea. Wintermeyer SM, et al. **Otolaryngol Head Neck Surg** 1996 Feb;114(2):332–4 (15 ref.)

OTITIS MEDIA WITH EFFUSION

Middle ear effusion. Bassila MK. **J Med Liban** 1994; 42(4):227–9 (22 ref.)

COMPLICATIONS

Otogenic Fusobacterium necrophorum meningitis in children. Figueras G, et al. **Pediatr Infect Dis J** 1995 Jul; 14(7):627–8 (10 ref.)

DRUG THERAPY

Rational selection of antimicrobials for pediatric upper respiratory infections. Harrison CJ. **Pediatr Infect Dis J** 1995 Jul;14(7 Suppl):S121–9 (28 ref.)

ETIOLOGY

Middle ear effusion—allergy relationships [see comments] Mattucci KF, et al. **Ear Nose Throat J** 1995 Nov; 74(11):752–6, 758 (18 ref.) Comment in: Ear Nose Throat J 1995 Nov;74(11):739.
Role of allergy in eustachian tube blockage and otitis media with effusion: a review. Bernstein JM. **Otolaryngol Head Neck Surg** 1996 Apr;114(4):562–8 (28 ref.)

PHYSIOPATHOLOGY

[Otitis media with effusion in children] Zielnik B. **Otolaryngol Pol** 1995;49(3):214–9 (53 ref.) (Eng. Abstr.) **(Pol)**

SURGERY

Implications of middle ear hyperoxia induced by ventilation tubes in otitis media with effusion. Ovesen T. **APMIS Suppl** 1995;54:1–36 (233 ref.)
The management of childhood otitis media with effusion. Mills R. **J R Soc Med** 1996 Mar;89(3):132–4 (36 ref.)

THERAPY

Management of acute otitis media and glue ear. **Drug Ther Bull** 1995 Feb;33(2):12–5 (52 ref.)

OTOACOUSTIC EMISSIONS, SPONTANEOUS

Bilateral evoked otoacoustic emissions in a child with bilateral profound hearing loss. Laccourreye L, et al. **Ann Otol Rhinol Laryngol** 1996 Apr;105(4):286–8 (15 ref.)
Tinnitus and otoacoustic emissions. Ceranic BJ, et al. **Clin Otolaryngol** 1995 Jun;20(3):192–200 (89 ref.)

PHYSIOLOGY

Otoacoustic emissions. Richardson M. **Arch Dis Child** 1995 Oct;73(4):284–6 (34 ref.)

OTOLARYNGOLOGY

see related
OTORHINOLARYNGOLOGIC DISEASES

TRENDS

What's new in otorhinolaryngology. Miller RH. **J Am Coll Surg** 1996 Feb;182(2):139–44 (23 ref.)

OTOLOGY see OTOLARYNGOLOGY

OTORHINOLARYNGOLOGIC DISEASES

see related
EAR DISEASES
LARYNGEAL DISEASES
NOSE DISEASES
PHARYNGEAL DISEASES

Primary care for women. Management of common problems of the head and neck. Phillips LP, et al. **J Nurse Midwifery** 1996 Mar–Apr;41(2):101–16 (55 ref.)

DIAGNOSIS

[Modern radiologic diagnosis for the ENT physician] Dammann F, et al. **HNO** 1995 Oct;43(10):590–5 (17 ref.) (Eng. Abstr.) **(Ger)**

[Modern neuroradiologic diagnosis and interventional strategies for the ENT physician] Hofmann E, et al. **HNO** 1995 Oct;43(10):584–9 (29 ref.) (Eng. Abstr.) **(Ger)**

[Medical ENT diagnosis and therapy of sleep–associated respiratory disorders with obstruction of the upper airways] Riechelmann H, et al. **Pneumologie** 1995 Oct;49(10):523–7 (33 ref.) **(Ger)**

[Facial and cervical manifestations of AIDS] Gebrim EM, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1995 Jul–Aug; 50(4):222–6 (22 ref.) (Eng. Abstr.) **(Por)**

ETIOLOGY

Passive smoking. Lejeune HB, et al. **J La State Med Soc** 1995 Oct;147(10):444–7 (17 ref.)

[Hemorrhage from the ORL area] Baerthold W. **Z Arztl Fortbild (Jena)** 1995 Dec;89(7):703–6 (0 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Review of uses of the laryngeal mask in ENT anaesthesia [see comments] Nair I, et al. **Anaesthesia** 1995 Oct; 50(10):898–900 (27 ref.) Comment in: Anaesthesia 1996 Apr;51(4):409.

Lasers in otorhinolaryngology–head and neck surgery. Rebeiz EE. **J Med Liban** 1994;42(4):242–9 (21 ref.)

Choice of wound dressings and ointments. Brown CD, et al. **Otolaryngol Clin North Am** 1995 Oct;28(5):1081–91 (52 ref.)

Respiratory mucosa wound healing and its management. An overview. Dohar JE, et al. **Otolaryngol Clin North Am** 1995 Oct;28(5):897–912 (28 ref.)

Wound healing after laser surgery. Hendrick DA, et al. **Otolaryngol Clin North Am** 1995 Oct;28(5):969–86 (89 ref.)

Cutaneous wound healing. An overview. Koopmann CF Jr. **Otolaryngol Clin North Am** 1995 Oct;28(5):835–45 (14 ref.)

Methods and materials for wound closure. Reiter D. **Otolaryngol Clin North Am** 1995 Oct;28(5):1069–80 (64 ref.)

Management of scar contractures, hypertrophic scars, and keloids. Sherris DA, et al. **Otolaryngol Clin North Am** 1995 Oct;28(5):1057–68 (29 ref.)

Cartilage wound healing. An overview. Silver FH, et al. **Otolaryngol Clin North Am** 1995 Oct;28(5):847–64 (81 ref.)

Facial bone wound healing. An overview. Szachowicz EH. **Otolaryngol Clin North Am** 1995 Oct;28(5):865–80 (35 ref.)

[Hemorrhagic complications of ORL surgery] Boisson–Bertrand D, et al. **Cah Anesthesiol** 1995; 43(5):489–95 (48 ref.) **(Fre)**

[Heart arrest in children after intravenous injection of succinylcholine in the ENT operating room (see comments)] Schulte–Sasse U. **HNO** 1995 Nov;43(11):676–9 (29 ref.) (Eng. Abstr.) Comment in: Hosp Formul 1995 Nov;43(11):640–1. **(Ger)**

THERAPY

[Manual medicine in otorhinolaryngology. Theoretical principles— clinical practice—principles of therapy and prevention] Seifert K. **Laryngorhinootologie** 1995 Oct; 74(10):583–90 (38 ref.) (Eng. Abstr.) **(Ger)**

OTORHINOLARYNGOLOGIC NEOPLASMS

DIAGNOSIS

[Modern radiologic diagnosis for the ENT physician] Dammann F, et al. **HNO** 1995 Oct;43(10):590–5 (17 ref.) (Eng. Abstr.) **(Ger)**

[Modern neuroradiologic diagnosis and interventional strategies for the ENT physician] Hofmann E, et al. **HNO** 1995 Oct;43(10):584–9 (29 ref.) (Eng. Abstr.) **(Ger)**

RADIOTHERAPY

[Intraoperative radiotherapy of ORL cancers. Review of the literature] Demange L. **Bull Cancer Radiother** 1996; 83(2):75–8 (25 ref.) (Eng. Abstr.) **(Fre)**

[Contribution of curietherapy in the treatment of ENT tumors] Beauvois S. **Rev Med Brux** 1996 Apr;17(2):86–90 (23 ref.) (Eng. Abstr.) **(Fre)**

[Radiotherapy of ENT tumors and risk of lymphedema] Ewald H. **Z Lymphol** 1996 Jun;20(1):21–6 (10 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

The infected wound and its management. Bumpous JM, et al. **Otolaryngol Clin North Am** 1995 Oct;28(5):987–1001 (44 ref.)

OTORHINOLARYNGOLOGY see OTOLARYNGOLOGY

OTOSCLEROSIS

see related
FENESTRATION

PATHOLOGY

[Pathogenesis of otosclerosis. "State of the art"] Arnold W, et al. **HNO** 1996 Mar;44(3):121–9 (61 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Long–term hearing results following stapedotomy. Dornhoffer JL, et al. **Am J Otol** 1994 Sep;15(5):674–8 (14 ref.)

OTOSPONGIOSIS see OTOSCLEROSIS

OUABAIN

BLOOD

Endogenous ouabain, sodium balance and blood pressure: a review and a hypothesis [see comments] Hamlyn JM, et al. **J Hypertens** 1996 Feb;14(2):151–67 (136 ref.) Comment in: J Hypertens 1996 Feb;14(2):169–71.

Endogenous ouabain, sodium balance and blood pressure [comment] Pidgeon GB, et al. **J Hypertens** 1996 Feb; 14(2):169–71 (28 ref.) Comment on: J Hypertens 1996 Feb;14(2):151–67.

OUTBREAKS see DISEASE OUTBREAKS

OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE)

The effectiveness of psychotherapy. The Consumer Reports study. Seligman ME. **Am Psychol** 1995 Dec;50(12):965–74 (11 ref.)

Psychiatric nursing outcome research: the state of the science. Merwin E, et al. **Arch Psychiatr Nurs** 1995 Dec;9(6):311–31 (101 ref.)

Current status of family–based outcome and process research. Diamond GS, et al. **J Am Acad Child Adolesc Psychiatry** 1996 Jan;35(1):6–16 (120 ref.)

An approach to psychotherapy change process research: introduction to the special section. Greenberg LS, et al. **J Consult Clin Psychol** 1996 Jun;64(3):435–8 (27 ref.)

Bridging the gap between laboratory and clinic in child and adolescent psychotherapy. Weisz JR, et al. **J Consult Clin Psychol** 1995 Oct;63(5):688–701 (70 ref.)

Implant prosthodontic treatment options for the edentulous patient. Zarb GA, et al. **J Oral Rehabil** 1995 Aug; 22(8):661–71 (17 ref.)

Patient satisfaction with nursing care as an outcome variable: dilemmas for nursing evaluation researchers. Lin CC. **J Prof Nurs** 1996 Jul–Aug;12(4):207–16 (47 ref.)

Clinical economics and noncoronary vascular disease. Schwartz JS. **J Vasc Interv Radiol** 1995 Nov–Dec;6(6 Pt 2 Su):116S–124S (16 ref.)

Strategies to Prevent and Control the Emergence and Spread of Antimicrobial–Resistant Microorganisms in Hospitals. A challenge to hospital leadership [see comments] Goldmann DA, et al. **JAMA** 1996 Jan 17;275(3):234–40 (81 ref.) Comment in: JAMA 1996 May 22–29;275(20):1544.

Quality and effectiveness issues related to oral health. Antczak–Bouckoms A. **Med Care** 1995 Nov;33(11 Suppl):NS123–42 (60 ref.)

Classics in Spine. Surgery literature revisited. Bessette L, et al. **Spine** 1996 Feb 1;21(3):259–63 (13 ref.)

Reducing risks in blood transfusion: process and outcome. McClelland DB, et al. **Transfus Med** 1996 Mar;6(1):1–10 (35 ref.)

Performance measurement in prostate cancer care: beyond report cards. Ullman M, et al. **Urology** 1996 Mar; 47(3):356–65 (80 ref.)

[Emotion–focused couples therapy—treatment approach—evaluating effectiveness and process research] Heekerens HP. **Z Klin Psychol Psychopathol Psychother** 1995;43(4):308–24 (50 ref.) (Eng. Abstr.) **(Ger)**

[Methodologic decisions in evaluation of psychotherapy] Langenmayr A, et al. **Z Klin Psychol Psychopathol Psychother** 1995;43(4):273–90 (60 ref.) (Eng. Abstr.) **(Ger)**

ORGANIZATION & ADMINISTRATION

Quality in residency training: toward a broader, multidimensional definition. Elliott RL, et al. **Acad Med** 1996 Mar;71(3):243–7 (15 ref.)

Quality assurance and medical outcomes in the era of cost containment. Campion FX, et al. **Surg Clin North Am** 1996 Feb;76(1):139–59 (35 ref.)

TRENDS

What will be the outcome of the outcomes movement? Braithwaite J, et al. **Aust N Z J Med** 1995 Dec;25(6):731–5 (49 ref.)

Why it is important to demonstrate linkages between outcomes of care and processes and structures of care. Hammermeister KE, et al. **Med Care** 1995 Oct;33(10 Suppl):OS5–16 (58 ref.)

OUTCOME ASSESSMENT (HEALTH CARE)

Overview of pharmacoeconomics and pharmaceutical outcomes evaluations. Reeder CE. **Am J Health Syst Pharm** 1995 Oct 1;52(19 Suppl 4):S5–8 (4 ref.)

Approaches for assessing the efficacy of occupational health and safety standards. Stayner L, et al. **Am J Ind Med** 1996 Apr;29(4):353–7 (12 ref.)

Strong quasi–experimental designs for research on the effectiveness of rehabilitation. Johnston MV, et al. **Am J Phys Med Rehabil** 1995 Sep–Oct;74(5):383–92 (50 ref.)

Organizational redesign: effect on institutional and consumer outcomes. Ingersoll GL. **Annu Rev Nurs Res** 1996; 14:121–43 (52 ref.)

Disability as a public health outcome in the aging population. Guralnik JM, et al. **Annu Rev Public Health** 1996;17:25–46 (98 ref.)

Quality of life measures. Carr AJ, et al. **Br J Rheumatol** 1996 Mar;35(3):275–81 (63 ref.)

Review of outcome instruments for evaluation of anterior cruciate ligament reconstruction. Vangsness CT Jr, et al. **Bull Hosp Jt Dis** 1995;54(1):25–9 (29 ref.)

Prevention. How much harm? How much benefit? 2. Ten potential pitfalls in determining the clinical significance of benefits. Marshall KG. **Can Med Assoc J** 1996 Jun 15; 154(12):1837–43 (61 ref.)

Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome [see comments] Marshall JC, et al. **Crit Care Med** 1995 Oct;23(10):1638–52 (40 ref.) Comment in: Crit Care Med 1995 Oct;23(10):1619–20. Comment in: Crit Care Med 1996 Jul;24(7):1272–3.

Update on measurement of relevant outcomes in rheumatology. Pioro MH, et al. **Curr Opin Rheumatol** 1996 Mar;8(2):101–5 (35 ref.)

The outcomes movement and new measures of the severity of psoriasis. Mckenna KE, et al. **J Am Acad Dermatol** 1996 Mar;34(3):534–8 (47 ref.)

Nutritional status outcomes for children: ethnic, cultural, and environmental contexts. Bronner YL. **J Am Diet Assoc** 1996 Sep;96(9):891–903 (88 ref.)

Health–related quality of life as an outcome for patients with heart failure. Shively M, et al. **J Cardiovasc Nurs** 1996 Jan; 10(2):89–96 (14 ref.)

An overview of self–reported outcome assessment in dental research. Reisine S. **J Dent Educ** 1996 Jun;60(6):488–93 (25 ref.)

Informed decisions about protecting and promoting public health: rationale for a National Human Exposure Assessment Survey. Sexton K, et al. **J Expo Anal Environ Epidemiol** 1995 Jul–Sep;5(3):233–56 (52 ref.)

Methodologic issues regarding outcome measures for clinical drug trials of psychiatric complications in dementia. Teri L, et al. **J Geriatr Psychiatry Neurol** 1995 Oct;8 Suppl 1:S8–17 (63 ref.)

A conceptual framework for understanding outcomes of oral implant therapy. Guckes AD, et al. **J Prosthet Dent** 1996 Jun;75(6):633–9 (76 ref.)

Evaluating the effectiveness of addiction treatments: reasonable expectations, appropriate comparisons. McLellan AT, et al. **Milbank Q** 1996;74(1):51–85 (69 ref.)

Impact of quality of life outcomes on clinical practice. Ganz PA. **Oncology (Huntingt)** 1995 Nov;9(11 Suppl):61–5 (37 ref.)

Including oncology outcomes of care in the computer–based patient record. McCormick KA. **Oncology (Huntingt)** 1995 Nov;9(11 Suppl):161–7 (44 ref.)

Quality of life: an overview of the concept and measures. Dedhiya S, et al. **Pharm World Sci** 1995 Sep 22;17(5):141–8 (48 ref.)

Outcomes in cardiopulmonary rehabilitation. Pashkow P. **Phys Ther** 1996 Jun;76(6):643–56 (164 ref.)

Promises and limitations of the Patient Outcome Research Teams: the low–back pain example. Deyo RA. **Proc Assoc Am Physicians** 1995 Oct;107(3):324–8 (22 ref.)

Using prediction models and cost–effectiveness analysis to improve clinical decisions: emergency department patients

with acute chest pain. Goldman L.
Proc Assoc Am Physicians 1995 Oct;107(3):329–33 (22 ref.)
Rheumatoid arthritis. Outcome measures. Paulus HE, et al.
Rheum Dis Clin North Am 1995 Aug;21(3):605–18 (52 ref.)
Assessment of long-term outcomes of rheumatoid arthritis. How choices of measures and study designs may lead to apparently different conclusions. Pincus T.
Rheum Dis Clin North Am 1995 Aug;21(3):619–54 (112 ref.)
Clinical and public health perspectives and applications of health-related quality of life measurement. Ebrahim S.
Soc Sci Med 1995 Nov;41(10):1383–94 (68 ref.)
Evaluating the efficacy of medical treatment: possibilities and limitations. Jenkinson C. **Soc Sci Med** 1995 Nov; 41(10):1395–401 (49 ref.)
[QALYS or not QALYS: that is the question?] Moatti JP, et al. **Rev Epidemiol Sante Publique** 1995 Dec;43(6):573–83 (27 ref.) (Eng. Abstr.) **(Fre)**
[Assessment of disease course in chronic rheumatoid arthritis: new quantitative dimensions for clinical practice] Stucki G, et al. **Schweiz Med Wochenschr** 1995 Oct 21; 125(42):2003–14 (39 ref.) (Eng. Abstr.) **(Ger)**
[The measurement of outcomes in chronic pathology. Its application to arthritis] Zeni L. **Minerva Med** 1995 May; 86(5):215–22 (35 ref.) **(Ita)**

ECONOMICS

The use of condition specific outcome measures in economic appraisal. Brazier J, et al. **Health Econ** 1995 Jul-Aug; 4(4):255–64 (35 ref.)
Economic analysis alongside clinical trials: practical considerations. The Economics Workgroup. Drummond M, et al. **J Rheumatol** 1995 Jul;22(7):1418–9 (4 ref.)
Economic analysis alongside clinical trials: problems and potential. Drummond M. **J Rheumatol** 1995 Jul; 22(7):1403–7 (15 ref.)
OMERACT II: the biologics perspective. Strand V.
J Rheumatol 1995 Jul;22(7):1415–7 (24 ref.)

ORGANIZATION & ADMINISTRATION

Strategic service quality management for health care. Anderson EA, et al. **Am J Med Qual** 1996 Spring; 11(1):3–10 (48 ref.)
The imperative of outcome assessment in psychiatry. Sederer LI, et al. **Am J Med Qual** 1995 Fall;10(3):127–32 (32 ref.)
The challenge of health outcomes. Hall J.
J Qual Clin Pract 1996 Mar;16(1):5–15; discussion 17–8 (43 ref.)
Outcomes that provide evidence of change in cancer pain management. Dalton JA. **Nurs Clin North Am** 1995 Dec; 30(4):683–95 (53 ref.)

STATISTICS & NUMERICAL DATA

Multivariate statistical analysis for pathologist. Part I, The logistic model. Vollmer RT. **Am J Clin Pathol** 1996 Jan; 105(1):115–26 (16 ref.)
Outcomes monitoring: adjusting for risk factors, severity of illness, and complexity of care. Petryshen P, et al.
J Am Med Inform Assoc 1995 Jul-Aug;2(4):243–9 (40 ref.)
Statistical methods and strategies for working with large data bases. Marshall G, et al. **Med Care** 1995 Oct;33(10 Suppl):OS35–42 (20 ref.)

OUTCOME MEASUREMENT ERRORS see **BIAS (EPIDEMIOLOGY)**

OUTCOMES RESEARCH see **OUTCOME ASSESSMENT (HEALTH CARE)**

OUTER MEMBRANE PROTEINS, BACTERIAL see **BACTERIAL OUTER MEMBRANE PROTEINS**

OUTPATIENT CARE see **AMBULATORY CARE**

OUTPATIENT CLINICS see **AMBULATORY CARE FACILITIES**

OUTPATIENT CLINICS, HOSPITAL

see related
AMBULATORY CARE

ORGANIZATION & ADMINISTRATION

Haemophilia care in Zimbabwe. Adewuyi JO, et al.
Cent Afr J Med 1996 May;42(5):153–6 (15 ref.)

OUTPATIENT HEALTH SERVICES see **AMBULATORY CARE**

OUTPATIENT INFUSION THERAPY see **HOME INFUSION THERAPY**

OUTPATIENT MONITORING see **MONITORING, AMBULATORY**

OUTPATIENT SURGERY see **AMBULATORY SURGERY**

OVALBUMIN

ADMINISTRATION & DOSAGE

Effects of oral antigen in T-cell receptor transgenic mice. Hurst SD, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:163–73 (20 ref.)

GENETICS

Chicken ovalbumin upstream promoter-transcription factors and their regulation. Qiu Y, et al.
J Steroid Biochem Mol Biol 1996 Jan;56(1–6 Spec No):81–5 (30 ref.)

ISOLATION & PURIFICATION

On hen egg fractionation: applications of liquid chromatography to the isolation and the purification of hen egg white and egg yolk proteins. Awade AC.
Z Lebensm Unters Forsch 1996 Jan;202(1):1–14 (108 ref.)

OVARIAN CYCLE see **MENSTRUAL CYCLE**

OVARIAN CYSTS

see related
OVARIAN HYPERSTIMULATION SYNDROME

Hyperreactio luteinalis associated with pregnancy: a case report and review of the literature. Schnorr JA Jr, et al.
Am J Perinatol 1996 Feb;13(2):95–7 (6 ref.)
Ovarian cysts. Minelli L.
Eur J Obstet Gynecol Reprod Biol 1996 Mar;65(1):81–9 (106 ref.)
[Current approaches to the diagnosis and management of patients with tumors and tumor-like formations of the ovaries] Strizhakov AN, et al. **Akush Ginekol (Mosk)** 1995; (4):15–8 (82 ref.) **(Rus)**

CHEMICALLY INDUCED

[Lowering the steroid dose in oral contraception and risk of functional ovarian cysts] Mayenga JM, et al.
Contracept Fertil Sex 1995 Jul-Aug;23(7–8):439–41 (11 ref.) **(Fre)**
[Environmental pollutants in ovarian cysts] Rixner-Koschade R. **Arch Gynecol Obstet** 1995;257(1–4):117–21 (11 ref.) **(Ger)**

PATHOLOGY

Fine-needle aspiration cytology of the ovary. Ganjei P.
Clin Lab Med 1995 Sep;15(3):705–26 (19 ref.)
Pathology of ovarian cancer precursors. Scully RE.
J Cell Biochem Suppl 1995;23:208–18 (23 ref.)

RADIOGRAPHY

Dermoid cyst of the ovary: computed tomography diagnosis of an unusual case. Garant M, et al.
Can Assoc Radiol J 1996 Apr;47(2):107–10 (9 ref.)

SURGERY

The case for laparoscopic management of the adnexal mass. Parker WH. **Clin Obstet Gynecol** 1995 Jun;38(2):362–9 (32 ref.)
Laparoscopic oophorectomy. Russell JB.
Curr Opin Obstet Gynecol 1995 Aug;7(4):295–8 (20 ref.)
[Granulomatous peritonitis after laparoscopic surgery of an ovarian dermoid cyst. Diagnosis, management, prevention, a case report] Huss M, et al.
J Gynecol Obstet Biol Reprod (Paris) 1996;25(4):365–72 (54 ref.) (Eng. Abstr.) **(Fre)**
[Indications for celioscopic surgery in children (editorial)] Heloury Y. **Presse Med** 1995 Oct 14;24(30):1374–5 (9 ref.) **(Fre)**

OVARIAN DISEASES

COMPLICATIONS

Massive edema of the ovary associated with androgenic manifestations. Siller BS, et al. **South Med J** 1995 Nov; 88(11):1153–5 (45 ref.)

DIAGNOSIS

Malacoplakia. Two case reports and a comparison of treatment modalities based on a literature review. van der Voort HJ, et al. **Arch Intern Med** 1996 Mar 11; 156(5):577–83 (118 ref.)

ETIOLOGY

Ovarian remnant syndrome: experience at Jackson Memorial Hospital, University of Miami, 1985 through 1993. Lafferty HW, et al. **Am J Obstet Gynecol** 1996 Feb;174(2):641–5 (23 ref.)
Preovulatory overripeness of the oocyte as a cause of ovarian dysfunction in the human female. Smits LJ, et al.
Med Hypotheses 1995 Nov;45(5):441–8 (116 ref.)

SURGERY

Severe endometriosis and operative laparoscopy. Nezhat C, et al. **Curr Opin Obstet Gynecol** 1995 Aug;7(4):299–306 (55 ref.)
[Indications for celioscopic surgery in children (editorial)] Heloury Y. **Presse Med** 1995 Oct 14;24(30):1374–5 (9 ref.) **(Fre)**
[Neonatal ovarian endometriosis. Its conservative treatment] Díez García R, et al. **An Esp Pediatr** 1996 Apr;44(4):397–8 (16 ref.) **(Spa)**

OVARIAN FAILURE, PREMATURE

ETIOLOGY

[Physiopathologic anomalies in ovarian response] Christin-Maitre S, et al. **Contracept Fertil Sex** 1996 Feb; 24(2):105–10 (27 ref.) **(Fre)**

IMMUNOLOGY

Autoimmune premature ovarian failure. Kim JG, et al.
J Obstet Gynaecol 1995 Feb;21(1):59–66 (53 ref.)

PHYSIOPATHOLOGY

[Physiopathologic anomalies in ovarian response] Christin-Maitre S, et al. **Contracept Fertil Sex** 1996 Feb; 24(2):105–10 (27 ref.) **(Fre)**

OVARIAN FUNCTION TESTS

METHODS

[Evaluation of ovarian sensitivity to gonadotrophins: role of ovarian reserve tests] Hugues JN, et al.
Contracept Fertil Sex 1996 Apr;24(4):303–6 (23 ref.) (Eng. Abstr.) **(Fre)**

OVARIAN HYPERSTIMULATION SYNDROME

Diagnosis, prevention and management of ovarian hyperstimulation syndrome [see comments] Brinsden PR, et al. **Br J Obstet Gynaecol** 1995 Oct;102(10):767–72 (48 ref.) Comment in: Br J Obstet Gynaecol 1996 May;103(5):490.

CHEMICALLY INDUCED

[Update on ovarian hyperstimulation syndrome] Delbaere A, et al. **Rev Med Brux** 1995 Nov;16(5):354–60 (39 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

[Thromboembolism and ovarian hyperstimulation] Hocke C, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(7):691–6 (30 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Ovarian hyperstimulation syndrome may be more likely if multiple pregnancy occurs following assisted conception. Mathur RS, et al. **Acta Genet Med Gemellol (Roma)** 1995; 44(3-4):233–5 (15 ref.)

PHYSIOPATHOLOGY

The pathophysiology of ovarian hyperstimulation syndrome (OHSS). A proposal role of the ovarian derived prorenin to angiotensin cascade (ODPAC). Morris RS, et al.
Adv Exp Med Biol 1995;377:391–8 (37 ref.)

PREVENTION & CONTROL

The prevention of ovarian hyperstimulation syndrome. Mathur RS, et al. **Br J Obstet Gynaecol** 1996 Aug; 103(8):740–6 (64 ref.)
Ovarian hyperstimulation: effects of GnRH analogues. Triggering the final stage of ovulation using gonadotrophin-releasing hormone analogues: effective dose, prevention of ovarian hyperstimulation syndrome and the luteal phase. Ben-Arie A, et al. **Hum Reprod** 1996 Jun; 11(6):1146–8 (31 ref.)
Ovarian hyperstimulation: effects of GnRH analogues. Does triggering ovulation with gonadotrophin-releasing hormone analogue prevent severe ovarian hyperstimulation syndrome? Casper RF. **Hum Reprod** 1996 Jun;11(6):1144–6 (12 ref.)
Ovarian hyperstimulation: effects of GnRH analogues. Ovarian hyperstimulation syndrome after using gonadotrophin-releasing hormone analogue as a trigger of ovulation: causes and implications. Kol S, et al.
Hum Reprod 1996 Jun;11(6):1143–4 (15 ref.)

OVARIAN NEOPLASMS

see related
PSEUDOMYXOMA PERITONEI

Borderline ovarian tumors. Link CJ Jr, et al. **Am J Med** 1996 Aug;101(2):217–25 (70 ref.)
Ovarian cancer. Westhoff C. **Annu Rev Public Health** 1996; 17:85–96 (78 ref.)
Early ovarian cancer: a review of its genetic and biologic factors, detection, and treatment. Boente MP, et al.
Curr Probl Cancer 1996 Mar-Apr;20(2):83–137 (156 ref.)
Squamous cell carcinoma in the ovary of a 14-year-old girl. Khanfar NM, et al. **Mayo Clin Proc** 1996 Apr;71(4):380–3

(22 ref.)
The management of early ovarian cancer. Schilder RJ, et al. **Oncology (Huntingt)** 1995 Feb;9(2):171–82; discussion 185–7 (63 ref.)
[Molecular biology of epithelial ovarian carcinoma] Piura B, et al. **Harefuah** 1995 Nov 1;129(9):351–7 (42 ref.) **(Heb)**
[Current approaches to the diagnosis and management of patients with tumors and tumor-like formations of the ovaries] Strizhakov AN, et al. **Akush Ginekol (Mosk)** 1995; (4):15–8 (82 ref.) **(Rus)**

BLOOD

An ovarian tumor of probable Wolffian origin with hormonal function. Inoue H, et al. **Gynecol Oncol** 1995 Nov; 59(2):304–8 (11 ref.)

CHEMICALLY INDUCED

The risk of ovarian cancer after treatment for infertility. Bristow RE, et al. **Curr Opin Obstet Gynecol** 1996 Feb; 8(1):32–7 (35 ref.)
Postmenopausal estrogens and progestogens and the incidence of gynecologic cancer. Weiss NS, et al. **Maturitas** 1996 Mar;23(2):235–9 (43 ref.)

CHEMISTRY

Glycosylation of alpha-1-proteinase inhibitor and haptoglobin in ovarian cancer: evidence for two different mechanisms. Turner GA, et al. **Glycoconj J** 1995 Jun; 12(3):211–8 (62 ref.)
Biomarkers in the ovary. Berchuck A. **J Cell Biochem Suppl** 1995;23:223–6 (20 ref.)

CLASSIFICATION

[Classification of ovarian tumors based on embryogenesis] Minh HN, et al. **Arch Anat Cytol Pathol** 1995;43(3):126–39 (17 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

Ovarian hemangioma associated with concomitant stromal luteinization and ascites. Yamawaki T, et al. **Gynecol Oncol** 1996 Jun;61(3):438–41 (13 ref.)
Vesicle formation in dermatomyositis associated with gynecologic malignancies. Kubo M, et al. **J Am Acad Dermatol** 1996 Feb;34(2 Pt 2):391–4 (27 ref.)
Ovarian cancer and gangrene of the digits: case report and review of the literature. Chow SF, et al. **Mayo Clin Proc** 1996 Mar;71(3):253–8 (45 ref.)
[Favorable prognosis in a case of recurrent cerebral infarctions caused by chronic disseminated intravascular coagulation due to ovarian carcinoma] Izumi M, et al. **No To Shinkei** 1996 Jun;48(6):581–5 (16 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Is early detection of ovarian cancer possible? Schwartz PE, et al. **Ann Med** 1995 Oct;27(5):519–28 (46 ref.)
The emerging role of the physician in genetic counselling and testing for heritable breast, ovarian and colon cancer. Taylor KM, et al. **Can Med Assoc J** 1996 Apr 15; 154(8):1155–8 (23 ref.)
Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection. Berek JS, et al. **Cancer** 1995 Nov 15;76(10 Suppl):2092–6 (25 ref.)
Ovarian cancer screening. van Nagell JR Jr, et al. **Cancer** 1995 Nov 15;76(10 Suppl):2086–91 (27 ref.)
Pelvic masses and endoscopic surgery: diagnosis. Miralles RM. **Eur J Obstet Gynecol Reprod Biol** 1996 Mar; 65(1):75–9 (28 ref.)
Screening for ovarian cancer: what are the optimal surrogate endpoints for clinical trials? Karlan BY. **J Cell Biochem Suppl** 1995;23:227–32 (40 ref.)
Office laparoscopy as a screening tool for early detection of ovarian cancer. Runowicz CD. **J Cell Biochem Suppl** 1995;23:238–42 (12 ref.)
Early detection and screening for ovarian cancer. Schwartz PE, et al. **J Cell Biochem Suppl** 1995;23:233–7 (20 ref.)
Imaging of ovarian cancer. Forstner R, et al. **J Magn Reson Imaging** 1995 Sep–Oct;5(5):606–13 (82 ref.)
Magnetic resonance imaging of the ovary. Outwater EK, et al. **Magn Reson Imaging Clin N Am** 1994 May; 2(2):245–74 (104 ref.)
[Ovarian carcinoma in the elderly; a diagnostic and therapeutic dilemma] Wymenga AN, et al. **Ned Tijdschr Geneeskd** 1996 Mar 23;140(12):650–3 (42 ref.) **(Dut)**
[Study on the pretherapeutic differential diagnosis of adnexal tumors] Kunz J, et al. **Schweiz Rundsch Med Prax** 1995 Nov 14;84(46):1342–8 (39 ref.) (Eng. Abstr.) **(Ger)**
[Applications of tumor markers to the screening of endometrial and ovarian cancers] Nozawa S, et al. **Nippon Rinsho** 1996 Jun;54(6):1665–73 (19 ref.) (Eng. Abstr.) **(Jpn)**
[Primary malignant neoplasms of the female genitalia] Saraiva J, et al. **Acta Med Port** 1995 Oct;8(10):585–8 (11 ref.) (Eng. Abstr.) **(Por)**

DRUG THERAPY

The importance of dose and schedule in cancer chemotherapy: epithelial ovarian cancer. Mainwaring PN, et al. **Anticancer Drugs** 1995 Oct;6 Suppl 5:29–41 (116 ref.)
Promising new therapies in the treatment of advanced ovarian cancer. Runowicz CD, et al. **Cancer** 1995 Nov 15; 76(10 Suppl):2028–33 (37 ref.)
The search for optimal chemotherapy for advanced epithelial ovarian cancer. Harrington KJ, et al. **Clin Oncol (R Coll Radiol)** 1995;7(6):359–65 (63 ref.)
Chemotherapy for gynecologic malignancies. Vermorken JB, et al. **Curr Opin Oncol** 1995 Sep;7(5):457–65 (79 ref.)
Current drug treatment guidelines for epithelial ovarian cancer. Lorigan PC, et al. **Drugs** 1996 Apr;51(4):571–84 (65 ref.)
Paclitaxel in patients with platinum-resistant ovarian cancer: a selected review of literature and clinical experience. Kudelka AP, et al. **J Med Assoc Thai** 1996 Apr;79(4):240–5 (26 ref.)
Role of chemotherapy dose intensification in the treatment of advanced ovarian cancer. Fennelly D, et al. **Oncology (Huntingt)** 1995 Oct;9(10):911–21; discussion 922, 924, 926 (59 ref.)
Carboplatin versus cisplatin in ovarian cancer. Alberts DS. **Semin Oncol** 1995 Oct;22(5 Suppl 12):88–90 (6 ref.)
Ifosfamide in the treatment of ovarian cancer. Markman M. **Semin Oncol** 1996 Jun;23(3 Suppl 6):47–9 (22 ref.)
Current status of chemotherapy for ovarian cancer. Ozols RF. **Semin Oncol** 1995 Oct;22(5 Suppl 12):61–6 (33 ref.)
Combination regimens of paclitaxel and the platinum drugs as first-line regimens for ovarian cancer. Ozols RF. **Semin Oncol** 1995 Dec;22(6 Suppl 15):1–6 (17 ref.)
The role of paclitaxel in the management of coelomic epithelial carcinoma of the ovary: a review with emphasis on the Gynecologic Oncology Group experience. Thigpen T, et al. **Semin Oncol** 1995 Dec;22(6 Suppl 14):23–31 (30 ref.)
[Multidrug resistance—genes and chemotherapy of ovarian cancer] Leng J, et al. **Chung Hua I Hsueh Tsa Chih** 1995 Sep;75(9):567–9 (7 ref.) **(Chi)**
[Paclitaxel, a new anticancer drug] Jekunen A, et al. **Duodecim** 1994;110(13):1235–40 (39 ref.) **(Fin)**
[Carboplatin and etoposide combination for the treatment of recurrent epithelial ovarian cancer] Chauvergne J, et al. **Bull Cancer (Paris)** 1996 Apr;83(4):315–23 (52 ref.) (Eng. Abstr.) **(Fre)**
[Maintenance of the dose-intensity of chemotherapy combining carboplatin, cyclophosphamide, etoposide in women with ovarian cancer aged 70 and over] Delva R, et al. **Bull Cancer (Paris)** 1996 Jan;83(1):63–69 (36 ref.) (Eng. Abstr.) **(Fre)**
[Paclitaxel (Taxol)—drug of choice in ovarian cancer] Fishman A. **Harefuah** 1996 Apr 15;130(8):557–60 (47 ref.) **(Heb)**
[Chemotherapy for recurrent ovarian cancer] Nishimura H, et al. **Gan To Kagaku Ryoho** 1996 Aug;23(9):1124–8 (22 ref.) (Eng. Abstr.) **(Jpn)**
[The intraperitoneal chemotherapy of patients with ovarian cancer] Shparyk IaV, et al. **Vrach Delo** 1995 Jan–Feb; (1-2):29–35 (48 ref.) **(Ukr)**

EPIDEMIOLOGY

The epidemiology of ovarian cancer. Tortolero-Luna G, et al. **J Cell Biochem Suppl** 1995;23:200–7 (55 ref.)
[Epidemiology of ovarian cancer] Mosgaard BJ, et al. **Ugeskr Laeger** 1996 Sep 9;158(37):5150–3 (40 ref.) (Eng. Abstr.) **(Dan)**

ETIOLOGY

Ovulation induction, infertility, and ovarian cancer risk. Bristow RE, et al. **Fertil Steril** 1996 Oct;66(4):499–507 (49 ref.)
Mechanisms of hormone-mediated carcinogenesis of the ovary in mice. Capen CC, et al. **Mutat Res** 1995 Dec; 333(1-2):143–51 (23 ref.)
Hormones and cancer in humans. Key TJ. **Mutat Res** 1995 Dec;333(1-2):59–67 (85 ref.)
Chemically associated toxicity and carcinogenicity of the ovary. Davis BJ, et al. **Prog Clin Biol Res** 1996;394:285–308 (72 ref.)

GENETICS

BRCA1, a gene involved in inherited predisposition to breast and ovarian cancer. Feunteun J, et al. **Biochim Biophys Acta** 1996 Mar 18;1242(3):177–80 (42 ref.)
The genetics of breast and ovarian cancer. Ford D, et al. **Br J Cancer** 1995 Oct;72(4):805–12 (69 ref.)
Genetic counselling and testing for susceptibility to breast, ovarian and colon cancer: where are we today? Cole DE, et al. **Can Med Assoc J** 1996 Jan 15;154(2):149–55 (56 ref.)
Familial ovarian cancer. Update and clinical applications. Claus EB, et al. **Cancer** 1995 Nov 15;76(10 Suppl):1998–2003 (62 ref.)
The molecular basis of ovarian cancer. Gallion HH, et al. **Cancer** 1995 Nov 15;76(10 Suppl):1992–7 (37 ref.)
Hereditary breast and ovarian cancer: epidemiology, genetics, screening and predictive testing. Foulkes WD, et al. **Clin Invest Med** 1995 Dec;18(6):473–83 (52 ref.)
Genetic counseling for familial cancer risk. Weitzel JN. **Hosp Pract (Off Ed)** 1996 Feb 15;31(2):57–69 (17 ref.)
Inherited breast and ovarian cancer. Szabo CI, et al. **Hum Mol Genet** 1995;4 Spec No:1811–7 (64 ref.)
Molecular genetics of familial breast-ovarian cancer. van Rensburg EJ, et al. **J Clin Pathol** 1995 Sep;48(9):789–95 (64 ref.)
Translational research on hereditary colon, breast, and ovarian cancers. Li FP. **J Natl Cancer Inst Monogr** 1995; (17):1–4 (26 ref.)
Molecular genetic features of ovarian cancer. Berchuck A, et al. **Prog Clin Biol Res** 1996;394:269–84 (85 ref.)
Mutations of the BRCA1 gene in human cancer. Xu CF, et al. **Semin Cancer Biol** 1996 Feb;7(1):33–40 (63 ref.)
[Hereditary ovarian cancer syndrome] Chen W, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1996 Apr;31(4):249–51 (24 ref.) **(Chi)**
[Evaluation of prognostic factors in gynecological cancer examined by molecular biological study] Nagai N. **Gan To Kagaku Ryoho** 1996 Jul;23(8):1004–9 (27 ref.) (Eng. Abstr.) **(Jpn)**
[Familial ovarian cancer, uterine cancer] Fushiki H, et al. **Nippon Rinsho** 1995 Nov;53(11):2769–72 (20 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

The humoral hypercalcemia of benignancy. A newly appreciated syndrome [see comments] Knecht TP, et al. **Am J Clin Pathol** 1996 Apr;105(4):487–92 (42 ref.) Comment in: Am J Clin Pathol 1996 Apr;105(4):377–9.
Expression of alpha-fetoprotein by ovarian Sertoli-Leydig cell tumors. Case report and review of the literature. Hammad A, et al. **Arch Pathol Lab Med** 1995 Nov; 119(11):1075–9 (29 ref.)

PATHOLOGY

Hepatic metastases from granulosa cell tumor of the ovary: CT and sonographic findings. Neste MG, et al. **AJR Am J Roentgenol** 1996 May;166(5):1122–4 (8 ref.)
Expression of alpha-fetoprotein by ovarian Sertoli-Leydig cell tumors. Case report and review of the literature. Hammad A, et al. **Arch Pathol Lab Med** 1995 Nov; 119(11):1075–9 (29 ref.)
Luteinized thecoma with sclerosing peritonitis. Werness BA. **Arch Pathol Lab Med** 1996 Mar;120(3):303–6 (9 ref.)
Ovarian tumours in Africans: a study of 512 cases. Lancaster EJ, et al. **Cent Afr J Med** 1995 Aug;41(8):245–8 (13 ref.)
Fine-needle aspiration cytology of the ovary. Ganjei P. **Clin Lab Med** 1995 Sep;15(3):705–26 (19 ref.)
Epithelial neoplasms of the ovary. An update on current concepts. Gordon MD, et al. **Clin Lab Med** 1995 Sep; 15(3):575–93 (46 ref.)
New developments in sex cord-stromal and germ cell tumors of the ovary. Gordon MD, et al. **Clin Lab Med** 1995 Sep; 15(3):595–610 (50 ref.)
Squamous cell carcinoma arising from mature cystic teratoma: a report of three cases. Bontis J, et al. **Eur J Gynaecol Oncol** 1996;17(1):49–52 (20 ref.)
Thyroid carcinoma originating in a teratoma of the ovary. Ferrer J, et al. **Eur J Gynaecol Oncol** 1995;16(5):396–402 (24 ref.)
Primary lymphoma of the ovary. A case report and critical review of the literature. Granovsky-Grisaru S, et al. **Eur J Gynaecol Oncol** 1995;16(5):392–5 (14 ref.)
Laparoscopic surgical staging of ovarian cancer. Childers JM, et al. **Gynecol Oncol** 1995 Oct;59(1):25–33 (30 ref.)
Primary ovarian carcinoid tumors. Davis KP, et al. **Gynecol Oncol** 1996 May;61(2):259–65 (46 ref.)
Epithelial ovarian carcinoma metastatic to the central nervous system: a report on two cases with review of literature. Sood A, et al. **Gynecol Oncol** 1996 Jul; 62(1):113–8 (36 ref.)
Microinvasion in low malignant potential tumors of the ovary. Nayar R, et al. **Hum Pathol** 1996 Jun;27(6):521–7 (17 ref.)
Early de novo ovarian cancer and cancer developing in benign ovarian lesions. Scully RE. **Int J Gynaecol Obstet** 1995 Jul;49 Suppl:S9–15 (13 ref.)
Desmoplastic small cell tumor of the ovary: a unique polyphenotypic tumor with an unfavorable prognosis. Zaloudek C, et al. **Int J Gynecol Pathol** 1995 Jul;14(3):260–5 (28 ref.)
Pathology of ovarian cancer precursors. Scully RE. **J Cell Biochem Suppl** 1995;23:208–18 (23 ref.)
The efficacy of cranial irradiation in ovarian cancer metastatic to the brain: analysis of 32 cases. Corn BW, et al. **Obstet Gynecol** 1995 Dec;86(6):955–9 (17 ref.)
[Struma ovarii. A case report] Barhmi R, et al. **Rev Fr Gynecol Obstet** 1995 Dec;90(12):539–41 (10 ref.) (Eng. Abstr.) **(Fre)**
[Struma ovarii. Three malignant cases and one benign case] Gamoudi A, et al. **Rev Fr Gynecol Obstet** 1995 Dec; 90(12):542–7 (17 ref.) (Eng. Abstr.) **(Fre)**
[Value of prognostic factors in early stage ovarian carcinoma] Sevelda P. **Zentralbl Gynakol** 1996;118(6):326–9 (11 ref.) (Eng. Abstr.) **(Ger)**
[A mucinous ovarian tumor with foci of anaplastic carcinoma] Buzzi A, et al. **Minerva Ginecol** 1996 Apr; 48(4):163–6 (5 ref.) (Eng. Abstr.) **(Ita)**
[Rhombencephalic tissue in an ovarian teratoma with cerebellar foliation and maturation of the postnatal type] Fichera G. **Pathologica** 1995 Apr;87(2):203–10 (36 ref.) (Eng. Abstr.) **(Ita)**

OVARIAN NEOPLASMS

[Prognostic factors in ovarian epithelial cancer] Nishida T. **Gan To Kagaku Ryoho** 1996 May;23(6):805–9 (40 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

Tumor–stromal cytokine interactions in ovarian neoplasms. Kacinski BM. **EXS** 1995;74:181–90 (59 ref.)

PREVENTION & CONTROL

Prevention of ovarian cancer with bilateral oophorectomy at time of hysterectomy. McGuire PA, et al. **Alaska Med** 1996 Apr–Jun;38(2):69–70, 81 (13 ref.)

Genetic counselling and testing for susceptibility to breast, ovarian and colon cancer: where are we today? Cole DE, et al. **Can Med Assoc J** 1996 Jan 15;154(2):149–55 (56 ref.)

Potential criteria for cohort selection in chemoprevention trials of epithelial ovarian cancer. Baker VV. **J Cell Biochem Suppl** 1995;23:243–6 (19 ref.)

Molecular approaches to prevention and detection of epithelial ovarian cancer. Bast RC Jr, et al. **J Cell Biochem Suppl** 1995;23:219–22 (21 ref.)

Prospective on ovarian cancer: why prevent? Hoskins WJ. **J Cell Biochem Suppl** 1995;23:189–99 (15 ref.)

Strategies for phase II cancer chemoprevention trials: cervix, endometrium, and ovary. Kelloff GJ, et al. **J Cell Biochem Suppl** 1995;23:1–9 (51 ref.)

RADIONUCLIDE IMAGING

Monoclonal antibodies used in the detection and treatment of epithelial ovarian cancer. Muto MG, et al. **Cancer** 1995 Nov 15;76(10 Suppl):2016–27 (100 ref.)

[Methodology and clinical usefulness of radioimmunoimaging using radiolabeled monoclonal antibodies] Endo K, et al. **Nippon Rinsho** 1996 Jun;54(6):1604–9 (12 ref.) (Eng. Abstr.) **(Jpn)**

RADIOTHERAPY

Radioimmunotherapy of ovarian cancer. Syrigos KN, et al. **Hybridoma** 1995 Apr;14(2):121–4 (45 ref.)

SECONDARY

Prolactin–secreting pituitary carcinoma with implants in the cheek pouch and metastases to the ovaries. A case report and literature review. Gollard R, et al. **Cancer** 1995 Nov 15;76(10):1814–20 (43 ref.)

[Metastasizing pancreatic vipoma. Its diagnosis and therapy with the somatostatin analog octreotide] Scheffold N, et al. **Dtsch Med Wochenschr** 1995 Oct 27;120(43):1463–7 (21 ref.) (Eng. Abstr.) **(Ger)**

[Metastatic malignant melanoma of the ovary] Tribbia G, et al. **Minerva Ginecol** 1996 Apr;48(4):159–62 (10 ref.) (Eng. Abstr.) **(Ita)**

SURGERY

Second–look laparotomy for stage III epithelial ovarian cancer: rationale and current issues. Muderspach L, et al. **Cancer Treat Rev** 1996 Nov;21(6):499–511 (60 ref.)

Laparoscopic lymphadenectomy. Melendez TD, et al. **Curr Opin Obstet Gynecol** 1995 Aug;7(4):307–10 (20 ref.)

Surgery in ovarian cancer: the concept of cytoreductive surgery. Peter A, et al. **Curr Opin Obstet Gynecol** 1996 Feb;8(1):8–11 (15 ref.)

Primary ovarian carcinoid tumors. Davis KP, et al. **Gynecol Oncol** 1996 May;61(2):259–65 (46 ref.)

[Primary therapy of advanced ovarian carcinoma: current status and perspectives] Köchli OR, et al. **Gynakol Geburtshilfliche Rundsch** 1996;36(1):3–8 (25 ref.) (Eng. Abstr.) **(Ger)**

[The future of surgical gynecology: from dogma to science—from science to practice standard] Sevelda P. **Gynakol Geburtshilfliche Rundsch** 1995;35(3):149–52 (7 ref.) (Eng. Abstr.) **(Ger)**

[Characteristics of rare ovarian tumors—possibilities of organ preservation] Grischke EM, et al. **Zentralbl Gynakol** 1996; 118(6):322–5 (10 ref.) (Eng. Abstr.) **(Ger)**

[Results of fertility preserving operations in malignant ovarian tumors] Kleine W. **Zentralbl Gynakol** 1996; 118(6):317–21 (21 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Treatment of advanced epithelial ovarian cancer: past, present and future. Hoskins PJ. **Crit Rev Oncol Hematol** 1995 Aug;20(1–2):41–59 (201 ref.)

Prognosis and management of borderline tumours of the ovary. Tropé C, et al. **Curr Opin Obstet Gynecol** 1996 Feb; 8(1):12–6 (15 ref.)

Biologic therapies for gynecologic cancer. Bookman MA. **Curr Opin Oncol** 1995 Sep;7(5):478–84 (73 ref.)

A phase I study of intraperitoneal interferon–alpha 2b and intravenous cis–platinum plus cyclophosphamide chemotherapy in patients with untreated stage III epithelial ovarian cancer: a Gynecologic Oncology Group pilot study. Moore DH, et al. **Gynecol Oncol** 1995 Nov; 59(2):267–72 (25 ref.)

Outcome issues in ovarian cancer. Ozols RF. **Oncology (Huntingt)** 1995 Nov;9(11 Suppl):135–9 (33 ref.)

The treatment of early stage ovarian cancer. Young RC. **Semin Oncol** 1995 Oct;22(5 Suppl 12):76–9 (7 ref.)

Quality of life in patients with ovarian cancer: current state of research. Montazeri A, et al. **Support Care Cancer** 1996 May;4(3):169–79 (60 ref.)

[Ovarian carcinoma in the elderly; a diagnostic and therapeutic dilemma] Wymenga AN, et al. **Ned Tijdschr Geneeskd** 1996 Mar 23;140(12):650–3 (42 ref.) **(Dut)**

[Epithelial ovarian cancer: what is the consensus in 1995?] Chevallier B, et al. **Bull Cancer (Paris)** 1995 Nov; 82(11):923–8 (26 ref.) (Eng. Abstr.) **(Fre)**

[High–dose therapy and hematopoietic cell autotransplantation in the treatment of adult gynecologic tumors] Lotz JP, et al. **Contracept Fertil Sex** 1996 Apr; 24(4):307–18 (71 ref.) (Eng. Abstr.) **(Fre)**

[Therapeutic approach to epithelial cancer of the ovary at CHU Sart Tilman. Conclusions of the interdisciplinary meeting of 22 March 1995. Consensus Group] Jerusalem G, et al. **Rev Med Liege** 1995 Nov;50(11):469–71 (9 ref.) **(Fre)**

[Ovarian carcinoma—diagnosis and treatment. Consensus conference of the National Institute of Health] Bornkessel B. **Med Monatsschr Pharm** 1995 Oct;18(10):292–6 (0 ref.) **(Ger)**

[The postoperative therapy of epithelial ovarian carcinoma. Has systemic cytostasis replaced percutaneous radiation?] Souchon R, et al. **Strahlenther Onkol** 1995 Nov; 171(11):630–40 (83 ref.) (Eng. Abstr.) **(Ger)**

[High–dose chemotherapy (HDCT) with peripheral blood stem cell transplantation (PBSCT) in ovarian cancer patients with poor prognosis] Hayakawa S, et al. **Gan To Kagaku Ryoho** 1995 Oct;22(12):1756–61 (13 ref.) (Eng. Abstr.) **(Jpn)**

ULTRASONOGRAPHY

Controversies in assessment of ovarian tumors with transvaginal color Doppler ultrasound. Tekay A, et al. **Acta Obstet Gynecol Scand** 1996 Apr;75(4):316–29 (89 ref.)

Ovarian cancer screening. The role of ultrasound in early detection. Karlan BY, et al. **Cancer** 1995 Nov 15;76(10 Suppl):2011–5 (35 ref.)

Transvaginal color Doppler and pelvic tumor vascularity: lessons learned and future challenges. Kurjak A, et al. **Ultrasound Obstet Gynecol** 1995 Aug;6(2):145–59 (38 ref.)

[Assessing of ovarian physiology and pathology with color Doppler imaging] Tibi Y, et al. **Harefuah** 1995 Dec 1; 129(11):485–8 (38 ref.) **(Heb)**

VIROLOGY

Bilateral primary ovarian squamous cell carcinoma associated with human papilloma virus infection and vulvar and cervical intraepithelial neoplasia. A case report with review of the literature. Mai KT, et al. **Am J Surg Pathol** 1996 Jun;20(6):767–72 (23 ref.)

OVARIECTOMY

Prevention of ovarian cancer with bilateral oophorectomy at time of hysterectomy. McGuire PA, et al. **Alaska Med** 1996 Apr–Jun;38(2):69–70, 81 (13 ref.)

Laparoscopic oophorectomy. Russell JB. **Curr Opin Obstet Gynecol** 1995 Aug;7(4):295–8 (20 ref.)

[Primary therapy of advanced ovarian carcinoma: current status and perspectives] Köchli OR, et al. **Gynakol Geburtshilfliche Rundsch** 1996;36(1):3–8 (25 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Ovarian remnant syndrome: experience at Jackson Memorial Hospital, University of Miami, 1985 through 1993. Lafferty HW, et al. **Am J Obstet Gynecol** 1996 Feb;174(2):641–5 (23 ref.)

METHODS

[Ultrasonic diagnosis and laparoscopic treatment of an ovarian pregnancy. A case report and review of the literature] Riethmuller D, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(4):378–83 (25 ref.) (Eng. Abstr.) **(Fre)**

VETERINARY

[Urinary incontinence in castrated female dogs. 2. Therapy] Blendinger C, et al. **Tierarztl Prax** 1995 Aug;23(4):402–6 (30 ref.) (Eng. Abstr.) **(Ger)**

OVARY

see related
OVARIECTOMY

ABNORMALITIES

Hernia uteri (correction of: uterus) inguinale associated with unilateral renal agenesis. Keating JP, et al. **Aust N Z J Surg** 1995 Sep;65(9):688–90 (10 ref.)

CYTOLOGY

Gonadal cell apoptosis. Hsueh AJ, et al. **Recent Prog Horm Res** 1996;51:433–55; discussion 455–6 (66 ref.)

DRUG EFFECTS

Assessment of follicle destruction in chemical–induced ovarian toxicity. Hoyer PB, et al. **Annu Rev Pharmacol Toxicol** 1996;36:307–31 (122 ref.)

Mifepristone and ovarian function. Curry TE Jr, et al. **Clin Obstet Gynecol** 1996 Jun;39(2):486–97 (64 ref.)

The effects of ovulation induction with gonadotrophins on the ovary and uterus and implications for assisted reproduction. Balen A. **Hum Reprod** 1995 Sep;10(9):2233–7 (55 ref.)

Ovulation induction. Effects of ovulation induction with gonadotrophins on the ovary and uterus and their implications for assisted reproduction. Rojas FJ. **Hum Reprod** 1995 Sep;10(9):2219–24 (47 ref.)

Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. Bines J, et al. **J Clin Oncol** 1996 May;14(5):1718–29 (91 ref.)

EMBRYOLOGY

Sex differentiation — gonadogenesis and novel genes. Nordqvist K. **Int J Dev Biol** 1995 Oct;39(5):727–36 (76 ref.)

Molecular aspects of the ontogeny of the pituitary–gonadal axis. Huhtaniemi I. **Reprod Fertil Dev** 1995;7(5):1025–35 (57 ref.)

[Classification of ovarian tumors based on embryogenesis] Minh HN, et al. **Arch Anat Cytol Pathol** 1995;43(3):126–39 (17 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Regulation of angiotensin II receptor expression in ovarian follicles. A review. Nielsen AH, et al. **Adv Exp Med Biol** 1995;377:407–10 (19 ref.)

Progesterone receptors: expression and regulation in the mammalian ovary. Pinter JH, et al. **Clin Obstet Gynecol** 1996 Jun;39(2):424–35 (85 ref.)

Are estradiol–producing cells incompletely endowed? A chronicle of the emergence of certitude from conjecture. Lieberman S. **Gynecol Obstet Invest** 1996;41(3):147–72 (152 ref.)

Regulation of ovarian androgen production: a key parameter to success during ovarian stimulation? Andersen CY. **Hum Reprod** 1995 Sep;10(9):2227–33 (58 ref.)

[Progress in the study of inhibin subunit gene expression and regulation in mammalian ovary] Kong DJ, et al. **Sheng Li Ko Hsueh Chin Chan** 1995 Jul;26(3):204–8 (17 ref.) (Eng. Abstr.) **(Chi)**

PATHOLOGY

Fine–needle aspiration cytology of the ovary. Ganjei P. **Clin Lab Med** 1995 Sep;15(3):705–26 (19 ref.)

[Assessing of ovarian physiology and pathology with color Doppler imaging] Tibi Y, et al. **Harefuah** 1995 Dec 1; 129(11):485–8 (38 ref.) **(Heb)**

PHYSIOLOGY

The ovarian renin–angiotensin system. A paracrine–intracrine regulator of ovarian function. Pepperell JR, et al. **Adv Exp Med Biol** 1995;377:379–89 (85 ref.)

The ovarian insulin and insulin–like growth factor system with an emphasis on domestic animals. Spicer LJ, et al. **Domest Anim Endocrinol** 1995 Jul;12(3):223–45 (182 ref.)

Paracrine mechanism of ovarian regulation. Dor J, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Mar;65(1):25–8 (26 ref.)

Estrogen biosynthesis—regulation, action, remote effects, and value of monitoring in ovarian stimulation cycles. Shoham Z, et al. **Fertil Steril** 1996 Apr;65(4):687–701 (161 ref.)

Effects of aging on the female reproductive system. Pellicer A, et al. **Hum Reprod** 1995 Dec;10 Suppl 2:77–83 (37 ref.)

The human menopausal gonadotropin (hMG) dose in in vitro fertilization (IVF): what is the optimal dose? van Hooff MH. **J Assist Reprod Genet** 1995 Apr;12(4):233–5 (13 ref.)

The endocrinology of the menopause. Burger HG. **Maturitas** 1996 Mar;23(2):129–36 (44 ref.)

Apoptosis in the human female reproductive tract. Spencer SJ, et al. **Obstet Gynecol Surv** 1996 May;51(5):314–23 (103 ref.)

Menopause: the aging of multiple pacemakers. Wise PM, et al. **Science** 1996 Jul 5;273(5271):67–70 (67 ref.)

Ovarian regulation of sperm progression in the fallopian tubes. Hunter RH. **Zygote** 1994 Nov;2(4):363–6 (22 ref.)

[Assessing of ovarian physiology and pathology with color Doppler imaging] Tibi Y, et al. **Harefuah** 1995 Dec 1; 129(11):485–8 (38 ref.) **(Heb)**

[Regulation of hypothalamo–hypophyseal–ovarian function] Ibuki Y. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Aug;47(8):809–13 (15 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Corticotropin–releasing factor (CRF) and stress–related reproductive failure: the brain as a state of the art or the ovary as a novel clue? Nappi RE, et al. **J Endocrinol Invest** 1995 Dec;18(11):872–80 (89 ref.)

OVER–THE–COUNTER DRUGS see **DRUGS, NON–PRESCRIPTION**

OVERDENTURE see **DENTURE, OVERLAY**

OVERDOSE

Antidepressant toxicity and the need for identification and concentration monitoring in overdose. Power BM, et al. **Clin Pharmacokinet** 1995 Sep;29(3):154–71 (137 ref.)
Errors involving pediatric patients receiving chemotherapy: a literature review. Trinkle R, et al. **Med Pediatr Oncol** 1996 May;26(5):344–51 (47 ref.)

VETERINARY

Treatment of acute isoniazid overdose in dogs. Villar D, et al. **Vet Hum Toxicol** 1995 Oct;37(5):473–7 (50 ref.)

OVEREATING see **HYPERPHAGIA**

OVERUSE SYNDROMES see **REPETITION STRAIN INJURY**

OVERUTILIZATION OF HEALTH SERVICES see **HEALTH SERVICES MISUSE**

OVIDUCTS, MAMMALIAN see **FALLOPIAN TUBES**

OVINE CATARRHAL FEVER VIRUS see **BLUETONGUE VIRUS**

OVOCYTES see **OOCYTES**

OVULATION

DRUG EFFECTS

Pharmacological interventions for the induction of ovulation. Collins JA, et al. **Drugs** 1995 Sep;50(3):480–94 (91 ref.)
Gestodene. A review of its pharmacology, efficacy and tolerability in combined contraceptive preparations. Wilde MI, et al. **Drugs** 1995 Aug;50(2):364–95 (128 ref.)

PHYSIOLOGY

Ovarian follicular growth, ovulation and atresia. Endocrine, paracrine and autocrine regulation. Moley KH, et al. **Adv Exp Med Biol** 1995;377:103–19 (105 ref.)
Ovulation as a tissue remodelling process. Proteolysis and cumulus expansion. Tsafriri A. **Adv Exp Med Biol** 1995; 377:121–40 (191 ref.)

OVULATION DETECTION

METHODS

[Clinical study of ovulatory cervical mucus] Chrétien FC, et al. **Contracept Fertil Sex** 1996 May;24(5):359–67 (18 ref.) **(Fre)**

OVULATION INDUCTION

see related
OVARIAN HYPERSTIMULATION SYNDROME

The application of transvaginal ultrasound for ovulation induction and in vitro fertilization. Nachtigall MJ, et al. **Clin Obstet Gynecol** 1996 Mar;39(1):231–47 (72 ref.)
The role of the GnRH dose and the route of administration on treatment outcome and complications. Schoemaker J. **Eur J Obstet Gynecol Reprod Biol** 1996 Apr;65 Suppl:S13–6 (13 ref.)
Regulation of ovarian androgen production: a key parameter to success during ovarian stimulation? Andersen CY. **Hum Reprod** 1995 Sep;10(9):2227–33 (58 ref.)
The effects of ovulation induction with gonadotrophins on the ovary and uterus and implications for assisted reproduction. Balen A. **Hum Reprod** 1995 Sep;10(9):2233–7 (55 ref.)
Ovulation induction. Effects of ovulation induction with gonadotrophins on the ovary and uterus and their implications for assisted reproduction. Rojas FJ. **Hum Reprod** 1995 Sep;10(9):2219–24 (47 ref.)
Endometrial responses to corpus luteum products in cycles with induced ovulation: theoretical and practical considerations. Seppälä M, et al. **Hum Reprod** 1995 Dec; 10 Suppl 2:67–76 (101 ref.)
Ovulation induction in the era of recombinant gonadotropins and GnRH analogues. Insler V, et al. **Isr J Med Sci** 1996 Feb;32(2):79–89 (68 ref.)

ADVERSE EFFECTS

Ovulation induction, infertility, and ovarian cancer risk. Bristow RE, et al. **Fertil Steril** 1996 Oct;66(4):499–507 (49 ref.)
[Update on ovarian hyperstimulation syndrome] Delbaere A, et al. **Rev Med Brux** 1995 Nov;16(5):354–60 (39 ref.) (Eng. Abstr.) **(Fre)**

METHODS

Induction of ovulation. Derman SG, et al. **Compr Ther** 1995 Oct;21(10):583–9 (16 ref.)
Pharmacological interventions for the induction of ovulation. Collins JA, et al. **Drugs** 1995 Sep;50(3):480–94 (91 ref.)
Ovarian hyperstimulation: effects of GnRH analogues. Triggering the final stage of ovulation using gonadotrophin-releasing hormone analogues: effective dose, prevention of ovarian hyperstimulation syndrome and the luteal phase. Ben-Arie A, et al. **Hum Reprod** 1996 Jun; 11(6):1146–8 (31 ref.)
Ovarian hyperstimulation: effects of GnRH analogues. Does triggering ovulation with gonadotrophin-releasing hormone analogue prevent severe ovarian hyperstimulation syndrome? Casper RF. **Hum Reprod** 1996 Jun;11(6):1144–6 (12 ref.)
Ovarian hyperstimulation: effects of GnRH analogues. Ovarian hyperstimulation syndrome after using gonadotrophin-releasing hormone analogue as a trigger of ovulation: causes and implications. Kol S, et al. **Hum Reprod** 1996 Jun;11(6):1143–4 (15 ref.)
Clinical review 81: Gonadotropin-releasing hormone analogs in ovulation induction: current status and perspectives. Filicori M. **J Clin Endocrinol Metab** 1996 Jul;81(7):2413–6 (23 ref.)

OVUM

see related
GRAAFIAN FOLLICLE

CYTOLOGY

Nuclear transplantation in mammalian eggs and embryos. Sun FZ, et al. **Curr Top Dev Biol** 1995;30:147–76 (137 ref.)

GROWTH & DEVELOPMENT

Ovarian follicular growth, ovulation and atresia. Endocrine, paracrine and autocrine regulation. Moley KH, et al. **Adv Exp Med Biol** 1995;377:103–19 (105 ref.)
Actin-membrane cytoskeletal dynamics in early sea urchin development. Bonder EM, et al. **Curr Top Dev Biol** 1995; 31:101–37 (131 ref.)
Remodeling of the specialized intermediate filament network in mammalian eggs and embryos during development: regulation by protein kinase C and protein kinase M. Gallicano GI, et al. **Curr Top Dev Biol** 1995;31:277–320 (95 ref.)
Cytoskeleton in teleost eggs and early embryos: contributions to cytoarchitecture and motile events. Hart NH, et al. **Curr Top Dev Biol** 1995;31:343–81 (144 ref.)
Development and evolution of an egg cytoskeletal domain in ascidians. Jeffery WR. **Curr Top Dev Biol** 1995;31:243–76 (77 ref.)

PHYSIOLOGY

Molecular basis of mammalian egg activation. Schultz RM, et al. **Curr Top Dev Biol** 1995;30:21–62 (186 ref.)
Mechanisms of calcium regulation in sea urchin eggs and their activities during fertilization. Shen SS. **Curr Top Dev Biol** 1995;30:63–101 (270 ref.)

ULTRASTRUCTURE

Cytoskeleton and ctenophore development. Houliston E, et al. **Curr Top Dev Biol** 1995;31:41–63 (401 ref.)
Cortical cytoskeleton of the Xenopus oocyte, egg, and early embryo. Larabell CA. **Curr Top Dev Biol** 1995;31:433–53 (72 ref.)
Role of the cytoskeleton in the generation of spatial patterns in Tubifex eggs. Shimizu T. **Curr Top Dev Biol** 1995; 31:197–235 (57 ref.)
Sea urchin microtubules. Suprenant KA, et al. **Curr Top Dev Biol** 1995;31:65–99 (206 ref.)

OVUM DONATION see **OOCYTE DONATION**

OVUM IMPLANTATION

Hydrosalpinx affects the implantation of previously cryopreserved embryos. Akman MA, et al. **Hum Reprod** 1996 May;11(5):1013–4 (8 ref.)
Differential implantation rates and variations in the sex ratio. Mittwoch U. **Hum Reprod** 1996 Jan;11(1):8–9 (14 ref.)
Exploring the mechanism(s) of endometriosis-related infertility: an analysis of embryo development and implantation in assisted reproduction. Pellicer A, et al. **Hum Reprod** 1995 Dec;10 Suppl 2:91–7 (33 ref.)
The signals and molecular pathways involved in implantation, a symbiotic interaction between blastocyst and endometrium involving adhesion and tissue invasion. Tabibzadeh S, et al. **Hum Reprod** 1995 Jun;10(6):1579–602 (200 ref.)
A biological model for the regulation of peri-implantational hemostasis and menstruation. Lockwood CJ, et al. **J Soc Gynecol Investig** 1996 Jul-Aug;3(4):159–65 (79 ref.)

DRUG EFFECTS

Sterility in neonatally androgenized female rats and the decidual cell reaction. Ohta Y. **Int Rev Cytol** 1995;160:1–52 (250 ref.)

IMMUNOLOGY

[Early immunosuppression and implantation] Chaouat G. **Contracept Fertil Sex** 1995 Oct;23(10):617–21 (58 ref.) (Eng. Abstr.) **(Fre)**
[Adhesion molecules and trophoblastic invasion] Loke YW, et al. **Contracept Fertil Sex** 1995 Sep;23(9):573–5 (40 ref.) (Eng. Abstr.) **(Fre)**
[The interleukin-1 system during human implantation] Simon C, et al. **Contracept Fertil Sex** 1995 Oct;23(10):626–30 (41 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

MUC1, endometrium and embryo implantation. Aplin JD, et al. **Biochem Soc Trans** 1995 Nov;23(4):826–31 (49 ref.)
Clinical approaches to increasing uterine receptivity during human implantation. Edwards RG. **Hum Reprod** 1995 Dec; 10 Suppl 2:60–6 (26 ref.)
Decidua in human implantation. Loke YW, et al. **Hum Reprod** 1995 Dec;10 Suppl 2:14–21 (62 ref.)
Role of embryonic factors in human implantation. Polan ML, et al. **Hum Reprod** 1995 Dec;10 Suppl 2:22–9 (32 ref.)
The role of prostaglandins in blastocyst implantation. Psychoyos A, et al. **Hum Reprod** 1995 Dec;10 Suppl 2:30–42 (105 ref.)
Interleukin-1 system crosstalk between embryo and endometrium in implantation. Simón C, et al. **Hum Reprod** 1995 Dec;10 Suppl 2:43–54 (67 ref.)
Blood vessel growth in the endometrium. Goodger AM, et al. **Microcirculation** 1995 Dec;2(4):329–43 (102 ref.)
Current studies on human implantation: a brief overview. Rogers PA. **Reprod Fertil Dev** 1995;7(6):1395–9 (24 ref.)

OVUM PROTEINS see **EGG PROTEINS**

OVUM-SPERM INTERACTIONS see **SPERM-OVUM INTERACTIONS**

OVUM TRANSPORT

PHYSIOLOGY

Oviductal function is critical for very early human life. Pulkkinen MO. **Ann Med** 1995 Jun;27(3):307–10 (12 ref.)

OWNERSHIP

Health enhancement and companion animal ownership. Beck AM, et al. **Annu Rev Public Health** 1996;17:247–57 (60 ref.)

OXALAMIC ACID see **OXAMIC ACID**

OXALATES

see related
HYPEROXALURIA
HYPEROXALURIA, PRIMARY

ANALYSIS

Plasma and urine measurements for monitoring of treatment in the primary hyperoxaluric patient. Kasidas GP. **Nephrol Dial Transplant** 1995;10 Suppl 8:8–10 (25 ref.)
[Oxalic acid] Isshiki G, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:593–6 (11 ref.) **(Jpn)**

METABOLISM

[Oxalosis] Cordonnier C, et al. **Ann Pathol** 1995;15(6):415–23 (88 ref.) **(Fre)**
[Primary hyperoxaluria] De Pauw L, et al. **Rev Med Brux** 1996 Apr;17(2):67–74 (25 ref.) (Eng. Abstr.) **(Fre)**

OXALURIA see **HYPEROXALURIA**

OXALURIA, PRIMARY see **HYPEROXALURIA, PRIMARY**

OXAMIC ACID

ANALOGS & DERIVATIVES

Lodoxamide in vernal keratoconjunctivitis. Lee S, et al. **Ann Pharmacother** 1996 May;30(5):535–7 (19 ref.)

OXAMIDIC ACID see **OXAMIC ACID**

OXIDANTS

see related
ANTIOXIDANTS

ADVERSE EFFECTS

Heme oxygenase-1: function, regulation, and implication of a novel stress-inducible protein in oxidant-induced lung injury. Choi AM, et al. **Am J Respir Cell Mol Biol** 1996 Jul;15(1):9–19 (58 ref.)
Role of oxidants in ischemic brain damage. Chan PH. **Stroke** 1996 Jun;27(6):1124–9 (56 ref.)

METABOLISM

Oxidants and antioxidants in exercise. Sen CK. **J Appl Physiol** 1995 Sep;79(3):675–86 (100 ref.)
Free radicals and aging of anterior segment tissues of the eye: a hypothesis. Green K. **Ophthalmic Res** 1995;27 Suppl 1:143–9 (41 ref.)
Oxidants/antioxidants in idiopathic pulmonary fibrosis. MacNee W, et al. **Thorax** 1995 Sep;50 Suppl 1:S53–8 (64 ref.)

OXIDANTS

PHARMACOLOGY

Asthma and oxidant stress: nutritional, environmental, and genetic risk factors. Greene LS. **J Am Coll Nutr** 1995 Aug; 14(4):317–24 (80 ref.)

Antioxidants, oxidants and free radical stress in cardiovascular disease. Singh RB, et al. **J Assoc Physicians India** 1996 Jan;44(1):43–8 (55 ref.)

The dual roles of nutrients as antioxidants and prooxidants: their effects on tumor cell growth. Schwartz JL. **J Nutr** 1996 Apr;126(4 Suppl):1221S–7S (42 ref.)

TOXICITY

DNA damage profiles induced by oxidizing agents. Epe B. **Rev Physiol Biochem Pharmacol** 1996;127:223–49 (160 ref.)

OXIDANTS, PHOTOCHEMICAL

THERAPEUTIC USE

Does ozone therapy normalize the cellular redox balance? Implications for therapy of human immunodeficiency virus infection and several other diseases. Bocci V. **Med Hypotheses** 1996 Feb;46(2):150–4 (40 ref.)

TOXICITY

Effect of oxidant air pollutants on the respiratory system: insights from experimental animal research. Chitano P, et al. **Eur Respir J** 1995 Aug;8(8):1357–71 (182 ref.)

OXIDASES see **OXIDOREDUCTASES**

OXIDATION-REDUCTION

see related
ANTIOXIDANTS
OXIDANTS

[Antioxidants in nutrition and their importance in the anti-/oxidative balance in the immune system] Biesalski HK, et al. **Immun Infekt** 1995 Oct;23(5):166–73 (72 ref.) (Eng. Abstr.) **(Ger)**

[Nitric oxide and oxidative metabolism: heads or tails in inflammatory gastric disease] Esteban Carretero J, et al. **Rev Esp Enferm Dig** 1996 Jun;88(6):423–30 (90 ref.) **(Spa)**

OXIDATIVE BURST see **RESPIRATORY BURST**

OXIDATIVE PHOSPHORYLATION

Regulation of oxidative phosphorylation: the flexible respiratory network of Paracoccus denitrificans. Van Spanning RJ, et al. **J Bioenerg Biomembr** 1995 Oct; 27(5):499–512 (93 ref.)

OXIDATIVE STRESS

Oxidative stress in acute and chronic pancreatitis. Schoenberg MH, et al. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1306S–1314S (69 ref.)

Increased sensitivity to oxidative stress and the loss of muscarinic receptor responsiveness in senescence. Joseph JA, et al. **Ann N Y Acad Sci** 1996 Jun 15;786:112–9 (47 ref.)

Critical evaluation of the free radical theory of aging. A proposal for the oxidative stress hypothesis. Yu BP, et al. **Ann N Y Acad Sci** 1996 Jun 15;786:1–11 (44 ref.)

Oxidative stress in neurodegenerative diseases. Simonian NA, et al. **Annu Rev Pharmacol Toxicol** 1996;36:83–106 (177 ref.)

Mineral fiber-induced oxidative stress in phagocytes. Savolainen KM, et al. **Arch Toxicol Suppl** 1996;18:236–47 (53 ref.)

Exercise-induced muscle damage and inflammation: a review. Pyne DB. **Aust J Sci Med Sport** 1994 Sep–Dec; 26(3–4):49–58 (133 ref.)

Oxidative stress: the paradox of aerobic life. Davies KJ. **Biochem Soc Symp** 1995;61:1–31 (228 ref.)

Oxidative damage by ozone and nitrogen dioxide: synergistic toxicity in vivo but no evidence of synergistic oxidative damage in an extracellular fluid. O'Neill CA, et al. **Biochem Soc Symp** 1995;61:139–52 (49 ref.)

Progress in identifying clinical relevance of inhibition, stimulation and measurements of poly ADP-ribosylation. Pero RW, et al. **Biochimie** 1995;77(5):385–93 (45 ref.)

Role of oxidative stress in non-genotoxic carcinogenesis with special reference to liver tumors induced by peroxisome proliferators. Sai-Kato K, et al. **Biomed Environ Sci** 1995 Sep;8(3):269–79 (64 ref.)

Hypoxia, oxidative stress and rheumatoid arthritis. Mapp PI, et al. **Br Med Bull** 1995 Apr;51(2):419–36 (43 ref.)

Free radicals, oxidative stress, oxidized low density lipoprotein (LDL), and the heart: antioxidants and other strategies to limit cardiovascular damage. Sinatra ST, et al. **Conn Med** 1995 Oct;59(10):579–88 (94 ref.)

Oxidative stress and diabetic vascular complications. Giugliano D, et al. **Diabetes Care** 1996 Mar;19(3):257–67 (152 ref.)

The need for a 'free radical initiative' [comment] Cominacini L, et al. **Diabetologia** 1996 Mar;39(3):364–6 (20 ref.) Comment on: Diabetologia 1996 Mar;39(3):357–63.

Oxidative stress and insulin action: is there a relationship? [see comments] Paolisso G, et al. **Diabetologia** 1996 Mar; 39(3):357–63 (51 ref.) Comment in: Diabetologia 1996 Mar;39(3):364–6.

Role of oxygen free radicals in cancer development. Dreher D, et al. **Eur J Cancer** 1996 Jan;32A(1):30–8 (115 ref.)

Exercise and oxidative stress: role of the cellular antioxidant systems. Ji LL. **Exerc Sport Sci Rev** 1995;23:135–66 (140 ref.)

Rapid development and a long life: an association expected under a stress theory of aging. Parsons PA. **Experientia** 1996 Jul 15;52(7):643–6 (54 ref.)

Oxidant stress and endothelial membrane transport. Elliott SJ, et al. **Free Radic Biol Med** 1995 Nov;19(5):649–58 (98 ref.)

How do Ca2+ and 5-aminolevulinic acid-derived oxyradicals promote injury to isolated mitochondria? Hermes-Lima M. **Free Radic Biol Med** 1995 Sep; 19(3):381–90 (87 ref.)

The role of oxidative stress in HIV disease. Pace GW, et al. **Free Radic Biol Med** 1995 Oct;19(4):523–8 (93 ref.)

Oxidative stress and aging: still a hypothesis [editorial; comment] Kritchevsky SB, et al. **J Am Geriatr Soc** 1996 Jul;44(7):873–5 (25 ref.) Comment on: J Am Geriatr Soc 1996 Jul;44(7):823–7.

Antioxidants, oxidants and free radical stress in cardiovascular disease. Singh RB, et al. **J Assoc Physicians India** 1996 Jan;44(1):43–8 (55 ref.)

Free radical damage and oxidative stress in Huntington's disease. Borlongan CV, et al. **J Fla Med Assoc** 1996 May; 83(5):335–41 (0 ref.)

Interventions based on the possibility that oxidative stress contributes to sarcopenia. Weindruch R. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:157–61 (54 ref.)

Transgenic mice and knockout mutants in the study of oxidative stress in brain injury. Chan PH, et al. **J Neurotrauma** 1995 Oct;12(5):815–24 (63 ref.)

Role of oxidative stress in the development of diabetic nephropathy. Ha H, et al. **Kidney Int Suppl** 1995 Sep; 51:S18–21 (59 ref.)

Apoptosis overview emphasizing the role of oxidative stress, DNA damage and signal-transduction pathways. Payne CM, et al. **Leuk Lymphoma** 1995 Sep;19(1–2):43–93 (720 ref.)

Bioenergetic and oxidative stress in neurodegenerative diseases. Bowling AC, et al. **Life Sci** 1995;56(14):1151–71 (257 ref.)

Oxidative stress and heart failure. Singh N, et al. **Mol Cell Biochem** 1995 Jun 7–21;147(1–2):77–81 (36 ref.)

The beneficial effects of dietary restriction: reduced oxidative damage and enhanced apoptosis. Wachsman JT. **Mutat Res** 1996 Feb 19;350(1):25–34 (75 ref.)

Genetic analysis of ageing: role of oxidative damage and environmental stresses. Martin GM, et al. **Nat Genet** 1996 May;13(1):25–34 (151 ref.)

Oxidative stress and Alzheimer's disease [comment] Choi BH. **Neurobiol Aging** 1995 Jul–Aug;16(4):675–8 (49 ref.) Comment on: Neurobiol Aging 1995 Jul–Aug;16(4):661–74.

Atherosclerosis, oxidative stress, and antioxidant protection in endothelium-derived relaxing factor action. Keaney JF Jr, et al. **Prog Cardiovasc Dis** 1995 Sep–Oct;38(2):129–54 (202 ref.)

Oxidative stress, caloric restriction, and aging. Sohal RS, et al. **Science** 1996 Jul 5;273(5271):59–63 (59 ref.)

LDL-platelet interaction under oxidative stress induces macrophage foam cell formation. Aviram M. **Thromb Haemost** 1995 Jul;74(1):560–4 (41 ref.)

Amplification of glutamate-induced oxidative stress. Savolainen KM, et al. **Toxicol Lett** 1995 Dec;82–83:399–405 (46 ref.)

Signalling mechanisms and oxidative stress in apoptosis. Slater AF, et al. **Toxicol Lett** 1995 Dec;82–83:149–53 (24 ref.)

[Oxidative stress and cell aging] Hervonen A. **Duodecim** 1994; 110(17):1653–8 (33 ref.) **(Fin)**

[Oxidative stress and HIV infection. A concept to be specified and a therapeutic approach to be studied] Constans J, et al. **Ann Med Interne (Paris)** 1995;146(7):514–9 (53 ref.) **(Fre)**

[Does nitric oxide stress exist?] Torreilles J, et al. **C R Seances Soc Biol Fil** 1995;189(3):389–400 (42 ref.) (Eng. Abstr.) **(Fre)**

[The oxidative stress in the cataract formation] Obara Y. **Nippon Ganka Gakkai Zasshi** 1995 Dec;99(12):1303–41 (83 ref.) (Eng. Abstr.) **(Jpn)**

DRUG EFFECTS

Metals, oxidative stress, and hepatic fibrogenesis. Pietrangelo A. **Semin Liver Dis** 1996 Feb;16(1):13–30 (117 ref.)

[Lipid peroxidation in the presence of inorganic compounds. Relation to oxidative stress mechanisms] Fournier J, et al. **C R Seances Soc Biol Fil** 1995;189(3):429–42 (36 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Aetiology of age-associated aneuploidy: a mechanism based on the 'free radical theory of ageing'. Tarín JJ. **Hum Reprod** 1995 Jun;10(6):1563–5 (25 ref.)

Free-radical-induced mutation vs redox regulation: costs and benefits of genes in organelles. Allen JF, et al. **J Mol Evol** 1996 May;42(5):482–92 (76 ref.)

[Oxidative stress as a basic mechanism of the carcinogenic effect of man made mineral fibers on the human body] Lutz W, et al. **Med Pr** 1995;46(3):275–84 (18 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOLOGY

Oxidative damage and defense. Jacob RA, et al. **Am J Clin Nutr** 1996 Jun;63(6):985S–990S (43 ref.)

Heme oxygenase-1: function, regulation, and implication of a novel stress-inducible protein in oxidant-induced lung injury. Choi AM, et al. **Am J Respir Cell Mol Biol** 1996 Jul;15(1):9–19 (58 ref.)

Evolution of chlorophyll biosynthesis--the challenge to survive photooxidation. Reinbothe S, et al. **Cell** 1996 Sep 6;86(5):703–5 (14 ref.)

Low pH adaptation and the acid tolerance response of Salmonella typhimurium. Foster JW. **Crit Rev Microbiol** 1995;21(4):215–37 (90 ref.)

The role of oxidative stress in neuropathy and other diabetic complications. Van Dam PS, et al. **Diabetes Metab Rev** 1995 Oct;11(3):181–92 (72 ref.)

Free radicals and exercise: effects of nutritional antioxidant supplementation. Kanter M. **Exerc Sport Sci Rev** 1995; 23:375–97 (142 ref.)

Asthma and oxidant stress: nutritional, environmental, and genetic risk factors. Greene LS. **J Am Coll Nutr** 1995 Aug; 14(4):317–24 (80 ref.)

Oxidative stress: its role in the pathogenesis of amyotrophic lateral sclerosis. Bergeron C. **J Neurol Sci** 1995 May;129 Suppl:81–4 (57 ref.)

Determinants of antioxidant status in humans. Papas AM. **Lipids** 1996 Mar;31 Suppl:S77–82 (66 ref.)

The role of the neurohormone melatonin as a buffer against macromolecular oxidative damage. Reiter RJ. **Neurochem Int** 1995 Dec;27(6):453–60 (54 ref.)

The potential role of oxidative stress in nongenotoxic carcinogenesis in the mouse liver. Bachowski S, et al. **Prog Clin Biol Res** 1995;391:385–96 (48 ref.)

Oxidative stress and antioxidant therapy in Parkinson's disease. Ebadi M, et al. **Prog Neurobiol** 1996 Jan;48(1):1–19 (340 ref.)

The epididymis as protector of maturing spermatozoa. Hinton BT, et al. **Reprod Fertil Dev** 1995;7(4):731–45 (149 ref.)

[Reactive oxygen species and gene expression regulation] Jurgowiak M, et al. **Postepy Biochem** 1996;42(1):6–13 (75 ref.) **(Pol)**

[Oxidative damage repair of DNA in prokaryotes] Zastawny TH. **Postepy Biochem** 1996;42(1):31–41 (118 ref.) **(Pol)**

OXIDES

ADVERSE EFFECTS

[The endorem tolerance profile] Laniado M, et al. **Radiologe** 1995 Nov;35(11 Suppl 2):S266–70 (16 ref.) (Eng. Abstr.) **(Ger)**

CHEMISTRY

Radicals from one-electron reduction of nitro compounds, aromatic N-oxides and quinones: the kinetic basis for hypoxia-selective, bioreductive drugs. Wardman P, et al. **Biochem Soc Symp** 1995;61:171–94 (126 ref.)

DIAGNOSTIC USE

Liver. II: Iron oxide-based reticuloendothelial contrast agents for MR imaging. Clinical review. Petersein J, et al. **Magn Reson Imaging Clin N Am** 1996 Feb;4(1):53–60 (38 ref.)

[Detection of liver tumors] Rummeny EJ, et al. **Radiologe** 1995 Nov;35(11 Suppl 2):S252–8 (29 ref.) (Eng. Abstr.) **(Ger)**

TOXICITY

Comparison of neurite outgrowth with neurofilament protein subunit levels in neuroblastoma cells following mercuric oxide exposure. Abdulla EM, et al. **Clin Exp Pharmacol Physiol** 1995 May;22(5):362–3 (5 ref.)

OXIDIZING AGENTS see **OXIDANTS**

OXIDOREDUCTASES

ANTAGONISTS & INHIBITORS

Drug interactions and the cytochrome P450 system. The role of cytochrome P450 1A2. Brøsen K. **Clin Pharmacokinet** 1995;29 Suppl 1:20–5 (20 ref.)

Consensus meeting on new approaches in the pharmacotherapy of benign prostatic hyperplasia (BPH). Proceedings of the meeting held on the 8th and 9th October 1994 in St. Tropez, France, under the patronage of the International Academy of Biomedical and Drug Research. **Eur Urol** 1996;29(3):374–84 (52 ref.)

5alpha-reductase inhibitors/finasteride. Stoner E. **Prostate Suppl** 1996;6:82–7 (28 ref.)

BIOSYNTHESIS

Induction of cytochrome P450 isoforms by carcinogenic aromatic amines and carcinogenic susceptibility of rodent animals. Hashimoto Y, et al. **Pharmacogenetics** 1995;5 Spec No:S80–3 (22 ref.)

CHEMISTRY

Structure and mechanism of the iron-sulfur flavoprotein phthalate dioxygenase reductase. Gassner GT, et al. **FASEB J** 1995 Nov;9(14):1411–8 (41 ref.)

A structural model for the membrane-integral domain of succinate: quinone oxidoreductases. Hägerhäll C, et al. **FEBS Lett** 1996 Jun 24;389(1):25–31 (59 ref.)

Structure-function relationships of the alternative oxidase of plant mitochondria: a model of the active site. Moore AL, et al. **J Bioenerg Biomembr** 1995 Aug;27(4):367–77 (70 ref.)

Biological electron transfer. Moser CC, et al. **J Bioenerg Biomembr** 1995 Jun;27(3):263–74 (70 ref.)

DEFICIENCY

Diagnostic analysis, clinical importance and molecular basis of dihydropyrimidine dehydrogenase deficiency. Gonzalez FJ, et al. **Trends Pharmacol Sci** 1995 Oct;16(10):325–7 (22 ref.)

[Severe 5-fluorouracil toxicity in a woman treated for breast cancer with concurrent osteogenesis imperfecta and dehydrogenase deficiency] Beuzeboc P, et al. **Bull Cancer (Paris)** 1996 Apr;83(4):324–7 (24 ref.) (Eng. Abstr.) **(Fre)**

[Congenital disorders of the bile acid metabolism (3 beta-hydroxy-delta 5-steroid dehydrogenase/isomerase deficiency, delta 4-3-oxosteroid 5 beta-reductase deficiency, cerebrotendinous xanthomatosis, and peroxisomal disorders] Kondo KH, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):362–6 (23 ref.) **(Jpn)**

GENETICS

The alcohol dehydrogenase system. Jörnvall H, et al. **Adv Exp Med Biol** 1995;372:281–94 (51 ref.)

Short-chain dehydrogenases/reductases. Persson B, et al. **Adv Exp Med Biol** 1995;372:383–95 (38 ref.)

METABOLISM

Enzymic and interindividual differences in the human metabolism of heterocyclic amines. Boobis AR, et al. **Arch Toxicol Suppl** 1996;18:286–302 (65 ref.)

Enzymes and associated electron transport systems that catalyse the respiratory reduction of nitrogen oxides and oxyanions. Berks BC, et al. **Biochim Biophys Acta** 1995 Dec 12;1232(3):97–173 (625 ref.)

Tyrosinase and related proteins in mammalian pigmentation. del Marmol V, et al. **FEBS Lett** 1996 Mar 4;381(3):165–8 (48 ref.)

Regulation of alternative oxidase activity in higher plants. Day DA, et al. **J Bioenerg Biomembr** 1995 Aug;27(4):379–85 (41 ref.)

Kinetic and regulatory aspects of the function of the alternative oxidase in plant respiration. Krab K. **J Bioenerg Biomembr** 1995 Aug;27(4):387–96 (47 ref.)

Structure-function relationships of the alternative oxidase of plant mitochondria: a model of the active site. Moore AL, et al. **J Bioenerg Biomembr** 1995 Aug;27(4):367–77 (70 ref.)

Biological electron transfer. Moser CC, et al. **J Bioenerg Biomembr** 1995 Jun;27(3):263–74 (70 ref.)

Functional molecular aspects of the NADH dehydrogenases of plant mitochondria. Soole KL, et al. **J Bioenerg Biomembr** 1995 Aug;27(4):397–406 (64 ref.)

Role of cytochrome P4501A2 in chemical carcinogenesis: implications for human variability in expression and enzyme activity. Eaton DL, et al. **Pharmacogenetics** 1995 Oct;5(5):259–74 (128 ref.)

Iron metabolism in eukaryotes: Mars and Venus at it again [comment] Kaplan J, et al. **Science** 1996 Mar 15;271(5255):1510–2 (25 ref.) Comment on: Science 1996 Mar 15;271(5255):1552–7.

[5-alpha-reductases: physiology and pathology] Mowszowicz I, et al. **Ann Endocrinol (Paris)** 1995;56(6):555–9 (27 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Fluoropyrimidine catabolism. Diasio RB, et al. **Cancer Treat Res** 1995;78:71–93 (103 ref.)

OXIDOREDUCTASES, N-DEMETHYLATING

[Gene technology to overproduce the enzymes useful as diagnostic reagents] Sugiyama M, et al. **Rinsho Byori** 1995 Aug;43(8):765–71 (8 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Risk assessment: toxicity from chemical exposure resulting from enhanced expression of CYP2E1. Raucy JL. **Toxicology** 1995 Dec 28;105(2–3):217–24 (48 ref.)

PHYSIOLOGY

The emerging role of cytochrome P450 3A in psychopharmacology. Ketter TA, et al. **J Clin Psychopharmacol** 1995 Dec;15(6):387–98 (173 ref.)

OXIDOREDUCTASES, NADH, NADPH see **NADH, NADPH OXIDOREDUCTASES**

OXIMES

CHEMISTRY

On the mechanism of nitric oxide formation upon oxidative cleavage of C = N(OH) bonds by NO-synthases and cytochromes P450. Mansuy D, et al. **Biochimie** 1995;77(7–8):661–7 (28 ref.)

DIAGNOSTIC USE

Imaging infection and inflammation in veterinary practice [editorial; comment] Peters AM. **Equine Vet J** 1995 Jul;27(4):242–4 (20 ref.) Comment on: Equine Vet J 1995 Jul;27(4):313–5.

[Frontal type dementia and amyotrophic lateral sclerosis. 3 cases with (HmPAO Tc99m) single-photon emission tomography study] Vercelletto M, et al. **Rev Neurol (Paris)** 1995 Nov;151(11):640–7 (43 ref.) (Eng. Abstr.) **(Fre)**

OXIMETRY

From oxygen content to pulse oximetry: completing the picture in the newborn. Whyte RK, et al. **Acta Anaesthesiol Scand Suppl** 1995;107:95–100 (28 ref.)

Intrapartum fetal pulse oximetry: past, present, and future. Dildy GA, et al. **Am J Obstet Gynecol** 1996 Jul;175(1):1–9 (57 ref.)

Uses and abuses of pulse oximetry. Moyle JT. **Arch Dis Child** 1996 Jan;74(1):77–80 (14 ref.)

Uses and limitations of pulse oximetry. Stoneham MD. **Br J Hosp Med** 1995 Jun 21–Jul 11;54(1):35–41 (21 ref.)

Intrapartum fetal pulse oximetry: present and future. Elchalal U, et al. **Int J Gynaecol Obstet** 1995 Aug;50(2):131–7 (33 ref.)

Pulse oximetry for preoperative vascular assessment in a thumb near-amputation [see comments] Schumer E, et al. **J Emerg Med** 1995 Nov-Dec;13(6):753–5 (20 ref.) Comment in: J Emerg Med 1995 Nov-Dec;13(6):815–6.

Continuous fetal monitoring of HbO2 with pulse oximetry. Knitza R, et al. **J Perinat Med** 1996;24(1):55–9 (5 ref.)

INSTRUMENTATION

From oxygen content to pulse oximetry: completing the picture in the newborn. Whyte RK, et al. **Acta Anaesthesiol Scand Suppl** 1995;107:95–100 (28 ref.)

Symbiosis of nurse and machine through fuzzy logic: improved specificity of a neonatal pulse oximeter alarm. Bosque EM. **ANS Adv Nurs Sci** 1995 Dec;18(2):67–75 (60 ref.)

METHODS

[Problems and limits in noninvasive oxygen monitoring] Bardenheuer HJ, et al. **Anaesthesist** 1996 Jul;45(7):614–25 (86 ref.) (Eng. Abstr.) **(Ger)**

[Transcutaneous pulse oximetry] Gorzelak K. **Pneumonol Alergol Pol** 1995;63(7–8):460–8 (37 ref.) **(Pol)**

[Cerebral oximetry] Lubnin AIu, et al. **Anesteziol Reanimatol** 1996 Mar-Apr;(2):85–90 (50 ref.) **(Rus)**

OXOPROPANAL see **PYRUVALDEHYDE**

OXOQUINOLINES see **QUINOLONES**

3-OXOSTEROID ISOMERASES see **STEROID ISOMERASES**

17-OXOSTEROIDS see **17-KETOSTEROIDS**

OXYCEPHALY see **CRANIOSYNOSTOSES**

OXYCHLOROCHIN see **HYDROXYCHLOROQUINE**

OXYCHLOROQUINE see **HYDROXYCHLOROQUINE**

OXYGEN

see related
ANOXEMIA
ANOXIA
HYPEROXIA

The Leeuwenhoek Lecture, 1995. Adaptation to life without oxygen. Guest JR. **Philos Trans R Soc Lond B Biol Sci** 1995 Nov 29;350(1332):189–202 (61 ref.)

ADVERSE EFFECTS

Role of xanthine oxidase and its inhibitor in hypoxia: reoxygenation injury. Saugstad OD. **Pediatrics** 1996 Jul;98(1):103–7 (83 ref.)

Toxic and therapeutic properties of oxygen--a review. Doležal V. **Sb Lek** 1995;96(3):231–4 (28 ref.)

BLOOD

Oxygen uptake/oxygen supply dependency: fact or fiction? Vincent JL, et al. **Acta Anaesthesiol Scand Suppl** 1995;107:229–37 (83 ref.)

Quantifying pulmonary oxygen transfer deficits in critically ill patients. Wandrup JH. **Acta Anaesthesiol Scand Suppl** 1995;107:37–44 (54 ref.)

From oxygen content to pulse oximetry: completing the picture in the newborn. Whyte RK, et al. **Acta Anaesthesiol Scand Suppl** 1995;107:95–100 (28 ref.)

Use of Oxygent, a perfluorochemical-based oxygen carrier, as an alternative to intraoperative blood transfusion. Keipert PE. **Artif Cells Blood Substit Immobil Biotechnol** 1995;23(3):381–94 (29 ref.)

Increase in carotid body sensitivity during sustained hypoxia. Bisgard GE. **Biol Signals** 1995 Sep-Oct;4(5):292–7 (43 ref.)

Possible role of coupling between glomus cells in carotid body chemoreception. Eyzaguirre C, et al. **Biol Signals** 1995 Sep-Oct;4(5):263–70 (30 ref.)

Oxygen sensing in the carotid body. Gonzalez C, et al. **Biol Signals** 1995 Sep-Oct;4(5):245–56 (59 ref.)

Carotid body O2 chemoreception: respiratory and nonrespiratory aspects. Lahiri S. **Biol Signals** 1995 Sep-Oct;4(5):257–62 (22 ref.)

Perfluorocarbon-associated gas exchange improves oxygenation, lung mechanics, and survival in a model of adult respiratory distress syndrome. Papo MC, et al. **Crit Care Med** 1996 Mar;24(3):466–74 (40 ref.)

Continuous fetal monitoring of HbO2 with pulse oximetry. Knitza R, et al. **J Perinat Med** 1996;24(1):55–9 (5 ref.)

Monitoring of O2 transport and tissue oxygenation in paediatric critical care. Hüttemann E, et al. **Paediatr Anaesth** 1995;5(5):281–6 (54 ref.)

Oxygen delivery and autoxidation of hemoglobin. Marden MC, et al. **Transfus Clin Biol** 1995;2(6):473–80 (21 ref.)

[VO2 and DO2 during cardiogenic shock and infection] Beale R. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May;31(1 Suppl):S22–5 (19 ref.) **(Ger)**

[Anesthesia with low fresh gas flow in clinical routine use (see comments)] Hargasser S, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Aug;30(5):268–75 (79 ref.) (Eng. Abstr.) Comment in: Anasthesiol Intensivmed Notfallmed Schmerzther 1995 Aug;30(5):265–7. **(Ger)**

[Microcirculation and oxygen supply to the liver in hemorrhagic shock and sepsis] Vollmar B. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Oct;30 Suppl 1:S52–4 (21 ref.) **(Ger)**

[Arterial oxygen tension and oxygen saturation] Matsuzaki K. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:796–9 (5 ref.) **(Jpn)**

METABOLISM

An integrative view of limitations to muscular performance. Dempsey JA, et al. **Adv Exp Med Biol** 1995;384:393–9 (17 ref.)

Simulation of intraluminal gas transport processes in the microcirculation. Hellums JD, et al. **Ann Biomed Eng** 1996 Jan-Feb;24(1):1–24 (97 ref.)

Reactive oxygen species as causal agents in the neurotoxicity of the Alzheimer's disease-associated amyloid beta peptide. Hensley K, et al. **Ann N Y Acad Sci** 1996 Jun 15;786:120–34 (49 ref.)

O2-sensing and O2-dependent gene regulation in facultatively anaerobic bacteria. Unden G, et al. **Arch Microbiol** 1995 Aug;164(2):81–90 (112 ref.)

Ocular oxygen measurement. Hogeboom van Buggenum IM, et al. **Br J Ophthalmol** 1996 Jun;80(6):567–73 (110 ref.)

Ion channels, oxygen sensation and signal transduction in pulmonary arterial smooth muscle. Kozlowski RZ. **Cardiovasc Res** 1995 Sep;30(3):318–25 (73 ref.)

Physiological attributes of microbial BTEX degradation in oxygen-limited environments. Olsen RH, et al. **Environ Health Perspect** 1995 Jun;103 Suppl 5:49–51 (7 ref.)

Oxygenic photosynthesis. Electron transfer in photosystem I and photosystem II. Nugent JH. **Eur J Biochem** 1996 May 1;237(3):519–31 (122 ref.)

Magnetic resonance imaging and spectroscopy in studying exercise in children. Cooper DM, et al. **Exerc Sport Sci Rev** 1996;24:475–99 (78 ref.)

An introduction to oxygen free radicals. Kerr ME, et al. **Heart Lung** 1996 May-Jun;25(3):200–9; quiz 210–1 (52 ref.)

Kinetic pathways and barriers for ligand binding to myoglobin. Olson JS, et al. **J Biol Chem** 1996 Jul 26;271(30):17593–6 (28 ref.)

Influence of microvascular architecture on oxygen exchange in skeletal muscle. Pittman RN. **Microcirculation** 1995 May;2(1):1–18 (67 ref.)

Retinal oxygen distribution. Its role in the physiopathology of vasoproliferative microangiopathies. Pournaras CJ. **Retina** 1995;15(4):332–47 (143 ref.)

Hypoxia and modification of the endothelium: implications for regulation of vascular homeostatic properties. Pinsky DJ, et al. **Semin Cell Biol** 1995 Oct;6(5):283–94 (49 ref.)

[Changes in vitreous structure caused by oxygen free radicals] Ueno N. **Nippon Ganka Gakkai Zasshi** 1995 Dec;99(12):1342–60 (90 ref.) (Eng. Abstr.) **(Jpn)**

[Bacterial nutrition and respiration] Dumitrescu V. **Bacteriol Virusol Parazitol Epidemiol** 1995 Jan-Mar;40(1):9–16 (8 ref.) **(Rum)**

[Nonphosphorylating respiration as the mechanism preventing the formation of active forms of oxygen] Skulachev VP. **Mol Biol (Mosk)** 1995 Nov-Dec;29(6):1199–209 (54 ref.) **(Rus)**

PHARMACOKINETICS

An overview on oxygen carriers in cancer therapy. Teicher

OXYGEN

BA. **Artif Cells Blood Substit Immobil Biotechnol** 1995; 23(3):395–405 (60 ref.)

Structural basis for oxygen delivery: muscle capillaries and manifolds in tuna red muscle. Mathieu-Costello O, et al. **Comp Biochem Physiol A Physiol** 1996 Jan;113(1):25–31 (37 ref.)

PHYSIOLOGY

Oxygen sensing and molecular adaptation to hypoxia. Bunn HF, et al. **Physiol Rev** 1996 Jul;76(3):839–85 (388 ref.)

Unifying theory of hypoxia tolerance: molecular/metabolic defense and rescue mechanisms for surviving oxygen lack. Hochachka PW, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9493–8 (63 ref.)

Hypoxia-inducible gene expression. Fandrey J. **Respir Physiol** 1995 Jul;101(1):1–10 (47 ref.)

[Is sepsis and septic shock due to a global oxygen insufficiency? A review in 2 parts. 2: Sepsis and lactate] Ensinger H, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May; 31(4):205–15 (175 ref.) **(Ger)**

THERAPEUTIC USE

The effects of hypoxaemia and recommendations for postoperative oxygen therapy. Powell JF, et al. **Anaesthesia** 1996 Aug;51(8):769–72 (41 ref.)

[Symptomatic treatment of cluster headache] Titus F. **Rev Neurol** 1995;23 Suppl 4:S519–24 (46 ref.) **(Spa)**

TOXICITY

Oxygen toxicity and antioxidants: state of the art. Sen CK. **Indian J Physiol Pharmacol** 1995 Jul;39(3):177–96 (91 ref.)

[Glutathione homeostasis: the cardinal physiological defense against oxygen toxicity induced by physical exercise] Sen CK, et al. **Fiziol Zh Im I M Sechenova** 1995 Nov; 81(11):143–50 (15 ref.) **(Rus)**

OXYGEN CONSUMPTION

Permissive hypercapnia in ARDS and its effect on tissue oxygenation. Hickling KG, et al. **Acta Anaesthesiol Scand Suppl** 1995;107:201–8 (53 ref.)

Oxygen uptake/oxygen supply dependency: fact or fiction? Vincent JL, et al. **Acta Anaesthesiol Scand Suppl** 1995; 107:229–37 (83 ref.)

Quantifying pulmonary oxygen transfer deficits in critically ill patients. Wandrup JH. **Acta Anaesthesiol Scand Suppl** 1995;107:37–44 (54 ref.)

Is the slow component of exercise VO2 a respiratory adaptation to anaerobiosis? Wasserman K, et al. **Adv Exp Med Biol** 1995;393:187–94 (11 ref.)

Near infra-red spectroscopy [editorial] Harris DN. **Anaesthesia** 1995 Dec;50(12):1015–6 (19 ref.)

Pulmonary oxygen uptake kinetics in nonsteady state. Koga S, et al. **Appl Human Sci** 1996 Jan;15(1):1–4 (26 ref.)

Myocardial stunning: the role of oxidative substrate metabolism. Lerch R. **Basic Res Cardiol** 1995 Jul–Aug; 90(4):276–8 (10 ref.)

Monitoring tissue perfusion. Vincent JL. **Can J Anaesth** 1996 May;43(5 Pt 2):R55–60 (16 ref.) **(Eng, Fre)**

The slow component of oxygen uptake kinetics in humans. Gaesser GA, et al. **Exerc Sport Sci Rev** 1996;24:35–71 (130 ref.)

Kinetic and regulatory aspects of the function of the alternative oxidase in plant respiration. Krab K. **J Bioenerg Biomembr** 1995 Aug;27(4):387–96 (47 ref.)

Design of the oxygen and substrate pathways. I. Model and strategy to test symmorphosis in a network structure. Taylor CR, et al. **J Exp Biol** 1996 Aug;199 (Pt 8):1643–9 (25 ref.)

Design of the oxygen and substrate pathways. VII. Different structural limits for oxygen and substrate supply to muscle mitochondria. Weibel ER, et al. **J Exp Biol** 1996 Aug;199 (Pt 8):1699–709 (18 ref.)

The effect of associated injuries, blood loss, and oxygen debt on death and disability in blunt traumatic brain injury: the need for early physiologic predictors of severity. Siegel JH. **J Neurotrauma** 1995 Aug;12(4):579–90 (18 ref.)

The nitric oxide/ascorbate cycle: how neurones may control their own oxygen supply. Millar J. **Med Hypotheses** 1995 Jul;45(1):21–6 (65 ref.)

Criteria for maximal oxygen uptake: review and commentary. Howley ET, et al. **Med Sci Sports Exerc** 1995 Sep; 27(9):1292–301 (61 ref.)

Monitoring of O2 transport and tissue oxygenation in paediatric critical care. Hüttemann E, et al. **Paediatr Anaesth** 1995;5(5):281–6 (54 ref.)

The currents of life: the terminal electron-transfer complex of respiration [comment] Ramirez BE, et al. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):11949–51 (27 ref.) Comment on: Proc Natl Acad Sci U S A 1995 Dec 19;92(26):11955–9.

[Changes in the generation of free oxygen radicals in shock and their significance in the irreversibility of a pathological process] Oborin AN. **Klin Khir** 1995;(6):34–8 (59 ref.) **(Rus)**

[The importance of determining oxygen consumption in the indications for a heart transplant] Gómez Sánchez MA, et al. **Rev Esp Cardiol** 1995;48 Suppl 7:19–23 (25 ref.) (Eng. Abstr.) **(Spa)**

DRUG EFFECTS

Effects of catecholamines on regional perfusion and oxygenation in critically ill patients. Meier-Hellmann A, et al. **Acta Anaesthesiol Scand Suppl** 1995;107:239–48 (106 ref.)

PHYSIOLOGY

Determinants of maximal oxygen transport and utilization. Wagner PD. **Annu Rev Physiol** 1996;58:21–50 (116 ref.)

Tumor oxygenation: a matter of supply and demand. Gulledge CJ, et al. **Anticancer Res** 1996 Mar-Apr; 16(2):741–9 (68 ref.)

Functional diffusive/convective interaction determining maximal oxygen uptake in humans: its modeling perspective. Fukuba Y, et al. **Appl Human Sci** 1995 Nov; 14(6):259–70 (47 ref.)

Maximizing oxygen delivery in critically ill patients: a methodologic appraisal of the evidence. Heyland DK, et al. **Crit Care Med** 1996 Mar;24(3):517–24 (42 ref.)

Scaling, normalizing, and per ratio standards: an allometric modeling approach. Nevill AM, et al. **J Appl Physiol** 1995 Sep;79(3):1027–31 (28 ref.)

Selecting training workloads using treadmill test heart rate/oxygen uptake regressions. McConnell TR. **J Cardpulm Rehabil** 1996 May-Jun;16(3):160–2 (8 ref.)

Interventions based on the possibility that oxidative stress contributes to sarcopenia. Weindruch R. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:157–61 (54 ref.)

Substrate selection and oxygen uptake by the lactating mammary gland. Williamson DH, et al. **Proc Nutr Soc** 1995 Mar;54(1):165–75 (62 ref.)

Maximal and submaximal oxygen uptake during running: how should body mass be accounted for? Svedenhag J. **Scand J Med Sci Sports** 1995 Aug;5(4):175–80 (33 ref.)

Near infrared spectroscopy: methodological principles and clinical application in preterm infants. Bernert G, et al. **Wien Klin Wochenschr** 1995;107(19):569–73 (36 ref.)

[Coronary microangiopathy in hypertensive heart disease: pathogenesis, diagnosis and therapy] Motz W, et al. **Herz** 1995 Dec;20(6):355–64 (52 ref.) (Eng. Abstr.) **(Ger)**

OXYGEN DEFICIENCY see **ANOXIA**

OXYGEN INHALATION THERAPY

Domiciliary oxygen. Wilkinson J, et al. **Br J Clin Pract** 1996 Apr-May;50(3):151–3 (8 ref.)

Current aspects in the management of pneumonia. Woodhead M. **Br J Clin Pract** 1995 Jul-Aug;49(4):205–10 (83 ref.)

Current thoughts regarding treatment of chronic obstructive pulmonary disease. Celli BR. **Med Clin North Am** 1996 May;80(3):589–609 (120 ref.)

Home oxygen therapy. O'Donohue WJ Jr. **Med Clin North Am** 1996 May;80(3):611–22 (38 ref.)

Selection criteria for pulmonary rehabilitation. Ambrosino N, et al. **Respir Med** 1996 Jul;90(6):317–22 (36 ref.)

[Is infection and septic shock caused by a global oxygen deficiency? An overview in 2 parts. 1: Infection and correlation between DO2 and VO2] Ensinger H, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Apr; 31(3):132–42 (0 ref.) (Eng. Abstr.) **(Ger)**

[Oxygen therapy and pulmonary hypertension in chronic obstructive bronchopneumopathies] Gensini G, et al. **Recenti Prog Med** 1996 Feb;87(2):81–5 (31 ref.) (Eng. Abstr.) **(Ita)**

[Home days ratio in patients treated with long-term oxygen therapy] Ando M, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Oct; 33(10):1086–92 (7 ref.) (Eng. Abstr.) **(Jpn)**

INSTRUMENTATION

Noninvasive nasal mask positive pressure ventilation in a pediatric patient with acute hypoxic respiratory failure. Padman R, et al. **Pediatr Emerg Care** 1996 Feb;12(1):44–7 (63 ref.)

NURSING

Mastering emergency airway management. Somerson SJ, et al. **Am J Nurs** 1996 May;96(5):24–30; quiz 31 (11 ref.)

OXYGEN SPECIES, REACTIVE see **REACTIVE OXYGEN SPECIES**

OXYGENASES

[Metabolic enzymes of neurotoxin: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and Parkinson's disease] Wu RF, et al. **Seikagaku** 1995 Nov; 67(11):1307–11 (15 ref.) **(Jpn)**

ANTAGONISTS & INHIBITORS

Cytochrome P450 monooxygenases and interactions of psychotropic drugs: a five-year update. Shen WW. **Int J Psychiatry Med** 1995;25(3):277–90 (78 ref.)

METABOLISM

Renal cytochrome P450. Schwartzman ML, et al. **J Lipid Mediat Cell Signal** 1995 Oct;12(2–3):229–42 (58 ref.)

Pesticide-metabolizing enzymes. Hodgson E, et al. **Toxicol Lett** 1995 Dec;82–83:73–81 (41 ref.)

PHYSIOLOGY

[Cytochrome P450-dependent monooxygenase system and anesthetics] Chen TL, et al. **Acta Anaesthesiol Sin** 1995 Sep;33(3):185–94 (64 ref.) (Eng. Abstr.) **(Chi)**

OXYGENATION, EXTRACORPOREAL MEMBRANE see **EXTRACORPOREAL MEMBRANE OXYGENATION**

OXYGENATION, HYPERBARIC see **HYPERBARIC OXYGENATION**

OXYMETHOLONE

ADVERSE EFFECTS

Hepatocellular carcinoma associated with anabolic steroid therapy: report of a case and review of the Japanese literature. Kosaka A, et al. **J Gastroenterol** 1996 Jun; 31(3):450–4 (24 ref.)

OXYNEURINE see **BETAINE**

OXYNTIC CELLS see **PARIETAL CELLS, GASTRIC**

OXYNTOMODULIN see **ENTEROGLUCAGON**

OXYPROLINE see **HYDROXYPROLINE**

OXYTHIAMINE

PHARMACOLOGY

[Is oxythiamine an antivitamin?] Vinogradov VV, et al. **Biokhimiia** 1995 Oct;60(10):1564–74 (107 ref.) (Eng. Abstr.) **(Rus)**

OXYTOCICS

Oxytocin to induce labor. Shyken JM, et al. **Clin Obstet Gynecol** 1995 Jun;38(2):232–45 (70 ref.)

The role of prostaglandins in labor and delivery. O'Brien WF. **Clin Perinatol** 1995 Dec;22(4):973–84 (40 ref.)

The use of oxytocin. Shyken JM, et al. **Clin Perinatol** 1995 Dec;22(4):907–31 (93 ref.)

[Induced labor by pharmacological methods. Advantages and disadvantages] Rotten D. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24 Suppl 1:13–27 (42 ref.) **(Fre)**

ADMINISTRATION & DOSAGE

Intraumbilical vein injection of prostaglandin F2 alpha in retained placenta. Bider D, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Jan;64(1):59–61 (13 ref.)

THERAPEUTIC USE

Prevention of postpartum haemorrhage. de Groot AN. **Baillieres Clin Obstet Gynaecol** 1995 Sep;9(3):619–31 (41 ref.)

[Postpartum hemorrhage. Current management] Bertault D, et al. **Presse Med** 1995 Oct 14;24(30):1397–9 (15 ref.) (Eng. Abstr.) **(Fre)**

OXYTOCIN

see related
OXYTOCICS
RECEPTORS, OXYTOCIN

Oxytocin to induce labor. Shyken JM, et al. **Clin Obstet Gynecol** 1995 Jun;38(2):232–45 (70 ref.)

ADMINISTRATION & DOSAGE

Novel approach to oxytocin induction-augmentation of labor. Application of oxytocin physiology during pregnancy. Dawood MY. **Adv Exp Med Biol** 1995; 395:585–94 (41 ref.)

ANALOGS & DERIVATIVES

Structure and organization of the isotocin and vasotocin genes from teleosts. Venkatesh B, et al. **Adv Exp Med Biol** 1995;395:629–38 (24 ref.)

ANTAGONISTS & INHIBITORS

Potential use of oxytocin and vasopressin V1a antagonists in the treatment of preterm labour and primary dysmenorrhoea. Akerlund M, et al. **Adv Exp Med Biol** 1995; 395:595–600 (32 ref.)

Progress in the development of oxytocin antagonists for use in preterm labor. Pettibone DJ, et al. **Adv Exp Med Biol** 1995;395:601–12 (49 ref.)

Atosiban. Shubert PJ. **Clin Obstet Gynecol** 1995 Dec; 38(4):722–4 (12 ref.)

BIOSYNTHESIS

Synthesis and metabolism of oxytocin in late gestation in human decidua. Mitchell BF, et al. **Adv Exp Med Biol** 1995;

395:365–80 (69 ref.)
Oxytocin synthesis and metabolism in human decidua. Mitchell BF. **Reprod Fertil Dev** 1995;7(3):319–21 (12 ref.)

BLOOD

[Oxytocin (OT)—measurement and its clinical implication] **Tanaka T, et al. Nippon Rinsho** 1995 Mar;53 Su Pt 2:308–14 (32 ref.) **(Jpn)**

GENETICS

Man and the chimaera. Selective versus neutral oxytocin evolution. Acher R, et al. **Adv Exp Med Biol** 1995; 395:615–27 (59 ref.)
Functional domains in the oxytocin gene for regulation of expression and biosynthesis of gene products. Burbach JP, et al. **Adv Exp Med Biol** 1995;395:9–21 (81 ref.)
Oxytocin transgenic mice. Murphy D, et al. **Adv Exp Med Biol** 1995;395:67–78 (57 ref.)
Regulation of oxytocin expression in the bovine corpus luteum. Orphan receptors and the oxytocin promoter. Walther N, et al. **Adv Exp Med Biol** 1995;395:79–90 (63 ref.)
Vasopressin and oxytocin: molecular biology and evolution of the peptide hormones and their receptors. Mohr E, et al. **Vitam Horm** 1995;51:235–66 (137 ref.)

IMMUNOLOGY

Development and evolutionary aspects of thymic T cell education to neuroendocrine self. Geenen V, et al. **Acta Haematol** 1996;95(3–4):263–7 (27 ref.)

METABOLISM

Strategies for cell biological studies in oxytocinergic neurons. Gainer H, et al. **Adv Exp Med Biol** 1995;395:1–8 (58 ref.)

PHYSIOLOGY

Comparative aspects of oxytocin–like hormones in marsupials. Bathgate RA, et al. **Adv Exp Med Biol** 1995; 395:639–55 (99 ref.)
Novel approach to oxytocin induction–augmentation of labor. Application of oxytocin physiology during pregnancy. Dawood MY. **Adv Exp Med Biol** 1995; 395:585–94 (41 ref.)
Pathways to parturition. Douglas AJ, et al. **Adv Exp Med Biol** 1995;395:381–94 (69 ref.)
Somatodendritic autoreceptors on oxytocin neurones. Freund–Mercier MJ, et al. **Adv Exp Med Biol** 1995; 395:185–94 (31 ref.)
Estrogen modulation of oxytocin and its relation to behavior. McCarthy MM. **Adv Exp Med Biol** 1995;395:235–45 (67 ref.)
Oxytocin and prostatic function. Nicholson HD, et al. **Adv Exp Med Biol** 1995;395:529–38 (42 ref.)
Oxytocin and the anterior pituitary gland. Samson WK, et al. **Adv Exp Med Biol** 1995;395:355–64 (63 ref.)
Establishing behavioral and physiological functions of central oxytocin: insights from studies of oxytocin and ingestive behaviors. Verbalis JG, et al. **Adv Exp Med Biol** 1995; 395:209–25 (61 ref.)
Influence of reproductive state and ovarian steroids on facilitation of the milk–ejection reflex by central oxytocin. Wakerley JB, et al. **Adv Exp Med Biol** 1995;395:117–32 (56 ref.)
Luteotropic and luteolytic effects of oxytocin in the porcine corpus luteum. Wuttke W, et al. **Adv Exp Med Biol** 1995; 395:495–506 (42 ref.)
Some aspects on the mechanism of human labor and delivery. Husslein P, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 May;59 Suppl:S3–7 (32 ref.)
Oxytocin and female sexuality. Anderson–Hunt M, et al. **Gynecol Obstet Invest** 1995;40(4):217–21 (40 ref.)

SECRETION

Release of oxytocin within the supraoptic nucleus. Mechanisms, physiological significance and antisense targeting. Neumann I, et al. **Adv Exp Med Biol** 1995; 395:173–83 (44 ref.)
Oxytocin in bovine and porcine granulosa cells. Regulation of secretion and biological effects. Sirotkin AV, et al. **Adv Exp Med Biol** 1995;395:541–2 (11 ref.)

THERAPEUTIC USE

The use of oxytocin. Shyken JM, et al. **Clin Perinatol** 1995 Dec;22(4):907–31 (93 ref.)
[Postpartum hemorrhage. Current management] Bertault D, et al. **Presse Med** 1995 Oct 14;24(30):1397–9 (15 ref.) (Eng. Abstr.) **(Fre)**

OXYTOCIN RECEPTORS see **RECEPTORS, OXYTOCIN**

OXYTOCINASE

BLOOD

[Cystine aminopeptidase] Murai T. **Nippon Rinsho** 1995 Feb; 53 Su Pt 1:307–10 (14 ref.) **(Jpn)**

OXYVANADIUM see **VANADATES**

OZONE

Ozone depletion update. Coldiron BM. **Dermatol Surg** 1996 Mar;22(3):296–9 (11 ref.)
Respiratory effects of air pollutants: experimental studies in humans [see comments] Sandström T. **Eur Respir J** 1995 Jun;8(6):976–95 (221 ref.) Comment in: Eur Respir J 1995 Jun;8(6):883–4.
[Ozone depletion—does the incidence of skin cancer increase? (editorial)] Jokela K, et al. **Duodecim** 1994; 110(19):1756–9 (20 ref.) **(Fin)**
[Chlorination and ozonation of contaminants in water environment and role of free radicals] Hamada A. **Yakugaku Zasshi** 1995 Oct;115(10):790–804 (52 ref.) (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Abatement of tropospheric ozone: effects of strategies to improve air quality on public health and other sectors. Guest CS, et al. **Aust N Z J Public Health** 1996 Jun; 20(3):301–8 (55 ref.)
The free radical basis of air pollution: focus on ozone. Kelly FJ, et al. **Respir Med** 1995 Nov;89(10):647–56 (77 ref.)

CHEMISTRY

The ozone hole. Lehmann P. **Med J Aust** 1995 Dec 4–18; 163(11–12):576–8 (7 ref.)

METABOLISM

The cascade mechanism to explain ozone toxicity: the role of lipid ozonation products. Pryor WA, et al. **Free Radic Biol Med** 1995 Dec;19(6):935–41 (42 ref.)

PHARMACOKINETICS

Uptake and fate of ozone in the respiratory tract. Miller FJ. **Toxicol Lett** 1995 Dec;82–83:277–85 (43 ref.)

THERAPEUTIC USE

Does ozone therapy normalize the cellular redox balance? Implications for therapy of human immunodeficiency virus infection and several other diseases. Bocci V. **Med Hypotheses** 1996 Feb;46(2):150–4 (40 ref.)
[Therapeutic potential of ozone—possible side–effects] Avivi I, et al. **Harefuah** 1996 Mar 1;130(5):327–30 (53 ref.) **(Heb)**

TOXICITY

Oxidative damage by ozone and nitrogen dioxide: synergistic toxicity in vivo but no evidence of synergistic oxidative damage in an extracellular fluid. O'Neill CA, et al. **Biochem Soc Symp** 1995;61:139–52 (49 ref.)
Effect of oxidant air pollutants on the respiratory system: insights from experimental animal research. Chitano P, et al. **Eur Respir J** 1995 Aug;8(8):1357–71 (182 ref.)
The cascade mechanism to explain ozone toxicity: the role of lipid ozonation products. Pryor WA, et al. **Free Radic Biol Med** 1995 Dec;19(6):935–41 (42 ref.)
Ozone–induced human respiratory dysfunction and disease. Bromberg PA, et al. **Toxicol Lett** 1995 Dec;82–83:307–16 (57 ref.)
Genetic susceptibility to ozone exposure. Kleeberger SR. **Toxicol Lett** 1995 Dec;82–83:295–300 (32 ref.)
A new mechanism for the toxicity of ozone. Pryor WA, et al. **Toxicol Lett** 1995 Dec;82–83:287–93 (40 ref.)
Dose–effect models for ozone exposure: tool for quantitative risk estimation. van Bree L, et al. **Toxicol Lett** 1995 Dec; 82–83:317–21 (33 ref.)
Interaction of air pollutants and pulmonary allergic responses in experimental animals. Gilmour MI. **Toxicology** 1995 Dec 28;105(2–3):335–42 (48 ref.)
[Ozone: myths and reality] Gebbers JO. **Schweiz Rundsch Med Prax** 1996 Aug 13;85(33):971–7 (70 ref.) (Eng. Abstr.) **(Ger)**

P1 PURINOCEPTORS see **RECEPTORS, PURINERGIC P1**

P2 PROTEIN see **MYELIN P2 PROTEIN**

P2 PURINOCEPTORS see **RECEPTORS, PURINERGIC P2**

P21(C-HA-RAS) see **PROTO-ONCOGENE PROTEIN P21(RAS)**

P21(C-KI-RAS) see **PROTO-ONCOGENE PROTEIN P21(RAS)**

P21(C-RAS) see **PROTO-ONCOGENE PROTEIN P21(RAS)**

P21(N-RAS) see **PROTO-ONCOGENE PROTEIN P21(RAS)**

P21(RAS) see **PROTO-ONCOGENE PROTEIN P21(RAS)**

P21(V-HA-RAS) see **ONCOGENE PROTEIN P21(RAS)**

P21(V-KI-RAS) see **ONCOGENE PROTEIN P21(RAS)**

P34CDC2 PROTEIN see **PROTEIN P34CDC2**

P39(C-JUN) see **PROTO-ONCOGENE PROTEINS C-JUN**

P40(TAX) see **GENE PRODUCTS, TAX**

P53 GENES see **GENES, P53**

P53 PROTEIN see **PROTEIN P53**

P55(C-FOS) see **PROTO-ONCOGENE PROTEINS C-FOS**

P55(V-FOS) see **ONCOGENE PROTEINS V-FOS**

P62(C-MYC) see **PROTO-ONCOGENE PROTEINS C-MYC**

P65(GAG-JUN) see **ONCOGENE PROTEIN P65(GAG-JUN)**

P75(GAG-FOS-FOX) see **ONCOGENE PROTEINS V-FOS**

P105-RB PROTEIN see **RETINOBLASTOMA PROTEIN**

P145(C-KIT) see **PROTO-ONCOGENE PROTEINS C-KIT**

P185(C-NEU) see **PROTO-ONCOGENE PROTEINS C-ERBB-2**

P300 EVENT-RELATED POTENTIALS see **EVENT-RELATED POTENTIALS, P300**

P-CADHERINS see **CADHERINS**

P-CELL STIMULATING FACTOR see **INTERLEUKIN-3**

P-GLYCOPROTEIN

see related
DRUG RESISTANCE, MULTIPLE

[Multidrug resistance and its reversal. General review of fundamental aspects] Robert J. **Ann Biol Clin (Paris)** 1996; 54(1):3–8 (50 ref.) (Eng. Abstr.) **(Fre)**

ANALYSIS

Methods to detect P-glycoprotein–associated multidrug resistance in patients' tumors: consensus recommendations. Beck WT, et al. **Cancer Res** 1996 Jul 1;56(13):3010–20 (66 ref.)
P-glycoprotein: clinical significance and methods of analysis. van der Heyden S, et al. **Crit Rev Clin Lab Sci** 1995; 32(3):221–64 (174 ref.)
How to probe clinical tumour samples for P-glycoprotein and multidrug resistance–associated protein. Broxterman HJ, et al. **Eur J Cancer** 1996 Jun;32A(6):1024–33 (86 ref.)
Diagnosis and reversal of multidrug resistance in paediatric cancers. Chan HS, et al. **Eur J Cancer** 1996 Jun; 32A(6):1051–61 (153 ref.)
MDR1/P-glycoprotein in haematological neoplasms. Marie JP, et al. **Eur J Cancer** 1996 Jun;32A(6):1034–8 (81 ref.)
[Biology and clinical relevance of multidrug resistance associated antigen] Utsumi M, et al. **Nippon Rinsho** 1996 Jun;54(6):1690–7 (56 ref.) (Eng. Abstr.) **(Jpn)**

ANTAGONISTS & INHIBITORS

Clinical trials of P-glycoprotein reversal in solid tumours. Ferry DR, et al. **Eur J Cancer** 1996 Jun;32A(6):1070–81 (119 ref.)
Pharmacological considerations in the modulation of multidrug resistance. Fisher GA, et al. **Eur J Cancer** 1996 Jun;32A(6):1082–8 (69 ref.)
Experimental reversal of P-glycoprotein–mediated multidrug resistance by pharmacological chemosensitisers. Ford JM. **Eur J Cancer** 1996 Jun;32A(6):991–1001 (161 ref.)
Reversal of multidrug resistance in acute myeloid leukaemia and other haematological malignancies. Sonneveld P. **Eur J Cancer** 1996 Jun;32A(6):1062–9 (97 ref.)

BIOSYNTHESIS

Regulation of multidrug resistance through the cAMP and EGF signalling pathways. Rohlff C, et al. **Cell Signal** 1995 Jul;7(5):431–43 (131 ref.)
P-glycoprotein expression and regulation. Age–related changes and potential effects on drug therapy. Gupta S. **Drugs Aging** 1995 Jul;7(1):19–29 (81 ref.)
Intrinsic expression of the multidrug transporter, P-glycoprotein 170, in multiple myeloma: implications for treatment. Pilarski LM, et al. **Leuk Lymphoma** 1995 May; 17(5–6):367–74 (70 ref.)

CHEMISTRY

[Structure and function of P-glycoprotein in antitumor agent resistance; implication for clinical setting] Tsuruo T. **Nippon Rinsho** 1995 Oct;53(10):2604–11 (38 ref.) (Eng. Abstr.) **(Jpn)**

DEFICIENCY

Multidrug resistance and the role of P-glycoprotein knockout mice. Schinkel AH, et al. **Eur J Cancer** 1995 Jul–Aug; 31A(7–8):1295–8 (30 ref.)

P-GLYCOPROTEIN

DRUG EFFECTS

MDR1 reversal: criteria for clinical trials designed to overcome the multidrug resistance phenotype. Hegewisch-Becker S. **Leukemia** 1996 Jul;10 Suppl 3:S32-S38 (53 ref.)

GENETICS

The multidrug-resistance gene in gene therapy of cancer and hematopoietic disorders. Licht T, et al. **Ann Hematol** 1996 Apr;72(4):184-93 (118 ref.)

Multidrug resistance. Moscow JA, et al. **Cancer Chemother Biol Response Modif** 1996;16:111-31 (149 ref.)

Transfer of the MDR1 gene into haematopoietic cells. Baudard M, et al. **Eur J Cancer** 1996 Jun;32A(6):1019-23 (52 ref.)

What have we learnt thus far from mice with disrupted P-glycoprotein genes? Borst P, et al. **Eur J Cancer** 1996 Jun;32A(6):985-90 (39 ref.)

Oligonucleotide modulation of multidrug resistance. Bouffard DY, et al. **Eur J Cancer** 1996 Jun;32A(6):1010-8 (111 ref.)

METABOLISM

Multidrug resistance proteins and other drug transport-related resistance to natural product agents. Broxterman HJ, et al. **Curr Opin Oncol** 1995 Nov; 7(6):532-40 (78 ref.)

MDR1 gene expression in solid tumours. Goldstein LJ. **Eur J Cancer** 1996 Jun;32A(6):1039-50 (84 ref.)

MDR1/P-glycoprotein expression in colorectal cancer. Linn SC, et al. **Eur J Cancer** 1995 Jul-Aug;31A(7-8):1291-4 (30 ref.)

MDR1 gene expression: evaluation of its use as a molecular marker for prognosis and chemotherapy of bone and soft tissue sarcomas. Stein U, et al. **Eur J Cancer** 1996 Jan; 32A(1):86-92 (82 ref.)

The catalytic cycle of P-glycoprotein. Senior AE, et al. **FEBS Lett** 1995 Dec 27;377(3):285-9 (42 ref.)

[Resistance to chemotherapy in cancers of the kidney and therapeutic perspectives] Oudard S, et al. **J Urol (Paris)** 1995;101(3):122-4 (25 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

P-glycoprotein: its role in drug resistance. Ling V. **Am J Med** 1995 Dec 29;99(6A):31S-34S (55 ref.)

P-glycoproteins and multidrug resistance. Bellamy WT. **Annu Rev Pharmacol Toxicol** 1996;36:161-83 (127 ref.)

The role of the MDR protein in altered drug translocation across tumor cell membranes. Roepe PD. **Biochim Biophys Acta** 1995 Dec 20;1241(3):385-405 (135 ref.)

P-glycoprotein--a mediator of multidrug resistance in tumour cells. Germann UA. **Eur J Cancer** 1996 Jun; 32A(6):927-44 (280 ref.)

Biology of the multidrug resistance-associated protein, MRP. Loe DW, et al. **Eur J Cancer** 1996 Jun;32A(6):945-57 (188 ref.)

Experimental modulation of MRP (multidrug resistance-associated protein)-mediated resistance. Twentyman PR, et al. **Eur J Cancer** 1996 Jun; 32A(6):1002-9 (61 ref.)

The role of mdr2 P-glycoprotein in biliary lipid secretion. Cross-talk between cancer research and biliary physiology. Oude Elferink RP, et al. **J Hepatol** 1995 Nov;23(5):617-25 (62 ref.)

Structure-activity-relationship studies on modulators of the multidrug transporter P-glycoprotein--an overview. Ecker G, et al. **Wien Klin Wochenschr** 1995;107(22):681-6 (51 ref.)

[Structure and function of P-glycoprotein in antitumor agent resistance; implication for clinical setting] Tsuruo T. **Nippon Rinsho** 1995 Oct;53(10):2604-11 (38 ref.) (Eng. Abstr.) **(Jpn)**

[Mechanism of resistance to antitumor agents--its involvement in blood-brain barrier] Tsuruo T. **Yakugaku Zasshi** 1995 Jul;115(7):513-22 (36 ref.) (Eng. Abstr.) **(Jpn)**

P SELECTIN see **P-SELECTIN**

PABA see **4-AMINOBENZOIC ACID**

PACEMAKER, ARTIFICIAL

Basic principles of permanent cardiac pacing. Rozkovec A. **Br J Hosp Med** 1996 Jan 17-Feb 6;55(1-2):31-7 (16 ref.)

Advances in pacing. Skehan JD. **Br J Hosp Med** 1996 Jan 17-Feb 6;55(1-2):41-3 (6 ref.)

The patient with a pacemaker or related device. Bourke ME. **Can J Anaesth** 1996 May;43(5 Pt 2):R24-41 (28 ref.) **(Eng, Fre)**

Pacing and atrial fibrillation. Kerr CR, et al. **Can J Cardiol** 1996 Jan;12 Suppl A:36A-39A (31 ref.)

Nonpharmacological therapy of atrial fibrillation. Klein GJ, et al. **Can J Cardiol** 1996 Jan;12 Suppl A:49A-50A (18 ref.)

Issues in cardiac pacing: optimising pacemaker therapy [editorial] Gambhir DS. **Indian Heart J** 1996 Mar-Apr; 48(2):115-7 (32 ref.)

Cardiac pacing [see comments] Kusumoto FM, et al. **N Engl J Med** 1996 Jan 11;334(2):89-97 (53 ref.) Comment in: N Engl J Med 1996 May 30;334(22):1476-7.

Management of intracardiac device recalls: a consensus conference. Participants of the Consensus Conference. North American Society of Cardiac Pacing and Electrophysiology (NASPE). Goldman BS, et al. **Pacing Clin Electrophysiol** 1996 Jan;19(1):7-17 (14 ref.)

[Multifactor prevention of endocarditis and cardiac pacemakers. A prospective study apropos of 207 patients] Graux P, et al. **Ann Cardiol Angeiol (Paris)** 1996 Mar; 45(3):113-8 (34 ref.) (Eng. Abstr.) **(Fre)**

[New indications for cardiac pacing] Davy JM, et al. **Arch Mal Coeur Vaiss** 1995 Dec;88 Spec No 5:55-62 (43 ref.) (Eng. Abstr.) **(Fre)**

[Cardiac pacemaker dysfunction secondary to outside interference: a review] Grobéty M, et al. **Schweiz Med Wochenschr** 1996 Apr 27;126(17):723-33 (32 ref.) (Eng. Abstr.) **(Fre)**

[Electrocoagulation in patients with cardiac pacemakers: what should be considered?] Habicht JM, et al. **Chirurg** 1995 Aug;66(8):774-9 (22 ref.) (Eng. Abstr.) **(Ger)**

[Current pacemaker treatment and technology] Candinas R, et al. **Schweiz Rundsch Med Prax** 1996 May 14; 85(20):663-70 (24 ref.) (Eng. Abstr.) **(Ger)**

[How to regulate the heart rate in a wearer of a cardiac pacemaker] Rossi P. **Cardiologia** 1996 Mar;41(3):227-40 (29 ref.) **(Ita)**

ADVERSE EFFECTS

Pacemaker lead infection: detection by multiplane transesophageal echocardiography. Tighe DA, et al. **Am Heart J** 1996 Mar;131(3):616-8 (8 ref.)

[Septicemia and endocarditis related to transvenous pacing leads of pacemakers: surgical indications and results] Leprince P, et al. **Arch Mal Coeur Vaiss** 1995 Feb; 88(2):241-6 (20 ref.) (Eng. Abstr.) **(Fre)**

[Contact dermatitis following cardiac pacemaker implantation] Moïni C, et al. **Arch Mal Coeur Vaiss** 1996 Feb;89(2):253-6 (12 ref.) (Eng. Abstr.) **(Fre)**

[Paroxysmal nocturnal dyspnea as a severe expression of the pacemaker syndrome] Minutiello L. **Minerva Cardioangiol** 1996 Mar;44(3):133-40 (9 ref.) (Eng. Abstr.) **(Ita)**

[Removal of infected pacemaker leads in the elderly under extracorporeal circulation: two case reports and review of Japanese literature] Sato M, et al. **Kyobu Geka** 1995 Nov; 48(12):1009-12 (11 ref.) (Eng. Abstr.) **(Jpn)**

PSYCHOLOGY

How to evaluate quality-of-life in pacemaker patients: problems and pitfalls [editorial] Linde C. **Pacing Clin Electrophysiol** 1996 Apr;19(4 Pt 1):391-7 (31 ref.)

STANDARDS

Management of intracardiac device recalls: a consensus conference. Goldman BS, et al. **Can J Cardiol** 1996 Jan; 12(1):37-45 (12 ref.)

PACEMAKERS, BIOLOGICAL see **BIOLOGICAL CLOCKS**

PACHYDERMOPERIOSTOSIS see **OSTEOARTHROPATHY, PRIMARY HYPERTROPHIC**

PACIFIC ISLAND AMERICANS see **ASIAN AMERICANS**

PACIFIERS see **INFANT CARE**

PACING, CARDIAC, ARTIFICIAL see **CARDIAC PACING, ARTIFICIAL**

PACINIAN CORPUSCLES

ANATOMY & HISTOLOGY

The structure and function of Pacinian corpuscles: a review. Bell J, et al. **Prog Neurobiol** 1994 Jan;42(1):79-128 (360 ref.)

PHYSIOLOGY

The structure and function of Pacinian corpuscles: a review. Bell J, et al. **Prog Neurobiol** 1994 Jan;42(1):79-128 (360 ref.)

PACKAGE INSERTS, DRUG see **DRUG LABELING**

PACKAGING, DRUG see **DRUG PACKAGING**

PACKAGING, FOOD see **FOOD PACKAGING**

PACKAGING, VIRAL see **VIRUS ASSEMBLY**

PACLITAXEL

[Paclitaxel (Taxol)] Hájek R. **Cas Lek Cesk** 1996 Jun 12; 135(12):393-6 (20 ref.) (Eng. Abstr.) **(Cze)**

ADMINISTRATION & DOSAGE

Theoretical and practical aspects of paclitaxel scheduling [editorial; comment] Gianni L. **Ann Oncol** 1995 Nov; 6(9):861-3 (26 ref.) Comment on: Ann Oncol 1995 Nov;6(9):883-5.

Treatment of metastatic breast cancer with paclitaxel and doxorubicin. Dombernowsky P, et al. **Semin Oncol** 1995 Dec;22(6 Suppl 15):13-7 (14 ref.)

Single-agent paclitaxel for the treatment of breast cancer: an overview. Hortobagyi GN, et al. **Semin Oncol** 1996 Feb; 23(1 Suppl 1):4-9 (17 ref.)

Combination regimens of paclitaxel and the platinum drugs as first-line regimens for ovarian cancer. Ozols RF. **Semin Oncol** 1995 Dec;22(6 Suppl 15):1-6 (17 ref.)

Role of paclitaxel in the treatment of breast cancer: the American Cooperative Group Experience. Sledge GW Jr. **Semin Oncol** 1996 Feb;23(1 Suppl 1):10-2 (9 ref.)

ADVERSE EFFECTS

Case report: paclitaxel-induced myocardial ischemia. Soe MS, et al. **Md Med J** 1996 Jan;45(1):41-3 (4 ref.)

Transient encephalopathy after paclitaxel (Taxol) infusion. Perry JR, et al. **Neurology** 1996 Jun;46(6):1596-9 (15 ref.)

ANALOGS & DERIVATIVES

Docetaxel: meeting the challenge of non-small cell lung cancer management. Le Chevalier T. **Anticancer Drugs** 1995 Jul;6 Suppl 4:13-7 (23 ref.)

Docetaxel: a new defence in the management of breast cancer. Piccart M. **Anticancer Drugs** 1995 Jul;6 Suppl 4:7-11 (12 ref.)

Docetaxel delivers new management opportunities for gastrointestinal carcinomas. Rougier P. **Anticancer Drugs** 1995 Jul;6 Suppl 4:25-9 (16 ref.)

Progress in preclinical and clinical studies for the development of new anticancer drugs in Japan, with emphasis on taxanes. Saijo N, et al. **Cancer Chemother Pharmacol** 1996;38 Suppl:S11-5 (21 ref.)

Taxoid compounds in breast cancer: current status and future prospects. Piccart MJ. **Cancer Treat Res** 1995;78:185-207 (56 ref.)

Docetaxel (Taxotere): single agent activity, development of combination treatment and reducing side-effects. Pronk LC, et al. **Cancer Treat Rev** 1995 Sep;21(5):463-78 (93 ref.)

Docetaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer. Fulton B, et al. **Drugs** 1996 Jun;51(6):1075-92 (86 ref.)

Early clinical studies with docetaxel. Docetaxel Investigators Group. Aapro M, et al. **Eur J Cancer** 1995;31A Suppl 4:S7-10 (13 ref.)

Preclinical pharmacology of docetaxel. Bissery MC. **Eur J Cancer** 1995;31A Suppl 4:S1-6 (42 ref.)

Docetaxel. Cortes JE, et al. **J Clin Oncol** 1995 Oct; 13(10):2643-55 (104 ref.)

Paclitaxel (Taxol) and docetaxel (Taxotere): active chemotherapeutic agents in lung cancer. Francis PA, et al. **Lung Cancer** 1995 Apr;12 Suppl 1:S163-72 (40 ref.)

The role of taxanes in the treatment of breast cancer. Capri G, et al. **Semin Oncol** 1996 Feb;23(1 Suppl 2):68-75 (62 ref.)

Taxoids: effective agents in anthracycline-resistant breast cancer. Ravdin PM. **Semin Oncol** 1995 Dec;22(6 Suppl 13):29-34 (34 ref.)

[Paclitaxel (Taxol) and docetaxel (Taxotere): results of phase II trials in monochemotherapy] Fumoleau P, et al. **Bull Cancer (Paris)** 1995 Aug;82(8):629-36 (58 ref.) (Eng. Abstr.) **(Fre)**

PHARMACOLOGY

Effects of taxol on the polymerization and posttranslational modification of class III beta-tubulin in P19 embryonal carcinoma cells. Laferrière NB, et al. **Biochem Cell Biol** 1995 Sep-Oct;73(9-10):687-94 (36 ref.)

[Combined effect of Paclitaxel and ionizing radiation. Experimental data of in-vitro and in-vivo models] Rübe C, et al. **Strahlenther Onkol** 1996 May;172 Suppl 1:2-5 (30 ref.) **(Ger)**

THERAPEUTIC USE

Progress in preclinical and clinical studies for the development of new anticancer drugs in Japan, with emphasis on taxanes. Saijo N, et al. **Cancer Chemother Pharmacol** 1996;38 Suppl:S11-5 (21 ref.)

Taxoid compounds in breast cancer: current status and future prospects. Piccart MJ. **Cancer Treat Res** 1995;78:185-207 (56 ref.)

Taxol plus radiation for head and neck cancer. Rosenthal DI, et al. **J Infus Chemother** 1995 Spring;5(2):46-54 (99 ref.)

Paclitaxel in patients with platinum-resistant ovarian cancer: a selected review of literature and clinical experience. Kudelka AP, et al. **J Med Assoc Thai** 1996 Apr;79(4):240-5 (26 ref.)

Paclitaxel (Taxol) and docetaxel (Taxotere): active chemotherapeutic agents in lung cancer. Francis PA, et al. **Lung Cancer** 1995 Apr;12 Suppl 1:S163-72 (40 ref.)

Paclitaxel: a unique tubulin interacting anticancer agent. Vyas DM, et al. **Prog Med Chem** 1995;32:289-337 (301 ref.)

The role of taxanes in the treatment of breast cancer. Capri G, et al. **Semin Oncol** 1996 Feb;23(1 Suppl 2):68-75 (62 ref.)

Combined-modality therapy for advanced non-small cell

lung cancer: paclitaxel and thoracic irradiation. Choy H, et al. **Semin Oncol** 1995 Dec;22(6 Suppl 15):38–44 (41 ref.)
Taxoids: effective agents in anthracycline-resistant breast cancer. Ravdin PM. **Semin Oncol** 1995 Dec;22(6 Suppl 13):29–34 (34 ref.)
The role of paclitaxel in the therapy of bladder cancer. Roth BJ. **Semin Oncol** 1995 Oct;22(5 Suppl 12):33–40 (73 ref.)
Memorial Sloan-Kettering Cancer Center experience with paclitaxel in the treatment of breast cancer. Seidman AD, et al. **Semin Oncol** 1995 Oct;22(5 Suppl 12):108–16 (53 ref.)
The role of paclitaxel in the management of coelomic epithelial carcinoma of the ovary: a review with emphasis on the Gynecologic Oncology Group experience. Thigpen T, et al. **Semin Oncol** 1995 Dec;22(6 Suppl 14):23–31 (30 ref.)
The role of paclitaxel in the treatment of head and neck cancer. Vokes EE, et al. **Semin Oncol** 1995 Oct;22(5 Suppl 12):8–12 (27 ref.)
[Paclitaxel, a new anticancer drug] Jekunen A, et al. **Duodecim** 1994;110(13):1235–40 (39 ref.) **(Fin)**
[Paclitaxel (Taxol) and docetaxel (Taxotere): results of phase II trials in monochemotherapy] Fumoleau P, et al. **Bull Cancer (Paris)** 1995 Aug;82(8):629–36 (58 ref.) (Eng. Abstr.) **(Fre)**
[Paclitaxel (Taxol)—drug of choice in ovarian cancer] Fishman A. **Harefuah** 1996 Apr 15;130(8):557–60 (47 ref.) **(Heb)**
[Use of taxol in the management of malignant tumors] Eckhardt S. **Orv Hetil** 1995 Sep 10;136(37):1987–93 (85 ref.) (Eng. Abstr.) **(Hun)**

PACS (RADIOLOGY) see RADIOLOGY INFORMATION SYSTEMS

PADUTIN see KALLIKREIN

PAECILOMYCES

Paecilomyces varioti peritonitis in patients on continuous ambulatory peritoneal dialysis. Chan TH, et al. **Am J Kidney Dis** 1996 Jan;27(1):138–42 (24 ref.)

PAF-ACETHER see PLATELET ACTIVATING FACTOR

PAGET'S DISEASE, EXTRAMAMMARY

ETIOLOGY

Paget's disease. Kürzl RG. **Semin Dermatol** 1996 Mar; 15(1):60–6 (62 ref.)

PATHOLOGY

Extramammary Paget's disease: a report of three cases and review of the literature. Png JC, et al. **Ann Acad Med Singapore** 1995 Jul;24(4):636–9 (30 ref.)
Ectopic extramammary Paget's disease affecting the upper abdomen. Onishi Y, et al. **Br J Dermatol** 1996 May; 134(5):958–61 (18 ref.)
The pathology of vulvar neoplasia. Lininger RA, et al. **Curr Opin Obstet Gynecol** 1996 Feb;8(1):63–8 (28 ref.)
Paget's sarcoma of the mandible. Gleich LL, et al. **Head Neck** 1995 Sep–Oct;17(5):425–30 (20 ref.)

PAGET'S DISEASE, MAMMARY

Paget's disease of the nipple-areola complex. Jamali FR, et al. **Surg Clin North Am** 1996 Apr;76(2):365–81 (82 ref.)

PAGET'S DISEASE OF BONE see OSTEITIS DEFORMANS

PAGET'S DISEASE OF BREAST see PAGET'S DISEASE, MAMMARY

PAH see P-AMINOHIPPURIC ACID

PAI-1 see PLASMINOGEN ACTIVATOR INHIBITOR 1

PAI-2 see PLASMINOGEN ACTIVATOR INHIBITOR 2

PAI-3 see PROTEIN C INHIBITOR

PAIN

see related
ANALGESIA
ANALGESICS
HYPERALGESIA
PALLIATIVE CARE

Influence of sex on pain assessment and management. Nevin K. **Ann Emerg Med** 1996 Apr;27(4):424–6 (26 ref.)
Pediatric pain control. Terndrup TE. **Ann Emerg Med** 1996 Apr;27(4):466–70 (17 ref.)
Prehospital pain research. Yealy DM. **Ann Emerg Med** 1996 Apr;27(4):471–3 (14 ref.)
Minimizing the pain of office procedures in children. Rothman KF. **Curr Opin Pediatr** 1995 Aug;7(4):415–22 (17 ref.)
Chronic pelvic pain. Lipscomb GH, et al. **Med Clin North Am** 1995 Nov;79(6):1411–25 (30 ref.)
Ontogeny of nociception and antinociception. Barr GA. **NIDA Res Monogr** 1995;158:172–201 (56 ref.)
The association of neuropathic pain, morphine tolerance and dependence, and the translocation of protein kinase C. Mayer DJ, et al. **NIDA Res Monogr** 1995;147:269–98 (111 ref.)
Chronic testicular pain. A workup and treatment guide for the primary care physician. Baum N, et al. **Postgrad Med** 1995 Oct;98(4):151–3, 156–8 (16 ref.)
The economics of pain. Mental health care costs among minorities. Ruiz P, et al. **Psychiatr Clin North Am** 1995 Sep;18(3):659–70 (23 ref.)
[Pelvic pain caused by pregnancy; a new disease?] Mens JM. **Ned Tijdschr Geneeskd** 1995 Sep 30;139(39):1964–6 (11 ref.) **(Dut)**
[Pain in hospitalized children] Foussat C, et al. **Arch Pediatr** 1995 Nov;2(11):1097–100 (14 ref.) (Eng. Abstr.) **(Fre)**
[Clinical examination of the shoulder and diagnostic maneuvers] Hallez R, et al. **Rev Med Brux** 1995 Jul–Aug; 16(4):164–7 (4 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

[On alleged radicular pain in patients with lumbar intervertebral disc hernias] Styczyński T, et al. **Neurol Neurochir Pol** 1995 Sep–Oct;29(5):747–52 (20 ref.) (Eng. Abstr.) **(Pol)**

DIAGNOSIS

Review of pain-measurement tools. Ho K, et al. **Ann Emerg Med** 1996 Apr;27(4):427–32 (64 ref.)
Measuring pain at baseline and over time. Menegazzi J. **Ann Emerg Med** 1996 Apr;27(4):433–5 (40 ref.)
Pain assessment and ethnicity. Todd KH. **Ann Emerg Med** 1996 Apr;27(4):421–3 (28 ref.)
Clinical versus statistical significance in the assessment of pain relief. Todd KH. **Ann Emerg Med** 1996 Apr; 27(4):439–41 (11 ref.)
Review: DSM-IV and pain. King SA. **Clin J Pain** 1995 Sep; 11(3):171–6 (24 ref.)
Muscle weakness and myalgia. MR imaging investigation. Fleckenstein JL. **Magn Reson Imaging Clin N Am** 1995 Nov;3(4):773–803 (43 ref.)
[Varicella-zoster-virus myelitis without herpes. An important differential diagnosis of the radicular syndrome] Jacobs A, et al. **Dtsch Med Wochenschr** 1996 Mar 15; 121(11):331–5 (25 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Clinical applications of excitatory amino acid antagonists in pain management. Wong CS, et al. **Acta Anaesthesiol Sin** 1995 Dec;33(4):227–32 (48 ref.)
Pharmacokinetics, efficacy, and safety of analgesia with a focus on tramadol HCl. Gibson TP. **Am J Med** 1996 Jul 31;101(1A):47S–53S (30 ref.)
Concerns with chronic analgesic therapy in elderly patients. Gloth FM 3rd. **Am J Med** 1996 Jul 31;101(1A):19S–24S (39 ref.)
A novel approach to the pharmacology of analgesics. Raffa RB. **Am J Med** 1996 Jul 31;101(1A):40S–46S (33 ref.)
Local anesthetics. Sklar DP. **Ann Emerg Med** 1996 Apr; 27(4):464–5 (10 ref.)
New pharmacological strategies for pain relief. Dray A, et al. **Annu Rev Pharmacol Toxicol** 1996;36:253–80 (193 ref.)
A guide to the understanding and use of tricyclic antidepressants in the overall management of fibromyalgia and other chronic pain syndromes. Godfrey RG. **Arch Intern Med** 1996 May 27;156(10):1047–52 (44 ref.)
Morphine in cancer pain: modes of administration. Expert Working Group of the European Association for Palliative Care. **BMJ** 1996 Mar 30;312(7034):823–6 (39 ref.)
Anticonvulsant drugs for management of pain: a systematic review. McQuay H, et al. **BMJ** 1995 Oct 21; 311(7012):1047–52 (53 ref.)
Neurophysiology of opioid poorly responsive pain. Dickenson AH. **Cancer Surv** 1994;21:5–16 (49 ref.)
Opioids and pain. Kanjhan R. **Clin Exp Pharmacol Physiol** 1995 Jun–Jul;22(6–7):397–403 (72 ref.)
Effective pain management in terminal care. Dahl JL. **Clin Geriatr Med** 1996 May;12(2):279–300 (92 ref.)
Pharmacology of neuropathic pain. Ollat H, et al. **Clin Neuropharmacol** 1995 Oct;18(5):391–404 (62 ref.)
Lornoxicam. A review of its pharmacology and therapeutic potential in the management of painful and inflammatory conditions. Balfour JA, et al. **Drugs** 1996 Apr;51(4):639–57 (76 ref.)
Amitriptyline. A review of its pharmacological properties and therapeutic use in chronic pain states. Bryson HM, et al. **Drugs Aging** 1996 Jun;8(6):459–76 (111 ref.)
Epidural analgesia during labor: continuous infusion or patient-controlled administration? Benhamou D. **Eur J Obstet Gynecol Reprod Biol** 1995 May;59 Suppl:S55–6 (9 ref.)
Spinal opioid systems in inflammation. Stanfa L, et al. **Inflamm Res** 1995 Jun;44(6):231–41 (119 ref.)
Opioid use in HIV patients with neurological changes. Paice JA, et al. **J Assoc Nurses AIDS Care** 1995 Jul–Aug; 6(4):28–36 (27 ref.)
The analgesic efficacy of ketorolac for acute pain. Catapano MS. **J Emerg Med** 1996 Jan–Feb;14(1):67–75 (101 ref.)
Implementation of a formal treatment agreement for outpatient management of chronic nonmalignant pain with opioid analgesics. Burchman SL, et al. **J Pain Symptom Manage** 1995 Oct;10(7):556–63 (19 ref.)
Government regulatory influences on opioid prescribing and their impact on the treatment of pain of nonmalignant origin. Hill CS Jr. **J Pain Symptom Manage** 1996 May; 11(5):287–98 (38 ref.)
Quality improvement guidelines for the treatment of acute pain and cancer pain. American Pain Society Quality of Care Committee [see comments] **JAMA** 1995 Dec 20; 274(23):1874–80 (67 ref.) Comment in: **JAMA** 1995 Dec 20;274(23):1881–2.
The WHO analgesic ladder for cancer pain management. Stepping up the quality of its evaluation [see comments] Jadad AR, et al. **JAMA** 1995 Dec 20;274(23):1870–3 (40 ref.) Comment in: **JAMA** 1995 Dec 20;274(23):1881–2. Comment in: **JAMA** 1996 Mar 20;275(11):835; discussion 836. Comment in: **JAMA** 1996 Mar 20;275(11):835–6.
Managing cancer pain: basic principles and invasive treatments. Marshall KA. **Mayo Clin Proc** 1996 May; 71(5):472–7 (10 ref.)
Techniques to reduce the discomfort of paediatric laceration repair. Roberts PA, et al. **Med J Aust** 1996 Jan 1; 164(1):32–5 (37 ref.)
Pharmacologic treatment of cancer pain. Levy MH. **N Engl J Med** 1996 Oct 10;335(15):1124–32 (101 ref.)
Efficacy of famciclovir in the treatment of herpes zoster: reduction of pain associated with zoster. Boon RJ, et al. **Neurology** 1995 Dec;45(12 Suppl 8):S76–7 (9 ref.)
Etorphine elicits unique inhibitory-agonist and excitatory-antagonist actions at opioid receptors on sensory neurons: new rationale for improved clinical analgesia and treatment of opiate addiction. Crain SM, et al. **NIDA Res Monogr** 1995;147:234–68 (67 ref.)
Dual inhibitors of enkephalin-degrading enzymes (neutral endopeptidase 24.11 and aminopeptidase N) as potential new medications in the management of pain and opioid addiction. Roques BP, et al. **NIDA Res Monogr** 1995; 147:104–45 (149 ref.)
Future directions in the pharmacological management of hyperalgesic and allodynic pain states: the NMDA receptor. Yaksh TL, et al. **NIDA Res Monogr** 1995; 147:84–103 (63 ref.)
Pharmacologic management of cancer pain. Niles R. **Nurs Clin North Am** 1995 Dec;30(4):745–63 (83 ref.)
Sublingual and oral morphine administration. Review and new findings. Robison JM, et al. **Nurs Clin North Am** 1995 Dec;30(4):725–43 (51 ref.)
Use of nonsteroidal anti-inflammatory drugs in cancer. Pace V. **Palliat Med** 1995 Oct;9(4):273–86 (105 ref.)
Effective management of chronic pain. The analgesic dilemma. Stacey BR. **Postgrad Med** 1996 Sep;100(3):281–4, 287–90, 293 passim (27 ref.)
The management of central post-stroke pain. Bowsher D. **Postgrad Med J** 1995 Oct;71(840):598–604 (36 ref.)
Controlling the pain of cancer. Foley KM. **Sci Am** 1996 Sep; 275(3):164–5 (0 ref.)
The use of access devices in cancer pain control. Brant JM. **Semin Oncol Nurs** 1995 Aug;11(3):203–12 (44 ref.)
[Oral opioids for long-term treatment of chronic non-cancer pain] Dertwinkel R, et al. **Anaesthesist** 1996 Jun; 45(6):495–505 (53 ref.) (Eng. Abstr.) **(Ger)**
[Pain management in cancer patients] Willenbrink HJ, et al. **Dtsch Med Wochenschr** 1995 Oct 6;120(40):1363–6 (13 ref.) **(Ger)**
[Drug treatment of tumor pain] Larsen B, et al. **Internist (Berl)** 1996 Apr;37(4):425–40 (10 ref.) **(Ger)**
[Pain crises in patients with sickle cell diseases. Pathogenesis, clinical aspects, therapy] Dickerhoff R, et al. **Klin Padiatr** 1995 Nov–Dec;207(6):321–5 (29 ref.) (Eng. Abstr.) **(Ger)**
[Effectiveness of fixed analgesic combinations exemplified by thomapyrin] Aicher B, et al. **Wien Klin Wochenschr** 1996;108(8):219–33 (104 ref.) (Eng. Abstr.) **(Ger)**
[Ambulatory pain treatment in tumor patients] Keseberg A. **Z Gerontol Geriatr** 1995 Sep–Oct;28(5):328–34 (0 ref.) (Eng. Abstr.) **(Ger)**
[Capsaicin for arthritic pain] Niv D, et al. **Harefuah** 1996 Mar 15;130(6):415–20 (43 ref.) **(Heb)**
[Specific problems of analgesic therapy in hospital environment] Baños JE, et al. **Med Clin (Barc)** 1996 Feb 17;106(6):222–6 (59 ref.) **(Spa)**

ETHNOLOGY

Pain assessment and ethnicity. Todd KH. **Ann Emerg Med** 1996 Apr;27(4):421–3 (28 ref.)
Cultural aspects of pain in childbearing women. Weber SE. **J Obstet Gynecol Neonatal Nurs** 1996 Jan;25(1):67–72 (20 ref.)

ETIOLOGY

Famciclovir: efficacy in zoster and issues in the assessment of pain. Boon RJ, et al. **Adv Exp Med Biol** 1996;394:17–31 (37 ref.)
Diagnostic imaging of patients with acute scrotal pain. Barloon TJ, et al. **Am Fam Physician** 1996 Apr; 53(5):1734–50 (17 ref.)
Shoulder pain: the role of diagnostic injections. Larson HM, et al. **Am Fam Physician** 1996 Apr;53(5):1637–47 (10 ref.)
Match and mismatch: identifying the neuronal determinants of pain [comment] [see comments] Casey KL.

Ann Intern Med 1996 Jun 1;124(11):995–8 (35 ref.)
Comment on: Ann Intern Med 1996 Jun 1;124(11):939–49. Comment on: Ann Intern Med 1996 Jun 1;124(11):950–8. Comment on: Ann Intern Med 1996 Jun 1;124(11):959–69. Comment on: Ann Intern Med 1996 Jun 1;124(11):1006–8. Comment on: Ann Intern Med 1996 Jun 1;124(11):1008–1011. Comment in: Ann Intern Med 1996 Jun 1;124(11):939–49. Comment in: Ann Intern Med 1996 Jun 1;124(11):950–8. Comment in: Ann Intern Med 1996 Jun 1;124(11):959–8.

Chronic pain syndromes. Carette S. **Ann Rheum Dis** 1996 Aug;55(8):497–501 (75 ref.)

Soft tissue syndromes. Katz JN, et al.
Baillieres Clin Rheumatol 1995 Aug;9(3):585–98 (33 ref.)

Fibromyalgia. Raspe H, et al. **Baillieres Clin Rheumatol** 1995 Aug;9(3):599–614 (80 ref.)

Somatic pain--pathogenesis and prevention. Woolf CJ.
Br J Anaesth 1995 Aug;75(2):169–76 (126 ref.)

Pain and infertility—a rationale for different treatment approaches. Martin DC. **Br J Obstet Gynaecol** 1995 Oct; 102 Suppl 12:2–3 (20 ref.)

The sickle cell painful crisis in adults: phases and objective signs. Ballas SK. **Hemoglobin** 1995;19(6):323–33 (47 ref.)

Cervical discogenic syndrome: a cause of chronic head and neck pain. Senter BS. **J Miss State Med Assoc** 1995 Aug; 36(8):231–4 (15 ref.)

Understanding central post-stroke pain. Segatore M.
J Neurosci Nurs 1996 Feb;28(1):28–35 (74 ref.)

Magnetic resonance imaging of plantar fasciitis and other causes of heel pain. Kier R.
Magn Reson Imaging Clin N Am 1994 Feb;2(1):97–107 (35 ref.)

Diagnostic tests for the evaluation of back and neck pain. Haldeman S. **Neurol Clin** 1996 Feb;14(1):103–17 (52 ref.)

Central pain: diagnosis and treatment strategies. Gonzales GR. **Neurology** 1995 Dec;45(12 Suppl 9):S11–6; discussion S35–6 (24 ref.)

NGF as a mediator of inflammatory pain. McMahon SB. **Philos Trans R Soc Lond B Biol Sci** 1996 Mar 29; 351(1338):431–40 (86 ref.)

Phenotypic modification of primary sensory neurons: the role of nerve growth factor in the production of persistent pain. Woolf CJ. **Philos Trans R Soc Lond B Biol Sci** 1996 Mar 29;351(1338):441–8 (34 ref.)

1994 ASRA Lecture. The pathogenesis of neuropathic pain. Myers RR. **Reg Anesth** 1995 May–Jun;20(3):173–84 (56 ref.)

Exercise-induced lower leg pain. Rochcongar P.
Rev Rhum Engl Ed 1995 Nov;62(10):627–31 (35 ref.)

Controlling the pain of cancer. Foley KM. **Sci Am** 1996 Sep; 275(3):164–5 (0 ref.)

[Isolated punched-out lesions of the carpus and pain of the wrist] Dumontier C, et al. **Ann Radiol (Paris)** 1995; 38(5):287–92 (50 ref.) (Eng. Abstr.) **(Fre)**

[Molecular mechanisms of chronic pain] Tokunaga A, et al. **Masui** 1996 May;45(5):547–57 (63 ref.) (Eng. Abstr.) **(Jpn)**

[Pain mechanisms in reflex sympathetic dystrophy] Yokota T. **Nippon Seikeigeka Gakkai Zasshi** 1995 Sep;69(9):788–97 (30 ref.) **(Jpn)**

[Pain in the upper extremity after a stroke] Marchuk G, et al. **Lik Sprava** 1995 May–Jun;(5–6):55–61 (108 ref.) (Eng. Abstr.) **(Rus)**

GENETICS

The genetics of pain and pain inhibition. Mogil JS, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2;93(7):3048–55 (141 ref.)

IMMUNOLOGY

Immune activation: the role of pro-inflammatory cytokines in inflammation, illness responses and pathological pain states. Watkins LR, et al. **Pain** 1995 Dec;63(3):289–302 (135 ref.)

METABOLISM

Pharmacokinetics, efficacy, and safety of analgesia with a focus on tramadol HCl. Gibson TP. **Am J Med** 1996 Jul 31;101(1A):47S–53S (30 ref.)

Molecular biology of pain. Munglani R, et al.
Br J Anaesth 1995 Aug;75(2):186–92 (84 ref.)

Alterations in neurokinin 1 receptor gene expression in models of pain and inflammation. Krause JE, et al.
Can J Physiol Pharmacol 1995 Jul;73(7):854–9 (49 ref.)

Possible therapeutic application of GABAB receptor agonists and antagonists. Malcangio M, et al.
Clin Neuropharmacol 1995 Aug;18(4):285–305 (162 ref.)

NURSING

Special needs of preterm infants in the management of pain and discomfort. Stevens BJ, et al.
J Obstet Gynecol Neonatal Nurs 1995 Nov–Dec; 24(9):856–62 (65 ref.)

An algorithmic approach to cancer pain management. Hudzinski DM. **Nurs Clin North Am** 1995 Dec;30(4):711–23 (11 ref.)

PHYSIOPATHOLOGY

Approach to the management of nonmalignant pain. Katz WA. **Am J Med** 1996 Jul 31;101(1A):54S–63S (64 ref.)

Mechanisms of chronic pain. Markenson JA. **Am J Med** 1996 Jul 31;101(1A):6S–18S (141 ref.)

Cerebral mechanisms operating in the presence and absence of inflammatory pain. Jones AK, et al. **Ann Rheum Dis** 1996 Jul;55(7):411–20 (83 ref.)

Pathophysiology of joint pain. Kidd BL, et al.
Ann Rheum Dis 1996 May;55(5):276–83 (100 ref.)

Exercise-induced muscle damage and inflammation: a review. Pyne DB. **Aust J Sci Med Sport** 1994 Sep–Dec; 26(3–4):49–58 (133 ref.)

Nerve growth factor regulates nociception in human health and disease. Anand P. **Br J Anaesth** 1995 Aug;75(2):201–8 (64 ref.)

Imaging pain in humans. Berman J. **Br J Anaesth** 1995 Aug; 75(2):209–16 (40 ref.)

Spinal cord pharmacology of pain. Dickenson AH.
Br J Anaesth 1995 Aug;75(2):193–200 (71 ref.)

Inflammatory mediators of pain. Dray A. **Br J Anaesth** 1995 Aug;75(2):125–31 (60 ref.)

Developmental biology of inflammatory pain. Fitzgerald M. **Br J Anaesth** 1995 Aug;75(2):177–85 (124 ref.)

Visceral pain. McMahon SB, et al. **Br J Anaesth** 1995 Aug; 75(2):132–44 (114 ref.)

Descending control of pain. Stamford JA. **Br J Anaesth** 1995 Aug;75(2):217–27 (133 ref.)

Capsaicin and pain mechanisms. Winter J, et al.
Br J Anaesth 1995 Aug;75(2):157–68 (120 ref.)

Why does an inflammation in the joint hurt? [editorial] Schaible HG. **Br J Rheumatol** 1996 May;35(5):405–6 (11 ref.)

Neurophysiology of opioid poorly responsive pain. Dickenson AH. **Cancer Surv** 1994;21:5–16 (49 ref.)

Pain mechanisms and management: an update. Siddall PJ, et al. **Clin Exp Pharmacol Physiol** 1995 Oct;22(10):679–88 (91 ref.)

Comparison of functional characteristics of intradental A- and C-nerve fibres in dental pain. Ngassapa DN.
East Afr Med J 1996 Mar;73(3):207–9 (30 ref.)

The nature and consequences of childbirth pain. Brownridge P. **Eur J Obstet Gynecol Reprod Biol** 1995 May;59 Suppl:S9–15 (64 ref.)

Role of patient-controlled epidural analgesia in obstetrics. Gambling DR, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 May;59 Suppl:S39–46 (45 ref.)

Pain due to nerve damage: are inflammatory mediators involved? Tracey DJ, et al. **Inflamm Res** 1995 Oct; 44(10):407–11 (67 ref.)

Itch and pain. Teofoli P, et al. **Int J Dermatol** 1996 Mar; 35(3):159–66 (98 ref.)

The pain and discomfort of labor and birth. Lowe NK.
J Obstet Gynecol Neonatal Nurs 1996 Jan;25(1):82–92 (56 ref.)

Pain sensitivity, exercise and stoicism. Janal MN.
J R Soc Med 1996 Jul;89(7):376–81 (38 ref.)

The pathogenesis of chronic pain and fatigue syndromes, with special reference to fibromyalgia. Clauw DJ.
Med Hypotheses 1995 May;44(5):369–78 (83 ref.)

How should we measure pain in herpes zoster? Wood MJ. **Neurology** 1995 Dec;45(12 Suppl 8):S61–2 (5 ref.)

Biological rhythms in pain and in the effects of opioid analgesics. Labrecque G, et al. **Pharmacol Ther** 1995; 68(1):129–47 (80 ref.)

The genetics of pain and pain inhibition. Mogil JS, et al. **Proc Natl Acad Sci U S A** 1996 Apr 2;93(7):3048–55 (141 ref.)

Immediate early genes (IEGs) encoding for inducible transcription factors (ITFs) and neuropeptides in the nervous system: functional network for long-term plasticity and pain. Herdegen T, et al. **Prog Brain Res** 1995; 104:299–321 (184 ref.)

Interaction of neuropeptides and excitatory amino acids in the rat superficial spinal dorsal horn. Randić M, et al.
Prog Brain Res 1995;104:225–53 (306 ref.)

Peptidergic afferents: physiological aspects. Urban L, et al.
Prog Brain Res 1995;104:255–69 (71 ref.)

Prostaglandin-induced neuropeptide release from spinal cord. Vasko MR. **Prog Brain Res** 1995;104:367–80 (80 ref.)

Neuropeptides and spinal cord reflexes. Wiesenfeld-Hallin Z. **Prog Brain Res** 1995;104:271–82 (104 ref.)

[The roles of thalamic nucleus submedius in nociception and pain modulation] Tang JS, et al.
Sheng Li Ko Hsueh Chin Chan 1995 Oct;26(4):312–6 (20 ref.) (Eng. Abstr.) **(Chi)**

[From nociception to pain: to feel or not to feel (editorial)] Konttinen YT, et al. **Duodecim** 1994;110(6):545–8 (15 ref.) **(Fin)**

[Pain—from the physiological and internal medicine viewpoint] Lang E, et al. **Z Gerontol Geriatr** 1995 Sep–Oct; 28(5):318–27 (30 ref.) (Eng. Abstr.) **(Ger)**

[The nociceptive flexor reflex: a method for studying the brain mechanisms of pain control] Danilov AB, et al.
Zh Nevropatol Psikhiatr Im S S Korsakova 1996; 96(1):107–11 (63 ref.) **(Rus)**

PREVENTION & CONTROL

Assessing patient comfort: local infiltration of lidocaine during femoral sheath removal. Bowden SM, et al.
Am J Crit Care 1995 Sep;4(5):368–9 (4 ref.)

Studying emergency patients outside the emergency department. Sivilotti ML, et al. **Ann Emerg Med** 1996 Apr; 27(4):442–7 (24 ref.)

Pain evaluation and management in the nursing home. Ferrell BA. **Ann Intern Med** 1995 Nov 1;123(9):681–7 (75 ref.)

Pain management in children. Rice LJ. **Can J Anaesth** 1996 May;43(5 Pt 2):R155–62 (31 ref.) **(Eng, Fre)**

Management of painful procedures in the newborn. Stevens B. **Curr Opin Pediatr** 1996 Apr;8(2):102–7 (55 ref.)

Cancer pain management and the role of social work: barriers and interventions. Glajchen M, et al. **Health Soc Work** 1995 Aug;20(3):200–6 (35 ref.)

Multiple meanings of pain and complexities of pain management. Benoliel JQ. **Nurs Clin North Am** 1995 Dec; 30(4):583–96 (91 ref.)

Outcomes that provide evidence of change in cancer pain management. Dalton JA. **Nurs Clin North Am** 1995 Dec; 30(4):683–95 (53 ref.)

The importance of nursing research design and methods in cancer pain management. Enhancing care.
Gaston-Johansson F, et al. **Nurs Clin North Am** 1995 Dec; 30(4):597–607 (90 ref.)

[Pre-emptive analgesia] Wilder-Smith OH. **Anaesthesist** 1995 Dec;44 Suppl 3:S529–34 (49 ref.) (Eng. Abstr.) **(Ger)**

PSYCHOLOGY

Pain relief versus patient satisfaction. Afilalo M, et al.
Ann Emerg Med 1996 Apr;27(4):436–8 (8 ref.)

Psychological aspects of pain. Large RG.
Ann Rheum Dis 1996 Jun;55(6):340–5 (48 ref.)

Musculoskeletal pain syndromes that affect adolescents. Szer IS. **Arch Pediatr Adolesc Med** 1996 Jul;150(7):740–7 (23 ref.)

Language and pain expression. Waddie NA. **J Adv Nurs** 1996 May;23(5):868–72 (15 ref.)

Annotation: aspects of pain in children and adolescents. McGrath PJ. **J Child Psychol Psychiatry** 1995 Jul; 36(5):717–30 (50 ref.)

The pain and discomfort of labor and birth. Lowe NK.
J Obstet Gynecol Neonatal Nurs 1996 Jan;25(1):82–92 (56 ref.)

'Functional overlay', and illness behaviour in chronic pain: distress or malingering? Conceptual difficulties in medico-legal assessment of personal injury claims. Main CJ, et al. **J Psychosom Res** 1995 Aug;39(6):737–53 (58 ref.)

A multidimensional model of the antecedents of stress and coping appraisals: an approach to studying patients' perceptions of post cardiac surgery pain and their coping strategies. Shih FJ, et al.
Kao Hsiung I Hsueh Ko Hsueh Tsa Chih 1996 Apr; 12(4):202–15 (22 ref.)

Psychiatric aspects of chronic pain. Eisendrath SJ.
Neurology 1995 Dec;45(12 Suppl 9):S26–34; discussion S35–6 (36 ref.)

Multiple meanings of pain and complexities of pain management. Benoliel JQ. **Nurs Clin North Am** 1995 Dec; 30(4):583–96 (91 ref.)

The impact of pain on quality of life. A decade of research. Ferrell BR. **Nurs Clin North Am** 1995 Dec;30(4):609–24 (29 ref.)

Perspectives of chronic pain: an evaluative comparison of restrictive and comprehensive models. Novy DM, et al.
Psychol Bull 1995 Sep;118(2):238–47 (100 ref.)

Determinants and consequences of children's coping in the medical setting: conceptualization, review, and critique. Rudolph KD, et al. **Psychol Bull** 1995 Nov;118(3):328–57 (130 ref.)

[Pain and pain perception in the elderly from the viewpoint of rheumatology] Nehen HG. **Z Gerontol Geriatr** 1995 Sep–Oct;28(5):335–8 (10 ref.) (Eng. Abstr.) **(Ger)**

[Psychological diagnosis of pain and pain treatment in the elderly] Wilz G, et al. **Z Gerontol Geriatr** 1995 Sep–Oct; 28(5):312–7 (54 ref.) (Eng. Abstr.) **(Ger)**

[Pain and psychological disorders in the elderly] Wojnar J, et al. **Z Gerontol Geriatr** 1995 Sep–Oct;28(5):369–73 (22 ref.) (Eng. Abstr.) **(Ger)**

[Psychosomatic pain in children—a psychomuscular stress reaction?] Alfvén G. **Nord Med** 1995;110(11):275–9 (15 ref.) (Eng. Abstr.) **(Swe)**

RADIOTHERAPY

Strontium-89 for treatment of painful bone metastasis from prostate cancer. Altman GB, et al. **Oncol Nurs Forum** 1996 Apr;23(3):523–7 (30 ref.)

REHABILITATION

A rehabilitation approach to chronic pain in rheumatologic practice. Rome JD, et al. **Curr Opin Rheumatol** 1996 Mar; 8(2):163–8 (32 ref.)

The role of quadriceps exercise in the treatment of patellofemoral pain syndrome. Callaghan MJ, et al.
Sports Med 1996 May;21(5):384–91 (55 ref.)

[Psychological pain therapy] Budde HG. **Z Gastroenterol** 1996 Jun;34 Suppl 2:85–8 (25 ref.) **(Ger)**

SURGERY

Pain—old and new methods of study and treatment. Sweet WH. **Acta Neurochir Suppl (Wien)** 1995;64:83–7 (24 ref.)

THERAPY

The role of adjunctive therapy in the management of chronic nonmalignant pain. Allegrante JP. **Am J Med** 1996 Jul 31; 101(1A):33S–39S (69 ref.)

Approach to the management of nonmalignant pain. Katz WA. **Am J Med** 1996 Jul 31;101(1A):54S–63S (64 ref.)

Pain relief versus patient satisfaction. Afilalo M, et al. **Ann Emerg Med** 1996 Apr;27(4):436–8 (8 ref.)
Current pain-control practices and research. Afilalo M, et al. **Ann Emerg Med** 1996 Apr;27(4):404–7 (19 ref.)
Pain-control research opportunities and future directions. Cordell WH. **Ann Emerg Med** 1996 Apr;27(4):474–8 (7 ref.)
Establishing pain policies in emergency medicine. Terndrup TE. **Ann Emerg Med** 1996 Apr;27(4):408–11 (31 ref.)
Workshop on chronic pain, pain control, and patient outcomes in rheumatoid arthritis and osteoarthritis. Bellamy N, et al. **Arthritis Rheum** 1996 Mar;39(3):357–62 (26 ref.)
Recent advances in pain management. Siddall PJ, et al. **Aust N Z J Surg** 1995 Sep;65(9):674–85 (83 ref.)
Pain management in patients with pancreatic carcinoma. Caraceni A, et al. **Cancer** 1996 Aug 1;78(3 Suppl):639–53 (141 ref.)
Pain and symptom control in paediatric palliative care. Stevens MM, et al. **Cancer Surv** 1994;21:211–31 (47 ref.)
Nonpharmacologic pain management in terminal care. Urba SG. **Clin Geriatr Med** 1996 May;12(2):301–11 (37 ref.)
Infections complicating tunneled intraspinal catheter systems used to treat chronic pain. Byers K, et al. **Clin Infect Dis** 1995 Aug;21(2):403–8 (30 ref.)
Pain associated with spinal cord injury. Siddall PJ, et al. **Curr Opin Neurol** 1995 Dec;8(6):447–50 (40 ref.)
Management of chronic pain. Part II. Barkin RL, et al. **Dis Mon** 1996 Aug;42(8):457–507 (356 ref.)
Management of chronic pain. Part I. Barkin RL, et al. **Dis Mon** 1996 Jul;42(7):389–454 (242 ref.)
Managing chronic pain in children. **Drug Ther Bull** 1995 Jul; 33(7):52–5 (21 ref.)
Managing acute pain in children. **Drug Ther Bull** 1995 Jun; 33(6):41–4 (25 ref.)
Recent clinical trials of pain control: impact on quality of life. Ahmedzai S. **Eur J Cancer** 1995;31A Suppl 6:S2–7 (31 ref.)
Hypnosis treatment of clinical pain: understanding why hypnosis is useful. Holroyd J. **Int J Clin Exp Hypn** 1996 Jan;44(1):33–51 (130 ref.)
Meta-analyses to evaluate analgesic interventions: a systematic qualitative review of their methodology. Jadad AR, et al. **J Clin Epidemiol** 1996 Feb;49(2):235–43 (100 ref.)
A risk assessment of cervical manipulation vs. NSAIDs for the treatment of neck pain. Dabbs V, et al. **J Manipulative Physiol Ther** 1995 Oct;18(8):530–6 (43 ref.)
Special needs related to the pain and discomfort of patients with gynecologic cancer. Miaskowski C. **J Obstet Gynecol Neonatal Nurs** 1996 Feb;25(2):181–8 (26 ref.)
France: status of cancer pain and palliative care. Larue F, et al. **J Pain Symptom Manage** 1996 Aug;12(2):106–8 (11 ref.)
The Philippines: status of cancer pain and palliative care. Laudico AV. **J Pain Symptom Manage** 1996 Aug; 12(2):133–5 (10 ref.)
Development of the World Health Organization Guidelines on Cancer Pain Relief and Palliative Care in Children. McGrath PA. **J Pain Symptom Manage** 1996 Aug; 12(2):87–92 (12 ref.)
The World Health Organization Cancer Pain and Palliative Care Program. Past, present, and future. Stjernswärd J, et al. **J Pain Symptom Manage** 1996 Aug;12(2):65–72 (31 ref.)
The Netherlands: status of cancer pain and palliative care. Zylicz Z. **J Pain Symptom Manage** 1996 Aug;12(2):136–8 (13 ref.)
Integration of behavioral and relaxation approaches into the treatment of chronic pain and insomnia. NIH Technology Assessment Panel on Integration of Behavioral and Relaxation Approaches into the Treatment of Chronic Pain and Insomnia. **JAMA** 1996 Jul 24–31;276(4):313–8 (0 ref.)
Central pain: diagnosis and treatment strategies. Gonzales GR. **Neurology** 1995 Dec;45(12 Suppl 9):S11–6; discussion S35–6 (24 ref.)
Chronic pain: from theory to practical management. Rowbotham MC. **Neurology** 1995 Dec;45(12 Suppl 9):S5–10; discussion S35–6 (63 ref.)
Issues in the economic analysis of therapies for cancer pain. Portenoy RK. **Oncology (Huntingt)** 1995 Nov;9(11 Suppl):71–8 (36 ref.)
The attentional control of pain: methodological and theoretical concerns. Eccleston C. **Pain** 1995 Oct; 63(1):3–10 (45 ref.)
Relief of suffering: where the art and science of medicine meet. O'Brien ME. **Postgrad Med** 1996 Jun;99(6):189–92, 197–200, 206–8 (14 ref.)
Progress in the treatment of pain. Mehta M. **Practitioner** 1996 Apr;240(1561):214–24 (11 ref.)
Update on cellular transplantation into the CNS as a novel therapy for chronic pain. Czech KA, et al. **Prog Neurobiol** 1995 Aug;46(5):507–29 (126 ref.)
Management of cancer pain. Conroy JM, et al. **South Med J** 1996 Aug;89(8):744–60; quiz 761 (153 ref.)
[Creation of a committee for pain evaluation and treatment (editorial)] Chauvin M. **Ann Fr Anesth Reanim** 1996; 15(3):257–8 (0 ref.) **(Fre)**
[Strategy of treatment of cancer pain in children] Pichard-Léandri E, et al. **Rev Med Interne** 1995; 16(9):708–16 (28 ref.) (Eng. Abstr.) **(Fre)**
[Dermatologic pain therapy. Selected clinical aspects] Ladner E, et al. **Hautarzt** 1995 Dec;46(12):892–906 (12 ref.) **(Ger)**

VETERINARY

Treating moderate and severe pain in small animals. Brock N. **Can Vet J** 1995 Oct;36(10):658–60 (3 ref.)

PAIN ASSESSMENT see **PAIN MEASUREMENT**

PAIN CENTERS see **PAIN CLINICS**

PAIN CLINICS

TRENDS

[Recent trend and future in pain clinic in Japan] Suzuki H. **Masui** 1995;44 Suppl:S6–11 (18 ref.) **(Jpn)**

PAIN, FACIAL see **FACIAL PAIN**

PAIN, INTRACTABLE

see related
PALLIATIVE CARE

The debate on assisted suicide—redefining morally appropriate care for people with intractable suffering. Reitman JS. **Issues Law Med** 1995 Winter;11(3):299–329 (118 ref.)
Orofacial phantom pain: theory and phenomenology. Marbach JJ. **J Am Dent Assoc** 1996 Feb;127(2):221–9 (48 ref.)
Pain in chronic pancreatitis. Jansen JB, et al. **Scand J Gastroenterol Suppl** 1995;212:117–25 (114 ref.)

DRUG THERAPY

Cancer pain. O'Neill WM. **Middle East J Anesthesiol** 1996 Feb;13(4):373–8 (7 ref.)
Intracerebroventricular administration of morphine for control of irreducible cancer pain. Lazorthes YR, et al. **Neurosurgery** 1995 Sep;37(3):422–8; discussion 428–9 (26 ref.)
Concerns about analgesics among patients and family caregivers in a hospice setting. Ward SE, et al. **Res Nurs Health** 1996 Jun;19(3):205–11 (31 ref.)
[Continuous spinal analgesia in home care of oncologic pain] Ricci V, et al. **Minerva Med** 1995 Oct;86(10):409–14 (30 ref.) (Eng. Abstr.) **(Ita)**
[Cancer patient care—management of intractable pain in patients with cancers] Takeda F. **Nippon Naika Gakkai Zasshi** 1996 Mar 10;85(3):360–4 (5 ref.) **(Jpn)**

SURGERY

CT-guided pain procedures for intractable pain in malignancy. Kanpolat Y, et al. **Acta Neurochir Suppl (Wien)** 1995;64:88–91 (24 ref.)

PAIN MEASUREMENT

see related
PAIN THRESHOLD
SENSORY THRESHOLDS

Pain relief versus patient satisfaction. Afilalo M, et al. **Ann Emerg Med** 1996 Apr;27(4):436–8 (8 ref.)
Review of pain-measurement tools. Ho K, et al. **Ann Emerg Med** 1996 Apr;27(4):427–32 (64 ref.)
Measuring pain at baseline and over time. Menegazzi J. **Ann Emerg Med** 1996 Apr;27(4):433–5 (40 ref.)
Influence of sex on pain assessment and management. Nevin K. **Ann Emerg Med** 1996 Apr;27(4):424–6 (26 ref.)
Pain assessment and ethnicity. Todd KH. **Ann Emerg Med** 1996 Apr;27(4):421–3 (28 ref.)
Annotation: aspects of pain in children and adolescents. McGrath PJ. **J Child Psychol Psychiatry** 1995 Jul; 36(5):717–30 (50 ref.)
How should we measure pain in herpes zoster? Wood MJ. **Neurology** 1995 Dec;45(12 Suppl 8):S61–2 (5 ref.)
[Creation of a committee for pain evaluation and treatment (editorial)] Chauvin M. **Ann Fr Anesth Reanim** 1996; 15(3):257–8 (0 ref.) **(Fre)**
[Pain and pain perception in the elderly from the viewpoint of rheumatology] Nehen HG. **Z Gerontol Geriatr** 1995 Sep–Oct;28(5):335–8 (10 ref.) (Eng. Abstr.) **(Ger)**
[Psychological diagnosis of pain and pain treatment in the elderly] Wilz G, et al. **Z Gerontol Geriatr** 1995 Sep–Oct; 28(5):312–7 (54 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Assessment and control of pain in children [editorial] Lloyd-Thomas A. **Anaesthesia** 1995 Sep;50(9):753–5 (43 ref.)

NURSING

Assessment and measurement of acute pain. Dick MJ. **J Obstet Gynecol Neonatal Nurs** 1995 Nov–Dec; 24(9):843–8 (17 ref.)
Issues of assessment of pain and discomfort in neonates. Stevens BJ, et al. **J Obstet Gynecol Neonatal Nurs** 1995 Nov–Dec;24(9):849–55 (53 ref.)

STATISTICS & NUMERICAL DATA

Clinical versus statistical significance in the assessment of pain relief. Todd KH. **Ann Emerg Med** 1996 Apr; 27(4):439–41 (11 ref.)

PAIN, POSTOPERATIVE

DRUG THERAPY

Assessment and control of pain in children [editorial] Lloyd-Thomas A. **Anaesthesia** 1995 Sep;50(9):753–5 (43 ref.)
Introducing an acute pain service. Hall PA, et al. **Br J Hosp Med** 1996 Jan 17–Feb 6;55(1–2):15–7 (10 ref.)
The emerging roles of topical non-steroidal anti-inflammatory agents in ophthalmology. Koay P. **Br J Ophthalmol** 1996 May;80(5):480–5 (98 ref.)
Transnasal butorphanol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute pain management. Gillis JC, et al. **Drugs** 1995 Jul; 50(1):157–75 (47 ref.)
Control of pain after photorefractive keratectomy. Verma S, et al. **J Refract Surg** 1996 Mar–Apr;12(3):358–64 (37 ref.)
[Analgesia after surgery of the spine in adults and adolescents] Bernard JM, et al. **Cah Anesthesiol** 1995; 43(6):557–64 (78 ref.) (Eng. Abstr.) **(Fre)**
[Optimal use of the administration of morphine derivatives] Langlade A. **Cah Anesthesiol** 1995;43(3):251–7 (66 ref.) (Eng. Abstr.) **(Fre)**
[Treatment of postoperative pain with peridural administration of opioids] Chrubasik S, et al. **Anaesthesiol Reanim** 1995;20(1):16–25 (148 ref.) (Eng. Abstr.) **(Ger)**
[Peridural anesthesia in postoperative pain therapy] Standl T. **Zentralbl Chir** 1995;120(12):916–26 (80 ref.) (Eng. Abstr.) **(Ger)**
[Epidural analgesia for postoperative pain in infants and children] Efrat R, et al. **Harefuah** 1996 Mar 1;130(5):304–7, 358 (28 ref.) (Eng. Abstr.) **(Heb)**
[Epidural anesthesia and postoperative analgesia] Yokoyama K. **Nippon Ika Daigaku Zasshi** 1995 Oct;62(5):413–9 (30 ref.) **(Jpn)**

ETIOLOGY

[Anesthesia for celiosurgery] Schoeffler P, et al. **Ann Chir** 1995;49(10):878–80 (19 ref.) **(Fre)**

NURSING

The use of different research methodologies to evaluate the effectiveness of programmes to improve the care of patients in postoperative pain. Allcock N. **J Adv Nurs** 1996 Jan; 23(1):32–8 (34 ref.)

PREVENTION & CONTROL

Pain after tonsillectomy. Husband AD, et al. **Clin Otolaryngol** 1996 Apr;21(2):99–101 (44 ref.)
[Postoperative analgesia in children: what is new?] Murat I. **Rev Med Suisse Romande** 1996 Apr;116(4):247–50 (18 ref.) **(Fre)**

THERAPY

[Postoperative pain relief in children] Hansen TG, et al. **Ugeskr Laeger** 1996 Apr 15;158(16):2241–5 (40 ref.) (Eng. Abstr.) **(Dan)**
[Epidural analgesia for surgery and postoperative pain] Kosaka Y. **Masui** 1995;44 Suppl:S78–82 (28 ref.) **(Jpn)**
[Patient-controlled analgesia as a method for postoperative anesthesia] Lebedeva RN, et al. **Anesteziol Reanimatol** 1996 Jan–Feb;(1):66–71 (145 ref.) **(Rus)**

PAIN RECEPTORS see **NOCICEPTORS**

PAIN RELIEF UNITS see **PAIN CLINICS**

PAIN THRESHOLD

Pain sensitivity, exercise and stoicism. Janal MN. **J R Soc Med** 1996 Jul;89(7):376–81 (38 ref.)

PALATAL EXPANSION TECHNIQUE

Maxillary orthopedics in the presurgical management of infants with cleft lip and palate. Sierra FJ, et al. **Pediatr Dent** 1995 Nov–Dec;17(7):419–23 (24 ref.)

PALATAL NEOPLASMS

COMPLICATIONS

Co-occurrence of plasma cell orificial mucositis and plasmoacanthoma. Report of a case and review of the literature. van de Kerkhof PC, et al. **Dermatology** 1995; 191(1):53–5 (21 ref.)

DIAGNOSIS

[Bucco-sinusal site of primary leiomyosarcoma] Le Toux G, et al. **Ann Otolaryngol Chir Cervicofac** 1995;112(5):244–7 (26 ref.) (Eng. Abstr.) **(Fre)**

PALATAL NEOPLASMS

PATHOLOGY

Nerve-sheath myxoma (neurothekeoma) of the oral cavity: a case report and review of the literature. Katsourakis M, et al. **J Oral Maxillofac Surg** 1996 Jul;54(7):904–6 (17 ref.)

RADIOTHERAPY

[Place of iridium 192 implantation in irradiation of T1–T2 squamous cell carcinoma of the velopharyngeal arch] Mazeron JJ, et al. **Bull Cancer Radiother** 1996;83(1):47–53 (43 ref.) (Eng. Abstr.) **(Fre)**

[Value of the combination of external radiotherapy and curietherapy in carcinoma of the velo-tonsillar region. Statistical study of a series of 361 patients] Pernot M, et al. **Bull Cancer Radiother** 1996;83(1):40–6 (32 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Recurrent melanoma of the hard palate treated by en bloc excision and reconstruction with an autologous palatal bone graft subjected to cryotherapy and a buccal mucosal flap. Rosales J, et al. **J Oral Maxillofac Surg** 1995 Oct; 53(10):1218–20 (16 ref.)

PALATAL OBTURATORS

Complete dentures for the obturator patient. King GE, et al. **Dent Clin North Am** 1996 Jan;40(1):217–37 (26 ref.)

PALATE

ABNORMALITIES

[Mice carrying null mutations of the homeotic genes Hoxa10 and Msx1] Satokata I, et al. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2134–43 (50 ref.) **(Jpn)**

EMBRYOLOGY

Review of the interaction between TCDD and glucocorticoids in embryonic palate. Abbott BD. **Toxicology** 1995 Dec 28;105(2–3):365–73 (86 ref.)

GROWTH & DEVELOPMENT

Significance of programmed cell death (apoptosis) in mammalian limb and palate development. Mori C. **Kaibogaku Zasshi** 1995 Dec;70(6):503–8 (12 ref.)

PATHOLOGY

Torus palatinus and torus mandibularis: a review of the literature. Seah YH. **Aust Dent J** 1995 Oct;40(5):318–21 (31 ref.)

PHYSIOLOGY

New developments in EPG3 software. Jones W, et al. **Eur J Disord Commun** 1995;30(2):183–92 (22 ref.)

SURGERY

Bilateral maxillectomy and midfacial reconstruction. Panje WR, et al. **Ann Otol Rhinol Laryngol** 1995 Nov; 104(11):845–9 (12 ref.)

PALATE, SOFT

PHYSIOLOGY

The functional role of the adenoids in speech. Finkelstein Y, et al. **Int J Pediatr Otorhinolaryngol** 1996 Jan; 34(1–2):61–74 (73 ref.)

RADIATION EFFECTS

[Place of iridium 192 implantation in irradiation of T1–T2 squamous cell carcinoma of the velopharyngeal arch] Mazeron JJ, et al. **Bull Cancer Radiother** 1996;83(1):47–53 (43 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Methodological and statistical problems in sleep apnea research: the literature on uvulopalatopharyngoplasty. Schechtman KB, et al. **Sleep** 1995 Oct;18(8):659–66 (44 ref.)

[The surgical treatment of obstructive sleep apnea syndrome] Cimino A, et al. **Acta Otorhinolaryngol Ital** 1995 Apr;15(2 Suppl 47):3–14 (58 ref.) (Eng. Abstr.) **(Ita)**

PALATINE TONSIL see **TONSIL**

PALATOPHARYNGEAL INCOMPETENCE see **VELOPHARYNGEAL INSUFFICIENCY**

PALEOPATHOLOGY

Paleopathology, its character and contribution to understanding and distinguishing among rheumatologic diseases: perspectives on rheumatoid arthritis and spondyloarthropathy. Rothschild BM. **Clin Exp Rheumatol** 1995 Sep–Oct;13(5):657–62 (31 ref.)

PALEOSTRIATUM see **GLOBUS PALLIDUS**

PALLADIUM

Biological effects of palladium and risk of using palladium in dental casting alloys. Wataha JC, et al. **J Oral Rehabil** 1996 May;23(5):309–20 (53 ref.)

Mechanistic insight from kinetic studies on the interaction of model palladium (II) complexes with nucleic acid components. Rau T, et al. **Met Ions Biol Syst** 1996; 32:339–78 (95 ref.)

PALLIATIVE CARE

Strontium chloride Sr 89 for treating pain from metastatic bone disease. Nightengale B, et al. **Am J Health Syst Pharm** 1995 Oct 15;52(20):2189–95 (87 ref.)

Palliative and supportive care: at the frontier of medical omnipotence. Stiefel F, et al. **Ann Oncol** 1996 Feb; 7(2):135–8 (24 ref.)

Palliation of malignant dysphagia from oesophageal cancer. Ellul JP, et al. **Br J Hosp Med** 1996 Mar 6–19;55(5):272–4 (15 ref.)

Palliation. Surgical and otherwise. Lillemoe KD, et al. **Cancer** 1996 Aug 1;78(3 Suppl):605–14 (31 ref.)

Pain and symptom control in paediatric palliative care. Stevens MM, et al. **Cancer Surv** 1994;21:211–31 (47 ref.)

Patient assessment in palliative cancer care. Bruera E. **Cancer Treat Rev** 1996 Jan;22 Suppl A:3–12 (15 ref.)

Hospice and palliative care. Rousseau P. **Dis Mon** 1995 Dec; 41(12):769–842 (196 ref.)

A proposed matrix for organisational changes to improve quality of life in oncology. MacDonald N. **Eur J Cancer** 1995;31A Suppl 6:S18–21 (30 ref.)

Update on urology—prostate cancer. 3—Systemic and palliative treatment of prostate cancer. Ekman P. **Eur J Surg Oncol** 1995 Oct;21(5):555–7; quiz 557, 567 (12 ref.)

The management of localised cancer of the prostate. Boccon-Gibod L. **Eur Urol** 1996;29 Suppl 2:62–8 (51 ref.)

Supportive care is not the only option in prostate cancer patients resistant to hormone therapy: the argument against. Jewett MA, et al. **Eur Urol** 1996;29 Suppl 2:45–8 (11 ref.)

Psychosocial support, treatment of metastatic disease and palliative care [see comments] Ashby MA, et al. **Med J Aust** 1996 Jan 1;164(1):43–9 (23 ref.) Comment in: Med J Aust 1996 Jun 17;164(12):759–60.

Managing HIV. Part 5: Treating secondary outcomes. 5.19 HIV and palliative care. Glare PA, et al. **Med J Aust** 1996 May 20;164(10):612–5 (9 ref.)

Palliative pelvic exenteration: patient selection and results. Finlayson CA, et al. **Oncology (Huntingt)** 1996 Apr; 10(4):479–84; discussion 484–6, 490, 493 (33 ref.)

Radiotherapy for bone pain [editorial] Hoskin PJ. **Pain** 1995 Nov;63(2):137–9 (12 ref.)

Rehydration in palliative and terminal care: if not—why not? Dunphy K, et al. **Palliat Med** 1995 Jul;9(3):221–8 (32 ref.)

Interventional radiology in a palliative care setting. Jones SN. **Palliat Med** 1995 Oct;9(4):319–26 (23 ref.)

Laser therapy in the palliation of dysphagia in oesophageal malignancy. Lewis-Jones CM, et al. **Palliat Med** 1995 Oct; 9(4):327–30 (15 ref.)

The life so short, the craft so hard to learn: a model for post-basic education in palliative care. Sheldon F, et al. **Palliat Med** 1996 Apr;10(2):99–104 (21 ref.)

Advanced prostate cancer. Endocrine therapies and palliative measures. Taub M, et al. **Postgrad Med** 1996 Sep; 100(3):139–40, 143–6, 152 passim (16 ref.)

Carcinoma of the pancreatic head area. Therapy: nonoperative biliary drainage for palliation. Costamagna G, et al. **Rays** 1995 Jul–Sep;20(3):326–37 (11 ref.) **(Eng, Ita)**

Palliative and supportive care of patients with pancreatic cancer. Alter CL. **Semin Oncol** 1996 Apr;23(2):229–40 (36 ref.)

Palliative radiation therapy. Thrall DE, et al. **Semin Vet Med Surg (Small Anim)** 1995 Aug;10(3):205–8 (14 ref.)

Supportive palliative treatment, psychological care and the hospice movement in Hungary. Muszbek K, et al. **Support Care Cancer** 1996 Jan;4(1):7–9 (10 ref.)

Laparoscopy for staging and palliation of gastrointestinal malignancy. Bogen GL, et al. **Surg Clin North Am** 1996 Jun;76(3):557–69 (56 ref.)

Anorectal melanoma. Successful palliation in a 59-year-old woman. Mostafapour SP, et al. **West J Med** 1996 May; 164(5):448–50 (18 ref.)

[Palliative care and HIV infection. Medical benchmarks] Mallet D, et al. **Ann Med Interne (Paris)** 1995;146(7):510–3 (14 ref.) **(Fre)**

[Palliative care of patients with neoplasm] Shima Y. **Nippon Naika Gakkai Zasshi** 1996 Mar 10;85(3):365–8 (5 ref.) **(Jpn)**

METHODS

Carcinoma of the prostate: treatment of bone metastasis. Scalliet P. **Acta Urol Belg** 1996 May;64(2):87–90 (13 ref.)

Treatment principles in advanced colorectal cancer. Zalcberg JR, et al. **Aust N Z J Surg** 1996 Apr;66(4):202–5 (30 ref.)

Clinical features and management of carcinoma of the pancreas. Carter DC. **Br J Hosp Med** 1995 Nov 1–14; 54(9):459–64 (31 ref.)

1995 Roussel Lecture. Management of adenocarcinoma of the head of the pancreas: 10 questions for the 1990s [see comments] Taylor B. **Can J Surg** 1996 Aug;39(4):271–83 (129 ref.) Comment in: Can J Surg 1996 Aug;39(4):265–6.

Airway stents. Present and future. Colt HG, et al. **Clin Chest Med** 1995 Sep;16(3):465–78 (96 ref.)

Endobronchial brachytherapy. Villanueva AG, et al. **Clin Chest Med** 1995 Sep;16(3):445–54 (45 ref.)

Palliative endoscopic therapy of rectal carcinoma. Dohmoto M, et al. **Eur J Cancer** 1996 Jan;32A(1):25–9 (45 ref.)

Development of the World Health Organization Guidelines on Cancer Pain Relief and Palliative Care in Children. McGrath PA. **J Pain Symptom Manage** 1996 Aug; 12(2):87–92 (12 ref.)

A palliative accelerated irradiation regimen (PAIR) for advanced non-small-cell lung cancer (NSCLC). Nestle U, et al. **Radiother Oncol** 1996 Mar;38(3):195–203 (48 ref.)

Palliative procedures for pancreatic cancer: when and which one? Shumate CR, et al. **South Med J** 1996 Jan;89(1):27–32 (28 ref.)

Endoscopic management of acute respiratory failure related to tracheobronchial malignancies. Ninane V. **Support Care Cancer** 1995 Nov;3(6):418–21 (40 ref.)

Endoluminal high-dose-rate brachytherapy with a palliative aim in esophageal cancer: preliminary results at the Institut Gustave Roussy. Rovirosa A, et al. **Tumori** 1995 Sep–Oct; 81(5):359–63 (37 ref.)

[The use of self-expanding stents in the recanalization of gastric antrum neoplastic obstructions. The experience of a case] Profili S, et al. **Radiol Med (Torino)** 1995 Sep; 90(3):330–3 (23 ref.) **(Ita)**

PSYCHOLOGY

[Psychological pain therapy] Budde HG. **Z Gastroenterol** 1996 Jun;34 Suppl 2:85–8 (25 ref.) **(Ger)**

STANDARDS

Comfort at the end of life: palliative care policy. Jett LG. **J Nurs Adm** 1995 Nov;25(11):55–60 (23 ref.)

TRENDS

France: status of cancer pain and palliative care. Larue F, et al. **J Pain Symptom Manage** 1996 Aug;12(2):106–8 (11 ref.)

The Philippines: status of cancer pain and palliative care. Laudico AV. **J Pain Symptom Manage** 1996 Aug; 12(2):133–5 (10 ref.)

The World Health Organization Cancer Pain and Palliative Care Program. Past, present, and future. Stjernswärd J, et al. **J Pain Symptom Manage** 1996 Aug;12(2):65–72 (31 ref.)

The Netherlands: status of cancer pain and palliative care. Zylicz Z. **J Pain Symptom Manage** 1996 Aug;12(2):136–8 (13 ref.)

PALLIATIVE TREATMENT see **PALLIATIVE CARE**

PALMITATES

ADVERSE EFFECTS

Adverse effects of bone wax in surgery of the orbit. Katz SE, et al. **Ophthal Plast Reconstr Surg** 1996 Jun;12(2):121–6 (15 ref.)

PALMITIC ACIDS

ANALYSIS

[Rare gallstone (calcium carbonate calculus)] Goto K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):418–20 (11 ref.) **(Jpn)**

CHEMISTRY

G-protein palmitoylation: regulation and functional significance. Milligan G, et al. **Biochem Soc Trans** 1995 Aug;23(3):583–7 (36 ref.)

METABOLISM

Dynamic regulation of G-protein coupled receptor palmitoylation: potential role in receptor function. Bouvier M, et al. **Biochem Soc Trans** 1995 Aug;23(3):577–81 (35 ref.)

G-protein palmitoylation: regulation and functional significance. Milligan G, et al. **Biochem Soc Trans** 1995 Aug;23(3):583–7 (36 ref.)

Protein palmitoylation in membrane trafficking. Mundy DI. **Biochem Soc Trans** 1995 Aug;23(3):572–6 (43 ref.)

PALMITOYLCARNITINE

CHEMISTRY

Palmitoylcarnitine, a surface-active metabolite. Goñi FM, et al. **FEBS Lett** 1996 Jul 15;390(1):1–5 (45 ref.)

PHYSIOLOGY

Palmitoylcarnitine, a surface-active metabolite. Goñi FM, et al. **FEBS Lett** 1996 Jul 15;390(1):1–5 (45 ref.)

PALMITYLCARNITINE see **PALMITOYLCARNITINE**

PALMOPLANTAR KERATODERMA see **KERATODERMA, PALMOPLANTAR**

PALMOPLANTARIS PUSTULOSIS see **PSORIASIS**

PALPATION

Pelvic masses and endoscopic surgery: diagnosis. Miralles RM. **Eur J Obstet Gynecol Reprod Biol** 1996 Mar; 65(1):75–9 (28 ref.)

PALSY, PROGRESSIVE SUPRANUCLEAR see **SUPRANUCLEAR PALSY, PROGRESSIVE**

PALYAM VIRUS see **ORBIVIRUS**

PANCREAS

see related
PANCREATECTOMY
PANCREATICOJEJUNOSTOMY

[Heterotopic tissues in the gallbladder (heterotopic gastric mucosa, heterotopic intestinal epithelium, heterotopic pancreatic tissue and ectopic liver in the gallbladder] Kodama T, et al. **Ryoikibetsu Shokogun Shirizu** 1996; (9):360–2 (17 ref.) **(Jpn)**

ABNORMALITIES

Mucin-producing adenoma associated with pancreas divisum and hepatic hilar carcinoma: an autopsy case. Origuchi N, et al. **J Gastroenterol** 1996 Jun;31(3):455–9 (40 ref.)

[Acute pancreatitis disclosing an uncommon form of annular pancreas] Sevenet F, et al. **Gastroenterol Clin Biol** 1996; 20(5):494–6 (19 ref.) (Eng. Abstr.) **(Fre)**

[Developmental anomalies and congenital diseases of the pancreas] Brambs HJ. **Radiologe** 1996 May;36(5):381–8 (56 ref.) (Eng. Abstr.) **(Ger)**

[Anomalous arrangement of the pancreaticobiliary ductal system] Matsumoto Y, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):163–6 (10 ref.) **(Jpn)**

ANATOMY & HISTOLOGY

[The modern aspects of the microsurgical anatomy of the pancreas] Zheleznov LM. **Morfologiia** 1995;108(2):76–80 (79 ref.) **(Rus)**

BLOOD SUPPLY

Aneurysms of the pancreaticoduodenal artery associated with occlusion of the celiac artery. Uher P, et al. **Abdom Imaging** 1995 Sep–Oct;20(5):470–3 (22 ref.)

Ischemia- and reperfusion-related injury in pancreatitis [editorial; comment] Warshaw AL. **Dig Dis Sci** 1996 May; 41(5):821–2 (18 ref.) Comment on: Dig Dis Sci 1996 May;41(5):823–30.

Aneurysms of the pancreaticoduodenal artery. Paty PS, et al. **J Vasc Surg** 1996 Apr;23(4):710–3 (12 ref.)

Hypothesis: vascular compromise is the central pathogenic mechanism for acute hemorrhagic pancreatitis. Blackstone MO. **Perspect Biol Med** 1995 Autumn;39(1):56–63 (23 ref.)

The arterial blood supply of the pancreas: a review. I. The superior pancreaticoduodenal and the anterior superior pancreaticoduodenal arteries. An anatomical and radiological study. Bertelli E, et al. **Surg Radiol Anat** 1995; 17(2):97–106, 1–3 (61 ref.) **(Eng, Fre)**

The arterial blood supply of the pancreas: a review. III. The inferior pancreaticoduodenal artery. An anatomical review and a radiological study. Bertelli E, et al. **Surg Radiol Anat** 1996;18(2):67–74 (42 ref.)

The arterial blood supply of the pancreas: a review. II. The posterior superior pancreaticoduodenal artery. An anatomical and radiological study. Bertelli E, et al. **Surg Radiol Anat** 1996;18(1):1–9 (51 ref.)

[Vascular factors in the mechanism of acute pancreatitis] Sendur R, et al. **Przegl Lek** 1996;53(1):41–5 (38 ref.) (Eng. Abstr.) **(Pol)**

CYTOLOGY

Toward understanding pancreatic disease: from architecture to cell signaling. Bockman DE. **Pancreas** 1995 Nov; 11(4):324–9 (29 ref.)

DRUG EFFECTS

Pancreatic and nephrotoxicity of immunomodulator compounds. Hammond TG, et al. **Toxicol Lett** 1995 Dec; 82–83:99–105 (17 ref.)

ENZYMOLOGY

Bovine pancreatic ribonuclease A as a model of an enzyme with multiple substrate binding sites. Nogués MV, et al. **Biochim Biophys Acta** 1995 Nov 15;1253(1):16–24 (55 ref.)

Use of pancreatic enzyme supplements for patients with cystic fibrosis in the context of fibrosing colonopathy. Consensus Committee. Borowitz DS, et al. **J Pediatr** 1995 Nov;127(5):681–4 (22 ref.)

[Pancreatic phospholipase A2] Ogawa M. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:333–7 (5 ref.) **(Jpn)**

[Pancreatic lipase] Sugano K. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:435–7 (8 ref.) **(Jpn)**

[Pancreatic lipase deficiency and linear IgA disease in childhood] Olivera Olmedo JE, et al. **An Esp Pediatr** 1996 Jan;44(1):73–5 (15 ref.) **(Spa)**

GROWTH & DEVELOPMENT

Nutritional influences on pancreatic development and potential links with non-insulin-dependent diabetes. Dahri S, et al. **Proc Nutr Soc** 1995 Jul;54(2):345–56 (32 ref.)

INJURIES

Diagnosis of pancreatic injury after blunt abdominal trauma. Lane MJ, et al. **Semin Ultrasound CT MR** 1996 Apr; 17(2):177–82 (29 ref.)

Complex pancreatic injuries. Patton JH Jr, et al. **Surg Clin North Am** 1996 Aug;76(4):783–95 (39 ref.)

[Traumatic disease of the pancreas] Di Lorenzo M, et al. **Ann Ital Chir** 1995 May–Jun;66(3):353–61 (44 ref.) (Eng. Abstr.) **(Ita)**

METABOLISM

Pancreatic calcium waves and secretion. Kasai H. **Ciba Found Symp** 1995;188:104–16; discussion 116–20 (31 ref.)

Local calcium spiking in pancreatic acinar cells. Petersen OH. **Ciba Found Symp** 1995;188:85–94; discussion 94–103 (47 ref.)

PATHOLOGY

Pancreatic pathology in non-insulin dependent diabetes (NIDDM). Clark A, et al. **Diabetes Res Clin Pract** 1995 Aug;28 Suppl:S39–47 (50 ref.)

Contrast-enhanced MR imaging of the pancreas. Kettritz U, et al. **Magn Reson Imaging Clin N Am** 1996 Feb;4(1):87–100 (62 ref.)

Hepatic transdifferentiation in the pancreas. Rao MS, et al. **Semin Cell Biol** 1995 Jun;6(3):151–6 (53 ref.)

[Management of pancreatic necrosis] Csáky G, et al. **Orv Hetil** 1995 Sep 24;136(39):2105–11 (50 ref.) (Eng. Abstr.) **(Hun)**

PHYSIOLOGY

Development and regulation of porcine pancreatic function. Pierzynowski SG, et al. **Int J Pancreatol** 1995 Oct; 18(2):81–94 (101 ref.)

PHYSIOPATHOLOGY

Changes in autonomic nervous system activity and consecutive hyperinsulinaemia: respective roles in the development of obesity in rodents. Pénicaud L, et al. **Diabetes Metab** 1996 Feb;22(1):15–24 (67 ref.)

Exocrine pancreatic function in diabetes mellitus. Gröger G, et al. **Eur J Gastroenterol Hepatol** 1995 Aug;7(8):740–6 (70 ref.)

SECRETION

Regulation of cholecystokinin secretion by intraluminal releasing factors. Liddle RA. **Am J Physiol** 1995 Sep;269(3 Pt 1):G319–27 (78 ref.)

[Food regulation of exocrine pancreatic secretion and bile secretion in swine] Corring T. **Fiziol Zh Im I M Sechenova** 1995 Nov;81(11):70–81 (55 ref.) **(Rus)**

SURGERY

[The modern aspects of the microsurgical anatomy of the pancreas] Zheleznov LM. **Morfologiia** 1995;108(2):76–80 (79 ref.) **(Rus)**

ULTRASONOGRAPHY

Endosonography of the pancreas: normal variation versus changes of early chronic pancreatitis. Wiersema MJ, et al. **Gastrointest Endosc Clin N Am** 1995 Jul;5(3):487–96 (24 ref.)

PANCREAS, ARTIFICIAL ENDOCRINE see **INSULIN INFUSION SYSTEMS**

PANCREAS, ENDOCRINE see **ISLETS OF LANGERHANS**

PANCREAS TRANSPLANTATION

Pancreas transplantation for diabetes mellitus. Pirsch JD, et al. **Am J Kidney Dis** 1996 Mar;27(3):444–50 (56 ref.)

Pancreas transplantation: a managed cure approach to diabetes. Stratta RJ, et al. **Curr Probl Surg** 1996 Sep; 33(9):709–808 (250 ref.)

Pancreas and islet transplantation in humans. Kendall DM, et al. **Diabetes Metab** 1996 Jun;22(3):157–63 (40 ref.)

Pancreas transplantation: a treatment option for insulin-dependent diabetes mellitus. Larsen JL, et al. **Diabetes Metab** 1996 Apr;22(2):139–46 (76 ref.)

The case for pancreas transplantation. Sutherland DE. **Diabetes Metab** 1996 Apr;22(2):132–8 (39 ref.)

Pancreas transplantation: an update. Sutherland DE, et al. **Diabetes Metab Rev** 1995 Dec;11(4):337–63 (218 ref.)

Pancreas transplantation. Stratta RJ, et al. **Int J Pancreatol** 1995 Feb;17(1):1–13 (85 ref.)

Consequences of pancreas transplantation. Larsen JL, et al. **J Investig Med** 1994 Dec;42(4):622–31 (78 ref.)

Pancreas transplantation. Stratta RJ, et al. **Ren Fail** 1995 Jul; 17(4):323–37 (85 ref.)

[Historical course of surgical techniques in pancreas transplantation] Toledo-Pereyra LH, et al. **Gac Med Mex** 1994 Nov–Dec;130(6):487–94 (65 ref.) (Eng. Abstr.) **(Spa)**

METHODS

Whole-organ versus islet pancreatic transplantation. Brunicardi FC, et al. **Curr Opin Gen Surg** 1994;:179–85 (37 ref.)

Simultaneous pancreas-kidney and sequential pancreas-after-kidney transplantation. Holohan TV. **Health Technol Assess** 1995 Aug;(4):1–53 (110 ref.)

[Advantages and disadvantages of combination kidney and pancreas transplantation] Marti HP, et al. **Ther Umsch** 1995 Sep;52(9):594–601 (44 ref.) (Eng. Abstr.) **(Ger)**

[Pancreas transplantation--indication, technique and results] Schilling M, et al. **Ther Umsch** 1996 May;53(5):413–8 (30 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Pregnancy after pancreas transplantation: report of four new cases and review of the literature. Barrou B, et al. **Transplant Proc** 1995 Dec;27(6):3043–4 (2 ref.)

Long-term pancreatic function: potential benefits. Bartlett ST, et al. **Transplant Proc** 1996 Aug;28(4):2128–30 (18 ref.)

STATISTICS & NUMERICAL DATA

Pancreas and islet cell transplantation: now and then. Sutherland DE. **Transplant Proc** 1996 Aug;28(4):2131–3 (20 ref.)

PANCREASE see **PANCREATIN**

PANCREATECTOMY

see related
PANCREATICOJEJUNOSTOMY

Pancreatic adenocarcinoma: an update. Tan HP, et al. **J Am Coll Surg** 1996 Aug;183(2):164–84 (159 ref.)

Surgical treatment of obstructive pancreatitis. Howard TJ, et al. **Surgery** 1995 Oct;118(4):727–34; discussion 734–5 (19 ref.)

METHODS

Laparoscopic excision of distal pancreas including insulinoma. Sussman LA, et al. **Aust N Z J Surg** 1996 Jun; 66(6):414–6 (15 ref.)

Treatment of pancreatic carcinoma. Livingston EH, et al. **Curr Opin Gen Surg** 1993;:294–8 (40 ref.)

Surgical therapy in chronic pancreatitis. Rao R, et al. **Curr Opin Gen Surg** 1993;:287–93 (30 ref.)

[Surgical therapy of pancreatic diseases] Rumstadt B, et al. **Radiologe** 1996 May;36(5):375–80 (30 ref.) (Eng. Abstr.) **(Ger)**

[Pancreatic carcinoma: surgical therapy] Baer HU, et al. **Ther Umsch** 1996 May;53(5):394–400 (45 ref.) (Eng. Abstr.) **(Ger)**

[Surgical therapy in chronic pancreatitis] Büchler MW, et al. **Ther Umsch** 1996 May;53(5):365–76 (37 ref.) (Eng. Abstr.) **(Ger)**

[Technique and outcome of surgical therapy in acute pancreatitis] Uhl W, et al. **Ther Umsch** 1996 May; 53(5):346–53 (41 ref.) (Eng. Abstr.) **(Ger)**

PANCREATIC ALPHA CELLS see **ISLETS OF LANGERHANS**

PANCREATIC BETA CELLS see **ISLETS OF LANGERHANS**

PANCREATIC CHOLERA see **VIPOMA**

PANCREATIC CYST

DIAGNOSIS

Leiomyosarcoma of the pancreas. Aranha GV, et al. **Int J Pancreatol** 1995 Feb;17(1):95–7 (5 ref.)

PATHOLOGY

Solitary true cyst of the pancreas in adults. Report of three cases and review of the literature. Sperti C, et al. **Int J Pancreatol** 1995 Oct;18(2):161–7 (23 ref.)

The Ivemark syndrome: prenatal diagnosis of an uncommon cystic renal lesion with heterogeneous associations. Larson RS, et al. **Pediatr Nephrol** 1995 Oct;9(5):594–8 (16 ref.)

Lymphoepithelial cyst of the pancreas: a preoperatively diagnosed case based on an aspiration biopsy. Rino Y, et al. **Surg Today** 1995;25(12):1043–6 (11 ref.)

Papillary cystic and solid tumors of the pancreas: a pancreatic embryonic tumor? Studies of three cases and cumulative review of the world's literature. Mao C, et al. **Surgery** 1995 Nov;118(5):821–8 (97 ref.)

PANCREATIC CYSTIC FIBROSIS see **CYSTIC FIBROSIS**

PANCREATIC DELTA CELLS see **ISLETS OF**

PANCREATIC DELTA CELLS

LANGERHANS

PANCREATIC DISEASES

see related
HYPERINSULINISM

Pancreatic diseases in children. Lerner A, et al. **Pediatr Clin North Am** 1996 Feb;43(1):125–56 (155 ref.)

BLOOD

Non-radiological investigation of pancreatic disease. Brown CM, et al. **Br J Hosp Med** 1995 Oct 18–31;54(8):400–4 (19 ref.)

COMPLICATIONS

[Nesidioblastosis of the pancreas as a cause of hyperinsulinemic hypoglycemia in adults] Tavčar I, et al. **Vojnosanit Pregl** 1994 Jan–Feb;51(1):73–81 (31 ref.) **(Scr)**

DIAGNOSIS

Nesidioblastosis unravelled [comment] Milner RD. **Arch Dis Child** 1996 May;74(5):369–72 (43 ref.) Comment on: Arch Dis Child 1996 May;74(5):373–8. Comment on: Arch Dis Child 1996 May;74(5):379–85.

Pyoderma gangrenosum with hepatopancreatic manifestations in a patient with rheumatoid arthritis. Hastier P, et al. **Dig Dis Sci** 1996 Mar;41(3):594–7 (9 ref.)

Contrast-enhanced MR imaging of the pancreas. Kettritz U, et al. **Magn Reson Imaging Clin N Am** 1996 Feb;4(1):87–100 (62 ref.)

[Pancreaticoscopy: experiences, possibilities and limits] Wegerle W, et al. **Bildgebung** 1996 Mar;63(1):28–33 (34 ref.) (Eng. Abstr.) **(Ger)**

[MRI of the pancreas: radiologic-pathologic correlation] Helmberger T, et al. **Radiologe** 1996 May;36(5):419–26 (32 ref.) (Eng. Abstr.) **(Ger)**

[1995 literature review: ultrasound and roentgen diagnosis of gallbladder, bile ducts and pancreas] Brambs HJ, et al. **Roentgenpraxis** 1996 Apr;49(4):94–9 (31 ref.) **(Ger)**

[A case of intrapancreatic accessory spleen with epidermoid cyst] Kanemaki N, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Aug;92(8):1212–6 (12 ref.) **(Jpn)**

DRUG THERAPY

Review article: the relative effectiveness of somatostatin and octreotide therapy in pancreatic disease [see comments] Jenkins SA, et al. **Aliment Pharmacol Ther** 1995 Aug; 9(4):349–61 (91 ref.) Comment in: Aliment Pharmacol Ther 1995 Oct;9(5):581–3.

ETIOLOGY

[Cytokines and pancreatic diseases] Böcker U, et al. **Dtsch Med Wochenschr** 1995 Nov 10;120(45):1555–60 (50 ref.) **(Ger)**

GENETICS

[Developmental anomalies and congenital diseases of the pancreas] Brambs HJ. **Radiologe** 1996 May;36(5):381–8 (56 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

Isolated intra-abdominal esophageal cyst. Case report and review of the literature. Harvell JD, et al. **Am J Surg Pathol** 1996 Apr;20(4):476–9 (17 ref.)

Nesidioblastosis and persistent neonatal hyperinsulinism. Sempoux C, et al. **Diabete Metab** 1995 Dec;21(6):402–7 (32 ref.)

Lymphoepithelial cyst of the pancreas. Report of two cases and review of the literature. Iacono C, et al. **Int J Pancreatol** 1996 Feb;19(1):71–6 (20 ref.)

Toward understanding pancreatic disease: from architecture to cell signaling. Bockman DE. **Pancreas** 1995 Nov; 11(4):324–9 (29 ref.)

Pancreatic fungal infections: a case report and review of the literature. Robbins EG 2nd, et al. **Pancreas** 1996 Apr; 12(3):308–12 (27 ref.)

PHYSIOPATHOLOGY

[Chronic pancreatitis and pancreatic dysfunction associated with Sjögren's syndrome] Sumii T, et al. **Nippon Rinsho** 1995 Oct;53(10):2525–9 (24 ref.) (Eng. Abstr.) **(Jpn)**

PREVENTION & CONTROL

Review article: the relative effectiveness of somatostatin and octreotide therapy in pancreatic disease [see comments] Jenkins SA, et al. **Aliment Pharmacol Ther** 1995 Aug; 9(4):349–61 (91 ref.) Comment in: Aliment Pharmacol Ther 1995 Oct;9(5):581–3.

SURGERY

Liver, biliary tract, and pancreas [editorial] Rikkers LF, et al. **Curr Opin Gen Surg** 1993;:233–8 (16 ref.)

ULTRASONOGRAPHY

Endoscopic ultrasonography in pancreatobiliary disease using radial instruments. Buscail L. **Gastrointest Endosc Clin N Am** 1995 Oct;5(4):781–7 (25 ref.)

PANCREATIC DUCTS

CYTOLOGY

In vivo cell transformation: neogenesis of beta cells from pancreatic ductal cells. Rosenberg L. **Cell Transplant** 1995 Jul–Aug;4(4):371–83 (80 ref.)

PATHOLOGY

Pancreatic duct stricture caused by islet cell tumors. Heller SJ, et al. **Am J Gastroenterol** 1996 Jan;91(1):147–9 (15 ref.)

Surgical treatment of obstructive pancreatitis. Howard TJ, et al. **Surgery** 1995 Oct;118(4):727–34; discussion 734–5 (19 ref.)

[Intraductal pancreatic adenomatosis. Apropos of a new case] Brassier D, et al. **Ann Gastroenterol Hepatol (Paris)** 1996 Jan–Feb;32(1):19–23 (21 ref.) (Eng. Abstr.) **(Fre)**

[Mucinous pancreatic ductal ectasia: mucus secreting tumor of malignant potential] Michelin T, et al. **Presse Med** 1996 Apr 13;25(13):625–7 (10 ref.) (Eng. Abstr.) **(Fre)**

SECRETION

Mucin-producing neoplasms of the pancreas. Intraductal papillary and mucinous cystic neoplasms. Shyr YM, et al. **Ann Surg** 1996 Feb;223(2):141–6 (27 ref.)

PANCREATIC ELASTASE see PANCREATOPEPTIDASE

PANCREATIC EXTRACTS

ADMINISTRATION & DOSAGE

[Differential therapy of exocrine pancreatic insufficiency--current aspects and future prospects of substitution therapy with pancreatic enzymes] Löser C, et al. **Z Gastroenterol** 1995 Dec;33(12):715–22 (65 ref.) (Eng. Abstr.) **(Ger)**

PANCREATIC FISTULA

SURGERY

Pancreatic pseudocysts, ascites, and fistulas. Yeo CJ. **Curr Opin Gen Surg** 1994;:173–8 (36 ref.)

PANCREATIC FUNCTION TESTS

Non-radiological investigation of pancreatic disease. Brown CM, et al. **Br J Hosp Med** 1995 Oct 18–31;54(8):400–4 (19 ref.)

METHODS

[BT-PABA test] Koizumi M, et al. **Nippon Rinsho** 1995 Feb; 53 Su Pt 1:1088–91 (12 ref.) **(Jpn)**

PANCREATIC HORMONES

PHYSIOLOGY

Pancreastatin action in the liver: dual coupling to different G proteins. Sánchez-Margalet V, et al. **Cell Signal** 1996 Jan;8(1):9–12 (53 ref.)

Pancreastatin: further evidence for its consideration as a regulatory peptide. Sánchez-Margalet V, et al. **J Mol Endocrinol** 1996 Feb;16(1):1–8 (100 ref.)

PANCREATIC INSUFFICIENCY

DIAGNOSIS

Shwachman-Diamond syndrome: the clinical imitator of cystic fibrosis. Lozada-Muñoz L, et al. **P R Health Sci J** 1995 Dec;14(4):275–7 (15 ref.)

ETIOLOGY

[Cystic fibrosis in adults] Durieu I, et al. **Presse Med** 1995 Dec 16–23;24(39):1882–7 (23 ref.) (Eng. Abstr.) **(Fre)**

[Lemmel's syndrome caused by a giant diverticulum in the third portion of the duodenum, report of a case] Hirano A, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Nov; 92(11):1863–70 (11 ref.) **(Jpn)**

THERAPY

[Differential therapy of exocrine pancreatic insufficiency--current aspects and future prospects of substitution therapy with pancreatic enzymes] Löser C, et al. **Z Gastroenterol** 1995 Dec;33(12):715–22 (65 ref.) (Eng. Abstr.) **(Ger)**

PANCREATIC ISLETS TRANSPLANTATION see ISLETS OF LANGERHANS TRANSPLANTATION

PANCREATIC JUICE

see related
CHYMOTRYPSIN
TRYPSIN

CHEMISTRY

[Extraction of DNA from pancreatic and/or duodenal juice] Fukayama N, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr; 41(5):466–8 (3 ref.) **(Jpn)**

PANCREATIC NEOPLASMS

Pancreatic carcinoma in perspective. A continuing challenge. Wanebo HJ, et al. **Cancer** 1996 Aug 1;78(3 Suppl):580–91 (181 ref.)

Pancreatic cancer. Johnson R. **Hepatogastroenterology** 1995 Jul;42(3):294–7 (41 ref.)

Pancreatoblastoma: case report and review of treatment in the literature. Murakami T, et al. **Med Pediatr Oncol** 1996 Sep;27(3):193–7 (22 ref.)

[Muscular metastasis of cancer of the pancreas. A propos of a case] Wafflart E, et al. **J Chir (Paris)** 1996 Jun; 133(4):167–70 (16 ref.) (Eng. Abstr.) **(Fre)**

CHEMISTRY

Solid and cystic papillary neoplasm of the pancreas: a clinico-cytopathologic and immunocytochemical study of five new cases diagnosed by fine-needle aspiration cytology and a review of the literature. Pelosi G, et al. **Diagn Cytopathol** 1995 Oct;13(3):233–46 (106 ref.)

COMPLICATIONS

Pancreatic duct stricture caused by islet cell tumors. Heller SJ, et al. **Am J Gastroenterol** 1996 Jan;91(1):147–9 (15 ref.)

A case of pancreatic carcinoma causing massive bronchial fluid production and electrolyte abnormalities. Lembo T, et al. **Chest** 1995 Oct;108(4):1161–3 (8 ref.)

Somatostatinoma of the pancreas associated with von Hippel-Lindau disease. Maki M, et al. **Intern Med** 1995 Jul;34(7):661–5 (20 ref.)

[Pancreatic somatostatinoma and MEN 1. Apropos of a case. Review of the literature] Roy J, et al. **Ann Endocrinol (Paris)** 1996;57(1):71–6 (26 ref.) (Eng. Abstr.) **(Fre)**

[Diabetes and pancreatic tumors] Löffler J, et al. **Rev Med Suisse Romande** 1995 Sep;115(9):727–31 (25 ref.) **(Fre)**

DIAGNOSIS

Preoperative endocrine tumor localization utilizing a cost-effective approach. Leight GS Jr, et al. **Curr Opin Gen Surg** 1993;:108–14 (19 ref.)

Malignant lymphoma of the pancreas [letter] Tanaka T, et al. **Dig Dis Sci** 1996 Feb;41(2):402–4 (18 ref.)

Advances in diagnosis and treatment of pancreatic cancer. Bramhall SR, et al. **Gastroenterologist** 1995 Dec;3(4):301–10 (106 ref.)

Genetic markers: the key to early diagnosis and improved survival in pancreatic cancer? [editorial; comment] [see comments] Urrutia R, et al. **Gastroenterology** 1996 Jan; 110(1):306–10 (57 ref.) Comment on: Gastroenterology 1996 Jan;110(1):221–6. Comment on: Gastroenterology 1996 Jan;110(1):227–31. Comment in: Gastroenterology 1996 Aug;111(2):566–7.

Tumor markers in the diagnosis, monitoring and therapy of pancreatic cancer: state of the art. Plebani M, et al. **Int J Biol Markers** 1995 Oct–Dec;10(4):189–99 (95 ref.)

Leiomyosarcoma of the pancreas. Aranha GV, et al. **Int J Pancreatol** 1995 Feb;17(1):95–7 (5 ref.)

Localization of gastrinomas. Prinz RA. **Int J Pancreatol** 1996 Apr;19(2):79–91 (53 ref.)

Tumour-induced hypoglycaemia in a patient with insulin-dependent diabetes mellitus. Svartberg J, et al. **J Intern Med** 1996 Feb;239(2):181–5 (16 ref.)

Contrast-enhanced MR imaging of the pancreas. Kettritz U, et al. **Magn Reson Imaging Clin N Am** 1996 Feb;4(1):87–100 (62 ref.)

Carcinoma of the pancreatic head area. Diagnostic imaging. Direct cholangiography: ERCP. Costamagna G, et al. **Rays** 1995 Jul–Sep;20(3):269–79 (17 ref.) **(Eng, Ita)**

Carcinoma of the pancreatic head area. Epidemiology, natural history and clinical findings. Frontera D, et al. **Rays** 1995 Jul–Sep;20(3):226–36 (66 ref.) **(Eng, Ita)**

Carcinoma of the pancreatic head area. Diagnostic imaging: magnetic resonance imaging. Kelekis NL, et al. **Rays** 1995 Jul–Sep;20(3):289–303 (35 ref.) **(Eng, Ita)**

[Imaging of endocrine tumors of the pancreas] Thérasse E, et al. **Ann Endocrinol (Paris)** 1995;56(5):509–10 (4 ref.) **(Fre)**

[Pancreaticoscopy: experiences, possibilities and limits] Wegerle W, et al. **Bildgebung** 1996 Mar;63(1):28–33 (34 ref.) (Eng. Abstr.) **(Ger)**

[Metastasizing pancreatic vipoma. Its diagnosis and therapy with the somatostatin analog octreotide] Scheffold N, et al. **Dtsch Med Wochenschr** 1995 Oct 27;120(43):1463–7 (21 ref.) (Eng. Abstr.) **(Ger)**

[MRI of the pancreas: radiologic-pathologic correlation] Helmberger T, et al. **Radiologe** 1996 May;36(5):419–26 (32 ref.) (Eng. Abstr.) **(Ger)**

[Prognosis in pancreatic carcinoma] Friess H, et al. **Ther Umsch** 1996 May;53(5):401–7 (43 ref.) (Eng. Abstr.) **(Ger)**

[Endocrine pancreatic tumors] Goretzki PE, et al. **Ther Umsch** 1996 May;53(5):408–12 (18 ref.) (Eng. Abstr.) **(Ger)**

[Pancreatic carcinoma: diagnosis] Scheurer U. **Ther Umsch** 1996 May;53(5):377–86 (41 ref.) (Eng. Abstr.) **(Ger)**

[Benign schwannoma of the celiac tripod simulating a pancreatic neoplasm] Cedolini C, et al. **Minerva Chir** 1996 Jan–Feb;51(1–2):47–9 (15 ref.) (Eng. Abstr.) **(Ita)**

[A rare pediatric tumor of the pancreas: pancreatoblastoma] Catalano O, et al. **Radiol Med (Torino)** 1996 Mar; 91(3):321–2 (6 ref.) **(Ita)**

[Prospects of early immunocytochemical diagnosis in periampullary tumors (a review of foreign literature)] Kubyshkin VA, et al. **Khirurgiia (Mosk)** 1995;(6):50–2 (42 ref.) **(Rus)**

[A solid epithelial papillary–cystic pancreatic tumor. A report of a clinical case and review of the literature] Chávez M, et al. **Rev Gastroenterol Peru** 1996 Jan–Apr;16(1):64–71 (29 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Chemotherapy for pancreatic carcinoma. Ahlgren JD. **Cancer** 1996 Aug 1;78(3 Suppl):654–63 (74 ref.)

Activity of gemcitabine in patients with advanced pancreatic carcinoma. A review. Moore M. **Cancer** 1996 Aug 1;78(3 Suppl):633–8 (21 ref.)

Clinical implications of tumor–associated neovascularization and current antiangiogenic strategies for the treatment of malignancies of pancreas. Pluda JM, et al. **Cancer** 1996 Aug 1;78(3 Suppl):680–7 (88 ref.)

Preclinical studies of chemotherapy and radiation therapy for pancreatic carcinoma. Robertson JM, et al. **Cancer** 1996 Aug 1;78(3 Suppl):674–9 (48 ref.)

The role of chemotherapy in the treatment of adenocarcinoma of the pancreas. Fennelly D, et al. **Hepatogastroenterology** 1996 Mar–Apr;43(8):356–62 (30 ref.)

Preoperative chemoradiation for adenocarcinoma of the pancreas: excessive toxicity of prophylactic hepatic irradiation [see comments] Evans DB, et al. **Int J Radiat Oncol Biol Phys** 1995 Nov 1;33(4):913–8 (35 ref.) Comment in: Int J Radiat Oncol Biol Phys 1995 Nov 1;33(4):969–70.

Pancreatic blastomatous tumor in a child responding to therapy used for hepatoblastoma: case report and review of the literature. Morgan ER, et al. **Med Pediatr Oncol** 1996 Apr;26(4):284–92 (29 ref.)

Carcinoma of the pancreatic head area. Therapy: concomitant radiochemotherapy. Cellini N, et al. **Rays** 1995 Jul–Sep;20(3):350–9 (30 ref.) **(Eng, Ita)**

Chemotherapy of adenocarcinoma of the pancreas. Schnall SF, et al. **Semin Oncol** 1996 Apr;23(2):220–8 (81 ref.)

[Metastasizing pancreatic vipoma. Its diagnosis and therapy with the somatostatin analog octreotide] Scheffold N, et al. **Dtsch Med Wochenschr** 1995 Oct 27;120(43):1463–7 (21 ref.) (Eng. Abstr.) **(Ger)**

ENZYMOLOGY

Neuroendocrine tumors of the liver and pancreas associated with elevated serum prostatic acid phosphatase. Kaneko Y, et al. **Intern Med** 1995 Sep;34(9):886–91 (35 ref.)

EPIDEMIOLOGY

Adult pancreatoblastoma: a case report and review of the literature. Levey JM, et al. **Am J Gastroenterol** 1996 Sep; 91(9):1841–4 (16 ref.)

Carcinoma of the pancreatic head area. Epidemiology, natural history and clinical findings. Frontera D, et al. **Rays** 1995 Jul–Sep;20(3):226–36 (66 ref.) **(Eng, Ita)**

Epidemiology and risk factors in pancreatic cancer. Ahlgren JD. **Semin Oncol** 1996 Apr;23(2):241–50 (127 ref.)

ETIOLOGY

Dose–response relationship between coffee and the risk of pancreas cancer. Nishi M, et al. **Jpn J Clin Oncol** 1996 Feb;26(1):42–8 (38 ref.)

GENETICS

Type–1 growth factor receptors in pancreatic and gastrointestinal neoplasia. Lemoine NR, et al. **Eur J Gastroenterol Hepatol** 1995 Oct;7(10):939–44 (74 ref.)

Genetic markers: the key to early diagnosis and improved survival in pancreatic cancer? [editorial; comment] [see comments] Urrutia R, et al. **Gastroenterology** 1996 Jan; 110(1):306–10 (57 ref.) Comment on: Gastroenterology 1996 Jan;110(1):221–6. Comment on: Gastroenterology 1996 Jan;110(1):227–31. Comment in: Gastroenterology 1996 Aug;111(2):566–7.

K–ras mutation and pancreatic adenocarcinoma. Caldas C, et al. **Int J Pancreatol** 1995 Aug;18(1):1–6 (66 ref.)

Familial pancreatic cancer: a review. Lynch HT, et al. **Semin Oncol** 1996 Apr;23(2):251–75 (208 ref.)

METABOLISM

[A case report of the VIP producing tumor with liver metastasis presenting WDHA syndrome] Inoue S, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Aug;92(8):1217–22 (13 ref.) **(Jpn)**

MORTALITY

Carcinoma of the pancreas: critical analysis of costs, results of resections, and the need for standardized reporting [see comments] Gudjonsson B. **J Am Coll Surg** 1995 Dec; 181(6):483–503 (350 ref.) Comment in: J Am Coll Surg 1995 Dec;181(6):558–60.

[Possibilities and limitations of curative resections in cancers of the pancreas] Klempnauer J, et al. **J Chir (Paris)** 1996 May;133(3):117–22 (27 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Pancreatoblastoma. A clinicopathologic study and review of the literature. Klimstra DS, et al. **Am J Surg Pathol** 1995 Dec;19(12):1371–89 (81 ref.)

Clinical implications of tumor–associated neovascularization and current antiangiogenic strategies for the treatment of malignancies of pancreas. Pluda JM, et al. **Cancer** 1996 Aug 1;78(3 Suppl):680–7 (88 ref.)

Solid and cystic papillary neoplasm of the pancreas: a clinico–cytopathologic and immunocytochemical study of five new cases diagnosed by fine–needle aspiration cytology and a review of the literature. Pelosi G, et al. **Diagn Cytopathol** 1995 Oct;13(3):233–46 (106 ref.)

Carcinoid of the pancreas: clinical characteristics and morphological features. Maurer CA, et al. **Eur J Cancer** 1996 Jun;32A(7):1109–16 (55 ref.)

Staging of pancreatic cancer. Analysis of literature results. Rösch T. **Gastrointest Endosc Clin N Am** 1995 Oct; 5(4):735–9 (18 ref.)

A case of macrocystic serous cystadenoma of the pancreas. Mori K, et al. **Int J Pancreatol** 1995 Feb;17(1):91–3 (8 ref.)

Mucin–producing adenoma associated with pancreas divisum and hepatic hilar carcinoma: an autopsy case. Origuchi N, et al. **J Gastroenterol** 1996 Jun;31(3):455–9 (40 ref.)

Papillary cystic and solid tumors of the pancreas: a pancreatic embryonic tumor? Studies of three cases and cumulative review of the world's literature. Mao C, et al. **Surgery** 1995 Nov;118(5):821–8 (97 ref.)

[Recent advances in research on pathology of pancreatic tumors] Liu T. **Chung Hua Ping Li Hsueh Tsa Chih** 1995 Aug;24(4):221–4 (23 ref.) **(Chi)**

[Intraductal pancreatic adenomatosis. Apropos of a new case] Brassier D, et al. **Ann Gastroenterol Hepatol (Paris)** 1996 Jan–Feb;32(1):19–23 (21 ref.) (Eng. Abstr.) **(Fre)**

[Solid and papillary tumor of the pancreas] Spay G, et al. **Chirurgie** 1994–95;120(12):107–10 (33 ref.) (Eng. Abstr.) **(Fre)**

[Bilateral choroidal metastases of pancreatic carcinoma] Castillo J, et al. **J Fr Ophtalmol** 1995;18(12):795–8 (6 ref.) (Eng. Abstr.) **(Fre)**

[A case of leiomyosarcoma of the pancreas] Ishida K, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Mar;93(3):220–5 (12 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Pain management in patients with pancreatic carcinoma. Caraceni A, et al. **Cancer** 1996 Aug 1;78(3 Suppl):639–53 (141 ref.)

PSYCHOLOGY

Depression in patients with pancreatic carcinoma. Diagnostic and treatment issues. Passik SD, et al. **Cancer** 1996 Aug 1;78(3 Suppl):615–26 (84 ref.)

RADIOGRAPHY

Carcinoma of the pancreatic head area. Diagnostic imaging: computed tomography. Brizi MG, et al. **Rays** 1995 Jul–Sep; 20(3):249–68 (47 ref.) **(Eng, Ita)**

Carcinoma of the pancreatic head area. Diagnostic imaging. Direct cholangiography: PTC. Cotroneo AR, et al. **Rays** 1995 Jul–Sep;20(3):280–8 (11 ref.) **(Eng, Ita)**

[Early diagnosis of pancreatic carcinoma and utility of helical CT] Ichikawa T, et al. **Nippon Rinsho** 1995 Nov; 53(11):2868–73 (11 ref.) (Eng. Abstr.) **(Jpn)**

RADIOTHERAPY

Preclinical studies of chemotherapy and radiation therapy for pancreatic carcinoma. Robertson JM, et al. **Cancer** 1996 Aug 1;78(3 Suppl):674–9 (48 ref.)

Brachytherapy for pancreatic cancer: a review. Dobelbower RR, et al. **Hepatogastroenterology** 1996 Mar–Apr; 43(8):333–7 (33 ref.)

Preoperative chemoradiation for adenocarcinoma of the pancreas: excessive toxicity of prophylactic hepatic irradiation [see comments] Evans DB, et al. **Int J Radiat Oncol Biol Phys** 1995 Nov 1;33(4):913–8 (35 ref.) Comment in: Int J Radiat Oncol Biol Phys 1995 Nov 1;33(4):969–70.

Neutron therapy for pancreatic cancer: thirty years of unrealized promise [editorial; comment] Donahue BR, et al. **Radiology** 1996 Sep;200(3):608–9 (13 ref.) Comment on: Radiology 1996 Sep;200(3):627–30.

Carcinoma of the pancreatic head area. Therapy: concomitant radiochemotherapy. Cellini N, et al. **Rays** 1995 Jul–Sep;20(3):350–9 (30 ref.) **(Eng, Ita)**

Carcinoma of the pancreatic head area. Therapy: intraluminal brachytherapy. Montemaggi P, et al. **Rays** 1995 Jul–Sep; 20(3):338–49 (51 ref.) **(Eng, Ita)**

Carcinoma of the pancreatic head area. Therapy: intraoperative radiotherapy. Trodella L, et al. **Rays** 1995 Jul–Sep;20(3):316–25 (65 ref.) **(Eng, Ita)**

Radiotherapy for carcinoma of the pancreas. Thomas PR. **Semin Oncol** 1996 Apr;23(2):213–9 (52 ref.)

SECONDARY

Various features and surgical approach of solitary pancreatic metastasis from renal cell carcinoma. Fabre JM, et al. **Eur J Surg Oncol** 1995 Dec;21(6):683–6 (47 ref.)

Solitary pancreatic metastasis occurring eight years after nephrectomy for renal cell carcinoma. A case report and surgical review. Hirota T, et al. **Int J Pancreatol** 1996 Apr; 19(2):145–53 (63 ref.)

[Retroperitoneal liposarcoma with lung, skin and pancreatic metastases] Alcalá Pedrajas JN, et al. **Arch Bronconeumol** 1996 Jun–Jul;32(6):313–5 (21 ref.) (Eng. Abstr.) **(Spa)**

SECRETION

Pancreatic somatostatin–secreting gangliocytic paraganglioma with lymph node metastases. Tomic S, et al. **Am J Gastroenterol** 1996 Mar;91(3):607–8 (12 ref.)

Mucin–producing neoplasms of the pancreas. Intraductal papillary and mucinous cystic neoplasms. Shyr YM, et al. **Ann Surg** 1996 Feb;223(2):141–6 (27 ref.)

[Mucinous pancreatic ductal ectasia: mucus secreting tumor of malignant potential] Michelin T, et al. **Presse Med** 1996 Apr 13;25(13):625–7 (10 ref.) (Eng. Abstr.) **(Fre)**

[Insulin producing cells as therapy in diabetes mellitus] Schnedl WJ, et al. **Naturwissenschaften** 1996 Jan;83(1):1–5 (41 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Vascular resection and intraoperative radiation therapy during pancreaticoduodenectomy: rationale and technique. Evans DB, et al. **Adv Surg** 1996;29:235–62 (87 ref.)

Surgery for pancreatic tumors during pregnancy: a case report and review of the literature. Sciscione AC, et al. **Am J Perinatol** 1996 Jan;13(1):21–5 (28 ref.)

Laparoscopic excision of distal pancreas including insulinoma. Sussman LA, et al. **Aust N Z J Surg** 1996 Jun; 66(6):414–6 (15 ref.)

Clinical features and management of carcinoma of the pancreas. Carter DC. **Br J Hosp Med** 1995 Nov 1–14; 54(9):459–64 (31 ref.)

Management of the pancreatic stump following pancreaticoduodenectomy. Sikora SS, et al. **Br J Surg** 1995 Dec;82(12):1590–7 (88 ref.)

1995 Roussel Lecture. Management of adenocarcinoma of the head of the pancreas: 10 questions for the 1990s [see comments] Taylor B. **Can J Surg** 1996 Aug;39(4):271–83 (129 ref.) Comment in: Can J Surg 1996 Aug;39(4):265–6.

The place for curative surgical procedures in the treatment of sporadic and familial Zollinger–Ellison syndrome. Delcore R, et al. **Curr Opin Gen Surg** 1994;:69–76 (119 ref.)

Treatment of pancreatic carcinoma. Livingston EH, et al. **Curr Opin Gen Surg** 1993;:294–8 (40 ref.)

Endocrine tumors of the pancreas. Meko JB, et al. **Curr Opin Gen Surg** 1994;:186–94 (75 ref.)

Carcinoma of the pancreas: critical analysis of costs, results of resections, and the need for standardized reporting [see comments] Gudjonsson B. **J Am Coll Surg** 1995 Dec; 181(6):483–503 (350 ref.) Comment in: J Am Coll Surg 1995 Dec;181(6):558–60.

Pancreatic adenocarcinoma: an update. Tan HP, et al. **J Am Coll Surg** 1996 Aug;183(2):164–84 (159 ref.)

Evolving strategies for the treatment of adenocarcinoma of the pancreas. A review. Ettinghausen SE, et al. **J Clin Gastroenterol** 1995 Jul;21(1):48–60 (123 ref.)

Carcinoma of the pancreatic head area. Therapy: resectability and surgical management of resectable tumors. Crucitti F, et al. **Rays** 1995 Jul–Sep;20(3):304–15 (57 ref.) **(Eng, Ita)**

Carcinoma of the pancreatic head area. Therapy: intraoperative radiotherapy. Trodella L, et al. **Rays** 1995 Jul–Sep;20(3):316–25 (65 ref.) **(Eng, Ita)**

Surgical management of pancreatic carcinoma. McGrath PC, et al. **Semin Oncol** 1996 Apr;23(2):200–12 (109 ref.)

Mucoepidermoid carcinoma of the pancreas: report of a case. Onoda N, et al. **Surg Today** 1995;25(9):843–7 (16 ref.)

[Is preoperative site diagnosis in organic hyperinsulinism from the viewpoint of the surgeon still necessary today? Results of a consecutive series and analysis of the literature] Böttger T, et al. **Chirurg** 1996 Mar;67(3):268–72 (17 ref.) (Eng. Abstr.) **(Ger)**

[Surgical therapy of pancreatic diseases] Rumstadt B, et al. **Radiologe** 1996 May;36(5):375–80 (30 ref.) (Eng. Abstr.) **(Ger)**

[Pancreatic carcinoma: surgical therapy] Baer HU, et al. **Ther Umsch** 1996 May;53(5):394–400 (45 ref.) (Eng. Abstr.) **(Ger)**

[Endocrine pancreatic tumors] Goretzki PE, et al. **Ther Umsch** 1996 May;53(5):408–12 (18 ref.) (Eng. Abstr.) **(Ger)**

[Progress in pancreatic endocrine tumor surgery: with special reference to the Zollinger–Ellison syndrome] Imamura M.

Nippon Shokakibyo Gakkai Zasshi 1995 Dec;92(12):1905–10 (10 ref.) **(Jpn)**

THERAPY

Systemic and adjuvant therapy for patients with pancreatic carcinoma. Clark JW, et al. **Cancer** 1996 Aug 1;78(3 Suppl):688–93 (59 ref.)

Preoperative chemoradiotherapy for localized pancreatic carcinoma. A perspective. Hoffman JP, et al. **Cancer** 1996 Aug 1;78(3 Suppl):592–7 (36 ref.)

Intraoperative radiotherapy for pancreatic carcinoma. Experimental and clinical studies. Kinsella TJ, et al. **Cancer** 1996 Aug 1;78(3 Suppl):598–604 (36 ref.)

Palliation. Surgical and otherwise. Lillemoe KD, et al. **Cancer** 1996 Aug 1;78(3 Suppl):605–14 (31 ref.)

A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma. Rothenberg ML, et al. **Cancer** 1996 Aug 1;78(3 Suppl):627–32 (48 ref.)

Advances in diagnosis and treatment of pancreatic cancer. Bramhall SR, et al. **Gastroenterologist** 1995 Dec;3(4):301–10 (106 ref.)

Tumor markers in the diagnosis, monitoring and therapy of pancreatic cancer: state of the art. Plebani M, et al. **Int J Biol Markers** 1995 Oct–Dec;10(4):189–99 (95 ref.)

Carcinoma of the pancreatic head area. Therapy: nonoperative biliary drainage for palliation. Costamagna G, et al. **Rays** 1995 Jul–Sep;20(3):326–37 (11 ref.) **(Eng, Ita)**

Palliative and supportive care of patients with pancreatic cancer. Alter CL. **Semin Oncol** 1996 Apr;23(2):229–40 (36 ref.)

Adjuvant therapy of upper gastrointestinal tract cancers. Kelsen DP. **Semin Oncol** 1995 Dec;22(6):582–99 (78 ref.)

Palliative procedures for pancreatic cancer: when and which one? Shumate CR, et al. **South Med J** 1996 Jan;89(1):27–32 (28 ref.)

Management of pancreatic carcinoma. Hunstad DA, et al. **Surg Oncol** 1995;4(2):61–74 (75 ref.)

[Pancreatic carcinoma: conservative and adjuvant therapy] Schmassmann A. **Ther Umsch** 1996 May;53(5):387–93 (20 ref.) (Eng. Abstr.) **(Ger)**

[Gene therapy for pancreatic cancer] Yoshida T, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2727–31 (12 ref.) **(Jpn)**

ULTRASONOGRAPHY

Differential diagnosis of pancreatic tumors. Forsmark CE. **Gastrointest Endosc Clin N Am** 1995 Oct;5(4):713–21 (20 ref.)

Pancreatic cancer. Influence of endoscopic ultrasonography on management and outcomes. Snady H. **Gastrointest Endosc Clin N Am** 1995 Oct;5(4):755–62 (20 ref.)

Carcinoma of the pancreatic head area. Diagnostic imaging: ultrasound. De Gaetano AM, et al. **Rays** 1995 Jul–Sep; 20(3):237–48 (38 ref.) **(Eng, Ita)**

[Ultrasonic laparoscopy in digestive diseases] Catheline JM, et al. **Ann Chir** 1996;50(1):51–7 (30 ref.) (Eng. Abstr.) **(Fre)**

[Indications for endosonography in tumors of the pancreas and bile ducts] Nattermann C. **Bildgebung** 1995 Oct;62 Suppl 2:35–9 (37 ref.) **(Ger)**

PANCREATIC POLYPEPTIDE

BLOOD

[Human pancreatic polypeptide (hPP)] Funakoshi A. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:666–9 (12 ref.) **(Jpn)**

[Pancreatic polypeptide (PP)] Seino Y. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:648–50 (5 ref.) **(Jpn)**

GENETICS

Evolution of neuropeptide Y, peptide YY and pancreatic polypeptide. Larhammar D. **Regul Pept** 1996 Apr 9; 62(1):1–11 (104 ref.)

PANCREATIC PSEUDOCYST

Spontaneous rupture of a pancreatic pseudocyst into the portal vein. Procacci C, et al. **Cardiovasc Intervent Radiol** 1995 Nov–Dec;18(6):399–402 (15 ref.)

Pancreatic pseudocyst. Gumaste VV, et al. **Gastroenterologist** 1996 Mar;4(1):33–43 (88 ref.)

[Pseudocysts of the pancreas. Diagnosis, course and principles of treatment] Lesur G, et al. **Presse Med** 1996 Jun 8;25(20):939–43 (28 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

[A case of pancreatic pseudocyst with splenic infarction] Sugiyama H, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Apr;93(4):293–8 (16 ref.) **(Jpn)**

SURGERY

Pancreatic pseudocysts, ascites, and fistulas. Yeo CJ. **Curr Opin Gen Surg** 1994;:173–8 (36 ref.)

THERAPY

[Two cases of mediastinal pancreatic pseudocyst improved with conservative treatment] Muto M, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Jan;93(1):57–63 (20 ref.) **(Jpn)**

PANCREATIC SECRETORY TRYPSIN INHIBITOR, KAZAL see **TRYPSIN INHIBITOR, KAZAL PANCREATIC**

PANCREATIC TRYPSIN SECRETORY INHIBITOR, KAZAL see **TRYPSIN INHIBITOR, KAZAL PANCREATIC**

PANCREATICODUODENECTOMY

Surgical management of pancreatic carcinoma. McGrath PC, et al. **Semin Oncol** 1996 Apr;23(2):200–12 (109 ref.)

Surgical treatment of obstructive pancreatitis. Howard TJ, et al. **Surgery** 1995 Oct;118(4):727–34; discussion 734–5 (19 ref.)

METHODS

Vascular resection and intraoperative radiation therapy during pancreaticoduodenectomy: rationale and technique. Evans DB, et al. **Adv Surg** 1996;29:235–62 (87 ref.)

Management of the pancreatic stump following pancreaticoduodenectomy. Sikora SS, et al. **Br J Surg** 1995 Dec;82(12):1590–7 (88 ref.)

1995 Roussel Lecture. Management of adenocarcinoma of the head of the pancreas: 10 questions for the 1990s [see comments] Taylor B. **Can J Surg** 1996 Aug;39(4):271–83 (129 ref.) Comment in: Can J Surg 1996 Aug;39(4):265–6.

PANCREATICOJEJUNOSTOMY

Surgical treatment of obstructive pancreatitis. Howard TJ, et al. **Surgery** 1995 Oct;118(4):727–34; discussion 734–5 (19 ref.)

PANCREATIN

ADVERSE EFFECTS

Fibrosing colonopathy in cystic fibrosis. Smyth RL. **Arch Dis Child** 1996 May;74(5):464–8 (24 ref.)

PANCREATITIS

Pain in chronic pancreatitis. Jansen JB, et al. **Scand J Gastroenterol Suppl** 1995;212:117–25 (114 ref.)

Acute pancreatitis: current concepts and practice. Archampong EQ. **West Afr J Med** 1996 Jan–Mar; 15(1):64–73 (46 ref.)

[Pancreatitis in children] Sarles J. **Gastroenterol Clin Biol** 1996;20(5 Pt 2):B74–79 (29 ref.) **(Fre)**

[Advances and perspectives in acute pancreatitis (editorial)] Di Carlo V, et al. **Chir Ital** 1995;47(2):1–8 (89 ref.) (Eng. Abstr.) **(Ita)**

CHEMICALLY INDUCED

Acute lethal necrotising pancreatitis in childhood systemic lupus erythematosus--possible toxicity of immunosuppressive therapy. Kolk A, et al. **Clin Exp Rheumatol** 1995 May–Jun;13(3):399–403 (31 ref.)

Erythromycin-induced acute pancreatitis. Fang CC, et al. **J Toxicol Clin Toxicol** 1996;34(1):93–5 (13 ref.)

[Acute pancreatitis caused by valproic acid: apropos a case] Bahamonde Carrasco A, et al. **Gastroenterol Hepatol** 1996 May;19(5):253–4 (21 ref.) (Eng. Abstr.) **(Spa)**

[Acute pancreatitis associated with hepatotoxicity induced by amoxicillin-clavulanic acid] Galindo C, et al. **Rev Esp Enferm Dig** 1995 Aug;87(8):597–600 (23 ref.) (Eng. Abstr.) **(Spa)**

COMPLICATIONS

Hemosuccus pancreaticus as a source of obscure upper gastrointestinal bleeding: three cases and literature review. Risti B, et al. **Am J Gastroenterol** 1995 Oct;90(10):1878–80 (14 ref.)

Idiopathic fibrosing pancreatitis: a rare cause of obstructive jaundice in children. Amerson JL, et al. **Am Surg** 1996 Apr;62(4):295–9 (09 ref.)

Conservative management strategy for pancreatitis-associated mesenteric venous thrombosis. Krummen DM, et al. **Am Surg** 1996 Jun;62(6):432–4 (12 ref.)

Complications of acute pancreatitis and their management. Büchler M, et al. **Curr Opin Gen Surg** 1993;:282–6 (59 ref.)

The contribution of insulitis to diabetes development in tumor necrosis factor transgenic mice. Flavell RA, et al. **Curr Top Microbiol Immunol** 1996;206:33–50 (72 ref.)

Chronic pancreatitis in homocystinuria. Patil RV, et al. **Indian Pediatr** 1995 Apr;32(4):469–70 (5 ref.)

Hyperparathyroidism and pancreatitis during pregnancy. Inabnet WB, et al. **Surgery** 1996 Jun;119(6):710–3 (32 ref.)

[A unusual cause of acute pancreatitis: obstruction of the afferent loop after gastrectomy according to Bilroth II. Apropos of a case and review of the literature] Moschopoulos C, et al. **Ann Radiol (Paris)** 1995; 38(7–8):426–9 (16 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Acute pancreatitis caused by biliary ascaris in pregnancy. Asrat T, et al. **J Perinatol** 1995 Jul–Aug;15(4):330–2 (15 ref.)

Chronic pancreatitis: diagnosis and treatment. Sidhu S, et al. **Postgrad Med J** 1996 Jun;72(848):327–33 (51 ref.)

[Diagnosis of chronic pancreatitis] Löser C, et al. **Dtsch Med Wochenschr** 1996 Feb 23;121(8):243–7 (15 ref.) **(Ger)**

[Acute pancreatitis: diagnosis] Glasbrenner B, et al. **Ther Umsch** 1996 May;53(5):333–41 (30 ref.) (Eng. Abstr.) **(Ger)**

[Acute pancreatitis in children. Diagnosis and procedures] Dziechciarz P, et al. **Pediatr Pol** 1995 Oct;70(10):suppl 1–10 (10 ref.) **(Pol)**

EPIDEMIOLOGY

Risk factors for morbidity and mortality in pancreatitis. Lam S, et al. **Dig Dis** 1996 Mar–Apr;14(2):83–98 (100 ref.)

ETIOLOGY

Evaluation of hypotheses on pathogenesis of alcoholic pancreatitis. Pitchumoni CS, et al. **Am J Gastroenterol** 1996 Apr;91(4):637–47 (121 ref.)

Pancreatitis secondary to percutaneous liver biopsy-associated hemobilia. Van Os EC, et al. **Am J Gastroenterol** 1996 Mar;91(3):577–80 (18 ref.)

Chronic relapsing pancreatitis from a scorpion sting in Trinidad. George Angus LD, et al. **Ann Trop Paediatr** 1995 Dec;15(4):285–9 (18 ref.)

Pancreatitis with normal serum amylase associated with sodium valproate: a case report. Otusbo S, et al. **Brain Dev** 1995 May–Jun;17(3):219–21 (7 ref.)

Ischemia- and reperfusion-related injury in pancreatitis [editorial; comment] Warshaw AL. **Dig Dis Sci** 1996 May; 41(5):821–2 (18 ref.) Comment on: Dig Dis Sci 1996 May;41(5):823–30.

Gallstone pancreatitis: an update. Wassef W, et al. **Gastroenterologist** 1996 Mar;4(1):70–5 (66 ref.)

Is an elevated concentration of acinar cytosolic free ionised calcium the trigger for acute pancreatitis? Ward JB, et al. **Lancet** 1995 Oct 14;346(8981):1016–9 (42 ref.)

Hypothesis: vascular compromise is the central pathogenic mechanism for acute hemorrhagic pancreatitis. Blackstone MO. **Perspect Biol Med** 1995 Autumn;39(1):56–63 (23 ref.)

The pathogenesis of chronic pancreatitis. Braganza JM. **QJM** 1996 Apr;89(4):243–50 (55 ref.)

[Fulminant pancreatitis] Haapiainen R, et al. **Duodecim** 1994; 110(20):1913–7 (23 ref.) **(Fin)**

[Varicella-zoster virus pancreatitis in hematologic diseases] Pulik M, et al. **Ann Med Interne (Paris)** 1995;146(5):292–4 (10 ref.) (Eng. Abstr.) **(Fre)**

[Acute pancreatitis disclosing an uncommon form of annular pancreas] Sevenet F, et al. **Gastroenterol Clin Biol** 1996; 20(5):494–6 (19 ref.) (Eng. Abstr.) **(Fre)**

[Lipoprotein lipase: a multifunctional enzyme in lipoprotein metabolism] Foubert L, et al. **Presse Med** 1996 Feb 10; 25(5):207–10 (25 ref.) (Eng. Abstr.) **(Fre)**

[Etiology and pathophysiology of acute pancreatitis] Schmidt J, et al. **Ther Umsch** 1996 May;53(5):322–32 (105 ref.) (Eng. Abstr.) **(Ger)**

[Chronic pancreatitis and pancreatic dysfunction associated with Sjögren's syndrome] Sumii T, et al. **Nippon Rinsho** 1995 Oct;53(10):2525–9 (24 ref.) (Eng. Abstr.) **(Jpn)**

[Lemmel's syndrome caused by a giant diverticulum in the third portion of the duodenum, report of a case] Hirano A, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Nov; 92(11):1863–70 (11 ref.) **(Jpn)**

[Biliary pancreatitis] Yamaguchi A, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):506–8 (5 ref.) **(Jpn)**

[Vascular factors in the mechanism of acute pancreatitis] Sendur R, et al. **Przegl Lek** 1996;53(1):41–5 (38 ref.) (Eng. Abstr.) **(Pol)**

IMMUNOLOGY

[Critical evaluation of factors influencing pancreatic cytoprotection] Kisfalvi K, et al. **Orv Hetil** 1996 Apr 14; 137(15):787–91 (63 ref.) (Eng. Abstr.) **(Hun)**

METABOLISM

Oxidative stress in acute and chronic pancreatitis. Schoenberg MH, et al. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1306S–1314S (69 ref.)

MORTALITY

Morbidity and mortality in 602 patients with acute pancreatitis seen between the years 1980–1994. Lankisch PG, et al. **Z Gastroenterol** 1996 Jun;34(6):371–7 (45 ref.)

PATHOLOGY

[Necrotizing pancreatitis] Jakobsen HL, et al. **Ugeskr Laeger** 1995 Oct 2;157(40):5534–7 (40 ref.) (Eng. Abstr.) **(Dan)**

PHYSIOPATHOLOGY

[Etiology and pathophysiology of acute pancreatitis] Schmidt J, et al. **Ther Umsch** 1996 May;53(5):322–32 (105 ref.) (Eng.

Abstr.) (Ger)
[Physiopathology of acute pancreatitis] Guillaumes S, et al. **Gastroenterol Hepatol** 1996 Apr;19(4):224–30 (100 ref.) (Spa)

SURGERY

Safe laparoendoscopic approach to biliary pancreatitis in older patients. McGrath MF, et al. **Arch Surg** 1996 Aug; 131(8):826–31; discussion 831–3 (21 ref.)
Surgical therapy in chronic pancreatitis. Rao R, et al. **Curr Opin Gen Surg** 1993;:287–93 (30 ref.)
Endotherapy for chronic pancreatitis. Kozarek RA, et al. **Int J Pancreatol** 1996 Apr;19(2):93–102 (43 ref.)
Surgical treatment of obstructive pancreatitis. Howard TJ, et al. **Surgery** 1995 Oct;118(4):727–34; discussion 734–5 (19 ref.)
[Laparoscopic cholecystectomy in pregnancy. A description of 2 cases and review of the literature] Lang RD, et al. **Chirurg** 1995 Dec;66(12):1225–9 (49 ref.) (Eng. Abstr.) (Ger)
[Surgical therapy of pancreatic diseases] Rumstadt B, et al. **Radiologe** 1996 May;36(5):375–80 (30 ref.) (Eng. Abstr.) (Ger)
[Surgical therapy in chronic pancreatitis] Büchler MW, et al. **Ther Umsch** 1996 May;53(5):365–76 (37 ref.) (Eng. Abstr.) (Ger)
[Technique and outcome of surgical therapy in acute pancreatitis] Uhl W, et al. **Ther Umsch** 1996 May; 53(5):346–53 (41 ref.) (Eng. Abstr.) (Ger)
[The role of emergency therapeutic endoscopic retrograde cholangiopancreatography in acute biliary pancreatitis] Moreira Vicente V, et al. **Rev Clin Esp** 1995 Sep; 195(9):645–8 (56 ref.) (Spa)

THERAPY

Chronic pancreatitis: diagnosis and treatment. Sidhu S, et al. **Postgrad Med J** 1996 Jun;72(848):327–33 (51 ref.)
[Acute pancreatitis: conservative therapy)] Inauen W. **Ther Umsch** 1996 May;53(5):342–5 (36 ref.) (Eng. Abstr.) (Ger)
[Chronic pancreatitis: conservative therapy] Radun D, et al. **Ther Umsch** 1996 May;53(5):359–64 (33 ref.) (Eng. Abstr.) (Ger)
[Nutritional support in acute pancreatitis] Dionigi P, et al. **Chir Ital** 1995;47(2):9–13 (55 ref.) (Eng. Abstr.) (Ita)
[Emergency drug therapy of acute pancreatitis] Otsuki M. **Nippon Naika Gakkai Zasshi** 1995 Nov 10;84(11):1826–31 (5 ref.) (Jpn)

ULTRASONOGRAPHY

Endosonography of the pancreas: normal variation versus changes of early chronic pancreatitis. Wiersema MJ, et al. **Gastrointest Endosc Clin N Am** 1995 Jul;5(3):487–96 (24 ref.)

PANCREATODUODENECTOMY see **PANCREATICODUODENECTOMY**

PANCREATOJEJUNOSTOMY see **PANCREATICOJEJUNOSTOMY**

PANCREATOPEPTIDASE

ANTAGONISTS & INHIBITORS

The pathogenesis of emphysema: the elastase:antielastase hypothesis 30 years later. Shapiro SD. **Proc Assoc Am Physicians** 1995 Oct;107(3):346–52 (40 ref.)

BLOOD

[Serum elastin peptide concentration and human leukocyte elastase/antiproteinase balance in peripheral obstructive atherosclerosis] Mohácsi A, et al. **Orv Hetil** 1996 Jan 7; 137(1):15–21 (49 ref.) (Eng. Abstr.) (Hun)
[Elastase] Hayakawa T, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:326–8 (10 ref.) (Jpn)
[Human neutrophil elastase] Ishizaki T, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:262–4 (17 ref.) (Jpn)

METABOLISM

A role for neutrophil elastase in solar elastosis. Starcher B, et al. **Ciba Found Symp** 1995;192:338–46; discussion 346–7 (6 ref.)
The pathogenesis of emphysema: the elastase:antielastase hypothesis 30 years later. Shapiro SD. **Proc Assoc Am Physicians** 1995 Oct;107(3):346–52 (40 ref.)

THERAPEUTIC USE

Elastase in the prevention of arterial aging and the treatment of atherosclerosis. Ooyama T, et al. **Ciba Found Symp** 1995; 192:307–17; discussion 318–20 (36 ref.)

PANCREOZYMIN see **CHOLECYSTOKININ**

PANCREOZYMIN RECEPTORS see **RECEPTORS, CHOLECYSTOKININ**

PANCYTOPENIA

CHEMICALLY INDUCED

Pancytopenia and severe cytopenia induced by low-dose methotrexate. Eight case-reports and a review of one hundred cases from the literature (with twenty-four deaths) [see comments] Berthelot JM, et al. **Rev Rhum Engl Ed** 1995 Jul-Sep;62(7–8):477–86 (108 ref.) Comment in: Rev Rhum Engl Ed 1995 Jul-Sep;62(7–8):471–3.

CONGENITAL

Gastrointestinal problems in a child with dyskeratosis congenita. Berezin S, et al. **Am J Gastroenterol** 1996 Jun; 91(6):1271–2 (6 ref.)

ETIOLOGY

Recent-onset myelodysplastic syndrome mimicking acute leukemia during infection. Friedman HD, et al. **Ann Hematol** 1996 Feb;72(2):85–8 (23 ref.)

THERAPY

[Mobilization and transplantation of autologous hematopoietic stem and progenitor cells from peripheral blood: principles and applications] Ghielmini M, et al. **Schweiz Med Wochenschr** 1996 Mar 2;126(9):348–56 (44 ref.) (Eng. Abstr.) (Ger)

VIROLOGY

Cytomegalovirus as a cause of pancytopenia. Almeida-Porada GD, et al. **Leuk Lymphoma** 1996 Apr; 21(3–4):217–23 (59 ref.)

PANENCEPHALITIS, SUBACUTE SCLEROSING see **SUBACUTE SCLEROSING PANENCEPHALITIS**

PANIC

Anxiety and panic in recreational scuba divers. Morgan WP. **Sports Med** 1995 Dec;20(6):398–421 (117 ref.)

PHYSIOLOGY

Panic attacks and panic disorder: the great neurologic imposters. Stahl SM, et al. **Semin Neurol** 1995 Jun; 15(2):126–32 (14 ref.)

PANIC ATTACKS see **PANIC DISORDER**

PANIC DISORDER

CHEMICALLY INDUCED

Provocative agents in panic disorder. Bourin M, et al. **Therapie** 1995 Jul-Aug;50(4):301–6 (42 ref.)

COMPLICATIONS

Panic anxiety, dyspnea, and respiratory disease. Theoretical and clinical considerations. Smoller JW, et al. **Am J Respir Crit Care Med** 1996 Jul;154(1):6–17 (220 ref.)

DIAGNOSIS

Panic disorder [see comments] Weinstein RS. **Am Fam Physician** 1995 Nov 15;52(7):2055–63, 2067–8 (35 ref.) Comment in: Am Fam Physician 1995 Nov 15;52(7):1999–2000.
The panic-agoraphobic syndrome: a paradigm of the anxiety group of disorders and its implications for psychiatric practice and theory. Roth M. **Am J Psychiatry** 1996 Jul; 153(7 Suppl):111–24 (90 ref.)
[Capgras syndrome in adolescence: a review apropos of one case] Chabrol H, et al. **Encephale** 1995 Nov-Dec; 21(6):477–80 (31 ref.) (Eng. Abstr.) (Fre)
[Prognostic aspects of panic disorder] Kurz A. **Versicherungsmedizin** 1996 Apr 1;48(2):53–6 (33 ref.) (Eng. Abstr.) (Ger)

DRUG THERAPY

Panic disorder [see comments] Weinstein RS. **Am Fam Physician** 1995 Nov 15;52(7):2055–63, 2067–8 (35 ref.) Comment in: Am Fam Physician 1995 Nov 15;52(7):1999–2000.
[Panic disorder and agoraphobia: what is effective?] Bandelow B, et al. **Fortschr Neurol Psychiatr** 1995 Nov; 63(11):451–64 (120 ref.) (Eng. Abstr.) (Ger)

ETIOLOGY

Factors in the etiology and pathogenesis of panic disorder: revisiting the attachment-separation paradigm. Shear MK. **Am J Psychiatry** 1996 Jul;153(7 Suppl):125–36 (64 ref.)
Panic disorder and agoraphobia: hypothesis hothouse. Klein DF. **J Clin Psychiatry** 1996;57 Suppl 6:21–7 (38 ref.)

PHYSIOPATHOLOGY

How good are patients with panic disorder at perceiving their heartbeats? Ehlers A, et al. **Biol Psychol** 1996 Jan 5;42(1–2):165–82 (55 ref.)
The neurobiology of anxiety disorders. Johnson MR, et al. **Psychiatr Clin North Am** 1995 Dec;18(4):681–725 (152 ref.)
[Conceptual aspects of panic disorders] Kukumberg P. **Cas Lek Cesk** 1996 Mar 20;135(6):167–9 (15 ref.) (Eng. Abstr.) (Slo)

PSYCHOLOGY

Panic attacks and panic disorder: the great neurologic imposters. Stahl SM, et al. **Semin Neurol** 1995 Jun; 15(2):126–32 (14 ref.)
[Hypnotic desensitization as a supplemental method in dental care of patients with panic disorder. Report of a case] Fábián TK. **Fogorv Sz** 1996 Feb;89(2):57–62 (19 ref.) (Hun)

THERAPY

Behavior therapy: endogenous serotonin therapy? Baer L. **J Clin Psychiatry** 1996;57 Suppl 6:33–5 (12 ref.)
Cognitive-behavior therapy and the longitudinal course of panic disorder. Otto MW, et al. **Psychiatr Clin North Am** 1995 Dec;18(4):803–20 (78 ref.)
The longitudinal course and outcome of panic disorder. Pollack MH, et al. **Psychiatr Clin North Am** 1995 Dec; 18(4):785–801 (95 ref.)
Psychotherapy for panic disorder. Shear MK. **Psychiatr Q** 1995 Winter;66(4):321–8 (16 ref.)

PANNICULITIS

COMPLICATIONS

Dermatomyositis treated with high-dose intravenous immunoglobulins and associated with panniculitis. Sabroe RA, et al. **Clin Exp Dermatol** 1995 Mar;20(2):164–7 (16 ref.)

DIAGNOSIS

Eosinophilic panniculitis: diagnostic considerations and evaluation. Adame J, et al. **J Am Acad Dermatol** 1996 Feb; 34(2 Pt 1):229–34 (37 ref.)
The fasciitis-panniculitis syndromes. Clinical and pathologic features. Naschitz JE, et al. **Medicine (Baltimore)** 1996 Jan; 75(1):6–16 (59 ref.)

PANNICULITIS, LUPUS ERYTHEMATOSUS

ETIOLOGY

[Panniculitis-fasciitis syndrome disclosing systemic erythematous lupus] Carsuzaa F, et al. **Ann Dermatol Venereol** 1996;123(4):259–61 (23 ref.) (Eng. Abstr.) (Fre)

PANNICULITIS, NODULAR NONSUPPURATIVE

DIAGNOSIS

[Weber-Christian disease] Iino S. **Ryoikibetsu Shokogun Shirizu** 1995;(8):276–9 (12 ref.) (Jpn)

PANNICULITIS, PERITONEAL

PATHOLOGY

[Necrotizing panniculitis of the colon--a rare form of mesenterial panniculitis] Herzig R, et al. **Swiss Surg** 1996; (3):131–3 (17 ref.) (Eng. Abstr.) (Ger)

RADIOGRAPHY

[Mesenteric panniculitis: computerized tomography features. Report of 5 cases] Cusati B, et al. **Radiol Med (Torino)** 1996 May;91(5):645–9 (17 ref.) (Ita)

PANNICULITIS, SUBACUTE NODULAR MIGRATORY see **PANNICULITIS**

PANORAMIC RADIOGRAPHY see **RADIOGRAPHY, PANORAMIC**

PANTOMOGRAPHY see **RADIOGRAPHY, PANORAMIC**

PANTOTHENIC ACID

BLOOD

[Pantothenic acid] Yasuda K. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:697–700 (10 ref.) (Jpn)

PAP-I see **ANNEXIN V**

PAPANICOLAOU SMEAR see **VAGINAL SMEARS**

PAPAVERINE

ADMINISTRATION & DOSAGE

[Long-term results of the treatment with intracavernous injection of vasoactive drugs] Rodríguez Vela L, et al. **Arch Esp Urol** 1996 Apr;49(3):257–69 (25 ref.) (Eng. Abstr.)

PAPAVERINE

(Spa)

PHARMACOLOGY

Membrane transport of nucleobases: interaction with inhibitors. Kraupp M, et al. **Gen Pharmacol** 1995 Oct; 26(6):1185–90 (29 ref.)

THERAPEUTIC USE

Pharmacological management of erectile dysfunction. Montorsi F, et al. **Drugs** 1995 Sep;50(3):465–79 (59 ref.)

PAPER

Clinical–epidemiologic study of alopecia areata. Roselino AM, et al. **Int J Dermatol** 1996 Mar;35(3):181–4 (8 ref.)

PAPILLARY MUSCLES

see related
CHORDAE TENDINEAE

Pitfalls in the diagnosis and management of papillary muscle rupture: a study of four cases and review of the literature. Samman B, et al. **Clin Cardiol** 1995 Oct;18(10):591–6 (34 ref.)

Papillary fibroelastoma of the mitral valve. A rare cause of embolic events. Colucci V, et al. **Tex Heart Inst J** 1995; 22(4):327–31 (31 ref.)

[Papillary muscle rupture complicating acute myocardial infarction—treatment with mitral valve replacement and coronary bypass surgery in acute phase] Kyo S, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Jun;44(6):874–81 (23 ref.) (Eng. Abstr.) (Jpn)

PAPILLEDEMA

see related
OPHTHALMOSCOPY

DIAGNOSIS

Six signs in children with life–threatening implications. Tien DR. **R I Med** 1995 Dec;78(12):342–5 (6 ref.)

PAPILLOMA

see related
WARTS

[Gallbladder papilloma] Ono T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):324–5 (17 ref.) (Jpn)

[Intrahepatic biliary papillomatosis] Terada T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):411–3 (7 ref.) (Jpn)

[Biliary papillomatosis] Tsuneyama K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):81–4 (16 ref.) (Jpn)

PATHOLOGY

Laryngeal carcinoma ex–papilloma in a non–irradiated, non–smoking patient: a clinical record and review of the literature. Hasan S, et al. **J Laryngol Otol** 1995 Aug; 109(8):762–6 (33 ref.)

Papillomas of the breast. A histologic spectrum including atypical hyperplasia and carcinoma in situ. McKinney CD, et al. **Pathol Annu** 1995;30 Pt 2:137–78 (47 ref.)

Benign mucosal tumors of the nose and paranasal sinuses. Michaels L. **Semin Diagn Pathol** 1996 May;13(2):113–7 (15 ref.)

VETERINARY

Green turtle fibropapillomatosis: challenges to assessing the role of environmental cofactors. Herbst LH, et al. **Environ Health Perspect** 1995 May;103 Suppl 4:27–30 (37 ref.)

VIROLOGY

Recurrent laryngeal papillomatosis developing into laryngeal carcinoma with human papilloma virus (HPV) type 18: a case report. Sakakura A, et al. **J Laryngol Otol** 1996 Jan; 110(1):75–7 (18 ref.)

PAPILLOMA, CHOROID PLEXUS see **GLIOMA**

PAPILLOMA, INVERTED

[Urothelial inverted papilloma] Rodríguez–Rubio FI, et al. **Actas Urol Esp** 1995 Sep;19(8):611–9 (49 ref.) (Eng. Abstr.) (Spa)

PATHOLOGY

Management of the frontal sinus with inverted papilloma. Shohet JA, et al. **Otolaryngol Head Neck Surg** 1996 Apr; 114(4):649–52 (14 ref.)

Benign mucosal tumors of the nose and paranasal sinuses. Michaels L. **Semin Diagn Pathol** 1996 May;13(2):113–7 (15 ref.)

[Inverted papilloma of the female urethra] Viguri Díaz A, et al. **Arch Esp Urol** 1995 Nov;48(9):954–6 (8 ref.) (Eng. Abstr.) (Spa)

PAPILLOMA, SHOPE see **TUMOR VIRUS INFECTIONS**

PAPILLOMA, SQUAMOUS CELL see **PAPILLOMA**

PAPILLOMATOSIS see **PAPILLOMA**

PAPILLOMAVIRUS

see related
CONDYLOMATA ACUMINATA

Roots and perspectives of contemporary papillomavirus research. zur Hausen H. **J Cancer Res Clin Oncol** 1996; 122(1):3–13 (133 ref.)

[Molecular bases of papillomavirus and polyomavirus carcinogenesis] Taja–Chayeb L, et al. **Salud Publica Mex** 1996 Jan–Feb;38(1):47–57 (40 ref.) (Eng. Abstr.) (Spa)

PAPILLOMAVIRUS, BOVINE

GENETICS

[Bovine papillomavirus vector] Ohe Y. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2539–44 (16 ref.) (Jpn)

PAPILLOMAVIRUS, HUMAN

Papillomavirus vaccines: current status and future prospects. Schiller JT, et al. **Adv Dermatol** 1996;11:355–80; discussion 381 (96 ref.)

Human papillomavirus infection: treatment options for warts [see comments] Miller DM, et al. **Am Fam Physician** 1996 Jan;53(1):135–43, 148–50 (30 ref.) Comment in: Am Fam Physician 1996 Jul;54(1):59, 62.

Genital oncogenic human papillomavirus infection: a short review on the mode of transmission. Tay SK. **Ann Acad Med Singapore** 1995 Jul;24(4):598–601 (39 ref.)

Cervical intraepithelial neoplasia, cervical cancer, and HPV. Holly EA. **Annu Rev Public Health** 1996;17:69–84 (96 ref.)

The epidemiology of cervical carcinogenesis. Schiffman MH, et al. **Cancer** 1995 Nov 15;76(10 Suppl):1888–901 (165 ref.)

Human papillomavirus infection and associated disease in persons infected with human immunodeficiency virus. Vernon SD, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S121–4 (27 ref.)

Human papillomavirus–associated malignancies in HIV–positive men and women. Palefsky J. **Curr Opin Oncol** 1995 Sep;7(5):437–41 (46 ref.)

Interferons. Gross G. **Curr Probl Dermatol** 1996;24:233–46 (59 ref.)

Human papillomavirus infections. Rüdlinger R, et al. **Curr Probl Dermatol** 1996;24:67–76 (24 ref.)

Clinical aspects of genito–anal papillomavirus infection with a focus on when and how to investigate. von Krogh G. **Curr Probl Dermatol** 1996;24:140–50 (42 ref.)

Viral infections in the immunocompetent patient. Miller CS. **Dermatol Clin** 1996 Apr;14(2):225–41 (206 ref.)

Epidemiology of human papillomaviruses. Vittorio CC, et al. **Dermatol Clin** 1995 Jul;13(3):561–74 (165 ref.)

Medical therapy of genital human papilloma virus–related disease. Lacey CJ, et al. **Int J STD AIDS** 1995 Nov–Dec; 6(6):399–407 (45 ref.)

Human papillomavirus type 18: association with poor prognosis in early stage cervical cancer [see comments] Burger RA, et al. **J Natl Cancer Inst** 1996 Oct 2; 88(19):1361–8 (42 ref.) Comment in: J Natl Cancer Inst 1996 Oct 2;88(19):1331–2.

College health providers' knowledge, attitudes, and management practices of genital HPV infection. Linnehan MJ, et al. **Nurse Pract** 1996 May;21(5):122–4, 127–9 (55 ref.)

Human papillomaviruses: their clinical significance in the management of cervical carcinoma [see comments] Hines JF, et al. **Oncology (Huntingt)** 1995 Apr;9(4):279–85; discussion 286–8, 291 (50 ref.) Comment in: Oncology (Huntingt) 1995 Aug;9(8):702.

Human papilloma virus infection of the vulva. Beutner KR. **Semin Dermatol** 1996 Mar;15(1):2–7 (63 ref.)

[Human papilloma virus infection and renal transplantation. Two personally observed cases and a review of the literature] Lefebvre G, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(6):600–3 (20 ref.) (Eng. Abstr.) (Fre)

[Molecular biology of human papilloma virus infection of the female genital tract] Davidson B, et al. **Harefuah** 1995 Nov 15;129(10):417–20 (37 ref.) (Heb)

[Current concepts on human papillomavirus infection] Garfias Cano R, et al. **Ginecol Obstet Mex** 1995 Dec; 63:509–13 (36 ref.) (Eng. Abstr.) (Spa)

[Association of Chlamydia trachomatis and human papilloma virus as predisposing factors in cervical intraepithelial neoplasia] González Sánchez JL, et al. **Ginecol Obstet Mex** 1995 Oct;63:422–6 (30 ref.) (Eng. Abstr.) (Spa)

CLASSIFICATION

Spontaneous evolution of intraepithelial lesions according to the grade and type of the implicated human papillomavirus (HPV). Syrjänen KJ. **Eur J Obstet Gynecol Reprod Biol** 1996 Mar;65(1):45–53 (98 ref.)

GENETICS

Epidermodysplasia verruciformis as a model of human papillomavirus–induced genetic cancer of the skin. Majewski S, et al. **Arch Dermatol** 1995 Nov;131(11):1312–8 (62 ref.)

Molecular biology of cervical cancer and its precursors. Park TW, et al. **Cancer** 1995 Nov 15;76(10 Suppl):1902–13 (90 ref.)

Cervical cancer: is herpes simplex virus type II a cofactor? Jones C. **Clin Microbiol Rev** 1995 Oct;8(4):549–56 (122 ref.)

P53–mediated radioresistance does not correlate with metastatic potential in tumorigenic rat embryo cell lines following oncogene transfection. Bristow RG, et al. **Int J Radiat Oncol Biol Phys** 1996 Jan 15;34(2):341–55 (81 ref.)

Recurrent laryngeal papillomatosis developing into laryngeal carcinoma with human papilloma virus (HPV) type 18: a case report. Sakakura A, et al. **J Laryngol Otol** 1996 Jan; 110(1):75–7 (18 ref.)

[Human papillomavirus type 16–gene functions relevant to molecular human carcinogenesis] Yasumoto S. **Nippon Rinsho** 1995 Nov;53(11):2858–67 (20 ref.) (Eng. Abstr.) (Jpn)

[P53 protein and human papillomavirus oncogenes in carcinogenesis of the uterine cervix] Toledo–Cuevas EM, et al. **Rev Invest Clin** 1996 Jan–Feb;48(1):59–68 (42 ref.) (Eng. Abstr.) (Spa)

IMMUNOLOGY

Immunity to human papillomavirus–associated cervical neoplasia. Stern PL. **Adv Cancer Res** 1996;69:175–211 (187 ref.)

Prospects for a vaccine against human papillomavirus. Hines JF, et al. **Obstet Gynecol** 1995 Nov;86(5):860–6 (30 ref.)

ISOLATION & PURIFICATION

Bilateral primary ovarian squamous cell carcinoma associated with human papilloma virus infection and vulvar and cervical intraepithelial neoplasia. A case report with review of the literature. Mai KT, et al. **Am J Surg Pathol** 1996 Jun;20(6):767–72 (23 ref.)

Perinatal acquisition of cervical cancer–associated papillomaviruses. Cason J. **Br J Obstet Gynaecol** 1996 Sep; 103(9):853–8 (66 ref.)

Human papillomaviruses in gynecological cancer. Duggan MA. **Curr Opin Obstet Gynecol** 1996 Feb;8(1):56–62 (41 ref.)

Virologic screening. Schneider A. **Eur J Obstet Gynecol Reprod Biol** 1996 Mar;65(1):61–3 (23 ref.)

Cervical intraepithelial neoplasia. Crum CP, et al. **J Cell Biochem Suppl** 1995;23:71–9 (44 ref.)

The molecular biology of cervical cancer. Münger K. **J Cell Biochem Suppl** 1995;23:55–60 (36 ref.)

Do human papillomaviruses have a role in the pathogenesis of bladder carcinoma? Mvula M, et al. **J Urol** 1996 Feb; 155(2):471–4 (24 ref.)

Unsuccessful effort to detect human papillomavirus DNA in urinary bladder cancers by the polymerase chain reaction and in situ hybridization. Sano T, et al. **Pathol Int** 1995 Jul;45(7):506–12 (32 ref.)

[Histopathological application of in situ PCR (in situ hybridization after amplification by PCR)] Shindoh M, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):660–3 (10 ref.) (Jpn)

[Detection and typing of HPV genome: consensus PCR method] Yamashita T, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):664–8 (21 ref.) (Jpn)

PATHOGENICITY

Human papillomaviruses, cervical cancer and the developing world. Birley HD. **Ann Trop Med Parasitol** 1995 Oct; 89(5):453–63 (69 ref.)

PHYSIOLOGY

Human papillomavirus E6 and E7: proteins which deregulate the cell cycle. Tommasino M, et al. **Bioessays** 1995 Jun; 17(6):509–18 (62 ref.)

Pathobiology of human papillomavirus. Prasad CJ. **Clin Lab Med** 1995 Sep;15(3):685–704 (81 ref.)

[Cellular and molecular pathogenesis of cancer of the cervix] Monsonego J. **Contracept Fertil Sex** 1995 Dec; 23(12):731–40 (63 ref.) (Eng. Abstr.) (Fre)

PAPILLON–LEAGE AND PSAUME SYNDROME see **OROFACIODIGITAL SYNDROMES**

PAPOVAVIRIDAE INFECTIONS

[Progresses in orodentofacial surgery in China, 1995] Qiu W. **Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):759–60 (0 ref.) (Chi)

[Molecular biology of human papilloma virus infection of the female genital tract] Davidson B, et al. **Harefuah** 1995 Nov 15;129(10):417–20 (37 ref.) (Heb)

[Current concepts on human papillomavirus infection] Garfias Cano R, et al. **Ginecol Obstet Mex** 1995 Dec; 63:509–13 (36 ref.) (Eng. Abstr.) (Spa)

[Molecular bases of papillomavirus and polyomavirus

carcinogenesis] Taja-Chayeb L, et al. **Salud Publica Mex** 1996 Jan-Feb;38(1):47-57 (40 ref.) (Eng. Abstr.) **(Spa)**

COMPLICATIONS

Human papillomaviruses, cervical cancer and the developing world. Birley HD. **Ann Trop Med Parasitol** 1995 Oct; 89(5):453-63 (69 ref.)

Cervical intraepithelial neoplasia, cervical cancer, and HPV. Holly EA. **Annu Rev Public Health** 1996;17:69-84 (96 ref.)

Human papillomaviruses in gynecological cancer. Duggan MA. **Curr Opin Obstet Gynecol** 1996 Feb;8(1):56-62 (41 ref.)

The pathology of vulvar neoplasia. Lininger RA, et al. **Curr Opin Obstet Gynecol** 1996 Feb;8(1):63-8 (28 ref.)

Human papillomavirus-associated malignancies in HIV-positive men and women. Palefsky J. **Curr Opin Oncol** 1995 Sep;7(5):437-41 (46 ref.)

Cervical intraepithelial neoplasia. Crum CP, et al. **J Cell Biochem Suppl** 1995;23:71-9 (44 ref.)

The molecular biology of cervical cancer. Münger K. **J Cell Biochem Suppl** 1995;23:55-60 (36 ref.)

Human papillomavirus type 18: association with poor prognosis in early stage cervical cancer [see comments] Burger RA, et al. **J Natl Cancer Inst** 1996 Oct 2; 88(19):1361-8 (42 ref.) Comment in: J Natl Cancer Inst 1996 Oct 2;88(19):1331-2.

Human papillomaviruses: their clinical significance in the management of cervical carcinoma [see comments] Hines JF, et al. **Oncology (Huntingt)** 1995 Apr;9(4):279-85; discussion 286-8, 291 (50 ref.) Comment in: Oncology (Huntingt) 1995 Aug;9(8):702.

DIAGNOSIS

Human papillomavirus infections. Rüdlinger R, et al. **Curr Probl Dermatol** 1996;24:67-76 (24 ref.)

Clinical aspects of genito-anal papillomavirus infection with a focus on when and how to investigate. von Krogh G. **Curr Probl Dermatol** 1996;24:140-50 (42 ref.)

EPIDEMIOLOGY

Human papillomavirus infection and associated disease in persons infected with human immunodeficiency virus. Vernon SD, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S121-4 (27 ref.)

Epidemiology of human papillomaviruses. Vittorio CC, et al. **Dermatol Clin** 1995 Jul;13(3):561-74 (165 ref.)

ETIOLOGY

The epidemiology of cervical carcinogenesis. Schiffman MH, et al. **Cancer** 1995 Nov 15;76(10 Suppl):1888-901 (165 ref.)

Human papilloma virus infection of the vulva. Beutner KR. **Semin Dermatol** 1996 Mar;15(1):2-7 (63 ref.)

[Human papilloma virus infection and renal transplantation. Two personally observed cases and a review of the literature] Lefebvre G, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(6):600-3 (20 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Epidermodysplasia verruciformis as a model of human papillomavirus-induced genetic cancer of the skin. Majewski S, et al. **Arch Dermatol** 1995 Nov;131(11):1312-8 (62 ref.)

[Cellular and molecular pathogenesis of cancer of the cervix] Monsonego J. **Contracept Fertil Sex** 1995 Dec; 23(12):731-40 (63 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Immunity to human papillomavirus-associated cervical neoplasia. Stern PL. **Adv Cancer Res** 1996;69:175-211 (187 ref.)

PATHOLOGY

Progressive multifocal leukoencephalopathy: a review of the pathology and pathogenesis. Aksamit AJ Jr. **Microsc Res Tech** 1995 Nov 1;32(4):302-11 (39 ref.)

Human polyoma virus infection of renal allografts: histopathologic diagnosis, clinical significance, and literature review. Pappo O, et al. **Mod Pathol** 1996 Feb; 9(2):105-9 (23 ref.)

[Cellular and molecular pathogenesis of cancer of the cervix] Monsonego J. **Contracept Fertil Sex** 1995 Dec; 23(12):731-40 (63 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

Prospects for a vaccine against human papillomavirus. Hines JF, et al. **Obstet Gynecol** 1995 Nov;86(5):860-6 (30 ref.)

THERAPY

Human papillomavirus infection: treatment options for warts [see comments] Miller DM, et al. **Am Fam Physician** 1996 Jan;53(1):135-43, 148-50 (30 ref.) Comment in: Am Fam Physician 1996 Jul;54(1):59, 62.

Interferons. Gross G. **Curr Probl Dermatol** 1996;24:233-46 (59 ref.)

Medical therapy of genital human papilloma virus-related disease. Lacey CJ, et al. **Int J STD AIDS** 1995 Nov-Dec; 6(6):399-407 (45 ref.)

TRANSMISSION

Genital oncogenic human papillomavirus infection: a short review on the mode of transmission. Tay SK. **Ann Acad Med Singapore** 1995 Jul;24(4):598-601 (39 ref.)

Perinatal acquisition of cervical cancer-associated papillomaviruses. Cason J. **Br J Obstet Gynaecol** 1996 Sep; 103(9):853-8 (66 ref.)

VIROLOGY

Mammary tumors induced by polyomavirus. Fluck MM, et al. **Breast Cancer Res Treat** 1996;39(1):45-56 (49 ref.)

Pathobiology of human papillomavirus. Prasad CJ. **Clin Lab Med** 1995 Sep;15(3):685-704 (81 ref.)

Roots and perspectives of contemporary papillomavirus research. zur Hausen H. **J Cancer Res Clin Oncol** 1996; 122(1):3-13 (133 ref.)

College health providers' knowledge, attitudes, and management practices of genital HPV infection. Linnehan MJ, et al. **Nurse Pract** 1996 May;21(5):122-4, 127-9 (55 ref.)

[P53 protein and human papillomavirus oncogenes in carcinogenesis of the uterine cervix] Toledo-Cuevas EM, et al. **Rev Invest Clin** 1996 Jan-Feb;48(1):59-68 (42 ref.) (Eng. Abstr.) **(Spa)**

PAPP-D see **PLACENTAL LACTOGEN**

PAPPATACI FEVER see **PHLEBOTOMUS FEVER**

PAPULOSQUAMOUS DISORDERS see **SKIN DISEASES, PAPULOSQUAMOUS**

PARA-AMINOBENZOIC ACID see **4-AMINOBENZOIC ACID**

PARA-AMINOHIPPURIC ACID see **P-AMINOHIPPURIC ACID**

PARA-AMINOSALICYLIC ACID see **P-AMINOSALICYLIC ACID**

PARA-DIHYDROXYBENZENES see **HYDROQUINONES**

PARA-FLUOROPHENYLALANINE see **P-FLUOROPHENYLALANINE**

PARA-HYDROXYBENZOATE HYDROXYLASE see **4-HYDROXYBENZOATE-3-MONOOXYGENASE**

PARA-OCTOPAMINE see **OCTOPAMINE**

PARACETAMOL see **ACETAMINOPHEN**

PARACHUTING see **AVIATION**

PARACOCCIDIOIDES

IMMUNOLOGY

Biochemistry and molecular biology of the main diagnostic antigen of Paracoccidioides brasiliensis. Travassos LR, et al. **Arch Med Res** 1995 Autumn;26(3):297-304 (30 ref.)

ISOLATION & PURIFICATION

In search of the natural habitat of Paracoccidioides brasiliensis. McEwen JG, et al. **Arch Med Res** 1995 Autumn;26(3):305-6 (5 ref.)

PARACOCCIDIOIDOMYCOSIS

COMPLICATIONS

Paracoccidioidomycosis and AIDS: an overview. Goldani LZ, et al. **Clin Infect Dis** 1995 Nov;21(5):1275-81 (41 ref.)

[Bone involvement in chronic disseminated paracoccidioidomycosis. A report on the first cases in Rio Grande do Sul] Severo LC, et al. **Rev Soc Bras Med Trop** 1996 May-Jun;29(3):241-4 (12 ref.) (Eng. Abstr.) **(Por)**

DIAGNOSIS

Biochemistry and molecular biology of the main diagnostic antigen of Paracoccidioides brasiliensis. Travassos LR, et al. **Arch Med Res** 1995 Autumn;26(3):297-304 (30 ref.)

PATHOLOGY

[The diagnosis of severe disseminated paracoccidioidomycosis in a bone marrow aspirate: a case report] Ozaki KS, et al. **Rev Soc Bras Med Trop** 1996 Jul-Aug;29(4):363-6 (15 ref.) (Eng. Abstr.) **(Por)**

PARACOCCUS DENITRIFICANS

ENZYMOLOGY

Cytochrome c oxidase. Ostermeier C, et al. **Curr Opin Struct Biol** 1996 Aug;6(4):460-6 (49 ref.)

METABOLISM

Regulation of oxidative phosphorylation: the flexible respiratory network of Paracoccus denitrificans. Van Spanning RJ, et al. **J Bioenerg Biomembr** 1995 Oct; 27(5):499-512 (93 ref.)

PARADENTIUM see **PERIODONTIUM**

PARADOXICAL SLEEP see **SLEEP, REM**

PARAFFIN

ADVERSE EFFECTS

[Destructive paraffinoma of the breast and thoracic wall caused by paraffin injection for mammary increase. Apropos of 3 cases with review of the literature] Zekri A, et al. **Ann Chir Plast Esthet** 1996 Feb;41(1):90-3 (7 ref.) (Eng. Abstr.) **(Fre)**

TOXICITY

Variable responses of species and strains to white mineral oils and paraffin waxes. Miller MJ, et al. **Regul Toxicol Pharmacol** 1996 Feb;23(1 Pt 1):55-68 (78 ref.)

PARAFFIN EMBEDDING

Discordant CD3 expression in lymphomas when studied on frozen and paraffin sections. Chan JK, et al. **Hum Pathol** 1995 Oct;26(10):1139-43 (48 ref.)

Interphase cytogenetics on paraffin sections of paediatric extragonadal yolk sac tumours. Jenderny J, et al. **Virchows Arch** 1996 Apr;428(1):53-7 (13 ref.)

[PCR application for paraffin-embedded tissues] Shindoh M, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):463-6 (8 ref.) **(Jpn)**

PARAGANGLIOMA

Paraganglioma of the cauda equina. A case report and review of the literature. Bak J, et al. **APMIS** 1996 Mar; 104(3):234-40 (29 ref.)

PATHOLOGY

Paraganglioma of the prostatic urethra. A report of three cases and a review of the literature. Boyle M, et al. **Br J Urol** 1996 Mar;77(3):445-8 (16 ref.)

Laryngeal paraganglioma. A review and report of a single case. Özünlü A, et al. **J Laryngol Otol** 1996 Jun; 110(6):519-26 (60 ref.)

PHYSIOPATHOLOGY

Primary paraganglioma of the lung. Report of two cases and review of the literature. Skødt V, et al. **APMIS** 1995 Jul-Aug;103(7-8):597-603 (57 ref.)

SECRETION

Pancreatic somatostatin-secreting gangliocytic paraganglioma with lymph node metastases. Tomic S, et al. **Am J Gastroenterol** 1996 Mar;91(3):607-8 (12 ref.)

SURGERY

[Cervical paragangliomas. Results apropos of a series of 33 patients] Guerrier B, et al. **J Chir (Paris)** 1995 Jun-Jul; 132(6-7):287-94 (34 ref.) (Eng. Abstr.) **(Fre)**

PARAGANGLIOMA, CAROTID BODY see **CAROTID BODY TUMOR**

PARAGANGLIOMA, EXTRA-ADRENAL

COMPLICATIONS

Life-threatening lower intestinal bleeding leading to discovery of a colonic paraganglioma [letter] Velitchkov NG, et al. **Dis Colon Rectum** 1996 Aug;39(8):943-5 (4 ref.)

DIAGNOSIS

Functioning glomus vagale tumor: report of case. Guiral H, et al. **J Oral Maxillofac Surg** 1996 Feb;54(2):227-30 (12 ref.)

PARAGANGLIOMA, GANGLIOCYTIC see **PARAGANGLIOMA**

PARAGANGLIOMA, NONCHROMAFFIN see **PARAGANGLIOMA, EXTRA-ADRENAL**

PARAGONIMIASIS

Paragonimus mexicanus pericarditis: report of two cases and review of the literature. Saborio P, et al. **J Trop Med Hyg** 1995 Oct;98(5):316-8 (9 ref.)

PARAIMMUNOGLOBULINEMIAS see **PARAPROTEINEMIAS**

PARAINFLUENZA

COMPLICATIONS

[Gianotti–Crosti syndrome due to a mixed infection produced by the mumps virus and the parainfluenza virus type 2] Hergueta Lendínez R, et al. **An Esp Pediatr** 1996 Jan; 44(1):65–6 (17 ref.) **(Spa)**

DIAGNOSIS

Respiratory syncytial virus and parainfluenza virus infections in the immunocompromised host. Wendt CH, et al. **Semin Respir Infect** 1995 Dec;10(4):224–31 (35 ref.)

ETIOLOGY

Orthomyxoviral and paramyxoviral infections in transplant patients. Sable CA, et al. **Infect Dis Clin North Am** 1995 Dec;9(4):987–1003 (70 ref.)

PARAINFLUENZA VIRUS TYPE 1

GENETICS

Novel strategy of gene therapy in cardiovascular disease with HVJ–liposome method. Morishita R, et al. **Contrib Nephrol** 1996;118:254–64 (26 ref.)

GROWTH & DEVELOPMENT

[Pathogenic mechanism of Sendai virus—virus activation and germination polarity by host proteases] Tashiro M. **Uirusu** 1995 Jun;45(1):76–80 (12 ref.) **(Jpn)**

PATHOGENICITY

[Pathogenic mechanism of Sendai virus—virus activation and germination polarity by host proteases] Tashiro M. **Uirusu** 1995 Jun;45(1):76–80 (12 ref.) **(Jpn)**

PARAINFLUENZA VIRUS TYPE 2

[Gianotti–Crosti syndrome due to a mixed infection produced by the mumps virus and the parainfluenza virus type 2] Hergueta Lendínez R, et al. **An Esp Pediatr** 1996 Jan; 44(1):65–6 (17 ref.) **(Spa)**

PARALYSIS

Delayed central cord syndrome after a handstand in a child: case report. Lee KS, et al. **Paraplegia** 1996 Mar;34(3):176–8 (25 ref.)

DIAGNOSIS

Thyrotoxic periodic paralysis associated with hypokalemia and hypophosphatemia. Norris KC, et al. **Am J Kidney Dis** 1996 Aug;28(2):270–3 (28 ref.)

ETIOLOGY

Vertical gaze paralysis and intermittent unresponsiveness in a patient with a thalamomesencephalic stroke. Beversdorf DQ, et al. **J Neuroophthalmol** 1995 Dec;15(4):230–5 (21 ref.)

Hopkins syndrome: T2–weighted high intensity of anterior horn on spinal MR imaging. Arita J, et al. **Pediatr Neurol** 1995 Oct;13(3):263–5 (15 ref.)

PATHOLOGY

Hopkins syndrome: T2–weighted high intensity of anterior horn on spinal MR imaging. Arita J, et al. **Pediatr Neurol** 1995 Oct;13(3):263–5 (15 ref.)

PHYSIOPATHOLOGY

Physiology of REM sleep, cataplexy, and sleep paralysis. Hishikawa Y, et al. **Adv Neurol** 1995;67:245–71 (125 ref.)

Mutism and pseudobulbar symptoms after resection of posterior fossa tumors in children: incidence and pathophysiology. Pollack IF, et al. **Neurosurgery** 1995 Nov; 37(5):885–93 (39 ref.)

Ion–channel defects and aberrant excitability in myotonia and periodic paralysis. Cannon SC. **Trends Neurosci** 1996 Jan; 19(1):3–10 (59 ref.)

PARALYSIS AGITANS see **PARKINSON DISEASE**

PARALYSIS, BULBAR

DIAGNOSIS

The diagnosis of amyotrophic lateral sclerosis. Pouget J, et al. **Adv Neurol** 1995;68:143–52 (82 ref.)

PARALYSIS, FAMILIAL PERIODIC

DIAGNOSIS

Hypokalaemic periodic paralysis associated with thyrotoxicosis. Agarwal AK, et al. **J Indian Med Assoc** 1995 Sep;93(9):359–60, 358 (21 ref.)

GENETICS

Hereditary nondystrophic myotonias and periodic paralyses. Lehmann–Horn F, et al. **Curr Opin Neurol** 1995 Oct; 8(5):402–10 (62 ref.)

PARALYSIS, OBSTETRIC

DIAGNOSIS

An approach to obstetrical brachial plexus injuries. Clarke HM, et al. **Hand Clin** 1995 Nov;11(4):563–80; discussion 580–1 (52 ref.)

ETIOLOGY

Medico–legal aspects of brachial plexus injury: the obstetrician's point of view. Jakobovits A. **Med Law** 1996; 15(1):175–82 (30 ref.)

PARALYSIS, PSEUDOBULBAR see **PARALYSIS**

PARALYTIC ILEUS see **INTESTINAL PSEUDO–OBSTRUCTION**

PARAMAGNETIC RESONANCE see **ELECTRON SPIN RESONANCE SPECTROSCOPY**

PARAMECIUM

CHEMISTRY

The unique structures of protozoan myoglobin and yeast hemoglobin: an evolutionary diversity. Shikama K, et al. **Int J Biochem Cell Biol** 1995 Nov;27(11):1107–15 (35 ref.)

PHYSIOLOGY

Regulation of ciliary beat frequency by a dynein light chain. Hamasaki T, et al. **Cell Motil Cytoskeleton** 1995;32(2):121–4 (27 ref.)

PARAMEDICAL PERSONNEL see **ALLIED HEALTH PERSONNEL**

PARAMEDICS see **ALLIED HEALTH PERSONNEL**

PARAMEDICS, EMERGENCY see **EMERGENCY MEDICAL TECHNICIANS**

PARAMYXOVIRUS TYPE 1, AVIAN see **NEWCASTLE DISEASE VIRUS**

PARANASAL SINUS DISEASES

SURGERY

Blindness due to electrocoagulation following functional endoscopic sinus surgery. Vanden Abeele D, et al. **J Laryngol Otol** 1996 Mar;110(3):261–4 (26 ref.)

PARANASAL SINUS NEOPLASMS

COMPLICATIONS

[Frontal cerebral abscess, a rare complication of nasosinusal polyposis. Apropos of a case] Abgrall S, et al. **Neurochirurgie** 1995;41(5):367–71 (13 ref.) (Eng. Abstr.) **(Fre)**

[Pneumocephalus complicating osteoma of the frontal sinus] Attane F, et al. **Rev Neurol (Paris)** 1996 Apr;152(4):279–82 (13 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

[Primary lymphoma of the sphenoid sinus. Report of a case and review of the literature] Ferrario F, et al. **Ann Otolaryngol Chir Cervicofac** 1995;112(6):298–302 (44 ref.) (Eng. Abstr.) **(Fre)**

[Bucco–sinusal site of primary leiomyosarcoma] Le Toux G, et al. **Ann Otolaryngol Chir Cervicofac** 1995;112(5):244–7 (26 ref.) (Eng. Abstr.) **(Fre)**

[Churg–Strauss syndrome. A differential diagnosis in chronic polypoid sinusitis] Trittel C, et al. **Laryngorhinootologie** 1995 Sep;74(9):577–80 (23 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Sinonasal non–Hodgkin's lymphoma in patients infected with human immunodeficiency virus: report of three cases and review. Pomilla PV, et al. **Clin Infect Dis** 1995 Jul; 21(1):137–49 (117 ref.)

PATHOLOGY

Ethmoidal myofibroblastoma. Samuel D, et al. **J Otolaryngol** 1995 Oct;24(5):313–6 (18 ref.)

Sinonasal malignant melanoma—a clinicopathologic analysis of 18 cases. Crawford RI, et al. **Melanoma Res** 1995 Aug; 5(4):261–5 (34 ref.)

Management of the frontal sinus with inverted papilloma. Shohet JA, et al. **Otolaryngol Head Neck Surg** 1996 Apr; 114(4):649–52 (14 ref.)

Benign mucosal tumors of the nose and paranasal sinuses. Michaels L. **Semin Diagn Pathol** 1996 May;13(2):113–7 (15 ref.)

Magnetic resonance imaging of massive intracranial invasion by an ethmoidal adenoid cystic carcinoma (cylindroma). Veillon BJ, et al. **South Med J** 1996 Mar;89(3):321–3 (10 ref.)

SECONDARY

Breast carcinoma metastatic to paranasal sinuses. Austin JR, et al. **Head Neck** 1995 Mar–Apr;17(2):161–5 (20 ref.)

SURGERY

Tension pneumocephalus following craniofacial resection. Wanamaker JR, et al. **Head Neck** 1995 Mar–Apr; 17(2):152–6 (22 ref.)

VIROLOGY

Epstein–Barr virus in T and natural killer (NK) cell non–Hodgkin's lymphomas. Kanavaros P, et al. **Leukemia** 1996 Jun;10 Suppl 2:s84–7 (44 ref.)

PARANASAL SINUSES

[Endonasal ethmoidectomy in naso–sinusal polyposis. Results in 110 surgically treated patients] Simon D, et al. **Ann Otolaryngol Chir Cervicofac** 1995;112(8):359–66 (35 ref.) (Eng. Abstr.) **(Fre)**

DRUG EFFECTS

[Azithromycin: tissue pharmacology] Bergogne–Bérézin E. **Pathol Biol (Paris)** 1995 Jun;43(6):498–504 (29 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

A review of the penetration of sparfloxacin into the lower respiratory tract and sinuses. Wise R, et al. **J Antimicrob Chemother** 1996 May;37 Suppl A:57–63 (18 ref.)

PHYSIOLOGY

A role for the nasal cycle in respiratory defence. Eccles R. **Eur Respir J** 1996 Feb;9(2):371–6 (58 ref.)

RADIATION EFFECTS

Pre versus post–operative radiotherapy of resectable squamous cell carcinoma of the head and neck. Wennerberg J. **Acta Otolaryngol (Stockh)** 1995 Jul;115(4):465–74 (63 ref.)

SURGERY

Pre versus post–operative radiotherapy of resectable squamous cell carcinoma of the head and neck. Wennerberg J. **Acta Otolaryngol (Stockh)** 1995 Jul;115(4):465–74 (63 ref.)

Bilateral maxillectomy and midfacial reconstruction. Panje WR, et al. **Ann Otol Rhinol Laryngol** 1995 Nov; 104(11):845–9 (12 ref.)

Functional endoscopic sinus surgery. Slack R, et al. **Practitioner** 1995 Oct;239(1555):591–5 (3 ref.)

PARANEOPLASTIC SYNDROMES

Paraneoplastic dermatopathology: cutaneous paraneoplastic syndromes. Cohen PR. **Adv Dermatol** 1996;11:215–52; discussion 253 (146 ref.)

Paraneoplastic syndromes. Eckhardt SJ. **Cancer Surv** 1994; 21:197–209 (63 ref.)

Genetic and acquired cutaneous disorders associated with internal malignancy. Loucas E, et al. **Int J Dermatol** 1995 Nov;34(11):749–58 (128 ref.)

Paraneoplastic syndromes. Agarwala SS. **Med Clin North Am** 1996 Jan;80(1):173–84 (35 ref.)

[Paraneoplastic retinopathy associated with cutaneous melanoma. An update apropos of a case] Rougier MB, et al. **J Fr Ophtalmol** 1995;18(5):396–403 (16 ref.) (Eng. Abstr.) **(Fre)**

[Paraneoplastic pemphigus: review of the literature, apropos of a case associated with chronic lymphoid leukemia] Rodot S, et al. **Rev Med Interne** 1995;16(12):938–43 (25 ref.) (Eng. Abstr.) **(Fre)**

[Pure cerebellar syndrome associated with anti–Hu antibodies] Pradat PF, et al. **Rev Neurol (Paris)** 1995 May; 151(5):341–3 (12 ref.) (Eng. Abstr.) **(Fre)**

[Paraneoplastic syndrome of hepatocellular carcinoma] Tagawa K, et al. **Ryoikibetsu Shokogun Shirizu** 1995; (7):453–5 (13 ref.) **(Jpn)**

DIAGNOSIS

[Paraneoplastic neurologic syndromes. Classification and diagnosis] Grisold W, et al. **Nervenarzt** 1995 Oct; 66(10):736–44 (107 ref.) (Eng. Abstr.) **(Ger)**

[Paraneoplastic syndromes] Kaboth U, et al. **Urologe A** 1995 Sep;34(5):431–6 (0 ref.) **(Ger)**

ETIOLOGY

The humoral hypercalcemia of benignancy. A newly appreciated syndrome [see comments] Knecht TP, et al. **Am J Clin Pathol** 1996 Apr;105(4):487–92 (42 ref.) Comment in: Am J Clin Pathol 1996 Apr;105(4):377–9.

Cutaneous paraneoplastic syndromes in solid tumors. Kurzrock R, et al. **Am J Med** 1995 Dec;99(6):662–71 (70 ref.)

Diagnosis of cancer–associated vascular disorders. Naschitz JE, et al. **Cancer** 1996 May 1;77(9):1759–67 (110 ref.)

Onconeural antigens and the paraneoplastic neurologic disorders: at the intersection of cancer, immunity, and the brain. Darnell RB. **Proc Natl Acad Sci U S A** 1996 May 14;93(10):4529–36 (107 ref.)

[Paraneoplastic syndromes of the nervous system and muscles during the course of small cell lung carcinoma] Joachimowicz-Jaśkowiak E. **Pneumonol Pol** 1990 Nov–Dec;58(11–12):647–50 (21 ref.) **(Pol)**

IMMUNOLOGY

The immunobiology and clinical features of paraneoplastic syndromes. Anderson NE. **Curr Opin Neurol** 1995 Dec; 8(6):424–9 (64 ref.)

[Neurologic paraneoplastic syndromes and anti-neuronal antibodies] Mygland A. **Tidsskr Nor Laegeforen** 1996 Jan 30;116(3):361–5 (44 ref.) (Eng. Abstr.) **(Nor)**

PATHOLOGY

Sign of Leser–Trélat. Schwartz RA.
J Am Acad Dermatol 1996 Jul;35(1):88–95 (129 ref.)

Paraneoplastic pemphigus: report of a case. Izaki S, et al. **J Dermatol** 1996 Jun;23(6):397–404 (24 ref.)

Erythematous papules in a patient with cardiac myxoma: a case report and review of the literature. Misago N, et al. **J Dermatol** 1995 Aug;22(8):600–5 (22 ref.)

PARANOIA see **PARANOID DISORDERS**

PARANOID DISORDER, SHARED see **SHARED PARANOID DISORDER**

PARANOID DISORDERS

COMPLICATIONS

Acute lymphocytic leukemia and psychosis: treatment with electroconvulsive therapy. Magen JG, et al.
Ann Clin Psychiatry 1995 Sep;7(3):133–7 (27 ref.)

DIAGNOSIS

Delusional disorder: the recognition and management of paranoia. Manschreck TC. **J Clin Psychiatry** 1996;57 Suppl 3:32–8; discussion 49 (43 ref.)

PSYCHOLOGY

Violence: the scientific medical perspective. Pincus JH.
Isr J Med Sci 1996 Jul;32(7):511–4 (24 ref.)

THERAPY

Acute lymphocytic leukemia and psychosis: treatment with electroconvulsive therapy. Magen JG, et al.
Ann Clin Psychiatry 1995 Sep;7(3):133–7 (27 ref.)

An overview of treatment in paranoia/delusional disorder. Munro A, et al. **Can J Psychiatry** 1995 Dec;40(10):616–22 (132 ref.)

PARANOID PSYCHOSES see **PARANOID DISORDERS**

PARANOID SCHIZOPHRENIA see **SCHIZOPHRENIA, PARANOID**

PARAPARESIS, TROPICAL SPASTIC

Human T lymphotropic virus type I (HTLV-I)-associated myelopathy/tropical spastic paraparesis (HAM/TSP): recent perspectives. Ijichi S, et al. **Intern Med** 1995 Aug; 34(8):713–21 (126 ref.)

COMPLICATIONS

Human T-cell lymphotropic virus type 1-associated myelopathy, Sjögren syndrome, and lymphocytic pneumonitis. Kompoliti A, et al. **Arch Neurol** 1996 Sep; 53(9):940–2 (31 ref.)

IMMUNOLOGY

Human T lymphotropic virus, type-I myelopathy: an immunopathologically mediated chronic progressive disease of the central nervous system. Jacobson S.
Curr Opin Neurol 1995 Jun;8(3):179–83 (35 ref.)

VIROLOGY

Chronic progressive myeloneuropathy in WKAH rats induced by HTLV-I infection as an animal model for HAM/TSP in humans. Yoshiki T. **Intervirology** 1995; 38(3–4):229–37 (40 ref.)

[In situ PCR detection of HTLV-1 provirus in spinal cord lesions with HAM/TSP] Izumo S, et al.
Tanpakushitsu Kakusan Koso 1996 Apr;41(5):656–9 (16 ref.) **(Jpn)**

PARAPHILIAS

see related
SEX OFFENSES

DRUG THERAPY

Policing "perversions": Depo-Provera and John Money's new sexual order. Tsang DC. **J Homosex** 1995;28(3–4):397–426 (110 ref.)

EPIDEMIOLOGY

Review: autoerotic asphyxiation in the United States [retracted in J Forensic Sci 1995 Nov;40(6):932] Uva JL. **J Forensic Sci** 1995 Jul;40(4):574–81 (76 ref.)

PSYCHOLOGY

[Some medico-psychological perspectives on sexual homicides. Three cases] Bénézech M.
Ann Med Psychol (Paris) 1995 Oct;153(8):501–11 (22 ref.) (Eng. Abstr.) **(Fre)**

PARAPHIMOSIS

THERAPY

ABC of Urology. Urological emergencies in general practice [see comments] Dawson C, et al. **BMJ** 1996 Mar 30; 312(7034):838–40 (0 ref.) Comment in: BMJ 1996 Jul 13;313(7049):112; discussion 112–3.

PARAPHRENIA, INVOLUTIONAL see **DEPRESSION, INVOLUTIONAL**

PARAPLEGIA

COMPLICATIONS

Post-traumatic syringomyelia (cystic myelopathy): a prospective study of 449 patients with spinal cord injury. Schurch B, et al. **J Neurol Neurosurg Psychiatry** 1996 Jan; 60(1):61–7 (42 ref.)

[A case of urethral diverticulum in a male paraplegic patient] Kawakami T, et al. **Hinyokika Kiyo** 1995 Nov; 41(11):887–90 (8 ref.) (Eng. Abstr.) **(Jpn)**

ETIOLOGY

Fibrocartilaginous embolism of the spinal cord: a clinical and pathogenetic reconsideration. Tosi L, et al.
J Neurol Neurosurg Psychiatry 1996 Jan;60(1):55–60 (44 ref.)

[A case of thoracic meningioma presenting paraplegia at 4.5 years after removal of a falx meningioma] Suga T, et al. **No Shinkei Geka** 1996 Jun;24(6):567–72 (23 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Inversion duplication of the short arm of chromosome 8: clinical data on seven patients and review of the literature. de Die-Smulders CE, et al. **Am J Med Genet** 1995 Nov 20;59(3):369–74 (16 ref.)

PREVENTION & CONTROL

Spinal cord protection during surgical procedures on the descending thoracic and thoracoabdominal aorta: review of current techniques. Gharagozloo F, et al. **Chest** 1996 Mar;109(3):799–809 (98 ref.)

PARAPLEGIA, SPASTIC see **PARAPLEGIA**

PARAPLEGIA, SPASTIC, HEREDITARY see **SPASTIC PARAPLEGIA, HEREDITARY**

PARAPROTEINEMIAS

[Concept and classification of immunoglobulin abnormalities] Kano T. **Nippon Naika Gakkai Zasshi** 1995 Jul 10; 84(7):1043–9 (4 ref.) **(Jpn)**

CLASSIFICATION

Plasma cell dyscrasias: classification, clinical and laboratory characteristics, and differential diagnosis. Boccadoro M, et al. **Baillieres Clin Haematol** 1995 Dec;8(4):705–19 (75 ref.)

COMPLICATIONS

Chronic neutrophilic leukemia associated with monoclonal gammopathy of undetermined significance. Ito T, et al. **Acta Haematol** 1996;95(2):140–3 (24 ref.)

Arthritis associated with monoclonal gammapathy: clinical characteristics. Jorgensen C, et al. **Br J Rheumatol** 1996 Mar;35(3):241–3 (14 ref.)

Neuropathies associated with monoclonal gammopathies. Kissel JT, et al. **Neuromuscul Disord** 1996 Jan;6(1):3–18 (95 ref.)

[Renal involvement in monoclonal gammopathies] Spička I, et al. **Cas Lek Cesk** 1996 Jun 12;135(12):374–7 (29 ref.) (Eng. Abstr.) **(Cze)**

[The Schnitzler syndrome as a cause of recurrent fever of unknown origin] Winckelmann G, et al.
Dtsch Med Wochenschr 1996 Jul 5;121(27):860–4 (14 ref.) (Eng. Abstr.) **(Ger)**

[Renal disorders in patients with immunoproliferative disorder] Horiuchi A, et al.
Nippon Naika Gakkai Zasshi 1995 Jul 10;84(7):1081–5 (5 ref.) **(Jpn)**

[Nerve lesions in patients with immunoproliferative disorders] Ito H, et al. **Nippon Naika Gakkai Zasshi** 1995 Jul 10;84(7):1075–80 (6 ref.) **(Jpn)**

DIAGNOSIS

Plasma cell dyscrasias: classification, clinical and laboratory characteristics, and differential diagnosis. Boccadoro M, et al. **Baillieres Clin Haematol** 1995 Dec;8(4):705–19 (75 ref.)

Paraproteinaemic neuropathies. Miescher GC, et al.
Baillieres Clin Neurol 1996 Mar;5(1):219–32 (88 ref.)

[Hematologic causes of vascular diseases of the central nervous system] Arboix A, et al. **Rev Neurol** 1995;23 Suppl 1:S41–9 (62 ref.) **(Spa)**

DRUG THERAPY

[Intravenous immunoglobulins in the treatment of neurologic diseases] Illa I, et al. **Neurologia** 1996 Jun–Jul;11(6):220–8 (56 ref.) **(Spa)**

EPIDEMIOLOGY

The epidemiology of monoclonal gammopathy of unknown significance: a review. Herrinton LJ.
Curr Top Microbiol Immunol 1996;210:389–95 (22 ref.)

The incidence and epidemiology of plasma cell neoplasms. Bergsagel D. **Stem Cells (Dayt)** 1995 Aug;13 Suppl 2:1–9 (56 ref.)

ETIOLOGY

Pathogenetic relation between monoclonal gammopathies of undetermined significance and multiple myeloma. Greipp PR, et al. **Stem Cells (Dayt)** 1995 Aug;13 Suppl 2:10–21 (82 ref.)

[Monoclonal gammopathy and primary hyperparathyroidism. Apropos of 2 cases and review of the literature] Bellou A, et al. **Rev Med Interne** 1996;17(4):325–8 (29 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Monoclonal gammopathies antigen driven in autoimmune diseases. Osterland CK. **Clin Exp Rheumatol** 1996 Jan–Feb; 14 Suppl 14:S37–44 (34 ref.)

Sjögren's syndrome, mixed cryoglobulinaemia and the monoclonal gammopathies. Vitali C, et al.
Clin Exp Rheumatol 1996 Jan–Feb;14 Suppl 14:S59–63 (44 ref.)

Autoimmune diseases and monoclonal gammopathies. Youinou P, et al. **Clin Exp Rheumatol** 1996 Jan–Feb;14 Suppl 14:S55–8 (27 ref.)

PATHOLOGY

Angiogenesis in B cell lymphoproliferative diseases. Biological and clinical studies. Vacca A, et al.
Leuk Lymphoma 1995 Dec;20(1–2):27–38 (61 ref.)

PARAPROTEINS

ANALYSIS

Monoclonal gammopathy of undetermined significance (MGUS). Kyle RA. **Baillieres Clin Haematol** 1995 Dec; 8(4):761–81 (92 ref.)

METABOLISM

Amyotrophic lateral sclerosis with paraproteins and autoantibodies. Rowland LP. **Adv Neurol** 1995;68:93–105; discussion 107–11 (136 ref.)

PARAPSYCHOLOGY

Near-death experiences. Blackmore SJ. **J R Soc Med** 1996 Feb;89(2):73–6 (44 ref.)

PARAQUAT

ANALYSIS

[Paraquat and diquat poisoning] Sugita K. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:1064–70 (36 ref.) **(Jpn)**

POISONING

[Paraquat and diquat poisoning] Sugita K. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:1064–70 (36 ref.) **(Jpn)**

PARASITE-HOST RELATIONS see **HOST-PARASITE RELATIONS**

PARASITEMIA

DRUG THERAPY

Human antiprotozoal therapy: past, present, and future. Khaw M, et al. **Clin Microbiol Rev** 1995 Jul;8(3):427–39 (182 ref.)

PARASITES

see related
ANTHELMINTICS
ANTI-INFECTIVE AGENTS
ANTIPROTOZOAL AGENTS

PARASITES

FOOD PARASITOLOGY
HOST-PARASITE RELATIONS

[Hazards of insect vectors of parasites: from theory to practice] Alvar Ezquerra JP.
An R Acad Nac Med (Madr) 1995;112(3):617-45; discussion 646 (93 ref.) **(Spa)**

METABOLISM

The mevalonate pathway in parasitic protozoa and helminths. Coppens I, et al. **Exp Parasitol** 1996 Jan;82(1):76-85 (60 ref.)

PATHOGENICITY

The evolution of virulence: a unifying link between parasitology and ecology. Ewald PW. **J Parasitol** 1995 Oct; 81(5):659-69 (71 ref.)
The scope for virulence management: a comment on Ewald's view on the evolution of virulence. van Baalen M, et al. **Trends Microbiol** 1995 Nov;3(11):414-6; discussion 416-7 (11 ref.)
[Parasitic liver disease] Sekiya C.
Ryoikibetsu Shokogun Shirizu 1995;(7):66-9 (10 ref.) **(Jpn)**

PHYSIOLOGY

The art of parasite survival. Camus D, et al.
Braz J Med Biol Res 1995 Apr;28(4):399-413 (92 ref.)
Parasites and carotenoid-based signal intensity: how general should the relationship be? Shykoff JA, et al.
Naturwissenschaften 1996 Mar;83(3):113-21 (66 ref.)
The varied lifestyles of intracellular pathogens within eukaryotic vacuolar compartments. Garcia-del Portillo F, et al. **Trends Microbiol** 1995 Oct;3(10):373-80 (69 ref.)

PARASITIC DISEASES

[Parasitic infections in the extrahepatic biliary tree] Nakazawa O. **Ryoikibetsu Shokogun Shirizu** 1996;(9):485-8 (6 ref.) **(Jpn)**

COMPLICATIONS

The aetiologies of epilepsy in tropical Africa. Adamolekun B. **Trop Geogr Med** 1995;47(3):115-7 (29 ref.)

DRUG THERAPY

Dreamtime, devastation and deviation: Australia's contribution to the chemotherapy of human parasitic infections. Boreham PF. **Int J Parasitol** 1995 Sep; 25(9):1009-22 (73 ref.)

ETIOLOGY

Foodborne and waterborne illness in children. Rivera-Matos IR, et al. **Adv Pediatr Infect Dis** 1996;11:101-34 (112 ref.)

HISTORY

Dreamtime, devastation and deviation: Australia's contribution to the chemotherapy of human parasitic infections. Boreham PF. **Int J Parasitol** 1995 Sep; 25(9):1009-22 (73 ref.)

IMMUNOLOGY

Natural resistance to infection with intracellular parasites: molecular genetics identifies Nramp1 as the Bcg/Ity/Lsh locus. Vidal S, et al. **J Leukoc Biol** 1995 Oct;58(4):382-90 (61 ref.)

PARASITOLOGY

Microsporidium in AIDS patients: a perspective. Chukwuma C Sr. **East Afr Med J** 1996 Jan;73(1):72-5 (35 ref.)
Role of nitric oxide in parasitic infections. James SL.
Microbiol Rev 1995 Dec;59(4):533-47 (204 ref.)
[New opportunistic pathogens in AIDS] Morillon M.
Med Trop (Mars) 1996;56(1):17-20 (20 ref.) **(Fre)**
[Pseudo-parasites in histology and cytopathology] Pierre C, et al. **Med Trop (Mars)** 1995;55(2):165-71 (24 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

[Pseudo-parasites in histology and cytopathology] Pierre C, et al. **Med Trop (Mars)** 1995;55(2):165-71 (24 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

[The current status of the problem of parasitic diseases and their prevention] Sergiev VP. **Voen Med Zh** 1995 Sep; (9):45-8 (12 ref.) **(Rus)**

TRANSMISSION

Current concepts on the transmission of bacteria and parasites by blood components. Wendel Neto S. **Rev Paul Med** 1995 Nov-Dec;113(6):1036-52 (107 ref.)
[The effect of economic activities altering water resources on the parasitological situation] Artamoshin AS, et al.
Med Parazitol (Mosk) 1995 Apr-Jun;(2):51-7 (50 ref.) (Eng. Abstr.) **(Rus)**
[Hazards of insect vectors of parasites: from theory to practice] Alvar Ezquerra JP.
An R Acad Nac Med (Madr) 1995;112(3):617-45; discussion 646 (93 ref.) **(Spa)**

VETERINARY

Endectocidal drugs: ecological risks and counter-measures. Herd R. **Int J Parasitol** 1995 Aug;25(8):875-85 (82 ref.)
Costs of major parasites to the Australian livestock industries. McLeod RS. **Int J Parasitol** 1995 Nov;25(11):1363-7 (25 ref.)
Parasitisms of catfish and other farm-raised food fish [see comments] Klesius P, et al. **J Am Vet Med Assoc** 1995 Dec 1;207(11):1473-8 (40 ref.) Comment in: J Am Vet Med Assoc 1996 Feb 1;208(3):338.
Evolutionary pressures in the spread and persistence of infectious agents in vertebrate populations. Anderson RM. **Parasitology** 1995;111 Suppl:S15-31 (69 ref.)
Introduction: ecological impact of parasitism on wildlife host populations. Grenfell BT, et al. **Parasitology** 1995;111 Suppl:S3-14 (185 ref.)
Structure and activity of avermectins and milbemycins in animal health. Shoop WL, et al. **Vet Parasitol** 1995 Sep; 59(2):139-56 (54 ref.)

PARASITIC EYE INFECTIONS see **EYE INFECTIONS, PARASITIC**

PARASITIC INTESTINAL DISEASES see **INTESTINAL DISEASES, PARASITIC**

PARASITIC LIVER DISEASES see **LIVER DISEASES, PARASITIC**

PARASITIC LUNG DISEASES see **LUNG DISEASES, PARASITIC**

PARASITIC PREGNANCY COMPLICATIONS see **PREGNANCY COMPLICATIONS, PARASITIC**

PARASITICIDES see **ANTIPARASITIC AGENTS**

PARASITOLOGY

METHODS

ACP Broadsheet no 148. July 1996. Laboratory diagnosis of malaria. Warhurst DC, et al. **J Clin Pathol** 1996 Jul; 49(7):533-8 (16 ref.)

TRENDS

[Antiparasitic therapeutics: the present] Magnaval JF.
Med Trop (Mars) 1995;55(3 Suppl):10-2 (15 ref.) **(Fre)**

PARASYMPATHECTOMY

METHODS

Tympanic neurectomy in the management of parotid sialectasis. Daud AS, et al. **J Laryngol Otol** 1995 Dec; 109(12):1155-8 (12 ref.)

PARASYMPATHETIC DENERVATION see **PARASYMPATHECTOMY**

PARASYMPATHETIC NERVOUS SYSTEM

see related
PARASYMPATHECTOMY
PARASYMPATHOMIMETICS

INJURIES

Urinary bladder dysfunction following anterior lumbosacral spine fusion: case report and review of the literature. Faraj AA, et al. **Eur Spine J** 1996;5(2):121-4 (11 ref.)

METABOLISM

Cholinergic channel activators: novel opportunities for the treatment of CNS disorders. Sullivan JP, et al.
Proc West Pharmacol Soc 1995;38:127-30 (29 ref.)

PATHOLOGY

Lesions of mediastinal paraganglia in chronic chagasic cardiomyopathy: cause of sudden death? [editorial] Ramos SG, et al. **Am Heart J** 1996 Feb;131(2):417-20 (32 ref.)

PHYSIOLOGY

Cognitive functions of the basal forebrain cholinergic system in monkeys: memory or attention? Voytko ML.
Behav Brain Res 1996 Feb;75(1-2):13-25 (123 ref.)
The physiology of the cerebrovascular parasympathetic innervation. Branston NM. **Br J Neurosurg** 1995; 9(3):319-29 (25 ref.)
Reflex parasympathetic vasodilatation in facial skin. Izumi H. **Gen Pharmacol** 1995 Mar;26(2):237-44 (74 ref.)
Serotonergic modulation of cholinergic function in the central nervous system: cognitive implications. Cassel JC, et al. **Neuroscience** 1995 Nov;69(1):1-41 (261 ref.)

PHYSIOPATHOLOGY

The parasympathetic system and its muscarinic receptors in hypertensive disease. van Zwieten PA, et al.
J Hypertens 1995 Oct;13(10):1079-90 (79 ref.)

PARASYMPATHOLYTICS

see related
ANTIPARKINSON AGENTS
ANTI-ULCER AGENTS
MUSCARINIC ANTAGONISTS

PARASYMPATHOMIMETICS

see related
CHOLINESTERASE INHIBITORS
MUSCARINIC AGONISTS

Cisapride [see comments] Washabau RJ, et al.
J Am Vet Med Assoc 1995 Nov 15;207(10):1285-8 (33 ref.) Comment in: J Am Vet Med Assoc 1996 Jan 15;208(2):184.

THERAPEUTIC USE

Cholesterol gallstone formation in man and potential treatments of the gallbladder motility defect. Portincasa P, et al. **Scand J Gastroenterol Suppl** 1995;212:63-78 (294 ref.)

PARATHYROID DISEASES

DIAGNOSIS

Parathyroid and thyroid imaging. Yousem DM.
Neuroimaging Clin N Am 1996 May;6(2):435-59 (96 ref.)
Histopathological diagnosis of parathyroid diseases. Grimelius L, et al. **Pathol Res Pract** 1995 May; 191(4):353-65 (68 ref.)
Thyroid and parathyroid imaging. Hopkins CR, et al.
Semin Ultrasound CT MR 1995 Aug;16(4):279-95 (76 ref.)

PATHOLOGY

Histopathological diagnosis of parathyroid diseases. Grimelius L, et al. **Pathol Res Pract** 1995 May; 191(4):353-65 (68 ref.)

PHYSIOPATHOLOGY

The pathogenesis of parathyroid gland hyperplasia in chronic renal failure. Drüeke TB. **Kidney Int** 1995 Jul;48(1):259-72 (119 ref.)

RADIONUCLIDE IMAGING

Parathyroid imaging. Coakley AJ. **Nucl Med Commun** 1995 Jul;16(7):522-33 (96 ref.)

PARATHYROID GLANDS

see related
PARATHYROIDECTOMY

CYTOLOGY

A cloned extracellular Ca(2+)-sensing receptor: molecular mediator of the actions of extracellular Ca2+ on parathyroid and kidney cells? Brown EM, et al.
Kidney Int 1996 Apr;49(4):1042-6 (37 ref.)
Amphibian parathyroids: morphological and functional aspects. Srivastav AK, et al. **Microsc Res Tech** 1995 Oct 1;32(2):79-90 (113 ref.)
Morphology and physiological significance of parathyroid glands in reptilia. Srivastav AK, et al.
Microsc Res Tech 1995 Oct 1;32(2):91-103 (80 ref.)
Quantitative and three-dimensional aspects of the rat parathyroid gland in normo-, hypo-, and hypercalcemia. Wernerson A, et al. **Microsc Res Tech** 1995 Oct 1; 32(2):129-47 (172 ref.)
Mammalian parathyroids: morphological and functional implications. Wild P, et al. **Microsc Res Tech** 1995 Oct 1;32(2):120-8 (57 ref.)

METABOLISM

Cloning and functional characterization of extracellular Ca(2+)-sensing receptors from parathyroid and kidney. Brown EM, et al. **Bone** 1995 Aug;17(2 Suppl):7S-11S (30 ref.)

PATHOLOGY

Quantitative and three-dimensional aspects of the rat parathyroid gland in normo-, hypo-, and hypercalcemia. Wernerson A, et al. **Microsc Res Tech** 1995 Oct 1; 32(2):129-47 (172 ref.)
Pathogenesis and management of parathyroid hyperplasia in chronic renal failure: role of calcitriol. Fukagawa M, et al. **Miner Electrolyte Metab** 1995;21(1-3):97-100 (22 ref.)
Parathyroid imaging. Coakley AJ. **Nucl Med Commun** 1995 Jul;16(7):522-33 (96 ref.)

PHYSIOLOGY

The role of the parathyroid glands in the uremic syndrome. Ritz E, et al. **Am J Kidney Dis** 1995 Nov;26(5):808-13 (53 ref.)

The First Annual Bayard D. Catherwood Memorial Lecture. Ca2+-receptor-mediated regulation of parathyroid and renal function. Brown EM, et al. **Am J Med Sci** 1996 Sep; 312(3):99–109 (69 ref.)
The calcium/parathyroid hormone concept of the parathyroid glands. Lewin E, et al. **Curr Opin Nephrol Hypertens** 1995 Jul;4(4):324–33 (49 ref.)
Amphibian parathyroids: morphological and functional aspects. Srivastav AK, et al. **Microsc Res Tech** 1995 Oct 1;32(2):79–90 (113 ref.)
Morphology and physiological significance of parathyroid glands in reptilia. Srivastav AK, et al. **Microsc Res Tech** 1995 Oct 1;32(2):91–103 (80 ref.)
Mammalian parathyroids: morphological and functional implications. Wild P, et al. **Microsc Res Tech** 1995 Oct 1;32(2):120–8 (57 ref.)
[Relation between the parathyroid glands and arterial pressure: is there a parathyroid hypertensive factor?] Barlet JP, et al. **Presse Med** 1995 Nov 25;24(36):1703–6 (25 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Primary hyperparathyroidism: genetic heterogeneity suggesting different pathogenesis in sporadic and familial forms of parathyroid hyperplasia and tumors [comment] Calender A, et al. **Eur J Endocrinol** 1996 Mar;134(3):263–6 (20 ref.) Comment on: Eur J Endocrinol 1996 Mar;134(3):314–9.

RADIONUCLIDE IMAGING

Parathyroid imaging. Coakley AJ. **Nucl Med Commun** 1995 Jul;16(7):522–33 (96 ref.)
Sestamibi parathyroid imaging. McBiles M, et al. **Semin Nucl Med** 1995 Jul;25(3):221–34 (62 ref.)

ULTRASTRUCTURE

The biological significance of storage granules in rat parathyroid cells. Setoguti T, et al. **Microsc Res Tech** 1995 Oct 1;32(2):148–63 (81 ref.)

PARATHYROID HORMONE RECEPTORS see **RECEPTORS, PARATHYROID HORMONE**

PARATHYROID HORMONES

see related
HYPOPARATHYROIDISM

Parathyroid hormone-related peptide in hypercalcemia associated with adult T cell leukemia/lymphoma: molecular and cellular mechanism of parathyroid hormone-related peptide overexpression in HTLV-I-infected T cells. Ikeda K, et al. **Miner Electrolyte Metab** 1995;21(1-3):166–70 (36 ref.)

BIOSYNTHESIS

[Ectopic hormone producing cholangiocarcinoma] Kawanami C, et al. **Ryoikibetsu Shokogun Shirizu** 1996; (9):99–102 (14 ref.) **(Jpn)**

BLOOD

[Parathyroid hormone (PTH)] Takuwa Y. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:393–6 (4 ref.) **(Jpn)**
[Parathyroid hormone-related protein (PTHrP)] Watanabe K, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:397–400 (12 ref.) **(Jpn)**

GENETICS

Transcriptional control and the regulation of endocrine genes. Zajac JD, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22(12):935–43 (68 ref.)

METABOLISM

Function and metabolism of brain synaptosomes in chronic renal failure. Smogorzewski M, et al. **Artif Organs** 1995 Aug;19(8):795–800 (55 ref.)
Functional properties of the PTH/PTHrP receptor. Jüppner H. **Bone** 1995 Aug;17(2 Suppl):39S–42S (20 ref.)
The carboxy-terminus of parathyroid hormone--inert or invaluable? [editorial; comment] Orloff JJ, et al. **Endocrinology** 1995 Nov;136(11):4729–31 (20 ref.) Comment on: Endocrinology 1995 Nov;136(11):4732–40.
Approaches to studying the biomolecular interaction between the parathyroid hormone/parathyroid hormone-related protein receptor and its ligands. Chorev M, et al. **Miner Electrolyte Metab** 1995;21(1-3):133–9 (51 ref.)
Some aspects of the anabolic action of parathyroid hormone. Martin TJ, et al. **Miner Electrolyte Metab** 1995; 21(1-3):87–90 (25 ref.)

PHARMACOLOGY

The mechanisms responsible for the PTH-induced rise in cytosolic calcium in various cells are not uniform. Massry SG, et al. **Miner Electrolyte Metab** 1995;21(1-3):13–28 (75 ref.)
PTH-mediated osteoblast retraction: possible participation of the calpain pathway. Murray EJ, et al. **Miner Electrolyte Metab** 1995;21(1-3):184–8 (20 ref.)
Signal transduction mechanisms of parathyroid hormone- and parathyroid hormone-related-peptide-stimulated osteoclast-like cell formation from hemopoietic blast cells. Sugimoto T, et al. **Miner Electrolyte Metab** 1995; 21(1-3):161–5 (22 ref.)
Vascular actions of the calcium-regulating hormones. Bukoski RD, et al. **Semin Nephrol** 1995 Nov;15(6):536–49 (154 ref.)

PHYSIOLOGY

The role of the parathyroid glands in the uremic syndrome. Ritz E, et al. **Am J Kidney Dis** 1995 Nov;26(5):808–13 (53 ref.)
The calcium/parathyroid hormone concept of the parathyroid glands. Lewin E, et al. **Curr Opin Nephrol Hypertens** 1995 Jul;4(4):324–33 (49 ref.)
Parathyroid hormone and hypothalamo-pituitary function. Harvey S, et al. **Miner Electrolyte Metab** 1995;21(1-3):40–4 (35 ref.)
Non-traditional actions of parathyroid hormone: an overview. Potts JT Jr. **Miner Electrolyte Metab** 1995; 21(1-3):9–12 (12 ref.)
Pathogenesis of secondary hyperparathyroidism. Slatopolsky E, et al. **Miner Electrolyte Metab** 1995;21(1-3):91–6 (35 ref.)
Defining the roles of parathyroid hormone-related protein in normal physiology. Philbrick WM, et al. **Physiol Rev** 1996 Jan;76(1):127–73 (293 ref.)
Parathyroid hormone-related protein. An analog of parathyroid hormone involved in regulation of growth, development, and gestation [editorial] Rizzoli R. **Rev Rhum Engl Ed** 1996 Feb;63(2):79–82 (40 ref.)
[Endocrinology update--I] Allolio B, et al. **Med Klin** 1996 Apr 1;91 Suppl 1:24–32 (112 ref.) **(Ger)**

THERAPEUTIC USE

Small bone-building fragments of parathyroid hormone: new therapeutic agents for osteoporosis. Whitfield JF, et al. **Trends Pharmacol Sci** 1995 Nov;16(11):382–6 (47 ref.)
[Can parathormone be used to treat osteoporosis?] Hoppe A. **Pol Tyg Lek** 1995 Nov;50(44-47):59–61 (36 ref.) **(Pol)**

PARATHYROID NEOPLASMS

COMPLICATIONS

Unusual cases of hyperparathyroidism [see comments] Vázquez-Quintana E, et al. **P R Health Sci J** 1995 Sep; 14(3):227–32 (8 ref.) Comment in: P R Health Sci J 1995 Sep;14(3):191–3.

DIAGNOSIS

Preoperative endocrine tumor localization utilizing a cost-effective approach. Leight GS Jr, et al. **Curr Opin Gen Surg** 1993;:108–14 (19 ref.)
Histopathological diagnosis of parathyroid diseases. Grimelius L, et al. **Pathol Res Pract** 1995 May; 191(4):353–65 (68 ref.)
[The imaging diagnosis of primary hyperparathyroidism due to parathyroid adenocarcinoma. A case report] Prato N, et al. **Radiol Med (Torino)** 1995 Sep;90(3):323–6 (11 ref.) **(Ita)**

GENETICS

Primary hyperparathyroidism: genetic heterogeneity suggesting different pathogenesis in sporadic and familial forms of parathyroid hyperplasia and tumors [comment] Calender A, et al. **Eur J Endocrinol** 1996 Mar;134(3):263–6 (20 ref.) Comment on: Eur J Endocrinol 1996 Mar;134(3):314–9.
The cyclin D1/PRAD1 oncogene in human neoplasia. Arnold A. **J Investig Med** 1995 Dec;43(6):543–9 (44 ref.)

PATHOLOGY

Histologic, flow cytometric, and genetic criteria in endocrine surgery. Flynn SD, et al. **Curr Opin Gen Surg** 1993;:115–20 (45 ref.)
Parathyroid lipoadenoma: case report and review of the literature. Turner WJ, et al. **Otolaryngol Head Neck Surg** 1996 Feb;114(2):313–6 (19 ref.)
Histopathological diagnosis of parathyroid diseases. Grimelius L, et al. **Pathol Res Pract** 1995 May; 191(4):353–65 (68 ref.)

RADIONUCLIDE IMAGING

Parathyroid imaging. Coakley AJ. **Nucl Med Commun** 1995 Jul;16(7):522–33 (96 ref.)
Sestamibi parathyroid imaging. McBiles M, et al. **Semin Nucl Med** 1995 Jul;25(3):221–34 (62 ref.)

PARATHYROIDECTOMY

Reoperation for persistent or recurrent primary hyperparathyroidism. Shen W, et al. **Arch Surg** 1996 Aug; 131(8):861–7; discussion 867–9 (20 ref.)
Uremic small-artery disease with medial calcification and intimal hyperplasia (so-called calciphylaxis): a complication of chronic renal failure and benefit from parathyroidectomy. Hafner J, et al. **J Am Acad Dermatol** 1995 Dec;33(6):954–62 (61 ref.)

PARATOPES see **BINDING SITES, ANTIBODY**

PARATYPHOID VACCINE see **TYPHOID-PARATYPHOID VACCINES**

PARAVENTRICULAR HYPOTHALAMIC NUCLEUS

METABOLISM

Neuropeptide Y, the hypothalamus, and diabetes: insights into the central control of metabolism. Frankish HM, et al. **Peptides** 1995;16(4):757–71 (154 ref.)

PHYSIOLOGY

Cardiovascular function of the paraventricular nucleus of the hypothalamus. Coote JH. **Biol Signals** 1995 May-Jun; 4(3):142–9 (31 ref.)
Central insulin may up-regulate thyroid activity by suppressing neuropeptide Y release in the paraventricular nucleus. McCarty MF. **Med Hypotheses** 1995 Aug; 45(2):193–9 (114 ref.)

PHYSIOPATHOLOGY

The role of the paraventricular system in the pathogenesis of cyclic vomiting. Pasricha PJ. **J Pediatr Gastroenterol Nutr** 1995;21 Suppl 1:S29–30 (26 ref.)

PARENT-CHILD RELATIONS

Stepfamilies and children's adjustment. Dunn J. **Arch Dis Child** 1995 Dec;73(6):487–9 (23 ref.)
The role of the father in parental postnatal mental health. Marks M, et al. **Br J Med Psychol** 1995 Jun;68 (Pt 2):157–68 (75 ref.)
Preserving families at risk of child abuse and neglect: the role of the helping alliance [see comments] Dore MM, et al. **Child Abuse Negl** 1996 Apr;20(4):349–61 (80 ref.) Comment in: Child Abuse Negl 1996 Apr;20(4):345–7.
A representational perspective of child abuse and prevention: internal working models of attachment and caregiving. George C. **Child Abuse Negl** 1996 May;20(5):411–24 (62 ref.)
Looking for 'fresh' food: diet and lone parents. Dowler E, et al. **Proc Nutr Soc** 1996 Nov;54(3):759–69 (22 ref.)
Parental influences on children's diets. Wardle J. **Proc Nutr Soc** 1996 Nov;54(3):747–58 (63 ref.)
[Counseling male adolescents with homosexual orientation and their parents] Rauchfleisch U. **Prax Kinderpsychol Kinderpsychiatr** 1996 May-Jun; 45(5):166–70 (35 ref.) (Eng. Abstr.) **(Ger)**

PARENT, SINGLE see **SINGLE PARENT**

PARENTAL IMPRINTING see **GENOMIC IMPRINTING**

PARENTERAL FEEDING see **PARENTERAL NUTRITION**

PARENTERAL FEEDING, HOME see **PARENTERAL NUTRITION, HOME**

PARENTERAL HYPERALIMENTATION see **PARENTERAL NUTRITION, TOTAL**

PARENTERAL INFUSIONS see **INFUSIONS, PARENTERAL**

PARENTERAL NUTRITION

see related
FAT EMULSIONS, INTRAVENOUS

The short-bowel syndrome. Nightingale JM. **Eur J Gastroenterol Hepatol** 1995 Jun;7(6):514–20 (60 ref.)
Nutrition support in hospitalized patients with diabetes mellitus. McMahon MM, et al. **Mayo Clin Proc** 1996 Jun; 71(6):587–94 (9 ref.)
The effect of infused nutrients and absorbed foods on daily food intake in rats. Koopmans HS. **Obes Res** 1995 Dec;3 Suppl 5:675S–684S (62 ref.)
Neonatal enteral and parenteral nutrition. Pittard WB 3rd, et al. **Pediatr Ann** 1995 Nov;24(11):592–8 (62 ref.)
[Enteral vs parenteral nutrition?] Nuutinen L, et al. **Duodecim** 1994;110(20):1935–43 (42 ref.) **(Fin)**
[Artificial (parenteral and enteral) nutrition in postoperative rehabilitation] Vantini I, et al. **Chir Ital** 1994;46(6):54–67 (112 ref.) (Eng. Abstr.) **(Ita)**

ADVERSE EFFECTS

Pulmonary embolism in parenteral nutrition. Dollery CM. **Arch Dis Child** 1996 Feb;74(2):95–8 (35 ref.)
[Hepatic complications in parenteral nutrition] Müller MJ. **Z Gastroenterol** 1996 Jan;34(1):36–40 (50 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Management of nutrition in the critically ill patient. Kudsk KA, et al. **Curr Opin Gen Surg** 1994;:24–9 (15 ref.)
Techniques for the provision of parenteral nutrition. Messing

B, et al. **Eur J Gastroenterol Hepatol** 1995 Jun;7(6):507–13 (33 ref.)

PARENTERAL NUTRITION, HOME

[A case of arteriovenous malformation of the ileum complicated with decompensated liver cirrhosis: effective case of home parenteral nutrition for intestinal bleeding] Fukushima M, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Nov;92(11):1871–5 (15 ref.) **(Jpn)**

PARENTERAL NUTRITION, TOTAL

see related
PROTEIN HYDROLYSATES

Trace elements in parenteral micronutrition. Leung FY. **Clin Biochem** 1995 Dec;28(6):561–6 (76 ref.)

Malnutrition, injury, and the host immune response: nutrient substitution. Gallagher HJ, et al. **Curr Opin Gen Surg** 1993; :92–104 (116 ref.)

The role of total parenteral nutrition in the patient with cancer. Harrison LE, et al. **Curr Probl Surg** 1995 Oct; 32(10):833–917 (225 ref.)

The necessity of selenium substitution in total parenteral nutrition and artificial alimentation. Gramm HJ, et al. **J Trace Elem Med Biol** 1995 Mar;9(1):1–12 (75 ref.)

The role of glutamine, short-chain fatty acids, and nucleotides in intestinal adaptation to gastrointestinal disease. LeLeiko NS, et al. **Pediatr Clin North Am** 1996 Apr;43(2):451–70 (98 ref.)

Current indications for intravenous nutritional support in oncology patients. Hill AD, et al. **Surg Oncol Clin N Am** 1995 Jul;4(3):549–63 (78 ref.)

[Parenteral and enteral nutrition in patients with diseases of the gastrointestinal tract] Bureš J. **Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove** 1995;38(1 Suppl):21–35 (207 ref.) (Eng. Abstr.) **(Cze)**

[The choice of substrates in total parenteral nutrition] Chiarla C, et al. **Chir Ital** 1994;46(6):20–30 (52 ref.) (Eng. Abstr.) **(Ita)**

[The use of lipids in total parenteral nutrition] Motton G, et al. **Chir Ital** 1994;46(6):31–5 (49 ref.) (Eng. Abstr.) **(Ita)**

[Trace elements in long-term total parenteral nutrition] Itokawa Y. **Nippon Rinsho** 1996 Jan;54(1):172–8 (20 ref.) (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Extrapyramidal symptoms in a BMT recipient with hyperintense basal ganglia and elevated manganese. Fredstrom S, et al. **Bone Marrow Transplant** 1995 Jun; 15(6):989–92 (19 ref.)

Liver and biliary tract changes and injury associated with total parenteral nutrition: pathogenesis and prevention. Briones ER, et al. **J Am Coll Nutr** 1995 Jun;14(3):219–28 (119 ref.)

Total parenteral nutrition and immune system activity: a review [see comments] Gogos CA, et al. **Nutrition** 1995 Jul–Aug;11(4):339–44 (74 ref.) Comment in: Nutrition 1995 Jul–Aug;11(4):394–5.

The refeeding syndrome: an approach to understanding its complications and preventing its occurrence. Brooks MJ, et al. **Pharmacotherapy** 1995 Nov–Dec;15(6):713–26 (76 ref.)

[Total parenteral nutrition] Hosoda S, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):309–11 (16 ref.) **(Jpn)**

[Intrahepatic cholestasis associated with neonatal small intestinal obstruction] Tajiri H, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):569–70 (9 ref.) **(Jpn)**

[A possible hypersensitivity reaction to total parenteral nutrition] Vázquez Mora JR, et al. **Nutr Hosp** 1996 Mar–Apr;11(2):148–50 (13 ref.) (Eng. Abstr.) **(Spa)**

METHODS

[Post-appendectomy fistulas of the cecum. Apropos of 22 cases] Genier F, et al. **J Chir (Paris)** 1995 Oct;132(10):393–8 (17 ref.) (Eng. Abstr.) **(Fre)**

UTILIZATION

Current uses and abuses of total parenteral nutrition. Archer SB, et al. **Adv Surg** 1996;29:165–89 (140 ref.)

PARENTERALLY-TRANSMITTED NON-A, NON-B HEPATITIS see **HEPATITIS C**

PARENTING

see related
CHILD REARING

Age and assisted reproduction. Pennings G. **Med Law** 1995; 14(7–8):531–41 (20 ref.)

Divorce and custody: the rights, needs, and obligations of mothers, fathers, and children. Maccoby EE. **Nebr Symp Motiv** 1995;42:135–72 (58 ref.)

Parental influences on children's diets. Wardle J. **Proc Nutr Soc** 1996 Nov;54(3):747–58 (63 ref.)

PSYCHOLOGY

Reinventing the mother–daughter relationship. van Mens-Verhulst J. **Am J Psychother** 1995 Fall;49(4):526–39 (49 ref.)

The role of the father in parental postnatal mental health. Marks M, et al. **Br J Med Psychol** 1995 Jun;68 (Pt 2):157–68 (75 ref.)

A representational perspective of child abuse and prevention: internal working models of attachment and caregiving. George C. **Child Abuse Negl** 1996 May;20(5):411–24 (62 ref.)

Treatment needs of drug-addicted mothers. Integrated parenting psychotherapy interventions. Luthar SS, et al. **J Subst Abuse Treat** 1995 Sep–Oct;12(5):341–8 (64 ref.)

Skills training for pregnant and parenting adolescents. Hall JA. **NIDA Res Monogr** 1995;156:255–90 (70 ref.)

PARENTS

see related
CHILD OF IMPAIRED PARENTS
SINGLE PARENT

Effects of welfare reform on teenage parents and their children. Aber JL, et al. **Future Child** 1995 Summer–Fall; 5(2):53–71 (60 ref.)

Parents' speech and children's stuttering: a critique of the literature. Nippold MA, et al. **J Speech Hear Res** 1995 Oct; 38(5):978–89 (57 ref.)

Telling parents their child has severe congenital anomalies. Ryan S. **Postgrad Med J** 1995 Sep;71(839):529–33 (14 ref.)

PSYCHOLOGY

Parents' attributions for their children's behavior. Miller SA. **Child Dev** 1995 Dec;66(6):1557–84 (110 ref.)

Parent participation: a concept analysis. Coyne IT. **J Adv Nurs** 1996 Apr;23(4):733–40 (78 ref.)

Family and parental functioning in cystic fibrosis. Ievers CE, et al. **J Dev Behav Pediatr** 1996 Feb;17(1):48–55 (45 ref.)

Evolution of parental stress and coping processes: a framework for critical care practice. LaMontagne LL, et al. **J Pediatr Nurs** 1995 Aug;10(4):212–8 (13 ref.)

Your child is brain dead. Blair AW, et al. **Postgrad Med J** 1996 Mar;72(845):137–40 (33 ref.)

PARESTHESIA

DIAGNOSIS

[Meralgia paresthetica. A rare differential diagnosis of circumscribed alopecia] Nabavi DG, et al. **Dtsch Med Wochenschr** 1996 Jun 21;121(25–26):834–8 (25 ref.) (Eng. Abstr.) **(Ger)**

PARIETAL BONE

[Primary non-Hodgkin's lymphoma of the skull in an 11-year-old girl. Follow-up and review of the literature] Daldrup HE, et al. **Radiologe** 1996 Apr;36(4):354–9 (31 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

The use of the temporoparietal fascial flap in temporal bone reconstruction. Cheney ML, et al. **Am J Otol** 1996 Jan; 17(1):137–42 (11 ref.)

ULTRASONOGRAPHY

The length of human pregnancy as calculated by ultrasonographic measurement of the fetal biparietal diameter. Kieler H, et al. **Ultrasound Obstet Gynecol** 1995 Nov;6(5):353–7 (26 ref.)

PARIETAL CELLS, GASTRIC

see related
GASTRIC ACID
INTRINSIC FACTOR

PHYSIOLOGY

Gastric endocrine cells: gene expression, processing, and targeting of active products. Dockray GJ, et al. **Physiol Rev** 1996 Jul;76(3):767–98 (387 ref.)

PARIETAL LOBE

[Saccadic latencies and unilateral spatial neglect caused by parietal lesions] Cochin JP, et al. **Rev Neurol (Paris)** 1996 Jan;152(1):32–7 (35 ref.) (Eng. Abstr.) **(Fre)**

[Oligodendroglioma in childhood: a case report (letter)] del Val Río MR, et al. **An Esp Pediatr** 1996 Jan;44(1):80–2 (10 ref.) **(Spa)**

PATHOLOGY

Primary Ki-1-positive T-cell lymphoma of the brain—an aggressive subtype of lymphoma: case report and review of the literature. Goldbrunner R, et al. **Surg Neurol** 1996 Jul;46(1):37–41 (24 ref.)

[Extracerebral metastases of a glioblastoma, in the absence of surgery] Chretien F, et al. **Arch Anat Cytol Pathol** 1995; 43(5–6):342–9 (16 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Encoding of intention and spatial location in the posterior parietal cortex. Andersen RA. **Cereb Cortex** 1995 Sep–Oct; 5(5):457–69 (58 ref.)

The sources of visual information to the primate frontal lobe: a novel role for the superior parietal lobule. Caminiti R, et al. **Cereb Cortex** 1996 May–Jun;6(3):319–28 (102 ref.)

Oculocentric spatial representation in parietal cortex. Colby CL, et al. **Cereb Cortex** 1995 Sep–Oct;5(5):470–81 (38 ref.)

The parietal system and some higher brain functions. Mountcastle VB. **Cereb Cortex** 1995 Sep–Oct;5(5):377–90 (41 ref.)

The brain's visual world: representation of visual targets in cerebral cortex. Maunsell JH. **Science** 1995 Nov 3; 270(5237):764–9 (43 ref.)

PHYSIOPATHOLOGY

The effects of visual cortex lesions on the perception of rotated shapes. Walsh V, et al. **Behav Brain Res** 1996 Apr; 76(1–2):127–42 (75 ref.)

SURGERY

Pleomorphic xanthoastrocytoma: case report and analysis of the literature concerning the efficacy of resection and the significance of necrosis. Pahapill PA, et al. **Neurosurgery** 1996 Apr;38(4):822–8; discussion 828–9 (32 ref.)

PARKINSON DISEASE

see related
ANTIPARKINSON AGENTS
LEWY BODIES

The anatomy of the basal ganglia and Parkinson's disease: a review. Lee TK, et al. **Singapore Med J** 1995 Feb; 36(1):74–6 (14 ref.)

[Drug treatment of frequent disorders in patients with Parkinson's disease] Martí Massó JF, et al. **Neurologia** 1996 Mar;11(3):109–15 (61 ref.) (Eng. Abstr.) **(Spa)**

COMPLICATIONS

Contribution of dopaminergic and glutamatergic mechanisms to the pathogenesis of motor response complications in Parkinson's disease. Chase TN, et al. **Adv Neurol** 1996; 69:497–501 (30 ref.)

Disorders affecting autonomic function in parkinsonian patients. Mathias CJ. **Adv Neurol** 1996;69:383–91 (20 ref.)

Swallowing and esophageal function in Parkinson's disease. Johnston BT, et al. **Am J Gastroenterol** 1995 Oct; 90(10):1741–6 (54 ref.)

Acetylcholine and hallucinations: disease-related compared to drug-induced alterations in human consciousness. Perry EK, et al. **Brain Cogn** 1995 Aug;28(3):240–58 (65 ref.)

Autonomic disorders in Parkinson's disease. Martignoni E, et al. **J Neural Transm Suppl** 1995;45:11–9 (51 ref.)

Clozapine as a treatment for psychosis in Parkinson's disease: a review. Musser WS, et al. **J Neuropsychiatry Clin Neurosci** 1996 Winter;8(1):1–9 (52 ref.)

[Mental dysfunction in Parkinson's disease] Ružička E. **Cas Lek Cesk** 1996 Apr 3;135(7):199–203 (37 ref.) (Eng. Abstr.) **(Cze)**

[Clozapine in the treatment of mental manifestations of Parkinson disease] Diederich N, et al. **Rev Neurol (Paris)** 1995 Apr;151(4):251–7 (54 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

The neuropathologic diagnosis of secondary parkinsonian syndromes. Jellinger KA. **Adv Neurol** 1996;69:293–303 (49 ref.)

Peripheral markers in Parkinson's disease. An overview. Oertel WH, et al. **Adv Neurol** 1996;69:283–91 (69 ref.)

The neuropathology of parkinsonism: an overview. Cornford ME, et al. **Brain Cogn** 1995 Aug;28(3):321–41 (72 ref.)

Lewy body diseases with dementia: pathophysiology and treatment. Cummings JL. **Brain Cogn** 1995 Aug; 28(3):266–80 (64 ref.)

Neuropsychiatric features of Lewy body disease. Filley CM. **Brain Cogn** 1995 Aug;28(3):229–39 (33 ref.)

Genetic evidence that the Lewy body variant is indeed a phenotypic variant of Alzheimer's disease. Katzman R, et al. **Brain Cogn** 1995 Aug;28(3):259–65 (43 ref.)

The use of PET in Parkinson's disease. Shinotoh H, et al. **Brain Cogn** 1995 Aug;28(3):297–310 (67 ref.)

The neuropsychology of Parkinson's disease. Taylor AE, et al. **Brain Cogn** 1995 Aug;28(3):281–96 (31 ref.)

Neuropsychiatric manifestations of diffuse Lewy body disease. Beck BJ. **J Geriatr Psychiatry Neurol** 1995 Jul; 8(3):189–96 (70 ref.)

Differential diagnosis of parkinsonism. Manfredi M, et al. **J Neural Transm Suppl** 1995;45:1–9 (28 ref.)

[Initial symptomatology of Parkinson disease] Fuhr P, et al. **Schweiz Arch Neurol Psychiatr** 1995;146(4):175–9 (43 ref.) (Eng. Abstr.) **(Ger)**

[Information giving in Parkinson's disease] Kuzuhara S. **No To Shinkei** 1996 May;48(5):417–23 (10 ref.) **(Jpn)**

DRUG THERAPY

Possible neuroprotective therapy for Parkinson's disease. Ogawa N. **Acta Med Okayama** 1995 Aug;49(4):179–85 (70 ref.)

New drugs in the treatment of Parkinson's disease. An introduction. Bracco F. **Adv Neurol** 1996;69:513–7 (66 ref.)

Controversies in the therapy of Parkinson's disease. Fahn S. **Adv Neurol** 1996;69:477–86 (72 ref.)

Preclamol. A "designer drug" in the treatment of advanced Parkinson's disease. Pirtošek Z, et al. **Adv Neurol** 1996; 69:535–40 (26 ref.)

Treatment options for early Parkinson's disease. Stacy M, et al. **Am Fam Physician** 1996 Mar;53(4):1281–7 (29 ref.)

The response to levodopa in Parkinson's disease: imposing pharmacological law and order. Nutt JG, et al. **Ann Neurol** 1996 May;39(5):561–73 (98 ref.)

Drug management of Parkinson's disease. Kishore A, et al. **Can Fam Physician** 1996 May;42:946–52 (13 ref.)

Concentration–effect relationship of levodopa in patients with Parkinson's disease. Harder S, et al. **Clin Pharmacokinet** 1995 Oct;29(4):243–56 (51 ref.)

Management of parkinsonism and treatment of associated complications. Nutt JG. **Curr Opin Neurol** 1995 Aug; 8(4):327–30 (31 ref.)

Drugs for Parkinson's disease reviewed. **Drug Ther Bull** 1995 Jul;33(7):49–52 (25 ref.)

Dihydroergocryptine in the treatment of Parkinson's disease. Bonuccelli U, et al. **J Neural Transm Suppl** 1995;45:239–45 (33 ref.)

Ropinirole in the symptomatic treatment of Parkinson's disease. Brooks DJ, et al. **J Neural Transm Suppl** 1995; 45:231–8 (15 ref.)

Apomorphine continuous stimulation in Parkinson's disease: receptor desensitization as a possible mechanism of reduced motor response. Maggio R, et al. **J Neural Transm Suppl** 1995;45:133–6 (22 ref.)

Dopaminergic agonists in the treatment of Parkinson's disease: a review. Piccoli F, et al. **J Neural Transm Suppl** 1995;45:187–95 (46 ref.)

Second generation of dopamine agonists: pros and cons. Rabey JM. **J Neural Transm Suppl** 1995;45:213–24 (63 ref.)

Treatment of early Parkinson's disease: are complicated strategies justified? Ahlskog JE. **Mayo Clin Proc** 1996 Jul; 71(7):659–70 (90 ref.)

Dopamine receptors—the present state of research and perspectives. Wolfarth S, et al. **Pol J Pharmacol** 1995 May–Jun;47(3):207–18 (95 ref.)

Moderate Parkinson's disease. Strategies for maximizing treatment. Silverstein PM. **Postgrad Med** 1996 Jan; 99(1):52–4, 61–3, 67–8, passim (21 ref.)

Oxidative stress and antioxidant therapy in Parkinson's disease. Ebadi M, et al. **Prog Neurobiol** 1996 Jan;48(1):1–19 (340 ref.)

Drug therapy for Parkinson's disease. Charles PD, et al. **South Med J** 1996 Sep;89(9):851–6 (22 ref.)

[Value of clozapine in treatment of psychotic disorder in Parkinson disease] Abbar M, et al. **Encephale** 1996 Jan–Feb; 22(1):53–63 (46 ref.) (Eng. Abstr.) **(Fre)**

[Levodopa and malignant melanoma—case report and review of the literature. A contribution to causal relationship between levodopa and the development of malignant melanoma] Kleinhans M, et al. **Hautarzt** 1996 Jun; 47(6):432–7 (29 ref.) (Eng. Abstr.) **(Ger)**

[Parkinson syndrome: iatrogenic causes, iatrogenic treatment results] Burgunder JM. **Schweiz Med Wochenschr** 1996 Mar 30;126(13):522–7 (22 ref.) (Eng. Abstr.) **(Ger)**

[Stage-adjusted treatment of idiopathic Parkinson syndrome] Ludin HP. **Wien Med Wochenschr** 1995;145(13):294–8 (15 ref.) (Eng. Abstr.) **(Ger)**

[Clinical aspects and conservative therapy of Parkinson disease] Dengler R. **Zentralbl Neurochir** 1995;56(4):148–52 (5 ref.) (Eng. Abstr.) **(Ger)**

[The role of enzymatic systems in pathophysiology and pharmacotherapy of Parkinson's disease] Kuran W. **Neurol Neurochir Pol** 1995 Jul–Aug;29(4):561–8 (30 ref.) (Eng. Abstr.) **(Pol)**

[Treatment of Parkinson disease] Cardoso F. **Arq Neuropsiquiatr** 1995 Mar;53(1):1–10 (34 ref.) (Eng. Abstr.) **(Por)**

ENZYMOLOGY

The molecular biology of xenobiotic enzymes and the predisposition to idiopathic Parkinson's disease. Ho SL, et al. **Adv Neurol** 1996;69:53–60 (36 ref.)

Gene–environment interaction in parkinson's disease. The case of CYP2D6 gene polymorphism. Landi MT, et al. **Adv Neurol** 1996;69:61–72 (80 ref.)

The role of monoamine oxidase and catechol O-methyltransferase in dopaminergic neurotransmission. Napolitano A, et al. **J Neural Transm Suppl** 1995;45:35–45 (60 ref.)

Aromatic L-amino acid decarboxylase modulation and Parkinson's disease. Neff NH, et al. **Prog Brain Res** 1995; 106:91–7 (39 ref.)

[The role of enzymatic systems in pathophysiology and pharmacotherapy of Parkinson's disease] Kuran W. **Neurol Neurochir Pol** 1995 Jul–Aug;29(4):561–8 (30 ref.) (Eng. Abstr.) **(Pol)**

EPIDEMIOLOGY

The "protective" influence of cigarette smoking on Alzheimer's and Parkinson's diseases. Quagmire or opportunity for neuroepidemiology? Riggs JE. **Neurol Clin** 1996 May;14(2):353–8 (24 ref.)

Epidemiology of Parkinson's disease. Tanner CM, et al. **Neurol Clin** 1996 May;14(2):317–35 (161 ref.)

ETIOLOGY

How far are we in understanding the cause of Parkinson's disease? Ben-Shlomo Y. **J Neurol Neurosurg Psychiatry** 1996 Jul;61(1):4–16 (165 ref.)

[Etiology and pathogenesis of parkinson's disease] Mizuno Y, et al. **No To Shinkei** 1996 Jan;48(1):5–17 (136 ref.) **(Jpn)**

[Metabolic enzymes of neurotoxin: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and Parkinson's disease] Wu RF, et al. **Seikagaku** 1995 Nov; 67(11):1307–11 (15 ref.) **(Jpn)**

GENETICS

Recent advances in the genetics of Parkinson's disease. Duvoisin RC. **Adv Neurol** 1996;69:33–40 (55 ref.)

The molecular biology of xenobiotic enzymes and the predisposition to idiopathic Parkinson's disease. Ho SL, et al. **Adv Neurol** 1996;69:53–60 (36 ref.)

Gene–environment interaction in parkinson's disease. The case of CYP2D6 gene polymorphism. Landi MT, et al. **Adv Neurol** 1996;69:61–72 (80 ref.)

Glutamate receptor genes in Parkinson's disease. Penney JB, et al. **Adv Neurol** 1996;69:79–86 (30 ref.)

Genetic evidence that the Lewy body variant is indeed a phenotypic variant of Alzheimer's disease. Katzman R, et al. **Brain Cogn** 1995 Aug;28(3):259–65 (43 ref.)

Analysis of MAOA mutations in humans. Hsu YP, et al. **Prog Brain Res** 1995;106:67–75 (54 ref.)

METABOLISM

Parkinson's disease and free radicals. Mechanism of neurodegeneration and neuroprotection. Kondo T. **Ann N Y Acad Sci** 1996 Jun 15;786:206–16 (35 ref.)

Concentration–effect relationship of levodopa in patients with Parkinson's disease. Harder S, et al. **Clin Pharmacokinet** 1995 Oct;29(4):243–56 (51 ref.)

Pharmacokinetics of apomorphine in Parkinson's disease. Gancher S. **J Neural Transm Suppl** 1995;45:137–41 (21 ref.)

PET studies of the striatal dopaminergic system in Parkinson's disease (PD). Piccini P, et al. **J Neural Transm Suppl** 1995;45:123–31 (57 ref.)

[Parkinson disease and the neuronal dopamine uptake complex] Costentin J. **Ann Pharm Fr** 1995;53(4):145–54 (87 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

The neuropathologic diagnosis of secondary parkinsonian syndromes. Jellinger KA. **Adv Neurol** 1996;69:293–303 (49 ref.)

Neurotoxicity and the mechanisms of cell death in Parkinson's disease. Schapira AH. **Adv Neurol** 1996; 69:161–5 (33 ref.)

Parkinson's disease. The apoptosis hypothesis. Stern G. **Adv Neurol** 1996;69:101–7 (29 ref.)

Dopamine-induced, genotoxic activation of programmed cell death. A role in nigrostriatal neuronal degeneration in Parkinson's disease? Ziv I, et al. **Adv Neurol** 1996;69:229–33 (26 ref.)

Lewy body disease and dementia. A review. Kalra S, et al. **Arch Intern Med** 1996 Mar 11;156(5):487–93 (62 ref.)

Making the diagnosis of mixed and non-Alzheimer's dementias. Hansen LA, et al. **Arch Pathol Lab Med** 1995 Nov;119(11):1023–31 (34 ref.)

Neuropathology of Parkinson's disease. Forno LS. **J Neuropathol Exp Neurol** 1996 Mar;55(3):259–72 (101 ref.)

PHYSIOPATHOLOGY

The performance of rapid arm movements in Parkinson's disease. A review. Agostino R, et al. **Adv Neurol** 1996; 69:135–46 (61 ref.)

Basal ganglia function during normal and parkinsonian movement. PET activation studies. Brooks DJ. **Adv Neurol** 1996;69:433–41 (38 ref.)

Contribution of dopaminergic and glutamatergic mechanisms to the pathogenesis of motor response complications in Parkinson's disease. Chase TN, et al. **Adv Neurol** 1996; 69:497–501 (30 ref.)

From basal ganglia to motoneurons. Probable involvement of pathways relaying in the medulla. Delwaide PJ, et al. **Adv Neurol** 1996;69:111–6 (26 ref.)

The freezing phenomenon in parkinsonism. Fahn S. **Adv Neurol** 1995;67:53–63 (49 ref.)

Autonomic nervous system dysfunction and adrenoceptor regulation in Parkinson's disease. Clinical and pharmacological consequences. Montastruc JL, et al. **Adv Neurol** 1996;69:377–81 (36 ref.)

Molecular biology of catecholamine neurons in relation to Parkinson's disease. Nagatsu T, et al. **Adv Neurol** 1996; 69:147–52 (22 ref.)

Biochemical and pharmacologic assessment of autonomic function. Polinsky RJ. **Adv Neurol** 1996;69:373–6 (17 ref.)

Swallowing and esophageal function in Parkinson's disease. Johnston BT, et al. **Am J Gastroenterol** 1995 Oct; 90(10):1741–6 (54 ref.)

Review article: the functions of the basal ganglia and the paradox of stereotaxic surgery in Parkinson's disease [letter; comment] Iansek R, et al. **Brain** 1995 Dec;118 (Pt 6):1613–7 (21 ref.) Comment on: Brain 1994 Aug;117 (Pt 4):877–97.

The use of PET in Parkinson's disease. Shinotoh H, et al. **Brain Cogn** 1995 Aug;28(3):297–310 (67 ref.)

The neural mechanisms and progressive nature of symptoms of Parkinson's disease—based on clinical, neurophysiological and morphological studies. Narabayashi H. **J Neural Transm Park Dis Dement Sect** 1995;10(1):63–75 (26 ref.)

Glutamate and Parkinson's disease. Blandini F, et al. **Mol Neurobiol** 1996 Feb;12(1):73–94 (165 ref.)

Oxidative stress and antioxidant therapy in Parkinson's disease. Ebadi M, et al. **Prog Neurobiol** 1996 Jan;48(1):1–19 (340 ref.)

[Degeneration of catecholaminergic neurons (editorial)] Chatellard-Causse C, et al. **Pathol Biol (Paris)** 1995 Sep; 43(7):577–80 (13 ref.) **(Fre)**

[Pathogenesis and neuroprotective therapy trial in chronic degenerative diseases. Status of antioxidants] Gerlach M, et al. **Med Klin** 1996 Mar 15;91(3):163–70 (69 ref.) **(Ger)**

[Most frequent causes for hand tremor in clinical practice] Málly J. **Orv Hetil** 1995 Oct 8;136(41):2211–6 (53 ref.) (Eng. Abstr.) **(Hun)**

[The role of enzymatic systems in pathophysiology and pharmacotherapy of Parkinson's disease] Kuran W. **Neurol Neurochir Pol** 1995 Jul–Aug;29(4):561–8 (30 ref.) (Eng. Abstr.) **(Pol)**

[Neurobiology of parkinsonism. I. Neural substrates an neurochemistry of the basal ganglia] Ponzoni S, et al. **Arq Neuropsiquiatr** 1995 Sep;53(3–B):706–10 (13 ref.) (Eng. Abstr.) **(Por)**

[Neurobiology of parkinsonism. II. Experimental models] Ponzoni S, et al. **Arq Neuropsiquiatr** 1995 Sep; 53(3–B):711–7 (33 ref.) (Eng. Abstr.) **(Por)**

PSYCHOLOGY

Involvement of serotonin in clinical features of Parkinson's disease and complications of L-DOPA therapy. Melamed E, et al. **Adv Neurol** 1996;69:545–50 (47 ref.)

Do cognitive changes of Parkinson's disease result from dopamine depletion? Dubois B, et al. **J Neural Transm Suppl** 1995;45:27–34 (28 ref.)

Psychosis in Parkinson's disease: diagnosis and treatment. Doraiswamy M, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1995 Sep; 19(5):835–46 (27 ref.)

Refining the taxonomy of memory [comment] Robbins TW. **Science** 1996 Sep 6;273(5280):1353–4 (11 ref.) Comment on: Science 1996 Sep 6;273(5280):1399–402.

RADIONUCLIDE IMAGING

Fluorodopa PET scanning in Parkinson's disease. Snow BJ. **Adv Neurol** 1996;69:449–57 (73 ref.)

[Positron-emission tomography in akinetic rigidity syndrome] Goldman S. **Rev Med Brux** 1995 Dec; 16(6):399–403 (35 ref.) (Eng. Abstr.) **(Fre)**

[Positron-emission tomographic studies of the brain in parkinsonism patients] Berezhkova LV. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995;95(6):93–7 (43 ref.) **(Rus)**

REHABILITATION

[Parkinson disease and neurologic rehabilitation] Auff E, et al. **Wien Med Wochenschr** 1995;145(13):302–5 (27 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Does stereotactic treatment for Parkinson's disease slow the progression of the disease? Narabayashi H. **Adv Neurol** 1996;69:557–62 (18 ref.)

Review article: the functions of the basal ganglia and the paradox of stereotaxic surgery in Parkinson's disease [letter; comment] Iansek R, et al. **Brain** 1995 Dec;118 (Pt 6):1613–7 (21 ref.) Comment on: Brain 1994 Aug;117 (Pt 4):877–97.

Neural transplantation. Lindvall O. **Cell Transplant** 1995 Jul–Aug;4(4):393–400 (35 ref.)

Chromaffin cell survival and host dopaminergic fiber recovery in a patient with Parkinson's disease treated by cografts of adrenal medulla and pretransected peripheral nerve. Case report. Date I, et al. **J Neurosurg** 1996 Apr; 84(4):685–9 (33 ref.)

[Neurosurgical methods in Parkinson disease] Alesch F. **Wien Med Wochenschr** 1995;145(13):305–9 (23 ref.) (Eng. Abstr.) **(Ger)**

[Identity and the personality and personal identity: philosophical questions in relation to transplantation of brain tissue] Birnbacher D. **Zentralbl Neurochir** 1995; 56(4):180–5 (6 ref.) (Eng. Abstr.) **(Ger)**

[Psychological aspects of neurotransplantation] Ellgring H. **Zentralbl Neurochir** 1995;56(4):168–72 (11 ref.) (Eng. Abstr.) **(Ger)**

[Neurotransplantation in Parkinson disease: experimental and clinical results of functional reconstruction of the dopaminergic system] Nikkhah G, et al. **Zentralbl Neurochir** 1995;56(4):153–60 (29 ref.) (Eng. Abstr.) **(Ger)**

[Open questions in neurotransplantation. Attempted at an

PARKINSON DISEASE

unbiased ethical analysis] Reiter-Theil S. **Zentralbl Neurochir** 1995;56(4):173-9 (8 ref.) (Eng. Abstr.) **(Ger)**

[Neuronal transplantation in animal models of Parkinson disease: in vivo voltammetry, tissue cryopreservation and immunology] Sautter J, et al. **Zentralbl Neurochir** 1995; 56(4):161-7 (28 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Radical directions in Parkinson's disease [comment] Fisher LJ, et al. **Nat Med** 1995 Mar;1(3):201-3 (20 ref.) Comment on: Nat Med 1995 Mar;1(3):226-31.

There is a renaissance of interest in pallidotomy for Parkinson's disease. Goetz CG, et al. **Nat Med** 1996 May; 2(5):510-4 (21 ref.)

Toward trophic treatment in parkinsonism: a primate step. Olson L. **Nat Med** 1996 Apr;2(4):400-1 (18 ref.)

[Future aspects of modern Parkinson therapy] Ransmayr G, et al. **Wien Med Wochenschr** 1995;145(13):299-301 (53 ref.) (Eng. Abstr.) **(Ger)**

[Present strategy and future perspective of therapy in Parkinson's disease] Kuno S. **No To Shinkei** 1996 Jan; 48(1):18-25 (35 ref.) **(Jpn)**

PARKINSON DISEASE, POSTENCEPHALITIC

see related
ENCEPHALITIS, EPIDEMIC

PARKINSON DISEASE, SYMPTOMATIC

CHEMICALLY INDUCED

Excitatory amino acids and MPTP toxicity. Fornai F, et al. **Adv Neurol** 1996;69:167-76 (52 ref.)

Extrapyramidal symptoms in a BMT recipient with hyperintense basal ganglia and elevated manganese. Fredstrom S, et al. **Bone Marrow Transplant** 1995 Jun; 15(6):989-92 (19 ref.)

Parkinsonism in alcohol withdrawal: case report and review of the literature. Luijckx GJ, et al. **Clin Neurol Neurosurg** 1995 Nov;97(4):336-9 (18 ref.)

ETIOLOGY

Tremor as the result of shunt obstruction: four patients with cysticercosis and secondary parkinsonism: report of four cases. Keane JR. **Neurosurgery** 1995 Sep;37(3):520-2 (3 ref.)

METABOLISM

Excitatory amino acids and MPTP toxicity. Fornai F, et al. **Adv Neurol** 1996;69:167-76 (52 ref.)

The dopamine transporter. The cloned target site of parkinsonism-inducing toxins and of drugs of abuse. Pifl C, et al. **Adv Neurol** 1996;69:235-8 (9 ref.)

RADIONUCLIDE IMAGING

Hemiatrophy, juvenile-onset exertional alternating leg paresis, hypotonia, and hemidystonia and adult-onset hemiparkinsonism: the spectrum of hemiparkinsonism-hemiatrophy syndrome. Lang AE. **Mov Disord** 1995 Jul;10(4):489-95 (32 ref.)

SURGERY

[Neuronal transplantation in animal models of Parkinson disease: in vivo voltammetry, tissue cryopreservation and immunology] Sautter J, et al. **Zentralbl Neurochir** 1995; 56(4):161-7 (28 ref.) (Eng. Abstr.) **(Ger)**

PARKINSONIAN SYNDROME see PARKINSON DISEASE, SYMPTOMATIC

PAROTID DISEASES

DIAGNOSIS

Sialadenosis of the salivary glands. Pape SA, et al. **Br J Plast Surg** 1995 Sep;48(6):419-22 (33 ref.)

[Anatomy and pathology of the parotid gland. COrrelation with magnetic resonance tomography] Sartoretti-Schefer S, et al. **Radiologe** 1995 Nov;35(11):848-65 (70 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Parotid salivary fistula following rhytidectomy. Wolf K, et al. **Plast Reconstr Surg** 1996 Mar;97(3):641-2 (7 ref.)

PATHOLOGY

Unilateral polycystic (dysgenetic) disease of the parotid gland. Ortiz-Hidalgo C, et al. **South Med J** 1995 Nov; 88(11):1173-5 (9 ref.)

[Our experience with parotid cysts] Assimakopoulos D, et al. **Rev Stomatol Chir Maxillofac** 1995;96(5):313-6 (21 ref.) (Eng. Abstr.) **(Fre)**

[A cystic lymphoepithelial lesion of the parotid in HIV-1-infected patients] Calderón-Osuna E, et al. **Med Clin (Barc)** 1995 Oct 14;105(12):461-3 (10 ref.) (Eng. Abstr.) **(Spa)**

SURGERY

Tympanic neurectomy in the management of parotid sialectasis. Daud AS, et al. **J Laryngol Otol** 1995 Dec; 109(12):1155-8 (12 ref.)

PAROTID GLAND

CYTOLOGY

The role of phosphotyrosine signaling pathway in a parotid gland proliferation and function. Purushotham KR, et al. **Crit Rev Oral Biol Med** 1995;6(2):119-31 (113 ref.)

PATHOLOGY

[Lymphoepithelial hyperplasia of the parotid gland and HIV infection] Barry B, et al. **Ann Otolaryngol Chir Cervicofac** 1995;112(8):387-92 (28 ref.) (Eng. Abstr.) **(Fre)**

[Anatomy and pathology of the parotid gland. COrrelation with magnetic resonance tomography] Sartoretti-Schefer S, et al. **Radiologe** 1995 Nov;35(11):848-65 (70 ref.) (Eng. Abstr.) **(Ger)**

[Lymph node problem in cutaneous head and neck carcinomas] Spriano G, et al. **Acta Otorhinolaryngol Ital** 1995 Jun;15(3):159-62; discussion 163 (32 ref.) (Eng. Abstr.) **(Ita)**

[Bilateral Warthin tumors. Case report and review of literature] Sancipriano JA, et al. **Acta Otorrinolaringol Esp** 1996 Mar-Apr;47(2):157-9 (21 ref.) (Eng. Abstr.) **(Spa)**

SECRETION

The role of phosphotyrosine signaling pathway in a parotid gland proliferation and function. Purushotham KR, et al. **Crit Rev Oral Biol Med** 1995;6(2):119-31 (113 ref.)

SURGERY

[Bilateral Warthin tumors. Case report and review of literature] Sancipriano JA, et al. **Acta Otorrinolaringol Esp** 1996 Mar-Apr;47(2):157-9 (21 ref.) (Eng. Abstr.) **(Spa)**

PAROTID NEOPLASMS

DIAGNOSIS

[Anatomy and pathology of the parotid gland. COrrelation with magnetic resonance tomography] Sartoretti-Schefer S, et al. **Radiologe** 1995 Nov;35(11):848-65 (70 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

Cutaneous metastasis from a parotid adenocarcinoma. Report of a case with immunohistochemical findings and review of the literature. Tok J, et al. **Am J Dermatopathol** 1995 Jun;17(3):303-6 (9 ref.)

Malignant myoepithelioma of the parotid gland: case report and review of the literature. Klumpp TR, et al. **J Laryngol Otol** 1995 Oct;109(10):995-8 (27 ref.)

Leiomyosarcoma of the parotid gland. Oncel S, et al. **J Laryngol Otol** 1996 Apr;110(4):401-3 (9 ref.)

[Bilateral Warthin tumors. Case report and review of literature] Sancipriano JA, et al. **Acta Otorrinolaringol Esp** 1996 Mar-Apr;47(2):157-9 (21 ref.) (Eng. Abstr.) **(Spa)**

RADIOGRAPHY

[Hemangiopericytoma with parotid localization. Apropos of a case] Oujilal A, et al. **Ann Otolaryngol Chir Cervicofac** 1995;112(7):350-2 (17 ref.) (Eng. Abstr.) **(Fre)**

SECONDARY

[Lymph node problem in cutaneous head and neck carcinomas] Spriano G, et al. **Acta Otorhinolaryngol Ital** 1995 Jun;15(3):159-62; discussion 163 (32 ref.) (Eng. Abstr.) **(Ita)**

SURGERY

[Iatrogenic lesions of the facial nerve during parotid surgery for pleomorphic adenoma] Colella G, et al. **Minerva Stomatol** 1995 Dec;44(12):591-6 (40 ref.) (Eng. Abstr.) **(Ita)**

[Bilateral Warthin tumors. Case report and review of literature] Sancipriano JA, et al. **Acta Otorrinolaringol Esp** 1996 Mar-Apr;47(2):157-9 (21 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

[The interferon alfa-2a treatment of the severe form of the Kasabach-Merritt syndrome with neonatal onset] González de Dios J, et al. **An Esp Pediatr** 1996 Feb;44(2):179-83 (67 ref.) **(Spa)**

ULTRASTRUCTURE

Basal cell adenocarcinoma of the parotid gland: a case report with immunohistochemical, ultrastructural findings and review of the literature. Raslan WF, et al. **J Oral Maxillofac Surg** 1995 Dec;53(12):1457-62 (15 ref.)

PAROTITIS

ETIOLOGY

Self-induced pneumoparotitis. Goguen LA, et al. **Arch Otolaryngol Head Neck Surg** 1995 Dec;121(12):1426-9 (28 ref.)

THERAPY

Management of parotid swelling. Krause GE, et al. **Compr Ther** 1996 Apr;22(4):256-61 (17 ref.)

PAROXETINE

ADVERSE EFFECTS

Akathisia: a review and case report following paroxetine treatment. Baldassano CF, et al. **Compr Psychiatry** 1996 Mar-Apr;37(2):122-4 (40 ref.)

PARTIAL MASTECTOMY see MASTECTOMY, SEGMENTAL

PARTIAL MONOSOMY see CHROMOSOME DELETION

PARTIAL THROMBOPLASTIN TIME

Relation between systemic anticoagulation as determined by activated partial thromboplastin time and heparin measurements and in-hospital clinical events in unstable angina and non-Q wave myocardiaL infarction. Thrombolysis in Myocardial Ischemia III B Investigators. Becker RC, et al. **Am Heart J** 1996 Mar;131(3):421-33 (66 ref.)

Activated clotting time versus activated partial thromboplastin time for therapeutic monitoring of heparin [see comments] Simko RJ, et al. **Ann Pharmacother** 1995 Oct;29(10):1015-21; quiz 1061 (36 ref.) Comment in: Ann Pharmacother 1995 Oct;29(10):1045-6.

Resistance to activate protein C, the Arg506 to Gln mutation in the factor V gene, and venous thrombosis. Functional tests and DNA-based assays, pros and cons [see comments] Dahlbäck B. **Thromb Haemost** 1995 May;73(5):739-42 (33 ref.) Comment in: Thromb Haemost 1995 Nov;74(5):1380-1.

[APC resistance: pathogenesis, diagnosis, prevalence and importance of a new thrombosis risk factor] Wankmüller H, et al. **Med Klin** 1996 May 15;91(5):308-12, 324 (49 ref.) **(Ger)**

[Activated partial thromboplastin time (APTT), partial thromboplastin time (PTT)] Fukutake K, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:6-9 (3 ref.) **(Jpn)**

PARTICLE ACCELERATORS

see related
RADIOSURGERY

[Radiosurgery by linear accelerators in the treatment of 84 arteriovenous malformations] Schlienger M, et al. **Bull Cancer (Paris)** 1995 Dec;82 Suppl 5:581s-585s (25 ref.) (Eng. Abstr.) **(Fre)**

[The present and future of heavy charged particle therapy] Tsujii H. **Nippon Rinsho** 1996 Jan;54(1):268-73 (13 ref.) (Eng. Abstr.) **(Jpn)**

PARTICLE-INDUCED X-RAY EMISSION SPECTROMETRY see SPECTROMETRY, X-RAY EMISSION

PARTNER NOTIFICATION see CONTACT TRACING

PARTURITION see LABOR

PARVALBUMINS

PHYSIOLOGY

The Ca2+(-)binding proteins parvalbumin and oncomodulin and their genes: new structural and functional findings. Pauls TL, et al. **Biochim Biophys Acta** 1996 Apr 10; 1306(1):39-54 (168 ref.)

PARVOVIRIDAE

GENETICS

Parvoviral vectors for the gene therapy of cancer. Shaughnessy E, et al. **Semin Oncol** 1996 Feb;23(1):159-71 (116 ref.)

PARVOVIRIDAE INFECTIONS

DIAGNOSIS

[[Human parvovirus B19 and its clinical significance] Schwarz TF, et al. **Hautarzt** 1995 Dec;46(12):831-5 (44 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Diverse hematologic effects of parvovirus B19 infection. Mustafa MM, et al. **Pediatr Clin North Am** 1996 Jun; 43(3):809–21 (70 ref.)

VIROLOGY

Viral arthritis including HIV. Naides SJ. **Curr Opin Rheumatol** 1995 Jul;7(4):337–42 (36 ref.)

PARVOVIRUS B19, HUMAN

see related
ERYTHEMA INFECTIOSUM

Parvovirus B19 infection and hematopoiesis. Brown KE, et al. **Blood Rev** 1995 Sep;9(3):176–82 (30 ref.)
Parvovirus infection and its treatment. Young NS. **Clin Exp Immunol** 1996 May;104 Suppl 1:26–30 (31 ref.)
Viral arthritis: the lessons of parvovirus B19. Mangi RJ. **Hosp Pract (Off Ed)** 1995 Nov 15;30(11):65–72 (7 ref.)
New pathogens, and diseases old and new. I) Afipia felis and Rochalimaea. II) Parvovirus B 19. III) herpesvirus 6. Zannolli R, et al. **Panminerva Med** 1995 Dec;37(4):238–47 (111 ref.)
[[Human parvovirus B19 and its clinical significance] Schwarz TF, et al. **Hautarzt** 1995 Dec;46(12):831–5 (44 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Leukophagocytosis in human parvovirus B19–induced transient bicytopenia in a healthy child. Wakamoto H, et al. **Acta Paediatr Jpn** 1996 Jun;38(3):278–81 (19 ref.)

ISOLATION & PURIFICATION

[Cardiac involvement in fetal parvovirus B19 infection] Soulié JC. **Pathol Biol (Paris)** 1995 May;43(5):416–9 (22 ref.) (Eng. Abstr.) **(Fre)**
[Parvovirus B19 infection. New physiopathological approaches] Labau E, et al. **Presse Med** 1996 Feb 3; 25(4):162–6 (26 ref.) (Eng. Abstr.) **(Fre)**

PATHOGENICITY

Parvovirus B19: an expanding spectrum of disease. Cohen B. **BMJ** 1995 Dec 9;311(7019):1549–52 (45 ref.)
Diverse hematologic effects of parvovirus B19 infection. Mustafa MM, et al. **Pediatr Clin North Am** 1996 Jun; 43(3):809–21 (70 ref.)
[Parvovirus B19 (PV–B19) and the human diseases it causes] Iavorkovskiĭ LI. **Ter Arkh** 1995;67(11):56–8 (30 ref.) (Eng. Abstr.) **(Rus)**

PARVOVIRUS INFECTIONS see PARVOVIRIDAE INFECTIONS

PAS see P-AMINOSALICYLIC ACID

PASSIVE ADDICTION, NEONATAL see NEONATAL ABSTINENCE SYNDROME

PASSIVE ANTIBODY TRANSFER see IMMUNIZATION, PASSIVE

PASSIVE MOTION THERAPY, CONTINUOUS see MOTION THERAPY, CONTINUOUS PASSIVE

PASSIVE RANGE OF MOTION see RANGE OF MOTION, ARTICULAR

PASSIVE SMOKING see TOBACCO SMOKE POLLUTION

PASSIVE TRANSFER OF IMMUNITY see IMMUNIZATION, PASSIVE

PASTEURELLA

DRUG EFFECTS

[In vitro susceptibility of Pasteurella and related bacteria to five orally administered antibiotics] Lion C, et al. **Pathol Biol (Paris)** 1996 May;44(5):341–6 (13 ref.) (Eng. Abstr.) **(Fre)**

PASTEURELLA INFECTIONS

[A case of Pasteurella multocida subsp. multocida septicemia due to cat bites in liver cirrhosis patient] Shimizu T, et al. **Kansenshogaku Zasshi** 1995 Nov;69(11):1302–6 (11 ref.) (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

Septic shock due to Pasteurella multocida subspecies multocida in a previously healthy woman [letter] Ruiz-Irastorza G, et al. **Clin Infect Dis** 1995 Jul;21(1):232–4 (13 ref.)

DIAGNOSIS

[Interstitial pneumonia and sepsis due to a Pasteurella multocida infection] Schlichthaar H, et al. **Dtsch Med Wochenschr** 1995 Nov 17;120(46):1582–6 (19 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

An interesting case of failed renal transplant complicated by a lymphocele infected with Pasteurella multocida and a review of the literature. Mayo RR, et al. **Am J Nephrol** 1996;16(4):361–6 (38 ref.)
Persistent postoperative wound infection with Pasteurella multocida: case report and literature review [letter] Cook PP. **Infection** 1995 Jul–Aug;23(4):252 (4 ref.)

TRANSMISSION

Exposure to domestic cats: risk factor for Pasteurella multocida peritonitis in liver cirrhosis? Koch CA, et al. **Am J Gastroenterol** 1996 Jul;91(7):1447–9 (29 ref.)

PASTEURELLA MULTOCIDA

Exposure to domestic cats: risk factor for Pasteurella multocida peritonitis in liver cirrhosis? Koch CA, et al. **Am J Gastroenterol** 1996 Jul;91(7):1447–9 (29 ref.)
An interesting case of failed renal transplant complicated by a lymphocele infected with Pasteurella multocida and a review of the literature. Mayo RR, et al. **Am J Nephrol** 1996;16(4):361–6 (38 ref.)
Persistent postoperative wound infection with Pasteurella multocida: case report and literature review [letter] Cook PP. **Infection** 1995 Jul–Aug;23(4):252 (4 ref.)
[Interstitial pneumonia and sepsis due to a Pasteurella multocida infection] Schlichthaar H, et al. **Dtsch Med Wochenschr** 1995 Nov 17;120(46):1582–6 (19 ref.) (Eng. Abstr.) **(Ger)**

ISOLATION & PURIFICATION

Septic shock due to Pasteurella multocida subspecies multocida in a previously healthy woman [letter] Ruiz-Irastorza G, et al. **Clin Infect Dis** 1995 Jul;21(1):232–4 (13 ref.)

PASTEURELLA PESTIS see YERSINIA PESTIS

PASTEURELLA TULARENSIS see FRANCISELLA TULARENSIS

PASTEURELLACEAE

PATHOGENICITY

Bacterial transferrin and lactoferrin receptors. Gray-Owen SD, et al. **Trends Microbiol** 1996 May;4(5):185–91 (49 ref.)

PASTEURELLOSIS see PASTEURELLA INFECTIONS

PASTORAL CARE

A critical analysis of nursing: meeting the spiritual needs of patients. Oldnall A. **J Adv Nurs** 1996 Jan;23(1):138–44 (43 ref.)

LEGISLATION & JURISPRUDENCE

Regulating pastoral counseling practice: the problem of sexual misconduct. Young JL, et al. **Bull Am Acad Psychiatry Law** 1995;23(3):421–32 (32 ref.)

PATCH-CLAMP TECHNIQUES

The cardiac Na–Ca exchanger in giant membrane patches. Hilgemann DW. **Ann N Y Acad Sci** 1996 Apr 15;779:136–58 (28 ref.)

METHODS

Molecular biology and physiology at the single-cell level. Monyer H, et al. **Curr Opin Neurobiol** 1995 Jun;5(3):382–7 (21 ref.)
Probing dendritic function with patch pipettes. Stuart G, et al. **Curr Opin Neurobiol** 1995 Jun;5(3):389–94 (27 ref.)

PATCH TESTS

Contact allergy testing alternatives: 1996. Scheman A. **Cutis** 1996 Apr;57(4):235–40 (22 ref.)

STANDARDS

The European standard series. European Environmental and Contact Dermatitis Research Group (EECDRG). Bruynzeel DP, et al. **Contact Dermatitis** 1995 Sep; 33(3):145–8 (16 ref.)

PATELLA

Should total prosthetization of the patella be used in knee surgery? A review of the literature and personal experience. Murena PF, et al. **Chir Organi Mov** 1995 Jul–Aug; 80(3):323–8 (30 ref.)
Unicameral bone cyst of the patella. A case report. Saglik Y, et al. **Int Orthop** 1995;19(5):280–1 (15 ref.)
Bilateral patellar metastases as the clinical presentation of bronchogenic adenocarcinoma. Pauzner R, et al. **J Rheumatol** 1996 May;23(5):939–41 (22 ref.)

ABNORMALITIES

Complications of extensor mechanism surgery for patellar malalignment. Flandry F, et al. **Am J Orthop** 1995 Jul; 24(7):534–43 (25 ref.)
Double congenital patella: case report and review of the literature. Visconti D, et al. **Eur Radiol** 1996;6(4):566–9 (7 ref.)
Double patella syndrome with a form of multiple epiphyseal dysplasia. Yochum TR, et al. **J Manipulative Physiol Ther** 1995 Jul–Aug;18(6):407–10 (11 ref.)

INJURIES

Magnetic resonance imaging of the extensor mechanism. Sonin AH. **Magn Reson Imaging Clin N Am** 1994 Aug; 2(3):401–11 (30 ref.)
[Patellar subluxation: where are we in 1995? (see comments)] Dupont JY. **Acta Orthop Belg** 1995;61(3):155–68 (43 ref.) (Eng. Abstr.) Comment in: Acta Orthop Belg 1996 Mar;62(1):71. **(Fre)**

PATHOLOGY

Pathological infrapatellar plica: a report of two cases and literature review. Kim SJ, et al. **Arthroscopy** 1996 Apr; 12(2):236–9 (18 ref.)
MR imaging of the patellofemoral compartment. Quinn SF, et al. **Magn Reson Imaging Clin N Am** 1994 Aug;2(3):425–40 (53 ref.)
[Biophysical bases of the effects of holmium laser on articular cartilage and their impact on clinical application technics] Gerber BE, et al. **Orthopade** 1996 Feb;25(1):21–9 (37 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

The role of quadriceps exercise in the treatment of patellofemoral pain syndrome. Callaghan MJ, et al. **Sports Med** 1996 May;21(5):384–91 (55 ref.)

SURGERY

[Lateral release of the patella. I--Diagnostics, indications] Latosiewicz R. **Chir Narzadow Ruchu Ortop Pol** 1994; 59(3):231–4 (19 ref.) (Eng. Abstr.) **(Pol)**
[Lateral release of the patella. II. Arthroscopic technique of subcutaneous lateral release, complications] Latosiewicz R. **Chir Narzadow Ruchu Ortop Pol** 1994;59(3):235–8 (19 ref.) (Eng. Abstr.) **(Pol)**

PATELLAR LIGAMENT

see related
ANTERIOR CRUCIATE LIGAMENT
POSTERIOR CRUCIATE LIGAMENT

[Imaging of external instabilities of the patella. State of the art] Frot B, et al. **J Radiol** 1996 Jan;77(1):5–15 (36 ref.) (Eng. Abstr.) **(Fre)**

INJURIES

Magnetic resonance imaging of the extensor mechanism. Sonin AH. **Magn Reson Imaging Clin N Am** 1994 Aug; 2(3):401–11 (30 ref.)

PATENCY, VASCULAR see VASCULAR PATENCY

PATENT MEDICINES see DRUGS, NON-PRESCRIPTION

PATENTS

The development and dissemination of non-patentable therapies (NPTs). Root-Bernstein RS. **Perspect Biol Med** 1995 Autumn;39(1):110–7 (26 ref.)

LEGISLATION & JURISPRUDENCE

The North American Free Trade Agreement's effect on pharmaceutical patents: a bitter pill to swallow or a therapeutic solution? Silbermann JM. **J Contemp Health Law Policy** 1996 Spring;12(2):607–36 (176 ref.)

PATERNAL EXPOSURE

see related
MATERNAL EXPOSURE

Effects of parental exposure to solvents on pregnancy outcome. Lindbohm ML. **J Occup Environ Med** 1995 Aug; 37(8):908–14 (48 ref.)

ADVERSE EFFECTS

Effects of parental occupational exposure to lead and other metals on spontaneous abortion. Anttila A, et al. **J Occup Environ Med** 1995 Aug;37(8):915–21 (36 ref.)

PATERNITY

see related
DNA FINGERPRINTING

PATHOGEN-FREE ORGANISMS see SPECIFIC PATHOGEN-FREE ORGANISMS

PATHOGENS, BLOOD-BORNE see BLOOD-BORNE PATHOGENS

PATHOLOGICAL WASTE see MEDICAL WASTE

PATHOLOGY

EDUCATION

Audit of continuing medical education for pathologists: strategies and implications. du Boulay C. **J Clin Pathol** 1996 Feb;49(2):100–1 (16 ref.)

HISTORY

The Army Medical Museum/Armed Forces Institute of Pathology and Emerging Infections: from camp fevers and diarrhea during the American Civil War in the 1860's to global molecular epidemiology and pathology in the 1990s. Nelson AM, et al. **Arch Pathol Lab Med** 1996 Feb; 120(2):129–33 (21 ref.)

METHODS

Image management in pathology. Weinberg DS, et al. **Am J Clin Pathol** 1996 Apr;105(4 Suppl 1):S54–9 (20 ref.)

Artificial neural networks in pathology and medical laboratories [see comments] Dybowski R, et al. **Lancet** 1995 Nov 4;346(8984):1203–7 (34 ref.) Comment in: Lancet 1995 Nov 4;346(8984):1175–7. Comment in: Lancet 1995 Dec 23–30;346(8991–8992):1712.

Fractals in pathology: are they really useful? Losa GA. **Pathologica** 1995 Jun;87(3):310–7 (74 ref.)

[Microsensory systems in cell biology basic research and medical diagnostics] Brischwein M, et al. **Naturwissenschaften** 1996 May;83(5):193–200 (28 ref.) (Eng. Abstr.) **(Ger)**

ORGANIZATION & ADMINISTRATION

College of American Pathologists Conference XXIX on restructuring autopsy practice for health care reform. Let's make this autopsy conference matter. Lundberg GD. **Arch Pathol Lab Med** 1996 Aug;120(8):736–8 (11 ref.)

Maximizing the benefits of autopsy for clinicians and families. What needs to be done. McPhee SJ. **Arch Pathol Lab Med** 1996 Aug;120(8):743–8 (53 ref.)

STANDARDS

Peer review in toxicologic pathology. Ward JM, et al. **Toxicol Pathol** 1995 Mar–Apr;23(2):226–34 (26 ref.)

TRENDS

Will pathologists play as important a role in the future as they have in the past against the challenge of infectious diseases. Walker DH, et al. **Infect Agents Dis** 1995 Sep; 4(3):167–70 (8 ref.)

A toxicologic pathologist's view of apoptosis or I used to call it necrobiosis, but now I'm singing the apoptosis blues [see comments] Levin S. **Toxicol Pathol** 1995 Jul–Aug; 23(4):533–9 (34 ref.) Comment in: Toxicol Pathol 1995 Sep–Oct;23(5):617–21.

[Progresses in pathology in China, 1995] Wang W, et al. **Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):776–7 (0 ref.) **(Chi)**

PATHOLOGY, CLINICAL

Role of the pathologist in biomarker studies. Wilkinson EJ, et al. **J Cell Biochem Suppl** 1995;23:10–8 (29 ref.)

[Quick Return Service in endocrinological tests] Hashimoto T. **Rinsho Byori** 1995 Oct;43(10):1034–7 (3 ref.) (Eng. Abstr.) **(Jpn)**

[Hospital management and the role of clinical microbiology laboratory for preventing nosocomial infection] Ichiyama S. **Rinsho Byori** 1995 Oct;43(10):1005–9 (4 ref.) (Eng. Abstr.) **(Jpn)**

[Laboratory management] Kawai T. **Rinsho Byori** 1995 Oct; 43(10):991–3 (0 ref.) (Eng. Abstr.) **(Jpn)**

[The assessment of quick turnaround service in clinical laboratories] Kondoh T, et al. **Rinsho Byori** 1995 Oct; 43(10):1038–43 (1 ref.) (Eng. Abstr.) **(Jpn)**

[Cost performance and TQC in laboratory management from the aspect of a commercial laboratory] Takahashi M. **Rinsho Byori** 1995 Oct;43(10):999–1004 (5 ref.) (Eng. Abstr.) **(Jpn)**

[Present and future of classification for white cells and leukemic cells in the routine clinical laboratory] Tatsumi N, et al. **Rinsho Byori** 1995 Sep;43(9):913–6 (16 ref.) (Eng. Abstr.) **(Jpn)**

EDUCATION

[Strategy for getting many experts in clinical pathology] Ohkubo A. **Rinsho Byori** 1995 Oct;43(10):1010–3 (0 ref.) (Eng. Abstr.) **(Jpn)**

METHODS

The role of the hemostasis laboratory in cardiopulmonary bypass surgery [editorial] Brandt JT. **Am J Clin Pathol** 1996 Jul;106(1):3–5 (26 ref.)

Beneath the surface of the mud... [editorial] Swanson PE. **Am J Clin Pathol** 1996 Jul;106(1):1–2 (9 ref.)

Specimen collection and storage for diagnostic molecular pathology investigation. Farkas DH, et al. **Arch Pathol Lab Med** 1996 Jun;120(6):591–6 (50 ref.)

Computerised image handling in pathology. Cheong SK, et al. **J Clin Pathol** 1995 Sep;48(9):796–802 (4 ref.)

Confocal laser scanning microscopy: a new optical microscopic technique for applications in pathology and dermatology. Fink-Puches R, et al. **J Cutan Pathol** 1995 Jun;22(3):252–9 (27 ref.)

Self-similarity and fractal irregularity in pathologic tissues. Losa GA, et al. **Mod Pathol** 1996 Mar;9(3):174–82 (79 ref.)

Role of cytology in intraoperative diagnosis. A practical guide. Czerniak B, et al. **Pathol Annu** 1995;30 Pt 2:83–102 (52 ref.)

Applications of neural networks in histopathology. Becker RL JR. **Pathologica** 1995 Jun;87(3):246–54 (82 ref.)

Clinical applications of Bayesian belief networks in pathology. Hamilton PW, et al. **Pathologica** 1995 Jun; 87(3):237–45 (11 ref.)

Unbiased stereologic techniques for practical use in diagnostic histopathology. Sørensen FB. **Pathologica** 1995 Jun;87(3):263–78 (86 ref.)

Syntactic structure analysis. van Diest PJ, et al. **Pathologica** 1995 Jun;87(3):255–62 (41 ref.)

3D reconstruction and quantitation of pathological tissues. Whimster WF, et al. **Pathologica** 1995 Jun;87(3):279–85 (40 ref.)

ORGANIZATION & ADMINISTRATION

Workflow computing. Improving management and efficiency of pathology diagnostic services. Buffone GJ, et al. **Am J Clin Pathol** 1996 Apr;105(4 Suppl 1):S17–24 (7 ref.)

STANDARDS

Laboratory turnaround time. Valenstein P. **Am J Clin Pathol** 1996 Jun;105(6):676–88 (59 ref.)

Harmonization of animal clinical pathology testing in toxicity and safety studies. The Joint Scientific Committee for International Harmonization of Clinical Pathology Testing. Weingand K, et al. **Fundam Appl Toxicol** 1996 Feb; 29(2):198–201 (26 ref.)

TRENDS

The challenge of managing laboratory information in a managed care environment. Friedman BA. **Am J Clin Pathol** 1996 Apr;105(4 Suppl 1):S3–9 (23 ref.)

Alternate site testing. The old and new paradigm or the past is prologue. Bachner P. **Arch Pathol Lab Med** 1995 Oct; 119(10):881–5 (31 ref.)

Epidemiologic and clinical challenges in reviving the necropsy. Feinstein AR. **Arch Pathol Lab Med** 1996 Aug; 120(8):749–52 (11 ref.)

College of American Pathologists Conference XXVIII on alternate site testing: introduction. Handorf CR. **Arch Pathol Lab Med** 1995 Oct;119(10):867–73 (9 ref.)

College of American Pathologists Conference XXVIII on alternate site testing. What must we now do? Howanitz PJ. **Arch Pathol Lab Med** 1995 Oct;119(10):979–83 (30 ref.)

Update of immunocytochemistry in cytopathology. van Hoeven KH, et al. **Pathol Annu** 1995;30 Pt 2:245–67 (84 ref.)

PATHOLOGY DEPARTMENT, HOSPITAL

STANDARDS

The autopsy. Some ethical reflections on the obligations of pathologists, hospitals, families, and society. Pellegrino ED. **Arch Pathol Lab Med** 1996 Aug;120(8):739–42 (0 ref.)

STATISTICS & NUMERICAL DATA

High autopsy rates at a university medical center. What has gone right? Haque AK, et al. **Arch Pathol Lab Med** 1996 Aug;120(8):727–32 (19 ref.)

PATHOLOGY, SURGICAL

Polyps and polypectomy surveillance--role of the histopathologist. Riddell RH. **Eur J Cancer** 1995 Jul–Aug; 31A(7–8):1138–40 (6 ref.)

EDUCATION

Recommendations for the reporting of urinary bladder specimens containing bladder neoplasms. Association of Directors of Anatomic and Surgical Pathology. **Virchows Arch** 1996 Apr;428(1):1–3 (6 ref.)

METHODS

Quantitation in immunohistochemistry. A research method or a diagnostic tool in surgical pathology? Fritz P, et al. **Pathologica** 1995 Jun;87(3):300–9 (76 ref.)

Recommendations for the reporting of urinary bladder specimens containing bladder neoplasms. Association of Directors of Anatomic and Surgical Pathology. **Virchows Arch** 1996 Apr;428(1):1–3 (6 ref.)

ORGANIZATION & ADMINISTRATION

Workflow computing. Improving management and efficiency of pathology diagnostic services. Buffone GJ, et al. **Am J Clin Pathol** 1996 Apr;105(4 Suppl 1):S17–24 (7 ref.)

STANDARDS

Recommendations for the reporting of resected prostate carcinomas. Fechner RE. **Virchows Arch** 1996 Jul; 428(4–5):203–6 (21 ref.)

PATIENT ACCEPTANCE OF HEALTH CARE

Barriers to help-seeking for change in drinking: a gender-focused review of the literature. Schober R, et al. **Addict Behav** 1996 Jan–Feb;21(1):81–92 (96 ref.)

The primary care of patients who have bodily concerns. Blackwell B, et al. **Arch Fam Med** 1996 Sep;5(9):457–63 (65 ref.)

Cervical cancer screening: meeting the needs of minority ethnic women. Luke K. **Br J Cancer** 1996 Sep;74 Suppl 29:S47–50 (11 ref.)

Acceptability of medical abortion in early pregnancy. Winikoff B. **Fam Plann Perspect** 1995 Jul–Aug;27(4):142–8, 185 (36 ref.)

Why do people consult the doctor? Campbell SM, et al. **Fam Pract** 1996 Feb;13(1):75–83 (111 ref.)

Infertility, involuntary infecundity, and the seeking of medical advice in industrialized countries 1970–1992: a review of concepts, measurements and results. Schmidt L, et al. **Hum Reprod** 1995 Jun;10(6):1407–18 (32 ref.)

Cancer fatalism among African-Americans: a review of the literature. Powe BD. **Nurs Outlook** 1996 Jan–Feb; 44(1):18–21 (25 ref.)

STATISTICS & NUMERICAL DATA

Who cares? Pathways to psychiatric care for young people experiencing a first episode of psychosis. Lincoln CV, et al. **Psychiatr Serv** 1995 Nov;46(11):1166–71 (89 ref.)

PATIENT ADMISSION

see related
PATIENT READMISSION

Use of a token economy with seriously mentally ill patients: criticisms and misconceptions. Corrigan PW. **Psychiatr Serv** 1995 Dec;46(12):1258–63 (52 ref.)

[Functions of the social worker in a multi-professional team in inpatient psychosomatic rehabilitation] Mans EJ. **Rehabilitation (Stuttg)** 1996 May;35(2):119–25 (27 ref.) (Eng. Abstr.) **(Ger)**

LEGISLATION & JURISPRUDENCE

[What can the hospital deliver? What must the hospital deliver?] Pannike A. **Unfallchirurgie** 1995 Aug;21(4):204–18 (68 ref.) **(Ger)**

STANDARDS

Evaluation of appropriateness of paediatric admission. Werneke U, et al. **Arch Dis Child** 1996 Mar;74(3):268–73 (24 ref.)

Appropriateness of admissions: the French experience. Lang T, et al. **Int J Qual Health Care** 1995 Sep;7(3):233–8 (16 ref.)

PATIENT ADVOCACY

Withholding and withdrawing medical treatment: an emergency medicine perspective. Iserson KV. **Ann Emerg Med** 1996 Jul;28(1):51–4 (14 ref.)

Advocacy and empowerment: dichotomous or synchronous concepts? Rafael AR. **ANS Adv Nurs Sci** 1995 Dec; 18(2):25–32 (56 ref.)

On advancing advance directives. Why should we believe the promise? [editorial; comment] McIntyre KM. **Arch Intern Med** 1995 Nov 27;155(21):2271–3 (12 ref.) Comment on: Arch Intern Med 1994 Oct 24;154(20):2299–308.

Helping the vulnerable or condoning control within the family: where is nursing? Cody A. **J Adv Nurs** 1996 May; 23(5):882–6 (51 ref.)

HIV and homophobia: nurses as advocates. Mackereth PA. **J Adv Nurs** 1995 Oct;22(4):670–6 (42 ref.)

The patient as commodity: managed care and the question of ethics. Zoloth-Dorfman L, et al. **J Clin Ethics** 1995 Winter;6(4):339–57 (70 ref.)

New legislation on civil commitment in Hungary. Dósa A. **Med Law** 1995;14(7–8):581–7 (15 ref.)

Deception in medical and behavioral research: is it ever acceptable? Wendler D. **Milbank Q** 1996;74(1):87–114 (18 ref.)

HIV infection. Clinical research. Considerations for prospective participants. Hutchins SA, et al. **Nurs Clin North Am** 1996 Mar;31(1):125–35 (17 ref.)

[What is our approach to patients in persistent vegetative state? (editorial)] Roth F. **Schweiz Med Wochenschr** 1996 Jul 9;126(27–28):1187–90 (20 ref.) **(Ger)**

[Communication of bad facts. To inform or not to inform the patient: a choice between 2 alternatives?] Saltini A. **Recenti Prog Med** 1995 Sep;86(9):359–66 (40 ref.) (Eng. Abstr.) **(Ita)**

[Patients' rights--a Scandinavian perspective] Fallberg LH.

Nord Med 1996 Mar;111(3):67–70 (15 ref.) **(Swe)**

ECONOMICS

Current challenges to the principles of medical law and their new interpretation. Paaso I. **Med Law** 1995;14(7–8):611–21 (15 ref.)

LEGISLATION & JURISPRUDENCE

Narrowing the gap between rhetoric and the reality of medical ethics. Silverman DR. **Acad Med** 1996 Mar; 71(3):227–37 (109 ref.)

Legal & ethical safeguards: protection of society's most vulnerable participants in a commercialized organ transplantation system. Banks GJ. **Am J Law Med** 1995; 21(1):45–110 (505 ref.)

In camera inspections of privileged records in sexual assault trials: balancing defendants' rights and state interests under Massachusetts's Bishop Test. Crowley EM. **Am J Law Med** 1995;21(1):131–64 (313 ref.)

Special report: protection and advocacy: what nurses need to know. Schauer C. **Arch Psychiatr Nurs** 1995 Oct; 9(5):233–9 (15 ref.)

Denouement of an execution competency case: is Perry pyrrhic? Mossman D. **Bull Am Acad Psychiatry Law** 1995; 23(2):269–84 (113 ref.)

Can healthcare providers obtain judicial intervention against surrogates who demand "medically inappropriate" life support for incompetent patients? [see comments] Cantor NL. **Crit Care Med** 1996 May;24(5):883–7 (28 ref.) Comment in: Crit Care Med 1996 May;24(5):730–2.

The 1994 Multi-Society Task Force consensus statement on the Persistent Vegetative State: a critical analysis. Howsepian AA. **Issues Law Med** 1996 Summer;12(1):3–29 (87 ref.)

Privacy and autonomy in the physician-patient relationship. Independent contracting under Medicare and implications for expansion into managed care. Coleman PG, et al. **J Leg Med** 1995 Dec;16(4):509–43 (197 ref.)

Formal complaints and disciplinary proceedings involving medical practitioners: recent developments in New South Wales, Australia. Buetow SA. **Med Law** 1995; 14(7–8):559–69 (33 ref.)

PATIENT CARE PLANNING

see related
AFTERCARE
CONSUMER PARTICIPATION

Reversing a history of unmet needs: approaches to care for persons with co-occurring addictive and mental disorders. Osher FC, et al. **Am J Orthopsychiatry** 1996 Jan;66(1):4–11 (40 ref.)

Bela Schick Lecture, 1995. The three Ps: unabridged [editorial] Wray BB. **Ann Allergy Asthma Immunol** 1996 May;76(5):412–5 (18 ref.)

Predicting clinical states in individual patients. Braitman LE, et al. **Ann Intern Med** 1996 Sep 1;125(5):406–12 (28 ref.)

Vancomycin-resistant Staphylococcus aureus: perspectives on measures needed for control. Edmond MB, et al. **Ann Intern Med** 1996 Feb 1;124(3):329–34 (53 ref.)

Cardiovascular, pulmonary, and cancer rehabilitation. 2. Pulmonary rehabilitation. Bach JR, et al. **Arch Phys Med Rehabil** 1996 Mar;77(3 Suppl):S45–51 (58 ref.)

Cardiovascular, pulmonary, and cancer rehabilitation. 3. Cancer rehabilitation. Brennan MJ, et al. **Arch Phys Med Rehabil** 1996 Mar;77(3 Suppl):S52–8 (38 ref.)

Cardiovascular, pulmonary, and cancer rehabilitation. 1. Cardiac rehabilitation. Hertanu JS, et al. **Arch Phys Med Rehabil** 1996 Mar;77(3 Suppl):S38–44 (92 ref.)

Focused review: physiatric management of HIV-related disability. O'Dell MW, et al. **Arch Phys Med Rehabil** 1996 Mar;77(3 Suppl):S66–73 (59 ref.)

Individualizing the treatment of gout. George TM, et al. **Cleve Clin J Med** 1996 May-Jun;63(3):150–5 (16 ref.)

Decision-making situations in health care. Murdach AD. **Health Soc Work** 1995 Aug;20(3):187–91 (37 ref.)

Towards an individualized client's care: implication for education. The transcultural approach. Abdullah SN. **J Adv Nurs** 1995 Oct;22(4):715–20 (36 ref.)

Perspective of facial esthetics in dental treatment planning. Mack MR. **J Prosthet Dent** 1996 Feb;75(2):169–76 (48 ref.)

Intracarotid amobarbital procedure. The Wada test. Trenerry MR, et al. **Neuroimaging Clin N Am** 1995 Nov;5(4):721–8 (41 ref.)

An algorithmic approach to cancer pain management. Hudzinski DM. **Nurs Clin North Am** 1995 Dec;30(4):711–23 (11 ref.)

The role of cladribine in the treatment of lymphoid malignancies. Nelson MC, et al. **Oncol Nurs Forum** 1995 Oct;22(9):1395–400 (22 ref.)

Leukemia during pregnancy. Ramirez-Smiley M, et al. **Oncol Nurs Forum** 1995 Oct;22(9):1363–8 (16 ref.)

[Hormonal replacement treatment: (therapeutic protocols] Jamin C. **Contracept Fertil Sex** 1996 Feb;24(2):147–52 (39 ref.) (Eng. Abstr.) **(Fre)**

[Treatment plan for removable partial prostheses] Maes J, et al. **Rev Belge Med Dent** 1995;50(4):37–52 (47 ref.) (Eng. Abstr.) **(Fre)**

STANDARDS

Ethical and legal issues in nursing home care. Hayley DC, et al. **Arch Intern Med** 1996 Feb 12;156(3):249–56 (65 ref.)

PATIENT CARE TEAM

Complications after multidisciplinary treatment of cerebral arteriovenous malformations. Deruty R, et al. **Acta Neurochir (Wien)** 1996;138(2):119–31 (46 ref.)

A proposal for an integrated multidisciplinary assessment battery in elderly stroke patients. Kalra L. **Aging (Milano)** 1995 Jun;7(3):197–201 (57 ref.)

Guillain-Barré syndrome: a team approach to diagnosis and treatment. Dematteis JA. **Am Fam Physician** 1996 Jul; 54(1):197–200 (19 ref.)

Ideological singularity as a defense against clinical complexity. Schultz-Ross RA. **Am J Psychother** 1995 Fall; 49(4):540–7 (35 ref.)

An integrated behavioral medicine approach to improving care of patients with diabetes mellitus. Jenkins CD. **Behav Med** 1995 Summer;21(2):53–65; discussion 66–8 (19 ref.)

Community care of patients with schizophrenia: the role of the primary health care team. King M, et al. **Br J Gen Pract** 1996 Apr;46(405):231–7 (89 ref.)

Bullous emphysema: the role of the surgeon. Briffa N, et al. **Br J Hosp Med** 1996 Feb 21–Mar 5;55(4):213–7 (20 ref.)

Cystic fibrosis: adult clinical aspects. Conway SP. **Br J Hosp Med** 1996 Mar 6–19;55(5):248–52 (20 ref.)

Anaesthesia for patients with renal impairment. Cranshaw J, et al. **Br J Hosp Med** 1996 Feb 21–Mar 5;55(4):171–5 (23 ref.)

Introducing an acute pain service. Hall PA, et al. **Br J Hosp Med** 1996 Jan 17–Feb 6;55(1–2):15–7 (10 ref.)

Anaesthesia for day-case surgery. Hitchcock M, et al. **Br J Hosp Med** 1995 Sep 6–19;54(5):202–6 (20 ref.)

The eye in systemic disease. Stanbury RM, et al. **Br J Hosp Med** 1996 Jan 17–Feb 6;55(1–2):19–26 (16 ref.)

Cystic fibrosis: paediatric aspects. Wallis C. **Br J Hosp Med** 1996 Mar 6–19;55(5):241–7 (32 ref.)

Psychological interventions in infection with the human immunodeficiency virus. Catalan J. **Br J Psychiatry** 1995 Jul;167(1):104–11 (65 ref.)

Models of brain injury rehabilitation. Burke DC. **Brain Inj** 1995 Oct;9(7):735–43 (34 ref.)

Conceptual models and integrative therapy: anorexia nervosa as a prototype. Greben DH, et al. **Can J Psychiatry** 1995 Dec;40(10):584–92 (65 ref.)

The acute management of aggressive behaviour in hospitalized children and adolescents. Measham TJ. **Can J Psychiatry** 1995 Aug;40(6):330–6 (30 ref.)

Preserving families at risk of child abuse and neglect: the role of the helping alliance [see comments] Dore MM, et al. **Child Abuse Negl** 1996 Apr;20(4):349–61 (80 ref.) Comment in: Child Abuse Negl 1996 Apr;20(4):345–7.

A review of the usefulness of the standard EEG in psychiatry. Hughes JR. **Clin Electroencephalogr** 1996 Jan; 27(1):35–9 (0 ref.)

Selected topics in dermatology for the primary care physician. Bentz MA, et al. **Compr Ther** 1996 Mar; 22(3):135–43 (25 ref.)

Porphyria cutanea tarda: a clinical review. Cohen DJ, et al. **Compr Ther** 1996 Mar;22(3):175–8 (11 ref.)

Peptic ulcer disease, Helicobacter pylori, and the surgeon: changing of the guard. al-Assi MT, et al. **Curr Opin Gen Surg** 1994;:120–4 (28 ref.)

The efficacy of psychosocial treatments in primary care. A review of randomized clinical trials. Brown C, et al. **Gen Hosp Psychiatry** 1995 Nov;17(6):414–24 (43 ref.)

Nutrition support teams: an integral part of developing a gastroenterology service. Reynolds N, et al. **Gut** 1995 Dec; 37(6):740–2 (19 ref.)

Pathways linking affective disturbances and physical disorders. Cohen S, et al. **Health Psychol** 1995 Sep; 14(5):374–80 (50 ref.)

Social work and end-of-life decisions: self-determination and the common good. Wesley CA. **Health Soc Work** 1996 May;21(2):115–21 (52 ref.)

Management of congenital anorectal malformations. Wakhlu AK. **Indian Pediatr** 1995 Nov;32(11):1239–42 (0 ref.)

A multiple-level, comprehensive approach to the prevention of fetal alcohol syndrome (FAS) and other alcohol-related birth defects (ARBD). May PA. **Int J Addict** 1995; 30(12):1549–602 (160 ref.)

Anxiety in medically ill older patients: a review and update. Hocking LB, et al. **Int J Psychiatry Med** 1995;25(3):221–38 (74 ref.)

Medical disorders in the schizophrenic patient. Vieweg V, et al. **Int J Psychiatry Med** 1995;25(2):137–72 (179 ref.)

Nurse-physician collaboration: a poststructuralist view. Henneman EA. **J Adv Nurs** 1995 Aug;22(2):359–63 (15 ref.)

The surgeon as a leader in cancer care: lessons learned from the study of soft tissue sarcoma. Brennan MF. **J Am Coll Surg** 1996 Jun;182(6):520–9 (35 ref.)

Matching verbal repertoires: understanding the contingencies of practice in order to functionally communicate with clinicians. Montgomery RW, et al. **J Behav Ther Exp Psychiatry** 1995 Jun;26(2):99–105 (29 ref.)

Somatisation in children. Garralda ME. **J Child Psychol Psychiatry** 1996 Jan;37(1):13–33 (125 ref.)

Parents as partners: including mothers and fathers in the treatment of children who stutter. Kelly EM. **J Commun Disord** 1995 Jun;28(2):93–105 (50 ref.)

Psychology's role in the assessment of erectile dysfunction: historical precedents, current knowledge, and methods. Ackerman MD, et al. **J Consult Clin Psychol** 1995 Dec; 63(6):862–76 (185 ref.)

Women's sexuality: behaviors, responses, and individual differences. Andersen BL, et al. **J Consult Clin Psychol** 1995 Dec;63(6):891–906 (130 ref.)

Increased attention to human sexuality can improve HIV-AIDS prevention efforts: key research issues and directions. Kelly JA, et al. **J Consult Clin Psychol** 1995 Dec;63(6):907–18 (120 ref.)

Treatment of sexual disorders in the 1990s: an integrated approach. Rosen RC, et al. **J Consult Clin Psychol** 1995 Dec;63(6):877–90 (185 ref.)

Attachment and learning disability: a theoretical review informing three clinical interventions. Clegg JA, et al. **J Intellect Disabil Res** 1995 Aug;39 (Pt 4):295–305 (43 ref.)

Recovery from aphasia. Farmer LJ. **J Miss State Med Assoc** 1996 Aug;37(8):690–3 (52 ref.)

Myasthenia gravis: pathophysiology, diagnosis and collaborative care. Kernich CA, et al. **J Neurosci Nurs** 1995 Aug;27(4):207–15; quiz 216–8 (18 ref.)

Cardiac rehabilitation: how can it be improved? [editorial] Thompson DR. **J Psychosom Res** 1995 Jul;39(5):519–23 (20 ref.)

Key ingredients to effective addictions treatment. Waltman D. **J Subst Abuse Treat** ;995 Nov-Dec;12(6):429–39 (50 ref.)

Management of HIV infection. A 1995–96 overview for the clinician. Henry K. **Minn Med** 1995 Nov;78(11):17–24 (25 ref.)

Diagnostic tests in neuro-ophthalmology. Galetta SL, et al. **Neurol Clin** 1996 Feb;14(1):201–22 (114 ref.)

Diagnostic reasoning in neurology. Gifford DR, et al. **Neurol Clin** 1996 Feb;14(1):223–38 (59 ref.)

Teamwork in rural practice. Cunningham WF, et al. **Occas Pap R Coll Gen Pract** 1995 Sep;(71):19–22 (45 ref.)

Update on the diagnosis of and therapy for acute promyelocytic leukemia and chronic myelogenous leukemia. Wujcik D. **Oncol Nurs Forum** 1996 Apr; 23(3):478–87 (70 ref.)

Psychiatrists as treatment team leaders: pitfalls and rewards. Rodenhauser P. **Psychiatr Q** 1996 Spring;67(1):11–31 (100 ref.)

Patient requests for euthanasia and assisted suicide in terminal illness. The role of the psychiatrist. Block SD, et al. **Psychosomatics** 1995 Sep-Oct;36(5):445–57 (75 ref.)

Treatment outcomes in schizophrenia: implications for practice, policy, and research. Lehman AF, et al. **Schizophr Bull** 1995;21(4):669–75 (15 ref.)

Research in adolescent suicide: implications for training, service delivery, and public policy. Brent DA, et al. **Suicide Life Threat Behav** 1995 Summer;25(2):222–30 (40 ref.)

Management of venous leg ulcers. Hafner J, et al. **Vasa** 1996; 25(2):161–7 (49 ref.)

Unproven (questionable) cancer therapies. Brigden ML. **West J Med** 1995 Nov;163(5):463–9 (39 ref.)

Endovascular technology and its impact on the relationships among vascular surgeons, interventional radiologists, and other specialists. Veith FJ, et al. **World J Surg** 1996 Jul-Aug;20(6):687–91 (36 ref.)

[The cancer patient between academic medicine and alternative medicine--therapeutic concepts] Nagel GA. **Arch Gynecol Obstet** 1995;257(1–4):283–94 (13 ref.) **(Ger)**

[Sense and success of psychosomatic preparation for labor] Stauber M. **Arch Gynecol Obstet** 1995;257(1–4):129–35 (8 ref.) **(Ger)**

[Pelvic floor insufficiency as an interdisciplinary responsibility] Hansen H. **Chirurg** 1996 May;67(5):498–504 (14 ref.) (Eng. Abstr.) **(Ger)**

[The alcoholic patient in general practice. From initial contact to implementing therapy] Luderer HJ. **Fortschr Med** 1995 Nov 30;113(33):469–72 (17 ref.) (Eng. Abstr.) **(Ger)**

[Kidney diseases in the elderly from the internal medicine viewpoint. Diagnosis and therapy] Verwiebe R, et al. **Fortschr Med** 1995 Oct 20;113(29):418–22 (17 ref.) (Eng. Abstr.) **(Ger)**

[Surgical management of psychiatrically ill patients. Particular aspects of perioperative monitoring] Diefenbacher A, et al. **Gynakologe** 1995 Dec;28(6):412–9 (33 ref.) **(Ger)**

[Psychiatric diseases and pregnancy] Fuchs U. **Gynakologe** 1995 Dec;28(6):440–5 (16 ref.) **(Ger)**

[Psychiatric manifestations in climacteric. Diagnostic difficulties and therapeutic possibilities] Nijs P, et al. **Gynakologe** 1995 Dec;28(6):420–5 (22 ref.) **(Ger)**

[Self-injury behavior] Rechenberger I. **Gynakologe** 1995 Dec; 28(6):446–51 (13 ref.) **(Ger)**

[Psychiatric diseases with onset in puerperium] Woitalla D, et al. **Gynakologe** 1995 Dec;28(6):434–9 (33 ref.) **(Ger)**

[Indications for psychosomatically-oriented dermatologic rehabilitation] Wehrmann J. **Hautarzt** 1996 Apr;47(4):253–7 (34 ref.) (Eng. Abstr.) **(Ger)**

[Oncologic after-care--a patient-oriented concept. Basic diagnostic plan for pediatric oncology patients] Duffner U, et al. **Klin Padiatr** 1995 Jul-Aug;207(4):193–203 (55 ref.)

(Eng. Abstr.) (Ger)
[Preventing transmission of infection in endoscopy: hygienic maintainance of flexible endoscopes and measures for personal protection] Leiss O, et al. **Leber Magen Darm** 1995 Dec;25(6):251–7 (25 ref.) (Eng. Abstr.) (Ger)
[Therapy of germ cell tumors. Model for interdisciplinary treatment approach] Schmoll HJ. **Med Klin** 1996 Apr 12; 91 Suppl 3:80–4 (41 ref.) (Ger)
[Management dialogue within multi-professional teams: contribution of psychoanalysis to integrated therapy of psychotic patients] Böker H. **Psychiatr Prax** 1995 Sep; 22(5):201–5 (18 ref.) (Eng. Abstr.) (Ger)
[Particular aspects of psychiatric management of mentally retarded patients with psychiatric disorders] Hennicke K, et al. **Psychiatr Prax** 1995 Nov;22(6):240–3 (27 ref.) (Eng. Abstr.) (Ger)
[Surgical therapy of pancreatic diseases] Rumstadt B, et al. **Radiologe** 1996 May;36(5):375–80 (30 ref.) (Eng. Abstr.) (Ger)
[Functions of the social worker in a multi-professional team in inpatient psychosomatic rehabilitation] Mans EJ. **Rehabilitation (Stuttg)** 1996 May;35(2):119–25 (27 ref.) (Eng. Abstr.) (Ger)
[Interdisciplinary therapy of anal carcinoma] Döker R, et al. **Schweiz Rundsch Med Prax** 1995 Nov 21;84(47):1389–97 (43 ref.) (Eng. Abstr.) (Ger)
[Reiter's disease--a review of an interdisciplinary disease] Jelk W, et al. **Schweiz Rundsch Med Prax** 1995 Sep 12; 84(37):989–99 (66 ref.) (Eng. Abstr.) (Ger)
[25 years kidney replacement therapy in childhood and adolescence--success of somatic and psychosocial rehabilitation] Bulla M, et al. **Versicherungsmedizin** 1996 Jun 1;48(3):85–9 (56 ref.) (Eng. Abstr.) (Ger)
[Parkinson disease and neurologic rehabilitation] Auff E, et al. **Wien Med Wochenschr** 1995;145(13):302–5 (27 ref.) (Eng. Abstr.) (Ger)
[Frequent injuries of the shoulder joint] Gaudernak T. **Wien Med Wochenschr** 1996;146(6–7):130–4 (16 ref.) (Eng. Abstr.) (Ger)
[The psychiatric emergency] Felber W. **Z Arztl Fortbild (Jena)** 1995 Dec;89(7):707–10 (2 ref.) (Eng. Abstr.) (Ger)
[Psychological pain therapy] Budde HG. **Z Gastroenterol** 1996 Jun;34 Suppl 2:85–8 (25 ref.) (Ger)
[Short-bowel syndrome] Koblitz DK. **Z Gastroenterol** 1996 Jun;34 Suppl 2:41–6 (71 ref.) (Eng. Abstr.) (Ger)
[Principles and practice of control of hospital infection] Ohta M, et al. **Nippon Saikingaku Zasshi** 1995 Jul;50(3):765–75 (7 ref.) (Jpn)

ECONOMICS

Quality, cost-effective psychiatric treatment: A CNS--MD collaborative practice model. Saur CD, et al. **Arch Psychiatr Nurs** 1995 Dec;9(6):332–7 (15 ref.)
Care for depression in a changing environment. Wells KB, et al. **Health Aff (Millwood)** 1995 Fall;14(3):78–89 (15 ref.)

LEGISLATION & JURISPRUDENCE

[Forensic practice between commonality, the law and psychiatry. 2] Hoffmann-Richter U, et al. **Psychiatr Prax** 1996 May;23(3):150–4 (16 ref.) (Ger)

ORGANIZATION & ADMINISTRATION

Challenging old notions of professionalism: how can nurses work with paraprofessional ethnic health workers? Fuller J. **J Adv Nurs** 1995 Sep;22(3):465–72 (44 ref.)
Caring, curing, coping: towards an integrated model. Webb C. **J Adv Nurs** 1996 May;23(5):960–8 (44 ref.)
Re-engineering via patient-centered care. Dowd SB, et al. **Radiol Technol** 1996 May-Jun;67(5):421–4 (9 ref.)

STANDARDS

Can educational accreditation drive interdisciplinary learning in the health professions? Gelmon SB. **Jt Comm J Qual Improv** 1996 Mar;22(3):213–22 (27 ref.)
Refocusing the training of psychiatric rehabilitation staff. Corrigan PW, et al. **Psychiatr Serv** 1995 Nov;46(11):1172–7 (33 ref.)

STATISTICS & NUMERICAL DATA

[Epidemiology of rheumatologic health care in Germany] Zink A. **Z Rheumatol** 1995 Jul-Aug;54(4):184–91 (7 ref.) (Eng. Abstr.) (Ger)

TRENDS

Psychotherapy supervision in the 1990s: some observations and reflections. Watkins CE Jr. **Am J Psychother** 1995 Fall; 49(4):568–81 (87 ref.)
Workforce deployment: reconciling demands and resources. Andrews G. **Aust N Z J Psychiatry** 1995 Sep;29(3):394–402 (20 ref.)
The evolution of the clinician-scientist model of neurological rehabilitation. Peters MD, et al. **Brain Inj** 1995 Aug-Sep; 9(6):543–52 (28 ref.)
The future of consultation-liaison psychiatry and medical-psychiatric units in the era of managed care. Goldberg RJ, et al. **Gen Hosp Psychiatry** 1995 Jul; 17(4):268–77 (55 ref.)
Toward a more comprehensive medical anthropology: the case of adolescent psychopathology. Fabrega H Jr, et al. **Med Anthropol Q** 1995 Dec;9(4):431–61 (185 ref.)
The future of organ transplant psychiatry. Freeman AM 3rd, et al. **Psychosomatics** 1995 Sep-Oct;36(5):429–37 (68 ref.)
[Organization of cardiologic rehabilitation in central Europe: retrospect, present, future outlook] Halhuber MJ. **Wien Klin Wochenschr** 1995;107(24):756–9 (6 ref.) (Eng. Abstr.) (Ger)

UTILIZATION

The epidemiology of psychiatric disorders and the de facto mental health care system. Norquist GS, et al. **Annu Rev Med** 1996;47:473–9 (29 ref.)

PATIENT-CENTERED CARE

Multidisciplinarity and multimedia in quality of care--education. Heyrman J. **Eur J Cancer** 1995;31A Suppl 6:S11–4 (6 ref.)
The role of the nurse in patient-focused care: models of competence and implications for education and training. Burchell H, et al. **Int J Nurs Stud** 1996 Feb;33(1):67–75 (42 ref.)
Medication decision-making and management: a client-centered model. Chewning B, et al. **Soc Sci Med** 1996 Feb;42(3):389–98 (110 ref.)

ECONOMICS

Effects of availability of patient-related charges on practice patterns and cost containment in the pediatric intensive care unit. Sachdeva RC, et al. **Crit Care Med** 1996 Mar; 24(3):501–6 (44 ref.)

ORGANIZATION & ADMINISTRATION

Processes in the creation and diffusion of nursing knowledge: an examination of the developing concept of family-centred care. Bradley SF. **J Adv Nurs** 1996 Apr; 23(4):722–7 (33 ref.)
Ambulatory care of the HIV-infected child. O'Hara MJ, et al. **Nurs Clin North Am** 1996 Mar;31(1):179–205 (46 ref.)

PATIENT COMPLIANCE

see related
PATIENT DROPOUTS
TREATMENT REFUSAL

Compliance in the treatment of hypertension. A need for action. Sanson-Fisher RW, et al. **Am J Hypertens** 1995 Oct;8(10 Pt 2):82S–88S (57 ref.)
Estrogen replacement therapy in practice: trends and issues. Thompson W. **Am J Obstet Gynecol** 1995 Sep;173(3 Pt 2):990–3 (21 ref.)
Adherence to colorectal cancer screening. A brief overview. Vernon SW. **Ann N Y Acad Sci** 1995 Sep 30;768:292–5 (19 ref.)
Compliance with antihypertensive treatment. Costa FV. **Clin Exp Hypertens** 1996 Apr-May;18(3–4):463–72 (20 ref.)
Compliance and oral contraceptives: a review. Rosenberg MJ, et al. **Contraception** 1995 Sep;52(3):137–41 (35 ref.)
Managing behavior of precooperative children. Nathan JE. **Dent Clin North Am** 1995 Oct;39(4):789–816 (39 ref.)
Patient compliance with crucial drug regimens: implications for prostate cancer. Urquhart J. **Eur Urol** 1996;29 Suppl 2:124–31 (62 ref.)
The impact of different HRT regimens on compliance. Dören M, et al. **Int J Fertil Menopausal Stud** 1996 Jan-Feb; 41(1):29–39 (49 ref.)
Compliance to hormone replacement therapy. Rozenberg S, et al. **Int J Fertil Menopausal Stud** 1995;40 Suppl 1:23–32 (51 ref.)
Hormone replacement therapy: aspects of bleeding problems and compliance. Samsioe G. **Int J Fertil Menopausal Stud** 1996 Jan-Feb;41(1):11–5 (20 ref.)
Medication compliance and asthma: overlooking the trees because of the forest [see comments] Creer TL, et al. **J Asthma** 1996;33(4):203–11 (45 ref.) Comment in: J Asthma 1996;33(4):199–202.
Compliance issues in primary care. Lieberman JA 3rd. **J Clin Psychiatry** 1996;57 Suppl 7:76–82; discussion 83–5 (20 ref.)
Systematic review of randomised trials of interventions to assist patients to follow prescriptions for medications. Haynes RB, et al. **Lancet** 1996 Aug 10;348(9024):383–6 (26 ref.)
Breast cancer screening and compliance and evaluation of lesions. Schapira DV, et al. **Med Clin North Am** 1996 Jan; 80(1):15–26 (42 ref.)
Predictors of retention in therapeutic communities. Condelli WS. **NIDA Res Monogr** 1994;144:117–27 (22 ref.)
Compliance with contraceptives and other treatments. Cramer JA. **Obstet Gynecol** 1996 Sep;88(3 Suppl):4S–12S (42 ref.)
Adherence to physicians' instructions as a factor in managing streptococcal pharyngitis. Dajani AS. **Pediatrics** 1996 Jun; 97(6 Pt 2):976–80 (21 ref.)
How much compliance is enough? Urquhart J. **Pharm Res** 1996 Jan;13(1):10–1 (17 ref.)
Women's compliance with cardiac rehabilitation programs. Ginzel AR. **Prog Cardiovasc Nurs** 1996 Winter;11(1):30–5 (38 ref.)
Patient education and compliance issues associated with access devices. McDermott MK. **Semin Oncol Nurs** 1995 Aug;11(3):221–6 (19 ref.)
[Therapeutic compliance in adolescents with chronic disease] Alvin P, et al. **Arch Pediatr** 1995 Sep;2(9):874–82 (86 ref.) (Eng. Abstr.) (Fre)
[Reflections on compliance in menopause hormone replacement therapy] Berthet J, et al. **Rev Fr Gynecol Obstet** 1995 Dec;90(12):548–51 (0 ref.) (Eng. Abstr.) (Fre)

PSYCHOLOGY

Insight and adherence to treatment in psychotic disorders. Kemp RA, et al. **Br J Hosp Med** 1995 Sep 6–19;54(5):222–7 (46 ref.)
The difficult elderly patient: curable hostile depression or personality disorder? Monfort JC. **Int Psychogeriatr** 1995; 7 Suppl:95–111 (50 ref.)
Determinants and consequences of children's coping in the medical setting: conceptualization, review, and critique. Rudolph KD, et al. **Psychol Bull** 1995 Nov;118(3):328–57 (130 ref.)
Determinants of persistent compliance with screening for colorectal cancer. Neilson AR, et al. **Soc Sci Med** 1995 Aug;41(3):365–74 (36 ref.)

PATIENT COOPERATION see **PATIENT COMPLIANCE**

PATIENT DATA PRIVACY see **CONFIDENTIALITY**

PATIENT DISCHARGE

Ten tools of continuous quality improvement: a review and case example of hospital discharge. Ziegenfuss JT JR, et al. **Am J Med Qual** 1995 Winter;10(4):213–20 (8 ref.)
Studying emergency patients outside the emergency department. Sivilotti ML, et al. **Ann Emerg Med** 1996 Apr; 27(4):442–7 (24 ref.)
The impact of early obstetric discharge on newborn health care. Lee KS, et al. **Curr Opin Pediatr** 1996 Apr;8(2):96–101 (42 ref.)
Termination in inpatient groups. Brabender V, et al. **Int J Group Psychother** 1996 Jan;46(1):81–98 (25 ref.)
Bridging the gap between hospital and home for premature infants in Malawi. Mbweza E. **Int Nurs Rev** 1996 Mar-Apr; 43(2):53–7 (19 ref.)
Risk profile screening. Froelicher ES, et al. **J Cardiovasc Nurs** 1995 Oct;10(1):30–50 (89 ref.)
A discharge check list for psychiatric patients. Hochberger JM. **J Psychosoc Nurs Ment Health Serv** 1995 Dec; 33(12):35–8 (13 ref.)
Controversial issues surrounding early postpartum discharge. Brown LP, et al. **Nurs Clin North Am** 1996 Jun;31(2):333–9 (23 ref.)
Problems associated with early discharge of newborn infants. Early discharge of newborns and mothers: a critical review of the literature. Braveman P, et al. **Pediatrics** 1995 Oct; 96(4 Pt 1):716–26 (74 ref.)

PATIENT DROPOUTS

Retention in therapeutic communities: challenges for the nineties. Lewis BF, et al. **NIDA Res Monogr** 1994; 144:99–116 (45 ref.)
Prevention of infection dropout in PD. Viglino G, et al. **Perit Dial Int** 1996;16 Suppl 1:S355–61 (56 ref.)

PSYCHOLOGY

Behavioural abnormalities and retention rates of anti-epilepsy drugs during long-term treatment of epilepsy: a clinical perspective. Schmidt D. **Acta Neurol Scand Suppl** 1995; 162:7–10 (28 ref.)

STATISTICS & NUMERICAL DATA

Elevated rates of early discontinuation from pharmacotherapy trials in alcoholics and drug abusers. Kranzler HR, et al. **Alcohol Clin Exp Res** 1996 Feb; 20(1):16–20 (20 ref.)
Adolescents in therapeutic communities: retention and posttreatment outcome. Pompi KF. **NIDA Res Monogr** 1994;144:128–61 (28 ref.)

PATIENT DUMPING see **PATIENT TRANSFER**

PATIENT EDUCATION

Prescribing exercise for health: a simple framework for primary care [see comments] Will PM, et al. **Am Fam Physician** 1996 Feb 1;53(2):579–85 (16 ref.) Comment in: Am Fam Physician 1996 Feb 1;53(2):484–6.
An update on vaccine safety. Zimmerman RK, et al. **Am Fam Physician** 1996 Jul;54(1):185–93 (43 ref.)
The role of adjunctive therapy in the management of chronic nonmalignant pain. Allegrante JP. **Am J Med** 1996 Jul 31; 101(1A):33S–39S (69 ref.)
What every woman should know about menopause. Wasaha S, et al. **Am J Nurs** 1996 Jan;96(1):24–32; quiz 33 (9 ref.)
Readability of patient education materials: implications for clinical practice. Albright J, et al. **Appl Nurs Res** 1996 Aug; 9(3):139–43 (37 ref.)
Psycho-educational interventions in the treatment of

arthritis. Hawley DJ. **Baillieres Clin Rheumatol** 1995 Nov; 9(4):803–23 (46 ref.)
How to implement an asthma education program. Kohler CL, et al. **Clin Chest Med** 1995 Dec;16(4):557–65 (18 ref.)
Routine voluntary antepartum HIV antibody counseling and testing: a sound public health prevention strategy. Lindsay MK. **Clin Obstet Gynecol** 1996 Jun;39(2):305–15 (59 ref.)
Education and the diabetic foot. Edmonds ME, et al. **Diabet Med** 1996;13 Suppl 1:S61–4 (25 ref.)
Diabetes self-management education. Clement S. **Diabetes Care** 1995 Aug;18(8):1204–14 (114 ref.)
Social support and adjustment to cancer: reconciling descriptive, correlational, and intervention research. Helgeson VS, et al. **Health Psychol** 1996 Mar;15(2):135–48 (80 ref.)
Helping patients live with asthma. Rachelefsky GS. **Hosp Pract (Off Ed)** 1995 Nov 15;30(11):51–6, 59–64 (14 ref.)
Pharmacists as agents of change for rational drug therapy. Lipton HL, et al. **Int J Technol Assess Health Care** 1995 Summer;11(3):485–508 (138 ref.)
Risk profile screening. Froelicher ES, et al. **J Cardiovasc Nurs** 1995 Oct;10(1):30–50 (89 ref.)
Cardiac rehabilitation based on group light exercise and discussion. An Australian hospital model. Hare DL, et al. **J Cardpulm Rehabil** 1995 May–Jun;15(3):186–92 (27 ref.)
Diabetes mellitus and traffic incidents. Veneman TF. **Neth J Med** 1996 Jan;48(1):24–8 (27 ref.)
Addressing sexual dysfunction following radiation therapy for a gynecologic malignancy [published erratum appears in Oncol Nurs Forum 1995 Nov–Dec;22(10):1476] Cartwright-Alcarese F. **Oncol Nurs Forum** 1995 Sep; 22(8):1227–32 (27 ref.)
Strategies to support families of children with end-stage renal failure. Watson AR. **Pediatr Nephrol** 1995 Oct;9(5):628–31 (22 ref.)
Does counselling for angina and hypertension work? Browne D. **Practitioner** 1995 Nov;239(1556):679–81 (13 ref.)
Psychoeducation in first-episode psychosis: a therapeutic process. McGorry PD. **Psychiatry** 1995 Nov;58(4):313–28 (41 ref.)
Patient education and guided self-management plans. Neville R. **Respir Med** 1996 Aug;90(7):385–6 (15 ref.)
[Acquired experience with diabetes mellitus] Ernould C, et al. **Arch Pediatr** 1996;3 Suppl 1:315s–317s (5 ref.) **(Fre)**
[Recommendations for patient education in poor prognosis. Australian Consensus Document] Bornkessel B. **Med Monatsschr Pharm** 1996 May;19(5):143–5 (0 ref.) **(Ger)**
[Therapy of multiple sclerosis with interferon-beta-1b. Educating the patient and managing side-effects] Walther EU, et al. **Nervenarzt** 1996 Jun;67(6):452–6 (16 ref.) (Eng. Abstr.) **(Ger)**
[Psychoeducation--special reference to social skill training] Sarata Y. **Seishin Shinkeigaku Zasshi** 1995;97(7):522–8 (9 ref.) **(Jpn)**
[Patient information and conditioning for allogeneic stem cell transplantation] Brinch L. **Nord Med** 1995;110(12):318–9, 322 (16 ref.) (Eng. Abstr.) **(Nor)**
[Health education as a method of treating psycho-emotional disorders in patients with diabetes mellitus] Tatoń J, et al. **Pol Tyg Lek** 1996 Jan;51(1–5):46–9 (38 ref.) **(Pol)**

LEGISLATION & JURISPRUDENCE

Informed consent: process and clinical issues. Berry DL, et al. **Oncol Nurs Forum** 1996 Apr;23(3):507–12 (19 ref.)

METHODS

Improving patient education for patients with low literacy skills. Mayeaux EJ Jr, et al. **Am Fam Physician** 1996 Jan; 53(1):205–11 (34 ref.)
Application of computers in diabetes care--a review. II. Computers for decision support and education. Lehmann ED, et al. **Med Inf (Lond)** 1995 Oct–Dec;20(4):303–29 (147 ref.)
Hypnosis: teaching children self-regulation. Sugarman LI. **Pediatr Rev** 1996 Jan;17(1):5–11 (35 ref.)
Counseling patients about therapy for localized prostate cancer. Middleton RG. **Semin Urol Oncol** 1995 Aug; 13(3):187–90 (8 ref.)
[Pedagogic responsibilities in rehabilitation of brain damaged patients] Stadler H. **Rehabilitation (Stuttg)** 1996 May; 35(2):109–18 (25 ref.) (Eng. Abstr.) **(Ger)**
[Patient counseling by the physician in smoking cessation--conditions and prerequisites] Stössel U. **Z Arztl Fortbild (Jena)** 1995 Oct;89(5):489–98 (40 ref.) (Eng. Abstr.) **(Ger)**

STANDARDS

Ethical issues in urology: the patient's perspective. Wilkie P. **Br J Urol** 1995 Nov;76 Suppl 2:5–7 (6 ref.)

PATIENT-FAMILY LODGING see **HOUSING**

PATIENT-FOCUSED CARE see **PATIENT-CENTERED CARE**

PATIENT IDENTIFICATION SYSTEMS

Australian healthcare: a smart card for a clever country. Morris S, et al. **Int J Biomed Comput** 1995 Oct;40(2):101–5 (14 ref.)

PATIENT MONITORING see **MONITORING, PHYSIOLOGIC**

PATIENT NON-COMPLIANCE see **TREATMENT REFUSAL**

PATIENT OMBUDSMEN see **PATIENT ADVOCACY**

PATIENT OUTCOME ASSESSMENT see **OUTCOME ASSESSMENT (HEALTH CARE)**

PATIENT PARTICIPATION

A contextual approach for understanding individual autonomy in managed community long-term care. Capitman J, et al. **Gerontologist** 1995 Aug;35(4):533–40 (55 ref.)
When the patient chooses: describing unaided decisions in health care. Pierce PF. **Hum Factors** 1996 Jun;38(2):278–87 (30 ref.)
Parent participation: a concept analysis. Coyne IT. **J Adv Nurs** 1996 Apr;23(4):733–40 (78 ref.)
A selective review of the literature on nurse-patient communication: has the patient's contribution been neglected? Jarrett N, et al. **J Adv Nurs** 1995 Jul;22(1):72–8 (51 ref.)
Health-promoting nursing practice: the demise of the nursing process? Lindsey E, et al. **J Adv Nurs** 1996 Jan;23(1):106–12 (24 ref.)
Through the patient's eyes: strategies toward more successful contraception. Delbanco TL, et al. **Obstet Gynecol** 1996 Sep;88(3 Suppl):41S–47S (31 ref.)
Discussing cardiopulmonary resuscitation with patients and relatives. Stewart K. **Postgrad Med J** 1995 Oct; 71(840):585–9 (30 ref.)
Medication decision-making and management: a client-centered model. Chewning B, et al. **Soc Sci Med** 1996 Feb;42(3):389–98 (110 ref.)

PATIENT READMISSION

[The problem of the frequent hospitalizations of the mentally ill] Dolgov SA. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995;95(4):103–6 (73 ref.) **(Rus)**

PATIENT RECRUITMENT see **PATIENT SELECTION**

PATIENT REFUSAL OF TREATMENT see **TREATMENT REFUSAL**

PATIENT REPRESENTATIVES see **PATIENT ADVOCACY**

PATIENT SATISFACTION

see related
PATIENT ACCEPTANCE OF HEALTH CARE

Pain relief versus patient satisfaction. Afilalo M, et al. **Ann Emerg Med** 1996 Apr;27(4):436–8 (8 ref.)
Satisfying solutions? A review of some unresolved issues in the measurement of patient satisfaction. Avis M, et al. **J Adv Nurs** 1995 Aug;22(2):316–22 (60 ref.)
Measuring patients' satisfaction with nursing: 1990–1994. Thomas LH, et al. **J Adv Nurs** 1996 Apr;23(4):747–56 (48 ref.)
Patient satisfaction and normative decision theory. Brennan PF. **J Am Med Inform Assoc** 1995 Jul–Aug;2(4):250–9 (34 ref.)
Patient satisfaction with nursing care: concept clarification. Eriksen LR. **J Nurs Meas** 1995 Summer;3(1):59–76 (50 ref.)
Patient satisfaction with nursing care as an outcome variable: dilemmas for nursing evaluation researchers. Lin CC. **J Prof Nurs** 1996 Jul–Aug;12(4):207–16 (47 ref.)
Through the patient's eyes: strategies toward more successful contraception. Delbanco TL, et al. **Obstet Gynecol** 1996 Sep;88(3 Suppl):41S–47S (31 ref.)
[Induced labor without medical indications: the viewpoint of women. Bibliographic review] Garel M. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24 Suppl 1:116–9 (22 ref.) **(Fre)**

PATIENT SELECTION

Ambulatory phlebectomy compared to sclerotherapy for varicose and telangiectatic veins: indications and complications. Weiss RA, et al. **Adv Dermatol** 1996;11:3–16; discussion 17 (37 ref.)
Practical management of treatment-resistant affective disorders. Bridges PK, et al. **Br J Hosp Med** 1995 Nov 15–Dec 12;54(10):501–6 (58 ref.)
Assessing appropriateness of treatment: a case study of transplantation in older patients with congestive heart failure. Montague T, et al. **Can J Cardiol** 1996 Jan; 12(1):47–52 (33 ref.)
Prevention. How much harm? How much benefit? 1. Influence of reporting methods on perception of benefits [see comments] Marshall KG. **Can Med Assoc J** 1996 May 15;154(10):1493–9 (56 ref.) Comment in: Can Med Assoc J 1996 May 15;154(10):1510–2.
Local surgical treatment of rectal cancer [see comments] Baron PL, et al. **Cancer Invest** 1995;13(6):612–6 (22 ref.) Comment in: Cancer Invest 1995;13(6):660–1.
Evolving concepts regarding selection of patients for cardiac transplantation. Assessing risks and benefits. Torre-Amione G, et al. **Chest** 1996 Jan;109(1):223–32 (63 ref.)
Endocervical curettage has no place in the routine management of women with cervical intraepithelial neoplasia: debate. Ferenczy A. **Clin Obstet Gynecol** 1995 Sep;38(3):644–8 (9 ref.)
Every woman with an abnormal cervical smear should be referred for treatment: debate. Flannelly G, et al. **Clin Obstet Gynecol** 1995 Sep;38(3):585–91 (20 ref.)
Endocervical curettage: a technique in search of an indication?: debate. Noller KL. **Clin Obstet Gynecol** 1995 Sep;38(3):649–52 (2 ref.)
Every woman with an abnormal cervical smear should not be referred for colposcopy: debate. Prendiville W, et al. **Clin Obstet Gynecol** 1995 Sep;38(3):592–9 (16 ref.)
Rational antidepressant selection in the elderly. Christensen DD. **Geriatrics** 1995 Oct;50 Suppl 1:S41–50 (41 ref.)
27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 5. Stratification of patients into high, medium and low risk subgroups for purposes of risk factor management. Califf RM, et al. **J Am Coll Cardiol** 1996 Apr; 27(5):1007–19 (68 ref.)
When to transplant: Recipient selection for heart transplantation. Grady KL. **J Cardiovasc Nurs** 1996 Jan; 10(2):58–70 (55 ref.)
Potential criteria for cohort selection in chemoprevention trials of uterine adenocarcinoma. Baker VV. **J Cell Biochem Suppl** 1995;23:184–8 (32 ref.)
Potential criteria for cohort selection in chemoprevention trials of epithelial ovarian cancer. Baker VV. **J Cell Biochem Suppl** 1995;23:243–6 (19 ref.)
Chemoprevention trials in the cervix: design, feasibility, and recruitment. Mitchell MF, et al. **J Cell Biochem Suppl** 1995; 23:104–12 (43 ref.)
Reducing patient eligibility criteria in cancer clinical trials. George SL. **J Clin Oncol** 1996 Apr;14(4):1364–70 (24 ref.)
Indications for carotid artery stenting: a preview of the potential derived from early clinical experience [editorial] Diethrich EB. **J Endovasc Surg** 1996 May;3(2):132–9 (15 ref.)
Framework for the selection of subjects in human gene therapy and diagnostic trials. Modell SM. **J Investig Med** 1996 Jun;44(5):228–37 (59 ref.)
Recruiting minorities into clinical trials: toward a participant-friendly system [see comments] Swanson GM, et al. **J Natl Cancer Inst** 1995 Dec 6;87(23):1747–59 (107 ref.) Comment in: J Natl Cancer Inst 1996 Mar 20;88(6):377.
Controversies in the management of carotid stenosis. Macdonald RL. **J Neurosci Nurs** 1996 Apr;28(2):93–8 (33 ref.)
Age and assisted reproduction. Pennings G. **Med Law** 1995; 14(7–8):531–41 (20 ref.)
Nocturnal hypoxaemia in patients with chronic obstructive pulmonary disease: who should be treated and how? Heijdra YF, et al. **Neth J Med** 1995 Dec;47(6):296–301 (30 ref.)
Selection criteria for pulmonary rehabilitation. Ambrosino N, et al. **Respir Med** 1996 Jul;90(6):317–22 (36 ref.)
Multidisciplinary experience in the selection of patients for tubal sterilization. Barini R, et al. **Rev Paul Med** 1995 Jan–Feb;113(1):715–20 (8 ref.)
Selection of vascular access devices and nursing care. Winslow MN, et al. **Semin Oncol Nurs** 1995 Aug; 11(3):167–73 (37 ref.)
Selection and treatment of candidates for heart transplantation. Costanzo MR. **Semin Thorac Cardiovasc Surg** 1996 Apr;8(2):113–25 (88 ref.)
Assessing myocardial viability to help select patients for revascularization to improve left ventricular dysfunction due to coronary artery disease. Patterson RE, et al. **Semin Thorac Cardiovasc Surg** 1995 Oct;7(4):214–26 (61 ref.)
Current results and patient selection for nerve-sparing radical retropubic prostatectomy. Steiner MS. **Semin Urol Oncol** 1995 Aug;13(3):204–14 (47 ref.)
A personal view of some controversies in allocating treatment to patients in clinical trials [see comments] Senn S. **Stat Med** 1995 Dec 30;14(24):2661–74 (41 ref.) Comment in: Stat Med 1996 Jan 15;15(1):113–6.
"Routine" preoperative studies. Which studies in which patients? Marcello PW, et al. **Surg Clin North Am** 1996 Feb;76(1):11–23 (42 ref.)
[Hodgkin disease: should high-risk patients be selected and chemotherapy be intensified?] Carde P. **Bull Cancer (Paris)** 1995 Aug;82(8):637–49 (58 ref.) (Eng. Abstr.) **(Fre)**
[Surgical cure of varicocele and male infertility: for or against?] Adjiman M. **Contracept Fertil Sex** 1996 Jun; 24(6):439–41 (16 ref.) **(Fre)**
[Advantages and disadvantages of induced labor without medical indications: the viewpoint of the pediatrician] Dehan M. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24 Suppl 1:94–6 (5 ref.) **(Fre)**
[Stage I and II endometrial cancer: should lymphadenectomy still be done?] Descamps P, et al.

J Gynecol Obstet Biol Reprod (Paris) 1995;24(8):794–801 (48 ref.) (Eng. Abstr.) **(Fre)**

[Advantages and disadvantages of induced labor without medical indication: the viewpoint of the epidemiologist] Goffinet F. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24 Suppl 1:108–15 (21 ref.) **(Fre)**

[Advantages and disadvantages of induced labor without medical indications: the viewpoint of the anesthesiologist] Hamza J. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24 Suppl 1:97–107 (49 ref.) **(Fre)**

[Advantages and disadvantages of induced labor without medical indications: the viewpoint of the midwife] Kovacs C. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24 Suppl 1:89–93 (22 ref.) **(Fre)**

[Advantages and disadvantages of induced labor without medical indications: the viewpoint of the obstetrician in hospital practice] Maria B. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24 Suppl 1:67–77 (52 ref.) **(Fre)**

[Advantages and disadvantages of induced labor without medical indication: the viewpoint of obstetricians in private practice] Peter J. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24 Suppl 1:78–88 (40 ref.) **(Fre)**

[What are the medico-legal implications of induced labor?] Pierre F, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995; 24 Suppl 1:120–8 (0 ref.) **(Fre)**

[Is induced labor justified in cases of scarred uterus, breech presentation and multiple pregnancy?] Schaal JP, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24 Suppl 1:57–61 (39 ref.) **(Fre)**

[The epidemiologists' point of view on medical indications for induced labor] Subtil D. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24 Suppl 1:62–6 (29 ref.) **(Fre)**

[Is induced labor justified in diabetes, macrosomia and prolonged pregnancy?] Treisser A, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24 Suppl 1:41–7 (38 ref.) **(Fre)**

[Indications for pregnancy termination in cases of pre-eclampsia, hypertension, intrauterine growth retardation, liver and heart disease] Uzan S, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24 Suppl 1:33–40 (54 ref.) **(Fre)**

[Current indications for medical treatment of ectopic pregnancy] Darai E, et al. **Rev Fr Gynecol Obstet** 1995 Dec;90(12):552–7 (41 ref.) (Eng. Abstr.) **(Fre)**

[Are there still indications for cerclage in 1995?] Dufour P, et al. **Rev Fr Gynecol Obstet** 1995 Oct;90(10):423–30 (26 ref.) (Eng. Abstr.) **(Fre)**

[How to read a scientific article? 5. How to choose a treatment?] Demichelis B, et al. **G Ital Cardiol** 1995 Oct; 25(10):1339–50 (55 ref.) **(Ita)**

[Current status and aspect of cochlear implant] Komune S. **Fukuoka Igaku Zasshi** 1995 Dec;86(12):425–31 (5 ref.) **(Jpn)**

[Diseases relevant to gene therapy] Niitsu Y. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2496–7 (4 ref.) **(Jpn)**

PATIENT TRANSFER

[Severe preeclampsia. Principal management modalities before patient transfer] Aya AG, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(2):196–205 (78 ref.) (Eng. Abstr.) **(Fre)**

LEGISLATION & JURISPRUDENCE

Interhospital transfers of obstetric patients under the Emergency Medical Treatment and Active Labor Act. Cardwell MS. **J Leg Med** 1995 Sep;16(3):357–72 (98 ref.)

An overview and analysis of the impact of the Emergency Medical Treatment and Active Labor Act. Furrow BR. **J Leg Med** 1995 Sep;16(3):325–55 (157 ref.)

PATIENTS

see related
INPATIENTS

CLASSIFICATION

Using cluster analysis for medical resource decision making. Dilts D, et al. **Med Decis Making** 1995 Oct–Dec; 15(4):333–47 (72 ref.)

PSYCHOLOGY

Reformulation of deviance and labeling theory for nursing. Trexler JC. **Image J Nurs Sch** 1996 Summer;28(2):131–5 (39 ref.)

At the bedside. Influencing a patient's religious beliefs: mandate or no-man's land? Howe EG. **J Clin Ethics** 1995 Fall;6(3):194–201 (29 ref.)

[Communication of bad information: general indications and guidelines] Saltini A, et al. **Recenti Prog Med** 1995 Oct; 86(10):409–17 (12 ref.) (Eng. Abstr.) **(Ita)**

[Communication of bad facts. To inform or not to inform the patient: a choice between 2 alternatives?] Saltini A. **Recenti Prog Med** 1995 Sep;86(9):359–66 (40 ref.) (Eng. Abstr.) **(Ita)**

PATIENTS' RIGHTS see **PATIENT ADVOCACY**

PATTERN RECOGNITION, VISUAL

Cognitive components of picture naming. Johnson CJ, et al. **Psychol Bull** 1996 Jul;120(1):113–39 (310 ref.)

Reconciling simplicity and likelihood principles in perceptual organization. Chater N. **Psychol Rev** 1996 Jul;103(3):566–81 (80 ref.)

Goodness of visual regularities: a nontransformational approach. van der Helm PA, et al. **Psychol Rev** 1996 Jul; 103(3):429–56 (95 ref.)

PHYSIOLOGY

The representation of shape in the temporal lobe. Gochin PM. **Behav Brain Res** 1996 Apr;76(1–2):99–116 (155 ref.)

Pattern recognition in insects. Heisenberg M. **Curr Opin Neurobiol** 1995 Aug;5(4):475–81 (68 ref.)

[Influence of pattern stimulus modality on visual evoked potentials] Sobieszczańska M, et al. **Klin Oczna** 1995 Nov–Dec;97(11–12):353–5 (17 ref.) (Eng. Abstr.) **(Pol)**

PAUL-BUNNELL ANTIGENS see **ANTIGENS, HETEROPHILE**

PAVOR NOCTURNUS see **SLEEP DISORDERS**

PCBS see **POLYCHLORINATED BIPHENYLS**

PCNA see **PROLIFERATING CELL NUCLEAR ANTIGEN**

PCP see **PHENCYCLIDINE**

PCP RECEPTORS see **RECEPTORS, PHENCYCLIDINE**

PCR see **POLYMERASE CHAIN REACTION**

PDGF RECEPTORS see **RECEPTORS, PLATELET-DERIVED GROWTH FACTOR**

PEAK EXPIRATORY FLOW RATE

[Management of asthma based on their peak expiratory flow rate monitoring] Tamura G. **Nippon Naika Gakkai Zasshi** 1996 Feb 10;85(2):222–6 (11 ref.) **(Jpn)**

PEAS

CYTOLOGY

Root border cells as tools in plant cell studies. Brigham LA, et al. **Methods Cell Biol** 1995;49:377–87 (20 ref.)

PECTEN OCULI see **RETINAL VESSELS**

PECTINS

Evaluation of the safety of sodium pectate as a food ingredient. Borzelleca JF, et al. **Food Chem Toxicol** 1996 Jan;34(1):21–5 (18 ref.)

PHARMACOLOGY

[Structure and pharmacological activity of pectic polysaccharides from the roots of Bupleurum falcatum L.] Yamada H. **Nippon Yakurigaku Zasshi** 1995 Sep; 106(3):229–37 (17 ref.) (Eng. Abstr.) **(Jpn)**

PECTORAL NERVES see **THORACIC NERVES**

PECTORALIS MUSCLES

INJURIES

A rare complication of pectoralis major rupture. Pai VS, et al. **Aust N Z J Surg** 1995 Sep;65(9):694–5 (3 ref.)

PEDIATRIC DENTISTRY

see related
DENTAL CARE FOR CHILDREN

Dental practice considerations. Griffin AP, et al. **Dent Clin North Am** 1995 Oct;39(4):861–75 (14 ref.)

TRENDS

Immigrant children and pediatric dental practice. Waldman HB. **ASDC J Dent Child** 1995 Jul–Aug;62(4):288–94 (16 ref.)

PEDIATRIC INTENSIVE CARE UNITS see **INTENSIVE CARE UNITS, PEDIATRIC**

PEDIATRIC NURSING

see related
MATERNAL-CHILD NURSING

Knowing the score: using predictive scoring systems in clinical practice. Zollo MB, et al. **Am J Crit Care** 1996 Mar;5(2):147–51 (21 ref.)

Parent participation: a concept analysis. Coyne IT. **J Adv Nurs** 1996 Apr;23(4):733–40 (78 ref.)

METHODS

Life-threatening situations: supporting the child survivor and the family. Davenport LB, et al. **J Pediatr Nurs** 1995 Aug; 10(4):219–23 (7 ref.)

Spiritual care of the school-age child with a chronic condition. Fulton RA, et al. **J Pediatr Nurs** 1995 Aug; 10(4):224–31 (56 ref.)

Nursing management of children with sickle cell disease: an update. Gribbons D, et al. **J Pediatr Nurs** 1995 Aug; 10(4):232–42 (59 ref.)

Advanced HIV disease in children. Czarniecki L. **Nurs Clin North Am** 1996 Mar;31(1):207–19 (16 ref.)

ORGANIZATION & ADMINISTRATION

Pediatric hospice nursing. Martinson IM. **Annu Rev Nurs Res** 1995;13:195–214 (66 ref.)

Ambulatory care of the HIV-infected child. O'Hara MJ, et al. **Nurs Clin North Am** 1996 Mar;31(1):179–205 (46 ref.)

PEDIATRIC PSYCHOLOGY see **CHILD PSYCHOLOGY**

PEDIATRICS

Advances in pediatric pharmacology and toxicology. Berlin CM Jr. **Adv Pediatr** 1995;42:593–629 (106 ref.)

Gene therapy in pediatric medicine. Ledley FD. **Adv Pediatr** 1996;43:1–25 (90 ref.)

Hyperbaric oxygen therapy in pediatrics. Santamaria JP, et al. **Adv Pediatr** 1995;42:335–66 (48 ref.)

Preventive dentistry and the family physician. Clark MM, et al. **Am Fam Physician** 1996 Feb 1;53(2):619–26, 631–2 (30 ref.)

The role of the pediatrician in the promotion of cardiovascular health. Bronfin DR, et al. **Am J Med Sci** 1995 Dec;310 Suppl 1:S42–7 (43 ref.)

Inhalational anaesthesia at the extremes of age: paediatric anaesthesia. Olsson GL. **Anaesthesia** 1995 Oct;50 Suppl:34–6 (21 ref.)

Recommended guidelines for uniform reporting of pediatric advanced life support: the pediatric Utstein style. American Academy of Pediatrics, American Heart Association and the European Resuscitation Council. Zaritsky A, et al. **Ann Emerg Med** 1995 Oct;26(4):487–503 (60 ref.)

Medical informatics and pediatrics. Decision-support systems. Johnson KB, et al. **Arch Pediatr Adolesc Med** 1995 Dec;149(12):1371–80 (74 ref.)

On-line resources for pediatricians. Spooner SA. **Arch Pediatr Adolesc Med** 1995 Oct;149(10):1160–8 (23 ref.)

Violence among children and adolescents and the role of the pediatrician. Dukarm CP, et al. **Bull N Y Acad Med** 1995 Summer;72(1):5–15 (38 ref.)

Preventing children from smoking. How family physicians and pediatricians can help. Thomas RE, et al. **Can Fam Physician** 1995 Sep;41:1517–23 (50 ref.)

Pediatric poisonings. Goepp JG. **Clin Chem** 1996 Aug;42(8 Pt 2):1356–60 (11 ref.)

Updates in pediatric emergency medicine for the office practitioner. Carlson DW, et al. **Curr Opin Pediatr** 1995 Oct;7(5):523–8 (37 ref.)

Minimizing the pain of office procedures in children. Rothman KF. **Curr Opin Pediatr** 1995 Aug;7(4):415–22 (17 ref.)

When a randomised controlled trial is needed to assess drug safety. The case of paediatric ibuprofen. Mitchell AA, et al. **Drug Saf** 1995 Jul;13(1):15–24 (21 ref.)

Pediatric gastrointestinal endoscopy. Haight M, et al. **Gastroenterologist** 1995 Sep;3(3):181–6 (27 ref.)

Woman abuse and pediatrics: expanding the web of detection. Barkan SE, et al. **J Am Med Womens Assoc** 1996 May–Jul; 51(3):96–100 (81 ref.)

Pediatric echocardiography: current role and a review of technical advances. Rice MJ, et al. **J Pediatr** 1996 Jan; 128(1):1–14 (66 ref.)

Paediatric cardiopulmonary resuscitation. Richmond CE, et al. **Paediatr Anaesth** 1995;5(1):11–27 (173 ref.)

Environmental health during childhood: pediatrician advocacy. Carlson JE, et al. **Pediatr Ann** 1995 Dec; 24(12):624, 626–8 (19 ref.)

Incorporating effective smoking prevention and cessation counseling into practice. Klein JD. **Pediatr Ann** 1995 Dec; 24(12):646–52 (31 ref.)

Security in pediatric emergency departments. Graham CJ, et al. **Pediatr Emerg Care** 1995 Aug;11(4):220–2 (9 ref.)

Preparing for pediatric emergencies. Seidel J. **Pediatr Rev** 1995 Dec;16(12):466–72 (16 ref.)

The role of the pediatrician in implementing the Americans with Disabilities Act: subject review. American Academy of Pediatrics Committee on Children with Disabilities. **Pediatrics** 1996 Jul;98(1):146–8 (09 ref.)

Ethics and the care of critically ill infants and children. American Academy of Pediatrics Committee on Bioethics. **Pediatrics** 1996 Jul;98(1):149–52 (58 ref.)

What's new in pediatric surgery. Filston HC. **Pediatrics** 1995 Oct;96(4 Pt 1):748–57 (82 ref.)

Self-efficacy in pediatric resuscitation: implications for education and performance. Maibach EW, et al. **Pediatrics** 1996 Jan;97(1):94–9 (33 ref.)

Recommended guidelines for uniform reporting of pediatric advanced life support: the pediatric Utstein style. A statement for healthcare professionals from a task force of the American Academy of Pediatrics, the American

Heart Association, and the European Resuscitation Council. Zaritsky A, et al. **Pediatrics** 1995 Oct;96(4 Pt 1):765–79 (60 ref.)
Preventive health care for children. Natarajan A, et al. **Prim Care** 1995 Dec;22(4):619–36 (33 ref.)
Preventive health care for infants birth to two years of age. Sand PO, et al. **Prim Care** 1995 Dec;22(4):601–18 (25 ref.)
[Advantages and disadvantages of induced labor without medical indications: the viewpoint of the pediatrician] Dehan M. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24 Suppl 1:94–6 (5 ref.) **(Fre)**
[Progress and prospectives in the use of hematopoietic stem cells in pediatric oncohematology] Pession A, et al. **Minerva Pediatr** 1995 Jul–Aug;47(7–8):265–76 (19 ref.) **(Ita)**

CLASSIFICATION

The new BPA classification. Crawshaw P. **Arch Dis Child** 1995 Dec;73(6):563–7 (6 ref.)

EDUCATION

Educating pediatric residents in community settings. DeWitt TG, et al. **Curr Opin Pediatr** 1995 Oct;7(5):489–93 (26 ref.)
Pediatric emergency medicine fellow clinical work requirements. Wiley JF 2nd, et al. **Pediatr Emerg Care** 1995 Dec;11(6):381–8 (13 ref.)

INSTRUMENTATION

Technology seduction: lost opportunities in child health? Stanley FJ, et al. **J Paediatr Child Health** 1995 Aug; 31(4):302–6 (26 ref.)

METHODS

The Internet and the pediatrician: should there be a connection? Fikar CR. **Clin Pediatr (Phila)** 1996 May; 35(5):229–35 (19 ref.)

STANDARDS

Evaluation of appropriateness of paediatric admission. Werneke U, et al. **Arch Dis Child** 1996 Mar;74(3):268–73 (24 ref.)

STATISTICS & NUMERICAL DATA

Child health statistical review, 1995. Platt MJ, et al. **Arch Dis Child** 1995 Dec;73(6):541–8 (12 ref.)

TRENDS

Paediatric clinical pharmacology in the former Soviet Union: Ukraine. Rieder MJ. **Biol Neonate** 1995;68(4):276–81 (7 ref.)
What's new in pediatric surgery. Harrison MR. **J Am Coll Surg** 1996 Feb;182(2):145–9 (40 ref.)
[Hip dislocation and urinary tract. Two trends in pediatric radiology] Jorulf H, et al. **Lakartidningen** 1995 Nov 29; 92(48):4563–6 (20 ref.) **(Swe)**

PEDICULOSIS

DRUG THERAPY

Human lice and their management. Burgess IF. **Adv Parasitol** 1995;36:271–342 (410 ref.)
Infestations: pediculosis. Meinking TL, et al. **Curr Probl Dermatol** 1996;24:157–63 (11 ref.)
Permethrin. Taplin D, et al. **Curr Probl Dermatol** 1996; 24:255–60 (12 ref.)
[Lindane] Surber C, et al. **Hautarzt** 1995 Aug;46(8):528–36 (100 ref.) (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

[The epidemiological significance of human lice in relation to the characteristics of their parasitism] Khudobin VV. **Voen Med Zh** 1995 Oct;(10):52–8, 80 (32 ref.) (Eng. Abstr.) **(Rus)**

PREVENTION & CONTROL

[Pediculosis and the problems of its control at the current stage] Frolova AI, et al. **Med Parazitol (Mosk)** 1995 Jul–Sep;(3):51–5 (33 ref.) **(Rus)**

PEDICULUS

PATHOGENICITY

[The epidemiological significance of human lice in relation to the characteristics of their parasitism] Khudobin VV. **Voen Med Zh** 1995 Oct;(10):52–8, 80 (32 ref.) (Eng. Abstr.) **(Rus)**

PEDODONTICS see PEDIATRIC DENTISTRY

PEDOPHILIA

PHYSIOPATHOLOGY

The neurophysiology of sexual desire, with particular reference to paedophilia. Howard RC. **Ann Acad Med Singapore** 1995 Sep;24(5):724–7 (11 ref.)

PEEP see POSITIVE-PRESSURE RESPIRATION

PEEP, INTRINSIC see POSITIVE-PRESSURE RESPIRATION, INTRINSIC

PEEP, OCCULT see POSITIVE-PRESSURE RESPIRATION, INTRINSIC

PEER REVIEW

STANDARDS

Peer review in toxicologic pathology. Ward JM, et al. **Toxicol Pathol** 1995 Mar–Apr;23(2):226–34 (26 ref.)

PEER REVIEW, GRANTS see PEER REVIEW, RESEARCH

PEER REVIEW, HEALTH CARE

In pursuit of excellence: quality assurance, documentation, and peer review by home birth CNMs. Morales ME, et al. **J Nurse Midwifery** 1995 Nov–Dec;40(6):555–69 (56 ref.)

PEER REVIEW, PUBLISHING see PEER REVIEW, RESEARCH

PEER REVIEW, RESEARCH

STANDARDS

Medical reviews and the importance of being a "peer" in science. Beritic T. **Isr J Med Sci** 1996 Jul;32(7):573–5 (15 ref.)

PEFLOXACIN

THERAPEUTIC USE

[Fluoroquinolones in clinical practice. Pefloxacin (abaktal, peflacine)] Fomina IP, et al. **Antibiot Khimioter** 1995 Nov–Dec;40(11–12):70–7 (28 ref.) **(Rus)**

PELIOSIS HEPATIS

COMPLICATIONS

Bacillary angiomatosis and parenchymal peliosis: frequent absence of mucocutaneous lesions [editorial] Schwartzman WA. **Clin Infect Dis** 1996 May;22(5):801–2 (14 ref.)

DIAGNOSIS

Bacillary angiomatosis and parenchymal peliosis: frequent absence of mucocutaneous lesions [editorial] Schwartzman WA. **Clin Infect Dis** 1996 May;22(5):801–2 (14 ref.)

ETIOLOGY

[Peliosis hepatis] Shiga J. **Ryoikibetsu Shokogun Shirizu** 1995; (8):460–2 (12 ref.) **(Jpn)**

PELIZAEUS-MERZBACHER DISEASE see CEREBRAL SCLEROSIS, DIFFUSE

PELLETS, DRUG see DRUG IMPLANTS

PELVIC BONES

INJURIES

Surgical management of soft tissue lesions associated with pelvic ring injury. Kottmeier SA, et al. **Clin Orthop** 1996 Aug;(329):46–53 (43 ref.)
Thromboembolic complications in patients with pelvic trauma. Montgomery KD, et al. **Clin Orthop** 1996 Aug; (329):68–87 (94 ref.)
Radiologic evaluation of the pelvis. Mostafavi HR, et al. **Clin Orthop** 1996 Aug;(329):6–14 (17 ref.)
Assessment of pelvic ring stability after injury. Indications for surgical stabilization. Olson SA, et al. **Clin Orthop** 1996 Aug;(329):15–27 (26 ref.)
Indications and techniques for external fixation of the pelvis. Poka A, et al. **Clin Orthop** 1996 Aug;(329):54–9 (18 ref.)
Neurologic injuries in pelvic ring fractures. Reilly MC, et al. **Clin Orthop** 1996 Aug;(329):28–36 (32 ref.)
Urologic injuries in pelvic ring disruptions. Watnik NF, et al. **Clin Orthop** 1996 Aug;(329):37–45 (38 ref.)
Injuries about the hip and pelvis in the young athlete. Paletta GA Jr, et al. **Clin Sports Med** 1995 Jul;14(3):591–628 (224 ref.)
Fractures and luxations of the pelvis and proximal femur. Hull BL. **Vet Clin North Am Food Anim Pract** 1996 Mar; 12(1):47–58 (25 ref.)
[Traumatic hemipelvectomy. Experiences with 11 cases] Pohlemann T, et al. **Unfallchirurg** 1996 Apr;99(4):304–12 (45 ref.) (Eng. Abstr.) **(Ger)**

RADIOGRAPHY

Radiologic evaluation of the pelvis. Mostafavi HR, et al. **Clin Orthop** 1996 Aug;(329):6–14 (17 ref.)

PELVIC EXENTERATION

Palliative pelvic exenteration: patient selection and results. Finlayson CA, et al. **Oncology (Huntingt)** 1996 Apr; 10(4):479–84; discussion 484–6, 490, 493 (33 ref.)

METHODS

Pelvic exenteration for recurrent rectal cancer. Avradopoulos KA, et al. **Adv Surg** 1996;29:215–33 (71 ref.)
Pelvic exenteration and its modifications. Rodriguwz-Bigas MA, et al. **Am J Surg** 1996 Feb;171(2):293–8 (90 ref.)

PELVIC FLOOR

INJURIES

Preserving the pelvic floor and perineum during childbirth--elective caesarean section? Sultan AH, et al. **Br J Obstet Gynaecol** 1996 Aug;103(8):731–4 (21 ref.)

PHYSIOLOGY

Anorectal and pelvic floor function. Relevance of continence, incontinence, and constipation. Sagar PM, et al. **Gastroenterol Clin North Am** 1996 Mar;25(1):163–82 (102 ref.)
Electromyography of the perineal floor. Siroky MB. **Urol Clin North Am** 1996 May;23(2):299–307 (16 ref.)

PHYSIOPATHOLOGY

[Pro: a critical contribution to better understanding of possible functional disorders of the genital, bladder and pelvic floor system] Schüssler B. **Arch Gynecol Obstet** 1995; 257(1–4):359–62 (14 ref.) **(Ger)**

SURGERY

Minimally invasive treatment of urinary stress incontinence and laparoscopically directed repair of pelvic floor defects. Lyons TL. **Clin Obstet Gynecol** 1995 Jun;38(2):380–91 (42 ref.)
Correction of genital prolapse. Liu CY, et al. **J Endourol** 1996 Jun;10(3):259–65 (32 ref.)
[Pelvic floor insufficiency as an interdisciplinary responsibility] Hansen H. **Chirurg** 1996 May;67(5):498–504 (14 ref.) (Eng. Abstr.) **(Ger)**

PELVIC INFECTION see ADNEXITIS

PELVIC INFLAMMATORY DISEASE see ADNEXITIS

PELVIC NEOPLASMS

COMPLICATIONS

Intestinal obstruction. Baines MJ. **Cancer Surv** 1994;21:147–56 (32 ref.)
[Giant schwannoma in the pelvic cavity presenting as renal failure: a case report] Gotoh T, et al. **Hinyokika Kiyo** 1995 Aug;41(8):621–4 (10 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

[Desmoplastic small round cell tumors in adults: a new entity] Farhat F, et al. **Bull Cancer (Paris)** 1995 Aug;82(8):665–73 (39 ref.) (Eng. Abstr.) **(Fre)**
[Fast and ultra-fast sequences in MRI of the pelvis and retroperitoneum] Heuck A, et al. **Radiologe** 1995 Dec; 35(12):936–44 (44 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

Malignant sacrococcygeal germ cell tumour in an adult. Smithers BM, et al. **Aust N Z J Surg** 1996 Mar;66(3):185–9 (25 ref.)
Aggressive angiomyxoma of the pelvis and perineum. A case report. Fishman A, et al. **J Reprod Med** 1995 Sep; 40(9):665–9 (16 ref.)

RADIOTHERAPY

[Radiation injury of the small intestine. Radiobiological, radiopathological aspects; risk factors and prevention] Touboul E, et al. **Ann Chir** 1996;50(1):58–71 (95 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Pelvic exenteration and its modifications. Rodriguwz-Bigas MA, et al. **Am J Surg** 1996 Feb;171(2):293–8 (90 ref.)
Palliative pelvic exenteration: patient selection and results. Finlayson CA, et al. **Oncology (Huntingt)** 1996 Apr; 10(4):479–84; discussion 484–6, 490, 493 (33 ref.)

ULTRASONOGRAPHY

Presacral myelolipoma: sonographic appearance. Adetiloye VA, et al. **Pediatr Radiol** 1996;26(4):271–2 (5 ref.)
Transvaginal color Doppler and pelvic tumor vascularity: lessons learned and future challenges. Kurjak A, et al. **Ultrasound Obstet Gynecol** 1995 Aug;6(2):145–59 (38 ref.)

PELVIC PAIN

DRUG THERAPY

[Antalgic treatment in pelvic pain] Valade D. **Contracept Fertil Sex** 1996 Mar;24(3):207–12 (0 ref.) (Eng. Abstr.) **(Fre)**

PELVIC PAIN

THERAPY

Pain recurrence: a quality of life issue in endometriosis. Damario MA, et al. **Int J Gynaecol Obstet** 1995 Sep;50 Suppl 1:S27–42 (99 ref.)

PELVIMETRY

[Applications of magnetic resonance tomography (MRT) in obstetrics] Wischnik A, et al. **Gynakologe** 1995 Oct; 28(5):321–8 (18 ref.) **(Ger)**

PELVIS

see related

ADNEXITIS

The association of urinary tract infection with a recent pelvic examination in women. Tiemstra JD, et al. **Arch Fam Med** 1996 Jun;5(6):357–60 (18 ref.)

Pelvic masses and endoscopic surgery: diagnosis. Miralles RM. **Eur J Obstet Gynecol Reprod Biol** 1996 Mar; 65(1):75–9 (28 ref.)

Chronic pelvic pain. Lipscomb GH, et al. **Med Clin North Am** 1995 Nov;79(6):1411–25 (30 ref.)

Pelvic organ prolapse and stress urinary incontinence. Rush CB, et al. **Med Clin North Am** 1995 Nov;79(6):1473–9 (16 ref.)

ANATOMY & HISTOLOGY

MR imaging of the female pelvis. Mayo-Smith WW, et al. **Clin Radiol** 1995 Oct;50(10):667–76 (57 ref.)

Magnetic resonance imaging techniques in the pelvis. Outwater EK, et al. **Magn Reson Imaging Clin N Am** 1994 May;2(2):161–88 (115 ref.)

BLOOD SUPPLY

Preservation of the pelvic circulation during infrarenal aortic surgery. Connolly JE, et al. **Cardiovasc Surg** 1996 Feb; 4(1):65–70 (46 ref.)

Venography of the extremities and pelvis. Spritzer CE. **Magn Reson Imaging Clin N Am** 1993 Dec;1(2):239–51 (28 ref.)

[Uses of interventional arteriographic technics in gynecologic neoplasms] Yue D, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1995 Jul;30(7):435–7 (14 ref.) **(Chi)**

INJURIES

Imaging of pelvic trauma. Young JW. **J South Orthop Assoc** 1996 Spring;5(1):63–70 (23 ref.)

CT of abdominal and pelvic trauma. Roberts JL. **Semin Ultrasound CT MR** 1996 Apr;17(2):142–69 (71 ref.)

[Traumatic hemipelvectomy. Experiences with 11 cases] Pohlemann T, et al. **Unfallchirurg** 1996 Apr;99(4):304–12 (45 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

Pelvic pathology after hysterectomy. A pictorial essay. Kasales CJ, et al. **Clin Imaging** 1995 Jul–Sep;19(3):210–7 (5 ref.)

PHYSIOLOGY

Effects of sex hormones on oncogene expression in the vagina and on development of sexual dimorphism of the pelvis and anococcygeus muscle in the mouse. Iguchi T, et al. **Environ Health Perspect** 1995 Oct;103 Suppl 7:79–82 (34 ref.)

RADIOGRAPHY

Imaging of pelvic trauma. Young JW. **J South Orthop Assoc** 1996 Spring;5(1):63–70 (23 ref.)

PEMPHIGOID, BENIGN MUCOUS MEMBRANE

Cicatricial pemphigoid: diagnosis and treatment. Nguyen QD, et al. **Int Ophthalmol Clin** 1996 Winter;36(1):41–60 (52 ref.)

COMPLICATIONS

[Nasal localization of a cicatricial pemphigoid: apropos of a case] Stoll D, et al. **Rev Laryngol Otol Rhinol (Bord)** 1995;116(5):341–5 (13 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Benign mucous membrane pemphigoid with advanced periodontal involvement: diagnosis and therapy [see comments] Lilly JP, et al. **J Periodontol** 1995 Aug; 66(8):737–41 (20 ref.) Comment in: J Periodontol 1995 Aug;66(8):747–8.

DRUG THERAPY

Benign mucous membrane pemphigoid with advanced periodontal involvement: diagnosis and therapy [see comments] Lilly JP, et al. **J Periodontol** 1995 Aug; 66(8):737–41 (20 ref.) Comment in: J Periodontol 1995 Aug;66(8):747–8.

[Cicatricial pemphigoid—a therapeutic problem] Axt M, et al. **Hautarzt** 1995 Sep;46(9):620–7 (32 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Studies of patients with anti-epiligrin cicatricial pemphigoid. Yancey KB, et al. **J Dermatol** 1995 Nov;22(11):829–35 (25 ref.)

PEMPHIGOID, BULLOUS

CHEMICALLY INDUCED

Recurrent and chronic leg ulcers secondary to furosemide-induced bullous pemphigoid [letter] Siddiqui MA, et al. **J Am Geriatr Soc** 1995 Oct;43(10):1183–4 (7 ref.)

COMPLICATIONS

[A case of resected lung cancer associated with bullous pemphigoid] Sato Y, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Apr;44(4):524–8 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Diffuse panbronchiolilitis associated with bullous pemphigoid] Oshikawa K, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Sep; 33(9):1019–23 (21 ref.) (Eng. Abstr.) **(Jpn)**

DRUG THERAPY

Bilateral inguinal scrofuloderma during steroid therapy in a patient with bullous pemphigoid. Kawabata E, et al. **J Dermatol** 1995 Aug;22(8):582–6 (22 ref.)

ETIOLOGY

Burn-induced bullous pemphigoid [letter; comment] Vassileva S, et al. **Int J Dermatol** 1995 Jul;34(7):516–7 (10 ref.) Comment on: Int J Dermatol 1994 Jan;33(1):55–6.

Bullous pemphigoid possibly induced by psoralen plus ultraviolet A therapy. George PM. **Photodermatol Photoimmunol Photomed** 1996 Oct–Dec; 11(5–6):185–7 (15 ref.)

IMMUNOLOGY

An animal model of bullous pemphigoid: what can it teach us? Giudice GJ, et al. **Proc Assoc Am Physicians** 1995 Jul; 107(2):237–41 (33 ref.)

PEMPHIGOID, CICATRICIAL see **PEMPHIGOID, BENIGN MUCOUS MEMBRANE**

PEMPHIGUS

Pemphigus vulgaris and pregnancy. Ruach M, et al. **Obstet Gynecol Surv** 1995 Oct;50(10):755–60 (48 ref.)

COMPLICATIONS

Paraneoplastic pemphigus: report of a case. Izaki S, et al. **J Dermatol** 1996 Jun;23(6):397–404 (24 ref.)

DRUG THERAPY

The adjuvant therapy of pemphigus. An update. Bystryn JC, et al. **Arch Dermatol** 1996 Feb;132(2):203–12 (89 ref.)

[Pemphigus vulgaris. Clinical aspects, pathophysiology and therapy of a bullous autoimmune dermatosis] Sunderkötter CH, et al. **Med Monatsschr Pharm** 1995 Sep;18(9):255–63 (39 ref.) **(Ger)**

ETIOLOGY

[Paraneoplastic pemphigus: review of the literature, apropos of a case associated with chronic lymphoid leukemia] Rodot S, et al. **Rev Med Interne** 1995;16(12):938–43 (25 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Pemphigus: autoimmunity to epidermal cell adhesion molecules. Amagai M. **Adv Dermatol** 1996;11:319–52; discussion 353 (166 ref.)

Cell and humoral immunity in endemic pemphigus foliaceus. Barraviera SR, et al. **Rev Inst Med Trop Sao Paulo** 1995 Jan–Feb;37(1):25–33 (30 ref.)

[Ultrastructural localisation of pemphigus vulgaris and pemphigus foliaceus antigens by indirect immunoelectron microscopy. Apropos of 7 cases] Boulinguez S, et al. **Ann Dermatol Venereol** 1995;122(6–7):417–21 (25 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Neonatal pemphigus foliaceus. Walker DC, et al. **Arch Dermatol** 1995 Nov;131(11):1308–11 (21 ref.)

Paraneoplastic pemphigus: report of a case. Izaki S, et al. **J Dermatol** 1996 Jun;23(6):397–404 (24 ref.)

THERAPY

Management of the immunobullous disorders. II. Pemphigus. Huilgol SC, et al. **Clin Exp Dermatol** 1995 Jul;20(4):283–93 (95 ref.)

PEMPHIGUS VULGARIS see **PEMPHIGUS**

PENICILLAMINE

ADVERSE EFFECTS

Coexistent membranous nephropathy and ANCA-positive crescentic glomerulonephritis in association with penicillamine. Mathieson PW, et al. **Nephrol Dial Transplant** 1996 May;11(5):863–6 (26 ref.)

PENICILLIN, AMINOBENZYL see **AMPICILLIN**

PENICILLIN G

THERAPEUTIC USE

Antibiotic-resistant pneumococcal pneumonia [editorial] Feldman C, et al. **S Afr Med J** 1996 Jan;86(1):28–30 (38 ref.)

PENICILLIN G, BENZATHINE

ADMINISTRATION & DOSAGE

Are the currently recommended doses of benzathine penicillin G adequate for secondary prophylaxis of rheumatic fever? Currie BJ. **Pediatrics** 1996 Jun;97(6 Pt 2):989–91 (21 ref.)

THERAPEUTIC USE

Are the currently recommended doses of benzathine penicillin G adequate for secondary prophylaxis of rheumatic fever? Currie BJ. **Pediatrics** 1996 Jun;97(6 Pt 2):989–91 (21 ref.)

PENICILLIN RESISTANCE

Management of meningitis caused by penicillin-resistant Streptococcus pneumoniae. Paris MM, et al. **Antimicrob Agents Chemother** 1995 Oct;39(10):2171–5 (64 ref.)

Penicillin and multiply antibiotic-resistant Streptococcus pneumoniae. Estrada B, et al. **Compr Ther** 1995 Nov; 21(11):658–62 (32 ref.)

Surveillance of antibiotic resistance in Neisseria gonorrhoeae and implications for the therapy of gonorrhoea [editorial] Tapsall JW. **Int J STD AIDS** 1995 Jul–Aug;6(4):233–6 (24 ref.)

Antibiotic-resistant pneumococcal pneumonia [editorial] Feldman C, et al. **S Afr Med J** 1996 Jan;86(1):28–30 (38 ref.)

[Problems of resistance in Streptococcus pneumoniae] Meis JF, et al. **Ned Tijdschr Geneeskd** 1996 Jan 20;140(3):141–4 (25 ref.) (Eng. Abstr.) **(Dut)**

[Penicillin-resistant pneumococci are coming—are you prepared? (editorial)] Saxén H, et al. **Duodecim** 1994; 110(18):1669–71 (13 ref.) **(Fin)**

[Antibiotic resistance in pneumococci] Moreillon P, et al. **Schweiz Med Wochenschr** 1996 Feb 17;126(7):255–63 (30 ref.) (Eng. Abstr.) **(Fre)**

[Penicillin-resistant Streptococcus pneumoniae] Yamaguchi K. **Nippon Naika Gakkai Zasshi** 1996 Feb 10;85(2):292–6 (12 ref.) **(Jpn)**

[The therapeutic implications of pneumococcal penicillin resistance] Lior C, et al. **Aten Primaria** 1996 Jul–Aug; 18(3):136–45 (82 ref.) **(Spa)**

PHYSIOLOGY

The role of penicillin-binding proteins in penicillin resistance of Streptococcus pneumoniae. Hakenbeck R, et al. **Dev Biol Stand** 1995;85:115–23 (35 ref.)

PENICILLINS

ADVERSE EFFECTS

Allergic reactions to penicillins. A changing world? Blanca M. **Allergy** 1995 Oct;50(10):777–82 (76 ref.)

Flucloxacillin associated cholestatic hepatitis. An Australian and Swedish epidemic? Devereaux BM, et al. **Eur J Clin Pharmacol** 1995;49(1–2):81–5 (30 ref.)

[Acute pancreatitis associated with hepatotoxicity induced by amoxicillin-clavulanic acid] Galindo C, et al. **Rev Esp Enferm Dig** 1995 Aug;87(8):597–600 (23 ref.) (Eng. Abstr.) **(Spa)**

BIOSYNTHESIS

Enzymatic synthesis of hydrophobic penicillins. Luengo JM. **J Antibiot (Tokyo)** 1995 Nov;48(11):1195–212 (96 ref.)

METABOLISM

The role of penicillin-binding proteins in penicillin resistance of Streptococcus pneumoniae. Hakenbeck R, et al. **Dev Biol Stand** 1995;85:115–23 (35 ref.)

PHARMACOLOGY

Penicillin tolerance and treatment failure in group A streptococcal pharyngotonsillitis. van Asselt GJ, et al. **Eur J Clin Microbiol Infect Dis** 1996 Feb;15(2):107–15 (66 ref.)

Newer penicillins and beta-lactamase inhibitors. Bush LM, et al. **Infect Dis Clin North Am** 1995 Sep;9(3):653–86 (154

ref.)

THERAPEUTIC USE

Strategies for Helicobacter pylori eradication in 1995: a review of international and Belgian experience. Deltenre M, et al. **J Physiol Pharmacol** 1996 Mar;47(1):59–69 (66 ref.)
Adherence to physicians' instructions as a factor in managing streptococcal pharyngitis. Dajani AS. **Pediatrics** 1996 Jun; 97(6 Pt 2):976–80 (21 ref.)
Evaluation of penicillins, cephalosporins, and macrolides for therapy of streptococcal pharyngitis. Shulman ST. **Pediatrics** 1996 Jun;97(6 Pt 2):955–9 (34 ref.)
Antibiotic-resistant pneumococcal pneumonia [editorial] Feldman C, et al. **S Afr Med J** 1996 Jan;86(1):28–30 (38 ref.)
[How to eradicate Helicobacter pylori?] Cayla R. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S119–S130 (83 ref.) **(Fre)**
[Amoxycillin: 25 years of use in clinical practice] Iakovlev SV. **Antibiot Khimioter** 1995 Jun;40(6):49–55 (13 ref.) **(Rus)**
[Influence of colloidal bismuth subcitrate, metronidazole, and amoxycillin on Helicobacter pylori and gastroduodenal ulcer healing] Quintero M, et al. **G E N** 1995 Apr–Jun; 49(2):116–22 (21 ref.) (Eng. Abstr.) **(Spa)**
[Omeprazole and amoxycillin in the eradicating treatment of Helicobacter pylori] Gisbert JP, et al. **Rev Clin Esp** 1995 Nov;195(11):787–91 (74 ref.) **(Spa)**

PENICILLIUM

Infection with Penicillium marneffei. Wortman PD. **Int J Dermatol** 1996 Jun;35(6):393–9 (35 ref.)

PENILE DISEASES

DIAGNOSIS

Genital candidosis. Stary A. **Curr Probl Dermatol** 1996; 24:40–9 (23 ref.)
Clinical aspects of genito-anal papillomavirus infection with a focus on when and how to investigate. von Krogh G. **Curr Probl Dermatol** 1996;24:140–50 (42 ref.)

ETIOLOGY

ABC of general surgery in children. Problems with the penis and prepuce [see comments] Davenport M. **BMJ** 1996 Feb 3;312(7026):299–301 (0 ref.) Comment in: BMJ 1996 May 11;312(7040):1230–1.
Treating complications of circumcision. Baskin LS, et al. **Pediatr Emerg Care** 1996 Feb;12(1):62–8 (33 ref.)
[Erectile dysfunction in patients with diabetes] Franek E. **Przegl Lek** 1996;53(2):88–93 (30 ref.) (Eng. Abstr.) **(Pol)**

PATHOLOGY

Penile mass caused by the newly described organism Mycobacterium celatum. Dahl DM, et al. **Urology** 1996 Feb;47(2):266–8 (13 ref.)

THERAPY

Treating complications of circumcision. Baskin LS, et al. **Pediatr Emerg Care** 1996 Feb;12(1):62–8 (33 ref.)

PENILE ERECTION

Clinical approach to erectile dysfunction in spinal cord injured men. A review of clinical and experimental data. Courtois FJ, et al. **Paraplegia** 1995 Nov;33(11):628–35 (60 ref.)
[Treatment of erectile dysfunction in multiple sclerosis] Fernández O. **Rev Neurol** 1995 Mar–Apr;23(120):320–1 (16 ref.) **(Spa)**

DRUG EFFECTS

Intracavernous injection therapy for male erectile dysfunction. Fallon B. **Urol Clin North Am** 1995 Nov; 22(4):833–45 (68 ref.)
Oral and topical treatment of erectile dysfunction. Present and future. Morales A, et al. **Urol Clin North Am** 1995 Nov;22(4):879–86 (31 ref.)
[Drugs for impotence] Lukkarinen O, et al. **Duodecim** 1995; 111(8):771–6 (25 ref.) **(Fin)**

PHYSIOLOGY

The penis as a vascular organ. The importance of corporal smooth muscle tone in the control of erection. Christ GJ. **Urol Clin North Am** 1995 Nov;22(4):727–45 (77 ref.)
Neural control of penile erection. Giuliano FA, et al. **Urol Clin North Am** 1995 Nov;22(4):747–66 (271 ref.)
Use of nocturnal penile tumescence and rigidity in the evaluation of male erectile dysfunction. Levine LA, et al. **Urol Clin North Am** 1995 Nov;22(4):775–88 (58 ref.)
[Erectile dysfunction in patients with diabetes] Franek E. **Przegl Lek** 1996;53(2):88–93 (30 ref.) (Eng. Abstr.) **(Pol)**

PENILE INDURATION

PHYSIOPATHOLOGY

Penile vascular assessment using color duplex sonography in men with Peyronie's disease. Levine LA, et al. **J Urol** 1996 Apr;155(4):1270–3 (21 ref.)

PENILE NEOPLASMS

[Progress in the study of penile cancer] Zhong H, et al. **Chung Hua Wai Ko Tsa Chih** 1995 Jun;33(6):382–4 (16 ref.) **(Chi)**

COMPLICATIONS

[Kaposi sarcoma of the glans penis with meatal obstruction. Case report and literature review] John H, et al. **Swiss Surg** 1996;(3):134–6 (3 ref.) (Eng. Abstr.) **(Ger)**

DIAGNOSIS

[Cavernous hemangioma of the penis] Sergienko NF, et al. **Urol Nefrol (Mosk)** 1996 Mar–Apr;(2):47–9 (3 ref.) **(Rus)**

GENETICS

Hereditary multiple glomus tumors involving the glans penis. A case report and review of the literature. Kiyosawa T, et al. **Dermatol Surg** 1995 Oct;21(10):895–9 (36 ref.)

PATHOLOGY

Squamous cell carcinoma of the penis. Micali G, et al. **J Am Acad Dermatol** 1996 Sep;35(3 Pt 1):432–51 (219 ref.)
Glomus tumor of the penis. Khoudary KP, et al. **J Urol** 1996 Feb;155(2):707 (3 ref.)

SECONDARY

[Report of a case of penile metastasis. Review of the literature] Cuvillier X, et al. **Prog Urol** 1995 Dec; 5(6):1009–11 (17 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

[Complications of inguinal lymphadenectomy for penile carcinoma. Origin, management, and prevention] Martín Martínez JC, et al. **Actas Urol Esp** 1995 Nov–Dec; 19(10):759–71 (68 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

Management of carcinoma of the penis: a review. Magoha GA. **East Afr Med J** 1995 Sep;72(9):547–50 (55 ref.)

PENILE PROSTHESIS

Current thoughts on penile prosthetic surgery. Pryor JP. **Acta Chir Hung** 1995–96;35(1–2):129–35 (4 ref.)
Penile implant. Cartmill RA. **Ann Acad Med Singapore** 1995 Sep;24(5):745–8 (5 ref.)
Long-term results of penile prosthetic implants. Lewis RW. **Urol Clin North Am** 1995 Nov;22(4):847–56 (30 ref.)

ADVERSE EFFECTS

Prevention and treatment of complications of inflatable penile prosthesis surgery: a review article. Wilson SK, et al. **Arch Esp Urol** 1996 Apr;49(3):306–11 (9 ref.)

PENIS

see related
CIRCUMCISION

Pustular psoriasis limited to the penis. Quan MB, et al. **Int J Dermatol** 1996 Mar;35(3):202–4 (14 ref.)

ABNORMALITIES

Penoscrotal transposition and associated anomalies: report of five new cases and review of the literature. Parida SK, et al. **Am J Med Genet** 1995 Oct 23;59(1):68–75 (35 ref.)
Juberg-Marsidi syndrome: report of an additional case. Tsukahara M, et al. **Am J Med Genet** 1995 Sep 25; 58(4):353–5 (7 ref.)
Male gender assignment in penile agenesis: a case report and review of the literature. Ciftci AO, et al. **J Pediatr Surg** 1995 Sep;30(9):1358–60 (13 ref.)

BLOOD SUPPLY

Penile revascularization: an overview. Shah RS, et al. **Ann Acad Med Singapore** 1995 Sep;24(5):749–54 (39 ref.)
Penile vascular assessment using color duplex sonography in men with Peyronie's disease. Levine LA, et al. **J Urol** 1996 Apr;155(4):1270–3 (21 ref.)
The penis as a vascular organ. The importance of corporal smooth muscle tone in the control of erection. Christ GJ. **Urol Clin North Am** 1995 Nov;22(4):727–45 (77 ref.)
Penile revascularization. Sharaby JS, et al. **Urol Clin North Am** 1995 Nov;22(4):821–32 (52 ref.)
[Apical ulceration of the glans penis in hypervascularization syndrome. Sequelae of revascularization operation in erectile dysfunction] Hartwig R, et al. **Hautarzt** 1995 Nov; 46(11):808–10 (12 ref.) (Eng. Abstr.) **(Ger)**

INJURIES

Male genital self-mutilation. Romilly CS, et al. **Br J Hosp Med** 1996 Apr 3–16;55(7):427–31 (24 ref.)
[A gunshot wound of the penis and scrotum] Dmitriev DG, et al. **Urol Nefrol (Mosk)** 1996 Mar–Apr;(2):47 (6 ref.) **(Rus)**

INNERVATION

Neural control of penile erection. Giuliano FA, et al. **Urol Clin North Am** 1995 Nov;22(4):747–66 (271 ref.)
[Electrophysiologic diagnosis in erectile dysfunction] Jost WH, et al. **Urologe A** 1996 Mar;35(2):120–6 (32 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

[Male sexual dysfunction: neuroanatomy, neurophysiology and semiology] Singer C. **Rev Neurol** 1996 Jun; 24(130):664–5 (14 ref.) **(Spa)**

SURGERY

Penile revascularization. Sharaby JS, et al. **Urol Clin North Am** 1995 Nov;22(4):821–32 (52 ref.)

PENIS, ARTIFICIAL see PENILE PROSTHESIS

PENSIONS

Liability for managed care decisions: the Employee Retirement Income Security Act (ERISA) and the uneven playing field. Mariner WK. **Am J Public Health** 1996 Jun; 86(6):863–9 (66 ref.)
[Diagnosis and management of neurotic occupational disorders (before pension application)] Stevens A, et al. **Nervenarzt** 1995 Nov;66(11):811–9 (42 ref.) (Eng. Abstr.) **(Ger)**

PENTACHLOROPHENOL

METABOLISM

Oxidative DNA lesions in V79 cells mediated by pentachlorophenol metabolites. Dahlhaus M, et al. **Arch Toxicol** 1996;70(7):457–60 (39 ref.)

PENTAGASTRIN

see related
GASTROINTESTINAL AGENTS

PENTAMIDINE

ADVERSE EFFECTS

Diabetes mellitus associated with pentamidine isethionate in diffuse cutaneous leishmaniasis. Costa JM, et al. **Rev Soc Bras Med Trop** 1995 Oct–Dec;28(4):405–7 (13 ref.)

PENTAMIDINE ISETHIONATE see PENTAMIDINE

PENTANUCLEOTIDE REPEATS see MICROSATELLITE REPEATS

PENTETATES see DTPA

PENTHANIL see DTPA

PENTOBARBITAL

POISONING

Hemodiafiltration in pentobarbital poisoning. Bironneau E, et al. **Ren Fail** 1996 Mar;18(2):299–303 (11 ref.)

PENTOSE PHOSPHATE SHUNT see PENTOSEPHOSPHATE PATHWAY

PENTOSE SHUNT see PENTOSEPHOSPHATE PATHWAY

PENTOSEPHOSPHATE PATHWAY

Hereditary red cell enzymopathies. Arya R, et al. **Blood Rev** 1995 Sep;9(3):165–75 (155 ref.)
Reoxidation of the NADPH produced by the pentose phosphate pathway is necessary for the utilization of glucose by Kluyveromyces lactis rag2 mutants. González Siso MI, et al. **FEBS Lett** 1996 May 27;387(1):7–10 (27 ref.)

GENETICS

The molecular regulation of the reductive pentose phosphate pathway in Proteobacteria and Cyanobacteria. Gibson JL, et al. **Arch Microbiol** 1996 Sep;166(3):141–50 (69 ref.)
Genetics of pentose-phosphate pathway enzymes of Escherichia coli K-12. Sprenger GA. **Arch Microbiol** 1995 Nov;164(5):324–30 (47 ref.)

PENTOXIFYLLINE

ADMINISTRATION & DOSAGE

Influence of different volume therapies and pentoxifylline infusion on circulating soluble adhesion molecules in critically ill patients. Boldt J, et al. **Crit Care Med** 1996 Mar;24(3):385–91 (39 ref.)

PHARMACOLOGY

Cytokines, phagocytes, and pentoxifylline. Mandell GL. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S20–2 (7 ref.)

[Pentoxifylline] Paradowski PT, et al. **Postepy Hig Med Dosw** 1995;49(2):201–20 (112 ref.) (Eng. Abstr.) **(Pol)**

THERAPEUTIC USE

Pentoxifylline (oxpentifylline). A review of its therapeutic efficacy in the management of peripheral vascular and cerebrovascular disorders. Frampton JE, et al. **Drugs Aging** 1995 Dec;7(6):480–503 (150 ref.)

An argument for the past and continued use of pentoxifylline in assisted reproductive technology. Matson PL, et al. **Hum Reprod** 1995 Oct;10 Suppl 1:67–71 (38 ref.)

Use of pentoxifylline in assisted reproductive technology. Tournaye H, et al. **Hum Reprod** 1995 Oct;10 Suppl 1:72–9 (48 ref.)

Pentoxifylline and critical leg ischemia. Colgan MP, et al. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S58–60 (19 ref.)

Pentoxifylline: a potential treatment for thrombosis associated with abnormal tissue factor expression by monocytes and endothelial cells. de Prost D. **J Cardiovasc Pharmacol** 1995; 25 Suppl 2:S114–8 (41 ref.)

Pentoxifylline for the treatment of HIV infection and its complications. Dezube BJ, et al. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S139–42 (29 ref.)

Prevention studies with pentoxifylline: new clinical projects. Eugène-Jolchine I, et al. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S143–6 (29 ref.)

Pentoxifylline and intermittent claudication: review of clinical trials and cost-effectiveness analyses. Gillings DB. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S44–50 (20 ref.)

Pentoxifylline in severe inflammatory response syndrome. Graninger W, et al. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S134–8 (37 ref.)

[The treatment of cutaneous radiation-induced fibrosis with pentoxifylline and vitamin E. An empirical report] Gottlöber P, et al. **Strahlenther Onkol** 1996 Jan;172(1):34–8 (13 ref.) (Eng. Abstr.) **(Ger)**

[Mechanisms of radiation to the lung. Pentoxifylline—a new radioprotective drug?] Remiszewski P, et al. **Pneumonol Alergol Pol** 1995;63(5–6):349–54 (17 ref.) **(Pol)**

PENTYMAL see **AMOBARBITAL**

PEOPLE WITH DISABILITIES see **DISABLED**

PEPSINOGEN

METABOLISM

[The locus of pepsinogen A: molecular biologic studies in the carcinogenesis of gastric cancer] Shumakov AR, et al. **Vopr Onkol** 1996;42(2):7–11 (50 ref.) **(Rus)**

PEPTIC ULCER

see related
ANTI-ULCER AGENTS
GASTRECTOMY
ZOLLINGER-ELLISON SYNDROME

Critical issues in the pathophysiology and management of peptic ulcer disease. Hunt RH, et al. **Eur J Gastroenterol Hepatol** 1995 Jul;7(7):685–99 (156 ref.)

Helicobacter pylori and peptic disease in the pediatric patient. Bujanover Y, et al. **Pediatr Clin North Am** 1996 Feb; 43(1):213–34 (138 ref.)

[Current studies in the quality of ulcer healing] Yang X, et al. **Chung Hua Nei Ko Tsa Chih** 1995 Apr;34(4):274–6 (16 ref.) **(Chi)**

CHEMICALLY INDUCED

Nonsteroidal anti-inflammatory drugs and gastrointestinal disease: pathophysiology, treatment and prevention. Bjorkman DJ, et al. **Dig Dis** 1995 Mar-Apr;13(2):119–29 (81 ref.)

Risk factors for gastrointestinal complications of nonsteroidal antiinflammatory drugs. Florent C, et al. **Rev Rhum Engl Ed** 1996 Feb;63(2):125–30 (44 ref.)

NSAID-associated upper gastrointestinal damage in patients with rheumatoid arthritis. Dijkmans BA, et al. **Scand J Gastroenterol Suppl** 1995;212:105–8 (26 ref.)

COMPLICATIONS

The role of acid in upper gastrointestinal haemorrhage due to ulcer and stress-related mucosal damage. Peterson WL. **Aliment Pharmacol Ther** 1995;9 Suppl 1:43–6 (28 ref.)

Peptic ulcers and gastric cancer. Mera SL. **Br J Biomed Sci** 1995 Dec;52(4):271–81 (59 ref.)

Duodenocaval fistula complicating peptic ulcer disease: case report and review of the literature. Miller CA, et al. **Surgery** 1996 Jun;119(6):718–9 (14 ref.)

[Perforated gastroduodenal ulcers in women] Ponomarev AA, et al. **Vestn Khir Im I I Grek** 1992 Feb;148(2):242–7 (56 ref.) **(Rus)**

DIAGNOSIS

Review article: gastrin releasing peptide and its value in assessing gastric secretory function. McColl KE, et al. **Aliment Pharmacol Ther** 1995 Aug;9(4):341–7 (52 ref.)

DRUG THERAPY

Review article: the continuing development of proton pump inhibitors with particular reference to pantoprazole. Huber R, et al. **Aliment Pharmacol Ther** 1995 Aug;9(4):363–78 (59 ref.)

Drug therapy of peptic ulcer disease. Ching CK, et al. **Br J Hosp Med** 1995 Jul 12–Aug 15;54(2–3):101–6 (39 ref.)

Evolving therapies for peptic ulcer disease: Helicobacter pylori treatment. Cohen JC. **Gastroenterologist** 1995 Dec; 3(4):289–300 (129 ref.)

Bismuth therapy for Helicobacter pylori infection. A review of five years experience at a university hospital in Norway. Berstad A, et al. **J Physiol Pharmacol** 1996 Mar;47(1):31–49 (45 ref.)

Strategies for Helicobacter pylori eradication in 1995: a review of international and Belgian experience. Deltenre M, et al. **J Physiol Pharmacol** 1996 Mar;47(1):59–69 (66 ref.)

Critical evaluation of the treatment of peptic ulcer diseases associated with Helicobacter pylori infection. Gabryelewicz A. **J Physiol Pharmacol** 1996 Mar;47(1):51–8 (44 ref.)

Consensus conference. Medical treatment of peptic ulcer disease. Practice guidelines. Practice Parameters Committee of the American College of Gastroenterology [published erratum appears in JAMA 1996 May 1;275(17):1314] Soll AH. **JAMA** 1996 Feb 28;275(8):622–9 (99 ref.)

Helicobacter pylori eradication: unravelling the facts. Dixon JS. **Scand J Gastroenterol Suppl** 1995;212:48–62 (244 ref.)

Long-term strategies for peptic ulcer. Korman MG. **Scand J Gastroenterol Suppl** 1995;210:60–3 (39 ref.)

Growth factors: new 'endogenous drugs' for ulcer healing. Szabo S, et al. **Scand J Gastroenterol Suppl** 1995;210:15–8 (33 ref.)

Peptic ulcer and Helicobacter pylori: eradication and relapse. Tytgat GN. **Scand J Gastroenterol Suppl** 1995;210:70–2 (13 ref.)

[Losek (omeprazole), a new therapeutic agent in the treatment of peptic ulcer and hyperacidity states] Bulgakov SA. **Klin Med (Mosk)** 1995;73(5):11–6 (77 ref.) **(Rus)**

[Treatment of peptic ulcer and gastritis associated with Helicobacter pylori] López-Brea M, et al. **Enferm Infecc Microbiol Clin** 1995 Aug-Sep;13(7):422–8 (75 ref.) **(Spa)**

[Influence of colloidal bismuth subcitrate, metronidazole, and amoxycillin on Helicobacter pylori and gastroduodenal ulcer healing] Quintero M, et al. **G E N** 1995 Apr-Jun; 49(2):116–22 (21 ref.) (Eng. Abstr.) **(Spa)**

ECONOMICS

Cost-effectiveness of H. pylori eradication. Roesch W. **J Physiol Pharmacol** 1996 Mar;47(1):71–7 (20 ref.)

EPIDEMIOLOGY

Temporal trends and geographical variations of peptic ulcer disease. Sonnenberg A. **Aliment Pharmacol Ther** 1995;9 Suppl 2:3–12 (31 ref.)

ETIOLOGY

Growth factors and ulcerative gastrointestinal disease. Playford RJ, et al. **Baillieres Clin Gastroenterol** 1996 Mar; 10(1):135–49 (60 ref.)

Helicobacter pylori infection and peptic ulcer disease in children. Rowland M, et al. **Curr Opin Pediatr** 1995 Oct; 7(5):553–9 (65 ref.)

Gastric secretion and the pathogenesis of peptic ulcer in the Helicobacter pylori infection. Konturek PC, et al. **J Physiol Pharmacol** 1996 Mar;47(1):5–19 (80 ref.)

Helicobacter pylori and peptic ulcer disease. Blum AL. **Scand J Gastroenterol Suppl** 1996;214:24–7; discussion 42–3 (24 ref.)

Helicobacter pylori in ulcerogenesis. Lin SK, et al. **Scand J Gastroenterol Suppl** 1995;210:64–9 (72 ref.)

[Gastroduodenal stress lesions and hemorrhages—pathogenesis, diagnosis, prevention and therapy] Gheorghiu T. **Zentralbl Chir** 1995;120(9):670–6 (32 ref.) (Eng. Abstr.) **(Ger)**

[Helicobacter pylori and gastroduodenal diseases] Nakazawa T. **Nippon Saikingaku Zasshi** 1995 Jul;50(3):777–86 (14 ref.) **(Jpn)**

[Acute postoperative gastroduodenal erosions and ulcers] Prilma OB. **Vestn Khir Im I I Grek** 1992 Feb;148(2):247–51 (44 ref.) **(Rus)**

METABOLISM

Trefoil peptides. Poulsom R. **Baillieres Clin Gastroenterol** 1996 Mar;10(1):113–34 (110 ref.)

MICROBIOLOGY

The role of Helicobacter pylori in gastritis and its progression to peptic ulcer disease. Blaser MJ. **Aliment Pharmacol Ther** 1995;9 Suppl 1:27–30 (27 ref.)

The prevalence of Helicobacter pylori in peptic ulcer disease. Kuipers EJ, et al. **Aliment Pharmacol Ther** 1995;9 Suppl 2:59–69 (110 ref.)

No Helicobacter pylori, no Helicobacter pylori-associated peptic ulcer disease. Tytgat GN. **Aliment Pharmacol Ther** 1995;9 Suppl 1:39–42 (15 ref.)

Helicobacter pylori and ulcerogenesis. Peura DA. **Am J Med** 1996 May 20;100(5A):19S–25S; discussion 25S–26S (78 ref.)

Helicobacter pylori in peptic ulcer: have Koch's postulates been fulfilled? Marshall BJ. **Ann Med** 1995 Oct;27(5):565–8 (16 ref.)

We need to integrate new data concerning Helicobacter pylor into experimental ulcer research. Graham DY. **Dig Dis Sci** 1995 Nov;40(11):2487–9 (35 ref.)

Helicobacter pylori: who is positive and who is not? Kuipers EJ, et al. **Eur J Gastroenterol Hepatol** 1995 Jun;7(6):533–6 (25 ref.)

H. pylori infection: its role in chronic gastritis, carcinoma and peptic ulcer. Pajares JM. **Hepatogastroenterology** 1995 Nov-Dec;42(6):827–41 (141 ref.)

Helicobacter pylori and peptic ulcer disease: current status [editorial] Greenberger NJ. **Hosp Pract (Off Ed)** 1995 Nov 15;30(11):11–2 (7 ref.)

Helicobacter pylori and gastrointestinal disease. Gibaldi M. **J Clin Pharmacol** 1995 Jul;35(7):647–54 (44 ref.)

Helicobacter pylori infection and its' role in human disease—an overview. McColl KE. **Pharm World Sci** 1996 Apr;18(2):49–55 (84 ref.)

Helicobacter pylori and peptic ulcer. Korman MG, et al. **Scand J Gastroenterol Suppl** 1995;210:92–6 (61 ref.)

Helicobacter pylori in ulcerogenesis. Lin SK, et al. **Scand J Gastroenterol Suppl** 1995;210:64–9 (72 ref.)

Peptic ulcer and Helicobacter pylori: eradication and relapse. Tytgat GN. **Scand J Gastroenterol Suppl** 1995;210:70–2 (13 ref.)

The significance of Helicobacter pylori colonization of the stomach. Cilley RE, et al. **Semin Pediatr Surg** 1995 Nov; 4(4):221–7 (68 ref.)

[Cause-targeted treatment of ulcer disease] Seppälä K, et al. **Duodecim** 1994;110(20):1853–9 (39 ref.) **(Fin)**

[Peptic ulcer and gastritis in the time of Helicobacter pylori] **Ann Gastroenterol Hepatol (Paris)** 1996 Jan-Feb; 32(1):25–34 (0 ref.) **(Fre)**

[Helicobacter pylori as a cause of benign malignant peptic ulcer] Abou-Mouch S, et al. **Harefuah** 1995 Jun 15; 128(12):808–11 (44 ref.) **(Heb)**

[Helicobacter pylori infection in peptic ulcer and gastric cancer diseases] Matsukura N, et al. **Nippon Ika Daigaku Zasshi** 1995 Aug;62(4):313–9 (22 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Helicobacter pylori and ulcerogenesis. Peura DA. **Am J Med** 1996 May 20;100(5A):19S–25S; discussion 25S–26S (78 ref.)

Role of epidermal growth factor in peptic ulcer healing. Calabrò A, et al. **Dig Dis Sci** 1995 Nov;40(11):2497–504 (63 ref.)

PREVENTION & CONTROL

Stress ulcer prophylaxis. Do critically ill patients need it? DePriest JL. **Postgrad Med** 1995 Oct;98(4):159–61, 165–6, 168 (23 ref.)

Prevention of gastrointestinal damage induced by nonsalicylate nonsteroidal antiinflammatory drugs. Florent C, et al. **Rev Rhum Engl Ed** 1996 Feb;63(2):131–4 (15 ref.)

Stress ulcer prophylaxis: gastrointestinal bleeding and nosocomial pneumonia. Best evidence synthesis. Cook DJ. **Scand J Gastroenterol Suppl** 1995;210:48–52 (38 ref.)

Long-term strategies for peptic ulcer. Korman MG. **Scand J Gastroenterol Suppl** 1995;210:60–3 (39 ref.)

SURGERY

Peptic ulcer disease, Helicobacter pylori, and the surgeon: changing of the guard. al-Assi MT, et al. **Curr Opin Gen Surg** 1994;:120–4 (28 ref.)

Surgical treatment of peptic ulceration. Stabile BE. **Curr Opin Gen Surg** 1993;:206–15 (37 ref.)

Carcinogenesis after remote peptic ulcer surgery: the long-term prognosis of partial gastrectomy. Tersmette AC, et al. **Scand J Gastroenterol Suppl** 1995;212:96–9 (49 ref.)

Laparoscopic management of peptic ulcer disease. Casas AT, et al. **Surg Clin North Am** 1996 Jun;76(3):515–22 (23 ref.)

Minimal access surgery—the renaissance of gastric surgery? McCloy R, et al. **Yale J Biol Med** 1994 May-Aug; 67(3–4):159–66 (38 ref.)

[Sequelae of stomach resection and gastrectomy and its consequences] Kirchner R. **Z Gastroenterol** 1996 Jun;34 Suppl 2:20–3 (18 ref.) **(Ger)**

[Peptic ulcer: late complications of the surgical treatment] Pinatel Lopasso F. **Rev Gastroenterol Peru** 1995 Sep-Dec; 15(3):273–81 (109 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

Therapeutic applications of vagotomy. Olbe L.

Yale J Biol Med 1994 May-Aug;67(3-4):153-7 (13 ref.)
[Cause-targeted treatment of ulcer disease] Seppälä K, et al. **Duodecim** 1994;110(20):1853-9 (39 ref.) **(Fin)**
[Endoscopic treatment of upper gastrointestinal diseases] Kaneko E. **Nippon Naika Gakkai Zasshi** 1995 Sep 10; 84(9):1528-31 (0 ref.) **(Jpn)**

PEPTIC ULCER HEMORRHAGE

COMPLICATIONS

Fistula between duodenum and portal vein caused by peptic ulcer disease and complicated by hemorrhage and portal vein thrombosis. Soares MA, et al. **Am J Gastroenterol** 1996 Jul;91(7):1462-3 (7 ref.)

DIAGNOSIS

[Clinical aspects and diagnosis of peptic ulcer hemorrhage--risk factors] Bosseckert H. **Bildgebung** 1995 Oct;62 Suppl 2:5-10 (11 ref.) **(Ger)**

DRUG THERAPY

Helicobacter pylori eradication: the best long-term prophylaxis for ulcer bleeding recurrence? Jaspersen D. **Endoscopy** 1995 Oct;27(8):622-5 (21 ref.)
[Gastroduodenal hemorrhages of peptic origin and the outlook for using somatostatin (Stilamin)] Smakov GM. **Vestn Khir Im I I Grek** 1995;154(3):120-3 (37 ref.) **(Rus)**

ECONOMICS

A cost-effective approach to the patient with peptic ulcer bleeding. Jiranek GC, et al. **Surg Clin North Am** 1996 Feb; 76(1):83-103 (124 ref.)

ETIOLOGY

[Type I hypersensitivity reactions and etiopathogenesis of hemorrhagic rectocolitis] Leprince E, et al. **Presse Med** 1995 Dec 16-23;24(39):1902-6 (58 ref.) (Eng. Abstr.) **(Fre)**
[Gastroduodenal stress lesions and hemorrhages--pathogenesis, diagnosis, prevention and therapy] Gheorghiu T. **Zentralbl Chir** 1995;120(9):670-6 (32 ref.) (Eng. Abstr.) **(Ger)**

MICROBIOLOGY

Helicobacter pylori and complicated ulcer disease. Laine LA. **Am J Med** 1996 May 20;100(5A):52S-57S; discussion 57S-59S (47 ref.)
Helicobacter pylori eradication: the best long-term prophylaxis for ulcer bleeding recurrence? Jaspersen D. **Endoscopy** 1995 Oct;27(8):622-5 (21 ref.)

PREVENTION & CONTROL

Stress bleeding prophylaxis in the ICU: obligate or obsolete? [editorial] Bonten MJ, et al. **Neth J Med** 1996 Jan;48(1):4-7 (24 ref.)
Stress ulcer prophylaxis: gastrointestinal bleeding and nosocomial pneumonia. Best evidence synthesis. Cook DJ. **Scand J Gastroenterol Suppl** 1995;210:48-52 (38 ref.)
[What is the right therapeutic management of duodenal ulcer except in emergency?] Bouhnik Y. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S131-S134 (40 ref.) **(Fre)**
[Medical treatment of stomach ulcer except in emergency] Bretagne JF. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S73-S80 (68 ref.) **(Fre)**
[Therapeutic management of duodenal ulcer except in emergency: eradication of Helicobacter pylori] Lamouliatte H. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S58-S63 (63 ref.) **(Fre)**

SURGERY

[Surgical hemostasis in recurrent peptic ulcer hemorrhage after endoscopic hemostasis--indications and results] Thon KP, et al. **Bildgebung** 1995 Oct;62 Suppl 2:22-8 (29 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Role of endoscopic injection therapy in the treatment of bleeding peptic ulcer. Kubba AK, et al. **Br J Surg** 1996 Apr;83(4):461-8 (88 ref.)
What should be done when initial endoscopic therapy for bleeding peptic ulcer fails? [editorial] Swain P. **Endoscopy** 1995 May;27(4):321-8 (69 ref.)
A cost-effective approach to the patient with peptic ulcer bleeding. Jiranek GC, et al. **Surg Clin North Am** 1996 Feb; 76(1):83-103 (124 ref.)
[Possibilities and results of endoscopic hemostasis in peptic ulcer hemorrhage] Bode JC. **Bildgebung** 1995 Oct;62 Suppl 2:16-20 (29 ref.) **(Ger)**
[Fibrin sealing, a concept for early elective endoscopic therapy] Friedrichs O. **Wien Med Wochenschr** 1995; 145(14):313-8 (42 ref.) (Eng. Abstr.) **(Ger)**

PEPTIC ULCER PERFORATION

COMPLICATIONS

Fistula between duodenum and portal vein caused by peptic ulcer disease and complicated by hemorrhage and portal vein thrombosis. Soares MA, et al. **Am J Gastroenterol** 1996 Jul;91(7):1462-3 (7 ref.)
[Pneumopericardium: a race against time! Case report and literature review] Alvarez L, et al. **Rev Med Brux** 1996 Jun;17(3):143-6 (15 ref.) (Eng. Abstr.) **(Fre)**

EPIDEMIOLOGY

Risk factors, Helicobacter pylori and a role for laparoscopic treatment of perforated peptic ulcer? [editorial; comment] Branicki FJ. **J Gastroenterol Hepatol** 1996 Jan;11(1):93-6 (43 ref.) Comment on: J Gastroenterol Hepatol 1996 Jan;11(1):82-7.
[Perforated gastroduodenal ulcers in women] Ponomarev AA, et al. **Vestn Khir Im I I Grek** 1992 Feb;148(2):242-7 (56 ref.) **(Rus)**

SURGERY

Risk factors, Helicobacter pylori and a role for laparoscopic treatment of perforated peptic ulcer? [editorial; comment] Branicki FJ. **J Gastroenterol Hepatol** 1996 Jan;11(1):93-6 (43 ref.) Comment on: J Gastroenterol Hepatol 1996 Jan;11(1):82-7.

PEPTIDASE INHIBITORS see **PROTEASE INHIBITORS**

PEPTIDE ANTIBIOTICS see **ANTIBIOTICS, PEPTIDE**

PEPTIDE CHAIN ELONGATION

see related
PEPTIDE ELONGATION FACTORS

Elongation in bacterial protein biosynthesis. Nyborg J, et al. **Curr Opin Biotechnol** 1996 Aug;7(4):369-75 (48 ref.)
Xenobiotic lipids: the inclusion of xenobiotic compounds in pathways of lipid biosynthesis. Dodds PF. **Prog Lipid Res** 1995;34(3):219-47 (209 ref.)

DRUG EFFECTS

Eukaryotic polypeptide elongation system and its sensitivity to the inhibitory substances of plant origin. Gałasiński W. **Proc Soc Exp Biol Med** 1996 May;212(1):24-37 (189 ref.)

PEPTIDE CHAIN INITIATION

see related
PEPTIDE INITIATION FACTORS

A signaling pathway to translational control. Brown EJ, et al. **Cell** 1996 Aug 23;86(4):517-20 (20 ref.)
Translational control of eukaryotic gene expression. Role of the guanine nucleotide exchange factor and chain initiation factor-2. Singh LP, et al. **Enzyme Protein** 1994-95; 48(2):61-80 (101 ref.)
Initiation of protein synthesis in eukaryotic cells. Pain VM. **Eur J Biochem** 1996 Mar 15;236(3):747-71 (372 ref.)

PEPTIDE ELONGATION FACTOR TU

CHEMISTRY

Origin and early evolution of eukaryotes inferred from the amino acid sequences of translation elongation factors 1alpha/Tu and 2/G. Hashimoto T, et al. **Adv Biophys** 1996; 32:73-120 (138 ref.)

PEPTIDE ELONGATION FACTORS

ANTAGONISTS & INHIBITORS

Eukaryotic polypeptide elongation system and its sensitivity to the inhibitory substances of plant origin. Gałasiński W. **Proc Soc Exp Biol Med** 1996 May;212(1):24-37 (189 ref.)

CHEMISTRY

Origin and early evolution of eukaryotes inferred from the amino acid sequences of translation elongation factors 1alpha/Tu and 2/G. Hashimoto T, et al. **Adv Biophys** 1996; 32:73-120 (138 ref.)
Elongation in bacterial protein biosynthesis. Nyborg J, et al. **Curr Opin Biotechnol** 1996 Aug;7(4):369-75 (48 ref.)

GENETICS

E2F and cell proliferation: a world turned upside down. Weinberg RA. **Cell** 1996 May 17;85(4):457-9 (10 ref.)

METABOLISM

Elongation in bacterial protein biosynthesis. Nyborg J, et al. **Curr Opin Biotechnol** 1996 Aug;7(4):369-75 (48 ref.)

PHYSIOLOGY

Multifunctional proteins in Tetrahymena: 14-nm filament protein/citrate synthase and translation elongation factor-1 alpha. Numata O. **Int Rev Cytol** 1996;164:1-35 (126 ref.)

PEPTIDE FRAGMENTS

ANALYSIS

Clinical applications of urinary gonadotropin peptides (UGP) in gynecologic oncology. Schwartz PE, et al. **Anticancer Res** 1996 Jul-Aug;16(4B):2135-9 (35 ref.)
[Fibrinopeptide A (FPA) and fibrinopeptide B beta 15-42 (FPB beta 15-42)] Tatsumi N, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:39-42 (15 ref.) **(Jpn)**
[Cyfra 21-1--new marker for lung cancer] Luczak E, et al. **Pneumonol Alergol Pol** 1996;64(1-2):96-101 (19 ref.) (Eng. Abstr.) **(Pol)**

BLOOD

Toward the biochemical assessment of myocardial fibrosis in hypertensive patients. Díez J, et al. **Am J Cardiol** 1995 Nov 2;76(13):14D-17D (36 ref.)

CHEMISTRY

Expression of Na(+)-Ca2+ exchanger with modified C-terminal hydrophobic domains and enhanced activity. Gabellini N, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:110-4 (9 ref.)
Neurofilament phosphorylation. Pant HC, et al. **Biochem Cell Biol** 1995 Sep-Oct;73(9-10):575-92 (84 ref.)
Antibacterial and immunostimulating casein-derived substances from milk: casecidin, isracidin peptides. Lahov E, et al. **Food Chem Toxicol** 1996 Jan;34(1):131-45 (49 ref.)

GENETICS

Neuronal calcium channels encoded by the alpha 1A subunit and their contribution to excitatory synaptic transmission in the CNS. Wheeler DB, et al. **Prog Brain Res** 1995; 105:65-78 (51 ref.)

IMMUNOLOGY

Analysis of MHC-specific peptide motifs. Applications in immunotherapy. Loftus DJ, et al. **Adv Exp Med Biol** 1995; 383:201-10 (71 ref.)
Curing metastases? Gene and peptide therapy. Eisenbach L. **Curr Top Microbiol Immunol** 1996;213 (Pt 3):85-100 (150 ref.)

ISOLATION & PURIFICATION

Production of crystallizable fragments of membrane proteins. Hendrickson WA. **J Bioenerg Biomembr** 1996 Feb; 28(1):35-40 (40 ref.)

METABOLISM

Expression of Na(+)-Ca2+ exchanger with modified C-terminal hydrophobic domains and enhanced activity. Gabellini N, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:110-4 (9 ref.)
Remnant particles and their metabolism. Eisenberg S, et al. **Baillieres Clin Endocrinol Metab** 1995 Oct;9(4):739-53 (40 ref.)
Peptide ligation and semisynthesis. Wallace CJ. **Curr Opin Biotechnol** 1995 Aug;6(4):403-10 (45 ref.)
The carboxy-terminus of parathyroid hormone--inert or invaluable? [editorial; comment] Orloff JJ, et al. **Endocrinology** 1995 Nov;136(11):4729-31 (20 ref.) Comment on: Endocrinology 1995 Nov;136(11):4732-40.
New insight into lysosomal protein storage disease: delayed catabolism of ATP synthase subunit c in Batten disease. Kominami E, et al. **Neurochem Res** 1995 Nov;20(11):1305-9 (26 ref.)

PHARMACOLOGY

The 'septide-sensitive' tachykinin receptor: still an enigma. Glowinski J. **Trends Pharmacol Sci** 1995 Nov;16(11):365-7 (34 ref.)

PHYSIOLOGY

Glucagon-like peptide-1 and control of insulin secretion. Thorens B. **Diabete Metab** 1995 Dec;21(5):311-8 (83 ref.)
Angiogenesis inhibitors generated by tumors. Folkman J. **Mol Med** 1995 Jan;1(2):120-2 (23 ref.)
New clues to Alzheimer's disease: unraveling the roles of amyloid and tau [comment] Yankner BA. **Nat Med** 1996 Aug;2(8):850-2 (22 ref.) Comment on: Nat Med 1996 Aug;2(8):864-70.

THERAPEUTIC USE

T cell receptor peptides in treatment of autoimmune disease: rationale and potential. Vandenbark AA, et al. **J Neurosci Res** 1996 Feb 15;43(4):391-402 (80 ref.)
Small bone-building fragments of parathyroid hormone: new therapeutic agents for osteoporosis. Whitfield JF, et al. **Trends Pharmacol Sci** 1995 Nov;16(11):382-6 (47 ref.)

URINE

Beta-core fragment (beta-core/UGF/UGP), a tumor marker: a 7-year report. Cole LA, et al. **Gynecol Oncol** 1996 Feb;60(2):264-70 (38 ref.)

PEPTIDE HORMONE RECEPTORS see **RECEPTORS, PEPTIDE**

PEPTIDE HYDROLASE INHIBITORS

PEPTIDE HYDROLASE INHIBITORS see **PROTEASE INHIBITORS**

PEPTIDE HYDROLASES

ANALYSIS

Methods for assessing proteolysis in cheese during maturation. Fox PF, et al. **Adv Exp Med Biol** 1995; 367:161–94 (244 ref.)

[Thrombin antithrombin III complex (TAT)] Sakuragawa N. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:48–50 (14 ref.) **(Jpn)**

CHEMISTRY

Subunits of the regulatory complex of the 26S protease. Dubiel W, et al. **Mol Biol Rep** 1995;21(1):27–34 (40 ref.)

Structural features of archaebacterial and eukaryotic proteasomes. Koster AJ, et al. **Mol Biol Rep** 1995; 21(1):11–20 (42 ref.)

Molecular biology of proteasomes. Tanaka K. **Mol Biol Rep** 1995;21(1):21–6 (54 ref.)

METABOLISM

The 20S/26S proteasomal pathway of protein degradation in muscle tissue. Dahlmann B, et al. **Mol Biol Rep** 1995; 21(1):57–62 (88 ref.)

Inactivation of neuropeptides. Csuhai E, et al. **Prog Brain Res** 1995;104:131–42 (122 ref.)

PHYSIOLOGY

Regulatory features of multicatalytic and 26S proteases. Hoffman L, et al. **Curr Top Cell Regul** 1996;34:1–32 (192 ref.)

Proteasomes of the yeast S. cerevisiae: genes, structure and functions. Hilt W, et al. **Mol Biol Rep** 1995;21(1):3–10 (74 ref.)

PEPTIDE INITIATION FACTORS

METABOLISM

Protein synthesis in eukaryotic organisms: new insights into the function of translation initiation factor eIF-3. Hannig EM. **Bioessays** 1995 Nov;17(11):915–9 (49 ref.)

Initiation of protein synthesis in eukaryotic cells. Pain VM. **Eur J Biochem** 1996 Mar 15;236(3):747–71 (372 ref.)

PHYSIOLOGY

A signaling pathway to translational control. Brown EJ, et al. **Cell** 1996 Aug 23;86(4):517–20 (20 ref.)

PEPTIDE MAPPING

see related
PEPTIDE FRAGMENTS

METHODS

Mapping of opioid receptors using antisense oligodeoxynucleotides: correlating their molecular biology and pharmacology. Pasternak GW, et al. **Trends Pharmacol Sci** 1995 Oct;16(10):344–50 (57 ref.)

PEPTIDE PEPTIDOHYDROLASE INHIBITORS see **PROTEASE INHIBITORS**

PEPTIDE PEPTIDOHYDROLASES

Proteases. Nduwimana J, et al. **Ann Biol Clin (Paris)** 1995; 53(5):251–64 (120 ref.)

[Proteolytic enzymes in cell physiology and pathophysiology] Chaloupka J. **Cas Lek Cesk** 1995 Oct 4; 134(19):611–4 (37 ref.) (Eng. Abstr.) **(Cze)**

BIOSYNTHESIS

Review: biosynthesis and function of yeast vacuolar proteases. Van Den Hazel HB, et al. **Yeast** 1996 Jan; 12(1):1–16 (110 ref.)

CHEMISTRY

Proteolytic processing of the arterivirus replicase. Snijder E, et al. **Adv Exp Med Biol** 1995;380:443–51 (28 ref.)

Structural features of archaebacterial and eukaryotic proteasomes. Koster AJ, et al. **Mol Biol Rep** 1995; 21(1):11–20 (42 ref.)

DRUG EFFECTS

Protease-mediated signalling: new paradigms for cell regulation and drug development. Hollenberg MD. **Trends Pharmacol Sci** 1996 Jan;17(1):3–6 (28 ref.)

METABOLISM

Contribution of milk-clotting enzymes and plasmin to cheese ripening. Farkye NY. **Adv Exp Med Biol** 1995;367:195–207 (64 ref.)

Proteolytic processing of the arterivirus replicase. Snijder E, et al. **Adv Exp Med Biol** 1995;380:443–51 (28 ref.)

Contribution of lactic acid bacteria to cheese ripening. Steele JL. **Adv Exp Med Biol** 1995;367:209–20 (43 ref.)

Proteinases and inhibitors. Cawston TE. **Br Med Bull** 1995 Apr;51(2):385–401 (65 ref.)

Processing and intracellular targeting of prosomatostatin-derived peptides: the role of mammalian endoproteases. Patel YC, et al. **Ciba Found Symp** 1995; 190:26–40; discussion 40–50 (50 ref.)

The role of proteases during apoptosis. Patel T, et al. **FASEB J** 1996 Apr;10(5):587–97 (97 ref.)

Endosomal proteolysis of internalized proteins. Authier F, et al. **FEBS Lett** 1996 Jun 24;389(1):55–60 (55 ref.)

Role of multiple cellular proteases in the execution of programmed cell death. Kumar S, et al. **FEBS Lett** 1995 Nov 20;375(3):169–73 (53 ref.)

Roles of molecular chaperones in protein degradation. Hayes SA, et al. **J Cell Biol** 1996 Feb;132(3):255–8 (24 ref.)

Proteolysis and the biochemistry of life-or-death decisions [comment] Ashkenas J, et al. **J Exp Med** 1996 May 1; 183(5):1947–51 (34 ref.) Comment on: J Exp Med 1996 May 1;183(5):1957–64.

Impaired proteolytic activity as a potential cause of progressive renal disease. Heidland A, et al. **Miner Electrolyte Metab** 1996;22(1–3):157–61 (52 ref.)

Necessary but not sufficient: the role of glucocorticoids in the acidosis-induced increase in levels of mRNAs encoding proteins of the ATP-dependent proteolytic pathway in rat muscle. Price SR, et al. **Miner Electrolyte Metab** 1996; 22(1–3):72–5 (14 ref.)

Interaction between pregnancy-induced bioactive peptides and the placental proteases. Mizutani S, et al. **Reprod Fertil Dev** 1995;7(6):1431–6 (26 ref.)

The proteolytic pathway of Lactococcus lactis. Poolman B, et al. **Soc Appl Bacteriol Symp Ser** 1995;24:65S–75S (46 ref.)

[Studies on the pathogenicity of microbial proteases] Maeda H. **Nippon Saikingaku Zasshi** 1995 Oct;50(4):921–36 (45 ref.) **(Jpn)**

[Proteolytic enzymes and regulation of the level of active neuropeptides] Vernigora AN, et al. **Biokhimiia** 1995 Oct; 60(10):1575–9 (46 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Nutrition, lysosomal proteases, and protein breakdown [see comments] Andreu AL, et al. **Nutrition** 1995 Jul–Aug; 11(4):382–7 (66 ref.) Comment in: Nutrition 1995 Jul–Aug;11(4):398.

Are bacterial proteinases pathogenic factors? Travis J, et al. **Trends Microbiol** 1995 Oct;3(10):405–7 (28 ref.)

Protease-mediated signalling: new paradigms for cell regulation and drug development. Hollenberg MD. **Trends Pharmacol Sci** 1996 Jan;17(1):3–6 (28 ref.)

[Pathogenic mechanism of Sendai virus—virus activation and germination polarity by host proteases] Tashiro M. **Uirusu** 1995 Jun;45(1):76–80 (12 ref.) **(Jpn)**

TOXICITY

In vitro activity of BaH1, the main hemorrhagic toxin of Bothrops asper snake venom on bovine endothelial cells. Borkow G, et al. **Toxicon** 1995 Oct;33(10):1387–91 (23 ref.)

PEPTIDE RECEPTORS see **RECEPTORS, PEPTIDE**

PEPTIDE RECEPTORS, INVERTEBRATE see **RECEPTORS, INVERTEBRATE PEPTIDE**

PEPTIDE SYNTHETASES

GENETICS

Engineered biosynthesis of peptide antibiotics. Stachelhaus T, et al. **Biochem Pharmacol** 1996 Jul 26;52(2):177–86 (64 ref.)

PEPTIDES

see related
AMINO ACID SEQUENCE

Peptide, peptidomimetic, and organic synthetic combinatorial libraries. Eichler J, et al. **Med Res Rev** 1995 Nov; 15(6):481–96 (67 ref.)

[Factors with insulin-like effects: IGF-I and GLP-1] Páv J. **Vnitr Lek** 1995 Sep;41(9):624–8 (35 ref.) (Eng. Abstr.) **(Cze)**

ADMINISTRATION & DOSAGE

Biodegradable polymers for protein and peptide drug delivery. Gombotz WR, et al. **Bioconjug Chem** 1995 Jul–Aug;6(4):332–51 (234 ref.)

AGONISTS

SH2 and SH3 domains: potential targets for anti-cancer drug design. Smithgall TE. **J Pharmacol Toxicol Methods** 1995 Nov;34(3):125–32 (52 ref.)

ANALYSIS

Methods for assessing proteolysis in cheese during maturation. Fox PF, et al. **Adv Exp Med Biol** 1995; 367:161–94 (244 ref.)

Capillary isoelectric focusing as a tool in the examination of antibodies, peptides and proteins of pharmaceutical interest. Liu X, et al. **J Chromatogr A** 1996 May 31; 735(1–2):165–90 (72 ref.)

Bioactive peptides from lizard venoms. Raufman JP. **Regul Pept** 1996 Jan 16;61(1):1–18 (165 ref.)

[Peptide hormone] Ohnami S, et al. **Nippon Rinsho** 1996 Jun; 54(6):1510–4 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Plasma-desorption mass spectrometry of natural compounds. 1. Basic properties of the method and its use for analyzing proteins and peptides] Reztsova NA, et al. **Bioorg Khim** 1996 Jan;22(1):3–13 (141 ref.) (Eng. Abstr.) **(Rus)**

BIOSYNTHESIS

Design and pharmacology of peptide mimetics. Moore GJ, et al. **Adv Pharmacol** 1995;33:91–41 (112 ref.)

Peptide and peptide-derived antibiotics. Vining LC, et al. **Biotechnology** 1995;28:121–7 (12 ref.)

Peptides. von Döhren H. **Biotechnology** 1995;28:129–71 (256 ref.)

New disulfide bond-forming reactions for peptide and protein synthesis. Kiso Y, et al. **Braz J Med Biol Res** 1994 Dec;27(12):2733–44 (24 ref.)

Protein biogenesis: chaperones for nascent polypeptides. Rassow J, et al. **Curr Biol** 1996 Feb 1;6(2):115–8 (29 ref.)

A nonribosomal system of peptide biosynthesis. Kleinkauf H, et al. **Eur J Biochem** 1996 Mar 1;236(2):335–51 (273 ref.)

Synthesis and assembly of MHC-peptide complexes. Benham A, et al. **Immunol Today** 1995 Jul;16(7):359–62 (20 ref.)

CHEMICAL SYNTHESIS

Urethane-protected alpha-amino acid N-carboxyanhydrides and peptide synthesis. Fuller WD, et al. **Biopolymers** 1996; 40(2):183–205 (56 ref.)

Multiple peptide synthesis. Fox JE. **Mol Biotechnol** 1995 Jun; 3(3):249–58 (20 ref.)

Synthetic peptides in biochemical research. Hancock DC, et al. **Mol Biotechnol** 1995 Aug;4(1):73–86 (104 ref.)

Radiolabelled peptides: now and the future. Thakur ML. **Nucl Med Commun** 1995 Sep;16(9):724–32 (41 ref.)

Design of experimental synthetic peptide immunogens for prevention of HIV-1 and HTLV-I retroviral infections. Hart MK, et al. **Pharm Biotechnol** 1995;6:821–45 (175 ref.)

Combinatorial peptide synthesis: statistical evaluation of peptide distribution. Boutin JA, et al. **Trends Pharmacol Sci** 1996 Jan;17(1):8–12 (14 ref.)

CHEMISTRY

Middle molecules: toxicity and removal by hemodialysis and related strategies. Vanholder R, et al. **Artif Organs** 1995 Nov;19(11):1120–5 (46 ref.)

Peptide models for membrane channels. Marsh D. **Biochem J** 1996 Apr 15;315 (Pt 2):345–61 (143 ref.)

Peptide nucleic acids (PNA): synthesis, properties and potential applications. Hyrup B, et al. **Bioorg Med Chem** 1996 Jan;4(1):5–23 (66 ref.)

X-ray crystallography of peptides: the contributions of the Italian laboratories. Benedetti E. **Biopolymers** 1996; 40(1):3–44 (273 ref.)

Conformational characteristics of peptides containing alpha, beta-dehydroamino acid residues. Jain R, et al. **Biopolymers** 1996;40(1):105–19 (80 ref.)

Flexibility in peptide molecules and restraints imposed by hydrogen bonds, the Aib residue, and core inserts. Karle IL. **Biopolymers** 1996;40(1):157–80 (84 ref.)

Crystal structures of peptides and modified peptides. Marraud M, et al. **Biopolymers** 1996;40(1):45–83 (275 ref.)

Peptide chemistry: development of high performance liquid chromatography and capillary zone electrophoresis. Miller C, et al. **Biopolymers** 1996;40(3):265–317 (124 ref.)

Oxidative folding of cystine-rich peptides vs regioselective cysteine pairing strategies. Moroder L, et al. **Biopolymers** 1996;40(2):207–34 (206 ref.)

Recent structural studies of peptides in Japan. Okuyama K, et al. **Biopolymers** 1996;40(1):85–103 (28 ref.)

Developments in matrix-assisted laser desorption/ionization peptide mass spectrometry. Mann M, et al. **Curr Opin Biotechnol** 1996 Feb;7(1):11–9 (74 ref.)

Immunosuppressive peptides corresponding to MHC class I sequences. Clayberger C, et al. **Curr Opin Immunol** 1995 Oct;7(5):644–8 (34 ref.)

Use of macromolecular assemblies as expression systems for peptides and synthetic vaccines. Lomonossoff GP, et al. **Curr Opin Struct Biol** 1996 Apr;6(2):176–82 (66 ref.)

'Peptoid' design. Horwell DC, et al. **Drug Des Discov** 1994 Jul;12(1):63–75 (35 ref.)

Analysis of the structure of naturally processed peptides bound by class I and class II major histocompatibility complex molecules. Appella E, et al. **EXS** 1995;73:105–19 (190 ref.)

Chemical techniques employed for the primary structural analysis of proteins and peptides. Inglis AS, et al. **EXS** 1995;73:141–71 (73 ref.)

Nickel complexes as probes of guanine sites in nucleic acid folding. Burrows CJ, et al. **Met Ions Biol Syst** 1996; 33:537–60 (41 ref.)

[Surface potential energy of peptides and conformation of amino acid residues in proteins. Preliminary results of processing using databank protein structures] Basharov MA. **Biofizika** 1995 Mar–Apr;40(2):260–73 (50 ref.) (Eng. Abstr.) **(Rus)**

GENETICS

Molecular basis for a geographic variation of varicella-zoster virus recognized by a peptide antibody. Kinchington PR, et al. **Neurology** 1995 Dec;45(12 Suppl 8):S13-4 (7 ref.)
Evolution of neuropeptide Y, peptide YY and pancreatic polypeptide. Larhammar D. **Regul Pept** 1996 Apr 9; 62(1):1-11 (104 ref.)
In vivo applications of antisense oligonucleotides for peptide research. [editorial] Phillips MI, et al. **Regul Pept** 1995 Oct 20;59(2):131-41 (56 ref.)
Antisense oligonucleotides in in vivo regulatory peptide research [editorial] Phillips MI. **Regul Pept** 1995 Oct 20; 59(2):iii-v (13 ref.)

IMMUNOLOGY

Autoimmune recognition of acetylcholine receptor and manipulation of the autoimmune responses by synthetic peptides. Atassi MZ, et al. **Adv Exp Med Biol** 1995; 383:141-56 (71 ref.)
The use of multiple antigen peptides in the analysis and induction of protective immune responses against infectious diseases. Nardin EH, et al. **Adv Immunol** 1995;60:105-49 (135 ref.)
Generation, translocation, and presentation of MHC class I-restricted peptides. Heemels MT, et al. **Annu Rev Biochem** 1995;64:463-91 (192 ref.)
Presentation of self peptides by dendritic cells: possible implications for the pathogenesis of rheumatoid arthritis. Thomas R, et al. **Arthritis Rheum** 1996 Feb;39(2):183-90 (85 ref.)
Presentation of N-formylated peptides by H2-M3. Lindahl KF, et al. **Biochem Soc Trans** 1995 Aug;23(3):669-74 (34 ref.)
Elucidation of T-cell epitopes: a synthetic approach with random peptide libraries. Walden P, et al. **Biochem Soc Trans** 1995 Aug;23(3):678-81 (16 ref.)
Selection of ligands for polyclonal antibodies from random peptide libraries: potential identification of (auto)antigens that may trigger B and T cell responses in autoimmune diseases. Sioud M, et al. **Clin Immunol Immunopathol** 1996 May;79(2):105-14 (65 ref.)
Lonely MHC molecules seeking immunogenic peptides for meaningful relationships. Mellman I, et al. **Curr Opin Cell Biol** 1995 Aug;7(4):564-72 (72 ref.)
Peptide modulation of allergen-specific immune responses. Hoyne GF, et al. **Curr Opin Immunol** 1995 Dec;7(6):757-61 (41 ref.)
Peptide binding to MHC class I molecules: implications for antigenic peptide prediction. Parker KC, et al. **Immunol Res** 1995;14(1):34-57 (129 ref.)
Liposomes as carriers of peptide antigens: induction of antibodies and cytotoxic T lymphocytes to conjugated and unconjugated peptides. Alving CR, et al. **Immunol Rev** 1995 Jun;145:5-31 (104 ref.)
Lupus autoimmunity: from peptides to particles. Mamula MJ. **Immunol Rev** 1995 Apr;144:301-14 (58 ref.)
Induction of antigen-specific unresponsiveness with synthetic peptides: specific immunotherapy for treatment of allergic and autoimmune conditions. Wraith DC. **Int Arch Allergy Immunol** 1995 Dec;108(4):355-9 (29 ref.)
Heat shock protein-peptide complexes for use in vaccines. Heike M, et al. **J Leukoc Biol** 1996 Aug;60(2):153-8 (75 ref.)
Design and testing of peptide-based cytotoxic T-cell-mediated immunotherapeutics to treat infectious diseases and cancer. Chesnut RW, et al. **Pharm Biotechnol** 1995;6:847-74 (170 ref.)
Synthetic peptide vaccines for schistosomiasis. Harn DA, et al. **Pharm Biotechnol** 1995;6:891-905 (41 ref.)
Design of experimental synthetic peptide immunogens for prevention of HIV-1 and HTLV-1 retroviral infections. Hart MK, et al. **Pharm Biotechnol** 1995;6:821-45 (175 ref.)
The MAP system. A flexible and unambiguous vaccine design of branched peptides. Nardelli B, et al. **Pharm Biotechnol** 1995;6:803-19 (57 ref.)
Thoughtful cruises in oceans of peptides and T cells. Kourilsky P. **Res Immunol** 1995 May-Jun;146(4-5):309-20 (33 ref.)

METABOLISM

Angiotensin peptides in the brain. Campbell DJ. **Adv Exp Med Biol** 1995;377:349-55 (30 ref.)
Generation, translocation, and presentation of MHC class I-restricted peptides. Heemels MT, et al. **Annu Rev Biochem** 1995;64:463-91 (192 ref.)
Interaction of protein kinase C with RACK1, a receptor for activated C-kinase: a role in beta protein kinase C mediated signal transduction. Mochly-Rosen D, et al. **Biochem Soc Trans** 1995 Aug;23(3):596-600 (32 ref.)
Interaction of antigenic peptides with MHC and TCR molecules. Sette A, et al. **Clin Immunol Immunopathol** 1995 Sep;76(3 Pt 2):S168-71 (7 ref.)
How peptides cross biological membranes [editorial] Nussberger S, et al. **Exp Nephrol** 1995 Jul-Aug;3(4):211-8 (37 ref.)
Peptides as active probes. Undén A, et al. **EXS** 1995; 73:229-55 (82 ref.)
Peptide binding to MHC class I molecules: implications for antigenic peptide prediction. Parker KC, et al. **Immunol Res** 1995;14(1):34-57 (129 ref.)
Ruminal microbial metabolism of peptides and amino acids. Wallace RJ. **J Nutr** 1996 Apr;126(4 Suppl):1326S-34S (79 ref.)
Why does Escherichia coli recycle its cell wall peptides? Park JT. **Mol Microbiol** 1995 Aug;17(3):421-6 (41 ref.)
The PTR family: a new group of peptide transporters. Steiner HY, et al. **Mol Microbiol** 1995 Jun;16(5):825-34 (59 ref.)
Decrypting class I MHC-bound peptides with peptide libraries. Udaka K. **Trends Biochem Sci** 1996 Jan;21(1):7-11 (23 ref.)
Anchorage and release of Gram-positive bacterial cell-surface polypeptides. Jenkinson HF. **Trends Microbiol** 1995 Sep;3(9):333-5 (15 ref.)
[A family of Kex2-like endoproteases involved in processing of precursors for biologically active peptides and proteins] Nakayama K. **Seikagaku** 1995 Aug;67(8):995-1009 (95 ref.) **(Jpn)**

PHARMACOKINETICS

Conformationally constrained peptide drugs targeted at the blood-brain barrier. Davis TP, et al. **NIDA Res Monogr** 1995;154:47-60 (24 ref.)
Oral peptide delivery: improving the systemic availability of small peptides and enkephalin analogs. Lee HJ, et al. **NIDA Res Monogr** 1995;154:86-106 (16 ref.)
Cerebrovascular permeability to peptides: manipulations of transport systems at the blood-brain barrier. Zlokovic BV. **Pharm Res** 1995 Oct;12(10):1395-406 (72 ref.)

PHARMACOLOGY

Cationic bactericidal peptides. Hancock RE, et al. **Adv Microb Physiol** 1995;37:135-75 (215 ref.)
Design and pharmacology of peptide mimetics. Moore GJ, et al. **Adv Pharmacol** 1995;33:91-41 (112 ref.)
Mechanism of XIP in cardiac sarcolemmal vesicles. Hale CC. **Ann N Y Acad Sci** 1996 Apr 15;779:171-81 (7 ref.)
Peptide nucleic acids (PNA): synthesis, properties and potential applications. Hyrup B, et al. **Bioorg Med Chem** 1996 Jan;4(1):5-23 (66 ref.)
A VIP hybrid antagonist: from developmental neurobiology to clinical applications. Gozes I, et al. **Cell Mol Neurobiol** 1995 Dec;15(6):675-87 (74 ref.)
Nutrient intake is modulated by peripheral peptide administration. Bray GA. **Obes Res** 1995 Nov;3 Suppl 4:569S-572S (31 ref.)
HLA-derived peptides as novel immunosuppressives. Krensky AM. **Pediatr Res** 1995 Sep;38(3):275-9 (25 ref.)
[Anti-adhesive and anti-thrombotic effects of integrin-inhibiting tripeptides (Arg-Gly-Asp)] Udvardy M. **Orv Hetil** 1995 Oct 1;136(40):2155-9 (42 ref.) (Eng. Abstr.) **(Hun)**
[Antimicrobial peptides and resistance in animals] Kharchenko EP. **Antibiot Khimioter** 1995 Jul;40(7):45-53 (33 ref.) **(Rus)**

PHYSIOLOGY

Review article: gastrin releasing peptide and its value in assessing gastric secretory function. McColl KE, et al. **Aliment Pharmacol Ther** 1995 Aug;9(4):341-7 (52 ref.)
Myelopeptides: new immunoregulatory peptides. Petrov R. **Allergy Proc** 1995 Jul-Aug;16(4):177-84 (14 ref.)
Salt and water homeostasis: uroguanylin is a circulating peptide hormone with natriuretic activity. Forte LR, et al. **Am J Kidney Dis** 1996 Aug;28(2):296-304 (35 ref.)
Roles of bombesin-like peptides in lung development and lung injury [comment] Spindel ER. **Am J Respir Cell Mol Biol** 1996 May;14(5):407-8 (18 ref.) Comment on: Am J Respir Cell Mol Biol 1996 May;14(5):409-16.
The trefoil peptide family. Sands BE, et al. **Annu Rev Physiol** 1996;58:253-73 (87 ref.)
Trefoil peptides. Poulsom R. **Baillieres Clin Gastroenterol** 1996 Mar;10(1):113-34 (110 ref.)
Systemin--a polypeptide defense signal in plants. Schaller A, et al. **Bioessays** 1996 Jan;18(1):27-33 (69 ref.)
Spinal cord pharmacology of pain. Dickenson AH. **Br J Anaesth** 1995 Aug;75(2):193-200 (71 ref.)
Adrenomedullin [editorial] Richards AM, et al. **Clin Sci (Colch)** 1996 Jul;91(1):3-16 (84 ref.)
Peptide signaling in human placenta and membranes: autocrine, paracrine, and endocrine mechanisms. Petraglia F, et al. **Endocr Rev** 1996 Apr;17(2):156-86 (431 ref.)
Cross talk between peptide growth factor and estrogen receptor signaling systems. Ignar-Trowbridge DM, et al. **Environ Health Perspect** 1995 Oct;103 Suppl 7:35-8 (34 ref.)
Structural remodelling of the heart by fibrous tissue: role of circulating hormones and locally produced peptides. Weber KT, et al. **Eur Heart J** 1995 Dec;16 Suppl N:12-8 (83 ref.)
Basic actions of transforming growth factor-alpha and related peptides. Coffey RJ, et al. **Eur J Gastroenterol Hepatol** 1995 Oct;7(10):923-7 (49 ref.)
The role of regulatory peptides in the pathogenesis of cutaneous necrotizing vasculitis. Hautmann G, et al. **Int Angiol** 1995 Jun;14(2):138-50 (104 ref.)
Endocrine regulation of food intake and body weight. Figlewicz DP, et al. **J Lab Clin Med** 1996 Apr; 127(4):328-32 (43 ref.)
Peptide hormone action on renal phosphate handling [see comments] Kempson SA. **Kidney Int** 1996 Apr;49(4):1005-9 (52 ref.) Comment in: Kidney Int 1996 Apr;49(4):1010-1.
Ribosome regulation by the nascent peptide. Lovett PS, et al. **Microbiol Rev** 1996 Jun;60(2):366-85 (148 ref.)
Pheromone communication in the fission yeast Schizosaccharomyces pombe. Nielsen O, et al. **Semin Cell Biol** 1995 Apr;6(2):95-104 (105 ref.)
[Adrenomedullin] Zeng Z. **Chung Hua Nei Ko Tsa Chih** 1995 Sep;34(9):635-7 (14 ref.) **(Chi)**
[Role of peptidergic mechanisms in thermoregulation] Marianovich AT. **Fiziol Cheloveka** 1996 Mar-Apr; 22(2):35-42 (83 ref.) **(Rus)**

SECRETION

A peptide hormone causing abnormal hair-growth associated with malignancy. Pilsczek FH. **Med Hypotheses** 1995 Sep; 45(3):223-4 (6 ref.)

THERAPEUTIC USE

Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective. Tcheng JE. **Am J Cardiol** 1996 Aug 14; 78(3A):35-40 (27 ref.)
Peptide therapy for treatment of allergic diseases. Wallner BP, et al. **Clin Immunol Immunopathol** 1996 Aug; 80(2):105-9 (51 ref.)

PEPTIDES, CYCLIC

ANALYSIS

[New fluorogenic dienophile: synthesis, reaction with vitamin D, vitamin A and microcystins, and application to fluorometric assays] Shimizu M, et al. **Yakugaku Zasshi** 1995 Aug;115(8):584-602 (67 ref.) (Eng. Abstr.) **(Jpn)**

BIOSYNTHESIS

Peptidolactones. Keller U. **Biotechnology** 1995;28:173-96 (74 ref.)

PHARMACOLOGY

[Discovery and pharmacological properties of selective neurokinin-receptor antagonists, FK224 and FK888] Fujii T. **Nippon Yakurigaku Zasshi** 1995 Sep;106(3):193-204 (34 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Effects of endothelin-1 and the ETA receptor antagonist BQ-123 on resistance arteries from normal pregnant and preeclamptic women. Wolff K, et al. **Acta Obstet Gynecol Scand** 1996 May;75(5):432-8 (34 ref.)

PEPTIDOGLYCAN

Disulfide cross-linked envelope proteins: the functional equivalent of peptidoglycan in chlamydiae? Hatch TP. **J Bacteriol** 1996 Jan;178(1):1-5 (49 ref.)

BIOSYNTHESIS

A hypothetical holoenzyme involved in the replication of the murein sacculus of Escherichia coli. Höltje JV. **Microbiology** 1996 Aug;142 (Pt 8):1911-8 (45 ref.)

CHEMISTRY

A hypothetical holoenzyme involved in the replication of the murein sacculus of Escherichia coli. Höltje JV. **Microbiology** 1996 Aug;142 (Pt 8):1911-8 (45 ref.)

METABOLISM

Lysozyme substrates. Höltje JV. **EXS** 1996;75:105-10 (34 ref.)
Lytic transglycosylases. Höltje JV. **EXS** 1996;75:425-9 (20 ref.)
Bacterial lysozymes. Höltje JV. **EXS** 1996;75:65-74 (48 ref.)

PEPTIDYL-DIPEPTIDASE A

BLOOD

[Angiotensin I converting enzyme] Wanaka Y, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:389-91 (16 ref.) **(Jpn)**

CHEMISTRY

Recent advances in knowledge of the structure and function of the angiotensin I converting enzyme. Corvol P, et al. **J Hypertens Suppl** 1995 Sep;13 Suppl 3:S3-10 (63 ref.)

GENETICS

Role of angiotensin-converting enzyme gene polymorphism in progressive loss of renal function in chronic renal diseases. Yoshida H, et al. **Contrib Nephrol** 1996;118:249-53 (21 ref.)
Association studies, ACE polymorphisms and renal disease [editorial] Harden PN, et al. **Nephrol Dial Transplant** 1996 May;11(5):757-9 (31 ref.)

METABOLISM

Biochemistry and cell biology of angiotensin-converting enzyme and converting enzyme inhibitors. Berecek KH, et al. **Adv Exp Med Biol** 1995;377:141-68 (256 ref.)

PEPTIDYL-DIPEPTIDASE A

PHYSIOLOGY

Tachykinin peptides, receptors, and peptidases in airway disease. Piedimonte G. **Exp Lung Res** 1995 Nov-Dec; 21(6):809-34 (154 ref.)

Recent advances in knowledge of the structure and function of the angiotensin I converting enzyme. Corvol P, et al. **J Hypertens Suppl** 1995 Sep;13 Suppl 3:S3-10 (63 ref.)

PEPTOSTREPTOCOCCUS

[Computed tomographic demonstration of intraspinal air after an infection with peptostreptococci] Lorenzen J, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Feb;164(2):173-5 (10 ref.) **(Ger)**

PERCEPTION

see related
SENSATION

Words and sentences: event-related brain potential measures. van Petten C. **Psychophysiology** 1995 Nov;32(6):511-25 (141 ref.)

[Study of functional neuro-anatomy of perception using positron emission tomography] Baron JC. **Rev Neurol (Paris)** 1995 Aug-Sep;151(8-9):511-7 (58 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Frontal lobe mechanisms subserving vision-for-action versus vision-for-perception. Boussaoud D, et al. **Behav Brain Res** 1995 Dec 14;72(1-2):1-15 (145 ref.)

Representation of perceptual dimensions of insect prey during terminal pursuit by echolocating bats. Simmons JA, et al. **Biol Bull** 1996 Aug;191(1):109-21 (56 ref.)

How good are patients with panic disorder at perceiving their heartbeats? Ehlers A, et al. **Biol Psychol** 1996 Jan 5;42(1-2):165-82 (55 ref.)

Interoception. Vaitl D. **Biol Psychol** 1996 Jan 5;42(1-2):1-27 (100 ref.)

Perception and memory: action and interaction. Eacott MJ, et al. **Crit Rev Neurobiol** 1995;9(4):311-20 (50 ref.)

Binding in models of perception and brain function. von der Malsburg C. **Curr Opin Neurobiol** 1995 Aug;5(4):520-6 (70 ref.)

Motor imagery: perception or action? Annett J. **Neuropsychologia** 1995 Nov;33(11):1395-417 (101 ref.)

The attentional control of pain: methodological and theoretical concerns. Eccleston C. **Pain** 1995 Oct; 63(1):3-10 (45 ref.)

'My most true mind thus makes mine eye untrue'. Albright TD. **Trends Neurosci** 1995 Aug;18(8):331-3 (10 ref.)

Second-order neurones and receptor mechanisms in visual- and olfactory-information processing. Nakanishi S. **Trends Neurosci** 1995 Aug;18(8):359-64 (50 ref.)

[The perception of muscle loading and the role of locomotor and respiratory sensation] Breslav IS. **Fiziol Zh Im I M Sechenova** 1994 Dec;80(12):10-20 (69 ref.) **(Rus)**

PERCEPTION, SOCIAL see **SOCIAL PERCEPTION**

PERCEPTRONS see **NEURAL NETWORKS (COMPUTER)**

PERCEPTUAL DISORDERS

DRUG THERAPY

Managing agitation in critically ill patients. Harvey MA. **Am J Crit Care** 1996 Jan;5(1):7-16; quiz 17-8 (72 ref.)

ETIOLOGY

[Saccadic latencies and unilateral spatial neglect caused by parietal lesions] Cochin JP, et al. **Rev Neurol (Paris)** 1996 Jan;152(1):32-7 (35 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Object segmentation and visual neglect. Driver J. **Behav Brain Res** 1995 Nov;71(1-2):135-46 (74 ref.)

The effects of visual cortex lesions on the perception of rotated shapes. Walsh V, et al. **Behav Brain Res** 1996 Apr; 76(1-2):127-42 (75 ref.)

PSYCHOLOGY

[Acoustic and optical perceptual disorders in depressive diseases--an overview of results from experimental studies] Kallert TW. **Schweiz Arch Neurol Psychiatr** 1996; 147(1):4-11 (61 ref.) (Eng. Abstr.) **(Ger)**

PERCEPTUAL DISTORTION

see related
PERCEPTUAL DISORDERS

PERCEPTUAL MASKING

PHYSIOLOGY

Relation between backward masking deficits and smooth pursuit dysfunction in schizophrenia? Allen JS. **Optom Vis Sci** 1995 Jul;72(7):493-501 (61 ref.)

PERCEPTUAL MOTOR PERFORMANCE see **PSYCHOMOTOR PERFORMANCE**

PERCHLORIC ACID

TOXICITY

Perchlorates. Von Burg R. **J Appl Toxicol** 1995 May-Jun; 15(3):237-41 (64 ref.)

PERCHLOROETHYLENE see **TETRACHLOROETHYLENE**

PERCUSSION

Percussion and physical diagnosis: separating myth from science. McGee SR. **Dis Mon** 1995 Oct;41(10):641-92 (163 ref.)

Chest percussion. Yernault JC, et al. **Eur Respir J** 1995 Oct; 8(10):1756-60 (33 ref.)

PERCUTANEOUS ATHERECTOMY see **ATHERECTOMY**

PERCUTANEOUS ELECTRIC NERVE STIMULATION see **TRANSCUTANEOUS ELECTRIC NERVE STIMULATION**

PERCUTANEOUS NEPHROLITHOTOMY see **NEPHROSTOMY, PERCUTANEOUS**

PERCUTANEOUS NEPHROSTOMY see **NEPHROSTOMY, PERCUTANEOUS**

PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY see **ANGIOPLASTY, BALLOON**

PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY see **ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY**

PERCUTANEOUS TRANSLUMINAL LASER ANGIOPLASTY see **ANGIOPLASTY, BALLOON, LASER-ASSISTED**

PERCUTANEOUS ULTRASONIC LITHOTRIPSY see **LITHOTRIPSY**

PERFLUOROCARBONS see **FLUOROCARBONS**

PERFORMANCE APPRAISAL, EMPLOYEE see **EMPLOYEE PERFORMANCE APPRAISAL**

PERFUSION, PULSATILE see **PULSATILE FLOW**

PERFUSION PUMPS see **INFUSION PUMPS**

PERFUSION PUMPS, IMPLANTABLE see **INFUSION PUMPS, IMPLANTABLE**

PERFUSION, REGIONAL

[Results of resection and adjuvant therapy of liver metastases of primary colorectal tumors--a review of the literature] Lorenz M, et al. **Zentralbl Chir** 1995;120(10):769-79 (74 ref.) (Eng. Abstr.) **(Ger)**

PERGOLIDE

ADVERSE EFFECTS

[Retroperitoneal fibrosis secondary to treatment with L-dopa analogues for Parkinson disease] Sánchez-Chapado M, et al. **Arch Esp Urol** 1995 Dec;48(10):979-83 (28 ref.) (Eng. Abstr.) **(Spa)**

THERAPEUTIC USE

Pergolide mesylate in Parkinson's disease treatment. Pezzoli G, et al. **J Neural Transm Suppl** 1995;45:203-12 (48 ref.)

PERGOLIDE MESYLATE see **PERGOLIDE**

PERIADENITIS MUCOSA NECROTICA RECURRENS see **STOMATITIS, APHTHOUS**

PERIANEURYSMAL FIBROSIS, INFLAMMATORY see **RETROPERITONEAL FIBROSIS**

PERIAORTITIS, CHRONIC see **RETROPERITONEAL FIBROSIS**

PERIAPICAL ABSCESS

COMPLICATIONS

Uncommon complications of odontogenic infections. Ferrera PC, et al. **Am J Emerg Med** 1996 May;14(3):317-22 (49 ref.)

SURGERY

[Odontogenic diseases of the maxillary sinuses] Lambrecht JT. **Fortschr Kiefer Gesichtschir** 1995;40:106-13 (115 ref.) (Eng. Abstr.) **(Ger)**

PERIAPICAL CYST see **RADICULAR CYST**

PERIAPICAL PERIODONTITIS

ETIOLOGY

Periapical neural changes after pulpectomy. Holland GR. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1995 Dec;80(6):726-34 (55 ref.)

IMMUNOLOGY

[Activation of the immune system in periapical infection. 1. Lympho-monocytoid and plasma cellular elements of reactive soft tissue cells] Milia E, et al. **Minerva Stomatol** 1996 Jan-Feb;45(1-2):37-48 (47 ref.) (Eng. Abstr.) **(Ita)**

SURGERY

[Odontogenic diseases of the maxillary sinuses] Lambrecht JT. **Fortschr Kiefer Gesichtschir** 1995;40:106-13 (115 ref.) (Eng. Abstr.) **(Ger)**

PERIAPICAL PERIODONTITIS, SUPPURATIVE see **PERIAPICAL ABSCESS**

PERIAPICAL TISSUE

INNERVATION

Periapical neural changes after pulpectomy. Holland GR. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1995 Dec;80(6):726-34 (55 ref.)

PERIAQUEDUCTAL GRAY

PHYSIOLOGY

Neuroanatomical and neurochemical mechanisms underlying amygdaloid control of defensive rage behavior in the cat. Shaikh MB, et al. **Braz J Med Biol Res** 1994 Dec; 27(12):2759-79 (43 ref.)

Functional characteristics of the midbrain periaqueductal gray. Behbehani MM. **Prog Neurobiol** 1995 Aug; 46(6):575-605 (325 ref.)

PERIARTERITIS NODOSA see **POLYARTERITIS NODOSA**

PERIARTHRITIS

ETIOLOGY

Acute calcific periarthritis of the fingers. Gálvez J, et al. **Rev Rhum Engl Ed** 1995 Oct;62(9):602-4 (11 ref.)

[Periarthritis humeroscapularis--clinical diagnosis and analysis of the syndrome concept] Jerosch J. **Wien Med Wochenschr** 1996;146(6-7):142 (22 ref.) (Eng. Abstr.) **(Ger)**

PERICARDIAL CYST see **MEDIASTINAL CYST**

PERICARDIAL EFFUSION

see related
CARDIAC TAMPONADE

COMPLICATIONS

[Loculated pericardial effusion leading to functional tricuspid stenosis in a case of rheumatoid arthritis] Galli CA, et al. **Cardiologia** 1995 Sep;40(9):685-8 (11 ref.) (Eng. Abstr.) **(Ita)**

DIAGNOSIS

Malignancy-related pericardial effusion. 127 cases from the Roswell Park Cancer Institute. Wilkes JD, et al. **Cancer** 1995 Oct 15;76(8):1377-87 (91 ref.)

Pericardial effusion and tamponade: evaluation, imaging modalities, and management. Chong HH, et al. **Compr Ther** 1995 Jul;21(7):378-85 (35 ref.)

ETIOLOGY

Intrapericardial rupture of amebic liver abscess managed with percutaneous drainage of liver abscess alone. Takhtani D, et al. **Am J Gastroenterol** 1996 Jul;91(7):1460-2 (9 ref.)

Unexplained effusions: association with allogeneic bone marrow transplantation and acute or chronic graft-versus-host disease. Seber A, et al. **Bone Marrow Transplant** 1996 Feb;17(2):207-11 (28 ref.)

Malignancy-related pericardial effusion. 127 cases from the Roswell Park Cancer Institute. Wilkes JD, et al. **Cancer** 1995 Oct 15;76(8):1377-87 (91 ref.)

[Mediastinal malignant schwannoma disclosed by pericardial tamponade in von Recklinghausen disease] Soulami S, et al. **Ann Cardiol Angeiol (Paris)** 1995 Oct;44(8):418-21 (11 ref.) (Eng. Abstr.) **(Fre)**

[Pericardial effusion in heart surgery interventions] Pepi M, et al. **Cardiologia** 1995 Apr;40(4):267–72 (31 ref.) **(Ita)**

SURGERY

Intrapericardial rupture of amebic liver abscess managed with percutaneous drainage of liver abscess alone. Takhtani D, et al. **Am J Gastroenterol** 1996 Jul;91(7):1460–2 (9 ref.)

THERAPY

Pericardial effusion and tamponade: evaluation, imaging modalities, and management. Chong HH, et al. **Compr Ther** 1995 Jul;21(7):378–85 (35 ref.)

Pericardial metastasis in carcinoma of the uterine cervix. Jamshed A, et al. **Gynecol Oncol** 1996 Jun;61(3):451–3 (16 ref.)

PERICARDITIS

CHEMICALLY INDUCED

Pleuropericarditis related to the use of mesalamine. Gujral N, et al. **Dig Dis Sci** 1996 Mar;41(3):624–6 (12 ref.)

ETIOLOGY

Cardiac manifestations of Lyme disease: a review. Nagi KS, et al. **Can J Cardiol** 1996 May;12(5):503–6 (38 ref.)

Asymptomatic pericarditis in Adamantiadis–Behçet's disease. Vaiopoulos G, et al. **Clin Exp Rheumatol** 1995 Sep–Oct; 13(5):649–51 (18 ref.)

MICROBIOLOGY

Purulent pericarditis caused by Candida species: case report and review. Schrank JH Jr, et al. **Clin Infect Dis** 1995 Jul; 21(1):182–7 (40 ref.)

PARASITOLOGY

Paragonimus mexicanus pericarditis: report of two cases and review of the literature. Saborio P, et al. **J Trop Med Hyg** 1995 Oct;98(5):316–8 (9 ref.)

PERICARDITIS, CONSTRICTIVE

CHEMICALLY INDUCED

Hydralazine-induced constrictive pericarditis. Franssen CF, et al. **Neth J Med** 1996 May;48(5):193–7 (21 ref.)

DIAGNOSIS

Chronic constrictive pericarditis presenting as mass lesion in infancy. Dharmapuran AK, et al. **Indian Heart J** 1996 May–Jun;48(3):290–1 (7 ref.)

[Dwarfism with constrictive pericarditis. A case report] Alonso Falcón F, et al. **An Esp Pediatr** 1996 Mar; 44(3):279–81 (9 ref.) **(Spa)**

ETIOLOGY

[Pericarditis and other cardiac disorders, late consequences of radiotherapy] Chappuis MA, et al. **Rev Med Suisse Romande** 1996 Jun;116(6):429–39 (25 ref.) **(Fre)**

PERICARDITIS, TUBERCULOUS

Tuberculous pericarditis in an HIV-infected patient. Antony SJ, et al. **Scand J Infect Dis** 1995;27(4):411–3 (26 ref.)

PERICARDIUM

Defibrillator patch electrode constriction: an underrecognized entity [see comments] Barrington WW, et al. **Ann Thorac Surg** 1995 Oct;60(4):1112–5; discussion 1115–6 (11 ref.) Comment in: Ann Thorac Surg 1996 Mar;61(3):1042.

Pericardial metastasis in carcinoma of the uterine cervix. Jamshed A, et al. **Gynecol Oncol** 1996 Jun;61(3):451–3 (16 ref.)

Non-immunological hydrops fetalis and intrapericardial teratoma: case report and review. Perez-Aytes A, et al. **Prenat Diagn** 1995 Sep;15(9):859–63 (20 ref.)

INJURIES

[Posttraumatic pericardial laceration and cleft of the anterior mitral leaflet] Venturini E, et al. **G Ital Cardiol** 1995 Aug; 25(8):1037–41 (11 ref.) (Eng. Abstr.) **(Ita)**

PATHOLOGY

Pericardial angiosarcoma after mediastinal irradiation for seminoma. A case report and a review of the literature. Killion MJ, et al. **Cancer** 1996 Aug 15;78(4):912–7 (30 ref.)

MR evaluation of the pericardium and cardiac malignancies. White CS. **Magn Reson Imaging Clin N Am** 1996 May; 4(2):237–51 (48 ref.)

MR evaluation of the pericardium. White CS. **Top Magn Reson Imaging** 1995 Fall;7(4):258–66 (32 ref.)

[Periaortic fibrosis with pericardial and perirenal involvement: apropos of a case] Cerisier A, et al. **Rev Med Interne** 1996;17(2):154–6 (11 ref.) (Eng. Abstr.) **(Fre)**

RADIATION EFFECTS

Pericardial angiosarcoma after mediastinal irradiation for seminoma. A case report and a review of the literature. Killion MJ, et al. **Cancer** 1996 Aug 15;78(4):912–7 (30 ref.)

PERICEMENTITIS see **PERIODONTITIS**

PERIDINIUM see **DINOFLAGELLIDA**

PERIDURAL INJECTIONS see **INJECTIONS, EPIDURAL**

PERILENE see **PERYLENE**

PERIMENOPAUSAL BONE LOSS see **OSTEOPOROSIS, POSTMENOPAUSAL**

PERIMENOPAUSE see **PREMENOPAUSE**

PERIMETRY

METHODS

Clirical alternative for reducing the time needed to perform automated threshold perimetry. Fingeret M. **J Am Optom Assoc** 1995 Nov;66(11):699–705 (14 ref.)

The Glenn A. Fry Award Lecture. Early losses of visual function in glaucoma. Johnson CA. **Optom Vis Sci** 1995 Jun;72(6):359–70 (67 ref.)

PERINATAL CARE

Management of labor and labor complications. Weinstein D, et al. **Curr Opin Obstet Gynecol** 1995 Dec;7(6):437–41 (37 ref.)

The regionalization of perinatal care in France—description of a missing policy. Papiernik E, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Aug;61(2):99–103 (40 ref.)

The impact of assisted reproduction on perinatal health care. Keirse MJ, et al. **Soz Praventivmed** 1995;40(6):343–51 (59 ref.)

LEGISLATION & JURISPRUDENCE

Interhospital transfers of obstetric patients under the Emergency Medical Treatment and Active Labor Act. Cardwell MS. **J Leg Med** 1995 Sep;16(3):357–72 (98 ref.)

METHODS

Neonatal considerations when birth occurs at home. Toepke ML, et al. **J Nurse Midwifery** 1995 Nov–Dec;40(6):529–33 (29 ref.)

STANDARDS

Drug treatment in the perinatal period and the risk of functional teratogenicity. Benešová O. **Arch Toxicol Suppl** 1996;18:89–96 (9 ref.)

PERINATAL MORTALITY see **INFANT MORTALITY**

PERINATAL NURSING see **NEONATAL NURSING**

PERINATOLOGY

see related
FETAL DISEASES
INFANT, NEWBORN, DISEASES
MATERNAL-CHILD NURSING
PERINATAL CARE
PREGNANCY COMPLICATIONS

ORGANIZATION & ADMINISTRATION

Perinatal management at the lower margin of viability. Rennie JM. **Arch Dis Child Fetal Neonatal Ed** 1996 May; 74(3):F214–8 (36 ref.)

TRENDS

The impact of recent advances in microbiology and immunology on perinatal and women's health care. Munro CL. **J Obstet Gynecol Neonatal Nurs** 1995 Jul–Aug; 24(6):525–31 (32 ref.)

PERINEUM

Aggressive angiomyxoma of the pelvis and perineum. A case report. Fishman A, et al. **J Reprod Med** 1995 Sep; 40(9):665–9 (16 ref.)

Peritoneographic diagnosis of perineal enterocele after hysterectomy. Tepetes K, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1995 Oct;163(4):367–8 (12 ref.)

Gangrene of the perineum. Benizri E, et al. **Urology** 1996 Jun;47(6):935–9 (36 ref.)

[Accessory scrotum with lipoma: a case report] Konya E, et al. **Hinyokika Kiyo** 1996 Mar;42(3):233–6 (28 ref.) (Eng. Abstr.) **(Jpn)**

ABNORMALITIES

Congenital posterior urethral perineal fistulae: a unique form of urethral duplication. Wagner JR, et al. **Urology** 1996 Aug;48(2):277–80 (12 ref.)

INJURIES

Preserving the pelvic floor and perineum during childbirth—elective caesarean section? Sultan AH, et al. **Br J Obstet Gynaecol** 1996 Aug;103(8):731–4 (21 ref.)

The relationship of episiotomy to third and fourth degree lacerations. Golden WE, et al. **J Ark Med Soc** 1996 Feb; 92(9):447–8 (15 ref.)

Benefits and risks of episiotomy: a review of the English-language literature since 1980. Part I. Woolley RJ. **Obstet Gynecol Surv** 1995 Nov;50(11):806–20 (189 ref.)

PHYSIOLOGY

Electromyography of the perineal floor. Siroky MB. **Urol Clin North Am** 1996 May;23(2):299–307 (16 ref.)

PERINEURIUM see **PERIPHERAL NERVES**

PERINEURONAL SATELLITE CELLS see **OLIGODENDROGLIA**

PERIODIC DISEASE

Children with hyperimmunoglobulinemia D and periodic fever syndrome. Grose C, et al. **Pediatr Infect Dis J** 1996 Jan;15(1):72–7 (16 ref.)

[Update on familial Mediterranean fever] Zaglio A. **Rev Med Univ Navarra** 1995 Jul–Sep;39(3):153–63 (50 ref.) **(Spa)**

COMPLICATIONS

[Hyperimmunoglobulinemia D or periodic fever syndrome. Cutaneous manifestations in 3 cases] Cartier H, et al. **Ann Dermatol Venereol** 1996;123(5):314–21 (34 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

[Colchicine in familial Mediterranean fever: practical problems and their solutions] Ben-Chetrit E, et al. **Harefuah** 1995 Nov 15;129(10):413–6 (31 ref.) **(Heb)**

PERIODICALS

A review of the statistical analysis used in papers published in Clinical Radiology and British Journal of Radiology. Goldin J, et al. **Clin Radiol** 1996 Jan;51(1):47–50 (33 ref.)

[Bibliometry of biomedical periodicals] Similowski T, et al. **Rev Mal Respir** 1995;12(6):543–50 (32 ref.) (Eng. Abstr.) **(Fre)**

[Writing and reading scientific texts] Kuss E, et al. **Geburtshilfe Frauenheilkd** 1995 Jul;55(7):414–24 (85 ref.) **(Ger)**

[The level of use of statistical data in articles in the Orvosi Hetilap] Vitrai J, et al. **Orv Hetil** 1996 Mar 3;137(9):465–72 (46 ref.) (Eng. Abstr.) **(Hun)**

[Knowing how to read a scientific article. 3. Knowing how to assess the natural history of a disease] Longo M, et al. **G Ital Cardiol** 1995 Aug;25(8):1067–75 (30 ref.) **(Ita)**

[The impact of our journals] Alvarez-Sala JL, et al. **Arch Bronconeumol** 1995 Oct;31(8):403–6 (19 ref.) **(Spa)**

STANDARDS

Medical reviews and the importance of being a "peer" in science. Beritic T. **Isr J Med Sci** 1996 Jul;32(7):573–5 (15 ref.)

STATISTICS & NUMERICAL DATA

A review of articles published in Aviation, Space, and Environmental Medicine, 1975–94. Rudge FW. **Aviat Space Environ Med** 1995 Oct;66(10):1005–9 (4 ref.)

TRENDS

A review of articles published in Aviation, Space, and Environmental Medicine, 1975–94. Rudge FW. **Aviat Space Environ Med** 1995 Oct;66(10):1005–9 (4 ref.)

The role of nursing journals in the advancement of professional nursing. Smith JP. **J Adv Nurs** 1996 Jan; 23(1):12–6 (7 ref.)

PERIODICITY

see related
BIOLOGICAL CLOCKS
CIRCADIAN RHYTHM

Thyrotoxic periodic paralysis associated with hypokalemia and hypophosphatemia. Norris KC, et al. **Am J Kidney Dis** 1996 Aug;28(2):270–3 (28 ref.)

Chaos and complexity. Can it help us to understand mood and behavior? Ehlers CL. **Arch Gen Psychiatry** 1995 Nov; 52(11):960–4 (57 ref.)

Population cycles in northern small mammals. Norrdahl K. **Biol Rev Camb Philos Soc** 1995 Nov;70(4):621–37 (147 ref.)

Interactions among neural networks for behavior. Dickinson PS. **Curr Opin Neurobiol** 1995 Dec;5(6):792–8 (48 ref.)

Spontaneous episodic release of adenohypophyseal hormones in hypothalamic amenorrhea. Genazzani AD, et al. **Gynecol Endocrinol** 1995 Dec;9(4):325–34 (63 ref.)

PERIODICITY

Fast rhythms in the hippocampus are a part of the diffuse gamma-response system [letter] Başar E, et al. **Hippocampus** 1995;5(3):240-1 (14 ref.)
Management of cyclic vomiting syndrome. Fleisher DR. **J Pediatr Gastroenterol Nutr** 1995;21 Suppl 1:S52-6 (20 ref.)
The cyclic vomiting syndrome described. Fleisher DR. **J Pediatr Gastroenterol Nutr** 1995;21 Suppl 1:S1-5 (7 ref.)
Differential diagnosis of cyclic vomiting syndrome. Forbes D. **J Pediatr Gastroenterol Nutr** 1995;21 Suppl 1:S11-4 (42 ref.)
Prophylactic therapy in cyclic vomiting syndrome. Forbes D, et al. **J Pediatr Gastroenterol Nutr** 1995;21 Suppl 1:S57-9 (7 ref.)
Metabolic etiologies of cyclic or recurrent vomiting. Korson M. **J Pediatr Gastroenterol Nutr** 1995;21 Suppl 1:S15-9 (11 ref.)
Cyclic vomiting: the pattern and syndrome paradigm. Li BU. **J Pediatr Gastroenterol Nutr** 1995;21 Suppl 1:S6-10 (11 ref.)
Psychophysiologic treatment of cyclic vomiting. Magagna J. **J Pediatr Gastroenterol Nutr** 1995;21 Suppl 1:S31-6 (10 ref.)
The role of the paraventricular system in the pathogenesis of cyclic vomiting. Pasricha PJ. **J Pediatr Gastroenterol Nutr** 1995;21 Suppl 1:S29-30 (26 ref.)
The relationship between cyclic vomiting syndrome and abdominal migraine. Symon DN, et al. **J Pediatr Gastroenterol Nutr** 1995;21 Suppl 1:S42-3 (18 ref.)
Neuroendocrine dysrhythmias. Elks ML. **Med Hypotheses** 1995 May;44(5):319-24 (43 ref.)
Spontaneous periodic hypothermia. Kloos RT. **Medicine (Baltimore)** 1995 Sep;74(5):268-80 (131 ref.)
Issues associated with repeated neuropsychological assessments. McCaffrey RJ, et al. **Neuropsychol Rev** 1995 Sep;5(3):203-21 (55 ref.)
Modulation of pulsatile GH release through a novel receptor in hypothalamus and pituitary gland. Smith RG, et al. **Recent Prog Horm Res** 1996;51:261-85; discussion 285-6 (59 ref.)
[Cyclic strabismus. Presentation of two new cases and critical review of the literature] Tapiero B, et al. **J Fr Ophtalmol** 1995;18(6-7):411-20 (50 ref.) (Eng. Abstr.) **(Fre)**
[Ecology, adaptation and biorhythms] Agadzhanian NA, et al. **Aviakosm Ekolog Med** 1995;29(3):16-9 (17 ref.) (Eng. Abstr.) **(Rus)**
[The participation of the respiration in the rhythmic interactions in the body] Malkin VB, et al. **Usp Fiziol Nauk** 1996 Apr-Jun;27(2):61-77 (131 ref.) (Eng. Abstr.) **(Rus)**
[The individual manifestations of respiratory rhythms] Malkin VB, et al. **Usp Fiziol Nauk** 1996 Jan-Mar;27(1):87-99 (68 ref.) (Eng. Abstr.) **(Rus)**
[World cholera pandemics as mono- and polycyclic phenomena] Arutiunov IuI. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Mar-Apr; (2):113-7 (26 ref.) **(Rus)**
[The epiphysis in reproduction (the diapause and the sexual cycle)] Pérez Pérez F. **An R Acad Nac Med (Madr)** 1995; 112(2):383-406 (27 ref.) **(Spa)**

PERIODONTAL ABSCESS

COMPLICATIONS

Uncommon complications of odontogenic infections. Ferrera PC, et al. **Am J Emerg Med** 1996 May;14(3):317-22 (49 ref.)

PERIODONTAL BONE LOSS see **ALVEOLAR BONE LOSS**

PERIODONTAL CYST, APICAL see **RADICULAR CYST**

PERIODONTAL DISEASES

Periodontal diseases affecting children and young adults. Debevc TM, et al. **J Can Dent Assoc** 1996 Aug;62(8):650-2, 655-6 (33 ref.)
Periodontal diseases of children and adolescents. **J Periodontol** 1996 Jan;67(1):57-62 (112 ref.)
[Relation between interleukin-1 and periodontal diseases] Zou S. **Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao** 1995 Jun; 17(3):234-6 (21 ref.) **(Chi)**

COMPLICATIONS

Diabetes and periodontal diseases. **J Periodontol** 1996 Feb; 67(2):166-76 (127 ref.)

DIAGNOSIS

Periodontal diagnosis in treated periodontitis. Why, when and how to use clinical parameters. Lang NP, et al. **J Clin Periodontol** 1996 Mar;23(3 Pt 2):240-50 (102 ref.)
Understanding diagnostic testing for periodontal diseases. Greenstein G, et al. **J Periodontol** 1995 Aug;66(8):659-66 (22 ref.)
Benign mucous membrane pemphigoid with advanced periodontal involvement: diagnosis and therapy [see comments] Lilly JP, et al. **J Periodontol** 1995 Aug; 66(8):737-41 (20 ref.) Comment in: J Periodontol 1995 Aug;66(8):747-8.

DRUG THERAPY

Principles of pharmacologic intervention. Goodson JM. **J Clin Periodontol** 1996 Mar;23(3 Pt 2):268-72 (17 ref.)
Local and systemic chemotherapy in the management of periodontal disease: an opinion and review of the concept. Addy M, et al. **J Oral Rehabil** 1996 Apr;23(4):219-31 (101 ref.)
Clinical significance of bacterial resistance to tetracyclines in the treatment of periodontal diseases. Greenstein G. **J Periodontol** 1995 Nov;66(11):925-32 (72 ref.)
Benign mucous membrane pemphigoid with advanced periodontal involvement: diagnosis and therapy [see comments] Lilly JP, et al. **J Periodontol** 1995 Aug; 66(8):737-41 (20 ref.) Comment in: J Periodontol 1995 Aug;66(8):747-8.

ETIOLOGY

Tobacco use and the periodontal patient. **J Periodontol** 1996 Jan;67(1):51-6 (97 ref.)
Periodontal and microbiological changes associated with the placement of orthodontic appliances. A review. Atack NE, et al. **J Periodontol** 1996 Feb;67(2):78-85 (61 ref.)
[The pathogenesis of and treatment principles in functional overload of the periodontium] Kalamkarov KhA. **Stomatologiia (Mosk)** 1995;74(3):44-51 (78 ref.) (Eng. Abstr.) **(Rus)**

GENETICS

Genetic influences in caries and periodontal diseases. Hassell TM, et al. **Crit Rev Oral Biol Med** 1995;6(4):319-42 (203 ref.)

MICROBIOLOGY

The biochemical milieu of the host in the selection of anaerobic species in the oral cavity. Shah HN, et al. **Clin Infect Dis** 1995 Jun;20 Suppl 2:S291-300 (59 ref.)
Taxonomy, biology, and periodontal aspects of Fusobacterium nucleatum. Bolstad AI, et al. **Clin Microbiol Rev** 1996 Jan;9(1):55-71 (319 ref.)
Microbiological monitoring. Mombelli A. **J Clin Periodontol** 1996 Mar;23(3 Pt 2):251-7 (95 ref.)

PREVENTION & CONTROL

Evaluation of clinical trials of agents and procedures to prevent caries and periodontal disease: choosing products and recommending procedures. Addy M. **Int Dent J** 1995 Jun;45(3):185-96 (57 ref.)
Rationale of mechanical plaque control. Westfelt E. **J Clin Periodontol** 1996 Mar;23(3 Pt 2):263-7 (54 ref.)

SURGERY

Periodontal regenerative potential of space-providing expanded polytetrafluoroethylene membranes and recombinant human bone morphogenetic proteins. Sigurdsson TJ, et al. **J Periodontol** 1995 Jun;66(6):511-21 (37 ref.)
The potential role of bone morphogenetic proteins in periodontal reconstruction. Wozney JM. **J Periodontol** 1995 Jun;66(6):506-10 (34 ref.)

THERAPY

Periodontal and soft-tissue abnormalities. Delaney JE. **Dent Clin North Am** 1995 Oct;39(4):837-50 (14 ref.)
Regenerative therapy. The future of periodontics. Breault MR, et al. **N Y State Dent J** 1995 Dec;61(10):34-7 (0 ref.)
[The pathogenesis of and treatment principles in functional overload of the periodontium] Kalamkarov KhA. **Stomatologiia (Mosk)** 1995;74(3):44-51 (78 ref.) (Eng. Abstr.) **(Rus)**

PERIODONTAL INDEX

[Oral disease epidemiologic illness indices and oral health measures--traditional concepts are supplemented by new socio-dental indicators] Strippel H. **Gesundheitswesen** 1996 Mar;58(3):162-8 (50 ref.) (Eng. Abstr.) **(Ger)**

PERIODONTAL LIGAMENT

CYTOLOGY

Expression and role of epidermal growth factor receptors during differentiation of cementoblasts, osteoblasts, and periodontal ligament fibroblasts in the rat. Cho MI, et al. **Anat Rec** 1996 Jun;245(2):342-60 (69 ref.)
Periodontal ligament cell population: the central role of fibroblasts in creating a unique tissue. Lekic P, et al. **Anat Rec** 1996 Jun;245(2):327-41 (190 ref.)

PHYSIOLOGY

Implications of cellular and molecular biology advances in periodontal regeneration. Amar S. **Anat Rec** 1996 Jun; 245(2):361-73 (137 ref.)
The potential role of growth and differentiation factors in periodontal regeneration. **J Periodontol** 1996 May; 67(5):545-53 (128 ref.)

SURGERY

Cerebral abscess complicating dental treatment. Case report and review of the literature. Renton TF, et al. **Aust Dent J** 1996 Feb;41(1):12-5 (32 ref.)

PERIODONTAL RESORPTION see **ALVEOLAR BONE LOSS**

PERIODONTICS

[Maintenance therapy: an indispensible complement to periodontal treatment and the surgical implant] Fanali S, et al. **Minerva Stomatol** 1995 May;44(5):245-55 (89 ref.) (Eng. Abstr.) **(Ita)**

METHODS

[The GTR technic within the framework of combined periodontal-orthodontic treatments. A case report] Stelzel M, et al. **Fortschr Kieferorthop** 1995 Nov;56(6):347-52 (28 ref.) (Eng. Abstr.) **(Ger)**

PERIODONTITIS

IMMUNOLOGY

Host response assessment in recurring periodontitis. Ebersole JL, et al. **J Clin Periodontol** 1996 Mar;23(3 Pt 2):258-62 (22 ref.)

PREVENTION & CONTROL

Long-term periodontal maintenance in private practice. Nevins M. **J Clin Periodontol** 1996 Mar;23(3 Pt 2):273-7 (41 ref.)

PSYCHOLOGY

Psychosocial factors in inflammatory periodontal diseases. A review. da Silva AM, et al. **J Clin Periodontol** 1995 Jul; 22(7):516-26 (103 ref.)

SURGERY

Bone allografts in periodontal therapy. Mellonig JT. **Clin Orthop** 1996 Mar;(324):116-25 (84 ref.)

THERAPY

Risk assessment of recurrence of disease during supportive periodontal care. Epidemiological considerations. Ainamo J, et al. **J Clin Periodontol** 1996 Mar;23(3 Pt 2):232-9 (141 ref.)
Refractory periodontitis: critical questions in clinical management. Kornman KS. **J Clin Periodontol** 1996 Mar; 23(3 Pt 2):293-8 (48 ref.)
Periodontal diagnosis in treated periodontitis. Why, when and how to use clinical parameters. Lang NP, et al. **J Clin Periodontol** 1996 Mar;23(3 Pt 2):240-50 (102 ref.)
Refractory periodontitis or recurrence of disease. Magnusson I, et al. **J Clin Periodontol** 1996 Mar;23(3 Pt 2):289-92 (23 ref.)

PERIODONTITIS, APICAL see **PERIAPICAL PERIODONTITIS**

PERIODONTITIS, APICAL, SUPPURATIVE see **PERIAPICAL ABSCESS**

PERIODONTITIS, JUVENILE see **PERIODONTOSIS**

PERIODONTIUM

PHYSIOLOGY

Devices for dentoalveolar regeneration: an up-to-date literature review. Hardwick R, et al. **J Periodontol** 1995 Jun;66(6):495-505 (58 ref.)
Periodontal regenerative potential of space-providing expanded polytetrafluoroethylene membranes and recombinant human bone morphogenetic proteins. Sigurdsson TJ, et al. **J Periodontol** 1995 Jun;66(6):511-21 (37 ref.)

PHYSIOPATHOLOGY

[The pathogenesis of and treatment principles in functional overload of the periodontium] Kalamkarov KhA. **Stomatologiia (Mosk)** 1995;74(3):44-51 (78 ref.) (Eng. Abstr.) **(Rus)**

PERIODONTIUM, APICAL see **PERIAPICAL TISSUE**

PERIODONTOSIS

MICROBIOLOGY

Virulence factors of Actinobacillus actinomycetemcomitans relevant to the pathogenesis of inflammatory periodontal diseases. Wilson M, et al. **FEMS Microbiol Rev** 1995 Dec; 17(4):365-79 (108 ref.)

PERIOPERATIVE NURSING

see related
OPERATING ROOM NURSING

Surgical treatment of patients with open tibial fractures. Brown C, et al. **AORN J** 1996 May;63(5):875–81, 885–96; quiz 899–906 (31 ref.)

Multiple subpial transection for Landau–Kleffner syndrome. Buelow JM, et al. **AORN J** 1996 Apr;63(4):727–9, 732–5, 737–9; quiz 741–4 (26 ref.)

Traumatic rupture of the descending thoracic aorta. Butler KL, et al. **AORN J** 1996 May;63(5):917–25 (32 ref.)

Arthroscopic rotator cuff repairs using suture anchors. Farrall LA. **AORN J** 1995 Nov;62(5):739–46, 748, 750; quiz 754, 756–8 (18 ref.)

Dental restorations using titanium osseointegrated dental implants. McEwen DR, et al. **AORN J** 1995 Aug; 62(2):189–91, 193–8, 201–5; quiz 207–9 (14 ref.)

Surgical management of patients with severe head injuries. Pieper DR, et al. **AORN J** 1996 May;63(5):854–64, 867 (29 ref.)

Management of upper abdominal solid organ injuries. Richardson JD, et al. **AORN J** 1996 May;63(5):907–16 (15 ref.)

Separation of conjoined twins. Wirt SW, et al. **AORN J** 1995 Oct;62(4):527–40, 543–5; quiz 546–50 (25 ref.)

HISTORY

A historical decline of educational perioperative clinical experiences. Wagner VD, et al. **AORN J** 1995 Nov; 62(5):771–2, 775–80, 782 (46 ref.)

LEGISLATION & JURISPRUDENCE

Becoming knowledgeable in the legislative process can help nurses shape their own future. Porter J, et al. **AORN J** 1996 Mar;63(3):618–21; quiz 622–4 (0 ref.)

METHODS

Leech therapy in digital replantation. Golden MA, et al. **AORN J** 1995 Sep;62(3):364–6, 369, 371–2, passim (0 ref.)

Intraoperative positioning of surgical patients. McEwen DR. **AORN J** 1996 Jun;63(6):1059–63, 1066–79; quiz 1080–6 (38 ref.)

ORGANIZATION & ADMINISTRATION

The perioperative nurse's role in anesthesia management. Stein RH. **AORN J** 1995 Nov;62(5):794–8, 801, 803–4 (21 ref.)

PERIOSTEUM

PATHOLOGY

Periosteal ganglion: a report of three new cases including MRI findings and a review of the literature. Okada K, et al. **Skeletal Radiol** 1996 Feb;25(2):153–7 (14 ref.)

PERIOSTITIS

DIAGNOSIS

Periosteal ganglion: a report of three new cases including MRI findings and a review of the literature. Okada K, et al. **Skeletal Radiol** 1996 Feb;25(2):153–7 (14 ref.)

ETIOLOGY

Periostitis of the upper extremity: a report of 2 cases and literature review. Meese MA, et al. **Clin Orthop** 1996 Mar; (324):222–6 (17 ref.)

SURGERY

A retrospective comparison of endoscopic plantar fasciotomy to open plantar fasciotomy with heel spur resection for chronic plantar fasciitis/heel spur syndrome. Tomczak RL, et al. **J Foot Ankle Surg** 1995 May–Jun;34(3):305–11 (41 ref.)

PERIPHERAL ANGIOPATHIES see **PERIPHERAL VASCULAR DISEASES**

PERIPHERAL CATHETERIZATION see **CATHETERIZATION, PERIPHERAL**

PERIPHERAL EQUIPMENT, COMPUTER see **COMPUTER PERIPHERALS**

PERIPHERAL NERVE DISEASES see **PERIPHERAL NERVOUS SYSTEM DISEASES**

PERIPHERAL NERVE NEOPLASMS

Paraganglioma of the cauda equina. A case report and review of the literature. Bak J, et al. **APMIS** 1996 Mar; 104(3):234–40 (29 ref.)

CHEMISTRY

Peripheral nerve sheath neoplasms. Clinicopathologic and immunochemical observations. Swanson PE, et al. **Pathol Annu** 1995;30 Pt 2:1–82 (500 ref.)

METABOLISM

Expression of the CD44 adhesion molecule in tumours of the central and peripheral nervous system. Baltuch GH, et al. **J Neurooncol** 1995 Dec;26(3):191–8 (62 ref.)

PATHOLOGY

Pathology of the major peripheral nerve sheath neoplasms. Woodruff JM. **Monogr Pathol** 1996;38:129–61 (67 ref.)

Purely epithelioid schwannoma. Two case reports and a review of the literature. Artico M, et al. **Neurochirurgie** 1996;42(1):61–5 (20 ref.)

Peripheral nerve sheath neoplasms. Clinicopathologic and immunochemical observations. Swanson PE, et al. **Pathol Annu** 1995;30 Pt 2:1–82 (500 ref.)

SECONDARY

Diagnosis and management of brachial plexus lesions in cancer patients. Kori SH. **Oncology (Huntingt)** 1995 Aug; 9(8):756–60; discussion 765 (31 ref.)

Intradural metastasis to the cauda equina from carcinoma of the anus. Cho DY, et al. **Spine** 1995 Nov 1;20(21):2341–4 (15 ref.)

THERAPY

Diagnosis and management of brachial plexus lesions in cancer patients. Kori SH. **Oncology (Huntingt)** 1995 Aug; 9(8):756–60; discussion 765 (31 ref.)

PERIPHERAL NERVES

see related
NERVE FIBERS

Anatomy, function, and pathophysiology of peripheral nerves and nerve compression. Lundborg G, et al. **Hand Clin** 1996 May;12(2):185–93 (77 ref.)

ANATOMY & HISTOLOGY

Anatomic considerations of the peripheral nerve in compressive neuropathies of the upper extremity. George V, et al. **Orthop Clin North Am** 1996 Apr;27(2):211–8 (22 ref.)

BLOOD SUPPLY

Vasculitic neuropathy. Fathers E, et al. **Br J Hosp Med** 1996 May 15–Jun 4;55(10):643–7 (28 ref.)

CHEMISTRY

Structure and function of peripheral nerve myelin proteins. Uyemura K, et al. **Prog Brain Res** 1995;105:311–8 (27 ref.)

GROWTH & DEVELOPMENT

Regulatory role of ATP at developing neuromuscular junctions. Fu WM. **Prog Neurobiol** 1995 Sep;47(1):31–44 (101 ref.)

INJURIES

Paradoxical clinical consequences of peripheral nerve injury: a review of anatomical, neurophysiological and psychological mechanisms. McAllister RM, et al. **Br J Plast Surg** 1995 Sep;48(6):384–95 (159 ref.)

Peripheral nerve injury and regeneration. Terenghi G. **Histol Histopathol** 1995 Jul;10(3):709–18 (71 ref.)

Pain due to nerve damage: are inflammatory mediators involved? Tracey DJ, et al. **Inflamm Res** 1995 Oct; 44(10):407–11 (67 ref.)

Prospects for the treatment of spinal cord and peripheral nerve injury [editorial] Hems TE, et al. **J Bone Joint Surg Br** 1996 Mar;78(2):176–7 (18 ref.)

Nerve wound healing. An overview. Wong BJ, et al. **Otolaryngol Clin North Am** 1995 Oct;28(5):881–95 (130 ref.)

Neurotrophins and nerve injury in the adult. Verge VM, et al. **Philos Trans R Soc Lond B Biol Sci** 1996 Mar 29; 351(1338):423–30 (57 ref.)

[Recovery processes in interrupted peripheral nerves] Jennekens FG, et al. **Ned Tijdschr Geneeskd** 1996 Feb 17; 140(7):348–52 (23 ref.) **(Dut)**

[Anterior interosseus syndrome from the surgical viewpoint] Axmann HD, et al. **Nervenarzt** 1995 Aug;66(8):610–3 (44 ref.) (Eng. Abstr.) **(Ger)**

[Principles of surgical treatment of war injuries of the peripheral nerves] Roganović Z, et al. **Vojnosanit Pregl** 1995 Sep–Oct;52(5):483–7 (52 ref.) **(Scr)**

PATHOLOGY

Nerve biopsy. Vallat JM, et al. **Curr Opin Neurol** 1995 Oct; 8(5):345–8 (24 ref.)

PHYSIOLOGY

Axonal regeneration. Brecknell JE, et al. **Biol Rev Camb Philos Soc** 1996 May;71(2):227–55 (260 ref.)

Nerve regeneration. Pollock M. **Curr Opin Neurol** 1995 Oct; 8(5):354–8 (33 ref.)

Biomechanical properties of peripheral nerves. Grewal R, et al. **Hand Clin** 1996 May;12(2):195–204 (63 ref.)

Regulatory role of ATP at developing neuromuscular junctions. Fu WM. **Prog Neurobiol** 1995 Sep;47(1):31–44 (101 ref.)

[The factors supporting peripheral nerve regeneration] Chelyshev IuA. **Usp Fiziol Nauk** 1995 Jul–Sep;26(3):57–77 (220 ref.) (Eng. Abstr.) **(Rus)**

[Degeneration and regeneration of the peripheral nervous system with aging] Verdú E, et al. **Rev Neurol** 1995 May–Jun;23(121):648–55 (98 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

The leprosy granuloma in nerve: summary of recent work. Ridley MJ. **Indian J Lepr** 1996 Jan–Mar;68(1):93–4 (5 ref.)

Assessment of nerve function under field conditions and its usefulness in leprosy. van Brakel WH. **Indian J Lepr** 1996 Jan–Mar;68(1):119–25 (33 ref.)

Dynamics and pathophysiology of nerve compression in the upper extremity. Delfiner JS. **Orthop Clin North Am** 1996 Apr;27(2):219–26 (25 ref.)

SURGERY

Chromaffin cell survival and host dopaminergic fiber recovery in a patient with Parkinson's disease treated by cografts of adrenal medulla and pretransected peripheral nerve. Case report. Date I, et al. **J Neurosurg** 1996 Apr; 84(4):685–9 (33 ref.)

TRANSPLANTATION

Nerve allotransplantation following severe tibial nerve injury. Case report. Mackinnon SE. **J Neurosurg** 1996 Apr; 84(4):671–6 (67 ref.)

[Nerve transplantation in the central nervous system: a strategy for inducing nerve fiber regeneration in lesions of the brain and spinal cord] Gauthier P, et al. **Rev Neurol (Paris)** 1996 Feb;152(2):106–15 (62 ref.) (Eng. Abstr.) **(Fre)**

PERIPHERAL NERVOUS SYSTEM

see related
NEURAL PATHWAYS

CHEMISTRY

Molecular anatomy and genetics of myelin proteins in the peripheral nervous system. Snipes GJ, et al. **J Anat** 1995 Jun;186 (Pt 3):483–94 (120 ref.)

DRUG EFFECTS

Neurosteroids: synthesis and functions in the central and peripheral nervous systems. Schumacher M, et al. **Ciba Found Symp** 1995;191:90–106; discussion 106–12 (50 ref.)

Involvement of cytoskeletal proteins in the mechanisms of organophosphorus ester-induced delayed neurotoxicity. Abou-Donia MB. **Clin Exp Pharmacol Physiol** 1995 May; 22(5):358–9 (5 ref.)

IMMUNOLOGY

Autoimmunity in the peripheral nervous system. Hartung HP, et al. **Baillieres Clin Neurol** 1996 Mar;5(1):1–45 (310 ref.)

METABOLISM

[Pulmonary and pulmonary-related reflexes mediated by serotonin receptors in the peripheral nervous system] Yoshioka M. **Nippon Yakurigaku Zasshi** 1995 Nov; 106(5):311–20 (49 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Animal model for leprous neuropathy: our contribution. Shetty VP, et al. **Indian J Lepr** 1996 Jan–Mar;68(1):95–104 (28 ref.)

PHYSIOLOGY

Role of peripheral autonomic neurones in maintaining adequate cardiac function. Horackova M, et al. **Cardiovasc Res** 1995 Sep;30(3):326–35 (88 ref.)

Peripheral nerve injury and regeneration. Terenghi G. **Histol Histopathol** 1995 Jul;10(3):709–18 (71 ref.)

Is there a third peripheral catecholaminergic system? Endogenous dopamine as an autocrine/paracrine substance derived from plasma DOPA and inactivated by conjugation. Goldstein DS, et al. **Hypertens Res** 1995 Jun; 18 Suppl 1:S93–9 (76 ref.)

The cell biology of myelin degeneration and regeneration in the peripheral nervous system. Goodrum JF, et al. **J Neuropathol Exp Neurol** 1996 Sep;55(9):943–53 (47 ref.)

PHYSIOPATHOLOGY

Neurobiology of muscle fatigue. Advances and issues. Gandevia SC, et al. **Adv Exp Med Biol** 1995;384:515–25 (31 ref.)

PERIPHERAL NERVOUS SYSTEM DISEASES

see related
NEUROMUSCULAR DISEASES
SPINAL CORD DISEASES

Multifocal motor neuropathy and chronic inflammatory

demyelinating polyradiculoneuropathy. Léger JM. **Curr Opin Neurol** 1995 Oct;8(5):359–63 (23 ref.)
[Peripheral neuropathies: diagnosis and treatment] Suárez GA. **Rev Neurol** 1996 Jun;24(130):676–90 (6 ref.) **(Spa)**

CHEMICALLY INDUCED

Drug-induced neuropathies. Windebank AJ. **Baillieres Clin Neurol** 1995 Nov;4(3):529–73 (170 ref.)
Toxic neuropathies. Mizisin AP, et al. **Curr Opin Neurol** 1995 Oct;8(5):367–71 (33 ref.)
Neuropathy target esterase (NTE) and organophosphorus-induced delayed polyneuropathy (OPIDP): recent advances. Johnson MK, et al. **Toxicol Lett** 1995 Dec;82–83:459–63 (24 ref.)

COMPLICATIONS

Peripheral neuropathy: an often-overlooked cause of falls in the elderly. Richardson JK, et al. **Postgrad Med** 1996 Jun;99(6):161–72 (20 ref.)
Peripheral neuropathy and peripheral nerve injury. Nickell K, et al. **Urol Clin North Am** 1996 Aug;23(3):491–500 (93 ref.)
[Neurogenic muscle hypertrophy: 3 cases] Deffond D, et al. **Rev Neurol (Paris)** 1996 Apr;152(4):272–8 (45 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Critical-illness polyneuropathy complicating cardiac operation. Alhan HC, et al. **Ann Thorac Surg** 1996 Apr; 61(4):1237–9 (8 ref.)
Magnetic stimulation in the assessment of peripheral nerve disorders. Benecke R. **Baillieres Clin Neurol** 1996 Mar; 5(1):115–28 (37 ref.)
Tropical neuropathies. Román GC. **Baillieres Clin Neurol** 1995 Nov;4(3):469–87 (63 ref.)
Immune neuropathies in childhood. Sladky JT. **Baillieres Clin Neurol** 1996 Mar;5(1):233–44 (31 ref.)
Immunocytochemistry as a diagnostic tool. Stoll G. **Baillieres Clin Neurol** 1996 Mar;5(1):129–42 (54 ref.)
Undiagnosed neuropathies: the impact of ancillary investigations. Thomas PK. **Baillieres Clin Neurol** 1996 Mar;5(1):157–70 (58 ref.)
Electron microscopy as a tool to diagnose neuropathies. Vallat JM. **Baillieres Clin Neurol** 1996 Mar;5(1):143–56 (8 ref.)
Leprous neuropathies. Waters MF, et al. **Baillieres Clin Neurol** 1996 Mar;5(1):171–97 (61 ref.)
DNA diagnostics for Charcot-Marie-Tooth disease and related inherited neuropathies [editorial; comment] Lupski JR. **Clin Chem** 1996 Jul;42(7):995–8 (46 ref.) Comment on: Clin Chem 1996 Jul;42(7):1021–5.
Electrodiagnosis. Sheean GL, et al. **Curr Opin Neurol** 1995 Oct;8(5):339–44 (29 ref.)
The clinical significance of the communicating branches of the somatic sensory supply of the middle and external ear. Grey P. **J Laryngol Otol** 1995 Dec;109(12):1141–5 (35 ref.)
Laboratory testing in peripheral nerve disease. Griffin JW, et al. **Neurol Clin** 1996 Feb;14(1):119–33 (58 ref.)
[Atypical entrapment syndrome of the distal suprascapular nerve of the incisura scapulae. Case report and overview of the literature] Röhrich E, et al. **Nervenarzt** 1995 Aug; 66(8):638–42 (28 ref.) (Eng. Abstr.) **(Ger)**
[Electrophysiological diagnosis and therapy of peripheral nerve demyelinating diseases] Kimura J. **Nippon Naika Gakkai Zasshi** 1996 Mar 10;85(3):389–92 (10 ref.) **(Jpn)**
[Diabetic neuropathy: overview of clinical problems] Czech A, et al. **Pol Tyg Lek** 1996 Jan;51(1–5):33–4 (11 ref.) **(Pol)**

DRUG THERAPY

Drug trials in neuropathy. Hughes RA, et al. **Baillieres Clin Neurol** 1995 Nov;4(3):607–27 (87 ref.)
Drugs to treat the tissue complications of diabetes: peripheral neuropathy. Emanuele NV, et al. **Compr Ther** 1995 Oct; 21(10):579–82 (30 ref.)

EPIDEMIOLOGY

Epidemiology of peripheral neuropathy [editorial] Hughes RA. **Curr Opin Neurol** 1995 Oct;8(5):335–8 (22 ref.)

ETIOLOGY

Neuritic leprosy: further progression and significance. Mishra B, et al. **Acta Leprol** 1995;9(4):187–94 (28 ref.)
Lumbosacral plexopathy after gynecologic surgery: case report and review of the literature. Alsever JD. **Am J Obstet Gynecol** 1996 Jun;174(6):1769–77; discussion 1777–8 (32 ref.)
Lyme borreliosis neuropathy. A case report. Deltombe T, et al. **Am J Phys Med Rehabil** 1996 Jul–Aug;75(4):314–6 (21 ref.)
Central and peripheral nervous complications of dental treatment. Rosaitti EO. **Arq Neuropsiquiatr** 1995 Sep; 53(3–A):513–7 (33 ref.)
Neurotrophic factors in the therapy of peripheral neuropathy. Apfel SC, et al. **Baillieres Clin Neurol** 1995 Nov; 4(3):593–606 (70 ref.)
Toxic neuropathies and their treatment. Ludolph AC, et al. **Baillieres Clin Neurol** 1995 Nov;4(3):505–27 (75 ref.)
Paraneoplastic peripheral neuropathy. Senitt PS, et al. **Baillieres Clin Neurol** 1995 Nov;4(3):443–68 (120 ref.)
Cytotoxic T lymphocytes and HIV-1 related neurologic disorders. Kalams SA, et al. **Curr Top Microbiol Immunol** 1995;202:79–88 (51 ref.)
Cryoglobulinemia: recent findings in cutaneous and extracutaneous manifestations. Davis MD, et al. **Int J Dermatol** 1996 Apr;35(4):240–8 (50 ref.)
Partial unilateral phrenic nerve paralysis caused by a large intrathoracic goitre. van Doorn LG, et al. **Neth J Med** 1996 Jun;48(6):216–9 (3 ref.)
Neurotrophins and peripheral neuropathy. Anand P. **Philos Trans R Soc Lond B Biol Sci** 1996 Mar 29; 351(1338):449–54 (55 ref.)
Peripheral nerve disorders in electrical and lightning injuries. Wilbourn AJ. **Semin Neurol** 1995 Sep;15(3):241–55 (95 ref.)
[Nervous microangiopathy and POEMS syndrome] Maillot F, et al. **Rev Med Interne** 1995;16(12):934–7 (12 ref.) (Eng. Abstr.) **(Fre)**
[Peripheral neuropathies in HIV infection] Gastaut JL. **Rev Neurol (Paris)** 1995 Oct;151(10):532–40 (96 ref.) **(Fre)**
[Conduction blocks and peripheral neuropathies] Kuntzer T, et al. **Rev Neurol (Paris)** 1995 Jun–Jul;151(6–7):368–82 (163 ref.) (Eng. Abstr.) **(Fre)**
[Neuro-psychiatric involvement in primary Sjögren's syndrome] Sagawa A, et al. **Nippon Rinsho** 1995 Oct; 53(10):2563–7 (13 ref.) (Eng. Abstr.) **(Jpn)**
[Progressive neuronal degeneration and childhood cirrhosis] Kumada S, et al. **Ryoikibetsu Shokogun Shirizu** 1995; (8):442–5 (15 ref.) **(Jpn)**

GENETICS

Absence makes the search grow longer [editorial; comment] Dobyns WB. **Am J Hum Genet** 1996 Jan;58(1):7–16 (121 ref.) Comment on: Am J Hum Genet 1996 Jan;58(1):28–34.
Molecular genetics of peripheral neuropathies. Harding AE. **Baillieres Clin Neurol** 1995 Nov;4(3):383–400 (100 ref.)
The molecular basis of the neuropathies of mouse and human. Snipes GJ, et al. **Prog Brain Res** 1995;105:319–25 (29 ref.)
X-linked dominant Charcot-Marie-Tooth disease and other potential gap-junction diseases of the nervous system [see comments] Spray DC, et al. **Trends Neurosci** 1995 Jun; 18(6):256–62 (92 ref.) Comment in: Trends Neurosci 1995 Dec;18(12):520–1.

IMMUNOLOGY

Immunological investigation. O'Leary C, et al. **Curr Opin Neurol** 1995 Oct;8(5):349–53 (42 ref.)
Leprous neuropathy as an autoimmune phenomenon. Desikan P. **Indian J Lepr** 1996 Jan–Mar;68(1):15–21 (34 ref.)

PATHOLOGY

Peripheral neuropathies and neurotrophic factors: animal models and clinical perspectives. McMahon SB, et al. **Curr Opin Neurobiol** 1995 Oct;5(5):616–24 (77 ref.)
Nerve biopsy. Vallat JM, et al. **Curr Opin Neurol** 1995 Oct; 8(5):345–8 (24 ref.)

PHYSIOPATHOLOGY

Fatigue brought on by malfunction of the central and peripheral nervous systems. McComas AJ, et al. **Adv Exp Med Biol** 1995;384:495–512 (59 ref.)
Wallerian degeneration in peripheral nerve disease. Griffin JW, et al. **Baillieres Clin Neurol** 1996 Mar;5(1):65–75 (99 ref.)
Neuritic leprosy. Girdhar BK. **Indian J Lepr** 1996 Jan–Mar; 68(1):35–42 (22 ref.)
Nerve in reversal reaction. Job CK. **Indian J Lepr** 1996 Jan–Mar;68(1):43–7 (11 ref.)
The role of neurophysiological investigation in traumatic brachial plexus lesions in adults and children. Smith SJ. **J Hand Surg [Br]** 1996 Apr;21(2):145–7 (20 ref.)
Peripheral neuropathy: an often-overlooked cause of falls in the elderly. Richardson JK, et al. **Postgrad Med** 1996 Jun;99(6):161–72 (20 ref.)

THERAPY

Management of cervical radiculopathy. van Gijn J, et al. **Eur Neurol** 1995;35(6):309–20 (31 ref.)
[Diabetic neuropathy: overview of clinical problems] Czech A, et al. **Pol Tyg Lek** 1996 Jan;51(1–5):33–4 (11 ref.) **(Pol)**

PERIPHERAL RESISTANCE see **VASCULAR RESISTANCE**

PERIPHERAL STEM CELL TRANSPLANTATION see **HEMATOPOIETIC STEM CELL TRANSPLANTATION**

PERIPHERAL T-CELL LYMPHOMA see **LYMPHOMA, T-CELL, PERIPHERAL**

PERIPHERAL VASCULAR DISEASES

Peripheral arterial-vascular disease in women: prevalence, prognosis, and treatment. Gerhard M, et al. **Cardiology** 1995;86(4):349–55 (56 ref.)
Epidural spinal cord stimulation in the treatment of limb threatening vasospasm--report of a case with a five-year follow-up. Lepantalo M, et al. **Eur J Vasc Endovasc Surg** 1996 Apr;11(3):368–70 (5 ref.)

CLASSIFICATION

Classification and grading of chronic venous disease in the lower limbs. A consensus statement. Beebe HG, et al. **Int Angiol** 1995 Jun;14(2):197–201 (45 ref.)

DIAGNOSIS

Identifying chronic peripheral arterial disease. Cantwell-Gab K. **Am J Nurs** 1996 Jul;96(7):40–6; quiz 47 (11 ref.)
Diagnosis of arterial disease of the lower extremities with duplex ultrasonography. Koelemay MJ, et al. **Br J Surg** 1996 Mar;83(3):404–9 (48 ref.)

DRUG THERAPY

Thrombolytic therapy in peripheral vascular disease. Ouriel K. **Adv Surg** 1996;29:191–206 (53 ref.)
Antithrombotic therapy in peripheral arterial occlusive disease. Clagett GP, et al. **Chest** 1995 Oct;108(4 Suppl):431S–443S (193 ref.)
Pentoxifylline (oxpentifylline). A review of its therapeutic efficacy in the management of peripheral vascular and cerebrovascular disorders. Frampton JE, et al. **Drugs Aging** 1995 Dec;7(6):480–503 (150 ref.)

ETIOLOGY

Peripheral vascular complications following coronary interventional procedures. Nasser TK, et al. **Clin Cardiol** 1995 Nov;18(11):609–14 (54 ref.)
Osteochondroma: an unusual cause of vascular disease in young adults. Eschelman DJ, et al. **J Vasc Interv Radiol** 1995 Jul–Aug;6(4):605–13 (54 ref.)

NURSING

Identifying chronic peripheral arterial disease. Cantwell-Gab K. **Am J Nurs** 1996 Jul;96(7):40–6; quiz 47 (11 ref.)

PHYSIOPATHOLOGY

Microcirculation in venous disorders: the role of the white blood cells. Dormandy JA. **Int J Microcirc Clin Exp** 1995; 15 Suppl 1:3–8 (16 ref.)
Microcirculatory homeostasis 1930–1990: insight into microcirculatory readjustments provided by studies on the peripheral circulatory insufficiency of the shock syndrome. Zweifach BW. **Microcirculation** 1995 Sep;2(3):245–51 (44 ref.)

RADIOGRAPHY

Intraarterial pressure measurements during angiographic evaluation of peripheral vascular disease: techniques, interpretation, applications, and limitations. Kinney TB, et al. **AJR Am J Roentgenol** 1996 Feb;166(2):277–84 (44 ref.)

REHABILITATION

Exercise rehabilitation for patients with peripheral arterial disease. Regensteiner JG, et al. **Exerc Sport Sci Rev** 1995; 23:1–24 (95 ref.)

SURGERY

Revascularization versus amputation for elderly patients. Bunt TJ. **AORN J** 1995 Sep;62(3):433–5 (7 ref.)

THERAPY

Percutaneous revascularization in peripheral arterial disease. Rosenfield K, et al. **Curr Probl Cardiol** 1996 Jan;21(1):7–93 (228 ref.)

PERIPHLEBITIS see **PHLEBITIS**

PERIPLANETA

METABOLISM

Actions of neurotoxins (bungarotoxins, neosurugatoxin and lophotoxins) on insect and nematode nicotinic acetylcholine receptors. Tornøe C, et al. **Toxicon** 1995 Apr;33(4):411–24 (61 ref.)

PERIPLANETA AMERICANA see **COCKROACHES**

PERISSODACTYLA

Quarantine requirements for the importation of black rhinoceros from Zimbabwe into Australia. Doyle KA, et al. **Aust Vet J** 1995 Oct;72(10):364–8 (4 ref.)
The importation of the black rhinoceros (Diceros bicornis) from Zimbabwe into Australia. Kelly JD, et al. **Aust Vet J** 1995 Oct;72(10):369–74 (10 ref.)

PERISTALTIC PUMPS, IMPLANTABLE see **INFUSION PUMPS, IMPLANTABLE**

PERITONEAL CAVITY

see related
ASCITIC FLUID
LAPAROSCOPY

ANATOMY & HISTOLOGY

Anatomic CT demonstration of the peritoneal spaces, ligaments, and mesenteries: normal and pathologic processes. DeMeo JH, et al. **Radiographics** 1995 Jul; 15(4):755–70 (18 ref.)

CYTOLOGY

The Na+/K(+)-pump in rat peritoneal mast cells: some aspects of regulation of activity and cellular function. Knudsen T. **Dan Med Bull** 1995 Nov;42(5):441–54 (261 ref.)

PHYSIOLOGY

Physiological approaches to increase biocompatibility of peritoneal dialysis. Breborowicz A, et al. **Perit Dial Int** 1995;15(7 Suppl):S76–85; discussion S85–6 (127 ref.)

First-line defense mechanisms in the peritoneal cavity during peritoneal dialysis. Brulez HF, et al. **Perit Dial Int** 1995; 15(7 Suppl):S24–33; discussion S33–4 (79 ref.)

PERITONEAL DIALYSIS

see related
DIALYSIS SOLUTIONS
KIDNEY, ARTIFICIAL

Recombinant human growth hormone (rhGH) in dialysis patients: update 1995. Fine RN. **Adv Perit Dial** 1995; 11:261–5 (15 ref.)

The significance of protein intake and catabolism. Flanigan MJ, et al. **Adv Ren Replace Ther** 1995 Oct;2(4):330–40 (62 ref.)

Dialysis and renal transplantation in infants with irreversible renal failure. Neu AM, et al. **Adv Ren Replace Ther** 1996 Jan;3(1):48–59 (109 ref.)

Peritoneal dialysis kinetics. Ponferrada LP, et al. **Adv Ren Replace Ther** 1995 Oct;2(4):341–8 (29 ref.)

Techniques for modelling adequacy in patients on peritoneal dialysis. Blake PG. **Am J Kidney Dis** 1996 May;27(5):750–3 (21 ref.)

Foregoing renal dialysis: a case study and review of ethical issues. The End-Stage Renal Disease Group. Tobe SW, et al. **Am J Kidney Dis** 1996 Jul;28(1):147–53 (33 ref.)

Peritoneal dialysis complicated by Bipolaris hawaiiensis peritonitis: successful therapy with catheter removal and oral itraconazol without the use of amphotericin-B. Gadallah MF, et al. **Am J Nephrol** 1995;15(4):348–52 (19 ref.)

Nutritional treatment of hemodialysis and peritoneal dialysis patients. Schmicker R. **Artif Organs** 1995 Aug;19(8):837–41 (34 ref.)

An update on peritoneal dialysis and hemodialysis in the pediatric population. Warady BA, et al. **Curr Opin Pediatr** 1996 Apr;8(2):135–40 (58 ref.)

Acute renal failure in infants and children. Ehrich JH. **Int J Artif Organs** 1996 Feb;19(2):121–3 (9 ref.)

Acute renal failure and membranes. Some medical and ethical questions [editorial] Schaefer K, et al. **Int J Artif Organs** 1996 Mar;19(3):145–6 (4 ref.)

The rapid reversal of profound hypothermia using peritoneal dialysis. Vella J, et al. **Ir J Med Sci** 1996 Apr–Jun; 165(2):113–4 (9 ref.)

Connecting devices in CAPD and their impact on peritonitis. Shetty A, et al. **J Postgrad Med** 1994 Jul–Sep;40(3):179–84 (33 ref.)

Endocrinology and PD: optimal treatment of anemia in peritoneal dialysis patients. Bárány P. **Perit Dial Int** 1996; 16 Suppl 1:S260–6 (65 ref.)

The impact of intraperitoneal glucose and insulin on the liver. Bargman JM. **Perit Dial Int** 1996;16 Suppl 1:S211–4 (27 ref.)

Long-term consequences of peritonitis. Boeschoten EW. **Perit Dial Int** 1996;16 Suppl 1:S349–54 (43 ref.)

In vitro studies to assess biocompatibility of peritoneal dialysis solutions: strengths and limitations. Breborowicz A, et al. **Perit Dial Int** 1996;16 Suppl 1:S119–23 (28 ref.)

First-line defense mechanisms in the peritoneal cavity during peritoneal dialysis. Brulez HF, et al. **Perit Dial Int** 1995; 15(7 Suppl):S24–33; discussion S33–4 (79 ref.)

Advanced glycation end products in peritoneal dialysis. Dawnay A. **Perit Dial Int** 1996;16 Suppl 1:S50–3 (39 ref.)

Peritoneal dialysis solution biocompatibility testing in animals. Di Paolo N, et al. **Perit Dial Int** 1995;15(7 Suppl):S61–9; discussion S69–70 (40 ref.)

The importance of the interstitium in peritoneal transport. Flessner MF. **Perit Dial Int** 1996;16 Suppl 1:S76–9 (19 ref.)

New strategies in clinical nutrition. Fürst P. **Perit Dial Int** 1996;16 Suppl 1:S28–35 (25 ref.)

The impact of peritoneal permeability and residual renal function on PD prescription. Harty J, et al. **Perit Dial Int** 1996;16 Suppl 1:S147–52 (18 ref.)

The biology of the mesothelium during peritoneal dialysis. Hjelle JT, et al. **Perit Dial Int** 1995;15(7 Suppl):S13–22; discussion S22–3 (108 ref.)

Water channels in the peritoneum [editorial] Ho-dac-Pannekeet MM, et al. **Perit Dial Int** 1996 May–Jun;16(3):255–9 (62 ref.)

Peritoneal dialysis and endocrinology. Lim VS. **Perit Dial Int** 1996;16 Suppl 1:S257–9 (6 ref.)

Optimal use of glucose polymer (icodextrin) in peritoneal dialysis. Mistry CD, et al. **Perit Dial Int** 1996;16 Suppl 1:S104–8 (23 ref.)

Peritoneal equilibration in children. Morgenstern BZ. **Perit Dial Int** 1996;16 Suppl 1:S532–9 (43 ref.)

Quality of life elderly and diabetic patients on peritoneal dialysis. Nissenson AR. **Perit Dial Int** 1996;16 Suppl 1:S406–9 (33 ref.)

Bicarbonate: the alternative buffer for peritoneal dialysis. Passlick-Deetjen J, et al. **Perit Dial Int** 1996;16 Suppl 1:S109–13 (44 ref.)

Cardiovascular disease in peritoneal dialysis. Prichard S, et al. **Perit Dial Int** 1996;16 Suppl 1:S19–22 (33 ref.)

Theoretical analysis of osmotic agents in peritoneal dialysis. What size is an ideal osmotic agent? Rippe B, et al. **Perit Dial Int** 1996;16 Suppl 1:S97–103 (18 ref.)

Peritoneal blood flow: does it matter? Ronco C, et al. **Perit Dial Int** 1996;16 Suppl 1:S70–5 (15 ref.)

Integration of peritoneal dialysis in active uremia treatment. Ronco C, et al. **Perit Dial Int** 1996;16 Suppl 1:S393–7 (8 ref.)

Quality-of-life assessment in patients on peritoneal dialysis: a review of the state of the art. Salek S. **Perit Dial Int** 1996;16 Suppl 1:S398–401 (13 ref.)

Peritoneal dialysis in diabetics. Optimal insulin therapy on CAPD: intraperitoneal versus subcutaneous treatment. Scarpioni L, et al. **Perit Dial Int** 1996;16 Suppl 1:S275–8 (33 ref.)

Peritoneal dialysis in liver disorders. Selgas R, et al. **Perit Dial Int** 1996;16 Suppl 1:S215–9 (35 ref.)

Bioelectrical impedance analysis and dual energy x-ray absorptiometry to monitor nutritional status. Stall S, et al. **Perit Dial Int** 1995;15(5 Suppl):S59–62 (31 ref.)

What is the ideal technique for testing the biocompatibility of peritoneal dialysis solutions? [editorial] Topley N. **Perit Dial Int** 1995 Jul–Sep;15(6):205–9 (29 ref.)

Treatment of sexual dysfunction. Uttley L. **Perit Dial Int** 1996;16 Suppl 1:S402–5 (13 ref.)

Prevention of infection dropout in PD. Viglino G, et al. **Perit Dial Int** 1996;16 Suppl 1:S355–61 (56 ref.)

Heat sterilization of glucose-containing fluids for peritoneal dialysis: biological consequences of chemical alterations. Wieslander AP, et al. **Perit Dial Int** 1995;15(7 Suppl):S52–9; discussion S59–60 (32 ref.)

[Treatment of chronic kidney failure in diabetics with peritoneal dialysis] Bednářová V, et al. **Cas Lek Cesk** 1996 May 29;135(11):340–3 (27 ref.) (Eng. Abstr.) **(Cze)**

[Kidney diseases in the elderly from the internal medicine viewpoint. Diagnosis and therapy] Verwiebe R, et al. **Fortschr Med** 1995 Oct 20;113(29):418–22 (17 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

The renal bone diseases in children treated with dialysis. Sanchez CP, et al. **Adv Ren Replace Ther** 1996 Jan; 3(1):14–23 (78 ref.)

Nutrition and the dialysis prescription. Chertow GM, et al. **Am J Nephrol** 1996;16(1):79–89 (85 ref.)

Staphylococcus aureus infections during peritoneal dialysis. Coles GA. **J Chemother** 1995 Jul;7 Suppl 3:67–70 (22 ref.)

Ultrafiltration failure in CAPD. Shetty A, et al. **J Postgrad Med** 1994 Jul–Sep;40(3):185–93 (47 ref.)

Intraperitoneal amino acids: a therapy whose time has come? Jones MR. **Perit Dial Int** 1995;15(5 Suppl):S67–74 (68 ref.)

ECONOMICS

Health-care economics and peritoneal dialysis. Nissenson AR. **Perit Dial Int** 1996;16 Suppl 1:S373–7 (17 ref.)

INSTRUMENTATION

Management of catheter-related infections. Piraino B. **Am J Kidney Dis** 1996 May;27(5):754–8 (33 ref.)

Peritoneal access. Bhatla B, et al. **J Postgrad Med** 1994 Jul–Sep;40(3):170–8 (50 ref.)

Significance, epidemiology, and prevention of peritoneal dialysis catheter infections. Burkart JM. **Perit Dial Int** 1996; 16 Suppl 1:S340–6 (38 ref.)

Peritoneoscopic placement of Swan neck peritoneal dialysis catheters. Copley JB, et al. **Perit Dial Int** 1996;16 Suppl 1:S330–2 (18 ref.)

Implantation techniques for peritoneal dialysis catheters. Cruz C. **Perit Dial Int** 1996;16 Suppl 1:S319–21 (14 ref.)

How to reach optimal creatinine clearances in automated peritoneal dialysis. Durand PY, et al. **Perit Dial Int** 1996; 16 Suppl 1:S167–70 (14 ref.)

The peritoneal access. Lee HB, et al. **Perit Dial Int** 1996;16 Suppl 1:S322–6 (24 ref.)

Exit-site care. Piraino B. **Perit Dial Int** 1996;16 Suppl 1:S336–9 (28 ref.)

[Tools for determining adequateness and dialysis dose in peritoneal dialysis (see comments)] Lameire N. **Nephrologie** 1995;16(6):407–11 (50 ref.) Comment in: Nephrologie 1995;16(6):393–7. **(Fre)**

METHODS

Daily home hemodialysis: a hybrid of hemodialysis and peritoneal dialysis. Twardowski ZJ. **Adv Ren Replace Ther** 1996 Apr;3(2):124–32 (55 ref.)

Targets in CAPD and APD prescription. Blake PG. **Perit Dial Int** 1996;16 Suppl 1:S143–6 (17 ref.)

Peritoneal dialysis prescription for neonates. Fischbach M. **Perit Dial Int** 1996;16 Suppl 1:S512–4 (23 ref.)

[Tools for determining adequateness and dialysis dose in peritoneal dialysis (see comments)] Lameire N. **Nephrologie** 1995;16(6):407–11 (50 ref.) Comment in: Nephrologie 1995;16(6):393–7. **(Fre)**

PSYCHOLOGY

Psychosocial burdens of dialysis treatment modalities: do they differ and does it matter? Reynolds JM, et al. **Perit Dial Int** 1996;16 Suppl 1:S548–50 (13 ref.)

UTILIZATION

Peritoneal dialysis update 1994. Nolph KD. **J Postgrad Med** 1994 Jul–Sep;40(3):151–7 (60 ref.)

PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY

Assessment of nutritional status in dialysis patients. Wolfson M, et al. **Adv Ren Replace Ther** 1996 Apr;3(2):174–9 (24 ref.)

Techniques for modelling adequacy in patients on peritoneal dialysis. Blake PG. **Am J Kidney Dis** 1996 May;27(5):750–3 (21 ref.)

Biocompatibility of peritoneal dialysis solutions. Breborowicz A, et al. **Am J Kidney Dis** 1996 May;27(5):738–43 (54 ref.)

Nutritional management of the continuous ambulatory peritoneal dialysis patient. Wolfson M. **Am J Kidney Dis** 1996 May;27(5):744–9 (49 ref.)

Mechanisms regulating cytokine release from peritoneal macrophages during continuous ambulatory peritoneal dialysis. Fieren MW. **Blood Purif** 1996;14(2):179–87 (60 ref.)

Effect of peritoneal dialysis on cytokine production by peritoneal cells. Topley N, et al. **Blood Purif** 1996; 14(2):188–97 (62 ref.)

Cytokine patterns in the effluent of continuous ambulatory peritoneal dialysis: relationship to peritoneal permeability. Zemel D, et al. **Blood Purif** 1996;14(2):198–216 (171 ref.)

Which treatment for which patient in the future? Possible modifications in CAPD. Maiorca R, et al. **Nephrol Dial Transplant** 1995;10 Suppl 7:20–6 (68 ref.)

The impact of intraperitoneal glucose and insulin on the liver. Bargman JM. **Perit Dial Int** 1996;16 Suppl 1:S211–4 (27 ref.)

Appetite in CAPD patients. Bergström J. **Perit Dial Int** 1996; 16 Suppl 1:S181–4 (29 ref.)

Answers to all your questions about peritoneal urea clearance and nutrition in CAPD patients [editorial] Blake PG, et al. **Perit Dial Int** 1996 May–Jun;16(3):248–51 (25 ref.)

Growth hormone and malnutrition in dialysis patients. Blake PG. **Perit Dial Int** 1995 Jul–Sep;15(6):210–6 (49 ref.)

Long-term consequences of peritonitis. Boeschoten EW. **Perit Dial Int** 1996;16 Suppl 1:S349–54 (43 ref.)

In vitro studies to assess biocompatibility of peritoneal dialysis solutions: strengths and limitations. Breborowicz A, et al. **Perit Dial Int** 1996;16 Suppl 1:S119–23 (28 ref.)

Physiological approaches to increase biocompatibility of peritoneal dialysis. Breborowicz A, et al. **Perit Dial Int** 1995;15(7 Suppl):S76–85; discussion S85–6 (127 ref.)

Effect of peritoneal dialysis prescription and peritoneal membrane transport characteristics on nutritional status. Burkart JM. **Perit Dial Int** 1995;15(5 Suppl):S20–35 (94 ref.)

Nutritional status in children receiving chronic peritoneal dialysis. Canepa A, et al. **Perit Dial Int** 1996;16 Suppl 1:S526–31 (37 ref.)

Advanced glycation end products in peritoneal dialysis. Dawnay A. **Perit Dial Int** 1996;16 Suppl 1:S50–3 (39 ref.)

Durability of the peritoneal membrane. Dobbie JW. **Perit Dial Int** 1995;15(7 Suppl):S87–91; discussion S91–2 (18 ref.)

Infectious complications in pediatric patients treated with chronic peritoneal dialysis (CPD). Edefonti A, et al. **Perit Dial Int** 1996;16 Suppl 1:S543–7 (11 ref.)

The importance of the interstitium in peritoneal transport. Flessner MF. **Perit Dial Int** 1996;16 Suppl 1:S76–9 (19 ref.)

New strategies in clinical nutrition. Fürst P. **Perit Dial Int** 1996;16 Suppl 1:S28–35 (25 ref.)

CAPD overview. Gokal R. **Perit Dial Int** 1996;16 Suppl 1:S13–8 (38 ref.)

The impact of peritoneal permeability and residual renal function on PD prescription. Harty J, et al. **Perit Dial Int** 1996;16 Suppl 1:S147–52 (18 ref.)

Low turnover bone disease. Hutchison AJ, et al. **Perit Dial Int** 1996;16 Suppl 1:S295–9 (21 ref.)

Malnutrition in peritoneal dialysis patients: etiologic factors and treatment options. Ikizler TA, et al. **Perit Dial Int** 1995; 15(5 Suppl):S63–6 (28 ref.)

Markers of peritoneal membrane status. Krediet RT, et al. **Perit Dial Int** 1996;16 Suppl 1:S42–9 (89 ref.)

Dialysis in patients with diabetic nephropathy: CAPD versus hemodialysis. Lee HB, et al. **Perit Dial Int** 1996;16 Suppl 1:S269–74 (28 ref.)

Peritoneal dialysis and endocrinology. Lim VS. **Perit Dial Int** 1996;16 Suppl 1:S257–9 (6 ref.)

Optimal use of glucose polymer (icodextrin) in peritoneal dialysis. Mistry CD, et al. **Perit Dial Int** 1996;16 Suppl 1:S104–8 (23 ref.)

Peritoneal equilibration in children. Morgenstern BZ. **Perit Dial Int** 1996;16 Suppl 1:S532–9 (43 ref.)

Bicarbonate: the alternative buffer for peritoneal dialysis. Passlick-Deetjen J, et al. **Perit Dial Int** 1996;16 Suppl 1:S109–13 (44 ref.)

Lactate-versus bicarbonate-based peritoneal dialysis

solutions. Pedersen FB. **Perit Dial Int** 1995;15(7 Suppl):S47–50; discussion S51 (33 ref.)
Cardiovascular disease in peritoneal dialysis. Prichard S, et al. **Perit Dial Int** 1996;16 Suppl 1:S19–22 (33 ref.)
Theoretical analysis of osmotic agents in peritoneal dialysis. What size is an ideal osmotic agent? Rippe B, et al. **Perit Dial Int** 1996;16 Suppl 1:S97–103 (18 ref.)
Prescription of calcium concentration and PTH control. Ritz E, et al. **Perit Dial Int** 1996;16 Suppl 1:S300–4 (31 ref.)
Peritoneal blood flow: does it matter? Ronco C, et al. **Perit Dial Int** 1996;16 Suppl 1:S70–5 (15 ref.)
Autosomal dominant polycystic liver disease as an etiology for hemoperitoneum during CCPD. Rutecki GW, et al. **Perit Dial Int** 1995 Oct–Dec;15(8):367–9 (11 ref.)
Peritoneal dialysis in diabetics. Optimal insulin therapy on CAPD: intraperitoneal versus subcutaneous treatment. Scarpioni L, et al. **Perit Dial Int** 1996;16 Suppl 1:S275–8 (33 ref.)
Effect of different buffers on the biocompatibility of CAPD solutions. Schambye HT. **Perit Dial Int** 1996;16 Suppl 1:S130–6 (48 ref.)
Peritoneal dialysis in liver disorders. Selgas R, et al. **Perit Dial Int** 1996;16 Suppl 1:S215–9 (35 ref.)
Management of foot problems in diabetes. Shaw JE, et al. **Perit Dial Int** 1996;16 Suppl 1:S279–82 (26 ref.)
Treatment of sexual dysfunction. Uttley L. **Perit Dial Int** 1996;16 Suppl 1:S402–5 (13 ref.)
Prevention of infection dropout in PD. Viglino G, et al. **Perit Dial Int** 1996;16 Suppl 1:S355–61 (56 ref.)
[Recent progress in continuous ambulatory peritoneal dialysis] Nomoto Y. **Nippon Naika Gakkai Zasshi** 1995 Oct 10;84(10):1622–6 (10 ref.) **(Jpn)**

ADVERSE EFFECTS

Neisseria meningitidis peritonitis in a CAPD patient: first case report and review of the literature. Kleinpeter MA, et al. **Adv Perit Dial** 1995;11:168–71 (14 ref.)
Paecilomyces varioti peritonitis in patients on continuous ambulatory peritoneal dialysis. Chan TH, et al. **Am J Kidney Dis** 1996 Jan;27(1):138–42 (24 ref.)
Pharmacokinetic issues in the treatment of continuous ambulatory peritoneal dialysis–associated peritonitis. Bailie GR, et al. **J Antimicrob Chemother** 1995 May;35(5):563–7 (33 ref.)
Interleukin-1 and interleukin-1 receptor antagonist production during haemodialysis: which cytokine is a surrogate marker for dialysis-related complications? Dinarello CA. **Nephrol Dial Transplant** 1995;10 Suppl 3:25–8 (32 ref.)
Host defences in continuous ambulatory peritoneal dialysis and the genesis of peritonitis. Cameron JS. **Pediatr Nephrol** 1995 Oct;9(5):647–62 (203 ref.)
Nutritional Markers as predictors of survival in patients on CAPD. Dombros NV, et al. **Perit Dial Int** 1995;15(5 Suppl):S10–9 (66 ref.)
Fusarium peritonitis in a child on peritoneal dialysis: case report and review of the literature. Flynn JT, et al. **Perit Dial Int** 1996 Jan–Feb;16(1):52–7 (45 ref.)
[Sclerosing peritonitis. A series of 10 cases and review of the literature] Carbonnel F, et al. **Gastroenterol Clin Biol** 1995 Nov;19(11):876–82 (33 ref.) (Eng. Abstr.) **(Fre)**

INSTRUMENTATION

Peritoneal dialysis catheter complications. Bernardini J. **Perit Dial Int** 1996;16 Suppl 1:S486–71 (42 ref.)

METHODS

Targets in CAPD and APD prescription. Blake PG. **Perit Dial Int** 1996;16 Suppl 1:S143–6 (17 ref.)
Nasogastric tube feeding in infants on peritoneal dialysis. Warady BA, et al. **Perit Dial Int** 1996;16 Suppl 1:S521–5 (32 ref.)

NURSING

The team approach to the management of children on chronic peritoneal dialysis. Harvey E, et al. **Adv Ren Replace Ther** 1996 Jan;3(1):3–13 (59 ref.)

PSYCHOLOGY

Psychosocial burdens of dialysis treatment modalities: do they differ and does it matter? Reynolds JM, et al. **Perit Dial Int** 1996;16 Suppl 1:S548–50 (13 ref.)

STANDARDS

Does CAPD provide adequate dialysis? [editorial] Harty J, et al. **Nephrol Dial Transplant** 1995;10(7):1115–7 (19 ref.)

PERITONEAL DISEASES

DIAGNOSIS

[Peritoneal and tubal Schistosoma haematobium bilharziasis. Two case reports] Ekoukou D, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(8):819–24 (20 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

A case of abdominal cocoon. Yoon YW, et al. **J Korean Med Sci** 1995 Jun;10(3):220–5 (18 ref.)

PERITONEAL EFFUSION see **ASCITIC FLUID**

PERITONEAL FLUID see **ASCITIC FLUID**

PERITONEAL INFUSIONS see **INFUSIONS, PARENTERAL**

PERITONEAL MACROPHAGES see **MACROPHAGES, PERITONEAL**

PERITONEAL NEOPLASMS

[Peritoneal pseudomyxoma] Sánchez Muñoz LA, et al. **Rev Clin Esp** 1995 Nov;195(11):781–6 (20 ref.) **(Spa)**

CHEMICALLY INDUCED

[Malignant peritoneal mesothelioma: its relation to asbestos] Pentimone F, et al. **Minerva Med** 1995 Oct;86(10):439–43 (38 ref.) (Eng. Abstr.) **(Ita)**

COMPLICATIONS

Pheocromocytoma and gastrointestinal bleeding. Vázquez-Quintana E, et al. **Am Surg** 1995 Nov; 61(11):937–9 (12 ref.)
[Peritoneal mesothelioma as a rare case of acute abdomen. Review of the literature] Cipollone G, et al. **Chir Ital** 1994; 46(6):73–9 (86 ref.) (Eng. Abstr.) **(Ita)**

DIAGNOSIS

[Peritoneal mesothelioma. Contribution of MRI. Apropos of a case] Guzelian J, et al. **J Radiol** 1996 Jul;77(7):497–501 (15 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

Chemotherapy treatment of chyloperitoneum and peritoneal carcinomatosis due to cervical cancer—review of literature. Keung YK, et al. **Gynecol Oncol** 1996 Jun;61(3):448–50 (11 ref.)
Pharmacokinetic and pharmacodynamic optimization of intraperitoneal chemotherapy. Balthasar JP, et al. **Life Sci** 1996;58(7):535–43 (71 ref.)

ETIOLOGY

Malignant peritoneal mesothelioma. Case report and review of the literature. Watteeuw G, et al. **Acta Clin Belg** 1995; 50(4):222–6 (18 ref.)
Abdominal wall metastasis and peritoneal carcinomatosis after laparoscopic-assisted colectomy for colon cancer. Jacquet P, et al. **Eur J Surg Oncol** 1995 Oct;21(5):568–70 (25 ref.)

GENETICS

Asbestos and mesothelioma: genetic lessons from a tragedy [comment] Knudson A. **Proc Natl Acad Sci U S A** 1995 Nov 21;92(24):10819–20 (21 ref.) Comment on: Proc Natl Acad Sci U S A 1995 Nov 21;92(24):10854–8.

PATHOLOGY

Malignant mixed müllerian tumor of the extraovarian secondary müllerian system. Report of two cases and review of the English literature. Mira JL, et al. **Arch Pathol Lab Med** 1995 Nov;119(11):1044–9 (31 ref.)
Peritoneal implantation of meningeal melanosis via ventriculoperitoneal shunt: a case report and review of the literature. Gattuso P, et al. **Diagn Cytopathol** 1995 Oct; 13(3):257–9 (19 ref.)
Leiomyomatosis peritonealis disseminata: clinicopathologic analysis of five cases. Hardman WJ 3rd, et al. **South Med J** 1996 Mar;89(3):291–4 (22 ref.)
[Peritoneal mesothelioma and abdominal hernias] Mirabella F. **Minerva Med** 1996 Jan–Feb;87(1–2):21–4 (51 ref.) (Eng. Abstr.) **(Ita)**

PREVENTION & CONTROL

[Prophylaxis and treatment of peritoneal metastasis from gastric cancer] Kaibara N. **Nippon Geka Gakkai Zasshi** 1996 Apr;97(4):308–11 (10 ref.) (Eng. Abstr.) **(Jpn)**

RADIOGRAPHY

[Place of celioscopy in the diagnosis of invasiveness of digestive cancers] Chambon JP, et al. **Ann Chir** 1995; 49(6):513–8 (25 ref.) (Eng. Abstr.) **(Fre)**

SECONDARY

[Prophylaxis and treatment of peritoneal metastasis from gastric cancer] Kaibara N. **Nippon Geka Gakkai Zasshi** 1996 Apr;97(4):308–11 (10 ref.) (Eng. Abstr.) **(Jpn)**

SURGERY

Peritoneal cystic mesothelioma treated with minimally invasive approach. Navarra G, et al. **Surg Endosc** 1996 Jan; 10(1):60–1 (23 ref.)

THERAPY

Sequential treatment of recurrent mesenteric desmoid tumor. Bauernhofer T, et al. **Cancer** 1996 Mar 15;77(6):1061–5 (44 ref.)
[Immediate intraperitoneal chemotherapy after surgery for the reduction of peritoneal malignancies: for what purpose and for whom? (editorial)] Elias D. **Ann Chir** 1995; 49(7):567–72 (34 ref.) (Eng. Abstr.) **(Fre)**

PERITONEOSCOPY see **LAPAROSCOPY**

PERITONEOVENOUS SHUNT

Peritoneovenous shunting in cirrhosis: its role in the management of refractory ascites in the 1990s [editorial; comment] Wong F, et al. **Am J Gastroenterol** 1995 Dec; 90(12):2086–9 (39 ref.) Comment on: Am J Gastroenterol 1995 Dec;90(12):2097–102.
[Surgical treatment of refractory ascites with peritoneovenous shunt] Massari R, et al. **Chir Ital** 1995; 47(1):57–0 (14 ref.) (Eng. Abstr.) **(Ita)**

PERITONEUM

see related
ASCITIC FLUID
LAPAROSCOPY

BLOOD SUPPLY

The importance of the interstitium in peritoneal transport. Flessner MF. **Perit Dial Int** 1996;16 Suppl 1:S76–9 (19 ref.)
Peritoneal blood flow: does it matter? Ronco C, et al. **Perit Dial Int** 1996;16 Suppl 1:S70–5 (15 ref.)

CYTOLOGY

The role of TGF-beta in growth inhibition of peritoneal mesothelial cells in high-glucose dialysate. Kumano K, et al. **Perit Dial Int** 1995;15(7 Suppl):S93–5 (18 ref.)

DRUG EFFECTS

Peritoneal dialysis solution biocompatibility testing in animals. Di Paolo N, et al. **Perit Dial Int** 1995;15(7 Suppl):S61–9; discussion S69–70 (40 ref.)
Lactate-versus bicarbonate-based peritoneal dialysis solutions. Pedersen FB. **Perit Dial Int** 1995;15(7 Suppl):S47–50; discussion S51 (33 ref.)

EMBRYOLOGY

The development of the genital peritoneum in domestic mammals. An analysis of the literature and nomenclature. Martin E. **Anat Histol Embryol** 1995 Dec;24(4):285–7 (18 ref.)

METABOLISM

Answers to all your questions about peritoneal urea clearance and nutrition in CAPD patients [editorial] Blake PG, et al. **Perit Dial Int** 1996 May–Jun;16(3):248–51 (25 ref.)
Effect of peritoneal dialysis prescription and peritoneal membrane transport characteristics on nutritional status. Burkart JM. **Perit Dial Int** 1995;15(5 Suppl):S20–35 (94 ref.)
Water channels in the peritoneum [editorial] Ho-dac-Pannekeet MM, et al. **Perit Dial Int** 1996 May–Jun;16(3):255–9 (62 ref.)

PATHOLOGY

[Sclerosing peritonitis. A series of 10 cases and review of the literature] Carbonnel F, et al. **Gastroenterol Clin Biol** 1995 Nov;19(11):876–82 (33 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Durability of the peritoneal membrane. Dobbie JW. **Perit Dial Int** 1995;15(7 Suppl):S87–91; discussion S91–2 (18 ref.)
The biology of the mesothelium during peritoneal dialysis. Hjelle JT, et al. **Perit Dial Int** 1995;15(7 Suppl):S13–22; discussion S22–3 (108 ref.)

PHYSIOPATHOLOGY

Effect of peritoneal dialysis on cytokine production by peritoneal cells. Topley N, et al. **Blood Purif** 1996; 14(2):188–97 (62 ref.)
Cytokine patterns in the effluent of continuous ambulatory peritoneal dialysis: relationship to peritoneal permeability. Zemel D, et al. **Blood Purif** 1996;14(2):198–216 (171 ref.)
Ultrafiltration failure in CAPD. Shetty A, et al. **J Postgrad Med** 1994 Jul–Sep;40(3):185–93 (47 ref.)
How to reach optimal creatinine clearances in automated peritoneal dialysis. Durand PY, et al. **Perit Dial Int** 1996; 16 Suppl 1:S167–70 (14 ref.)
The impact of peritoneal permeability and residual renal function on PD prescription. Harty J, et al. **Perit Dial Int** 1996;16 Suppl 1:S147–52 (18 ref.)

SURGERY

Laparoscopy in surgical treatment of vaginal aplasia: laparoscopy-assisted colpopoiesis and perineal hysterectomy with colpopoiesis. Adamian LV, et al. **Int J Fertil Menopausal Stud** 1996 Jan–Feb;41(1):40–5 (10

ref.)

PERITONITIS

Sclerosing encapsulating peritonitis—a review. Eldar S, et al. **S Afr J Surg** 1995 Jun;33(2):70–2 (39 ref.)

COMPLICATIONS

Experience with cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis. Rimola A, et al. **Diagn Microbiol Infect Dis** 1995 May–Jun;22(1–2):141–5 (30 ref.)

[Sclerosing peritonitis. A series of 10 cases and review of the literature] Carbonnel F, et al. **Gastroenterol Clin Biol** 1995 Nov;19(11):876–82 (33 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

Peritoneal dialysis complicated by Bipolaris hawaiiensis peritonitis: successful therapy with catheter removal and oral itraconazol without the use of amphotericin-B. Gadallah MF, et al. **Am J Nephrol** 1995;15(4):348–52 (19 ref.)

Experience with cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis. Rimola A, et al. **Diagn Microbiol Infect Dis** 1995 May–Jun;22(1–2):141–5 (30 ref.)

Pharmacokinetic issues in the treatment of continuous ambulatory peritoneal dialysis-associated peritonitis. Bailie GR, et al. **J Antimicrob Chemother** 1995 May;35(5):563–7 (33 ref.)

[Treatment of severe infections: should one always administer an aminoglycoside?] Cometta A, et al. **Schweiz Med Wochenschr Suppl** 1996;76:28S–33S (30 ref.) (Eng. Abstr.) **(Fre)**

EPIDEMIOLOGY

Cirrhosis: a risk factor for cryptococcal peritonitis. Mabee CL, et al. **Am J Gastroenterol** 1995 Nov;90(11):2042–5 (20 ref.)

ETIOLOGY

Neisseria meningitidis peritonitis in a CAPD patient: first case report and review of the literature. Kleinpeter MA, et al. **Adv Perit Dial** 1995;11:168–71 (14 ref.)

Exposure to domestic cats: risk factor for Pasteurella multocida peritonitis in liver cirrhosis? Koch CA, et al. **Am J Gastroenterol** 1996 Jul;91(7):1447–9 (29 ref.)

Connecting devices in CAPD and their impact on peritonitis. Shetty A, et al. **J Postgrad Med** 1994 Jul–Sep;40(3):179–84 (33 ref.)

Intraperitoneal rupture of an infected urachal cyst: a rare cause of peritonitis in children. Ogbevoen JO, et al. **Pediatr Emerg Care** 1996 Feb;12(1):41–3 (19 ref.)

Peritoneal dialysis catheter complications. Bernardini J. **Perit Dial Int** 1996;16 Suppl 1:S486–71 (42 ref.)

Significance, epidemiology, and prevention of peritoneal dialysis catheter infections. Burkart JM. **Perit Dial Int** 1996; 16 Suppl 1:S340–6 (38 ref.)

Fusarium peritonitis in a child on peritoneal dialysis: case report and review of the literature. Flynn JT, et al. **Perit Dial Int** 1996 Jan–Feb;16(1):52–7 (45 ref.)

Peritonitis biliaris: some aspects of its origin. Vomela J, et al. **Rocz Akad Med Bialymst** 1995;40(1):58–64 (24 ref.)

[Granulomatous peritonitis after laparoscopic surgery of an ovarian dermoid cyst. Diagnosis, management, prevention, a case report] Huss M, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(4):365–72 (54 ref.) (Eng. Abstr.) **(Fre)**

[Biliary peritonitis] Toyama K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):496–9 (15 ref.) **(Jpn)**

[New aspects of the pathogenesis of peritonitis] Iarovaia GA, et al. **Khirurgiia (Mosk)** 1996;(1):77–9 (45 ref.) **(Rus)**

IMMUNOLOGY

Host defences in continuous ambulatory peritoneal dialysis and the genesis of peritonitis. Cameron JS. **Pediatr Nephrol** 1995 Oct;9(5):647–62 (203 ref.)

The cytokine network controlling peritoneal inflammation. Topley N. **Perit Dial Int** 1995;15(7 Suppl):S35–9; discussion S39–40 (39 ref.)

METABOLISM

Hypothesis: compartmentalization of cytokines in intraabdominal infection. Schein M, et al. **Surgery** 1996 Jun; 119(6):694–700 (80 ref.)

MICROBIOLOGY

Spontaneous bacterial peritonitis. Planas R, et al. **Acta Gastroenterol Belg** 1995 May–Aug;58(3–4):297–310 (100 ref.)

Cirrhosis: a risk factor for cryptococcal peritonitis. Mabee CL, et al. **Am J Gastroenterol** 1995 Nov;90(11):2042–5 (20 ref.)

Paecilomyces varioti peritonitis in patients on continuous ambulatory peritoneal dialysis. Chan TH, et al. **Am J Kidney Dis** 1996 Jan;27(1):138–42 (24 ref.)

Spontaneous bacterial peritonitis in a patient with nephrogenic ascites during an episode of acute renal transplant rejection. Horn S, et al. **Am J Kidney Dis** 1996 Mar;27(3):441–3 (22 ref.)

Clinical correlates of anaerobic bacteriology in peritonitis. Wilson SE, et al. **Clin Infect Dis** 1995 Jun;20 Suppl 2:S251–6 (38 ref.)

Spontaneous bacterial peritonitis: pathogenesis, diagnosis, and management. Guarner C, et al. **Gastroenterologist** 1995 Dec;3(4):311–28 (153 ref.)

MORTALITY

Long-term consequences of peritonitis. Boeschoten EW. **Perit Dial Int** 1996;16 Suppl 1:S349–54 (43 ref.)

PATHOLOGY

Luteinized thecoma with sclerosing peritonitis. Werness BA. **Arch Pathol Lab Med** 1996 Mar;120(3):303–6 (9 ref.)

Markers of peritoneal membrane status. Krediet RT, et al. **Perit Dial Int** 1996;16 Suppl 1:S42–9 (89 ref.)

PREVENTION & CONTROL

Prevention of infection dropout in PD. Viglino G, et al. **Perit Dial Int** 1996;16 Suppl 1:S355–61 (56 ref.)

SURGERY

Antenatal diagnosis and management of meconium peritonitis: a case report and review of the literature. Konje JC, et al. **Ultrasound Obstet Gynecol** 1995 Jul;6(1):66–9 (13 ref.)

[The use of laparostomy in treating peritonitis] Komarov NV, et al. **Klin Khir** 1995;(9–10):45–8 (45 ref.) **(Rus)**

THERAPY

Management of secondary peritonitis. Wittmann DH, et al. **Ann Surg** 1996 Jul;224(1):10–8 (76 ref.)

Infectious complications in pediatric patients treated with chronic peritoneal dialysis (CPD). Edefonti A, et al. **Perit Dial Int** 1996;16 Suppl 1:S543–7 (11 ref.)

ULTRASONOGRAPHY

Antenatal diagnosis and management of meconium peritonitis: a case report and review of the literature. Konje JC, et al. **Ultrasound Obstet Gynecol** 1995 Jul;6(1):66–9 (13 ref.)

PERITONITIS, TUBERCULOUS see **TUBERCULOSIS, PERITONEAL**

PERITONSILLAR ABSCESS

MICROBIOLOGY

Staphylococcus aureus peritonsillar abscess in an 11-week old infant. Akhtar MJ, et al. **J Laryngol Otol** 1996 Jan; 110(1):78–80 (22 ref.)

PERIVASCULAR OLIGODENDROGLIA see **OLIGODENDROGLIA**

PERMEABILITY, CAPILLARY see **CAPILLARY PERMEABILITY**

PERMEABILITY, CELL MEMBRANE see **CELL MEMBRANE PERMEABILITY**

PERMEABILITY, MICROVASCULAR see **CAPILLARY PERMEABILITY**

PERMEASES

CHEMISTRY

Phylogenetic analyses of the ATP-binding constituents of bacterial extracytoplasmic receptor-dependent ABC-type nutrient uptake permeases. Kuan G, et al. **Res Microbiol** 1995 May;146(4):271–8 (16 ref.)

GENETICS

Engineering the lac permease for purification and crystallization. Prive GG, et al. **J Bioenerg Biomembr** 1996 Feb;28(1):29–34 (28 ref.)

ISOLATION & PURIFICATION

Engineering the lac permease for purification and crystallization. Prive GG, et al. **J Bioenerg Biomembr** 1996 Feb;28(1):29–34 (28 ref.)

METABOLISM

Molecular biology of the lactose carrier of Escherichia coli. Varela MF, et al. **Biochim Biophys Acta** 1996 Aug 7; 1276(1):21–34 (120 ref.)

Iron metabolism in eukaryotes: Mars and Venus at it again [comment] Kaplan J, et al. **Science** 1996 Mar 15; 271(5255):1510–2 (25 ref.) Comment on: Science 1996 Mar 15;271(5255):1552–7.

PEROMYSCUS

PHYSIOLOGY

Sexually dimorphic spatial learning in meadow voles Microtus pennsylvanicus and deer mice Peromyscus maniculatus. Galea LA, et al. **J Exp Biol** 1996 Jan;199 (Pt 1):195–200 (29 ref.)

PEROPERATIVE CARE see **INTRAOPERATIVE CARE**

PEROPERATIVE COMPLICATIONS see **INTRAOPERATIVE COMPLICATIONS**

PEROPERATIVE PERIOD see **INTRAOPERATIVE PERIOD**

PEROXIDASE

BLOOD

[Myeloperoxidase] Saito K, et al. **Nippon Rinsho** 1995 Mar; 53 Su Pt 2:251–3 (6 ref.) **(Jpn)**

GENETICS

Molecular genetics of hereditary thyroid diseases due to a defect in the thyroglobulin or thyroperoxidase synthesis. Targovnik HM, et al. **Braz J Med Biol Res** 1994 Dec; 27(12):2745–57 (31 ref.)

METABOLISM

Myeloperoxidase as a generator of drug free radicals. Uetrecht JP. **Biochem Soc Symp** 1995;61:163–70 (44 ref.)

PEROXIDASE-ANTIPEROXIDASE COMPLEX TECHNIQUE see **IMMUNOENZYME TECHNIQUES**

PEROXIDASE-LABELED ANTIBODY TECHNIQUE see **IMMUNOENZYME TECHNIQUES**

PEROXIDASES

[A variety of halogenating enzymes and their roles in organisms] Itoh N. **Tanpakushitsu Kakusan Koso** 1996 Mar; 41(3):256–66 (49 ref.) **(Jpn)**

METABOLISM

Vanadium-dependent haloperoxidases. Vilter H. **Met Ions Biol Syst** 1995;31:325–62 (192 ref.)

PEROXIDES

see related
BENZOYL PEROXIDE
LIPID PEROXIDES

METABOLISM

Cytochrome P450 2: peroxidative reactions of diversozymes. Coon MJ, et al. **FASEB J** 1996 Mar;10(4):428–34 (42 ref.)

THERAPEUTIC USE

Artemisinin and the antimalarial endoperoxides: from herbal remedy to targeted chemotherapy. Meshnick SR, et al. **Microbiol Rev** 1996 Jun;60(2):301–15 (189 ref.)

PEROXISOMAL DISORDERS

GENETICS

Adrenoleukodystrophy: molecular genetics, pathology, and Lorenzo's oil. Moser HW, et al. **Brain Pathol** 1995 Jul; 5(3):259–66 (72 ref.)

Disorders of peroxisome biogenesis. Braverman N, et al. **Hum Mol Genet** 1995;4 Spec No:1791–8 (115 ref.)

METABOLISM

Very long-chain fatty acids in diagnosis, pathogenesis, and therapy of peroxisomal disorders. Moser HW, et al. **Lipids** 1996 Mar;31 Suppl:S141–4 (18 ref.)

[Congenital disorders of the bile acid metabolism (3 beta-hydroxy-delta 5-steroid dehydrogenase/isomerase deficiency, delta 4-3-oxosteroid 5 beta-reductase deficiency, cerebrotendinous xanthomatosis, and peroxisomal disorders] Kondo KH, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):362–6 (23 ref.) **(Jpn)**

PATHOLOGY

Rhizomelic chondrodysplasia punctata: report of a case with review of the literature and correlation with other peroxisomal disorders. Agamanolis DP, et al. **Pediatr Pathol Lab Med** 1995 May–Jun;15(3):503–13 (25 ref.)

PHYSIOPATHOLOGY

[Peroxisomal diseases—oxygen and free radicals] Kremser K, et al. **Wien Klin Wochenschr** 1995;107(22):690–3 (46 ref.) (Eng. Abstr.) **(Ger)**

PEROXISOMAL DISORDERS

THERAPY

Microglia: the effector cell for reconstitution of the central nervous system following bone marrow transplantation for lysosomal and peroxisomal storage diseases. Krivit W, et al. **Cell Transplant** 1995 Jul-Aug;4(4):385-92 (71 ref.)

PEROXISOMES see **MICROBODIES**

PERSIAN GULF SYNDROME

War syndromes and their evaluation: from the U.S. Civil War to the Persian Gulf War. Hyams KC, et al. **Ann Intern Med** 1996 Sep 1;125(5):398-405 (131 ref.)

ETIOLOGY

Medical mystery: Gulf war syndrome. Ficarra BJ. **J Med** 1995;26(1-2):87-94 (9 ref.)

PERSISTENT FETAL CIRCULATION SYNDROME

CHEMICALLY INDUCED

[A possible association between the maternal administration of metamizole and persistent pulmonary hypertension in a newborn infant] Martí Solé JJ, et al. **An Esp Pediatr** 1996 Apr;44(4):387-8 (10 ref.) **(Spa)**

DIAGNOSIS

[Persistent pulmonary hypertension in newborns] Ganowicz J, et al. **Pediatr Pol** 1995 Mar;70(3):249-53 (14 ref.) (Eng. Abstr.) **(Pol)**

DRUG THERAPY

Inhaled nitric oxide therapy for persistent pulmonary hypertension of the newborn. Fineman JR, et al. **Acta Paediatr Jpn** 1995 Aug;37(4):425-30 (41 ref.)

Inhaled nitric oxide therapy of pulmonary hypertension and respiratory failure in premature and term neonates. Abman SH, et al. **Adv Pharmacol** 1995;34:457-74 (71 ref.)

Inhaled nitric oxide for persistent pulmonary hypertension of the newborn: the physiology matters! [comment] [see comments] Abman SH, et al. **Pediatrics** 1995 Dec; 96(6):1153-5 (14 ref.) Comment on: Pediatrics 1995 Dec;96(6):1147-51. Comment in: Pediatrics 1996 Mar;97(3):438-9.

Inhaled nitric oxide for persistent pulmonary hypertension of the newborn: implications and strategy for future "high-tech" neonatal clinical trials [see comments] Stark AR, et al. **Pediatrics** 1995 Dec;96(6):1147-51 (19 ref.) Comment in: Pediatrics 1995 Dec;96(6):1153-5.

ETIOLOGY

Alveolar capillary dysplasia--a cause of persistent pulmonary hypertension unresponsive to a second course of extracorporeal membrane oxygenation. Chelliah BP, et al. **Pediatrics** 1995 Dec;96(6):1159-61 (13 ref.)

PHYSIOPATHOLOGY

Mechanisms of abnormal vasoreactivity in persistent pulmonary hypertension of the newborn infant. Abman SH, et al. **J Perinatol** 1996 Mar-Apr;16(2 Pt 2 Su):S18-23 (44 ref.)

Clinical pathophysiology of persistent pulmonary hypertension of the newborn and the role of inhaled nitric oxide therapy. Kinsella JP, et al. **J Perinatol** 1996 Mar-Apr; 16(2 Pt 2 Su):S24-7 (28 ref.)

PERSISTENT PULMONARY HYPERTENSION OF NEWBORN see **PERSISTENT FETAL CIRCULATION SYNDROME**

PERSISTENT VEGETATIVE STATE

DIAGNOSIS

The 1994 Multi-Society Task Force consensus statement on the Persistent Vegetative State: a critical analysis. Howsepian AA. **Issues Law Med** 1996 Summer;12(1):3-29 (87 ref.)

THERAPY

[What is our approach to patients in persistent vegetative state? (editorial)] Roth F. **Schweiz Med Wochenschr** 1996 Jul 9;126(27-28):1187-90 (20 ref.) **(Ger)**

PERSONAL CONSTRUCT THEORY

[Constructivism: a characteristic of the psychic process] Ruiz RH. **Acta Psiquiatr Psicol Am Lat** 1995 May;41(2):114-20 (17 ref.) (Eng. Abstr.) **(Spa)**

PERSONAL EXPENDITURES see **FINANCING, PERSONAL**

PERSONAL LIABILITY see **LIABILITY, LEGAL**

PERSONALITY

A study of the development of traits of entry-level occupational therapy students. Donohue MV. **Am J Occup Ther** 1995 Jul-Aug;49(7):703-9 (22 ref.)

Hypnotizability and traumatic experience: a diathesis-stress model of dissociative symptomatology. Butler LD, et al. **Am J Psychiatry** 1996 Jul;153(7 Suppl):42-63 (155 ref.)

Hardiness and stress: a critical review. Huang C. **Matern Child Nurs J** 1995 Jul-Sep;23(3):82-9 (36 ref.)

The correlation between platelet MAO activity and personality: short review of findings and a discussion on possible mechanisms. Oreland L, et al. **Prog Brain Res** 1995; 106:77-84 (52 ref.)

Perception, personality, and respiratory control in life-threatening asthma. Gibson GJ. **Thorax** 1995 Sep;50 Suppl 1:S2-4 (15 ref.)

[Identity of the personality and personal identity: philosophical questions in relation to transplantation of brain tissue] Birnbacher D. **Zentralbl Neurochir** 1995; 56(4):180-5 (6 ref.) (Eng. Abstr.) **(Ger)**

[The psychological investigation of personality toward a multidimensional definition of characteristics] Lolas F. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1996 May-Jun;24(3):129-34 (22 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

Personality, emotions and the temporolimbic system: a neuropsychological approach. Beeckmans K, et al. **Acta Neurol Belg** 1996 Mar;96(1):35-42 (51 ref.)

PERSONALITY ASSESSMENT

The assessment of unwanted intrusive thoughts: a review and critique of the literature. Clark DA, et al. **Behav Res Ther** 1995 Nov;33(8):967-76 (60 ref.)

The neurology of alcoholic denial: implications for assessment and treatment. Duffy JD. **Can J Psychiatry** 1995 Jun;40(5):257-63 (30 ref.)

Migraine: association with personality characteristics and psychopathology. Silberstein SD, et al. **Cephalalgia** 1995 Oct;15(5):358-69; discussion 336 (64 ref.)

Annotation: self-injurious behaviour in children with learning disabilities: recent advances in assessment and intervention. Oliver C. **J Child Psychol Psychiatry** 1995 Sep;36(6):909-27 (100 ref.)

Levels and domains in personality: an introduction. Emmons RA. **J Pers** 1995 Sep;63(3):341-64 (70 ref.)

Multiple identities and the integration of personality. Gregg GS. **J Pers** 1995 Sep;63(3):617-41 (35 ref.)

Self-with-other representations and a taxonomy of motives: two approaches to studying persons. Ogilvie DM, et al. **J Pers** 1995 Sep;63(3):643-79 (80 ref.)

A clinical-empirical model of personality: life after the Mischelian ice age and the NEO-lithic era. Westen D. **J Pers** 1995 Sep;63(3):495-524 (95 ref.)

Assessing, diagnosing and treating culturally diverse individuals: a Hispanic perspective. Ruiz P. **Psychiatr Q** 1995 Winter;66(4):329-41 (34 ref.)

Psychological science and the use of anatomically detailed dolls in child sexual-abuse assessments. Koocher GP, et al. **Psychol Bull** 1995 Sep;118(2):199-222 (160 ref.)

STATISTICS & NUMERICAL DATA

Evaluating psychotropic drugs in people with mental retardation: where are the social validity data? Poling A, et al. **Am J Ment Retard** 1995 Sep;100(2):193-200 (48 ref.)

Personality: individual differences and clinical assessment. Butcher JN, et al. **Annu Rev Psychol** 1996;47:87-111 (240 ref.)

Assessment of sexual abuse and trauma: clinical measures. Miller TW, et al. **Child Psychiatry Hum Dev** 1995 Fall; 26(1):3-10 (20 ref.)

Recent developments for diagnostic measures in psychiatry. Ustün TB, et al. **Epidemiol Rev** 1995;17(1):210-20 (87 ref.)

The Child and Adolescent Psychiatric Assessment (CAPA). Angold A, et al. **Psychol Med** 1995 Jul;25(4):739-53 (35 ref.)

[Psychometric evaluation of obsessive compulsive disorder. Recent diagnostic scales] Buisson G, et al. **Encephale** 1989 May-Jun;15(3):359-67 (33 ref.) (Eng. Abstr.) **(Fre)**

[Measuring scales for assessment of coping behavior: a critical evaluation] Wendt A, et al. **Z Klin Psychol Psychopathol Psychother** 1996;44(1):3-32 (90 ref.) (Eng. Abstr.) **(Ger)**

PERSONALITY DEVELOPMENT

see related
SOCIALIZATION

Adoption and mental health: a theoretical critique of the psychopathological model. Wegar K. **Am J Orthopsychiatry** 1995 Oct;65(4):540-8 (55 ref.)

"Freedom's just another word": aboriginal youth and mental health. Hunter E. **Aust N Z J Psychiatry** 1995 Sep; 29(3):374-84 (64 ref.)

A clinical concept of the self: the experiential being. De Waele M. **Br J Med Psychol** 1995 Sep;68 (Pt 3):223-42 (85 ref.)

Transpersonal processes: a bridge between object relations and attachment theory in normal and psychopathological development. Muir RC. **Br J Med Psychol** 1995 Sep;68 (Pt 3):243-57 (85 ref.)

Antisocial personality disorder: a biopsychosocial model. Paris J. **Can J Psychiatry** 1996 Mar;41(2):75-80 (70 ref.)

Parents' attributions for their children's behavior. Miller SA. **Child Dev** 1995 Dec;66(6):1557-84 (110 ref.)

Children of alcoholic parents. A review. Steinhausen HC. **Eur Child Adolesc Psychiatry** 1995 Jul;4(3):143-52 (55 ref.)

The familiar and the strange: the dynamics of change. Lazar R. **Isr J Psychiatry Relat Sci** 1995;32(3):157-66 (25 ref.)

The role of affects in the process of change in psychotherapy. Stein R. **Isr J Psychiatry Relat Sci** 1995;32(3):174-83 (26 ref.)

Psychological characteristics of Turner syndrome. el Abd S, et al. **J Child Psychol Psychiatry** 1995 Oct;36(7):1109-25 (60 ref.)

Child and adolescent sex abuse perpetrators: a review of the research literature. Vizard E, et al. **J Child Psychol Psychiatry** 1995 Jul;36(5):731-56 (115 ref.)

An approach to psychotherapy change process research: introduction to the special section. Greenberg LS, et al. **J Consult Clin Psychol** 1996 Jun;64(3):435-8 (27 ref.)

Attachment and risk for psychopathology: the early years. Crittenden PM. **J Dev Behav Pediatr** 1995 Jun;16(3 Suppl):S12-6 (16 ref.)

Levels and domains in personality: an introduction. Emmons RA. **J Pers** 1995 Sep;63(3):341-64 (70 ref.)

Multiple identities and the integration of personality. Gregg GS. **J Pers** 1995 Sep;63(3):617-41 (35 ref.)

A multifactorial approach to the study of gender characteristics. Koestner R, et al. **J Pers** 1995 Sep; 63(3):681-710 (80 ref.)

The system-topics framework and the structural arrangement of systems within and around personality. Mayer JD. **J Pers** 1995 Sep;63(3):459-93 (93 ref.)

Self-with-other representations and a taxonomy of motives: two approaches to studying persons. Ogilvie DM, et al. **J Pers** 1995 Sep;63(3):643-79 (80 ref.)

Psychological needs and the facilitation of integrative processes. Ryan RM. **J Pers** 1995 Sep;63(3):397-427 (115 ref.)

Seeing one's self: locating narrative memory in a framework of personality. Singer JA. **J Pers** 1995 Sep;63(3):429-57 (75 ref.)

A clinical-empirical model of personality: life after the Mischelian ice age and the NEO-lithic era. Westen D. **J Pers** 1995 Sep;63(3):495-524 (95 ref.)

Somatoform and personality disorders: syndromal comorbidity and overlapping developmental pathways [comment] Bass C, et al. **J Psychosom Res** 1995 May; 39(4):403-27 (99 ref.) Comment on: J Psychosom Res 1995 May;39(4):395-7.

Familial and ecological correlates of self-esteem in African American children. Walker K, et al. **New Dir Child Dev** 1995 Summer;(68):23-34 (70 ref.)

Anxiety disorders of childhood, Implications for adult psychopathology. Pollock RA, et al. **Psychiatr Clin North Am** 1995 Dec;18(4):745-66 (102 ref.)

Issues in personality as diathesis for depression: the case of sociotropy-dependency and autonomy-self-criticism. Coyne JC, et al. **Psychol Bull** 1995 Nov;118(3):358-78 (125 ref.)

Contingency detection and the contingent organization of behavior in interactions: implications for socioemotional development in infancy. Tarabulsy GM, et al. **Psychol Bull** 1996 Jul;120(1):25-41 (110 ref.)

Models of development: understanding risk in adolescence. Graber JA, et al. **Suicide Life Threat Behav** 1995;25 Suppl:18-25 (35 ref.)

Adolescent development and the emergence of sexuality. Petersen AC, et al. **Suicide Life Threat Behav** 1995;25 Suppl:4-17 (95 ref.)

Sexual orientation and developmental challenges experienced by gay and lesbian youths. Rotheram-Borus MJ, et al. **Suicide Life Threat Behav** 1995;25 Suppl:26-34; discussion 35-9 (60 ref.)

[Anorexia nervosa. A frequent antecedent of obsessive compulsive disorder] Zribi S, et al. **Encephale** 1989 May-Jun;15(3):355-8 (19 ref.) (Eng. Abstr.) **(Fre)**

[White walls for black holes: essay on graffiti psychopathology] Catheline-Antipoff N, et al. **Psychiatr Enfant** 1995;38(2):625-53 (16 ref.) (Eng. Abstr.) **(Fre)**

[Development of the affect system] Moser U, et al. **Psyche (Stuttg)** 1996 Jan;50(1):32-84 (110 ref.) (Eng. Abstr.) **(Ger)**

[Psychoanalytic theories of hypochondria] Röder CH, et al. **Psyche (Stuttg)** 1995 Nov;49(11):1068-98 (65 ref.) (Eng. Abstr.) **(Ger)**

[Ontogenesis of affect regulation] Beckmann D, et al. **Psychother Psychosom Med Psychol** 1995 Dec; 45(12):427-35 (60 ref.) (Eng. Abstr.) **(Ger)**

[Life review: promoting the developmental potentials in aging] Lohmann R, et al. **Z Gerontol Geriatr** 1995 Jul-Aug; 28(4):236-41 (35 ref.) (Eng. Abstr.) **(Ger)**

PERSONALITY DISORDER, ANTISOCIAL see **ANTISOCIAL PERSONALITY DISORDER**

PERSONALITY DISORDER, BORDERLINE see **BORDERLINE PERSONALITY DISORDER**

PERSONALITY DISORDER, SCHIZOTYPAL see SCHIZOTYPAL PERSONALITY DISORDER

PERSONALITY DISORDERS

The role of Axis II comorbidity in the management of patients with treatment-resistant depression. Thase ME. **Psychiatr Clin North Am** 1996 Jun;19(2):287-309 (97 ref.)

CLASSIFICATION

The characterological basis of multiple personality. Brenner I. **Am J Psychother** 1996 Spring;50(2):154-66 (30 ref.)

DIAGNOSIS

The typology of personality disorders--diagnostic problems and their relevance for suicidal behavior [see comments] Bronisch T. **Crisis** 1996;17(2):55-8 (28 ref.) Comment in: Crisis 1996;17(2):50.

Dimensional classification and behavioral pharmacology of personality disorders; a review and hypothesis. Tuinier S, et al. **Eur Neuropsychopharmacol** 1995 Jun;5(2):135-46 (132 ref.)

The difficult elderly patient: curable hostile depression or personality disorder? Monfort JC. **Int Psychogeriatr** 1995; 7 Suppl:95-111 (50 ref.)

Clinical diagnoses and MCMI codetypes. Craig RJ. **J Clin Psychol** 1995 May;51(3):352-60 (75 ref.)

Issues in the assessment of personality disorder and substance abuse using the Millon Clinical Multiaxial Inventory (MCMI-II). Flynn PM, et al. **J Clin Psychol** 1995 May; 51(3):415-21 (24 ref.)

Chronic mood disorder and depressive personality. Shea MT, et al. **Psychiatr Clin North Am** 1996 Mar;19(1):103-20 (42 ref.)

DRUG THERAPY

Dimensional classification and behavioral pharmacology of personality disorders; a review and hypothesis. Tuinier S, et al. **Eur Neuropsychopharmacol** 1995 Jun;5(2):135-46 (132 ref.)

EPIDEMIOLOGY

Comorbidity of personality disorders and unipolar major depression: a review. Corruble E, et al. **J Affect Disord** 1996 Apr 12;37(2-3):157-70 (100 ref.)

PSYCHOLOGY

Basic behavioral science research for mental health. Vulnerability and resilience. Basic Behavioral Science Task Force of the National Advisory Mental Health Council. **Am Psychol** 1996 Jan;51(1):22-8 (7 ref.)

Transpersonal processes: a bridge between object relations and attachment theory in normal and psychopathological development. Muir RC. **Br J Med Psychol** 1995 Sep;68 (Pt 3):243-57 (85 ref.)

Somatoform and personality disorders: syndromal comorbidity and overlapping developmental pathways [comment] Bass C, et al. **J Psychosom Res** 1995 May; 39(4):403-27 (99 ref.) Comment on: J Psychosom Res 1995 May;39(4):395-7.

Adolescent substance use disorder with conduct disorder and comorbid conditions. Crowley TJ, et al. **NIDA Res Monogr** 1995;156:49-111 (178 ref.)

PERSONALITY INVENTORY

[Expectations of control in the context of personality. More about the factorial structure of Levenson's IPC scale] Verissimo R. **Acta Med Port** 1996 Jan;9(1):21-8 (42 ref.) (Eng. Abstr.) **(Por)**

STATISTICS & NUMERICAL DATA

Contrasting self-report screens for alcohol problems: a review. Maisto SA, et al. **Alcohol Clin Exp Res** 1995 Dec; 19(6):1510-6 (24 ref.)

Personality: individual differences and clinical assessment. Butcher JN, et al. **Annu Rev Psychol** 1996;47:87-111 (240 ref.)

Present use of the Hamilton Depression Rating Scale: observation on method of assessment in research of depressive disorders. Snaith RP. **Br J Psychiatry** 1996 May; 168(5):594-7 (11 ref.)

Clinical diagnoses and MCMI codetypes. Craig RJ. **J Clin Psychol** 1995 May;51(3):352-60 (75 ref.)

Issues in the assessment of personality disorder and substance abuse using the Millon Clinical Multiaxial Inventory (MCMI-II). Flynn PM, et al. **J Clin Psychol** 1995 May; 51(3):415-21 (24 ref.)

[Psychometric evaluation of obsessive compulsive disorder. Recent diagnostic scales] Buisson G, et al. **Encephale** 1989 May-Jun;15(3):359-67 (33 ref.) (Eng. Abstr.) **(Fre)**

[Measuring scales for assessment of coping behavior: a critical evaluation] Wendt A, et al. **Z Klin Psychol Psychopathol Psychother** 1996;44(1):3-32 (90 ref.) (Eng. Abstr.) **(Ger)**

PERSONALITY TESTS

STATISTICS & NUMERICAL DATA

Recent developments for diagnostic measures in psychiatry. Ustün TB, et al. **Epidemiol Rev** 1995;17(1):210-20 (87 ref.)

PERSONALITY TYPE A see TYPE A PERSONALITY

PERSONNEL, HOSPITAL

How safe is your ED? Keep NB, et al. **Am J Nurs** 1995 Sep;95(9):44-50; quiz 51 (5 ref.)

Contact lens wear by hospital health care staff: is there cause for concern? Hay J, et al. **J Hosp Infect** 1995 Jun;30 Suppl:275-81 (40 ref.)

[Effect of vaccination on the risk of hepatitis B infection in hospital personnel] Mihály I, et al. **Orv Hetil** 1996 Mar 31;137(13):681-5 (36 ref.) (Eng. Abstr.) **(Hun)**

PERSONNEL RECRUITMENT see PERSONNEL SELECTION

PERSONNEL SELECTION

[Atopy, asthma and the judgement of preemployment fitness] Innocenti A. **Med Lav** 1995 Jul-Aug;86(4):303-8 (36 ref.) (Eng. Abstr.) **(Ita)**

LEGISLATION & JURISPRUDENCE

Implications of negligent selection and retention of physicians in the age of ERISA. Dorros TA, et al. **Am J Law Med** 1995;21(4):383-418 (346 ref.)

METHODS

Making medical recruitment practices fair. Maddock S. **Postgrad Med J** 1996 Mar;72(845):147-50 (8 ref.)

STANDARDS

A critical review of personnel standards. Peddecord KM. **Clin Chem** 1996 May;42(5):790-6 (25 ref.)

TRENDS

Recruitment and workforce issues in late 20th century American psychiatry. Weissman S. **Psychiatr Q** 1996 Summer;67(2):125-37 (8 ref.)

PERSUASION see PERSUASIVE COMMUNICATION

PERSUASIVE COMMUNICATION

see related
PROPAGANDA
SUGGESTION

Transferring research findings on persuasion to improve drug abuse prevention programs. McGuire WJ. **NIDA Res Monogr** 1995;155:225-45 (8 ref.)

Creating strong attitudes: two routes to persuasion. Petty RE. **NIDA Res Monogr** 1995;155:209-24 (33 ref.)

PERTECHNETATE SODIUM see SODIUM PERTECHNETATE TC 99M

PERTUSSIGEN see PERTUSSIS TOXINS

PERTUSSIS see WHOOPING COUGH

PERTUSSIS TOXINS

CHEMISTRY

A proposed mechanism of ADP-ribosylation catalyzed by the pertussis toxin S1 subunit. Locht C, et al. **Biochimie** 1995;77(5):333-40 (56 ref.)

METABOLISM

A proposed mechanism of ADP-ribosylation catalyzed by the pertussis toxin S1 subunit. Locht C, et al. **Biochimie** 1995;77(5):333-40 (56 ref.)

PERTUSSIS VACCINE

Acellular pertussis vaccines. Miller E. **Arch Dis Child** 1995 Nov;73(5):390-1 (15 ref.)

Control of whooping cough in New Zealand; slow progress [see comments] Lennon D, et al. **N Z Med J** 1995 Dec 8;108(1013):495-7 (37 ref.) Comment in: N Z Med J 1996 Mar 8;109(1017):84. Comment in: N Z Med J 1996 Mar 22;109(1018):107-8.

IMMUNOLOGY

[Efficacy of acellular pertussis vaccines] Wirsing von König CH, et al. **Immun Infekt** 1995 Aug;23(4):125-9 (15 ref.) (Eng. Abstr.) **(Ger)**

PHARMACOLOGY

Acellular pertussis vaccines: a turning point in infant and adolescent vaccination. Rappuoli R. **Infect Agents Dis** 1996 Jan;5(1):21-8 (51 ref.)

PERVASIVE CHILD DEVELOPMENT DISORDERS see CHILD DEVELOPMENT DISORDERS, PERVASIVE

PERYLENE

ANALOGS & DERIVATIVES

Novel therapeutic and diagnostic applications of hypocrellins and hypericins. Diwu Z. **Photochem Photobiol** 1995 Jun; 61(6):529-39 (118 ref.)

PES CAVUS see FOOT DEFORMITIES

PES PLANUS see FLATFOOT

PESSARIES, INTRACERVICAL see INTRAUTERINE DEVICES

PESSARIES, INTRAUTERINE see INTRAUTERINE DEVICES

PEST CONTROL

Virus-vectored immunocontraception for control of wild rabbits: identification of target antigens and construction of recombinant viruses. Holland MK, et al. **Reprod Fertil Dev** 1994;6(5):631-42 (61 ref.)

STANDARDS

Swedish pesticide risk reduction 1981-1995: food residues, health hazard, and reported poisonings. Ekström G, et al. **Rev Environ Contam Toxicol** 1996;147:119-47 (67 ref.)

Environmental fate of rice pesticides in California. Mabury SA, et al. **Rev Environ Contam Toxicol** 1996;147:71-117 (202 ref.)

PEST CONTROL, BIOLOGICAL

Biocontrol from a mosquito control director's point of view. Beidler EJ. **J Am Mosq Control Assoc** 1995 Jun;11(2 Pt 2):258-9 (6 ref.)

The future of microbial insecticides as vector control agents. Federici BA. **J Am Mosq Control Assoc** 1995 Jun;11(2 Pt 2):260-8 (32 ref.)

Control of tsetse flies (Diptera: Glossinidae) with the aid of attractants. Jordan AM. **J Am Mosq Control Assoc** 1995 Jun;11(2 Pt 2):249-55 (52 ref.)

The future of insect growth regulators in vector control. Mulla MS. **J Am Mosq Control Assoc** 1995 Jun;11(2 Pt 2):269-73 (32 ref.)

Regulatory factors affecting larval mosquito populations in container and pool habitats: implications for biological control. Washburn JO. **J Am Mosq Control Assoc** 1995 Jun;11(2 Pt 2):279-83 (13 ref.)

The safety of Bacillus species as insect vector control agents. Drobniewski FA. **J Appl Bacteriol** 1994 Feb;76(2):101-9 (80 ref.)

Baculovirus bounty. Volkman LE. **Science** 1995 Sep 29; 269(5232):1834 (12 ref.)

METHODS

Bacillus thuringiensis: fermentation process and risk assessment. A short review. Capalbo DM. **Mem Inst Oswaldo Cruz** 1995 Jan-Feb;90(1):135-8 (27 ref.)

PESTICIDE RESIDUES

ANALYSIS

Accreditation in the UK for pesticide residue analysis in foods. Thorpe SA, et al. **J Chromatogr A** 1996 Jun 14; 737(1):3-7 (4 ref.)

Persistent pesticides in Mexico. Albert LA. **Rev Environ Contam Toxicol** 1996;147:1-44 (85 ref.)

[Enzyme immunoassay of pesticide residues in foods] Nishijima M. **Nippon Rinsho** 1995 Sep;53(9):2310-5 (16 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Environmental fate of rice pesticides in California. Mabury SA, et al. **Rev Environ Contam Toxicol** 1996;147:71-117 (202 ref.)

PHARMACOKINETICS

Bioavailability of bound pesticide residues and potential toxicologic consequences - an update. Kacew S, et al. **Proc Soc Exp Biol Med** 1996 Jan;211(1):62-68 (73 ref.)

POISONING

Swedish pesticide risk reduction 1981-1995: food residues, health hazard, and reported poisonings. Ekström G, et al. **Rev Environ Contam Toxicol** 1996;147:119-47 (67 ref.)

TOXICITY

International safety assessment of pesticides: dithiocarbamate pesticides, ETU, and PTU--a review and update. Vettorazzi G, et al. **Teratog Carcinog Mutagen** 1995-96; 15(6):313-37 (88 ref.)

PESTICIDES

ADVERSE EFFECTS

Developmental neurotoxicology in the neonate—effects of pesticides and polychlorinated organic substances. Eriksson P. **Arch Toxicol Suppl** 1996;18:81–8 (26 ref.)

The reproductive toxicology of Great Lakes contaminants. Foster WG. **Environ Health Perspect** 1995 Dec;103 Suppl 9:63–9 (85 ref.)

Reproductive effects in birds exposed to pesticides and industrial chemicals. Fry DM. **Environ Health Perspect** 1995 Oct;103 Suppl 7:165–71 (85 ref.)

Pesticides: an important but underused model for the environmental health sciences. Hodgson E, et al. **Environ Health Perspect** 1996 Mar;104 Suppl 1:97–106 (105 ref.)

Maternal pesticide exposure and pregnancy outcome. Nurminen T. **J Occup Environ Med** 1995 Aug;37(8):935–40 (27 ref.)

A review of the acceptable daily intakes of pesticides assessed by WHO. Lu FC. **Regul Toxicol Pharmacol** 1995 Jun; 21(3):352–64 (9 ref.)

The cat, the flea, and pesticides. Logas DB. **Vet Clin North Am Small Anim Pract** 1995 Jul;25(4):801–11 (60 ref.)

ANALYSIS

Immunoassay of pesticides: an update. Kaufman BM, et al. **J AOAC Int** 1995 Jul–Aug;78(4):1079–90 (111 ref.)

METABOLISM

Pesticide–metabolizing enzymes. Hodgson E, et al. **Toxicol Lett** 1995 Dec;82–83:73–81 (41 ref.)

PHARMACOLOGY

Molecular biology and evolution of resistance of toxicants. Taylor M, et al. **Mol Biol Evol** 1996 Jul;13(6):719–34 (141 ref.)

The study of interactive effects of pollutants: a biomarker approach. Johnston G. **Sci Total Environ** 1995 Oct 27; 171(1–3):205–12 (18 ref.)

POISONING

Pesticides—how research has succeeded and failed to translate science into policy: endocrinological effects on wildlife. Colborn T. **Environ Health Perspect** 1995 Sep;103 Suppl 6:81–5 (55 ref.)

Oral aluminium phosphide poisoning. Sharma A. **Indian Pediatr** 1995 Mar;32(3):339–42 (17 ref.)

Pesticides and children. Reigart JR. **Pediatr Ann** 1995 Dec; 24(12):663–8 (18 ref.)

Swedish pesticide risk reduction 1981–1995: food residues, health hazard, and reported poisonings. Ekström G, et al. **Rev Environ Contam Toxicol** 1996;147:119–47 (67 ref.)

Recent epidemics of poisoning by pesticides. Ferrer A, et al. **Toxicol Lett** 1995 Dec;82–83:55–63 (24 ref.)

[A case of acute peroral poisoning by the preparation Nitrafen] Nikitin PV, et al. **Sud Med Ekspert** 1996 Jan–Mar; 39(1):33–5 (9 ref.) **(Rus)**

TOXICITY

Pesticide–induced immunotoxicity: are Great Lakes residents at risk? Thomas PT. **Environ Health Perspect** 1995 Dec; 103 Suppl 9:55–61 (78 ref.)

Brain tumor and exposure to pesticides in humans: a review of the epidemiologic data. Bohnen NI, et al. **J Neurol Sci** 1995 Oct;132(2):110–21 (93 ref.)

Clinical immunotoxicity of pesticides. Vial T, et al. **J Toxicol Environ Health** 1996 Jun 28;48(3):215–29 (59 ref.)

A review of the acceptable daily intakes of pesticides assessed by WHO. Lu FC. **Regul Toxicol Pharmacol** 1995 Jun; 21(3):352–64 (9 ref.)

Pesticide exposure assessment. Krieger RI. **Toxicol Lett** 1995 Dec;82–83:65–72 (26 ref.)

Regulatory and research issues related to cholinesterase inhibition. Padilla S. **Toxicology** 1995 Sep 1;102(1–2):215–20 (29 ref.)

PESTIVIRUS

Ruminant pestiviruses. Nettleton PF, et al. **Br Vet J** 1995 Nov–Dec;151(6):615–42 (130 ref.)

CLASSIFICATION

Pestivirus diversity. Paton DJ. **J Comp Pathol** 1995 Apr; 112(3):215–36 (167 ref.)

IMMUNOLOGY

Antigenic differences among pestiviruses. Edwards S, et al. **Vet Clin North Am Food Anim Pract** 1995 Nov;11(3):563–77 (107 ref.)

ISOLATION & PURIFICATION

Ruminant pestivirus infections in animals other than cattle and sheep. Løken T. **Vet Clin North Am Food Anim Pract** 1995 Nov; 11(3):597–614 (97 ref.)

[Simple detection of the contamination in animal cell cultures] Harasawa R, et al. **Tanpakushitsu Kakusan Koso** 1995 Nov;40(15):2361–8 (15 ref.) **(Jpn)**

PESTIVIRUS, BOVINE see **DIARRHEA VIRUS, BOVINE VIRAL**

PESTIVIRUS INFECTIONS

VETERINARY

Ruminant pestiviruses. Nettleton PF, et al. **Br Vet J** 1995 Nov–Dec;151(6):615–42 (130 ref.)

Antigenic differences among pestiviruses. Edwards S, et al. **Vet Clin North Am Food Anim Pract** 1995 Nov;11(3):563–77 (107 ref.)

Ruminant pestivirus infections in animals other than cattle and sheep. Løken T. **Vet Clin North Am Food Anim Pract** 1995 Nov; 11(3):597–614 (97 ref.)

PET–HUMAN BONDING see **BONDING, HUMAN–PET**

PET SCAN see **TOMOGRAPHY, EMISSION–COMPUTED**

PETECHIAE see **PURPURA**

PETHIDINE see **MEPERIDINE**

PETIT MAL EPILEPSY see **EPILEPSY, ABSENCE**

PETIT MAL STATUS see **STATUS EPILEPTICUS**

PETRIELLIDIUM see **PSEUDALLESCHERIA**

PETROLATUM, LIQUID see **MINERAL OIL**

PETROLEUM

Field evaluations of marine oil spill bioremediation. Swannell RP, et al. **Microbiol Rev** 1996 Jun;60(2):342–65 (121 ref.)

POISONING

An overview of exposure to, and effects of, petroleum oil and organochlorine pollution in grey seals (Halichoerus grypus). Jenssen BM. **Sci Total Environ** 1996 Jul 16; 186(1–2):109–18 (54 ref.)

Toxicology of oil field pollutants in cattle: a review. Coppock RW, et al. **Vet Hum Toxicol** 1995 Dec;37(6):569–76 (59 ref.)

TOXICITY

The influence of petrochemicals and stress on the immune system of seabirds. Briggs KT, et al. **Regul Toxicol Pharmacol** 1996 Apr;23(2):145–55 (77 ref.)

PETROUS BONE

[Malignant tumors of the petrous bone. Apropos of 25 cases] Depondt J, et al. **Ann Otolaryngol Chir Cervicofac** 1995; 112(7):309–16 (11 ref.) (Eng. Abstr.) **(Fre)**

BLOOD SUPPLY

Imaging quiz case 1. Ectopic internal carotid artery (ICA) within the petrous temporal bone. Saada AA, et al. **Arch Otolaryngol Head Neck Surg** 1996 Jul;122(7):792, 794 (10 ref.)

RADIOGRAPHY

Imaging quiz case 2. Bilateral osteomas of the petrous temporal bones. Hamilton MM, et al. **Arch Otolaryngol Head Neck Surg** 1996 Jul;122(7):793, 795 (9 ref.)

PETROUS PYRAMID see **PETROUS BONE**

PETS see **ANIMALS, DOMESTIC**

PEUTZ–JEGHERS SYNDROME

Polyposis: the Peutz–Jeghers syndrome. Spigelman AD, et al. **Br J Surg** 1995 Oct;82(10):1311–4 (31 ref.)

[Hamartomatous polyposis syndrome] Tamura K, et al. **Nippon Rinsho** 1995 Nov;53(11):2728–33 (24 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

[Peutz–Jeghers syndrome. Apropos a familial case at Hospital Arzobispo Loayza] Lozano A, et al. **Rev Gastroenterol Peru** 1996 Jan–Apr;16(1):72–6 (19 ref.) (Eng. Abstr.) **(Spa)**

PEYER'S PATCHES

ANATOMY & HISTOLOGY

Expanding the role of Peyer's patches in B–cell ontogeny. Griebel PJ, et al. **Immunol Today** 1996 Jan;17(1):30–9 (76 ref.)

CYTOLOGY

M cells in Peyer's patches of the intestine. Gebert A, et al. **Int Rev Cytol** 1996;167:91–159 (310 ref.)

IMMUNOLOGY

Entry of microbes into the host: using M cells to break the mucosal barrier. Jones B, et al. **Curr Opin Immunol** 1995 Aug;7(4):474–8 (46 ref.)

Oral tolerance: mobilizing the gut. Weiner HL. **Hosp Pract (Off Ed)** 1995 Sep 15;30(9):53–8 (6 ref.)

MICROBIOLOGY

Entry of microbes into the host: using M cells to break the mucosal barrier. Jones B, et al. **Curr Opin Immunol** 1995 Aug;7(4):474–8 (46 ref.)

PEYRONIE'S DISEASE see **PENILE INDURATION**

PF 4 see **PLATELET FACTOR 4**

PFAUNDLER–HURLER SYNDROME see **MUCOPOLYSACCHARIDOSIS I**

PG ANALOGS see **PROSTAGLANDINS, SYNTHETIC**

PGA see **PROSTAGLANDINS A**

PGD2 see **PROSTAGLANDIN D2**

PGE see **PROSTAGLANDINS E**

PGE RECEPTORS see **RECEPTORS, PROSTAGLANDIN E**

PGE1 see **ALPROSTADIL**

PGE2 see **DINOPROSTONE**

PGE2ALPHA see **DINOPROSTONE**

PGE2 RECEPTORS see **RECEPTORS, PROSTAGLANDIN E**

PGF see **PROSTAGLANDINS F**

PGF SYNETHETIC see **PROSTAGLANDINS F, SYNTHETIC**

PGF2 see **DINOPROST**

PGF2ALPHA see **DINOPROST**

PGH SYNTHASE see **PROSTAGLANDIN–ENDOPEROXIDE SYNTHASE**

PGI2 see **EPOPROSTENOL**

PGX see **EPOPROSTENOL**

PH see **HYDROGEN–ION CONCENTRATION**

PH1 CHROMOSOME see **PHILADELPHIA CHROMOSOME**

PHACOEMULSIFICATION

Intraocular lens implantation in patients with juvenile rheumatoid arthritis–associated uveitis: an unresolved management issue [editorial; comment] Holland GN. **Am J Ophthalmol** 1996 Aug;122(2):255–7 (10 ref.) Comment on: Am J Ophthalmol 1996 Aug;122(2):161–70.

Intraocular lens implantation in patients with juvenile rheumatoid arthritis [see comments] Probst LE, et al. **Am J Ophthalmol** 1996 Aug;122(2):161–70 (24 ref.) Comment in: Am J Ophthalmol 1996 Aug;122(2):255–7.

METHODS

Phacoemulsification: small incision cataract surgery. Craig EA. **Scott Med J** 1995 Jun;40(3):72–3 (16 ref.)

PHAGE LAMBDA see **BACTERIOPHAGE LAMBDA**

PHAGE M13 see **BACTERIOPHAGE M13**

PHAGE MU see **BACTERIOPHAGE MU**

PHAGE MU 1 see **BACTERIOPHAGE MU**

PHAGE PHI 29 see **BACILLUS PHAGES**

PHAGE PHI 105 see **BACILLUS PHAGES**

PHAGE RECEPTORS see **RECEPTORS, VIRUS**

PHAGE T4 see **BACTERIOPHAGE T4**

PHAGES see **BACTERIOPHAGES**

PHAGOCYTES

The mononuclear phagocyte–dendritic cell dichotomy:

myths, facts, and a revised concept. Goerdt S, et al. **Clin Exp Immunol** 1996 Jul;105(1):1–9 (143 ref.)

DRUG EFFECTS

Mineral fiber–induced oxidative stress in phagocytes. Savolainen KM, et al. **Arch Toxicol Suppl** 1996;18:236–47 (53 ref.)

Cytokines, phagocytes, and pentoxifylline. Mandell GL. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S20–2 (7 ref.)

ENZYMOLOGY

Intracellular regulation. Rac and Bcr regulate phagocytic phoxes. Ridley AJ. **Curr Biol** 1995 Jul 1;5(7):710–2 (19 ref.)

The NADPH oxidase complex of phagocytic leukocytes: a biochemical and cytochemical view. Robinson JM, et al. **Histochem Cell Biol** 1995 Mar;103(3):163–80 (197 ref.)

IMMUNOLOGY

Nonopsonic phagocytosis of microorganisms. Ofek I, et al. **Annu Rev Microbiol** 1995;49:239–76 (187 ref.)

Entry of Mycobacterium tuberculosis into mononuclear phagocytes. Schlesinger LS. **Curr Top Microbiol Immunol** 1996;215:71–96 (150 ref.)

Parasite escape mechanisms: the role of Leishmania lipophosphoglycan on the human phagocyte functions. A review. Panaro MA, et al. **Immunopharmacol Immunotoxicol** 1995 Aug;17(3):595–605 (50 ref.)

Fc gamma receptors of phagocytes. de Haas M, et al. **J Lab Clin Med** 1995 Oct;126(4):330–41 (128 ref.)

[Increased activity of phagocytes in cigarette smokers—supposed connection with lung emphysema] Zięba M, et al. **Pneumonol Pol** 1990 Nov–Dec; 58(11–12):651–4 (23 ref.) **(Pol)**

[Molecular genetic aspects of invasive and antiphagocytic properties of pathogenic Yersinia] Kukleva LM, et al. **Mol Gen Mikrobiol Virusol** 1996 Jan–Mar;(1):11–6 (95 ref.) **(Rus)**

MICROBIOLOGY

Association of bacteria with human phagocytes. Rest RF. **Methods Enzymol** 1995;253:12–26 (22 ref.)

PHYSIOLOGY

Vitamins in the maintenance of optimum immune functions and in the prevention of phagocyte-mediated tissue damage and carcinogenesis. Anderson R, et al. **Bibl Nutr Dieta** 1995;(52):66–74 (34 ref.)

Cytokines, phagocytes, and pentoxifylline. Mandell GL. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S20–2 (7 ref.)

Role of mononuclear phagocytes in M tuberculosis pathogenesis. Schlesinger LS. **J Investig Med** 1996 Aug; 44(6):312–23 (161 ref.)

Effects of selenium and vitamin E on the immune responses of domestic animals. Finch JM, et al. **Res Vet Sci** 1996 Mar;60(2):97–106 (108 ref.)

[Role of hematopoietic factors in regulation of proliferation and function of phagocytes] Czygier M, et al. **Postepy Hig Med Dosw** 1995;49(4):563–79 (80 ref.) (Eng. Abstr.) **(Pol)**

PHAGOCYTOSIS

Haemophagocytosis in bone marrow aspirate—a review of the clinical course of 10 cases. Linn YC, et al. **Acta Haematol** 1995;94(4):182–91 (25 ref.)

Tuberculosis-associated haemophagocytic syndrome: a report of two cases and a review of the literature. Undar L, et al. **Acta Haematol** 1996;96(2):73–8 (36 ref.)

Pulmonary intravascular phagocytosis in liver disease. Chang SW, et al. **Clin Chest Med** 1996 Mar;17(1):137–50 (62 ref.)

Entry of Mycobacterium tuberculosis into mononuclear phagocytes. Schlesinger LS. **Curr Top Microbiol Immunol** 1996;215:71–96 (150 ref.)

The phagocytosis of mycoplasmas. Marshall AJ, et al. **J Med Microbiol** 1995 Oct;43(4):239–50 (163 ref.)

[Disorders of clearance of pollutants from the lung] Mustajbegović J, et al. **Lijec Vjesn** 1996 Jan–Feb; 118(1–2):39–43 (88 ref.) (Eng. Abstr.) **(Ser)**

IMMUNOLOGY

Leukophagocytosis in human parvovirus B19–induced transient bicytopenia in a healthy child. Wakamoto H, et al. **Acta Paediatr Jpn** 1996 Jun;38(3):278–81 (19 ref.)

PHYSIOLOGY

Nonopsonic phagocytosis of microorganisms. Ofek I, et al. **Annu Rev Microbiol** 1995;49:239–76 (187 ref.)

The molecular dissection of Fc gamma receptor mediated phagocytosis. Indik ZK, et al. **Blood** 1995 Dec 15; 86(12):4389–99 (85 ref.)

Intracytoplasmic sequences involved in the biological properties of low-affinity receptors for IgG expressed by murine macrophages. Daëron M. **Braz J Med Biol Res** 1995 Mar;28(3):263–74 (50 ref.)

Myelodysplastic syndrome associated with erythrophagocytosis by blasts and myeloid cells. Kuyama J, et al. **Int J Hematol** 1995 Dec;62(4):243–6 (14 ref.)

[Oxidants and antioxidants. Biological effects and therapeutic perspectives] Urban T, et al. **Ann Chir** 1995;49(5):427–34 (55 ref.) (Eng. Abstr.) **(Fre)**

[Assessing the basic stages of the phagocytic process: current approaches to and prospects for research development] Khaitov RM, et al. **Patol Fiziol Eksp Ter** 1995 Jul–Sep; (3):3–10 (59 ref.) (Eng. Abstr.) **(Rus)**

PHAGOSOMES

see related
PHAGOCYTOSIS

PHARMACEUTIC AIDS (PRESERVATIVES) see **PRESERVATIVES, PHARMACEUTICAL**

PHARMACEUTICAL ECONOMICS see **ECONOMICS, PHARMACEUTICAL**

PHARMACEUTICAL SERVICES

Evolving role of the pharmacist in the critical care environment. Dasta JF. **J Clin Anesth** 1996 May;8(3 Suppl):99S–102S (31 ref.)

ORGANIZATION & ADMINISTRATION

[The new pharmacy practice: can pharmaceutical intervention improve therapeutical efficiency] Alvarez de Toledo F, et al. **Rev Esp Salud Publica** 1995 May–Aug; 69(3–4):277–82 (19 ref.) (Eng. Abstr.) **(Spa)**

TRENDS

Recent advances: ambulatory care and family medicine. Gums JG. **Ann Pharmacother** 1995 Jul–Aug;29(7–8):716–8 (10 ref.)

PHARMACISTS

Advanced counseling techniques: integrating assessment and intervention. Foster SL, et al. **Am Pharm** 1995 Oct; NS35(10):40–8; quiz 48–50 (10 ref.)

Pharmacists as agents of change for rational drug therapy. Lipton HL, et al. **Int J Technol Assess Health Care** 1995 Summer;11(3):485–508 (138 ref.)

PHARMACOECONOMICS see **ECONOMICS, PHARMACEUTICAL**

PHARMACOEPIDEMIOLOGY

Pharmacoepidemiology in practice. Current status and future trends. Alvarez-Requejo A, et al. **Drug Saf** 1995 Jul; 13(1):1–7 (39 ref.)

Presymptomatic testing for genetic diseases of later life. Pharmacoepidemiological considerations. Rossiter BJ, et al. **Drugs Aging** 1995 Aug;7(2):117–30 (131 ref.)

METHODS

Comparing period prevalences with application to drug utilization. McFarland BH. **J Clin Epidemiol** 1996 Apr; 49(4):473–82 (21 ref.)

PHARMACOGENETICS

Mechanisms of drug eruptions: Part I. Breathnach SM. **Australas J Dermatol** 1995 Aug;36(3):121–7 (100 ref.)

Pharmacogenetic models of alcoholism. Li TK, et al. **Clin Neurosci** 1995;3(3):182–8 (62 ref.)

PHARMACOGNOSY

Recent advances in pharmacognosy research in China. Wang ZT, et al. **Gen Pharmacol** 1995 Oct;26(6):1211–24 (186 ref.)

PHARMACOKINETICS

Prediction of in vivo drug disposition from in vitro data based on physiological pharmacokinetics. Iwatsubo T, et al. **Biopharm Drug Dispos** 1996 May;17(4):273–310 (123 ref.)

Drug removal in continuous haemofiltration and haemodialysis. Davies JG, et al. **Br J Hosp Med** 1995 Nov 15–Dec 12;54(10):524–8 (30 ref.)

The 1994 G. Malcolm Brown Lecture. Biological barriers and medicine. Goresky CA. **Clin Invest Med** 1995 Dec; 18(6):484–501 (23 ref.)

The backpropagation neural network—a Bayesian classifier. Introduction and applicability to pharmacokinetics. Erb RJ. **Clin Pharmacokinet** 1995 Aug;29(2):69–79 (50 ref.)

Clinical pharmacokinetics of various topical ophthalmic delivery systems. Frangie JP. **Clin Pharmacokinet** 1995 Aug;29(2):130–8 (37 ref.)

The target concentration approach to clinical drug development. Holford NH. **Clin Pharmacokinet** 1995 Nov; 29(5):287–91 (17 ref.)

Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. An update. Morgan DJ, et al. **Clin Pharmacokinet** 1995 Nov; 29(5):370–91 (145 ref.)

Effects of dietary fat on drug absorption. Zhi J, et al. **Clin Pharmacol Ther** 1995 Nov;58(5):487–91 (47 ref.)

Species similarities and differences in pharmacokinetics. Lin JH. **Drug Metab Dispos** 1995 Oct;23(10):1008–21 (141 ref.)

Drug interactions of clinical importance. An updated guide. Quinn DI, et al. **Drug Saf** 1995 Jun;12(6):393–452 (14 ref.)

Gender effects in pharmacokinetics and pharmacodynamics. Harris RZ, et al. **Drugs** 1995 Aug;50(2):222–39 (170 ref.)

Causes and problems of nonresponse or poor response to drugs. Salvà Lacombe P, et al. **Drugs** 1996 Apr; 51(4):552–70 (162 ref.)

Pharmacokinetics during continuous renal replacement therapy. Keller E. **Int J Artif Organs** 1996 Feb;19(2):113–7 (8 ref.)

Analysis of errors due to assigned model constants in pharmacokinetic calculations based on functional optimization. Thomaseth K. **Int J Clin Pharmacol Ther** 1995 Oct;33(10):555–9 (8 ref.)

Pharmacokinetics of continuous renal replacement therapy. Schetz M, et al. **Intensive Care Med** 1995 Jul;21(7):612–20 (33 ref.)

Perspectives in pharmacokinetics. Physiologically based pharmacokinetic modeling as a tool for drug development [see comments] Charnick SB, et al. **J Pharmacokinet Biopharm** 1995 Apr;23(2):217–29 (70 ref.)
Comment in: J Pharmacokinet Biopharm 1995 Apr;23(2):231–5.

Design of drugs involving the concepts and theories of drug metabolism and pharmacokinetics. Smith DA, et al. **Med Res Rev** 1996 May;16(3):243–66 (54 ref.)

Progressive application of autoradiography in pharmacokinetic and metabolic studies for the development of new drugs. Shigematsu A, et al. **Regul Toxicol Pharmacol** 1995 Oct;22(2):122–42 (20 ref.)

Modifying toxicokinetics with antidotes. Baud FJ, et al. **Toxicol Lett** 1995 Dec;82–83:785–93 (20 ref.)

Toxicokinetic models for volatile industrial chemicals and reactive metabolites. Filser JG, et al. **Toxicol Lett** 1995 Dec;82–83:357–66 (28 ref.)

Extrapolation of physiological parameters for physiologically based simulation models. Fiserova-Bergerova V. **Toxicol Lett** 1995 Sep;79(1–3):77–86 (39 ref.)

Physiologically based pharmacokinetic models: mathematical fundamentals and simulation implementations. Hoang K. **Toxicol Lett** 1995 Sep;79(1–3):99–106 (20 ref.)

Development of partition coefficients, Vmax and Km values, and allometric relationships. Knaak JB, et al. **Toxicol Lett** 1995 Sep;79(1–3):87–98 (26 ref.)

Applications and prospects for physiologically based pharmacokinetic (PB–PK) models involving pharmaceutical agents. Suzuki H, et al. **Toxicol Lett** 1995 Dec;82–83:349–55 (31 ref.)

The use of physiologically-based pharmacokinetic/pharmacodynamic dosimetry models for chemical mixtures. Yang RS, et al. **Toxicol Lett** 1995 Dec; 82–83:497–504 (21 ref.)

Basic principles of pharmacokinetics. Benet LZ, et al. **Toxicol Pathol** 1995 Mar–Apr;23(2):115–23 (15 ref.)

Concomitant toxicokinetics: techniques for and interpretation of exposure data obtained during the conduct of toxicology studies. Dahlem AM, et al. **Toxicol Pathol** 1995 Mar–Apr; 23(2):170–8 (9 ref.)

Differences between pharmacokinetics and toxicokinetics. Welling PG. **Toxicol Pathol** 1995 Mar–Apr;23(2):143–7 (23 ref.)

[Pharmacology in the elderly. Changes in the pharmacodynamic response to a given drug concentration and changes in mechanisms of regulation] Jolliet P, et al. **Ann Med Interne (Paris)** 1995;146(5):328–34 (71 ref.) **(Fre)**

[Circadian rhythm in the sensitivity of target systems to drugs: an underestimated phenomenon] Reinberg AE. **Bull Acad Natl Med** 1996 Mar;180(3):533–43; discussion 544–7 (31 ref.) (Eng. Abstr.) **(Fre)**

[The fundamentals of pharmacokinetics] Lauven PM, et al. **Anaesthesist** 1995 Sep;44(9):663–76 (14 ref.) **(Ger)**

[Pharmacologic principles of drug prescribing in pregnancy] Estler CJ. **Z Arztl Fortbild (Jena)** 1995 Dec;89(7):743–8 (18 ref.) (Eng. Abstr.) **(Ger)**

[Age as a factor in dose-response relationship of drugs] Gundert-Remy U. **Z Gerontol Geriatr** 1995 Nov–Dec; 28(6):408–14 (68 ref.) (Eng. Abstr.) **(Ger)**

[Disease states and changes in drug pharmacokinetics] Ventresca GP, et al. **Clin Ter** 1996 Mar;147(3):131–44 (25 ref.) (Eng. Abstr.) **(Ita)**

[Enzyme immunoassay of drug in blood (serum)] Nishihara K. **Nippon Rinsho** 1995 Sep;53(9):2301–9 (2 ref.) (Eng. Abstr.) **(Jpn)**

[Molecular pharmacological and toxicological studies of drug-metabolizing enzymes] Kato R. **Yakugaku Zasshi** 1995 Sep;115(9):661–80 (94 ref.) (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

see related
DRUGS

Intent and coincidence in pharmaceutical discovery. The impact of biotechnology. Drews J. **Arzneimittelforschung** 1995 Aug;45(8):934–9 (24 ref.)

Interest and limits of human tissue and cell use in pharmacotoxicology. Potier M, et al. **Cell Biol Toxicol** 1995 Aug;11(3–4):133–9 (30 ref.)

The target concentration approach to clinical drug development. Holford NH. **Clin Pharmacokinet** 1995 Nov; 29(5):287–91 (17 ref.)

Racial, ethnic and gender differences in response to medicines. Matthews HW. **Drug Metabol Drug Interact**

PHARMACOLOGY

1995;12(2):77–91 (38 ref.)
Pharmacodynamics as a research tool. Bailey JM. **J Clin Anesth** 1996 May;8(3 Suppl):48S–52S (12 ref.)
[Pharmacology and society] Habermann E. **Pharm Unserer Zeit** 1995 Sep;24(5):273–80 (26 ref.) **(Ger)**
[The present and the future of alcohol study in the field of Pharmacology] Suzuki T. **Arukoru Kenkyuto Yakubutsu Ison** 1996 Apr;31(2):135–45 (24 ref.) **(Jpn)**
[Application of the common marmoset to pharmacological studies] Nomoto M. **Nippon Yakurigaku Zasshi** 1995 Jul; 106(1):11–8 (23 ref.) (Eng. Abstr.) **(Jpn)**

HISTORY

A personal view of pharmacology. Black J. **Annu Rev Pharmacol Toxicol** 1996;36:1–33 (57 ref.)

METHODS

Microdialysis sampling for pharmacological studies: HPLC and CE analysis. Lunte SM, et al. **Adv Chromatogr** 1996; 36:383–432 (73 ref.)
Precision-cut tissue slices: applications in pharmacology and toxicology. Parrish AR, et al. **Life Sci** 1995;57(21):1887–901 (151 ref.)

TRENDS

Strategies and recent technologies in drug discovery. Kubinyi H. **Pharmazie** 1995 Oct;50(10):647–62 (311 ref.)

PHARMACOLOGY, CLINICAL

Science, medicine and clinical pharmacology. The Lilly Lecture 1994. Breckenridge A. **Br J Clin Pharmacol** 1995 Jul;40(1):1–9 (41 ref.)
Standard operating procedure (SOP) for the registration and computer-supported evaluation of pharmaco-EEG data. Working Team "EEG in Phase I" of CIPS. Versavel M, et al. **Pharmacopsychiatry** 1995 Nov;28(6):245–8 (8 ref.)
[Cardiointervalography in the practice of experimental and clinical pharmacology] Arushanian EB. **Eksp Klin Farmakol** 1995 Sep–Oct;58(5):74–8 (18 ref.) (Eng. Abstr.) **(Rus)**

TRENDS

Paediatric clinical pharmacology in the former Soviet Union: Ukraine. Rieder MJ. **Biol Neonate** 1995;68(4):276–81 (7 ref.)

PHARMACOPOEIAS

[Improving on the Japanese pharmacopeia—on assays and determinations] Ishibashi M. **Eisei Shikenjo Hokoku** 1995; (113):137–9 (4 ref.) (Eng. Abstr.) **(Jpn)**

PHARMACOTHERAPY see **DRUG THERAPY**

PHARMACY

see related
COMMUNITY PHARMACY SERVICES
PHARMACY SERVICE, HOSPITAL
PRESCRIPTIONS, DRUG
TECHNOLOGY, PHARMACEUTICAL

PHARMACY ADMINISTRATION

see related
INSURANCE, PHARMACEUTICAL SERVICES

PHARMACY SERVICE, CLINICAL see **PHARMACY SERVICE, HOSPITAL**

PHARMACY SERVICE, HOSPITAL

STANDARDS

Practical guides. II: Hospital pharmacy quality control services. Sewell GJ. **J Clin Pharm Ther** 1995 Jun; 20(3):149–57 (36 ref.)

PHARYNGEAL DISEASES

COMPLICATIONS

Pharyngeal and swallowing disorders in infants. Jolley SG, et al. **Semin Pediatr Surg** 1995 Aug;4(3):157–65 (38 ref.)

DIAGNOSIS

Diagnostic imaging in the evaluation of dysphagia. Barloon TJ, et al. **Am Fam Physician** 1996 Feb 1;53(2):535–46 (22 ref.)
[Clinical differential diagnosis of the mouth and oropharynx] Grevers G. **Radiologe** 1996 Mar;36(3):181–7 (26 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Oropharyngeal dysphagia and disorders of the upper esopharyngeal sphincter. Durancesu A. **Ann Chir Gynaecol** 1995;84(2):225–33 (15 ref.)
Pharyngoesophageal swallowing disorders. Jamieson JR. **Curr Opin Gen Surg** 1993;:189–94 (33 ref.)

PHARYNGEAL DIVERTICULUM see **ZENKER'S DIVERTICULUM**

PHARYNGEAL MUSCLES

SURGERY

Cricopharyngeal myotomy may be effective treatment for selected patients with neurogenic oropharyngeal dysphagia. Buchholz DW. **Dysphagia** 1995 Fall;10(4):255–8 (20 ref.)

PHARYNGEAL NEOPLASMS

DIAGNOSIS

Base of skull, nasopharynx, and parapharyngeal space. Vogl TJ, et al. **Neuroimaging Clin N Am** 1996 May;6(2):357–78 (25 ref.)

PATHOLOGY

Retropharyngeal liposarcoma. Yueh B, et al. **Am J Otolaryngol** 1995 Sep–Oct;16(5):331–40 (65 ref.)
Schwannoma of the posterior pharyngeal wall: a case report. Haraguchi H, et al. **J Laryngol Otol** 1996 Feb;110(2):170–1 (3 ref.)
Synovial sarcoma of the pharynx. Ramamurthy L, et al. **J Laryngol Otol** 1995 Dec;109(12):1207–10 (19 ref.)
[Rhabdomyoma of the adult type. Apropos of a case of parapharyngeal site] Birtwisle-Peyrottes I, et al. **Arch Anat Cytol Pathol** 1996;44(2–3):117–21 (11 ref.) (Eng. Abstr.) **(Fre)**
[Incidence and risk factors of second primary cancers in patients treated for primary pharyngeal cancer] Brochet F, et al. **Bull Cancer Radiother** 1996;83(1):8–11 (34 ref.) (Eng. Abstr.) **(Fre)**

RADIOTHERAPY

Squamous cell carcinoma of the pharyngeal walls treated with radiotherapy. Chang L, et al. **Int J Radiat Oncol Biol Phys** 1996 Jun 1;35(3):477–83 (16 ref.)

SURGERY

Dysphagia after pharyngolaryngeal cancer surgery. Part II: Implications for reconstructive procedures. Herberhold C, et al. **Dysphagia** 1995 Fall;10(4):279–81 (28 ref.)
Dysphagia after pharyngolaryngeal cancer surgery. Part I: Pathophysiology of postsurgical deglutition. Walther EK. **Dysphagia** 1995 Fall;10(4):275–8 (25 ref.)

PHARYNGITIS

Acute pharyngitis: etiology and diagnosis. Bisno AL. **Pediatrics** 1996 Jun;97(6 Pt 2):949–54 (76 ref.)

DIAGNOSIS

Diagnosis and treatment of streptococcal sore throat. **Drug Ther Bull** 1995 Feb;33(2):9–12 (28 ref.)
[Pharyngo-tonsillitis: Current clinical, bacteriological, serological and therapeutic aspects] Sternon J, et al. **Rev Med Brux** 1995 Nov;16(5):344–8 (12 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

Diagnosis and treatment of streptococcal sore throat. **Drug Ther Bull** 1995 Feb;33(2):9–12 (28 ref.)
Penicillin tolerance and treatment failure in group A streptococcal pharyngotonsillitis. van Asselt GJ, et al. **Eur J Clin Microbiol Infect Dis** 1996 Feb;15(2):107–15 (66 ref.)
Adherence to physicians' instructions as a factor in managing streptococcal pharyngitis. Dajani AS. **Pediatrics** 1996 Jun; 97(6 Pt 2):976–80 (21 ref.)
Evaluation of penicillins, cephalosporins, and macrolides for therapy of streptococcal pharyngitis. Shulman ST. **Pediatrics** 1996 Jun;97(6 Pt 2):955–9 (34 ref.)
Recurrent streptococcal pharyngitis. Using practical treatment options to interrupt the cycle. Ruoff GE. **Postgrad Med** 1996 Feb;99(2):211–4, 219–22 (19 ref.)

ETIOLOGY

Differential diagnosis of common causes of pediatric pharyngitis. Ruppert SD. **Nurse Pract** 1996 Apr; 21(4):38–42, 44, 47–8 (21 ref.)
Adherence to physicians' instructions as a factor in managing streptococcal pharyngitis. Dajani AS. **Pediatrics** 1996 Jun; 97(6 Pt 2):976–80 (21 ref.)

MICROBIOLOGY

Lemierre syndrome: postanginal sepsis. Leugers CM, et al. **J Am Board Fam Pract** 1995 Sep–Oct;8(5):384–91 (40 ref.)
Evaluation of penicillins, cephalosporins, and macrolides for therapy of streptococcal pharyngitis. Shulman ST. **Pediatrics** 1996 Jun;97(6 Pt 2):955–9 (34 ref.)
Recurrent streptococcal pharyngitis. Using practical treatment options to interrupt the cycle. Ruoff GE. **Postgrad Med** 1996 Feb;99(2):211–4, 219–22 (19 ref.)

PHARYNGO-CONJUNCTIVAL FEVER see **ADENOVIRUS INFECTIONS, HUMAN**

PHARYNGOESOPHAGEAL DIVERTICULUM see **ZENKER'S DIVERTICULUM**

PHARYNX

ANATOMY & HISTOLOGY

Upper airway shape: Is it important in the pathogenesis of obstructive sleep apnea? Leiter JC. **Am J Respir Crit Care Med** 1996 Mar;153(3):894–8 (38 ref.)
[The peripharyngeal space. Anatomy and normal imaging] Kahn JL, et al. **J Radiol** 1996 Feb;77(2):87–97 (10 ref.) (Eng. Abstr.) **(Fre)**

INJURIES

Pharyngo-esophageal perforation due to blunt trauma. Polsky S, et al. **Am Surg** 1995 Nov;61(11):994–6 (11 ref.)

PHYSIOLOGY

Esophago/pharyngo/laryngeal interrelationships: airway protection mechanisms. Kidder TM. **Dysphagia** 1995 Fall; 10(4):228–31 (21 ref.)

PHYSIOPATHOLOGY

Pathological pharyngo-esophageal interactions. Massey BT. **Dysphagia** 1995 Fall;10(4):232–4 (21 ref.)
[The pharyngoesophageal segment] Ekberg O, et al. **Radiologe** 1995 Oct;35(10):689–92 (22 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Dysphagia after pharyngolaryngeal cancer surgery. Part II: Implications for reconstructive procedures. Herberhold C, et al. **Dysphagia** 1995 Fall;10(4):279–81 (28 ref.)
Dysphagia after pharyngolaryngeal cancer surgery. Part I: Pathophysiology of postsurgical deglutition. Walther EK. **Dysphagia** 1995 Fall;10(4):275–8 (25 ref.)
Methodological and statistical problems in sleep apnea research: the literature on uvulopalatopharyngoplasty. Schechtman KB, et al. **Sleep** 1995 Oct;18(8):659–66 (44 ref.)

PHASE I CLINICAL TRIALS see **CLINICAL TRIALS, PHASE I**

PHASE II CLINICAL TRIALS see **CLINICAL TRIALS, PHASE II**

PHASE III CLINICAL TRIALS see **CLINICAL TRIALS, PHASE III**

PHASEOLUS see **LEGUMES**

PHENACETIN

ADVERSE EFFECTS

Habitual use of acetaminophen as a risk factor for chronic renal failure: a comparison with phenacetin. Buckalew VM Jr. **Am J Kidney Dis** 1996 Jul;28(1 Suppl 1):S7–13 (31 ref.)

PHENADONE see **METHADONE**

PHENANTHRENES

THERAPEUTIC USE

[Correct usage of amino alcohols] Touze JE. **Med Trop (Mars)** 1995;55(3 Suppl):24–5 (8 ref.) **(Fre)**

PHENANTHRIDINES

Benzo[c]phenanthridine alkaloids sanguinarine and chelerythrine: biological activities and dental care applications. Walterová D, et al. **Acta Univ Palacki Olomuc Fac Med** 1995;139:7–16 (110 ref.)

PHENANTHROLINES

Nucleic acid chemistry of the cuprous complexes of 1,10-phenanthroline and derivatives. Sigman DS, et al. **Met Ions Biol Syst** 1996;33:485–513 (60 ref.)

PHENANTOIN see **PHENYTOIN**

PHENCYCLIDINE

see related
RECEPTORS, PHENCYCLIDINE

ADVERSE EFFECTS

A review of NMDA receptors and the phencyclidine model of schizophrenia. Thornberg SA, et al. **Pharmacotherapy** 1996 Jan–Feb;16(1):82–93 (122 ref.)
[Glutamatergic hypothesis of schizophrenia: psychoses induced by phencyclidine and cortical-subcortical imbalance] Krebs MO. **Encephale** 1995 Sep–Oct; 21(5):581–8 (52 ref.) (Eng. Abstr.) **(Fre)**

PHARMACOLOGY

The phencyclidine-glutamate model of schizophrenia. Halberstadt AL. **Clin Neuropharmacol** 1995 Jun; 18(3):237-49 (108 ref.)

PHENCYCLIDINE RECEPTORS see **RECEPTORS, PHENCYCLIDINE**

PHENEMAL see **PHENOBARBITAL**

PHENETHYLAMINES

PHARMACOKINETICS

The use of toxicokinetics for the safety assessment of drugs acting in the brain. Campbell DB. **Mol Neurobiol** 1995 Aug-Dec;11(1-3):193-216 (125 ref.)

TOXICITY

The use of toxicokinetics for the safety assessment of drugs acting in the brain. Campbell DB. **Mol Neurobiol** 1995 Aug-Dec;11(1-3):193-216 (125 ref.)

PHENOBARBITAL

BLOOD

[Phenobarbital] Kawasaki H, et al. **Nippon Rinsho** 1995 Feb; 53 Su Pt 1:921-3 (12 ref.) **(Jpn)**

PHARMACOLOGY

Localization and characterization of cytochrome P450 in the brain. In vivo and in vitro investigations on phenytoin- and phenobarbital-inducible isoforms. Volk B, et al. **Toxicol Lett** 1995 Dec;82-83:655-62 (11 ref.)

THERAPEUTIC USE

Psychopharmacology in child and adolescent psychiatry: a review of the past seven years. Part II. Campbell M, et al. **J Am Acad Child Adolesc Psychiatry** 1995 Oct; 34(10):1262-72 (138 ref.)

TOXICITY

Phenobarbital mouse liver tumors: implications of hepatic tumor promotion for cancer risk assessment. McClain RM. **Prog Clin Biol Res** 1995;391:325-36 (35 ref.)

The species specificity of dieldrin- or phenobarbital- induced hepatocarcinogenesis: case studies with implications for human health risk assessment. Stevenson DE, et al. **Prog Clin Biol Res** 1995;391:337-45 (28 ref.)

PHENOBARBITONE see **PHENOBARBITAL**

PHENOL RED see **PHENOLSULFONPHTHALEIN**

PHENOLOXIDASE see **MONOPHENOL MONOOXYGENASE**

PHENOLS

CHEMISTRY

Plant polyphenols: free radical scavengers or chain-breaking antioxidants? Rice-Evans C. **Biochem Soc Symp** 1995; 61:103-16 (53 ref.)

Hydrolyzable tannins and related polyphenols. Okuda T, et al. **Fortschr Chem Org Naturst** 1995;66:1-117 (266 ref.)

Wresting the muscle from mussel beards: research and applications. Rzepecki LM, et al. **Mol Mar Biol Biotechnol** 1995 Dec;4(4):313-22 (45 ref.)

PHARMACOLOGY

[Inhibitors of protein-tyrosine kinases: pharmacological perspectives? (editorial)] Jacquemin-Sablon A, et al. **Pathol Biol (Paris)** 1995 May;43(5):389-94 (66 ref.) **(Fre)**

THERAPEUTIC USE

Polyphenols as cancer chemopreventive agents. Stoner GD, et al. **J Cell Biochem Suppl** 1995;22:169-80 (87 ref.)

TOXICITY

Structure-toxicity relationships for phenols to Tetrahymena pyriformis. Cronin MT, et al. **Chemosphere** 1996 Apr; 32(8):1453-68 (36 ref.)

PHENOLSULFONPHTHALEIN

DIAGNOSTIC USE

[Phenolsulfonphthalein (PSP)] Tomita K. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:1085-7 (5 ref.) **(Jpn)**

PHENOTHIAZINE ANTIPSYCHOTIC AGENTS see **ANTIPSYCHOTIC AGENTS, PHENOTHIAZINE**

PHENOTHIAZINE TRANQUILIZERS see **ANTIPSYCHOTIC AGENTS, PHENOTHIAZINE**

PHENOTHIAZINES

see related
ANTIPSYCHOTIC AGENTS, PHENOTHIAZINE

THERAPEUTIC USE

Pharmacologic treatment of recurrent pediatric headache. Graf WD, et al. **Pediatr Ann** 1995 Sep;24(9):477-84 (27 ref.)

PHENOTYPE

see related
SOMATOTYPES

Identifying alcoholism vulnerability alleles. Goldman D. **Alcohol Clin Exp Res** 1995 Aug;19(4):824-31 (71 ref.)

Gene expression and vascular smooth muscle cell phenotype. Weissberg PL, et al. **Blood Press Suppl** 1995;2:68-73 (19 ref.)

Genetic evidence that the Lewy body variant is indeed a phenotypic variant of Alzheimer's disease. Katzman R, et al. **Brain Cogn** 1995 Aug;28(3):259-65 (43 ref.)

The place of airway hyperresponsiveness in the asthma phenotype. Sterk PJ. **Clin Exp Allergy** 1995 Nov;25 Suppl 2:8-11; discussion 17-8 (30 ref.)

Problems in the phenotypic assessment of asthma. Weiss ST. **Clin Exp Allergy** 1995 Nov;25 Suppl 2:12-4; discussion 17-8 (4 ref.)

Discordance between phenotype and genotype in malignant hyperthermia. MacLennan DH. **Curr Opin Neurol** 1995 Oct;8(5):397-401 (33 ref.)

Variability of clinical and immunological phenotype in immunodeficiency-centromeric instability-facial anomalies syndrome. Report of two new patients and review of the literature. Franceschini P, et al. **Eur J Pediatr** 1995 Oct; 154(10):840-6 (21 ref.)

A distinct phenotype associated with partial trisomy 10q due to proximal direct duplication 10q11 --> q223? van Buggenhout G, et al. **Genet Couns** 1996;7(1):53-9 (14 ref.)

Relationship between genotype and phenotype in monogenic diseases: relevance to polygenic diseases. Summers KM. **Hum Mutat** 1996;7(4):283-93 (98 ref.)

Arabidopsis in Madison: genes and phenotypes spread like weeds. Chasan R. **Plant Cell** 1995 Nov;7(11):1737-48 (34 ref.)

Estrogen receptor gene disruption: molecular characterization and experimental and clinical phenotypes. Korach KS, et al. **Recent Prog Horm Res** 1996;51:159-86; discussion 186-8 (50 ref.)

Transcriptional control of cell phenotypes in the neuroendocrine system. Rosenfeld MG, et al. **Recent Prog Horm Res** 1996;51:217-38; discussion 238-9 (98 ref.)

PHENTOLAMINE

THERAPEUTIC USE

Pharmacological management of erectile dysfunction. Montorsi F, et al. **Drugs** 1995 Sep;50(3):465-79 (59 ref.)

PHENYL ETHERS

POISONING

[A case of acute peroral poisoning by the preparation Nitrafen] Nikitin PV, et al. **Sud Med Ekspert** 1996 Jan-Mar; 39(1):33-5 (9 ref.) **(Rus)**

PHENYLACETATES

THERAPEUTIC USE

Butyrate and phenylacetate as differentiating agents: practical problems and opportunities. Newmark HL, et al. **J Cell Biochem Suppl** 1995;22:247-53 (45 ref.)

PHENYLALANINE

ANALOGS & DERIVATIVES

Matrix metalloproteinase inhibition: a review of anti-tumour activity. Brown PD, et al. **Ann Oncol** 1995 Dec; 6(10):967-74 (48 ref.)

METABOLISM

Cation-pi interactions in chemistry and biology: a new view of benzene, Phe, Tyr, and Trp. Dougherty DA. **Science** 1996 Jan 12;271(5246):163-8 (66 ref.)

PHENYLALANINE HYDROXYLASE

PHYSIOLOGY

Structure and function of the aromatic amino acid hydroxylases. Hufton SE, et al. **Biochem J** 1995 Oct 15; 311 (Pt 2):353-66 (223 ref.)

PHENYLALANINE MUSTARD see **MELPHALAN**

PHENYLALANINE-SPECIFIC TRNA see **RNA, TRANSFER, PHE**

PHENYLAMINES see **ANILINE COMPOUNDS**

PHENYLBARBITAL see **PHENOBARBITAL**

PHENYLBUTAZONE

ADVERSE EFFECTS

Nonsteroidal anti-inflammatory drug-induced colonic strictures: two cases and literature review. Gargot D, et al. **Am J Gastroenterol** 1995 Nov;90(11):2035-8 (18 ref.)

PHENYLETHYLAMINES see **PHENETHYLAMINES**

PHENYLKETONURIA

COMPLICATIONS

Late effects of phenylketonuria. Walter JH. **Arch Dis Child** 1995 Dec;73(6):485-6 (37 ref.)

DIET THERAPY

[Methodology of care for children with phenylketonuria and maple-syrup urine disease] Jiménez Soto Z. **Arch Latinoam Nutr** 1993 Sep;43(3):204-10 (22 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

An enzyme/brain-barrier theory of psychiatric pathogenesis: unifying observations on phenylketonuria, autism, schizophrenia and postpartum psychosis. Seim AR, et al. **Med Hypotheses** 1995 Nov;45(5):498-502 (36 ref.)

METABOLISM

Lipid status and fatty acid metabolism in phenylketonuria. Giovannini M, et al. **J Inherit Metab Dis** 1995;18(3):265-72 (28 ref.)

PREVENTION & CONTROL

Maternal phenylketonuria: a metabolic teratogen. Levy HL, et al. **Teratology** 1996 Mar;53(3):176-84 (54 ref.)

PHENYLKETONURIA, MATERNAL

COMPLICATIONS

[Pregnancy and the child of a mother with phenylketonuria] Abadie V, et al. **Arch Pediatr** 1996 May;3(5):489-6 (38 ref.) (Eng. Abstr.) **(Fre)**

DIET THERAPY

Nutrition support of maternal phenylketonuria. Acosta PB. **Semin Perinatol** 1995 Jun;19(3):182-90 (46 ref.)

PHENYTOIN

ADVERSE EFFECTS

Prenatal exposure to phenytoin, facial development, and a possible role for vitamin K. Howe AM, et al. **Am J Med Genet** 1995 Sep 11;58(3):238-44 (52 ref.)

Hand anomalies in fetal-hydantoin syndrome: from nail/phalangeal hypoplasia to unilateral acheiria [letter] Sabry MA, et al. **Am J Med Genet** 1996 Apr 24;62(4):410-2 (34 ref.)

Systemic corticosteroids in the phenytoin hypersensitivity syndrome. Chopra S, et al. **Br J Dermatol** 1996 Jun; 134(6):1109-12 (19 ref.)

Dilantin hypersensitivity reaction. Conger LA Jr, et al. **Cutis** 1996 Apr;57(4):223-6 (32 ref.)

Lymphoblastic lymphoma following prenatal exposure to phenytoin. Murray JC, et al. **J Pediatr Hematol Oncol** 1996 May;18(2):241-3 (23 ref.)

[Side effects of phenytoin and carbamazepine on cognitive functioning] Pulliainen V, et al. **Duodecim** 1994; 110(14):1320-8 (44 ref.) **(Fin)**

[Multiple myeloma associated with phenytoin (diphenylhydantoin) therapy] Kanoh T, et al. **Rinsho Ketsueki** 1996 Mar;37(3):239-43 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Toxic cholestatic hepatitis due to phenytoin] de la Serna Higuera C, et al. **Gastroenterol Hepatol** 1995 Nov; 18(9):471-3 (11 ref.) (Eng. Abstr.) **(Spa)**

ANALOGS & DERIVATIVES

Pharmacology and pharmacokinetics of fosphenytoin. Browne TR, et al. **Neurology** 1996 Jun;46(6 Suppl 1):S3-7 (48 ref.)

Fosphenytoin use in children. Pellock JM. **Neurology** 1996 Jun;46(6 Suppl 1):S14-6 (8 ref.)

Intravenous administration of fosphenytoin: options for the management of seizures. Ramsay RE, et al. **Neurology** 1996 Jun;46(6 Suppl 1):S17-9 (12 ref.)

Emergency treatment of status epilepticus. Runge JW, et al. **Neurology** 1996 Jun;46(6 Suppl 1):S20-3 (25 ref.)

Intramuscular use of fosphenytoin: an overview. Uthman BM, et al. **Neurology** 1996 Jun;46(6 Suppl 1):S24-8 (28 ref.)

BLOOD

[Phenytoin] Furuno K, et al. **Nippon Rinsho** 1995 Feb;53 Su

PHENYTOIN

Pt 1:924–7 (21 ref.) **(Jpn)**

METABOLISM

Cytochrome P450 isozymes and antiepileptic drug interactions. Levy RH. **Epilepsia** 1995;36 Suppl 5:S8–13 (13 ref.)

PHARMACOKINETICS

Phenytoin disposition and toxicity: role of pharmacogenetic and interethnic factors. Edeki TI, et al. **Drug Metab Rev** 1995;27(3):449–69 (89 ref.)

PHARMACOLOGY

Phenytoin–folic acid interaction [see comments] Lewis DP, et al. **Ann Pharmacother** 1995 Jul–Aug;29(7–8):726–35 (65 ref.) Comment in: Ann Pharmacother 1995 Dec;29(12):1303–4.

Localization and characterization of cytochrome P450 in the brain. In vivo and in vitro investigations on phenytoin- and phenobarbital-inducible isoforms. Volk B, et al. **Toxicol Lett** 1995 Dec;82–83:655–62 (11 ref.)

THERAPEUTIC USE

Possible interaction involving phenytoin, dexamethasone, and antineoplastic agents: a case report and review. Gattis WA, et al. **Ann Pharmacother** 1996 May;30(5):520–6 (20 ref.)

Psychopharmacology in child and adolescent psychiatry: a review of the past seven years. Part II. Campbell M, et al. **J Am Acad Child Adolesc Psychiatry** 1995 Oct; 34(10):1262–72 (138 ref.)

TOXICITY

Phenytoin disposition and toxicity: role of pharmacogenetic and interethnic factors. Edeki TI, et al. **Drug Metab Rev** 1995;27(3):449–69 (89 ref.)

Pathogenesis of drug-induced gingival overgrowth. A review of studies in the rat model. Nishikawa S, et al. **J Periodontol** 1996 May;67(5):463–71 (94 ref.)

PHEOCHROMOCYTOMA

see related
MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A
MULTIPLE ENDOCRINE NEOPLASIA TYPE 2B

[Pheochromocytoma and pregnancy. Two case reports] Barhmi R, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995; 24(5):543–8 (24 ref.) (Eng. Abstr.) **(Fre)**

BLOOD SUPPLY

Intracardiac pheochromocytoma with dual coronary blood supply: case report and literature review. Fitzgerald PJ, et al. **Cardiovasc Surg** 1995 Oct;3(5):557–61 (20 ref.)

COMPLICATIONS

Pheocromocytoma and gastrointestinal bleeding. Vázquez-Quintana E, et al. **Am Surg** 1995 Nov; 61(11):937–9 (12 ref.)

Acute reversal of pheochromocytoma-induced catecholamine cardiomyopathy. Nanda AS, et al. **Clin Cardiol** 1995 Jul;18(7):421–3 (8 ref.)

[Tumors outside of the central nervous system in Von Hippel–Lindau disease] Veltman GA, et al. **Ned Tijdschr Geneeskd** 1996 Apr 13;140(15):823–6 (33 ref.) **(Dut)**

DIAGNOSIS

Investigation of phaeochromocytoma. Bouloux PG, et al. **Clin Endocrinol (Oxf)** 1995 Dec;43(6):657–64 (31 ref.)

[Pheochromocytoma in children: 2 cases] Fernández Córdoba MS, et al. **An Esp Pediatr** 1996 Mar;44(3):277–8 (6 ref.) **(Spa)**

[Laboratory contribution to the diagnosis of pheochromocytoma] Rivero Marcotegui A, et al. **An Med Interna** 1996 Jan;13(1):40–4 (60 ref.) **(Spa)**

PATHOLOGY

Two cases of pheochromocytoma diagnosed histopathologically as mixed neuroendocrine–neural tumor. Watanabe T, et al. **Intern Med** 1995 Jul;34(7):683–7 (47 ref.)

RADIOTHERAPY

Radiation therapy of metastatic pheochromocytoma: case report and review of the literature. Yu L, et al. **Am J Clin Oncol** 1996 Aug;19(4):389–93 (29 ref.)

SECONDARY

Radiation therapy of metastatic pheochromocytoma: case report and review of the literature. Yu L, et al. **Am J Clin Oncol** 1996 Aug;19(4):389–93 (29 ref.)

SECRETION

Pheochromocytoma and secondary erythrocytosis: role of tumour erythropoietin secretion. Drénou B, et al. **Nouv Rev Fr Hematol** 1995;37(3):197–9 (18 ref.)

SURGERY

[Laparoscopic adrenalectomy in pheochromocytoma] Vogelbach P, et al. **Schweiz Med Wochenschr** 1995 Sep 16;125(37):1735–9 (25 ref.) (Eng. Abstr.) **(Ger)**

URINE

The clinical and laboratory correlates of an increased urinary 5-hydroxyindoleacetic acid. Tormey WP, et al. **Postgrad Med J** 1995 Sep;71(839):542–5 (16 ref.)

PHERESIS see BLOOD COMPONENT REMOVAL

PHEROMONES

CHEMISTRY

Chemical signaling in ciliates. Luporini P, et al. **J Eukaryot Microbiol** 1995 May–Jun;42(3):208–12 (30 ref.)

GENETICS

How is pheromone specificity encoded in proteins? Prestwich GD, et al. **Chem Senses** 1995 Aug;20(4):461–9 (36 ref.)

PHYSIOLOGY

Proteins that smell: pheromone recognition and signal transduction. Prestwich GD. **Bioorg Med Chem** 1996 Mar; 4(3):505–13 (55 ref.)

Chemical signaling in ciliates. Luporini P, et al. **J Eukaryot Microbiol** 1995 May–Jun;42(3):208–12 (30 ref.)

Fungal lipopeptide mating pheromones: a model system for the study of protein prenylation. Caldwell GA, et al. **Microbiol Rev** 1995 Sep;59(3):406–22 (181 ref.)

Synaptic mechanisms of olfactory recognition memory. Kaba H, et al. **Rev Neurosci** 1995 Apr–Jun;6(2):125–41 (128 ref.)

Pheromone communication in the fission yeast Schizosaccharomyces pombe. Nielsen O, et al. **Semin Cell Biol** 1995 Apr;6(2):95–104 (105 ref.)

PHEROMONES, SEXUAL see SEX ATTRACTANTS

PHIALAPHORA JEANSELMEI see EXOPHIALA

PHIALOPHORA

Subcutaneous phaeohyphomycosis in a renal transplant recipient: a case report and review of the literature. Jha V, et al. **Am J Kidney Dis** 1996 Jul;28(1):137–9 (21 ref.)

PHIALOPHORA GOUGEROTII see EXOPHIALA

PHILADELPHIA CHROMOSOME

see related
ONCOGENE PROTEINS, FUSION

[Chronic myeloid leukemia, biological aspects] Costello R, et al. **Rev Med Interne** 1996;17(3):213–23 (139 ref.) (Eng. Abstr.) **(Fre)**

[Fluorescent in-situ hybridization technique (FISH) in the diagnosis of Philadelphia translocation in chronic myeloid leukemia] Martinet D, et al. **Schweiz Med Wochenschr** 1996 May 18;126(20):855–63 (30 ref.) (Eng. Abstr.) **(Fre)**

PHILOSOPHY

Spirituality as integrative energy: a philosophical analysis as requisite precursor to holistic nursing practice. Goddard NC. **J Adv Nurs** 1995 Oct;22(4):808–15 (40 ref.)

Postmodernism, health and illness. Mitchell DP. **J Adv Nurs** 1996 Jan;23(1):201–5 (28 ref.)

Language and pain expression. Waddie NA. **J Adv Nurs** 1996 May;23(5):868–72 (15 ref.)

The phenomenological movement: implications for nursing research. Walters AJ. **J Adv Nurs** 1995 Oct;22(4):791–9 (23 ref.)

On the battle between behavior and cognition: lessons from physicists and pragmatists. Corrigan PW. **J Behav Ther Exp Psychiatry** 1995 Sep;26(3):209–14 (44 ref.)

Pain sensitivity, exercise and stoicism. Janal MN. **J R Soc Med** 1996 Jul;89(7):376–81 (38 ref.)

Health-related quality of life between naturalism and hermeneutics. Rosenberg R. **Soc Sci Med** 1995 Nov; 41(10):1411–5 (17 ref.)

Limits of natural science: brain research and computers. Stieve H. **Z Naturforsch [C]** 1995 May–Jun;50(5–6):317–36 (86 ref.)

[Is the mind located in the brain?] Louhiala P. **Duodecim** 1994;110(1):35–41 (22 ref.) **(Fin)**

[2 basic problems of psychoanalytic psychotherapy and their philosophical revision] Bürgy M. **Psychother Psychosom Med Psychol** 1995 Nov; 45(11):389–94 (57 ref.) (Eng. Abstr.) **(Ger)**

[The concept of reification in psychiatry and sociology] Morozov VM, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1996;96(1):112–4 (15 ref.) **(Rus)**

HISTORY

Chinese Confucian culture and the medical ethical tradition. Guo Z. **J Med Ethics** 1995 Aug;21(4):239–46 (13 ref.)

PHILOSOPHY, MEDICAL

Freudian suspicion versus suspicion of Freud. Crews F. **Ann N Y Acad Sci** 1996 Jun 24;775:470–82 (58 ref.)

Constructivism in psychotherapy. Truth and consequences. Held BS. **Ann N Y Acad Sci** 1996 Jun 24;775:198–206 (43 ref.)

The biopsychosocial paradigm and the future of psychiatry. Freedman AM. **Compr Psychiatry** 1995 Nov–Dec; 36(6):397–406 (44 ref.)

Evidence based critical care medicine; what is it and what can it do for us? Evidence Based Medicine in Critical Care Group. Cook DJ, et al. **Crit Care Med** 1996 Feb;24(2):334–7 (46 ref.)

Expanding the horizon of reflection on health and disease. Khushf G. **J Med Philos** 1995 Oct;20(5):461–73 (31 ref.)

Health as an analogical concept. Mordacci R. **J Med Philos** 1995 Oct;20(5):475–97 (46 ref.)

Euthanasia and the good life. Lemmens T. **Perspect Biol Med** 1995 Autumn;39(1):15–27 (25 ref.)

The philosophy of psychopathy. Stein DJ. **Perspect Biol Med** 1996 Summer;39(4):569–80 (26 ref.)

The outlook of the Tekhne Iatrike and the Medical Act to the third millenium. Araya RF. **Theor Med** 1996 Jun; 17(2):163–73 (46 ref.)

[Identity of the personality and personal identity: philosophical questions in relation to transplantation of brain tissue] Birnbacher D. **Zentralbl Neurochir** 1995; 56(4):180–5 (6 ref.) (Eng. Abstr.) **(Ger)**

PHILOSOPHY, NURSING

Environmental paradigms: moving toward an ecocentric perspective. Kleffel D. **ANS Adv Nurs Sci** 1996 Jun; 18(4):1–10 (38 ref.)

Dialectical analysis concerning the rational aspect of the art of nursing. Johnson JL. **Image J Nurs Sch** 1996 Summer; 28(2):169–75 (106 ref.)

The proper focus of nursing: a critique of the "caring" ideology. Barker PJ, et al. **Int J Nurs Stud** 1995 Aug; 32(4):386–97 (44 ref.)

A classical view of the theory–practice gap in nursing. Allmark P. **J Adv Nurs** 1995 Jul;22(1):18–23 (23 ref.)

Hermeneutic phenomenology: philosophical perspectives and current use in nursing research. Annells M. **J Adv Nurs** 1996 Apr;23(4):705–13 (52 ref.)

A view from somewhere: the presence and function of religious commitment in nursing practice. Cusveller BS. **J Adv Nurs** 1995 Nov;22(5):973–8 (15 ref.)

A sharing in critical thought by nursing faculty. Hendricks-Thomas J, et al. **J Adv Nurs** 1995 Sep; 22(3):594–9 (35 ref.)

Nurse–physician collaboration: a poststructuralist view. Henneman EA. **J Adv Nurs** 1995 Aug;22(2):359–63 (15 ref.)

Intuition and expertise: comments on the Benner debate. Paley J. **J Adv Nurs** 1996 Apr;23(4):665–71 (38 ref.)

Humanism and positivism in nursing: contradictions and conflicts. Playle JF. **J Adv Nurs** 1995 Nov;22(5):979–84 (46 ref.)

Transcultural nursing: a perspective derived from Jean-Paul Sartre. Rajan MF. **J Adv Nurs** 1995 Sep;22(3):450–5 (20 ref.)

Technology and the lifeworld of critical care nursing. Walters AJ. **J Adv Nurs** 1995 Aug;22(2):338–46 (26 ref.)

Health promotion and the "ideology of choice". Lowenberg JS. **Public Health Nurs** 1995 Oct;12(5):319–23 (37 ref.)

The contrary ideals of individualism and nursing value of care. Katims I. **Sch Inq Nurs Pract** 1995 Fall;9(3):231–40; discussion 241–4 (30 ref.)

PHLEBITIS

COMPLICATIONS

Severe occlusive retinal periphlebitis with vitreous hemorrhage in multiple sclerosis. Ronzani M, et al. **Ger J Ophthalmol** 1995 Nov;4(6):328–31 (15 ref.)

DIAGNOSIS

[Postappendectomy vascular complications in childhood] Diez García R, et al. **An Esp Pediatr** 1996 Mar;44(3):270–2 (19 ref.) **(Spa)**

DRUG THERAPY

Pylephlebitis: a case report and review of outcome in the antibiotic era. Saxena R, et al. **Am J Gastroenterol** 1996 Jun;91(6):1251–3 (17 ref.)

PATHOLOGY

[Thrombosis and phlebitis of superficial veins. Differential histopathologic diagnosis] Leu HJ. **Pathologe** 1995 Nov; 16(6):386–90 (9 ref.) (Eng. Abstr.) **(Ger)**

PHLEBOTOMUS

PARASITOLOGY

Phlebotomine sandflies (Diptera:, Psychodidae): their importance and some aspects of control. Mutinga MJ. **East Afr Med J** 1996 Jan;73(1):48–9 (9 ref.)

PHLEBOTOMUS FEVER

COMPLICATIONS

[Neurological symptoms after an infection by the sandfly fever virus] Pauli C, et al. **Dtsch Med Wochenschr** 1995 Oct 27;120(43):1468–72 (22 ref.) (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

Sandfly fever viruses in Italy. Nicoletti L, et al. **Arch Virol Suppl** 1996;11:41–7 (42 ref.)

PHLEBOTOMY

Review: selective filtration—a phlebotomy strategy for sickle cell therapy. Nusbaum NJ. **Am J Med Sci** 1995 Dec; 310(6):264–6 (12 ref.)

VETERINARY

The response of various hematologic parameters in the young bovine subjected to multiple phlebotomies. Harper SB, et al. **ASAIO J** 1994 Jul–Sep;40(3):M816–25 (128 ref.)

PHLEGMASIA ALBA DOLENS see **THROMBOPHLEBITIS**

PHLEGMON see **CELLULITIS**

PHOBIA, SCHOOL see **PHOBIC DISORDERS**

PHOBIA, SOCIAL see **PHOBIC DISORDERS**

PHOBIAS see **PHOBIC DISORDERS**

PHOBIC DISORDERS

Links between growth hormone deficiency, adaptation and social phobia. Stabler B, et al. **Horm Res** 1996;45(1–2):30–3 (27 ref.)

Phobic postural vertigo. Brandt T. **Neurology** 1996 Jun; 46(6):1515–9 (31 ref.)

DIAGNOSIS

[Diagnosis of Taijin–Kyofu and social phobia] Kasahara T. **Seishin Shinkeigaku Zasshi** 1995;97(5):357–66 (47 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Social phobia: everyone's disorder? Jefferson JW. **J Clin Psychiatry** 1996;57 Suppl 6:28–32 (28 ref.)

The neurobiology of anxiety disorders. Johnson MR, et al. **Psychiatr Clin North Am** 1995 Dec;18(4):681–725 (152 ref.)

THERAPY

Individual response patterns and treatment matching in the phobic disorders: a review. Menzies RG. **Br J Clin Psychol** 1996 Feb;35 (Pt 1):1–10 (36 ref.)

Social phobia: diagnostic issues and review of cognitive behavioral treatment strategies. Juster HR, et al. **Prog Behav Modif** 1996;30:74–98 (90 ref.)

Social phobia. Longitudinal course and long–term outcome of cognitive–behavioral treatment. Juster HR, et al. **Psychiatr Clin North Am** 1995 Dec;18(4):821–42 (77 ref.)

PHOBIC NEUROSES see **PHOBIC DISORDERS**

PHOCOMELIA see **ECTROMELIA**

PHONATION

PHYSIOLOGY

Neural control of vocalization: respiratory and emotional influences. Davis PJ, et al. **J Voice** 1996 Mar;10(1):23–38 (107 ref.)

External laryngeal frame function in voice production revisited: a review. Vilkman E, et al. **J Voice** 1996 Mar; 10(1):78–92 (90 ref.)

PHONATION DISORDERS see **VOICE DISORDERS**

PHONETICS

The difficulty with recalling people's names: the plausible phonology hypothesis. Brennen T. **Memory** 1993 Dec; 1(4):409–31 (45 ref.)

Feature, phoneme, syllable or word: how is speech mentally represented? Sendlmeier WF. **Phonetica** 1995;52(3):131–43 (30 ref.)

PHONOPHORESIS

Physical enhancement of dermatologic drug delivery: iontophoresis and phonophoresis. Kassan DG, et al. **J Am Acad Dermatol** 1996 Apr;34(4):657–66 (74 ref.)

PHORBOL ESTERS

CHEMISTRY

[Structural studies of phorbol ester–binding domain of protein kinase C by photoaffinity labeling] Irie K. **Seikagaku** 1996 Feb;68(2):129–32 (16 ref.) **(Jpn)**

PHARMACOLOGY

Protein kinase D (PKD): a novel target for diacylglycerol and phorbol esters. Rozengurt E, et al. **Mutat Res** 1995 Dec;333(1–2):153–60 (47 ref.)

PHORBOL MYRISTATE ACETATE see **TETRADECANOYLPHORBOL ACETATE**

PHORBOLS

The tumor promoter receptor protein kinase C: a novel target for chemoprevention and therapy of human colon cancer. O'Brian CA, et al. **Prog Clin Biol Res** 1995;391:117–20 (20 ref.)

PHORIAS see **STRABISMUS**

PHOSGENE

POISONING

Occupational phosgene poisoning: a case report and review. Wyatt JP, et al. **J Accid Emerg Med** 1995 Sep;12(3):212–3 (11 ref.)

PHOSPHAMIDE see **DIMETHOATE**

PHOSPHATASES see **PHOSPHORIC MONOESTER HYDROLASES**

PHOSPHATE DIABETES see **HYPOPHOSPHATEMIA, FAMILIAL**

PHOSPHATES

see related
HYPOPHOSPHATEMIA

ADMINISTRATION & DOSAGE

Oral phosphate binders without aluminium and calcium – a pipe–dream? [editorial] Ritz E, et al. **Nephrol Dial Transplant** 1996 May;11(5):766–8 (20 ref.)

ADVERSE EFFECTS

Oral sodium phosphate catharsis and acute renal failure. Ahmed M, et al. **Am J Gastroenterol** 1996 Jun;91(6):1261–2 (9 ref.)

Colonoscopy preps: what's best? [editorial; comment] Keeffe EB. **Gastrointest Endosc** 1996 May;43(5):524–8 (30 ref.) Comment on: Gastrointest Endosc 1996 May;43(5):463–6. Comment on: Gastrointest Endosc 1996 May;43(5):467–9.

BLOOD

Pseudohyperphosphatemia. Larner AJ. **Clin Biochem** 1995 Aug;28(4):391–3 (40 ref.)

Treatment of hyperparathyroidism—why is it crucial to control serum phosphate? [editorial] Brancaccio D, et al. **Nephrol Dial Transplant** 1996 Mar;11(3):420–3 (23 ref.)

[Inorganic phosphate in serum and urine] Nagata N. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:772–5 (10 ref.) **(Jpn)**

CHEMICAL SYNTHESIS

[Synthesis of oligodeoxyribonucleotides with modified internucleotide phosphate residues] Hayakawa Y, et al. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1306–14 (33 ref.) **(Jpn)**

[Synthesis and properties of 2'–phosphorylated oligoribonucleotides] Sekine M. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1315–22 (52 ref.) **(Jpn)**

CHEMISTRY

Nuclear magnetic resonance investigation of the structures of phosphate and phosphate–containing glasses: a review. Kirkpatrick RJ, et al. **Solid State Nucl Magn Reson** 1995 Oct;5(1):9–21 (51 ref.)

[The chemistry of phosphorus: pseudorotation] Taira K. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1323–32 (53 ref.) **(Jpn)**

[Calorimetric study of stable complexes of myosin subfragment I with adenosine diphosphate and phosphate analogs] Levitskii DI, et al. **Biofizika** 1996 Jan–Feb; 41(1):64–72 (29 ref.) (Eng. Abstr.) **(Rus)**

METABOLISM

Phosphate load as the evolutionary driving force for the development of a high filtration rate based excretory organ: a hypothesis. Ilani A. **J Basic Clin Physiol Pharmacol** 1993 Apr–Jun;4(1–2):123–38 (32 ref.)

Renal Na/Pi–cotransporters. Biber J, et al. **Kidney Int** 1996 Apr;49(4):981–5 (33 ref.)

Endoplasmic reticulum phosphate transport. Burchell A. **Kidney Int** 1996 Apr;49(4):953–8 (40 ref.)

Characteristics and regulation of Pi transport in osteogenic cells for bone metabolism. Caverzasio J, et al. **Kidney Int** 1996 Apr;49(4):975–80 (24 ref.)

Phosphate metabolism: contribution of different cellular compartments. Dennis VW. **Kidney Int** 1996 Apr; 49(4):938–42 (33 ref.)

Role of renal handling of extracellular nucleotides in modulation of phosphate transport. Friedlander G, et al. **Kidney Int** 1996 Apr;49(4):1019–22 (43 ref.)

Identification and characterization of a widely expressed phosphate transporter/retrovirus receptor family. Kavanaugh MP, et al. **Kidney Int** 1996 Apr;49(4):959–63 (23 ref.)

Peptide hormone action on renal phosphate handling [see comments] Kempson SA. **Kidney Int** 1996 Apr;49(4):1005–9 (52 ref.) Comment in: Kidney Int 1996 Apr;49(4):1010–1.

Structural and functional aspects of the phosphate carrier from mitochondria. Krämer R. **Kidney Int** 1996 Apr; 49(4):947–52 (55 ref.)

Atomic basis of the exquisite specificity of phosphate and sulfate transport receptors. Quiocho FA. **Kidney Int** 1996 Apr;49(4):943–6 (14 ref.)

Epithelial phosphate transport in ruminants, mechanisms and regulation. Shirazi–Beechey SP, et al. **Kidney Int** 1996 Apr; 49(4):992–6 (39 ref.)

Use of vanadate–induced photocleavage for detecting phosphate binding sites in proteins. Muhlrad A, et al. **Met Ions Biol Syst** 1995;31:211–30 (65 ref.)

Inhibition of phosphate–metabolizing enzymes by oxovanadium(V) complexes. Stankiewicz PJ, et al. **Met Ions Biol Syst** 1995;31:287–324 (169 ref.)

Structural requirements of parathyroid hormone/parathyroid hormone–related peptide receptors for phospholipase C activation and regulation of phosphate uptake. Iida–Klein A, et al. **Miner Electrolyte Metab** 1995;21(1–3):177–9 (16 ref.)

The signal–transduction network for Pho regulation in Bacillus subtilis. Hulett FM. **Mol Microbiol** 1996 Mar; 19(5):933–9 (27 ref.)

Molecular mechanisms in renal phosphate reabsorption [editorial] Murer H, et al. **Nephrol Dial Transplant** 1995; 10(9):1501–4 (19 ref.)

The effect of fasting and fructose and glucose infusion on gluconeogenesis and triose phosphate flux in rats in vivo. Wolf G. **Nutr Rev** 1995 Oct;53(10):299–301 (2 ref.)

PHARMACOLOGY

Effects of bicarbonate, citrate, and phosphate loading on performance. Horswill CA. **Int J Sport Nutr** 1995 Jun;5 Suppl:S111–9 (49 ref.)

PHYSIOLOGY

Signal transduction in the control of phosphate–regulated genes of Escherichia coli. Wanner BL. **Kidney Int** 1996 Apr;49(4):964–7 (24 ref.)

PHOSPHATES, INORGANIC see **PHOSPHATES**

PHOSPHATIDATE PHOSPHATASE

PHYSIOLOGY

Phosphatidate phosphohydrolase and signal transduction. Brindley DN, et al. **Chem Phys Lipids** 1996 May 24; 80(1–2):45–57 (78 ref.)

PHOSPHATIDATE PHOSPHOHYDROLASE see **PHOSPHATIDATE PHOSPHATASE**

PHOSPHATIDES see **PHOSPHOLIPIDS**

PHOSPHATIDIC ACIDS

ANALYSIS

High–performance liquid chromatography of phosphatidic acid. Abidi SL, et al. **J Chromatogr B Biomed Appl** 1995 Sep 15;671(1–2):281–97 (100 ref.)

BIOSYNTHESIS

ESBRA 1994 Award Lecture. Phosphatidylethanol formation: specific effects of ethanol mediated via phospholipase D. Gustavsson L. **Alcohol Alcohol** 1995 Jul; 30(4):391–406 (84 ref.)

METABOLISM

Glycerophospholipid metabolism and human labour. Rice GE. **Reprod Fertil Dev** 1995;7(3):613–22 (118 ref.)

PHYSIOLOGY

Messenger functions of phosphatidic acid. English D, et al. **Chem Phys Lipids** 1996 May 24;80(1–2):117–32 (140 ref.)

PHOSPHATIDYLETHANOLAMINES

ADMINISTRATION & DOSAGE

Biologic therapy for osteosarcoma using liposome–encapsulated muramyl tripeptide. Kleinerman ES. **Hematol Oncol Clin North Am** 1995 Aug;9(4):927–38 (37 ref.)

PHOSPHATIDYLETHANOLAMINES

METABOLISM

Phosphatidylethanolamine methylation and hepatoma cell growth. Vance DE, et al. **Anticancer Res** 1996 May-Jun; 16(3B):1413-6 (17 ref.)

PHOSPHATIDYLINOSITOL PHOSPHATES

METABOLISM

Nuclear inositol lipid cycle and differentiation. Cocco L, et al. **Adv Enzyme Regul** 1995;35:23-33 (31 ref.)

Cross talk between cyclic AMP and the polyphosphoinositide signaling cascade in iris sphincter and other nonvascular smooth muscle. Abdel-Latif AA. **Proc Soc Exp Biol Med** 1996 Feb;211(2):163-77 (126 ref.)

PHOSPHATIDYLINOSITOLS

Signalling pathways activated by endothelin stimulation of renal cells. Nord EP. **Clin Exp Pharmacol Physiol** 1996 Apr;23(4):331-6 (54 ref.)

ANALYSIS

Quantitative chromatographic analysis of inositol phospholipids and related compounds. Singh AK, et al. **J Chromatogr B Biomed Appl** 1995 Sep 15;671(1-2):255-80 (130 ref.)

METABOLISM

Inositol lipid signal transduction in phytoalexin elicitation. Walton TJ. **Biochem Soc Trans** 1995 Nov;23(4):862-7 (38 ref.)

Intracellular signalling. New directions for phosphatidylinositol transfer. Martin T. **Curr Biol** 1995 Sep 1;5(9):990-2 (13 ref.)

Effects of aluminum on neuronal signal transduction: mechanisms underlying disruption of phosphoinositide hydrolysis. Shafer TJ, et al. **Gen Pharmacol** 1995 Sep; 26(5):889-95 (46 ref.)

Transmembrane signaling and phosphoinositides. Cho MH, et al. **Methods Cell Biol** 1995;49:543-54 (50 ref.)

Phosphoinositide-generated messengers in cardiac signal transduction. van Heugten HA, et al. **Mol Cell Biochem** 1996 Apr 12-26;157(1-2):5-14 (88 ref.)

Phosphoinositides as regulators in membrane traffic. De Camilli P, et al. **Science** 1996 Mar 15;271(5255):1533-9 (74 ref.)

Phosphoinositide turnover and its role in plant signal transduction. Coté GG, et al. **Subcell Biochem** 1996; 26:317-43 (156 ref.)

PHYSIOLOGY

Role of phosphatidylinositol-linked proteins in paroxysmal nocturnal hemoglobinuria pathogenesis. Kinoshita T, et al. **Annu Rev Med** 1996;47:1-10 (48 ref.)

Phosphoinositide signalling in plant and algal responses to physiological stimuli. Crain RC, et al. **Biochem Soc Trans** 1995 Nov;23(4):853-6 (28 ref.)

Phosphoinositide second messengers in olfaction. Bruch RC. **Comp Biochem Physiol B Biochem Mol Biol** 1996 Mar; 113(3):451-9 (95 ref.)

Phosphoinositides and synaptic transmission. Hawthorne JN. **Subcell Biochem** 1996;26:43-57 (64 ref.)

PHOSPHATIDYLSERINES

ANALYSIS

Membrane phospholipid asymmetry: host response to the externalization of phosphatidylserine. Bruckheimer EM, et al. **J Leukoc Biol** 1996 Jun;59(6):784-8 (58 ref.)

METABOLISM

Intracellular trafficking of phospholipids: import of phosphatidylserine into mitochondria. Vance JE, et al. **Anticancer Res** 1996 May-Jun;16(3B):1333-9 (48 ref.)

Role of translocases in the generation of phosphatidylserine asymmetry. Diaz C, et al. **J Membr Biol** 1996 May; 151(1):1-9 (99 ref.)

PHOSPHINES

POISONING

Oral aluminium phosphide poisoning. Sharma A. **Indian Pediatr** 1995 Mar;32(3):339-42 (17 ref.)

PHOSPHODIESTERASE ANTAGONISTS see **PHOSPHODIESTERASE INHIBITORS**

PHOSPHODIESTERASE INHIBITORS

[Selective type III phosphodiesterase inhibitor as an antithrombotic agent] Kimura Y. **Nippon Yakurigaku Zasshi** 1995 Sep;106(3):205-16 (39 ref.) (Eng. Abstr.) **(Jpn)**

[Phosphodiesterase inhibitor: griseolic acid, its' derivatives and their biological activities] Kaneko M, et al. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1268-76 (23 ref.) **(Jpn)**

CHEMISTRY

Phosphodiesterase type IV inhibitors. Palfreyman MN, et al. **Prog Med Chem** 1996;33:1-52 (306 ref.)

PHARMACOLOGY

Milrinone: basic and clinical pharmacology and acute and chronic management. Shipley JB, et al. **Am J Med Sci** 1996 Jun;311(6):286-91 (36 ref.)

Cyclic nucleotide phosphodiesterases and vascular smooth muscle. Polson JB, et al. **Annu Rev Pharmacol Toxicol** 1996; 36:403-27 (87 ref.)

PDE isoenzymes as targets for anti-asthma drugs. Schudt C, et al. **Eur Respir J** 1995 Jul;8(7):1179-83 (18 ref.)

Second messenger systems as targets for new therapeutic agents: focus on selective phosphodiesterase inhibitors. Palacios JM, et al. **Farmaco** 1995 Dec;50(12):819-27 (81 ref.)

Cytokines, phagocytes, and pentoxifylline. Mandell GL. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S20-2 (7 ref.)

Phosphodiesterase inhibition and Ca2+ sensitization. Ravens U, et al. **Mol Cell Biochem** 1996 Apr 12-26;157(1-2):245-9 (21 ref.)

Immunomodulatory actions of xanthines and isoenzyme selective phosphodiesterase inhibitors. Banner KH, et al. **Monaldi Arch Chest Dis** 1995 Aug;50(4):286-92 (96 ref.)

[Pentoxifylline] Paradowski PT, et al. **Postepy Hig Med Dosw** 1995;49(2):201-20 (112 ref.) (Eng. Abstr.) **(Pol)**

THERAPEUTIC USE

Theophylline and selective phosphodiesterase inhibitors as anti-inflammatory drugs in the treatment of bronchial asthma. Banner KH, et al. **Eur Respir J** 1995 Jun; 8(6):996-1000 (50 ref.)

Pentoxifylline for the treatment of HIV infection and its complications. Dezube BJ, et al. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S139-42 (29 ref.)

Prevention studies with pentoxifylline: new clinical projects. Eugène-Jolchine I, et al. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S143-6 (29 ref.)

Adrenergic and muscarinic receptor regulation and therapeutic implications in heart failure. Schmitz W, et al. **Mol Cell Biochem** 1996 Apr 12-26;157(1-2):251-8 (91 ref.)

Multiple sclerosis: TNF revisited, with promise [comment] Raine CS. **Nat Med** 1995 Mar;1(3):211-4 (28 ref.) Comment on: Nat Med 1995 Mar;1(3):244-8.

Phosphodiesterase inhibitors: Lily the Pink's medicinal compound for asthma? Dent G, et al. **Thorax** 1996 Jun; 51(6):647-9 (12 ref.)

PHOSPHODIESTERASES see **PHOSPHORIC DIESTER HYDROLASES**

PHOSPHOENOLPYRUVATE CARBOXYKINASES

GENETICS

New connections in the regulation of PEPCK gene expression by insulin. Sutherland C, et al. **Philos Trans R Soc Lond B Biol Sci** 1996 Feb 29; 351(1336):191-9 (100 ref.)

PHOSPHOENOLPYRUVATE HEXOSE PHOSPHOTRANSFERASES see **PHOSPHOENOLPYRUVATE SUGAR PHOSPHOTRANSFERASE SYSTEM**

PHOSPHOENOLPYRUVATE SUGAR PHOSPHOTRANSFERASE SYSTEM

CHEMISTRY

Interactions of protein antigens with antibodies. Davies DR, et al. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):7-12 (69 ref.)

GENETICS

The catabolite repressor/activator (Cra) protein of enteric bacteria. Saier MH Jr, et al. **J Bacteriol** 1996 Jun; 178(12):3411-7 (46 ref.)

Novel PTS proteins revealed by bacterial genome sequencing: a unique fructose-specific phosphoryl transfer protein with two HPr-like domains in Haemophilus influenzae. Reizer J, et al. **Res Microbiol** 1996 May; 147(4):209-15 (29 ref.)

METABOLISM

HPr: a model protein. Anderson JW. **Biochem Cell Biol** 1995 May-Jun;73(5-6):219-22 (15 ref.)

HPr: heteromorphous protein. Vadeboncoeur C. **Res Microbiol** 1995 Sep;146(7):525-30 (41 ref.)

6-PHOSPHOFRUCTOKINASE

see related
GLYCOGEN STORAGE DISEASE TYPE VII

ANALYSIS

[Phosphofructokinase (PFK)] Kono N. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:438-41 (20 ref.) **(Jpn)**

GENETICS

Mutations in muscle phosphofructokinase gene. Raben N, et al. **Hum Mutat** 1995;6(1):1-6 (37 ref.)

METABOLISM

Conservation, evolution, and specificity in cellular control by protein phosphorylation. Hofer HW. **Experientia** 1996 May 15;52(5):449-54 (27 ref.)

The phosphofructokinase-uncharged tRNA interaction in metabolic and cell cycle control: an interpretive review. Rabinovitz M. **Nucleic Acids Symp Ser** 1995;(33):182-9 (53 ref.)

PHOSPHOGLUCOMUTASE

ISOLATION & PURIFICATION

[Phosphoglucomutase (PGM)] Takahashi N. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:210-4 (19 ref.) **(Jpn)**

PHOSPHOGLUCOSE ISOMERASE see **GLUCOSEPHOSPHATE ISOMERASE**

PHOSPHOGLYCERALDEHYDE DEHYDROGENASE see **GLYCERALDEHYDEPHOSPHATE DEHYDROGENASE**

PHOSPHOHEXOSE ISOMERASE see **GLUCOSEPHOSPHATE ISOMERASE**

PHOSPHOHYDROLASES see **PHOSPHORIC MONOESTER HYDROLASES**

PHOSPHOINOSITIDES see **PHOSPHATIDYLINOSITOLS**

PHOSPHOLIPASE A1 see **PHOSPHOLIPASES A**

PHOSPHOLIPASE A2 see **PHOSPHOLIPASES A**

PHOSPHOLIPASE C

METABOLISM

Nuclear inositol lipid cycle and differentiation. Cocco L, et al. **Adv Enzyme Regul** 1995;35:23-33 (31 ref.)

Mechanisms regulating oxytocin receptor coupling to phospholipase C in rat and human myometrium. Sanborn BM, et al. **Adv Exp Med Biol** 1995;395:469-79 (54 ref.)

Signalling pathways activated by endothelin stimulation of renal cells. Nord EP. **Clin Exp Pharmacol Physiol** 1996 Apr;23(4):331-6 (54 ref.)

Dopamine D1 receptor regulation of phospholipase C. Jose PA, et al. **Hypertens Res** 1995 Jun;18 Suppl 1:S39-42 (45 ref.)

Structural requirements of parathyroid hormone/parathyroid hormone-related peptide receptors for phospholipase C activation and regulation of phosphate uptake. Iida-Klein A, et al. **Miner Electrolyte Metab** 1995;21(1-3):177-9 (16 ref.)

Polyunsaturated fatty acids and signalling via phospholipase C-beta and A2 in myocardium. de Jonge HW, et al. **Mol Cell Biochem** 1996 Apr 12-26;157(1-2):199-210 (79 ref.)

PHYSIOLOGY

Phosphoinositide-specific phospholipase C and mitogenic signaling. Noh DY, et al. **Biochim Biophys Acta** 1995 Dec 18;1242(2):99-113 (143 ref.)

[Regulation of phospholipase C-delta 1] Hirata M, et al. **Seikagaku** 1995 Sep;67(9):1128-32 (15 ref.) **(Jpn)**

PHOSPHOLIPASE D

[Multiplicity and purification of animal phospholipase D] Okamura S, et al. **Seikagaku** 1995 Nov;67(11):1290-5 (15 ref.) **(Jpn)**

BLOOD

Phospholipase D in platelets and megakaryocytic cells. Halenda SP, et al. **Chem Phys Lipids** 1996 May 24; 80(1-2):21-6 (18 ref.)

Impaired activation of phospholipase D in polycythaemia vera-implications for the pathogenesis of the disease? Samuelsson J. **Leuk Lymphoma** 1995 Sep;19(1-2):21-6 (60 ref.)

CHEMISTRY

Structure and regulation of phospholipase D. Morris AJ, et al. **Trends Pharmacol Sci** 1996 May;17(5):182-5 (29 ref.)

METABOLISM

ESBRA 1994 Award Lecture. Phosphatidylethanol formation: specific effects of ethanol mediated via

phospholipase D. Gustavsson L. **Alcohol Alcohol** 1995 Jul; 30(4):391–406 (84 ref.)
ARF-regulated phospholipase D: a potential role in membrane traffic. Cockcroft S. **Chem Phys Lipids** 1996 May 24;80(1–2):59–80 (165 ref.)
Phospholipase D in platelets and megakaryocytic cells. Halenda SP, et al. **Chem Phys Lipids** 1996 May 24; 80(1–2):21–6 (18 ref.)
Enzymology of mammalian phospholipases D: in vitro studies. Liscovitch M, et al. **Chem Phys Lipids** 1996 May 24;80(1–2):37–44 (82 ref.)
The N-acylation–phosphodiesterase pathway and cell signalling. Schmid HH, et al. **Chem Phys Lipids** 1996 May 24;80(1–2):133–42 (64 ref.)
Sphingoid bases and phospholipase D activation. Spiegel S, et al. **Chem Phys Lipids** 1996 May 24;80(1–2):27–36 (87 ref.)
Signalling pathways activated by endothelin stimulation of renal cells. Nord EP. **Clin Exp Pharmacol Physiol** 1996 Apr;23(4):331–6 (54 ref.)
Role of phospholipase D activation in nervous system physiology and pathophysiology. Klein J, et al. **J Neurochem** 1995 Oct;65(4):1445–55 (83 ref.)
Regulation and functional significance of phospholipase D in myocardium. Eskildsen-Helmond YE, et al. **Mol Cell Biochem** 1996 Apr 12–26;157(1–2):39–48 (72 ref.)
The transphosphatidylation activity of phospholipase D. Yu CH, et al. **Mol Cell Biochem** 1996 Apr 12–26;157(1–2):101–5 (40 ref.)

PHYSIOLOGY

Regulation of phospholipase D by protein kinase C. Kiss Z. **Chem Phys Lipids** 1996 May 24;80(1–2):81–102 (243 ref.)
Regulation of phospholipase D by tyrosine kinases. Natarajan V, et al. **Chem Phys Lipids** 1996 May 24;80(1–2):103–16 (156 ref.)
Biochemistry and cell biology of phospholipase D in human neutrophils. Olson SC, et al. **Chem Phys Lipids** 1996 May 24;80(1–2):3–19 (124 ref.)
Structure and regulation of phospholipase D. Morris AJ, et al. **Trends Pharmacol Sci** 1996 May;17(5):182–5 (29 ref.)
[Phospholipase D. New pathways of signal transduction] Höer A, et al. **Med Monatsschr Pharm** 1996 May; 19(5):122–31 (81 ref.) **(Ger)**

PHOSPHOLIPASES

CHEMISTRY

Phospholipases: structural and functional motifs for working at an interface. Roberts MF. **FASEB J** 1996 Aug; 10(10):1159–72 (41 ref.)

METABOLISM

Activation of the phospholipase/cyclooxygenase cascade in the rabbit cornea by platelet-activating factor is challenged by PAF receptor antagonists. Hurst JS, et al. **J Ocul Pharmacol Ther** 1995 Fall;11(3):329–37 (39 ref.)

PHYSIOLOGY

Phospholipases: structural and functional motifs for working at an interface. Roberts MF. **FASEB J** 1996 Aug; 10(10):1159–72 (41 ref.)

PHOSPHOLIPASES A

Mammalian calcium-independent phospholipase A2. Ackermann EJ, et al. **Biochim Biophys Acta** 1995 Nov 16; 1259(2):125–36 (102 ref.)
Mammalian platelet-activating factor acetylhydrolases. Stafforini DM, et al. **Biochim Biophys Acta** 1996 Jun 11; 1301(3):161–73 (138 ref.)

ANTAGONISTS & INHIBITORS

Phospholipase A2 inhibitors: a challenge for the future. Berenbaum F. **Rev Rhum Engl Ed** 1995 Jun;62(6):409–14 (45 ref.)

BLOOD

[Pancreatic phospholipase A2] Ogawa M. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:333–7 (5 ref.) **(Jpn)**
[Phospholipase A] Tsujita T. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:678–80 (8 ref.) **(Jpn)**

CHEMISTRY

Cytosolic phospholipase A2. Clark JD, et al. **J Lipid Mediat Cell Signal** 1995 Oct;12(2–3):83–117 (139 ref.)

DRUG EFFECTS

Stimulation of phospholipase A2 expression in rat cultured astrocytes by LPS, TNF alpha and IL-1 beta. Sun GY, et al. **Prog Brain Res** 1995;105:231–8 (27 ref.)

METABOLISM

Interfacial enzymology of glycerolipid hydrolases: lessons from secreted phospholipases A2. Gelb MH, et al. **Annu Rev Biochem** 1995;64:653–88 (208 ref.)
Cytosolic phospholipase A2. Clark JD, et al. **J Lipid Mediat Cell Signal** 1995 Oct;12(2–3):83–117 (139 ref.)
Myocardial phospholipase A2. Gross RW. **J Lipid Mediat Cell Signal** 1995 Oct;12(2–3):131–7 (25 ref.)
Effect of high glucose concentration on phospholipase A2 activity in mesangial cells. Choi K. **Kidney Int Suppl** 1995 Sep;51:S22–7 (48 ref.)
Polyunsaturated fatty acids and signalling via phospholipase C-beta and A2 in myocardium. de Jonge HW, et al. **Mol Cell Biochem** 1996 Apr 12–26;157(1–2):199–210 (79 ref.)

PHYSIOLOGY

Phospholipase-A2-dependent signalling in the heart. Van Bilsen M, et al. **Cardiovasc Res** 1995 Oct;30(4):518–29 (125 ref.)
Platelet-activating factor is a synapse messenger and a modulator of gene expression in the nervous system. Bazan NG, et al. **Neurochem Int** 1995 May;26(5):435–41 (72 ref.)

SECRETION

Secretory phospholipases A2. Murakami M, et al. **J Lipid Mediat Cell Signal** 1995 Oct;12(2–3):119–30 (64 ref.)
Secretory type II phospholipase A2 and the generation of intrauterine signals. Rice GE. **Reprod Fertil Dev** 1995; 7(6):1471–9 (99 ref.)

TOXICITY

Phospholipase A2 myotoxins from Bothrops snake venoms. Gutiérrez JM, et al. **Toxicon** 1995 Nov;33(11):1405–24 (129 ref.)

PHOSPHOLIPIDS

see related
ANTIBODIES, ANTIPHOSPHOLIPID
ANTIPHOSPHOLIPID SYNDROME

ANALYSIS

Age-dependency of surfactant phospholipids and surfactant protein A in bronchoalveolar lavage fluid of children without bronchopulmonary disease. Ratjen F, et al. **Eur Respir J** 1996 Feb;9(2):328–33 (34 ref.)

BIOSYNTHESIS

Eukaryotic phospholipid biosynthesis. Kent C. **Annu Rev Biochem** 1995;64:315–43 (221 ref.)
Regulation of phospholipid biosynthesis in the yeast Saccharomyces cerevisiae. Carman GM, et al. **J Biol Chem** 1996 Jun 7;271(23):13293–6 (105 ref.)

BLOOD

[Phospholipids and its fractions] Suzuki H, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:623–6 (15 ref.) **(Jpn)**

CHEMISTRY

Model of a sub-main transition in phospholipid bilayers. Nielsen M, et al. **Biochim Biophys Acta** 1996 Sep 4; 1283(2):170–6 (20 ref.)

METABOLISM

Phospholipid metabolites in 1H-decoupled 31P MRS in vivo in human cancer: implications for experimental models and clinical studies. Negendank W, et al. **Anticancer Res** 1996 May-Jun;16(3B):1539–44 (32 ref.)
Magnetic resonance spectroscopy in cancer: phospholipid, neutral lipid and lipoprotein metabolism and function. Podo F, et al. **Anticancer Res** 1996 May-Jun;16(3B):1305–15 (57 ref.)
Phospholipid vesicles and other cholesterol carriers in bile. Gilat T, et al. **Biochim Biophys Acta** 1996 Jun 10; 1286(2):95–115 (108 ref.)
Phospholipid metabolism and membrane dynamics. Alb JG, et al. **Curr Opin Cell Biol** 1996 Aug;8(4):534–41 (46 ref.)
Cell cycle regulation of membrane phospholipid metabolism. Jackowski S. **J Biol Chem** 1996 Aug 23;271(34):20219–22 (69 ref.)
Role of translocases in the generation of phosphatidylserine asymmetry. Diaz C, et al. **J Membr Biol** 1996 May; 151(1):1–9 (99 ref.)
Breakdown of membrane phospholipids in Alzheimer disease. Involvement of excitatory amino acid receptors. Farooqui AA, et al. **Mol Chem Neuropathol** 1995 Jun-Aug; 25(2–3):155–73 (94 ref.)
A family of phospholipid autacoids: occurrence, metabolism and bioactions. Tokumura A. **Prog Lipid Res** 1995; 34(2):151–84 (240 ref.)
[Sidedness of biomembrane: asymmetrical distribution and flip-flop of phospholipids across lipid bilayer] Anzai K. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(16):2418–26 (93 ref.) **(Jpn)**
[Flippases—phospholipid transporting proteins] Pulaski L. **Postepy Biochem** 1995;41(2):131–8 (78 ref.) **(Pol)**

PHYSIOLOGY

Membrane phospholipids and adrenergic receptor function. Williams S, et al. **Mol Cell Biochem** 1995 Aug-Sep; 149–150:217–21 (47 ref.)

PHOSPHOMONOESTERASES see PHOSPHORIC MONOESTER HYDROLASES

PHOSPHONOFORMATE see FOSCARNET

PHOSPHONOFORMIC ACID see FOSCARNET

PHOSPHOPEPTIDES

CHEMICAL SYNTHESIS

The synthesis and compositional analysis of phosphopeptides. Sanderson SD, et al. **Mol Biotechnol** 1995 Oct;4(2):139–49 (70 ref.)

CHEMISTRY

The synthesis and compositional analysis of phosphopeptides. Sanderson SD, et al. **Mol Biotechnol** 1995 Oct;4(2):139–49 (70 ref.)

PHOSPHOPROTEIN PHOSPHATASE

Serine/threonine protein phosphatases. Wera S, et al. **Biochem J** 1995 Oct 1;311 (Pt 1):17–29 (170 ref.)

ANTAGONISTS & INHIBITORS

Protein serine/threonine phosphatases as binding proteins for okadaic acid. Nagao M, et al. **Mutat Res** 1995 Dec; 333(1–2):173–9 (33 ref.)
Protein phosphatase regulation by endogenous inhibitors. Shenolikar S. **Semin Cancer Biol** 1995 Aug;6(4):219–27 (60 ref.)

CHEMISTRY

Protein serine/threonine phosphatases. Villafranca JE, et al. **Curr Opin Biotechnol** 1996 Aug;7(4):397–402 (42 ref.)
Insights derived from the structures of the Ser/Thr phosphatases calcineurin and protein phosphatase 1. Lohse DL, et al. **Structure** 1995 Oct 15;3(10):987–90 (24 ref.)
[The structure of smooth muscle myosin phosphatase] Ito M, et al. **Seikagaku** 1996 Feb;68(2):147–51 (15 ref.) **(Jpn)**

METABOLISM

Phosphorylation of paired helical filament tau in Alzheimer's disease neurofibrillary lesions: focusing on phosphatases. Trojanowski JQ, et al. **FASEB J** 1995 Dec;9(15):1570–6 (77 ref.)
Aspartyl-phosphate phosphatases deactivate the response regulator components of the sporulation signal transduction system in Bacillus subtilis. Perego M, et al. **Mol Microbiol** 1996 Mar;19(6):1151–7 (25 ref.)
Flicking the switches: phosphorylation of serine/threonine protein phosphatases. Brautigan DL. **Semin Cancer Biol** 1995 Aug;6(4):211–7 (37 ref.)

PHARMACOLOGY

Protein kinases and phosphatases that act on histidine, lysine, or arginine residues in eukaryotic proteins: a possible regulator of the mitogen-activated protein kinase cascade. Matthews HR. **Pharmacol Ther** 1995;67(3):323–50 (154 ref.)

PHYSIOLOGY

Regulation of dynein-driven microtubule sliding by an axonemal kinase and phosphatase in Chlamydomonas flagella. Habermacher G, et al. **Cell Motil Cytoskeleton** 1995;32(2):106–9 (23 ref.)
Protein serine/threonine phosphatases. Villafranca JE, et al. **Curr Opin Biotechnol** 1996 Aug;7(4):397–402 (42 ref.)
The role of calcineurin in immune system responses. Kincaid RL. **J Allergy Clin Immunol** 1995 Dec;96(6 Pt 2):1170–7 (40 ref.)
Regulation of phospholamban and troponin-I phosphorylation in the intact rat cardiomyocytes by adrenergic and cholinergic stimuli: roles of cyclic nucleotides, calcium, protein kinases and phosphatases and depolarization. Sulakhe PV, et al. **Mol Cell Biochem** 1995 Aug-Sep;149–150:103–26 (96 ref.)
The role of protein phosphatase type-2A in the Xenopus cell cycle: initiation of the G2/M transition. Lee TH. **Semin Cancer Biol** 1995 Aug;6(4):203–9 (39 ref.)
Control and activity of type-1 serine/threonine protein phosphatase during the cell cycle. Ludlow JW, et al. **Semin Cancer Biol** 1995 Aug;6(4):195–202 (42 ref.)
Regulation by tumour antigens defines a role for PP2A in signal transduction. Mumby M. **Semin Cancer Biol** 1995 Aug;6(4):229–37 (59 ref.)
Regulation of gene expression by serine/threonine protein phosphatases. Schönthal AH. **Semin Cancer Biol** 1995 Aug; 6(4):239–48 (102 ref.)

PHOSPHOPROTEIN PHOSPHOHYDROLASE see PHOSPHOPROTEIN PHOSPHATASE

PHOSPHOPROTEIN PP53 see PROTEIN P53

PHOSPHOPROTEINS

BIOSYNTHESIS

Protein phosphorylation in apoptosis. Gjertsen BT, et al. **Biochim Biophys Acta** 1995 Nov 9;1269(2):187–99 (309 ref.)

GENETICS

Mutations in the X-linked and autosomal recessive forms of chronic granulomatous disease. Roos D, et al. **Blood** 1996 Mar 1;87(5):1663–81 (151 ref.)

METABOLISM

The signal transduction pathway leading from the toll receptor to nuclear localization of dorsal transcription factor. Gay NJ, et al. **Biochem Soc Trans** 1996 Feb; 24(1):35–8 (26 ref.)

Perilipin: unique proteins associated with intracellular neutral lipid droplets in adipocytes and steroidogenic cells. Londos C, et al. **Biochem Soc Trans** 1995 Aug;23(3):611–5 (16 ref.)

PHYSIOLOGY

Role of the steroidogenic acute regulatory protein (StAR) in steroidogenesis. Stocco DM, et al. **Biochem Pharmacol** 1996 Feb 9;51(3):197–205 (125 ref.)

Zonula occludens (ZO)–1 and ZO–2: membrane–associated guanylate kinase homologues (MAGuKs) of the tight junction. Anderson JM, et al. **Biochem Soc Trans** 1995 Aug; 23(3):470–5 (45 ref.)

Perilipin: possible roles in structure and metabolism of intracellular neutral lipids in adipocytes and steroidogenic cells. Londos C, et al. **Int J Obes Relat Metab Disord** 1996 Mar;20 Suppl 3:S97–101 (13 ref.)

Regulation of the interferon system and cell growth by the IRF transcription factors. Taniguchi T, et al. **J Cancer Res Clin Oncol** 1995;121(9–10):516–20 (34 ref.)

The IRS–signalling system in insulin and cytokine action. White MF. **Philos Trans R Soc Lond B Biol Sci** 1996 Feb 29;351(1336):181–9 (80 ref.)

PHOSPHOPYRUVATE DIKINASE see **PYRUVATE, ORTHOPHOSPHATE DIKINASE**

PHOSPHORESCENCE see **LUMINESCENCE**

PHOSPHORIBOSYL PYROPHOSPHATE SYNTHETASE see **RIBOSE–PHOSPHATE PYROPHOSPHOKINASE**

PHOSPHORIC DIESTER HYDROLASE INHIBITORS see **PHOSPHODIESTERASE INHIBITORS**

PHOSPHORIC DIESTER HYDROLASES

PDE isoenzymes as targets for anti–asthma drugs. Schudt C, et al. **Eur Respir J** 1995 Jul;8(7):1179–83 (18 ref.)

GENETICS

Genetics of myo–inositol phosphate synthesis and accumulation. Raboy V, et al. **Subcell Biochem** 1996; 26:257–85 (161 ref.)

METABOLISM

Compartmentalization of cyclic AMP phosphodiesterases, signalling 'crosstalk', desensitization and the phosphorylation of Gi–2 add cell specific personalization to the control of the levels of the second messenger cyclic AMP. Houslay MD. **Adv Enzyme Regul** 1995;35:303–38 (68 ref.)

Phosphodiesterase activity as a mediator of renal resistance to ANP in pathological salt retention. Lee EY, et al. **Am J Physiol** 1996 Jul;271(1 Pt 2):F3–6 (27 ref.)

Regulation of phosphoinositide phospholipases by hormones, neurotransmitters, and other agonists linked to G proteins. Exton JH. **Annu Rev Pharmacol Toxicol** 1996;36:481–509 (170 ref.)

Cyclic nucleotide phosphodiesterases and vascular smooth muscle. Polson JB, et al. **Annu Rev Pharmacol Toxicol** 1996; 36:403–27 (87 ref.)

Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Beavo JA. **Physiol Rev** 1995 Oct; 75(4):725–48 (179 ref.)

PHYSIOLOGY

Phosphoinositide–specific phospholipase C and mitogenic signaling. Noh DY, et al. **Biochim Biophys Acta** 1995 Dec 18;1242(2):99–113 (143 ref.)

PHOSPHORIC MONOESTER HYDROLASES

ANTAGONISTS & INHIBITORS

Inhibition of phosphate–metabolizing enzymes by oxovanadium(V) complexes. Stankiewicz PJ, et al. **Met Ions Biol Syst** 1995;31:287–324 (169 ref.)

Inositol monophosphatase—a putative target for Li+ in the treatment of bipolar disorder. Atack JR, et al. **Trends Neurosci** 1995 Aug;18(8):343–9 (97 ref.)

GENETICS

Genetics of myo–inositol phosphate synthesis and accumulation. Raboy V, et al. **Subcell Biochem** 1996; 26:257–85 (161 ref.)

METABOLISM

6–Phosphofructo–2–kinase/fructose–2,6–bisphosphatase: a metabolic signaling enzyme. Pilkis SJ, et al. **Annu Rev Biochem** 1995;64:799–835 (221 ref.)

Subcellular targeting of kinases and phosphatases by association with bifunctional anchoring proteins. Coghlan VM, et al. **Biochem Soc Trans** 1995 Aug;23(3):592–6 (40 ref.)

Mitogen and stress response pathways: MAP kinase cascades and phosphatase regulation in mammals and yeast. Waskiewicz AJ, et al. **Curr Opin Cell Biol** 1995 Dec; 7(6):798–805 (79 ref.)

Inositols do it all. Majerus PW. **Genes Dev** 1996 May 1; 10(9):1051–3 (11 ref.)

Covalent control of 6–phosphofructo–2–kinase/fructose–2,6–bisphosphatase: insights into autoregulation of a bifunctional enzyme. Kurland IJ, et al. **Protein Sci** 1995 Jun;4(6):1023–37 (70 ref.)

PHYSIOLOGY

Angiotensin II–mediated signal transduction events in vascular smooth muscle cells: kinases and phosphatases. Duff JL, et al. **Blood Press Suppl** 1995;2:55–60 (68 ref.)

A prospective view on phosphatases and replicative senescence. Bernier L, et al. **Exp Gerontol** 1996 Jan–Apr; 31(1–2):13–9 (30 ref.)

PHOSPHORUS

see related
ORGANOPHOSPHORUS COMPOUNDS
ORGANOTHIOPHOSPHORUS COMPOUNDS

Calcium and phosphorus nutrition in infants. Demarini S, et al. **J Pediatr Gastroenterol Nutr** 1995 Nov;21(4):367–73 (85 ref.)

METABOLISM

Effects of growth hormone on phosphocalcium homeostasis and bone metabolism. Saggese G, et al. **Horm Res** 1995; 44 Suppl 3:55–63 (86 ref.)

[Physiology of intestinal absorption of phosphorus in animals] Barlet JP, et al. **Reprod Nutr Dev** 1995;35(5):475–89 (128 ref.) (Eng. Abstr.) **(Fre)**

PHOSPHORUS, DIETARY

ADMINISTRATION & DOSAGE

Calcium, phosphorus and human bone development. Anderson JJ. **J Nutr** 1996 Apr;126(4 Suppl):1153S–8S (32 ref.)

ADVERSE EFFECTS

Changing phosphorus content of the U.S. diet: potential for adverse effects on bone. Calvo MS, et al. **J Nutr** 1996 Apr; 126(4 Suppl):1168S–80S (72 ref.)

PHARMACOLOGY

Calcium, magnesium and phosphorus in the nutrition of the newborn. Venkataraman PS, et al. **J Am Coll Nutr** 1995 Oct;14(5):439–47 (102 ref.)

PHOSPHORUS RADIOISOTOPES

32P and beta emitting radionuclides in microbiology and cell biology. Rees B. **Health Phys** 1996 May;70(5):639–42 (20 ref.)

PHOSPHORYLATION

Mechanisms of phosphoryl and acyl transfer. Cleland WW, et al. **FASEB J** 1995 Dec;9(15):1585–94 (50 ref.)

PHOSPHORYLCHOLINE

IMMUNOLOGY

[Phosphocholine antigens in muscle larvae of Trichinella spiralis] Bitkowska E. **Wiad Parazytol** 1996;42(1):57–63 (37 ref.) (Eng. Abstr.) **(Pol)**

PHOSPHORYLCHOLINE, ACETYL GLYCERYL ETHER see **PLATELET ACTIVATING FACTOR**

PHOSPHORYLCHOLINE CHLORIDE see **PHOSPHORYLCHOLINE**

PHOSPHOSERINE

METABOLISM

O–linked N–acetylglucosamine: the "yin–yang" of Ser/Thr phosphorylation? Nuclear and cytoplasmic glycosylation. Hart GW, et al. **Adv Exp Med Biol** 1995;376:115–23 (45 ref.)

PHOSPHOTHREONINE

METABOLISM

O–linked N–acetylglucosamine: the "yin–yang" of Ser/Thr phosphorylation? Nuclear and cytoplasmic glycosylation. Hart GW, et al. **Adv Exp Med Biol** 1995;376:115–23 (45 ref.)

PHOSPHOTRANSFERASES

ANTAGONISTS & INHIBITORS

Inhibition of phosphate–metabolizing enzymes by oxovanadium(V) complexes. Stankiewicz PJ, et al. **Met Ions Biol Syst** 1995;31:287–324 (169 ref.)

METABOLISM

Subcellular targeting of kinases and phosphatases by association with bifunctional anchoring proteins. Coghlan VM, et al. **Biochem Soc Trans** 1995 Aug;23(3):592–6 (40 ref.)

Metallocene interactions with DNA and DNA–processing enzymes. Kuo LY, et al. **Met Ions Biol Syst** 1996;33:53–85 (113 ref.)

Phosphotransfer reactions as a means of G protein activation. Piacentini L, et al. **Mol Cell Biochem** 1996 Apr 12–26; 157(1–2):59–63 (45 ref.)

PHYSIOLOGY

PIK–related kinases: DNA repair, recombination, and cell cycle checkpoints. Keith CT, et al. **Science** 1995 Oct 6; 270(5233):50–1 (22 ref.)

PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR)

Relationship of the ataxia–telangiectasia protein ATM to phosphoinositide 3–kinase. Lavin MF, et al. **Trends Biochem Sci** 1995 Oct;20(10):382–3 (22 ref.)

ANALYSIS

NPTII assays for measuring gene expression and enzyme activity in transgenic plants. Curtis IS, et al. **Methods Mol Biol** 1995;49:149–59 (20 ref.)

CHEMISTRY

When is a lipid kinase not a lipid kinase? When it is a protein kinase. Hunter T. **Cell** 1995 Oct 6;83(1):1–4 (19 ref.)

Structural and functional diversity of phosphoinositide 3–kinases. Zvelebil MJ, et al. **Philos Trans R Soc Lond B Biol Sci** 1996 Feb 29; 351(1336):217–23 (60 ref.)

[Heterogenity of diacylglycerol Kinase—Structure, biochemical characteristics and gene expression in the brain] Goto K. **Kaibogaku Zasshi** 1995 Dec;70(6):509–11 (4 ref.) **(Jpn)**

GENETICS

Genetics of myo–inositol phosphate synthesis and accumulation. Raboy V, et al. **Subcell Biochem** 1996; 26:257–85 (161 ref.)

The ataxia–telangiectasia gene: a link between checkpoint controls, neurodegeneration and cancer. Lehmann AR, et al. **Trends Genet** 1995 Oct;11(10):375–7 (23 ref.)

METABOLISM

Receptor–mediated protein sorting to the vacuole in yeast: roles for a protein kinase, a lipid kinase and GTP–binding proteins. Stack JH, et al. **Ann Rev Cell Dev Biol** 1995; 11:1–33 (146 ref.)

6–Phosphofructo–2–kinase/fructose–2,6–bisphosphatase: a metabolic signaling enzyme. Pilkis SJ, et al. **Annu Rev Biochem** 1995;64:799–835 (221 ref.)

The TOR signalling pathway and growth control in yeast. Hall MN. **Biochem Soc Trans** 1996 Feb;24(1):234–9 (42 ref.)

Phosphoinositide 3–kinase and CD28–mediated T–cell co–stimulation. Ward SG. **Biochem Soc Trans** 1996 Feb; 24(1):240–5 (50 ref.)

Molecular study and regulation of D–myo–inositol 1,4,5–trisphosphate 3–kinase. Communi D, et al. **Cell Signal** 1995 Sep;7(7):643–50 (52 ref.)

Phosphoinositide kinases. Carpenter CL, et al. **Curr Opin Cell Biol** 1996 Apr;8(2):153–8 (53 ref.)

Signaling through CD28/CTLA–4 family receptors: puzzling participation of phosphatidylinositol–3 kinase. Hutchcroft JE, et al. **J Immunol** 1996 Jun 1;156(11):4071–4 (69 ref.)

Mammalian deoxyribonucleoside kinases. Arnér ES, et al. **Pharmacol Ther** 1995;67(2):155–86 (241 ref.)

A heterotrimeric GTPase–regulated isoform of PI3K and the regulation of its potential effectors. Stephens L, et al. **Philos Trans R Soc Lond B Biol Sci** 1996 Feb 29; 351(1336):211–5 (40 ref.)

Covalent control of 6–phosphofructo–2–kinase/fructose–2,6–bisphosphatase: insights into autoregulation of a bifunctional enzyme. Kurland IJ, et al. **Protein Sci** 1995 Jun;4(6):1023–37 (70

ref.)
A target for phosphoinositide 3-kinase: Akt/PKB. Bos JL. **Trends Biochem Sci** 1995 Nov;20(11):441-2 (11 ref.)

PHYSIOLOGY

Phosphoinositide 3-kinase and the regulation of cell growth. Carpenter CL, et al. **Biochim Biophys Acta** 1996 Aug 8; 1288(1):M11-6 (65 ref.)
Novel functions of phosphatidylinositol 3-kinase in terminally differentiated cells. Nakanishi S, et al. **Cell Signal** 1995 Aug;7(6):545-57 (127 ref.)
Phosphatidylinositol 3' kinase: one of the effectors of Ras. Rodriguez-Viciana P, et al. **Philos Trans R Soc Lond B Biol Sci** 1996 Feb 29; 351(1336):225-31; discussion 231-2 (50 ref.)
PIK-related kinases: DNA repair, recombination, and cell cycle checkpoints. Keith CT, et al. **Science** 1995 Oct 6; 270(5233):50-1 (22 ref.)

PHOSPHOTRANSFERASES, ATP see **PHOSPHOTRANSFERASES**

PHOSPHOTRANSFERASES (CARBOXYL GROUP ACCEPTOR)

METABOLISM

The carbamoyl-phosphate synthase family and carbamate kinase: structure-function studies. Rubio V, et al. **Biochem Soc Trans** 1995 Nov;23(4):879-83 (33 ref.)

PHOSPHOTRANSFERASES (PHOSPHATE GROUP ACCEPTOR)

METABOLISM

[Batten disease (Neuronal ceroid lipofuscinoses)--accumulation of ATP synthase subunit c caused by the delay of lysosomal degradation] Ezaki J, et al. **Nippon Rinsho** 1995 Dec;53(12):3055-61 (22 ref.) (Eng. Abstr.) **(Jpn)**

PHOSPHOTYROSINE

PHYSIOLOGY

The role of phosphotyrosine signaling pathway in a parotid gland proliferation and function. Purushotham KR, et al. **Crit Rev Oral Biol Med** 1995;6(2):119-31 (113 ref.)
Modulation of biological tyrosine reactions by tyrosine phosphorylation. Gmeiner BM, et al. **Wien Klin Wochenschr** 1995;107(22):687-9 (12 ref.)

PHOSPHOTYROSINE PHOSPHATASE see **PROTEIN-TYROSINE-PHOSPHATASE**

PHOTIC STIMULATION

ADVERSE EFFECTS

Photosensitive temporal lobe epilepsy. Benbadis SR, et al. **Neurology** 1996 Jun;46(6):1540-2 (10 ref.)

PHOTOAGING OF SKIN see **SKIN AGING**

PHOTOBACTERIUM

METABOLISM

Biochemistry of bacterial bioluminescence. Tu SC, et al. **Photochem Photobiol** 1995 Oct;62(4):615-24 (106 ref.)

PHOTOBIOLOGY

see related
LIGHT
PHOTOSYNTHESIS
Langmuir-Blodgett films of photosensitive proteins. Pepe IM, et al. **J Photochem Photobiol B** 1996 May;33(3):191-200 (82 ref.)

PHOTOCHEMICAL REACTION CENTER, BACTERIAL see **PHOTOSYNTHETIC REACTION CENTER, BACTERIAL**

PHOTOCHEMICAL REACTION CENTER, PLANT see **PHOTOSYNTHETIC REACTION CENTER, PLANT**

PHOTOCHEMOTHERAPY

Adjuvant therapy for pituitary adenomas: the possible role of photodynamic therapy. Marks PV. **Ann R Coll Surg Engl** 1995 Jul;77(4):308-12 (25 ref.)
Photodynamic therapy for psoriasis? Fergin P. **Australas J Dermatol** 1996 May;37(2):87-8 (17 ref.)
Photodynamic therapy of primary skin cancer: a review. Roberts DJ, et al. **Br J Plast Surg** 1995 Sep;48(6):360-70 (71 ref.)
Photodynamic therapy. Stables GI, et al. **Cancer Treat Rev** 1995 Jul;21(4):311-23 (98 ref.)
Future therapeutic procedures. Edell ES. **Chest Surg Clin N Am** 1996 May;6(2):381-95 (93 ref.)
The role of photodynamic therapy in the management of oral cancer and precancer. Hopper C. **Eur J Cancer B Oral Oncol** 1996 Mar;32B(2):71-2 (7 ref.)
Photodynamic therapy in dermatology. Frazier CC. **Int J Dermatol** 1996 May;35(5):312-6 (50 ref.)
T-cell responses in photoimmune therapy. Heald PW, et al. **J Clin Apheresis** 1995;10(3):144-9 (26 ref.)
Clinical and preclinical photodynamic therapy. Fisher AM, et al. **Lasers Surg Med** 1995;17(1):2-31 (241 ref.)
Prevention of late lumen loss after coronary angioplasty by photodynamic therapy: role of activated neutrophils. Sluiter W, et al. **Mol Cell Biochem** 1996 Apr 12-26; 157(1-2):233-8 (44 ref.)
Psoralen photobiology: recent advances. Gasparro FP. **Photochem Photobiol** 1996 May;63(5):553-7 (36 ref.)
Use of photodynamic therapy for the management of pleural malignancies. Pass HI, et al. **Semin Surg Oncol** 1995 Sep-Oct;11(5):360-7 (21 ref.)
Photodynamic therapy of brain tumors. Popovic EA, et al. **Semin Surg Oncol** 1995 Sep-Oct;11(5):335-45 (31 ref.)
Laser photochemotherapy: a less invasive approach for treatment of cancer. Saxton RE, et al. **Semin Surg Oncol** 1995 Jul-Aug;11(4):283-9 (76 ref.)
[Photodynamic therapy of malignant tumors] Jirsa M. **Sb Lek** 1996;97(1):115-34 (98 ref.) **(Cze)**
[Photodynamic therapy of centrally located early-stage lung cancer] Furuse K. **Gan To Kagaku Ryoho** 1996 Jan; 23(1):27-30 (17 ref.) (Eng. Abstr.) **(Jpn)**
[Photodynamic therapy for multiple primary lung cancer] Konaka C, et al. **Gan To Kagaku Ryoho** 1996 Jan;23(1):31-5 (8 ref.) (Eng. Abstr.) **(Jpn)**
[Photodynamic therapy for gastric cancer] Mimura S, et al. **Gan To Kagaku Ryoho** 1996 Jan;23(1):41-6 (5 ref.) (Eng. Abstr.) **(Jpn)**
[Photodynamic therapy (PDT) for early cervical cancer] Muroya T, et al. **Gan To Kagaku Ryoho** 1996 Jan; 23(1):47-56 (10 ref.) (Eng. Abstr.) **(Jpn)**
[Photodynamic therapy for esophageal cancer] Shimao H, et al. **Gan To Kagaku Ryoho** 1996 Jan;23(1):36-40 (13 ref.) (Eng. Abstr.) **(Jpn)**
[Mechanism of photodynamic therapy] Takemura T, et al. **Gan To Kagaku Ryoho** 1996 Jan;23(1):16-21 (6 ref.) (Eng. Abstr.) **(Jpn)**

TRENDS

[History of photodynamic therapy--past, present and future] Kato H. **Gan To Kagaku Ryoho** 1996 Jan;23(1):8-15 (31 ref.) (Eng. Abstr.) **(Jpn)**

PHOTOCHEMOTHERAPY, EXTRACORPOREAL see **PHOTOPHERESIS**

PHOTOCHEMOTHERAPY, HEMATOPORPHYRIN see **HEMATOPORPHYRIN PHOTORADIATION**

PHOTOCOAGULATION see **LIGHT COAGULATION**

PHOTODENSITOMETRY see **DENSITOMETRY, X-RAY**

PHOTODERMATITIS see **PHOTOSENSITIVITY DISORDERS**

PHOTODYNAMIC THERAPY see **PHOTOCHEMOTHERAPY**

PHOTOGRAMMETRY

METHODS

PAR Corneal Topography System (PAR CTS): the clinical application of close-range photogrammetry. Belin MW, et al. **Optom Vis Sci** 1995 Nov;72(11):828-37 (16 ref.)

PHOTOGRAPHY

METHODS

Retinal nerve fiber layer [editorial; comment] Sommer A. **Am J Ophthalmol** 1995 Nov;120(5):665-7 (20 ref.)
Comment on: Am J Ophthalmol 1995 Nov;120(5):577-86.

STANDARDS

Nudity in clinical photography: a literature review and the quest for standardization. Peres M, et al. **J Biol Photogr** 1996 Jan;64(1):3-13 (25 ref.)

PHOTOKERATECTOMY see **KERATECTOMY, PHOTOREFRACTIVE, EXCIMER LASER**

PHOTOLYSIS

Use of vanadate-induced photocleavage for detecting phosphate binding sites in proteins. Muhlrad A, et al. **Met Ions Biol Syst** 1995;31:211-30 (65 ref.)

PHOTOMETRY

METHODS

Prediction and non-invasive assessment of neonatal jaundice in the term healthy newborn infant. Knudsen A. **Acta Paediatr** 1996 Apr;85(4):393-7 (32 ref.)
Electroretinogram flicker photometry and its applications. Jacobs GH, et al. **J Opt Soc Am A** 1996 Mar;13(3):641-8 (42 ref.)

PHOTOMICROGRAPHY

Time-lapse cinephotomicrography, videography, and videomicrography of the avian blastoderm. Bortier H, et al. **Methods Cell Biol** 1996;51:331-54 (18 ref.)

PHOTONS

How photons start vision. Baylor D. **Proc Natl Acad Sci U S A** 1996 Jan 23;93(2):560-5 (44 ref.)

PHOTOPERIOD

The influence of season, photoperiod, and pineal melatonin on immune function. Nelson RJ, et al. **J Pineal Res** 1995 Nov;19(4):149-65 (209 ref.)

PHOTOPHERESIS

Photopheresis for the treatment of cutaneous T-cell lymphoma. Lim HW, et al. **Hematol Oncol Clin North Am** 1995 Oct;9(5):1117-26 (25 ref.)

PHOTOPLETHYSMOGRAPHY

INSTRUMENTATION

[Methods of microcirculatory monitoring (laser Doppler flowmetry, photoplethysmography and computer-assisted venous occlusion plethysmography)] Christ F. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May; 31(1 Suppl):S37-43 (77 ref.) **(Ger)**

PHOTOPROTEINS see **LUMINESCENT PROTEINS**

PHOTORADIATION see **LIGHT**

PHOTORADIATION, HEMATOPORPHYRIN see **HEMATOPORPHYRIN PHOTORADIATION**

PHOTORADIATION THERAPY see **PHOTOTHERAPY**

PHOTOREACTIVATING ENZYME see **DNA PHOTOLYASE**

PHOTORECEPTORS

METABOLISM

Turnover rate and number of Na(+)-Ca2+, K+ exchange sites in retinal photoreceptors. Rispoli G, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:346-55 (26 ref.)

PHYSIOLOGY

Mechanisms of photoreceptor death in retinal degenerations. From the cell biology of the 1990s to the ophthalmology of the 21st century? Adler R. **Arch Ophthalmol** 1996 Jan; 114(1):79-83 (43 ref.)
Photoreceptor apoptosis in animal models. Implications for retinitis pigmentosa research [editorial] Wong F. **Arch Ophthalmol** 1995 Oct;113(10):1245-7 (24 ref.)
Control of photoreceptor proteins by Ca2+. Koch KW. **Cell Calcium** 1995 Oct;18(4):314-21 (72 ref.)

PHOTORECEPTORS, CONE see **CONES (RETINA)**

PHOTORECEPTORS, INVERTEBRATE

EMBRYOLOGY

Early decisions in Drosophila eye morphogenesis. Bonini NM, et al. **Curr Opin Genet Dev** 1995 Aug;5(4):507-15 (73 ref.)

METABOLISM

TRP: its role in phototransduction and store-operated Ca2+ entry. Friel DD. **Cell** 1996 May 31;85(5):617-9 (20 ref.)
Calcium signalling. Cracking ICRAC in the eye. Bennett DL, et al. **Curr Biol** 1995 Nov 1;5(11):1225-8 (22 ref.)

PHYSIOLOGY

Phosphoinositide-mediated phototransduction in Drosophila photoreceptors: the role of Ca2+ and trp. Hardie RC, et al. **Cell Calcium** 1995 Oct;18(4):256-74 (125 ref.)
Distinguishing between roles for calcium in Limulus photoreceptor excitation. Richard EA, et al. **Cell Calcium** 1995 Oct;18(4):331-41 (45 ref.)
Structure and cellular physiology of Ca2+ stores in invertebrate photoreceptors. Walz B, et al. **Cell Calcium** 1995 Oct;18(4):342-51 (52 ref.)
The biology of vision of Drosophila. Zuker CS. **Proc Natl Acad Sci U S A** 1996 Jan 23;93(2):571-6 (52 ref.)

PHOTORECEPTORS, RETINAL see **RODS AND CONES**

PHOTORECEPTORS, ROD

PHOTORECEPTORS, ROD see RODS (RETINA)

PHOTORECEPTORS, VERTEBRATE see RODS AND CONES

PHOTOSENSITIVITY DISORDERS

Photosensitivity. Baker CS. **Med J Aust** 1996 Jul 15; 165(2):96–101 (17 ref.)

[Light-induced eruptions and their photoprotection] Jeanmougin M. **Rev Med Interne** 1995;16 Suppl 3:348S–353s (27 ref.) **(Fre)**

CHEMICALLY INDUCED

Photosensitivity associated with antipsychotics, antidepressants and anxiolytics. Harth Y, et al. **Drug Saf** 1996 Apr;14(4):252–9 (47 ref.)

COMPLICATIONS

The coexistence of psoriasis with lupus erythematosus and other photosensitive disorders. Zalla MJ, et al. **Acta Derm Venereol Suppl (Stockh)** 1996;195:1–15 (103 ref.)

ETIOLOGY

Erythropoietic protoporphyria presenting in an adult. Henderson CA, et al. **J R Soc Med** 1995 Aug; 88(8):476P–477P (8 ref.)

[Photosensitivity] Granlund H. **Duodecim** 1995;111(5):457–65 (19 ref.) **(Fin)**

[Heliodermatitis or photo-induced skin aging] Leccia MT, et al. **Ann Dermatol Venereol** 1995;122(10):720–8 (89 ref.) **(Fre)**

THERAPY

Plasma exchange therapy for solar urticaria. Collins P, et al. **Br J Dermatol** 1996 Jun;134(6):1093–7 (20 ref.)

PHOTOSENSITIZERS see PHOTOSENSITIZING AGENTS

PHOTOSENSITIZING AGENTS

see related
HEMATOPORPHYRIN PHOTORADIATION
PHOTOCHEMOTHERAPY
PUVA THERAPY

Psoralen photobiology: recent advances. Gasparro FP. **Photochem Photobiol** 1996 May;63(5):553–7 (36 ref.)

The photodecontamination of cellular blood components: mechanisms and use of photosensitization in transfusion medicine. Ben-Hur E, et al. **Transfus Med Rev** 1996 Jan; 10(1):15–22 (71 ref.)

PHARMACOKINETICS

[Dynamics of photosensitizer in the cell] Aizawa K, et al. **Gan To Kagaku Ryoho** 1996 Jan;23(1):22–6 (5 ref.) (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

Light scattering of human skin: a comparison between zinc (II)-phthalocyanine and photofrin II. Ochsner M. **J Photochem Photobiol B** 1996 Jan;32(1–2):3–9 (23 ref.)

THERAPEUTIC USE

Current treatment of vitiligo in China. Shao C, et al. **Chin Med J (Engl)** 1995 Sep;108(9):647–9 (10 ref.)

[Photodynamic therapy (PDT) for early cervical cancer] Muroya T, et al. **Gan To Kagaku Ryoho** 1996 Jan; 23(1):47–56 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Mechanism of photodynamic therapy] Takemura T, et al. **Gan To Kagaku Ryoho** 1996 Jan;23(1):16–21 (6 ref.) (Eng. Abstr.) **(Jpn)**

PHOTOSYNTHESIS

The contribution of mitochondria to energetic metabolism in photosynthetic cells. Gardeström P, et al. **J Bioenerg Biomembr** 1995 Aug;27(4):415–21 (53 ref.)

Photosystem I. Chitnis PR. **Plant Physiol** 1996 Jul; 111(3):661–9 (35 ref.)

GENETICS

Regulatory circuits controlling photosynthesis gene expression. Bauer CE, et al. **Cell** 1996 Apr 5;85(1):5–8 (19 ref.)

Evolution and expression of C4 photosynthesis genes. Ku MS, et al. **Plant Physiol** 1996 Aug;111(4):949–57 (48 ref.)

PHYSIOLOGY

Photosynthesis. Regulation by redox signalling. Allen JF, et al. **Curr Biol** 1995 Aug 1;5(8):869–72 (14 ref.)

Oxygenic photosynthesis. Electron transfer in photosystem I and photosystem II. Nugent JH. **Eur J Biochem** 1996 May 1;237(3):519–31 (122 ref.)

PHOTOSYNTHETIC REACTION CENTER, BACTERIAL

Langmuir-Blodgett films of photosensitive proteins. Pepe IM, et al. **J Photochem Photobiol B** 1996 May;33(3):191–200 (82 ref.)

CHEMISTRY

Electron and proton transfer to the quinones in bacterial photosynthetic reaction centers: insight from combined approaches of molecular genetics and biophysics. Sebban P, et al. **Biochimie** 1995;77(7–8):677–94 (67 ref.)

Structure and function of photosystem I. Fromme P. **Curr Opin Struct Biol** 1996 Aug;6(4):473–84 (73 ref.)

Purple bacterial antenna complexes. Fyfe PK, et al. **Curr Opin Struct Biol** 1996 Aug;6(4):467–72 (41 ref.)

Relationship between the oxidation potential of the bacteriochlorophyll dimer and electron transfer in photosynthetic reaction centers. Allen JP, et al. **J Bioenerg Biomembr** 1995 Jun;27(3):275–83 (50 ref.)

Structure and function of bacterial light-harvesting complexes. Kühlbrandt W. **Structure** 1995 Jun 15;3(6):521–5 (17 ref.)

METABOLISM

Relationship between the oxidation potential of the bacteriochlorophyll dimer and electron transfer in photosynthetic reaction centers. Allen JP, et al. **J Bioenerg Biomembr** 1995 Jun;27(3):275–83 (50 ref.)

Structure and function of bacterial light-harvesting complexes. Kühlbrandt W. **Structure** 1995 Jun 15;3(6):521–5 (17 ref.)

PHOTOSYNTHETIC REACTION CENTER, PLANT

CHEMISTRY

Structure and function of photosystem I. Fromme P. **Curr Opin Struct Biol** 1996 Aug;6(4):473–84 (73 ref.)

Photosystem I. Chitnis PR. **Plant Physiol** 1996 Jul; 111(3):661–9 (35 ref.)

METABOLISM

Photosystem I. Chitnis PR. **Plant Physiol** 1996 Jul; 111(3):661–9 (35 ref.)

PHOTOSYSTEM I REACTION CENTER see PHOTOSYNTHETIC REACTION CENTER, PLANT

PHOTOSYSTEM II REACTION CENTER see PHOTOSYNTHETIC REACTION CENTER, PLANT

PHOTOTHERAPY

Melanin, melatonin, melanocyte-stimulating hormone, and the susceptibility to autoimmune demyelination: a rationale for light therapy in multiple sclerosis. Constantinescu CS. **Med Hypotheses** 1995 Nov;45(5):455–8 (38 ref.)

Is phototherapy safe for HIV-infected individuals? Adams ML, et al. **Photochem Photobiol** 1996 Aug;64(2):234–7 (41 ref.)

PUVA therapy is preferable to UVB phototherapy in the management of HIV-associated dermatoses. Morison WL. **Photochem Photobiol** 1996 Aug;64(2):267–8 (11 ref.)

[Phototherapy of atopic dermatitis] Marguery MC, et al. **Ann Dermatol Venereol** 1995;122(10):729–34 (27 ref.) **(Fre)**

[Phototherapy in psychiatry: clinical update and review of indications] Gross F, et al. **Encephale** 1996 Mar–Apr; 22(2):143–8 (37 ref.) (Eng. Abstr.) **(Fre)**

[Seasonal affective syndrome and phototherapy: theoretical concepts and clinical applications] Sartori S, et al. **Encephale** 1996 Jan–Feb;22(1):7–16 (59 ref.) (Eng. Abstr.) **(Fre)**

ADVERSE EFFECTS

[Bullous eruptions induced by phototherapy] Jeanmougin M. **Ann Dermatol Venereol** 1995;122(3):124–8 (36 ref.) **(Fre)**

METHODS

[Light therapy can restore a disturbed sleep/wake rhythm in dementia: but what is the basis of its efficacy?] Beullens J. **Tijdschr Gerontol Geriatr** 1995 Dec;26(6):264–9 (40 ref.) (Eng. Abstr.) **(Dut)**

PHOTOTOXICITY see DERMATITIS, PHOTOTOXIC

PHOTOTROPHIC BACTERIA

METABOLISM

Biotechnological potentials of anoxygenic phototrophic bacteria. I. Production of single-cell protein, vitamins, ubiquinones, hormones, and enzymes and use in waste treatment. Sasikala C, et al. **Adv Appl Microbiol** 1995; 41:173–226 (311 ref.)

Biotechnological potentials of anoxygenic phototrophic bacteria. II. Biopolyesters, biopesticide, biofuel, and biofertilizer. Sasikala C, et al. **Adv Appl Microbiol** 1995; 41:227–78 (327 ref.)

PHRENIC NERVE

Partial unilateral phrenic nerve paralysis caused by a large intrathoracic goitre. van Doorn LG, et al. **Neth J Med** 1996 Jun;48(6):216–9 (3 ref.)

PHTHIRAPTERA see LICE

PHYLLODES TUMOR

PATHOLOGY

Phyllodes tumours of the breast: a clinicopathological review of thirty-two cases. Moffat CJ, et al. **Histopathology** 1995 Sep;27(3):205–18 (38 ref.)

SURGERY

[Phyllodes breast tumors: apropos 2 cases] Bruzzese A, et al. **G Chir** 1995 Aug–Sep;16(8–9):366–8 (9 ref.) (Eng. Abstr.) **(Ita)**

PHYLLOQUINONE see PHYTONADIONE

PHYLLOQUINONE REDUCTASE see NAD(P)H DEHYDROGENASE (QUINONE)

PHYLOGENY

Origin and early evolution of eukaryotes inferred from the amino acid sequences of translation elongation factors 1alpha/Tu and 2/G. Hashimoto T, et al. **Adv Biophys** 1996; 32:73–120 (138 ref.)

Unconventional myosins. Mooseker MS, et al. **Ann Rev Cell Dev Biol** 1995;11:633–75 (159 ref.)

Molecular Phylogenetic classification of fungi. Taylor JW. **Arch Med Res** 1995 Autumn;26(3):307–14 (72 ref.)

Phylogeny and the function of REM sleep. Siegel JM. **Behav Brain Res** 1995 Jul–Aug;69(1–2):29–34 (42 ref.)

Analysis of biological function of poly(ADP-ribosyl)ation in Drosophila melanogaster. Miwa M, et al. **Biochimie** 1995; 77(6):466–71 (32 ref.)

Regeneration in the vertebrate central nervous system: phylogeny, ontogeny, and mechanisms. Larner AJ, et al. **Biol Rev Camb Philos Soc** 1995 Nov;70(4):597–619 (159 ref.)

A hot topic: the origin of hyperthermophiles. Forterre P. **Cell** 1996 Jun 14;85(6):789–92 (20 ref.)

Human immunodeficiency virus type 2: human biology of the other AIDS virus. D'Aquila RT. **Curr Clin Top Infect Dis** 1996;16:84–101 (86 ref.)

Coadaptation and immunodeficiency virus: lessons from the Felidae. Carpenter MA, et al. **Curr Opin Genet Dev** 1995 Dec;5(6):739–45 (53 ref.)

Phylogeny and natural history of the primate lentiviruses, SIV and HIV. Hirsch VM, et al. **Curr Opin Genet Dev** 1995 Dec;5(6):798–806 (28 ref.)

MADS-box genes in plant ontogeny and phylogeny: Haeckel's 'biogenetic law' revisited. Theissen G, et al. **Curr Opin Genet Dev** 1995 Oct;5(5):628–39 (97 ref.)

Fish major histocompatibility complex genes: an expansion. Dixon B, et al. **Dev Comp Immunol** 1995 Mar–Apr; 19(2):109–33 (77 ref.)

Arbitrarily amplified DNA in systematics and phylogenetics. Schierwater B. **Electrophoresis** 1995 Sep;16(9):1643–7 (45 ref.)

Homologizing primate facial displays: a critical review of methods. Preuschoft S, et al. **Folia Primatol (Basel)** 1995; 65(3):121–37 (71 ref.)

The week in phylogeny and ontogeny: opportunities for oncology. Halberg F. **In Vivo** 1995 Jul–Aug;9(4):269–78 (92 ref.)

DNA "fossils" and phylogenetic analysis. Using L1 (LINE-1, long interspersed repeated) DNA to determine the evolutionary history of mammals. Furano AV, et al. **J Biol Chem** 1995 Oct 27;270(43):25301–4 (66 ref.)

The PTR family: a new group of peptide transporters. Steiner HY, et al. **Mol Microbiol** 1995 Jun;16(5):825–34 (59 ref.)

Primate phylogeny: morphological vs. molecular results. Shoshani J, et al. **Mol Phylogenet Evol** 1996 Feb;5(1):102–54 (299 ref.)

An evolutionary view of drug-receptor interaction: the bioamine receptor family. Vernier P, et al. **Trends Pharmacol Sci** 1995 Nov;16(11):375–81 (56 ref.)

[Comparative biochemistry of the triune brain] Bureau M, et al. **Acta Psychiatr Belg** 1994;94(4–6):225–47 (63 ref.) (Eng. Abstr.) **(Fre)**

[Phylogeny of myelin and myelin forming cells] Zalc B. **C R Seances Soc Biol Fil** 1995;189(2):239–44 (11 ref.) (Eng. Abstr.) **(Fre)**

[Comparison of 18S ribosomal RNA genes in invertebrate phylogeny] Aleshin VV, et al. **Mol Biol (Mosk)** 1995 Nov–Dec;29(6):1408–26 (58 ref.) **(Rus)**

[The development of the active sleep phase in phylogeny and ontogeny] Aristakesian EA, et al. **Zh Evol Biokhim Fiziol** 1995 May–Jun;31(3):346–65 (85 ref.) **(Rus)**

PHYSARUM POLYCEPHALUM

GROWTH & DEVELOPMENT

Plasmodium development in the myxomycete Physarum polycephalum: genetic control and cellular events. Bailey J. **Microbiology** 1995 Oct;141 (Pt 10):2355–65 (80 ref.)

PHYSIATRY see **PHYSICAL MEDICINE**

PHYSICAL CONDITIONING, ANIMAL

ADVERSE EFFECTS

Racing horses, nitroglycerin and exercise induced pulmonary haemorrhage (EIPH) [editorial; comment] Harkins JD, et al. **Equine Vet J** 1995 Jul;27(4):240–1 (12 ref.) Comment on: Equine Vet J 1995 Jul;27(4):275–9.

PHYSIOLOGY

Sodium bicarbonate loading and the rules of racing [editorial; comment] Williams RB. **Br Vet J** 1995 Sep–Oct; 151(5):473–5 (6 ref.) Comment on: Br Vet J 1995 Sep–Oct;151(5):523–45.

Effects of exercise training on endothelium–dependent peripheral vascular responsiveness. Delp MD. **Med Sci Sports Exerc** 1995 Aug;27(8):1152–7 (38 ref.)

Endothelium–mediated control of coronary vascular tone after chronic exercise training. Laughlin MH. **Med Sci Sports Exerc** 1995 Aug;27(8):1135–44 (34 ref.)

Contribution of endothelium–derived nitric oxide (EDNO) to the skeletal muscle blood flow response to exercise. McAllister RM, et al. **Med Sci Sports Exerc** 1995 Aug; 27(8):1145–51 (49 ref.)

[Glutathione homeostasis: the cardinal physiological defense against oxygen toxicity induced by physical exercise] Sen CK, et al. **Fiziol Zh Im I M Sechenova** 1995 Nov; 81(11):143–50 (15 ref.) **(Rus)**

PHYSICAL CONDITIONING, HUMAN see **EXERCISE THERAPY**

PHYSICAL EDUCATION AND TRAINING

Effects of training on potassium, calcium and hydrogen ion regulation in skeletal muscle and blood during exercise. McKenna MJ, et al. **Acta Physiol Scand** 1996 Mar; 156(3):335–46 (68 ref.)

Assessment of nutrition and physical activity education programmes in children. Burke V, et al. **Clin Exp Pharmacol Physiol** 1995 Mar;22(3):212–6 (33 ref.)

The effects of endurance and resistance training on blood pressure. Schwartz RS, et al. **Int J Obes Relat Metab Disord** 1995 Oct;19 Suppl 4:S52–7 (38 ref.)

[Contraindications for physical training (editorial)] Näveri H. **Duodecim** 1994;110(12):1181–3 (16 ref.) **(Fin)**

[Patients with lung diseases and sports] Villiger B. **Schweiz Rundsch Med Prax** 1995 Sep 5;84(36):953–62 (38 ref.) (Eng. Abstr.) **(Ger)**

PHYSICAL EFFORT see **EXERTION**

PHYSICAL ENDURANCE

Integration of the physiological factors determining endurance performance ability. Coyle EF. **Exerc Sport Sci Rev** 1995;23:25–63 (67 ref.)

DRUG EFFECTS

Effects of bicarbonate, citrate, and phosphate loading on performance. Horswill CA. **Int J Sport Nutr** 1995 Jun;5 Suppl:S111–9 (49 ref.)

Caffeine and performance. Spriet LL. **Int J Sport Nutr** 1995 Jun;5 Suppl:S84–99 (56 ref.)

Inhibition of citrate lyase may aid aerobic endurance. McCarty MF. **Med Hypotheses** 1995 Sep;45(3):247–54 (77 ref.)

IMMUNOLOGY

The impact of exercise on the immune system: NK cells, interleukins 1 and 2, and related responses. Shephard RJ, et al. **Exerc Sport Sci Rev** 1995;23:215–41 (233 ref.)

PHYSIOLOGY

Sodium bicarbonate loading and the rules of racing [editorial; comment] Williams RB. **Br Vet J** 1995 Sep–Oct; 151(5):473–5 (6 ref.) Comment on: Br Vet J 1995 Sep–Oct;151(5):523–45.

The effects of endurance and resistance training on blood pressure. Schwartz RS, et al. **Int J Obes Relat Metab Disord** 1995 Oct;19 Suppl 4:S52–7 (38 ref.)

Carbohydrates, branched–chain amino acids, and endurance: the central fatigue hypothesis. Davis JM. **Int J Sport Nutr** 1995 Jun;5 Suppl:S29–38 (42 ref.)

Do athletes need more dietary protein and amino acids? Lemon PW. **Int J Sport Nutr** 1995 Jun;5 Suppl:S39–61 (91 ref.)

Micronutrients (magnesium, zinc, and copper): are mineral supplements needed for athletes? Lukaski HC. **Int J Sport Nutr** 1995 Jun;5 Suppl:S74–83 (37 ref.)

Fat loading: the next magic bullet? Sherman WM, et al. **Int J Sport Nutr** 1995 Jun;5 Suppl:S1–12 (29 ref.)

Muscle fuel selection: effect of exercise and training. Henriksson J. **Proc Nutr Soc** 1995 Mar;54(1):125–38 (100 ref.)

PHYSICAL EXAMINATION

The preparticipation sports physical: are we dropping the ball? Cavanaugh RM Jr, et al. **Pediatrics** 1995 Dec; 96(6):1151–3 (25 ref.)

[The concept of risk factors and flight certificate examination] Vlasov VV. **Aviakosm Ekolog Med** 1995;29(5):4–9 (60 ref.) (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

The association of urinary tract infection with a recent pelvic examination in women. Tiemstra JD, et al. **Arch Fam Med** 1996 Jun;5(6):357–60 (18 ref.)

METHODS

Physical examination of the adult patient with respiratory diseases: inspection and palpation. Maitre B, et al. **Eur Respir J** 1995 Sep;8(9):1584–93 (64 ref.)

Examining separated symphysis pubis. Davidson MR. **J Nurse Midwifery** 1996 May–Jun;41(3):259–62 (15 ref.)

Adult cancer detection screening by physical examination. **Nurse Pract** 1996 Mar;21(3):85–6, 89–90, 92–6 passim (0 ref.)

[Shoulder problems in leisure athletes: physical examination, diagnosis and therapy. Sensible procedures in daily practice] Vaeckenstedt J, et al. **Schweiz Med Wochenschr** 1996 Mar 16;126(11):447–56 (21 ref.) (Eng. Abstr.) **(Ger)**

PHYSICAL EXAMINATION, PREADMISSION see **DIAGNOSTIC TESTS, ROUTINE**

PHYSICAL FITNESS

see related
EXERCISE

Physical activity assessment: a review of methods. Melanson EL Jr, et al. **Crit Rev Food Sci Nutr** 1996 May;36(5):385–96 (91 ref.)

Do physical activity and physical fitness avert premature mortality? Lee IM, et al. **Exerc Sport Sci Rev** 1996; 24:135–71 (113 ref.)

Physical activity and health–related quality of life. Rejeski WJ, et al. **Exerc Sport Sci Rev** 1996;24:71–108 (102 ref.)

Epidemiology of physical activity, physical fitness and coronary heart disease. Whaley MH, et al. **J Cardiovasc Risk** 1995 Aug;2(4):289–95 (38 ref.)

Effects of training on potassium homeostasis during exercise. McKenna MJ. **J Mol Cell Cardiol** 1995 Apr;27(4):941–9 (52 ref.)

Physical activity and cardiovascular health. NIH Consensus Development Panel on Physical Activity and Cardiovascular Health. **JAMA** 1996 Jul 17;276(3):241–6 (0 ref.)

Measuring nutrition status, physical activity, and fitness, with special emphasis on populations at nutritional risk. Rodrigues Matsudo VK. **Nutr Rev** 1996 Apr;54(4 Pt 2):S79–96 (171 ref.)

Physical fitness in children with juvenile rheumatoid arthritis and other chronic pediatric illnesses. Singsen BH. **Pediatr Clin North Am** 1995 Oct;42(5):1035–50 (61 ref.)

[Physical fitness in children and adolescents: how can it be measured? A review of the literature] Michaud PA, et al. **Arch Pediatr** 1996 May;3(5):497–504 (45 ref.) (Eng. Abstr.) **(Fre)**

[Effect of physical exercise in fibromyalgia] Mengshoel AM. **Tidsskr Nor Laegeforen** 1996 Feb 28;116(6):746–8 (31 ref.) (Eng. Abstr.) **(Nor)**

PHYSIOLOGY

Physical fitness, mortality and obesity. Barlow CE, et al. **Int J Obes Relat Metab Disord** 1995 Oct;19 Suppl 4:S41–4 (14 ref.)

The measurement and interpretation of aerobic fitness in children: current issues. Welsman JR, et al. **J R Soc Med** 1996 May;89(5):281P–5P (57 ref.)

Optimal physical performance in athletes: key roles of dopamine in a specific neurotransmitter/hormonal mechanism. Gilbert C. **Mech Ageing Dev** 1995 Oct 13; 84(2):83–102 (85 ref.)

PHYSICAL MEDICINE

see related
BIOMECHANICS

ECONOMICS

Case–mix measurement in medical rehabilitation. Stineman MG. **Arch Phys Med Rehabil** 1995 Dec;76(12):1163–70 (40 ref.)

METHODS

Cardiovascular, pulmonary, and cancer rehabilitation. 2. Pulmonary rehabilitation. Bach JR, et al. **Arch Phys Med Rehabil** 1996 Mar;77(3 Suppl):S45–51 (58 ref.)

Cardiovascular, pulmonary, and cancer rehabilitation. 3. Cancer rehabilitation. Brennan MJ, et al. **Arch Phys Med Rehabil** 1996 Mar;77(3 Suppl):S52–8 (38 ref.)

Focused review: postmastectomy lymphedema. Brennan MJ, et al. **Arch Phys Med Rehabil** 1996 Mar;77(3 Suppl):S74–80 (55 ref.)

Cardiovascular, pulmonary, and cancer rehabilitation. 1. Cardiac rehabilitation. Hertanu JS, et al. **Arch Phys Med Rehabil** 1996 Mar;77(3 Suppl):S38–44 (92 ref.)

Focused review: physiatric management of HIV–related disability. O'Dell MW, et al. **Arch Phys Med Rehabil** 1996 Mar;77(3 Suppl):S66–73 (59 ref.)

Assessment methods for rehabilitation. Biefang S, et al. **Int J Rehabil Res** 1995 Sep;18(3):201–13 (47 ref.)

PHYSICAL THERAPY

Effects of early motion on healing of musculoskeletal tissues. Buckwalter JA. **Hand Clin** 1996 Feb;12(1):13–24 (81 ref.)

Early motion after extensor tendon surgery. Crosby CA, et al. **Hand Clin** 1996 Feb;12(1):57–64 (37 ref.)

Early motion after arthroplasty. Kirkpatrick WH, et al. **Hand Clin** 1996 Feb;12(1):73–86 (45 ref.)

Early motion after flexor tendon surgery. Wang AW, et al. **Hand Clin** 1996 Feb;12(1):43–55 (47 ref.)

Total hip and knee replacement treatment programs: a report using consensus. Enloe LJ, et al. **J Orthop Sports Phys Ther** 1996 Jan;23(1):3–11 (20 ref.)

Heart failure. Cahalin LP. **Phys Ther** 1996 May;76(5):516–33 (84 ref.)

Physical therapy in lung transplantation. Downs AM. **Phys Ther** 1996 Jun;76(6):626–42 (102 ref.)

The influence of subject and test design on dynamometric measurements of extremity muscles. Keating JL, et al. **Phys Ther** 1996 Aug;76(8):866–89 (224 ref.)

Spine update. Functional restoration. Hazard RG. **Spine** 1995 Nov 1;20(21):2345–8 (20 ref.)

Rehabilitation following arthroscopic meniscectomy. St–Pierre DM. **Sports Med** 1995 Nov;20(5):338–47 (147 ref.)

[Kinesitherapy for mucoviscidosis] Wils J, et al. **Rev Pneumol Clin** 1995;51(3):164–74 (71 ref.) (Eng. Abstr.) **(Fre)**

[Therapy of rheumatoid arthritis] Sieper J, et al. **Dtsch Med Wochenschr** 1996 Apr 26;121(17):563–7 (12 ref.) **(Ger)**

[The therapeutic use of physical factors in the combined therapy of patients with psoriatic arthritis] Grigor'eva VD, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1995 Nov–Dec; (6):48–52 (51 ref.) **(Rus)**

INSTRUMENTATION

Identifying patients with diabetes mellitus who are at risk for lower–extremity complications: use of Semmes–Weinstein monofilaments. Mueller MJ. **Phys Ther** 1996 Jan;76(1):68–71 (15 ref.)

METHODS

How should treatments be critiqued for scientific merit? [see comments] Harris SR. **Phys Ther** 1996 Feb;76(2):175–81 (37 ref.) Comment in: Phys Ther 1996 Jun;76(6):667–8. Comment in: Phys Ther 1996 Jul;76(7):786–7.

[Effectiveness, indications and contraindications of manual lymph drainage therapy in painful edema] Asdonk J. **Z Lymphol** 1995 Aug;19(1):16–22 (22 ref.) **(Ger)**

[Adjuvant therapy in lymphedema] Brenke R, et al. **Z Lymphol** 1996 Jun;20(1):31–5 (10 ref.) (Eng. Abstr.) **(Ger)**

[Physical treatment methods in dysplastic scoliosis in children] Nenasheva TV, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1995 Sep–Oct;(5):44–6 (58 ref.) **(Rus)**

[Demyelinating diseases and physical treatment methods] Strelkova NI, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1996 Jan–Feb;(1):41–4 (24 ref.) **(Rus)**

STANDARDS

Outcomes in cardiopulmonary rehabilitation. Pashkow P. **Phys Ther** 1996 Jun;76(6):643–56 (164 ref.)

PHYSICALLY CHALLENGED see **DISABLED**

PHYSICALLY HANDICAPPED see **DISABLED**

PHYSICIAN ASSIGNMENT ACCEPTANCE see **MEDICARE ASSIGNMENT**

PHYSICIAN ASSISTANTS

The role of midlevel providers in cancer screening. Reed CA, et al. **Med Clin North Am** 1996 Jan;80(1):135–44 (34 ref.)

PHYSICIAN-ASSISTED SUICIDE

PHYSICIAN-ASSISTED SUICIDE see SUICIDE, ASSISTED

PHYSICIAN-HOSPITAL ORGANIZATIONS see HOSPITAL-PHYSICIAN JOINT VENTURES

PHYSICIAN-HOSPITAL RELATIONS see HOSPITAL-PHYSICIAN RELATIONS

PHYSICIAN IMPAIRMENT

Quality improvement and substance abuse: rethinking impaired provider policies. Corsino BV, et al. **Am J Med Qual** 1996 Summer;11(2):94–9 (21 ref.)

PHYSICIAN-PATIENT RELATIONS

see related
TRUTH DISCLOSURE

Treating patients from other cultures. Orr RD. **Am Fam Physician** 1996 May 1;53(6):2004–6 (22 ref.)

The primary care of patients who have bodily concerns. Blackwell B, et al. **Arch Fam Med** 1996 Sep;5(9):457–63 (65 ref.)

Domestic violence: a hidden problem for general practice. Richardson J, et al. **Br J Gen Pract** 1996 Apr; 46(405):239–42 (43 ref.)

Intimacy in the patient–physician relationship. Committee on Ethics of the College of Family Physicians of Canada. Yeo M, et al. **Can Fam Physician** 1996 Aug;42:1505–8 (4 ref.)

Managing erotic feelings in the physician–patient relationship [see comments] Golden GA, et al. **Can Med Assoc J** 1995 Nov 1;153(9):1241–5 (52 ref.) Comment in: Can Med Assoc J 1996 Apr 15;154(8):1149; discussion 1150. Comment in: Can Med Assoc J 1996 Apr 15;154(8):1149–50.

Prevention. How much harm? How much benefit? 4. The ethics of informed consent for preventive screening programs. Marshall KG. **Can Med Assoc J** 1996 Aug 15; 155(4):377–83 (57 ref.)

White coat hypertension. Pickering TG. **Curr Opin Nephrol Hypertens** 1996 Mar;5(2):192–8 (36 ref.)

Logic, hermeneutics, and informed consent. Little JM, et al. **Eur J Surg** 1996 Jan;162(1):3–10 (31 ref.)

Primary care of lesbian and gay patients: educating ourselves and our students [see comments] Harrison AE. **Fam Med** 1996 Jan;28(1):10–23 (86 ref.) Comment in: Fam Med 1996 Jan;28(1):57–8.

Situational disease. Gannik DE. **Fam Pract** 1995 Jun; 12(2):202–6 (14 ref.)

Primary care of the adolescent patient. Faigel HC. **Hosp Pract (Off Ed)** 1996 Apr 15;31(4):127–33, 137–8, 144–8 (10 ref.)

Deception/trust. Sobel R. **Isr J Med Sci** 1996 Mar–Apr; 32(3–4):256–9 (15 ref.)

Privacy and autonomy in the physician–patient relationship. Independent contracting under Medicare and implications for expansion into managed care. Coleman PG, et al. **J Leg Med** 1995 Dec;16(4):509–43 (197 ref.)

Communication with cancer patients: does it matter? Butow PN, et al. **J Palliat Care** 1995 Winter;11(4):34–8 (50 ref.)

Aggression against doctors: a review. Hobbs FD, et al. **J R Soc Med** 1996 Feb;89(2):69–72 (38 ref.)

Breaking bad news. A review of the literature. Ptacek JT, et al. **JAMA** 1996 Aug 14;276(6):496–502 (83 ref.)

The disclosure of the diagnosis of cancer. Carnes JW, et al. **Med Clin North Am** 1996 Jan;80(1):145–51 (10 ref.)

Physician–patient interaction in reproductive counseling. Lipkin M Jr. **Obstet Gynecol** 1996 Sep;88(3 Suppl):31S–40S (51 ref.)

Rituals and roles in medical practice. Elks ML. **Perspect Biol Med** 1996 Summer;39(4):601–9 (28 ref.)

Discussing the diagnosis and prognosis with cancer patients. Bennett M, et al. **Postgrad Med J** 1996 Jan;72(843):25–9 (14 ref.)

A surgeon with HIV. Cembrowicz S, et al. **Practitioner** 1996 Jan;240(1558):9–12 (2 ref.)

Motivating change in health behavior. Implications for health promotion and disease prevention. Botelho RJ, et al. **Prim Care** 1995 Dec;22(4):565–89 (52 ref.)

Medication decision-making and management: a client-centered model. Chewning B, et al. **Soc Sci Med** 1996 Feb;42(3):389–98 (110 ref.)

[Standards, options and recommendations for a successful practice in psycho-oncology. National Federation of Centers for the fight against cancer] Saltel P, et al. **Bull Cancer (Paris)** 1995 Oct;82(10):847–64 (55 ref.) **(Fre)**

[Transcultural symptomatology. Its expression in family practice] Ferron M. **Can Fam Physician** 1995 Oct; 41:1718–25 (20 ref.) (Eng. Abstr.) **(Fre)**

[Reflections on transference, countertransference, session frequency and the analytic process] Holder A. **Psychiatr Enfant** 1995;38(2):603–23 (5 ref.) (Eng. Abstr.) **(Fre)**

[Oncologic after-care and rehabilitation—physician–patient interaction in gynecologic oncology] Schünemann H, et al. **Arch Gynecol Obstet** 1995;257(1–4):277–83 (14 ref.) **(Ger)**

[The alcoholic patient in general practice. From initial contact to implementing therapy] Luderer HJ. **Fortschr Med** 1995 Nov 30;113(33):469–72 (17 ref.) (Eng. Abstr.) **(Ger)**

[Help or hinderniss? The effect of legal norms on the physician–patient relationship] Ulsenheimer K. **Geburtshilfe Frauenheilkd** 1995 Sep;55(9):M110–9 (113 ref.) **(Ger)**

[The physician–patient relationship and sophisticated modern technology] Wenz W. **Rontgenpraxis** 1995 Aug; 48(8):238–44 (21 ref.) **(Ger)**

[Patient counseling by the physician in smoking cessation—conditions and prerequisites] Stössel U. **Z Arztl Fortbild (Jena)** 1995 Oct;89(5):489–98 (40 ref.) (Eng. Abstr.) **(Ger)**

[Communication of bad facts. To inform or not to inform the patient: a choice between 2 alternatives?] Saltini A. **Recenti Prog Med** 1995 Sep;86(9):359–66 (40 ref.) (Eng. Abstr.) **(Ita)**

[Communication of bad information: general indications and guidelines] Saltini A, et al. **Recenti Prog Med** 1995 Oct; 86(10):409–17 (12 ref.) (Eng. Abstr.) **(Ita)**

PHYSICIAN SHORTAGE AREA see MEDICALLY UNDERSERVED AREA

PHYSICIANS

Point-of-care testing in the intensive care unit. The intensive care physician's perspective. Castro HJ, et al. **Am J Clin Pathol** 1995 Oct;104(4 Suppl 1):S95–9 (22 ref.)

Improving physician prescribing practices: bridge over troubled waters [editorial] MacLeod SM. **Can Med Assoc J** 1996 Mar 1;154(5):675–7 (10 ref.)

Nurse–physician collaboration: a poststructuralist view. Henneman EA. **J Adv Nurs** 1995 Aug;22(2):359–63 (15 ref.)

Making medical recruitment practices fair. Maddock S. **Postgrad Med J** 1996 Mar;72(845):147–50 (8 ref.)

Electrical safety measures for physicians using electromedical equipment. Laks MM, et al. **Semin Neurol** 1995 Sep; 15(3):311–6 (24 ref.)

ECONOMICS

Physician remuneration methods: the need for change and flexibility [editorial] Wright CJ. **Can Med Assoc J** 1996 Mar 1;154(5):678–80 (12 ref.)

PSYCHOLOGY

Managing erotic feelings in the physician–patient relationship [see comments] Golden GA, et al. **Can Med Assoc J** 1995 Nov 1;153(9):1241–5 (52 ref.) Comment in: Can Med Assoc J 1996 Apr 15;154(8):1149; discussion 1150. Comment in: Can Med Assoc J 1996 Apr 15;154(8):1149–50.

The nurse–doctor relationship: a selective literature review. Sweet SJ, et al. **J Adv Nurs** 1995 Jul;22(1):165–70 (41 ref.)

Physicians' prevention counseling behaviors: current status and future directions [editorial; comment] Frank E, et al. **Prev Med** 1995 Nov;24(6):543–5 (26 ref.) Comment on: Prev Med 1995 Nov;24(6):546–2.

[Pregnancy after breast cancer] Mignot L, et al. **Contracept Fertil Sex** 1996 Apr;24(4):319–21 (16 ref.) (Eng. Abstr.) **(Fre)**

[Humanitarianism: the gardener, the truck driver and the "shrink"] Maqueda F. **Psychiatr Enfant** 1995;38(1):311–43 (4 ref.) (Eng. Abstr.) **(Fre)**

[Evolution in consumption of and attitude towards tobacco towards physicians at the regional hospital "Reina Sofia," Córdoba] Mengual Luque P, et al. **Gac Sanit** 1996 Jan–Feb; 10(52):18–24 (32 ref.) (Eng. Abstr.) **(Spa)**

PHYSICIANS' ASSISTANTS see PHYSICIAN ASSISTANTS

PHYSICIANS' EXTENDERS see PHYSICIAN ASSISTANTS

PHYSICIANS, FAMILY

The role of the family physician in the day care setting. Olsen CG, et al. **Am Fam Physician** 1996 Sep 15;54(4):1257–65, 1267–8 (32 ref.)

Prevention of HIV infection in primary care: current practices, future possibilities. Makadon HJ, et al. **Ann Intern Med** 1995 Nov 1;123(9):715–9 (65 ref.)

PSYCHOLOGY

Intimacy in the patient–physician relationship. Committee on Ethics of the College of Family Physicians of Canada. Yeo M, et al. **Can Fam Physician** 1996 Aug;42:1505–8 (4 ref.)

STANDARDS

[Professional profile of primary health care personnel. A Delphi study] Molina Durán F, et al. **Aten Primaria** 1996 Jan;17(1):24–32 (21 ref.) (Eng. Abstr.) **(Spa)**

SUPPLY & DISTRIBUTION

A physician workforce for the 21st century. Cooper RA. **Ann Thorac Surg** 1995 Nov;60(5):1541–6 (10 ref.)

Balancing primary versus specialty care [see comments] Shi L. **J R Soc Med** 1995 Aug;88(8):428–32 (62 ref.) Comment in: J R Soc Med 1995 Aug;88(8):425.

PHYSICIAN'S PRACTICE PATTERNS

Is it safe to prescribe digoxin after acute myocardial infarction? Update on continued controversy [editorial] Leor J, et al. **Am Heart J** 1995 Dec;130(6):1322–6 (47 ref.)

Prevention of HIV infection in primary care: current practices, future possibilities. Makadon HJ, et al. **Ann Intern Med** 1995 Nov 1;123(9):715–9 (65 ref.)

Strategies for improving prescribing practice [see comments] Anderson GM, et al. **Can Med Assoc J** 1996 Apr 1; 154(7):1013–7 (38 ref.) Comment in: Can Med Assoc J 1996 Jun 1;154(11):1620.

The clinical interface—a British physician's view. Neuberger J, et al. **Clin Chim Acta** 1996 Apr 15;248(1):11–8 (9 ref.)

Indicators for assessment of compliance with quality standards for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. Gross PA, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S138–41 (0 ref.)

The clinical use of antenatal corticosteroids. Gardner MO, et al. **Clin Obstet Gynecol** 1995 Dec;38(4):746–54 (39 ref.)

Drugs for the doctor's bag [see comments] **Drug Ther Bull** 1995 Jan 19;33(1):3–5 (8 ref.) Comment in: Drug Ther Bull 1995 Jul;33(7):56.

On the need for evidence-based medicine. Sackett DL, et al. **J Public Health Med** 1995 Sep;17(3):330–4 (22 ref.)

Unapproved uses of approved drugs: the physician, the package insert, and the Food and Drug Administration: subject review. American Academy of Pediatrics Committee on Drugs [see comments] **Pediatrics** 1996 Jul; 98(1):143–5 (00 ref.) Comment in: Pediatrics 1996 Jul;98(1):118–23.

The language of acupuncture: should Western physicians learn it? Erickson JK. **Pharos** 1995 Fall;58(4):21–5 (14 ref.)

ECONOMICS

Effects of availability of patient-related charges on practice patterns and cost containment in the pediatric intensive care unit. Sachdeva RC, et al. **Crit Care Med** 1996 Mar; 24(3):501–6 (44 ref.)

LEGISLATION & JURISPRUDENCE

Strains in the fiduciary metaphor: divided physician loyalties and obligations in a changing health care system. Rodwin MA. **Am J Law Med** 1995;21(2–3):241–57 (108 ref.)

Legal implications of treating patients with HIV. Katine M. **J Am Podiatr Med Assoc** 1995 Aug;85(8):406–19 (38 ref.)

Recent medical-legal proceedings and their effect on the practice of medicine in Chicago. Heim SE, et al. **J Spinal Disord** 1995 Oct;8(5):419–21 (13 ref.)

STATISTICS & NUMERICAL DATA

A Scottish national audit of current patterns of management for patients with testicular non-seminomatous germ-cell tumours. The Scottish Radiological Society and the Scottish Committee of the Royal College of Radiologists. Howard GC, et al. **Br J Cancer** 1995 Nov;72(5):1303–6 (17 ref.)

Variation in dentists' clinical decisions. Bader JD, et al. **J Public Health Dent** 1995 Summer;55(3):181–8 (67 ref.)

Physicians' prevention counseling behaviors: current status and future directions [editorial; comment] Frank E, et al. **Prev Med** 1995 Nov;24(6):543–5 (26 ref.) Comment on: Prev Med 1995 Nov;24(6):546–2.

PHYSICIAN'S ROLE

Incorporating gun safety into clinical practice. Camosy PA. **Am Fam Physician** 1996 Sep 1;54(3):971–5, 977–8 (16 ref.)

Chemically dependent patients in recovery: roles for the family physician. Del Toro IM, et al. **Am Fam Physician** 1996 Apr;53(5):1667–81 (19 ref.)

Care at the twilight: ethics and end-of-life care. Doukas DJ, et al. **Am Fam Physician** 1995 Oct;52(5):1294–6, 1299 (12 ref.)

SAFE questions: overcoming barriers to the detection of domestic violence. Neufeld B. **Am Fam Physician** 1996 Jun; 53(8):2575–80, 2582 (32 ref.)

The role of the family physician in the day care setting. Olsen CG, et al. **Am Fam Physician** 1996 Sep 15;54(4):1257–65, 1267–8 (32 ref.)

The role of the transfusion medicine consultant. Popovsky MA, et al. **Am J Clin Pathol** 1996 Jun;105(6):798–801 (12 ref.)

Medical futility and implications for physician autonomy. Daar JF. **Am J Law Med** 1995;21(2–3):221–40 (117 ref.)

Strains in the fiduciary metaphor: divided physician loyalties and obligations in a changing health care system. Rodwin MA. **Am J Law Med** 1995;21(2–3):241–57 (108 ref.)

The role of the pediatrician in the promotion of cardiovascular health. Bronfin DR, et al. **Am J Med Sci** 1995 Dec;310 Suppl 1:S42–7 (43 ref.)

Physician-run health plans and antitrust. American College of Physicians. **Ann Intern Med** 1996 Jul 1;125(1):59–65 (20 ref.)

Violence in intimate relationships and the practicing internist: new "disease" or new agenda? [comment] [see comments] Alpert EJ. **Ann Intern Med** 1995 Nov 15;123(10):774–81 (33 ref.) Comment on: Ann Intern Med 1995 Nov 15;123(10):737–46. Comment on: Ann Intern Med 1995 Nov 15;123(10):782–94. Comment on: Ann Intern Med

1995 Nov 15;123(10):800–2. Comment on: Ann Intern Med 1995 Nov 15;123(10):804–5. Comment in: Ann Intern Med 1996 Sep 1;125(5):426; discussion 426–7.
Prevention of HIV infection in primary care: current practices, future possibilities. Makadon HJ, et al. **Ann Intern Med** 1995 Nov 1;123(9):715–9 (65 ref.)
Improving postoperative care: the role of the surgeon in the high dependency unit. Coggins R, et al. **Ann R Coll Surg Engl** 1996 May;78(3 (Pt 1)):163–7 (29 ref.)
The role of medical examiners and coroners in public health surveillance and epidemiologic research. Hanzlick R, et al. **Annu Rev Public Health** 1996;17:383–409 (85 ref.)
Increased flight surgeon role in military aeromedical evacuation. Lyons TJ, et al. **Aviat Space Environ Med** 1995 Oct;66(10):927–9 (16 ref.)
Pathways to suicide prevention. Murphy BM, et al. **Br J Hosp Med** 1995 Jun 21–Jul 11;54(1):11–4 (18 ref.)
Violence among children and adolescents and the role of the pediatrician. Dukarm CP, et al. **Bull N Y Acad Med** 1995 Summer;72(1):5–15 (38 ref.)
A dying child. Dawson SA. **Can Fam Physician** 1995 Sep; 41:1534–40 (27 ref.)
Managing early presentation of rheumatoid arthritis. Systematic overview. Glazier R. **Can Fam Physician** 1996 May;42:913–22 (85 ref.)
Preventing adolescent pregnancy and associated risks. Miller R. **Can Fam Physician** 1995 Sep;41:1525–31 (42 ref.)
Preventing children from smoking. How family physicians and pediatricians can help. Thomas RE, et al. **Can Fam Physician** 1995 Sep;41:1517–23 (50 ref.)
Acknowledging the weather–health link. Bart JL, et al. **Can Med Assoc J** 1995 Oct 1;153(7):941–4 (30 ref.)
Bioethics for clinicians: 1. Consent [see comments] Etchells E, et al. **Can Med Assoc J** 1996 Jul 15;155(2):177–80 (31 ref.) Comment in: Can Med Assoc J 1996 Jul 15;155(2):189–90.
The emerging role of the physician in genetic counselling and testing for heritable breast, ovarian and colon cancer. Taylor KM, et al. **Can Med Assoc J** 1996 Apr 15; 154(8):1155–8 (23 ref.)
The medical director in the multi-level long-term care facility. Applebaum GE. **Clin Geriatr Med** 1995 Aug; 11(3):359–72 (4 ref.)
The medical director in non-institutional long-term care programs. Finucane TE, et al. **Clin Geriatr Med** 1995 Aug; 11(3):391–402 (15 ref.)
The corporate medical director. Krein K. **Clin Geriatr Med** 1995 Aug;11(3):403–17 (10 ref.)
Policy and procedure development and implementation. Levenson SA. **Clin Geriatr Med** 1995 Aug;11(3):449–65 (8 ref.)
Current role of the medical director in community-based nursing facilities. Levinson MJ, et al. **Clin Geriatr Med** 1995 Aug;11(3):343–58 (10 ref.)
The medical director in hospital-based transitional care units. Smith RL, et al. **Clin Geriatr Med** 1995 Aug;11(3):373–89 (11 ref.)
The future of long-term care and the role of the medical director. Willging P. **Clin Geriatr Med** 1995 Aug; 11(3):531–45 (10 ref.)
Home healthcare: the role of the primary care physician. Goldberg AI. **Compr Ther** 1995 Nov;21(11):633–8 (20 ref.)
Polyps and polypectomy surveillance—role of the histopathologist. Riddell RH. **Eur J Cancer** 1995 Jul–Aug; 31A(7–8):1138–40 (6 ref.)
Illness and family functioning: theoretical and practical considerations from the primary care point of view. Tansella CZ. **Fam Pract** 1995 Jun;12(2):214–20 (14 ref.)
Managed care and the role and training of psychiatrists. Meyer RE, et al. **Health Aff (Millwood)** 1995 Fall; 14(3):65–77 (23 ref.)
Medical ethics under managed care. Schwartz P. **Int J Fertil Menopausal Stud** 1996 Mar–Apr;41(2):124–8 (16 ref.)
Diagnosing and managing elder abuse. Jogerst G. **Iowa Med** 1996 Jan;86(1):29–31 (9 ref.)
The surgeon as a leader in cancer care: lessons learned from the study of soft tissue sarcoma. Brennan MF. **J Am Coll Surg** 1996 Jun;182(6):520–9 (35 ref.)
Making a difference for children: the medical community's role in improving child care. Reisman B. **J Am Med Wom Assoc** 1995 Sep–Oct;50(5):170–4 (21 ref.)
Domestic violence: changing theory, changing practice. Warshaw C. **J Am Med Womens Assoc** 1996 May–Jul; 51(3):87–91, 100 (70 ref.)
Legal implications of treating patients with HIV. Katine M. **J Am Podiatr Med Assoc** 1995 Aug;85(8):406–19 (38 ref.)
Human rights and medical practice, including reference to the joint Oslo statements of September 1993 and March 1994. Alderslade R. **J Public Health Med** 1995 Sep; 17(3):335–42 (7 ref.)
Smoking cessation counseling in adults and children: the clinician's role. Adams JA. **Md Med J** 1995 Oct; 44(10):779–87 (26 ref.)
Preconception counseling for the primary care physician. Leuzzi RA, et al. **Med Clin North Am** 1996 Mar; 80(2):337–74 (113 ref.)
Psychosocial support, treatment of metastatic disease and palliative care [see comments] Ashby MA, et al. **Med J Aust** 1996 Jan 1;164(1):43–9 (23 ref.) Comment in: Med J Aust 1996 Jun 17;164(12):759–60.
Why oncologists should get involved in practice guideline development. ASCO Health Services Committee Program. **Oncology (Huntingt)** 1995 May;9(5):412, 415 (0 ref.)
The role of the pediatrician in implementing the Americans with Disabilities Act: subject review. American Academy of Pediatrics Committee on Children with Disabilities. **Pediatrics** 1996 Jul;98(1):146–8 (09 ref.)
Domestic violence. Do you know when and how to intervene? Steiner RP, et al. **Postgrad Med** 1996 Jul; 100(1):103–6, 111–4, 116 (19 ref.)
Telling parents their child has severe congenital anomalies. Ryan S. **Postgrad Med J** 1995 Sep;71(839):529–33 (14 ref.)
Patient requests for euthanasia and assisted suicide in terminal illness. The role of the psychiatrist. Block SD, et al. **Psychosomatics** 1995 Sep–Oct;36(5):445–57 (75 ref.)
Prevention of colorectal cancer by screening flexible sigmoidoscopy: possible role of the primary care physician. Abbas Z, et al. **Scott Med J** 1995 Jun;40(3):67–9 (41 ref.)
Family violence: practical recommendations for physicians and the medical community. Buel SM, et al. **Womens Health Issues** 1995 Winter;5(4):158–72 (24 ref.)
The primary health care provider's role in sexual assault prevention. Holmes MM. **Womens Health Issues** 1995 Winter;5(4):224–32 (42 ref.)
[Humanitarianism: the gardener, the truck driver and the "shrink"] Maqueda F. **Psychiatr Enfant** 1995;38(1):311–43 (4 ref.) (Eng. Abstr.) **(Fre)**
[Identification of victims of violence and torture: the practitioner's role] Subilia L, et al. **Schweiz Med Wochenschr** 1996 Jul 27;126(30):1291–6 (20 ref.) (Eng. Abstr.) **(Fre)**

PHYSICIANS, WOMEN

Harassment of women physicians. Schiffman M, et al. **J Am Med Womens Assoc** 1995 Nov–Dec;50(6):207–11 (36 ref.)

STATISTICS & NUMERICAL DATA

Women doctors—a review. Bewley BR. **J R Soc Med** 1995 Jul;88(7):399P–405P (37 ref.)

PHYSICS

On the battle between behavior and cognition: lessons from physicists and pragmatists. Corrigan PW. **J Behav Ther Exp Psychiatry** 1995 Sep;26(3):209–14 (44 ref.)

HISTORY

Henri Becquerel (1852–1908). Dutreix J, et al. **Med Phys** 1995 Nov;22(11 Pt 2):1869–75 (47 ref.)
The quest for the laws governing radiations and the search for beneficial innovations. Laughlin JS. **Radiat Res** 1995 Nov;144(2):129–40 (59 ref.)

PHYSIOGNOMY

see related
FACIAL EXPRESSION

PHYSIOLOGIC AVAILABILITY see BIOLOGICAL AVAILABILITY

PHYSIOLOGY

A new representation of knowledge concerning human anatomy and function. Höhne KH, et al. **Nat Med** 1995 Jun;1(6):506–11 (33 ref.)
[The information principle in physiology: an analysis from the position of the general theory of functional systems] Sudakov KV. **Usp Fiziol Nauk** 1995 Oct–Dec;26(4):3–27 (79 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOTHERAPY see PHYSICAL THERAPY

PHYTAGGLUTININS see LECTINS

6-PHYTASE

GENETICS

Genetics of myo-inositol phosphate synthesis and accumulation. Raboy V, et al. **Subcell Biochem** 1996; 26:257–85 (161 ref.)

PHYTIC ACID

Phytic acid in health and disease. Zhou JR, et al. **Crit Rev Food Sci Nutr** 1995 Nov;35(6):495–508 (171 ref.)

METABOLISM

Inositolpolyphosphates and their binding proteins—a short review. Huisamen B, et al. **Mol Cell Biochem** 1996 Apr 12–26;157(1–2):229–32 (29 ref.)
Inositol pentakis- and hexakisphosphate metabolism adds versatility to the actions of inositol polyphosphates. Novel effects on ion channels and protein traffic. Shears SB. **Subcell Biochem** 1996;26:187–226 (181 ref.)

PHYTIN see PHYTIC ACID

PHYTOCHROME

CHEMISTRY

[Phytochrome—structure and properties] Tretyn A, et al. **Postepy Biochem** 1996;42(1):57–64 (25 ref.) **(Pol)**

GENETICS

Phytochrome signal-transduction: characterization of pathways and isolation of mutants. Barnes SA, et al. **Philos Trans R Soc Lond B Biol Sci** 1995 Oct 30; 350(1331):67–74 (20 ref.)

METABOLISM

Light signal transduction mediated by phytochromes: preliminary studies and possible approaches. Song PS, et al. **Indian J Biochem Biophys** 1996 Feb;33(1):1–19 (131 ref.)
[Phytochrome—structure and properties] Tretyn A, et al. **Postepy Biochem** 1996;42(1):57–64 (25 ref.) **(Pol)**

PHYTOHORMONES see PLANT GROWTH REGULATORS

PHYTOMENADIONE see PHYTONADIONE

PHYTOMITOGENS see LECTINS

PHYTONADIONE

ADMINISTRATION & DOSAGE

Oral vitamin K1: an option to reduce warfarin's activity. Harrell CC, et al. **Ann Pharmacother** 1995 Dec; 29(12):1228–32 (26 ref.)

ADVERSE EFFECTS

[Cutaneous hypersensitivity at the site of injection of vitamin K1] Moreau-Cabarrot A, et al. **Ann Dermatol Venereol** 1996;123(3):177–9 (22 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Observations on vitamin K deficiency in the fetus and newborn: has nature made a mistake? Israels LG, et al. **Semin Thromb Hemost** 1995;21(4):357–63 (36 ref.)

PHYTOPHAGINEAE see PLANT VIRUSES

PHYTOREOVIRUS see REOVIRIDAE

PHYTOTHERAPY see MEDICINE, HERBAL

PIA MATER

BLOOD SUPPLY

Postsurgical development of dural arteriovenous malformations after transpetrosal and transtentorial operations: case report. Sasaki T, et al. **Neurosurgery** 1995 Oct;37(4):820–4; discussion 824–5 (14 ref.)

PIAL VEIN see CEREBRAL VEINS

PICIBANIL

THERAPEUTIC USE

[Immunotherapy of patients with head and neck carcinomas] Tsukuda M. **Gan To Kagaku Ryoho** 1996 Feb;23(3):283–90 (32 ref.) (Eng. Abstr.) **(Jpn)**

PICK'S DISEASE OF BRAIN see DEMENTIA, PRESENILE

PICK'S DISEASE OF HEART see PERICARDITIS, CONSTRICTIVE

PICODNAVIRUSES see PARVOVIRIDAE

PICOLINIC ACIDS

THERAPEUTIC USE

Anabolic effects of insulin on bone suggest a role for chromium picolinate in preservation of bone density. McCarty MF. **Med Hypotheses** 1995 Sep;45(3):241–6 (69 ref.)

PICORNAVIRIDAE

ENZYMOLOGY

The picornaviral 3C proteinases: cysteine nucleophiles in serine proteinase folds. Malcolm BA. **Protein Sci** 1995 Aug; 4(8):1439–45 (65 ref.)

GENETICS

The use of picornaviruses as vectors for the engineering of live recombinant vaccines. Girard M, et al. **Biologicals** 1995 Jun;23(2):165–9 (32 ref.)
The role of the La autoantigen in internal initiation. Belsham GJ, et al. **Curr Top Microbiol Immunol** 1995;203:85–98 (57

PICORNAVIRIDAE

ref.)
Internal initiation of translation in eukaryotes: the picornavirus paradigm and beyond. Jackson RJ, et al. **RNA** 1995 Dec;1(10):985–1000 (104 ref.)

IMMUNOLOGY

Antibody recognition of picornaviruses and escape from neutralization: a structural view. Mateu MG. **Virus Res** 1995 Sep;38(1):1–24 (161 ref.)

PICORNAVIRIDAE INFECTIONS

DRUG THERAPY

Update on therapy of influenza and rhinovirus infections. Arruda E, et al. **Adv Exp Med Biol** 1996;394:175–87 (93 ref.)

VIROLOGY

Natural and experimental rhinovirus infections of the lower respiratory tract. Johnston SL.
Am J Respir Crit Care Med 1995 Oct;152(4 Pt 2):S46–52 (71 ref.)

PICORNAVIRUS INFECTIONS see **PICORNAVIRIDAE INFECTIONS**

PICTURE ARCHIVING AND COMMUNICATION SYSTEMS see **RADIOLOGY INFORMATION SYSTEMS**

PICTURE ARCHIVING, RADIOLOGIC see **RADIOLOGY INFORMATION SYSTEMS**

PIEBALDISM

see related
WAARDENBURG'S SYNDROME

PIG SKIN DRESSINGS see **BIOLOGICAL DRESSINGS**

PIGEON BREEDER'S LUNG see **BIRD FANCIER'S LUNG**

PIGEONS

PHYSIOLOGY

Regulation of pigeon cropmilk secretion and parental behaviors by prolactin. Horseman ND, et al.
Annu Rev Nutr 1995;15:213–38 (130 ref.)

PIGMENT EPITHELIUM OF EYE

CYTOLOGY

From lens regeneration in the newt to in-vitro transdifferentiation of vertebrate pigmented epithelial cells. Kodama R, et al. **Semin Cell Biol** 1995 Jun;6(3):143–9 (39 ref.)

METABOLISM

Deletion mutants in human cytomegalovirus glycoprotein US9 are impaired in cell–cell transmission and in altering tight junctions of polarized human retinal pigment epithelial cells. Pereira L, et al. **Scand J Infect Dis Suppl** 1995;99:82–7 (42 ref.)

PATHOLOGY

Acute posterior multifocal placoid pigment epitheliopathy. Heath JD, et al. **Int Ophthalmol Clin** 1995 Spring; 35(2):93–105 (43 ref.)

PHYSIOLOGY

Microfilament organization and wound repair in retinal pigment epithelium. Kalnins VI, et al.
Biochem Cell Biol 1995 Sep–Oct;73(9–10):709–22 (97 ref.)

PIGMENTARY RETINOPATHY see **RETINITIS PIGMENTOSA**

PIGMENTATION

see related
SKIN PIGMENTATION

The melanocortin receptors: agonists, antagonists, and the hormonal control of pigmentation. Cone RD, et al.
Recent Prog Horm Res 1996;51:287–317; discussion 318 (102 ref.)

RADIATION EFFECTS

Mechanisms of ultraviolet light-induced pigmentation. Gilchrest BA, et al. **Photochem Photobiol** 1996 Jan; 63(1):1–10 (110 ref.)

PIGMENTATION DISORDERS

Common disorders of pigmentation: when are more than cosmetic cover-ups required? Hacker SM.
Postgrad Med 1996 Jun;99(6):177–86 (14 ref.)

CHEMICALLY INDUCED

Longitudinal melanonychia induced by hydroxyurea: four case reports and review of the literature. Delmas-Marsalet B, et al. **Nouv Rev Fr Hematol** 1995;37(3):205–10 (17 ref.)

COMPLICATIONS

[Neurocutaneous disorders with achromic spots. Tuberous sclerosis of Bourneville. Diagnostic criteria and follow-up protocol] Prats-Viñas JM. **Rev Neurol** 1996 Sep; 24(133):1056–9 (7 ref.) **(Spa)**

DIAGNOSIS

[Ito's hypomelanosis] Aver'ianov IuN, et al.
Zh Nevropatol Psikhiatr Im S S Korsakova 1995;95(6):84–6 (8 ref.) (Eng. Abstr.) **(Rus)**

GENETICS

Dyskeratosis congenita: an inherited bone marrow failure syndrome. Dokal I. **Br J Haematol** 1996 Mar;92(4):775–9 (52 ref.)
Hypomelanosis of Ito and X;autosome translocations: a unifying hypothesis. Hatchwell E. **J Med Genet** 1996 Mar; 33(3):177–83 (61 ref.)

THERAPY

The role of pulsed laser in the management of cosmetically significant pigmented lesions. Bekhor PS.
Australas J Dermatol 1995 Nov;36(4):221–3 (5 ref.)

PIGMENTS

[Fiber optic chemical gas sensors based on environmental chromism] Sadaoka Y. **Tanpakushitsu Kakusan Koso** 1995 Nov;40(15):2355–60 (14 ref.) **(Jpn)**

ANALYSIS

[Dipyrrole bile pigments] Yamaguchi T, et al.
Nippon Rinsho 1995 Feb;53 Su Pt 1:895–8 (9 ref.) **(Jpn)**

BIOSYNTHESIS

Tyrosinase and related proteins in mammalian pigmentation. del Marmol V, et al. **FEBS Lett** 1996 Mar 4;381(3):165–8 (48 ref.)

CHEMISTRY

Vanadium in ascidians and the chemistry of tunichromes. Smith MJ, et al. **Met Ions Biol Syst** 1995;31:423–90 (361 ref.)
Pigments of the gastrointestinal tract: a comparison of light microscopic and electron microscopic findings. Ghadially FN, et al. **Ultrastruct Pathol** 1995 Jul–Aug;19(4):213–9 (36 ref.)

PIGS see **SWINE**

PILAR CYST see **EPIDERMAL CYST**

PILI, BACTERIAL see **FIMBRIAE, BACTERIAL**

PILI, COMMON see **FIMBRIAE, BACTERIAL**

PILI, SEX

see related
CONJUGATION, GENETIC

PILOCARPINE

TOXICITY

Lithium–pilocarpine neurotoxicity: a potential model of status epilepticus. Kulkarni SK, et al.
Methods Find Exp Clin Pharmacol 1995 Oct;17(8):551–67 (195 ref.)

PILOMATRIXOMA

PATHOLOGY

Perforating pilomatricoma. Alli N, et al.
J Am Acad Dermatol 1996 Jul;35(1):116–8 (11 ref.)

PILONIDAL CYST

ETIOLOGY

[Pilonidal sinus] Berger A, et al. **Ann Chir** 1995; 49(10):889–901 (27 ref.) (Eng. Abstr.) **(Fre)**

PILONIDAL SINUS see **PILONIDAL CYST**

PINEAL BODY

Extragonadal germ cell tumor: a clinical study. Bassetto MA, et al. **Anticancer Res** 1995 Nov–Dec;15(6B):2751–4 (17 ref.)
Intraventricular neurocytoma. Ng P, et al.
Australas Radiol 1996 May;40(2):125–33 (27 ref.)
Radiation-induced meningioma in children: report of two cases and review of the literature. Starshak RJ.
Pediatr Radiol 1996;26(8):537–41 (30 ref.)
Pineal germinoma with cranial nerve metastasis. Incesu L, et al. **Radiol Med (Torino)** 1996 Apr;91(4):471–2 (11 ref.)
Tumors of the pineal region. Piovan E, et al. **Rays** 1996 Jan–Mar;21(1):87–100 (19 ref.) **(Eng, Ita)**
Nonresective treatment of pineoblastoma: a case report. Patil AA, et al. **Surg Neurol** 1995 Oct;44(4):386–903; discussion 390–1 (36 ref.)
[Double localization of intracranial germinoma. Apropos of a case] Alifdal M, et al. **Neurochirurgie** 1995;41(6):424–8 (23 ref.) (Eng. Abstr.) **(Fre)**
[Progress in pineal research] Shiotani Y.
Nippon Naibunpi Gakkai Zasshi 1995 Jul 20;71(5):647–50 (17 ref.) **(Jpn)**

ANATOMY & HISTOLOGY

The pineal gland: structural and functional diversity. Shedpure M, et al. **Indian J Exp Biol** 1995 Sep;33(9):625–40 (80 ref.)

CHEMISTRY

The chemical neuroanatomy of the mammalian pineal gland: neuropeptides. Møller M, et al. **Neurochem Int** 1996 Jan; 28(1):23–33 (72 ref.)

IMMUNOLOGY

The influence of season, photoperiod, and pineal melatonin on immune function. Nelson RJ, et al. **J Pineal Res** 1995 Nov;19(4):149–65 (209 ref.)

METABOLISM

Pineal gene expression: dawn in a dark matter. Stehle JH. **J Pineal Res** 1995 May;18(4):179–90 (90 ref.)

PATHOLOGY

Pineal and suprasellar metastasis of lung cancer: case report and review of the literature. Izumihara A, et al.
Comput Med Imaging Graph 1995 Sep–Oct;19(5):435–7 (14 ref.)

PHYSIOLOGY

Functional connections between the pineal gland and immune system. Skwarło-Sońta K. **Acta Neurobiol Exp (Warsz)** 1996;56(1):341–57 (111 ref.)
Melatonin as a chronobiotic: PROS and CONS. Steinlechner S. **Acta Neurobiol Exp (Warsz)** 1996;56(1):363–72 (64 ref.)
The mammalian pineal gland and reproduction. Controversies and strategies for future research. Olcese J. **Adv Exp Med Biol** 1995;377:1–14 (97 ref.)
The pineal gland and cancer. Ronco AL, et al.
Anticancer Res 1996 Jul–Aug;16(4A):2033–9 (68 ref.)
Biorhythms and the biological clock involvement of melatonin and the pineal gland in life and disease. Nir I. **Biomed Environ Sci** 1995 Jun;8(2):90–105 (54 ref.)
Cholinergic signaling in the rat pineal gland. Laitinen JT, et al. **Cell Mol Neurobiol** 1995 Apr;15(2):177–92 (72 ref.)
Functional diversity of the pineal hormone melatonin: its role as an antioxidant. Reiter RJ.
Exp Clin Endocrinol Diabetes 1996;104(1):10–6 (52 ref.)
The pineal gland and melatonin in relation to aging: a summary of the theories and of the data. Reiter RJ.
Exp Gerontol 1995 May–Aug;30(3–4):199–212 (73 ref.)
The pineal gland: structural and functional diversity. Shedpure M, et al. **Indian J Exp Biol** 1995 Sep;33(9):625–40 (80 ref.)
The clinical neuroimmunotherapeutic role of melatonin in oncology. Conti A, et al. **J Pineal Res** 1995 Oct; 19(3):103–10 (38 ref.)
Thirty years of human pineal research: do we know its clinical relevance? García-Patterson A, et al.
J Pineal Res 1996 Jan;20(1):1–6 (66 ref.)
[Pineal gland and melatonin] Masuzawa T, et al.
No Shinkei Geka 1995 Oct;23(10):857–68 (74 ref.) **(Jpn)**
[The epiphysis in the visual analyzer system] Arushanian EB, et al. **Usp Fiziol Nauk** 1995 Jul–Sep;26(3):25–40 (98 ref.) (Eng. Abstr.) **(Rus)**
[The complex interaction of the hypothalamic suprachiasmatic nuclei with the epiphysis and corpus striatum—a functionally unified system for regulating circadian behavioral fluctuations] Arushanian EB.
Zh Vyssh Nerv Deiat Im I P Pavlova 1996 Jan–Feb; 46(1):15–22 (44 ref.) (Eng. Abstr.) **(Rus)**
[Pineal functioning (melatonin levels) in healthy children of different ages. An update and the value of pineal gland study in pediatrics] Molina Carballo A, et al.
An Esp Pediatr 1996 Jul;45(1):33–44 (124 ref.) (Eng. Abstr.) **(Spa)**
[The epiphysis in reproduction (the diapause and the sexual cycle)] Pérez Pérez F. **An R Acad Nac Med (Madr)** 1995; 112(2):383–406 (27 ref.) **(Spa)**

PHYSIOPATHOLOGY

The pineal gland and cancer. Ronco AL, et al.
Anticancer Res 1996 Jul–Aug;16(4A):2033–9 (68 ref.)

PINEAL GLAND see **PINEAL BODY**

PINEALOCYTOMA see **PINEALOMA**

PINEALOMA

DRUG THERAPY

Nonresective treatment of pineoblastoma: a case report. Patil AA, et al. **Surg Neurol** 1995 Oct;44(4):386–903; discussion 390–1 (36 ref.)

RADIOTHERAPY

Radiation-induced meningioma in children: report of two cases and review of the literature. Starshak RJ. **Pediatr Radiol** 1996;26(8):537–41 (30 ref.)

Nonresective treatment of pineoblastoma: a case report. Patil AA, et al. **Surg Neurol** 1995 Oct;44(4):386–903; discussion 390–1 (36 ref.)

PINEOBLASTOMA see **PINEALOMA**

PINEOCYTOMA see **PINEALOMA**

PIPECOLIC ACIDS

THERAPEUTIC USE

Strategies for neuroprotection with glutamate antagonists. Extrapolating from evidence taken from the first stroke and head injury studies. Bullock R. **Ann N Y Acad Sci** 1995 Sep 15;765:272–8; discussion 298 (11 ref.)

PIPERAZINES

PHARMACOKINETICS

Clinical pharmacokinetics of zopiclone. Fernandez C, et al. **Clin Pharmacokinet** 1995 Dec;29(6):431–41 (38 ref.)

PHARMACOLOGY

Delavirdine mesylate, a potent non-nucleoside HIV-1 reverse transcriptase inhibitor. Freimuth WW. **Adv Exp Med Biol** 1996;394:279–89 (42 ref.)

[4-Arylpiperazine derivatives: a seedbed of drugs for various therapeutic indications] Coudert P, et al. **J Pharm Belg** 1995 Sep-Oct;50(5):445–54 (67 ref.) (Eng. Abstr.) **(Fre)**

THERAPEUTIC USE

Treatment of pulmonary hypertension in patients with chronic obstructive pulmonary disease: position of vasodilators with special focus on urapidil. Adnot S, et al. **Blood Press** 1995;Suppl 3:47–57 (43 ref.)

Review of studies with urapidil in elderly hypertensives. Hansson L, et al. **Blood Press** 1995;Suppl 3:21–5 (21 ref.)

Potential beneficial effects of urapidil in primary and secondary prevention of stroke. Späh F, et al. **Blood Press** 1995;Suppl 3:62–7 (49 ref.)

Review of studies with urapidil in elderly hypertensives. Hansson L, et al. **Blood Press Suppl** 1995;3:21–5 (21 ref.)

Pathophysiology of postischemic hypoxia and cerebral protection: implications of the almitrine and raubasine combination. Chan P. **Eur Neurol** 1995;35 Suppl 1:23–7 (41 ref.)

A review of the effects of dopaminergic agents on humans, animals, and drug-seeking behavior, and its implications for medication development.Focus on GBR 12909. Rothman RB, et al. **Mol Neurobiol** 1995 Aug-Dec; 11(1-3):1–19 (130 ref.)

[New non-benzodiazepine hypnotics. Progress in therapy of sleep disorders?] Hajak G, et al. **Internist (Berl)** 1995 Nov; 36(11):1085–90; discussion 1090–1 (51 ref.) **(Ger)**

[The treatment of intraoperative arterial hypertension with Urapidil] Filosso PL. **Minerva Cardioangiol** 1996 Apr; 44(4):197–207 (45 ref.) **(Ita)**

PIPERIDINES

Remifentanil: a novel, short-acting, mu-opioid. Bürkle H, et al. **Anesth Analg** 1996 Sep;83(3):646–51 (52 ref.)

Cisapride [see comments] Washabau RJ, et al. **J Am Vet Med Assoc** 1995 Nov 15;207(10):1285–8 (33 ref.) Comment in: J Am Vet Med Assoc 1996 Jan 15;208(2):184.

Remifentanil: a new opioid. Glass PS. **J Clin Anesth** 1995 Nov;7(7):558–63 (24 ref.)

PHARMACOKINETICS

Remifentanil pharmacokinetics and pharmacodynamics. A preliminary appraisal. Egan TD. **Clin Pharmacokinet** 1995 Aug;29(2):80–94 (41 ref.)

The pharmacokinetic properties of topical levocabastine. A review. Heykants J, et al. **Clin Pharmacokinet** 1995 Oct; 29(4):221–30 (39 ref.)

PHARMACOLOGY

Tachykinin NK2 receptors further characterized in the lung with nonpeptide receptor antagonists. Advenier C. **Can J Physiol Pharmacol** 1995 Jul;73(7):878–84 (73 ref.)

Remifentanil pharmacokinetics and pharmacodynamics. A preliminary appraisal. Egan TD. **Clin Pharmacokinet** 1995 Aug;29(2):80–94 (41 ref.)

Levocabastine. An update of its pharmacology, clinical efficacy and tolerability in the topical treatment of allergic rhinitis and conjunctivitis. Noble S, et al. **Drugs** 1995 Dec; 50(6):1032–49 (60 ref.)

Ebastine. a review of its pharmacological properties and clinical efficacy in the treatment of allergic disorders. Wiseman LR, et al. **Drugs** 1996 Feb;51(2):260–77 (90 ref.)

The interaction of 4-DAMP mustard with subtypes of the muscarinic receptor. Ehlert FJ. **Life Sci** 1996;58(22):1971–8 (39 ref.)

POISONING

Cisapride toxicosis in dogs. Volmer PA. **Vet Hum Toxicol** 1996 Apr;38(2):118–20 (20 ref.)

THERAPEUTIC USE

Preclamol. A "designer drug" in the treatment of advanced Parkinson's disease. Pirtošek Z, et al. **Adv Neurol** 1996; 69:535–40 (26 ref.)

Cisapride for the treatment of chronic idiopathic constipation. Gardner VY, et al. **Ann Pharmacother** 1995 Nov;29(11):1161–3 (12 ref.)

A risk-benefit assessment of cisapride in the treatment of gastrointestinal disorders. Tack J, et al. **Drug Saf** 1995 Jun; 12(6):384–92 (103 ref.)

Levocabastine. An update of its pharmacology, clinical efficacy and tolerability in the topical treatment of allergic rhinitis and conjunctivitis. Noble S, et al. **Drugs** 1995 Dec; 50(6):1032–49 (60 ref.)

Ebastine. a review of its pharmacological properties and clinical efficacy in the treatment of allergic disorders. Wiseman LR, et al. **Drugs** 1996 Feb;51(2):260–77 (90 ref.)

Cisapride therapy for gastrointestinal disease. Cucchiara S. **J Pediatr Gastroenterol Nutr** 1996 Apr;22(3):259–69 (90 ref.)

Cholesterol gallstone formation in man and potential treatments of the gallbladder motility defect. Portincasa P, et al. **Scand J Gastroenterol Suppl** 1995;212:63–78 (294 ref.)

[Estrogen agonists, especially raloxifene, in the treatment of osteoporosis] Lips P, et al. **Ned Tijdschr Geneeskd** 1996 Jun 8;140(23):1215–7 (31 ref.) **(Dut)**

[Resistance to chemotherapy in cancers of the kidney and therapeutic perspectives] Oudard S, et al. **J Urol (Paris)** 1995;101(3):122–4 (25 ref.) (Eng. Abstr.) **(Fre)**

[Agonists-antagonists of estrogens, their potential use in prophylaxis and treatment of osteoporosis] Hoszowski K. **Pol Tyg Lek** 1995 Nov;50(44-47):41–2 (16 ref.) (Eng. Abstr.) **(Pol)**

PIRACETAM

PHARMACOLOGY

On the possible role of nootropica in geriatric prevention and therapy. Nagy IZ. **Ann N Y Acad Sci** 1996 Jun 15; 786:444–52 (45 ref.)

PIROPLASMA see **BABESIA**

PIROPLASMOSIS see **BABESIOSIS**

PIROXICAM

ANALOGS & DERIVATIVES

Lornoxicam. A review of its pharmacology and therapeutic potential in the management of painful and inflammatory conditions. Balfour JA, et al. **Drugs** 1996 Apr;51(4):639–57 (76 ref.)

PISUM SATIVUM see **PEAS**

PIT VIPER VENOMS see **CROTALID VENOMS**

PITHECINAE see **CEBIDAE**

PITUITARY ADENOMA, PROLACTIN-SECRETING see **PROLACTINOMA**

PITUITARY-ADRENAL SYSTEM

DRUG EFFECTS

Alcohol stimulates ACTH secretion in the rat: mechanisms of action and interactions with other stimuli. Rivier C. **Alcohol Clin Exp Res** 1996 Apr;20(2):240–54 (207 ref.)

IMMUNOLOGY

Activation of the HPA axis by immune insults: roles and interactions of cytokines, eicosanoids, glucocorticoids. Buckingham JC, et al. **Pharmacol Biochem Behav** 1996 May; 54(1):285–98 (138 ref.)

METABOLISM

The potential role of excessive cortisol induced by HPA hyperfunction in the pathogenesis of depression. Stokes PE. **Eur Neuropsychopharmacol** 1995;5 Suppl:77–82 (48 ref.)

PHYSIOLOGY

The hypothalamic-pituitary-adrenocortical system and sleep in man. Friess E, et al. **Adv Neuroimmunol** 1995;5(2):111–25 (63 ref.)

Aging is associated in the 344/N Fischer rat with decreased stress responsivity of central and peripheral catecholaminergic systems and impairment of the hypothalamic-pituitary-adrenal axis. Cizza G, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:491–511 (68 ref.)

The neural network that regulates energy balance is responsive to glucocorticoids and insulin and also regulates HPA axis responsivity at a site proximal to CRF neurons. Dallman MF, et al. **Ann N Y Acad Sci** 1995 Dec 29; 771:730–42 (43 ref.)

Sympathoadrenal system in stress. Interaction with the hypothalamic-pituitary-adrenocortical system. Kvetňanský R, et al. **Ann N Y Acad Sci** 1995 Dec 29; 771:131–58 (158 ref.)

Production of corticotropin-releasing hormone-deficient mice by targeted mutation in embryonic stem cells. Muglia L, et al. **Ann N Y Acad Sci** 1996 Mar 22;780:49–59 (36 ref.)

The role of gonadal steroids in hypothalamic-pituitary-adrenal axis regulation. Young EA. **Crit Rev Neurobiol** 1995;9(4):371–81 (78 ref.)

Interactions of the endocrine and immune systems in children and young adults. Papanicolaou DA, et al. **Curr Opin Pediatr** 1995 Aug;7(4):440–4 (27 ref.)

Individual differences in hypothalamic-pituitary-adrenal activity in later life and hippocampal aging. Meaney MJ, et al. **Exp Gerontol** 1995 May-Aug;30(3-4):229–51 (125 ref.)

Hypothalamic-pituitary-adrenal-glucocorticoid axis function in rheumatoid arthritis [editorial; comment] Masi AT, et al. **J Rheumatol** 1996 Apr;23(4):577–81 (19 ref.) Comment on: J Rheumatol 1996 Apr;23(4):596–602.

The hypothalamic-pituitary-adrenal axis in obesity. Chalew S, et al. **Obes Res** 1995 Jul;3(4):371–82 (136 ref.)

Activation of the HPA axis by immune insults: roles and interactions of cytokines, eicosanoids, glucocorticoids. Buckingham JC, et al. **Pharmacol Biochem Behav** 1996 May; 54(1):285–98 (138 ref.)

Current topic: the placental corticotrophin-releasing hormone-adrenocorticotrophin axis. Challis JR, et al. **Placenta** 1995 Sep;16(6):481–502 (98 ref.)

[Aging and the morphofunctional changes in the hypothalamo-hypophyseal-adrenal cortical system] Bazhanova ED. **Zh Evol Biokhim Fiziol** 1995 Jan-Feb; 31(1):92–102 (74 ref.) **(Rus)**

PHYSIOPATHOLOGY

The protective role of the hypothalamic-pituitary-adrenal axis against lethality produced by immune, infectious, and inflammatory stress. Kapcala LP, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:419–37 (87 ref.)

Effects of the immune/inflammatory reaction on the hypothalamic-pituitary-adrenal axis. Mastorakos G, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:438–48 (34 ref.)

Hormonal control of rheumatoid inflammation. Panayi GS. **Br Med Bull** 1995 Apr;51(2):462–71 (34 ref.)

Lymphoid cell resistance to glucocorticoids in HIV infection. Kawa SK, et al. **J Steroid Biochem Mol Biol** 1996 Mar; 57(5-6):259–63 (68 ref.)

[Endocrinology update--I] Allolio B, et al. **Med Klin** 1996 Apr 1;91 Suppl 1:24–32 (112 ref.) **(Ger)**

[Gastric stress ulcers: the protective role of hormones of the hypothalamo-hypophyseal-adrenocortical system] Filaretova LP. **Fiziol Zh Im I M Sechenova** 1995 Mar; 81(3):50–60 (80 ref.) (Eng. Abstr.) **(Rus)**

PITUITARY APOPLEXY

ETIOLOGY

[A case of pituitary adenoma progressing to pituitary apoplexy on the occasion of cerebral angiography] Suga T, et al. **No Shinkei Geka** 1996 May;24(5):475–9 (12 ref.) (Eng. Abstr.) **(Jpn)**

PITUITARY DISEASES

COMPLICATIONS

[Diabetes insipidus and panhypopituitarism in an 8-year-old girl due to probable lymphocytic hypophysitis] Bastida Eizaguirre M, et al. **An Esp Pediatr** 1996 Apr;44(4):402–4 (20 ref.) **(Spa)**

DIAGNOSIS

Role of magnetic resonance imaging in hypothalamic-pituitary disorders. Zucchini S, et al. **Horm Res** 1995;44 Suppl 3:8–14 (42 ref.)

Current concepts of imaging in patients with pituitary/hypothalamic dysfunction. Korogi Y, et al. **Semin Ultrasound CT MR** 1995 Aug;16(4):270–8 (36 ref.)

[Imaging in hypothalamo-hypophyseal diseases] Vézina JL. **Ann Endocrinol (Paris)** 1995;56(5):511–2 (5 ref.) **(Fre)**

[Lymphocytic hypophysitis: a reality] Virally-Monod ML, et al. **Presse Med** 1996 Jun 8;25(20):933–8 (15 ref.) (Eng. Abstr.) **(Fre)**

[Magnetic resonance imaging and hypothalamo-hypophyseal disorders in children: morpho-functional and etiologic aspects] Zucchini S, et al. **Pediatr Med Chir** 1995 Sep-Oct; 17(5):397–401 (33 ref.) (Eng. Abstr.) **(Ita)**

PITUITARY DISEASES

METABOLISM

Involvement of brain catecholamines and acetylcholine in growth hormone hypersecretory states. Pathophysiological, diagnostic and therapeutic implications. Müller EE, et al. **Drugs** 1995 Nov; 50(5):805–37 (285 ref.)

PITUITARY GLAND

see related
HYPOPHYSECTOMY

[Cystic ectopic pituitary adenoma: report of a case] Akimoto J, et al. **No To Shinkei** 1995 Nov;47(11):1092–7 (12 ref.) (Eng. Abstr.) **(Jpn)**

ABNORMALITIES

The foetal pituitary, postmaturity and breech presentation [comment] de Zegher F, et al. **Acta Paediatr** 1995 Oct; 84(10):1100–2 (32 ref.) Comment on: Acta Paediatr 1995 Oct;84(10):1201–3.

BLOOD SUPPLY

Dynamics of the regulation of the hypothalamo–pituitary–adrenal (HPA) axis determined using a nonsurgical method for collecting pituitary venous blood from horses. Alexander SL, et al. **Front Neuroendocrinol** 1996 Jan;17(1):1–50 (220 ref.)

CHEMISTRY

Mass spectrometry, high performance liquid chromatography, and brain peptides. Desiderio DM. **Biopolymers** 1996;40(3):257–64 (45 ref.)

DRUG EFFECTS

Novel aspects of GnRH-induced intracellular signaling and secretion in pituitary gonadotrophs. Stojilkovic SS, et al. **J Neuroendocrinol** 1995 Oct;7(10):739–57 (110 ref.)

EMBRYOLOGY

Molecular aspects of the ontogeny of the pituitary–gonadal axis. Huhtaniemi I. **Reprod Fertil Dev** 1995;7(5):1025–35 (57 ref.)

Hypothalamic pituitary adrenal function in the sheep fetus. Matthews SG, et al. **Reprod Fertil Dev** 1995;7(3):509–16 (52 ref.)

METABOLISM

Modulatory actions of corticotropin–releasing factor–binding protein. Behan DP, et al. **Ann N Y Acad Sci** 1996 Mar 22;780:81–95 (55 ref.)

Endocrine interaction between zinc and prolactin. An interpretative review. Brandão–Neto J, et al. **Biol Trace Elem Res** 1995 Aug–Sep;49(2–3):139–49 (57 ref.)

Somatostatin modulates voltage–dependent Ca2+ channels in GH3 cells via a specific G(o) splice variant. Kleuss C. **Ciba Found Symp** 1995;190:171–82; discussion 182–6 (38 ref.)

IGF–I receptor signalling: lessons from the somatotroph. Melmed S, et al. **Recent Prog Horm Res** 1996;51:189–215; discussion 215–6 (65 ref.)

PHYSIOLOGY

Characterization of corticotropin–releasing factor receptor subtypes. Grigoriadis DE, et al. **Ann N Y Acad Sci** 1996 Mar 22;780:60–80 (60 ref.)

Dynamics of the regulation of the hypothalamo–pituitary–adrenal (HPA) axis determined using a nonsurgical method for collecting pituitary venous blood from horses. Alexander SL, et al. **Front Neuroendocrinol** 1996 Jan;17(1):1–50 (220 ref.)

IGFs in the feedback control of GH secretion: Hypothalamic and/or pituitary action? [editorial] Ceda GP. **J Endocrinol Invest** 1995 Oct;18(9):734–7 (26 ref.)

The endocrinology of the menopause. Burger HG. **Maturitas** 1996 Mar;23(2):129–36 (44 ref.)

Modulation of pulsatile GH release through a novel receptor in hypothalamus and pituitary gland. Smith RG, et al. **Recent Prog Horm Res** 1996;51:261–85; discussion 285–6 (59 ref.)

PHYSIOPATHOLOGY

Antidepressants and hypothalamic–pituitary–adrenocortical regulation. Holsboer F, et al. **Endocr Rev** 1996 Apr; 17(2):187–205 (237 ref.)

Canine pituitary–dependent hyperadrenocorticism: a spontaneous animal model for neurodegenerative disorders and their treatment with 1–deprenyl. Bruyette DS, et al. **Prog Brain Res** 1995;106:207–15 (30 ref.)

[Pituitary function in hemochromatosis] Pedersen–Bjergaard U, et al. **Ugeskr Laeger** 1996 Mar 25;158(13):1818–22 (35 ref.) (Eng. Abstr.) **(Dan)**

[Endocrine function (pituitary, thyroid, adrenal gland) of obesity] Ogino Y, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:316–9 (13 ref.) **(Jpn)**

[Preservation of gonadotrophic function and pregnancy in Sheehan's syndrome: a case report and review of the literature] Vieira HB, et al. **Rev Assoc Med Bras** 1995 Mar–Apr;41(2):135–8 (17 ref.) (Eng. Abstr.) **(Por)**

SECRETION

Interaction between sleep and growth hormone. Evaluated by manual polysomnography and automatic power spectrum analysis. Aström C. **Acta Neurol Scand** 1995 Oct; 92(4):281–96 (103 ref.)

Influence of thyroid hormones on the regulation of growth hormone secretion. Giustina A, et al. **Eur J Endocrinol** 1995 Dec;133(6):646–53 (52 ref.)

PITUITARY GLAND, ANTERIOR

BLOOD SUPPLY

Blood supply, blood flow and autoregulation in the adenohypophysis, and altered patterns in oestrogen–induced adenomatous hyperplasia. Jakubowski J. **Br J Neurosurg** 1995;9(3):331–46 (103 ref.)

CYTOLOGY

Anterior pituitary cells: getting to know their neighbors. Perez FM, et al. **Mol Cell Endocrinol** 1995 Jun;111(2):C1–6 (41 ref.)

DRUG EFFECTS

Anterior pituitary function during critical illness and dopamine treatment. Van den Berghe G, et al. **Crit Care Med** 1996 Sep;24(9):1580–90 (178 ref.)

METABOLISM

Control of growth hormone synthesis. Tuggle CK, et al. **Domest Anim Endocrinol** 1996 Jan;13(1):1–33 (256 ref.)

The role of transcription factors in the pituitary expression of the glycoprotein hormone alpha–subunit gene. Aylwin SJ, et al. **J Mol Endocrinol** 1995 Dec;15(3):221–31 (82 ref.)

PHYSIOLOGY

Oxytocin and the anterior pituitary gland. Samson WK, et al. **Adv Exp Med Biol** 1995;395:355–64 (63 ref.)

Blood supply, blood flow and autoregulation in the adenohypophysis, and altered patterns in oestrogen–induced adenomatous hyperplasia. Jakubowski J. **Br J Neurosurg** 1995;9(3):331–46 (103 ref.)

Anterior pituitary function during critical illness and dopamine treatment. Van den Berghe G, et al. **Crit Care Med** 1996 Sep;24(9):1580–90 (178 ref.)

Pituitary adenylate cyclase–activating polypeptide (PACAP) and PACAP/vasoactive intestinal polypeptide receptors: actions on the anterior pituitary gland. Rawlings SR, et al. **Endocr Rev** 1996 Feb;17(1):4–29 (170 ref.)

Anterior pituitary cells: getting to know their neighbors. Perez FM, et al. **Mol Cell Endocrinol** 1995 Jun;111(2):C1–6 (41 ref.)

The role of the growth and lactogenic hormone family in immune function. Berczi I. **Neuroimmunomodulation** 1994 Jul–Aug;1(4):201–16 (182 ref.)

SECRETION

[Prolactin and female gonadal endocrine regulation] Takeya U. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Aug; 47(8):824–32 (28 ref.) **(Jpn)**

SURGERY

[Role of hormonal exploration in avoiding of the failures of anterior pituitary gland surgery in Cushing disease] Bachelot I, et al. **Ann Endocrinol (Paris)** 1995;56(6):620–4 (15 ref.) (Eng. Abstr.) **(Fre)**

PITUITARY GLAND, POSTERIOR

ABNORMALITIES

Posterior pituitary ectopia and hypopituitarism--magnetic resonance appearances of four cases and a review of the literature. Denton ER, et al. **Br J Radiol** 1996 May; 69(821):402–6 (31 ref.)

PHYSIOLOGY

The neurohypophysial endocrine regulatory cascade: precursors, mediators, receptors, and effectors. Acher R, et al. **Front Neuroendocrinol** 1995 Jul;16(3):237–89 (236 ref.)

PHYSIOPATHOLOGY

[Water–electrolyte imbalance and posterior pituitary gland hormone] Yoshida S. **Nippon Naika Gakkai Zasshi** 1995 Sep 10;84(9):1388–95 (20 ref.) **(Jpn)**

PITUITARY GLYCOPROTEIN HORMONE, ALPHA SUBUNIT see **GLYCOPROTEIN HORMONES, ALPHA SUBUNIT**

PITUITARY GONADOTROPIN RECEPTORS see **RECEPTORS, GONADOTROPIN**

PITUITARY GROWTH HORMONE see **SOMATOTROPIN**

PITUITARY HORMONE RECEPTORS see **RECEPTORS, PITUITARY HORMONE**

PITUITARY HORMONE–RELEASING HORMONES

CHEMISTRY

Mass spectrometry, high performance liquid chromatography, and brain peptides. Desiderio DM. **Biopolymers** 1996;40(3):257–64 (45 ref.)

PITUITARY HORMONES

see related
HYPOPITUITARISM
RECEPTORS, PITUITARY HORMONE

GENETICS

The molecular pathology of pituitary hormone deficiency and resistance. Woods KA, et al. **Baillieres Clin Endocrinol Metab** 1995 Jul;9(3):453–87 (140 ref.)

PHARMACOLOGY

Extrapulmonary effects of antenatally administered steroids. Padbury JF, et al. **J Pediatr** 1996 Feb;128(2):167–72 (61 ref.)

PHYSIOLOGY

[Gastric stress ulcers: the protective role of hormones of the hypothalamo–hypophyseal–adrenocortical system] Filaretova LP. **Fiziol Zh Im I M Sechenova** 1995 Mar; 81(3):50–60 (80 ref.) (Eng. Abstr.) **(Rus)**

SECRETION

Mechanism of action of cytokines to induce the pattern of pituitary hormone secretion in infection. McCann SM, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:386–95 (29 ref.)

Induction by cytokines of the pattern of pituitary hormone secretion in infection. McCann SM, et al. **Neuroimmunomodulation** 1994 Jan;1(1):2–13 (50 ref.)

PITUITARY HORMONES, ANTERIOR

SECRETION

Spontaneous episodic release of adenohypophyseal hormones in hypothalamic amenorrhea. Genazzani AD, et al. **Gynecol Endocrinol** 1995 Dec;9(4):325–34 (63 ref.)

PITUITARY HORMONES, POSTERIOR

see related
NEUROPHYSINS

METABOLISM

[Water homeostasis in amphibia: vasotocin and hydrins] Acher R. **C R Seances Soc Biol Fil** 1995;189(2):199–214 (59 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

The neurohypophysial endocrine regulatory cascade: precursors, mediators, receptors, and effectors. Acher R, et al. **Front Neuroendocrinol** 1995 Jul;16(3):237–89 (236 ref.)

PITUITARY NEOPLASMS

BLOOD SUPPLY

Blood supply, blood flow and autoregulation in the adenohypophysis, and altered patterns in oestrogen–induced adenomatous hyperplasia. Jakubowski J. **Br J Neurosurg** 1995;9(3):331–46 (103 ref.)

CHEMICALLY INDUCED

Lactotroph hyperplasia in an estrogen treated male–to–female transsexual patient. Serri O, et al. **J Clin Endocrinol Metab** 1996 Sep;81(9):3177–9 (12 ref.)

COMPLICATIONS

[A case of pituitary adenoma progressing to pituitary apoplexy on the occasion of cerebral angiography] Suga T, et al. **No Shinkei Geka** 1996 May;24(5):475–9 (12 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Distinction of masses involving the sella and suprasellar space: specificity of imaging features. Donovan JL, et al. **AJR Am J Roentgenol** 1996 Sep;167(3):597–603 (69 ref.)

Diagnosis and management of nonfunctioning pituitary tumors. Greenman Y, et al. **Annu Rev Med** 1996;47:95–106 (51 ref.)

Diagnosis and drug therapy of prolactinoma. Ciccarelli E, et al. **Drugs** 1996 Jun;51(6):954–65 (63 ref.)

Differential diagnosis and treatment of steroid–induced affective syndromes. Pies R. **Ges Hosp Psychiatry** 1995 Sep;17(5):353–61 (27 ref.)

[Prolactinoma; diagnosis and treatment] van der Lely AJ, et al. **Ned Tijdschr Geneeskd** 1996 Jul 13;140(28):1445–9

(53 ref.) (Dut)
[Cystic ectopic pituitary adenoma: report of a case] Akimoto J, et al. **No To Shinkei** 1995 Nov;47(11):1092–7 (12 ref.) (Eng. Abstr.) (Jpn)

DRUG THERAPY

Adjuvant therapy for pituitary adenomas: the possible role of photodynamic therapy. Marks PV.
Ann R Coll Surg Engl 1995 Jul;77(4):308–12 (25 ref.)
Diagnosis and drug therapy of prolactinoma. Ciccarelli E, et al. **Drugs** 1996 Jun;51(6):954–65 (63 ref.)
[The therapy of a macroprolactinoma with the intramuscular application of a long-acting bromocriptine preparation] Kreft B, et al. **Dtsch Med Wochenschr** 1996 Jul 5; 121(27):865–8 (10 ref.) (Eng. Abstr.) (Ger)

EPIDEMIOLOGY

Pituitary adenomas in childhood and adolescence. Mindermann T, et al. **J Pediatr Endocrinol Metab** 1995 Apr–Jun;8(2):79–83 (39 ref.)

GENETICS

The classification and molecular biology of pituitary adenomas. Thapar K, et al. **Adv Tech Stand Neurosurg** 1995; 22:3–53 (130 ref.)
[Familial pituitary tumors] Yoshimoto K, et al.
Nippon Rinsho 1995 Nov;53(11):2691–6 (21 ref.) (Eng. Abstr.) (Jpn)

PATHOLOGY

Ganglion cell–containing tumors of the pituitary gland. Towfighi J, et al. **Arch Pathol Lab Med** 1996 Apr; 120(4):369–77 (44 ref.)
Prolactin-secreting pituitary carcinoma with implants in the cheek pouch and metastases to the ovaries. A case report and literature review. Gollard R, et al. **Cancer** 1995 Nov 15;76(10):1814–20 (43 ref.)
Carcinomas of the pituitary: definition and review of the literature. Lübke D, et al. **Gen Diagn Pathol** 1995 Oct; 141(2):81–92 (83 ref.)
Pituitary lesions in multiple endocrine neoplasia syndrome (MENS) type 1. Capella C, et al. **Pathol Res Pract** 1995 May;191(4):345–7 (27 ref.)
Null cell adenomas and oncocytomas of the pituitary gland. Holm R. **Pathol Res Pract** 1995 May;191(4):348–52 (38 ref.)
[Retrospect and prospect of endocrinological pathology] Tan Y. **Chung Hua Ping Li Hsueh Tsa Chih** 1995 Aug; 24(4):239–41 (21 ref.) (Chi)
[Prolactin producing hypophyseal carcinoma. Case report of an extremely rare metastatic tumor] Saeger W, et al. **Pathologe** 1995 Sep;16(5):354–8 (19 ref.) (Eng. Abstr.) (Ger)

RADIONUCLIDE IMAGING

Remission of acromegaly caused by pituitary carcinoma after surgical excision of growth hormone–secreting metastasis detected by 111-indium pentetreotide scan. Greenman Y, et al. **J Clin Endocrinol Metab** 1996 Apr;81(4):1628–33 (29 ref.)

SECONDARY

Pituitary gland metastases. Sioutos P, et al.
Ann Surg Oncol 1996 Jan;3(1):94–9 (31 ref.)

SECRETION

Thyrotropin-secreting pituitary tumors in hyper- and hypothyroidism. Beck-Peccoz P, et al.
Acta Med Austriaca 1996;23(1–2):41–6 (45 ref.)

SURGERY

Recovery of vision following transsphenoidal surgery for pituitary adenomas. Powell M. **Br J Neurosurg** 1995; 9(3):367–73 (7 ref.)
Remission of acromegaly caused by pituitary carcinoma after surgical excision of growth hormone–secreting metastasis detected by 111-indium pentetreotide scan. Greenman Y, et al. **J Clin Endocrinol Metab** 1996 Apr;81(4):1628–33 (29 ref.)
Benign brain tumors. Meningiomas, pituitary tumors, and acoustic neuromas. Black PM. **Neurol Clin** 1995 Nov; 13(4):927–52 (115 ref.)
Delayed onset of hyponatremia after transsphenoidal surgery for pituitary adenomas. Taylor SL, et al. **Neurosurgery** 1995 Oct;37(4):649–53; discussion 653–4 (26 ref.)
Expanding intracerebral hematoma from pituitary adenoma: case report. Wakai S, et al. **Neurosurgery** 1995 Oct; 37(4):807–8; discussion 808–9 (2 ref.)
Gamma Knife treatment of pituitary adenomas. Ganz JC. **Stereotact Funct Neurosurg** 1995;64 Suppl 1:3–10 (38 ref.)

THERAPY

[Prolactinoma; diagnosis and treatment] van der Lely AJ, et al. **Ned Tijdschr Geneeskd** 1996 Jul 13;140(28):1445–9 (53 ref.) (Dut)
[Prolactinoma and pregnancy. Six cases and review of the literature] Helie C, et al.
J Gynecol Obstet Biol Reprod (Paris) 1996;25(2):174–8 (27 ref.) (Eng. Abstr.) (Fre)
[The treatment of prolactinomas during pregnancy and the lactation period] Rau H, et al. **Dtsch Med Wochenschr** 1996 Jan 5;121(1–2):28–32 (46 ref.) (Ger)
[Treatment of hypothalamic–pituitary tumors––experiences at Hiroshima University School of Medicine] Uozumi T. **Nippon Naibunpi Gakkai Zasshi** 1995 Nov 20;71(7):1019–36 (43 ref.) (Eng. Abstr.) (Jpn)

PITUITRIN see **PITUITARY HORMONES, POSTERIOR**

PITYRIASIS ROSEA

Pityriasis rosea. Allen RA, et al. **Cutis** 1995 Oct;56(4):198–202 (70 ref.)

PITYRIASIS RUBRA PILARIS

COMPLICATIONS

Pityriasis rubra pilaris and human immunodeficiency virus infection. Miralles ES, et al. **Br J Dermatol** 1995 Dec; 133(6):990–3 (14 ref.)

PITYRIASIS VERSICOLOR see **TINEA VERSICOLOR**

PITYROSPORUM see **MALASSEZIA**

PIXE see **SPECTROMETRY, X-RAY EMISSION**

PLACEBO EFFECT

Harnessing the power of the placebo effect and renaming it "remembered wellness". Benson H, et al.
Annu Rev Med 1996;47:193–9 (18 ref.)
Placebo effects. Issues for clinical practice in psychiatry and medicine. Straus JL, et al. **Psychosomatics** 1996 Jul–Aug; 37(4):315–26 (121 ref.)

PLACEBOS

THERAPEUTIC USE

Placebo effects. Issues for clinical practice in psychiatry and medicine. Straus JL, et al. **Psychosomatics** 1996 Jul–Aug; 37(4):315–26 (121 ref.)

PLACENTA

see related
MATERNAL-FETAL EXCHANGE
UTEROPLACENTAL CIRCULATION

Placental site trophoblastic tumor: three case reports and literature review. Denny LA, et al. **Gynecol Oncol** 1995 Nov;59(2):300–3 (15 ref.)

ABNORMALITIES

Zonary placenta. Steemers NY, et al.
Int J Gynaecol Obstet 1995 Dec;51(3):251–3 (3 ref.)

BLOOD SUPPLY

Selected vascular lesions of the placenta. Gersell DJ.
Clin Lab Med 1995 Sep;15(3):611–29 (73 ref.)
Current topic: in vivo investigation of the placental circulations by Doppler echography [see comments] Jauniaux E, et al. **Placenta** 1995 Jun;16(4):323–31 (52 ref.)
Comment in: Placenta 1995 Jun;16(4):333–4.
Interrelationships between the renin angiotensin system and uteroplacental blood flow––a recent perspective. Binder ND, et al. **Reprod Fertil Dev** 1995;7(6):1437–42 (55 ref.)
Regulation of human placental fetal vessel tone: role of nitric oxide. King RG, et al. **Reprod Fertil Dev** 1995;7(6):1407–11 (56 ref.)
Advances in understanding permeability in fetal capillaries of the human placenta: a review of organization of the endothelial paracellular clefts and their junctional complexes. Leach L, et al. **Reprod Fertil Dev** 1995; 7(6):1451–6 (51 ref.)

ENZYMOLOGY

Placental 11 beta-hydroxysteroid dehydrogenase and the programming of hypertension. Seckl JR, et al.
J Steroid Biochem Mol Biol 1995 Dec;55(5–6):447–55 (104 ref.)
Interaction between pregnancy-induced bioactive peptides and the placental proteases. Mizutani S, et al.
Reprod Fertil Dev 1995;7(6):1431–6 (26 ref.)

GROWTH & DEVELOPMENT

Maternal nutrition in relation to fetal and placental growth. Godfrey KM, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Jul;61(1):15–22 (62 ref.)
Ontogenic changes in the nutritive function of the placenta. Schneider H. **Placenta** 1996 Jan;17(1):15–26 (135 ref.)

METABOLISM

Regulation of utero-placental prorenin. Poisner AM.
Adv Exp Med Biol 1995;377:411–26 (96 ref.)
Placental steroid hormone synthesis: unique features and unanswered questions. Strauss JF 3rd, et al.
Biol Reprod 1996 Feb;54(2):303–11 (73 ref.)
Placental isoferritin: a new biomarker from conception to delivery. Maymon R, et al. **Br J Obstet Gynaecol** 1996 Apr;103(4):301–5 (29 ref.)
Actions of placental and fetal adrenal steroid hormones in primate pregnancy. Pepe GJ, et al. **Endocr Rev** 1995 Oct; 16(5):608–48 (617 ref.)
Inhibin and activin production in human placenta. Qu J, et al. **Endocr Rev** 1995 Aug;16(4):485–507 (258 ref.)
Comparative aspects of placental exchange functions. Schröder HJ. **Eur J Obstet Gynecol Reprod Biol** 1995 Nov; 63(1):81–90 (25 ref.)
Are estradiol-producing cells incompletely endowed? A chronicle of the emergence of certitude from conjecture. Lieberman S. **Gynecol Obstet Invest** 1996;41(3):147–72 (152 ref.)
Placental permeability for drugs of abuse and their metabolites. Olsen GD. **NIDA Res Monogr** 1995;154:152–62 (45 ref.)
Pharmacodynamics in the maternal–fetal–placental unit. Rudolph AM. **NIDA Res Monogr** 1995;154:163–74 (15 ref.)
Current topic: the placental corticotrophin-releasing hormone–adrenocorticotrophin axis. Challis JR, et al.
Placenta 1995 Sep;16(6):481–502 (98 ref.)
Regulation of placental metabolism by glucose supply. Hay WW Jr. **Reprod Fertil Dev** 1995;7(3):365–75 (45 ref.)
Placental nitric oxide metabolism. Sooranna SR, et al.
Reprod Fertil Dev 1995;7(6):1525–31 (38 ref.)

PATHOLOGY

Risk of fetal mosaicism when placental mosaicism is diagnosed by chorionic villus sampling. Phillips OP, et al.
Am J Obstet Gynecol 1996 Mar;174(3):850–5 (24 ref.)
Mechanism of visceral damage in fetofetal transfusion syndrome. Rehan VK, et al.
Arch Dis Child Fetal Neonatal Ed 1995 Jul;73(1):F48–50 (32 ref.)
Selected vascular lesions of the placenta. Gersell DJ.
Clin Lab Med 1995 Sep;15(3):611–29 (73 ref.)
Placental changes in a first trimester missed abortion in maternal systemic lupus erythematosus with antiphospholipid syndrome; a case report and review of the literature. Nayar R, et al. **Hum Pathol** 1996 Feb; 27(2):201–6 (36 ref.)
Placental pathology casebook. Liveborn twin of an extramembranous pregnancy. Baergen RN, et al.
J Perinatol 1995 Nov–Dec;15(6):510–3 (7 ref.)
Sonography of the placenta with emphasis on pathological correlation. Harris RD, et al. **Semin Ultrasound CT MR** 1996 Feb;17(1):66–89 (39 ref.)

PHYSIOLOGY

Peptide signaling in human placenta and membranes: autocrine, paracrine, and endocrine mechanisms. Petraglia F, et al. **Endocr Rev** 1996 Apr;17(2):156–86 (431 ref.)
The fetal and infant origins of disease. Barker DJ.
Eur J Clin Invest 1995 Jul;25(7):457–63 (51 ref.)
The temporary anatomical structures prominent in the first trimester may be fulfilling exchange functions assigned to the placenta in the second and third trimester. Docherty SM, et al. **Hum Reprod** 1996 Jun;11(6):1157–61 (38 ref.)
Conference report: placental growth and function. Challis JR, et al. **Placenta** 1995 Jul;16(5):471–5 (1 ref.)
Hepatocyte growth factor/scatter factor and the placenta. Uehara Y, et al. **Placenta** 1996 Mar–Apr;17(2–3):97–101 (64 ref.)
Role of epidermal growth factor (EGF) and its receptor in the development of the human placenta. Maruo T, et al.
Reprod Fertil Dev 1995;7(6):1465–70 (15 ref.)
Placental control of fetal growth. Robinson J, et al.
Reprod Fertil Dev 1995;7(3):333–44 (133 ref.)
The placenta and the control of fetal breathing movements. Thorburn GD. **Reprod Fertil Dev** 1995;7(3):577–94 (107 ref.)

PHYSIOPATHOLOGY

The physiology of pre-eclampsia. Brown MA.
Clin Exp Pharmacol Physiol 1995 Nov;22(11):781–91 (85 ref.)

SECRETION

[Corticotropin-releasing hormone in pregnancy] Sun G.
Sheng Li Ko Hsueh Chin Chan 1995 Jul;26(3):270–2 (10 ref.) (Chi)

PLACENTA ACCRETA

[Placenta accreta. Ten cases] Benzineb N, et al.
J Gynecol Obstet Biol Reprod (Paris) 1995;24(7):751–5 (24 ref.) (Eng. Abstr.) (Fre)

PLACENTA DISEASES

[Placental chorioangioma. Two cases and review of the literature] Rousseau O, et al.
J Gynecol Obstet Biol Reprod (Paris) 1995;24(5):529–33 (27 ref.) (Eng. Abstr.) (Fre)

COMPLICATIONS

Asphyxia. Mac Donald D.
Baillieres Clin Obstet Gynaecol 1995 Sep;9(3):579–94 (65

PLACENTA DISEASES

ref.)

PATHOLOGY

Selected vascular lesions of the placenta. Gersell DJ. **Clin Lab Med** 1995 Sep;15(3):611-29 (73 ref.)
Gestational trophoblastic disease. New approaches to diagnosis. Lage JM, et al. **Clin Lab Med** 1995 Sep; 15(3):631-64 (50 ref.)
Sonography of the placenta with emphasis on pathological correlation. Harris RD, et al. **Semin Ultrasound CT MR** 1996 Feb;17(1):66-89 (39 ref.)
[Non-trophoblastic tumors of the placenta] Dukovski A. **Akush Ginekol (Sofiia)** 1994;33(2):40-3 (28 ref.) **(Bul)**

ULTRASONOGRAPHY

Sonography of the placenta with emphasis on pathological correlation. Harris RD, et al. **Semin Ultrasound CT MR** 1996 Feb;17(1):66-89 (39 ref.)

PLACENTA, RETAINED

DRUG THERAPY

Intraumbilical vein injection of prostaglandin F2 alpha in retained placenta. Bider D, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Jan;64(1):59-61 (13 ref.)

PLACENTAL ANTICOAGULANT PROTEIN I see ANNEXIN V

PLACENTAL ANTICOAGULANT PROTEINS see ANNEXINS

PLACENTAL INSUFFICIENCY

ETIOLOGY

[Basic pathogenetic mechanisms of chronic placental insufficiency] Milovanov AP, et al. **Arkh Patol** 1995 Jul-Aug;57(4):11-6 (54 ref.) (Eng. Abstr.) **(Rus)**

PATHOLOGY

Placental pathology casebook. Liveborn twin of an extramembranous pregnancy. Baergen RN, et al. **J Perinatol** 1995 Nov-Dec;15(6):510-3 (7 ref.)

PLACENTAL LACTOGEN

see related
RECEPTORS, SOMATOTROPIN

BLOOD

[Human placental lactogen (hPL)] Mochizuki M. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:600-3 (8 ref.) **(Jpn)**

PLACENTAL PROTEINS see PREGNANCY PROTEINS

PLACENTAL-SITE TROPHOBLASTIC TUMOR see TROPHOBLASTIC TUMOR, PLACENTAL SITE

PLACENTATION

IMMUNOLOGY

[Regulation by maternally derived cytokines of pre-implantation development and uterine receptiveness] Stewart CL, et al. **Contracept Fertil Sex** 1995 Sep; 23(9):555-61 (37 ref.) (Eng. Abstr.) **(Fre)**

PLACENTOMA, NORMAL see PLACENTA

PLACENTOME see PLACENTA

PLAGUE

MICROBIOLOGY

Relationship between virulence and immunity as revealed in recent studies of the F1 capsule of Yersinia pestis. Friedlander AM, et al. **Clin Infect Dis** 1995 Oct;21 Suppl 2:S178-81 (28 ref.)
[Shibasaburo Kitasato's discovery of plague bacillus and its historical background--on the occasion of the centennial anniversary] Nakase Y. **Nippon Saikingaku Zasshi** 1995 Jul; 50(3):637-50 (53 ref.) **(Jpn)**
[The problem of natural foci of plague: the search for ways for its resolution (editorial)] Lomaradskil IV, et al. **Med Parazitol (Mosk)** 1995 Oct-Dec;(4):3-9 (46 ref.) (Eng. Abstr.) **(Rus)**

PLANETS

see related
EXTRATERRESTRIAL ENVIRONMENT

PLANKTON

CLASSIFICATION

Molecular identification of nanoplanktonic protists based on small subunit ribosomal RNA gene sequences for ecological studies. Lim EL. **J Eukaryot Microbiol** 1996 Mar-Apr; 43(2):101-6 (47 ref.)

GENETICS

Molecular identification of nanoplanktonic protists based on small subunit ribosomal RNA gene sequences for ecological studies. Lim EL. **J Eukaryot Microbiol** 1996 Mar-Apr; 43(2):101-6 (47 ref.)

PLANNED PARENTHOOD see FAMILY PLANNING

PLANNING, HEALTH AND WELFARE see HEALTH PLANNING

PLANNING TECHNIQUES

see related
HEALTH PLANNING

Information systems and strategic management. Austin CJ, et al. **Health Care Manage Rev** 1995 Summer;20(3):26-33; discussion 34-42 (17 ref.)
Strategic planning in hospitals: a review and proposal. Bruton GD, et al. **Health Care Manage Rev** 1995 Summer; 20(3):16-25 (45 ref.)

PLANNING THEORIES see PLANNING TECHNIQUES

PLANT AGGLUTININS see LECTINS

PLANT DISEASES

Inside avirulence [comment] Taylor CB. **Plant Cell** 1996 Jul; 8(7):1091-3 (22 ref.) Comment on: Plant Cell 1996 Jul;8(7):1095-105.

MICROBIOLOGY

Current status of the plasmodiophorids. Braselton JP. **Crit Rev Microbiol** 1995;21(4):263-75 (50 ref.)
Mechanisms of fungicide resistance in phytopathogenic fungi. Steffens JJ, et al. **Curr Opin Biotechnol** 1996 Jun; 7(3):348-55 (77 ref.)
Biological control of plant root pathogens. Thomashow LS. **Curr Opin Biotechnol** 1996 Jun;7(3):343-7 (53 ref.)

VIROLOGY

Immunotherapy of plant viral diseases. Benvenuto E, et al. **Trends Microbiol** 1995 Jul;3(7):272-5 (33 ref.)

PLANT DNA see DNA, PLANT

PLANT EMBRYOS see SEEDS

PLANT EXTRACTS

Recent advances in Annonaceous acetogenins. Zeng L, et al. **Nat Prod Rep** 1996 Aug;13(4):275-306 (177 ref.)

ADMINISTRATION & DOSAGE

[Garlic (Allium sativum)--a potent medicinal plant] Resch KL, et al. **Fortschr Med** 1995 Jul 20;113(20-21):311-5 (43 ref.) (Eng. Abstr.) **(Ger)**

BIOSYNTHESIS

Inositol lipid signal transduction in phytoalexin elicitation. Walton TJ. **Biochem Soc Trans** 1995 Nov;23(4):862-7 (38 ref.)

PHARMACOLOGY

Ayurvedic herbal drugs with possible cytostatic activity. Smit HF, et al. **J Ethnopharmacol** 1995 Jul 7;47(2):75-84 (53 ref.)
The neuroprotective properties of the Ginkgo biloba leaf: a review of the possible relationship to platelet-activating factor (PAF). Smith PF, et al. **J Ethnopharmacol** 1996 Mar; 50(3):131-9 (62 ref.)
Plant-derived triterpenoid sweetness inhibitors. Suttisri R, et al. **J Ethnopharmacol** 1995 Jun 23;47(1):9-26 (109 ref.)
Therapeutic actions of garlic constituents. Agarwal KC. **Med Res Rev** 1996 Jan;16(1):111-24 (132 ref.)
Natural antimutagenic agents. Mitscher LA, et al. **Mutat Res** 1996 Feb 19;350(1):143-52 (38 ref.)
Eukaryotic polypeptide elongation system and its sensitivity to the inhibitory substances of plant origin. Gałasiński W. **Proc Soc Exp Biol Med** 1996 May;212(1):24-37 (189 ref.)

THERAPEUTIC USE

Medical ethnobotany of the Siddis of Uttara Kannada district, Karnataka, India. Bhandary MJ, et al. **J Ethnopharmacol** 1995 Jul 28;47(3):149-58 (15 ref.)
Therapeutic utility, constituents and toxicity of some medicinal plants: a review. Bakhiet AO, et al. **Vet Hum Toxicol** 1995 Jun;37(3):255-8 (76 ref.)
[Phytotherapeutic aspects of diseases of the cardiovascular system. 5. Saponins and possibilities of their use in prevention and therapy] Purmová J, et al. **Ceska Slov Farm** 1995 Oct;44(5):246-51 (53 ref.) (Eng. Abstr.) **(Cze)**
[Medical treatment of benign hypertrophy of the prostate] Bensadoun H. **Presse Med** 1995 Oct 28;24(32):1485-9 (16 ref.) (Eng. Abstr.) **(Fre)**
[St. John's wort as antidepressive therapy] Ernst E. **Fortschr Med** 1995 Sep 10;113(25):354-5 (13 ref.) (Eng. Abstr.) **(Ger)**
[Phytopharmaceutic drugs in treatment of sleep disorders] Nachtmann A, et al. **Internist (Berl)** 1996 Jul;37(7):743-9 (50 ref.) **(Ger)**
[Current drug therapy of benign prostatic hyperplasia] Schmidbauer CP, et al. **Wien Med Wochenschr** 1996; 146(8):161-4 (12 ref.) (Eng. Abstr.) **(Ger)**
[Echinacea drugs--effects and active ingredients] Bauer R. **Z Arztl Fortbild (Jena)** 1996 Apr;90(2):111-5 (23 ref.) (Eng. Abstr.) **(Ger)**
[Clinical application of extracts of Echinacea purpurea or Echinacea pallida. Critical evaluation of controlled clinical studies] Dorsch W. **Z Arztl Fortbild (Jena)** 1996 Apr; 90(2):117-22 (20 ref.) (Eng. Abstr.) **(Ger)**

PLANT EXTRACTS, CHINESE see DRUGS, CHINESE HERBAL

PLANT GENE EXPRESSION REGULATION see GENE EXPRESSION REGULATION, PLANT

PLANT GENES see GENES, PLANT

PLANT GENOME see GENOME, PLANT

PLANT GROWTH REGULATORS

BIOSYNTHESIS

Synthesis of phytohormones by plant-associated bacteria. Costacurta A, et al. **Crit Rev Microbiol** 1995;21(1):1-18 (169 ref.)

CHEMISTRY

[Ethylene--its role in fruit ripening and senescence of blossoms. Biotechnologic aspects] Jakubowicz M. **Postepy Biochem** 1996;42(1):65-72 (70 ref.) **(Pol)**

METABOLISM

Plant hormones: more than one way to detect ethylene. Theologis A. **Curr Biol** 1996 Feb 1;6(2):144-5 (14 ref.)
Green light for steroid hormones [comment] Russell DW. **Science** 1996 Apr 19;272(5260):370-1 (7 ref.) Comment on: Science 1996 Apr 19;272(5260):398-401.
[Ethylene--its role in fruit ripening and senescence of blossoms. Biotechnologic aspects] Jakubowicz M. **Postepy Biochem** 1996;42(1):65-72 (70 ref.) **(Pol)**

PHARMACOLOGY

Phytoestrogens: epidemiology and a possible role in cancer protection. Adlercreutz H. **Environ Health Perspect** 1995 Oct;103 Suppl 7:103-12 (133 ref.)
Genetic analysis of a seedling stress response to ethylene in Arabidopsis. Roman G, et al. **Philos Trans R Soc Lond B Biol Sci** 1995 Oct 30; 350(1331):75-81 (48 ref.)

PHYSIOLOGY

Molecular genetic studies confirm the role of brassinosteroids in plant growth and development. Clouse SD. **Plant J** 1996 Jul;10(1):1-8 (61 ref.)

PLANT HORMONES see PLANT GROWTH REGULATORS

PLANT LICE see APHIDS

PLANT OILS

POISONING

Eosinophilia-myalgia syndrome, toxic-oil syndrome, and diffuse fasciitis with eosinophilia. Kaufman LD, et al. **Curr Opin Rheumatol** 1995 Nov;7(6):560-7 (89 ref.)

THERAPEUTIC USE

Marine and botanical lipids as immunomodulatory and therapeutic agents in the treatment of rheumatoid arthritis. DeLuca P, et al. **Rheum Dis Clin North Am** 1995 Aug; 21(3):759-77 (91 ref.)

PLANT PHOTOSYNTHETIC PROTEIN COMPLEXES see PHOTOSYNTHETIC REACTION CENTER, PLANT

PLANT PHOTOSYNTHETIC REACTION CENTER see PHOTOSYNTHETIC REACTION CENTER, PLANT

PLANT POISONING

[Veno-occlusive disease of small hepatic vein (Bush tea disease)] Saito K, et al. **Ryoikibetsu Shokogun Shirizu** 1995; (8):176-9 (24 ref.) **(Jpn)**

BLOOD

Pennyroyal toxicity: measurement of toxic metabolite levels in two cases and review of the literature. Anderson IB,

et al. **Ann Intern Med** 1996 Apr 15;124(8):726–34 (46 ref.)

COMPLICATIONS

[Severe hyponatremia and hypopotassemia induced by the consumption of Equisetum telmateia (letter)] Miró O, et al. **Med Clin (Barc)** 1996 Apr 27;106(16):639 (2 ref.) **(Spa)**

ETIOLOGY

Oleander toxicity: an examination of human and animal toxic exposures. Langford SD, et al. **Toxicology** 1996 May 3; 109(1):1–13 (76 ref.)

VETERINARY

Plant poisonings and mycotoxicoses as constraints in livestock production in east Africa: the southern African experience. Naudé TW, et al. **J S Afr Vet Assoc** 1996 Mar; 67(1):8–11 (18 ref.)

PLANT PROTEINS

[Role of soybean proteins in human nutrition (review)] Vysotskiĭ VG, et al. **Vopr Pitan** 1995;(5):20–7 (45 ref.) (Eng. Abstr.) **(Rus)**

ANALYSIS

Immunocytochemical localization of receptor protein kinases in plants. Counihan VP, et al. **Methods Cell Biol** 1995; 49:515–29 (25 ref.)

Western blotting analysis. Fido RJ, et al. **Methods Mol Biol** 1995;49:423–37 (24 ref.)

BIOSYNTHESIS

Issues and advances in the use of transgenic organisms for the production of thaumatin, the intensely sweet protein from Thaumatococcus danielli. Zemanek EC, et al. **Crit Rev Food Sci Nutr** 1995 Sep;35(5):455–66 (44 ref.)

CHEMISTRY

Nonenzymatic deamidation of food proteins. Riha WE 3rd, et al. **Crit Rev Food Sci Nutr** 1996 Feb;36(3):225–55 (102 ref.)

Phytochelatins and related peptides. Structure, biosynthesis, and function. Rauser WE. **Plant Physiol** 1995 Dec; 109(4):1141–9 (36 ref.)

GENETICS

Issues and advances in the use of transgenic organisms for the production of thaumatin, the intensely sweet protein from Thaumatococcus danielli. Zemanek EC, et al. **Crit Rev Food Sci Nutr** 1995 Sep;35(5):455–66 (44 ref.)

Co-suppression of beta-1,3-glucanase genes in Nicotiana tabacum. de Carvalho Niebel F, et al. **Curr Top Microbiol Immunol** 1995;197:91–103 (39 ref.)

Suppression of flavonoid flower pigmentation genes in Petunia hybrida by the introduction of antisense and sense genes. de Lange P, et al. **Curr Top Microbiol Immunol** 1995; 197:57–75 (88 ref.)

Developmental regulation of co-suppression in Petunia hybrida. Flavell RB, et al. **Curr Top Microbiol Immunol** 1995;197:43–56 (63 ref.)

Xenopus oocytes as a heterologous expression system. Theodoulou FL, et al. **Methods Mol Biol** 1995;49:317–40 (48 ref.)

Heterologous expression in yeast. Trueman LJ. **Methods Mol Biol** 1995;49:341–54 (18 ref.)

Green light for steroid hormones [comment] Russell DW. **Science** 1996 Apr 19;272(5260):370–1 (7 ref.) Comment on: Science 1996 Apr 19;272(5260):398–401.

Cf9 and Avr9, two major players in the gene-for-gene game. de Wit PJ. **Trends Microbiol** 1995 Jul;3(7):251–2 (15 ref.)

ISOLATION & PURIFICATION

Separation of plant proteins by electrophoresis. Shewry PR, et al. **Methods Mol Biol** 1995;49:399–422 (26 ref.)

Seeing blue: the discovery of cryptochrome. Ahmad M, et al. **Plant Mol Biol** 1996 Mar;30(5):851–61 (84 ref.)

METABOLISM

Shedding light on the chloroplast protein import machinery. Schnell DJ. **Cell** 1995 Nov 17;83(4):521–4 (14 ref.)

Plasmodesmata: intercellular channels for macromolecular transport in plants. Lucas WJ. **Curr Opin Cell Biol** 1995 Oct;7(5):673–80 (48 ref.)

DNA methylation and activity of the maize Spm transposable element. Fedoroff NV. **Curr Top Microbiol Immunol** 1995; 197:143–64 (54 ref.)

URF13, a ligand-gated, pore-forming receptor for T-toxin in the inner membrane of cms-T mitochondria. Rhoads DM, et al. **J Bioenerg Biomembr** 1995 Aug;27(4):437–45 (52 ref.)

Vanadium-dependent haloperoxidases. Vilter H. **Met Ions Biol Syst** 1995;31:325–62 (192 ref.)

Targeting of foreign proteins to the chloroplast. Napier JA. **Methods Mol Biol** 1995;49:369–76 (20 ref.)

Targeting plant toxins to the urokinase and alpha 2-macroglobulin receptors. Cavallaro U, et al. **Semin Cancer Biol** 1995 Oct;6(5):269–78 (60 ref.)

PHYSIOLOGY

The role of the Opaque2 transcriptional factor in the regulation of protein accumulation and amino acid metabolism in maize seeds. Yunes JA, et al. **An Acad Bras Cienc** 1994;66 Su 1 (Pt 2):227–37; quiz 237–8 (60 ref.)

Protein targeting to the plant vacuole--a historical perspective. Dombrowski JE, et al. **Braz J Med Biol Res** 1996 Apr;29(4):413–30 (221 ref.)

Flagellar kinesins: new moves with an old beat. Bernstein M. **Cell Motil Cytoskeleton** 1995;32(2):125–8 (27 ref.)

Regulation of dynein-driven microtubule sliding by an axonemal kinase and phosphatase in Chlamydomonas flagella. Habermacher G, et al. **Cell Motil Cytoskeleton** 1995;32(2):106–9 (23 ref.)

Exploring the function of inner and outer dynein arms with Chlamydomonas mutants. Kamiya R. **Cell Motil Cytoskeleton** 1995;32(2):98–102 (34 ref.)

Photomorphogenesis. Seeing the light in plant development. Terzaghi WB, et al. **Curr Biol** 1995 May 1;5(5):466–8 (11 ref.)

Phytochelatins and related peptides. Structure, biosynthesis, and function. Rauser WE. **Plant Physiol** 1995 Dec; 109(4):1141–9 (36 ref.)

PLANT ROOTS

CYTOLOGY

Root border cells as tools in plant cell studies. Brigham LA, et al. **Methods Cell Biol** 1995;49:377–87 (20 ref.)

The development of cell pattern in the root epidermis. Dolan L, et al. **Philos Trans R Soc Lond B Biol Sci** 1995 Oct 30;350(1331):95–9 (42 ref.)

GROWTH & DEVELOPMENT

Plant development: pulled up by the roots. Dolan L, et al. **Curr Opin Genet Dev** 1995 Aug;5(4):432–8 (37 ref.)

PLANT SHOOTS

GROWTH & DEVELOPMENT

Shoot development in plants: time for a change. Lawson EJ, et al. **Trends Genet** 1995 Jul;11(7):263–8 (32 ref.)

PLANT STRUCTURAL GENES see **GENES, STRUCTURAL, PLANT**

PLANT VIRUSES

Seed transmission of plant viruses: a lesson in biological complexity. Maule AJ, et al. **Trends Microbiol** 1996 Apr; 4(4):153–8 (24 ref.)

GENETICS

Use of plant viruses for delivery of vaccine epitopes. Beachy RN, et al. **Ann N Y Acad Sci** 1996 May 25;792:43–9 (16 ref.)

Early events in virus-plant interactions. Maia IG, et al. **Braz J Med Biol Res** 1994 Nov;27(11):2521–32 (54 ref.)

PCR and non-isotopic labeling techniques for plant virus detection. Fenby NS, et al. **Cell Mol Biol (Noisy-le-grand)** 1995 Jul;41(5):639–52 (94 ref.)

Genetic elements of plant viruses as tools for genetic engineering. Mushegian AR, et al. **Microbiol Rev** 1995 Dec; 59(4):548–78 (375 ref.)

IMMUNOLOGY

Immunotherapy of plant viral diseases. Benvenuto E, et al. **Trends Microbiol** 1995 Jul;3(7):272–5 (33 ref.)

ISOLATION & PURIFICATION

PCR and non-isotopic labeling techniques for plant virus detection. Fenby NS, et al. **Cell Mol Biol (Noisy-le-grand)** 1995 Jul;41(5):639–52 (94 ref.)

PHYSIOLOGY

Vascular movement of plant viruses. Séron K, et al. **Mol Plant Microbe Interact** 1996 Aug;9(6):435–42 (59 ref.)

PLANTAR ULCER see **FOOT ULCER**

PLANTARIS MUSCLE see **MUSCLE, SKELETAL**

PLANTS

see related
HERBICIDES
POLLEN
SEEDS

Phytoestrogens, body composition, and breast cancer. Horn-Ross PL. **Cancer Causes Control** 1995 Nov; 6(6):567–73 (59 ref.)

Recent advances in Annonaceous acetogenins. Zeng L, et al. **Nat Prod Rep** 1996 Aug;13(4):275–306 (177 ref.)

A review of the clinical effects of phytoestrogens. Knight DC, et al. **Obstet Gynecol** 1996 May;87(5 Pt 2):897–904 (90 ref.)

ANATOMY & HISTOLOGY

Vascular movement of plant viruses. Séron K, et al. **Mol Plant Microbe Interact** 1996 Aug;9(6):435–42 (59 ref.)

CHEMISTRY

Isolation and biological activities of signal transduction inhibitors from microorganisms and plants. Umezawa K. **Adv Enzyme Regul** 1995;35:43–53 (35 ref.)

Plant carotenoids and related molecules: important dietary antioxidants. Krinsky NI. **Biochem Soc Symp** 1995; 61:117–26 (47 ref.)

Plant polyphenols: free radical scavengers or chain-breaking antioxidants? Rice-Evans C. **Biochem Soc Symp** 1995; 61:103–16 (53 ref.)

CYTOLOGY

Cytokinesis in higher plants. Staehelin LA, et al. **Cell** 1996 Mar 22;84(6):821–4 (20 ref.)

Confocal epipolarization microscopy of gold probes in plant cells and protoplasts. Griffing LR, et al. **Methods Cell Biol** 1995;49:109–21 (40 ref.)

Monoclonal antibodies to cell-specific cell surface carbohydrates in plant cell biology and development. Pennell RI, et al. **Methods Cell Biol** 1995;49:123–41 (61 ref.)

Genetic tagging of cells and cell layers for studies of plant development. Spena A, et al. **Methods Cell Biol** 1995; 49:331–54 (110 ref.)

Cell-context signalling. Pennell RI, et al. **Philos Trans R Soc Lond B Biol Sci** 1995 Oct 30; 350(1331):87–93 (48 ref.)

In and out of the plant cell cycle. Hirt H. **Plant Mol Biol** 1996 Jun;31(3):459–64 (29 ref.)

DRUG EFFECTS

The effects of near ultraviolet radiation on the toxic effects of polycyclic aromatic hydrocarbons in animals and plants: a review. Arfsten DP, et al. **Ecotoxicol Environ Saf** 1996 Feb;33(1):1–24 (109 ref.)

EMBRYOLOGY

Extracellular matrix and pattern in plant embryos: on the lookout for developmental information. Brownlee C, et al. **Trends Genet** 1995 Sep;11(9):344–8 (52 ref.)

[Molecular cloning of differentially expressed genes during plant somatic embryogenesis] Kayano T, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):721–6 (32 ref.) **(Jpn)**

ENZYMOLOGY

Structure and possible function of aspartic proteinases in barley and other plants. Kervinen J, et al. **Adv Exp Med Biol** 1995;362:241–54 (72 ref.)

Do de-N-glycosylation enzymes have an important role in plant cells? Berger S, et al. **Biochimie** 1995;77(9):751–60 (98 ref.)

The regulation of enzymes involved in chlorophyll biosynthesis. Reinbothe S, et al. **Eur J Biochem** 1996 Apr 15;237(2):323–43 (312 ref.)

Plant lysozymes. Beintema JJ, et al. **EXS** 1996;75:75–86 (52 ref.)

Regulation of alternative oxidase activity in higher plants. Day DA, et al. **J Bioenerg Biomembr** 1995 Aug; 27(4):379–85 (41 ref.)

Structure-function relationships of the alternative oxidase of plant mitochondria: a model of the active site. Moore AL, et al. **J Bioenerg Biomembr** 1995 Aug;27(4):367–77 (70 ref.)

Glycine decarboxylase: protein chemistry and molecular biology of the major protein in leaf mitochondria. Oliver DJ, et al. **J Bioenerg Biomembr** 1995 Aug;27(4):407–14 (57 ref.)

Functional molecular aspects of the NADH dehydrogenases of plant mitochondria. Soole KL, et al. **J Bioenerg Biomembr** 1995 Aug;27(4):397–406 (64 ref.)

Plant lipoxygenases. Shibata D, et al. **J Lipid Mediat Cell Signal** 1995 Oct;12(2-3):213–28 (80 ref.)

Plant homologues of components of MAPK (mitogen-activated protein kinase) signal pathways in yeast and animal cells. Nishihama R, et al. **Plant Cell Physiol** 1995 Jul;36(5):749–57 (100 ref.)

GENETICS

Antibody production and engineering in plants. Ma JK, et al. **Ann N Y Acad Sci** 1996 May 25;792:72–81 (35 ref.)

DNA elements responsive to auxin. Abel S, et al. **Bioessays** 1996 Aug;18(8):647–54 (62 ref.)

Plant genetics: fast flowering. Smyth DR. **Curr Biol** 1996 Feb 1;6(2):122–4 (10 ref.)

Molecular responses to drought and cold stress. Shinozaki K, et al. **Curr Opin Biotechnol** 1996 Apr;7(2):161–7 (64 ref.)

LTR-retrotransposons and MITEs: important players in the evolution of plant genomes. Wessler SR, et al. **Curr Opin Genet Dev** 1995 Dec;5(6):814–21 (65 ref.)

Polymerase chain reaction-based assays for the characterisation of plant genetic resources. Powell W, et al. **Electrophoresis** 1995 Sep;16(9):1726–30 (36 ref.)

Agrobacterium-mediated transfer of geminiviruses to plant

tissues. Boulton MI. **Methods Mol Biol** 1995;49:77–93 (47 ref.)
In vitro transcription of class II promoters in higher plants. Cooke R, et al. **Methods Mol Biol** 1995;49:271–89 (19 ref.)
Chloramphenicol acetyl transferase assay. Davey MR, et al. **Methods Mol Biol** 1995;49:143–8 (11 ref.)
Regulation of Agrobacterium gene manipulation. Dewhurst F. **Methods Mol Biol** 1995;44:369–91 (33 ref.)
Tools for expressing foreign genes in plants. Guerineau F. **Methods Mol Biol** 1995;49:1–32 (82 ref.)
Gene transfer into plant protoplasts by electroporation. Jones H. **Methods Mol Biol** 1995;49:107–12 (10 ref.)
Isolation and characterization of plant genomic DNA sequences via (inverse) PCR amplification. Offringa R, et al. **Methods Mol Biol** 1995;49:181–95 (38 ref.)
Northern analysis and nucleic acid probes. Sabelli PA, et al. **Methods Mol Biol** 1995;49:213–28 (32 ref.)
Gene characterization by southern analysis. Sabelli PA, et al. **Methods Mol Biol** 1995;49:161–80 (39 ref.)
Agrobacterium rhizogenes as a vector for transforming higher plants. Application in Lotus corniculatus transformation. Stougaard J. **Methods Mol Biol** 1995; 49:49–61 (18 ref.)
Enrichment of food staples through plant breeding: a new strategy for fighting micronutrient malnutrition. Bouis H. **Nutr Rev** 1996 May;54(5):131–7 (31 ref.)
Genetic analysis of a seedling stress response to ethylene in Arabidopsis. Roman G, et al.
Philos Trans R Soc Lond B Biol Sci 1995 Oct 30; 350(1331):75–81 (48 ref.)
Inside avirulence [comment] Taylor CB. **Plant Cell** 1996 Jul; 8(7):1091–3 (22 ref.) Comment on: Plant Cell 1996 Jul;8(7):1095–105.
RNA editing in plant organelles: a fertile field. Gray MW. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8157–9 (53 ref.)
A brief history of hemoglobins: plant, animal, protist, and bacteria. Hardison RC. **Proc Natl Acad Sci U S A** 1996 Jun 11;93(12):5675–9 (33 ref.)
The G-box: a ubiquitous regulatory DNA element in plants bound by the GBF family of bZIP proteins. Menkens AE, et al. **Trends Biochem Sci** 1995 Dec;20(12):506–10 (39 ref.)
Shoot development in plants: time for a change. Lawson EJ, et al. **Trends Genet** 1995 Jul;11(7):263–8 (32 ref.)
[Loop-domain organization of genes in eukaryotic chromosomes] Glazkov MV. **Mol Biol (Mosk)** 1995 Sep–Oct;29(5):965–82 (118 ref.) **(Rus)**
[Molecular biological research on the origin of the angiosperms] Bobrova VK, et al. **Zh Obshch Biol** 1995 Nov–Dec;56(6):645–61 (51 ref.) (Eng. Abstr.) **(Rus)**

GROWTH & DEVELOPMENT

Molecular genetic studies confirm the role of brassinosteroids in plant growth and development. Clouse SD. **Plant J** 1996 Jul;10(1):1–8 (61 ref.)
Arabinogalactan proteins and plant differentiation. Kreuger M, et al. **Plant Mol Biol** 1996 Mar;30(6):1077–86 (66 ref.)
Shoot development in plants: time for a change. Lawson EJ, et al. **Trends Genet** 1995 Jul;11(7):263–8 (32 ref.)

METABOLISM

Energy metabolism in plants under water deficits. Zagdańska B. **Acta Biochim Pol** 1995;42(3):281–9 (45 ref.)
The functional relationship of plant lipid-derived second messengers and plant lipid-activated protein kinase. Scherer GF. **Biochem Soc Trans** 1995 Nov;23(4):871–5 (48 ref.)
Recent advances in the biosynthesis of plant fatty acids. Harwood JL. **Biochim Biophys Acta** 1996 May 31; 1301(1–2):7–56 (588 ref.)
ADP-ribosylation reactions in plants. O'Farrell M. **Biochimie** 1995;77(6):486–91 (54 ref.)
Evolution of chlorophyll biosynthesis--the challenge to survive photooxidation. Reinbothe S, et al. **Cell** 1996 Sep 6;86(5):703–5 (14 ref.)
Plasmodesmata: intercellular channels for macromolecular transport in plants. Lucas WJ. **Curr Opin Cell Biol** 1995 Oct;7(5):673–80 (48 ref.)
Isoprene synthesis by plants and animals. Sharkey TD. **Endeavour** 1996;20(2):74–8 (45 ref.)
The regulation of enzymes involved in chlorophyll biosynthesis. Reinbothe S, et al. **Eur J Biochem** 1996 Apr 15;237(2):323–43 (312 ref.)
Carotenoids 3: in vivo function of carotenoids in higher plants. Demmig-Adams B, et al. **FASEB J** 1996 Mar; 10(4):403–12 (57 ref.)
Glutamate transfer RNA: a cofactor for heme and chlorophyll biosynthesis. Madan Kumar A, et al.
Indian J Biochem Biophys 1996 Feb;33(1):30–4 (31 ref.)
The contribution of mitochondria to energetic metabolism in photosynthetic cells. Gardeström P, et al.
J Bioenerg Biomembr 1995 Aug;27(4):415–21 (53 ref.)
Kinetic and regulatory aspects of the function of the alternative oxidase in plant respiration. Krab K.
J Bioenerg Biomembr 1995 Aug;27(4):387–96 (47 ref.)
Transmembrane signaling and phosphoinositides. Cho MH, et al. **Methods Cell Biol** 1995;49:543–54 (50 ref.)
The formation of mRNA 3'-ends in plants. Wu L, et al.
Plant J 1995 Sep;8(3):323–9 (35 ref.)
Ethylene sensors: how perceptive! [comment] Theologis A. **Science** 1995 Dec 15;270(5243):1774 (10 ref.) Comment on: Science 1995 Dec 15;270(5243):1804. Comment on: Science 1995 Dec 15;270(5243):1807–9. Comment on: Science 1995 Dec 15;270(5243):1809–11.
Plasmodesmata: plant channels for molecules on the move [see comments] Zambryski P. **Science** 1995 Dec 22; 270(5244):1943–4 (15 ref.) Comment in: Science 1995 Dec 22;270(5244):1980–3. Comment in: Science 1995 Dec 22;270(5244):1983–5.
Metabolism of myo-inositol phosphates and the alternative pathway in generation of myo-inositol trisphosphate involved in calcium mobilization in plants. Biswas S, et al. **Subcell Biochem** 1996;26:287–316 (203 ref.)
Phosphoinositide turnover and its role in plant signal transduction. Coté GG, et al. **Subcell Biochem** 1996; 26:317–43 (156 ref.)
Inositol phosphates and their metabolism in plants. Murthy PP. **Subcell Biochem** 1996;26:227–55 (90 ref.)
Cyclic AMP, the reluctant messenger in plants. Bolwell GP. **Trends Biochem Sci** 1995 Dec;20(12):492–5 (43 ref.)
[Chlorophyll biogenesis] Tanaka A, et al.
Tanpakushitsu Kakusan Koso 1996 Feb;41(2):136–45 (82 ref.) **(Jpn)**

MICROBIOLOGY

Current status of the plasmodiophorids. Braselton JP.
Crit Rev Microbiol 1995;21(4):263–75 (50 ref.)
Synthesis of phytohormones by plant-associated bacteria. Costacurta A, et al. **Crit Rev Microbiol** 1995;21(1):1–18 (169 ref.)
What makes nodulation signals host-plant specific? Schultze M, et al. **Trends Microbiol** 1995 Oct;3(10):370–2 (24 ref.)
[Pathogenic bacteria common to man and plants: the problem and the facts] Litvin VIu, et al.
Zh Mikrobiol Epidemiol Immunobiol 1996 Mar–Apr; (2):101–4 (45 ref.) **(Rus)**

PHYSIOLOGY

Phosphoinositide signalling in plant and algal responses to physiological stimuli. Crain RC, et al.
Biochem Soc Trans 1995 Nov;23(4):853–6 (28 ref.)
Systemin--a polypeptide defense signal in plants. Schaller A, et al. **Bioessays** 1996 Jan;18(1):27–33 (69 ref.)
Talking through walls: signaling in plant development. Dangl JL, et al. **Cell** 1995 Dec 29;83(7):1071–7 (35 ref.)
Self-incompatibility in flowering plants. Golz JF, et al.
Curr Opin Genet Dev 1995 Oct;5(5):640–5 (38 ref.)
MADS-box genes in plant ontogeny and phylogeny: Haeckel's biogenetic law' revisited. Theissen G, et al.
Curr Opin Genet Dev 1995 Oct;5(5):628–39 (97 ref.)
The origin of the oxidative burst in plants. Bolwell GP, et al. **Free Radic Res** 1995 Dec;23(6):517–32 (49 ref.)
Light signal transduction mediated by phytochromes: preliminary studies and possible approaches. Song PS, et al. **Indian J Biochem Biophys** 1996 Feb;33(1):1–19 (131 ref.)
Characteristics of plant cell walls affecting intake and digestibility of forages by ruminants. Jung HG, et al.
J Anim Sci 1995 Sep;73(9):2774–90 (147 ref.)
How do alterations in plant mitochondrial genomes disrupt pollen development? Conley CA, et al.
J Bioenerg Biomembr 1995 Aug;27(4):447–57 (78 ref.)
Calcium and the generation of plant form. Knight MR, et al. **Philos Trans R Soc Lond B Biol Sci** 1995 Oct 30; 350(1331):83–6 (23 ref.)
Light control of seedling morphogenetic pattern. McNellis TW, et al. **Plant Cell** 1995 Nov;7(11):1749–61 (94 ref.)
Annexins of plant cells. Clark GB, et al. **Plant Physiol** 1995 Dec;109(4):1133–9 (53 ref.)
Lectins as plant defense proteins. Peumans WJ, et al.
Plant Physiol 1995 Oct;109(2):347–52 (27 ref.)
Phytochelatins and related peptides. Structure, biosynthesis, and function. Rauser WE. **Plant Physiol** 1995 Dec; 109(4):1141–9 (36 ref.)
Light-induced signal transduction pathway involving inositol phosphates. Sopory SK, et al. **Subcell Biochem** 1996; 26:345–70 (117 ref.)
Lipoxygenases in plants--their role in development and stress response. Rosahl S. **Z Naturforsch [C]** 1996 Mar–Apr; 51(3–4):123–38 (139 ref.)

ULTRASTRUCTURE

Nuclear matrix isolated from plant cells. Moreno Díaz de la Espina SM. **Int Rev Cytol** 1995;162B:75–139 (172 ref.)

PLANTS, EDIBLE

The diet as a source of dietary fibre. Southgate DA.
Eur J Clin Nutr 1995 Oct;49 Suppl 3:S22–6 (20 ref.)

CHEMISTRY

Nonenzymatic deamidation of food proteins. Riha WE 3rd, et al. **Crit Rev Food Sci Nutr** 1996 Feb;36(3):225–55 (102 ref.)
Cell-wall chemistry and architecture in relation to sources of dietary fibre. Selvendran RR, et al. **Eur J Clin Nutr** 1995 Oct;49 Suppl 3:S27–41 (40 ref.)

IMMUNOLOGY

Type 1 allergic reactions to plant-derived food: a consequence of primary sensitization to pollen allergens. Valenta R, et al. **J Allergy Clin Immunol** 1996 Apr; 97(4):893–5 (29 ref.)

PLANTS, MEDICINAL

see related
ALKALOIDS
PHARMACOGNOSY
PLANT EXTRACTS

The efficacy, history, and politics of medicinal plants. Lipp FJ. **Altern Ther Health Med** 1996 Jul;2(4):36–41 (40 ref.)
Health risks of herbal remedies. De Smet PA. **Drug Saf** 1995 Aug;13(2):81–93 (137 ref.)
Some ethnopharmacological notes on African hallucinogens. De Smet PA. **J Ethnopharmacol** 1996 Mar;50(3):141–6 (50 ref.)
The ethnopharmacopoeia of Rotuma. McClatchey W.
J Ethnopharmacol 1996 Mar;50(3):147–56 (9 ref.)
Psychoactive constituents of the genus Sceletium N.E.Br. and other Mesembryanthemaceae: a review. Smith MT, et al. **J Ethnopharmacol** 1996 Mar;50(3):119–30 (67 ref.)
Plant-derived triterpenoid sweetness inhibitors. Suttisri R, et al. **J Ethnopharmacol** 1995 Jun 23;47(1):9–26 (109 ref.)
Marine natural products research: current directions and future potential. König GM, et al. **Planta Med** 1996 Jun; 62(3):193–211 (160 ref.)
Plant metabolites active against Trypanosoma cruzi. Sepúlveda-Boza S, et al. **Planta Med** 1996 Apr;62(2):98–105 (63 ref.)
[Prospects for application of molecular biotechnique to pharmacognosy] Huang L.
Chung Kuo Chung Yao Tsa Chih 1995 Nov;20(11):643–5, 702 (23 ref.) **(Chi)**
[Progress in the research of plant polysaccharides] Tian G, et al. **Chung Kuo Chung Yao Tsa Chih** 1995 Jul;20(7):441–4 (31 ref.) **(Chi)**
[Therapeutic effectiveness of Crataegus] Weihmayr T, et al. **Fortschr Med** 1996 Jan 20;114(1–2):27–9 (30 ref.) (Eng. Abstr.) **(Ger)**
[Phytopharmaceutic drugs in treatment of sleep disorders] Nachtmann A, et al. **Internist (Berl)** 1996 Jul;37(7):743–9 (50 ref.) **(Ger)**
[Echinacea drugs--effects and active ingredients] Bauer R. **Z Arztl Fortbild (Jena)** 1996 Apr;90(2):111–5 (23 ref.) (Eng. Abstr.) **(Ger)**
[Clinical application of extracts of Echinacea purpurea or Echinacea pallida. Critical evaluation of controlled clinical studies] Dorsch W. **Z Arztl Fortbild (Jena)** 1996 Apr; 90(2):117–22 (20 ref.) (Eng. Abstr.) **(Ger)**
[A complex antibiotic preparation obtained from a medicinal plant from the family Asteraceae] Smirnov VV, et al.
Mikrobiol Z 1995 Jul–Aug;57(4):73–82 (29 ref.) (Eng. Abstr.) **(Rus)**
[Severe hyponatremia and hypopotassemia induced by the consumption of Equisetum telmateia (letter)] Miró O, et al. **Med Clin (Barc)** 1996 Apr 27;106(16):639 (2 ref.) **(Spa)**

CHEMISTRY

Saffron chemoprevention in biology and medicine: a review. Nair SC, et al. **Cancer Biother** 1995 Winter;10(4):257–64 (41 ref.)
Amoebicidal compounds from medicinal plants. Di Stasi LC.
Parassitologia 1995 Apr;37(1):29–39 (56 ref.)
Therapeutic utility, constituents and toxicity of some medicinal plants: a review. Bakhiet AO, et al.
Vet Hum Toxicol 1995 Jun;37(3):255–8 (76 ref.)
[Advances in the study of the chemical constituents of gardenia] Wang G, et al.
Chung Kuo Chung Yao Tsa Chih 1996 Feb;21(2):67–9, 72 (34 ref.) **(Chi)**

CLASSIFICATION

Medical ethnobotany of the Siddis of Uttara Kannada district, Karnataka, India. Bhandary MJ, et al.
J Ethnopharmacol 1995 Jul 28;47(3):149–58 (15 ref.)

PLANTS, TOXIC

see related
PLANT POISONING

Lectins as plant defense proteins. Peumans WJ, et al.
Plant Physiol 1995 Oct;109(2):347–52 (27 ref.)
Plant dermatitis. Possible culprits go far beyond poison ivy. Juckett G. **Postgrad Med** 1996 Sep;100(3):159–63, 167–71 (20 ref.)
Oleander toxicity: an examination of human and animal toxic exposures. Langford SD, et al. **Toxicology** 1996 May 3; 109(1):1–13 (76 ref.)

CHEMISTRY

Directly toxic effects of plant chemicals which may occur in human and animal foods. Seawright AA. **Nat Toxins** 1995;3(4):227–32; discussion 242 (54 ref.)
Toxicological data needed for safety evaluation and regulation on inherent plant toxins. Speijers GJ.
Nat Toxins 1995;3(4):222–6; discussion 242 (9 ref.)

PLANTS, TRANSGENIC

Genetic modification of plants: significant issues and hurdles to success. Day PR. **Am J Clin Nutr** 1996 Apr;

63(4):651S–6S (34 ref.)
NPTII assays for measuring gene expression and enzyme activity in transgenic plants. Curtis IS, et al. **Methods Mol Biol** 1995;49:149–59 (20 ref.)
Western blotting analysis. Fido RJ, et al. **Methods Mol Biol** 1995;49:423–37 (24 ref.)
Leaf disk transformation using Agrobacterium tumefaciens–expression of heterologous genes in tobacco. Gallois P, et al. **Methods Mol Biol** 1995;49:39–48 (32 ref.)
The beta–glucuronidase (gus) reporter gene system. Gene fusions; spectrophotometric, fluorometric, and histochemical detection. Hull GA, et al. **Methods Mol Biol** 1995;49:125–41 (35 ref.)
Gene characterization by southern analysis. Sabelli PA, et al. **Methods Mol Biol** 1995;49:161–80 (39 ref.)
Agrobacterium rhizogenes as a vector for transforming higher plants. Application in Lotus corniculatus transformation. Stougaard J. **Methods Mol Biol** 1995; 49:49–61 (18 ref.)
Plant antibodies for immunotherapy. Ma JK, et al. **Plant Physiol** 1995 Oct;109(2):341–6 (30 ref.)

GENETICS

Co–suppression of beta–1,3–glucanase genes in Nicotiana tabacum. de Carvalho Niebel F, et al. **Curr Top Microbiol Immunol** 1995;197:91–103 (39 ref.)
Developmental regulation of co–suppression in Petunia hybrida. Flavell RB, et al. **Curr Top Microbiol Immunol** 1995;197:43–56 (63 ref.)
Sense and antisense inactivation of fruit ripening genes in tomato. Hamilton AJ, et al. **Curr Top Microbiol Immunol** 1995;197:77–89 (70 ref.)
trans–inactivation of homologous sequences in Nicotiana tabacum. Matzke AJ, et al. **Curr Top Microbiol Immunol** 1995;197:1–14 (30 ref.)
Gene silencing in transgenic plants: a heuristic autoregulation model. Meins F Jr, et al. **Curr Top Microbiol Immunol** 1995; 197:105–20 (55 ref.)
DNA methylation and transgene silencing in Petunia hybrida. Meyer P. **Curr Top Microbiol Immunol** 1995;197:15–28 (61 ref.)
Transgene inactivation in Arabidopsis thaliana. Scheid OM. **Curr Top Microbiol Immunol** 1995;197:29–42 (57 ref.)
Plant genetic engineering may help with environmental cleanup. Raskin I. **Proc Natl Acad Sci U S A** 1996 Apr 16;93(8):3164–6 (32 ref.)

METABOLISM

Plant genetic engineering may help with environmental cleanup. Raskin I. **Proc Natl Acad Sci U S A** 1996 Apr 16;93(8):3164–6 (32 ref.)

PLAQUE ASSAY

Antigenic variants in a plaque–isolate of foot–and–mouth disease virus: implications for vaccine production. Piatti P, et al. **Vaccine** 1995;13(8):781–4 (23 ref.)

PLAQUE THERAPY, RADIOISOTOPE see **BRACHYTHERAPY**

PLASMA

PHYSIOLOGY

Plasma skimming in vascular trees: numerical estimates of symmetry recovery lengths. Carr RT, et al. **Microcirculation** 1995 Dec;2(4):345–53 (25 ref.)

VIROLOGY

Virally inactivated fresh frozen plasma. Williamson LM, et al. **Vox Sang** 1995;69(3):159–65 (45 ref.)

PLASMA CELL ANTIGENS PC–1 see **ANTIGENS, DIFFERENTIATION, B–LYMPHOCYTE**

PLASMA CELL DYSCRASIAS see **PARAPROTEINEMIAS**

PLASMA CELL GRANULOMA see **GRANULOMA, PLASMA CELL**

PLASMA CELL GRANULOMA, ORBITAL see **GRANULOMA, PLASMA CELL, ORBITAL**

PLASMA CELLS

IMMUNOLOGY

Immunophenotype and DNA cell content in multiple myeloma. San Miguel JF, et al. **Baillieres Clin Haematol** 1995 Dec;8(4):735–59 (102 ref.)

PATHOLOGY

A plasma cell variant of Castleman's disease treated successfully with cimetidine. Case report and review of the literature. Barbounis V, et al. **Anticancer Res** 1996 Jan–Feb;16(1):545–7 (21 ref.)
Co–occurrence of plasma cell orificial mucositis and plasmoacanthoma. Report of a case and review of the literature. van de Kerkhof PC, et al. **Dermatology** 1995; 191(1):53–5 (21 ref.)
[Primary plasmacytoma of the lymph node (plasmocytic lymphoma). The differential diagnosis of nodal plasma–cell proliferates] Horny HP, et al. **Dtsch Med Wochenschr** 1995 Dec 15;120(50):1734–8 (15 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

[Multiple myeloma––the biology of malignant plasma cells] Paluszewska M. **Pol Arch Med Wewn** 1996 Jan;95(1):67–72 (33 ref.) **(Pol)**

PLASMA EXCHANGE

Thrombotic thrombocytopenic purpura in pregnancy: successful treatment with plasma exchange. Case report and review of the literature. Mokrzycki MH, et al. **Blood Purif** 1995;13(5):271–82 (100 ref.)
A comparison between IVIg and plasma exchange in Guillain–Barré syndrome: a review and decision analysis of the two treatment modalities. Dawson WB, et al. **Clin Neuropharmacol** 1995 Oct;18(5):377–90 (44 ref.)
Is there a scientific rationale for therapeutic plasma exchange or intravenous immune globulin in the treatment of acute Guillain–Barré syndrome? Weinstein R. **J Clin Apheresis** 1995;10(3):150–7 (94 ref.)
[Radical therapy of refractory hyperlipidemia: extracorporeal cholesterol elimination] Kostner KM. **Wien Med Wochenschr** 1994;144(12–13):333–5 (13 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Plasma exchange therapy for solar urticaria. Collins P, et al. **Br J Dermatol** 1996 Jun;134(6):1093–7 (20 ref.)
Therapeutic plasma exchange in renal diseases [editorial] Madore F, et al. **J Am Soc Nephrol** 1996 Mar;7(3):367–86 (133 ref.)

PLASMA FLOW, RENAL see **RENAL PLASMA FLOW**

PLASMA MEMBRANE see **CELL MEMBRANE**

PLASMA PROKALLIKREIN see **PREKALLIKREIN**

PLASMA PROTEINS see **BLOOD PROTEINS**

PLASMA SUBSTITUTES

see related
BLOOD SUBSTITUTES

THERAPEUTIC USE

The use of colloids in clinical practice. Cone A. **Br J Hosp Med** 1995 Aug 16–Sep 5;54(4):155–9 (20 ref.)

PLASMA THROMBOPLASTIN ANTECEDENT see **FACTOR XI**

PLASMA THROMBOPLASTIN COMPONENT see **FACTOR IX**

PLASMA VOLUME EXPANDERS see **PLASMA SUBSTITUTES**

PLASMACYTES see **PLASMA CELLS**

PLASMACYTOMA

Primary plasmacytoma of the skin. Tüting T, et al. **J Am Acad Dermatol** 1996 Feb;34(2 Pt 2):386–90 (29 ref.)

DIAGNOSIS

[Pulmonary plasmacytoma. Apropos of a case. Review of the literature] Etienne G, et al. **Rev Pneumol Clin** 1995; 51(5):280–3 (22 ref.) (Eng. Abstr.) **(Fre)**
[Primary plasmacytoma of the lymph node (plasmocytic lymphoma). The differential diagnosis of nodal plasma–cell proliferates] Horny HP, et al. **Dtsch Med Wochenschr** 1995 Dec 15;120(50):1734–8 (15 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

Extramedullary plasmacytoma mimicking primary colonic carcinoma in a patient with Crohn's disease. Case report and literature review. Ligato S, et al. **Arch Pathol Lab Med** 1996 Mar;120(3):279–82 (32 ref.)
Involvement of the larynx by hemopoietic neoplasms. An investigation of autopsy cases and review of the literature. Horny HP, et al. **Pathol Res Pract** 1995 Mar;191(2):130–8 (88 ref.)
The mechanisms of bone lesions in human plasmacytomas. Bataille R. **Stem Cells (Dayt)** 1995 Aug;13 Suppl 2:40–7 (67 ref.)
[Solitary plasmocytoma of the mandible. Report of one case and review of the literature] Ferrer Albiach C, et al. **An Otorrinolaringol Ibero Am** 1995;22(6):609–18 (16 ref.) (Eng. Abstr.) **(Spa)**

RADIOTHERAPY

Long–term disease–free survival after plasmacytoma of the urethra: a case report and review of the literature. Mordkin RM, et al. **Urology** 1996 Jul;48(1):149–50 (7 ref.)

THERAPY

Leukemias and myeloma. Wiernik PH. **Cancer Chemother Biol Response Modif** 1996;16:347–75 (164 ref.)

PLASMACYTOMA GROWTH FACTOR see **INTERLEUKIN–6**

PLASMAPHERESIS

Plasmapheresis in severe sepsis or septic shock. Stegmayr BG. **Blood Purif** 1996;14(1):94–101 (66 ref.)
Plasmapheresis in the therapy of septic disease. Reinke P. **Int J Artif Organs** 1996 Feb;19(2):127–8 (11 ref.)
Immunologic rebound. Dau PC. **J Clin Apheresis** 1995; 10(4):210–7 (44 ref.)
Role of plasmapheresis in thrombocytopenic purpura associated with Waldenström's macroglobulinemia. Patel TC, et al. **Mayo Clin Proc** 1996 Jun;71(6):597–600 (14 ref.)
[Radical therapy of refractory hyperlipidemia: extracorporeal cholesterol elimination] Kostner KM. **Wien Med Wochenschr** 1994;144(12–13):333–5 (13 ref.) (Eng. Abstr.) **(Ger)**
[Plasma– and lymphapheresis in autoimmune diseases] Schneider M. **Z Rheumatol** 1996 Mar–Apr;55(2):90–104 (165 ref.) (Eng. Abstr.) **(Ger)**
[Marked clinical improvement by plasmapheresis in a patient with stiff–man syndrome: a case with a negative anti–GAD antibody] Nakamagoe K, et al. **Rinsho Shinkeigaku** 1995 Aug;35(8):897–900 (12 ref.) (Eng. Abstr.) **(Jpn)**
[Use of plasmapheresis in the treatment of internal diseases] Usnarska–Zubkiewicz L. **Pol Arch Med Wewn** 1995 Sep; 94(3):250–8 (110 ref.) **(Pol)**
[Plasmapheresis as a method of intensive care in neurology] Piradov MA. **Anesteziol Reanimatol** 1996 Mar–Apr; (2):92–4 (3 ref.) **(Rus)**

ADVERSE EFFECTS

Infectious risk of plasma donations: relationship to safety of intravenous immune globulins. Dodd RY. **Clin Exp Immunol** 1996 May;104 Suppl 1:31–4 (25 ref.)

INSTRUMENTATION

[Current status of the plasmapheresis problem] Kalinin NN. **Gematol Transfuziol** 1995 Mar–Apr;40(2):46–8 (12 ref.) **(Rus)**

PLASMIDS

see related
EXTRACHROMOSOMAL INHERITANCE

Use of plasmid DNA for direct gene transfer and immunization. Davis HL, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:21–9 (29 ref.)
General vectors for archaeal hyperthermophiles: strategies based on a mobile intron and a plasmid. Aagaard C, et al. **FEMS Microbiol Rev** 1996 May;18(2–3):93–104 (38 ref.)
Viruses, plasmids and other genetic elements of thermophilic and hyperthermophilic Archaea. Zillig W, et al. **FEMS Microbiol Rev** 1996 May;18(2–3):225–36 (28 ref.)
Sexuality of mitochondria: fusion, recombination, and plasmids. Kawano S, et al. **Int Rev Cytol** 1995;161:49–110 (179 ref.)
Extended–spectrum plasmid–mediated beta–lactamases. Sirot D. **J Antimicrob Chemother** 1995 Jul;36 Suppl A:19–34 (129 ref.)
Plasmid–based transgenic mouse model for studying in vivo mutations. Boerrigter ME, et al. **Nature** 1995 Oct 19; 377(6550):657–9 (16 ref.)
Growth–phase regulation of plasmid virulence genes in Salmonella. Guiney DG, et al. **Trends Microbiol** 1995 Jul; 3(7):275–9 (29 ref.)

GENETICS

Potential DNA vaccine integration into host cell genome. Nichols WW, et al. **Ann N Y Acad Sci** 1995 Nov 27; 772:30–9 (8 ref.)
Biology and clinical significance of virulence plasmids in Salmonella serovars. Guiney DG, et al. **Clin Infect Dis** 1995 Oct;21 Suppl 2:S146–51 (37 ref.)
Site–specific recombination in gram–positive theta–replicating plasmids. Alonso JC, et al. **FEMS Microbiol Lett** 1996 Aug 15;142(1):1–10 (28 ref.)
Linear DNA plasmids of yeasts. Fukuhara H. **FEMS Microbiol Lett** 1995 Aug 15;131(1):1–9 (32 ref.)
Introduction of cloning plasmids into Agrobacterium tumefaciens. Shaw CH. **Methods Mol Biol** 1995;49:33–7 (14 ref.)
Natural plasmids of filamentous fungi. Griffiths AJ. **Microbiol Rev** 1995 Dec;59(4):673–85 (102 ref.)
Programmed cell death in bacteria: proteic plasmid stabilization systems. Jensen RB, et al. **Mol Microbiol** 1995 Jul;17(2):205–10 (48 ref.)
Polynucleotide–mediated immunization therapy of cancer. Conry RM, et al. **Semin Oncol** 1996 Feb;23(1):135–47 (79 ref.)
[beta–Lactamases of Branhamella catarrhalis and their phenotypic implications] Chaïbi EB, et al. **Res Microbiol** 1995 Nov–Dec;146(9):761–71 (40 ref.) (Eng. Abstr.) **(Fre)**

PLASMIDS

[Genetic regulation of plasmid transfer] Pekhov AP, et al. **Biull Eksp Biol Med** 1995 Jul;120(7):6–12 (37 ref.) **(Rus)**

IMMUNOLOGY

DNA vaccines: what can we expect? Siegrist CA, et al. **Infect Agents Dis** 1996 Jan;5(1):55–9 (19 ref.)

PLASMIN

ANALYSIS

[Plasminogen (PG), plasmin (PM)] Sakuragawa N. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:51–4 (20 ref.) **(Jpn)**

[alpha 2–Plasmin inhibitor–plasmin complex (PIC)] Yoshikawa Y, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:55–8 (13 ref.) **(Jpn)**

BIOSYNTHESIS

Cellular receptors in the regulation of plasmin generation. Hajjar KA. **Thromb Haemost** 1995 Jul;74(1):294–301 (113 ref.)

METABOLISM

Contribution of milk–clotting enzymes and plasmin to cheese ripening. Farkye NY. **Adv Exp Med Biol** 1995;367:195–207 (64 ref.)

PHYSIOLOGY

Cuts and scrapes? Plasmin heals! Vassalli JD, et al. **Nat Med** 1996 Mar;2(3):284–5 (13 ref.)

Gene targeting and gene transfer studies of the biological role of the plasminogen/plasmin system. Carmeliet P, et al. **Thromb Haemost** 1995 Jul;74(1):429–36 (66 ref.)

Lipoprotein(a), plasmin modulation, and atherogenesis. Harpel PC, et al. **Thromb Haemost** 1995 Jul;74(1):382–6 (83 ref.)

PLASMINOGEN

ANALYSIS

[Plasminogen (PG), plasmin (PM)] Sakuragawa N. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:51–4 (20 ref.) **(Jpn)**

METABOLISM

Plasminogen activation on tumor cell surface and its involvement in human leukemia. Tapiovaara H, et al. **Adv Cancer Res** 1996;69:101–33 (317 ref.)

PHYSIOLOGY

Angiogenesis inhibitors generated by tumors. Folkman J. **Mol Med** 1995 Jan;1(2):120–2 (23 ref.)

Gene targeting and gene transfer studies of the biological role of the plasminogen/plasmin system. Carmeliet P, et al. **Thromb Haemost** 1995 Jul;74(1):429–36 (66 ref.)

Lipoprotein(a), plasmin modulation, and atherogenesis. Harpel PC, et al. **Thromb Haemost** 1995 Jul;74(1):382–6 (83 ref.)

PLASMINOGEN ACTIVATOR INHIBITOR 1

ANALYSIS

Fibrinolysis components as prognostic markers in breast cancer and colorectal carcinoma. Gandolfo GM, et al. **Anticancer Res** 1996 Jul–Aug;16(4B):2155–9 (37 ref.)

[Plasminogen activator inhibitor–1 (PAI–1)] Iwabuchi S, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:64–7 (22 ref.) **(Jpn)**

METABOLISM

The PAI–1/vitronectin interaction: two cats in a bag? Deng G, et al. **Thromb Haemost** 1995 Jul;74(1):66–70 (47 ref.)

PHYSIOLOGY

Plasminogen activator inhibitor 1 (PAI–1) in plasma: its role in thrombotic disease. Wiman B. **Thromb Haemost** 1995 Jul;74(1):71–6 (65 ref.)

PLASMINOGEN ACTIVATOR INHIBITOR 2

The enigma PAI–2. Gene expression, evolutionary and functional aspects. Bachmann F. **Thromb Haemost** 1995 Jul; 74(1):172–9 (55 ref.)

ANALYSIS

Fibrinolysis components as prognostic markers in breast cancer and colorectal carcinoma. Gandolfo GM, et al. **Anticancer Res** 1996 Jul–Aug;16(4B):2155–9 (37 ref.)

PHYSIOLOGY

Biological and clinical aspects of plasminogen activator inhibitor type 2. Kruithof EK, et al. **Blood** 1995 Dec 1; 86(11):4007–24 (282 ref.)

PLASMINOGEN ACTIVATOR INHIBITOR 3 see **PROTEIN C INHIBITOR**

PLASMINOGEN ACTIVATOR INHIBITORS see **PLASMINOGEN INACTIVATORS**

PLASMINOGEN ACTIVATOR, TISSUE–TYPE see **ALTEPLASE**

PLASMINOGEN ACTIVATOR, UROKINASE–TYPE see **UROKINASE**

PLASMINOGEN ACTIVATORS

Plasminogen activators and plasminogen activator inhibitors: biochemical aspects. Rijken DC. **Baillieres Clin Haematol** 1995 Jun;8(2):291–312 (127 ref.)

Urokinase–type plasminogen activator (uPA) and its receptor (CD87): a new target in tumor invasion and metastasis. Schmitt M, et al. **J Obstet Gynaecol** 1995 Apr;21(2):151–65 (60 ref.)

ANALYSIS

Prognostic value of plasminogen activators and their inhibitors in colorectal cancer. Verspaget HW, et al. **Eur J Cancer** 1995 Jul–Aug;31A(7–8):1105–9 (28 ref.)

METABOLISM

Molecular basis of fibrinolysis, as relevant for thrombolytic therapy. Collen D, et al. **Thromb Haemost** 1995 Jul; 74(1):167–71 (40 ref.)

PHARMACOLOGY

Thrombolytic agents in development. Verstraete M, et al. **Drugs** 1995 Jul;50(1):29–42 (90 ref.)

PHYSIOLOGY

Plasminogen activation on tumor cell surface and its involvement in human leukemia. Tapiovaara H, et al. **Adv Cancer Res** 1996;69:101–33 (317 ref.)

Interactions between endothelial secretogogues. Gryglewski RJ. **Ann Med** 1995 Jun;27(3):421–7 (80 ref.)

Plasminogen activators and angiogenesis. Mignatti P, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 1):33–50 (137 ref.)

Different roles for plasminogen activators and metalloproteinases in melanoma metastasis. Mueller BM. **Curr Top Microbiol Immunol** 1996;213 (Pt 1):65–80 (80 ref.)

THERAPEUTIC USE

Treatment of complicated pleural fluid collections with image–guided drainage and intracavitary urokinase [see comments] Moulton JS, et al. **Chest** 1995 Nov; 108(5):1252–9 (20 ref.) Comment in: Chest 1995 Nov;108(5):1190–1.

Alteplase. A reappraisal of its pharmacological properties and therapeutic use in acute myocardial infarction. Gillis JC, et al. **Drugs** 1995 Jul;50(1):102–36 (154 ref.)

Alteplase. A reappraisal of its pharmacology and therapeutic use in vascular disorders other than acute myocardial infarction. Wagstaff AJ, et al. **Drugs** 1995 Aug; 50(2):289–316 (185 ref.)

Third generation plasminogen activators in the treatment of acute myocardial infarction. Talley JD. **J Ark Med Soc** 1996 Apr;92(11):587–8 (6 ref.)

Innovations in aneurysmal subarachnoid hemorrhage: intracisternal t–PA for the prevention of vasospasm. Bell TE, et al. **J Neurosci Nurs** 1996 Apr;28(2):107–13 (37 ref.)

Comparison of "accelerated" tissue plasminogen activator with streptokinase for treatment of suspected myocardial infarction [see comments] Kellett J, et al. **Med Decis Making** 1995 Oct–Dec;15(4):297–310 (145 ref.) Comment in: Med Decis Making 1995 Oct–Dec;15(4):395–6.

[Thrombolysis (Consensus about post–myocardial infarction treatment)] **Arq Bras Cardiol** 1995 Mar;64(3):271–80 (65 ref.) **(Por)**

PLASMINOGEN INACTIVATORS

Plasminogen activators and plasminogen activator inhibitors: biochemical aspects. Rijken DC. **Baillieres Clin Haematol** 1995 Jun;8(2):291–312 (127 ref.)

ANALYSIS

Prognostic value of plasminogen activators and their inhibitors in colorectal cancer. Verspaget HW, et al. **Eur J Cancer** 1995 Jul–Aug;31A(7–8):1105–9 (28 ref.)

PLASMODIUM

see related
ANTIMALARIALS

DRUG EFFECTS

Iron chelators: mode of action as antimalarials. Cabantchik ZI, et al. **Acta Haematol** 1996;95(1):70–7 (40 ref.)

[Malaria and drug resistance] Kager PA, et al. **Ned Tijdschr Geneeskd** 1996 Jan 20;140(3):151–5 (20 ref.) (Eng. Abstr.) **(Dut)**

GENETICS

[The utilization of molecular biological tools in the study of malaria transmission: example of programs conducted in Senegal] Fontenille D, et al. **Med Trop (Mars)** 1995;55(4 Suppl):52–5 (15 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Nucleic acid malaria vaccines. Current status and potential. Hoffman SL, et al. **Ann N Y Acad Sci** 1995 Nov 27; 772:88–94 (11 ref.)

[Towards a vaccination against malaria] Ambroise–Thomas P. **Rev Med Interne** 1995;16(9):717–23 (48 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Regulation of infectivity of Plasmodium to the mosquito vector. Sinden RE, et al. **Adv Parasitol** 1996;38:53–117 (314 ref.)

Simian malaria at two sites in the Brazilian Amazon. I—The infection rates of Plasmodium brasilianum in non–human primates. Lourenço–de–Oliveira R, et al. **Mem Inst Oswaldo Cruz** 1995 May–Jun;90(3):331–9 (70 ref.)

[Malaria—biological aspects of an infectious disease of importance to humans] Hildebrandt JP. **Naturwissenschaften** 1996 Aug;83(8):359–69 (86 ref.) (Eng. Abstr.) **(Ger)**

PLASMODIUM FALCIPARUM

CHEMISTRY

Glycobiology of Plasmodium falciparum: an emerging area of research [letter] Hoessli DC, et al. **Glycoconj J** 1996 Feb;13(1):1–3 (33 ref.)

DRUG EFFECTS

Iron chelators: mode of action as antimalarials. Cabantchik ZI, et al. **Acta Haematol** 1996;95(1):70–7 (40 ref.)

Mechanisms of drug resistance in malaria. Cowman AF. **Aust N Z J Med** 1995 Dec;25(6):837–44 (89 ref.)

Localized permanent epidemics: the genesis of chloroquine resistance in Plasmodium falciparum. Verdrager J. **Southeast Asian J Trop Med Public Health** 1995 Mar; 26(1):23–8 (18 ref.)

ENZYMOLOGY

A glutathione reductase–like flavoenzyme of the malaria parasite Plasmodium falciparum: structural considerations based on the DNA sequence. Becker K, et al. **Biochem Soc Trans** 1996 Feb;24(1):67–72 (37 ref.)

GROWTH & DEVELOPMENT

Early sporogonic development in local vectors of Plasmodium falciparum in rural Cameroon. Robert V, et al. **Mem Inst Oswaldo Cruz** 1994;89 Suppl 2:23–6 (10 ref.)

IMMUNOLOGY

Glycobiology of Plasmodium falciparum: an emerging area of research [letter] Hoessli DC, et al. **Glycoconj J** 1996 Feb;13(1):1–3 (33 ref.)

Immune mechanisms underlying the premunition against Plasmodium falciparum malaria. Pérignon JL, et al. **Mem Inst Oswaldo Cruz** 1994;89 Suppl 2:51–3 (13 ref.)

Development of vaccines against falciparum malaria. Ramalingam S, et al. **Natl Med J India** 1996 May–Jun; 9(3):120–4 (71 ref.)

Towards a vaccine against asexual blood stage infection by Plasmodium falciparum. Dubois P, et al. **Res Immunol** 1995 May–Jun;146(4–5):263–75 (64 ref.)

Malaria vaccines—now and the future. Targett GA. **Trans R Soc Trop Med Hyg** 1995 Nov–Dec;89(6):585–7 (26 ref.)

[Immunology of human Plasmodium falciparum malaria] Vanham G, et al. **Ann Soc Belg Med Trop** 1995 Sep; 75(3):159–78 (53 ref.) (Eng. Abstr.) **(Fre)**

[Antimalarial vaccination] Ambroise–Thomas P. **Sante** 1995 Nov–Dec;5(6):411–5 (19 ref.) (Eng. Abstr.) **(Fre)**

PATHOGENICITY

An overview of pathophysiological theories in Plasmodium falciparum cerebral malaria with the special reference to the role of cytokines. Kotlowski A. **Bull Inst Marit Trop Med Gdynia** 1993–94;44–45(1–4):103–8 (37 ref.)

Transport pathways in the malaria–infected erythrocyte: characterization and their use as potential targets for chemotherapy. Ginsburg H. **Mem Inst Oswaldo Cruz** 1994; 89 Suppl 2:99–109 (82 ref.)

PHYSIOLOGY

Dynamic interactions in malaria: host heterogeneity meets parasite polymorphism. Gupta S, et al. **Proc R Soc Lond B Biol Sci** 1995 Sep 22;261(1362):271–7 (39 ref.)

ULTRASTRUCTURE

Recent developments and rationale towards new strategies for malarial chemotherapy. Vial H. **Parasite** 1996 Mar; 3(1):3–23 (148 ref.)

PLASMODIUM FALCIPARUM MALARIA see MALARIA, FALCIPARUM

PLASMODIUM INFECTIONS see MALARIA

PLASMODIUM VIVAX

IMMUNOLOGY

Advances toward the development of an asexual blood stage MSP-1 vaccine of Plasmodium vivax. Levitus G, et al. **Mem Inst Oswaldo Cruz** 1994;89 Suppl 2:81–4 (13 ref.)

METABOLISM

Duffy and receptors for P. vivax and chemotactic peptides. Pogo AO, et al. **Transfus Clin Biol** 1995;2(4):269–76 (29 ref.)

PLASMODIUM VIVAX MALARIA see MALARIA, VIVAX

PLASMOSOME see CELL NUCLEOLUS

PLASTER CASTS see CASTS, SURGICAL

PLASTIC CASTS see CASTS, SURGICAL

PLASTIC EMBEDDING

High-resolution light microscopy for interpretation of renal biopsies. Hoffmann EO. **Pediatr Nephrol** 1995 Dec; 9(6):763–9 (81 ref.)

PLASTIC SURGERY see SURGERY, PLASTIC

PLASTICITY, NEURONAL see NEURONAL PLASTICITY

PLASTICS

Plastic surgery's plastics. Ousterhout DK, et al. **Clin Plast Surg** 1996 Jan;23(1):183–90 (46 ref.)

Objective and subjective observations of low-temperature thermoplastic materials. Lee DB. **J Hand Ther** 1995 Apr–Jun;8(2):138–43 (7 ref.)

[Plastic prostheses or self-expanding stents—is there an ideal drainage? Pro synthetics] Soehendra N, et al. **Bildgebung** 1995 Oct;62 Suppl 2:55–8 (23 ref.) **(Ger)**

METABOLISM

Breakdown of plastics and polymers by microorganisms. Kawai F. **Adv Biochem Eng Biotechnol** 1995;52:151–94 (190 ref.)

PLASTIDS

CHEMISTRY

Biochemistry and molecular biology of chromoplast development. Camara B, et al. **Int Rev Cytol** 1995; 163:175–247 (530 ref.)

PHYSIOLOGY

Biochemistry and molecular biology of chromoplast development. Camara B, et al. **Int Rev Cytol** 1995; 163:175–247 (530 ref.)

PLATANNA see XENOPUS LAEVIS

PLATELET ACTIVATING FACTOR

ANTAGONISTS & INHIBITORS

The neuroprotective properties of the Ginkgo biloba leaf: a review of the possible relationship to platelet-activating factor (PAF). Smith PF, et al. **J Ethnopharmacol** 1996 Mar; 50(3):131–9 (62 ref.)

BIOSYNTHESIS

Enzymes of platelet activating factor synthesis in brain. Baker RR. **Neurochem Res** 1995 Nov;20(11):1345–51 (70 ref.)

METABOLISM

Platelet-activating factor receptor: gene expression and signal transduction. Izumi T, et al. **Biochim Biophys Acta** 1995 Dec 7;1259(3):317–33 (231 ref.)

Platelet-activating factor receptor. Izumi T, et al. **J Lipid Mediat Cell Signal** 1995 Oct;12(2–3):429–42 (77 ref.)

[Biological role of cellular metabolites—structural analogs of platelet activating factor] Kulikov VI, et al. **Biokhimiia** 1996 Mar;61(3):387–403 (115 ref.) (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

Activation of the phospholipase/cyclooxygenase cascade in the rabbit cornea by platelet-activating factor is challenged by PAF receptor antagonists. Hurst JS, et al. **J Ocul Pharmacol Ther** 1995 Fall;11(3):329–37 (39 ref.)

PHYSIOLOGY

Gut-derived mediators of multiple organ failure: platelet-activating factor and interleukin-6. Biffl WL, et al. **Br J Hosp Med** 1995 Aug 16–Sep 5;54(4):134–8 (21 ref.)

Role of cytokines and platelet-activating factor in inflammatory bowel disease. Implications for therapy. Nassif A, et al. **Dis Colon Rectum** 1996 Feb;39(2):217–23 (66 ref.)

The role of prostaglandins in blastocyst implantation. Psychoyos A, et al. **Hum Reprod** 1995 Dec;10 Suppl 2:30–42 (105 ref.)

Platelet-activating factor is a synapse messenger and a modulator of gene expression in the nervous system. Bazan NG, et al. **Neurochem Int** 1995 May;26(5):435–41 (72 ref.)

Multiple roles of platelet-activating factor in the nervous system. Bussolino F, et al. **Neurochem Int** 1995 May; 26(5):425–33 (75 ref.)

Platelet-activating factor mediates procoagulant activity on the surface of endothelial cells by promoting leukocyte adhesion. Lorant DE, et al. **Semin Cell Biol** 1995 Oct; 6(5):295–303 (78 ref.)

[Lipid mediators and liver injury] Liu Y, et al. **Sheng Li Ko Hsueh Chin Chan** 1995 Oct;26(4):363–6 (10 ref.) **(Chi)**

[Progression of renal insufficiency and platelet activating factor (PAF)] Camici M. **Minerva Med** 1996 Jun; 87(6):289–98 (100 ref.) (Eng. Abstr.) **(Ita)**

PLATELET ACTIVATION

Platelet activation. Blockmans D, et al. **Blood Rev** 1995 Sep; 9(3):143–56 (124 ref.)

DRUG EFFECTS

Platelet activation by fibrinolytic agents: a potential mechanism for resistance to thrombolysis and reocclusion after successful thrombolysis. Leopold JA, et al. **Coron Artery Dis** 1995 Dec;6(12):923–9 (60 ref.)

PHYSIOLOGY

Novel antiplatelet therapies for treatment of patients with ischemic heart disease: inhibitors of the platelet glycoprotein IIb/IIIa integrin receptor. Frishman WH, et al. **Am Heart J** 1995 Oct;130(4):877–92 (69 ref.)

Neutrophil-mediated platelet activation: a key role for serine proteinases. Renesto P, et al. **Gen Pharmacol** 1995 Sep; 26(5):905–10 (54 ref.)

Platelet activation mechanisms and markers in arterial thrombosis. Wu KK. **J Intern Med** 1996 Jan;239(1):17–34 (110 ref.)

Platelet activation by polymorphonuclear leukocytes: role of cathepsin G and P-selectin. Cerletti C, et al. **Thromb Haemost** 1995 Jul;74(1):218–23 (82 ref.)

Platelet activation: signal transduction via membrane receptors. Clemetson KJ. **Thromb Haemost** 1995 Jul; 74(1):111–6 (57 ref.)

PLATELET ADHESIVENESS

see related
PLATELET MEMBRANE GLYCOPROTEINS

The role of von Willebrand factor and fibrinogen in the initiation of platelet adhesion to thrombogenic surfaces. Ruggeri ZM. **Thromb Haemost** 1995 Jul;74(1):460–3 (45 ref.)

Platelet adhesion to collagen. Sixma JJ, et al. **Thromb Haemost** 1995 Jul;74(1):454–9 (75 ref.)

GENETICS

The molecular mechanism of platelet adhesion. Berndt MC, et al. **Aust N Z J Med** 1995 Dec;25(6):822–30 (57 ref.)

PHYSIOLOGY

The alpha 2 beta 1 integrin: a collagen receptor on platelets and other cells. Santoro SA, et al. **Thromb Haemost** 1995 Sep;74(3):813–21 (105 ref.)

Flow-related platelet deposition on subendothelium. Weiss HJ. **Thromb Haemost** 1995 Jul;74(1):117–22 (78 ref.)

PLATELET AGGREGATION

see related
PLATELET MEMBRANE GLYCOPROTEINS

[Platelet aggregation] Terada H. **Nippon Rinsho** 1995 Mar; 53 Su Pt 2:141–6 (11 ref.) **(Jpn)**

DRUG EFFECTS

Glyceryl trinitrate enhances the adenosine-induced inhibition of platelet responses: a mechanism potentially involved in the in vivo anti-aggregating effects of organic nitrates. Anfossi G, et al. **Clin Exp Pharmacol Physiol** 1995 Nov; 22(11):803–11 (57 ref.)

Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors. Skop BP, et al. **Psychosomatics** 1996 Jan–Feb;37(1):12–6 (41 ref.)

Characterization of biochemical and functional effects of antiplatelet drugs as a key to their clinical development. Patrono C, et al. **Thromb Haemost** 1995 Jul;74(1):396–400 (45 ref.)

GENETICS

The molecular mechanism of platelet adhesion. Berndt MC, et al. **Aust N Z J Med** 1995 Dec;25(6):822–30 (57 ref.)

PLATELET AGGREGATION INHIBITORS

Ticlopidine. A review of its pharmacology, clinical efficacy and tolerability in the prevention of cerebral ischaemia and stroke. Noble S, et al. **Drugs Aging** 1996 Mar;8(3):214–32 (125 ref.)

ADMINISTRATION & DOSAGE

Patterns of aspirin use in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study. Shahar E, et al. **Am Heart J** 1996 May;131(5):915–22 (37 ref.)

Aspirin and other platelet-active drugs. The relationship among dose, effectiveness, and side effects. Hirsh J, et al. **Chest** 1995 Oct;108(4 Suppl):247S–257S (148 ref.)

–Is prevention of pre-eclampsia with low dosage aspirin possible? Critical assessment of available studies– Lippert TH, et al. **Geburtshilfe Frauenheilkd** 1996 Feb;56(2):88–92 (23 ref.) (Eng. Abstr.) **(Ger)**

[High dosage acetylsalicylic acid administration for prevention of acute cerebral ischemia] Hartmann A. **Nervenarzt** 1995 Dec;66(12):886–9; discussion 885 (18 ref.) (Eng. Abstr.) **(Ger)**

[Aspirin dosage for prevention of cerebral infarct: arguments for low dosage] Hennerici MG, et al. **Nervenarzt** 1995 Dec; 66(12):890–4; discussion 885 (38 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Is aspirin safe for patients with heart failure? Cleland JG, et al. **Br Heart J** 1995 Sep;74(3):215–9 (53 ref.)

Severe aplastic anemia induced by ticlopidine: report of a case. Su CC, et al. **J Formos Med Assoc** 1995 Nov; 94(11):689–91 (8 ref.)

[Adverse hematologic effects of ticlopidine (letter)] Lesesve JF, et al. **Therapie** 1995 Sep–Oct;50(5):468–70 (11 ref.) **(Fre)**

PHARMACOLOGY

Antiplatelet therapy. Schafer AI. **Am J Med** 1996 Aug; 101(2):199–209 (105 ref.)

Glyceryl trinitrate enhances the adenosine-induced inhibition of platelet responses: a mechanism potentially involved in the in vivo anti-aggregating effects of organic nitrates. Anfossi G, et al. **Clin Exp Pharmacol Physiol** 1995 Nov; 22(11):803–11 (57 ref.)

Antiplatelet drugs. A comparative review. Schrör K. **Drugs** 1995 Jul;50(1):7–28 (189 ref.)

ADP receptors on platelets and ADP-selective antiaggregating agents. Savi P, et al. **Med Res Rev** 1996 Mar;16(2):159–79 (206 ref.)

Characterization of biochemical and functional effects of antiplatelet drugs as a key to their clinical development. Patrono C, et al. **Thromb Haemost** 1995 Jul;74(1):396–400 (45 ref.)

[Anti-adhesive and anti-thrombotic effects of integrin-inhibiting tripeptides (Arg-Gly-Asp)] Udvardy M. **Orv Hetil** 1995 Oct 1;136(40):2155–9 (42 ref.) (Eng. Abstr.) **(Hun)**

THERAPEUTIC USE

Novel antiplatelet therapies for treatment of patients with ischemic heart disease: inhibitors of the platelet glycoprotein IIb/IIIa integrin receptor. Frishman WH, et al. **Am Heart J** 1995 Oct;130(4):877–92 (69 ref.)

Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective. Tcheng JE. **Am J Cardiol** 1996 Aug 14; 78(3A):35–40 (27 ref.)

Therapeutic uses of aspirin in renal diseases. Winchester JF. **Am J Kidney Dis** 1996 Jul;28(1 Suppl 1):S20–3 (44 ref.)

Antiplatelet therapy and the prevention of thrombosis. Rodgers A, et al. **Aust N Z J Med** 1996 Apr;26(2):210–5 (19 ref.)

The pharmacological prevention of pre-eclampsia. Dekker GA. **Baillieres Clin Obstet Gynaecol** 1995 Sep;9(3):509–28 (109 ref.)

Warfarin and aspirin as thromboprophylaxis in atrial fibrillation. Lip GY, et al. **Br J Clin Pharmacol** 1996 May; 41(5):369–79 (83 ref.)

Antithrombotic therapy in atrial fibrillation. Turpie AG, et al. **Can Fam Physician** 1996 Jul;42:1341–5 (16 ref.)

Platelets and platelet inhibitors in acute myocardial infarction. Kamat SG, et al. **Cardiol Clin** 1995 Aug; 13(3):435–47 (139 ref.)

Blockade of platelet GPIIb/IIIa receptors as an antithrombotic strategy. Coller BS. **Circulation** 1995 Nov 1;92(9):2373–80 (76 ref.)

The clinical role of platelet glycoprotein IIb/IIIa receptor inhibitors in ischemic heart disease. Lefkovits J, et al. **Cleve Clin J Med** 1996 May–Jun;63(3):181–9 (32 ref.)

Antiplatelet and anticoagulant use after myocardial infarction. Almony GT, et al. **Clin Cardiol** 1996 May;

19(5):357–65 (109 ref.)
Augmentation of thrombolysis with antiplatelet drugs. Coller BS. **Coron Artery Dis** 1995 Dec;6(12):911–4 (14 ref.)
Inhibitors of platelet glycoprotein IIb/IIIa as augmenters of thrombolysis. Eccleston D, et al. **Coron Artery Dis** 1995 Dec;6(12):947–55 (67 ref.)
Aspirin augmentation of the efficacy of thrombolysis. O'Donnell CJ, et al. **Coron Artery Dis** 1995 Dec;6(12):936–9 (23 ref.)
Antiplatelet, antithrombotic, and lytic therapy for unstable angina, and the appropriate role of revascularization. de Feyter PJ, et al. **Curr Opin Cardiol** 1995 Jul;10(4):389–98 (36 ref.)
Platelet glycoprotein IIb/IIIa receptor inhibitors in ischemic heart disease. Lefkovits J, et al. **Curr Opin Cardiol** 1995 Jul;10(4):420–6 (53 ref.)
Long-term aspirin in the prevention of cardiovascular disorders. Recent developments and variations on a theme. Catella-Lawson F, et al. **Drug Saf** 1995 Aug;13(2):69–75 (53 ref.)
Aspirin for primary prevention of coronary disease. Fuster V, et al. **Eur Heart J** 1995 Jul;16 Suppl E:16–20 (23 ref.)
Platelet glycoprotein IIb/IIIa receptor antagonists in coronary artery disease. Lefkovits J, et al. **Eur Heart J** 1996 Jan;17(1):9–18 (81 ref.)
Aspirin dose in stroke prevention: beautiful hypotheses slain by ugly facts [editorial; comment] Barnett HJ, et al. **Stroke** 1996 Apr;27(4):588–92 (60 ref.) Comment on: Stroke 1996 Apr;27(4):756–60.
Aspirin wars: the optimal dose of aspirin prevent stroke [editorial; comment] Hart RG, et al. **Stroke** 1996 Apr; 27(4):585–7 (45 ref.) Comment on: Stroke 1996 Apr;27(4):756–60.
Oral anticoagulant treatment with and without aspirin. Altman R, et al. **Thromb Haemost** 1995 Jul;74(1):506–10 (37 ref.)
New antiplatelet agents: platelet GPIIb/IIIa antagonists. Coller BS, et al. **Thromb Haemost** 1995 Jul;74(1):302–8 (38 ref.)
Antiplatelet therapy with aspirin: from clinical trials to practice. Goodnight SH. **Thromb Haemost** 1995 Jul; 74(1):401–5 (64 ref.)
Antithrombotic benefits and hemorrhagic risks of direct thrombin antagonists. Harker LA, et al. **Thromb Haemost** 1995 Jul;74(1):464–72 (80 ref.)
[Uterine velocimetry and vascular pregnancy pathologies prevented with low-dose aspirin] Haddad B, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(4):396–404 (51 ref.) (Eng. Abstr.) **(Fre)**
[Therapeutic role of coagulation in small cell lung cancers] LeBeau B. **Rev Mal Respir** 1996;13(1):21–6 (41 ref.) (Eng. Abstr.) **(Fre)**
[Platelet antiaggregants and atheromatous arteriopathy of the lower limbs] Lévesque H, et al. **Rev Med Interne** 1996; 17(2):163–8 (47 ref.) (Eng. Abstr.) **(Fre)**
[Antithrombotic agents and prevention of cerebrovascular accidents] Dewarrat A, et al. **Rev Med Suisse Romande** 1996 Aug;116(8):629–34 (38 ref.) (Eng. Abstr.) **(Fre)**
[Preventive treatment of cerebrovascular accidents of arterial origin] Castillo V, et al. **Schweiz Rundsch Med Prax** 1996 Feb 6;85(6):159–63 (33 ref.) (Eng. Abstr.) **(Fre)**
-New perspectives in therapy of unstable angina- Hamm CW. **Herz** 1996 Feb;21(1):37–43 (69 ref.) (Eng. Abstr.) **(Ger)**
-New aspects in antithrombotic therapy--platelet inhibitors- Terres W, et al. **Herz** 1996 Feb;21(1):1–11 (89 ref.) (Eng. Abstr.) **(Ger)**
[Ticlopidine in coronary artery diseases] Porter T, et al. **Harefuah** 1995 Nov 15;129(10):427–30 (26 ref.) **(Heb)**
[The new frontier of antithrombotic therapy: ASA + warfarin, the ideal solution?] Cimminiello C, et al. **G Ital Cardiol** 1995 Sep;25(9):1187–93 (36 ref.) (Eng. Abstr.) **(Ita)**
[Atrial fibrillation due to non-valvular causes: indications for antithrombotic therapy] Codinach Huix P. **Med Clin (Barc)** 1996 Apr 20;106(15):586–9 (25 ref.) **(Spa)**
[Guidelines for the management of acute cerebrovascular disease in patients] Alonso de Leciñana M, et al. **Rev Neurol** 1995 Mar-Apr;23(120):363–9 (54 ref.) (Eng. Abstr.) **(Spa)**
[Acetyl-salicylic acid and trifusal in the prevention of atherothrombotic stroke] Alvarez Sabín J. **Rev Neurol** 1995 Sep-Oct;23(123):1091–5 (36 ref.) **(Spa)**

PLATELET ALLOANTIGENS see **ANTIGENS, HUMAN PLATELET**

PLATELET ALPHA-GRANULE MEMBRANE PROTEIN see **P-SELECTIN**

PLATELET ANTAGONISTS see **PLATELET AGGREGATION INHIBITORS**

PLATELET ANTIAGGREGANTS see **PLATELET AGGREGATION INHIBITORS**

PLATELET COUNT

[Current views on pathophysiology of migraine. Part III: Biochemical hypothesis. The role of blood platelets] Prusiński A, et al. **Neurol Neurochir Pol** 1995 Nov-Dec; 29(6):867–76 (26 ref.) (Eng. Abstr.) **(Pol)**

PLATELET-DERIVED GROWTH FACTOR

see related
RECEPTORS, PLATELET-DERIVED GROWTH FACTOR

Reshaping the interstitium by platelet-derived growth factor. Implications for progressive renal disease. Nath KA. **Am J Pathol** 1996 Apr;148(4):1031–6 (63 ref.)

ANALYSIS

[Platelet-derived growth factor (PDGF)] Kaji K. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:830–4 (12 ref.) **(Jpn)**

BIOSYNTHESIS

Expression of genes coding for growth factors in experimental pneumoconiosis. Morris GF, et al. **Chest** 1996 Mar;109(3 Suppl):45S–49S (55 ref.)
Platelet derived growth factor expression, myelofibrosis and chronic myelogenous leukemia. Kimura A, et al. **Leuk Lymphoma** 1995 Jul;18(3–4):237–42 (47 ref.)

GENETICS

S1-nuclease-sensitive DNA structures contribute to transcriptional regulation of the human PDGF A-chain. Wang ZY, et al. **Prog Nucleic Acid Res Mol Biol** 1996; 55:227–44 (110 ref.)

METABOLISM

Platelet-derived growth factor in human glioma. Westermark B, et al. **Glia** 1995 Nov;15(3):257–63 (60 ref.)

PHARMACOLOGY

Platelet-derived growth factor. Distinct signal transduction pathways associated with migration versus proliferation. Bornfeldt KE, et al. **Ann N Y Acad Sci** 1995 Sep 7; 766:416–30 (67 ref.)
Convergent signalling in the action of integrins, neuropeptides, growth factors and oncogenes. Rozengurt E. **Cancer Surv** 1995;24:81–96 (49 ref.)

PHYSIOLOGY

Growth factors and the glomerulus: relationships between development and injury. Alpers CE, et al. **Adv Nephrol Necker Hosp** 1995;24:33–52 (85 ref.)
Platelet-derived growth factor. Distinct signal transduction pathways associated with migration versus proliferation. Bornfeldt KE, et al. **Ann N Y Acad Sci** 1995 Sep 7; 766:416–30 (67 ref.)
Basic fibroblast growth factor and PDGF in GI diseases. Szabo S, et al. **Baillieres Clin Gastroenterol** 1996 Mar; 10(1):97–112 (68 ref.)
Role of platelet-derived growth factors in mouse development. Betsholtz C. **Int J Dev Biol** 1995 Oct; 39(5):817–25 (76 ref.)
Multiple roles for platelet-derived growth factor in renal disease. Floege J, et al. **Miner Electrolyte Metab** 1995; 21(4–5):271–82 (108 ref.)

THERAPEUTIC USE

Platelet-derived growth factor-modulated guided tissue regenerative therapy. Cho MI, et al. **J Periodontol** 1995 Jun;66(6):522–30 (43 ref.)
Growth factors: new 'endogenous drugs' for ulcer healing. Szabo S, et al. **Scand J Gastroenterol Suppl** 1995;210:15–8 (33 ref.)

PLATELET-DERIVED GROWTH FACTOR RECEPTORS see **RECEPTORS, PLATELET-DERIVED GROWTH FACTOR**

PLATELET FACTOR 4

ANALYSIS

[Platelet factor 4 (PF 4)] Kimura A. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:109–11 (13 ref.) **(Jpn)**

PLATELET FUNCTION TESTS

The role of the hemostasis laboratory in cardiopulmonary bypass surgery [editorial] Brandt JT. **Am J Clin Pathol** 1996 Jul;106(1):3–5 (26 ref.)
Flow cytometry: a clinical test of platelet function. Michelson AD. **Blood** 1996 Jun 15;87(12):4925–36 (145 ref.)

STANDARDS

Bleeding time: an unreliable predictor of clinical hemostasis. De Rossi SS, et al. **J Oral Maxillofac Surg** 1996 Sep; 54(9):1119–20 (21 ref.)

PLATELET GLYCOPROTEIN GPIB-IX COMPLEX

METABOLISM

Platelet adhesion receptors. Williams MJ, et al. **Semin Cell Biol** 1995 Oct;6(5):305–14 (75 ref.)

PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX

ANTAGONISTS & INHIBITORS

Novel antiplatelet therapies for treatment of patients with ischemic heart disease: inhibitors of the platelet glycoprotein IIb/IIIa integrin receptor. Frishman WH, et al. **Am Heart J** 1995 Oct;130(4):877–92 (69 ref.)
Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective. Tcheng JE. **Am J Cardiol** 1996 Aug 14; 78(3A):35–40 (27 ref.)
New directions in anticoagulant and antiplatelet treatment [editorial] Simoons ML, et al. **Br Heart J** 1995 Oct; 74(4):337–40 (33 ref.)
The clinical role of platelet glycoprotein IIb/IIIa receptor inhibitors in ischemic heart disease. Lefkovits J, et al. **Cleve Clin J Med** 1996 May-Jun;63(3):181–9 (32 ref.)
Inhibitors of platelet glycoprotein IIb/IIIa as augmenters of thrombolysis. Eccleston D, et al. **Coron Artery Dis** 1995 Dec;6(12):947–55 (67 ref.)
Platelet glycoprotein IIb/IIIa receptor inhibitors in ischemic heart disease. Lefkovits J, et al. **Curr Opin Cardiol** 1995 Jul;10(4):420–6 (53 ref.)
Platelet glycoprotein IIb/IIIa receptor antagonists in coronary artery disease. Lefkovits J, et al. **Eur Heart J** 1996 Jan;17(1):9–18 (81 ref.)
New antiplatelet agents: platelet GPIIb/IIIa antagonists. Coller BS, et al. **Thromb Haemost** 1995 Jul;74(1):302–8 (38 ref.)

IMMUNOLOGY

Anti-platelet monoclonal antibodies for the prevention of arterial thrombosis: experience with ReoPro, a monoclonal antibody directed against the platelet GPIIb/IIIa receptor. Weisman HF, et al. **Biochem Soc Trans** 1995 Nov; 23(4):1051–7 (25 ref.)

METABOLISM

Platelet adhesion receptors. Williams MJ, et al. **Semin Cell Biol** 1995 Oct;6(5):305–14 (75 ref.)
Mechanisms involved in platelet vessel wall interaction. Hawiger J. **Thromb Haemost** 1995 Jul;74(1):369–72 (37 ref.)

PHYSIOLOGY

Role of platelets, thrombin, integrin IIb-IIIa, fibronectin and von Willebrand factor on tumor adhesion in vitro and metastasis in vivo. Nierodzik ML, et al. **Thromb Haemost** 1995 Jul;74(1):282–90 (67 ref.)
Function and regulation of the beta 3 integrins in hemostasis and vascular biology. Shattil SJ. **Thromb Haemost** 1995 Jul;74(1):149–55 (98 ref.)

PLATELET GLYCOPROTEIN IV see **ANTIGENS, CD36**

PLATELET MEMBRANE GLYCOPROTEIN IB see **PLATELET GLYCOPROTEIN GPIB-IX COMPLEX**

PLATELET MEMBRANE GLYCOPROTEIN IIB see **PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX**

PLATELET MEMBRANE GLYCOPROTEIN IIIA see **PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX**

PLATELET MEMBRANE GLYCOPROTEIN IIIB see **ANTIGENS, CD36**

PLATELET MEMBRANE GLYCOPROTEIN V see **PLATELET GLYCOPROTEIN GPIB-IX COMPLEX**

PLATELET MEMBRANE GLYCOPROTEIN IX see **PLATELET GLYCOPROTEIN GPIB-IX COMPLEX**

PLATELET MEMBRANE GLYCOPROTEINS

Platelet-activating factor receptor. Izumi T, et al. **J Lipid Mediat Cell Signal** 1995 Oct;12(2–3):429–42 (77 ref.)

ANTAGONISTS & INHIBITORS

Activation of the phospholipase/cyclooxygenase cascade in the rabbit cornea by platelet-activating factor is challenged by PAF receptor antagonists. Hurst JS, et al. **J Ocul Pharmacol Ther** 1995 Fall;11(3):329–37 (39 ref.)

GENETICS

Platelet-activating factor receptor: gene expression and signal transduction. Izumi T, et al. **Biochim Biophys Acta** 1995 Dec 7;1259(3):317–33 (231 ref.)
Polymorphisms of human platelet membrane glycoproteins:

structure and clinical significance. Nurden AT. **Thromb Haemost** 1995 Jul;74(1):345–51 (53 ref.)

IMMUNOLOGY

Human platelet alloantigens: recent findings, new perspectives. Newman PJ, et al. **Thromb Haemost** 1995 Jul; 74(1):234–9 (26 ref.)

[Platelet antigens: immunology and immuno-allergology] de Sousa JC, et al. **Allerg Immunol (Paris)** 1996 Feb; 28(2):48–51 (22 ref.) (Eng. Abstr.) **(Fre)**

[Antiplatelet glycoprotein monoclonal antibodies: properties and practical value] Saffroy R, et al. **Ann Biol Clin (Paris)** 1995;53(3):97–105 (119 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Platelet integrins. Ginsberg MH, et al. **Thromb Haemost** 1995 Jul;74(1):352–9 (176 ref.)

PHYSIOLOGY

Platelet activation: signal transduction via membrane receptors. Clemetson KJ. **Thromb Haemost** 1995 Jul; 74(1):111–6 (57 ref.)

Function and regulation of the beta 3 integrins in hemostasis and vascular biology. Shattil SJ. **Thromb Haemost** 1995 Jul;74(1):149–55 (98 ref.)

[Platelet collagen receptors] Kralisz U. **Postepy Biochem** 1995;41(3):188–94 (78 ref.) **(Pol)**

PLATELET NUMBER see **PLATELET COUNT**

PLATELET-SPECIFIC ANTIGENS see **ANTIGENS, HUMAN PLATELET**

PLATELET TRANSFORMING GROWTH FACTOR see **TRANSFORMING GROWTH FACTOR BETA**

PLATELET TRANSFUSION

Platelet transfusion therapy for medical and surgical patients. Hussein MA, et al. **Cleve Clin J Med** 1996 Jul-Aug; 63(4):245–50 (44 ref.)

Platelet transfusion and alternatives to transfusion in patients with malignancy. Vaickus L, et al. **Stem Cells (Dayt)** 1995 Nov;13(6):588–96 (86 ref.)

Platelet transfusion. Machin SJ, et al. **Thromb Haemost** 1995 Jul;74(1):246–52 (46 ref.)

Platelet transfusion therapy in newborn infants. Blanchette VS, et al. **Transfus Med Rev** 1995 Jul;9(3):215–30 (82 ref.)

ADVERSE EFFECTS

[Transfusion-refractory thrombocytopenia during chemotherapy: pathogenesis, frequency and treatment] Helleberg C, et al. **Ugeskr Laeger** 1995 Sep 11; 157(37):5082–6 (40 ref.) (Eng. Abstr.) **(Dan)**

PLATELETS see **BLOOD PLATELETS**

PLATINUM

see related
ORGANOPLATINUM COMPOUNDS

Mechanistic insight from kinetic studies on the interaction of model palladium (II) complexes with nucleic acid components. Rau T, et al. **Met Ions Biol Syst** 1996; 32:339–78 (95 ref.)

Proteins that bind to and mediate the biological activity of platinum anticancer drug-DNA adducts. Whitehead JP, et al. **Met Ions Biol Syst** 1996;32:687–726 (111 ref.)

CHEMISTRY

Evidences for a catalytic activity of the DNA double helix in the reaction between DNA, platinum(II), and intercalators. Boudvillain M, et al. **Met Ions Biol Syst** 1996; 33:87–104 (44 ref.)

PLATINUM BLACK see **PLATINUM**

PLATINUM COMPOUNDS

Paclitaxel in patients with platinum-resistant ovarian cancer: a selected review of literature and clinical experience. Kudelka AP, et al. **J Med Assoc Thai** 1996 Apr;79(4):240–5 (26 ref.)

PHARMACOLOGY

Mechanisms of resistance of human tumours to anticancer drugs of the platinum family: a review. Ferguson PJ. **J Otolaryngol** 1995 Aug;24(4):242–52 (100 ref.)

THERAPEUTIC USE

Mechanisms of resistance of human tumours to anticancer drugs of the platinum family: a review. Ferguson PJ. **J Otolaryngol** 1995 Aug;24(4):242–52 (100 ref.)

PLATINUM COMPOUNDS, INORGANIC see **PLATINUM COMPOUNDS**

PLATINUM DIAMMINODICHLORIDE see **CISPLATIN**

PLATYBASIA

see related
ARNOLD-CHIARI DEFORMITY

GENETICS

Craniovertebral junction anomalies in inherited disorders: part of the syndrome or caused by the disorder? Crockard HA, et al. **Eur J Pediatr** 1995 Jul;154(7):504–12 (48 ref.)

PLATYFISH see **CYPRINODONTIFORMES**

PLATYHELMINTHS

PHYSIOLOGY

Platyhelminth FMRFamide-related peptides. Shaw C, et al. **Int J Parasitol** 1996 Apr;26(4):335–45 (59 ref.)

PLATYRRHINA see **CEBIDAE**

PLAY AND PLAYTHINGS

Psychological science and the use of anatomically detailed dolls in child sexual-abuse assessments. Koocher GP, et al. **Psychol Bull** 1995 Sep;118(2):199–222 (160 ref.)

PLETHYSMOGRAPHY

Plethysmography: safety, effectiveness, and clinical utility in diagnosing vascular disease. Graham AA. **Health Technol Assess** 1996;(7):1–46 (182 ref.)

INSTRUMENTATION

[Methods of microcirculatory monitoring (laser Doppler flowmetry, photoplethysmography and computer-assisted venous occlusion plethysmography)] Christ F. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May; 31(1 Suppl):S37–43 (77 ref.) **(Ger)**

PLEURA

see related
PNEUMONOLYSIS

Evaluation of intrapleural analgesia in the management of blunt traumatic chest wall pain: a clinical trial. Short K, et al. **Am Surg** 1996 Jun;62(6):488–93 (50 ref.)

Pro: intrapleural anesthesia is useful for thoracic analgesia [see comments] McIlvaine WB. **J Cardiothorac Vasc Anesth** 1996 Apr;10(3):425–8 (41 ref.) Comment in: J Cardiothorac Vasc Anesth 1996 Apr;10(3):429–31.

Con: unreliable benefit after thoracotomy--epidural is a better choice [comment] Riegler FX. **J Cardiothorac Vasc Anesth** 1996 Apr;10(3):429–31 (20 ref.) Comment on: J Cardiothorac Vasc Anesth 1996 Apr;10(3):425–8.

PATHOLOGY

The mesothelial cell and its role in asbestos-induced pleural injury. Kuwahara M, et al. **Int J Exp Pathol** 1995 Jun; 76(3):163–70 (58 ref.)

PLEURAL DISEASES

New developments in asbestos-related pleural disease. Rudd RM. **Thorax** 1996 Feb;51(2):210–6 (59 ref.)

[Pleural amyloidosis. Apropos of a case and review of the literature] Quinquenel ML, et al. **Rev Pneumol Clin** 1996; 52(1):39–41 (12 ref.) (Eng. Abstr.) **(Fre)**

CHEMICALLY INDUCED

Bronchoesophagopleural fistula after photodynamic therapy for malignant mesothelioma. Luketich JD, et al. **Ann Thorac Surg** 1996 Jul;62(1):283–4 (7 ref.)

DIAGNOSIS

Medical thoracoscopy. Technical details. Mathur PN, et al. **Clin Chest Med** 1995 Sep;16(3):479–86 (27 ref.)

Medical thoracoscopy. Role in pleural and lung diseases. Mathur PN, et al. **Clin Chest Med** 1995 Sep;16(3):487–96 (85 ref.)

[Principles for assessment and diagnosis of work-related pulmonary and pleural diseases] Aasen TB, et al. **Tidsskr Nor Laegeforen** 1996 Feb 28;116(6):739–41 (23 ref.) (Eng. Abstr.) **(Nor)**

ETIOLOGY

The pleural space and organ transplantation. Judson MA, et al. **Am J Respir Crit Care Med** 1996 Mar;153(3):1153–65 (182 ref.)

[Pleuropulmonary manifestations of rheumatoid arthritis] Crestani B, et al. **Presse Med** 1996 May 18;25(17):807–12 (25 ref.) (Eng. Abstr.) **(Fre)**

RADIOGRAPHY

Imaging of pleural diseases. Maffessanti M, et al. **Monaldi Arch Chest Dis** 1996 Apr;51(2):138–44 (22 ref.)

[Roentgen findings in pleural diseases] Uhrmeister P, et al. **Internist (Berl)** 1995 Sep;36(9):937–47; quiz 948 (0 ref.) **(Ger)**

SURGERY

Role of thoracoscopy (VATS) in pleural and pulmonary pathology. Van Schil P, et al. **Acta Chir Belg** 1996 Feb; 96(1):23–7 (28 ref.)

Surgical treatment of complications 45 years after extraperiosteal pneumonolysis and plombage using acrylic resin balls for cavitary pulmonary tuberculosis. Thomas GE, et al. **Chest** 1995 Oct;108(4):1163–4 (8 ref.)

THERAPY

[The treatment of a bronchopleural fistula with fibrin adhesive in a premature infant] Galiana Ferré C, et al. **An Esp Pediatr** 1996 Jun;44(6):596–8 (11 ref.) **(Spa)**

PLEURAL EFFUSION

DIAGNOSIS

[Usefulness of biological markers in pleural effusion] Díez J de M, et al. **Rev Clin Esp** 1996 Feb;196(2):107–12 (73 ref.) **(Spa)**

ETIOLOGY

Unexplained effusions: association with allogeneic bone marrow transplantation and acute or chronic graft-versus-host disease. Seber A, et al. **Bone Marrow Transplant** 1996 Feb;17(2):207–11 (28 ref.)

[Pleural effusion of non-neoplastic etiology in a patient with a rare form of myeloma] Alvares E, et al. **Acta Med Port** 1995 Oct;8(10):579–84 (10 ref.) (Eng. Abstr.) **(Por)**

MICROBIOLOGY

Clinical problem solving in geriatric medicine: an older man with a pleural effusion. Berg J, et al. **J Am Geriatr Soc** 1996 Sep;44(9):1093–7 (41 ref.)

THERAPY

Treatment of complicated pleural fluid collections with image-guided drainage and intracavitary urokinase [see comments] Moulton JS, et al. **Chest** 1995 Nov; 108(5):1252–9 (20 ref.) Comment in: Chest 1995 Nov;108(5):1190–1.

PLEURAL EFFUSION, MALIGNANT

CHEMISTRY

[Coagulation and fibrinolysis parameters in neoplastic pleural exudates] Talalaj J. **Pneumonol Alergol Pol** 1995; 63(5–6):339–43 (15 ref.) **(Pol)**

DRUG THERAPY

First-line systemic therapy for metastatic breast cancer and management of pleural effusion. Perrone F, et al. **Ann Oncol** 1995 Dec;6(10):1033–43 (93 ref.)

ETIOLOGY

Lung cancer and ipsilateral pleural effusion. Rodriguez Panadero F. **Ann Oncol** 1995;6 Suppl 3:S25–7 (13 ref.)

GENETICS

Immunoglobulin gene rearrangement in T-cell-rich reactive pleural effusion of a patient with B-cell chronic lymphocytic leukemia. Miyahara M, et al. **Acta Haematol** 1996;96(1):41–4 (24 ref.)

PATHOLOGY

Epithelioid hemangioendothelioma of the lung: pleural effusion cytology, ultrastructure, and brief literature review. Buggage RR, et al. **Diagn Cytopathol** 1995 Jul; 13(1):54–60 (14 ref.)

THERAPY

Thoracoscopic management of malignant pleural effusions. Colt HG. **Clin Chest Med** 1995 Sep;16(3):505–18 (108 ref.)

[Current treatment strategy in malignant pleural effusion] Türler A, et al. **Wien Klin Wochenschr** 1996;108(9):255–61 (56 ref.) (Eng. Abstr.) **(Ger)**

PLEURAL NEOPLASMS

Pleuro-pulmonary blastoma: a case report and review of the literature. Schmaltz C, et al. **Med Pediatr Oncol** 1995 Dec; 25(6):479–84 (18 ref.)

Malignant pleural mesothelioma: newer aspects of carcinogenesis, molecular genetics, and prospects for future therapies. Donington JS, et al. **Surg Oncol** 1995 Aug; 4(4):175–85 (45 ref.)

[Peritoneal mesothelioma. Contribution of MRI. Apropos of a case] Guzelian J, et al. **J Radiol** 1996 Jul;77(7):497–501 (15 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Methods to improve the diagnostic accuracy of malignant mesothelioma. Dejmek A. **Respir Med** 1996 Apr; 90(4):191–9 (129 ref.)

PLEURAL NEOPLASMS

DRUG THERAPY

Bronchoesophagopleural fistula after photodynamic therapy for malignant mesothelioma. Luketich JD, et al. **Ann Thorac Surg** 1996 Jul;62(1):283–4 (7 ref.)

Chemotherapy in malignant pleural mesothelioma. A review. Ong ST, et al. **J Clin Oncol** 1996 Mar;14(3):1007–17 (79 ref.)

Use of photodynamic therapy for the management of pleural malignancies. Pass HI, et al. **Semin Surg Oncol** 1995 Sep–Oct;11(5):360–7 (21 ref.)

ETIOLOGY

Primary Epstein–Barr virus–related non–Hodgkin's lymphoma of the pleural cavity following long–standing tuberculous empyema. Molinie V, et al. **Arch Pathol Lab Med** 1996 Mar;120(3):288–91 (18 ref.)

GENETICS

Asbestos and mesothelioma: genetic lessons from a tragedy [comment] Knudson A. **Proc Natl Acad Sci U S A** 1995 Nov 21;92(24):10819–20 (21 ref.) Comment on: Proc Natl Acad Sci U S A 1995 Nov 21;92(24):10854–8.

PATHOLOGY

Malignant pleural mesothelioma. A proposed new staging system [editorial; comment] Jett JR. **Chest** 1995 Oct; 108(4):895–7 (18 ref.) Comment on: Chest 1995 Oct;108(4):1122–8.

Smooth muscle tumours of the pleura. Gibbs AR. **Histopathology** 1995 Sep;27(3):295–6 (17 ref.)

Intracranial meningioma masquerading as a primary pleuropulmonary tumor. Hishima T, et al. **Pathol Int** 1995 Aug;45(8):617–21 (23 ref.)

Malignant mesenchymoma of the pleura. Sheffield M, et al. **South Med J** 1996 May;89(5):526–8 (7 ref.)

PHYSIOPATHOLOGY

Clinical features and current treatment of diffuse malignant pleural mesothelioma. Rusch VW. **Lung Cancer** 1995 Jun; 12 Suppl 2:S127–46 (81 ref.)

RADIOGRAPHY

[Roentgen findings in pleural diseases] Uhrmeister P, et al. **Internist (Berl)** 1995 Sep;36(9):937–47; quiz 948 (0 ref.) **(Ger)**

SECONDARY

Case report: pleural encasement secondary to acinar adenocarcinoma of the submandibular gland. Hynes J, et al. **Br J Radiol** 1996 Mar;69(819):276–7 (12 ref.)

SURGERY

[Benign pleural mesothelioma. Report of 2 cases] Ruff S, et al. **Langenbecks Arch Chir** 1995;380(6):345–9 (12 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Clinical features and current treatment of diffuse malignant pleural mesothelioma. Rusch VW. **Lung Cancer** 1995 Jun; 12 Suppl 2:S127–46 (81 ref.)

PLEURAL RUB see **RESPIRATORY SOUNDS**

PLEURISY

CHEMICALLY INDUCED

Pleuropericarditis related to the use of mesalamine. Gujral N, et al. **Dig Dis Sci** 1996 Mar;41(3):624–6 (12 ref.)

[Drug–induced pleurisy] Benard A, et al. **Rev Mal Respir** 1996 Jul;13(3):227–34 (82 ref.) (Eng. Abstr.) **(Fre)**

PLEURODESIS

Thoracoscopy in the diagnosis and treatment of spontaneous pneumothorax. Boutin C, et al. **Clin Chest Med** 1995 Sep; 16(3):497–503 (30 ref.)

Medical thoracoscopy. Technical details. Mathur PN, et al. **Clin Chest Med** 1995 Sep;16(3):479–86 (27 ref.)

METHODS

[Current treatment strategy in malignant pleural effusion] Türler A, et al. **Wien Klin Wochenschr** 1996;108(9):255–61 (56 ref.) (Eng. Abstr.) **(Ger)**

[The treatment of a bronchopleural fistula with fibrin adhesive in a premature infant] Galiana Ferré C, et al. **An Esp Pediatr** 1996 Jun;44(6):596–8 (11 ref.) **(Spa)**

PLEURODYNIA VIRUS see **COXSACKIEVIRUSES B**

PLEUROPNEUMONIA, CONTAGIOUS

DIAGNOSIS

Uses of serology for the diagnosis of contagious bovine pleuropneumonia. Rurangirwa FR. **Rev Sci Tech** 1995 Sep; 14(3):603–9 (30 ref.)

[Complement fixation reaction for the serologic diagnosis of bovine contagious pleuropneumonia: application and interpretation of the results] Regalla J. **Rev Sci Tech** 1995 Sep;14(3):631–44 (11 ref.) (Eng. Abstr.) **(Fre)**

EPIDEMIOLOGY

Overview and epidemiology of contagious bovine pleuropneumonia in Africa. Masiga WN, et al. **Rev Sci Tech** 1995 Sep;14(3):611–30 (26 ref.)

MICROBIOLOGY

Mycoplasma mycoides subspecies mycoides (small colony variant): the agent of contagious bovine pleuropneumonia and member of the "Mycoplasma mycoides cluster". Nicholas RA, et al. **J Comp Pathol** 1995 Jul;113(1):1–27 (122 ref.)

PREVENTION & CONTROL

Contagious bovine pleuropneumonia vaccines: the need for improvements. Rweyemamu MM, et al. **Rev Sci Tech** 1995 Sep;14(3):593–601 (14 ref.)

[Vaccination strategies for contagious bovine pleuropneumonia in Africa] Sylla D, et al. **Rev Sci Tech** 1995 Sep;14(3):577–92 (8 ref.) (Eng. Abstr.) **(Fre)**

PLEUROPNEUMONIA–LIKE ORGANISMS see **MYCOPLASMA**

PLOIDIES

Vascular smooth muscle polyploidy in genetic hypertension: the role of angiotensin II. Devlin AM, et al. **J Hum Hypertens** 1995 Jun;9(6):497–500 (16 ref.)

The influence of intrinsic and extrinsic factors on the developmental potential and chromosomal normality of the human oocyte. Van Blerkom J. **J Soc Gynecol Investig** 1996 Jan–Feb;3(1):3–11 (38 ref.)

Clinical application of flow cytometry to urological malignancies. Tachibana M. **Keio J Med** 1996 Jun; 45(2):73–80 (54 ref.)

PLUMMER–VINSON SYNDROME

Plummer–Vinson syndrome. A case report and literature review. Hoffman RM, et al. **Arch Intern Med** 1995 Oct 9;155(18):2008–11 (25 ref.)

PLURALISM see **CULTURAL DIVERSITY**

PNEUMATOSIS CYSTOIDES INTESTINALIS

Pneumatosis intestinalis: a review. Heng Y, et al. **Am J Gastroenterol** 1995 Oct;90(10):1747–58 (118 ref.)

COMPLICATIONS

Pneumatosis cystoides intestinalis. Conservative approach in non surgical pneumoperitoneum: a case report and literature review. Brewaeys P, et al. **Acta Chir Belg** 1995; 95(4 Suppl):195–8 (25 ref.)

ETIOLOGY

Pneumatosis intestinalis and portal venous air associated with needle catheter jejunostomy. North JH Jr, et al. **Am Surg** 1995 Dec;61(12):1045–8 (25 ref.)

PATHOLOGY

Mixed connective tissue disease complicated by pneumatosis cystoides intestinalis and malabsorption syndrome: case report and literature review. Wakamatsu M, et al. **Pathol Int** 1995 Nov;45(11):875–8 (18 ref.)

RADIOGRAPHY

[Pneumoperitoneum in asymptomatic pneumatosis intestinalis—much ado about nothing?] Bücker A, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Mar;164(3):266–8 (10 ref.) **(Ger)**

PNEUMOCEPHALUS

COMPLICATIONS

Traumatic occlusion of the anterior cerebral artery—case report. Ishibashi A, et al. **Neurol Med Chir (Tokyo)** 1995 Dec;35(12):882–5 (7 ref.)

ETIOLOGY

Tension pneumocephalus following craniofacial resection. Wanamaker JR, et al. **Head Neck** 1995 Mar–Apr; 17(2):152–6 (22 ref.)

Diffuse pneumocephalus due to meningitis: CT findings. Goyal M, et al. **Pediatr Radiol** 1996;26(4):278–9 (5 ref.)

[Pneumocephalus complicating osteoma of the frontal sinus] Attane F, et al. **Rev Neurol (Paris)** 1996 Apr;152(4):279–82 (13 ref.) (Eng. Abstr.) **(Fre)**

RADIOGRAPHY

Pneumocephalus due to nasopharyngeal carcinoma: case report. Kiu MC, et al. **Neuroradiology** 1996 Jan;38(1):70–2 (24 ref.)

Diffuse pneumocephalus due to meningitis: CT findings. Goyal M, et al. **Pediatr Radiol** 1996;26(4):278–9 (5 ref.)

THERAPY

Tension pneumocephalus following craniofacial resection. Wanamaker JR, et al. **Head Neck** 1995 Mar–Apr; 17(2):152–6 (22 ref.)

PNEUMOCOCCAL INFECTIONS

Pneumococcal pyomyositis. Case report, review of the literature, and comparison with classic pyomyositis caused by other bacteria. Collazos J, et al. **Arch Intern Med** 1996 Jul 8;156(13):1470–4 (40 ref.)

The pneumococcal problem. Obaro SK, et al. **BMJ** 1996 Jun 15;312(7045):1521–5 (49 ref.)

Pneumococcal virulence factors and host immune responses to them. Watson DA, et al. **Eur J Clin Microbiol Infect Dis** 1995 Jun;14(6):479–90 (87 ref.)

Remediable recurrent meningitis. Rajeshwari K, et al. **Indian Pediatr** 1995 Apr;32(4):491–6 (28 ref.)

Liver abscess: an unusual manifestation of pneumococcal infection. Lund–Tønnesen S. **Scand J Infect Dis** 1995; 27(4):397–8 (5 ref.)

COMPLICATIONS

Recurrent Streptococcus pneumoniae endocarditis. Cunningham R, et al. **Eur J Clin Microbiol Infect Dis** 1995 Jun;14(6):526–8 (11 ref.)

DIAGNOSIS

Evaluation of the invasive techniques for diagnosing bacterial respiratory infections. Pozzi E, et al. **J Chemother** 1995 Aug;7(4):286–91 (26 ref.)

DRUG THERAPY

Pneumococcal infections in an era of multiple antibiotic resistance. Gray BM. **Adv Pediatr Infect Dis** 1996;11:55–99 (156 ref.)

Penicillin and multiply antibiotic–resistant Streptococcus pneumoniae. Estrada B, et al. **Compr Ther** 1995 Nov; 21(11):658–62 (32 ref.)

Lower respiratory tract infection therapy—the role of ciprofloxacin. Ball AP, et al. **J Int Med Res** 1995 Sep–Oct; 23(5):315–27 (55 ref.)

[The therapeutic implications of pneumococcal penicillin resistance] Lior C, et al. **Aten Primaria** 1996 Jul–Aug; 18(3):136–45 (82 ref.) **(Spa)**

[Pneumococcus resistance. Reconsiderations on its empirical treatment] Pallarés M. **Rev Med Univ Navarra** 1995 Apr–Jun;40(2):90–2 (13 ref.) **(Spa)**

ETIOLOGY

The molecular basis of pneumococcal infection: a hypothesis. Cundell D, et al. **Clin Infect Dis** 1995 Dec;21 Suppl 3:S204–11 (114 ref.)

Early postsplenectomy arthritis caused by penicillin–resistant Streptococcus pneumoniae. Merle–Melet M, et al. **Eur J Clin Microbiol Infect Dis** 1996 Feb;15(2):159–60 (7 ref.)

[Pneumococcal septic arthritis in HIV infection] Trivalle C, et al. **Presse Med** 1995 Nov 4;24(33):1566–8 (13 ref.) (Eng. Abstr.) **(Fre)**

MICROBIOLOGY

Streptococcus pneumoniae: virulence factors, pathogenesis, and vaccines. AlonsoDeVelasco E, et al. **Microbiol Rev** 1995 Dec;59(4):591–603 (163 ref.)

[Antibiotic resistance in pneumococci] Moreillon P, et al. **Schweiz Med Wochenschr** 1996 Feb 17;126(7):255–63 (30 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

The value of influenza and pneumococcal vaccines in the elderly. Monto AS, et al. **Drugs Aging** 1996 Jun;8(6):445–51 (35 ref.)

PNEUMOCOCCUS see **STREPTOCOCCUS PNEUMONIAE**

PNEUMOCONIOSIS

ETIOLOGY

Rare earth (cerium oxide) pneumoconiosis: analytical scanning electron microscopy and literature review. McDonald JW, et al. **Mod Pathol** 1995 Oct;8(8):859–65 (24 ref.)

[Allergies in agriculture] Gassner M. **Schweiz Rundsch Med Prax** 1996 Aug 13;85(33):950–60 (37 ref.) (Eng. Abstr.) **(Ger)**

METABOLISM

Expression of genes coding for growth factors in experimental pneumoconiosis. Morris GF, et al. **Chest** 1996 Mar;109(3 Suppl):45S–49S (55 ref.)

PATHOLOGY

Rare earth (cerium oxide) pneumoconiosis: analytical scanning electron microscopy and literature review. McDonald JW, et al. **Mod Pathol** 1995 Oct;8(8):859–65 (24 ref.)

PHYSIOPATHOLOGY

[Cellular reactions of the lung to mineral fibers] Gillissen A, et al. **Pneumologie** 1996 Jan;50(1):5–17 (137 ref.) **(Ger)**

RADIOGRAPHY

[Computed tomography of pneumoconiosis] Zhang X, et al. **Sangyo Eiseigaku Zasshi** 1995 Sep;37(5):321–8 (77 ref.) (Eng. Abstr.) **(Jpn)**

PNEUMOCYSTIS CARINII

METABOLISM

Surfactant protein-D modulates interaction of Pneumocystis carinii with alveolar macrophages [see comments] Limper AH, et al. **J Lab Clin Med** 1995 Nov;126(5):416–22 (37 ref.) Comment in: J Lab Clin Med 1995 Nov;126(5):414–5.

Surfactant protein binding to Pneumocystis carinii organisms [editorial; comment] Pottratz ST. **J Lab Clin Med** 1995 Nov;126(5):414–5 (18 ref.) Comment on: J Lab Clin Med 1995 Nov;126(5):416–22.

PNEUMOCYSTIS CARINII INFECTIONS

DIAGNOSIS

HIV-related Pneumocystis carinii thyroiditis: a unique case and literature review. Danahey DG, et al. **Otolaryngol Head Neck Surg** 1996 Jan;114(1):158–61 (15 ref.)

DRUG THERAPY

Therapeutic progress. IV: Treatment and prophylaxis of Pneumocystis carinii infection. Jolley AE, et al. **J Clin Pharm Ther** 1995 Jun;20(3):121–30 (89 ref.)

PNEUMOCYSTIS CARINII PNEUMONIA see **PNEUMONIA, PNEUMOCYSTIS CARINII**

PNEUMOGASTRIC NERVE see **VAGUS NERVE**

PNEUMONECTOMY

Resection of an unsuspected primary pulmonary choriocarcinoma. Canver CC, et al. **Ann Thorac Surg** 1996 Apr;61(4):1249–51 (8 ref.)

Isolated incisional recurrence after curative resection for primary lung cancer. Yokoi K, et al. **Ann Thorac Surg** 1996 Apr;61(4):1236–7 (9 ref.)

Reduction pneumoplasty for giant bullous emphysema. Implications for surgical treatment of nonbullous emphysema. Snider GL. **Chest** 1996 Feb;109(2):540–8 (44 ref.)

Tumor embolism to LAD during pneumonectomy. A case report. Shah R, et al. **J Cardiovasc Surg (Torino)** 1996 Jun; 37(3):319–21 (13 ref.)

Lung reduction surgery in chronic obstructive lung disease. Rogers RM, et al. **Med Clin North Am** 1996 May; 80(3):623–44 (42 ref.)

[A case report of pulmonary blastoma—well differentiated fetal adenocarcinoma] Okano T, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Jan;44(1):69–73 (13 ref.) (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Pneumoscrotum: an unusual complication of pulmonary resection. Raudat CW, et al. **J Am Osteopath Assoc** 1996 Jun;96(6):362–3 (16 ref.)

Perioperative fluid management for thoracic surgery: the puzzle of postpneumonectomy pulmonary edema. Slinger PD. **J Cardiothorac Vasc Anesth** 1995 Aug;9(4):442–51 (52 ref.)

METHODS

The current status of lung volume reduction operations for emphysema. Naunheim KS, et al. **Ann Thorac Surg** 1996 Aug;62(2):601–12 (97 ref.)

Radiology of pulmonary emphysema and lung volume reduction surgery. Slone RM, et al. **Semin Thorac Cardiovasc Surg** 1996 Jan;8(1):61–82 (61 ref.)

[A case of bilateral thoracoscopic partial resection for unilateral spontaneous pneumothorax] Kinugasa S, et al. **Kyobu Geka** 1995 Oct;48(11):978–81 (12 ref.) (Eng. Abstr.) **(Jpn)**

[A case of resected small-sized (4 mm in diameter) lung cancer and its way of surgical treatment] Morita H. **Kyobu Geka** 1996 Mar;49(3):175–8; discussion 179–81 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Early peripheral cancer of the lung: long-term results of combined therapy using sparing resection techniques] Kharchenko VP, et al. **Vopr Onkol** 1996;42(2):77–81 (13 ref.) (Eng. Abstr.) **(Rus)**

PNEUMONIA

Community-acquired pneumonia: an update. Meeker DP, et al. **Cleve Clin J Med** 1996 Jan-Feb;63(1):16–30 (97 ref.)

Etiopathogenesis and management of pneumonia. Mokshagundam SL, et al. **Compr Ther** 1995 Aug; 21(8):413–20 (23 ref.)

Community-acquired pneumonia [see comments] Bartlett JG, et al. **N Engl J Med** 1995 Dec 14;333(24):1618–24 (48 ref.) Comment in: N Engl J Med 1996 Mar 28;334(13):861; discussion 862–3. Comment in: N Engl J Med 1996 Mar 28;334(13):862; discussion 862–3.

Delayed resolution of pneumonia. When is slow healing too slow? Cassiere H, et al. **Postgrad Med** 1996 Jan;99(1):151–4, 157–8 (9 ref.)

Community-acquired pneumonia requiring hospitalisation. Factors of importance for the short-and long term prognosis. Hedlund J. **Scand J Infect Dis Suppl** 1995; 97:1–60 (175 ref.)

Severe community-acquired pneumonia. Leeper KV Jr. **Semin Respir Infect** 1996 Jun;11(2):96–108 (82 ref.)

CHEMICALLY INDUCED

Benefits of extracorporeal membrane oxygenation for hydrocarbon pneumonitis. Chyka PA. **J Toxicol Clin Toxicol** 1996;34(4):357–63 (34 ref.)

COMPLICATIONS

Pneumonia in cancer patients. Whimbey E, et al. **Cancer Treat Res** 1995;79:185–210 (144 ref.)

The role of inflammation in the pathogenesis of bronchopulmonary dysplasia. Pierce MR, et al. **Pediatr Pulmonol** 1995 Jun;19(6):371–8 (89 ref.)

DIAGNOSIS

Pulmonary complications of HIV infection. Murray JF. **Annu Rev Med** 1996;47:117–26 (30 ref.)

Diagnosis and treatment of nosocomial pneumonia in patients in intensive care units. Chastre J, et al. **Clin Infect Dis** 1995 Dec;21 Suppl 3:S226–37 (61 ref.)

Evaluation of the invasive techniques for diagnosing bacterial respiratory infections. Pozzi E, et al. **J Chemother** 1995 Aug;7(4):286–91 (26 ref.)

Community-acquired pneumonia. What's needed for accurate diagnosis. File TM Jr, et al. **Postgrad Med** 1996 Jan;99(1):95–102, 105–7 (13 ref.)

Neoplastic mimics of pneumonia. Casey KR. **Semin Respir Infect** 1995 Sep;10(3):131–42 (86 ref.)

Diagnosis of pulmonary infections in mechanically ventilated patients. Chastre J, et al. **Semin Respir Infect** 1996 Jun; 11(2):65–76 (58 ref.)

Radiation pneumonitis: a mimic of infectious pneumonitis. Salinas FV, et al. **Semin Respir Infect** 1995 Sep;10(3):143–53 (38 ref.)

Nosocomial pneumonia during mechanical ventilation: problems with diagnostic criteria [editorial] Brun-Buisson C. **Thorax** 1995 Nov;50(11):1128–30 (27 ref.)

[Nosocomial pneumonia] Jébrak G, et al. **Presse Med** 1996 Jun 8;25(20):944–50 (25 ref.) (Eng. Abstr.) **(Fre)**

[Atypical pneumonias] Irigaray R, et al. **Arch Bronconeumol** 1996 Apr;32(4):187–95 (66 ref.) **(Spa)**

DRUG THERAPY

Diagnosis and treatment of nosocomial pneumonia in patients in intensive care units. Chastre J, et al. **Clin Infect Dis** 1995 Dec;21 Suppl 3:S226–37 (61 ref.)

Community-acquired pneumonia. Musher DM, et al. **Curr Clin Top Infect Dis** 1996;16:102–24 (36 ref.)

Community-acquired pneumonia. Cost-effective antimicrobial therapy [see comments] Cunha BA. **Postgrad Med** 1996 Jan;99(1):109–10, 113–4, 117–9, passim (13 ref.) Comment in: Postgrad Med 1996 Apr;99(4):62–4.

[Antibiotic therapy for pneumonias acquired outside the hospital] Achermann E, et al. **Dtsch Med Wochenschr** 1996 Aug 23;121(34–35):1057–9 (14 ref.) **(Ger)**

EPIDEMIOLOGY

Epidemiology of lower respiratory tract infections. Bariffi F, et al. **J Chemother** 1995 Aug;7(4):263–76 (79 ref.)

ETIOLOGY

Predicting acute respiratory distress syndrome and intrapulmonary inflammation. Reid PT, et al. **Br J Hosp Med** 1996 Apr 17–30;55(8):499–502 (22 ref.)

Pneumonia due to blastomyces dermatitidis in a European renal transplant recipient. Winkler S, et al. **Nephrol Dial Transplant** 1996 Jul;11(7):1376–9 (13 ref.)

[Pneumonia in patients on the mechanical respirator] Ben-Abraham R, et al. **Harefuah** 1995 Jul;129(1–2):46–51 (35 ref.) **(Heb)**

IMMUNOLOGY

Role of inflammation in respiratory tract infections. Stockley RA. **Am J Med** 1995 Dec 29;99(6B):8S–13S (15 ref.)

MICROBIOLOGY

Coxiella burnetii (Q fever) pneumonia. Marrie TJ. **Clin Infect Dis** 1995 Dec;21 Suppl 3:S253–64 (89 ref.)

Community-acquired pneumonia. Musher DM, et al. **Curr Clin Top Infect Dis** 1996;16:102–24 (36 ref.)

Etiology and risk factors of adult pneumonia. Ginesu F, et al. **J Chemother** 1995 Aug;7(4):277–85 (32 ref.)

PHYSIOPATHOLOGY

Gene transfer for cytokine functional studies in the lung: the multifunctional role of GM-CSF in pulmonary inflammation. Xing Z, et al. **J Leukoc Biol** 1996 Apr; 59(4):481–8 (55 ref.)

Polymorphonuclear leucocyte traffic in lung inflammation [editorial] Hogg JC, et al. **Thorax** 1995 Aug;50(8):819–20 (24 ref.)

PREVENTION & CONTROL

Postoperative atelectasis and pneumonia: risk factors. Brooks-Brunn JA. **Am J Crit Care** 1995 Sep;4(5):340–9; quiz 350–1 (90 ref.)

Role of corticosteroids in cystic fibrosis lung disease. Balfour-Lynn IM, et al. **J R Soc Med** 1996;89 Suppl 27:8–13 (37 ref.)

Stress ulcer prophylaxis: gastrointestinal bleeding and nosocomial pneumonia. Best evidence synthesis. Cook DJ. **Scand J Gastroenterol Suppl** 1995;210:48–52 (38 ref.)

Potential interventions for preventing pneumonia among young children in developing countries: promoting maternal education. van Ginneken JK, et al. **Trop Med Int Health** 1996 Jun;1(3):283–94 (34 ref.)

RADIOGRAPHY

Radiographic mimics of pneumonia. Pulmonary disorders to consider in differential diagnosis. Cabreros LJ, et al. **Postgrad Med** 1996 Jan;99(1):139–42, 145–6 (0 ref.)

THERAPY

Current aspects in the management of pneumonia. Woodhead M. **Br J Clin Pract** 1995 Jul-Aug;49(4):205–10 (83 ref.)

Benefits of extracorporeal membrane oxygenation for hydrocarbon pneumonitis. Chyka PA. **J Toxicol Clin Toxicol** 1996;34(4):357–63 (34 ref.)

PNEUMONIA, ASPIRATION

Aspiration in patients in critical care units. Shifrin RY, et al. **Radiol Clin North Am** 1996 Jan;34(1):83–96 (33 ref.)

PHYSIOPATHOLOGY

Subglottic air pressure: a key component of swallowing efficiency. Eibling DE, et al. **Ann Otol Rhinol Laryngol** 1996 Apr;105(4):253–8 (19 ref.)

PREVENTION & CONTROL

[The child with minor trauma. Does observation of fasting times reduce the risk of aspiration?] Kraus GB, et al. **Anaesthesist** 1996 May;45(5):420–7 (71 ref.) (Eng. Abstr.) **(Ger)**

[Medicamentous prevention of acid aspiration syndrome] Kurz-Müller K, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May; 31(4):261–5 (77 ref.) **(Ger)**

[Is traditional preoperative fasting still applicable?] Wrenger K, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May; 31(4):250–4 (36 ref.) **(Ger)**

THERAPY

[Treatment of aspiration of gastric contents] Müller E. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May; 31(4):265–9 (24 ref.) **(Ger)**

PNEUMONIA, BACTERIAL

Nosocomial pneumonia: trying to make sense of the literature. Broughton WA, et al. **Postgrad Med** 1996 Mar; 99(3):221–31, 235–6, 241–2 (31 ref.)

Nosocomial pneumonia. Lipchik RJ, et al. **Radiol Clin North Am** 1996 Jan;34(1):47–58 (69 ref.)

COMPLICATIONS

[Rhodococcus equi pneumonia in patients with HIV infection: report of 2 cases and review of the literature] Berna JD, et al. **Enferm Infecc Microbiol Clin** 1996 Mar; 14(3):177–80 (57 ref.) (Eng. Abstr.) **(Spa)**

[Primary cutaneous cryptococcosis and bacterial pneumonia caused by Pseudomonas aeruginosa in AIDS: clinical case and review of the literature] Dronda F, et al. **Enferm Infecc Microbiol Clin** 1996 Feb;14(2):101–5 (35 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies. A consensus statement, American Thoracic Society, November 1995. **Am J Respir Crit Care Med** 1996 May;153(5):1711–25 (110 ref.)

PNEUMONIA, BACTERIAL

Diagnosis and treatment of nosocomial pneumonia. Bonten MJ, et al. **Br J Hosp Med** 1995 Oct 4–17;54(7):335–40 (25 ref.)

Actinomyces odontolyticus thoracopulmonary infections. Two cases in lung and heart–lung transplant recipients and a review of the literature. Bassiri AG, et al. **Chest** 1996 Apr;109(4):1109–11 (10 ref.)

Pneumonia due to Chlamydia pneumoniae: prevalence, clinical features, diagnosis, and treatment. Kauppinen M, et al. **Clin Infect Dis** 1995 Dec;21 Suppl 3:S244–52 (120 ref.)

The role of bronchoalveolar lavage in the diagnosis of bacterial pneumonia. Sanchez Nieto JM, et al. **Eur J Clin Microbiol Infect Dis** 1995 Oct;14(10):839–50 (93 ref.)

The lung in HIV infection: can pulmonary function testing help? Mitchell DM, et al. **Monaldi Arch Chest Dis** 1996 Jun;51(3):214–22 (30 ref.)

Atypical pneumonia. Extrapulmonary clues guide the way to diagnosis [published erratum appears in Postgrad Med 1996 Apr;99(4):64] Cunha BA, et al. **Postgrad Med** 1996 Jan;99(1):123–8, 131–2 (11 ref.)

[Interstitial pneumonia and sepsis due to a Pasteurella multocida infection] Schlichthaar H, et al. **Dtsch Med Wochenschr** 1995 Nov 17;120(46):1582–6 (19 ref.) (Eng. Abstr.) **(Ger)**

[Hospital pneumonia due to Xanthomonas maltophilia and AIDS (letter)] Sitges M, et al. **Arch Bronconeumol** 1996 May;32(5):259–60 (6 ref.) **(Spa)**

DRUG THERAPY

Diagnosis and treatment of nosocomial pneumonia. Bonten MJ, et al. **Br J Hosp Med** 1995 Oct 4–17;54(7):335–40 (25 ref.)

[Azithromycin and bronchopulmonary infections] Leophonte P. **Pathol Biol (Paris)** 1995 Jun;43(6):534–41 (38 ref.) (Eng. Abstr.) **(Fre)**

[Treatment of severe infections: should one always administer an aminoglycoside?] Cometta A, et al. **Schweiz Med Wochenschr Suppl** 1996;76:28S–33S (30 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Gastric alkalinization, pneumonia, and systemic infections: the controversy. Tryba M, et al. **Scand J Gastroenterol Suppl** 1995;210:53–9 (69 ref.)

[Disappearance of emphysematous bullae after infectious episodes] Guimard Y, et al. **Rev Pneumol Clin** 1995; 51(4):253–6 (12 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Pulmonary immunity to Pseudomonas aeruginosa. Cripps AW, et al. **Immunol Cell Biol** 1995 Oct;73(5):418–24 (84 ref.)

Expression and regulation of chemokines in bacterial pneumonia. Standiford TJ, et al. **J Leukoc Biol** 1996 Jan; 59(1):24–8 (33 ref.)

MICROBIOLOGY

Pneumonia due to Chlamydia pneumoniae: prevalence, clinical features, diagnosis, and treatment. Kauppinen M, et al. **Clin Infect Dis** 1995 Dec;21 Suppl 3:S244–52 (120 ref.)

Pneumonia during pregnancy. Rigby FB, et al. **Clin Obstet Gynecol** 1996 Mar;39(1):107–19 (79 ref.)

[Various new pathogens in pneumonia] Regamey C. **Schweiz Med Wochenschr** 1995 Nov 11;125(45):2171–7 (26 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

Preventing bacterial respiratory tract infections among persons infected with human immunodeficiency virus. Keller DW, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S77–83 (66 ref.)

Selective decontamination of the digestive tract: indications and problems [editorial] Lode H, et al. **Infection** 1995 May–Jun;23(3):129–32 (31 ref.)

THERAPY

Pneumonia during pregnancy. Rigby FB, et al. **Clin Obstet Gynecol** 1996 Mar;39(1):107–19 (79 ref.)

Management of the transplant recipient with pulmonary infection. Houston SH, et al. **Infect Dis Clin North Am** 1995 Dec;9(4):965–85 (113 ref.)

PNEUMONIA, EOSINOPHILIC see **PULMONARY EOSINOPHILIA**

PNEUMONIA, INTERSTITIAL see **LUNG DISEASES, INTERSTITIAL**

PNEUMONIA, INTERSTITIAL PLASMA CELL see **PNEUMONIA, PNEUMOCYSTIS CARINII**

PNEUMONIA, LOBAR

COMPLICATIONS

[Pneumococcal pneumonia in a patient with HIV infection. Development to excavation. Apropos of a case] Venot P, et al. **Rev Pneumol Clin** 1996;52(1):29–32 (11 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

Antibiotic-resistant pneumococcal pneumonia [editorial] Feldman C, et al. **S Afr Med J** 1996 Jan;86(1):28–30 (38 ref.)

[Azithromycin and bronchopulmonary infections] Leophonte P. **Pathol Biol (Paris)** 1995 Jun;43(6):534–41 (38 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

Preventing bacterial respiratory tract infections among persons infected with human immunodeficiency virus. Keller DW, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S77–83 (66 ref.)

Pneumococcal conjugate vaccines. Eby R. **Pharm Biotechnol** 1995;6:695–718 (140 ref.)

PNEUMONIA, MYCOPLASMA

COMPLICATIONS

[Transverse myelitis caused by Mycoplasma pneumoniae infection] Albucher JF, et al. **Rev Neurol (Paris)** 1995 May; 151(5):350–3 (10 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Mycoplasma pneumoniae infection associated with an acute brainstem syndrome. Pellegrini M, et al. **Acta Neurol Scand** 1996 Feb–Mar;93(2–3):203–6 (10 ref.)

[Detection of Mycoplasma pneumoniae by using polymerase chain reaction and nonradioactive DNA probes] Yamashita K, et al. **Rinsho Byori** 1995 Dec;43(12):1251–5 (17 ref.) (Eng. Abstr.) **(Jpn)**

PNEUMONIA, PNEUMOCOCCAL see **PNEUMONIA, LOBAR**

PNEUMONIA, PNEUMOCYSTIS CARINII

CHEMICALLY INDUCED

[Pneumocystis carinii pneumonia associated with low dose methotrexate treatment for malignant rheumatoid arthritis] Okuda Y, et al. **Ryumachi** 1995 Aug;35(4):699–704 (18 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

The lung in HIV infection: can pulmonary function testing help? Mitchell DM, et al. **Monaldi Arch Chest Dis** 1996 Jun;51(3):214–22 (30 ref.)

Pneumocystic infections: the radiologist's perspective. Kuhlman JE. **Radiology** 1996 Mar;198(3):623–35 (96 ref.)

DRUG THERAPY

Atovaquone. A review of its pharmacological properties and therapeutic efficacy in opportunistic infections. Spencer CM, et al. **Drugs** 1995 Jul;50(1):176–96 (64 ref.)

New drug developments for opportunistic infections in immunosuppressed patients: Pneumocystis carinii. Queener SF. **J Med Chem** 1995 Nov 24;38(24):4739–59 (158 ref.)

Options in the management of pneumonia caused by Pneumocystis carinii in patients with acquired immune deficiency syndrome and intolerance to trimethoprim/sulfamethoxazole. Korraa H, et al. **South Med J** 1996 Mar;89(3):272–7 (38 ref.)

[Intolerance to trimethoprim-sulfamethoxazole in Pneumocystis carinii pneumonia in AIDS. Search for predictive factors] Pinzani V, et al. **Ann Med Interne (Paris)** 1995;146(7):505–9 (25 ref.) (Eng. Abstr.) **(Fre)**

[Cotrimoxazole induced dermatitis and curative treatment of AIDS pneumocystosis] Caumes E. **Rev Mal Respir** 1996; 13(2):101–6 (45 ref.) (Eng. Abstr.) **(Fre)**

[Therapy and prevention of pneumocystis carinii pneumonia] Goebel FD, et al. **Internist (Berl)** 1995 Dec;36(12):1150–5 (31 ref.) **(Ger)**

ETIOLOGY

Pneumocystis carinii and parasitic infections in transplantation. Fishman JA. **Infect Dis Clin North Am** 1995 Dec;9(4):1005–44 (128 ref.)

PREVENTION & CONTROL

Recent advances in the prevention of pneumocystis carinii pneumonia. Hughes WT. **Adv Pediatr Infect Dis** 1996; 11:163–86 (74 ref.)

Quality standard for the prophylaxis of Pneumocystis carinii pneumonia in adults and adolescents infected with human immunodeficiency virus. Phair JP, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S128–9 (8 ref.)

Preventing Pneumocystis carinii pneumonia in persons infected with human immunodeficiency virus. Simonds RJ, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S44–8 (41 ref.)

Quality standard for the prophylaxis of Pneumocystis carinii pneumonia in infants and children born to women infected with human immunodeficiency virus. Wilfert CM, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S132–3 (4 ref.)

PNEUMONIA, RADIATION see **RADIATION PNEUMONITIS**

PNEUMONIA, VIRAL

DIAGNOSIS

Laboratory diagnosis of viral infections of the lung. Leland DS, et al. **Semin Respir Infect** 1995 Dec;10(4):189–98 (38 ref.)

Cytomegalovirus pneumonia: presentation, diagnosis, and treatment. Ljungman P. **Semin Respir Infect** 1995 Dec; 10(4):209–15 (44 ref.)

[Cytomegalovirus pneumopathies. What role should be given to cytomegaloviruses isolated from blood and bronchoalveolar lavage fluid in AIDS and from organ and bone marrow grafts?] Blot F, et al. **Rev Pneumol Clin** 1995; 51(6):309–20 (102 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

Anti-infective therapy for viral pneumonia. Mahmood W, et al. **Semin Respir Infect** 1995 Dec;10(4):270–81 (39 ref.)

EPIDEMIOLOGY

[Varicella in pregnancy] Lécuru F, et al. **Presse Med** 1995 Oct 7;24(29):1352–7 (23 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Severe respiratory insufficiency complicating Epstein–Barr virus infection: case report and review. Haller A, et al. **Clin Infect Dis** 1995 Jul;21(1):206–9 (24 ref.)

"Childhood" viruses as a cause of pneumonia in adults. Yang E, et al. **Semin Respir Infect** 1995 Dec;10(4):232–43 (40 ref.)

IMMUNOLOGY

Pathogenesis of cytomegalovirus pneumonia in immunocompromised hosts. Riddell SR. **Semin Respir Infect** 1995 Dec;10(4):199–208 (71 ref.)

PHYSIOPATHOLOGY

[Can outcome of varicella pneumonia be predicted in a non-immunosuppressed patient?] Jeanfaivre T, et al. **Rev Pneumol Clin** 1995;51(6):348–50 (15 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

Vaccines in the prevention of viral pneumonia. Betts RF. **Semin Respir Infect** 1995 Dec;10(4):282–7 (34 ref.)

THERAPY

Management of the transplant recipient with pulmonary infection. Houston SH, et al. **Infect Dis Clin North Am** 1995 Dec;9(4):965–85 (113 ref.)

Cytomegalovirus pneumonia: presentation, diagnosis, and treatment. Ljungman P. **Semin Respir Infect** 1995 Dec; 10(4):209–15 (44 ref.)

Influenza virus pneumonia: pathogenesis, treatment, and prevention. Piedra PA. **Semin Respir Infect** 1995 Dec; 10(4):216–23 (43 ref.)

VIROLOGY

Human herpesvirus 6 as a possible cause of pneumonia. Cone RW. **Semin Respir Infect** 1995 Dec;10(4):254–8 (32 ref.)

Influenza virus pneumonia: pathogenesis, treatment, and prevention. Piedra PA. **Semin Respir Infect** 1995 Dec; 10(4):216–23 (43 ref.)

PNEUMONITIS, HYPERSENSITIVITY see **ALVEOLITIS, EXTRINSIC ALLERGIC**

PNEUMONITIS, HYPERSENSITIVITY, AVIAN see **BIRD FANCIER'S LUNG**

PNEUMONITIS, INTERSTITIAL see **LUNG DISEASES, INTERSTITIAL**

PNEUMONITIS, RADIATION see **RADIATION PNEUMONITIS**

PNEUMONOLYSIS

ADVERSE EFFECTS

Surgical treatment of complications 45 years after extraperiosteal pneumonolysis and plombage using acrylic resin balls for cavitary pulmonary tuberculosis. Thomas GE, et al. **Chest** 1995 Oct;108(4):1163–4 (8 ref.)

PNEUMOPERICARDIUM

DIAGNOSIS

[Pneumopericardium: a race against time! Case report and literature review] Alvarez L, et al. **Rev Med Brux** 1996 Jun;17(3):143–6 (15 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Tension pneumopericardium following blunt injury. Capizzi PJ, et al. **J Trauma** 1995 Oct;39(4):775–80 (80 ref.)

PNEUMOPERITONEUM

ETIOLOGY

Pneumatosis cystoides intestinalis. Conservative approach in non surgical pneumoperitoneum: a case report and literature review. Brewaeys P, et al. **Acta Chir Belg** 1995; 95(4 Suppl):195–8 (25 ref.)

[Anesthesia for celiosurgery] Schoeffler P, et al. **Ann Chir** 1995;49(10):878–80 (19 ref.) **(Fre)**

[Retroperitoneal abscess formation accompanied by intraabdominal free air, a rare complication of transcatheter arterial embolization of renal tumor: a case report] Koga F, et al. **Hinyokika Kiyo** 1996 Jun;42(6):443–6 (7 ref.) (Eng. Abstr.) **(Jpn)**

RADIOGRAPHY

Pneumomediastinum: old signs and new signs. Bejvan SM, et al. **AJR Am J Roentgenol** 1996 May;166(5):1041–8 (18 ref.)

[Pneumoperitoneum in asymptomatic pneumatosis intestinalis—much ado about nothing?] Bücker A, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Mar;164(3):266–8 (10 ref.) **(Ger)**

PNEUMOPERITONEUM, ARTIFICIAL

Cardiopulmonary physiology and pathophysiology as a consequence of laparoscopic surgery. Sharma KC, et al. **Chest** 1996 Sep;110(3):810–5 (76 ref.)

METHODS

[Progressive pneumoperitoneum in treatment of inguinal and scar hernias. Results of animal experiments and clinical applications] Willis S, et al. **Langenbecks Arch Chir** 1996; 381(3):132–7 (37 ref.) (Eng. Abstr.) **(Ger)**

PNEUMORETROPERITONEUM see **RETROPNEUMOPERITONEUM**

PNEUMOTHORAX

see related
HEMOPNEUMOTHORAX
HYDROPNEUMOTHORAX

DIAGNOSIS

Thoracoscopy in the diagnosis and treatment of spontaneous pneumothorax. Boutin C, et al. **Clin Chest Med** 1995 Sep; 16(3):497–503 (30 ref.)

ETIOLOGY

Acute ventilatory complications during laparoscopic upper abdominal surgery. Wahba RW, et al. **Can J Anaesth** 1996 Jan;43(1):77–83 (35 ref.)

Spontaneous pneumothorax in children with AIDS. Schroeder SA, et al. **Chest** 1995 Oct;108(4):1173–6 (25 ref.)

[Parietal problems in thoracic injuries by gunshot] Houdelette P. **J Chir (Paris)** 1996 Apr;133(2):82–90 (23 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

[Menstruation-associated (catamenial) pneumothorax and catamenial hemoptysis] Hamacher J, et al. **Schweiz Med Wochenschr** 1996 May 25;126(21):924–32 (100 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Videothoracoscopic operations for bullous lung disease. Jacques LF. **Chest Surg Clin N Am** 1995 Nov;5(4):751–63 (29 ref.)

Surgery for complications of chronic obstructive lung disease. Tanaka F, et al. **Chest Surg Clin N Am** 1995 Nov; 5(4):797–813 (33 ref.)

Management of spontaneous pneumothorax during pregnancy: case report and review of the literature. VanWinter JT, et al. **Mayo Clin Proc** 1996 Mar; 71(3):249–52 (27 ref.)

Herniation of the lung following video-assisted minithoracotomy. van den Brink WA, et al. **Surg Endosc** 1995 Jun;9(6):706–8 (10 ref.)

[A case of bilateral thoracoscopic partial resection for unilateral spontaneous pneumothorax] Kinugasa S, et al. **Kyobu Geka** 1995 Oct;48(11):978–81 (12 ref.) (Eng. Abstr.) **(Jpn)**

THERAPY

Thoracoscopy in the diagnosis and treatment of spontaneous pneumothorax. Boutin C, et al. **Clin Chest Med** 1995 Sep; 16(3):497–503 (30 ref.)

PNEUMOTHORAX, ARTIFICIAL

ADVERSE EFFECTS

Primary Epstein-Barr virus-related non-Hodgkin's lymphoma of the pleural cavity following long-standing tuberculous empyema. Molinie V, et al. **Arch Pathol Lab Med** 1996 Mar;120(3):288–91 (18 ref.)

PODIATRY

see related
FOOT DISEASES

Applications of biodegradable lactides and glycolides in podiatry. Athanasiou KA, et al. **Clin Podiatr Med Surg** 1995 Jul;12(3):475–95 (90 ref.)

STANDARDS

Considerations of prescription medications for the pregnant podiatric patient. Haverstock BD, et al. **J Am Podiatr Med Assoc** 1996 Jul;86(7):334–46 (108 ref.)

PODOPHYLLOTOXIN

THERAPEUTIC USE

Podophyllotoxin in the treatment of genital warts. Beutner KR. **Curr Probl Dermatol** 1996;24:227–32 (23 ref.)

POEMS SYNDROME

[Polyneuritis, endocrine disorders associated with plasma cell dyscrasia] Takatsuki K. **Nippon Naika Gakkai Zasshi** 1995 Jul 10;84(7):1117–21 (6 ref.) **(Jpn)**

COMPLICATIONS

Acute arterial obliteration: a new feature of the POEMS syndrome? Lesprit P, et al. **Medicine (Baltimore)** 1996 Jul; 75(4):226–32 (45 ref.)

[Nervous microangiopathy and POEMS syndrome] Maillot F, et al. **Rev Med Interne** 1995;16(12):934–7 (12 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

[Myocardiopathy in POEMS syndrome (letter)] Gacon PH, et al. **Ann Med Interne (Paris)** 1996;147(2):124–6 (16 ref.) **(Fre)**

PHYSIOPATHOLOGY

[POEMS syndrome: role and value of interleukin-6] Andrès E, et al. **Rev Med Interne** 1996;17(2):145–9 (33 ref.) (Eng. Abstr.) **(Fre)**

POIKILODERMA CONGENITALE

COMPLICATIONS

Osteogenic sarcoma in the Rothmund-Thomson syndrome. Leonard A, et al. **Med Pediatr Oncol** 1996 Apr;26(4):249–53 (22 ref.)

POINT MUTATION

Deficient expression of the small proteoglycan decorin in a case of severe/lethal osteogenesis imperfecta. Dyne KM, et al. **Am J Med Genet** 1996 May 3;63(1):161–6 (34 ref.)

Mutations in the cartilage oligomeric matrix protein (COMP) gene in pseudoachondroplasia and multiple epiphyseal dysplasia. Cohn DH, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:188–94 (18 ref.)

The G protein-coupled receptor family and one of its members, the TSH receptor. Vassart G, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:23–30 (43 ref.)

Keratins and the skin. Fuchs E. **Ann Rev Cell Dev Biol** 1995; 11:123–53 (171 ref.)

Human DNA topoisomerase II: biochemistry and role in chemotherapy resistance (review). Withoff S, et al. **Anticancer Res** 1996 Jul-Aug;16(4A):1867–80 (184 ref.)

Antagonistic mutant proteins of interleukin-4. Duschl A, et al. **Behring Inst Mitt** 1995 Jun;(96):87–94 (27 ref.)

Genetic and epigenetic inactivation of repetitive sequences in Neurospora crassa: RIP, DNA methylation, and quelling. Singer MJ, et al. **Curr Top Microbiol Immunol** 1995; 197:165–77 (54 ref.)

Maternally inherited diabetes and deafness: a new diabetes subtype. Maassen JA, et al. **Diabetologia** 1996 Apr; 39(4):375–82 (53 ref.)

The PIG-A gene somatic mutation responsible for paroxysmal nocturnal hemoglobinuria. Rotoli B, et al. **Haematologica** 1995 Nov-Dec;80(6):539–45 (44 ref.)

Hyperproinsulinemia in a three-generation Caucasian family due to mutant proinsulin (Arg65-His) not associated with imparied glucose tolerance: the contribution of mutant proinsulin to insulin bioactivity. Röder ME, et al. **J Clin Endocrinol Metab** 1996 Apr;81(4):1634–40 (29 ref.)

P53 gene mutations in lymphoid diseases and their possible relevance to drug resistance. Newcomb EW. **Leuk Lymphoma** 1995 Apr;17(3-4):211–21 (86 ref.)

Structural requirements of parathyroid hormone/parathyroid hormone-related peptide receptors for phospholipase C activation and regulation of phosphate uptake. Iida-Klein A, et al. **Miner Electrolyte Metab** 1995;21(1-3):177–9 (16 ref.)

Mutant ras epitopes as targets for cancer vaccines. Abrams SI, et al. **Semin Oncol** 1996 Feb;23(1):118–34 (79 ref.)

Duchenne muscular dystrophy. Matsuo M. **Southeast Asian J Trop Med Public Health** 1995;26 Suppl 1:166–71 (31 ref.)

Red cell enzymopathies as a model of inborn errors of metabolism. Miwa S, et al. **Southeast Asian J Trop Med Public Health** 1995;26 Suppl 1:112–9 (39 ref.)

Vitreous amyloidosis in familial amyloidotic polyneuropathy. Report of a case with the Val30Met transthyretin mutation. Ciulla TA, et al. **Surv Ophthalmol** 1995 Nov-Dec; 40(3):197–206 (123 ref.)

Resistance to activate protein C, the Arg506 to Gln mutation in the factor V gene, and venous thrombosis. Functional tests and DNA-based assays, pros and cons [see comments] Dahlbäck B. **Thromb Haemost** 1995 May;73(5):739–42 (33 ref.) Comment in: Thromb Haemost 1995 Nov;74(5):1380–1.

[Aspartylglucosaminuria: a point mutation as a cause of mental defect] Ikonen E, et al. **Duodecim** 1994; 110(7):667–73 (21 ref.) **(Fin)**

[Glucokinase: the first hit in the hunt for a gene in late-onset diabetes (editorial)] Laakso M. **Duodecim** 1994;110(1):13–5 (18 ref.) **(Fin)**

[Mutant allele specific amplification (MASA)] Sugai S, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):546–8 (11 ref.) **(Jpn)**

[Molecular diagnosis of cancer by non-radioisotopic PCR/SSCP analysis] Sugano K. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):638–42 (8 ref.) **(Jpn)**

[Detection of rare target gene with a point mutation by improved PCR] Tada M, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):549–52 (7 ref.) **(Jpn)**

[Point mutation G-->A nucleotide 1691 factor V gene as a cause of developing thrombotic complications in a family with plasma resistance to activated protein C] Lew Andowski KL, et al. **Pol Arch Med Wewn** 1996 May; 95(5):464–70 (11 ref.) (Eng. Abstr.) **(Pol)**

GENETICS

Putting the bits and pieces of the RET proto-oncogene puzzle together. Gagel RF. **Bone** 1995 Aug;17(2 Suppl):13S–16S (30 ref.)

Molecular studies on thyrotropin (TSH) receptor and anti-TSH receptor antibodies. Akamizu T, et al. **Endocr J** 1995 Oct;42(5):617–27 (46 ref.)

TSH receptor and LH receptor, 1995. Kosugi S, et al. **Endocr J** 1995 Oct;42(5):587–606 (95 ref.)

Human aging is associated with stochastic somatic mutations of mitochondrial DNA. Kadenbach B, et al. **Mutat Res** 1995 Oct;338(1-6):161–72 (112 ref.)

POINT-OF-CARE SYSTEMS

Point-of-care testing in the intensive care unit. The intensive care physician's perspective. Castro HJ, et al. **Am J Clin Pathol** 1995 Oct;104(4 Suppl 1):S95–9 (22 ref.)

Regulatory requirements (CLIA '88, JCAHO, CAP) for decentralized testing. Ehrmeyer SS, et al. **Am J Clin Pathol** 1995 Oct;104(4 Suppl 1):S40–9 (22 ref.)

The satellite laboratory and point-of-care testing. Integration of information. Jacobs E, et al. **Am J Clin Pathol** 1995 Oct;104(4 Suppl 1):S33–9 (17 ref.)

Guidelines for point-of-care testing. Improving patient outcomes. Kost GJ. **Am J Clin Pathol** 1995 Oct;104(4 Suppl 1):S111–27 (167 ref.)

Thrombosis and hemostasis testing at the point of care. Oberhardt BJ. **Am J Clin Pathol** 1995 Oct;104(4 Suppl 1):S72–8 (19 ref.)

Critical care profiling for informed treatment of severely ill patients. Shirey TL. **Am J Clin Pathol** 1995 Oct;104(4 Suppl 1):S79–87 (77 ref.)

Alternate site testing. The old and new paradigm or the past is prologue. Bachner P. **Arch Pathol Lab Med** 1995 Oct; 119(10):881–5 (31 ref.)

Exploring the medical need for alternate site testing. A clinician's perspective. Becker RC. **Arch Pathol Lab Med** 1995 Oct;119(10):894–7 (47 ref.)

College of American Pathologists Conference XXVIII on alternate site testing: introduction. Handorf CR. **Arch Pathol Lab Med** 1995 Oct;119(10):867–73 (9 ref.)

College of American Pathologists Conference XXVIII on alternate site testing. What must we now do? Howanitz PJ. **Arch Pathol Lab Med** 1995 Oct;119(10):979–83 (30 ref.)

Designing a point-of-care program for coagulation testing. Macik BG. **Arch Pathol Lab Med** 1995 Oct;119(10):929–38 (34 ref.)

Bedside diagnosis of wide QRS tachycardia [editorial; comment] Barold SS. **Pacing Clin Electrophysiol** 1995 Dec; 18(12 Pt 1):2109–15 (79 ref.) Comment on: Pacing Clin Electrophysiol 1995 Dec;18(12 Pt 1):2194–208.

ECONOMICS

Economic considerations of point-of-care testing. Keffer JH. **Am J Clin Pathol** 1995 Oct;104(4 Suppl 1):S107–10 (14 ref.)

POINT OF CARE TECHNOLOGY

POINT OF CARE TECHNOLOGY see POINT-OF-CARE SYSTEMS

POISON CONTROL CENTERS

The use of poison prevention and education strategies to enhance the awareness of the poison information center and to prevent accidental pediatric poisonings. Krenzelok EP. **J Toxicol Clin Toxicol** 1995;33(6):663–7 (7 ref.)

STANDARDS

International Poison Information Center data collection capabilities. Krenzelok EP, et al. **Vet Hum Toxicol** 1995 Jun;37(3):246–8 (3 ref.)

POISON IVY DERMATITIS see DERMATITIS, TOXICODENDRON

POISONING

see related
ANTIDOTES

Outcome following organ removal from poisoned donors in brain death status: a report of 12 cases and review of the literature. Hantson P, et al. **J Toxicol Clin Toxicol** 1995; 33(6):709–12 (8 ref.)

[Reality of drug poisoning and screening tests] Kudo K. **Fukuoka Igaku Zasshi** 1995 Nov;86(11):399–404 (3 ref.) **(Jpn)**

COMPLICATIONS

Risks of extracorporeal membrane oxygenation: is there a role for use in the management of the acutely poisoned patient? Banner W Jr. **J Toxicol Clin Toxicol** 1996; 34(4):365–71 (18 ref.)

DIAGNOSIS

The poisoned patient: the role of the laboratory. Flanagan RJ. **Br J Biomed Sci** 1995 Sep;52(3):202–13 (30 ref.)

Application of biological monitoring to the diagnosis of poisoning. Ikeda M. **J Toxicol Clin Toxicol** 1995; 33(6):617–23 (32 ref.)

EPIDEMIOLOGY

Pediatric poisonings. Goepp JG. **Clin Chem** 1996 Aug;42(8 Pt 2):1356–60 (11 ref.)

Clinical evaluation of the poisoned patient and toxic syndromes. Liang HK. **Clin Chem** 1996 Aug;42(8 Pt 2):1350–5 (20 ref.)

International Poison Information Center data collection capabilities. Krenzelok EP, et al. **Vet Hum Toxicol** 1995 Jun;37(3):246–8 (3 ref.)

PHYSIOPATHOLOGY

Cardiotoxic drugs. Derlet RW, et al.
Emerg Med Clin North Am 1995 Nov;13(4):771–91 (93 ref.)

[Late effects of organophosphate poisoning on the heart] Lev E, et al. **Harefuah** 1995 Dec 1;129(11):507–11 (40 ref.) **(Heb)**

PREVENTION & CONTROL

Drug poisoning in older patients. Preventative and management strategies. Haselberger MB, et al.
Drugs Aging 1995 Oct;7(4):292–7 (32 ref.)

The use of poison prevention and education strategies to enhance the awareness of the poison information center and to prevent accidental pediatric poisonings. Krenzelok EP. **J Toxicol Clin Toxicol** 1995;33(6):663–7 (7 ref.)

REHABILITATION

[The theoretical bases of rehabilitation in exotoxicosis] Begliarov MI, et al.
Vopr Kurortol Fizioter Lech Fiz Kult 1995 May–Jun; (3):41–3 (42 ref.) **(Rus)**

THERAPY

Advances in poison management. Bayer MJ, et al.
Clin Chem 1996 Aug;42(8 Pt 2):1361–6 (32 ref.)

The poisoned patient. Toxicologic emergencies. Norris LH, et al. **Dent Clin North Am** 1995 Jul;39(3):595–619 (72 ref.)

Drug poisoning in older patients. Preventative and management strategies. Haselberger MB, et al.
Drugs Aging 1995 Oct;7(4):292–7 (32 ref.)

Use of continuous renal replacement therapy for detoxification? Riegel W. **Int J Artif Organs** 1996 Feb; 19(2):111–2 (9 ref.)

[Removal of toxic substances from the body as a method for normalization of the functioning of the immune system] Lebedev KA, et al. **Fiziol Cheloveka** 1995 Sep–Oct; 21(5):131–43 (22 ref.) **(Rus)**

POISONS

ANALYSIS

Forensic science. Brettell TA, et al. **Anal Chem** 1995 Jun 15;67(12):273R–294R (843 ref.)

The poisoned patient: the role of the laboratory. Flanagan RJ. **Br J Biomed Sci** 1995 Sep;52(3):202–13 (30 ref.)

PHARMACOLOGY

Cardiotoxic drugs. Derlet RW, et al.
Emerg Med Clin North Am 1995 Nov;13(4):771–91 (93 ref.)

TOXICITY

Role of arsenic as a reproductive toxin with particular attention to neural tube defects. Shalat SL, et al.
J Toxicol Environ Health 1996 Jun 28;48(3):253–72 (130 ref.)

POL III see DNA POLYMERASE III

POLAR RECOMBINATION see GENE CONVERSION

POLARON see GENE CONVERSION

POLICY MAKING

see related
HEALTH POLICY
PUBLIC POLICY

Foundations' impact on policy making: results from a pilot study. Weissert CS, et al. **Health Aff (Millwood)** 1995 Winter;14(4):275–86 (31 ref.)

Joint nursing appointments: a vehicle for influencing health care change. Tamlyn D, et al. **J Adv Nurs** 1995 Sep; 22(3):490–3 (18 ref.)

Allocating health care: cost-utility analysis, informed democratic decision making, or the veil of ignorance? Goold SD. **J Health Polit Policy Law** 1996 Spring; 21(1):69–98 (41 ref.)

The use of geographical information systems in studies on environment and health. Briggs DJ, et al.
World Health Stat Q 1995;48(2):85–94 (31 ref.)

Health and environment analysis for decision making. Corvalán C, et al. **World Health Stat Q** 1995;48(2):71–7 (16 ref.)

Linkage failures in ecological studies. Nurminen M.
World Health Stat Q 1995;48(2):78–84 (20 ref.)

POLIODYSTROPHIA CEREBRI see CEREBRAL SCLEROSIS, DIFFUSE

POLIOMYELITIS

see related
POSTPOLIOMYELITIS SYNDROME

Two models for multiple sclerosis: experimental allergic encephalomyelitis and Theiler's murine encephalomyelitis virus. Tsunoda I, et al. **J Neuropathol Exp Neurol** 1996 Jun;55(6):673–86 (136 ref.)

EPIDEMIOLOGY

Poliomyelitis in The Netherlands: a review of population immunity and exposure between the epidemics in 1978 and 1992. Rümke HC, et al. **Epidemiol Infect** 1995 Oct; 115(2):289–98 (31 ref.)

ETIOLOGY

Poliovirus biology and pathogenesis. Racaniello VR, et al. **Curr Top Microbiol Immunol** 1996;206:305–25 (103 ref.)

GENETICS

[Infection of the mouse by Theiler's virus; a model for the study of demyelinating diseases of the central nervous system] Brahic M. **Bull Acad Natl Med** 1996 Feb; 180(2):305–15; discussion 315–6 (27 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Poliomyelitis in The Netherlands: a review of population immunity and exposure between the epidemics in 1978 and 1992. Rümke HC, et al. **Epidemiol Infect** 1995 Oct; 115(2):289–98 (31 ref.)

Immunology of Theiler's murine encephalomyelitis virus infection. Oleszak EL, et al. **Immunol Res** 1995;14(1):13–33 (153 ref.)

Evolution of the T-cell repertoire during the course of experimental immune-mediated demyelinating diseases. Miller SD, et al. **Immunol Rev** 1995 Apr;144:225–44 (66 ref.)

PATHOLOGY

Two models of multiple sclerosis: experimental allergic encephalomyelitis (EAE) and Theiler's murine encephalomyelitis virus (TMEV) infection. A pathological and immunological comparison. Dal Canto MC, et al. **Microsc Res Tech** 1995 Oct 15;32(3):215–29 (74 ref.)

Spontaneous and induced remyelination in multiple sclerosis and the Theiler's virus model of central nervous system demyelination. Miller DJ, et al. **Microsc Res Tech** 1995 Oct 15;32(3):230–45 (119 ref.)

PREVENTION & CONTROL

Inactivated polio vaccine for the United States: a missed vaccination opportunity. Plotkin SA.
Pediatr Infect Dis J 1995 Oct;14(10):835–9 (0 ref.)

[Polio vaccination today: critical remarks (see comments)] Hof H, et al. **Immun Infekt** 1995 Aug;23(4):130–3 (6 ref.) (Eng. Abstr.) Comment in: Immun Infekt 1995 Dec;23(6):III–IV, 234. **(Ger)**

[Poliomyelitis: vaccination is still important] Pregliasco F, et al. **Ann Ig** 1994 Jul–Dec;6(4–6):675–84 (36 ref.) (Eng. Abstr.) **(Ita)**

[Global eradication project for poliomyelitis] Miyamura T. **Uirusu** 1995 Jun;45(1):51–2 (3 ref.) **(Jpn)**

POLIOVIRUS VACCINE

ADMINISTRATION & DOSAGE

Inactivated polio vaccine for the United States: a missed vaccination opportunity. Plotkin SA.
Pediatr Infect Dis J 1995 Oct;14(10):835–9 (0 ref.)

IMMUNOLOGY

[Poliomyelitis: vaccination is still important] Pregliasco F, et al. **Ann Ig** 1994 Jul–Dec;6(4–6):675–84 (36 ref.) (Eng. Abstr.) **(Ita)**

STANDARDS

[Polio vaccination today: critical remarks (see comments)] Hof H, et al. **Immun Infekt** 1995 Aug;23(4):130–3 (6 ref.) (Eng. Abstr.) Comment in: Immun Infekt 1995 Dec;23(6):III–IV, 234. **(Ger)**

TOXICITY

Evaluation of new approaches to poliovirus vaccine neurovirulence tests. Wood DJ. **Dev Biol Stand** 1996; 86:79–83 (16 ref.)

POLIOVIRUS VACCINE, ORAL

Influence of breast-feeding and oral poliovirus vaccine on the immunogenicity and efficacy of rotavirus vaccines. Rennels MB. **J Infect Dis** 1996 Sep;174 Suppl 1:S107–11 (35 ref.)

ADMINISTRATION & DOSAGE

Inactivated polio vaccine for the United States: a missed vaccination opportunity. Plotkin SA.
Pediatr Infect Dis J 1995 Oct;14(10):835–9 (0 ref.)

IMMUNOLOGY

[Application and development of immunity of childhood vaccines] Yang Y. **Chung Hua I Hsueh Tsa Chih** 1996 Apr; 76(4):318–9 (21 ref.) **(Chi)**

[Poliomyelitis: vaccination is still important] Pregliasco F, et al. **Ann Ig** 1994 Jul–Dec;6(4–6):675–84 (36 ref.) (Eng. Abstr.) **(Ita)**

POLIOVIRUSES

GENETICS

Anatomy of the poliovirus internal ribosome entry site. Ehrenfeld E, et al. **Curr Top Microbiol Immunol** 1995; 203:65–83 (86 ref.)

PATHOGENICITY

Safety requirements for maintenance and distribution of transgenic mice susceptible to human viruses: the example of poliovirus-susceptible transgenic mice. Ghendon Y, et al. **Curr Top Microbiol Immunol** 1996;206:327–40 (31 ref.)

Poliovirus biology and pathogenesis. Racaniello VR, et al. **Curr Top Microbiol Immunol** 1996;206:305–25 (103 ref.)

POLIOVIRUSES, MURINE

Immunology of Theiler's murine encephalomyelitis virus infection. Oleszak EL, et al. **Immunol Res** 1995;14(1):13–33 (153 ref.)

Two models for multiple sclerosis: experimental allergic encephalomyelitis and Theiler's murine encephalomyelitis virus. Tsunoda I, et al. **J Neuropathol Exp Neurol** 1996 Jun;55(6):673–86 (136 ref.)

Two models of multiple sclerosis: experimental allergic encephalomyelitis (EAE) and Theiler's murine encephalomyelitis virus (TMEV) infection. A pathological and immunological comparison. Dal Canto MC, et al. **Microsc Res Tech** 1995 Oct 15;32(3):215–29 (74 ref.)

Spontaneous and induced remyelination in multiple sclerosis and the Theiler's virus model of central nervous system demyelination. Miller DJ, et al. **Microsc Res Tech** 1995 Oct 15;32(3):230–45 (119 ref.)

GENETICS

[Infection of the mouse by Theiler's virus; a model for the study of demyelinating diseases of the central nervous system] Brahic M. **Bull Acad Natl Med** 1996 Feb; 180(2):305–15; discussion 315–6 (27 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Evolution of the T-cell repertoire during the course of experimental immune-mediated demyelinating diseases. Miller SD, et al. **Immunol Rev** 1995 Apr;144:225–44 (66 ref.)

PHYSIOLOGY

Experimental strategies to promote central nervous system remyelination in multiple sclerosis: insights gained from the Theiler's virus model system. Miller DJ, et al. **J Neurosci Res** 1995 Jun 15;41(3):291–6 (40 ref.)

POLISHES, DENTAL see DENTIFRICES

POLITEF see POLYTETRAFLUOROETHYLENE

POLITICAL ACTIVITY see POLITICS

POLITICS

Ethical issues in healthcare prioritization: a political viewpoint. McColl. **Br J Urol** 1995 Nov;76 Suppl 2:55–7 (4 ref.)

Rationing health care: the political perspective. Hunter DJ. **Br Med Bull** 1995 Oct;51(4):876–84 (14 ref.)

Interpretations of risk: the use of scientific information in the development of the alcohol warning label policy. Kaskutas LA. **Int J Addict** 1995;30(12):1519–48 (70 ref.)

Publicity-stunt participation and sound bites polemics: the health care debate 1993–94. Disch L. **J Health Polit Policy Law** 1996 Spring;21(1):3–33 (78 ref.)

The politics of nutrition in North America. Levenstein HA. **Neurosci Biobehav Rev** 1996;20(1):75–8 (14 ref.)

POLLEN

see related
ALLERGENS
HAY FEVER

CYTOLOGY

Manipulation of pollen grains for gametophytic and sporophytic types of growth. Raghavan V. **Methods Cell Biol** 1995;49:367–75 (11 ref.)

GENETICS

A molecular perspective on pollination in flowering plants. Dodds PN, et al. **Cell** 1996 Apr 19;85(2):141–4 (20 ref.)

IMMUNOLOGY

Food reactions in pollen and latex allergic patients [editorial] Frankland AW. **Clin Exp Allergy** 1995 Jul;25(7):580–1 (22 ref.)

Type 1 allergic reactions to plant-derived food: a consequence of primary sensitization to pollen allergens. Valenta R, et al. **J Allergy Clin Immunol** 1996 Apr; 97(4):893–5 (29 ref.)

PHYSIOLOGY

How do alterations in plant mitochondrial genomes disrupt pollen development? Conley CA, et al. **J Bioenerg Biomembr** 1995 Aug;27(4):447–57 (78 ref.)

POLY(A)+ MRNA see RNA, MESSENGER

POLY(A)+ RNA see RNA, MESSENGER

POLY(A) TAIL see RNA, MESSENGER

POLY ADENOSINE DIPHOSPHATE RIBOSE

METABOLISM

NAD and poly(ADP-ribose) regulation of proteins involved in response to cellular stress and DNA damage. Berger NA, et al. **Biochimie** 1995;77(5):364–7 (16 ref.)

Evaluating the role of niacin in human carcinogenesis. Jacobson EL, et al. **Biochimie** 1995;77(5):394–8 (22 ref.)

New aspects of the physiological significance of NAD, poly ADP-ribose and cyclic ADP-ribose. Okamoto H, et al. **Biochimie** 1995;77(5):356–63 (41 ref.)

Progress in identifying clinical relevance of inhibition, stimulation and measurements of poly ADP-ribosylation. Pero RW, et al. **Biochimie** 1995;77(5):385–93 (45 ref.)

POLY ADP RIBOSE see POLY ADENOSINE DIPHOSPHATE RIBOSE

POLY ADP RIBOSE POLYMERASE see NAD+ ADP-RIBOSYLTRANSFERASE

POLY(ADP-RIBOSE) SYNTHASE see NAD+ ADP-RIBOSYLTRANSFERASE

POLYACRYLAMIDE GEL ELECTROPHORESIS, TWO-DIMENSIONAL see ELECTROPHORESIS, GEL, TWO-DIMENSIONAL

POLYAMINES

ANALYSIS

[Amines and pteridines] Shimpo K, et al. **Nippon Rinsho** 1996 Jun;54(6):1515–20 (22 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Ion channels. A physiological function for polyamines? Forsythe ID. **Curr Biol** 1995 Nov 1;5(11):1248–51 (19 ref.)

DNA methylation and polyamines in embryonic development and cancer. Heby O. **Int J Dev Biol** 1995 Oct;39(5):737–57 (169 ref.)

PHARMACOLOGY

Transgenic animals as models in the study of the neurobiological role of polyamines. Kauppinen RA, et al. **Prog Neurobiol** 1995 Dec;47(6):545–63 (140 ref.)

URINE

[Polyamine and ornithine decarboxylase] Kubota S. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:501–5 (20 ref.) **(Jpn)**

POLYAMINES, BIOGENIC see BIOGENIC POLYAMINES

POLYANGIACEAE see MYXOCOCCALES

POLYANGIUM see MYXOCOCCALES

POLYARTERITIS NODOSA

Microscopic polyangiitis: clinical aspects and treatment. Lhote F, et al. **Ann Med Interne (Paris)** 1996;147(3):165–77 (88 ref.)

Polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome. Clinical aspects and treatment. Lhote F, et al. **Rheum Dis Clin North Am** 1995 Nov; 21(4):911–47 (132 ref.)

[Isolated periarteritis nodosa of the gallbladder] Tsugu Y, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):222–4 (21 ref.) **(Jpn)**

COMPLICATIONS

Polyarteritis nodosa in human immunodeficiency virus infection: report of four cases and review of the literature. Font C, et al. **Br J Rheumatol** 1996 Aug;35(8):796–9 (31 ref.)

Kidney-limited recurrence in a patient with microscopic polyarteritis [see comments] Sato Y, et al. **Intern Med** 1995 Oct;34(10):1000–4 (18 ref.) Comment in: Intern Med 1995 Oct;34(10):936–7.

Mononeuritis multiplex in systemic lupus erythematosus: response to pulse intravenous cyclophosphamide. Martinez-Taboada VM, et al. **Lupus** 1996 Feb;5(1):74–6 (21 ref.)

Acute renal failure induced by angiotensin converting enzyme inhibitor in a patient with polyarteritis nodosa. Wang AY, et al. **Ren Fail** 1996 Mar;18(2):293–8 (17 ref.)

[Inflammatory pseudotumor of the intestine caused by necrotizing vasculitis in the course of Horton disease] Fontaney F, et al. **Gastroenterol Clin Biol** 1995 Nov; 19(11):940–3 (25 ref.) (Eng. Abstr.) **(Fre)**

[An autopsy case of segmental mediolytic arteritis (SMA) accompanied with microscopic polyarteritis nodosa] Ito MR, et al. **Ryumachi** 1995 Aug;35(4):693–8 (16 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

[ANCA-associated vasculitis (Wegener's granulomatosis, Churg-Strauss syndrome, microscopic polyangiitis). 2. Diagnostic procedure (see comments] de Groot K, et al. **Z Rheumatol** 1995 Sep-Oct;54(5):291–302 (59 ref.) (Eng. Abstr.) Comment in: Z Rheumatol 1995 Sep-Oct;54(5):277–8. **(Ger)**

ETIOLOGY

Vasculitides in hairy cell leukemia. Hasler P, et al. **Semin Arthritis Rheum** 1995 Oct;25(2):134–42 (48 ref.)

IMMUNOLOGY

Cutaneous polyarteritis nodosa in a child with positive antiphospholipid and P-ANCA. Pereira BA, et al. **Scand J Rheumatol** 1995;24(6):386–8 (14 ref.)

[ANCA-associated vasculitis (Wegener's granulomatosis, Churg-Strauss syndrome, microscopic polyangiitis). 1. Systemic aspects, pathogenesis and clinical aspects (see comments)] Gross WL, et al. **Z Rheumatol** 1995 Sep-Oct; 54(5):279–90 (22 ref.) (Eng. Abstr.) Comment in: Z Rheumatol 1995 Sep-Oct;54(5):277–8. **(Ger)**

PATHOLOGY

Microscopic polyarteritis during polymyalgia rheumatica remission. Uematsu-Yanagita M, et al. **Am J Kidney Dis** 1996 Aug;28(2):289–91 (6 ref.)

THERAPY

[ANCA-associated vasculitis (Wegener's granulomatosis, Churg-Strauss syndrome, microscopic polyangiitis). 3. Therapeutic procedure (see comments)] Reinhold-Keller E, et al. **Z Rheumatol** 1995 Sep-Oct;54(5):303–9 (30 ref.) (Eng. Abstr.) Comment in: Z Rheumatol 1995 Sep-Oct;54(5):277–8. **(Ger)**

POLYARTHRALGIA see ARTHRALGIA

POLYARTHRITIS see ARTHRITIS

POLYAZIRIDINE see POLYETHYLENEIMINE

POLYCHEMOTHERAPY see DRUG THERAPY, COMBINATION

POLYCHLORINATED BIPHENYLS

ADVERSE EFFECTS

Developmental neurotoxicology in the neonate—effects of pesticides and polychlorinated organic substances. Eriksson P. **Arch Toxicol Suppl** 1996;18:81–8 (26 ref.)

The reproductive toxicology of Great Lakes contaminants. Foster WG. **Environ Health Perspect** 1995 Dec;103 Suppl 9:63–9 (85 ref.)

Neurotoxicity of lead, methylmercury, and PCBs in relation to the Great Lakes. Rice DC. **Environ Health Perspect** 1995 Dec;103 Suppl 9:71–87 (221 ref.)

Health implications for Faroe islanders of heavy metals and PCBs from pilot whales. Weihe P, et al. **Sci Total Environ** 1996 Jul 16;186(1-2):141–8 (37 ref.)

ANALYSIS

Biomarkers for Great Lakes priority contaminants: halogenated aromatic hydrocarbons. Feeley MM. **Environ Health Perspect** 1995 Dec;103 Suppl 9:7–16 (106 ref.)

Reliability of the determinations of polychlorinated contaminants (biphenyls, dioxins, furans). Horwitz W, et al. **J AOAC Int** 1996 May-Jun;79(3):589–621 (55 ref.)

Current developments in the analysis of water pollution by polychlorinated biphenyls. Font G, et al. **J Chromatogr A** 1996 May 10;733(1-2):449–71 (154 ref.)

PHARMACOKINETICS

Uncertainty in estimated half-lives of PCBS in humans: impact on exposure assessment. Shirai JH, et al. **Sci Total Environ** 1996 Sep 9;187(3):199–210 (30 ref.)

POISONING

Growth abnormalities in the population exposed in utero and early postnatally to polychlorinated biphenyls and dibenzofurans. Guo YL, et al. **Environ Health Perspect** 1995 Sep;103 Suppl 6:117–22 (53 ref.)

An overview of exposure to, and effects of, petroleum oil and organochlorine pollution in grey seals (Halichoerus grypus). Jenssen BM. **Sci Total Environ** 1996 Jul 16; 186(1-2):109–18 (54 ref.)

TOXICITY

The effects on mammals of pre- and postnatal environmental exposure to PCBS. The Dutch Collaborative PCB/Dioxin Study. Smits-van Prooije AE, et al. **Arch Toxicol Suppl** 1996;18:97–102 (22 ref.)

The role of estrogen in turtle sex determination and the effect of PCBs. Crews D, et al. **Environ Health Perspect** 1995 Oct;103 Suppl 7:73–7 (19 ref.)

Immunotoxicity of PCBs (Aroclors) in relation to Great Lakes. Tryphonas H. **Environ Health Perspect** 1995 Dec; 103 Suppl 9:35–46 (97 ref.)

A case study of cancer data set combinations for PCBs. Vater ST, et al. **Regul Toxicol Pharmacol** 1995 Aug;22(1):2–10 (26 ref.)

POLYCHLOROBIPHENYL COMPOUNDS see POLYCHLORINATED BIPHENYLS

POLYCHLOROETHYLENE see POLYVINYL CHLORIDE

POLYCHONDRITIS, CHRONIC ATROPHIC see POLYCHONDRITIS, RELAPSING

POLYCHONDRITIS, RELAPSING

COMPLICATIONS

[Isolated ocular recurrence of relapsing polychondritis. Apropos of a case] Gatinel D, et al. **J Fr Ophtalmol** 1996; 19(2):153–7 (7 ref.) (Eng. Abstr.) **(Fre)**

POLYCYCLIC COMPOUNDS see POLYCYCLIC HYDROCARBONS

POLYCYCLIC HYDROCARBONS

ANALYSIS

[Distribution of polycyclic aromatic hydrocarbons in the environment and personal exposure] Sišović A. **Arh Hig Rada Toksikol** 1995 Jun;46(2):243–58 (71 ref.) (Eng. Abstr.) **(Scr)**

METABOLISM

Fossil fuel biodegradation: laboratory studies. Chapman PJ, et al. **Environ Health Perspect** 1995 Jun;103 Suppl 5:79–83

POLYCYCLIC HYDROCARBONS

(14 ref.)
Natural selection of PAH-degrading bacterial guilds at coal-tar disposal sites. Ghiorse WC, et al. **Environ Health Perspect** 1995 Jun;103 Suppl 5:107–11 (15 ref.)
Mechanisms for polycyclic aromatic hydrocarbon degradation by ligninolytic fungi. Hammel KE. **Environ Health Perspect** 1995 Jun;103 Suppl 5:41–3 (14 ref.)

POLYCYCLIC HYDROCARBONS, AROMATIC

ADVERSE EFFECTS

Diet as a confounder of the association between air pollution and female lung cancer: Hong Kong studies on exposures to environmental tobacco smoke, incense, and cooking fumes as examples. Koo LC, et al. **Lung Cancer** 1996 Mar; 14 Suppl 1:S47–61 (21 ref.)

METABOLISM

Environmental aspects of PAH biodegradation. Shuttleworth KL, et al. **Appl Biochem Biotechnol** 1995 Jul–Sep; 54(1–3):291–302 (41 ref.)
Central role of radical cations in metabolic activation of polycyclic aromatic hydrocarbons. Cavalieri EL, et al. **Xenobiotica** 1995 Jul;25(7):677–88 (49 ref.)
[Biodegradation of polycyclic aromatic hydrocarbons and its application to the bioremediation of contaminated soils and sludges] Ferrari MD. **Rev Argent Microbiol** 1996 Apr–Jun;28(2):83–98 (71 ref.) (Eng. Abstr.) **(Spa)**

PHARMACOKINETICS

Bioaccumulation of polycyclic aromatic hydrocarbons by marine organisms. Meador JP, et al. **Rev Environ Contam Toxicol** 1995;143:79–165 (320 ref.)

PHARMACOLOGY

[Fjord-region polycyclic aromatic hydrocarbons: carcinogenic properties and mechanism of action] Likhachev AI, et al. **Vopr Onkol** 1996;42(1):23–33 (69 ref.) **(Rus)**

TOXICITY

The effects of near ultraviolet radiation on the toxic effects of polycyclic aromatic hydrocarbons in animals and plants: a review. Arfsten DP, et al. **Ecotoxicol Environ Saf** 1996 Feb;33(1):1–24 (109 ref.)
Mutagenic nitroarenes, diesel emissions, particulate-induced mutations and cancer: an essay on cancer-causation by a moving target. Rosenkranz HS. **Mutat Res** 1996 Feb; 367(2):65–72 (85 ref.)
Contaminant-induced immunotoxicity in harbour seals: wildlife at risk? Ross P, et al. **Toxicology** 1996 Aug 16; 112(2):157–69 (91 ref.)

POLYCYSTIC KIDNEY see **KIDNEY, POLYCYSTIC**

POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT see **KIDNEY, POLYCYSTIC, AUTOSOMAL DOMINANT**

POLYCYSTIC KIDNEY, AUTOSOMAL RECESSIVE see **KIDNEY, POLYCYSTIC, AUTOSOMAL RECESSIVE**

POLYCYSTIC OVARY SYNDROME

see related
HYPERANDROGENISM

Polycystic ovarian disease: a new look at an old subject. Udoff L, et al. **Curr Opin Obstet Gynecol** 1995 Oct; 7(5):340–3 (19 ref.)
Polycystic ovary syndrome – from gynaecological curiosity to multisystem endocrinopathy. Homburg R. **Hum Reprod** 1996 Jan;11(1):29–39 (123 ref.)

COMPLICATIONS

Recurrent maternal virilization during pregnancy associated with polycystic ovarian syndrome: a case report and review of the literature. Ben-Chetrit A, et al. **Hum Reprod** 1995 Nov;10(11):3057–60 (34 ref.)

ETIOLOGY

[Gynecological diseases in obesity] Takahashi J, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:388–91 (5 ref.) **(Jpn)**
[Molecular basis of polycystic ovarian syndrome] Katulski K, et al. **Ginekol Pol** 1995 Oct;66(10):561–8 (23 ref.) (Eng. Abstr.) **(Pol)**

METABOLISM

Adrenal androgen production in polycystic ovary syndrome. McKenna TJ, et al. **Eur J Endocrinol** 1995 Oct;133(4):383–9 (35 ref.)

PHYSIOPATHOLOGY

Growth hormone and fertility—clinical studies. Homburg R. **Horm Res** 1996;45(1–2):81–5 (27 ref.)
[Physiopathology and therapy of polycystic ovary syndrome] Mihashi N, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Aug;47(8):814–23 (32 ref.) **(Jpn)**

SURGERY

Laparoscopic management of polycystic ovarian disease. Rose BI. **Curr Opin Obstet Gynecol** 1995 Aug;7(4):273–6 (30 ref.)

THERAPY

Polycystic ovary syndrome: pathophysiology and outcome with in vitro fertilization. Buyalos RP, et al. **Fertil Steril** 1996 Jan;65(1):1–10 (63 ref.)
[Physiopathology and therapy of polycystic ovary syndrome] Mihashi N, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Aug;47(8):814–23 (32 ref.) **(Jpn)**

POLYCYTHEMIA

The myomatous erythrocytosis syndrome: a review. LevGur M, et al. **Obstet Gynecol** 1995 Dec;86(6):1026–30 (38 ref.)

CONGENITAL

Neonatal polycythemia and hyperviscosity. Werner EJ. **Clin Perinatol** 1995 Sep;22(3):693–710 (97 ref.)

ETIOLOGY

Pheochromocytoma and secondary erythrocytosis: role of tumour erythropoietin secretion. Drénou B, et al. **Nouv Rev Fr Hematol** 1995;37(3):197–9 (18 ref.)
[Pathogenesis of polyglobulia after kidney transplantation] Darocha Z, et al. **Postepy Hig Med Dosw** 1995;49(2):181–7 (46 ref.) (Eng. Abstr.) **(Pol)**

POLYCYTHEMIA VERA

Polycythemia vera. Knoop T. **Semin Oncol Nurs** 1996 Feb; 12(1):70–7 (31 ref.)
[Chronic myeloproliferative diseases. New knowledge about well known diseases] Aulitzky WE, et al. **Dtsch Med Wochenschr** 1996 May 3;121(18):600–4 (42 ref.) (Eng. Abstr.) **(Ger)**

ENZYMOLOGY

Impaired activation of phospholipase D in polycythaemia vera–implications for the pathogenesis of the disease? Samuelsson J. **Leuk Lymphoma** 1995 Sep;19(1–2):21–6 (60 ref.)

HISTORY

Polycythemia vera—a climatological disease. Berlin NI. **Trans Am Clin Climatol Assoc** 1994;106:25–36; discussion 36–7 (33 ref.)

THERAPY

Efficacy of recombinant interferon-alpha (rIFN-alpha) in polycythaemia vera: a study of 17 patients and an analysis of published data. Taylor PC, et al. **Br J Haematol** 1996 Jan;92(1):55–9 (36 ref.)
The role of alpha-interferon in essential thrombocythaemia, polycythaemia vera and myelofibrosis with myeloid metaplasia (MMM): a concise update. Sacchi S. **Leuk Lymphoma** 1995 Sep;19(1–2):13–20 (86 ref.)

POLYDACTYLY

DIAGNOSIS

[The Townes–Brocks syndrome] Arroyo Carrera I, et al. **An Esp Pediatr** 1996 Apr;44(4):364–6 (18 ref.) **(Spa)**

GENETICS

Absence/hypoplasia of tibia, polydactyly, retrocerebellar arachnoid cyst, and other anomalies: an autosomal recessive disorder. Holmes LB, et al. **J Med Genet** 1995 Nov; 32(11):896–900 (29 ref.)

POLYDEOXYRIBONUCLEOTIDE LIGASES see **POLYDEOXYRIBONUCLEOTIDE SYNTHETASES**

POLYDEOXYRIBONUCLEOTIDE SYNTHETASES

GENETICS

Xeroderma pigmentosum and molecular cloning of DNA repair genes. Boulikas T. **Anticancer Res** 1996 Mar–Apr; 16(2):693–708 (161 ref.)
RNA capping enzyme and DNA ligase: a superfamily of covalent nucleotidyl transferases. Shuman S, et al. **Mol Microbiol** 1995 Aug;17(3):405–10 (36 ref.)

METABOLISM

[Polymerase chain reaction and ligase reactions. Principles, traditional methods, and innovations] Belokhvostov AS. **Mol Gen Mikrobiol Virusol** 1995 Apr–Jun;(2):21–6 (50 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

DNA lesion-recognizing proteins and the p53 connection. Boulikas T. **Anticancer Res** 1996 Jan–Feb;16(1):225–42 (187 ref.)
Recognition and processing of damaged DNA. Lindahl T. **J Cell Sci Suppl** 1995;19:73–7 (33 ref.)

POLYENDOCRINOPATHIES, AUTOIMMUNE

COMPLICATIONS

[Tolosa Hunt syndrome and autoimmune polyglandular syndrome. A rare case report] Cesareo R, et al. **Minerva Endocrinol** 1995 Jun;20(2):149–52 (13 ref.) (Eng. Abstr.) **(Ita)**

DIAGNOSIS

Case report: autoimmune polyglandular syndrome. Khalil S, et al. **N J Med** 1995 Oct;92(10):671–4 (22 ref.)

POLYENES

Rapamycin: distribution, pharmacokinetics, and therapeutic range investigations. Yatscoff RW, et al. **Ther Drug Monit** 1995 Dec;17(6):666–71 (32 ref.)
[Enigma of rapamycin] Terada N. **Seikagaku** 1995 Oct; 67(10):1241–5 (17 ref.) **(Jpn)**

PHARMACOKINETICS

Pharmacokinetics of rapamycin. Yatscoff RW. **Transplant Proc** 1996 Apr;28(2):970–3 (28 ref.)

PHARMACOLOGY

Molecular mechanisms of immunosuppression by cyclosporine, FK506, and rapamycin. Cardenas ME, et al. **Curr Opin Nephrol Hypertens** 1995 Nov;4(6):472–7 (83 ref.)
Rapamycin (sirolimus, rapamune). Sehgal SN, et al. **Curr Opin Nephrol Hypertens** 1995 Nov;4(6):482–7 (49 ref.)
Mechanism of action of the immunosuppressant rapamycin. Dumont FJ, et al. **Life Sci** 1996;58(5):373–95 (196 ref.)
Mechanisms of action of immunosuppressive agents: cyclosporin A, FK506, and rapamycin. Bierer BE. **Proc Assoc Am Physicians** 1995 Apr;107(1):28–40 (135 ref.)
Rapamune (Sirolimus, rapamycin): an overview and mechanism of action. Sehgal SN. **Ther Drug Monit** 1995 Dec;17(6):660–5 (43 ref.)
Mechanism of action of rapamycin (Sirolimus, Rapamune). Molnar-Kimber KL. **Transplant Proc** 1996 Apr;28(2):964–9 (127 ref.)

THERAPEUTIC USE

Potential applications of therapeutic drug monitoring of sirolimus immunosuppression in clinical renal transplantation. Kahan BD, et al. **Ther Drug Monit** 1995 Dec;17(6):672–5 (17 ref.)
Consensus guidelines for therapeutic drug monitoring of rapamycin: report of the consensus panel. Yatscoff RW, et al. **Ther Drug Monit** 1995 Dec;17(6):676–80 (28 ref.)

POLYERGIN see **TRANSFORMING GROWTH FACTOR BETA**

POLYESTERS

[Impregnated polyester prostheses: a theoretical advantage] Becquemin JP, et al. **J Mal Vasc** 1996;21 Suppl A:41–7 (25 ref.) (Eng. Abstr.) **(Fre)**

CHEMICAL SYNTHESIS

Production of poly(hydroxyalkanoic acid). Lee SY, et al. **Adv Biochem Eng Biotechnol** 1995;52:27–58 (131 ref.)

CHEMISTRY

Orientruded polylactide based body-absorbable osteosynthesis devices: a short review. Tunc DC. **J Biomater Sci Polym Ed** 1995;7(4):375–80 (9 ref.)

METABOLISM

New hydrophilic polyesters and related polymers as bioerodible polymeric matrices. Chiellini E, et al. **J Biomater Sci Polym Ed** 1995;7(4):307–28 (34 ref.)

POLYETHYLENE GLYCOLS

ADMINISTRATION & DOSAGE

Bowel preparation before colonoscopy. Choosing the best lavage regimen. Tooson JD, et al. **Postgrad Med** 1996 Aug; 100(2):203–4, 207–12, 214 (30 ref.)

ADVERSE EFFECTS

Exacerbation of congestive heart failure after administration of polyethylene glycol–electrolyte lavage solution. Granberry MC, et al. **Ann Pharmacother** 1995 Dec; 29(12):1232–35 (12 ref.)

CHEMISTRY

[Polyoxyethylene tensides as vesicle components. 2.] Nürnberg E, et al. **Pharm Unserer Zeit** 1995 Nov;

24(6):331–8 (17 ref.) **(Ger)**

POLYETHYLENE TEREPHTHALATES

Carotid Dacron patch angioplasty: immediate and long-term results of a prospective series. Perler BA, et al. **Cardiovasc Surg** 1995 Dec;3(6):631–6 (43 ref.)

POLYETHYLENEIMINE

PHARMACOLOGY

PEI6, a new basic secretagogue in rat peritoneal mast cells: characteristics of polyethylenimine PEI6 resemble those of compound 48/80. Suzuki-Nishimura T, et al. **Gen Pharmacol** 1995 Oct;26(6):1171–8 (41 ref.)

POLYETHYLENES

Metal versus polyethylene wear particles in total hip replacements. A review. Doorn PF, et al. **Clin Orthop** 1996 Aug;(329 Suppl):S206–16 (64 ref.)

Factors influencing the longevity of UHMWPE tibial components. Heim CS, et al. **Instr Course Lect** 1996; 45:303–12 (110 ref.)

Spontaneous fracture of the ceramic ball in a ceramic-polyethylene total hip arthroplasty. Michaud RJ, et al. **J Arthroplasty** 1995 Dec;10(6):863–7 (27 ref.)

Is polyethylene still the best prosthetic bearing surface? [editorial] Amis AA. **J Bone Joint Surg Br** 1996 May; 78(3):345–8 (39 ref.)

Polypropylene mesh closure after emergency laparotomy: morbidity and outcome. Brandt CP, et al. **Surgery** 1995 Oct;118(4):736–40; discussion 740–1 (17 ref.)

[Use of porous plyethylene (Medpor) in maxillofacial surgery] Cenzi R, et al. **Minerva Stomatol** 1995 Dec; 44(12):559–82 (17 ref.) (Eng. Abstr.) **(Ita)**

ADVERSE EFFECTS

The role of polyethylene properties in osteolysis after total hip replacement. Gómez-Barrena E, et al. **Instr Course Lect** 1996;45:187–97 (80 ref.)

TOXICITY

Cancer risk after metal on metal and polyethylene on metal total hip arthroplasty. Visuri T, et al. **Clin Orthop** 1996 Aug;(329 Suppl):S280–9 (51 ref.)

POLYGLANDULAR TYPE I AUTOIMMUNE SYNDROME see **POLYENDOCRINOPATHIES, AUTOIMMUNE**

POLYGLANDULAR TYPE II AUTOIMMUNE SYNDROME see **POLYENDOCRINOPATHIES, AUTOIMMUNE**

POLYGLUCOSES see **GLUCANS**

POLYGLYCOLIC ACID

Applications of biodegradable lactides and glycolides in podiatry. Athanasiou KA, et al. **Clin Podiatr Med Surg** 1995 Jul;12(3):475–95 (90 ref.)

POLYGLYCOLIDE see **POLYGLYCOLIC ACID**

POLYGONUM see **PLANTS, MEDICINAL**

POLYHYDRAMNIOS

ULTRASONOGRAPHY

[Polyhydramnios and its relationship with congenital malformations: ultrasonographic diagnosis] Gaxiola Castro R, et al. **Ginecol Obstet Mex** 1995 Dec;63:505–8 (12 ref.) (Eng. Abstr.) **(Spa)**

POLYISOCYANATES see **POLYURETHANES**

POLYKARYOCYTES see **GIANT CELLS**

POLYMENORRHEA see **MENSTRUATION DISORDERS**

POLYMERASE CHAIN REACTION

see related
SEQUENCE TAGGED SITES

The sensitivity of HIV-1 DNA polymerase chain reaction in the neonatal period and the relative contributions of intra-uterine and intra-partum transmission. Dunn DT, et al. **AIDS** 1995 Sep;9(9):F7–11 (29 ref.)

Inter-Alu polymerase chain reaction: advancements and applications. Kass DH, et al. **Anal Biochem** 1995 Jul 1; 228(2):185–93 (65 ref.)

Applications and limitations of polymerase chain reaction amplification [see comments] Ma TS. **Chest** 1995 Nov; 108(5):1393–404 (112 ref.) Comment in: Chest 1996 Jul;110(1):300–1.

Molecular and immunological detection of circulating tumor cells and micrometastases from solid tumors. Pelkey TJ, et al. **Clin Chem** 1996 Sep;42(9):1369–81 (163 ref.)

The polymerase chain reaction: applications for the detection of foodborne pathogens. Hill WE. **Crit Rev Food Sci Nutr** 1996 Jan;36(1-2):123–73 (294 ref.)

The challengers to PCR: a proliferation of chain reactions. Landegren U. **Curr Opin Biotechnol** 1996 Feb;7(1):95–7 (16 ref.)

Application of DNA-based technologies in the diagnosis of sexually transmitted diseases. Mårdh PA, et al. **Curr Probl Dermatol** 1996;24:174–83 (43 ref.)

Polymerase chain reaction-based assays for the characterisation of plant genetic resources. Powell W, et al. **Electrophoresis** 1995 Sep;16(9):1726–30 (36 ref.)

Molecular diagnosis of tuberculosis. Richeldi L, et al. **Eur Respir J Suppl** 1995 Sep;20:689s–700s (95 ref.)

Probes and polymerase chain reaction for detection of food-borne bacterial pathogens. Olsen JE, et al. **Int J Food Microbiol** 1995 Nov;28(1):1–78 (331 ref.)

The polymerase chain reaction: a revolutionary new procedure for the laboratory diagnosis of infectious disease. Buck GE. **J Ky Med Assoc** 1996 Apr;94(4):148–52 (23 ref.)

Microsatellites and PCR genomic analysis. Koreth J, et al. **J Pathol** 1996 Mar;178(3):239–48 (152 ref.)

Detection of chromosomal translocations in leukemia-lymphoma cells by polymerase chain reaction. Drexler HG, et al. **Leuk Lymphoma** 1995 Nov; 19(5–6):359–80 (278 ref.)

Use of molecular probes and PCR for detection and typing of Leishmania—a mini-review. Degrave W, et al. **Mem Inst Oswaldo Cruz** 1994 Jul–Sep;89(3):463–9 (31 ref.)

Nucleic acid fingerprinting by PCR-based methods: applications to problems in aging and mutagenesis. Welsh J, et al. **Mutat Res** 1995 Oct;338(1–6):215–29 (72 ref.)

Quantitative RT-PCR for neuroendocrine studies. A minireview. Zamorano PL, et al. **Neuroendocrinology** 1996 May;63(5):397–407 (39 ref.)

Resistance to activate protein C, the Arg506 to Gln mutation in the factor V gene, and venous thrombosis. Functional tests and DNA-based assays, pros and cons [see comments] Dahlbäck B. **Thromb Haemost** 1995 May;73(5):739–42 (33 ref.) Comment in: Thromb Haemost 1995 Nov;74(5):1380–1.

Rh haemolytic disease of the newborn and Rh genotyping by RFLP—and allele-specific—PCR. Le Van Kim C, et al. **Transfus Clin Biol** 1995;2(4):317–24 (16 ref.)

Identification and analysis of Rh genes: application of PCR and RFLP typing tests. Hyland CA, et al. **Transfus Med Rev** 1995 Oct;9(4):289–301 (58 ref.)

Generation of DNA probes for detection of microorganisms by polymerase chain reaction fingerprinting [editorial] Giesendorf BA, et al. **Zentralbl Bakteriol** 1996 Apr; 283(4):417–30 (47 ref.)

[Cerebrospinal fluid diagnosis using polymerase chain reaction] van Manen SR, et al. **Ned Tijdschr Geneeskd** 1996 Jun 15;140(24):1259–63 (38 ref.) **(Dut)**

[Is polymerase chain reaction practical in the diagnosis of microbes?] Ranki-Pesonen M. **Duodecim** 1994; 110(6):615–21 (15 ref.) **(Fin)**

[Aseptic meningitis. Demonstration of bacterial DNA in cerebrospinal fluid by gene amplification] Salord F, et al. **Ann Fr Anesth Reanim** 1995;14(4):320–5 (28 ref.) (Eng. Abstr.) **(Fre)**

[Pre-symptomatic diagnosis of Huntington disease by polymerase chain reaction] Tóth T, et al. **Orv Hetil** 1996 Mar 3;137(9):451–4 (25 ref.) (Eng. Abstr.) **(Hun)**

[In situ PCR: its applications and problems] Mukai M, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Feb; 19(1):15–26 (42 ref.) **(Jpn)**

[Practical application of DNA-diagnosis in the Nippon Medical School Hospital] Kawanami O, et al. **Nippon Ika Daigaku Zasshi** 1995 Aug;62(4):401–5 (21 ref.) **(Jpn)**

[Direct sequencing for PCR products] Daikoku M, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:305–9 (8 ref.) **(Jpn)**

[PCR-SSCP.direct sequencing] Kagimoto S. **Nippon Rinsho** 1995 Oct;53 Suppl:310–5 (5 ref.) **(Jpn)**

[Thermostable DNA Polymerases and PCR] Ishino Y. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):429–36 (42 ref.) **(Jpn)**

[PCR amplification on forensic science] Kasai K. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):738–43 (20 ref.) **(Jpn)**

[Primer for PCR method, synthesis and purification] Kawase Y. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):446–52 (20 ref.) **(Jpn)**

[Application of PCR technique to mouse genetics] Kominami R, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):623–8 (21 ref.) **(Jpn)**

[Labelling of PCR products] Makino R. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):494–8 (6 ref.) **(Jpn)**

[Method of determining optimal PCR primers] Mitsuhashi M. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):439–45 (8 ref.) **(Jpn)**

[Reaction conditions of PCR] Mukai H. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):425–8 (17 ref.) **(Jpn)**

[PCR and DNA sequencing] Saito M, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):522–30 (6 ref.) **(Jpn)**

[Isolation of DNA from cells and tissues for PCR] Sekiya T. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):453–6 (4 ref.) **(Jpn)**

[Principles of PCR-based technologies] Sekiya T. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):415–24 (17 ref.) **(Jpn)**

[Quantitative PCR: DNA quantification by PCR] Yasuda J. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):499–502 (14 ref.) **(Jpn)**

[Applications of the polymerase chain reaction (PCR) to the diagnosis of central nervous system infections] Querol JM, et al. **An Med Interna** 1996 May;13(5):235–8 (20 ref.) (Eng. Abstr.) **(Spa)**

INSTRUMENTATION

[PCR machine] Kimura S, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):514–7 (7 ref.) **(Jpn)**

METHODS

Differential display RT-PCR for identifying novel gene expression in the lung. Sunday ME. **Am J Physiol** 1995 Sep;269(3 Pt 1):L273–84 (72 ref.)

Revolutions in rapid amplification of cDNA ends: new strategies for polymerase chain reaction cloning of full-length cDNA ends. Schaefer BC. **Anal Biochem** 1995 May 20;227(2):255–73 (79 ref.)

Polymerase chain reaction in the detection of micrometastases and circulating tumor cells [see comments] Ghossein RA, et al. **Cancer** 1996 Jul 1;78(1):10–6 (41 ref.) Comment in: Cancer 1996 Jul 1;78(1):1–3.

PCR and non-isotopic labeling techniques for plant virus detection. Fenby NS, et al. **Cell Mol Biol (Noisy-le-grand)** 1995 Jul;41(5):639–52 (94 ref.)

Detection and identification of Campylobacter spp. using the polymerase chain reaction. Giesendorf BA, et al. **Cell Mol Biol (Noisy-le-grand)** 1995 Jul;41(5):625–38 (123 ref.)

The applications of the polymerase chain reaction in the life sciences. Lenstra JA. **Cell Mol Biol (Noisy-le-grand)** 1995 Jul;41(5):603–14 (89 ref.)

Applications of random PCR. von Eggeling F, et al. **Cell Mol Biol (Noisy-le-grand)** 1995 Jul;41(5):653–70 (70 ref.)

Recent advances in differential display. Liang P, et al. **Curr Opin Immunol** 1995 Apr;7(2):274–80 (41 ref.)

Introduction to quantitative reverse transcription polymerase chain reaction. Salomon RN. **Diagn Mol Pathol** 1995 Jun; 4(2):82–4 (8 ref.)

Immunoprinting reveals different genetic bases for (auto)immuno diseases. Epplen C, et al. **Electrophoresis** 1995 Sep;16(9):1693–7 (32 ref.)

RT-PCR and alternative methods to PCR for in vitro amplification of nucleic acids. Hagen-Mann K, et al. **Exp Clin Endocrinol Diabetes** 1995;103(3):150–5 (22 ref.)

Polymerase chain reaction in situ: an appraisal of an emerging technique. Teo IA, et al. **Histochem J** 1995 Sep; 27(9):647–59 (67 ref.)

Single-cell analysis of unstable genes. Daniels R, et al. **J Assist Reprod Genet** 1996 Feb;13(2):163–9 (28 ref.)

Fluorescent PCR: a new technique for PGD of sex and single-gene defects. Findlay I, et al. **J Assist Reprod Genet** 1996 Feb;13(2):96–103 (28 ref.)

PCR in clinical diagnosis. Ronai Z, et al. **J Clin Lab Anal** 1995;9(4):269–83 (206 ref.)

In situ PCR: pathologist's dream or nightmare? O'Leary JJ, et al. **J Pathol** 1996 Jan;178(1):11–20 (22 ref.)

The clinical significance of residual disease in childhood acute lymphoblastic leukemia as detected by polymerase chain reaction amplification by antigen-receptor gene sequences. Roberts WM, et al. **Leuk Lymphoma** 1996 Jan; 20(3–4):181–97 (50 ref.)

Reverse transcription polymerase chain reaction for cytokines in the mixed lymphocyte culture. Is there a role in renal transplantation? [editorial] Danzer SG, et al. **Nephrol Dial Transplant** 1996 Jul;11(7):1246–7 (10 ref.)

Expression-PCR (E-PCR): overview and applications. Lanar DE, et al. **PCR Methods Appl** 1994 Oct;4(2):S92–6 (13 ref.)

Advances in PCR-based detection of mycoplasmas contaminating cell cultures. Rawadi G, et al. **PCR Methods Appl** 1995 Feb;4(4):199–208 (70 ref.)

A RT-PCR study of gene expression in a mechanical injury model. Eng LF, et al. **Prog Brain Res** 1995;105:219–29 (29 ref.)

[The utilization of molecular biological tools in the study of malaria transmission: example of programs conducted in Senegal] Fontenille D, et al. **Med Trop (Mars)** 1995;55(4 Suppl):52–5 (15 ref.) (Eng. Abstr.) **(Fre)**

[Molecular biology in the diagnosis and phenotypic expression of familial hypercholesterolemia in French Canadians] Vohl MC, et al. **Union Med Can** 1995 Sep; 124(2):48–53 (23 ref.) **(Fre)**

[PCR: basics and new developments] Berchtold MW, et al. **Schweiz Arch Tierheilkd** 1996;138(2):53–8 (0 ref.) (Eng. Abstr.) **(Ger)**

[New technique: PCR method for diagnosis of patients with leprosy] Sugita Y. **Nippon Rai Gakkai Zasshi** 1995 Jul; 64(2):100–4 (17 ref.) **(Jpn)**

[Quantitation of HCV-RNA by competitive-PCR] Kaneko S, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:281–6 (5 ref.) **(Jpn)**

[Detection of hepatitis C virus (HCV) infected cell using in situ hybridization and PCR in situ hybridization] Kawai H, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:307–11 (23 ref.)

(Jpn)
[Method of detecting plus and minus strands of hepatitis C viral RNA by strand specific reverse transcription-polymerase chain reaction] Kawashima T, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:294-9 (11 ref.) (Jpn)

[Detection of tumor markers by genetic diagnostic methods and its clinical application] Yamamoto H, et al. **Nippon Rinsho** 1996 Jun;54(6):1574-9 (19 ref.) (Eng. Abstr.) (Jpn)

[Representational difference analysis: identification of the differences between genomes] Aburatani H, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):573-9 (11 ref.) (Jpn)

[Detection and analysis of human herpesvirus genomes by polymerase chain reaction] Aono T, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):669-75 (24 ref.) (Jpn)

[In situ PCR: principles, problems and application to molecular biology] Aoyagi K. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):608-13 (32 ref.) (Jpn)

[Problems in PCR] Hayashi K. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):510-3 (7 ref.) (Jpn)

[RNase protection analysis] Horii A. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):561-3 (2 ref.) (Jpn)

[Immuno-PCR: a sensitive method for detecting antigen] Imai K, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr; 41(5):614-7 (13 ref.) (Jpn)

[In situ PCR detection of HTLV-1 provirus in spinal cord lesions with HAM/TSP] Izumo S, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):656-9 (16 ref.) (Jpn)

[Hepatitis C virus] Kato N, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):676-80 (19 ref.) (Jpn)

[Quantitative PCR] Kawakami B, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):503-9 (16 ref.) (Jpn)

[Molecular cloning of differentially expressed genes during plant somatic embryogenesis] Kayano T, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):721-6 (32 ref.) (Jpn)

[AP-PCR genomic fingerprinting] Kohno T, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):629-32 (3 ref.) (Jpn)

[Detection of gene expression using digoxigenin-labeled probes] Kubota S, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):486-90 (14 ref.) (Jpn)

[Hot start method] Mukai H. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):469-71 (3 ref.) (Jpn)

[LA PCR] Mukai H. **Tanpakushitsu Kakusan Koso** 1996 Apr; 41(5):585-94 (7 ref.) (Jpn)

[Reverse transcriptase-polymerase chain reaction] Murakami Y. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):595-602 (12 ref.) (Jpn)

[PCR-RFLP analysis] Nagase S, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):564-7 (6 ref.) (Jpn)

[Differential display analysis of mRNA] Nakagama H, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):580-4 (4 ref.) (Jpn)

[Detection of Borna disease virus RNA by RT-PCR in PBMC] Nakaya T, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):700-4 (20 ref.) (Jpn)

[Detection of DNA aberrations in human cancers by AP-PCR-SSCP analysis] Okano A, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):633-7 (12 ref.) (Jpn)

[Denaturing gradient gel electrophoresis of DNA fragments attached with a GC-clamp] Satoh C, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):556-60 (15 ref.) (Jpn)

[Single-strand conformation polymorphism (SSCP) analysis: a convenient, rapid method for detection of single-base changes in DNA] Sekiya T. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):539-45 (4 ref.) (Jpn)

[PCR application for paraffin-embedded tissues] Shindoh M, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):463-6 (8 ref.) (Jpn)

[Histopathological application of in situ PCR (in situ hybridization after amplification by PCR)] Shindoh M, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):660-3 (10 ref.) (Jpn)

[Mutant allele specific amplification (MASA)] Sugai S, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):546-8 (11 ref.) (Jpn)

[Molecular diagnosis of cancer by non-radioisotopic PCR/SSCP analysis] Sugano K. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):638-42 (8 ref.) (Jpn)

[Isolation of mRNA 5'-end using oligo-capping] Suzuki Y, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):603-7 (0 ref.) (Jpn)

[Detection of rare target gene with a point mutation by improved PCR] Tada M, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):549-52 (7 ref.) (Jpn)

[Hot-start PCR by using antibody] Takahashi M, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):472-6 (12 ref.) (Jpn)

[Novel molecular technology for HIV detection and analysis] Tamatsukuri S, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):686-95 (36 ref.) (Jpn)

[Application of PCR to hospital epidemiology] Tokue Y, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):705-7 (14 ref.) (Jpn)

[Detection and typing of HPV genome: consensus PCR method] Yamashita T, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):664-8 (21 ref.) (Jpn)

[Site-directed mutagenesis by PCR] Yamashita T, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):534-8 (13 ref.) (Jpn)

[Arbitrarily primed PCR: an unique technique for molecular genetical analysis] Yasuda J. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):568-72 (12 ref.) (Jpn)

[PCR-SSOP (sequence specific oligonucleotide probe) method] Yasunaga S, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):553-5 (3 ref.) (Jpn)

[Slide PCR for gene mapping] Yoshida MC. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):652-5 (3 ref.) (Jpn)

[Polymerase chain reaction and ligase reactions. Principles, traditional methods, and innovations] Belokhvostov AS. **Mol Gen Mikrobiol Virusol** 1995 Apr-Jun;(2):21-6 (50 ref.) (Eng. Abstr.) (Rus)

TRENDS

[PCR: principles and prospects in clinical biology] Billiald P, et al. **Ann Pharm Fr** 1995;53(4):155-62 (79 ref.) (Eng. Abstr.) (Fre)

VETERINARY

Applications of DNA amplification techniques in veterinary diagnostics. Pfeffer M, et al. **Vet Res Commun** 1995; 19(5):375-407 (284 ref.)

[Diagnosis of contagious diseases in animals using PCR] Hofmann MA, et al. **Schweiz Arch Tierheilkd** 1995; 137(12):531-6 (9 ref.) (Eng. Abstr.) (Ger)

POLYMERS

see related

MACROMOLECULAR SYSTEMS

Biodegradable polymers for protein and peptide drug delivery. Gombotz WR, et al. **Bioconjug Chem** 1995 Jul-Aug;6(4):332-51 (234 ref.)

Sterilization, toxicity, biocompatibility and clinical applications of polylactic acid/polyglycolic acid copolymers. Athanasiou KA, et al. **Biomaterials** 1996 Jan; 17(2):93-102 (100 ref.)

Role of bone substitutes. Hollinger JO, et al. **Clin Orthop** 1996 Mar;(324):55-65 (89 ref.)

Applications of biodegradable lactides and glycolides in podiatry. Athanasiou KA, et al. **Clin Podiatr Med Surg** 1995 Jul;12(3):475-95 (90 ref.)

ANALYSIS

Polyion-sensitive membrane electrodes for biomedical analysis. Meyerhoff ME, et al. **Anal Chem** 1996 Mar 1; 68(5):168A-175A (20 ref.)

CHEMICAL SYNTHESIS

Development of vaccines based on formulations containing nonionic block copolymers. Brey RN. **Pharm Biotechnol** 1995;6:297-311 (52 ref.)

CHEMISTRY

Logarithmic growth in surface adsorption. Nygren H. **Adv Colloid Interface Sci** 1995 Dec 1;62(2-3):137-59 (71 ref.)

Conducting polymers and the bioanalytical sciences: new tools for biomolecular communication. A review. Adeloju SB, et al. **Analyst** 1996 Jun;121(6):699-703 (46 ref.)

Plant polyphenols: free radical scavengers or chain-breaking antioxidants? Rice-Evans C. **Biochem Soc Symp** 1995; 61:103-16 (53 ref.)

Characterization of hydrogels using nuclear magnetic resonance spectroscopy. Mathur AM, et al. **Biomaterials** 1996 Mar;17(6):547-57 (80 ref.)

Surface modification of polymers: chemical, biological and surface analytical challenges. Ratner BD. **Biosens Bioelectron** 1995;10(9-10):797-804 (41 ref.)

Wresting the muscle from mussel beards: research and applications. Rzepecki LM, et al. **Mol Mar Biol Biotechnol** 1995 Dec;4(4):313-22 (45 ref.)

Water-soluble phosphazene polymers for parenteral and mucosal vaccine delivery. Payne LG, et al. **Pharm Biotechnol** 1995;6:473-93 (15 ref.)

Molecular trees: a new branch of chemistry [comment] Bell TW. **Science** 1996 Feb 23;271(5252):1077-8 (19 ref.) Comment on: Science 1996 Feb 23;271(5252):1095-8.

New designs of macroporous polymers and supports: from separation to biocatalysis. Svec F, et al. **Science** 1996 Jul 12;273(5272):205-11 (48 ref.)

METABOLISM

Breakdown of plastics and polymers by microorganisms. Kawai F. **Adv Biochem Eng Biotechnol** 1995;52:151-94 (190 ref.)

Mechanisms of polymer degradation and erosion. Göpferich A. **Biomaterials** 1996 Jan;17(2):103-14 (120 ref.)

PHARMACOKINETICS

The use of polymers in the construction of controlled-release devices. Heller J. **NIDA Res Monogr** 1995;154:107-31 (33 ref.)

PHARMACOLOGY

Copolymer adjuvants. Brey RN. **Adv Exp Med Biol** 1995; 383:23-34 (47 ref.)

THERAPEUTIC USE

Role of polymers in improving the results of stenting in coronary arteries. Peng T, et al. **Biomaterials** 1996 Apr; 17(7):685-94 (90 ref.)

Polyphenols as cancer chemopreventive agents. Stoner GD, et al. **J Cell Biochem Suppl** 1995;22:169-80 (87 ref.)

TOXICITY

A review of inhalation toxicology studies with para-aramid fibrils. Warheit DB. **Ann Occup Hyg** 1995 Oct;39(5):691-7 (14 ref.)

Toxicity of combustion products of polymeric materials. Cempel M. **Bull Inst Marit Trop Med Gdynia** 1993-94; 44-45(1-4):75-81 (21 ref.)

POLYMETHYLMETHACRYLATE see **METHYLMETHACRYLATES**

POLYMORPHISM (GENETICS)

Review of studies of polymorphic blood systems in the Aymara indigenous population from Bolivia, Peru, and Chile. Dittmar M. **Anthropol Anz** 1995 Dec;53(4):289-315 (55 ref.)

Specific factors leading to interindividual variability in response to occupational toxicants. Goergens HW. **Arch Toxicol Suppl** 1996;18:357-61 (28 ref.)

Polyglot and polymorphism. An HLA update. Nepom BS, et al. **Arthritis Rheum** 1995 Dec;38(12):1715-21 (4 ref.)

Genetic variation of apolipoprotein B can produce both low and high levels of apoB-containing lipoproteins in plasma. Schonfeld G. **Can J Cardiol** 1995 Oct;11 Suppl G:86G-92G (79 ref.)

Apolipoprotein E polymorphism and dietary plasma cholesterol response. Tikkanen M, et al. **Can J Cardiol** 1995 Oct;11 Suppl G:93G-96G (25 ref.)

Metabolic polymorphisms and cancer susceptibility. Smith G, et al. **Cancer Surv** 1995;25:27-65 (249 ref.)

Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Bertilsson L. **Clin Pharmacokinet** 1995 Sep;29(3):192-209 (103 ref.)

Role of angiotensin-converting enzyme gene polymorphism in progressive loss of renal function in chronic renal diseases. Yoshida H, et al. **Contrib Nephrol** 1996;118:249-53 (21 ref.)

Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer. Nebert DW, et al. **DNA Cell Biol** 1996 Apr;15(4):273-80 (96 ref.)

TCR gene polymorphisms and autoimmune disease. Kay RA. **Eur J Immunogenet** 1996 Apr;23(2):161-77 (129 ref.)

Forensic applications of genetic polymorphisms detected in human body fluids (urine, semen and blood). Kishi K, et al. **Forensic Sci Int** 1996 Jun 28;80(1-2):89-97 (55 ref.)

Mutations in pyruvate kinase. Beutler E, et al. **Hum Mutat** 1996;7(1):1-6 (40 ref.)

Evolution of Mhc class II polymorphism: the rise and fall of class II gene function in primates. Bergström T, et al. **Immunol Rev** 1995 Feb;143:13-31 (45 ref.)

A "minimal essential Mhc" and an "unrecognized Mhc": two extremes in selection for polymorphism. Kaufman J, et al. **Immunol Rev** 1995 Feb;143:63-88 (84 ref.)

Evolution of MHC class II allelic diversity. McDevitt H. **Immunol Rev** 1995 Feb;143:113-22 (25 ref.)

Pathogen-based models favoring MHC genetic diversity. Potts WK, et al. **Immunol Rev** 1995 Feb;143:181-97 (37 ref.)

Exonic MHC-DRB polymorphisms and intronic simple repeat sequences: Janus' faces of DNA sequence evolution. Schwaiger FW, et al. **Immunol Rev** 1995 Feb;143:199-224 (55 ref.)

A genetic herd-immunity model for the maintenance of MHC polymorphism. Wills C, et al. **Immunol Rev** 1995 Feb;143:263-92 (70 ref.)

Vitamin D receptor gene alleles and osteoporosis: an affirmative view [editorial] Eisman JA. **J Bone Miner Res** 1995 Sep;10(9):1289-93 (43 ref.)

Red cell polymorphisms in nonhuman primates: a review. Socha WW, et al. **J Med Primatol** 1995 Dec;24(4):282-305 (115 ref.)

Association studies, ACE polymorphisms and renal disease [editorial] Harden PN, et al. **Nephrol Dial Transplant** 1996 May;11(5):757-9 (31 ref.)

Origins and evolution of Huntington disease chromosomes.

Andrew SE, et al. **Neurodegeneration** 1995 Sep;4(3):239–44 (50 ref.)

Lung cancer and CYP2D6 (the debrisoquine polymorphism): sources of heterogeneity in the proposed association. Caporaso N, et al. **Pharmacogenetics** 1995;5 Spec No:S129–34 (44 ref.)

Polymorphic forms of the Ah receptor and induction of the CYP1A1 gene. Fujii-Kuriyama Y, et al. **Pharmacogenetics** 1995;5 Spec No:S149–53 (30 ref.)

Assessment of cancer susceptibility in humans by use of genetic polymorphisms in carcinogen metabolism. Ikawa S, et al. **Pharmacogenetics** 1995;5 Spec No:S154–60 (42 ref.)

Metabolic polymorphisms and carcinogen–DNA adduct formation in human populations. Kaderlik KR, et al. **Pharmacogenetics** 1995;5 Spec No:S108–17 (112 ref.)

Genetic polymorphisms of drug-metabolizing enzymes and lung cancer susceptibility. Kawajiri K, et al. **Pharmacogenetics** 1995;5 Spec No:S70–3 (17 ref.)

Primate photopigments and primate color vision. Jacobs GH. **Proc Natl Acad Sci U S A** 1996 Jan 23;93(2):577–81 (61 ref.)

Polymorphisms of human platelet membrane glycoproteins: structure and clinical significance. Nurden AT. **Thromb Haemost** 1995 Jul;74(1):345–51 (53 ref.)

Heat shock protein 70 gene polymorphisms and multiple sclerosis. Ramachandran S, et al. **Tissue Antigens** 1995 Aug; 46(2):140–1 (18 ref.)

DNA markers in forensic medicine. Mayr WR. **Transfus Clin Biol** 1995;2(4):325–8 (4 ref.)

[Polymorphism of enzymes involved in drug metabolism: gene structure and enzymatic activity] Krynetskii EI. **Mol Biol (Mosk)** 1996 Jan–Feb;30(1):33–42 (58 ref.) **(Rus)**

GENETICS

Gene–environment interaction in parkinson's disease. The case of CYP2D6 gene polymorphism. Landi MT, et al. **Adv Neurol** 1996;69:61–72 (80 ref.)

Underexpression of the apolipoprotein E2 and E4 alleles in the Greek Cypriot population of Cyprus. Cariolou MA, et al. **Genet Epidemiol** 1995;12(5):489–97 (29 ref.)

Evolution of major histocompatibility complex polymorphisms and T-cell receptor diversity in primates. Bontrop RE, et al. **Immunol Rev** 1995 Feb;143:33–62 (96 ref.)

Chromosome-length polymorphism in fungi. Zolan ME. **Microbiol Rev** 1995 Dec;59(4):686–98 (145 ref.)

IMMUNOLOGY

The origins of HLA-A,B,C polymorphism. Parham P, et al. **Immunol Rev** 1995 Feb;143:141–80 (57 ref.)

MHC diversity and selection. Takahata N. **Immunol Rev** 1995 Feb;143:225–47 (43 ref.)

Evolution of class I promoter sequences: relationship to function and diversity. Vallejo AN, et al. **Immunol Rev** 1995 Feb;143:249–62 (54 ref.)

POLYMORPHISM, RESTRICTION FRAGMENT LENGTH

Polymorphism and utilization of human VH Genes. Milner EC, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:50–61 (23 ref.)

Immunoglobulin allotypes and RFLPs in disease association. Propert D. **Exp Clin Immunogenet** 1995;12(3):198–205 (42 ref.)

Genetic polymorphisms of drug-metabolizing enzymes and lung cancer susceptibility. Kawajiri K, et al. **Pharmacogenetics** 1995;5 Spec No:S70–3 (17 ref.)

Restriction fragment length polymorphism typing of Mycobacterium tuberculosis. Hayward AC. **Thorax** 1995 Nov;50(11):1211–8 (66 ref.)

Rh haemolytic disease of the newborn and Rh genotyping by RFLP—and allele-specific—PCR. Le Van Kim C, et al. **Transfus Clin Biol** 1995;2(4):317–24 (16 ref.)

Identification and analysis of Rh genes: application of PCR and RFLP typing tests. Hyland CA, et al. **Transfus Med Rev** 1995 Oct;9(4):289–301 (58 ref.)

[PCR–RFLP analysis] Nagase S, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):564–7 (6 ref.) **(Jpn)**

[The relationship of apoB gene polymorphism to dyslipoproteinemia as the cause of atherosclerosis] Kravchenko NA. **Tsitol Genet** 1995 Jul–Aug;29(4):84–7 (33 ref.) (Eng. Abstr.) **(Rus)**

POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL

[PCR–SSCP.direct sequencing] Kagimoto S. **Nippon Rinsho** 1995 Oct;53 Suppl:310–5 (5 ref.) **(Jpn)**

[Analysis of hepatitis C virus quasispecies populations using PCR–SSCP method] Kurosaki M, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:339–45 (16 ref.) **(Jpn)**

[Detection of DNA aberrations in human cancers by AP–PCR–SSCP analysis] Okano A, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):633–7 (12 ref.) **(Jpn)**

[Single-strand conformation polymorphism (SSCP) analysis: a convenient, rapid method for detection of single-base changes in DNA] Sekiya T. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):539–45 (4 ref.) **(Jpn)**

[Molecular diagnosis of cancer by non-radioisotopic PCR/SSCP analysis] Sugano K. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):638–42 (8 ref.) **(Jpn)**

POLYMORPHONUCLEAR LEUKOCYTES see **NEUTROPHILS**

POLYMYALGIA RHEUMATICA

see related

TEMPORAL ARTERITIS

Polymyalgia rheumatica and giant cell arteritis. Cimmino MA, et al. **Baillieres Clin Rheumatol** 1995 Aug;9(3):515–27 (60 ref.)

DIAGNOSIS

[Polymyalgia rheumatica] Efimenko IS, et al. **Ter Arkh** 1995; 67(11):71–3 (17 ref.) (Eng. Abstr.) **(Rus)**

PATHOLOGY

Microscopic polyarteritis during polymyalgia rheumatica remission. Uematsu-Yanagita M, et al. **Am J Kidney Dis** 1996 Aug;28(2):289–91 (6 ref.)

POLYMYOSITIS

Inflammatory myopathies. Oddis CV, et al. **Baillieres Clin Rheumatol** 1995 Aug;9(3):497–514 (57 ref.)

[Polymyositis and dermatomyositis. Current status] Cherin P, et al. **Ann Dermatol Venereol** 1995;122(6–7):447–54 (71 ref.) **(Fre)**

COMPLICATIONS

Case report: polymyositis-induced myoglobinuric acute renal failure. Thakur V, et al. **Am J Med Sci** 1996 Aug; 312(2):85–7 (11 ref.)

Polymyositis and Sjögren's syndrome associated with bronchiolitis obliterans organizing pneumonia. Imasaki T, et al. **Intern Med** 1996 Mar;35(3):231–5 (22 ref.)

[Association of polymyositis and rheumatoid arthritis. Apropos of a new case not related to drug ingestion] Jardin H, et al. **Rev Med Interne** 1996;17(4):321–4 (27 ref.) (Eng. Abstr.) **(Fre)**

POLYMYXIN B

ADVERSE EFFECTS

Ototoxicity of ear drops: a clinical perspective. Linder TE, et al. **Am J Otol** 1995 Sep;16(5):653–7 (23 ref.)

PHARMACOLOGY

Inhibition of lipopolysaccharide-induced TNF-alpha production by semisynthetic polymyxin-B conjugated dextran. Coyne CP, et al. **Biotechnol Ther** 1994–95; 5(3–4):137–62 (108 ref.)

Bacterial responses to host-defense peptides. Groisman EA. **Trends Microbiol** 1996 Apr;4(4):127–8; discussion 128–9 (17 ref.)

POLYNEURITIS

THERAPY

[The treatment of distal neuropathy—an important means for preventing the development of diabetic gangrene] Datsun IH, et al. **Vrach Delo** 1995 Jan–Feb;(1–2):25–9 (29 ref.) **(Ukr)**

POLYNUCLEAR AROMATIC HYDROCARBONS see **POLYCYCLIC HYDROCARBONS, AROMATIC**

POLYNUCLEOTIDES

ADMINISTRATION & DOSAGE

Prospects for gene therapy with direct injection of polynucleotides. Kass-Eisler A, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:232–40 (33 ref.)

Polynucleotide-mediated immunization therapy of cancer. Conry RM, et al. **Semin Oncol** 1996 Feb;23(1):135–47 (79 ref.)

CHEMISTRY

Application of combinatorial libraries and protein engineering to the discovery of novel anti-thrombotic drugs. Leung LL. **Thromb Haemost** 1995 Jul;74(1):373–6 (19 ref.)

POLYOMAVIRUS

Mammary tumors induced by polyomavirus. Fluck MM, et al. **Breast Cancer Res Treat** 1996;39(1):45–56 (49 ref.)

Human polyoma virus infection of renal allografts: histopathologic diagnosis, clinical significance, and literature review. Pappo O, et al. **Mod Pathol** 1996 Feb; 9(2):105–9 (23 ref.)

[Molecular bases of papillomavirus and polyomavirus carcinogenesis] Taja-Chayeb L, et al. **Salud Publica Mex** 1996 Jan–Feb;38(1):47–57 (40 ref.) (Eng. Abstr.) **(Spa)**

POLYOMAVIRUS HOMINIS 1

BK virus-induced osteosarcoma (Os515) as a model of human osteosarcoma. Sekiguchi M, et al. **Anticancer Res** 1996 Jul–Aug;16(4A):1835–42 (40 ref.)

GENETICS

Noncoding control region of naturally occurring BK virus variants: sequence comparison and functional analysis. Moens U, et al. **Virus Genes** 1995;10(3):261–75 (112 ref.)

ISOLATION & PURIFICATION

JCV-DNA and BKV-DNA in the CNS tissue and CSF of AIDS patients and normal subjects. Study of 41 cases and review of the literature. Vago L, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Jun 1;12(2):139–46 (43 ref.)

POLYOMAVIRUS HOMINIS 2

Progressive multifocal leukoencephalopathy: a review of the pathology and pathogenesis. Aksamit AJ Jr. **Microsc Res Tech** 1995 Nov 1;32(4):302–11 (39 ref.)

GENETICS

Transcriptional regulation: lessons from the human neurotropic polyomavirus, JCV. Raj GV, et al. **Virology** 1995 Nov 10;213(2):283–91 (79 ref.)

ISOLATION & PURIFICATION

JCV-DNA and BKV-DNA in the CNS tissue and CSF of AIDS patients and normal subjects. Study of 41 cases and review of the literature. Vago L, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Jun 1;12(2):139–46 (43 ref.)

POLYOMAVIRUS LARGE T ANTIGENS see **ANTIGENS, POLYOMAVIRUS TRANSFORMING**

POLYOMAVIRUS MACACAE

GENETICS

SV40-mediated immortalization of human fibroblasts. Ozer HL, et al. **Exp Gerontol** 1996 Jan–Apr;31(1–2):303–10 (30 ref.)

[Eukaryotic DNA replication: analysis of reconstitution of SV40 DNA replication] Waga S. **Seikagaku** 1995 Sep; 67(9):1142–8 (19 ref.) **(Jpn)**

POLYOMAVIRUS MIDDLE T ANTIGENS see **ANTIGENS, POLYOMAVIRUS TRANSFORMING**

POLYOMAVIRUS SMALL T ANTIGENS see **ANTIGENS, POLYOMAVIRUS TRANSFORMING**

POLYOMAVIRUS T PROTEINS see **ANTIGENS, POLYOMAVIRUS TRANSFORMING**

POLYOMAVIRUS TRANSFORMING ANTIGENS see **ANTIGENS, POLYOMAVIRUS TRANSFORMING**

POLYOMAVIRUS TUMOR ANTIGENS see **ANTIGENS, POLYOMAVIRUS TRANSFORMING**

POLYOXYETHYLENES see **POLYETHYLENE GLYCOLS**

POLYPEPTIDES see **PEPTIDES**

POLYPHOSPHATES

CHEMICAL SYNTHESIS

[New and large scale syntheses of nucleoside polyphosphates] Ishikawa M, et al. **Tanpakushitsu Kakusan Koso** 1994 Jul; 40(10):1333–41 (22 ref.) **(Jpn)**

POLYPHOSPHOINOSITIDES see **PHOSPHATIDYLINOSITOL PHOSPHATES**

POLYPLOIDY

Atypical polypoid adenomyomas of the uterus. Fukunaga M, et al. **Histopathology** 1995 Jul;27(1):35–42 (18 ref.)

[Polyploidy in the myocardium. Compensatory reserve of the heart] Brodskil VIa. **Biull Eksp Biol Med** 1995 May; 119(5):454–9 (49 ref.) **(Rus)**

POLYPOSIS COLI, FAMILIAL see **ADENOMATOUS POLYPOSIS COLI**

POLYPOSIS SYNDROME, FAMILIAL see **ADENOMATOUS POLYPOSIS COLI**

POLYPROPYLENES

Polypropylene mesh closure after emergency laparotomy: morbidity and outcome. Brandt CP, et al. **Surgery** 1995 Oct;118(4):736–40; discussion 740–1 (17 ref.)

POLYPROTEINS see PROTEINS

POLYPS

[Fibroepithelial polyps of the ureter and the kidney pelvis. Report of 3 cases] Robert M, et al. **Prog Urol** 1996 Apr; 6(2):282–7 (31 ref.) (Eng. Abstr.) **(Fre)**

[Atopic stomach polyp as the cause of invagination of Meckel's diverticulum] Schütter FW, et al. **Chirurg** 1995 Oct;66(10):1016–8 (24 ref.) (Eng. Abstr.) **(Ger)**

[Inflammatory polyp of the extra-hepatic bile duct] Adachi K, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):149–51 (7 ref.) **(Jpn)**

[Polyp and polypoid lesions of the gallbladder] Itoi T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):348–51 (12 ref.) **(Jpn)**

[Pseudotumors of the gallbladder] Iwase H, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):329–32 (20 ref.) **(Jpn)**

[Granulation polyp of the gallbladder, inflammation of the Rokitansky–Aschoff sinus] Liao CM, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):321–3 (6 ref.) **(Jpn)**

[Inflammatory polyp] Taira A, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):248–50 (22 ref.) **(Jpn)**

[Hyperplastic polyp, metaplastic polyp] Taira A, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):256–8 (22 ref.) **(Jpn)**

[Fibrous polyp of the gallbladder] Takashimizu I, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):295–8 (16 ref.) **(Jpn)**

[Fibroepithelial polyp of the gallbladder] Tokoi S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):292–4 (8 ref.) **(Jpn)**

COMPLICATIONS

[Frontal cerebral abscess, a rare complication of nasosinusal polyposis. Apropos of a case] Abgrall S, et al. **Neurochirurgie** 1995;41(5):367–71 (13 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Fibroepithelial polyps of the renal pelvis: report of two cases and review of the literature. Fernández Aceñero MJ, et al. **Minerva Urol Nefrol** 1995 Sep;47(3):133–6 (10 ref.)

Signet ring cell carcinoma in hyperplastic polyp. Zea-Iriarte WL, et al. **Scand J Gastroenterol** 1995 Jun;30(6):604–8 (26 ref.)

[Small polypoid lesions of the gallbladder] Itoi T, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):287–9 (5 ref.) **(Jpn)**

[Cholesterol polyp] Taira A, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):280–2 (8 ref.) **(Jpn)**

[Pseudopolyp of the gallbladder] Watanabe H, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):273–4 (5 ref.) **(Jpn)**

SURGERY

[The secondary prevention of colorectal carcinoma by polyp removal] Riemann JF. **Strahlenther Onkol** 1995 Nov; 171(11):611–4 (21 ref.) (Eng. Abstr.) **(Ger)**

POLYRADICULITIS

THERAPY

Inflammatory neuropathies—pathogenesis and the role of intravenous immune globulin. van der Meché FG, et al. **J Clin Immunol** 1995 Nov;15(6 Suppl):63S–69S (64 ref.)

POLYRADICULONEURITIS

Multifocal motor neuropathy and chronic inflammatory demyelinating polyradiculoneuropathy. Léger JM. **Curr Opin Neurol** 1995 Oct;8(5):359–63 (23 ref.)

COMPLICATIONS

Membranous glomerulonephritis associated with inflammatory demyelinating peripheral neuropathies. Panjwani M, et al. **Am J Kidney Dis** 1996 Feb;27(2):279–83 (20 ref.)

Neuropathies in HIV infection. Dalakas MC, et al. **Baillieres Clin Neurol** 1996 Mar;5(1):199–218 (65 ref.)

[A case of Guillain-Barré syndrome associated with SIADH, treated by intravenous gammaglobulins] De Decker V, et al. **Acta Clin Belg** 1996;51(3):170–4 (13 ref.) (Eng. Abstr.) **(Fre)**

[Guillain-Barré syndrome associated with external ophthalmoplegia, consciousness disturbance, and extensor plantar responses: an overlap between Guillain-Barré syndrome and Bickerstaff's brainstem encephalitis] Kitazawa K, et al. **Rinsho Shinkeigaku** 1995 Jun; 35(6):626–32 (30 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Guillain-Barré syndrome: a team approach to diagnosis and treatment. Dematteis JA. **Am Fam Physician** 1996 Jul; 54(1):197–200 (19 ref.)

Guillain-Barre syndrome in six cities and provinces of northern China: is it a new entity? Zhang X, et al. **Chin Med J (Engl)** 1995 Oct;108(10):734–8 (27 ref.)

Childhood Guillain-Barré syndrome: clinical presentation, diagnosis, and therapy. Jones HR. **J Child Neurol** 1996 Jan; 11(1):4–12 (76 ref.)

Axonal CIDP: a premature concept? Feasby TE. **Muscle Nerve** 1996 Mar;19(3):372–4 (16 ref.)

[The Guillain-Barré syndrome in childhood] Tarallo MR, et al. **Pediatr Med Chir** 1995 May-Jun;17(3):283–5 (10 ref.) (Eng. Abstr.) **(Ita)**

DRUG THERAPY

[A case of Guillain-Barré syndrome associated with anti-GM2 antibody due to cytomegalovirus infection--special reference to the effect of ganciclovir] Niwa K, et al. **Rinsho Shinkeigaku** 1995 Jun;35(6):652–6 (18 ref.) (Eng. Abstr.) **(Jpn)**

[Intravenous immunoglobulins in the treatment of neurologic diseases] Illa I, et al. **Neurologia** 1996 Jun-Jul;11(6):220–8 (56 ref.) **(Spa)**

ETIOLOGY

[Neuropathy and anti-ganglioside antibodies] Kusunoki S. **Nippon Naika Gakkai Zasshi** 1996 Apr 10;85(4):629–34 (13 ref.) **(Jpn)**

[Campylobacter jejuni and autoimmune-mediated neurologic diseases: pathogenesis of Guillain-Barré syndrome and Fisher's syndrome] Yuki N. **Nippon Saikingaku Zasshi** 1995 Oct;50(4):991–1003 (41 ref.) **(Jpn)**

IMMUNOLOGY

Pathogenesis of inflammatory demyelination: implications for therapy [editorial] Hartung HP. **Curr Opin Neurol** 1995 Jun;8(3):191–9 (49 ref.)

Guillain-Barré syndrome: clinical and immunological aspects. Rostami AM. **Springer Semin Immunopathol** 1995; 17(1):29–42 (94 ref.)

THERAPY

Guillain-Barré syndrome: a team approach to diagnosis and treatment. Dematteis JA. **Am Fam Physician** 1996 Jul; 54(1):197–200 (19 ref.)

A comparison between IVIg and plasma exchange in Guillain-Barré syndrome: a review and decision analysis of the two treatment modalities. Dawson WB, et al. **Clin Neuropharmacol** 1995 Oct;18(5):377–90 (44 ref.)

Is there a scientific rationale for therapeutic plasma exchange or intravenous immune globulin in the treatment of acute Guillain-Barré syndrome? Weinstein R. **J Clin Apheresis** 1995;10(3):150–7 (94 ref.)

[Treatment of Guillain-Barré syndrome] Zagar M. **Lijec Vjesn** 1995 Sep-Oct;117(9–10):246–9 (31 ref.) (Eng. Abstr.) **(Scr)**

POLYRIBONUCLEOTIDES

ADMINISTRATION & DOSAGE

Nutritional pharmacology and malignant disease: a therapeutic modality in patients with cancer. Heys SD, et al. **Br J Surg** 1996 May;83(5):608–19 (135 ref.)

POLYSACCHARIDES

BIOSYNTHESIS

Mechanisms in the glucansucrase synthesis of polysaccharides and oligosaccharides from sucrose. Robyt JF. **Adv Carbohydr Chem Biochem** 1995;51:133–68 (146 ref.)

Murine beta 1,4-galactosyltransferase. Analysis of a gene that serves both a housekeeping and a cell specific function. Shaper JH, et al. **Adv Exp Med Biol** 1995;376:95–104 (33 ref.)

CHEMISTRY

Cell wall polysaccharides of pathogenic yeasts. Fukazawa Y, et al. **Curr Top Med Mycol** 1995;6:189–219 (166 ref.)

Physical properties of polysaccharides in food. Brosio E. **Eur J Clin Nutr** 1995 Oct;49 Suppl 3:S63–7 (7 ref.)

Specific beta glucanases as tools for polysaccharide structure determination. Mishra C, et al. **Glycobiology** 1995 Oct; 5(7):645–54 (84 ref.)

Structure–activity relationship of antithrombotic polysaccharide derivatives. Franz G, et al. **Int J Biol Macromol** 1995 Dec;17(6):311–4 (16 ref.)

GENETICS

The regulation of cell- and tissue-specific expression of glycans by glycosyltransferases. Dinter A, et al. **Adv Exp Med Biol** 1995;376:53–82 (187 ref.)

METABOLISM

The impact of complex carbohydrates on energy balance. Livesey G. **Eur J Clin Nutr** 1995 Oct;49 Suppl 3:S89–96 (30 ref.)

Histochemical demonstration and analysis of poly-N-acetyllactosamine structures in normal and malignant human tissues. Ito N, et al. **Histol Histopathol** 1996 Jan;11(1):203–14 (110 ref.)

PHARMACOLOGY

[Progress in the research of plant polysaccharides] Tian G, et al. **Chung Kuo Chung Yao Tsa Chih** 1995 Jul;20(7):441–4 (31 ref.) **(Chi)**

PHYSIOLOGY

Glycosyltransferase mutants: key to new insights in glycobiology. Stanley P, et al. **FASEB J** 1995 Nov; 9(14):1436–44 (48 ref.)

POLYSACCHARIDES, BACTERIAL

Bacterial polysaccharides in sickness and in health. The 1995 Fleming Lecture. Roberts IS. **Microbiology** 1995 Sep;141 (Pt 9):2023–31 (95 ref.)

Haemophilus influenzae: capsule vaccine and capsulation genetics. Kroll JS, et al. **Mol Med Today** 1996 Apr; 2(4):160–5 (37 ref.)

[Radiation-protective action of microbial substances] Andrushchenko VN, et al. **Radiats Biol Radioecol** 1996 Mar-Apr;36(2):195–208 (95 ref.) (Eng. Abstr.) **(Rus)**

ADMINISTRATION & DOSAGE

The contribution of the case-control approach to vaccine evaluation: Pneumococcal and Haemophilus influenzae type B PRP vaccines. Mills OF, et al. **J Clin Epidemiol** 1996 Jun;49(6):631–6 (34 ref.)

BIOSYNTHESIS

Exopolysaccharide alginate synthesis in Pseudomonas aeruginosa: enzymology and regulation of gene expression. Shankar S, et al. **Adv Enzymol Relat Areas Mol Biol** 1995; 70:221–55 (84 ref.)

GENETICS

Characterization of the capsular polysaccharide genes of group B streptococci. Rubens CE, et al. **Dev Biol Stand** 1995;85:237–44 (31 ref.)

IMMUNOLOGY

Are polysaccharide antibody responses independent: the T cell enigma? Lane P. **Clin Exp Immunol** 1996 Jul; 105(1):10–1 (16 ref.)

ISOLATION & PURIFICATION

Isolation and structural characterization of adhesin polysaccharide receptors. Cassels FJ, et al. **Methods Enzymol** 1995;253:69–91 (44 ref.)

METABOLISM

Lysozyme substrates. Höltje JV. **EXS** 1996;75:105–10 (34 ref.)

PHYSIOLOGY

Bacterial modulins: a novel class of virulence factors which cause host tissue pathology by inducing cytokine synthesis. Henderson B, et al. **Microbiol Rev** 1996 Jun;60(2):316–41 (260 ref.)

POLYSOMNOGRAPHY

Normal sleep architecture in infants and children. Kahn A, et al. **J Clin Neurophysiol** 1996 May;13(3):184–97 (100 ref.)

The laboratory assessment of daytime sleepiness in childhood. Kotagal S, et al. **J Clin Neurophysiol** 1996 May; 13(3):208–18 (50 ref.)

Obstructive sleep apnea in infants and young children. Ward SL, et al. **J Clin Neurophysiol** 1996 May;13(3):198–207 (40 ref.)

Diagnostic testing. Sleep disorders. Mahowald MW. **Neurol Clin** 1996 Feb;14(1):183–200 (86 ref.)

POLYSORBATE 20 see POLYSORBATES

POLYSORBATE 80 see POLYSORBATES

POLYSORBATES

CHEMICAL SYNTHESIS

MF59. Design and evaluation of a safe and potent adjuvant for human vaccines. Ott G, et al. **Pharm Biotechnol** 1995; 6:277–96 (36 ref.)

POLYSTYRENES

ADVERSE EFFECTS

Cecal perforation associated with sodium polystyrene sulfonate-sorbitol enemas in a 650 gram infant with hyperkalemia. Bennett LN, et al. **Am J Perinatol** 1996 Apr; 13(3):167–70 (12 ref.)

POLYTEF see POLYTETRAFLUOROETHYLENE

POLYTETRAFLUOROETHYLENE

The use of expanded polytetrafluoroethylene (Gore-Tex) in rhinoplasty. A 6-year experience. Godin MS, et al. **Arch Otolaryngol Head Neck Surg** 1995 Oct;121(10):1131-6 (20 ref.)

Coarctation of the aorta. Repair with polytetrafluoroethylene patch aortoplasty. Backer CL, et al. **Circulation** 1995 Nov 1;92(9 Suppl):II132-6 (37 ref.)

The current status of expanded polytetrafluoroethylene (Gore-Tex) in facial plastic surgery. Levine B, et al. **Ear Nose Throat J** 1995 Oct;74(10):681-2, 684 (17 ref.)

Periodontal regenerative potential of space-providing expanded polytetrafluoroethylene membranes and recombinant human bone morphogenetic proteins. Sigurdsson TJ, et al. **J Periodontol** 1995 Jun;66(6):511-21 (37 ref.)

Neo-endothelialisation of PTFE microvascular grafts: a five-year experience. Lanzetta M, et al. **Microsurgery** 1995; 16(6):404-11 (35 ref.)

POLYURETHANES

The male polyurethane condom: a review of current knowledge. Rosenberg MJ, et al. **Contraception** 1996 Mar; 53(3):141-6 (18 ref.)

POLYURIA

VETERINARY

The differential diagnosis of polyuria/polydipsia in dogs. Belshaw BE. **Vet Q** 1995 Apr;17 Suppl 1:S19-21 (0 ref.)

POLYVINYL CHLORIDE

ADVERSE EFFECTS

Hospitals and plastics. Dioxin prevention and medical waste incinerators. Thornton J, et al. **Public Health Rep** 1996 Jul-Aug;111(4):299-313 (121 ref.)

POLYVINYLS

THERAPEUTIC USE

[Transvenous closure of persistent ductus arteriosus with an Ivalon plug] Fassbender D, et al. **Dtsch Med Wochenschr** 1996 May 17;121(20):653-7 (36 ref.) (Eng. Abstr.) **(Ger)**

POMC see **PRO-OPIOMELANOCORTIN**

POMPE'S DISEASE see **GLYCOGEN STORAGE DISEASE TYPE II**

PONS

Central nervous system medulloepithelioma: a series of eight cases including two arising in the pons. Molloy PT, et al. **J Neurosurg** 1996 Mar;84(3):430-6 (45 ref.)

PHYSIOLOGY

The pedunculopontine tegmental nucleus: where the striatum meets the reticular formation. Inglis WL, et al. **Prog Neurobiol** 1995 Sep;47(1):1-29 (205 ref.)

Gustatory function in the parabrachial nuclei: implications from lesion studies in rats. Spector AC. **Rev Neurosci** 1995 Apr-Jun;6(2):143-75 (163 ref.)

RADIOGRAPHY

Case report: Pontine haemorrhage following iohexol lumbar myelography. Yeh YF, et al. **Br J Radiol** 1996 Apr; 69(820):368-70 (28 ref.)

POPLITEAL ARTERY

Thrombolysis to treat arterial thrombotic complications of heparin-induced thrombocytopenia. Calligaro KD, et al. **Ann Vasc Surg** 1995 Jul;9(4):397-400 (8 ref.)

Aneurysms of the infrapopliteal arteries. Marmorale A, et al. **J R Coll Surg Edinb** 1995 Oct;40(5):324-6 (4 ref.)

True infrapopliteal artery aneurysms: report of two cases and literature review. Mönig SP, et al. **J Vasc Surg** 1996 Aug; 24(2):276-8 (20 ref.)

Popliteal artery entrapment syndrome. Anatomic and embryologic bases, diagnostic and therapeutic considerations following a series of 15 cases with a review of the literature. Rosset E, et al. **Surg Radiol Anat** 1995; 17(2):161-9, 23-7 (89 ref.) **(Eng, Fre)**

[The popliteal artery entrapment syndrome in an older patient. Its diagnosis after unsuccessful laser-assisted percutaneous transluminal angioplasty] Bail DH, et al. **Dtsch Med Wochenschr** 1996 Mar 15;121(11):336-40 (18 ref.) (Eng. Abstr.) **(Ger)**

[Aneurysms of the popliteal artery. A clinical case and revision of the literature] Giani L, et al. **Minerva Chir** 1995 Nov;50(11):1019-23 (21 ref.) (Eng. Abstr.) **(Ita)**

INJURIES

Bilateral popliteal artery injury from bumper crush injury. Tominaga GT, et al. **J Trauma** 1996 Feb;40(2):311-3 (19 ref.)

PATHOLOGY

Cystic adventitial disease of the popliteal artery--a case of young boy. Ishibashi S, et al. **Tohoku J Exp Med** 1995 Jul;176(3):173-80 (20 ref.)

SURGERY

Late rupture of femoropopliteal Dacron grafts: a rare complication. Vrancken Peeters MT, et al. **Eur J Vasc Endovasc Surg** 1996 Feb;11(2):243-6 (5 ref.)

ULTRASONOGRAPHY

Demonstration of cystic adventitial disease by intravascular ultrasound imaging. Koppensteiner R, et al. **J Vasc Surg** 1996 Mar;23(3):534-6 (9 ref.)

[Ultrasound diagnosis, follow-up and therapy of cystic degeneration of the adventitia. 2 case reports and review of the literature] Schäberle W, et al. **Ultraschall Med** 1996 Jun;17(3):131-7 (39 ref.) (Eng. Abstr.) **(Ger)**

POPLITEAL CYST

COMPLICATIONS

Popliteal cysts and associated disorders of the knee. Critical review with MR imaging. Sansone V, et al. **Int Orthop** 1995;19(5):275-9 (20 ref.)

DIAGNOSIS

Popliteal cysts and associated disorders of the knee. Critical review with MR imaging. Sansone V, et al. **Int Orthop** 1995;19(5):275-9 (20 ref.)

[Pseudothrombophlebitis due to an expansive popliteal cyst associated with Reiter's syndrome] Mangiafico RA, et al. **Minerva Med** 1995 Sep;86(9):391-4 (14 ref.) (Eng. Abstr.) **(Ita)**

SURGERY

Computed tomography--guided aspiration of a ganglion cyst of the anterior cruciate ligament: a case report. Campagnolo DI, et al. **Arch Phys Med Rehabil** 1996 Jul; 77(7):732-3 (22 ref.)

POPLITEAL VEIN

Popliteal vein aneurysm. al Zahrani HA. **Cardiovasc Surg** 1995 Oct;3(5):505-7 (11 ref.)

POPULATION

Primary hyperparathyroidism: genetic heterogeneity suggesting different pathogenesis in sporadic and familial forms of parathyroid hyperplasia and tumors [comment] Calender A, et al. **Eur J Endocrinol** 1996 Mar;134(3):263-6 (20 ref.) Comment on: Eur J Endocrinol 1996 Mar;134(3):314-9.

POPULATION-BASED PLANNING see **COMMUNITY HEALTH PLANNING**

POPULATION CONTROL

see related
ABORTION, LEGAL
CONTRACEPTION
FAMILY PLANNING

Population and women's reproductive health: an international perspective. Miller K, et al. **Annu Rev Public Health** 1996; 17:359-82 (79 ref.)

TRENDS

Immunization to regulate fertility: biological and cultural frameworks. Schrater AF. **Soc Sci Med** 1995 Sep; 41(5):657-71 (85 ref.)

POPULATION DENSITY

see related
SOCIAL ISOLATION

POPULATION DISTRIBUTION see **DEMOGRAPHY**

POPULATION EXPLOSION see **POPULATION GROWTH**

POPULATION GROWTH

Population growth in the 21st century: cause for crisis or celebration? Cleland J. **Trop Med Int Health** 1996 Feb; 1(1):15-26 (22 ref.)

[Fertility] Tica V. **Contracept Fertil Sex** 1996 Mar; 24(3):173-83 (110 ref.) **(Fre)**

POPULATION SURVEILLANCE

Population laboratories and health needs assessment. Clarke M. **Int J Epidemiol** 1995;24 Suppl 1:S65-8 (26 ref.)

Colorectal cancer: the role of screening and surveillance. Westergaard H. **J Investig Med** 1996 Jun;44(5):216-27 (104 ref.)

Target populations and interventions in prevention research: what is high risk? Pentz MA. **NIDA Res Monogr** 1994; 139:75-93 (32 ref.)

The need for epidemic intelligence. Bloch AB, et al. **Public Health Rep** 1996 Jan-Feb;111(1):26-31; discussion 32-3 (57 ref.)

Review of the Wisconsin DHSS report on health concerns attributed to reformulated gasoline use in southeastern Wisconsin [editorial] Rudo K. **Toxicol Ind Health** 1995 Sep-Oct;11(5):463-6 (3 ref.)

METHODS

Surveillance in environmental public health: issues, systems, and sources [see comments] Thacker SB, et al. **Am J Public Health** 1996 May;86(5):633-8 (51 ref.) Comment in: Am J Public Health 1996 May;86(5):624-5. Comment in: Am J Public Health 1996 May;86(5):638-41.

The role of medical examiners and coroners in public health surveillance and epidemiologic research. Hanzlick R, et al. **Annu Rev Public Health** 1996;17:383-409 (85 ref.)

Monitoring cardiovascular disease in Zimbabwe: a review of needs and options. Razum O. **Cent Afr J Med** 1996 Apr; 42(4):120-4 (23 ref.)

The role of surveillance after infrainguinal bypass grafting. Giannoukas AD, et al. **Eur J Vasc Endovasc Surg** 1996 Apr;11(3):279-89 (107 ref.)

The computer-based patient record: the role of the hospital epidemiologist. Classen DC, et al. **Infect Control Hosp Epidemiol** 1995 Dec;16(12):729-36 (32 ref.)

[Public health surveillance and the environment] Quénel P. **Rev Epidemiol Sante Publique** 1995;43(5):412-22 (38 ref.) (Eng. Abstr.) **(Fre)**

PORCELAIN-METAL ALLOYS see **METAL CERAMIC ALLOYS**

PORCINE HEMAGGLUTINATING ENCEPHALOMYELITIS VIRUS see **CORONAVIRUS**

PORCINE XENOGRAFT BIOPROSTHESIS see **BIOPROSTHESIS**

PORCINE XENOGRAFT DRESSINGS see **BIOLOGICAL DRESSINGS**

PORCUPINES see **RODENTIA**

PORE PROTEINS see **PORINS**

PORINS

CHEMISTRY

Further evidence for multitopological localization of mammalian porin (VDAC) in the plasmalemma forming part of a chloride channel complex affected in cystic fibrosis and encephalomyopathy. Reymann S, et al. **Biochem Mol Med** 1995 Apr;54(2):75-87 (74 ref.)

Porins: general to specific, native to engineered passive pores. Schulz GE. **Curr Opin Struct Biol** 1996 Aug;6(4):485-90 (61 ref.)

Structure and function of the porin channel. Welte W, et al. **Kidney Int** 1995 Oct;48(4):930-40 (121 ref.)

METABOLISM

Structure and function of the porin channel. Welte W, et al. **Kidney Int** 1995 Oct;48(4):930-40 (121 ref.)

Colicin import and pore formation: a system for studying protein transport across membranes? Lazdunski CJ. **Mol Microbiol** 1995 Jun;16(6):1059-66 (84 ref.)

POROKERATOSIS

COMPLICATIONS

Porokeratosis and cutaneous malignancy. A review. Sasson M, et al. **Dermatol Surg** 1996 Apr;22(4):339-42 (30 ref.)

PATHOLOGY

Destructive facial porokeratosis. Rahbari H, et al. **J Am Acad Dermatol** 1995 Dec;33(6):1049-50 (7 ref.)

POROKERATOSIS PALMARIS ET PLANTARIS DISSEMINATA see **POROKERATOSIS**

PORP see **OSSICULAR REPLACEMENT PROSTHESIS**

PORPHOBILINOGEN AMMONIA-LYASE see **PORPHOBILINOGEN DEAMINASE**

PORPHOBILINOGEN DEAMINASE

ANALYSIS

[Porphobilinogen deaminase (PBGD)] Kondo M. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:891-4 (21 ref.) **(Jpn)**

PORPHOBILINOGEN DEAMINASE

CHEMISTRY

Porphobilinogen deaminase and uroporphyrinogen III synthase: structure, molecular biology, and mechanism. Shoolingin-Jordan PM. **J Bioenerg Biomembr** 1995 Apr; 27(2):181–95 (111 ref.)

GENETICS

Porphobilinogen deaminase gene structure and molecular defects. Deybach JC, et al. **J Bioenerg Biomembr** 1995 Apr; 27(2):197–205 (73 ref.)

PORPHOBILINOGEN SYNTHASE see **AMINOLEVULINIC ACID DEHYDRATASE**

PORPHYRIA

CLASSIFICATION

[Porphyrias] Komatsu M. **Ryoikibetsu Shokogun Shirizu** 1995; (8):410–3 (7 ref.) **(Jpn)**

DIAGNOSIS

The porphyrias: a brief overview based on 25 years of experience (1969–1994) by the Department of Dermatology of the Hospital Clinic and Faculty of Medicine of Barcelona, Spain. Mascaro JM. **J Dermatol** 1995 Nov; 22(11):823–8 (28 ref.)

The diagnosis and follow-up of porphyria. Ratnaike S, et al. **Pathology** 1995 Apr;27(2):142–53 (59 ref.)

Porphyria: reexamination of psychiatric implications. Burgovne K, et al. **Psychother Psychosom** 1995; 64(3–4):121–30 (75 ref.)

GENETICS

Porphyrias: animal models and prospects for cellular and gene therapy. de Verneuil H, et al. **J Bioenerg Biomembr** 1995 Apr;27(2):239–48 (55 ref.)

[The molecular basis and genetics of diseases associated with disorders of heme biosynthesis] Fuchs O. **Cas Lek Cesk** 1996 Jan 17;135(2):54–8 (42 ref.) (Eng. Abstr.) **(Cze)**

METABOLISM

Diseases of metabolism (porphyrias). McCarroll NA. **Anal Chem** 1995 Jun 15;67(12):425R–4284 (60 ref.)

[The molecular basis and genetics of diseases associated with disorders of heme biosynthesis] Fuchs O. **Cas Lek Cesk** 1996 Jan 17;135(2):54–8 (42 ref.) (Eng. Abstr.) **(Cze)**

PSYCHOLOGY

Porphyria: reexamination of psychiatric implications. Burgovne K, et al. **Psychother Psychosom** 1995; 64(3–4):121–30 (75 ref.)

THERAPY

Porphyrias: animal models and prospects for cellular and gene therapy. de Verneuil H, et al. **J Bioenerg Biomembr** 1995 Apr;27(2):239–48 (55 ref.)

PORPHYRIA, ACUTE INTERMITTENT

COMPLICATIONS

[Epilepsy is difficult to treat during an attack of porphyria] Bylesjö EI, et al. **Lakartidningen** 1996 Jun 26; 93(26–27):2506–8 (15 ref.) **(Swe)**

GENETICS

[Acute intermittent porphyria in 2 Moroccan families. Clinical and biological study] Aquaron R, et al. **Rev Med Interne** 1996;17(6):477–81 (21 ref.) (Eng. Abstr.) **(Fre)**

PORPHYRIA CUTANEA TARDA

[Porphyria cutanea tarda (chronic hepatic porphyria)] Köstler E, et al. **Dtsch Med Wochenschr** 1995 Oct 13; 120(41):1405–10 (50 ref.) **(Ger)**

DIAGNOSIS

Porphyria cutanea tarda: a clinical review. Cohen DJ, et al. **Compr Ther** 1996 Mar;22(3):175–8 (11 ref.)

ETIOLOGY

[Extrahepatic manifestations related to hepatitis C virus] Opolon P, et al. **Pathol Biol (Paris)** 1995 Oct;43(8):709–15 (59 ref.) (Eng. Abstr.) **(Fre)**

[Skin manifestations related to hepatitis C viruses] Doutre MS, et al. **Rev Med Interne** 1995;16(9):666–72 (71 ref.) (Eng. Abstr.) **(Fre)**

PORPHYRIA, ERYTHROHEPATIC

COMPLICATIONS

Erythropoietic protoporphyria presenting in an adult. Henderson CA, et al. **J R Soc Med** 1995 Aug; 88(8):476P–477P (8 ref.)

ENZYMOLOGY

The ferrochelatase gene structure and molecular defects associated with erythropoietic protoporphyria. Taketani S, et al. **J Bioenerg Biomembr** 1995 Apr;27(2):231–8 (57 ref.)

GENETICS

The ferrochelatase gene structure and molecular defects associated with erythropoietic protoporphyria. Taketani S, et al. **J Bioenerg Biomembr** 1995 Apr;27(2):231–8 (57 ref.)

PHYSIOPATHOLOGY

[Cholestatic erythrohepatic protoporphyria: porphyrin metabolism before and after liver transplantation] Doss MO, et al. **Z Gastroenterol** 1993 Feb;31 Suppl 2:85–9 (31 ref.) (Eng. Abstr.) **(Ger)**

PORPHYRIA, HEPATIC

COMPLICATIONS

[Acute hepatic porphyria and its neurological syndrome] Bont A, et al. **Schweiz Med Wochenschr** 1996 Jan 9; 126(1–2):6–14 (45 ref.) (Eng. Abstr.) **(Ger)**

ENZYMOLOGY

Molecular abnormalities of coproporphyrinogen oxidase in patients with hereditary coproporphyria. Grandchamp B, et al. **J Bioenerg Biomembr** 1995 Apr;27(2):215–9 (22 ref.)

GENETICS

Molecular abnormalities of coproporphyrinogen oxidase in patients with hereditary coproporphyria. Grandchamp B, et al. **J Bioenerg Biomembr** 1995 Apr;27(2):215–9 (22 ref.)

PORPHYRIA, VARIEGATE see **PORPHYRIA, HEPATIC**

PORPHYRIN-METAL CHELATASE see **FERROCHELATASE**

PORPHYRINS

[Molecular design of oligonucleotide porphyrin derivatives] Shimidzu T. **Tanpakushitsu Kakusan Koso** 1994 Jul; 40(10):1357–63 (18 ref.) **(Jpn)**

ANALYSIS

The diagnosis and follow-up of porphyria. Ratnaike S, et al. **Pathology** 1995 Apr;27(2):142–53 (59 ref.)

[Porphyrin] Kakishita E. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:871–6 (9 ref.) **(Jpn)**

CHEMISTRY

Photophysical properties of porphyrins in biological membranes. Ricchelli F. **J Photochem Photobiol B** 1995 Aug;29(2–3):109–18 (94 ref.)

Porphyrin and metalloporphyrin interactions with nucleic acids. Pasternack RF, et al. **Met Ions Biol Syst** 1996; 33:367–97 (114 ref.)

PHARMACOKINETICS

[Dynamics of photosensitizer in the cell] Aizawa K, et al. **Gan To Kagaku Ryoho** 1996 Jan;23(1):22–6 (5 ref.) (Eng. Abstr.) **(Jpn)**

THERAPEUTIC USE

Prevention of late lumen loss after coronary angioplasty by photodynamic therapy: role of activated neutrophils. Sluiter W, et al. **Mol Cell Biochem** 1996 Apr 12–26; 157(1–2):233–8 (44 ref.)

PORPHYROMONAS GINGIVALIS

ENZYMOLOGY

Porphyromonas gingivalis: a proteinase/gene accounting audit. Potempa J, et al. **Trends Microbiol** 1995 Nov; 3(11):430–4 (30 ref.)

PORPOISES see **DOLPHINS**

PORTACAVAL SHUNT, SURGICAL

ADVERSE EFFECTS

[Eck fistula syndrome] Fukasawa M, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):220–5 (22 ref.) **(Jpn)**

PORTAL SYSTEM

see related
LIVER CIRCULATION
PORTOGRAPHY

ABNORMALITIES

[Late manifestation of congenital intrahepatic portacaval shunt in a healthy liver] Kerleau JM, et al. **Rev Med Interne** 1995;16(8):616–8 (7 ref.) (Eng. Abstr.) **(Fre)**

ANATOMY & HISTOLOGY

[Anatomico-functional correlations between the pulmonary and portal circulations: the prerequisites for a modern functional imaging diagnosis] Sallustio G, et al. **Radiol Med (Torino)** 1996 Apr;91(4):394–404 (27 ref.) (Eng. Abstr.) **(Ita)**

PATHOLOGY

[An immunohistochemical analysis in portal lymphocytic aggregation of chronic hepatitis C] Tsuno S, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:635–41 (24 ref.) **(Jpn)**

PHYSIOLOGY

Control of motor and secretory functions of the stomach by a portal glucose signal. Sakaguchi T. **Neurosci Biobehav Rev** 1995 Fall;19(3):469–78 (134 ref.)

Hemodynamic consequences of therapeutic portosystemic shunting: recent experience with transjugular intrahepatic portosystemic shunts. Somberg KA. **Semin Gastrointest Dis** 1995 Jul;6(3):165–77 (58 ref.)

ULTRASONOGRAPHY

Portal hypertension: review of data and influence on management. Caletti GC, et al. **Gastrointest Endosc Clin N Am** 1995 Jul;5(3):655–65 (29 ref.)

PORTAL VEIN

see related
PORTOGRAPHY

Pylephlebitis: a case report and review of outcome in the antibiotic era. Saxena R, et al. **Am J Gastroenterol** 1996 Jun;91(6):1251–3 (17 ref.)

Fistula between duodenum and portal vein caused by peptic ulcer disease and complicated by hemorrhage and portal vein thrombosis. Soares MA, et al. **Am J Gastroenterol** 1996 Jul;91(7):1462–3 (7 ref.)

Portal and mesenteric thrombosis in protein S (pS) deficiency. Zigrossi P, et al. **Am J Gastroenterol** 1996 Jan;91(1):163–5 (11 ref.)

Pneumatosis intestinalis and portal venous air associated with needle catheter jejunostomy. North JH Jr, et al. **Am Surg** 1995 Dec;61(12):1045–8 (25 ref.)

Hepatic-portal venous gas associated with ileus. Quirke TE. **Am Surg** 1995 Dec;61(12):1084–6 (12 ref.)

Spontaneous rupture of a pancreatic pseudocyst into the portal vein. Procacci C, et al. **Cardiovasc Intervent Radiol** 1995 Nov–Dec;18(6):399–402 (15 ref.)

Septic thrombophlebitis of the portal vein (pylephlebitis): diagnosis and management in the modern era. Plemmons RM, et al. **Clin Infect Dis** 1995 Nov;21(5):1114–20 (32 ref.)

[Hemobilia due to a portobiliary fistula as a complication of a fine-needle liver biopsy] De Santis M, et al. **Radiol Med (Torino)** 1996 Apr;91(4):482–5 (18 ref.) **(Ita)**

[A case of cholangiocarcinoma with temporary subsegmental fatty liver and intrahepatic portal aneurysm] Miyanaga O, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Sep; 92(9):1297–303 (9 ref.) **(Jpn)**

[Porto-systemic shunt] Hamazaki K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):243–7 (21 ref.) **(Jpn)**

[Intrahepatic portal-hepatic venous fistula] Iwahashi K. **Ryoikibetsu Shokogun Shirizu** 1995;(8):214–7 (19 ref.) **(Jpn)**

[Extrahepatic portal vein aneurysm] Iwasaki M, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):180–3 (24 ref.) **(Jpn)**

[Portal vein thrombosis] Kajikawa M, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):239–42 (24 ref.) **(Jpn)**

[Intrahepatic arterioportal shunt and arteriovenous shunt] Nagayama K, et al. **Ryoikibetsu Shokogun Shirizu** 1995; (8):210–3 (21 ref.) **(Jpn)**

[Intrahepatic arteriovenous fistula] Toshima K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):207–9 (23 ref.) **(Jpn)**

[Intrahepatic portal vein aneurysm] Toshima K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):218–20 (19 ref.) **(Jpn)**

[Postappendectomy vascular complications in childhood] Diez Garcia R, et al. **An Esp Pediatr** 1996 Mar;44(3):270–2 (19 ref.) **(Spa)**

ABNORMALITIES

Congenital absence of portal venous system associated with a large inferior mesenteric-caval shunt: a case report. Komatsu S, et al. **Hepatogastroenterology** 1995 Jul; 42(3):286–90 (17 ref.)

Hepatic artery ligation for hepatic vascular tumors with arteriovenous and arterioportal venous shunts in the newborn: successful management of two cases and review of the literature. Hazebroek FW, et al. **J Pediatr Surg** 1995 Aug;30(8):1127–30 (15 ref.)

[Congenital anomaly of the portal venous system] Hoso M, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):231–4 (22 ref.) **(Jpn)**

[Congenital intrahepatic venous shunt as a cause of hepatic encephalopathy] Cosme Jiménez A, et al. **Gastroenterol Hepatol** 1995 Nov;18(9):460–3 (25 ref.) (Eng. Abstr.) **(Spa)**

INJURIES

Rapidly progressive portal hypertension 23 years after post-traumatic arterioportal fistula of the liver. Kayser S, et al. **Am J Gastroenterol** 1996 Jul;91(7):1442–6 (30 ref.)

PATHOLOGY

Portal magnetic resonance angiography. Finn JP, et al. **Magn Reson Imaging Clin N Am** 1993 Dec;1(2):271–80 (31 ref.)

Hepatoportal sclerosis. Bioulac-Sage P, et al. **Semin Liver Dis** 1995 Nov;15(4):329–39 (32 ref.)

[Hepatoportal sclerosis, nodular regenerative hyperplasia, incomplete septal cirrhosis: lesions of hepatic microcirculation?] Bernard PH, et al. **Gastroenterol Clin Biol** 1996;20(4):335–8 (30 ref.) **(Fre)**

[Cavernous transformation of the portal vein] Ukita M, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):228–30 (18 ref.) **(Jpn)**

RADIOGRAPHY

Calcifications of portal venous system wall: CT findings in three patients. Egiebor O, et al. **Abdom Imaging** 1995 Sep–Oct;20(5):477–9 (7 ref.)

[Hepatic portal venous gas] Kudo M, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):595–7 (18 ref.) **(Jpn)**

SURGERY

Surgical treatment of an enormous aneurysmal portahepatic venous fistula: report of a case. Miyauchi A, et al. **Surg Today** 1995;25(9):855–8 (11 ref.)

ULTRASONOGRAPHY

Intraportal tumor thrombus of gallbladder carcinoma: detection with intravascular ultrasonography. Kaneko T, et al. **Am J Gastroenterol** 1996 Jun;91(6):1268–9 (8 ref.)

PORTASYSTEMIC SHUNT, SURGICAL

Hepatic venoocclusive disease as a complication of whole abdominopelvic irradiation and treatment with the transjuglar intrahepatic portosystemic shunt: case report and literature review. Shen-Gunther J, et al. **Gynecol Oncol** 1996 May;61(2):282–6 (25 ref.)

The role of transjugular intrahepatic portosystemic shunt for treatment of portal hypertension and its complications: a conference sponsored by the National Digestive Diseases Advisory Board. Shiffman ML, et al. **Hepatology** 1995 Nov; 22(5):1591–7 (78 ref.)

The transjugular intrahepatic portosystemic stent-shunt: a review of the literature and own experiences. Rössle M, et al. **J Gastroenterol Hepatol** 1996 Mar;11(3):293–8 (48 ref.)

[Portal hypertension and splenic circulation] Romero Torres R. **Rev Gastroenterol Peru** 1995;15 Suppl 1:S110–7 (31 ref.) (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Mortality during transjugular intrahepatic portosystemic shunt placement. Yonker-Sell AE, et al. **Anesthesiology** 1996 Jan;84(1):231–3 (17 ref.)

[Physiopathology and surgical treatment of hepatic encephalopathy after porto-caval anastomosis] Porcheron J, et al. **Ann Gastroenterol Hepatol (Paris)** 1995 Oct; 31(5):287–94 (60 ref.) (Eng. Abstr.) **(Fre)**

METHODS

Transjugular intrahepatic portasystemic stent-shunt in the treatment of variceal haemorrhage. Jalan R, et al. **Br J Surg** 1995 Sep;82(9):1158–64 (46 ref.)

Transjugular intrahepatic portosystemic shunt: a medical perspective. Sanyal AJ, et al. **Dig Dis** 1995 May-Jun; 13(3):153–62 (47 ref.)

Transjugular intrahepatic portal-systemic shunt [editorial] Sherlock S. **J Intern Med** 1996 Feb;239(2):95–8 (25 ref.)

Hemodynamic consequences of therapeutic portosystemic shunting: recent experience with transjugular intrahepatic portosystemic shunts. Somberg KA. **Semin Gastrointest Dis** 1995 Jul;6(3):165–77 (58 ref.)

[Intrahepatic portasystemic shunt and hemorrhagic emergencies in the cirrhotic patient] Perarnau JM, et al. **Ann Chir** 1995;49(7):580–6; discussion 587–8 (17 ref.) (Eng. Abstr.) **(Fre)**

[Recurrent bleeding from colonic varices in portal hypertension. The successful prevention of recurrence by the implantation of a transjugular intrahepatic stent-shunt (TIPS)] Allgaier HP, et al. **Dtsch Med Wochenschr** 1995 Dec 22;120(51-52):1773–6 (29 ref.) (Eng. Abstr.) **(Ger)**

PORTOENTEROSTOMY, HEPATIC

METHODS

Is there a place for the Kasai procedure in biliary atresia? Grosfeld J. **Curr Opin Gen Surg** 1994;:168–72 (22 ref.)

PORTOGRAPHY

CT during arterial portography. Soyer P. **Eur Radiol** 1996; 6(3):349–57 (69 ref.)

PORTOSYSTEMIC ENCEPHALOPATHY see **HEPATIC ENCEPHALOPATHY**

PORTOSYSTEMIC SHUNT, SURGICAL see **PORTASYSTEMIC SHUNT, SURGICAL**

POSITION DESCRIPTION see **JOB DESCRIPTION**

POSITIVE END-EXPIRATORY PRESSURE see **POSITIVE-PRESSURE RESPIRATION**

POSITIVE-PRESSURE RESPIRATION

Pressure support ventilation. Dekel B, et al. **Arch Intern Med** 1996 Feb 26;156(4):369–73 (44 ref.)

Treatment of obstructive sleep apnea: the role of nasal continuous positive airway pressure. Patel SR, et al. **Cleve Clin J Med** 1996 Jan-Feb;63(1):12–5 (29 ref.)

Inverse ratio ventilation: simply an alternative, or something more? [letter; comment] Rimensberger P, et al. **Crit Care Med** 1995 Oct;23(10):1786–9 (14 ref.) Comment on: Crit Care Med 1995 Feb;23(2):224–8.

Noninvasive ventilation in the management of decompensated COPD. Polkey MI, et al. **Monaldi Arch Chest Dis** 1995 Oct;50(5):378–82 (31 ref.)

Orthodeoxia and platypnoea after acute organophosphorus poisoning reversed by CPAP: a newly described cause and review of the literature. Bouros D, et al. **Respir Med** 1995 Oct;89(9):625–8 (33 ref.)

Sleep-related breathing disorders. 5. Nasal continuous positive airway pressure treatment for obstructive sleep apnoea. Grunstein RR. **Thorax** 1995 Oct;50(10):1106–13 (56 ref.)

[Nasal positive pressure ventilation--renewal of ventilation technique] Shpirer I, et al. **Harefuah** 1995 Dec 15; 129(12):586–90 (43 ref.) **(Heb)**

[Pulmonary ventilation with assisted pressure. Technical aspects and features of use] Koniukov IuA, et al. **Anesteziol Reanimatol** 1995 Jul-Aug;(4):49–57 (83 ref.) **(Rus)**

INSTRUMENTATION

Noninvasive nasal mask positive pressure ventilation in a pediatric patient with acute hypoxic respiratory failure. Padman R, et al. **Pediatr Emerg Care** 1996 Feb;12(1):44–7 (63 ref.)

[Biphasic positive "airway pressure" (BIPAP). Principles and clinical applications of a new ventilatory method in acute respiratory insufficiency] Sydow M, et al. **Internist (Berl)** 1995 Aug;36(8):802–11 (38 ref.) **(Ger)**

METHODS

Bi-level positive airway pressure support system use in acute congestive heart failure: preliminary case series. Sacchetti AD, et al. **Acad Emerg Med** 1995 Aug;2(8):714–8 (21 ref.)

Permissive hypercapnia in ARDS: just do it? [editorial; comment] Lewandowski K. **Intensive Care Med** 1996 Mar; 22(3):179–81 (13 ref.) Comment on: Intensive Care Med 1996 Mar;22(3):182–91.

Wasted efforts and dyssynchrony: is the patient-ventilator battle back? [editorial; comment] Rossi A, et al. **Intensive Care Med** 1995 Nov;21(11):867–70 (24 ref.) Comment on: Intensive Care Med 1995 Nov;21(11):871–9.

Noninvasive positive pressure ventilation: what is its role in treating acute respiratory failure? Curreri JP, et al. **Postgrad Med** 1996 Jun;99(6):221–4, 227–30 (12 ref.)

[Invasive ventilation. Classification, technique and clinical experiences with BiPAP/APRV (Biphasic Positive Airway Pressure/Airway Pressure Release Ventilation)] Antonsen K, et al. **Ugeskr Laeger** 1996 Jan 22;158(4):413–9 (23 ref.) (Eng. Abstr.) **(Dan)**

POSITIVE-PRESSURE RESPIRATION, INTRINSIC

Intrinsic positive end-expiratory pressure (PEEPi). Rossi A, et al. **Intensive Care Med** 1995 Jun;21(6):522–36 (107 ref.)

ETIOLOGY

Occult, occult auto-PEEP in status asthmaticus [editorial; comment] Stewart TE, et al. **Crit Care Med** 1996 Mar; 24(3):379–80 (13 ref.) Comment on: Crit Care Med 1996 Mar;24(3):541–6.

Wasted efforts and dyssynchrony: is the patient-ventilator battle back? [editorial; comment] Rossi A, et al. **Intensive Care Med** 1995 Nov;21(11):867–70 (24 ref.) Comment on: Intensive Care Med 1995 Nov;21(11):871–9.

POSITIVE-PRESSURE RESPIRATION, OCCULT see **POSITIVE-PRESSURE RESPIRATION, INTRINSIC**

POSITIVE REINFORCEMENT see **REINFORCEMENT (PSYCHOLOGY)**

POSITRON-EMISSION TOMOGRAPHY see **TOMOGRAPHY, EMISSION-COMPUTED**

POSITRONS see **ELECTRONS**

POST AND CORE TECHNIQUE

Factors to consider for predictable post and core build-ups of endodontically treated teeth. Part I: Basic theoretical concepts. Manning KE, et al. **J Can Dent Assoc** 1995 Aug; 61(8):685–8, 690, 693–5 (40 ref.)

Factors to consider for predictable post and core build-ups of endodontically treated teeth. Part II: Clinical application of basic concepts. Manning KE, et al. **J Can Dent Assoc** 1995 Aug;61(8):696–701, 703, 705–7 (46 ref.)

Restoration of pulpless teeth: application of traditional principles in present and future contexts. Morgano SM. **J Prosthet Dent** 1996 Apr;75(4):375–80 (66 ref.)

POSTCHOLECYSTECTOMY SYNDROME

[Cystic duct and gallbladder remnant] Ishihara F, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):425–7 (14 ref.) **(Jpn)**

[Postcholecystectomy syndrome] Takagi I, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):459–61 (19 ref.) **(Jpn)**

POSTCOITAL CONTRACEPTIVES see **CONTRACEPTIVES, POSTCOITAL**

POSTERIOR CRUCIATE LIGAMENT

see related
ANTERIOR CRUCIATE LIGAMENT

INJURIES

Posterior cruciate ligament injuries. New treatment options. Miller MD, et al. **Am J Knee Surg** 1995 Fall;8(4):145–54 (53 ref.)

Positioning of the posterior cruciate ligament. Juergensen K, et al. **Knee Surg Sports Traumatol Arthrosc** 1994; 2(3):133–7 (21 ref.)

[Arthroscopic approaches to reconstruction of the cruciate ligament: refresher course] Kohn D. **Sportverletz Sportschaden** 1995 Dec;9(4):A31–42 (0 ref.) **(Ger)**

[Rupture of the posterior cruciate ligament: status of current treatment] Lobenhoffer P, et al. **Unfallchirurg** 1996 Jun; 99(6):382–99 (118 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Posterior cruciate ligament injuries. New treatment options. Miller MD, et al. **Am J Knee Surg** 1995 Fall;8(4):145–54 (53 ref.)

Positioning of the posterior cruciate ligament. Juergensen K, et al. **Knee Surg Sports Traumatol Arthrosc** 1994; 2(3):133–7 (21 ref.)

POSTERIOR LONGITUDINAL LIGAMENT see **LONGITUDINAL LIGAMENTS**

POSTGASTRECTOMY SYNDROMES

[Cholelithiasis following gastrectomy] Miyazaki I, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):388–90 (26 ref.) **(Jpn)**

ETIOLOGY

[Sequelae of stomach resection and gastrectomy and its consequences] Kirchner R. **Z Gastroenterol** 1996 Jun;34 Suppl 2:20–3 (18 ref.) **(Ger)**

PREVENTION & CONTROL

[Vagus-saving D2 procedure for early gastric carcinoma] Miwa K, et al. **Nippon Geka Gakkai Zasshi** 1996 Apr; 97(4):286–90 (11 ref.) (Eng. Abstr.) **(Jpn)**

POST-INFARCTION HEART RUPTURE see **HEART RUPTURE, POST-INFARCTION**

POSTMARKETING PRODUCT SURVEILLANCE see **PRODUCT SURVEILLANCE, POSTMARKETING**

POSTMENOPAUSAL BONE LOSS see **OSTEOPOROSIS, POSTMENOPAUSAL**

POSTMENOPAUSAL HORMONE REPLACEMENT THERAPY see **ESTROGEN REPLACEMENT THERAPY**

POSTMENOPAUSAL OSTEOPOROSIS see **OSTEOPOROSIS, POSTMENOPAUSAL**

POSTMENOPAUSE

Transvaginal ultrasonography in nonpregnant and postmenopausal women. Weissman AM, et al.

Am Fam Physician 1996 May 1;53(6):2065–72 (23 ref.)

Postmenopausal oestrogens and arteries. Vyas S, et al. **Br J Obstet Gynaecol** 1995 Dec;102(12):942–6 (30 ref.)

A closer look at reproductive technology and postmenopausal motherhood [comment] Parks JA. **Can Med Assoc J** 1996 Apr 15;154(8):1189–91 (10 ref.) Comment on: Can Med Assoc J 1994 Aug 1;151(3):353, 355.

Cardiovascular effects of estrogen and lipid–lowering therapies in postmenopausal women. Guetta V, et al. **Circulation** 1996 May 15;93(10):1928–37 (153 ref.)

Health consequences of short– and long–term postmenopausal hormone therapy. Weiss NS. **Clin Chem** 1996 Aug;42(8 Pt 2):1342–4 (17 ref.)

Mechanisms whereby oestrogens influence arterial health. Stevenson JC. **Eur J Obstet Gynecol Reprod Biol** 1996 Mar; 65(1):39–42 (30 ref.)

Review of the endometrial safety during intravaginal treatment with estriol. Vooijs GP, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Sep;62(1):101–6 (50 ref.)

The risks and benefits of estrogen replacement therapy: Leisure World. Paganini–Hill A. **Int J Fertil Menopausal Stud** 1995;40 Suppl 1:54–62 (37 ref.)

Compliance to hormone replacement therapy. Rozenberg S, et al. **Int J Fertil Menopausal Stud** 1995;40 Suppl 1:23–32 (51 ref.)

Is HRT indicated for the prevention of cardiovascular disease? Samsioe G. **Int J Fertil Menopausal Stud** 1995;40 Suppl 1:33–9 (17 ref.)

The importance of life style after menopause. Zichella L. **Int J Fertil Menopausal Stud** 1995;40 Suppl 1:9–15 (19 ref.)

Hormone replacement therapy in women with breast cancer. Do the risks outweigh the benefits? Roy JA, et al. **J Clin Oncol** 1996 Mar;14(3):997–1006 (85 ref.)

Perimenopausal and postmenopausal hormone replacement therapy. Part 2. Hormonal regimens and complementary and alternative therapies. Lichtman R. **J Nurse Midwifery** 1996 May–Jun;41(3):195–210 (109 ref.)

The demography of menopause. Hill K. **Maturitas** 1996 Mar; 23(2):113–27 (18 ref.)

The prevalence of urogenital symptoms in postmenopausal women. Stenberg A, et al. **Maturitas** 1995 Dec;22 Suppl:S17–S20 (22 ref.)

Age and assisted reproduction. Pennings G. **Med Law** 1995; 14(7–8):531–41 (20 ref.)

Postmenopausal hormone therapy and breast cancer. Speroff L. **Obstet Gynecol** 1996 Feb;87(2 Suppl):44S–54S (81 ref.)

Diagnostic value of ultrasound analysis and bone densitometry as predictors of vertebral deformity in postmenopausal women. Gonnelli S, et al. **Osteoporos Int** 1995;5(6):413–8 (40 ref.)

The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. Grodstein F, et al. **Prog Cardiovasc Dis** 1995 Nov–Dec;38(3):199–210 (86 ref.)

Coronary arteriography in estrogen–treated postmenopausal women. Sullivan JM. **Prog Cardiovasc Dis** 1995 Nov–Dec; 38(3):211–22 (34 ref.)

[Physical activity and bone mineral content in postmenopausal women] Eiken PA. **Ugeskr Laeger** 1995 Sep 11;157(37):5086–91 (47 ref.) (Eng. Abstr.) **(Dan)**

[Pregnancy after diagnosis of menopause] Jamin C, et al. **Contracept Fertil Sex** 1995 Nov;23(11):677–81 (55 ref.) (Eng. Abstr.) **(Fre)**

[Reflections on compliance in menopause hormone replacement therapy] Berthet J, et al. **Rev Fr Gynecol Obstet** 1995 Dec;90(12):548–51 (0 ref.) (Eng. Abstr.) **(Fre)**

[Breast angiosarcoma. Five case reports] Gamoudi A, et al. **Rev Fr Gynecol Obstet** 1995 Oct;90(10):435–41 (18 ref.) (Eng. Abstr.) **(Fre)**

BLOOD

[Contemporary views on estrogen replacement therapy. II. Hormonal therapy in women with imminent ischemic heart disease] Krasomski G. **Ginekol Pol** 1995 Feb;66(2):93–6 (27 ref.) (Eng. Abstr.) **(Pol)**

DRUG EFFECTS

The effects of estradiol valerate plus medroxyprogesterone acetate and conjugated estrogens plus medrogestone on climacteric symptoms and metabolic variables in perimenopausal women. Egarter C, et al. **Acta Obstet Gynecol Scand** 1996 Apr;75(4):386–93 (40 ref.)

Estrogen therapy for postmenopausal symptoms and prevention of osteoporosis. Sagraves R. **J Clin Pharmacol** 1995 Sep;35(9 Suppl):2S–10S (46 ref.)

[Estrogens in menopause—therapy and prevention. I. Hormone substitution in climacteric and postmenopause] Wuttke W. **Internist (Berl)** 1996 Apr;37(4):402–5 (50 ref.) **(Ger)**

PHYSIOLOGY

Hypertension in postmenopausal women: pathophysiology and management. Oparil S. **Curr Opin Nephrol Hypertens** 1995 Sep;4(5):438–42 (26 ref.)

POSTMORTEM CHANGES

Investigations on the mechanism of adipocere formation and its relation to other biochemical reactions. Takatori T. **Forensic Sci Int** 1996 Jun 28;80(1–2):49–61 (25 ref.)

Study on electrocution death by low–voltage. Zhang P, et al. **Forensic Sci Int** 1995 Dec 18;76(2):115–9 (4 ref.)

[Relationship among "kenshi" (inquest), "kenshi" (postmortem examination) and "ken–an" (postmortem inspection) in Japan] Mikami H, et al. **Nippon Hoigaku Zasshi** 1995 Dec; 49(6):488–97 (74 ref.) (Eng. Abstr.) **(Jpn)**

POSTNATAL CARE

Postpartum care. Stover AM, et al. **Am Fam Physician** 1995 Oct;52(5):1465–72 (32 ref.)

Prenatal and postnatal: use of corticosteroids. Corbett JV, et al. **MCN Am J Matern Child Nurs** 1995 Nov–Dec; 20(6):346 (9 ref.)

[Postgravid health care and laboratory tests] Hidaka Y, et al. **Rinsho Byori** 1995 Nov;43(11):1101–7 (14 ref.) (Eng. Abstr.) **(Jpn)**

ORGANIZATION & ADMINISTRATION

The 6–week postnatal visit: are we doing it right? Sharif K, et al. **Br J Hosp Med** 1995 Jun 21–Jul 11;54(1):7–10 (18 ref.)

POSTNATAL DEPRESSION see **DEPRESSION, POSTPARTUM**

POSTOPERATIVE CARE

Pre versus post–operative radiotherapy of resectable squamous cell carcinoma of the head and neck. Wennerberg J. **Acta Otolaryngol (Stockh)** 1995 Jul;115(4):465–74 (63 ref.)

Management of the pancreatic stump following pancreaticoduodenectomy. Sikora SS, et al. **Br J Surg** 1995 Dec;82(12):1590–7 (88 ref.)

Antithrombotic therapy in patients with saphenous vein and internal mammary artery bypass grafts. Stein PD, et al. **Chest** 1995 Oct;108(4 Suppl):424S–430S (30 ref.)

Postsplenectomy care. Strategies to decrease the risk of infection. Williams DN, et al. **Postgrad Med** 1996 Jul; 100(1):195–8, 201, 205 (15 ref.)

[Perioperative artificial nutrition programmed for the adult surgical patient. Saint–Mandé, December 16, 1994: The Francophone Society of Enteral and Parenteral Nutrition and the French Society of Anesthesia and Resuscitation] **Ann Gastroenterol Hepatol (Paris)** 1995 Oct;31(5):310–9 (0 ref.) **(Fre)**

[Balanced anesthesia for postoperative management] Namiki A, et al. **Masui** 1995;44 Suppl:S162–6; discussion S173–6 (1 ref.) **(Jpn)**

[Patient–controlled analgesia as a method for postoperative anesthesia] Lebedeva RN, et al. **Anesteziol Reanimatol** 1996 Jan–Feb;(1):66–71 (145 ref.) **(Rus)**

METHODS

Improving postoperative care: the role of the surgeon in the high dependency unit. Coggins R, et al. **Ann R Coll Surg Engl** 1996 May;78(3 (Pt 1)):163–7 (29 ref.)

Fast–tracking in cardiac surgery. Aps C. **Br J Hosp Med** 1995 Aug 16–Sep 5;54(4):139–42 (5 ref.)

Target–controlled infusion delivery systems: application outside the operating room. Bovill JG, et al. **J Clin Anesth** 1996 May;8(3 Suppl):21S–25S (33 ref.)

Exit–site care. Piraino B. **Perit Dial Int** 1996;16 Suppl 1:S336–9 (28 ref.)

Perioperative care in the elderly urologic patient. Smith R, et al. **Urol Clin North Am** 1996 Feb;23(1):27–41 (51 ref.)

[Patient management following cardiac transplantation] Seydoux C, et al. **Schweiz Med Wochenschr** 1995 Oct 14; 125(41):1913–22 (103 ref.) (Eng. Abstr.) **(Fre)**

[Orthodontic pre– and postoperative treatment in bimaxillary osteotomy] Scheuer H, et al. **Fortschr Kiefer Gesichtschir** 1995;40:11–20 (19 ref.) **(Ger)**

[The postoperative therapy of epithelial ovarian carcinoma. Has systemic cytostasis replaced percutaneous radiation?] Souchon R, et al. **Strahlenther Onkol** 1995 Nov; 171(11):630–40 (83 ref.) (Eng. Abstr.) **(Ger)**

[Artificial (parenteral and enteral) nutrition in postoperative rehabilitation] Vantini I, et al. **Chir Ital** 1994;46(6):54–67 (112 ref.) (Eng. Abstr.) **(Ita)**

POSTOPERATIVE COMPLICATIONS

Acute gastrointestinal complications after cardiac surgery. Halm MA. **Am J Crit Care** 1996 Mar;5(2):109–18; quiz 119–20 (34 ref.)

The effects of hypoxaemia and recommendations for postoperative oxygen therapy. Powell JF, et al. **Anaesthesia** 1996 Aug;51(8):769–72 (41 ref.)

Mycoplasma hominis infections occurring in cardiovascular surgical patients. Sielaff TD, et al. **Ann Thorac Surg** 1996 Jan;61(1):99–103 (21 ref.)

Sight–threatening complications after radial keratotomy [editorial; comment] McDonnell PJ. **Arch Ophthalmol** 1996 Feb;114(2):211–2 (5 ref.) Comment on: Arch Ophthalmol 1996 Feb;114(2):129–34.

Subcutaneous pretibial cyst formation associated with anterior cruciate ligament allografts: a report of four cases and literature review. Victoroff BN, et al. **Arthroscopy** 1995 Aug;11(4):486–94 (25 ref.)

Postoperative sleep disturbances: mechanisms and clinical implications. Rosenberg–Adamsen S, et al. **Br J Anaesth** 1996 Apr;76(4):552–9 (71 ref.)

The emerging roles of topical non–steroidal anti–inflammatory agents in ophthalmology. Koay P. **Br J Ophthalmol** 1996 May;80(5):480–5 (98 ref.)

Aqueous contamination during small incision cataract surgery: a lesson in study design [editorial; comment] Towler H. **Br J Ophthalmol** 1995 Oct;79(10):873 (12 ref.) Comment on: Br J Ophthalmol 1995 Oct;79(10):878–80.

Delayed right heart failure following lung transplantation. Kirshbom PM, et al. **Chest** 1996 Feb;109(2):575–7 (9 ref.)

Assessment of cardiac risk in noncardiac surgery. Forgosh LB, et al. **Clin Cardiol** 1995 Oct;18(10):556–62 (45 ref.)

Pulmonary complications of liver transplantation. O'Brien JD, et al. **Clin Chest Med** 1996 Mar;17(1):99–114 (95 ref.)

Pelvic pathology after hysterectomy. A pictorial essay. Kasales CJ, et al. **Clin Imaging** 1995 Jul–Sep;19(3):210–7 (5 ref.)

Audiovestibular complications of non–otological surgery. Mahoney CF, et al. **Clin Otolaryngol** 1995 Dec;20(6):510–6 (53 ref.)

Complications of skull base surgery. Nguyen TT, et al. **Clin Plast Surg** 1995 Jul;22(3):573–80 (18 ref.)

Complications of shoulder instability surgery. Wall MS, et al. **Clin Sports Med** 1995 Oct;14(4):973–1000 (153 ref.)

Complications of urogynaecological surgery. Neale R. **Curr Opin Obstet Gynecol** 1995 Oct;7(5):400–3 (21 ref.)

Postoperative fatigue. Christensen T. **Dan Med Bull** 1995 Sep; 42(4):314–22 (132 ref.)

Vein patch rupture: early complication of carotid endarterectomy. Blok JG, et al. **Eur J Surg** 1995 Jul; 161(7):519–21 (17 ref.)

Tension pneumocephalus following craniofacial resection. Wanamaker JR, et al. **Head Neck** 1995 Mar–Apr; 17(2):152–6 (22 ref.)

Inflammatory and immunologic effects of obstructive jaundice: pathogenesis and treatment. Kimmings AN, et al. **J Am Coll Surg** 1995 Dec;181(6):567–81 (186 ref.)

Myocardial ischemia after cardiopulmonary bypass. Jain U. **J Card Surg** 1995 Jul;10(4 Suppl):520–6 (97 ref.)

The management of temperature during cardiopulmonary bypass: effect on neuropsychological outcome. Nathan HJ, et al. **J Card Surg** 1995 Jul;10(4 Suppl):481–7 (50 ref.)

Endothelial changes following refractive surgery. Frueh BE, et al. **J Cataract Refract Surg** 1996 May;22(4):490–6 (47 ref.)

Pre–operative information in mastoidectomy: what about the facial nerve and hearing loss? Wormald PJ. **J Laryngol Otol** 1996 Jan;110(1):10–2 (8 ref.)

Delayed graft function in renal transplantation: etiology, management and long–term significance. Shoskes DA, et al. **J Urol** 1996 Jun;155(6):1831–40 (141 ref.)

Inflammatory pseudocyst associated with trisomy 21 and Hirschsprung's disease. DuBois JJ, et al. **Mil Med** 1995 Sep;160(9):477–9 (28 ref.)

Postoperative uterine granulomata following endometrial resection. Smart PJ, et al. **Pathology** 1995 Apr;27(2):209–11 (14 ref.)

Plesiomonas shigelloides septicemia: case report and literature review. Lee AC, et al. **Pediatr Hematol Oncol** 1996 May–Jun;13(3):265–9 (23 ref.)

Postsplenectomy care. Strategies to decrease the risk of infection. Williams DN, et al. **Postgrad Med** 1996 Jul; 100(1):195–8, 201, 205 (15 ref.)

Clinical and physiological aspects of ileal pouch–anal anastomosis. Salemans JM, et al. **Scand J Gastroenterol Suppl** 1995;212:3–12 (98 ref.)

Carcinogenesis after remote peptic ulcer surgery: the long–term prognosis of partial gastrectomy. Tersmette AC, et al. **Scand J Gastroenterol Suppl** 1995;212:96–9 (49 ref.)

Retained intraaortic balloon. Case report and review of the literature. Grande AM, et al. **Tex Heart Inst J** 1995; 22(4):332–4 (19 ref.)

Neoplasia: an example of plasticity of the immune response. Penn I. **Transplant Proc** 1996 Aug;28(4):2089–93 (29 ref.)

[Post–heart surgery auricular fibrillation] Pagé PL, et al. **Can J Cardiol** 1996 Feb;12 Suppl A:38A–43A (45 ref.) **(Fre)**

[Vascular complications of lumbar disk surgery. Report of two cases and review of the literature on 122 cases] Pillet JC, et al. **J Mal Vasc** 1995;20(3):219–23 (85 ref.) (Eng. Abstr.) **(Fre)**

[Thyroid surgery: risks and complications. Apropos of 134 cases] Duclos JY, et al. **Rev Laryngol Otol Rhinol (Bord)** 1995;116(3):199–207 (25 ref.) (Eng. Abstr.) **(Fre)**

[Transplant vasculopathy following heart transplantation] Weis M, et al. **Dtsch Med Wochenschr** 1995 Sep 29; 120(39):1327–33 (50 ref.) **(Ger)**

[Rheumatic manifestations of transplant recipients] Levy G, et al. **Harefuah** 1996 Apr 15;130(8):546–8 (23 ref.) **(Heb)**

[Complications of the surgical treatment of hemorrhoids and its therapy] Corno F, et al. **Ann Ital Chir** 1995 Nov–Dec; 66(6):813–6 (15 ref.) (Eng. Abstr.) **(Ita)**

[Left ventricular rupture following aortic and mitral valve replacement in a patient with osteogenesis imperfecta: a case report] Ichikawa H, et al. **Kyobu Geka** 1996 Apr;

49(4):294–6 (13 ref.) (Eng. Abstr.) **(Jpn)**

[A case report of a left atrial ball thrombus at 16 years after mitral valve replacement] Iida M, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Apr;44(4):539–44 (28 ref.) (Eng. Abstr.) **(Jpn)**

[Eck fistula syndrome] Fukasawa M, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):220–5 (22 ref.) **(Jpn)**

[Post operative bile duct stricture] Hoshino M, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):155–8 (8 ref.) **(Jpn)**

[Postoperative acute cholecystitis] Nakajima Y, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):213–5 (7 ref.) **(Jpn)**

[Post–operative liver failure] Omori Y, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):256–8 (18 ref.) **(Jpn)**

[Postoperative liver damage, postoperative jaundice, and benign postoperative cholestasis] Ouchi K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):538–40 (6 ref.) **(Jpn)**

[Infections in intensive care units. A challenge for the specialist of infectious diseases?] von der Lippe E, et al. **Tidsskr Nor Laegeforen** 1995 Nov 20;115(28):3508–10 (12 ref.) (Eng. Abstr.) **(Nor)**

[Principal factors affecting postoperative astigmatism after cataract extraction] Naim Dzheries Dzhadalla Kalkikh. **Vestn Oftalmol** 1995 Jul–Sep;111(3):34–6 (49 ref.) **(Rus)**

BLOOD

Thrombophilia and the surgeon. Rhodes EG. **Ann R Coll Surg Engl** 1996 Jul;78(4):331–5 (33 ref.)

CHEMICALLY INDUCED

[Hair–like hyperkeratoses in patients with kidney transplants. A new cyclosporin side–effect] Izakovic J, et al. **Hautarzt** 1995 Dec;46(12):841–6 (45 ref.) (Eng. Abstr.) **(Ger)**

DIAGNOSIS

Seromas in the breast: imaging findings. Soo MS, et al. **Crit Rev Diagn Imaging** 1995;36(5):385–440 (34 ref.)

Late rupture of femoropopliteal Dacron grafts: a rare complication. Vrancken Peeters MT, et al. **Eur J Vasc Endovasc Surg** 1996 Feb;11(2):243–6 (5 ref.)

Imaging of the total hip arthroplasty. Allen AM, et al. **J South Orthop Assoc** 1995 Summer;4(2):96–123 (71 ref.)

MRI hippocampal volume and neuropsychology in epilepsy surgery. Trenerry MR, et al. **Magn Reson Imaging** 1995; 13(8):1125–32 (47 ref.)

[The TUR syndrome] Glogov S. **Khirurgila (Sofiia)** 1995; 48(5):66–70 (32 ref.) (Eng. Abstr.) **(Bul)**

–Possibilities and limits of imaging for evaluating breast implants– Tristant H. **Arch Gynecol Obstet** 1995;256 Suppl:S135–47 (31 ref.) **(Fre)**

[Recommendations for initial diagnosis and therapy in acute blood coagulation disorders] Sütterlin R, et al. **Anaesthesiol Reanim** 1996;21(3):76–80 (24 ref.) (Eng. Abstr.) **(Ger)**

[Perioperative and postoperative normovolemic anemia. Physiological compensation, monitoring and risk evaluation] Ostgaard G. **Tidsskr Nor Laegeforen** 1996 Jan 10;116(1):57–60 (43 ref.) (Eng. Abstr.) **(Nor)**

[Postappendectomy vascular complications in childhood] Díez García R, et al. **An Esp Pediatr** 1996 Mar;44(3):270–2 (19 ref.) **(Spa)**

DRUG THERAPY

Inotropic agents in the treatment of postoperative low cardiac output syndrome. Husedžinović I, et al. **Acta Med Croatica** 1995;49(4–5):201–5 (55 ref.)

Treatment of hyperlipidemia after heart transplantation and rationale for the Heart Transplant Lipid Registry. Ballantyne CM, et al. **Am J Cardiol** 1996 Sep 1;78(5):532–5 (34 ref.)

Fungal infection in surgical patients. Dean DA, et al. **Am J Surg** 1996 Mar;171(3):374–82 (100 ref.)

Antimicrobial prophylaxis in patients undergoing solid organ transplantation. Basgoz N, et al. **Curr Clin Top Infect Dis** 1995;15:344–64 (79 ref.)

Epoetin alfa. A review of its clinical efficacy in the management of anaemia associated with renal failure and chronic disease and its use in surgical patients. Dunn CJ, et al. **Drugs Aging** 1995 Aug;7(2):131–56 (186 ref.)

Impact of converting enzyme inhibitors and calcium entry blockers on cardiac allograft vasculopathy: from bench to bedside. Mehra MR, et al. **J Heart Lung Transplant** 1995 Nov–Dec;14(6 Pt 2):S246–9 (16 ref.)

[Prevention and treatment of postoperative nausea and vomiting with 5–HT3–receptor blockers] Alon E, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May; 31(4):200–4 (47 ref.) (Eng. Abstr.) **(Ger)**

[Postoperative thrombolytic therapy] Kolben M, et al. **Internist (Berl)** 1996 Jun;37(6):619–22 (27 ref.) **(Ger)**

[The usefulness of inhaled nitric oxide in the treatment of pulmonary hypertension in the postoperative period of cardiac surgery in infancy] de Lucas García N, et al. **An Esp Pediatr** 1996 Apr;44(4):373–6 (27 ref.) **(Spa)**

[Gastrointestinal fistulas. Treatment with a somatostatin analogue (SMS 201–995)] Gerardo Pérez D, et al. **G E N** 1994 Oct–Dec;48(4):209–18 (51 ref.) (Eng. Abstr.) **(Spa)**

EPIDEMIOLOGY

Mediastinitis after coronary artery bypass graft surgery. Risk factors and long–term survival. Milano CA, et al. **Circulation** 1995 Oct 15;92(8):2245–51 (18 ref.)

Early complications of abdominal and vaginal hysterectomy. Harris WJ. **Obstet Gynecol Surv** 1995 Nov;50(11):795–805 (65 ref.)

Benefits and risks of episiotomy: a review of the English–language literature since 1980. Part II. Woolley RJ. **Obstet Gynecol Surv** 1995 Nov;50(11):821–35 (189 ref.)

Recurrent cytomegalovirus disease in solid–organ transplant recipients. Falagas ME, et al. **Transplant Proc** 1995 Oct; 27(5 Suppl 1):34–7 (23 ref.)

Risk factors and pathogenesis of posttransplant lymphoproliferative disorders. Ho M. **Transplant Proc** 1995 Oct;27(5 Suppl 1):38–40 (36 ref.)

Bone marrow transplantation. Storb R. **Transplant Proc** 1995 Oct;27(5):2649–52 (6 ref.)

[Retrospective study of postoperative infectious morbidity following cesarean section] Di Lieto A, et al. **Minerva Ginecol** 1996 Mar;48(3):85–92 (45 ref.) (Eng. Abstr.) **(Ita)**

[Peptic ulcer: late complications of the surgical treatment] Pinatel Lopasso F. **Rev Gastroenterol Peru** 1995 Sep–Dec; 15(3):273–81 (109 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

Current thoughts on penile prosthetic surgery. Pryor JP. **Acta Chir Hung** 1995–96;35(1–2):129–35 (4 ref.)

Complications after multidisciplinary treatment of cerebral arteriovenous malformations. Deruty R, et al. **Acta Neurochir (Wien)** 1996;138(2):119–31 (46 ref.)

Latest advances in epilepsy surgery. Silfvenius H. **Acta Neurol Scand Suppl** 1995;162:11–6 (32 ref.)

Severe dysphagia, dysmotility, and unusual saccular dilation (diverticulum) of the esophagus following excision of an asymptomatic congenital cyst. Mahajan RJ, et al. **Am J Gastroenterol** 1996 Jun;91(6):1254–8 (23 ref.)

Retroperitoneal and abdominal wall emphysema after transanal excision of a rectal carcinoma. Petros JG, et al. **Am Surg** 1996 Sep;62(9):759–61 (8 ref.)

Oesophageal atresia—need for life–long follow–up? Lindahl H. **Ann Chir Gynaecol** 1995;84(2):235–9 (27 ref.)

Vascular complications of lung transplantation. Clark SC, et al. **Ann Thorac Surg** 1996 Apr;61(4):1079–82 (7 ref.)

Late aneurysm after subclavian flap aortoplasty for coarctation of the aorta. Kino K, et al. **Ann Thorac Surg** 1996 Apr;61(4):1262–4 (8 ref.)

Coronary–pulmonary steal syndrome. Najm HK, et al. **Ann Thorac Surg** 1996 Jul;62(1):264–5 (7 ref.)

Massive endobronchial hemorrhage after pulmonary embolectomy. Shimokawa S, et al. **Ann Thorac Surg** 1996 Apr;61(4):1241–2 (11 ref.)

Complications of laparoscopic cholecystectomy. Jones DB, et al. **Annu Rev Med** 1996;47:31–44 (45 ref.)

Acute ventilatory complications during laparoscopic upper abdominal surgery. Wahba RW, et al. **Can J Anaesth** 1996 Jan;43(1):77–83 (35 ref.)

Colocutaneous fistula: a rare and silent complication of percutaneous endoscopic gastrostomy. Siddique I, et al. **Dig Dis Sci** 1996 Feb;41(2):301–4 (14 ref.)

Dysphagia after pharyngolaryngeal cancer surgery. Part II: Implications for reconstructive procedures. Herberhold C, et al. **Dysphagia** 1995 Fall;10(4):279–81 (28 ref.)

Dysphagia after pharyngolaryngeal cancer surgery. Part I: Pathophysiology of postsurgical deglutition. Walther EK. **Dysphagia** 1995 Fall;10(4):275–8 (25 ref.)

Native hepatic artery pseudoaneurysm after liver transplantation: an unusual presentation with biliary leak. Soin AS, et al. **Eur J Vasc Endovasc Surg** 1995 Oct; 10(3):376–9 (9 ref.)

Malignant tumor developed in colon–esophagus. Altorjay A, et al. **Hepatogastroenterology** 1995 Nov–Dec;42(6):797–9 (19 ref.)

Thermal necrosis after tibial reaming for intramedullary nail fixation. A report of three cases. Leunig M, et al. **J Bone Joint Surg Br** 1996 Jul;78(4):584–7 (26 ref.)

Surgical hemostasis by pneumatic ankle tourniquet during 3027 podiatric operations. Derner R, et al. **J Foot Ankle Surg** 1995 May–Jun;34(3):236–46 (87 ref.)

Small bowel obstruction following endoscopic extraperitoneal–preperitoneal herniorrhaphy. Azurin DJ, et al. **J Laparoendosc Surg** 1995 Aug;5(4):263–6 (10 ref.)

The potential risks, complications, and prevention of deep vein thrombosis in oral and maxillofacial surgery patients. Solomon JM, et al. **J Oral Maxillofac Surg** 1995 Dec; 53(12):1441–7 (28 ref.)

Toxic shock syndrome as a complication of orthopaedic surgery. Grimes J, et al. **J Pediatr Orthop** 1995 Sep–Oct; 15(5):666–71 (28 ref.)

Intracerebral hemorrhage after carotid endarterectomy associated with ipsilateral fibrinoid necrosis: a consequence of the hyperperfusion syndrome? Mansoor GA, et al. **J Vasc Surg** 1996 Jan;23(1):147–51 (20 ref.)

Hypertension and the kidney: new insights from results of renal transplantation studies. Rettig R, et al. **Nephrol Dial Transplant** 1995 Oct;10 Suppl 9:9–16 (45 ref.)

Cerebellar mutism: report of seven cases and review of the literature. Erşahin Y, et al. **Neurosurgery** 1996 Jan; 38(1):60–5;discussion 66 (30 ref.)

Tremor as the result of shunt obstruction: four patients with cysticercosis and secondary parkinsonism: report of four cases. Keane JR. **Neurosurgery** 1995 Sep;37(3):520–2 (3 ref.)

Recurrence of hemifacial spasm after microvascular decompression. Payner TD, et al. **Neurosurgery** 1996 Apr; 38(4):686–90; discussion 690–1 (28 ref.)

Delayed onset of hyponatremia after transsphenoidal surgery for pituitary adenomas. Taylor SL, et al. **Neurosurgery** 1995 Oct;37(4):649–53; discussion 653–4 (26 ref.)

Treating complications of circumcision. Baskin LS, et al. **Pediatr Emerg Care** 1996 Feb;12(1):62–8 (33 ref.)

Multifocal osteolysis following limb–sparing procedures: imaging findings and a review of the literature. Kaste SC, et al. **Pediatr Radiol** 1996;26(2):158–61 (17 ref.)

External abdominal hernia of mucocele of the appendix in drain–tube removal site. Bacchin P, et al. **Radiol Med (Torino)** 1995 Dec;90(6):827–9 (13 ref.)

Peritonitis biliaris: some aspects of its origin. Vomela J, et al. **Rocz Akad Med Bialymst** 1995;40(1):58–64 (24 ref.)

[Spontaneous perforation of the small intestine in primary lung carcinoma] Kolarov I, et al. **Khirurgila (Sofiia)** 1995; 48(6):47–9 (0 ref.) **(Bul)**

[Vascular complications in kidney transplantation (a review of the literature and the authors' own experience)] Nikolovski M, et al. **Khirurgila (Sofiia)** 1994;47(5):30–3 (60 ref.) (Eng. Abstr.) **(Bul)**

–Breast neoplasms: axillary lymph node excision—at what price– Rageth JC. **Arch Gynecol Obstet** 1995;256 Suppl:S85–92 (45 ref.) **(Ger)**

–Complications. Surgical endoscopy versus gynecologic minimal invasive surgery– Wallwiener D, et al. **Arch Gynecol Obstet** 1995;256 Suppl:S21–31 (18 ref.) **(Ger)**

–Complications of hysteroscopy and laparoscopy from the anesthesiologic viewpoint– Zollinger A. **Arch Gynecol Obstet** 1995;256 Suppl:S12–20 (25 ref.) **(Ger)**

[Ischemic colitis after vascular surgery reconstruction of an abdominal aortic aneurysm] Kaiser MM, et al. **Chirurg** 1996 Apr;67(4):380–6 (30 ref.) (Eng. Abstr.) **(Ger)**

[Possibilities and limits of conservative management of cruciate ligament injuries] Paar O, et al. **Chirurg** 1995 Nov; 66(11):1050–60 (48 ref.) (Eng. Abstr.) **(Ger)**

[The pathogenesis, diagnosis and therapy of posttransplantation osteoporosis] Hofbauer LC, et al. **Dtsch Med Wochenschr** 1996 Jul 26;121(30):953–7 (45 ref.) **(Ger)**

[Osteoporosis following heart transplantation. Pathogenesis and therapy] Stempfle HU. **Dtsch Med Wochenschr** 1996 Sep 6;121(36):1103–7 (44 ref.) **(Ger)**

[Severe complications after surgical removal of wisdom teeth] Locher MC, et al. **Fortschr Kiefer Gesichtschir** 1995; 40:123–8 (55 ref.) (Eng. Abstr.) **(Ger)**

[Complications in bimaxillary surgical interventions] Sailer HF, et al. **Fortschr Kiefer Gesichtschir** 1995;40:41–9 (65 ref.) **(Ger)**

[Introduction of laparoscopic surgery in extrauterine pregnancy] Rempen A. **Geburtshilfe Frauenheilkd** 1995 Jul; 55(7):357–64 (28 ref.) (Eng. Abstr.) **(Ger)**

[Apical ulceration of the glans penis in hypervascularization syndrome. Sequelae of revascularization operation in erectile dysfunction] Hartwig R, et al. **Hautarzt** 1995 Nov; 46(11):808–10 (12 ref.) (Eng. Abstr.) **(Ger)**

[Current evaluation of myopia correction with the excimer laser] Seiler T. **Ophthalmologe** 1995 Aug;92(4):379–84 (18 ref.) (Eng. Abstr.) **(Ger)**

[Local complications of intramedullary nailing] Strecker W, et al. **Orthopade** 1996 Jun;25(3):274–91 (59 ref.) (Eng. Abstr.) **(Ger)**

[Coronary endothelial dysfunction and graft atheromatosis following heart transplantation] Vassalli G. **Schweiz Med Wochenschr** 1995 Oct 14;125(41):1923–30 (51 ref.) (Eng. Abstr.) **(Ger)**

[Complications of patient positioning] Staender S. **Swiss Surg** 1995;(3):152–5 (16 ref.) (Eng. Abstr.) **(Ger)**

[Complications of laparoscopic interventions in urology] Fahlenkamp D, et al. **Urologe A** 1996 May;35(3):238–45 (20 ref.) (Eng. Abstr.) **(Ger)**

[Significance of the radial compression syndrome for the diagnosis and surgical therapy of so–called epicondylitis humeri radialis (Epic. hum. rad.)] Totkas D, et al. **Z Orthop Ihre Grenzgeb** 1995 Jul–Aug;133(4):317–22 (73 ref.) (Eng. Abstr.) **(Ger)**

[Gastroduodenal stress lesions and hemorrhages—pathogenesis, diagnosis, prevention and therapy] Gheorghiu T. **Zentralbl Chir** 1995;120(9):670–6 (32 ref.) (Eng. Abstr.) **(Ger)**

[Classification, therapy and complications of pediatric femoral neck fractures] Hahn MP, et al. **Zentralbl Chir** 1995;120(11):832–40 (56 ref.) (Eng. Abstr.) **(Ger)**

[Dura–plasty in intracranial operations] Ernestus RI, et al. **Zentralbl Neurochir** 1995;56(3):106–10 (20 ref.) (Eng. Abstr.) **(Ger)**

[Endometriosis of the abdominal wall. A report of a case secondary to cesarean section] Capanna A, et al. **G Chir** 1995 Aug–Sep;16(8–9):352–6 (19 ref.) (Eng. Abstr.) **(Ita)**

[Choledochal calculosis due to a suture thread] Lo Casto RM, et al. **Minerva Chir** 1996 Jan–Feb;51(1–2):63–5 (11 ref.) (Eng. Abstr.) **(Ita)**

POSTOPERATIVE COMPLICATIONS

[Corneal edema, a complication of cataract surgery] Chercota V. **Oftalmologia** 1995 Oct–Dec;39(4):343–8. (9 ref.) (Eng. Abstr.) **(Rum)**

[Acute postoperative gastroduodenal erosions and ulcers] Prilma OB. **Vestn Khir Im I I Grek** 1992 Feb;148(2):247–51 (44 ref.) **(Rus)**

[Rhabdomyolysis and acute kidney failure after an orthopedic intervention] Méndez Bustelo MJ, et al. **An Esp Pediatr** 1996 Apr;44(4):385–6 (20 ref.) **(Spa)**

[Lymphoproliferative disease and cancer in the transplant patient] Herreros J, et al. **Rev Esp Cardiol** 1995;48 Suppl 7:129–34 (44 ref.) (Eng. Abstr.) **(Spa)**

[The significance of cytomegalovirus infection in the period after a heart transplant] Manito N, et al. **Rev Esp Cardiol** 1995;48 Suppl 7:108–14 (36 ref.) (Eng. Abstr.) **(Spa)**

[Graft vascular disease. Its pathogenesis and diagnosis] Muñoz Aguilera R, et al. **Rev Esp Cardiol** 1995;48 Suppl 7:115–28 (164 ref.) (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

Macrophages and transplant arteriosclerosis: known and novel molecules. Russell ME. **J Heart Lung Transplant** 1995 Nov–Dec;14(6 Pt 2):S111–5 (31 ref.)

The effect of thymectomy on myasthenia gravis, thrombocytopenia, and granulocytopenia associated with thymoma: report of a case. Kobayashi M, et al. **Surg Today** 1995;25(12):1061–5 (14 ref.)

METABOLISM

[Role of hormonal exploration in avoiding of the failures of anterior pituitary gland surgery in Cushing disease] Bachelot I, et al. **Ann Endocrinol (Paris)** 1995;56(6):620–4 (15 ref.) (Eng. Abstr.) **(Fre)**

MICROBIOLOGY

[A case of a patient with post-operative empyema due to Mycobacterium chelonae] Takemoto N, et al. **Kyobu Geka** 1996 Apr;49(4):301–5 (12 ref.) (Eng. Abstr.) **(Jpn)**

[Neurosurgical infections] Martínez E, et al. **Enferm Infecc Microbiol Clin** 1996 Jan;14(1):34–43 (161 ref.) **(Spa)**

PATHOLOGY

Cardiac allograft vasculopathy: the central pathogenetic role of ischemia-induced endothelial cell injury. Day JD, et al. **J Heart Lung Transplant** 1995 Nov–Dec;14(6 Pt 2):S142–9 (84 ref.)

The pathogenesis of graft vascular disease: implications of vascular remodeling. Gibbons GH. **J Heart Lung Transplant** 1995 Nov–Dec;14(6 Pt 2):S149–58 (59 ref.)

The prognostic significance of intimal proliferation in cardiac allograft vasculopathy: a paradigm shift. Mehra MR, et al. **J Heart Lung Transplant** 1995 Nov–Dec;14(6 Pt 2):S207–11 (20 ref.)

[Results and conclusions from 328 radical operations of rectal carcinoma by one surgeon. Comparative anatomic studies with Brachydanio rerio and Latimeria chalumnae] Stelzner F. **Chirurg** 1995 Dec;66(12):1230–8 (22 ref.) (Eng. Abstr.) **(Ger)**

[Epididymal malacoplakia in a heart transplant recipient: clinico-pathologic study of a case] Soria Corón MR, et al. **Arch Esp Urol** 1996 Mar;49(2):172–6 (15 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

Brain damage and postoperative hyponatremia: the role of gender. Ayus JC, et al. **Neurology** 1996 Feb;46(2):323–8 (72 ref.)

Visual integration in the split brain. Corballis MC. **Neuropsychologia** 1995 Aug;33(8):937–59 (78 ref.)

Mutism and pseudobulbar symptoms after resection of posterior fossa tumors in children: incidence and pathophysiology. Pollack IF, et al. **Neurosurgery** 1995 Nov; 37(5):885–93 (39 ref.)

Transient cerebellar mutism after posterior fossa surgery in children. Van Calenbergh F, et al. **Neurosurgery** 1995 Nov; 37(5):894–8 (32 ref.)

[Pro: a critical contribution to better understanding of possible functional disorders of the genital, bladder and pelvic floor system] Schüssler B. **Arch Gynecol Obstet** 1995; 257(1–4):359–62 (14 ref.) **(Ger)**

[Contra cervix extirpation] Semm K. **Arch Gynecol Obstet** 1995;257(1–4):362–71 (25 ref.) **(Ger)**

[Pathophysiology of the abdominal wall] Klinge U, et al. **Chirurg** 1996 Mar;67(3):229–33 (12 ref.) (Eng. Abstr.) **(Ger)**

[Biomechanical changes in the hip, femur and knee joint after removal of a tensor fasciae latae flap] Lattermann C, et al. **Handchir Mikrochir Plast Chir** 1996 Mar;28(2):76–82 (33 ref.) (Eng. Abstr.) **(Ger)**

[Cholestatic erythrohepatic protoporphyria: porphyrin metabolism before and after liver transplantation] Doss MO, et al. **Z Gastroenterol** 1993 Feb;31 Suppl 2:85–9 (31 ref.) (Eng. Abstr.) **(Ger)**

[Normal pregnancy duration after maternal Fontan operation of univentricular heart] Osmers R, et al. **Z Geburtshilfe Neonatol** 1995 Sep–Oct;199(5):195–8 (15 ref.) (Eng. Abstr.) **(Ger)**

[Physiology and physiopathology of postoperative disease. Therapeutic implications] Vara-Thorbeck R. **Nutr Hosp** 1995 Sep–Oct;10(5):286–96 (68 ref.) (Eng. Abstr.) **(Spa)**

PREVENTION & CONTROL

Postoperative atelectasis and pneumonia: risk factors. Brooks-Brunn JA. **Am J Crit Care** 1995 Sep;4(5):340–9; quiz 350–1 (90 ref.)

Preservation of auditory and vestibular function after surgical removal of bilateral vestibular schwannomas in a patient with neurofibromatosis type 2. Black FO, et al. **Am J Otol** 1995 Jul;16(4):431–43 (51 ref.)

Morbidity risk assessment in the surgically anemic patient. Carson JL. **Am J Surg** 1995 Dec;170(6A Suppl):32S–36S (53 ref.)

Surgical infections: prevention and treatment—1965 to 1995. Nichols RL. **Am J Surg** 1996 Jul;172(1):68–74 (54 ref.)

Minimising cardiac anaesthetic risk: the tortoise or the hare? Juste RN, et al. **Anaesthesia** 1996 Mar;51(3):255–62 (63 ref.)

Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation [see comments] Blackshear JL, et al. **Ann Thorac Surg** 1996 Feb;61(2):755–9 (59 ref.) Comment in: Ann Thorac Surg 1996 Feb;61(2):515.

Intraoperative positioning of surgical patients. McEwen DR. **AORN J** 1996 Jun;63(6):1059–63, 1066–79; quiz 1080–6 (38 ref.)

Prevention of postoperative venous thromboembolism. Bullingham A, et al. **Br J Anaesth** 1995 Nov;75(5):622–30 (85 ref.)

Prevention of vomiting after paediatric strabismus surgery: a systematic review using the numbers-needed-to-treat method. Tramèr M, et al. **Br J Anaesth** 1995 Nov; 75(5):556–61 (48 ref.)

Recovery room problems or problems in the PACU. Rose DK. **Can J Anaesth** 1996 May;43(5 Pt 2):R116–28 (50 ref.) **(Eng, Fre)**

Spinal cord protection during surgical procedures on the descending thoracic and thoracoabdominal aorta: review of current techniques. Gharagozloo F, et al. **Chest** 1996 Mar;109(3):799–809 (98 ref.)

Postoperative pulmonary complications: risk assessment, prevention, and treatment. Hayden SP, et al. **Cleve Clin J Med** 1995 Nov–Dec;62(6):401–7 (27 ref.)

Preoperative cardiac risk assessment and management. Abrams J. **Curr Opin Gen Surg** 1993;:13–8 (30 ref.)

Surgical infections: blocking the mediator cascade responsible for sepsis and septic shock. Fink MP. **Curr Opin Gen Surg** 1993;:19–25 (45 ref.)

Continence-preserving procedures for benign and malignant disease. Lewis WG, et al. **Curr Opin Gen Surg** 1993;:157–63 (53 ref.)

Guidelines for prevention of thromboembolic events in valvular heart disease. Study Group of the Working Group on Valvular Heart Disease of the European Society of Cardiology. Gohlke-Bärwolf C, et al. **Eur Heart J** 1995 Oct;16(10):1320–30 (165 ref.)

The role of low-molecular-weight heparins in the prevention of venous thrombosis in surgery with special reference to enoxaparin. Haas S. **Haemostasis** 1996;26 Suppl 2:39–48 (21 ref.)

Prevention of complications after autogenous bone-patellar tendon-bone ACL reconstruction. Shelbourne KD, et al. **Instr Course Lect** 1996;45:253–62 (30 ref.)

Oral fleroxacin prophylaxis in transurethral surgery. Gasser TC, et al. **J Urol** 1996 Jul;156(1):146–8 (27 ref.)

Prevention of postoperative venous thromboembolism [editorial; comment] Chong BH. **Med J Aust** 1996 Jun 3; 164(11):646–7 (13 ref.) Comment on: Med J Aust 1996 Jun 3;164(11):652–4, 656.

Benefits and risks of episiotomy: a review of the English-language literature since 1980. Part I. Woolley RJ. **Obstet Gynecol Surv** 1995 Nov;50(11):806–20 (189 ref.)

Postsplenectomy care. Strategies to decrease the risk of infection. Williams DN, et al. **Postgrad Med** 1996 Jul; 100(1):195–8, 201, 205 (15 ref.)

Prophylactic cytomegalovirus management strategies. Martin M. **Transplant Proc** 1995 Oct;27(5 Suppl 1):23–7 (30 ref.)

[The high risk cardiac patient in anesthesia] Francke A. **Anaesthesiol Reanim** 1996;21(2):32–42 (89 ref.) (Eng. Abstr.) **(Ger)**

[Medicamentous prevention of acid aspiration syndrome] Kurz-Müller K, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May; 31(4):261–5 (77 ref.) **(Ger)**

[Is traditional preoperative fasting still applicable?] Wrenger K, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May; 31(4):250–4 (36 ref.) **(Ger)**

[Risk predictors and secondary prevention after PTCA and bypass operations] Gulba DC, et al. **Internist (Berl)** 1995 Sep;36(9):891–901 (82 ref.) **(Ger)**

[Characteristics of rare ovarian tumors—possibilities of organ preservation] Grischke EM, et al. **Zentralbl Gynakol** 1996; 118(6):322–5 (10 ref.) (Eng. Abstr.) **(Ger)**

[Results of fertility preserving operations in malignant ovarian tumors] Kleine W. **Zentralbl Gynakol** 1996; 118(6):317–21 (21 ref.) (Eng. Abstr.) **(Ger)**

[The prevention of adhesion formation in surgical gynecology (the role of suture materials and barriers)] Mynbaev OA, et al. **Akush Ginekol (Mosk)** 1995;(5):37–40 (38 ref.) **(Rus)**

PSYCHOLOGY

Prolonged dysphagia after orthognathic surgery: report of a case and review of the literature. Nagler RM, et al. **J Oral Maxillofac Surg** 1996 Apr;54(4):523–5 (21 ref.)

[Identity of the personality and personal identity: philosophical questions in relation to transplantation of brain tissue] Birnbacher D. **Zentralbl Neurochir** 1995; 56(4):180–5 (6 ref.) (Eng. Abstr.) **(Ger)**

[Psychological aspects of neurotransplantation] Ellgring H. **Zentralbl Neurochir** 1995;56(4):168–72 (11 ref.) (Eng. Abstr.) **(Ger)**

RADIOGRAPHY

Noncardiac thoracic surgical procedures. Definitions, indications, and postoperative radiology. Bhalla M. **Radiol Clin North Am** 1996 Jan;34(1):137–55 (28 ref.)

Radiologic evaluation of the patient after cardiac surgery. Henry DA. **Radiol Clin North Am** 1996 Jan;34(1):119–35 (43 ref.)

Peritoneographic diagnosis of perineal enterocele after hysterectomy. Tepetes K, et al. **Rofo Fortschr Geb Roatgenstr Neuen Bildgeb Verfahr** 1995 Oct;163(4):367–8 (12 ref.)

Radiology of pulmonary emphysema and lung volume reduction surgery. Slone RM, et al. **Semin Thorac Cardiovasc Surg** 1996 Jan;8(1):61–82 (61 ref.)

REHABILITATION

Posttraumatic stiffness in the hand. Putnam MD. **Clin Orthop** 1996 Jun;(327):182–90 (47 ref.)

SURGERY

Reoperations after failed antireflux procedures. Siewert JR, et al. **Ann Chir Gynaecol** 1995;84(2):122–8 (29 ref.)

Spontaneous fracture of the ceramic ball in a ceramic-polyethylene total hip arthroplasty. Michaud RJ, et al. **J Arthroplasty** 1995 Dec;10(6):863–7 (27 ref.)

Early thoracic duct ligation for postoperative chylothorax. Sieczka EM, et al. **J Surg Oncol** 1996 Jan;61(1):56–60 (27 ref.)

Postsurgical development of dural arteriovenous malformations after transpetrosal and transtentorial operations: case report. Sasaki T, et al. **Neurosurgery** 1995 Oct;37(4):820–4; discussion 824–5 (14 ref.)

Revision total knee arthroplasty: how much constraint is necessary? Cuckler JM. **Orthopedics** 1995 Sep;18(9):932–3, 936 (11 ref.)

The surgical management of allograft coronary disease: a paradigm shift. Miller LW, et al. **Semin Thorac Cardiovasc Surg** 1996 Apr;8(2):133–8 (54 ref.)

Necrotizing fasciitis following laparoscopic surgery. Case report and review of the literature. Golshani S, et al. **Surg Endosc** 1996 Jul;10(7):751–4 (20 ref.)

[Surgical therapy of recurrent Crohn disease] Buhr HJ, et al. **Chirurg** 1995 Aug;66(8):764–73 (35 ref.) (Eng. Abstr.) **(Ger)**

[Progressive pneumoperitoneum in treatment of inguinal and scar hernias. Results of animal experiments and clinical applications] Willis S, et al. **Langenbecks Arch Chir** 1996; 381(3):132–7 (37 ref.) (Eng. Abstr.) **(Ger)**

[Progression of arthrosis after alloplasty—what factors play a role?] Küllmer K, et al. **Unfallchirurgie** 1996 Jun; 22(3):130–8 (36 ref.) (Eng. Abstr.) **(Ger)**

[Unilateral pulmonary embolectomy without extracorporeal circulation. A report of a clinical case] Barboso G, et al. **Acta Biomed Ateneo Parmense** 1995;66(1–2):53–5 (10 ref.) (Eng. Abstr.) **(Ita)**

THERAPY

Multiple organ failure. Buchman TG. **Curr Opin Gen Surg** 1993;:26–31 (30 ref.)

Intravascular stents: current applications. Bailey SR, et al. **Curr Probl Cardiol** 1995 Sep;20(9):614–78 (191 ref.)

Fish oil and antioxidants after heart transplantation: future strategies or eye of newt and wing of bat revisited? Young JB. **J Heart Lung Transplant** 1995 Nov–Dec;14(6 Pt 2):S250–4 (29 ref.)

Can acupuncture have specific effects on health? A systematic review of acupuncture antiemesis trials. Vickers AJ. **J R Soc Med** 1996 Jun;89(6):303–11 (49 ref.)

Treating complications of circumcision. Baskin LS, et al. **Pediatr Emerg Care** 1996 Feb;12(1):62–8 (33 ref.)

[Patient management following cardiac transplantation] Seydoux C, et al. **Schweiz Med Wochenschr** 1995 Oct 14; 125(41):1913–22 (103 ref.) (Eng. Abstr.) **(Fre)**

[Treatment of aspiration of gastric contents] Müller E. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May; 31(4):265–9 (24 ref.) **(Ger)**

[Deep venous thrombosis and the prevention of a pulmonary embolism with temporary caval filters: the experience in 2 pediatric cases] Patti G, et al. **Pediatr Med Chir** 1995 May–Jun;17(3):265–9 (10 ref.) (Eng. Abstr.) **(Ita)**

[Operative complications of obese patients and its countermeasure] Kawamura I. **Nippon Rinsho** 1995 Jun;53 Suppl:545–9 (16 ref.) **(Jpn)**

[Percutaneous surgical interventions and extracorporeal lithotripsy in the treatment of the urological complications after a kidney transplant] Urenkov SB, et al.

Urol Nefrol (Mosk) 1995 Jul-Aug;(4):45-9 (122 ref.) **(Rus)**

[Special anesthesia care in heart transplantation. The management of right ventricular failure] Gómez-Arnau J, et al. **Rev Esp Cardiol** 1995;48 Suppl 7:60-4 (22 ref.) (Eng. Abstr.) **(Spa)**

ULTRASONOGRAPHY

[Intensive medical monitoring with transesophageal echocardiography in fulminant pulmonary embolism] Bruch C, et al. **Dtsch Med Wochenschr** 1996 Jun 21; 121(25-26):829-33 (23 ref.) (Eng. Abstr.) **(Ger)**

[Vaginal ultrasound of surgical gynecologic complications] Klug PW. **Gynakologe** 1995 Aug;28(4):262-9 (25 ref.) **(Ger)**

VETERINARY

The risks of the game: the confidential enquiry into perioperative equine fatalities [editorial] Johnston GM. **Br Vet J** 1995 Jul-Aug;151(4):347-50 (8 ref.)

VIROLOGY

Cytomegalovirus infection in marrow transplantation. Boeckh M, et al. **Cancer Treat Res** 1995;76:97-136 (203 ref.)

POSTOPERATIVE HEMORRHAGE

CHEMICALLY INDUCED

Aspirin, a silent risk factor in urology. Zhu JP, et al. **Scand J Urol Nephrol** 1995 Dec;29(4):369-74 (64 ref.)

DIAGNOSIS

Sonoclot analysis. Hett DA, et al. **Br J Anaesth** 1995 Dec; 75(6):771-6 (41 ref.)

ETIOLOGY

[Hemorrhagic complications of ORL surgery] Boisson-Bertrand D, et al. **Can Anesthesiol** 1995; 43(5):489-95 (48 ref.) **(Fre)**

PREVENTION & CONTROL

Current methods to reduce the adverse haematological consequences of cardiopulmonary bypass. John LC, et al. **Br J Clin Pract** 1996 Jun;50(4):203-6 (66 ref.)

Antifibrinolytic therapy in cardiac surgery. Chen RH, et al. **Tex Heart Inst J** 1995;22(3):211-5 (73 ref.)

Limiting excessive postoperative blood transfusion after cardiac procedures. A review. Ferraris VA, et al. **Tex Heart Inst J** 1995;22(3):216-30 (167 ref.)

THERAPY

Blindness due to electrocoagulation following functional endoscopic sinus surgery. Vanden Abeele D, et al. **J Laryngol Otol** 1996 Mar;110(3):261-4 (26 ref.)

POSTOPERATIVE WOUND INFECTION see **SURGICAL WOUND INFECTION**

POSTPARTUM DEPRESSION see **DEPRESSION, POSTPARTUM**

POSTPARTUM HEMORRHAGE

EPIDEMIOLOGY

Postpartum haemorrhage. Jouppila P. **Curr Opin Obstet Gynecol** 1995 Dec;7(6):446-50 (20 ref.)

[Postpartum hemorrhage. Current management] Bertault D, et al. **Presse Med** 1995 Oct 14;24(30):1397-9 (15 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

Prevention of postpartum haemorrhage. de Groot AN. **Baillieres Clin Obstet Gynaecol** 1995 Sep;9(3):619-31 (41 ref.)

THERAPY

Postpartum haemorrhage. Jouppila P. **Curr Opin Obstet Gynecol** 1995 Dec;7(6):446-50 (20 ref.)

Place of emergency arterial embolisation in obstetric haemorrhage about 16 personal cases. Merland JJ, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Mar;65(1):141-3 (20 ref.)

[Hemorrhage during the third stage of labor and the postpartum period] Hohlfeld P. **Rev Med Suisse Romande** 1996 Apr;116(4):261-5 (33 ref.) **(Fre)**

POSTPARTUM PERIOD see **PUERPERIUM**

POSTPHLEBITIC DISEASE see **POSTPHLEBITIC SYNDROME**

POSTPHLEBITIC SYNDROME

Pathogenesis and pathophysiology of the post-thrombotic syndrome: clinical implications. Rutherford RB. **Semin Vasc Surg** 1996 Mar;9(1):21-5 (22 ref.)

DRUG THERAPY

[Prevention and treatment of thrombosis in pregnancy] Winkler UH, et al. **Geburtshilfe Frauenheilkd** 1996 Jun; 56(6):301-12 (83 ref.) (Eng. Abstr.) **(Ger)**

POSTPHLEBITIC ULCER see **POSTPHLEBITIC SYNDROME**

POSTPOLIOMYELITIS MUSCULAR ATROPHY see **POSTPOLIOMYELITIS SYNDROME**

POSTPOLIOMYELITIS SYNDROME

The challenge of the continuing effects of poliomyelitis in New Zealand. Botting CH, et al. **N Z Med J** 1995 Sep 22;108(1008):386-8 (26 ref.)

[Postpoliomyelitis syndrome and progressive postpoliomyelitis muscular atrophy] Bednařík J, et al. **Cas Lek Cesk** 1995 Dec 6;134(23):746-8 (25 ref.) (Eng. Abstr.) **(Cze)**

COMPLICATIONS

Achalasia. A possible late cause of postpolio dysphagia. Benini L, et al. **Dig Dis Sci** 1996 Mar;41(3):516-8 (20 ref.)

DIAGNOSIS

Recognizing post-polio syndrome. Bartfeld H, et al. **Hosp Pract (Off Ed)** 1996 May 15;31(5):95-7, 101-3, 107 passim (6 ref.)

PHYSIOPATHOLOGY

Postpoliomyelitis syndrome problems of knee function: a review. Grant AD, et al. **Bull Hosp Jt Dis** 1993-95; 53(4):27-9 (16 ref.)

[Post-polio syndrome; the limit of neuromuscular adaptation?] Nollet F, et al. **Ned Tijdschr Geneeskd** 1996 Jun 1;140(22):1169-73 (39 ref.) **(Dut)**

POST-TRANSCRIPTIONAL RNA MODIFICATION see **RNA PROCESSING, POST-TRANSCRIPTIONAL**

POST-TRANSLATIONAL ISOPRENYLATION see **PROTEIN ISOPRENYLATION**

POST-TRANSLATIONAL PROTEIN MODIFICATION see **PROTEIN PROCESSING, POST-TRANSLATIONAL**

POST-TRAUMATIC STRESS DISORDERS see **STRESS DISORDERS, POST-TRAUMATIC**

POSTURE

see related
HYPOTENSION, ORTHOSTATIC
KINESICS

Positioning your patient properly. Metzler DJ, et al. **Am J Nurs** 1996 Mar;96(3):33-7 (21 ref.)

Benign paroxysmal positional vertigo: analysis of 44 cases treated by the canalith repositioning procedure of Epley. Weider DJ, et al. **Am J Otol** 1994 May;15(3):321-6 (44 ref.)

Intraoperative positioning of surgical patients. McEwen DR. **AORN J** 1996 Jun;63(6):1059-63, 1066-79; quiz 1080-6 (38 ref.)

Benign paroxysmal positional vertigo. Gordon N. **Br J Clin Pract** 1996 Jun;50(4):208-10 (17 ref.)

Posturography--applications and limitations in the management of the dizzy patient. Harcourt JP. **Clin Otolaryngol** 1995 Aug;20(4):299-302 (24 ref.)

Influence of body position on breathing and its implications for the evaluation and treatment of speech and voice disorders. Hoit JD. **J Voice** 1995 Dec;9(4):341-7 (37 ref.)

Phobic postural vertigo. Brandt T. **Neurology** 1996 Jun; 46(6):1515-9 (31 ref.)

PHYSIOLOGY

New diagnostic tests for the function of utricles, saccules and somatic graviceptors. Mittelstaedt H. **Acta Otolaryngol Suppl (Stockh)** 1995;520 Pt 1:188-93 (5 ref.)

Neuroanatomical and neurophysiological bases of postural control. Mori S, et al. **Adv Neurol** 1995;67:289-303 (59 ref.)

Dangling: a review of relevant physiology, research, and practice. Winslow EH, et al. **Heart Lung** 1995 Jul-Aug; 24(4):263-72 (35 ref.)

Neurodevelopmental treatment: application to nursing and effects on the hemiplegic stroke patient. Hafsteinsdóttir TB. **J Neurosci Nurs** 1996 Feb;28(1):36-47 (45 ref.)

Neural networks that co-ordinate locomotion and body orientation in lamprey. Grillner S, et al. **Trends Neurosci** 1995 Jun;18(6):270-9 (64 ref.)

[Body positions which increase orthostatic tolerance] Wieling W, et al. **Ned Tijdschr Geneeskd** 1996 Jul 6;140(27):1394-7 (22 ref.) **(Dut)**

[Relationship between sleeping position and sudden infant death syndrome] Eidelman A, et al. **Harefuah** 1995 Sep; 129(5-6):197-200 (38 ref.) **(Heb)**

[Jaw position, head position, body posture: development of an integrated system of examination, Part I] Takigawa T, et al. **Kokubyo Gakkai Zasshi** 1995 Sep;62(3):441-50 (23 ref.) (Eng. Abstr.) **(Jpn)**

POSTVIRAL FATIGUE SYNDROME see **FATIGUE SYNDROME, CHRONIC**

POTASSIUM

see related
HYPERKALEMIA
HYPOKALEMIA

BLOOD

[Potassium] Kinouchi T. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:753-7 (26 ref.) **(Jpn)**

METABOLISM

K+ balance in humans during exercise. Hallén J. **Acta Physiol Scand** 1996 Mar;156(3):279-86 (38 ref.)

Effects of training on potassium, calcium and hydrogen ion regulation in skeletal muscle and blood during exercise. McKenna MJ, et al. **Acta Physiol Scand** 1996 Mar; 156(3):335-46 (68 ref.)

Extrarenal potassium adaptation: review of a concept [editorial] Spital A, et al. **Am J Nephrol** 1995;15(5):367-73 (29 ref.)

Proton and potassium transport by H+/K(+)-ATPases. van Driel IR, et al. **Clin Exp Pharmacol Physiol** 1995 Dec; 22(12):952-60 (91 ref.)

Molecular characterization of the epithelial Na-K-Cl cotransporter isoforms. Payne JA, et al. **Curr Opin Cell Biol** 1995 Aug;7(4):493-503 (73 ref.)

Potassium homeostasis and hyperkalemic syndromes. Clark BA, et al. **Endocrinol Metab Clin North Am** 1995 Sep; 24(3):573-91 (84 ref.)

The stimulation of Na,K,Cl cotransport and of system A for neutral amino acid transport is a mechanism for cell volume increase during the cell cycle. Bussolati O, et al. **FASEB J** 1996 Jun;10(8):920-6 (49 ref.)

Synaptic feed-backs mediated by potassium ions. Matyushkin DP, et al. **Gen Physiol Biophys** 1995 Oct;14(5):369-81 (45 ref.)

Potassium regulation during exercise and recovery in humans: implications for skeletal and cardiac muscle. Lindinger MI. **J Mol Cell Cardiol** 1995 Apr;27(4):1011-22 (83 ref.)

Effects of training on potassium homeostasis during exercise. McKenna MJ. **J Mol Cell Cardiol** 1995 Apr;27(4):941-9 (52 ref.)

View of K+ secretion through the apical K channel of cortical collecting duct. Wang WH. **Kidney Int** 1995 Oct; 48(4):1024-30 (87 ref.)

PHYSIOLOGY

Role of potassium in the regulation of systemic physiological function during exercise. Paterson DJ. **Acta Physiol Scand** 1996 Mar;156(3):287-94 (77 ref.)

Potassium and fatigue: the pros and cons. Sjøgaard G. **Acta Physiol Scand** 1996 Mar;156(3):257-64 (58 ref.)

Role of interstitial potassium. Sjøgaard G, et al. **Adv Exp Med Biol** 1995;384:69-80 (81 ref.)

Routes of calcium entry and extrusion in turtle hair cells. Tucker T, et al. **Ann N Y Acad Sci** 1996 Jun 19;781:123-37 (44 ref.)

URINE

Urea recycling: an aid to the excretion of potassium during antidiuresis. Halperin ML, et al. **Nephron** 1996;72(4):507-11 (32 ref.)

POTASSIUM CHANNELS

see related
NA(+)-K(+)-EXCHANGING ATPASE

[About K+ channels] Higashida H, et al. **Tanpakushitsu Kakusan Koso** 1995 Nov;40(15):2275-9 (29 ref.) **(Jpn)**

[A pH-sensitive K+ channel] Suzuki M. **Tanpakushitsu Kakusan Koso** 1995 Nov;40(15):2307-10 (8 ref.) **(Jpn)**

CHEMISTRY

The role of potassium channels in excitable cells. Edwards G, et al. **Diabetes Res Clin Pract** 1995 Aug;28 Suppl:S57-66 (37 ref.)

Structural motifs underlying voltage-dependent K+ channel function. Taglialatela M, et al. **Kidney Int** 1995 Oct; 48(4):918-22 (80 ref.)

[Primary structure and biophysical properties of inward rectifier K+ channels] Kubo Y. **Tanpakushitsu Kakusan Koso** 1995 Nov;40(15):2288-96 (37 ref.) **(Jpn)**

DRUG EFFECTS

Activation of ATP-sensitive potassium channels: a novel pharmacological approach to myocardial protection? Hearse DJ. **Cardiovasc Res** 1995 Jul;30(1):1-17 (94 ref.)

Do KCa channels and carbonic anhydrase play a role in thiazide-induced hyperglycaemia? Pickkers P, et al.

POTASSIUM CHANNELS

J Hum Hypertens 1995 Aug;9(8):691–3 (22 ref.)
Depolarization-induced 86Rb+ efflux in CHO cells expressing a recombinant potassium channel. Hu W, et al. **J Pharmacol Toxicol Methods** 1995 Sep;34(1):1–7 (83 ref.)
Scorpion venoms: taking the sting out of lung disease. Rogers DF. **Thorax** 1996 May;51(5):546–8 (12 ref.)
Modulation of channel function by polyamines. Johnson TD. **Trends Pharmacol Sci** 1996 Jan;17(1):22–7 (52 ref.)

GENETICS

The inward rectifier potassium channel family. Doupnik CA, et al. **Curr Opin Neurobiol** 1995 Jun;5(3):268–77 (86 ref.)
Surfing the DNA databases for K+ channels nets yet more diversity. Salkoff L, et al. **Neuron** 1995 Sep;15(3):489–92 (35 ref.)
Molecular physiology of cardiac potassium channels. Deal KK, et al. **Physiol Rev** 1996 Jan;76(1):49–67 (186 ref.)
The molecular organization of voltage-dependent K+ channels in vivo. Sheng M, et al. **Prog Brain Res** 1995; 105:87–93 (30 ref.)

ISOLATION & PURIFICATION

Purification and characterization of epithelial Ca(2+)-activated K+ channels. Klaerke DA. **Kidney Int** 1995 Oct;48(4):1047–56 (63 ref.)

METABOLISM

Criteria for a mediator or effector of myocardial preconditioning: do KATP channels meet the requirements? Gross GJ, et al. **Basic Res Cardiol** 1996 Jan–Feb;91(1):31–4 (12 ref.)
Regulation of ATP-sensitive potassium channels by phosphorylation. Light P. **Biochim Biophys Acta** 1996 May 6;1286(1):65–73 (139 ref.)
Ion channels, oxygen sensation and signal transduction in pulmonary arterial smooth muscle. Kozlowski RZ. **Cardiovasc Res** 1995 Sep;30(3):318–25 (73 ref.)
The structure, regulation and pathophysiology of potassium channels. Desir GV. **Curr Opin Nephrol Hypertens** 1995 Sep;4(5):402–5 (22 ref.)
Hypoxic and metabolic regulation of voltage-gated K+ channels in rat pulmonary artery smooth muscle cells. Yuan XJ, et al. **Exp Physiol** 1995 Sep;80(5):803–13 (24 ref.)
Depolarization-induced 86Rb+ efflux in CHO cells expressing a recombinant potassium channel. Hu W, et al. **J Pharmacol Toxicol Methods** 1995 Sep;34(1):1–7 (83 ref.)
Molecular characterization of voltage and cyclic nucleotide-gated potassium channels in kidney. Desir GV. **Kidney Int** 1995 Oct;48(4):1031–5 (57 ref.)
Renal potassium channels: an overview. Giebisch G. **Kidney Int** 1995 Oct;48(4):1004–9 (46 ref.)
Cross-talk between sodium and potassium channels in tight epithelia. Harvey BJ. **Kidney Int** 1995 Oct;48(4):1191–9 (100 ref.)
An ATP-regulated, inwardly rectifying potassium channel from rat kidney (ROMK). Hebert SC. **Kidney Int** 1995 Oct; 48(4):1010–6 (66 ref.)
K+ channels in the basolateral membrane of rat cortical collecting duct. Hirsch J, et al. **Kidney Int** 1995 Oct; 48(4):1036–46 (89 ref.)
Purification and characterization of epithelial Ca(2+)-activated K+ channels. Klaerke DA. **Kidney Int** 1995 Oct;48(4):1047–56 (63 ref.)
View of K+ secretion through the apical K channel of cortical collecting duct. Wang WH. **Kidney Int** 1995 Oct; 48(4):1024–30 (87 ref.)
Cross-talk and the role of KATP channels in the proximal tubule. Welling PA. **Kidney Int** 1995 Oct;48(4):1017–23 (79 ref.)
Cloning of a pH sensitive K+ channel in the kidney. Suzuki M. **Nippon Jinzo Gakkai Shi** 1995 Aug;37(8):422–7 (15 ref.)
[Molecular mechanism of the G protein regulation of inwardly rectifying potassium channels] Yamada M, et al. **Tanpakushitsu Kakusan Koso** 1995 Nov;40(15):2297–306 (36 ref.) **(Jpn)**

PHYSIOLOGY

Modulation of muscle contractility during fatigue and recovery by ATP sensitive potassium channel. Renaud JM, et al. **Acta Physiol Scand** 1996 Mar;156(3):203–12 (50 ref.)
G protein regulation of cardiac muscarinic potassium channel. Kurachi Y. **Am J Physiol** 1995 Oct;269(4 Pt 1):C821–30 (80 ref.)
Cardiac ATP-sensitive K+ channels: regulation by intracellular nucleotides and K+ channel-opening drugs. Terzic A, et al. **Am J Physiol** 1995 Sep;269(3 Pt 1):C525–45 (196 ref.)
Ionic conductances and hair cell tuning in the turtle cochlea. Art JJ, et al. **Ann N Y Acad Sci** 1996 Jun 19;781:103–22 (27 ref.)
Myocardial potassium channels: electrophysiological and molecular diversity. Barry DM, et al. **Annu Rev Physiol** 1996;58:363–94 (211 ref.)
Do ATP-sensitive potassium channels play a role in myocardial stunning? Gross GJ. **Basic Res Cardiol** 1995 Jul–Aug;90(4):266–8 (10 ref.)
Co-assembly of potassium channel subunits in Drosophila: the combinatorial hypothesis revisited. Wu CF, et al. **Chin J Physiol** 1995;38(3):131–8 (50 ref.)
Of oocytes and runny noses [editorial; comment] Rosen MR. **Circulation** 1996 Aug 15;94(4):607–9 (20 ref.) Comment on: Circulation 1996 Aug 15;94(4):817–23.
Molecular and functional diversity of K+ channels. Christie MJ. **Clin Exp Pharmacol Physiol** 1995 Dec;22(12):944–51 (68 ref.)
K+ channels: generating excitement in pancreatic beta-cells. Dukes ID, et al. **Diabetes** 1996 Jul;45(7):845–53 (143 ref.)
The beta-cell response to oral hypoglycemic agents. Cook DL. **Diabetes Res Clin Pract** 1995 Aug;28 Suppl:S81–9 (72 ref.)
The role of potassium channels in excitable cells. Edwards G, et al. **Diabetes Res Clin Pract** 1995 Aug;28 Suppl:S57–66 (37 ref.)
The molecular interaction of sulfonylureas with beta-cell ATP-sensitive K(+)-channels. Kramer W, et al. **Diabetes Res Clin Pract** 1995 Aug;28 Suppl:S67–80 (25 ref.)
Potassium channels in the cardiovascular system. Pogátsa G. **Diabetes Res Clin Pract** 1995 Aug;28 Suppl:S91–8 (48 ref.)
Sulfonylurea receptors and mechanism of sulfonylurea action. Panten U, et al. **Exp Clin Endocrinol Diabetes** 1996; 104(1):1–9 (100 ref.)
The role of ATP sensitive potassium channels in myocardial protection. Cason BA, et al. **J Card Surg** 1995 Jul;10(4 Suppl):441–4 (32 ref.)
Mechanisms of K+ channel regulation. Breitwieser GE. **J Membr Biol** 1996 Jul;152(1):1–11 (197 ref.)
Structural motifs underlying voltage-dependent K+ channel function. Taglialatela M, et al. **Kidney Int** 1995 Oct; 48(4):918–22 (80 ref.)
Clinical relevance of ATP-dependent potassium channels. Ligtenberg JJ, et al. **Neth J Med** 1995 Nov;47(5):241–51 (82 ref.)
Molecular physiology of cardiac potassium channels. Deal KK, et al. **Physiol Rev** 1996 Jan;76(1):49–67 (186 ref.)
Potassium currents in motoneurones. McLarnon JG. **Prog Neurobiol** 1995 Dec;47(6):513–31 (82 ref.)
Ca(2+)-activated K+ currents in neurones: types, physiological roles and modulation. Sah P. **Trends Neurosci** 1996 Apr;19(4):150–4 (66 ref.)
Modulation of channel function by polyamines. Johnson TD. **Trends Pharmacol Sci** 1996 Jan;17(1):22–7 (52 ref.)
[Hyperpolarization-relaxation coupling in vascular smooth muscle] Yanagisawa T. **Nippon Yakurigaku Zasshi** 1995 Sep;106(3):157–69 (57 ref.) (Eng. Abstr.) **(Jpn)**
[Primary structure and biophysical properties of inward rectifier K+ channels] Kubo Y. **Tanpakushitsu Kakusan Koso** 1995 Nov;40(15):2288–96 (37 ref.) **(Jpn)**
[Molecular structure and function of voltage-dependent K channels] Yamane T, et al. **Tanpakushitsu Kakusan Koso** 1995 Nov;40(15):2280–7 (36 ref.) **(Jpn)**

POTASSIUM DEFICIENCY

see related
HYPOKALEMIA

COMPLICATIONS

Vitamin and mineral deficiencies which may predispose to glucose intolerance of pregnancy. Jovanovic-Peterson L, et al. **J Am Coll Nutr** 1996 Feb;15(1):14–20 (64 ref.)

METABOLISM

Effects of K+, Mg2+ deficiency and adrenal steroids on Na+, K(+)-pump concentration in skeletal muscle. Dørup I. **Acta Physiol Scand** 1996 Mar;156(3):305–11 (51 ref.)

PHYSIOPATHOLOGY

Role of skeletal muscle sodium pumps in the adaptation to potassium deprivation. McDonough AA, et al. **Acta Physiol Scand** 1996 Mar;156(3):295–304 (77 ref.)

POTASSIUM, DIETARY

ADVERSE EFFECTS

Dietary salt and blood pressure [comment] Dyer AR, et al. **Nat Med** 1995 Oct;1(10):994–6 (18 ref.) Comment on: Nat Med 1995 Oct;1(10):1009–16.

POTASSIUM GLUTAMATE see **GLUTAMATES**

POTASSIUM PUMP see **NA(+)-K(+)-EXCHANGING ATPASE**

POTATO VIRUS Y see **POTYVIRUS**

POTATOES

ENZYMOLOGY

The bifunctional cytochrome c reductase/processing peptidase complex from plant mitochondria. Braun HP, et al. **J Bioenerg Biomembr** 1995 Aug;27(4):423–36 (110 ref.)

POTT'S DISEASE see **TUBERCULOSIS, SPINAL**

POTYVIRUS

PHYSIOLOGY

Potyviral HC-Pro: a multifunctional protein. Maia IG, et al. **J Gen Virol** 1996 Jul;77 (Pt 7):1335–41 (51 ref.)

POULTRY

Playing chicken with people: the occupational safety and health consequences of throughput über alles. Linder M. **Int J Health Serv** 1995;25(4):633–66 (184 ref.)

PHYSIOLOGY

["Breeding for distress" in fowl] Bartels T. **DTW Dtsch Tierarztl Wochenschr** 1995 Mar;102(3):117–9 (34 ref.) (Eng. Abstr.) **(Ger)**

POULTRY DISEASES

DIAGNOSIS

[Infectious coryza: review of diagnostic methods and vaccines] Blackall PJ, et al. **Rev Argent Microbiol** 1995 Jul–Sep;27(3):156–74 (62 ref.) **(Spa)**

EPIDEMIOLOGY

Australian studies on Newcastle disease virus. The French heritage. Spradbrow PB, et al. **Vet Microbiol** 1995 Sep; 46(1–3):15–9, 1–2 (14 ref.)

PREVENTION & CONTROL

Disinfecting poultry production premises. Meroz M, et al. **Rev Sci Tech** 1995 Jun;14(2):273–91 (27 ref.)
Application of disinfectants in poultry hatcheries. Samberg Y, et al. **Rev Sci Tech** 1995 Jun;14(2):365–80 (31 ref.)
[Infectious coryza: review of diagnostic methods and vaccines] Blackall PJ, et al. **Rev Argent Microbiol** 1995 Jul–Sep;27(3):156–74 (62 ref.) **(Spa)**

POVERTY

see related
CULTURAL DEPRIVATION

Coming to voice: the power of emancipatory community interventions. Drevdahl D. **ANS Adv Nurs Sci** 1995 Dec; 18(2):13–24 (50 ref.)
Cancer among special populations: women, ethnic minorities, and the poor. Haynes A. **Environ Health Perspect** 1995 Nov;103 Suppl 8:319–20 (10 ref.)
The effects of poverty environments on elders' subjective well-being: a conceptual model. Brown V. **Gerontologist** 1995 Aug;35(4):541–8 (48 ref.)
What is the ultimate cause of socio-economic inequalities in health? An explanation in terms of evolutionary psychology. Charlton BG. **J R Soc Med** 1996 Jan;89(1):3–8 (47 ref.)
Growing up in a socially toxic environment: life for children and families in the 1990s. Garbarino J. **Nebr Symp Motiv** 1995;42:1–20 (37 ref.)
Rural deprivation. Bonnar BC. **Occas Pap R Coll Gen Pract** 1995 Sep;(71):26–9 (21 ref.)
Nutritional risk factors among low-income pregnant US women: the Centers for Disease Control and Prevention (CDC) Pregnancy Nutrition Surveillance System, 1979 through 1993. Perry GS, et al. **Semin Perinatol** 1995 Jun; 19(3):211–21 (46 ref.)
Problems with public health outreach. Azzarto J. **Soc Work Health Care** 1995;22(1):57–67 (20 ref.)

PSYCHOLOGY

Perils and pitfalls on the path to normal potential: the role of impaired attention. Homage to Herbert G. Birch. Mirsky AF. **J Clin Exp Neuropsychol** 1995 Aug;17(4):481–98 (36 ref.)

STATISTICS & NUMERICAL DATA

Deprivation indices: their interpretation and use in relation to health. Carstairs V. **J Epidemiol Community Health** 1995 Dec;49 Suppl 2:S3–8 (27 ref.)

POVERTY AREAS

Inner-city hospitals: a call for research. Gautam K, et al. **J Health Care Poor Underserved** 1995;6(4):387–402 (49 ref.)

POWASSAN VIRUS see **ENCEPHALITIS VIRUSES, TICK-BORNE**

POWER (PSYCHOLOGY)

Anger in nurses: don't lose it, use it. Droppleman PG, et al. **Am J Nurs** 1996 Apr;96(4):26–31; quiz 32 (11 ref.)
Advocacy and empowerment: dichotomous or synchronous concepts? Rafael AR. **ANS Adv Nurs Sci** 1995 Dec; 18(2):25–32 (56 ref.)
The paradoxical power of the depressed patient: a problem for the ranking theory of depression. Price J, et al. **Br J Med Psychol** 1995 Sep;68 (Pt 3):193–206; discussion 207–22 (37 ref.)
Terms of address: implications for nursing. Bowie I.

J Adv Nurs 1996 Jan;23(1):113–9 (17 ref.)
An analysis of the concept of empowerment. Rodwell CM. J Adv Nurs 1996 Feb;23(2):305–13 (74 ref.)
Gender-power relations and safer sex negotiation. Taylor BM. J Adv Nurs 1995 Oct;22(4):687–93 (46 ref.)
Empowerment of graduate nursing students: a dialogue toward change. Roberts SJ, et al. J Prof Nurs 1996 Jul–Aug;12(4):233–9 (25 ref.)

POWER, PERSONAL see **POWER (PSYCHOLOGY)**

POWER PLANTS

Biokinetics of nuclear fuel compounds and biological effects of nonuniform radiation. Lang S, et al. Environ Health Perspect 1995 Oct;103(10):920–34 (191 ref.)
Cancer consequences of the Chernobyl accident in Europe outside the former USSR: a review. Sali D, et al. Int J Cancer 1996 Jul 29;67(3):343–52 (33 ref.)
[From Hiroshima to Chernobyl. Increasing number of late fatal cases of cancer] Drottz-Sjöberg BM, et al. Lakartidningen 1995 Nov 1;92(44):4100–2, 4105 (18 ref.) **(Swe)**

POWER, PROFESSIONAL see **POWER (PSYCHOLOGY)**

POWER, SOCIAL see **POWER (PSYCHOLOGY)**

POWER SOURCES

Power sources in endoscopic surgery. Sutton C. Curr Opin Obstet Gynecol 1995 Aug;7(4):248–56 (43 ref.)
Power sources. Luciano AA. Obstet Gynecol Clin North Am 1995 Sep;22(3):423–43 (36 ref.)

ADVERSE EFFECTS

Health risks of electric and magnetic fields caused by high-voltage systems in Finland. Valjus J. Scand J Work Environ Health 1996 Apr;22(2):85–93 (31 ref.)

POWER SUPPLIES see **POWER SOURCES**

POXVIRIDAE

Non-replicating expression vectors: applications in vaccine development and gene therapy. Limbach KJ, et al. Epidemiol Infect 1996 Jun;116(3):241–56 (87 ref.)

GENETICS

Poxvirus-based vectors as vaccine candidates. Pincus S, et al. Biologicals 1995 Jun;23(2):159–64 (31 ref.)

IMMUNOLOGY

[Present state of preclinical research on the efficacy and safety of para immunity inducers from poxviruses. A study of the literature] Mayr B, et al. Tierarztl Prax 1995 Dec; 23(6):542–52 (39 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Cytokine receptors encoded by poxviruses: a lesson in cytokine biology. Alcamí A, et al. Immunol Today 1995 Oct;16(10):474–8 (39 ref.)

POXVIRIDAE INFECTIONS

VETERINARY

[Present state of preclinical research on the efficacy and safety of para immunity inducers from poxviruses. A study of the literature] Mayr B, et al. Tierarztl Prax 1995 Dec; 23(6):542–52 (39 ref.) (Eng. Abstr.) **(Ger)**

POXVIRUS INFECTIONS see **POXVIRIDAE INFECTIONS**

POXVIRUS OFFICINALE see **VACCINIA VIRUS**

POXVIRUS VARIOLAE see **VARIOLA VIRUS**

PP60(C-SRC) see **PROTO-ONCOGENE PROTEIN PP60(C-SRC)**

PPLO see **MYCOPLASMA**

PRACTICE GUIDELINES

Establishing pain policies in emergency medicine. Terndrup TE. Ann Emerg Med 1996 Apr;27(4):408–11 (31 ref.)
Developing evidence-based clinical practice guidelines: lessons learned by the US Preventive Services Task Force. Woolf SH, et al. Annu Rev Public Health 1996;17:511–38 (104 ref.)
Review of new guidelines for management of dyslipidaemia. Betteridge DJ, et al. Baillieres Clin Endocrinol Metab 1995 Oct;9(4):867–90 (64 ref.)
Clinical practice guidelines—do they enhance value for money in health care? Grimshaw JM, et al. Br Med Bull 1995 Oct;51(4):927–40 (33 ref.)
Impact of guidelines for antihypertensive treatment on clinical practice. Chalmers J. Clin Exp Hypertens 1996 Apr-May;18(3–4):415–23 (15 ref.)
Indicators for assessment of compliance with quality standards for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. Gross PA, et al. Clin Infect Dis 1995 Aug;21 Suppl 1:S138–41 (0 ref.)
Impact of varying panel membership on ratings of appropriateness in consensus panels: a comparison of a multi- and single disciplinary panel. Coulter I, et al. Health Serv Res 1995 Oct;30(4):577–91 (34 ref.)
Practice parameters in dentistry: where do we stand? Shugars DA, et al. J Am Dent Assoc 1995 Aug;126(8):1134–43 (36 ref.)
Clinical practice guidelines: their purposes and uses [see comments] Taler G. J Am Geriatr Soc 1996 Sep; 44(9):1108–11 (25 ref.) Comment in: J Am Geriatr Soc 1996 Sep;44(9):1123–4.
Hope or experience? Clinical practice guidelines in family practice [editorial] Worrall G, et al. J Fam Pract 1996 Apr; 42(4):353–6 (33 ref.)
Human rights and medical practice, including reference to the joint Oslo statements of September 1993 and March 1994. Alderslade R. J Public Health Med 1995 Sep; 17(3):335–42 (7 ref.)
Quality improvement guidelines for the treatment of acute pain and cancer pain. American Pain Society Quality of Care Committee [see comments] JAMA 1995 Dec 20; 274(23):1874–80 (67 ref.) Comment in: JAMA 1995 Dec 20;274(23):1881–2.
The WHO analgesic ladder for cancer pain management. Stepping up the quality of its evaluation [see comments] Jadad AR, et al. JAMA 1995 Dec 20;274(23):1870–3 (40 ref.) Comment in: JAMA 1995 Dec 20;274(23):1881–2. Comment in: JAMA 1996 Mar 20;275(11):835; discussion 836. Comment in: JAMA 1996 Mar 20;275(11):835–6.
Why oncologists should get involved in practice guideline development. ASCO Health Services Committee Program. Oncology (Huntingt) 1995 May;9(5):412, 415 (0 ref.)
The role of oncology clinical practice guidelines in the managed care era. Winn RJ. Oncology (Huntingt) 1995 Nov;9(11 Suppl):177–83 (28 ref.)
Clinical guidelines and their implementation. Forrest D, et al. Postgrad Med J 1996 Jan;72(843):19–22 (13 ref.)
Inhaled glucocorticoids: new developments relevant to updating of the asthma management guidelines. Barnes PJ. Respir Med 1996 Aug;90(7):379–84 (44 ref.)
Inhaled sodium cromoglycate. Holgate ST. Respir Med 1996 Aug;90(7):387–90 (45 ref.)
The efficacy and therapeutic position of nedocromil sodium. Holgate ST. Respir Med 1996 Aug;90(7):391–4 (32 ref.)
Patient education and guided self-management plans. Neville R. Respir Med 1996 Aug;90(7):385–6 (15 ref.)
Do-not-resuscitate orders: towards a policy in Singapore [see comments] Sahadevan S, et al. Singapore Med J 1995 Jun; 36(3):267–70 (28 ref.) Comment in: Singapore Med J 1995 Jun;36(3):258–9.
Use of knee braces in sport. Current recommendations [editorial] Albright JP, et al. Sports Med 1995 Nov; 20(5):281–301 (49 ref.)
Practice guidelines in surgery. Wright JG, et al. Surgery 1996 Jun;119(6):706–9 (29 ref.)
[Recommendations for clinical practice. Methodological bases and use] Durieux P, et al. Ann Med Interne (Paris) 1995;146(6):438–46 (50 ref.) **(Fre)**
[Standards, options and recommendations for the practice of external radiotherapy and brachytherapy in oncology. National Federation of Centers for the fight against Cancer] Bey P, et al. Bull Cancer (Paris) 1995 Oct;82(10):811–22 (81 ref.) **(Fre)**
[Hypertension. A new way to approach an old problem] Aubin M. Can Fam Physician 1996 Apr;42:702–8 (30 ref.) (Eng. Abstr.) **(Fre)**
[Guidelines for the treatment of asthma] Akiyama K. Nippon Naika Gakkai Zasshi 1996 Feb 10;85(2):199–204 (3 ref.) **(Jpn)**
[Guide line for gene therapy] Takaku F. Tanpakushitsu Kakusan Koso 1995 Dec;40(17):2498–502 (4 ref.) **(Jpn)**

STANDARDS

Evaluation of clinical practice guidelines. Basinski AS. Can Med Assoc J 1995 Dec 1;153(11):1575–81 (40 ref.)
Clinical guidelines: an introduction to their development and implementation. Duff LA, et al. J Adv Nurs 1996 May; 23(5):887–95 (35 ref.)
Clinical practice guidelines in oncology: pros and cons [editorial] Markman M. J Cancer Res Clin Oncol 1996; 122(7):381–2 (5 ref.)

PRACTICE MANAGEMENT, DENTAL

Dental practice considerations. Griffin AP, et al. Dent Clin North Am 1995 Oct;39(4):861–75 (14 ref.)

PRACTICE MANAGEMENT, MEDICAL

ORGANIZATION & ADMINISTRATION

Nursing homes: what you need to know for quality patient care. Cefalu CA. Geriatrics 1995 Dec;50(12):37–40, 49–50 (22 ref.)

PRACTICE PATTERNS, PROFESSIONAL see **PHYSICIAN'S PRACTICE PATTERNS**

PRADER-WILLI SYNDROME

COMPLICATIONS

[Genetic syndrome with obesity] Tsuda K, et al. Nippon Rinsho 1995 Jun;53 Suppl:436–40 (19 ref.) **(Jpn)**

SURGERY

[Bronchospasm during anesthesia in a patient with Prader-Willi syndrome] Kawahito S, et al. Masui 1995 Dec;44(12):1675–9 (19 ref.) (Eng. Abstr.) **(Jpn)**

PRASTERONE

ANALOGS & DERIVATIVES

Biosynthesis of DHEAS by the human adrenal cortex and its age-related decline. Hornsby PJ. Ann N Y Acad Sci 1995 Dec 29;774:29–46 (64 ref.)
DHEA and peripheral androgen and estrogen formation: intracinology. Labrie F, et al. Ann N Y Acad Sci 1995 Dec 29;774:16–28 (70 ref.)
Neuronal actions of dehydroepiandrosterone. Possible roles in brain development, aging, memory, and affect. Majewska MD. Ann N Y Acad Sci 1995 Dec 29;774:111–20 (86 ref.)
Does DHEAS restore immune competence in aged animals through its capacity to function as a natural modulator of peroxisome activities? Spencer NF, et al. Ann N Y Acad Sci 1995 Dec 29;774:200–16 (129 ref.)
Dehydroepiandrosterone sulfate and aging. Vermeulen A. Ann N Y Acad Sci 1995 Dec 29;774:121–7 (54 ref.)
[Dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulfate (DHEA-S)] Okabe T, et al. Nippon Rinsho 1995 Mar;53 Su Pt 2:460–3 (10 ref.) **(Jpn)**

BLOOD

[Dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulfate (DHEA-S)] Okabe T, et al. Nippon Rinsho 1995 Mar;53 Su Pt 2:460–3 (10 ref.) **(Jpn)**

HISTORY

An abbreviated account of some aspects of the biochemistry of DHEA, 1934–1995. Lieberman S. Ann N Y Acad Sci 1995 Dec 29;774:1–15 (34 ref.)

METABOLISM

DHEA and peripheral androgen and estrogen formation: intracinology. Labrie F, et al. Ann N Y Acad Sci 1995 Dec 29;774:16–28 (70 ref.)

PHARMACOLOGY

Extrapulmonary effects of antenatally administered steroids. Padbury JF, et al. J Pediatr 1996 Feb;128(2):167–72 (61 ref.)

PHYSIOLOGY

Neuronal actions of dehydroepiandrosterone. Possible roles in brain development, aging, memory, and affect. Majewska MD. Ann N Y Acad Sci 1995 Dec 29;774:111–20 (86 ref.)
Dehydroepiandrosterone (DHEA) is a neuroactive neurosteroid. Robel P, et al. Ann N Y Acad Sci 1995 Dec 29;774:82–110 (75 ref.)
Dehydroepiandrosterone sulfate and aging. Vermeulen A. Ann N Y Acad Sci 1995 Dec 29;774:121–7 (54 ref.)
A review of dehydroepiandrosterone (DHEA). Shealy CN. Integr Physiol Behav Sci 1995 Sep-Dec;30(4):308–13 (52 ref.)
Dehydroepiandrosterone (DHEA): a fountain of youth? [editorial] Baulieu EE. J Clin Endocrinol Metab 1996 Sep; 81(9):3147–51 (14 ref.)
Dehydroepiandrosterone and body fat. Clore JN. Obes Res 1995 Nov;3 Suppl 4:613S–616S (46 ref.)
[Physiologic importance of dehydroepiandrosterone] Danenberg HD, et al. Harefuah 1996 Mar 1;130(5):353–6 (44 ref.) **(Heb)**

THERAPEUTIC USE

Mechanism of cancer preventive action of DHEA. Role of glucose-6-phosphate dehydrogenase. Schwartz AG, et al. Ann N Y Acad Sci 1995 Dec 29;774:180–6 (57 ref.)
Cancer prevention with dehydroepiandrosterone and non-androgenic structural analogs. Schwartz AG, et al. J Cell Biochem Suppl 1995;22:210–7 (58 ref.)

PRAVASTATIN

PHARMACOLOGY

[The pharmacology of the statins: the evidence of a direct antiatherosclerotic action] Raiteri M, et al. Ann Ital Med Int 1995 Oct;10 Suppl:35S–42S (74 ref.) (Eng. Abstr.) **(Ita)**

PRAVASTATIN

THERAPEUTIC USE

Treatment of hyperlipidemia after heart transplantation and rationale for the Heart Transplant Lipid Registry. Ballantyne CM, et al. **Am J Cardiol** 1996 Sep 1;78(5):532–5 (34 ref.)

PRAYER HEALING see **MENTAL HEALING**

PRAZOSIN

ANALOGS & DERIVATIVES

Blood pressure–lowering effect of adding grapefruit juice to nifedipine and terazosin in a patient with severe renovascular hypertension. Pisarik P. **Arch Fam Med** 1996 Jul–Aug;5(7):413–6 (17 ref.)

PHARMACOLOGY

Vascular alpha–adrenoceptors: from the gene to the human. Bylund DB, et al. **Can J Physiol Pharmacol** 1995 May; 73(5):533–43 (87 ref.)

PRE–B–CELL LEUKEMIA see **LEUKEMIA, PRE–B–CELL**

PREALBUMIN

ANALYSIS

[Prealbumin] Nakano E. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:186–8 (10 ref.) **(Jpn)**

GENETICS

Diagnosis of thyroid hormone transport protein anomalies: an overview. Langsteger W. **Acta Med Austriaca** 1996; 23(1–2):31–40 (140 ref.)

Leptomeningeal amyloid and variant transthyretins [comment] Benson MD. **Am J Pathol** 1996 Feb; 148(2):351–4 (19 ref.) Comment on: Am J Pathol 1996 Feb;148(2):361–6.

Vitreous amyloidosis in familial amyloidotic polyneuropathy. Report of a case with the Val30Met transthyretin mutation. Ciulla TA, et al. **Surv Ophthalmol** 1995 Nov–Dec; 40(3):197–206 (123 ref.)

PHYSIOLOGY

Hormone delivery systems to the brain–transthyretin. Schreiber G, et al. **Exp Clin Endocrinol Diabetes** 1995; 103(2):75–80 (51 ref.)

PREANESTHETIC MEDICATION

Use of oral premedicants in pediatric dental population. Krost BG, et al. **N Y State Dent J** 1996 Jan;62(1):40–3 (8 ref.)

[Medicamentous prevention of acid aspiration syndrome] Kurz–Müller K, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May; 31(4):261–5 (77 ref.) **(Ger)**

PREBETA–LIPOPROTEINS see **LIPOPROTEINS, VLDL**

PRECANCEROUS CONDITIONS

Premalignant and early malignant lesions in the gastrointestinal tract: definitions, terminology, and problems. Riddell RH. **Am J Gastroenterol** 1996 May; 91(5):864–72 (69 ref.)

Prospectives for cutaneous malignant melanoma. Considerations of the precursor state and heritability. Clark WH, et al. **Br Med Bull** 1995 Jul;51(3):717–46 (104 ref.)

Hereditary nonpolyposis colorectal cancer and colonic adenomas: aggressive adenomas? Lynch HT, et al. **Semin Surg Oncol** 1995 Nov–Dec;11(6):406–10 (24 ref.)

Premalignant changes in ulcerative colitis. Nixon JB, et al. **Semin Surg Oncol** 1995 Nov–Dec;11(6):386–93 (52 ref.)

The woman at high risk for breast cancer. Importance of hyperplasia. Page DL. **Surg Clin North Am** 1996 Apr; 76(2):221–30 (43 ref.)

CHEMISTRY

Molecular analysis of premalignant and carcinoma in situ lesions of the human breast. Steeg PS, et al. **Am J Pathol** 1996 Sep;149(3):733–8 (49 ref.)

[Biological markers of precancer of the large intestine] Zagrebin VM. **Arkh Patol** 1995 Jul–Aug;57(4):89–92 (50 ref.) (Eng. Abstr.) **(Rus)**

DIAGNOSIS

Nonmelanoma skin cancer. Epstein JH. **Compr Ther** 1996 Mar;22(3):179–82 (17 ref.)

DRUG THERAPY

The role of photodynamic therapy in the management of oral cancer and precancer. Hopper C. **Eur J Cancer B Oral Oncol** 1996 Mar;32B(2):71–2 (7 ref.)

Retinoids in cancer chemoprevention. Lotan R. **FASEB J** 1996 Jul;10(9):1031–9 (47 ref.)

Effects of protease inhibitors on levels of proteolytic activity in normal and premalignant cells and tissues. Kennedy AR, et al. **J Cell Biochem Suppl** 1995;22:188–94 (22 ref.)

ENZYMOLOGY

The role of glutathione S–transferases in head and neck squamous cell carcinogenesis. Bongers V, et al. **Eur J Cancer B Oral Oncol** 1995 Nov;31B(6):349–54 (63 ref.)

EPIDEMIOLOGY

Gastric premalignancy and cancer screening in high–risk patients. Yoshida S, et al. **Am J Gastroenterol** 1996 May; 91(5):839–43 (24 ref.)

Hereditary and environmental risk factors; clinical and laboratory risk matters for head and neck, especially oral, cancer and precancer. Johnson NW, et al. **Eur J Cancer Prev** 1996 Feb;5(1):5–17 (139 ref.)

Gastrointestinal cancer: epidemiological data and premalignant lesions. Hertan HI, et al. **Gastroenterologist** 1995 Sep;3(3):199–219 (189 ref.)

Oral cancer and precancer related to betel and miang chewing in Thailand: a review. Reichart PA. **J Oral Pathol Med** 1995 Jul;24(6):241–3 (17 ref.)

ETIOLOGY

Barrett's esophagus: a model of human neoplastic progression. Neshat K, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:577–83 (58 ref.)

Endoscopic appearance of dysplasia and cancer in inflammatory bowel disease. Tytgat GN, et al. **Eur J Cancer** 1995 Jul–Aug;31A(7–8):1174–7 (41 ref.)

Effectiveness of vaginal Papanicolaou smear screening after total hysterectomy for benign disease. Fetters MD, et al. **JAMA** 1996 Mar 27;275(12):940–7 (90 ref.)

Preneoplastic transformation of human mammary epithelial cells. Band V. **Semin Cancer Biol** 1995 Jun;6(3):185–92 (50 ref.)

Premalignant conditions of the small intestine. Ryan JC. **Semin Gastrointest Dis** 1996 Apr;7(2):88–93 (72 ref.)

GENETICS

Genetic markers and premalignancy. Grandjouan S. **Am J Gastroenterol** 1996 May;91(5):844–6 (31 ref.)

Somatic genetic changes in lung cancer and precancerous lesions. Sundaresan V, et al. **Ann Oncol** 1995;6 Suppl 1:27–31; discussion 31–2 (14 ref.)

Molecular biology of cervical cancer and its precursors. Park TW, et al. **Cancer** 1995 Nov 15;76(10 Suppl):1902–13 (90 ref.)

Molecular genetic changes found in human lung cancer and its precursor lesions. Gazdar AF, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:565–72 (77 ref.)

Molecular genetics of dysplasia in ulcerative colitis. Benhattar J, et al. **Eur J Cancer** 1995 Jul–Aug; 31A(7–8):1171–3 (15 ref.)

Hereditary and environmental risk factors; clinical and laboratory risk matters for head and neck, especially oral, cancer and precancer. Johnson NW, et al. **Eur J Cancer Prev** 1996 Feb;5(1):5–17 (139 ref.)

[Precancerous lesion in colorectal cancer] Nagawa H, et al. **Gan To Kagaku Ryoho** 1995 Dec;22(14):2043–7 (19 ref.) (Eng. Abstr.) **(Jpn)**

MICROBIOLOGY

Bacteria in the actio–pathogenesis of gastric cancer: a review. Houben GM, et al. **Scand J Gastroenterol Suppl** 1995; 212:13–8 (61 ref.)

PATHOLOGY

Barrett's esophagus and esophageal adenocarcinoma: the scope of the problem. Levine MS, et al. **Abdom Imaging** 1995 Jul–Aug;20(4):291–8 (69 ref.)

Benign to malignant progression in cervical squamous epithelium. Ehrmann RL. **Compr Ther** 1996 Feb; 22(2):67–75 (43 ref.)

Precancerous and cancerous lesions of the oral cavity. Summerlin DJ. **Dermatol Clin** 1996 Apr;14(2):205–23 (22 ref.)

Grading of dysplasia. Riddell RH. **Eur J Cancer** 1995 Jul–Aug;31A(7–8):1169–70 (14 ref.)

Pre–neoplastic lesions of the prostate. Parkinson MC. **Histopathology** 1995 Oct;27(4):301–11 (103 ref.)

Early de novo ovarian cancer and cancer developing in benign ovarian lesions. Scully RE. **Int J Gynaecol Obstet** 1995 Jul;49 Suppl:S9–15 (13 ref.)

Granulomatous slack skin: a possible precursor of Hodgkin's disease. DeGregorio R, et al. **J Am Acad Dermatol** 1995 Dec;33(6):1044–7 (22 ref.)

Premalignant keratinocytic neoplasms. Schwartz RA. **J Am Acad Dermatol** 1996 Aug;35(2 Pt 1):223–42 (399 ref.)

Pathology of ovarian cancer precursors. Scully RE. **J Cell Biochem Suppl** 1995;23:208–18 (23 ref.)

Biology of gastric cancer: gastritis–metaplasia–dysplasia sequence, role of H Pylori, and molecular correlates of tumor progression. Lynch P. **J Infus Chemother** 1995 Summer;5(3):93–6 (23 ref.)

Malignant and premalignant change in odontogenic cysts. Fanibunda K, et al. **J Oral Maxillofac Surg** 1995 Dec; 53(12):1469–72 (19 ref.)

Oral white lesions with special reference to precancerous and tobacco– related lesions: conclusions of an international symposium held in Uppsala, Sweden, May 18–21 1994. International Collaborative Group on Oral White Lesions. Axéll T, et al. **J Oral Pathol Med** 1996 Feb;25(2):49–54 (3 ref.)

Morphogenetic aspects of normal and abnormal prostatic growth. Bonkhoff H, et al. **Pathol Res Pract** 1995 Sep; 191(9):833–5 (14 ref.)

Prostatic intraepithelial neoplasia and other changes during promotion and progression. Pretlow TG, et al. **Pathol Res Pract** 1995 Sep;191(9):842–9 (49 ref.)

Preneoplastic transformation of human mammary epithelial cells. Band V. **Semin Cancer Biol** 1995 Jun;6(3):185–92 (50 ref.)

Premalignant lesions of the stomach. Ho SB. **Semin Gastrointest Dis** 1996 Apr;7(2):61–73 (85 ref.)

Preneoplastic conditions of the liver. Riegler JL. **Semin Gastrointest Dis** 1996 Apr;7(2):74–87 (79 ref.)

Risk of dysplasia in anal condyloma. Metcalf AM, et al. **Surgery** 1995 Oct;118(4):724–6 (14 ref.)

Gastric carcinoma arising from a hyperplasiogenic polyp with a diameter of less than 2 centimeters. Gschwantler M, et al. **Z Gastroenterol** 1995 Oct;33(10):610–2 (15 ref.)

[Diseases of the breast] Bässler R. **Pathologe** 1996 Jan; 17(1):92–106 (23 ref.) **(Ger)**

[The malignant transformation of leukoplakia of the oral cavity. A review of the literature and clinical case reports] Colella G, et al. **Minerva Stomatol** 1995 Jun;44(6):291–300 (62 ref.) (Eng. Abstr.) **(Ita)**

[Reevaluation of preneoplastic lung lesions in lung carcinoma? In bronchial carcinoma?] Kato H, et al. **Gan To Kagaku Ryoho** 1995 Dec;22(14):2048–54 (32 ref.) (Eng. Abstr.) **(Jpn)**

[New concepts on precancerous lesions of the stomach] Mai M, et al. **Gan To Kagaku Ryoho** 1995 Dec;22(14):2029–37 (49 ref.) (Eng. Abstr.) **(Jpn)**

[Reevaluation of precancerous lesion of squamous cell carcinoma] Sumiyoshi K, et al. **Gan To Kagaku Ryoho** 1995 Dec;22(14):2038–42 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Precancerous stages of hepatocellular carcinoma] Tanikawa K. **Gan To Kagaku Ryoho** 1995 Dec;22(14):2055–61 (29 ref.) (Eng. Abstr.) **(Jpn)**

[Reevaluation of precancerous lesions of the skin] Tsuchida T, et al. **Gan To Kagaku Ryoho** 1995 Dec;22(14):2062–6 (7 ref.) (Eng. Abstr.) **(Jpn)**

[Liver cell dysplasia] Okanoue T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):273–6 (18 ref.) **(Jpn)**

[Concepts related to the course of gastric cancer] Espejo Romero H, et al. **Rev Gastroenterol Peru** 1995;15 Suppl 1:S46–70 (32 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

The role of growth factors in mouse skin tumor promotion and premalignant progression. Yuspa SH, et al. **Prog Clin Biol Res** 1995;391:39–48 (43 ref.)

[Cellular reactions of the lung to mineral fibers] Gillissen A, et al. **Pneumologie** 1996 Jan;50(1):5–17 (137 ref.) **(Ger)**

[Transgenic mice for analysis of neoplasm transformation processes of T and B lymphocytes] Kobzdej M, et al. **Postepy Hig Med Dosw** 1996;50(2):113–29 (61 ref.) (Eng. Abstr.) **(Pol)**

PREVENTION & CONTROL

Colorectal cancer and polyps: clinical decisions for screening, early diagnosis, and surveillance of high–risk groups. Bond JH. **Compr Ther** 1996 Feb;22(2):100–6 (47 ref.)

Strengths and weaknesses of screening programmes for oral malignancies and potentially malignant lesions. Warnakulasuriya KA, et al. **Eur J Cancer Prev** 1996 Apr; 5(2):93–8 (33 ref.)

Chemoprevention of head and neck cancer. Voravud N. **J Med Assoc Thai** 1996 Mar;79(3):185–93 (65 ref.)

SURGERY

Surgical management of Barrett's esophagus. Clark GW, et al. **Ann Chir Gynaecol** 1995;84(2):139–44 (30 ref.)

Cryosurgery of malignant and premalignant diseases of the skin: a simple approach. Sinclair RD, et al. **Australas J Dermatol** 1995 Aug;36(3):133–42 (60 ref.)

[Laser therapy of the skin] Hohenleutner U, et al. **HNO** 1995 Sep;43(9):557–71 (64 ref.) **(Ger)**

[Therapy of preinvasive vulvar neoplasia––standardized or individual?] Schnürch HG, et al. **Zentralbl Gynakol** 1996; 118(6):345–9 (30 ref.) (Eng. Abstr.) **(Ger)**

PRECAUTIONS, UNIVERSAL see **UNIVERSAL PRECAUTIONS**

PRECIPITATION

[Radical therapy of refractory hyperlipidemia: extracorporeal cholesterol elimination] Kostner KM. **Wien Med Wochenschr** 1994;144(12–13):333–5 (13 ref.) (Eng. Abstr.) **(Ger)**

PRECONCEPTION CARE

see related
PRENATAL CARE

Preconception care: a means of prevention. Cefalo RC, et al. **Baillieres Clin Obstet Gynaecol** 1995 Sep;9(3):403–16

(38 ref.)
Primary prevention of birth defects by periconceptional care, including multivitamin supplementation. Czeizel AE. **Baillieres Clin Obstet Gynaecol** 1995 Sep;9(3):417–30 (26 ref.)
Preconception counseling for the primary care physician. Leuzzi RA, et al. **Med Clin North Am** 1996 Mar; 80(2):337–74 (113 ref.)
A fertility diet for planning pregnancy. Wynn M, et al. **Nutr Health** 1995;10(3):219–38 (50 ref.)

PRECURSOR RNA see **RNA PRECURSORS**

PREDATORY BEHAVIOR

PHYSIOLOGY

Representation of perceptual dimensions of insect prey during terminal pursuit by echolocating bats. Simmons JA, et al. **Biol Bull** 1996 Aug;191(1):109–21 (56 ref.)
Exploration and predation models of anxiety: evidence from laboratory and wild species. Hendrie CA, et al. **Pharmacol Biochem Behav** 1996 May;54(1):13–20 (56 ref.)

PREDICTIVE VALUE OF TESTS

[The ROC curve in the measurement of the diagnostic value of tests] Forsström JJ. **Duodecim** 1995;111(3):237–44 (41 ref.) **(Fin)**

PREDISPOSING FACTORS see **CAUSALITY**

PREDNISOLONE

ADMINISTRATION & DOSAGE

Low dose corticosteroids in early rheumatoid arthritis. Can these drugs slow disease progression? Kirwan JR, et al. **Drugs Aging** 1996 Mar;8(3):157–61 (16 ref.)
[Emergency therapy of collagen diseases and their complications] Ichikawa Y, et al. **Nippon Naika Gakkai Zasshi** 1995 Nov 10;84(11):1865–9 (5 ref.) **(Jpn)**

ADVERSE EFFECTS

[Acute exacerbation by reactivation of HBV in steroid withdrawal therapy] Arase Y. **Nippon Rinsho** 1995 Oct;53 Suppl:522–6 (6 ref.) **(Jpn)**

BLOOD

[Synthetic steroids] Miyazaki S. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:1036–9 (19 ref.) **(Jpn)**

PHARMACOKINETICS

Pharmacokinetics and receptor-mediated pharmacodynamics of corticosteroids. Jusko WJ. **Toxicology** 1995 Sep 1; 102(1–2):189–96 (28 ref.)

PHARMACOLOGY

Pharmacokinetics and receptor-mediated pharmacodynamics of corticosteroids. Jusko WJ. **Toxicology** 1995 Sep 1; 102(1–2):189–96 (28 ref.)

THERAPEUTIC USE

Drug trials in neuropathy. Hughes RA, et al. **Baillieres Clin Neurol** 1995 Nov;4(3):607–27 (87 ref.)
Systemic corticosteroids in the phenytoin hypersensitivity syndrome. Chopra S, et al. **Br J Dermatol** 1996 Jun; 134(6):1109–12 (19 ref.)
Cyclosporin in steroid-resistant idiopathic nephrotic syndrome. Tejani A, et al. **Contrib Nephrol** 1995;114:73–7 (32 ref.)
Therapeutic uses of methyl prednisolone. Mondal T, et al. **Indian Pediatr** 1995 Jul;32(7):787–93 (26 ref.)
Bilateral inguinal scrofuloderma during steroid therapy in a patient with bullous pemphigoid. Kawabata E, et al. **J Dermatol** 1995 Aug;22(8):582–6 (22 ref.)
[Specific respiratory manifestations associated with hemorrhagic rectocolitis. Analysis of a case and review of the literature] Lagier E, et al. **Gastroenterol Clin Biol** 1996;20(4):397–400 (28 ref.) (Eng. Abstr.) **(Fre)**

PREDNISOLONE, TOPICAL

ADVERSE EFFECTS

Contact allergy to topical corticosteroids and systemic contact dermatitis from prednisolone with tolerance of triamcinolone. Bircher AJ, et al. **Acta Derm Venereol** 1995 Nov;75(6):490–3 (38 ref.)

PREDNISONE

ADMINISTRATION & DOSAGE

Complete remission of multicentric reticulohistiocytosis with combination therapy of steroid, cyclophosphamide, and low-dose pulse methotrexate. Case report, review of the literature, and proposal for treatment. Liang GC, et al. **Arthritis Rheum** 1996 Jan;39(1):171–4 (15 ref.)

BLOOD

[Synthetic steroids] Miyazaki S. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:1036–9 (19 ref.) **(Jpn)**

THERAPEUTIC USE

Long-term effect of interferon alpha alone or after prednisone withdrawal in chronic hepatitis B. Interim report and review of the literature. Gonzalez-Mateos F, et al. **Hepatogastroenterology** 1995 Nov-Dec;42(6):893–9 (25 ref.)
[For the present Duchenne' disease should not be treated with prednisone] Jennekens FG, et al. **Ned Tijdschr Geneeskd** 1996 May 25;140(21):1109–11 (21 ref.) **(Dut)**
[New treatments for multiple sclerosis] Masdeu JC. **Rev Neurol** 1996 Jun;24(130):708–11 (38 ref.) **(Spa)**

PRE-ECLAMPSIA

Preeclampsia and hypertensive disorders of pregnancy. Zamorski MA, et al. **Am Fam Physician** 1996 Apr; 53(5):1595–610 (32 ref.)
Preeclampsia: not simply pregnancy-induced hypertension. Roberts JM. **Hosp Pract (Off Ed)** 1995 Dec 15;30(12):25–8, 31–6 (7 ref.)
[Progresses in prenatal medicine in China, 1995] Zhou Z. **Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):748–9 (0 ref.) **(Chi)**

COMPLICATIONS

Renal disease in pregnancy. Marwah D, et al. **Curr Opin Nephrol Hypertens** 1996 Mar;5(2):147–50 (18 ref.)
[Preeclamptic liver disease] Kato K. **Ryoikibetsu Shokogun Shirizu** 1995;(8):575–7 (12 ref.) **(Jpn)**

DRUG THERAPY

Established role of magnesium sulfate as prophylactic anticonvulsive agent in preeclampsia/eclampsia. Skajaa K. **Acta Obstet Gynecol Scand** 1996 Apr;75(4):313–5 (18 ref.)
The use of calcium-channel blockers in pregnancy. Lewis R, et al. **New Horiz** 1996 Feb;4(1):115–22 (45 ref.)

ETIOLOGY

Recent advances in the aetiology and management of pre-eclampsia. Scott A, et al. **Br J Hosp Med** 1996 Apr 17–30;55(8):476–8 (18 ref.)
Potential pathogenic roles of aberrant lipoprotein and fatty acid metabolism in pre-eclampsia. Sattar N, et al. **Br J Obstet Gynaecol** 1996 Jul;103(7):614–20 (57 ref.)
Lighting and fattening--evolving concepts in the pathogenesis of preeclampsia [editorial; comment] Taylor RN. **West J Med** 1996 Apr;164(4):359–61 (12 ref.) Comment on: West J Med 1996 Apr;164(4):315–20.
[The role of nitric oxide in the pathogenesis of pregnancy induced hypertension] Li A, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1996 Jan;31(1):52–4 (17 ref.) **(Chi)**
-Obstetric prognosis after pre-eclampsia, eclampsia or HELLP syndrome- Niesert S. **Geburtshilfe Frauenheilkd** 1996 Feb;56(2):93–6 (18 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Pre-eclampsia: physiology and immunological aspects. Vinatier D, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Aug;61(2):85–97 (163 ref.)

METABOLISM

Effects of endothelin-1 and the ETA receptor antagonist BQ-123 on resistance arteries from normal pregnant and preeclamptic women. Wolff K, et al. **Acta Obstet Gynecol Scand** 1996 May;75(5):432–8 (34 ref.)
Hyperuricemia and xanthine oxidase in preeclampsia, revisited. Many A, et al. **Am J Obstet Gynecol** 1996 Jan; 174(1 Pt 1):288–91 (60 ref.)

PHYSIOPATHOLOGY

Recent developments in the pathophysiology and management of pre-eclampsia [see comments] Mushambi MC, et al. **Br J Anaesth** 1996 Jan;76(1):133–48 (146 ref.) Comment in: Br J Anaesth 1996 May;76(5):748–9. Comment in: Br J Anaesth 1996 Jun;76(6):889–90.
Nitric oxide, the endothelium, pregnancy and pre-eclampsia. Morris NH, et al. **Br J Obstet Gynaecol** 1996 Jan; 103(1):4–15 (152 ref.)
The physiology of pre-eclampsia. Brown MA. **Clin Exp Pharmacol Physiol** 1995 Nov;22(11):781–91 (85 ref.)
Pre-eclampsia: physiology and immunological aspects. Vinatier D, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Aug;61(2):85–97 (163 ref.)
Fibrinolytic system and reproductive process with special reference to fibrinolytic failure in pre-eclampsia. Gilabert J, et al. **Hum Reprod** 1995 Dec;10 Suppl 2:121–31 (83 ref.)
Pre-eclampsia, autoimmune diseases and breast cancer etiology. Polednak AP. **Med Hypotheses** 1995 May; 44(5):414–8 (46 ref.)
Preeclampsia. Still an enigma [see comments] Duda J. **West J Med** 1996 Apr;164(4):315–20 (75 ref.) Comment in: West J Med 1996 Apr;164(4):359–61.
[The role of vascular nitric oxide (NO) in the pathomechanism of pre-eclampsia] Visontai ZZ, et al. **Orv Hetil** 1995 Nov 19;136(47):2547–51 (50 ref.) (Eng. Abstr.) **(Hun)**

PREVENTION & CONTROL

The pharmacological prevention of pre-eclampsia. Dekker GA. **Baillieres Clin Obstet Gynaecol** 1995 Sep;9(3):509–28 (109 ref.)
[Can nitrogen monoxide replace aspirin in the prevention of preeclampsia?] Ohl J, et al. **Contracept Fertil Sex** 1996 Apr;24(4):259–61 (16 ref.) **(Fre)**
[Uterine velocimetry and vascular pregnancy pathologies prevented with low-dose aspirin] Haddad B, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(4):396–404 (51 ref.) (Eng. Abstr.) **(Fre)**
[Aspirin during pregnancy. Indications and modalities of prescription after the publication of the later trials] Uzan S, et al. **Presse Med** 1996 Jan 6–13;25(1):31–6 (30 ref.) (Eng. Abstr.) **(Fre)**
-Is prevention of pre-eclampsia with low dosage aspirin possible? Critical assessment of available studies- Lippert TH, et al. **Geburtshilfe Frauenheilkd** 1996 Feb;56(2):88–92 (23 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Recent developments in the pathophysiology and management of pre-eclampsia [see comments] Mushambi MC, et al. **Br J Anaesth** 1996 Jan;76(1):133–48 (146 ref.) Comment in: Br J Anaesth 1996 May;76(5):748–9. Comment in: Br J Anaesth 1996 Jun;76(6):889–90.
Treatment of hypertension in pregnant women. Sibai BM. **N Engl J Med** 1996 Jul 25;335(4):257–65 (93 ref.)
[Severe preeclampsia. Principal management modalities before patient transfer] Aya AG, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(2):196–205 (78 ref.) (Eng. Abstr.) **(Fre)**
[Indications for pregnancy termination in cases of pre-eclampsia, hypertension, intrauterine growth retardation, liver and heart disease] Uzan S, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24 Suppl 1:33–40 (54 ref.) **(Fre)**

ULTRASONOGRAPHY

[Uterine velocimetry and vascular pregnancy pathologies prevented with low-dose aspirin] Haddad B, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(4):396–404 (51 ref.) (Eng. Abstr.) **(Fre)**

PREENING see **GROOMING**

PRE-EXCITATION SYNDROMES

DIAGNOSIS

["Malignant Kent" arrhythmia, clinical case and literature review] Baroud I, et al. **Rev Med Brux** 1996 Apr;17(2):51–6 (10 ref.) (Eng. Abstr.) **(Fre)**
[Electrocardiogram in pre-excitation] Oreto G, et al. **G Ital Cardiol** 1996 Mar;26(3):303–22 (55 ref.) **(Ita)**
[Electrocardiographic Holter monitoring in patients with ventricular pre-excitation: possibilities of its uses and pitfalls] Jurkovičová O, et al. **Vnitr Lek** 1995 Sep; 41(9):629–36 (21 ref.) (Eng. Abstr.) **(Slo)**

PATHOLOGY

Mahaim, Kent and abnormal atrioventricular conduction. Anderson RH, et al. **Cardiovasc Res** 1996 Apr;31(4):480–91 (44 ref.)

PHYSIOPATHOLOGY

Electrocardiographic and clinical precursors of ventricular fibrillation: chain of events. Bayés-Genís A, et al. **J Cardiovasc Electrophysiol** 1995 May;6(5):410–7 (47 ref.)

PREFERRED PROVIDER ORGANIZATIONS

LEGISLATION & JURISPRUDENCE

Physician-run health plans and antitrust. American College of Physicians. **Ann Intern Med** 1996 Jul 1;125(1):59–65 (20 ref.)

ORGANIZATION & ADMINISTRATION

Managed care contracting/capitation. Reardon TM. **Ann Thorac Surg** 1995 Nov;60(5):1500–8 (0 ref.)

PREFRONTAL CORTEX

Planning and script analysis following prefrontal lobe lesions. Sirigu A, et al. **Ann N Y Acad Sci** 1995 Dec 15;769:277–88 (18 ref.)

ANATOMY & HISTOLOGY

Architecture of the prefrontal cortex and the central executive. Goldman-Rakic PS. **Ann N Y Acad Sci** 1995

PREFRONTAL CORTEX

Dec 15;769:71–83 (37 ref.)
Anatomic basis of cognitive–emotional interactions in the primate prefrontal cortex. Barbas H. **Neurosci Biobehav Rev** 1995 Fall;19(3):499–510 (155 ref.)

PHYSIOLOGY

No–go potential in the prefrontal cortex and electrical stimulation of its loci in monkeys. Sasaki K. **Adv Neurol** 1995;67:131–41 (20 ref.)
On some functions of the human prefrontal cortex. Damasio AR. **Ann N Y Acad Sci** 1995 Dec 15;769:241–51 (32 ref.)
Neuronal models of prefrontal cortical functions. Dehaene S, et al. **Ann N Y Acad Sci** 1995 Dec 15;769:305–19 (37 ref.)
Temporal processing. Fuster JM. **Ann N Y Acad Sci** 1995 Dec 15;769:173–81 (19 ref.)
Similarities and distinctions among current models of prefrontal cortical functions. Grafman J. **Ann N Y Acad Sci** 1995 Dec 15;769:337–68 (116 ref.)
A model of the dynamics of prefrontal cortico–thalamo–basal ganglionic loops in verbal response selection tasks. Gullapalli V, et al. **Ann N Y Acad Sci** 1995 Dec 15; 769:375–80 (22 ref.)
Types of planning: can artificial intelligence yield insights into prefrontal function? Hendler JA. **Ann N Y Acad Sci** 1995 Dec 15;769:265–76 (45 ref.)
Forms of reasoning: insight into prefrontal functions? Holyoak KJ, et al. **Ann N Y Acad Sci** 1995 Dec 15; 769:253–63 (55 ref.)
A computer model of prefrontal cortex function. Levinson R. **Ann N Y Acad Sci** 1995 Dec 15;769:381–8 (9 ref.)
Procedural learning and prefrontal cortex. Pascual–Leone A, et al. **Ann N Y Acad Sci** 1995 Dec 15;769:61–70 (20 ref.)
Memory and the prefrontal cortex. Shimamura AP. **Ann N Y Acad Sci** 1995 Dec 15;769:151–9 (44 ref.)
The contribution of alpha 2–noradrenergic mechanisms of prefrontal cortical cognitive function. Potential significance for attention–deficit hyperactivity disorder. Arnsten AF, et al. **Arch Gen Psychiatry** 1996 May;53(5):448–55 (130 ref.)
Anatomic basis of cognitive–emotional interactions in the primate prefrontal cortex. Barbas H. **Neurosci Biobehav Rev** 1995 Fall;19(3):499–510 (155 ref.)
Functional brain imaging studies of cortical mechanisms for memory. Ungerleider LG. **Science** 1995 Nov 3; 270(5237):769–75 (94 ref.)

PHYSIOPATHOLOGY

Cognitive functioning in "diffuse" pathology. Role of prefrontal and limbic structures. Boller F, et al. **Ann N Y Acad Sci** 1995 Dec 15;769:23–39 (51 ref.)
Experimental approach to prefrontal functions in humans. Dubois B, et al. **Ann N Y Acad Sci** 1995 Dec 15;769:41–60 (65 ref.)
Schizophrenia: a disconnection syndrome? Friston KJ, et al. **Clin Neurosci** 1995;3(2):89–97 (61 ref.)
The functional architecture of the prefrontal cortex and schizophrenia [editorial] Lewis DA, et al. **Psychol Med** 1995 Sep;25(5):887–94 (80 ref.)
[Psychopathy and neuropsychology of the prefrontal cortex] Jurado MA, et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1996 May–Jun;24(3):148–55 (49 ref.) (Eng. Abstr.) **(Spa)**

PREGNADIENEDIOLS

ADMINISTRATION & DOSAGE

Once–a–day topical corticosteroids. **Drug Ther Bull** 1995 Mar;33(3):21–2 (15 ref.)

PREGNADIENES

THERAPEUTIC USE

Corticosteroid therapy of eye disease. Fifty years later [editorial; comment] Raizman M. **Arch Ophthalmol** 1996 Aug;114(8):1000–1 (25 ref.) Comment on: Arch Ophthalmol 1996 Aug;114(8):933–7.

PREGNANCY

see related

PRENATAL CARE

Conservative versus radical surgery for tubal pregnancy. A review. Clausen I. **Acta Obstet Gynecol Scand** 1996 Jan; 75(1):8–12 (44 ref.)
Pregnancy in patients with cystic fibrosis. Hilman BC, et al. **Clin Obstet Gynecol** 1996 Mar;39(1):70–86 (54 ref.)
Cervical pregnancy: three case reports and a review of the literature. Van de Meersache M, et al. **Hum Reprod** 1995 Jul;10(7):1850–5 (42 ref.)
Conservative management options for cervical pregnancy; case reports and literature review. Creinin MD, et al. **Int J Fertil Menopausal Stud** 1995 Jul–Aug;40(4):175–86 (67 ref.)
Magnetic resonance imaging in pregnancy. Colletti PM, et al. **Magn Reson Imaging Clin N Am** 1994 May;2(2):291–307 (53 ref.)
Pregnancy and the safety of magnetic resonance imaging. Kanal E. **Magn Reson Imaging Clin N Am** 1994 May; 2(2):309–17 (74 ref.)
The Role of General Practice in Maternity Care. Royal College of General Practitioners. Report of the RCGP Maternity Care Group. **Occas Pap R Coll Gen Pract** 1995 Nov;(72):1–14 (24 ref.)
Working conditions, maternity legislation, and preterm birth. Berkowitz GS, et al. **Semin Perinatol** 1995 Aug;19(4):272–8 (40 ref.)
The influence of fetal and maternal factors on the distribution of birthweight. Cogswell ME, et al. **Semin Perinatol** 1995 Jun;19(3):222–40 (58 ref.)
[Violence towards pregnant women] Rasmussen KL, et al. **Ugeskr Laeger** 1996 Apr 22;158(17):2373–6 (35 ref.) (Eng. Abstr.) **(Dan)**
[Underwater diving during pregnancy] Revel A, et al. **Harefuah** 1995 Jun 1;128(11):707–10 (28 ref.) **(Heb)**
[Effect of pregnancy and delivery on genuine stress incontinence] Zilberman B, et al. **Harefuah** 1995 Jul; 129(1–2):43–6 (21 ref.) **(Heb)**

BLOOD

Blood folic acid and vitamin B12 in relation to neural tube defects. Wald NJ, et al. **Br J Obstet Gynaecol** 1996 Apr; 103(4):319–24 (16 ref.)
Can nucleated erythrocytes found in maternal venous blood be used in the noninvasive prenatal diagnosis of fetal chromosome abnormalities? Slunga–Tallberg A, et al. **Eur J Hum Genet** 1995;3(4):264–70 (46 ref.)
Why is there a peak of human chorionic gonadotrophin (HCG) in early pregnancy? Chard T, et al. **Hum Reprod** 1995 Jul;10(7):1837–40 (61 ref.)
Is an elevated circulating maternal homocysteine concentration a risk factor for neural tube defects? Ubbink JB. **Nutr Rev** 1995 Jun;53(6):173–5 (14 ref.)
[Detection of fetal cells in maternal blood: towards a noninvasive prenatal diagnosis] Simpson JL, et al. **Contracept Fertil Sex** 1995 Jul–Aug;23(7–8):445–50 (64 ref.) (Eng. Abstr.) **(Fre)**

DRUG EFFECTS

Use of antithrombotic agents during pregnancy. Ginsberg JS, et al. **Chest** 1995 Oct;108(4 Suppl):305S–311S (53 ref.)
"Moderate" drinking during pregnancy: cause for concern? Abel EL. **Clin Chim Acta** 1996 Mar 15;246(1–2):149–54 (15 ref.)
[The use of drugs in pregnant and nursing women with dermatologic diseases] Miteva L, et al. **Akush Ginekol (Sofiia)** 1995;34(2):42–6 (20 ref.) **(Bul)**

IMMUNOLOGY

Materno–fetal immunobiology in normal pregnancy and its possible failure in recurrent spontaneous abortion? Vince GS, et al. **Hum Reprod** 1995 Dec;10 Suppl 2:107–13 (50 ref.)
Stress, immune function, and relationship to pregnancy outcome. Gennaro S, et al. **Nurs Clin North Am** 1996 Jun; 31(2):293–303 (69 ref.)

METABOLISM

Aspects of metabolism in normal and gestational diabetic pregnancy. Johnston DG, et al. **Biochem Soc Trans** 1995 Aug;23(3):512–6 (20 ref.)
Nitric oxide, the endothelium, pregnancy and pre–eclampsia. Morris NH, et al. **Br J Obstet Gynaecol** 1996 Jan; 103(1):4–15 (152 ref.)
Glucose metabolism assessment in pregnancy. Garner PR. **Clin Biochem** 1995 Oct;28(5):499–502 (18 ref.)
Calcium homeostasis in pregnancy. Hosking DJ. **Clin Endocrinol (Oxf)** 1996 Jul;45(1):1–6 (45 ref.)
Prostaglandin–metabolizing enzymes during pregnancy: characterization of NAD(+)–dependent prostaglandin dehydrogenase, carbonyl reductase, and cytochrome P450–dependent prostaglandin omega–hydroxylase. Okita RT, et al. **Crit Rev Biochem Mol Biol** 1996 Apr; 31(2):101–26 (100 ref.)
Energy requirements of pregnant and lactating women. Prentice AM, et al. **Eur J Clin Nutr** 1996 Feb;50 Suppl 1:S82–110; discussion S10–1 (114 ref.)
Energy requirements of pregnancy for healthy Dutch women. van Raaij JM. **Eur J Obstet Gynecol Reprod Biol** 1995 Jul;61(1):7–13 (12 ref.)
Selenium in human lactation. Sanz Alaejos M, et al. **Nutr Rev** 1995 Jun;53(6):159–66 (101 ref.)
Fuel metabolism in pregnancy and in gestational diabetes mellitus. Boden G. **Obstet Gynecol Clin North Am** 1996 Mar;23(1):1–10 (53 ref.)
[Corticotropin–releasing hormone in pregnancy] Sun G. **Sheng Li Ko Hsueh Chin Chan** 1995 Jul;26(3):270–2 (10 ref.) **(Chi)**

PHYSIOLOGY

Effects of endothelin–1 and the ETA receptor antagonist BQ–123 on resistance arteries from normal pregnant and preeclamptic women. Wolff K, et al. **Acta Obstet Gynecol Scand** 1996 May;75(5):432–8 (34 ref.)
A critique of the new recommendations for weight gain in pregnancy. Johnson JW, et al. **Am J Obstet Gynecol** 1996 Jan;174(1 Pt 1):254–8 (25 ref.)
Maternal recognition of pregnancy. Roberts RM, et al. **Biol Reprod** 1996 Feb;54(2):294–302 (80 ref.)
Blood pressure measurement in pregnancy [see comments] de Swiet M, et al. **Br J Obstet Gynaecol** 1996 Sep; 103(9):862–3 (12 ref.) Comment in: Br J Obstet Gynaecol 1996 Sep;103(9):vii.
Normal cardiopulmonary physiology during pregnancy. Crapo RO. **Clin Obstet Gynecol** 1996 Mar;39(1):3–16 (54 ref.)
Relaxin used to produce the cervical ripening of labor. Weiss G. **Clin Obstet Gynecol** 1995 Jun;38(2):293–300 (16 ref.)
Maternal adaptation to pregnancy. Sibai BM, et al. **Curr Opin Obstet Gynecol** 1995 Dec;7(6):420–6 (55 ref.)
Actions of placental and fetal adrenal steroid hormones in primate pregnancy. Pepe GJ, et al. **Endocr Rev** 1995 Oct; 16(5):608–48 (617 ref.)
Autonomic cardiovascular control in pregnancy. Ekholm EM, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Jan; 64(1):29–36 (75 ref.)
Maternal nutrition in relation to fetal and placental growth. Godfrey KM, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Jul;61(1):15–22 (62 ref.)
Essential fatty acids in pregnancy and early human development. Hornstra G, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Jul;61(1):57–62 (35 ref.)
Iron supplementation during pregnancy. Roodenburg AJ. **Eur J Obstet Gynecol Reprod Biol** 1995 Jul;61(1):65–71 (66 ref.)
The pregnant worker: how much is too much? Assessing safe activity levels. Feinberg JS, et al. **Hawaii Med J** 1996 May;55(5):85–6 (15 ref.)
Immuno–endocrine interactions in early pregnancy. Chaouat G, et al. **Hum Reprod** 1995 Dec;10 Suppl 2:55–9 (45 ref.)
Growth factors in pregnancy. Cooper JC, et al. **Indian J Physiol Pharmacol** 1995 Jul;39(3):197–203 (22 ref.)
Do receptors get pregnant too? Adrenergic receptor alterations in human pregnancy. Smiley RM, et al. **J Matern Fetal Med** 1996 May–Jun;5(3):106–14 (60 ref.)
Considerations in the management of maxillofacial infections in the pregnant patient. Lawrenz DR, et al. **J Oral Maxillofac Surg** 1996 Apr;54(4):474–85 (47 ref.)
Diagnosis of early pregnancy and early complications. Cartwright PS. **Med Clin North Am** 1995 Nov; 79(6):1319–35 (33 ref.)
Calcium supplementation prevents pregnancy–induced hypertension by increasing the production of vascular nitric oxide. López–Jaramillo P, et al. **Med Hypotheses** 1995 Jul; 45(1):68–72 (73 ref.)
Pregnancy, lactation, and menopause: how physiology and gender affect the toxicity of chemicals. Roberts JS, et al. **Mt Sinai J Med** 1995 Oct;62(5):343–55 (66 ref.)
Pregnancy as a risk factor for obesity: lessons from the Stockholm Pregnancy and Weight Development Study. Rössner S, et al. **Obes Res** 1995 Sep;3 Suppl 2:267s–275s (22 ref.)
Cardiac output in normal pregnancy: a critical review. van Oppen AC, et al. **Obstet Gynecol** 1996 Feb;87(2):310–8 (81 ref.)
Impact of the L–arginine/nitric oxide system in pregnancy. Neri I, et al. **Obstet Gynecol Surv** 1995 Dec;50(12):851–8 (64 ref.)
Somatostatin levels during infancy, pregnancy, and lactation: a review. Goldstein A, et al. **Peptides** 1995;16(7):1321–6 (63 ref.)
Priorities for nutrition interventions in reproductive health: a bilateral agency perspective. Davidson FR. **Proc Nutr Soc** 1995 Jul;54(2):361–6 (19 ref.)
The Nutrition Society 1994 Silver Medal Lecture. Pregnancy, parturition and neonatal development: interactions between nutrition and thyroid hormones. Symonds ME. **Proc Nutr Soc** 1995 Jul;54(2):329–43 (97 ref.)
Renal reserve in pregnancy. Gaboury CL, et al. **Semin Nephrol** 1995 Sep;15(5):449–53 (27 ref.)
Calcium metabolism in normal and hypertensive pregnancy. Hojo M, et al. **Semin Nephrol** 1995 Nov;15(6):504–11 (51 ref.)
Individual nutrient effects on length of gestation and pregnancy outcome. Murtaugh MA, et al. **Semin Perinatol** 1995 Jun;19(3):197–210 (138 ref.)
The length of human pregnancy as calculated by ultrasonographic measurement of the fetal biparietal diameter. Kieler H, et al. **Ultrasound Obstet Gynecol** 1995 Nov;6(5):353–7 (26 ref.)
[Physiological review of the mammary gland development during pregnancy] Merviel P, et al. **Contracept Fertil Sex** 1996 Mar;24(3):218–22 (25 ref.) (Eng. Abstr.) **(Fre)**
[Nitric oxide: new horizons in gynecology and obstetrics] Ohl J, et al. **Contracept Fertil Sex** 1995 Nov;23(11):645–50 (51 ref.) **(Fre)**
[Vaginal environment. The vaginal climate and its variations] Nicoli JM, et al. **Rev Fr Gynecol Obstet** 1995 Nov; 90(11):471–80 (8 ref.) (Eng. Abstr.) **(Fre)**
[Bioelectric profiles and nutritional status in pregnancy: protocol of a multicentric project to measure bioimpedance in pregnancy] Mele MC, et al. **Minerva Ginecol** 1996 Jan–Feb;48(1–2):25–33 (23 ref.) (Eng. Abstr.) **(Ita)**
[The respiratory system in pregnancy] Buchacz P, et al. **Ginekol Pol** 1995 Jun;66(6):347–50 (48 ref.) (Eng. Abstr.) **(Pol)**

PSYCHOLOGY

Stress, immune function, and relationship to pregnancy outcome. Gennaro S, et al. **Nurs Clin North Am** 1996 Jun; 31(2):293–303 (69 ref.)

Identification and care of problems associated with alcohol ingestion in pregnancy. Hankin JR, et al. **Semin Perinatol** 1995 Aug;19(4):286–92 (24 ref.)

Smoking cessation interventions for pregnant women: review and future directions. O'Campo P, et al. **Semin Perinatol** 1995 Aug;19(4):279–85 (37 ref.)

Pregnancy behind bars. Safyer SM, et al. **Semin Perinatol** 1995 Aug;19(4):314–22 (37 ref.)

[Induced labor without medical indications: the viewpoint of women. Bibliographic review] Garel M. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24 Suppl 1:116–9 (22 ref.) **(Fre)**

[Fear as a risk factor in perinatology] Zdziennicki A. **Wiad Lek** 1994 Sep;47(17–18):698–9 (21 ref.) (Eng. Abstr.) **(Pol)**

RADIATION EFFECTS

[Protection from ionizing radiation for pregnant workers] Campos Venuti G, et al. **Epidemiol Prev** 1996 Apr–Sep; 20(2–3):194–6 (15 ref.) **(Ita)**

STATISTICS & NUMERICAL DATA

Prevalence of violence against pregnant women. Gazmararian JA, et al. **JAMA** 1996 Jun 26;275(24):1915–20 (38 ref.)

[Pregnancy after diagnosis of menopause] Jamin C, et al. **Contracept Fertil Sex** 1995 Nov;23(11):677–81 (55 ref.) (Eng. Abstr.) **(Fre)**

PREGNANCY, ABDOMINAL

[Primary hepatic pregnancy] Kato K. **Ryoikibetsu Shokogun Shirizu** 1995;(8):523–5 (14 ref.) **(Jpn)**

PREGNANCY, ADOLESCENT see **PREGNANCY IN ADOLESCENCE**

PREGNANCY, ANIMAL

see related
ANIMALS, NEWBORN

DRUG EFFECTS

Vanadium: a review of the reproductive and developmental toxicity. Domingo JL. **Reprod Toxicol** 1996 May–Jun; 10(3):175–82 (61 ref.)

METABOLISM

Carbohydrate–lipid interactions during gestation and their control by insulin. Herrera E, et al. **Braz J Med Biol Res** 1994 Nov;27(11):2499–519 (74 ref.)

Regulation of organic nutrient metabolism during transition from late pregnancy to early lactation. Bell AW. **J Anim Sci** 1995 Sep;73(9):2804–19 (117 ref.)

Impact of changes in organic nutrient metabolism on feeding the transition dairy cow. Grummer RR. **J Anim Sci** 1995 Sep;73(9):2820–33 (81 ref.)

Maternal–fetal pharmacokinetics: summary and future directions. Szeto HH. **NIDA Res Monogr** 1995;154:203–17 (36 ref.)

New approaches for drug and kinetic analysis in the maternal–fetal unit. Tonn GR, et al. **NIDA Res Monogr** 1995;154:175–202 (43 ref.)

PHYSIOLOGY

Growth factors in pregnancy. Cooper JC, et al. **Indian J Physiol Pharmacol** 1995 Jul;39(3):197–203 (22 ref.)

Whole-body fuel selection: 'reproduction'. Robinson JJ, et al. **Proc Nutr Soc** 1995 Mar;54(1):283–99 (108 ref.)

Interferon, the oxytocin receptor and the maternal recognition of pregnancy in ruminants and non-ruminants: a comparative approach. Flint AP. **Reprod Fertil Dev** 1995; 7(3):313–8 (31 ref.)

PREGNANCY COMPLICATIONS

see related
PREGNANCY, PROLONGED

Thyroid disease during pregnancy. Bishnoi A, et al. **Am Fam Physician** 1996 Jan;53(1):215–20 (19 ref.)

Rapidly reversible acute renal failure from ureteral obstruction in pregnancy. Jena M, et al. **Am J Kidney Dis** 1996 Sep;28(3):457–60 (22 ref.)

Ethically justified clinically comprehensive guidelines for the management of the depressed pregnant patient. Coverdale JH, et al. **Am J Obstet Gynecol** 1996 Jan;174(1 Pt 1):169–73 (25 ref.)

Headaches in women, including women who are pregnant. Paulson GW. **Am J Obstet Gynecol** 1995 Dec; 173(6):1734–41 (53 ref.)

Hyperreactio luteinalis associated with pregnancy: a case report and review of the literature. Schnorr JA Jr, et al. **Am J Perinatol** 1996 Feb;13(2):95–7 (6 ref.)

The diagnosis and management of breast problems during pregnancy and lactation. Scott-Conner CE, et al. **Am J Surg** 1995 Oct;170(4):401–5 (47 ref.)

Unexpected sudden death in a young pregnant woman: unusual presentation of neurosarcoidosis. Maisel JA, et al. **Ann Emerg Med** 1996 Jul;28(1):94–7 (12 ref.)

Pregnancy in spinal cord injured women. Baker ER, et al. **Arch Phys Med Rehabil** 1996 May;77(5):501–7 (67 ref.)

Asphyxia. Mac Donald D. **Baillieres Clin Obstet Gynaecol** 1995 Sep;9(3):579–94 (65 ref.)

The fetus as a passive smoker. Koren G. **Can Fam Physician** 1996 Jul;42:1301–3 (15 ref.)

Obstetric complications in pulmonary and critical care medicine. Rizk NW, et al. **Chest** 1996 Sep;110(3):791–809 (196 ref.)

Diagnostic imaging of the lung during pregnancy. Diethelm L, et al. **Clin Obstet Gynecol** 1996 Mar;39(1):36–55 (41 ref.)

Cushing's disease and pregnancy: report of six cases. Chico A, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Jan; 64(1):143–6 (20 ref.)

Asthma in the pregnant adolescent: a review. Shulman V, et al. **J Adolesc Health** 1996 Mar;18(3):168–76 (89 ref.)

Prenatal cocaine exposure. Consequences for child and family. Eyler FD, et al. **J Fla Med Assoc** 1995 Sep; 82(9):603–6 (52 ref.)

Examining separated symphysis pubis. Davidson MR. **J Nurse Midwifery** 1996 May–Jun;41(3):259–62 (15 ref.)

The discomforts of pregnancy. Davis DC. **J Obstet Gynecol Neonatal Nurs** 1996 Jan;25(1):73–81 (40 ref.)

Placental pathology casebook. Liveborn twin of an extramembranous pregnancy. Baergen RN, et al. **J Perinatol** 1995 Nov–Dec;15(6):510–3 (7 ref.)

Liver disease in pregnancy. Knox TA, et al. **N Engl J Med** 1996 Aug 22;335(8):569–76 (60 ref.)

Overview of the effects of abuse and drugs on pregnancy and offspring. Zuckerman B, et al. **NIDA Res Monogr** 1995; 149:16–38 (89 ref.)

Maternal obesity increases congenital malformations. Prentice A, et al. **Nutr Rev** 1996 May;54(5):146–50 (19 ref.)

Lower urinary tract dysfunction in pregnancy: a review. Mikhail MS, et al. **Obstet Gynecol Surv** 1995 Sep; 50(9):675–83 (99 ref.)

Pemphigus vulgaris and pregnancy. Ruach M, et al. **Obstet Gynecol Surv** 1995 Oct;50(10):755–60 (48 ref.)

Hyperthermia and birth defects. Edwards MJ, et al. **Reprod Toxicol** 1995 Sep–Oct;9(5):411–25 (109 ref.)

Gastrointestinal motility disorders in pregnancy. Torbey CF, et al. **Semin Gastrointest Dis** 1995 Oct;6(4):203–16 (138 ref.)

Hyperparathyroidism and pancreatitis during pregnancy. Inabnet WB, et al. **Surgery** 1996 Jun;119(6):710–3 (32 ref.)

Xanthogranulomatous pyelonephritis in a pregnant woman: a case report and review of the literature. Figueroa AJ, et al. **Urology** 1996 Aug;48(2):294–7 (14 ref.)

[Pregnancy and the child of a mother with phenylketonuria] Abadie V, et al. **Arch Pediatr** 1996 May;3(5):489–6 (38 ref.) (Eng. Abstr.) **(Fre)**

[Central serous chorioretinopathy in a pregnant woman] Khairallah M, et al. **J Fr Ophtalmol** 1996;19(3):216–21 (14 ref.) (Eng. Abstr.) **(Fre)**

[Prognostic value of a single umbilical artery. 87 cases] Blache G, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995; 24(5):522–8 (34 ref.) (Eng. Abstr.) **(Fre)**

[Prolonged pregnancy. Review of the literature] Boisselier P, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995; 24(7):739–46 (52 ref.) (Eng. Abstr.) **(Fre)**

[Association of Takayasu's arteritis, pregnancy and Still's disease] Fignon A, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(7):747–50 (13 ref.) (Eng. Abstr.) **(Fre)**

[Myasthenia and pregnancy. Two case reports] Lucot JP, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996; 25(2):179–85 (19 ref.) (Eng. Abstr.) **(Fre)**

[Possible implication of obstetric risk factors in the etiopathogenesis of schizophrenia] Verdoux H, et al. **Rev Fr Gynecol Obstet** 1995 Oct;90(10):417–22 (25 ref.) (Eng. Abstr.) **(Fre)**

[Pregnancy-associated osteoporosis] Ohana N, et al. **Harefuah** 1996 Mar 1;130(5):344–6 (32 ref.) **(Heb)**

[Obesity in pregnancy and delivery] Yamamoto T, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:553–8 (21 ref.) **(Jpn)**

[Pregnancy and antiphospholipid syndrome] Aoki K, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Aug; 47(8):852–62 (27 ref.) **(Jpn)**

[A case report of vaginal delivery controlled by epidural anesthesia in a woman with high spinal cord injury] Kase H, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Sep; 47(9):957–60 (14 ref.) **(Jpn)**

[A case report of congenital liver fibrosis tolerated 3 normal deliveries] Yonekawa H, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Mar;93(3):201–5 (10 ref.) **(Jpn)**

[Idiopathic acute fatty liver of pregnancy: IAFLP] Ibe T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):24–7 (23 ref.) **(Jpn)**

[Liver disease in pregnancy] Kato K. **Ryoikibetsu Shokogun Shirizu** 1995;(8):400–2 (12 ref.) **(Jpn)**

[Pregnancy course in women with terminal kidney failure treated with hemodialysis] Gumprecht J, et al. **Ginekol Pol** 1995 Jul;66(7):425–9 (36 ref.) (Eng. Abstr.) **(Pol)**

[Spontaneous hepatic rupture during pregnancy. Report of a case. Review of the literature] Villarreal Peral C, et al. **Ginecol Obstet Mex** 1995 Sep;63:395–7 (9 ref.) (Eng. Abstr.) **(Spa)**

[Ictus, pregnancy and contraception] Pareja A, et al. **Rev Neurol** 1995;23 Suppl 1:S87–90 (27 ref.) **(Spa)**

BLOOD

Disseminated intravascular coagulation and antithrombin III depression in acute fatty liver of pregnancy. Castro MA, et al. **Am J Obstet Gynecol** 1996 Jan;174(1 Pt 1):211–6 (13 ref.)

CHEMICALLY INDUCED

Cocaine during pregnancy: a critical review of the literature. Offidani C, et al. **Minerva Ginecol** 1995 Sep;47(9):381–90 (40 ref.)

DIAGNOSIS

Diagnosis of early pregnancy and early complications. Cartwright PS. **Med Clin North Am** 1995 Nov; 79(6):1319–35 (33 ref.)

Liver disease in pregnancy. Wolf JL. **Med Clin North Am** 1996 Sep;80(5):1167–87 (86 ref.)

In vitro assays to predict the severity of hemolytic disease of the newborn. Hadley AG. **Transfus Med Rev** 1995 Oct; 9(4):302–13 (68 ref.)

[Intestinal obstruction and pregnancy] Dufour P, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(3):297–300 (10 ref.) (Eng. Abstr.) **(Fre)**

[Appendicitis and pregnancy. Seven case reports] Dufour P, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(4):411–5 (14 ref.) (Eng. Abstr.) **(Fre)**

[Rheumatic diseases in pregnancy--problems from the viewpoint of the gynecologist] Heyl W, et al. **Geburtshilfe Frauenheilkd** 1995 Oct;55(10):M121–4 (21 ref.) **(Ger)**

[Applications of magnetic resonance tomography (MRT) in obstetrics] Wischnik A, et al. **Gynakologe** 1995 Oct; 28(5):321–8 (18 ref.) **(Ger)**

[Factors related to the recognition of alarm signals during pregnancy] Ortigosa-Corona E, et al. **Ginecol Obstet Mex** 1996 Feb;64:90–5 (24 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Effects of immunosuppressive drugs during pregnancy. Bermas BL, et al. **Arthritis Rheum** 1995 Dec;38(12):1722–32 (107 ref.)

Administration of iodized oil during pregnancy: a summary of the published evidence. Delange F. **Bull World Health Organ** 1996;74(1):101–8 (74 ref.)

Pulmonary pharmacology. Hornby PJ, et al. **Clin Obstet Gynecol** 1996 Mar;39(1):17–35 (25 ref.)

Considerations of prescription medications for the pregnant podiatric patient. Haverstock BD, et al. **J Am Podiatr Med Assoc** 1996 Jul;86(7):334–46 (108 ref.)

Guidelines for anticoagulation therapy in pregnancy. Ryan K, et al. **JPMA J Pak Med Assoc** 1995 May;45(5):133–6 (4 ref.)

Reproductive and developmental toxicity of aluminum: a review. Domingo JL. **Neurotoxicol Teratol** 1995 Jul–Aug; 17(4):515–21 (59 ref.)

Pharmacologic treatment of psychiatric disease in pregnancy and lactation: fetal and neonatal effects. Kuller JA, et al. **Obstet Gynecol** 1996 May;87(5 Pt 1):789–94 (38 ref.)

Drug delivery during pregnancy: evaluation in vitro of new drugs. Dancis J, et al. **Reprod Fertil Dev** 1995;7(6):1485–9 (33 ref.)

Treatment of migraine during pregnancy and lactation. Miles CB. **S D J Med** 1995 Nov;48(11):373–7 (24 ref.)

Antenatal drugs affecting vitamin K status of the fetus and the newborn. Astedt B. **Semin Thromb Hemost** 1995; 21(4):364–70 (84 ref.)

[Nitric oxide: new horizons in gynecology and obstetrics] Ohl J, et al. **Contracept Fertil Sex** 1995 Nov;23(11):645–50 (51 ref.) **(Fre)**

[Maternal corticotherapy . Pharmacology and effect on the fetus] Guillonneau M, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(2):160–7 (53 ref.) (Eng. Abstr.) **(Fre)**

[Pharmacologic principles of drug prescribing in pregnancy] Estler CJ. **Z Arztl Fortbild (Jena)** 1995 Dec;89(7):743–8 (18 ref.) (Eng. Abstr.) **(Ger)**

[Amidazophen. Yes or no?] Jákó J, et al. **Orv Hetil** 1995 Sep 24;136(39):2121–4 (50 ref.) (Eng. Abstr.) **(Hun)**

EPIDEMIOLOGY

Cytogenetic evaluation of cystic hygroma associated with hydrops fetalis, oligohydramnios or intrauterine fetal death: the roles of amniocentesis, postmortem chorionic villus sampling and cystic hygroma paracentesis. Chen CP, et al. **Acta Obstet Gynecol Scand** 1996 May;75(5):454–8 (29 ref.)

Maternal depressive symptoms and the risk of poor pregnancy outcome. Review of the literature and preliminary findings. Orr ST, et al. **Epidemiol Rev** 1995; 17(1):165–71 (34 ref.)

Neurobiological plausibility of prenatal nutritional deprivation as a risk factor for schizophrenia. Brown AS, et al. **J Nerv Ment Dis** 1996 Feb;184(2):71–85 (98 ref.)

Pregnancy as a risk factor for obesity: lessons from the Stockholm Pregnancy and Weight Development Study. Rössner S, et al. **Obes Res** 1995 Sep;3 Suppl 2:267s–275s (22 ref.)

Nutritional risk factors among low-income pregnant US women: the Centers for Disease Control and Prevention (CDC) Pregnancy Nutrition Surveillance System, 1979 through 1993. Perry GS, et al. **Semin Perinatol** 1995 Jun; 19(3):211–21 (46 ref.)

ETIOLOGY

The hazards of reproduction in space. Sullivan R. **Acta Obstet Gynecol Scand** 1996 Apr;75(4):372–7 (72 ref.)

Acute respiratory failure in pregnancy. Deblieux PM, et al. **Clin Obstet Gynecol** 1996 Mar;39(1):143–52 (14 ref.)

Airway obstruction secondary to rhinoscleroma during pregnancy. Armstrong WB, et al. **Ear Nose Throat J** 1995 Nov;74(11):768–73 (40 ref.)

Recurrent maternal virilization during pregnancy associated with polycystic ovarian syndrome: a case report and review of the literature. Ben-Chetrit A, et al. **Hum Reprod** 1995 Nov;10(11):3057–60 (34 ref.)

Gas embolism in obstetrics and gynecology. A review. Weissman A, et al. **J Reprod Med** 1996 Feb;41(2):103–11 (89 ref.)

[Does coitus have an effect on the course of pregnancy?] Kurki T. **Duodecim** 1994;110(18):1681–5 (32 ref.) **(Fin)**

[Obstetrical complications of adenomyosis. Literature review and two case reports] Bensaid F, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(4):416–8 (5 ref.) (Eng. Abstr.) **(Fre)**

[Effect of smoking on the fetus and the child during pregnancy] Gueguen C, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(8):853–9 (63 ref.) (Eng. Abstr.) **(Fre)**

[Emergencies in obstetrics] Ludwig H. **Ther Umsch** 1996 Jun; 53(6):477–96 (54 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

The effects of pregnancy on autoimmune diseases. Buyon JP, et al. **Clin Immunol Immunopathol** 1996 Feb; 78(2):99–104 (57 ref.)

The antiphospholipid-protein syndrome. Cines DB, et al. **J Clin Immunol** 1995 Nov;15(6 Suppl):86S–100S (186 ref.)

Neurological and obstetric manifestations of the antiphospholipid syndrome. Gatenby PA. **Lupus** 1996 Apr; 5(2):170–2 (13 ref.)

Obstetric outcome in systemic lupus erythematosus. Lima F, et al. **Semin Arthritis Rheum** 1995 Dec;25(3):184–92 (43 ref.)

MORTALITY

Spontaneous rupture of the spleen. A fatal complication of pregnancy. McCormick GM 2nd, et al. **Am J Forensic Med Pathol** 1995 Jun;16(2):132–4 (15 ref.)

PATHOLOGY

Subcutaneous and superficial granuloma pyogenicum. Park YH, et al. **Int J Dermatol** 1996 Mar;35(3):205–6 (9 ref.)

PHYSIOPATHOLOGY

Umbilical artery Doppler velocimetry: clinical utility in high-risk pregnancies. Divon MY. **Am J Obstet Gynecol** 1996 Jan;174(1 Pt 1):10–4 (36 ref.)

Renal disease in pregnancy. Marwah D, et al. **Curr Opin Nephrol Hypertens** 1996 Mar;5(2):147–50 (18 ref.)

Pregnancy as a risk factor for obesity: lessons from the Stockholm Pregnancy and Weight Development Study. Rössner S, et al. **Obes Res** 1995 Sep;3 Suppl 2:267s–275s (22 ref.)

Hormonal and pregnancy relationships to rheumatoid arthritis: convergent effects with immunologic and microvascular systems. Masi AT, et al. **Semin Arthritis Rheum** 1995 Aug;25(1):1–27 (166 ref.)

[Pelvic pain caused by pregnancy; a new disease?] Mens JM. **Ned Tijdschr Geneeskd** 1995 Sep 30;139(39):1964–6 (11 ref.) **(Dut)**

[Minor symptoms in family practice; chloasma or 'pregnancy mask' (see comments)] van Stralen-Bohlmann A, et al. **Ned Tijdschr Geneeskd** 1995 Sep 30;139(39):1971–4 (17 ref.) Comment in: Ned Tijdschr Geneeskd 1995 Dec 2;139(48):2513–4. Comment in: Ned Tijdschr Geneeskd 1995 Dec 23;139(51):2698. **(Dut)**

[Preservation of gonadotrophic function and pregnancy in Sheehan's syndrome: a case report and review of the literature] Vieira HB, et al. **Rev Assoc Med Bras** 1995 Mar-Apr;41(2):135–8 (17 ref.) (Eng. Abstr.) **(Por)**

[Clinical approach to physiologic dispnea in pregnancy] García Río F, et al. **Aten Primaria** 1996 Jan;17(1):70–4 (23 ref.) **(Spa)**

PREVENTION & CONTROL

Diabetes. Oats JN. **Baillieres Clin Obstet Gynaecol** 1995 Sep; 9(3):481–95 (67 ref.)

Preventing adolescent pregnancy and associated risks. Miller R. **Can Fam Physician** 1995 Sep;41:1525–31 (42 ref.)

Asthma in pregnancy. Mabie WC. **Clin Obstet Gynecol** 1996 Mar;39(1):56–69 (44 ref.)

Multifetal pregnancies. Smith-Levitin M, et al. **Curr Opin Obstet Gynecol** 1995 Dec;7(6):465–71 (52 ref.)

Vitamin B12 deficiency and the fortification of food with folic acid. Bower C, et al. **Eur J Clin Nutr** 1995 Nov; 49(11):787–93 (34 ref.)

Benefits and risks of episiotomy: a review of the English-language literature since 1980. Part II. Woolley RJ. **Obstet Gynecol Surv** 1995 Nov;50(11):821–35 (189 ref.)

Addressing battering during pregnancy: reducing low birth weight and ongoing abuse. Campbell JC. **Semin Perinatol** 1995 Aug;19(4):301–6 (37 ref.)

Maternal phenylketonuria: a metabolic teratogen. Levy HL, et al. **Teratology** 1996 Mar;53(3):176–84 (54 ref.)

PSYCHOLOGY

Treatment strategies for anxiety, stress, and developmental conflict during reproduction [see comments] Lederman RP. **Behav Med** 1995 Fall;21(3):113–22 (69 ref.) Comment in: Behav Med 1996 Fall;21(3):123–9.

Pharmacologic treatment of psychiatric disease in pregnancy and lactation: fetal and neonatal effects. Kuller JA, et al. **Obstet Gynecol** 1996 May;87(5 Pt 1):789–94 (38 ref.)

[Psychiatric diseases and pregnancy] Fuchs U. **Gynakologe** 1995 Dec;28(6):440–5 (16 ref.) **(Ger)**

[Fear as a risk factor in perinatology] Zdziennicki A. **Wiad Lek** 1994 Sep;47(17–18):698–9 (21 ref.) (Eng. Abstr.) **(Pol)**

RADIOGRAPHY

Radiologic management of abdominal trauma in pregnancy. Goldman SM, et al. **AJR Am J Roentgenol** 1996 Apr; 166(4):763–7 (33 ref.)

SURGERY

Primary aldosteronism in pregnancy--should it be treated surgically? Aboud E, et al. **Ir J Med Sci** 1995 Oct-Dec; 164(4):279–80 (12 ref.)

Management of spontaneous pneumothorax during pregnancy: case report and review of the literature. VanWinter JT, et al. **Mayo Clin Proc** 1996 Mar; 71(3):249–52 (27 ref.)

Laparoscopic cholecystectomy in pregnancy. A report of 6 cases and review of the literature. Wishner JD, et al. **Surg Endosc** 1996 Mar;10(3):314–8 (29 ref.)

Laparoscopic cholecystectomy during pregnancy. Lanzafame RJ. **Surgery** 1995 Oct;118(4):627–31; discussion 631–3 (28 ref.)

[Appendicitis and pregnancy. Seven case reports] Dufour P, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(4):411–5 (14 ref.) (Eng. Abstr.) **(Fre)**

[Laparoscopic cholecystectomy in pregnancy. A description of 2 cases and review of the literature] Lang RD, et al. **Chirurg** 1995 Dec;66(12):1225–9 (49 ref.) (Eng. Abstr.) **(Ger)**

[Trauma in the last trimester of pregnancy] Prokop A, et al. **Unfallchirurg** 1996 Jun;99(6):450–3 (11 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Treatment of pregnancy-related illnesses. Prevost RR. **Am Pharm** 1995 Oct;NS35(10):25–32 (14 ref.)

Clinical review 80: Management of hyperthyroidism and hypothyroidism in the pregnant woman. Roti E, et al. **J Clin Endocrinol Metab** 1996 May;81(5):1679–82 (15 ref.)

The maternal-fetal rights dilemma: honoring a woman's choice of medical care during pregnancy. Arch RR. **J Contemp Health Law Policy** 1996 Spring;12(2):637–73 (255 ref.)

Bed rest and high-risk pregnancy. Differentiating the effects of diagnosis, setting, and treatment. Maloni JA. **Nurs Clin North Am** 1996 Jun;31(2):313–25 (35 ref.)

Acute spinal cord injury and neurogenic shock in pregnancy. Gilson GJ, et al. **Obstet Gynecol Surv** 1995 Jul;50(7):556–60 (11 ref.)

The introduction of human monoclonal anti-D for therapeutic use. Fletcher A, et al. **Transfus Med Rev** 1995 Oct;9(4):314–26 (87 ref.)

[Indications for pregnancy termination in cases of pre-eclampsia, hypertension, intrauterine growth retardation, liver and heart disease] Uzan S, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24 Suppl 1:33–40 (54 ref.) **(Fre)**

[Myasthenic crisis during pregnancy: case report and literature survey] Kwieciński H, et al. **Pol Tyg Lek** 1995 Oct;50(40–44):50–2 (14 ref.) (Eng. Abstr.) **(Pol)**

[Methods of gravitational surgery on the blood in obstetrics and gynecology] Abubakirova AM, et al. **Akush Ginekol (Mosk)** 1995;(5):40–3 (45 ref.) **(Rus)**

ULTRASONOGRAPHY

First-trimester ultrasound: the essentials. Sohaey R, et al. **Semin Ultrasound CT MR** 1996 Feb;17(1):2–14 (64 ref.)

PREGNANCY COMPLICATIONS, CARDIOVASCULAR

Preeclampsia and hypertensive disorders of pregnancy. Zamorski MA, et al. **Am Fam Physician** 1996 Apr; 53(5):1595–610 (32 ref.)

Peripartum cardiomyopathy. Lampert MB, et al. **Am Heart J** 1995 Oct;130(4):860–70 (80 ref.)

Acute myocardial infarction during pregnancy and puerperium: a review. Badui E, et al. **Angiology** 1996 Aug; 47(8):739–56 (128 ref.)

Pregnancy and heart disease. Oakley CM. **Br J Hosp Med** 1996 Apr 3–16;55(7):423–6 (15 ref.)

Deep venous thrombosis and pulmonary embolism. Brown HL, et al. **Clin Obstet Gynecol** 1996 Mar;39(1):87–100 (70 ref.)

[Post-partum cardiomyopathy: medical aspects, role of heart transplantation] Bertrand E. **Arch Mal Coeur Vaiss** 1995 Nov;88(11):1635–40 (42 ref.) (Eng. Abstr.) **(Fre)**

[Cerebral venous thrombosis and arterial infarction in pregnancy and puerperium. A series of 60 cases] Ben Hamouda-M'Rad I, et al. **Rev Neurol (Paris)** 1995 Oct; 151(10):563–8 (29 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

[Pulmonary embolism and pregnancy: report of a case; review of the literature] Blondel S, et al. **J Mal Vasc** 1995; 20(4):317–22 (20 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

Treatment of hypertension in pregnant women. Sibai BM. **N Engl J Med** 1996 Jul 25;335(4):257–65 (93 ref.)

The use of calcium-channel blockers in pregnancy. Lewis R, et al. **New Horiz** 1996 Feb;4(1):115–22 (45 ref.)

Use of thrombolytics for the treatment of thromboembolic disease during pregnancy. Turrentine MA, et al. **Obstet Gynecol Surv** 1995 Jul;50(7):534–41 (52 ref.)

ETIOLOGY

When is hypertension a cause for concern? Redman C. **Practitioner** 1996 Apr;240(1561):264–8 (0 ref.)

[The role of endothelial dysfunction in the genesis of hypertensive states in pregnant women] Supriaga OM. **Akush Ginekol (Mosk)** 1995;(6):5–9 (40 ref.) **(Rus)**

METABOLISM

Calcium metabolism in normal and hypertensive pregnancy. Hojo M, et al. **Semin Nephrol** 1995 Nov;15(6):504–11 (51 ref.)

PATHOLOGY

Selected vascular lesions of the placenta. Gersell DJ. **Clin Lab Med** 1995 Sep;15(3):611–29 (73 ref.)

PHYSIOPATHOLOGY

Pre-eclampsia, autoimmune diseases and breast cancer etiology. Polednak AP. **Med Hypotheses** 1995 May; 44(5):414–8 (46 ref.)

[Hypertension and pregnancy. Diagnosis, physiopathology and treatment] Fournier A, et al. **Schweiz Med Wochenschr** 1995 Nov 25;125(47):2273–98 (145 ref.) (Eng. Abstr.) **(Fre)**

[Pregnancy in patients with congenital heart defect] Schlemmer M. **Wien Klin Wochenschr** 1995;107(20):608–12 (20 ref.) (Eng. Abstr.) **(Ger)**

[Normal pregnancy duration after maternal Fontan operation of univentricular heart] Osmers R, et al. **Z Geburtshilfe Neonatol** 1995 Sep-Oct;199(5):195–8 (15 ref.) (Eng. Abstr.) **(Ger)**

[Blood circulation in retarded and normal offspring of hypertonic pregnant women] Jakobovits A, et al. **Orv Hetil** 1996 Apr 14;137(15):793–7 (46 ref.) (Eng. Abstr.) **(Hun)**

[Clinical approach to physiologic dispnea in pregnancy] García Río F, et al. **Aten Primaria** 1996 Jan;17(1):70–4 (23 ref.) **(Spa)**

PREVENTION & CONTROL

Thrombosis and embolism. Horn EH. **Baillieres Clin Obstet Gynaecol** 1995 Sep;9(3):595–618 (95 ref.)

Calcium supplementation prevents pregnancy-induced hypertension by increasing the production of vascular nitric oxide. López-Jaramillo P, et al. **Med Hypotheses** 1995 Jul; 45(1):68–72 (73 ref.)

SURGERY

Cardiopulmonary bypass during pregnancy. Parry AJ, et al. **Ann Thorac Surg** 1996 Jun;61(6):1865–9 (47 ref.)

Cardiopulmonary bypass in pregnancy. Pomini F, et al. **Ann Thorac Surg** 1996 Jan;61(1):259–68 (65 ref.)

THERAPY

Treatment of arrhythmias during pregnancy. Page RL. **Am Heart J** 1995 Oct;130(4):871–6 (50 ref.)

Interventional cardiology in pregnancy. Presbitero P, et al. **Eur Heart J** 1996 Feb;17(2):182–8 (104 ref.)

Care of the patient with severe pregnancy induced hypertension. Walker JJ. **Eur J Obstet Gynecol Reprod Biol** 1996 Mar;65(1):127–35 (34 ref.)

Venous thromboembolism during pregnancy. Toglia MR, et al. **N Engl J Med** 1996 Jul 11;335(2):108–14 (70 ref.)

Management of diabetic pregnancy complicated by coronary artery disease and neuropathy. Hagay Z, et al.

Obstet Gynecol Clin North Am 1996 Mar;23(1):205–20 (38 ref.)

[Basic principles of current trends in the management of hypertension and kidney disease in pregnancy] Vajó Z, et al. **Orv Hetil** 1995 Nov 19;136(47):2561–6 (45 ref.) (Eng. Abstr.) **(Hun)**

[Treatment of cardiac arrhythmias during pregnancy] Rodríguez Blanco VM, et al. **Med Clin (Barc)** 1996 Jun 1;107(1):29–36 (125 ref.) **(Spa)**

URINE

Microalbuminuria: prognostic and therapeutic implications in diabetic and hypertensive pregnancy. Bar J, et al. **Diabet Med** 1995 Aug;12(8):649–56 (110 ref.)

PREGNANCY COMPLICATIONS, HEMATOLOGIC

Sickle cell disease and pregnancy. Koshy M. **Blood Rev** 1995 Sep;9(3):157–64 (60 ref.)

Megaloblastic anemia in pregnancy. Campbell BA. **Clin Obstet Gynecol** 1995 Sep;38(3):455–62 (44 ref.)

Thalassemia in pregnancy. Kilpatrick SJ, et al. **Clin Obstet Gynecol** 1995 Sep;38(3):485–96 (62 ref.)

Hemolytic anemias in pregnancy. Leduc L. **Clin Obstet Gynecol** 1995 Sep;38(3):463–71 (44 ref.)

Management of disseminated intravascular coagulopathy. Richey ME, et al. **Clin Obstet Gynecol** 1995 Sep; 38(3):514–20 (19 ref.)

Inherited disorders of coagulation in pregnancy. Rigby FB, et al. **Clin Obstet Gynecol** 1995 Sep;38(3):497–513 (81 ref.)

Pregnancy complicated by sickle hemoglobinopathy. Rust OA, et al. **Clin Obstet Gynecol** 1995 Sep;38(3):472–84 (42 ref.)

Hematologic malignancies during pregnancy. Sadural E, et al. **Clin Obstet Gynecol** 1995 Sep;38(3):535–46 (26 ref.)

Iron deficiency anemia in pregnancy. Schwartz WJ 3rd, et al. **Clin Obstet Gynecol** 1995 Sep;38(3):443–54 (45 ref.)

Management of the obstetric patient with thrombocytopenia. Sullivan CA, et al. **Clin Obstet Gynecol** 1995 Sep; 38(3):521–34 (39 ref.)

Management of the Rh-sensitized mother. Gollin YG, et al. **Clin Perinatol** 1995 Sep;22(3):545–59 (45 ref.)

Anemia of pregnancy. Mani S, et al. **Clin Perinatol** 1995 Sep; 22(3):593–607 (41 ref.)

[Consumption coagulopathy during pregnancy: a case of afibrinogenemia during the second trimester] Debiéve F, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(8):860–2 (9 ref.) (Eng. Abstr.) **(Fre)**

[Pregnancy in essential thrombocythemia. Manifestation time and risk for mother and child] Zahner J, et al. **Dtsch Med Wochenschr** 1995 Nov 3;120(44):1517–23 (55 ref.) **(Ger)**

[Hereditary antithrombin III deficiency. Report of an obstetric case and review of the literature] Leal-Tijerina G, et al. **Ginecol Obstet Mex** 1996 Apr;64:177–83 (18 ref.) (Eng. Abstr.) **(Spa)**

CHEMICALLY INDUCED

[Thromboembolism and ovarian hyperstimulation] Hocke C, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(7):691–6 (30 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Prenatal diagnosis of hematologic disorders. Phillips OP, et al. **Clin Obstet Gynecol** 1995 Sep;38(3):558–72 (30 ref.)

DRUG THERAPY

[Iron and pregnancy] Beaufrère B, et al. **Arch Pediatr** 1995 Dec;2(12):1209–18 (65 ref.) (Eng. Absr.) **(Fre)**

[Prevention and treatment of thrombosis in pregnancy] Winkler UH, et al. **Geburtshilfe Frauenheilkd** 1996 Jun; 56(6):301–12 (83 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

The aetiology of anaemia in pregnancy in West Africa. van den Broek N. **Trop D[illegible]** 1996 Jan;26(1):5–7 (16 ref.)

IMMUNOLOGY

Alloimmunization during pregnancy treated with high dose intravenous immunoglobulin. Effects on fetal hemoglobin concentration and anti-D concentrations in the mother and fetus. Gottvall T, et al. **Acta Obstet Gynecol Scand** 1995 Nov;74(10):777–83 (30 ref.)

PREVENTION & CONTROL

Anticoagulants in pregnancy. Oakley CM. **Br Heart J** 1995 Aug;74(2):107–11 (54 ref.)

Anticoagulation and pregnancy. Oakley CM. **Eur Heart J** 1995 Oct;16(10):1317–9 (22 ref.)

Management of patients with hereditary defects predisposing to thrombosis including pregnant women. Bauer KA. **Thromb Haemost** 1995 Jul;74(1):94–100 (93 ref.)

THERAPY

Therapy and prevention of thrombotic thrombocytopenic purpura during pregnancy: a clinical study of 16 pregnancies. Ezra Y, et al. **Am J Hematol** 1996 Jan; 51(1):1–6 (21 ref.)

Thrombotic thrombocytopenic purpura in pregnancy: successful treatment with plasma exchange. Case report and review of the literature. Mokrzycki MH, et al. **Blood Purif** 1995;13(5):271–82 (100 ref.)

Transfusion therapy in pregnancy. Naef RW 3rd, et al. **Clin Obstet Gynecol** 1995 Sep;38(3):547–57 (29 ref.)

Successful treatment of essential thrombocythemia in a pregnancy with recombinant interferon-alpha 2a. Milano V, et al. **J Matern Fetal Med** 1996 Mar-Apr;5(2):74–8 (30 ref.)

Treatment of essential thrombocythemia during pregnancy with interferon-alpha. Delage R, et al. **Obstet Gynecol** 1996 May;87(5 Pt 2):814–7 (15 ref.)

PREGNANCY COMPLICATIONS, INFECTIOUS

The role of urogenital tract infections in the etiology of preterm birth: a review. Martius J, et al. **Arch Gynecol Obstet** 1996;258(1):1–19 (166 ref.)

Pregnancy and leprosy neuropathy. Duncan ME. **Indian J Lepr** 1996 Jan-Mar;68(1):23–34 (34 ref.)

Human parvovirus B19 in pregnancy. Finch CM. **J Obstet Gynecol Neonatal Nurs** 1995 Jul-Aug;24(6):495–8 (20 ref.)

Group B streptococcus during the perinatal period. Shermer RH. **J Obstet Gynecol Neonatal Nurs** 1995 Jul-Aug; 24(6):562–6 (21 ref.)

Sepsis during pregnancy. Simpson KR. **J Obstet Gynecol Neonatal Nurs** 1995 Jul-Aug;24(6):550–6 (26 ref.)

Lues-lues: maternal and fetal considerations of syphilis. Ray JG. **Obstet Gynecol Surv** 1995 Dec;50(12):845–50 (30 ref.)

Perinatal herpes: current status and obstetric management strategies. Scott LL. **Pediatr Infect Dis J** 1995 Oct; 14(10):827–32; discussion 832–5 (73 ref.)

[Pregnant women with HIV infection: medical decision] Ciraru-Vigneron N. **Presse Med** 1996 May 25; 25(18):847–52 (29 ref.) (Eng. Abstr.) **(Fre)**

[Human immunodeficiency virus infection in pregnancy. General aspects] d'Ercole C, et al. **Presse Med** 1996 Jan 20;25(2):77–80 (24 ref.) (Eng. Abstr.) **(Fre)**

[Clinical aspects, diagnosis and treatment of intrauterine infections] Simakova MG, et al. **Akush Ginekol (Mosk)** 1995;(4):7–10 (54 ref.) **(Rus)**

[Current concepts on the course of pregnancies complicated by tuberculosis] Ambriz-Lopez R, et al. **Ginecol Obstet Mex** 1996 Jun;64:272–7 (30 ref.) (Eng. Abstr.) **(Spa)**

[Human immunodeficiency virus (HIV) infection in obstetrics and gynaecology] Balsdon MJ. **Rev Chil Obstet Ginecol** 1994;59(6):476–84 (0 ref.) (Eng. Abstr.) **(Spa)**

[Bacterial vaginosis II. Related pathology and therapy] Oyarzún E, et al. **Rev Chil Obstet Ginecol** 1995;60(2):135–42 (43 ref.) **(Spa)**

DIAGNOSIS

The sensitivity of HIV-1 DNA polymerase chain reaction in the neonatal period and the relative contributions of intra-uterine and intra-partum transmission. Dunn DT, et al. **AIDS** 1995 Sep;9(9):F7–11 (29 ref.)

Hepatitis E: an overview. Mast EE, et al. **Annu Rev Med** 1996;47:257–66 (55 ref.)

Tuberculosis in pregnancy: interactions, diagnosis, and management. Miller KS, et al. **Clin Obstet Gynecol** 1996 Mar;39(1):120–42 (87 ref.)

[Chlamydia infections in gynecology and obstetrics] Dieterle S. **Geburtshilfe Frauenheilkd** 1995 Sep;55(9):510–7 (65 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Tuberculosis in pregnancy: interactions, diagnosis, and management. Miller KS, et al. **Clin Obstet Gynecol** 1996 Mar;39(1):120–42 (87 ref.)

The role of antiretroviral therapy in the management of HIV infection in women. Mofenson LM. **Clin Obstet Gynecol** 1996 Jun;39(2):361–85 (113 ref.)

Treating sexually transmitted diseases in pregnancy. Vetter K. **Curr Probl Dermatol** 1996;24:164–73 (36 ref.)

The risks and benefits of antimicrobial therapy in pregnancy. Garland SM, et al. **Drug Saf** 1995 Sep;13(3):188–205 (46 ref.)

Guidelines for the use of zidovudine in pregnant women with HIV infection. De Santis M, et al. **Drugs** 1995 Jul;50(1):43–7 (34 ref.)

Antibacterial agents in pregnancy. Korzeniowski OM. **Infect Dis Clin North Am** 1995 Sep;9(3):639–51 (65 ref.)

Metronidazole: utilization in the obstetric and gynecologic patient. Schwebke JR. **Sex Transm Dis** 1995 Nov-Dec; 22(6):370–6 (84 ref.)

EPIDEMIOLOGY

Epidemiology of HIV infection in women and newborns. Gwinn M, et al. **Clin Obstet Gynecol** 1996 Jun; 39(2):292–304 (22 ref.)

Substance abuse and HIV pregnancy. Sprauve ME. **Clin Obstet Gynecol** 1996 Jun;39(2):316–32 (98 ref.)

Tuberculosis: current implications and management in obstetrics. Robinson CA, et al. **Obstet Gynecol Surv** 1996 Feb;51(2):115–24 (52 ref.)

ETHNOLOGY

Racial disparities in preterm births. The role of urogenital infections [see comments] Fiscella K. **Public Health Rep** 1996 Mar-Apr;111(2):104–13 (15 ref.) Comment in: Public Health Rep 1996 Mar-Apr;111(2):114–5.

ETIOLOGY

Preterm labor: emerging role of genital tract infections. Andrews WW, et al. **Infect Agents Dis** 1995 Dec; 4(4):196–211 (185 ref.)

[The etiology and pathogenesis of intrauterine infection] Durova AA, et al. **Akush Ginekol (Mosk)** 1995;(6):9–12 (59 ref.) **(Rus)**

MICROBIOLOGY

Pneumonia during pregnancy. Rigby FB, et al. **Clin Obstet Gynecol** 1996 Mar;39(1):107–19 (79 ref.)

[Progresses in prenatal medicine in China, 1995] Zhou Z. **Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):748–9 (0 ref.) **(Chi)**

[Genital infections as a cause of abortion in the first trimester of pregnancy. Review of the literature] Capuzzo E, et al. **Minerva Ginecol** 1995 Dec;47(12):557–60 (15 ref.) (Eng. Abstr.) **(Ita)**

[Mycoplasma infections] Silva S, et al. **Rev Chil Obstet Ginecol** 1994;59(6):485–91 (25 ref.) **(Spa)**

PREVENTION & CONTROL

Infectious diseases. Gilbert GL. **Baillieres Clin Obstet Gynaecol** 1995 Sep;9(3):529–43 (63 ref.)

Routine voluntary antepartum HIV antibody counseling and testing: a sound public health prevention strategy. Lindsay MK. **Clin Obstet Gynecol** 1996 Jun;39(2):305–15 (59 ref.)

Preventive care in obstetrics: toxoplasmosis, cytomegalovirus, and hepatitis B. Ledger WJ. **J Matern Fetal Med** 1996 May-Jun;5(3):100–5 (26 ref.)

Tuberculosis: current implications and management in obstetrics. Robinson CA, et al. **Obstet Gynecol Surv** 1996 Feb;51(2):115–24 (52 ref.)

[Prevention of infection and therapy of premature labor] Martius J. **Arch Gynecol Obstet** 1995;257(1–4):451–7 (35 ref.) **(Ger)**

[Screening for hepatitis B in pregnancy and sequelae for the newborn infant] Albrecht K. **Z Geburtshilfe Neonatol** 1995 Nov-Dec;199(6):253–6 (24 ref.) **(Ger)**

THERAPY

Management of HIV infection for the childbearing age woman. Bardeguez AD. **Clin Obstet Gynecol** 1996 Jun; 39(2):344–60 (107 ref.)

Common ethical dilemmas encountered in the management of HIV-infected women and newborns. Chervenak FA, et al. **Clin Obstet Gynecol** 1996 Jun;39(2):411–9 (16 ref.)

Pneumonia during pregnancy. Rigby FB, et al. **Clin Obstet Gynecol** 1996 Mar;39(1):107–19 (79 ref.)

Considerations in the management of maxillofacial infections in the pregnant patient. Lawrenz DR, et al. **J Oral Maxillofac Surg** 1996 Apr;54(4):474–85 (47 ref.)

Sexual infections in the antenatal patient. Priestley C, et al. **Practitioner** 1995 Sep;239(1554):552–7 (6 ref.)

Chickenpox in pregnancy: how dangerous? Venkatesan P. **Practitioner** 1996 Apr;240(1561):256–9 (5 ref.)

VETERINARY

Pathogenesis of intrauterine infections with bovine viral diarrhea virus. Moennig V, et al. **Vet Clin North Am Food Anim Pract** 1995 Nov;11(3):477–87 (51 ref.)

VIROLOGY

[HIV and family planning] Vartti AM. **Duodecim** 1994; 110(19):1765–9 (27 ref.) **(Fin)**

[Interactions between chronic viral hepatitis C and pregnancy] Grangé JD, et al. **Gastroenterol Clin Biol** 1995 May;19(5):520–4 (29 ref.) (Eng. Abstr.) **(Fre)**

[Congenital varicella. Problems with prenatal diagnosis after an early, primary maternal infection] Lécuru F, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(6):618–21 (24 ref.) (Eng. Abstr.) **(Fre)**

[Cardiac involvement in fetal parvovirus B19 infection] Soulié JC. **Pathol Biol (Paris)** 1995 May;43(5):416–9 (22 ref.) (Eng. Abstr.) **(Fre)**

[Transmission of human immunodeficiency virus to the fetus during pregnancy] d'Ercole C, et al. **Presse Med** 1996 Jan 27;25(3):119–25 (41 ref.) (Eng. Abstr.) **(Fre)**

[Varicella in pregnancy] Lécuru F, et al. **Presse Med** 1995 Oct 7;24(29):1352–7 (23 ref.) (Eng. Abstr.) **(Fre)**

PREGNANCY COMPLICATIONS, NEOPLASTIC

Clinical significance of neurofibromatosis in pregnancy. Hadi HA. **Am J Perinatol** 1995 Nov;12(6):459–61 (11 ref.)

Hematologic malignancies during pregnancy. Sadural E, et al. **Clin Obstet Gynecol** 1995 Sep;38(3):535–46 (26 ref.)

Cervical intraepithelial neoplasia in pregnancy. Harper DM, et al. **J Fam Pract** 1996 Jan;42(1):79–83 (27 ref.)
Myomas and pregnancy. Phelan JP.
Obstet Gynecol Clin North Am 1995 Dec;22(4):801–5 (28 ref.)
Cancer in pregnancy: a review of the literature. Part I. Antonelli NM, et al. **Obstet Gynecol Surv** 1996 Feb; 51(2):125–34 (185 ref.)
Cancer in pregnancy: a review of the literature. Part II. Antonelli NM, et al. **Obstet Gynecol Surv** 1996 Feb; 51(2):135–42 (185 ref.)
Leukemia during pregnancy. Ramirez-Smiley M, et al.
Oncol Nurs Forum 1995 Oct;22(9):1363–8 (16 ref.)
Breast cancer in pregnancy and lactation. DiFronzo LA, et al. **Surg Clin North Am** 1996 Apr;76(2):267–78 (45 ref.)
[Breast cancer during pregnancy] Merviel P, et al.
Bull Cancer (Paris) 1996 Apr;83(4):266–75 (51 ref.) (Eng. Abstr.) **(Fre)**
[Pheochromocytoma and pregnancy. Two case reports] Barhmi R, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995; 24(5):543–8 (24 ref.) (Eng. Abstr.) **(Fre)**
[Breast angiosarcoma. Five case reports] Gamoudi A, et al. **Rev Fr Gynecol Obstet** 1995 Oct;90(10):435–41 (18 ref.) (Eng. Abstr.) **(Fre)**
[Malignant melanoma and pregnancy] Rozen A, et al.
Harefuah 1996 Apr 15;130(8):555–7 (17 ref.) **(Heb)**

DIAGNOSIS

[Breast cancer during pregnancy.
Epidemiology—diagnosis—prognosis] Gorins A, et al.
Contracept Fertil Sex 1996 Feb;24(2):153–6 (11 ref.) (Eng. Abstr.) **(Fre)**
[Choroid metastasis in a patient with adenocarcinoma of the cervix. A case report] Wiegel T, et al.
Strahlenther Onkol 1995 Sep;171(9):539–42 (16 ref.) (Eng. Abstr.) **(Ger)**
[Pseudosarcoma botryoides during pregnancy] Lasso de la Vega J, et al. **Rev Med Panama** 1995 Jan–May;20(1–2):45–9 (8 ref.) (Eng. Abstr.) **(Spa)**

EPIDEMIOLOGY

[Breast cancer during pregnancy.
Epidemiology—diagnosis—prognosis] Gorins A, et al.
Contracept Fertil Sex 1996 Feb;24(2):153–6 (11 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Bilateral primary breast lymphoma in pregnancy: a case report and literature review. Kirkpatrick AW, et al.
Can J Surg 1996 Aug;39(4):333–5 (26 ref.)
Acute promyelocytic leukemia and pregnancy. A case report. Hoffman MA, et al. **Cancer** 1995 Dec 1;76(11):2237–41 (32 ref.)
Benign cervical leiomyoma leading to disseminated fatal malignancy. O'Connell MP, et al. **Gynecol Oncol** 1996 Jul; 62(1):119–22 (5 ref.)
Management of a carcinoma of the tongue during pregnancy: report of case. Lasaridis N, et al.
J Oral Maxillofac Surg 1996 Feb;54(2):221–4 (16 ref.)
Leiomyomatosis peritonealis disseminata: clinicopathologic analysis of five cases. Hardman WJ 3rd, et al.
South Med J 1996 Mar;89(3):291–4 (22 ref.)
[Rhombencephalic tissue in an ovarian teratoma with cerebellar foliation and maturation of the postnatal type] Fichera G. **Pathologica** 1995 Apr;87(2):203–10 (36 ref.) (Eng. Abstr.) **(Ita)**

RADIOTHERAPY

Mantle irradiation for Hodgkin's disease during pregnancy: safe and practical? [editorial; comment] Byram D.
Australas Radiol 1996 May;40(2):101–3 (30 ref.) Comment on: Australas Radiol 1996 May;40(2):146–8.

SURGERY

Surgery for pancreatic tumors during pregnancy: a case report and review of the literature. Sciscione AC, et al.
Am J Perinatol 1996 Jan;13(1):21–5 (28 ref.)
Primary aldosteronism in pregnancy—should it be treated surgically? Aboud E, et al. **Ir J Med Sci** 1995 Oct–Dec; 164(4):279–80 (12 ref.)

THERAPY

The management of urological malignancies during pregnancy. Loughlin KR. **Br J Urol** 1995 Nov;76(5):639–44 (60 ref.)
[Prolactinoma and pregnancy. Six cases and review of the literature] Helie C, et al.
J Gynecol Obstet Biol Reprod (Paris) 1996;25(2):174–8 (27 ref.) (Eng. Abstr.) **(Fre)**
[The treatment of prolactinomas during pregnancy and the lactation period] Rau H, et al. **Dtsch Med Wochenschr** 1996 Jan 5;121(1–2):28–32 (46 ref.) **(Ger)**
[Breast cancer during pregnancy] Jereczek B. **Ginekol Pol** 1995 Aug;66(8):480–3 (24 ref.) (Eng. Abstr.) **(Pol)**
[Leukemia and pregnancy. Review apropos of a clinical case] Perucca E, et al. **Rev Chil Obstet Ginecol** 1995; 60(2):118–23; discussion 123–4 (13 ref.) (Eng. Abstr.) **(Spa)**

VIROLOGY

Do human papillomaviruses have a role in the pathogenesis of bladder carcinoma? Mvula M, et al. **J Urol** 1996 Feb; 155(2):471–4 (24 ref.)

PREGNANCY COMPLICATIONS, PARASITIC

BLOOD

[Ultrasonic signs of fetal toxoplasmosis. Review of the literature] Abboud P, et al.
J Gynecol Obstet Biol Reprod (Paris) 1995;24(7):733–8 (17 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Pinworms in pregnancy. Hamblin J, et al.
J Am Board Fam Pract 1995 Jul–Aug;8(4):321–4 (15 ref.)
Acute pancreatitis caused by biliary ascaris in pregnancy. Asrat T, et al. **J Perinatol** 1995 Jul–Aug;15(4):330–2 (15 ref.)

DRUG THERAPY

Treating sexually transmitted diseases in pregnancy. Vetter K. **Curr Probl Dermatol** 1996;24:164–73 (36 ref.)
The risks and benefits of antimicrobial therapy in pregnancy. Garland SM, et al. **Drug Saf** 1995 Sep;13(3):188–205 (46 ref.)

ETIOLOGY

[Toxoplasmosis as a risk factor in pregnant women after renal transplantation] Ejmocka-Ambroziak A, et al. **Wiad Lek** 1994 Sep;47(17–18):700–1 (9 ref.) (Eng. Abstr.) **(Pol)**

IMMUNOLOGY

[Immunological interactions between malaria and pregnancy] Deloron P, et al. **Med Trop (Mars)** 1995;55(4 Suppl):67–8 (11 ref.) **(Fre)**

PREVENTION & CONTROL

Preventive care in obstetrics: toxoplasmosis, cytomegalovirus, and hepatitis B. Ledger WJ.
J Matern Fetal Med 1996 May–Jun;5(3):100–5 (26 ref.)

PREGNANCY, ECTOPIC

Cervical pregnancy: three case reports and a review of the literature. Van de Meersche M, et al. **Hum Reprod** 1995 Jul;10(7):1850–5 (42 ref.)

DIAGNOSIS

Ectopic pregnancy—Part I: Clinical and laboratory diagnosis. Brennan DF. **Acad Emerg Med** 1995 Dec;2(12):1081–9 (82 ref.)
Ectopic pregnancy—Part II: Diagnostic procedures and imaging. Brennan DF. **Acad Emerg Med** 1995 Dec; 2(12):1090–7 (76 ref.)
Ectopic pregnancy. Duchatel FC.
Curr Opin Obstet Gynecol 1995 Dec;7(6):472–6 (34 ref.)
[Current state of conservative management of ectopic pregnancy] Marin Cantu VA, et al.
Ginecol Obstet Mex 1996 Mar;64:123–30 (49 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Medical management should be routinely used as primary therapy for ectopic pregnancy. Stovall TG.
Clin Obstet Gynecol 1995 Jun;38(2):346–52 (28 ref.)
Methotrexate for nonsurgical treatment of ectopic pregnancy: nursing implications. Maiolatesi CR, et al.
J Obstet Gynecol Neonatal Nurs 1996 Mar–Apr;25(3):205–8 (16 ref.)
[Current indications for medical treatment of ectopic pregnancy] Darai E, et al. **Rev Fr Gynecol Obstet** 1995 Dec;90(12):552–7 (41 ref.) (Eng. Abstr.) **(Fre)**

EPIDEMIOLOGY

Previous cesarean delivery and the risk of ectopic pregnancy. Kendrick JS, et al. **Obstet Gynecol** 1996 Feb;87(2):297–301 (19 ref.)
[Epidemiology of ectopic pregnancy: incidence and risk factors] Coste J, et al. **Contracept Fertil Sex** 1996 Feb; 24(2):135–9 (30 ref.) (Eng. Abstr.) **(Fre)**

ETHNOLOGY

Ectopic pregnancy: a nursing approach to excess risk among minority women. Bernstein J.
J Obstet Gynecol Neonatal Nurs 1995 Nov–Dec; 24(9):803–10 (71 ref.)

ETIOLOGY

Oviductal function is critical for very early human life. Pulkkinen MO. **Ann Med** 1995 Jun;27(3):307–10 (12 ref.)
[Ectopic pregnancy: factors related to ovum anomalies?] Bouyer J, et al. **Rev Epidemiol Sante Publique** 1996 Apr; 44(2):101–10 (48 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Laparoscopic management of ectopic pregnancy. Grainger DA, et al. **Curr Opin Obstet Gynecol** 1995 Aug;7(4):277–82 (58 ref.)
Ectopic pregnancy and laparoscopy: review of 1197 patients treated by salpingectomy or salpingotomy. Maymon R, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Sep;62(1):61–7 (62 ref.)
[Ultrasonic diagnosis and laparoscopic treatment of an ovarian pregnancy. A case report and review of the literature] Riethmuller D, et al.
J Gynecol Obstet Biol Reprod (Paris) 1996;25(4):378–83 (25 ref.) (Eng. Abstr.) **(Fre)**
[Introduction of laparoscopic surgery in extrauterine pregnancy] Rempen A. **Geburtshilfe Frauenheilkd** 1995 Jul; 55(7):357–64 (28 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Ectopic pregnancy. Duchatel FC.
Curr Opin Obstet Gynecol 1995 Dec;7(6):472–6 (34 ref.)
Conservative management options for cervical pregnancy; case reports and literature review. Creinin MD, et al.
Int J Fertil Menopausal Stud 1995 Jul–Aug;40(4):175–86 (67 ref.)
[Role of conservative therapy and medical treatment in ectopic pregnancy: literature review and clinical trial comparing medical treatment and conservative laparoscopic treatment] Fernandez H, et al.
Contracept Fertil Sex 1996 Apr;24(4):297–302 (36 ref.) (Eng. Abstr.) **(Fre)**

ULTRASONOGRAPHY

Clinician's approach to ectopic pregnancy. Emerson DS, et al. **Clin Obstet Gynecol** 1996 Mar;39(1):199–222 (77 ref.)
[Ultrasonic diagnosis and laparoscopic treatment of an ovarian pregnancy. A case report and review of the literature] Riethmuller D, et al.
J Gynecol Obstet Biol Reprod (Paris) 1996;25(4):378–83 (25 ref.) (Eng. Abstr.) **(Fre)**

PREGNANCY, FIRST TRIMESTER see **PREGNANCY TRIMESTER, FIRST**

PREGNANCY, HIGH-RISK

see related
PREGNANCY COMPLICATIONS

The NST-EXPERT project: the need to evolve. Alonso-Betanzos A, et al. **Artif Intell Med** 1995 Aug; 7(4):297–313 (40 ref.)
Preconception care: a means of prevention. Cefalo RC, et al. **Baillieres Clin Obstet Gynaecol** 1995 Sep;9(3):403–16 (38 ref.)
Framing the debate: can prenatal care help to reduce the black–white disparity in infant mortality? Rowley DL.
J Am Med Wom Assoc 1995 Sep–Oct;50(5):187–93 (119 ref.)
Pregnancy after cardiac transplantation: principles of nursing care. Jordan E, et al. **J Obstet Gynecol Neonatal Nurs** 1996 Feb;25(2):131–5 (15 ref.)
Bed rest and high-risk pregnancy. Differentiating the effects of diagnosis, setting, and treatment. Maloni JA.
Nurs Clin North Am 1996 Jun;31(2):313–25 (35 ref.)
A model of home care for high-risk childbearing families. Women with diabetes in pregnancy. Persily CA, et al.
Nurs Clin North Am 1996 Jun;31(2):327–32 (11 ref.)
Use of ultrasonography in the home care of high-risk childbearing women. Stringer M. **Nurs Clin North Am** 1996 Jun;31(2):305–12 (17 ref.)
First-trimester ultrasound screening for chromosomal defects. Snijders RJ, et al. **Ultrasound Obstet Gynecol** 1996 Mar;7(3):216–26 (58 ref.)
[Possible implication of obstetric risk factors in the etiopathogenesis of schizophrenia] Verdoux H, et al.
Rev Fr Gynecol Obstet 1995 Oct;90(10):417–22 (25 ref.) (Eng. Abstr.) **(Fre)**
[Twins and multiple pregnancy] Arabin B, et al.
Arch Gynecol Obstet 1995;257(1–4):394–403 (40 ref.) **(Ger)**
[Diagnostic and clinical value of Doppler ultrasound in obstetrics] Gonser M, et al. **Geburtshilfe Frauenheilkd** 1995 Nov;55(11):605–15 (127 ref.) (Eng. Abstr.) **(Ger)**
-Obstetric prognosis after pre-eclampsia, eclampsia or HELLP syndrome- Niesert S. **Geburtshilfe Frauenheilkd** 1996 Feb;56(2):93–6 (18 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

[Rheumatic diseases in pregnancy—problems from the viewpoint of the gynecologist] Heyl W, et al.
Geburtshilfe Frauenheilkd 1995 Oct;55(10):M121–4 (21 ref.) **(Ger)**

PHYSIOLOGY

[Pregnancy in patients with congenital heart defect] Schlemmer M. **Wien Klin Wochenschr** 1995;107(20):608–12 (20 ref.) (Eng. Abstr.) **(Ger)**
[Normal pregnancy duration after maternal Fontan operation of univentricular heart] Osmers R, et al.
Z Geburtshilfe Neonatol 1995 Sep–Oct;199(5):195–8 (15 ref.) (Eng. Abstr.) **(Ger)**

PREGNANCY IN ADOLESCENCE

Preventing adolescent pregnancy and associated risks. Miller R. **Can Fam Physician** 1995 Sep;41:1525–31 (42 ref.)
Asthma in the pregnant adolescent: a review. Shulman V, et al. **J Adolesc Health** 1996 Mar;18(3):168–76 (89 ref.)
Teenage abortion in Germany: with reference to the legal system in the United States. Belling DW, et al. **J Contemp Health Law Policy** 1996 Spring;12(2):475–502 (128 ref.)
An overview of adolescent pregnancy. Yordan EE, et al. **J Pediatr Adolesc Gynecol** 1996 Aug;9(3):111–8 (46 ref.)
Sequelae of premature sexual life [comment] Creatsas G. **J R Soc Med** 1995 Jul;88(7):369–71 (12 ref.) Comment on: J R Soc Med 1995 Jul;88(7):384–8.
Public policy and adolescent pregnancy: a reexamination of the issues. Montessoro AC, et al. **Nurs Outlook** 1996 Jan–Feb;44(1):31–6 (18 ref.)

PSYCHOLOGY

Contraceptive methods: do Hispanic adolescents and their family planning care providers think about contraceptive methods the same way? Erickson PI. **Med Anthropol** 1996 May;17(1):65–82 (53 ref.)
Skills training for pregnant and parenting adolescents. Hall JA. **NIDA Res Monogr** 1995;156:255–90 (70 ref.)

STATISTICS & NUMERICAL DATA

Teenage pregnancy in the United Kingdom in the 1990s: the implications for primary care. Jacobson LD, et al. **Fam Pract** 1995 Jun;12(2):232–6 (60 ref.)

PREGNANCY IN DIABETES

see related
DIABETES, GESTATIONAL

Pre-conception care of diabetes, congenital malformations, and spontaneous abortions. Kitzmiller JL, et al. **Diabetes Care** 1996 May;19(5):514–41 (324 ref.)
Role of fetal surveillance in diabetic pregnancies. Fuentes A, et al. **J Matern Fetal Med** 1996 Mar–Apr;5(2):85–8 (12 ref.)
Fuel metabolism in deviant fetal growth in offspring of diabetic women. Hod M, et al. **Obstet Gynecol Clin North Am** 1996 Mar;23(1):259–77 (105 ref.)
The pathogenesis of diabetes-associated congenital malformations. Reece EA, et al. **Obstet Gynecol Clin North Am** 1996 Mar;23(1):29–45 (144 ref.)
The infant of the diabetic mother. Tyrala EE. **Obstet Gynecol Clin North Am** 1996 Mar;23(1):221–41 (89 ref.)
Pregnancy after pancreas transplantation: report of four new cases and review of the literature. Barrou B, et al. **Transplant Proc** 1995 Dec;27(6):3043–4 (2 ref.)
[Diabetes and pregnancy] Omori Y. **Nippon Naika Gakkai Zasshi** 1996 Mar 10;85(3):379–83 (8 ref.) **(Jpn)**

BLOOD

Glucose monitoring and insulin therapy during pregnancy. Homko CJ, et al. **Obstet Gynecol Clin North Am** 1996 Mar; 23(1):47–74 (95 ref.)

COMPLICATIONS

[Diabetic retinopathy and pregnancy] Verougstraete C. **Bull Soc Belge Ophtalmol** 1995;256:33–41 (39 ref.) (Eng. Abstr.) **(Fre)**
[Prenatal diagnosis of three caudal regression syndromes associated with maternal diabetes] Houfflin V, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(4):389–95 (40 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

[Diabetes mellitus during pregnancy] Omori Y. **Nippon Naika Gakkai Zasshi** 1996 Apr 10;85(4):536–40 (6 ref.) **(Jpn)**

MORTALITY

[Diabetes and pregnancy] Biesenbach G. **Wien Klin Wochenschr** 1996;108(10):281–8 (65 ref.) (Eng. Abstr.) **(Ger)**

NURSING

A model of home care for high-risk childbearing families. Women with diabetes in pregnancy. Persily CA, et al. **Nurs Clin North Am** 1996 Jun;31(2):327–32 (11 ref.)

PHYSIOPATHOLOGY

Guessing the weight of the baby [comment] Hall MH. **Br J Obstet Gynaecol** 1996 Aug;103(8):734–6 (24 ref.) Comment on: Br J Obstet Gynaecol 1996 Aug;103(8):747–54.

PREVENTION & CONTROL

Diabetes. Oats JN. **Baillieres Clin Obstet Gynaecol** 1995 Sep; 9(3):481–95 (67 ref.)

THERAPY

Management of diabetic pregnancy complicated by coronary artery disease and neuropathy. Hagay Z, et al. **Obstet Gynecol Clin North Am** 1996 Mar;23(1):205–20 (38 ref.)
Diabetic nephropathy and pregnancy. Kitzmiller JL, et al. **Obstet Gynecol Clin North Am** 1996 Mar;23(1):173–203 (192 ref.)
Management of hypoglycemia and diabetic ketoacidosis in pregnancy. Whiteman VE, et al. **Obstet Gynecol Clin North Am** 1996 Mar;23(1):87–107 (90 ref.)
[Is induced labor justified in diabetes, macrosomia and prolonged pregnancy?] Treisser A, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24 Suppl 1:41–7 (38 ref.) **(Fre)**
[Monitoring the pregnant diabetic patient] Heyl W, et al. **Z Geburtshilfe Neonatol** 1995 Jul–Aug;199(4):132–7 (41 ref.) (Eng. Abstr.) **(Ger)**
[Diabetes mellitus during pregnancy] Omori Y. **Nippon Naika Gakkai Zasshi** 1996 Apr 10;85(4):536–40 (6 ref.) **(Jpn)**

URINE

Microalbuminuria: prognostic and therapeutic implications in diabetic and hypertensive pregnancy. Bar J, et al. **Diabet Med** 1995 Aug;12(8):649–56 (110 ref.)

PREGNANCY, MULTIPLE

see related
PREGNANCY REDUCTION, MULTIFETAL

Ovarian hyperstimulation syndrome may be more likely if multiple pregnancy occurs following assisted conception. Mathur RS, et al. **Acta Genet Med Gemellol (Roma)** 1995; 44(3–4):233–5 (15 ref.)
The current status of multifetal pregnancy reduction. Berkowitz RL, et al. **Am J Obstet Gynecol** 1996 Apr; 174(4):1265–72 (39 ref.)
Umbilical veins in dichorionic twins. A morpho-functional assessment. Cester N, et al. **Clin Exp Obstet Gynecol** 1995; 22(3):183–97 (34 ref.)
Intrapartum management of multiple gestations. Houlihan C, et al. **Clin Perinatol** 1996 Mar;23(1):91–116 (92 ref.)
Multifetal pregnancies. Smith-Levitin M, et al. **Curr Opin Obstet Gynecol** 1995 Dec;7(6):465–71 (52 ref.)
[Thromboembolism and ovarian hyperstimulation] Hocke C, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(7):691–6 (30 ref.) (Eng. Abstr.) **(Fre)**
[Is induced labor justified in cases of scarred uterus, breech presentation and multiple pregnancy?] Schaal JP, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24 Suppl 1:57–61 (39 ref.) **(Fre)**
[Labor and delivery in twin pregnancy] Wirthner D, et al. **Rev Med Suisse Romande** 1996 Apr;116(4):255–60 (49 ref.) **(Fre)**
[Twins and multiple pregnancy] Arabin B, et al. **Arch Gynecol Obstet** 1995;257(1–4):394–403 (40 ref.) **(Ger)**

PSYCHOLOGY

Multifetal pregnancy reduction. A review of an evolving technology and its psychosocial implications. Ormont MA, et al. **Psychosomatics** 1995 Nov–Dec;36(6):522–30 (29 ref.)
[Pregnancy, labor and partnership in a family with an IVF child] Pastor VS, et al. **Geburtshilfe Frauenheilkd** 1995 Aug; 55(8):M83–7 (45 ref.) **(Ger)**

STATISTICS & NUMERICAL DATA

Assisted reproductive technologies: estimates of their contribution to multiple births and newborn hospital days in the United States. Wilcox LS, et al. **Fertil Steril** 1996 Feb;65(2):361–6 (25 ref.)

PREGNANCY OUTCOME

On intrapartum fetal monitoring. Cibils LA. **Am J Obstet Gynecol** 1996 Apr;174(4):1382–9 (71 ref.)
Clinical significance of neurofibromatosis in pregnancy. Hadi HA. **Am J Perinatol** 1995 Nov;12(6):459–61 (11 ref.)
Maternal nutrition and obstetric outcome. Steegers-Theunissen BP. **Baillieres Clin Obstet Gynaecol** 1995 Sep;9(3):431–43 (65 ref.)
Pregnancy in patients with cystic fibrosis. Hilman BC, et al. **Clin Obstet Gynecol** 1996 Mar;39(1):70–86 (54 ref.)
Asthma in pregnancy. Mabie WC. **Clin Obstet Gynecol** 1996 Mar;39(1):56–69 (44 ref.)
Maternal depressive symptoms and the risk of poor pregnancy outcome. Review of the literature and preliminary findings. Orr ST, et al. **Epidemiol Rev** 1995; 17(1):165–71 (34 ref.)
Employment-related physical activity and pregnancy outcome. Berkowitz GS. **J Am Med Wom Assoc** 1995 Sep–Oct;50(5):167–9, 174 (33 ref.)
Effects of parental exposure to solvents on pregnancy outcome. Lindbohm ML. **J Occup Environ Med** 1995 Aug; 37(8):908–14 (48 ref.)
Magnetic fields of video display terminals and pregnancy outcome. Lindbohm ML, et al. **J Occup Environ Med** 1995 Aug;37(8):952–6 (30 ref.)
Maternal pesticide exposure and pregnancy outcome. Nurminen T. **J Occup Environ Med** 1995 Aug;37(8):935–40 (27 ref.)
Female noise exposure, shift work, and reproduction. Nurminen T. **J Occup Environ Med** 1995 Aug;37(8):945–50 (31 ref.)
Psychosocial factors and pregnancy outcome: a review with emphasis on methodological issues. Paarlberg KM, et al. **J Psychosom Res** 1995 Jul;39(5):563–95 (136 ref.)
Maternal risk factors in fetal alcohol syndrome: provocative and permissive influences. Abel EL, et al. **Neurotoxicol Teratol** 1995 Jul–Aug;17(4):445–62 (327 ref.)
Race, perinatal outcome, and amniotic infection. Fiscella K. **Obstet Gynecol Surv** 1996 Jan;51(1):60–6 (54 ref.)
Individual nutrient effects on length of gestation and pregnancy outcome. Murtaugh MA, et al. **Semin Perinatol** 1995 Jun;19(3):197–210 (138 ref.)
The length of human pregnancy as calculated by ultrasonographic measurement of the fetal biparietal diameter. Kieler H, et al. **Ultrasound Obstet Gynecol** 1995 Nov;6(5):353–7 (26 ref.)
[Questions about the future of the child] David G. **Bull Acad Natl Med** 1995 Nov;179(8):1751–7 (21 ref.) (Eng. Abstr.) **(Fre)**
[Pregnancy after breast cancer] Mignot L, et al. **Contracept Fertil Sex** 1996 Apr;24(4):319–21 (16 ref.) (Eng. Abstr.) **(Fre)**
[Prognostic value of a single umbilical artery. 87 cases] Blache G, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995; 24(5):522–8 (34 ref.) (Eng. Abstr.) **(Fre)**
[Effect of smoking on the fetus and the child during pregnancy] Gueguen C, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(8):853–9 (63 ref.) (Eng. Abstr.) **(Fre)**
[Pregnancy outcome in long-term survivors with adult acute leukemia, malignant lymphoma and breast cancer] Kawamura S, et al. **Gan To Kagaku Ryoho** 1996 Jun; 23(7):821–6 (30 ref.) (Eng. Abstr.) **(Jpn)**
[Pregnancy after heart transplantation] Almeida DR, et al. **Arq Bras Cardiol** 1995 Sep;65(3):237–42 (41 ref.) (Eng. Abstr.) **(Por)**

EPIDEMIOLOGY

Trend of birthweights of African newborns: an overview. Airede AK. **East Afr Med J** 1996 Apr;73(4):271–5 (48 ref.)
Assessing congenital anomalies after preimplantation genetic diagnosis. Simpson JL, et al. **J Assist Reprod Genet** 1996 Feb;13(2):170–6 (30 ref.)
Nutritional risk factors among low-income pregnant US women: the Centers for Disease Control and Prevention (CDC) Pregnancy Nutrition Surveillance System, 1979 through 1993. Perry GS, et al. **Semin Perinatol** 1995 Jun; 19(3):211–21 (46 ref.)

ETHNOLOGY

The influence of race and previous pregnancy outcome on outcomes in the current pregnancy. Gardner MO, et al. **Semin Perinatol** 1995 Jun;19(3):191–6 (23 ref.)

PREGNANCY, PROLONGED

[Prolonged pregnancy. Review of the literature] Boisselier P, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995; 24(7):739–46 (52 ref.) (Eng. Abstr.) **(Fre)**
[Is induced labor justified in diabetes, macrosomia and prolonged pregnancy?] Treisser A, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24 Suppl 1:41–7 (38 ref.) **(Fre)**
[Postterm pregnancy--importance of this problem in modern obstetrics] Chazan B, et al. **Ginekol Pol** 1996 Mar; 67(3):148–56 (20 ref.) (Eng. Abstr.) **(Pol)**

PREGNANCY PROTEINS

METABOLISM

Interaction between pregnancy-induced bioactive peptides and the placental proteases. Mizutani S, et al. **Reprod Fertil Dev** 1995;7(6):1431–6 (26 ref.)

PREGNANCY RATE

How effective are contraceptives? The determination and measurement of pregnancy rates. Potter LS. **Obstet Gynecol** 1996 Sep;88(3 Suppl):13S–23S (51 ref.)

PREGNANCY REDUCTION, MULTIFETAL

The current status of multifetal pregnancy reduction. Berkowitz RL, et al. **Am J Obstet Gynecol** 1996 Apr; 174(4):1265–72 (39 ref.)

PSYCHOLOGY

Multifetal pregnancy reduction. A review of an evolving technology and its psychosocial implications. Ormont MA, et al. **Psychosomatics** 1995 Nov–Dec;36(6):522–30 (29 ref.)

PREGNANCY, TEENAGE see **PREGNANCY IN ADOLESCENCE**

PREGNANCY TESTS

Emergency department pregnancy testing. Olshaker JS. **J Emerg Med** 1996 Jan–Feb;14(1):59–65 (75 ref.)

PREGNANCY TRIMESTER, FIRST

The spectrum of first-trimester ultrasound findings. Sohaey R, et al. **Curr Probl Diagn Radiol** 1996 Mar–Apr; 25(2):54–75 (93 ref.)

Experience with early amniocentesis. Sundberg K, et al. **J Perinat Med** 1995;23(3):149–58 (35 ref.)

First trimester serum screening for Down's syndrome [see comments] Wald NJ, et al. **Prenat Diagn** 1995 Dec; 15(13):1227–40 (44 ref.) Comment in: Prenat Diagn 1995 Dec;15(3):1209–13.

Early amniocentesis: a clinical review. Wilson RD. **Prenat Diagn** 1995 Dec;15(13):1259–73 (97 ref.)

PHYSIOLOGY

The temporary anatomical structures prominent in the first trimester may be fulfilling exchange functions assigned to the placenta in the second and third trimester. Docherty SM, et al. **Hum Reprod** 1996 Jun;11(6):1157–61 (38 ref.)

PREGNANCY, TUBAL

DIAGNOSIS

[Current state of conservative management of ectopic pregnancy] Marin Cantu VA, et al. **Ginecol Obstet Mex** 1996 Mar;64:123–30 (49 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

[Obstetrical complications of adenomyosis. Literature review and two case reports] Bensaid F, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(4):416–8 (5 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Conservative versus radical surgery for tubal pregnancy. A review. Clausen I. **Acta Obstet Gynecol Scand** 1996 Jan; 75(1):8–12 (44 ref.)

For tubal pregnancy, surgical treatment is usually best. Gomel V. **Clin Obstet Gynecol** 1995 Jun;38(2):353–61 (48 ref.)

[Radical laparoscopic surgery of ectopic pregnancy: results from a continuous series of 383 interventions] Dubuisson JB, et al. **Contracept Fertil Sex** 1996 Feb;24(2):140–6 (36 ref.) (Eng. Abstr.) **(Fre)**

PREGNANCY, UNWANTED

Contraception, unintended pregnancies, and sexually transmitted diseases: why isn't a simple solution possible? Cates W Jr. **Am J Epidemiol** 1996 Feb 15;143(4):311–8 (30 ref.)

Consensus statement on emergency contraception. **Contraception** 1995 Oct;52(4):211–3 (6 ref.)

PSYCHOLOGY

Directive counseling on long-acting contraception. Moskowitz E, et al. **Am J Public Health** 1996 Jun; 86(6):787–90 (24 ref.)

PREGNANEDIOL

URINE

[Pregnanediol (P2)] Kambegawa A. **Nippon Rinsho** 1995 Mar; 53 Su Pt 2:576–9 (11 ref.) **(Jpn)**

PREGNANETRIOL

URINE

[Pregnanetriol (P3)] Kambegawa A. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:580–3 (11 ref.) **(Jpn)**

PREGNATRIENES

THERAPEUTIC USE

Lazaroids. CNS pharmacology and current research. Clark WM, et al. **Drugs** 1995 Dec;50(6):971–83 (64 ref.)

Possibilities of brain protection with tirilazad after cardiac arrest. Sterz F, et al. **Semin Thromb Hemost** 1996; 22(1):105–12 (37 ref.)

PREGNENEDIONES

ADMINISTRATION & DOSAGE

[Crohn disease: prevention and drug therapy] Gross V, et al. **Chirurg** 1995 Aug;66(8):757–63 (42 ref.) (Eng. Abstr.) **(Ger)**

THERAPEUTIC USE

Deflazacort. A review of its pharmacological properties and therapeutic efficacy. Markham A, et al. **Drugs** 1995 Aug; 50(2):317–33 (68 ref.)

Budesonide. A review of its pharmacological properties and therapeutic efficacy in inflammatory bowel disease. Spencer CM, et al. **Drugs** 1995 Nov;50(5):854–72 (51 ref.)

PREGNENOLONE

BLOOD

[Pregnenolone] Nakamura S, et al. **Nippon Rinsho** 1995 Mar; 53 Su Pt 2:464–6 (7 ref.) **(Jpn)**

PREHOSPITAL EMERGENCY CARE see **EMERGENCY MEDICAL SERVICES**

PREIMPLANTATION PHASE

Update in preimplantation genetic diagnosis: successes, advances, and problems. Grifo JA, et al. **Curr Opin Obstet Gynecol** 1996 Apr;8(2):135–8 (31 ref.)

Preimplantation genetic diagnosis of cystic fibrosis (delta F508). Ao A, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Mar;65(1):7–10 (23 ref.)

IMMUNOLOGY

[Expression and role of complement regulatory proteins on human gametes and pre-implantation embryos] Fénichel P, et al. **Contracept Fertil Sex** 1995 Sep;23(9):576–80 (50 ref.) (Eng. Abstr.) **(Fre)**

[Regulation by maternally derived cytokines of pre-implantation development and uterine receptiveness] Stewart CL, et al. **Contracept Fertil Sex** 1995 Sep; 23(9):555–61 (37 ref.) (Eng. Abstr.) **(Fre)**

PREJUDICE

Freudian suspicion versus suspicion of Freud. Crews F. **Ann N Y Acad Sci** 1996 Jun 24;775:470–82 (58 ref.)

The value of curiosity and naiveté for the cross-cultural psychotherapist. Dyche L, et al. **Fam Process** 1995 Dec; 34(4):389–99 (33 ref.)

Gender bias in the diagnosis and treatment of coronary artery disease. Beery TA. **Heart Lung** 1995 Nov–Dec;24(6):427–35 (64 ref.)

HIV and homophobia: nurses as advocates. Mackereth PA. **J Adv Nurs** 1995 Oct;22(4):670–6 (42 ref.)

Heterosexism in nursing education. Gray DP, et al. **J Nurs Educ** 1996 May;35(5):204–10 (12 ref.)

Making medical recruitment practices fair. Maddock S. **Postgrad Med J** 1996 Mar;72(845):147–50 (8 ref.)

Stigma, HIV and AIDS: an exploration and elaboration of a stigma trajectory. Alonzo AA, et al. **Soc Sci Med** 1995 Aug;41(3):303–15 (79 ref.)

PREKALLIKREIN

ANALYSIS

[Fletcher factor, Fitzgerald factor] Saito H. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:167–70 (10 ref.) **(Jpn)**

PREMARIN see **ESTROGENS, CONJUGATED**

PREMATURE ATRIAL BEATS see **ATRIAL PREMATURE COMPLEXES**

PREMATURE ATRIAL CONTRACTIONS see **ATRIAL PREMATURE COMPLEXES**

PREMATURE BEATS see **CARDIAC COMPLEXES, PREMATURE**

PREMATURE CARDIAC COMPLEXES see **CARDIAC COMPLEXES, PREMATURE**

PREMATURE SUPRAVENTRICULAR BEATS see **ATRIAL PREMATURE COMPLEXES**

PREMATURE VENTRICULAR BEATS see **VENTRICULAR PREMATURE COMPLEXES**

PREMATURE VENTRICULAR CONTRACTIONS see **VENTRICULAR PREMATURE COMPLEXES**

PREMEDICAL EDUCATION see **EDUCATION, PREMEDICAL**

PREMEDICATION

see related
ANTIBIOTIC PROPHYLAXIS
PREANESTHETIC MEDICATION

Amifostine: the preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies. Capizzi R. **Semin Oncol** 1996 Aug;23(4 Suppl 8):2–17 (99 ref.)

[Is preventive perioperative dopamine administration of value?] Bund M, et al. **Anaesthesiol Reanim** 1995; 20(3):76–81 (45 ref.) (Eng. Abstr.) **(Ger)**

PREMENOPAUSE

Breast cancer screening in premenopausal women: current recommendations and opportunities for research. Mettlin C, et al. **Ann Med** 1995 Aug;27(4):461–5 (15 ref.)

The perimenopause: a critical time in a woman's life. Sulak PJ. **Int J Fertil Menopausal Stud** 1996 Mar–Apr;41(2):85–9 (18 ref.)

Perimenopausal and postmenopausal hormone replacement therapy. Part 2. Hormonal regimens and complementary and alternative therapies. Lichtman R. **J Nurse Midwifery** 1996 May–Jun;41(3):195–210 (109 ref.)

Discomforts of the perimenopause. LeBoeuf FJ, et al. **J Obstet Gynecol Neonatal Nurs** 1996 Feb;25(2):173–80 (29 ref.)

The perimenopause and contraception. Shaaban MM. **Maturitas** 1996 Mar;23(2):181–92 (77 ref.)

DRUG EFFECTS

The effects of estradiol valerate plus medroxyprogesterone acetate and conjugated estrogens plus medrogestone on climacteric symptoms and metabolic variables in perimenopausal women. Egarter C, et al. **Acta Obstet Gynecol Scand** 1996 Apr;75(4):386–93 (40 ref.)

PHYSIOLOGY

Exercise and bone mass in young and premenopausal women. Snow CM. **Bone** 1996 Jan;18(1 Suppl):51S–55S (30 ref.)

PREMENSTRUAL SYNDROME

A clinician's guide to the premenstrual syndrome. Barnhart KT, et al. **Med Clin North Am** 1995 Nov;79(6):1457–72 (73 ref.)

Rethinking the label: who benefits from the PMS construct? Gurevich M. **Women Health** 1995;23(2):67–98 (102 ref.)

EPIDEMIOLOGY

[Premenstrual dysphoric disorder: an epidemiological study] de la Gándara Martín JJ, et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1996 May–Jun;24(3):111–7 (10 ref.) (Eng. Abstr.) **(Spa)**

PSYCHOLOGY

The menstrual cycle and the well being of women. Bancroft J. **Soc Sci Med** 1995 Sep;41(6):785–91 (29 ref.)

The menstrual cycle, science and femininity: assumptions underlying menstrual cycle research. Nicolson P. **Soc Sci Med** 1995 Sep;41(6):779–84 (64 ref.)

Theory and methodology in premenstrual syndrome research. Walker A. **Soc Sci Med** 1995 Sep;41(6):793–800 (56 ref.)

[Psychological aspects of the premenstrual syndrome] Ben-Zion IZ, et al. **Harefuah** 1995 Dec 1;129(11):512–5 (15 ref.) **(Heb)**

[Premenstrual dysphoric disorder: an epidemiological study] de la Gándara Martín JJ, et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1996 May–Jun;24(3):111–7 (10 ref.) (Eng. Abstr.) **(Spa)**

PREMENSTRUAL TENSION see **PREMENSTRUAL SYNDROME**

PREMOLAR see **BICUSPID**

PRENATAL CARE

The active mismanagement of labour [comment] Oláh KS, et al. **Br J Obstet Gynaecol** 1996 Aug;103(8):729–31 (12 ref.) Comment on: Br J Obstet Gynaecol 1996 Aug;103(8):763–8. Comment on: Br J Obstet Gynaecol 1996 Aug;103(8):769–75.

Routine voluntary antepartum HIV antibody counseling and testing: a sound public health prevention strategy. Lindsay MK. **Clin Obstet Gynecol** 1996 Jun;39(2):305–15 (59 ref.)

Antenatal Care. Bréart G. **Curr Opin Obstet Gynecol** 1995 Dec;7(6):417–9 (10 ref.)

Intervention model for substance-using women. Tiedje LB, et al. **Image J Nurs Sch** 1996 Summer;28(2):113–8 (69 ref.)

Role of fetal surveillance in diabetic pregnancies. Fuentes A, et al. **J Matern Fetal Med** 1996 Mar–Apr;5(2):85–8 (12 ref.)

Prenatal and postnatal: use of corticosteroids. Corbett JV, et al. **MCN Am J Matern Child Nurs** 1995 Nov–Dec; 20(6):346 (9 ref.)

The Role of General Practice in Maternity Care. Royal College of General Practitioners. Report of the RCGP Maternity Care Group. **Occas Pap R Coll Gen Pract** 1995 Nov;(72):1–14 (24 ref.)

Gestational diabetes: ensuring a successful outcome. Davidson JA, et al. **Postgrad Med** 1996 Mar;99(3):165–72 (14 ref.)

Preventive care in pregnancy. Morrow CE. **Prim Care** 1995 Dec;22(4):755–84 (93 ref.)

[Indication of corticotherapy for fetal pulmonary maturation] Tchobroutsky C. **Contracept Fertil Sex** 1996 May; 24(5):413–6 (11 ref.) (Eng. Abstr.) **(Fre)**

[Sense and success of psychosomatic preparation for labor] Stauber M. **Arch Gynecol Obstet** 1995;257(1–4):129–35 (8 ref.) **(Ger)**

[Postterm pregnancy--importance of this problem in modern

obstetrics] Chazan B, et al. **Ginekol Pol** 1996 Mar; 67(3):148–56 (20 ref.) (Eng. Abstr.) **(Pol)**

LEGISLATION & JURISPRUDENCE

Prenatal care and public policy: lessons for promoting women's health. Hughes DC, et al. **J Am Med Wom Assoc** 1995 Sep–Oct;50(5):156–9, 163 (32 ref.)

METHODS

Enhancing perinatal outcome in homeless women: the challenge of providing comprehensive health care. Beal AC, et al. **Semin Perinatol** 1995 Aug;19(4):307–13 (19 ref.)

Cocaine using during pregnancy and low birth weight: the impact of prenatal care and drug treatment. Chazotte C, et al. **Semin Perinatol** 1995 Aug;19(4):293–300 (40 ref.)

Pregnancy behind bars. Safyer SM, et al. **Semin Perinatol** 1995 Aug;19(4):314–22 (37 ref.)

[Monitoring the pregnant diabetic patient] Heyl W, et al. **Z Geburtshilfe Neonatol** 1995 Jul–Aug;199(4):132–7 (41 ref.) (Eng. Abstr.) **(Ger)**

ORGANIZATION & ADMINISTRATION

Family planning: an essential component of prenatal care. Klerman LV, et al. **J Am Med Wom Assoc** 1995 Sep–Oct; 50(5):147–51 (31 ref.)

Framing the debate: can prenatal care help to reduce the black–white disparity in infant mortality? Rowley DL. **J Am Med Wom Assoc** 1995 Sep–Oct;50(5):187–93 (119 ref.)

Transforming prenatal care: reflections on the past and present with implications for the future. Maloni JA, et al. **J Obstet Gynecol Neonatal Nurs** 1996 Jan;25(1):17–23 (51 ref.)

TRENDS

Prenatal care: an update and future trends. Groutz A, et al. **Curr Opin Obstet Gynecol** 1995 Dec;7(6):452–60 (83 ref.)

UTILIZATION

A review of problems of universal access to prenatal care. York R, et al. **Nurs Clin North Am** 1996 Jun;31(2):279–92 (40 ref.)

PRENATAL DIAGNOSIS

see related
GENETIC COUNSELING

Molecular diagnosis of Duchenne muscular dystrophy in Singapore. Low PS, et al. **Ann Acad Med Singapore** 1996 Jan;25(1):84–9 (18 ref.)

Compound W: a potential marker in maternal serum for assessing fetal thyroid function. Wu SY, et al. **Compr Ther** 1995 Oct;21(10):594–6 (17 ref.)

Can nucleated erythrocytes found in maternal venous blood be used in the noninvasive prenatal diagnosis of fetal chromosome abnormalities? Slunga–Tallberg A, et al. **Eur J Hum Genet** 1995;3(4):264–70 (46 ref.)

Preimplantation genetic diagnosis of cystic fibrosis (delta F508). Ao A, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Mar;65(1):7–10 (23 ref.)

Maternal serum markers for fetal trisomy 21 screening. Muller F, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Mar;65(1):3–6 (30 ref.)

Advances in the prenatal and molecular diagnosis of the hemoglobinopathies and thalassemias. Embury SH. **Hemoglobin** 1995 Sep;19(5):237–61 (125 ref.)

Uniparental disomy in humans: development of an imprinting map and its implications for prenatal diagnosis. Ledbetter DH, et al. **Hum Mol Genet** 1995;4 Spec No:1757–64 (100 ref.)

Prenatal diagnosis by analysis of fetal cells in maternal blood. Bianchi DW. **J Pediatr** 1995 Dec;127(6):847–56 (91 ref.)

Pitfalls in the diagnosis of nonconjoined monoamniotic twins. Strohbehn K, et al. **J Perinatol** 1995 Nov–Dec;15(6):484–93 (56 ref.)

Intrauterine diagnosis of sex chromosome aneuploidy. Linden MG, et al. **Obstet Gynecol** 1996 Mar;87(3):468–75 (51 ref.)

Prenatal diagnosis of trisomy 9. Six cases and a review of the literature. Saura R, et al. **Prenat Diagn** 1995 Jul; 15(7):609–14 (25 ref.)

Screening for Down syndrome in the first trimester. Powell KJ, et al. **Reprod Fertil Dev** 1995;7(6):1413–7 (54 ref.)

In vitro assays to predict the severity of hemolytic disease of the newborn. Hadley AG. **Transfus Med Rev** 1995 Oct; 9(4):302–13 (68 ref.)

Prevalence of fetal facial cleft at different stages of pregnancy. Snijders RJ, et al. **Ultrasound Obstet Gynecol** 1995 Nov;6(5):327–9 (11 ref.)

[Improved prenatal diagnostic possibilities for congenital abnormalities and chromosomal disorders. Advantages and disadvantages of screening and diagnostic methods] Nørgaard–Pedersen B, et al. **Ugeskr Laeger** 1996 Feb 26; 158(9):1201–7 (29 ref.) (Eng. Abstr.) **(Dan)**

–Screening for toxoplasmosis in pregnancy– Extermann P. **Arch Gynecol Obstet** 1995;256 Suppl:S170–2 (10 ref.) **(Fre)**

–Toxoplasmosis in pregnancy: arguments in favor of systematic screening in Switzerland– Hohlfeld P. **Arch Gynecol Obstet** 1995;256 Suppl:S165–9 (26 ref.) **(Fre)**

–Prenatal diagnosis of brain damage in the fetus– Dürig P. **Arch Gynecol Obstet** 1995;256 Suppl:S43–9 (46 ref.) **(Ger)**

[Chlamydia infections in gynecology and obstetrics] Dieterle S. **Geburtshilfe Frauenheilkd** 1995 Sep;55(9):510–7 (65 ref.) (Eng. Abstr.) **(Ger)**

[Intrauterine diagnosis and therapy of fetal arrhythmias] Gembruch U, et al. **Gynakologe** 1995 Oct;28(5):329–45 (69 ref.) **(Ger)**

[Diagnostic–therapeutic concept in hydrocephalus] Voigt HJ. **Gynakologe** 1995 Oct;28(5):346–55 (27 ref.) **(Ger)**

[Applications of magnetic resonance tomography (MRT) in obstetrics] Wischnik A, et al. **Gynakologe** 1995 Oct; 28(5):321–8 (18 ref.) **(Ger)**

[Screening for hepatitis B in pregnancy and sequelae for the newborn infant] Albrecht K. **Z Geburtshilfe Neonatol** 1995 Nov–Dec;199(6):253–6 (24 ref.) **(Ger)**

[Prenatal diagnosis of lysosomal diseases] Owada M, et al. **Nippon Rinsho** 1995 Dec;53(12):2926–32 (22 ref.) **(Jpn)**

METHODS

The NST–EXPERT project: the need to evolve. Alonso–Betanzos A, et al. **Artif Intell Med** 1995 Aug; 7(4):297–313 (40 ref.)

Prenatal diagnosis of hematologic disorders. Phillips OP, et al. **Clin Obstet Gynecol** 1995 Sep;38(3):558–72 (30 ref.)

Prenatal diagnosis of genetic disorders. Kulkarni ML, et al. **Indian Pediatr** 1995 Nov;32(11):1229–38 (28 ref.)

The diagnosis of foetal distress: a challenge to midwives. Mead M. **J Adv Nurs** 1996 May;23(5):975–83 (73 ref.)

Fluorescent PCR: a new technique for PGD of sex and single–gene defects. Findlay I, et al. **J Assist Reprod Genet** 1996 Feb;13(2):96–103 (28 ref.)

What are the present possibilities for the prenatal diagnosis of primary hyperoxaluria? Danpure CJ. **Pediatr Nephrol** 1996 Apr;10(2):190 (7 ref.)

Non– or minimally invasive prenatal diagnostic tests on maternal blood samples or transcervical cells. Adinolfi M. **Prenat Diagn** 1995 Oct;15(10):889–96 (79 ref.)

The presence of hydrops fetalis in a fetus with congenital mesoblastic nephroma. Liu YC, et al. **Prenat Diagn** 1996 Apr;16(4):363–5 (8 ref.)

Prenatal diagnosis of Blackfan–Diamond syndrome: case report and review of the literature. McLennan AC, et al. **Prenat Diagn** 1996 Apr;16(4):349–53 (15 ref.)

Prenatal screening for haemoglobin disorders [see comments] Petrou M, et al. **Prenat Diagn** 1995 Dec;15(13):1275–95 (60 ref.) Comment in: Prenat Diagn 1995 Dec;15(13):1209–13.

Antenatal screening for Down syndrome. Wald NJ. **Prog Clin Biol Res** 1995;393:27–42 (25 ref.)

[Prenatal diagnosis of cutaneous genetic diseases by the study of fetal DNA] Hovnanian A, et al. **Ann Dermatol Venereol** 1995;122(4):173–85 (151 ref.) (Eng. Abstr.) **(Fre)**

[Detection of fetal cells in maternal blood: towards a noninvasive prenatal diagnosis] Simpson JL, et al. **Contracept Fertil Sex** 1995 Jul–Aug;23(7–8):445–50 (64 ref.) (Eng. Abstr.) **(Fre)**

[Congenital varicella. Problems with prenatal diagnosis after an early, primary maternal infection] Lécuru F, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(6):618–21 (24 ref.) (Eng. Abstr.) **(Fre)**

[Magnetic resonance imaging of the fetus. Contribution to antenatal diagnosis] Garel C, et al. **Presse Med** 1996 Mar 16;25(9):452–6 (23 ref.) (Eng. Abstr.) **(Fre)**

[Reliability of invasive prenatal diagnosis in the first trimester in comparison with standard amniocentesis] Crombach G, et al. **Gynakologe** 1995 Oct;28(5):302–14 (93 ref.) **(Ger)**

[Maternal serum screening for detection of fetal chromosome abnormalities] Holzgreve W, et al. **Gynakologe** 1995 Oct; 28(5):280–8 (44 ref.) **(Ger)**

[Noninvasive prenatal diagnosis of fetal cells in maternal blood] Tutschek B, et al. **Gynakologe** 1995 Oct; 28(5):289–301 (74 ref.) **(Ger)**

[Blood markers in the prenatal diagnosis of Down's syndrome: the triple test] Ortega–Benito JM. **Med Clin (Barc)** 1995 Sep 9;105(7):264–8 (32 ref.) **(Spa)**

PSYCHOLOGY

Towards informed decisions about prenatal testing: a review [see comments] Marteau TM. **Prenat Diagn** 1995 Dec; 15(13):1215–26 (75 ref.) Comment in: Prenat Diagn 1995 Dec;15(13):1209–13.

STATISTICS & NUMERICAL DATA

Assessing congenital anomalies after preimplantation genetic diagnosis. Simpson JL, et al. **J Assist Reprod Genet** 1996 Feb;13(2):170–6 (30 ref.)

TRENDS

The development of magnetic resonance imaging in obstetrics. Duncan KR. **Br J Hosp Med** 1996 Feb 21–Mar 5;55(4):178–81 (20 ref.)

PRENATAL DIAGNOSIS, ULTRASONIC see **ULTRASONOGRAPHY, PRENATAL**

PRENATAL EXPOSURE DELAYED EFFECTS

see related
MATERNAL EXPOSURE
PATERNAL EXPOSURE

Prenatal exposure to phenytoin, facial development, and a possible role for vitamin K. Howe AM, et al. **Am J Med Genet** 1995 Sep 11;58(3):238–44 (52 ref.)

Introduction to functional teratology. Dencker L. **Arch Toxicol Suppl** 1996;18:51–6 (10 ref.)

Aplasia cutis congenita after exposure to methimazole: a causal relationship? Vogt T, et al. **Br J Dermatol** 1995 Dec; 133(6):994–6 (23 ref.)

Ethanol neurobehavioural teratogenesis and the role of L–glutamate in the fetal hippocampus. Reynolds JD, et al. **Can J Physiol Pharmacol** 1995 Sep;73(9):1209–23 (175 ref.)

Prenatally drug–exposed children in out–of–home care: are we looking at the whole picture? Franck EJ. **Child Welfare** 1996 Jan–Feb;75(1):19–34 (30 ref.)

The risk of childhood cancer from intrauterine and preconceptional exposure to ionizing radiation. Wakeford R. **Environ Health Perspect** 1995 Nov;103(11):1018–25 (84 ref.)

Perinatal risk factors and schizophrenia: selective review and methodological concerns. McNeil TF. **Epidemiol Rev** 1995; 17(1):107–12 (46 ref.)

Recent changes in the etiology of hearing disorders: perinatal drug exposure. Gerber SE, et al. **J Am Acad Audiol** 1995 Sep;6(5):371–7 (50 ref.)

Brief report: genetic, prenatal, and immunologic factors. Smalley SL, et al. **J Autism Dev Disord** 1996 Apr; 26(2):195–8 (16 ref.)

Prenatal cocaine exposure. Consequences for child and family. Eyler FD, et al. **J Fla Med Assoc** 1995 Sep; 82(9):603–6 (52 ref.)

Neurobiological plausibility of prenatal nutritional deprivation as a risk factor for schizophrenia. Brown AS, et al. **J Nerv Ment Dis** 1996 Feb;184(2):71–85 (98 ref.)

Favism in a female newborn infant whose mother ingested fava beans before delivery. Corchia C, et al. **J Pediatr** 1995 Nov;127(5):807–8 (8 ref.)

Lymphoblastic lymphoma following prenatal exposure to phenytoin. Murray JC, et al. **J Pediatr Hematol Oncol** 1996 May;18(2):241–3 (23 ref.)

Prenatal cocaine produces biochemical and functional changes in brain serotonin systems in rat progeny. Battaglia G, et al. **NIDA Res Monogr** 1995;158:115–48 (56 ref.)

Effects of prenatal morphine and cocaine on postnatal behaviors and brain neurotransmitters. Vathy I. **NIDA Res Monogr** 1995;158:88–114 (118 ref.)

Overview of the effects of abuse and drugs on pregnancy and offspring. Zuckerman B, et al. **NIDA Res Monogr** 1995; 149:16–38 (89 ref.)

Children's passive and prenatal exposure to cigarette smoke. Byrd RS, et al. **Pediatr Ann** 1995 Dec;24(12):640–2, 644–5 (37 ref.)

Methylene blue–induced phototoxicity: an unrecognized complication. Porat R, et al. **Pediatrics** 1996 May; 97(5):717–21 (19 ref.)

Behavioural consequences of maternal exposure to natural cannabinoids in rats. Navarro M, et al. **Psychopharmacology (Berl)** 1995 Nov;122(1):1–14 (110 ref.)

Sustained alterations in postnatal respiratory function following sub–optimal intrauterine conditions. Harding R. **Reprod Fertil Dev** 1995;7(3):431–41 (67 ref.)

Postnatal consequences of chronic intrauterine compromise. Henderson–Smart DJ. **Reprod Fertil Dev** 1995;7(3):559–65 (44 ref.)

Time trends in schizophrenia: changes in obstetric risk factors with industrialization. Warner R. **Schizophr Bull** 1995; 21(3):483–500 (160 ref.)

Cocaine using during pregnancy and low birth weight: the impact of prenatal care and drug treatment. Chazotte C, et al. **Semin Perinatol** 1995 Aug;19(4):293–300 (40 ref.)

Antenatal drugs affecting vitamin K status of the fetus and the newborn. Astedt B. **Semin Thromb Hemost** 1995; 21(4):364–70 (84 ref.)

Observations on vitamin K deficiency in the fetus and newborn: has nature made a mistake? Israels LG, et al. **Semin Thromb Hemost** 1995;21(4):357–63 (36 ref.)

[Isotretinoin (RoAccutane) embryopathy. A case report] Pilorget H, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(5):511–5 (14 ref.) (Eng. Abstr.) **(Fre)**

[Fetal environment and coronary ischemia risk: review of the literature with particular reference to syndrome X] Lehingue Y. **Rev Epidemiol Sante Publique** 1996 Jun; 44(3):262–77 (57 ref.) (Eng. Abstr.) **(Fre)**

[Possible implication of obstetric risk factors in the etiopathogenesis of schizophrenia] Verdoux H, et al. **Rev Fr Gynecol Obstet** 1995 Oct;90(10):417–22 (25 ref.) (Eng. Abstr.) **(Fre)**

[A possible association between the maternal administration of metamizole and persistent pulmonary hypertension in a newborn infant] Martí Solé JJ, et al. **An Esp Pediatr** 1996 Apr;44(4):387–8 (10 ref.) **(Spa)**

PRENEOPLASTIC CONDITIONS see **PRECANCEROUS CONDITIONS**

PRENIDATION PHASE see **PREIMPLANTATION**

PRENIDATION PHASE

PHASE

PREOPERATIVE CARE

Pre versus post-operative radiotherapy of resectable squamous cell carcinoma of the head and neck. Wennerberg J. **Acta Otolaryngol (Stockh)** 1995 Jul;115(4):465-74 (63 ref.)

The preoperative bleeding time test: assessing its clinical usefulness. Gewirtz AS, et al. **Cleve Clin J Med** 1995 Nov-Dec;62(6):379-82 (41 ref.)

Prophylaxis in bowel surgery. Nichols RL, et al. **Curr Clin Top Infect Dis** 1995;15:76-96 (89 ref.)

Preoperative assessment of the patient with cardiac disease. Mangano DT. **Curr Opin Cardiol** 1995 Sep;10(5):530-42 (121 ref.)

Preoperative assessment and perioperative management of cardiac ischemic risk in noncardiac surgery. Coley CM, et al. **Curr Probl Cardiol** 1996 May;21(5):289-382 (325 ref.)

What are the risks of cystectomy and the advances in perioperative care? Montie JE, et al. **Int J Urol** 1995 Jun; 2 Suppl 2:89-104 (78 ref.)

Preoperative assessment of patients with known or suspected coronary disease. Mangano DT, et al. **N Engl J Med** 1995 Dec 28;333(26):1750-6 (55 ref.)

Clinical evaluation and noninvasive electroencephalography. Preoperative evaluation. Cascino GD. **Neuroimaging Clin N Am** 1995 Nov;5(4):547-58 (58 ref.)

Preoperative investigations. Hannallah RS. **Paediatr Anaesth** 1995;5(5):325-9 (17 ref.)

The preoperative management of the child with a heart murmur. McEwan AI, et al. **Paediatr Anaesth** 1995; 5(3):151-6 (28 ref.)

Surgically significant nutritional supplements. Petry JJ. **Plast Reconstr Surg** 1996 Jan;97(1):233-40 (70 ref.)

Preoperative cardiac evaluation. Assessing risk before noncardiac surgery. Almany SL, et al. **Postgrad Med** 1995 Oct;98(4):171-4, 180-2 (12 ref.)

Preoperative estimate of extent of disease in T1c: how well can we predict? Austenfeld MS. **Semin Urol Oncol** 1995 Aug;13(3):176-80 (42 ref.)

Consensus conference on autologous transfusion. Preoperative autologous donation. Thomas MJ, et al. **Transfusion** 1996 Jul;36(7):633-9 (94 ref.)

[Perioperative artificial nutrition programmed for the adult surgical patient. Saint-Mandé, December 16, 1994: The Francophone Society of Enteral and Parenteral Nutrition and the French Society of Anesthesia and Resuscitation] **Ann Gastroenterol Hepatol (Paris)** 1995 Oct;31(5):310-9 (0 ref.) **(Fre)**

[Is traditional preoperative fasting still applicable?] Wrenger K, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May; 31(4):250-4 (36 ref.) **(Ger)**

[The recent trend in preoperative fasting] Kawasaki J, et al. **Masui** 1995 Aug;44(8):1154-8 (31 ref.) (Eng. Abstr.) **(Jpn)**

[Preparing patients with hematologic diseases for surgical interventions] Podolak-Dawidziak M, et al. **Pol Arch Med Wewn** 1995 May;93(5):390-4 (21 ref.) **(Pol)**

ECONOMICS

"Routine" preoperative studies. Which studies in which patients? Marcello PW, et al. **Surg Clin North Am** 1996 Feb;76(1):11-23 (42 ref.)

METHODS

Minimising cardiac anaesthetic risk: the tortoise or the hare? Juste RN, et al. **Anaesthesia** 1996 Mar;51(3):255-62 (63 ref.)

Preoperative risk assessment: many studies, few solutions. Is a cardiac risk assessment paradigm possible? [editorial; comment] Mangano DT. **Anesthesiology** 1995 Nov; 83(5):897-901 (11 ref.) Comment on: Anesthesiology 1995 Nov;83(5):906-17.

Preoperative strategies in the management of Wilms tumor. de Kraker J, et al. **Hematol Oncol Clin North Am** 1995 Dec;9(6):1275-85 (12 ref.)

Preoperative laboratory evaluation. Velanovich V. **J Am Coll Surg** 1996 Jul;183(1):79-87 (75 ref.)

Patient preparation and monitoring for carotid stenting: the operating room nurse's perspective. Plat S, et al. **J Endovasc Surg** 1996 May;3(2):224-7 (6 ref.)

How to assess the nose for rhinoplasty. Willett JM. **J Otolaryngol** 1996 Feb;25(1):23-5 (5 ref.)

Perioperative care in the elderly urologic patient. Smith R, et al. **Urol Clin North Am** 1996 Feb;23(1):27-41 (51 ref.)

[Blood salvage: a conditional safety] Andreassian B, et al. **J Mal Vasc** 1996;21 Suppl A:22-35 (48 ref.) (Eng. Abstr.) **(Fre)**

[Orthodontic pre- and postoperative treatment in bimaxillary osteotomy] Scheuer H, et al. **Fortschr Kiefer Gesichtschir** 1995;40:11-20 (19 ref.) **(Ger)**

STANDARDS

Evaluating cardiac risk in noncardiac surgery patients. Bronson DL, et al. **Cleve Clin J Med** 1995 Nov-Dec; 62(6):391-400 (39 ref.)

Postoperative pulmonary complications: risk assessment, prevention, and treatment. Hayden SP, et al. **Cleve Clin J Med** 1995 Nov-Dec;62(6):401-7 (27 ref.)

Preoperative screening: what tests are necessary? Jones T, et al. **Cleve Clin J Med** 1995 Nov-Dec;62(6):374-8 (39 ref.)

PREOPTIC AREA

ENZYMOLOGY

Effects of testosterone and its metabolites on aromatase-immunoreactive cells in the quail brain: relationship with the activation of male reproductive behavior. Balthazart J, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1-6 Spec No):185-200 (125 ref.)

PHYSIOLOGY

The sexually dimorphic medial preoptic nucleus of quail: a key brain area mediating steroid action on male sexual behavior. Panzica GC, et al. **Front Neuroendocrinol** 1996 Jan;17(1):51-125 (287 ref.)

Differential control of proceptive and receptive components of female rat sexual behavior by the preoptic area. Sakuma Y. **Jpn J Physiol** 1995;45(2):211-28 (103 ref.)

PREOVULATORY PHASE see **FOLLICULAR PHASE**

PREPAID GROUP HEALTH ORGANIZATIONS see **HEALTH MAINTENANCE ORGANIZATIONS**

PREPAID HEALTH PLANS

ECONOMICS

Breakeven under capitation: pure and simple? Boles KE, et al. **Health Care Manage Rev** 1996 Winter;21(1):38-47 (15 ref.)

PREPROSTHETIC ORAL SURGERY see **SURGERY, ORAL, PREPROSTHETIC**

PRESBYCUSIS

Presbycusis and occupational hearing loss. Rosenhall U, et al. **Occup Med** 1995 Jul-Aug;10(3):593-607 (73 ref.)

PRESBYOPIA

ETIOLOGY

The aetiology of presbyopia: a summary of the role of lenticular and extralenticular structures. Gilmartin B. **Ophthalmic Physiol Opt** 1995 Sep;15(5):431-7 (82 ref.)

PATHOLOGY

[Ophthalmoscopic study of the retinal nerve fiber layer] Jonas JB, et al. **Klin Monatsbl Augenheilkd** 1996 Feb;208(2):aA3-9 (0 ref.) **(Ger)**

SURGERY

Success of monovision in presbyopes: review of the literature and potential applications to refractive surgery. Jain S, et al. **Surv Ophthalmol** 1996 May-Jun;40(6):491-9 (67 ref.)

PRESBYTIS see **CERCOPITHECIDAE**

PRESCRIPTION INSURANCE see **INSURANCE, PHARMACEUTICAL SERVICES**

PRESCRIPTIONS, DRUG

Strategies for improving prescribing practice [see comments] Anderson GM, et al. **Can Med Assoc J** 1996 Apr 1; 154(7):1013-7 (38 ref.) Comment in: Can Med Assoc J 1996 Jun 1;154(11):1620.

Switching drug availability from prescription only to over-the-counter status. Are elderly patients at increased risk? Benrimoj SI, et al. **Drugs Aging** 1995 Oct;7(4):255-65 (152 ref.)

Drug prescription in Italy. Maggini M, et al. **Eur J Clin Pharmacol** 1996;49(6):429-30 (7 ref.)

Government regulatory influences on opioid prescribing and their impact on the treatment of pain of nonmalignant origin. Hill CS Jr. **J Pain Symptom Manage** 1996 May; 11(5):287-98 (38 ref.)

Prescriptive authority for advanced practice nurses: current and future perspectives. McDermott KC. **Oncol Nurs Forum** 1995 Sep;22(8 Suppl):25-30 (33 ref.)

[[Wallonian general physicians. Which prescriptions should be given to elderly persons over 75 years?] Franck J, et al. **Rev Med Liege** 1996 Feb;51(2):163-74 (47 ref.) **(Fre)**

[Indication for gastroscopy is not the problem. It may prevent medication without previous diagnosis!] Järhult J. **Lakartidningen** 1996 Jun 26;93(26-27):2518-20 (22 ref.) **(Swe)**

STANDARDS

Setting standards of prescribing performance in primary care: use of a consensus group of general practitioners and application of standards to practices in the north of England. Bateman DN, et al. **Br J Gen Pract** 1996 Jan; 46(402):20-5 (12 ref.)

Improving physician prescribing practices: bridge over troubled waters [editorial] MacLeod SM. **Can Med Assoc J** 1996 Mar 1;154(5):675-7 (10 ref.)

STATISTICS & NUMERICAL DATA

[Epidemiology of the use of anxiolytic and hypnotic drugs in France and in the world] Pélissolo A, et al. **Encephale** 1996 May-Jun;22(3):187-96 (68 ref.) (Eng. Abstr.) **(Fre)**

PRESCRIPTIONS, NON-DRUG

Hemodialysis vascular access: effect on urea kinetics and the dialysis prescription. Butterly DW, et al. **Am J Nephrol** 1996;16(1):45-51 (32 ref.)

The dialysis prescription: reuse. Maidment HJ, et al. **Am J Nephrol** 1996;16(1):52-9 (73 ref.)

Targets in CAPD and APD prescription. Blake PG. **Perit Dial Int** 1996;16 Suppl 1:S143-6 (17 ref.)

Peritoneal dialysis prescription for neonates. Fischbach M. **Perit Dial Int** 1996;16 Suppl 1:S512-4 (23 ref.)

The impact of peritoneal permeability and residual renal function on PD prescription. Harty J, et al. **Perit Dial Int** 1996;16 Suppl 1:S147-52 (18 ref.)

STANDARDS

Impaired delivery of dialysis: diagnosis and correction. Delmez JA, et al. **Am J Nephrol** 1996;16(1):29-34 (15 ref.)

PRESENTATION, BREECH see **BREECH PRESENTATION**

PRESERVATION, BIOLOGICAL

Trehalose metabolism--new horizons in technological applications. Panek AD. **Braz J Med Biol Res** 1995 Feb; 28(2):169-81 (98 ref.)

METHODS

Storage and preservation of blood and urine for trace element analysis. A review. Subramanian KS. **Biol Trace Elem Res** 1995 Aug-Sep;49(2-3):187-210 (96 ref.)

PRESERVATION, FOOD see **FOOD PRESERVATION**

PRESERVATIVES, PHARMACEUTICAL

see related
ANTIOXIDANTS

ADVERSE EFFECTS

[Source and clinical significance of allergy for thiomersal, an organic mercury compound] van 't Veen AJ, et al. **Ned Tijdschr Geneeskd** 1996 Feb 10;140(6):297-300 (31 ref.) **(Dut)**

PRESSORECEPTORS

see related
BAROREFLEX

PHYSIOLOGY

Baroreflex and chemoreflex control of fetal hormone secretion. Wood CE. **Reprod Fertil Dev** 1995;7(3):479-89 (94 ref.)

ULTRASTRUCTURE

Elastin and mechanoreceptor mechanisms with special reference to the mammalian carotid sinus. Kimani JK. **Ciba Found Symp** 1995;192:215-30; discussion 230-6 (68 ref.)

PRESSURE

see related
ATMOSPHERIC PRESSURE
BLOOD PRESSURE
MANOMETRY

Intramuscular pressures for monitoring different tasks and muscle conditions. Sejersted OM, et al. **Adv Exp Med Biol** 1995;384:339-50 (56 ref.)

Understanding physical inactivation processes: combined preservation opportunities using heat, ultrasound and pressure. Earnshaw RG, et al. **Int J Food Microbiol** 1995 Dec;28(2):197-219 (122 ref.)

High pressure influences on gene and protein expression. Bartlett DH, et al. **Res Microbiol** 1995 Oct;146(8):697-706 (63 ref.)

[Treatment of keloids of the earlobe (see comments)] Vegter F, et al. **Ned Tijdschr Geneeskd** 1995 Aug 19; 139(33):1678-80 (18 ref.) Comment in: Ned Tijdschr Geneeskd 1995 Oct 14;139(41):2110-1. Comment in: Ned Tijdschr Geneeskd 1995 Nov 25;139(47):2453. **(Dut)**

ADVERSE EFFECTS

Major vascular injury from high-pressure water jet. Harvey RL, et al. **J Trauma** 1996 Jan;40(1):165-7 (15 ref.)

PRESSURE SORE see **DECUBITUS ULCER**

PRESSURE ULCER see **DECUBITUS ULCER**

PRESYNAPTIC RECEPTORS see **RECEPTORS, PRESYNAPTIC**

PRESYNAPTIC TERMINALS

DRUG EFFECTS

Excitotoxic blocking strategies in amyotrophic lateral sclerosis. Hugon J. **Adv Neurol** 1995;68:245–52; discussion 253–8 (56 ref.)

METABOLISM

Excitotoxic blocking strategies in amyotrophic lateral sclerosis. Hugon J. **Adv Neurol** 1995;68:245–52; discussion 253–8 (56 ref.)

Mediatophore and other presynaptic proteins. A cybernetic linking at the active zone. Dunant Y, et al. **J Physiol Paris** 1995;89(3):147–56 (68 ref.)

PHYSIOLOGY

Fatigue at the neuromuscular junction. Branch point vs. presynaptic vs. postsynaptic mechanisms. Sieck GC, et al. **Adv Exp Med Biol** 1995;384:83–100 (90 ref.)

Backpropagation of action potentials generated at ectopic axonal loci: hypothesis that axon terminals integrate local environmental signals. Pinault D. **Brain Res Brain Res Rev** 1995 Jul;21(1):42–92 (484 ref.)

The basement membrane at the neuromuscular junction: a synaptic mediatrix. Carbonetto S, et al. **Curr Opin Neurobiol** 1995 Oct;5(5):596–605 (64 ref.)

Presynaptic excitability. Jackson MB. **Int Rev Neurobiol** 1995; 38:201–51 (296 ref.)

Presynaptic facilitation revisited: state and time dependence. Byrne JH, et al. **J Neurosci** 1996 Jan 15;16(2):425–35 (132 ref.)

Synaptic plasticity: stairway to memory. Jodar L, et al. **Jpn J Pharmacol** 1995 Aug;68(4):359–87 (285 ref.)

SECRETION

The neuronal exocytotic fusion machine: some new developments. Chapman ER, et al. **Neuropharmacology** 1995 Nov;34(11):1343–9 (64 ref.)

v- and t-SNAREs in neuronal exocytosis: a need for additional components to define sites of release. Galli T, et al. **Neuropharmacology** 1995 Nov;34(11):1351–60 (63 ref.)

PREVALENCE

Sources of variability in prevalence rates of Alzheimer's disease. Corrada M, et al. **Int J Epidemiol** 1995 Oct; 24(5):1000–5 (37 ref.)

The law of halves. Herman J. **J Clin Epidemiol** 1996 May; 49(5):595–8 (40 ref.)

PREVALENCE STUDIES see **CROSS-SECTIONAL STUDIES**

PREVENTION, PRIMARY see **PRIMARY PREVENTION**

PREVENTIVE HEALTH SERVICES

see related
HEALTH PROMOTION
IMMUNIZATION

Prevention. How much harm? How much benefit? 4. The ethics of informed consent for preventive screening programs. Marshall KG. **Can Med Assoc J** 1996 Aug 15; 155(4):377–83 (57 ref.)

Prevention. How much harm? How much benefit? 3. Physical, psychological and social harm. Marshall KG. **Can Med Assoc J** 1996 Jul 15;155(2):169–76 (94 ref.)

[Parent and child care: medical efficacy] Verloove-Vanhorick SP. **Ned Tijdschr Geneeskd** 1996 Apr 20;140(16):874–8 (40 ref.) **(Dut)**

ECONOMICS

The cost of comprehensive preventive medical services for adolescents. Gans JE, et al. **Arch Pediatr Adolesc Med** 1995 Nov;149(11):1226–34 (52 ref.)

ORGANIZATION & ADMINISTRATION

Prevention and the reforming U.S. health care system: changing roles and responsibilities for public health. Gordon RL, et al. **Annu Rev Public Health** 1996;17:489–509 (86 ref.)

Secondary prevention of excessive alcohol use: assessing the prospects of implementation. Botelho RJ, et al. **Fam Pract** 1996 Apr;13(2):182–93 (139 ref.)

Alcohol-problem prevention research policy: the need for a phases research model. Holder H, et al. **J Public Health Policy** 1995;16(3):324–46 (43 ref.)

The primary health care provider's role in sexual assault prevention. Holmes MM. **Womens Health Issues** 1995 Winter;5(4):224–32 (42 ref.)

STANDARDS

Developing evidence-based clinical practice guidelines: lessons learned by the US Preventive Services Task Force. Woolf SH, et al. **Annu Rev Public Health** 1996;17:511–38 (104 ref.)

Prevention. How much harm? How much benefit? 2. Ten potential pitfalls in determining the clinical significance of benefits. Marshall KG. **Can Med Assoc J** 1996 Jun 15; 154(12):1837–43 (61 ref.)

Cervical cancer screening: are the 1989 recommendations still valid? National Workshop on Screening for Cancer of the Cervix [see comments] Parboosingh EJ, et al. **Can Med Assoc J** 1996 Jun 15;154(12):1847–53 (18 ref.) Comment in: Can Med Assoc J 1996 Jun 15;154(12):1867–9.

TRENDS

Strengthening individual and community capacity to prevent disease and promote health: in search of relevant theories and principles. Freudenberg N, et al. **Health Educ Q** 1995 Aug;22(3):290–306 (83 ref.)

PREVENTIVE MEDICINE

see related
HEALTH PROMOTION

Aging and disease: extending functional life span. Harman D. **Ann N Y Acad Sci** 1996 Jun 15;786:321–36 (87 ref.)

Beta-carotene, carotenoids, and disease prevention in humans. Mayne ST. **FASEB J** 1996 May;10(7):690–701 (70 ref.)

Preventive care in obstetrics: toxoplasmosis, cytomegalovirus, and hepatitis B. Ledger WJ. **J Matern Fetal Med** 1996 May-Jun;5(3):100–5 (26 ref.)

Head injury mechanisms and the concept of preventive management: a review and critical synthesis. Ommaya AK. **J Neurotrauma** 1995 Aug;12(4):527–46 (101 ref.)

The potentiality and practicality of a 'salt-free' diet for the prevention and amelioration of human disorders. Leeming RA. **Med Hypotheses** 1996 Jan;46(1):45–51 (45 ref.)

EDUCATION

Preventive medicine: notes toward an agenda for change. Guidotti TL. **Am J Prev Med** 1996 May-Jun;12(3):165–71 (24 ref.)

Medical schools, the social contract and population medicine: McMaster revisited. Coulter ID, et al. **J Manipulative Physiol Ther** 1995 Oct;18(8):554–8 (25 ref.)

ORGANIZATION & ADMINISTRATION

Preventive medicine: notes toward an agenda for change. Guidotti TL. **Am J Prev Med** 1996 May-Jun;12(3):165–71 (24 ref.)

TRENDS

The future of preventive medicine. Council on Long Range Planning and Development. **Prev Med** 1996 Jan-Feb; 25(1):73–81 (65 ref.)

PRIAPISM

Priapism: a historical and update review. Magoha GA. **East Afr Med J** 1995 Jun;72(6):399–401 (61 ref.)

CHEMICALLY INDUCED

Priapism associated with psychotropic drugs. Patel AG, et al. **Br J Hosp Med** 1996 Mar 20-Apr 2;55(6):315–9 (63 ref.)

[Erection disorders and priapism due to drugs] Meinhardt W, et al. **Ned Tijdschr Geneeskd** 1995 Sep 16;139(37):1871–3 (24 ref.) **(Dut)**

DRUG THERAPY

Intracavernous pharmacotherapy: treatment for the aging erectile response. Broderick GA. **Urol Clin North Am** 1996 Feb;23(1):111–26 (123 ref.)

ETIOLOGY

Posttraumatic high-flow priapism treated by N-butyl-cyanoacrylate embolization. Numan F, et al. **Cardiovasc Intervent Radiol** 1996 Jul-Aug;19(4):278–80 (22 ref.)

[Klinefelter's syndrome as the only pathology associated with priapism. A clinical case] Fernández Fernández A, et al. **Arch Esp Urol** 1995 Nov;48(9):962–3 (4 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

ABC of Urology. Urological emergencies in general practice [see comments] Dawson C, et al. **BMJ** 1996 Mar 30; 312(7034):838–40 (0 ref.) Comment in: BMJ 1996 Jul 13;313(7049):112; discussion 112–3.

Posttraumatic high-flow priapism treated by N-butyl-cyanoacrylate embolization. Numan F, et al. **Cardiovasc Intervent Radiol** 1996 Jul-Aug;19(4):278–80 (22 ref.)

PRILOCAINE

[Use of topical anesthesia--EMLA cream] Raveh T, et al. **Harefuah** 1996 Apr 1;130(7):490–1 (26 ref.) **(Heb)**

PRIMACLONE see **PRIMIDONE**

PRIMARY CARE see **PRIMARY HEALTH CARE**

PRIMARY CARE PHYSICIANS see **PHYSICIANS, FAMILY**

PRIMARY HEALTH CARE

Prescribing exercise for health: a simple framework for primary care [see comments] Will PM, et al. **Am Fam Physician** 1996 Feb 1;53(2):579–85 (16 ref.) Comment in: Am Fam Physician 1996 Feb 1;53(2):484–6.

Evaluating primary care follow-up of breast cancer: methods and preliminary results of three studies. Grunfeld E, et al. **Ann Oncol** 1995;6 Suppl 2:47–52 (30 ref.)

The primary care of patients who have bodily concerns. Blackwell B, et al. **Arch Fam Med** 1996 Sep;5(9):457–63 (65 ref.)

Bereavement: a protocol for primary care. Charlton R, et al. **Br J Gen Pract** 1995 Aug;45(397):427–30 (49 ref.)

Primary care of children with HIV infection. Forsyth BW. **Curr Opin Pediatr** 1995 Oct;7(5):502–12 (57 ref.)

Ethnography: a stepwise approach for primary care researchers. Ventres WB, et al. **Fam Med** 1996 Jan; 28(1):52–6 (25 ref.)

Community-oriented primary care programs. Bailey RN. **J Am Optom Assoc** 1995 Oct;66(10):631–3 (7 ref.)

Compliance issues in primary care. Lieberman JA 3rd. **J Clin Psychiatry** 1996;57 Suppl 7:76–82; discussion 83–5 (20 ref.)

Psychiatric screening in geriatric primary care: should it be for depression alone? Lish JD, et al. **J Geriatr Psychiatry Neurol** 1995 Jul;8(3):141–53 (129 ref.)

Is cardiovascular screening in primary care worthwhile? Coope JR. **J Hum Hypertens** 1995 Oct;9(10):785–6 (20 ref.)

Primary care for women. Assessment and management of headache. Barrett E. **J Nurse Midwifery** 1996 Mar-Apr; 41(2):117–24 (23 ref.)

Primary care for women. Management of common musculoskeletal disorders. Benetti MC, et al. **J Nurse Midwifery** 1996 Mar-Apr;41(2):173–87 (40 ref.)

Primary care for women. Management of common respiratory problems. Mays M, et al. **J Nurse Midwifery** 1996 Mar-Apr;41(2):139–54 (50 ref.)

Primary care for women. Management of common problems of the head and neck. Phillips LP, et al. **J Nurse Midwifery** 1996 Mar-Apr;41(2):101–16 (55 ref.)

Primary care for women. Management and treatment of gastrointestinal disorders. Shaw B. **J Nurse Midwifery** 1996 Mar-Apr;41(2):155–72 (20 ref.)

Primary care for women. Comprehensive assessment and management of common mental health problems. Weintraub TA, et al. **J Nurse Midwifery** 1996 Mar-Apr; 41(2):125–38 (53 ref.)

Primary care of the HIV patient: standard practice and new developments in the era of managed care. Kocurek K. **Med Clin North Am** 1996 Mar;80(2):375–410 (204 ref.)

Recurrent aphthous stomatitis: primary care management. Petersen MJ, et al. **Nurse Pract** 1996 May;21(5):36–40, 42, 47 (32 ref.)

[Diagnostic ultrasound imaging in municipal health care centers (editorial)] Kunnamo I. **Duodecim** 1994; 110(21):1971–3 (11 ref.) **(Fin)**

[Management and monitoring of transient work incapacity. Is the primary care model effective?] Alberquilla Menéndez-Asenjo A, et al. **Aten Primaria** 1996 Jan; 17(1):40–6 (33 ref.) (Eng. Abstr.) **(Spa)**

[Classification systems in case-mix groups in ambulatory care. Perspectives for our primary health care] Juncosa S, et al. **Aten Primaria** 1996 Jan;17(1):76–82 (34 ref.) **(Spa)**

MANPOWER

The virtual health economy: telemedicine and the supply of primary care physicians in rural America. McCarthy D. **Am J Law Med** 1995;21(1):111–30 (176 ref.)

Balancing primary versus specialty care [see comments] Shi L. **J R Soc Med** 1995 Aug;88(8):428–32 (62 ref.) Comment in: J R Soc Med 1995 Aug;88(8):425.

Primary care: specialists or generalists. Gabriel SE. **Mayo Clin Proc** 1996 Apr;71(4):415–9 (62 ref.)

METHODS

Developmental monitoring in primary care. Goldfarb CE, et al. **Can Fam Physician** 1996 Aug;42:1527–32, 1535–6 (22 ref.)

Primary care of the adolescent patient. Faigel HC. **Hosp Pract (Off Ed)** 1996 Apr 15;31(4):127–33, 137–8, 144–8 (10 ref.)

[Family counseling in primary health care: a systemic approach] Jarabo Crespo Y, et al. **Aten Primaria** 1995 Nov 30;16(9):557–62 (27 ref.) **(Spa)**

ORGANIZATION & ADMINISTRATION

Primary care and the maelstrom of health care reform in the United States of America. Curtis P.

Br J Gen Pract 1995 Aug;45(397):433–7 (36 ref.)
Structured management in primary care of patients with epilepsy [editorial; comment] White P. **Br J Gen Pract** 1996 Jan;46(402):3–4 (14 ref.) Comment on: Br J Gen Pract 1996 Jan;46(402):37–42.
Home healthcare: the role of the primary care physician. Goldberg AI. **Compr Ther** 1995 Nov;21(11):633–8 (20 ref.)
Primary health care progress in nursing citations. MacIntosh J, et al. **Int Nurs Rev** 1995 Jul–Aug;42(4):115–20 (13 ref.)
Linking quality improvement with primary health care. Sukati NA. **Int Nurs Rev** 1995 Jul–Aug;42(4):109–14, 124 (36 ref.)
Nurse-managed primary care center. Newland JA, et al. **Nurs Clin North Am** 1996 Sep;31(3):471–86 (20 ref.)
Teamwork in rural practice. Cunningham WF, et al. **Occas Pap R Coll Gen Pract** 1995 Sep;(71):19–22 (45 ref.)
Clinical guidelines and their implementation. Forrest D, et al. **Postgrad Med J** 1996 Jan;72(843):19–22 (13 ref.)
The primary health care provider's role in sexual assault prevention. Holmes MM. **Womens Health Issues** 1995 Winter;5(4):224–32 (42 ref.)

STANDARDS

The quality of cervical cancer screening: a primary care perspective. Curtis P, et al. **Am J Med Qual** 1996 Spring; 11(1):11–7 (49 ref.)
Primary care as form or content? Mottur-Pilson C. **Am J Med Qual** 1995 Winter;10(4):177–82 (26 ref.)
Health care for persons with non-insulin-dependent diabetes mellitus. The German experience. Berger M, et al. **Ann Intern Med** 1996 Jan 1;124(1 Pt 2):153–5 (11 ref.)
Working effectively with interpreters in the primary care setting. Poss JE, et al. **Nurse Pract** 1995 Dec;20(12):43–7 (9 ref.)
[Professional profile of primary health care personnel. A Delphi study] Molina Durán F, et al. **Aten Primaria** 1996 Jan;17(1):24–32 (21 ref.) (Eng. Abstr.) **(Spa)**

STATISTICS & NUMERICAL DATA

Epidemiology of mental disorders in primary care settings. Goldberg D. **Epidemiol Rev** 1995;17(1):182–90 (59 ref.)

PRIMARY PREVENTION

Preventive dentistry and the family physician. Clark MM, et al. **Am Fam Physician** 1996 Feb 1;53(2):619–26, 631–2 (30 ref.)
Extending the benefit of lipid-regulating therapy to primary prevention. Jones PH, et al. **Am J Cardiol** 1995 Sep 28; 76(9):118C–121C (17 ref.)
Accounting for cluster randomization: a review of primary prevention trials, 1990 through 1993. Simpson JM, et al. **Am J Public Health** 1995 Oct;85(10):1378–83 (43 ref.)
Interdisciplinary "case studies" and training experts for primary prevention of environmentally-born health hazard. Dobrowolski JW. **Arch Toxicol Suppl** 1996;18:391–403 (16 ref.)
Primary prevention of coronary heart disease in women. Meilahn EN, et al. **Cardiology** 1995;86(4):286–98 (134 ref.)
Epidemiology, prevention and screening for prostate cancer. Pavone-Macaluso M. **Eur Urol** 1996;29 Suppl 2:49–53 (21 ref.)
Primary prevention of hepatocellular carcinoma. Yu SZ. **J Gastroenterol Hepatol** 1995 Nov–Dec;10(6):674–82 (24 ref.)
Cancer prevention strategies for the future: risk identification and preventive intervention. Colditz GA, et al. **Milbank Q** 1995;73(4):621–51 (104 ref.)
Screening, health promotion, and prevention in women. Bowman MA, et al. **Prim Care** 1995 Dec;22(4):661–77 (98 ref.)
Prevention and screening in the nursing home. Gershman K, et al. **Prim Care** 1995 Dec;22(4):731–53 (106 ref.)
Health maintenance and prevention in the elderly. Gleich GS. **Prim Care** 1995 Dec;22(4):697–711 (50 ref.)
Screening, health promotion, and prevention in men. Horst T, et al. **Prim Care** 1995 Dec;22(4):679–95 (72 ref.)
Screening for disease, cost-effectiveness, and guidelines. Meyer DL. **Prim Care** 1995 Dec;22(4):591–9 (18 ref.)
Prevention in practice. Ethnic groups. Millar J, et al. **Prim Care** 1995 Dec;22(4):713–30 (27 ref.)
Prevention in adults. Molberg P. **Prim Care** 1995 Dec; 22(4):653–60 (21 ref.)
Preventive care in pregnancy. Morrow CE. **Prim Care** 1995 Dec;22(4):755–84 (93 ref.)
Preventive health care for children. Natarajan A, et al. **Prim Care** 1995 Dec;22(4):619–36 (33 ref.)
The primary care physician as a sports medicine and exercise advocate and activist. Rouzier PA. **Prim Care** 1995 Dec; 22(4):785–804 (43 ref.)
Preventive health care for infants birth to two years of age. Sand PO, et al. **Prim Care** 1995 Dec;22(4):601–18 (25 ref.)
Preventive health care for teenagers and young adults. Schaff EA, et al. **Prim Care** 1995 Dec;22(4):637–52 (27 ref.)
Ethical aspects of prevention. Tomatis L. **Scand J Work Environ Health** 1995 Aug;21(4):245–51 (44 ref.)
[Is breast cancer prevention by tamoxifen possible?] Namer M, et al. **Bull Cancer (Paris)** 1995 Jul;82 Suppl 3:155s–167s (65 ref.) (Eng. Abstr.) **(Fre)**
[Prevention, standards and future developments in medical specialties--prevention] Vosteen KH. **Z Arztl Fortbild (Jena)** 1995 Dec;89(7):749–59 (0 ref.) **(Ger)**
[The treatment of hypercholesterolemia in primary and secondary prevention] Sirtori CR. **Ann Ital Med Int** 1995 Oct;10 Suppl:48S–52S (22 ref.) (Eng. Abstr.) **(Ita)**
[The primary and secondary prevention of allergic diseases in the child "at risk" for atopy: a review of the literature and the authors' personal experience] Bruno G, et al. **Pediatr Med Chir** 1995 May–Jun;17(3):199–207 (125 ref.) (Eng. Abstr.) **(Ita)**
[Quality in preventive and health promotion activities] Blomberg I. **Nord Med** 1995;110(10):246–9 (15 ref.) (Eng. Abstr.) **(Swe)**

ECONOMICS

Economic evaluation of HIV prevention programs. Holtgrave DR, et al. **Annu Rev Public Health** 1996; 17:467–88 (114 ref.)
Cost-effectiveness of alternative interventions for the prevention and treatment of coronary heart disease. Crowley S, et al. **Aust J Public Health** 1995 Aug; 19(4):336–46 (77 ref.)
Prophylaxis for stress-related gastrointestinal hemorrhage: a cost effectiveness analysis. Ben-Menachem T, et al. **Crit Care Med** 1996 Feb;24(2):338–45 (59 ref.)

METHODS

Epidemiology and prevention of breast cancer. Kelsey JL, et al. **Annu Rev Public Health** 1996;17:47–67 (65 ref.)
Pathways to suicide prevention. Murphy BM, et al. **Br J Hosp Med** 1995 Jun 21–Jul 11;54(1):11–4 (18 ref.)
Preventing adolescent pregnancy and associated risks. Miller R. **Can Fam Physician** 1995 Sep;41:1525–31 (42 ref.)
Nonlipid primary and secondary prevention strategies for coronary heart disease. Maron DJ. **Clin Cardiol** 1996 May; 19(5):419–23 (36 ref.)
The effect of hypo-allergenic formulas in infants at risk of allergic disease. Halken S, et al. **Eur J Clin Nutr** 1995 Sep; 49 Suppl 1:S77–83 (35 ref.)
Allergy prevention--an attainable objective? Hide DW. **Eur J Clin Nutr** 1995 Sep;49 Suppl 1:S71–6 (23 ref.)
The use of hydrolysates in allergy prevention programmes. Vandenplas Y. **Eur J Clin Nutr** 1995 Sep;49 Suppl 1:S84–91 (52 ref.)
'Prevention programmes'—a dietetic minefield. Wolfe SP. **Eur J Clin Nutr** 1995 Sep;49 Suppl 1:S92–9 (65 ref.)
Type II diabetes: a treatment approach for the older patient. Miller M. **Geriatrics** 1996 Aug;51(8):43–4, 47–9; quiz 50 (20 ref.)
Preventing falls: how to identify risk factors, reduce complications. Tideiksaar R. **Geriatrics** 1996 Feb; 51(2):43–6, 49–50, 53, quiz 54–5 (5 ref.)
Epidemiology for prevention. Wall S. **Int J Epidemiol** 1995 Aug;24(4):655–64 (55 ref.)
Primary prevention of coronary artery disease. St. Pierre M, et al. **J Ark Med Soc** 1996 Jul;93(2):89–91 (14 ref.)
Analysis of mediating variables in prevention and intervention research. MacKinnon DP. **NIDA Res Monogr** 1994;139:127–53 (68 ref.)
Prevention of traumatic deaths to children in the United States: how far have we come and where do we need to go? Rivara FP, et al. **Pediatrics** 1996 Jun;97(6 Pt 1):791–7 (58 ref.)
Cardiovascular risk-factor reduction in elderly patients with cardiac disease. Williams MA. **Phys Ther** 1996 May; 76(5):469–80 (103 ref.)
Family violence: practical recommendations for physicians and the medical community. Buel SM, et al. **Womens Health Issues** 1995 Winter;5(4):158–72 (24 ref.)

ORGANIZATION & ADMINISTRATION

Community-based approaches for the prevention of alcohol, tobacco, and other drug use. Aguirre-Molina M, et al. **Annu Rev Public Health** 1996;17:337–58 (121 ref.)
Is there a role for prevention in aboriginal mental health? Hunter E. **Aust J Public Health** 1995 Dec;19(6):573–9 (50 ref.)
Health promotion, health protection, and preventive services. Cooke BE. **Prim Care** 1995 Dec;22(4):555–64 (36 ref.)

STANDARDS

Prevention. How much harm? How much benefit? 1. Influence of reporting methods on perception of benefits [see comments] Marshall KG. **Can Med Assoc J** 1996 May 15;154(10):1493–9 (56 ref.) Comment in: Can Med Assoc J 1996 May 15;154(10):1510–2.

STATISTICS & NUMERICAL DATA

Physicians' prevention counseling behaviors: current status and future directions [editorial; comment] Frank E, et al. **Prev Med** 1995 Nov;24(6):543–5 (26 ref.) Comment on: Prev Med 1995 Nov;24(6):546–2.

PRIMATE DISEASES

Simian immunodeficiency virus variants: threat of new lentiviruses. McClure HM, et al. **Am J Med Sci** 1996 Jan; 311(1):30–3 (46 ref.)

PRIMATES

ANATOMY & HISTOLOGY

Primate phylogeny: morphological vs. molecular results. Shoshani J, et al. **Mol Phylogenet Evol** 1996 Feb;5(1):102–54 (299 ref.)
Chemical anatomy of primate basal ganglia. Parent A, et al. **Prog Neurobiol** 1995 Jun;46(2–3):131–97 (500 ref.)
Receptive field structure in the primate retina. Lee BB. **Vision Res** 1996 Mar;36(5):631–44 (97 ref.)

BLOOD

Red cell polymorphisms in nonhuman primates: a review. Socha WW, et al. **J Med Primatol** 1995 Dec;24(4):282–305 (115 ref.)

GENETICS

The evolution of major histocompatibility class I genes in primates. Watkins DI. **Crit Rev Immunol** 1995;15(1):1–29 (135 ref.)
Evolution of Mhc class II polymorphism: the rise and fall of class II gene function in primates. Bergström T, et al. **Immunol Rev** 1995 Feb;143:13–31 (45 ref.)
Evolution of major histocompatibility complex polymorphisms and T-cell receptor diversity in primates. Bontrop RE, et al. **Immunol Rev** 1995 Feb;143:33–62 (96 ref.)
Quantifying the degree of convergence in primate Mhc-DRB genes. O hUigin C. **Immunol Rev** 1995 Feb;143:123–40 (24 ref.)
Support for interordinal eutherian relationships with an emphasis on primates and their archontan relatives. Allard MW, et al. **Mol Phylogenet Evol** 1996 Feb;5(1):78–88 (74 ref.)
Primate phylogeny: morphological vs. molecular results. Shoshani J, et al. **Mol Phylogenet Evol** 1996 Feb;5(1):102–54 (299 ref.)

PHYSIOLOGY

Actions of placental and fetal adrenal steroid hormones in primate pregnancy. Pepe GJ, et al. **Endocr Rev** 1995 Oct; 16(5):608–48 (617 ref.)
Anatomic basis of cognitive-emotional interactions in the primate prefrontal cortex. Barbas H. **Neurosci Biobehav Rev** 1995 Fall;19(3):499–510 (155 ref.)
Primate photopigments and primate color vision. Jacobs GH. **Proc Natl Acad Sci U S A** 1996 Jan 23;93(2):577–81 (61 ref.)
The nonhuman primate model of the relationship between gonadal steroids and coronary heart disease. Clarkson TB, et al. **Prog Cardiovasc Dis** 1995 Nov–Dec;38(3):189–98 (34 ref.)

PSYCHOLOGY

Homologizing primate facial displays: a critical review of methods. Preuschoft S, et al. **Folia Primatol (Basel)** 1995; 65(3):121–37 (71 ref.)

PRIMIDONE

BLOOD

[Primidone] Furuno K, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:928–30 (21 ref.) **(Jpn)**

PRIMITIVE GUT see **GASTRULA**

PRIMITIVE STREAK see **GASTRULA**

PRINZMETAL'S ANGINA see **ANGINA PECTORIS, VARIANT**

PRION DISEASES

Human prion diseases and neurodegeneration. Prusiner SB. **Curr Top Microbiol Immunol** 1996;207:1–17 (118 ref.)
The folding intermediate concept of prion protein formation and conformational links to infectivity. Safar J. **Curr Top Microbiol Immunol** 1996;207:69–76 (14 ref.)
Prion diseases. Tateishi J. **Microbiol Immunol** 1995; 39(12):923–8 (44 ref.)
[Human spongiform encephalopathies. Diseases caused by prions] Jørn N, et al. **Ugeskr Laeger** 1996 Jul 8; 158(28):4066–72 (40 ref.) (Eng. Abstr.) **(Dan)**
[Fatal familial insomnia and prion diseases] Seilhean D, et al. **Rev Neurol (Paris)** 1995 Apr;151(4):225–30 (61 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Human prion diseases. Parchi P, et al. **Curr Opin Neurol** 1995 Aug;8(4):286–93 (55 ref.)
[Conference at the Salpêtrière. April 1994. Familial dementia and onirism in a 63-year-old woman] Laurent B, et al. **Rev Neurol (Paris)** 1995 Jun–Jul;151(6–7):420–8 (50 ref.) **(Fre)**
[Transmissible spongiform encephalopathies--an unconventional contagious agent] Degré M. **Tidsskr Nor Laegeforen** 1995 Oct 20;115(25):3137–40 (32 ref.) (Eng. Abstr.) **(Nor)**

ETIOLOGY

Transgenetics and neuropathology of prion diseases. DeArmond SJ, et al. **Curr Top Microbiol Immunol** 1996; 207:125–46 (80 ref.)

The Ninth Datta Lecture. Molecular biology of transmissible spongiform encephalopathies. Weissmann C. **FEBS Lett** 1996 Jun 24;389(1):3–11 (75 ref.)

Pathogenesis of spongiform encephalopathies: an update. Aguzzi A. **Int Arch Allergy Immunol** 1996 Jun; 110(2):99–106 (67 ref.)

[Non-conventional infectious agents or PRIONS (editorial)] Hauw JJ, et al. **Ann Pathol** 1995;15(6):409–14 (54 ref.) **(Fre)**

GENETICS

Prions, beta-sheets and transmissible dementias: is there still something missing? Liberski PP. **Acta Neuropathol (Berl)** 1995;90(2):113–25 (202 ref.)

Fatal familial insomnia and familial Creutzfeldt-Jakob disease: a tale of two diseases with the same genetic mutation. Gambetti P. **Curr Top Microbiol Immunol** 1996; 207:19–25 (17 ref.)

Transgenetics of prion diseases. Prusiner SB. **Curr Top Microbiol Immunol** 1996;206:275–304 (134 ref.)

Transgenetics and gene targeting in studies of prion diseases. Scott MR, et al. **Curr Top Microbiol Immunol** 1996; 207:95–123 (134 ref.)

Molecular biology of transmissible spongiform encephalopathies. Weissmann C. **Prog Brain Res** 1995; 105:15–22 (43 ref.)

Transmissibility of Creutzfeldt-Jakob disease and related disorders. Collins SJ, et al. **Sci Prog** 1995;78 (Pt 3):217–27 (30 ref.)

[Molecular genetics of familial and sporadic forms of human prion diseases] Laplanche JL, et al. **Ann Pharm Fr** 1995; 53(5):193–200 (76 ref.) (Eng. Abstr.) **(Fre)**

[Importance of genetic factors in pathogenesis of subacute spongiform viral encephalitis] Wierzba W, et al. **Postepy Hig Med Dosw** 1995;49(2):253–61 (22 ref.) (Eng. Abstr.) **(Pol)**

METABOLISM

Human prion disease and human prion protein disease. Kitamoto T, et al. **Curr Top Microbiol Immunol** 1996; 207:27–34 (28 ref.)

PATHOLOGY

[Consensus report: tissue handling in suspected Creutzfeldt-Jakob disease and other spongiform encephalopathies (prion diseases) in the human.European Union Biomed-1 Concerted Action] Budka H, et al. **Pathologe** 1996 Mar;17(2):171–5 (16 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

The 'infective' process in scrapie and human spongiform encephalopathy disease. Adams DH. **Med Hypotheses** 1995 Aug;45(2):214–8 (37 ref.)

TRANSMISSION

Tissue handling in suspected Creutzfeldt-Jakob disease (CJD) and other human spongiform encephalopathies (prion diseases). Budka H, et al. **Brain Pathol** 1995 Jul; 5(3):319–22 (20 ref.)

Transplantation of corneal tissue from donors with diseases of the central nervous system [see comments] Hogan RN, et al. **Cornea** 1995 Nov;14(6):547–53 (67 ref.) Comment in: Cornea 1995 Nov;14(6):545–6.

Sleepless in Bologna: transmission of fatal familial insomnia. Aguzzi A, et al. **Trends Microbiol** 1996 Apr;4(4):129–31; discussion 131–2 (33 ref.)

[Pros and cons of use of collagenated arterial prostheses] Barral X, et al. **J Mal Vasc** 1996;21 Suppl A:36–40 (11 ref.) (Eng. Abstr.) **(Fre)**

[Human prion diseases and experimental transmission] Tateishi J. **Uirusu** 1995 Jun;45(1):1–4 (13 ref.) **(Jpn)**

VIROLOGY

Tubulovesicular structures (TVS): virus-like particles specific for all subacute spongiform virus encephalopathies--what are they really? Liberski PP. **Arch Immunol Ther Exp (Warsz)** 1994;42(2):89–93 (18 ref.)

The nature of the scrapie agent: the virus theory. Narang H. **Proc Soc Exp Biol Med** 1996 Jul;212(3):208–24 (139 ref.)

Reflections on scrapie and related disorders, with consideration of the possibility of a viral aetiology. Darcel C. **Vet Res Commun** 1995;19(3):231–52 (130 ref.)

[Prions] Scheffer U. **Med Klin** 1995 Nov 15;90(11):653–7 (31 ref.) **(Ger)**

PRION PROTEINS see **PRIONS**

PRIONS

Evidence for two prions in yeast: [URE3] and [PSI] Wickner RB, et al. **Curr Top Microbiol Immunol** 1996;207:147–60 (39 ref.)

Prions of yeast and heat-shock protein 104: 'coprion' and cure. Wickner RB. **Trends Microbiol** 1995 Oct;3(10):367–9 (21 ref.)

Molecular genetics and biophysics of prions. Prusiner SB. **Uirusu** 1995 Jun;45(1):5–42 (221 ref.)

[Prion-like cytoplasmic genetic determinants of the budding yeast: conformations and biological functions of protein] Ono B. **Tanpakushitsu Kakusan Koso** 1995 Nov; 40(15):2320–8 (49 ref.) **(Jpn)**

[Prion-type pathologies: from scrapie to prion-related dementias. On the borderline between veterinary and human pathology] Domich L. **Rev Neurol** 1996 Jul; 24(131):785–802 (250 ref.) **(Spa)**

CHEMISTRY

[Structure and functional similarity of yeast Sup35p and Ure2p proteins to mammalian prions] Kushnirov VV, et al. **Mol Biol (Mosk)** 1995 Jul-Aug;29(4):750–5 (27 ref.) (Eng. Abstr.) **(Rus)**

CLASSIFICATION

Prion strains. Carlson GA. **Curr Top Microbiol Immunol** 1996; 207:35–47 (41 ref.)

GENETICS

Prions, beta-sheets and transmissible dementias: is there still something missing? Liberski PP. **Acta Neuropathol (Berl)** 1995;90(2):113–25 (202 ref.)

Transgenetics and neuropathology of prion diseases. DeArmond SJ, et al. **Curr Top Microbiol Immunol** 1996; 207:125–46 (80 ref.)

The Ninth Datta Lecture. Molecular biology of transmissible spongiform encephalopathies. Weissmann C. **FEBS Lett** 1996 Jun 24;389(1):3–11 (75 ref.)

[PSI] and [URE3] as yeast prions. Wickner RB, et al. **Yeast** 1995 Dec;11(16):1671–85 (79 ref.)

[Prions] Scheffer U. **Med Klin** 1995 Nov 15;90(11):653–7 (31 ref.) **(Ger)**

[A case of variant Gerstmann-Sträussler-Scheinker disease with the mutation of codon P105L] Kubo M, et al. **Rinsho Shinkeigaku** 1995 Aug;35(8):873–7 (9 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Cell biology of the prion protein. Harris DA, et al. **Curr Top Microbiol Immunol** 1996;207:77–93 (42 ref.)

The folding intermediate concept of prion protein formation and conformational links to infectivity. Safar J. **Curr Top Microbiol Immunol** 1996;207:69–76 (14 ref.)

PATHOGENICITY

Pathogenesis of spongiform encephalopathies: an update. Aguzzi A. **Int Arch Allergy Immunol** 1996 Jun; 110(2):99–106 (67 ref.)

The 'infective' process in scrapie and human spongiform encephalopathy disease. Adams DH. **Med Hypotheses** 1995 Aug;45(2):214–8 (37 ref.)

[Non-conventional infectious agents or PRIONS (editorial)] Hauw JJ, et al. **Ann Pathol** 1995;15(6):409–14 (54 ref.) **(Fre)**

PRIORITIES, HEALTH see **HEALTH PRIORITIES**

PRISONERS

AIDS behind bars: preventing HIV spread among incarcerated drug injectors [editorial] Dolan K, et al. **AIDS** 1995 Aug;9(8):825–32 (72 ref.)

HIV in UK prisons: a review of seroprevalence, transmission and patterns of risk [editorial] Curtis SP, et al. **Int J STD AIDS** 1995 Nov-Dec;6(6):387–91 (46 ref.)

Pregnancy behind bars. Safyer SM, et al. **Semin Perinatol** 1995 Aug;19(4):314–22 (37 ref.)

PSYCHOLOGY

Therapeutic communities in corrections and work release: some clinical and policy considerations. Inciardi JA, et al. **NIDA Res Monogr** 1994;144:259–67 (3 ref.)

Therapeutic communities in prison. Wexler HK, et al. **NIDA Res Monogr** 1994;144:181–208 (40 ref.)

PRISONS

Serving time: psychiatric mental health nursing in corrections. Peternelj-Taylor CA, et al. **J Psychosoc Nurs Ment Health Serv** 1995 Aug;33(8):12–9 (35 ref.)

Health care in correctional facilities. Thorburn KM. **West J Med** 1995 Dec;163(6):560–4 (47 ref.)

ORGANIZATION & ADMINISTRATION

The development of healthcare services for diabetic prisoners. MacFarlane IA. **Postgrad Med J** 1996 Apr; 72(846):214–7 (15 ref.)

STANDARDS

Environmental health issues in prisoner of war camps. Korte DV, et al. **Mil Med** 1995 Oct;160(10):483–6 (24 ref.)

PRISTINAMYCIN see **VIRGINIAMYCIN**

PRIVACY

see related
CONFIDENTIALITY
SELF DISCLOSURE

Genetic privacy: from the laboratory to the legislature. Andrews LB. **Genome Res** 1995 Oct;5(3):209–13 (17 ref.)

LEGISLATION & JURISPRUDENCE

Privacy and autonomy in the physician-patient relationship. Independent contracting under Medicare and implications for expansion into managed care. Coleman PG, et al. **J Leg Med** 1995 Dec;16(4):509–43 (197 ref.)

PRIVACY ACT see **PRIVACY**

PRIVACY OF PATIENT DATA see **CONFIDENTIALITY**

PRIVATE PRACTICE

[Advantages and disadvantages of induced labor without medical indication: the viewpoint of obstetricians in private practice] Peter J. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24 Suppl 1:78–88 (40 ref.) **(Fre)**

PRIVATIZATION

TRENDS

Population-centered and patient-focused purchasing: the U.K. experience. Ham C. **Milbank Q** 1996;74(2):191–214 (58 ref.)

PRIVILEGED COMMUNICATION see **CONFIDENTIALITY**

PRL-SECRETING PITUITARY ADENOMA see **PROLACTINOMA**

PROACCELERIN see **FACTOR V**

PROACTIVATOR CONVERTASE see **PROPERDIN FACTOR D**

PROALBUMIN see **PREALBUMIN**

PROBABILISTIC MODELS see **MODELS, STATISTICAL**

PROBABILITY

Statistical and genetic aspects of quality control for DNA identification. Morton NE, et al. **Electrophoresis** 1995 Sep; 16(9):1670–7 (30 ref.)

Sensitivity analysis in economic evaluation: a review of published studies. Briggs A, et al. **Health Econ** 1995 Sep-Oct;4(5):355–71 (109 ref.)

PROBECID see **PROBENECID**

PROBENECID

THERAPEUTIC USE

An evidence based appraisal of the management of nontophaceous interval gout [editorial] [see comments] Ferraz MB. **J Rheumatol** 1995 Sep;22(9):1618–9 (26 ref.) Comment in: J Rheumatol 1995 Sep;22(9):1621–3.

PROBLEM-BASED LEARNING

Self directed learning. Towle A, et al. **Arch Dis Child** 1996 Apr;74(4):357–9 (9 ref.)

Inquiry based learning, nursing student attitudes and the HIV patient. Cerny JE, et al. **J Nurs Educ** 1996 May; 35(5):219–22 (24 ref.)

Controversies in community based education. Ogunbode O. **West Afr J Med** 1996 Jan-Mar;15(1):18–23 (15 ref.)

[Problem-oriented education, problem-based learning and activating teaching methods] Nikkarinen T, et al. **Duodecim** 1994;110(16):1548–55 (23 ref.) **(Fin)**

PROBLEM SOLVING

see related
DECISION MAKING

Theoretical and empirical considerations of resourcefulness. Zauszniewski JA. **Image J Nurs Sch** 1995 Fall;27(3):177–80 (31 ref.)

Breastfeeding kinetics. A problem-solving approach to breastfeeding difficulties. Livingstone V. **World Rev Nutr Diet** 1995;78:28–54 (59 ref.)

PROBUCOL

PHARMACOLOGY

Combination therapy with probucol prevents adriamycin-induced cardiomyopathy. Singal PK, et al. **J Mol Cell Cardiol** 1995 Apr;27(4):1055–63 (80 ref.)

[Cholesterol turnover in triglyceride transport and effect of probucol] Titov VN. **Vopr Med Khim** 1995 Sep-Oct; 41(5):2–8 (80 ref.) **(Rus)**

PROCAINAMIDE

BLOOD

[Procainamide] Nishihara K. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:954–6 (8 ref.) **(Jpn)**

PROCAINE AMIDE see **PROCAINAMIDE**

PROCESS ASSESSMENT (HEALTH CARE)

Assessment methods for rehabilitation. Biefang S, et al. **Int J Rehabil Res** 1995 Sep;18(3):201–13 (47 ref.)

PROCETOFEN

THERAPEUTIC USE

[Fenofibrate and arteriosclerosis. The new developments of the last 5 years (editorial)] Millán Núñez Cortés J, et al. **Rev Clin Esp** 1995 Dec;195(12):817–9 (46 ref.) **(Spa)**

PROCHLORPERAZINE

ADVERSE EFFECTS

Drug-induced vanishing bile duct syndrome: response to ursodiol. O'Brien CB, et al. **Am J Gastroenterol** 1996 Jul; 91(7):1456–7 (10 ref.)

PROCOLLAGEN

ANALYSIS

[Collagen, procollagen peptide] Mizuta T. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:182–5 (16 ref.) **(Jpn)**

BLOOD

Toward the biochemical assessment of myocardial fibrosis in hypertensive patients. Díez J, et al. **Am J Cardiol** 1995 Nov 2;76(13):14D–17D (36 ref.)

METABOLISM

Collagen propeptides as indicators of collagen assembly. Risteli J, et al. **Acta Orthop Scand Suppl** 1995 Oct;266:183–8 (18 ref.)

PHYSIOLOGY

Evans' syndrome, myelofibrosis and systemic lupus erythematosus: role of procollagens in myelofibrosis. Ramakrishna R, et al. **Pathology** 1995 Jul;27(3):255–9 (23 ref.)

PROCOLLAGEN-PROLINE DIOXYGENASE

BLOOD

[Prolyl hydroxylase] Yamada S, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:383–5 (11 ref.) **(Jpn)**

PROCONVERTIN see **FACTOR VII**

PROCTITIS

DIAGNOSIS

Radiation proctitis: a review. Babb RR. **Am J Gastroenterol** 1996 Jul;91(7):1309–11 (31 ref.)

[Diagnosis of perianal and perirectal fistulas and abscesses] Rieber A, et al. **Rontgenpraxis** 1996 May;49(5):110–4 (20 ref.) **(Ger)**

DRUG THERAPY

Budesonide. A review of its pharmacological properties and therapeutic efficacy in inflammatory bowel disease. Spencer CM, et al. **Drugs** 1995 Nov;50(5):854–72 (51 ref.)

SURGERY

Perianal inflammatory conditions in inflammatory bowel disease. Stein BL, et al. **Curr Opin Gen Surg** 1993;:141–6 (17 ref.)

[Fistula, fissure, abscess] Girona J, et al. **Chirurg** 1996 Mar; 67(3):222–8 (28 ref.) (Eng. Abstr.) **(Ger)**

[Coloanal anastomosis (Parks operation) in the treatment of acute radiation rectitis] San Martín S, et al. **Rev Med Chil** 1995 Mar;123(3):321–5 (15 ref.) (Eng. Abstr.) **(Spa)**

PROCTOCOLECTOMY, RESTORATIVE

Recurrent polyps in the ileo-anal pouch or rectum in familial adenomatous polyposis. Tytgat GN, et al. **Eur J Cancer** 1995 Jul-Aug;31A(7–8):1154–9 (45 ref.)

Clinical and physiological aspects of ileal pouch-anal anastomosis. Salemans JM, et al. **Scand J Gastroenterol Suppl** 1995;212:3–12 (98 ref.)

Surgical options for familial adenomatous polyposis. Ambroze WL Jr, et al. **Semin Surg Oncol** 1995 Nov-Dec; 11(6):423–7 (27 ref.)

[The 3rd national workshop on defecography: the functional radiology of (neo) rectal ampullae (ileal reservoir, colo-anal anastomosis, continent perineal colostomy)] Piloni V, et al. **Radiol Med (Torino)** 1996 Jan-Feb;91(1–2):66–72 (34 ref.) (Eng. Abstr.) **(Ita)**

ADVERSE EFFECTS

Technique of sacral hernia repair. Kaplan LJ, et al. **Am Surg** 1996 Sep;62(9):762–4 (4 ref.)

METHODS

Continence-preserving procedures for benign and malignant disease. Lewis WG, et al. **Curr Opin Gen Surg** 1993;:157–63 (53 ref.)

[Surgical treatment of ulcero-hemorrhagic rectocolitis] Dozois RR, et al. **Ann Chir** 1995;49(7):628–36 (60 ref.) (Eng. Abstr.) **(Fre)**

PROCTOCOLITIS, HEMORRHAGIC see **COLITIS, ULCERATIVE**

PROCTOCOLITIS, ULCERATIVE see **COLITIS, ULCERATIVE**

PROCTOLOGY see **COLON AND RECTAL SURGERY (SPECIALTY)**

PROCTOSCOPY

[The role of ultrasonic endoscopy in the examination of post-obstetrical anal incontinence] Roseau G. **Contracept Fertil Sex** 1995 Dec;23(12):752–7 (28 ref.) (Eng. Abstr.) **(Fre)**

[Rectal prolapse--choice of procedure and minimal invasive possibilities] Köckerling F, et al. **Chirurg** 1996 May; 67(5):471–82 (38 ref.) (Eng. Abstr.) **(Ger)**

INSTRUMENTATION

[Current proctology--modern functional diagnosis] Feifel G, et al. **Chirurg** 1996 Mar;67(3):205–12 (33 ref.) (Eng. Abstr.) **(Ger)**

PROCTOSIGMOIDOSCOPY see **SIGMOIDOSCOPY**

PRODRUGS

Minireview: nucleotide prodrugs. Jones RJ, et al. **Antiviral Res** 1995 May;27(1–2):1–17 (119 ref.)

ADMINISTRATION & DOSAGE

Antibody-enzyme conjugates for cancer therapy. Melton RG, et al. **J Natl Cancer Inst** 1996 Feb 21;88(3–4):153–65 (85 ref.)

CHEMISTRY

Prodrugs revisited: the "ad hoc" approach as a complement to ligand design. Testa B, et al. **Med Res Rev** 1996 May; 16(3):233–41 (17 ref.)

METABOLISM

Biochemical toxicology of chemical teratogenesis. Wells PG, et al. **Crit Rev Biochem Mol Biol** 1996 Feb;31(1):1–40 (200 ref.)

Metabolism of Zidovudine. Veal GJ, et al. **Gen Pharmacol** 1995 Nov;26(7):1469–75 (54 ref.)

Genetic delivery of enzymes for cancer therapy. Deonarain MP, et al. **Gene Ther** 1995 Jun;2(4):235–44 (76 ref.)

The procarcinogen hypothesis for bladder cancer: activities of individual drug metabolizing enzymes as risk factors. Branch RA, et al. **Pharmacogenetics** 1995;5 Spec No:S97–102 (26 ref.)

PHARMACOKINETICS

Valacyclovir HCl (Valtrex): an acyclovir prodrug with improved pharmacokinetics and better efficacy for treatment of zoster. Smiley ML, et al. **Adv Exp Med Biol** 1996;394:33–9 (23 ref.)

Clinical pharmacokinetics of new antiepileptic drugs. Walker MC, et al. **Pharmacol Ther** 1995;67(3):351–84 (164 ref.)

PHARMACOLOGY

Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Plunkett W, et al. **Semin Oncol** 1995 Aug; 22(4 Suppl 11):3–10 (26 ref.)

THERAPEUTIC USE

Valacyclovir HCl (Valtrex): an acyclovir prodrug with improved pharmacokinetics and better efficacy for treatment of zoster. Smiley ML, et al. **Adv Exp Med Biol** 1996;394:33–9 (23 ref.)

Metastatic colorectal cancer: advances in biochemical modulation and new drug development. Meropol NJ, et al. **Semin Oncol** 1995 Oct;22(5):509–24 (153 ref.)

Prodrugs in cancer chemotherapy. Connors TA, et al. **Stem Cells (Dayt)** 1995 Sep;13(5):501–11 (76 ref.)

PRODUCT LABELING, DRUG see **DRUG LABELING**

PRODUCT LABELING, FOOD see **FOOD LABELING**

PRODUCT RECYCLING see **EQUIPMENT REUSE**

PRODUCT SURVEILLANCE, POSTMARKETING

Ventricular fibrillation, automatic external defibrillators, and the United States Food and Drug Administration: confrontation without comprehension. Cummins RO, et al. **Ann Emerg Med** 1995 Nov;26(5):621–31; discussion 632–4 (95 ref.)

Management of intracardiac device recalls: a consensus conference. Participants of the Consensus Conference. North American Society of Cardiac Pacing and Electrophysiology (NASPE). Goldman BS, et al. **Pacing Clin Electrophysiol** 1996 Jan;19(1):7–17 (14 ref.)

[Drug surveillance within the pharmaceutical industry: present and future] Soto J, et al. **Med Clin (Barc)** 1996 May 4;106(17):665–9 (31 ref.) **(Spa)**

PRODUCTIVITY, ORGANIZATIONAL see **EFFICIENCY, ORGANIZATIONAL**

PROENZYMES see **ENZYME PRECURSORS**

PROFESSIONAL AUTONOMY

Preventive medicine: notes toward an agenda for change. Guidotti TL. **Am J Prev Med** 1996 May-Jun;12(3):165–71 (24 ref.)

Professionalization of nurse practitioners. Bullough B. **Annu Rev Nurs Res** 1995;13:239–65 (106 ref.)

Feminism and nursing. Chinn PL. **Annu Rev Nurs Res** 1995; 13:267–89 (110 ref.)

Nursing research in Israel. Golander H, et al. **Annu Rev Nurs Res** 1996;14:207–24 (41 ref.)

The evolution of nursing research in Brazil. Mendes IA, et al. **Annu Rev Nurs Res** 1996;14:225–42 (68 ref.)

The development of community psychiatric nursing: a professional project? Godin P. **J Adv Nurs** 1996 May; 23(5):925–34 (60 ref.)

The role of nursing journals in the advancement of professional nursing. Smith JP. **J Adv Nurs** 1996 Jan; 23(1):12–6 (7 ref.)

Nursing theory: everything the artist spits is art? Timpson J. **J Adv Nurs** 1996 May;23(5):1030–6 (65 ref.)

Prescriptive authority for advanced practice nurses: current and future perspectives. McDermott KC. **Oncol Nurs Forum** 1995 Sep;22(8 Suppl):25–30 (33 ref.)

PROFESSIONAL COMPETENCE

Narrowing the gap between rhetoric and the reality of medical ethics. Silverman DR. **Acad Med** 1996 Mar; 71(3):227–37 (109 ref.)

Medical reviews and the importance of being a "peer" in science. Beritic T. **Isr J Med Sci** 1996 Jul;32(7):573–5 (15 ref.)

Is the professional code still the cornerstone of clinical nursing practice? Esterhuizen P. **J Adv Nurs** 1996 Jan; 23(1):25–31 (39 ref.)

The future of graduate education in nursing: scholarship, the health of communities, and health care reform. Hall JM, et al. **J Prof Nurs** 1995 Nov-Dec;11(6):332–8 (22 ref.)

PROFESSIONAL-FAMILY RELATIONS

Maximizing the benefits of autopsy for clinicians and families. What needs to be done. McPhee SJ. **Arch Pathol Lab Med** 1996 Aug;120(8):743–8 (53 ref.)

Life-threatening situations: supporting the child survivor and the family. Davenport LB, et al. **J Pediatr Nurs** 1995 Aug; 10(4):219–23 (7 ref.)

Your child is brain dead. Blair AW, et al. **Postgrad Med J** 1996 Mar;72(845):137–40 (33 ref.)

PROFESSIONAL IMPAIRMENT

LEGISLATION & JURISPRUDENCE

Legal considerations in infectious diseases and dentistry. Burris S. **Dent Clin North Am** 1996 Apr;40(2):425–35 (62 ref.)

PROFESSIONAL LIABILITY see **LIABILITY, LEGAL**

PROFESSIONAL-PATIENT RELATIONS

see related
TRUTH DISCLOSURE

Nationally speaking. Life history and narrative research: generating a humanistic knowledge base for occupational therapy. Larson EA, et al. **Am J Occup Ther** 1996 Apr; 50(4):247–50 (27 ref.)

Understanding and differentiating clients' positive feelings in psychotherapy. Chance SE, et al. **Am J Psychother** 1995

Fall;49(4):514–25 (23 ref.)
Directive counseling on long-acting contraception. Moskowitz E, et al. **Am J Public Health** 1996 Jun; 86(6):787–90 (24 ref.)
A self psychologist in couplesland: multisubjective approach to transference and countertransference-like phenomena in marital relationships. Livingston MS. **Fam Process** 1995 Dec;34(4):427–39 (26 ref.)
Intersubjectivity in psychoanalysis: a critical review. Dunn J. **Int J Psychoanal** 1995 Aug;76 (Pt 4):723–38 (90 ref.)
Desire and the female analyst. Schaverien J. **J Anal Psychol** 1996 Apr;41(2):261–87 (91 ref.)
Attachment and learning disability: a theoretical review informing three clinical interventions. Clegg JA, et al. **J Intellect Disabil Res** 1995 Aug;39 (Pt 4):295–305 (43 ref.)
The Hippocratic Oath: a code for physicians, not a Pythagorean manifesto. Prioreschi P. **Med Hypotheses** 1995 Jun;44(6):447–62 (122 ref.)
Communication issues in breast imaging. D'Orsi CJ, et al. **Radiol Clin North Am** 1995 Nov;33(6):1231–45 (31 ref.)
[Management dialogue within multi-professional teams: contribution of psychoanalysis to integrated therapy of psychotic patients] Böker H. **Psychiatr Prax** 1995 Sep; 22(5):201–5 (18 ref.) (Eng. Abstr.) **(Ger)**

PROFESSIONAL PRACTICE

see related
PRACTICE MANAGEMENT, DENTAL
PRACTICE MANAGEMENT, MEDICAL

Bela Schick Lecture, 1995. The three Ps: unabridged [editorial] Wray BB. **Ann Allergy Asthma Immunol** 1996 May;76(5):412–5 (18 ref.)
What are the implications for the community of the discrepancy between the theory and practice of BP control? Jackson R. **J Hum Hypertens** 1995 Jul;9 Suppl 2:S25–8 (8 ref.)
Improving the management of hypertension in clinical practice. Mancia G. **J Hum Hypertens** 1995 Jul;9 Suppl 2:S29–31 (13 ref.)
Limiting factors in the control of BP: why is there a gap between theory and practice? Ménard J, et al. **J Hum Hypertens** 1995 Jul;9 Suppl 2:S19–23 (17 ref.)
Caring advanced nursing practice [letter] Martin SR. **Nurse Pract** 1995 Nov;20(11 Pt 1):16, 21, 23 (29 ref.)

ORGANIZATION & ADMINISTRATION

Challenging old notions of professionalism: how can nurses work with paraprofessional ethnic health workers? Fuller J. **J Adv Nurs** 1995 Sep;22(3):465–72 (44 ref.)
Professional dynamics and the changing nature of medical work. Hafferty FW, et al. **J Health Soc Behav** 1995;Spec No:132–53 (130 ref.)
The influence of surgical training on the practice of surgery. Are changes necessary? Stone MD, et al. **Surg Clin North Am** 1996 Feb;76(1):1–10 (33 ref.)

TRENDS

Practice-building seminars in chiropractic: a Petit Bourgeois response to biomedical domination. Baer HA. **Med Anthropol Q** 1996 Mar;10(1):29–44 (45 ref.)
Integrating lasers into clinical practice. Rounds RS, et al. **Optom Clin** 1995;4(4):125–40 (10 ref.)

PROFESSIONAL STAFF COMMITTEES

see related
UTILIZATION REVIEW

ORGANIZATION & ADMINISTRATION

Member responsibilities on a nursing research committee. Martin PA. **Appl Nurs Res** 1996 Aug;9(3):154–7 (15 ref.)

PROFIBRINOLYSIN see **PLASMINOGEN**

PROGENITOR CELLS see **STEM CELLS**

PROGENITOR CELLS, ERYTHROPOIETIC see **ERYTHROID PROGENITOR CELLS**

PROGENITOR CELLS, HEMATOPOIETIC see **HEMATOPOIETIC STEM CELLS**

PROGERIA, ADULT see **WERNER'S SYNDROME**

PROGESTATIONAL HORMONE ANALOGS see **PROGESTATIONAL HORMONES, SYNTHETIC**

PROGESTATIONAL HORMONES

Progestogens, progesterone antagonists, progesterone, and androgens: synthesis, classification, and uses. Peterson CM. **Clin Obstet Gynecol** 1995 Dec;38(4):813–20 (13 ref.)
[35 years of estrogen-progestagen pills: where is the vascular risk?] Gaspard U. **Rev Med Liege** 1996 Jan;51(1):133–8 (15 ref.) **(Fre)**

ADMINISTRATION & DOSAGE

Emerging delivery systems for estrogen replacement: aspects of transdermal and oral delivery. Nachtigall LE. **Am J Obstet Gynecol** 1995 Sep;173(3 Pt 2):993–7 (15 ref.)
Hormones and breast and endometrial cancers: preventive strategies and future research. Hulka BS, et al. **Environ Health Perspect** 1995 Nov;103 Suppl 8:185–9 (49 ref.)
Rationale for estrogen with interrupted progestin as a new low-dose hormonal replacement therapy. Casper RF, et al. **J Soc Gynecol Investig** 1996 Sep–Oct;3(5):225–34 (79 ref.)
Practical aspects of hormone replacement therapy. Thorneycroft IH. **Prog Cardiovasc Dis** 1995 Nov–Dec; 38(3):243–54 (83 ref.)
[Estrogen-gestagen substitution in geriatric gynecology. Long-term prevention for the third segment of life after menopause] Lauritzen C. **Fortschr Med** 1996 May 30; 114(15):187–90 (0 ref.) (Eng. Abstr.) **(Ger)**
[Gestagens and hormone substitution] Klinger G. **Zentralbl Gynakol** 1995;117 Suppl:25–9 (0 ref.) **(Ger)**
[Hormone therapy of endometriosis--principles and clinical aspects of gestagen treatment] Köhler G. **Zentralbl Gynakol** 1995;117 Suppl:6–13 (46 ref.) **(Ger)**
[The role of gestagens in prevention and therapy of endometrial hyperplasia] Römer T. **Zentralbl Gynakol** 1995; 117 Suppl:14–8 (10 ref.) **(Ger)**
[Gestagens and corpus luteum insufficiency] Rothe K. **Zentralbl Gynakol** 1995;117 Suppl:2–5 (24 ref.) **(Ger)**

ANTAGONISTS & INHIBITORS

Novel mechanisms of antiprogestin action. Horwitz KB, et al. **Acta Oncol** 1996;35(2):129–40 (61 ref.)
The endocrine prevention of breast cancer. Spicer DV, et al. **Cancer Invest** 1995;13(5):495–504 (72 ref.)
Clinical applications of the antiprogestins. Kettel LM. **Clin Obstet Gynecol** 1995 Dec;38(4):921–34 (56 ref.)
[Multiple usages for antiprogestins] Heikinheimo O. **Duodecim** 1994;110(10):1001–8 (39 ref.) **(Fin)**

PHARMACOLOGY

Norgestimate. Corson SL. **Clin Obstet Gynecol** 1995 Dec; 38(4):841–8 (25 ref.)
Comparative pharmacology of newer progestogens. Kuhl H. **Drugs** 1996 Feb;51(2):188–215 (121 ref.)
New insights in the molecular mechanism of progestin-induced proliferation of mammary epithelium: induction of the local biosynthesis of growth hormone (GH) in the mammary glands of dogs, cats and humans. Mol JA, et al. **J Steroid Biochem Mol Biol** 1996 Jan; 57(1–2):67–71 (44 ref.)
Androgen and progestagen effects on plasma lipids. Bagatell CJ, et al. **Prog Cardiovasc Dis** 1995 Nov–Dec;38(3):255–71 (125 ref.)

PHYSIOLOGY

Novel mechanisms of antiprogestin action. Horwitz KB, et al. **Acta Oncol** 1996;35(2):129–40 (61 ref.)
Endometrial morphology and bleeding patterns as a function of progestogen supplementation. Sturdee DW. **Int J Fertil Menopausal Stud** 1996 Jan–Feb;41(1):22–8 (31 ref.)

STANDARDS

Progestogens in estrogen-replacement therapy. Gambrell RD Jr. **Clin Obstet Gynecol** 1995 Dec;38(4):890–901 (43 ref.)

THERAPEUTIC USE

Oestrogen replacement therapy and Alzheimer's disease. Paganini-Hill A. **Br J Obstet Gynaecol** 1996 May;103 Suppl 13:80–6 (49 ref.)
The case for postmenopausal hormone therapy. Speroff L. **Hosp Pract (Off Ed)** 1996 Feb 15;31(2):75–89 (13 ref.)
[Progestins and osteoporosis. Does progestin contribute to the effectiveness of estrogen replacement therapy in menopause?] Lopes P. **Rev Fr Gynecol Obstet** 1995 May–Jun;90(5–6):307–8 (17 ref.) **(Fre)**
[Gestagens and breast diseases] Lober R. **Zentralbl Gynakol** 1995;117 Suppl:19–24 (27 ref.) **(Ger)**

PROGESTATIONAL HORMONES, SYNTHETIC

see related
ANTINEOPLASTIC AGENTS, HORMONAL
CONTRACEPTIVE AGENTS, FEMALE
CONTRACEPTIVES, ORAL, SYNTHETIC

Desogestrel, norgestimate, and gestodene: the newer progestins. Kaplan B. **Ann Pharmacother** 1995 Jul–Aug; 29(7–8):736–42 (51 ref.)

ADMINISTRATION & DOSAGE

[Depot gestagens] Zahradnik HP. **Arch Gynecol Obstet** 1995; 257(1–4):536–41 (9 ref.) **(Ger)**

ADVERSE EFFECTS

Discovery of novel intracellular receptor modulating drugs. Jones TK, et al. **J Steroid Biochem Mol Biol** 1996 Jan; 56(1–6 Spec No):61–6 (26 ref.)

BLOOD

[Synthetic steroids] Miyazaki S. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:1036–9 (19 ref.) **(Jpn)**

PHARMACOLOGY

The effects of estradiol valerate plus medroxyprogesterone acetate and conjugated estrogens plus medrogestone on climacteric symptoms and metabolic variables in perimenopausal women. Egarter C, et al. **Acta Obstet Gynecol Scand** 1996 Apr;75(4):386–93 (40 ref.)
Gestodene-containing contraceptives. Kuhl H, et al. **Clin Obstet Gynecol** 1995 Dec;38(4):829–40 (32 ref.)
Desogestrel. Stone SC. **Clin Obstet Gynecol** 1995 Dec; 38(4):821–8 (39 ref.)

STANDARDS

The progestin-only pills and the levonorgestrel-releasing IUD: two progestin-only contraceptives. Chi IC. **Clin Obstet Gynecol** 1995 Dec;38(4):872–89 (71 ref.)

THERAPEUTIC USE

Norethindrone--a review of therapeutic applications. Taitel HF, et al. **Int J Fertil Menopausal Stud** 1995 Jul–Aug; 40(4):207–23 (64 ref.)
[Treatment of uterine fibromas] Amiel C, et al. **Ann Chir** 1996;50(1):40–50 (79 ref.) (Eng. Abstr.) **(Fre)**
[Chemotherapy of metastatic endometrial carcinoma. Review of the literature] Pierga JY, et al. **Bull Cancer (Paris)** 1995 Dec;82(12):1005–18 (110 ref.) (Eng. Abstr.) **(Fre)**
[Synthetic progestational hormones in the treatment of neoplastic cachexia] Freyer G, et al. **Rev Med Interne** 1996; 17(1):79–84 (21 ref.) (Eng. Abstr.) **(Fre)**

PROGESTERONE

see related
RECEPTORS, PROGESTERONE

Progestogens, progesterone antagonists, progesterone, and androgens: synthesis, classification, and uses. Peterson CM. **Clin Obstet Gynecol** 1995 Dec;38(4):813–20 (13 ref.)

ADMINISTRATION & DOSAGE

Micronized progesterone: vaginal and oral uses. Simon JA. **Clin Obstet Gynecol** 1995 Dec;38(4):902–14 (41 ref.)

ADVERSE EFFECTS

Hormone replacement therapy in women with breast cancer. Do the risks outweigh the benefits? Roy JA, et al. **J Clin Oncol** 1996 Mar;14(3):997–1006 (85 ref.)
[Steroid-induced liver tumor] Nishizawa Y, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):449–52 (21 ref.) **(Jpn)**

ANALYSIS

[Biochemical basis for detection of estrogen and progesterone receptors in breast tumors using immunohistochemistry] Goussard J. **Ann Pathol** 1996;16(2):91–7 (41 ref.) **(Fre)**

ANTAGONISTS & INHIBITORS

Progestogens, progesterone antagonists, progesterone, and androgens: synthesis, classification, and uses. Peterson CM. **Clin Obstet Gynecol** 1995 Dec;38(4):813–20 (13 ref.)
The combined use of prostaglandin and antiprogestin in human fertility control. Baulieu EE. **Eur J Obstet Gynecol Reprod Biol** 1996 Mar;65(1):115–9 (42 ref.)

BLOOD

[Progesterone] Yoshimi T, et al. **Nippon Rinsho** 1995 Mar; 53 Su Pt 2:573–5 (8 ref.) **(Jpn)**

CONTRAINDICATIONS

Hormonal therapy and genital tract cancer. Wren B. **Curr Opin Obstet Gynecol** 1996 Feb;8(1):38–41 (31 ref.)

METABOLISM

[Relation between progesterone and pathogenesis of uterine leiomyomas] Yang Y, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1996 Mar;31(3):184–5 (13 ref.) **(Chi)**

PHARMACOLOGY

Oviduct during early pregnancy: hormonal regulation and interactions with the fertilized ovum. Murray MK, et al. **Microsc Res Tech** 1995 Aug 15;31(6):497–506 (49 ref.)

PHYSIOLOGY

Mifepristone and ovarian function. Curry TE Jr, et al. **Clin Obstet Gynecol** 1996 Jun;39(2):486–97 (64 ref.)
Estrogen, progesterone, and vascular reactivity: potential cellular mechanisms. White MM, et al. **Endocr Rev** 1995 Dec;16(6):739–51 (172 ref.)
Diverse modes of action of progesterone and its metabolites. Mahesh VB, et al. **J Steroid Biochem Mol Biol** 1996 Jan;

PROGESTERONE

56(1-6 Spec No):209-19 (135 ref.)
Second messenger signalling during hormone-induced Xenopus oocyte maturation. Cork RJ, et al. **Zygote** 1994 Nov;2(4):289-99 (101 ref.)
[Progesterone and its metabolites in central nervous system function] Camacho-Arroyo I, et al. **Rev Invest Clin** 1995 Jul-Aug;47(4):329-40 (118 ref.) (Eng. Abstr.) **(Spa)**

PROGESTERONE RECEPTORS see **RECEPTORS, PROGESTERONE**

PROGESTERONE REDUCTASE

DEFICIENCY

[Congenital disorders of the bile acid metabolism (3 beta-hydroxy-delta 5-steroid dehydrogenase/isomerase deficiency, delta 4-3-oxosteroid 5 beta-reductase deficiency, cerebrotendinous xanthomatosis, and peroxisomal disorders] Kondo KH, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):362-6 (23 ref.) **(Jpn)**

PROGESTIN ANALOGS see **PROGESTATIONAL HORMONES, SYNTHETIC**

PROGESTIN RECEPTORS see **RECEPTORS, PROGESTERONE**

PROGESTINS see **PROGESTATIONAL HORMONES**

PROGESTINS, SYNTHETIC see **PROGESTATIONAL HORMONES, SYNTHETIC**

PROGESTOGENS see **PROGESTATIONAL HORMONES**

PROGESTOGENS, SYNTHETIC see **PROGESTATIONAL HORMONES, SYNTHETIC**

PROGLUMIDE RECEPTORS see **RECEPTORS, CHOLECYSTOKININ**

PROGNOSIS

Breaking bad news. A review of the literature. Ptacek JT, et al. **JAMA** 1996 Aug 14;276(6):496-502 (83 ref.)
A reader's guide to the evaluation of prognostic studies. van Walraven C, et al. **Postgrad Med J** 1996 Jan;72(843):6-11 (7 ref.)

PROGNOSTIC NUTRITIONAL INDEX (PNI) see **NUTRITION ASSESSMENT**

PROGRAM DEVELOPMENT

Reducing impediments to technology transfer in drug abuse programming. Brown BS. **NIDA Res Monogr** 1995; 155:169-85 (38 ref.)
Transferring research findings on persuasion to improve drug abuse prevention programs. McGuire WJ. **NIDA Res Monogr** 1995;155:225-45 (8 ref.)

PROGRAM EFFICIENCY see **EFFICIENCY, ORGANIZATIONAL**

PROGRAM EVALUATION

Policy evaluation: better living through research. Boden LI. **Am J Ind Med** 1996 Apr;29(4):346-52 (40 ref.)
The family cap: a popular but unproven method of welfare reform. Donovan P. **Fam Plann Perspect** 1995 Jul-Aug; 27(4):166-71 (41 ref.)

METHODS

Prevention. How much harm? How much benefit? 2. Ten potential pitfalls in determining the clinical significance of benefits. Marshall KG. **Can Med Assoc J** 1996 Jun 15; 154(12):1837-43 (61 ref.)
Evaluating the effectiveness of addiction treatments: reasonable expectations, appropriate comparisons. McLellan AT, et al. **Milbank Q** 1996;74(1):51-85 (69 ref.)

PROGRAM EVALUATION, NURSING see **NURSING EVALUATION RESEARCH**

PROGRAMMABLE IMPLANTABLE INSULIN PUMP see **INSULIN INFUSION SYSTEMS**

PROGRAMMABLE IMPLANTABLE MEDICATION SYSTEMS see **INFUSION PUMPS, IMPLANTABLE**

PROGRAMMED INSTRUCTION

Self directed learning. Towle A, et al. **Arch Dis Child** 1996 Apr;74(4):357-9 (9 ref.)

PROGRAMMED INSTRUCTION, COMPUTERIZED see **COMPUTER-ASSISTED INSTRUCTION**

PROGRAMMED LEARNING see **PROGRAMMED INSTRUCTION**

PROGRANULOCYTIC LEUKEMIA see **LEUKEMIA, PROMYELOCYTIC, ACUTE**

PROGRESSIVE LENTICULAR DEGENERATION see **HEPATOLENTICULAR DEGENERATION**

PROGRESSIVE MUSCULAR ATROPHY see **MUSCULAR ATROPHY, SPINAL**

PROGRESSIVE PATIENT CARE

Transferring to adult health care: experiences of adolescents with cystic fibrosis. Russell MT, et al. **J Pediatr Nurs** 1996 Aug;11(4):262-8 (44 ref.)

ORGANIZATION & ADMINISTRATION

The acute and long-term care interface. Integrating the continuum. Phillips-Harris C, et al. **Clin Geriatr Med** 1995 Aug;11(3):481-501 (24 ref.)

PROINSULIN

BLOOD

[Determination of plasma proinsulins, insulin and C-peptide] Chevenne D, et al. **Ann Biol Clin (Paris)** 1995;53(1-2):3-9 (59 ref.) (Eng. Abstr.) **(Fre)**
[Proinsulin] Sato Y, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:616-8 (13 ref.) **(Jpn)**

GENETICS

Hyperproinsulinemia in a three-generation Caucasian family due to mutant proinsulin (Arg65-His) not associated with impaired glucose tolerance: the contribution of mutant proinsulin to insulin bioactivity. Röder ME, et al. **J Clin Endocrinol Metab** 1996 Apr;81(4):1634-40 (29 ref.)

PHYSIOLOGY

Hyperinsulinemia, hyperproinsulinemia and insulin resistance in the metabolic syndrome. Schrezenmeir J. **Experientia** 1996 May 15;52(5):426-32 (26 ref.)
Role of insulin and proinsulin in diabetic vascular disease. Wareham NJ, et al. **Metabolism** 1995 Oct;44(10 Suppl 4):76-82 (56 ref.)

SECRETION

Hyperproinsulinemia in a three-generation Caucasian family due to mutant proinsulin (Arg65-His) not associated with impaired glucose tolerance: the contribution of mutant proinsulin to insulin bioactivity. Röder ME, et al. **J Clin Endocrinol Metab** 1996 Apr;81(4):1634-40 (29 ref.)

PROJECTIONS AND PREDICTIONS see **FORECASTING**

PROKARYOTIC CELLS

CYTOLOGY

[Evolution of cells] Maier UG, et al. **Naturwissenschaften** 1996 Mar;83(3):103-12 (54 ref.) (Eng. Abstr.) **(Ger)**

ENZYMOLOGY

NADPH-P-450 reductase: structural and functional comparisons of the eukaryotic and prokaryotic isoforms. Sevrioukova IF, et al. **Biochimie** 1995;77(7-8):562-72 (59 ref.)

METABOLISM

Analysis and modeling of substrate uptake and product release by prokaryotic and eukaryotic cells. Krämer R. **Adv Biochem Eng Biotechnol** 1996;54:31-74 (147 ref.)
Fancy meeting you here! A fresh look at "prokaryotic" protein phosphorylation. Kennelly PJ, et al. **J Bacteriol** 1996 Aug;178(16):4759-64 (54 ref.)

PHYSIOLOGY

[Oxidative damage repair of DNA in prokaryotes] Zastawny TH. **Postepy Biochem** 1996;42(1):31-41 (118 ref.) **(Pol)**

PROLACTIN

see related
HYPERPROLACTINEMIA
RECEPTORS, PROLACTIN

BIOSYNTHESIS

Endocrine interaction between zinc and prolactin. An interpretative review. Brandão-Neto J, et al. **Biol Trace Elem Res** 1995 Aug-Sep;49(2-3):139-49 (57 ref.)

BLOOD

Prolactin and rapid eye movement sleep regulation. Roky R, et al. **Sleep** 1995 Sep;18(7):536-42 (96 ref.)
[Prolactin (PRL)] Aono T, et al. **Nippon Rinsho** 1995 Mar; 53 Su Pt 2:275-7 (8 ref.) **(Jpn)**

GENETICS

Are both genetic and reproductive associations with rheumatoid arthritis linked to prolactin? Brennan P, et al. **Lancet** 1996 Jul 13;348(9020):106-9 (40 ref.)

IMMUNOLOGY

Endocrine, paracrine and autocrine actions of prolactin on immune cells. Matera L. **Life Sci** 1996;59(8):599-614 (173 ref.)

PHYSIOLOGY

Regulation of pigeon cropmilk secretion and parental behaviors by prolactin. Horseman ND, et al. **Annu Rev Nutr** 1995;15:213-38 (130 ref.)
Prolactin-mediated gene activation in mammary epithelial cells. Groner B, et al. **Curr Opin Genet Dev** 1995 Oct; 5(5):587-94 (73 ref.)
Endocrine, paracrine and autocrine actions of prolactin on immune cells. Matera L. **Life Sci** 1996;59(8):599-614 (173 ref.)
The role of the growth and lactogenic hormone family in immune function. Berczi I. **Neuroimmunomodulation** 1994 Jul-Aug;1(4):201-16 (182 ref.)

SECRETION

Prolactin release after mating and genitosensory stimulation in females. Erskine MS. **Endocr Rev** 1995 Aug;16(4):508-28 (222 ref.)
[Prolactin and female gonadal endocrine regulation] Takeya U. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Aug; 47(8):824-32 (28 ref.) **(Jpn)**

PROLACTIN-PRODUCING PITUITARY ADENOMA see **PROLACTINOMA**

PROLACTIN RECEPTORS see **RECEPTORS, PROLACTIN**

PROLACTINOMA

see related
HYPERPROLACTINEMIA

CHEMICALLY INDUCED

Lactotroph hyperplasia in an estrogen treated male-to-female transsexual patient. Serri O, et al. **J Clin Endocrinol Metab** 1996 Sep;81(9):3177-9 (12 ref.)

DIAGNOSIS

Diagnosis and drug therapy of prolactinoma. Ciccarelli E, et al. **Drugs** 1996 Jun;51(6):954-65 (63 ref.)
[Prolactinoma; diagnosis and treatment] van der Lely AJ, et al. **Ned Tijdschr Geneeskd** 1996 Jul 13;140(28):1445-9 (53 ref.) **(Dut)**

DRUG THERAPY

Diagnosis and drug therapy of prolactinoma. Ciccarelli E, et al. **Drugs** 1996 Jun;51(6):954-65 (63 ref.)
[The therapy of a macroprolactinoma with the intramuscular application of a long-acting bromocriptine preparation] Kreft B, et al. **Dtsch Med Wochenschr** 1996 Jul 5; 121(27):865-8 (10 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

Prolactin-secreting pituitary carcinoma with implants in the cheek pouch and metastases to the ovaries. A case report and literature review. Gollard R, et al. **Cancer** 1995 Nov 15;76(10):1814-20 (43 ref.)
Carcinomas of the pituitary: definition and review of the literature. Lübke D, et al. **Gen Diagn Pathol** 1995 Oct; 141(2):81-92 (83 ref.)
[Prolactin producing hypophyseal carcinoma. Case report of an extremely rare metastatic tumor] Saeger W, et al. **Pathologe** 1995 Sep;16(5):354-8 (19 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

[Prolactinoma; diagnosis and treatment] van der Lely AJ, et al. **Ned Tijdschr Geneeskd** 1996 Jul 13;140(28):1445-9 (53 ref.) **(Dut)**
[Prolactinoma and pregnancy. Six cases and review of the literature] Helie C, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(2):174-8 (27 ref.) (Eng. Abstr.) **(Fre)**
[The treatment of prolactinomas during pregnancy and the lactation period] Rau H, et al. **Dtsch Med Wochenschr** 1996 Jan 5;121(1-2):28-32 (46 ref.) **(Ger)**
[Treatment of hypothalamic-pituitary tumors--experiences at Hiroshima University School of Medicine] Uozumi T. **Nippon Naibunpi Gakkai Zasshi** 1995 Nov 20;71(7):1019-36 (43 ref.) (Eng. Abstr.) **(Jpn)**

PROLAPSE

Pelvic organ prolapse and stress urinary incontinence. Rush CB, et al. **Med Clin North Am** 1995 Nov;79(6):1473-9 (16 ref.)

PROLAPSED DISK see **INTERVERTEBRAL DISK DISPLACEMENT**

PROLIFERATING CELL NUCLEAR ANTIGEN

CHEMISTRY

Structural and functional similarities of prokaryotic and eukaryotic DNA polymerase sliding clamps. Kelman Z, et al. **Nucleic Acids Res** 1995 Sep 25;23(18):3613–20 (41 ref.)

PROLIFERATIVE PHASE see **MENSTRUAL CYCLE**

PROLINE

Towards prediction of cognate complexes between the WW domain and proline-rich ligands. Einbond A, et al. **FEBS Lett** 1996 Apr 8;384(1):1–8 (53 ref.)

PROLINE HYDROXYLASE see **PROCOLLAGEN-PROLINE DIOXYGENASE**

PROLINE,2-OXOGLUTARATE 4-DIOXYGENASE see **PROCOLLAGEN-PROLINE DIOXYGENASE**

PROLONGED-ACTION PREPARATIONS see **DELAYED-ACTION PREPARATIONS**

PROLYMPHOCYTIC LEUKEMIA see **LEUKEMIA, PROLYMPHOCYTIC**

PROM (PREGNANCY) see **FETAL MEMBRANES, PREMATURE RUPTURE**

PROMETHAZINE

THERAPEUTIC USE

Successful cancer therapy with promethazine: the rationale. Jones GR. **Med Hypotheses** 1996 Jan;46(1):25–9 (28 ref.)

PROMOTER (GENETICS) see **PROMOTER REGIONS (GENETICS)**

PROMOTER REGIONS (GENETICS)

see related
GENES, REPORTER

The architecture of the interleukin-2 promoter: a reflection of T lymphocyte activation. Serfling E, et al. **Biochim Biophys Acta** 1995 Sep 19;1263(3):181–200 (244 ref.)

DNA elements responsive to auxin. Abel S, et al. **Bioessays** 1996 Aug;18(8):647–54 (62 ref.)

Transcriptional control by steroid hormones: the role of chromatin. Truss M, et al. **Ciba Found Symp** 1995;191:7–17; discussion 17–23 (45 ref.)

Skin elastic fibres: regulation of human elastin promoter activity in transgenic mice. Uitto J, et al. **Ciba Found Symp** 1995;192:237–53; discussion 253–8 (49 ref.)

Mitochondrial transcription initiation: promoter structures and RNA polymerases. Tracy RL, et al. **Curr Genet** 1995 Aug;28(3):205–16 (103 ref.)

Start-specific transcription in yeast. Breeden L. **Curr Top Microbiol Immunol** 1996;208:95–127 (112 ref.)

Interleukin-5 receptor alpha subunit gene regulation in human eosinophil development: identification of a unique cis-element that acts lie an enhancer in regulating activity of the IL-5R alpha promoter. Sun Z, et al. **Curr Top Microbiol Immunol** 1996;211:173–87 (64 ref.)

Journey to the surface of the cell: Fos regulation and the SRE. Treisman R. **EMBO J** 1995 Oct 16;14(20):4905–13 (100 ref.)

Regulation of gene expression by alternative promoters. Ayoubi TA, et al. **FASEB J** 1996 Mar;10(4):453–60 (41 ref.)

Transcriptional regulation of the genes involved in lipoprotein transport. The role of proximal promoters and long-range regulatory elements and factors in apolipoprotein gene regulation. Kardassis D, et al. **Hypertension** 1996 Apr;27(4):980–1008 (116 ref.)

Regulation of the c-fos promoter. Janknecht R. **Immunobiology** 1995 Jul;193(2–4):137–42 (14 ref.)

Chicken ovalbumin upstream promoter-transcription factors and their regulation. Qiu Y, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1–6 Spec No):81–5 (30 ref.)

Induction of signal transduction pathways through promoter activation. Walden R, et al. **Methods Cell Biol** 1995; 49:455–69 (26 ref.)

Open complex formation by Escherichia coli RNA polymerase: the mechanism of polymerase-induced strand separation of double helical DNA. deHaseth PL, et al. **Mol Microbiol** 1995 Jun;16(5):817–24 (72 ref.)

Regulatory noise in prokaryotic promoters: how bacteria learn to respond to novel environmental signals. de Lorenzo V, et al. **Mol Microbiol** 1996 Mar;19(6):1177–84 (37 ref.)

Hepatocarcinogenesis in transgenic mice. Sandgren EP, et al. **Prog Clin Biol Res** 1995;391:213–22 (35 ref.)

A nuclear matrix acceptor site for the progesterone receptor in the avian c-myc gene promoter. Spelsberg TC, et al. **Recent Prog Horm Res** 1996;51:63–96 (121 ref.)

A model for understanding gene regulation during spermatogenesis: the mouse testis Pdha-2 promoter. Iannello RC, et al. **Reprod Fertil Dev** 1995;7(4):705–12 (51 ref.)

Characterization of the cis-acting elements required for somatic hypermutation of murine antibody V genes using conventional transgenic and transgene homologous recombination approaches. Tumas-Brundage K, et al. **Semin Immunol** 1996 Jun;8(3):141–50 (68 ref.)

Transcriptional regulation: lessons from the human neurotropic polyomavirus, JCV. Raj GV, et al. **Virology** 1995 Nov 10;213(2):283–91 (79 ref.)

[Several transcription factors participate in the functioning of the alpha-fetoprotein gene promoter] Bois-Joyeux B, et al. **Bull Cancer (Paris)** 1995 Jul;82(7):541–50 (51 ref.) (Eng. Abstr.) **(Fre)**

[Expression of HCV genes using adenovirus vector with CAG promoter] Makimura M, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:91–4 (9 ref.) **(Jpn)**

[Transcriptional machinery and its regulatory elements of HBV genome] Nishizono A, et al. **Nippon Rinsho** 1995 Oct; 53 Suppl:28–34 (30 ref.) **(Jpn)**

[Usefulness of myelin basic protein gene promoter for the gene therapy of malignant glioma] Miyao Y, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2618–23 (13 ref.) **(Jpn)**

[Promoter and enhancer of the ornithine transcarbamylase gene] Nishiyori A, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2606–12 (26 ref.) **(Jpn)**

[Inducible regulatable promoter—ionizing radiation-inducible promoter EGR-1] Ohno T. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2624–30 (25 ref.) **(Jpn)**

GENETICS

Transcription of the human neuronal nitric oxide synthase gene in the central nervous system is mediated by multiple promoters. Young AP, et al. **Adv Pharmacol** 1995;34:91–112 (51 ref.)

Yeast RNA polymerase III: transcription complexes and RNA synthesis. Geiduschek EP, et al. **Braz J Med Biol Res** 1995 Feb;28(2):147–59 (133 ref.)

Contacts in context: promoter specificity and macromolecular interactions in transcription. Goodrich JA, et al. **Cell** 1996 Mar 22;84(6):825–30 (32 ref.)

In vitro transcription of class II promoters in higher plants. Cooke R, et al. **Methods Mol Biol** 1995;49:271–89 (19 ref.)

Analysis of varicella-zoster virus promoter sequences. Kantakamalakul W, et al. **Neurology** 1995 Dec;45(12 Suppl 8):S28–9 (3 ref.)

Interplay between nucleosomes and transcription factors at the yeast PHO5 promoter. Svaren J, et al. **Semin Cell Biol** 1995 Aug;6(4):177–83 (52 ref.)

IMMUNOLOGY

The inducible transcription factor NF-AT plays an important role in the activation of the murine interleukin-4 promoter. Schneider G, et al. **Immunobiology** 1995 Jul; 193(2–4):268–72 (14 ref.)

Evolution of class I promoter sequences: relationship to function and diversity. Vallejo AN, et al. **Immunol Rev** 1995 Feb;143:249–62 (54 ref.)

PHYSIOLOGY

gamma-Glutamyl transpeptidase. What does the organization and expression of a multipromoter gene tell us about its functions? Lieberman MW, et al. **Am J Pathol** 1995 Nov; 147(5):1175–85 (91 ref.)

The glucocorticoid receptor synergizes with Jun homodimers to activate AP-1-regulated promoters lacking GR binding sites. Teurich S, et al. **Chem Senses** 1995 Apr;20(2):251–5 (17 ref.)

PROMOTION OF HEALTH see **HEALTH PROMOTION**

PROMYELOCYTES see **GRANULOCYTES**

PROMYELOCYTIC LEUKEMIA, ACUTE see **LEUKEMIA, PROMYELOCYTIC, ACUTE**

PRONE POSITION

[Ventilation in the prone position in acute respiratory distress syndrome (ARDS)] Jolliet P, et al. **Schweiz Med Wochenschr** 1996 May 18;126(20):879–92 (77 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Sleeping position and sudden infant death syndrome: a review of the literature and the implications for infants in the United States. Bradshaw CM. **Indiana Med** 1996 Jan–Feb; 89(1):64–73 (0 ref.)

[Complications of patient positioning] Staender S. **Swiss Surg** 1995;(3):152–5 (16 ref.) (Eng. Abstr.) **(Ger)**

PRO-OPIOCORTIN see **PRO-OPIOMELANOCORTIN**

PRO-OPIOMELANOCORTIN

ANALOGS & DERIVATIVES

Proopiomelanocortin, its derived peptides, and the skin. Wintzen M, et al. **J Invest Dermatol** 1996 Jan;106(1):3–10 (155 ref.)

BIOSYNTHESIS

Current topic: the placental corticotrophin-releasing hormone-adrenocorticotrophin axis. Challis JR, et al. **Placenta** 1995 Sep;16(6):481–502 (98 ref.)

METABOLISM

Proopiomelanocortin, its derived peptides, and the skin. Wintzen M, et al. **J Invest Dermatol** 1996 Jan;106(1):3–10 (155 ref.)

PROPAFENONE

THERAPEUTIC USE

Guidelines for the use of propafenone in treating supraventricular arrhythmias. Kishore AG, et al. **Drugs** 1995 Aug;50(2):250–62 (73 ref.)

Propafenone: an effective agent for the management of supraventricular arrhythmias. Grant AO. **J Cardiovasc Electrophysiol** 1996 Apr;7(4):353–64 (74 ref.)

PROPAGANDA

Antiscience trends in the rise of the "alternative medicine" movement. Sampson W. **Ann N Y Acad Sci** 1996 Jun 24; 775:188–97 (34 ref.)

PROPANEDIAL see **MALONDIALDEHYDE**

PROPANEDIOLS

THERAPEUTIC USE

Felbamate. Leppik IE. **Epilepsia** 1995;36 Suppl 2:S66–72 (55 ref.)

[Advances in the diagnostic and treatment of infantile epilepsy] Legido A. **Rev Neurol** 1996 Jun;24(130):688–93 (25 ref.) **(Spa)**

[Felbamate: perspectives for new antiepileptic treatment] Pérez-Miranda J, et al. **Rev Neurol** 1995 Nov–Dec; 23(124):1220–5 (46 ref.) (Eng. Abstr.) **(Spa)**

PROPANOL see **ALCOHOL, PROPYL**

PROPANOLAMINES

PHARMACOLOGY

Carvedilol, a novel vasodilating beta-blocker with the potential for cardiovascular organ protection. Feuerstein GZ, et al. **Eur Heart J** 1996 Apr;17 Suppl B:24–9 (24 ref.)

Cardiac adrenergic receptor effects of carvedilol. Yoshikawa T, et al. **Eur Heart J** 1996 Apr;17 Suppl B:8–16 (37 ref.)

THERAPEUTIC USE

The actions of talinolol, a beta 1-selective beta blocker, in cardiac arrhythmia and acute myocardial infarction. Assmann I. **Curr Med Res Opin** 1995;13(6):325–42 (43 ref.)

Carvedilol for hypertension. **Drug Ther Bull** 1995 May; 33(5):39–40 (19 ref.)

Carvedilol, a novel multiple action antihypertensive agent with antioxidant activity and the potential for myocardial and vascular protection. Feuerstein GZ, et al. **Eur Heart J** 1995 Jul;16 Suppl F:38–42 (21 ref.)

[Evaluation of the antihypertensive drugs carvedilol, doxazosin and moxonidine] Dominiak P. **Wien Med Wochenschr** 1995;145(15–16):373–82 (92 ref.) (Eng. Abstr.) **(Ger)**

PROPENE POLYMERS see **POLYPROPYLENES**

PROPERDIN

DEFICIENCY

[Partial properdin deficiency revealed by a septicemia caused by Neisseria meningitidis] Frémeaux-Bacchi V, et al. **Presse Med** 1995 Sep 30;24(28):1305–7 (14 ref.) (Eng. Abstr.) **(Fre)**

PROPERDIN FACTOR D

PHYSIOLOGY

Complement factor D, a novel serine protease. Volanakis JE, et al. **Protein Sci** 1996 Apr;5(4):553–64 (70 ref.)

PROPHAGE EXCISION see **VIRUS ACTIVATION**

PROPHAGE INDUCTION see **VIRUS ACTIVATION**

PROPIDIUM

PHARMACOLOGY

[Comparison of 2 techniques for measuring lymphocyte proliferation: tritiated methyl-thymidine incorporation and propidium iodide fluorometry] Brohee D, et al. **Rev Med Brux** 1995 Nov;16(5):368-71 (10 ref.) (Eng. Abstr.) **(Fre)**

PROPIONIBACTERIUM ACNES

Propionibacterium acnes vertebral osteomyelitis following lumbar puncture: case report and review [letter] Abolnik IZ, et al. **Clin Infect Dis** 1995 Sep;21(3):694-5 (10 ref.)

PROPIONIC ACIDS

METABOLISM

The management and outcome of propionic and methylmalonic acidaemia. Leonard JV. **J Inherit Metab Dis** 1995;18(4):430-4 (29 ref.)

PHARMACOLOGY

Effects of chronic MPTP and 3-nitropropionic acid in nonhuman primates. Brouillet E, et al. **Curr Opin Neurol** 1995 Dec;8(6):469-73 (44 ref.)

Tiaprofenic acid. A reappraisal of its pharmacological properties and use in the management of rheumatic diseases. Plosker GL, et al. **Drugs** 1995 Dec;50(6):1050-75 (146 ref.)

THERAPEUTIC USE

Tiaprofenic acid. A reappraisal of its pharmacological properties and use in the management of rheumatic diseases. Plosker GL, et al. **Drugs** 1995 Dec;50(6):1050-75 (146 ref.)

PROPITOCAINE see **PRILOCAINE**

PROPOFOL

Optimal intravenous dosing strategies for sedatives and analgesics in the intensive care unit. Barr J, et al. **Crit Care Clin** 1995 Oct;11(4):827-47 (64 ref.)

Barbiturates, neuroleptics, and propofol for sedation. Lund N, et al. **Crit Care Clin** 1995 Oct;11(4):875-86 (38 ref.)

[Prospects of balanced anesthesia--combination with propofol] Shingu K, et al. **Masui** 1995;44 Suppl:S158-61; discussion S173-6 (6 ref.) **(Jpn)**

ADVERSE EFFECTS

Propofol. An update of its use in anaesthesia and conscious sedation. Bryson HM, et al. **Drugs** 1995 Sep;50(3):513-59 (622 ref.)

PHARMACOLOGY

Propofol. An update of its use in anaesthesia and conscious sedation. Bryson HM, et al. **Drugs** 1995 Sep;50(3):513-59 (622 ref.)

Propofol. An overview of its pharmacology and a review of its clinical efficacy in intensive care sedation. Fulton B, et al. **Drugs** 1995 Oct;50(4):636-57 (205 ref.)

THERAPEUTIC USE

Propofol. An update of its use in anaesthesia and conscious sedation. Bryson HM, et al. **Drugs** 1995 Sep;50(3):513-59 (622 ref.)

Propofol. An overview of its pharmacology and a review of its clinical efficacy in intensive care sedation. Fulton B, et al. **Drugs** 1995 Oct;50(4):636-57 (205 ref.)

Perioperative use of propofol for cardiac surgery. Jain U. **J Clin Anesth** 1996 May;8(3 Suppl):61S-66S (81 ref.)

PROPOLIS

PHARMACOLOGY

[Propolis: its use in technology and research] Gallo FR, et al. **Boll Chim Farm** 1995 Oct;134(9):483-91 (15 ref.) (Eng. Abstr.) **(Ita)**

PROPRANOLOL

beta-blockers. Drug interactions of clinical significance. Blaufarb I, et al. **Drug Saf** 1995 Dec;13(6):359-70 (114 ref.)

THERAPEUTIC USE

Drug treatment of esophageal variceal bleeding: alternative or supplement to endoscopic therapy? Zoller WG, et al. **Endoscopy** 1995 Oct;27(8):616-21 (65 ref.)

PROPRIOCEPTION

Peripheral neuropathy: an often-overlooked cause of falls in the elderly. Richardson JK, et al. **Postgrad Med** 1996 Jun;99(6):161-72 (20 ref.)

PHYSIOLOGY

Egocentric visual target position and velocity coding: role of ocular muscle proprioception. Gauthier GM, et al. **Ann Biomed Eng** 1995 Jul-Aug;23(4):423-35 (34 ref.)

Interoception. Vaitl D. **Biol Psychol** 1996 Jan 5;42(1-2):1-27 (100 ref.)

Proprioceptive regulation of locomotion. Pearson KG. **Curr Opin Neurobiol** 1995 Dec;5(6):786-91 (38 ref.)

[The central effects of interoceptive signalization] Zakharzhevskii VB. **Fiziol Zh Im I M Sechenova** 1995 Sep; 81(9):1-12 (64 ref.) **(Rus)**

PROPTOSIS see **EXOPHTHALMOS**

PROPYLENE GLYCOLS see **PROPANEDIOLS**

PROPYLENE POLYMERS see **POLYPROPYLENES**

PROSENCEPHALON

ANATOMY & HISTOLOGY

A segmental morphological paradigm for understanding vertebrate forebrains. Puelles L. **Brain Behav Evol** 1995; 46(4-5):319-37 (145 ref.)

Magnocellular nuclei of the basal forebrain: substrates of sleep and arousal regulation. Szymusiak R. **Sleep** 1995 Jul; 18(6):478-500 (181 ref.)

CYTOLOGY

Lineage, migration, and fate determination of postnatal subventricular zone cells in the mammalian CNS. Goldman JE. **J Neurooncol** 1995;24(1):61-4 (15 ref.)

EMBRYOLOGY

Longitudinal organization of the anterior neural plate and neural tube. Shimamura K, et al. **Development** 1995 Dec; 121(12):3923-33 (66 ref.)

Sonic hedgehog: a common signal for ventral patterning along the rostrocaudal axis of the neural tube. Ericson J, et al. **Int J Dev Biol** 1995 Oct;39(5):809-16 (45 ref.)

Mechanisms of estrogen action during neural development: mediation by interactions with the neurotrophins and their receptors? Toran-Allerand CD. **J Steroid Biochem Mol Biol** 1996 Jan;56(1-6 Spec No):169-78 (77 ref.)

Regionalization of the forebrain from neural plate to neural tube. Papalopulu N. **Perspect Dev Neurobiol** 1995; 3(1):39-52 (125 ref.)

GROWTH & DEVELOPMENT

Regulation of neural precursor differentiation in the embryonic and adult forebrain. Bartlett PF, et al. **Clin Exp Pharmacol Physiol** 1995 Aug;22(8):559-62 (21 ref.)

PHYSIOLOGY

Cognitive functions of the basal forebrain cholinergic system in monkeys: memory or attention? Voytko ML. **Behav Brain Res** 1996 Feb;75(1-2):13-25 (123 ref.)

Comparative aspects of forebrain organization in the ray-finned fishes: touchstones or not? Braford MR Jr. **Brain Behav Evol** 1995;46(4-5):259-74 (96 ref.)

The forebrain of gnathostomes: in search of a morphotype. Northcutt RG. **Brain Behav Evol** 1995;46(4-5):275-318 (256 ref.)

Discrete, patterned and purposeful adaptive physiological adjustments integrated by forebrain influences. Wolf S. **Integr Physiol Behav Sci** 1995 Jul-Sep;30(3):190-9 (21 ref.)

Tempting fate and commitment in the developing forebrain. Barbe MF. **Neuron** 1996 Jan;16(1):1-4 (16 ref.)

Magnocellular nuclei of the basal forebrain: substrates of sleep and arousal regulation. Szymusiak R. **Sleep** 1995 Jul; 18(6):478-500 (181 ref.)

PROSPECTIVE STUDIES

[Alternatives and access routes in hysterectomies. Are randomizations dangerous?] Cosson M, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(3):257-63 (15 ref.) (Eng. Abstr.) **(Fre)**

PROSTACYCLIN see **EPOPROSTENOL**

PROSTAGLANDIN ANALOGS see **PROSTAGLANDINS, SYNTHETIC**

PROSTAGLANDIN ANTAGONISTS

see related
CYCLOOXYGENASE INHIBITORS

PHARMACOLOGY

Prostaglandins, their inhibitors and cancer. Lupulescu A. **Prostaglandins Leukot Essent Fatty Acids** 1996 Feb; 54(2):83-94 (109 ref.)

PROSTAGLANDIN D2

ANALOGS & DERIVATIVES

Biological actions of delta 12-prostaglandin J2. Negishi M, et al. **J Lipid Mediat Cell Signal** 1995 Oct;12(2-3):443-8 (23 ref.)

PROSTAGLANDIN E RECEPTORS see **RECEPTORS, PROSTAGLANDIN E**

PROSTAGLANDIN E1 see **ALPROSTADIL**

PROSTAGLANDIN E2 see **DINOPROSTONE**

PROSTAGLANDIN E2ALPHA see **DINOPROSTONE**

PROSTAGLANDIN-ENDOPEROXIDE SYNTHASE

BIOSYNTHESIS

Prostaglandin synthase 2. Herschman HR. **Biochim Biophys Acta** 1996 Jan 5;1299(1):125-40 (136 ref.)

Constitutive cyclooxygenase (COX-1) and inducible cyclooxygenase (COX-2): rationale for selective inhibition and progress to date. Griswold DE, et al. **Med Res Rev** 1996 Mar;16(2):181-206 (143 ref.)

CHEMISTRY

Prostaglandin endoperoxide synthases-1 and -2. Otto JC, et al. **J Lipid Mediat Cell Signal** 1995 Oct;12(2-3):139-56 (85 ref.)

DRUG EFFECTS

Aspirin--now we can see it. Allen KN. **Nat Med** 1995 Sep; 1(9):882-3 (13 ref.)

GENETICS

Studies on glucocorticoid hormone actions in the regulation of human amnion PGHS. Zakar T, et al. **Reprod Fertil Dev** 1995;7(3):517-20 (12 ref.)

METABOLISM

Effects of mesalazine on the formation of lipoxygenase and cyclooxygenase products. Lauritsen K, et al. **Adv Exp Med Biol** 1995;371B:1301-6 (66 ref.)

Inducible cyclooxygenase and nitric oxide synthase. Wu KK. **Adv Pharmacol** 1995;33:179-207 (148 ref.)

Prostaglandin endoperoxide synthase: why two isoforms? Williams CS, et al. **Am J Physiol** 1996 Mar;270(3 Pt 1):G393-400 (75 ref.)

Cyclooxygenase-2: regulation and relevance in inflammation. Mitchell JA, et al. **Biochem Pharmacol** 1995 Nov 9; 50(10):1535-42 (92 ref.)

Prostaglandin endoperoxide synthases-1 and -2. Otto JC, et al. **J Lipid Mediat Cell Signal** 1995 Oct;12(2-3):139-56 (85 ref.)

Activation of the phospholipase/cyclooxygenase cascade in the rabbit cornea by platelet-activating factor is challenged by PAF receptor antagonists. Hurst JS, et al. **J Ocul Pharmacol Ther** 1995 Fall;11(3):329-37 (39 ref.)

PHYSIOLOGY

Inflammation, reproduction, cancer and all that.... The regulation and role of the inducible prostaglandin synthase. Herschman HR, et al. **Bioessays** 1995 Dec;17(12):1031-7 (65 ref.)

Cyclooxygenase 2 induction: molecular mechanism and pathophysiologic roles. Wu KK. **J Lab Clin Med** 1996 Sep; 128(3):242-5 (28 ref.)

PROSTAGLANDIN ENDOPEROXIDE SYNTHASE INHIBITORS see **CYCLOOXYGENASE INHIBITORS**

PROSTAGLANDIN ENDOPEROXIDE SYNTHETASE see **PROSTAGLANDIN-ENDOPEROXIDE SYNTHASE**

PROSTAGLANDIN F ANALOGS see **PROSTAGLANDINS F, SYNTHETIC**

PROSTAGLANDIN F2 see **DINOPROST**

PROSTAGLANDIN F2ALPHA see **DINOPROST**

PROSTAGLANDIN H SYNTHASE see **PROSTAGLANDIN-ENDOPEROXIDE SYNTHASE**

PROSTAGLANDIN I2 see **EPOPROSTENOL**

PROSTAGLANDIN INHIBITORS see **PROSTAGLANDIN ANTAGONISTS**

PROSTAGLANDIN RECEPTORS see **RECEPTORS, PROSTAGLANDIN**

PROSTAGLANDIN SYNTHASE see **PROSTAGLANDIN-ENDOPEROXIDE SYNTHASE**

PROSTAGLANDIN SYNTHASE INHIBITORS see **CYCLOOXYGENASE INHIBITORS**

PROSTAGLANDIN SYNTHESIS ANTAGONISTS see **CYCLOOXYGENASE INHIBITORS**

PROSTAGLANDIN X see **EPOPROSTENOL**

PROSTAGLANDINS

see related
PROSTAGLANDIN ANTAGONISTS
RECEPTORS, PROSTAGLANDIN

The combined use of prostaglandin and antiprogestin in human fertility control. Baulieu EE.
Eur J Obstet Gynecol Reprod Biol 1996 Mar;65(1):115–9 (42 ref.)

[Induced labor by pharmacological methods. Advantages and disadvantages] Rotten D.
J Gynecol Obstet Biol Reprod (Paris) 1995;24 Suppl 1:13–27 (42 ref.) **(Fre)**

ADVERSE EFFECTS

[Uterine rupture during induced abortion with prostaglandins in the second trimester] Zieger W, et al.
Geburtshilfe Frauenheilkd 1995 Oct;55(10):592–8 (43 ref.) (Eng. Abstr.) **(Ger)**

BIOSYNTHESIS

Inducible cyclooxygenase and nitric oxide synthase. Wu KK.
Adv Pharmacol 1995;33:179–207 (148 ref.)

Prostaglandin synthase 2. Herschman HR.
Biochim Biophys Acta 1996 Jan 5;1299(1):125–40 (136 ref.)

CHEMISTRY

Clavulones and related tert-hydroxycyclopentenone fatty acids: occurrence, physiological activity and problem of biogenetic origin. Grechkin AN.
J Lipid Mediat Cell Signal 1995 May;11(3):205–18 (68 ref.)

METABOLISM

Prostaglandin-metabolizing enzymes during pregnancy: characterization of NAD(+)-dependent prostaglandin dehydrogenase, carbonyl reductase, and cytochrome P450-dependent prostaglandin omega-hydroxylase. Okita RT, et al. **Crit Rev Biochem Mol Biol** 1996 Apr; 31(2):101–26 (100 ref.)

PHYSIOLOGY

Prostaglandins and sleep. Hayaishi O, et al.
Adv Neuroimmunol 1995;5(2):211–6 (9 ref.)

Insulin and prostaglandins as signals between tumor and the host immune system. Curi R, et al.
Braz J Med Biol Res 1995 Jul;28(7):773–9 (46 ref.)

Yes, but do they still get headaches? DeWitt D, et al.
Cell 1995 Nov 3;83(3):345–8 (16 ref.)

Prostaglandins and sodium handling in Lyon hypertensive rats. Sassard J, et al. **Clin Exp Pharmacol Physiol** 1995 Dec; 22(12):S423–5 (18 ref.)

Mechanism and treatment of diarrhoea due to Vibrio cholerae and Escherichia coli: roles of drugs and prostaglandins. Rabbani GH. **Dan Med Bull** 1996 Apr;43(2):173–85 (169 ref.)

The role of prostaglandins in blastocyst implantation. Psychoyos A, et al. **Hum Reprod** 1995 Dec;10 Suppl 2:30–42 (105 ref.)

Endothelium, fibrinolysis, cardiac risk factors, and prostaglandins: a unified model of atherogenesis. Kadish J. **Med Hypotheses** 1995 Aug;45(2):205–13 (106 ref.)

Prostaglandin-induced neuropeptide release from spinal cord. Vasko MR. **Prog Brain Res** 1995;104:367–80 (80 ref.)

Prostaglandins, their inhibitors and cancer. Lupulescu A.
Prostaglandins Leukot Essent Fatty Acids 1996 Feb; 54(2):83–94 (109 ref.)

Prostaglandins and parturition. Mitchell MD, et al.
Reprod Fertil Dev 1995;7(3):623–32 (79 ref.)

The role of prostaglandins in gastric mucosal protection. Wilson DE. **Trans Am Clin Climatol Assoc** 1995;107:99–113; discussion 113–4 (78 ref.)

[Lipid mediators and liver injury] Liu Y, et al.
Sheng Li Ko Hsueh Chin Chan 1995 Oct;26(4):363–6 (10 ref.) **(Chi)**

[The prostanoid system in patients with disordered heart rhythm] Bobrov VA, et al. **Ter Arkh** 1995;67(8):68–71 (69 ref.) **(Rus)**

[Prostaglandins in chronic liver diseases] Loginov AS, et al.
Vestn Ross Akad Med Nauk 1995;(12):32–8 (83 ref.) (Eng. Abstr.) **(Rus)**

[The prostaglandin system in the kidney] Stošić Z.
Med Pregl 1996;49(1–2):32–6 (38 ref.) (Eng. Abstr.) **(Scr)**

[Neurohormonal factors in heart failure. II] Cosín Aguilar J, et al. **Rev Esp Cardiol** 1996 May;49(5):317–27 (47 ref.) (Eng. Abstr.) **(Spa)**

THERAPEUTIC USE

The role of prostaglandins in labor and delivery. O'Brien WF. **Clin Perinatol** 1995 Dec;22(4):973–84 (40 ref.)

PROSTAGLANDINS A

CHEMISTRY

Clavulones and related tert-hydroxycyclopentenone fatty acids: occurrence, physiological activity and problem of biogenetic origin. Grechkin AN.
J Lipid Mediat Cell Signal 1995 May;11(3):205–18 (68 ref.)

PROSTAGLANDINS E

PHYSIOLOGY

[Role of prostaglandins F and E in regulation of bronchial activity] Mastalerz L. **Pol Arch Med Wewn** 1995 Feb; 93(2):179–83 (35 ref.) (Eng. Abstr.) **(Pol)**

PROSTAGLANDINS F

PHYSIOLOGY

[Role of prostaglandins F and E in regulation of bronchial activity] Mastalerz L. **Pol Arch Med Wewn** 1995 Feb; 93(2):179–83 (35 ref.) (Eng. Abstr.) **(Pol)**

PROSTAGLANDINS F, SYNTHETIC

THERAPEUTIC USE

Will latanoprost be the 'wonder' drug of the '90s for the treatment of glaucoma? [editorial; comment] Higginbotham EJ. **Arch Ophthalmol** 1996 Aug;114(8):998–9 (16 ref.)
Comment on: Arch Ophthalmol 1996 Aug;114(8):929–32.

PROSTAGLANDINS, SYNTHETIC

Acceptability of medical abortion in early pregnancy. Winikoff B. **Fam Plann Perspect** 1995 Jul–Aug;27(4):142–8, 185 (36 ref.)

PROSTATE

see related
PROSTATECTOMY

ANATOMY & HISTOLOGY

Prostate gland: structure, functions and regulation. Kumar VL, et al. **Int Urol Nephrol** 1995;27(3):231–43 (104 ref.)

CYTOLOGY

Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model. Bonkhoff H, et al. **Prostate** 1996 Feb;28(2):98–106 (52 ref.)

DRUG EFFECTS

Growth factors as mediators of androgen action during male urogenital development. Cunha GR. **Prostate Suppl** 1996; 6:22–5 (33 ref.)

Role of androgen in prostate growth and regression: stromal-epithelial interaction. Lee C. **Prostate Suppl** 1996; 6:52–6 (26 ref.)

[Azithromycin: tissue pharmacology] Bergogne-Bérézin E.
Pathol Biol (Paris) 1995 Jun;43(6):498–504 (29 ref.) (Eng. Abstr.) **(Fre)**

[Effect of the molecular structure of azithromycin on pharmacokinetics and the antimicrobial activity] Pechère JC. **Pathol Biol (Paris)** 1995 Jun;43(6):483–7 (8 ref.) (Eng. Abstr.) **(Fre)**

EMBRYOLOGY

Growth factors as mediators of androgen action during the development of the male urogenital tract. Cunha GR, et al. **World J Urol** 1995;13(5):264–76 (124 ref.)

ENZYMOLOGY

Neuroendocrine tumors of the liver and pancreas associated with elevated serum prostatic acid phosphatase. Kaneko Y, et al. **Intern Med** 1995 Sep;34(9):886–91 (35 ref.)

GROWTH & DEVELOPMENT

Normal development and carcinogenesis of the prostate. A unifying hypothesis. Hayward SW, et al.
Ann N Y Acad Sci 1996 Apr 30;784:50–62 (41 ref.)

Peptide growth factors in the prostate as mediators of stromal epithelial interaction. Byrne RL, et al. **Br J Urol** 1996 May; 77(5):627–33 (65 ref.)

Regulation of prostatic growth and function by peptide growth factors. Culig Z, et al. **Prostate** 1996 Jun; 28(6):392–405 (142 ref.)

Regulation of prostate growth by fibroblast growth factors. Story MT. **World J Urol** 1995;13(5):297–305 (96 ref.)

PATHOLOGY

Tumor-like lesions of the prostate gland [editorial; comment] Young RH. **Am J Clin Pathol** 1995 Dec;104(6):607–10 (41 ref.) Comment on: Am J Clin Pathol 1995 Dec;104(6):620–6.

ACP Broadsheet No 146: August 1995. Macroscopic examination of prostatic specimens [see comments] Harnden P, et al. **J Clin Pathol** 1995 Aug;48(8):693–700 (48 ref.) Comment in: J Clin Pathol 1996 Feb;49(2):187–8.

Contrast-enhanced MR imaging of the bladder and prostate. Siegelman ES, et al. **Magn Reson Imaging Clin N Am** 1996 Feb;4(1):153–69 (61 ref.)

Undergrading of prostate cancer biopsies: a paradox inherent in all biologic bivariate distributions. Gleason DF.
Urology 1996 Mar;47(3):289–91 (6 ref.)

[Results of endorectal MRI in local staging of prostatic cancer. Correlation with specimens from prostatectomy. Apropos of 47 cases] Chefchaouni MC, et al.
J Urol (Paris) 1996;102(2):51–5 (18 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Oxytocin and prostatic function. Nicholson HD, et al.
Adv Exp Med Biol 1995;395:529–38 (42 ref.)

Prostate gland: structure, functions and regulation. Kumar VL, et al. **Int Urol Nephrol** 1995;27(3):231–43 (104 ref.)

Regulation of prostatic growth and function by peptide growth factors. Culig Z, et al. **Prostate** 1996 Jun; 28(6):392–405 (142 ref.)

Roles of estrogen and SHBG in prostate physiology. Farnsworth WE. **Prostate** 1996 Jan;28(1):17–23 (49 ref.)

Growth factors as mediators of androgen action during the development of the male urogenital tract. Cunha GR, et al. **World J Urol** 1995;13(5):264–76 (124 ref.)

Keratinocyte growth factor: an androgen-regulated mediator of stromal-epithelial interactions in the prostate. Peehl DM, et al. **World J Urol** 1995;13(5):312–7 (43 ref.)

The insulin-like growth factor system in the prostate. Peehl DM, et al. **World J Urol** 1995;13(5):306–11 (38 ref.)

Epidermal growth factor-related peptides and the epidermal growth factor receptor in normal and malignant prostate. Sherwood ER, et al. **World J Urol** 1995;13(5):290–6 (65 ref.)

SECRETION

[Diagnostic value of Stamey's test in chronic prostatitis] Sibert L, et al. **Prog Urol** 1996 Feb;6(1):107–11 (20 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Compliance with hormonal treatment for prostate cancer. Kaisary AV. **Br J Hosp Med** 1996 Mar 20–Apr 2; 55(6):359–66 (59 ref.)

ULTRASONOGRAPHY

Transrectal ultrasonography of the prostate. el Din KE, et al. **Br J Urol** 1996 Jul;78(1):2–9 (64 ref.)

PROSTATE-SPECIFIC ANTIGEN

ANALYSIS

Cancer (prostate-specific antigen). Castellani WJ.
Anal Chem 1995 Jun 15;67(12):399R–403R (67 ref.)

[Early diagnosis and screening of cancer of the prostate] Fendler JP, et al. **Presse Med** 1995 Oct 28;24(32):1461–3 (10 ref.) (Eng. Abstr.) **(Fre)**

BIOSYNTHESIS

Expression and androgenic regulation of human prostate-specific kallikreins. Young CY, et al. **J Androl** 1995 Mar–Apr;16(2):97–9 (16 ref.)

Biochemical characteristics and recent biological knowledge on prostate-specific antigen. Seregni E, et al. **Tumori** 1996 Jan–Feb;82(1):72–7 (70 ref.)

BLOOD

Prostate cancer: emerging concepts. Part I. Garnick MB, et al. **Ann Intern Med** 1996 Jul 15;125(2):118–25 (50 ref.)

Tumour serum markers: clinical and economical aspects. Kardamakis D. **Anticancer Res** 1996 Jul–Aug; 16(4B):2285–8 (17 ref.)

Early detection of prostate cancer. Role of prostate-specific antigen. Prabhakaran VM. **Can Fam Physician** 1996 Apr; 42:709–12 (20 ref.)

A guide to the interpretation of serum prostate specific antigen levels. Bunting PS. **Clin Biochem** 1995 Jun; 28(3):221–41 (174 ref.)

Supportive care is not the only option in prostate cancer patients resistant to hormone therapy: the argument against. Jewett MA, et al. **Eur Urol** 1996;29 Suppl 2:45–8 (11 ref.)

Supportive care is not the only option in prostate cancer patients resistant to hormone therapy: the argument for. Scher HI. **Eur Urol** 1996;29 Suppl 2:40–4 (36 ref.)

The prostate specific antigen. Its use as a tumor marker for prostate cancer. Kantoff PW, et al.
Hematol Oncol Clin North Am 1994 Jun;8(3):555–72 (66 ref.)

Prospective characterization of pathological features of prostatic carcinomas detected via serum prostate specific antigen based screening [see comments] Humphrey PA, et al. **J Urol** 1996 Mar;155(3):816–20 (34 ref.) Comment in: J Urol 1996 Mar;155(3):827.

Screening for prostate cancer with prostate-specific antigen. An examination of the evidence [see comments] Woolf SH. **N Engl J Med** 1995 Nov 23;333(21):1401–5 (62 ref.) Comment in: N Engl J Med 1996 Mar 7;344(10):666–7; discussion 667–8. Comment in: N Engl J Med 1996 Mar 7;344(10):667; discussion 667–8.

Prostate-specific antigen testing for prostate cancer. Practical interpretation of values. Randrup E, et al.
Postgrad Med 1996 Feb;99(2):227–8, 231–4 (14 ref.)

T1c cancer: what is it? Flanigan RC, et al.
Semin Urol Oncol 1995 Aug;13(3):173–5 (18 ref.)

Impact of prostate-specific antigen screening on the natural history of prostate cancer. Rosen MA. **Urology** 1995 Dec; 46(6):757–68 (95 ref.)

PROSTATE-SPECIFIC ANTIGEN

[Clinical usefulness of the new criteria based on the serum quantification of prostate-specific antigen in the early diagnosis of prostatic cancer (editorial)] Morote Robles J. **Actas Urol Esp** 1996 Jan;20(1):1–12 (71 ref.) **(Spa)**

DRUG EFFECTS

The effect of finasteride on prostate specific antigen: review of available data. Guess HA, et al. **J Urol** 1996 Jan; 155(1):3–9 (33 ref.)

IMMUNOLOGY

[Prostate specific antigen. Clinical applications of ultrasensitive assay] Haab F, et al. **Presse Med** 1995 Nov 25;24(36):1697–702 (43 ref.) (Eng. Abstr.) **(Fre)**

[Radical prostatectomy] Maréchal JM. **Presse Med** 1995 Oct 28;24(32):1473–6 (11 ref.) (Eng. Abstr.) **(Fre)**

PROSTATECTOMY

Transurethral laser therapy and urinary tract infections. Miller J, et al. **Ann Urol (Paris)** 1996;30(3):131–8 (38 ref.)

Prostate cancer: anatomical and surgical considerations. Gil-Vernet JM. **Br J Urol** 1996 Aug;78(2):161–8 (28 ref.)

The risks outweigh the benefits of radical prostatectomy in localised prostate cancer: the argument for. Abrahamsson PA. **Eur Urol** 1996;29 Suppl 2:27–30 (12 ref.)

The risks outweigh the benefits of radical prostatectomy in localised prostate cancer: the argument against. Huland H. **Eur Urol** 1996;29 Suppl 2:31–3 (16 ref.)

The role of induction androgen deprivation prior to radical prostatectomy. Soloway MS, et al. **Eur Urol** 1996;29 Suppl 2:114–8 (27 ref.)

Is there always a role for radical prostatectomy in the treatment of localized prostate cancer? Di Silverio F, et al. **Minerva Urol Nefrol** 1995 Sep;47(3):117–24 (26 ref.)

Optimal duration of neoadjuvant androgen withdrawal therapy before radical prostatectomy in clinically confined prostate cancer. Gleave ME, et al. **Semin Urol Oncol** 1996 May;14(2 Suppl 2):39–45; discussion 46–7 (26 ref.)

Risk factors for progression in patients with prostate cancer treated with radical prostatectomy. Lerner SE, et al. **Semin Urol Oncol** 1996 May;14(2 Suppl 2):12–20; discussion 21 (36 ref.)

Neoadjuvant total androgen suppression and radiotherapy in the management of locally advanced prostate cancer. Roach M 3rd. **Semin Urol Oncol** 1996 May;14(2 Suppl 2):32–7; discussion 38 (33 ref.)

Neoadjuvant hormonal treatment before radical prostatectomy. Watson RB, et al. **Semin Urol Oncol** 1996 May;14(2 Suppl 2):48–55; discussion 55–6 (59 ref.)

[Anatomopathologic reassessment of prostatic tumors exclusively affecting the organ with biologic progression and survival study of prostatectomized patients, in terms of the histologic characteristics of the tumor] Ravery V, et al. **Prog Urol** 1995 Dec;5(6):968–73 (17 ref.) (Eng. Abstr.) **(Fre)**

[Laser technology in prostatic surgery] Kornev AI, et al. **Urol Nefrol (Mosk)** 1996 Mar-Apr;(2):49–52 (39 ref.) **(Rus)**

ADVERSE EFFECTS

Follow-up after therapy for prostate cancer. Treating the problems and caring for the man. Freedman A, et al. **Postgrad Med** 1996 Sep;100(3):125–9, 133–4, 136 (18 ref.)

Management of erectile dysfunction after radical prostatectomy. Hall MC. **Semin Urol Oncol** 1995 Aug; 13(3):215–23 (46 ref.)

Prevention and treatment of incontinence after radical prostatectomy. Milam DF, et al. **Semin Urol Oncol** 1995 Aug;13(3):224–37 (50 ref.)

Postprostatectomy incontinence. Haab F, et al. **Urol Clin North Am** 1996 Aug;23(3):447–57 (70 ref.)

Rhabdomyolysis and acute renal failure following radical perineal prostatectomy. Bruce RG, et al. **Urology** 1996 Mar; 47(3):427–30 (14 ref.)

[The TUR syndrome] Glogov S. **Khirurgiia (Sofiia)** 1995; 48(5):66–70 (32 ref.) (Eng. Abstr.) **(Bul)**

METHODS

Current results and patient selection for nerve-sparing radical retropubic prostatectomy. Steiner MS. **Semin Urol Oncol** 1995 Aug;13(3):204–14 (47 ref.)

Cryosurgery of the prostate: techniques and pitfalls. Zippe CD. **Urol Clin North Am** 1996 Feb;23(1):147–63 (11 ref.)

[Simplified vesico-urethral anastomosis after radical retropubic prostatectomy for cancer. A preliminary comparative study] Doré B, et al. **J Urol (Paris)** 1995; 101(3):113–21 (31 ref.) (Eng. Abstr.) **(Fre)**

[Radical prostatectomy] Maréchal JM. **Presse Med** 1995 Oct 28;24(32):1473–6 (11 ref.) (Eng. Abstr.) **(Fre)**

[Minimal invasive therapy of benign prostatic hyperplasia] Madersbacher S, et al. **Wien Med Wochenschr** 1996; 146(8):169–75 (31 ref.) (Eng. Abstr.) **(Ger)**

MORTALITY

[Recent improvements and results of radical prostatectomy] Usami M. **Gan To Kagaku Ryoho** 1996 Mar;23(4):407–12 (20 ref.) (Eng. Abstr.) **(Jpn)**

PROSTATECTOMY, TRANSURETHRAL see **PROSTATECTOMY**

PROSTATIC ADENOMA see **PROSTATIC HYPERPLASIA**

PROSTATIC DISEASES

COMPLICATIONS

[Tuberculous prostatic abscess in a patient with AIDS] Duarte Ojeda JM, et al. **Actas Urol Esp** 1995 Sep; 19(8):655–61 (22 ref.) (Eng. Abstr.) **(Spa)**

CONGENITAL

Prostatic cyst. An unusual but important finding in male urogenital dysfunction. Zhu JP, et al. **Scand J Urol Nephrol** 1995 Sep;29(3):345–9 (30 ref.)

DIAGNOSIS

Contrast-enhanced MR imaging of the bladder and prostate. Siegelman ES, et al. **Magn Reson Imaging Clin N Am** 1996 Feb;4(1):153–69 (61 ref.)

METABOLISM

A guide to the interpretation of serum prostate specific antigen levels. Bunting PS. **Clin Biochem** 1995 Jun; 28(3):221–41 (174 ref.)

PATHOLOGY

[Malacoplakia of the prostate and seminal vesicle. Ultrastructural study and review of the literature] Sánchez Chapado M, et al. **Arch Esp Urol** 1995 Oct;48(8):775–8 (34 ref.) (Eng. Abstr.) **(Spa)**

ULTRASONOGRAPHY

Transrectal ultrasonography of the prostate. el Din KE, et al. **Br J Urol** 1996 Jul;78(1):2–9 (64 ref.)

PROSTATIC HYPERPLASIA

Controversies about the clinical assessment of benign prostatic hyperplasia. Riehmann M, et al. **Scand J Urol Nephrol Suppl** 1995;172:81–94 (155 ref.)

[Basic study in the natural history of benign prostatic hyperplasia: biology of prostatic growth] Sugimura Y. **Nippon Hinyokika Gakkai Zasshi** 1996 Apr;87(4):721–39 (157 ref.) **(Jpn)**

DIAGNOSIS

Measurement properties of the AUA symptom score: a methodological clarification. Lawrence K. **Br J Urol** 1996 Feb;77(2):175–80 (25 ref.)

Benign prostatic hyperplasia: an approach for the internist. Zippe CD. **Cleve Clin J Med** 1996 Jul-Aug;63(4):226–36 (23 ref.)

Venous obstruction due to a distended urinary bladder. Evans JM, et al. **Mayo Clin Proc** 1995 Nov;70(11):1077–9 (17 ref.)

Adenosis (atypical adenomatous hyperplasia): histopathology and relationship to carcinoma. Epstein JI. **Pathol Res Pract** 1995 Sep;191(9):888–98 (21 ref.)

[Evaluation of symptoms in patients with benign prostatic hyperplasia] Riehmann M, et al. **Ugeskr Laeger** 1996 May 13;158(20):2853–8 (40 ref.) (Eng. Abstr.) **(Dan)**

[Clinical use of endorectal coil MR in the study of prostatic pathology with special reference to hyperplasia and carcinoma] Gualdi GF, et al. **Clin Ter** 1996 Jan-Feb; 147(1-2):51–66 (29 ref.) (Eng. Abstr.) **(Ita)**

DRUG THERAPY

Pharmacotherapy in benign prostatic hyperplasia. Tan EC. **Ann Acad Med Singapore** 1995 Jul;24(4):615–8 (35 ref.)

Current treatment of BPH. Roylance P, et al. **Biomed Pharmacother** 1995;49(7-8):332–8 (68 ref.)

Doxazosin: a new approach to hypertension and benign prostatic hyperplasia. Pool JL. **Br J Clin Pract** 1996 Apr-May;50(3):154–63 (70 ref.)

Benign prostatic hyperplasia: pathophysiology and pharmacological treatment. Madsen FA, et al. **Curr Opin Nephrol Hypertens** 1995 Sep;4(5):455–9 (23 ref.)

Finasteride and benign prostatic hyperplasia. **Drug Ther Bull** 1995 Mar;33(3):19–21 (24 ref.)

Consensus meeting on new approaches in the pharmacotherapy of benign prostatic hyperplasia (BPH). Proceedings of the meeting held on the 8th and 9th October 1994 in St. Tropez, France, under the patronage of the International Academy of Biomedical and Drug Research. **Eur Urol** 1996;29(3):374–84 (52 ref.)

Selective alpha 1-adrenoceptor antagonists in benign prostatic hyperplasia: rationale and clinical experience. Chapple CR. **Eur Urol** 1996;29(2):129–44 (67 ref.)

The effect of finasteride on prostate specific antigen: review of available data. Guess HA, et al. **J Urol** 1996 Jan; 155(1):3–9 (33 ref.)

Benign prostatic hyperplasia. Current strategy and pharmacotherapeutical potential. Dutkiewicz S. **Mater Med Pol** 1995 Jan-Mar;27(1):3–6 (41 ref.)

5alpha-reductase inhibitors/finasteride. Stoner E. **Prostate Suppl** 1996;6:82–7 (28 ref.)

[The current principles of the conservative treatment of patients with benign prostatic hypertrophy] Ianev V, et al. **Khirurgiia (Sofiia)** 1994;47(3):36–8 (19 ref.) (Eng. Abstr.) **(Bul)**

[Medical treatment of benign hypertrophy of the prostate] Bensadoun H. **Presse Med** 1995 Oct 28;24(32):1485–9 (16 ref.) (Eng. Abstr.) **(Fre)**

[The effect of 5-alpha-reductase inhibitors on benign prostatic hyperplasia] Djavan B, et al. **Wien Med Wochenschr** 1996;146(8):165–8 (21 ref.) (Eng. Abstr.) **(Ger)**

[Current drug therapy of benign prostatic hyperplasia] Schmidbauer CP, et al. **Wien Med Wochenschr** 1996; 146(8):161–4 (12 ref.) (Eng. Abstr.) **(Ger)**

ECONOMICS

Is medical therapy an expensive way for delaying surgery in BPH patients? Di Silverio F, et al. **Minerva Urol Nefrol** 1995 Dec;47(4):177–84 (20 ref.)

ETIOLOGY

Benign prostatic hyperplasia: a review of its histogenesis and natural history. Oesterling JE. **Prostate Suppl** 1996;6:67–73 (36 ref.)

PATHOLOGY

Tumor-like lesions of the prostate gland [editorial; comment] Young RH. **Am J Clin Pathol** 1995 Dec;104(6):607–10 (41 ref.) Comment on: Am J Clin Pathol 1995 Dec;104(6):620–6.

Prospective origins of prostate carcinoma. Prostatic intraepithelial neoplasia and atypical adenomatous hyperplasia. Bostwick DG. **Cancer** 1996 Jul 15;78(2):330–6 (67 ref.)

Morphogenetic aspects of normal and abnormal prostatic growth. Bonkhoff H, et al. **Pathol Res Pract** 1995 Sep; 191(9):833–5 (14 ref.)

Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model. Bonkhoff H, et al. **Prostate** 1996 Feb;28(2):98–106 (52 ref.)

PHYSIOPATHOLOGY

Benign prostatic hyperplasia: pathophysiology and pharmacological treatment. Madsen FA, et al. **Curr Opin Nephrol Hypertens** 1995 Sep;4(5):455–9 (23 ref.)

The insulin-like growth factor system in the prostate. Peehl DM, et al. **World J Urol** 1995;13(5):306–11 (38 ref.)

[Pathophysiology of benign prostatic hyperplasia] Frick J. **Wien Med Wochenschr** 1996;146(8):158–60 (29 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Minimally invasive surgery for benign prostatic hyperplasia—a review. Kour NW. **Ann Acad Med Singapore** 1995 Jul;24(4):619–26 (77 ref.)

Transurethral laser therapy and urinary tract infections. Miller J, et al. **Ann Urol (Paris)** 1996;30(3):131–8 (38 ref.)

Case report: uneventful treatment of a giant prostate. La Marca F, et al. **Arch Esp Urol** 1995 Dec;48(10):1060–1 (7 ref.)

[Surgical treatment of benign hypertrophy of the prostate] Lanson Y. **Presse Med** 1995 Oct 28;24(32):1481–4 (6 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Transurethral microwave thermotherapy: an evolving technology in the treatment of benign prostatic enlargement [see comments] de Wildt MJ, et al. **Br J Urol** 1995 Nov;76(5):531–8 (47 ref.) Comment in: Br J Urol 1996 May;77(5):764.

Benign prostatic hyperplasia: an approach for the internist. Zippe CD. **Cleve Clin J Med** 1996 Jul-Aug;63(4):226–36 (23 ref.)

Is medical therapy an expensive way for delaying surgery in BPH patients? Di Silverio F, et al. **Minerva Urol Nefrol** 1995 Dec;47(4):177–84 (20 ref.)

Prostatism: benign prostatic hyperplasia. Hollander JB, et al. **Urol Clin North Am** 1996 Feb;23(1):75–86 (96 ref.)

Phytotherapy in treatment of benign prostatic hyperplasia: a critical review. Lowe FC, et al. **Urology** 1996 Jul; 48(1):12–20 (55 ref.)

[Non-surgical instrumental treatment of benign hypertrophy of the prostate] Anidjar M, et al. **Presse Med** 1995 Oct 28;24(32):1477–80 (9 ref.) (Eng. Abstr.) **(Fre)**

[Minimal invasive therapy of benign prostatic hyperplasia] Madersbacher S, et al. **Wien Med Wochenschr** 1996; 146(8):169–75 (31 ref.) (Eng. Abstr.) **(Ger)**

[Transurethral radiofrequency thermotherapy using the Thermex unit in benign prostatic hyperplasia] Dolgopiatov DG, et al. **Urol Nefrol (Mosk)** 1995 Nov-Dec;(6):48–50 (38 ref.) **(Rus)**

PROSTATIC HYPERTROPHY see **PROSTATIC HYPERPLASIA**

PROSTATIC HYPERTROPHY, BENIGN see **PROSTATIC HYPERPLASIA**

PROSTATIC INTRAEPITHELIAL NEOPLASIA

PATHOLOGY

Prospective origins of prostate carcinoma. Prostatic intraepithelial neoplasia and atypical adenomatous hyperplasia. Bostwick DG. **Cancer** 1996 Jul 15;78(2):330–6 (67 ref.)

Prostatic intraepithelial neoplasia and other changes during promotion and progression. Pretlow TG, et al. **Pathol Res Pract** 1995 Sep;191(9):842–9 (49 ref.)

Molecular biology of prostatic intraepithelial neoplasia. Bostwick DG, et al. **Prostate** 1996 Aug;29(2):117–34 (157 ref.)

PROSTATIC NEOPLASMS

Prostate cancer: emerging concepts. Part I. Garnick MB, et al. **Ann Intern Med** 1996 Jul 15;125(2):118–25 (50 ref.)

ABC of urology. Urological malignancy—1: Prostate cancer. Dawson C, et al. **BMJ** 1996 Apr 20;312(7037):1032–4 (0 ref.)

Prostate cancer: anatomical and surgical considerations. Gil-Vernet JM. **Br J Urol** 1996 Aug;78(2):161–8 (28 ref.)

An update on prostate cancer. Klein EA. **Cleve Clin J Med** 1995 Sep–Oct;62(5):325–38 (81 ref.)

Quality of life in prostate cancer: what are the issues and how are they measured? Fossâ SD. **Eur Urol** 1996;29 Suppl 2:121–3 (15 ref.)

Small cell carcinoma of the bladder and prostate. Abbas F, et al. **Urology** 1995 Nov;46(5):617–30 (114 ref.)

Performance measurement in prostate cancer care: beyond report cards. Ullman M, et al. **Urology** 1996 Mar; 47(3):356–65 (80 ref.)

[Natural history of prostatic adenocarcinoma. Recent advances in prognostic parameters and biological behavior] Mirone V, et al. **Minerva Urol Nefrol** 1995 Dec;47(4):171–5 (11 ref.) (Eng. Abstr.) **(Ita)**

[Primary mucinous adenocarcinoma of the prostate] Gomiz Léon JJ, et al. **Actas Urol Esp** 1995 Jun;19(6):473–5 (16 ref.) (Eng. Abstr.) **(Spa)**

BLOOD

Prostate-specific antigen testing for prostate cancer. Practical interpretation of values. Randrup E, et al. **Postgrad Med** 1996 Feb;99(2):227–8, 231–4 (14 ref.)

BLOOD SUPPLY

Quantitative microvessel density. A staging and prognostic marker for human prostatic carcinoma. Brawer MK. **Cancer** 1996 Jul 15;78(2):345–9 (25 ref.)

CLASSIFICATION

The TNM classification of prostate cancer: a discussion of the 1992 classification. The British Association of Urological Surgeons TNM Subcommittee. **Br J Urol** 1995 Sep;76(3):279–85 (22 ref.)

COMPLICATIONS

Adenocarcinoma of the prostate and Eaton–Lambert syndrome. A previously unreported association. Agarawal SK, et al. **Scand J Urol Nephrol** 1995 Sep;29(3):351–3 (8 ref.)

DIAGNOSIS

Imaging of prostate cancer. Choyke PL. **Abdom Imaging** 1995 Nov–Dec;20(6):505–15 (40 ref.)

Changes in early detection of prostate cancer in the United States. Mettlin C. **Ann N Y Acad Sci** 1995 Sep 30;768:68–72 (14 ref.)

Tumour serum markers: clinical and economical aspects. Kardamakis D. **Anticancer Res** 1996 Jul–Aug; 16(4B):2285–8 (17 ref.)

College of American Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors. Report of the Prostate Cancer Working Group. Grignon DJ, et al. **Arch Pathol Lab Med** 1995 Dec;119(12):1122–6 (79 ref.)

Update on urology—prostate cancer. Screening for prostate cancer: an European view. de Silva FC. **Eur J Surg Oncol** 1996 Apr;22(2):189–91, 196 (9 ref.)

Advances in the assessment of clinically localized prostate cancer. Ravery V, et al. **Eur Urol** 1996;29(3):257–65 (34 ref.)

The prostate specific antigen. Its use as a tumor marker for prostate cancer. Kantoff PW, et al. **Hematol Oncol Clin North Am** 1994 Jun;8(3):555–72 (66 ref.)

Cytogenetic analysis of prostate carcinoma by fluorescence in situ hybridization. Takahashi S, et al. **Int J Urol** 1995 Sep;2(4):215–23 (49 ref.)

Contrast-enhanced MR imaging of the bladder and prostate. Siegelman ES, et al. **Magn Reson Imaging Clin N Am** 1996 Feb;4(1):153–69 (61 ref.)

Screening for prostate cancer with prostate-specific antigen. An examination of the evidence [see comments] Woolf SH. **N Engl J Med** 1995 Nov 23;333(21):1401–5 (62 ref.) Comment in: N Engl J Med 1996 Mar 7;344(10):666–7; discussion 667–8. Comment in: N Engl J Med 1996 Mar 7;344(10):667; discussion 667–8.

Adenosis (atypical adenomatous hyperplasia): histopathology and relationship to carcinoma. Epstein JI. **Pathol Res Pract** 1995 Sep;191(9):888–98 (21 ref.)

Screening for prostate cancer. Is it a service or a disservice? Luttge S, et al. **Postgrad Med** 1996 Sep;100(3):90–2, 95–6, 101–2 (5 ref.)

Prostate-specific antigen testing for prostate cancer. Practical interpretation of values. Randrup E, et al. **Postgrad Med** 1996 Feb;99(2):227–8, 231–4 (14 ref.)

Role of laparoscopy in the diagnosis and treatment of prostate cancer. Moore RG, et al. **Semin Surg Oncol** 1996 Mar–Apr; 12(2):139–44 (51 ref.)

Preoperative estimate of extent of disease in T1c: how well can we predict? Austenfeld MS. **Semin Urol Oncol** 1995 Aug;13(3):176–80 (42 ref.)

Detection of latent prostate cancer from routine screening: comparison with breast cancer screening. Benoit RM, et al. **Urology** 1995 Oct;46(4):533–6; discussion 536–7 (43 ref.)

Neurofibromatosis with involvement of the prostate gland. Chung AK, et al. **Urology** 1996 Mar;47(3):448–51 (34 ref.)

[Early diagnosis and screening of cancer of the prostate] Fendler JP, et al. **Presse Med** 1995 Oct 28;24(32):1461–3 (10 ref.) (Eng. Abstr.) **(Fre)**

[Prostate specific antigen. Clinical applications of ultrasensitive assay] Haab F, et al. **Presse Med** 1995 Nov 25;24(36):1697–702 (43 ref.) (Eng. Abstr.) **(Fre)**

[Screening for prostatic cancer] Laufer M, et al. **Harefuah** 1995 Jul;129(1–2):39–43 (28 ref.) **(Heb)**

[Clinical use of endorectal coil MR in the study of prostatic pathology with special reference to hyperplasia and carcinoma] Gualdi GF, et al. **Clin Ter** 1996 Jan–Feb; 147(1–2):51–66 (29 ref.) (Eng. Abstr.) **(Ita)**

[Prognostic factors of prostatic cancer] Okada Y, et al. **Gan To Kagaku Ryoho** 1995 Nov;22(13):1999–2005 (19 ref.) (Eng. Abstr.) **(Jpn)**

[A case of genitourinary double cancers detected by health screening] Ito T, et al. **Hinyokika Kiyo** 1996 Jun; 42(6):461–4 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Approaches in the prognostication of prostatic neoplasms] Teploukhova IM, et al. **Vopr Onkol** 1996;42(2):12–6 (42 ref.) **(Rus)**

[Clinical usefulness of the new criteria based on the serum quantification of prostate-specific antigen in the early diagnosis of prostatic cancer (editorial)] Morote Robles J. **Actas Urol Esp** 1996 Jan;20(1):1–12 (71 ref.) **(Spa)**

DRUG THERAPY

Gn-RH agonists in the treatment of prostatic carcinoma. Vacher P. **Biomed Pharmacother** 1995;49(7–8):325–31 (60 ref.)

Compliance with hormonal treatment for prostate cancer. Kaisary AV. **Br J Hosp Med** 1996 Mar 20–Apr 2; 55(6):359–66 (59 ref.)

Anti-androgens in the treatment of prostate cancer. Newling DW. **Br J Urol** 1996 Jun;77(6):776–84 (51 ref.)

Estramustine revisited. Kreis W. **Cancer Treat Res** 1995; 78:163–84 (90 ref.)

Treatment approaches for metastatic cancer of the prostate based on recent molecular evidence. Middleman MN, et al. **Cancer Treat Rev** 1996 Mar;22(2):105–18 (61 ref.)

Estramustine phosphate sodium. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer. Perry CM, et al. **Drugs Aging** 1995 Jul;7(1):49–74 (124 ref.)

Update on urology—prostate cancer. 3—Systemic and palliative treatment of prostate cancer. Ekman P. **Eur J Surg Oncol** 1995 Oct;21(5):555–7; quiz 557, 567 (12 ref.)

Clinical progress with a new antiandrogen, Casodex (bicalutamide). Blackledge GR. **Eur Urol** 1996;29 Suppl 2:96–104 (15 ref.)

Combined androgen blockade. Crawford ED. **Eur Urol** 1996; 29 Suppl 2:54–61 (28 ref.)

Combined androgen blockade is the treatment of choice for patients with advanced prostate cancer: the argument for. Debruyne FM. **Eur Urol** 1996;29 Suppl 2:34–6 (8 ref.)

Combined androgen blockade is the treatment of choice for patients with advanced prostate cancer: the argument against. Fitzpatrick JM. **Eur Urol** 1996;29 Suppl 2:37–9 (7 ref.)

The development of Casodex (bicalutamide): preclinical studies. Furr BJ. **Eur Urol** 1996;29 Suppl 2:83–95 (53 ref.)

Supportive care is not the only option in prostate cancer patients resistant to hormone therapy: the argument against. Jewett MA, et al. **Eur Urol** 1996;29 Suppl 2:45–8 (11 ref.)

Androgens, antiandrogens and androgen receptor abnormalities. Kuil CW, et al. **Eur Urol** 1996;29 Suppl 2:78–82 (30 ref.)

The management of hormone refractory prostate cancer. Newling DW. **Eur Urol** 1996;29 Suppl 2:69–74 (24 ref.)

Supportive care is not the only option in prostate cancer patients resistant to hormone therapy: the argument for. Scher HI. **Eur Urol** 1996;29 Suppl 2:40–4 (36 ref.)

The role of induction androgen deprivation prior to radical prostatectomy. Soloway MS, et al. **Eur Urol** 1996;29 Suppl 2:114–8 (27 ref.)

Patient compliance with crucial drug regimens: implications for prostate cancer. Urquhart J. **Eur Urol** 1996;29 Suppl 2:124–31 (62 ref.)

P450-dependent enzymes as targets for prostate cancer therapy. De Coster R, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1–6 Spec No):133–43 (101 ref.)

Estrogens in the treatment of prostate cancer. Cox RL, et al. **J Urol** 1995 Dec;154(6):1991–8 (96 ref.)

The effect of finasteride on prostate specific antigen: review of available data. Guess HA, et al. **J Urol** 1996 Jan; 155(1):3–9 (33 ref.)

Commentary on maximal androgen blockade in prostate cancer: a theory to put into practice? Denis L. **Prostate** 1995 Nov;27(5):233–40 (43 ref.)

Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Denmeade SR, et al. **Prostate** 1996 Apr;28(4):251–65 (94 ref.)

Current status of neoadjuvant therapy in localized prostate cancer. Witjes WP, et al. **Prostate** 1995 Dec;27(6):297–303 (69 ref.)

Control of tumor progression by maintenance of apoptosis. Bruchovsky N, et al. **Prostate Suppl** 1996;6:13–21 (27 ref.)

Neoadjuvant hormonal treatment before radical prostatectomy. Watson RB, et al. **Semin Urol Oncol** 1996 May;14(2 Suppl 2):48–55; discussion 55–6 (59 ref.)

Worldwide activity and safety of bicalutamide: a summary review. Kolvenbag GJ, et al. **Urology** 1996 Jan;47(1A Suppl):70–9; discussion 80–4 (29 ref.)

Defining the role of antiandrogens in the treatment of prostate cancer. McLeod DG, et al. **Urology** 1996 Jan; 47(1A Suppl):85–9; discussion 90–6 (40 ref.)

Hormone and antihormone withdrawal: implications for the management of androgen-independent prostate cancer. Scher HI, et al. **Urology** 1996 Jan;47(1A Suppl):61–9 (50 ref.)

[Hot flushes in men after surgical or pharmacologic castration] Aubert J, et al. **Prog Urol** 1995 Sep;5(4):507–9 (13 ref.) (Eng. Abstr.) **(Fre)**

[Hot flashes and hormonal treatment of prostate cancer] Lanfrey P, et al. **Prog Urol** 1996 Feb;6(1):17–22 (31 ref.) (Eng. Abstr.) **(Fre)**

[What is the role of neoadjuvant therapy in prostate cancer?] Witjes WP, et al. **Minerva Urol Nefrol** 1995 Dec; 47(4):209–14 (53 ref.) **(Ita)**

[An overview of clinical trials in endocrine therapy for cancer] Hinotsu S, et al. **Gan To Kagaku Ryoho** 1996 May; 23(6):689–94 (9 ref.) (Eng. Abstr.) **(Jpn)**

[Treatment for hormone-refractory or relapsing prostatic cancer] Hirao Y, et al. **Gan To Kagaku Ryoho** 1996 Mar; 23(4):418–26 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Progress of endocrine therapy for prostate cancer and results] Kanetake H. **Gan To Kagaku Ryoho** 1996 Mar; 23(4):413–7 (15 ref.) (Eng. Abstr.) **(Jpn)**

[New development of endocrine therapy in prostate cancer] Naito S. **Gan To Kagaku Ryoho** 1996 May;23(6):684–8 (18 ref.) (Eng. Abstr.) **(Jpn)**

EPIDEMIOLOGY

Familial prostate cancer in Sweden. A nationwide register cohort study. Grönberg H, et al. **Cancer** 1996 Jan 1; 77(1):138–43 (20 ref.)

The practice of causal inference in cancer epidemiology. Weed DL, et al. **Cancer Epidemiol Biomarkers Prev** 1996 Apr;5(4):303–11 (175 ref.)

Diet, nutrition, and avoidable cancer. Willett WC. **Environ Health Perspect** 1995 Nov;103 Suppl 8:165–70 (58 ref.)

Incidence of prostate cancer will double by the year 2030: the argument for. Boyle P, et al. **Eur Urol** 1996;29 Suppl 2:3–9 (31 ref.)

Incidence of prostate cancer will double by the year 2030: the argument against. George NJ. **Eur Urol** 1996;29 Suppl 2:10–2 (7 ref.)

Prospects for prostatic cancer incidence and treatment by the year 2000. Forti G, et al. **Int J Androl** 1996 Feb; 19(1):1–10 (81 ref.)

ETIOLOGY

Normal development and carcinogenesis of the prostate. A unifying hypothesis. Hayward SW, et al. **Ann N Y Acad Sci** 1996 Apr 30;784:50–62 (41 ref.)

Farmers at risk for prostate cancer. Van Der Gulden JW, et al. Br J Urol 1996 Jan;77(1):6–14 (98 ref.)

Hormonal factors in carcinogenesis of the prostate and testis in humans and in animal models. Bosland MC. **Prog Clin Biol Res** 1996;394:309–52 (225 ref.)

Cellular biology of prostatic growth factors. Peehl DM. **Prostate Suppl** 1996;6:74–8 (55 ref.)

Androgen regulation of gene expression. Perry JE, et al. **Prostate Suppl** 1996;6:79–81 (22 ref.)

[Risk factors in carcinoma of the prostate] Kohout J, et al. **Cas Lek Cesk** 1995 Nov 1;134(21):679–80 (31 ref.) (Eng. Abstr.) **(Cze)**

GENETICS

Genetic basis and clonal evolution of human prostate cancer. Kallioniemi OP, et al. **Adv Cancer Res** 1996;68:225–55 (118 ref.)

Hereditary aspects of prostate cancer [see comments] McLellan DL, et al. **Can Med Assoc J** 1995 Oct 1; 153(7):895–900 (26 ref.) Comment in: Can Med Assoc J 1995 Oct 1;153(7):935–8. Comment in: Can Med Assoc J 1996 Feb 1;154(3):300–1.

Familial prostate cancer in Sweden. A nationwide register cohort study. Grönberg H, et al. **Cancer** 1996 Jan 1;

77(1):138–43 (20 ref.)
Genetic characteristics of prostate cancer. Huncharek M, et al. **Cancer Epidemiol Biomarkers Prev** 1995 Sep;4(6):681–7 (65 ref.)
Molecular genetics of prostate cancer. Isaacs WB. **Cancer Surv** 1995;25:357–79 (133 ref.)
Genetic alterations in prostate cancer. Isaacs WB, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:653–9 (67 ref.)
Provocative aspects of androgen genetics. Brown TR. **Prostate Suppl** 1996;6:9–12 (14 ref.)
DNA methylation, molecular genetic, and linkage studies in prostate cancer. Jarrard DF, et al. **Prostate Suppl** 1996; 6:36–44 (88 ref.)
[Hereditary prostate carcinoma. National Work Group Hereditary Urological tumors. Foundation Tracing Hereditary Tumors] Kiemeney LA, et al. **Ned Tijdschr Geneeskd** 1996 May 18;140(20):1068–72 (29 ref.) **(Dut)**

IMMUNOLOGY

Early detection of prostate cancer. Role of prostate-specific antigen. Prabhakaran VM. **Can Fam Physician** 1996 Apr; 42:709–12 (20 ref.)

METABOLISM

Cancer (prostate-specific antigen). Castellani WJ. **Anal Chem** 1995 Jun 15;67(12):399R–403R (67 ref.)
The alpha 6 beta 1 and alpha 6 beta 4 integrins in human prostate cancer progression. Cress AE, et al. **Cancer Metastasis Rev** 1995 Sep;14(3):219–28 (67 ref.)

MORTALITY

[Prognostic factors in prostatic carcinoma treated with radical radiotherapy: stages A, B, and C] Rodríguez Villalba S, et al. **Actas Urol Esp** 1996 Apr;20(4):336–45 (46 ref.) (Eng. Abstr.) **(Spa)**

PATHOLOGY

Carcinoma of the prostate: treatment of bone metastasis. Scalliet P. **Acta Urol Belg** 1996 May;64(2):87–90 (13 ref.)
Genetic basis and clonal evolution of human prostate cancer. Kallioniemi OP, et al. **Adv Cancer Res** 1996;68:225–55 (118 ref.)
Tumor-like lesions of the prostate gland [editorial; comment] Young RH. **Am J Clin Pathol** 1995 Dec;104(6):607–10 (41 ref.) Comment on: Am J Clin Pathol 1995 Dec;104(6):620–6.
Apoptosis in prostate cancer. Molecular basis to study hormone refractory mechanisms. Colombel M, et al. **Ann N Y Acad Sci** 1996 Apr 30;784:63–9 (20 ref.)
Paraganglioma of the prostatic urethra. A report of three cases and a review of the literature. Boyle M, et al. **Br J Urol** 1996 Mar;77(3):445–8 (16 ref.)
Prospective origins of prostate carcinoma. Prostatic intraepithelial neoplasia and atypical adenomatous hyperplasia. Bostwick DG. **Cancer** 1996 Jul 15;78(2):330–6 (67 ref.)
Neuroendocrine differentiation in prostatic malignancy. di Sant'Agnese PA, et al. **Cancer** 1996 Jul 15;78(2):357–61 (32 ref.)
The diagnosis and reporting of adenocarcinoma of the prostate in core needle biopsy specimens. Epstein JI. **Cancer** 1996 Jul 15;78(2):350–6 (39 ref.)
Pathologic staging of prostate carcinoma. What are the issues? Grignon DJ, et al. **Cancer** 1996 Jul 15;78(2):337–40 (29 ref.)
Current prognostic factors for prostate carcinoma. Montie JE. **Cancer** 1996 Jul 15;78(2):341–4 (24 ref.)
The alpha 6 beta 1 and alpha 6 beta 4 integrins in human prostate cancer progression. Cress AE, et al. **Cancer Metastasis Rev** 1995 Sep;14(3):219–28 (67 ref.)
Primary non-Hodgkin's lymphoma of the prostate gland: case report and review of the literature. Bell CR, et al. **Clin Oncol (R Coll Radiol)** 1995;7(6):409–10 (11 ref.)
5—Surgical pathology of prostate cancer. Algaba F. **Eur J Surg Oncol** 1996 Feb;22(1):102–7 (18 ref.)
Primary staging of prostate cancer. Jager GJ, et al. **Eur Radiol** 1996;6(2):134–9 (47 ref.)
Pre-neoplastic lesions of the prostate. Parkinson MC. **Histopathology** 1995 Oct;27(4):301–11 (103 ref.)
Diffuse spinal leptomeningeal metastases from prostatic cancer. A case report. Matsui H, et al. **Int Orthop** 1995; 19(5):315–8 (18 ref.)
Role of growth factors, steroid and peptide hormones in the regulation of human prostatic tumor growth. Motta M, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1–6 Spec No):107–11 (36 ref.)
Prospective characterization of pathological features of prostatic carcinomas detected via serum prostate specific antigen based screening [see comments] Humphrey PA, et al. **J Urol** 1996 Mar;155(3):816–20 (34 ref.) Comment in: J Urol 1996 Mar;155(3):827.
Pathologic evaluation of prostatic carcinoma: critical information for the oncologist. Epstein JI. **Oncology (Huntingt)** 1996 Apr;10(4):527–34; discussion 539, 541–3 (50 ref.)
Morphogenetic aspects of normal and abnormal prostatic growth. Bonkhoff H, et al. **Pathol Res Pract** 1995 Sep; 191(9):833–5 (14 ref.)
Prostatic intraepithelial neoplasia and other changes during promotion and progression. Pretlow TG, et al. **Pathol Res Pract** 1995 Sep;191(9):842–9 (49 ref.)
Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model. Bonkhoff H, et al. **Prostate** 1996 Feb;28(2):98–106 (52 ref.)
Molecular biology of prostatic intraepithelial neoplasia. Bostwick DG, et al. **Prostate** 1996 Aug;29(2):117–34 (157 ref.)
Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Denmeade SR, et al. **Prostate** 1996 Apr;28(4):251–65 (94 ref.)
Neuroendocrine differentiation and hormone-refractory prostate cancer. Abrahamsson PA. **Prostate Suppl** 1996; 6:3–8 (26 ref.)
Control of tumor progression by maintenance of apoptosis. Bruchovsky N, et al. **Prostate Suppl** 1996;6:13–21 (27 ref.)
Laparoscopic pelvic lymphadenectomy: transperitoneal approach. Gill IS. **Semin Surg Oncol** 1996 Mar-Apr; 12(2):126–33 (39 ref.)
Are T1c tumors different from incidental tumors found at autopsy? The risk and reality of overdetection. Belville WD. **Semin Urol Oncol** 1995 Aug;13(3):181–6 (22 ref.)
T1c cancer: what is it? Flanigan RC, et al. **Semin Urol Oncol** 1995 Aug;13(3):173–5 (18 ref.)
Risk factors for progression in patients with prostate cancer treated with radical prostatectomy. Lerner SE, et al. **Semin Urol Oncol** 1996 May;14(2 Suppl 2):12–20; discussion 21 (36 ref.)
Recent advances in prostate cancer metastasis. Waltregny D, et al. **Tumori** 1996 May-Jun;82(3):193–204 (120 ref.)
Undergrading of prostate cancer biopsies: a paradox inherent in all biologic bivariate distributions. Gleason DF. **Urology** 1996 Mar;47(3):289–91 (6 ref.)
Mucinous adenocarcinoma of the prostate: a report of a case of long-term survival. Olivas TP, et al. **Urology** 1996 Feb; 47(2):256–8 (7 ref.)
Recommendations for the reporting of resected prostate carcinomas. Fechner RE. **Virchows Arch** 1996 Jul; 428(4–5):203–6 (21 ref.)
[Imaging of osteosclerotic metastases] Feydy A, et al. **J Radiol** 1995 Sep;76(9):561–72 (61 ref.) (Eng. Abstr.) **(Fre)**
[Results of endorectal MRI in local staging of prostatic cancer. Correlation with specimens from prostatectomy. Apropos of 47 cases] Chefchaouni MC, et al. **J Urol (Paris)** 1996;102(2):51–5 (18 ref.) (Eng. Abstr.) **(Fre)**
[Anatomopathologic reassessment of prostatic tumors exclusively affecting the organ with biologic progression and survival study of prostatectomized patients, in terms of the histologic characteristics of the tumor] Ravery V, et al. **Prog Urol** 1995 Dec;5(6):968–73 (17 ref.) (Eng. Abstr.) **(Fre)**
[Carcinoma of the prostate, stage C] Zattoni F, et al. **Minerva Urol Nefrol** 1995 Dec;47(4):197–201 (32 ref.) **(Ita)**
[Primary squamous cell carcinoma of the prostate: a case report] Okamoto T, et al. **Hinyokika Kiyo** 1996 Jan; 42(1):67–70 (12 ref.) (Eng. Abstr.) **(Jpn)**
[A case report of prostate cancer with Paneth cell-like change] Soga N, et al. **Hinyokika Kiyo** 1995 Nov; 41(11):891–4 (9 ref.) (Eng. Abstr.) **(Jpn)**
[Complications of ultrasound-guided transperineal puncture biopsy of the prostate] Castiñeiras J, et al. **Actas Urol Esp** 1995 Jul-Aug;19(7):544–8 (12 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

Human prostate cancer: a direct role for oestrogens. Castagnetta LA, et al. **Ciba Found Symp** 1995;191:269–86; discussion 286–9 (55 ref.)
The insulin-like growth factor system in the prostate. Peehl DM, et al. **World J Urol** 1995;13(5):306–11 (38 ref.)
Epidermal growth factor-related peptides and the epidermal growth factor receptor in normal and malignant prostate. Sherwood ER, et al. **World J Urol** 1995;13(5):290–6 (65 ref.)
[Fibrinolysis process in prostatic carcinoma] Ziętek Z, et al. **Pol Tyg Lek** 1996 Feb;51(6–9):107–8 (26 ref.) **(Pol)**

PREVENTION & CONTROL

The potential application of finasteride for chemoprevention of prostate cancer. Gormley GJ, et al. **Ann N Y Acad Sci** 1995 Sep 30;768:163–9 (22 ref.)
Changes in early detection of prostate cancer in the United States. Mettlin C. **Ann N Y Acad Sci** 1995 Sep 30;768:68–72 (14 ref.)
The preventive role of diet in prostatic disease. Morton MS, et al. **Br J Urol** 1996 Apr;77(4):481–93 (149 ref.)
Ethical issues in urology: the patient's perspective. Wilkie P. **Br J Urol** 1995 Nov;76 Suppl 2:5–7 (6 ref.)
Update on urology—prostate cancer. Screening for prostate cancer: an European view. de Silva FC. **Eur J Surg Oncol** 1996 Apr;22(2):189–91, 196 (9 ref.)
Screening and early detection of prostate cancer will decrease morbidity and mortality from prostate cancer: the argument for. Brawer MK. **Eur Urol** 1996;29 Suppl 2:19–23 (43 ref.)
Healthcare resources should be targeted to chemoprevention in prostate cancer: the argument for. Denis LJ. **Eur Urol** 1996;29 Suppl 2:13–6 (13 ref.)
Screening and early detection of prostate cancer will decrease morbidity and mortality from prostate cancer: the argument against. Hall RR. **Eur Urol** 1996;29 Suppl 2:24–6 (5 ref.)
Epidemiology, prevention and screening for prostate cancer. Pavone-Macaluso M. **Eur Urol** 1996;29 Suppl 2:49–53 (21 ref.)
Healthcare resources should be targeted to chemoprevention: the argument against. Trachtenberg J. **Eur Urol** 1996;29 Suppl 2:17–8 (1 ref.)
Prostate cancer screening. Hostetler RM, et al. **Med Clin North Am** 1996 Jan;80(1):83–98 (70 ref.)
An overview cost-utility analysis of prostate cancer screening. Thompson IM, et al. **Oncology (Huntingt)** 1995 Nov;9(11 Suppl):141–5 (24 ref.)
Are T1c tumors different from incidental tumors found at autopsy? The risk and reality of overdetection. Belville WD. **Semin Urol Oncol** 1995 Aug;13(3):181–6 (22 ref.)
Screening for prostate cancer: opportunities for prevention. Thompson IM, et al. **Semin Urol Oncol** 1996 May;14(2 Suppl 2):4–10; discussion 10–1 (28 ref.)
Impact of prostate-specific antigen screening on the natural history of prostate cancer. Rosen MA. **Urology** 1995 Dec; 46(6):757–68 (95 ref.)

RADIOTHERAPY

Radiotherapy for prostate cancer: the changing scene [editorial] Dearnaley DP. **Clin Oncol (R Coll Radiol)** 1995; 7(3):147–50 (35 ref.)
Role of interstitial radiotherapy in the management of clinically organ-confined prostate cancer: the jury is still out [see comments] D'Amico AV, et al. **J Clin Oncol** 1996 Jan;14(1):304–15 (35 ref.) Comment in: J Clin Oncol 1996 Jun;14(6):1965. Comment in: J Clin Oncol 1996 Jun;14(6):1965–7.
125I seeds implantation plus pelvic lymphadenectomy in the management of localized prostate cancer. D'Addessi A, et al. **Minerva Urol Nefrol** 1995 Sep;47(3):105–11 (33 ref.)
Strontium-89 for treatment of painful bone metastasis from prostate cancer. Altman GB, et al. **Oncol Nurs Forum** 1996 Apr;23(3):523–7 (30 ref.)
Radiotherapy of T1c prostate cancer. Ben-Josef E, et al. **Semin Urol Oncol** 1995 Aug;13(3):191–6 (52 ref.)
[Leiomyosarcoma of the prostate: a case report of remission for 9 years by radiotherapy] Sakano Y, et al. **Hinyokika Kiyo** 1995 Aug;41(8):629–32 (15 ref.) (Eng. Abstr.) **(Jpn)**
[Brachytherapy in the treatment of prostatic carcinoma] Casas F, et al. **Actas Urol Esp** 1995 Sep;19(8):662–9 (34 ref.) (Eng. Abstr.) **(Spa)**
[Prognostic factors in prostatic carcinoma treated with radical radiotherapy: stages A, B, and C] Rodríguez Villalba S, et al. **Actas Urol Esp** 1996 Apr;20(4):336–45 (46 ref.) (Eng. Abstr.) **(Spa)**

SURGERY

Total androgenic blockade: a review. Bianchi G, et al. **Acta Urol Belg** 1995 Sep;63(3):11–9 (54 ref.)
Compliance with hormonal treatment for prostate cancer. Kaisary AV. **Br J Hosp Med** 1996 Mar 20-Apr 2; 55(6):359–66 (59 ref.)
5—Surgical pathology of prostate cancer. Algaba F. **Eur J Surg Oncol** 1996 Feb;22(1):102–7 (18 ref.)
The risks outweigh the benefits of radical prostatectomy in localised prostate cancer: the argument for. Abrahamsson PA. **Eur Urol** 1996;29 Suppl 2:27–30 (12 ref.)
The risks outweigh the benefits of radical prostatectomy in localised prostate cancer: the argument against. Huland H. **Eur Urol** 1996;29 Suppl 2:31–3 (16 ref.)
The role of induction androgen deprivation prior to radical prostatectomy. Soloway MS, et al. **Eur Urol** 1996;29 Suppl 2:114–8 (27 ref.)
Is there always a role for radical prostatectomy in the treatment of localized prostate cancer? Di Silverio F, et al. **Minerva Urol Nefrol** 1995 Sep;47(3):117–24 (26 ref.)
Role of laparoscopy in the diagnosis and treatment of prostate cancer. Moore RG, et al. **Semin Surg Oncol** 1996 Mar-Apr; 12(2):139–44 (51 ref.)
Stage T1c prostate cancer: perspectives on clinical management. Smith JA Jr. **Semin Urol Oncol** 1995 Aug; 13(3):238–44 (27 ref.)
Current results and patient selection for nerve-sparing radical retropubic prostatectomy. Steiner MS. **Semin Urol Oncol** 1995 Aug;13(3):204–14 (47 ref.)
Neoadjuvant hormonal treatment before radical prostatectomy. Watson RB, et al. **Semin Urol Oncol** 1996 May;14(2 Suppl 2):48–55; discussion 55–6 (59 ref.)
Management of prostate and bladder cancer in the elderly. Dreicer R, et al. **Urol Clin North Am** 1996 Feb;23(1):87–97 (85 ref.)
Recommendations for the reporting of resected prostate carcinomas. Fechner RE. **Virchows Arch** 1996 Jul; 428(4–5):203–6 (21 ref.)
[Simplified vesico-urethral anastomosis after radical retropubic prostatectomy for cancer. A preliminary comparative study] Doré B, et al. **J Urol (Paris)** 1995; 101(3):113–21 (31 ref.) (Eng. Abstr.) **(Fre)**
[Radical prostatectomy] Maréchal JM. **Presse Med** 1995 Oct 28;24(32):1473–6 (11 ref.) (Eng. Abstr.) **(Fre)**
[Hot flushes in men after surgical or pharmacologic castration] Aubert J, et al. **Prog Urol** 1995 Sep;5(4):507–9 (13 ref.) (Eng. Abstr.) **(Fre)**
[Anatomopathologic reassessment of prostatic tumors

exclusively affecting the organ with biologic progression and survival study of prostatectomized patients, in terms of the histologic characteristics of the tumor] Ravery V, et al. **Prog Urol** 1995 Dec;5(6):968–73 (17 ref.) (Eng. Abstr.) **(Fre)**

[Recent improvements and results of radical prostatectomy] Usami M. **Gan To Kagaku Ryoho** 1996 Mar;23(4):407–12 (20 ref.) (Eng. Abstr.) **(Jpn)**

THERAPY

Prostate cancer—treatment of disseminated disease. Abi-Aad AS, et al. **Acta Urol Belg** 1996 May;64(2):67–76 (78 ref.)

Neoadjuvant hormonal deprivation in locally advanced prostate cancer: does it make sense? Schulman CC, et al. **Acta Urol Belg** 1996 May;64(2):57–61 (32 ref.)

Prostate cancer: current and evolving strategies. Cersosimo RJ, et al. **Am J Health Syst Pharm** 1996 Feb 15; 53(4):381–96; quiz 446–8 (153 ref.)

Prostate cancer: emerging concepts. Part II. Garnick MB, et al. **Ann Intern Med** 1996 Aug 1;125(3):205–12 (60 ref.)

Management of localized prostate cancer: an epidemiological perspective. Harwood RH. **Clin Oncol (R Coll Radiol)** 1995; 7(3):151–9 (43 ref.)

The treatment of hormone refractory prostate cancer. Panvichian R, et al. **Compr Ther** 1996 Feb;22(2):81–7 (27 ref.)

Prostate cancer—what should be studied? [editorial; comment] James ND, et al. **Eur J Cancer** 1995 Sep; 31A(10):1565–6 (15 ref.) Comment on: Eur J Cancer 1995 Sep;31A(10):1622–6.

The management of localised cancer of the prostate. Boccon-Gibod L. **Eur Urol** 1996;29 Suppl 2:62–8 (51 ref.)

Advances and trends in hormonal therapy for advanced prostate cancer. Debruyne FM, et al. **Eur Urol** 1995; 28(3):177–88 (98 ref.)

Current controversies in the management of localized prostate cancer. Dilliogluğil O, et al. **Eur Urol** 1995; 28(2):85–101 (120 ref.)

The future management of prostate cancer? Kirby RS. **Eur Urol** 1996;29 Suppl 2:132–3 (6 ref.)

Appraisal of current therapies for prostate cancer. Trachtenberg J. **Eur Urol** 1996;29 Suppl 2:110–3 (18 ref.)

Prospects for prostatic cancer incidence and treatment by the year 2000. Forti G, et al. **Int J Androl** 1996 Feb; 19(1):1–10 (81 ref.)

Locoregional therapies for early-stage prostate cancer. Stock RG. **Oncology (Huntingt)** 1995 Sep;9(9):803–11; discussion 815–6 (82 ref.)

Follow-up after therapy for prostate cancer. Treating the problems and caring for the man. Freedman A, et al. **Postgrad Med** 1996 Sep;100(3):125–9, 133–4, 136 (18 ref.)

Advanced prostate cancer. Endocrine therapies and palliative measures. Taub M, et al. **Postgrad Med** 1996 Sep; 100(3):139–40, 143–6, 152 passim (16 ref.)

Treatment of localized prostate cancer. Choosing the best alternative. Williams TR, et al. **Postgrad Med** 1996 Sep; 100(3):105–7, 111–2, 118–20 (25 ref.)

Future directions in prostate cancer treatment: an oncologist's perspective. Hussain M. **Prostate Suppl** 1996; 6:26–30 (40 ref.)

A glimpse at the future of some endocrine aspects of prostate cancer. Montie JE. **Prostate Suppl** 1996;6:57–61 (27 ref.)

Adjuvant systemic therapy of prostate cancer. Raghavan D. **Semin Oncol** 1995 Dec;22(6):633–40 (72 ref.)

Optimal duration of neoadjuvant androgen withdrawal therapy before radical prostatectomy in clinically confined prostate cancer. Gleave ME, et al. **Semin Urol Oncol** 1996 May;14(2 Suppl 2):39–45; discussion 46–7 (26 ref.)

Risk factors for progression in patients with prostate cancer treated with radical prostatectomy. Lerner SE, et al. **Semin Urol Oncol** 1996 May;14(2 Suppl 2):12–20; discussion 21 (36 ref.)

Counseling patients about therapy for localized prostate cancer. Middleton RG. **Semin Urol Oncol** 1995 Aug; 13(3):187–90 (8 ref.)

Neoadjuvant total androgen suppression and radiotherapy in the management of locally advanced prostate cancer. Roach M 3rd. **Semin Urol Oncol** 1996 May;14(2 Suppl 2):32–7; discussion 38 (33 ref.)

Hormone therapy for prostate cancer: a topical perspective. Klein EA. **Urology** 1996 Jan;47(1A Suppl):3–12; discussion 29–32 (33 ref.)

Combined androgen blockade for the treatment of metastatic cancer of the prostate. Schellhammer PF. **Urology** 1996 May;47(5):622–8 (46 ref.)

[Treatment of metastatic cancer of the prostate] Fournier G, et al. **Presse Med** 1995 Oct 28;24(32):1465–70 (10 ref.) (Eng. Abstr.) **(Fre)**

[Theoretical considerations and initial clinical results of intermittent hormone treatment of patients with advanced prostatic carcinoma] Bruchovsky N, et al. **Urologe A** 1995 Sep;34(5):389–92 (8 ref.) (Eng. Abstr.) **(Ger)**

[Recent multicenter study protocols in the USA for patients with metastatic prostatic carcinoma] DeAntoni E, et al. **Urologe A** 1995 Sep;34(5):382–8 (14 ref.) (Eng. Abstr.) **(Ger)**

[Clinical protocols in treatment of prostatic carcinoma in Europe. The role of EORTC and other organizations] Newling DW. **Urologe A** 1995 Sep;34(5):374–81 (32 ref.) (Eng. Abstr.) **(Ger)**

[Renaissance of estrogen therapy in advanced prostate carcinoma?] Smith PH, et al. **Urologe A** 1995 Sep; 34(5):393–7 (17 ref.) (Eng. Abstr.) **(Ger)**

[Intramuscular depot estrogens (Estradurin) in treatment of patients with prostate carcinoma. Historical aspects, mechanism of action, results and current clinical status] Stege R, et al. **Urologe A** 1995 Sep;34(5):398–403 (52 ref.) (Eng. Abstr.) **(Ger)**

[Advanced prostatic carcinoma—which hormone therapy when?] Studer UE. **Urologe A** 1995 Sep;34(5):361–6 (34 ref.) **(Ger)**

PROSTATITIS

MICROBIOLOGY

[Diagnostic value of Stamey's test in chronic prostatitis] Sibert L, et al. **Prog Urol** 1996 Feb;6(1):107–11 (20 ref.) (Eng. Abstr.) **(Fre)**

URINE

[Diagnostic value of Stamey's test in chronic prostatitis] Sibert L, et al. **Prog Urol** 1996 Feb;6(1):107–11 (20 ref.) (Eng. Abstr.) **(Fre)**

PROSTHESIS

see related
PROSTHODONTICS

Should total prosthetization of the patella be used in knee surgery? A review of the literature and personal experience. Murena PF, et al. **Chir Organi Mov** 1995 Jul-Aug; 80(3):323–8 (30 ref.)

Endoprosthetic bone reconstruction following malignant tumor resection in skeletally immature patients. Ward WG, et al. **Orthop Clin North Am** 1996 Jul;27(3):493–502 (43 ref.)

Papers from the consensus conference on appropriate prosthetic technology for developing countries held in Phnom Penh, Kingdom of Cambodia, 5–10 June 1995. **Prosthet Orthot Int** 1996 Apr;20(1):12–64 (0 ref.)

Prosthetics in the developing world: a review of the literature. Cummings D. **Prosthet Orthot Int** 1996 Apr; 20(1):51–60 (63 ref.)

A review of the consensus conference on appropriate prosthetic technology in developing countries. Day HJ. **Prosthet Orthot Int** 1996 Apr;20(1):15–23 (0 ref.)

Induction of soft connective tissue formation by various prosthetic implants. Oryan A. **Transplant Proc** 1995 Oct; 27(5):2754–5 (23 ref.)

[Using temporal bone artificial implantation for the fixation of external ear prosthesis] Chen X, et al. **Chung Hua Cheng Hsing Shao Shang Wai Ko Tsa Chih** 1995 Sep;11(5):379–81 (15 ref.) **(Chi)**

[Artificial cornea] Renard G. **Bull Acad Natl Med** 1996 Mar; 180(3):659–65; discussion 665–8 (14 ref.) (Eng. Abstr.) **(Fre)**

[Use of prostheses in emergency surgery. Retrospective study of 204 strangulated inguinal hernias] Palot JP, et al. **Chirurgie** 1996;121(1):48–50 (16 ref.) **(Fre)**

[Non-surgical instrumental treatment of benign hypertrophy of the prostate] Anidjar M, et al. **Presse Med** 1995 Oct 28;24(32):1477–80 (9 ref.) (Eng. Abstr.) **(Fre)**

[Sense and nonsense of cruciate ligament prostheses] Neumann K, et al. **Chirurg** 1995 Nov;66(11):1079–84 (32 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

[Complication of keratoprosthesis of posterior fixation: retroprosthetic membranes. Apropos of 4 cases] Mortemousque B, et al. **J Fr Ophtalmol** 1995;18(10):608–13 (23 ref.) (Eng. Abstr.) **(Fre)**

STANDARDS

[European regulations concerning medical devices] Savarino L, et al. **Minerva Med** 1995 Nov;86(11):481–93 (26 ref.) (Eng. Abstr.) **(Ita)**

VETERINARY

Amputation and prosthesis. St. Jean G. **Vet Clin North Am Food Anim Pract** 1996 Mar;12(1):249–61 (13 ref.)

PROSTHESIS, DENTAL see **DENTAL PROSTHESIS**

PROSTHESIS DESIGN

see related
DENTURE DESIGN

PROSTHESIS-RELATED INFECTIONS

see related
BIOFILMS

DIAGNOSIS

Aortic graft infection with mycoplasma (Ureaplasma urealyticum). Levi N, et al. **Eur J Vasc Endovasc Surg** 1995 Oct;10(3):374–5 (14 ref.)

Diagnosis and management of the infected hip prosthesis. Fitzgerald RH Jr. **Orthopedics** 1995 Sep;18(9):833–5 (18 ref.)

DRUG THERAPY

[Role of antibiotics in the treatment of infected joint prosthesis] Zimmerli W. **Orthopade** 1995 Aug;24(4):308–13 (22 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Infection after total hip arthroplasty. Past, present, and future. Garvin KL, et al. **J Bone Joint Surg Am** 1995 Oct; 77(10):1576–88 (139 ref.)

[Prognostic factors of prosthetic valve endocarditis. Apropos of 122 cases] Witchitz S, et al. **Arch Mal Coeur Vaiss** 1996 Jun;89(6):671–7 (30 ref.) (Eng. Abstr.) **(Fre)**

[A case report of mediastinitis due to methicillin resistant Staphylococcus aureus after total aortic arch replacement] Asano S, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Jun;44(6):814–9 (18 ref.) (Eng. Abstr.) **(Jpn)**

MICROBIOLOGY

Salmonella prosthetic valve endocarditis. Fukushima N, et al. **J Thorac Cardiovasc Surg** 1996 Sep;112(3):840–2 (5 ref.)

MORTALITY

[Prognostic factors of prosthetic valve endocarditis. Apropos of 122 cases] Witchitz S, et al. **Arch Mal Coeur Vaiss** 1996 Jun;89(6):671–7 (30 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

[Antibiotic bonding on arterial prostheses: a necessity] Goeau-Brissonniere O. **J Mal Vasc** 1996;21 Suppl A:146–51 (42 ref.) (Eng. Abstr.) **(Fre)**

[Prevention and therapy of prosthesis infections in the thoracic area] Haverich A, et al. **Zentralbl Chir** 1995; 120(8):630–4 (21 ref.) (Eng. Abstr.) **(Ger)**

RADIOGRAPHY

[Infection following shoulder and elbow arthroplasty. Diagnosis and therapy] Schwyzer HK, et al. **Orthopade** 1995 Aug;24(4):367–75 (44 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

An overview of the treatment of infected prosthetic vascular grafts. Calligaro KD, et al. **Adv Surg** 1996;29:3–16 (52 ref.)

The case for conservative management of infected prosthetic grafts. Perler BA. **Adv Surg** 1996;29:17–32 (85 ref.)

The case against the conservative nonresectional management of infected prosthetic grafts. Yeager RA, et al. **Adv Surg** 1996;29:33–9 (35 ref.)

Periprosthetic infections due to Mycobacterium tuberculosis in patients with no prior history of tuberculosis. Spinner RJ, et al. **J Arthroplasty** 1996 Feb;11(2):217–22 (46 ref.)

[Treatment of periprosthetic infection of the hip using one-stage exchange surgery] Steinbrink K, et al. **Orthopade** 1995 Aug;24(4):335–43 (30 ref.) (Eng. Abstr.) **(Ger)**

[A case of secondary valve replacement caused by pulmonary bioprosthetic valve endocarditis] Fujii H, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Jul;43(7):1081–5 (18 ref.) (Eng. Abstr.) **(Jpn)**

THERAPY

[Treatment of infected total prosthesis arthroplasty of the hip joint] Herzog R, et al. **Orthopade** 1995 Aug; 24(4):326–34 (75 ref.) (Eng. Abstr.) **(Ger)**

ULTRASONOGRAPHY

Pacemaker lead infection: detection by multiplane transesophageal echocardiography. Tighe DA, et al. **Am Heart J** 1996 Mar;131(3):616–8 (8 ref.)

PROSTHODONTICS

see related
SURGERY, ORAL, PREPROSTHETIC

Occlusal vertical dimension in prosthodontics. Chou TM, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1996 May; 12(5):260–6 (34 ref.)

PROSTITUTION

Condom use among female commercial sex workers in Nevada's legal brothels [see comments] Albert AE, et al. **Am J Public Health** 1995 Nov;85(11):1514–20 (50 ref.) Comment in: Am J Public Health 1995 Nov;85(11):1485–8.

HIV/AIDS risks among male, heterosexual noninjecting drug users who exchange crack for sex. Inciardi JA. **NIDA Res Monogr** 1994;143:26–40 (66 ref.)

Drug use and HIV risk among male sex workers: results of two samples in San Francisco. Waldorf D. **NIDA Res Monogr** 1994;143:114–31 (18 ref.)

Understanding the social needs of streetwalking prostitutes. Weiner A. **Soc Work** 1996 Jan;41(1):97–105 (12 ref.)

PROTEASE ANTAGONISTS see **PROTEASE INHIBITORS**

PROTEASE INHIBITORS

[Non-nucleoside antiretroviral agents] Sereni D, et al.

PROTEASE INHIBITORS

Presse Med 1996 Mar 2-9;25(8):361-4, 366-9 (29 ref.) (Eng. Abstr.) **(Fre)**

BLOOD

[Serum elastin peptide concentration and human leukocyte elastase/antiproteinase balance in peripheral obstructive atherosclerosis] Mohácsi A, et al. **Orv Hetil** 1996 Jan 7; 137(1):15-21 (49 ref.) (Eng. Abstr.) **(Hun)**

[Plasma proteinase inhibitors and their clinical significance] Prandota J, et al. **Pediatr Pol** 1995 Aug;70(8):667-72 (31 ref.) (Eng. Abstr.) **(Pol)**

CHEMICAL SYNTHESIS

[Synthetic inhibitors targeting serine and aspartic acid proteases] Reboud-Ravaux MC, et al. **J Pharm Belg** 1996 May-Jun;51(3):161-4 (44 ref.) (Eng. Abstr.) **(Fre)**

CHEMISTRY

Proteinase inhibitors from the European medicinal leech Hirudo medicinalis: structural, functional and biomedical aspects. Ascenzi P, et al. **Mol Aspects Med** 1995; 16(3):215-313 (319 ref.)

METABOLISM

Proteinases and inhibitors. Cawston TE. **Br Med Bull** 1995 Apr;51(2):385-401 (65 ref.)

Utilization of transgenic mice in the study of matrix degrading proteinases and their inhibitors. Khokha R, et al. **Cancer Metastasis Rev** 1995 Jun;14(2):97-111 (109 ref.)

Chronic renal disease: do metalloproteinase inhibitors have a demonstrable role in extracellular matrix accumulation? Baricos WH. **Curr Opin Nephrol Hypertens** 1995 Jul; 4(4):365-8 (24 ref.)

[The effect of smoking on the status of immunity and on antiprotease protection] Golub NI. **Ter Arkh** 1996; 68(1):64-7 (43 ref.) **(Rus)**

PHARMACOKINETICS

Clinical pharmacokinetics and efficacy of renin inhibitors. Rongen GA, et al. **Clin Pharmacokinet** 1995 Jul;29(1):6-14 (71 ref.)

PHARMACOLOGY

Hemodynamic effects of renin inhibitors. Kleinert HD. **Am J Nephrol** 1996;16(3):252-60 (58 ref.)

Cytokine-processing enzymes. Stopping the cuts. Dinarello CA, et al. **Curr Biol** 1995 Jun 1;5(6):587-90 (34 ref.)

[Synthetic inhibitors targeting serine and aspartic acid proteases] Reboud-Ravaux MC, et al. **J Pharm Belg** 1996 May-Jun;51(3):161-4 (44 ref.) (Eng. Abstr.) **(Fre)**

THERAPEUTIC USE

Matrix metalloproteinase inhibition: a review of anti-tumour activity. Brown PD, et al. **Ann Oncol** 1995 Dec; 6(10):967-74 (48 ref.)

Effects of protease inhibitors on levels of proteolytic activity in normal and premalignant cells and tissues. Kennedy AR, et al. **J Cell Biochem Suppl** 1995;22:188-94 (22 ref.)

Calpain as a novel target for treating acute neurodegenerative disorders. Bartus RT, et al. **Neurol Res** 1995 Aug; 17(4):249-58 (40 ref.)

PROTECTIVE CLOTHING

Prevention of blood exposure. Body and facial protection. Fry DE, et al. **Surg Clin North Am** 1995 Dec;75(6):1141-57 (27 ref.)

PROTECTIVE DEVICES

Silicone rubber splinting for athletic hand and wrist injuries. Canelón MF. **J Hand Ther** 1995 Oct-Dec;8(4):252-7 (43 ref.)

Use of knee braces in sport. Current recommendations [editorial] Albright JP, et al. **Sports Med** 1995 Nov; 20(5):281-301 (49 ref.)

Effectiveness of prophylactic ankle stabilisers for prevention of ankle injuries. Sitler MR, et al. **Sports Med** 1995 Jul; 20(1):53-7 (24 ref.)

Prevention of blood exposure. Body and facial protection. Fry DE, et al. **Surg Clin North Am** 1995 Dec;75(6):1141-57 (27 ref.)

PROTECTIVE GLOVES see **GLOVES, PROTECTIVE**

PROTEIN A see **STAPHYLOCOCCAL PROTEIN A**

PROTEIN BINDING

see related
BINDING SITES
CARRIER PROTEINS
METALLOPROTEINS
THYROXINE-BINDING PROTEINS

Protein-protein interfaces: architectures and interactions in protein-protein interfaces and in protein cores. Their similarities and differences. Tsai CJ, et al. **Crit Rev Biochem Mol Biol** 1996 Apr;31(2):127-52 (50 ref.)

Computational methods to predict binding free energy in ligand-receptor complexes. Murcko A, et al. **J Med Chem** 1995 Dec 22;38(26):4953-67 (90 ref.)

Principles of protein-protein interactions. Jones S, et al. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):13-20 (47 ref.)

IMMUNOLOGY

New methods to predict MHC-binding sequences within protein antigens. Hammer J. **Curr Opin Immunol** 1995 Apr; 7(2):263-9 (60 ref.)

Tissue-specific, peptide-binding transplantation antigens: lessons from the Qa-2 system. Stroynowski I. **Immunol Rev** 1995 Oct;147:91-108 (85 ref.)

PROTEIN-BOUND IODINE TEST see **THYROID FUNCTION TESTS**

PROTEIN C

ANALYSIS

[Protein C] Hayashi T, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:112-6 (17 ref.) **(Jpn)**

[Activated protein C-protein C inhibitor complex (APC-PCI complex)] Nishioka J, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:125-9 (14 ref.) **(Jpn)**

DEFICIENCY

Thrombophilia: the discovery of activated protein C resistance. Dahlbäck B. **Adv Genet** 1995;33:135-75 (114 ref.)

Eosinophilic gastro-enteritis associated with protein-losing enteropathy and protein C deficiency. Wing-Harkins DL, et al. **J Int Med Res** 1996 Jan-Feb;24(1):155-63 (44 ref.)

Replacement therapy with a monoclonal antibody purified protein C concentrate in newborns with severe congenital protein C deficiency. Dreyfus M, et al. **Semin Thromb Hemost** 1995;21(4):371-81 (26 ref.)

Protein C deficiency: a database of mutations, 1995 update. On behalf of the Subcommittee on Plasma Coagulation Inhibitors of the Scientific and Standardization Committee of the ISTH. Reitsma PH, et al. **Thromb Haemost** 1995 May;73(5):876-89 (112 ref.)

GENETICS

A review of mutations causing deficiencies of antithrombin, protein C and protein S. Aiach M, et al. **Thromb Haemost** 1995 Jul;74(1):81-9 (120 ref.)

Protein C deficiency: a database of mutations, 1995 update. On behalf of the Subcommittee on Plasma Coagulation Inhibitors of the Scientific and Standardization Committee of the ISTH. Reitsma PH, et al. **Thromb Haemost** 1995 May;73(5):876-89 (112 ref.)

[Point mutation G-->A nucleotide 1691 factor V gene as a cause of developing thrombotic complications in a family with plasma resistance to activated protein C] Lew Andowski KL, et al. **Pol Arch Med Wewn** 1996 May; 95(5):464-70 (11 ref.) (Eng. Abstr.) **(Pol)**

IMMUNOLOGY

[Resistance to activated protein C. A common genetic risk factor in venous thrombosis] Berntorp E, et al. **Lakartidningen** 1995 Sep 27;92(39):3587-90 (27 ref.) **(Swe)**

METABOLISM

Resistance to activated protein C due to mutated factor V as a novel cause of inherited thrombophilia. De Stefano V, et al. **Haematologica** 1995 Jul-Aug;80(4):344-56 (99 ref.)

Resistance to activated protein C and factor V Leiden as risk factors for venous thrombosis. Bertina RM, et al. **Thromb Haemost** 1995 Jul;74(1):449-53 (53 ref.)

New molecular insights into the genetics of thrombophilia. Resistance to activated protein C caused by Arg506 to Gln mutation in factor V as a pathogenic risk factor for venous thrombosis. Dahlbäck B. **Thromb Haemost** 1995 Jul; 74(1):139-48 (112 ref.)

Resistance to activate protein C, the Arg506 to Gln mutation in the factor V gene, and venous thrombosis. Functional tests and DNA-based assays, pros and cons [see comments] Dahlbäck B. **Thromb Haemost** 1995 May;73(5):739-42 (33 ref.) Comment in: Thromb Haemost 1995 Nov;74(5):1380-1.

Activated protein C resistance: molecular mechanisms. Griffin JH, et al. **Thromb Haemost** 1995 Jul;74(1):444-8 (35 ref.)

[Resistance to activated protein C] Yang L, et al. **Chung Hua Nei Ko Tsa Chih** 1995 Nov;34(11):776-8 (19 ref.) (Eng. Abstr.) **(Chi)**

[A new cause of hereditary venous thrombosis: activated protein C resistance] Trossaërt M, et al. **Ann Cardiol Angeiol (Paris)** 1995 Oct;44(8):438-42 (7 ref.) **(Fre)**

PHARMACOLOGY

Resistance to activated protein C, the FV:Q506 allele, and venous thrombosis. Dahlbäck B, et al. **Ann Hematol** 1996 Apr;72(4):166-76 (152 ref.)

[Activated protein C resistance: role in venous and arterial thrombosis] Emmerich J, et al. **Arch Mal Coeur Vaiss** 1996 Jun;89(6):741-5 (31 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Thrombophilia: the discovery of activated protein C resistance. Dahlbäck B. **Adv Genet** 1995;33:135-75 (114 ref.)

Thrombophilia: some recent advances in understanding. James CM. **J R Nav Med Serv** 1995 Winter;81(3):203-6 (15 ref.)

Activated protein C resistance and thrombosis. Nichols WL, et al. **Mayo Clin Proc** 1996 Sep;71(9):897-8 (6 ref.)

Cellular regulation of the protein C pathway. Esmon CT, et al. **Semin Cell Biol** 1995 Oct;6(5):259-68 (73 ref.)

THERAPEUTIC USE

Replacement therapy with a monoclonal antibody purified protein C concentrate in newborns with severe congenital protein C deficiency. Dreyfus M, et al. **Semin Thromb Hemost** 1995;21(4):371-81 (26 ref.)

[APC resistance: pathogenesis, diagnosis, prevalence and importance of a new thrombosis risk factor] Wankmüller H, et al. **Med Klin** 1996 May 15;91(5):308-12, 324 (49 ref.) **(Ger)**

PROTEIN C INHIBITOR

ANALYSIS

[Activated protein C-protein C inhibitor complex (APC-PCI complex)] Nishioka J, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:125-9 (14 ref.) **(Jpn)**

PROTEIN-CALORIE MALNUTRITION see **PROTEIN-ENERGY MALNUTRITION**

PROTEIN CONFORMATION

Structure of IgA: facts and gaps in our data on disulfide bonds. Biewenga J. **Adv Exp Med Biol** 1995;371A:575-9 (18 ref.)

Enthalpic contribution to protein stability: insights from atom-based calculations and statistical mechanics. Lazaridis T, et al. **Adv Protein Chem** 1995;47:231-306 (129 ref.)

Energetics of protein structure. Makhatadze GI, et al. **Adv Protein Chem** 1995;47:307-425 (338 ref.)

Molten globule and protein folding. Ptitsyn OB. **Adv Protein Chem** 1995;47:83-229 (423 ref.)

Ca(2+)-dependent sugar recognition by animal lectins. Drickamer K. **Biochem Soc Trans** 1996 Feb;24(1):146-50 (20 ref.)

Molecular recognition in protein complexes involved in electron transfer. Gómez-Moreno C, et al. **Biochem Soc Trans** 1996 Feb;24(1):111-6 (19 ref.)

Force field development and conformational search strategy in the simulation of biomolecular recognition processes. Tenette C, et al. **Biochem Soc Trans** 1996 Feb;24(1):268-74 (43 ref.)

Inactivation precedes overall molecular conformation changes during enzyme denaturation. Tsou CL. **Biochim Biophys Acta** 1995 Dec 6;1253(2):151-62 (107 ref.)

Recent developments in the theory of protein folding: searching for the global energy minimum. Scheraga HA. **Biophys Chem** 1996 Apr 16;59(3):329-39 (102 ref.)

G protein heterodimers: new structures propel new questions. Neer EJ, et al. **Cell** 1996 Jan 26;84(2):175-8 (15 ref.)

Protein structure prediction: recognition of primary, secondary, and tertiary structural features from amino acid sequence. Eisenhaber F, et al. **Crit Rev Biochem Mol Biol** 1995;30(1):1-94 (487 ref.)

New strategies in protein design. Desjarlais JR, et al. **Curr Opin Biotechnol** 1995 Aug;6(4):460-6 (52 ref.)

Evidence on close packing and cavities in proteins. Hubbard SJ, et al. **Curr Opin Biotechnol** 1995 Aug;6(4):375-81 (75 ref.)

Modeling mutations and homologous proteins. Sali A. **Curr Opin Biotechnol** 1995 Aug;6(4):437-51 (222 ref.)

Circular assemblies. Antson AA, et al. **Curr Opin Struct Biol** 1996 Apr;6(2):142-50 (41 ref.)

The TATA box binding protein. Burley SK. **Curr Opin Struct Biol** 1996 Feb;6(1):69-75 (38 ref.)

Sequence space, folding and protein design. Cordes MH, et al. **Curr Opin Struct Biol** 1996 Feb;6(1):3-10 (104 ref.)

Novel methods for molecular dynamics simulations. Elber R. **Curr Opin Struct Biol** 1996 Apr;6(2):232-5 (29 ref.)

Structure-derived potentials and protein simulations. Jernigan RL, et al. **Curr Opin Struct Biol** 1996 Apr; 6(2):195-209 (92 ref.)

Alternative conformations of amyloidogenic proteins govern their behavior. Kelly JW. **Curr Opin Struct Biol** 1996 Feb; 6(1):11-7 (44 ref.)

Mean-field minimization methods for biological macromolecules. Koehl P, et al. **Curr Opin Struct Biol** 1996 Apr;6(2):222-6 (36 ref.)

Seeking significance in three-dimensional protein structure comparisons. Mizuguchi K, et al. **Curr Opin Struct Biol** 1995 Jun;5(3):377-82 (43 ref.)

RNA-protein complexes. Nagai K. **Curr Opin Struct Biol** 1996 Feb;6(1):53-61 (60 ref.)

Genetic algorithms for protein structure prediction. Pedersen JT, et al. **Curr Opin Struct Biol** 1996 Apr;6(2):227-31 (40 ref.)

Retroviral integrases and their cousins. Rice P, et al. **Curr Opin Struct Biol** 1996 Feb;6(1):76-83 (65 ref.)

Structural analysis of non-native states of proteins by NMR

methods. Shortle DR. **Curr Opin Struct Biol** 1996 Feb; 6(1):24–30 (58 ref.)
Modeling side-chain conformation. Vásquez M. **Curr Opin Struct Biol** 1996 Apr;6(2):217–21 (53 ref.)
Homeodomain interactions. Wolberger C. **Curr Opin Struct Biol** 1996 Feb;6(1):62–8 (39 ref.)
The emerging three-dimensional structure of a receptor. The nicotinic acetylcholine receptor. Hucho F, et al. **Eur J Biochem** 1996 Aug 1;239(3):539–57 (180 ref.)
Protein motifs. 8. The triple-helix motif in proteins. Brodsky B, et al. **FASEB J** 1995 Dec;9(15):1537–46 (65 ref.)
Assigning amino acid sequences to 3-dimensional protein folds. Fischer D, et al. **FASEB J** 1996 Jan;10(1):126–36 (54 ref.)
Structure-function relationships of the alternative oxidase of plant mitochondria: a model of the active site. Moore AL, et al. **J Bioenerg Biomembr** 1995 Aug;27(4):367–77 (70 ref.)
Transmembrane topology of the glutamate receptors. A tale of novel twists and turns. Hughes TE. **J Mol Neurosci** 1994–95;5(4):211–7 (36 ref.)
Targeting of nucleic acids by iron complexes. Draganescu A, et al. **Met Ions Biol Syst** 1996;33:453–84 (92 ref.)
Synthetic metallopeptides as probes of protein-DNA interactions. Long EC, et al. **Met Ions Biol Syst** 1996; 33:427–52 (65 ref.)
Use of vanadate-induced photocleavage for detecting phosphate binding sites in proteins. Muhlrad A, et al. **Met Ions Biol Syst** 1995;31:211–30 (65 ref.)
Ternary metal ion-nucleic acid base-protein complexes. Sabat M. **Met Ions Biol Syst** 1996;32:521–55 (153 ref.)
Role of oxidized amino acids in protein breakdown and stability. Stadtman ER. **Methods Enzymol** 1995;258:379–93 (56 ref.)
Recent developments for crystallographic refinement of macromolecules. Brünger AT. **Methods Mol Biol** 1996; 56:245–66 (81 ref.)
Density modification in x-ray crystallography. Podjarny AD, et al. **Methods Mol Biol** 1996;56:205–26 (88 ref.)
Molecular replacement using known structural information. Tickle IJ, et al. **Methods Mol Biol** 1996;56:173–203 (92 ref.)
Refinement of protein and nucleic acid structures. Westhof E, et al. **Methods Mol Biol** 1996;56:227–44 (39 ref.)
Genetic origins of protein shape and interaction rules [comment] [see comments] Blalock JE. **Nat Med** 1995 Sep; 1(9):876–8 (20 ref.) Comment on: Nat Med 1995 Sep;1(9):894–901. Comment in: Nat Med 1995 Dec;1(12):1222. Comment in: Nat Med 1995 Dec;1(12):1222–3.
Are database-derived potentials valid for scoring both forward and inverted protein folding? Rooman MJ, et al. **Protein Eng** 1995 Sep;8(9):849–58 (82 ref.)
Side-chain conformational entropy in protein folding. Doig AJ, et al. **Protein Sci** 1995 Nov;4(11):2247–51 (31 ref.)
High pressure effects on protein structure and function. Mozhaev VV, et al. **Proteins** 1996 Jan;24(1):81–91 (56 ref.)
Protein design: a hierarchic approach. Bryson JW, et al. **Science** 1995 Nov 10;270(5238):935–41 (107 ref.)
Mapping the protein universe. Holm L, et al. **Science** 1996 Aug 2;273(5275):595–603 (36 ref.)
Copper amine oxidase: a novel use for a tyrosine [comment] Fontecave M, et al. **Structure** 1995 Nov 15;3(11):1127–9 (22 ref.) Comment on: Structure 1995 Nov 15;3(11):1171–84.
How to make my blood boil [comment] Goldman A. **Structure** 1995 Dec 15;3(12):1277–9 (18 ref.) Comment on: Structure 1995 Dec 15;3(12):1295–306.
The use of antibody fragments for crystallization and structure determinations. Kovari LC, et al. **Structure** 1995 Dec 15;3(12):1291–3 (34 ref.)
Structuring cell-cycle biology [comment] Levine K, et al. **Structure** 1995 Nov 15;3(11):1131–4 (52 ref.) Comment on: Structure 1995 Nov 15;3(11):1235–47.
14-3-3 proteins: structure resolved, functions less clear. Marais R, et al. **Structure** 1995 Aug 15;3(8):751–3 (18 ref.)
A chemical approach to the construction of multimeric protein assemblies. Muir TW. **Structure** 1995 Jul 15; 3(7):649–52 (18 ref.)
Viral envelope glycoproteins swing into action. Stuart D, et al. **Structure** 1995 Jul 15;3(7):645–8 (27 ref.)
Homeodomains: together again for the first time. Tullius T. **Structure** 1995 Nov 15;3(11):1143–5 (15 ref.)
Rubisco, an old challenge with new perspectives. Wildner GF, et al. **Z Naturforsch [C]** 1996 May-Jun;51(5-6):273–86 (63 ref.)
[Amyloidosis, protein conformation dynamics and neurologic diseases] Tranchant C, et al. **Rev Neurol (Paris)** 1996 Mar; 152(3):153–7 (26 ref.) (Eng. Abstr.) **(Fre)**

PROTEIN CONFORMATION, ALPHA-HELICAL see **PROTEIN STRUCTURE, SECONDARY**

PROTEIN CONFORMATION, BETA-SHEET see **PROTEIN STRUCTURE, SECONDARY**

PROTEIN DENATURATION

Inactivation precedes overall molecular conformation changes during enzyme denaturation. Tsou CL. **Biochim Biophys Acta** 1995 Dec 6;1253(2):151–62 (107 ref.)
Thermodynamics of denaturation of staphylococcal nuclease mutants: an intermediate state in protein folding. Carra JH, et al. **FASEB J** 1996 Jan;10(1):67–74 (52 ref.)
The denatured state (the other half of the folding equation) and its role in protein stability. Shortle D. **FASEB J** 1996 Jan;10(1):27–34 (39 ref.)
How to make my blood boil [comment] Goldman A. **Structure** 1995 Dec 15;3(12):1277–9 (18 ref.) Comment on: Structure 1995 Dec 15;3(12):1295–306.

PHYSIOLOGY

[The formation and development of the denaturation theory of injuries and irritation] Aleksandrov VIa. **Tsitologiia** 1995; 37(12):1101–22 (124 ref.) (Eng. Abstr.) **(Rus)**
[The functional state of denatured proteins: the principles of modelling and the first results] Bychkova VE, et al. **Tsitologiia** 1995;37(12):1238–50 (48 ref.) (Eng. Abstr.) **(Rus)**

PROTEIN-ENERGY MALNUTRITION

Undernutrition and elderly hospital patients: a review. Tierney AJ. **J Adv Nurs** 1996 Feb;23(2):228–36 (66 ref.)
[Malnutrition] Hosoda S, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):297–300 (9 ref.) **(Jpn)**

COMPLICATIONS

The role of nutrition in increased morbidity and mortality. Sullivan DH. **Clin Geriatr Med** 1995 Nov;11(4):661–74 (49 ref.)

EPIDEMIOLOGY

The role of nutrition in increased morbidity and mortality. Sullivan DH. **Clin Geriatr Med** 1995 Nov;11(4):661–74 (49 ref.)

ETIOLOGY

Appetite in CAPD patients. Bergström J. **Perit Dial Int** 1996; 16 Suppl 1:S181–4 (29 ref.)
Nutritional Markers as predictors of survival in patients on CAPD. Dombros NV, et al. **Perit Dial Int** 1995;15(5 Suppl):S10–9 (66 ref.)

IMMUNOLOGY

Malnutrition, injury, and the host immune response: nutrient substitution. Gallagher HJ, et al. **Curr Opin Gen Surg** 1993; :92–104 (116 ref.)
Nutrition and immunity with emphasis on infection and autoimmune disease. Harbige LS. **Nutr Health** 1996; 10(4):285–312 (136 ref.)

MORTALITY

Why have mortality rates for severe malnutrition remained so high? Schofield C, et al. **Bull World Health Organ** 1996; 74(2):223–9 (71 ref.)

PHYSIOPATHOLOGY

Nutrition and the gut mucosal barrier. Deitch EA. **Curr Opin Gen Surg** 1993;:85–91 (34 ref.)

PREVENTION & CONTROL

Glutamine—a conditionally essential amino acid in cirrhosis? Teran JC, et al. **Am J Clin Nutr** 1995 Nov;62(5):897–900 (40 ref.)
Enrichment of food staples through plant breeding: a new strategy for fighting micronutrient malnutrition. Bouis H. **Nutr Rev** 1996 May;54(5):131–7 (31 ref.)

PSYCHOLOGY

Perils and pitfalls on the path to normal potential: the role of impaired attention. Homage to Herbert G. Birch. Mirsky AF. **J Clin Exp Neuropsychol** 1995 Aug;17(4):481–98 (36 ref.)

THERAPY

Nutritional support during liver failure. Gecelter GR, et al. **Crit Care Clin** 1995 Jul;11(3):675–83 (52 ref.)
Nutritional support during pulmonary failure. Pinard B, et al. **Crit Care Clin** 1995 Jul;11(3):705–15 (33 ref.)
Nutritional support in liver disease. Cabré E, et al. **Eur J Gastroenterol Hepatol** 1995 Jun;7(6):528–32 (42 ref.)
Nutritional status in children receiving chronic peritoneal dialysis. Canepa A, et al. **Perit Dial Int** 1996;16 Suppl 1:S526–31 (37 ref.)
Intraperitoneal amino acids: a therapy whose time has come? Jones MR. **Perit Dial Int** 1995;15(5 Suppl):S67–74 (68 ref.)
Nasogastric tube feeding in infants on peritoneal dialysis. Warady BA, et al. **Perit Dial Int** 1996;16 Suppl 1:S521–5 (32 ref.)

PROTEIN ENGINEERING

Molecular engineering of cholera toxin. Burnette WN, et al. **Adv Exp Med Biol** 1995;371B:1513–8 (43 ref.)
Are engineered proteins getting competition from RNA? Breaker RR. **Curr Opin Biotechnol** 1996 Aug;7(4):442–8 (54 ref.)
Theoretical approaches to designing novel sequences to fit a given fold. Jones DT. **Curr Opin Biotechnol** 1995 Aug; 6(4):452–9 (50 ref.)
Helix design, prediction and stability. Muñoz V, et al. **Curr Opin Biotechnol** 1995 Aug;6(4):382–6 (59 ref.)
Engineering membrane proteins. Popot JL, et al. **Curr Opin Biotechnol** 1995 Aug;6(4):394–402 (90 ref.)
Protein engineering as a tool for crystallography. Price SR, et al. **Curr Opin Biotechnol** 1995 Aug;6(4):425–30 (40 ref.)
Engineering thermostability: lessons from thermophilic proteins. Russell RJ, et al. **Curr Opin Biotechnol** 1995 Aug; 6(4):370–4 (22 ref.)
The emerging role of insertions and deletions in protein engineering. Shortle D, et al. **Curr Opin Biotechnol** 1995 Aug;6(4):387–93 (40 ref.)
Sequence space, folding and protein design. Cordes MH, et al. **Curr Opin Struct Biol** 1996 Feb;6(1):3–10 (104 ref.)
Antibody engineering. Nilsson B. **Curr Opin Struct Biol** 1995 Aug;5(4):450–6 (77 ref.)
Phage display: protein engineering by directed evolution. O'Neil KT, et al. **Curr Opin Struct Biol** 1995 Aug; 5(4):443–9 (54 ref.)
Engineering and design of blood substitutes. Sanders KE, et al. **Curr Opin Struct Biol** 1996 Aug;6(4):534–40 (60 ref.)
Engineering new functions and altering existing functions. Shao Z, et al. **Curr Opin Struct Biol** 1996 Aug;6(4):513–8 (52 ref.)
Engineering of lysozyme. Imoto T. **EXS** 1996;75:163–81 (80 ref.)
Cell-surface engineering with GPI-anchored proteins. Medof ME, et al. **FASEB J** 1996 Apr;10(5):574–86 (82 ref.)
Complement-specific antibodies: designing novel anti-inflammatories. Matis LA, et al. **Nat Med** 1995 Aug; 1(8):839–42 (18 ref.)
Protein design: a hierarchic approach. Bryson JW, et al. **Science** 1995 Nov 10;270(5238):935–41 (107 ref.)
Application of combinatorial libraries and protein engineering to the discovery of novel anti-thrombotic drugs. Leung LL. **Thromb Haemost** 1995 Jul;74(1):373–6 (19 ref.)
[Nucleic acid chemistry and protein engineering] Ikehara M. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1660–2 (0 ref.) **(Jpn)**

METHODS

Production of antibody fragments in Escherichia coli. Harrison JS, et al. **Ann N Y Acad Sci** 1996 May 15; 782:143–58 (81 ref.)
Depletion and replacement of protein metal ligands. Barrick D. **Curr Opin Biotechnol** 1995 Aug;6(4):411–8 (59 ref.)
Designing DNA-binding proteins on the surface of filamentous phage. Choo Y, et al. **Curr Opin Biotechnol** 1995 Aug;6(4):431–6 (23 ref.)
Sequence 'minimization': exploring the sequence landscape with simplified sequences. Clarke ND. **Curr Opin Biotechnol** 1995 Aug;6(4):467–72 (19 ref.)
New strategies in protein design. Desjarlais JR, et al. **Curr Opin Biotechnol** 1995 Aug;6(4):460–6 (52 ref.)
Metalloprotein design. Hellinga HW. **Curr Opin Biotechnol** 1996 Aug;7(4):437–41 (56 ref.)
Enhancing expression of recombinant proteins in mammalian cells using the herpesvirus VP16 transactivator. Hippenmeyer PJ, et al. **Curr Opin Biotechnol** 1995 Oct; 6(5):548–52 (15 ref.)
Interfacial metal-binding site design. Matthews DJ. **Curr Opin Biotechnol** 1995 Aug;6(4):419–24 (49 ref.)
Peptide ligation and semisynthesis. Wallace CJ. **Curr Opin Biotechnol** 1995 Aug;6(4):403–10 (45 ref.)
Protein engineering and design for drug delivery. Murphy JR. **Curr Opin Struct Biol** 1996 Aug;6(4):541–5 (25 ref.)
Engineering enzymes for stability. Shaw A, et al. **Curr Opin Struct Biol** 1996 Aug;6(4):546–50 (45 ref.)
A review of protein engineering for the food industry. Goodenough PW. **Mol Biotechnol** 1995 Oct;4(2):151–66 (55 ref.)
Synthetic human antibodies. Barbas CF 3rd. **Nat Med** 1995 Aug;1(8):837–9 (32 ref.)
Applying genetic engineering to the structural analysis of proteins. Hamilton PT. **Pharm Biotechnol** 1995;7:329–50 (102 ref.)

PROTEIN FOLDING

see related
PROTEIN CONFORMATION

Enthalpic contribution to protein stability: insights from atom-based calculations and statistical mechanics. Lazaridis T, et al. **Adv Protein Chem** 1995;47:231–306 (129 ref.)
Molten globule and protein folding. Ptitsyn OB. **Adv Protein Chem** 1995;47:83–229 (423 ref.)
Protein engineering of domains in flavoprotein disulphide oxidoreductases: contributions to folding and assembly. Perham RN, et al. **Biochem Soc Trans** 1996 Feb;24(1):61–6 (45 ref.)
Recent developments in the theory of protein folding: searching for the global energy minimum. Scheraga HA. **Biophys Chem** 1996 Apr 16;59(3):329–39 (102 ref.)
Thermal unfolding of Acanthamoeba myosin II and skeletal muscle myosin. Zolkiewski M, et al. **Biophys Chem** 1996 Apr 16;59(3):365–71 (45 ref.)
Oxidative folding of cystine-rich peptides vs regioselective cysteine pairing strategies. Moroder L, et al. **Biopolymers** 1996;40(2):207–34 (206 ref.)
For protein misassembly, it's the "I" decade. Wetzel R. **Cell** 1996 Sep 6;86(5):699–702 (20 ref.)

PROTEIN FOLDING

Protein folding. Prolyl isomerases join the fold. Schmid FX. **Curr Biol** 1995 Sep 1;5(9):993–4 (12 ref.)
Expression of correctly folded proteins in Escherichia coli. Georgiou G, et al. **Curr Opin Biotechnol** 1996 Apr; 7(2):190–7 (40 ref.)
Evidence on close packing and cavities in proteins. Hubbard SJ, et al. **Curr Opin Biotechnol** 1995 Aug;6(4):375–81 (75 ref.)
Theoretical approaches to designing novel sequences to fit a given fold. Jones DT. **Curr Opin Biotechnol** 1995 Aug; 6(4):452–9 (50 ref.)
The role of protein–solvent interactions in protein unfolding. Schiffer CA, et al. **Curr Opin Biotechnol** 1996 Aug; 7(4):428–32 (38 ref.)
Effects of overexpressing folding modulators on the in vivo folding of heterologous proteins in Escherichia coli. Wall JG, et al. **Curr Opin Biotechnol** 1995 Oct;6(5):507–16 (77 ref.)
Folding of beta-sheet proteins. Carlsson U, et al. **Curr Opin Struct Biol** 1995 Aug;5(4):482–7 (51 ref.)
Molecular chaperones in protein folding and translocation. Clarke AR. **Curr Opin Struct Biol** 1996 Feb;6(1):43–50 (73 ref.)
Sequence space, folding and protein design. Cordes MH, et al. **Curr Opin Struct Biol** 1996 Feb;6(1):3–10 (104 ref.)
Potential energy functions for threading. Jones DT, et al. **Curr Opin Struct Biol** 1996 Apr;6(2):210–6 (40 ref.)
Collapse and cooperativity in protein folding. Miranker AD, et al. **Curr Opin Struct Biol** 1996 Feb;6(1):31–42 (80 ref.)
Protein folds in channel structure. Montal M. **Curr Opin Struct Biol** 1996 Aug;6(4):499–510 (111 ref.)
Protein folding and association: in vitro studies for self-organization and targeting in the cell. Jaenicke R. **Curr Top Cell Regul** 1996;34:209–314 (520 ref.)
Folding of lysozyme. Fischer B. **EXS** 1996;75:143–61 (59 ref.)
Supervising the fold: functional principles of molecular chaperones. Buchner J. **FASEB J** 1996 Jan;10(1):10–9 (73 ref.)
Thermodynamics of denaturation of staphylococcal nuclease mutants: an intermediate state in protein folding. Carra JH, et al. **FASEB J** 1996 Jan;10(1):67–74 (52 ref.)
The roles of partly folded intermediates in protein folding. Creighton TE, et al. **FASEB J** 1996 Jan;10(1):110–8 (55 ref.)
Protein folding in the cell: competing models of chaperonin function. Ellis RJ, et al. **FASEB J** 1996 Jan;10(1):20–6 (43 ref.)
Assigning amino acid sequences to 3-dimensional protein folds. Fischer D, et al. **FASEB J** 1996 Jan;10(1):126–36 (54 ref.)
The role of molecular chaperones in protein folding. Hendrick JP, et al. **FASEB J** 1995 Dec;9(15):1559–69 (76 ref.)
Stability and folding of ultrastable proteins: eye lens crystallins and enzymes from thermophiles. Jaenicke R. **FASEB J** 1996 Jan;10(1):84–92 (50 ref.)
Thermolabile folding intermediates: inclusion body precursors and chaperonin substrates. King J, et al. **FASEB J** 1996 Jan;10(1):57–66 (63 ref.)
The molten globule state of alpha-lactalbumin. Kuwajima K. **FASEB J** 1996 Jan;10(1):102–9 (103 ref.)
Protein folding by a biased Monte Carlo procedure in the dihedral angle space. Lee B, et al. **FASEB J** 1996 Jan; 10(1):119–25 (43 ref.)
A quantitative assessment of the role of the chaperonin proteins in protein folding in vivo. Lorimer GH. **FASEB J** 1996 Jan;10(1):5–9 (43 ref.)
Structural and genetic analysis of the folding and function of T4 lysozyme. Matthews BW. **FASEB J** 1996 Jan; 10(1):35–41 (29 ref.)
Investigation of protein folding by mass spectrometry. Miranker A, et al. **FASEB J** 1996 Jan;10(1):93–101 (47 ref.)
Forces contributing to the conformational stability of proteins. Pace CN, et al. **FASEB J** 1996 Jan;10(1):75–83 (52 ref.)
A determinable but unresolved problem. Ptitsyn OB. **FASEB J** 1996 Jan;10(1):3–4 (34 ref.)
In vitro folding of inclusion body proteins. Rudolph R, et al. **FASEB J** 1996 Jan;10(1):49–56 (80 ref.)
Sequence determinants of folding and stability for the P22 Arc repressor dimer. Sauer RT, et al. **FASEB J** 1996 Jan; 10(1):42–8 (21 ref.)
The denatured state (the other half of the folding equation) and its role in protein stability. Shortle D. **FASEB J** 1996 Jan;10(1):27–34 (39 ref.)
Chaperonin-mediated folding of actin and tubulin. Lewis SA, et al. **J Cell Biol** 1996 Jan;132(1–2):1–4 (32 ref.)
Intermediate states in protein folding. Privalov PL. **J Mol Biol** 1996 May 24;258(5):707–25 (122 ref.)
Pro-sequence-assisted protein folding. Eder J, et al. **Mol Microbiol** 1995 May;16(4):609–14 (59 ref.)
Genetic origins of protein shape and interaction rules [comment] [see comments] Blalock JE. **Nat Med** 1995 Sep; 1(9):876–8 (20 ref.) Comment on: Nat Med 1995 Sep;1(9):894–901. Comment in: Nat Med 1995 Dec;1(12):1222. Comment in: Nat Med 1995 Dec;1(12):1222–3.
Molecular chaperones in cellular protein folding. Hartl FU. **Nature** 1996 Jun 13;381(6583):571–9 (154 ref.)
Are database-derived potentials valid for scoring both forward and inverted protein folding? Rooman MJ, et al. **Protein Eng** 1995 Sep;8(9):849–58 (82 ref.)
Side-chain conformational entropy in protein folding. Doig AJ, et al. **Protein Sci** 1995 Nov;4(11):2247–51 (31 ref.)
The "bio" in biochemistry: protein folding inside and outside the cell [comment] Ellis RJ. **Science** 1996 Jun 7; 272(5267):1448–9 (10 ref.) Comment on: Science 1996 Jun 7;272(5267):1497–502.
Weighing the evidence for structure: electrospray ionization mass spectrometry of proteins. Robinson CV, et al. **Structure** 1995 Sep 15;3(9):861–5 (19 ref.)
How the molten globule became. Ptitsyn OB. **Trends Biochem Sci** 1995 Sep;20(9):376–9 (43 ref.)
Defective protein folding as a basis of human disease. Thomas PJ, et al. **Trends Biochem Sci** 1995 Nov;20(11):456–9 (43 ref.)

PROTEIN FOLDING, GLOBULAR see **PROTEIN FOLDING**

PROTEIN HYDROLYSATES

THERAPEUTIC USE

The effect of hypo-allergenic formulas in infants at risk of allergic disease. Halken S, et al. **Eur J Clin Nutr** 1995 Sep; 49 Suppl 1:S77–83 (35 ref.)
The use of hydrolysates in allergy prevention programmes. Vandenplas Y. **Eur J Clin Nutr** 1995 Sep;49 Suppl 1:S84–91 (52 ref.)

PROTEIN ISOPRENYLATION

DRUG EFFECTS

Development of inhibitors of protein farnesylation as potential chemotherapeutic agents. Kohl NE, et al. **J Cell Biochem Suppl** 1995;22:145–50 (29 ref.)

PHYSIOLOGY

Isoprenoids and Ras: potential role in chronic rejection. O'Donnell MP, et al. **Kidney Int Suppl** 1995 Dec;52:S29–33 (49 ref.)
Fungal lipopeptide mating pheromones: a model system for the study of protein prenylation. Caldwell GA, et al. **Microbiol Rev** 1995 Sep;59(3):406–22 (181 ref.)

PROTEIN KINASE A see **CYCLIC AMP-DEPENDENT PROTEIN KINASES**

PROTEIN KINASE C

ANTAGONISTS & INHIBITORS

Potential for protein kinase C inhibitors in cancer therapy. Philip PA, et al. **Cancer Treat Res** 1995;78:3–27 (156 ref.)
Diabetes complications: why is glucose potentially toxic? [see comments] Porte D Jr, et al. **Science** 1996 May 3; 272(5262):699–700 (12 ref.) Comment in: Science 1996 May 3;272(5262):728–31.

CHEMISTRY

The protein kinase C and protein kinase C related gene families. Dekker LV, et al. **Curr Opin Struct Biol** 1995 Jun; 5(3):396–402 (35 ref.)
Protein kinase C: structure, function, and regulation. Newton AC. **J Biol Chem** 1995 Dec 1;270(48):28495–8 (78 ref.)
[Structural studies of phorbol ester–binding domain of protein kinase C by photoaffinity labeling] Irie K. **Seikagaku** 1996 Feb;68(2):129–32 (16 ref.) **(Jpn)**

DRUG EFFECTS

Modulation of gap junctional intercellular communication by phosphorylation: effects of growth factors, kinase activators and phosphatase inhibitors. Mikalsen SO, et al. **Prog Clin Biol Res** 1995;391:425–38 (72 ref.)
The tumor promoter receptor protein kinase C: a novel target for chemoprevention and therapy of human colon cancer. O'Brian CA, et al. **Prog Clin Biol Res** 1995;391:117–20 (20 ref.)

METABOLISM

Protein serine/threonine kinases (PKA, PKC and CaMKII) involved in ischemic brain pathology. Domańska-Janik K. **Acta Neurobiol Exp (Warsz)** 1996;56(2):579–85 (44 ref.)
Role of protein kinase C in ischemic preconditioning: in search of the "pure and simple truth". Przyklenk K, et al. **Basic Res Cardiol** 1996 Jan–Feb;91(1):41–3 (11 ref.)
The MARCKS family of protein kinase-C substrates. Aderem A. **Biochem Soc Trans** 1995 Aug;23(3):587–91 (31 ref.)
Intracellular targeting of protein kinase C isoenzymes: functional implications. Kiley SC, et al. **Biochem Soc Trans** 1995 Aug;23(3):601–5 (34 ref.)
Interaction of protein kinase C with RACK1, a receptor for activated C-kinase: a role in beta protein kinase C mediated signal transduction. Mochly-Rosen D, et al. **Biochem Soc Trans** 1995 Aug;23(3):596–600 (32 ref.)
Protein kinase C and growth regulation of malignant gliomas. Baltuch GH, et al. **Can J Neurol Sci** 1995 Nov;22(4):264–71 (98 ref.)
Signal transduction of the gonadotropin releasing hormone (GnRH) receptor: cross-talk of calcium, protein kinase C (PKC), and arachidonic acid. Naor Z, et al. **Cell Mol Neurobiol** 1995 Oct;15(5):527–44 (142 ref.)
Protein kinase C. Seeing two domains. Newton AC. **Curr Biol** 1995 Sep 1;5(9):973–6 (20 ref.)
Protein kinase C isozymes and substrates. Jaken S. **Curr Opin Cell Biol** 1996 Apr;8(2):168–73 (58 ref.)
Protein kinase C-delta, an important signaling molecule in the platelet-derived growth factor beta receptor pathway. Li W, et al. **Curr Top Microbiol Immunol** 1996;211:55–65 (23 ref.)
Diacylglycerol production, Ca2+ influx, and protein kinase C activation in sustained cellular responses. Rasmussen H, et al. **Endocr Rev** 1995 Oct;16(5):649–81 (268 ref.)
Protein kinase C: structure, function, and regulation. Newton AC. **J Biol Chem** 1995 Dec 1;270(48):28495–8 (78 ref.)
Possible role for protein kinase C in the pathogenesis of inborn errors of metabolism. Boneh A. **J Cell Biochem** 1995 Sep;59(1):27–32 (38 ref.)
Role of protein kinase C and cyclic AMP/protein kinase A in high glucose-stimulated transcriptional activation of collagen alpha 1 (IV) in glomerular mesangial cells. Ziyadeh FN, et al. **J Diabetes Complications** 1995 Oct–Dec; 9(4):255–61 (35 ref.)
Signalling by protein kinase C isoforms in the heart. Pucéat M, et al. **Mol Cell Biochem** 1996 Apr 12–26;157(1–2):65–72 (72 ref.)
The association of neuropathic pain, morphine tolerance and dependence, and the translocation of protein kinase C. Mayer DJ, et al. **NIDA Res Monogr** 1995;147:269–98 (111 ref.)

PHYSIOLOGY

Physiological inhibitors of protein kinase C. Melner MH. **Biochem Pharmacol** 1996 Apr 12;51(7):869–77 (79 ref.)
Regulation of phospholipase D by protein kinase C. Kiss Z. **Chem Phys Lipids** 1996 May 24;80(1–2):81–102 (243 ref.)
Role of protein kinase C in ischemic preconditioning: player or spectator? [editorial] Brooks G, et al. **Circ Res** 1996 Sep;79(3):627–30 (32 ref.)
Remodeling of the specialized intermediate filament network in mammalian eggs and embryos during development: regulation by protein kinase C and protein kinase M. Gallicano GI, et al. **Curr Top Dev Biol** 1995;31:277–320 (95 ref.)
Protein kinase C involvement in apoptosis. Lucas M, et al. **Gen Pharmacol** 1995 Sep;26(5):881–7 (70 ref.)
Glucose-induced vascular smooth muscle dysfunction: the role of protein kinase C. Williams B. **J Hypertens** 1995 May;13(5):477–86 (96 ref.)
Up-regulation of intracellular signalling pathways may play a central pathogenic role in hypertension, atherogenesis, insulin resistance, and cancer promotion--the 'PKC syndrome'. McCarty MF. **Med Hypotheses** 1996 Mar; 46(3):191–221 (402 ref.)
Modulation of protein kinase C by adenosine: involvement of adenosine A1 receptor-pertussis toxin sensitive nucleotide binding protein system. Marala RB, et al. **Mol Cell Biochem** 1995 Aug–Sep;149–150:51–8 (56 ref.)
Protein kinase C and skin tumor promotion. Marks F, et al. **Mutat Res** 1995 Dec;333(1–2):161–72 (100 ref.)
The involvement of PKC and multifunctional CaM kinase II of the postsynaptic neuron in induction and maintenance of long-term potentiation. Feng TP. **Prog Brain Res** 1995; 105:55–63 (27 ref.)

PROTEIN KINASES

ANALYSIS

Expression and assay of autophosphorylation of recombinant protein kinases. Horn MA, et al. **Methods Cell Biol** 1995; 49:531–41 (12 ref.)

ANTAGONISTS & INHIBITORS

Cyclin kinase inhibitors add a new dimension to cell cycle control. Yeudall WA, et al. **Eur J Cancer B Oral Oncol** 1995 Sep;31B(5):291–8 (102 ref.)
Activation by GABAb, reduction of the intracellular concentration of Ca++, and inhibition of protein kinases are possible mechanisms of the long-term posttetanic modification of the efficiency of inhibitory transmission in the new cortex. Sil'kis IG. **Neurosci Behav Physiol** 1996 Jan–Feb;26(1):88–97 (41 ref.)

CHEMISTRY

When is a lipid kinase not a lipid kinase? When it is a protein kinase. Hunter T. **Cell** 1995 Oct 6;83(1):1–4 (19 ref.)
Active and inactive protein kinases: structural basis for regulation. Johnson LN, et al. **Cell** 1996 Apr 19; 85(2):149–58 (37 ref.)

DRUG EFFECTS

Protein kinases and phosphatases that act on histidine, lysine, or arginine residues in eukaryotic proteins: a possible regulator of the mitogen-activated protein kinase cascade. Matthews HR. **Pharmacol Ther** 1995;67(3):323–50 (154 ref.)

GENETICS

Nonsteroid nuclear receptors: what are genetic studies telling

us about their role in real life? Kastner P, et al. **Cell** 1995 Dec 15;83(6):859–69 (71 ref.)
Role of kinases in HTLV-I transformation. Xu X, et al. **J Investig Med** 1996 Apr;44(4):113–23 (169 ref.)
[DNA diagnosis in myotonic dystrophy] Tachi N. **Hokkaido Igaku Zasshi** 1996 Jan;71(1):3–8 (38 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Cell cycle–related protein kinases and T cell death. Lahti JM, et al. **Adv Exp Med Biol** 1995;376:247–58 (84 ref.)
Protein serine/threonine kinases of the MAPK cascade. Graves JD, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:320–43 (151 ref.)
The stress-activated protein kinases. A novel ERK subfamily responsive to cellular stress and inflammatory cytokines. Kyriakis JM, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:303–19 (48 ref.)
Regulation of expression of sodium–calcium exchanger and plasma membrane calcium ATPase by protein kinases, glucocorticoids, and growth factors. Smith JB, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:258–71 (36 ref.)
Receptor–mediated protein sorting to the vacuole in yeast: roles for a protein kinase, a lipid kinase and GTP–binding proteins. Stack JH, et al. **Ann Rev Cell Dev Biol** 1995; 11:1–33 (146 ref.)
Interleukin I receptors and signal transduction. O'Neill LA. **Biochem Soc Trans** 1996 Feb;24(1):207–11 (44 ref.)
The functional relationship of plant lipid–derived second messengers and plant lipid–activated protein kinase. Scherer GF. **Biochem Soc Trans** 1995 Nov;23(4):871–5 (48 ref.)
Protein phosphorylation in apoptosis. Gjertsen BT, et al. **Biochim Biophys Acta** 1995 Nov 9;1269(2):187–99 (309 ref.)
Tumour suppressors, kinases and clamps: how p53 regulates the cell cycle in response to DNA damage. Cox LS, et al. **Bioessays** 1995 Jun;17(6):501–8 (98 ref.)
Some tumor cell protein kinases activated by receptors as markers, including elastin receptors. Parsons DF. **Cancer Invest** 1995;13(6):629–36 (61 ref.)
Molecular glue: kinase anchoring and scaffold proteins. Faux MC, et al. **Cell** 1996 Apr 5;85(1):9–12 (19 ref.)
Cell polarity. The importance of being polar. Glotzer M, et al. **Curr Biol** 1995 Oct 1;5(10):1102–5 (21 ref.)
Protein phosphorylation in neuronal plasticity and gene expression. Schulman H. **Curr Opin Neurobiol** 1995 Jun; 5(3):375–81 (47 ref.)
Insulin signaling network — waiting for Copernicus [editorial; comment] Draznin B. **Endocrinology** 1996 Jul; 137(7):2647–8 (20 ref.) Comment on: Endocrinology 1996 Jul;137(7):2649–58.
Association of leukocyte surface receptors with protein kinases. Hořejší V. **Int Arch Allergy Immunol** 1996 May; 110(1):1–6 (27 ref.)
The insulin/Ras pathway of adipocytic differentiation of 3T3 L1 cells: dissociation between Raf–1 kinase and the MAPK/RSK cascade. Porras A, et al. **Int J Obes Relat Metab Disord** 1996 Mar;20 Suppl 3:S43–51 (47 ref.)

PHARMACOLOGY

Protein kinases and phosphatases that act on histidine, lysine, or arginine residues in eukaryotic proteins: a possible regulator of the mitogen–activated protein kinase cascade. Matthews HR. **Pharmacol Ther** 1995;67(3):323–50 (154 ref.)

PHYSIOLOGY

Angiotensin II–mediated signal transduction events in vascular smooth muscle cells: kinases and phosphatases. Duff JL, et al. **Blood Press Suppl** 1995;2:55–60 (68 ref.)
Intracellular signalling through protein kinases in the heart. Sugden PH, et al. **Cardiovasc Res** 1995 Oct;30(4):478–92 (206 ref.)
KSR: a novel player in the RAS pathway [comment] Downward J. **Cell** 1995 Dec 15;83(6):831–4 (17 ref.) Comment on: Cell 1995 Dec 15;83(6):879–88. Comment on: Cell 1995 Dec 15;83(6):889–901. Comment on: Cell 1995 Dec 15;83(6):903–13.
Stress–activated protein kinases in cardiovascular disease. Force T, et al. **Circ Res** 1996 Jun;78(6):947–53 (39 ref.)
The role of protein kinases in adaptational growth of the heart. Bogoyevitch MA, et al. **Int J Biochem Cell Biol** 1996 Jan;28(1):1–12 (101 ref.)
The anatomy of a molecular giant: how the sarcomere cytoskeleton is assembled from immunoglobulin superfamily molecules. Fürst DO, et al. **J Mol Cell Cardiol** 1995 Apr;27(4):951–9 (76 ref.)
Dual regulation of the epidermal growth factor family of growth factors in breast cancer by sex steroids and protein kinase C. Martinez–Lacaci I, et al. **J Steroid Biochem Mol Biol** 1996 Jan;57(1–2):1–11 (145 ref.)
Regulation of phospholamban and troponin–I phosphorylation in the intact rat cardiomyocytes by adrenergic and cholinergic stimuli: roles of cyclic nucleotides, calcium, protein kinases and phosphatases and depolarization. Sulakhe PV, et al. **Mol Cell Biochem** 1995 Aug–Sep;149–150:103–26 (96 ref.)
Switching to Rac and Rho. Block C, et al. **Structure** 1995 Dec 15;3(12):1281–4 (30 ref.)
Protein phosphorylation and signal transduction. Barik S. **Subcell Biochem** 1996;26:115–64 (182 ref.)

RADIATION EFFECTS

Both ATF–2 and c–Jun are phosphorylated by stress–activated protein kinases in response to UV irradiation. Wilhelm D, et al. **Immunobiology** 1995 Jul; 193(2–4):143–8 (22 ref.)

PROTEIN–LOSING ENTEROPATHIES

COMPLICATIONS

Eosinophilic gastro–enteritis associated with protein–losing enteropathy and protein C deficiency. Wing–Harkins DL, et al. **J Int Med Res** 1996 Jan–Feb;24(1):155–63 (44 ref.)

PROTEIN P34CDC2

METABOLISM

Cell cycle regulation in Aspergillus by two protein kinases. Osmani SA, et al. **Biochem J** 1996 Aug 1;317 (Pt 3):633–41 (127 ref.)
Cell cycle. The NIMA kinase joins forces with Cdc2. Fry AM, et al. **Curr Biol** 1995 Oct 1;5(10):1122–5 (16 ref.)

PROTEIN P53

The two faces of tumor suppressor p53. Smith ML, et al. **Am J Pathol** 1996 Apr;148(4):1019–22 (39 ref.)

CHEMISTRY

Structural aspects of the p53 protein in relation to gene evolution: a second look. Soussi T, et al. **J Mol Biol** 1996 Aug 2;260(5):623–37 (143 ref.)

GENETICS

Inactivation of tumor suppressor proteins in lung cancer. Weintraub SJ. **Am J Respir Cell Mol Biol** 1996 Aug; 15(2):150–5 (39 ref.)
Clinical implications of the p53 gene. Sidransky D, et al. **Annu Rev Med** 1996;47:285–301 (89 ref.)
The 1995 Walter Hubert Lecture—molecular epidemiology of human cancer: insights from the mutational analysis of the p53 tumour–suppressor gene. Harris CC. **Br J Cancer** 1996 Feb;73(3):261–9 (89 ref.)
Germline mutations in the TP53 gene. Eeles RA. **Cancer Surv** 1995;25:101–24 (106 ref.)
P53–mediated radioresistance does not correlate with metastatic potential in tumorigenic rat embryo cell lines following oncogene transfection. Bristow RG, et al. **Int J Radiat Oncol Biol Phys** 1996 Jan 15;34(2):341–55 (81 ref.)
The clinical significance of p53 aberrations in human tumours. Bosari S, et al. **Virchows Arch** 1995;427(3):229–41 (158 ref.)
[P53 protein: a new tool for the clinician? (editorial)] Laurent–Puig P. **Gastroenterol Clin Biol** 1995 May; 19(5):463–4 (8 ref.) **(Fre)**
[Tumor suppressor gene p53. Theoretical principles and their significance for pathology] Poremba C, et al. **Pathologe** 1996 May;17(3):181–8 (62 ref.) (Eng. Abstr.) **(Ger)**

METABOLISM

Tumour suppressors, kinases and clamps: how p53 regulates the cell cycle in response to DNA damage. Cox LS, et al. **Bioessays** 1995 Jun;17(6):501–8 (98 ref.)
The significance of alterations in p53 expression in gynaecological neoplasms. Manek S, et al. **Curr Opin Obstet Gynecol** 1996 Feb;8(1):52–5 (33 ref.)
p53 overexpression in head and neck squamous cell carcinoma: review of the literature. Raybaud–Diogène H, et al. **Eur J Cancer B Oral Oncol** 1996 May;32B(3):143–9 (66 ref.)
p53–positive squamous cell carcinoma originating from an odontogenic cyst. McDonald AR, et al. **J Oral Maxillofac Surg** 1996 Feb;54(2):216–8 (9 ref.)
Nuclear p53 overexpression is an independent prognostic parameter in node–negative non–small cell lung carcinoma. Dalquen P, et al. **J Pathol** 1996 Jan;178(1):53–8 (41 ref.)
New insights into p53 function from structural studies. Arrowsmith CH, et al. **Oncogene** 1996 Apr 4;12(7):1379–85 (59 ref.)

PHYSIOLOGY

DNA lesion–recognizing proteins and the p53 connection. Boulikas T. **Anticancer Res** 1996 Jan–Feb;16(1):225–42 (187 ref.)
p53 and translational control. Ewen ME, et al. **Biochim Biophys Acta** 1996 Mar 18;1242(3):181–4 (48 ref.)
p53 in growth control and neoplasia. Gottlieb TM, et al. **Biochim Biophys Acta** 1996 Jun 7;1287(2–3):77–102 (357 ref.)
Signalling to p53: where does it all start? Kastan MB. **Bioessays** 1996 Aug;18(8):617–9 (28 ref.)
Biological and clinical importance of the p53 tumor suppressor gene. Velculescu VE, et al. **Clin Chem** 1996 Jun;42(6 Pt 1):858–68 (169 ref.)
Regulation of p53–dependent apoptosis by E1A and E1B. White E. **Curr Top Microbiol Immunol** 1995;199 (Pt 3):34–58 (103 ref.)
From telomere loss to p53 induction and activation of a DNA–damage pathway at senescence: the telomere loss/DNA damage model of cell aging. Vaziri H, et al. **Exp Gerontol** 1996 Jan–Apr;31(1–2):295–301 (42 ref.)
p53: puzzle and paradigm. Ko LJ, et al. **Genes Dev** 1996 May 1;10(9):1054–72 (245 ref.)
DNA damage, p53 and anticancer therapies. Milner J. **Nat Med** 1995 Sep;1(9):879–80 (8 ref.)
p53: DNA damage, DNA repair, and apoptosis. Götz C, et al. **Rev Physiol Biochem Pharmacol** 1996;127:65–95 (230 ref.)
[P53 protein and human papillomavirus oncogenes in carcinogenesis of the uterine cervix] Toledo–Cuevas EM, et al. **Rev Invest Clin** 1996 Jan–Feb;48(1):59–68 (42 ref.) (Eng. Abstr.) **(Spa)**

PROTEIN PHOSPHATASES see **PHOSPHOPROTEIN PHOSPHATASE**

PROTEIN PRECURSORS

see related
ENZYME PRECURSORS

ANALYSIS

[Early diagnosis of hepatocellular carcinoma by serum AFP and PIVKA–II analysis] Aoyagi Y, et al. **Nippon Naika Gakkai Zasshi** 1995 Dec 10;84(12):2003–7 (5 ref.) **(Jpn)**
[Clinical significance of the pre–S antigens and the binding activity of polymerized human serum albumin to the receptor on hepatitis B virus particles] Matsuura K, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:265–74 (26 ref.) **(Jpn)**

BIOSYNTHESIS

Proteolytic processing mechanisms in the biosynthesis of neuroendocrine peptides: the subtilisin–like proprotein convertases. Rouillé Y, et al. **Front Neuroendocrinol** 1995 Oct;16(4):322–61 (202 ref.)

CHEMISTRY

Molecular biology of neurohormone precursors in the eyestalk of Crustacea. De Kleijn DP, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1995 Dec; 112(4):573–9 (32 ref.)
Pro–sequence–assisted protein folding. Eder J, et al. **Mol Microbiol** 1995 May;16(4):609–14 (59 ref.)

GENETICS

Proenkephalin gene regulation in the neuroendocrine hypothalamus: a model of gene regulation in the CNS. Borsook D, et al. **Am J Physiol** 1995 Sep;269(3 Pt 1):E393–408 (203 ref.)
Transcriptional control of neuropeptide gene expression in sensory neurons, using the preprotachykinin–A gene as a model. Quinn JP, et al. **Can J Physiol Pharmacol** 1995 Jul; 73(7):957–62 (59 ref.)
[Mutations in precore and core nucleotide sequence of hepatitis B virus correlated with fulminant and severe hepatitis] Ehata T, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:457–62 (10 ref.) **(Jpn)**
[Precore/core mutation and clinical course of chronic hepatitis B virus infection from the view point of asymptomatic carriers] Fujiwara K, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:401–5 (20 ref.) **(Jpn)**
[Precore region mutation in anti–HBe antibody positive asymptomatic healthy carriers] Fukuda R. **Nippon Rinsho** 1995 Oct;53 Suppl:189–94 (16 ref.) **(Jpn)**
[Changes in precore and core region of hepatitis B virus during the course of chronic hepatitis B virus carriers] Hamasaki K, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:411–4 (9 ref.) **(Jpn)**
[Nucleotide mutations in the precore and core region of hepatitis B virus] Karasawa T, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:52–7 (20 ref.) **(Jpn)**
[Detection of HBV precore mutation by PCR–RFLP] Niitsuma H, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:316–20 (7 ref.) **(Jpn)**
[Mutant of the pre–S and S region of HBV] Nishikawa M, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:47–51 (15 ref.) **(Jpn)**
[Disorders of sphingolipid activator proteins] Suzuki Y. **Nippon Rinsho** 1995 Dec;53(12):3025–7 (14 ref.) (Eng. Abstr.) **(Jpn)**
[Mutation site–specific assay (MSSA) for the detection of hepatitis B virus precore defective mutant in hepatitis B infection] Tsubota A. **Nippon Rinsho** 1995 Oct;53 Suppl:321–4 (6 ref.) **(Jpn)**
[Possible roles of pre–S2 peptide in generation of chronic hepatitis B] Yamauchi K, et al. **Nippon Rinsho** 1995 Oct; 53 Suppl:144–7 (11 ref.) **(Jpn)**

IMMUNOLOGY

Advances toward the development of an asexual blood stage MSP–1 vaccine of Plasmodium vivax. Levitus G, et al. **Mem Inst Oswaldo Cruz** 1994;89 Suppl 2:81–4 (13 ref.)
[The potential attachment sites of hepatitis B virus to the hepatocyte—the pre–S(2) antigen and the receptor for polymerized human serum albumin of hepatitis B virus] Matsuura K, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:125–31 (25 ref.) **(Jpn)**

PROTEIN PRECURSORS

METABOLISM

Proenkephalin-processing enzymes in chromaffin granules: model for neuropeptide biosynthesis. Hook VY, et al. **Ann N Y Acad Sci** 1996 Mar 22;780:121-33 (22 ref.)

Sec-dependent preprotein translocation in bacteria. den Blaauwen T, et al. **Arch Microbiol** 1996 Jan;165(1):1-8 (73 ref.)

SecA, a novel ATPase that converts chemical energy into a mechanical force to drive precursor protein translocation. Driessen AJ, et al. **Biochem Soc Trans** 1995 Nov; 23(4):981-5 (32 ref.)

The genetics of lantibiotic biosynthesis. Jack R, et al. **Bioessays** 1995 Sep;17(9):793-802 (69 ref.)

Processing and intracellular targeting of prosomatostatin-derived peptides: the role of mammalian endoproteases. Patel YC, et al. **Ciba Found Symp** 1995; 190:26-40; discussion 40-50 (50 ref.)

Cytokine-processing enzymes. Stopping the cuts. Dinarello CA, et al. **Curr Biol** 1995 Jun 1;5(6):587-90 (34 ref.)

Furin/PACE/SPC1: a convertase involved in exocytic and endocytic processing of precursor proteins. Denault JB, et al. **FEBS Lett** 1996 Jan 29;379(2):113-6 (46 ref.)

Molecular role of sulfated glycoprotein-1 (SGP-1/prosaposin) in Sertoli cells. Morales CR, et al. **Histol Histopathol** 1995 Oct;10(4):1023-34 (11 ref.)

Prepilin-like molecules in type 4 pilus biogenesis: minor subunits, chaperones or mediators of organelle translocation? Koomey M. **Trends Microbiol** 1995 Nov; 3(11):409-10; discussion 411-3 (49 ref.)

[A family of Kex2-like endoproteases involved in processing of precursors for biologically active peptides and proteins] Nakayama K. **Seikagaku** 1995 Aug;67(8):995-1009 (95 ref.) **(Jpn)**

PHARMACOLOGY

T cell differentiation: control by the pre-TCR and alpha beta TCR. von Boehmer H. **Clin Immunol Immunopathol** 1995 Sep;76(3 Pt 2):S145-50 (47 ref.)

PHYSIOLOGY

Transgenic mice: preproenkephalin and the mu opiate receptor. Donovan DM, et al. **Ann N Y Acad Sci** 1996 Mar 22;780:19-28 (28 ref.)

Glucagon-like peptide-1 and control of insulin secretion. Thorens B. **Diabete Metab** 1995 Dec;21(5):311-8 (83 ref.)

Prothymosin alpha: in search of a function. Smith MR. **Leuk Lymphoma** 1995 Jul;18(3-4):209-14 (41 ref.)

PROTEIN PRENYLATION see **PROTEIN ISOPRENYLATION**

PROTEIN PROCESSING, POST-TRANSLATIONAL

Proteolytic processing of the arterivirus replicase. Snijder E, et al. **Adv Exp Med Biol** 1995;380:443-51 (28 ref.)

Regulation of APP processing by intra- and intercellular signals. Buxbaum JD, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:327-31 (17 ref.)

Proenkephalin-processing enzymes in chromaffin granules: model for neuropeptide biosynthesis. Hook VY, et al. **Ann N Y Acad Sci** 1996 Mar 22;780:121-33 (22 ref.)

Regulation of APP processing. Potential for the therapeutical reduction of brain amyloid burden. Nitsch RM, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:175-82 (28 ref.)

The role of APP processing and trafficking pathways in the formation of amyloid beta-protein. Selkoe DJ, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:57-64 (19 ref.)

Effects of taxol on the polymerization and posttranslational modification of class III beta-tubulin in P19 embryonal carcinoma cells. Laferrière NB, et al. **Biochem Cell Biol** 1995 Sep-Oct;73(9-10):687-94 (36 ref.)

Production and utilization of detyrosinated tubulin in developing Artemia larvae: evidence for a tubulin-reactive carboxypeptidase. Xiang H, et al. **Biochem Cell Biol** 1995 Sep-Oct;73(9-10):673-85 (82 ref.)

Chemical biology of protein isoprenylation/methylation. Rando RR. **Biochim Biophys Acta** 1996 Mar 29; 1300(1):5-16 (75 ref.)

ADP-ribosylation reactions in plants. O'Farrell M. **Biochimie** 1995;77(6):486-91 (54 ref.)

Thrombopoietin induces tyrosine phosphorylation of Stat3 and Stat5 in human blood platelets. Miyakawa Y, et al. **Blood** 1996 Jan 15;87(2):439-46 (36 ref.)

The molecular basis of paroxysmal nocturnal hemoglobinuria. Rosse WF, et al. **Blood** 1995 Nov 1;86(9):3277-86 (123 ref.)

Regulation of dynein-driven microtubule sliding by an axonemal kinase and phosphatase in Chlamydomonas flagella. Habermacher G, et al. **Cell Motil Cytoskeleton** 1995;32(2):106-9 (23 ref.)

Regulation of the Jak/STAT signalling pathway. Finbloom DS, et al. **Cell Signal** 1995 Nov;7(8):739-45 (49 ref.)

Phosphorylation of paired helical filament tau in Alzheimer's disease neurofibrillary lesions: focusing on phosphatases. Trojanowski JQ, et al. **FASEB J** 1995 Dec;9(15):1570-6 (77 ref.)

Furin/PACE/SPC1: a convertase involved in exocytic and endocytic processing of precursor proteins. Denault JB, et al. **FEBS Lett** 1996 Jan 29;379(2):113-6 (46 ref.)

N-glycosylation/deglycosylation as a mechanism for the post-translational modification/remodification of proteins. Suzuki T, et al. **Glycoconj J** 1995 Jun;12(3):183-93 (141 ref.)

Processing of the beta-amyloid precursor protein and its regulation in Alzheimer's disease. Checler F. **J Neurochem** 1995 Oct;65(4):1431-44 (101 ref.)

Protein phosphorylation and signal transduction. Barik S. **Subcell Biochem** 1996;26:115-64 (182 ref.)

Post-translational protein translocation: not all hsc70s are created equal. Brodsky JL. **Trends Biochem Sci** 1996 Apr; 21(4):122-6 (40 ref.)

[Processing of hepatitis C virus envelope proteins] Matsuura Y, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:51-6 (17 ref.) **(Jpn)**

[Mechanism of hepatitis C virus protein processing] Tanji Y, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:25-9 (12 ref.) **(Jpn)**

[Mechanisms of regulation and the biological role of carboxypeptidase H--a neuropeptide-processing enzyme] Vernigora AN, et al. **Biokhimiia** 1995 Dec;60(12):1953-63 (124 ref.) (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

Cytokine-processing enzymes. Stopping the cuts. Dinarello CA, et al. **Curr Biol** 1995 Jun 1;5(6):587-90 (34 ref.)

Intervention in receptor tyrosine kinase-mediated pathways: recombinant antibody fusion proteins targeted to ErbB2. Wels W, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 3):113-28 (47 ref.)

GENETICS

The genetics of lantibiotic biosynthesis. Jack R, et al. **Bioessays** 1995 Sep;17(9):793-802 (69 ref.)

PHYSIOLOGY

Angiotensin II signalling events mediated by tyrosine phosphorylation. Marrero MB, et al. **Cell Signal** 1996 Jan; 8(1):21-6 (30 ref.)

PROTEIN-RESTRICTED DIET see **DIET, PROTEIN-RESTRICTED**

PROTEIN S

ANALYSIS

[Protein S] Hayashi T, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:117-21 (18 ref.) **(Jpn)**

GENETICS

A review of mutations causing deficiencies of antithrombin, protein C and protein S. Aiach M, et al. **Thromb Haemost** 1995 Jul;74(1):81-9 (120 ref.)

METABOLISM

Inflammation. They're not just for clots anymore. Esmon CT. **Curr Biol** 1995 Jul 1;5(7):743-6 (15 ref.)

PROTEIN S DEFICIENCY

COMPLICATIONS

Portal and mesenteric thrombosis in protein S (pS) deficiency. Zigrossi P, et al. **Am J Gastroenterol** 1996 Jan;91(1):163-5 (11 ref.)

New molecular insights into the genetics of thrombophilia. Resistance to activated protein C caused by Arg506 to Gln mutation in factor V as a pathogenic risk factor for venous thrombosis. Dahlbäck B. **Thromb Haemost** 1995 Jul; 74(1):139-48 (112 ref.)

GENETICS

A review of mutations causing deficiencies of antithrombin, protein C and protein S. Aiach M, et al. **Thromb Haemost** 1995 Jul;74(1):81-9 (120 ref.)

PROTEIN-SERINE-THREONINE KINASES

ANTAGONISTS & INHIBITORS

Inhibitors of serine/threonine kinases. Lee JC, et al. **Curr Opin Biotechnol** 1995 Dec;6(6):657-61 (35 ref.)

BIOSYNTHESIS

Positive regulation of the nuclear activator CREM by the mitogen-induced p70 S6 kinase. de Groot RP, et al. **Immunobiology** 1995 Jul;193(2-4):155-60 (9 ref.)

CHEMISTRY

Structuring cell-cycle biology [comment] Levine K, et al. **Structure** 1995 Nov 15;3(11):1131-4 (52 ref.) Comment on: Structure 1995 Nov 15;3(11):1235-47.

How Ras works: structure of a Rap-Raf complex. Sprang SR. **Structure** 1995 Jul 15;3(7):641-3 (17 ref.)

GENETICS

DNA-dependent protein kinase defects are linked to deficiencies in DNA repair and V(D)J recombination. Finnie NJ, et al. **Philos Trans R Soc Lond B Biol Sci** 1996 Feb 29;351(1336):173-9 (50 ref.)

DNA double-strand break repair and V(D)J recombination: involvement of DNA-PK. Jackson SP, et al. **Trends Biochem Sci** 1995 Oct;20(10):412-5 (41 ref.)

METABOLISM

Protein serine/threonine kinases (PKA, PKC and CaMKII) involved in ischemic brain pathology. Domańska-Janik K. **Acta Neurobiol Exp (Warsz)** 1996;56(2):579-85 (44 ref.)

Microfilament dynamics: regulation of actin polymerization by actin-fragmin kinase and phosphatases. Waelkens E, et al. **Adv Enzyme Regul** 1995;35:199-227 (60 ref.)

Protein serine/threonine kinases of the MAPK cascade. Graves JD, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:320-43 (151 ref.)

Cell cycle regulation in Aspergillus by two protein kinases. Osmani SA, et al. **Biochem J** 1996 Aug 1;317 (Pt 3):633-41 (127 ref.)

Menage à trois: double strand break repair, V(D)J recombination and DNA-PK. Jeggo PA, et al. **Bioessays** 1995 Nov;17(11):949-57 (67 ref.)

Proteins of the 14-3-3 family associate with Raf and contribute to its activation. Freed E, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:187-93 (45 ref.)

Protein-protein interactions. Putting the pieces together. Bax B, et al. **Curr Biol** 1995 Oct 1;5(10):1119-21 (21 ref.)

Cell cycle. The NIMA kinase joins forces with Cdc2. Fry AM, et al. **Curr Biol** 1995 Oct 1;5(10):1122-5 (16 ref.)

Signaling via hetero-oligomeric complexes of type I and type II serine/threonine kinase receptors. ten Dijke P, et al. **Curr Opin Cell Biol** 1996 Apr;8(2):139-45 (58 ref.)

How do protein kinases discriminate between serine/threonine and tyrosine? Structural insights from the insulin receptor protein-tyrosine kinase. Taylor SS, et al. **FASEB J** 1995 Oct;9(13):1255-66 (41 ref.)

Protein kinases in the control of mitosis: focus on nucleocytoplasmic trafficking. Gallant P, et al. **J Cell Sci Suppl** 1995;19:21-8 (86 ref.)

Ras-Raf complexes: analyses of complexes formed in vivo. Finney R, et al. **Methods Enzymol** 1995;255:310-23 (24 ref.)

Interactions between Ras and Raf: key regulatory proteins in cellular transformation. Marshall M. **Mol Reprod Dev** 1995 Dec;42(4):493-9 (24 ref.)

Mechanisms regulating Raf-1 activity in signal transduction pathways. Morrison DK. **Mol Reprod Dev** 1995 Dec; 42(4):507-14 (27 ref.)

Networking with proline-directed protein kinases implicated in tau phosphorylation. Pelech SL. **Neurobiol Aging** 1995 May-Jun;16(3):247-56; discussion 257-61 (135 ref.)

A target for phosphoinositide 3-kinase: Akt/PKB. Bos JL. **Trends Biochem Sci** 1995 Nov;20(11):441-2 (11 ref.)

PHYSIOLOGY

CAK in TFIIH: crucial connection or confounding coincidence? Fisher RP, et al. **Biochim Biophys Acta** 1996 Aug 8;1288(1):O7-10 (51 ref.)

The 70 kDa S6 kinase: regulation of a kinase with multiple roles in mitogenic signalling. Chou MM, et al. **Curr Opin Cell Biol** 1995 Dec;7(6):806-14 (72 ref.)

The effect of c-raf antisense oligonucleotides on growth factor-induced proliferation of hematopoietic cells. Keller JR, et al. **Curr Top Microbiol Immunol** 1996;211:43-53 (25 ref.)

Positive regulation of the nuclear activator CREM by the mitogen-induced p70 S6 kinase. de Groot RP, et al. **Immunobiology** 1995 Jul;193(2-4):155-60 (9 ref.)

Regulatory properties of neuronal cdc2-like kinase. Qi Z, et al. **Mol Cell Biochem** 1995 Aug-Sep;149-150:35-9 (38 ref.)

Protein kinase D (PKD): a novel target for diacylglycerol and phorbol esters. Rozengurt E, et al. **Mutat Res** 1995 Dec;333(1-2):153-60 (47 ref.)

Feedback regulation of map kinase signal pathways. Errede B, et al. **Philos Trans R Soc Lond B Biol Sci** 1996 Feb 29;351(1336):143-8; discussion 148-9 (30 ref.)

Switching to Rac and Rho. Block C, et al. **Structure** 1995 Dec 15;3(12):1281-4 (30 ref.)

What to do at an end: DNA double-strand-break repair. Weaver DT. **Trends Genet** 1995 Oct;11(10):388-92 (51 ref.)

PROTEIN STRUCTURE, PRIMARY see **AMINO ACID SEQUENCE**

PROTEIN STRUCTURE, QUATERNARY see **PROTEIN CONFORMATION**

PROTEIN STRUCTURE, SECONDARY

Multi-helical DNA-binding domains: their structures and modes of DNA-binding. Suzuki M, et al. **Adv Biophys** 1996; 32:31-52 (88 ref.)

DNA conformation and its changes upon binding transcription factors. Suzuki M, et al. **Adv Biophys** 1996; 32:53-72 (47 ref.)

Fibronectin and cell adhesion: specificity of integrin-ligand interaction. Aota S, et al. **Adv Enzymol Relat Areas Mol Biol** 1995;70:1-21 (81 ref.)

Structure and function of the ion channel model system annexin V. Voges D, et al.

Adv Enzymol Relat Areas Mol Biol 1995;71:209–39 (144 ref.)
Structure and possible function of aspartic proteinases in barley and other plants. Kervinen J, et al. **Adv Exp Med Biol** 1995;362:241–54 (72 ref.)
Structural aspects of cytokine/receptor interactions. Nicola NA. **Ann N Y Acad Sci** 1995 Sep 7;766:253–62 (23 ref.)
The G protein-coupled receptor family and one of its members, the TSH receptor. Vassart G, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:23–30 (43 ref.)
Antagonistic mutant proteins of interleukin-4. Duschl A, et al. **Behring Inst Mitt** 1995 Jun;(96):87–94 (27 ref.)
Flavocytochrome b2: an ideal model system for studying protein-mediated electron transfer. Chapman SK, et al. **Biochem Soc Trans** 1996 Feb;24(1):73–7 (17 ref.)
Protein engineering of domains in flavoprotein disulphide oxidoreductases: contributions to folding and assembly. Perham RN, et al. **Biochem Soc Trans** 1996 Feb;24(1):61–6 (45 ref.)
Ion channel hypothesis for Alzheimer amyloid peptide neurotoxicity. Pollard HB, et al. **Cell Mol Neurobiol** 1995 Oct;15(5):513–26 (67 ref.)
Structure prediction. How good are we? Russell RB, et al. **Curr Biol** 1995 May 1;5(5):488–90 (23 ref.)
Helix design, prediction and stability. Muñoz V, et al. **Curr Opin Biotechnol** 1995 Aug;6(4):382–6 (59 ref.)
The emerging role of insertions and deletions in protein engineering. Shortle D, et al. **Curr Opin Biotechnol** 1995 Aug;6(4):387–93 (40 ref.)
Protein secondary structure prediction. Barton GJ. **Curr Opin Struct Biol** 1995 Jun;5(3):372–6 (39 ref.)
Native-like and structurally characterized designed alpha-helical bundles. Betz SF, et al. **Curr Opin Struct Biol** 1995 Aug;5(4):457–63 (34 ref.)
Folding of beta-sheet proteins. Carlsson U, et al. **Curr Opin Struct Biol** 1995 Aug;5(4):482–7 (51 ref.)
The role of potassium channels in excitable cells. Edwards G, et al. **Diabetes Res Clin Pract** 1995 Aug;28 Suppl:S57–66 (37 ref.)
Energised (entatic) states of groups and of secondary structures in proteins and metalloproteins. Williams RJ. **Eur J Biochem** 1995 Dec 1;234(2):363–81 (76 ref.)
On the role of extracellular loops of opioid receptors in conferring ligand selectivity. Metzger TG, et al. **FEBS Lett** 1995 Nov 13;375(1-2):1–4 (21 ref.)
Predicted structure and possible ionmotive mechanism of the sodium-linked NADH-ubiquinone oxidoreductase of Vibrio alginolyticus. Rich PR, et al. **FEBS Lett** 1995 Nov 13;375(1-2):5–10 (42 ref.)
A model for DNA polymerase translocation: worm-like movement of DNA within the binding cleft. Wlassoff WA, et al. **FEBS Lett** 1996 Jul 15;390(1):6–9 (37 ref.)
Transmembrane domains participate in functions of integral membrane proteins. Ramasarma T. **Indian J Biochem Biophys** 1996 Feb;33(1):20–9 (25 ref.)
Electron transfer in ruthenium-modified proteins. Bjerrum MJ, et al. **J Bioenerg Biomembr** 1995 Jun;27(3):295–302 (39 ref.)
Pathways, pathway tubes, pathway docking, and propagators in electron transfer proteins. Curry WB, et al. **J Bioenerg Biomembr** 1995 Jun;27(3):285–93 (65 ref.)
Electron transfer from cytochrome b5 to cytochrome c. Durham B, et al. **J Bioenerg Biomembr** 1995 Jun; 27(3):331–40 (52 ref.)
Experimental and theoretical analysis of the interaction between cytochrome c and cytochrome b5. Mauk AG, et al. **J Bioenerg Biomembr** 1995 Jun;27(3):311–30 (78 ref.)
Electron transfer between cytochrome c and cytochrome c peroxidase. Millett F, et al. **J Bioenerg Biomembr** 1995 Jun; 27(3):341–51 (53 ref.)
The structural basis of the myosin ATPase activity [see comments] Rayment I. **J Biol Chem** 1996 Jul 5; 271(27):15850–3 (44 ref.) Comment in: J Biol Chem 1996 Jul 5;271(27):15849.
Development of drug resistance to HIV-1 protease inhibitors. Ridky T, et al. **J Biol Chem** 1995 Dec 15;270(50):29621–3 (28 ref.)
Chemical signaling in ciliates. Luporini P, et al. **J Eukaryot Microbiol** 1995 May-Jun;42(3):208–12 (30 ref.)
The nerve growth factor/tumor necrosis factor receptor family. Lotz M, et al. **J Leukoc Biol** 1996 Jul;60(1):1–7 (91 ref.)
What is the orientation of DNA polymerases on their templates? Hughes SH, et al. **J Virol** 1996 May; 70(5):2679–83 (34 ref.)
Repair, refold, recycle: how bacteria can deal with spontaneous and environmental damage to proteins. Visick JE, et al. **Mol Microbiol** 1995 Jun;16(5):835–45 (124 ref.)
Structural domains of P450-containing monooxygenase systems. Degtyarenko KN. **Protein Eng** 1995 Aug; 8(8):737–47 (119 ref.)
hSRY: molecular gender bender. Bramham J, et al. **Structure** 1995 Jul 15;3(7):631–3 (19 ref.)
Counting the calories to stay in the groove. Ladbury JE. **Structure** 1995 Jul 15;3(7):635–9 (21 ref.)
Unraveling transposition: gamma delta resolvase in complex with DNA. Mondragón A. **Structure** 1995 Aug 15; 3(8):755–8 (16 ref.)
How Ras works: structure of a Rap-Raf complex. Sprang SR. **Structure** 1995 Jul 15;3(7):641–3 (17 ref.)
Viral envelope glycoproteins swing into action. Stuart D, et al. **Structure** 1995 Jul 15;3(7):645–8 (27 ref.)
The S100 family of EF-hand calcium-binding proteins: functions and pathology. Schäfer BW, et al. **Trends Biochem Sci** 1996 Apr;21(4):134–40 (29 ref.)

PROTEIN STRUCTURE, TERTIARY

NADPH-P-450 reductase: structural and functional comparisons of the eukaryotic and prokaryotic isoforms. Sevrioukova IF, et al. **Biochimie** 1995;77(7-8):562–72 (59 ref.)
Protein-protein interfaces: architectures and interactions in protein-protein interfaces and in protein cores. Their similarities and differences. Tsai CJ, et al. **Crit Rev Biochem Mol Biol** 1996 Apr;31(2):127–52 (50 ref.)
Integrin-ligand binding. Do integrins use a 'MIDAS touch' to grasp an Asp? Bergelson JM, et al. **Curr Biol** 1995 Jun 1;5(6):615–7 (15 ref.)
Origins of replication and the nuclear matrix: the DHFR domain as a paradigm. Dijkwel PA, et al. **Int Rev Cytol** 1995;162A:455–84 (180 ref.)
Structural organization of transcription termination factor Rho. Richardson JP. **J Biol Chem** 1996 Jan 19; 271(3):1251–4 (50 ref.)

PROTEIN TP53 see PROTEIN P53

PROTEIN-TYROSINE KINASE

see related

SRC HOMOLOGY DOMAINS

The JAK-STAT pathway: summary of initial studies and recent advances. Darnell JE Jr. **Recent Prog Horm Res** 1996;51:391–403; discussion 403–4 (75 ref.)
The Janus protein tyrosine kinases in hematopoietic cytokine signaling. Ihle JN. **Semin Immunol** 1995 Aug;7(4):247–54 (57 ref.)
Abl tyrosine protein kinase. Laneuville P. **Semin Immunol** 1995 Aug;7(4):255–66 (95 ref.)
The Btk subfamily of cytoplasmic tyrosine kinases: structure, regulation and function. Rawlings DJ, et al. **Semin Immunol** 1995 Aug;7(4):237–46 (81 ref.)
[Src family of protein-tyrosine kinases and their regulator tyrosine kinase, Csk] Okada M. **Seikagaku** 1996 Apr; 68(4):251–64 (94 ref.) **(Jpn)**

ANTAGONISTS & INHIBITORS

Signal transduction interception as a novel approach to disease management. Levitzki A. **Ann N Y Acad Sci** 1995 Sep 7;766:363–8 (22 ref.)
Inhibitors of protein tyrosine kinases. Fry DW, et al. **Curr Opin Biotechnol** 1995 Dec;6(6):662–7 (37 ref.)
Protein tyrosine kinase inhibitors. Groundwater PW, et al. **Prog Med Chem** 1996;33:233–329 (277 ref.)
[Advances in the research on tyrosine protein kinase inhibitors] Pang SH, et al. **Yao Hsueh Hsueh Pao** 1996; 31(1):75–80 (43 ref.) **(Chi)**
[Inhibitors of protein-tyrosine kinases: pharmacological perspectives? (editorial)] Jacquemin-Sablon A, et al. **Pathol Biol (Paris)** 1995 May;43(5):389–94 (66 ref.) **(Fre)**

CHEMISTRY

Why two heads are better. Mayer BJ. **Structure** 1995 Oct 15;3(10):977–80 (27 ref.)

DEFICIENCY

Syk deficiency--a knockout for B-cell development. Harnett M. **Immunol Today** 1996 Jan;17(1):4 (6 ref.)

GENETICS

Putting the bits and pieces of the RET proto-oncogene puzzle together. Gagel RF. **Bone** 1995 Aug;17(2 Suppl):13S–16S (30 ref.)
The spectrum of mutations in Btk that cause X-linked agammaglobulinemia. Conley ME, et al. **Clin Immunol Immunopathol** 1995 Sep;76(3 Pt 2):S192–7 (33 ref.)
Molecular and genetic insights into the role of protein tyrosine kinases in T cell receptor signaling. Weiss A. **Clin Immunol Immunopathol** 1995 Sep;76(3 Pt 2):S158–62 (30 ref.)
Genetic approaches to defining signaling by the CML-associated tyrosine kinase BCR-ABL. Afar DE, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:589–94 (49 ref.)
Locoregional immuno-chemotherapy transplenic and transtumoral in vivo immunostimulation. Lygidakis NJ, et al. **Hepatogastroenterology** 1996 Mar-Apr;43(8):440–7 (38 ref.)
Induction of lytic pathways in T cell clones derived from wild-type or protein tyrosine kinase Fyn mutant mice. Lancki DW, et al. **Immunol Rev** 1995 Aug;146:117–44 (56 ref.)
BTKbase: a database of XLA-causing mutations. International Study Group. Vihinen M, et al. **Immunol Today** 1995 Oct;16(10):460–5 (39 ref.)
[Does the c-ets 1 oncogene participate in the regulation of tumor angiogenesis?] Vandenbunder B, et al. **Arch Inst Pasteur Tunis** 1994 Jul-Oct;71(3-4):493–509 (56 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Protein tyrosine kinases in the initiation of antigen receptor signaling. Bolen JB. **Curr Opin Immunol** 1995 Jun; 7(3):306–11 (54 ref.)
Cytokine receptor signaling mechanisms. Karnitz LM, et al. **Curr Opin Immunol** 1995 Jun;7(3):320–6 (60 ref.)

METABOLISM

Cytokine signal transduction through a homo- or heterodimer of gp130. Kishimoto T, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:224–34 (22 ref.)
Signal transduction mediated by the T-cell antigen receptor. Samelson LE, et al. **Ann N Y Acad Sci** 1995 Sep 7; 766:157–72 (68 ref.)
IL-2 signaling involves recruitment and activation of multiple protein tyrosine kinases by the IL-2 receptor. Taniguchi T, et al. **Ann N Y Acad Sci** 1995 Sep 7; 766:235–44 (22 ref.)
Molecular and genetic insights into T-cell antigen receptor signaling. Weiss A, et al. **Ann N Y Acad Sci** 1995 Sep 7; 766:149–56 (39 ref.)
Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Schindler C, et al. **Annu Rev Biochem** 1995;64:621–51 (145 ref.)
Integrin-mediated signaling in normal and malignant cells: a role of protein tyrosine kinases. Malik RK, et al. **Biochim Biophys Acta** 1996 Jun 7;1287(2-3):73–6 (61 ref.)
Thrombopoietin induces tyrosine phosphorylation of Stat3 and Stat5 in human blood platelets. Miyakawa Y, et al. **Blood** 1996 Jan 15;87(2):439–46 (36 ref.)
Convergent signalling in the action of integrins, neuropeptides, growth factors and oncogenes. Rozengurt E. **Cancer Surv** 1995;24:81–96 (49 ref.)
Intracellular signalling. Switching off signals. Imboden JB, et al. **Curr Biol** 1995 Jul 1;5(7):727–9 (12 ref.)
Integrin-mediated signalling: regulation by protein tyrosine kinases and small GTP-binding proteins. Parsons JT. **Curr Opin Cell Biol** 1996 Apr;8(2):146–52 (47 ref.)
Nuclear tyrosine kinases: from Abl to WEE1. Pendergast AM. **Curr Opin Cell Biol** 1996 Apr;8(2):174–81 (46 ref.)
Protein tyrosine phosphatases in signaling. Streuli M. **Curr Opin Cell Biol** 1996 Apr;8(2):182–8 (81 ref.)
Early events in neurotrophin signalling via Trk and p75 receptors. Greene LA, et al. **Curr Opin Neurobiol** 1995 Oct;5(5):579–87 (72 ref.)
pp125FAK in the focal adhesion. Otey CA. **Int Rev Cytol** 1996;167:161–83 (85 ref.)
The focal adhesion kinase. Schaller MD. **J Endocrinol** 1996 Jul;150(1):1–7 (88 ref.)
SH2 and SH3 domains: potential targets for anti-cancer drug design. Smithgall TE. **J Pharmacol Toxicol Methods** 1995 Nov;34(3):125–32 (52 ref.)
Tyrosine kinases in megakaryocytopoiesis. Avraham H, et al. **Stem Cells (Dayt)** 1995 Jul;13(4):380–92 (141 ref.)
Why two heads are better. Mayer BJ. **Structure** 1995 Oct 15;3(10):977–80 (27 ref.)
Recognition and specificity in protein tyrosine kinase-mediated signalling. Zhou S, et al. **Trends Biochem Sci** 1995 Nov;20(11):470–5 (46 ref.)

PHYSIOLOGY

The Janus protein tyrosine kinase family and its role in cytokine signaling. Ihle JN. **Adv Immunol** 1995;60:1–35 (230 ref.)
The role of Bruton's tyrosine kinase in B-cell development and function in mice and man. Khan WN, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:27–38 (36 ref.)
A combined genetic and biochemical approach to mammalian signal transduction. Della NG, et al. **Aust N Z J Med** 1995 Dec;25(6):845–51 (36 ref.)
The cbl oncogene: a novel substrate of protein tyrosine kinases. Langdon WY. **Aust N Z J Med** 1995 Dec; 25(6):859–64 (19 ref.)
Regulation of the Jak/STAT signalling pathway. Finbloom DS, et al. **Cell Signal** 1995 Nov;7(8):739–45 (49 ref.)
Regulation of phospholipase D by tyrosine kinases. Natarajan V, et al. **Chem Phys Lipids** 1996 May 24;80(1-2):103–16 (156 ref.)
Nonreceptor protein tyrosine kinase involvement in signal transduction and immunodeficiency disease. Saouaf SJ, et al. **Clin Immunol Immunopathol** 1995 Sep;76(3 Pt 2):S151–7 (65 ref.)
Molecular and genetic insights into the role of protein tyrosine kinases in T cell receptor signaling. Weiss A. **Clin Immunol Immunopathol** 1995 Sep;76(3 Pt 2):S158–62 (30 ref.)
The Jak-STAT pathway: specific signal transduction from the cell membrane to the nucleus. Heim MH. **Eur J Clin Invest** 1996 Jan;26(1):1–12 (133 ref.)
Knockouts of Src-family kinases: stiff bones, wimpy T cells, and bad memories. Lowell CA, et al. **Genes Dev** 1996 Aug 1;10(15):1845–57 (111 ref.)
Role of tyrosine kinases in lymphocyte activation: targets for drug intervention. Hanke JH, et al. **Inflamm Res** 1995 Sep;44(9):357–71 (190 ref.)
Cytokine receptor signalling through two novel families of transducer molecules: Janus kinases, and signal transducers and activators of transcription. Finidori J, et al. **J Endocrinol** 1995 Oct;147(1):11–23 (117 ref.)
Fak and focal adhesions. Martin GM. **Jpn J Cancer Res** 1996 Mar;87(3):inside front cover (34 ref.)

PROTEIN-TYROSINE KINASE

The function of src family tyrosine kinases in hematopoietic cells. Xu Y, et al. **Leuk Res** 1996 Mar;20(3):229–34 (60 ref.)
Tyrosine kinase–mediated signal transduction pathways and the actions of polypeptide growth factors and G-protein–coupled agonists in smooth muscle. Hollenberg MD. **Mol Cell Biochem** 1995 Aug–Sep;149–150:77–85 (77 ref.)
Protein tyrosine phosphorylation in cardiovascular system. Srivastava AK. **Mol Cell Biochem** 1995 Aug–Sep; 149–150:87–94 (90 ref.)
JAKs, STATs and signal transduction in response to the interferons and other cytokines. Briscoe J, et al. **Philos Trans R Soc Lond B Biol Sci** 1996 Feb 29; 351(1336):167–71 (12 ref.)
Janus kinases in cytokine signalling. Ihle JN. **Philos Trans R Soc Lond B Biol Sci** 1996 Feb 29; 351(1336):159–66 (120 ref.)
Molecular mechanism of T-cell activation: role of protein tyrosine kinases in antigen receptor–mediated signal transduction. Thome M, et al. **Res Immunol** 1995 May–Jun; 146(4–5):291–307 (104 ref.)
The Syk/ZAP-70 protein tyrosine kinase connection to antigen receptor signalling processes. van Oers NS, et al. **Semin Immunol** 1995 Aug;7(4):227–36 (71 ref.)

PROTEIN-TYROSINE-PHOSPHATASE

CHEMISTRY

Structure and catalytic properties of protein tyrosine phosphatases. Dixon JE. **Ann N Y Acad Sci** 1995 Sep 7; 766:18–22 (16 ref.)
Protein tyrosine phosphatases take off. Barford D, et al. **Nat Struct Biol** 1995 Dec;2(12):1043–53 (80 ref.)

IMMUNOLOGY

Regulation of immune function by protein tyrosine phosphatases. Okumura M, et al. **Curr Opin Immunol** 1995 Jun;7(3):312–9 (101 ref.)

METABOLISM

Structure and catalytic properties of protein tyrosine phosphatases. Dixon JE. **Ann N Y Acad Sci** 1995 Sep 7; 766:18–22 (16 ref.)
Intracellular signalling. Switching off signals. Imboden JB, et al. **Curr Biol** 1995 Jul 1;5(7):727–9 (12 ref.)

PHYSIOLOGY

Roles of protein-tyrosine phosphatases in growth factor signalling. Matozaki T, et al. **Cell Signal** 1996 Jan;8(1):13–9 (67 ref.)
Prote'n tyrosine phosphatases as adhesion receptors. Brady-Kalnay SM, et al. **Curr Opin Cell Biol** 1995 Oct; 7(5):650–7 (58 ref.)
Protein tyrosine phosphatases take off. Barford D, et al. **Nat Struct Biol** 1995 Dec;2(12):1043–53 (80 ref.)
PY in the fly receptor–like tyrosine phosphatases in axonal pathfinding. Chien CB. **Neuron** 1996 Jun;16(6):1065–8 (17 ref.)
Protein tyrosine phosphatases: their roles in signal transduction. Dixon JE. **Recent Prog Horm Res** 1996; 51:405–14; discussion 415 (31 ref.)
Positive and negative regulation of leukocyte activation by protein tyrosine phosphatases. Thomas ML. **Semin Immunol** 1995 Aug;7(4):279–88 (85 ref.)

PROTEINASE INHIBITORS see **PROTEASE INHIBITORS**

PROTEINASES see **PEPTIDE PEPTIDOHYDROLASES**

PROTEINS

see related
AMINO ACID SEQUENCE
BLOOD PROTEINS
PROTEIN CONFORMATION

Bone morphogenetic protein-2: biology and applications. Riley EH, et al. **Clin Orthop** 1996 Mar;(324):39–46 (70 ref.)
Tissue expression, structure and function of the murine Ly-6 family of molecules. Gumley TP, et al. **Immunol Cell Biol** 1995 Aug;73(4):277–96 (111 ref.)
The Janus protein tyrosine kinases in hematopoietic cytokine signaling. Ihle JN. **Semin Immunol** 1995 Aug;7(4):247–54 (57 ref.)
[14–3–3; a novel protein family which regulates intracellular signaling] Ichimura T, et al. **Seikagaku** 1995 Sep; 67(9):1156–62 (27 ref.) **(Jpn)**
[Measurements of density and partial specific volume] Gekko K. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(16):2461–5 (11 ref.) **(Jpn)**
[Circular dichroism of proteins: recent developments in analysis and prediction] Woody RW, et al. **Tanpakushitsu Kakusan Koso** 1996 Jan;41(1):56–69 (120 ref.) **(Jpn)**
[Heterogeneity of GTPase–activating proteins for Ras in the regulation of Ras signal transduction pathway] Hattori S, et al. **Yakugaku Zasshi** 1996 Jan;116(1):21–38 (58 ref.) (Eng. Abstr.) **(Jpn)**
[Establishment of fundamentals for protein research. Stabilization of protein] Imoto T. **Yakugaku Zasshi** 1996 Apr;116(4):259–65 (20 ref.) (Eng. Abstr.) **(Jpn)**

ADMINISTRATION & DOSAGE

Biodegradable polymers for protein and peptide drug delivery. Gombotz WR, et al. **Bioconjug Chem** 1995 Jul–Aug;6(4):332–51 (234 ref.)
Protein and amino acids in nutritional support. McNurlan MA, et al. **Crit Care Clin** 1995 Jul;11(3):635–50 (114 ref.)
Role of angiotensin in the regulation of renal response to proteins. Gabbai FB, et al. **Semin Nephrol** 1995 Sep; 15(5):396–404 (56 ref.)

ADVERSE EFFECTS

Chemicals and proteins as allergens and adjuvants. Kapsenberg ML. **Toxicol Lett** 1996 Aug;86(2–3):79–83 (30 ref.)

ANALYSIS

Bioanalytical mass spectrometry: many flavors to choose [editorial] Loo JA. **Bioconjug Chem** 1995 Nov–Dec; 6(6):644–65 (262 ref.)
Mass spectrometric approaches for the identification of gel-separated proteins. Patterson SD, et al. **Electrophoresis** 1995 Oct;16(10):1791–814 (202 ref.)
Capillary isoelectric focusing as a tool in the examination of antibodies, peptides and proteins of pharmaceutical interest. Liu X, et al. **J Chromatogr A** 1996 May 31; 735(1–2):165–90 (72 ref.)
[Protein 1 (Clara cell 10 kDa protein)] Itoh Y, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:150–3 (10 ref.) **(Jpn)**
[Parathyroid hormone–related protein (PTHrP)] Watanabe K, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:397–400 (12 ref.) **(Jpn)**
[Plasma–desorption mass spectrometry of natural compounds. 1. Basic properties of the method and its use for analyzing proteins and peptides] Reztsova NA, et al. **Bioorg Khim** 1996 Jan;22(1):3–13 (141 ref.) (Eng. Abstr.) **(Rus)**

BIOSYNTHESIS

The humoral hypercalcemia of benignancy. A newly appreciated syndrome [see comments] Knecht TP, et al. **Am J Clin Pathol** 1996 Apr;105(4):487–92 (42 ref.) Comment in: Am J Clin Pathol 1996 Apr;105(4):377–9.
Protein synthesis in eukaryotic organisms: new insights into the function of translation initiation factor eIF-3. Hannig EM. **Bioessays** 1995 Nov;17(11):915–9 (49 ref.)
For protein misassembly, it's the "I" decade. Wetzel R. **Cell** 1996 Sep 6;86(5):699–702 (20 ref.)
Peptide ligation and semisynthesis. Wallace CJ. **Curr Opin Biotechnol** 1995 Aug;6(4):403–10 (45 ref.)
The role of coat proteins in the biosynthesis of secretory proteins. Salama NR, et al. **Curr Opin Cell Biol** 1995 Aug; 7(4):536–43 (54 ref.)
Sonic hedgehog: a common signal for ventral patterning along the rostrocaudal axis of the neural tube. Ericson J, et al. **Int J Dev Biol** 1995 Oct;39(5):809–16 (45 ref.)
A case of acute lymphoblastic leukemia accompanied with the production of parathyroid hormone–related protein. Harutsumi M, et al. **Miner Electrolyte Metab** 1995; 21(1–3):171–6 (24 ref.)
Parathyroid hormone–related peptide in hypercalcemia associated with adult T cell leukemia/lymphoma: molecular and cellular mechanism of parathyroid hormone–related peptide overexpression in HTLV-I–infected T cells. Ikeda K, et al. **Miner Electrolyte Metab** 1995;21(1–3):166–70 (36 ref.)
Secretogranin II: molecular properties, regulation of biosynthesis and processing to the neuropeptide secretoneurin. Fischer-Colbrie R, et al. **Prog Neurobiol** 1995 May;46(1):49–70 (209 ref.)
Strategies for production of pharmaceutical proteins in milk. Wilmut I, et al. **Reprod Fertil Dev** 1994;6(5):625–30 (51 ref.)
Reassessing the manipulation of protein synthesis by rumen microbes. Broudiscou L, et al. **Reprod Nutr Dev** 1995; 35(5):517–35 (144 ref.)

CHEMICAL SYNTHESIS

Peptide ligation and semisynthesis. Wallace CJ. **Curr Opin Biotechnol** 1995 Aug;6(4):403–10 (45 ref.)
A chemical approach to the construction of multimeric protein assemblies. Muir TW. **Structure** 1995 Jul 15; 3(7):649–52 (18 ref.)

CHEMISTRY

Logarithmic growth in surface adsorption. Nygren H. **Adv Colloid Interface Sci** 1995 Dec 1;62(2–3):137–59 (71 ref.)
Enthalpic contribution to protein stability: insights from atom–based calculations and statistical mechanics. Lazaridis T, et al. **Adv Protein Chem** 1995;47:231–306 (129 ref.)
Energetics of protein structure. Makhatadze GI, et al. **Adv Protein Chem** 1995;47:307–425 (338 ref.)
Molten globule and protein folding. Ptitsyn OB. **Adv Protein Chem** 1995;47:83–229 (423 ref.)
Prediction of human immunodeficiency virus protease cleavage sites in proteins. Chou KC. **Anal Biochem** 1996 Jan 1;233(1):1–14 (62 ref.)
The multiplicity of domains in proteins. Doolittle RF. **Annu Rev Biochem** 1995;64:287–314 (237 ref.)
Protein crystallography in Australia. Parker MW. **Aust N Z J Med** 1995 Dec;25(6):876–82 (40 ref.)
The lipocalin protein family: structure and function. Flower DR. **Biochem J** 1996 Aug 15;318 (Pt 1):1–14 (149 ref.)
14–3–3 proteins: biological function and domain structure. Aitken A, et al. **Biochem Soc Trans** 1995 Aug;23(3):605–11 (47 ref.)
Understanding and increasing protein stability. Fágáin CO. **Biochim Biophys Acta** 1995 Sep 27;1252(1):1–14 (126 ref.)
Biological electron transfer: structural and mechanistic studies. Canters GW, et al. **Biochimie** 1995;77(7–8):506–15 (87 ref.)
Principles of protein–protein recognition from structure to thermodynamics. Janin J. **Biochimie** 1995;77(7–8):497–505 (43 ref.)
Recent developments in the theory of protein folding: searching for the global energy minimum. Scheraga HA. **Biophys Chem** 1996 Apr 16;59(3):329–39 (102 ref.)
Prediction of protein structural classes. Chou KC, et al. **Crit Rev Biochem Mol Biol** 1995;30(4):275–349 (104 ref.)
Structures of protein complexes by multidimensional heteronuclear magnetic resonance spectroscopy. Gronenborn AM, et al. **Crit Rev Biochem Mol Biol** 1995; 30(5):351–85 (156 ref.)
Characterization of protein glycosylation by mass spectrometry. Burlingame AL. **Curr Opin Biotechnol** 1996 Feb;7(1):4–10 (78 ref.)
Local sequence–structure correlations in proteins. Bystroff C, et al. **Curr Opin Biotechnol** 1996 Aug;7(4):417–21 (37 ref.)
Sequence 'minimization': exploring the sequence landscape with simplified sequences. Clarke ND. **Curr Opin Biotechnol** 1995 Aug;6(4):467–72 (19 ref.)
Evidence on close packing and cavities in proteins. Hubbard SJ, et al. **Curr Opin Biotechnol** 1995 Aug;6(4):375–81 (75 ref.)
Theoretical approaches to designing novel sequences to fit a given fold. Jones DT. **Curr Opin Biotechnol** 1995 Aug; 6(4):452–9 (50 ref.)
Interfacial metal-binding site design. Matthews DJ. **Curr Opin Biotechnol** 1995 Aug;6(4):419–24 (49 ref.)
The current state of the art in protein structure prediction. Moult J. **Curr Opin Biotechnol** 1996 Aug;7(4):422–7 (36 ref.)
Helix design, prediction and stability. Muñoz V, et al. **Curr Opin Biotechnol** 1995 Aug;6(4):382–6 (59 ref.)
Pitfalls of protein sequence analysis. Rost B, et al. **Curr Opin Biotechnol** 1996 Aug;7(4):457–61 (12 ref.)
Engineering thermostability: lessons from thermophilic proteins. Russell RJ, et al. **Curr Opin Biotechnol** 1995 Aug; 6(4):370–4 (22 ref.)
Modeling mutations and homologous proteins. Sali A. **Curr Opin Biotechnol** 1995 Aug;6(4):437–51 (222 ref.)
The role of protein–solvent interactions in protein unfolding. Schiffer CA, et al. **Curr Opin Biotechnol** 1996 Aug; 7(4):428–32 (58 ref.)
Protein complexes studied by NMR spectroscopy. Wand AJ, et al. **Curr Opin Biotechnol** 1996 Aug;7(4):403–8 (100 ref.)
Circular assemblies. Antson AA, et al. **Curr Opin Struct Biol** 1996 Apr;6(2):142–50 (41 ref.)
Modeling protein–ligand complexes. Bamborough P, et al. **Curr Opin Struct Biol** 1996 Apr;6(2):236–41 (54 ref.)
Protein secondary structure prediction. Barton GJ. **Curr Opin Struct Biol** 1995 Jun;5(3):372–6 (39 ref.)
Epitaxial growth of protein crystals from two–dimensional crystals on lipid layers. Darst SA, et al. **Curr Opin Struct Biol** 1995 Oct;5(5):640–4 (58 ref.)
Structure–derived potentials and protein simulations. Jernigan RL, et al. **Curr Opin Struct Biol** 1996 Apr; 6(2):195–209 (92 ref.)
Potential energy functions for threading. Jones DT, et al. **Curr Opin Struct Biol** 1996 Apr;6(2):210–6 (40 ref.)
Statistical significance of sequence patterns in proteins. Karlin S. **Curr Opin Struct Biol** 1995 Jun;5(3):360–71 (47 ref.)
Field gradient techniques in NMR spectroscopy. Kay LE. **Curr Opin Struct Biol** 1995 Oct;5(5):674–81 (58 ref.)
Proteins with leucine–rich repeats. Kobe B, et al. **Curr Opin Struct Biol** 1995 Jun;5(3):409–16 (53 ref.)
Seeking significance in three–dimensional protein structure comparisons. Mizuguchi K, et al. **Curr Opin Struct Biol** 1995 Jun;5(3):377–82 (43 ref.)
Freeze trapping of reaction intermediates. Moffat K, et al. **Curr Opin Struct Biol** 1995 Oct;5(5):656–63 (57 ref.)
Genetic algorithms for protein structure prediction. Pedersen JT, et al. **Curr Opin Struct Biol** 1996 Apr;6(2):227–31 (40 ref.)
Calorimetry of proteins and nucleic acids. Plum GE, et al. **Curr Opin Struct Biol** 1995 Oct;5(5):682–90 (71 ref.)
Ab initio phase determination and phase extension using non–crystallographic symmetry. Rossmann MG. **Curr Opin Struct Biol** 1995 Oct;5(5):650–5 (51 ref.)
The use of hydrostatic pressure as a tool to study viruses and other macromolecular assemblages. Silva JL, et al. **Curr Opin Struct Biol** 1996 Apr;6(2):166–75 (79 ref.)
Matrix–assisted laser desorption/ionization mass spectrometry (MALDI–MS). Stults JT. **Curr Opin Struct Biol** 1995 Oct;5(5):691–8 (120 ref.)
Surface plasmon resonance and its use in biomolecular

interaction analysis (BIA). Szabo A, et al. **Curr Opin Struct Biol** 1995 Oct;5(5):699–705 (38 ref.)
Modeling side–chain conformation. Vásquez M. **Curr Opin Struct Biol** 1996 Apr;6(2):217–21 (53 ref.)
Automated analysis of nuclear magnetic resonance assignments for proteins. Zimmerman DE, et al. **Curr Opin Struct Biol** 1995 Oct;5(5):664–73 (65 ref.)
The molecular biology of multidomain proteins. Selected examples. Hawkins AR, et al. **Eur J Biochem** 1995 Aug 15;232(1):7–18 (147 ref.)
Chemical techniques employed for the primary structural analysis of proteins and peptides. Inglis AS, et al. **EXS** 1995;73:141–71 (73 ref.)
Towards prediction of cognate complexes between the WW domain and proline–rich ligands. Einbond A, et al. **FEBS Lett** 1996 Apr 8;384(1):1–8 (53 ref.)
Exploring the nucleotide–binding site in proteins by affinity labeling and site–directed mutagenesis. Fukui T. **J Biochem (Tokyo)** 1995 Jun;117(6):1139–44 (45 ref.)
Pathways, pathway tubes, pathway docking, and propagators in electron transfer proteins. Curry WB, et al. **J Bioenerg Biomembr** 1995 Jun;27(3):285–93 (65 ref.)
Biological electron transfer. Moser CC, et al. **J Bioenerg Biomembr** 1995 Jun;27(3):263–74 (70 ref.)
Fluorescence resonance energy transfer spectroscopy is a reliable "ruler" for measuring structural changes in proteins. Dispelling the problem of the unknown orientation factor. dos Remedios CG, et al. **J Struct Biol** 1995 Sep–Oct; 115(2):175–85 (48 ref.)
Role of oxidized amino acids in protein breakdown and stability. Stadtman ER. **Methods Enzymol** 1995;258:379–93 (56 ref.)
Crystallography in the study of protein–DNA interactions. Brown DG, et al. **Methods Mol Biol** 1996;56:293–318 (109 ref.)
Density modification in x–ray crystallography. Podjarny AD, et al. **Methods Mol Biol** 1996;56:205–26 (88 ref.)
Crystallographic methods and protocols. Introduction. Sanderson MR. **Methods Mol Biol** 1996;56:1–21 (70 ref.)
Overexpression, isolation, and crystallization of proteins. Skelly JV, et al. **Methods Mol Biol** 1996;56:23–53 (85 ref.)
Refinement of protein and nucleic acid structures. Westhof E, et al. **Methods Mol Biol** 1996;56:227–44 (39 ref.)
Wresting the muscle from mussel beards: research and applications. Rzepecki LM, et al. **Mol Mar Biol Biotechnol** 1995 Dec;4(4):313–22 (45 ref.)
Structural information on proteins from circular dichroism spectroscopy possibilities and limitations. Bloemendal M, et al. **Pharm Biotechnol** 1995;7:65–100 (112 ref.)
Fourier transform infrared spectroscopy investigations of protein structure. Cooper EA, et al. **Pharm Biotechnol** 1995; 7:101–43 (114 ref.)
Application of fluorescence spectroscopy for determining the structure and function of proteins. Jiskoot W, et al. **Pharm Biotechnol** 1995;7:1–63 (185 ref.)
Thermodynamic strategies for rational protein and drug design. Murphy KP, et al. **Pharm Biotechnol** 1995;7:219–41 (57 ref.)
Mass spectrometry in protein structural analysis. Roepstorff P. **Pharm Biotechnol** 1995;7:145–77 (79 ref.)
Two–, three–, and four–dimensional nuclear magnetic resonance spectroscopy of protein pharmaceuticals. Vander Velde DG, et al. **Pharm Biotechnol** 1995;7:179–218 (186 ref.)
Protein minimization: downsizing through mutation. DeGrado WF, et al. **Proc Natl Acad Sci U S A** 1996 Jun 11;93(12):5680–1 (19 ref.)
Principles of protein–protein interactions. Jones S, et al. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):13–20 (47 ref.)
Pulsed field gradient multi–dimensional NMR methods for the study of protein structure and dynamics in solution. Kay LE. **Prog Biophys Mol Biol** 1995;63(3):277–99 (80 ref.)
Thermal diffuse X–ray scattering and its contribution to understanding protein dynamics. Thüne T, et al. **Prog Biophys Mol Biol** 1995;63(3):251–76 (60 ref.)
3D domain swapping: a mechanism for oligomer assembly. Bennett MJ, et al. **Protein Sci** 1995 Dec;4(12):2455–68 (67 ref.)
Side–chain conformational entropy in protein folding. Doig AJ, et al. **Protein Sci** 1995 Nov;4(11):2247–51 (31 ref.)
High pressure effects on protein structure and function. Mozhaev VV, et al. **Proteins** 1996 Jan;24(1):81–91 (56 ref.)
Diffuse scattering in protein crystallography. Benoit JP, et al. **Q Rev Biophys** 1995 May;28(2):131–69 (92 ref.)
The "bio" in biochemistry: protein folding inside and outside the cell [comment] Ellis RJ. **Science** 1996 Jun 7; 272(5267):1448–9 (10 ref.) Comment on: Science 1996 Jun 7;272(5267):1497–502.
Mapping the protein universe. Holm L, et al. **Science** 1996 Aug 2;273(5275):595–603 (36 ref.)
Supported membranes: scientific and practical applications. Sackmann E. **Science** 1996 Jan 5;271(5245):43–8 (40 ref.)
Counting the calories to stay in the groove. Ladbury JE. **Structure** 1995 Jul 15;3(7):635–9 (21 ref.)
The science of macromolecular crystallization. McPherson A, et al. **Structure** 1995 Aug 15;3(8):759–68 (90 ref.)
14–3–3 proteins: structure resolved, functions less clear. Marais R, et al. **Structure** 1995 Aug 15;3(8):751–3 (18 ref.)
A chemical approach to the construction of multimeric protein assemblies. Muir TW. **Structure** 1995 Jul 15; 3(7):649–52 (18 ref.)
Weighing the evidence for structure: electrospray ionization mass spectrometry of proteins. Robinson CV, et al. **Structure** 1995 Sep 15;3(9):861–5 (19 ref.)
DNA repair in three dimensions. Pearl LH, et al. **Trends Biochem Sci** 1995 Oct;20(10):421–6 (32 ref.)
How the molten globule became. Ptitsyn OB. **Trends Biochem Sci** 1995 Sep;20(9):376–9 (43 ref.)
[Advanced mass spectrometry in biochemical sciences] Ohashi Y. **Seikagaku** 1995 Nov;67(11):1295–301 (14 ref.) **(Jpn)**
[14–3–3 protein family: the structure and function in cell signaling pathway] Shinkai F, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(4):313–26 (53 ref.) **(Jpn)**
[Surface potential energy of peptides and conformation of amino acid residues in proteins. Preliminary results of processing using databank protein structures] Basharov MA. **Biofizika** 1995 Mar–Apr;40(2):260–73 (50 ref.) (Eng. Abstr.) **(Rus)**
[The role of disulfide bridges of the residual protein in chromosomal DNA organization] Struchkov VA, et al. **Biofizika** 1995 Mar–Apr;40(2):296–316 (96 ref.) (Eng. Abstr.) **(Rus)**
[Comparison of three–dimensional structures of flexible protein molecules] Andreeva NS, et al. **Mol Biol (Mosk)** 1995 Sep–Oct;29(5):1102–13 (31 ref.) **(Rus)**
[Dolichol–coupled biosynthesis of an oligosaccharide precursor for N–glycosylated proteins in the rough endoplasmic reticulum] Shpakov AO. **Ukr Biokhim Zh** 1995 Mar–Apr;67(2):3–17 (87 ref.) (Eng. Abstr.) **(Rus)**

CLASSIFICATION

Prediction of protein structural classes. Chou KC, et al. **Crit Rev Biochem Mol Biol** 1995;30(4):275–349 (104 ref.)

GENETICS

Molecular cloning of the von Hippel–Lindau tumor suppressor gene and its role in renal carcinoma. Gnarra JR, et al. **Biochim Biophys Acta** 1996 Mar 18;1242(3):201–10 (60 ref.)
Selenium and cellular immunity. Evidence that selenoproteins may be encoded in the +1 reading frame overlapping the human CD4, CD8, and HLA–DR genes. Taylor EW. **Biol Trace Elem Res** 1995 Aug–Sep;49(2–3):85–95 (37 ref.)
Von Hippel–Lindau disease and sporadic renal cell carcinoma. Zbar B. **Cancer Surv** 1995;25:219–32 (32 ref.)
The bond between sisters [comment] Sekelsky JJ, et al. **Cell** 1995 Oct 20;83(2):157–60 (23 ref.) Comment on: Cell 1995 Oct 20;83(2):247–56.
Transcriptional control and the regulation of endocrine genes. Zajac JD, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22(12):935–43 (68 ref.)
Cancer predisposition. Ataxia–telangiectasia at the crossroads. Jackson SP. **Curr Biol** 1995 Nov 1;5(11):1210–2 (13 ref.)
Mx transgenic mice—animal models of health. Arnheiter H, et al. **Curr Top Microbiol Immunol** 1996;206:119–47 (88 ref.)
Protein families in the metazoan genome. Chothia C. **Dev Suppl** 1994;:27–33 (41 ref.)
The accessory gland proteins in male Drosophila: structural, reproductive, and evolutionary aspects. Chen PS. **Experientia** 1996 Jun 15;52(6):503–10 (69 ref.)
Forensic applications of genetic polymorphisms detected in human body fluids (urine, semen and blood). Kishi K, et al. **Forensic Sci Int** 1996 Jun 28;80(1–2):89–97 (55 ref.)
The ATM gene and the radiobiology of ataxia–telangiectasia. Jorgensen TJ, et al. **Int J Radiat Biol** 1996 May; 69(5):527–37 (104 ref.)
Lymphocyte development and function in T–cell receptor and RAG–1 mutant mice. Mombaerts P. **Int Rev Immunol** 1995;13(1):43–63 (23 ref.)
Evolutionary recruitment of biochemically specialized subdivisions of Family I within the protein superfamily of aminotransferases. Jensen RA, et al. **J Bacteriol** 1996 Apr; 178(8):2161–71 (68 ref.)
Parathyroid hormone–related protein gene expression and human T cell leukemia virus–1 infection. Ejima E, et al. **Miner Electrolyte Metab** 1995;21(1–3):143–7 (53 ref.)
Identification of a gene for autosomal dominant polycystic kidney disease: implications for understanding the pathogenesis and treatment of the disease. Harris PC. **Nephrol Dial Transplant** 1996 Feb;11(2):258–62 (60 ref.)
period and timeless tango: a dance of two clock genes. Reppert SM, et al. **Neuron** 1995 Nov;15(5):983–6 (23 ref.)
Modular cis–regulatory organization of developmentally expressed genes: two genes transcribed territorially in the sea urchin embryo, and additional examples. Kirchhamer CV, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3; 93(18):9322–8 (67 ref.)
The expanding world of trinucleotide repeats [comment] Warren ST. **Science** 1996 Mar 8;271(5254):1374–5 (7 ref.) Comment on: Science 1996 Mar 8;271(5254):1423–7.
Protein splicing: self–splicing of genetically mobile elements at the protein level. Cooper AA, et al. **Trends Biochem Sci** 1995 Sep;20(9):351–6 (33 ref.)
Cellular responses to DNA damage: cell–cycle checkpoints, apoptosis and the roles of p53 and ATM. Enoch T, et al. **Trends Biochem Sci** 1995 Oct;20(10):426–30 (45 ref.)
The ataxia–telangiectasia gene: a link between checkpoint controls, neurodegeneration and cancer. Lehmann AR, et al. **Trends Genet** 1995 Oct;11(10):375–7 (23 ref.)
[Leptin—a peptide hormone from adipocytes. Sensation of the 23rd FEBS Meeting] Pankov IuA. **Bioorg Khim** 1996 Mar;22(3):228–33 (13 ref.) (Eng. Abstr.) **(Rus)**

IMMUNOLOGY

Interferons, Mx genes, and resistance to influenza virus. Horisberger MA. **Am J Respir Crit Care Med** 1995 Oct; 152(4 Pt 2):S67–71 (56 ref.)
Predicting major histocompatibility complex–binding sequences within protein antigens. Sinigaglia F, et al. **Biochem Soc Trans** 1995 Aug;23(3):675–7 (18 ref.)
New methods to predict MHC–binding sequences within protein antigens. Hammer J. **Curr Opin Immunol** 1995 Apr; 7(2):263–9 (60 ref.)

ISOLATION & PURIFICATION

Chromatography in the downstream processing of biotechnological products. Freitag R, et al. **Adv Biochem Eng Biotechnol** 1996;53:17–59 (383 ref.)
Protein purification in the nineties. Scopes RK. **Biotechnol Appl Biochem** 1996 Jun;23 (Pt 3):197–204 (10 ref.)
Expanded bed chromatography and radial flow column chromatography: the approaches for adsorption chromatography of biomolecules on industrial scale. Ambedkar SS, et al. **Hindustan Antibiot Bull** 1994 Aug–Nov;36(3–4):164–72 (22 ref.)
Developments and newer approaches in downstream processing of biopharmaceuticals. Chatterjee NR, et al. **Hindustan Antibiot Bull** 1994 Aug–Nov;36(3–4):78–97 (66 ref.)
New trends in downstream processing of biotechnological products. Patkar AY, et al. **Hindustan Antibiot Bull** 1994 Aug–Nov;36(3–4):141–56 (64 ref.)
Proteins and protein assemblies. Epstein HF, et al. **Methods Cell Biol** 1995;48:437–50 (23 ref.)
Chromatographic techniques for the characterization of proteins. Holthuis JJ, et al. **Pharm Biotechnol** 1995;7:243–99 (144 ref.)
Capillary electrophoresis of proteins. van de Goor TA. **Pharm Biotechnol** 1995;7:301–27 (103 ref.)
[An ambient and low temperature two–dimensional electrophoresis: a convenient way to detect cold–dissociable proteins] Matsuo T. **Tanpakushitsu Kakusan Koso** 1995 Sep;40(12):1867–70 (7 ref.) **(Jpn)**

METABOLISM

Heparan sulphate and protein recognition. Binding specificities and activation mechanisms. Gallagher JT. **Adv Exp Med Biol** 1995;376:125–34 (33 ref.)
The role of the Opaque2 transcriptional factor in the regulation of protein accumulation and amino acid metabolism in maize seeds. Yunes JA, et al. **An Acad Bras Cienc** 1994;66 Su 1 (Pt 2):227–37; quiz 237–8 (60 ref.)
Prediction of human immunodeficiency virus protease cleavage sites in proteins. Chou KC. **Anal Biochem** 1996 Jan 1;233(1):1–14 (62 ref.)
Carbohydrate–protein interactions in vascular biology. Nelson RM, et al. **Ann Rev Cell Dev Biol** 1995;11:601–31 (185 ref.)
Protein–RNA recognition. Draper DE. **Annu Rev Biochem** 1995;64:593–620 (183 ref.)
Whole–body protein turnover in humans—past, present, and future. Waterlow JC. **Annu Rev Nutr** 1995;15:57–92 (171 ref.)
Roles of ubiquitinylation in proteolysis and cellular regulation. Wilkinson KD. **Annu Rev Nutr** 1995;15:161–89 (136 ref.)
Exocytosis: proteins and perturbations. Augustine GJ, et al. **Annu Rev Pharmacol Toxicol** 1996;36:659–701 (273 ref.)
The nutritional significance of endogenous N–losses along the gastro–intestinal tract of farm animals. Tamminga S, et al. **Arch Tierernahr** 1995;48(1–2):9–22 (44 ref.)
The MARCKS family of protein kinase–C substrates. Aderem A. **Biochem Soc Trans** 1995 Aug;23(3):587–91 (31 ref.)
Subcellular targeting of kinases and phosphatases by association with bifunctional anchoring proteins. Coghlan VM, et al. **Biochem Soc Trans** 1995 Aug;23(3):592–6 (40 ref.)
Dynamic protein acylation and the regulation of localization and function of signal–transducing proteins. Jackson CS, et al. **Biochem Soc Trans** 1995 Aug;23(3):568–71 (40 ref.)
The secretory pathway: mechanisms of protein sorting and transport. Harter C, et al. **Biochim Biophys Acta** 1996 Jun 10;1286(2):75–93 (276 ref.)
Transport of proteins across membranes—a paradigm in transition. Isenman L, et al. **Biochim Biophys Acta** 1995 Dec 20;1241(3):341–70 (207 ref.)
Ribosomal 5S RNA: tertiary structure and interactions with proteins. Barciszewska MZ, et al. **Biol Rev Camb Philos Soc** 1996 Feb;71(1):1–25 (135 ref.)
Poly(alpha–hydroxy acids): carriers for bone morphogenetic proteins. Hollinger JO, et al. **Biomaterials** 1996 Jan; 17(2):187–94 (101 ref.)
Peptide–surface association: the case of PDZ and PTB domains. Harrison SC. **Cell** 1996 Aug 9;86(3):341–3 (17 ref.)
Protein degradation or regulation: Ub the judge. Hochstrasser M. **Cell** 1996 Mar 22;84(6):813–5 (15 ref.)

Selective protein degradation: a journey's end within the proteasome. Jentsch S, et al. **Cell** 1995 Sep 22;82(6):881–4 (22 ref.)

Osmotic effects of water compartments in protein polymers. Lew VL, et al. **Cell Biochem Funct** 1995 Sep;13(3):173–6 (15 ref.)

Proteins of the 14–3–3 family associate with Raf and contribute to its activation. Freed E, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:187–93 (45 ref.)

Storage proteins in ants (Hymenoptera:Formicidae). Wheeler DE, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1995 Sep;112(1):15–9 (41 ref.)

Crosslines, fluorophores in the AGE–related cross–linked proteins. Ienaga K, et al. **Contrib Nephrol** 1995;112:42–51 (14 ref.)

Proteins abnormally filtered throughout glomerular capillary have an intrinsic renal toxicity. Remuzzi G, et al. **Contrib Nephrol** 1996;118:164–72 (66 ref.)

Formation of methylglyoxal–modified proteins in vitro and in vivo and their involvement in AGE–related processes. Thornalley PJ, et al. **Contrib Nephrol** 1995;112:24–31 (31 ref.)

Protein–protein interactions. Putting the pieces together. Bax B, et al. **Curr Biol** 1995 Oct 1;5(10):1119–21 (21 ref.)

Molecular chaperones. Resurrection or destruction? Horwich AL. **Curr Biol** 1995 May 1;5(5):455–8 (26 ref.)

Protein translocation: nuclear export—out of the dark. Moore MS. **Curr Biol** 1996 Feb 1;6(2):137–40 (20 ref.)

Proteolysis. The proteasome: a protein–degrading organelle? Rubin DM, et al. **Curr Biol** 1995 Aug 1;5(8):854–8 (32 ref.)

Genetic and biochemical dissection of the mitochondrial protein–import machinery. Kübrich M, et al. **Curr Genet** 1995 Apr;27(5):393–403 (110 ref.)

Current computational tools for de novo ligand design. Böhm HJ. **Curr Opin Biotechnol** 1996 Aug;7(4):433–6 (61 ref.)

Quality control in the secretory pathway. Hammond C, et al. **Curr Opin Cell Biol** 1995 Aug;7(4):523–9 (98 ref.)

Biogenesis of mitochondrial proteins. Lill R, et al. **Curr Opin Cell Biol** 1996 Aug;8(4):505–12 (62 ref.)

Approaching the mechanism of protein transport across the ER membrane. Rapoport TA, et al. **Curr Opin Cell Biol** 1996 Aug;8(4):499–504 (53 ref.)

Convergence of model systems for peroxisome biogenesis. Subramani S. **Curr Opin Cell Biol** 1996 Aug;8(4):513–8 (52 ref.)

Regulation of protein metabolism during stress. Matthews DE, et al. **Curr Opin Gen Surg** 1993;:72–7 (45 ref.)

Uremic acidosis and protein metabolism. Mitch WE. **Curr Opin Nephrol Hypertens** 1995 Nov;4(6):488–92 (41 ref.)

Stretch–induced parathyroid hormone–related peptide gene expression: implication in the regulation of myogenic tone. Noda M, et al. **Curr Opin Nephrol Hypertens** 1995 Sep; 4(5):383–7 (23 ref.)

Abnormal protein traffic through the glomerular barrier induces proximal tubular cell dysfunction and causes renal injury [editorial] Remuzzi G. **Curr Opin Nephrol Hypertens** 1995 Jul;4(4):339–42 (20 ref.)

Proteins that interact with the pore–forming subunits of voltage–gated ion channels. Adelman JP. **Curr Opin Neurobiol** 1995 Jun;5(3):286–95 (83 ref.)

Molecular chaperones in protein folding and translocation. Clarke AR. **Curr Opin Struct Biol** 1996 Feb;6(1):43–50 (73 ref.)

Mechanisms and uses of hydrogen exchange. Englander SW, et al. **Curr Opin Struct Biol** 1996 Feb;6(1):18–23 (92 ref.)

RNA–protein complexes. Nagai K. **Curr Opin Struct Biol** 1996 Feb;6(1):53–61 (60 ref.)

Engineering new functions and altering existing functions. Shao Z, et al. **Curr Opin Struct Biol** 1996 Aug;6(4):513–8 (52 ref.)

Characterization of the first enzyme in 2,4–dichlorophenoxyacetic acid metabolism. Hausinger RP, et al. **Environ Health Perspect** 1995 Jun;103 Suppl 5:37–9 (8 ref.)

Translational control of eukaryotic gene expression. Role of the guanine nucleotide exchange factor and chain initiation factor–2. Singh LP, et al. **Enzyme Protein** 1994–95; 48(2):61–80 (101 ref.)

The molecular biology of multidomain proteins. Selected examples. Hawkins AR, et al. **Eur J Biochem** 1995 Aug 15;232(1):7–18 (147 ref.)

Von Hippel–Lindau tumor suppressor protein and transcription elongation: new insights into regulation of gene expression. Bertherat J. **Eur J Endocrinol** 1996 Feb; 134(2):137, 159 (2 ref.)

Synthesis, modifications, and turnover of proteins during aging. Rattan SI. **Exp Gerontol** 1996 Jan–Apr;31(1–2):33–47 (88 ref.)

Protein sorting signals: simple peptides with complex functions. von Heijne G. **EXS** 1995;73:67–76 (57 ref.)

Endosomal proteolysis of internalized proteins. Authier F, et al. **FEBS Lett** 1996 Jun 24;389(1):55–60 (55 ref.)

Protein import into the nucleus. Schlenstedt G. **FEBS Lett** 1996 Jun 24;389(1):75–9 (89 ref.)

Prediction of ruminal volatile fatty acids and pH within the net carbohydrate and protein system. Pitt RE, et al. **J Anim Sci** 1996 Jan;74(1):226–44 (126 ref.)

Pathways, pathway tubes, pathway docking, and propagators in electron transfer proteins. Curry WB, et al. **J Bioenerg Biomembr** 1995 Jun;27(3):285–93 (65 ref.)

Biological electron transfer. Moser CC, et al. **J Bioenerg Biomembr** 1995 Jun;27(3):263–74 (70 ref.)

Oligosaccharides containing beta 1,4–linked N–acetylgalactosamine, a paradigm for protein–specific glycosylation. Manzella SM, et al. **J Biol Chem** 1996 May 24;271(21):12117–20 (54 ref.)

Roles of molecular chaperones in protein degradation. Hayes SA, et al. **J Cell Biol** 1996 Feb;132(3):255–8 (24 ref.)

Computational methods to predict binding free energy in ligand–receptor complexes. Murcko A, et al. **J Med Chem** 1995 Dec 22;38(26):4953–67 (90 ref.)

The renal toxicity of sustained glomerular protein traffic. Benigni A, et al. **Lab Invest** 1995 Oct;73(4):461–8 (78 ref.)

Vanadium–protein interactions. Chasteen ND. **Met Ions Biol Syst** 1995;31:231–47 (68 ref.)

Use of vanadate–induced photocleavage for detecting phosphate binding sites in proteins. Muhlrad A, et al. **Met Ions Biol Syst** 1995;31:211–30 (65 ref.)

The interaction trap: in vivo analysis of protein–protein associations. Shirley BW, et al. **Methods Cell Biol** 1995; 49:401–16 (27 ref.)

Role of oxidized amino acids in protein breakdown and stability. Stadtman ER. **Methods Enzymol** 1995;258:379–93 (56 ref.)

Crystallography in the study of protein–DNA interactions. Brown DG, et al. **Methods Mol Biol** 1996;56:293–318 (109 ref.)

Impaired proteolytic activity as a potential cause of progressive renal disease. Heidland A, et al. **Miner Electrolyte Metab** 1996;22(1–3):157–61 (52 ref.)

Metabolic acidosis stimulates protein metabolism in uremia. Mitch WE. **Miner Electrolyte Metab** 1996;22(1–3):62–5 (20 ref.)

Protein transport via amino–terminal targeting sequences: common themes in diverse systems. Rusch SL, et al. **Mol Membr Biol** 1995 Oct–Dec;12(4):295–307 (175 ref.)

Guanine nucleotide exchange factors: activators of Ras superfamily proteins. Overbeck AF, et al. **Mol Reprod Dev** 1995 Dec;42(4):468–76 (32 ref.)

The fates of proteins in cells. Bohley P. **Naturwissenschaften** 1995 Dec;82(12):544–50 (112 ref.)

Nutrition, lysosomal proteases, and protein breakdown [see comments] Andreu AL, et al. **Nutrition** 1995 Jul–Aug; 11(4):382–7 (66 ref.) Comment in: Nutrition 1995 Jul–Aug;11(4):398.

Influence of acidosis on protein metabolism. Ballmer PE, et al. **Nutrition** 1995 Sep–Oct;11(5):462–8; discussion 470 (66 ref.)

Does DG42 synthesize hyaluronan or chitin?: A controversy about oligosaccharides in vertebrate development. Varki A. **Proc Natl Acad Sci U S A** 1996 May 14;93(10):4523–5 (53 ref.)

Effects of exercise training in the elderly: impact of progressive– resistance training on skeletal muscle and whole–body protein metabolism. Fielding RA. **Proc Nutr Soc** 1996 Nov;54(3):665–75 (58 ref.)

The protein machinery of vesicle budding and fusion. Rothman JE. **Protein Sci** 1996 Feb;5(2):185–94 (92 ref.)

Protein thiol modification and apoptotic cell death as cGMP–independent nitric oxide (NO) signaling pathways. Brüne B, et al. **Rev Physiol Biochem Pharmacol** 1996; 127:1–30 (105 ref.)

Cation–pi interactions in chemistry and biology: a new view of benzene, Phe, Tyr, and Trp. Dougherty DA. **Science** 1996 Jan 12;271(5246):163–8 (66 ref.)

Nucleocytoplasmic transport. Görlich D, et al. **Science** 1996 Mar 15;271(5255):1513–8 (77 ref.)

Protein sorting by transport vesicles. Rothman JE, et al. **Science** 1996 Apr 12;272(5259):227–34 (86 ref.)

Common principles of protein translocation across membranes. Schatz G, et al. **Science** 1996 Mar 15; 271(5255):1519–26 (60 ref.)

Coat proteins and vesicle budding. Schekman R, et al. **Science** 1996 Mar 15;271(5255):1526–33 (83 ref.)

Glomerular protein trafficking and progression of renal disease to terminal uremia. Benigni A, et al. **Semin Nephrol** 1996 May;16(3):151–9 (85 ref.)

Organic acids and the uremic syndrome: protein metabolite hypothesis in the progression of chronic renal failure. Niwa T. **Semin Nephrol** 1996 May;16(3):167–82 (204 ref.)

14–3–3 proteins: structure resolved, functions less clear. Marais R, et al. **Structure** 1995 Aug 15;3(8):751–3 (18 ref.)

Inositol pentakis– and hexakisphosphate metabolism adds versatility to the actions of inositol polyphosphates. Novel effects on ion channels and protein traffic. Shears SB. **Subcell Biochem** 1996;26:187–226 (181 ref.)

Glycosomes—the organelles of glycogen metabolism. Rybicka KK. **Tissue Cell** 1996 Jun;28(3):253–65 (63 ref.)

Monitoring of human exposure to carcinogens through DNA and protein adduct determination. Farmer PB. **Toxicol Lett** 1995 Dec;82–83:757–62 (24 ref.)

Ornithine decarboxylase antizyme: a novel type of regulatory protein. Hayashi S, et al. **Trends Biochem Sci** 1996 Jan; 21(1):27–30 (47 ref.)

The use of phage display in neurobiology. Bradbury A, et al. **Trends Neurosci** 1995 Jun;18(6):243–9 (63 ref.)

[Protein–carbohydrate recognition. Foundation and medical application with illustrations of tumor lectin studies] Gabius HJ, et al. **Naturwissenschaften** 1995 Dec;82(12):533–43 (162 ref.) (Eng. Abstr.) **(Ger)**

[Fundamental aspects of osteoinductive activity of bone tissue and potential clinical application] Aldinger G, et al. **Z Orthop Ihre Grenzgeb** 1996 May–Jun;134(3):205–9 (22 ref.) (Eng. Abstr.) **(Ger)**

[Protein translocation machinery—how far it has been elucidated by membrane reconstitution approach] Watanabe M. **Seikagaku** 1995 Dec;67(12):1401–6 (18 ref.) **(Jpn)**

[COP–coated vesicles in intracellular protein transport] Kuge O, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec; 40(16):2427–35 (39 ref.) **(Jpn)**

[Interaction of free radicals with proteins] Skrzydlewska E, et al. **Postepy Hig Med Dosw** 1995;49(6):747–66 (92 ref.) (Eng. Abstr.) **(Pol)**

[The hormone leptin reduces body weight. A mutant gene makes the mouse obese] Meister B, et al. **Lakartidningen** 1996 Jan 24;93(4):247–51 (18 ref.) (Eng. Abstr.) **(Swe)**

PHARMACOLOGY

Gonadotrophin surge–inhibiting/attenuating factor governs luteinizing hormone secretion during the ovarian cycle: physiology and pathology. de Koning J. **Hum Reprod** 1995 Nov;10(11):2854–61 (86 ref.)

Histogranin, a modified histone H4 fragment endowed with N–methyl–D–aspartate antagonist and immunostimulatory activities. Lemaire S, et al. **Life Sci** 1995 Mar 3; 56(15):1233–41 (34 ref.)

Signal transduction mechanisms of parathyroid hormone– and parathyroid hormone–related–peptide–stimulated osteoclast–like cell formation from hemopoietic blast cells. Sugimoto T, et al. **Miner Electrolyte Metab** 1995; 21(1–3):161–5 (22 ref.)

PHYSIOLOGY

Cartilage–derived morphogenetic proteins. Key regulators in chondrocyte differentiation? Luyten FP. **Acta Orthop Scand Suppl** 1995 Oct;266:51–4 (22 ref.)

BMP signaling in Drosophila embryogenesis. Arora K, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:80–97 (68 ref.)

The role of BMPs and GDFs in development of region–specific skeletal structures. King JA, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:70–9 (56 ref.)

Signaling pathways in skeletal formation: a role for BMP receptors. Rosen V, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:59–69 (45 ref.)

14–3–3 proteins: biological function and domain structure. Aitken A, et al. **Biochem Soc Trans** 1995 Aug;23(3):605–11 (47 ref.)

BMP–1 and the astacin family of metalloproteinases: a potential link between the extracellular matrix, growth factors and pattern formation. Sarras MP Jr. **Bioessays** 1996 Jun;18(6):439–42 (26 ref.)

Serpentine proteins slither into the wingless and hedgehog fields. Perrimon N. **Cell** 1996 Aug 23;86(4):513–6 (19 ref.)

Osteogenic protein–1: biology and applications. Cook SD, et al. **Clin Orthop** 1996 Mar;(324):29–38 (45 ref.)

Regulation of bone formation by bone morphogenetic proteins and other growth factors. Mundy GR. **Clin Orthop** 1996 Mar;(324):24–8 (25 ref.)

Parathyroid hormone–related protein. Moseley JM, et al. **Crit Rev Clin Lab Sci** 1995;32(3):299–343 (295 ref.)

Somite differentiation. Sonic signals somites. Bumcrot DA, et al. **Curr Biol** 1995 Jun 1;5(6):612–4 (13 ref.)

Morphogenetic signalling. Responses to hedgehog. Kalderon D. **Curr Biol** 1995 Jun 1;5(6):580–2 (15 ref.)

Signalling by hedgehog family proteins in Drosophila and vertebrate development. Ingham PW. **Curr Opin Genet Dev** 1995 Aug;5(4):492–8 (67 ref.)

Natriuretic peptides and hypertension. Prins BA, et al. **Curr Opin Nephrol Hypertens** 1996 Mar;5(2):170–3 (29 ref.)

Maspin: a tumor suppressing serpin. Sager R, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 1):51–64 (14 ref.)

The nature and function of putative gonadotropin surge–attenuating/inhibiting factor (GnSAF/IF). Fowler PA, et al. **Endocr Rev** 1996 Apr;17(2):103–20 (240 ref.)

Discovery and clinical applications of bone morphogenetic proteins. Vukičević S, et al. **Eur J Clin Chem Clin Biochem** 1995 Oct;33(10):661–71 (81 ref.)

Parathyroid hormone–related protein: a polyhormone involved in growth, development and gestation [comment] Rizzoli R, et al. **Eur J Endocrinol** 1995 Sep;133(3):272–4 (35 ref.) Comment on: Eur J Endocrinol 1995 Sep;133(3):278–83.

Prohibitin and the senescent phenotype. Dell'Orco RT, et al. **Exp Gerontol** 1996 Jan–Apr;31(1–2):245–52 (46 ref.)

Prohibitin: potential role in senescence, development, and tumor suppression. McClung JK, et al. **Exp Gerontol** 1995 Mar–Apr;30(2):99–124 (90 ref.)

The accessory gland proteins in male Drosophila: structural, reproductive, and evolutionary aspects. Chen PS. **Experientia** 1996 Jun 15;52(6):503–10 (69 ref.)

Genomes with distinct function composition. Tamames J, et al. **FEBS Lett** 1996 Jun 24;389(1):96–101 (13 ref.)

Bone morphogenetic proteins: multifunctional regulators of vertebrate development. Hogan BL. **Genes Dev** 1996 Jul 1;10(13):1580–94 (160 ref.)

Functions of proteins secreted by oviduct epithelial cells. Gandolfi F. **Microsc Res Tech** 1995 Sep 1;32(1):1–12 (133 ref.)

Parathyroid hormone–related peptide and models of vascular disease: its expression and action in vascular smooth muscle

cells. Nishizawa Y, et al. **Miner Electrolyte Metab** 1995; 21(1-3):152-6 (36 ref.)

Application of fluorescence spectroscopy for determining the structure and function of proteins. Jiskoot W, et al. **Pharm Biotechnol** 1995;7:1-63 (185 ref.)

Defining the roles of parathyroid hormone-related protein in normal physiology. Philbrick WM, et al. **Physiol Rev** 1996 Jan;76(1):127-73 (293 ref.)

Secretogranin II: molecular properties, regulation of biosynthesis and processing to the neuropeptide secretoneurin. Fischer-Colbrie R, et al. **Prog Neurobiol** 1995 May;46(1):49-70 (209 ref.)

Parathyroid hormone-related protein. An analog of parathyroid hormone involved in regulation of growth, development, and gestation [editorial] Rizzoli R. **Rev Rhum Engl Ed** 1996 Feb;63(2):79-82 (40 ref.)

Relationship of the ataxia-telangiectasia protein ATM to phosphoinositide 3-kinase. Lavin MF, et al. **Trends Biochem Sci** 1995 Oct;20(10):382-3 (22 ref.)

[Leptin--a new way to diet?] Holst JJ. **Ugeskr Laeger** 1996 Aug 5;158(32):4505-8 (25 ref.) (Eng. Abstr.) **(Dan)**

[Parathyroid hormone related peptide (PTHrP) and bone metabolism] Rouffet J, et al. **Arch Physiol Biochem** 1995 Apr;103(1):3-13 (76 ref.) (Eng. Abstr.) **(Fre)**

[Induction of an additional limb by FGF and duplication of digits by Sonic hedgehog] Ohuchi H, et al. **Seikagaku** 1995 Oct;67(10):1232-6 (16 ref.) **(Jpn)**

[14-3-3 protein family: the structure and function in cell signaling pathway] Shinkai F, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(4):313-26 (53 ref.) **(Jpn)**

[Interactions of proteins with damaged DNA] Widłak P. **Postepy Biochem** 1995;41(3):195-200 (71 ref.) **(Pol)**

SECRETION

Functions of proteins secreted by oviduct epithelial cells. Gandolfi F. **Microsc Res Tech** 1995 Sep 1;32(1):1-12 (133 ref.)

STANDARDS

[1995: a decisive progress for the interlaboratory transferability of results by using enzyme and protein reference materials (editorial)] Férard G, et al. **Ann Biol Clin (Paris)** 1995;53(9):469-71 (14 ref.) (Eng. Abstr.) **(Fre)**

THERAPEUTIC USE

Discovery and clinical applications of bone morphogenetic proteins. Vukičević S, et al. **Eur J Clin Chem Clin Biochem** 1995 Oct;33(10):661-71 (81 ref.)

Periodontal regenerative potential of space-providing expanded polytetrafluoroethylene membranes and recombinant human bone morphogenetic proteins. Sigurdsson TJ, et al. **J Periodontol** 1995 Jun;66(6):511-21 (37 ref.)

The potential role of bone morphogenetic proteins in periodontal reconstruction. Wozney JM. **J Periodontol** 1995 Jun;66(6):506-10 (34 ref.)

Recombinant bone morphogenetic proteins: novel substances for enhancing bone healing. Kirker-Head CA. **Vet Surg** 1995 Sep-Oct;24(5):408-19 (80 ref.)

PROTEINS, ACUTE-PHASE see **ACUTE-PHASE PROTEINS**

PROTEINS, RIBOSOMAL see **RIBOSOMAL PROTEINS**

PROTEINURIA

COMPLICATIONS

Proteinuria: a mediator of interstitial fibrosis? Harris KP, et al. **Contrib Nephrol** 1996;118:173-9 (28 ref.)

DRUG THERAPY

Is there any reason to lower proteinuria in a child with nephrotic-range proteinuria who is not clinically edematous? Kees-Folts D. **Pediatr Nephrol** 1996 Apr; 10(2):180 (17 ref.)

ETIOLOGY

Bence Jones proteinuria and myeloma kidney [editorial] Chauveau D, et al. **Nephrol Dial Transplant** 1996 Mar; 11(3):413-5 (7 ref.)

METABOLISM

Species comparison of the content and composition of urinary proteins. Hard GC. **Food Chem Toxicol** 1995 Sep; 33(9):731-46 (173 ref.)

PHYSIOPATHOLOGY

The role of proteinuria in the progression of chronic renal failure. Burton C, et al. **Am J Kidney Dis** 1996 Jun; 27(6):765-75 (94 ref.)

PREVENTION & CONTROL

Glycosaminoglycans: a new paradigm in the prevention of proteinuria and progression of glomerular disease [editorial] Gambaro G, et al. **Nephrol Dial Transplant** 1996 May; 11(5):762-4 (17 ref.)

URINE

[Diabetic nephropathy: significance of microalbuminuria and proteinuria in Type I and Type II diabetes mellitus] Lehmann R, et al. **Schweiz Rundsch Med Prax** 1995 Oct 31;84(44):1265-71 (53 ref.) (Eng. Abstr.) **(Ger)**

[Urine protein and its fractionation] Ohno I, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:125-8 (6 ref.) **(Jpn)**

PROTEINURIA-EDEMA-HYPERTENSION GESTOSIS see **GESTOSIS, EPH**

PROTEOCHONDROITIN SULFATES

METABOLISM

Aggrecan degradation in osteoarthritis and rheumatoid arthritis. Lark MW, et al. **Acta Orthop Scand Suppl** 1995 Oct;266:92-7 (31 ref.)

PROTEOGLYCANS

Proteoglycans of the extracellular environment: clues from the gene and protein side offer novel perspectives in molecular diversity and function. Iozzo RV, et al. **FASEB J** 1996 Apr;10(5):598-614 (92 ref.)

[Structure and function of extracellular matrix with special references to proteoglycan] Takeuchi J. **Rinsho Byori** 1995 Oct;43(10):979-87 (32 ref.) (Eng. Abstr.) **(Jpn)**

BIOSYNTHESIS

Intracellular membranes in the synthesis, transport, and metabolism of proteoglycans. Silbert JE, et al. **Biochim Biophys Acta** 1995 Dec 20;1241(3):371-84 (163 ref.)

Cell surface chondroitin sulfate proteoglycans in tumor cell adhesion, motility and invasion. Iida J, et al. **Semin Cancer Biol** 1996 Jun;7(3):155-62 (64 ref.)

BLOOD

[Proteoglycans] Murata K. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:575-8 (18 ref.) **(Jpn)**

GENETICS

Deficient expression of the small proteoglycan decorin in a case of severe/lethal osteogenesis imperfecta. Dyne KM, et al. **Am J Med Genet** 1996 May 3;63(1):161-6 (34 ref.)

METABOLISM

Anabolic and catabolic markers of proteoglycan metabolism in osteoarthritis. Caterson B, et al. **Acta Orthop Scand Suppl** 1995 Oct;266:121-4 (32 ref.)

Aggrecan degradation in osteoarthritis and rheumatoid arthritis. Lark MW, et al. **Acta Orthop Scand Suppl** 1995 Oct;266:92-7 (31 ref.)

A family of chondrodysplasias caused by mutations in the diastrophic dysplasia sulfate transporter gene and associated with impaired sulfation of proteoglycans. Superti-Furga A, et al. **Ann N Y Acad Sci** 1996 Jun 8; 785:195-201 (26 ref.)

Intracellular membranes in the synthesis, transport, and metabolism of proteoglycans. Silbert JE, et al. **Biochim Biophys Acta** 1995 Dec 20;1241(3):371-84 (163 ref.)

Heparan sulfate proteoglycan/low density lipoprotein receptor-related protein pathway involved in type III hyperlipoproteinemia and Alzheimer's disease. Mahley RW. **Isr J Med Sci** 1996 Jun;32(6):414-29 (72 ref.)

Extracellular matrix, supramolecular organisation and shape. Scott JE. **J Anat** 1995 Oct;187 (Pt 2):259-69 (21 ref.)

Entry and egress of varicella-zoster virus: role of mannose 6-phosphate, heparan sulfate proteoglycan, and signal sequences in targeting virions and viral glycoproteins. Zhu Z, et al. **Neurology** 1995 Dec;45(12 Suppl 8):S15-7 (9 ref.)

[Metabolic pathway of the degradation of macromolecules by lysosomal enzymes] Arai K, et al. **Nippon Rinsho** 1995 Dec;53(12):2904-10 (12 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

The role of proteoglycans in bladder structure and function. Levy BJ, et al. **Adv Exp Med Biol** 1995;385:191-205; discussion 223-8 (66 ref.)

The role of heparan sulfate proteoglycans in the pathogenesis of Alzheimer's disease. Small DH, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:316-21 (18 ref.)

The chondrocyte, architect of cartilage. Biomechanics, structure, function and molecular biology of cartilage matrix macromolecules. Muir H. **Bioessays** 1995 Dec; 17(12):1039-48 (79 ref.)

Regulation of growth factor activation by proteoglycans: what is the role of the low affinity receptors? Schlessinger J, et al. **Cell** 1995 Nov 3;83(3):357-60 (20 ref.)

Syndecan family of cell surface proteoglycans: developmentally regulated receptors for extracellular effector molecules. Salmivirta M, et al. **Experientia** 1995 Sep 29;51(9-10):863-72 (118 ref.)

Role of proteoglycans in neural development, regeneration, and the aging brain. Small DH, et al. **J Neurochem** 1996 Sep;67(3):889-99 (140 ref.)

Calories lost--another mediator of cancer cachexia? Nabel GJ, et al. **Nat Med** 1996 Apr;2(4):397-8 (16 ref.)

Role of fatty acids and eicosanoids in modulating proteoglycan metabolism in endothelial cells. Hennig B, et al. **Prostaglandins Leukot Essent Fatty Acids** 1995 Nov; 53(5):315-24 (114 ref.)

Control of cell proliferation by heparan sulfate and heparin-binding growth factors. Vlodavsky I, et al. **Thromb Haemost** 1995 Jul;74(1):534-40 (33 ref.)

PROTEOLIPID PROTEIN, MYELIN see **MYELIN PROTEOLIPID PROTEIN**

PROTEOLIPIDS

see related **LIPOPROTEINS**

Neonatal respiratory disease due to surfactant protein B deficiency. Ballard PL. **J Perinatol** 1996 Mar-Apr;16(2 Pt 2 Su):S28-34 (42 ref.)

ANALYSIS

Age-dependency of surfactant phospholipids and surfactant protein A in bronchoalveolar lavage fluid of children without bronchopulmonary disease. Ratjen F, et al. **Eur Respir J** 1996 Feb;9(2):328-33 (34 ref.)

GENETICS

Human surfactant protein B: structure, function, regulation, and genetic disease. Whitsett JA, et al. **Physiol Rev** 1995 Oct;75(4):749-57 (66 ref.)

Molecular and cellular pathobiology of pulmonary surfactant protein B deficiency. Colten HR. **Proc Assoc Am Physicians** 1995 Oct;107(3):334-9 (60 ref.)

METABOLISM

[Neonatal pulmonary alveolar proteinosis and SP-B deficiency: pulmonary surfactant at the time of molecular pathology (editorial)] Lacaze-Masmonteil T, et al. **Arch Pediatr** 1996 Apr;3(4):309-12 (33 ref.) **(Fre)**

PHYSIOLOGY

Human surfactant protein B: structure, function, regulation, and genetic disease. Whitsett JA, et al. **Physiol Rev** 1995 Oct;75(4):749-57 (66 ref.)

PROTEOLYTIC ENZYMES see **PEPTIDE HYDROLASES**

PROTESTANTISM see **CHRISTIANITY**

PROTEUS INFECTIONS

[A case of psoas abscess associated in the elderly] Yamamoto T, et al. **Kansenshogaku Zasshi** 1996 Apr;70(4):371-6 (17 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

[Emphysematous pyelonephritis] Monllor Gisbert J, et al. **Arch Esp Urol** 1995 Nov;48(9):956-9 (8 ref.) (Eng. Abstr.) **(Spa)**

MICROBIOLOGY

Swarming and pathogenicity of Proteus mirabilis in the urinary tract. Mobley HL, et al. **Trends Microbiol** 1995 Jul;3(7):280-4 (36 ref.)

PROTEUS MIRABILIS

[A case of psoas abscess associated in the elderly] Yamamoto T, et al. **Kansenshogaku Zasshi** 1996 Apr;70(4):371-6 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Emphysematous pyelonephritis] Monllor Gisbert J, et al. **Arch Esp Urol** 1995 Nov;48(9):956-9 (8 ref.) (Eng. Abstr.) **(Spa)**

PATHOGENICITY

Swarming and pathogenicity of Proteus mirabilis in the urinary tract. Mobley HL, et al. **Trends Microbiol** 1995 Jul;3(7):280-4 (36 ref.)

PROTHROMBIN

ANALYSIS

[Early diagnosis of hepatocellular carcinoma by serum AFP and PIVKA-II analysis] Aoyagi Y, et al. **Nippon Naika Gakkai Zasshi** 1995 Dec 10;84(12):2003-7 (5 ref.) **(Jpn)**

IMMUNOLOGY

Transient hemorrhagic diathesis associated with an inhibitor of prothrombin with lupus anticoagulant in a 1 1/2-year-old girl: report of a case and review of the literature. Lee MT, et al. **Am J Hematol** 1996 Apr; 51(4):307-14 (46 ref.)

PROTHROMBIN TIME

International Normalized Ratio (INR): an improved way to monitor oral anticoagulant therapy. Oertel LB. **Nurse Pract** 1995 Sep;20(9):15–6, 21–2 (12 ref.)
Calibration of thromboplastins. Finney DJ. **Proc R Soc Lond B Biol Sci** 1995 Oct 23;262(1363):71–5 (18 ref.)
[Prothrombin time (PT)] Fukutake K, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:10–3 (4 ref.) **(Jpn)**
[Thrombotest (TBT), hepaplastin test (HPT)] Ueda M. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:14–7 (5 ref.) **(Jpn)**

PROTIRELIN

see related
RECEPTORS, THYROTROPIN-RELEASING HORMONE

BLOOD

[Thyrotropin releasing hormone (TRH)] Oshima I. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:300–3 (11 ref.) **(Jpn)**

PHYSIOLOGY

Thyrotropin releasing hormone. Occurrence and role outside the central nervous system. Iversen E. **Dan Med Bull** 1995 Jun;42(3):257–68 (216 ref.)
Thyrotrophin-releasing hormone (TRH) and lung maturation. Liggins GC. **Reprod Fertil Dev** 1995; 7(3):443–50 (54 ref.)

PROTIRELIN RECEPTORS see **RECEPTORS, THYROTROPIN-RELEASING HORMONE**

PROTO-ONCOGENE PROTEIN P21(RAS)

Mutant ras epitopes as targets for cancer vaccines. Abrams SI, et al. **Semin Oncol** 1996 Feb;23(1):118–34 (79 ref.)

CHEMISTRY

Ras-catalyzed hydrolysis of GTP: a new perspective from model studies. Maegley KA, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8160–6 (93 ref.)

IMMUNOLOGY

Mutant ras epitopes as targets for cancer vaccines. Abrams SI, et al. **Semin Oncol** 1996 Feb;23(1):118–34 (79 ref.)

PHYSIOLOGY

Ras target proteins in eukaryotic cells. Marshall MS. **FASEB J** 1995 Oct;9(13):1311–8 (78 ref.)
Mutant Ras proteins and peptides: bad news for tumors [editorial; comment] Stauss HJ. **J Natl Cancer Inst** 1995 Dec 20;87(24):1820–2 (18 ref.) Comment on: J Natl Cancer Inst 1995 Dec 20;87(24):1853–61.

PROTO-ONCOGENE PROTEIN P185(NEU) see **PROTO-ONCOGENE PROTEINS C-ERBB-2**

PROTO-ONCOGENE PROTEIN PP60(C-SRC)

The Src and Csk families of tyrosine protein kinases in hemopoietic cells. Chow LM, et al. **Semin Immunol** 1995 Aug;7(4):207–26 (222 ref.)

ANTAGONISTS & INHIBITORS

SRC as a target for anti-cancer drugs. Levitzki A. **Anticancer Drug Des** 1996 Apr;11(3):175–82 (45 ref.)

PHYSIOLOGY

Src and the control of cell division. Taylor SJ, et al. **Bioessays** 1996 Jan;18(1):9–11 (40 ref.)

PROTO-ONCOGENE PROTEINS

[Mechanism of DNA recognition by a protooncogene product, Myb] Ogata K, et al. **Seikagaku** 1996 Feb; 68(2):111–28 (24 ref.) **(Jpn)**

BIOSYNTHESIS

Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells. Drexler HG. **Leukemia** 1996 Apr; 10(4):588–99 (118 ref.)
Correlation between proto-oncogene, fibroblast growth factor and adaptive response in brain infarct. Liu HM. **Prog Brain Res** 1995;105:239–44 (44 ref.)

CHEMISTRY

How Ras works: structure of a Rap-Raf complex. Sprang SR. **Structure** 1995 Jul 15;3(7):641–3 (17 ref.)

DRUG EFFECTS

Thrombopoietin induces tyrosine phosphorylation of Stat3 and Stat5 in human blood platelets. Miyakawa Y, et al. **Blood** 1996 Jan 15;87(2):439–46 (36 ref.)

GENETICS

The cbl oncogene: a novel substrate of protein tyrosine kinases. Langdon WY. **Aust N Z J Med** 1995 Dec; 25(6):859–64 (19 ref.)
RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma. Cote GJ, et al. **Baillieres Clin Endocrinol Metab** 1995 Jul; 9(3):609–30 (64 ref.)
Putting the bits and pieces of the RET proto-oncogene puzzle together. Gagel RF. **Bone** 1995 Aug;17(2 Suppl):13S–16S (30 ref.)
Mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2. Ponder BA. **Cancer Surv** 1995;25:195–205 (31 ref.)
BCL-6 and the molecular pathogenesis of B-cell lymphoma. Dalla-Favera R, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:117–23 (49 ref.)
Oncogenic activation of the ret protooncogene in thyroid cancer. Takahashi M. **Crit Rev Oncog** 1995;6(1):35–46 (96 ref.)
The Dbl family of oncogenes. Cerione RA, et al. **Curr Opin Cell Biol** 1996 Apr;8(2):216–22 (46 ref.)
Life and death during lymphocyte development and function: evidence for two distinct killing mechanisms. Strasser A. **Curr Opin Immunol** 1995 Apr;7(2):228–34 (97 ref.)
The c-myb negative regulatory domain. Gonda TJ, et al. **Curr Top Microbiol Immunol** 1996;211:99–109 (43 ref.)
Molecular defects in thyroid carcinomas: role of the RET oncogene in thyroid neoplastic transformation. Santoro M, et al. **Eur J Endocrinol** 1995 Nov;133(5):513–22 (114 ref.)
Degeneration of human oncogenes and mitochondrial genes occurs in cells that exhibit age-related pathology. Cortopassi G, et al. **Exp Gerontol** 1996 Jan-Apr; 31(1-2):253–65 (43 ref.)
Life, death, and the pursuit of apoptosis. White E. **Genes Dev** 1996 Jan 1;10(1):1–15 (191 ref.)
Locoregional immuno-chemotherapy transplenic and transtumoral in vivo immunostimulation. Lygidakis NJ, et al. **Hepatogastroenterology** 1996 Mar-Apr;43(8):440–7 (38 ref.)
bcl-2: role in epithelial differentiation and oncogenesis. Lu QL, et al. **Hum Pathol** 1996 Feb;27(2):102–10 (85 ref.)
Induction of lytic pathways in T cell clones derived from wild-type or protein tyrosine kinase Fyn mutant mice. Lancki DW, et al. **Immunol Rev** 1995 Aug;146:117–44 (56 ref.)
Molecular biology of breast cancer: integration of cellular and molecular concepts into therapeutic strategies. Konstadoulakis MM, et al. **R I Med** 1995 Sep;78(9):257–60 (67 ref.)
The bcl-2 gene family. Craig RW. **Semin Cancer Biol** 1995 Feb;6(1):35–43 (71 ref.)
c-mpl, the thrombopoietin receptor. Vainchenker W, et al. **Thromb Haemost** 1995 Jul;74(1):526–8 (15 ref.)
Role of three cancer "master genes" p53, bcl2 and c-myc on the apoptotic process. Chiarugi V, et al. **Tumori** 1996 May-Jun;82(3):205–9 (57 ref.)
[Does the c-ets 1 oncogene participate in the regulation of tumor angiogenesis?] Vandenbunder B, et al. **Arch Inst Pasteur Tunis** 1994 Jul-Oct;71(3-4):493–509 (56 ref.) (Eng. Abstr.) **(Fre)**
[The direct gene test in familial medullary thyroid gland carcinoma and in MEN syndromes. Detection of mutations in the ret proto-oncogene saves screening studies] Stuhrmann M. **Fortschr Med** 1995 Dec 20;113(35-36):503–6 (23 ref.) (Eng. Abstr.) **(Ger)**
[Prognostic factors for esophageal cancer--from the viewpoint of molecular biology] Shimada Y, et al. **Gan To Kagaku Ryoho** 1996 Jul;23(8):972–81 (98 ref.) (Eng. Abstr.) **(Jpn)**
[Clinicopathological study on primary lung cancer—immunohistochemical expression of p53 suppressor gene and bcl-2 oncogene in relation to prognosis] Irie K, et al. **Rinsho Byori** 1996 Jan;44(1):32–41 (23 ref.) (Eng. Abstr.) **(Jpn)**
[Ret proto-oncogene mutations associated with type 2 multiple endocrine neoplasms (MEN 2). Clinical implications] Bugalho MJ, et al. **Acta Med Port** 1995 Jul-Aug;8(7-8):419–24 (66 ref.) (Eng. Abstr.) **(Por)**

IMMUNOLOGY

Immunity to oncogenic proteins. Cheever MA, et al. **Immunol Rev** 1995 Jun;145:33–59 (81 ref.)

ISOLATION & PURIFICATION

[Detection of RET-proto-oncogene mutations in the diagnosis of Type 2 endocrine neoplasia (MEN 2)] Komminoth P, et al. **Schweiz Med Wochenschr** 1996 Aug 6;126(31-32):1329–38 (57 ref.) (Eng. Abstr.) **(Ger)**

METABOLISM

Proteins of the 14-3-3 family associate with Raf and contribute to its activation. Freed E, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:187–93 (45 ref.)
The Ets family of proteins: weak modulators of gene expression in quest for transcriptional partners. Crepieux P, et al. **Crit Rev Oncog** 1994;5(6):615–38 (192 ref.)
Protein-protein interactions. Putting the pieces together. Bax B, et al. **Curr Biol** 1995 Oct 1;5(10):1119–21 (21 ref.)
Early events in neurotrophin signalling via Trk and p75 receptors. Greene LA, et al. **Curr Opin Neurobiol** 1995 Oct;5(5):579–87 (72 ref.)
Rel/NF-kappa B/I kappa B family: intimate tales of association and dissociation. Verma IM, et al. **Genes Dev** 1995 Nov 15;9(22):2723–35 (114 ref.)
Ras-Raf complexes: analyses of complexes formed in vivo. Finney R, et al. **Methods Enzymol** 1995;255:310–23 (24 ref.)
Interactions between Ras and Raf: key regulatory proteins in cellular transformation. Marshall M. **Mol Reprod Dev** 1995 Dec;42(4):493–9 (24 ref.)
Mechanisms regulating Raf-1 activity in signal transduction pathways. Morrison DK. **Mol Reprod Dev** 1995 Dec; 42(4):507–14 (27 ref.)
Notch and Wingless signals collide [see comments] Blair SS. **Science** 1996 Mar 29;271(5257):1822–3 (16 ref.) Comment in: Science 1996 Mar 29;271(5257):1826–32.
A target for phosphoinositide 3-kinase: Akt/PKB. Bos JL. **Trends Biochem Sci** 1995 Nov;20(11):441–2 (11 ref.)
p75 and Trk: a two-receptor system. Chao MV, et al. **Trends Neurosci** 1995 Jul;18(7):321–6 (61 ref.)
[Analysis of Fas and bcl-2 expression on peripheral blood lymphocytes from primary Sjögren's syndrome] Ohashi H, et al. **Nippon Rinsho** 1995 Oct;53(10):2451–5 (24 ref.) (Eng. Abstr.) **(Jpn)**
[Lymphoproliferative disorders in patients with Sjögren's syndrome--Vg gene rearrangement and expression of bcl-2 protein] Sugai S, et al. **Nippon Rinsho** 1995 Oct; 53(10):2580–6 (15 ref.) (Eng. Abstr.) **(Jpn)**
[Sjögren's syndrome as a lymphoaggressive disorder; bcl-2 expression in lymphocytes infiltrated in salivary glands] Takeshita S, et al. **Nippon Rinsho** 1995 Oct;53(10):2440–5 (10 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Role of VEGF-flt receptor system in normal and tumor angiogenesis. Shibuya M. **Adv Cancer Res** 1995;67:281–316 (141 ref.)
Rel signalling pathway and the melanotic tumour phenotype of Drosophila. Govind S. **Biochem Soc Trans** 1996 Feb; 24(1):39–44 (44 ref.)
Molecular thanatopsis: a discourse on the BCL2 family and cell death. Yang E, et al. **Blood** 1996 Jul 15;88(2):386–401 (150 ref.)
The heterogeneity of the osteopetroses reflects the diversity of cellular influences during skeletal development. Popoff SN, et al. **Bone** 1995 Nov;17(5):437–45 (131 ref.)
Biologic effects of thrombopoietin, the Mpl ligand, and its therapeutic potential. Papayannopoulou T. **Cancer Chemother Pharmacol** 1996;38 Suppl:S69–73 (32 ref.)
Serpentine proteins slither into the wingless and hedgehog fields. Perrimon N. **Cell** 1996 Aug 23;86(4):513–6 (19 ref.)
Apoptosis. A sticky business. Häcker G, et al. **Curr Biol** 1995 Jun 1;5(6):622–4 (26 ref.)
Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance. Reed JC. **Curr Opin Oncol** 1995 Nov;7(6):541–6 (57 ref.)
Structure and function of the proteins encoded by the myb gene family. Kanei-Ishii C, et al. **Curr Top Microbiol Immunol** 1996;211:89–98 (51 ref.)
The effect of c-raf antisense oligonucleotides on growth factor-induced proliferation of hematopoietic cells. Keller JR, et al. **Curr Top Microbiol Immunol** 1996;211:43–53 (25 ref.)
Functional similarity between adenovirus E1B 19-kDa protein and proteins encoded by Bcl-2 proto-oncogene and Epstein-Barr virus BHRF1 gene. Subramanian T, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 1):153–61 (52 ref.)
bcl-2: role in epithelial differentiation and oncogenesis. Lu QL, et al. **Hum Pathol** 1996 Feb;27(2):102–10 (85 ref.)
Gene regulation by NF-M and Myb during differentiation and leukemic transformation. Kowenz-Leutz E, et al. **Immunobiology** 1995 Jul;193(2-4):356–62 (15 ref.)
Biology of flt3 ligand and receptor. Lyman SD. **Int J Hematol** 1995 Aug;62(2):63–73 (42 ref.)
Thrombopoietin: expression of its receptor MPL and proliferative effects on leukemic cells. Drexler HG, et al. **Leukemia** 1996 Sep;10(9):1405–21 (136 ref.)
Interaction between erbB-receptors and heregulin in breast cancer tumor progression and drug resistance. Lupu R, et al. **Semin Cancer Biol** 1995 Jun;6(3):135–45 (143 ref.)
Switching to Rac and Rho. Block C, et al. **Structure** 1995 Dec 15;3(12):1281–4 (30 ref.)
Thrombopoietin: the primary regulator of megakaryocyte and platelet production. Kaushansky K. **Thromb Haemost** 1995 Jul;74(1):521–5 (43 ref.)
c-mpl, the thrombopoietin receptor. Vainchenker W, et al. **Thromb Haemost** 1995 Jul;74(1):526–8 (15 ref.)
Bcl-2 family proteins: regulators of chemoresistance in cancer. Reed JC. **Toxicol Lett** 1995 Dec;82–83:155–8 (21 ref.)
The Bcl-2 family of proteins, and the regulation of neuronal survival. Davies AM. **Trends Neurosci** 1995 Aug; 18(8):355–8 (49 ref.)
[Bcl-2 with anti-apoptotic activity] Katsumata M, et al. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2062–73 (64 ref.) **(Jpn)**
[Regulation of apoptosis by products of the bcl-2 gene

family] Miyawaki T, et al. **Tanpakushitsu Kakusan Koso** 1996 Feb;41(2):127–35 (44 ref.) **(Jpn)**

PROTO-ONCOGENE PROTEINS C-ABL

see related
FUSION PROTEINS, BCR-ABL

Abl tyrosine protein kinase. Laneuville P. **Semin Immunol** 1995 Aug;7(4):255–66 (95 ref.)

METABOLISM

Nuclear tyrosine kinases: from Abl to WEE1. Pendergast AM. **Curr Opin Cell Biol** 1996 Apr;8(2):174–81 (46 ref.)

PROTO-ONCOGENE PROTEINS C-ERBA see **RECEPTORS, THYROID HORMONE**

PROTO-ONCOGENE PROTEINS C-ERBB-1 see **RECEPTORS, EPIDERMAL GROWTH FACTOR-UROGASTRONE**

PROTO-ONCOGENE PROTEINS C-ERBB-2

ANTAGONISTS & INHIBITORS

Intervention in receptor tyrosine kinase-mediated pathways: recombinant antibody fusion proteins targeted to ErbB2. Wels W, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 3):113–28 (47 ref.)

BLOOD

The c-erbB transmembrane growth factor receptors as serum biomarkers in human cancer studies. Brandt-Rauf PW. **Mutat Res** 1995 Dec;333(1–2):203–8 (25 ref.)

DRUG EFFECTS

The performance of e23(Fv)PEs, recombinant toxins targeting the erbB–2 protein. King CR, et al. **Semin Cancer Biol** 1996 Apr;7(2):79–86 (48 ref.)

IMMUNOLOGY

G-CSF-stimulated PMN in immunotherapy of breast cancer with a bispecific antibody to Fc gamma RI and to HER-2/neu (MDX-210). Repp R, et al. **J Hematother** 1995 Oct;4(5):415–21 (26 ref.)

PROTO-ONCOGENE PROTEINS C-FOS

see related
TRANSCRIPTION FACTOR AP-1

BIOSYNTHESIS

c-Fos expression as a tool to search for the neurobiological base of the sexual behaviour of males. Bialy M, et al. **Acta Neurobiol Exp (Warsz)** 1996;56(2):567–77 (52 ref.)

c-fos expression as a marker of central cardiovascular neurons. Dun NJ, et al. **Biol Signals** 1995 May–Jun; 4(3):117–23 (25 ref.)

Implications of prolonged expression of Fos-related antigens. Pennypacker KR, et al. **Trends Pharmacol Sci** 1995 Sep; 16(9):317–21 (44 ref.)

GENETICS

Regulation of the c-fos promoter. Janknecht R. **Immunobiology** 1995 Jul;193(2–4):137–42 (14 ref.)

METABOLISM

Molecular biology of pain. Munglani R, et al. **Br J Anaesth** 1995 Aug;75(2):186–92 (84 ref.)

PHYSIOLOGY

Fos and bone cell development: lessons from a nuclear oncogene. Grigoriadis AE, et al. **Trends Genet** 1995 Nov; 11(11):436–41 (57 ref.)

PROTO-ONCOGENE PROTEINS C-JUN

see related
TRANSCRIPTION FACTOR AP-1

PHYSIOLOGY

The NF-jun transcription factor in the hematopoietic response to mitogenic signals. Sott C, et al. **Immunobiology** 1995 Jul;193(2–4):149–54 (16 ref.)

RADIATION EFFECTS

Both ATF-2 and c-Jun are phosphorylated by stress-activated protein kinases in response to UV irradiation. Wilhelm D, et al. **Immunobiology** 1995 Jul; 193(2–4):143–8 (22 ref.)

PROTO-ONCOGENE PROTEINS C-KIT

CHEMISTRY

Structural aspects of receptor dimerization. c-kit as an example. Blechman JM, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:344–62 (79 ref.)

METABOLISM

Structural aspects of receptor dimerization. c-kit as an example. Blechman JM, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:344–62 (79 ref.)

PROTO-ONCOGENE PROTEINS C-MOS

see related
PROTEIN-SERINE-THREONINE KINASES

PROTO-ONCOGENE PROTEINS C-MYC

GENETICS

Retroviral insertional mutagenesis in murine promonocytic leukemias: c-myb and Mml1. Wolff L, et al. **Curr Top Microbiol Immunol** 1996;211:191–9 (33 ref.)

The mycN/max protein complex in neuroblastoma. Short review. Wenzel A, et al. **Eur J Cancer** 1995;31A(4):516–9 (40 ref.)

METABOLISM

Transcriptional regulation. Flipping the Myc switch. Bernards R. **Curr Biol** 1995 Aug 1;5(8):859–61 (13 ref.)

PHYSIOLOGY

Proteins of the Myc network: essential regulators of cell growth and differentiation. Henriksson M, et al. **Adv Cancer Res** 1996;68:109–82 (267 ref.)

Role of c-myc in myeloid differentiation, growth arrest and apoptosis. Hoffman B, et al. **Curr Top Microbiol Immunol** 1996;211:17–27 (51 ref.)

PROTO-ONCOGENE PROTEINS HER-2 see **PROTO-ONCOGENE PROTEINS C-ERBB-2**

PROTO-ONCOGENES

Mutation and cancer: a personal odyssey. Knudson AG Jr. **Adv Cancer Res** 1995;67:1–23 (144 ref.)

Mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2. Ponder BA. **Cancer Surv** 1995;25:195–205 (31 ref.)

Proto-oncogenes and plasticity in cell signaling. Bishop JM, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:165–71 (25 ref.)

BCL-6 and the molecular pathogenesis of B-cell lymphoma. Dalla-Favera R, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:117–23 (49 ref.)

Molecular genetics of proto-oncogenes and candidate tumor suppressors in Caenorhabditis elegans. Sternberg PW, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:155–63 (49 ref.)

Oncogenic activation of the ret protooncogene in thyroid cancer. Takahashi M. **Crit Rev Oncog** 1995;6(1):35–46 (96 ref.)

The role of scatter factor and the c-met proto-oncogene in angiogenic responses. Polverini PJ, et al. **EXS** 1995; 74:51–67 (82 ref.)

Molecular pathogenesis of non-Hodgkin lymphoma: a clinical perspective. Gaidano G, et al. **Haematologica** 1995 Sep–Oct;80(5):454–72 (151 ref.)

Progress against cancer. Broder S, et al. **J Cancer Res Clin Oncol** 1995;121(11):633–47 (134 ref.)

Molecular biology of testicular germ cell tumors: current status. Schmidt B, et al. **J Mol Med** 1995 Jul;73(7):355–67 (189 ref.)

BCR-ABL: an anti-apoptosis gene in chronic myelogenous leukemia. Cotter TG. **Leuk Lymphoma** 1995 Jul; 18(3–4):231–6 (32 ref.)

Molecular events in lung cancer. Roth JA. **Lung Cancer** 1995 Jun;12 Suppl 2:S3–15 (51 ref.)

Proto-oncogenes: basic concepts and stimulation induced changes in the spinal cord. Munglani R, et al. **Prog Brain Res** 1995;104:283–98 (114 ref.)

[Correlation of c-met activation with human carcinogenesis] Gao CF, et al. **Sheng Li Ko Hsueh Chin Chan** 1995 Jul; 26(3):243–5 (8 ref.) **(Chi)**

[Determination of the activated proto-oncogene (Ki-ras) in feces. A new laboratory analysis for early diagnosis of colorectal cancer] Koornstra JJ, et al. **Tidsskr Nor Laegeforen** 1995 Oct 30;115(26):3266–70 (42 ref.) (Eng. Abstr.) **(Nor)**

GENETICS

Journey to the surface of the cell: Fos regulation and the SRE. Treisman R. **EMBO J** 1995 Oct 16;14(20):4905–13 (100 ref.)

PAX genes: what's new in developmental biology and cancer? Stuart ET, et al. **Hum Mol Genet** 1995;4 Spec No:1717–20 (52 ref.)

RET gene and its implications for cancer. Goodfellow PJ, et al. **J Natl Cancer Inst** 1995 Oct 18;87(20):1515–23 (71 ref.)

Seminars in medicine of the Beth Israel Hospital, Boston. The RET proto-oncogene in multiple endocrine neoplasia type 2 and Hirschsprung's disease. Eng C. **N Engl J Med** 1996 Sep 26;335(13):943–51 (89 ref.)

Genetic clinical markers of human neuroblastoma with special reference to N-myc oncogene: amplified or not amplified?--An overview. Tsuchida Y, et al. **Tumour Biol** 1996;17(2):65–74 (78 ref.)

[Does the c-ets 1 oncogene participate in the regulation of tumor angiogenesis?] Vandenbunder B, et al. **Arch Inst Pasteur Tunis** 1994 Jul–Oct;71(3–4):493–509 (56 ref.) (Eng. Abstr.) **(Fre)**

[Biology of solid cancers: breast cancer as an example. First part: genetic systems implicated in carcinogenesis] Bièche I, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996; 25(2):131–41 (37 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Sex hormones, proto-oncogene expression and apoptosis: their effects on rheumatoid synovial tissue. Cutolo M, et al. **Clin Exp Rheumatol** 1996 Jan–Feb;14(1):87–94 (58 ref.)

[Transgenic mice for analysis of neoplasm transformation processes of T and B lymphocytes] Kobzdej M, et al. **Postepy Hig Med Dosw** 1996;50(2):113–29 (61 ref.) (Eng. Abstr.) **(Pol)**

PROTOCOL-DIRECTED THERAPY, COMPUTER-ASSISTED see **THERAPY, COMPUTER-ASSISTED**

PROTOCOL DRUG THERAPY, COMPUTER-ASSISTED see **DRUG THERAPY, COMPUTER-ASSISTED**

PROTOCOLLAGEN see **PROCOLLAGEN**

PROTOCOLLAGEN PROLYL HYDROXYLASE see **PROCOLLAGEN-PROLINE DIOXYGENASE**

PROTOCOLS, CLINICAL see **CLINICAL PROTOCOLS**

PROTOHEME see **HEME**

PROTON-INDUCED X-RAY EMISSION SPECTROMETRY see **SPECTROMETRY, X-RAY EMISSION**

PROTON-MOTIVE FORCE

see related
PROTON PUMP

PROTON PUMP

see related
H(+)-TRANSPORTING ATP SYNTHASE

Electron and proton transfer to the quinones in bacterial photosynthetic reaction centers: insight from combined approaches of molecular genetics and biophysics. Sebban P, et al. **Biochimie** 1995;77(7–8):677–94 (67 ref.)

ANTAGONISTS & INHIBITORS

The role of proton pump inhibitors in the treatment of gastro-oesophageal reflux disease. Bardhan KD. **Aliment Pharmacol Ther** 1995;9 Suppl 1:15–25 (73 ref.)

Drugs for pH control in upper gastrointestinal bleeding. Brunner G, et al. **Aliment Pharmacol Ther** 1995;9 Suppl 1:47–50 (26 ref.)

Why is the high grade inhibition of gastric acid secretion afforded by proton pump inhibitors often required for healing of reflux esophagitis? An epithelial perspective. Orlando RC. **Am J Gastroenterol** 1996 Sep;91(9):1692–6 (22 ref.)

[Proton pump blockers and their significance in gastroenterology] Dítě P, et al. **Vnitr Lek** 1995 Aug; 41(8):549–54 (23 ref.) (Eng. Abstr.) **(Cze)**

[Medical treatment of stomach ulcer except in emergency] Bretagne JF. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S73–S80 (68 ref.) **(Fre)**

[Treatment of stomach ulcer] Hudziak H. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S136–S142 (51 ref.) **(Fre)**

[Gastroesophageal reflux: current status of therapy] Seifert E. **Leber Magen Darm** 1995 Jul;25(4):156–60, 163 (55 ref.) (Eng. Abstr.) **(Ger)**

DRUG EFFECTS

Review article: the continuing development of proton pump inhibitors with particular reference to pantoprazole. Huber R, et al. **Aliment Pharmacol Ther** 1995 Aug;9(4):363–78 (59 ref.)

Proton pump inhibitors: new drugs and indications. Mears JM, et al. **Am Fam Physician** 1996 Jan;53(1):285–92 (38 ref.)

PROTON PUMP

METABOLISM

Membrane energization by proton pumps is important for compartmentalization of drugs and toxins: a new type of active transport. Moriyama Y. **J Exp Biol** 1996 Jul;199 (Pt 7):1447–54 (70 ref.)

PROTON-TRANSLOCATING ATPASE COMPLEX see **H(+)-TRANSPORTING ATP SYNTHASE**

PROTONS

Proton and potassium transport by H+/K(+)-ATPases. van Driel IR, et al. **Clin Exp Pharmacol Physiol** 1995 Dec; 22(12):952–60 (91 ref.)

Hydrogen ion-dependent oncogenesis and parallel new avenues to cancer prevention and treatment using a H(+)-mediated unifying approach: pH-related and pH-unrelated mechanisms. Harguindey S, et al. **Crit Rev Oncog** 1995;6(1):1–33 (303 ref.)

pH regulation and proton signalling by glial cells. Deitmer JW, et al. **Prog Neurobiol** 1996 Feb;48(2):73–103 (265 ref.)

[The present and future of heavy charged particle therapy] Tsujii H. **Nippon Rinsho** 1996 Jan;54(1):268–73 (13 ref.) (Eng. Abstr.) **(Jpn)**

THERAPEUTIC USE

A review of proton beam radiation therapy. Miller DW. **Med Phys** 1995 Nov;22(11 Pt 2):1943–54 (84 ref.)

Applications of proton beam therapy. Nicholson J, et al. **Radiol Technol** 1996 May–Jun;67(5):439–41 (9 ref.)

PROTOPORPHYRIA, ERYTHROPOIETIC see **PORPHYRIA, ERYTHROHEPATIC**

PROTOZOA

see related
ANTIPROTOZOAL AGENTS

CLASSIFICATION

Current status of the plasmodiophorids. Braselton JP. **Crit Rev Microbiol** 1995;21(4):263–75 (50 ref.)

Molecular identification of nanoplanktonic protists based on small subunit ribosomal RNA gene sequences for ecological studies. Lim EL. **J Eukaryot Microbiol** 1996 Mar–Apr; 43(2):101–6 (47 ref.)

DRUG EFFECTS

New mechanisms of drug resistance in parasitic protozoa. Borst P, et al. **Annu Rev Microbiol** 1995;49:427–60 (196 ref.)

The surface glycoconjugates of parasitic protozoa: potential targets for new drugs. McConville MJ. **Aust N Z J Med** 1995 Dec;25(6):768–76 (40 ref.)

GENETICS

Population genetics of parasitic protozoa and other microorganisms. Tibayrenc M. **Adv Parasitol** 1995; 36:47–115 (164 ref.)

Molecular identification of nanoplanktonic protists based on small subunit ribosomal RNA gene sequences for ecological studies. Lim EL. **J Eukaryot Microbiol** 1996 Mar–Apr; 43(2):101–6 (47 ref.)

A brief history of hemoglobins: plant, animal, protist, and bacteria. Hardison RC. **Proc Natl Acad Sci U S A** 1996 Jun 11;93(12):5675–9 (33 ref.)

IMMUNOLOGY

Nonopsonic phagocytosis of microorganisms. Ofek I, et al. **Annu Rev Microbiol** 1995;49:239–76 (187 ref.)

Direct antimicrobial activity of T cells. Levitz SM, et al. **Immunol Today** 1995 Aug;16(8):387–91 (36 ref.)

METABOLISM

Microbial recognition of target-cell glycoconjugates. Karlsson KA. **Curr Opin Struct Biol** 1995 Oct;5(5):622–35 (74 ref.)

The mevalonate pathway in parasitic protozoa and helminths. Coppens I, et al. **Exp Parasitol** 1996 Jan;82(1):76–85 (60 ref.)

Effect of rumen protozoa on nitrogen utilization by ruminants. Jouany JP. **J Nutr** 1996 Apr;126(4 Suppl):1335S–46S (127 ref.)

MICROBIOLOGY

[Protozoa as reservoirs for human bacterial pathogens] Kołodyński J. **Wiad Parazytol** 1996;42(1):37–43 (34 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOLOGY

Understanding intestinal spore-forming protozoa: cryptosporidia, microsporidia, isospora, and cyclospora. Goodgame RW. **Ann Intern Med** 1996 Feb 15; 124(4):429–41 (170 ref.)

Symposium introductory remarks: "protistan molecular ecology and systematics". Caron DA. **J Eukaryot Microbiol** 1996 Mar–Apr;43(2):87–8 (22 ref.)

ULTRASTRUCTURE

Structural organization of the cell surface of pathogenic protozoa. De Souza W. **Micron** 1995;26(5):405–30 (156 ref.)

PROTOZOAN ANTIBODIES see **ANTIBODIES, PROTOZOAN**

PROTOZOAN ANTIGENS see **ANTIGENS, PROTOZOAN**

PROTOZOAN DNA see **DNA, PROTOZOAN**

PROTOZOAN GENES see **GENES, PROTOZOAN**

PROTOZOAN INFECTIONS

see related
ANTIPROTOZOAL AGENTS

Management of protozoan infections in AIDS. The Jefferiss Wing Therapeutics and Protocols Group. Tomlinson DR, et al. **Int J STD AIDS** 1995 Jul–Aug;6(4):237–40 (7 ref.)

Protozoan infections in the male genital tract. Martínez-García F, et al. **J Urol** 1996 Aug;156(2 Pt 1):340–9 (171 ref.)

[Infectious diseases of the liver due to protozoa] Kume H, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):82–6 (8 ref.) **(Jpn)**

BLOOD

Infectious hazards associated with blood transfusion. Hurley DR. **Adverse Drug React Toxicol Rev** 1995 Autumn; 14(3):157–74 (69 ref.)

COMPLICATIONS

Pathology of microsporidiosis: emerging parasitic infections in patients with acquired immunodeficiency syndrome. Schwartz DA, et al. **Arch Pathol Lab Med** 1996 Feb; 120(2):173–88 (72 ref.)

DRUG THERAPY

New mechanisms of drug resistance in parasitic protozoa. Borst P, et al. **Annu Rev Microbiol** 1995;49:427–60 (196 ref.)

Human antiprotozoal therapy: past, present, and future. Khaw M, et al. **Clin Microbiol Rev** 1995 Jul;8(3):427–39 (182 ref.)

Secnidazole. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic use in the management of protozoal infections and bacterial vaginosis. Gillis JC, et al. **Drugs** 1996 Apr;51(4):621–38 (56 ref.)

Antiparasitic drugs. Liu LX, et al. **N Engl J Med** 1996 May 2;334(18):1178–84 (100 ref.)

EPIDEMIOLOGY

[3 emerging protozoal infections in The Netherlands: Cyclospora, Dientamoeba, and Microspora infections] van Gool T, et al. **Ned Tijdschr Geneeskd** 1996 Jan 20; 140(3):155–60 (31 ref.) (Eng. Abstr.) **(Dut)**

ETIOLOGY

Pneumocystis carinii and parasitic infections in transplantation. Fishman JA. **Infect Dis Clin North Am** 1995 Dec;9(4):1005–44 (128 ref.)

PARASITOLOGY

[3 emerging protozoal infections in The Netherlands: Cyclospora, Dientamoeba, and Microspora infections] van Gool T, et al. **Ned Tijdschr Geneeskd** 1996 Jan 20; 140(3):155–60 (31 ref.) (Eng. Abstr.) **(Dut)**

TRANSMISSION

[The interrelationships of ixodid ticks (Ixodidae) with the causative agents of transmissible vertebrate infections] Balashov IuS. **Parazitologiia** 1995 Sep–Oct;29(5):337–52 (90 ref.) (Eng. Abstr.) **(Rus)**

VETERINARY

Recent acquisitions on tick and tick-borne disease resistance in N'dama (Bos taurus) and Gobra zebu (Bos indicus) cattle. Mattioli RC, et al. **Parassitologia** 1995 Apr;37(1):63–7 (40 ref.)

Eosinophilic colitis and hepatitis in a horse with colonic intramucosal ciliated protozoa. French RA, et al. **Vet Pathol** 1996 Mar;33(2):235–8 (10 ref.)

PROTOZOAN PROTEINS

ADMINISTRATION & DOSAGE

Randomised trial of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania. Alonzo PL, et al. **Med Trop (Mars)** 1995;55(4 Suppl):41–6 (6 ref.)

IMMUNOLOGY

Nucleic acid malaria vaccines. Current status and potential. Hoffman SL, et al. **Ann N Y Acad Sci** 1995 Nov 27; 772:88–94 (11 ref.)

Advances toward the development of an asexual blood stage MSP-1 vaccine of Plasmodium vivax. Levitus G, et al. **Mem Inst Oswaldo Cruz** 1994;89 Suppl 2:81–4 (13 ref.)

[The investigational vaccine SPf66 against Plasmodium falciparum: myth or reality?] Robert F, et al. **Sante** 1996 Jan–Feb;6(1):56–7 (11 ref.) **(Fre)**

METABOLISM

Protein trafficking in kinetoplastid protozoa. Clayton C, et al. **Microbiol Rev** 1995 Sep;59(3):325–44 (250 ref.)

PHYSIOLOGY

Flagellar kinesins: new moves with an old beat. Bernstein M. **Cell Motil Cytoskeleton** 1995;32(2):125–8 (27 ref.)

Regulation of dynein-driven microtubule sliding by an axonemal kinase and phosphatase in Chlamydomonas flagella. Habermacher G, et al. **Cell Motil Cytoskeleton** 1995;32(2):106–9 (23 ref.)

Regulation of ciliary beat frequency by a dynein light chain. Hamasaki T, et al. **Cell Motil Cytoskeleton** 1995;32(2):121–4 (27 ref.)

Exploring the function of inner and outer dynein arms with Chlamydomonas mutants. Kamiya R. **Cell Motil Cytoskeleton** 1995;32(2):98–102 (34 ref.)

Multifunctional proteins in Tetrahymena: 14-nm filament protein/citrate synthase and translation elongation factor-1 alpha. Numata O. **Int Rev Cytol** 1996;164:1–35 (126 ref.)

PROTOZOAN RNA see **RNA, PROTOZOAN**

PROTOZOAN STRUCTURAL GENES see **GENES, STRUCTURAL, PROTOZOAN**

PROVIRUS INTEGRATION see **VIRUS INTEGRATION**

PROVIRUSES

see related
MUTAGENESIS, INSERTIONAL

GENETICS

Viral load in peripheral blood mononuclear cells as surrogate for clinical progression. Ferre F, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995;10 Suppl 2:S51–6 (24 ref.)

ISOLATION & PURIFICATION

No detection of HTLV-I proviral DNA in lesional skin biopsies from Swiss and German patients with cutaneous T-cell lymphoma. Böni R, et al. **Br J Dermatol** 1996 Feb; 134(2):282–4 (20 ref.)

Primary adult T cell leukemia of bone: two patients with primary bone lesion showing monoclonal integration of HTLV-I proviral DNA. Takemoto S, et al. **Leukemia** 1996 Feb;10(2):333–7 (24 ref.)

PROVOCATION TESTS, BRONCHIAL see **BRONCHIAL PROVOCATION TESTS**

PROVOCATION TESTS, NASAL see **NASAL PROVOCATION TESTS**

PROXIMAL RENAL TUBULAR DYSFUNCTION see **FANCONI SYNDROME**

PROZAMINE see **PROMETHAZINE**

PRP PROTEINS see **PRIONS**

PRPC PROTEINS

GENETICS

The Ninth Datta Lecture. Molecular biology of transmissible spongiform encephalopathies. Weissmann C. **FEBS Lett** 1996 Jun 24;389(1):3–11 (75 ref.)

METABOLISM

Human prion disease and human prion protein disease. Kitamoto T, et al. **Curr Top Microbiol Immunol** 1996; 207:27–34 (28 ref.)

PRPP SYNTHETASE see **RIBOSE-PHOSPHATE PYROPHOSPHOKINASE**

PRPSC PROTEINS

GENETICS

The Ninth Datta Lecture. Molecular biology of transmissible spongiform encephalopathies. Weissmann C. **FEBS Lett** 1996 Jun 24;389(1):3–11 (75 ref.)

The nature of the scrapie agent: the virus theory. Narang H. **Proc Soc Exp Biol Med** 1996 Jul;212(3):208–24 (139 ref.)

METABOLISM

Human prion disease and human prion protein disease. Kitamoto T, et al. **Curr Top Microbiol Immunol** 1996; 207:27–34 (28 ref.)

PRUNE BELLY SYNDROME

The prune-belly syndrome: current insights. Sutherland RS, et al. **Pediatr Nephrol** 1995 Dec;9(6):770–8 (72 ref.)

PRURITUS

see related
ANTIPRURITICS

DIAGNOSIS

The itchy scalp and other pruritic curiosities. Bernhard JD. **Semin Dermatol** 1995 Dec;14(4):326–9 (27 ref.)
Investigation of the pruritic patient in daily practice. Kantor GR, et al. **Semin Dermatol** 1995 Dec;14(4):290–6 (32 ref.)
The measurement of scratching. Savin J. **Semin Dermatol** 1995 Dec;14(4):285–9 (33 ref.)
Measurement of itch. Wahlgren CF. **Semin Dermatol** 1995 Dec;14(4):277–84 (53 ref.)

DRUG THERAPY

Hepatobiliary pruritus: what are effective treatments? Connolly CS, et al. **J Am Acad Dermatol** 1995 Nov;33(5 Pt 1):801–5 (32 ref.)
Treating pruritus. What's new in safe relief of symptoms? Millikan LE. **Postgrad Med** 1996 Jan;99(1):173–6, 179–84 (17 ref.)
Pruritus of chronic cholestasis. Raiford DS. **QJM** 1995 Sep; 88(9):603–7 (34 ref.)
Treatment of itch. Hägermark O, et al. **Semin Dermatol** 1995 Dec;14(4):320–5 (62 ref.)

ETIOLOGY

Hepatobiliary pruritus: what are effective treatments? Connolly CS, et al. **J Am Acad Dermatol** 1995 Nov;33(5 Pt 1):801–5 (32 ref.)
Pruritus of chronic cholestasis. Raiford DS. **QJM** 1995 Sep; 88(9):603–7 (34 ref.)
The pruritus of cholestasis. Bergasa NV. **Semin Dermatol** 1995 Dec;14(4):302–12 (86 ref.)
Aquagenic pruritus. du Peloux Menagé H, et al. **Semin Dermatol** 1995 Dec;14(4):313–6 (40 ref.)
Uremic pruritus. Ståhle-Bäckdahl M. **Semin Dermatol** 1995 Dec;14(4):297–301 (43 ref.)
[Uremic pruritus. Pathophysiologic and therapeutic concepts] Mettang T, et al. **Dtsch Med Wochenschr** 1996 Aug 16; 121(33):1025–31 (66 ref.) **(Ger)**
[Pruritus] Reinauer S, et al. **Hautarzt** 1996 Mar;47(3):229–42 (11 ref.) **(Ger)**
[Pruritus. Physiology, pathophysiology, clinical aspects and therapy] Heyer G. **Med Monatsschr Pharm** 1995 Nov; 18(11):320–9 (77 ref.) **(Ger)**

PATHOLOGY

Pruritus in the elderly. Gilchrest BA. **Semin Dermatol** 1995 Dec;14(4):317–9 (22 ref.)

PHYSIOPATHOLOGY

Itch and pain. Teofoli P, et al. **Int J Dermatol** 1996 Mar; 35(3):159–66 (98 ref.)
Some neurophysiological aspects of itch. Ekblom A. **Semin Dermatol** 1995 Dec;14(4):262–70 (60 ref.)
Itch mediators. Hägermark O. **Semin Dermatol** 1995 Dec; 14(4):271–6 (76 ref.)

THERAPY

Medical therapy of pruritus of cholestasis. Luketic VA, et al. **Gastroenterologist** 1995 Sep;3(3):257–60 (11 ref.)

PSAMMOMYS see **GERBILLINAE**

PSEUDALLESCHERIA

Pseudallescheria boydii in an immunocompromised host. Successful treatment with debridement and itraconazole. Ruxin TA, et al. **Arch Dermatol** 1996 Apr;132(4):382–4 (23 ref.)

PSEUDARTHROSIS

COMPLICATIONS

Posttraumatic spinal osteolysis in ankylosing spondylitis as part of pseudoarthrosis. A case report. Albertsen AM, et al. **Acta Radiol** 1996 Jan;37(1):98–100 (10 ref.)
Congenital clavicular pseudoarthrosis associated with vascular thoracic outlet syndrome: case presentation and review of the literature. Hahn K, et al. **Cathet Cardiovasc Diagn** 1995 Aug;35(4):321–7 (30 ref.)

CONGENITAL

Congenital clavicular pseudoarthrosis associated with vascular thoracic outlet syndrome: case presentation and review of the literature. Hahn K, et al. **Cathet Cardiovasc Diagn** 1995 Aug;35(4):321–7 (30 ref.)
Congenital annular constricting band: a case report with pseudarthrosis and review of the literature. Martinot-Duquennoy V, et al. **Eur J Pediatr Surg** 1995 Dec;5(6):380–4 (23 ref.)

RADIOGRAPHY

[Pseudarthrosis of the atlas after Jefferson's fracture] Wichmann HU, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1995 Nov;163(5):452–3 (11 ref.) **(Ger)**

PSEUDO-HURLER POLYDYSTROPHY see **MUCOLIPIDOSIS**

PSEUDO-OBSTRUCTION, COLONIC see **COLONIC PSEUDO-OBSTRUCTION**

PSEUDO-OBSTRUCTION, INTESTINAL see **INTESTINAL PSEUDO-OBSTRUCTION**

PSEUDOBULBAR PARALYSIS see **PARALYSIS**

PSEUDODEMENTIA see **FACTITIOUS DISORDERS**

PSEUDOEPHEDRINE see **EPHEDRINE**

PSEUDOGOUT see **CHONDROCALCINOSIS**

PSEUDOHERMAPHRODITISM

GENETICS

[Genetics and endocrinology of male sex differentiation: application to molecular study of male pseudohermaphroditism] Sultan C, et al. **C R Seances Soc Biol Fil** 1995;189(5):713–40 (83 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

[Genetics and endocrinology of male sex differentiation: application to molecular study of male pseudohermaphroditism] Sultan C, et al. **C R Seances Soc Biol Fil** 1995;189(5):713–40 (83 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Transsphinctericanorectal reconstruction of ambiguous genitalia: an innovative approach to neovaginoplasty, pioneer in Brazil. Braz A, et al. **Rev Paul Med** 1995 Nov–Dec;113(6):1022–32 (25 ref.)

PSEUDOMONAS

Resistant nosocomial gram-negative bacillary pathogens: Acinetobacter baumannii, Xanthomonas maltophilia, and Pseudomonas cepacia. Fang FC, et al. **Curr Clin Top Infect Dis** 1996;16:52–83 (363 ref.)

GENETICS

Regulatory noise in prokaryotic promoters: how bacteria learn to respond to novel environmental signals. de Lorenzo V, et al. **Mol Microbiol** 1996 Mar;19(6):1177–84 (37 ref.)
Gene regulation of siderophore-mediated iron acquisition in Pseudomonas: not only the Fur repressor. Venturi V, et al. **Mol Microbiol** 1995 Aug;17(4):603–10 (40 ref.)
[Study on Pseudomonas transposons and molecular genetic analysis of Pseudomonas by use of transposons] Tsuda M. **Nippon Saikingaku Zasshi** 1995 Oct;50(4):947–59 (58 ref.) **(Jpn)**

METABOLISM

Synthesis of phytohormones by plant-associated bacteria. Costacurta A, et al. **Crit Rev Microbiol** 1995;21(1):1–18 (169 ref.)

PATHOGENICITY

Inside avirulence [comment] Taylor CB. **Plant Cell** 1996 Jul; 8(7):1091–3 (22 ref.) Comment on: Plant Cell 1996 Jul;8(7):1095–105.

PSEUDOMONAS AERUGINOSA

CLASSIFICATION

[Evaluation of multiple Pseudomonas aeruginosa strains with different characteristics in clinical specimens; combined results from serotyping, drug susceptibility and enzyme production] Nakasone I, et al. **Rinsho Byori** 1995 Nov; 43(11):1135–9 (18 ref.) (Eng. Abstr.) **(Jpn)**

ENZYMOLOGY

Genetic analysis of exoenzyme S expression by Pseudomonas aeruginosa. Goranson J, et al. **FEMS Microbiol Lett** 1996 Jan 15;135(2–3):149–55 (39 ref.)

GENETICS

Production of rhamnolipid biosurfactants. Ochsner UA, et al. **Adv Biochem Eng Biotechnol** 1996;53:89–118 (70 ref.)

IMMUNOLOGY

[Structure and properties of the common polysaccharide antigen of Pseudomonas aeruginosa bacteria (review)] Knirel' IuA, et al. **Biokhimiia** 1995 Dec;60(12):1964–76 (53 ref.) (Eng. Abstr.) **(Rus)**

METABOLISM

Microbial oxidation of unsaturated fatty acids. Hou CT. **Adv Appl Microbiol** 1995;41:1–23 (37 ref.)
Exopolysaccharide alginate synthesis in Pseudomonas aeruginosa: enzymology and regulation of gene expression. Shankar S, et al. **Adv Enzymol Relat Areas Mol Biol** 1995; 70:221–55 (84 ref.)
Prepilin-like molecules in type 4 pilus biogenesis: minor subunits, chaperones or mediators of organelle translocation? Koomey M. **Trends Microbiol** 1995 Nov; 3(11):409–10; discussion 411–3 (49 ref.)
[Alginates of Pseudomonas aeruginosa: a complex regulation of the pathway of biosynthesis] Schmitt-Andrieu L, et al. **C R Acad Sci III** 1996 Mar;319(3):153–60 (62 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Pseudomonas aeruginosa, mucoidy and the chronic infection phenotype in cystic fibrosis. Deretic V, et al. **Trends Microbiol** 1995 Sep;3(9):351–6 (59 ref.)

PSEUDOMONAS CEPACIA see **BURKHOLDERIA CEPACIA**

PSEUDOMONAS INFECTIONS

COMPLICATIONS

Cystic fibrosis and the pseudomonads. Wright KC. **Br J Biomed Sci** 1996 Jun;53(2):140–5 (51 ref.)
[Primary cutaneous cryptococcosis and bacterial pneumonia caused by Pseudomonas aeruginosa in AIDS: clinical case and review of the literature] Dronda F, et al. **Enferm Infecc Microbiol Clin** 1996 Feb;14(2):101–5 (35 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Aminoglycoside dosing: one, two or three times a day? [see comments] McLean AJ, et al. **Med J Aust** 1996 Jan 1; 164(1):39–42 (54 ref.) Comment in: Med J Aust 1996 May 20;164(10):636–7.

ETIOLOGY

[Cystic fibrosis in adults] Durieu I, et al. **Presse Med** 1995 Dec 16–23;24(39):1882–7 (23 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Pulmonary immunity to Pseudomonas aeruginosa. Cripps AW, et al. **Immunol Cell Biol** 1995 Oct;73(5):418–24 (84 ref.)

MICROBIOLOGY

Pseudomonas aeruginosa, mucoidy and the chronic infection phenotype in cystic fibrosis. Deretic V, et al. **Trends Microbiol** 1995 Sep;3(9):351–6 (59 ref.)

PREVENTION & CONTROL

Inhalation of antibiotics in cystic fibrosis. Touw DJ, et al. **Eur Respir J** 1995 Sep;8(9):1594–604 (65 ref.)

PSEUDOMONIC ACID see **MUPIROCIN**

PSEUDOMYXOMA PERITONEI

[Peritoneal pseudomyxoma] Sánchez Muñoz LA, et al. **Rev Clin Esp** 1995 Nov;195(11):781–6 (20 ref.) **(Spa)**

PSEUDONEUROTIC SCHIZOPHRENIA see **SCHIZOTYPAL PERSONALITY DISORDER**

PSEUDOPELADE see **ALOPECIA**

PSEUDOPOLYARTHRITIS, RHIZOMELIC see **POLYMYALGIA RHEUMATICA**

PSEUDOPROMOTER (GENETICS) see **PROMOTER REGIONS (GENETICS)**

PSEUDOPSYCHOPATHIC SCHIZOPHRENIA see **SCHIZOTYPAL PERSONALITY DISORDER**

PSEUDOPSYCHOSIS see **FACTITIOUS DISORDERS**

PSEUDORABIES

PREVENTION & CONTROL

Pseudorabies virus eradication by area-wide vaccination is feasible. Stegeman A. **Vet Q** 1995 Dec;17(4):150–6 (85 ref.)
[Progress in the development of vaccines against Aujeszky's disease] Mettenleiter TC. **Tierarztl Prax** 1995 Dec; 23(6):570–4 (22 ref.) (Eng. Abstr.) **(Ger)**

PSEUDORABIES VIRUS see **HERPESVIRUS 1, SUID**

PSEUDOSCLEROSIS see **HEPATOLENTICULAR DEGENERATION**

PSEUDOTUBERCULOSIS, PASTEURELLA see **YERSINIA PSEUDOTUBERCULOSIS INFECTIONS**

PSEUDOTUMOR CEREBRI

CHEMICALLY INDUCED

All-trans-retinoic acid and pseudotumor cerebri in a young adult with acute promyelocytic leukemia: a possible disease association. Visani G, et al. **Haematologica** 1996 Mar-Apr; 81(2):152-4 (12 ref.)

COMPLICATIONS

Pseudotumor cerebri in systemic lupus erythematosus. Green L, et al. **Semin Arthritis Rheum** 1995 Oct;25(2):103-8 (14 ref.)

DIAGNOSIS

Monitoring and management of raised intracranial pressure (ICP) in the intensive care unit with an analysis of one year of intracranial pressure monitoring. Kapadia F, et al. **J Assoc Physicians India** 1995 Nov;43(11):783-90 (16 ref.)

SURGERY

Lumboperitoneal shunt for the treatment of pseudotumor cerebri. Eggenberger ER, et al. **Neurology** 1996 Jun; 46(6):1524-30 (49 ref.)

THERAPY

Monitoring and management of raised intracranial pressure (ICP) in the intensive care unit with an analysis of one year of intracranial pressure monitoring. Kapadia F, et al. **J Assoc Physicians India** 1995 Nov;43(11):783-90 (16 ref.)

PSEUDOTUMOR, INFLAMMATORY see **GRANULOMA, PLASMA CELL**

PSEUDOTUMOR, INFLAMMATORY, ORBITAL see **GRANULOMA, PLASMA CELL, ORBITAL**

PSEUDOXANTHOMA ELASTICUM

COMPLICATIONS

[Ictus and cutaneous vascular syndromes] Trejo Gabriel y Galán JM. **Rev Neurol** 1995;23 Suppl 1:S99-105 (46 ref.) **(Spa)**

PATHOLOGY

Fibroelastolytic patterns of intrinsic skin aging: pseudoxanthoma-elasticum-like papillary dermal elastolysis and white fibrous papulosis of the neck. Rongioletti F, et al. **Dermatology** 1995;191(1):19-24 (32 ref.)

PHYSIOPATHOLOGY

Calcification of elastic fibers in pseudoxanthoma elasticum. Truter S, et al. **Mt Sinai J Med** 1996 May-Sep; 63(3-4):210-5 (53 ref.)

PSITTACINES

Chlamydia psittaci infections: a review with emphasis on avian chlamydiosis. Vanrompay D, et al. **Vet Microbiol** 1995 Jul;45(2-3):93-119 (237 ref.)

Diseases of the respiratory tract in psittacine birds. Zwart P. **Vet Q** 1995 Apr;17 Suppl 1:S52-3 (3 ref.)

PSITTACOSIS see **ORNITHOSIS**

PSITTACOSIS-LYMPHOGRANULOMA GROUP see **CHLAMYDIA**

PSOAS ABSCESS

Iliopsoas abscess: etiology, diagnosis, and treatment. Desandre AR, et al. **Am Surg** 1995 Dec;61(12):1087-91 (22 ref.)

Tuberculous psoas abscess. Harrigan RA, et al. **J Emerg Med** 1995 Jul-Aug;13(4):493-8 (32 ref.)

MICROBIOLOGY

Pneumococcal pyomyositis. Case report, review of the literature, and comparison with classic pyomyositis caused by other bacteria. Collazos J, et al. **Arch Intern Med** 1996 Jul 8;156(13):1470-4 (40 ref.)

[A case of psoas abscess associated in the elderly] Yamamoto T, et al. **Kansenshogaku Zasshi** 1996 Apr;70(4):371-6 (17 ref.) (Eng. Abstr.) **(Jpn)**

THERAPY

[Percutaneous catheter drainage of an unusually extensive tuberculous hypostatic abscess] Freund M, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Jul;165(1):96-8 (11 ref.) **(Ger)**

ULTRASONOGRAPHY

[Diagnosis of a retroperitoneal BCG abscess in an infant. Case report and review of the literature] Stegmann J. **Ultraschall Med** 1996 Feb;17(1):27-30 (21 ref.) (Eng. Abstr.) **(Ger)**

PSOAS MUSCLES

Solitary contralateral psoas metastasis 14 years after radical nephrectomy for organ confined renal cell carcinoma. Linn JF, et al. **J Urol** 1996 Jul;156(1):173 (2 ref.)

[Femoral neuropathy due to a spontaneous hematoma of the iliopsoas muscle during therapy with heparin-calcium] Casoni P, et al. **Acta Biomed Ateneo Parmense** 1994; 65(5-6):289-96 (5 ref.) (Eng. Abstr.) **(Ita)**

BLOOD SUPPLY

Spontaneous iliopsoas hematoma in patients with unstable coronary syndromes receiving intravenous heparin in therapeutic doses. Sasson Z, et al. **Can J Cardiol** 1996 May; 12(5):490-4 (35 ref.)

RADIOGRAPHY

Iliopsoas compartment: normal anatomy and pathologic processes. Torres GM, et al. **Radiographics** 1995 Nov; 15(6):1285-97 (12 ref.)

PSORALEN ULTRAVIOLET A THERAPY see **PUVA THERAPY**

PSORALENS

see related

COUMARINS

Psoralen photobiology: recent advances. Gasparro FP. **Photochem Photobiol** 1996 May;63(5):553-7 (36 ref.)

PSORIASIS

Psoriasis: changing clinical patterns. Rotstein H. **Australas J Dermatol** 1996 May;37 Suppl 1:S27-9 (46 ref.)

Psoriasis. Naldi L. **Dermatol Clin** 1995 Jul;13(3):635-47 (97 ref.)

Research models for psoriasis: "great expectations". Wolf R, et al. **Int J Dermatol** 1995 Jul;34(7):448-55 (106 ref.)

Why the "SAPHO" syndrome? [editorial] Kahn MF. **J Rheumatol** 1995 Nov;22(11):2017-9 (20 ref.)

BLOOD

[Trans-acitretin is metabolized back to etretinate. Importance for oral retinoid therapy] Almond-Roesler B, et al. **Hautarzt** 1996 Mar;47(3):173-7 (29 ref.) (Eng. Abstr.) **(Ger)**

CLASSIFICATION

Guttate and plaque psoriasis. Christophers E, et al. **Dermatol Clin** 1995 Oct;13(4):751-6 (34 ref.)

Pustular and erythrodermic psoriasis. Prystowsky JH, et al. **Dermatol Clin** 1995 Oct;13(4):757-70 (28 ref.)

COMPLICATIONS

The coexistence of psoriasis with lupus erythematosus and other photosensitive disorders. Zalla MJ, et al. **Acta Derm Venereol Suppl (Stockh)** 1996;195:1-15 (103 ref.)

CONGENITAL

Congenital erythrodermic psoriasis: case report and literature review. Salleras M, et al. **Pediatr Dermatol** 1995 Sep; 12(3):231-4 (35 ref.)

DIAGNOSIS

Pustular psoriasis limited to the penis. Quan MB, et al. **Int J Dermatol** 1996 Mar;35(3):202-4 (14 ref.)

The outcomes movement and new measures of the severity of psoriasis. Mckenna KE, et al. **J Am Acad Dermatol** 1996 Mar;34(3):534-8 (47 ref.)

DRUG THERAPY

Hazards of low dose methotrexate [editorial] Conaghan PG, et al. **Aust N Z J Med** 1995 Dec;25(6):670-3 (30 ref.)

Psoriasis: mechanisms and entry points for possible therapeutic interventions. Christophers E. **Australas J Dermatol** 1996 May;37 Suppl 1:S4-6 (27 ref.)

Photodynamic therapy for psoriasis? Fergin P. **Australas J Dermatol** 1996 May;37(2):87-8 (17 ref.)

PUVA for psoriasis. González E. **Dermatol Clin** 1995 Oct; 13(4):851-66 (109 ref.)

Methotrexate and other chemotherapeutic agents used to treat psoriasis. Jeffes EW III, et al. **Dermatol Clin** 1995 Oct;13(4):875-90 (128 ref.)

Topical corticosteroids. Katz HI. **Dermatol Clin** 1995 Oct; 13(4):805-15 (91 ref.)

Cyclosporine: what clinicians need to know. Koo J, et al. **Dermatol Clin** 1995 Oct;13(4):897-907 (69 ref.)

Vitamin D3 analogues. Kragballe K. **Dermatol Clin** 1995 Oct; 13(4):835-9 (37 ref.)

Future psoriasis therapy. Lebwohl M. **Dermatol Clin** 1995 Oct;13(4):915-23 (81 ref.)

Modifications of PUVA. Momtaz-T K, et al. **Dermatol Clin** 1995 Oct;13(4):867-73 (71 ref.)

Tars and anthralins. Silverman A, et al. **Dermatol Clin** 1995 Oct;13(4):817-33 (137 ref.)

Antimicrobial treatment of psoriasis. Skinner RB Jr, et al. **Dermatol Clin** 1995 Oct;13(4):909-13 (18 ref.)

Systemic retinoids for psoriasis. Wieder JM, et al. **Dermatol Clin** 1995 Oct;13(4):891-6 (34 ref.)

Current treatment options in psoriasis. Phillips TJ. **Hosp Pract (Off Ed)** 1996 Apr 15;31(4):155-7, 161-4, 166 (6 ref.)

Topical therapy for psoriasis. Lebwohl M, et al. **Int J Dermatol** 1995 Oct;34(10):673-84 (67 ref.)

Neuropathogenesis and neuropharmacology of psoriasis. Raychaudhuri SP, et al. **Int J Dermatol** 1995 Oct; 34(10):685-93 (114 ref.)

Calcipotriol: a new drug for topical psoriasis treatment. Kragballe K. **Pharmacol Toxicol** 1995 Oct;77(4):241-6 (41 ref.)

EPIDEMIOLOGY

Epidemiology of psoriasis. Stern RS. **Dermatol Clin** 1995 Oct; 13(4):717-22 (60 ref.)

ETIOLOGY

Pathogenesis of psoriasis. Kadunce DP, et al. **Dermatol Clin** 1995 Oct;13(4):723-37 (144 ref.)

The immunopathology of psoriasis. Christophers E. **Int Arch Allergy Immunol** 1996 Jul;110(3):199-206 (81 ref.)

Therapeutic perspectives in psoriasis. Farber EM. **Int J Dermatol** 1995 Jul;34(7):456-60 (50 ref.)

Neuropathogenesis and neuropharmacology of psoriasis. Raychaudhuri SP, et al. **Int J Dermatol** 1995 Oct; 34(10):685-93 (114 ref.)

IMMUNOLOGY

Immunopathogenesis and immunotherapy of psoriasis. Griffiths TW, et al. **Dermatol Clin** 1995 Oct;13(4):739-49 (159 ref.)

The immunopathology of psoriasis. Christophers E. **Int Arch Allergy Immunol** 1996 Jul;110(3):199-206 (81 ref.)

Psoriasis, T cells and autoimmunity. Griffiths CE, et al. **J R Soc Med** 1996 Jun;89(6):315-9 (60 ref.)

PATHOLOGY

Problem sites: scalp, palm and sole, and nail. Larko O. **Dermatol Clin** 1995 Oct;13(4):771-7 (91 ref.)

PHYSIOPATHOLOGY

[Resolution of psoriasis vulgaris following allogeneic bone marrow transplantation for aplastic anemia] Yokota A, et al. **Rinsho Ketsueki** 1996 Jan;37(1):35-9 (12 ref.) (Eng. Abstr.) **(Jpn)**

PSYCHOLOGY

Psychological and psychophysiological aspects of psoriasis. Ginsburg IH. **Dermatol Clin** 1995 Oct;13(4):793-804 (113 ref.)

REHABILITATION

[Dermatologic climate therapy--definition, indications and public health necessity] Vocks E, et al. **Rehabilitation (Stuttg)** 1995 Aug;34(3):148-53 (21 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Phototherapy. Abel EA. **Dermatol Clin** 1995 Oct;13(4):841-9 (44 ref.)

Immunopathogenesis and immunotherapy of psoriasis. Griffiths TW, et al. **Dermatol Clin** 1995 Oct;13(4):739-49 (159 ref.)

Therapeutic perspectives in psoriasis. Farber EM. **Int J Dermatol** 1995 Jul;34(7):456-60 (50 ref.)

The outcomes movement and new measures of the severity of psoriasis. Mckenna KE, et al. **J Am Acad Dermatol** 1996 Mar;34(3):534-8 (47 ref.)

PUVA therapy is preferable to UVB phototherapy in the management of HIV-associated dermatoses. Morison WL. **Photochem Photobiol** 1996 Aug;64(2):267-8 (11 ref.)

VIROLOGY

PUVA therapy is preferable to UVB phototherapy in the management of HIV-associated dermatoses. Morison WL. **Photochem Photobiol** 1996 Aug;64(2):267-8 (11 ref.)

PSORIASIS, ARTHRITIC see **ARTHRITIS, PSORIATIC**

PSORIASIS ARTHROPATHICA see **ARTHRITIS, PSORIATIC**

PSYCHEDELIC AGENTS see **HALLUCINOGENS**

PSYCHIATRIC DEPARTMENT, HOSPITAL

TRENDS

The future of consultation-liaison psychiatry and medical-psychiatric units in the era of managed care. Goldberg RJ, et al. **Gen Hosp Psychiatry** 1995 Jul; 17(4):268-77 (55 ref.)

PSYCHIATRIC NURSING

The psychiatric model: a critical analysis of its undermining effects on nursing in chronic mental illness. Hall BA. **ANS Adv Nurs Sci** 1996 Mar;18(3):16–26 (28 ref.)

Geropsychiatric public sector nursing: placement challenges. Fuller K, et al. **J Psychosoc Nurs Ment Health Serv** 1995 Aug;33(8):20–2 (6 ref.)

Serving time: psychiatric mental health nursing in corrections. Peternelj-Taylor CA, et al. **J Psychosoc Nurs Ment Health Serv** 1995 Aug;33(8):12–9 (35 ref.)

The role of the consultation–liaison nurse. Caring for patients with AIDS dementia complex. Price N. **J Psychosoc Nurs Ment Health Serv** 1995 Dec;33(12):31–4 (14 ref.)

The role of the psychiatric nurse practitioner. Caverly SE. **Nurs Clin North Am** 1996 Sep;31(3):449–63 (36 ref.)

ECONOMICS

Quality, cost-effective psychiatric treatment: A CNS--MD collaborative practice model. Saur CD, et al. **Arch Psychiatr Nurs** 1995 Dec;9(6):332–7 (15 ref.)

EDUCATION

State of the art: nursing knowledge and electroconvulsive therapy. Froimson L, et al. **Convuls Ther** 1995 Sep; 11(3):205–11 (60 ref.)

METHODS

Special report: protection and advocacy: what nurses need to know. Schauer C. **Arch Psychiatr Nurs** 1995 Oct; 9(5):233–9 (15 ref.)

Control and restraint in contemporary psychiatric nursing: some ethical considerations. Hopton J. **J Adv Nurs** 1995 Jul;22(1):110–5 (48 ref.)

ORGANIZATION & ADMINISTRATION

The development of community psychiatric nursing: a professional project? Godin P. **J Adv Nurs** 1996 May; 23(5):925–34 (60 ref.)

TRENDS

Psychiatric nursing outcome research: the state of the science. Merwin E, et al. **Arch Psychiatr Nurs** 1995 Dec;9(6):311–31 (101 ref.)

Mental health nurses working purposefully with people with serious and enduring mental illness--an international perspective. Gournay K. **Int J Nurs Stud** 1995 Aug; 32(4):341–52 (68 ref.)

PSYCHIATRIC SOCIAL WORK see **SOCIAL WORK, PSYCHIATRIC**

PSYCHIATRIC STATUS RATING SCALES

The clinical boundaries of posttraumatic stress disorder. McGorry PD. **Aust N Z J Psychiatry** 1995 Sep; 29(3):385–93 (38 ref.)

Negative symptoms and affective disturbance in schizophrenia and related disorders. Malla AK. **Can J Psychiatry** 1995 Sep;40(7 Suppl 2):S55–9 (49 ref.)

Demography of DSM–III borderline personality disorder (PD): a comparison with Axis II PDs, affective illness and schizophrenia convergent and discriminant validation. Taub JM. **Int J Neurosci** 1995 Jun;82(3–4):191–214 (96 ref.)

Classification of child and adolescent psychopathology. Cantwell DP. **J Child Psychol Psychiatry** 1996 Jan; 37(1):3–12 (80 ref.)

The prevalent clinical spectrum of bipolar disorders: beyond DSM–IV. Akiskal HS. **J Clin Psychopharmacol** 1996 Apr; 16(2 Suppl 1):4S–14S (91 ref.)

Culture and psychiatric diagnosis. Impact on DSM–IV and ICD–10. Alarcon RD. **Psychiatr Clin North Am** 1995 Sep; 18(3):449–65 (80 ref.)

Nosology of chronic mood disorders. First MB, et al. **Psychiatr Clin North Am** 1996 Mar;19(1):29–39 (10 ref.)

Symptomatology in dysthymic and major depressive disorder. Klein DN, et al. **Psychiatr Clin North Am** 1996 Mar;19(1):41–53 (18 ref.)

Differential diagnosis of chronic depressive disorders. McCullough JP, et al. **Psychiatr Clin North Am** 1996 Mar; 19(1):55–71 (80 ref.)

Culture and major depression. Current challenges in the diagnosis of mood disorders. Manson SM. **Psychiatr Clin North Am** 1995 Sep;18(3):487–501 (95 ref.)

[DSM IV and research. The problem of clinical trials] Boyer P. **Encephale** 1995 Dec;21 Spec No 5:41–6 (3 ref.) (Eng. Abstr.) **(Fre)**

[Methodological constraints in evaluating anti-deficit effects] Boyer P, et al. **Encephale** 1996 Jun;22 Spec No 2:25–7 (16 ref.) (Eng. Abstr.) **(Fre)**

[The importance of classifications in psychiatry] Lempérière T. **Encephale** 1995 Dec;21 Spec No 5:3–7 (14 ref.) (Eng. Abstr.) **(Fre)**

[Deficit: the value and difficulty of defining the primary or secondary character of observed symptoms] Petit M, et al. **Encephale** 1996 Jun;22 Spec No 2:13–8 (20 ref.) (Eng. Abstr.) **(Fre)**

[Diagnosis of Taijin-Kyofu and social phobia] Kasahara T. **Seishin Shinkeigaku Zasshi** 1995;97(5):357–66 (47 ref.) **(Jpn)**

HISTORY

The neo–Kraepelinian revolution in psychiatric diagnosis. Compton WM, et al. **Eur Arch Psychiatry Clin Neurosci** 1995;245(4–5):196–201 (29 ref.)

STATISTICS & NUMERICAL DATA

Recent developments for diagnostic measures in psychiatry. Ustün TB, et al. **Epidemiol Rev** 1995;17(1):210–20 (87 ref.)

Issues in the taxonomy of psychopathology in mental retardation. Einfeld SL, et al. **J Autism Dev Disord** 1995 Apr;25(2):143–67 (105 ref.)

DSM–III–R and persons with dual diagnoses: conceptual issues and strategies for future research. Sturmey P. **J Intellect Disabil Res** 1995 Oct;39 (Pt 5):357–64 (42 ref.)

[Importance of DSM IV (APA) and ICD–10 (WHO) in diagnosis and treatment of mood disorders] Bourgeois M. **Encephale** 1995 Dec;21 Spec No 5:47–52 (22 ref.) (Eng. Abstr.) **(Fre)**

[Classification and psychiatric practice] Ferreri M. **Encephale** 1995 Dec;21 Spec No 5:53–8 (10 ref.) (Eng. Abstr.) **(Fre)**

[Classification of mood disorders in adults] Guelfi JD. **Encephale** 1995 Dec;21 Spec No 5:21–9 (4 ref.) (Eng. Abstr.) **(Fre)**

[Depression in the child and adolescent] Klein R. **Encephale** 1995 Dec;21 Spec No 5:31–3 (19 ref.) (Eng. Abstr.) **(Fre)**

[DSM–IV] Pull CB. **Encephale** 1995 Dec;21 Spec No 5:15–20 (17 ref.) (Eng. Abstr.) **(Fre)**

[Classification of mental disorders according to ICD 10] Sartorius N. **Encephale** 1995 Dec;21 Spec No 5:9–13 (7 ref.) (Eng. Abstr.) **(Fre)**

[Hysteria, dissociation and conversion. A review of concepts, classification and diagnostic instruments] Spitzer C, et al. **Psychiatr Prax** 1996 Mar;23(2):63–8 (55 ref.) (Eng. Abstr.) **(Ger)**

PSYCHIATRY

The Internet and the future of psychiatry. Huang MP, et al. **Am J Psychiatry** 1996 Jul;153(7):861–9 (67 ref.)

Why do psychiatrists neglect religion? Neeleman J, et al. **Br J Med Psychol** 1995 Jun;68 (Pt 2):169–78 (83 ref.)

The biopsychosocial paradigm and the future of psychiatry. Freedman AM. **Compr Psychiatry** 1995 Nov–Dec; 36(6):397–406 (44 ref.)

The essential elements of culturally sensitive psychiatric services. Bhui K, et al. **Int J Soc Psychiatry** 1995 Winter; 41(4):242–56 (83 ref.)

Culture and psychiatric diagnosis. Impact on DSM–IV and ICD–10. Alarcon RD. **Psychiatr Clin North Am** 1995 Sep; 18(3):449–65 (80 ref.)

The cultural context of anxiety disorders. Kirmayer LJ, et al. **Psychiatr Clin North Am** 1995 Sep;18(3):503–21 (88 ref.)

Cultural considerations in the assessment and treatment of religious and spiritual problems. Lukoff D, et al. **Psychiatr Clin North Am** 1995 Sep;18(3):467–85 (93 ref.)

Psychiatrists as treatment team leaders: pitfalls and rewards. Rodenhauser P. **Psychiatr Q** 1996 Spring;67(1):11–31 (100 ref.)

A model for the classification and diagnosis of relational disorders. Committee on the Family, Group for the Advancement of Psychiatry. **Psychiatr Serv** 1995 Sep; 46(9):926–31 (61 ref.)

Patient requests for euthanasia and assisted suicide in terminal illness. The role of the psychiatrist. Block SD, et al. **Psychosomatics** 1995 Sep–Oct;36(5):445–57 (75 ref.)

[Humanitarianism: the gardener, the truck driver and the "shrink"] Maqueda F. **Psychiatr Enfant** 1995;38(1):311–43 (4 ref.) (Eng. Abstr.) **(Fre)**

[Violence--an element of the psychiatric profession] Cahn T. **Schweiz Arch Neurol Psychiatr** 1995;146(3):109–14 (25 ref.) (Eng. Abstr.) **(Ger)**

[Psychiatric studies on alcoholism in Japan] Saito T. **Arukoru Kenkyuto Yakubutsu Ison** 1995 Dec;30(6):411–25 (137 ref.) **(Jpn)**

[The Italian situation in psychiatry after fifteen years of the psychiatric reform: the mental health service in north Italy] Mizuno M. **Seishin Shinkeigaku Zasshi** 1996;98(1):27–40 (27 ref.) **(Jpn)**

[The concept of reification in psychiatry and sociology] Morozov VM, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1996;96(1):112–4 (15 ref.) **(Rus)**

EDUCATION

Ideological singularity as a defense against clinical complexity. Schultz-Ross RA. **Am J Psychother** 1995 Fall; 49(4):540–7 (35 ref.)

Managed care and the role and training of psychiatrists. Meyer RE, et al. **Health Aff (Millwood)** 1995 Fall; 14(3):65–77 (23 ref.)

HISTORY

[Ernö Jendrassik, internist-neurologist, his interest and activities in the field of psychiatry] Pisztora F. **Orv Hetil** 1995 Oct 29;136(44):2401–5 (52 ref.) **(Hun)**

INSTRUMENTATION

Nuclear magnetic resonance spectroscopy: a review of neuropsychiatric applications. Passe TJ, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1995 Jul; 19(4):541–63 (155 ref.)

LEGISLATION & JURISPRUDENCE

APA resource document: legal sanctions for mental health professional-patient sexual misconduct. Hoge SK, et al. **Bull Am Acad Psychiatry Law** 1995;23(3):433–48 (56 ref.)

MANPOWER

Decline of U.S. medical student career choice of psychiatry and what to do about it. Sierles FS, et al. **Am J Psychiatry** 1995 Oct;152(10):1416–26 (127 ref.)

Recruitment and workforce issues in late 20th century American psychiatry. Weissman S. **Psychiatr Q** 1996 Summer;67(2):125–37 (8 ref.)

METHODS

Review: DSM–IV and pain. King SA. **Clin J Pain** 1995 Sep; 11(3):171–6 (24 ref.)

[The use of the contingent negative wave in neurology and psychiatry] Vein AM, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995; 95(4):99–102 (79 ref.) **(Rus)**

ORGANIZATION & ADMINISTRATION

[How is new selective neuropsychiatry being structured?] Barraquer-Bordas LI. **Rev Neurol** 1996 Aug; 24(132):999–1007 (104 ref.) **(Spa)**

STATISTICS & NUMERICAL DATA

[Epidemiology of violence in psychiatry] Ferrero F, et al. **Schweiz Arch Neurol Psychiatr** 1995;146(3):121–5 (28 ref.) (Eng. Abstr.) **(Fre)**

TRENDS

Freudian suspicion versus suspicion of Freud. Crews F. **Ann N Y Acad Sci** 1996 Jun 24;775:470–82 (58 ref.)

The future of consultation–liaison psychiatry and medical–psychiatric units in the era of managed care. Goldberg RJ, et al. **Gen Hosp Psychiatry** 1995 Jul; 17(4):268–77 (55 ref.)

Cultural psychiatry. Theoretical, clinical, and research issues. Lewis-Fernández R, et al. **Psychiatr Clin North Am** 1995 Sep;18(3):433–48 (88 ref.)

The future of organ transplant psychiatry. Freeman AM 3rd, et al. **Psychosomatics** 1995 Sep–Oct;36(5):429–37 (68 ref.)

PSYCHIATRY, BIOLOGICAL see **BIOLOGICAL PSYCHIATRY**

PSYCHIATRY, GERIATRIC see **GERIATRIC PSYCHIATRY**

PSYCHICAL RESEARCH see **PARAPSYCHOLOGY**

PSYCHOACTIVE AGENTS see **PSYCHOTROPIC DRUGS**

PSYCHOANALYSIS

Predictors of outcome in child psychoanalysis: a retrospective study of 763 cases at the Anna Freud Centre. Fonagy P, et al. **J Am Psychoanal Assoc** 1996;44(1):27–77 (90 ref.)

The transference and the zone of proximal development. Wilson A, et al. **J Am Psychoanal Assoc** 1996;44(1):167–200 (51 ref.)

Countertransference as instrument and obstacle: a comprehensive and descriptive framework. Bouchard MA, et al. **Psychoanal Q** 1995 Oct;64(4):717–45 (36 ref.)

Of creatures large and small: size anxiety, psychic size, shame, and the analytic situation. Kilborne B. **Psychoanal Q** 1995 Oct;64(4):672–90 (24 ref.)

On those wrecked by success: a clinical inquiry. Levy ST, et al. **Psychoanal Q** 1995 Oct;64(4):639–57 (11 ref.)

The written dream: action, resistance and revelation. Stimmel B. **Psychoanal Q** 1995 Oct;64(4):658–71 (14 ref.)

Bernfeld's "The facts of observation in psychoanalysis": a response from psychoanalytic research. Weiss J. **Psychoanal Q** 1995 Oct;64(4):699–716 (40 ref.)

[The evolution of the concept of archetypes in Jungian psychology] Pérez Urdaniz A, et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1995 Sep–Oct;23(5):262–5 (25 ref.) (Eng. Abstr.) **(Spa)**

PSYCHOANALYTIC INTERPRETATION

Cultural psychopathology and the "false memory syndrome" debates: a view from psychoanalysis. Berger LS. **Am J Psychother** 1996 Spring;50(2):167–77 (41 ref.)

Countertransference as instrument and obstacle: a comprehensive and descriptive framework. Bouchard MA, et al. **Psychoanal Q** 1995 Oct;64(4):717–45 (36 ref.)

PSYCHOANALYTIC INTERPRETATION

On those wrecked by success: a clinical inquiry. Levy ST, et al. **Psychoanal Q** 1995 Oct;64(4):639–57 (11 ref.)
Bernfeld's "The facts of observation in psychoanalysis": a response from psychoanalytic research. Weiss J. **Psychoanal Q** 1995 Oct;64(4):699–716 (40 ref.)

PSYCHOANALYTIC THEORY

The characterological basis of multiple personality. Brenner I. **Am J Psychother** 1996 Spring;50(2):154–66 (30 ref.)
The borderline patient: update on the diagnosis, theory, and treatment from a psychodynamic perspective. Goldstein WN. **Am J Psychother** 1995 Summer;49(3):317–37 (59 ref.)
Transtheoretical practice of psychotherapy. Karasu TB. **Am J Psychother** 1995 Fall;49(4):484–503 (62 ref.)
Unconscious fantasy in psychotherapy. Levin K. **Am J Psychother** 1996 Spring;50(2):137–53 (54 ref.)
A clinical concept of the self: the experiential being. De Waele M. **Br J Med Psychol** 1995 Sep;68 (Pt 3):223–42 (85 ref.)
A self psychologist in couplesland: multisubjective approach to transference and countertransference-like phenomena in marital relationships. Livingston MS. **Fam Process** 1995 Dec;34(4):427–39 (26 ref.)
Intersubjectivity in psychoanalysis: a critical review. Dunn J. **Int J Psychoanal** 1995 Aug;76 (Pt 4):723–38 (90 ref.)
On those wrecked by success: a clinical inquiry. Levy ST, et al. **Psychoanal Q** 1995 Oct;64(4):639–57 (11 ref.)
The psychoanalytical concept from a neurophysiological perspective. Derevenco P. **Rom J Physiol** 1994 Jan–Dec; 31(1–4):13–8 (35 ref.)
[The development of susceptibility to depression and its psychodynamics] Tähkä V. **Duodecim** 1994;110(3):267–76 (20 ref.) **(Fin)**
[Difficulties in becoming a woman and staying a woman. On the problems of female identity in menopause] Hettlage-Varjas A, et al. **Psyche (Stuttg)** 1995 Sep–Oct; 49(9–10):903–37 (40 ref.) (Eng. Abstr.) **(Ger)**
[Development of the affect system] Moser U, et al. **Psyche (Stuttg)** 1996 Jan;50(1):32–84 (110 ref.) (Eng. Abstr.) **(Ger)**
[Psychoanalytic theories of hypochondria] Röder CH, et al. **Psyche (Stuttg)** 1995 Nov;49(11):1068–98 (65 ref.) (Eng. Abstr.) **(Ger)**
[Transsexual wish and and cis-sexual defense] Sigusch V. **Psyche (Stuttg)** 1995 Sep–Oct;49(9–10):811–37 (75 ref.) (Eng. Abstr.) **(Ger)**
[The evolution of the concept of archetypes in Jungian psychology] Pérez Urdaniz A, et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1995 Sep–Oct;23(5):262–5 (25 ref.) (Eng. Abstr.) **(Spa)**

PSYCHOANALYTIC THERAPY

The third step: Freud, the feminists, and postmodernism. Dimen M. **Am J Psychoanal** 1995 Dec;55(4):303–19; discussion 321–30 (31 ref.)
The borderline patient: update on the diagnosis, theory, and treatment from a psychodynamic perspective. Goldstein WN. **Am J Psychother** 1995 Summer;49(3):317–37 (59 ref.)
Intersubjectivity in psychoanalysis: a critical review. Dunn J. **Int J Psychoanal** 1995 Aug;76 (Pt 4):723–38 (90 ref.)
The role of affects in the process of change in psychotherapy. Stein R. **Isr J Psychiatry Relat Sci** 1995;32(3):174–83 (26 ref.)
Desire and the female analyst. Schaverien J. **J Anal Psychol** 1996 Apr;41(2):261–87 (91 ref.)
Jungian metapsychology and neurobiological theory. Tresan DI. **J Anal Psychol** 1996 Jul;41(3):399–436 (140 ref.)
Chaotic analysis in psychology and psychoanalysis. Kincanon E, et al. **J Psychol** 1995 Sep;129(5):495–505 (14 ref.)
[Between idealization and devaluation—problems and perspectives of theoretical analyses of female homo- and heterosexuality] Flaake K. **Psyche (Stuttg)** 1995 Sep–Oct; 49(9–10):867–85 (70 ref.) (Eng. Abstr.) **(Ger)**
[Management dialogue within multi-professional teams: contribution of psychoanalysis to integrated therapy of psychotic patients] Böker H. **Psychiatr Prax** 1995 Sep; 22(5):201–5 (18 ref.) (Eng. Abstr.) **(Ger)**
[Remembering in the transference—on the interdisciplinary dialogue between psychoanalysis and biological memory research] Leuzinger-Bohleber M. **Psychother Psychosom Med Psychol** 1996 Jun;46(6):217–27 (53 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Enactments: an evolving dyadic concept of acting out. Frayn DH. **Am J Psychother** 1996 Spring;50(2):194–207 (35 ref.)
Transtheoretical practice of psychotherapy. Karasu TB. **Am J Psychother** 1995 Fall;49(4):484–503 (62 ref.)
Unconscious fantasy in psychotherapy. Levin K. **Am J Psychother** 1996 Spring;50(2):137–53 (54 ref.)
Orphans of the 'Real': II. The future of object relations theory in the treatment of the psychoses and other primitive mental disorders. Grotstein JS. **Bull Menninger Clin** 1995 Summer;59(3):312–32 (75 ref.)
Orphans of the 'Real': I. Some modern and postmodern perspectives on the neurobiological and psychosocial dimensions of psychosis and other primitive mental disorders. Grotstein JS. **Bull Menninger Clin** 1995 Summer; 59(3):287–311 (115 ref.)
The couple and the psychotherapeutic group. Kretsch RA, et al. **Isr J Psychiatry Relat Sci** 1995;32(3):184–93 (18 ref.)
The familiar and the strange: the dynamics of change. Lazar R. **Isr J Psychiatry Relat Sci** 1995;32(3):157–66 (25 ref.)
[Reflections on transference, countertransference, session frequency and the analytic process] Holder A. **Psychiatr Enfant** 1995;38(2):603–23 (5 ref.) (Eng. Abstr.) **(Fre)**
[2 basic problems of psychoanalytic psychotherapy and their philosophical revision] Bürgy M. **Psychother Psychosom Med Psychol** 1995 Nov; 45(11):389–94 (57 ref.) (Eng. Abstr.) **(Ger)**

TRENDS

[Anna, Irma and Dora—the key to the mothers in the creation of psychoanalysis] King V. **Psyche (Stuttg)** 1995 Sep–Oct; 49(9–10):838–66 (60 ref.) (Eng. Abstr.) **(Ger)**

PSYCHODRAMA

see related
ACTING OUT

PSYCHOGENETICS see **GENETICS, BEHAVIORAL**

PSYCHOGERIATRICS see **GERIATRIC PSYCHIATRY**

PSYCHOIMMUNOLOGY see **PSYCHONEUROIMMUNOLOGY**

PSYCHOLINGUISTICS

see related
LANGUAGE DEVELOPMENT

PSYCHOLOGICAL TESTS

What are the functional consequences of neurocognitive deficits in schizophrenia? Green MF. **Am J Psychiatry** 1996 Mar;153(3):321–30 (73 ref.)
[Experienced quality of life of somatic nursing home patients: a review of measuring instruments] van Campen C, et al. **Tijdschr Gerontol Geriatr** 1996 Feb;27(1):20–8 (62 ref.) (Eng. Abstr.) **(Dut)**
[Presentation by the GRECO group of the French adaptation of a cognitive assessment scale used in Alzheimer type dementia] Puel M, et al. **Presse Med** 1996 Jun 22; 25(22):1028–32 (14 ref.) (Eng. Abstr.) **(Fre)**
[Indications for psychological examination in diagnosis, certification and prevention of occupational diseases] Waszkowska M. **Med Pr** 1995;46(5):505–8 (14 ref.) (Eng. Abstr.) **(Pol)**

PSYCHOLOGICAL THEORY

Constructivist developmental theory and therapy: implications for counseling adolescents. Crespi TD, et al. **Adolescence** 1995 Fall;30(119):735–43 (20 ref.)
Social and cognitive approaches to depression: towards a new synthesis. Champion LA, et al. **Br J Clin Psychol** 1995 Nov;34 (Pt 4):485–503 (96 ref.)
Reminiscence: a continuity theory framework. Parker RG. **Gerontologist** 1995 Aug;35(4):515–25 (81 ref.)
Post-natal depression: the relevance of sociological approaches. Thurtle V. **J Adv Nurs** 1995 Sep;22(3):416–24 (43 ref.)
Language and pain expression. Waddie NA. **J Adv Nurs** 1996 May;23(5):868–72 (15 ref.)
Naming and framing: the social construction of diagnosis and illness. Brown P. **J Health Soc Behav** 1995;Spec No:34–52 (69 ref.)
Evolution of parental stress and coping processes: a framework for critical care practice. LaMontagne LL, et al. **J Pediatr Nurs** 1995 Aug;10(4):212–8 (13 ref.)
The difficulty with recalling people's names: the plausible phonology hypothesis. Brennen T. **Memory** 1993 Dec; 1(4):409–31 (45 ref.)
Naming faces and naming names: exploring an interactive activation model of person recognition. Burton AM, et al. **Memory** 1993 Dec;1(4):457–80 (26 ref.)
Proper names and how they are learned. La Palme Reyes M, et al. **Memory** 1993 Dec;1(4):433–55 (32 ref.)
Forgotten variables in memory theory and research. Mullin PA, et al. **Memory** 1993 Mar;1(1):43–64 (130 ref.)
[An update on merycism and early depression: a critical review of the literature and a psychopathological hypothesis] Guedeney A. **Psychiatr Enfant** 1995; 38(1):345–63 (69 ref.) (Eng. Abstr.) **(Fre)**
[Theoretical perspectives on autism] Klin A, et al. **Psychiatr Enfant** 1995;38(2):477–94 (14 ref.) (Eng. Abstr.) **(Fre)**

PSYCHOLOGICAL WARFARE

see related
PERSUASIVE COMMUNICATION
PROPAGANDA

PSYCHOLOGY

EDUCATION

The changing workforce: the role of health psychology. Frank RG, et al. **Health Psychol** 1995 Nov;14(6):519–25 (33 ref.)

MANPOWER

The changing workforce: the role of health psychology. Frank RG, et al. **Health Psychol** 1995 Nov;14(6):519–25 (33 ref.)

PSYCHOLOGY, CLINICAL

Behavioral medicine, clinical health psychology, and cost offset. Friedman R, et al. **Health Psychol** 1995 Nov; 14(6):509–18 (52 ref.)

PSYCHOLOGY, COMPARATIVE

Mechanisms related to psychological well-being in older women with chronic illnesses: age and disease comparisons. Heidrich SM. **Res Nurs Health** 1996 Jun;19(3):225–35 (47 ref.)

PSYCHOLOGY, CRIMINAL see **CRIMINAL PSYCHOLOGY**

PSYCHOLOGY, EDUCATIONAL

[Psychoeducation—special reference to social skill training] Sarata Y. **Seishin Shinkeigaku Zasshi** 1995;97(7):522–8 (9 ref.) **(Jpn)**

PSYCHOLOGY, INDUSTRIAL

see related
HUMAN ENGINEERING

PSYCHOLOGY, MEDICAL

TRENDS

Bridging theory and practice: cognitive science and medical informatics. Patel VL, et al. **Medinfo** 1995;8 Pt 2:1278–82 (26 ref.)

PSYCHOLOGY, PASTORAL see **PASTORAL CARE**

PSYCHOLOGY, PHYSIOLOGICAL see **PSYCHOPHYSIOLOGY**

PSYCHOLOGY, SCHIZOPHRENIC see **SCHIZOPHRENIC PSYCHOLOGY**

PSYCHOLOGY, SOCIAL

What do connectionism and social psychology offer each other? Smith ER. **J Pers Soc Psychol** 1996 May; 70(5):893–912 (132 ref.)
What is the ultimate cause of socio-economic inequalities in health? An explanation in terms of evolutionary psychology. Charlton BG. **J R Soc Med** 1996 Jan;89(1):3–8 (47 ref.)

PSYCHOMETRICS

Satisfying solutions? A review of some unresolved issues in the measurement of patient satisfaction. Avis M, et al. **J Adv Nurs** 1995 Aug;22(2):316–22 (60 ref.)
Definitions of quality of life: a taxonomy. Farquhar M. **J Adv Nurs** 1995 Sep;22(3):502–8 (41 ref.)
Health-related quality of life as an outcome for patients with heart failure. Shively M, et al. **J Cardiovasc Nurs** 1996 Jan; 10(2):89–96 (14 ref.)
Evaluating teaching effectiveness. Kirschling JM, et al. **J Nurs Educ** 1995 Dec;34(9):401–10 (30 ref.)
Memory tools for the researcher and clinician. Gathercole SE, et al. **Memory** 1994 Jun;2(2):97–101 (14 ref.)
The California Verbal Learning Test: psychometric characteristics and clinical application. Elwood RW. **Neuropsychol Rev** 1995 Sep;5(3):173–201 (122 ref.)
Evaluating the efficacy of medical treatment: possibilities and limitations. Jenkinson C. **Soc Sci Med** 1995 Nov; 41(10):1395–401 (49 ref.)
Environmental and health-related quality of life: conceptual and methodological similarities. Rogerson RJ. **Soc Sci Med** 1995 Nov;41(10):1373–82 (80 ref.)
Health-related quality of life between naturalism and hermeneutics. Rosenberg R. **Soc Sci Med** 1995 Nov; 41(10):1411–5 (17 ref.)

METHODS

Developmental testing. Gilbride KE. **Pediatr Rev** 1995 Sep; 16(9):338–45 (25 ref.)
MRC quality of life studies using a daily diary card—practical lessons learned from cancer trials. Fayers P. **Qual Life Res** 1995 Aug;4(4):343–52 (42 ref.)
Clinical and public health perspectives and applications of health-related quality of life measurement. Ebrahim S. **Soc Sci Med** 1995 Nov;41(10):1383–94 (68 ref.)

PSYCHOMOTOR AGITATION

[Motor units hyperactivity syndromes] Vílchez JJ. **Rev Neurol** 1995 Jan–Feb;23(119):28–9 (37 ref.) **(Spa)**

DRUG THERAPY

Sedation of the agitated, critically ill patient without an artificial airway. Durbin CG Jr. **Crit Care Clin** 1995 Oct; 11(4):913–36 (86 ref.)

Neuroleptic treatment of agitation and psychosis in dementia. Devanand DP, et al. **J Geriatr Psychiatry Neurol** 1995 Oct; 8 Suppl 1:S18–27 (141 ref.)

Anticonvulsant and other non-neuroleptic treatment of agitation in dementia. Tariot PN, et al. **J Geriatr Psychiatry Neurol** 1995 Oct;8 Suppl 1:S28–39 (103 ref.)

Neuroleptic malignant syndrome in a trauma patient [see comments] Burke C, et al. **J Trauma** 1995 Oct;39(4):796–8 (11 ref.) Comment in: J Trauma 1996 Apr;40(4):673.

NURSING

Agitation: measurement, management, and intervention research. Weinrich S, et al. **Arch Psychiatr Nurs** 1995 Oct; 9(5):251–60 (112 ref.)

PHYSIOPATHOLOGY

Biologic markers and neurochemical correlates of agitation and psychosis in dementia. Kirby M, et al. **J Geriatr Psychiatry Neurol** 1995 Oct;8 Suppl 1:S2–7 (63 ref.)

PREVENTION & CONTROL

Difficult dementia: six steps to control problem behaviors. Banazak DA. **Geriatrics** 1996 Feb;51(2):36–42 (16 ref.)

PSYCHOMOTOR DISORDERS

CLASSIFICATION

[Motor deficiencies in children: for a nosologic clarification in epidemiological studies] Cans C, et al. **Arch Pediatr** 1996 Jan;3(1):75–80 (20 ref.) (Eng. Abstr.) **(Fre)**

PSYCHOMOTOR PERFORMANCE

Motor problems in children with developmental coordination disorder: review of the literature. Willoughby C, et al. **Am J Occup Ther** 1995 Sep;49(8):787–94 (40 ref.)

Origins and early development of perception, action, and representation. Bertenthal BI. **Annu Rev Psychol** 1996; 47:431–59 (150 ref.)

Penetrating gunshots to the head and lack of immediate incapacitation. I. Wound ballistics and mechanisms of incapacitation. Karger B. **Int J Legal Med** 1995; 108(2):53–61 (90 ref.)

Habitual physical activity, psychomotor performance, and older workers. Ilmarinen J, et al. **Nutr Rev** 1996 Apr;54(4 Pt 2):S44–52 (39 ref.)

[Factors limiting performance in the triathlon] Margaritis I. **Can J Appl Physiol** 1996 Feb;21(1):1–15 (69 ref.) (Eng. Abstr.) **(Fre)**

DRUG EFFECTS

The neurobehavioural toxicology and teratology of lead. Winneke G, et al. **Arch Toxicol Suppl** 1996;18:57–70 (60 ref.)

Neurobehavioral pharmacology of cocaine: role for serotonin in its locomotor and discriminative stimulus effects. Cunningham KA, et al. **NIDA Res Monogr** 1994;145:40–66 (95 ref.)

PHYSIOLOGY

Follow-up of children born with an umbilical arterial blood pH < 7 [see comments] Nagel HT, et al. **Am J Obstet Gynecol** 1995 Dec;173(6):1758–64 (26 ref.) Comment in: Am J Obstet Gynecol 1996 Jul;175(1):229.

Task dependency of visual processing in the human visual system. Orban GA, et al. **Behav Brain Res** 1996 Apr; 76(1–2):215–23 (41 ref.)

Transfer of coded information from sensory to motor networks. Salinas E, et al. **J Neurosci** 1995 Oct; 15(10):6461–74 (80 ref.)

Corpus callosum and simple visuomotor integration. Berlucchi G, et al. **Neuropsychologia** 1995 Aug; 33(8):923–36 (74 ref.)

Sensory information from the upper airway: role in the control of breathing. Sant'Ambrogio G, et al. **Respir Physiol** 1995 Oct;102(1):1–16 (59 ref.)

PSYCHONEUROIMMUNOLOGY

see related
NEUROIMMUNOMODULATION

"Sucking with vampires". The medicine of unreason. Weissmann G. **Ann N Y Acad Sci** 1996 Jun 24;775:179–87 (26 ref.)

Psychoneuroimmunological studies in HIV disease. McCain NL, et al. **Annu Rev Nurs Res** 1996;14:23–55 (75 ref.)

Psychoneuroimmunology: an emerging framework for nursing research. Zeller JM, et al. **J Adv Nurs** 1996 Apr; 23(4):657–64 (63 ref.)

[Stress and the immune system] Schedlowski M, et al. **Naturwissenschaften** 1996 May;83(5):214–20 (78 ref.) (Eng. Abstr.) **(Ger)**

[Psychoneuroimmunology: brain–immunity related medicine] Kaminiwa S, et al. **Seishin Shinkeigaku Zasshi** 1995; 97(8):567–74 (22 ref.) **(Jpn)**

PSYCHONEUROSES see **NEUROTIC DISORDERS**

PSYCHOPATHIC PERSONALITY see **ANTISOCIAL PERSONALITY DISORDER**

PSYCHOPHARMACEUTICALS see **PSYCHOTROPIC DRUGS**

PSYCHOPHARMACOLOGY

see related
PSYCHOTROPIC DRUGS

Stress: a major variable in the psychopharmacologic response. Stanford SC. **Pharmacol Biochem Behav** 1996 May;54(1):211–7 (49 ref.)

Psychopharmacology of central serotonergic systems. Baumgarten HG, et al. **Pharmacopsychiatry** 1995 Oct;28 Suppl 2:73–9 (42 ref.)

[Psychosocial effects in pharmacology: something more than an anecdote?] Salvador-Carulla L, et al. **Med Clin (Barc)** 1995 Oct 14;105(12):464–9 (38 ref.) **(Spa)**

PSYCHOPHYSICS

Psychophysical approaches to motor control. Soechting JF, et al. **Curr Opin Neurobiol** 1995 Dec;5(6):742–8 (80 ref.)

Adaptive psychophysical procedures. Treutwein B. **Vision Res** 1995 Sep;35(17):2503–22 (77 ref.)

PSYCHOPHYSIOLOGIC DISORDERS

DIAGNOSIS

Psychological and psychophysiological aspects of psoriasis. Ginsburg IH. **Dermatol Clin** 1995 Oct;13(4):793–804 (113 ref.)

Medical disorders in the schizophrenic patient. Vieweg V, et al. **Int J Psychiatry Med** 1995;25(2):137–72 (179 ref.)

What is the evidence for an organic lesion in whiplash injury? Gargan MF. **J Psychosom Res** 1995 Aug;39(6):777–81 (27 ref.)

Occupational stress and the law: some current issues for employers. Howard G. **J Psychosom Res** 1995 Aug; 39(6):707–19 (27 ref.)

The post-concussional syndrome: physiogenesis, psychogenesis and malingering. An integrative model. Jacobson RR. **J Psychosom Res** 1995 Aug;39(6):675–93 (119 ref.)

The detection of exaggerated or simulated memory disorder by neuropsychological methods. Leng NR, et al. **J Psychosom Res** 1995 Aug;39(6):767–76 (37 ref.)

Medico-legal aspects of road traffic accidents. Mayou R. **J Psychosom Res** 1995 Aug;39(6):789–98 (13 ref.)

Legal and medical aspects of liability for negligently occasioned nervous shock: a current perspective. Mendelson D. **J Psychosom Res** 1995 Aug;39(6):721–35 (81 ref.)

[The psychosomatics and psychotherapy of the cardiac anxiety syndrome] Csef H. **Dtsch Med Wochenschr** 1996 Jun 7;121(23):771–6 (53 ref.) **(Ger)**

DRUG THERAPY

Psychodermatology: an update. Gupta MA, et al. **J Am Acad Dermatol** 1996 Jun;34(6):1030–46 (196 ref.)

The management of treatment-resistant depression in disorders on the interface of psychiatry and medicine. Fibromyalgia, chronic fatigue syndrome, migraine, irritable bowel syndrome, atypical facial pain, and premenstrual dysphoric disorder. Gruber AJ, et al. **Psychiatr Clin North Am** 1996 Jun;19(2):351–69 (79 ref.)

EPIDEMIOLOGY

Psychiatric and physical morbidity effects of dementia caregiving: prevalence, correlates, and causes. Schulz R, et al. **Gerontologist** 1995 Dec;35(6):771–91 (90 ref.)

ETIOLOGY

Phobic postural vertigo. Brandt T. **Neurology** 1996 Jun; 46(6):1515–9 (31 ref.)

Clinically relevant EEG studies and psychophysiological findings: possible neural mechanisms for multiple chemical sensitivity. Bell IR. **Toxicology** 1996 Jul 17;111(1–3):101–17 (122 ref.)

-Psychosomatic aspects around the period of menopause- Czubalski K. **Ginekol Pol** 1995 Dec;66(12):692–6 (22 ref.) **(Pol)**

IMMUNOLOGY

Health psychology: psychological factors and physical disease from the perspective of human psychoneuroimmunology. Cohen S, et al. **Annu Rev Psychol** 1996;47:113–42 (155 ref.)

Are cytokines associated with neuropsychiatric syndromes in humans? Hickie I, et al. **Int J Immunopharmacol** 1995 Aug;17(8):677–83 (27 ref.)

[Current developments in psychoneuroimmunology and psycho-oncology] Müller N. **Geburtshilfe Frauenheilkd** 1996 Jun;56(6):M82–6 (34 ref.) **(Ger)**

MICROBIOLOGY

[Recurrent vaginal candidiasis. Reflections of a psychosomatic gynecologist] Bechart E. **Contracept Fertil Sex** 1996 Mar;24(3):233–7 (29 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Psychogenic seizures and the supplementary sensorimotor area. Kanner AM. **Adv Neurol** 1996;70:461–6 (42 ref.)

Discrete, patterned and purposeful adaptive physiological adjustments integrated by forebrain influences. Wolf S. **Integr Physiol Behav Sci** 1995 Jul-Sep;30(3):190–9 (21 ref.)

Beyond specificity: effects of serotonin and serotonergic treatments on psychobiological dysfunction. Dubovsky SL, et al. **J Psychosom Res** 1995 May;39(4):429–44 (103 ref.)

Neuroendocrine dysrhythmias. Elks ML. **Med Hypotheses** 1995 May;44(5):319–24 (43 ref.)

Clinically relevant EEG studies and psychophysiological findings: possible neural mechanisms for multiple chemical sensitivity. Bell IR. **Toxicology** 1996 Jul 17;111(1–3):101–17 (122 ref.)

[Neurobiological and psychodynamic correlations in obsessive-compulsive disorders and bulimia nervosa] Csef H. **Z Klin Psychol Psychopathol Psychother** 1996; 44(3):267–79 (70 ref.) (Eng. Abstr.) **(Ger)**

[Psychological stress and neuronal plasticity. An expanded model of the stress reaction process as the basis for understand central nervous system adaptation processes] Huether G, et al. **Z Psychosom Med Psychoanal** 1996; 42(2):107–27 (70 ref.) (Eng. Abstr.) **(Ger)**

PSYCHOLOGY

Association between psychopathology and headache syndromes. Merikangas KR. **Curr Opin Neurol** 1995 Jun; 8(3):248–51 (19 ref.)

Pathways linking affective disturbances and physical disorders. Cohen S, et al. **Health Psychol** 1995 Sep; 14(5):374–80 (50 ref.)

Stress, stigmatization and psychosomatic purpuras. Panconesi E, et al. **Int Angiol** 1995 Jun;14(2):130–7 (51 ref.)

Stress: clarification of a confused concept. Morse DR. **Int J Psychosom** 1995;42(1–4):4–24 (136 ref.)

Duodenal ulcer: the helicobacterization of a psychosomatic disease? Melmed RN, et al. **Isr J Med Sci** 1996 Mar–Apr; 32(3–4):211–6 (66 ref.)

Annotation: aspects of pain in children and adolescents. McGrath PJ. **J Child Psychol Psychiatry** 1995 Jul; 36(5):717–30 (50 ref.)

Psychology's role in the assessment of erectile dysfunction: historical precedents, current knowledge, and methods. Ackerman MD, et al. **J Consult Clin Psychol** 1995 Dec; 63(6):862–76 (185 ref.)

Organic and psychosocial risk factors for duodenal ulcer. Lewin J, et al. **J Psychosom Res** 1995 Jul;39(5):531–48 (85 ref.)

'Functional overlay', and illness behaviour in chronic pain: distress or malingering? Conceptual difficulties in medico-legal assessment of personal injury claims. Main CJ, et al. **J Psychosom Res** 1995 Aug;39(6):737–53 (58 ref.)

Are life events related to the onset of breast cancer [editorial] McGee R, et al. **Psychol Med** 1996 May;26(3):441–7 (35 ref.)

[Psychological and psychiatric problems in chronic somatic patients; recommendations for future studies and implications for care] Poppelaars CA, et al. **Ned Tijdschr Geneeskd** 1996 Feb 24;140(8):415–8 (32 ref.) **(Dut)**

[What is somatization?] Rooijmans HG, et al. **Ned Tijdschr Geneeskd** 1996 Jun 8;140(23):1217–20 (16 ref.) **(Dut)**

[Stuttering] Grönroos M. **Duodecim** 1995;111(6):560–6 (24 ref.) **(Fin)**

[Psycho-oncology in gynecology] **Arch Gynecol Obstet** 1995; 257(1–4):270–7 (28 ref.) **(Ger)**

[Sense and success of psychosomatic preparation for labor] Stauber M. **Arch Gynecol Obstet** 1995;257(1–4):129–35 (8 ref.) **(Ger)**

[Chronic fatigue syndrome--psychiatric aspects] Lemke MR. **Fortschr Neurol Psychiatr** 1996 Apr;64(4):132–41 (77 ref.) (Eng. Abstr.) **(Ger)**

[Psychiatric emergencies and crises in gynecology] Gaebel W, et al. **Gynakologe** 1995 Dec;28(6):403–11 (19 ref.) **(Ger)**

[Recent psychosomatic contributions to the pathogenesis and therapy of irritable colon (irritable bowel syndrome)] Csef H. **Z Gastroenterol** 1996 Apr;34(4):250–5 (102 ref.) (Eng. Abstr.) **(Ger)**

[Pain and psychological disorders in the elderly] Wojnar J, et al. **Z Gerontol Geriatr** 1995 Sep–Oct;28(5):369–73 (22 ref.) (Eng. Abstr.) **(Ger)**

[Methodologic aspects of the body-mind problem in psychosomatic medicine and psychotherapy] Frommer J. **Z Klin Psychol Psychopathol Psychother** 1996;44(3):231–42 (43 ref.) (Eng. Abstr.) **(Ger)**

[Psychosomatic pain in children--a psychomuscular stress reaction?] Alfvén G. **Nord Med** 1995;110(11):275–9 (15 ref.) (Eng. Abstr.) **(Swe)**

PSYCHOPHYSIOLOGIC DISORDERS

REHABILITATION

[Indications for psychosomatically-oriented dermatologic rehabilitation] Wehrmann J. **Hautarzt** 1996 Apr;47(4):253-7 (34 ref.) (Eng. Abstr.) **(Ger)**

[Functions of the social worker in a multi-professional team in inpatient psychosomatic rehabilitation] Mans EJ. **Rehabilitation (Stuttg)** 1996 May;35(2):119-25 (27 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

The efficacy of psychosocial treatments in primary care. A review of randomized clinical trials. Brown C, et al. **Gen Hosp Psychiatry** 1995 Nov;17(6):414-24 (43 ref.)

Anxiety and its control. Morse DR. **Int J Psychosom** 1995; 42(1-4):54-64 (40 ref.)

[The psychosomatics and psychotherapy of the cardiac anxiety syndrome] Csef H. **Dtsch Med Wochenschr** 1996 Jun 7;121(23):771-6 (53 ref.) **(Ger)**

PSYCHOPHYSIOLOGY

see related
PSYCHOSOMATIC MEDICINE

Preliminary process theory: towards an integrated account of the psychophysiology of cognitive processes. Barry RJ. **Acta Neurobiol Exp (Warsz)** 1996;56(1):469-84 (24 ref.)

[Methodologic aspects of the body-mind problem in psychosomatic medicine and psychotherapy] Frommer J. **Z Klin Psychol Psychopathol Psychother** 1996;44(3):231-42 (43 ref.) (Eng. Abstr.) **(Ger)**

PSYCHOSES see **PSYCHOTIC DISORDERS**

PSYCHOSES, AFFECTIVE see **AFFECTIVE DISORDERS, PSYCHOTIC**

PSYCHOSES, ALCOHOLIC

PHYSIOPATHOLOGY

The neurology of alcoholic denial: implications for assessment and treatment. Duffy JD. **Can J Psychiatry** 1995 Jun;40(5):257-63 (30 ref.)

PSYCHOSES, DRUG see **PSYCHOSES, SUBSTANCE-INDUCED**

PSYCHOSES, ORGANIC see **ORGANIC MENTAL DISORDERS, PSYCHOTIC**

PSYCHOSES, PARANOID see **PARANOID DISORDERS**

PSYCHOSES, PRESENILE see **DEMENTIA, PRESENILE**

PSYCHOSES, SENILE see **DEMENTIA, SENILE**

PSYCHOSES, SUBSTANCE-INDUCED

A review of NMDA receptors and the phencyclidine model of schizophrenia. Thornberg SA, et al. **Pharmacotherapy** 1996 Jan-Feb;16(1):82-93 (122 ref.)

DRUG THERAPY

[Value of clozapine in treatment of psychotic disorder in Parkinson disease] Abbar M, et al. **Encephale** 1996 Jan-Feb; 22(1):53-63 (46 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Behavioural abnormalities and retention rates of anti-epilepsy drugs during long-term treatment of epilepsy: a clinical perspective. Schmidt D. **Acta Neurol Scand Suppl** 1995; 162:7-10 (28 ref.)

Vigabatrin-associated reversible acute psychosis in a child. Cánovas Martínez A, et al. **Ann Pharmacother** 1995 Nov; 29(11):1115-7 (10 ref.)

[An anticholinergic syndrome with hallucinatory psychosis after diphenhydramine poisoning] Lang K, et al. **Dtsch Med Wochenschr** 1995 Dec 8;120(49):1695-8 (17 ref.) (Eng. Abstr.) **(Ger)**

[Steroid-induced psychoses] Whitworth AB, et al. **Hautarzt** 1995 Sep;46(9):666-73; quiz 672 (34 ref.) **(Ger)**

[Psychiatrically relevant side effects of non-psychopharmacological pharmacotherapy] Kasper S, et al. **Nervenarzt** 1995 Sep;66(9):649-61 (95 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

[Glutamatergic hypothesis of schizophrenia: psychoses induced by phencyclidine and cortical-subcortical imbalance] Krebs MO. **Encephale** 1995 Sep-Oct; 21(5):581-8 (52 ref.) (Eng. Abstr.) **(Fre)**

PSYCHOLOGY

Ecstasy intoxication: an overlap between serotonin syndrome and neuroleptic malignant syndrome. Demirkiran M, et al. **Clin Neuropharmacol** 1996 Apr;19(2):157-64 (43 ref.)

PSYCHOSES, TOXIC see **PSYCHOSES, SUBSTANCE-INDUCED**

PSYCHOSES, TRAUMATIC see **ORGANIC MENTAL DISORDERS, PSYCHOTIC**

PSYCHOSEXUAL DEVELOPMENT

The role of the testicles in male psychological development. Friedman RM. **J Am Psychoanal Assoc** 1996;44(1):201-53 (72 ref.)

Psychological characteristics of Turner syndrome. el Abd S, et al. **J Child Psychol Psychiatry** 1995 Oct;36(7):1109-25 (60 ref.)

Identity formation for lesbian, bisexual, and gay persons: beyond a "minoritizing" view. Eliason MJ. **J Homosex** 1996; 30(3):31-58 (40 ref.)

A multifactorial approach to the study of gender characteristics. Koestner R, et al. **J Pers** 1995 Sep; 63(3):681-710 (80 ref.)

Models of development: understanding risk in adolescence. Graber JA, et al. **Suicide Life Threat Behav** 1995;25 Suppl:18-25 (35 ref.)

Adolescent development and the emergence of sexuality. Petersen AC, et al. **Suicide Life Threat Behav** 1995;25 Suppl:4-17 (95 ref.)

Sexual orientation and developmental challenges experienced by gay and lesbian youths. Rotheram-Borus MJ, et al. **Suicide Life Threat Behav** 1995;25 Suppl:26-34; discussion 35-9 (60 ref.)

[Difficulties in becoming a woman and staying a woman. On the problems of female identity in menopause] Hettlage-Varjas A, et al. **Psyche (Stuttg)** 1995 Sep-Oct; 49(9-10):903-37 (40 ref.) (Eng. Abstr.) **(Ger)**

PSYCHOSEXUAL DISORDERS

PSYCHOLOGY

Women's sexuality: behaviors, responses, and individual differences. Andersen BL, et al. **J Consult Clin Psychol** 1995 Dec;63(6):891-906 (130 ref.)

Hypoactive sexual desire disorder: an overview. Beck JG. **J Consult Clin Psychol** 1995 Dec;63(6):919-27 (60 ref.)

THERAPY

Treatment of sexual dysfunctions by sex therapy and other approaches. Hawton K. **Br J Psychiatry** 1995 Sep; 167(3):307-14 (45 ref.)

Treatment of sexual disorders in the 1990s: an integrated approach. Rosen RC, et al. **J Consult Clin Psychol** 1995 Dec;63(6):877-90 (185 ref.)

Treatment of sexual dysfunction. Uttley L. **Perit Dial Int** 1996;16 Suppl 1:S402-5 (13 ref.)

PSYCHOSEXUAL DYSFUNCTIONS

[Disorders of erection and ejaculation. Diagnosis and management] Singer C. **Rev Neurol** 1996 Jun; 24(130):666-70 (54 ref.) **(Spa)**

ETIOLOGY

Clinical implications of antidepressant drug effects on sexual function. Harvey KV, et al. **Ann Clin Psychiatry** 1995 Dec; 7(4):189-201 (107 ref.)

PHYSIOPATHOLOGY

[Male sexual dysfunction: neuroanatomy, neurophysiology and semiology] Singer C. **Rev Neurol** 1996 Jun; 24(130):664-5 (14 ref.) **(Spa)**

PSYCHOLOGY

Women's sexuality: behaviors, responses, and individual differences. Andersen BL, et al. **J Consult Clin Psychol** 1995 Dec;63(6):891-906 (130 ref.)

THERAPY

An overview of sexual counselling. Devan GS. **Ann Acad Med Singapore** 1995 Sep;24(5):732-5 (28 ref.)

Treatment of sexual dysfunctions by sex therapy and other approaches. Hawton K. **Br J Psychiatry** 1995 Sep; 167(3):307-14 (45 ref.)

Treatment of sexual disorders in the 1990s: an integrated approach. Rosen RC, et al. **J Consult Clin Psychol** 1995 Dec;63(6):877-90 (185 ref.)

Treatment of sexual dysfunction. Uttley L. **Perit Dial Int** 1996;16 Suppl 1:S402-5 (13 ref.)

PSYCHOSIS, BRIEF REACTIVE see **PSYCHOTIC DISORDERS**

PSYCHOSIS, INVOLUTIONAL see **DEPRESSION, INVOLUTIONAL**

PSYCHOSIS, MANIC-DEPRESSIVE see **BIPOLAR DISORDER**

PSYCHOSOCIAL DEPRIVATION

[Synaptic reorganization in early childhood experience and learning processes: relevance for the development of psychological diseases] Braun K. **Z Klin Psychol Psychopathol Psychother** 1996;44(3):253-66 (60 ref.) (Eng. Abstr.) **(Ger)**

PSYCHOSOCIAL SUPPORT SYSTEMS see **SOCIAL SUPPORT**

PSYCHOSOMATIC DISORDERS see **PSYCHOPHYSIOLOGIC DISORDERS**

PSYCHOSOMATIC MEDICINE

see related
PSYCHOPHYSIOLOGIC DISORDERS
PSYCHOPHYSIOLOGY

[Ecology and thermal parks in the context of the environment. Psychological and possible therapeutic aspects: trends in medicine] Grossi F, et al. **Clin Ter** 1995 Dec;146(12):781-92 (32 ref.) (Eng. Abstr.) **(Ita)**

PSYCHOSURGERY

Latest advances in epilepsy surgery. Silfvenius H. **Acta Neurol Scand Suppl** 1995;162:11-6 (32 ref.)

MRI hippocampal volume and neuropsychology in epilepsy surgery. Trenerry MR, et al. **Magn Reson Imaging** 1995; 13(8):1125-32 (47 ref.)

METHODS

Pain--old and new methods of study and treatment. Sweet WH. **Acta Neurochir Suppl (Wien)** 1995;64:83-7 (24 ref.)

Practical management of treatment-resistant affective disorders. Bridges PK, et al. **Br J Hosp Med** 1995 Nov 15-Dec 12;54(10):501-6 (58 ref.)

PSYCHOTHERAPY

Psychological treatments for irritable bowel syndrome: a critique of controlled treatment trials. Talley NJ, et al. **Am J Gastroenterol** 1996 Feb;91(2):277-83 (34 ref.)

Treating the traumatic memories of patients with dissociative identity disorder. Kluft RP. **Am J Psychiatry** 1996 Jul;153(7 Suppl):103-10 (77 ref.)

The destructiveness of perfectionism. Implications for the treatment of depression. Blatt SJ. **Am Psychol** 1995 Dec; 50(12):1003-20 (175 ref.)

The effectiveness of psychotherapy. The Consumer Reports study. Seligman ME. **Am Psychol** 1995 Dec;50(12):965-74 (11 ref.)

African-American women: considering diverse identities and societal barriers in psychotherapy. Greene B. **Ann N Y Acad Sci** 1996 Jun 18;789:191-209 (30 ref.)

Constructivism in psychotherapy. Truth and consequences. Held BS. **Ann N Y Acad Sci** 1996 Jun 24;775:198-206 (43 ref.)

Advances in the psychosocial treatment of anxiety disorders. Implications for national health care. Barlow DH, et al. **Arch Gen Psychiatry** 1996 Aug;53(8):727-35 (117 ref.)

Psychotherapy of depression. Implications for reform of the health care system. Clarkin JF, et al. **Arch Gen Psychiatry** 1996 Aug;53(8):717-23 (69 ref.)

Psychosocial treatment for drug abuse. Selected review and recommendations for national health care. Crits-Christoph P, et al. **Arch Gen Psychiatry** 1996 Aug;53(8):749-56 (54 ref.)

PTSD diagnosis and treatment for mental health clinicians. Friedman MJ. **Community Ment Health J** 1996 Apr; 32(2):173-89; discussion 191-3 (50 ref.)

Pharmacotherapy and psychotherapy for the treatment of alcoholism in Germany. Soyka M. **Drug Alcohol Depend** 1995 Sep;39 Suppl 1:S9-13 (40 ref.)

Matching verbal repertoires: understanding the contingencies of practice in order to functionally communicate with clinicians. Montgomery RW, et al. **J Behav Ther Exp Psychiatry** 1995 Jun;26(2):99-105 (29 ref.)

Psychotherapy in combination with drug treatment for bipolar disorder. Miklowitz DJ. **J Clin Psychopharmacol** 1996 Apr;16(2 Suppl 1):56S-66S (68 ref.)

An approach to psychotherapy change process research: introduction to the special section. Greenberg LS, et al. **J Consult Clin Psychol** 1996 Jun;64(3):435-8 (27 ref.)

Psychophysiologic treatment of cyclic vomiting. Magagna J. **J Pediatr Gastroenterol Nutr** 1995;21 Suppl 1:S31-6 (10 ref.)

The psychological care of patients with insulin-dependent diabetes mellitus. Jacobson AM. **N Engl J Med** 1996 May 9;334(19):1249-53 (65 ref.)

Ethnicity and psychotherapy. A component in the treatment of cocaine addiction in African Americans. Foulks EF, et al. **Psychiatr Clin North Am** 1995 Sep;18(3):607-20 (59 ref.)

Cultural considerations in the assessment and treatment of religious and spiritual problems. Lukoff D, et al. **Psychiatr Clin North Am** 1995 Sep;18(3):467-85 (93 ref.)

Assessing, diagnosing and treating culturally diverse individuals: a Hispanic perspective. Ruiz P. **Psychiatr Q** 1995 Winter;66(4):329-41 (34 ref.)

Psychological intervention with couples after mastectomy. Baider L. **Support Care Cancer** 1995 Jul;3(4):239-43 (43 ref.)

Some problems and some solutions in research on psychotherapeutic intervention in cancer. Fox BH. **Support Care Cancer** 1995 Jul;3(4):257-63 (19 ref.)

Improving quality of life: adjuvant psychological therapy for

patients with cancer. Greer S. **Support Care Cancer** 1995 Jul;3(4):248–51 (8 ref.)
Essentials of psychotherapeutic intervention for cancer patients. Spiegel D. **Support Care Cancer** 1995 Jul; 3(4):252–6 (49 ref.)
[The psychosomatics and psychotherapy of the cardiac anxiety syndrome] Csef H. **Dtsch Med Wochenschr** 1996 Jun 7;121(23):771–6 (53 ref.) **(Ger)**
[Particular aspects of psychiatric management of mentally retarded patients with psychiatric disorders] Hennicke K, et al. **Psychiatr Prax** 1995 Nov;22(6):240–3 (27 ref.) (Eng. Abstr.) **(Ger)**
[Psychotherapy with dyssocial patients] Rauchfleisch U. **Schweiz Arch Neurol Psychiatr** 1995;146(3):115–20 (13 ref.) (Eng. Abstr.) **(Ger)**
[Plasticity of brain structure and function as the neurobiological principle of psychotherapy] Bogerts B. **Z Klin Psychol Psychopathol Psychother** 1996;44(3):243–52 (22 ref.) (Eng. Abstr.) **(Ger)**
[Methodologic aspects of the body–mind problem in psychosomatic medicine and psychotherapy] Frommer J. **Z Klin Psychol Psychopathol Psychother** 1996;44(3):231–42 (43 ref.) (Eng. Abstr.) **(Ger)**
[Methodologic decisions in evaluation of psychotherapy] Langenmayr A, et al. **Z Klin Psychol Psychopathol Psychother** 1995;43(4):273–90 (60 ref.) (Eng. Abstr.) **(Ger)**
[Psychotherapy for obesity] Noda S, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:475–80 (19 ref.) **(Jpn)**

ECONOMICS

Psychotherapy assessment and treatment selection. Tillett R. **Br J Psychiatry** 1996 Jan;168(1):10–5 (59 ref.)

EDUCATION

Training of psychotherapists. Norcross J. **Acta Psychiatr Belg** 1996 May–Aug;96(3–4):218–37 (79 ref.)
Psychotherapy supervision in the 1990s: some observations and reflections. Watkins CE Jr. **Am J Psychother** 1995 Fall; 49(4):568–81 (87 ref.)
The value of curiosity and naiveté for the cross–cultural psychotherapist. Dyche L, et al. **Fam Process** 1995 Dec; 34(4):389–99 (33 ref.)

LEGISLATION & JURISPRUDENCE

[Dangers and therapist obligations: Canadian perspective] Melançon G, et al. **Can J Psychiatry** 1995 Oct;40(8):474–8 (18 ref.) (Eng. Abstr.) **(Fre)**

METHODS

Constructivist developmental theory and therapy: implications for counseling adolescents. Crespi TD, et al. **Adolescence** 1995 Fall;30(119):735–43 (20 ref.)
Cultural psychopathology and the "false memory syndrome" debates: a view from psychoanalysis. Berger LS. **Am J Psychother** 1996 Spring;50(2):167–77 (41 ref.)
Understanding and differentiating clients' positive feelings in psychotherapy. Chance SE, et al. **Am J Psychother** 1995 Fall;49(4):514–25 (23 ref.)
Reinventing the mother–daughter relationship. van Mens–Verhulst J. **Am J Psychother** 1995 Fall;49(4):526–39 (49 ref.)
An overview of sexual counselling. Devan GS. **Ann Acad Med Singapore** 1995 Sep;24(5):732–5 (28 ref.)
Creating a culturally responsive psychotherapeutic environment for African American youths: a critical analysis. Kendall J. **ANS Adv Nurs Sci** 1996 Jun;18(4):11–28 (43 ref.)
Intensive interventions in conduct disorders. Bailey VF. **Arch Dis Child** 1996 Apr;74(4):352–6 (41 ref.)
Psycho–educational interventions in the treatment of arthritis. Hawley DJ. **Baillieres Clin Rheumatol** 1995 Nov; 9(4):803–23 (46 ref.)
Supportive psychotherapy. The search for positive meanings. Holmes J. **Br J Psychiatry** 1995 Oct;167(4):439–45; discussion 446–7 (48 ref.)
Psychological treatments for depression. An update [editorial] Scott J. **Br J Psychiatry** 1995 Sep;167(3):289–92 (39 ref.)
Psychotherapy for bipolar disorder. Scott J. **Br J Psychiatry** 1995 Nov;167(5):581–8 (29 ref.)
Psychological approaches to the management of sensory urgency and idiopathic detrusor instability. Hunt J. **Br J Urol** 1996 Mar;77(3):339–41 (37 ref.)
The psychiatrist's perspective on quality of life and quality of care in oncology: concepts, symptom management, communication issues. Razavi D, et al. **Eur J Cancer** 1995; 31A Suppl 6:S25–9 (41 ref.)
Psychorehabilitation aspects in older age groups. Kaufmann C, et al. **Exp Gerontol** 1995 May–Aug;30(3–4):423–30 (36 ref.)
The value of curiosity and naiveté for the cross–cultural psychotherapist. Dyche L, et al. **Fam Process** 1995 Dec; 34(4):389–99 (33 ref.)
The efficacy of psychosocial treatments in primary care. A review of randomized clinical trials. Brown C, et al. **Gen Hosp Psychiatry** 1995 Nov;17(6):414–24 (43 ref.)
Improving the transition from basic efficacy research to effectiveness studies: methodological issues and procedures. Clarke GN. **J Consult Clin Psychol** 1995 Oct;63(5):718–25 (50 ref.)
Bridging the gap between laboratory and clinic in child and adolescent psychotherapy. Weisz JR, et al. **J Consult Clin Psychol** 1995 Oct;63(5):688–701 (70 ref.)
Try to remember ... reminiscence as a nursing intervention. Nugent E. **J Psychosoc Nurs Ment Health Serv** 1995 Nov; 33(11):7–11 (16 ref.)
The SolCos model: facilitating reminiscence therapy. Soltys FG, et al. **J Psychosoc Nurs Ment Health Serv** 1995 Nov; 33(11):21–6 (27 ref.)
Treatment of co–occurring substance abuse and major mental illness. Carey KB. **New Dir Ment Health Serv** 1996 Summer;(70):19–31 (31 ref.)
Psychosocial interventions for adolescent depression: issues, evidence, and future directions. Hoberman HM, et al. **Prog Behav Modif** 1996;30:25–73 (250 ref.)
Psychotherapy for dysthymic disorder. Markowitz JC. **Psychiatr Clin North Am** 1996 Mar;19(1):133–49 (68 ref.)
Combined medication and psychotherapy in the treatment of chronic mood disorders. Miller IW, et al. **Psychiatr Clin North Am** 1996 Mar;19(1):151–71 (70 ref.)
Psychotherapeutic issues in long–term treatment of anxiety disorder patients. Shear MK. **Psychiatr Clin North Am** 1995 Dec;18(4):885–94 (90 ref.)
Psychological interventions for schizophrenia. Scott JE, et al. **Schizophr Bull** 1995;21(4):621–30 (42 ref.)
The psychotherapies. Devan GS. **Singapore Med J** 1995 Dec; 36(6):661–3 (25 ref.)
[Effectiveness of validation. A literature study] Schrijnemaekers VJ, et al. **Tijdschr Gerontol Geriatr** 1995 Oct;26(5):205–13 (37 ref.) (Eng. Abstr.) **(Dut)**
[What is used as a drug for problem drinking?] Heinälä P, et al. **Duodecim** 1995;111(8):761–8 (30 ref.) **(Fin)**
[Psychotherapy in depressive conditions] Huttunen MO. **Duodecim** 1994;110(3):307–19 (26 ref.) **(Fin)**
[Psychotherapy research and child psychotherapy practice] Märtens M, et al. **Prax Kinderpsychol Kinderpsychiatr** 1995 Oct;44(8):302–21 (250 ref.) (Eng. Abstr.) **(Ger)**
[Perspectives and time as relevant phenomena in the psychopathology of obsessive–compulsive neuroses] Kraus MR, et al. **Z Klin Psychol Psychopathol Psychother** 1995; 43(4):348–54 (33 ref.) (Eng. Abstr.) **(Ger)**
[With problem of applying modern systems theories in clinical practice] Manteufel A, et al. **Z Klin Psychol Psychopathol Psychother** 1995;43(4):325–47 (55 ref.) (Eng. Abstr.) **(Ger)**
[Integrated psychotherapy for eating disorders] Tomizawa O. **Seishin Shinkeigaku Zasshi** 1995;97(5):326–56 (49 ref.) (Eng. Abstr.) **(Jpn)**

PSYCHOTHERAPY, BRIEF

Interpreting the evidence on brief interventions for excessive drinkers: the need for caution. Heather N. **Alcohol Alcohol** 1995 May;30(3):287–96 (35 ref.)
A consideration of factors influencing the utilization of time–limited, short–term group therapy. Piper WE, et al. **Int J Group Psychother** 1996 Jul;46(3):311–28 (16 ref.)
Group psychotherapy and managed behavioral health care: current trends and future challenges. Steenbarger BN, et al. **Int J Group Psychother** 1996 Jul;46(3):297–309 (42 ref.)

PSYCHOTHERAPY, COGNITIVE see **COGNITIVE THERAPY**

PSYCHOTHERAPY, GROUP

Termination in inpatient groups. Brabender V, et al. **Int J Group Psychother** 1996 Jan;46(1):81–98 (25 ref.)
Time–limited group psychotherapy. MacKenzie KR. **Int J Group Psychother** 1996 Jan;46(1):41–60 (39 ref.)
A consideration of factors influencing the utilization of time–limited, short–term group therapy. Piper WE, et al. **Int J Group Psychother** 1996 Jul;46(3):311–28 (16 ref.)
Termination in group psychotherapy from the perspectives of contemporary object relations theory and self psychology. Schermer VL, et al. **Int J Group Psychother** 1996 Jan;46(1):99–115 (38 ref.)
Group psychotherapy and managed behavioral health care: current trends and future challenges. Steenbarger BN, et al. **Int J Group Psychother** 1996 Jul;46(3):297–309 (42 ref.)
Group psychological therapy for cancer patients. A brief discussion of indications for its use, and the range of interventions available. Cunningham AJ. **Support Care Cancer** 1995 Jul;3(4):244–7 (29 ref.)
[Group treatment programs for obese subjects] Melcarne R, et al. **Minerva Gastroenterol Dietol** 1996 Mar;42(1):27–38 (75 ref.) (Eng. Abstr.) **(Ita)**

CLASSIFICATION

Group psychological therapy for cancer patients: a point of view, and discussion of the hierarchy of options. Cunningham AJ, et al. **Int J Psychiatry Med** 1996; 26(1):51–82 (82 ref.)

LEGISLATION & JURISPRUDENCE

Confidentiality in group psychotherapy: empirical findings and the law. Roback HB, et al. **Int J Group Psychother** 1996 Jan;46(1):117–35 (38 ref.)

METHODS

Group therapy as an effective treatment modality for people of color. Fenster A. **Int J Group Psychother** 1996 Jul; 46(3):399–416 (42 ref.)
The couple and the psychotherapeutic group. Kretsch RA, et al. **Isr J Psychiatry Relat Sci** 1995;32(3):184–93 (18 ref.)
Group treatment for dually diagnosed clients. Mueser KT, et al. **New Dir Ment Health Serv** 1996 Summer;(70):33–51 (35 ref.)

STANDARDS

Behaviour change in practice: group approaches. Hayaki J, et al. **Int J Obes Relat Metab Disord** 1996 Feb;20 Suppl 1:S27–30 (18 ref.)

PSYCHOTIC DISORDERS

CLASSIFICATION

Schizoaffective psychoses: genetical clues to classification. Bertelsen A, et al. **Am J Med Genet** 1995 Feb 27;60(1):7–11 (35 ref.)

COMPLICATIONS

Risk of HIV infection in psychiatrically ill patients. Grassi L. **AIDS Care** 1996 Feb;8(1):103–16 (79 ref.)

DIAGNOSIS

Insight in clinical psychiatry revisited. Marková IS, et al. **Compr Psychiatry** 1995 Sep–Oct;36(5):367–76 (37 ref.)
Childhood and adolescent psychosis: a review of the past 10 years. Volkmar FR. **J Am Acad Child Adolesc Psychiatry** 1996 Jul;35(7):843–51 (57 ref.)
Psychoses in children and adolescents: a review. Tolbert HA. **J Clin Psychiatry** 1996;57 Suppl 3:4–8; discussion 46–7 (13 ref.)
Psychosis in Parkinson's disease: diagnosis and treatment. Doraiswamy M, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1995 Sep; 19(5):835–46 (27 ref.)
[Progresses in psychiatry in China, 1995] Zhang M, et al. **Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):725–6 (0 ref.) **(Chi)**

DRUG THERAPY

Insight and adherence to treatment in psychotic disorders. Kemp RA, et al. **Br J Hosp Med** 1995 Sep 6–19;54(5):222–7 (46 ref.)
Denouement of an execution competency case: is Perry pyrrhic? Mossman D. **Bull Am Acad Psychiatry Law** 1995; 23(2):269–84 (113 ref.)
Management of late–life psychosis. Jeste DV, et al. **J Clin Psychiatry** 1996;57 Suppl 3:39–45; discussion 49–50 (40 ref.)
New developments in the pharmacologic treatment of schizoaffective disorder. Keck PE Jr, et al. **J Clin Psychiatry** 1996;57 Suppl 9:41–8 (78 ref.)
Clinical experience with risperidone. Marder SR. **J Clin Psychiatry** 1996;57 Suppl 9:57–61 (36 ref.)
Treatment of the elderly suffering from psychosis and dementia. Sunderland T. **J Clin Psychiatry** 1996;57 Suppl 9:53–6 (30 ref.)
Modulation of NMDA and dopaminergic neurotransmissions by sigma ligands: possible implications for the treatment of psychiatric disorders. Debonnel G, et al. **Life Sci** 1996; 58(9):721–34 (179 ref.)
Pharmacologic treatment of psychiatric disease in pregnancy and lactation: fetal and neonatal effects. Kuller JA, et al. **Obstet Gynecol** 1996 May;87(5 Pt 1):789–94 (38 ref.)
The emerging role of valproate in bipolar disorder and other psychiatric disorders. Guay DR. **Pharmacotherapy** 1995 Sep–Oct;15(5):631–47 (146 ref.)
[Therapeutic problems in the application of antiparkinsonian drugs in psychiatry] Piasecki T. **Psychiatr Pol** 1996 Jan–Feb;30(1):137–50 (26 ref.) (Eng. Abstr.) **(Pol)**

EPIDEMIOLOGY

Who cares? Pathways to psychiatric care for young people experiencing a first episode of psychosis. Lincoln CV, et al. **Psychiatr Serv** 1995 Nov;46(11):1166–71 (89 ref.)

ETIOLOGY

The development of psychosis in epilepsy: a re–examination of the kindling hypothesis. Smith PF, et al. **Behav Brain Res** 1996 Feb;75(1–2):59–66 (94 ref.)
A theory of the evolutionary origins of psychosis. Crow TJ. **Eur Neuropsychopharmacol** 1995;5 Suppl:59–63 (20 ref.)

GENETICS

Genes and psychosis: old wine in new bottles? Baron M. **Acta Psychiatr Scand** 1995 Aug;92(2):81–6 (74 ref.)
Schizoaffective psychoses: genetical clues to classification. Bertelsen A, et al. **Am J Med Genet** 1995 Feb 27;60(1):7–11 (35 ref.)
A Darwinian approach to the origins of psychosis [published erratum appears in Br J Psychiatry 1995 Sep;167(3):414] Crow TJ. **Br J Psychiatry** 1995 Jul;167(1):12–25 (77 ref.)
Dynamic mutations and psychiatric genetics [editorial]

O'Donovan MC, et al. **Psychol Med** 1996 Jan;26(1):1–6 (30 ref.)
A continuum of psychosis, one human gene, and not much else—the case for homogeneity. Crow TJ. **Schizophr Res** 1995 Oct;17(2):135–45 (85 ref.)
[Current concepts of anticipation in endogenous psychoses] Trubnikov VI, et al. **Vestn Ross Akad Med Nauk** 1996; (4):11–3 (19 ref.) (Eng. Abstr.) **(Rus)**

METABOLISM

Postmortem and cerebrospinal fluid studies of corticotropin-releasing factor in humans. Hartline KM, et al. **Ann N Y Acad Sci** 1996 Mar 22;780:96–105 (44 ref.)

NURSING

Object relations and nursing care of persons experiencing psychosis. Connick Jamison S, et al. **Arch Psychiatr Nurs** 1996 Jun;10(3):129–35 (18 ref.)

PREVENTION & CONTROL

[Risk factor assessment and prevention of psychosis] van Os J. **Ned Tijdschr Geneeskd** 1996 Jun 22;140(25):1295–9 (31 ref.) **(Dut)**

PSYCHOLOGY

The development of psychosis in epilepsy: a re-examination of the kindling hypothesis. Smith PF, et al. **Behav Brain Res** 1996 Feb;75(1–2):59–66 (94 ref.)
The role of the father in parental postnatal mental health. Marks M, et al. **Br J Med Psychol** 1995 Jun;68 (Pt 2):157–68 (75 ref.)
Insight and psychosis: a social perspective. Johnson S, et al. **Psychol Med** 1995 May;25(3):515–20 (24 ref.)
Psychosis and violence: the case for a content analysis of psychotic experience. Junginger J. **Schizophr Bull** 1996; 22(1):91–103 (50 ref.)
[Delusions and imagination] Schmidt-Degenhard M. **Fortschr Neurol Psychiatr** 1995 Sep;63(9):350–7 (57 ref.) (Eng. Abstr.) **(Ger)**
[Othello syndrome—jealousy and jealous delusions as symptoms of psychiatric disorders] Soyka M. **Fortschr Neurol Psychiatr** 1995 Dec;63(12):487–94 (93 ref.) (Eng. Abstr.) **(Ger)**
[Psychiatric diseases with onset in puerperium] Woitalla D, et al. **Gynakologe** 1995 Dec;28(6):434–9 (33 ref.) **(Ger)**

REHABILITATION

Treatment of co-occurring substance abuse and major mental illness. Carey KB. **New Dir Ment Health Serv** 1996 Summer;(70):19–31 (31 ref.)

THERAPY

Supportive psychotherapy. The search for positive meanings. Holmes J. **Br J Psychiatry** 1995 Oct;167(4):439–45; discussion 446–7 (48 ref.)
Orphans of the 'Real': I. Some modern and postmodern perspectives on the neurobiological and psychosocial dimensions of psychosis and other primitive mental disorders. Grotstein JS. **Bull Menninger Clin** 1995 Summer; 59(3):287–311 (115 ref.)
Orphans of the 'Real': II. The future of object relations theory in the treatment of the psychoses and other primitive mental disorders. Grotstein JS. **Bull Menninger Clin** 1995 Summer;59(3):312–32 (75 ref.)
Psychosis in Parkinson's disease: diagnosis and treatment. Doraiswamy M, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1995 Sep; 19(5):835–46 (27 ref.)
Psychoeducation in first-episode psychosis: a therapeutic process. McGorry PD. **Psychiatry** 1995 Nov;58(4):313–28 (41 ref.)
[Surgical management of psychiatrically ill patients. Particular aspects of perioperative monitoring] Diefenbacher A, et al. **Gynakologe** 1995 Dec;28(6):412–9 (33 ref.) **(Ger)**
[Management dialogue within multi-professional teams: contribution of psychoanalysis to integrated therapy of psychotic patients] Böker H. **Psychiatr Prax** 1995 Sep; 22(5):201–5 (18 ref.) (Eng. Abstr.) **(Ger)**

PSYCHOTOMIMETIC AGENTS see HALLUCINOGENS

PSYCHOTROPIC DRUGS

Substance misuse in individuals with spinal cord injury. Radnitz CL, et al. **Int J Addict** 1995 Jul;30(9):1117–40 (50 ref.)
Financing strategies for drug abuse treatment programs. Zarkin GA, et al. **J Subst Abuse Treat** 1995 Nov–Dec; 12(6):385–99 (26 ref.)
Pharmacotherapy for adolescents with psychoactive substance use disorders. Kaminer Y. **NIDA Res Monogr** 1995;156:291–324 (101 ref.)
[Medical prescription and consumption of psychotropic drugs: questions on the differences between men and women] Baumann M, et al. **Cah Sociol Demogr Med** 1996 Jan–Mar;36(1):63–78 (38 ref.) (Eng. Abstr.) **(Fre)**
[Schizophrenia and substance dependence] Uchtenhagen A. **Schweiz Arch Neurol Psychiatr** 1995;146(5):215–23 (80 ref.) (Eng. Abstr.) **(Ger)**
[Neurobiology of learning and memory and anti-dementia drug] Ishikawa K. **Nippon Yakurigaku Zasshi** 1995 Aug; 106(2):67–76 (76 ref.) (Eng. Abstr.) **(Jpn)**

ADMINISTRATION & DOSAGE

Bipolar mood disorder: practical strategies for acute and maintenance phase treatment. Sachs GS. **J Clin Psychopharmacol** 1996 Apr;16(2 Suppl 1):32S–47S (87 ref.)
Adjunctive treatments in schizophrenia: pharmacotherapies and electroconvulsive therapy. Johns CA, et al. **Schizophr Bull** 1995;21(4):607–19 (85 ref.)

ADVERSE EFFECTS

Psychoactive substance use in forensic psychiatry. Kermani EJ, et al. **Am J Drug Alcohol Abuse** 1996 Feb;22(1):1–27 (173 ref.)
Priapism associated with psychotropic drugs. Patel AG, et al. **Br J Hosp Med** 1996 Mar 20–Apr 2;55(6):315–9 (63 ref.)
Yawning behavior for preclinical drug evaluation. Furukawa T. **Methods Find Exp Clin Pharmacol** 1996 Mar; 18(2):141–55 (81 ref.)
[Abuse of psychotropic drugs during driving] Lemoine P, et al. **Encephale** 1996 Jan–Feb;22(1):1–6 (39 ref.) (Eng. Abstr.) **(Fre)**
[Main cardiotoxic drugs] Pettirossi G, et al. **Clin Ter** 1996 Jan–Feb;147(1–2):67–77 (34 ref.) (Eng. Abstr.) **(Ita)**
[Drug induced obesity] Murakami T, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:425–9 (16 ref.) **(Jpn)**
[Problematic points of psychotropic drugs] Murasaki M. **No To Shinkei** 1995 Nov;47(11):1027–37 (48 ref.) **(Jpn)**

ANALYSIS

Detection of psychoactive drugs using 19F MR spectroscopy. Bartels M, et al. **J Neural Transm Gen Sect** 1995;99(1–3):1–6 (13 ref.)

CHEMISTRY

Relationships between eicosanoids and cannabinoids. Are eicosanoids cannabimimetic agents?. Burstein SH, et al. **Biochem Pharmacol** 1995 Nov 27;50(11):1735–42 (44 ref.)

HISTORY

Psychoactive constituents of the genus Sceletium N.E.Br. and other Mesembryanthemaceae: a review. Smith MT, et al. **J Ethnopharmacol** 1996 Mar;50(3):119–30 (67 ref.)

METABOLISM

Psychotropic drugs and lactation. Maitra R, et al. **N Z Med J** 1996 Jun 28;109(1024):217–8 (20 ref.)

PHARMACOKINETICS

Cytochromes and psychotropic drug interactions [editorial] Taylor D, et al. **Br J Psychiatry** 1996 May;168(5):529–32 (30 ref.)
Therapeutic drug monitoring for the treatment of psychiatric disorders. Clinical use and cost effectiveness. Eilers R. **Clin Pharmacokinet** 1995 Dec;29(6):442–50 (40 ref.)
Pharmacokinetic optimisation of drug therapy in elderly patients. Parker BM, et al. **Drugs Aging** 1995 Jul;7(1):10–8 (38 ref.)
The emerging role of cytochrome P450 3A in psychopharmacology. Ketter TA, et al. **J Clin Psychopharmacol** 1995 Dec;15(6):387–98 (173 ref.)

PHARMACOLOGY

Initiation and adaptation: a paradigm for understanding psychotropic drug action. Hyman SE, et al. **Am J Psychiatry** 1996 Feb;153(2):151–62 (49 ref.)
Recent advances in geriatric psychopharmacology. Naranjo CA, et al. **Drugs Aging** 1995 Sep;7(3):184–202 (85 ref.)
Psychotropic drugs and lactation. Maitra R, et al. **N Z Med J** 1996 Jun 28;109(1024):217–8 (20 ref.)
Stress: a major variable in the psychopharmacologic response. Stanford SC. **Pharmacol Biochem Behav** 1996 May;54(1):211–7 (49 ref.)
Norepinephrine metabolism and psychoactive drugs in the endogenous depressions. 1968 [classical article] Schildkraut JJ, et al. **Pharmacopsychiatry** 1995 Sep;28 Suppl 1:24–37 (58 ref.)
Schizophrenia and psychostimulant abuse: a review and re-analysis of clinical evidence. LeDuc PA, et al. **Psychopharmacology (Berl)** 1995 Oct;121(4):407–27 (85 ref.)

THERAPEUTIC USE

Conference summary: Consensus Conference on Alcohol Dependence and the Role of Pharmacotherapy in its Treatment. Chick J, et al. **Alcohol Clin Exp Res** 1996 Apr; 20(2):391–402 (82 ref.)
Elevated rates of early discontinuation from pharmacotherapy trials in alcoholics and drug abusers. Kranzler HR, et al. **Alcohol Clin Exp Res** 1996 Feb; 20(1):16–20 (20 ref.)
Evaluating psychotropic drugs in people with mental retardation: where are the social validity data? Poling A, et al. **Am J Ment Retard** 1995 Sep;100(2):193–200 (48 ref.)
Psychopharmacology of Alzheimer's disease. Procter AW. **Br J Hosp Med** 1996 Feb 21–Mar 5;55(4):191–4 (20 ref.)
The treatment of negative symptoms: pharmacological and methodological issues. Carpenter WT Jr. **Br J Psychiatry Suppl** 1996 May;(29):17–22 (45 ref.)
Therapeutic drug monitoring for the treatment of psychiatric disorders. Clinical use and cost effectiveness. Eilers R. **Clin Pharmacokinet** 1995 Dec;29(6):442–50 (40 ref.)
Pharmacotherapy and psychotherapy for the treatment of alcoholism in Germany. Soyka M. **Drug Alcohol Depend** 1995 Sep;39 Suppl 1:S9–13 (40 ref.)
Psychopharmacology in child and adolescent psychiatry: a review of the past seven years. Part I. Campbell M, et al. **J Am Acad Child Adolesc Psychiatry** 1995 Sep; 34(9):1124–32 (132 ref.)
Brief report: psychopharmacology of autism spectrum disorders. Lewis MH. **J Autism Dev Disord** 1996 Apr; 26(2):231–5 (11 ref.)
A review of the effects of moderate alcohol intake on the treatment of anxiety and mood disorders. Castaneda R, et al. **J Clin Psychiatry** 1996 May;57(5):207–12 (82 ref.)
Role of newer medications for bipolar disorder. Bowden CL. **J Clin Psychopharmacol** 1996 Apr;16(2 Suppl 1):48S–55S (65 ref.)
Outcome in the pharmacologic treatment of bipolar disorder. Keck PE Jr, et al. **J Clin Psychopharmacol** 1996 Apr;16(2 Suppl 1):15S–23S (86 ref.)
A model for pharmacological research–treatment of cocaine dependence. Montoya ID, et al. **J Subst Abuse Treat** 1995 Nov–Dec;12(6):415–21 (44 ref.)
Pharmacologic treatment of psychiatric disease in pregnancy and lactation: fetal and neonatal effects. Kuller JA, et al. **Obstet Gynecol** 1996 May;87(5 Pt 1):789–94 (38 ref.)
Diagnostic-based pharmacological treatment of behavior disorders in persons with developmental disabilities: a review and a decision-making typology. Sturmey P. **Res Dev Disabil** 1995 Jul–Aug;16(4):235–52 (45 ref.)
[Associated psychotropic drugs in deficit schizophrenia] Beaufils B. **Encephale** 1996 Jun;22 Spec No 2:41–3 (18 ref.) (Eng. Abstr.) **(Fre)**
[Critical analysis of controlled pharmacologic studies in obsessive compulsive disorder] Brochier T, et al. **Encephale** 1989 May–Jun;15(3):325–33 (51 ref.) (Eng. Abstr.) **(Fre)**
[Psychopharmacology of autism] Chabrol H, et al. **Encephale** 1996 May–Jun;22(3):197–203 (40 ref.) (Eng. Abstr.) **(Fre)**
[Particular aspects of psychiatric management of mentally retarded patients with psychiatric disorders] Hennicke K, et al. **Psychiatr Prax** 1995 Nov;22(6):240–3 (27 ref.) (Eng. Abstr.) **(Ger)**
[Possibilities of concomitant drug treatment of stuttering in childhood and adolescence] Marcus A, et al. **Z Kinder Jugendpsychiatr** 1995 Sep;23(3):182–94 (115 ref.) **(Ger)**
[Cholecystokinin receptors. A target for tomorrow's psychopharmaceuticals?] Zachrisson O, et al. **Lakartidningen** 1996 Mar 27;93(13):1225–7 (47 ref.) (Eng. Abstr.) **(Swe)**

PTC see FACTOR IX

PTCA see ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY

PTDINS see PHOSPHATIDYLINOSITOLS

PTERIDINES

METABOLISM

Biosynthesis of nitric oxide: dependence on pteridine metabolism. Werner ER, et al. **Rev Physiol Biochem Pharmacol** 1996;127:97–135 (280 ref.)

PTEROYLGLUTAMIC ACID see FOLIC ACID

PTOSIS, EYELID see BLEPHAROPTOSIS

PTPASE see PROTEIN-TYROSINE-PHOSPHATASE

PTSD see STRESS DISORDERS, POST-TRAUMATIC

PUBERTY

Sex steroids, growth hormone, insulin-like growth factor-1: neuroendocrine and metabolic regulation in puberty. Mauras N, et al. **Horm Res** 1996;45(1–2):74–80 (41 ref.)

PHYSIOLOGY

Annotation: the impact of puberty. Alsaker FD. **J Child Psychol Psychiatry** 1996 Mar;37(3):249–58 (72 ref.)
Nutritional determinants of puberty. Cameron JL. **Nutr Rev** 1996 Feb;54(2 Pt 2):S17–22 (70 ref.)
Do dairy products improve bone density in adolescent girls? Kerstetter JE. **Nutr Rev** 1995 Nov;53(11):328–32 (26 ref.)
[Vaginal environment. The vaginal climate and its variations] Nicoli JM, et al. **Rev Fr Gynecol Obstet** 1995 Nov; 90(11):471–80 (8 ref.) (Eng. Abstr.) **(Fre)**

PUBERTY, DELAYED

DIAGNOSIS

Imaging assessment of pubertal disorders. Zwiebel WJ, et al. **Semin Ultrasound CT MR** 1995 Aug;16(4):296–303 (18 ref.)

[Delayed constitutional puberty or hypogonadotrophic hypogonadism?] Beas F. **Rev Med Chil** 1995 Feb; 123(2):233–40 (30 ref.) (Eng. Abstr.) **(Spa)**

PUBERTY, PRECOCIOUS

[Acceleration of pubertal development] Antoniazzi F, et al. **Pediatr Med Chir** 1996 Jan–Feb;18(1):19–25 (30 ref.) (Eng. Abstr.) **(Ita)**

DIAGNOSIS

Imaging assessment of pubertal disorders. Zwiebel WJ, et al. **Semin Ultrasound CT MR** 1995 Aug;16(4):296–303 (18 ref.)

[Magnetic resonance imaging and hypothalamo–hypophyseal disorders in children: morpho–functional and etiologic aspects] Zucchini S, et al. **Pediatr Med Chir** 1995 Sep–Oct; 17(5):397–401 (33 ref.) (Eng. Abstr.) **(Ita)**

PUBIC BONE

INJURIES

Insufficiency fractures of the sacrum and os pubis. Peh WC, et al. **Br J Hosp Med** 1995 Jun 21–Jul 11;54(1):15–9 (20 ref.)

PUBIC SYMPHYSIS

see related
SYMPHYSIOTOMY

Examining separated symphysis pubis. Davidson MR. **J Nurse Midwifery** 1996 May–Jun;41(3):259–62 (15 ref.)

Vertical fracture of the central sacral canal: plane and simple. Hatem SF, et al. **J Trauma** 1996 Jan;40(1):138–40 (12 ref.)

[Pelvic pain caused by pregnancy; a new disease?] Mens JM. **Ned Tijdschr Geneeskd** 1995 Sep 30;139(39):1964–6 (11 ref.) **(Dut)**

RADIOGRAPHY

[Pubalgia in sportsmen] Zeitoun F, et al. **Ann Radiol (Paris)** 1995;38(5):244–54 (31 ref.) (Eng. Abstr.) **(Fre)**

PUBLIC ADVOCACY see **CONSUMER ADVOCACY**

PUBLIC ASSISTANCE

see related
SOCIAL WELFARE

TRENDS

Entitlements and the federal budget: facts, folklore, and future. Gist JR. **Milbank Q** 1996;74(3):327–59 (42 ref.)

PUBLIC DOMAIN see **PUBLIC SECTOR**

PUBLIC ENTERPRISE see **PUBLIC SECTOR**

PUBLIC HEALTH

see related
SOCIAL MEDICINE
ZOONOSES

Viral respiratory infections and their role as public health problem in tropical countries (review). Karaivanova GM. **Afr J Med Med Sci** 1995 Mar;24(1):1–7 (72 ref.)

Contraception, unintended pregnancies, and sexually transmitted diseases: why isn't a simple solution possible? Cates W Jr. **Am J Epidemiol** 1996 Feb 15;143(4):311–8 (30 ref.)

Rape is a major public health issue. Schafran LH. **Am J Public Health** 1996 Jan;86(1):15–7 (13 ref.)

Firearm violence among youth: public health strategies for prevention. Powell EC, et al. **Ann Emerg Med** 1996 Aug; 28(2):204–12 (83 ref.)

Crack cocaine abuse: an epidemic with many public health consequences. Cornish JW, et al. **Annu Rev Public Health** 1996;17:259–73 (54 ref.)

Disability as a public health outcome in the aging population. Guralnik JM, et al. **Annu Rev Public Health** 1996;17:25–46 (98 ref.)

Health hazards to humans associated with domestic pets. Plaut M, et al. **Annu Rev Public Health** 1996;17:221–45 (87 ref.)

Pervasive media violence. Schooler C, et al. **Annu Rev Public Health** 1996;17:275–98 (216 ref.)

Public health aspects of ophthalmic disease: introduction. Sommer A. **Annu Rev Public Health** 1996;17:115–9 (26 ref.)

Folic acid and the prevention of neural tube defects: the need for public health action. Wald NJ. **Bibl Nutr Dieta** 1995; (52):56–65 (14 ref.)

Violence as a public health issue. Satcher D. **Bull N Y Acad Med** 1995 Summer;72(1):46–56 (30 ref.)

Periconceptional folic acid and neural tube defects: public health issues. Pérez–Escamilla R. **Bull Pan Am Health Organ** 1995 Sep;29(3):250–63 (70 ref.)

The contribution of vitamin A to public health. Underwood BA, et al. **FASEB J** 1996 Jul;10(9):1040–8 (57 ref.)

A public health approach to the problem of obesity. James WP. **Int J Obes Relat Metab Disord** 1995 Sep;19 Suppl 3:S37–45 (40 ref.)

Vector control without chemicals: a public health perspective. Mulrennan JA Jr. **J Am Mosq Control Assoc** 1995 Jun;11(2 Pt 2):256–7 (5 ref.)

Informed decisions about protecting and promoting public health: rationale for a National Human Exposure Assessment Survey. Sexton K, et al. **J Expo Anal Environ Epidemiol** 1995 Jul–Sep;5(3):233–56 (52 ref.)

Bovine spongiform encephalopathy and the public health. Patterson WJ, et al. **J Public Health Med** 1995 Sep; 17(3):261–8 (70 ref.)

The Department of Health Cardiovascular Review Group and public health policy: an alternative view [see comments] Gurr MI, et al. **J R Soc Health** 1995 Oct; 115(5):279–81 (20 ref.) Comment in: J R Soc Health 1996 Apr;116(2):121–2.

The role of UK tobacco advertising: no effect on the nation's health? Kinman BF, et al. **J R Soc Health** 1995 Oct; 115(5):296–302 (27 ref.)

A critique of Geoffrey Rose's 'population strategy' for preventive medicine [see comments] Charlton BG. **J R Soc Med** 1995 Nov;88(11):607–10 (18 ref.) Comment in: J R Soc Med 1995 Nov;88(11):605–6. Comment in: J R Soc Med 1996 Mar;89(3):179.

Reduction of tobacco health hazards in continuing users: individual behavioral and public health approaches. Kozlowski LT. **J Subst Abuse** 1989;1(3):345–57 (50 ref.)

Evolution of complex disasters. Burkholder BT, et al. **Lancet** 1995 Oct 14;346(8981):1012–5 (21 ref.)

Preventing influenza and its complications: a public health initiative for the year 2000. Reece SM. **Nurse Pract** 1995 Sep;20(9):32–6, 44 (13 ref.)

Iodine deficiency disorders: a public health challenge in developing countries. Ali O. **Nutrition** 1995 Sep–Oct;11(5 Suppl):517–20 (23 ref.)

Importance of radon as a threat to public health. Donohoe K, et al. **Otolaryngol Head Neck Surg** 1996 Feb; 114(2):271–6 (23 ref.)

Public health implications of emerging vaccine technologies. Lawrence DN, et al. **Pharm Biotechnol** 1995;6:43–60 (48 ref.)

Clinical and public health perspectives and applications of health-related quality of life measurement. Ebrahim S. **Soc Sci Med** 1995 Nov;41(10):1383–94 (68 ref.)

Regulating assisted reproductive technologies: public health, consumer protection, and public resources. Wilcox LS, et al. **Womens Health Issues** 1996 May–Jun;6(3):175–80 (22 ref.)

[Epidemiology and prevention of cancer: reflections on the ethics of public health measures] Sasco AJ. **Bull Acad Natl Med** 1995 May;179(5):987–1004; discussion 1005–7 (23 ref.) (Eng. Abstr.) **(Fre)**

[Present status and future of alcohol studies in the field of public health] Kamishima H. **Nihon Arukoru Yakubutsu Igakkai Zasshi** 1996 Feb; 31(1):33–53 (28 ref.) **(Jpn)**

[The knowledge on health and the social sciences] Jarillo Soto EC, et al. **Rev Esp Salud Publica** 1995 May–Aug; 69(3–4):265–76 (51 ref.) (Eng. Abstr.) **(Spa)**

[Quality in preventive and health promotion activities] Blomberg I. **Nord Med** 1995;110(10):246–9 (15 ref.) (Eng. Abstr.) **(Swe)**

LEGISLATION & JURISPRUDENCE

Public health and regulatory considerations of the Safe Drinking Water Act. Raucher RS. **Annu Rev Public Health** 1996;17:179–202 (20 ref.)

Regulatory reform proposals and the public health. Buffler PA, et al. **Environ Health Perspect** 1996 Apr;104(4):356–61 (55 ref.)

METHODS

Abatement of tropospheric ozone: effects of strategies to improve air quality on public health and other sectors. Guest CS, et al. **Aust N Z J Public Health** 1996 Jun; 20(3):301–8 (55 ref.)

Prevention and control of melanoma: the public health approach. Marks R. **CA Cancer J Clin** 1996 Jul–Aug; 46(4):199–216 (46 ref.)

STANDARDS

International harmonization of approaches to risk assessment: will resolution of scientific issues alone lead to success? Becking GC. **Drug Metab Rev** 1996 Feb–May; 28(1–2):269–83 (2 ref.)

TRENDS

Regulating controversial programs for unpopular people: methadone maintenance and syringe exchange programs [see comments] Des Jarlais DC, et al. **Am J Public Health** 1995 Nov;85(11):1577–84 (39 ref.) Comment in: Am J Public Health 1995 Nov;85(11):1490–1.

Traditional epidemiology, modern epidemiology, and public health [see comments] Pearce N. **Am J Public Health** 1996 May;86(5):678–83 (64 ref.) Comment in: Am J Public Health 1996 May;86(5):621–2.

Swedish pesticide risk reduction 1981–1995: food residues, health hazard, and reported poisonings. Ekström G, et al. **Rev Environ Contam Toxicol** 1996;147:119–47 (67 ref.)

[Public health in regard to the immigration phenomenon] Marceca M, et al. **Ann Ig** 1995 May–Jun;7(3):179–88 (67 ref.) (Eng. Abstr.) **(Ita)**

PUBLIC HEALTH ADMINISTRATION

see related
COMMUNITY HEALTH SERVICES

Addressing the epidemiologic transition in the former Soviet Union: strategies for health system and public health reform in Russia [see comments] Tulchinsky TH, et al. **Am J Public Health** 1996 Mar;86(3):313–20 (46 ref.) Comment in: Am J Public Health 1996 Mar;86(3):321–3.

Prevention and the reforming U.S. health care system: changing roles and responsibilities for public health. Gordon RL, et al. **Annu Rev Public Health** 1996;17:489–509 (86 ref.)

The role of medical examiners and coroners in public health surveillance and epidemiologic research. Hanzlick R, et al. **Annu Rev Public Health** 1996;17:383–409 (85 ref.)

Investing in health wisely. The role of needs-based technology assessment. Jamison DT, et al. **Int J Technol Assess Health Care** 1995 Fall;11(4):673–84 (6 ref.)

[Decision making policies on the utilization of antimalarials in response to a modification of chloroquine efficacy. Applications to Africa] Baudon D. **Med Trop (Mars)** 1995; 55(4 Suppl):37–40 (5 ref.) (Eng. Abstr.) **(Fre)**

[Public health surveillance and the environment] Quénel P. **Rev Epidemiol Sante Publique** 1995;43(5):412–22 (38 ref.) (Eng. Abstr.) **(Fre)**

ECONOMICS

Benefit–cost analysis in public health. Lave LB, et al. **Annu Rev Public Health** 1996;17:203–19 (28 ref.)

States' embrace of managed mental health care. Essock SM, et al. **Health Aff (Millwood)** 1995 Fall;14(3):34–44; discussion 45–9 (10 ref.)

STANDARDS

Benefit–cost analysis in public health. Lave LB, et al. **Annu Rev Public Health** 1996;17:203–19 (28 ref.)

PUBLIC HEALTH DENTISTRY

ORGANIZATION & ADMINISTRATION

Oral health policies and programs affecting the preschool child. Casamassimo PS. **Dent Clin North Am** 1995 Oct; 39(4):877–85 (23 ref.)

PUBLIC HEALTH NURSING

Building community capacity for health promotion: a challenge for public health nurses. Kang R. **Public Health Nurs** 1995 Oct;12(5):312–8 (24 ref.)

Health promotion and the "ideology of choice". Lowenberg JS. **Public Health Nurs** 1995 Oct;12(5):319–23 (37 ref.)

ORGANIZATION & ADMINISTRATION

A systematic overview of the effectiveness of home visiting as a delivery strategy for public health nursing interventions. Ciliska D, et al. **Can J Public Health** 1996 May–Jun;87(3):193–8 (17 ref.)

PUBLIC HEALTH SURVEILLANCE see **POPULATION SURVEILLANCE**

PUBLIC OPINION

see related
ATTITUDE TO HEALTH

Rationing health care and the need for credible scarcity: why Americans can't say no. Mariner WK. **Am J Public Health** 1995 Oct;85(10):1439–45 (50 ref.)

Involving the public: practical and ethical issues. Jacobson B, et al. **Br Med Bull** 1995 Oct;51(4):869–75 (16 ref.)

Information for public choice. McIver S. **Br Med Bull** 1995 Oct;51(4):900–13 (29 ref.)

The euthanasia debate: attitudes, practices and psychiatric considerations. Chochinov HM, et al. **Can J Psychiatry** 1995 Dec;40(10):593–602 (69 ref.)

Medical schools, the social contract and population medicine: McMaster revisited. Coulter ID, et al. **J Manipulative Physiol Ther** 1995 Oct;18(8):554–8 (25 ref.)

The menstrual cycle, science and femininity: assumptions underlying menstrual cycle research. Nicolson P. **Soc Sci Med** 1995 Sep;41(6):779–84 (64 ref.)

[Has the clinical trials in Japan been accepted by the society?] Saijo S, et al. **Gan To Kagaku Ryoho** 1996 Jan;23(2):129–35 (5 ref.) (Eng. Abstr.) **(Jpn)**

PUBLIC POLICY

Human response to environmental noise. Psychological research and public policy. Staples SL. **Am Psychol** 1996 Feb;51(2):143–50 (95 ref.)

Ethical and policy issues in human fetal tissue transplants. Vawter DE, et al. **Cell Transplant** 1995 Sep–Oct; 4(5):479–82 (4 ref.)

Health services research and policy studies. Prashker MJ. **Curr Opin Rheumatol** 1996 Mar;8(2):106–9 (8 ref.)

Immigrant children and their families: issues for research and policy. Board on Children and Families. **Future Child** 1995 Summer–Fall;5(2):72–89 (49 ref.)

Achieving and sustaining full employment. Rosen SM. **J Public Health Policy** 1995;16(3):286–303 (28 ref.)

The legislative role in defining medical futility. Warren DG. **N C Med J** 1995 Sep;56(9):453–5 (11 ref.)

Public policy and adolescent pregnancy: a reexamination of the issues. Montessoro AC, et al. **Nurs Outlook** 1996 Jan–Feb;44(1):31–6 (18 ref.)

The Human Genome Project: an overview of ethical issues and public policy concerns. Ott BB. **Nurs Outlook** 1995 Sep–Oct;43(5):228–31 (13 ref.)

Sociological dimensions of illness behavior. Mechanic D. **Soc Sci Med** 1995 Nov;41(9):1207–16 (54 ref.)

Research in adolescent suicide: implications for training, service delivery, and public policy. Brent DA, et al. **Suicide Life Threat Behav** 1995 Summer;25(2):222–30 (40 ref.)

PUBLIC RELATIONS

Public relations in disaster management and planning for emergency physicians. Friedman FD. **J Emerg Med** 1995 Sep–Oct;13(5):661–8 (25 ref.)

Publicity–stunt participation and sound bites polemics: the health care debate 1993–94. Disch L. **J Health Polit Policy Law** 1996 Spring;21(1):3–33 (78 ref.)

PUBLIC SECTOR

TRENDS

Managed care in the public mental health system. Cuffel BJ, et al. **Community Ment Health J** 1996 Apr;32(2):109–24 (42 ref.)

PUBLICATION BIAS

A critique of published studies into the effects of amateur boxing: why is there a lack of consensus? Kemp PL. **J R Nav Med Serv** 1995 Winter;81(3):182–9 (19 ref.)

PUBLISHING

see related
PERIODICALS

Mexican contributions to the knowledge of infectious diseases, published in Spanish. Gutiérrez G. **Arch Med Res** 1995;26 Spec No:S27–9 (22 ref.)

[Scientific literature: bibliometric and bibliographic indicators as integrative criteria for an objective evaluation of research activity] Dracos A, et al. **Ann Ist Super Sanita** 1995;31(3):381–90 (24 ref.) (Eng. Abstr.) **(Ita)**

STANDARDS

Quantitative analyses of scientific literature and their validity for judging Latin American production [comment] Spinak E. **Bull Pan Am Health Organ** 1995 Dec;29(4):352–9; discussion 359–60 (25 ref.) Comment on: Bull Pan Am Health Organ 1995 Mar;29(1):87–95.

Bias in the analysis and reporting of randomized controlled trials. Stewart LA, et al. **Int J Technol Assess Health Care** 1996 Spring;12(2):264–75 (35 ref.)

PUERICULTURE see **CHILD CARE**

PUERPERAL DISORDERS

Acquired von Willebrand's disease: a rare manifestation of postpartum thyroiditis. Aylesworth CA, et al. **Am J Hematol** 1995 Nov;50(3):217–9 (10 ref.)

Acute myocardial infarction during pregnancy and puerperium: a review. Badui E, et al. **Angiology** 1996 Aug; 47(8):739–56 (128 ref.)

Infections during the postpartum period. Clark RA. **J Obstet Gynecol Neonatal Nurs** 1995 Jul–Aug;24(6):542–8 (19 ref.)

Breast cancer in pregnancy and lactation. DiFronzo LA, et al. **Surg Clin North Am** 1996 Apr;76(2):267–78 (45 ref.)

[Upper genital tract infections in women infected with HIV: epidemiologic, diagnostic and therapeutic aspects] Panel P, et al. **Contracept Fertil Sex** 1996 Jun;24(6):488–94 (22 ref.) (Eng. Abstr.) **(Fre)**

[Cerebral venous thrombosis and arterial infarction in pregnancy and puerperium. A series of 60 cases] Ben Hamouda–M'Rad I, et al. **Rev Neurol (Paris)** 1995 Oct; 151(10):563–8 (29 ref.) (Eng. Abstr.) **(Fre)**

[Pregnancy–associated osteoporosis] Ohana N, et al. **Harefuah** 1996 Mar 1;130(5):344–6 (32 ref.) **(Heb)**

DIAGNOSIS

Abdominal pain in the postpartum: role of imaging. Van Hoe L, et al. **J Belge Radiol** 1995 Jun;78(3):186–9 (17 ref.)

DRUG THERAPY

Pharmacologic treatment of psychiatric disease in pregnancy and lactation: fetal and neonatal effects. Kuller JA, et al. **Obstet Gynecol** 1996 May;87(5 Pt 1):789–94 (38 ref.)

EPIDEMIOLOGY

[Post–partum dysthyroidism. Prospective study in a French region (1986–1988)] Mesrine S, et al. **Ann Endocrinol (Paris)** 1995;56(6):579–84 (38 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

[Spontaneous hepatic rupture during pregnancy. Report of a case. Review of the literature] Villarreal Peral C, et al. **Ginecol Obstet Mex** 1995 Sep;63:395–7 (9 ref.) (Eng. Abstr.) **(Spa)**

PSYCHOLOGY

The role of the father in parental postnatal mental health. Marks M, et al. **Br J Med Psychol** 1995 Jun;68 (Pt 2):157–68 (75 ref.)

Pharmacologic treatment of psychiatric disease in pregnancy and lactation: fetal and neonatal effects. Kuller JA, et al. **Obstet Gynecol** 1996 May;87(5 Pt 1):789–94 (38 ref.)

[Psychiatric diseases with onset in puerperium] Woitalla D, et al. **Gynakologe** 1995 Dec;28(6):434–9 (33 ref.) **(Ger)**

THERAPY

[Post–partum cardiomyopathy: medical aspects, role of heart transplantation] Bertrand E. **Arch Mal Coeur Vaiss** 1995 Nov;88(11):1635–40 (42 ref.) (Eng. Abstr.) **(Fre)**

ULTRASONOGRAPHY

[The role of ultrasonic endoscopy in the examination of post–obstetrical anal incontinence] Roseau G. **Contracept Fertil Sex** 1995 Dec;23(12):752–7 (28 ref.) (Eng. Abstr.) **(Fre)**

PUERPERAL INFECTION

Postpartum toxemia: hypertension, edema, proteinuria and unresponsiveness in an unknown female. Brady WJ, et al. **J Emerg Med** 1995 Sep–Oct;13(5):643–8 (27 ref.)

MICROBIOLOGY

[Mycoplasma infections] Silva S, et al. **Rev Chil Obstet Ginecol** 1994;59(6):485–91 (25 ref.) **(Spa)**

PUERPERIUM

A review of safety, efficacy, pros and cons, and issues of puerperal tubal sterilization—an update. Chi IC, et al. **Adv Contracept** 1995 Sep;11(3):187–206 (97 ref.)

Postpartum care. Stover AM, et al. **Am Fam Physician** 1995 Oct;52(5):1465–72 (32 ref.)

Normal puerperium and breast–feeding. Gaál G, et al. **Curr Opin Obstet Gynecol** 1995 Dec;7(6):442–5 (12 ref.)

[Postgravid health care and laboratory tests] Hidaka Y, et al. **Rinsho Byori** 1995 Nov;43(11):1101–7 (14 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Impact of changes in organic nutrient metabolism on feeding the transition dairy cow. Grummer RR. **J Anim Sci** 1995 Sep;73(9):2820–33 (81 ref.)

PHYSIOLOGY

Feeding behavior and management factors during the transition period in dairy cattle. Grant RJ, et al. **J Anim Sci** 1995 Sep;73(9):2791–803 (86 ref.)

Weight change in the postpartum period. A review of the literature. Crowell DT. **J Nurse Midwifery** 1995 Sep–Oct; 40(5):418–23 (37 ref.)

PUERTO RICANS see **HISPANIC AMERICANS**

PULMONARY ALVEOLAR PROTEINOSIS

Pulmonary alveolar proteinosis: experience with eight pediatric cases and a review. Mahut B, et al. **Pediatrics** 1996 Jan;97(1):117–22 (48 ref.)

CONGENITAL

Surfactant apoprotein B deficiency. Chetcuti PA, et al. **Arch Dis Child Fetal Neonatal Ed** 1995 Nov;73(3):F125–7 (30 ref.)

Molecular and cellular pathobiology of pulmonary surfactant protein B deficiency. Colten HR. **Proc Assoc Am Physicians** 1995 Oct;107(3):334–9 (60 ref.)

[Neonatal pulmonary alveolar proteinosis and SP–B deficiency: pulmonary surfactant at the time of molecular pathology (editorial)] Lacaze–Masmonteil T, et al. **Arch Pediatr** 1996 Apr;3(4):309–12 (33 ref.) **(Fre)**

DIAGNOSIS

[Alveolar proteinosis: diagnosis and therapeutic management. Apropos of 2 cases] Bonnet D, et al. **Rev Pneumol Clin** 1995;51(4):239–45 (47 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

[Alveolar lipoproteinosis treated by bronchopulmonary lavage] Montero MC, et al. **Arch Bronconeumol** 1995 Dec; 31(10):537–9 (22 ref.) (Eng. Abstr.) **(Spa)**

PULMONARY ALVEOLI

BLOOD SUPPLY

Clinical studies of alveolar–capillary permeability using technetium–99m DTPA aerosol. Sundram FX. **Ann Nucl Med** 1995 Nov;9(4):171–8 (26 ref.)

Alveolar capillary dysplasia—a cause of persistent pulmonary hypertension unresponsive to a second course of extracorporeal membrane oxygenation. Chelliah BP, et al. **Pediatrics** 1995 Dec;96(6):1159–61 (13 ref.)

CYTOLOGY

Morphometric characterisation of the fine structure of human type II pneumocytes. Fehrenbach H, et al. **Anat Rec** 1995 Sep;243(1):49–62 (87 ref.)

[Role of alveolar epithelial cells in the repair process after lung injury] Sugahara K. **Masui** 1995;44 Suppl:S134–9 (11 ref.) **(Jpn)**

GROWTH & DEVELOPMENT

Formation of pulmonary alveoli and gas–exchange surface area: quantitation and regulation. Massaro GD, et al. **Annu Rev Physiol** 1996;58:73–92 (100 ref.)

METABOLISM

Active transport in the alveolar epithelium of the adult lung: vestigial or vital? Dorrington KL, et al. **Respir Physiol** 1995 Jun;100(3):177–83 (40 ref.)

PHYSIOLOGY

Targeting the alveolar epithelium in acute lung injury: keratinocyte growth factor and regulation of the alveolar epithelial barrier [editorial; comment] Matuschak GM, et al. **Crit Care Med** 1996 Jun;24(6):905–7 (18 ref.) Comment on: Crit Care Med 1996 Jun;24(6):925–31.

[Nitric oxide in the lower respiratory tract] García Salgado MJ, et al. **An Med Interna** 1995 Jul;12(7):349–54 (53 ref.) (Eng. Abstr.) **(Spa)**

PULMONARY ARTERY

Giant aneurysm of main pulmonary artery. Chen YF, et al. **Ann Thorac Surg** 1996 Jul;62(1):272–4 (8 ref.)

Vascular complications of lung transplantation. Clark SC, et al. **Ann Thorac Surg** 1996 Apr;61(4):1079–82 (7 ref.)

Coronary–pulmonary steal syndrome. Najm HK, et al. **Ann Thorac Surg** 1996 Jul;62(1):264–5 (7 ref.)

Pulmonary artery aneurysm presenting as a lung mass. Chung CW, et al. **Chest** 1995 Oct;108(4):1164–6 (10 ref.)

Pulmonary artery aneurysm: review and case report. Lopez–Candales A, et al. **Clin Cardiol** 1995 Dec; 18(12):738–40 (15 ref.)

[Pulmonary artery catheter. Theory and practice] Versprille A. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May;31(1 Suppl):S9–16 (22 ref.) **(Ger)**

ABNORMALITIES

Multiple fistulas between coronary and pulmonary arteries. Van Dam DW, et al. **Eur J Cardiothorac Surg** 1995; 9(12):707–8 (10 ref.)

Anomalous origin of coronary artery in association with aorticopulmonary window. D'Souza VJ, et al. **Pediatr Cardiol** 1996 Sep–Oct;17(5):316–8 (12 ref.)

Chondrodysplasia punctata: case report and literature review of patients with heart lesions. Fourie DT. **Pediatr Cardiol** 1995 Sep–Oct;16(5):247–50 (33 ref.)

[Pulmonary arborization abnormalities in complex forms of pulmonary atresia with ventricular septal defect: unification, unifocalization and complete repair] Macé L, et al. **Arch Mal Coeur Vaiss** 1996 May;89(5):561–8 (31 ref.) (Eng. Abstr.) **(Fre)**

[Absence of unilateral pulmonary circulation, detected by perfusion scintigraphy of the lung, and its clinical significance] Galuska L, et al. **Orv Hetil** 1996 Feb 25; 137(8):411–4 (18 ref.) (Eng. Abstr.) **(Hun)**

[Pulmonary arteriovenous fistulae and brain abscesses: a report of 2 cases treated by embolization and a review of the literature] Ricci P, et al. **Radiol Med (Torino)** 1996 Apr; 91(4):497–501 (24 ref.) **(Ita)**

[A patient with Rendu–Osler–Weber disease and pulmonary arteriovenous malformations treated satisfactorily by embolization] Martín Díaz E, et al. **Arch Bronconeumol** 1996 Jun–Jul;32(6):307–9 (12 ref.) (Eng. Abstr.) **(Spa)**

DRUG EFFECTS

The effects of chronic hypoxia on the pharmacological responsiveness of the pulmonary artery. Karamsetty VS, et al. **Pharmacol Ther** 1995;68(2):233–46 (110 ref.)

GROWTH & DEVELOPMENT

Development of the normal and hypertensive pulmonary vasculature. Haworth SG. **Exp Physiol** 1995 Sep; 80(5):843–53 (19 ref.)

INJURIES

Swan–Ganz catheter induced pulmonary artery perforation during cardiac surgery concerning two cases. Sekkal S, et al. **J Cardiovasc Surg (Torino)** 1996 Jun;37(3):313–7 (33 ref.)

PATHOLOGY

MR imaging of pulmonary hypertension and right ventricular dysfunction. Boxt LM.
Magn Reson Imaging Clin N Am 1996 May;4(2):307–25 (94 ref.)

Pulmonary arteriography. Wielopolski PA.
Magn Reson Imaging Clin N Am 1993 Dec;1(2):295–313 (51 ref.)

[Pathogenesis, diagnosis and therapy of hepatopulmonary syndrome] Liu S, et al. **Chung Hua Nei Ko Tsa Chih** 1995 Aug;34(8):565–7 (20 ref.) **(Chi)**

PHYSIOLOGY

Ion channels, oxygen sensation and signal transduction in pulmonary arterial smooth muscle. Kozlowski RZ.
Cardiovasc Res 1995 Sep;30(3):318–25 (73 ref.)

Development of the normal and hypertensive pulmonary vasculature. Haworth SG. **Exp Physiol** 1995 Sep; 80(5):843–53 (19 ref.)

Hypoxic and metabolic regulation of voltage-gated K+ channels in rat pulmonary artery smooth muscle cells. Yuan XJ, et al. **Exp Physiol** 1995 Sep;80(5):803–13 (24 ref.)

Alterations in extracellular matrix protein expression in neonatal pulmonary hypertension: implications for vascular function. Durmowicz AG, et al. **J Perinatol** 1996 Mar–Apr; 16(2 Pt 2 Su):S11–8 (39 ref.)

Pulmonary input impedance or pulmonary vascular resistance? Morpurgo M, et al. **Monaldi Arch Chest Dis** 1995 Aug;50(4):282–5 (23 ref.)

PHYSIOPATHOLOGY

Mechanisms of abnormal vasoreactivity in persistent pulmonary hypertension of the newborn infant. Abman SH, et al. **J Perinatol** 1996 Mar–Apr;16(2 Pt 2 Su):S18–23 (44 ref.)

SURGERY

Aneurysm of the left pulmonary artery: surgical allograft repair. Casselman F, et al. **Ann Thorac Surg** 1995 Nov; 60(5):1423–5 (6 ref.)

Pulmonary artery reconstruction for tuberculosis. Cohen AS, et al. **Ann Thorac Surg** 1996 Apr;61(4):1257–9 (7 ref.)

Late conduit occlusion after modified Fontan procedure with classic Glenn shunt. Koutlas TC, et al.
Ann Thorac Surg 1996 Jul;62(1):258–61; discussion 261–2 (8 ref.)

Rupture of a dissecting thoracic aortic aneurysm into the pulmonary artery: successful surgical repair. Coselli JS, et al. **Cardiovasc Surg** 1995 Dec;3(6):697–701 (34 ref.)

Surgical treatment of an aortopulmonary artery fistula complicating a syphilitic aortic aneurysm. Pessotto R, et al. **Cardiovasc Surg** 1995 Dec;3(6):707–10 (17 ref.)

Congenitally corrected transposition of the great arteries: ventricle to pulmonary artery connection strategies. Bove EL. **Semin Thorac Cardiovasc Surg** 1995 Jul;7(3):139–44 (19 ref.)

PULMONARY ARTERY WEDGE PRESSURE see **PULMONARY WEDGE PRESSURE**

PULMONARY ATRESIA

SURGERY

[Pulmonary arborization abnormalities in complex forms of pulmonary atresia with ventricular septal defect: unification, unifocalization and complete repair] Macé L, et al. **Arch Mal Coeur Vaiss** 1996 May;89(5):561–8 (31 ref.) (Eng. Abstr.) **(Fre)**

PULMONARY BLASTOMA

Pleuro-pulmonary blastoma: a case report and review of the literature. Schmaltz C, et al. **Med Pediatr Oncol** 1995 Dec; 25(6):479–84 (18 ref.)

PATHOLOGY

Pulmonary blastoma—a case and review of literature. Prabhakar BR, et al. **Indian J Pathol Microbiol** 1994 Dec; 37 Suppl:S35–6 (3 ref.)

SECONDARY

Pulmonary blastoma presenting as a solitary lip metastasis: case report and review of the literature. Lee BY, et al. **J Spinal Cord Med** 1995 Jul;18(3):203–7 (19 ref.)

SURGERY

[A case report of pulmonary blastoma—well differentiated fetal adenocarcinoma] Okano T, et al.
Nippon Kyobu Geka Gakkai Zasshi 1996 Jan;44(1):69–73 (13 ref.) (Eng. Abstr.) **(Jpn)**

PULMONARY CAPILLARY WEDGE PRESSURE see **PULMONARY WEDGE PRESSURE**

PULMONARY CIRCULATION

see related
VENTILATION–PERFUSION RATIO

NO in the lung. Adnot S, et al. **Respir Physiol** 1995 Aug; 101(2):109–20 (32 ref.)

The vascular biology of heart and lung preservation for transplantation. Pinsky DJ. **Thromb Haemost** 1995 Jul; 74(1):58–65 (50 ref.)

[Absence of unilateral pulmonary circulation, detected by perfusion scintigraphy of the lung, and its clinical significance] Galuska L, et al. **Orv Hetil** 1996 Feb 25; 137(8):411–4 (18 ref.) (Eng. Abstr.) **(Hun)**

[Anatomico-functional correlations between the pulmonary and portal circulations: the prerequisites for a modern functional imaging diagnosis] Sallustio G, et al.
Radiol Med (Torino) 1996 Apr;91(4):394–404 (27 ref.) (Eng. Abstr.) **(Ita)**

DRUG EFFECTS

The role of the renin-angiotensin and natriuretic peptide systems in the pulmonary vasculature. Cargill RI, et al. **Br J Clin Pharmacol** 1995 Jul;40(1):11–8 (68 ref.)

PHYSIOLOGY

Development of the normal and hypertensive pulmonary vasculature. Haworth SG. **Exp Physiol** 1995 Sep; 80(5):843–53 (19 ref.)

Lung disease and pulmonary endothelial nitric oxide. Higenbottam T. **Exp Physiol** 1995 Sep;80(5):855–64 (29 ref.)

Clinical aspects of hypoxic pulmonary vasoconstriction. Leach RM, et al. **Exp Physiol** 1995 Sep;80(5):865–75 (29 ref.)

The role of the endothelium in hypoxic pulmonary vasoconstriction. Ward JP, et al. **Exp Physiol** 1995 Sep; 80(5):793–801 (24 ref.)

[Nitric oxide and regulation of fetal and neonatal pulmonary circulation. Group Français Pédiatrique d'étude du NO inhalé] Mercier JC, et al. **Arch Pediatr** 1996;3 Suppl 1:280s–283s (15 ref.) **(Fre)**

[Hypoxic pulmonary vasoconstriction] Theissen IL, et al.
Anaesthesist 1996 Jul;45(7):643–52 (137 ref.) (Eng. Abstr.) **(Ger)**

PULMONARY COIN LESION see **COIN LESION, PULMONARY**

PULMONARY DIFFUSING CAPACITY

Diffusing capacity in the clinical assessment of chronic airflow limitation. Cotton DJ, et al.
Med Clin North Am 1996 May;80(3):549–64 (121 ref.)

PULMONARY DISEASE, CHRONIC OBSTRUCTIVE see **LUNG DISEASES, OBSTRUCTIVE**

PULMONARY DISEASES see **LUNG DISEASES**

PULMONARY EDEMA

Noncardiogenic pulmonary edema. Riedel M. **Cesk Fysiol** 1996 Jun;45(2):112–9 (35 ref.)

CHEMICALLY INDUCED

Delayed pulmonary edema and bronchospasm after accidental lacrimator exposure. Vaca FE, et al.
Am J Emerg Med 1996 Jul;14(4):402–5 (32 ref.)

Noncardiogenic pulmonary edema due to radiocontrast media [clinical conference] Ramesh S, et al.
Ann Allergy Asthma Immunol 1995 Oct;75(4):308–10 (10 ref.)

COMPLICATIONS

[Disappearance of emphysematous bullae after infectious episodes] Guimard Y, et al. **Rev Pneumol Clin** 1995; 51(4):253–6 (12 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

High altitude pulmonary oedema: still a place for controversy? [editorial] Richalet JP. **Thorax** 1995 Sep; 50(9):923–9 (133 ref.)

Acute lung injury following lung resection: is one lung anaesthesia to blame? [editorial] Williams EA, et al.
Thorax 1996 Feb;51(2):114–6 (41 ref.)

METABOLISM

The role of active Na+ transport by lung epithelium in the clearance of airspace fluid. O'Brodovich HM.
New Horiz 1995 May;3(2):240–7 (55 ref.)

PHYSIOPATHOLOGY

High-altitude pulmonary edema: current concepts. Hultgren HN. **Annu Rev Med** 1996;47:267–84 (71 ref.)

Hemodynamic mechanisms of neurogenic pulmonary edema. Chen HI. **Biol Signals** 1995 May–Jun;4(3):186–92 (40 ref.)

Effects of lung water on respiratory mechanics. Cutillo AG. **Cardiologia** 1995 Nov;40(11):813–28 (136 ref.)

The lungs in chronic heart failure. Chua TP, et al.
Eur Heart J 1995 Jul;16(7):882–7 (75 ref.)

Pulmonary permeability oedema. Methods of estimation of pulmonary capillary permeability. Rogowski F, et al.
Rocz Akad Med Bialymst 1994;39:7–17 (30 ref.)

[Acute decompensation in chronic obstructive respiratory insufficiency. Pathogenesis of edema and role of noninvasive mechanical ventilation] Chevrolet JC.
Schweiz Rundsch Med Prax 1996 Mar 12;85(11):329–36 (49 ref.) (Eng. Abstr.) **(Fre)**

PULMONARY EMBOLISM

Clinical diagnosis and management of the patient with deep venous thromboembolism and acute pulmonary embolism. Eftychiou V. **Nurse Pract** 1996 Mar;21(3):50–2, 58, 61–2, passim, quiz 69–71 (34 ref.)

COMPLICATIONS

Massive endobronchial hemorrhage after pulmonary embolectomy. Shimokawa S, et al. **Ann Thorac Surg** 1996 Apr;61(4):1241–2 (11 ref.)

Sudden death caused by testicular germ cell tumour. Dada MA, et al. **Med Sci Law** 1995 Oct;35(4):357–9 (12 ref.)

[Chronic pulmonary heart disease: therapeutic indications] Azarian R, et al. **Arch Mal Coeur Vaiss** 1995 Nov;88(11 Suppl):1799–805 (22 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

D-dimer testing and acute venous thromboembolism. A shortcut to accurate diagnosis? Becker DM, et al.
Arch Intern Med 1996 May 13;156(9):939–46 (46 ref.)

Pulmonary thromboembolism: recent developments in diagnosis with CT and MR imaging. Gefter WB, et al. **Radiology** 1995 Dec;197(3):561–74 (102 ref.)

Pulmonary embolism: difficulties in the clinical diagnosis. Hampson NB. **Semin Respir Infect** 1995 Sep;10(3):123–30 (59 ref.)

Pulmonary embolism. II. Diagnosis and treatment. Janata-Schwatczek K, et al. **Semin Thromb Hemost** 1996; 22(1):33–52 (169 ref.)

Diagnosis of pulmonary embolism [editorial] Hyers TM.
Thorax 1995 Sep;50(9):930–2 (13 ref.)

[New imaging techniques in pulmonary embolism] Blum A, et al. **Arch Mal Coeur Vaiss** 1995 Nov;88(11 Suppl):1735–43 (34 ref.) (Eng. Abstr.) **(Fre)**

[Contribution of laboratory tests and venous investigations in the diagnosis of pulmonary embolism] Perrier A, et al. **Arch Mal Coeur Vaiss** 1995 Nov;88(11 Suppl):1699–707 (48 ref.) (Eng. Abstr.) **(Fre)**

[Severe pulmonary embolism: value of clinical findings and complementary investigations] Vuillemenot A, et al.
Arch Mal Coeur Vaiss 1995 Nov;88(11 Suppl):1745–54 (41 ref.) (Eng. Abstr.) **(Fre)**

[Pulmonary embolism and pregnancy: report of a case; review of the literature] Blondel S, et al. **J Mal Vasc** 1995; 20(4):317–22 (20 ref.) (Eng. Abstr.) **(Fre)**

[Current data on diagnostic imaging methods in acute pulmonary embolus (editorial)] Musset D, et al.
Rev Mal Respir 1996;13(2):85–7 (16 ref.) **(Fre)**

[Diagnosis of pulmonary embolism] Lotter R, et al.
Dtsch Med Wochenschr 1996 May 3;121(18):595–9 (30 ref.) **(Ger)**

DRUG THERAPY

Pulmonary embolism—the role of thrombolytic therapy in its management. More RS, et al. **Postgrad Med J** 1996 Mar; 72(845):157–61 (50 ref.)

Treatment of a patient with an undefined hypercoagulable state with long-term low-molecular-weight heparin. Dobie SA, et al. **West J Med** 1996 Apr;164(4):350–3 (6 ref.)

[Complications of thrombolytic therapy in pulmonary embolism] Meneveau N, et al. **Arch Mal Coeur Vaiss** 1995 Nov;88(11 Suppl):1769–76 (42 ref.) (Eng. Abstr.) **(Fre)**

[Postoperative thrombolytic therapy] Kolben M, et al.
Internist (Berl) 1996 Jun;37(6):619–22 (27 ref.) **(Ger)**

[Thrombolytic therapy of acute pulmonary embolism] Pilger E, et al. **Internist (Berl)** 1996 Jun;37(6):574–84 (56 ref.) **(Ger)**

[Treatment possibilities for extensive pulmonary embolism as an alternative to the Trendelenburg operation] Sárosi I, et al. **Orv Hetil** 1995 Nov 19;136(47):2553–9 (51 ref.) (Eng. Abstr.) **(Hun)**

[Emergency drug therapy of pulmonary thromboembolism] Shibuya Y, et al. **Nippon Naika Gakkai Zasshi** 1995 Nov 10;84(11):1798–803 (6 ref.) **(Jpn)**

PULMONARY EMBOLISM

EPIDEMIOLOGY

Chronobiological aspects of pulmonary thromboembolism. Manfredini R, et al. **Int J Cardiol** 1995 Nov 10;52(1):31–7 (98 ref.)

Pulmonary thromboembolism: epidemiology and techniques of nuclear medicine. Weiss K. **Semin Thromb Hemost** 1996; 22(1):27–32 (62 ref.)

[Epidemiology of pulmonary embolism] Ferrari E, et al. **Arch Mal Coeur Vaiss** 1995 Nov;88(11 Suppl):1687–91 (34 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Pulmonary embolism in parenteral nutrition. Dollery CM. **Arch Dis Child** 1996 Feb;74(2):95–8 (35 ref.)

Acute ventilatory complications during laparoscopic upper abdominal surgery. Wahba RW, et al. **Can J Anaesth** 1996 Jan;43(1):77–83 (35 ref.)

Deep venous thrombosis with pulmonary embolus after selective embolization of an internal iliac artery aneurysm. Su WT, et al. **J Vasc Surg** 1996 Jan;23(1):152–5 (13 ref.)

Pulmonary thromboembolism: current concepts and chronobiological perspectives. Manfredini R, et al. **Panminerva Med** 1995 Mar;37(1):38–43 (62 ref.)

[Pulmonary embolism and thrombi of the right heart] Chapoutot L, et al. **Arch Mal Coeur Vaiss** 1995 Nov;88(11 Suppl):1723–8 (35 ref.) (Eng. Abstr.) **(Fre)**

[Systemic complications in intramedullary nailing] Wenda K, et al. **Orthopade** 1996 Jun;25(3):292–9 (28 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Right ventricular dysfunction after acute pulmonary embolism: pathophysiologic factors, detection, and therapeutic implications. Lualdi JC, et al. **Am Heart J** 1995 Dec;130(6):1276–82 (49 ref.)

The role of thrombosis in severe pulmonary hypertension. Chaouat A, et al. **Eur Respir J** 1996 Feb;9(2):356–63 (86 ref.)

PREVENTION & CONTROL

Management of venous thromboembolic (VTE) disease—Part I: Prevention. Kayser SR. **Prog Cardiovasc Nurs** 1995 Fall;10(4):31–6 (18 ref.)

Current indications for caval interruption: should they be liberalized in view of improving technology? Greenfield LJ, et al. **Semin Vasc Surg** 1996 Mar;9(1):50–8 (32 ref.)

Caval interruption methods: comparison of options. Whitehill TA. **Semin Vasc Surg** 1996 Mar;9(1):59–69 (90 ref.)

[Indications of partial interruption of the inferior vena cava in pulmonary embolism] Schleich JM, et al. **Arch Mal Coeur Vaiss** 1995 Nov;88(11 Suppl):1785–91 (45 ref.) (Eng. Abstr.) **(Fre)**

[Pulmonary embolism prophylaxis with vena cava filters] Obergassel L, et al. **Dtsch Med Wochenschr** 1996 Aug 23; 121(34–35):1060–5 (52 ref.) **(Ger)**

[Deep venous thrombosis and the prevention of a pulmonary embolism with temporary caval filters: the experience in 2 pediatric cases] Patti G, et al. **Pediatr Med Chir** 1995 May–Jun;17(3):265–9 (10 ref.) (Eng. Abstr.) **(Ita)**

RADIOGRAPHY

Pulmonary thromboembolism: recent developments in diagnosis with CT and MR imaging. Gefter WB, et al. **Radiology** 1995 Dec;197(3):561–74 (102 ref.)

[Spiral scanning angiography of pulmonary embolism] Rémy J, et al. **J Radiol** 1996 May;77(5):325–38 (60 ref.) **(Fre)**

[Spiral CT in chronic lung thromboembolism] Kontrus M, et al. **Radiologe** 1996 Jun;36(6):496–502 (27 ref.) (Eng. Abstr.) **(Ger)**

RADIONUCLIDE IMAGING

Comprehensive analysis of the results of the PIOPED Study. Prospective Investigation of Pulmonary Embolism Diagnosis Study. Worsley DF, et al. **J Nucl Med** 1995 Dec; 36(12):2380–7 (32 ref.)

The use of 99Tcm–Technegas in the investigation of patients with pulmonary thromboembolism. James JM, et al. **Nucl Med Commun** 1995 Oct;16(10):802–10 (34 ref.)

Pulmonary thromboembolism: epidemiology and techniques of nuclear medicine. Weiss K. **Semin Thromb Hemost** 1996; 22(1):27–32 (62 ref.)

SURGERY

[Extensive acute pulmonary embolism: fragmentation treatment with a rotatable pigtail catheter] Schmitz-Rode T, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Feb;164(2):150–2 (12 ref.) (Eng. Abstr.) **(Ger)**

[Unilateral pulmonary embolectomy without extracorporeal circulation. A report of a clinical case] Barboso G, et al. **Acta Biomed Ateneo Parmense** 1995;66(1–2):53–5 (10 ref.) (Eng. Abstr.) **(Ita)**

[Chronic thromboembolic pulmonary hypertension: a surgical syndrome? (editorial)] Visioli O, et al. **G Ital Cardiol** 1995 Aug;25(8):1077–82 (37 ref.) **(Ita)**

[The successful treatment of a massive pulmonary artery embolism] Mikheev AA, et al. **Voen Med Zh** 1995 Sep; (9):30–2 (0 ref.) **(Rus)**

[Bilateral pulmonary thromboendarterectomy in chronic pulmonary thromboembolism. A case report and review of the literature] Ruyra Baliarda X, et al. **Rev Esp Cardiol** 1995 Oct;48(10):693–6 (9 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

Cardiovascular shock. Rodgers KG. **Emerg Med Clin North Am** 1995 Nov;13(4):793–810 (61 ref.)

Vena cava filters: available devices and current practices. Cooper JM. et al. **Mt Sinai J Med** 1996 May–Sep; 63(3–4):273–81 (54 ref.)

Pulmonary embolism. II. Diagnosis and treatment. Janata-Schwatczek K, et al. **Semin Thromb Hemost** 1996; 22(1):33–52 (169 ref.)

[Therapy of pulmonary embolism] Zahn R, et al. **Dtsch Med Wochenschr** 1996 May 10;121(19):629–34 (38 ref.) **(Ger)**

ULTRASONOGRAPHY

[Echocardiography in pulmonary embolism] Augusseau-Richard MP, et al. **Arch Mal Coeur Vaiss** 1995 Nov;88(11 Suppl):1715–22 (30 ref.) (Eng. Abstr.) **(Fre)**

[Intensive medical monitoring with transesophageal echocardiography in fulminant pulmonary embolism] Bruch C, et al. **Dtsch Med Wochenschr** 1996 Jun 21; 121(25–26):829–33 (23 ref.) (Eng. Abstr.) **(Ger)**

PULMONARY EMPHYSEMA

Quality of life and predictions of survival in patients with advanced emphysema. Corris PA. **Chest Surg Clin N Am** 1995 Nov;5(4):659–71 (42 ref.)

[Basic and clinical study of pulmonary emphysema] Yoshida M. **Nippon Naika Gakkai Zasshi** 1995 Sep 10;84(9):1549–54 (15 ref.) **(Jpn)**

COMPLICATIONS

Surgery for complications of chronic obstructive lung disease. Tanaka F, et al. **Chest Surg Clin N Am** 1995 Nov; 5(4):797–813 (33 ref.)

[Two complications of bullous emphysema. Apropos of a case] Guichenez P, et al. **Rev Pneumol Clin** 1995; 51(4):250–2 (14 ref.) (Eng. Abstr.) **(Fre)**

CONGENITAL

Lobar emphysema and atelectasis syndrome, a nosological unity. Ring-Mrozik E, et al. **Eur J Pediatr Surg** 1995 Jun; 5(3):131–5 (27 ref.)

DIAGNOSIS

Evaluation of the emphysematous patient. Dennie C, et al. **Chest Surg Clin N Am** 1995 Nov;5(4):635–57 (87 ref.)

METABOLISM

Elastin in lung development and disease. Pierce RA, et al. **Ciba Found Symp** 1995;192:199–212; discussion 212–4 (37 ref.)

[Metabolism of elastin and pulmonary emphysema] Marks J, et al. **Pneumonol Pol** 1990 Jul–Aug;58(7–8):403–9 (55 ref.) **(Pol)**

PATHOLOGY

Overview of the pathology of emphysema in humans. Cosio MG, et al. **Chest Surg Clin N Am** 1995 Nov;5(4):603–21 (30 ref.)

RADIOGRAPHY

Thin-section CT, emphysema, air trapping, and airway obstruction [editorial; comment] Müller NL, et al. **Radiology** 1996 Jun;199(3):621–2 (22 ref.) Comment on: Radiology 1996 Jun;199(3):825–9.

CT of the lungs in patients with pulmonary emphysema. Stern EJ, et al. **Semin Ultrasound CT MR** 1995 Oct; 16(5):345–52 (43 ref.)

SURGERY

Effect of bullectomy on diaphragm strength. Travaline JM, et al. **Am J Respir Crit Care Med** 1995 Nov;152(5 Pt 1):1697–701 (25 ref.)

The current status of lung volume reduction operations for emphysema. Naunheim KS, et al. **Ann Thorac Surg** 1996 Aug;62(2):601–12 (97 ref.)

Bullous emphysema: the role of the surgeon. Briffa N, et al. **Br J Hosp Med** 1996 Feb 21–Mar 5;55(4):213–7 (20 ref.)

Lung volume reduction surgery for emphysema. Brenner M, et al. **Chest** 1996 Jul;110(1):205–18 (61 ref.)

Reduction pneumoplasty for giant bullous emphysema. Implications for surgical treatment of nonbullous emphysema. Snider GL. **Chest** 1996 Feb;109(2):540–8 (44 ref.)

Results of bullectomy. Connolly JE. **Chest Surg Clin N Am** 1995 Nov;5(4):765–76 (24 ref.)

Videothoracoscopic operations for bullous lung disease. Jacques LF. **Chest Surg Clin N Am** 1995 Nov;5(4):751–63 (29 ref.)

Radiology of pulmonary emphysema and lung volume reduction surgery. Slone RM, et al. **Semin Thorac Cardiovasc Surg** 1996 Jan;8(1):61–82 (61 ref.)

[New techniques in thoracic surgery. I] Andreassian B. **Presse Med** 1995 Jun 24;24(23):1078–83 (53 ref.) (Eng. Abstr.) **(Fre)**

[Pulmonary emphysema: surgical indications] Mal H, et al. **Presse Med** 1996 Apr 13;25(13):637–40 (25 ref.) (Eng. Abstr.) **(Fre)**

[Pulmonary emphysema—lung transplantation] Matthys H. **Versicherungsmedizin** 1995 Dec 1;47(6):201–3 (14 ref.) (Eng. Abstr.) **(Ger)**

[Lung volume reduction surgery (VRS) for lung diffuse emphysema] Shiraishi T, et al. **Kyobu Geka** 1996 Apr; 49(4):281–4 (7 ref.) (Eng. Abstr.) **(Jpn)**

THERAPY

Medical management of emphysema. Maltais F, et al. **Chest Surg Clin N Am** 1995 Nov;5(4):673–89 (100 ref.)

PULMONARY EOSINOPHILIA

[Acute eosinophilic pneumonia: presentation of a case and review of the literature] Riestra A, et al. **An Med Interna** 1995 Oct;12(10):495–7 (22 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

[A case of acute eosinophilic pneumonia: bronchoalveolar lavage findings before and after steroid treatment] Kawaguchi H, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Jul;33(7):738–44 (21 ref.) (Eng. Abstr.) **(Jpn)**

PULMONARY FIBROSIS

[Clinical study of idiopathic pulmonary fibrosis] Izumi T. **Nippon Naika Gakkai Zasshi** 1995 Sep 10;84(9):1396–406 (33 ref.) **(Jpn)**

CHEMICALLY INDUCED

Fatal pulmonary fibrosis complicating low dose methotrexate therapy for rheumatoid arthritis. van der Veen MJ, et al. **J Rheumatol** 1995 Sep;22(9):1766–8 (20 ref.)

[The first case of severe pneumopathy due to hard metals successfully undergoing a lung transplant] Tomasini M, et al. **Med Lav** 1995 Jul–Aug;86(4):325–31 (6 ref.) (Eng. Abstr.) **(Ita)**

COMPLICATIONS

Clinical characteristics of synchronous multiple lung cancer associated with idiopathic pulmonary fibrosis. A review of Japanese cases [see comments] Mizushima Y, et al. **Chest** 1995 Nov;108(5):1272–7 (37 ref.) Comment in: Chest 1995 Nov;108(5):1193–4.

DRUG THERAPY

Does the treatment of cryptogenic fibrosing alveolitis influence prognosis? Egan JJ, et al. **Respir Med** 1996 Mar; 90(3):127–30 (26 ref.)

Oxidants/antioxidants in idiopathic pulmonary fibrosis. MacNee W, et al. **Thorax** 1995 Sep;50 Suppl 1:S53–8 (64 ref.)

ETIOLOGY

[Scleroderma and alveolar inflammation] Crestani B, et al. **Rev Mal Respir** 1996;13(1):15–20 (45 ref.) (Eng. Abstr.) **(Fre)**

[Relationship between the physiochemical properties of asbestos and pulmonary fibrosis] Wrzaszczyk B, et al. **Med Pr** 1996;47(4):401–9 (39 ref.) (Eng. Abstr.) **(Pol)**

[Metabolic disturbances and collagen distribution in interstitial pulmonary fibrosis] Siemińska A. **Pneumonol Alergol Pol** 1995;63(7–8):446–52 (40 ref.) **(Pol)**

IMMUNOLOGY

[Scleroderma and alveolar inflammation] Crestani B, et al. **Rev Mal Respir** 1996;13(1):15–20 (45 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Elastin in lung development and disease. Pierce RA, et al. **Ciba Found Symp** 1995;192:199–212; discussion 212–4 (37 ref.)

PATHOLOGY

Cytokines in human lung fibrosis. Martinet Y, et al. **Arch Toxicol Suppl** 1996;18:127–39 (39 ref.)

[Interstitial lung involvement in collagen diseases with special reference to bronchoalveolar lavage and lung biopsy] Witt C, et al. **Pneumologie** 1995 Sep;49(9):487–91 (64 ref.) **(Ger)**

PHYSIOPATHOLOGY

The role of cytokines in human lung fibrosis. Vaillant P, et al. **Monaldi Arch Chest Dis** 1996 Apr;51(2):145–52 (49 ref.)

SURGERY

[The first case of severe pneumopathy due to hard metals successfully undergoing a lung transplant] Tomasini M, et al. **Med Lav** 1995 Jul-Aug;86(4):325-31 (6 ref.) (Eng. Abstr.) **(Ita)**

PULMONARY FUNCTION TESTS see **RESPIRATORY FUNCTION TESTS**

PULMONARY GAS EXCHANGE

Mechanisms of gas exchange impairment in patients with liver cirrhosis. Agusti AG, et al. **Clin Chest Med** 1996 Mar; 17(1):49-66 (159 ref.)

[External respiration and gas exchange in space flights] Baranov VM, et al. **Kosm Biol Aviakosm Med** 1991 Nov-Dec;25(6):4-8 (48 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOLOGY

Formation of pulmonary alveoli and gas-exchange surface area: quantitation and regulation. Massaro GD, et al. **Annu Rev Physiol** 1996;58:73-92 (100 ref.)

PULMONARY HEART DISEASE

COMPLICATIONS

[Clinical approach to physiologic dispnea in pregnancy] García Río F, et al. **Aten Primaria** 1996 Jan;17(1):70-4 (23 ref.) **(Spa)**

ETIOLOGY

[Chronic cor pulmonale] Zieliński J. **Pneumonol Pol** 1990 Sep-Oct;58(9-10):559-64 (23 ref.) **(Pol)**

PATHOLOGY

[Retrospect and prospect of cardiovascular pathology] Wang T, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1995 Aug; 24(4):210-3 (25 ref.) **(Chi)**

PHYSIOPATHOLOGY

[The "cardiac lung": radiology correlations with respiratory physiopathology and clinical features] Schiavon F, et al. **Radiol Med (Torino)** 1996 May;91(5):526-36 (30 ref.) **(Ita)**

RADIOGRAPHY

[The "cardiac lung": radiology correlations with respiratory physiopathology and clinical features] Schiavon F, et al. **Radiol Med (Torino)** 1996 May;91(5):526-36 (30 ref.) **(Ita)**

THERAPY

[Chronic pulmonary heart disease: therapeutic indications] Azarian R, et al. **Arch Mal Coeur Vaiss** 1995 Nov;88(11 Suppl):1799-805 (22 ref.) (Eng. Abstr.) **(Fre)**

ULTRASONOGRAPHY

[Echocardiography in pulmonary embolism] Augusseau-Richard MP, et al. **Arch Mal Coeur Vaiss** 1995 Nov;88(11 Suppl):1715-22 (30 ref.) (Eng. Abstr.) **(Fre)**

PULMONARY INCOMPETENCE see **PULMONARY VALVE INSUFFICIENCY**

PULMONARY MACROPHAGES see **MACROPHAGES, ALVEOLAR**

PULMONARY NEOPLASMS see **LUNG NEOPLASMS**

PULMONARY NODULE, SOLITARY see **COIN LESION, PULMONARY**

PULMONARY REGURGITATION see **PULMONARY VALVE INSUFFICIENCY**

PULMONARY SARCOIDOSIS see **SARCOIDOSIS, PULMONARY**

PULMONARY SEQUESTRATION see **BRONCHOPULMONARY SEQUESTRATION**

PULMONARY STENOSIS see **PULMONARY VALVE STENOSIS**

PULMONARY SURFACTANTS

Neonatal respiratory disease due to surfactant protein B deficiency. Ballard PL. **J Perinatol** 1996 Mar-Apr;16(2 Pt 2 Su):S28-34 (42 ref.)

ANALYSIS

Age-dependency of surfactant phospholipids and surfactant protein A in bronchoalveolar lavage fluid of children without bronchopulmonary disease. Ratjen F, et al. **Eur Respir J** 1996 Feb;9(2):328-33 (34 ref.)

DEFICIENCY

Molecular and cellular pathobiology of pulmonary surfactant protein B deficiency. Colten HR. **Proc Assoc Am Physicians** 1995 Oct;107(3):334-9 (60 ref.)

GENETICS

Human surfactant protein B: structure, function, regulation, and genetic disease. Whitsett JA, et al. **Physiol Rev** 1995 Oct;75(4):749-57 (66 ref.)

Molecular and cellular pathobiology of pulmonary surfactant protein B deficiency. Colten HR. **Proc Assoc Am Physicians** 1995 Oct;107(3):334-9 (60 ref.)

METABOLISM

Surfactant protein-D modulates interaction of Pneumocystis carinii with alveolar macrophages [see comments] Limper AH, et al. **J Lab Clin Med** 1995 Nov;126(5):416-22 (37 ref.) Comment in: J Lab Clin Med 1995 Nov;126(5):414-5.

Surfactant protein binding to Pneumocystis carinii organisms [editorial; comment] Pottratz ST. **J Lab Clin Med** 1995 Nov;126(5):414-5 (18 ref.) Comment on: J Lab Clin Med 1995 Nov;126(5):416-22.

[Neonatal pulmonary alveolar proteinosis and SP-B deficiency: pulmonary surfactant at the time of molecular pathology (editorial)] Lacaze-Masmonteil T, et al. **Arch Pediatr** 1996 Apr;3(4):309-12 (33 ref.) **(Fre)**

PHYSIOLOGY

Lung surfactants and asthma [editorial] Postle AD. **Clin Exp Allergy** 1995 Nov;25(11):1030-3 (31 ref.)

Role of surfactant in the pathophysiology of the acute respiratory distress syndrome (ARDS). Hartog A, et al. **Monaldi Arch Chest Dis** 1995 Oct;50(5):372-7 (58 ref.)

Human surfactant protein B: structure, function, regulation, and genetic disease. Whitsett JA, et al. **Physiol Rev** 1995 Oct;75(4):749-57 (66 ref.)

[Pulmonary surfactant system] van Golde LM. **Ned Tijdschr Geneeskd** 1996 Feb 3;140(5):236-40 (19 ref.) **(Dut)**

[Methodological approaches to the study of the pulmonary surfactant system] Bestuzheva SV. **Klin Lab Diagn** 1995 May-Jun;(3):32-6 (62 ref.) **(Rus)**

THERAPEUTIC USE

Exogenous surfactant use in neonates. Ishisaka DY. **Ann Pharmacother** 1996 Apr;30(4):389-98 (45 ref.)

Use of surfactant in pulmonary disorders in full-term infants. Sun B. **Curr Opin Pediatr** 1996 Apr;8(2):113-7 (27 ref.)

Natural vs synthetic surfactants in neonatal respiratory distress syndrome. Halliday HL. **Drugs** 1996 Feb; 51(2):226-37 (48 ref.)

Role of surfactant in the pathophysiology of the acute respiratory distress syndrome (ARDS). Hartog A, et al. **Monaldi Arch Chest Dis** 1995 Oct;50(5):372-7 (58 ref.)

Surfactant replacement therapy in neonatal respiratory distress syndrome. Hellmann J. **Paediatr Anaesth** 1995; 5(2):81-8 (62 ref.)

[Natural or artificial surfactants? Arguments in favour of natural surfactants] Walti H. **Arch Pediatr** 1996 Feb; 3(2):165-75 (93 ref.) (Eng. Abstr.) **(Fre)**

[Exogenous surfactants in neonatology] Zupan V, et al. **Rev Mal Respir** 1995;12(6):642-5 (17 ref.) **(Fre)**

PULMONARY VALVE

TRANSPLANTATION

Surgical treatment of aortic valve disease in the nineties with special emphasis on the use of the pulmonary autograft (Ross-operation). Pettersson G. **Ann Chir Gynaecol** 1995; 84(3):251-9 (10 ref.)

PULMONARY VALVE ATRESIA see **PULMONARY ATRESIA**

PULMONARY VALVE INCOMPETENCE see **PULMONARY VALVE INSUFFICIENCY**

PULMONARY VALVE INSUFFICIENCY

ETIOLOGY

[Cystic fibrosis in adults] Durieu I, et al. **Presse Med** 1995 Dec 16-23;24(39):1882-7 (23 ref.) (Eng. Abstr.) **(Fre)**

PULMONARY VALVE STENOSIS

EPIDEMIOLOGY

Isolated peripheral pulmonary artery stenoses in the adult. Kreutzer J, et al. **Circulation** 1996 Apr 1;93(7):1417-23 (49 ref.)

SURGERY

Aneurysm of the left pulmonary artery: surgical allograft repair. Casselman F, et al. **Ann Thorac Surg** 1995 Nov; 60(5):1423-5 (6 ref.)

THERAPY

[Percutaneous pulmonary valvuloplasty in neonates and infants with tetralogy of Fallot] Godart F, et al. **Arch Mal Coeur Vaiss** 1996 May;89(5):533-9 (30 ref.) (Eng. Abstr.) **(Fre)**

PULMONARY VEINS

Vascular complications of lung transplantation. Clark SC, et al. **Ann Thorac Surg** 1996 Apr;61(4):1079-82 (7 ref.)

[Pulmonary vein stenosis. Report of 2 cases and review of the literature] Zamorano M de M. **Arq Bras Cardiol** 1995 Jul;65(1):47-53 (22 ref.) (Eng. Abstr.) **(Por)**

ABNORMALITIES

The levoatriocardinal vein: morphology and echocardiographic identification of the pulmonary-systemic connection. Bernstein HS, et al. **J Am Coll Cardiol** 1995 Oct;26(4):995-1001 (15 ref.)

Unusual form of total anomalous pulmonary venous connection with double drainage. Lee ML, et al. **Pediatr Cardiol** 1995 Nov-Dec;16(6):301-3 (6 ref.)

[The integrated imaging of a rare case of partial anomalous pulmonary venous connections] Midiri M, et al. **Radiol Med (Torino)** 1995 Sep;90(3):320-3 (10 ref.) **(Ita)**

[Pulmonary arteriovenous fistulae and brain abscesses: a report of 2 cases treated by embolization and a review of the literature] Ricci P, et al. **Radiol Med (Torino)** 1996 Apr; 91(4):497-501 (24 ref.) **(Ita)**

[A patient with Rendu-Osler-Weber disease and pulmonary arteriovenous malformations treated satisfactorily by embolization] Martín Díaz E, et al. **Arch Bronconeumol** 1996 Jun-Jul;32(6):307-9 (12 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

[The importance of measuring pulmonary venous flow using doppler echocardiography] Veselka J. **Vnitr Lek** 1995 Nov; 41(11):787-91 (32 ref.) (Eng. Abstr.) **(Cze)**

PHYSIOPATHOLOGY

[Recording of pulmonary venous flow with Doppler echocardiography; normal and pathological aspects] Tribouilloy C, et al. **Arch Mal Coeur Vaiss** 1995 Sep; 88(9):1335-44 (26 ref.) (Eng. Abstr.) **(Fre)**

PULMONARY VENO-OCCLUSIVE DISEASE

CONGENITAL

[Pulmonary vein stenosis. Report of 2 cases and review of the literature] Zamorano M de M. **Arq Bras Cardiol** 1995 Jul;65(1):47-53 (22 ref.) (Eng. Abstr.) **(Por)**

ETIOLOGY

Pulmonary veno-occlusive disease in an adult following bone marrow transplantation. Case report and review of the literature. Williams LM, et al. **Chest** 1996 May; 109(5):1388-91 (26 ref.)

PULMONARY VENOUS WEDGE PRESSURE see **PULMONARY WEDGE PRESSURE**

PULMONARY WEDGE PRESSURE

Monitoring pulmonary artery wedge pressure in medical patients. Sharma S, et al. **Am Fam Physician** 1996 Sep 1; 54(3):1039-49 (39 ref.)

PULPECTOMY

ADVERSE EFFECTS

Periapical neural changes after pulpectomy. Holland GR. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1995 Dec;80(6):726-34 (55 ref.)

PULSATILE FLOW

Pulse reverse osmosis: a new theory in the maintenance of fluid balance. Prior FG, et al. **Perfusion** 1995 May; 10(3):159-70 (19 ref.)

DRUG EFFECTS

Thrombolysis, flow, and vessel wall interactions. Grabowski EF. **J Vasc Interv Radiol** 1995 Nov-Dec;6(6 Pt 2 Su):25S-29S (37 ref.)

PHYSIOLOGY

The assessment of pulsatile blood flow. Wright G. **Perfusion** 1995 May;10(3):135-40 (20 ref.)

[The significance of the pulsator factor for the functioning of the cerebral circulatory system (a brief review)] Vainshtein GB, et al. **Fiziol Zh Im I M Sechenova** 1995 Jun;81(6):54-8 (28 ref.) **(Rus)**

PULSE OXIMETRY see **OXIMETRY**

PULSELESS DISEASE see **TAKAYASU'S ARTERITIS**

PUMPING, INTRA-AORTIC BALLOON see INTRA-AORTIC BALLOON PUMPING

PUMPS, HEART-ASSIST see HEART-ASSIST DEVICES

PUMPS, INFUSION see INFUSION PUMPS

PUNCTURE BIOPSY see BIOPSY, NEEDLE

PUNCTURES

TMJ arthrocentesis. A conservative surgical alternative. Stein JI. **N Y State Dent J** 1995 Nov;61(9):68–76 (23 ref.)

PUPIL

[Abnormalities of the pupils] Furukawa T. **Nippon Naika Gakkai Zasshi** 1995 Sep 10;84(9):1417–21 (8 ref.) **(Jpn)**

PHYSIOLOGY

Neuronal circuitry controlling the near response. Mays LE, et al. **Curr Opin Neurobiol** 1995 Dec;5(6):763–8 (29 ref.)

PUPPET CHILDREN see ANGELMAN SYNDROME

PUPPETS see PLAY AND PLAYTHINGS

PURE RED-CELL APLASIA see RED-CELL APLASIA, PURE

PURGATIVES see CATHARTICS

PURINE NUCLEOTIDES

ADMINISTRATION & DOSAGE

Dietary purine nucleotides and the gastrointestinal tract. Leleiko NS, et al. **Nutrition** 1995 Nov-Dec;11(6):725–30 (44 ref.)

METABOLISM

Nucleobase and nucleoside transport in mammalian cells. Kraupp M, et al. **Wien Klin Wochenschr** 1995; 107(22):677–80 (36 ref.)

PHARMACOLOGY

Gene expression in the intestine: the effect of dietary nucleotides. LeLeiko NS, et al. **Adv Pediatr** 1995;42:145–69 (65 ref.)

PURINE-PYRIMIDINE METABOLISM, INBORN ERRORS

ENZYMOLOGY

Diagnostic analysis, clinical importance and molecular basis of dihydropyrimidine dehydrogenase deficiency. Gonzalez FJ, et al. **Trends Pharmacol Sci** 1995 Oct;16(10):325–7 (22 ref.)

PURINE RECEPTORS see RECEPTORS, PURINERGIC

PURINERGIC P1 RECEPTORS see RECEPTORS, PURINERGIC P1

PURINERGIC P2 RECEPTORS see RECEPTORS, PURINERGIC P2

PURINERGIC RECEPTORS see RECEPTORS, PURINERGIC

PURINES

Mechanistic insight from kinetic studies on the interaction of model palladium (II) complexes with nucleic acid components. Rau T, et al. **Met Ions Biol Syst** 1996; 32:339–78 (95 ref.)

METABOLISM

Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF). Allison AC, et al. **Clin Transplant** 1996 Feb;10(1 Pt 2):77–84 (33 ref.)

Accumulation of purine catabolites in solid tumors exposed to therapeutic hyperthermia. Busse M, et al. **Experientia** 1996 May 15;52(5):469–73 (26 ref.)

Hepatic purine and pyrimidine metabolism: implications for antiviral chemotherapy of viral hepatitis. Shaw T, et al. **Liver** 1995 Aug;15(4):169–84 (117 ref.)

[Purine derivatives] Ishibashi Y, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:514–7 (3 ref.) **(Jpn)**

PURINOCEPTORS see RECEPTORS, PURINERGIC

PURKINJE CELLS

PHYSIOLOGY

Cerebellar long-term depression might normalize excitation of Purkinje cells: a hypothesis. De Schutter E. **Trends Neurosci** 1995 Jul;18(7):291–5 (79 ref.)

PURPLE MEMBRANE

see related
BACTERIORHODOPSIN

PURPURA

Papular-purpuric 'gloves and socks' syndrome [letter] Veraldi S, et al. **Arch Dermatol** 1996 Aug;132(8):975–7 (17 ref.)

COMPLICATIONS

Acute transverse myelopathy and cutaneous vasculopathy in primary Sjögren's syndrome. Lyu RK, et al. **Eur Neurol** 1995;35(6):359–62 (24 ref.)

ETIOLOGY

Palpable purpura: an algorithmic approach. Stevens GL, et al. **Am Fam Physician** 1995 Oct;52(5):1355–62 (25 ref.)

Systemic lupus erythematosus diagnosed during interferon alfa therapy. Morris LF, et al. **South Med J** 1996 Aug; 89(8):810–4 (30 ref.)

[Necrotic purpura of the head disclosing Churg-Strauss syndrome] Ly S, et al. **Ann Dermatol Venereol** 1995; 122(3):94–6 (17 ref.) (Eng. Abstr.) **(Fre)**

[Parvovirus B19 infection. New physiopathological approaches] Labau E, et al. **Presse Med** 1996 Feb 3; 25(4):162–6 (26 ref.) (Eng. Abstr.) **(Fre)**

PSYCHOLOGY

Stress, stigmatization and psychosomatic purpuras. Panconesi E, et al. **Int Angiol** 1995 Jun;14(2):130–7 (51 ref.)

THERAPY

[Cytokine inhibitors in intensive care] Villard J, et al. **Rev Mal Respir** 1995;12(4):335–42 (66 ref.) (Eng. Abstr.) **(Fre)**

PURPURA, NONTHROMBOCYTOPENIC see PURPURA, SCHOENLEIN-HENOCH

PURPURA, SCHOENLEIN-HENOCH

COMPLICATIONS

[Rheumatoid purpura in adults. Apropos of 40 cases] Lasseur C, et al. **Rev Med Interne** 1996;17(5):381–9 (33 ref.) (Eng. Abstr.) **(Fre)**

[Schonlein-Henoch syndrome with severe abdominal involvement in an adult] Vogt M, et al. **Dtsch Med Wochenschr** 1996 Jul 5;121(27):871–5 (49 ref.) **(Ger)**

DIAGNOSIS

Chronic glomerulonephritis in childhood. Membranoproliferative glomerulonephritis, Henoch-Schönlein purpura nephritis, and IgA nephropathy. Andreoli SP. **Pediatr Clin North Am** 1995 Dec;42(6):1487–503 (60 ref.)

PATHOLOGY

IgA-associated renal diseases. Fogazzi GB, et al. **Curr Opin Nephrol Hypertens** 1996 Mar;5(2):134–40 (43 ref.)

Henoch-Schonlein purpura presenting as hemorrhagic vesicles and bullae: case report and literature review. Wananukul S, et al. **Pediatr Dermatol** 1995 Dec;12(4):314–7 (17 ref.)

PURPURA, THROMBOCYTOPENIC

COMPLICATIONS

Role of plasmapheresis in thrombocytopenic purpura associated with Waldenström's macroglobulinemia. Patel TC, et al. **Mayo Clin Proc** 1996 Jun;71(6):597–600 (14 ref.)

ETIOLOGY

Thrombotic microangiopathic syndromes after bone marrow transplantation [see comments] Byrnes JJ, et al. **Cancer Invest** 1996;14(2):151–7 (45 ref.) Comment in: Cancer Invest 1996;14(2):180–1.

IMMUNOLOGY

Immune thrombocytopenia in children: the immune character of destructive thrombocytopenia and the treatment of bleeding. Imbach P. **Semin Thromb Hemost** 1995; 21(3):305–12 (69 ref.)

THERAPY

Role of plasmapheresis in thrombocytopenic purpura associated with Waldenström's macroglobulinemia. Patel TC, et al. **Mayo Clin Proc** 1996 Jun;71(6):597–600 (14 ref.)

Immune thrombocytopenia in children: the immune character of destructive thrombocytopenia and the treatment of bleeding. Imbach P. **Semin Thromb Hemost** 1995; 21(3):305–12 (69 ref.)

PURPURA, THROMBOCYTOPENIC, AUTOIMMUNE see PURPURA, THROMBOCYTOPENIC, IDIOPATHIC

PURPURA, THROMBOCYTOPENIC, IDIOPATHIC

[Immune thrombocytopenic purpura in children—controversy and consensus. How much investigation and treatment is meaningful?] Zeller B, et al. **Tidsskr Nor Laegeforen** 1996 Aug 10;116(18):2160–4 (54 ref.) (Eng. Abstr.) **(Nor)**

COMPLICATIONS

Concurrent thrombotic thrombocytopenic purpura and immune thrombocytopenic purpura in an HIV-positive patient: case report and review of the literature. Yospur LS, et al. **Am J Hematol** 1996 Jan;51(1):73–8 (29 ref.)

DIAGNOSIS

Acute childhood immune thrombocytopenic purpura. Diagnosis and treatment. Souid AK, et al. **Clin Pediatr (Phila)** 1995 Sep;34(9):487–94 (50 ref.)

Current controversies in the management of idiopathic thrombocytopenic purpura during childhood. Medeiros D, et al. **Pediatr Clin North Am** 1996 Jun;43(3):757–72 (66 ref.)

[Fetal and neonatal immune thrombocytopenias] Neuhart D, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996; 25(2):206–11 (30 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

[Treatment of idiopathic thrombocytopenic purpura with danazol] Ruberto E, et al. **Sangre (Barc)** 1995 Aug; 40(4):307–10 (18 ref.) (Eng. Abstr.) **(Spa)**

EPIDEMIOLOGY

Combined autoimmune cytopenias. Martino R, et al. **Haematologica** 1995 Jul-Aug;80(4):305–10 (25 ref.)

ETIOLOGY

Immune thrombocytopenic purpura in three patients with preexisting ulcerative colitis. Yoshida EM, et al. **Am J Gastroenterol** 1996 Jun;91(6):1232–5 (22 ref.)

IMMUNOLOGY

Immunthrombocytopenic purpura as a model for pathogenesis and treatment of autoimmunity. Imbach P, et al. **Eur J Pediatr** 1995;154(9 Suppl 4):S60–4 (37 ref.)

Abnormal cellular immune mechanisms associated with autoimmune thrombocytopenia. Semple JW, et al. **Transfus Med Rev** 1995 Oct;9(4):327–38 (102 ref.)

PHYSIOPATHOLOGY

Diagnosis, treatment and pathophysiology of autoimmune thrombocytopenias. Chong BH. **Crit Rev Oncol Hematol** 1995 Oct;20(3):271–96 (218 ref.)

THERAPY

Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology [see comments] George JN, et al. **Blood** 1996 Jul 1;88(1):3–40 (295 ref.) Comment in: Blood 1996 Jul 1;88(1):1–2.

Diagnosis, treatment and pathophysiology of autoimmune thrombocytopenias. Chong BH. **Crit Rev Oncol Hematol** 1995 Oct;20(3):271–96 (218 ref.)

The thrombocytopenic purpuras. Recognition and management. Gillis S. **Drugs** 1996 Jun;51(6):942–53 (104 ref.)

Idiopathic thrombocytopenic purpura (ITP): immunomodulation by intravenous immunoglobulin (IVIg). Imbach P, et al. **Int Rev Immunol** 1989;5(2):181–8 (34 ref.)

[Fetal and neonatal immune thrombocytopenias] Neuhart D, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996; 25(2):206–11 (30 ref.) (Eng. Abstr.) **(Fre)**

PURPURA, THROMBOPENIC see PURPURA, THROMBOCYTOPENIC

PURPURA, THROMBOTIC THROMBOCYTOPENIC

Thrombotic thrombocytopenic purpura [editorial] Thomas M, et al. **J Assoc Physicians India** 1995 Oct;43(10):667–8 (22 ref.)

Thrombotic thrombocytopenic purpura. Moake JL. **Thromb Haemost** 1995 Jul;74(1):240–5 (33 ref.)

CHEMICALLY INDUCED

Thrombotic thrombo-cytopenic purpura associated with histamine H2-receptor antagonist therapy. Kallal SM, et al. **West J Med** 1996 May;164(5):446–8 (25 ref.)

COMPLICATIONS

Concurrent thrombotic thrombocytopenic purpura and immune thrombocytopenic purpura in an HIV-positive patient: case report and review of the literature. Yospur LS, et al. **Am J Hematol** 1996 Jan;51(1):73–8 (29 ref.)

ETIOLOGY

Thrombotic thrombocytopenic purpura (TTP): 4 case reports and review of the literature. Sathawarawong W. **J Med Assoc Thai** 1995 Jun;78(6):322–31 (62 ref.)

PHYSIOPATHOLOGY

The pathophysiology and management of thrombotic thrombocytopenic purpura. Ruggenenti P, et al. **Eur J Haematol** 1996 Apr;56(4):191–207 (144 ref.)

THERAPY

Therapy and prevention of thrombotic thrombocytopenic purpura during pregnancy: a clinical study of 16 pregnancies. Ezra Y, et al. **Am J Hematol** 1996 Jan; 51(1):1–6 (21 ref.)

Thrombotic thrombocytopenic purpura in pregnancy: successful treatment with plasma exchange. Case report and review of the literature. Mokrzycki MH, et al. **Blood Purif** 1995;13(5):271–82 (100 ref.)

The thrombocytopenic purpuras. Recognition and management. Gillis S. **Drugs** 1996 Jun;51(6):942–53 (104 ref.)

[A case of thrombotic thrombopenic purpura. Literature review] des Grottes JM, et al. **Rev Med Brux** 1996 Jun; 17(3):136–9 (16 ref.) (Eng. Abstr.) **(Fre)**

PURPURA, THROMBOTIC THROMBOPENIC see **PURPURA, THROMBOTIC THROMBOCYTOPENIC**

PURSUIT, SACCADIC see **SACCADES**

PURSUIT, SMOOTH

PHYSIOLOGY

Relation between backward masking deficits and smooth pursuit dysfunction in schizophrenia? Allen JS. **Optom Vis Sci** 1995 Jul;72(7):493–501 (61 ref.)

PUSTULANTS see **IRRITANTS**

PUSTULAR DERMATOSIS, SUBCORNEAL see **SKIN DISEASES, VESICULOBULLOUS**

PUSTULAR PSORIASIS OF PALMS AND SOLES see **PSORIASIS**

PUSTULOSIS OF PALMS AND SOLES see **PSORIASIS**

PUSTULOSIS PALMARIS ET PLANTARIS see **PSORIASIS**

PUUMALA VIRUS see **HANTAVIRUS**

PUVA THERAPY

Current treatment of vitiligo in China. Shao C, et al. **Chin Med J (Engl)** 1995 Sep;108(9):647–9 (10 ref.)

PUVA for psoriasis. González E. **Dermatol Clin** 1995 Oct; 13(4):851–66 (109 ref.)

Is phototherapy safe for HIV-infected individuals? Adams ML, et al. **Photochem Photobiol** 1996 Aug;64(2):234–7 (41 ref.)

PUVA therapy is preferable to UVB phototherapy in the management of HIV-associated dermatoses. Morison WL. **Photochem Photobiol** 1996 Aug;64(2):267–8 (11 ref.)

[Phototherapy of atopic dermatitis] Marguery MC, et al. **Ann Dermatol Venereol** 1995;122(10):729–34 (27 ref.) **(Fre)**

[Significance of PUVA therapy for adult T-cell leukemia/lymphoma—PUVA therapy can induce apoptosis in leukemic cells] Takemori N, et al. **Hum Cell** 1995 Sep; 8(3):121–6 (30 ref.) (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Bullous pemphigoid possibly induced by psoralen plus ultraviolet A therapy. George PM. **Photodermatol Photoimmunol Photomed** 1996 Oct–Dec; 11(5–6):185–7 (15 ref.)

METHODS

Modifications of PUVA. Momtaz-T K, et al. **Dermatol Clin** 1995 Oct;13(4):867–73 (71 ref.)

PX GENES see **GENES, PX**

PYELITIS

DIAGNOSIS

[Cystic pyeloureteritis. A review of the literature in the period of 1946–1994 and a report of a new case] Romero Pérez P, et al. **Actas Urol Esp** 1995 Mar;19(3):252–7 (20 ref.) (Eng. Abstr.) **(Spa)**

PYELONEPHRITIS

see related
KIDNEY FAILURE, CHRONIC

Bilateral emphysematous pyelonephritis: a case report and review of the literature. Stein JP, et al. **Urology** 1996 Jan; 47(1):129–34 (14 ref.)

COMPLICATIONS

Nephrobronchial fistula and lung abscess resulting from nephrolithiasis and pyelonephritis. O'Brien JD, et al. **Chest** 1995 Oct;108(4):1166–8 (6 ref.)

DIAGNOSIS

Acute renal infections. Papanicolaou N, et al. **Radiol Clin North Am** 1996 Sep;34(5):965–95 (46 ref.)

[Emphysematous pyelonephritis] Monllor Gisbert J, et al. **Arch Esp Urol** 1995 Nov;48(9):956–9 (8 ref.) (Eng. Abstr.) **(Spa)**

MICROBIOLOGY

Isolated renal mucormycosis: case report and review. Levy E, et al. **J Am Soc Nephrol** 1995 Jun;5(12):2014–9 (25 ref.)

[Interstitial nephropathy due to chronic bacterial pyelonephritis] Hirose T. **Nippon Rinsho** 1995 Aug; 53(8):1963–8 (11 ref.) (Eng. Abstr.) **(Jpn)**

PREVENTION & CONTROL

[Primary vesico-ureteral reflux. Current data and perspectives (editorial)] Lottmann H, et al. **Presse Med** 1996 Feb 10;25(5):185–7 (8 ref.) (Eng. Abstr.) **(Fre)**

PYELONEPHRITIS, XANTHOGRANULOMATOUS

Xanthogranulomatous pyelonephritis in a pregnant woman: a case report and review of the literature. Figueroa AJ, et al. **Urology** 1996 Aug;48(2):294–7 (14 ref.)

COMPLICATIONS

Nephrobronchocutaneous fistula. Aly SA, et al. **Ulster Med J** 1994 Apr;63(1):116–8 (5 ref.)

DIAGNOSIS

An unusual manifestation of xanthogranulomatous pyelonephritis: bilateral focal solid renal masses [letter] Ozcan H, et al. **AJR Am J Roentgenol** 1995 Dec; 165(6):1552–3 (4 ref.)

[Pseudotumoral xanthogranulomatous pyelonephritis. A propos of 2 cases] Mozziconacci JG, et al. **J Radiol** 1996 Jul;77(7):503–8 (28 ref.) (Eng. Abstr.) **(Fre)**

PYGATHRIX see **CERCOPITHECIDAE**

PYKNOLEPSY see **EPILEPSY, ABSENCE**

PYLORIC ANTRUM

ABNORMALITIES

Pyloric duplications: review and case study. Cooper S, et al. **Am Surg** 1995 Dec;61(12):1092–4 (18 ref.)

PATHOLOGY

Antral G-cell hyperplasia: a vanishing disease? Kwan CP, et al. **Eur J Gastroenterol Hepatol** 1995 Nov; 7(11):1099–1103 (44 ref.)

PYLORIC STENOSIS

COMPLICATIONS

Pyloric duplications: review and case study. Cooper S, et al. **Am Surg** 1995 Dec;61(12):1092–4 (18 ref.)

ETIOLOGY

[Wernicke's encephalopathy: report of a case with obstructive pyloric syndrome] Oliveira HA, et al. **Arq Neuropsiquiatr** 1995 Sep;53(3-A):488–93 (24 ref.) (Eng. Abstr.) **(Por)**

PYLORUS

see related
GASTRIC EMPTYING

[Pylorus-preserving gastrectomy for early gastric cancer] Sasaki I, et al. **Nippon Geka Gakkai Zasshi** 1996 Apr; 97(4):291–6 (22 ref.) (Eng. Abstr.) **(Jpn)**

PYODERMA

DRUG THERAPY

Common bacterial pyodermas. Taking aim against the most likely pathogens. Carroll JA. **Postgrad Med** 1996 Sep; 100(3):311–3, 317–22 (22 ref.)

MICROBIOLOGY

Recurrent chancriform pyoderma: report of a case with tongue lesions. Is Staphylococcus aureus implicated? Holmes SC, et al. **Br J Dermatol** 1995 Aug;133(2):326–7 (5 ref.)

Common bacterial pyodermas. Taking aim against the most likely pathogens. Carroll JA. **Postgrad Med** 1996 Sep; 100(3):311–3, 317–22 (22 ref.)

PYODERMA GANGRENOSUM

CLASSIFICATION

Pyoderma gangrenosum: classification and management. Powell FC, et al. **J Am Acad Dermatol** 1996 Mar; 34(3):395–409; quiz 410–2 (168 ref.)

COMPLICATIONS

Pyoderma gangrenosum and cranial osteolysis: case report and review of the paediatric literature. Samlaska CP, et al. **Br J Dermatol** 1995 Dec;133(6):972–7 (61 ref.)

DIAGNOSIS

Pyoderma gangrenosum with hepatopancreatic manifestations in a patient with rheumatoid arthritis. Hastier P, et al. **Dig Dis Sci** 1996 Mar;41(3):594–7 (9 ref.)

DRUG THERAPY

Treatment of pyoderma gangrenosum. Chow RK, et al. **J Am Acad Dermatol** 1996 Jun;34(6):1047–60 (199 ref.)

ETIOLOGY

Recurring postoperative pyoderma gangrenosum. Esnault P, et al. **Int J Dermatol** 1995 Sep;34(9):647–50 (35 ref.)

[Paraneoplastic pyoderma gangrenosum (letter)] Bayle-Lebey P, et al. **Ann Med Interne (Paris)** 1995; 146(8):585–7 (12 ref.) **(Fre)**

PYONEPHROSIS see **PYELONEPHRITIS**

PYORRHEA ALVEOLARIS see **PERIODONTAL DISEASES**

PYOTHORAX see **EMPYEMA, PLEURAL**

PYRAMIDAL CELLS

METABOLISM

GM2 ganglioside and pyramidal neuron dendritogenesis. Walkley SU, et al. **Neurochem Res** 1995 Nov; 20(11):1287–99 (115 ref.)

PYRAMIDAL TRACTS

ANATOMY & HISTOLOGY

Anatomy, development and lesion-induced plasticity of rodent corticospinal tract. Terashima T. **Neurosci Res** 1995 May;22(2):139–61 (180 ref.)

PYRAZINAMIDE

[Status quo of pyrazinamide as an antituberculosis drug] Kameda K. **Kekkaku** 1995 Jul;70(7):445–55 (80 ref.) (Eng. Abstr.) **(Jpn)**

PYRAZINES

THERAPEUTIC USE

Effects of oltipraz and related chemoprevention compounds on gene expression in rat liver. Anderson L, et al. **J Cell Biochem Suppl** 1995;22:108–16 (20 ref.)

Oltipraz: clinical opportunities for cancer chemoprevention. p Kensler TW, et al. **J Cell Biochem Suppl** 1995;22:101–7 (38 ref.)

Oltipraz, a novel inhibitor of human immunodeficiency virus type 1 (HIV-1) replication. Prochaska HJ, et al. **J Cell Biochem Suppl** 1995;22:117–25 (40 ref.)

[Recent advances in experimental and clinical study on ligustrazine in treating respiratory disease] Zhang KJ, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Oct; 15(10):638–40 (22 ref.) **(Chi)**

PYRAZINOPYRIMIDINES see **PTERIDINES**

PYRAZOLES

PHARMACOLOGY

New drugs. The anthrapyrazoles. Gogas H, et al. **Cancer Treat Rev** 1996 Nov;21(6):541–52 (53 ref.)

Status of new anthrapyrazole and pyrazoloacridine derivatives. Berg SL. **Crit Rev Oncol Hematol** 1996 Mar; 22(2):79–87 (57 ref.)

PYRETHRINS

kdr-Type resistance in insects with special reference to the German cockroach, Blattella germanica. Scott JG, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1994 Oct–Nov; 109(2–3):191–8 (68 ref.)

ECONOMICS

Economic aspects of the use of impregnated mosquito nets for malaria control. Brinkmann U, et al.

PYRETHRINS

Bull World Health Organ 1995;73(5):651–8 (23 ref.)

THERAPEUTIC USE

Permethrin. Taplin D, et al. **Curr Probl Dermatol** 1996; 24:255–60 (12 ref.)

TOXICITY

Sodium channels and GABAA receptor–channel complex as targets of environmental toxicants. Narahashi T, et al. **Toxicol Lett** 1995 Dec;82–83:239–45 (20 ref.)

PYREXIA see **FEVER**

PYRIDINE NUCLEOTIDE TRANSHYDROGENASE see **NADP TRANSHYDROGENASE**

PYRIDINES

[Prostacyclin mimetics with non–prostanoid structures] Kondo K, et al. **Nippon Yakurigaku Zasshi** 1995 Sep; 106(3):181–91 (21 ref.) (Eng. Abstr.) **(Jpn)**

PHARMACOKINETICS

Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications. Salvà P, et al. **Clin Pharmacokinet** 1995 Sep;29(3):142–53 (37 ref.)

PHARMACOLOGY

In vivo selection of HIV–1 variants with reduced susceptibility to the protease inhibitor L–735,524 and related compounds. Emini EA, et al. **Adv Exp Med Biol** 1996;394:327–31 (8 ref.)

Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications. Salvà P, et al. **Clin Pharmacokinet** 1995 Sep;29(3):142–53 (37 ref.)

[Epibatidine—a nicotine-related, analgesic alkaloid from poison-dart frogs] Müller CE. **Pharm Unserer Zeit** 1996 Apr;25(2):85–92 (27 ref.) **(Ger)**

THERAPEUTIC USE

Current clinical experience with nevirapine for HIV infection. Carr A, et al. **Adv Exp Med Biol** 1996; 394:299–304 (17 ref.)

Clinical experience with non–nucleoside reverse transcriptase inhibitors: L–697,661 and nevirapine. Kilby JM, et al. **Adv Exp Med Biol** 1996;394:291–8 (23 ref.)

Zolpidem—a hypnotic with a difference? **Drug Ther Bull** 1995 May;33(5):37–9 (17 ref.)

[New non–benzodiazepine hypnotics. Progress in therapy of sleep disorders?] Hajak G, et al. **Internist (Berl)** 1995 Nov; 36(11):1085–90; discussion 1090–1 (51 ref.) **(Ger)**

PYRIDINIUM COMPOUNDS

METABOLISM

[Pyridinium cross–links: sensitive markers of bone catabolism] Sela BA. **Harefuah** 1995 Oct;129(7–8):264–8 (30 ref.) **(Heb)**

PYRIDINONES see **PYRIDONES**

PYRIDONES

ADVERSE EFFECTS

Long–term therapy with deferiprone. Olivieri NF. **Acta Haematol** 1996;95(1):37–48 (90 ref.)

PHARMACOLOGY

Milrinone: basic and clinical pharmacology and acute and chronic management. Shipley JB, et al. **Am J Med Sci** 1996 Jun;311(6):286–91 (36 ref.)

Comparative efficacy and toxicity of desferrioxamine, deferiprone and other iron and aluminium chelating drugs. Kontoghiorghes GJ. **Toxicol Lett** 1995 Oct;80(1–3):1–18 (151 ref.)

THERAPEUTIC USE

Long–term therapy with deferiprone. Olivieri NF. **Acta Haematol** 1996;95(1):37–48 (90 ref.)

Clinical experience with non–nucleoside reverse transcriptase inhibitors: L–697,661 and nevirapine. Kilby JM, et al. **Adv Exp Med Biol** 1996;394:291–8 (23 ref.)

Chemical, pharmacological, toxicological and therapeutic advances of deferiprone (L1) and other iron and aluminium chelators. Kontoghiorghes GJ. **Arch Toxicol Suppl** 1996; 18:202–14 (56 ref.)

Oral iron chelation. Hoffbrand AV. **Semin Hematol** 1996 Jan; 33(1):1–8 (57 ref.)

TOXICITY

Comparative efficacy and toxicity of desferrioxamine, deferiprone and other iron and aluminium chelating drugs. Kontoghiorghes GJ. **Toxicol Lett** 1995 Oct;80(1–3):1–18 (151 ref.)

PYRIDOXAL PHOSPHATE

ANALOGS & DERIVATIVES

Exploring the nucleotide–binding site in proteins by affinity labeling and site–directed mutagenesis. Fukui T. **J Biochem (Tokyo)** 1995 Jun;117(6):1139–44 (45 ref.)

Mangafodipir trisodium injection (Mn–DPDP). A contrast agent for abdominal MR imaging. Rofsky NM, et al. **Magn Reson Imaging Clin N Am** 1996 Feb;4(1):73–85 (49 ref.)

METABOLISM

Stereochemical constraint in the evolution of pyridoxal–5'–phosphate–dependent enzymes. A hypothesis. Christen P, et al. **FEBS Lett** 1996 Jun 24;389(1):12–4 (21 ref.)

Pyridoxal enzymes: mechanistic diversity and uniformity. Hayashi H. **J Biochem (Tokyo)** 1995 Sep;118(3):463–73 (54 ref.)

PYRIDOXINE

ADMINISTRATION & DOSAGE

Pharmacokinetics of vitamin B6 supplements in humans. Zempleni J. **J Am Coll Nutr** 1995 Dec;14(6):579–86 (64 ref.)

BIOSYNTHESIS

The biosynthesis of pyridoxine. Spenser ID, et al. **Nat Prod Rep** 1995 Dec;12(6):555–65 (51 ref.)

BLOOD

Vitamin B6 and hemodialysis: the impact of high–flux/high–efficiency dialysis and review of the literature. Kasama R, et al. **Am J Kidney Dis** 1996 May; 27(5):680–6 (17 ref.)

[Vitamin B6 (pyridoxine)] Yasuda K, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:701–3 (5 ref.) **(Jpn)**

PHARMACOKINETICS

Pharmacokinetics of vitamin B6 supplements in humans. Zempleni J. **J Am Coll Nutr** 1995 Dec;14(6):579–86 (64 ref.)

THERAPEUTIC USE

Vitamin B6 (pyridoxine) therapy for carpal tunnel syndrome. Jacobson MD, et al. **Hand Clin** 1996 May;12(2):253–7 (38 ref.)

Efficacy of vitamin B6 and magnesium in the treatment of autism: a methodology review and summary of outcomes. Pfeiffer SI, et al. **J Autism Dev Disord** 1995 Oct; 25(5):481–93 (36 ref.)

TOXICITY

Bendectin: review of the medical literature of a comprehensively studied human nonteratogen and the most prevalent tortogen–litigen. Brent RL. **Reprod Toxicol** 1995 Jul–Aug;9(4):337–49 (178 ref.)

PYRIDOXINE DEFICIENCY

see related
ANEMIA, SIDEROBLASTIC

COMPLICATIONS

Vitamin and mineral deficiencies which may predispose to glucose intolerance of pregnancy. Jovanovic–Peterson L, et al. **J Am Coll Nutr** 1996 Feb;15(1):14–20 (64 ref.)

PYRIMETHAMINE

ADMINISTRATION & DOSAGE

[Clarithromycin combined with pyrimethamine in cerebral toxoplasmosis—a a report of 2 cases] Dalston MO, et al. **Rev Soc Bras Med Trop** 1995 Oct–Dec;28(4):409–13 (11 ref.) (Eng. Abstr.) **(Por)**

PYRIMIDINE DIMERS

METABOLISM

No "End of History" for photolyases [comment] Sancar A. **Science** 1996 Apr 5;272(5258):48–9 (14 ref.) Comment on: Science 1996 Apr 5;272(5258):109–12.

PYRIMIDINE NUCLEOSIDES

CHEMISTRY

The 5,6–double bond of pyrimidine nucleosides, a fragile site in nucleic acids. Hayatsu H. **J Biochem (Tokyo)** 1996 Mar; 119(3):391–5 (62 ref.)

PYRIMIDINE 5'-NUCLEOTIDASE see **5'-NUCLEOTIDASE**

PYRIMIDINE NUCLEOTIDES

BLOOD

[Nucleotides] Fujii H. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:243–6 (5 ref.) **(Jpn)**

METABOLISM

Nucleobase and nucleoside transport in mammalian cells. Kraupp M, et al. **Wien Klin Wochenschr** 1995; 107(22):677–80 (36 ref.)

PYRIMIDINE PHOSPHORYLASE see **THYMIDINE PHOSPHORYLASE**

PYRIMIDINES

Mechanistic insight from kinetic studies on the interaction of model palladium (II) complexes with nucleic acid components. Rau T, et al. **Met Ions Biol Syst** 1996; 32:339–78 (95 ref.)

METABOLISM

Hepatic purine and pyrimidine metabolism: implications for antiviral chemotherapy of viral hepatitis. Shaw T, et al. **Liver** 1995 Aug;15(4):169–84 (117 ref.)

PHARMACOLOGY

Antipsychotics and neuropeptides: the atypical profile of CI–943 and its relationship to neurotensin. Liégeois JF, et al. **Neurosci Biobehav Rev** 1995 Winter;19(4):519–31 (101 ref.)

PYROGENS

IMMUNOLOGY

Bacterial pyrogenic exotoxins as superantigens. Kotb M. **Clin Microbiol Rev** 1995 Jul;8(3):411–26 (292 ref.)

The neurological basis of fever. Samii A. **Surg Neurol** 1996 Apr;45(4):392–3 (11 ref.)

PYRROLES

ANALYSIS

[Dipyrrole bile pigments] Yamaguchi T, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:895–8 (9 ref.) **(Jpn)**

PYRROLIDINES

DIAGNOSTIC USE

D2–receptor imaging with [123I]IBZM and single photon emission tomography in psychiatry: a survey of current status. Schlösser R, et al. **J Neural Transm Gen Sect** 1995; 99(1–3):173–85 (52 ref.)

PHARMACOLOGY

N–methyl–D–aspartate (NMDA) receptors, mu and kappa opioid tolerance, and perspectives on new analgesic drug development. Elliott K, et al. **Neuropsychopharmacology** 1995 Dec;13(4):347–56 (58 ref.)

PYRROLIDINONES

THERAPEUTIC USE

Multiple sclerosis: TNF revisited, with promise [comment] Raine CS. **Nat Med** 1995 Mar;1(3):211–4 (28 ref.) Comment on: Nat Med 1995 Mar;1(3):244–8.

PYRROLIDONES see **PYRROLIDINONES**

PYRROLIZIDINE ALKALOIDS

POISONING

[Veno–occlusive disease of small hepatic vein (Bush tea disease)] Saito K, et al. **Ryoikibetsu Shokogun Shirizu** 1995; (8):176–9 (24 ref.) **(Jpn)**

TOXICITY

Directly toxic effects of plant chemicals which may occur in human and animal foods. Seawright AA. **Nat Toxins** 1995;3(4):227–32; discussion 242 (54 ref.)

PYRUVALDEHYDE

METABOLISM

Methylglyoxal and regulation of its metabolism in microorganisms. Inoue Y, et al. **Adv Microb Physiol** 1995; 37:177–227 (310 ref.)

Formation of methylglyoxal–modified proteins in vitro and in vivo and their involvement in AGE–related processes. Thornalley PJ, et al. **Contrib Nephrol** 1995;112:24–31 (31 ref.)

[Role of glyoxalases and methylglyoxal in cell proliferation and differentiation] Piskorska D, et al. **Postepy Hig Med Dosw** 1995;49(3):433–44 (56 ref.) (Eng.

Abstr.) (Pol)

PHARMACOLOGY

Advances in glyoxalase research. Glyoxalase expression in malignancy, anti-proliferative effects of methylglyoxal, glyoxalase I inhibitor diesters and S-D-lactoylglutathione, and methylglyoxal-modified protein binding and endocytosis by the advanced glycation endproduct receptor. Thornalley PJ. **Crit Rev Oncol Hematol** 1995 Aug;20(1-2):99-128 (225 ref.)

PYRUVATE KINASE

see related
ANEMIA, HEMOLYTIC

BLOOD

[Pyruvate kinase] Tani K. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:369-72 (5 ref.) (Jpn)

DEFICIENCY

Mutations in pyruvate kinase. Beutler E, et al. **Hum Mutat** 1996;7(1):1-6 (40 ref.)

Red cell enzymopathies as a model of inborn errors of metabolism. Miwa S, et al. **Southeast Asian J Trop Med Public Health** 1995;26 Suppl 1:112-9 (39 ref.)

GENETICS

Molecular basis of erythroenzymopathies associated with hereditary hemolytic anemia: tabulation of mutant enzymes. Miwa S, et al. **Am J Hematol** 1996 Feb;51(2):122-32 (105 ref.)

Mutations in pyruvate kinase. Beutler E, et al. **Hum Mutat** 1996;7(1):1-6 (40 ref.)

METABOLISM

The allosteric regulation of pyruvate kinase. Mattevi A, et al. **FEBS Lett** 1996 Jun 24;389(1):15-9 (23 ref.)

PYRUVATE, ORTHOPHOSPHATE DIKINASE

GENETICS

The gene for pyruvate, orthophosphate dikinase in C4 plants: structure, regulation and evolution. Matsuoka M. **Plant Cell Physiol** 1995 Sep;36(6):937-43 (55 ref.)

PYRUVATE, PHOSPHATE DIKINASE see **PYRUVATE, ORTHOPHOSPHATE DIKINASE**

PYRUVATES

BLOOD

[Pyruvate] Shimizu T. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:586-9 (3 ref.) (Jpn)

METABOLISM

Respiratory-chain and pyruvate metabolism defects: Italian collaborative survey on 72 patients. Caruso U, et al. **J Inherit Metab Dis** 1996;19(2):143-8 (6 ref.)

Q FEVER

Q fever and trench fever. Gluckman SJ. **Clin Dermatol** 1996 May-Jun;14(3):283-7 (36 ref.)

Q fever: still a query after all these years [editorial] Raoult D. **J Med Microbiol** 1996 Feb;44(2):77-8 (15 ref.)

[Q-fever--occurrence and significance of this disease in the Czech Republic and Slovak Republic] Literák I, et al. **Vet Med (Praha)** 1996 Feb;41(2):45-63 (200 ref.) (Eng. Abstr.) (Cze)

COMPLICATIONS

[Rhabdomyolysis and Q fever (letter)] Alberto Navarro L, et al. **Enferm Infecc Microbiol Clin** 1996 Feb;14(2):129-30 (9 ref.) (Spa)

DIAGNOSIS

Coxiella burnetii (Q fever) pneumonia. Marrie TJ. **Clin Infect Dis** 1995 Dec;21 Suppl 3:S253-64 (89 ref.)

MICROBIOLOGY

[Q fever and Coxiella burnetii] Oda H, et al. **Nippon Saikingaku Zasshi** 1995 Jul;50(3):703-15 (84 ref.) (Jpn)

QALY see **QUALITY-ADJUSTED LIFE YEARS**

QIGONG see **BREATHING EXERCISES**

QUADRIGEMINAL PLATE see **CORPORA QUADRIGEMINA**

QUADRIPLEGIA

COMPLICATIONS

Post-traumatic syringomyelia (cystic myelopathy): a prospective study of 449 patients with spinal cord injury. Schurch B, et al. **J Neurol Neurosurg Psychiatry** 1996 Jan; 60(1):61-7 (42 ref.)

ETIOLOGY

Cervical spinal stenosis with cord neurapraxia and transient quadriplegia. Torg JS. **Sports Med** 1995 Dec;20(6):429-34 (10 ref.)

REHABILITATION

Outcomes of tendon transfer surgery and occupational therapy in a child with tetraplegia secondary to spinal cord injury. Mulcahey MJ, et al. **Am J Occup Ther** 1995 Jul-Aug;49(7):607-17 (45 ref.)

Functional hand surgery following tetraplegia. Waters RL, et al. **Arch Phys Med Rehabil** 1996 Jan;77(1):86-94 (48 ref.)

SURGERY

Outcomes of tendon transfer surgery and occupational therapy in a child with tetraplegia secondary to spinal cord injury. Mulcahey MJ, et al. **Am J Occup Ther** 1995 Jul-Aug;49(7):607-17 (45 ref.)

THERAPY

Acute spinal cord injury and neurogenic shock in pregnancy. Gilson GJ, et al. **Obstet Gynecol Surv** 1995 Jul;50(7):556-60 (11 ref.)

QUAIL

EMBRYOLOGY

[Do several waves of stem cells follow themselves during hematopoietic development?] Dieterlen-Lièvre F. **C R Seances Soc Biol Fil** 1995;189(4):591-6 (16 ref.) (Eng. Abstr.) (Fre)

QUALITY-ADJUSTED LIFE YEARS

Health policy approaches to measuring and valuing human life: conceptual and ethical issues [see comments] Morrow RH, et al. **Am J Public Health** 1995 Oct;85(10):1356-60 (20 ref.) Comment in: Am J Public Health 1995 Oct;85(10):1345-6.

The use of condition specific outcome measures in economic appraisal. Brazier J, et al. **Health Econ** 1995 Jul-Aug; 4(4):255-64 (35 ref.)

The person-trade-off approach to valuing health care programs [see comments] Nord E. **Med Decis Making** 1995 Jul-Sep;15(3):201-8 (32 ref.) Comment in: Med Decis Making 1995 Jul-Sep;15(3):287-8.

[QALYS or not QALYS: that is the question?] Moatti JP, et al. **Rev Epidemiol Sante Publique** 1995 Dec;43(6):573-83 (27 ref.) (Eng. Abstr.) (Fre)

QUALITY ASSESSMENT, HEALTH CARE see **QUALITY ASSURANCE, HEALTH CARE**

QUALITY ASSURANCE, HEALTH CARE

The origins of health services research in radiology: a review. Kundel HL. **AJR Am J Roentgenol** 1996 Jun;166(6):1255-7 (34 ref.)

Think before you prep: defining the terms of change in American healthcare. Tanenbaum SJ. **Ann Thorac Surg** 1995 Nov;60(5):1530-3 (12 ref.)

Quality assurance in burn patient care: the James Laing Memorial Essay, 1994. Wood FM. **Burns** 1995 Dec; 21(8):563-8 (19 ref.)

Quality assurance in 3-D treatment planning. Ten Haken RK, et al. **Front Radiat Ther Oncol** 1996;29:104-14 (9 ref.)

Gene delivery systems for use in gene therapy: an overview of quality assurance and safety issues. Smith KT, et al. **Gene Ther** 1996 Mar;3(3):190-200 (52 ref.)

Securing health care quality for Medicare. Palmer RH. **Health Aff (Millwood)** 1995 Winter;14(4):89-100 (31 ref.)

The use of different research methodologies to evaluate the effectiveness of programmes to improve the care of patients in postoperative pain. Allcock N. **J Adv Nurs** 1996 Jan; 23(1):32-8 (34 ref.)

Satisfying solutions? A review of some unresolved issues in the measurement of patient satisfaction. Avis M, et al. **J Adv Nurs** 1995 Aug;22(2):316-22 (60 ref.)

Organizational and psychological consultation in collegiate sports medicine groups. Anderson MB, et al. **J Am Coll Health** 1995 Sep;44(2):63-9 (18 ref.)

Improving the management of hypertension in clinical practice. Mancia G. **J Hum Hypertens** 1995 Jul;9 Suppl 2:S29-31 (13 ref.)

Assessment: Clinical autonomic testing report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. **Neurology** 1996 Mar;46(3):873-80 (101 ref.)

Quality assurance in early breast cancer treatment: clinical aspects of postoperative, external, whole breast irradiation. Valdagni R, et al. **Recent Results Cancer Res** 1996; 140:251-61 (64 ref.)

A review of research on the nature and quality of HIV testing services: a proposal for process-based studies. Beardsell S, et al. **Soc Sci Med** 1996 Mar;42(5):733-43 (112 ref.)

Improving the quality of care for persons with HIV infection in sub-Saharan Africa. Colebunders R, et al. **Trop Geogr Med** 1995;47(2):78-81 (26 ref.)

[Quality assurance] **Kaste M**, et al. **Duodecim** 1995; 111(1):56-62 (37 ref.) (Fin)

[Quality assurance of bacterial incidents associated with blood transfusion] Noël L. **Transfus Clin Biol** 1996; 3(1):35-42 (28 ref.) (Eng. Abstr.) (Fre)

[Quality assurance in neuroradiology] Huk WJ. **Aktuelle Radiol** 1995 Nov;5(6):343-5 (4 ref.) (Eng. Abstr.) (Ger)

[Quality criteria in diagnostic radiology, goals and reality] St. Stender H, et al. **Aktuelle Radiol** 1995 Nov;5(6):337-42 (73 ref.) (Eng. Abstr.) (Ger)

[Effectiveness of preclinical emergency management. Fiction or fact?] Dick WF. **Anaesthesist** 1996 Jan;45(1):75-87 (83 ref.) (Eng. Abstr.) (Ger)

[Drug side-effects of the eye--a contribution to quality assurance in ophthalmology] Dangelmaier S, et al. **Klin Monatsbl Augenheilkd** 1996 May;208(5):385-8 (4 ref.) (Eng. Abstr.) (Ger)

[Usefulness and risk of roentgen diagnosis. A contribution to quality assurance] Angerstein W. **Rontgenpraxis** 1995 Sep;48(9):261-6 (58 ref.) (Ger)

[Blood transmission and infections] Eggen BM. **Tidsskr Nor Laegeforen** 1995 Oct 10;115(24):3035-8 (73 ref.) (Eng. Abstr.) (Nor)

[Quality assurance in occupational health services] Michalak J. **Med Pr** 1996;47(3):267-75 (15 ref.) (Eng. Abstr.) (Pol)

[Valuable methods for lung function measurements. Spirometry at ambulatory centers is excellent for early diagnosis] Larsson M. **Lakartidningen** 1995 Nov 22; 92(47):4427-30, 4435-7 (27 ref.) (Swe)

[Quality in preventive and health promotion activities] Blomberg I. **Nord Med** 1995;110(10):246-9 (15 ref.) (Eng. Abstr.) (Swe)

ECONOMICS

Quality, cost-effective psychiatric treatment: A CNS--MD collaborative practice model. Saur CD, et al. **Arch Psychiatr Nurs** 1995 Dec;9(6):332-7 (15 ref.)

LEGISLATION & JURISPRUDENCE

Quo vademus? A review of the regulatory environment. Huss H, et al. **Qual Assur** 1995 Sep;4(3):181-6 (6 ref.)

[What can the hospital deliver? What must the hospital deliver?] Pannike A. **Unfallchirurgie** 1995 Aug;21(4):204-18 (68 ref.) (Ger)

ORGANIZATION & ADMINISTRATION

Optimizing cardiothoracic surgery information for a managed care environment. Denton TA, et al. **Ann Thorac Surg** 1995 Nov;60(5):1522-5 (22 ref.)

Quality initiatives and the power of the database: what they are and how they run. Grover FL, et al. **Ann Thorac Surg** 1995 Nov;60(5):1514-21 (15 ref.)

Quality initiatives and the power of the database: where we stand. Kouchoukos NT. **Ann Thorac Surg** 1995 Nov; 60(5):1526-9 (13 ref.)

Starting in the middle: social work and quality assurance. Cooper L. **Aust Clin Rev** 1991;11:82-6 (5 ref.)

In pursuit of excellence: quality assurance, documentation, and peer review by home birth CNMs. Morales ME, et al. **J Nurse Midwifery** 1995 Nov-Dec;40(6):555-69 (56 ref.)

Functionally dependent veterans. Issues related to providing and improving their oral health care. Henry RG. **Med Care** 1995 Nov;33(11 Suppl):NS143-63 (82 ref.)

Quality assurance and medical outcomes in the era of cost containment. Campion FX, et al. **Surg Clin North Am** 1996 Feb;76(1):139-59 (35 ref.)

STANDARDS

[Quality assurance and prevention of immuno-hemolytic incidents in blood transfusion] Boëlle PY, et al. **Transfus Clin Biol** 1996;3(1):27-34 (26 ref.) (Eng. Abstr.) (Fre)

[Quality control for trace elements in occupational and environmental medicine] Morisi G, et al. **Ann Ist Super Sanita** 1995;31(2):245-54 (8 ref.) (Eng. Abstr.) (Ita)

TRENDS

What will be the outcome of the outcomes movement? Braithwaite J, et al. **Aust N Z J Med** 1995 Dec;25(6):731-5 (49 ref.)

Standards in fibrinolysis--current status and future challenges. Gaffney PJ. **Thromb Haemost** 1995 Dec; 74(6):1389-97 (59 ref.)

[Conceptual approaches in quality evaluation, quality promotion and quality assurance] Gebert AJ. **Swiss Surg** 1995;(1):8-14 (83 ref.) (Eng. Abstr.) (Ger)

QUALITY CONTROL

see related
REFERENCE STANDARDS
TOTAL QUALITY MANAGEMENT

QUALITY OF HEALTH CARE

see related
PROFESSIONAL STAFF COMMITTEES

Primary care as form or content? Mottur-Pilson C. **Am J Med Qual** 1995 Winter;10(4):177–82 (26 ref.)

The current state of health care in the former Soviet Union: implications for health care policy and reform [see comments] Barr DA, et al. **Am J Public Health** 1996 Mar; 86(3):307–12 (61 ref.) Comment in: Am J Public Health 1996 Mar;86(3):321–3.

Setting standards of prescribing performance in primary care: use of a consensus group of general practitioners and application of standards to practices in the north of England. Bateman DN, et al. **Br J Gen Pract** 1996 Jan; 46(402):20–5 (12 ref.)

Care of patients with epilepsy in the community: will new initiatives address old problems? [see comments] Thapar AK. **Br J Gen Pract** 1996 Jan;46(402):37–42 (69 ref.) Comment in: Br J Gen Pract 1996 Jan;46(402):3–4.

Quality in anaesthesia: an integrated and constructive model. Hardy JF, et al. **Can J Anaesth** 1996 May;43(5 Pt 2):R75–88 (23 ref.) **(Eng, Fre)**

How is telepathology being used to improve patient care? Weinberg DS. **Clin Chem** 1996 May;42(5):831–5 (20 ref.)

Multidisciplinarity and multimedia in quality of care—education. Heyrman J. **Eur J Cancer** 1995;31A Suppl 6:S11–4 (6 ref.)

The psychiatrist's perspective on quality of life and quality of care in oncology: concepts, symptom management, communication issues. Razavi D, et al. **Eur J Cancer** 1995; 31A Suppl 6:S25–9 (41 ref.)

Nursing homes: what you need to know for quality patient care. Cefalu CA. **Geriatrics** 1995 Dec;50(12):37–40, 49–50 (22 ref.)

Towards a conceptual model of 'quality care'. Attree M. **Int J Nurs Stud** 1996 Feb;33(1):13–28 (38 ref.)

Improving the use of information in medical effectiveness research. Phillips KA, et al. **Int J Qual Health Care** 1996 Feb;8(1):21–30 (96 ref.)

The impact of multiskilling on quality of care. Holzemer WL. **Int Nurs Rev** 1996 Jan–Feb;43(1):21–5 (32 ref.)

Making a difference for children: the medical community's role in improving child care. Reisman B. **J Am Med Wom Assoc** 1995 Sep–Oct;50(5):170–4 (21 ref.)

Managed care: "new moves, moral uncertainty, and a radical attitude. Howe EG. **J Clin Ethics** 1995 Winter;6(4):290–305 (57 ref.)

Managed care: will the healthcare needs of rural citizens be met? Pierce SF, et al. **J Nurs Adm** 1996 Apr;26(4):28–32 (10 ref.)

The Injury Severity Score is unable to differentiate between poor care and severe injury. Rutledge R. **J Trauma** 1996 Jun;40(6):944–50 (36 ref.)

Classics in Spine. Surgery literature revisited. Bessette L, et al. **Spine** 1996 Feb 1;21(3):259–63 (13 ref.)

[Impact of HMOs on costs and quality of care] Perneger TV, et al. **Rev Med Suisse Romande** 1995 Dec; 115(12):971–6 (42 ref.) **(Fre)**

ECONOMICS

Can improved quality of care reduce the costs of managing angina pectoris? Cleland JG. **Eur Heart J** 1996 Mar;17 Suppl A:29–40 (74 ref.)

STANDARDS

Quality standard for the enumeration of CD4+ lymphocytes in adults and adolescents infected with human immunodeficiency virus. Gross PA, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S126–7 (7 ref.)

Quality standard for the prophylaxis of Pneumocystis carinii pneumonia in adults and adolescents infected with human immunodeficiency virus. Phair JP, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S128–9 (8 ref.)

Quality standard for the identification and treatment of persons coinfected with human immunodeficiency virus and Mycobacterium tuberculosis. Phair JP, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S130–1 (4 ref.)

Quality standard for the immunization of infants and children born to women infected with human immunodeficiency virus. Wilfert CM, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S136–7 (5 ref.)

Quality standard for the prophylaxis of Pneumocystis carinii pneumonia in infants and children born to women infected with human immunodeficiency virus. Wilfert CM, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S132–3 (4 ref.)

Quality standard for the enumeration of CD4+ lymphocytes in infants and children exposed to or infected with human immunodeficiency virus. Wilfert CM, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S134–5 (10 ref.)

Identifying complications and low provider adherence to normative practices using administrative data. Kuykendall DH, et al. **Health Serv Res** 1995 Oct;30(4):531–54 (28 ref.)

STATISTICS & NUMERICAL DATA

Developing a quality improvement database using health insurance data: a guided tour with application to Medicare's National Claims History file. Parente ST, et al. **Am J Med Qual** 1995 Winter;10(4):162–76 (21 ref.)

TRENDS

Why it is important to demonstrate linkages between outcomes of care and processes and structures of care. Hammermeister KE, et al. **Med Care** 1995 Oct;33(10 Suppl):OS5–16 (58 ref.)

QUALITY OF LIFE

see related
LIFE STYLE
SICKNESS IMPACT PROFILE

Assessment of quality of life in breast cancer. Fallowfield LJ. **Acta Oncol** 1995;34(5):689–94 (41 ref.)

Measurement and practical aspects of quality of life in breast cancer. Hietanen PS. **Acta Oncol** 1996;35(1):39–42 (40 ref.)

Osteoporosis. It steals more than bone. Galsworthy TD, et al. **Am J Nurs** 1996 Jun;96(6):26–33; quiz 34 (10 ref.)

Rationale and development of a quality-of-life instrument for head-and-neck cancer patients. Morton RP, et al. **Am J Otolaryngol** 1995 Sep–Oct;16(5):284–93 (69 ref.)

The GIVIO trial on the impact of follow-up care on survival and quality of life in breast cancer patients. Interdisciplinary Group for Cancer Care Evaluation. Liberati A. **Ann Oncol** 1995;6 Suppl 2:41–6 (12 ref.)

Long-term outcome and quality of life after thymectomy for myasthenia gravis. Busch C, et al. **Ann Surg** 1996 Aug; 224(2):225–32 (22 ref.)

Quality of life and the spectrum of HIV infection. Holzemer WL, et al. **Annu Rev Nurs Res** 1995;13:3–29 (99 ref.)

Quality of life and caregiving in technological home care. Smith CE. **Annu Rev Nurs Res** 1996;14:95–118 (141 ref.)

The clinical impact of vertebral fractures: quality of life in women with osteoporosis. Gold DT. **Bone** 1996 Mar;18(3 Suppl):185S–189S (29 ref.)

Measuring symptomatic benefit and quality of life in paediatric oncology [editorial] Eiser C, et al. **Br J Cancer** 1996 Jun;73(11):1313–6 (35 ref.)

Quality of life measures. Carr AJ, et al. **Br J Rheumatol** 1996 Mar;35(3):275–81 (63 ref.)

Quality of life, bypass surgery and the elderly. Page SA, et al. **Can J Cardiol** 1995 Oct;11(9):777–82 (29 ref.)

Hope and quality of life, two central issues for cancer patients: a theoretical analysis. Rustøen T. **Cancer Nurs** 1995 Oct;18(5):355–61 (60 ref.)

Assessment of values, utilities and preferences in cancer patients. de Haes JC, et al. **Cancer Treat Rev** 1996 Jan;22 Suppl A:13–26 (21 ref.)

Quality of life and predictions of survival in patients with advanced emphysema. Corris PA. **Chest Surg Clin N Am** 1995 Nov;5(4):659–71 (42 ref.)

Futile care or caregiver frustration? A practical approach. Civetta JM. **Crit Care Med** 1996 Feb;24(2):346–51 (13 ref.)

Measuring the effects of antihypertensive therapy upon the quality of life. Fletcher A. **Curr Opin Nephrol Hypertens** 1995 Nov;4(6):538–42 (33 ref.)

Quality of life and urinary incontinence. Kelleher CJ, et al. **Curr Opin Obstet Gynecol** 1995 Oct;7(5):404–8 (26 ref.)

Effect of intervention in inflammatory bowel disease on health-related quality of life: a critical review. Maunder RG, et al. **Dis Colon Rectum** 1995 Nov;38(11):1147–61 (77 ref.)

Recent clinical trials of pain control: impact on quality of life. Ahmedzai S. **Eur J Cancer** 1995;31A Suppl 6:S2–7 (31 ref.)

Multidisciplinarity and multimedia in quality of care—education. Heyrman J. **Eur J Cancer** 1995;31A Suppl 6:S11–4 (6 ref.)

Using quality of life assessment methods in patients with advanced cancer: a clinical perspective. Kaasa S. **Eur J Cancer** 1995;31A Suppl 6:S15–7 (16 ref.)

A proposed matrix for organisational changes to improve quality of life in oncology. MacDonald N. **Eur J Cancer** 1995;31A Suppl 6:S18–21 (30 ref.)

Clinical trials and quality of life assessment: the nurses' viewpoint. Molin C, et al. **Eur J Cancer** 1995;31A Suppl 6:S8–10 (25 ref.)

The psychiatrist's perspective on quality of life and quality of care in oncology: concepts, symptom management, communication issues. Razavi D, et al. **Eur J Cancer** 1995; 31A Suppl 6:S25–9 (41 ref.)

Quality of life in prostate cancer: what are the issues and how are they measured? Fossâ SD. **Eur Urol** 1996;29 Suppl 2:121–3 (15 ref.)

Physical activity and health-related quality of life. Rejeski WJ, et al. **Exerc Sport Sci Rev** 1996;24:71–108 (102 ref.)

Dworkin on dementia. Elegant theory, questionable policy. Dresser R. **Hastings Cent Rep** 1995 Nov–Dec;25(6):32–8 (17 ref.)

Growth hormone deficiency and quality of life. McGauley G, et al. **Horm Res** 1996;45(1–2):34–7 (23 ref.)

Pain recurrence: a quality of life issue in endometriosis. Damario MA, et al. **Int J Gynaecol Obstet** 1995 Sep;50 Suppl 1:S27–42 (99 ref.)

The spiritual dimension: its importance to patients' health, well-being and quality of life and its implications for nursing practice. Ross L. **Int J Nurs Stud** 1995 Oct; 32(5):457–68 (66 ref.)

Psychosocial factors and quality of life in obesity. Sarlio-Lähteenkorva S, et al. **Int J Obes Relat Metab Disord** 1995 Nov;19 Suppl 6:S1–5 (49 ref.)

Definitions of quality of life: a taxonomy. Farquhar M. **J Adv Nurs** 1995 Sep;22(3):502–8 (41 ref.)

Assessment of quality of life in recovery settings. Kinney MR. **J Cardiovasc Nurs** 1995 Oct;10(1):88–96 (41 ref.)

Health-related quality of life as an outcome for patients with heart failure. Shively M, et al. **J Cardiovasc Nurs** 1996 Jan; 10(2):89–96 (14 ref.)

Quality of life with ACE inhibitors in chronic heart failure. Bulpitt CJ. **J Cardiovasc Pharmacol** 1996;27 Suppl 2:S31–5 (35 ref.)

Evolution of quality of life assessment in head and neck cancer. Morton RP. **J Laryngol Otol** 1995 Nov; 109(11):1029–35 (63 ref.)

Quality-of-life research in the Pediatric Oncology Group: 1991–1995. Bradlyn AS, et al. **J Natl Cancer Inst Monogr** 1996;(20):49–53 (21 ref.)

Trial-related quality of life: using quality-of-life assessment to distinguish among cancer therapies. Gotay CC. **J Natl Cancer Inst Monogr** 1996;(20):1–6 (44 ref.)

Monitoring the impact of traumatic brain injury: a review and update. Waxweiler RJ, et al. **J Neurotrauma** 1995 Aug; 12(4):509–16 (21 ref.)

Care at home and quality of life: an overview of the issues. Henwood M. **J R Soc Health** 1995 Oct;115(5):323–5 (6 ref.)

Oral health, health, and health-related quality of life. Gift HC, et al. **Med Care** 1995 Nov;33(11 Suppl):NS57–77 (95 ref.)

The impact of pain on quality of life. A decade of research. Ferrell BR. **Nurs Clin North Am** 1995 Dec;30(4):609–24 (29 ref.)

Definition and measurement of quality of life in oncology nursing research: review and theoretical implications. Mast ME. **Oncol Nurs Forum** 1995 Jul;22(6):957–64 (66 ref.)

Measuring quality of life: 1995 update. Cella DF, et al. **Oncology (Huntingt)** 1995 Nov;9(11 Suppl):47–60 (97 ref.)

Impact of quality of life outcomes on clinical practice. Ganz PA. **Oncology (Huntingt)** 1995 Nov;9(11 Suppl):61–5 (37 ref.)

Economic and quality of life outcomes: managed care perspectives. Glandon GL, et al. **Oncology (Huntingt)** 1995 Nov;9(11 Suppl):111–9 (31 ref.)

Applications of QOL measurements: a managed care perspective. Peskin SR. **Oncology (Huntingt)** 1995 Nov;9(11 Suppl):127–8 (3 ref.)

Economic and quality of life outcomes in oncology: the regulatory perspective. Turner S. **Oncology (Huntingt)** 1995 Nov;9(11 Suppl):121–5 (0 ref.)

Measurement of utilities and quality-adjusted survival. Weeks J. **Oncology (Huntingt)** 1995 Nov;9(11 Suppl):67–70 (10 ref.)

How to evaluate quality-of-life in pacemaker patients: problems and pitfalls [editorial] Linde C. **Pacing Clin Electrophysiol** 1996 Apr;19(4 Pt 1):391–7 (31 ref.)

Quality of life elderly and diabetic patients on peritoneal dialysis. Nissenson AR. **Perit Dial Int** 1996;16 Suppl 1:S406–9 (33 ref.)

Quality-of-life assessment in patients on peritoneal dialysis: a review of the state of the art. Salek S. **Perit Dial Int** 1996;16 Suppl 1:S398–401 (13 ref.)

Quality of life: an overview of the concept and measures. Dedhiya S, et al. **Pharm World Sci** 1995 Sep 22;17(5):141–8 (48 ref.)

Functional ability and nutritional status of free-living elderly people. Manandhar MC. **Proc Nutr Soc** 1996 Nov; 54(3):677–91 (99 ref.)

MRC quality of life studies using a daily diary card—practical lessons learned from cancer trials. Fayers P. **Qual Life Res** 1995 Aug;4(4):343–52 (42 ref.)

Evaluation in pulmonary rehabilitation. Ambrosino N, et al. **Respir Med** 1996 Aug;90(7):395–400 (50 ref.)

Quality of life and cost of therapy in reflux disease. Glise H. **Scand J Gastroenterol Suppl** 1995;210:38–42 (33 ref.)

Comparison of instruments for measuring quality of life in patients with lung cancer. Hollen PJ, et al. **Semin Oncol** 1996 Apr;23(2 Suppl 5):31–40 (31 ref.)

The menstrual cycle and the well being of women. Bancroft J. **Soc Sci Med** 1995 Sep;41(6):785–91 (29 ref.)

Clinical and public health perspectives and applications of health-related quality of life measurement. Ebrahim S. **Soc Sci Med** 1995 Nov;41(10):1383–94 (68 ref.)

Evaluating the efficacy of medical treatment: possibilities and limitations. Jenkinson C. **Soc Sci Med** 1995 Nov; 41(10):1395–401 (49 ref.)

Environmental and health-related quality of life: conceptual and methodological similarities. Rogerson RJ. **Soc Sci Med** 1995 Nov;41(10):1373–82 (80 ref.)

Health-related quality of life between naturalism and hermeneutics. Rosenberg R. **Soc Sci Med** 1995 Nov; 41(10):1411–5 (17 ref.)

Spinal cord injury, exercise and quality of life. Noreau L, et al. **Sports Med** 1995 Oct;20(4):226–50 (171 ref.)

Improving quality of life: adjuvant psychological therapy for patients with cancer. Greer S. **Support Care Cancer** 1995 Jul;3(4):248–51 (8 ref.)

Quality of life in patients with ovarian cancer: current state of research. Montazeri A, et al. **Support Care Cancer** 1996 May;4(3):169–79 (60 ref.)
Healthy aging and the quality of life. Darnton-Hill I. **World Health Forum** 1995;16(4):335–43; discussion 344–72 (13 ref.)
[Quality of life in the evaluation of cancer therapy] Sprangers MA, et al. **Ned Tijdschr Geneeskd** 1996 Mar 23; 140(12):646–9 (34 ref.) **(Dut)**
[Experienced quality of life of somatic nursing home patients: a review of measuring instruments] van Campen C, et al. **Tijdschr Gerontol Geriatr** 1996 Feb;27(1):20–8 (62 ref.) (Eng. Abstr.) **(Dut)**
[Why and how to measure the quality of life? Questions to be asked by the urologist] Lukacs B. **Presse Med** 1995 Oct 28;24(32):1514–8 (16 ref.) (Eng. Abstr.) **(Fre)**
[Quality of life—attempt at a definition of the concept] Schnürch HG. **Arch Gynecol Obstet** 1995;257(1–4):257–64 (8 ref.) **(Ger)**
[Schizophrenia and quality of life—sex-specific aspects] Röder-Wanner UU, et al. **Fortschr Neurol Psychiatr** 1995 Oct;63(10):393–401 (115 ref.) (Eng. Abstr.) **(Ger)**
[Quality of life in chronic inflammatory bowel diseases] Bregenzer N, et al. **Med Klin** 1996 Jun 15;91(6):396–401 (36 ref.) **(Ger)**
[Psychological diagnosis of pain and pain treatment in the elderly] Wilz G, et al. **Z Gerontol Geriatr** 1995 Sep–Oct; 28(5):312–7 (54 ref.) (Eng. Abstr.) **(Ger)**
[Quality of life after an episode of myocardial infarct] Borrello G, et al. **Minerva Cardioangiol** 1995 Jul–Aug; 43(7–8):315–27 (39 ref.) (Eng. Abstr.) **(Ita)**
[Treatment of chronic congestive heart failure to improve their quality of life—clinical study of thermal vasodilation therapy] Tei C, et al. **Nippon Naika Gakkai Zasshi** 1995 Sep 10;84(9):1475–82 (35 ref.) **(Jpn)**
[Rheumatoid arthritis and quality of life] Kawai S. **Ryumachi** 1995 Jun;35(3):609–20 (43 ref.) **(Jpn)**
[Chronic mental illness: quality of life] Główczak M, et al. **Psychiatr Pol** 1996 May–Jun;30(3):368–79 (20 ref.) (Eng. Abstr.) **(Pol)**
[Conceptualization and measurement of the quality of life of cancer patients] Lara-Muñoz MC, et al. **Rev Invest Clin** 1995 Jul–Aug;47(4):315–27 (108 ref.) (Eng. Abstr.) **(Spa)**
[Quality of life and migraine] Asensio M, et al. **Rev Neurol** 1996 Aug;24(132):926–9 (26 ref.) (Eng. Abstr.) **(Spa)**
[Epilepsy and quality of life] Forcadas I. **Rev Neurol** 1995 Nov–Dec;23(124):1212–3 (10 ref.) **(Spa)**

QUANTUM THEORY

Cell growth signal transduction is quantal. Smith KA. **Ann N Y Acad Sci** 1995 Sep 7;766:263–71 (27 ref.)

QUARANTINE

VETERINARY

Quarantine requirements for the importation of black rhinoceros from Zimbabwe into Australia. Doyle KA, et al. **Aust Vet J** 1995 Oct;72(10):364–8 (4 ref.)

QUERCETIN

ADMINISTRATION & DOSAGE

Potential health effects of the dietary flavonol quercetin. Hertog MG, et al. **Eur J Clin Nutr** 1996 Feb;50(2):63–71 (98 ref.)

PHARMACOLOGY

Review of the biology of Quercetin and related bioflavonoids. Formica JV, et al. **Food Chem Toxicol** 1995 Dec;33(12):1061–80 (210 ref.)
[Inhibitors of protein-tyrosine kinases: pharmacological perspectives? (editorial)] Jacquemin-Sablon A, et al. **Pathol Biol (Paris)** 1995 May;43(5):389–94 (66 ref.) **(Fre)**

QUESTIONNAIRES

Screening for child abuse: problems and possibilities. Doueck HJ. **Appl Nurs Res** 1995 Nov;8(4):191–8 (53 ref.)
Functional status instruments: outcome measure in the evaluation of patients with chronic obstructive pulmonary disease. Lareau SC, et al. **Heart Lung** 1996 May–Jun; 25(3):212–24 (63 ref.)
Questionnaire based exposure assessment methods. Coggon D. **Sci Total Environ** 1995 Jun 16;168(2):175–8 (8 ref.)
[Quality of life in the evaluation of cancer therapy] Sprangers MA, et al. **Ned Tijdschr Geneeskd** 1996 Mar 23; 140(12):646–9 (34 ref.) **(Dut)**
[Questionnaires as research tools—Social Insurance Institution's Sleep Habit Questionnaire as an example] Hyyppä MT, et al. **Duodecim** 1994;110(17):1581–7 (28 ref.) **(Fin)**

STANDARDS

Case-control studies of screening efficacy: the use of persons newly diagnosed with cancer who later sustain an unfavorable outcome. Weiss NS, et al. **Am J Epidemiol** 1996 Feb 15;143(4):319–22 (4 ref.)
The accuracy of a lead questionnaire in predicting elevated pediatric blood lead levels. France EK, et al. **Arch Pediatr Adolesc Med** 1996 Sep;150(9):958–63 (14 ref.)
[Evaluating correctly the validity of a rating scale: the numerous pitfalls to avoid] Fermanian J. **Rev Epidemiol Sante Publique** 1996 Jun;44(3):278–86 (19 ref.) (Eng. Abstr.) **(Fre)**

QUETELET'S INDEX see **BODY MASS INDEX**

QUEUING THEORY see **SYSTEMS THEORY**

QUICK TEST see **PROTHROMBIN TIME**

QUINAZOLINES

THERAPEUTIC USE

Thymidylate synthase inhibition, a dead end? [editorial] Herrmann R. **Eur J Cancer** 1995 Nov;31A(12):1919–20 (7 ref.)
ZD1694 (Tomudex): a new thymidylate synthase inhibitor with activity in colorectal cancer. Jackman AL, et al. **Eur J Cancer** 1995 Jul–Aug;31A(7–8):1277–82 (30 ref.)

QUINCKE'S EDEMA see **ANGIONEUROTIC EDEMA**

QUINIDINE

ADVERSE EFFECTS

Drug-induced lupus. The list of culprits grows. Rich MW. **Postgrad Med** 1996 Sep;100(3):299–302, 307–8 (6 ref.)

BLOOD

[Quinidine] Yamada K. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:957–9 (8 ref.) **(Jpn)**

IMMUNOLOGY

Three autacoids—endogenous digitalis-like factor, clonidine-displacing substance, and quinidine-like immunoreactivity. Kölbel F, et al. **Sb Lek** 1995; 96(4):405–15 (65 ref.)

PHARMACOLOGY

Topical beta-adrenergic antagonists and quinidine. A risky interaction [editorial] Higginbotham EJ. **Arch Ophthalmol** 1996 Jun;114(6):745–6 (7 ref.)

QUININE

THERAPEUTIC USE

Quinine for nocturnal leg cramps? **Drug Ther Bull** 1996 Jan; 34(1):7–8 (15 ref.)
Benign nocturnal leg cramps. Current controversies over use of quinine. Leclerc KM, et al. **Postgrad Med** 1996 Feb; 99(2):177–8, 181–4 (13 ref.)
[Correct usage of amino alcohols] Touze JE. **Med Trop (Mars)** 1995;55(3 Suppl):24–5 (8 ref.) **(Fre)**

QUINOLINES

ADVERSE EFFECTS

Vesnarinone-induced granulocytopenia: incidence in Japan and recommendations for safety. Furusawa S, et al. **J Clin Pharmacol** 1996 May;36(5):477–81 (13 ref.)

METABOLISM

Formation and processing of reactive metabolites of the heterocyclic amines. Alexander J. **Arch Toxicol Suppl** 1996; 18:275–85 (52 ref.)

PHARMACOLOGY

Saquinavir: an HIV proteinase inhibitor. Bragman K. **Adv Exp Med Biol** 1996;394:305–17 (25 ref.)

THERAPEUTIC USE

Drug-resistance patterns of saquinavir and other HIV proteinase inhibitors. Roberts NA. **AIDS** 1995 Dec;9 Suppl 2:27–S32 (34 ref.)
Clinical experience with saquinavir. Vella S. **AIDS** 1995 Dec; 9 Suppl 2:S21–S25 (22 ref.)

QUINOLINIC ACIDS

METABOLISM

[Biochemical studies on AIDS dementia complex—possible contribution of quinolinic acid during brain damage] Saito K. **Rinsho Byori** 1995 Sep;43(9):891–901 (36 ref.) (Eng. Abstr.) **(Jpn)**

QUINOLINOLS see **HYDROXYQUINOLINES**

QUINOLINONES see **QUINOLONES**

QUINOLONE ANTI-INFECTIVE AGENTS see **ANTI-INFECTIVE AGENTS, QUINOLONE**

QUINOLONES

see related
ANTI-INFECTIVE AGENTS, QUINOLONE

ADVERSE EFFECTS

Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group. Jaillon P, et al. **J Antimicrob Chemother** 1996 May;37 Suppl A:161–7 (4 ref.)

CHEMISTRY

4-quinolones as potential cardiovascular agents. Davies RV, et al. **Prog Med Chem** 1995;32:115–55 (78 ref.)

PHARMACOKINETICS

Pharmacokinetics of sparfloxacin in healthy volunteers and patients: a review. Montay G. **J Antimicrob Chemother** 1996 May;37 Suppl A:27–39 (20 ref.)
A review of the penetration of sparfloxacin into the lower respiratory tract and sinuses. Wise R, et al. **J Antimicrob Chemother** 1996 May;37 Suppl A:57–63 (18 ref.)

PHARMACOLOGY

In-vitro activity of sparfloxacin in comparison with currently available antimicrobials against respiratory tract pathogens. Baquero F, et al. **J Antimicrob Chemother** 1996 May;37 Suppl A:1–18 (76 ref.)

THERAPEUTIC USE

Quinolones: a practical review of clinical uses, dosing considerations, and drug interactions. Borcherding SM, et al. **J Fam Pract** 1996 Jan;42(1):69–78 (70 ref.)

QUINONE REDUCTASE see **NAD(P)H DEHYDROGENASE (QUINONE)**

QUINONES

CHEMISTRY

Radicals from one-electron reduction of nitro compounds, aromatic N-oxides and quinones: the kinetic basis for hypoxia-selective, bioreductive drugs. Wardman P, et al. **Biochem Soc Symp** 1995;61:171–94 (126 ref.)
Electron and proton transfer to the quinones in bacterial photosynthetic reaction centers: insight from combined approaches of molecular genetics and biophysics. Sebban P, et al. **Biochimie** 1995;77(7–8):677–94 (67 ref.)

DIAGNOSTIC USE

Novel therapeutic and diagnostic applications of hypocrellins and hypericins. Diwu Z. **Photochem Photobiol** 1995 Jun; 61(6):529–39 (118 ref.)

METABOLISM

Biogenesis of novel quinone coenzymes. Tanizawa K. **J Biochem (Tokyo)** 1995 Oct;118(4):671–8 (52 ref.)

THERAPEUTIC USE

Novel therapeutic and diagnostic applications of hypocrellins and hypericins. Diwu Z. **Photochem Photobiol** 1995 Jun; 61(6):529–39 (118 ref.)

QUINOXALINES

ADVERSE EFFECTS

Chemical methods for assessing systemic exposure to dietary heterocyclic amines in man. Davies DS, et al. **Arch Toxicol Suppl** 1996;18:251–8 (29 ref.)

CHEMICAL SYNTHESIS

[New fluorogenic dienophile: synthesis, reaction with vitamin D, vitamin A and microcystins, and application to fluorometric assays] Shimizu M, et al. **Yakugaku Zasshi** 1995 Aug;115(8):584–602 (67 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Enzymic and interindividual differences in the human metabolism of heterocyclic amines. Boobis AR, et al. **Arch Toxicol Suppl** 1996;18:286–302 (65 ref.)

QUISQUALATE RECEPTORS see **RECEPTORS, AMPA**

R FACTORS

CHEMISTRY

Where freedom is given, liberties are taken. Kleywegt GJ, et al. **Structure** 1995 Jun 15;3(6):535–40 (34 ref.)

R PLASMIDS see **R FACTORS**

R REPETITIVE SEQUENCE see **REPETITIVE SEQUENCES, NUCLEIC ACID**

RABBIT AORTA CONTRACTING SUBSTANCE see **THROMBOXANE A2**

RABBITPOX VIRUS see **VACCINIA VIRUS**

RABBITS

Virus-vectored immunocontraception for control of wild rabbits: identification of target antigens and construction of recombinant viruses. Holland MK, et al. **Reprod Fertil Dev** 1994;6(5):631–42 (61 ref.)

[Transgenic rabbit] Imai H, et al. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2234–40 (16 ref.) **(Jpn)**

IMMUNOLOGY

Development of the antibody repertoire in rabbits. Knight KL, et al. **Ann N Y Acad Sci** 1995 Sep 29;764:198–206 (23 ref.)

PHYSIOLOGY

Artificial insemination in rabbits. Morrell JM. **Br Vet J** 1995 Sep–Oct;151(5):477–88 (38 ref.)

The older rabbit as an animal model: implications for Alzheimer's disease. Woodruff-Pak DS, et al. **Neurobiol Aging** 1996 Mar–Apr;17(2):283–90 (87 ref.)

RABIES

DIAGNOSIS

Antemortem diagnosis of human rabies. Sang E, et al. **J Fam Pract** 1996 Jul;43(1):83–7 (36 ref.)

EPIDEMIOLOGY

Epidemiology and prevention of rabies. Fisher DJ. **Curr Probl Pediatr** 1995 Nov–Dec;25(10):304–13 (41 ref.)

Rabies: the emergence of a microbial threat. Borus P. **East Afr Med J** 1996 Jan;73(1):32–4 (12 ref.)

[Use of molecular biology in epidemiology in rabies] Sadkowska M. **Przegl Epidemiol** 1995;49(3):215–25 (14 ref.) (Eng. Abstr.) **(Pol)**

PREVENTION & CONTROL

Epidemiology and prevention of rabies. Fisher DJ. **Curr Probl Pediatr** 1995 Nov–Dec;25(10):304–13 (41 ref.)

[Immunoprophylaxis of rabies: current recommendations] Strady A, et al. **Presse Med** 1996 Jun 22;25(22):1023–7 (25 ref.) (Eng. Abstr.) **(Fre)**

TRANSMISSION

[Considerations on human rabies transmitted by bats] Schneider MC, et al. **Salud Publica Mex** 1995 Jul–Aug; 37(4):354–62 (36 ref.) (Eng. Abstr.) **(Spa)**

VETERINARY

Rabies: the emergence of a microbial threat. Borus P. **East Afr Med J** 1996 Jan;73(1):32–4 (12 ref.)

RABIES VACCINE

ADMINISTRATION & DOSAGE

[Immunoprophylaxis of rabies: current recommendations] Strady A, et al. **Presse Med** 1996 Jun 22;25(22):1023–7 (25 ref.) (Eng. Abstr.) **(Fre)**

RACCOON DOGS see **CARNIVORA**

RACE see **RACIAL STOCKS**

RACE RELATIONS

see related
CIVIL RIGHTS

RACHITIS see **RICKETS**

RACIAL STOCKS

The Bell Curve: on race, social class, and epidemiologic research. Muntaner C, et al. **Am J Epidemiol** 1996 Sep 15; 144(6):531–6 (76 ref.)

Lessons on the interaction of race and antihypertensive drugs from the VA cooperative study group on antihypertensive agents. Materson BJ. **Am J Hypertens** 1995 Dec;8(12 Pt 2):91s–93s (13 ref.)

The medicalization of race: scientific legitimization of a flawed social construct [see comments] Witzig R. **Ann Intern Med** 1996 Oct 15;125(8):675–9 (57 ref.) Comment in: Ann Intern Med 1996 Oct 15;125(8):688–9.

Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Bertilsson L. **Clin Pharmacokinet** 1995 Sep;29(3):192–209 (103 ref.)

Racial, ethnic and gender differences in response to medicines. Matthews HW. **Drug Metabol Drug Interact** 1995;12(2):77–91 (38 ref.)

Race, class, and environmental health: a review and systematization of the literature. Brown P. **Environ Res** 1995 Apr;69(1):15–30 (53 ref.)

Racial differences in skin pathophysiology. Berardesca E, et al. **J Am Acad Dermatol** 1996 Apr;34(4):667–72 (50 ref.)

RACISM see **PREJUDICE**

RADIAL KERATOTOMY see **KERATOTOMY, RADIAL**

RADIAL NERVE

Radial nerve entrapment. Kleinert JM, et al. **Orthop Clin North Am** 1996 Apr;27(2):305–15 (18 ref.)

[Significance of the radial compression syndrome for the diagnosis and surgical therapy of so-called epicondylitis humeri radialis (Epic. hum. rad.)] Totkas D, et al. **Z Orthop Ihre Grenzgeb** 1995 Jul–Aug;133(4):317–22 (73 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

Anatomic considerations of the peripheral nerve in compressive neuropathies of the upper extremity. George V, et al. **Orthop Clin North Am** 1996 Apr;27(2):211–8 (22 ref.)

RADIATION

see related
NUCLEAR WARFARE

d'Arsonval Medal: address. some bioelectromagnetics research at the University of Utah: acceptance speech on the occasion of receiving the d'Arsonval Medal. Gandhi OP. **Bioelectromagnetics** 1996;17(1):3–9 (51 ref.)

The quest for the laws governing radiations and the search for beneficial innovations. Laughlin JS. **Radiat Res** 1995 Nov;144(2):129–40 (59 ref.)

Exposure assessment strategies in epidemiological studies of health effects of electric and magnetic fields. Savitz DA. **Sci Total Environ** 1995 Jun 16;168(2):143–53 (41 ref.)

[Fundamentals of plasma chemistry and its application to drug engineering] Kuzuya M. **Yakugaku Zasshi** 1996 Apr; 116(4):266–85 (57 ref.) (Eng. Abstr.) **(Jpn)**

RADIATION ACCIDENTS see **ACCIDENTS, RADIATION**

RADIATION BIOLOGY see **RADIOBIOLOGY**

RADIATION DOSAGE

see related
DOSE-RESPONSE RELATIONSHIP, RADIATION
RADIOTHERAPY DOSAGE

Internal dosimetry: developments and limitations [editorial] Mountford PJ. **Eur J Nucl Med** 1996 May;23(5):491–3 (25 ref.)

Radiobiological challenges posed by microdosimetry. Kellerer AM. **Health Phys** 1996 Jun;70(6):832–6 (32 ref.)

The present system of quantities and units for radiation protection. Sinclair WK. **Health Phys** 1996 Jun;70(6):781–6 (31 ref.)

How dangerous is low level radiation? Cohen BL. **Risk Anal** 1995 Dec;15(6):645–53 (30 ref.)

RADIATION EFFECTS

Effects of low doses of radiation. Fry RJ. **Health Phys** 1996 Jun;70(6):823–7 (24 ref.)

A limited bibliography of the Federal Government-funded human radiation experiments. Samei E, et al. **Health Phys** 1995 Dec;69(6):885–91 (55 ref.)

Alleged health effects of electromagnetic fields: the misconceptions continue. Jauchem JR. **J Microw Power Electromagn Energy** 1995;30(3):165–77 (141 ref.)

Heavy ion effects in non-biological matter. Balanzat E. **Radiat Environ Biophys** 1995 Nov;34(4):207–12 (38 ref.)

The stress response--a radiation study section workshop. **Radiat Res** 1996 Jan;145(1):107–17 (97 ref.)

How dangerous is low level radiation? Cohen BL. **Risk Anal** 1995 Dec;15(6):645–53 (30 ref.)

Dose, effect severity, and imparted energy in assessing biological effects. Bond VP. **Stem Cells (Dayt)** 1995 May; 13 Suppl 1:21–9 (3 ref.)

Are there 'common denominators' in different radiation exposure scenarios as a target for predictive assessment? Densow D. **Stem Cells (Dayt)** 1995 May;13 Suppl 1:307–17 (69 ref.)

What is the status of molecular and cell biology approaches relevant to radiation effects assessment? Plappert U, et al. **Stem Cells (Dayt)** 1995 May;13 Suppl 1:318–22 (35 ref.)

Biologic indicators of exposure: are markers associated with oncogenesis useful as biologic markers of effect? Ziegler BL, et al. **Stem Cells (Dayt)** 1995 May;13 Suppl 1:326–38 (151 ref.)

[Exposure to ionizing radiation: radiobiological and pathogenic effects (2)] Wambersie A, et al. **Rev Med Brux** 1996 Apr;17(2):75–84 (29 ref.) (Eng. Abstr.) **(Fre)**

[A critical analysis of the current concepts and approaches to assessing the biological action of low doses of ionizing radiation] Geras'kin SA. **Radiats Biol Radioecol** 1995 Sep–Oct;35(5):563–71 (24 ref.) (Eng. Abstr.) **(Rus)**

[The biomedical effects of ultraviolet radiation and their mechanisms] Strzhizhovskiĭ AD. **Usp Fiziol Nauk** 1995 Oct–Dec;26(4):98–112 (129 ref.) (Eng. Abstr.) **(Rus)**

RADIATION-INDUCED DERMATITIS see **RADIODERMATITIS**

RADIATION INJURIES

see related
ACCIDENTS, RADIATION

Complete heart block and severe tricuspid regurgitation after radiotherapy. Case report and review of the literature [see comments] Knight CJ, et al. **Chest** 1995 Dec;108(6):1748–51 (26 ref.) Comment in: Chest 1996 Aug;110(2):580–1.

Radiation risks: threshold or no threshold. The centenary of the discovery of X-rays by W.C. Roentgen. Liu S. **Chin Med J (Engl)** 1996 Feb;109(2):122–6 (24 ref.)

Intraoperative retinal phototoxicity. Michels M. **Int Ophthalmol Clin** 1995 Fall;35(4):157–72 (91 ref.)

Retropharyngeal abscess after radiation therapy and cis-platinum, 5-fluorouracil treatment for nasopharyngeal carcinoma with collagen disease: report of two patients and a review of the literature. Hareyama M, et al. **Jpn J Clin Oncol** 1996 Jun;26(3):189–93 (15 ref.)

Radiation enteropathy--incidence, aetiology, risk factors, pathology and symptoms. Rodier JF. **Tumori** 1995 May–Jun;81(3 Suppl):122–5 (12 ref.)

[Endocrine function of the thymus and ionizing radiation] Grinevich IuA, et al. **Radiats Biol Radioecol** 1995 May–Jun; 35(3):391–404 (126 ref.) (Eng. Abstr.) **(Rus)**

COMPLICATIONS

[Medical treatment of chronic radiation induced enteritis] Cosnes J. **Ann Chir** 1996;50(1):36–9 (23 ref.) (Eng. Abstr.) **(Fre)**

[Radiation injury of the small intestine. Radiobiological, radiopathological aspects; risk factors and prevention] Touboul E, et al. **Ann Chir** 1996;50(1):58–71 (95 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Radiation proctitis: a review. Babb RR. **Am J Gastroenterol** 1996 Jul;91(7):1309–11 (31 ref.)

EPIDEMIOLOGY

Hazards of ionising radiation: 100 years of observations on man [editorial] Doll R. **Br J Cancer** 1995 Dec;72(6):1339–49 (109 ref.)

Methodological considerations for future epidemiological studies of solar ultraviolet radiation and eye disease. Dolin PJ. **Ophthalmic Epidemiol** 1994 Dec;1(3):165–70 (16 ref.)

Solar ultraviolet radiation and ocular disease: a review of the epidemiological and experimental evidence. Dolin PJ, et al. **Ophthalmic Epidemiol** 1994 Dec;1(3):155–64 (79 ref.)

ETIOLOGY

Radiation injury of the brain. Valk PE, et al. **AJNR Am J Neuroradiol** 1991 Jan;12(1):45–62 (90 ref.)

Light damage revisited: converging evidence, diverging views? Remé C, et al. **Graefes Arch Clin Exp Ophthalmol** 1996 Jan;234(1):2–11 (88 ref.)

Spontaneous rupture of the urinary bladder: a late complication of radiotherapy--case report and review of the literature. Addar MH, et al. **Gynecol Oncol** 1996 Aug; 62(2):314–6 (16 ref.)

Risk of radiation at low doses. Beninson D. **Health Phys** 1996 Aug;71(2):122–5 (0 ref.)

Bactericidal UV-C lamp misuse [letter] [corrected] [published erratum appears in Isr J Med Sci 1995 Nov;31(11):701] Zamir E. **Isr J Med Sci** 1995 Sep;31(9):578 (5 ref.)

The pathogenesis and conservative management of radiation injuries. Michalowski A. **Neoplasma** 1995;42(6):289–92 (18 ref.)

Solar ultraviolet radiation and ocular disease: a review of the epidemiological and experimental evidence. Dolin PJ, et al. **Ophthalmic Epidemiol** 1994 Dec;1(3):155–64 (79 ref.)

Late effects consensus conference: RTOG/EORTC. **Radiother Oncol** 1995 Apr;35(1):5–7 (9 ref.)

Initiation of non-neoplastic late effects: the role of endothelium and connective tissue. Rezvani M, et al. **Stem Cells (Dayt)** 1995 May;13 Suppl 1:248–56 (72 ref.)

Radiation enteropathy. Bozzetti F, et al. **Tumori** 1995 May–Jun;81(3 Suppl):117–21 (26 ref.)

Damage to the urinary tract secondary to irradiation. Fichtner J, et al. **World J Urol** 1995;13(4):240–2 (23 ref.)

[Pulmonary toxicity of drugs and thoracic irradiation in children] Fauroux B, et al. **Rev Mal Respir** 1996 Jul; 13(3):235–42 (58 ref.) (Eng. Abstr.) **(Fre)**

[Exposure to ionizing radiation: radiobiological and pathogenic effects (2)] Wambersie A, et al. **Rev Med Brux** 1996 Apr;17(2):75–84 (29 ref.) (Eng. Abstr.) **(Fre)**

[Pericarditis and other cardiac disorders, late consequences of radiotherapy] Chappuis MA, et al. **Rev Med Suisse Romande** 1996 Jun;116(6):429–39 (25 ref.) **(Fre)**

[Radiogenic lung reactions. Pathogenesis--prevention--therapy] Herrmann T, et al.

Strahlenther Onkol 1995 Sep;171(9):490–8 (73 ref.) (Eng. Abstr.) **(Ger)**

[Acute gastrointestinal side effects of radiotherapy. What is certain in the treatment?] Paulsen F, et al. **Strahlenther Onkol** 1996 Feb;172(2):53–63 (77 ref.) (Eng. Abstr.) **(Ger)**

[Radiotherapy of ENT tumors and risk of lymphedema] Ewald H. **Z Lymphol** 1996 Jun;20(1):21–6 (10 ref.) (Eng. Abstr.) **(Ger)**

[Radiation hepatitis] Iwata N, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):588–90 (20 ref.) **(Jpn)**

[Liver injury due to thorotrast] Ukida M. **Ryoikibetsu Shokogun Shirizu** 1995;(8):52–4 (6 ref.) **(Jpn)**

[Disordered thymus function and endocrine control as one of the bases for the development of a late postradiation immunodeficiency (a review of the literature)] Savina NP, et al. **Radiats Biol Radioecol** 1995 Jul–Aug;35(4):463–80 (155 ref.) (Eng. Abstr.) **(Rus)**

METABOLISM

Eicosanoids and radiation. Milas L, et al. **Eur J Cancer** 1995 Sep;31A(10):1580–5 (57 ref.)

Radiation protection and radiation recovery with essential metalloelement chelates. Sorenson JR, et al. **Proc Soc Exp Biol Med** 1995 Dec;210(3):191–204 (97 ref.)

NURSING

A nursing perspective on radiation-induced xerostomia. Iwamoto RR. **Oncology (Huntingt)** 1996 Mar;10(3 Suppl):12–5 (42 ref.)

PATHOLOGY

Radiation nephropathy: a review. Robbins ME, et al. **Scanning Microsc** 1995 Jun;9(2):535–60 (210 ref.)

Apoptosis and the assessment of radiation injury. Vincent PC. **Stem Cells (Dayt)** 1995 May;13 Suppl 1:153–64 (129 ref.)

PHYSIOPATHOLOGY

Cellular basis of radiation-induced fibrosis. Rodemann HP, et al. **Radiother Oncol** 1995 May;35(2):83–90 (49 ref.)

[Exposure to ionizing radiation: radiobiological effects and pathogenesis. 1] Wambersie A, et al. **Rev Med Brux** 1996 Feb;17(1):27–38 (15 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

Radiation therapy tolerance limits. For one or for all?—Janeway Lecture. Peters LJ. **Cancer** 1996 Jun 1; 77(11):2379–85 (39 ref.)

Protection of normal tissue from the cytotoxic effects of chemotherapy and radiation by amifostine: clinical experiences. Capizzi RL, et al. **Eur J Cancer** 1995;31A Suppl 1:S8–13 (11 ref.)

The prevention of radiation-induced small bowel complications. Letschert JG. **Eur J Cancer** 1995 Jul–Aug; 31A(7–8):1361–5 (26 ref.)

Prevention of radiation related complications in the treatment of rectal adenocarcinoma. The importance of the dose volume relationship. Gerard JP, et al. **Tumori** 1995 May–Jun;81(3 Suppl):114–6 (20 ref.)

[Cardiotoxicity and cardioprotection in chemo- and radiotherapy for malignant diseases (editorial)] Wagdi P, et al. **Schweiz Rundsch Med Prax** 1995 Oct 24;84(43):1216–9 (46 ref.) **(Ger)**

[Vitamins as radioprotectors of normal cells] Konopacka M. **Postepy Hig Med Dosw** 1996;50(2):145–56 (67 ref.) (Eng. Abstr.) **(Pol)**

SURGERY

[Coloanal anastomosis (Parks operation) in the treatment of acute radiation rectitis] San Martin S, et al. **Rev Med Chil** 1995 Mar;123(3):321–5 (15 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

Is blood a better source of allogeneic hematopoietic stem cells for use after radiation accidents? Frickhofen N, et al. **Bone Marrow Transplant** 1996 Feb;17(2):131–5 (48 ref.)

Radiation disasters and emergency department preparedness. Fong F, et al. **Emerg Med Clin North Am** 1996 May; 14(2):349–70 (18 ref.)

Intestinal complications of radiotherapy in gynecologic malignancy—clinical presentation and management. Kao MS. **Int J Gynaecol Obstet** 1995 Jul;49 Suppl:S69–75 (35 ref.)

[Hyperbaric oxygen therapy in chronic radiation injury of soft tissues] Kooijman R, et al. **Ned Tijdschr Geneeskd** 1996 Aug 17;140(33):1671–4 (43 ref.) **(Dut)**

[Acute gastrointestinal side effects of radiotherapy. What is certain in the treatment?] Paulsen F, et al. **Strahlenther Onkol** 1996 Feb;172(2):53–63 (77 ref.) (Eng. Abstr.) **(Ger)**

[Medical management of radiation casualties] Dushnitsky T, et al. **Harefuah** 1995 Dec 1;129(11):481–4 (28 ref.) **(Heb)**

RADIATION INJURIES, EXPERIMENTAL

ETIOLOGY

Light damage revisited: converging evidence, diverging views? Remé C, et al. **Graefes Arch Clin Exp Ophthalmol** 1996 Jan;234(1):2–11 (88 ref.)

PREVENTION & CONTROL

Protection of normal tissues from the cytotoxic effects of chemotherapy and radiation by amifostine (WR-2721): preclinical aspects. Peters GJ, et al. **Eur J Cancer** 1995;31A Suppl 1:S1–7 (45 ref.)

Radiation protection and radiation recovery with essential metalloelement chelates. Sorenson JR, et al. **Proc Soc Exp Biol Med** 1995 Dec;210(3):191–204 (97 ref.)

[Mechanisms of radiation to the lung. Pentoxifylline—a new radioprotective drug?] Remiszewski P, et al. **Pneumonol Alergol Pol** 1995;63(5–6):349–54 (17 ref.) **(Pol)**

RADIATION, IONIZING

Risk of radiation at low doses. Beninson D. **Health Phys** 1996 Aug;71(2):122–5 (0 ref.)

A limited bibliography of the Federal Government-funded human radiation experiments. Samei E, et al. **Health Phys** 1995 Dec;69(6):885–91 (55 ref.)

Effects in society of ionizing radiation. Yalow RS. **Mt Sinai J Med** 1995 Oct;62(5):339–42 (15 ref.)

Role of induced genetic instability in the mutagenic effects of chemicals and radiation. Murnane JP. **Mutat Res** 1996 Jan;367(1):11–23 (160 ref.)

Stimulating effects of ionizing radiation: new issue for regulatory policy. Jaworowski Z. **Regul Toxicol Pharmacol** 1995 Oct;22(2):172–9 (40 ref.)

Methodology for assessment of exposure to environmental factors in application to epidemiological studies: assessment of exposure to natural ionizing radiation. Akerblom G. **Sci Total Environ** 1995 Jun 16;168(2):155–68 (69 ref.)

[Exposure to ionizing radiation: radiobiological effects and pathogenesis. 1] Wambersie A, et al. **Rev Med Brux** 1996 Feb;17(1):27–38 (15 ref.) (Eng. Abstr.) **(Fre)**

RADIATION MONITORING

Radiation monitoring with reference to the medical environment. St. Germain J. **Health Phys** 1995 Nov; 69(5):728–49 (41 ref.)

Methodology for assessment of exposure to environmental factors in application to epidemiological studies: assessment of exposure to natural ionizing radiation. Akerblom G. **Sci Total Environ** 1995 Jun 16;168(2):155–68 (69 ref.)

RADIATION ONCOLOGY

Present status of radiation oncology in China. Second survey of Chinese Society of Radiation Oncology. Yin W, et al. **Chin Med J (Engl)** 1996 Feb;109(2):117–8 (2 ref.)

[Standards, options and recommendations for the practice of external radiotherapy and brachytherapy in oncology. National Federation of Centers for the fight against Cancer] Bey P, et al. **Bull Cancer (Paris)** 1995 Oct;82(10):811–22 (81 ref.) **(Fre)**

[Radiotherapeutic oncology: a little known specialty] Casas F, et al. **Med Clin (Barc)** 1995 Dec 8;105(20):784–7 (19 ref.) **(Spa)**

ECONOMICS

The managed care contract: implementation in radiation oncology. Bruner DW. **Oncol Nurs Forum** 1996 Apr; 23(3):451–4 (21 ref.)

TRENDS

[Radiobiology and the progress of radiation oncology] Khanson KP, et al. **Vopr Onkol** 1995;41(2):54–61 (23 ref.) **(Rus)**

RADIATION PNEUMONITIS

DIAGNOSIS

Radiation pneumonitis: a mimic of infectious pneumonitis. Salinas FV, et al. **Semin Respir Infect** 1995 Sep;10(3):143–53 (38 ref.)

RADIATION PROTECTION

Basic anatomical and physiological data for use in radiological protection: the skeleton. A report of a Task Group of Committee 2 of the International Commission on Radiological Protection. **Ann ICRP** 1995;25(2):1–80 (223 ref.)

Current concepts. Photoprotection. Kaminester LH. **Arch Fam Med** 1996 May;5(5):289–95 (135 ref.)

Internal dosimetry: developments and limitations [editorial] Mountford PJ. **Eur J Nucl Med** 1996 May;23(5):491–3 (25 ref.)

ICRP recommendations applicable to the mining and minerals processing industries and to natural sources. International Commission on Radiological Protection. Clarke RH. **Health Phys** 1995 Oct;69(4):454–60 (18 ref.)

The present system of quantities and units for radiation protection. Sinclair WK. **Health Phys** 1996 Jun;70(6):781–6 (31 ref.)

Radiation protection issues associated with nuclear medicine out-patients [see comments] Thomson WH, et al. **Nucl Med Commun** 1995 Nov;16(11):879–92 (43 ref.) Comment in: Nucl Med Commun 1995 Nov;16(11):877–8.

Issues in protection from galactic cosmic rays. Wilson JW, et al. **Radiat Environ Biophys** 1995 Nov;34(4):217–22 (17 ref.)

[Protection from ionizing radiation for pregnant workers] Campos Venuti G, et al. **Epidemiol Prev** 1996 Apr–Sep; 20(2–3):194–6 (15 ref.) **(Ita)**

[Radiation protection in medicine] Huyskens CJ. **Nippon Igaku Hoshasen Gakkai Zasshi** 1995 Oct; 55(13):517–23 (14 ref.) (Eng. Abstr.) **(Jpn)**

METHODS

[Basis of radiation protection] Roth J, et al. **Schweiz Med Wochenschr** 1996 Jun 29;126(26):1157–71 (33 ref.) (Eng. Abstr.) **(Ger)**

RADIATION-PROTECTIVE AGENTS

[Radiation-protective action of microbial substances] Andrushchenko VN, et al. **Radiats Biol Radioecol** 1996 Mar–Apr;36(2):195–208 (95 ref.) (Eng. Abstr.) **(Rus)**

PHARMACOKINETICS

Pharmacokinetic profile of amifostine. Shaw LM, et al. **Semin Oncol** 1996 Aug;23(4 Suppl 8):18–22 (19 ref.)

PHARMACOLOGY

Amifostine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as a radioprotector and cytotoxic chemoprotector. Spencer CM, et al. **Drugs** 1995 Dec;50(6):1001–31 (176 ref.)

Radioprotective and antioxidant action of caffeine: mechanistic considerations. Devasagayam TP, et al. **Indian J Exp Biol** 1996 Apr;34(4):291–7 (69 ref.)

THERAPEUTIC USE

Protection of normal tissue from the cytotoxic effects of chemotherapy and radiation by amifostine: clinical experiences. Capizzi RL, et al. **Eur J Cancer** 1995;31A Suppl 1:S8–13 (11 ref.)

Protection of normal tissues from the cytotoxic effects of chemotherapy and radiation by amifostine (WR-2721): preclinical aspects. Peters GJ, et al. **Eur J Cancer** 1995;31A Suppl 1:S1–7 (45 ref.)

Radiation protection and radiation recovery with essential metalloelement chelates. Sorenson JR, et al. **Proc Soc Exp Biol Med** 1995 Dec;210(3):191–204 (97 ref.)

Amifostine and radiation therapy: past, present, and future. Tannehill SP, et al. **Semin Oncol** 1996 Aug;23(4 Suppl 8):69–77 (40 ref.)

The potential role of amifostine in conjunction with cisplatin in the treatment of locally advanced carcinoma of the cervix. Wadler S, et al. **Semin Oncol** 1996 Aug;23(4 Suppl 8):64–8 (33 ref.)

[Mechanisms of radiation to the lung. Pentoxifylline—a new radioprotective drug?] Remiszewski P, et al. **Pneumonol Alergol Pol** 1995;63(5–6):349–54 (17 ref.) **(Pol)**

RADIATION SENSITIVITY see **RADIATION TOLERANCE**

RADIATION-SENSITIZING AGENTS

Radiosensitizing nucleosides. McGinn CJ, et al. **J Natl Cancer Inst** 1996 Sep 4;88(17):1193–203 (107 ref.)

ADMINISTRATION & DOSAGE

Preclinical studies of chemotherapy and radiation therapy for pancreatic carcinoma. Robertson JM, et al. **Cancer** 1996 Aug 1;78(3 Suppl):674–9 (48 ref.)

Antibody-targeted polymer-bound drugs. Říhová B. **Folia Microbiol (Praha)** 1995;40(4):367–84 (121 ref.)

DIAGNOSTIC USE

Novel therapeutic and diagnostic applications of hypocrellins and hypericins. Diwu Z. **Photochem Photobiol** 1995 Jun; 61(6):529–39 (118 ref.)

PHARMACOLOGY

Current status of radiation sensitization by fluoropyrimidines. Pu AT, et al. **Oncology (Huntingt)** 1995 Aug;9(8):707–14; discussion 714, 717–8, 721 (42 ref.)

[Combined effect of Paclitaxel and ionizing radiation. Experimental data of in-vitro and in-vivo models] Rübe C, et al. **Strahlenther Onkol** 1996 May;172 Suppl 1:2–5 (30 ref.) **(Ger)**

THERAPEUTIC USE

Nicotinamide and other benzamide analogs as agents for

overcoming hypoxic cell radiation resistance in tumours. A review. Horsman MR. **Acta Oncol** 1995;34(5):571–87 (158 ref.)

Progress in identifying clinical relevance of inhibition, stimulation and measurements of poly ADP-ribosylation. Pero RW, et al. **Biochimie** 1995;77(5):385–93 (45 ref.)

Activity of gemcitabine in patients with advanced pancreatic carcinoma. A review. Moore M. **Cancer** 1996 Aug 1;78(3 Suppl):633–8 (21 ref.)

Taxol plus radiation for head and neck cancer. Rosenthal DI, et al. **J Infus Chemother** 1995 Spring;5(2):46–54 (99 ref.)

Novel therapeutic and diagnostic applications of hypocrellins and hypericins. Diwu Z. **Photochem Photobiol** 1995 Jun; 61(6):529–39 (118 ref.)

Combined-modality therapy for advanced non-small cell lung cancer: paclitaxel and thoracic irradiation. Choy H, et al. **Semin Oncol** 1995 Dec;22(6 Suppl 15):38–44 (41 ref.)

[Neutron capturing irradiation: principle, current results and perspectives] Pignol JP, et al. **Bull Cancer Radiother** 1995; 82(3):283–97 (145 ref.) (Eng. Abstr.) **(Fre)**

[Percutaneous and intraluminal radiotherapy and radiochemotherapy in esophageal carcinoma] Staar S, et al. **Schweiz Rundsch Med Prax** 1996 Mar 5;85(10):307–12 (41 ref.) (Eng. Abstr.) **(Ger)**

RADIATION SICKNESS see **RADIATION INJURIES**

RADIATION SYNDROME see **RADIATION INJURIES**

RADIATION TOLERANCE

see related
RADIATION-PROTECTIVE AGENTS
RADIATION-SENSITIZING AGENTS

Invited review: intrinsic radiosensitivity as a predictor of patient response to radiotherapy. West CM. **Br J Radiol** 1995 Aug;68(812):827–37 (87 ref.)

Radiation therapy tolerance limits. For one or for all?—Janeway Lecture. Peters LJ. **Cancer** 1996 Jun 1; 77(11):2379–85 (39 ref.)

Normal tissue radiosensitivity—how important is it? Burnet NG, et al. **Clin Oncol (R Coll Radiol)** 1996;8(1):25–34 (88 ref.)

The ATM gene and the radiobiology of ataxia-telangiectasia. Jorgensen TJ, et al. **Int J Radiat Biol** 1996 May; 69(5):527–37 (104 ref.)

Normal tissue tolerance and management of radiation injury. Gillette EL, et al. **Semin Vet Med Surg (Small Anim)** 1995 Aug;10(3):209–13 (12 ref.)

[Predictive tests of radiocurability: towards a custom-made radiotherapy?] Cosset JM, et al. **Bull Cancer Radiother** 1990;77(2):83–94 (54 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Dominant oncogenes, tumor suppressors, and radiosensitivity. Chiarugi V, et al. **Cell Mol Biol Res** 1995; 41(3):161–6 (63 ref.)

P53-mediated radioresistance does not correlate with metastatic potential in tumorigenic rat embryo cell lines following oncogene transfection. Bristow RG, et al. **Int J Radiat Oncol Biol Phys** 1996 Jan 15;34(2):341–55 (81 ref.)

Repair of ionizing-radiation damage in the radiation resistant bacterium Deinococcus radiodurans. Minton KW. **Mutat Res** 1996 May 15;363(1):1–7 (34 ref.)

RADIATION, VISIBLE see **LIGHT**

RADIATION, WHOLE-BODY see **WHOLE-BODY IRRADIATION**

RADICAL NECK DISSECTION

Management of carcinoma of the supraglottic larynx: evolution, current concepts, and future trends. Myers EN, et al. **Laryngoscope** 1996 May;106(5 Pt 1):559–67 (46 ref.)

ADVERSE EFFECTS

Posterior ischemic optic neuropathy following bilateral radical neck dissection. Schobel GA, et al. **Int J Oral Maxillofac Surg** 1995 Aug;24(4):283–7 (22 ref.)

RADICULAR CYST

PATHOLOGY

A clinical and histopathological study of radicular cysts associated with primary molars. Mass E, et al. **J Oral Pathol Med** 1995 Nov;24(10):458–61 (9 ref.)

RADICULITIS

DRUG THERAPY

Contemporary concepts in spine care. Epidural steroid injections. Weinstein SM, et al. **Spine** 1995 Aug 15; 20(16):1842–6 (46 ref.)

ETIOLOGY

Magnetic resonance imaging. Use in patients with low back or radicular pain. Herzog RJ, et al. **Spine** 1995 Aug 15; 20(16):1834–8 (31 ref.)

RADIOACTIVE AIR POLLUTANTS see **AIR POLLUTANTS, RADIOACTIVE**

RADIOACTIVE POLLUTANTS

ADVERSE EFFECTS

The risk of childhood cancer from intrauterine and preconceptional exposure to ionizing radiation. Wakeford R. **Environ Health Perspect** 1995 Nov;103(11):1018–25 (84 ref.)

[Cancer epidemiology of radiation workers] Hosoda Y, et al. **Sangyo Eiseigaku Zasshi** 1996 May;38(3):107–18 (83 ref.) (Eng. Abstr.) **(Jpn)**

RADIOACTIVE WASTE

ADVERSE EFFECTS

Citizen perceptions of risks associated with moving radiological waste. McBeth MK, et al. **Risk Anal** 1996 Jun; 16(3):421–7 (19 ref.)

RADIOAUTOGRAPHY see **AUTORADIOGRAPHY**

RADIOBIOLOGY

see related
NUCLEAR MEDICINE

Radiation physics and radiobiology. Rossi HH. **Health Phys** 1996 Jun;70(6):828–31 (7 ref.)

Cytogenetics research in radiation biology. Bender MA. **Stem Cells (Dayt)** 1995 May;13 Suppl 1:172–81 (49 ref.)

Dose, effect severity, and imparted energy in assessing biological effects. Bond VP. **Stem Cells (Dayt)** 1995 May; 13 Suppl 1:21–9 (3 ref.)

[A working hypothesis. Multiparameter functional imaging as a possible course for radiobiology (editorial)] Cardinale AE, et al. **Radiol Med (Torino)** 1995 Sep;90(3):177–80 (26 ref.) **(Ita)**

TRENDS

[Radiobiology and the progress of radiation oncology] Khanson KP, et al. **Vopr Onkol** 1995;41(2):54–61 (23 ref.) **(Rus)**

RADIOCINEMATOGRAPHY see **CINERADIOGRAPHY**

RADIODERMATITIS

DIAGNOSIS

Metastatic squamous cell carcinoma of the hand and review of the literature. Foley SJ, et al. **J R Army Med Corps** 1995 Jun;141(2):102–4 (8 ref.)

DRUG THERAPY

[The treatment of cutaneous radiation-induced fibrosis with pentoxifylline and vitamin E. An empirical report] Gottlöber P, et al. **Strahlenther Onkol** 1996 Jan;172(1):34–8 (13 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Irradiated soft tissue and its management. Hom DB, et al. **Otolaryngol Clin North Am** 1995 Oct;28(5):1003–19 (47 ref.)

RADIOGRAPHIC IMAGE ENHANCEMENT

Digital imaging of cephalometric radiography, Part 1: Advantages and limitations of digital imaging. Forsyth DB, et al. **Angle Orthod** 1996;66(1):37–42 (29 ref.)

Digital dental imaging systems: a review. McDonnell D. **J Can Dent Assoc** 1995 Nov;61(11):962–4 (19 ref.)

Image acquisition. Sites, technologies, and approaches. Horii SC. **Radiol Clin North Am** 1996 May;34(3):469–94 (56 ref.)

[Possibilities of spiral-CT for diagnosis of focal liver lesions] Helmberger H, et al. **Rontgenpraxis** 1996 Mar;49(3):49–54 (35 ref.) **(Ger)**

[Digitized medical images] Nishitani H. **Nippon Igaku Hoshasen Gakkai Zasshi** 1995 Oct; 55(13):487–95 (5 ref.) (Eng. Abstr.) **(Jpn)**

METHODS

Current techniques in three-dimensional CT simulation and radiation treatment planning. Stephenson JA, et al. **Oncology (Huntingt)** 1995 Nov;9(11):1225–32, 1235; discussion 1235–40 (26 ref.)

Effect of quantum mottle on radiographic image quality. Hedrick WR. **Radiol Technol** 1996 May-Jun;67(5):401–6 (5 ref.)

Skeletal 3-D CT: advantages of volume rendering over surface rendering. Kuszyk BS, et al. **Skeletal Radiol** 1996 Apr;25(3):207–14 (16 ref.)

TRENDS

Critical pathways for the future: MR imaging and digital mammography. Newstead GM, et al. **Radiographics** 1995 Jul;15(4):951–62 (40 ref.)

RADIOGRAPHIC IMAGE INTERPRETATION, COMPUTER-ASSISTED

INSTRUMENTATION

[Radiation dosage of various CT techniques in diagnostic lung imaging] Heinz-Peer G, et al. **Radiologe** 1996 Jun; 36(6):470–4 (18 ref.) (Eng. Abstr.) **(Ger)**

[Virtual reality in medicine] Völter S, et al. **Radiologe** 1995 Sep;35(9):563–8 (25 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Toward consensus on quantitative assessment of medical imaging systems. Metz CE, et al. **Med Phys** 1995 Jul; 22(7):1057–61 (47 ref.)

RADIOGRAPHY

see related
CONTRAST MEDIA
EXTRAVASATION OF DIAGNOSTIC AND THERAPEUTIC MATERIALS
TECHNOLOGY, RADIOLOGIC

The origins of health services research in radiology: a review. Kundel HL. **AJR Am J Roentgenol** 1996 Jun;166(6):1255–7 (34 ref.)

Selective use of radiographic low-osmolality contrast media in the 1990s. Ellis JH, et al. **Radiology** 1996 Aug; 200(2):297–311 (178 ref.)

[Quality criteria in diagnostic radiology, goals and reality] St. Stender H, et al. **Aktuelle Radiol** 1995 Nov;5(6):337–42 (73 ref.) (Eng. Abstr.) **(Ger)**

[Usefulness and risk of roentgen diagnosis. A contribution to quality assurance] Angerstein W. **Rontgenpraxis** 1995 Sep;48(9):261–6 (58 ref.) **(Ger)**

[1995 literature review: ultrasound and roentgen diagnosis of gallbladder, bile ducts and pancreas] Brambs HJ, et al. **Rontgenpraxis** 1996 Apr;49(4):94–9 (31 ref.) **(Ger)**

[Imaging science and technology in diagnostic radiology: expectations in the second century of Roentgen's discography of X-rays] Doi K. **Nippon Igaku Hoshasen Gakkai Zasshi** 1995 Oct; 55(13):475–86 (42 ref.) (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

Ionising radiation in diagnosis: do the risks outweigh the benefits? Roebuck DJ. **Med J Aust** 1996 Jun 17; 164(12):743–7 (33 ref.)

HISTORY

The early history of x-ray diagnosis with emphasis on the contributions of physics 1895–1915. Mould RF. **Phys Med Biol** 1995 Nov;40(11):1741–87 (87 ref.)

The quest for the laws governing radiations and the search for beneficial innovations. Laughlin JS. **Radiat Res** 1995 Nov;144(2):129–40 (59 ref.)

METHODS

[Analysis of texture in medical imaging. Review of the literature] Rolland Y, et al. **Ann Radiol (Paris)** 1995; 38(6):315–47 (102 ref.) (Eng. Abstr.) **(Fre)**

STANDARDS

Effect of quantum mottle on radiographic image quality. Hedrick WR. **Radiol Technol** 1996 May-Jun;67(5):401–6 (5 ref.)

TRENDS

[An opinion regarding diagnostic radiology in new century] Kono M. **Nippon Igaku Hoshasen Gakkai Zasshi** 1995 Oct; 55(13):467–74 (9 ref.) (Eng. Abstr.) **(Jpn)**

VETERINARY

Radiographic artifacts. Kirberger RM, et al. **J S Afr Vet Assoc** 1995 Jun;66(2):85–94 (8 ref.)

Clinical applications of radiography and ancillary imaging. O'Brien RT, et al. **Vet Clin North Am Food Anim Pract** 1996 Mar;12(1):263–75 (7 ref.)

RADIOGRAPHY, BITEWING

TRENDS

Current trends in radiographic caries imaging. Wenzel A. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1995 Nov;80(5):527–39 (149 ref.)

RADIOGRAPHY, DENTAL

Global trends in oral and maxillofacial radiology education. Rohlin M, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1995 Nov;80(5):517–26 (52 ref.)

METHODS

Digital dental imaging systems: a review. McDonnell D. **J Can Dent Assoc** 1995 Nov;61(11):962–4 (19 ref.)
Diagnostic imaging in dental implantology. Frederiksen NL. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1995 Nov;80(5):540–54 (48 ref.)

TRENDS

Future trends in dental radiology. Vandre RH, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1995 Oct;80(4):471–8 (46 ref.)

RADIOGRAPHY, INTERVENTIONAL

Interventional radiology. Application to family practice. Asch M, et al. **Can Fam Physician** 1996 Aug;42:1511–8, 1521–3 (24 ref.)
Interventional neuroradiology of the head and neck. Hurst RW. **Neuroimaging Clin N Am** 1996 May;6(2):473–95 (38 ref.)
Arteriography and interventional therapy for diseases of the hand. Loring LA, et al. **Radiographics** 1995 Nov; 15(6):1299–310 (25 ref.)
Interventional procedures in the intensive care unit patient. Mewissen MW, et al. **Radiol Clin North Am** 1996 Jan; 34(1):157–76 (110 ref.)
[Uses of interventional arteriographic technics in gynecologic neoplasms] Yue D, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1995 Jul;30(7):435–7 (14 ref.) **(Chi)**
[Progresses in radiology in China, 1995] Zhang X. **Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):770–1 (0 ref.) **(Chi)**

METHODS

Computed tomography—guided aspiration of a ganglion cyst of the anterior cruciate ligament: a case report. Campagnolo DI, et al. **Arch Phys Med Rehabil** 1996 Jul; 77(7):732–3 (22 ref.)
Interventional radiology in a palliative care setting. Jones SN. **Palliat Med** 1995 Oct;9(4):319–26 (23 ref.)
Interventional procedures in the gastrointestinal tract in children. Kaye RD, et al. **Radiol Clin North Am** 1996 Jul; 34(4):903–17 (87 ref.)

RADIOGRAPHY, PANORAMIC

Use of orthopantomography in forensic identification. Doychinov I, et al. **Folia Med (Plovdiv)** 1994;36(3):57–61 (6 ref.)
The use of panoramic radiology in dental practice. Rushton VE, et al. **J Dent** 1996 May;24(3):185–201 (167 ref.)

RADIOIMMUNOASSAY

Thyroglobulin measurement. Techniques, clinical benefits, and pitfalls. Spencer CA, et al. **Endocrinol Metab Clin North Am** 1995 Dec;24(4):841–63 (76 ref.)
[Competitive immunoassay and immunometric immunoassay] Miyachi Y. **Nippon Rinsho** 1995 Sep;53(9):2112–8 (8 ref.) (Eng. Abstr.) **(Jpn)**

METHODS

Current status and performance goals for serum thyroglobulin assays. Spencer CA, et al. **Clin Chem** 1996 Jan;42(1):164–73 (54 ref.)
[Radioimmune analysis: the scientific and methodological procedures for its realization] Starovoitov NS, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1995 Sep–Oct; (5):116–8 (17 ref.) **(Rus)**

RADIOIMMUNOCONJUGATES see **IMMUNOCONJUGATES**

RADIOIMMUNODETECTION

Generation of human monoclonal antibodies against ganglioside antigens and their applications in the diagnosis and therapy of cancer. Alfonso M, et al. **Acta Oncol** 1996; 35(3):287–95 (67 ref.)
Immunoscintigraphy: Importance for researchers and patients. Britton KE, et al. **Acta Oncol** 1996;35(3):313–7 (35 ref.)
Secondary antibodies as tools to improve tumor to non tumor ratio at radioimmunolocalisation and radioimmunotherapy. Ullén A, et al. **Acta Oncol** 1996;35(3):281–5 (37 ref.)
Novel approaches to tumor detection and therapy using a combination of monoclonal antibody and cytokine. Greiner JW, et al. **Anticancer Res** 1996 Jul–Aug;16(4B):2129–33 (23 ref.)
Monoclonal antibodies used in the detection and treatment of epithelial ovarian cancer. Muto MG, et al. **Cancer** 1995 Nov 15;76(10 Suppl):2016–27 (100 ref.)
Non-invasive detection of myocyte necrosis in myocarditis and dilated cardiomyopathy with radiolabelled antimyosin. Khaw BA, et al. **Eur Heart J** 1995 Dec;16 Suppl O:119–23 (16 ref.)
Radio-immunotargeting in colorectal carcinoma. Rutgers EJ. **Eur J Cancer** 1995 Jul–Aug;31A(7–8):1243–7 (28 ref.)
The contribution of nuclear medicine to the patient with infection. Becker W. **Eur J Nucl Med** 1995 Oct; 22(10):1195–211 (114 ref.)
Radiolabelled monoclonal antibodies in tumour imaging and therapy: out of fashion? Delaloye AB, et al. **Eur J Nucl Med** 1995 Jun;22(6):571–80 (106 ref.)
Radioimmunoguided surgery and colorectal cancer. Aftab F, et al. **Eur J Surg Oncol** 1996 Aug;22(4):381–8 (81 ref.)
[Progresses in nuclear medicine in China, 1995] Lin X. **Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):771–2 (0 ref.) **(Chi)**
[Immunoscintigraphy in oncology] Vuillez JP. **Rev Med Interne** 1995;16(11):833–42 (70 ref.) (Eng. Abstr.) **(Fre)**

ADVERSE EFFECTS

Hematologic side effects of radiolabeled immunoglobulin therapy. Vriesendorp HM, et al. **Exp Hematol** 1996 Aug; 24(10):1183–90 (52 ref.)

INSTRUMENTATION

Radioimmunoguided Surgery system improves survival for patients with recurrent colorectal cancer. Bertsch DJ, et al. **Surgery** 1995 Oct;118(4):634–8; discussion 638–9 (9 ref.)

METHODS

Radiolabeled monoclonal antibodies. Brumley CL, et al. **AORN J** 1995 Sep;62(3):343–50, 353–5; quiz 356–8, 361–2 (12 ref.)
Radiolabelled human immunoglobulins. Buscombe J. **Nucl Med Commun** 1995 Dec;16(12):990–1001 (54 ref.)
[Methodology and clinical usefulness of radioimmunoimaging using radiolabeled monoclonal antibodies] Endo K, et al. **Nippon Rinsho** 1996 Jun;54(6):1604–9 (12 ref.) (Eng. Abstr.) **(Jpn)**

TRENDS

Twenty years with monoclonal antibodies: State of the art—Where do we go? Stigbrand T, et al. **Acta Oncol** 1996; 35(3):259–65 (33 ref.)
Improving the balance between treatment and diagnosis: a role for radioimmunodetection. Larson SM. **Cancer Res** 1995 Dec 1;55(23 Suppl):5756s–5758s (7 ref.)

RADIOIMMUNOIMAGING see **RADIOIMMUNODETECTION**

RADIOIMMUNOSCINTIGRAPHY see **RADIOIMMUNODETECTION**

RADIOIMMUNOTHERAPY

Generation of human monoclonal antibodies against ganglioside antigens and their applications in the diagnosis and therapy of cancer. Alfonso M, et al. **Acta Oncol** 1996; 35(3):287–95 (67 ref.)
Cancer therapy with radiolabeled antibodies. An overview. Bruland OS. **Acta Oncol** 1995;34(8):1085–94 (115 ref.)
Radioimmunotherapy of solid cancers: A review. Kairemo KJ. **Acta Oncol** 1996;35(3):343–55 (92 ref.)
Secondary antibodies as tools to improve tumor to non tumor ratio at radioimmunolocalisation and radioimmunotherapy. Ullén A, et al. **Acta Oncol** 1996;35(3):281–5 (37 ref.)
Radioimmunotherapy with alpha-particle emitting radioimmunoconjugates. Zalutsky MR, et al. **Acta Oncol** 1996;35(3):373–9 (36 ref.)
Monoclonal antibodies used in the detection and treatment of epithelial ovarian cancer. Muto MG, et al. **Cancer** 1995 Nov 15;76(10 Suppl):2016–27 (100 ref.)
Review of five consecutive studies of radiolabeled immunoglobulin therapy in Hodgkin's disease. Vriesendorp HM, et al. **Cancer Res** 1995 Dec 1;55(23 Suppl):5888s–5892s (15 ref.)
Myeloablative radiolabeled antibody therapy with autologous bone marrow transplantation for relapsed B cell lymphomas. Press OW, et al. **Cancer Treat Res** 1995; 76:281–97 (68 ref.)
Radiolabelled monoclonal antibodies in tumour imaging and therapy: out of fashion? Delaloye AB, et al. **Eur J Nucl Med** 1995 Jun;22(6):571–80 (106 ref.)
Bifunctional antibodies for radioimmunotherapy. Chatal JF, et al. **Hybridoma** 1995 Apr;14(2):125–8 (9 ref.)
Radioimmunotherapy of ovarian cancer. Syrigos KN, et al. **Hybridoma** 1995 Apr;14(2):121–4 (45 ref.)
Radioimmunotherapy: recent results and future directions. Wilder RB, et al. **J Clin Oncol** 1996 Apr;14(4):1383–400 (209 ref.)
Experimental radioimmunotherapy: biological effectiveness and comparison with external beam radiation. Buchsbaum DJ, et al. **Recent Results Cancer Res** 1996;141:9–18 (28 ref.)
Problems and advances in the dosimetry of radionuclide targeted therapy. Humm JL. **Recent Results Cancer Res** 1996;141:37–65 (105 ref.)
The use of radioimmunotherapy in combination with bioreductive agents. Langmuir VK. **Recent Results Cancer Res** 1996;141:137–43 (40 ref.)

ADVERSE EFFECTS

Hematologic side effects of radiolabeled immunoglobulin therapy. Vriesendorp HM, et al. **Exp Hematol** 1996 Aug; 24(10):1183–90 (52 ref.)

METHODS

Experimental approaches to increase radiolabeled antibody localization in tumors. Buchsbaum DJ. **Cancer Res** 1995 Dec 1;55(23 Suppl):5729s–5732s (65 ref.)
Overview of studies on experimental radioimmunotherapy. Knox SJ. **Cancer Res** 1995 Dec 1;55(23 Suppl):5832s–5836s (91 ref.)
Optimising the radioimmunotherapy of malignant disease: the broadening choice of carrier and effector moieties. Schubiger PA, et al. **Pharm Acta Helv** 1995 Sep; 70(3):203–17 (67 ref.)
Optimal therapeutic strategies for radioimmunotherapy. O'Donoghue JA. **Recent Results Cancer Res** 1996; 141:77–99 (26 ref.)
Two approaches for enhancing radioimmunotherapy: alpha emitters and hyperthermia. Zalutsky MR, et al. **Recent Results Cancer Res** 1996;141:101–22 (41 ref.)
[Application of tumor marker for immunotargeting therapy of cancer] Yamaguchi T, et al. **Nippon Rinsho** 1996 Jun; 54(6):1674–9 (17 ref.) (Eng. Abstr.) **(Jpn)**

TRENDS

Twenty years with monoclonal antibodies: State of the art—Where do we go? Stigbrand T, et al. **Acta Oncol** 1996; 35(3):259–65 (33 ref.)

RADIOISOTOPE BRACHYTHERAPY see **BRACHYTHERAPY**

RADIOISOTOPE RENOGRAPHY

Radionuclide techniques for the evaluation of renal function: advantages over conventional methodology. Bubeck B. **Curr Opin Nephrol Hypertens** 1995 Nov;4(6):514–9 (15 ref.)

RADIOISOTOPE SCANNING see **RADIONUCLIDE IMAGING**

RADIOISOTOPES

see related
ISOTOPE LABELING
Radionuclides in the Great Lakes basin. Ahier BA, et al. **Environ Health Perspect** 1995 Dec;103 Suppl 9:89–101 (41 ref.)
A limited bibliography of the Federal Government-funded human radiation experiments. Samei E, et al. **Health Phys** 1995 Dec;69(6):885–91 (55 ref.)

DIAGNOSTIC USE

The contribution of nuclear medicine to the patient with infection. Becker W. **Eur J Nucl Med** 1995 Oct; 22(10):1195–211 (114 ref.)
Radiolabelled human immunoglobulins. Buscombe J. **Nucl Med Commun** 1995 Dec;16(12):990–1001 (54 ref.)
Radiation protection issues associated with nuclear medicine out-patients [see comments] Thomson WH, et al. **Nucl Med Commun** 1995 Nov;16(11):879–92 (43 ref.)
Comment in: Nucl Med Commun 1995 Nov;16(11):877–8.
Tracers and contrast agents in cardiovascular imaging: present and future. Marmion M, et al. **Q J Nucl Med** 1996 Mar;40(1):121–31 (43 ref.)
Is there life after technetium: what is the potential for developing new broad-based radionuclides? Srivastava SC. **Semin Nucl Med** 1996 Apr;26(2):119–31 (78 ref.)
[Pulmonary nuclear medicine] Isawa T. **Kaku Igaku** 1995 Nov;32(11):1281–8 (64 ref.) (Eng. Abstr.) **(Jpn)**

PHARMACOKINETICS

Biokinetics of nuclear fuel compounds and biological effects of nonuniform radiation. Lang S, et al. **Environ Health Perspect** 1995 Oct;103(10):920–34 (191 ref.)

THERAPEUTIC USE

Is there life after technetium: what is the potential for developing new broad-based radionuclides? Srivastava SC. **Semin Nucl Med** 1996 Apr;26(2):119–31 (78 ref.)

RADIOLOGIC PHYSICS see **HEALTH PHYSICS**

RADIOLOGY

Therapeutic radiology: a potential unfolding through bioelectromagnetic sciences. Jacobson JI. **Altern Ther Health Med** 1996 Sep;2(5):49–55 (48 ref.)
A review of the statistical analysis used in papers published in Clinical Radiology and British Journal of Radiology. Goldin J, et al. **Clin Radiol** 1996 Jan;51(1):47–50 (33 ref.)
Research in radiology. Drane WE. **J Fla Med Assoc** 1995 Nov;82(11):754–7 (27 ref.)
Magnetic resonance spectroscopy and imaging in radiology. Mahmood U, et al. **Med Phys** 1995 Nov;22(11 Pt 2):1935–41 (65 ref.)
Decision aids in radiology. Kahn CE Jr. **Radiol Clin North Am** 1996 May;34(3):607–28 (106 ref.)
[How should informed consent for an invasive radiologic procedure be phrased in order that responsibility for contrast agent reactions be blamed on the patient himself] Barzilai M. **Harefuah** 1995 Jun 1;128(11):732–4 (33 ref.) **(Heb)**

RADIOLOGY

ECONOMICS

Profit-managed health care. Clements R. **Radiol Technol** 1996 May-Jun;67(5):377-8 (13 ref.)

EDUCATION

A guide to clinical epidemiology for radiologists: Part I study design and research methods. Goldin J, et al. **Clin Radiol** 1996 May;51(5):313-6 (30 ref.)

A guide to clinical epidemiology for radiologists: Part II statistical analysis. Goldin J, et al. **Clin Radiol** 1996 May; 51(5):317-24 (68 ref.)

Global trends in oral and maxillofacial radiology education. Rohlin M, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1995 Nov;80(5):517-26 (52 ref.)

Educational challenges. Jaffe CC, et al. **Radiol Clin North Am** 1996 May;34(3):629-46 (13 ref.)

Using critical thinking to teach empathy. Greathouse GF, et al. **Radiol Technol** 1996 May-Jun;67(5):435-7 (2 ref.)

STANDARDS

Responsible dissemination of scholarly work in radiology. Dowd SB, et al. **Radiol Technol** 1996 May-Jun;67(5):407-14 (22 ref.)

TRENDS

[Progresses in radiology in China, 1995] Zhang X. **Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):770-1 (0 ref.) **(Chi)**

[Radiology in the past, present and future] Katayama H. **Nippon Igaku Hoshasen Gakkai Zasshi** 1995 Oct; 55(13):450-8 (0 ref.) (Eng. Abstr.) **(Jpn)**

[Hip dislocation and urinary tract. Two trends in pediatric radiology] Jorulf H, et al. **Lakartidningen** 1995 Nov 29; 92(48):4563-6 (20 ref.) **(Swe)**

RADIOLOGY DEPARTMENT, HOSPITAL

ORGANIZATION & ADMINISTRATION

Re-engineering via patient-centered care. Dowd SB, et al. **Radiol Technol** 1996 May-Jun;67(5):421-4 (9 ref.)

RADIOLOGY, DIAGNOSTIC X-RAY see **RADIOGRAPHY**

RADIOLOGY INFORMATION SYSTEMS

Invited review: computer aids for decision-making in diagnostic radiology--a literature review. Taylor P. **Br J Radiol** 1995 Sep;68(813):945-57 (55 ref.)

Design and implementation of a picture archiving and communication system: the second time. Huang HK, et al. **J Digit Imaging** 1996 May;9(2):47-59 (18 ref.)

Reporting and communications. Bauman RA. **Radiol Clin North Am** 1996 May;34(3):597-606 (54 ref.)

Networks for electronic radiology. Blaine GJ, et al. **Radiol Clin North Am** 1996 May;34(3):505-24 (31 ref.)

Radiology systems architecture. Deibel SR, et al. **Radiol Clin North Am** 1996 May;34(3):681-96 (17 ref.)

Imaging system architectures for picture archiving and communication systems. Dwyer SJ 3rd. **Radiol Clin North Am** 1996 May;34(3):495-503 (43 ref.)

Image acquisition. Sites, technologies, and approaches. Horii SC. **Radiol Clin North Am** 1996 May;34(3):469-94 (56 ref.)

Decision aids in radiology. Kahn CE Jr. **Radiol Clin North Am** 1996 May;34(3):607-28 (106 ref.)

Technology assessment methods for radiology systems. Langlotz CP, et al. **Radiol Clin North Am** 1996 May; 34(3):667-79 (35 ref.)

Workstation design. Image manipulation, image set handling, and display issues. Lou SL, et al. **Radiol Clin North Am** 1996 May;34(3):525-44 (18 ref.)

[Digitized medical images] Nishitani H. **Nippon Igaku Hoshasen Gakkai Zasshi** 1995 Oct; 55(13):487-95 (5 ref.) (Eng. Abstr.) **(Jpn)**

STANDARDS

Modular extension of the ACR-NEMA DICOM standard to support new diagnostic imaging modalities and services. Bidgood WD Jr, et al. **J Digit Imaging** 1996 May;9(2):67-77 (37 ref.)

RADIOLOGY, INTERVENTIONAL

Interventional radiology and cross sectional imaging in venous access. Perry LJ, et al. **Surg Oncol Clin N Am** 1995 Jul;4(3):505-35 (82 ref.)

[Interventional radiology and abdominal emergencies] Rotenberg L, et al. **Ann Radiol (Paris)** 1996;39(2):89-103 (35 ref.) (Eng. Abstr.) **(Fre)**

[Essential bone cysts in children. Value of systematic cystography. Apropos of a series of 42 cysts] Journeau P, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1995; 81(3):248-56 (26 ref.) (Eng. Abstr.) **(Fre)**

[Modern neuroradiologic diagnosis and interventional strategies for the ENT physician] Hofmann E, et al. **HNO** 1995 Oct;43(10):584-9 (29 ref.) (Eng. Abstr.) **(Ger)**

[Imaging guided biopsy: principles, technique and indication] Vollrath T. **Schweiz Med Wochenschr** 1996 Jul 20; 126(29):1264-9 (17 ref.) (Eng. Abstr.) **(Ger)**

HISTORY

A short history of non-vascular interventional radiology. Dondelinger RF. **J Belge Radiol** 1995 Dec;78(6):363-70 (117 ref.)

INSTRUMENTATION

Interventional catheterization in paediatric cardiology. Gatzoulis MA, et al. **Eur Heart J** 1995 Dec;16(12):1767-72 (75 ref.)

Equipment configuration and procedures: preferences for interventional microtherapy. Grönemeyer D, et al. **J Digit Imaging** 1996 May;9(2):81-96 (31 ref.)

Vascular imaging before, during, and after endovascular repair. White RA, et al. **World J Surg** 1996 Jul-Aug; 20(6):622-9 (42 ref.)

LEGISLATION & JURISPRUDENCE

[The physician's duty to inform in interventional radiological therapeutic procedures] Duda SH, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1995 Oct;163(4):335-40 (28 ref.) (Eng. Abstr.) **(Ger)**

TRENDS

Interventional neuroradiology [see comments] Taylor W, et al. **BMJ** 1995 Sep 23;311(7008):789-92 (42 ref.) Comment in: BMJ 1995 Dec 9;311(7019):1575.

[Interventional radiology: current and future] Ishiguchi T. **Nippon Igaku Hoshasen Gakkai Zasshi** 1995 Oct; 55(13):496-502 (7 ref.) (Eng. Abstr.) **(Jpn)**

RADIOLOGY, THERAPEUTIC see **RADIATION ONCOLOGY**

RADIOMETRY

Internal dosimetry: developments and limitations [editorial] Mountford PJ. **Eur J Nucl Med** 1996 May;23(5):491-3 (25 ref.)

INSTRUMENTATION

State-of-the-art instruments for measuring radon/thoron and their progeny in dwellings--a review. George AC. **Health Phys** 1996 Apr;70(4):451-63 (31 ref.)

[Radiation dosage of various CT techniques in diagnostic lung imaging] Heinz-Peer G, et al. **Radiologe** 1996 Jun; 36(6):470-4 (18 ref.) (Eng. Abstr.) **(Ger)**

RADIONUCLIDE IMAGING

Where are we with nuclear medicine in pediatrics? Nadel HR. **Eur J Nucl Med** 1995 Dec;22(12):1433-51 (280 ref.)

METHODS

Cardiac imaging techniques: which, when, and why. Thomas JD, et al. **Cleve Clin J Med** 1996 Jul-Aug;63(4):213-20 (35 ref.)

[Analysis of texture in medical imaging. Review of the literature] Rolland Y, et al. **Ann Radiol (Paris)** 1995; 38(6):315-47 (102 ref.) (Eng. Abstr.) **(Fre)**

RADIONUCLIDE TOMOGRAPHY, COMPUTED see **TOMOGRAPHY, EMISSION-COMPUTED**

RADIONUCLIDE TOMOGRAPHY, SINGLE-PHOTON EMISSION-COMPUTED see **TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON**

RADIONUCLIDE VENTRICULOGRAPHY

Management decisions in valvular heart disease: the role of radionuclide-based assessment of ventricular function and performance. Borer JS, et al. **J Nucl Cardiol** 1996 Jan-Feb; 3(1):72-81 (83 ref.)

RADIONUCLIDES see **RADIOISOTOPES**

RADIOPAQUE MEDIA see **CONTRAST MEDIA**

RADIOPROTECTIVE AGENTS see **RADIATION-PROTECTIVE AGENTS**

RADIOSENSITIVITY see **RADIATION TOLERANCE**

RADIOSENSITIZING AGENTS see **RADIATION-SENSITIZING AGENTS**

RADIOSURGERY

Complications after multidisciplinary treatment of cerebral arteriovenous malformations. Deruty R, et al. **Acta Neurochir (Wien)** 1996;138(2):119-31 (46 ref.)

Stereotactic radiosurgery for primary and metastatic brain tumors. Petrovich Z, et al. **Cancer Invest** 1996;14(5):445-54 (46 ref.)

The physical, biologic, and clinical basis of radiosurgery. Mehta MP. **Curr Probl Cancer** 1995 Sep-Oct;19(5):265-329 (163 ref.)

Vestibular schwannoma and the only hearing ear. Bhatia S, et al. **J Laryngol Otol** 1996 Apr;110(4):366-9 (18 ref.)

Stereotactic radiosurgery for postgeniculate visual pathway arteriovenous malformations. Pollock BE, et al. **J Neurosurg** 1996 Mar;84(3):437-41 (29 ref.)

Gamma Knife treatment of pituitary adenomas. Ganz JC. **Stereotact Funct Neurosurg** 1995;64 Suppl 1:3-10 (38 ref.)

[Radiosurgery by linear accelerators in the treatment of 84 arteriovenous malformations] Schlienger M, et al. **Bull Cancer (Paris)** 1995 Dec;82 Suppl 5:581s-585s (25 ref.) (Eng. Abstr.) **(Fre)**

[Therapeutic risk in multidisciplinary approach of cerebral arteriovenous malformations] Deruty R, et al. **Neurochirurgie** 1996;42(1):35-43 (46 ref.) (Eng. Abstr.) **(Fre)**

ADVERSE EFFECTS

Complications of the gamma knife. Wiet RJ, et al. **Arch Otolaryngol Head Neck Surg** 1996 Apr;122(4):414-6 (13 ref.)

ECONOMICS

[Gamma knife versus stereotactic linear accelerator. Utilization, clinical results and cost-benefit relations] Becker G, et al. **Radiologe** 1996 Apr;36(4):345-53 (30 ref.) (Eng. Abstr.) **(Ger)**

INSTRUMENTATION

Primary cavernous sinus malignant lymphoma treated by gamma knife radiosurgery: case report and review of the literature. Nakatomi H, et al. **Surg Neurol** 1996 Sep; 46(3):272-8; discussion 278-9 (15 ref.)

METHODS

Stereotactic radiosurgery. Maciunas RJ. **Nat Med** 1996 Jun; 2(6):712-3 (30 ref.)

[Oral lesions in Kaposi sarcoma: clinical and radiotherapeutic considerations] Barberis M, et al. **Minerva Stomatol** 1996 Jan-Feb;45(1-2):17-27 (62 ref.) (Eng. Abstr.) **(Ita)**

TRENDS

Stereotactic radiosurgery. Maciunas RJ. **Nat Med** 1996 Jun; 2(6):712-3 (30 ref.)

RADIOTHERAPY

The case against the routine use of radiation therapy in advanced-stage Hodgkin's disease. Longo DL. **Cancer Invest** 1996;14(4):353-60 (49 ref.)

Radiation-induced apoptosis: relevance to radiotherapy. Dewey WC, et al. **Int J Radiat Oncol Biol Phys** 1995 Nov 1;33(4):781-96 (78 ref.)

A review of proton beam radiation therapy. Miller DW. **Med Phys** 1995 Nov;22(11 Pt 2):1943-54 (84 ref.)

Experimental radioimmunotherapy: biological effectiveness and comparison with external beam radiation. Buchsbaum DJ, et al. **Recent Results Cancer Res** 1996;141:9-18 (28 ref.)

[Cisplatin and radiotherapy: towards a new therapeutic system?] Reboul F, et al. **Bull Cancer Radiother** 1990; 77(2):95-100 (28 ref.) **(Fre)**

[The biological significance and clinical prospects of apoptosis within the parameters of radiotherapy response (editorial)] Tordiglione M, et al. **Radiol Med (Torino)** 1996 Mar;91(3):286-91 (44 ref.) **(Ita)**

ADVERSE EFFECTS

Radiation injury of the brain. Valk PE, et al. **AJNR Am J Neuroradiol** 1991 Jan;12(1):45-62 (90 ref.)

Effects of cranial irradiation on hearing acuity: a review of the literature. Sataloff RT, et al. **Am J Otol** 1994 Nov; 15(6):772-80 (28 ref.)

Postirradiation colitis cystica profunda. Case report and literature review. Ng WK, et al. **Arch Pathol Lab Med** 1995 Dec;119(12):1170-3 (17 ref.)

Mechanism and management of treatment-related gonadal failure in recipients of high dose chemoradiotherapy. Apperley JF, et al. **Blood Rev** 1995 Jun;9(2):93-116 (158 ref.)

Is blood a better source of allogeneic hematopoietic stem cells for use after radiation accidents? Frickhofen N, et al. **Bone Marrow Transplant** 1996 Feb;17(2):131-5 (48 ref.)

Radiation therapy tolerance limits. For one or for all?--Janeway Lecture. Peters LJ. **Cancer** 1996 Jun 1; 77(11):2379-85 (39 ref.)

Long-term effects of treatment of childhood malignancy. Malpas JS. **Clin Radiol** 1996 Jul;51(7):466-74 (65 ref.)

Oral complications of local and systemic cancer treatment. Carl W. **Curr Opin Oncol** 1995 Jul;7(4):320-4 (28 ref.)

Management of diarrhea induced by tumors or cancer therapy. Cascinu S. **Curr Opin Oncol** 1995 Jul;7(4):325-9 (63 ref.)

Radiation treatment effects in cervical cytology. Powers CN. **Diagn Cytopathol** 1995 Jul;13(1):75-80 (18 ref.)

Hepatic venoocclusive disease as a complication of whole abdominopelvic irradiation and treatment with the transjuglar intrahepatic portosystemic shunt: case report

and literature review. Shen-Gunther J, et al. **Gynecol Oncol** 1996 May;61(2):282-6 (25 ref.)

An overview of the oral complications of adult patients with malignant haematological conditions who have undergone radiotherapy or chemotherapy. Coleman S. **J Adv Nurs** 1995 Dec;22(6):1085-91 (47 ref.)

Mechanisms of chemotherapy/radiotherapy-induced emesis in animal models. Naylor RJ, et al. **Oncology** 1996 Jun;53 Suppl 1:8-17 (77 ref.)

A nursing perspective on radiation-induced xerostomia. Iwamoto RR. **Oncology (Huntingt)** 1996 Mar;10(3 Suppl):12-5 (42 ref.)

Late effects of cancer treatment in children. Ried H, et al. **Pediatr Dent** 1995 Jul-Aug;17(4):273-84 (117 ref.)

Late effects consensus conference: RTOG/EORTC. **Radiother Oncol** 1995 Apr;35(1):5-7 (9 ref.)

Sucralfate: prophylaxis of mucosal damage during cancer therapy. Henriksson R, et al. **Scand J Gastroenterol Suppl** 1995;210:45-7 (29 ref.)

Radiation enteropathy. Bozzetti F, et al. **Tumori** 1995 May-Jun;81(3 Suppl):117-21 (26 ref.)

Radiation enteropathy--incidence, aetiology, risk factors, pathology and symptoms. Rodier JF. **Tumori** 1995 May-Jun;81(3 Suppl):122-5 (12 ref.)

[Late complications of radiotherapy. Radiofibrosis is reversible] Baillet F. **Bull Cancer Radiother** 1995; 82(2):113-9 (37 ref.) **(Fre)**

[Late complications of chemoradiotherapeutic combinations: fundamental aspects and clinical experience] Balosso J, et al. **Bull Cancer Radiother** 1995;82(2):101-12 (37 ref.) **(Fre)**

[Arterial stenosis after radiotherapy] Piedbois P, et al. **Bull Cancer Radiother** 1990;77(1):3-13 (89 ref.) (Eng. Abstr.) **(Fre)**

[Pulmonary toxicity of drugs and thoracic irradiation in children] Fauroux B, et al. **Rev Mal Respir** 1996 Jul; 13(3):235-42 (58 ref.) (Eng. Abstr.) **(Fre)**

[Radiogenic lung reactions. Pathogenesis--prevention--therapy] Herrmann T, et al. **Strahlenther Onkol** 1995 Sep;171(9):490-8 (73 ref.) (Eng. Abstr.) **(Ger)**

[Acute gastrointestinal side effects of radiotherapy. What is certain in the treatment?] Paulsen F, et al. **Strahlenther Onkol** 1996 Feb;172(2):53-63 (77 ref.) (Eng. Abstr.) **(Ger)**

[Radiation-induced coronary ostial stenosis, a case of redo coronary bypass for the restenosis following patch angioplasty] Takewa Y, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Feb;44(2):220-5 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Radiation hepatitis] Iwata N, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):588-90 (20 ref.) **(Jpn)**

[Lung toxicity of cancer treatment] de Castro Carpeño J, et al. **Med Clin (Barc)** 1995 Nov 18;105(17):661-8 (76 ref.) **(Spa)**

[Coloanal anastomosis (Parks operation) in the treatment of acute radiation rectitis] San Martin S, et al. **Rev Med Chil** 1995 Mar;123(3):321-5 (15 ref.) (Eng. Abstr.) **(Spa)**

HISTORY

Uses of therapeutic x rays in medicine. Orton CG. **Health Phys** 1995 Nov;69(5):662-76 (65 ref.)

METHODS

The case for adjuvant radiation therapy in advanced Hodgkin's disease. Prosnitz LR, et al. **Cancer Invest** 1996; 14(4):361-70 (77 ref.)

Radiotherapy for genes that cause cancer. McBride WH, et al. **Nat Med** 1995 Nov;1(11):1215-7 (29 ref.)

Water calorimetry for radiation dosimetry. Ross CK, et al. **Phys Med Biol** 1996 Jan;41(1):1-29 (72 ref.)

Applications of proton beam therapy. Nicholson J, et al. **Radiol Technol** 1996 May-Jun;67(5):439-41 (9 ref.)

[Value of the combination of external radiotherapy and curietherapy in carcinoma of the velo-tonsillar region. Statistical study of a series of 361 patients] Pernot M, et al. **Bull Cancer Radiother** 1996;83(1):40-6 (32 ref.) (Eng. Abstr.) **(Fre)**

TRENDS

Roentgen Centennial Lecture: discovering the past, inventing the future. Hellman S. **Int J Radiat Oncol Biol Phys** 1996 Apr 1;35(1):15-20 (30 ref.)

[Current consideration and future in radiotherapy] Okawa T. **Nippon Igaku Hoshasen Gakkai Zasshi** 1995 Oct; 55(13):503-7 (11 ref.) (Eng. Abstr.) **(Jpn)**

[The present and future of heavy charged particle therapy] Tsujii H. **Nippon Rinsho** 1996 Jan;54(1):268-73 (13 ref.) (Eng. Abstr.) **(Jpn)**

VETERINARY

Principles of radiation therapy. Gillette EL, et al. **Semin Vet Med Surg (Small Anim)** 1995 Aug;10(3):129-34 (14 ref.)

Physics and treatment planning. Thrall DE, et al. **Semin Vet Med Surg (Small Anim)** 1995 Aug;10(3):135-47 (8 ref.)

RADIOTHERAPY, ADJUVANT

The case for adjuvant radiation therapy in advanced Hodgkin's disease. Prosnitz LR, et al. **Cancer Invest** 1996; 14(4):361-70 (77 ref.)

[The role of adjuvant therapy in the management of pN2 non-small-cell carcinoma of the lung] Chella A, et al. **Minerva Chir** 1995 Dec;50(12):1029-38 (40 ref.) (Eng. Abstr.) **(Ita)**

STANDARDS

Quality assurance in early breast cancer treatment: clinical aspects of postoperative, external, whole breast irradiation. Valdagni R, et al. **Recent Results Cancer Res** 1996; 140:251-61 (64 ref.)

RADIOTHERAPY DOSAGE

see related
DOSE-RESPONSE RELATIONSHIP, RADIATION

Radiation therapy tolerance limits. For one or for all?--Janeway Lecture. Peters LJ. **Cancer** 1996 Jun 1; 77(11):2379-85 (39 ref.)

Clinical interpretation of dose-volume histograms: the basis for normal tissue preservation and tumor dose escalation. Lawrence TS, et al. **Front Radiat Ther Oncol** 1996;29:57-66 (12 ref.)

Computer-controlled radiation therapy and multileaf collimation. Mohan R, et al. **Front Radiat Ther Oncol** 1996; 29:123-38 (21 ref.)

Defining our goals: volume and dose specification for 3-D conformal radiation therapy. Purdy JA. **Front Radiat Ther Oncol** 1996;29:24-30 (11 ref.)

3-D conformal therapy using beam intensity modulation. Verhey LJ. **Front Radiat Ther Oncol** 1996;29:139-55 (39 ref.)

Water calorimetry for radiation dosimetry. Ross CK, et al. **Phys Med Biol** 1996 Jan;41(1):1-29 (72 ref.)

Problems and advances in the dosimetry of radionuclide targeted therapy. Humm JL. **Recent Results Cancer Res** 1996;141:37-65 (105 ref.)

RADIOTHERAPY, HIGH-ENERGY

Combined-modality therapy for advanced non-small cell lung cancer: paclitaxel and thoracic irradiation. Choy H, et al. **Semin Oncol** 1995 Dec;22(6 Suppl 15):38-44 (41 ref.)

[Indications for percutaneous radiotherapy in carcinoma of the thyroid gland. Freiburg consensus] Reinhardt M, et al. **Radiologe** 1995 Aug;35(8):535-9 (32 ref.) (Eng. Abstr.) **(Ger)**

METHODS

[Intraoperative radiotherapy of ORL cancers. Review of the literature] Demange L. **Bull Cancer Radiother** 1996; 83(2):75-8 (25 ref.) (Eng. Abstr.) **(Fre)**

RADIOTHERAPY, INTERSTITIAL see **BRACHYTHERAPY**

RADIOTHERAPY, INTRACAVITY see **BRACHYTHERAPY**

RADIOTHERAPY PLANNING, COMPUTER-ASSISTED

Aspects of enhanced three-dimensional radiotherapy treatment planning. Ten Haken RK, et al. **Bull Cancer (Paris)** 1995 Dec;82 Suppl 5:592s-600s (78 ref.)

Electronic portal imaging. van Herk M, et al. **Bull Cancer (Paris)** 1995 Dec;82 Suppl 5:601s-606s (37 ref.)

Imaging: the basis for effective therapy. Chen GT, et al. **Front Radiat Ther Oncol** 1996;29:31-42 (34 ref.)

Quantitative plan evaluation: TCP/NTCP models. Kutcher GJ. **Front Radiat Ther Oncol** 1996;29:67-80 (24 ref.)

The CT-simulation 3-D treatment planning process. Michalski JM, et al. **Front Radiat Ther Oncol** 1996;29:43-56 (10 ref.)

Computer-controlled radiation therapy and multileaf collimation. Mohan R, et al. **Front Radiat Ther Oncol** 1996; 29:123-38 (21 ref.)

Optimization of 3-D conformal radiation treatment plans. Mohan R, et al. **Front Radiat Ther Oncol** 1996;29:86-103 (50 ref.)

Defining our goals: volume and dose specification for 3-D conformal radiation therapy. Purdy JA. **Front Radiat Ther Oncol** 1996;29:24-30 (11 ref.)

3-D radiation treatment planning: a new era. Purdy JA. **Front Radiat Ther Oncol** 1996;29:1-16 (49 ref.)

On-line portal imaging: contributions and limitations in clinical practice. Shalev S. **Front Radiat Ther Oncol** 1996; 29:156-67 (37 ref.)

Tissue inhomogeneity in the thorax: implications for 3-D treatment planning. Ten Haken RK, et al. **Front Radiat Ther Oncol** 1996;29:180-7 (15 ref.)

Quality assurance in 3-D treatment planning. Ten Haken RK, et al. **Front Radiat Ther Oncol** 1996;29:104-14 (9 ref.)

METHODS

3-D conformal therapy using beam intensity modulation. Verhey LJ. **Front Radiat Ther Oncol** 1996;29:139-55 (39 ref.)

Current techniques in three-dimensional CT simulation and radiation treatment planning. Stephenson JA, et al. **Oncology (Huntingt)** 1995 Nov;9(11):1225-32, 1235; discussion 1235-40 (26 ref.)

RADIOTHERAPY, SURFACE see **BRACHYTHERAPY**

RADIOTHERAPY, TARGETED see **RADIOTHERAPY**

RADIUS

Chronic disorders of the forearm. Richards RR. **J Bone Joint Surg Am** 1996 Jun;78(6):916-30 (143 ref.)

ABNORMALITIES

Is there a Baller-Gerold syndrome? [editorial; comment] Cohen MM Jr, et al. **Am J Med Genet** 1996 Jan 2;61(1):63-4 (38 ref.) Comment on: Am J Med Genet 1996 Jan 2;61(1):65-7.

Congenital radioulnar synostosis. Surgical correction by derotational osteotomy. Castelló JR, et al. **Ann Chir Main Memb Super** 1996;15(1):11-7 (8 ref.)

[Congenital humeroradial synostosis] Fernández Torrico J, et al. **An Esp Pediatr** 1996 Jun;44(6):612-4 (10 ref.) **(Spa)**

[Thrombocytopenia with absence of the radius in a 24-year-old woman] Fortuna AM, et al. **Sangre (Barc)** 1995 Jun;40(3):223-5 (13 ref.) (Eng. Abstr.) **(Spa)**

INJURIES

Acute dislocations of the distal radioulnar joint. Bruckner JD, et al. **Instr Course Lect** 1996;45:27-36 (96 ref.)

Traumatic plastic deformity of an adult forearm: case report and literature review. Simonian PT, et al. **J Orthop Trauma** 1996;10(3):213-5 (12 ref.)

Isolated dislocation of the radial head in an adult: case report and review of the literature. Deehan DJ, et al. **J R Coll Surg Edinb** 1995 Dec;40(6):421-3 (26 ref.)

RADIUS FRACTURES

COMPLICATIONS

Traumatic ulnar physeal arrest after distal forearm fractures in children. Ray TD, et al. **J Pediatr Orthop** 1996 Mar-Apr; 16(2):195-200 (15 ref.)

REHABILITATION

Current management of fractures of distal radius and ulna. Williams RL, et al. **Br J Hosp Med** 1996 Mar 20-Apr 2; 55(6):320-8 (60 ref.)

SURGERY

Operative treatment of intraarticular distal radial fractures. Lipton HA, et al. **Clin Orthop** 1996 Jun;(327):110-24 (91 ref.)

Traumatic plastic deformity of an adult forearm: case report and literature review. Simonian PT, et al. **J Orthop Trauma** 1996;10(3):213-5 (12 ref.)

[Fractures of the distal humerus and proximal forearm] Dorow C, et al. **Unfallchirurg** 1996 Jun;99(6):440-9 (10 ref.) **(Ger)**

VETERINARY

Treatment of fractures of the tibia and radius-ulna by external coaptation. Adams SB, et al. **Vet Clin North Am Food Anim Pract** 1996 Mar;12(1):181-98 (15 ref.)

RADON

see related
AIR POLLUTANTS, RADIOACTIVE

ICRP recommendations applicable to the mining and minerals processing industries and to natural sources. International Commission on Radiological Protection. Clarke RH. **Health Phys** 1995 Oct;69(4):454-60 (18 ref.)

ADVERSE EFFECTS

Empirical and biologically based models for cancer risk assessment. Zielinski JM, et al. **Drug Metab Rev** 1996 Feb-May;28(1-2):53-75 (29 ref.)

Genetic, cytogenetic, and carcinogenic effects of radon: a review. Jostes RF. **Mutat Res** 1996 Jun;340(2-3):125-39 (87 ref.)

Importance of radon as a threat to public health. Donohoe K, et al. **Otolaryngol Head Neck Surg** 1996 Feb; 114(2):271-6 (23 ref.)

ANALYSIS

State-of-the-art instruments for measuring radon/thoron and their progeny in dwellings--a review. George AC. **Health Phys** 1996 Apr;70(4):451-63 (31 ref.)

RAEB see **ANEMIA, REFRACTORY, WITH EXCESS OF BLASTS**

RAEM see **ANEMIA, REFRACTORY, WITH EXCESS OF**

RAEM

BLASTS

RAILLIETINA see CESTODA

RAILLIETINIASIS see CESTODE INFECTIONS

RAILROADS

Transportation disasters--a review. Lundin T. **J Trauma Stress** 1995 Jul;8(3):381-9 (27 ref.)

RAIN, ACID see ACID RAIN

RALES see RESPIRATORY SOUNDS

RAMAN SPECTROSCOPY see SPECTRUM ANALYSIS, RAMAN

RAMIPRIL

PHARMACOLOGY

Angiotensin converting enzyme inhibitors, left ventricular hypertrophy and fibrosis. Linz W, et al. **Mol Cell Biochem** 1995 Jun 7-21;147(1-2):89-97 (73 ref.)

RAMSAY HUNT AURICULAR SYNDROME see HERPES ZOSTER OTICUS

RAMSAY HUNT PARALYSIS SYNDROME see PARKINSON DISEASE

RANA ESCULENTA

PHYSIOLOGY

'Vestibular compensation': neural plasticity and its relations to functional recovery after labyrinthine lesions in frogs and other vertebrates. Dieringer N. **Prog Neurobiol** 1995 Jun;46(2-3):97-129 (225 ref.)

The frog taste disc: a prototype of the vertebrate gustatory organ. Osculati F, et al. **Prog Neurobiol** 1995 Jul; 46(4):351-99 (241 ref.)

RANDOM ALLOCATION

A personal view of some controversies in allocating treatment to patients in clinical trials [see comments] Senn S. **Stat Med** 1995 Dec 30;14(24):2661-74 (41 ref.) Comment in: Stat Med 1996 Jan 15;15(1):113-6.

RANDOM AMPLIFIED POLYMORPHIC DNA TECHNIQUE

see related
DNA FINGERPRINTING
GENETIC MARKERS

Arbitrarily amplified DNA in systematics and phylogenetics. Schierwater B. **Electrophoresis** 1995 Sep;16(9):1643-7 (45 ref.)

RANDOMIZATION see RANDOM ALLOCATION

RANDOMIZED CONTROLLED TRIALS

Matching to guide the design and predict the outcome of randomized atherectomy trials [editorial] Umans VA, et al. **Am Heart J** 1995 Nov;130(5):1135-43 (48 ref.)

Accounting for cluster randomization: a review of primary prevention trials, 1990 through 1993. Simpson JM, et al. **Am J Public Health** 1995 Oct;85(10):1378-83 (43 ref.)

Submacular surgery. Are randomized trials necessary? [editorial] Bressler NM. **Arch Ophthalmol** 1995 Dec; 113(12):1557-60 (31 ref.)

Meta-analyses and overviews of randomised trials. Richards SM. **Blood Rev** 1995 Jun;9(2):85-91 (16 ref.)

The need for systematic reviews in the treatment of menstrual disorders--another Cochrane collaborative review group is born. Farquhar CM. **Br J Obstet Gynaecol** 1996 Jun; 103(6):497-500 (20 ref.)

Preterm breech babies and randomised trials of rare conditions [comment] Thornton JG, et al. **Br J Obstet Gynaecol** 1996 Jul;103(7):611-3 (5 ref.) Comment on: Br J Obstet Gynaecol 1996 Jul;103(7):684-9.

Interpreting results from thrombolytic megatrials: distinguishing fact from fiction. Brophy JM. **Can J Cardiol** 1996 Jan;12(1):89-92 (22 ref.)

Ethical issues in the case of surgical repair of cleft palate. Berkowitz S. **Cleft Palate Craniofac J** 1995 Jul;32(4):271-6; discussion 277-81 (66 ref.)

When a randomised controlled trial is needed to assess drug safety. The case of paediatric ibuprofen. Mitchell AA, et al. **Drug Saf** 1995 Jul;13(1):15-24 (21 ref.)

Soft tissue sarcoma--messages from completed randomized trials. Gortzak E, et al. **Eur J Surg Oncol** 1995 Oct; 21(5):469-71 (25 ref.)

Soft tissue sarcomas--what is currently being done. Issels RD. **Eur J Surg Oncol** 1995 Oct;21(5):471-4 (12 ref.)

Randomised controlled trials of physical activity promotion in free living populations: a review. Hillsdon M, et al. **J Epidemiol Community Health** 1995 Oct;49(5):448-53 (23 ref.)

On the need for evidence-based medicine. Sackett DL, et al. **J Public Health Med** 1995 Sep;17(3):330-4 (22 ref.)

The need for evidence-based medicine. Sackett DL, et al. **J R Soc Med** 1995 Nov;88(11):620-4 (22 ref.)

Overview of randomized clinical trials of oral branched-chain amino acid treatment in chronic hepatic encephalopathy. Fabbri A, et al. **JPEN J Parenter Enteral Nutr** 1996 Mar-Apr;20(2):159-64 (44 ref.)

Randomised trialomania? The multicentre liver transplant trials of tacrolimus [see comments] Starzl TE, et al. **Lancet** 1995 Nov 18;346(8986):1346-50 (28 ref.) Comment in: Lancet 1995 Nov 18;346(8986):1310-1.

The case for randomized clinical trials on the treatment of obesity. Stern MP. **Obes Res** 1995 Sep;3 Suppl 2:299s-306s (25 ref.)

Current status of vinorelbine for breast cancer. Smith GA. **Oncology (Huntingt)** 1995 Aug;9(8):767-73; discussion 774, 776, 779 (41 ref.)

Design and current status of the NSABP breast cancer prevention trial. Redmond CK, et al. **Recent Results Cancer Res** 1996;140:309-17 (4 ref.)

A personal view of some controversies in allocating treatment to patients in clinical trials [see comments] Senn S. **Stat Med** 1995 Dec 30;14(24):2661-74 (41 ref.) Comment in: Stat Med 1996 Jan 15;15(1):113-6.

Observational studies as alternatives to randomized clinical trials in surgical clinical research. Hu X, et al. **Surgery** 1996 Apr;119(4):473-5 (6 ref.)

Randomized controlled trials in surgery: Issues and problems. McLeod RS, et al. **Surgery** 1996 May;119(5):483-6 (13 ref.)

[Alternatives and access routes in hysterectomies. Are randomizations dangerous?] Cosson M, et al **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(3):257-63 (15 ref.) (Eng. Abstr.) **(Fre)**

ECONOMICS

Role of the pathologist in biomarker studies. Wilkinson EJ, et al. **J Cell Biochem Suppl** 1995;23:10-8 (29 ref.)

LEGISLATION & JURISPRUDENCE

[Research in psychiatry and legislative restrictions] Bougerol T. **Encephale** 1996 May;22 Spec No 1:63-8 (5 ref.) (Eng. Abstr.) **(Fre)**

METHODS

Experimental approaches to determining the choice of first-step therapy for patients with hypertension. The ALLHAT Research Group Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Whelton PK, et al. **Clin Exp Hypertens** 1996 Apr-May; 18(3-4):569-79 (17 ref.)

Randomised consent designs in cancer clinical trials. Altman DG, et al. **Eur J Cancer** 1995 Nov;31A(12):1934-44 (53 ref.)

An approach to the design and implementation of clinical trials of empirical antibiotic therapy in febrile and neutropenic cancer patients. Viscoli C, et al. **Eur J Cancer** 1995 Nov;31A(12):2013-22 (60 ref.)

New developments in the conduct and management of multi-center trials: an international review of clinical trial units. Gluud C, et al. **Fundam Clin Pharmacol** 1995; 9(3):284-9 (16 ref.)

Chemoprevention trials in the cervix: design, feasibility, and recruitment. Mitchell MF, et al. **J Cell Biochem Suppl** 1995; 23:104-12 (43 ref.)

STANDARDS

A critique of the double-blind clinical trial. Part 1. Kiene H. **Altern Ther Health Med** 1996 Jan;2(1):74-80 (41 ref.)

Competing or complementary? Ethical considerations and the quality of randomized trials. Lumley J, et al. **Int J Technol Assess Health Care** 1996 Spring;12(2):247-63 (103 ref.)

Assessing the quality of randomized controlled trials. Current issues and future directions. Moher D, et al. **Int J Technol Assess Health Care** 1996 Spring;12(2):195-208 (55 ref.)

Bias in the analysis and reporting of randomized controlled trials. Stewart LA, et al. **Int J Technol Assess Health Care** 1996 Spring;12(2):264-75 (35 ref.)

An overview of pharmacoepidemiology. Wertheimer AL, et al. **Pharm World Sci** 1995 May 26;17(3):61-6 (13 ref.)

STATISTICS & NUMERICAL DATA

Elevated rates of early discontinuation from pharmacotherapy trials in alcoholics and drug abusers. Kranzler HR, et al. **Alcohol Clin Exp Res** 1996 Feb; 20(1):16-20 (20 ref.)

Treatment of cluster headache: clinical trials, design and results. Ekbom K. **Cephalalgia** 1995 Oct;15 Suppl 15:33-6 (35 ref.)

[Regional adjuvant therapy in colorectal liver metastases: requirements for clinical therapy studies from the statistical viewpoint (see comments)] Müller HH, et al. **Zentralbl Chir** 1995;120(10):755-9 (10 ref.) (Eng. Abstr.) Comment in: Zentralbl Chir 1995;120(10):753-4. **(Ger)**

TRENDS

[Current methodologies and clinical research] Beuzen JN. **Encephale** 1996 May;22 Spec No 1:57-61 (6 ref.) (Eng. Abstr.) **(Fre)**

RANGE OF MOTION, ARTICULAR

Thumb movements, motions, and moments. Hollister A, et al. **J Hand Ther** 1995 Apr-Jun;8(2):106-14 (8 ref.)

PHYSIOLOGY

[Biomechanical changes in the hip, femur and knee joint after removal of a tensor fasciae latae flap] Lattermann C, et al. **Handchir Mikrochir Plast Chir** 1996 Mar;28(2):76-82 (33 ref.) (Eng. Abstr.) **(Ger)**

RANITIDINE

PHARMACOLOGY

[Ranitidine: consequences on secretory function and gastric mucosa] Vallot T, et al. **Rev Med Suisse Romande** 1995 Oct;115(10):773-80 (23 ref.) **(Fre)**

THERAPEUTIC USE

Drug therapy of peptic ulcer disease. Ching CK, et al. **Br J Hosp Med** 1995 Jul 12-Aug 15;54(2-3):101-6 (39 ref.)

H2-receptor antagonists an Helicobacter pylori eradication. Lamers CB. **Scand J Gastroenterol Suppl** 1995;212:126-7 (8 ref.)

[How to eradicate Helicobacter pylori in 1995? Critical review of available treatments] Deltenre M, et al. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S44-S52 (122 ref.) **(Fre)**

[Therapeutic management of duodenal ulcer except in emergency cases: antisecretory treatment] Ruszniewski P. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S53-S57 (48 ref.) **(Fre)**

RANK-SUM TESTS see STATISTICS, NONPARAMETRIC

RANULA

Ranula, or, what's in a name? Mandel L. **N Y State Dent J** 1996 Jan;62(1):37-9 (28 ref.)

RAPD-PCR see RANDOM AMPLIFIED POLYMORPHIC DNA TECHNIQUE

RAPD TECHNIQUE see RANDOM AMPLIFIED POLYMORPHIC DNA TECHNIQUE

RAPE

Rape is a major public health issue. Schafran LH. **Am J Public Health** 1996 Jan;86(1):15-7 (13 ref.)

Delayed reporting of the rape victim. Burgess AW, et al. **J Psychosoc Nurs Ment Health Serv** 1995 Sep;33(9):21-9 (14 ref.)

[Rape and sexually transmitted diseases] Pawlaczyk M. **Ginekol Pol** 1996 Apr;67(4):210-4 (20 ref.) (Eng. Abstr.) **(Pol)**

LEGISLATION & JURISPRUDENCE

Male rape: the impact of a legal definition on the clinical area. Rogers P. **Med Sci Law** 1995 Oct;35(4):303-6 (14 ref.)

PREVENTION & CONTROL

The primary health care provider's role in sexual assault prevention. Holmes MM. **Womens Health Issues** 1995 Winter;5(4):224-32 (42 ref.)

PSYCHOLOGY

Delayed reporting of sexual assault. Implications for counseling. Plumbo MA. **J Nurse Midwifery** 1995 Sep-Oct; 40(5):424-7 (9 ref.)

Trauma, traumatic memory, and research: where do we go from here? Wolfe J. **J Trauma Stress** 1995 Oct;8(4):717-26 (5 ref.)

Male and female sexual victimization in dating relationships: gender differences in coercion techniques and outcomes. Waldner-Haugrud LK, et al. **Violence Vict** 1995 Fall; 10(3):203-15 (23 ref.)

RAPESEED see BRASSICA

RAPHE NUCLEI

CHEMISTRY

[New concepts relating to histochemistry of the serotonergic neural systems of the raphe nucleus] Villar MJ. **Acta Psiquiatr Psicol Am Lat** 1994 Dec;40(4):293-300 (36 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

The basis for behavioural disturbances in dementia [editorial] Esiri MM. **J Neurol Neurosurg Psychiatry** 1996 Aug; 61(2):127-30 (57 ref.)

RAPID EYE MOVEMENTS see SLEEP, REM

RARE EARTH METALS see METALS, RARE EARTH

RAS GENES see GENES, RAS

RAS ONCOGENE PROTEIN P21 see ONCOGENE PROTEIN P21(RAS)

RAS PROTEINS

The Ras superfamily of GTPases. Macara IG, et al. **FASEB J** 1996 Apr;10(5):625–30 (45 ref.)

CHEMISTRY

How Ras works: structure of a Rap–Raf complex. Sprang SR. **Structure** 1995 Jul 15;3(7):641–3 (17 ref.)

DRUG EFFECTS

Signal transduction by Ras–like GTPases: a potential target for anticancer drugs. Spaargaren M, et al. **Gene Expr** 1995; 4(6):345–56 (122 ref.)

METABOLISM

The stress–activated protein kinases. A novel ERK subfamily responsive to cellular stress and inflammatory cytokines. Kyriakis JM, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:303–19 (48 ref.)

Activation of Ras and other signaling pathways by receptor tyrosine kinases. Schlessinger J, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:173–9 (43 ref.)

Ras partners. Van Aelst L, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:181–6 (43 ref.)

Interactions between Ras proteins and their effectors. McCormick F, et al. **Curr Opin Biotechnol** 1996 Aug; 7(4):449–56 (101 ref.)

Ras–Raf complexes: analyses of complexes formed in vivo. Finney R, et al. **Methods Enzymol** 1995;255:310–23 (24 ref.)

Carboxyl methylation of Ras–related proteins. Volker C, et al. **Methods Enzymol** 1995;255:65–82 (82 ref.)

Ras–related proteins in signal transduction and growth control. McCormick F. **Mol Reprod Dev** 1995 Dec; 42(4):500–6 (8 ref.)

Interactions between Ras and Raf: key regulatory proteins in cellular transformation. Marshall M. **Mol Reprod Dev** 1995 Dec;42(4):493–9 (24 ref.)

Guanine nucleotide exchange factors: activators of Ras superfamily proteins. Overbeck AF, et al. **Mol Reprod Dev** 1995 Dec;42(4):468–76 (32 ref.)

How Ras works: structure of a Rap–Raf complex. Sprang SR. **Structure** 1995 Jul 15;3(7):641–3 (17 ref.)

PHARMACOLOGY

The insulin/Ras pathway of adipocytic differentiation of 3T3 L1 cells: dissociation between Raf–1 kinase and the MAPK/RSK cascade. Porras A, et al. **Int J Obes Relat Metab Disord** 1996 Mar;20 Suppl 3:S43–51 (47 ref.)

PHYSIOLOGY

KSR: a novel player in the RAS pathway [comment] Downward J. **Cell** 1995 Dec 15;83(6):831–4 (17 ref.) Comment on: Cell 1995 Dec 15;83(6):879–88. Comment on: Cell 1995 Dec 15;83(6):889–901. Comment on: Cell 1995 Dec 15;83(6):903–13.

The Ras superfamily of GTPases. Macara IG, et al. **FASEB J** 1996 Apr;10(5):625–30 (45 ref.)

Phosphatidylinositol 3' kinase: one of the effectors of Ras. Rodriguez–Viciana P, et al. **Philos Trans R Soc Lond B Biol Sci** 1996 Feb 29; 351(1336):225–31; discussion 231–2 (50 ref.)

RAS PROTO–ONCOGENE PROTEIN P21 see PROTO–ONCOGENE PROTEIN P21(RAS)

RATIONING, HEALTH CARE see HEALTH CARE RATIONING

RATS

Transgenesis in rats: technical aspects and models. Charreau B, et al. **Transgenic Res** 1996 Jul;5(4):223–34 (75 ref.)

[Procedures for health monitoring in a breeding facility for specific pathogen free mice and rats] Wyss–Spillmann SK, et al. **Schweiz Arch Tierheilkd** 1995;137(11):505–14 (39 ref.) (Eng. Abstr.) **(Ger)**

METABOLISM

Corticosteroid metabolism in isolated perfused rat liver and kidney. Experimental studies with emphasis on aldosterone. Egfjord M. **Acta Physiol Scand Suppl** 1995;627:1–42 (226 ref.)

PHYSIOLOGY

Differential control of proceptive and receptive components of female rat sexual behavior by the preoptic area. Sakuma Y. **Jpn J Physiol** 1995;45(2):211–28 (103 ref.)

The rat, a useful animal model for pharmacological studies on apolipoprotein E. Leininger–Muller B, et al. **Life Sci** 1996;58(6):455–67 (102 ref.)

Review article. The rat incisor in toxicologic pathology. Kuijpers MH, et al. **Toxicol Pathol** 1996 May–Jun; 24(3):346–60 (28 ref.)

RATS, INBRED SHR

PHYSIOLOGY

Na+, K(+)–pump activity and skeletal muscle contractile deficits in the spontaneously hypertensive rat. Carlsen RC, et al. **Acta Physiol Scand** 1996 Mar;156(3):237–45 (24 ref.)

Altered L–DOPA systems for blood pressure regulation in the lower brainstem of spontaneously hypertensive rats. Misu Y, et al. **Hypertens Res** 1995 Dec;18(4):267–77 (77 ref.)

Adrenoceptors in SHR: alterations in binding characteristics and intracellular signal transduction pathways. Takata Y, et al. **Life Sci** 1996;58(2):91–106 (199 ref.)

RATS, INBRED STRAINS

Strain as a determinant factor in the differential responsiveness of rats to chemicals. Kacew S, et al. **Toxicol Pathol** 1995 Nov–Dec;23(6):701–14; discussion 714–5 (95 ref.)

[Transgenic rat] Matsumoto K. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2223–33 (49 ref.) **(Jpn)**

GENETICS

Role of rat strain in the differential sensitivity to pharmaceutical agents and naturally occurring substances. Kacew S, et al. **J Toxicol Environ Health** 1996 Jan; 47(1):1–30 (145 ref.)

RATS, LABORATORY see RATS

RATS, MUTANT STRAINS

GENETICS

Role of rat strain in the differential sensitivity to pharmaceutical agents and naturally occurring substances. Kacew S, et al. **J Toxicol Environ Health** 1996 Jan; 47(1):1–30 (145 ref.)

RATS, NORWAY see RATS

RATS, SAND see GERBILLINAE

RATS, SPONTANEOUSLY HYPERTENSIVE see RATS, INBRED SHR

RATTLESNAKE VENOMS see CROTALID VENOMS

RATTUS NORVEGICUS see RATS

RAUWOLSCINE see YOHIMBINE

RAYNAUD'S DISEASE

Cold extremities: investigation and management of Raynaud's phenomenon. Farrington NK, et al. **J South Orthop Assoc** 1996 Spring;5(1):37–45 (27 ref.)

COMPLICATIONS

Raynaud's phenomenon and the vascular disease in scleroderma. Kahaleh MB. **Curr Opin Rheumatol** 1995 Nov; 7(6):529–34 (37 ref.)

DIAGNOSIS

Overlapping syndromes, undifferentiated connective tissue disease, and other fibrosing conditions. Kallenberg CG. **Curr Opin Rheumatol** 1995 Nov;7(6):568–73 (42 ref.)

PHYSIOPATHOLOGY

[Raynaud phenomenon and scleroderma] Haustein UF. **Hautarzt** 1996 May;47(5):336–40 (61 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

[Therapeutic (im)possibilities in Raynaud's phenomenon] Smilde TJ, et al. **Ned Tijdschr Geneeskd** 1996 Feb 17; 140(7):352–7 (21 ref.) **(Dut)**

RAZOXANE

THERAPEUTIC USE

Cardiotoxicity and cardioprotection during chemotherapy. Hochster H, et al. **Curr Opin Oncol** 1995 Jul;7(4):304–9 (37 ref.)

RB GENES see GENES, RETINOBLASTOMA

RB PROTEIN see RETINOBLASTOMA PROTEIN

REACTANTS, ACUTE–PHASE see ACUTE–PHASE PROTEINS

REACTION, ACUTE–PHASE see ACUTE–PHASE REACTION

REACTION CENTER PROTEIN, BACTERIAL see PHOTOSYNTHETIC REACTION CENTER, BACTERIAL

REACTION CENTER PROTEIN, PLANT see PHOTOSYNTHETIC REACTION CENTER, PLANT

REACTION TIME

The processing–speed theory of adult age differences in cognition. Salthouse TA. **Psychol Rev** 1996 Jul; 103(3):403–28 (110 ref.)

[Saccadic latencies and unilateral spatial neglect caused by parietal lesions] Cochin JP, et al. **Rev Neurol (Paris)** 1996 Jan;152(1):32–7 (35 ref.) (Eng. Abstr.) **(Fre)**

[Methods of studying somatosensory evoked responses and long–latency reflexes] Jovičić A, et al. **Vojnosanit Pregl** 1994 Nov–Dec;51(6):527–33 (38 ref.) **(Scr)**

PHYSIOLOGY

The role of neuroimaging in the discovery of processing stages. A review. Mulder G, et al. **Acta Psychol (Amst)** 1995 Nov;90(1–3):63–79 (66 ref.)

Covert orienting to non–informative cues: reaction time studies. Tassinari G, et al. **Behav Brain Res** 1995 Nov; 71(1–2):101–12 (58 ref.)

REACTIVE OXYGEN SPECIES

see related

FREE RADICALS

Nitric oxide and reactive oxygen species in vascular injury. Rubbo H, et al. **Biochem Soc Symp** 1995;61:33–45 (59 ref.)

Free radicals in health and disease. Hollán S. **Haematologia (Budap)** 1995;26(4):177–89 (73 ref.)

An introduction to oxygen free radicals. Kerr ME, et al. **Heart Lung** 1996 May–Jun;25(3):200–9; quiz 210–1 (52 ref.)

Nitric oxide, oxygen–derived free radicals and vascular endothelium. Marin J, et al. **J Auton Pharmacol** 1995 Aug; 15(4):279–307 (223 ref.)

[Reactive oxygen species (comment] Botzenhart K. **Immun Infekt** 1995 Oct;23(5):147 (0 ref.) Comment on: Immun Infekt 1995 Oct;23(5):158–60. **(Ger)**

[Clinical significance of reactive oxygen species] Bruchelt G. **Immun Infekt** 1995 Oct;23(5):174–8 (40 ref.) (Eng. Abstr.) **(Ger)**

[Reactive oxygen species and arachidonic acid metabolites of polymorphonuclear leukocytes] Döring G, et al. **Immun Infekt** 1995 Oct;23(5):148–57 (163 ref.) (Eng. Abstr.) **(Ger)**

[Active oxygen species: physiology and pathology] Nakano M. **Masui** 1995;44 Suppl:S26–32 (17 ref.) **(Jpn)**

[Basic and clinical study of reactive oxygen species] Yoshikawa T, et al. **Nippon Naika Gakkai Zasshi** 1995 Jul 10;84(7):1186–91 (11 ref.) **(Jpn)**

[Physiological roles of metallothionein as possible scavenger and promoter for active oxygen species] Sakurai H. **Nippon Rinsho** 1996 Jan;54(1):2–4 (5 ref.) **(Jpn)**

[8–Oxoguanine repair system and its role in mitochondria] Kang D, et al. **Seikagaku** 1996 Apr;68(4):289–95 (22 ref.) **(Jpn)**

[DNA lesions produced by active oxygen and their induced mutations] Kamiya H, et al. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1571–7 (36 ref.) **(Jpn)**

[New findings on reactive oxidative materials and their role in biological systems] Jovičić A, et al. **Vojnosanit Pregl** 1995 Nov–Dec;52(6):579–84 (24 ref.) **(Scr)**

ADVERSE EFFECTS

Lipid peroxidation and antioxidants as biomarkers of tissue damage. Gutteridge JM. **Clin Chem** 1995 Dec;41(12 Pt 2):1819–28 (56 ref.)

The oxidative stress response. Camhi SL, et al. **New Horiz** 1995 May;3(2):170–82 (114 ref.)

Antioxidants in pediatric gastrointestinal disease. Sokol RJ, et al. **Pediatr Clin North Am** 1996 Apr;43(2):471–88 (102 ref.)

METABOLISM

Molecular mechanisms for neurodegeneration. Synergism between reactive oxygen species, calcium, and excitotoxic amino acids. Gerlach M, et al. **Adv Neurol** 1996;69:177–94 (119 ref.)

Oxygen radical–nitric oxide reactions in vascular diseases. Freeman BA, et al. **Adv Pharmacol** 1995;34:45–69 (81 ref.)

Regulation of nitric oxide synthase: role of oxygen radicals and cations in nitric oxide formation. Mittal CK, et al. **Adv Pharmacol** 1995;34:235–50 (50 ref.)

Ethanol–induced oxidative stress in the liver. Kurose I, et al. **Alcohol Clin Exp Res** 1996 Feb;20(1 Suppl):77A–85A (88 ref.)

Antioxidants in neonatal lung disease. Fardy CH, et al. **Arch Dis Child Fetal Neonatal Ed** 1995 Sep;73(2):F112–7 (66 ref.)

Environmental hazard assessment of chemicals and products. Part VI. Abiotic degradation in the troposphere. Klöpffer W. **Chemosphere** 1996 Sep;33(6):1083–99 (71 ref.)

REACTIVE OXYGEN SPECIES

Oxygen free radicals, melatonin, and aging. Pierrefiche G, et al. **Exp Gerontol** 1995 May–Aug;30(3–4):213–27 (75 ref.)
Reactive oxygen and nitrogen metabolites as mediators of secretory diarrhea. Gaginella TS, et al. **Gastroenterology** 1995 Dec;109(6):2019–28 (147 ref.)
Impact of reactive oxygen species on spermatozoa: a balancing act between beneficial and detrimental effects. de Lamirande E, et al. **Hum Reprod** 1995 Oct;10 Suppl 1:15–21 (43 ref.)
Free radical damage and oxidative stress in Huntington's disease. Borlongan CV, et al. **J Fla Med Assoc** 1996 May; 83(5):335–41 (0 ref.)
Regulation of cytokine gene expression by reactive oxygen and reactive nitrogen intermediates. Remick DG, et al. **J Leukoc Biol** 1996 Apr;59(4):471–5 (34 ref.)
The role of oxygen free radicals in preconditioning. Ambrosio G, et al. **J Mol Cell Cardiol** 1995 Apr; 27(4):1035–9 (49 ref.)
Reactive oxygen species and vascular signal transduction mechanisms. Wolin MS. **Microcirculation** 1996 Mar; 3(1):1–17 (131 ref.)
Oxygen–radical/nitric oxide mediate calcium–dependent hormone action on cyclic GMP system: a novel concept in signal transduction mechanisms. Mittal CK. **Mol Cell Biochem** 1995 Aug–Sep;149–150:257–62 (37 ref.)
Antioxidant defences against reactive oxygen species causing genetic and other damage. Anderson D. **Mutat Res** 1996 Feb 19;350(1):103–8 (46 ref.)
Are reactive oxygen species involved in Alzheimer's disease? [see comments] Benzi G, et al. **Neurobiol Aging** 1995 Jul–Aug;16(4):661–74 (201 ref.) Comment in: Neurobiol Aging 1995 Jul–Aug;16(4):675–8. Comment in: Neurobiol Aging 1995 Jul–Aug;16(4):667–82; discussion 683. Comment in: Neurobiol Aging 1995 Jul–Aug;16(4):679–82; discussion 683.
Scavenging of reactive oxygen species as the mechanism of drug action. Robak J, et al. **Pol J Pharmacol** 1995 Mar–Apr; 47(2):89–98 (134 ref.)
Cytochrome P450: structure, function, and generation of reactive oxygen species. Bernhardt R. **Rev Physiol Biochem Pharmacol** 1996;127:137–221 (483 ref.)
[Reactive oxygen species and homeostasis] Wilhelm J. **Cesk Fysiol** 1995 Jun;44(2):86–91 (50 ref.) (Eng. Abstr.) **(Cze)**
[Oxidants and antioxidants. Biological effects and therapeutic perspectives] Urban T, et al. **Ann Chir** 1995;49(5):427–34 (55 ref.) (Eng. Abstr.) **(Fre)**
[Lipid peroxidation in the presence of inorganic compounds. Relation to oxidative stress mechanisms] Fournier J, et al. **C R Seances Soc Biol Fil** 1995;189(3):429–42 (36 ref.) (Eng. Abstr.) **(Fre)**
[Cellular reactions of the lung to mineral fibers] Gillissen A, et al. **Pneumologie** 1996 Jan;50(1):5–17 (137 ref.) **(Ger)**
[Peroxisomal diseases--oxygen and free radicals] Kremser K, et al. **Wien Klin Wochenschr** 1995;107(22):690–3 (46 ref.) (Eng. Abstr.) **(Ger)**
[Reactive oxygen species and gene expression regulation] Jurgowiak M, et al. **Postepy Biochem** 1996;42(1):6–13 (75 ref.) **(Pol)**
[Role of reactive oxygen metabolites in the pathogenesis of chronic inflammatory bowel disease] Fernández–Bañares F. **Gastroenterol Hepatol** 1995 Dec;18(10):526–36 (55 ref.) **(Spa)**

PHARMACOLOGY

Functional aspects of the pineal hormone melatonin in combating cell and tissue damage induced by free radicals. Reiter RJ. **Eur J Endocrinol** 1996 Apr;134(4):412–20 (89 ref.)
Role of reactive intermediates in tumor promotion and progression. Kensler T, et al. **Prog Clin Biol Res** 1995; 391:103–16 (51 ref.)

TOXICITY

Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer. Wiseman H, et al. **Biochem J** 1996 Jan 1;313 (Pt 1):17–29 (213 ref.)
Oxygen toxicity and antioxidants: state of the art. Sen CK. **Indian J Physiol Pharmacol** 1995 Jul;39(3):177–96 (91 ref.)
Reactive oxygen species in developmental toxicity: review and hypothesis. Fantel AG. **Teratology** 1996 Mar; 53(3):196–217 (123 ref.)
Nitric oxide (NO) protects against cellular damage by reactive oxygen species. Wink DA, et al. **Toxicol Lett** 1995 Dec;82–83:221–6 (25 ref.)

REACTIVE SITE see **BINDING SITES**

READINESS POTENTIAL see **CONTINGENT NEGATIVE VARIATION**

READING

Readability of patient education materials: implications for clinical practice. Albright J, et al. **Appl Nurs Res** 1996 Aug; 9(3):139–43 (37 ref.)
Dyslexia. Reading between the laminae. Walsh V. **Curr Biol** 1995 Nov 1;5(11):1216–7 (10 ref.)
Annotation: contemporary approaches to the teaching of reading. Snowling MJ. **J Child Psychol Psychiatry** 1996 Feb;37(2):139–48 (40 ref.)
Luminance and chromatic contrast effects on reading and object recognition in low vision: a review of the literature. Eperjesi F, et al. **Ophthalmic Physiol Opt** 1995 Nov; 15(6):561–8 (20 ref.)
The emotional Stroop task and psychopathology. Williams JM, et al. **Psychol Bull** 1996 Jul;120(1):3–24 (95 ref.)
Eye movements and reading. O'Regan JK. **Rev Oculomot Res** 1990;4:395–453 (204 ref.)
Eye–movement models for arithmetic and reading performance. Suppes P. **Rev Oculomot Res** 1990;4:455–77 (53 ref.)
[Writing and reading scientific texts] Kuss E, et al. **Geburtshilfe Frauenheilkd** 1995 Jul;55(7):414–24 (85 ref.) **(Ger)**
[Knowing how to read a scientific article. 3. Knowing how to assess the natural history of a disease] Longo M, et al. **G Ital Cardiol** 1995 Aug;25(8):1067–75 (30 ref.) **(Ita)**

READING DISABILITY, DEVELOPMENTAL see **DYSLEXIA**

REAGENT KITS, DIAGNOSTIC

Home HIV testing and conflicts with state HIV testing regulations. Fabbri WO. **Am J Law Med** 1995;21(4):419–44 (230 ref.)
[Progresses in laboratory medicine in China, 1995] Tao Q, et al. **Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):773–4 (0 ref.) **(Chi)**
[Gene technology to overproduce the enzymes useful as diagnostic reagents] Sugiyama M, et al. **Rinsho Byori** 1995 Aug;43(8):765–71 (8 ref.) (Eng. Abstr.) **(Jpn)**

REAGENT STRIPS

Glucose monitoring as a guide to diabetes management. Critical subject review. Koch B. **Can Fam Physician** 1996 Jun;42:1142–6, 1149–52 (65 ref.)

STANDARDS

Assessment of gastric acidity in intensive care patients: intermittent pH registration cannot replace continuous pH monitoring. Bonten MJ, et al. **Intensive Care Med** 1996 Mar;22(3):220–5 (26 ref.)

REAL–TIME SYSTEMS see **COMPUTER SYSTEMS**

REALITY TESTING

Orphans of the 'Real': II. The future of object relations theory in the treatment of the psychoses and other primitive mental disorders. Grotstein JS. **Bull Menninger Clin** 1995 Summer;59(3):312–32 (75 ref.)
Orphans of the 'Real': I. Some modern and postmodern perspectives on the neurobiological and psychosocial dimensions of psychosis and other primitive mental disorders. Grotstein JS. **Bull Menninger Clin** 1995 Summer; 59(3):287–311 (115 ref.)

REC A PROTEIN

[Mechanisms of the recognition of homologous DNA molecules by RecA protein] Kurumizaka H, et al. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1647–55 (61 ref.) **(Jpn)**

CHEMISTRY

Alignment of 3 (but not 4) DNA strands within a RecA protein filament. Cox MM. **J Biol Chem** 1995 Nov 3; 270(44):26021–4 (68 ref.)

METABOLISM

Alignment of 3 (but not 4) DNA strands within a RecA protein filament. Cox MM. **J Biol Chem** 1995 Nov 3; 270(44):26021–4 (68 ref.)
Role of recombination enzymes in mammalian cell survival. Edelmann W, et al. **Proc Natl Acad Sci U S A** 1996 Jun 25;93(13):6225–7 (25 ref.)
Getting down to the core of homologous recombination [comment] Stasiak A. **Science** 1996 May 10;272(5263):828–9 (9 ref.) Comment on: Science 1996 May 10;272(5263):868–72.

RECA PROTEIN see **REC A PROTEIN**

RECALL

What do infants recall of their lives? Memory for specific events by one– to two–year–olds. Bauer PJ. **Am Psychol** 1996 Jan;51(1):29–41 (75 ref.)
Harnessing the power of the placebo effect and renaming it "remembered wellness". Benson H, et al. **Annu Rev Med** 1996;47:193–9 (18 ref.)
ECT and non–memory cognition: a review. Calev A, et al. **Br J Clin Psychol** 1995 Nov;34 (Pt 4):505–15 (60 ref.)
Recall of psychiatric history in cross–sectional surveys: implications for epidemiologic research. Simon GE, et al. **Epidemiol Rev** 1995;17(1):221–7 (48 ref.)
Seeing one's self: locating narrative memory in a framework of personality. Singer JA. **J Pers** 1995 Sep;63(3):429–57 (75 ref.)
Try to remember ... reminiscence as a nursing intervention. Nugent E. **J Psychosoc Nurs Ment Health Serv** 1995 Nov; 33(11):7–11 (16 ref.)
The SolCos model: facilitating reminiscence therapy. Soltys FG, et al. **J Psychosoc Nurs Ment Health Serv** 1995 Nov; 33(11):21–6 (27 ref.)
Say it once again: effects of repeated questions on children's event recall. Fivush R, et al. **J Trauma Stress** 1995 Oct; 8(4):555–80 (75 ref.)
Children's long–term retention of salient personal experiences. Ornstein PA. **J Trauma Stress** 1995 Oct; 8(4):581–605 (60 ref.)
Factors influencing recall of childhood sexual abuse. Rogers ML. **J Trauma Stress** 1995 Oct;8(4):691–716 (115 ref.)
Dissociation and the fragmentary nature of traumatic memories: overview and exploratory study. van der Kolk BA, et al. **J Trauma Stress** 1995 Oct;8(4):505–25 (85 ref.)
Trauma, traumatic memory, and research: where do we go from here? Wolfe J. **J Trauma Stress** 1995 Oct;8(4):717–26 (5 ref.)
The difficulty with recalling people's names: the plausible phonology hypothesis. Brennen T. **Memory** 1993 Dec; 1(4):409–31 (45 ref.)
Naming faces and naming names: exploring an interactive activation model of person recognition. Burton AM, et al. **Memory** 1993 Dec;1(4):457–80 (26 ref.)
Flashbulb memories: conceptual and methodological issues. Wright DB, et al. **Memory** 1995 Mar;3(1):67–80 (55 ref.)
Does job–related training performance decline with age? Kubeck JE, et al. **Psychol Aging** 1996 Mar;11(1):92–107 (100 ref.)
Cognitive components of picture naming. Johnson CJ, et al. **Psychol Bull** 1996 Jul;120(1):113–39 (310 ref.)
Monitoring and control processes in the strategic regulation of memory accuracy. Koriat A, et al. **Psychol Rev** 1996 Jul;103(3):490–517 (140 ref.)
Facial emotion recognition by persons with mental retardation: a review of the experimental literature. Rojahn J, et al. **Res Dev Disabil** 1995 Sep–Oct;16(5):393–414 (75 ref.)
Facial processing in schizophrenia and delusional misidentification: cognitive neuropsychiatric approaches. Phillips ML, et al. **Schizophr Res** 1995 Sep;17(1):109–14 (45 ref.)
[Dream recall in depressed patients] Schredl M. **Psychother Psychosom Med Psychol** 1995 Dec;45(12):414–7 (29 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

General and specific speed mediation of adult age differences in memory. Salthouse TA. **J Gerontol B Psychol Sci Soc Sci** 1996 Jan;51(1):P30–42 (32 ref.)
Functional neuroanatomical correlates of the effects of stress on memory. Bremner JD, et al. **J Trauma Stress** 1995 Oct; 8(4):527–53 (115 ref.)
MRI hippocampal volume and neuropsychology in epilepsy surgery. Trenerry MR, et al. **Magn Reson Imaging** 1995; 13(8):1125–32 (47 ref.)
Neuroanatomical correlates of category–specific semantic disorders: a critical survey. Gainotti G, et al. **Memory** 1995 Sep–Dec;3(3–4):247–64 (50 ref.)
Distinguishing false from true in human memory [comment] Blaxton TA. **Neuron** 1996 Aug;17(2):191–4 (17 ref.) Comment on: Neuron 1996 Aug;17(2):267–74.
Memory and consciousness: a selective review of issues and data. Rugg MD. **Neuropsychologia** 1995 Sep;33(9):1131–41 (66 ref.)
[Remembering in the transference--on the interdisciplinary dialogue between psychoanalysis and biological memory research] Leuzinger–Bohleber M. **Psychother Psychosom Med Psychol** 1996 Jun;46(6):217–27 (53 ref.) (Eng. Abstr.) **(Ger)**

RECEIVER OPERATING CHARACTERISTIC see **ROC CURVE**

RECEPTOR–CD3 COMPLEX, ANTIGEN, T–CELL

see related
SIGNAL TRANSDUCTION

CHEMISTRY

Composition of TCR–CD3 complex in human intestinal intraepithelial lymphocytes: lack of Fc epsilon RI gamma chain. Balk SP, et al. **Int Immunol** 1995 Aug;7(8):1237–41 (40 ref.)

DEFICIENCY

T lymphocyte receptor deficiencies. Kappes DJ, et al. **Curr Opin Immunol** 1995 Aug;7(4):441–7 (53 ref.)
[Regulation of T cell development by T cell receptor complex--analysis by TCR–CD3 chains–deficient mice] Saito T, et al. **Tanpakushitsu Kakusan Koso** 1995 Oct; 40(14):2097–106 (18 ref.) **(Jpn)**

GENETICS

T cell development in CD3-zeta mutant mice. Huang MT. **Int Rev Immunol** 1995;13(1):29-41 (81 ref.)

PHYSIOLOGY

[Regulation of T cell development by T cell receptor complex--analysis by TCR-CD3 chains-deficient mice] Saito T, et al. **Tanpakushitsu Kakusan Koso** 1995 Oct; 40(14):2097-106 (18 ref.) **(Jpn)**

RECEPTOR-MEDIATED SIGNAL TRANSDUCTION see **SIGNAL TRANSDUCTION**

RECEPTOR PROTEIN-TYROSINE KINASE

see related
PROTO-ONCOGENE PROTEINS C-KIT

[Involvement of the VEGF-Flt-receptor family in angiogenesis] Shibuya M. **Nippon Yakurigaku Zasshi** 1996 Mar;107(3):119-31 (44 ref.) (Eng. Abstr.) **(Jpn)**

[Gas6: a ligand for receptor tyrosine kinase containing gamma-carboxyglutamic acids] Nakano T. **Seikagaku** 1996 Apr;68(4):299-302 (11 ref.) **(Jpn)**

ANALYSIS

Immunocytochemical localization of receptor protein kinases in plants. Counihan VP, et al. **Methods Cell Biol** 1995; 49:515-29 (25 ref.)

BIOSYNTHESIS

Regulation of the expression of the VEGF/VPS and its receptors: role in tumor angiogenesis. Kolch W, et al. **Breast Cancer Res Treat** 1995;36(2):139-55 (156 ref.)

Regulation of HGF and HGFR gene expression. Zarnegar R. **EXS** 1995;74:33-49 (59 ref.)

Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells. Drexler HG. **Leukemia** 1996 Apr; 10(4):588-99 (118 ref.)

GENETICS

RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma. Cote GJ, et al. **Baillieres Clin Endocrinol Metab** 1995 Jul; 9(3):609-30 (64 ref.)

Putting the bits and pieces of the RET proto-oncogene puzzle together. Gagel RF. **Bone** 1995 Aug;17(2 Suppl):13S-16S (30 ref.)

Mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2. Ponder BA. **Cancer Surv** 1995;25:195-205 (31 ref.)

Transgenic manipulation of myocardial G protein-coupled receptors and receptor kinases. Koch WJ, et al. **Circ Res** 1996 Apr;78(4):511-6 (29 ref.)

Oncogenic activation of the ret protooncogene in thyroid cancer. Takahashi M. **Crit Rev Oncog** 1995;6(1):35-46 (96 ref.)

Molecular defects in thyroid carcinomas: role of the RET oncogene in thyroid neoplastic transformation. Santoro M, et al. **Eur J Endocrinol** 1995 Nov;133(5):513-22 (114 ref.)

Novel FGFR2 mutations in Crouzon and Jackson-Weiss syndromes show allelic heterogeneity and phenotypic variability. Park WJ, et al. **Hum Mol Genet** 1995 Jul; 4(7):1229-33 (18 ref.)

The role of growth factor receptors in central nervous system development and neoplasia. Weiner HL. **Neurosurgery** 1995 Aug;37(2):179-93; discussion 193-4 (187 ref.)

[The direct gene test in familial medullary thyroid gland carcinoma and in MEN syndromes. Detection of mutations in the ret proto-oncogene saves screening studies] Stuhrmann M. **Fortschr Med** 1995 Dec 20;113(35-36):503-6 (23 ref.) (Eng. Abstr.) **(Ger)**

[Ret proto-oncogene mutations associated with type 2 multiple endocrine neoplasms (MEN 2). Clinical implications] Bugalho MJ, et al. **Acta Med Port** 1995 Jul-Aug;8(7-8):419-24 (66 ref.) (Eng. Abstr.) **(Por)**

ISOLATION & PURIFICATION

[Detection of RET-proto-oncogene mutations in the diagnosis of Type 2 endocrine neoplasia (MEN 2)] Komminoth P, et al. **Schweiz Med Wochenschr** 1996 Aug 6;126(31-32):1329-38 (57 ref.) (Eng. Abstr.) **(Ger)**

METABOLISM

Structural and functional properties of the TRK family of neurotrophin receptors. Barbacid M. **Ann N Y Acad Sci** 1995 Sep 7;766:442-58 (67 ref.)

Activation of Ras and other signaling pathways by receptor tyrosine kinases. Schlessinger J, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:173-9 (43 ref.)

Inflammation. They're not just for clots anymore. Esmon CT. **Curr Biol** 1995 Jul 1;5(7):743-6 (15 ref.)

Cell signalling. Receptor orphans find a family. Pandey A, et al. **Curr Biol** 1995 Sep 1;5(9):986-9 (30 ref.)

Receptor signalling and the regulation of endocytic membrane transport. Seaman MN, et al. **Curr Opin Cell Biol** 1996 Aug;8(4):549-56 (67 ref.)

Early events in neurotrophin signalling via Trk and p75 receptors. Greene LA, et al. **Curr Opin Neurobiol** 1995 Oct;5(5):579-87 (72 ref.)

Dissection of the Torso signal transduction pathway in Drosophila. Perrimon N, et al. **Mol Reprod Dev** 1995 Dec; 42(4):515-22 (29 ref.)

Induction of non-catalytic TrkB neurotrophin receptors during lesion-induced synaptic rearrangement in the adult rat hippocampus. Beck KD, et al. **Prog Brain Res** 1995; 105:197-210 (80 ref.)

p75 and Trk: a two-receptor system. Chao MV, et al. **Trends Neurosci** 1995 Jul;18(7):321-6 (61 ref.)

PHYSIOLOGY

Scatter factor and angiogenesis. Rosen EM, et al. **Adv Cancer Res** 1995;67:257-79 (93 ref.)

Role of VEGF-flt receptor system in normal and tumor angiogenesis. Shibuya M. **Adv Cancer Res** 1995;67:281-316 (141 ref.)

Melanoma formation in Xiphophorus: a model system for the role of receptor tyrosine kinases in tumorigenesis. Malitschek B, et al. **Bioessays** 1995 Dec;17(12):1017-23 (39 ref.)

Angiotensin II signalling events mediated by tyrosine phosphorylation. Marrero MB, et al. **Cell Signal** 1996 Jan; 8(1):21-6 (30 ref.)

The role of scatter factor and the c-met proto-oncogene in angiogenic responses. Polverini PJ, et al. **EXS** 1995; 74:51-67 (82 ref.)

Biology of flt3 ligand and receptor. Lyman SD. **Int J Hematol** 1995 Aug;62(2):63-73 (42 ref.)

G-protein-coupled receptor kinases. Lohse MJ, et al. **Kidney Int** 1996 Apr;49(4):1047-52 (65 ref.)

Hepatocyte growth factor--pleiotropic cytokine produced by human leukemia cells. Gohda E, et al. **Leuk Lymphoma** 1995 Oct;19(3-4):197-205 (97 ref.)

Membrane bound receptor tyrosine kinases and chemical carcinogenesis. Shawver LK, et al. **Mutat Res** 1995 Dec; 333(1-2):23-8 (27 ref.)

Role of neurotrophins and trk receptors in the development and maintenance of sensory neurons: an overview. Lindsay RM. **Philos Trans R Soc Lond B Biol Sci** 1996 Mar 29; 351(1338):365-73 (53 ref.)

Receptor tyrosine kinases and the regulation of hematopoiesis. Paulson RF, et al. **Semin Immunol** 1995 Aug; 7(4):267-77 (84 ref.)

Regulation of G protein-coupled receptors by receptor kinases and arrestins. Sterne-Marr R, et al. **Vitam Horm** 1995;51:193-234 (121 ref.)

RECEPTOR TYROSINE KINASE see **RECEPTOR PROTEIN-TYROSINE KINASE**

RECEPTORS, ACETYLCHOLINE see **RECEPTORS, CHOLINERGIC**

RECEPTORS, ACTH see **RECEPTORS, CORTICOTROPIN**

RECEPTORS, ADENOSINE see **RECEPTORS, PURINERGIC P1**

RECEPTORS, ADP see **RECEPTORS, PURINERGIC P2**

RECEPTORS, ADRENERGIC

ANALYSIS

[Adrenergic receptors] Uchino K, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:540-6 (27 ref.) **(Jpn)**

CLASSIFICATION

[Adrenergic receptors--nomenclature and classification of types and subtypes] Hynie S. **Cesk Fysiol** 1995 Jun; 44(2):107-11 (16 ref.) (Eng. Abstr.) **(Cze)**

GENETICS

Transgenic manipulation of myocardial G protein-coupled receptors and receptor kinases. Koch WJ, et al. **Circ Res** 1996 Apr;78(4):511-6 (29 ref.)

METABOLISM

Adrenaline and its receptors: one hundred years of research. García-Sáinz JA. **Arch Med Res** 1995 Autumn;26(3):205-12 (70 ref.)

Transgenic manipulation of myocardial G protein-coupled receptors and receptor kinases. Koch WJ, et al. **Circ Res** 1996 Apr;78(4):511-6 (29 ref.)

Pharmacology of ingestive behaviour. Samanin R, et al. **Therapie** 1996 Mar-Apr;51(2):107-15 (85 ref.)

PHYSIOLOGY

The role of adrenoceptor-mediated signals in the modulation of lymphocyte function. Sanders VM. **Adv Neuroimmunol** 1995;5(3):283-98 (112 ref.)

Autonomic nervous system dysfunction and adrenoceptor regulation in Parkinson's disease. Clinical and pharmacological consequences. Montastruc JL, et al. **Adv Neurol** 1996;69:377-81 (36 ref.)

Adrenoceptors and serotonin receptor function: relevance to antidepressant mechanisms of action. Potter WZ. **J Clin Psychiatry** 1996;57 Suppl 4:4-8 (45 ref.)

Do receptors get pregnant too? Adrenergic receptor alterations in human pregnancy. Smiley RM, et al. **J Matern Fetal Med** 1996 May-Jun;5(3):106-14 (60 ref.)

Adrenoceptors in SHR: alterations in binding characteristics and intracellular signal transduction pathways. Takata Y, et al. **Life Sci** 1996;58(2):91-106 (199 ref.)

Polyunsaturated fatty acids and signalling via phospholipase C-beta and A2 in myocardium. de Jonge HW, et al. **Mol Cell Biochem** 1996 Apr 12-26;157(1-2):199-210 (79 ref.)

Seminars in medicine of the Beth Israel Hospital, Boston. Adrenergic receptors--evolving concepts and clinical implications. Insel PA. **N Engl J Med** 1996 Feb 29; 334(9):580-5 (47 ref.)

Adrenergic receptor signal transduction and regulation. Hein L, et al. **Neuropharmacology** 1995 Apr;34(4):357-66 (78 ref.)

The role of the locus coeruleus and N-methyl-D-aspartic acid (NMDA) and AMPA receptors in opiate withdrawal. Rasmussen K. **Neuropsychopharmacology** 1995 Dec; 13(4):295-300 (165 ref.)

The adrenergic regulation of the lipid metabolism. Ferlito S. **Panminerva Med** 1996 Mar;38(1):33-6 (30 ref.)

[The sympathetic-adrenergic system in heart failure] Ungerer M, et al. **Dtsch Med Wochenschr** 1996 Feb 2;121(5):141-5 (60 ref.) **(Ger)**

RECEPTORS, ADRENERGIC, ALPHA

CHEMISTRY

alpha 1-adrenergic receptor subtypes. Molecular structure, function, and signaling. Graham RM, et al. **Circ Res** 1996 May;78(5):737-49 (109 ref.)

GENETICS

Vascular alpha-adrenoceptors: from the gene to the human. Bylund DB, et al. **Can J Physiol Pharmacol** 1995 May; 73(5):533-43 (87 ref.)

PHYSIOLOGY

Vascular alpha-adrenoceptors: from the gene to the human. Bylund DB, et al. **Can J Physiol Pharmacol** 1995 May; 73(5):533-43 (87 ref.)

alpha 1-adrenergic receptor subtypes. Molecular structure, function, and signaling. Graham RM, et al. **Circ Res** 1996 May;78(5):737-49 (109 ref.)

Regulation of phospholamban and troponin-I phosphorylation in the intact rat cardiomyocytes by adrenergic and cholinergic stimuli: roles of cyclic nucleotides, calcium, protein kinases and phosphatases and depolarization. Sulakhe PV, et al. **Mol Cell Biochem** 1995 Aug-Sep;149-150:103-26 (96 ref.)

Membrane phospholipids and adrenergic receptor function. Williams S, et al. **Mol Cell Biochem** 1995 Aug-Sep; 149-150:217-21 (47 ref.)

Adrenergic receptors and fat cells: differential recruitment by physiological amines and homologous regulation. Lafontan M, et al. **Obes Res** 1995 Nov;3 Suppl 4:507S-514S (56 ref.)

Pharmacology of descending noradrenergic systems in relation to motor function. Ono H, et al. **Pharmacol Ther** 1995;68(1):105-12 (61 ref.)

RECEPTORS, ADRENERGIC, ALPHA-1

CLASSIFICATION

Classification of alpha 1-adrenoceptor subtypes. Michel MC, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Jul; 352(1):1-10 (70 ref.)

International Union of Pharmacology. X. Recommendation for nomenclature of alpha 1-adrenoceptors: consensus update. Hieble JP, et al. **Pharmacol Rev** 1995 Jun; 47(2):267-70 (41 ref.)

Alpha 1-adrenoceptors: pharmacological classification and newer therapeutic applications. Ruffolo RR Jr, et al. **Proc West Pharmacol Soc** 1995;38:121-6 (59 ref.)

DRUG EFFECTS

Classification of alpha 1-adrenoceptor subtypes. Michel MC, et al. **Naunyn Schmiedebergs Arch Pharmacol** 1995 Jul; 352(1):1-10 (70 ref.)

Alpha 1-adrenoceptors: pharmacological classification and newer therapeutic applications. Ruffolo RR Jr, et al. **Proc West Pharmacol Soc** 1995;38:121-6 (59 ref.)

PHYSIOLOGY

Modulation of Ca2+ channels by alpha 1A- and alpha 2A-adrenoceptors in vascular myocytes: involvement of different transduction pathways. Mironneau J, et al. **Cell Signal** 1995 Jul;7(5):471-9 (29 ref.)

Vascular alpha-1 adrenergic receptor subtypes in the regulation of arterial pressure. Vargas HM, et al. **Life Sci** 1995;57(25):2291-308 (139 ref.)

RECEPTORS, ADRENERGIC, ALPHA-2

CLASSIFICATION

Distribution and pharmacology of alpha 2-adrenoceptors in the central nervous system. MacDonald E, et al. **J Physiol Pharmacol** 1995 Sep;46(3):241-58 (104 ref.)

DRUG EFFECTS

Distribution and pharmacology of alpha 2-adrenoceptors in the central nervous system. MacDonald E, et al. **J Physiol Pharmacol** 1995 Sep;46(3):241-58 (104 ref.)

GENETICS

Molecular pharmacology of alpha 2-adrenoceptor subtypes. Aantaa R, et al. **Ann Med** 1995 Aug;27(4):439-49 (111 ref.)

PHYSIOLOGY

The contribution of alpha 2-noradrenergic mechanisms of prefrontal cortical cognitive function. Potential significance for attention-deficit hyperactivity disorder. Arnsten AF, et al. **Arch Gen Psychiatry** 1996 May;53(5):448-55 (130 ref.)

Modulation of Ca2+ channels by alpha 1A- and alpha 2A-adrenoceptors in vascular myocytes: involvement of different transduction pathways. Mironneau J, et al. **Cell Signal** 1995 Jul;7(5):471-9 (29 ref.)

Fat cell alpha 2-adrenoceptors: the regulation of fat cell function and lipolysis. Lafontan M, et al. **Endocr Rev** 1995 Dec;16(6):716-38 (234 ref.)

Distribution and pharmacology of alpha 2-adrenoceptors in the central nervous system. MacDonald E, et al. **J Physiol Pharmacol** 1995 Sep;46(3):241-58 (104 ref.)

Alpha 2-adrenoceptors and I2 sites in the mammalian central nervous system. French N. **Pharmacol Ther** 1995; 68(2):175-208 (300 ref.)

RECEPTORS, ADRENERGIC, BETA

CHEMISTRY

Structure, function, and regulation of the three beta-adrenergic receptors. Strosberg AD. **Obes Res** 1995 Nov;3 Suppl 4:501S-505S (32 ref.)

DRUG EFFECTS

Differential activation of beta 1-, beta 2- and beta 3-adrenoceptors by catecholamines in white and brown adipocytes. Galitzky J, et al. **Fundam Clin Pharmacol** 1995; 9(4):324-31 (54 ref.)

Beta 3-adrenoceptors and intestinal motility. Manara L, et al. **Fundam Clin Pharmacol** 1995;9(4):332-42 (70 ref.)

Pharmacological characteristics and species-related variations of beta 3-adrenergic receptors. Pietri-Rouxel F, et al. **Fundam Clin Pharmacol** 1995;9(3):211-8 (66 ref.)

Risk assessment of adverse pulmonary effects induced by adrenaline beta-receptor antagonists and rational drug dosage regimen based on receptor occupancy. Yamada Y, et al. **J Pharmacokinet Biopharm** 1995 Oct;23(5):463-78 (30 ref.)

[Adrenergic betablockers] Alvarez Sabín J. **Rev Neurol** 1995; 23 Suppl 2:S185-9 (23 ref.) **(Spa)**

METABOLISM

Signal transduction mechanisms controlling cardiac contractility and their alterations in chronic heart failure. Brodde OE, et al. **Cardiovasc Res** 1995 Oct;30(4):570-84 (214 ref.)

Alterations of beta-adrenoceptor-G-protein-regulated adenylyl cyclase in heart failure. Böhm M. **Mol Cell Biochem** 1995 Jun 7-21;147(1-2):147-60 (84 ref.)

PHYSIOLOGY

Molecular mechanisms of beta-adrenergic relaxation of airway smooth muscle. Kotlikoff MI, et al. **Annu Rev Physiol** 1996;58:115-41 (164 ref.)

Adrenergic control of the force-frequency relation. Ross J Jr, et al. **Circulation** 1995 Oct 15;92(8):2327-32 (48 ref.)

Beta 3-adrenoceptors in the cardiovascular system. Berlan M, et al. **Fundam Clin Pharmacol** 1995;9(3):234-9 (39 ref.)

Beta-adrenergic receptors and G-proteins in the ob/ob mouse. Bégin-Heick N. **Int J Obes Relat Metab Disord** 1996 Mar;20 Suppl 3:S32-5 (21 ref.)

The third beta is not the charm. [editorial; comment] Bond RA, et al. **J Clin Invest** 1996 Jul 15;98(2):241 (8 ref.) Comment on: J Clin Invest 1996 Jul 15;98(2):556-62.

Adrenergic and muscarinic receptor regulation and therapeutic implications in heart failure. Schmitz W, et al. **Mol Cell Biochem** 1996 Apr 12-26;157(1-2):251-8 (91 ref.)

Regulation of phospholamban and troponin-I phosphorylation in the intact rat cardiomyocytes by adrenergic and cholinergic stimuli: roles of cyclic nucleotides, calcium, protein kinases and phosphatases and depolarization. Sulakhe PV, et al. **Mol Cell Biochem** 1995 Aug-Sep;149-150:103-26 (96 ref.)

Membrane phospholipids and adrenergic receptor function. Williams S, et al. **Mol Cell Biochem** 1995 Aug-Sep; 149-150:217-21 (47 ref.)

Adrenergic receptors and fat cells: differential recruitment by physiological amines and homologous regulation. Lafontan M, et al. **Obes Res** 1995 Nov;3 Suppl 4:507S-514S (56 ref.)

Structure, function, and regulation of the three beta-adrenergic receptors. Strosberg AD. **Obes Res** 1995 Nov;3 Suppl 4:501S-505S (32 ref.)

[Beta-receptor and inflammation] Jiang MZ, et al. **Sheng Li Ko Hsueh Chin Chan** 1995 Oct;26(4):370-2 (9 ref.) **(Chi)**

[Adrenergic beta receptors in anesthesia and intensive care medicine] Heesen M, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Mar; 31(2):62-71 (154 ref.) (Eng. Abstr.) **(Ger)**

RECEPTORS, ADRENERGIC, BETA-1

DRUG EFFECTS

Cardiac adrenergic receptor effects of carvedilol. Yoshikawa T, et al. **Eur Heart J** 1996 Apr;17 Suppl B:8-16 (37 ref.)

Differential activation of beta 1-, beta 2- and beta 3-adrenoceptors by catecholamines in white and brown adipocytes. Galitzky J, et al. **Fundam Clin Pharmacol** 1995; 9(4):324-31 (54 ref.)

PHYSIOLOGY

[Adrenergic beta receptors in anesthesia and intensive care medicine] Heesen M, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Mar; 31(2):62-71 (154 ref.) (Eng. Abstr.) **(Ger)**

RECEPTORS, ADRENERGIC, BETA-2

AGONISTS

The use of beta 2-adrenoceptor agonists in the treatment of bronchial asthma. Svedmyr N, et al. **Pharmacol Toxicol** 1996 Jan;78(1):3-11 (94 ref.)

CHEMISTRY

Implications of genetic variability of human beta 2-adrenergic receptor structure. Green SA, et al. **Pulm Pharmacol** 1995 Feb;8(1):1-10 (45 ref.)

DRUG EFFECTS

Cardiac adrenergic receptor effects of carvedilol. Yoshikawa T, et al. **Eur Heart J** 1996 Apr;17 Suppl B:8-16 (37 ref.)

Differential activation of beta 1-, beta 2- and beta 3-adrenoceptors by catecholamines in white and brown adipocytes. Galitzky J, et al. **Fundam Clin Pharmacol** 1995; 9(4):324-31 (54 ref.)

[Beta 2-sympathomimetic drugs] Criée CP, et al. **Internist (Berl)** 1995 Sep;36(9):918-23 (28 ref.) **(Ger)**

GENETICS

Genetic abnormalities of the human beta 2 adrenergic receptor. Potter PC. **Clin Exp Allergy** 1995 Jul;25(7):596-8 (18 ref.)

PHYSIOLOGY

[Adrenergic beta receptors in anesthesia and intensive care medicine] Heesen M, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Mar; 31(2):62-71 (154 ref.) (Eng. Abstr.) **(Ger)**

RECEPTORS, ADRENOCORTICOTROPIC HORMONE see **RECEPTORS, CORTICOTROPIN**

RECEPTORS, AH see **RECEPTORS, ARYL HYDROCARBON**

RECEPTORS, ALBUMIN

IMMUNOLOGY

[The potential attachment sites of hepatitis B virus to the hepatocyte--the pre-S(2) antigen and the receptor for polymerized human serum albumin of hepatitis B virus] Matsuura K, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:125-31 (25 ref.) **(Jpn)**

PHYSIOLOGY

[Clinical significance of the pre-S antigens and the binding activity of polymerized human serum albumin to the receptor on hepatitis B virus particles] Matsuura K, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:265-74 (26 ref.) **(Jpn)**

RECEPTORS, ALDOSTERONE

PHYSIOLOGY

Aldosterone and its mechanism of action: more questions than answers. Fuller PJ. **Aust N Z J Med** 1995 Dec;25(6):800-7 (57 ref.)

RECEPTORS, ALPHA-ADRENERGIC see **RECEPTORS, ADRENERGIC, ALPHA**

RECEPTORS, ALPHA-1 ADRENERGIC see **RECEPTORS, ADRENERGIC, ALPHA-1**

RECEPTORS, ALPHA-2 ADRENERGIC see **RECEPTORS, ADRENERGIC, ALPHA-2**

RECEPTORS, AMPA

GENETICS

Molecular mechanisms controlling calcium entry through AMPA-type glutamate receptor channels. Jonas P, et al. **Neuron** 1995 Nov;15(5):987-90 (30 ref.)

PHYSIOLOGY

Molecular mechanisms controlling calcium entry through AMPA-type glutamate receptor channels. Jonas P, et al. **Neuron** 1995 Nov;15(5):987-90 (30 ref.)

The role of the locus coeruleus and N-methyl-D-aspartic acid (NMDA) and AMPA receptors in opiate withdrawal. Rasmussen K. **Neuropsychopharmacology** 1995 Dec; 13(4):295-300 (165 ref.)

RECEPTORS, ANDROGEN

Androgen receptor: an overview. Chang C, et al. **Crit Rev Eukaryot Gene Expr** 1995;5(2):97-125 (236 ref.)

Roles of estrogen and SHBG in prostate physiology. Farnsworth WE. **Prostate** 1996 Jan;28(1):17-23 (49 ref.)

ANTAGONISTS & INHIBITORS

Anti-androgens in the treatment of prostate cancer. Newling DW. **Br J Urol** 1996 Jun;77(6):776-84 (51 ref.)

DRUG EFFECTS

Androgens, antiandrogens and androgen receptor abnormalities. Kuil CW, et al. **Eur Urol** 1996;29 Suppl 2:78-82 (30 ref.)

Androgen receptor mediated growth control of breast cancer and endometrial cancer modulated by antiandrogen- and androgen-like steroids. Hackenberg R, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1-6 Spec No):113-7 (56 ref.)

GENETICS

Human androgen insensitivity syndrome. Brown TR. **J Androl** 1995 Jul-Aug;16(4):299-303 (17 ref.)

Defects of androgen receptor function: from sex reversal to motor neurone disease. MacLean HE, et al. **Mol Cell Endocrinol** 1995 Aug 11;112(2):133-41 (104 ref.)

Provocative aspects of androgen genetics. Brown TR. **Prostate Suppl** 1996;6:9-12 (14 ref.)

Genetic regulation of androgen action. Kallio PJ, et al. **Prostate Suppl** 1996;6:45-51 (46 ref.)

Androgen regulation of gene expression. Perry JE, et al. **Prostate Suppl** 1996;6:79-81 (22 ref.)

Spinal and bulbar muscular atrophy: a trinucleotide-repeat expansion neurodegenerative disease. Brooks BP, et al. **Trends Neurosci** 1995 Oct;18(10):459-61 (25 ref.)

METABOLISM

Activation of the androgen receptor by polypeptide growth factors and cellular regulators. Culig Z, et al. **World J Urol** 1995;13(5):285-9 (43 ref.)

PHYSIOLOGY

Defects of androgen receptor function: from sex reversal to motor neurone disease. MacLean HE, et al. **Mol Cell Endocrinol** 1995 Aug 11;112(2):133-41 (104 ref.)

[Steroidal sex hormones and insensitivity syndromes] Stárka L, et al. **Bratisl Lek Listy** 1995 Nov;96(11):600-4 (20 ref.) (Eng. Abstr.) **(Slo)**

RECEPTORS, ANF see **RECEPTORS, ATRIAL NATRIURETIC FACTOR**

RECEPTORS, ANGIOTENSIN

Angiotensin II receptor antagonism: losartan - sites and mechanisms of action. Triggle DJ. **Clin Ther** 1995 Nov-Dec;17(6):1005-30 (132 ref.)

Angiotensin receptors and their antagonists. Goodfriend TL, et al. **N Engl J Med** 1996 Jun 20;334(25):1649-54 (81 ref.)

ANALYSIS

Ontogeny of angiotensin II receptors. Shanmugam S, et al. **Cell Biol Int** 1996 Mar;20(3):169-76 (42 ref.)

Angiotensin II--receptor subtypes characterization and pathophysiological implications. Gulati K, et al. **Indian J Exp Biol** 1996 Feb;34(2):91-7 (73 ref.)

ANTAGONISTS & INHIBITORS

Angiotensin-II receptor antagonists: a new class of antihypertensive agents. Weir MR. **Am Fam Physician** 1996 Feb 1;53(2):589-94 (26 ref.)

Direct selective blockade of the vascular angiotensin II receptors in therapy for hypertension and severe congestive heart failure. Awan NA, et al. **Am Heart J** 1996 Jan; 131(1):177-85 (81 ref.)

Angiotensin II receptor blockers. A new class of antihypertensive drugs. Velasquez MT. **Arch Fam Med** 1996 Jun;5(6):351-6 (60 ref.)

Angiotensin II antagonists: a new class of antihypertensive agent. Waeber B, et al. **Br J Clin Pract** 1996 Jul-Aug; 50(5):265-8 (35 ref.)

Angiotensin II receptor antagonists in heart failure: rationale and design of the evaluation of losartan in the elderly (ELITE) trial. Pitt B, et al. **Cardiovasc Drugs Ther** 1995 Oct;9(5):693-700 (80 ref.)

Effects of angiotensin receptor antagonists in heart failure: clinical and experimental aspects. Regitz-Zagrosek V, et al. **Eur Heart J** 1995 Dec;16 Suppl N:86-91 (19 ref.)

Effect of angiotensin II blockade on cardiac hypertrophy and remodelling: a review. Dahlöf B. **J Hum Hypertens** 1995 Nov;9 Suppl 5:S37-44 (84 ref.)

The future role of losartan. Hansson L. **J Hum Hypertens** 1995 Nov;9 Suppl 5:S55-8 (24 ref.)

Discovery of losartan, the first angiotensin II receptor antagonist. Timmermans PB, et al. **J Hum Hypertens** 1995 Nov;9 Suppl 5:S3-18 (199 ref.)

Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy. Wexler RR, et al. **J Med Chem** 1996 Feb 2;39(3):625-56 (326 ref.)

Angiotensin receptor antagonists: focus on losartan. Johnston CI. **Lancet** 1995 Nov 25;346(8987):1403-7 (36 ref.)

Angiotensin II receptor blockers: novel therapy for heart failure? Munger MA, et al. **Pharmacotherapy** 1996 Mar-Apr;16(2 Pt 2):59S-68S (86 ref.)

[Angiotensin receptor antagonists. A new class of antihypertensive agents] Mann J. **Dtsch Med Wochenschr** 1996 Apr 26;121(17):568-71 (22 ref.) **(Ger)**

[Angiotensin II receptor antagonists. Clinical relevance] Scholze J. **Internist (Berl)** 1996 Jun;37(6):636-42 (47 ref.) **(Ger)**

[Inhibitors of renin-angiotensin system] Kawabe H, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:994-7 (18 ref.) **(Jpn)**

[Losartan and the LIFE-study. Antihypertensive treatment with AT1-receptor antagonist] Kjeldsen SE, et al. **Tidsskr Nor Laegeforen** 1996 Feb 10;116(4):504-7 (25 ref.) (Eng. Abstr.) **(Nor)**

[Antagonists of angiotensin II receptor] Karasek D, et al. **Postepy Hig Med Dosw** 1996;50(1):21-32 (64 ref.) (Eng. Abstr.) **(Pol)**

BIOSYNTHESIS

Cloning, expression and regulation of angiotensin II receptors. Inagami T, et al. **Adv Exp Med Biol** 1995; 377:311-7 (36 ref.)

CHEMISTRY

Angiotensin II receptors: protein and gene structures, expression and potential pathological involvements. Clauser E, et al. **Eur J Endocrinol** 1996 Apr;134(4):403-11 (79 ref.)

[Comparative study of the structure and molecular functions of angiotensin II and vasopressin receptors] Clauser E. **C R Seances Soc Biol Fil** 1995;189(2):179-90 (37 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Angiotensin II receptors: protein and gene structures, expression and potential pathological involvements. Clauser E, et al. **Eur J Endocrinol** 1996 Apr;134(4):403-11 (79 ref.)

Molecular biology of angiotensin receptors and their role in human cardiovascular disease. Regitz-Zagrosek V, et al. **J Mol Med** 1996 May;74(5):233-51 (229 ref.)

[Angiotensin receptors--organ and subtype specific regulation in cardiovascular diseases by modulation of the renin-angiotensin system. Studies of the rat model and in human myocardium] Regitz-Zagrosek V, et al. **Z Kardiol** 1995;84 Suppl 4:61-9 (34 ref.) (Eng. Abstr.) **(Ger)**

METABOLISM

The angiotensin type 1 and type 2 receptor families. Siblings or cousins? Fluharty SJ, et al. **Adv Exp Med Biol** 1995; 377:193-215 (99 ref.)

Regulation of angiotensin II receptor expression in ovarian follicles. A review. Nielsen AH, et al. **Adv Exp Med Biol** 1995;377:407-10 (19 ref.)

AT1 receptors and angiotensin actions in the brain and neuronal cultures of normotensive and hypertensive rats. Raizada MK, et al. **Adv Exp Med Biol** 1995;377:331-48 (124 ref.)

Angiotensin II receptors. Structural and functional considerations. Speth RC, et al. **Adv Exp Med Biol** 1995; 377:169-92 (170 ref.)

The role of angiotensin II and its receptors in regulation of adipose tissue metabolism and cellularity. Zorad S, et al. **Gen Physiol Biophys** 1995 Oct;14(5):383-91 (43 ref.)

Importance of tyrosine phosphorylation in angiotensin II type 1 receptor signaling. Schieffer B, et al. **Hypertension** 1996 Mar;27(3 Pt 2):476-80 (51 ref.)

Brain angiotensin receptor subtypes AT1, AT2, and AT4 and their functions. Wright JW, et al. **Regul Pept** 1995 Nov 10;59(3):269-95 (294 ref.)

[Comparative study of the structure and molecular functions of angiotensin II and vasopressin receptors] Clauser E. **C R Seances Soc Biol Fil** 1995;189(2):179-90 (37 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

The role of angiotensin receptor subtypes in cerebrovascular regulation in the rat. Näveri L. **Acta Physiol Scand Suppl** 1995;630:1-48 (170 ref.)

The renin angiotensin system and the stress response. Aguilera G, et al. **Ann N Y Acad Sci** 1995 Dec 29; 771:173-86 (41 ref.)

Angiotensin receptors and their therapeutic implications. Griendling KK, et al. **Annu Rev Pharmacol Toxicol** 1996; 36:281-306 (135 ref.)

Angiotensin II: biosynthesis, molecular recognition, and signal transduction. Riordan JF. **Cell Mol Neurobiol** 1995 Dec;15(6):637-51 (62 ref.)

Angiotensin receptors in the brain. Höhle S, et al. **Pharmacol Toxicol** 1995 Nov;77(5):306-15 (84 ref.)

Angiotensin II and its different receptor subtypes in placenta and fetal membranes. Kalenga MK, et al. **Placenta** 1996 Mar-Apr;17(2-3):103-110 (50 ref.)

RECEPTORS, ANTIGEN

GENETICS

Immediate-early genes induced by antigen receptor stimulation. Kelly K, et al. **Curr Opin Immunol** 1995 Jun; 7(3):327-32 (45 ref.)

Potential targets for autosomal SCID mutations. Taccioli GE, et al. **Curr Opin Immunol** 1995 Aug;7(4):436-40 (50 ref.)

IMMUNOLOGY

Protein tyrosine kinases in the initiation of antigen receptor signaling. Bolen JB. **Curr Opin Immunol** 1995 Jun; 7(3):306-11 (54 ref.)

PHYSIOLOGY

Multisubunit receptors in the immune system and their association with the cytoskeleton: in search of functional significance. Caplan S, et al. **Immunol Res** 1995; 14(2):98-118 (150 ref.)

RECEPTORS, ANTIGEN, B-CELL

IMMUNOLOGY

Unconventional B-cell antigens and human immune repertoires. Silverman GJ. **Ann N Y Acad Sci** 1995 Sep 29;764:342-55 (42 ref.)

Antigen receptor 'capacity' and the sensitivity of self-tolerance. Nemazee D. **Immunol Today** 1996 Jan; 17(1):25-9 (28 ref.)

The B-cell antigen receptor complex and co-receptors. Reth M. **Immunol Today** 1995 Jul;16(7):310-3 (9 ref.)

PHYSIOLOGY

Tolerance sensitivity of immature-stage B cells: can developmentally regulated B cell antigen receptor (BCR) signal transduction play a role? Monroe JG. **J Immunol** 1996 Apr 15;156(8):2657-60 (38 ref.)

Fc gamma RII-mediated regulation of human B cells. Gergely J, et al. **Scand J Immunol** 1996 Jul;44(1):1-10 (70 ref.)

Co-stimulation and co-inhibition: equal partners in regulation. Sinclair NR, et al. **Scand J Immunol** 1996 Jun; 43(6):597-603 (78 ref.)

Receptor tails unlock developmental checkpoints for B lymphocytes [comment] Roth PE, et al. **Science** 1996 Jun 21;272(5269):1752-4 (7 ref.) Comment on: Science 1996 Jun 21;272(5269):1804-8.

The Syk/ZAP-70 protein tyrosine kinase connection to antigen receptor signalling processes. van Oers NS, et al. **Semin Immunol** 1995 Aug;7(4):227-36 (71 ref.)

RECEPTORS, ANTIGEN, T-CELL

see related
ANTIGENS, CD3
GENE REARRANGEMENT, T-LYMPHOCYTE

How selective is the transporter associated with antigen processing? Androlewicz MJ, et al. **Immunity** 1996 Jul; 5(1):1-5 (41 ref.)

T cell receptor usage in autoimmune disease. Olive C. **Immunol Cell Biol** 1995 Aug;73(4):297-307 (174 ref.)

Molecular recognition of antigen involves lattice formation between CD4, MHC class II and TCR molecules. Sakihama T, et al. **Immunol Today** 1995 Dec;16(12):581-7 (43 ref.)

Analysis of TCR usage in human tumors: a new tool for assessing tumor-specific immune responses. Sensi M, et al. **Immunol Today** 1995 Dec;16(12):588-95 (64 ref.)

ANALYSIS

Single T cell probes for antigen/MHC expression. Shastri N. **Curr Opin Immunol** 1995 Apr;7(2):258-62 (33 ref.)

ANTAGONISTS & INHIBITORS

Interaction of antigenic peptides with MHC and TCR molecules. Sette A, et al. **Clin Immunol Immunopathol** 1995 Sep;76(3 Pt 2):S168-71 (7 ref.)

Viral mutations, TCR antagonism and escape from the immune response. Franco A, et al. **Curr Opin Immunol** 1995 Aug;7(4):524-31 (62 ref.)

BIOSYNTHESIS

Biological meaning of the MHC. Ivanyi P. **Folia Biol (Praha)** 1995;41(3-4):178-89 (25 ref.)

CHEMISTRY

T cell receptor peptides in treatment of autoimmune disease: rationale and potential. Vandenbark AA, et al. **J Neurosci Res** 1996 Feb 15;43(4):391-402 (80 ref.)

The structure of the antigen-binding site of immunoglobulins and T-cell receptors. Bentley GA, et al. **Res Immunol** 1995 May-Jun;146(4-5):277-90 (27 ref.)

CLASSIFICATION

The repertoire of T-cell receptors in systemic sclerosis. Yurovsky VV. **Crit Rev Immunol** 1995;15(2):155-65 (66 ref.)

GENETICS

Collagen arthritis in T cell receptor congenic mice. A unique approach to study the role of T cell receptor genotypes in autoimmune arthritis. Nabozny GH, et al. **Adv Exp Med Biol** 1995;383:99-104 (20 ref.)

Genetic dissection of the transducing subunits of the T-cell antigen receptor. Malissen B, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:173-81 (23 ref.)

Molecular and genetic insights into T-cell antigen receptor signaling. Weiss A, et al. **Ann N Y Acad Sci** 1995 Sep 7; 766:149-56 (39 ref.)

T-cell receptor gene analysis in cutaneous T-cell lymphomas. Whittaker S. **Clin Exp Dermatol** 1996 Mar;21(2):81-7 (67 ref.)

Positive selection of T cells. Fowlkes BJ, et al. **Curr Opin Immunol** 1995 Apr;7(2):188-95 (54 ref.)

TCR gene polymorphisms and autoimmune disease. Kay RA. **Eur J Immunogenet** 1996 Apr;23(2):161-77 (129 ref.)

Evolution of major histocompatibility complex polymorphisms and T-cell receptor diversity in primates. Bontrop RE, et al. **Immunol Rev** 1995 Feb;143:33-62 (96 ref.)

T cell repertoire usage in humans, from newborns to centenarians. Cossarizza A, et al. **Int Rev Immunol** 1995; 12(1):41-55 (71 ref.)

T cell development in CD3-zeta mutant mice. Huang MT. **Int Rev Immunol** 1995;13(1):29-41 (81 ref.)

[Susceptibility to multiple sclerosis and T-lymphocyte receptor genes. A synthetic review] Bongioanni P, et al. **Minerva Med** 1995 Dec;86(12):543-9 (57 ref.) (Eng. Abstr.) **(Ita)**

IMMUNOLOGY

The development and use of T cell receptor peptide vaccines. Brostoff S. **Adv Exp Med Biol** 1995;383:249-54 (18 ref.)

Effects of oral antigen in T-cell receptor transgenic mice. Hurst SD, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:163-73 (20 ref.)

Control of T-cell development by the pre-T and alpha beta T-cell receptor. Von Boehmer H. **Ann N Y Acad Sci** 1995 Sep 7;766:52-61 (47 ref.)

Oral tolerance in experimental autoimmune encephalomyelitis. Whitacre CC, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:217-27 (17 ref.)

How MHC class II molecules acquire peptide cargo: biosynthesis and trafficking through the endocytic pathway. Wolf PR, et al. **Ann Rev Cell Dev Biol** 1995; 11:267-306 (169 ref.)

From epitopes to peptides to immunotherapy. Hoyne G, et al. **Clin Immunol Immunopathol** 1996 Sep;80(3 Pt 2):S23-30 (90 ref.)

Natural killer cells. Right-side-up and up-side-down NK-cell receptors. Yokoyama WM. **Curr Biol** 1995 Sep 1;5(9):982-5 (33 ref.)

Viral mutations, TCR antagonism and escape from the immune response. Franco A, et al. **Curr Opin Immunol** 1995 Aug;7(4):524-31 (62 ref.)

T-cell activation: integration of signals from the antigen receptor and costimulatory molecules. Robey E, et al. **Immunol Today** 1995 Jul;16(7):306-10 (29 ref.)

Essential flexibility in the T-cell recognition of antigen. Kersh GJ, et al. **Nature** 1996 Apr 11;380(6574):495-8 (69 ref.)

How T cells count [comment] Rothenberg EV. **Science** 1996 Jul 5;273(5271):78-9 (14 ref.) Comment on: Science 1996 Jul 5;273(5271):104-6.

Decrypting class I MHC-bound peptides with peptide libraries. Udaka K. **Trends Biochem Sci** 1996 Jan;21(1):7-11 (23 ref.)

[Structure and function of the T-lymphocyte antigen receptor and its role in infectious diseases] Peralta Zaragoza O, et al. **Rev Invest Clin** 1996 Jan-Feb;48(1):69-79 (84 ref.) (Eng. Abstr.) **(Spa)**

METABOLISM

Interaction of antigenic peptides with MHC and TCR molecules. Sette A, et al. **Clin Immunol Immunopathol** 1995 Sep;76(3 Pt 2):S168-71 (7 ref.)

RECEPTORS, ANTIGEN, T-CELL

T cell-mediated immune mechanisms in myositis. O'Hanlon TP, et al. **Curr Opin Rheumatol** 1995 Nov;7(6):503-9 (51 ref.)

The structural basis of CD4-MHC class II interactions: coreceptor contributions to T cell receptor antigen recognition and oligomerization-dependent signal transduction. König R, et al. **Curr Top Microbiol Immunol** 1996;205:19-46 (93 ref.)

PHYSIOLOGY

T-cell recognition of antigen. A process controlled by transient intermolecular interactions. Boniface JJ, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:62-9 (34 ref.)

Signal transduction by the B-cell antigen receptor. DeFranco AL, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:195-201 (26 ref.)

Coreceptors and adapter proteins in T-cell signaling. Ravichandran KS, et al. **Ann N Y Acad Sci** 1995 Sep 7; 766:117-33 (91 ref.)

Signal transduction mediated by the T-cell antigen receptor. Samelson LE, et al. **Ann N Y Acad Sci** 1995 Sep 7; 766:157-72 (68 ref.)

Molecular and genetic insights into T-cell antigen receptor signaling. Weiss A, et al. **Ann N Y Acad Sci** 1995 Sep 7; 766:149-56 (39 ref.)

T cell differentiation: control by the pre-TCR and alpha beta TCR. von Boehmer H. **Clin Immunol Immunopathol** 1995 Sep;76(3 Pt 2):S145-50 (47 ref.)

The T cell receptor. Structural and functional studies. Geisler C. **Dan Med Bull** 1995 Sep;42(4):342-57 (187 ref.)

Complex complexes: signaling at the TCR. Wange RL, et al. **Immunity** 1996 Sep;5(3):197-205 (82 ref.)

Molecular mechanism of T-cell activation: role of protein tyrosine kinases in antigen receptor-mediated signal transduction. Thome M, et al. **Res Immunol** 1995 May-Jun; 146(4-5):291-307 (104 ref.)

Co-stimulation and co-inhibition: equal partners in regulation. Sinclair NR, et al. **Scand J Immunol** 1996 Jun; 43(6):597-603 (78 ref.)

The Syk/ZAP-70 protein tyrosine kinase connection to antigen receptor signalling processes. van Oers NS, et al. **Semin Immunol** 1995 Aug;7(4):227-36 (71 ref.)

RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA

Positive selection of thymocytes. Fink PJ, et al. **Adv Immunol** 1995;59:99-133 (144 ref.)

The TCR-beta chain repertoire of gut-derived T lymphocytes. Regnault A, et al. **Semin Immunol** 1995 Oct; 7(5):307-19 (91 ref.)

ANALYSIS

Expression of CD11a and CD45R isoforms defines distinct subsets of CD8+ TCR alpha beta and TCR gamma delta CTL in vivo. Hedlund G, et al. **Immunol Rev** 1995 Aug; 146:82-94 (33 ref.)

[T cell receptor repertoire of infiltrating T cells in the interstitial nephritis of patients with Sjögren's syndrome] Murata H, et al. **Nippon Rinsho** 1995 Oct;53(10):2510-5 (19 ref.) (Eng. Abstr.) **(Jpn)**

BIOSYNTHESIS

Developmental regulation of alpha beta T cell antigen receptor assembly in immature CD4+CD8+ thymocytes. Kearse KP, et al. **Bioessays** 1995 Dec;17(12):1049-54 (41 ref.)

CHEMISTRY

The structure of the antigen-binding site of immunoglobulins and T-cell receptors. Bentley GA, et al. **Res Immunol** 1995 May-Jun;146(4-5):277-90 (27 ref.)

GENETICS

Human T-cell receptor variable gene segment families. Arden B, et al. **Immunogenetics** 1995;42(6):455-500 (151 ref.)

Mouse T-cell receptor variable gene segment families. Arden B, et al. **Immunogenetics** 1995;42(6):501-30 (118 ref.)

Comparison of human and mouse T-cell receptor variable gene segment subfamilies. Clark SP, et al. **Immunogenetics** 1995;42(6):531-40 (31 ref.)

V beta gene repertoire in the aging mouse: a developmental perspective. González-Quintial R, et al. **Int Rev Immunol** 1995;12(1):27-40 (81 ref.)

Lymphocyte development and function in T-cell receptor and RAG-1 mutant mice. Mombaerts P. **Int Rev Immunol** 1995;13(1):43-63 (23 ref.)

[Molecular mechanism on Sjögren's syndrome] Sumida T, et al. **Nippon Rinsho** 1995 Oct;53(10):2395-400 (13 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Control of T-cell development by the pre-T and alpha beta T-cell receptor. Von Boehmer H. **Ann N Y Acad Sci** 1995 Sep 7;766:52-61 (47 ref.)

T cell receptor usage in rheumatoid arthritis. Lanchbury JS, et al. **Br Med Bull** 1995 Apr;51(2):346-58 (62 ref.)

The origin of CD4-CD8-TCR alpha beta+ thymocytes: a model based on T-cell receptor avidity. Budd RC, et al. **Immunol Today** 1995 Sep;16(9):428-31 (27 ref.)

Issues concerning the nature of antigen recognition by alpha beta and gamma delta T-cell receptors. Davis MM, et al. **Immunol Today** 1995 Jul;16(7):316-8 (21 ref.)

[Use of anti-H-Y/Db transgenic mice in studies on T-lymphocyte development and mechanisms of leukemogenesis] Matuszyk J. **Postepy Hig Med Dosw** 1995; 49(1):61-5 (12 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOLOGY

MHC class I-selected CD4-CD8-TCR alpha beta+ T cells: an important source of IL-4. Leite-de-Moraes MC, et al. **Braz J Med Biol Res** 1995 Aug;28(8):903-5 (28 ref.)

T cell differentiation: control by the pre-TCR and alpha beta TCR. von Boehmer H. **Clin Immunol Immunopathol** 1995 Sep;76(3 Pt 2):S145-50 (47 ref.)

RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA

see related
GENE REARRANGEMENT, DELTA-CHAIN T-CELL ANTIGEN RECEPTOR

Development of TCR gamma delta iIELs. Barrett TA, et al. **Semin Immunol** 1995 Oct;7(5):299-305 (27 ref.)

ANALYSIS

Expression of CD11a and CD45R isoforms defines distinct subsets of CD8+ TCR alpha beta and TCR gamma delta CTL in vivo. Hedlund G, et al. **Immunol Rev** 1995 Aug; 146:82-94 (33 ref.)

GENETICS

Transcriptional regulation of the human T cell receptor delta gene. Redondo JM, et al. **Immunobiology** 1995 Jul; 193(2-4):288-92 (14 ref.)

Mouse T-cell receptor variable gene segment families. Arden B, et al. **Immunogenetics** 1995;42(6):501-30 (118 ref.)

Human T-cell receptor variable gene segment families. Arden B, et al. **Immunogenetics** 1995;42(6):455-500 (151 ref.)

Comparison of human and mouse T-cell receptor variable gene segment subfamilies. Clark SP, et al. **Immunogenetics** 1995;42(6):531-40 (31 ref.)

Lymphocyte development and function in T-cell receptor and RAG-1 mutant mice. Mombaerts P. **Int Rev Immunol** 1995;13(1):43-63 (23 ref.)

[Gamma delta T cells--gene to biology] Itohara S. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2118-25 (31 ref.) **(Jpn)**

IMMUNOLOGY

Role of gamma delta T cells in the regulation of mucosal IgA response and oral tolerance. Fujihashi K, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:55-63 (42 ref.)

TCR gamma delta cells: a specialized T-cell subset in the immune system. Bluestone JA, et al. **Ann Rev Cell Dev Biol** 1995;11:307-53 (241 ref.)

Gamma delta T cells. T cells with B-cell-like recognition properties. Chien YH, et al. **Curr Biol** 1995 Oct 1; 5(10):1116-8 (11 ref.)

The enigmatic specificity of gamma delta T cells. Weintraub BC, et al. **Immunol Res** 1995;14(3):163-75 (92 ref.)

Issues concerning the nature of antigen recognition by alpha beta and gamma delta T-cell receptors. Davis MM, et al. **Immunol Today** 1995 Jul;16(7):316-8 (21 ref.)

[Role of gamma-delta T-cells and heat shock proteins in immunological response and in pathogenesis of neurological diseases] Fiszer U. **Neurol Neurochir Pol** 1995 Sep-Oct;29(5):737-45 (30 ref.) (Eng. Abstr.) **(Pol)**

[Gamma delta lymphocytes] Szczepanik M, et al. **Przegl Lek** 1995;52(8):400-2 (41 ref.) **(Pol)**

PHYSIOLOGY

gamma/delta and other unconventional T lymphocytes: what do they see and what do they do? Kaufmann SH. **Proc Natl Acad Sci U S A** 1996 Mar 19;93(6):2272-9 (135 ref.)

RECEPTORS, ARYL HYDROCARBON

[Structure and function of PAS proteins] Sogawa K. **Seikagaku** 1995 Nov;67(11):1283-7 (14 ref.) **(Jpn)**

DRUG EFFECTS

Modulation of gene expression and endocrine response pathways by 2,3,7,8-tetrachlorodibenzo-p-dioxin and related compounds. Safe SH. **Pharmacol Ther** 1995; 67(2):247-81 (369 ref.)

Dioxins: model chemicals for assessing receptor-mediated toxicity. DeVito MJ, et al. **Toxicology** 1995 Sep 1; 102(1-2):115-23 (72 ref.)

GENETICS

Polymorphic forms of the Ah receptor and induction of the CYP1A1 gene. Fujii-Kuriyama Y, et al. **Pharmacogenetics** 1995;5 Spec No:S149-53 (30 ref.)

Xenobiotic receptor knockout mice. Gonzalez FJ, et al. **Toxicol Lett** 1995 Dec;82-83:117-21 (11 ref.)

METABOLISM

Receptor-mediated carcinogenesis: the role of biological effect modeling for risk assessment of dioxin and tamoxifen. Demby KB, et al. **Prog Clin Biol Res** 1996;394:113-29 (57 ref.)

PHYSIOLOGY

Mechanisms for species differences in receptor-mediated carcinogenesis. Barrett JC. **Mutat Res** 1995 Dec; 333(1-2):189-202 (111 ref.)

Receptor-mediated events and the evaluation of the Environmental Protection Agency (EPA) of dioxin risks. Sewall CH, et al. **Mutat Res** 1995 Dec;333(1-2):111-22 (54 ref.)

Receptor-mediated toxicity. Gustafsson JA. **Toxicol Lett** 1995 Dec;82-83:465-70 (24 ref.)

Chlorinated hydrocarbons: estrogens and antiestrogens. Safe S, et al. **Toxicol Lett** 1995 Dec;82-83:731-6 (30 ref.)

RECEPTORS, ATP see **RECEPTORS, PURINERGIC P2**

RECEPTORS, ATRIAL NATRIURETIC FACTOR

PHYSIOLOGY

Defective ANF-R2/ANP-C receptor-mediated signalling in hypertension. Marcil J, et al. **Mol Cell Biochem** 1995 Aug-Sep;149-150:223-31 (92 ref.)

RECEPTORS, ATRIOPEPTIN see **RECEPTORS, ATRIAL NATRIURETIC FACTOR**

RECEPTORS, BENZODIAZEPINE see **RECEPTORS, GABA-A**

RECEPTORS, BENZODIAZEPINE-GABA see **RECEPTORS, GABA-A**

RECEPTORS, BETA-ADRENERGIC see **RECEPTORS, ADRENERGIC, BETA**

RECEPTORS, BETA-1 ADRENERGIC see **RECEPTORS, ADRENERGIC, BETA-1**

RECEPTORS, BETA-2 ADRENERGIC see **RECEPTORS, ADRENERGIC, BETA-2**

RECEPTORS, BIOGENIC AMINE

DRUG EFFECTS

Pharmacology and molecular biology of octopamine receptors from different insect species. Roeder T, et al. **Prog Brain Res** 1995;106:249-58 (32 ref.)

METABOLISM

Agonist-specific coupling of G-protein-coupled receptors to second-messenger systems. Evans PD, et al. **Prog Brain Res** 1995;106:259-68 (35 ref.)

RECEPTORS, BOMBESIN

DRUG EFFECTS

Review article: gastrin releasing peptide and its value in assessing gastric secretory function. McColl KE, et al. **Aliment Pharmacol Ther** 1995 Aug;9(4):341-7 (52 ref.)

PHYSIOLOGY

Bombesin receptors in the brain. Woodruff GN, et al. **Ann N Y Acad Sci** 1996 Mar 22;780:223-43 (74 ref.)

Mammalian bombesin receptors. Kroog GS, et al. **Med Res Rev** 1995 Sep;15(5):389-417 (142 ref.)

RECEPTORS, BRADYKININ

Kinin B1 receptors: a review. Marceau F. **Immunopharmacology** 1995 Jun;30(1):1-26 (176 ref.)

ANTAGONISTS & INHIBITORS

Pharmacology and structure--activity relationships of the nonpeptide bradykinin receptor antagonist WIN 64338. Sawutz DG, et al. **Can J Physiol Pharmacol** 1995 Jul; 73(7):805-11 (32 ref.)

Bradykinin B2 receptor antagonists: development and applications. Stewart JM. **Can J Physiol Pharmacol** 1995 Jul;73(7):787-90 (31 ref.)

Kinin receptor antagonists: unique probes in basic and clinical research. Wirth KJ, et al. **Can J Physiol Pharmacol** 1995 Jul;73(7):797-804 (57 ref.)

RECEPTORS, CAERULEIN see **RECEPTORS, CHOLECYSTOKININ**

RECEPTORS, CALCITONIN

Serpentine receptors for parathyroid hormone, calcitonin and

extracellular calcium ions. Brown EM, et al. **Baillieres Clin Endocrinol Metab** 1996 Jan;10(1):123–61 (173 ref.)

ANALYSIS

Receptors for calcitonin, calcitonin gene related peptide, amylin, and adrenomedullin. Muff R, et al. **Can J Physiol Pharmacol** 1995 Jul;73(7):963–7 (54 ref.)

RECEPTORS, CALCITONIN GENE-RELATED PEPTIDE

ANALYSIS

Receptors for calcitonin, calcitonin gene related peptide, amylin, and adrenomedullin. Muff R, et al. **Can J Physiol Pharmacol** 1995 Jul;73(7):963–7 (54 ref.)

CLASSIFICATION

Pharmacology of receptors for calcitonin gene-related peptide and amylin. Poyner D. **Trends Pharmacol Sci** 1995 Dec;16(12):424–8 (56 ref.)

METABOLISM

Multiple affinity and guanine nucleotide sensitive forms of the calcitonin gene related peptide (CGRP) receptor. Chatterjee TK, et al. **Can J Physiol Pharmacol** 1995 Jul; 73(7):968–73 (34 ref.)

RECEPTORS, CALCITRIOL

DRUG EFFECTS

Vitamin D in the treatment of osteoporosis revisited. Fujita T. **Proc Soc Exp Biol Med** 1996 Jun;212(2):110–5 (76 ref.)

GENETICS

Vitamin D receptor gene alleles and osteoporosis: an affirmative view [editorial] Eisman JA. **J Bone Miner Res** 1995 Sep;10(9):1289–93 (43 ref.)

METABOLISM

Genomic mechanisms involved in the pleiotropic actions of 1,25-dihydroxyvitamin D3. Christakos S, et al. **Biochem J** 1996 Jun 1;316 (Pt 2):361–71 (169 ref.)

New understanding of the molecular mechanism of receptor-mediated genomic actions of the vitamin D hormone. Haussler MR, et al. **Bone** 1995 Aug;17(2 Suppl):33S–38S (30 ref.)

Altered vitamin D metabolism and receptor interaction with the target genes in renal failure: calcitriol receptor interaction with its target gene in renal failure. Hsu CH, et al. **Curr Opin Nephrol Hypertens** 1995 Jul;4(4):302–6 (36 ref.)

Differing shapes of 1 alpha,25-dihydroxyvitamin D3 function as ligands for the D-binding protein, nuclear receptor and membrane receptor: a status report. Norman AW, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1–6 Spec No):13–22 (34 ref.)

Calcipotriol: a new drug for topical psoriasis treatment. Kragballe K. **Pharmacol Toxicol** 1995 Oct;77(4):241–6 (41 ref.)

RECEPTORS, CALCIUM CHANNEL BLOCKER see **CALCIUM CHANNELS**

RECEPTORS, CCK see **RECEPTORS, CHOLECYSTOKININ**

RECEPTORS, CD4 see **ANTIGENS, CD4**

RECEPTORS, CELL-ADHESION PROTEIN see **INTEGRINS**

RECEPTORS, CELL SURFACE

Serpentine receptors for parathyroid hormone, calcitonin and extracellular calcium ions. Brown EM, et al. **Baillieres Clin Endocrinol Metab** 1996 Jan;10(1):123–61 (173 ref.)

The urokinase/urokinase-receptor system and cancer invasion. Conese M, et al. **Baillieres Clin Haematol** 1995 Jun;8(2):365–89 (237 ref.)

Receptors for plasminogen and t-PA: an update. Redlitz A, et al. **Baillieres Clin Haematol** 1995 Jun;8(2):313–27 (95 ref.)

G-protein-coupled receptors in insect cells. Vanden Broeck JJ. **Int Rev Cytol** 1996;164:189–268 (319 ref.)

Urokinase-type plasminogen activator (uPA) and its receptor (CD87): a new target in tumor invasion and metastasis. Schmitt M, et al. **J Obstet Gynaecol** 1995 Apr;21(2):151–65 (60 ref.)

Bacterial transferrin and lactoferrin receptors. Gray-Owen SD, et al. **Trends Microbiol** 1996 May;4(5):185–91 (49 ref.)

[Receptor-mediated targeted gene delivery by ligand-receptor system] Neda H, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2556–61 (15 ref.) **(Jpn)**

ANTAGONISTS & INHIBITORS

Steroid hormones, receptors, and antagonists. Jensen EV. **Ann N Y Acad Sci** 1996 Apr 30;784:1–17 (68 ref.)

Blockade of platelet GPIIb/IIIa receptors as an antithrombotic strategy. Coller BS. **Circulation** 1995 Nov 1;92(9):2373–80 (76 ref.)

Effect of antisense inhibition of Urokinase receptor on malignancy. Ossowski L. **Curr Top Microbiol Immunol** 1996;213 (Pt 3):101–12 (71 ref.)

CHEMISTRY

The G protein-coupled receptor family and one of its members, the TSH receptor. Vassart G, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:23–30 (43 ref.)

NMR structural studies on the zinc finger domains of nuclear hormone receptors. Knegtel RM, et al. **EXS** 1995;73:279–95 (30 ref.)

Molecular characterization of a common binding site for small molecules within the transmembrane domain of G-protein coupled receptors. Cascieri MA, et al. **J Pharmacol Toxicol Methods** 1995 Aug;33(4):179–85 (32 ref.)

Atomic basis of the exquisite specificity of phosphate and sulfate transport receptors. Quiocho FA. **Kidney Int** 1996 Apr;49(4):943–6 (14 ref.)

Structure and function of phospholipase A2 receptor. Ohara O, et al. **Prog Lipid Res** 1995;34(2):117–38 (82 ref.)

CLASSIFICATION

[Nomenclature and classification of membrane receptors and the subtypes] Hynie S. **Cesk Fysiol** 1995 Jun;44(2):102–6 (9 ref.) (Eng. Abstr.) **(Cze)**

GENETICS

G protein-coupled receptor structure and function: the impact of disease-causing mutations. Shenker A. **Baillieres Clin Endocrinol Metab** 1995 Jul;9(3):427–51 (114 ref.)

Mutations in G proteins and G protein-coupled receptors in endocrine disease. Spiegel AM. **J Clin Endocrinol Metab** 1996 Jul;81(7):2434–42 (71 ref.)

Duffy and receptors for P. vivax and chemotactic peptides. Pogo AO, et al. **Transfus Clin Biol** 1995;2(4):269–76 (29 ref.)

[Nuclear hormone receptors] Kallio PJ, et al. **Duodecim** 1994; 110(4):383–94 (40 ref.) **(Fin)**

IMMUNOLOGY

Adhesion receptors in malignant transformation and dissemination of gastrointestinal tumors. Streit M, et al. **J Mol Med** 1996 May;74(5):253–68 (140 ref.)

[Role of Fas system in apoptosis induced by hepatitis C virus infection] Mita E, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:198–202 (14 ref.) **(Jpn)**

METABOLISM

Diversity and selectivity of receptor-G protein interaction. Gudermann T, et al. **Annu Rev Pharmacol Toxicol** 1996; 36:429–59 (216 ref.)

Dynamic regulation of G-protein coupled receptor palmitoylation: potential role in receptor function. Bouvier M, et al. **Biochem Soc Trans** 1995 Aug;23(3):577–81 (35 ref.)

Interaction of protein kinase C with RACK1, a receptor for activated C-kinase: a role in beta protein kinase C mediated signal transduction. Mochly-Rosen D, et al. **Biochem Soc Trans** 1995 Aug;23(3):596–600 (32 ref.)

Cross-linking reconsidered: binding and cross-linking fields and the cellular response. Sulzer B, et al. **Biophys J** 1996 Mar;70(3):1154–68 (60 ref.)

Platelet activation. Blockmans D, et al. **Blood Rev** 1995 Sep; 9(3):143–56 (124 ref.)

Some tumor cell protein kinases activated by receptors as markers, including elastin receptors. Parsons DF. **Cancer Invest** 1995;13(6):629–36 (61 ref.)

Interaction of tumour cells with elastin and the metastatic phenotype. Timár J, et al. **Ciba Found Symp** 1995; 192:321–35; discussion 335–7 (44 ref.)

Transcriptional control by protein phosphorylation: signal transmission from the cell surface to the nucleus. Karin M, et al. **Curr Biol** 1995 Jul 1;5(7):747–57 (102 ref.)

Developmental signaling. Vertebrate ligands for Notch. Nye JS, et al. **Curr Biol** 1995 Sep 1;5(9):966–9 (25 ref.)

Cell signalling. Receptor orphans find a family. Pandey A, et al. **Curr Biol** 1995 Sep 1;5(9):986–9 (30 ref.)

Microbial recognition of target-cell glycoconjugates. Karlsson KA. **Curr Opin Struct Biol** 1995 Oct;5(5):622–35 (74 ref.)

G protein-coupled receptors and signaling pathways regulating growth responses. Post GR, et al. **FASEB J** 1996 May;10(7):741–9 (137 ref.)

Adhesion molecules and cell surface receptors in the heart transplant-associated arteriosclerosis. Hinek A. **Folia Histochem Cytobiol** 1996;34(1):3–19 (140 ref.)

Association of leukocyte surface receptors with protein kinases. Hořejší V. **Int Arch Allergy Immunol** 1996 May; 110(1):1–6 (27 ref.)

Receptor mediated glycotargeting. Wadhwa MS, et al. **J Drug Target** 1995;3(2):111–27 (179 ref.)

The Duffy antigen receptor for chemokines: structural analysis and expression in the brain. Horuk R, et al. **J Leukoc Biol** 1996 Jan;59(1):29–38 (28 ref.)

Immunomodulatory role of melatonin: specific binding sites in human and rodent lymphoid cells. Calvo JR, et al. **J Pineal Res** 1995 Apr;18(3):119–26 (64 ref.)

The orphan receptor family RZR/ROR, melatonin and 5-lipoxygenase: an unexpected relationship. Carlberg C, et al. **J Pineal Res** 1995 May;18(4):171–8 (51 ref.)

A new receptor for growth hormone-release peptide [comment] Conn PM, et al. **Science** 1996 Aug 16; 273(5277):923 (13 ref.) Comment on: Science 1996 Aug 16;273(5277):974–7.

Ethylene sensors: how perceptive! [comment] Theologis A. **Science** 1995 Dec 15;270(5243):1774 (10 ref.) Comment on: Science 1995 Dec 15;270(5243):1804. Comment on: Science 1995 Dec 15;270(5243):1807–9. Comment on: Science 1995 Dec 15;270(5243):1809–11.

Role of verotoxin receptors in pathogenesis. Lingwood CA. **Trends Microbiol** 1996 Apr;4(4):147–53 (89 ref.)

Is there a 'lock' for all agonist 'keys' in 7TM receptors? Schwartz TW, et al. **Trends Pharmacol Sci** 1996 Jun; 17(6):213–6 (37 ref.)

An evolutionary view of drug-receptor interaction: the bioamine receptor family. Vernier P, et al. **Trends Pharmacol Sci** 1995 Nov;16(11):375–81 (56 ref.)

Signals that make you different: receptor-mediated signal transduction in early development. Saxe CL 3rd. **Zygote** 1994 Aug;2(3):179–83 (42 ref.)

[Nuclear hormone receptors] Kallio PJ, et al. **Duodecim** 1994; 110(4):383–94 (40 ref.) **(Fin)**

[Vascular aging. Role of elastin receptor] Robert L. **C R Seances Soc Biol Fil** 1995;189(6):959–66 (21 ref.) (Eng. Abstr.) **(Fre)**

[Establishment of in vitro model for HBV infection via asialoglycoprotein receptor] Neda H, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:121–4 (15 ref.) **(Jpn)**

[Interaction of cytokines with cellular receptors] Danilkovich AV, et al. **Biokhimiia** 1995 Sep;60(9):1382–95 (102 ref.) (Eng. Abstr.) **(Rus)**

[Cell membrane targets and steroid hormones: the beginning or end of the dispute?] Sergeev PV, et al. **Biull Eksp Biol Med** 1995 Oct;120(10):342–8 (22 ref.) **(Rus)**

[Structure and functional properties of GTP-binding proteins of plasma membranes] Usatiuk SA, et al. **Ukr Biokhim Zh** 1995 Jan-Feb;67(1):14–25 (25 ref.) (Eng. Abstr.) **(Ukr)**

PHYSIOLOGY

The First Annual Bayard D. Catherwood Memorial Lecture. Ca2+-receptor-mediated regulation of parathyroid and renal function. Brown EM, et al. **Am J Med Sci** 1996 Sep; 312(3):99–109 (69 ref.)

BMP signaling in Drosophila embryogenesis. Arora K, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:80–97 (68 ref.)

Steroid hormones, receptors, and antagonists. Jensen EV. **Ann N Y Acad Sci** 1996 Apr 30;784:1–17 (68 ref.)

Signaling pathways in skeletal formation: a role for BMP receptors. Rosen V, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:59–69 (45 ref.)

The G protein-coupled receptor family and one of its members, the TSH receptor. Vassart G, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:23–30 (43 ref.)

Biological specificity and measurable physical properties of cell surface receptors and their possible role in signal transduction through the cytoskeleton. Forgacs G. **Biochem Cell Biol** 1995 Jul-Aug;73(7–8):317–26 (50 ref.)

Evidence that molecules on the surface of one cell can adhere to the oligosaccharide portion of gangliosides on the surface of another cell. Schengrund CL. **Biol Signals** 1995 Jan-Feb;4(1):1–13 (85 ref.)

Cloning and functional characterization of extracellular Ca(2+)-sensing receptors from parathyroid and kidney. Brown EM, et al. **Bone** 1995 Aug;17(2 Suppl):7S–11S (30 ref.)

Calcium ions as extracellular messengers. Brown EM, et al. **Cell** 1995 Dec 1;83(5):679–82 (20 ref.)

Serpentine proteins slither into the wingless and hedgehog fields. Perrimon N. **Cell** 1996 Aug 23;86(4):513–6 (19 ref.)

Melatonin madness. Reppert SM, et al. **Cell** 1995 Dec 29; 83(7):1059–62 (19 ref.)

Ligand-independent hormone secretion. Laue L. **Curr Opin Pediatr** 1995 Aug;7(4):434–9 (47 ref.)

Dynamin and receptor-mediated endocytosis. Damke H. **FEBS Lett** 1996 Jun 24;389(1):48–51 (49 ref.)

Delivery of DNA into mammalian cells by receptor-mediated endocytosis and gene therapy. Guy J, et al. **Mol Biotechnol** 1995 Jun;3(3):237–48 (60 ref.)

Oxygen-radical/nitric oxide mediate calcium-dependent hormone action on cyclic GMP system: a novel concept in signal transduction mechanisms. Mittal CK. **Mol Cell Biochem** 1995 Aug-Sep;149–150:257–62 (37 ref.)

Receptor-mediated mechanisms in carcinogenesis: an overview. Capen CC, et al. **Mutat Res** 1995 Dec; 333(1–2):215–24 (15 ref.)

The role of receptors in multistage carcinogenesis. Pitot HC. **Mutat Res** 1995 Dec;333(1–2):3–14 (87 ref.)

Role of receptors in human and rodent hepatocarcinogenesis. Schwarz M, et al. **Mutat Res** 1995 Dec;333(1–2):69–79 (52 ref.)

A brief appraisal on some aspects of the receptor-receptor

interaction. Agnati LF, et al. **Neurochem Int** 1995 Aug; 27(2):139–46 (43 ref.)
Roles of steroid hormones and their receptors in structural organization in the nervous system. Kawata M. **Neurosci Res** 1995 Dec;24(1):1–46 (655 ref.)
Receptor cell biology: receptor-mediated endocytosis. Schwartz AL. **Pediatr Res** 1995 Dec;38(6):835–43 (133 ref.)
Ion channel regulation by G proteins. Wickman K, et al. **Physiol Rev** 1995 Oct;75(4):865–85 (261 ref.)
Desensitization of G protein–coupled receptors. Freedman NJ, et al. **Recent Prog Horm Res** 1996;51:319–51; discussion 352–3 (109 ref.)
Cross-linking of cell surface receptors as a trigger or cell apoptosis and proliferation. Korystov YN. **Scanning Microsc** 1995 Sep;9(3):757–62 (55 ref.)
Platelet activation: signal transduction via membrane receptors. Clemetson KJ. **Thromb Haemost** 1995 Jul; 74(1):111–6 (57 ref.)
Cellular receptors in the regulation of plasmin generation. Hajjar KA. **Thromb Haemost** 1995 Jul;74(1):294–301 (113 ref.)
The nuclear hormone-receptor family in the brain: classics and orphans. Lopes da Silva S, et al. **Trends Neurosci** 1995 Dec;18(12):542–8 (47 ref.)
Regulation of G protein–coupled receptors by receptor kinases and arrestins. Sterne-Marr R, et al. **Vitam Horm** 1995;51:193–234 (121 ref.)
[Receptors—one component of intercellular communication pathways] Mysliveček J. **Cesk Fysiol** 1996 Jun;45(2):99–111 (38 ref.) (Eng. Abstr.) **(Cze)**
[Evolution of the endocrine system] Leinonen P. **Duodecim** 1994;110(10):939–48 (28 ref.) **(Fin)**
[Regulatory factors in food intake: glucoreceptor neuron and gluco-sensitive neuron] Aou S, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:26–32 (20 ref.) **(Jpn)**
[Receptor-mediated signal transduction] Murayama T. **Yakugaku Zasshi** 1996 Apr;116(4):309–22 (31 ref.) (Eng. Abstr.) **(Jpn)**
[The Fas/APO-1 antigen—a molecule mediating apoptosis] Baryshnikov AIu, et al. **Gematol Transfuziol** 1995 Nov-Dec;40(6):35–8 (28 ref.) **(Rus)**

RECEPTORS, CGRP see **RECEPTORS, CALCITONIN GENE-RELATED PEPTIDE**

RECEPTORS, CHOLECYSTOKININ

ANTAGONISTS & INHIBITORS

[Gastrin/CCK-B receptor antagonists for a novel antiulcer agent] Miyata K, et al. **Nippon Yakurigaku Zasshi** 1995 Sep;106(3):171–80 (38 ref.) (Eng. Abstr.) **(Jpn)**

DRUG EFFECTS

[Cholecystokinin receptors. A target for tomorrow's psychopharmaceuticals?] Zachrisson O, et al. **Lakartidningen** 1996 Mar 27;93(13):1225–7 (47 ref.) (Eng. Abstr.) **(Swe)**

GENETICS

Cholecystokinin receptors [editorial] Wank SA. **Am J Physiol** 1995 Nov;269(5 Pt 1):G628–46 (245 ref.)

PHYSIOLOGY

Cholecystokinin receptors [editorial] Wank SA. **Am J Physiol** 1995 Nov;269(5 Pt 1):G628–46 (245 ref.)
Cholecystokinin receptors. Boden P, et al. **Cell Mol Neurobiol** 1995 Oct;15(5):545–59 (64 ref.)

RECEPTORS, CHOLINERGIC

ANTAGONISTS & INHIBITORS

Noncompetitive inhibitors of the acetylcholine receptor help paint a picture of its ion channel. Eterovic VA, et al. **P R Health Sci J** 1995 Sep;14(3):199–209 (71 ref.)
Cholinergic channel activators: novel opportunities for the treatment of CNS disorders. Sullivan JP, et al. **Proc West Pharmacol Soc** 1995;38:127–30 (29 ref.)

CLASSIFICATION

Neuronal nicotinic receptors: molecular organization and regulations. Galzi JL, et al. **Neuropharmacology** 1995 Jun; 34(6):563–82 (215 ref.)

DRUG EFFECTS

[An anticholinergic syndrome with hallucinatory psychosis after diphenhydramine poisoning] Lang K, et al. **Dtsch Med Wochenschr** 1995 Dec 8;120(49):1695–8 (17 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

Autoimmune recognition of acetylcholine receptor and manipulation of the autoimmune responses by synthetic peptides. Atassi MZ, et al. **Adv Exp Med Biol** 1995; 383:141–56 (71 ref.)
Establishment of a mouse model of myasthenia gravis which mimics human myasthenia gravis pathogenesis for immune intervention. Christadoss P, et al. **Adv Exp Med Biol** 1995; 383:195–9 (16 ref.)

PHYSIOLOGY

Acetylcholine receptors and the cytoskeletal connection. Phillips WD. **Clin Exp Pharmacol Physiol** 1995 Dec; 22(12):961–5 (40 ref.)
Cholinergic and purinergic signalling in outer hair cells of mammalian cochlea. Heilbronn E, et al. **Neurochem Int** 1995 Oct-Nov;27(4–5):301–11 (79 ref.)
[Cholinergic-dependent airway obstruction] Małolepszy J. **Pneumonol Alergol Pol** 1995;63(5–6):319–21 (17 ref.) **(Pol)**

RECEPTORS, CHORIONIC GONADOTROPIN see **RECEPTORS, LH**

RECEPTORS, COLONY-STIMULATING FACTOR

GENETICS

Function of PU.1 (Spi-1), C/EBP, and AML1 in early myelopoiesis: regulation of multiple myeloid CSF receptor promoters. Zhang DE, et al. **Curr Top Microbiol Immunol** 1996;211:137–47 (61 ref.)

RECEPTORS, COMPLEMENT

Erythrocyte complement receptors. Birmingham DJ. **Crit Rev Immunol** 1995;15(2):133–54 (155 ref.)
Complement receptors in neutrophils. Sengeløv H. **Crit Rev Immunol** 1995;15(2):107–31 (223 ref.)

PHYSIOLOGY

Human regulator of complement activation (RCA) gene family proteins and their relationship to microbial infection. Seya T. **Microbiol Immunol** 1995;39(5):295–305 (82 ref.)

RECEPTORS, CORTICOSTEROID see **RECEPTORS, STEROID**

RECEPTORS, CORTICOTROPIN

The ACTH receptor. Clark AJ, et al. **Baillieres Clin Endocrinol Metab** 1996 Jan;10(1):29–47 (82 ref.)
[Progress in the study of the central ACTH receptors] Fang Y, et al. **Sheng Li Ko Hsueh Chin Chan** 1995 Jul; 26(3):199–203 (19 ref.) (Eng. Abstr.) **(Chi)**

PHYSIOLOGY

ACTH-related peptides: receptors and signal transduction systems involved in their neurotrophic and neuroprotective actions. Hol EM, et al. **Peptides** 1995;16(5):979–93 (150 ref.)
The melanocortin receptors: agonists, antagonists, and the hormonal control of pigmentation. Cone RD, et al. **Recent Prog Horm Res** 1996;51:287–317; discussion 318 (102 ref.)

RECEPTORS, CORTICOTROPIN-RELEASING HORMONE

CLASSIFICATION

Characterization of corticotropin-releasing factor receptor subtypes. Grigoriadis DE, et al. **Ann N Y Acad Sci** 1996 Mar 22;780:60–80 (60 ref.)

METABOLISM

Corticotropin releasing factor (CRF) binding protein: a novel regulator of CRF and related peptides. Behan DP, et al. **Front Neuroendocrinol** 1995 Oct;16(4):362–82 (87 ref.)

RECEPTORS, CRH see **RECEPTORS, CORTICOTROPIN-RELEASING HORMONE**

RECEPTORS, CYCLIC AMP

see related
CYCLIC AMP-DEPENDENT PROTEIN KINASES
CYCLIC AMP RECEPTOR PROTEIN

RECEPTORS, CYTOKINE

ANALYSIS

Plasma concentrations of cytokines, their soluble receptors, and antioxidant vitamins can predict the development of multiple organ failure in patients at risk. Borrelli E, et al. **Crit Care Med** 1996 Mar;24(3):392–7 (38 ref.)
Analysis of receptors for cytokines and growth factors in human disease. Zola H. **Dis Markers** 1996 Mar;12(4):225–40 (57 ref.)
Assays for measuring soluble cellular adhesion molecules and soluble cytokine receptors. Meager A, et al. **J Immunol Methods** 1996 May 27;191(2):97–112 (146 ref.)

ANTAGONISTS & INHIBITORS

Selectivity and antagonism of chemokine receptors. Wells TN, et al. **J Leukoc Biol** 1996 Jan;59(1):53–60 (25 ref.)

CHEMISTRY

Structural aspects of receptor dimerization. c-kit as an example. Blechman JM, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:344–62 (79 ref.)
Structural aspects of cytokine/receptor interactions. Nicola NA. **Ann N Y Acad Sci** 1995 Sep 7;766:253–62 (23 ref.)
Transmembrane and intracellular signalling by interleukin-4: receptor dimerization and beyond. Duschl A, et al. **Eur Cytokine Netw** 1996 Jan-Mar;7(1):37–49 (122 ref.)
[The classes, structures, functions and signaling transduction of cytokine receptors] Lu J. **Sheng Li Ko Hsueh Chin Chan** 1995 Oct;26(4):305–11 (20 ref.) (Eng. Abstr.) **(Chi)**

GENETICS

Cytokine signaling in mesothelial cells: receptor expression closes the autocrine loop. Gerwin BI. **Am J Respir Cell Mol Biol** 1996 Jun;14(6):505–7 (27 ref.)
The molecular basis of X-linked severe combined immunodeficiency: defective cytokine receptor signaling. Leonard WJ. **Annu Rev Med** 1996;47:229–39 (52 ref.)
Dysfunctional cytokine receptor signaling in severe combined immunodeficiency. Leonard WJ. **J Investig Med** 1996 Aug;44(6):304–11 (66 ref.)
New members of the chemokine receptor gene family. Raport CJ, et al. **J Leukoc Biol** 1996 Jan;59(1):18–23 (33 ref.)
Cytokine receptor genes: structure, chromosomal location, and involvement in human disease. Baird PN, et al. **Leuk Lymphoma** 1995 Aug;18(5–6):373–83 (130 ref.)
Duffy and receptors for P. vivax and chemotactic peptides. Pogo AO, et al. **Transfus Clin Biol** 1995;2(4):269–76 (29 ref.)
Cloning and characterization of human chemokine receptors. Power CA, et al. **Trends Pharmacol Sci** 1996 Jun; 17(6):209–13 (4 ref.)

IMMUNOLOGY

Cytokine receptor signaling mechanisms. Karnitz LM, et al. **Curr Opin Immunol** 1995 Jun;7(3):320–6 (60 ref.)

METABOLISM

Structural aspects of receptor dimerization. c-kit as an example. Blechman JM, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:344–62 (79 ref.)
Structural aspects of cytokine/receptor interactions. Nicola NA. **Ann N Y Acad Sci** 1995 Sep 7;766:253–62 (23 ref.)
Soluble cytokine receptors. Heaney ML, et al. **Blood** 1996 Feb 1;87(3):847–57 (146 ref.)
Chemoattractants attract HIV researchers [comment] Moore JP, et al. **J Exp Med** 1996 Aug 1;184(2):311–3 (35 ref.) Comment on: J Exp Med 1996 Aug 1;184(2):569–77.
The Duffy antigen receptor for chemokines: structural analysis and expression in the brain. Horuk R, et al. **J Leukoc Biol** 1996 Jan;59(1):29–38 (28 ref.)
Selectivity and antagonism of chemokine receptors. Wells TN, et al. **J Leukoc Biol** 1996 Jan;59(1):53–60 (25 ref.)
Cytokine receptor signalling. Ihle JN. **Nature** 1995 Oct 19; 377(6550):591–4 (93 ref.)
Cloning and characterization of human chemokine receptors. Power CA, et al. **Trends Pharmacol Sci** 1996 Jun; 17(6):209–13 (4 ref.)

PHYSIOLOGY

Signaling by the cytokine receptor superfamily in normal and transformed hematopoietic cells. Ihle JN. **Adv Cancer Res** 1996;68:23–65 (263 ref.)
Cytokines: sources, receptors and signalling. Barrett KE. **Baillieres Clin Gastroenterol** 1996 Mar;10(1):1–15 (60 ref.)
Chemokine receptors and HIV-1: an attractive pair? Bates P. **Cell** 1996 Jul 12;86(1):1–3 (15 ref.)
Cytokine receptors encoded by poxviruses: a lesson in cytokine biology. Alcami A, et al. **Immunol Today** 1995 Oct;16(10):474–8 (39 ref.)
Soluble cytokine receptors in disease. Barak V. **Isr J Med Sci** 1995 Sep;31(9):565–71 (82 ref.)
Cytokine receptor signalling through two novel families of transducer molecules: Janus kinases, and signal transducers and activators of transcription. Finidori J, et al. **J Endocrinol** 1995 Oct;147(1):11–23 (117 ref.)
Regulation of cytokine gene expression: tumor necrosis factor, interleukin-1, and the emerging biology of cytokine receptors. Williams G, et al. **New Horiz** 1995 May; 3(2):276–87 (123 ref.)
Alpha 4 integrin-induced cytokine production and eosinophil function. Broide DH. **Springer Semin Immunopathol** 1995; 16(4):405–15 (85 ref.)
The physiologic role and therapeutic potential of the Mpl-ligand in thrombopoiesis. Hunt P. **Stem Cells** 1995 Nov;13(6):579–87 (66 ref.)
Chemokines, inflammation and the immune system. Taub DD, et al. **Ther Immunol** 1994 Aug;1(4):229–46 (190 ref.)
[The classes, structures, functions and signaling transduction of cytokine receptors] Lu J. **Sheng Li Ko Hsueh Chin Chan** 1995 Oct;26(4):305–11 (20 ref.) (Eng. Abstr.) **(Chi)**

RECEPTORS, CYTOPLASMIC AND NUCLEAR

see related
TRANSCRIPTION FACTORS

The inositol triphosphate receptor family. Joseph SK. **Cell Signal** 1996 Jan;8(1):1-7 (97 ref.)

CHEMISTRY

Human nuclear receptor heterodimers: opportunities for detecting targets of transcriptional regulation using yeast. Butt TR, et al. **Gene Expr** 1996;5(4-5):255-68 (87 ref.)

Transcription factors 3: nuclear receptors. Gronemeyer H, et al. **Protein Profile** 1995;2(11):1173-308 (3351 ref.)

DRUG EFFECTS

PPAR: a mediator of peroxisome proliferator action. Green S. **Mutat Res** 1995 Dec;333(1-2):101-9 (65 ref.)

Pharmacological modulators of the inositol 1,4,5-trisphosphate receptor. Michelangeli F, et al. **Neuropharmacology** 1995 Sep;34(9):1111-22 (108 ref.)

GENETICS

Xenobiotic receptor knockout mice. Gonzalez FJ, et al. **Toxicol Lett** 1995 Dec;82-83:117-21 (11 ref.)

[Nuclear receptors and ontogenesis of the hematopoietic tissue] Chomienne C, et al. **C R Seances Soc Biol Fil** 1995; 189(4):493-501 (34 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

The inositol trisphosphate receptor of Xenopus oocytes. Parys JB, et al. **Cell Calcium** 1995 Nov;18(5):353-63 (89 ref.)

Convergence of model systems for peroxisome biogenesis. Subramani S. **Curr Opin Cell Biol** 1996 Aug;8(4):513-8 (52 ref.)

Insect nuclear receptors: a developmental and comparative perspective. Henrich VC, et al. **Insect Biochem Mol Biol** 1995 Sep;25(8):881-97 (149 ref.)

Intracellular receptors and signal transducers and activators of transcription superfamilies: novel targets for small-molecule drug discovery. Rosen J, et al. **J Med Chem** 1995 Dec 8;38(25):4855-74 (124 ref.)

The inositol 1,4,5-trisphosphate (InsP3) receptor. Bezprozvanny I, et al. **J Membr Biol** 1995 Jun; 145(3):205-16 (131 ref.)

The orphan receptor family RZR/ROR, melatonin and 5-lipoxygenase: an unexpected relationship. Carlberg C, et al. **J Pineal Res** 1995 May;18(4):171-8 (51 ref.)

Polyunsaturated fatty acid regulation of hepatic gene transcription. Clarke SD, et al. **Lipids** 1996 Mar;31 Suppl:S7-11 (50 ref.)

Transcription factors 3: nuclear receptors. Gronemeyer H, et al. **Protein Profile** 1995;2(11):1173-308 (3351 ref.)

[Mechanisms of mobilization of intracellular stored calcium] Li HW, et al. **Sheng Li Ko Hsueh Chin Chan** 1995 Jul; 26(3):209-12 (17 ref.) (Eng. Abstr.) **(Chi)**

PHYSIOLOGY

The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation. Schoonjans K, et al. **Biochim Biophys Acta** 1996 Jul 26;1302(2):93-109 (259 ref.)

Nonsteroid nuclear receptors: what are genetic studies telling us about their role in real life? Kastner P, et al. **Cell** 1995 Dec 15;83(6):859-69 (71 ref.)

The nuclear receptor superfamily: the second decade. Mangelsdorf DJ, et al. **Cell** 1995 Dec 15;83(6):835-9 (21 ref.)

From embryogenesis to metamorphosis: the regulation and function of Drosophila nuclear receptor superfamily members. Thummel CS. **Cell** 1995 Dec 15;83(6):871-7 (56 ref.)

Regulation of adipocyte gene expression and differentiation by peroxisome proliferator activated receptor gamma. Tontonoz P, et al. **Curr Opin Genet Dev** 1995 Oct; 5(5):571-6 (51 ref.)

Co-activators and co-repressors: mediators of gene activation by nuclear hormone receptors. Meier CA. **Eur J Endocrinol** 1996 Feb;134(2):158-9 (5 ref.)

Inositolpolyphosphate binding sites and their likely role in calcium regulation in smooth muscle. Zhang L, et al. **Int J Biochem Cell Biol** 1995 Dec;27(12):1231-48 (135 ref.)

Calcium and inositol trisphosphate receptors. Taylor CW, et al. **J Membr Biol** 1995 May;145(2):109-18 (108 ref.)

Inositolpolyphosphates and their binding proteins--a short review. Huisamen B, et al. **Mol Cell Biochem** 1996 Apr 12-26;157(1-2):229-32 (29 ref.)

Mechanisms for species differences in receptor-mediated carcinogenesis. Barrett JC. **Mutat Res** 1995 Dec; 333(1-2):189-202 (111 ref.)

Receptor-mediated toxicity. Gustafsson JA. **Toxicol Lett** 1995 Dec;82-83:465-70 (24 ref.)

[Receptors--one component of intercellular communication pathways] Mysliveček J. **Cesk Fysiol** 1996 Jun;45(2):99-111 (38 ref.) (Eng. Abstr.) **(Cze)**

[Toward the treatment of obesity: role of PPAR gamma in adipogenesis] Motojima K. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(13):1936-41 (32 ref.) **(Jpn)**

RECEPTORS, DELTA see **RECEPTORS, OPIOID, DELTA**

RECEPTORS, DELTA OPIOID see **RECEPTORS, OPIOID, DELTA**

RECEPTORS, DIAZEPAM see **RECEPTORS, GABA-A**

RECEPTORS, DIIODOTYROSINE see **RECEPTORS, THYROID HORMONE**

RECEPTORS, DIOXIN see **RECEPTORS, ARYL HYDROCARBON**

RECEPTORS, DOPAMINE

BIOSYNTHESIS

Expression of newly cloned brain dopamine receptors in peripheral organs. O'Connell DP. **Biochem Soc Trans** 1996 Feb;24(1):169-72 (16 ref.)

CHEMISTRY

The binding of agonists and antagonists to dopamine receptors. Strange PG. **Biochem Soc Trans** 1996 Feb; 24(1):188-92 (28 ref.)

Dopamine receptors--the present state of research and perspectives. Wolfarth S, et al. **Pol J Pharmacol** 1995 May-Jun;47(3):207-18 (95 ref.)

CLASSIFICATION

Does the dopamine receptor subtype selectivity of antipsychotic agents provide useful leads for the development of novel therapeutic agents? Hacksell U, et al. **Pharmacol Toxicol** 1995 May;76(5):320-4 (21 ref.)

[Dopaminergic receptors--nomenclature and classification of types and subtypes] Hynie S. **Cesk Fysiol** 1995 Sep; 44(3):131-4 (10 ref.) (Eng. Abstr.) **(Cze)**

DRUG EFFECTS

Aminotetralin drugs and D3 receptor functions. What may partially selective D3 receptor ligands tell us about dopamine D3 receptor functions? Lévesque D. **Biochem Pharmacol** 1996 Aug 23;52(4):511-8 (102 ref.)

Pharmacological characterisation and autoradiographic localisation of dopamine receptor subtypes in the cardiovascular system and in the kidney. Amenta F, et al. **Hypertens Res** 1995 Jun;18 Suppl 1:S23-7 (10 ref.)

Apomorphine continuous stimulation in Parkinson's disease: receptor desensitization as a possible mechanism of reduced motor response. Maggio R, et al. **J Neural Transm Suppl** 1995;45:133-6 (22 ref.)

Behavioral sensitization and tolerance to cocaine and the occupation of dopamine receptors by dopamine. Martin-Iverson MT, et al. **Mol Neurobiol** 1995 Aug-Dec; 11(1-3):31-46 (69 ref.)

New insights into the biology of schizophrenia through the mechanism of action of clozapine. Brunello N, et al. **Neuropsychopharmacology** 1995 Nov;13(3):177-213 (400 ref.)

[Neuroleptics and nicotine] Erdmann R. **Psychiatr Prax** 1995 Nov;22(6):223-7 (34 ref.) (Eng. Abstr.) **(Ger)**

GENETICS

The dopamine D3 receptor and schizophrenia: pharmacological, anatomical and genetic approaches. Griffon N, et al. **Eur Neuropsychopharmacol** 1995;5 Suppl:3-9 (33 ref.)

Genetic variation of CNS receptors--a new perspective for pharmacogenetics. Propping P, et al. **Pharmacogenetics** 1995 Oct;5(5):318-25 (75 ref.)

[Dopamine D4-receptor variants, schizophrenia and clozapine therapy] Ewald HL, et al. **Ugeskr Laeger** 1996 Jun 17;158(25):3601-3 (17 ref.) (Eng. Abstr.) **(Dan)**

METABOLISM

Dopamine receptor signaling defects in spontaneous hypertension. Jose PA, et al. **Am J Hypertens** 1996 Apr; 9(4 Pt 1):400-5 (53 ref.)

The binding of agonists and antagonists to dopamine receptors. Strange PG. **Biochem Soc Trans** 1996 Feb; 24(1):188-92 (28 ref.)

The dopamine D3 receptor and schizophrenia: pharmacological, anatomical and genetic approaches. Griffon N, et al. **Eur Neuropsychopharmacol** 1995;5 Suppl:3-9 (33 ref.)

Pharmacology of ingestive behaviour. Samanin R, et al. **Therapie** 1996 Mar-Apr;51(2):107-15 (85 ref.)

PHYSIOLOGY

Dopamine receptors and schizophrenia. Reynolds GP. **Biochem Soc Trans** 1996 Feb;24(1):202-5 (35 ref.)

Is striatal dopaminergic receptor imbalance responsible for levodopa-induced dyskinesia? Blanchet PJ, et al. **Fundam Clin Pharmacol** 1995;9(5):434-42 (103 ref.)

The modulation of dopamine receptors in rat striatum. Stefani A, et al. **J Neural Transm Suppl** 1995;45:61-6 (24 ref.)

Cortical maldevelopment, anti-psychotic drugs, and schizophrenia: a search for common ground. Weinberger DR, et al. **Schizophr Res** 1995 Aug 1;16(2):87-110 (215 ref.)

Novel dopamine receptors half a decade later [see comments] Sokoloff P, et al. **Trends Pharmacol Sci** 1995 Aug; 16(8):270-5 (60 ref.) Comment in: Trends Pharmacol Sci 1995 Dec;16(12):406-8.

RECEPTORS, DOPAMINE D1

CHEMISTRY

The dopamine D1 receptor family: structural and functional aspects. Jensen AA, et al. **Biochem Soc Trans** 1996 Feb; 24(1):163-9 (35 ref.)

CLASSIFICATION

Behavioural pharmacology of 'D-1-like' dopamine receptors: further subtyping, new pharmacological probes and interactions with 'D-2-like' receptors. Waddington JL, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1995 Sep; 19(5):811-31 (65 ref.)

DRUG EFFECTS

The D-1 dopamine receptor: past, present and future an idiosyncratic review. Kebabian JW, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1995 Sep; 19(5):757-78 (44 ref.)

Electrophysiology of dopamine D-1 receptors in the basal ganglia: old facts and new perspectives. Stefani A, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1995 Sep; 19(5):779-93 (45 ref.)

D1/D2 actions of dopaminergic drugs studied with [14C]-2-deoxyglucose autoradiography. Trugman JM. **Prog Neuropsychopharmacol Biol Psychiatry** 1995 Sep; 19(5):795-810 (35 ref.)

Behavioural pharmacology of 'D-1-like' dopamine receptors: further subtyping, new pharmacological probes and interactions with 'D-2-like' receptors. Waddington JL, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1995 Sep; 19(5):811-31 (65 ref.)

PHYSIOLOGY

The dopamine D1 receptor family: structural and functional aspects. Jensen AA, et al. **Biochem Soc Trans** 1996 Feb; 24(1):163-9 (35 ref.)

Dopamine receptor multiplicity: "D1-like'-"D2-like' interactions and " D1-like" receptors not linked to adenylate cyclase. Waddington JL, et al. **Biochem Soc Trans** 1996 Feb;24(1):177-82 (77 ref.)

Dopamine D1 receptor regulation of phospholipase C. Jose PA, et al. **Hypertens Res** 1995 Jun;18 Suppl 1:S39-42 (45 ref.)

DOPA-induced "peak dose" dyskinesia: clues implicating D2 receptor-mediated mechanisms using dopaminergic agonists in MPTP monkeys. Blanchet PJ, et al. **J Neural Transm Suppl** 1995;45:103-12 (52 ref.)

On the functional significance of primate retinal dopamine receptors. Bodis-Wollner I, et al. **J Neural Transm Suppl** 1995;45:67-74 (32 ref.)

D-1 receptors in neurology and psychiatry an overview. Bédard PJ. **Prog Neuropsychopharmacol Biol Psychiatry** 1995 Sep;19(5):713-26 (73 ref.)

The D-1 dopamine receptor: past, present and future an idiosyncratic review. Kebabian JW, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1995 Sep; 19(5):757-78 (44 ref.)

Electrophysiology of dopamine D-1 receptors in the basal ganglia: old facts and new perspectives. Stefani A, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1995 Sep; 19(5):779-93 (45 ref.)

Behavioural pharmacology of 'D-1-like' dopamine receptors: further subtyping, new pharmacological probes and interactions with 'D-2-like' receptors. Waddington JL, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1995 Sep; 19(5):811-31 (65 ref.)

RECEPTORS, DOPAMINE D2

DRUG EFFECTS

Pharmacologic evidence for D2 dopamine receptor heterogeneity. Missale C, et al. **Adv Neurol** 1996;69:245-51 (39 ref.)

D1/D2 actions of dopaminergic drugs studied with [14C]-2-deoxyglucose autoradiography. Trugman JM. **Prog Neuropsychopharmacol Biol Psychiatry** 1995 Sep; 19(5):795-810 (35 ref.)

GENETICS

The D2 dopamine receptor gene as a determinant of reward deficiency syndrome. Blum K, et al. **J R Soc Med** 1996 Jul;89(7):396-400 (66 ref.)

Dopamine D2 receptor gene variants: association and linkage studies in impulsive-addictive-compulsive behaviour. Blum K, et al. **Pharmacogenetics** 1995 Jun;5(3):121-41 (122 ref.)

METABOLISM

D2-receptor imaging with [123I]IBZM and single photon emission tomography in psychiatry: a survey of current status. Schlösser R, et al. **J Neural Transm Gen Sect** 1995; 99(1-3):173-85 (52 ref.)

RECEPTORS, DOPAMINE D2

PHYSIOLOGY

Functional models for the dopamine D3 receptor. Griffon N, et al. **Biochem Soc Trans** 1996 Feb;24(1):193–8 (29 ref.)
D2 receptor agonists and partial agonists: relationship between receptor binding measures and functional activity. O'Boyle KM, et al. **Biochem Soc Trans** 1996 Feb; 24(1):183–8 (43 ref.)
Dopamine receptors and schizophrenia. Reynolds GP. **Biochem Soc Trans** 1996 Feb;24(1):202–5 (35 ref.)
Dopamine receptor multiplicity: "D1-like'-"D2-like' interactions and " D1-like" receptors not linked to adenylate cyclase. Waddington JL, et al. **Biochem Soc Trans** 1996 Feb;24(1):177–82 (77 ref.)
DOPA-induced "peak dose" dyskinesia: clues implicating D2 receptor-mediated mechanisms using dopaminergic agonists in MPTP monkeys. Blanchet PJ, et al. **J Neural Transm Suppl** 1995;45:103–12 (52 ref.)
On the functional significance of primate retinal dopamine receptors. Bodis-Wollner I, et al. **J Neural Transm Suppl** 1995;45:67–74 (32 ref.)
The dopamine D4 receptor in schizophrenia: an update [editorial] Kerwin RW, et al. **Psychol Med** 1996 Mar; 26(2):221–7 (56 ref.)

RECEPTORS, DRUG

[Mutagenesis study of pharmacological receptors: approach to their structure-function relationships] Sakamoto A, et al. **Nippon Yakurigaku Zasshi** 1995 Nov;106(5):321–6 (16 ref.) (Eng. Abstr.) **(Jpn)**

AGONISTS

[Anandamide: an endogenous cannabinoid receptor agonist] Ueda N. **Seikagaku** 1995 Aug;67(8):1036–40 (19 ref.) **(Jpn)**

ANTAGONISTS & INHIBITORS

[Imidazol receptor agonists--new possibilities for treating hypertension] Nowicki M, et al. **Postepy Hig Med Dosw** 1995;49(5):631–43 (56 ref.) (Eng. Abstr.) **(Pol)**

CHEMISTRY

Alpha 2-adrenoceptors and I2 sites in the mammalian central nervous system. French N. **Pharmacol Ther** 1995; 68(2):175–208 (300 ref.)

DRUG EFFECTS

Central imidazoline receptors as a target for centrally acting antihypertensive drugs. van Zwieten PA. **Pharm World Sci** 1995 Nov 24;17(6):186–90 (28 ref.)
The tumor promoter receptor protein kinase C: a novel target for chemoprevention and therapy of human colon cancer. O'Brian CA, et al. **Prog Clin Biol Res** 1995;391:117–20 (20 ref.)

METABOLISM

Imidazoline receptors and their endogenous ligands. Regunathan S, et al. **Annu Rev Pharmacol Toxicol** 1996; 36:511–44 (168 ref.)
Ion channels as pharmacologic receptors: the chirality of drug interactions. Triggle DJ. **Chirality** 1996;8(1):35–8 (18 ref.)
Receptor regulation: why should an anesthesiologist care? Smiley RM. **J Clin Anesth** 1996 May;8(3 Suppl):42S–47S (40 ref.)
Receptor-mediated carcinogenesis: the role of biological effect modeling for risk assessment of dioxin and tamoxifen. Demby KB, et al. **Prog Clin Biol Res** 1996;394:113–29 (57 ref.)
The elusive family of imidazoline binding sites. Parini A, et al. **Trends Pharmacol Sci** 1996 Jan;17(1):13–6 (37 ref.)
An evolutionary view of drug-receptor interaction: the bioamine receptor family. Vernier P, et al. **Trends Pharmacol Sci** 1995 Nov;16(11):375–81 (56 ref.)

PHYSIOLOGY

Role of cyclic AMP in the actions of cannabinoid receptors. Childers SR, et al. **Biochem Pharmacol** 1996 Sep 27; 52(6):819–27 (68 ref.)
The molecular interaction of sulfonylureas with beta-cell ATP-sensitive K(+)-channels. Kramer W, et al. **Diabetes Res Clin Pract** 1995 Aug;28 Suppl:S67–80 (25 ref.)
Sulfonylurea receptors and mechanism of sulfonylurea action. Panten U, et al. **Exp Clin Endocrinol Diabetes** 1996; 104(1):1–9 (100 ref.)
Imidazoline receptors: from basic concepts to recent developments. Bousquet P. **J Cardiovasc Pharmacol** 1995; 26 Suppl 2:S1–6 (54 ref.)
Alpha 2-adrenoceptors and I2 sites in the mammalian central nervous system. French N. **Pharmacol Ther** 1995; 68(2):175–208 (300 ref.)
Modulation of pulsatile GH release through a novel receptor in hypothalamus and pituitary gland. Smith RG, et al. **Recent Prog Horm Res** 1996;51:261–85; discussion 285–6 (59 ref.)

RECEPTORS, ENDOGENOUS SUBSTANCES see **RECEPTORS, CELL SURFACE**

RECEPTORS, ENDORPHIN see **RECEPTORS, OPIOID**

RECEPTORS, ENDOTHELIN

AGONISTS

Endothelin-1 and the regulation of vascular tone. La M, et al. **Clin Exp Pharmacol Physiol** 1995 May;22(5):315–23 (85 ref.)

ANTAGONISTS & INHIBITORS

Endothelin receptor antagonism. Opgenorth TJ. **Adv Pharmacol** 1995;33:1–65 (316 ref.)
Endothelin-1 and the regulation of vascular tone. La M, et al. **Clin Exp Pharmacol Physiol** 1995 May;22(5):315–23 (85 ref.)
Defining the role of endothelins in renal pathophysiology on the basis of selective and unselective endothelin receptor antagonist studies. Benigni A. **Curr Opin Nephrol Hypertens** 1995 Jul;4(4):349–53 (51 ref.)
Therapeutic effects of endothelin receptor antagonists in stroke. Barone FC, et al. **Neurol Res** 1995 Aug;17(4):259–64 (70 ref.)

CLASSIFICATION

Endothelin receptor antagonism. Opgenorth TJ. **Adv Pharmacol** 1995;33:1–65 (316 ref.)

GENETICS

Endothelins and the lung. Michael JR, et al. **Am J Respir Crit Care Med** 1996 Sep;154(3 Pt 1):555–81 (446 ref.)

METABOLISM

Endothelin in chronic heart failure: current position and future prospects. Love MP, et al. **Cardiovasc Res** 1996 May; 31(5):665–74 (99 ref.)
Endothelin receptors in normal and diseased kidneys. Nambi P. **Clin Exp Pharmacol Physiol** 1996 Apr;23(4):326–30 (86 ref.)
Endothelin receptor subtypes and their role in transmembrane signaling mechanisms. Sokolovsky M. **Pharmacol Ther** 1995;68(3):435–71 (208 ref.)

PHYSIOLOGY

Effects of endothelin-1 and the ETA receptor antagonist BQ-123 on resistance arteries from normal pregnant and preeclamptic women. Wolff K, et al. **Acta Obstet Gynecol Scand** 1996 May;75(5):432–8 (34 ref.)
Endothelins as cardiovascular peptides. Levin ER. **Am J Nephrol** 1996;16(3):246–51 (64 ref.)
Endothelin receptor heterogeneity, G-proteins, and signaling via cAMP and cGMP cascades. Sokolovsky M. **Cell Mol Neurobiol** 1995 Oct;15(5):561–71 (40 ref.)
Endothelins: renal tubule synthesis and actions. Kohan DE. **Clin Exp Pharmacol Physiol** 1996 Apr;23(4):337–44 (91 ref.)
Endothelin and endothelin antagonists: potential role in cardiovascular and renal disease. Noll G, et al. **Mol Cell Biochem** 1996 Apr 12–26;157(1-2):259–67 (105 ref.)
Inositol lipid-mediated signalling in response to endothelin and ATP in the mammalian testis. Rudge SA, et al. **Mol Cell Biochem** 1995 Aug-Sep;149-150:161–74 (86 ref.)
[Receptors and its signal transduction pathway in the renal interstitial cells] Arima S, et al. **Nippon Rinsho** 1995 Aug; 53(8):1861–7 (16 ref.) (Eng. Abstr.) **(Jpn)**

RECEPTORS, ENDOTHELIUM-DERIVED VASOCONSTRICTOR FACTOR see **RECEPTORS, ENDOTHELIN**

RECEPTORS, ENKEPHALIN see **RECEPTORS, OPIOID**

RECEPTORS, EPIDERMAL GROWTH FACTOR-UROGASTRONE

ANALYSIS

[Expression of EGF receptor subfamily in tumor] Gamou S, et al. **Nippon Rinsho** 1996 Jun;54(6):1521–8 (29 ref.) (Eng. Abstr.) **(Jpn)**
[The clinical prospects for the study of epidermal growth factor receptors in human tumors] Kushpinskii NE, et al. **Klin Lab Diagn** 1996 Jan-Feb;(1):9–12 (20 ref.) **(Rus)**

CHEMISTRY

Interaction of signaling and trafficking proteins with the carboxyterminus of the epidermal growth factor receptor. Carpenter G, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:44–51 (28 ref.)

GENETICS

Type-1 growth factor receptors in pancreatic and gastrointestinal neoplasia. Lemoine NR, et al. **Eur J Gastroenterol Hepatol** 1995 Oct;7(10):939–44 (74 ref.)

METABOLISM

Targeting the epidermal growth factor receptor for therapy of carcinomas. Davies DE, et al. **Biochem Pharmacol** 1996 May 3;51(9):1101–10 (125 ref.)
Recent advances in understanding signal transduction pathways in worms and flies. Duffy JB, et al. **Curr Opin Cell Biol** 1996 Apr;8(2):231–8 (44 ref.)

PHYSIOLOGY

Expression and role of epidermal growth factor receptors during differentiation of cementoblasts, osteoblasts, and periodontal ligament fibroblasts in the rat. Cho MI, et al. **Anat Rec** 1996 Jun;245(2):342–60 (69 ref.)
Interaction of signaling and trafficking proteins with the carboxyterminus of the epidermal growth factor receptor. Carpenter G, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:44–51 (28 ref.)
Epidermal growth factor receptor function in early mammalian development. Wiley LM, et al. **Bioessays** 1995 Oct;17(10):839–46 (65 ref.)
The epidermal growth factor/transforming growth factor-alpha family and their receptors. Brown KD. **Eur J Gastroenterol Hepatol** 1995 Oct;7(10):914–22 (58 ref.)
Role of epidermal growth factor (EGF) and its receptor in the development of the human placenta. Maruo T, et al. **Reprod Fertil Dev** 1995;7(6):1465–70 (15 ref.)
Interaction between erbB-receptors and heregulin in breast cancer tumor progression and drug resistance. Lupu R, et al. **Semin Cancer Biol** 1995 Jun;6(3):135–45 (143 ref.)
Epidermal growth factor-related peptides and the epidermal growth factor receptor in normal and malignant prostate. Sherwood ER, et al. **World J Urol** 1995;13(5):290–6 (65 ref.)

RECEPTORS, EPINEPHRINE see **RECEPTORS, ADRENERGIC**

RECEPTORS, ESTRADIOL

ANALYSIS

[Should immunohistochemistry be used to evaluate estrogen and progesterone receptors in breast cancers? (editorial)] Balaton AJ, et al. **Ann Pathol** 1996;16(2):78–80 (11 ref.) **(Fre)**

RECEPTORS, ESTROGEN

ANALYSIS

Correlation between pS2 protein positivity, steroid receptor status and other prognostic factors in breast cancer. Racca S, et al. **Int J Biol Markers** 1995 Apr-Jun;10(2):87–93 (35 ref.)
[Biochemical basis for detection of estrogen and progesterone receptors in breast tumors using immunohistochemistry] Goussard J. **Ann Pathol** 1996;16(2):91–7 (41 ref.) **(Fre)**

ANTAGONISTS & INHIBITORS

Oestrogen- and anti-oestrogen-regulated genes in human breast cancer. Rochefort H. **Ciba Found Symp** 1995; 191:254–65; discussion 265–8 (40 ref.)

CHEMISTRY

Structure and function of estrogen receptors. Parker MG. **Vitam Horm** 1995;51:267–87 (87 ref.)

GENETICS

Molecular aspects of estrogen receptor variants in breast cancer. Fuqua SA, et al. **Breast Cancer Res Treat** 1995 Sep;35(3):233–41 (19 ref.)
Molecular analysis of the estrogen receptor (ER) gene in association with ER negativity in breast cancer. Iwase H, et al. **Gan To Kagaku Ryoho** 1996 Mar;23 Suppl 1:61–5 (13 ref.)
Alternative splicing of the estrogen receptor primary transcript normally occurs in estrogen receptor positive tissues and cell lines. Pfeffer U, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1-6 Spec No):99–105 (37 ref.)
Autoinduction of nuclear receptor genes and its significance. Tata JR, et al. **J Steroid Biochem Mol Biol** 1993 Aug; 46(2):105–19 (54 ref.)
Estrogen receptor gene disruption: molecular characterization and experimental and clinical phenotypes. Korach KS, et al. **Recent Prog Horm Res** 1996;51:159–86; discussion 186–8 (50 ref.)

METABOLISM

Oestrogen receptor activation in the absence of ligand. Smith CL, et al. **Biochem Soc Trans** 1995 Nov;23(4):935–9 (44 ref.)
Toxicity of endogenous and environmental estrogens: what is the role of elemental interactions? Stancel GM, et al. **Environ Health Perspect** 1995 Oct;103 Suppl 7:29–33 (48 ref.)

PHYSIOLOGY

Estrogen receptor mRNA variants. Do they have a physiological role? Pfeffer U. **Ann N Y Acad Sci** 1996 Apr 30;784:304–13 (38 ref.)
Estrogen receptors: bioactivities and interactions with cell

signaling pathways. Katzenellenbogen BS. **Biol Reprod** 1996 Feb;54(2):287–93 (74 ref.)
Oestrogen receptor: a stable phenotype in breast cancer. Robertson JF. **Br J Cancer** 1996 Jan;73(1):5–12 (115 ref.)
The oestrogen receptor in bone–evolution of our knowledge. Lindsay R. **Br J Obstet Gynaecol** 1996 May;103 Suppl 13:16–8; discussion 18–9 (27 ref.)
Third annual William L. McGuire Memorial Lecture. "Studies on the estrogen receptor in breast cancer"—20 years as a target for the treatment and prevention of cancer. Jordan VC. **Breast Cancer Res Treat** 1995;36(3):267–85 (123 ref.)
Embryonic estrogen receptors: do they have a physiological function? Gorski J, et al. **Environ Health Perspect** 1995 Oct;103 Suppl 7:69–72 (19 ref.)
Cross talk between peptide growth factor and estrogen receptor signaling systems. Ignar–Trowbridge DM, et al. **Environ Health Perspect** 1995 Oct;103 Suppl 7:35–8 (34 ref.)
Regulation of estrogen/progestogen receptors in the endometrium. Casper RF. **Int J Fertil Menopausal Stud** 1996 Jan–Feb;41(1):16–21 (35 ref.)
The role of the estrogen receptor in tumor progression. Lemieux P, et al. **J Steroid Biochem Mol Biol** 1996 Jan; 56(1–6 Spec No):87–91 (21 ref.)
Mechanisms for species differences in receptor–mediated carcinogenesis. Barrett JC. **Mutat Res** 1995 Dec; 333(1–2):189–202 (111 ref.)
Estrogen receptor gene disruption: molecular characterization and experimental and clinical phenotypes. Korach KS, et al. **Recent Prog Horm Res** 1996;51:159–86; discussion 186–8 (50 ref.)
Structure and function of estrogen receptors. Parker MG. **Vitam Horm** 1995;51:267–87 (87 ref.)
[Steroidal sex hormones and insensitivity syndromes] Stárka L, et al. **Bratisl Lek Listy** 1995 Nov;96(11):600–4 (20 ref.) (Eng. Abstr.) **(Slo)**

RECEPTORS, EXCITATORY AMINO ACID see **RECEPTORS, GLUTAMATE**

RECEPTORS, FC

IMMUNOLOGY

Molecular mimicry between Fc receptors and viral antigens. Oleszak EL. **Arch Immunol Ther Exp (Warsz)** 1994; 42(2):83–8 (53 ref.)
Antigen and Fc receptor signaling. The awesome power of the immunoreceptor tyrosine–based activation motif (ITAM). Cambier JC. **J Immunol** 1995 Oct 1;155(7):3281–5 (65 ref.)

PHYSIOLOGY

Signaling difference between class IgM and IgD antigen receptors. Kim KM, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:81–8 (45 ref.)
Intracytoplasmic sequences involved in the biological properties of low–affinity receptors for IgG expressed by murine macrophages. Daëron M. **Braz J Med Biol Res** 1995 Mar;28(3):263–74 (50 ref.)

RECEPTORS, FC EPSILON see **RECEPTORS, IGE**

RECEPTORS, FC GAMMA see **RECEPTORS, IGG**

RECEPTORS, FGF see **RECEPTORS, FIBROBLAST GROWTH FACTOR**

RECEPTORS, FIBRINOGEN see **PLATELET GLYCOPROTEIN GPIIB–IIIA COMPLEX**

RECEPTORS, FIBROBLAST GROWTH FACTOR

GENETICS

Mutations in fibroblast growth factor receptors: phenotypic consequences during eukaryotic development [editorial] Park WJ, et al. **Am J Hum Genet** 1995 Oct;57(4):748–54 (45 ref.)
Hypochondroplasia: molecular analysis of the fibroblast growth factor receptor 3 gene. Bellus GA, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:182–7 (25 ref.)
Fibroblast growth factor receptor–2 mutations in craniosynostosis. Malcolm S, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:164–70 (29 ref.)
Mutations of the fibroblast growth factor receptor–3 gene in achondroplasia. Rousseau F, et al. **Horm Res** 1996; 45(1–2):108–10 (18 ref.)
Novel FGFR2 mutations in Crouzon and Jackson–Weiss syndromes show allelic heterogeneity and phenotypic variability. Park WJ, et al. **Hum Mol Genet** 1995 Jul; 4(7):1229–33 (18 ref.)
Fibroblast–growth–factor receptor mutations in human skeletal disorders. Muenke M, et al. **Trends Genet** 1995 Aug; 11(8):308–13 (50 ref.)

METABOLISM

Expression of heparin–binding growth factors and their receptors in neural development. Wanaka A. **Kaibogaku Zasshi** 1995 Dec;70(6):512–20 (17 ref.)
Tumor targeting through fibroblast growth factor receptors. Lappi DA. **Semin Cancer Biol** 1995 Oct;6(5):279–88 (78 ref.)
Control of cell proliferation by heparan sulfate and heparin–binding growth factors. Vlodavsky I, et al. **Thromb Haemost** 1995 Jul;74(1):534–40 (33 ref.)

PHYSIOLOGY

Axonal growth mediated by cell adhesion molecules requires activation of fibroblast growth factor receptors. Saffell JL, et al. **Biochem Soc Trans** 1995 Aug;23(3):469–70 (12 ref.)
Promiscuity of fibroblast growth factor receptors. Green PJ, et al. **Bioessays** 1996 Aug;18(8):639–46 (78 ref.)
Functions of fibroblast growth factors and their receptors. Wilkie AO, et al. **Curr Biol** 1995 May 1;5(5):500–7 (56 ref.)
Regulation of prostate growth by fibroblast growth factors. Story MT. **World J Urol** 1995;13(5):297–305 (96 ref.)

ULTRASTRUCTURE

Outline structures for the extracellular domains of the fibroblast growth factor receptors. Bateman A, et al. **Nat Struct Biol** 1995 Dec;2(12):1068–74 (41 ref.)

RECEPTORS, FIBRONECTIN

METABOLISM

[Modulation of integrin alpha–v–beta–1 expression on human tumor cells by leukemia inhibitory factor (LIF) and oncostatin M (OSM)] Heymann D, et al. **Bull Cancer (Paris)** 1996 Jan;83(1):13–21 (41 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Interactions of connective tissue cells with the extracellular matrix. Horton MA. **Bone** 1995 Aug;17(2 Suppl):51S–53S (20 ref.)

RECEPTORS, FOLLICLE–STIMULATING HORMONE see **RECEPTORS, FSH**

RECEPTORS, FSH

GENETICS

[Pituitary glycoprotein hormone receptors] Misrahi M, et al. **Ann Endocrinol (Paris)** 1995;56(5):487–93 (39 ref.) (Eng. Abstr.) **(Fre)**

RECEPTORS, GABA

DRUG EFFECTS

Neurosteroids: molecular mechanisms of action and psychopharmacological significance. Rupprecht R, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1–6 Spec No):163–8 (50 ref.)
[Regulatory actions of general anesthetics on inhibitory receptor channels] Akagi H. **Masui** 1995;44 Suppl:S125–6 (4 ref.) **(Jpn)**

GENETICS

Molecular genetic analysis of the role of GABAergic systems in the behavioral and cellular actions of alcohol. Buck KJ. **Behav Genet** 1996 May;26(3):313–23 (72 ref.)

METABOLISM

[Comparative biochemistry of the triune brain] Bureau M, et al. **Acta Psychiatr Belg** 1994;94(4–6):225–47 (63 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Neuroactive steroid modulators of the stress response. Morrow AL, et al. **Ann N Y Acad Sci** 1995 Dec 29; 771:257–72 (78 ref.)
Frank A. Beach Award. Functional significance of steroid modulation of GABAergic neurotransmission: analysis at the behavioral, cellular, and molecular levels. McCarthy MM. **Horm Behav** 1995 Jun;29(2):131–40 (48 ref.)
GABAC receptors. Bormann J, et al. **Trends Neurosci** 1995 Dec;18(12):515–9 (40 ref.)

RECEPTORS, GABA-A

Recent advances in the GABA–A–benzodiazepine receptor pharmacology. Kostowski W. **Pol J Pharmacol** 1995 May–Jun;47(3):237–46 (57 ref.)

ANALYSIS

Which GABAA–receptor subtypes really occur in the brain? McKernan RM, et al. **Trends Neurosci** 1996 Apr; 19(4):139–43 (48 ref.)

CHEMISTRY

Molecular and functional properties of mitochondrial benzodiazepine receptors. Krueger KE. **Biochim Biophys Acta** 1995 Dec 20;1241(3):453–70 (189 ref.)
Deciphering the native GABAA receptor: is there hope? Yeh HH, et al. **J Neurosci Res** 1995 Aug 1;41(5):567–71 (50 ref.)

CLASSIFICATION

Structure and pharmacology of vertebrate GABAA receptor subtypes. Whiting PJ, et al. **Int Rev Neurobiol** 1995; 38:95–138 (476 ref.)

DRUG EFFECTS

Actions of anesthetics on ligand–gated ion channels: role of receptor subunit composition. Harris RA, et al. **FASEB J** 1995 Nov;9(14):1454–62 (59 ref.)
Pharmacology of barbiturate tolerance/dependence: GABAA receptors and molecular aspects. Ito T, et al. **Life Sci** 1996;59(3):169–95 (176 ref.)
Perinatal benzodiazepine modulation of GABAA receptor function: influence on adaptive responses. Kellogg CK. **NIDA Res Monogr** 1995;158:202–26 (78 ref.)
Structure and pharmacology of gamma–aminobutyric acidA receptor subtypes. Sieghart W. **Pharmacol Rev** 1995 Jun; 47(2):181–234 (504 ref.)
Sodium channels and GABAA receptor–channel complex as targets of environmental toxicants. Narahashi T, et al. **Toxicol Lett** 1995 Dec;82–83:239–45 (20 ref.)
Neurosteroids and GABAA receptor function. Lambert JJ, et al. **Trends Pharmacol Sci** 1995 Sep;16(9):295–303 (52 ref.)
[Steroid modulation of GABA(A) receptors] Gniot–Szulżycka J, et al. **Postepy Hig Med Dosw** 1995; 49(3):409–24 (71 ref.) (Eng. Abstr.) **(Pol)**

GENETICS

Regulation of GABAA receptor function and gene expression in the central nervous system. Morrow AL. **Int Rev Neurobiol** 1995;38:1–41 (275 ref.)

METABOLISM

A putative receptor for neurosteroids on the GABAA receptor complex: the pharmacological properties and therapeutic potential of epalons. Gee KW, et al. **Crit Rev Neurobiol** 1995;9(2–3):207–27 (102 ref.)
Steroid anesthetics: old compounds, new drugs. Sear JW. **J Clin Anesth** 1996 May;8(3 Suppl):91S–98S (70 ref.)
Presynaptic GABAA receptors in vertebrate synapses. Xi ZX, et al. **Kurume Med J** 1996;43(2):115–22 (84 ref.)
Recent advances in benzodiazepine receptor (BZR) binding studies. Gupta SP. **Prog Drug Res** 1995;45:67–106 (141 ref.)

PHYSIOLOGY

Molecular and functional properties of mitochondrial benzodiazepine receptors. Krueger KE. **Biochim Biophys Acta** 1995 Dec 20;1241(3):453–70 (189 ref.)
Regulation of GABAA receptor function and gene expression in the central nervous system. Morrow AL. **Int Rev Neurobiol** 1995;38:1–41 (275 ref.)
Structure and pharmacology of vertebrate GABAA receptor subtypes. Whiting PJ, et al. **Int Rev Neurobiol** 1995; 38:95–138 (476 ref.)
Deciphering the native GABAA receptor: is there hope? Yeh HH, et al. **J Neurosci Res** 1995 Aug 1;41(5):567–71 (50 ref.)
Involvement of endogenous benzodiazepine receptor ligands in brain disorders: therapeutic potential for benzodiazepine antagonists? Polc P. **Med Hypotheses** 1995 Jun;44(6):439–46 (51 ref.)
Brain GABAA receptors studied with subunit–specific antibodies. De Blas AL. **Mol Neurobiol** 1996 Feb; 12(1):55–71 (139 ref.)
Alcohol addiction: an enigma among us. Tabakoff B, et al. **Neuron** 1996 May;16(5):909–12 (25 ref.)
From ion currents to genomic analysis: recent advances in GABAA receptor research. Rabow LE, et al. **Synapse** 1995 Nov;21(3):189–274 (675 ref.)
Retrograde signaling at GABAA–receptor synapses in the mammalian CNS. Alger BE, et al. **Trends Neurosci** 1995 Aug;18(8):333–40 (42 ref.)

RECEPTORS, GABA-B

Recent advances in the GABA–A–benzodiazepine receptor pharmacology. Kostowski W. **Pol J Pharmacol** 1995 May–Jun;47(3):237–46 (57 ref.)

AGONISTS

Possible therapeutic application of GABAB receptor agonists and antagonists. Malcangio M, et al. **Clin Neuropharmacol** 1995 Aug;18(4):285–305 (162 ref.)

ANTAGONISTS & INHIBITORS

Possible therapeutic application of GABAB receptor agonists and antagonists. Malcangio M, et al. **Clin Neuropharmacol** 1995 Aug;18(4):285–305 (162 ref.)

DRUG EFFECTS

A physiological role for GABAB receptors and the effects of baclofen in the mammalian central nervous system. Misgeld U, et al. **Prog Neurobiol** 1995 Jul;46(4):423–62 (412 ref.)

RECEPTORS, GABA-B

METABOLISM

GABAB receptors. Kerr DI, et al. **Pharmacol Ther** 1995; 67(2):187–246 (584 ref.)

PHYSIOLOGY

Activation by GABAb, reduction of the intracellular concentration of Ca++, and inhibition of protein kinases are possible mechanisms of the long-term posttetanic modification of the efficiency of inhibitory transmission in the new cortex. Sík kis IG. **Neurosci Behav Physiol** 1996 Jan-Feb;26(1):88–97 (41 ref.)

A physiological role for GABAB receptors and the effects of baclofen in the mammalian central nervous system. Misgeld U, et al. **Prog Neurobiol** 1995 Jul;46(4):423–62 (412 ref.)

[Progress in the study of gamma-aminobutyric acid B receptors] Gao DM, et al.
Sheng Li Ko Hsueh Chin Chan 1995 Jul;26(3):246–8 (10 ref.) **(Chi)**

RECEPTORS, GABA-BENZODIAZEPINE see **RECEPTORS, GABA-A**

RECEPTORS, GAMMA-AMINOBUTYRIC ACID see **RECEPTORS, GABA**

RECEPTORS, GASTRIN see **RECEPTORS, CHOLECYSTOKININ**

RECEPTORS, GASTRIN-RELEASING PEPTIDE see **RECEPTORS, BOMBESIN**

RECEPTORS, GASTROINTESTINAL HORMONE

PHYSIOLOGY

Galanin and 5-HT1A receptor interactions as an integrative mechanism in 5-HT neurotransmission in the brain. Hedlund PB, et al. **Ann N Y Acad Sci** 1996 Mar 22; 780:193–212 (82 ref.)

Galanin--a neuropeptide with inhibitory actions. Kask K, et al. **Cell Mol Neurobiol** 1995 Dec;15(6):653–73 (146 ref.)

RECEPTORS, GASTROINTESTINAL PEPTIDES see **RECEPTORS, GASTROINTESTINAL HORMONE**

RECEPTORS, GLUCAGON

PHYSIOLOGY

Regulation of cellular calcium through signaling cross-talk involves an intricate interplay between the actions of receptors, G-proteins, and second messengers. Bygrave FL, et al. **FASEB J** 1995 Oct;9(13):1297–303 (62 ref.)

RECEPTORS, GLUCOCORTICOID

ANALYSIS

[Examination of glucocorticoid receptor] Ichikawa Y, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:675–8 (15 ref.) **(Jpn)**

DRUG EFFECTS

Molecular mechanisms of steroid action in asthma. Barnes PJ. **J Allergy Clin Immunol** 1996 Jan;97(1 Pt 2):159–68 (74 ref.)

[Molecular mechaniam of glucocorticoid action] Grzanka A, et al. **Pol Arch Med Wewn** 1996 Apr;95(4):375–82 (30 ref.) **(Pol)**

METABOLISM

[Glucocorticoid receptor anomalies in asthma] Demoly P, et al. **Presse Med** 1996 May 4–11;25(16):769–74 (26 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Control of transcription by steroid hormones. Beato M, et al. **Ann N Y Acad Sci** 1996 Apr 30;784:93–123 (266 ref.)

Molecular mechanisms of anti-inflammatory action of glucocorticoids. Cato AC, et al. **Bioessays** 1996 May; 18(5):371–8 (67 ref.)

The glucocorticoid receptor synergizes with Jun homodimers to activate AP-1-regulated promoters lacking GR binding sites. Teurich S, et al. **Chem Senses** 1995 Apr;20(2):251–5 (17 ref.)

Glucocorticoid receptors in depression. Pariante CM, et al. **Isr J Med Sci** 1995 Dec;31(12):705–12 (25 ref.)

Enhancement of nuclear receptor transcriptional signalling. Renkawitz R, et al. **J Steroid Biochem Mol Biol** 1996 Jan; 56(1-6 Spec No):39–45 (29 ref.)

Mechanisms of transcription activation by nuclear receptors: studies on the human glucocorticoid receptor tau 1 transactivation domain. McEwan IJ, et al. **Mutat Res** 1995 Dec;333(1-2):15–22 (43 ref.)

Receptor-mediated toxicity. Gustafsson JA. **Toxicol Lett** 1995 Dec;82-83:465–70 (24 ref.)

[New data on mineralocorticoid hormones. Physiopathological implications (editorial)] Corvol P, et al. **Presse Med** 1995 Sep 23;24(27):1235–7 (12 ref.) (Eng. Abstr.) **(Fre)**

RECEPTORS, GLUTAMATE

CHEMISTRY

Transmembrane topology of the glutamate receptors. A tale of novel twists and turns. Hughes TE. **J Mol Neurosci** 1994-95;5(4):211–7 (36 ref.)

CLASSIFICATION

Get receptive to metabotropic glutamate receptors. Pin JP, et al. **Curr Opin Neurobiol** 1995 Jun;5(3):342–9 (60 ref.)

Excitatory amino acid receptors in glia: different subtypes for distinct functions? Gallo V, et al. **J Neurosci Res** 1995 Sep 1;42(1):1–8 (69 ref.)

Ionotropic glutamate receptors--focus on non-NMDA receptors. Jørgensen M, et al. **Pharmacol Toxicol** 1995 May; 76(5):312–9 (48 ref.)

DRUG EFFECTS

Actions of anesthetics on ligand-gated ion channels: role of receptor subunit composition. Harris RA, et al.
FASEB J 1995 Nov;9(14):1454–62 (59 ref.)

NMDA antagonists as neurotherapeutic drugs, psychotogens, neurotoxins, and research tools for studying schizophrenia. Olney JW, et al. **Neuropsychopharmacology** 1995 Dec; 13(4):335–45 (75 ref.)

[Glutamatergic hypothesis of schizophrenia: psychoses induced by phencyclidine and cortical-subcortical imbalance] Krebs MO. **Encephale** 1995 Sep-Oct; 21(5):581–8 (52 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Glutamate receptor genes in Parkinson's disease. Penney JB, et al. **Adv Neurol** 1996;69:79–86 (30 ref.)

RNA editing. An I for editing. Bass BL. **Curr Biol** 1995 Jun 1;5(6):598–600 (15 ref.)

METABOLISM

Synaptic targeting of glutamate receptors. Ehlers MD, et al. **Curr Opin Cell Biol** 1996 Aug;8(4):484–9 (54 ref.)

Current concepts of excitotoxicity. Whetsell WO Jr.
J Neuropathol Exp Neurol 1996 Jan;55(1):1–13 (127 ref.)

Breakdown of membrane phospholipids in Alzheimer disease. Involvement of excitatory amino acid receptors. Farooqui AA, et al. **Mol Chem Neuropathol** 1995 Jun-Aug; 25(2-3):155–73 (94 ref.)

Excitatory amino acid receptors and neurodegeneration. Doble A. **Therapie** 1995 Jul-Aug;50(4):319–37 (175 ref.)

[Anesthetics and the glutamate receptor channels expressed in Xenopus oocytes] Yamakura T, et al. **Masui** 1995;44 Suppl:S121–4 (14 ref.) **(Jpn)**

PHYSIOLOGY

Structure and function of glutamate and nicotinic acetylcholine receptors. Dani JA, et al.
Curr Opin Neurobiol 1995 Jun;5(3):310–7 (81 ref.)

Get receptive to metabotropic glutamate receptors. Pin JP, et al. **Curr Opin Neurobiol** 1995 Jun;5(3):342–9 (60 ref.)

Excitatory amino acids in health and disease. Thomas RJ. **J Am Geriatr Soc** 1995 Nov;43(11):1279–89 (132 ref.)

The role of RNA editing in controlling glutamate receptor channel properties. Seeburg PH. **J Neurochem** 1996 Jan; 66(1):1–5 (38 ref.)

Excitatory amino acid receptors in glia: different subtypes for distinct functions? Gallo V, et al. **J Neurosci Res** 1995 Sep 1;42(1):1–8 (69 ref.)

Excitatory amino acid receptor-mediated neuronal signal transduction: modulation by polyamines and calcium. Iqbal Z. **Mol Cell Biochem** 1995 Aug-Sep;149-150:233–40 (61 ref.)

Ionotropic glutamate receptors. Their possible role in the expression of hippocampal synaptic plasticity. Asztély F, et al. **Mol Neurobiol** 1996 Feb;12(1):1–11 (122 ref.)

Functions of ionotropic and metabotropic glutamate receptors in sensory transmission in the mammalian thalamus. Salt TE, et al. **Prog Neurobiol** 1996 Jan; 48(1):55–72 (220 ref.)

[Glutamate receptors in the central nervous system] Kolonko A. **Postepy Hig Med Dosw** 1995;49(6):719–31 (40 ref.) (Eng. Abstr.) **(Pol)**

RECEPTORS, GLUTAMATE, METABOTROPIC see **RECEPTORS, METABOTROPIC GLUTAMATE**

RECEPTORS, GLYCINE

CHEMISTRY

The inhibitory glycine receptor: architecture, synaptic localization and molecular pathology of a postsynaptic ion-channel complex. Kuhse J, et al.
Curr Opin Neurobiol 1995 Jun;5(3):318–23 (60 ref.)

DRUG EFFECTS

Actions of anesthetics on ligand-gated ion channels: role of receptor subunit composition. Harris RA, et al.
FASEB J 1995 Nov;9(14):1454–62 (59 ref.)

[Regulatory actions of general anesthetics on inhibitory receptor channels] Akagi H. **Masui** 1995;44 Suppl:S125–6 (4 ref.) **(Jpn)**

GENETICS

The inhibitory glycine receptor: architecture, synaptic localization and molecular pathology of a postsynaptic ion-channel complex. Kuhse J, et al.
Curr Opin Neurobiol 1995 Jun;5(3):318–23 (60 ref.)

PHYSIOLOGY

The inhibitory glycine receptor: architecture, synaptic localization and molecular pathology of a postsynaptic ion-channel complex. Kuhse J, et al.
Curr Opin Neurobiol 1995 Jun;5(3):318–23 (60 ref.)

RECEPTORS, GNRH see **RECEPTORS, LHRH**

RECEPTORS, GONADOLIBERIN see **RECEPTORS, LHRH**

RECEPTORS, GONADORELIN see **RECEPTORS, LHRH**

RECEPTORS, GONADOTROPIN

PHYSIOLOGY

[Physiopathologic anomalies in ovarian response] Christin-Maitre S, et al. **Contracept Fertil Sex** 1996 Feb; 24(2):105–10 (27 ref.) **(Fre)**

RECEPTORS, GRANULOCYTE COLONY-STIMULATING FACTOR

PHYSIOLOGY

Molecular analysis of the granulocyte colony-stimulating factor receptor. Avalos BR. **Blood** 1996 Aug 1;88(3):761–77 (181 ref.)

RECEPTORS, GROWTH FACTOR

[Involvement of the VEGF-Flt-receptor family in angiogenesis] Shibuya M. **Nippon Yakurigaku Zasshi** 1996 Mar;107(3):119–31 (44 ref.) (Eng. Abstr.) **(Jpn)**

ANALYSIS

Can systematic research of hormone and growth factor receptors contribute to the recognition of acute and chronic types of breast cancer, of their specific mammary dysplasias, and of specific treatments? [editorial] Mathé G. **Biomed Pharmacother** 1995;49(9):385–8 (28 ref.)

Analysis of receptors for cytokines and growth factors in human disease. Zola H. **Dis Markers** 1996 Mar;12(4):225–40 (57 ref.)

BIOSYNTHESIS

Regulation of the expression of the VEGF/VPS and its receptors: role in tumor angiogenesis. Kolch W, et al. **Breast Cancer Res Treat** 1995;36(2):139–55 (156 ref.)

GENETICS

The role of growth factor receptors in central nervous system development and neoplasia. Weiner HL. **Neurosurgery** 1995 Aug;37(2):179–93; discussion 193–4 (187 ref.)

METABOLISM

Targeting diphtheria toxin to growth factor receptors. Murphy JR, et al. **Semin Cancer Biol** 1995 Oct;6(5):259–67 (64 ref.)

Surface markers and growth factor receptors of immature hemopoietic stem cell subsets. Wagemaker G, et al.
Stem Cells (Dayt) 1995 May;13 Suppl 1:165–71 (29 ref.)

Signals that make you different: receptor-mediated signal transduction in early development. Saxe CL 3rd.
Zygote 1994 Aug;2(3):179–83 (42 ref.)

PHYSIOLOGY

Role of VEGF-flt receptor system in normal and tumor angiogenesis. Shibuya M. **Adv Cancer Res** 1995;67:281–316 (141 ref.)

Definition of signals for neuronal differentiation. Obermeier A, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:1–17 (55 ref.)

Coreceptors and adapter proteins in T-cell signaling. Ravichandran KS, et al. **Ann N Y Acad Sci** 1995 Sep 7; 766:117–33 (91 ref.)

Molecular biology of neurotrophic factors. Sendtner M.
Baillieres Clin Neurol 1995 Nov;4(3):575–91 (100 ref.)

Regulation of growth factor activation by proteoglycans: what is the role of the low affinity receptors? Schlessinger J, et al. **Cell** 1995 Nov 3;83(3):357–60 (20 ref.)

The PI/PTB domain: a new protein interaction domain involved in growth factor receptor signaling. Margolis B. **J Lab Clin Med** 1996 Sep;128(3):235–41 (66 ref.)

Tyrosine kinase-mediated signal transduction pathways and the actions of polypeptide growth factors and G-protein-coupled agonists in smooth muscle. Hollenberg MD. **Mol Cell Biochem** 1995 Aug-Sep;149-150:77–85 (77 ref.)

Agrin: toward a molecular understanding of synapse regeneration. Deyst KA, et al. **Neurosurgery** 1995 Jul; 37(1):71–7 (81 ref.)

RECEPTORS, GROWTH HORMONE see **RECEPTORS, SOMATOTROPIN**

RECEPTORS, HEMATOPOIETIC GROWTH FACTORS see **RECEPTORS, COLONY-STIMULATING FACTOR**

RECEPTORS, HISTAMINE

DRUG EFFECTS

An update on histamine receptors and gastroprotection. Bertaccini G, et al. **Ital J Gastroenterol** 1995 Jun; 27(5):259–64 (54 ref.)

METABOLISM

Molecular pharmacological aspects of histamine receptors. Leurs R, et al. **Pharmacol Ther** 1995 Jun;66(3):413–63 (386 ref.)

PHYSIOLOGY

Histamine receptor and its regulation of energy metabolism. Sakata T. **Obes Res** 1995 Nov;3 Suppl 4:341S–548S (62 ref.)

RECEPTORS, HISTAMINE H1

GENETICS

[Mutagenesis of the human histamine H1 receptor and design of new antihistamine agents] Differding E, et al. **J Pharm Belg** 1996 May–Jun;51(3):155–60 (15 ref.) (Eng. Abstr.) **(Fre)**

RECEPTORS, HISTAMINE H3

ANTAGONISTS & INHIBITORS

The medicinal chemistry and therapeutic potentials of ligands of the histamine H3 receptor. Leurs R, et al. **Prog Drug Res** 1995;45:107–65 (149 ref.)

PHYSIOLOGY

New aspects of the role of histamine in cardiovascular function: identification, characterization, and potential pathophysiological importance of H3 receptors. Göthert M, et al. **Can J Physiol Pharmacol** 1995 May;73(5):558–64 (23 ref.)

An update on histamine H3 receptors and gastrointestinal functions. Bertaccini G, et al. **Dig Dis Sci** 1995 Sep; 40(9):2052–63 (90 ref.)

RECEPTORS, HIV

see related
HIV ENVELOPE PROTEIN GP120

CHEMISTRY

The receptor for HIV: dissection of CD4 and studies on putative accessory factors. James W, et al. **Curr Top Microbiol Immunol** 1996;205:137–58 (152 ref.)

RECEPTORS, HUMAN CHORIONIC GONADOTROPIN see **RECEPTORS, LH**

RECEPTORS, HYALURONAN see **ANTIGENS, CD44**

RECEPTORS, IGE

DEFICIENCY

Composition of TCR-CD3 complex in human intestinal intraepithelial lymphocytes: lack of Fc epsilon RI gamma chain. Balk SP, et al. **Int Immunol** 1995 Aug;7(8):1237–41 (40 ref.)

GENETICS

11q and high-affinity IgE receptor in asthma and allergy. Cookson WO. **Clin Exp Allergy** 1995 Nov;25 Suppl 2:71–3; discussion 95–6 (23 ref.)

IMMUNOLOGY

CD23 and B-cell activation. Bonnefoy JY, et al. **Curr Opin Immunol** 1995 Jun;7(3):355–9 (39 ref.)

Consequences of IgE/CD23-mediated antigen presentation in allergy. Mudde GC, et al. **Immunol Today** 1995 Aug; 16(8):380–3 (41 ref.)

[Role of Langerhans cells in the physiopathology of atopic dermatitis] Bieber T. **Pathol Biol (Paris)** 1995 Dec; 43(10):871–5 (39 ref.) (Eng. Abstr.) **(Fre)**

[Immunoglobulins E and inflammatory cells] Tunon de Lara JM. **Rev Mal Respir** 1996;13(1):27–36 (32 ref.) (Eng. Abstr.) **(Fre)**

[CD23/sCD23--receptor/cytokine in IgE-dependent reactions] Rogala B, et al. **Postepy Hig Med Dosw** 1995; 49(3):425–32 (35 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOLOGY

Nitric oxide production by human monocytes: evidence for a role of CD23. Dugas B, et al. **Immunol Today** 1995 Dec; 16(12):574–80 (54 ref.)

Cell signalling by integrins and immunoglobulin receptors in primed neutrophils. Edwards SW. **Trends Biochem Sci** 1995 Sep;20(9):362–7 (34 ref.)

RECEPTORS, IGF-I see **RECEPTORS, INSULIN-LIKE-GROWTH FACTOR I**

RECEPTORS, IGF-II see **RECEPTORS, INSULIN-LIKE-GROWTH-FACTOR II**

RECEPTORS, IGG

BIOSYNTHESIS

Down regulation of Fc receptors by IVIgG. Mannhalter JW, et al. **Int Rev Immunol** 1989;5(2):173–9 (24 ref.)

CLASSIFICATION

Human Fc receptors for IgG. Unkeless JC. **Int Rev Immunol** 1989;5(2):165–71 (56 ref.)

GENETICS

Intracytoplasmic sequences involved in the biological properties of low-affinity receptors for IgG expressed by murine macrophages. Daëron M. **Braz J Med Biol Res** 1995 Mar;28(3):263–74 (50 ref.)

IMMUNOLOGY

G-CSF-stimulated PMN in immunotherapy of breast cancer with a bispecific antibody to Fc gamma RI and to HER-2/neu (MDX-210). Repp R, et al. **J Hematother** 1995 Oct;4(5):415–21 (26 ref.)

[The role of Fc gamma R specific autoantibodies in autoimmune diseases. Review of the literature and authors' own research] Szegedi A, et al. **Orv Hetil** 1996 Mar 17; 137(11):581–4 (34 ref.) (Eng. Abstr.) **(Hun)**

METABOLISM

Targeting lipoproteins to Fc gamma receptors with bispecific antibodies. Morganelli PM. **J Hematother** 1995 Oct; 4(5):457–61 (19 ref.)

PHYSIOLOGY

The molecular dissection of Fc gamma receptor mediated phagocytosis. Indik ZK, et al. **Blood** 1995 Dec 15; 86(12):4389–99 (85 ref.)

Fc gamma receptors of phagocytes. de Haas M, et al. **J Lab Clin Med** 1995 Oct;126(4):330–41 (128 ref.)

Fc gamma RII-mediated regulation of human B cells. Gergely J, et al. **Scand J Immunol** 1996 Jul;44(1):1–10 (70 ref.)

[Fc gamma receptors. Properties and participation in IgG binding and other biological processes] Sokal I. **Postepy Hig Med Dosw** 1995;49(1):47–51 (21 ref.) (Eng. Abstr.) **(Pol)**

RECEPTORS, IL-1 see **RECEPTORS, INTERLEUKIN-1**

RECEPTORS, IL-2 see **RECEPTORS, INTERLEUKIN-2**

RECEPTORS, IMMUNOLOGIC

G-protein-coupled receptors in HL-60 human leukemia cells. Klinker JF, et al. **Gen Pharmacol** 1996 Jan;27(1):33–54 (247 ref.)

Receptors for HLA class I molecules in human NK cells. Bottino C, et al. **Semin Immunol** 1995 Apr;7(2):67–73 (23 ref.)

CHEMISTRY

Sialoadhesin and related cellular recognition molecules of the immunoglobulin superfamily. Crocker PR, et al. **Biochem Soc Trans** 1996 Feb;24(1):150–6 (50 ref.)

CD28/CTLA-4 receptor structure, binding stoichiometry and aggregation during T-cell activation. Linsley PS, et al. **Res Immunol** 1995 Mar–Apr;146(3):130–40 (78 ref.)

DRUG EFFECTS

Adhesive receptors expressed by tumor cells and platelets: novel targets for therapeutic anti-metastatic strategies. Oleksowicz L, et al. **Med Oncol** 1995 Jun;12(2):95–102 (161 ref.)

GENETICS

Amebiasis and the Entamoeba histolytica Gal/GalNAc lectin: from lab bench to bedside. Petri Wa Jr. **J Investig Med** 1996 Feb;44(2):24–36 (84 ref.)

NK cell recognition of major histocompatibility complex class I molecules. Lanier LL, et al. **Semin Immunol** 1995 Apr;7(2):75–82 (67 ref.)

A family of murine NK cell receptors specific for target cell MHC class I molecules. Yokoyama WM, et al. **Semin Immunol** 1995 Apr;7(2):89–101 (93 ref.)

IMMUNOLOGY

Natural killer cells. Right-side-up and up-side-down NK-cell receptors. Yokoyama WM. **Curr Biol** 1995 Sep 1;5(9):982–5 (33 ref.)

Receptors and signals in early thymic selection. Levelt CN, et al. **Immunity** 1995 Dec;3(6):667–72 (68 ref.)

ISOLATION & PURIFICATION

Isolation and structural characterization of adhesin polysaccharide receptors. Cassels FJ, et al. **Methods Enzymol** 1995;253:69–91 (44 ref.)

METABOLISM

Sialoadhesin and related cellular recognition molecules of the immunoglobulin superfamily. Crocker PR, et al. **Biochem Soc Trans** 1996 Feb;24(1):150–6 (50 ref.)

Knowledge of cellular receptors for bacterial endotoxin—1995. Viriyakosol S, et al. **Clin Infect Dis** 1995 Oct;21 Suppl 2:S190–5 (41 ref.)

Antigen and Fc receptor signaling. The awesome power of the immunoreceptor tyrosine-based activation motif (ITAM). Cambier JC. **J Immunol** 1995 Oct 1;155(7):3281–5 (65 ref.)

How do multichain immune recognition receptors signal? A structural hypothesis. Ortega E. **Mol Immunol** 1995 Sep; 32(13):941–5 (40 ref.)

CD28/CTLA-4 receptor structure, binding stoichiometry and aggregation during T-cell activation. Linsley PS, et al. **Res Immunol** 1995 Mar–Apr;146(3):130–40 (78 ref.)

Targeting plant toxins to the urokinase and alpha 2-macroglobulin receptors. Cavallaro U, et al. **Semin Cancer Biol** 1995 Oct;6(5):269–78 (60 ref.)

PHYSIOLOGY

C-type lectins of natural killer cells: carbchydrate ligands and role in tumour cell lysis. Bezouška K. **Biochem Soc Trans** 1996 Feb;24(1):156–61 (24 ref.)

Membrane molecules and macrophage endocytosis: scavenger receptor and macrosialin as markers of plasma-membrane and vacuolar functions. da Silva RP, et al. **Biochem Soc Trans** 1996 Feb;24(1):220–4 (17 ref.)

Protein tyrosine phosphorylation as a mechanism of signalling in mast cells and basophils. Hamawy MM, et al. **Cell Signal** 1995 Aug;7(6):535–44 (90 ref.)

RAGE: a novel cellular receptor for advanced glycation end products. Schmidt AM, et al. **Diabetes** 1996 Jul;45 Suppl 3:S77–80 (14 ref.)

Recent progress in advanced glycation and diabetic vascular disease: role of advanced glycation end product receptors. Vlassara H, et al. **Diabetes** 1996 Jul;45 Suppl 3:S65–6 (17 ref.)

RECEPTORS, INSULIN

[Insulin receptor] Clauser E, et al. **Ann Endocrinol (Paris)** 1995;56(5):515–21 (25 ref.) (Eng. Abstr.) **(Fre)**

ANALYSIS

[Functional tests on insulin receptors] Kobayashi M. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:670–4 (6 ref.) **(Jpn)**

BIOSYNTHESIS

Insulin receptor gene expression and insulin resistance. Brunetti A, et al. **J Endocrinol Invest** 1995 May; 18(5):398–405 (44 ref.)

GENETICS

Mutant insulin receptors in syndromes of insulin resistance. Krook A, et al. **Baillieres Clin Endocrinol Metab** 1996 Jan; 10(1):97–122 (163 ref.)

Insulin receptor gene expression and insulin resistance. Brunetti A, et al. **J Endocrinol Invest** 1995 May; 18(5):398–405 (44 ref.)

METABOLISM

Insulin signal transduction and the IRS proteins. Myers MG Jr, et al. **Annu Rev Pharmacol Toxicol** 1996;36:615–58 (234 ref.)

Signal transduction through the IL-4 and insulin receptor families. Wang LM, et al. **Stem Cells (Dayt)** 1995 Jul; 13(4):360–8 (47 ref.)

PHYSIOLOGY

Diverse signaling pathways in the cellular actions of insulin. Saltiel AR. **Am J Physiol** 1996 Mar;270(3 Pt 1):E375–85 (97 ref.)

Insulin receptors in breast cancer. Belfiore A, et al. **Ann N Y Acad Sci** 1996 Apr 30;784:173–88 (18 ref.)

Mechanism of insulin and IGF-I receptor activation and signal transduction specificity. Receptor dimer cross-linking, bell-shaped curves, and sustained versus transient signaling. De Meyts P, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:388–401 (43 ref.)

Glucose transporters and insulin receptors in skeletal muscle. Physiology and pathophysiology. Handberg A. **Dan Med Bull** 1995 Jun;42(3):211–26 (173 ref.)

Pathogenesis of insulin resistance: modulation of the insulin signal at receptor level. Kellerer M, et al.

Diabetes Res Clin Pract 1995 Aug;28 Suppl:S173-7 (36 ref.)

RECEPTORS, INSULIN-LIKE-GROWTH FACTOR I

Insulin-like growth factor receptors and binding proteins. LeRoith D. **Baillieres Clin Endocrinol Metab** 1996 Jan; 10(1):49-73 (186 ref.)

METABOLISM

The role of the insulin-like growth factor system in human cancer. Werner H, et al. **Adv Cancer Res** 1996;68:183-223 (184 ref.)

Regulation of Leydig cell function by insulin-like growth factor-I and binding proteins. Lin T. **J Androl** 1995 May-Jun;16(3):193-6 (20 ref.)

Role of the time factor in signaling specificity: application to mitogenic and metabolic signaling by the insulin and insulin-like growth factor-I receptor tyrosine kinases. De Meyts P, et al. **Metabolism** 1995 Oct;44(10 Suppl 4):2-11 (88 ref.)

PHYSIOLOGY

Mechanism of insulin and IGF-I receptor activation and signal transduction specificity. Receptor dimer cross-linking, bell-shaped curves, and sustained versus transient signaling. De Meyts P, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:388-401 (43 ref.)

The role of the insulin-like growth factor-I receptor in cancer. LeRoith D, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:402-8 (30 ref.)

Insulin-like growth factor-I (IGF-I) receptors in breast cancer. Pezzino V, et al. **Ann N Y Acad Sci** 1996 Apr 30; 784:189-201 (43 ref.)

Insulin-like growth factor-I receptor. Its role in cell proliferation, apoptosis, and tumorigenicity. Rubin R, et al. **Lab Invest** 1995 Sep;73(3):311-31 (274 ref.)

IGF-I receptor signalling: lessons from the somatotroph. Melmed S, et al. **Recent Prog Horm Res** 1996;51:189-215; discussion 215-6 (65 ref.)

RECEPTORS, INSULIN-LIKE-GROWTH-FACTOR II

Insulin-like growth factor receptors and binding proteins. LeRoith D. **Baillieres Clin Endocrinol Metab** 1996 Jan; 10(1):49-73 (186 ref.)

PHYSIOLOGY

Insulin-like growth factor II/cation-independent mannose 6-phosphate receptor and lysosomal enzyme recognition. Dahms NM. **Biochem Soc Trans** 1996 Feb;24(1):136-41 (46 ref.)

Function of the two mannose 6-phosphate receptors in lysosomal enzyme transport. Munier-Lehmann H, et al. **Biochem Soc Trans** 1996 Feb;24(1):133-6 (23 ref.)

RECEPTORS, INSULIN-LIKE GROWTH FACTORS see **RECEPTORS, SOMATOMEDIN**

RECEPTORS, INTERFERON

DRUG EFFECTS

Interferon-alpha hybrids. Horisberger MA, et al. **Pharmacol Ther** 1995 Jun;66(3):507-34 (132 ref.)

RECEPTORS, INTERLEUKIN

ANTAGONISTS & INHIBITORS

Antagonizing the differentiation and functions of human T helper type 2 cells. de Vries JE, et al. **Curr Opin Immunol** 1995 Dec;7(6):771-8 (63 ref.)

BIOSYNTHESIS

Control of the production of soluble interleukin-4 receptors: implications in immunoregulation. Fernandez-Botran R, et al. **J Leukoc Biol** 1996 Apr;59(4):499-504 (35 ref.)

CHEMISTRY

Biology of natural and recombinant soluble interleukin-4 receptor. Ensslе K, et al. **Behring Inst Mitt** 1995 Jun; (96):103-17 (78 ref.)

[Structure and function of IL-5 receptor] Takatsu K. **Yakugaku Zasshi** 1995 Aug;115(8):570-83 (60 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Interleukin-5 receptor alpha subunit gene regulation in human eosinophil development: identification of a unique cis-element that acts lie an enhancer in regulating activity of the IL-5R alpha promoter. Sun Z, et al. **Curr Top Microbiol Immunol** 1996;211:173-87 (64 ref.)

IMMUNOLOGY

Therapeutic interference with interferon-gamma (IFN-gamma) and soluble IL-4 receptor (sIL-4R) in allergic diseases. Nasert S, et al. **Behring Inst Mitt** 1995 Jun;(96):118-30 (55 ref.)

Control of the production of soluble interleukin-4 receptors: implications in immunoregulation. Fernandez-Botran R, et al. **J Leukoc Biol** 1996 Apr;59(4):499-504 (35 ref.)

METABOLISM

Antagonistic mutant proteins of interleukin-4. Duschl A, et al. **Behring Inst Mitt** 1995 Jun;(96):87-94 (27 ref.)

Biology of natural and recombinant soluble interleukin-4 receptor. Ensslе K, et al. **Behring Inst Mitt** 1995 Jun; (96):103-17 (78 ref.)

Regulation of interleukin-4 activity by soluble interleukin-4 receptors. Ensslе K, et al. **J Clin Lab Anal** 1995;9(6):450-5 (38 ref.)

Signal transduction through the IL-4 and insulin receptor families. Wang LM, et al. **Stem Cells (Dayt)** 1995 Jul; 13(4):360-8 (47 ref.)

PHYSIOLOGY

Cytokine signal transduction through a homo- or heterodimer of gp130. Kishimoto T, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:224-34 (22 ref.)

Functional significance of IL-4 receptor on B cells in IL-4-induced human IgE production. Yanagihara Y, et al. **J Allergy Clin Immunol** 1995 Dec;96(6 Pt 2):1145-51 (39 ref.)

Interleukin-12: a cytokine with therapeutic potential in oncology and infectious diseases. Gately MK, et al. **Ther Immunol** 1994 Jun;1(3):187-96 (70 ref.)

Interleukin-10 and its receptor. Ho AS, et al. **Ther Immunol** 1994 Jun;1(3):173-85 (136 ref.)

[Cytokine binding proteins: a model of interleukin 6] Brailly H, et al. **Arch Inst Pasteur Tunis** 1994 Jul-Oct; 71(3-4):535-48 (35 ref.) **(Fre)**

[Structure and function of IL-5 receptor] Takatsu K. **Yakugaku Zasshi** 1995 Aug;115(8):570-83 (60 ref.) (Eng. Abstr.) **(Jpn)**

RECEPTORS, INTERLEUKIN-1

METABOLISM

Interleukin-1 receptors in the brain-endocrine-immune axis. Modulation by stress and infection. Takao T, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:372-85 (52 ref.)

Regulation of IL-1 activity by soluble IL-1 receptors. Kurrle R, et al. **Behring Inst Mitt** 1995 Jun;(96):45-57 (20 ref.)

PHYSIOLOGY

Interleukin I receptors and signal transduction. O'Neill LA. **Biochem Soc Trans** 1996 Feb;24(1):207-11 (44 ref.)

Interleukin-1 antagonists. Dower SK, et al. **Ther Immunol** 1994 Apr;1(2):113-22 (73 ref.)

RECEPTORS, INTERLEUKIN-2

The common gamma-chain for multiple cytokine receptors. Sugamura K, et al. **Adv Immunol** 1995;59:225-77 (256 ref.)

GENETICS

The cis-acting elements controlling mouse IL-2R alpha transcription. Nabholz M, et al. **Immunobiology** 1995 Jul; 193(2-4):259-62 (4 ref.)

CD28 costimulation regulates long-term expression of the three genes (alpha, beta, gamma) encoding the high-affinity IL2 receptor. Cerdan C, et al. **Res Immunol** 1995 Mar-Apr; 146(3):164-8 (43 ref.)

IMMUNOLOGY

Interleukin 15 and its receptor. Cosman D, et al. **Ciba Found Symp** 1995;195:221-9; discussion 229-33 (30 ref.)

Genetically engineered proteins for immunoregulation. Strom TB, et al. **Transplant Proc** 1995 Oct;27(5 Suppl 1):18-20 (20 ref.)

PHYSIOLOGY

Cell growth signal transduction is quantal. Smith KA. **Ann N Y Acad Sci** 1995 Sep 7;766:263-71 (27 ref.)

IL-2 signaling involves recruitment and activation of multiple protein tyrosine kinases by the IL-2 receptor. Taniguchi T, et al. **Ann N Y Acad Sci** 1995 Sep 7; 766:235-44 (22 ref.)

[Interleukin 2 receptor (Il-2): structure and function] Dmoszyńska A, et al. **Acta Haematol Pol** 1995;26(3):257-62 (19 ref.) (Eng. Abstr.) **(Pol)**

RECEPTORS, INTERSTITIAL CELL-STIMULATING HORMONE see **RECEPTORS, LH**

RECEPTORS, INVERTEBRATE PEPTIDE

METABOLISM

Pattern formation. Gurken meets torpedo for the first time. Gavis ER. **Curr Biol** 1995 Nov 1;5(11):1252-4 (14 ref.)

RECEPTORS, KAPPA see **RECEPTORS, OPIOID, KAPPA**

RECEPTORS, KAPPA OPIOID see **RECEPTORS, OPIOID, KAPPA**

RECEPTORS, LAMININ

PHYSIOLOGY

The 67-kDa laminin receptor and tumor progression. Montuori N, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 1):205-14 (60 ref.)

RECEPTORS, LDL

GENETICS

German population data on the loci low-density-lipoprotein receptor, glycophorin A, hemoglobin gamma G, D7S8 and group-specific component. Huckenbeck W, et al. **Anthropol Anz** 1995 Sep;53(3):193-8 (14 ref.)

Gene therapy: prospects for treatment of liver disease. Sandig V, et al. **Z Gastroenterol** 1996 Jun;34 Suppl 3:25-6 (32 ref.)

HISTORY

Cholesterol homeostasis: role of the LDL receptor. Javitt NB. **FASEB J** 1995 Oct;9(13):1378-81 (30 ref.)

METABOLISM

Heparan sulfate proteoglycan/low density lipoprotein receptor-related protein pathway involved in type III hyperlipoproteinemia and Alzheimer's disease. Mahley RW. **Isr J Med Sci** 1996 Jun;32(6):414-29 (72 ref.)

PHYSIOLOGY

Cellular metabolism of triglyceride-rich lipoproteins: role of heparan sulfate, lipoprotein lipase and lipoprotein receptors. Sehayek E, et al. **Z Gastroenterol** 1996 Jun;34 Suppl 3:110-2 (16 ref.)

RECEPTORS, LEUKOCYTE-ADHESION

see related
LEUKOCYTE ADHESION DEFICIENCY SYNDROME

RECEPTORS, LEUKOTRIENE

ANTAGONISTS & INHIBITORS

Leukotriene receptor antagonists and biosynthesis inhibitors: potential breakthrough in asthma therapy. Chung KF. **Eur Respir J** 1995 Jul;8(7):1203-13 (117 ref.)

Cysteinyl leukotrienes in asthma: current state of therapeutic evaluation. Taylor IK. **Thorax** 1995 Sep;50(9):1005-10 (93 ref.)

METABOLISM

Leukotriene receptors. Metters KM. **J Lipid Mediat Cell Signal** 1995 Oct;12(2-3):413-27 (126 ref.)

Modulators of leukotriene biosynthesis and receptor activation. Brooks CD, et al. **J Med Chem** 1996 Jul 5; 39(14):2629-54 (296 ref.)

Development of novel anti-inflammatory agents: a pharmacologic perspective on leukotrienes and their receptors. Jackson WT, et al. **Prog Drug Res** 1996; 46:115-68 (322 ref.)

RECEPTORS, LEUKOTRIENE B4

METABOLISM

Leukotriene receptors. Metters KM. **J Lipid Mediat Cell Signal** 1995 Oct;12(2-3):413-27 (126 ref.)

RECEPTORS, LH

Gonadotrophin receptors. Clayton RN. **Baillieres Clin Endocrinol Metab** 1996 Jan;10(1):1-8 (25 ref.)

GENETICS

TSH receptor and LH receptor, 1995. Kosugi S, et al. **Endocr J** 1995 Oct;42(5):587-606 (95 ref.)

Luteinizing hormone receptor mutations and sex differentiation. Themmen AP, et al. **Eur J Endocrinol** 1996 May;134(5):533-40 (60 ref.)

[Pituitary glycoprotein hormone receptors] Misrahi M, et al. **Ann Endocrinol (Paris)** 1995;56(5):487-93 (39 ref.) (Eng. Abstr.) **(Fre)**

RECEPTORS, LHRH

see related
INHIBIN

PHYSIOLOGY

Luteinizing hormone-releasing hormone (LHRH) receptors

in the neuroendocrine–immune network. Biochemical bases and implications for reproductive physiopathology. Marchetti B, et al. **Ann N Y Acad Sci** 1996 Apr 30; 784:209–36 (117 ref.)

Signal transduction of the gonadotropin releasing hormone (GnRH) receptor: cross-talk of calcium, protein kinase C (PKC), and arachidonic acid. Naor Z, et al. **Cell Mol Neurobiol** 1995 Oct;15(5):527–44 (142 ref.)

RECEPTORS, LIPOPOLYSACCHARIDE see **ANTIGENS, CD14**

RECEPTORS, LIPOPROTEIN

METABOLISM

Chylomicron assembly and catabolism: role of apolipoproteins and receptors. Hussain MM, et al. **Biochim Biophys Acta** 1996 May 20;1300(3):151–70 (313 ref.)

Chylomicron remnants: hepatic receptors and metabolism. Havel RJ. **Curr Opin Lipidol** 1995 Oct;6(5):312–6 (41 ref.)

A docking receptor for HDL cholesterol esters [comment] Steinberg D. **Science** 1996 Jan 26;271(5248):460–1 (15 ref.) Comment on: Science 1996 Jan 26;271(5248):518–20.

PHYSIOLOGY

[Physiology and pathophysiology of the metabolism of lipoproteins] Sandhofer F. **Wien Med Wochenschr** 1994; 144(12–13):286–90 (0 ref.) (Eng. Abstr.) **(Ger)**

RECEPTORS, LOW DENSITY LIPOPROTEIN see **RECEPTORS, LDL**

RECEPTORS, LULIBERIN see **RECEPTORS, LHRH**

RECEPTORS, LUTEINIZING HORMONE see **RECEPTORS, LH**

RECEPTORS, LYMPHOCYTE HOMING

From thymic lineages back to hematopoietic stem cells, sometimes using homing receptors. Weissman IL. **J Immunol** 1996 Mar 15;156(6):2019–25 (114 ref.)

ANTAGONISTS & INHIBITORS

The integrin alpha 4 beta 1 (VLA–4) as a therapeutic target. Elices MJ. **Ciba Found Symp** 1995;189:79–85; discussion 85–90, 174–6 (56 ref.)

Therapeutic approaches to asthma based on VLA–4 integrin and its counter receptors. Metzger WJ. **Springer Semin Immunopathol** 1995;16(4):467–78 (65 ref.)

Treatment of delayed-type hypersensitivity with inhibitors of the VLA–4 integrin. Tamraz S, et al. **Springer Semin Immunopathol** 1995;16(4):437–41 (36 ref.)

IMMUNOLOGY

The gut associated addressins: lymphocyte homing in the gut. De Keyser F, et al. **Baillieres Clin Rheumatol** 1996 Feb;10(1):25–39 (65 ref.)

METABOLISM

Mechanisms of VCAM–1 and fibronectin binding to integrin alpha 4 beta 1: implications for integrin function and rational drug design. Humphries MJ, et al. **Ciba Found Symp** 1995;189:177–91; discussion 191–9 (43 ref.)

PHYSIOLOGY

Lymphocyte homing and homeostasis. Butcher EC, et al. **Science** 1996 Apr 5;272(5258):60–6 (57 ref.)

Alpha 4–integrin–dependent emigration of monocytes. Chuluyan HE, et al. **Springer Semin Immunopathol** 1995; 16(4):391–404 (82 ref.)

Pathophysiological aspects of VLA–4 interactions and possibilities for therapeutical interventions. Kuijpers TW. **Springer Semin Immunopathol** 1995;16(4):379–89 (89 ref.)

Therapeutic approaches to asthma based on VLA–4 integrin and its counter receptors. Metzger WJ. **Springer Semin Immunopathol** 1995;16(4):467–78 (65 ref.)

VLA–4 and its ligands: relevance to kidney diseases. Rabb H, et al. **Springer Semin Immunopathol** 1995;16(4):417–25 (48 ref.)

RECEPTORS, MANNOSE–6–PHOSPHATE see **RECEPTORS, INSULIN–LIKE–GROWTH–FACTOR II**

RECEPTORS, MENOTROPIN see **RECEPTORS, GONADOTROPIN**

RECEPTORS, METABOTROPIC GLUTAMATE

ANTAGONISTS & INHIBITORS

Pharmacological tools for the investigation of metabotropic glutamate receptors (mGluRs): phenylglycine derivatives and other selective antagonists--an update. Roberts PJ. **Neuropharmacology** 1995 Aug;34(8):813–9 (38 ref.)

GENETICS

Inactivation in vivo of metabotropic glutamate receptor 1 by specific chromosomal insertion of reporter gene lacZ. Conquet F. **Neuropharmacology** 1995 Aug;34(8):865–70 (14 ref.)

METABOLISM

Pharmacological tools for the investigation of metabotropic glutamate receptors (mGluRs): phenylglycine derivatives and other selective antagonists--an update. Roberts PJ. **Neuropharmacology** 1995 Aug;34(8):813–9 (38 ref.)

PHYSIOLOGY

Retrotrapezoid nucleus (RTN) metabotropic glutamate receptors and long-term stimulation of ventilatory output. RTN glutamate receptors and breathing. Nattie EE, et al. **Adv Exp Med Biol** 1995;393:39–45 (27 ref.)

Get receptive to metabotropic glutamate receptors. Pin JP, et al. **Curr Opin Neurobiol** 1995 Jun;5(3):342–9 (60 ref.)

RECEPTORS, N-METHYL-D-ASPARTATE

Structure and function of the NMDA receptor channel. Mori H, et al. **Neuropharmacology** 1995 Oct;34(10):1219–37 (142 ref.)

NMDA antagonists: antiepileptic–neuroprotective drugs with diversified neuropharmacological profiles. Sagratella S. **Pharmacol Res** 1995 Jul–Aug;32(1–2):1–13 (124 ref.)

AGONISTS

Co-agonism in drug–receptor interaction: illustrated by the NMDA receptors. Corsi M, et al. **Trends Pharmacol Sci** 1996 Jun;17(6):220–2 (14 ref.)

ANTAGONISTS & INHIBITORS

Should N-methyl-D-aspartate or non-N-methyl-D-aspartate glutamate receptor antagonist be used in amyotrophic lateral sclerosis? Blin O. **Adv Neurol** 1995;68:259–61 (16 ref.)

Excitotoxic blocking strategies in amyotrophic lateral sclerosis. Hugon J. **Adv Neurol** 1995;68:245–52; discussion 253–8 (56 ref.)

Neuroprotective properties of the uncompetitive NMDA receptor antagonist remacemide hydrochloride. Palmer GC, et al. **Ann N Y Acad Sci** 1995 Sep 15;765:236–47; discussion 248 (38 ref.)

N-methyl-D-aspartate (NMDA) receptors, mu and kappa opioid tolerance, and perspectives on new analgesic drug development. Elliott K, et al. **Neuropsychopharmacology** 1995 Dec;13(4):347–56 (58 ref.)

The effects of NMDA receptor antagonists and nitric oxide synthase inhibitors on opioid tolerance and withdrawal. Medication development issues for opiate addiction. Herman BH, et al. **Neuropsychopharmacology** 1995 Dec; 13(4):269–93 (165 ref.)

Effects of noncompetitive N-methyl-D-aspartate receptor antagonists on opiate tolerance and physical dependence. Trujillo KA. **Neuropsychopharmacology** 1995 Dec; 13(4):301–7 (38 ref.)

Noncompetitive NMDA receptor antagonists with fast open-channel blocking kinetics and strong voltage-dependency as potential therapeutic agents for Alzheimer's dementia. Müller WE, et al. **Pharmacopsychiatry** 1995 Jul;28(4):113–24 (90 ref.)

[New therapeutic possibilities with low-affinity NMDA receptor antagonists] Kornhuber J, et al. **Nervenarzt** 1996 Jan;67(1):77–82 (22 ref.) (Eng. Abstr.) **(Ger)**

CLASSIFICATION

Ionotropic glutamate receptors--focus on non-NMDA receptors. Jørgensen M, et al. **Pharmacol Toxicol** 1995 May; 76(5):312–9 (48 ref.)

DRUG EFFECTS

Perspectives on the N-methyl-D-aspartate/nitric oxide cascade and opioid tolerance. Pasternak GW, et al. **Neuropsychopharmacology** 1995 Dec;13(4):309–13 (24 ref.)

Future directions in the pharmacological management of hyperalgesic and allodynic pain states: the NMDA receptor. Yaksh TL, et al. **NIDA Res Monogr** 1995; 147:84–103 (63 ref.)

Modulation of channel function by polyamines. Johnson TD. **Trends Pharmacol Sci** 1996 Jan;17(1):22–7 (52 ref.)

METABOLISM

Synaptic targeting of glutamate receptors. Ehlers MD, et al. **Curr Opin Cell Biol** 1996 Aug;8(4):484–9 (54 ref.)

Alternatively spliced isoforms of the NMDAR1 receptor subunit. Zukin RS, et al. **Trends Neurosci** 1995 Jul; 18(7):306–13 (51 ref.)

NMDA receptor redox sites: are they targets for selective neuronal protection? [see comments] Gozlan H, et al. **Trends Pharmacol Sci** 1995 Nov;16(11):368–74 (80 ref.) Comment in: Trends Pharmacol Sci 1996 May;17(5):186–7; discussion 187–9.

[Hyperglycinemia without ketosis and NMDA receptor dysfunction] Ponsot G. **Arch Pediatr** 1996;3 Suppl 1:172s–175s (27 ref.) **(Fre)**

PHYSIOLOGY

Neuroprotective use-dependent blockers of Na+ and Ca2+ channels controlling presynaptic release of glutamate. Goldin SM, et al. **Ann N Y Acad Sci** 1995 Sep 15;765:210–29 (59 ref.)

Neurotransmitters. NMDA receptors: do glia hold the key? Cull-Candy S. **Curr Biol** 1995 Aug 1;5(8):841–3 (25 ref.)

The N-methyl-D-aspartate receptor and schizophrenia. Strous RD, et al. **Isr J Med Sci** 1996 May;32(5):275–81 (51 ref.)

Roles of cytokines in the neural–immune interactions: modulation of NMDA responses by IFN-alpha. Katafuchi T, et al. **Neurobiology (Bp)** 1995;3(3–4):319–27 (39 ref.)

The site of expression of NMDA receptor-dependent LTP: new fuel for an old fire. Kullmann DM, et al. **Neuron** 1995 Nov;15(5):997–1002 (22 ref.)

The role of the locus coeruleus and N-methyl-D-aspartic acid (NMDA) and AMPA receptors in opiate withdrawal. Rasmussen K. **Neuropsychopharmacology** 1995 Dec; 13(4):295–300 (165 ref.)

Long-term potentiation and N-methyl-D-aspartate receptors: foundations of memory and neurologic disease? Rison RA, et al. **Neurosci Biobehav Rev** 1995 Winter; 19(4):533–52 (223 ref.)

Modulation of channel function by polyamines. Johnson TD. **Trends Pharmacol Sci** 1996 Jan;17(1):22–7 (52 ref.)

NMDA receptor-dependent excitotoxicity: the role of intracellular Ca2+ release. Mody I, et al. **Trends Pharmacol Sci** 1995 Oct;16(10):356–9 (68 ref.)

RECEPTORS, MINERALOCORTICOID

ANTAGONISTS & INHIBITORS

Mineralocorticoid receptor blockade in chronic heart failure. Struthers AD. **J Hum Hypertens** 1995 Jun;9(6):443–6 (21 ref.)

METABOLISM

The promiscuous receptor: a case for the guardian enzyme. Weber KT, et al. **Cardiovasc Res** 1995 Aug;30(2):176–80 (34 ref.)

Mineralocorticoid receptors in the central nervous system. Funder JW. **J Steroid Biochem Mol Biol** 1996 Jan;56(1–6 Spec No):179–83 (44 ref.)

PHYSIOLOGY

[New data on mineralocorticoid hormones. Physiopathological implications (editorial)] Corvol P, et al. **Presse Med** 1995 Sep 23;24(27):1235–7 (12 ref.) (Eng. Abstr.) **(Fre)**

RECEPTORS, MORPHINE see **RECEPTORS, OPIOID, MU**

RECEPTORS, MU see **RECEPTORS, OPIOID, MU**

RECEPTORS, MU OPIOID see **RECEPTORS, OPIOID, MU**

RECEPTORS, MUSCARINIC

DRUG EFFECTS

Muscarinic signaling in the central nervous system. Recent developments and anesthetic implications. Durieux ME. **Anesthesiology** 1996 Jan;84(1):173–89 (171 ref.)

METABOLISM

Increased sensitivity to oxidative stress and the loss of muscarinic receptor responsiveness in senescence. Joseph JA, et al. **Ann N Y Acad Sci** 1996 Jun 15;786:112–9 (47 ref.)

Continuing the search for cholinergic factors in cognitive dysfunction. Russell RW. **Life Sci** 1996;58(22):1965–70 (15 ref.)

PHYSIOLOGY

Muscarinic signaling in the central nervous system. Recent developments and anesthetic implications. Durieux ME. **Anesthesiology** 1996 Jan;84(1):173–89 (171 ref.)

The parasympathetic system and its muscarinic receptors in hypertensive disease. van Zwieten PA, et al. **J Hypertens** 1995 Oct;13(10):1079–90 (79 ref.)

Adrenergic and muscarinic receptor regulation and therapeutic implications in heart failure. Schmitz W, et al. **Mol Cell Biochem** 1996 Apr 12–26;157(1–2):251–8 (91 ref.)

Regulation of phospholamban and troponin-I phosphorylation in the intact rat cardiomyocytes by adrenergic and cholinergic stimuli: roles of cyclic nucleotides, calcium, protein kinases and phosphatases and depolarization. Sulakhe PV, et al. **Mol Cell Biochem** 1995 Aug–Sep;149–150:103–26 (96 ref.)

[The muscarinic system of the gastrointestinal smooth muscle] Cuq P. **Gastroenterol Clin Biol** 1995 Aug–Sep; 19(8–9):675–84 (101 ref.) **(Fre)**

RECEPTORS, MUSCIMOL

RECEPTORS, MUSCIMOL see **RECEPTORS, GABA-A**

RECEPTORS, NARCOTIC see **RECEPTORS, OPIOID**

RECEPTORS, NERVE GROWTH FACTOR

BIOSYNTHESIS

Neurotrophins and their receptors in chicken neuronal development. Hallböok F, et al. **Int J Dev Biol** 1995 Oct; 39(5):855–68 (115 ref.)

Expression of the trk family of neurotrophin receptors in developing and adult dorsal root ganglion neurons. Phillips HS, et al. **Philos Trans R Soc Lond B Biol Sci** 1996 Mar 29;351(1338):413–6 (30 ref.)

CHEMISTRY

Structural and functional properties of the TRK family of neurotrophin receptors. Barbacid M. **Ann N Y Acad Sci** 1995 Sep 7;766:442–58 (67 ref.)

The nerve growth factor/tumor necrosis factor receptor family. Lotz M, et al. **J Leukoc Biol** 1996 Jul;60(1):1–7 (91 ref.)

METABOLISM

Early events in neurotrophin signalling via Trk and p75 receptors. Greene LA, et al. **Curr Opin Neurobiol** 1995 Oct;5(5):579–87 (72 ref.)

Induction of non-catalytic TrkB neurotrophin receptors during lesion-induced synaptic rearrangement in the adult rat hippocampus. Beck KD, et al. **Prog Brain Res** 1995; 105:197–210 (80 ref.)

Neurotrophic factors and their receptors. Ip NY, et al. **Prog Brain Res** 1995;105:189–95 (30 ref.)

p75 and Trk: a two-receptor system. Chao MV, et al. **Trends Neurosci** 1995 Jul;18(7):321–6 (61 ref.)

PHYSIOLOGY

Growth factors and the glomerulus: relationships between development and injury. Alpers CE, et al. **Adv Nephrol Necker Hosp** 1995;24:33–52 (85 ref.)

Structural and functional properties of the TRK family of neurotrophin receptors. Barbacid M. **Ann N Y Acad Sci** 1995 Sep 7;766:442–58 (67 ref.)

The nerve growth factor/tumor necrosis factor receptor family. Lotz M, et al. **J Leukoc Biol** 1996 Jul;60(1):1–7 (91 ref.)

Mechanisms of estrogen action during neural development: mediation by interactions with the neurotrophins and their receptors? Toran-Allerand CD. **J Steroid Biochem Mol Biol** 1996 Jan;56(1–6 Spec No):169–78 (77 ref.)

Dorsal root ganglion neurons require functional neurotrophin receptors for survival during development. Snider WD, et al. **Philos Trans R Soc Lond B Biol Sci** 1996 Mar 29; 351(1338):395–403 (56 ref.)

p75NTR: a receptor after all [see comments] Bothwell M. **Science** 1996 Apr 26;272(5261):506–7 (20 ref.) Comment in: Science 1996 Apr 26;272(5261):542–5.

RECEPTORS, NEU see **PROTO-ONCOGENE PROTEINS C-ERBB-2**

RECEPTORS, NEURAL see **RECEPTORS, SENSORY**

RECEPTORS, NEUROHUMOR see **RECEPTORS, NEUROTRANSMITTER**

RECEPTORS, NEUROKININ-1

ANTAGONISTS & INHIBITORS

Recent developments in tachykinin NK1 receptor antagonists: prospects for the treatment of migraine headache. Beattie DT, et al. **Can J Physiol Pharmacol** 1995 Jul;73(7):871–7 (53 ref.)

[Discovery and pharmacological properties of selective neurokinin-receptor antagonists, FK224 and FK888] Fujii T. **Nippon Yakurigaku Zasshi** 1995 Sep;106(3):193–204 (34 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Alterations in neurokinin 1 receptor gene expression in models of pain and inflammation. Krause JE, et al. **Can J Physiol Pharmacol** 1995 Jul;73(7):854–9 (49 ref.)

METABOLISM

Increased substance P receptor expression by blood vessels and lymphoid aggregates in Clostridium difficile-induced pseudomembranous colitis. Mantyh CR, et al. **Dig Dis Sci** 1996 Mar;41(3):614–20 (22 ref.)

PHYSIOLOGY

Neurokinin receptors subserving bronchoconstriction. Ellis JL. **Can J Physiol Pharmacol** 1995 Jul;73(7):923–6 (32 ref.)

Mutational analysis of neurokinin receptor function. Fong TM, et al. **Can J Physiol Pharmacol** 1995 Jul;73(7):860–5 (22 ref.)

Neurokinin receptors subserving airways secretion. Rogers DF. **Can J Physiol Pharmacol** 1995 Jul;73(7):932–9 (80 ref.)

RECEPTORS, NEUROKININ-2

ANTAGONISTS & INHIBITORS

Tachykinin NK2 receptors further characterized in the lung with nonpeptide receptor antagonists. Advenier C. **Can J Physiol Pharmacol** 1995 Jul;73(7):878–84 (73 ref.)

[Discovery and pharmacological properties of selective neurokinin-receptor antagonists, FK224 and FK888] Fujii T. **Nippon Yakurigaku Zasshi** 1995 Sep;106(3):193–204 (34 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Neurokinin receptors subserving bronchoconstriction. Ellis JL. **Can J Physiol Pharmacol** 1995 Jul;73(7):923–6 (32 ref.)

Neurokinin receptors subserving airways secretion. Rogers DF. **Can J Physiol Pharmacol** 1995 Jul;73(7):932–9 (80 ref.)

RECEPTORS, NEUROKININ-3

ANTAGONISTS & INHIBITORS

[Discovery and pharmacological properties of selective neurokinin-receptor antagonists, FK224 and FK888] Fujii T. **Nippon Yakurigaku Zasshi** 1995 Sep;106(3):193–204 (34 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Neurokinin receptors subserving bronchoconstriction. Ellis JL. **Can J Physiol Pharmacol** 1995 Jul;73(7):923–6 (32 ref.)

RECEPTORS, NEUROMEDIN B see **RECEPTORS, BOMBESIN**

RECEPTORS, NEUROPEPTIDE

ANALYSIS

Neuropeptides in the adrenal gland: distribution, localization of receptors, and effects on steroid hormone synthesis. Tóth IE, et al. **Endocr Res** 1995 Feb-May;21(1–2):39–51 (135 ref.)

Neuropeptide receptors in health and disease: the molecular basis for in vivo imaging. Reubi JC. **J Nucl Med** 1995 Oct; 36(10):1825–35 (61 ref.)

METABOLISM

Peptidergic transmission: from morphological correlates to functional implications. Zupanc GK. **Micron** 1996 Feb; 27(1):35–91 (630 ref.)

PHYSIOLOGY

Tachykinin peptides, receptors, and peptidases in airway disease. Piedimonte G. **Exp Lung Res** 1995 Nov-Dec; 21(6):809–34 (154 ref.)

Peptidergic transmission: from morphological correlates to functional implications. Zupanc GK. **Micron** 1996 Feb; 27(1):35–91 (630 ref.)

ACTH-related peptides: receptors and signal transduction systems involved in their neurotrophic and neuroprotective actions. Hol EM, et al. **Peptides** 1995;16(5):979–93 (150 ref.)

[Interactions of neuromediators and neurohormones on dendritic cells, monocytes and macrophages (out of the central nervous system)] Misery L, et al. **Pathol Biol (Paris)** 1995 Dec;43(10):876–81 (66 ref.) (Eng. Abstr.) **(Fre)**

RECEPTORS, NEUROTENSIN

CLASSIFICATION

The neurotensin receptor: is there more than one subtype? Le F, et al. **Trends Pharmacol Sci** 1996 Jan;17(1):1–3 (22 ref.)

METABOLISM

Functional consequences of retrograde axonal transport of receptor-bound neurotensin. Laduron PM. **Trends Pharmacol Sci** 1995 Oct;16(10):338–43 (55 ref.)

PHYSIOLOGY

Neurotensin receptors: binding properties, transduction pathways, and structure. Vincent JP. **Cell Mol Neurobiol** 1995 Oct;15(5):501–12 (71 ref.)

RECEPTORS, NEUROTRANSMITTER

[Analysis of receptor-ion channel functions in Xenopus oocyte translation system] Kaneko S. **Nippon Yakurigaku Zasshi** 1995 Oct;106(4):243–53 (50 ref.) (Eng. Abstr.) **(Jpn)**

DRUG EFFECTS

Psychopharmacology of Alzheimer's disease. Procter AW. **Br J Hosp Med** 1996 Feb 21–Mar 5;55(4):191–4 (20 ref.)

Antiepileptic drug mechanisms of action. Macdonald RL, et al. **Epilepsia** 1995;36 Suppl 2:S2–12 (112 ref.)

The pharmacologic profile of mirtazapine. de Boer T. **J Clin Psychiatry** 1996;57 Suppl 4:19–25 (48 ref.)

[Do general anesthetics act on specific receptors?] Urban BW, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Oct;30(6):375–82 (55 ref.) (Eng. Abstr.) **(Ger)**

METABOLISM

Anatomy and transmitter receptors of the supplementary motor areas in the human and nonhuman primate brain. Zilles K, et al. **Adv Neurol** 1996;70:29–43 (90 ref.)

Neurotransmitter receptors in the developing cerebral cortex. Lidow MS, et al. **Crit Rev Neurobiol** 1995;9(4):395–418 (162 ref.)

[Receptor mediated Ca influx and Ca-permeable channels] Inoue R. **Fukuoka Igaku Zasshi** 1996 Apr;87(4):92–6 (15 ref.) **(Jpn)**

PHYSIOLOGY

Neural receptors and asthma. Baraniuk JN. **Allergy Proc** 1995 Sep-Oct;16(5):227–33 (76 ref.)

Regulation of ionotropic receptors by protein phosphorylation. Pasqualotto BA, et al. **Biochem Pharmacol** 1996 Jun 14;51(11):1417–25 (77 ref.)

RECEPTORS, NGF see **RECEPTORS, NERVE GROWTH FACTOR**

RECEPTORS, NICOTINIC

CHEMISTRY

The emerging three-dimensional structure of a receptor. The nicotinic acetylcholine receptor. Hucho F, et al. **Eur J Biochem** 1996 Aug 1;239(3):539–57 (180 ref.)

Agonist self-inhibitory binding site of the nicotinic acetylcholine receptor. Arias HR. **J Neurosci Res** 1996 Apr 15;44(2):97–105 (72 ref.)

DRUG EFFECTS

Sites, mechanisms, and structural characteristics of the brain's nicotine receptor. Abood LG, et al. **J Subst Abuse** 1989; 1(3):259–71 (50 ref.)

Differential effect of chronic nicotine treatment on nicotinic receptor numbers in various brain regions of mice. Collins AC, et al. **J Subst Abuse** 1989;1(3):273–86 (43 ref.)

Actions of neurotoxins (bungarotoxins, neosurugatoxin and lophotoxins) on insect and nematode nicotinic acetylcholine receptors. Tornøe C, et al. **Toxicon** 1995 Apr;33(4):411–24 (61 ref.)

GENETICS

Neuronal nicotinic receptors: molecular organization and regulations. Galzi JL, et al. **Neuropharmacology** 1995 Jun; 34(6):563–82 (215 ref.)

PHYSIOLOGY

Alkaloids from frog skins: selective probes for ion channels and nicotinic receptors. Daly JW. **Braz J Med Biol Res** 1995 Oct;28(10):1033–42 (28 ref.)

Structure and function of glutamate and nicotinic acetylcholine receptors. Dani JA, et al. **Curr Opin Neurobiol** 1995 Jun;5(3):310–7 (81 ref.)

Agonist self-inhibitory binding site of the nicotinic acetylcholine receptor. Arias HR. **J Neurosci Res** 1996 Apr 15;44(2):97–105 (72 ref.)

Molecular and cellular aspects of nicotine abuse. Dani JA, et al. **Neuron** 1996 May;16(5):905–8 (25 ref.)

Toward a structural basis for the function of nicotinic acetylcholine receptors and their cousins. Karlin A, et al. **Neuron** 1995 Dec;15(6):1231–44 (138 ref.)

Nicotinic receptors in the development and modulation of CNS synapses. Role LW, et al. **Neuron** 1996 Jun; 16(6):1077–85 (132 ref.)

Neuronal nicotinic receptors: molecular organization and regulations. Galzi JL, et al. **Neuropharmacology** 1995 Jun; 34(6):563–82 (215 ref.)

RECEPTORS, NK-2 see **RECEPTORS, NEUROKININ-2**

RECEPTORS, NK-3 see **RECEPTORS, NEUROKININ-3**

RECEPTORS, NMDA see **RECEPTORS, N-METHYL-D-ASPARTATE**

RECEPTORS, NOREPINEPHRINE see **RECEPTORS, ADRENERGIC**

RECEPTORS, ODORANT

GENETICS

Spatial patterning and information coding in the olfactory system. Sullivan SL, et al. **Curr Opin Genet Dev** 1995 Aug; 5(4):516–23 (66 ref.)

PHYSIOLOGY

Olfactory learning. Keverne EB. **Curr Opin Neurobiol** 1995 Aug;5(4):482–8 (34 ref.)

Odor images and tunes. Laurent G. **Neuron** 1996 Mar; 16(3):473–6 (25 ref.)

RECEPTORS, OPIATE see RECEPTORS, OPIOID

RECEPTORS, OPIOID

[Molecular biology of opioid receptor] He XL, et al. **Sheng Li Ke Hsueh Chin Chan** 1995 Oct;26(4):341-3 (9 ref.) **(Chi)**

[Cloning and expression of cDNA for the opioid receptor] Fukuda K. **Masui** 1995;44 Suppl:S119-20 (4 ref.) **(Jpn)**

AGONISTS

Etorphine elicits unique inhibitory-agonist and excitatory-antagonist actions at opioid receptors on sensory neurons: new rationale for improved clinical analgesia and treatment of opiate addiction. Crain SM, et al. **NIDA Res Monogr** 1995;147:234-68 (67 ref.)

ANTAGONISTS & INHIBITORS

Etorphine elicits unique inhibitory-agonist and excitatory-antagonist actions at opioid receptors on sensory neurons: new rationale for improved clinical analgesia and treatment of opiate addiction. Crain SM, et al. **NIDA Res Monogr** 1995;147:234-68 (67 ref.)

CHEMISTRY

On the role of extracellular loops of opioid receptors in conferring ligand selectivity. Metzger TG, et al. **FEBS Lett** 1995 Nov 13;375(1-2):1-4 (21 ref.)

Molecular biology of the opioid receptors: structures, functions and distributions. Minami M, et al. **Neurosci Res** 1995 Sep;23(2):121-45 (164 ref.)

CLASSIFICATION

Molecular biology of the opioid receptors: structures, functions and distributions. Minami M, et al. **Neurosci Res** 1995 Sep;23(2):121-45 (164 ref.)

DRUG EFFECTS

Modulation of drug-induced sensitization processes by endogenous opioid systems. Spanagel R. **Behav Brain Res** 1995 Sep;70(1):37-49 (148 ref.)

Transnasal butorphanol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute pain management. Gillis JC, et al. **Drugs** 1995 Jul; 50(1):157-75 (47 ref.)

Opiate receptors. Reisine T. **Neuropharmacology** 1995 May; 34(5):463-72 (70 ref.)

GENETICS

Molecular pharmacology of the opioid receptors. Satoh M, et al. **Pharmacol Ther** 1995;68(3):343-64 (158 ref.)

METABOLISM

Opioids and pain. Kanjhan R. **Clin Exp Pharmacol Physiol** 1995 Jun-Jul;22(6-7):397-403 (72 ref.)

On the role of extracellular loops of opioid receptors in conferring ligand selectivity. Metzger TG, et al. **FEBS Lett** 1995 Nov 13;375(1-2):1-4 (21 ref.)

Molecular pharmacology of the opioid receptors. Satoh M, et al. **Pharmacol Ther** 1995;68(3):343-64 (158 ref.)

Mapping of opioid receptors using antisense oligodeoxynucleotides: correlating their molecular biology and pharmacology. Pasternak GW, et al. **Trends Pharmacol Sci** 1995 Oct;16(10):344-50 (57 ref.)

PHYSIOLOGY

Molecular mechanisms of opiate receptor coupling to G proteins and effector systems. Reisine T, et al. **Ann N Y Acad Sci** 1996 Mar 22;780:168-75 (34 ref.)

Recent advances in molecular recognition and signal transduction of active peptides: receptors for opioid peptides. Kieffer BL. **Cell Mol Neurobiol** 1995 Dec; 15(6):615-35 (101 ref.)

Opiate receptors. Reisine T. **Neuropharmacology** 1995 May; 34(5):463-72 (70 ref.)

Molecular biology of the opioid receptors: structures, functions and distributions. Minami M, et al. **Neurosci Res** 1995 Sep;23(2):121-45 (164 ref.)

Opioid receptors in the superficial layers of the rat spinal cord: functional implications in pain processing. Lombard MC, et al. **Prog Brain Res** 1995;104:77-92 (79 ref.)

Opioid receptors and the regulation of ion conductances. Grudt TJ, et al. **Rev Neurosci** 1995 Jul-Sep;6(3):279-86 (45 ref.)

RECEPTORS, OPIOID, DELTA

DRUG EFFECTS

Opioid infidelity: novel opioid peptides with dual high affinity for delta- and mu-receptors. Lazarus LH, et al. **Trends Neurosci** 1996 Jan;19(1):31-5 (64 ref.)

METABOLISM

Opioid receptor types and subtypes: the delta receptor as a model. Zaki PA, et al. **Annu Rev Pharmacol Toxicol** 1996; 36:379-401 (94 ref.)

RECEPTORS, OPIOID, KAPPA

DRUG EFFECTS

N-methyl-D-aspartate (NMDA) receptors, mu and kappa opioid tolerance, and perspectives on new analgesic drug development. Elliott K, et al. **Neuropsychopharmacology** 1995 Dec;13(4):347-56 (58 ref.)

METABOLISM

Opioid receptor types and subtypes: the delta receptor as a model. Zaki PA, et al. **Annu Rev Pharmacol Toxicol** 1996; 36:379-401 (94 ref.)

PHYSIOLOGY

Signal transduction in the cardiac k-receptor. Wong TM, et al. **Biol Signals** 1995 May-Jun;4(3):174-8 (18 ref.)

RECEPTORS, OPIOID, MU

AGONISTS

Remifentanil pharmacokinetics and pharmacodynamics. A preliminary appraisal. Egan TD. **Clin Pharmacokinet** 1995 Aug;29(2):80-94 (41 ref.)

Methoclocinnamox: a mu partial agonist with pharmacotherapeutic potential for heroin abuse. Woods JH, et al. **NIDA Res Monogr** 1995;147:195-219 (29 ref.)

DRUG EFFECTS

N-methyl-D-aspartate (NMDA) receptors, mu and kappa opioid tolerance, and perspectives on new analgesic drug development. Elliott K, et al. **Neuropsychopharmacology** 1995 Dec;13(4):347-56 (58 ref.)

Opioid infidelity: novel opioid peptides with dual high affinity for delta- and mu-receptors. Lazarus LH, et al. **Trends Neurosci** 1996 Jan;19(1):31-5 (64 ref.)

METABOLISM

Opioid receptor types and subtypes: the delta receptor as a model. Zaki PA, et al. **Annu Rev Pharmacol Toxicol** 1996; 36:379-401 (94 ref.)

PHYSIOLOGY

Transgenic mice: preproenkephalin and the mu opiate receptor. Donovan DM, et al. **Ann N Y Acad Sci** 1996 Mar 22;780:19-28 (28 ref.)

RECEPTORS, OXYTOCIN

Vasopressin and oxytocin receptors. Zingg HH. **Baillieres Clin Endocrinol Metab** 1996 Jan;10(1):75-96 (118 ref.)

ANTAGONISTS & INHIBITORS

Advances in the design of selective antagonists, potential tocolytics, and radioiodinated ligands for oxytocin receptors. Manning M, et al. **Adv Exp Med Biol** 1995; 395:559-83 (111 ref.)

The role of drug metabolism in drug discovery: a case study in the selection of an oxytocin receptor antagonist for development. Chiu SH, et al. **Toxicol Pathol** 1995 Mar-Apr;23(2):124-30 (12 ref.)

GENETICS

Vasopressin and oxytocin: molecular biology and evolution of the peptide hormones and their receptors. Mohr E, et al. **Vitam Horm** 1995;51:235-66 (137 ref.)

METABOLISM

Advances in the design of selective antagonists, potential tocolytics, and radioiodinated ligands for oxytocin receptors. Manning M, et al. **Adv Exp Med Biol** 1995; 395:559-83 (111 ref.)

Mechanisms regulating oxytocin receptor coupling to phospholipase C in rat and human myometrium. Sanborn BM, et al. **Adv Exp Med Biol** 1995;395:469-79 (54 ref.)

PHYSIOLOGY

Molecular neurobiology and pharmacology of the vasopressin/oxytocin receptor family. Peter J, et al. **Cell Mol Neurobiol** 1995 Oct;15(5):573-95 (100 ref.)

Molecular Endocrinology of the oxytocin receptor. Kimura T, et al. **Endocr J** 1995 Oct;42(5):607-15 (62 ref.)

Interferon, the oxytocin receptor and the maternal recognition of pregnancy in ruminants and non-ruminants: a comparative approach. Flint AP. **Reprod Fertil Dev** 1995; 7(3):313-8 (31 ref.)

RECEPTORS, PAIN see NOCICEPTORS

RECEPTORS, PANCREOZYMIN see RECEPTORS, CHOLECYSTOKININ

RECEPTORS, PARATHYROID HORMONE

Serpentine receptors for parathyroid hormone, calcitonin and extracellular calcium ions. Brown EM, et al. **Baillieres Clin Endocrinol Metab** 1996 Jan;10(1):123-61 (173 ref.)

CHEMISTRY

Structural requirements of parathyroid hormone/parathyroid hormone-related peptide receptors for phospholipase C activation and regulation of phosphate uptake. Iida-Klein A, et al. **Miner Electrolyte Metab** 1995;21(1-3):177-9 (16 ref.)

METABOLISM

Functional properties of the PTH/PTHrP receptor. Jüppner H. **Bone** 1995 Aug;17(2 Suppl):39S-42S (20 ref.)

Approaches to studying the biomolecular interaction between the parathyroid hormone/parathyroid hormone-related protein receptor and its ligands. Chorev M, et al. **Miner Electrolyte Metab** 1995;21(1-3):133-9 (51 ref.)

PHYSIOLOGY

Non-traditional actions of parathyroid hormone: an overview. Potts JT Jr. **Miner Electrolyte Metab** 1995; 21(1-3):9-12 (12 ref.)

RECEPTORS, PCP see RECEPTORS, PHENCYCLIDINE

RECEPTORS, PDGF see RECEPTORS, PLATELET-DERIVED GROWTH FACTOR

RECEPTORS, PEPTIDE

G-protein-coupled receptors in HL-60 human leukemia cells. Klinker JF, et al. **Gen Pharmacol** 1996 Jan;27(1):33-54 (247 ref.)

ANALYSIS

Receptors for calcitonin, calcitonin gene related peptide, amylin, and adrenomedullin. Muff R, et al. **Can J Physiol Pharmacol** 1995 Jul;73(7):963-7 (54 ref.)

CLASSIFICATION

Pharmacology of receptors for calcitonin gene-related peptide and amylin. Poyner D. **Trends Pharmacol Sci** 1995 Dec;16(12):424-8 (56 ref.)

DRUG EFFECTS

Adhesive receptors expressed by tumor cells and platelets: novel targets for therapeutic anti-metastatic strategies. Oleksowicz L, et al. **Med Oncol** 1995 Jun;12(2):95-102 (161 ref.)

METABOLISM

Gastric intrinsic factor and its receptor. Nicolas JP, et al. **Baillieres Clin Haematol** 1995 Sep;8(3):515-31 (99 ref.)

Transcobalamin II and the membrane receptor for the transcobalamin II-cobalamin complex. Rothenberg SP, et al. **Baillieres Clin Haematol** 1995 Sep;8(3):499-514 (100 ref.)

PHYSIOLOGY

[The peptidergic correction of hemorrhagic shock] Bastrikova NA, et al. **Usp Fiziol Nauk** 1996 Jan-Mar; 27(1):32-46 (100 ref.) (Eng. Abstr.) **(Rus)**

ULTRASTRUCTURE

[A morphofunctional analysis of the nuclear apparatus of the nonapeptidergic neurosecretory cells in the vertebrate hypothalamus] Polenov AL, et al. **Tsitologiia** 1996; 38(1):28-38 (55 ref.) (Eng. Abstr.) **(Rus)**

RECEPTORS, PEPTIDE, INVERTEBRATE see RECEPTORS, INVERTEBRATE PEPTIDE

RECEPTORS, PHENCYCLIDINE

DRUG EFFECTS

Enhanced N-methyl-D-aspartate (NMDA)-induced activity following morphine: sensitivity to sigma and PCP ligands. Larson AA, et al. **NIDA Res Monogr** 1995;147:146-60 (20 ref.)

RECEPTORS, PHEROMONE see CHEMORECEPTORS

RECEPTORS, PITUITARY HORMONE

GENETICS

[Recombinant receptors for testing agonists and antagonists of VIP and PACAP receptors] Robberecht P, et al. **J Pharm Belg** 1996 May-Jun;51(3):165-9 (28 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Pituitary adenylate cyclase-activating polypeptide (PACAP) and PACAP/vasoactive intestinal polypeptide receptors: actions on the anterior pituitary gland. Rawlings SR, et al. **Endocr Rev** 1996 Feb;17(1):4-29 (170 ref.)

RECEPTORS, PITUITARY HORMONE

PHYSIOLOGY

Regulation of cellular calcium through signaling cross-talk involves an intricate interplay between the actions of receptors, G-proteins, and second messengers. Bygrave FL, et al. **FASEB J** 1995 Oct;9(13):1297–303 (62 ref.)

ACTH-related peptides: receptors and signal transduction systems involved in their neurotrophic and neuroprotective actions. Hol EM, et al. **Peptides** 1995;16(5):979–93 (150 ref.)

The melanocortin receptors: agonists, antagonists, and the hormonal control of pigmentation. Cone RD, et al. **Recent Prog Horm Res** 1996;51:287–317; discussion 318 (102 ref.)

RECEPTORS, PLATELET-DERIVED GROWTH FACTOR

METABOLISM

Protein kinase C-delta, an important signaling molecule in the platelet-derived growth factor beta receptor pathway. Li W, et al. **Curr Top Microbiol Immunol** 1996;211:55–65 (23 ref.)

PHYSIOLOGY

Platelet-derived growth factor. Distinct signal transduction pathways associated with migration versus proliferation. Bornfeldt KE, et al. **Ann N Y Acad Sci** 1995 Sep 7; 766:416–30 (67 ref.)

Role of platelet-derived growth factors in mouse development. Betsholtz C. **Int J Dev Biol** 1995 Oct; 39(5):817–25 (76 ref.)

Ganglioside modulation of the PDGF receptor. A model for ganglioside functions. Yates AJ, et al. **J Neurooncol** 1995;24(1):65–73 (66 ref.)

RECEPTORS, PRESYNAPTIC

METABOLISM

Presynaptic GABAA receptors in vertebrate synapses. Xi ZX, et al. **Kurume Med J** 1996;43(2):115–22 (84 ref.)

PHYSIOLOGY

Biochemical assessment of sympathetic activity and prejunctional modulation of noradrenaline release in humans [editorial] Hjemdahl P, et al. **J Hypertens** 1996 Feb;14(2):147–50 (28 ref.)

Long-term regulation of short-term plasticity: a postsynaptic influence on presynaptic transmitter release. Davis GW. **J Physiol Paris** 1995;89(1):33–41 (39 ref.)

Cysteine string proteins and presynaptic function. Umbach JA, et al. **J Physiol Paris** 1995;89(2):95–101 (25 ref.)

RECEPTORS, PROGESTERONE

ANALYSIS

Correlation between pS2 protein positivity, steroid receptor status and other prognostic factors in breast cancer. Racca S, et al. **Int J Biol Markers** 1995 Apr-Jun;10(2):87–93 (35 ref.)

[Should immunohistochemistry be used to evaluate estrogen and progesterone receptors in breast cancers? (editorial)] Balaton AJ, et al. **Ann Pathol** 1996;16(2):78–80 (11 ref.) **(Fre)**

[Progesterone receptor in breast cancer: fundamental data and clinical applications] Ojasoo T. **Bull Cancer (Paris)** 1996;83 Suppl 1:1–5 (53 ref.) **(Fre)**

ANTAGONISTS & INHIBITORS

Antiprogestins: mechanism of action and contraceptive potential. Spitz IM, et al. **Annu Rev Pharmacol Toxicol** 1996;36:47–81 (161 ref.)

Surprises with antiprogestins: novel mechanisms of progesterone receptor action. Horwitz KB, et al. **Ciba Found Symp** 1995;191:235–49; discussion 250–3 (26 ref.)

BIOSYNTHESIS

Progesterone receptors: expression and regulation in the mammalian ovary. Pinter JH, et al. **Clin Obstet Gynecol** 1996 Jun;39(2):424–35 (85 ref.)

Progesterone receptor A and B protein expression in human breast cancer. Graham JD, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1–6 Spec No):93–8 (33 ref.)

DEFICIENCY

Reproductive phenotpes of the progesterone receptor null mutant mouse. Lydon JP, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1–6 Spec No):67–77 (78 ref.)

DRUG EFFECTS

Discovery of novel intracellular receptor modulating drugs. Jones TK, et al. **J Steroid Biochem Mol Biol** 1996 Jan; 56(1–6 Spec No):61–6 (26 ref.)

GENETICS

Molecular aspects of estrogen receptor variants in breast cancer. Fuqua SA, et al. **Breast Cancer Res Treat** 1995 Sep;35(3):233–41 (19 ref.)

METABOLISM

Gestodene. A review of its pharmacology, efficacy and tolerability in combined contraceptive preparations. Wilde MI, et al. **Drugs** 1995 Aug;50(2):364–95 (128 ref.)

A nuclear matrix acceptor site for the progesterone receptor in the avian c-myc gene promoter. Spelsberg TC, et al. **Recent Prog Horm Res** 1996;51:63–96 (121 ref.)

PHYSIOLOGY

Regulation of estrogen/progestogen receptors in the endometrium. Casper RF. **Int J Fertil Menopausal Stud** 1996 Jan-Feb;41(1):16–21 (35 ref.)

RECEPTORS, PROGESTIN see **RECEPTORS, PROGESTERONE**

RECEPTORS, PROGLUMIDE see **RECEPTORS, CHOLECYSTOKININ**

RECEPTORS, PROLACTIN

METABOLISM

Prolactin receptors and the immune system. Leite De Moraes MC, et al. **Ann Endocrinol (Paris)** 1995;56(6):567–70 (19 ref.)

RECEPTORS, PROSTAGLANDIN

Prostaglandin I receptor and prostaglandin D receptor. Hirata M, et al. **J Lipid Mediat Cell Signal** 1995 Oct; 12(2–3):393–404 (57 ref.)

Prostaglandin F2 alpha receptor. Sakamoto K, et al. **J Lipid Mediat Cell Signal** 1995 Oct;12(2–3):405–11 (16 ref.)

Molecular biology of prostanoid receptors; an overview. Ushikubi F, et al. **J Lipid Mediat Cell Signal** 1995 Oct; 12(2–3):343–59 (71 ref.)

[Molecular structure and function of the prostanoid receptors] Sugimoto Y, et al. **Seikagaku** 1995 Dec; 67(12):1351–65 (58 ref.) **(Jpn)**

AGONISTS

Focus on prostacyclin and its novel mimetics. Wise H, et al. **Trends Pharmacol Sci** 1996 Jan;17(1):17–21 (51 ref.)

CHEMISTRY

Molecular mechanisms of diverse actions of prostanoid receptors. Negishi M, et al. **Biochim Biophys Acta** 1995 Oct 26;1259(1):109–19 (80 ref.)

PHYSIOLOGY

Molecular mechanisms of diverse actions of prostanoid receptors. Negishi M, et al. **Biochim Biophys Acta** 1995 Oct 26;1259(1):109–19 (80 ref.)

RECEPTORS, PROSTAGLANDIN E

Prostaglandin E receptors. Negishi M, et al. **J Lipid Mediat Cell Signal** 1995 Oct;12(2–3):379–91 (57 ref.)

RECEPTORS, PROTIRELIN see **RECEPTORS, THYROTROPIN-RELEASING HORMONE**

RECEPTORS, PURINERGIC

[Purinergic receptors—nomenclature and classification of types and subtypes] Hynie S. **Cesk Fysiol** 1995 Sep; 44(3):139–44 (17 ref.) (Eng. Abstr.) **(Cze)**

PHYSIOLOGY

Inositol lipid-mediated signalling in response to endothelin and ATP in the mammalian testis. Rudge SA, et al. **Mol Cell Biochem** 1995 Aug-Sep;149–150:161–74 (86 ref.)

Cholinergic and purinergic signalling in outer hair cells of mammalian cochlea. Heilbronn E, et al. **Neurochem Int** 1995 Oct-Nov;27(4–5):301–11 (79 ref.)

RECEPTORS, PURINERGIC P1

ANTAGONISTS & INHIBITORS

[Recent adenosine antagonists] Suzuki F, et al. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1277–92 (73 ref.) **(Jpn)**

CHEMISTRY

Adenosine receptors. Palmer TM, et al. **Neuropharmacology** 1995 Jul;34(7):683–94 (98 ref.)

CLASSIFICATION

Adenosine receptors. Palmer TM, et al. **Neuropharmacology** 1995 Jul;34(7):683–94 (98 ref.)

DRUG EFFECTS

Adenosine receptors. Palmer TM, et al. **Neuropharmacology** 1995 Jul;34(7):683–94 (98 ref.)

PHYSIOLOGY

Role of extracellular ATP and P1 and P2 classes of purinergic receptors in T-cell development and cytotoxic T lymphocyte effector functions. Apasov S, et al. **Immunol Rev** 1995 Aug;146:5–19 (40 ref.)

Modulation of protein kinase C by adenosine: involvement of adenosine A1 receptor-pertussis toxin sensitive nucleotide binding protein system. Marala RB, et al. **Mol Cell Biochem** 1995 Aug-Sep;149–150:51–8 (56 ref.)

RECEPTORS, PURINERGIC P2

DRUG EFFECTS

ADP receptors on platelets and ADP-selective antiaggregating agents. Savi P, et al. **Med Res Rev** 1996 Mar;16(2):159–79 (206 ref.)

IMMUNOLOGY

The P2Z purinoceptor: an intriguing role in immunity, inflammation and cell death. Di Virgilio F. **Immunol Today** 1995 Nov;16(11):524–8 (37 ref.)

METABOLISM

P2 purinergic receptors for diadenosine polyphosphates in the nervous system. Pintor J, et al. **Gen Pharmacol** 1995 Mar;26(2):229–35 (49 ref.)

PHYSIOLOGY

Role of extracellular ATP and P1 and P2 classes of purinergic receptors in T-cell development and cytotoxic T lymphocyte effector functions. Apasov S, et al. **Immunol Rev** 1995 Aug;146:5–19 (40 ref.)

The P2Z purinoceptor: an intriguing role in immunity, inflammation and cell death. Di Virgilio F. **Immunol Today** 1995 Nov;16(11):524–8 (37 ref.)

ADP receptors on platelets and ADP-selective antiaggregating agents. Savi P, et al. **Med Res Rev** 1996 Mar;16(2):159–79 (206 ref.)

RECEPTORS, RETINOIC ACID

DRUG EFFECTS

Receptor-selective retinoid agonists and teratogenic activity. Willhite CC, et al. **Drug Metab Rev** 1996 Feb-May; 28(1–2):105–19 (33 ref.)

GENETICS

Altered retinoic acid receptors. de Thé H. **FASEB J** 1996 Jul;10(9):955–60 (43 ref.)

Retinoic acid regulatory pathways, chromosomal translocations, and acute promyelocytic leukemia. Chen Z, et al. **Genes Chromosomes Cancer** 1996 Mar;15(3):147–56 (123 ref.)

The gene responsible for adrenal hypoplasia congenita, DAX-1, encodes a nuclear hormone receptor that defines a new class within the superfamily. Burris TP, et al. **Recent Prog Horm Res** 1996;51:241–59; discussion 259–60 (94 ref.)

METABOLISM

A decade of molecular biology of retinoic acid receptors. Chambon P. **FASEB J** 1996 Jul;10(9):940–54 (120 ref.)

Retinoids in lung development. Chytil F. **FASEB J** 1996 Jul; 10(9):986–92 (53 ref.)

Embryonic development and pattern formation. Morriss-Kay GM, et al. **FASEB J** 1996 Jul;10(9):961–8 (55 ref.)

Retinoid receptors in human lung cancer and breast cancer. Zhang XK, et al. **Mutat Res** 1996 Feb 19;350(1):267–77 (87 ref.)

PHYSIOLOGY

Retinoid signaling in vertebrate limb development. Thaller C, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:1–11 (58 ref.)

Retinoids and their receptors in modulation of differentiation, development, and prevention of head and neck cancers. Lotan R. **Anticancer Res** 1996 Jul-Aug;16(4C):2415–9 (45 ref.)

Nonsteroid nuclear receptors: what are genetic studies telling us about their role in real life? Kastner P, et al. **Cell** 1995 Dec 15;83(6):859–69 (71 ref.)

The RXR heterodimers and orphan receptors. Mangelsdorf DJ, et al. **Cell** 1995 Dec 15;83(6):841–50 (80 ref.)

Retinoid receptors and keratinocytes. Fisher C, et al. **Crit Rev Oral Biol Med** 1995;6(4):284–301 (172 ref.)

Retinoic acid receptors in hematopoiesis. Collins SJ, et al. **Curr Top Microbiol Immunol** 1996;211:7–15 (15 ref.)

Pathogenetic role of the PML1RAR alpha fusion protein in acute promyelocytic leukemia. Grignani F, et al. **Curr Top Microbiol Immunol** 1996;211:269–78 (52 ref.)

Retinoic acid and retinoic acid receptors in development. Sucov HM, et al. **Mol Neurobiol** 1995 Apr-Jun; 10(2–3):169–84 (113 ref.)

Receptors as tools for understanding the toxicity of retinoids.

Levin AA. **Toxicol Lett** 1995 Dec;82-83:91-7 (57 ref.)

RECEPTORS, SENSORY

DRUG EFFECTS

An assessment of short-acting hypnotics. Mendelson WB, et al. **Drug Saf** 1995 Oct;13(4):257-70 (11 ref.)

METABOLISM

Traditional receptor theory and its application to neuroreceptor measurements in functional imaging. Kerwin RW, et al. **Eur J Nucl Med** 1995 Jul;22(7):699-710 (55 ref.)

PHYSIOLOGY

Evidence of somatic graviception from new and classical investigations. Mittelstaedt H.
Acta Otolaryngol Suppl (Stockh) 1995;520 Pt 1:186-7 (5 ref.)

New diagnostic tests for the function of utricles, saccules and somatic graviceptors. Mittelstaedt H.
Acta Otolaryngol Suppl (Stockh) 1995;520 Pt 1:188-93 (5 ref.)

Neurobiology of visceral afferent neurons: neuroanatomy, functions, organ regulations and sensations. Jänig W.
Biol Psychol 1996 Jan 5;42(1-2):29-51 (105 ref.)

Interoception. Vaitl D. **Biol Psychol** 1996 Jan 5;42(1-2):1-27 (100 ref.)

Convergent designs for electrogenesis and electroreception. Hopkins CD. **Curr Opin Neurobiol** 1995 Dec;5(6):769-77 (57 ref.)

Transduction and adaptation in sensory receptor cells. Torre V, et al. **J Neurosci** 1995 Dec;15(12):7757-68 (105 ref.)

Disturbances in signal transduction mechanisms in Alzheimer's disease. Fowler CJ, et al.
Mol Cell Biochem 1995 Aug-Sep;149-150:287-92 (34 ref.)

Magnetoreception: why is conditioning so seldom successful? Wiltschko R, et al. **Naturwissenschaften** 1996 Jun; 83(6):241-7 (57 ref.)

Second-order neurones and receptor mechanisms in visual- and olfactory-information processing. Nakanishi S.
Trends Neurosci 1995 Aug;18(8):359-64 (50 ref.)

[The receptor components of sensory systems: the conservatism of the principles of their interaction] Etingof RN. **Zh Evol Biokhim Fiziol** 1995 Mar-Apr;31(2):208-15 (35 ref.) **(Rus)**

[Exteroceptive suppression of voluntary muscular activity: a new method of studying central nociceptive mechanisms] Danilov AB, et al.
Zh Nevropatol Psikhiatr Im S S Korsakova 1995;95(3):90-5 (59 ref.) **(Rus)**

PHYSIOPATHOLOGY

New diagnostic tests for the function of utricles, saccules and somatic graviceptors. Mittelstaedt H.
Acta Otolaryngol Suppl (Stockh) 1995;520 Pt 1:188-93 (5 ref.)

Neural receptors and asthma. Baraniuk JN. **Allergy Proc** 1995 Sep-Oct;16(5):227-33 (76 ref.)

RADIONUCLIDE IMAGING

PET imaging of neuroreceptors in schizophrenia. Sedvall G, et al. **Eur Neuropsychopharmacol** 1995;5 Suppl:25-30 (18 ref.)

RECEPTORS, SEROTONIN

ANALYSIS

Radioligands for brain 5-HT2 receptor imaging in vivo: why do we need them? [editorial] Busatto GF.
Eur J Nucl Med 1996 Aug;23(8):867-70 (36 ref.)

CHEMISTRY

Models of 5-hydroxytryptamine receptors. A review. Chilmonczyk Z. **J Pharm Pharmacol** 1995 Oct; 47(10):791-801 (85 ref.)

CLASSIFICATION

5-hydroxytryptamine: considerations about discovery, receptor classification and relevance to medical research. Villalón CM, et al. **Arch Med Res** 1995 Winter;26(4):331-44 (128 ref.)

[5-hydroxytryptamine (serotonin) receptors--nomenclature and classification of types and subtypes] Hynie S.
Cesk Fysiol 1995 Sep;44(3):135-8 (15 ref.) (Eng. Abstr.) **(Cze)**

DRUG EFFECTS

Role of 5-hydroxytryptamine3 (5-HT3) antagonists in the prevention of emesis caused by anticancer therapy. Karim F, et al. **Biochem Pharmacol** 1996 Sep 13;52(5):685-92 (64 ref.)

Actions of anesthetics on ligand-gated ion channels: role of receptor subunit composition. Harris RA, et al.
FASEB J 1995 Nov;9(14):1454-62 (59 ref.)

5-HT3 receptors: pharmacologic and therapeutic aspects. Gyermek L. **J Clin Pharmacol** 1995 Sep;35(9):845-55 (100 ref.)

The pharmacologic profile of mirtazapine. de Boer T. **J Clin Psychiatry** 1996;57 Suppl 4:19-25 (48 ref.)

Therapeutic potential of drugs with mixed 5-HT4 agonist/5-HT3 antagonist action in the control of emesis. Tonini M, et al. **Pharmacol Res** 1995 May;31(5):257-60 (30 ref.)

[The serotonin syndrome: review of the literature and description of an original study] Lejoyeux M, et al.
Encephale 1995 Sep-Oct;21(5):537-43 (45 ref.) (Eng. Abstr.) **(Fre)**

[Pharmacology of 5-hydroxytryptamine receptors] Fontaine J. **J Pharm Belg** 1996 May-Jun;51(3):141-51 (28 ref.) **(Fre)**

GENETICS

Serotonin receptors. Genetic insights into serotonin function. Heath MJ, et al. **Curr Biol** 1995 Sep 1;5(9):997-9 (11 ref.)

Molecular biology of serotonin receptors. Baez M, et al.
Obes Res 1995 Nov;3 Suppl 4:441S-447S (22 ref.)

Genetic variation of CNS receptors--a new perspective for pharmacogenetics. Propping P, et al. **Pharmacogenetics** 1995 Oct;5(5):318-25 (75 ref.)

METABOLISM

The 5-HT1A receptor: signaling, desensitization, and gene transcription. Albert PR, et al.
Neuropsychopharmacology 1996 Jan;14(1):19-25 (45 ref.)

Pharmacology of ingestive behaviour. Samanin R, et al.
Therapie 1996 Mar-Apr;51(2):107-15 (85 ref.)

PHYSIOLOGY

Mechanisms and functions of serotonin neuronal systems: opportunities for neuropeptide interactions. Fuller RW.
Ann N Y Acad Sci 1996 Mar 22;780:176-84 (61 ref.)

Galanin and 5-HT1A receptor interactions as an integrative mechanism in 5-HT neurotransmission in the brain. Hedlund PB, et al. **Ann N Y Acad Sci** 1996 Mar 22; 780:193-212 (82 ref.)

5-hydroxytryptamine: considerations about discovery, receptor classification and relevance to medical research. Villalón CM, et al. **Arch Med Res** 1995 Winter;26(4):331-44 (128 ref.)

Regulation of 5-HT receptors by corticosteroids: where do we stand? Chaouloff F. **Fundam Clin Pharmacol** 1995; 9(3):219-33 (82 ref.)

5-HT3 receptors: pharmacologic and therapeutic aspects. Gyermek L. **J Clin Pharmacol** 1995 Sep;35(9):845-55 (100 ref.)

Serotonin receptor specificity in anxiety disorders. Lucki I. **J Clin Psychiatry** 1996;57 Suppl 6:5-10 (48 ref.)

Adrenoceptors and serotonin receptor function: relevance to antidepressant mechanisms of action. Potter WZ.
J Clin Psychiatry 1996;57 Suppl 4:4-8 (45 ref.)

Serotonergic mediation of vomiting. Gale JD.
J Pediatr Gastroenterol Nutr 1995;21 Suppl 1:S22-8 (72 ref.)

Beyond specificity: effects of serotonin and serotonergic treatments on psychobiological dysfunction. Dubovsky SL, et al. **J Psychosom Res** 1995 May;39(4):429-44 (103 ref.)

Multiple serotonin receptors: opportunities for new treatments for obesity? Dourish CT. **Obes Res** 1995 Nov; 3 Suppl 4:449S-462S (108 ref.)

Serotonin receptors and animal models of aggressive behavior. Olivier B, et al. **Pharmacopsychiatry** 1995 Oct; 28 Suppl 2:80-90 (92 ref.)

5-Hydroxytryptamine in the central nervous system. Chojnacka-Wójcik E. **Pol J Pharmacol** 1995 May-Jun; 47(3):219-35 (173 ref.)

Serotonin receptors and their function in sleep, anxiety disorders and depression. Leonard BE.
Psychother Psychosom 1996 Mar-Apr;65(2):66-75 (75 ref.)

Central 5-HT4 receptors. Eglen RM, et al.
Trends Pharmacol Sci 1995 Nov;16(11):391-8 (84 ref.)

[Pulmonary and pulmonary-related reflexes mediated by serotonin receptors in the peripheral nervous system] Yoshioka M. **Nippon Yakurigaku Zasshi** 1995 Nov; 106(5):311-20 (49 ref.) (Eng. Abstr.) **(Jpn)**

RECEPTORS, SIGMA

DRUG EFFECTS

Enhanced N-methyl-D-aspartate (NMDA)-induced activity following morphine: sensitivity to sigma and PCP ligands. Larson AA, et al. **NIDA Res Monogr** 1995;147:146-60 (20 ref.)

PHYSIOLOGY

Modulation of NMDA and dopaminergic neurotransmissions by sigma ligands: possible implications for the treatment of psychiatric disorders. Debonnel G, et al. **Life Sci** 1996; 58(9):721-34 (179 ref.)

RECEPTORS, SIGMA OPIOID see **RECEPTORS, SIGMA**

RECEPTORS, SINCALIDE see **RECEPTORS, CHOLECYSTOKININ**

RECEPTORS, SOMATOMEDIN

PHYSIOLOGY

IGF-I: a mitogen also involved in differentiation processes in mammalian cells. Benito M, et al.
Int J Biochem Cell Biol 1996 May;28(5):499-510 (95 ref.)

RECEPTORS, SOMATOMEDIN C see **RECEPTORS, INSULIN-LIKE-GROWTH FACTOR I**

RECEPTORS, SOMATOSTATIN

ANALYSIS

Somatostatin receptors: clinical implications for endocrinology and oncology. Lamberts SW, et al.
Ciba Found Symp 1995;190:222-36; discussion 236-9 (48 ref.)

Neuropeptide receptors in health and disease: the molecular basis for in vivo imaging. Reubi JC. **J Nucl Med** 1995 Oct; 36(10):1825-35 (61 ref.)

Somatostatin-receptor imaging in lymphoma. Goldsmith SJ, et al. **Semin Nucl Med** 1995 Jul;25(3):262-71 (13 ref.)

Somatostatin receptor imaging of neuroendocrine tumors with indium-111 pentetreotide (Octreoscan). Olsen JO, et al. **Semin Nucl Med** 1995 Jul;25(3):251-61 (25 ref.)

[Detection of endocrine tumors of the digestive tract. Value and limitations of scintigraphy of somatostatin receptors] Le Guludec D, et al. **Presse Med** 1996 Apr 20;25(14):677-82 (27 ref.) (Eng. Abstr.) **(Fre)**

BIOSYNTHESIS

Transient expression of somatostatin receptors in the brain during development. Leroux P, et al. **Ciba Found Symp** 1995;190:127-37; discussion 137-41 (45 ref.)

GENETICS

Molecular biology of somatostatin receptors. Bell GI, et al.
Ciba Found Symp 1995;190:65-79; discussion 80-8 (96 ref.)

Molecular biology of somatostatin receptors. Reisine T, et al. **Endocr Rev** 1995 Aug;16(4):427-42 (159 ref.)

METABOLISM

Somatostatin analogues and multiple receptors: possible physiological roles. Coy DH, et al. **Ciba Found Symp** 1995; 190:240-52; discussion 252-4 (20 ref.)

Interaction of somatostatin receptors with G proteins and cellular effector systems. Reisine T, et al.
Ciba Found Symp 1995;190:160-7; discussion 167-70 (40 ref.)

PHYSIOLOGY

Somatostatin receptors. Reisine T. **Am J Physiol** 1995 Dec; 269(6 Pt 1):G813-20 (88 ref.)

Somatostatin receptors and disease: role of receptor subtypes. Hofland LJ, et al. **Baillieres Clin Endocrinol Metab** 1996 Jan;10(1):163-76 (67 ref.)

Somatostatin. Reisine T. **Cell Mol Neurobiol** 1995 Dec; 15(6):597-614 (106 ref.)

Characterization of somatostatin receptor subtypes. Bruns C, et al. **Ciba Found Symp** 1995;190:89-101; discussion 101-10 (68 ref.)

Somatostatin and its receptor. Introduction. Reichlin S.
Ciba Found Symp 1995;190:1-6 (38 ref.)

Function and regulation of somatostatin receptor subtypes. Schonbrunn A, et al. **Ciba Found Symp** 1995;190:204-17; discussion 217-21 (47 ref.)

RECEPTORS, SOMATOTROPIN

ANALYSIS

The diagnostic utility of somatostatin receptor scintigraphy in oncology. Valkema R, et al.
J Cancer Res Clin Oncol 1996;122(9):513-32 (152 ref.)

CHEMISTRY

Growth hormone receptor: structure and signal transduction. Postel-Vinay MC, et al. **Eur J Endocrinol** 1995 Dec; 133(6):654-9 (57 ref.)

DEFICIENCY

Growth hormone insensitivity syndrome (Laron syndrome): main characteristics and effects of IGF1 treatment. Carel JC, et al. **Diabetes Metab** 1996 Jul;22(4):251-6 (34 ref.)

METABOLISM

Binding in the growth hormone receptor complex. Wells JA.
Proc Natl Acad Sci U S A 1996 Jan 9;93(1):1-6 (39 ref.)

PHYSIOLOGY

Growth hormone receptor: structure and signal transduction. Postel-Vinay MC, et al. **Eur J Endocrinol** 1995 Dec; 133(6):654-9 (57 ref.)

Growth hormone and its receptors in the central nervous system--location and functional significance. Nyberg F, et al. **Horm Res** 1996;45(1-2):18-22 (28 ref.)

[Growth hormone receptor and binding protein: roles in

cellular responsiveness to growth hormone] Maes M, et al. **Ann Endocrinol (Paris)** 1995;56(4):253–8 (47 ref.) (Eng. Abstr.) **(Fre)**

RECEPTORS, SOMATOTROPIN RELEASE INHIBITING HORMONE see **RECEPTORS, SOMATOSTATIN**

RECEPTORS, SRS-A see **RECEPTORS, LEUKOTRIENE**

RECEPTORS, STEM CELL FACTOR see **PROTO-ONCOGENE PROTEINS C-KIT**

RECEPTORS, STEROID

DRUG EFFECTS

Hormone resistance in cancer: the role of abnormal steroid receptors. Sluyser M. **Crit Rev Oncog** 1994;5(6):539–54 (122 ref.)

Pharmacokinetics and receptor-mediated pharmacodynamics of corticosteroids. Jusko WJ. **Toxicology** 1995 Sep 1; 102(1–2):189–96 (28 ref.)

GENETICS

Genes involved in testicular development and function. Lamb DJ. **World J Urol** 1995;13(5):277–84 (118 ref.)

METABOLISM

A putative receptor for neurosteroids on the GABAA receptor complex: the pharmacological properties and therapeutic potential of epalons. Gee KW, et al. **Crit Rev Neurobiol** 1995;9(2–3):207–27 (102 ref.)

Corticosteroid hypertension. Funder JW. **Curr Opin Nephrol Hypertens** 1995 Sep;4(5):432–7 (39 ref.)

Nuclear matrix acceptor binding sites for steroid hormone receptors: a candidate nuclear matrix acceptor protein. Lauber AH, et al. **Int Rev Cytol** 1995;162B:337–76 (178 ref.)

Interaction of steroid hormone receptors with transcription factors involves chromatin remodelling. Beato M, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1–6 Spec No):47–59 (144 ref.)

The Ernst Schering Poster Award. Intracellular traffic of steroid hormone receptors. Guiochon-Mantel A, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1–6 Spec No):3–9 (64 ref.)

Nucleocytoplasmic shuttling of steroid receptors. Defranco DB, et al. **Vitam Horm** 1995;51:315–38 (86 ref.)

PHYSIOLOGY

Steroid hormone receptors: many actors in search of a plot. Beato M, et al. **Cell** 1995 Dec 15;83(6):851–7 (66 ref.)

The RXR heterodimers and orphan receptors. Mangelsdorf DJ, et al. **Cell** 1995 Dec 15;83(6):841–50 (80 ref.)

From embryogenesis to metamorphosis: the regulation and function of Drosophila nuclear receptor superfamily members. Thummel CS. **Cell** 1995 Dec 15;83(6):871–7 (56 ref.)

Phosphorylation and steroid hormone action. Bai W, et al. **Vitam Horm** 1995;51:289–313 (115 ref.)

[Role of steroid hormone in adipocyte metabolism] Nagasaka Y, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:111–4 (9 ref.) **(Jpn)**

[Steroid hormone receptors in the CNS from animal models with fatty syndrome] Takeda R. **Nippon Rinsho** 1995 Jun; 53 Suppl:70–4 (13 ref.) **(Jpn)**

RECEPTORS, STRETCH see **MECHANORECEPTORS**

RECEPTORS, STRETCH, ARTERIAL see **PRESSORECEPTORS**

RECEPTORS, STRETCH, MUSCLE see **MUSCLE SPINDLES**

RECEPTORS, STRETCH, VASCULAR see **PRESSORECEPTORS**

RECEPTORS, SUBSTANCE K see **RECEPTORS, NEUROKININ-2**

RECEPTORS, SUBSTANCE P see **RECEPTORS, NEUROKININ-1**

RECEPTORS, SYNAPTIC see **RECEPTORS, NEUROTRANSMITTER**

RECEPTORS, T-CELL GROWTH FACTOR see **RECEPTORS, INTERLEUKIN-2**

RECEPTORS, TACHYKININ

ANTAGONISTS & INHIBITORS

Molecular characterization of a common binding site for small molecules within the transmembrane domain of G-protein coupled receptors. Cascieri MA, et al. **J Pharmacol Toxicol Methods** 1995 Aug;33(4):179–85 (32 ref.)

CHEMISTRY

Tachykinin receptors in the spinal cord. Routh VH, et al. **Prog Brain Res** 1995;104:93–108 (115 ref.)

DRUG EFFECTS

The 'keptide-sensitive' tachykinin receptor: still an enigma. Glowinski J. **Trends Pharmacol Sci** 1995 Nov;16(11):365–7 (34 ref.)

PHYSIOLOGY

The mammalian tachykinin receptors. Maggi CA. **Gen Pharmacol** 1995 Sep;26(5):911–44 (245 ref.)

RECEPTORS, TETRAGASTRIN see **RECEPTORS, CHOLECYSTOKININ**

RECEPTORS, TGF-ALPHA see **RECEPTORS, EPIDERMAL GROWTH FACTOR-UROGASTRONE**

RECEPTORS, TGF-BETA see **RECEPTORS, TRANSFORMING GROWTH FACTOR BETA**

RECEPTORS, THROMBIN

ANTAGONISTS & INHIBITORS

Issues in the development of thrombin receptor antagonists. Brass LF. **Thromb Haemost** 1995 Jul;74(1):499–505 (39 ref.)

METABOLISM

Cellular consequences of thrombin-receptor activation. Grand RJ, et al. **Biochem J** 1996 Jan 15;313 (Pt 2):353–68 (241 ref.)

PHYSIOLOGY

Thrombin and its receptor in growth control. Van Obberghen-Schilling E, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:431–41 (85 ref.)

RECEPTORS, THROMBOSPONDIN see **ANTIGENS, CD36**

RECEPTORS, THROMBOXANE

Thromboxane A2 receptors. Halushka PV, et al. **J Lipid Mediat Cell Signal** 1995 Oct;12(2–3):361–78 (114 ref.)

Molecular biology of prostanoid receptors; an overview. Ushikubi F, et al. **J Lipid Mediat Cell Signal** 1995 Oct; 12(2–3):343–59 (71 ref.)

[Molecular structure and function of the prostanoid receptors] Sugimoto Y, et al. **Seikagaku** 1995 Dec; 67(12):1351–65 (58 ref.) **(Jpn)**

CHEMISTRY

Molecular mechanisms of diverse actions of prostanoid receptors. Negishi M, et al. **Biochim Biophys Acta** 1995 Oct 26;1259(1):109–19 (80 ref.)

PHYSIOLOGY

Molecular mechanisms of diverse actions of prostanoid receptors. Negishi M, et al. **Biochim Biophys Acta** 1995 Oct 26;1259(1):109–19 (80 ref.)

RECEPTORS, THROMBOXANE A2 see **RECEPTORS, THROMBOXANE**

RECEPTORS, THYROID HORMONE

see related
THYROID HORMONE RESISTANCE SYNDROME

GENETICS

Autoinduction of nuclear receptor genes and its significance. Tata JR, et al. **J Steroid Biochem Mol Biol** 1993 Aug; 46(2):105–19 (54 ref.)

Genetic analysis of thyroid hormone receptors in development and disease. Forrest D, et al. **Recent Prog Horm Res** 1996;51:1–22 (78 ref.)

IMMUNOLOGY

[TSH receptor antibody] Shishiba Y. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:407–9 (11 ref.) **(Jpn)**

METABOLISM

[Molecular biology of thyroid diseases] Nagy E, et al. **Orv Hetil** 1996 Mar 17;137(11):563–8 (44 ref.) (Eng. Abstr.) **(Hun)**

PHYSIOLOGY

Nonsteroid nuclear receptors: what are genetic studies telling us about their role in real life? Kastner P, et al. **Cell** 1995 Dec 15;83(6):859–69 (71 ref.)

T3 or not T3—the slings and arrows of outrageous TR function [editorial; comment] Chin WW, et al. **Endocrinology** 1996 Feb;137(2):387–8 (23 ref.) Comment on: Endocrinology 1996 Feb;137(2):390–9.

Enhancement of nuclear receptor transcriptional signalling. Renkawitz R, et al. **J Steroid Biochem Mol Biol** 1996 Jan; 56(1–6 Spec No):39–45 (29 ref.)

RECEPTORS, THYROID STIMULATING HORMONE see **RECEPTORS, THYROTROPIN**

RECEPTORS, THYROLIBERIN see **RECEPTORS, THYROTROPIN-RELEASING HORMONE**

RECEPTORS, THYROTROPIN

CHEMISTRY

The G protein-coupled receptor family and one of its members, the TSH receptor. Vassart G, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:23–30 (43 ref.)

GENETICS

Activating mutations of the TSH receptor gene cause thyroid diseases. Vassart G, et al. **Ann Endocrinol (Paris)** 1996; 57(1):50–4 (31 ref.)

The TSH receptor and thyroid diseases. Paschke R, et al. **Baillieres Clin Endocrinol Metab** 1996 Jan;10(1):9–27 (93 ref.)

Molecular studies on thyrotropin (TSH) receptor and anti-TSH receptor antibodies. Akamizu T, et al. **Endocr J** 1995 Oct;42(5):617–27 (46 ref.)

TSH receptor and LH receptor, 1995. Kosugi S, et al. **Endocr J** 1995 Oct;42(5):587–606 (95 ref.)

Resistance to thyrotropin and other abnormalities of the thyrotropin receptor. Refetoff S, et al. **Recent Prog Horm Res** 1996;51:97–120; discussion 120–2 (67 ref.)

[Pituitary glycoprotein hormone receptors] Misrahi M, et al. **Ann Endocrinol (Paris)** 1995;56(5):487–93 (39 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Analytical and clinical performance goals for testing autoantibodies to thyroperoxidase, thyroglobulin, and thyrotropin receptor. Feldt-Rasmussen U. **Clin Chem** 1996 Jan;42(1):160–3 (20 ref.)

Molecular studies on thyrotropin (TSH) receptor and anti-TSH receptor antibodies. Akamizu T, et al. **Endocr J** 1995 Oct;42(5):617–27 (46 ref.)

Monoclonal, human autoantibodies to the TSH receptor—the Holy Grail and why are we looking for it? [editorial] McLachlan SM, et al. **J Clin Endocrinol Metab** 1996 Sep; 81(9):3152–4 (29 ref.)

METABOLISM

[Molecular biology of thyroid diseases] Nagy E, et al. **Orv Hetil** 1996 Mar 17;137(11):563–8 (44 ref.) (Eng. Abstr.) **(Hun)**

PHYSIOLOGY

The G protein-coupled receptor family and one of its members, the TSH receptor. Vassart G, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:23–30 (43 ref.)

TSH receptor and disease. Tonacchera M, et al. **Clin Endocrinol (Oxf)** 1996 Jun;44(6):621–33 (106 ref.)

Regulation of cellular calcium through signaling cross-talk involves an intricate interplay between the actions of receptors, G-proteins, and second messengers. Bygrave FL, et al. **FASEB J** 1995 Oct;9(13):1297–303 (62 ref.)

Involvement of the orbital fibroblast and TSH receptor in the pathogenesis of Graves' ophthalmopathy. Heufelder AE. **Thyroid** 1995 Aug;5(4):331–40 (84 ref.)

RECEPTORS, THYROTROPIN-RELEASING HORMONE

GENETICS

Molecular and cellular biology of thyrotropin-releasing hormone receptors. Gershengorn MC, et al. **Physiol Rev** 1996 Jan;76(1):175–91 (138 ref.)

PHYSIOLOGY

Molecular and cellular biology of thyrotropin-releasing hormone receptors. Gershengorn MC, et al. **Physiol Rev** 1996 Jan;76(1):175–91 (138 ref.)

RECEPTORS, THYROXINE see **RECEPTORS, THYROID HORMONE**

RECEPTORS, TRANSFERRIN

see related
CARRIER PROTEINS

Bacterial transferrin and lactoferrin receptors. Gray-Owen SD, et al. **Trends Microbiol** 1996 May;4(5):185–91 (49 ref.)

[Receptor-mediated targeted gene delivery by ligand-receptor system] Neda H, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2556–61 (15 ref.) **(Jpn)**

ANALYSIS

Plasma transferrin receptor helps to predict iron deficiency in the anemia of chronic disease. Fleming D, et al. **Nutr Rev** 1995 Jun;53(6):167–9 (23 ref.)

IMMUNOLOGY

Transferrin receptors of Neisseria meningitidis: promising candidates for a broadly cross-protective vaccine. Ala'Aldeen DA. **J Med Microbiol** 1996 Apr;44(4):237–43 (40 ref.)

RECEPTORS, TRANSFORMING-GROWTH FACTOR ALPHA see RECEPTORS, EPIDERMAL GROWTH FACTOR-UROGASTRONE

RECEPTORS, TRANSFORMING GROWTH FACTOR BETA

[Transforming growth factor-beta and its receptors] Miyazono K. **Nippon Yakurigaku Zasshi** 1996 Mar; 107(3):133–40 (28 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Signaling via hetero-oligomeric complexes of type I and type II serine/threonine kinase receptors. ten Dijke P, et al. **Curr Opin Cell Biol** 1996 Apr;8(2):139–45 (58 ref.)

PHYSIOLOGY

Signaling by the transforming growth factor-beta receptors. Yingling JM, et al. **Biochim Biophys Acta** 1995 Dec 18; 1242(2):115–36 (119 ref.)

Microsatellite instability and a TGF beta receptor: clues to a growth control pathway. Benson JR, et al. **Bioessays** 1995 Dec;17(12):1009–12 (34 ref.)

TGFbeta signaling: receptors, transducers, and Mad proteins. Massagué J. **Cell** 1996 Jun 28;85(7):947–50 (20 ref.)

TGF-beta: receptors and cell cycle arrest. Saltis J. **Mol Cell Endocrinol** 1996 Feb 5;116(2):227–32 (61 ref.)

RECEPTORS, TRH see RECEPTORS, THYROTROPIN-RELEASING HORMONE

RECEPTORS, TRIIODOTHYRONINE see RECEPTORS, THYROID HORMONE

RECEPTORS, TRYPTAMINE see RECEPTORS, SEROTONIN

RECEPTORS, TUMOR NECROSIS FACTOR

CHEMISTRY

The nerve growth factor/tumor necrosis factor receptor family. Lotz M, et al. **J Leukoc Biol** 1996 Jul;60(1):1–7 (91 ref.)

METABOLISM

A study on tumor necrosis factor, tumor necrosis factor receptors, and nitric oxide in human fetal glial cultures. St. Pierre BA, et al. **Adv Pharmacol** 1995;34:415–38 (94 ref.)

PHYSIOLOGY

Mechanisms of action of the tumor necrosis factor and lymphotoxin ligand-receptor system. Warzocha K, et al. **Eur Cytokine Netw** 1995 Mar-Apr;6(2):83–96 (143 ref.)

The nerve growth factor/tumor necrosis factor receptor family. Lotz M, et al. **J Leukoc Biol** 1996 Jul;60(1):1–7 (91 ref.)

The tumor necrosis factor ligand and receptor families. Bazzoni F, et al. **N Engl J Med** 1996 Jun 27;334(26):1717–25 (80 ref.)

p55 and p75 tumor necrosis factor receptor expression on human glioblastoma cells. Kato T, et al. **Neurol Med Chir (Tokyo)** 1995 Aug;35(8):567–74 (30 ref.)

Transducers of life and death: TNF receptor superfamily and associated proteins. Baker SJ, et al. **Oncogene** 1996 Jan 4; 12(1):1–9 (48 ref.)

[Signals for cellular selection for life and death by a new family of cytokines] Hintzen RQ, et al. **Ned Tijdschr Geneeskd** 1996 Jan 27;140(4):182–6 (29 ref.) **(Dut)**

RECEPTORS, UROGASTRONE see RECEPTORS, EPIDERMAL GROWTH FACTOR-UROGASTRONE

RECEPTORS, V1 see RECEPTORS, VASOPRESSIN

RECEPTORS, V2 see RECEPTORS, VASOPRESSIN

RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE

GENETICS

[Recombinant receptors for testing agonists and antagonists of VIP and PACAP receptors] Robberecht P, et al. **J Pharm Belg** 1996 May-Jun;51(3):165–9 (28 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

A VIP hybrid antagonist: from developmental neurobiology to clinical applications. Gozes I, et al. **Cell Mol Neurobiol** 1995 Dec;15(6):675–87 (74 ref.)

RECEPTORS, VASOPRESSIN

Vasopressin and oxytocin receptors. Zingg HH. **Baillieres Clin Endocrinol Metab** 1996 Jan;10(1):75–96 (118 ref.)

CHEMISTRY

[Comparative study of the structure and molecular functions of angiotensin II and vasopressin receptors] Clauser E. **C R Seances Soc Biol Fil** 1995;189(2):179–90 (37 ref.) (Eng. Abstr.) **(Fre)**

CLASSIFICATION

Molecular pharmacology of V1a vasopressin receptors. Howl J, et al. **Gen Pharmacol** 1995 Oct;26(6):1143–52 (72 ref.)

DRUG EFFECTS

Molecular pharmacology of V1a vasopressin receptors. Howl J, et al. **Gen Pharmacol** 1995 Oct;26(6):1143–52 (72 ref.)

GENETICS

Vasopressin and oxytocin: molecular biology and evolution of the peptide hormones and their receptors. Mohr E, et al. **Vitam Horm** 1995;51:235–66 (137 ref.)

METABOLISM

[Comparative study of the structure and molecular functions of angiotensin II and vasopressin receptors] Clauser E. **C R Seances Soc Biol Fil** 1995;189(2):179–90 (37 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Molecular neurobiology and pharmacology of the vasopressin/oxytocin receptor family. Peter J, et al. **Cell Mol Neurobiol** 1995 Oct;15(5):573–95 (100 ref.)

[Functional expression of vasopressin receptors V1a and V2 along the mammalian nephron] Imbert-Teboul M, et al. **C R Seances Soc Biol Fil** 1995;189(2):151–67 (50 ref.) (Eng. Abstr.) **(Fre)**

RECEPTORS, VIP see RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE

RECEPTORS, VIRUS

Structure of the receptor binding domain of adenovirus type 5 fiber protein. Xia D, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 1):39–46 (17 ref.)

ANALYSIS

[Clinical significance of the pre-S antigens and the binding activity of polymerized human serum albumin to the receptor on hepatitis B virus particles] Matsuura K, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:265–74 (26 ref.) **(Jpn)**

IMMUNOLOGY

Human blood groups: incidental receptors for viruses and bacteria. Moulds JM, et al. **Transfusion** 1996 Apr; 36(4):362–74 (126 ref.)

METABOLISM

HIV and CD26 [comment] Dalgleish A. **Nat Med** 1995 Sep; 1(9):881–2 (20 ref.) Comment on: Nat Med 1995 Sep;1(9):919–26.

PHYSIOLOGY

Human regulator of complement activation (RCA) gene family proteins and their relationship to microbial infection. Seya T. **Microbiol Immunol** 1995;39(5):295–305 (82 ref.)

[The potential attachment sites of hepatitis B virus to the hepatocyte--the pre-S(2) antigen and the receptor for polymerized human serum albumin of hepatitis B virus] Matsuura K, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:125–31 (25 ref.) **(Jpn)**

[Role of hepatitis B virus surface antigen in HBV infection--function of human hepatic sialoglycoprotein as HBV receptor] Suzuki T, et al. **Nippon Rinsho** 1995 Oct; 53 Suppl:132–7 (28 ref.) **(Jpn)**

RECEPTORS, VITAMIN D see RECEPTORS, CALCITRIOL

RECEPTORS, VITRONECTIN

IMMUNOLOGY

The vitronectin receptor (alpha V beta 3) as an example for the role of integrins in T lymphocyte stimulation. Halvorson MJ, et al. **Immunol Res** 1996;15(1):16–29 (94 ref.)

PHYSIOLOGY

Interactions of connective tissue cells with the extracellular matrix. Horton MA. **Bone** 1995 Aug;17(2 Suppl):51S–53S (20 ref.)

The role of the integrin vitronectin receptor, alpha v beta 3 in melanoma metastasis. Nip J, et al. **Cancer Metastasis Rev** 1995 Sep;14(3):241–52 (101 ref.)

Adhesion molecules in melanoma--more than just superglue? Mason MD, et al. **J R Soc Med** 1996 Jul;89(7):393–5 (13 ref.)

Function and regulation of the beta 3 integrins in hemostasis and vascular biology. Shattil SJ. **Thromb Haemost** 1995 Jul;74(1):149–55 (98 ref.)

RECEPTORS, VLA-5 see RECEPTORS, FIBRONECTIN

RECEPTOSOMES see ENDOSOMES

RECKLINGHAUSEN'S DISEASE OF NERVE see NEUROFIBROMATOSIS 1

RECOMBINANT DNA see DNA, RECOMBINANT

RECOMBINANT FUSION PROTEINS

see related
IMMUNOTOXINS

Finding prospective partners in the library: the two-hybrid system and phage display find a match. Allen JB, et al. **Trends Biochem Sci** 1995 Dec;20(12):511–6 (50 ref.)

ADMINISTRATION & DOSAGE

Protein engineering and design for drug delivery. Murphy JR. **Curr Opin Struct Biol** 1996 Aug;6(4):541–5 (25 ref.)

BIOSYNTHESIS

Gene fusion expression systems in Escherichia coli. LaVallie ER, et al. **Curr Opin Biotechnol** 1995 Oct;6(5):501–6 (47 ref.)

Suppression of flavonoid flower pigmentation genes in Petunia hybrida by the introduction of antisense and sense genes. de Lange P, et al. **Curr Top Microbiol Immunol** 1995; 197:57–75 (88 ref.)

Developmental regulation of co-suppression in Petunia hybrida. Flavell RB, et al. **Curr Top Microbiol Immunol** 1995;197:43–56 (63 ref.)

Expression of a large, nontoxic fragment of botulinum neurotoxin serotype A and its use as an immunogen. LaPenotiere HF, et al. **Toxicon** 1995 Oct;33(10):1383–6 (8 ref.)

CHEMISTRY

A proposed mechanism of ADP-ribosylation catalyzed by the pertussis toxin S1 subunit. Locht C, et al. **Biochimie** 1995;77(5):333–40 (56 ref.)

Artificial P450/reductase fusion enzymes: what can we learn from their structures? Yabusaki Y. **Biochimie** 1995; 77(7-8):594–603 (51 ref.)

GENETICS

Gene fusions encoding chimaeric transcription factors in solid tumours. Sorensen PH, et al. **Semin Cancer Biol** 1996 Feb; 7(1):3–14 (100 ref.)

IMMUNOLOGY

DNA immunization with bovine herpesvirus-1 genes. Babiuk LA, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:47–63 (56 ref.)

Nucleic acid malaria vaccines. Current status and potential. Hoffman SL, et al. **Ann N Y Acad Sci** 1995 Nov 27; 772:88–94 (11 ref.)

Direct gene transfer for treatment of human cancer. Nabel GJ, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:227–31 (40 ref.)

A genetic approach to idiotypic vaccination for B cell lymphoma. Stevenson FK, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:212–26 (23 ref.)

Retroviral vectors for HIV immunotherapy. Warner JF, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:105–16 (36 ref.)

DNA-mediated immunization to the hepatitis B surface antigen. Activation and entrainment of the immune response. Whalen RG, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:64–76 (31 ref.)

ISOLATION & PURIFICATION

Toward the production of bispecific antibody fragments for clinical applications. Carter P, et al. **J Hematother** 1995 Oct;4(5):463–70 (63 ref.)

METABOLISM

A proposed mechanism of ADP-ribosylation catalyzed by the pertussis toxin S1 subunit. Locht C, et al. **Biochimie** 1995;77(5):333–40 (56 ref.)

THERAPEUTIC USE

Recombinant antibody fusion proteins for cancer immunotherapy. Reisfeld RA, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 3):27–53 (67

ref.)
Intervention in receptor tyrosine kinase-mediated pathways: recombinant antibody fusion proteins targeted to ErbB2. Weis W, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 3):113–28 (47 ref.)
Antibody–interleukin 2 fusion proteins: a new approach to cancer therapy. Reinfeld RA, et al. **J Clin Lab Anal** 1996; 10(3):160–6 (34 ref.)
Clinical trials of targeted toxins. Frankel AE, et al. **Semin Cancer Biol** 1995 Oct;6(5):307–17 (78 ref.)
Targeting diphtheria toxin to growth factor receptors. Murphy JR, et al. **Semin Cancer Biol** 1995 Oct;6(5):259–67 (64 ref.)

RECOMBINANT INTERFERON ALFA-2A see **INTERFERON ALFA-2A**

RECOMBINANT INTERFERON ALFA-2B see **INTERFERON ALFA-2B**

RECOMBINANT INTERFERON ALFA-2C see **INTERFERON ALFA, RECOMBINANT**

RECOMBINANT INTERFERON-GAMMA see **INTERFERON-GAMMA, RECOMBINANT**

RECOMBINANT PROTEINS

Filgrastim (r-metHuG-CSF): the first 10 years. Welte K, et al. **Blood** 1996 Sep 15;88(6):1907–29 (176 ref.)
[Natural allergens and recombinant allergens] Deviller P. **Allerg Immunol (Paris)** 1995 Nov;27(9):316–9 (6 ref.) (Eng. Abstr.) **(Fre)**

ADMINISTRATION & DOSAGE

[Thrombolytic therapy of renal artery embolism. An expanded case report with review of the literature] Gulba DC, et al. **Internist (Berl)** 1996 Jun;37(6):623–7 (51 ref.) **(Ger)**

ADVERSE EFFECTS

Unanticipated human toxicology of recombinant proteins. Ryffel B. **Arch Toxicol Suppl** 1996;18:333–41 (32 ref.)

BIOSYNTHESIS

Improving productivity of heterologous proteins in recombinant Saccharomyces cerevisiae fermentations. Vasavada A. **Adv Appl Microbiol** 1995;41:25–54 (182 ref.)
Bioproduction of human enzymes in transgenic tobacco. Cramer CL, et al. **Ann N Y Acad Sci** 1996 May 25; 792:62–71 (50 ref.)
Production of antibody fragments in Escherichia coli. Harrison JS, et al. **Ann N Y Acad Sci** 1996 May 15; 782:143–58 (81 ref.)
Antibody production and engineering in plants. Ma JK, et al. **Ann N Y Acad Sci** 1996 May 25;792:72–81 (35 ref.)
Gene transfer and amplification in CHO cells. Efficient methods for maximizing specific productivity and assessment of genetic consequences. Wurm FM, et al. **Ann N Y Acad Sci** 1996 May 15;782:70–8 (25 ref.)
Expression of newly cloned brain dopamine receptors in peripheral organs. O'Connell DP. **Biochem Soc Trans** 1996 Feb;24(1):169–72 (16 ref.)
Enhancing expression of recombinant proteins in mammalian cells using the herpesvirus VP16 transactivator. Hippenmeyer PJ, et al. **Curr Opin Biotechnol** 1995 Oct; 6(5):548–52 (15 ref.)
Effects of rare codon clusters on high-level expression of heterologous proteins in Escherichia coli. Kane JF. **Curr Opin Biotechnol** 1995 Oct;6(5):494–500 (26 ref.)
Production of recombinant proteins in the filamentous fungus Trichoderma reesei. Keränen S, et al. **Curr Opin Biotechnol** 1995 Oct;6(5):534–7 (30 ref.)
Recombinant glycoprotein production in the slime mould Dictyostelium discoideum. Williams KL, et al. **Curr Opin Biotechnol** 1995 Oct;6(5):538–42 (43 ref.)
Advances in the use of Bacillus subtilis for the expression and secretion of heterologous proteins. Wong SL. **Curr Opin Biotechnol** 1995 Oct;6(5):517–22 (46 ref.)
Assembly of macromolecular complexes in bacterial and baculovirus expression systems. Roy P, et al. **Curr Opin Struct Biol** 1996 Apr;6(2):157–61 (53 ref.)
Plant antibodies for immunotherapy. Ma JK, et al. **Plant Physiol** 1995 Oct;109(2):341–6 (30 ref.)
The production of pharmaceutical proteins from the milk of transgenic animals. Houdebine LM. **Reprod Nutr Dev** 1995;35(6):609–17 (64 ref.)
Genetically engineered yeast cells and their applications. Pompon D, et al. **Toxicol Lett** 1995 Dec;82–83:815–22 (14 ref.)
Genetically engineered bacterial cells and applications. Waterman MR, et al. **Toxicol Lett** 1995 Dec;82–83:807–13 (27 ref.)
Review: methylotrophic yeasts as factories for the production of foreign proteins. Faber KN, et al. **Yeast** 1995 Nov; 11(14):1331–44 (111 ref.)

CHEMISTRY

Protein engineering of domains in flavoprotein disulphide oxidoreductases: contributions to folding and assembly. Perham RN, et al. **Biochem Soc Trans** 1996 Feb;24(1):61–6 (45 ref.)
Effects of overexpressing folding modulators on the in vivo folding of heterologous proteins in Escherichia coli. Wall JG, et al. **Curr Opin Biotechnol** 1995 Oct;6(5):507–16 (77 ref.)
Overexpression, isolation, and crystallization of proteins. Skelly JV, et al. **Methods Mol Biol** 1996;56:23–53 (85 ref.)

IMMUNOLOGY

DNA vectors. Precedents and safety. Hilleman MR. **Ann N Y Acad Sci** 1995 Nov 27;772:1–14 (52 ref.)

ISOLATION & PURIFICATION

Improved safety from plasma derivatives: purification and viral elimination characteristics of mononine. Feldman F, et al. **Acta Haematol** 1995;94 Suppl 1:25–32; discussion 33–4 (13 ref.)

METABOLISM

In vitro folding of inclusion body proteins. Rudolph R, et al. **FASEB J** 1996 Jan;10(1):49–56 (80 ref.)

PHARMACOLOGY

Epoetin beta. A review of its pharmacological properties and clinical use in the management of anaemia associated with chronic renal failure. Dunn CJ, et al. **Drugs** 1996 Feb; 51(2):299–318 (91 ref.)
Fibrinolytic mechanism, biochemistry, and preclinical pharmacology of recombinant prourokinase. Credo RB, et al. **J Vasc Interv Radiol** 1995 Nov–Dec;6(6 Pt 2 Su):8S–18S (59 ref.)

THERAPEUTIC USE

Recombinant hematopoietic growth factors in bone marrow transplantation. Nemunaitis J. **Cancer Treat Res** 1995; 76:225–48 (151 ref.)
Engineering recombinant antibodies for immunotherapy. Neri D, et al. **Cell Biophys** 1995 Aug;27(1):47–61 (62 ref.)
Recombinant proteins for medical use: the attractions and challenges. Koths K. **Curr Opin Biotechnol** 1995 Dec; 6(6):681–7 (54 ref.)
Epoetin beta. A review of its pharmacological properties and clinical use in the management of anaemia associated with chronic renal failure. Dunn CJ, et al. **Drugs** 1996 Feb; 51(2):299–318 (91 ref.)
New treatment strategies in cystic fibrosis: rhDNase. Shah PL, et al. **Monaldi Arch Chest Dis** 1996 Apr;51(2):125–9 (27 ref.)

RECOMBINATION, GENETIC

Transcription, replication, recombination, and engineering of coronavirus genes. Lai MM. **Adv Exp Med Biol** 1995; 380:463–71 (29 ref.)
Meiotic sister chromatid recombination. Petes TD, et al. **Adv Genet** 1995;33:41–62 (68 ref.)
Conjugative transposition. Scott JR, et al. **Annu Rev Microbiol** 1995;49:367–97 (108 ref.)
Recombination, mutation and the origin of species. Cox EC. **Bioessays** 1995 Sep;17(9):747–9 (23 ref.)
Meiotic recombination: a mechanism for tracking and eliminating mutations? McKee BD. **Bioessays** 1996 May; 18(5):411–9 (72 ref.)
Recombination by replication. Kogoma T. **Cell** 1996 May 31;85(5):625–7 (17 ref.)
Lymphocyte-specific genetic instability and cancer. Kirsch IR, et al. **Cold Spring Harb Symp Quant Biol** 1994; 59:287–95 (77 ref.)
Recombination. Pieces of the site-specific recombination puzzle. Oram M, et al. **Curr Biol** 1995 Oct 1;5(10):1106–9 (20 ref.)
Tn10 and IS10 transposition and chromosome rearrangements: mechanism and regulation in vivo and in vitro. Kleckner N, et al. **Curr Top Microbiol Immunol** 1996; 204:49–82 (96 ref.)
Homologous recombination in the replicative cycle of adenovirus and its relationship to DNA replication. Young CS. **Curr Top Microbiol Immunol** 1995;199 (Pt 2):89–108 (75 ref.)
Proliferative cell senescence, transformation, and the recombination potential of the genome. Macieira-Coelho A. **Exp Gerontol** 1996 Jan–Apr;31(1–2):227–34 (28 ref.)
Site-specific recombination in gram-positive theta-replicating plasmids. Alonso JC, et al. **FEMS Microbiol Lett** 1996 Aug 15;142(1):1–10 (28 ref.)
Sexuality of mitochondria: fusion, recombination, and plasmids. Kawano S, et al. **Int Rev Cytol** 1995;161:49–110 (179 ref.)
The RuvABC proteins and Holliday junction processing in Escherichia coli. West SC. **J Bacteriol** 1996 Mar; 178(5):1237–41 (59 ref.)
Is the synaptonemal complex a disjunction machine? Maguire MP. **J Hered** 1995 Sep–Oct;86(5):330–40 (91 ref.)
Old and new concepts for the role of chi in bacterial recombination. Stahl F, et al. **J Hered** 1995 Sep–Oct; 86(5):327–9 (48 ref.)
Relaxing and unwinding on Holliday: DNA helicase-mediated branch migration. Adams DE, et al. **Mutat Res** 1995 Nov;337(3):149–59 (70 ref.)
Somatic recombination, gene amplification and cancer. Ramel C, et al. **Mutat Res** 1996 Jun 12;353(1–2):85–107 (34 ref.)
Evidence that mammalian cells possess homologous recombinational repair pathways. Thompson LH. **Mutat Res** 1996 Jun 12;363(2):77–88 (119 ref.)
Role of recombination enzymes in mammalian cell survival. Edelmann W, et al. **Proc Natl Acad Sci U S A** 1996 Jun 25;93(13):6225–7 (25 ref.)
Meiosis: how could it work? Kleckner N. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8167–74 (103 ref.)
Analysis of the mechanism of DNA recombination using tangles. Sumners DW, et al. **Q Rev Biophys** 1995 Aug; 28(3):253–313 (85 ref.)
PIK-related kinases: DNA repair, recombination, and cell cycle checkpoints. Keith CT, et al. **Science** 1995 Oct 6; 270(5233):50–1 (22 ref.)
Getting down to the core of homologous recombination [comment] Stasiak A. **Science** 1996 May 10;272(5263):828–9 (9 ref.) Comment on: Science 1996 May 10;272(5263):868–72.
DNA double-strand break repair and V(D)J recombination: involvement of DNA-PK. Jackson SP, et al. **Trends Biochem Sci** 1995 Oct;20(10):412–5 (41 ref.)
Homologous recombination and the roles of double-strand breaks. Shinohara A, et al. **Trends Biochem Sci** 1995 Oct; 20(10):387–91 (32 ref.)
[Cellular proteins binding to the hot spot of DNA recombination on the HBV-DNA sequence] Kajino K, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:94–6 (8 ref.) **(Jpn)**
[Homologous recombination for gene targeting] Aizawa S. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2013–6 (3 ref.) **(Jpn)**
[Homologous recombination and triple helix DNA] Kotani H. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2654–60 (22 ref.) **(Jpn)**

GENETICS

Cutting apart V(D)J recombination. Oettinger MA. **Curr Opin Genet Dev** 1996 Apr;6(2):141–5 (43 ref.)
New insights into V(D)J recombination and its role in the evolution of the immune system. Thompson CB. **Immunity** 1995 Nov;3(5):531–9 (104 ref.)
Generation of MHC class II diversity by intra- and intergenic recombination. Andersson L, et al. **Immunol Rev** 1995 Feb; 143:5–12 (19 ref.)

IMMUNOLOGY

The Ku autoantigen: cast in a new light. Robinson A. **Can Med Assoc J** 1996 Jun 15;154(12):1871–3 (8 ref.)

RECORD LINKAGE, MEDICAL see **MEDICAL RECORD LINKAGE**

RECORDS

VETERINARY

NCA-IRM desk record. Kniffen D. **Vet Clin North Am Food Anim Pract** 1995 Jul;11(2):215–78 (0 ref.)

RECORDS CONTROL see **FORMS AND RECORDS CONTROL**

RECOVERY PERIOD, ANESTHESIA see **ANESTHESIA RECOVERY PERIOD**

RECOVERY ROOM

Recovery room problems or problems in the PACU. Rose DK. **Can J Anaesth** 1996 May;43(5 Pt 2):R116–28 (50 ref.) **(Eng, Fre)**
Pediatric postanesthesia recovery care. Hall SC. **J Clin Anesth** 1995 Nov;7(7):600–5 (27 ref.)
[Neuromuscular relaxants in the recovery room (see comments)] de la Cruz CA, et al. **Rev Esp Anestesiol Reanim** 1995 Oct;42(8):344–8 (25 ref.) Comment in: Rev Esp Anestesiol Reanim 1995 Oct;42(8):301–2. **(Spa)**

RECREATIONAL DRUGS see **STREET DRUGS**

RECRUDESCENCE see **RECURRENCE**

RECTAL DISEASES

CONGENITAL

Rectal atresia and stenosis. Zia-w-Miraj Ahmad M, et al. **J Pediatr Surg** 1995 Nov;30(11):1546–50 (39 ref.)

DIAGNOSIS

[Current proctology—modern functional diagnosis] Feifei G, et al. **Chirurg** 1996 Mar;67(3):205–12 (33 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Annular constriction of the rectum secondary to transitional cell carcinoma of the bladder. Langenstroer P, et al.

Urology 1996 Mar;47(3):442–4 (6 ref.)
[Ano-rectal and colonic complications of suppositories and enemas] de Parades V, et al. **Gastroenterol Clin Biol** 1996; 20(5):446–52 (118 ref.) **(Fre)**

SURGERY

Rare anorectal pathologic conditions. Denis J, et al. **Curr Opin Gen Surg** 1994;:103–7 (24 ref.)
Continence-preserving procedures for benign and malignant disease. Lewis WG, et al. **Curr Opin Gen Surg** 1993;:157–63 (53 ref.)
Colorectal stapled anastomoses. Experiences and results. Hansen O, et al. **Dis Colon Rectum** 1996 Jan;39(1):30–6 (39 ref.)

ULTRASONOGRAPHY

[Established indications for endosonography of the rectum and colon] Feifel G, et al. **Bildgebung** 1995 Oct;62 Suppl 2:40–6 (40 ref.) **(Ger)**

RECTAL FISTULA

CONGENITAL

Management of congenital anorectal malformations. Wakhlu AK. **Indian Pediatr** 1995 Nov;32(11):1239–42 (0 ref.)

DIAGNOSIS

[Diagnosis of perianal and perirectal fistulas and abscesses] Rieber A, et al. **Rontgenpraxis** 1996 May;49(5):110–4 (20 ref.) **(Ger)**

DRUG THERAPY

Management of rectourethral fistulas in Crohn's disease. Santoro GA, et al. **Int J Colorectal Dis** 1995;10(4):183–8 (47 ref.)

RADIOGRAPHY

The various types of anorectal fistula in male imperforate anus. Currarino G. **Pediatr Radiol** 1996;26(8):512–22; discussion 523 (35 ref.)

SURGERY

Perianal inflammatory conditions in inflammatory bowel disease. Stein BL, et al. **Curr Opin Gen Surg** 1993;:141–6 (17 ref.)
[Fistula, fissure, abscess] Girona J, et al. **Chirurg** 1996 Mar; 67(3):222–8 (28 ref.) (Eng. Abstr.) **(Ger)**

RECTAL NEOPLASMS

Treatment of non-disseminated cancer of the lower rectum. Nicholls RJ, et al. **Br J Surg** 1996 Jan;83(1):15–8 (43 ref.)
Recent study on colorectal cancer in China. Zheng S. **Chin Med J (Engl)** 1996 Mar;109(3):182–5 (19 ref.)

COMPLICATIONS

Nontraumatic subcutaneous emphysema in association with rectal carcinoma. Chow E, et al. **Can Assoc Radiol J** 1996 Apr;47(2):94–7 (12 ref.)

DIAGNOSIS

A case report of rectal schwannoma. Murakami N, et al. **Kurume Med J** 1996;43(1):101–6 (12 ref.)
Colorectal neoplasms. Screening can save lives. Truszkowski JA, et al. **Postgrad Med** 1995 Nov;98(5):97–9, 103–6, 109–12 (20 ref.)
[Determination of the activated proto-oncogene (Ki-ras) in feces. A new laboratory analysis for early diagnosis of colorectal cancer] Koornstra JJ, et al. **Tidsskr Nor Laegeforen** 1995 Oct 30;115(26):3266–70 (42 ref.) (Eng. Abstr.) **(Nor)**

DRUG THERAPY

An overview of adjuvant therapy for colorectal cancer. Haller DG. **Eur J Cancer** 1995 Jul-Aug;31A(7–8):1255–63 (47 ref.)
Adjuvant chemotherapy for colon and rectal cancer. Fuchs CS, et al. **Semin Oncol** 1995 Oct;22(5):472–87 (132 ref.)
[Adjuvant radiochemotherapy of rectal carcinoma] Keilholz L, et al. **Schweiz Rundsch Med Prax** 1995 Nov 21; 84(47):1377–82 (45 ref.) (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

Epidemiology of fibre, resistant starch and colorectal cancer. Kritchevsky D. **Eur J Cancer Prev** 1995 Oct;4(5):345–52 (65 ref.)

ETIOLOGY

Recurrent polyps in the ileo-anal pouch or rectum in familial adenomatous polyposis. Tytgat GN, et al. **Eur J Cancer** 1995 Jul-Aug;31A(7–8):1134–9 (45 ref.)
Butyrate and colorectal cancer in animals and in humans (mini-symposium: butyrate and colorectal cancer). Clausen MR. **Eur J Cancer Prev** 1995 Dec;4(6):483–90 (104 ref.)

GENETICS

Colorectal cancer: molecular genetic studies and their future clinical applications. Fearon ER. **Med Pediatr Oncol Suppl** 1996;1:35–40 (57 ref.)

METABOLISM

Oestrogen and colonic epithelial cell growth. Singh S, et al. **Gut** 1995 Dec;37(6):737–9 (42 ref.)

PATHOLOGY

The short-chain fatty acid butyrate induces apoptosis in colorectal tumour cell lines. Hague A, et al. **Eur J Cancer Prev** 1995 Oct;4(5):359–64 (36 ref.)
Primary tumour staging of gastric and colorectal cancer. Bruneton JN, et al. **Eur Radiol** 1996;6(2):140–6 (45 ref.)
[Report of a case of penile metastasis. Review of the literature] Cuvillier X, et al. **Prog Urol** 1995 Dec; 5(6):1009–11 (17 ref.) (Eng. Abstr.) **(Fre)**
[Ultrasonic tomography in the diagnosis of pararectal metastases of rectal cancers] Tsyb AF, et al. **Vopr Onkol** 1996;42(2):95–100 (47 ref.) **(Rus)**

RADIOGRAPHY

Barium enema: colorectal polyps and carcinoma. Ott DJ. **Semin Roentgenol** 1996 Apr;31(2):125–41 (64 ref.)

RADIOTHERAPY

Radiotherapy in addition to radical surgery in rectal cancer. Glimelius B, et al. **Acta Oncol** 1995;34(5):565–70 (42 ref.)
Rectal cancer: a review of randomized trials of adjuvant radiotherapy. McLean CM, et al. **Clin Oncol (R Coll Radiol)** 1995;7(6):349–58 (29 ref.)
Adjuvant radiation for rectal cancer: when and with what? Cummings BJ. **Curr Opin Gen Surg** 1994;:85–93 (54 ref.)
The current role of radiotherapy in colorectal cancer. Aleman BM, et al. **Eur J Cancer** 1995 Jul-Aug; 31A(7–8):1333–9 (28 ref.)
Improvement of the curative management of rectal cancers by better use of radiotherapy. Horiot JC, et al. **Eur J Cancer** 1995 Jul-Aug;31A(7–8):1382–4 (12 ref.)
The prevention of radiation-induced small bowel complications. Letschert JG. **Eur J Cancer** 1995 Jul-Aug; 31A(7–8):1361–5 (26 ref.)
Conservative treatment of rectal cancer with local excision and postoperative radiation therapy. Minsky BD. **Eur J Cancer** 1995 Jul-Aug;31A(7–8):1343–6 (24 ref.)
The value of adjuvant radio(chemo)therapy for rectal cancer. Påhlman L, et al. **Eur J Cancer** 1995 Jul-Aug; 31A(7–8):1347–50 (30 ref.)
Radiotherapy in rectal cancer: stage of the disease and therapeutic approach. Cellini N, et al. **Rays** 1995 Apr-Jun; 20(2):132–44 (72 ref.) **(Eng, Ita)**
Concomitant radiochemotherapy in rectal cancer: methodology and indications. Valentini V, et al. **Rays** 1995 Jan-Mar;20(1):90–111 (66 ref.) **(Eng, Ita)**
Prevention of radiation related complications in the treatment of rectal adenocarcinoma. The importance of the dose volume relationship. Gerard JP, et al. **Tumori** 1995 May-Jun;81(3 Suppl):114–6 (20 ref.)
Anorectal melanoma. Successful palliation in a 59-year-old woman. Mostafapour SP, et al. **West J Med** 1996 May; 164(5):448–50 (18 ref.)
[Concomitant preoperative radiochemotherapy for rectal cancers] Bosset JF, et al. **Ann Chir** 1996;50(4):302–10; discussion 311 (53 ref.) (Eng. Abstr.) **(Fre)**
[The role of radiotherapy in the treatment of rectal cancer] Dubois JB. **Bull Cancer Radiother** 1990;77(1):33–51 (119 ref.) **(Fre)**
[Adjuvant radiochemotherapy of rectal carcinoma] Keilholz L, et al. **Schweiz Rundsch Med Prax** 1995 Nov 21; 84(47):1377–82 (45 ref.) (Eng. Abstr.) **(Ger)**

SECONDARY

[Lymphomas of the colon complicating hemorrhagic rectocolitis] Baron P, et al. **Gastroenterol Clin Biol** 1995 Nov;19(11):935–9 (32 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Single and double stapled anastomoses in rectal cancer surgery; a retrospective study on the safety of the technique and its indication. Chiarugi M, et al. **Acta Chir Belg** 1996 Feb;96(1):31–6 (30 ref.)
Radical versus local surgical treatment for rectum carcinoma. A variety of options? Penninckx F, et al. **Acta Chir Belg** 1995;95(4 Suppl):171–5 (33 ref.)
Radiotherapy in addition to radical surgery in rectal cancer. Glimelius B, et al. **Acta Oncol** 1995;34(5):565–70 (42 ref.)
Pelvic exenteration for recurrent rectal cancer. Avradopoulos KA, et al. **Adv Surg** 1996;29:215–33 (71 ref.)
Retroperitoneal and abdominal wall emphysema after transanal excision of a rectal carcinoma. Petros JG, et al. **Am Surg** 1996 Sep;62(9):759–61 (8 ref.)
The morbidity of defunctioning stomata. Chen F, et al. **Aust N Z J Surg** 1996 Apr;66(4):218–21 (25 ref.)
Surgical management of locally recurrent rectal cancer. Sagar PM, et al. **Br J Surg** 1996 Mar;83(3):293–304 (159 ref.)
Local surgical treatment of rectal cancer [see comments] Baron PL, et al. **Cancer Invest** 1995;13(6):612–6 (22 ref.) Comment in: Cancer Invest 1995;13(6):660–1.
Rare anorectal pathologic conditions. Denis J, et al. **Curr Opin Gen Surg** 1994;:103–7 (24 ref.)
Continence-preserving procedures for benign and malignant disease. Lewis WG, et al. **Curr Opin Gen Surg** 1993;:157–63 (53 ref.)
Alternative surgical procedures for primary rectal carcinoma. Meagher AP, et al. **Curr Opin Gen Surg** 1994;:230–7 (52 ref.)
Transanal electroresection of small rectal cancer: a sole treatment? Faivre J, et al. **Dis Colon Rectum** 1996 Mar; 39(3):270–8 (39 ref.)
Local surgical treatment of rectal cancer. Buess GF. **Eur J Cancer** 1995 Jul-Aug;31A(7–8):1233–7 (20 ref.)
Palliative endoscopic therapy of rectal carcinoma. Dohmoto M, et al. **Eur J Cancer** 1996 Jan;32A(1):25–9 (45 ref.)
Analysis of local recurrence rates after surgery alone for rectal cancer. McCall JL, et al. **Int J Colorectal Dis** 1995; 10(3):126–32 (105 ref.)
Role of laparoscopic techniques in colorectal cancer surgery. Milsom JW, et al. **Oncology (Huntingt)** 1995 May; 9(5):393–8; discussion 398–9, 403–4, 409 (23 ref.)
Local recurrences from rectal cancer: impact of previous surgery. Bozzetti F, et al. **Tumori** 1995 May-Jun;81(3 Suppl):135–40 (84 ref.)
[Total mesorectal excision: a new standard for surgical treatment of rectal carcinoma (see comments)] Ottow RT, et al. **Ned Tijdschr Geneeskd** 1996 Jan 13;140(2):60–2 (15 ref.) Comment in: Ned Tijdschr Geneeskd 1996 Apr 27;140(17):951; discussion 952. Comment in: Ned Tijdschr Geneeskd 1996 Apr 27;140(17):951–2. Comment in: Ned Tijdschr Geneeskd 1996 Apr 27;140(17):952. **(Dut)**
[Results and conclusions from 328 radical operations of rectal carcinoma by one surgeon. Comparative anatomic studies with Brachydanio rerio and Latimeria chalumnae] Stelzner F. **Chirurg** 1995 Dec;66(12):1230–8 (22 ref.) (Eng. Abstr.) **(Ger)**
[The secondary prevention of colorectal carcinoma by polyp removal] Riemann JF. **Strahlenther Onkol** 1995 Nov; 171(11):611–4 (21 ref.) (Eng. Abstr.) **(Ger)**
[Role of the anterior resection in the surgical treatment of rectal cancer. Review of the literature] Santini L, et al. **Minerva Gastroenterol Dietol** 1995 Dec;41(4):283–7 (37 ref.) (Eng. Abstr.) **(Ita)**
[Anorectal malignant melanoma] Gramática L, et al. **Rev Fac Cien Med Univ Nac Cordoba** 1994;52(2):11–6 (26 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

Adjuvant and neoadjuvant treatment of rectal cancer. Freedman GM, et al. **Semin Oncol** 1995 Dec;22(6):611–24 (91 ref.)
[Therapeutic choices in cancer of the rectum] **Ann Chir** 1995; 49(5):373–81 (0 ref.) **(Fre)**
[Choice of treatment in rectal cancer. Consensus Conference, Chamber of Commerce and Industry, Paris, December 1–2, 1994] **Ann Gastroenterol Hepatol (Paris)** 1995 Sep; 31(4):226–30, 233–6 (0 ref.) **(Fre)**
[Low rectal cancer: conservative approach integrating radiotherapy] Allal AS. **Bull Cancer (Paris)** 1996 Mar; 83(3):189–96 (38 ref.) (Eng. Abstr.) **(Fre)**
[Local treatments of rectal cancer] Lasser P. **J Chir (Paris)** 1996 Jan;133(1):23–36 (77 ref.) **(Fre)**
[Treatment of fixed, primarily non-resected rectal cancer. Recommendations from Norwegian Gastrointestinal Cancer Group] Bjerkeset T, et al. **Tidsskr Nor Laegeforen** 1996 Jan 30;116(3):379–81 (42 ref.) (Eng. Abstr.) **(Nor)**

ULTRASONOGRAPHY

Review of artifacts associated with transrectal ultrascund: understanding, recognition, and prevention of misinterpretation. Hulsmans FJ, et al. **J Clin Ultrasound** 1995 Oct;23(8):483–94 (21 ref.)
Endoscopic ultrasonography. Wolfman NT, et al. **Semin Roentgenol** 1996 Apr;31(2):154–61 (44 ref.)
[Ultrasonic tomography in the diagnosis of pararectal metastases of rectal cancers] Tsyb AF, et al. **Vopr Onkol** 1996;42(2):95–100 (47 ref.) **(Rus)**

RECTAL PROLAPSE

DIAGNOSIS

[Internal rectal prolapse: therapy outcome and current status] Gemsenjäger E. **Schweiz Med Wochenschr** 1996 Aug 17; 126(33):1377–84 (70 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

[Pelvic floor insufficiency as an interdisciplinary responsibility] Hansen H. **Chirurg** 1996 May;67(5):498–504 (14 ref.) (Eng. Abstr.) **(Ger)**
[Rectal prolapse—choice of procedure and minimal invasive possibilities] Köckerling F, et al. **Chirurg** 1996 May; 67(5):471–82 (38 ref.) (Eng. Abstr.) **(Ger)**

RECTAL SURGERY (SPECIALTY) see **COLON AND RECTAL SURGERY (SPECIALTY)**

RECTOCOLITIS, HEMORRHAGIC see **COLITIS, ULCERATIVE**

RECTOCOLITIS, ULCERATIVE

RECTOCOLITIS, ULCERATIVE see COLITIS, ULCERATIVE

RECTOVAGINAL FISTULA

SURGERY

Perianal inflammatory conditions in inflammatory bowel disease. Stein BL, et al. **Curr Opin Gen Surg** 1993;:141–6 (17 ref.)

RECTUM

ABNORMALITIES

Rectal duplication in an adult. Alavanja G, et al. **Am Surg** 1995 Nov;61(11):997–1000 (22 ref.)

The Currarino syndrome—hereditary transmitted syndrome of anorectal, sacral and presacral anomalies. Case report and review of the literature. Köchling J, et al. **Eur J Pediatr Surg** 1996 Apr;6(2):114–9 (35 ref.)

Rectal atresia and stenosis. Zia–w–Miraj Ahmad M, et al. **J Pediatr Surg** 1995 Nov;30(11):1546–50 (39 ref.)

CYTOLOGY

Colorectal cell kinetics. Gilliland R, et al. **Br J Surg** 1996 Jun;83(6):739–49 (181 ref.)

INJURIES

Laparoscopic colostomy for a gunshot wound to the rectum. Namias N, et al. **J Laparoendosc Surg** 1995 Aug;5(4):251–3 (17 ref.)

PATHOLOGY

Colorectal adenocarcinoma: staging and histopathology. Johnson RD, et al. **Semin Roentgenol** 1996 Apr; 31(2):94–102 (36 ref.)

PHYSIOLOGY

Anorectal and pelvic floor function. Relevance of continence, incontinence, and constipation. Sagar PM, et al. **Gastroenterol Clin North Am** 1996 Mar;25(1):163–82 (102 ref.)

PHYSIOPATHOLOGY

[Anorectal manometry in hemorrhoidal disease] Girardi S, et al. **Ann Ital Chir** 1995 Nov–Dec;66(6):757–60 (17 ref.) (Eng. Abstr.) **(Ita)**

RADIOGRAPHY

[The 3rd national workshop on defecography: the functional radiology of (neo) rectal ampullae (ileal reservoir, colo–anal anastomosis, continent perineal colostomy)] Piloni V, et al. **Radiol Med (Torino)** 1996 Jan–Feb;91(1–2):66–72 (34 ref.) (Eng. Abstr.) **(Ita)**

SURGERY

Current controversies in laparoscopic colorectal surgery [editorial] Agachan F, et al. **G Chir** 1996 Mar;17(3):77–83 (67 ref.)

Laparoscopic colostomy for a gunshot wound to the rectum. Namias N, et al. **J Laparoendosc Surg** 1995 Aug;5(4):251–3 (17 ref.)

[Total mesorectal excision: a new standard for surgical treatment of rectal carcinoma (see comments)] Ottow RT, et al. **Ned Tijdschr Geneeskd** 1996 Jan 13;140(2):60–2 (15 ref.) Comment in: Ned Tijdschr Geneeskd 1996 Apr 27;140(17):951; discussion 952. Comment in: Ned Tijdschr Geneeskd 1996 Apr 27;140(17):951–2. Comment in: Ned Tijdschr Geneeskd 1996 Apr 27;140(17):952. **(Dut)**

[Results and conclusions from 328 radical operations of rectal carcinoma by one surgeon. Comparative anatomic studies with Brachydanio rerio and Latimeria chalumnae] Stelzner F. **Chirurg** 1995 Dec;66(12):1230–8 (22 ref.) (Eng. Abstr.) **(Ger)**

[Amputation of the rectum via laparoscopy] Vasilescu C, et al. **Chirurgia (Bucur)** 1995;44(3):55–8 (6 ref.) (Eng. Abstr.) **(Rum)**

[Coloanal anastomosis (Parks operation) in the treatment of acute radiation rectitis] San Martín S, et al. **Rev Med Chil** 1995 Mar;123(3):321–5 (15 ref.) (Eng. Abstr.) **(Spa)**

RECTUS ABDOMINIS

TRANSPLANTATION

Recurrent squamous cell carcinoma in a rectus abdominis neovagina. Carlson JW, et al. **Gynecol Oncol** 1995 Oct; 59(1):159–61 (17 ref.)

RECURRENCE

see related
NEOPLASM RECURRENCE, LOCAL

Ways of measuring rates of recurrent events. Glynn RJ, et al. **BMJ** 1996 Feb 10;312(7027):364–7 (29 ref.)

RECYCLING see CONSERVATION OF NATURAL RESOURCES

RECYCLING, EQUIPMENT see EQUIPMENT REUSE

RED BLOOD CELL MEMBRANE SIALOGLYCOPROTEIN see GLYCOPHORIN

RED BLOOD CELL TRANSFUSION see ERYTHROCYTE TRANSFUSION

RED BLOOD CELLS see ERYTHROCYTES

RED-CELL APLASIA, PURE

CHEMICALLY INDUCED

Azathioprine–induced pure red–cell aplasia. Pruijt JF, et al. **Nephrol Dial Transplant** 1996 Jul;11(7):1371–3 (20 ref.)

DRUG THERAPY

Successful treatment of pure red cell aplasia in systemic lupus erythematosus with erythropoietin. Orbach H, et al. **J Rheumatol** 1995 Nov;22(11):2166–9 (27 ref.)

ETIOLOGY

[Parvovirus B19 infection. New physiopathological approaches] Labau E, et al. **Presse Med** 1996 Feb 3; 25(4):162–6 (26 ref.) (Eng. Abstr.) **(Fre)**

RED CELL GHOST see ERYTHROCYTE MEMBRANE

RED CELL INDICES see ERYTHROCYTE INDICES

RED CELL MASS see ERYTHROCYTE VOLUME

RED CELL SUBSTITUTES see BLOOD SUBSTITUTES

RED MARROW see BONE MARROW

RED NUCLEUS

PATHOLOGY

[Clinical picture of DRPLA] Naito H. **No To Shinkei** 1995 Oct;47(10):931–8 (35 ref.) **(Jpn)**

[Neuropathology of dentatorubral–pallidoluysian atrophy and Machado–Joseph disease] Takahashi H, et al. **No To Shinkei** 1995 Oct;47(10):947–53 (34 ref.) **(Jpn)**

[How was the gene for dentatorubral–pallidoluysian atrophy discovered?] Tsuji S, et al. **No To Shinkei** 1996 Apr; 48(4):323–8 (27 ref.) **(Jpn)**

RED TIDE see DINOFLAGELLIDA

REDOX see OXIDATION–REDUCTION

REDUCTASES see OXIDOREDUCTASES

REED–STERNBERG CELLS

see related
HODGKIN'S DISEASE

[Cellular biology of Reed–Sternberg cells in Hodgkin's disease] Mikata A. **Rinsho Ketsueki** 1995 Jul;36(7):629–37 (81 ref.) **(Jpn)**

IMMUNOLOGY

The antigen–presenting cell function of Reed–Sternberg cells. Delabie J, et al. **Leuk Lymphoma** 1995 Jun;18(1–2):35–40 (55 ref.)

REELER MICE see MICE, NEUROLOGIC MUTANTS

REFERENCE BOOKS, MEDICAL

[Are the concepts of dementia according to DSM–4 and ICD–10 similar? Some theoretical aspects] Heinik J. **Harefuah** 1996 Mar 15;130(6):409–13 (32 ref.) **(Heb)**

REFERENCE STANDARDS

The need for accuracy in laboratory medicine. Büttner J. **Eur J Clin Chem Clin Biochem** 1995 Dec;33(12):981–8 (38 ref.)

Analytical quality specifications for reference methods and operating specifications for networks of reference laboratories. discussion paper from the members of the external quality assessment (EQA) Working Group B1) on target values in EQAS. Thienpont L, et al. **Eur J Clin Chem Clin Biochem** 1995 Dec;33(12):949–57 (52 ref.)

REFERRAL AND CONSULTATION

Every woman with an abnormal cervical smear should be referred for treatment: debate. Flannelly G, et al. **Clin Obstet Gynecol** 1995 Sep;38(3):585–91 (20 ref.)

Every woman with an abnormal cervical smear should not be referred for colposcopy: debate. Prendiville W, et al. **Clin Obstet Gynecol** 1995 Sep;38(3):592–9 (16 ref.)

Why do people consult the doctor? Campbell SM, et al. **Fam Pract** 1996 Feb;13(1):75–83 (111 ref.)

Effects of information–giving and communication during orthodontic consultation and treatment. Part 3: Optimized orthodontist–patient communication. Witt E, et al. **Fortschr Kieferorthop** 1996 Jun;57(3):154–67 (55 ref.) **(Eng, Ger)**

Guidelines for doctors on identifying and helping their patients who batter. Adams D. **J Am Med Womens Assoc** 1996 May–Jul;51(3):123–6 (22 ref.)

Rectal bleeding: when is it right to refer? Thompson M, et al. **Practitioner** 1996 Mar;240(1560):198–200 (9 ref.)

[Severe preeclampsia. Principal management modalities before patient transfer] Aya AG, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(2):196–205 (78 ref.) (Eng. Abstr.) **(Fre)**

[When should the family physician contact the cardiological transplantation team?] Mohacsi P, et al. **Ther Umsch** 1995 Sep;52(9):617–25 (31 ref.) (Eng. Abstr.) **(Ger)**

ORGANIZATION & ADMINISTRATION

Preserving the patient referral process in the managed care environment. Rosenthal TC, et al. **Am J Med** 1996 Mar; 100(3):338–43 (54 ref.)

STATISTICS & NUMERICAL DATA

Who cares? Pathways to psychiatric care for young people experiencing a first episode of psychosis. Lincoln CV, et al. **Psychiatr Serv** 1995 Nov;46(11):1166–71 (89 ref.)

TRENDS

The role of the transfusion medicine consultant. Popovsky MA, et al. **Am J Clin Pathol** 1996 Jun;105(6):798–801 (12 ref.)

REFETOFF SYNDROME see THYROID HORMONE RESISTANCE SYNDROME

REFLEX

Suprapontine influences on the micturition reflex. Torrens M. **Scand J Urol Nephrol Suppl** 1995;175:11–3 (24 ref.)

[Uncommon reflex automatisms after brain death] Awada A. **Rev Neurol (Paris)** 1995 Oct;151(10):586–8 (11 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Physiology of startle phenomena. Brown P. **Adv Neurol** 1995; 67:273–87 (79 ref.)

Physiology of negative myoclonus. Toro C, et al. **Adv Neurol** 1995;67:211–7 (16 ref.)

Neural mechanisms and axon reflexes in asthma. Where are we? Verleden GM. **Biochem Pharmacol** 1996 May 17; 51(10):1247–57 (176 ref.)

Short– and long–term modification of reflex function during learning and metamorphosis in Manduca. Weeks JC, et al. **Biol Bull** 1996 Aug;191(1):62–9 (34 ref.)

Actions of sex steroids on behaviours beyond reproductive reflexes. Priest CA, et al. **Ciba Found Symp** 1995;191:74–84; discussion 84–9 (69 ref.)

Neurophysiology of the cough reflex. Widdicombe JG. **Eur Respir J** 1995 Jul;8(7):1193–202 (98 ref.)

Reflex parasympathetic vasodilatation in facial skin. Izumi H. **Gen Pharmacol** 1995 Mar;26(2):237–44 (74 ref.)

Spinal cord tachykinins in the micturition reflex. Lecci A, et al. **Prog Brain Res** 1995;104:145–59 (93 ref.)

Neuropeptides and spinal cord reflexes. Wiesenfeld–Hallin Z. **Prog Brain Res** 1995;104:271–82 (104 ref.)

Presynaptic inhibition in humans. Stein RB. **Prog Neurobiol** 1995 Dec;47(6):533–44 (52 ref.)

[Pulmonary and pulmonary–related reflexes mediated by serotonin receptors in the peripheral nervous system] Yoshioka M. **Nippon Yakurigaku Zasshi** 1995 Nov; 106(5):311–20 (49 ref.) (Eng. Abstr.) **(Jpn)**

[The axon reflex: new views in an old area] Nozdrachev AD. **Fiziol Zh Im I M Sechenova** 1995 Nov;81(11):135–42 (24 ref.) **(Rus)**

[The chemical structure of the peripheral autonomic (visceral) reflex] Nozdrachev AD. **Usp Fiziol Nauk** 1996 Apr–Jun;27(2):28–60 (74 ref.) (Eng. Abstr.) **(Rus)**

[The nociceptive flexor reflex: a method for studying the brain mechanisms of pain control] Danilov AB, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1996; 96(1):107–11 (63 ref.) **(Rus)**

[Methods of studying somatosensory evoked responses and long–latency reflexes] Jovičić A, et al. **Vojnosanit Pregl** 1994 Nov–Dec;51(6):527–33 (38 ref.) **(Scr)**

REFLEX, ABNORMAL

[Campylobacter jejuni and autoimmune–mediated neurologic diseases: pathogenesis of Guillain–Barré syndrome and Fisher's syndrome] Yuki N. **Nippon Saikingaku Zasshi** 1995 Oct;50(4):991–1003 (41 ref.) **(Jpn)**

PHYSIOLOGY

Neurodevelopmental treatment: application to nursing and effects on the hemiplegic stroke patient. Hafsteinsdóttir TB. **J Neurosci Nurs** 1996 Feb;28(1):36–47 (45 ref.)

REFLEX, BARORECEPTOR see **BAROREFLEX**

REFLEX, BLINK see **BLINKING**

REFLEX, CONDITIONED see **CONDITIONING, CLASSICAL**

REFLEX, CORNEAL see **BLINKING**

REFLEX, ORBICULARIS OCULI see **BLINKING**

REFLEX, STRETCH

PHYSIOLOGY

Mechanical and electromyographic stretch responses in spastic and healthy subjects. Toft E.
Acta Neurol Scand Suppl 1995;163:1-24 (103 ref.)

REFLEX SYMPATHETIC DYSTROPHY

A review of reflex sympathetic dystrophy. Blombery PA. **Aust Fam Physician** 1995 Sep;24(9):1651-5 (6 ref.)
Reflex sympathetic dystrophy revisited. Musharafieh R, et al. **Middle East J Anesthesiol** 1996 Feb;13(4):345-71 (79 ref.)

CLASSIFICATION

Reflex sympathetic dystrophy: changing concepts and taxonomy. Stanton-Hicks M, et al. **Pain** 1995 Oct; 63(1):127-33 (38 ref.)

DIAGNOSIS

Reflex sympathetic dystrophy. Cooke E. **Practitioner** 1995 Sep;239(1554):521-3 (2 ref.)
[Atypical algodystrophy of the knee: apropos 2 partial cases] Macho Fernández JM, et al. **Rev Clin Esp** 1996 May; 196(5):306-9 (28 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

Autonomic nervous system disorders and reflex sympathetic dystrophy in lightning and electrical injuries. Cohen JA. **Semin Neurol** 1995 Dec;15(4):387-90 (23 ref.)

PHYSIOPATHOLOGY

[Reflex sympathetic algodystrophy] Heierli P, et al. **Rev Med Suisse Romande** 1996 Mar;116(3):197-203 (18 ref.) **(Fre)**
[Pain mechanisms in reflex sympathetic dystrophy] Yokota T. **Nippon Seikeigeka Gakkai Zasshi** 1995 Sep;69(9):788-97 (30 ref.) **(Jpn)**

RADIONUCLIDE IMAGING

[Bone scintigraphy and algodystrophy] Tondeur M, et al. **Rev Med Liege** 1995 Dec;50(12):510-6 (58 ref.) **(Fre)**

THERAPY

[Reflex sympathetic algodystrophies. Preventive and therapeutic aspects] Viel E, et al. **Cah Anesthesiol** 1995; 43(6):565-71 (69 ref.) (Eng. Abstr.) **(Fre)**

REFLEX, TENDON see **REFLEX, STRETCH**

REFLEXOLOGY see **MASSAGE**

REFRACTION, OCULAR

Retinal-image mediated ocular growth as a mechanism for juvenile onset myopia and for emmetropization. A literature review. Goss DA, et al. **Doc Ophthalmol** 1995; 90(4):341-75 (182 ref.)
Early refractive development in humans. Saunders KJ. **Surv Ophthalmol** 1995 Nov-Dec;40(3):207-16 (72 ref.)

REFRACTIVE ERRORS

ETIOLOGY

Early refractive development in humans. Saunders KJ. **Surv Ophthalmol** 1995 Nov-Dec;40(3):207-16 (72 ref.)

SURGERY

Endothelial changes following refractive surgery. Frueh BE, et al. **J Cataract Refract Surg** 1996 May;22(4):490-6 (47 ref.)
Intraocular lens power calculation for eyes after refractive keratotomy. Hoffer KJ. **J Refract Surg** 1995 Nov-Dec; 11(6):490-3 (4 ref.)
Barraquer Lecture. Refractive surgery: myth versus reality. Salz J. **J Refract Surg** 1995 Jul-Aug;11(4):284-300 (46 ref.)
Evaluating new refractive surgical procedures: free market madness versus regulatory rigor mortis [editorial] Waring GO 3rd. **J Refract Surg** 1995 Sep-Oct;11(5):335-9 (26 ref.)
Changing concepts in excimer laser corneal surgery [editorial] Waring GO 3rd. **J Refract Surg** 1995 May-Jun; 11(3 Suppl):S224-6 (7 ref.)
Photorefractive and phototherapeutic procedures. LaRussa FP, et al. **Optom Clin** 1995;4(4):51-67 (30 ref.)
Too good to be true? New technologies and surgical procedures for better vision. Perlman EM. **R I Med** 1995 Dec;78(12):359-62 (3 ref.)

REFRACTORY ANEMIA see **ANEMIA, REFRACTORY**

REFRACTORY ANEMIA WITH EXCESS OF BLASTS see **ANEMIA, REFRACTORY, WITH EXCESS OF BLASTS**

REFRIGERATION

see related
HYPOTHERMIA, INDUCED

REFSUM DISEASE

[Refsum disease] Hochner I, et al. **Rev Med Interne** 1996; 17(5):391-8 (36 ref.) (Eng. Abstr.) **(Fre)**

REFSUM DISEASE, INFANTILE see **PEROXISOMAL DISORDERS**

REFSUM'S DISEASE see **REFSUM DISEASE**

REFSUM'S SYNDROME see **REFSUM DISEASE**

REFUGEES

Evolution of complex disasters. Burkholder BT, et al. **Lancet** 1995 Oct 14;346(8981):1012-5 (21 ref.)
[Identification of victims of violence and torture: the practitioner's role] Subilia L, et al. **Schweiz Med Wochenschr** 1996 Jul 27;126(30):1291-6 (20 ref.) (Eng. Abstr.) **(Fre)**

PSYCHOLOGY

Psychosocial problems in refugee children exposed to war. McCloskey LA, et al. **Pediatrics** 1996 Mar;97(3):394-7 (36 ref.)

REFUSAL OF TREATMENT see **TREATMENT REFUSAL**

REFUSE DISPOSAL

Natural selection of PAH-degrading bacterial guilds at coal-tar disposal sites. Ghiorse WC, et al. **Environ Health Perspect** 1995 Jun;103 Suppl 5:107-11 (15 ref.)
Hazard to man and the environment posed by the use of urban waste compost: a review. Déportes I, et al. **Sci Total Environ** 1995 Nov 30;172(2-3):197-22 (182 ref.)

LEGISLATION & JURISPRUDENCE

A North American model to contain the spread of Aedes albopictus through tire legislation. Novak RJ. **Parassitologia** 1995 Dec;37(2-3):129-39 (17 ref.)

METHODS

[Biodegradation of polycyclic aromatic hydrocarbons and its application to the bioremediation of contaminated soils and sludges] Ferrari MD. **Rev Argent Microbiol** 1996 Apr-Jun;28(2):83-98 (71 ref.) (Eng. Abstr.) **(Spa)**

REGENERATION

see related
WOUND HEALING

Regeneration in the vertebrate central nervous system: phylogeny, ontogeny, and mechanisms. Larner AJ, et al. **Biol Rev Camb Philos Soc** 1995 Nov;70(4):597-619 (159 ref.)
Devices for dentoalveolar regeneration: an up-to-date literature review. Hardwick R, et al. **J Periodontol** 1995 Jun;66(6):495-505 (58 ref.)
Periodontal regenerative potential of space-providing expanded polytetrafluoroethylene membranes and recombinant human bone morphogenetic proteins. Sigurdsson TJ, et al. **J Periodontol** 1995 Jun;66(6):511-21 (37 ref.)
Neo-endothelialisation of PTFE microvascular grafts: a five-year experience. Lanzetta M, et al. **Microsurgery** 1995; 16(6):404-11 (35 ref.)
Transdifferentiation and retinal regeneration. Reh TA, et al. **Semin Cell Biol** 1995 Jun;6(3):137-42 (50 ref.)
Transdifferentiation as a basis for amphibian limb regeneration. Tsonis PA, et al. **Semin Cell Biol** 1995 Jun; 6(3):127-35 (58 ref.)
[Hepatocyte growth factor may accelerate the regeneration of nonhepatic tissues] Guo SH, et al. **Sheng Li Ko Hsueh Chin Chan** 1995 Oct;26(4):347-8 (10 ref.) **(Chi)**
[Use of cultured fibroblasts for restoration of skin in severe burns] Sarkisov DS, et al. **Biull Eksp Biol Med** 1995 Jun; 119(6):566-70 (28 ref.) **(Rus)**
[The urodelean retina as a model for studying the retinal regeneration potentials of other vertebrates] Grigorian EN. **Ontogenez** 1996 May-Jun;27(3):173-85 (117 ref.) (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

The potential role of growth and differentiation factors in periodontal regeneration. **J Periodontol** 1996 May; 67(5):545-53 (128 ref.)

GENETICS

Transformations in null mutants of Hox genes: do they represent intercalary regenerates? Crawford M. **Bioessays** 1995 Dec;17(12):1065-73 (48 ref.)

PHYSIOLOGY

Implications of cellular and molecular biology advances in periodontal regeneration. Amar S. **Anat Rec** 1996 Jun; 245(2):361-73 (137 ref.)
Reg protein: a potential beta-cell-specific growth factor? Baeza N, et al. **Diabetes Metab** 1996 Jul;22(4):229-34 (40 ref.)
New concepts in tissue repair: skin as an example. Meddahi A, et al. **Diabetes Metab** 1996 Jul;22(4):274-8 (28 ref.)
Saliva and growth factors: the fountain of youth resides in us all. Zelles T, et al. **J Dent Res** 1995 Dec;74(12):1826-32 (90 ref.)
[Cell sources, regulatory factors and gene expression in the regeneration of the crystalline lens and retina in vertebrate animals] Mitashov VI. **Izv Akad Nauk Ser Biol** 1996 May-Jun;(3):298-318 (183 ref.) (Eng. Abstr.) **(Rus)**

REGENERATION, GUIDED TISSUE see **GUIDED TISSUE REGENERATION**

REGENERATION, PERIODONTAL TISSUE see **GUIDED TISSUE REGENERATION**

REGENERATION, ROOT SURFACE see **GUIDED TISSUE REGENERATION**

REGIONAL BLOOD FLOW

MR angiography of the central nervous system. Basic flow phenomena. Bradley WG.
Magn Reson Imaging Clin N Am 1995 Aug;3(3):375-90 (25 ref.)

REGIONAL HEALTH PLANNING

Health policy planning: a look at consumer involvement in Nova Scotia. Sullivan MJ, et al. **Can J Public Health** 1995 Sep-Oct;86(5):317-20 (26 ref.)
The regionalization of perinatal care in France--description of a missing policy. Papiernik E, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Aug;61(2):99-103 (40 ref.)

ORGANIZATION & ADMINISTRATION

The role for regional autopsy centers in the evaluation of covered deaths. Survey of opinions of US and Canadian chairs of pathology and major health insurers in the United States. Trelstad RL, et al. **Arch Pathol Lab Med** 1996 Aug; 120(8):753-8 (48 ref.)
Population-centered and patient-focused purchasing: the U.K. experience. Ham C. **Milbank Q** 1996;74(2):191-214 (58 ref.)

REGIONAL HOSPITAL PLANNING see **HOSPITAL PLANNING**

REGIONAL MEDICAL PROGRAMS

Regionalized care established by neonatal intensive care units. Chance GW. **Pediatr Ann** 1995 Oct;24(10):519-24, 527-8 (23 ref.)

ORGANIZATION & ADMINISTRATION

Core services and the New Zealand health reforms. Cooper MH. **Br Med Bull** 1995 Oct;51(4):799-807 (10 ref.)

REGIONAL PERFUSION see **PERFUSION, REGIONAL**

REGISTRIES

Treatment of hyperlipidemia after heart transplantation and rationale for the Heart Transplant Lipid Registry. Ballantyne CM, et al. **Am J Cardiol** 1996 Sep 1;78(5):532-5 (34 ref.)
Primary corneal graft failure. A national reporting system [editorial; comment] Brightbill FS. **Arch Ophthalmol** 1995 Dec;113(12):1554-5 (9 ref.) Comment on: Arch Ophthalmol 1995 Dec;113(12):1497-502.
The role of cancer registries [editorial] Bell CM, et al. **Clin Oncol (R Coll Radiol)** 1995;7(3):143-4 (17 ref.)
Creation of a District Diabetes Register using the DIALOG system. Vaughan NJ, et al. **Diabet Med** 1996 Feb; 13(2):175-81 (12 ref.)
DIALOG: co-ordination of the annual review process through a District Diabetes Register linked to the FHSA database. Vaughan NJ, et al. **Diabet Med** 1996 Feb; 13(2):182-8 (11 ref.)
The Canadian Familial Adenomatous Polyposis Registry: past, present and future. Stern HS. **J R Soc Med** 1996 Mar; 89(3):153P-4P (10 ref.)
Childhood immunization registries. A national review of public health information systems and the protection of privacy [see comments] Gostin LO, et al. **JAMA** 1995 Dec

13;274(22):1793–9 (76 ref.) Comment in: JAMA 1996 May 1;275(17):1312–3.
What do we learn from the European Registry: what will be the underlying problems in the year 2000? Mallick NP. **Nephrol Dial Transplant** 1995;10 Suppl 7:2–6 (0 ref.)
Registration of veterinary products in Argentina. Butler E, et al. **Rev Sci Tech** 1995 Dec;14(4):1121–31 (4 ref.) **(Eng, Spa)**
Reporting results of laparoscopic procedures. The state-wide registry approach. Deveney K. **Surg Clin North Am** 1996 Jun;76(3):623–30 (21 ref.)
IRONFAN—a sonographic window into the natural history of fetal anomalies. International Registry of the Onset of Fetal Anomalies [editorial] Rottem S. **Ultrasound Obstet Gynecol** 1995 Jun;5(6):361–3 (6 ref.)
[Role of cancer registries] Schaffer P. **Bull Acad Natl Med** 1995 May;179(5):951–62; discussion 962–3 (24 ref.) (Eng. Abstr.) **(Fre)**

STATISTICS & NUMERICAL DATA

The UNOS OPTN waiting list: 1988 to 1994. United Network for Organ Sharing. Organ Procurement and Transplantation Network. Guo TJ, et al. **Clin Transpl** 1994; :69–86 (6 ref.)
The untapped potential of case registers and record-linkage studies in psychiatric epidemiology. Mortensen PB. **Epidemiol Rev** 1995;17(1):205–9 (36 ref.)
Weekly duration of dialysis treatment—does it matter for survival? Valderrábano F. **Nephrol Dial Transplant** 1996 Apr;11(4):569–72 (18 ref.)

REGRESSION ANALYSIS

Statistics from the inside. 16. Multiple regression (2). Healy MJ. **Arch Dis Child** 1995 Sep;73(3):270–4 (2 ref.)
Analysis of competitive agonist-antagonist interactions by nonlinear regression. Lew MJ, et al. **Trends Pharmacol Sci** 1995 Oct;16(10):328–37 (12 ref.)

REGRESSION DIAGNOSTICS see **REGRESSION ANALYSIS**

REGULATION OF GENE EXPRESSION see **GENE EXPRESSION REGULATION**

REGULATION OF GENE EXPRESSION, BACTERIAL see **GENE EXPRESSION REGULATION, BACTERIAL**

REGULATION OF GENE EXPRESSION, DEVELOPMENTAL see **GENE EXPRESSION REGULATION, DEVELOPMENTAL**

REGULATION OF GENE EXPRESSION, EMBRYOLOGIC see **GENE EXPRESSION REGULATION, DEVELOPMENTAL**

REGULATION OF GENE EXPRESSION, ENZYMOLOGIC see **GENE EXPRESSION REGULATION, ENZYMOLOGIC**

REGULATION OF GENE EXPRESSION, FUNGAL see **GENE EXPRESSION REGULATION, FUNGAL**

REGULATION OF GENE EXPRESSION, LEUKEMIC see **GENE EXPRESSION REGULATION, LEUKEMIC**

REGULATION OF GENE EXPRESSION, NEOPLASTIC see **GENE EXPRESSION REGULATION, NEOPLASTIC**

REGULATION OF GENE EXPRESSION, PLANT see **GENE EXPRESSION REGULATION, PLANT**

REGULATION OF GENE EXPRESSION, VIRAL see **GENE EXPRESSION REGULATION, VIRAL**

REGULATORY REGIONS, NUCLEIC ACID (GENETICS) see **REGULATORY SEQUENCES, NUCLEIC ACID**

REGULATORY SEQUENCES, NUCLEIC ACID

Transcriptional silencing of homeotic genes in Drosophila. Bienz M, et al. **Bioessays** 1995 Sep;17(9):775–84 (71 ref.)
The c-myb negative regulatory domain. Gonda TJ, et al. **Curr Top Microbiol Immunol** 1996;211:99–109 (43 ref.)
Identification and characterization of transcriptional regulatory elements of the human aromatase cytochrome P450 gene (CYP19). Toda K, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1–6 Spec No):151–9 (22 ref.)
S1-nuclease-sensitive DNA structures contribute to transcriptional regulation of the human PDGF A-chain. Wang ZY, et al. **Prog Nucleic Acid Res Mol Biol** 1996; 55:227–44 (110 ref.)
The G-box: a ubiquitous regulatory DNA element in plants bound by the GBF family of bZIP proteins. Menkens AE, et al. **Trends Biochem Sci** 1995 Dec;20(12):506–10 (39 ref.)
Noncoding control region of naturally occurring BK virus variants: sequence comparison and functional analysis. Moens U, et al. **Virus Genes** 1995;10(3):261–75 (112 ref.)

IMMUNOLOGY

The cis-acting elements controlling mouse IL-2R alpha transcription. Nabholz M, et al. **Immunobiology** 1995 Jul; 193(2–4):259–62 (4 ref.)

REGULON

Leucine-responsive regulatory protein: a global regulator of gene expression in E. coli. Newman EB, et al. **Annu Rev Microbiol** 1995;49:747–75 (122 ref.)
The signal-transduction network for Pho regulation in Bacillus subtilis. Hulett FM. **Mol Microbiol** 1996 Mar; 19(5):933–9 (27 ref.)

GENETICS

Experimental analysis of global gene regulation in Escherichia coli. Blumenthal RM, et al. **Prog Nucleic Acid Res Mol Biol** 1996;55:1–86 (304 ref.)

REGURGITATION, GASTRIC see **GASTROESOPHAGEAL REFLUX**

REHABILITATION

see related
DISABILITY EVALUATION
EARLY INTERVENTION (EDUCATION)

Strong quasi-experimental designs for research on the effectiveness of rehabilitation. Johnston MV, et al. **Am J Phys Med Rehabil** 1995 Sep-Oct;74(5):383–92 (50 ref.)
Rehabilitation and older people. Young J. **BMJ** 1996 Sep 14;313(7058):677–81 (2 ref.)
A review of the role of the agonist/antagonist muscle pairs ratio in rehabilitation. Calmels P, et al. **Disabil Rehabil** 1995 Aug-Sep;17(6):265–76 (54 ref.)
[Wrong beds and wrong care] Hertogh CM, et al. **Ned Tijdschr Geneeskd** 1996 Apr 20;140(16):868–70 (18 ref.) **(Dut)**
[Adolescents and rehabilitation] Kokkonen J, et al. **Duodecim** 1994;110(15):1410–6 (20 ref.) **(Fin)**
[Relaxation techniques in rehabilitation] Poulet R. **Z Gastroenterol** 1996 Jun;34 Suppl 2:80–4 (17 ref.) **(Ger)**

CLASSIFICATION

Case-mix measurement in medical rehabilitation. Stineman MG. **Arch Phys Med Rehabil** 1995 Dec;76(12):1163–70 (40 ref.)

ECONOMICS

[Methods in the economic assessment of rehabilitation] Pekurinen M. **Duodecim** 1994;110(15):1458–67 (17 ref.) **(Fin)**

INSTRUMENTATION

Clinical assessment, objectivity, and the ubiquitous laws of instrumentation. Buford WL Jr. **J Hand Ther** 1995 Apr-Jun;8(2):149–54 (9 ref.)
Guidelines for evaluating assessment instruments. Fess EE. **J Hand Ther** 1995 Apr-Jun;8(2):144–8 (17 ref.)

METHODS

Psychorehabilitation aspects in older age groups. Kaufmann C, et al. **Exp Gerontol** 1995 May-Aug;30(3–4):423–30 (36 ref.)
Assessment methods for rehabilitation. Biefang S, et al. **Int J Rehabil Res** 1995 Sep;18(3):201–13 (47 ref.)
Rehabilitation of geriatric patients. Weber DC, et al. **Mayo Clin Proc** 1995 Dec;70(12):1198–204 (18 ref.)
How should treatments be critiqued for scientific merit? [see comments] Harris SR. **Phys Ther** 1996 Feb;76(2):175–81 (37 ref.) Comment in: Phys Ther 1996 Jun;76(6):667–8. Comment in: Phys Ther 1996 Jul;76(7):786–7.

ORGANIZATION & ADMINISTRATION

[Progresses in physical and rehabilitation medicine in China, 1995] Wu Z. **Chung Hua I Hsueh Tsa Chih** 1995 Dec; 75(12):762 (0 ref.) **(Chi)**

REHABILITATION CENTERS

ECONOMICS

Level of care options for the low-functioning brain injury survivor. Walker WC, et al. **Brain Inj** 1996 Jan;10(1):65–75 (30 ref.)

TRENDS

[Responsibilities and goals of a rehabilitation clinical in the present and future] Genth E. **Z Rheumatol** 1995 Jul-Aug; 54(4):202–6 (6 ref.) (Eng. Abstr.) **(Ger)**

REHABILITATION CENTERS, DRUG see **SUBSTANCE ABUSE TREATMENT CENTERS**

REHABILITATION, VOCATIONAL

see related
EMPLOYMENT

The effectiveness of traumatic brain injury rehabilitation: a review. Cope DN. **Brain Inj** 1995 Oct;9(7):649–70 (56 ref.)
Employment supports for people with mental illness. Marrone J, et al. **Psychiatr Serv** 1995 Jul;46(7):707–11 (40 ref.)
[Short-bowel syndrome] Koblitz DK. **Z Gastroenterol** 1996 Jun;34 Suppl 2:41–6 (71 ref.) (Eng. Abstr.) **(Ger)**

PSYCHOLOGY

Vocational rehabilitation in schizophrenia. Lehman AF. **Schizophr Bull** 1995;21(4):645–56 (45 ref.)

REHYDRATION see **FLUID THERAPY**

REHYDRATION, ORAL see **FLUID THERAPY**

REHYDRATION SOLUTIONS

ADMINISTRATION & DOSAGE

Current status of oral rehydration as a strategy for the control of diarrhoeal diseases. Mahalanabis D. **Indian J Med Res** 1996 Jul;104:115–24 (67 ref.)

THERAPEUTIC USE

Oral rehydration therapy programme in India: standard case management of acute watery diarrhoea. Manchanda VK. **J Indian Med Assoc** 1995 Jun;93(6):220–6 (17 ref.)
Fluid management in patients with traumatic brain injury. Zornow MH, et al. **New Horiz** 1995 Aug;3(3):488–98 (55 ref.)

REICHEL'S SYNDROME see **CHONDROMATOSIS, SYNOVIAL**

REIMBURSEMENT, FEE-FOR-SERVICE see **FEE-FOR-SERVICE PLANS**

REIMBURSEMENT MECHANISMS

The economics of reimbursement and technological change in cancer care [see comments] Kesteloot K. **Eur J Cancer** 1995;31A(9):1406–9 (22 ref.) Comment in: Eur J Cancer 1995;31A(9):1387.
Current issues in oncology reimbursement. Bailes JS. **Oncology (Huntingt)** 1995 Nov;9(11 Suppl):185–9 (13 ref.)

ORGANIZATION & ADMINISTRATION

Long-term care reimbursement issues. Stone D, et al. **Clin Geriatr Med** 1995 Aug;11(3):517–29 (19 ref.)
Reimbursement issues for advanced practice. Camp-Sorrell D, et al. **Oncol Nurs Forum** 1995 Sep;22(8 Suppl):31–4 (11 ref.)

REIMPLANTATION see **REPLANTATION**

REINFORCEMENT (PSYCHOLOGY)

Addictive drugs as reinforcers: multiple partial actions on memory systems. White NM. **Addiction** 1996 Jul; 91(7):921–49; discussion 951–65 (304 ref.)
[Motivation and reinforcement in the systemic mechanisms of behavior: the dynamic engrams of reinforcement] Sudakov KV. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1995 Jul-Aug;45(4):627–37 (40 ref.) (Eng. Abstr.) **(Rus)**

REINFORCING FACTORS see **CAUSALITY**

REITER'S DISEASE

DIAGNOSIS

Seronegative spondyloarthropathies. El-Khoury GY, et al. **Radiol Clin North Am** 1996 Mar;34(2):343–57, xi (56 ref.)
[Reiter's disease—a review of an interdisciplinary disease] Jelk W, et al. **Schweiz Rundsch Med Prax** 1995 Sep 12; 84(37):989–99 (66 ref.) (Eng. Abstr.) **(Ger)**
[Pseudothrombophlebitis due to an expansive popliteal cyst associated with Reiter's syndrome] Mangiafico RA, et al. **Minerva Med** 1995 Sep;86(9):391–4 (14 ref.) (Eng. Abstr.) **(Ita)**

REL GENES see **ONCOGENES**

RELAPSE see **RECURRENCE**

RELAPSING FEVER

Louse-borne relapsing fever and its treatment. Rahlenbeck SI, et al. **Trop Geogr Med** 1995;47(2):49–52 (35 ref.)

RELAXATION TECHNIQUES

[Relaxation techniques in rehabilitation] Poulet R. **Z Gastroenterol** 1996 Jun;34 Suppl 2:80–4 (17 ref.) **(Ger)**

RELAXATION THERAPY see **RELAXATION**

TECHNIQUES

RELAXIN

PHYSIOLOGY

Relaxin used to produce the cervical ripening of labor. Weiss G. **Clin Obstet Gynecol** 1995 Jun;38(2):293–300 (16 ref.)
The emerging concept of relaxin as a centrally acting peptide hormone with hemodynamic actions. Geddes BJ, et al. **J Neuroendocrinol** 1995 Jun;7(6):411–7 (89 ref.)

RELIABILITY AND VALIDITY see **REPRODUCIBILITY OF RESULTS**

RELIGION

A view from somewhere: the presence and function of religious commitment in nursing practice. Cusveller BS. **J Adv Nurs** 1995 Nov;22(5):973–8 (15 ref.)

RELIGION AND MEDICINE

The effectiveness of words: religion and healing among the Lubavitch of Stamford Hill. Littlewood R, et al. **Cult Med Psychiatry** 1995 Sep;19(3):339–83 (125 ref.)
The spiritual dimension: its importance to patients' health, well-being and quality of life and its implications for nursing practice. Ross L. **Int J Nurs Stud** 1995 Oct; 32(5):457–68 (66 ref.)
The Good Samaritan and the "Good Death": Catholic reflections on euthanasia. Doerflinger RM. **Issues Law Med** 1995 Fall;11(2):149–58 (31 ref.)
At the bedside. Influencing a patient's religious beliefs: mandate or no-man's land? Howe EG. **J Clin Ethics** 1995 Fall;6(3):194–201 (29 ref.)
[Myth reconstruction and health representations in a Southern Congolese therapeutic sect] Hagenbucher-Sacripanti F. **Sante** 1996 Jan–Feb;6(1):43–52 (6 ref.) **(Fre)**

RELIGION AND PSYCHOLOGY

Why do psychiatrists neglect religion? Neeleman J, et al. **Br J Med Psychol** 1995 Jun;68 (Pt 2):169–78 (83 ref.)
The effectiveness of words: religion and healing among the Lubavitch of Stamford Hill. Littlewood R, et al. **Cult Med Psychiatry** 1995 Sep;19(3):339–83 (125 ref.)
African American families, religion, and disability: a conceptual framework. Rogers-Dulan J, et al. **Ment Retard** 1995 Aug;33(4):226–38 (65 ref.)
Cultural considerations in the assessment and treatment of religious and spiritual problems. Lukoff D, et al. **Psychiatr Clin North Am** 1995 Sep;18(3):467–85 (93 ref.)

RELIGIOUS BELIEFS see **RELIGION**

REMISSION INDUCTION

Neoadjuvant (induction) treatment for non-small cell lung cancer. Ginsberg RJ. **Lung Cancer** 1995 Jun;12 Suppl 2:S33–40 (22 ref.)

REMISSION, SPONTANEOUS NEOPLASM see **NEOPLASM REGRESSION, SPONTANEOUS**

RENAL AGENTS

ADMINISTRATION & DOSAGE

Desmopressin tablet treatment in nocturnal enuresis. Stenberg A, et al. **Scand J Urol Nephrol Suppl** 1995;173:95–9 (9 ref.)

THERAPEUTIC USE

[Progress on research of mechanism of Rheum palmatum in delaying the chronic renal failure] Huang CL, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Aug; 15(8):506–8 (22 ref.) **(Chi)**
[Desmopressin in the treatment of hemorrhagic diathesis] Haar D, et al. **Ugeskr Laeger** 1995 Nov 27;157(48):6713–5 (35 ref.) (Eng. Abstr.) **(Dan)**

RENAL ARTERY

Is listening for abdominal bruits useful in the evaluation of hypertension? Turnbull JM. **JAMA** 1995 Oct 25; 274(16):1299–301 (26 ref.)
[Arteriovenous fistula with cardiac insufficiency disclosing kidney cancer] Jan N, et al. **Rev Med Interne** 1996; 17(4):329–32 (30 ref.) (Eng. Abstr.) **(Fre)**
[Renovascular hypertension and hydronephrosis due to a renal artery aneurysm] Hering M, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Feb;164(2):176–8 (12 ref.) **(Ger)**

INJURIES

Renal artery pseudoaneurysm after blunt abdominal trauma: case report and literature review. Swana HS, et al. **J Trauma** 1996 Mar;40(3):459–61 (15 ref.)

PATHOLOGY

Pre-glomerular structural changes in the renal vasculature in hypertension. Anderson WP, et al. **Blood Press Suppl** 1995;2:74–80 (56 ref.)
Magnetic resonance angiography of the aorta and renal arteries. Grist TM. **Magn Reson Imaging Clin N Am** 1993 Dec;1(2):253–69 (42 ref.)

SURGERY

Delayed renal revascularisation after enalapril induced renal failure in renal artery stenosis. Khaira HS, et al. **Eur J Vasc Endovasc Surg** 1996 Apr;11(3):375–7 (17 ref.)

RENAL ARTERY OBSTRUCTION

see related
HYPERTENSION, RENOVASCULAR

COMPLICATIONS

Delayed renal revascularisation after enalapril induced renal failure in renal artery stenosis. Khaira HS, et al. **Eur J Vasc Endovasc Surg** 1996 Apr;11(3):375–7 (17 ref.)

DIAGNOSIS

Diagnostic imaging evaluation of renovascular hypertension. King BF Jr. **Abdom Imaging** 1995 Sep–Oct;20(5):395–405 (45 ref.)
Malignant vascular disease of the kidney: nature of the lesions, mediators of disease progression, and the case for bilateral nephrectomy. Ruggenenti P, et al. **Am J Kidney Dis** 1996 Apr;27(4):459–75 (123 ref.)
Time-of-flight magnetic resonance angiography of aorta and renal arteries: state-of-the-art. Laissy JP, et al. **Eur J Radiol** 1996 Feb;21(3):201–11 (71 ref.)
Renovascular hypertension. Mitty HA, et al. **Radiol Clin North Am** 1996 Sep;34(5):1017–36 (49 ref.)
Ischemic nephropathy: noninvasive testing. Wilcox CS. **Semin Nephrol** 1996 Jan;16(1):43–52 (52 ref.)
[Renovascular hypertension] Greminger P. **Schweiz Med Wochenschr** 1996 Jul 27;126(30):1314–20 (45 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

[Thrombolytic therapy of renal artery embolism. An expanded case report with review of the literature] Gulba DC, et al. **Internist (Berl)** 1996 Jun;37(6):623–7 (51 ref.) **(Ger)**

EPIDEMIOLOGY

The natural history of renal artery stenosis: who should be evaluated for suspected ischemic nephropathy? Greco BA, et al. **Semin Nephrol** 1996 Jan;16(1):2–11 (54 ref.)

PHYSIOPATHOLOGY

[Spontaneous remission of renal artery stenosis] Boyer L, et al. **J Radiol** 1996 Feb;77(2):129–31 (12 ref.) (Eng. Abstr.) **(Fre)**

RADIOGRAPHY

Spiral CT angiography—can we forget about arteriography to diagnose renal artery stenosis? [editorial] Olbricht CJ, et al. **Nephrol Dial Transplant** 1996 Jul;11(7):1227–31 (28 ref.)

SURGERY

Malignant vascular disease of the kidney: nature of the lesions, mediators of disease progression, and the case for bilateral nephrectomy. Ruggenenti P, et al. **Am J Kidney Dis** 1996 Apr;27(4):459–75 (123 ref.)
Ischemic nephropathy as an indication for renal artery reconstruction in renovascular hypertension. Newman VS, et al. **Curr Opin Gen Surg** 1994;:272–6 (30 ref.)
[Preservation of renal function by revascularization in renovascular disease] Halimi JM, et al. **J Mal Vasc** 1995; 20(4):241–6 (55 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Options for therapy of ischemic nephropathy: role of angioplasty and surgery. Novick AC. **Semin Nephrol** 1996 Jan;16(1):53–60 (61 ref.)
[Non-surgical treatments of renal artery stenoses] Plouin PF, et al. **Presse Med** 1996 Apr 27;25(15):725–30 (26 ref.) (Eng. Abstr.) **(Fre)**
[Renal revascularization for kidney salvage or preservation] Van Damme H, et al. **Rev Med Liege** 1996 Feb;51(2):175–86 (47 ref.) **(Fre)**

ULTRASONOGRAPHY

[Renovascular hypertension due to unilateral renal artery stenosis with hypokalemic alkalosis, the salt-losing syndrome and reversible hyperechogenicity of the contralateral kidney. A study of 2 infants] Castelló Girona F, et al. **An Esp Pediatr** 1996 Jul;45(1):49–52 (14 ref.) (Eng. Abstr.) **(Spa)**

RENAL ARTERY STENOSIS see **RENAL ARTERY OBSTRUCTION**

RENAL BLOOD FLOW see **RENAL CIRCULATION**

RENAL CALCULI see **KIDNEY CALCULI**

RENAL CIRCULATION

Current concepts of renal hemodynamics in diabetes. Anderson S, et al. **J Diabetes Complications** 1995 Oct–Dec; 9(4):304–7 (35 ref.)
Nitric oxide in the regulation of renal blood flow. Ito S, et al. **New Horiz** 1995 Nov;3(4):615–23 (68 ref.)
Charge structure of the glomerular capillary membrane. Wolgast M. **Ups J Med Sci** 1995;100(1):19–31 (16 ref.)
[Pathophysiologic mechanisms of early changes in renal hemodynamics in diabetes mellitus] Komers R. **Cas Lek Cesk** 1996 Mar 6;135(5):135–9 (68 ref.) (Eng. Abstr.) **(Cze)**
[Renal alterations in obesity] Kato A, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:359–64 (20 ref.) **(Jpn)**
[Natriuretic peptides and the homeostasis of renal circulation in cirrhosis (editorial)] Jiménez W. **Gastroenterol Hepatol** 1995 Nov;18(9):477–9 (20 ref.) **(Spa)**

DRUG EFFECTS

Renal circulation and blockade of the renin-angiotensin system. Is angiotensin-converting enzyme inhibition the last word? Hollenberg NK, et al. **Hypertension** 1995 Oct; 26(4):602–9 (108 ref.)
Vasoactive drugs and the importance of renal perfusion pressure. Bersten AD, et al. **New Horiz** 1995 Nov; 3(4):650–61 (94 ref.)
Renovascular elements of the cyclosporine injury. Curtis JJ. **Transplant Proc** 1996 Aug;28(4):2094–6 (18 ref.)

PHYSIOLOGY

Mechanisms of acute renal failure. Lote CJ, et al. **Br J Anaesth** 1996 Jul;77(1):82–9 (36 ref.)
Chaos and non-linear phenomena in renal vascular control. Yip KP, et al. **Cardiovasc Res** 1996 Mar;31(3):359–70 (87 ref.)
Mathematical description of transport of water and macromolecules through the glomerular capillary wall. Remuzzi A. **Curr Opin Nephrol Hypertens** 1995 Jul; 4(4):343–8 (23 ref.)
Role of atherogenic lipoproteins in cytokine-mediated renovascular injury. Kirschenbaum MA, et al. **Miner Electrolyte Metab** 1996;22(1–3):47–50 (20 ref.)
Intrarenal renin-angiotensin system and its contribution to the regulation of glomerular haemodynamics. Rosivall L. **Nephrol Dial Transplant** 1995;10(9):1565–8 (33 ref.)
Control of renal microcirculation. Steinhausen M, et al. **Nephrol Dial Transplant** 1995;10(9):1559–64 (19 ref.)
Developmental renal hemodynamics. Yao LP, et al. **Pediatr Nephrol** 1995 Oct;9(5):632–7 (59 ref.)
Paracrine regulation of the renal microcirculation. Navar LG, et al. **Physiol Rev** 1996 Apr;76(2):425–536 (1214 ref.)
[The prostaglandin system in the kidney] Stošić Z. **Med Pregl** 1996;49(1–2):32–6 (38 ref.) (Eng. Abstr.) **(Scr)**

RENAL CORTICAL NECROSIS see **KIDNEY CORTEX NECROSIS**

RENAL DIALYSIS, HOME see **HEMODIALYSIS, HOME**

RENAL DISEASE, END-STAGE see **KIDNEY FAILURE, CHRONIC**

RENAL FAILURE see **KIDNEY FAILURE**

RENAL FAILURE, ACUTE see **KIDNEY FAILURE, ACUTE**

RENAL FAILURE, CHRONIC see **KIDNEY FAILURE, CHRONIC**

RENAL FAILURE, END-STAGE see **KIDNEY FAILURE, CHRONIC**

RENAL INSUFFICIENCY see **KIDNEY FAILURE**

RENAL INSUFFICIENCY, ACUTE see **KIDNEY FAILURE, ACUTE**

RENAL INSUFFICIENCY, CHRONIC see **KIDNEY FAILURE, CHRONIC**

RENAL OSTEODYSTROPHY

ETIOLOGY

The renal bone diseases in children treated with dialysis. Sanchez CP, et al. **Adv Ren Replace Ther** 1996 Jan; 3(1):14–23 (78 ref.)
Renal osteodystrophy: pathogenesis and management. Gonzalez EA, et al. **Nephrol Dial Transplant** 1995;10 Suppl 3:13–21 (98 ref.)
The spectrum of renal bone disease. Hamdy NA. **Nephrol Dial Transplant** 1995;10 Suppl 4:14–8; discussion 37–43 (14 ref.)

RENAL OSTEODYSTROPHY

PATHOLOGY

Biomechanical stability of the skeleton--it is not only bone mass, but also bone structure that counts. Delling G, et al. **Nephrol Dial Transplant** 1995;10(5):601-6 (48 ref.)

PHYSIOPATHOLOGY

The renal bone diseases in children treated with dialysis. Sanchez CP, et al. **Adv Ren Replace Ther** 1996 Jan; 3(1):14-23 (78 ref.)

Growth hormone and calcitriol as modifiers of bone formation in renal osteodystrophy. Salusky IB, et al. **Kidney Int** 1995 Sep;48(3):657-65 (107 ref.)

Low turnover bone disease. Hutchison AJ, et al. **Perit Dial Int** 1996;16 Suppl 1:S295-9 (21 ref.)

PREVENTION & CONTROL

The need to treat predialysis patients. Hamdy NA. **Nephrol Dial Transplant** 1995;10 Suppl 4:19-22; discussion 37-43 (25 ref.)

The use of alfacalcidol in the prevention of bone disease in early renal failure. Kanis JA. **Nephrol Dial Transplant** 1995; 10 Suppl 4:23-8; discussion 37-43 (42 ref.)

Optimum route of administration of vitamin D in renal failure. Sweny P. **Nephrol Dial Transplant** 1995;10 Suppl 4:29-32; discussion 37-43 (37 ref.)

RADIOGRAPHY

Bone densitometry: patients with end-stage renal disease. Erlichman M, et al. **Health Technol Assess** 1996 Mar; (8):1-27 (174 ref.)

THERAPY

Renal osteodystrophy: pathogenesis and management. Gonzalez EA, et al. **Nephrol Dial Transplant** 1995;10 Suppl 3:13-21 (98 ref.)

RENAL PLASMA FLOW

Renal functional reserve in children. Anastasio P, et al. **Semin Nephrol** 1995 Sep;15(5):454-62 (38 ref.)

[Paraaminohippuric acid clearance] Nagase S, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:1082-4 (7 ref.) **(Jpn)**

RENAL REPLACEMENT THERAPY

see related
KIDNEY
KIDNEY DISEASES

Lipoprotein metabolism in renal replacement therapy: a review. Kronenberg F, et al. **Isr J Med Sci** 1996 Jun; 32(6):371-89 (184 ref.)

Initiation of dialysis [editorial] Hakim RM, et al. **J Am Soc Nephrol** 1995 Nov;6(5):1319-28 (64 ref.)

Observations on renal replacement services in Russia, Belarus and Lithuania. Boesken WH, et al. **Nephrol Dial Transplant** 1995 Nov;10(11):2013-6 (5 ref.)

Management choices in diabetic end-stage renal disease. Friedman EA. **Nephrol Dial Transplant** 1995;10 Suppl 7:61-9 (73 ref.)

Report on management of renal failure in Europe, XXV, 1994. The child-adult interface. The EDTA-ERA Registry. European Dialysis and Transplant Association-European Renal Association. Mehls O, et al. **Nephrol Dial Transplant** 1996;11 Suppl 1:22-36 (13 ref.)

When dialysis becomes worse than death [editorial; comment] Sessa A. **Nephrol Dial Transplant** 1995;10(7):1128-30 (24 ref.) Comment on: Nephrol Dial Transplant 1995;10(7):1142-4.

Principles of renal replacement therapy in children. Evans ED, et al. **Pediatr Clin North Am** 1995 Dec;42(6):1579-602 (44 ref.)

[Renal replacement therapy of patients with chronic diabetic nephropathy] Kawaguchi Y. **Nippon Naika Gakkai Zasshi** 1995 Oct 10;84(10):1632-6 (5 ref.) **(Jpn)**

[Renal replacement therapy of patients with acute renal failure] Kishimoto T. **Nippon Naika Gakkai Zasshi** 1995 Oct 10;84(10):1637-42 (16 ref.) **(Jpn)**

INSTRUMENTATION

Blood purification for prevention and treatment of multiple organ failure. Hirasawa H, et al. **World J Surg** 1996 May; 20(4):482-6 (15 ref.)

METHODS

Does continuous renal replacement therapy favourably influence the outcome of the patients? Jakob SM, et al. **Nephrol Dial Transplant** 1996 Jul;11(7):1250-5 (71 ref.)

Acute renal replacement in the intensive care unit: now and tomorrow. Bellomo R, et al. **New Horiz** 1995 Nov; 3(4):760-7 (39 ref.)

TRENDS

What do we learn from the European Registry: what will be the underlying problems in the year 2000? Mallick NP. **Nephrol Dial Transplant** 1995;10 Suppl 7:2-6 (0 ref.)

RENAL TRANSPLANTATION see **KIDNEY TRANSPLANTATION**

RENAL VEINS

Renal vein occlusion: a review. Witz M, et al. **J Urol** 1996 Apr;155(4):1173-9 (93 ref.)

[Arteriovenous fistula with cardiac insufficiency disclosing kidney cancer] Jan N, et al. **Rev Med Interne** 1996; 17(4):329-32 (30 ref.) (Eng. Abstr.) **(Fre)**

ABNORMALITIES

Congenital anomalies of left renal vein and its clinical importance: a case report and review of literature. Basri Turgut H, et al. **Clin Anat** 1996;9(2):133-5 (8 ref.)

SURGERY

[Preservation of renal function by revascularization in renovascular disease] Halimi JM, et al. **J Mal Vasc** 1995; 20(4):241-6 (55 ref.) (Eng. Abstr.) **(Fre)**

RENIN

ANTAGONISTS & INHIBITORS

Renin inhibition: a novel therapy for cardiovascular disease. Lin C, et al. **Am Heart J** 1996 May;131(5):1024-34 (115 ref.)

Hemodynamic effects of renin inhibitors. Kleinert HD. **Am J Nephrol** 1996;16(3):252-60 (58 ref.)

Renin inhibition. Kleinert HD. **Cardiovasc Drugs Ther** 1995 Oct;9(5):645-55 (80 ref.)

Clinical pharmacokinetics and efficacy of renin inhibitors. Rongen GA, et al. **Clin Pharmacokinet** 1995 Jul;29(1):6-14 (71 ref.)

Renal circulation and blockade of the renin-angiotensin system. Is angiotensin-converting enzyme inhibition the last word? Hollenberg NK, et al. **Hypertension** 1995 Oct; 26(4):602-9 (108 ref.)

Evolution of blockade of the renin-angiotensin system. Johnston CI, et al. **J Hum Hypertens** 1995 Jun;9(6):375-80 (46 ref.)

Renin inhibitors. Rosenberg SH. **Prog Med Chem** 1995; 32:37-114 (296 ref.)

BIOSYNTHESIS

Expression of renin in coagulating glands. Kon Y, et al. **Histol Histopathol** 1996 Jan;11(1):257-66 (104 ref.)

[Biosynthesis of hormones in renal tubular and interstitial cells] Kuwahara M, et al. **Nippon Rinsho** 1995 Aug; 53(8):1873-8 (22 ref.) (Eng. Abstr.) **(Jpn)**

BLOOD

Apparent mineralocorticoid excess. Funder JW. **Endocrinol Metab Clin North Am** 1995 Sep;24(3):613-21 (41 ref.)

[Plasma renin concentration (PRC)] Gotoh E, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:683-6 (9 ref.) **(Jpn)**

[Plasma renin activity (PRA)] Saruta T. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:679-82 (1 ref.) **(Jpn)**

[Active renin concentration (ARC)] Susuki K, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:687-91 (6 ref.) **(Jpn)**

GENETICS

Recent advances in the study of renin and angiotensinogen genes: from molecules to the whole body. Tamura K, et al. **Hypertens Res** 1995 Mar;18(1):7-18 (134 ref.)

METABOLISM

Regulation of utero-placental prorenin. Poisner AM. **Adv Exp Med Biol** 1995;377:411-26 (96 ref.)

The adrenal renin-angiotensin system: a local hormonal regulator of aldosterone production. Mulrow PJ, et al. **J Hypertens** 1996 Feb;14(2):173-6 (41 ref.)

PHYSIOLOGY

The pathophysiology of ovarian hyperstimulation syndrome (OHSS). A proposal role of the ovarian derived prorenin to angiotensin cascade (ODPAC). Morris RS, et al. **Adv Exp Med Biol** 1995;377:391-8 (37 ref.)

Relevance of the tissue prorenin-renin-angiotensin system to male reproductive physiology. Mukhopadhyay AK, et al. **Adv Exp Med Biol** 1995;377:269-77 (47 ref.)

The renin angiotensin system and the stress response. Aguilera G, et al. **Ann N Y Acad Sci** 1995 Dec 29; 771:173-86 (41 ref.)

Some physiological outcomes of renin gene studies. Morris BJ. **Clin Exp Pharmacol Physiol** 1995 Dec;22(12):966-75 (146 ref.)

Evidence for cardiovascular effects of prorenin. Sealey JE. **J Hum Hypertens** 1995 Jun;9(6):381-4 (32 ref.)

Renin and hypertension. Kurtz A. **Nephrol Dial Transplant** 1995;10(9):1521-3 (8 ref.)

SECRETION

Nitric oxide and the control of renin secretion. Reid IA, et al. **Fundam Clin Pharmacol** 1995;9(4):309-23 (118 ref.)

[The participation of the arteriolar endothelium in regulating renin secretion] Rudychenko VM, et al. **Vrach Delo** 1995 Jan-Feb;(1-2):19-25 (42 ref.) **(Ukr)**

RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM see **RENIN-ANGIOTENSIN SYSTEM**

RENIN-ANGIOTENSIN SYSTEM

see related
ANGIOTENSIN-CONVERTING ENZYME INHIBITORS

New concepts of the renin-angiotensin system--implications for vascular and endovascular surgery. O'Donohoe MK, et al. **Eur J Vasc Endovasc Surg** 1996 May;11(4):393-401 (117 ref.)

Evolution of blockade of the renin-angiotensin system. Johnston CI, et al. **J Hum Hypertens** 1995 Jun;9(6):375-80 (46 ref.)

[Diabetic nephropathy and molecular biology of the renin-angiotensin system in the diabetic kidney] Rodríguez Pérez JC, et al. **Med Clin (Barc)** 1995 Nov 25; 105(18):708-15 (103 ref.) **(Spa)**

DRUG EFFECTS

Renin inhibition: a novel therapy for cardiovascular disease. Lin C, et al. **Am Heart J** 1996 May;131(5):1024-34 (115 ref.)

Hemodynamic effects of renin inhibitors. Kleinert HD. **Am J Nephrol** 1996;16(3):252-60 (58 ref.)

Renin inhibition. Kleinert HD. **Cardiovasc Drugs Ther** 1995 Oct;9(5):645-55 (80 ref.)

Clinical pharmacokinetics and efficacy of renin inhibitors. Rongen GA, et al. **Clin Pharmacokinet** 1995 Jul;29(1):6-14 (71 ref.)

Does ACE inhibition limit structural changes in the heart following myocardial infarction? Smits JF, et al. **Eur Heart J** 1995 Dec;16 Suppl N:46-51 (48 ref.)

Drug differences between ACE inhibitors in experimental settings and clinical practice. Voors AA, et al. **J Cardiovasc Risk** 1995 Oct;2(5):413-22 (105 ref.)

[Anti-atherosclerotic action of ACE inhibitors. I. Inactivation of the renin-angiotensin system] Stajszczyk M, et al. **Postepy Hig Med Dosw** 1996;50(2):157-71 (80 ref.) (Eng. Abstr.) **(Pol)**

GENETICS

[Angiotensin receptors--organ and subtype specific regulation in cardiovascular diseases by modulation of the renin-angiotensin system. Studies of the rat model and in human myocardium] Regitz-Zagrosek V, et al. **Z Kardiol** 1995;84 Suppl 4:61-9 (34 ref.) (Eng. Abstr.) **(Ger)**

[Role of renin angiotensin system in the vasopressor mechanisms of hypertension--gene analyses and tissue renin angiotensin system] Nishimura M, et al. **Rinsho Byori** 1995 Nov;43(11):1128-32 (15 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Angiotensin and the brain. Andersson B, et al. **Acta Physiol Scand** 1995 Oct;155(2):117-25 (52 ref.)

Coda. Tissue renin-angiotensin systems, 1994. Ganong WF. **Adv Exp Med Biol** 1995;377:435-40 (29 ref.)

Relevance of the tissue prorenin-renin-angiotensin system to male reproductive physiology. Mukhopadhyay AK, et al. **Adv Exp Med Biol** 1995;377:269-77 (47 ref.)

The tissue renin-angiotensin system in the female reproductive tissues. A review. Nielsen AH, et al. **Adv Exp Med Biol** 1995;377:253-68 (145 ref.)

Role of the cardiac renin-angiotensin system in human heart failure. Paul M, et al. **Adv Exp Med Biol** 1995;377:279-83 (17 ref.)

The ovarian renin-angiotensin system. A paracrine-intracrine regulator of ovarian function. Pepperell JR, et al. **Adv Exp Med Biol** 1995;377:379-89 (85 ref.)

The adrenal renin/angiotensin system. Vinson GP. **Adv Exp Med Biol** 1995;377:237-51 (135 ref.)

The renin-angiotensin system in left ventricular remodeling. Blaufarb IS, et al. **Am J Cardiol** 1996 May 30; 77(13):8C-16C (121 ref.)

The cardiac renin-angiotensin-aldosterone system and hypertensive cardiac hypertrophy. Raman VK, et al. **Am J Cardiol** 1995 Nov 2;76(13):18D-23D (44 ref.)

The role of the renin-angiotensin and natriuretic peptide systems in the pulmonary vasculature. Cargill RI, et al. **Br J Clin Pharmacol** 1995 Jul;40(1):11-8 (68 ref.)

Stretching the evidence in the case of cardiac growth. Weber KT. **Cardiovasc Res** 1996 Apr;31(4):492-8 (45 ref.)

'Til death do us part: a case of failed affection. Weber KT, et al. **Cardiovasc Res** 1995 Jul;30(1):26-30 (32 ref.)

Functions of the renin-angiotensin system during development. Lumbers ER. **Clin Exp Pharmacol Physiol** 1995 Aug;22(8):499-505 (63 ref.)

Role of the renin-angiotensin system in essential hypertension. Paran E, et al. **Curr Opin Nephrol Hypertens** 1995 Jul;4(4):295-9 (65 ref.)

Secondary aldosteronism. Corry DB, et al. **Endocrinol Metab Clin North Am** 1995 Sep;24(3):511-29 (79 ref.)

The renin-angiotensin-aldosterone system and myocardial collagen matrix remodelling in congestive heart failure. Brilla CG, et al. **Eur Heart J** 1995 Dec;16 Suppl O:107-9

(24 ref.)
Changes in neurohumoral systems during the development of congestive heart failure: impact on cardiovascular and renal function. Elsner D. **Eur Heart J** 1995 Dec;16 Suppl N:52–8 (37 ref.)
The renin–angiotensin-system in the skin. Evidence for its presence and possible functional implications. Steckelings UM, et al. **Exp Dermatol** 1995 Dec;4(6):329–34 (37 ref.)
Recent advances in the study of renin and angiotensinogen genes: from molecules to the whole body. Tamura K, et al. **Hypertens Res** 1995 Mar;18(1):7–18 (134 ref.)
Renal circulation and blockade of the renin–angiotensin system. Is angiotensin–converting enzyme inhibition the last word? Hollenberg NK, et al. **Hypertension** 1995 Oct; 26(4):602–9 (108 ref.)
Angiotensin II—receptor subtypes characterization and pathophysiological implications. Gulati K, et al. **Indian J Exp Biol** 1996 Feb;34(2):91–7 (73 ref.)
Neurohumoral mechanisms in heart failure: a central role for the renin–angiotensin system. Teerlink JR. **J Cardiovasc Pharmacol** 1996;27 Suppl 2:S1–8 (70 ref.)
Pathophysiological aspects of the renin–angiotensin–aldosterone system in acute myocardial infarction. Dargie HJ, et al. **J Cardiovasc Risk** 1995 Oct; 2(5):389–95 (48 ref.)
Clinical review 79: Angiotensin II: an insulin–sensitizing vasoactive hormone? Morris AD, et al. **J Clin Endocrinol Metab** 1996 Apr;81(4):1303–6 (40 ref.)
Renin–angiotensin–aldosterone system for blood pressure and electrolyte homeostasis and its involvement in hypertension, in congestive heart failure and in associated cardiovascular damage (myocardial infarction and stroke). Laragh JH. **J Hum Hypertens** 1995 Jun;9(6):385–90 (47 ref.)
The adrenal renin–angiotensin system: a local hormonal regulator of aldosterone production. Mulrow PJ, et al. **J Hypertens** 1996 Feb;14(2):173–6 (41 ref.)
Local renin–angiotensin systems. Danser AH. **Mol Cell Biochem** 1996 Apr 12–26;157(1–2):211–6 (25 ref.)
Intrarenal renin–angiotensin system and its contribution to the regulation of glomerular haemodynamics. Rosivall L. **Nephrol Dial Transplant** 1995;10(9):1565–8 (33 ref.)
The renin–angiotensin system in transgenic rats. Wagner J, et al. **Pediatr Nephrol** 1996 Feb;10(1):108–12 (20 ref.)
Interrelationships between the renin angiotensin system and uteroplacental blood flow—a recent perspective. Binder ND, et al. **Reprod Fertil Dev** 1995;7(6):1437–42 (55 ref.)
[Role of the cardiac renin–angiotensin system in hypertensive heart disease] Holmer SR, et al. **Herz** 1995 Oct;20(5):322–9 (51 ref.) (Eng. Abstr.) **(Ger)**
[Left–ventricular hypertrophy as a cardiac risk factor: role of the renin–angiotensin–aldosterone system] Erne P. **Schweiz Rundsch Med Prax** 1996 Feb 20;85(8):227–33 (34 ref.) (Eng. Abstr.) **(Ger)**
[The coronary circulation, renin–angiotensin system and ACE inhibition] Campa PP. **Cardiologia** 1995 Sep; 40(9):635–41 (97 ref.) **(Ita)**
[Role of renin angiotensin system in the vasopressor mechanisms of hypertension—gene analyses and tissue renin angiotensin system] Nishimura M, et al. **Rinsho Byori** 1995 Nov;43(11):1128–32 (15 ref.) (Eng. Abstr.) **(Jpn)**
[Renin–angiotensin–aldosterone system and left ventricular diastolic dysfunction] Witkowska M. **Pol Arch Med Wewn** 1995 Sep;94(3):259–65 (32 ref.) **(Pol)**
[Alternative pathways of angiotensin I. The glimpse of new possibilities in the treatment of hypertension and heart failure (editorial)] Francischetti EA. **Arq Bras Cardiol** 1995 Mar;64(3):191–4 (49 ref.) **(Por)**
[Neurohormonal factors in heart failure. I] Cosín Aguilar J, et al. **Rev Esp Cardiol** 1996 Apr;49(4):239–52 (112 ref.) (Eng. Abstr.) **(Spa)**
[Neurohormonal factors in heart failure. II] Cosín Aguilar J, et al. **Rev Esp Cardiol** 1996 May;49(5):317–27 (47 ref.) (Eng. Abstr.) **(Spa)**

RENIN–SUBSTRATE see **ANGIOTENSINOGEN**

RENNIN see **CHYMOSIN**

RENOGRAPHY see **RADIOISOTOPE RENOGRAPHY**

REOPERATION

METHODS

Second–look laparotomy for stage III epithelial ovarian cancer: rationale and current issues. Muderspach L, et al. **Cancer Treat Rev** 1996 Nov;21(6):499–511 (60 ref.)

REOVIRIDAE

GENETICS

Molecular recognition in the assembly of the segmented reovirus genome. Joklik WK, et al. **Prog Nucleic Acid Res Mol Biol** 1996;53:249–81 (188 ref.)

ISOLATION & PURIFICATION

Viruses associated with the epizootic ulcerative syndrome (EUS) of fish in South–East Asia. Frerichs GN. **Vet Res** 1995;26(5–6):449–54 (26 ref.)

REOVIRIDAE INFECTIONS

VETERINARY

Viruses associated with the epizootic ulcerative syndrome (EUS) of fish in South–East Asia. Frerichs GN. **Vet Res** 1995;26(5–6):449–54 (26 ref.)

REOVIRUS INFECTIONS see **REOVIRIDAE INFECTIONS**

REOVIRUSES, AQUATIC see **REOVIRIDAE**

REPERFUSION

Mitochondrial dysfunction in ischaemia–reperfusion. Saris NE, et al. **Acta Anaesthesiol Scand Suppl** 1995;107:171–6 (75 ref.)
Revascularization versus amputation for elderly patients. Bunt TJ. **AORN J** 1995 Sep;62(3):433–5 (7 ref.)
Microcirculatory disturbances secondary to ischemia–reperfusion. Menger MD. **Transplant Proc** 1995 Oct;27(5):2863–5 (20 ref.)

REPERFUSION INJURY

Lung preservation: the importance of endothelial and alveolar type II cell integrity. Novick RJ, et al. **Ann Thorac Surg** 1996 Jul;62(1):302–14 (141 ref.)
Delayed graft function in renal transplantation: etiology, management and long–term significance. Shoskes DA, et al. **J Urol** 1996 Jun;155(6):1831–40 (141 ref.)

COMPLICATIONS

Splanchnic ischaemia/reperfusion and multiple organ failure. Biffl WL, et al. **Br J Anaesth** 1996 Jul;77(1):59–70 (136 ref.)
Ischemia– and reperfusion–related injury in pancreatitis [editorial; comment] Warshaw AL. **Dig Dis Sci** 1996 May; 41(5):821–2 (18 ref.) Comment on: Dig Dis Sci 1996 May;41(5):823–30.

ETIOLOGY

Global brain ischemia and reperfusion. White BC, et al. **Ann Emerg Med** 1996 May;27(5):588–94 (48 ref.)
Renal ischaemia—reperfusion injury. Weight SC, et al. **Br J Surg** 1996 Feb;83(2):162–70 (159 ref.)
The role of metals in ischemia/reperfusion injury of the liver. Arora AS, et al. **Semin Liver Dis** 1996 Feb;16(1):31–8 (65 ref.)
Mechanism and prevention of ischemia–reperfusion injury of the liver. Kurokawa T, et al. **Semin Surg Oncol** 1996 May–Jun;12(3):179–82 (21 ref.)
[Apical ulceration of the glans penis in hypervascularization syndrome. Sequelae of revascularization operation in erectile dysfunction] Hartwig R, et al. **Hautarzt** 1995 Nov; 46(11):808–10 (12 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

"The good, the bad, and the ugly." The role of chemokines in models of human disease. Strieter RM, et al. **J Immunol** 1996 May 15;156(10):3583–6 (33 ref.)

METABOLISM

Leukocyte and endothelial adhesion molecules in ischaemia/reperfusion injuries. Winn RK, et al. **Ciba Found Symp** 1995;189:63–71; discussion 72–6, 77–8 (52 ref.)

PATHOLOGY

The cell biology of reperfusion injury in the kidney. Paller MS. **J Investig Med** 1994 Dec;42(4):632–9 (85 ref.)

PHYSIOPATHOLOGY

Microcirculatory models of ischaemia–reperfusion in skin and striated muscle. Nolte D, et al. **Int J Microcirc Clin Exp** 1995;15 Suppl 1:9–16 (67 ref.)
Abnormal vascular function following ischemia–reperfusion injury. Conger JD, et al. **J Investig Med** 1995 Oct; 43(5):431–42 (62 ref.)
Microcirculatory disturbances secondary to ischemia–reperfusion. Menger MD. **Transplant Proc** 1995 Oct;27(5):2863–5 (20 ref.)
[Effect of organ preservation conditions on reperfusion after liver transplantation] Walcher F, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Oct; 30 Suppl 1:S55–7 (27 ref.) **(Ger)**
[The role of reperfusion damage] Post S, et al. **Chirurg** 1996 Apr;67(4):318–23 (38 ref.) (Eng. Abstr.) **(Ger)**
[Biochemical aspects of cardiomyocyte damage during ischemia and reperfusion] Skłodowska M. **Postepy Hig Med Dosw** 1995;49(2):287–96 (50 ref.) (Eng. Abstr.) **(Pol)**

PREVENTION & CONTROL

Preconditioning induced protection against post–ischaemic contractile dysfunction: characteristics and mechanisms. Cave AC. **J Mol Cell Cardiol** 1995 Apr;27(4):969–79 (48 ref.)
Preconditioning in man: progress and prospects. Lawson CS. **J Mol Cell Cardiol** 1995 Apr;27(4):961–7 (46 ref.)
Harnessing an endogenous cardioprotective mechanism: cellular sources and sites of action of adenosine. Mullane K, et al. **J Mol Cell Cardiol** 1995 Apr;27(4):1041–54 (145 ref.)
A "second window of protection" or delayed preconditioning phenomenon: future horizons for myocardial protection? Yellon DM, et al. **J Mol Cell Cardiol** 1995 Apr; 27(4):1023–34 (65 ref.)
Mechanism and prevention of ischemia–reperfusion injury of the liver. Kurokawa T, et al. **Semin Surg Oncol** 1996 May–Jun;12(3):179–82 (21 ref.)

REPERFUSION INJURY, MYOCARDIAL see **MYOCARDIAL REPERFUSION INJURY**

REPERFUSION, MYOCARDIAL see **MYOCARDIAL REPERFUSION**

REPETITION STRAIN INJURY

Upper extremity disorders: a literature review to determine work–relatedness. Vender MI, et al. **J Hand Surg [Am]** 1995 Jul;20(4):534–41 (79 ref.)
Repetitive strain injury (RSI) or cumulative trauma disorder (CTD) as legal and clinical entities. The need for a total reappraisal of this concept as being occupationally caused and therefore compensatable. Lam SJ. **Med Sci Law** 1995 Oct;35(4):279–86 (10 ref.)
Overuse injuries of the lower extremity in runners. Rolf C. **Scand J Med Sci Sports** 1995 Aug;5(4):181–90 (105 ref.)

COMPLICATIONS

Rhabdomyolysis secondary to keyboard overuse: occupational hazard of the computer age. Jolly BT, et al. **Am J Emerg Med** 1995 Nov;13(6):644–6 (18 ref.)
Periostitis of the upper extremity: a report of 2 cases and literature review. Meese MA, et al. **Clin Orthop** 1996 Mar; (324):222–6 (17 ref.)

DIAGNOSIS

The immature athlete. Common injuries and overuse syndromes of the elbow and wrist. Gill TJ 4th, et al. **Clin Sports Med** 1996 Apr;15(2):401–23 (49 ref.)
Medial and lateral epicondylitis in the athlete. Plancher KD, et al. **Clin Sports Med** 1996 Apr;15(2):283–305 (52 ref.)
Compressive neuropathies and tendinopathies in the athletic elbow and wrist. Plancher KD, et al. **Clin Sports Med** 1996 Apr;15(2):331–71 (142 ref.)
Bartender's hand an unusual form of occupational cumulative trauma disorder. David AM, et al. **West J Med** 1996 Apr; 164(4):353–4 (6 ref.)

DRUG THERAPY

Corticosteroid injection therapy for overuse injuries. Nelson KH, et al. **Am Fam Physician** 1995 Nov 1;52(6):1811–6 (31 ref.)

ETIOLOGY

Exercise loading of tendons and the development of overuse injuries. A review of current literature. Archambault JM, et al. **Sports Med** 1995 Aug;20(2):77–89 (71 ref.)
[A syndrome caused by separating rags in textile industry: a new clinical entity?] Fioravanti A, et al. **Minerva Med** 1995 Nov;86(11):467–4 (25 ref.) (Eng. Abstr.) **(Ita)**

PHYSIOPATHOLOGY

Overuse injuries in the young athlete. Outerbridge AR, et al. **Clin Sports Med** 1995 Jul;14(3):503–16 (38 ref.)

REPETITIVE REGION see **REPETITIVE SEQUENCES, NUCLEIC ACID**

REPETITIVE SEQUENCES, NUCLEIC ACID

Clinical implications of unstable DNA repeat sequences. Lindblad K, et al. **Acta Paediatr** 1996 Mar;85(3):265–71 (67 ref.)
Inter–Alu polymerase chain reaction: advancements and applications. Kass DH, et al. **Anal Biochem** 1995 Jul 1; 228(2):185–93 (65 ref.)
Simple sequences and the expanding genome. Hancock JM. **Bioessays** 1996 May;18(5):421–5 (50 ref.)
Defects in replication fidelity of simple repeated sequences reveal a new mutator mechanism for oncogenesis. Perucho M, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:339–48 (63 ref.)
LTR–retrotransposons and MITEs: important players in the evolution of plant genomes. Wessler SR, et al. **Curr Opin Genet Dev** 1995 Dec;5(6):814–21 (65 ref.)
Genetic and epigenetic inactivation of repetitive sequences in Neurospora crassa: RIP, DNA methylation, and quelling. Singer MJ, et al. **Curr Top Microbiol Immunol** 1995; 197:165–77 (54 ref.)
Simple repetitive sequences in the genome: structure and

functional significance. Brahmachari SK, et al. **Electrophoresis** 1995 Sep;16(9):1705–14 (92 ref.)
Genomic simple repetitive DNAs are targets for differential binding of nuclear proteins. Epplen JT, et al. **FEBS Lett** 1996 Jun 24;389(1):92–5 (40 ref.)
Molecular basis of genetic instability of triplet repeats. Wells RD. **J Biol Chem** 1996 Feb 9;271(6):2875–8 (49 ref.)
Origins and evolution of Huntington disease chromosomes. Andrew SE, et al. **Neurodegeneration** 1995 Sep;4(3):239–44 (50 ref.)
When more is less: pathogenesis of glutamine repeat neurodegenerative diseases. Ross CA. **Neuron** 1995 Sep; 15(3):493–6 (35 ref.)
Complex behavior of simple repeats: the fragile X syndrome. Oostra BA, et al. **Pediatr Res** 1995 Nov;38(5):629–37 (117 ref.)
The expanded trinucleotide repeat in Kennedy's disease. Fischbeck KH. **Proc Assoc Am Physicians** 1995 Jul; 107(2):228–30 (9 ref.)
Analysis of the CAG repeat and gene product in spinocerebellar ataxia type 1. Zoghbi HY. **Proc Assoc Am Physicians** 1995 Jul;107(2):231–6 (21 ref.)
Alu: structure, origin, evolution, significance and function of one-tenth of human DNA. Schmid CW. **Prog Nucleic Acid Res Mol Biol** 1996;53:283–319 (180 ref.)
Concerted evolution of repetitive DNA sequences in eukaryotes. Elder JF Jr, et al. **Q Rev Biol** 1995 Sep; 70(3):297–320 (146 ref.)

GENETICS

DNA "fossils" and phylogenetic analysis. Using L1 (LINE-1, long interspersed repeated) DNA to determine the evolutionary history of mammals. Furano AV, et al. **J Biol Chem** 1995 Oct 27;270(43):25301–4 (66 ref.)

REPLACEMENT THERAPY, ESTROGEN see **ESTROGEN REPLACEMENT THERAPY**

REPLANTATION

Leech therapy in digital replantation. Golden MA, et al. **AORN J** 1995 Sep;62(3):364–6, 369, 371–2, passim (0 ref.)
Entire scalp replantation: case report and review of the literature. Arashiro K, et al. **J Reconstr Microsurg** 1995 Jul;11(4):245–50 (32 ref.)

METHODS

Current concepts of replantation. Raskin KB, et al. **Ann Acad Med Singapore** 1995 Jul;24(4 Suppl):131–4 (29 ref.)

REPLICATION ORIGIN

Stepwise assembly of initiation complexes at budding yeast replication origins during the cell cycle. Diffley JF, et al. **J Cell Sci Suppl** 1995;19:67–72 (25 ref.)

PHYSIOLOGY

Replication origins in eukaryotes. Donovan S, et al. **Curr Opin Genet Dev** 1996 Apr;6(2):203–7 (45 ref.)

REPORTER GENES see **GENES, REPORTER**

REPRESSION

The False Memory Syndrome debate—will the victim please stand up? Choiniere M. **J Contemp Health Law Policy** 1996 Spring;12(2):675–700 (201 ref.)
Functional neuroanatomical correlates of the effects of stress on memory. Bremner JD, et al. **J Trauma Stress** 1995 Oct; 8(4):527–53 (115 ref.)
Factors influencing recall of childhood sexual abuse. Rogers ML. **J Trauma Stress** 1995 Oct;8(4):691–716 (115 ref.)
Dissociation and the fragmentary nature of traumatic memories: overview and exploratory study. van der Kolk BA, et al. **J Trauma Stress** 1995 Oct;8(4):505–25 (85 ref.)
Trauma, traumatic memory, and research: where do we go from here? Wolfe J. **J Trauma Stress** 1995 Oct;8(4):717–26 (5 ref.)

REPRESSION-SENSITIZATION

A cognitive science perspective on kindling and episode sensitization in recurrent affective disorder. Segal ZV, et al. **Psychol Med** 1996 Mar;26(2):371–80 (70 ref.)

REPRESSOR MOLECULES see **REPRESSOR PROTEINS**

REPRESSOR PROTEINS

Phylogenetic, structural and functional analyses of the LacI–GalR family of bacterial transcription factors. Nguyen CC, et al. **FEBS Lett** 1995 Dec 18;377(2):98–102 (23 ref.)
cAMP-dependent regulation of gene transcription by cAMP response element-binding protein and cAMP response element modulator. Habener JF, et al. **Vitam Horm** 1995; 51:1–57 (196 ref.)

CHEMISTRY

A heterodimeric transcriptional repressor becomes crystal clear [comment] Andrews BJ, et al. **Science** 1995 Oct 13; 270(5234):251–3 (18 ref.) Comment on: Science 1995 Oct 13;270(5234):262–9. Comment on: Science 1995 Oct 13;270(5234):262–9. Comment on: Science 1995 Oct 13;270(5234):290–3.
The whole lactose repressor [comment] Matthews KS. **Science** 1996 Mar 1;271(5253):1245–6 (16 ref.) Comment on: Science 1996 Mar 1;271(5253):1247–54.

GENETICS

The catabolite repressor/activator (Cra) protein of enteric bacteria. Saier MH Jr, et al. **J Bacteriol** 1996 Jun; 178(12):3411–7 (46 ref.)

METABOLISM

Transcriptional regulation. Flipping the Myc switch. Bernards R. **Curr Biol** 1995 Aug 1;5(8):859–61 (13 ref.)
Sequence determinants of folding and stability for the P22 Arc repressor dimer. Sauer RT, et al. **FASEB J** 1996 Jan; 10(1):42–8 (21 ref.)

PHYSIOLOGY

Transcriptional silencing of homeotic genes in Drosophila. Bienz M, et al. **Bioessays** 1995 Sep;17(9):775–84 (71 ref.)
The role of CcpA transcriptional regulator in carbon metabolism in Bacillus subtilis. Henkin TM. **FEMS Microbiol Lett** 1996 Jan 1;135(1):9–15 (35 ref.)
Repression and activation by multiprotein complexes that alter chromatin structure. Kingston RE, et al. **Genes Dev** 1996 Apr 15;10(8):905–20 (145 ref.)
Characterization of Pref-1 and its inhibitory role in adipocyte differentiation. Smas CM, et al. **Int J Obes Relat Metab Disord** 1996 Mar;20 Suppl 3:S65–72 (44 ref.)
The catabolite repressor/activator (Cra) protein of enteric bacteria. Saier MH Jr, et al. **J Bacteriol** 1996 Jun; 178(12):3411–7 (46 ref.)

REPRODUCIBILITY OF RESULTS

Problems in interpreting HIV sentinel seroprevalence studies. Strickler H, et al. **Ann Epidemiol** 1995 Nov;5(6):447–54 (51 ref.)
Valid arguments? a consideration of the concept of validity in establishing the credibility of research findings. Avis M. **J Adv Nurs** 1995 Dec;22(6):1203–9 (46 ref.)
[How to read a scientific article? 5. How to choose a treatment?] Demichelis B, et al. **G Ital Cardiol** 1995 Oct; 25(10):1339–50 (55 ref.) **(Ita)**

REPRODUCTION

Population and women's reproductive health: an international perspective. Miller K, et al. **Annu Rev Public Health** 1996; 17:359–82 (79 ref.)
Reproductive and sexual health: a research and developmental challenge. Mbizvo MT. **Cent Afr J Med** 1996 Mar;42(3):80–5 (35 ref.)
Reproductive decision-making and determinants of contraceptive use in HIV-infected women. Williams HA, et al. **Clin Obstet Gynecol** 1996 Jun;39(2):333–43 (40 ref.)
Molecular biology in reproductive endocrinology. Layman LC. **Curr Opin Obstet Gynecol** 1995 Oct;7(5):328–39 (104 ref.)
Reproductive health in young people with cystic fibrosis. Sawyer SM. **Curr Opin Pediatr** 1995 Aug;7(4):376–80 (46 ref.)
The evolutionary tangle of aging, sex, and reproduction and an experimental approach to its molecular dissection. Roy AK, et al. **Exp Gerontol** 1996 Jan-Apr;31(1-2):83–94 (36 ref.)
Female noise exposure, shift work, and reproduction. Nurminen T. **J Occup Environ Med** 1995 Aug;37(8):945–50 (31 ref.)
State-dependent life histories. McNamara JM, et al. **Nature** 1996 Mar 21;380(6571):215–21 (73 ref.)
The role of nitric oxide in reproduction. McCann SM, et al. **Proc Soc Exp Biol Med** 1996 Jan;211(1):7–15 (51 ref.)
Transgenic models to study the roles of inhibins and activins in reproduction, oncogenesis, and development. Matzuk MM, et al. **Recent Prog Horm Res** 1996;51:123–54; discussion 155–7 (107 ref.)
Reproductive biology and the Australian Society for Reproductive Biology in the 21st century. Findlay JK. **Reprod Fertil Dev** 1995;7(5):1021–4 (0 ref.)
Reproductive research on farm animals for Australia—some long-distance goals. Martin GB. **Reprod Fertil Dev** 1995; 7(5):967–82 (85 ref.)
Monotreme and marsupial reproduction. Renfree MB. **Reprod Fertil Dev** 1995;7(5):1003–20 (133 ref.)
Synaptic mechanisms of olfactory recognition memory. Kaba H, et al. **Rev Neurosci** 1995 Apr-Jun;6(2):125–41 (128 ref.)
Environmental effects on human reproduction: the basis for new efforts in eastern Europe. Kulin HE, et al. **Soc Sci Med** 1995 Dec;41(11):1479–86 (36 ref.)
[Congenital cardiopathies and reproductive risk] Lalatta F, et al. **Cardiologia** 1996 Jun;41(6):563–70 (16 ref.) **(Ita)**

DRUG EFFECTS

Do environmental estrogens contribute to the decline in male reproductive health? Jensen TK, et al. **Clin Chem** 1995 Dec; 41(12 Pt 2):1896–901 (68 ref.)
Occupational hazards for the male reproductive system. Tas S, et al. **Crit Rev Toxicol** 1996 May;26(3):261–307 (460 ref.)
Noncancer risk assessment: reproductive toxicology. Schwetz BA. **Drug Metab Rev** 1996 Feb-May; 28(1-2):77–84 (11 ref.)
Reproduction and caffeine consumption—a literature review. Golding J. **Early Hum Dev** 1995 Aug 30;43(1):1–14 (56 ref.)
Thyroid hormone and male gonadal function. Jannini EA, et al. **Endocr Rev** 1995 Aug;16(4):443–59 (226 ref.)
Possible interrelations among environmental toxicants, amphibian development, and decline of amphibian populations. Carey C, et al. **Environ Health Perspect** 1995 May;103 Suppl 4:13–7 (39 ref.)
Commentary on effects of anthropogenic and natural organic chemicals on development, swimming behavior, and reproduction of Daphnia, a key member of aquatic ecosystems. Dodson SI, et al. **Environ Health Perspect** 1995 May;103 Suppl 4:7–11 (60 ref.)
The reproductive toxicology of Great Lakes contaminants. Foster WG. **Environ Health Perspect** 1995 Dec;103 Suppl 9:63–9 (85 ref.)
Reproductive effects in birds exposed to pesticides and industrial chemicals. Fry DM. **Environ Health Perspect** 1995 Oct;103 Suppl 7:165–71 (85 ref.)
What we know and what we need to know about developmental aluminum toxicity. Golub MS, et al. **J Toxicol Environ Health** 1996 Aug 30;48(6):585–97 (74 ref.)
Role of arsenic as a reproductive toxin with particular attention to neural tube defects. Shalat SL, et al. **J Toxicol Environ Health** 1996 Jun 28;48(3):253–72 (130 ref.)
The adverse effects of tobacco smoking on reproduction and health: a review from the literature. Tuormaa TE. **Nutr Health** 1995;10(2):105–20 (155 ref.)
Health implications of nitrate and nitrite in drinking water: an update on methemoglobinemia occurrence and reproductive and developmental toxicity. Fan AM, et al. **Regul Toxicol Pharmacol** 1996 Feb;23(1 Pt 1):35–43 (54 ref.)
An evaluative process for assessing human reproductive and developmental toxicity of agents. Moore JA, et al. **Reprod Toxicol** 1995 Jan-Feb;9(1):61–95 (88 ref.)
Reproductive toxicity testing of therapeutic biotechnology agents. Henck JW, et al. **Teratology** 1996 Mar;53(3):185–95 (34 ref.)
Developmental effects of dioxins and related endocrine disrupting chemicals. Birnbaum LS. **Toxicol Lett** 1995 Dec; 82–83:743–50 (60 ref.)
Risk assessment policy for evaluating reproductive system toxicants and the impact of responses on sensitive populations. Briggs GB. **Toxicology** 1996 Jul 17; 111(1-3):305–13 (106 ref.)
[Toxicology of reproduction and development. Changes in the male reproductive function caused by drugs and pollutants: potential effects on offspring] Mariani L, et al. **Clin Ter** 1995 Oct;146(10):555–75 (71 ref.) (Eng. Abstr.) **(Ita)**

GENETICS

Hormonal and neurotransmitter regulation of GnRH gene expression and related reproductive behaviors. Sagrillo CA, et al. **Behav Genet** 1996 May;26(3):241–77 (360 ref.)

PHYSIOLOGY

Relevance of the tissue prorenin-renin-angiotensin system to male reproductive physiology. Mukhopadhyay AK, et al. **Adv Exp Med Biol** 1995;377:269–77 (47 ref.)
The mammalian pineal gland and reproduction. Controversies and strategies for future research. Olcese J. **Adv Exp Med Biol** 1995;377:1–14 (97 ref.)
Brain angiotensin and the female reproductive cycle. Phillips MI, et al. **Adv Exp Med Biol** 1995;377:357–70 (19 ref.)
Neuroendocrine control of reproduction. Steger RW, et al. **Adv Exp Med Biol** 1995;377:15–32 (131 ref.)
Luteinizing hormone-releasing hormone (LHRH) receptors in the neuroendocrine-immune network. Biochemical bases and implications for reproductive physiopathology. Marchetti B, et al. **Ann N Y Acad Sci** 1996 Apr 30; 784:209–36 (117 ref.)
Reproductive health: a rendezvous with human dignity. Diczfalusy E. **Contraception** 1995 Jul;52(1):1–12 (69 ref.)
A review of factors affecting productivity of bald eagles in the Great Lakes region: implications for recovery. Bowerman WW, et al. **Environ Health Perspect** 1995 May; 103 Suppl 4:51–9 (58 ref.)
Defining the role of pollutants in the disruption of reproduction in wildlife. Hose JE, et al. **Environ Health Perspect** 1995 May;103 Suppl 4:87–91 (44 ref.)
Fibrinolytic system and reproductive process with special reference to fibrinolytic failure in pre-eclampsia. Gilabert J, et al. **Hum Reprod** 1995 Dec;10 Suppl 2:121–31 (83 ref.)
Structural remodelling of reproductive tissues. Luck MR, et al. **J Endocrinol** 1995 Aug;146(2):191–5 (61 ref.)
Neuroendocrine involvement in aging: evidence from studies of reproductive aging and caloric restriction. Nelson JF, et al. **Neurobiol Aging** 1995 Sep-Oct;16(5):837–43; discussion 855–6 (50 ref.)

Reproductive performance and nutrition during childhood. Martorell R, et al. **Nutr Rev** 1996 Apr;54(4 Pt 2):S15–21 (15 ref.)
Not trophoblast alone: a review of the contribution of the fetal microvasculature to transplacental exchange. Firth JA, et al. **Placenta** 1996 Mar–Apr;17(2–3):89–96 (64 ref.)
Angiotensin II and its different receptor subtypes in placenta and fetal membranes. Kalenga MK, et al. **Placenta** 1996 Mar–Apr;17(2–3):103–110 (50 ref.)
Hepatocyte growth factor/scatter factor and the placenta. Uehara Y, et al. **Placenta** 1996 Mar–Apr;17(2–3):97–101 (64 ref.)
Whole-body fuel selection: 'reproduction'. Robinson JJ, et al. **Proc Nutr Soc** 1995 Mar;54(1):283–99 (108 ref.)
Synchronous multispecific spawning on coral reefs: potential for hybridization and roles of gamete recognition. Babcock R. **Reprod Fertil Dev** 1995;7(4):943–50 (74 ref.)
Timing of seasonal breeding in birds, with particular reference to New Zealand birds. Cockrem JF. **Reprod Fertil Dev** 1995;7(1):1–19 (72 ref.)
The sperm centrosome during fertilization in mammals: implications for fertility and reproduction. Navara CS, et al. **Reprod Fertil Dev** 1995;7(4):747–54 (30 ref.)
The interrelationships of body fat, exercise, and hormonal status and their impact on reproduction and bone health. Ramos RH, et al. **Semin Perinatol** 1995 Jun;19(3):163–70 (53 ref.)
[The epiphysis in reproduction (the diapause and the sexual cycle)] Pérez Pérez F. **An R Acad Nac Med (Madr)** 1995; 112(2):383–406 (27 ref.) **(Spa)**
[Role of nitric oxide in the reproductive function in mammals] Villalpando Ramos G, et al. **Ginecol Obstet Mex** 1995 Dec;63:518–23 (28 ref.) (Eng. Abstr.) **(Spa)**

REPRODUCTION TECHNIQUES

Strict criteria for the evaluation of human sperm morphology and its impact on assisted reproduction. Grow D, et al. **Andrologia** 1995 Nov–Dec;27(6):325–33 (47 ref.)
Ethical issues of fertility and reproduction. Baird PA. **Annu Rev Med** 1996;47:107–16 (30 ref.)
Ethical issues in assisted reproductive medicine: a pragmatic approach. Appleton T. **Br J Urol** 1995 Nov;76 Suppl 2:85–92 (26 ref.)
A closer look at reproductive technology and postmenopausal motherhood [comment] Parks JA. **Can Med Assoc J** 1996 Apr 15;154(8):1189–91 (10 ref.) Comment on: Can Med Assoc J 1994 Aug 1;151(3):353, 355.
Assisted reproductive technologies: estimates of their contribution to multiple births and newborn hospital days in the United States. Wilcox LS, et al. **Fertil Steril** 1996 Feb;65(2):361–6 (25 ref.)
The case of the switched embryos. Robertson JA. **Hastings Cent Rep** 1995 Nov–Dec;25(6):13–9 (24 ref.)
The effects of ovulation induction with gonadotrophins on the ovary and uterus and implications for assisted reproduction. Balen A. **Hum Reprod** 1995 Sep;10(9):2233–7 (55 ref.)
The role of maternal age in assisted reproduction. Rosenwaks Z, et al. **Hum Reprod** 1995 Oct;10 Suppl 1:165–73 (36 ref.)
Genetic aspects of artificial fertilization. Vogt PH. **Hum Reprod** 1995 Oct;10 Suppl 1:128–37 (56 ref.)
Is an animal model needed for intracytoplasmic sperm injection (ICSI) and other assisted reproduction technologies? Yanagimachi R. **Hum Reprod** 1995 Oct; 10(10):2525–6 (11 ref.)
Male subfertility: concepts in 1995. Yovich JL, et al. **Hum Reprod** 1995 Oct;10 Suppl 1:3–9 (43 ref.)
Potential use of embryo coculture with human in vitro fertilization procedures. Thibodeaux JK, et al. **J Assist Reprod Genet** 1995 Nov;12(10):665–77 (146 ref.)
Gamete microsurgery for assisted fertilization. Sparks AE. **Microsurgery** 1995;16(5):345–8 (25 ref.)
Hysteroscopy and assisted reproductive technology. Balmaceda JP, et al. **Obstet Gynecol Clin North Am** 1995 Sep;22(3):507–18 (52 ref.)
The impact of assisted reproduction on perinatal health care. Keirse MJ, et al. **Soz Praventivmed** 1995;40(6):343–51 (59 ref.)
Regulating assisted reproductive technologies: an ethical framework. Steinbock B. **Womens Health Issues** 1996 May–Jun;6(3):167–74 (12 ref.)
Regulating assisted reproductive technologies: public health, consumer protection, and public resources. Wilcox LS, et al. **Womens Health Issues** 1996 May–Jun;6(3):175–80 (22 ref.)
[Cytogenetic abnormalities in sperm: a risk factor for application of medical reproduction techniques?] Rosenbusch B, et al. **Geburtshilfe Frauenheilkd** 1995 Sep; 55(9):518–25 (40 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Potential health hazards of assisted reproduction. Problems facing the clinician. Amso NN. **Hum Reprod** 1995 Jul; 10(7):1628–30 (41 ref.)
Concerns and recommendations for intracytoplasmic sperm injection (ICSI) treatment. Cummins JM, et al. **Hum Reprod** 1995 Oct;10 Suppl 1:138–43 (47 ref.)
Genetic risk in micromanipulative assisted reproduction. Meschede D, et al. **Hum Reprod** 1995 Nov;10(11):2880–6 (72 ref.)
[Capabilities and limitations of research] Auroux M. **Bull Acad Natl Med** 1995 Nov;179(8):1729–41 (55 ref.) (Eng. Abstr.) **(Fre)**
[Medical assistance for procreation. Current medical problems] Laplane R, et al. **Bull Acad Natl Med** 1996 Feb; 180(2):397–412 (25 ref.) **(Fre)**
[Maternal risks of medical assistance with procreation] Zorn JR. **Bull Acad Natl Med** 1995 Nov;179(8):1743–50 (12 ref.) (Eng. Abstr.) **(Fre)**

ECONOMICS

Economic strategies in modern male subfertility treatment. Comhaire F. **Hum Reprod** 1995 Oct;10 Suppl 1:103–6 (16 ref.)

LEGISLATION & JURISPRUDENCE

Current differences and consequences of legislation on practice of assisted reproductive technology in the Nordic countries. The Nordic Committee on Assisted Reproduction of the Scandinavian Federation of Societies of Obstetrics and Gynecology. Hazekamp JT. **Acta Obstet Gynecol Scand** 1996 Feb;75(2):198–200 (6 ref.)

PSYCHOLOGY

Multifetal pregnancy reduction. A review of an evolving technology and its psychosocial implications. Ormont MA, et al. **Psychosomatics** 1995 Nov–Dec;36(6):522–30 (29 ref.)

STANDARDS

Assisted conception techniques. On what basis do health technologies become routinely available when they have been assessed as effective? Freemantle N, et al. **Int J Technol Assess Health Care** 1995 Fall;11(4):786–94 (35 ref.)

TRENDS

Recent developments in assisted fertilization. Gordts S, et al. **Hum Reprod** 1995 Oct;10 Suppl 1:107–14 (45 ref.)
[Results, evolution of assisted reproduction techniques] Frydman R. **Bull Acad Natl Med** 1995 Nov;179(8):1719–28 (25 ref.) (Eng. Abstr.) **(Fre)**

UTILIZATION

Assisted conception techniques. On what basis do health technologies become routinely available when they have been assessed as effective? Freemantle N, et al. **Int J Technol Assess Health Care** 1995 Fall;11(4):786–94 (35 ref.)

REPRODUCTIVE MEDICINE

see related
REPRODUCTION TECHNIQUES

METHODS

Recombinant technique and gonadotropins production: new era in reproductive medicine. Shoham Z, et al. **Fertil Steril** 1996 Aug;66(2):187–201 (137 ref.)

REPTILES

ANATOMY & HISTOLOGY

Homology in the evolution of the cerebral hemispheres. The case of reptilian dorsal ventricular ridge and its possible correspondence with mammalian neocortex. Aboitiz F. **J Hirnforsch** 1995;36(4):461–72 (84 ref.)
Morphology and physiological significance of parathyroid glands in reptilia. Srivastav AK, et al. **Microsc Res Tech** 1995 Oct 1;32(2):91–103 (80 ref.)

EMBRYOLOGY

Organization versus activation: the role of endocrine-disrupting contaminants (EDCs) during embryonic development in wildlife. Guillette LJ Jr, et al. **Environ Health Perspect** 1995 Oct;103 Suppl 7:157–64 (81 ref.)

MICROBIOLOGY

Reptile-associated salmonellosis in New York State. Ackman DM, et al. **Pediatr Infect Dis J** 1995 Nov;14(11):955–9 (22 ref.)

PHYSIOLOGY

The thalamus of reptiles and mammals: similarities and differences. Pritz MB. **Brain Behav Evol** 1995; 46(4–5):197–208 (54 ref.)
Veterinary nutritional management of amphibians and reptiles. Donoghue S. **J Am Vet Med Assoc** 1996 Jun 1; 208(11):1816–20 (22 ref.)

RESCUE WORK

ORGANIZATION & ADMINISTRATION

Urban search and rescue. Barbera JA, et al. **Emerg Med Clin North Am** 1996 May;14(2):399–412 (76 ref.)
A medical disaster response to reduce immediate mortality after an earthquake [see comments] Schultz CH, et al. **N Engl J Med** 1996 Feb 15;334(7):438–44 (53 ref.) Comment in: N Engl J Med 1996 Jun 27;334(26):1746; discussion 1747. Comment in: N Engl J Med 1996 Jun 27;334(26):1746–7.

RESEARCH

see related
DENTAL RESEARCH
INFORMATION SERVICES
NURSING RESEARCH
SYSTEMS ANALYSIS

Research Directions Conference: Research directions in emergency medicine. January 20–21, 1995. **Acad Emerg Med** 1996 Mar;3(3):274–6 (0 ref.)
Overview: bridging basic science and clinical medicine. Dodds WJ. **Adv Vet Sci Comp Med** 1995;39:1–28 (91 ref.)
Research Directions Conference: Research directions in emergency medicine. January 20–21, 1995. **Ann Emerg Med** 1996 Mar;27(3):339–42 (0 ref.)
The first gene for an idiopathic epilepsy: a fruitful collaboration of Australian clinical research and molecular genetics [editorial] Berkovic SF, et al. **Aust N Z J Med** 1996 Apr;26(2):154–6 (13 ref.)
Virology research and virulent human pandemics. Mims CA. **Epidemiol Infect** 1995 Dec;115(3):377–86 (49 ref.)
Prevention of cardiovascular disease: from biomedical research to health policy. Muntoni S. **Eur J Epidemiol** 1995 Oct;11(5):485–94 (74 ref.)
Ethics and research. Carriero A, et al. **Eur Radiol** 1996; 6(2):S11–5 (21 ref.)
Immigrant children and their families: issues for research and policy. Board on Children and Families. **Future Child** 1995 Summer–Fall;5(2):72–89 (49 ref.)
Research on the treatment of sexually abused children: a review and recommendations. Finkelhor D, et al. **J Am Acad Child Adolesc Psychiatry** 1995 Nov; 34(11):1408–23 (76 ref.)
Care of fish in biological research. Klontz GW. **J Anim Sci** 1995 Nov;73(11):3485–92 (24 ref.)
Mental retardation: genetic findings, clinical implications and research agenda. Simonoff E, et al. **J Child Psychol Psychiatry** 1996 Mar;37(3):259–80 (252 ref.)
Research directions in emergency medicine: 21–22 January 1995 [see comments] **J Emerg Med** 1996 Mar–Apr; 14(2):267–70 (0 ref.) Comment in: J Emerg Med 1996 Mar–Apr;14(2):242–3.
Informed consent for genetic research on stored tissue samples [see comments] Clayton EW, et al. **JAMA** 1995 Dec 13;274(22):1786–92 (31 ref.) Comment in: JAMA 1995 Dec 13;274(22):1806–7. Comment in: JAMA 1996 Apr 10;275(14):1085; discussion 1086. Comment in: JAMA 1996 Apr 10;275(14):1085–6.
The US Arctic Investigations Program: infectious disease prevention and control research in Alaska. Wainwright RB. **Lancet** 1996 Feb 24;347(9000):517–20 (52 ref.)
Research on the menopause. Hulka BS, et al. **Maturitas** 1996 Mar;23(2):109–12 (17 ref.)
Participatory approaches in occupational health research: a review. Loewenson R, et al. **Med Lav** 1995 May–Jun; 86(3):263–71 (13 ref.)
Measuring success in clinical gene therapy research. Culver KW. **Mol Med Today** 1996 Jun;2(6):234–6 (11 ref.)
From molecular biology to medicine: two decades of achievement in varicella-zoster virus research. Straus SE. **Neurology** 1995 Dec;45(12 Suppl 8):S11–2 (17 ref.)
Communicating emerging scientific information. **Nutr Rev** 1996 May;54(5):153–7 (2 ref.)
Thoughts over cell biology: a commentary. Henics T. **Physiol Chem Phys Med NMR** 1995;27(2):139–44 (49 ref.)
The colorful past and bright future of monoamine oxidase research. Singer TP. **Prog Brain Res** 1995;106:1–22 (86 ref.)
Cultural psychiatry. Theoretical, clinical, and research issues. Lewis-Fernández R, et al. **Psychiatr Clin North Am** 1995 Sep;18(3):433–48 (88 ref.)
Cultural formulation and comprehensive diagnosis. Clinical and research perspectives. Mezzich JE. **Psychiatr Clin North Am** 1995 Sep;18(3):649–57 (26 ref.)
Reproductive research on farm animals for Australia—some long-distance goals. Martin GB. **Reprod Fertil Dev** 1995; 7(5):967–82 (85 ref.)
Tuberculosis research—the way forward [editorial] Beyers AD, et al. **S Afr Med J** 1996 Jan;86(1):30–3 (24 ref.)
Academic research and HIV/AIDS in South Africa. Campbell CM, et al. **S Afr Med J** 1996 Jan;86(1):55–60 (63 ref.)
Extrapolating the future: research trends in modeling. Menzel DB. **Toxicol Lett** 1995 Sep;79(1–3):299–303 (8 ref.)
Risk assessment and research: an essential link. Vandenberg JJ. **Toxicol Lett** 1995 Sep;79(1–3):17–22 (11 ref.)
Limits of natural science: brain research and computers. Stieve H. **Z Naturforsch [C]** 1995 May–Jun;50(5–6):317–36 (86 ref.)
[Role of bibliometrics in the evaluation of medical research] Nieminen P, et al. **Duodecim** 1995;111(2):134–43 (20 ref.) **(Fin)**
[Some theoretical aspects of behavior research in domestic animals] Puppe B. **Berl Munch Tierarztl Wochenschr** 1995 Apr;108(4):133–7 (60 ref.) (Eng. Abstr.) **(Ger)**

[Analytic review in the era of the scientific information explosion] Shats V, et al. **Harefuah** 1996 Mar 15; 130(6):414–5 (19 ref.) **(Heb)**

[Scientific literature: bibliometric and bibliographic indicators as integrative criteria for an objective evaluation of research activity] Dracos A, et al. **Ann Ist Super Sanita** 1995;31(3):381–90 (24 ref.) (Eng. Abstr.) **(Ita)**

[Origin of the visual evoked potentials in the light of the conducted research] Sobieszczańska-Lampika M, et al. **Neurol Neurochir Pol** 1995 May–Jun;29(3):419–25 (17 ref.) (Eng. Abstr.) **(Pol)**

LEGISLATION & JURISPRUDENCE

Questing for grails: duplicity, betrayal and self-deception in postmodern medical research. Annas GJ. **J Contemp Health Law Policy** 1996 Spring;12(2):297–324 (101 ref.)

METHODS

Necropsy as a research method in the age of molecular pathology. Kleiner DE, et al. **Lancet** 1995 Oct 7; 346(8980):945–8 (31 ref.)

[Questionnaires as research tools—Social Insurance Institution's Sleep Habit Questionnaire as an example] Hyyppä MT, et al. **Duodecim** 1994;110(17):1581–7 (28 ref.) **(Fin)**

STANDARDS

Quantitative analyses of scientific literature and their validity for judging Latin American production [comment] Spinak E. **Bull Pan Am Health Organ** 1995 Dec;29(4):352–9; discussion 359–60 (25 ref.) Comment on: Bull Pan Am Health Organ 1995 Mar;29(1):87–95.

A limited bibliography of the Federal Government-funded human radiation experiments. Samei E, et al. **Health Phys** 1995 Dec;69(6):885–91 (55 ref.)

Using the evidence. A need for quantity, not quality? Hyde CJ. **Int J Technol Assess Health Care** 1996 Spring; 12(2):280–7 (41 ref.)

Valid arguments? a consideration of the concept of validity in establishing the credibility of research findings. Avis M. **J Adv Nurs** 1995 Dec;22(6):1203–9 (46 ref.)

Questing for grails: duplicity, betrayal and self-deception in postmodern medical research. Annas GJ. **J Contemp Health Law Policy** 1996 Spring;12(2):297–324 (101 ref.)

Qualitative research in medical practice. Ryan K, et al. **N Z Med J** 1996 Mar 22;109(1018):87–8 (30 ref.)

Responsible dissemination of scholarly work in radiology. Dowd SB, et al. **Radiol Technol** 1996 May–Jun;67(5):407–14 (22 ref.)

Recommended biocontainment features for research and diagnostic facilities where animal pathogens are used. First International Veterinary Biosafety Workshop. Barbeito MS, et al. **Rev Sci Tech** 1995 Sep;14(3):873–87 (8 ref.)

STATISTICS & NUMERICAL DATA

The importance and state of medical and public health research related to vision in Australia. McCarty CA, et al. **Aust N Z J Ophthalmol** 1996 Feb;24(1):3–5 (8 ref.)

[Interpretation of negative results in research in health sciences] Ramalle-Gómara E, et al. **Aten Primaria** 1995 Nov 30;16(9):564–70 (49 ref.) **(Spa)**

TRENDS

Eating disorder research in the past decade. Halmi KA. **Ann N Y Acad Sci** 1996 Jun 18;789:67–77 (56 ref.)

Progress and priorities in research on heartwater. Uilenberg G. **Ann N Y Acad Sci** 1996 Jul 23;791:1–16 (105 ref.)

Whole-body protein turnover in humans—past, present, and future. Waterlow JC. **Annu Rev Nutr** 1995;15:57–92 (171 ref.)

Transgenic animals: how they are made and their role in animal production and research. Dziadek M. **Aust Vet J** 1996 May;73(5):182–7 (67 ref.)

Significance of individual sensitivity to chemicals: elucidation of host susceptibility by use of biomarkers in environmental health research. Cullen MR, et al. **Clin Chem** 1995 Dec; 41(12 Pt 2):1809–13 (21 ref.)

Mouse mutations as animal models and biomedical tools for dermatological research. Sundberg JP, et al. **J Invest Dermatol** 1996 Feb;106(2):368–76 (170 ref.)

The role of energy expenditure in energy regulation: findings from a decade of research. Saltzman E, et al. **Nutr Rev** 1995 Aug;53(8):209–20 (64 ref.)

Aspects of current and future inhibin research. Burger HG, et al. **Reprod Fertil Dev** 1995;7(5):997–1002 (33 ref.)

Reproductive biology and the Australian Society for Reproductive Biology in the 21st century. Findlay JK. **Reprod Fertil Dev** 1995;7(5):1021–4 (0 ref.)

The future of mechanistic research in risk assessment: where are we going and can we get there from here? Goddard MJ, et al. **Toxicology** 1995 Sep 1;102(1–2):53–70 (84 ref.)

[What are expected improvements in the follow-up and treatment of stage I melanoma?] Thomas L. **Ann Dermatol Venereol** 1995;122(5):378–88 (243 ref.) **(Fre)**

RESEARCH, CLINICAL NURSING see **CLINICAL NURSING RESEARCH**

RESEARCH, DENTAL see **DENTAL RESEARCH**

RESEARCH DESIGN

The design of clinical trials in amyotrophic lateral sclerosis. Azulay JP. **Adv Neurol** 1995;68:225–7 (13 ref.)

Issues in amyotrophic lateral sclerosis clinical trial design. Munsat TL. **Adv Neurol** 1995;68:209–18 (33 ref.)

Case series analysis of adverse reactions to vaccines: a comparative evaluation. Farrington CP, et al. **Am J Epidemiol** 1996 Jun 1;143(11):1165–73 (18 ref.)

Methodological issues for intervention research in occupational health and safety. Goldenhar LM, et al. **Am J Ind Med** 1996 Apr;29(4):289–94 (52 ref.)

Qualitative methods for intervention research. Needleman C, et al. **Am J Ind Med** 1996 Apr;29(4):329–37 (77 ref.)

Strong quasi-experimental designs for research on the effectiveness of rehabilitation. Johnston MV, et al. **Am J Phys Med Rehabil** 1995 Sep–Oct;74(5):383–92 (50 ref.)

Accounting for cluster randomization: a review of primary prevention trials, 1990 through 1993. Simpson JM, et al. **Am J Public Health** 1995 Oct;85(10):1378–83 (43 ref.)

Stories and numbers: coexistence without compromise. Ford-Gilboe M, et al. **ANS Adv Nurs Sci** 1995 Sep; 18(1):14–26 (41 ref.)

Design and assessment of clinical trials on continuous infusion. Schulman S, et al. **Blood Coagul Fibrinolysis** 1996 Mar;7 Suppl 1:S7–9 (8 ref.)

A guide to clinical epidemiology for radiologists: Part I study design and research methods. Goldin J, et al. **Clin Radiol** 1996 May;51(5):313–6 (30 ref.)

Risk factors and their identification second part: study designs for identification of risk factors. Balkau B, et al. **Diabete Metab** 1995 Jun;21(3):225–31 (17 ref.)

Capture-recapture methods in epidemiology: methods and limitations. Hook EB, et al. **Epidemiol Rev** 1995; 17(2):243–64 (140 ref.)

Randomised consent designs in cancer clinical trials. Altman DG, et al. **Eur J Cancer** 1995 Nov;31A(12):1934–44 (53 ref.)

An approach to the design and implementation of clinical trials of empirical antibiotic therapy in febrile and neutropenic cancer patients. Viscoli C, et al. **Eur J Cancer** 1995 Nov;31A(12):2013–22 (60 ref.)

Sources of variability in prevalence rates of Alzheimer's disease. Corrada M, et al. **Int J Epidemiol** 1995 Oct; 24(5):1000–5 (37 ref.)

Current HIV clinical trial design issues. Lange JM. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995;10 Suppl 1:S47–51 (24 ref.)

Design and assessment of cost-effectiveness studies in AIDS populations. Simpson KN. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995;10 Suppl 4:S28–32 (17 ref.)

Quantitative methods in nursing research. Abrams KR, et al. **J Adv Nurs** 1996 May;23(5):1008–15 (26 ref.)

The use of different research methodologies to evaluate the effectiveness of programmes to improve the care of patients in postoperative pain. Allcock N. **J Adv Nurs** 1996 Jan; 23(1):32–8 (34 ref.)

An in-depth study of triangulation. Dootson S. **J Adv Nurs** 1995 Jul;22(1):183–7 (27 ref.)

Making sense of action research through the use of a typology. Hart E, et al. **J Adv Nurs** 1996 Jan;23(1):152–9 (14 ref.)

Action research as a professionalizing strategy: issues and dilemmas. Hart E, et al. **J Adv Nurs** 1996 Mar;23(3):454–61 (58 ref.)

Reducing patient eligibility criteria in cancer clinical trials. George SL. **J Clin Oncol** 1996 Apr;14(4):1364–70 (24 ref.)

Research methods for investigating causal relations between SLE disease variables and psychiatric symptomatology. Iverson GL, et al. **Lupus** 1995 Aug;4(4):249–54 (29 ref.)

The generalisability of confidence-accuracy studies in eyewitnessing. Gruneberg MM, et al. **Memory** 1993 Sep; 1(3):185–9 (8 ref.)

Forgotten variables in memory theory and research. Mullin PA, et al. **Memory** 1993 Mar;1(1):43–64 (130 ref.)

Treatment protocols for transgenic mutation assays in vivo. Heddle JA, et al. **Mutagenesis** 1995 Nov;10(6):467–70 (17 ref.)

Optimization of the Salmonella/mammalian microsome assay for urine mutagenesis by experimental designs. De Méo M, et al. **Mutat Res** 1996 Jun;340(2–3):51–65 (50 ref.)

Research practice and data management. van Es GA. **Neth J Med** 1996 Jan;48(1):38–44 (7 ref.)

Issues in drug abuse prevention intervention research with African Americans. Beatty LA. **NIDA Res Monogr** 1994; 139:171–201 (68 ref.)

Drug prevention research with Hispanic populations: theoretical and methodological issues and a generic structural model. Castro FG, et al. **NIDA Res Monogr** 1994; 139:203–33 (51 ref.)

Prevention intervention research: focus and perspective. Cázares A. **NIDA Res Monogr** 1994;139:5–35 (47 ref.)

Correction for the design effect in school-based substance use and abuse prevention research: sample size requirements and analysis considerations. Dielman TE. **NIDA Res Monogr** 1994;139:115–25 (38 ref.)

Testing theory through developmental epidemiologically based prevention research. Kellam SG. **NIDA Res Monogr** 1994;139:37–57 (33 ref.)

Drug abuse prevention research concerns in Asian and Pacific Islander populations. Kuramoto FH. **NIDA Res Monogr** 1994;139:249–72 (13 ref.)

Analysis of mediating variables in prevention and intervention research. MacKinnon DP. **NIDA Res Monogr** 1994;139:127–53 (68 ref.)

Drug prevention research with Native-American populations: some considerations. Powless Sage G. **NIDA Res Monogr** 1994;139:235–48 (18 ref.)

The importance of nursing research design and methods in cancer pain management. Enhancing care. Gaston-Johansson F, et al. **Nurs Clin North Am** 1995 Dec; 30(4):597–607 (90 ref.)

A review of important elements in sedation study methodology. Wilson S. **Pediatr Dent** 1995 Nov–Dec; 17(7):406–12 (57 ref.)

The influence of subject and test design on dynamometric measurements of extremity muscles. Keating JL, et al. **Phys Ther** 1996 Aug;76(8):866–89 (224 ref.)

A reader's guide to the evaluation of prognostic studies. van Walraven C, et al. **Postgrad Med J** 1996 Jan;72(843):6–11 (7 ref.)

Matching. Costanza MC. **Prev Med** 1995 Sep;24(5):425–33 (14 ref.)

Clinical research in aggressive patients, pitfalls in study design and measurement of aggression. Mak M, et al. **Prog Neuropsychopharmacol Biol Psychiatry** 1995 Oct; 19(6):993–1017 (48 ref.)

Focus on qualitative methods: Using qualitative methods in intervention studies. Sandelowski M. **Res Nurs Health** 1996 Aug;19(4):359–64 (39 ref.)

Formulae and tables for the determination of sample sizes and power in clinical trials for testing differences in proportions for the two-sample design: a review. Sahai H, et al. **Stat Med** 1996 Jan 15;15(1):1–21 (96 ref.)

A personal view of some controversies in allocating treatment to patients in clinical trials [see comments] Senn S. **Stat Med** 1995 Dec 30;14(24):2661–74 (41 ref.) Comment in: Stat Med 1996 Jan 15;15(1):113–6.

Tutorial in biostatistics. Designing studies for dose response. Wong WK, et al. **Stat Med** 1996 Feb 28;15(4):343–59 (16 ref.)

Study design for epidemiologic studies with measurement error. Holford TR, et al. **Stat Methods Med Res** 1995 Dec; 4(4):339–58 (43 ref.)

Design issues in cohort studies. Prentice RL. **Stat Methods Med Res** 1995 Dec;4(4):273–92 (94 ref.)

Design issues in case-control studies. Wacholder S. **Stat Methods Med Res** 1995 Dec;4(4):293–309 (102 ref.)

Prognosis in surgery: why they are determined, strategies for making them, and study design. Mahoney JE, et al. **Surgery** 1996 Sep;120(3):563–6 (21 ref.)

[Methodological problems of depression research (see comments)] Jepsen PW. **Ugeskr Laeger** 1996 Mar 11; 158(11):1508–12 (11 ref.) (Eng. Abstr.) Comment in: Ugeskr Laeger 1996 Jun 3;158(23):3332–3. **(Dun)**

[For new antimalarial drugs: the methods of fundamental research] Ambroise-Thomas P. **Med Trop (Mars)** 1995;55(4 Suppl):23–6 (11 ref.) (Eng. Abstr.) **(Fre)**

[Epidemiologic research on the environment and health: some methodologic aspects] Hémon D. **Rev Epidemiol Sante Publique** 1995;43(5):395–411 (55 ref.) (Eng. Abstr.) **(Fre)**

[How to read a scientific article? 5. How to choose a treatment?] Demichelis B, et al. **G Ital Cardiol** 1995 Oct; 25(10):1339–50 (55 ref.) **(Ita)**

LEGISLATION & JURISPRUDENCE

Ethical and legal issues in social network research: the real and the ideal. Woodhouse DE, et al. **NIDA Res Monogr** 1995;151:131–43 (11 ref.)

STANDARDS

Assessing bone quality—animal models in preclinical osteoporosis research. Mosekilde L. **Bone** 1995 Oct;17(4 Suppl):343S–352S (35 ref.)

Clinical trials: relevance of correlation between treatment responses. Cleophas TJ. **Eur J Clin Pharmacol** 1996; 50(1–2):1–6 (14 ref.)

Meta-analyses to evaluate analgesic interventions: a systematic qualitative review of their methodology. Jadad AR, et al. **J Clin Epidemiol** 1996 Feb;49(2):235–43 (100 ref.)

Some design, measurement, and analysis pitfalls in drug abuse prevention research and how to avoid them: let your model be your guide. Collins LM. **NIDA Res Monogr** 1994; 139:95–114 (26 ref.)

Hypothesis formulation and testing in substance use prevention research. Hansen WB. **NIDA Res Monogr** 1994; 139:59–74 (23 ref.)

Target populations and interventions in prevention research: what is high risk? Pentz MA. **NIDA Res Monogr** 1994; 139:75–93 (32 ref.)

TRENDS

Future directions in clinical research in Wilms tumor. Green DM, et al. **Hematol Oncol Clin North Am** 1995 Dec; 9(6):1329–39 (57 ref.)

Promising social network research results and suggestions for a research agenda. Friedman SR.

NIDA Res Monogr 1995;151:196–215 (28 ref.)
Therapeutic communities and treatment research. Tims FM, et al. NIDA Res Monogr 1994;144:1–15 (19 ref.)
[Assessing the basic stages of the phagocytic process: current approaches to and prospects for research development] Khaitov RM, et al. Patol Fiziol Eksp Ter 1995 Jul–Sep; (3):3–10 (59 ref.) (Eng. Abstr.) (Rus)

RESEARCH, HEALTH SERVICES see **HEALTH SERVICES RESEARCH**

RESEARCH INSTITUTES see **ACADEMIES AND INSTITUTES**

RESEARCH, NURSING see **NURSING RESEARCH**

RESEARCH, NURSING ADMINISTRATION see **NURSING ADMINISTRATION RESEARCH**

RESEARCH, NURSING EDUCATION see **NURSING EDUCATION RESEARCH**

RESEARCH, NURSING EVALUATION see **NURSING EVALUATION RESEARCH**

RESEARCH, NURSING METHODOLOGY see **NURSING METHODOLOGY RESEARCH**

RESEARCH PERSONNEL

PSYCHOLOGY

Agency and research team co-operation: an exploration of human territoriality. Ervin NE, et al. J Adv Nurs 1996 Apr;23(4):728–32 (11 ref.)

RESEARCH PROTOCOLS, CLINICAL see **CLINICAL PROTOCOLS**

RESEARCH SUPPORT

Taking a bite out of CRISP. Strategies on using and conducting searches in the Computer Retrieval of Information on Scientific Projects database. Bair AH, et al. Comput Nurs 1996 Jul–Aug;14(4):218–24; quiz 225–6 (10 ref.)
Promoting nursing practice through nursing research. Baumgart AJ. Int Nurs Rev 1996 Mar–Apr;43(2):45–8, 57 (7 ref.)

STATISTICS & NUMERICAL DATA

The importance and state of medical and public health research related to vision in Australia. McCarty CA, et al. Aust N Z J Ophthalmol 1996 Feb;24(1):3–5 (8 ref.)

RESEARCHERS see **RESEARCH PERSONNEL**

RESIDENCE CHARACTERISTICS

What is rurality? Rousseau N.
Occas Pap R Coll Gen Pract 1995 Sep;(71):1–4 (39 ref.)

RESIDENCY, DENTAL see **INTERNSHIP AND RESIDENCY**

RESIDENCY, MEDICAL see **INTERNSHIP AND RESIDENCY**

RESIDENCY, NONMEDICAL see **INTERNSHIP, NONMEDICAL**

RESIDENTIAL FACILITIES

STATISTICS & NUMERICAL DATA

Antihypertensive drug use in the long-term care facility: a pilot study and review of the literature. Fish JT, et al. Pharmacotherapy 1995 Nov–Dec;15(6):785–8 (11 ref.)

RESIDENTIAL TREATMENT

Adolescents in therapeutic communities: retention and posttreatment outcome. Pompi KF. NIDA Res Monogr 1994;144:128–61 (28 ref.)

RESIDUAL CANCER see **NEOPLASM, RESIDUAL**

RESIDUAL TUMOR see **NEOPLASM, RESIDUAL**

RESIN-BONDED ACID-ETCHED FIXED PARTIAL DENTURE see **DENTURE, PARTIAL, FIXED, RESIN-BONDED**

RESIN-BONDED BRIDGE see **DENTURE, PARTIAL, FIXED, RESIN-BONDED**

RESIN-BONDED FIXED PARTIAL DENTURE see **DENTURE, PARTIAL, FIXED, RESIN-BONDED**

RESINS

Impact of the resin blood culture medium on the treatment of critically ill patients. Levin PD, et al.
Crit Care Med 1996 May;24(5):797–801 (24 ref.)
[Intravesical foreign body caused arising from ureterostomy protective resin-gum] Oliver Llinares FJ, et al.
Arch Esp Urol 1995 Oct;48(8):847–8 (6 ref.) (Eng. Abstr.) (Spa)

RESINS, SYNTHETIC

CHEMISTRY

Does resin based dentine bonding work? Söderholm KJ.
Int Dent J 1995 Dec;45(6):371–81 (74 ref.)

RESISTANCE FACTORS see **R FACTORS**

RESISTANCE, NATURAL see **IMMUNITY, NATURAL**

RESISTANT OVARY SYNDROME see **OVARIAN FAILURE, PREMATURE**

RESORTS see **HEALTH RESORTS**

RESOURCE ALLOCATION see **HEALTH CARE RATIONING**

RESPIRATION

see related
APNEA
BREATH TESTS
BREATHING EXERCISES
DYSPNEA

Ventilatory responses to hypoxia and hypercapnia during inhalation anaesthesia and subparalytical muscle relaxation in humans [see comments] Lindahl SG.
Acta Anaesthesiol Scr 1995 Dec;33(4):223–6 (13 ref.)
Comment in: Acta Anaesthesiol Sin 1995 Dec;33(4):i–ii.
Evidence of expiratory CT scans of small-airway obstruction in sarcoidosis. Gleeson FV, et al.
AJR Am J Roentgenol 1996 May;166(5):1052–4 (12 ref.)
Cardiopulmonary physiology and pathophysiology as a consequence of laparoscopic surgery. Sharma KC, et al.
Chest 1996 Sep;110(3):810–5 (76 ref.)
Respiratory changes during laparoscopic operations [see comments] Moehlenhof O, et al.
Endosc Surg Allied Technol 1995 Aug;3(4):162–6 (42 ref.)
Comment in: Endosc Surg Allied Technol 1995 Aug;3(4):154–5.
The placenta and the control of fetal breathing movements. Thorburn GD. Reprod Fertil Dev 1995;7(3):577–94 (107 ref.)
[Cardio-respirography in neonatal medicine: value, interpretation, indications] Favre A, et al. Arch Pediatr 1996 May;3(5):480–8 (43 ref.) (Eng. Abstr.) (Fre)
[External respiration and gas exchange in space flights] Baranov VM, et al. Kosm Biol Aviakosm Med 1991 Nov–Dec;25(6):4–8 (48 ref.) (Eng. Abstr.) (Rus)

DRUG EFFECTS

The ventilatory effects of sevoflurane. Green WB Jr.
Anesth Analg 1995 Dec;81(6 Suppl):S23–6 (19 ref.)

PHYSIOLOGY

Exercise hyperpnea. Chairman's introduction. Dempsey JA.
Adv Exp Med Biol 1995;393:133–6 (4 ref.)
Neurobiology of breathing control. Where to look and what to look for. Feldman JL. Adv Exp Med Biol 1995;393:3–5 (2 ref.)
Fatigue and the design of the respiratory system. Lindstedt SL, et al. Adv Exp Med Biol 1995;384:383–91 (20 ref.)
Retrotrapezoid nucleus (RTN) metabotropic glutamate receptors and long-term stimulation of ventilatory output. RTN glutamate receptors and breathing. Nattie EE, et al.
Adv Exp Med Biol 1995;393:39–45 (27 ref.)
New computational models of the respiratory oscillator in mammals. Smith JC. Adv Exp Med Biol 1995;393:7–13 (10 ref.)
Control of intermittent ventilation in lower vertebrates. A computer dynamic model. Topor ZL, et al.
Adv Exp Med Biol 1995;393:21–2 (4 ref.)
Is the slow component of exercise VO2 a respiratory adaptation to anaerobiosis? Wasserman K, et al.
Adv Exp Med Biol 1995;393:187–94 (11 ref.)
The regulation of normal lung function. Braman SS.
Allergy Proc 1995 Sep–Oct;16(5):223–6 (6 ref.)
Birth under water—to breathe or not to breathe. Johnson P. Br J Obstet Gynaecol 1996 Mar;103(3):202–8 (37 ref.)
Contribution of acid–base changes to control of breathing during exercise. Forster HV, et al. Can J Appl Physiol 1995 Sep;20(3):380–94 (97 ref.)
A review of the control of breathing during exercise. Mateika JH, et al. Eur J Appl Physiol 1995;71(1):1–27 (277 ref.)
A role for the nasal cycle in respiratory defence. Eccles R.
Eur Respir J 1996 Feb;9(2):371–6 (58 ref.)
Influence of body position on breathing and its implications for the evaluation and treatment of speech and voice disorders. Hoit JD. J Voice 1995 Dec;9(4):341–7 (37 ref.)
Ventilatory depression during mild hypoxia in adult humans. Honda Y. Jpn J Physiol 1995;45(6):947–59 (41 ref.)
Neurotransmitters in the CNS control of breathing. Bonham AC. Respir Physiol 1995 Sep;101(3):219–30 (40 ref.)
Sensory information from the upper airway: role in the control of breathing. Sant'Ambrogio G, et al.
Respir Physiol 1995 Oct;102(1):1–16 (59 ref.)
[Normal and pathological aspects of respiration during sleep] Duron B. Rev Med Interne 1996;17 Suppl 1:11S–14S (20 ref.) (Fre)
[Lung problems in acute to subacute exposure to medium altitudes] Marugg D. Schweiz Rundsch Med Prax 1995 Oct 3;84(40):1101–7 (41 ref.) (Eng. Abstr.) (Ger)
[Chronobiological viewpoints of respiratory regulation] Raschke F. Wien Med Wochenschr 1995;145(17–18):435–9 (16 ref.) (Eng. Abstr.) (Ger)
[Pulmonary and pulmonary-related reflexes mediated by serotonin receptors in the peripheral nervous system] Yoshioka M. Nippon Yakurigaku Zasshi 1995 Nov; 106(5):311–20 (49 ref.) (Eng. Abstr.) (Jpn)
[Role of the autonomic nervous system (adrenergic, cholinergic and nonadrenergic, noncholinergic) in regulation of respiratory system function] Liebhart J, et al. Postepy Hig Med Dosw 1995;49(3):395–407 (45 ref.) (Eng. Abstr.) (Pol)
[Control of breathing] Bárbara C, et al. Acta Med Port 1995 Jul–Aug;8(7–8):433–40 (31 ref.) (Eng. Abstr.) (Por)
[The perception of muscle loading and the role of locomotor and respiratory sensation] Breslav IS.
Fiziol Zh Im I M Sechenova 1994 Dec;80(12):10–20 (69 ref.) (Rus)
[The individual manifestations of respiratory rhythms] Malkin VB, et al. Usp Fiziol Nauk 1996 Jan–Mar;27(1):87–99 (68 ref.) (Eng. Abstr.) (Rus)
[The participation of the respiration in the rhythmic interactions in the body] Malkin VB, et al.
Usp Fiziol Nauk 1996 Apr–Jun;27(2):61–77 (131 ref.) (Eng. Abstr.) (Rus)

RESPIRATION, ARTIFICIAL

see related
VENTILATORS, MECHANICAL

Permissive hypercapnia in ARDS and its effect on tissue oxygenation. Hickling KG, et al.
Acta Anaesthesiol Scand Suppl 1995;107:201–8 (53 ref.)
Mechanical ventilation: a review for the internist. Gammon RB, et al. Am J Med 1995 Nov;99(5):553–62 (06 ref.)
New concepts in mechanical ventilation for ARDS. Lessard MR. Can J Anaesth 1996 May;43(5 Pt 2):R42–54 (67 ref.) (Eng, Fre)
Noninvasive mechanical ventilation in patients with acute respiratory failure. Abou-Shala N, et al. Crit Care Med 1996 Apr;24(4):705–15 (66 ref.)
Lack of effects of recombinant growth hormone on muscle function in patients requiring prolonged mechanical ventilation: a prospective, randomized, controlled study. Pichard C, et al. Crit Care Med 1996 Mar;24(3):403–13 (55 ref.)
The management of acute respiratory failure. Shanley CJ, et al. Curr Opin Gen Surg 1994;:7–16 (82 ref.)
Bronchodilator delivery with metered-dose inhalers in mechanically-ventilated patients. Dhand R, et al.
Eur Respir J 1996 Mar;9(3):585–95 (69 ref.)
Extracorporeal life support (ECLS) for adult respiratory failure: the North American Experience. Bartlett RH, et al. Int J Artif Organs 1995 Oct;18(10):620–3 (10 ref.)
Perfluorochemical liquid ventilation: from the animal laboratory to the intensive care unit. Degraeuwe PL, et al. Int J Artif Organs 1995 Oct;18(10):674–83 (92 ref.)
Clinical application of novel ventilation techniques. Müller E. Int J Artif Organs 1995 Oct;18(10):656–69 (140 ref.)
Severity and outcome of ARDS: the present place of extracorporeal lung assist (ECLA). Steltzer H, et al.
Int J Artif Organs 1995 Oct;18(10):607–10 (11 ref.)
The delivery of aerosolized steroids from MDIs with nozzle extensions: quantitative laboratory evaluation of a method to improve aerosol delivery to intubated patients. Hess D, et al. Intensive Care Med 1995 Nov;21(11):945–51 (36 ref.)
Neonatal ventilator management and the role for pulmonary function tests. Greenspan JS. J Perinatol 1996 Mar–Apr; 16(2 Pt 2 Su):S56–60 (11 ref.)
Near-fatal asthma and mechanical ventilation [editorial] Rossi A, et al. Monaldi Arch Chest Dis 1996 Apr; 51(2):99–101 (36 ref.)
Ventilatory management in critical neurologic illness. Borel CO, et al. Neurol Clin 1995 Aug;13(3):627–44 (79 ref.)
Nosocomial pneumonia during mechanical ventilation: problems with diagnostic criteria [editorial] Brun-Buisson C. Thorax 1995 Nov;50(11):1128–30 (27 ref.)
[History of respiratory intensive care with reference to first aid for nearly-drowned persons] Leveau P.
Ann Fr Anesth Reanim 1996;15(1):86–100 (57 ref.) (Eng. Abstr.) (Fre)
[High frequency jet ventilation combined with conventional mechanical ventilation in the treatment of adult respiratory distress syndrome] Roustan JP. Ann Fr Anesth Reanim 1995;14(3):276–88 (55 ref.) (Eng. Abstr.) (Fre)
[Ventilatory assistance in acute exacerbations of chronic respiratory insufficiency in adults (with the exclusion of neuromuscular pathology and weaning). 13th Consensus Conference in Resuscitation and Emergency Medicine. 2 December 1994, Strasbourg] Rev Mal Respir 1995;12 Suppl 3:R158–61 (0 ref.) (Fre)
[Ventilatory assistance in acute decompensation of chronic

respiratory insufficiency in adults (excluding neuromuscular diseases and weaning). 13th Consensus Conference on resuscitation and emergency medicine, Strasbourg, 2 December 1994] **Rev Pneumol Clin** 1995; 51(5):302–5 (0 ref.) **(Fre)**

[Clinical aspects of acute lung failure in adults (ARDS)] Lewandowski K, et al. **Anaesthesist** 1996 Jan;45(1):1–18 (85 ref.) (Eng. Abstr.) **(Ger)**

[Respirator dependency. Intensive care unit or home ventilation?] Criée CP, et al. **Internist (Berl)** 1995 Aug; 36(8):812–7 (16 ref.) **(Ger)**

[Respiratory regulation and compensatory mechanisms in ventilatory insufficiency] Schönhofer B, et al. **Internist (Berl)** 1995 Aug;36(8):769–78 (64 ref.) **(Ger)**

[Pathogenesis of bronchopulmonary dysplasia] Groneck P, et al. **Z Geburtshilfe Neonatol** 1995 Sep–Oct;199(5):181–9 (68 ref.) (Eng. Abstr.) **(Ger)**

[A case of fulminant psittacosis necessitating mechanical ventilation diagnosed by chlamydial isolation form BALF] Taniguchi H, et al. **Kansenshogaku Zasshi** 1995 Dec; 69(12):1396–401 (9 ref.) (Eng. Abstr.) **(Jpn)**

[Cardiovascular and hemodynamic changes after artificial pulmonary ventilation] Gecelovská V, et al. **Bratisl Lek Listy** 1996 May;97(5):260–6 (45 ref.) (Eng. Abstr.) **(Slo)**

ADVERSE EFFECTS

Hyperventilation therapy for severe traumatic brain injury. Marion DW, et al. **New Horiz** 1995 Aug;3(3):439–47 (66 ref.)

Barotrauma. Tocino I, et al. **Radiol Clin North Am** 1996 Jan; 34(1):59–81 (126 ref.)

Diagnosis of pulmonary infections in mechanically ventilated patients. Chastre J, et al. **Semin Respir Infect** 1996 Jun; 11(2):65–76 (58 ref.)

Differential diagnosis of fever and pulmonary densities in mechanically ventilated patients. Louthan FB, et al. **Semin Respir Infect** 1996 Jun;11(2):77–95 (136 ref.)

[Tracheobronchial complications of assisted ventilation in children] Denoyelle F, et al. **Rev Mal Respir** 1996 Jul; 13(3):259–64 (34 ref.) (Eng. Abstr.) **(Fre)**

[Deleterious effects of mechanical ventilation on the lower lung] Dreyfuss D, et al. **Rev Mal Respir** 1995;12(6):551–7 (30 ref.) (Eng. Abstr.) **(Fre)**

[Pneumonia in patients on the mechanical respirator] Ben-Abraham R, et al. **Harefuah** 1995 Jul;129(1–2):46–51 (35 ref.) **(Heb)**

[Current topics of the artificial ventilation and respiratory management] Marukawa S. **Masui** 1995;44 Suppl:S33–9 (12 ref.) **(Jpn)**

METHODS

Initiation of mechanical ventilation in the emergency department. Orebaugh SL. **Am J Emerg Med** 1996 Jan; 14(1):59–69 (114 ref.)

Reassessing the need for ventilation during CPR. Idris AH. **Ann Emerg Med** 1996 May;27(5):569–75 (52 ref.)

Sedation for the mechanically ventilated patient. Mazzeo AJ. **Crit Care Clin** 1995 Oct;11(4):937–55 (56 ref.)

Adjunctive ventilation with tracheal gas insufflation--good vibrations? [editorial; comment] Marini JJ. **Crit Care Med** 1996 Mar;24(3):375–8 (27 ref.) Comment on: Crit Care Med 1996 Mar;24(3):451–7.

Assisted ventilation in neonates: the Indian perspective [editorial] Bhakoo ON. **Indian Pediatr** 1995 Dec; 32(12):1261–4 (15 ref.)

Permissive hypercapnia. Dries DJ. **J Trauma** 1995 Nov; 39(5):984–9 (48 ref.)

Current concepts in airway management for cardiopulmonary resuscitation. Reed AP. **Mayo Clin Proc** 1995 Dec;70(12):1172–84 (111 ref.)

Airway management and mechanical ventilation. Abrams KJ. **New Horiz** 1995 Aug;3(3):479–87 (65 ref.)

Hypothermia and hyperbaric oxygen as treatment modalities for severe head injury. Clifton GL. **New Horiz** 1995 Aug; 3(3):474–8 (42 ref.)

[13th Consensus Conference on Intensive Care and Emergency Medicine. Assisted respiration during acute decompensation in chronic respiratory failure in adults (excluding neuromuscular diseases and weaning). 2 December 1994, Strasbourg] **Ann Fr Anesth Reanim** 1995; 14(2):243–5 (0 ref.) **(Fre)**

[Ventilation in the prone position in acute respiratory distress syndrome (ARDS)] Jolliet P, et al. **Schweiz Med Wochenschr** 1996 May 18;126(20):879–92 (77 ref.) (Eng. Abstr.) **(Fre)**

[XIIIth Consensus Conference in Intensive Care and Emergency Medicine. Assisted respiration during acute decompensation in chronic respiratory failure in adults (excluding neuromuscular pathology and weaning)] **Therapie** 1996 Jan–Feb;51(1):71–4 (0 ref.) **(Fre)**

TRENDS

The changing role of mechanical ventilation in COPD [editorial] Shneerson JM. **Eur Respir J** 1996 Mar;9(3):393–8 (74 ref.)

The current status of intratracheal-pulmonary ventilation (ITPV). Kolobow T, et al. **Int J Artif Organs** 1995 Oct; 18(10):670–3 (13 ref.)

RESPIRATION DISORDERS

CHEMICALLY INDUCED

Respiratory effects of organic solvent exposure. Schenker MB, et al. **Tuber Lung Dis** 1996 Feb;77(1):4–18 (92 ref.)

ETIOLOGY

[Iatrogenic respiratory and sleep disorders and snoring] Gugger M. **Schweiz Med Wochenschr** 1996 Apr 13; 126(15):632–6 (15 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

[Normal and pathological aspects of respiration during sleep] Duron B. **Rev Med Interne** 1996;17 Suppl 1:11S–14S (20 ref.) **(Fre)**

[Cardiac diseases and sleep related breathing disorders] Shpirer I, et al. **Harefuah** 1996 Apr 15;130(8):551–4 (44 ref.) **(Heb)**

RESPIRATOR WEANING see **VENTILATOR WEANING**

RESPIRATORS see **VENTILATORS, MECHANICAL**

RESPIRATORY AIRFLOW

Effect of partial middle turbinectomy on nasal airflow and resistance. Cook PR, et al. **Otolaryngol Head Neck Surg** 1995 Oct;113(4):413–9 (32 ref.)

PHYSIOLOGY

Regulation of airway wall remodeling: prospects for the development of novel antiasthma drugs. Stewart AG, et al. **Adv Pharmacol** 1995;33:209–53 (204 ref.)

RESPIRATORY ALKALOSIS see **ALKALOSIS, RESPIRATORY**

RESPIRATORY BURST

see related
GRANULOMATOUS DISEASE, CHRONIC

Circulating neutrophils from patients with ulcerative colitis have a normal respiratory burst. Haydek JM, et al. **Inflammation** 1995 Dec;19(6):701–15 (42 ref.)

PHYSIOLOGY

The origin of the oxidative burst in plants. Bolwell GP, et al. **Free Radic Res** 1995 Dec;23(6):517–32 (49 ref.)

RESPIRATORY CARE UNITS

METHODS

Computerized patient record for a department of respiratory rehabilitation. Ballardini L, et al. **Monaldi Arch Chest Dis** 1996 Apr;51(2):153–8 (12 ref.)

RESPIRATORY CENTER

PHYSIOLOGY

The regulation of normal lung function. Braman SS. **Allergy Proc** 1995 Sep–Oct;16(5):223–6 (6 ref.)

RESPIRATORY CHAIN see **ELECTRON TRANSPORT**

RESPIRATORY DISTRESS SYNDROME

DRUG THERAPY

Exogenous surfactant use in neonates. Ishisaka DY. **Ann Pharmacother** 1996 Apr;30(4):389–98 (45 ref.)

Antenatal ambroxol usage in the prevention of infant respiratory distress syndrome. Beneficial and adverse effects. Kimya Y, et al. **Clin Exp Obstet Gynecol** 1995; 22(3):204–11 (39 ref.)

Natural vs synthetic surfactants in neonatal respiratory distress syndrome. Halliday HL. **Drugs** 1996 Feb; 51(2):226–37 (48 ref.)

Surfactant replacement therapy in neonatal respiratory distress syndrome. Hellmann J. **Paediatr Anaesth** 1995; 5(2):81–8 (62 ref.)

ETIOLOGY

Respiratory distress in the neonate. Sequela of a congenital dacryocystocele. Hepler KM, et al. **Arch Otolaryngol Head Neck Surg** 1995 Dec;121(12):1423–5 (16 ref.)

[Intralobar pulmonary sequestration as the cause of neonatal respiratory distress] Serrano A, et al. **Arch Bronconeumol** 1996 Jun–Jul;32(6):310–2 (18 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

Respiratory distress syndrome of the newborn infant. Verma RP. **Obstet Gynecol Surv** 1995 Jul;50(7):542–55 (54 ref.)

Acute respiratory distress syndrome (ARDS) in neonates and children. Pfenninger J. **Paediatr Anaesth** 1996;6(3):173–81 (84 ref.)

[Influence of surfactants on hemodynamics during neonatal respiratory distress syndrome] Pladys P, et al. **Arch Pediatr** 1996 Feb;3(2):156–63 (78 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

Exogenous surfactant use in neonates. Ishisaka DY. **Ann Pharmacother** 1996 Apr;30(4):389–98 (45 ref.)

The clinical use of antenatal corticosteroids. Gardner MO, et al. **Clin Obstet Gynecol** 1995 Dec;38(4):746–54 (39 ref.)

THERAPY

Commentary on neonatal ECMO: a North American and Scandinavian perspective. Milerad J, et al. **Acta Paediatr** 1995 Aug;84(8):841–7 (69 ref.)

Treatment of ARDS with nitric oxide and ECMO. Pappert D, et al. **Int J Artif Organs** 1995 Oct;18(10):611–9 (40 ref.)

Respiratory distress syndrome of the newborn infant. Verma RP. **Obstet Gynecol Surv** 1995 Jul;50(7):542–55 (54 ref.)

Respiratory distress syndrome for the practicing pediatrician. Haas M, et al. **Pediatr Ann** 1995 Nov;24(11):572–6, 579–80 (21 ref.)

[Pathogenesis of bronchopulmonary dysplasia] Groneck P, et al. **Z Geburtshilfe Neonatol** 1995 Sep–Oct;199(5):181–9 (68 ref.) (Eng. Abstr.) **(Ger)**

RESPIRATORY DISTRESS SYNDROME, ADULT

Acute respiratory distress syndrome. Watling SM, et al. **Ann Pharmacother** 1995 Oct;29(10):1002–9; quiz 1059–60 (73 ref.)

The acute respiratory distress syndrome: current trends in pathogenesis and management. Levy PC, et al. **Compr Ther** 1995 Aug;21(8):438–44 (24 ref.)

Acute respiratory distress syndrome. Schuster DP, et al. **Dis Mon** 1996 May;42(5):270–326 (180 ref.)

[Acute respiratory distress syndrome. Pathogenesis and therapy of acute pulmonary failure] Welling KL. **Ugeskr Laeger** 1996 Jun 17;158(25):3593–600 (40 ref.) (Eng. Abstr.) **(Dan)**

BLOOD

Inflammatory predictors for the development of the adult respiratory distress syndrome [editorial] Reid PT, et al. **Thorax** 1995 Oct;50(10):1023–6 (38 ref.)

DRUG THERAPY

Ketoconazole to prevent acute respiratory distress syndrome in critically ill patients. Frazee LA, et al. **Ann Pharmacother** 1995 Jul–Aug;29(7–8):784–6 (20 ref.)

Inhaled vasodilator therapy in acute lung injury: first, do NO harm? [editorial] Brett SJ, et al. **Thorax** 1995 Aug; 50(8):821–3 (4 ref.)

ETIOLOGY

Predicting acute respiratory distress syndrome and intrapulmonary inflammation. Reid PT, et al. **Br J Hosp Med** 1996 Apr 17–30;55(8):499–502 (22 ref.)

Mechanisms of the adult respiratory distress syndrome: selectins. Albert RK. **Thorax** 1995 Sep;50 Suppl 1:S49–52 (53 ref.)

[A case of adult onset Still's disease complicated with adult respiratory distress syndrome and disseminated intravascular coagulation] Yokoyama M, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Apr;18(2):207–14 (31 ref.) (Eng. Abstr.) **(Jpn)**

[The pathogenesis and treatment of the adult respiratory distress syndrome in patients with multiple organ failure] Iakovleva II, et al. **Anesteziol Reanimatol** 1996 Jan–Feb; (1):75–81 (184 ref.) **(Rus)**

IMMUNOLOGY

Acute lung injury: the role of cytokines in the elicitation of neutrophils [published erratum appears in J Investig Med 1995 Apr;43(2):204] Strieter RM, et al. **J Investig Med** 1994 Dec;42(4):640–51 (109 ref.)

[The role of polymorphonuclear neutrophilic leukocytes in the pathogenesis of acute respiratory distress syndrome (ARDS)] Thiel M, et al. **Anaesthesist** 1996 Feb;45(2):113–30 (88 ref.) (Eng. Abstr.) **(Ger)**

[Pulmonary (side)effects of extracorporeal therapy procedures] Kolb G. **Wien Klin Wochenschr Suppl** 1996; 1:15–20 (42 ref.) **(Ger)**

PATHOLOGY

The fibroproliferative phase of late adult respiratory distress syndrome. Meduri GU, et al. **Semin Respir Infect** 1995 Sep; 10(3):154–75 (118 ref.)

PHYSIOPATHOLOGY

Pathogenesis and treatment of the adult respiratory distress syndrome. Fulkerson WJ, et al. **Arch Intern Med** 1996 Jan 8;156(1):29–38 (182 ref.)

Targeting the alveolar epithelium in acute lung injury: keratinocyte growth factor and regulation of the alveolar

epithelial barrier [editorial; comment] Matuschak GM, et al. **Crit Care Med** 1996 Jun;24(6):905–7 (18 ref.) Comment on: Crit Care Med 1996 Jun;24(6):925–31.

Experimental pulmonary contusion: review of the literature and description of a new porcine model. Cohn SM, et al. **J Trauma** 1996 Sep;41(3):565–71 (43 ref.)

Role of surfactant in the pathophysiology of the acute respiratory distress syndrome (ARDS). Hartog A, et al. **Monaldi Arch Chest Dis** 1995 Oct;50(5):372–7 (58 ref.)

Acute respiratory distress syndrome (ARDS) in neonates and children. Pfenninger J. **Paediatr Anaesth** 1996;6(3):173–81 (84 ref.)

Pulmonary permeability oedema. Methods of estimation of pulmonary capillary permeability. Rogowski F, et al. **Rocz Akad Med Bialymst** 1994;39:7–17 (30 ref.)

PREVENTION & CONTROL

Use of iron chelators in preventing hydroxyl radical damage: adult respiratory distress syndrome as an experimental model for the pathophysiology and treatment of oxygen-radical-mediated tissue damage. Marx JJ, et al. **Acta Haematol** 1996;95(1):49–62 (181 ref.)

RADIOGRAPHY

Congestive heart failure and adult respiratory distress syndrome. New insights using computed tomography. Goodman LR. **Radiol Clin North Am** 1996 Jan;34(1):33–46 (30 ref.)

THERAPY

Permissive hypercapnia in ARDS and its effect on tissue oxygenation. Hickling KG, et al. **Acta Anaesthesiol Scand Suppl** 1995;107:201–8 (53 ref.)

Pathogenesis and treatment of the adult respiratory distress syndrome. Fulkerson WJ, et al. **Arch Intern Med** 1996 Jan 8;156(1):29–38 (182 ref.)

New approaches to acute lung injury. Bigatello LM, et al. **Br J Anaesth** 1996 Jul;77(1):99–109 (62 ref.)

New concepts in mechanical ventilation for ARDS. Lessard MR. **Can J Anaesth** 1996 May;43(5 Pt 2):R42–54 (67 ref.) **(Eng, Fre)**

Perfluorocarbon-associated gas exchange improves oxygenation, lung mechanics, and survival in a model of adult respiratory distress syndrome. Papo MC, et al. **Crit Care Med** 1996 Mar;24(3):466–74 (40 ref.)

Inverse ratio ventilation: simply an alternative, or something more? [letter; comment] Rimensberger P, et al. **Crit Care Med** 1995 Oct;23(10):1786–9 (14 ref.) Comment on: Crit Care Med 1995 Feb;23(2):224–8.

Extracorporeal life support (ECLS) for adult respiratory failure: the North American Experience. Bartlett RH, et al. **Int J Artif Organs** 1995 Oct;18(10):620–3 (10 ref.)

Severity and outcome of ARDS: the present place of extracorporeal lung assist (ECLA). Steltzer H, et al. **Int J Artif Organs** 1995 Oct;18(10):607–10 (11 ref.)

Low blood flow extracorporeal carbon dioxide removal (ECCO2R): a review of the concept and a case report. Habashi NM, et al. **Intensive Care Med** 1995 Jul;21(7):594–7 (33 ref.)

Permissive hypercapnia in ARDS: just do it? [editorial; comment] Lewandowski K. **Intensive Care Med** 1996 Mar; 22(3):179–81 (13 ref.) Comment on: Intensive Care Med 1996 Mar;22(3):182–91.

Wasted efforts and dyssynchrony: is the patient–ventilator battle back? [editorial; comment] Rossi A, et al. **Intensive Care Med** 1995 Nov;21(11):867–70 (24 ref.) Comment on: Intensive Care Med 1995 Nov;21(11):871–9.

[13th Consensus Conference on Intensive Care and Emergency Medicine. Assisted respiration during acute decompensation in chronic respiratory failure in adults (excluding neuromuscular diseases and weaning). 2 December 1994, Strasbourg] **Ann Fr Anesth Reanim** 1995; 14(2):243–5 (0 ref.) **(Fre)**

[High frequency jet ventilation combined with conventional mechanical ventilation in the treatment of adult respiratory distress syndrome] Roustan JP. **Ann Fr Anesth Reanim** 1995;14(3):276–88 (55 ref.) (Eng. Abstr.) **(Fre)**

[Cytokine inhibitors in intensive care] Villard J, et al. **Rev Mal Respir** 1995;12(4):335–42 (66 ref.) (Eng. Abstr.) **(Fre)**

[Ventilation in the prone position in acute respiratory distress syndrome (ARDS)] Jolliet P, et al. **Schweiz Med Wochenschr** 1996 May 18;126(20):879–92 (77 ref.) (Eng. Abstr.) **(Fre)**

[XIIIth Consensus Conference in Intensive Care and Emergency Medicine. Assisted respiration during acute decompensation in chronic respiratory failure in adults (excluding neuromuscular pathology and weaning)] **Therapie** 1996 Jan–Feb;51(1):71–4 (0 ref.) **(Fre)**

[Clinical aspects of acute lung failure in adults (ARDS)] Lewandowski K, et al. **Anaesthesist** 1996 Jan;45(1):1–18 (85 ref.) (Eng. Abstr.) **(Ger)**

[New supportive therapy measures in acute lung failure] Seeger W, et al. **Internist (Berl)** 1995 Dec;36(12):1139–49 (32 ref.) **(Ger)**

[ARDS. Intensive therapy of acute lung failure] Seeger W, et al. **Internist (Berl)** 1995 Aug;36(8):785–801 (35 ref.) **(Ger)**

[The current outlook in the treatment of the acute respiratory distress syndrome] Añón Elizalde J, et al. **Rev Clin Esp** 1995 Oct;195(10):693–700 (126 ref.) **(Spa)**

RESPIRATORY DRUG ADMINISTRATION see **ADMINISTRATION, INHALATION**

RESPIRATORY ENTERIC ORPHAN VIRUSES see **REOVIRIDAE**

RESPIRATORY FAILURE see **RESPIRATORY INSUFFICIENCY**

RESPIRATORY FUNCTION TESTS

The lung in HIV infection: can pulmonary function testing help? Mitchell DM, et al. **Monaldi Arch Chest Dis** 1996 Jun;51(3):214–22 (30 ref.)

[Indications for respiratory function tests (RFT). The role of RFT and blood gases in the monitoring of asthma and chronic obstructive bronchopnumopathies] **Rev Mal Respir** 1995;12 Suppl 3:R115–31 (57 ref.) **(Fre)**

METHODS

Infant lung function testing in the intensive care unit. Hammer J, et al. **Intensive Care Med** 1995 Sep;21(9):744–52 (66 ref.)

Neonatal ventilator management and the role for pulmonary function tests. Greenspan JS. **J Perinatol** 1996 Mar–Apr; 16(2 Pt 2 Su):S56–60 (11 ref.)

[Forced oscillation technique in respiratory system studies. II. Clinical interpretation of results in respiratory system diseases] Mazurek H, et al. **Pneumonol Alergol Pol** 1995; 63(11–12):685–9 (25 ref.) (Eng. Abstr.) **(Pol)**

[Forced oscillation technique in respiratory system studies. I. Theoretical basis, interpretation of results. Equipment] Tomalak W, et al. **Pneumonol Alergol Pol** 1995; 63(11–12):679–84 (19 ref.) (Eng. Abstr.) **(Pol)**

STANDARDS

[Normal values of respiratory function tests. Safety of normalized regression equations] Barthélémy L, et al. **Rev Pneumol Clin** 1995;51(6):330–3 (12 ref.) (Eng. Abstr.) **(Fre)**

RESPIRATORY HYPERSENSITIVITY

Fungal sinusitis: an update. Morpeth JF, et al. **Ann Allergy Asthma Immunol** 1996 Feb;76(2):128–39; quiz 139–40 (64 ref.)

CHEMICALLY INDUCED

Structure–activity relationships and computer-assisted analysis of respiratory sensitization potential. Karol MH, et al. **Toxicol Lett** 1996 Aug;86(2–3):187–91 (10 ref.)

Predictive testing for respiratory sensitization in the mouse. Kimber I, et al. **Toxicol Lett** 1996 Aug;86(2–3):193–8 (31 ref.)

Predictive testing for respiratory sensitisation. Pauluhn J. **Toxicol Lett** 1996 Aug;86(2–3):177–85 (17 ref.)

Adverse health effects of air pollutants in a nonsmoking population. Pope CA 3rd. **Toxicology** 1996 Jul 17; 111(1–3):149–55 (19 ref.)

COMPLICATIONS

Role of allergy in nasal polyposis: a review. Bernstein JM, et al. **Otolaryngol Head Neck Surg** 1995 Dec;113(6):724–32 (30 ref.)

[Type I hypersensitivity reactions and etiopathogenesis of hemorrhagic rectocolitis] Leprince E, et al. **Presse Med** 1995 Dec 16–23;24(39):1902–6 (58 ref.) (Eng. Abstr.) **(Fre)**

[Trigemino-vegetative physiopathology in the central dysnociceptive biorhythms in primary headache] Passàli D, et al. **Ital J Neurol Sci** 1995 Nov;16(8 Suppl):41–5 (14 ref.) (Eng. Abstr.) **(Ita)**

DIAGNOSIS

[Respiratory allergies: some medical history elements are useful to the practitioner] Kaeser P, et al. **Rev Med Suisse Romande** 1996 Jun;116(6):415–21 (14 ref.) **(Fre)**

EPIDEMIOLOGY

Environmental factors and respiratory hypersensitivity: the Americas. Bascom R. **Toxicol Lett** 1996 Aug; 86(2–3):115–30 (28 ref.)

Exposure to environmental chemicals relevant for respiratory hypersensitivity: global aspects. Schwela D. **Toxicol Lett** 1996 Aug;86(2–3):131–42 (13 ref.)

ETIOLOGY

Introduction. House dust mite allergy. Guérin B. **Clin Rev Allergy Immunol** 1995 Summer;13(2):107–13 (57 ref.)

Environmental chemicals relevant for respiratory hypersensitivity: the indoor environment. Becher R, et al. **Toxicol Lett** 1996 Aug;86(2–3):155–62 (47 ref.)

The role of the gastrointestinal tract in the development of respiratory hypersensitivities. Björkstén B. **Toxicol Lett** 1996 Aug;86(2–3):85–8 (15 ref.)

Environmental factors and respiratory hypersensitivity: experiences from studies in Eastern and Western Europe. Björkstén B. **Toxicol Lett** 1996 Aug;86(2–3):93–8 (17 ref.)

Air pollutants and respiratory hypersensitivity. Devalia JL, et al. **Toxicol Lett** 1996 Aug;86(2–3):169–76 (55 ref.)

Environmental chemicals and respiratory hypersensitization: a synopsis. Løvik M, et al. **Toxicol Lett** 1996 Aug; 86(2–3):211–22 (20 ref.)

Exposure to environmental chemicals relevant for respiratory hypersensitivity: European aspects. Sivertsen B, et al. **Toxicol Lett** 1996 Aug;86(2–3):143–53 (23 ref.)

Interaction of environmental chemicals with respiratory sensitization. Van Loveren H, et al. **Toxicol Lett** 1996 Aug; 86(2–3):163–7 (12 ref.)

[Latex allergy: from contact urticaria to asthma] Helbling A. **Schweiz Rundsch Med Prax** 1996 Aug 13;85(33):978–82 (22 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

The immunology of respiratory allergies. Frew AJ. **Toxicol Lett** 1996 Aug;86(2–3):65–72 (40 ref.)

The role of the skin in the development of chemical respiratory hypersensitivity. Kimber I. **Toxicol Lett** 1996 Aug;86(2–3):89–92 (29 ref.)

Interaction of air pollutants and pulmonary allergic responses in experimental animals. Gilmour MI. **Toxicology** 1995 Dec 28;105(2–3):335–42 (48 ref.)

PATHOLOGY

Nasal polyps—a model of chronic respiratory mucosal inflammation [editorial] Djukanović R. **Clin Exp Allergy** 1995 Jul;25(7):582–5 (35 ref.)

PHYSIOPATHOLOGY

Effect of air pollution in asthma and respiratory allergy. Peden DB. **Otolaryngol Head Neck Surg** 1996 Feb; 114(2):242–7 (33 ref.)

RESPIRATORY INSUFFICIENCY

CHEMICALLY INDUCED

Occupational phosgene poisoning: a case report and review. Wyatt JP, et al. **J Accid Emerg Med** 1995 Sep;12(3):212–3 (11 ref.)

[The first case of severe pneumopathy due to hard metals successfully undergoing a lung transplant] Tomasini M, et al. **Med Lav** 1995 Jul–Aug;86(4):325–31 (6 ref.) (Eng. Abstr.) **(Ita)**

COMPLICATIONS

Nutritional support during pulmonary failure. Pinard B, et al. **Crit Care Clin** 1995 Jul;11(3):705–15 (33 ref.)

[Ventilatory assistance in acute decompensation of chronic respiratory insufficiency in adults (excluding neuromuscular diseases and weaning). 13th Consensus Conference on resuscitation and emergency medicine, Strasbourg, 2 December 1994] **Rev Pneumol Clin** 1995; 51(5):302–5 (0 ref.) **(Fre)**

DRUG THERAPY

Inhaled nitric oxide therapy of pulmonary hypertension and respiratory failure in premature and term neonates. Abman SH, et al. **Adv Pharmacol** 1995;34:457–74 (71 ref.)

Use of surfactant in pulmonary disorders in full-term infants. Sun B. **Curr Opin Pediatr** 1996 Apr;8(2):113–7 (27 ref.)

Prevention studies with pentoxifylline: new clinical projects. Eugène-Jolchine I, et al. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S143–6 (29 ref.)

[Treatment of respiratory insufficiency in chronic nonspecific lung diseases] Kazanbiev NK. **Klin Med (Mosk)** 1995; 73(4):24–7 (16 ref.) **(Rus)**

ETIOLOGY

Acute respiratory failure due to extramedullary hematopoiesis. Yusen RD, et al. **Chest** 1995 Oct; 108(4):1170–2 (17 ref.)

Respiratory function in children with neuromuscular disease. Allen JL. **Monaldi Arch Chest Dis** 1996 Jun;51(3):230–5 (51 ref.)

Ventilatory management in critical neurologic illness. Borel CO, et al. **Neurol Clin** 1995 Aug;13(3):627–44 (79 ref.)

[Legionnaires' disease with acute respiratory insufficiency. Clinical and biological characteristics, comparison with pneumococcal pneumonia] Mallet JP, et al. **Presse Med** 1996 Apr 27;25(15):702–6 (17 ref.) (Eng. Abstr.) **(Fre)**

[Circulatory shock. Extrapulmonary etiology of respiratory insufficiency] Vogelmeier C, et al. **Internist (Berl)** 1995 Aug;36(8):756–64 (39 ref.) **(Ger)**

[Pulmonary function abnormalities and respiratory manifestations in Sjögren's syndrome] Shima H. **Nippon Rinsho** 1995 Oct;53(10):2516–20 (20 ref.) (Eng. Abstr.) **(Jpn)**

NURSING

Mastering emergency airway management. Somerson SJ, et al. **Am J Nurs** 1996 May;96(5):24–30; quiz 31 (11 ref.)

PATHOLOGY

[Acute respiratory failure in hemoblastoses: the types of diffuse lung lesions] Gorelov VG, et al. **Ter Arkh** 1995;

67(7):52–6 (17 ref.) **(Rus)**

PHYSIOPATHOLOGY

The lungs in chronic heart failure. Chua TP, et al. **Eur Heart J** 1995 Jul;16(7):882–7 (75 ref.)

[Acute decompensation in chronic obstructive respiratory insufficiency. Pathogenesis of edema and role of noninvasive mechanical ventilation] Chevrolet JC. **Schweiz Rundsch Med Prax** 1996 Mar 12;85(11):329–36 (49 ref.) (Eng. Abstr.) **(Fre)**

[Respiratory regulation and compensatory mechanisms in ventilatory insufficiency] Schönhofer B, et al. **Internist (Berl)** 1995 Aug;36(8):769–78 (64 ref.) **(Ger)**

RADIOGRAPHY

[Acute respiratory failure and multiple pulmonary nodules. Pulmonary metastases of colonic adenocarcinoma] Cordero PJ, et al. **Rev Clin Esp** 1995 Dec;195(12):845–6 (7 ref.) **(Spa)**

SURGERY

[Respiratory insufficiency. Role of lung and heart/lung transplantation. Indications and results] Wagner TO. **Internist (Berl)** 1995 Aug;36(8):818–27 (37 ref.) **(Ger)**

[The first case of severe pneumopathy due to hard metals successfully undergoing a lung transplant] Tomasini M, et al. **Med Lav** 1995 Jul–Aug;86(4):325–31 (6 ref.) (Eng. Abstr.) **(Ita)**

THERAPY

Initiation of mechanical ventilation in the emergency department. Orebaugh SL. **Am J Emerg Med** 1996 Jan; 14(1):59–69 (114 ref.)

Mastering emergency airway management. Somerson SJ, et al. **Am J Nurs** 1996 May;96(5):24–30; quiz 31 (11 ref.)

Current status of extracorporeal membrane oxygenation for severe respiratory failure. Ichiba S, et al. **Artif Organs** 1996 Feb;20(2):120–3 (12 ref.)

Acute respiratory failure in pregnancy. Deblieux PM, et al. **Clin Obstet Gynecol** 1996 Mar;39(1):143–52 (14 ref.)

Noninvasive mechanical ventilation in patients with acute respiratory failure. Abou-Shala N, et al. **Crit Care Med** 1996 Apr;24(4):705–15 (66 ref.)

The management of acute respiratory failure. Shanley CJ, et al. **Curr Opin Gen Surg** 1994;:7–16 (82 ref.)

Resuscitating the pediatric patient. Wright JL, et al. **Emerg Med Clin North Am** 1996 Feb;14(1):219–31 (36 ref.)

The changing role of mechanical ventilation in COPD [editorial] Shneerson JM. **Eur Respir J** 1996 Mar;9(3):393–8 (74 ref.)

Assisted ventilation in neonates: the Indian perspective [editorial] Bhakoo ON. **Indian Pediatr** 1995 Dec; 32(12):1261–4 (15 ref.)

Perfluorochemical liquid ventilation: from the animal laboratory to the intensive care unit. Degraeuwe PL, et al. **Int J Artif Organs** 1995 Oct;18(10):674–83 (92 ref.)

Extracorporeal membrane oxygenation (ECMO) for cardiorespiratory failure in children: the Leicester experience. Firmin RK, et al. **Int J Artif Organs** 1995 Oct; 18(10):603–6 (23 ref.)

The current status of intratracheal-pulmonary ventilation (ITPV). Kolobow T, et al. **Int J Artif Organs** 1995 Oct; 18(10):670–3 (13 ref.)

Clinical application of novel ventilation techniques. Müller E. **Int J Artif Organs** 1995 Oct;18(10):656–69 (140 ref.)

Neonatal ECMO: are indications changing? Short BL. **Int J Artif Organs** 1995 Oct;18(10):562–4 (20 ref.)

Clinical approaches to the use of high-frequency oscillatory ventilation in neonatal respiratory failure. Kinsella JP, et al. **J Perinatol** 1996 Mar–Apr;16(2 Pt 2 Su):S52–5 (16 ref.)

Risks of extracorporeal membrane oxygenation: is there a role for use in the management of the acutely poisoned patient? Banner W Jr. **J Toxicol Clin Toxicol** 1996; 34(4):365–71 (18 ref.)

Ventilatory management in critical neurologic illness. Borel CO, et al. **Neurol Clin** 1995 Aug;13(3):627–44 (79 ref.)

Noninvasive nasal mask positive pressure ventilation in a pediatric patient with acute hypoxic respiratory failure. Padman R, et al. **Pediatr Emerg Care** 1996 Feb;12(1):44–7 (63 ref.)

Noninvasive positive pressure ventilation: what is its role in treating acute respiratory failure? Curreri JP, et al. **Postgrad Med** 1996 Jun;99(6):221–4, 227–30 (12 ref.)

[13th Consensus Conference on Intensive Care and Emergency Medicine. Assisted respiration during acute decompensation in chronic respiratory failure in adults (excluding neuromuscular diseases and weaning). 2 December 1994, Strasbourg] **Ann Fr Anesth Reanim** 1995; 14(2):243–5 (0 ref.) **(Fre)**

[Ventilatory assistance in acute exacerbations of chronic respiratory insufficiency in adults (with the exclusion of neuromuscular pathology and weaning). 13th Consensus Conference in Resuscitation and Emergency Medicine. 2 December 1994, Strasbourg] **Rev Mal Respir** 1995;12 Suppl 3:R158–61 (0 ref.) **(Fre)**

[XIIIth Consensus Conference in Intensive Care and Emergency Medicine. Assisted respiration during acute decompensation in chronic respiratory failure in adults (excluding neuromuscular pathology and weaning)] **Therapie** 1996 Jan–Feb;51(1):71–4 (0 ref.) **(Fre)**

[Respirator dependency. Intensive care unit or home ventilation?] Criée CP, et al. **Internist (Berl)** 1995 Aug; 36(8):812–7 (16 ref.) **(Ger)**

[Biphasic positive "airway pressure" (BIPAP). Principles and clinical applications of a new ventilatory method in acute respiratory insufficiency] Sydow M, et al. **Internist (Berl)** 1995 Aug;36(8):802–11 (38 ref.) **(Ger)**

[Home days ratio in patients treated with long-term oxygen therapy] Ando M, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Oct; 33(10):1086–92 (7 ref.) (Eng. Abstr.) **(Jpn)**

VIROLOGY

Severe respiratory insufficiency complicating Epstein-Barr virus infection: case report and review. Haller A, et al. **Clin Infect Dis** 1995 Jul;21(1):206–9 (24 ref.)

RESPIRATORY MECHANICS

Effects of lung water on respiratory mechanics. Cutillo AG. **Cardiologia** 1995 Nov;40(11):813–28 (136 ref.)

Clinical assessment of the respiratory muscles. Clanton TL, et al. **Phys Ther** 1995 Nov;75(11):983–95 (80 ref.)

Inspiratory muscle training in the patient with neuromuscular disease. McCool FD, et al. **Phys Ther** 1995 Nov; 75(11):1006–14 (45 ref.)

DRUG EFFECTS

Perfluorocarbon-associated gas exchange improves oxygenation, lung mechanics, and survival in a model of adult respiratory distress syndrome. Papo MC, et al. **Crit Care Med** 1996 Mar;24(3):466–74 (40 ref.)

Effects of morphine and cocaine on breathing control in neonatal animals: a minireview. Olsen GD, et al. **NIDA Res Monogr** 1995;158:22–39 (106 ref.)

PHYSIOLOGY

Good vibrations? Respiratory rhythms in the central control of blood pressure. Pilowsky P. **Clin Exp Pharmacol Physiol** 1995 Sep;22(9):594–604 (90 ref.)

Hypoxic inhibition of breathing and motor activity in the foetus and newborn. Walker DW. **Clin Exp Pharmacol Physiol** 1995 Aug;22(8):533–6 (30 ref.)

Generation of respiratory rhythm and pattern in mammals: insights from developmental studies. Funk GD, et al. **Curr Opin Neurobiol** 1995 Dec;5(6):778–85 (53 ref.)

RESPIRATORY MUSCLE TRAINING see **BREATHING EXERCISES**

RESPIRATORY MUSCLES

DRUG EFFECTS

Lack of effects of recombinant growth hormone on muscle function in patients requiring prolonged mechanical ventilation: a prospective, randomized, controlled study. Pichard C, et al. **Crit Care Med** 1996 Mar;24(3):403–13 (55 ref.)

Scorpion venoms: taking the sting out of lung disease. Rogers DF. **Thorax** 1996 May;51(5):546–8 (12 ref.)

PHYSIOLOGY

Respiratory muscle fatigue. McKenzie DK, et al. **Adv Exp Med Biol** 1995;384:401–14 (74 ref.)

Clinical assessment of the respiratory muscles. Clanton TL, et al. **Phys Ther** 1995 Nov;75(11):983–95 (80 ref.)

Respiratory muscle training for patients with chronic obstructive pulmonary disease. Reid WD, et al. **Phys Ther** 1995 Nov;75(11):996–1005 (65 ref.)

Considerations when testing and training the respiratory muscles. Reid WD, et al. **Phys Ther** 1995 Nov; 75(11):971–82 (55 ref.)

[Respiratory muscle functions: implications for anesthesia and critical care medicine] Toyooka H. **Masui** 1995;44 Suppl:S65–70 (35 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Ascites and its effects upon respiratory muscle loading and work of breathing. Rosado M, et al. **Crit Care Med** 1996 Mar;24(3):538–40 (22 ref.)

Respiratory muscle function and COPD. Nardini S. **Monaldi Arch Chest Dis** 1995 Aug;50(4):325–6 (6 ref.)

Measurement of respiratory muscle strength. Gibson GJ. **Respir Med** 1995 Sep;89(8):529–35 (60 ref.)

Measurement of respiratory muscle strength [editorial] Polkey MI, et al. **Thorax** 1995 Nov;50(11):1131–5 (67 ref.)

RESPIRATORY PARALYSIS

[Diaphragmatic paralysis] Yu B, et al. **Chung Hua Chieh Ho Ho Hu Hsi Tsa Chih** 1995 Apr; 18(2):103–4 (9 ref.) **(Chi)**

ETIOLOGY

[Diaphragmatic paralysis after the catheterization of the internal jugular vein] Sánchez Castilla M, et al. **Nutr Hosp** 1995 Nov–Dec;10(6):377–8 (7 ref.) (Eng. Abstr.) **(Spa)**

RESPIRATORY SOUNDS

Respiratory infections and wheezing in children. Landau LI. **Curr Opin Pediatr** 1996 Feb;8(1):3–5 (17 ref.)

Acoustic properties of the normal chest. Dalmay F, et al. **Eur Respir J** 1995 Oct;8(10):1761–9 (68 ref.)

Pediatric stridor and airway compromise. Zalzal GH. **J Med Liban** 1994;42(4):221–6 (15 ref.)

DIAGNOSIS

Wheezes. Meslier N, et al. **Eur Respir J** 1995 Nov; 8(11):1942–8 (60 ref.)

Crackles: recording, analysis and clinical significance. Piirilä P, et al. **Eur Respir J** 1995 Dec;8(12):2139–48 (85 ref.)

Management of the wheezy infant. The Respiratory Committee of the Paediatric Society of New Zealand. Gillies JD, et al. **N Z Med J** 1996 Jan 26;109(1014):14–5 (10 ref.)

ETIOLOGY

Clinical diagnosis of wheezing in early childhood. Martinati LC, et al. **Allergy** 1995 Sep;50(9):701–10 (90 ref.)

Why do viruses make infants wheeze? Balfour-Lynn IM. **Arch Dis Child** 1996 Mar;74(3):251–9 (101 ref.)

Congenital vallecular cyst: a cause of failure to thrive. Oluwole M. **Br J Clin Pract** 1996 Apr–May;50(3):170 (9 ref.)

Myasthenia gravis presenting with stridor. Hanson JA, et al. **Thorax** 1996 Jan;51(1):108–9 (8 ref.)

RESPIRATORY SYNCYTIAL VIRUS, HUMAN

Respiratory syncytial virus bronchiolitis: clinical aspects and epidemiology. Boeck KD. **Monaldi Arch Chest Dis** 1996 Jun;51(3):210–3 (28 ref.)

ISOLATION & PURIFICATION

Testing models predicting severity of respiratory syncytial virus infection on the PICNIC RSV database. Pediatric Investigators Collaborative Network on Infections in Canada. Opavsky MA, et al. **Arch Pediatr Adolesc Med** 1995 Nov;149(11):1217–20 (25 ref.)

RESPIRATORY SYNCYTIAL VIRUS INFECTIONS

Respiratory syncytial virus in infants and children. Schwartz R. **Nurse Pract** 1995 Sep;20(9):24–9 (30 ref.)

[Progresses in pediatrics in China, 1995] Hu Y. **Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):751–2 (0 ref.) **(Chi)**

CHEMICALLY INDUCED

Pathogenesis of respiratory syncytial virus vaccine-augmented pathology. Graham BS. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 2):S63–6 (48 ref.)

COMPLICATIONS

Respiratory syncytial virus infection in children with congenital heart disease: a review. Fixler DE. **Pediatr Cardiol** 1996 May–Jun;17(3):163–8 (40 ref.)

DIAGNOSIS

Testing models predicting severity of respiratory syncytial virus infection on the PICNIC RSV database. Pediatric Investigators Collaborative Network on Infections in Canada. Opavsky MA, et al. **Arch Pediatr Adolesc Med** 1995 Nov;149(11):1217–20 (25 ref.)

Respiratory syncytial virus and parainfluenza virus infections in the immunocompromised host. Wendt CH, et al. **Semin Respir Infect** 1995 Dec;10(4):224–31 (35 ref.)

DRUG THERAPY

Management of respiratory syncytial virus infections. Mills J. **Adv Exp Med Biol** 1996;394:163–74 (59 ref.)

Reassessment of the indications for ribavirin therapy in respiratory syncytial virus infections. American Academy of Pediatrics Committee on Infectious Diseases. **Pediatrics** 1996 Jan;97(1):137–40 (28 ref.)

EPIDEMIOLOGY

Respiratory syncytial virus bronchiolitis: clinical aspects and epidemiology. Boeck KD. **Monaldi Arch Chest Dis** 1996 Jun;51(3):210–3 (28 ref.)

ETIOLOGY

Immunopathological mechanisms in respiratory syncytial virus disease. Openshaw PJ. **Springer Semin Immunopathol** 1995;17(2–3):187–201 (70 ref.)

IMMUNOLOGY

Immunity and immunopathology to respiratory syncytial virus. The mouse model. Openshaw PJ. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 2):S59–62

(34 ref.)
Immunopathological mechanisms in respiratory syncytial virus disease. Openshaw PJ.
Springer Semin Immunopathol 1995;17(2-3):187-201 (70 ref.)

PREVENTION & CONTROL

Anti-respiratory syncytial virus monoclonal antibodies show promise in the treatment and prophylaxis of viral disease. Taylor G, et al. **Biochem Soc Trans** 1995 Nov;23(4):1063-7 (24 ref.)
[Immunoprophylaxis of respiratory syncytial (RS-viral) infection: results and prospects] Leshchinskaia NP.
Tr Inst Im Pastera 1992;67:74-85 (33 ref.) **(Rus)**

THERAPY

Management of respiratory syncytial virus infections. Mills J. **Adv Exp Med Biol** 1996;394:163-74 (59 ref.)
Anti-respiratory syncytial virus monoclonal antibodies show promise in the treatment and prophylaxis of viral disease. Taylor G, et al. **Biochem Soc Trans** 1995 Nov;23(4):1063-7 (24 ref.)

RESPIRATORY SYNCYTIAL VIRUSES

IMMUNOLOGY

Anti-respiratory syncytial virus monoclonal antibodies show promise in the treatment and prophylaxis of viral disease. Taylor G, et al. **Biochem Soc Trans** 1995 Nov;23(4):1063-7 (24 ref.)
Immunopathological mechanisms in respiratory syncytial virus disease. Openshaw PJ.
Springer Semin Immunopathol 1995;17(2-3):187-201 (70 ref.)

PHYSIOLOGY

Pathogenesis of respiratory syncytial virus vaccine-augmented pathology. Graham BS.
Am J Respir Crit Care Med 1995 Oct;152(4 Pt 2):S63-6 (48 ref.)

RESPIRATORY SYSTEM

Deposition of inhaled asbestos and man-made mineral fibres in the respiratory tract. Morgan A. **Ann Occup Hyg** 1995 Oct;39(5):747-58 (40 ref.)
Airway foreign bodies. Kelly SM, et al.
Chest Surg Clin N Am 1996 May;6(2):253-76 (42 ref.)
Airway foreign bodies in children. Somanath BP, et al.
Indian Pediatr 1995 Aug;32(8):890-7 (26 ref.)

CYTOLOGY

Population dynamics and functions of respiratory tract dendritic cells in the rat. Holt PG, et al.
Adv Exp Med Biol 1995;378:177-81 (22 ref.)

DRUG EFFECTS

Regulation of airway wall remodeling: prospects for the development of novel antiasthma drugs. Stewart AG, et al. **Adv Pharmacol** 1995;33:209-53 (204 ref.)
A review of inhalation toxicology studies with para-aramid fibrils. Warheit DB. **Ann Occup Hyg** 1995 Oct;39(5):691-7 (14 ref.)
Long-and short-acting beta 2-adrenergic agonists. Effects on airway function in patients with asthma. Busse WW. **Arch Intern Med** 1996 Jul 22;156(14):1514-20 (63 ref.)
Impact of environmental pollution on respiratory sensitization and asthma. Kimber I. **Arch Toxicol Suppl** 1996;18:34-48 (85 ref.)
Effect of oxidant air pollutants on the respiratory system: insights from experimental animal research. Chitano P, et al. **Eur Respir J** 1995 Aug;8(8):1357-71 (182 ref.)
Understanding mechanisms of inhaled toxicants: implications for replacing default factors with chemical-specific data. Bogdanffy MS, et al. **Toxicol Lett** 1995 Dec;82-83:919-32 (46 ref.)
Predictive testing for respiratory sensitisation. Pauluhn J. **Toxicol Lett** 1996 Aug;86(2-3):177-85 (17 ref.)
Interaction of environmental chemicals with respiratory sensitization. Van Loveren H, et al. **Toxicol Lett** 1996 Aug; 86(2-3):163-7 (12 ref.)

GROWTH & DEVELOPMENT

Generation of respiratory rhythm and pattern in mammals: insights from developmental studies. Funk GD, et al.
Curr Opin Neurobiol 1995 Dec;5(6):778-85 (53 ref.)

IMMUNOLOGY

The biology of airway dendritic cells. McWilliam AS, et al.
Immunol Cell Biol 1995 Oct;73(5):405-13 (35 ref.)

INNERVATION

Sensory information from the upper airway: role in the control of breathing. Sant'Ambrogio G, et al.
Respir Physiol 1995 Oct;102(1):1-16 (59 ref.)

METABOLISM

Interactions between human respiratory mucins and pathogens. Scharfman A, et al. **Biochem Soc Trans** 1995 Nov;23(4):836-9 (45 ref.)
A review of the penetration of sparfloxacin into the lower respiratory tract and sinuses. Wise R, et al.
J Antimicrob Chemother 1996 May;37 Suppl A:57-63 (18 ref.)
Uptake and fate of ozone in the respiratory tract. Miller FJ. **Toxicol Lett** 1995 Dec;82-83:277-85 (43 ref.)

MICROBIOLOGY

Trends in antimicrobial susceptibility of bacterial pathogens of the respiratory tract. Doern GV. **Am J Med** 1995 Dec 29;99(6B):3S-7S (22 ref.)
Interactions between human respiratory mucins and pathogens. Scharfman A, et al. **Biochem Soc Trans** 1995 Nov;23(4):836-9 (45 ref.)

PHYSIOLOGY

Regulation of airway wall remodeling: prospects for the development of novel antiasthma drugs. Stewart AG, et al. **Adv Pharmacol** 1995;33:209-53 (204 ref.)
Molecular mechanisms of beta-adrenergic relaxation of airway smooth muscle. Kotlikoff MI, et al.
Annu Rev Physiol 1996;58:115-41 (164 ref.)
The respiratory system in a cold environment. Giesbrecht GG. **Aviat Space Environ Med** 1995 Sep;66(9):890-902 (163 ref.)
Roles of airway epithelial integrins in health and disease. The Parker B. Francis Lectureship. Sheppard D, et al.
Chest 1996 Mar;109(3 Suppl):29S-33S (44 ref.)
Airway permeability. Persson CG, et al. **Clin Exp Allergy** 1995 Sep;25(9):807-14 (56 ref.)
Normal cardiopulmonary physiology during pregnancy. Crapo RO. **Clin Obstet Gynecol** 1996 Mar;39(1):3-16 (54 ref.)
Generation of respiratory rhythm and pattern in mammals: insights from developmental studies. Funk GD, et al.
Curr Opin Neurobiol 1995 Dec;5(6):778-85 (53 ref.)
Biomechanics of snoring. Huang L, et al. **Endeavour** 1995; 19(3):96-100 (10 ref.)
Shear-augmented dispersion in the respiratory system. Kamm RD. **Symp Soc Exp Biol** 1995;49:277-95 (52 ref.)
[The respiratory system in pregnancy] Buchacz P, et al.
Ginekol Pol 1995 Jun;66(6):347-50 (48 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOPATHOLOGY

Physiological studies of gastro-oesophageal reflux and airway protective responses in the young animal and human infant. Jeffery HE, et al. **Clin Exp Pharmacol Physiol** 1995 Aug;22(8):544-9 (51 ref.)
The cardiopulmonary system and movement dysfunction. Peel C. **Phys Ther** 1996 May;76(5):448-55 (34 ref.)
Sustained alterations in postnatal respiratory function following sub-optimal intrauterine conditions. Harding R. **Reprod Fertil Dev** 1995;7(3):431-41 (67 ref.)
[Cardiorespiratory system adaptation after surgical correction of intracardiac hemodynamics] Shevchenko IuL.
Fiziol Cheloveka 1996 Mar-Apr;22(2):20-4 (14 ref.) **(Rus)**

SURGERY

[The surgical treatment of obstructive sleep apnea syndrome] Cimino A, et al. **Acta Otorhinolaryngol Ital** 1995 Apr;15(2 Suppl 47):3-14 (58 ref.) (Eng. Abstr.) **(Ita)**

RESPIRATORY THERAPY

see related
BREATHING EXERCISES
Physical therapy in lung transplantation. Downs AM.
Phys Ther 1996 Jun;76(6):626-42 (102 ref.)

INSTRUMENTATION

Home nebuliser-compressors. Ariyananda PL, et al.
Br J Hosp Med 1995 Nov 15-Dec 12;54(10):489-93 (22 ref.)

METHODS

Cardiovascular, pulmonary, and cancer rehabilitation. 2. Pulmonary rehabilitation. Bach JR, et al.
Arch Phys Med Rehabil 1996 Mar;77(3 Suppl):S45-51 (58 ref.)
Airway management and mechanical ventilation. Abrams KJ.
New Horiz 1995 Aug;3(3):479-87 (65 ref.)
Advanced ventilation in the neonate. Antunes MJ, et al.
Nurs Clin North Am 1996 Jun;31(2):405-22 (123 ref.)
Chest physical therapy for patients in the intensive care unit. Ciesla ND. **Phys Ther** 1996 Jun;76(6):609-25 (133 ref.)
[Inhalation therapy in young children with asthma] Roorda RJ. **Ned Tijdschr Geneeskd** 1995 Dec 9;139(49):2548-51 (43 ref.) **(Dut)**

RESPIRATORY TRACT DISEASES

Obstetric complications in pulmonary and critical care medicine. Rizk NW, et al. **Chest** 1996 Sep;110(3):791-809 (196 ref.)

CHEMICALLY INDUCED

Possible mechanisms for the respiratory tract effects of noncarcinogenic indoor-climate pollutants and bases for their risk assessment. Damgård Nielsen G, et al.
Scand J Work Environ Health 1995 Jun;21(3):165-78 (113 ref.)
Respiratory irritants encountered at work. Taylor AJ.
Thorax 1996 May;51(5):541-5 (17 ref.)
[Health damages from passive smoking] Sanner T, et al.
Tidsskr Nor Laegeforen 1996 Feb 20;116(5):617-20 (23 ref.) (Eng. Abstr.) **(Nor)**

COMPLICATIONS

Sleep-related breathing disorders. 7. Sleep and breathing problems in general medicine. Calverley PM. **Thorax** 1995 Dec;50(12):1311-6 (98 ref.)

DIAGNOSIS

Adolescent chest pain. Anzai AK, et al.
Am Fam Physician 1996 Apr;53(5):1682-90 (16 ref.)
Pediatric fiberoptic bronchoscopy. Nussbaum E.
Clin Pediatr (Phila) 1995 Aug;34(8):430-5 (53 ref.)
Physical examination of the adult patient with respiratory diseases: inspection and palpation. Maitre B, et al.
Eur Respir J 1995 Sep;8(9):1584-93 (64 ref.)
Chest percussion. Yernault JC, et al. **Eur Respir J** 1995 Oct; 8(10):1756-60 (33 ref.)
[Cough—work-up and therapy] Zellweger JP, et al.
Schweiz Med Wochenschr 1995 Nov 11;125(45):2194-200 (28 ref.) (Eng. Abstr.) **(Ger)**
[Application of thoracoscopy for diagnosis and therapy of respiratory tract diseases] Inui K.
Nippon Naika Gakkai Zasshi 1995 Sep 10;84(9):1594-9 (18 ref.) **(Jpn)**
[Exercise test in respiratory system] Miyazato I, et al.
Rinsho Byori 1995 Aug;43(8):813-9 (9 ref.) (Eng. Abstr.) **(Jpn)**
[Forced oscillation technique in respiratory system studies. II. Clinical interpretation of results in respiratory system diseases] Mazurek H, et al. **Pneumonol Alergol Pol** 1995; 63(11-12):685-9 (25 ref.) (Eng. Abstr.) **(Pol)**

DRUG THERAPY

Drug management of noninfective complications of cystic fibrosis. Sanchez I, et al. **Drugs** 1995 Oct;50(4):626-35 (40 ref.)
[Inhalation techniques] Huchon GJ.
Rev Med Suisse Romande 1996 May;116(5):319-23 (32 ref.) **(Fre)**

EPIDEMIOLOGY

Health effects of outdoor air pollution. Committee of the Environmental and Occupational Health Assembly of the American Thoracic Society.
Am J Respir Crit Care Med 1996 Jan;153(1):3-50 (578 ref.)

ETIOLOGY

The therapy of respiratory chain encephalomyopathy: a critical review of the past and current perspective. Walker UA, et al. **Acta Neurol Scand** 1995 Oct;92(4):273-80 (77 ref.)
ABC of work related disorders. Occupational asthma and other respiratory diseases. Madan I. **BMJ** 1996 Aug 3; 313(7052):291-4 (0 ref.)
Exposure to moderate altitude and cardiorespiratory diseases. Gong H Jr. **Cardiologia** 1995 Jul;40(7):477-88 (98 ref.)
Drug management of noninfective complications of cystic fibrosis. Sanchez I, et al. **Drugs** 1995 Oct;50(4):626-35 (40 ref.)
Respiratory effects of air pollutants: experimental studies in humans [see comments] Sandström T. **Eur Respir J** 1995 Jun;8(6):976-95 (221 ref.) Comment in: Eur Respir J 1995 Jun;8(6):883-4.
Particulate pollution and health: a review of the Utah valley experience. Pope CA 3rd.
J Expo Anal Environ Epidemiol 1996 Jan-Mar;6(1):23-34 (19 ref.)
Development of lower respiratory symptoms. Carlsen KH. **Pediatr Allergy Immunol** 1995;6 Suppl 7:36-41 (66 ref.)
Psychobiologic reactivity to stress and childhood respiratory illnesses: results of two prospective studies. Boyce WT, et al. **Psychosom Med** 1995 Sep-Oct;57(5):411-22 (113 ref.)
Sustained alterations in postnatal respiratory function following sub-optimal intrauterine conditions. Harding R. **Reprod Fertil Dev** 1995;7(3):431-41 (67 ref.)
[Reflux associated respiratory tract diseases] Jaspersen D. **Dtsch Med Wochenschr** 1996 Apr 5;121(14):449-52 (56 ref.) **(Ger)**

IMMUNOLOGY

Psychobiologic reactivity to stress and childhood respiratory illnesses: results of two prospective studies. Boyce WT, et al. **Psychosom Med** 1995 Sep-Oct;57(5):411-22 (113 ref.)

MICROBIOLOGY

Health effects of indoor-air microorganisms [see comments] Husman T. **Scand J Work Environ Health** 1996 Feb;

22(1):5–13 (95 ref.) Comment in: Scand J Work Environ Health 1996 Feb;22(1):1–3.

PHYSIOPATHOLOGY

Inflammation and asthma. Horwitz RJ, et al. **Clin Chest Med** 1995 Dec;16(4):583–602 (161 ref.)

Tachykinin peptides, receptors, and peptidases in airway disease. Piedimonte G. **Exp Lung Res** 1995 Nov–Dec; 21(6):809–34 (154 ref.)

PSYCHOLOGY

Panic anxiety, dyspnea, and respiratory disease. Theoretical and clinical considerations. Smoller JW, et al. **Am J Respir Crit Care Med** 1996 Jul;154(1):6–17 (220 ref.)

RADIOGRAPHY

A radiologic update on medical diseases of the newborn chest. Cleveland RH. **Pediatr Radiol** 1995;25(8):631–7 (17 ref.)

REHABILITATION

[Rehabilitation of patients with respiratory system diseases] Laitinen LA, et al. **Duodecim** 1994;110(15):1439–45 (20 ref.) **(Fin)**

SURGERY

Laser bronchoscopy. Colt HG. **Chest Surg Clin N Am** 1996 May;6(2):277–91 (60 ref.)

Respiratory mucosa wound healing and its management. An overview. Dohar JE, et al. **Otolaryngol Clin North Am** 1995 Oct;28(5):897–912 (28 ref.)

[Application of thoracoscopy for diagnosis and therapy of respiratory tract diseases] Inui K. **Nippon Naika Gakkai Zasshi** 1995 Sep 10;84(9):1594–9 (18 ref.) **(Jpn)**

THERAPY

Enteral nutrition in patients with respiratory disease. Pingleton SK. **Eur Respir J** 1996 Feb;9(2):364–70 (58 ref.)

Primary care for women. Management of common respiratory problems. Mays M, et al. **J Nurse Midwifery** 1996 Mar–Apr;41(2):139–54 (50 ref.)

VETERINARY

Diseases of the respiratory tract in psittacine birds. Zwart P. **Vet Q** 1995 Apr;17 Suppl 1:S52–3 (3 ref.)

RESPIRATORY TRACT INFECTIONS

The clinical impact of human respiratory virus infections. Denny FW Jr. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 2):S4–12 (40 ref.)

Fever without apparent source on clinical examination, lower respiratory infections in children, other infectious diseases, and acute gastroenteritis and diarrhea of infancy and early childhood. McCarthy PL, et al. **Curr Opin Pediatr** 1996 Feb;8(1):75–93 (134 ref.)

Anaesthesia in children with viral respiratory tract infections. Van der Walt J. **Paediatr Anaesth** 1995;5(4):257–62 (25 ref.)

Severe pulmonary infections in AIDS patients. Gatell JM, et al. **Semin Respir Infect** 1996 Jun;11(2):119–28 (57 ref.)

[Respiratory system changes in persons infected with the HIV virus] Niemirowska H. **Pneumonol Pol** 1990 Sep–Oct; 58(9–10):549–58 (42 ref.) **(Pol)**

BLOOD

Recent-onset myelodysplastic syndrome mimicking acute leukemia during infection. Friedman HD, et al. **Ann Hematol** 1996 Feb;72(2):85–8 (23 ref.)

COMPLICATIONS

Acute bronchial infection in chronic obstructive pulmonary disease. Dorca J. **Monaldi Arch Chest Dis** 1995 Oct; 50(5):366–71 (43 ref.)

The role of inflammation in the pathogenesis of bronchopulmonary dysplasia. Pierce MR, et al. **Pediatr Pulmonol** 1995 Jun;19(6):371–8 (89 ref.)

[The role of viral respiratory tract infections on pathogenesis of bronchial asthma. I. Clinical and experimental investigations] Kroczyńska-Bednarek J, et al. **Pneumonol Alergol Pol** 1995;63(9–10):566–9 (35 ref.) **(Pol)**

[Early identification of respiratory viruses in asthmatic children] Morfin Maciel BM, et al. **Rev Alerg Mex** 1996 Mar–Apr;43(2):45–8 (22 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Managing HIV. Part 5: Treating secondary outcomes. 5.7 HIV and respiratory disease. Smith AI, et al. **Med J Aust** 1996 Apr 1;164(7):425–8 (33 ref.)

Pulmonary sarcoidosis: a mimic of respiratory infection. Blackmon GM, et al. **Semin Respir Infect** 1995 Sep; 10(3):176–86 (79 ref.)

Chlamydia pneumoniae: defining the clinical spectrum of infection requires precise laboratory diagnosis. Bourke SJ, et al. **Thorax** 1995 Sep;50 Suppl 1:S43–8 (50 ref.)

[Pathogenesis and diagnosis of bacterial airway infections in patients with cystic fibrosis] Möller AV, et al. **Ned Tijdschr Geneeskd** 1995 Nov 18;139(46):2346–9 (28 ref.) **(Dut)**

[Belching, flatus, breath. Measurements of airborne nitric oxide in the non-invasive diagnosis of inflammation] Lundberg J, et al. **Lakartidningen** 1996 May 15; 93(20):1945–8 (22 ref.) (Eng. Abstr.) **(Swe)**

DRUG THERAPY

Resistant respiratory pathogens and extended-spectrum antibiotics. Pichichero ME. **Am Fam Physician** 1995 Nov 1;52(6):1739–46 (30 ref.)

Sequential therapy in the hospital management of lower respiratory infections. Vogel F. **Am J Med** 1995 Dec 29; 99(6B):14S–19S (27 ref.)

Emerging resistance to antibiotics: impact on respiratory infections in the outpatient setting. Green M, et al. **Ann Allergy Asthma Immunol** 1996 Sep;77(3):167–73; quiz 173–5 (21 ref.)

Oral cephalosporins in upper respiratory infections. Leibovitz E, et al. **Antibiot Chemother** 1995;47:110–22 (106 ref.)

Oral cephalosporins: clinical results in lower respiratory tract infections. Pozzi E, et al. **Antibiot Chemother** 1995; 47:123–44 (100 ref.)

The role of new quinolones in the treatment of respiratory tract infections. Finch RG. **Drugs** 1995;49 Suppl 2:144–51 (20 ref.)

A guide to the treatment of lower respiratory tract infections. Vogel F. **Drugs** 1995 Jul;50(1):62–72 (56 ref.)

Antimicrobial agents for community-acquired respiratory tract infections. Barry AL. **Infection** 1995;23 Suppl 2:S59–63; discussion S64 (25 ref.)

In-vitro activity of sparfloxacin in comparison with currently available antimicrobials against respiratory tract pathogens. Baquero F, et al. **J Antimicrob Chemother** 1996 May;37 Suppl A:1–18 (76 ref.)

The place of tobramycin in lower respiratory tract infections (LRTI). Gialdroni Grassi G. **J Chemother** 1995 Aug; 7(4):344–54 (80 ref.)

Once-daily dosing regimen for aminoglycoside plus betalactam combination therapy of serious lower respiratory tract infections. Paradisi F, et al. **J Chemother** 1995 Aug;7(4):338–43 (54 ref.)

Rational selection of antimicrobials for pediatric upper respiratory infections. Harrison CJ. **Pediatr Infect Dis J** 1995 Jul;14(7 Suppl):S121–9 (28 ref.)

Ceftibuten: minimal inhibitory concentrations, postantibiotic effect and beta-lactamase stability—a rationale for dosing programs. Neu HC. **Pediatr Infect Dis J** 1995 Jul;14(7 Suppl):S88–92 (29 ref.)

Antibiotic resistance: relationship to persistence of group A streptococci in the upper respiratory tract. Gerber MA. **Pediatrics** 1996 Jun;97(6 Pt 2):971–5 (59 ref.)

[Are antibiotics necessary for a child with the flu? (editorial)] Mäkelä M, et al. **Duodecim** 1995;111(7):583–4 (12 ref.) **(Fin)**

[Role of macrolides in the treatment of respiratory tract infections in children] Floret D. **Arch Pediatr** 1995 Dec; 2(12):1184–91 (41 ref.) (Eng. Abstr.) **(Fre)**

[Antibiotics in aerosols] Héritier F. **Rev Med Suisse Romande** 1996 May;116(5):341–4 (30 ref.) **(Fre)**

EPIDEMIOLOGY

Viral respiratory infections and their role as public health problem in tropical countries (review). Karaivanova GM. **Afr J Med Med Sci** 1995 Mar;24(1):1–7 (72 ref.)

Branhamella catarrhalis: epidemiology, surface antigenic structure, and immune response. Murphy TF. **Microbiol Rev** 1996 Jun;60(2):267–79 (186 ref.)

ETIOLOGY

Psychological stress and susceptibility to upper respiratory infections. Cohen S. **Am J Respir Crit Care Med** 1995 Oct; 152(4 Pt 2):S53–8 (43 ref.)

Environmental factors and primary T-cell sensitisation to inhalant allergens in infancy: reappraisal of the role of infections and air pollution. Holt PG. **Pediatr Allergy Immunol** 1995 Feb;6(1):1–10 (85 ref.)

Antibiotic resistance: relationship to persistence of group A streptococci in the upper respiratory tract. Gerber MA. **Pediatrics** 1996 Jun;97(6 Pt 2):971–5 (59 ref.)

Severe exacerbations of COPD patients: the role of pulmonary infections. Fagon JY, et al. **Semin Respir Infect** 1996 Jun;11(2):109–18 (62 ref.)

IMMUNOLOGY

Role of inflammation in respiratory tract infections. Stockley RA. **Am J Med** 1995 Dec 29;99(6B):8S–13S (15 ref.)

[Role of viral respiratory tract infections on the pathogenesis of bronchial asthma. II. Effect on the immune system] Kroczyńska-Bednarek J, et al. **Pneumonol Alergol Pol** 1995; 63(9–10):570–6 (40 ref.) **(Pol)**

MICROBIOLOGY

Pathogenesis of bacterial infections of the respiratory tract. Johnson JA. **Br J Biomed Sci** 1995 Jun;52(2):157–61 (10 ref.)

In-vitro activity of sparfloxacin in comparison with currently available antimicrobials against respiratory tract pathogens. Baquero F, et al. **J Antimicrob Chemother** 1996 May;37 Suppl A:1–18 (76 ref.)

[Cystic fibrosis and Burkholderia (formerly Pseudomonas) cepacia: an increasing clinical and psychosocial problem] Horrevorts AM, et al. **Ned Tijdschr Geneeskd** 1995 Nov 18;139(46):2343–6 (31 ref.) **(Dut)**

[Mechanism of antibiotic resistance in bacteria responsible for respiratory infections] Dye D, et al. **Rev Mal Respir** 1995;12(5):415–27 (67 ref.) (Eng. Abstr.) **(Fre)**

[Procedures of viral identification in respiratory infections] Aspa J, et al. **Arch Bronconeumol** 1995 Nov;31(9):470–80 (132 ref.) **(Spa)**

PHYSIOPATHOLOGY

Respiratory infections and wheezing in children. Landau LI. **Curr Opin Pediatr** 1996 Feb;8(1):3–5 (17 ref.)

PREVENTION & CONTROL

Preventing bacterial respiratory tract infections among persons infected with human immunodeficiency virus. Keller DW, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S77–83 (66 ref.)

Inhalation of antibiotics in cystic fibrosis. Touw DJ, et al. **Eur Respir J** 1995 Sep;8(9):1594–604 (65 ref.)

[Prevention and therapy of airway infections in patients with cystic fibrosis] Möller AV, et al. **Ned Tijdschr Geneeskd** 1995 Nov 18;139(46):2350–3 (26 ref.) **(Dut)**

[Mucosal immunity with implications for use in developing a new generation of vaccines] Osek J, et al. **Postepy Hig Med Dosw** 1995;49(4):469–86 (62 ref.) (Eng. Abstr.) **(Pol)**

THERAPY

Assessment of the clinical value of using an immunomodulator in recurrent respiratory infections. Bergmann KC. **Adv Exp Med Biol** 1995;371B:795–7 (15 ref.)

Acute respiratory infection: a global challenge. Campbell H. **Arch Dis Child** 1995 Oct;73(4):281–3 (38 ref.)

Atopic disease, rhinitis and conjunctivitis, and upper respiratory infections. Wood RA, et al. **Curr Opin Pediatr** 1995 Oct;7(5):615–27 (63 ref.)

TRANSMISSION

Common infectious diseases. Bagg J. **Dent Clin North Am** 1996 Apr;40(2):385–93 (33 ref.)

Virology research and virulent human pandemics. Mims CA. **Epidemiol Infect** 1995 Dec;115(3):377–86 (49 ref.)

VETERINARY

[Significance of PRRS virus infections for respiratory tract infections in swine—a literature review] Beilage EG. **DTW Dtsch Tierarztl Wochenschr** 1995 Dec;102(12):457–69 (127 ref.) (Eng. Abstr.) **(Ger)**

[Infectious coryza: review of diagnostic methods and vaccines] Blackall PJ, et al. **Rev Argent Microbiol** 1995 Jul–Sep;27(3):156–74 (62 ref.) **(Spa)**

VIROLOGY

Viral respiratory infections in the community: epidemiology, agents, and interventions. Monto AS. **Am J Med** 1995 Dec 29;99(6B):24S–27S (14 ref.)

Common infectious diseases. Bagg J. **Dent Clin North Am** 1996 Apr;40(2):385–93 (33 ref.)

RESPIRATORY TRACT NEOPLASMS

SURGERY

Laser bronchoscopy. Colt HG. **Chest Surg Clin N Am** 1996 May;6(2):277–91 (60 ref.)

RESPITE CARE

The parents of a severely dependent child. Keeley D, et al. **Practitioner** 1995 Sep;239(1554):505–8, 510, 512 (0 ref.)

RESPONSE, ACUTE-PHASE see **ACUTE-PHASE REACTION**

RESPONSE LATENCY see **REACTION TIME**

RESPONSE TIME see **REACTION TIME**

RESPONSIBILITY, SOCIAL see **SOCIAL RESPONSIBILITY**

REST

see related
BED REST

RESTING PHASE see **INTERPHASE**

RESTING POTENTIALS see **MEMBRANE POTENTIALS**

RESTLESS LEGS

Restless legs syndrome. A review. O'Keeffe ST.

Arch Intern Med 1996 Feb 12;156(3):243–8 (116 ref.)

DIAGNOSIS

Toward a better definition of the restless legs syndrome. The International Restless Legs Syndrome Study Group. Walters AS. Mov Disord 1995 Sep;10(5):634–42 (142 ref.)

DRUG THERAPY

[Therapy of idiopathic and uremic restless legs syndrome] Trenkwalder C, et al. Nervenarzt 1996 Apr;67(4):265–76 (79 ref.) (Eng. Abstr.) (Ger)

RESTLESSNESS see PSYCHOMOTOR AGITATION

RESTRAINT, PHYSICAL

see related
IMMOBILIZATION
PROTECTIVE DEVICES

Control and restraint in contemporary psychiatric nursing: some ethical considerations. Hopton J. J Adv Nurs 1995 Jul;22(1):110–5 (48 ref.)

Physical restraint use in the hospital setting: unresolved issues and directions for research. Mion LC, et al. Milbank Q 1996;74(3):411–33 (80 ref.)

Physical restraint procedures for managing challenging behaviours presented by mentally retarded adults and children. Harris J. Res Dev Disabil 1996 Mar–Apr; 17(2):99–134 (52 ref.)

RESTRICTION ENDONUCLEASES see DNA RESTRICTION ENZYMES

RESTRICTION FRAGMENT LENGTH POLYMORPHISM see POLYMORPHISM, RESTRICTION FRAGMENT LENGTH

RESTRICTION MAPPING

Optical mapping: a novel, single-molecule approach to genomic analysis. Samad A, et al. Genome Res 1995 Aug; 5(1):1–4 (12 ref.)

Analysis of bacterial genomes by pulsed field gel electrophoresis. Méndez-Alvarez S, et al. Microbiologia 1995 Sep;11(3):323–36 (93 ref.)

RESUSCITATION

Recommended guidelines for uniform reporting of pediatric advanced life support: the pediatric Utstein style. American Academy of Pediatrics, American Heart Association and the European Resuscitation Council. Zaritsky A, et al. Ann Emerg Med 1995 Oct;26(4):487–503 (60 ref.)

Cerebral resuscitation from cardiac arrest: pathophysiologic mechanisms. Vaagenes P, et al. Crit Care Med 1996 Feb; 24(2 Suppl):S57–68 (103 ref.)

Trauma systems, shock, and resuscitation. Fallon WF. Curr Opin Gen Surg 1993;:40–5 (24 ref.)

Resuscitation of the pediatric patient. Rosenberg MB, et al. Dent Clin North Am 1995 Jul;39(3):663–76 (26 ref.)

Acute blood loss. Baron BJ, et al. Emerg Med Clin North Am 1996 Feb;14(1):35–55 (64 ref.)

Resuscitating the pediatric patient. Wright JL, et al. Emerg Med Clin North Am 1996 Feb;14(1):219–31 (36 ref.)

Controversies in neonatal resuscitation. Jain L, et al. Pediatr Ann 1995 Oct;24(10):540–5 (33 ref.)

Self-efficacy in pediatric resuscitation: implications for education and performance. Maibach EW, et al. Pediatrics 1996 Jan;97(1):94–9 (33 ref.)

Recommended guidelines for uniform reporting of pediatric advanced life support: the pediatric Utstein style. A statement for healthcare professionals from a task force of the American Academy of Pediatrics, the American Heart Association, and the European Resuscitation Council. Zaritsky A, et al. Pediatrics 1995 Oct;96(4 Pt 1):765–79 (60 ref.)

The opioid/anti-opioid balance in shock: a new target for therapy in resuscitation. Bertolini A. Resuscitation 1995 Aug;30(1):29–42 (177 ref.)

[Invasive aspergillosis during resuscitation (comment)] Coronel B, et al. Ann Fr Anesth Reanim 1995;14(5):454–5 (13 ref.) Comment on: Ann Fr Anesth Reanim 1995;14(2):198–208. (Fre)

[Cerebral resuscitation: pathophysiological limitations and therapeutic possibilities (editorial)] Strebel S. Schweiz Rundsch Med Prax 1996 Jan 16;85(3):35–8 (33 ref.) (Ger)

ADVERSE EFFECTS

[Complications in preclinical resuscitation] Kersting A, et al. Dtsch Med Wochenschr 1995 Oct 27;120(43):1475–8 (30 ref.) (Ger)

METHODS

Resuscitation medicine research: quo vadis. Safar P. Ann Emerg Med 1996 May;27(5):542–52 (113 ref.)

Cardiopulmonary bypass for resuscitation after penetrating cardiac trauma. Karmy-Jones R, et al. Ann Thorac Surg 1996 Apr;61(4):1244–5 (5 ref.)

The use of colloids in clinical practice. Cone A. Br J Hosp Med 1995 Aug 16–Sep 5;54(4):155–9 (20 ref.)

Effective interventions for nearly drowned children. Macnab AJ. Can Fam Physician 1995 Sep;41:1545–8, 1551–2, 1555–6 (32 ref.)

Suspended animation for delayed resuscitation. Bellamy R, et al. Crit Care Med 1996 Feb;24(2 Suppl):S24–47 (137 ref.)

Cerebral resuscitation from cardiac arrest: treatment potentials. Gisvold SE, et al. Crit Care Med 1996 Feb;24(2 Suppl):S69–80 (79 ref.)

Resuscitative hypothermia. Marion DW, et al. Crit Care Med 1996 Feb;24(2 Suppl):S81–9 (75 ref.)

Resuscitation from severe brain trauma. Rosomoff HL, et al. Crit Care Med 1996 Feb;24(2 Suppl):S48–56 (69 ref.)

Cardiac arrest. DeBehnke DJ, et al. Emerg Med Clin North Am 1996 Feb;14(1):57–81 (112 ref.)

Resuscitation of the geriatric patient. Milzman DP, et al. Emerg Med Clin North Am 1996 Feb;14(1):233–44 (50 ref.)

Triage of critically ill patients: an overview of interventions. Rady MY. Emerg Med Clin North Am 1996 Feb;14(1):13–33 (91 ref.)

[Resuscitation in severe hepatic injuries] Wodey E, et al. Cah Anesthesiol 1996;44(1):55–69 (131 ref.) (Eng. Abstr.) (Fre)

STANDARDS

Fluid resuscitation of the trauma patient: how much is enough? Hamiliton SM, et al. Can J Surg 1996 Feb; 39(1):11–6 (39 ref.)

[Consensus 'Basic Resuscitation' from the Nederlandse Reanimatie Raad] van Vliet J. Ned Tijdschr Geneeskd 1996 Mar 16;140(11):596–9 (13 ref.) (Dut)

RESUSCITATION DECISIONS see RESUSCITATION ORDERS

RESUSCITATION ORDERS

Discussing cardiopulmonary resuscitation with patients and relatives. Stewart K. Postgrad Med J 1995 Oct; 71(840):585–9 (30 ref.)

Do-not-resuscitate orders: towards a policy in Singapore [see comments] Sahadevan S, et al. Singapore Med J 1995 Jun; 36(3):267–70 (28 ref.) Comment in: Singapore Med J 1995 Jun;36(3):258–9.

RETAINERS, ORTHODONTIC see ORTHODONTIC RETAINERS

RETE TESTIS

Adenocarcinoma of the rete testis. Sánchez-Chapado M, et al. Urology 1995 Oct;46(4):468–75 (48 ref.)

[Cystic ectasia of the rete testis: apropos of a case] Poddevin F, et al. J Urol (Paris) 1996;102(2):92–4 (10 ref.) (Eng. Abstr.) (Fre)

RETENTION (PSYCHOLOGY)

What do infants recall of their lives? Memory for specific events by one- to two-year-olds. Bauer PJ. Am Psychol 1996 Jan;51(1):29–41 (75 ref.)

Say it once again: effects of repeated questions on children's event recall. Fivush R, et al. J Trauma Stress 1995 Oct; 8(4):555–80 (75 ref.)

Children's long-term retention of salient personal experiences. Ornstein PA. J Trauma Stress 1995 Oct; 8(4):581–605 (60 ref.)

Long-term retention of memory for preverbal experience: evidence and implications. Nelson K. Memory 1994 Dec; 2(4):467–75 (5 ref.)

Monitoring and control processes in the strategic regulation of memory accuracy. Koriat A, et al. Psychol Rev 1996 Jul;103(3):490–517 (140 ref.)

PHYSIOLOGY

[Remembering in the transference--on the interdisciplinary dialogue between psychoanalysis and biological memory research] Leuzinger-Bohleber M. Psychother Psychosom Med Psychol 1996 Jun;46(6):217–27 (53 ref.) (Eng. Abstr.) (Ger)

RETICULAR FORMATION

PHYSIOLOGY

The pedunculopontine tegmental nucleus: where the striatum meets the reticular formation. Inglis WL, et al. Prog Neurobiol 1995 Sep;47(1):1–29 (205 ref.)

Arousal: revisiting the reticular activating system [comment] Steriade M. Science 1996 Apr 12;272(5259):225–6 (14 ref.) Comment on: Science 1996 Apr 12;272(5259):271–4. Comment on: Science 1996 Apr 12;272(5259):274–7.

RETICULOENDOTHELIAL SYSTEM

see related
HISTIOCYTES
KUPFFER CELLS
MACROPHAGES
PHAGOCYTES

PHYSIOPATHOLOGY

[Hepatic reticuloendothelial failure (HREF)] Masumoto A, et al. Ryoikibetsu Shokogun Shirizu 1995;(8):437–9 (20 ref.) (Jpn)

RETICULOENDOTHELIOSIS, LEUKEMIC see LEUKEMIA, HAIRY CELL

RETICULOENDOTHELIOSIS VIRUS, AVIAN

Lymphoid leukosis viruses, their recognition as 'persistent' viruses and comparisons with certain other retroviruses of veterinary importance. Darcel C. Vet Res Commun 1996; 20(1):83–108 (112 ref.)

RETICULOHISTIOCYTOMA see HISTIOCYTOSIS, NON-LANGERHANS-CELL

RETICULOLYMPHOSARCOMA see LYMPHOMA

RETICULUM-CELL SARCOMA see LYMPHOMA, LARGE-CELL

RETINA

see related
ELECTRORETINOGRAPHY

CYTOLOGY

Axon guidance: following the Eph plan. Orike N, et al. Curr Biol 1996 Feb 1;6(2):108–10 (15 ref.)

Transforming growth factor-beta-3 is mitogenic for rat retinal progenitor cells in vitro. Anchan RM, et al. J Neurobiol 1995 Oct;28(2):133–45 (50 ref.)

Receptive field structure in the primate retina. Lee BB. Vision Res 1996 Mar;36(5):631–44 (97 ref.)

EMBRYOLOGY

Retinal cultures. Finlay D, et al. Methods Cell Biol 1996; 51:265–83 (23 ref.)

Mechanisms and molecules controlling the development of retinal maps. Roskies A, et al. Perspect Dev Neurobiol 1995; 3(1):63–75 (122 ref.)

GROWTH & DEVELOPMENT

Developmental neurotransmitters. Signals for shaping neuronal circuitry. Redburn DA, et al. Invest Ophthalmol Vis Sci 1996 Jul;37(8):1479–82 (16 ref.)

IMMUNOLOGY

[Retinal antigens in eye diseases--clinical value of diagnostic tests] Misiuk-Hojło M, et al. Klin Oczna 1995 Mar–Apr; 97(3–4):86–9 (26 ref.) (Eng. Abstr.) (Pol)

INJURIES

An unusual intraocular foreign body. Gupta AK, et al. Acta Ophthalmol Scand 1996 Apr;74(2):200–1 (3 ref.)

METABOLISM

Somatostatin in the retina. Larsen JN. Acta Ophthalmol Scand Suppl 1995;(218):1–24 (91 ref.)

Ocular oxygen measurement. Hogeboom van Buggenum IM, et al. Br J Ophthalmol 1996 Jun;80(6):567–73 (110 ref.)

Calcium homeostasis in vertebrate retinal rod outer segments. Schnetkamp PP. Cell Calcium 1995 Oct;18(4):322–30 (54 ref.)

Neurotransmitters in the retina. Pourcho RG. Curr Eye Res 1996 Jul;15(7):797–803 (81 ref.)

Gap junctions in the vertebrate retina. Cook JE, et al. Microsc Res Tech 1995 Aug 1;31(5):408–19 (123 ref.)

Retinal oxygen distribution. Its role in the physiopathology of vasoproliferative microangiopathies. Pournaras CJ. Retina 1995;15(4):332–47 (143 ref.)

PATHOLOGY

Retinal nerve fiber layer [editorial; comment] Sommer A. Am J Ophthalmol 1995 Nov;120(5):665–7 (20 ref.) Comment on: Am J Ophthalmol 1995 Nov;120(5):577–86.

Retinopathy in animal models of diabetes. Engerman RL, et al. Diabetes Metab Rev 1995 Jul;11(2):109–20 (88 ref.)

The subretinal fibrosis and uveitis syndrome. Kaiser PK, et al. Int Ophthalmol Clin 1996 Winter;36(1):145–52 (19 ref.)

Recent advances in understanding the spectrum of canine generalised progressive retinal atrophy. Clements PJ, et al. J Small Anim Pract 1996 Apr;37(4):155–62 (54 ref.)

PHYSIOLOGY

Microfilament organization and wound repair in retinal pigment epithelium. Kalnins VI, et al. Biochem Cell Biol 1995 Sep–Oct;73(9–10):709–22 (97 ref.)

Plasticity following neonatal visual cortex damage in cats. Spear PD. Can J Physiol Pharmacol 1995 Sep;73(9):1389–97 (40 ref.)

Retinal development. Waves are swell. Catsicas M, et al. Curr Biol 1995 Sep 1;5(9):977–9 (20 ref.)

Retinal-image mediated ocular growth as a mechanism for juvenile onset myopia and for emmetropization. A

literature review. Goss DA, et al. **Doc Ophthalmol** 1995; 90(4):341–75 (182 ref.)
Substance P: a neurotransmitter of amacrine and ganglion cells in the vertebrate retina. Kolb H, et al. **Histol Histopathol** 1995 Oct;10(4):947–68 (127 ref.)
Developmental neurotransmitters. Signals for shaping neuronal circuitry. Redburn DA, et al. **Invest Ophthalmol Vis Sci** 1996 Jul;37(8):1479–82 (16 ref.)
Amino acids in neurotransmission and disease. Kalloniatis M. **J Am Optom Assoc** 1995 Dec;66(12):750–7 (57 ref.)
On the functional significance of primate retinal dopamine receptors. Bodis-Wollner I, et al. **J Neural Transm Suppl** 1995;45:67–74 (32 ref.)
Beta wave of the scotopic (rod) electroretinogram as a measure of the activity of human on-bipolar cells. Hood DC, et al. **J Opt Soc Am A** 1996 Mar;13(3):623–33 (54 ref.)
TRP is cracked but is CRAC TRP? Clapham DE. **Neuron** 1996 Jun;16(6):1069–72 (17 ref.)
Electrophysiology of the visual system: from neuroscience to human neuropharmacology. Sannita WG. **Neuropsychobiology** 1995;32(4):208–13 (44 ref.)
Physiological activity of retinoids in natural and artificial visual pigments. Corson DW, et al. **Photochem Photobiol** 1996 May;63(5):595–600 (61 ref.)
Circuitry for color coding in the primate retina. Dacey DM. **Proc Natl Acad Sci U S A** 1996 Jan 23;93(2):582–8 (55 ref.)
Emergence of order in visual system development. Shatz CJ. **Proc Natl Acad Sci U S A** 1996 Jan 23;93(2):602–8 (61 ref.)
Transdifferentiation and retinal regeneration. Reh TA, et al. **Semin Cell Biol** 1995 Jun;6(3):137–42 (50 ref.)
[Cell sources, regulatory factors and gene expression in the regeneration of the crystalline lens and retina in vertebrate animals] Mitashov VI. **Izv Akad Nauk Ser Biol** 1996 May-Jun;(3):298–318 (183 ref.) (Eng. Abstr.) **(Rus)**
[The urodelean retina as a model for studying the retinal regeneration potentials of other vertebrates] Grigorian EN. **Ontogenez** 1996 May-Jun;27(3):173–85 (117 ref.) (Eng. Abstr.) **(Rus)**

TRANSPLANTATION

[Retinal grafts: biological problems and clinical stakes] Sahel JA, et al. **Bull Acad Natl Med** 1996 Mar;180(3):633–43; discussion 643–4 (24 ref.) (Eng. Abstr.) **(Fre)**

RETINAL see **RETINALDEHYDE**

RETINAL ARTERY

[Chronic ischemic ophthalmopathy in Takayasu-Onishi disease] Chercoţă G, et al. **Oftalmologia** 1996 Jan-Mar; 40(1):39–44 (19 ref.) (Eng. Abstr.) **(Rum)**

RETINAL ARTERY OCCLUSION

DIAGNOSIS

Retinal artery occlusion [clinical conference] Mangat HS. **Surv Ophthalmol** 1995 Sep-Oct;40(2):145–56 (100 ref.)

RETINAL BREAKS see **RETINAL PERFORATIONS**

RETINAL DEGENERATION

GENETICS

Retinal dystrophies and genetic counselling. Jay M, et al. **Acta Ophthalmol Scand Suppl** 1996;(219):3–7 (31 ref.)

PHYSIOPATHOLOGY

Mechanisms of photoreceptor death in retinal degenerations. From the cell biology of the 1990s to the ophthalmology of the 21st century? Adler R. **Arch Ophthalmol** 1996 Jan; 114(1):79–83 (43 ref.)

RETINAL DETACHMENT

COMPLICATIONS

[Treatment of vitreoretinal proliferation in rhegmatogenous detachment and silicone oil tamponade] Berrod JP, et al. **J Fr Ophtalmol** 1996;19(2):97–105 (32 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Atopic retinal detachment. Report of four cases and a review of the literature. Yoneda K, et al. **Br J Dermatol** 1995 Oct; 133(4):586–91 (78 ref.)

SURGERY

The use of silicone oil for HIV-related retinal detachment [editorial; comment] Blumenkranz MS. **Arch Ophthalmol** 1995 Nov;113(11):1366–8 (14 ref.) Comment on: Arch Ophthalmol 1995 Nov;113(11):1401–9.
[Treatment with silicone oil in complicated retinal detachment. Anatomopathological test of 2 enucleated eyes] Bacin F, et al. **J Fr Ophtalmol** 1996;19(1):13–8 (25 ref.) (Eng. Abstr.) **(Fre)**
[The indications for vitrectomy in retinal detachment] Nicoară S. **Oftalmologia** 1995 Oct-Dec;39(4):362–7 (10 ref.) (Eng. Abstr.) **(Rum)**

RETINAL DIALYSES see **RETINAL PERFORATIONS**

RETINAL DISEASES

Vitreoretinal emergencies. Reichel E. **Am Fam Physician** 1995 Oct;52(5):1415–9 (16 ref.)
Advances in macular dystrophies. Saperstein DA. **Int Ophthalmol Clin** 1995 Fall;35(4):19–35 (65 ref.)

CHEMICALLY INDUCED

Retinal toxicity associated with commonly encountered systemic agents. Blair JR, et al. **Int Ophthalmol Clin** 1995 Fall;35(4):137–56 (171 ref.)

COMPLICATIONS

Glaucoma and findings simulating glaucoma in the Rubinstein-Taybi syndrome. Brei TJ, et al. **J Pediatr Ophthalmol Strabismus** 1995 Jul-Aug; 32(4):248–52 (56 ref.)
[Central serous chorioretinopathy in a pregnant woman] Khairallah M, et al. **J Fr Ophtalmol** 1996;19(3):216–21 (14 ref.) (Eng. Abstr.) **(Fre)**
[Vision disorders to vascular dysregulation] Flammer F, et al. **Ther Umsch** 1996 Jan;53(1):37–42 (20 ref.) (Eng. Abstr.) **(Ger)**

CONGENITAL

Congenital and childhood macular lesions. Drack AV. **Int Ophthalmol Clin** 1995 Fall;35(4):1–18 (34 ref.)

DIAGNOSIS

The ERG is alive and well [editorial; comment] Marmor MF. **Arch Ophthalmol** 1995 Nov;113(11):1371–2 (11 ref.) Comment on: Arch Ophthalmol 1995 Nov;113(11):1375–6.
Acute posterior multifocal placoid pigment epitheliopathy. Heath JD, et al. **Int Ophthalmol Clin** 1995 Spring; 35(2):93–105 (43 ref.)
Indocyanine green angiography. Lim JI, et al. **Int Ophthalmol Clin** 1995 Fall;35(4):59–70 (49 ref.)
MEWDS, MFC, PIC, AMN, AIBSE, and AZOOR: one disease or many? [editorial] Jampol LM, et al. **Retina** 1995; 15(5):373–8 (21 ref.)
[Dragged disk syndrome. Review of etiologies. Apropos of a case] Barreau E, et al. **J Fr Ophtalmol** 1996;19(1):58–63 (16 ref.) (Eng. Abstr.) **(Fre)**
[AIDS: infections of the retina and choroid] Schimkat M, et al. **Bildgebung** 1995 Dec;62(4):288–301 (100 ref.) (Eng. Abstr.) **(Ger)**
[A case of uncomplicated retinal astrocytoma] Ikeda T, et al. **Nippon Ganka Gakkai Zasshi** 1995 Sep;99(9):1052–5 (21 ref.) (Eng. Abstr.) **(Jpn)**

ETIOLOGY

Macular epiretinal membrane formation and treated retinal breaks. Saran BR, et al. **Am J Ophthalmol** 1995 Oct; 120(4):480–5 (27 ref.)
Intraoperative retinal phototoxicity. Michels M. **Int Ophthalmol Clin** 1995 Fall;35(4):157–72 (91 ref.)
[Paraneoplastic retinopathy associated with cutaneous melanoma. An update apropos of a case] Rougier MB, et al. **J Fr Ophtalmol** 1995;18(5):396–403 (16 ref.) (Eng. Abstr.) **(Fre)**
[Severe hereditary retinal diseases in childhood] Lorenz B. **Ther Umsch** 1996 Jan;53(1):7–19 (13 ref.) (Eng. Abstr.) **(Ger)**

GENETICS

Congenital and childhood macular lesions. Drack AV. **Int Ophthalmol Clin** 1995 Fall;35(4):1–18 (34 ref.)
Necessary but insufficient. Papermaster DS. **Nat Med** 1995 Sep;1(9):874–5 (9 ref.)

PHYSIOPATHOLOGY

Neurological manifestations of acute posterior multifocal placoid pigment epitheliopathy. Comu S, et al. **Stroke** 1996 May;27(5):996–1001 (38 ref.)

THERAPY

Multimodal management of diffuse neonatal hemangiomatosis. Stratte EG, et al. **J Am Acad Dermatol** 1996 Feb;34(2 Pt 2):337–42 (36 ref.)

VETERINARY

Retinal diseases: an update. Nasisse MP. **Vet Q** 1995 Apr; 17 Suppl 1:S43–5 (0 ref.)

RETINAL GANGLION CELLS

PATHOLOGY

Ganglion cell death in glaucoma: pathology recapitulates ontogeny. Quigley HA. **Aust N Z J Ophthalmol** 1995 May; 23(2):85–91 (42 ref.)
Evaluation of the retinal nerve fiber layer. Jonas JB, et al. **Surv Ophthalmol** 1996 Mar-Apr;40(5):369–78 (107 ref.)
[Ophthalmoscopic study of the retinal nerve fiber layer] Jonas JB, et al. **Klin Monatsbl Augenheilkd** 1996 Feb;208(2):aA3–9 (0 ref.) **(Ger)**

PHYSIOLOGY

Tubulin expression and axonal transport in injured and regenerating neurons in the adult mammalian central nervous system. Fournier AE, et al. **Biochem Cell Biol** 1995 Sep-Oct;73(9–10):659–64 (39 ref.)
Substance P: a neurotransmitter of amacrine and ganglion cells in the vertebrate retina. Kolb H, et al. **Histol Histopathol** 1995 Oct;10(4):947–68 (127 ref.)
Multineuronal codes in retinal signaling. Meister M. **Proc Natl Acad Sci U S A** 1996 Jan 23;93(2):609–14 (32 ref.)
Molecular biology of retinal ganglion cells. Xiang M, et al. **Proc Natl Acad Sci U S A** 1996 Jan 23;93(2):596–601 (41 ref.)

RETINAL HEMORRHAGE

Subretinal hemorrhage. Lim JI. **Int Ophthalmol Clin** 1995 Fall;35(4):95–104 (26 ref.)

DIAGNOSIS

Six signs in children with life-threatening implications. Tien DR. **R I Med** 1995 Dec;78(12):342–5 (6 ref.)

ETIOLOGY

Purtscher's retinopathy associated with mandibular fracture: a case report. Peled M, et al. **J Trauma** 1996 Jan;40(1):141–3 (11 ref.)

RETINAL HOLES see **RETINAL PERFORATIONS**

RETINAL NECROSIS SYNDROME, ACUTE

[Acute retinal necrosis syndrome] Labetoulle M. **J Fr Ophtalmol** 1995;18(12):799–818 (199 ref.) **(Fre)**

COMPLICATIONS

The use of silicone oil for HIV-related retinal detachment [editorial; comment] Blumenkranz MS. **Arch Ophthalmol** 1995 Nov;113(11):1366–8 (14 ref.) Comment on: Arch Ophthalmol 1995 Nov;113(11):1401–9.

ETIOLOGY

[Acute retinal necrosis syndrome. Retrospective study apropos of 14 eyes in 11 patients] Labetoulle M, et al. **J Fr Ophtalmol** 1995;18(12):777–87 (53 ref.) (Eng. Abstr.) **(Fre)**
[Bilateral acute retinal necrosis in a patient with acquired immunodeficiency syndrome] Menerath JM, et al. **J Fr Ophtalmol** 1995;18(10):625–33 (39 ref.) (Eng. Abstr.) **(Fre)**

RETINAL NEOVASCULARIZATION

COMPLICATIONS

[Neovascular glaucoma in the diabetic patient] Detry-Morel M. **Bull Soc Belge Ophtalmol** 1995;256:133–41 (27 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Retinal oxygen distribution. Its role in the physiopathology of vasoproliferative microangiopathies. Pournaras CJ. **Retina** 1995;15(4):332–47 (143 ref.)

RETINAL PERFORATIONS

ETIOLOGY

Macular holes. Pathogenesis, natural history and surgical outcomes. Luckie A, et al. **Aust N Z J Ophthalmol** 1995 May;23(2):93–100 (29 ref.)
[Age-dependent idiopathic macular foramen. Current concepts of the pathogenesis, diagnosis, and treatment] Gass JD. **Ophthalmologe** 1995 Oct;92(5):617–25 (24 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Macular hole. Sjaarda RN. **Int Ophthalmol Clin** 1995 Fall; 35(4):105–22 (62 ref.)

SURGERY

Macular epiretinal membrane formation and treated retinal breaks. Saran BR, et al. **Am J Ophthalmol** 1995 Oct; 120(4):480–5 (27 ref.)
Macular holes. Pathogenesis, natural history and surgical outcomes. Luckie A, et al. **Aust N Z J Ophthalmol** 1995 May;23(2):93–100 (29 ref.)
Macular hole. Sjaarda RN. **Int Ophthalmol Clin** 1995 Fall; 35(4):105–22 (62 ref.)
[Surgery of idiopathic macular holes] Hannouche D, et al. **J Fr Ophtalmol** 1995;18(8–9):559–63 (33 ref.) **(Fre)**
[Surgical treatment by vitrectomy and autologous serum of 36 idiopathic macular holes] Monin C, et al.

J Fr Ophtalmol 1996;19(5):341–8 (39 ref.) (Eng. Abstr.) **(Fre)**

RETINAL PHOTORECEPTORS see **RODS AND CONES**

RETINAL PIGMENT EPITHELIUM see **PIGMENT EPITHELIUM OF EYE**

RETINAL PIGMENTS

GENETICS

Molecular basis for tetrachromatic color vision. Okano T, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1995 Nov;112(3):405–14 (52 ref.)

Primate photopigments and primate color vision. Jacobs GH. **Proc Natl Acad Sci U S A** 1996 Jan 23;93(2):577–81 (61 ref.)

PHYSIOLOGY

Physiological activity of retinoids in natural and artificial visual pigments. Corson DW, et al. **Photochem Photobiol** 1996 May;63(5):595–600 (61 ref.)

RETINAL TEARS see **RETINAL PERFORATIONS**

RETINAL VEIN

PATHOLOGY

Severe occlusive retinal periphlebitis with vitreous hemorrhage in multiple sclerosis. Ronzani M, et al. **Ger J Ophthalmol** 1995 Nov;4(6):328–31 (15 ref.)

RETINAL VEIN OCCLUSION

COMPLICATIONS

Severe occlusive retinal periphlebitis with vitreous hemorrhage in multiple sclerosis. Ronzani M, et al. **Ger J Ophthalmol** 1995 Nov;4(6):328–31 (15 ref.)

RETINAL VESSELS

see related
FLUORESCEIN ANGIOGRAPHY

Indocyanine green angiography. Owens SL. **Br J Ophthalmol** 1996 Mar;80(3):263–6 (50 ref.)

ANATOMY & HISTOLOGY

Normal and pathological mechanisms in retinal vascular development. Gariano RF, et al. **Surv Ophthalmol** 1996 May–Jun;40(6):481–90 (147 ref.)

PHYSIOLOGY

New concepts of regulation of retinal vessel tone. Brown SM, et al. **Arch Ophthalmol** 1996 Feb;114(2):199–204 (58 ref.)

PHYSIOPATHOLOGY

Vascular endothelial growth factor and retinal neovascularisation: a new therapeutic approach for diabetic retinopathy. Favard C, et al. **Diabetes Metab** 1996 Jul; 22(4):268–73 (67 ref.)

[Vision disorders to vascular dysregulation] Flammer F, et al. **Ther Umsch** 1996 Jan;53(1):37–42 (20 ref.) (Eng. Abstr.) **(Ger)**

[State of microcirculation in the bulbar conjunctiva in retinal thrombosis of patients with hypertension and diabetes mellitus] Polunin GS, et al. **Vestn Oftalmol** 1996 Jan–Mar; 112(1):51–3 (60 ref.) **(Rus)**

RETINALDEHYDE

METABOLISM

Retinoic acid synthesizing enzymes in the embryonic and adult vertebrate. McCaffery P, et al. **Adv Exp Med Biol** 1995;372:173–83 (45 ref.)

RETINENE see **RETINALDEHYDE**

RETINITIS

Advances in the management of AIDS-related cytomegalovirus retinitis [see comments] Masur H, et al. **Ann Intern Med** 1996 Jul 15;125(2):126–36 (69 ref.) Comment in: Ann Intern Med 1996 Jul 15;125(2):144–5.

DIAGNOSIS

Neurologic complications of Bartonella henselae infection. Marra CM. **Curr Opin Neurol** 1995 Jun;8(3):164–9 (65 ref.)

DRUG THERAPY

Cytomegalovirus retinitis in AIDS: natural history, diagnosis, and treatment. Dunn JP, et al. **AIDS Clin Rev** 1995–96; :99–129 (120 ref.)

RETINITIS, CYTOMEGALOVIRUS see **CYTOMEGALOVIRUS RETINITIS**

RETINITIS PIGMENTOSA

CONGENITAL

[Late congenital glaucoma and pigmentary retinopathy] Ghenoiu R, et al. **Oftalmologia** 1995 Oct–Dec;39(4):333–7 (12 ref.) (Eng. Abstr.) **(Rum)**

DIAGNOSIS

[Juvenile nephronophthisis with tapetoretinal degeneration, skeletal changes and special phenotypic traits] Castro-Gago M, et al. **An Esp Pediatr** 1996 Jul;45(1):90–2 (16 ref.) **(Spa)**

ETIOLOGY

Retinitis pigmentosa: unfolding its mystery. Berson EL. **Proc Natl Acad Sci U S A** 1996 May 14;93(10):4526–8 (33 ref.)

GENETICS

Molecular genetics of retinitis pigmentosa. Dryja TP, et al. **Hum Mol Genet** 1995;4 Spec No:1739–43 (85 ref.)

[Molecular advances in ophthalmology—identifying the genes for retinitis pigmentosa] Stiebel H, et al. **Harefuah** 1995 Oct;129(7–8):261–4 (12 ref.) **(Heb)**

PHYSIOPATHOLOGY

Photoreceptor apoptosis in animal models. Implications for retinitis pigmentosa research [editorial] Wong F. **Arch Ophthalmol** 1995 Oct;113(10):1245–7 (24 ref.)

The relationship between visual field size and electroretinogram amplitude in retinitis pigmentosa. Sandberg MA, et al. **Invest Ophthalmol Vis Sci** 1996 Jul; 37(8):1693–8 (10 ref.)

RETINOBLASTOMA

see related
GENES, RETINOBLASTOMA

DIAGNOSIS

Intraocular retinoblastoma presenting as ocular and orbital inflammation. Foster BS, et al. **Int Ophthalmol Clin** 1996 Winter;36(1):153–60 (23 ref.)

Six signs in children with life-threatening implications. Tien DR. **R I Med** 1995 Dec;78(12):342–5 (6 ref.)

[Retinoblastoma: clinical and molecular diagnostic aspects] Thonney F, et al. **Schweiz Rundsch Med Prax** 1996 Aug 27;85(35):1058–62 (17 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Genetics of embryonal tumours of childhood: retinoblastoma, Wilms' tumour and neuroblastoma. Brodeur GM. **Cancer Surv** 1995;25:67–99 (209 ref.)

Role of transgenic mice in identification and characterization of tumour suppressor genes. Sharan SK, et al. **Cancer Surv** 1995;25:143–59 (103 ref.)

Genetics of retinoblastoma: implications for other human cancers. Yandell DW, et al. **Med Pediatr Oncol Suppl** 1996; 1:25–8 (17 ref.)

[Primary leiomyosarcoma of the liver 37 years after successful treatment of hereditary retinoblastoma] Abdelli N, et al. **Gastroenterol Clin Biol** 1996;20(5):502–5 (31 ref.) (Eng. Abstr.) **(Fre)**

[Genetics of retinoblastoma] Minoda K. **Nippon Rinsho** 1995 Nov;53(11):2774–8 (12 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

[Regressive bilateral retinoblastoma. Clinical and genetic study. Apropos of a case] Marrakchi S, et al. **J Fr Ophtalmol** 1995;18(5):390–5 (17 ref.) (Eng. Abstr.) **(Fre)**

RETINOBLASTOMA GENES see **GENES, RETINOBLASTOMA**

RETINOBLASTOMA NUCLEAR PHOSPHOPROTEIN P105-RB see **RETINOBLASTOMA PROTEIN**

RETINOBLASTOMA PROTEIN

GENETICS

Inactivation of tumor suppressor proteins in lung cancer. Weintraub SJ. **Am J Respir Cell Mol Biol** 1996 Aug; 15(2):150–5 (39 ref.)

METABOLISM

E2F and the molecular mechanisms of early cell-cycle control. La Thangue NB. **Biochem Soc Trans** 1996 Feb; 24(1):54–9 (29 ref.)

Cell cycle regulation by the retinoblastoma family of growth inhibitory proteins. Beijersbergen RL, et al. **Biochim Biophys Acta** 1996 Jun 7;1287(2–3):103–20 (223 ref.)

Growth suppression by members of the retinoblastoma protein family. Zhu L, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:75–84 (67 ref.)

Regulatory interactions among E2Fs and cell cycle control proteins. Cobrinik D. **Curr Top Microbiol Immunol** 1996; 208:31–61 (146 ref.)

Alterations of the retinoblastoma a susceptibility gene in chronic lymphocytic leukemia. Neubauer A, et al. **Leuk Lymphoma** 1995 Aug;18(5–6):399–404 (44 ref.)

PHYSIOLOGY

xRB as a modulator of transcription. Sellers WR, et al. **Biochim Biophys Acta** 1996 Aug 8;1288(1):M1–5 (77 ref.)

The retinoblastoma protein as a fundamental mediator of growth and differentiation signals. Chen PL, et al. **Crit Rev Eukaryot Gene Expr** 1995;5(1):79–95 (114 ref.)

RETINOIC ACID see **TRETINOIN**

13-CIS-RETINOIC ACID see **ISOTRETINOIN**

RETINOIC ACID-BINDING PROTEINS see **RECEPTORS, RETINOIC ACID**

RETINOIC ACID RECEPTORS see **RECEPTORS, RETINOIC ACID**

RETINOIDS

Physiological activity of retinoids in natural and artificial visual pigments. Corson DW, et al. **Photochem Photobiol** 1996 May;63(5):595–600 (61 ref.)

ADVERSE EFFECTS

Retinoids as teratogens. Soprano DR, et al. **Annu Rev Nutr** 1995;15:111–32 (117 ref.)

[Retinoids—drugs with a strong teratogenic side effect] Jendryczko A, et al. **Ginekol Pol** 1995 Jun;66(6):351–3 (17 ref.) (Eng. Abstr.) **(Pol)**

ANALYSIS

Chromatographic and electrophoretic analysis of biomedically important retinoids. Wyss R. **J Chromatogr B Biomed Appl** 1995 Sep 15;671(1–2):381–425 (313 ref.)

BLOOD

[Vitamin A (retinoids)] Moriwaki H, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:688–90 (4 ref.) **(Jpn)**

METABOLISM

The roles of retinoids in vertebrate development. Means AL, et al. **Annu Rev Biochem** 1995;64:201–33 (213 ref.)

Biochemical pathways of retinoid transport, metabolism, and signal transduction. Napoli JL. **Clin Immunol Immunopathol** 1996 Sep;80(3 Pt 2):S52–62 (62 ref.)

Retinoids in lung development. Chytil F. **FASEB J** 1996 Jul; 10(9):986–92 (53 ref.)

Molecular mechanisms of retinoid actions in skin. Fisher GJ, et al. **FASEB J** 1996 Jul;10(9):1002–13 (87 ref.)

Embryonic development and pattern formation. Morriss-Kay GM, et al. **FASEB J** 1996 Jul;10(9):961–8 (55 ref.)

Vitamin A and retinoids in antiviral responses. Ross AC, et al. **FASEB J** 1996 Jul;10(9):979–85 (53 ref.)

Retinoids: transport, metabolism, and mechanisms of action. Vieira AV, et al. **J Endocrinol** 1995 Aug;146(2):201–7 (74 ref.)

Retinoids and mouse embryonic development. Underhill TM, et al. **Vitam Horm** 1995;51:403–57 (263 ref.)

PHARMACOLOGY

4-Hydroxyphenylretinamide in the chemoprevention of cancer. Naik HR, et al. **Adv Pharmacol** 1995;33:315–47 (98 ref.)

Retinoid signaling in vertebrate limb development. Thaller C, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:1–11 (58 ref.)

Retinoids as teratogens. Soprano DR, et al. **Annu Rev Nutr** 1995;15:111–32 (117 ref.)

Topical retinoids and cutaneous biology. Craven NM, et al. **Clin Exp Dermatol** 1996 Jan;21(1):1–10 (141 ref.)

Retinoids and sebaceous gland activity. Geiger JM. **Dermatology** 1995;191(4):305–10 (52 ref.)

The dual roles of nutrients as antioxidants and prooxidants: their effects on tumor cell growth. Schwartz JL. **J Nutr** 1996 Apr;126(4 Suppl):1221S–7S (42 ref.)

Induction of retinoid resistance by all-trans retinoic acid in acute promyelocytic leukemia after remission. Cornic M, et al. **Leuk Lymphoma** 1995 Jul;18(3–4):249–57 (108 ref.)

THERAPEUTIC USE

Systemic retinoids for psoriasis. Wieder JM, et al. **Dermatol Clin** 1995 Oct;13(4):891–6 (34 ref.)

Risks and benefits of retinoids in the chemoprevention of cancer. de Palo G, et al. **Drug Saf** 1995 Oct;13(4):245–56 (80 ref.)

Retinoids in cancer chemoprevention. Lotan R. **FASEB J** 1996 Jul;10(9):1031–9 (47 ref.)

Retinoids and chemoprevention: clinical and basic studies. Lippman SM, et al. **J Cell Biochem Suppl** 1995;22:1–10 (66 ref.)

[Current knowledge on the action of retinoids in carcinoma of the head and neck] Dolivet G, et al.

RETINOIDS

Rev Laryngol Otol Rhinol (Bord) 1996;117(1):19–26 (34 ref.) (Eng. Abstr.) **(Fre)**

[Retinoids] Piérard GE, et al. **Rev Med Liege** 1996 Jan; 51(1):142–4 (13 ref.) **(Fre)**

[Preventive use of retinoids for occurrence of liver neoplasm] Muto Y. **Nippon Naika Gakkai Zasshi** 1995 Dec 10; 84(12):2032–7 (5 ref.) **(Jpn)**

TOXICITY

Receptor-selective retinoid agonists and teratogenic activity. Willhite CC, et al. **Drug Metab Rev** 1996 Feb–May; 28(1–2):105–19 (33 ref.)

Receptors as tools for understanding the toxicity of retinoids. Levin AA. **Toxicol Lett** 1995 Dec;82–83:91–7 (57 ref.)

RETINOL see **VITAMIN A**

RETINOL-BINDING PROTEINS

ANALYSIS

[Retinol-binding protein (RBP)] Moriwaki H, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:207–9 (12 ref.) **(Jpn)**

RETINOPATHY OF PREMATURITY

Retinopathy of prematurity: perspective for the nineties. Flynn JT. **Acta Ophthalmol Scand** 1995;73 Suppl 214:12–4 (4 ref.)

Retinopathy of prematurity: perspective for the nineties. Flynn JT. **Acta Ophthalmol Scand Suppl** 1995;(214):12–4; discussion 14–6 (4 ref.)

PHYSIOPATHOLOGY

Hypothesis: the possible role of magnesium and copper deficiency in retinopathy of prematurity. Caddell JL. **Magnes Res** 1995 Sep;8(3):261–70 (81 ref.)

RETIREMENT BENEFITS see **PENSIONS**

RETROLENTAL FIBROPLASIA see **RETINOPATHY OF PREMATURITY**

RETROPERITONEAL FIBROSIS

[Idiopathic retroperitoneal fibrosis. Report of 12 cases] Martín-Marquina A, et al. **Actas Urol Esp** 1995 Apr; 19(4):303–6 (7 ref.) (Eng. Abstr.) **(Spa)**

CHEMICALLY INDUCED

[Retroperitoneal fibrosis secondary to treatment with L-dopa analogues for Parkinson disease] Sánchez-Chapado M, et al. **Arch Esp Urol** 1995 Dec;48(10):979–83 (28 ref.) (Eng. Abstr.) **(Spa)**

COMPLICATIONS

[Periaortic fibrosis with pericardial and perirenal involvement: apropos of a case] Cerisier A, et al. **Rev Med Interne** 1996;17(2):154–6 (11 ref.) (Eng. Abstr.) **(Fre)**

RETROPERITONEAL NEOPLASMS

[Retroperitoneal liposarcoma. Two cases] Bennani S, et al. **Ann Urol (Paris)** 1995;29(3):154–8 (21 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Primary retroperitoneal liposarcoma: a case report and review of the literature. Ulusoy E, et al. **Int Urol Nephrol** 1995;27(6):691–5 (19 ref.)

[Retroperitoneal seminoma. A case report and literature review] Troisfontaines E, et al. **Acta Urol Belg** 1996 Mar; 64(1):55–9 (24 ref.) (Eng. Abstr.) **(Fre)**

[Fast and ultra-fast sequences in MRI of the pelvis and retroperitoneum] Heuck A, et al. **Radiologe** 1995 Dec; 35(12):936–44 (44 ref.) (Eng. Abstr.) **(Ger)**

[Benign schwannoma of the celiac tripod simulating a pancreatic neoplasm] Cedolini C, et al. **Minerva Chir** 1996 Jan–Feb;51(1–2):47–9 (15 ref.) (Eng. Abstr.) **(Ita)**

[Adipose retroperitoneal tumors. Apropos a giant myxoid liposarcoma] Romero Pérez P, et al. **Actas Urol Esp** 1996 Jan;20(1):79–84 (14 ref.) (Eng. Abstr.) **(Spa)**

[Retroperitoneal liposarcoma with lung, skin and pancreatic metastases] Alcalá Pedrajas JN, et al. **Arch Bronconeumol** 1996 Jun–Jul;32(6):313–5 (21 ref.) (Eng. Abstr.) **(Spa)**

EPIDEMIOLOGY

Extragonadal germ cell tumor: a clinical study. Bassetto MA, et al. **Anticancer Res** 1995 Nov–Dec;15(6B):2751–4 (17 ref.)

PATHOLOGY

Primary retroperitoneal mucinous cystadenocarcinoma of low malignant potential: a case report and literature review. Pearl ML, et al. **Gynecol Oncol** 1996 Apr;61(1):150–2 (16 ref.)

Retroperitoneal cystic lymphangioma. Nuzzo G, et al. **J Surg Oncol** 1996 Mar;61(3):234–7 (22 ref.)

Monozygotic twins concordant for congenital neuroblastoma: case report and review of the literature. Boyd TK, et al. **Pediatr Pathol Lab Med** 1995 Nov–Dec; 15(6):931–40 (16 ref.)

SECONDARY

[The surgical opportunity in metastatic lesions of renal-cell carcinoma after a response to adjuvant immunotherapy] Olivier C, et al. **Actas Urol Esp** 1995 Mar;19(3):203–10 (27 ref.) (Eng. Abstr.) **(Spa)**

SURGERY

Retroperitoneal leiomyosarcoma: eight cases and a literature review. Todd CS, et al. **Gynecol Oncol** 1995 Dec; 59(3):333–7 (24 ref.)

[Voluminous retroperitoneal liposarcoma. Apropos of a case and review of the literature] Lachachi F, et al. **J Chir (Paris)** 1995 Jun–Jul;132(6–7):309–13 (20 ref.) (Eng. Abstr.) **(Fre)**

[Surgical therapy of soft tissue sarcoma. I. General principles and resections of the trunk] Karakousis CP. **Chirurg** 1995 Sep;66(9):905–13 (17 ref.) (Eng. Abstr.) **(Ger)**

[Primary retroperitoneal pure choriocarcinoma] Okubo Y, et al. **Nippon Hinyokika Gakkai Zasshi** 1995 Dec; 86(12):1784–8 (14 ref.) (Eng. Abstr.) **(Jpn)**

RETROPERITONEAL SPACE

Retroperitoneal hematoma as a complication of pudendal block. Diagnosis made by computed tomography. Kurzel RB, et al. **West J Med** 1996 Jun;164(6):523–5 (15 ref.)

BLOOD SUPPLY

Vascular anatomy: how to identify the major retroperitoneal vessels. Snady H. **Gastrointest Endosc Clin N Am** 1995 Jul; 5(3):497–506 (10 ref.)

RETROPHARYNGEAL ABSCESS

DIAGNOSIS

Adult retropharyngeal abscess: a case report and review of the literature. Tannebaum RD. **J Emerg Med** 1996 Mar–Apr;14(2):147–58 (52 ref.)

[Retropharyngeal abscess. A report of 3 cases] Vázquez Rueda F, et al. **An Esp Pediatr** 1996 Jul;45(1):82–4 (10 ref.) **(Spa)**

ETIOLOGY

Retropharyngeal abscess after radiation therapy and cis-platinum, 5-fluorouracil treatment for nasopharyngeal carcinoma with collagen disease: report of two patients and a review of the literature. Hareyama M, et al. **Jpn J Clin Oncol** 1996 Jun;26(3):189–93 (15 ref.)

RETROPNEUMOPERITONEUM

ETIOLOGY

Retroperitoneal and abdominal wall emphysema after transanal excision of a rectal carcinoma. Petros JG, et al. **Am Surg** 1996 Sep;62(9):759–61 (8 ref.)

RETROPOSONS see **RETROTRANSPOSONS**

RETROTRANSPOSONS

LTR-retrotransposons and MITEs: important players in the evolution of plant genomes. Wessler SR, et al. **Curr Opin Genet Dev** 1995 Dec;5(6):814–21 (65 ref.)

Genetic and molecular analysis of the gypsy chromatin insulator of Drosophila. Gdula DA, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9378–83 (43 ref.)

The relationship between the flamenco gene and gypsy in Drosophila: how to tame a retrovirus. Bucheton A. **Trends Genet** 1995 Sep;11(9):349–53 (40 ref.)

IMMUNOLOGY

Retrovirus and retrotransposon particles as antigen presentation and delivery systems. Adams SE, et al. **Pharm Biotechnol** 1995;6:769–86 (63 ref.)

RETROVIRIDAE

Retroviruses and diabetes in animal models: hypotheses for the induction of the disease [published erratum appears in Diabete Metab 1995 Dec;21(5):384] Signore A, et al. **Diabete Metab** 1995 Jun;21(3):147–55 (54 ref.)

Non-replicating expression vectors: applications in vaccine development and gene therapy. Limbach KJ, et al. **Epidemiol Infect** 1996 Jun;116(3):241–56 (87 ref.)

Construction of retroviral vectors for targeted delivery and expression of therapeutic genes. Salmons B, et al. **Leukemia** 1995 Oct;9 Suppl 1:S53–60 (44 ref.)

[Retrovirus and autoimmune diseases] Shibata M, et al. **Ryumachi** 1995 Aug;35(4):705–11 (33 ref.) **(Jpn)**

CHEMISTRY

First glimpses at structure-function relationships of the nucleocapsid protein of retroviruses. Darlix JL, et al. **J Mol Biol** 1995 Dec 8;254(4):523–37 (140 ref.)

Identification and characterization of a widely expressed phosphate transporter/retrovirus receptor family. Kavanaugh MP, et al. **Kidney Int** 1996 Apr;49(4):959–63 (23 ref.)

DRUG EFFECTS

Antiretroviral drug resistance: mechanisms, pathogenesis, clinical significance. Richman DD. **Adv Exp Med Biol** 1996; 394:383–95 (94 ref.)

[Non-nucleoside antiretroviral agents] Sereni D, et al. **Presse Med** 1996 Mar 2–9;25(8):361–4, 366–9 (29 ref.) (Eng. Abstr.) **(Fre)**

ENZYMOLOGY

Retroviral integrases and their cousins. Rice P, et al. **Curr Opin Struct Biol** 1996 Feb;6(1):76–83 (65 ref.)

Retroviral integrase, putting the pieces together. Andrake MD, et al. **J Biol Chem** 1996 Aug 16;271(33):19633–6 (59 ref.)

GENETICS

Retroviral vectors for HIV immunotherapy. Warner JF, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:105–16 (36 ref.)

Retroviral insertional mutagenesis as a strategy to identify cancer genes. Jonkers J, et al. **Biochim Biophys Acta** 1996 May 16;1287(1):29–57 (410 ref.)

Internal transcriptional regulatory elements in HIV-1 and other retroviruses. Verdin E, et al. **Cell Mol Biol (Noisy-le-grand)** 1995 May;41(3):365–9 (26 ref.)

Development of retroviral vectors as safe, targeted gene delivery systems. Günzburg WH, et al. **J Mol Med** 1996 Apr;74(4):171–82 (92 ref.)

Retrovirus-mediated transfer of MHC class II cDNA into swine bone marrow cells. LeGuern C, et al. **J Mol Med** 1995 Jun;73(6):269–78 (86 ref.)

Molecular interactions between retroviruses and herpesviruses. Kawaguchi Y, et al. **J Vet Med Sci** 1995 Oct;57(5):801–11 (139 ref.)

Gene therapy against retroviral diseases. Essex M, et al. **Leukemia** 1995 Oct;9 Suppl 1:S71–4 (13 ref.)

Gene transfer using replication-defective retroviral and adenoviral vectors. Leber SM, et al. **Methods Cell Biol** 1996;51:161–83 (42 ref.)

Manipulating gene expression with replication-competent retroviruses. Morgan BA, et al. **Methods Cell Biol** 1996; 51:185–218 (25 ref.)

Pseudotyped retroviral vectors for studies of human gene therapy. Friedmann T, et al. **Nat Med** 1995 Mar;1(3):275–7 (29 ref.)

The viruses in all of us: characteristics and biological significance of human endogenous retrovirus sequences. Löwer R, et al. **Proc Natl Acad Sci U S A** 1996 May 28; 93(11):5177–84 (80 ref.)

Unity in transposition reactions. Craig NL. **Science** 1995 Oct 13;270(5234):253–4 (22 ref.)

Running the gamut of retroviral variation. Wain-Hobson S. **Trends Microbiol** 1996 Apr;4(4):135–41 (48 ref.)

[Safety issues of retrovirus vectors] Amanuma H. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2583–7 (21 ref.) **(Jpn)**

[Retrovirus vector] Wakimoto H, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2508–13 (19 ref.) **(Jpn)**

IMMUNOLOGY

Autoimmunity, apoptosis defects and retroviruses. Mountz JD, et al. **Adv Exp Med Biol** 1995;374:183–201 (84 ref.)

Nucleic acid vaccines. Vogel FR, et al. **Clin Microbiol Rev** 1995 Jul;8(3):406–10 (32 ref.)

Retrovirus and retrotransposon particles as antigen presentation and delivery systems. Adams SE, et al. **Pharm Biotechnol** 1995;6:769–86 (63 ref.)

ISOLATION & PURIFICATION

Retroviral aetiopathogenesis of ovine pulmonary carcinoma: a critical appraisal [see comments] Hecht SJ, et al. **Br Vet J** 1996 Jul;152(4):395–409 (56 ref.) Comment in: Br Vet J 1996 Jul;152(4):369–72.

A new look at viruses in type 1 diabetes. Yoon JW. **Diabetes Metab Rev** 1995 Jul;11(2):83–107 (194 ref.)

The viruses in all of us: characteristics and biological significance of human endogenous retrovirus sequences. Löwer R, et al. **Proc Natl Acad Sci U S A** 1996 May 28; 93(11):5177–84 (80 ref.)

The relationship between the flamenco gene and gypsy in Drosophila: how to tame a retrovirus. Bucheton A. **Trends Genet** 1995 Sep;11(9):349–53 (40 ref.)

[Detection of retrovirus in salivary glands of patients with Sjögren's syndrome] Yamano S, et al. **Nippon Rinsho** 1995 Oct;53(10):2456–60 (21 ref.) (Eng. Abstr.) **(Jpn)**

[Nervous system infections by retroviruses] Román GC. **Rev Neurol** 1996 Jun;24(130):703–7 (9 ref.) **(Spa)**

PATHOGENICITY

Human endogenous retroviruses: nature, occurrence, and clinical implications in human disease. Urnovitz HB, et al.

Clin Microbiol Rev 1996 Jan;9(1):72–99 (210 ref.)
[How does HIV–1 and other retroviruses affect the nervous system?] Elovaara I. **Duodecim** 1995;111(9):826–35 (40 ref.) **(Fin)**
[Retroviruses in human infectious pathology] Pokrovskiĭ VI, et al. **Ter Arkh** 1995;67(11):59–61 (54 ref.) **(Rus)**

PHYSIOLOGY

Molecular interactions between retroviruses and herpesviruses. Kawaguchi Y, et al. **J Vet Med Sci** 1995 Oct;57(5):801–11 (139 ref.)
Negative–strand virus M and retrovirus MA proteins: all in a family? Lenard J. **Virology** 1996 Feb 15;216(2):289–98 (116 ref.)
Comparison of packaging strategy in retroviruses and pararetroviruses. Mesnard JM, et al. **Virology** 1995 Oct 20; 213(1):1–6 (62 ref.)

RETROVIRIDAE INFECTIONS

Retroviruses and bone diseases. Labat ML. **Clin Orthop** 1996 May;(326):287–309 (109 ref.)
[An experimental model for gene therapy of murine retroviral leukemias] Aizaki K, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2679–85 (19 ref.) **(Jpn)**

COMPLICATIONS

Retroviruses and schizophrenia revisited. O'Reilly RL, et al. **Am J Med Genet** 1996 Feb 16;67(1):19–24 (65 ref.)

DRUG THERAPY

Efficacy of combination antiretroviral therapy. Collier AC. **Adv Exp Med Biol** 1996;394:355–72 (100 ref.)
Use of antiretroviral therapy in children and pregnant women. McKinney RE Jr. **Adv Exp Med Biol** 1996; 394:345–54 (22 ref.)
Antiretroviral drug resistance: mechanisms, pathogenesis, clinical significance. Richman DD. **Adv Exp Med Biol** 1996; 394:383–95 (94 ref.)
New initiatives in combination antiretroviral chemotherapy. Rooney JF, et al. **Adv Exp Med Biol** 1996;394:373–82 (29 ref.)
Controversies in initiating anti–retroviral therapy and in the use of combination therapies. Volberding PA. **Adv Exp Med Biol** 1996;394:333–43 (14 ref.)

ETIOLOGY

Regulation of expression and pathogenic potential of human foamy virus in vitro and in transgenic mice. Aguzzi A, et al. **Curr Top Microbiol Immunol** 1996;206:243–73 (123 ref.)
[Retroviruses in human infectious pathology] Pokrovskiĭ VI, et al. **Ter Arkh** 1995;67(11):59–61 (54 ref.) **(Rus)**

GENETICS

MMTV–induced mutations in mouse mammary tumors: their potential relevance to human breast cancer. Callahan R. **Breast Cancer Res Treat** 1996;39(1):33–44 (82 ref.)
Molecular analysis and characterization of two myeloid leukemia inducing murine retroviruses. Rassart E, et al. **Curr Top Microbiol Immunol** 1996;211:201–10 (36 ref.)
Gene regulation by NF–M and Myb during differentiation and leukemic transformation. Kowenz–Leutz E, et al. **Immunobiology** 1995 Jul;193(2–4):356–62 (15 ref.)

PREVENTION & CONTROL

Nucleic acid vaccines. Vogel FR, et al. **Clin Microbiol Rev** 1995 Jul;8(3):406–10 (32 ref.)

THERAPY

Alternative approaches for the application of ribozymes as gene therapies for retroviral infections. Campbell TB, et al. **Adv Pharmacol** 1995;33:143–78 (146 ref.)

TRANSMISSION

Transfusion–dependent thalassemia: viral complications (epidemiology and follow–up). de Montalembert M, et al. **Semin Hematol** 1995 Oct;32(4):280–7 (46 ref.)

VETERINARY

Retroviral aetiopathogenesis of ovine pulmonary carcinoma: a critical appraisal [see comments] Hecht SJ, et al. **Br Vet J** 1996 Jul;152(4):395–409 (56 ref.) Comment in: Br Vet J 1996 Jul;152(4):369–72.
Lymphoid leukosis viruses, their recognition as 'persistent' viruses and comparisons with certain other retroviruses of veterinary importance. Darcel C. **Vet Res Commun** 1996; 20(1):83–108 (112 ref.)
[Vaccination against feline retrovirus infections] Horzinek MC. **Tierarztl Prax** 1996 Apr;24(2):197–202 (16 ref.) (Eng. Abstr.) **(Ger)**

VIROLOGY

Human endogenous retroviruses: nature, occurrence, and clinical implications in human disease. Urnovitz HB, et al. **Clin Microbiol Rev** 1996 Jan;9(1):72–99 (210 ref.)
Viral arthritis including HIV. Naides SJ. **Curr Opin Rheumatol** 1995 Jul;7(4):337–42 (36 ref.)
Human retroviruses in the second decade: a personal perspective. Gallo RC. **Nat Med** 1995 Aug;1(8):753–9 (56 ref.)

RETROVIRIDAE PROTEINS

CHEMISTRY

Retroviral integrases and their cousins. Rice P, et al. **Curr Opin Struct Biol** 1996 Feb;6(1):76–83 (65 ref.)

IMMUNOLOGY

Immunosuppressive retroviral peptides: cAMP and cytokine patterns. Haraguchi S, et al. **Immunol Today** 1995 Dec; 16(12):595–603 (97 ref.)

PHYSIOLOGY

Transgenic models to assess the neuropathogenic potential of HIV–1 proteins and cytokines. Mucke L, et al. **Curr Top Microbiol Immunol** 1995;202:187–205 (98 ref.)

RETROVIRIDAE PROTEINS, ONCOGENIC

[Vaccination against feline retrovirus infections] Horzinek MC. **Tierarztl Prax** 1996 Apr;24(2):197–202 (16 ref.) (Eng. Abstr.) **(Ger)**

GENETICS

The Dbl family of oncogenes. Cerione RA, et al. **Curr Opin Cell Biol** 1996 Apr;8(2):216–22 (46 ref.)

METABOLISM

Rel/NF–kappa B/I kappa B family: intimate tales of association and dissociation. Verma IM, et al. **Genes Dev** 1995 Nov 15;9(22):2723–35 (114 ref.)
Interactions between Ras and Raf: key regulatory proteins in cellular transformation. Marshall M. **Mol Reprod Dev** 1995 Dec;42(4):493–9 (24 ref.)

RETROVIRUS INFECTIONS see **RETROVIRIDAE INFECTIONS**

RETROVIRUS PROTEINS see **RETROVIRIDAE PROTEINS**

RETROVIRUSES see **RETROVIRIDAE**

RETROVIRUSES, ALV–RELATED

Lymphoid leukosis viruses, their recognition as 'persistent' viruses and comparisons with certain other retroviruses of veterinary importance. Darcel C. **Vet Res Commun** 1996; 20(1):83–108 (112 ref.)

RETROVIRUSES TYPE C, AVIAN see **RETROVIRUSES, ALV–RELATED**

RETT SYNDROME

Rett syndrome: clinical peculiarities and biological mysteries. Hagberg B. **Acta Paediatr** 1995 Sep;84(9):971–6 (40 ref.)

DIAGNOSIS

[Rett's syndrome] Campos–Castelló J. **Rev Neurol** 1995 Nov–Dec;23(124):1208–11 (5 ref.) **(Spa)**

PHYSIOPATHOLOGY

The neuropathology of Rett syndrome—overview 1994. Armstrong DD. **Neuropediatrics** 1995 Apr;26(2):100–4 (47 ref.)

REUPTAKE INHIBITORS, NEUROTRANSMITTER see **NEUROTRANSMITTER UPTAKE INHIBITORS**

REV GENE PRODUCTS see **GENE PRODUCTS, REV**

REV GENES see **GENES, REV**

REV PROTEIN see **GENE PRODUCTS, REV**

REVERSE IMMUNOBLOTTING see **IMMUNOBLOTTING**

REVERSE TRANSCRIPTASE see **RNA–DIRECTED DNA POLYMERASE**

REVERSE TRANSCRIPTASE INHIBITORS

[Didanosine] **Enferm Infecc Microbiol Clin** 1995 Oct; 13(8):487–90 (0 ref.) **(Spa)**

CHEMICAL SYNTHESIS

Non–nucleoside anti–HIV–1 reverse transcriptase inhibitors (NNRTIs): a chemical survey from lead compounds to selected drugs for clinical trials. Artico M. **Farmaco** 1996 May;51(5):305–31 (92 ref.)

PHARMACOLOGY

Delavirdine mesylate, a potent non–nucleoside HIV–1 reverse transcriptase inhibitor. Freimuth WW. **Adv Exp Med Biol** 1996;394:279–89 (42 ref.)
Structural mechanisms of HIV drug resistance. Erickson JW, et al. **Annu Rev Pharmacol Toxicol** 1996;36:545–71 (74 ref.)
Antiretroviral activity of stavudine (2',3'–didehydro–3'–deoxythymidine, D4T). Riddler SA, et al. **Antiviral Res** 1995 Jun;27(3):189–203 (48 ref.)
Clinical significance of drug resistance in human immunodeficiency virus. Richman DD. **Clin Infect Dis** 1995 Oct;21 Suppl 2:S166–9 (26 ref.)
Knocking out human immunodeficiency virus through non–nucleoside reverse transcriptase inhibitors used as single agents or in combinations: a paradigm for the cure of AIDS? De Clercq E, et al. **Farmaco** 1995 Nov; 50(11):735–47 (48 ref.)

THERAPEUTIC USE

Clinical experience with non–nucleoside reverse transcriptase inhibitors: L–697,661 and nevirapine. Kilby JM, et al. **Adv Exp Med Biol** 1996;394:291–8 (23 ref.)
Antiretroviral therapy of human immunodeficiency virus type–1 (HIV–1) infection. Emery S, et al. **Aust N Z J Med** 1995 Aug;25(4):344–9 (41 ref.)
Zidovudine therapy in HIV infection: which patients should be treated and when. Barry MG, et al. **Br J Clin Pharmacol** 1995 Aug;40(2):107–10 (39 ref.)
Failure of antiretroviral therapy: role of viral and cellular factors. Cinatl J Jr, et al. **Intervirology** 1994;37(6):307–14 (76 ref.)
Studies of zidovudine in combination with didanosine and zalcitabine. Jablonowski H. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995;10 Suppl 1:S52–6 (17 ref.)
Rationale and experience with reverse transcriptase inhibitors and protease inhibitors. Vella S. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995;10 Suppl 1:S58–61 (15 ref.)
Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society–USA. Carpenter CC, et al. **JAMA** 1996 Jul 10;276(2):146–54 (109 ref.)
Non–nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of human immunodeficiency virus type 1 (HIV–1) infections: strategies to overcome drug resistance development. de Clercq E. **Med Res Rev** 1996 Mar;16(2):125–57 (180 ref.)

REVERSE TRANSCRIPTION see **TRANSCRIPTION, GENETIC**

REVERSE TRIIODOTHYRONINE see **TRIIODOTHYRONINE, REVERSE**

REVIEW LITERATURE

see related
META–ANALYSIS
Myosin minireview series [comment] Stull JT. **J Biol Chem** 1996 Jul 5;271(27):15849 (21 ref.) Comment on: J Biol Chem 1996 Jul 5;271(27):15850–3.

REVISION, JOINT see **REOPERATION**

REVISION, SURGICAL see **REOPERATION**

REWARD

Anorexia nervosa, self–starvation and the reward of stress. Bergh C, et al. **Nat Med** 1996 Jan;2(1):21–2 (13 ref.)
Food reward: brain substrates of wanting and liking. Berridge KC. **Neurosci Biobehav Rev** 1996;20(1):1–25 (162 ref.)
Effects of oral experience on rewarding properties of oral stimulation. Swithers SE. **Neurosci Biobehav Rev** 1996; 20(1):27–32 (22 ref.)
Action of opioid drugs on the brain–reward system. Kornetsky C. **NIDA Res Monogr** 1995;147:33–52 (47 ref.)
Dopamine, a common substrate for the rewarding effects of brain stimulation reward, cocaine, and morphine. Kornetsky C, et al. **NIDA Res Monogr** 1994;145:19–39 (66 ref.)
Cocaine reward and cocaine craving: the role of dopamine in perspective. Wise RA. **NIDA Res Monogr** 1994; 145:191–206 (92 ref.)

REWARMING

METHODS

The rapid reversal of profound hypothermia using peritoneal dialysis. Vella J, et al. **Ir J Med Sci** 1996 Apr–Jun; 165(2):113–4 (9 ref.)

REX GENES see **GENES, PX**

REYE'S SYNDROME

[Reye's syndrome and Reye's syndrome in adulthood] Kumagai K. **Ryoikibetsu Shokogun Shirizu** 1995;(8):265–71 (18 ref.) **(Jpn)**

REYE'S SYNDROME

ETIOLOGY

Reye's and Reye-like syndromes, drug-related diseases? (causative agents, etiology, pathogenesis, and therapeutic approaches). Visentin M, et al. **Drug Metab Rev** 1995; 27(3):517-39 (117 ref.)

THERAPY

Reye's and Reye-like syndromes, drug-related diseases? (causative agents, etiology, pathogenesis, and therapeutic approaches). Visentin M, et al. **Drug Metab Rev** 1995; 27(3):517-39 (117 ref.)

RFLP see POLYMORPHISM, RESTRICTION FRAGMENT LENGTH

RH FACTORS see RH-HR BLOOD-GROUP SYSTEM

RH-HR BLOOD-GROUP SYSTEM

see related
ERYTHROBLASTOSIS, FETAL

CHEMISTRY

Monoclonal anti-D specificity and Rh D structure: criteria for selection of monoclonal anti-D reagents for routine typing of patients and donors [see comments] Jones J, et al. **Transfus Med** 1995 Sep;5(3):171-84 (59 ref.) Comment in: Transfus Med 1995 Dec;5(4):304-5.

GENETICS

Molecular genetic basis of red cell markers and its forensic application. Ikemoto S, et al. **Forensic Sci Int** 1996 Jun 28;80(1-2):147-61 (42 ref.)

Rh haemolytic disease of the newborn and Rh genotyping by RFLP--and allele-specific--PCR. Le Van Kim C, et al. **Transfus Clin Biol** 1995;2(4):317-24 (16 ref.)

Identification and analysis of Rh genes: application of PCR and RFLP typing tests. Hyland CA, et al. **Transfus Med Rev** 1995 Oct;9(4):289-301 (58 ref.)

IMMUNOLOGY

Monoclonal anti-D specificity and Rh D structure: criteria for selection of monoclonal anti-D reagents for routine typing of patients and donors [see comments] Jones J, et al. **Transfus Med** 1995 Sep;5(3):171-84 (59 ref.) Comment in: Transfus Med 1995 Dec;5(4):304-5.

The introduction of human monoclonal anti-D for therapeutic use. Fletcher A, et al. **Transfus Med Rev** 1995 Oct;9(4):314-26 (87 ref.)

RH IMMUNE GLOBULIN see RHO(D) IMMUNE GLOBULIN

RH ISOIMMUNIZATION

see related
ERYTHROBLASTOSIS, FETAL

Management of the Rh-sensitized mother. Gollin YG, et al. **Clin Perinatol** 1995 Sep;22(3):545-59 (45 ref.)

DIAGNOSIS

In vitro assays to predict the severity of hemolytic disease of the newborn. Hadley AG. **Transfus Med Rev** 1995 Oct; 9(4):302-13 (68 ref.)

IMMUNOLOGY

Alloimmunization during pregnancy treated with high dose intravenous immunoglobulin. Effects on fetal hemoglobin concentration and anti-D concentrations in the mother and fetus. Gottvall T, et al. **Acta Obstet Gynecol Scand** 1995 Nov;74(10):777-83 (30 ref.)

THERAPY

The introduction of human monoclonal anti-D for therapeutic use. Fletcher A, et al. **Transfus Med Rev** 1995 Oct;9(4):314-26 (87 ref.)

RHABDOID TUMOR

DRUG THERAPY

Rhabdoid tumor of the kidney in an adult: review of the literature and report of a case responding to interleukin-2. Ebbinghaus SW, et al. **Cancer Biother** 1995 Fall; 10(3):237-41 (21 ref.)

PATHOLOGY

Clinicopathologic and cytogenetic analysis of malignant rhabdoid tumor of the central nervous system. Hasserjian RP, et al. **J Neurooncol** 1995;25(3):193-203 (36 ref.)

Malignant rhabdoid tumors: a clinicopathologic review and conceptual discussion. Wick MR, et al. **Semin Diagn Pathol** 1995 Aug;12(3):233-48 (119 ref.)

Malignant rhabdoid tumor of the vulva: a case report and review of the literature. Lupi G, et al. **Tumori** 1996 Jan-Feb;82(1):93-5 (15 ref.)

RHABDOMYOLYSIS

[Rhabdomyolysis] Yamazaki K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):305-8 (16 ref.) **(Jpn)**

CHEMICALLY INDUCED

[A case of rhabdomyolysis with administration of intravenous vasopressin] Hino A, et al. **Rinsho Shinkeigaku** 1995 Aug; 35(8):911-3 (10 ref.) (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

Carnitine palmitoyltransferase deficiency in a college athlete: a case report and literature review. Faigel HC. **J Am Coll Health** 1995 Sep;44(2):51-4 (40 ref.)

Systemic mucormycosis complicating acute renal failure: case report and review of the literature. Melnick JZ, et al. **Ren Fail** 1995 Sep;17(5):619-27 (31 ref.)

[Rhabdomyolysis and Q fever (letter)] Alberto Navarro L, et al. **Enferm Infecc Microbiol Clin** 1996 Feb;14(2):129-30 (9 ref.) **(Spa)**

DIAGNOSIS

Rhabdomyolysis secondary to keyboard overuse: occupational hazard of the computer age. Jolly BT, et al. **Am J Emerg Med** 1995 Nov;13(6):644-6 (18 ref.)

ETIOLOGY

Alcoholic rhabdomyolysis: a review. Bessa O Jr. **Conn Med** 1995 Sep;59(9):519-21 (19 ref.)

Rhabdomyolysis following electrical injury. Brumback RA, et al. **Semin Neurol** 1995 Dec;15(4):329-34 (22 ref.)

Primary varicella-zoster-induced rhabdomyolysis. Will MJ, et al. **South Med J** 1996 Sep;89(9):915-20 (15 ref.)

Rhabdomyolysis and acute renal failure following radical perineal prostatectomy. Bruce RG, et al. **Urology** 1996 Mar; 47(3):427-30 (14 ref.)

[Chronic rhabdomyolysis disclosing mitochondriopathy and malignant hyperthermia susceptibility] Etcharry-Bouyx F, et al. **Rev Neurol (Paris)** 1995 Oct;151(10):589-92 (10 ref.) (Eng. Abstr.) **(Fre)**

[Rhabdomyolysis and influenza infections] Baytner-Zamir H, et al. **Harefuah** 1996 Feb 1;130(3):208-10 (35 ref.) **(Heb)**

[Rhabdomyolysis and acute kidney failure after an orthopedic intervention] Méndez Bustelo MJ, et al. **An Esp Pediatr** 1996 Apr;44(4):385-6 (20 ref.) **(Spa)**

[Fulminant rhabdomyolysis secondary to Streptococcus viridans sepsis] Pérez Navero JL, et al. **An Esp Pediatr** 1996 Mar;44(3):282-4 (20 ref.) **(Spa)**

MICROBIOLOGY

Infectious etiologies of rhabdomyolysis: three case reports and review. Singh U, et al. **Clin Infect Dis** 1996 Apr; 22(4):642-9 (125 ref.)

PATHOLOGY

[A case of rhabdomyolysis with administration of intravenous vasopressin] Hino A, et al. **Rinsho Shinkeigaku** 1995 Aug; 35(8):911-3 (10 ref.) (Eng. Abstr.) **(Jpn)**

RADIOGRAPHY

[Computed tomography in acute rhabdomyolysis] Steidle B, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1995 Oct;163(4):353-5 (10 ref.) **(Ger)**

RHABDOMYOMA

PATHOLOGY

[Rhabdomyoma of the adult type. Apropos of a case of parapharyngeal site] Birtwisle-Peyrottes I, et al. **Arch Anat Cytol Pathol** 1996;44(2-3):117-21 (11 ref.) (Eng. Abstr.) **(Fre)**

RHABDOMYOSARCOMA

Laryngeal pleomorphic rhabdomyosarcoma. A critical review of the literature. Da Mosto MC, et al. **Ann Otol Rhinol Laryngol** 1996 Apr;105(4):289-94 (22 ref.)

Rhabdomyosarcoma and other soft tissue sarcomas of childhood. Pappo AS. **Curr Opin Oncol** 1995 Jul;7(4):361-6 (26 ref.)

Rhabdomyosarcoma arising in teratoma of the testis. Banfield GK, et al. **J R Army Med Corps** 1995 Oct;141(3):167-8 (5 ref.)

[Primary hepatic leiomyosarcoma and rhabdomyosarcoma] Hiyama Y. **Ryoikibetsu Shokogun Shirizu** 1995;(7):463-6 (22 ref.) **(Jpn)**

GENETICS

The molecular pathology of small round-cell tumours--relevance to diagnosis, prognosis, and classification. McManus AP, et al. **J Pathol** 1996 Feb; 178(2):116-21 (80 ref.)

PATHOLOGY

Primary pulmonary rhabdomyosarcoma in childhood: clinico-biologic features in two cases with review of the literature. Schiavetti A, et al. **Med Pediatr Oncol** 1996 Mar; 26(3):201-7 (26 ref.)

[What about histopathologic classifications of childhood rhabdomyosarcoma?] Boman F, et al. **Ann Pathol** 1996; 16(1):20-6 (17 ref.) **(Fre)**

RADIOTHERAPY

Damage to the urinary tract secondary to irradiation. Fichtner J, et al. **World J Urol** 1995;13(4):240-2 (23 ref.)

THERAPY

Paratesticular rhabdomyosarcoma. de Vries JD. **World J Urol** 1995;13(4):219-25 (31 ref.)

[The current therapeutic trends in rhabdomyosarcoma of the cervicofacial area. A review of the topic] Colella G, et al. **Minerva Stomatol** 1995 Jul-Aug;44(7-8):335-44 (37 ref.) (Eng. Abstr.) **(Ita)**

RHABDOMYOSARCOMA, ALVEOLAR

PATHOLOGY

Rhabdomyosarcoma of the hand. Two case reports and a review of the literature. Xarchas K, et al. **J Hand Surg [Br]** 1996 Jun;21(3):325-9 (11 ref.)

RHABDOMYOSARCOMA, EMBRYONAL

PATHOLOGY

Primary embryonal rhabdomyosarcoma of long bone. Case report and review of the literature. Lucas DR, et al. **Am J Surg Pathol** 1996 Feb;20(2):239-44 (32 ref.)

RHABDOVIRIDAE

IMMUNOLOGY

Immune response to synthetic peptides representing antigenic sites on the glycoprotein of infectious hematopoietic necrosis virus. Emmenegger E, et al. **Vet Res** 1995; 26(5-6):374-8 (21 ref.)

ISOLATION & PURIFICATION

Viruses associated with the epizootic ulcerative syndrome (EUS) of fish in South-East Asia. Frerichs GN. **Vet Res** 1995;26(5-6):449-54 (26 ref.)

RHABDOVIRIDAE INFECTIONS

VETERINARY

Immune response to synthetic peptides representing antigenic sites on the glycoprotein of infectious hematopoietic necrosis virus. Emmenegger E, et al. **Vet Res** 1995; 26(5-6):374-8 (21 ref.)

Viruses associated with the epizootic ulcerative syndrome (EUS) of fish in South-East Asia. Frerichs GN. **Vet Res** 1995;26(5-6):449-54 (26 ref.)

RHEOLOGY

The rheology of semiliquid foods. Barbosa-Cánovas GV, et al. **Adv Food Nutr Res** 1996;39:1-69 (143 ref.)

Haemorheological consequences of chronic cigarette smoking. Ernst E. **J Cardiovasc Risk** 1995 Oct;2(5):435-9 (70 ref.)

METHODS

Glossary: methods for the measurement of coronary blood flow and myocardial perfusion. Sakka SG, et al. **Basic Res Cardiol** 1996 Mar-Apr;91(2):155-78 (197 ref.)

RHESUS BLOOD-GROUP SYSTEM see RH-HR BLOOD-GROUP SYSTEM

RHESUS MONKEY see MACACA MULATTA

RHETINIC ACID see GLYCYRRHETINIC ACID

RHEUM see RHUBARB

RHEUMATIC DISEASES

An introduction to glycosylation and rheumatic disease. What is the current state of play? Axford JS, et al. **Adv Exp Med Biol** 1995;376:171-7 (33 ref.)

Soft tissue syndromes. Katz JN, et al. **Baillieres Clin Rheumatol** 1995 Aug;9(3):585-98 (33 ref.)

Common rheumatologic diseases in elderly patients. Michet CJ Jr, et al. **Mayo Clin Proc** 1995 Dec;70(12):1205-14 (61 ref.)

COMPLICATIONS

Cutaneous manifestations of selected rheumatologic diseases. Ostezan LB, et al. **Am Fam Physician** 1996 Apr; 53(5):1625-36 (14 ref.)

Cognitive deficit associated with rheumatic diseases: neuropsychological perspectives. Carbotte RM, et al.

Arthritis Rheum 1995 Oct;38(10):1363–74 (92 ref.)
Fever in rheumatic and autoimmune disease. Carsons SE. **Infect Dis Clin North Am** 1996 Mar;10(1):67–84 (49 ref.)
[Vision disorders in inflammatory-rheumatic diseases] Bernauer W. **Ther Umsch** 1996 Jan;53(1):58–67 (16 ref.) (Eng. Abstr.) **(Ger)**

DIAGNOSIS

The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Gladman D, et al. **Arthritis Rheum** 1996 Mar;39(3):363–9 (9 ref.)
Overlapping syndromes, undifferentiated connective tissue disease, and other fibrosing conditions. Kallenberg CG. **Curr Opin Rheumatol** 1995 Nov;7(6):568–73 (42 ref.)
Use and interpretation of rheumatologic tests: a guide for clinicians. Moder KG. **Mayo Clin Proc** 1996 Apr; 71(4):391–6 (17 ref.)
[Rheumatic diseases in pregnancy--problems from the viewpoint of the gynecologist] Heyl W, et al. **Geburtshilfe Frauenheilkd** 1995 Oct;55(10):M121–4 (21 ref.) **(Ger)**
[Diagnosis in rheumatology; advantages and limitations of diagnostic criteria] Naranjo Hernández A. **Rev Clin Esp** 1995 Aug;195(8):553–8 (49 ref.) (Eng. Abstr.) **(Spa)**

DIET THERAPY

Anti-inflammatory diet in rheumatic diseases. Adam O. **Eur J Clin Nutr** 1995 Oct;49(10):703–17 (56 ref.)

DRUG THERAPY

Effects of immunosuppressive drugs during pregnancy. Bermas BL, et al. **Arthritis Rheum** 1995 Dec;38(12):1722–32 (107 ref.)
The history of the use of sulphasalazine in rheumatology. Amos RS. **Br J Rheumatol** 1995 Nov;34 Suppl 2:2–6 (51 ref.)
Articular and periarticular corticosteroid injections. **Drug Ther Bull** 1995 Sep;33(9):67–70 (31 ref.)
Tiaprofenic acid. A reappraisal of its pharmacological properties and use in the management of rheumatic diseases. Plosker GL, et al. **Drugs** 1995 Dec;50(6):1050–75 (146 ref.)
Adverse drug reactions and their measurement in the rheumatic diseases. Day RO, et al. **J Rheumatol** 1995 May; 22(5):983–8 (48 ref.)
[Non steroidal anti-inflammatory drugs and rheumatic diseases] Cossermelli W, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1995 Mar-Apr; 50(2):115–24 (58 ref.) (Eng. Abstr.) **(Por)**
[Antimalarial preparations in rheumatology: new prospects] Nasonov EL. **Ter Arkh** 1996;68(1):67–71 (50 ref.) **(Rus)**

ECONOMICS

OMERACT II: the biologics perspective. Strand V. **J Rheumatol** 1995 Jul;22(7):1415–7 (24 ref.)

EPIDEMIOLOGY

Update on the epidemiology of the rheumatic diseases. Gabriel SE. **Curr Opin Rheumatol** 1996 Mar;8(2):96–100 (58 ref.)
[Epidemiology of rheumatologic health care in Germany] Zink A. **Z Rheumatol** 1995 Jul-Aug;54(4):184–91 (7 ref.) (Eng. Abstr.) **(Ger)**
[Why I do not grease up my axles... (editorial; comment)] Tena Marsà X. **Med Clin (Barc)** 1996 Apr 27;106(16):617–8 (21 ref.) Comment on: Med Clin (Barc) 1996 Apr 27;106(16):601–6. **(Spa)**

ETIOLOGY

Rheumatological complications of GI disorders. Fomberstein B, et al. **Am J Gastroenterol** 1996 Jun;91(6):1090–103 (200 ref.)
Rheumatological manifestations of haematological diseases. Menon S, et al. **Ann Rheum Dis** 1995 Oct;54(10):787–95 (126 ref.)
[Rheumatology update--I. Summary of clinically significant current knowledge and outlook of possible relevant trends in etiopathogenic research, diagnostic methods and therapeutic possibilities] Hein G, et al. **Med Klin** 1996 Apr 1;91 Suppl 1:47–55 (181 ref.) **(Ger)**
[Rheumatic manifestations of transplant recipients] Levy G, et al. **Harefuah** 1996 Apr 15;130(8):546–8 (23 ref.) **(Heb)**

GENETICS

MHC-encoded TAP genes in rheumatic diseases [editorial] Coakley G, et al. **Br J Rheumatol** 1996 Jun;35(6):501–3 (20 ref.)

IMMUNOLOGY

Immunologic mechanisms in common rheumatologic diseases. Miller-Blair DJ, et al. **Clin Orthop** 1996 May; (326):43–54 (28 ref.)
Use and interpretation of rheumatologic tests: a guide for clinicians. Moder KG. **Mayo Clin Proc** 1996 Apr; 71(4):391–6 (17 ref.)

METABOLISM

Nitric oxide. Farrell AJ, et al. **Ann Rheum Dis** 1996 Jan; 55(1):7–20 (261 ref.)
Cartilage matrix molecules in serum and synovial fluid. Simkin PA, et al. **Curr Opin Rheumatol** 1995 Jul;7(4):346–51 (28 ref.)
[Vitamins with antioxidant action and rheumatic diseases (a review)] Lobareva LS, et al. **Vopr Pitan** 1995;(4):24–9 (71 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

An overview of disability. Fitzpatrick F, et al. **Br J Rheumatol** 1996 Feb;35(2):184–7 (36 ref.)
A rehabilitation approach to chronic pain in rheumatologic practice. Rome JD, et al. **Curr Opin Rheumatol** 1996 Mar; 8(2):163–8 (32 ref.)
Functional measures in children with rheumatic diseases. Murray KJ, et al. **Pediatr Clin North Am** 1995 Oct; 42(5):1127–54 (79 ref.)

REHABILITATION

A rehabilitation approach to chronic pain in rheumatologic practice. Rome JD, et al. **Curr Opin Rheumatol** 1996 Mar; 8(2):163–8 (32 ref.)
Rehabilitation of the child with a rheumatic disease. Emery HM, et al. **Pediatr Clin North Am** 1995 Oct;42(5):1263–83 (14 ref.)
[Responsibilities and goals of a rehabilitation clinical in the present and future] Genth E. **Z Rheumatol** 1995 Jul-Aug; 54(4):202–6 (6 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Monoclonal antibody therapy of inflammatory rheumatic diseases. Breedveld FC, et al. **Br Med Bull** 1995 Apr; 51(2):493–502 (47 ref.)
Balneotherapy for rheumatic diseases at the Dead Sea area. Sukenik S. **Isr J Med Sci** 1996 Jul;32 Suppl:S16–9 (11 ref.)
[Rheumatology update--II. Summary of clinically significant current knowledge and outlook of prospective relevant trends in etiopathogenic research, diagnostic methods and therapeutic possibilities] Hein G, et al. **Med Klin** 1996 Apr 1;91 Suppl 1:56–64 (181 ref.) **(Ger)**
[Plasma- and lymphapheresis in autoimmune diseases] Schneider M. **Z Rheumatol** 1996 Mar-Apr;55(2):90–104 (165 ref.) (Eng. Abstr.) **(Ger)**

RHEUMATIC FEVER

Childhood systemic lupus erythematosus, vasculitis, and rheumatic fever and neonatal lupus. Pelkonen P. **Curr Opin Rheumatol** 1995 Sep;7(5):430–6 (62 ref.)

COMPLICATIONS

[Sydenham rheumatic chorea] Rodríguez Ormazabal J. **Rev Neurol** 1995;23 Suppl 3:S334–8 (79 ref.) **(Spa)**

DRUG THERAPY

Are the currently recommended doses of benzathine penicillin G adequate for secondary prophylaxis of rheumatic fever? Currie BJ. **Pediatrics** 1996 Jun;97(6 Pt 2):989–91 (21 ref.)

EPIDEMIOLOGY

The reemergence of serious group A streptococcal infections and acute rheumatic fever. Bronze MS, et al. **Am J Med Sci** 1996 Jan;311(1):41–54 (92 ref.)

IMMUNOLOGY

Solving the problem of the pathogenesis of rheumatic fever. Badr-Eldin MK. **Ann Trop Paediatr** 1996 Jun;16(2):113–21 (44 ref.)
Towards understanding the pathogenesis of rheumatic fever [editorial] Carapetis JR, et al. **Scand J Rheumatol** 1996; 25(3):127–31; discussion 132–3 (49 ref.)

MICROBIOLOGY

Rheumatic fever and poststreptococcal reactive arthritis. Gibofsky A, et al. **Curr Opin Rheumatol** 1995 Jul; 7(4):299–305 (72 ref.)

PREVENTION & CONTROL

Rheumatic fever prevention in industrializing countries: problems and approaches. Snitcowsky R. **Pediatrics** 1996 Jun;97(6 Pt 2):996–8 (12 ref.)

RHEUMATIC HEART DISEASE

DIAGNOSIS

[Echocardiography and Jones criteria in the diagnosis of rheumatic heart diseases: 138 cases reviewed at the Cardiology Institute of Abidjan] Zabsonre P, et al. **Med Trop (Mars)** 1995;55(4):347–50 (17 ref.) (Eng. Abstr.) **(Fre)**
[The progression of rheumatic heart defects (a review of the literature)] Novitskiĭ VA, et al. **Voen Med Zh** 1996 Apr; 317(4):26–9 (23 ref.) **(Rus)**

EPIDEMIOLOGY

Rheumatic heart disease: how big is the problem? [editorial] Ibrahim A, et al. **Med J Malaysia** 1995 Jun;50(2):121–4 (27 ref.)

PHYSIOPATHOLOGY

Persistent atrial mechanical dysfunction after spontaneous conversion of chronic atrial fibrillation to sinus rhythm. Kahn ZU, et al. **Am Heart J** 1996 Mar;131(3):606–8 (14 ref.)

RHEUMATISM see **RHEUMATIC DISEASES**

RHEUMATISM, ARTICULAR, ACUTE see **RHEUMATIC FEVER**

RHEUMATISM, MUSCULAR see **FIBROMYALGIA**

RHEUMATISM, PERI-EXTRA-ARTICULAR see **POLYMYALGIA RHEUMATICA**

RHEUMATOID FACTOR

GENETICS

[Lymphoproliferative disorders in patients with Sjögren's syndrome--Vg gene rearrangement and expression of bcl-2 protein] Sugai S, et al. **Nippon Rinsho** 1995 Oct; 53(10):2580–6 (15 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Rheumatoid factors, B cells and immunoglobulin genes. Jefferis R. **Br Med Bull** 1995 Apr;51(2):312–31 (46 ref.)
Cross-reactive idiotypes on cryoprecipitating monoclonal IgMk rheumatoid factors. Sinico RA, et al. **Clin Exp Rheumatol** 1995 Nov-Dec;13 Suppl 13:S105–7 (8 ref.)

METABOLISM

The effects of altered glycosylation of IgG on rheumatoid factor-binding and immune complex formation. Soltys AJ, et al. **Adv Exp Med Biol** 1995;376:155–60 (12 ref.)

RHEUMATOID PURPURA see **PURPURA, SCHOENLEIN-HENOCH**

RHEUMATOID SPONDYLITIS see **SPONDYLITIS, ANKYLOSING**

RHEUMATOLOGY

see related
COLLAGEN DISEASES
RHEUMATIC DISEASES

Health services research and policy studies. Prashker MJ. **Curr Opin Rheumatol** 1996 Mar;8(2):106–9 (8 ref.)

TRENDS

Update on measurement of relevant outcomes in rheumatology. Pioro MH, et al. **Curr Opin Rheumatol** 1996 Mar;8(2):101–5 (35 ref.)

RHINENCEPHALON see **LIMBIC SYSTEM**

RHINITIS

Rhinitis and sinusitis: office management. Guarderas JC. **Mayo Clin Proc** 1996 Sep;71(9):882–8 (8 ref.)
[Chronic non-allergic rhinitis. Etiology, diagnosis and treatment] Franzén G, et al. **Tidsskr Nor Laegeforen** 1996 Mar 30;116(9):1086–8 (13 ref.) (Eng. Abstr.) **(Nor)**

CHEMICALLY INDUCED

Rhinitis medicamentosa [editorial] Scadding GK. **Clin Exp Allergy** 1995 May;25(5):391–4 (37 ref.)
[Daily administration of nose drops can cause chronic nasal congestion] Graf P, et al. **Lakartidningen** 1996 Jan 24; 93(4):259–62 (17 ref.) **(Swe)**

DIAGNOSIS

[Nasal provocation tests] Mastalerz L, et al. **Pneumonol Alergol Pol** 1996;64(3–4):229–34 (33 ref.) **(Pol)**

DRUG THERAPY

Clinical implications of the pharmacological profile of Tilarin. Davies RJ. **Allergy** 1996;51(28 Suppl):8–13 (26 ref.)
Fluticasone propionate--an update on preclinical and clinical experience. Fuller R, et al. **Respir Med** 1995 Sep;89 Suppl A:3–18 (59 ref.)

THERAPY

Optimum treatment of rhinitis in the elderly. Tan R, et al. **Drugs Aging** 1995 Sep;7(3):168–75 (21 ref.)
Rhinitis: common, debilitating and treatable. Scadding G. **Practitioner** 1996 Jan;240(1558):48–53 (5 ref.)

RHINITIS, ALLERGIC, NONSEASONAL see **RHINITIS,**

RHINITIS, ALLERGIC, NONSEASONAL

ALLERGIC, PERENNIAL

RHINITIS, ALLERGIC, PERENNIAL

Allergic rhinitis. Baroody FM. **J Med Liban** 1994; 42(4):171–83 (105 ref.)

[Diagnosis of allergic rhinitis] Olivé-Pérez A. **Allergol Immunopathol (Madr)** 1995 Mar–Apr;23(2):85–90 (44 ref.) **(Spa)**

CHEMICALLY INDUCED

Phenomenology, pathogenesis, diagnosis and treatment of aspirin-sensitive rhinosinusitis. Schapowal AG, et al. **Acta Otorhinolaryngol Belg** 1995;49(3):235–50 (0 ref.)

DRUG THERAPY

Safety of antihistamines in the treatment of allergic rhinitis in elderly patients. McCue JD. **Arch Fam Med** 1996 Sep; 5(9):464–8 (40 ref.)

Effectiveness and safety of beclomethasone dipropionate, an intranasal corticosteroid, in the treatment of patients with allergic rhinitis. Edwards TB. **Clin Ther** 1995 Nov–Dec; 17(6):1032–41 (31 ref.)

Counseling patients about allergic rhinitis. Swanson KA. **J Am Pharm Assoc (Wash)** 1996 May;NS36(5):300–7 (40 ref.)

Diagnosis and treatment of allergic rhinitis. Smith LJ. **Nurse Pract** 1995 Oct;20(10):58–60, 62, 65–66 (23 ref.)

Behavioral side effects of medications used to treat asthma and allergic rhinitis. Milgrom H, et al. **Pediatr Rev** 1995 Sep;16(9):333–5; quiz 336 (21 ref.)

Allergic and nonallergic rhinitis. Directing medical therapy at specific symptoms. Graft DF. **Postgrad Med** 1996 Aug; 100(2):64–9, 73–4 (15 ref.)

ETIOLOGY

Role of mast cells and basophils in rhinitis. Peebles RS Jr, et al. **Chem Immunol** 1995;62:60–83 (113 ref.)

PHYSIOPATHOLOGY

Pathophysiology of allergic rhinitis. Bousquet J, et al. **Int Arch Allergy Immunol** 1996 Jul;110(3):207–18 (165 ref.)

THERAPY

Atopic disease, rhinitis and conjunctivitis, and upper respiratory infections. Wood RA, et al. **Curr Opin Pediatr** 1995 Oct;7(5):615–27 (63 ref.)

RHINITIS, ALLERGIC, SEASONAL see **HAY FEVER**

RHINOPHARYNX see **NASOPHARYNX**

RHINOPLASTY

The use of expanded polytetrafluoroethylene (Gore-Tex) in rhinoplasty. A 6-year experience. Godin MS, et al. **Arch Otolaryngol Head Neck Surg** 1995 Oct;121(10):1131–6 (20 ref.)

How to assess the nose for rhinoplasty. Willett JM. **J Otolaryngol** 1996 Feb;25(1):23–5 (5 ref.)

ADVERSE EFFECTS

Treatment of over-reduction of the nose and subsequent deformities. Aiach G, et al. **Br J Oral Maxillofac Surg** 1995 Aug;33(4):250–61 (6 ref.)

METHODS

Dynamic interplays during rhinoplasty. Guyuron B. **Clin Plast Surg** 1996 Apr;23(2):223–31 (5 ref.)

The residual cleft lip nasal deformity. An anatomic approach. Rifley W, et al. **Clin Plast Surg** 1996 Jan;23(1):81–92 (67 ref.)

Rethinking the logic and techniques of primary tip rhinoplasty. A perspective of the evolution of surgery of the nasal tip. Tebbetts JB. **Clin Plast Surg** 1996 Apr; 23(2):245–53 (11 ref.)

RHINOSCLEROMA

COMPLICATIONS

Airway obstruction secondary to rhinoscleroma during pregnancy. Armstrong WB, et al. **Ear Nose Throat J** 1995 Nov;74(11):768–73 (40 ref.)

RHINOSPORIDIOSIS

DIAGNOSIS

Rhinosporidiosis in India: a case report and review of literature. Mohan H, et al. **Mycoses** 1995 May–Jun; 38(5–6):223–5 (19 ref.)

RHINOVIRUS

Update on therapy of influenza and rhinovirus infections. Arruda E, et al. **Adv Exp Med Biol** 1996;394:175–87 (93 ref.)

The effects of rhinovirus infections on allergic airway responses. Gern JE, et al. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 2):S40–5 (40 ref.)

Natural and experimental rhinovirus infections of the lower respiratory tract. Johnston SL. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 2):S46–52 (71 ref.)

CHEMISTRY

Rhinoviruses and cells: molecular aspects. Rowlands DJ. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 2):S31–5 (41 ref.)

PHYSIOLOGY

Rhinovirus infection of the normal human airway. Gwaltney JM Jr. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 2):S36–9 (35 ref.)

Rhinoviruses and cells: molecular aspects. Rowlands DJ. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 2):S31–5 (41 ref.)

RHIZOBIACEAE

METABOLISM

Synthesis of phytohormones by plant-associated bacteria. Costacurta A, et al. **Crit Rev Microbiol** 1995;21(1):1–18 (169 ref.)

Heme synthesis in the rhizobium-legume symbiosis: a palette for bacterial and eukaryotic pigments. O'Brian MR. **J Bacteriol** 1996 May;178(9):2471–8 (95 ref.)

RHIZOBIUM

PHYSIOLOGY

What makes nodulation signals host-plant specific? Schultze M, et al. **Trends Microbiol** 1995 Oct;3(10):370–2 (24 ref.)

RHIZOMELIC CHONDRODYSPLASIA PUNCTATA see **CHONDRODYSPLASIA PUNCTATA, RHIZOMELIC**

RHIZOPUS

Chromomycosis. Bayles MA. **Curr Top Med Mycol** 1995; 6:221–43 (98 ref.)

RHO(D) IMMUNE GLOBULIN

IMMUNOLOGY

Alloimmunization during pregnancy treated with high dose intravenous immunoglobulin. Effects on fetal hemoglobin concentration and anti-D concentrations in the mother and fetus. Gottvall T, et al. **Acta Obstet Gynecol Scand** 1995 Nov;74(10):777–83 (30 ref.)

RHO FACTOR

CHEMISTRY

Structural organization of transcription termination factor Rho. Richardson JP. **J Biol Chem** 1996 Jan 19; 271(3):1251–4 (50 ref.)

PHYSIOLOGY

The Rac and Rho pathways as a source of drug targets for Ras-mediated malignancies. Symons M. **Curr Opin Biotechnol** 1995 Dec;6(6):668–74 (63 ref.)

RHODAMINES

DIAGNOSTIC USE

[Use of rhodamine 123 for the detection of multidrug resistance] Canitrot Y, et al. **Bull Cancer (Paris)** 1995 Sep; 82(9):687–97 (86 ref.) (Eng. Abstr.) **(Fre)**

RHODANATES see **THIOCYANATES**

RHODANESE see **THIOSULFATE SULFURTRANSFERASE**

RHODOCOCCUS EQUI

[Rhodococcus equi pulmonary abscess in HIV infection] About I, et al. **Rev Med Interne** 1996;17(5):410–4 (25 ref.) (Eng. Abstr.) **(Fre)**

[Rhodococcus equi lung infection in AIDS patients. A report of 4 cases] Carli Moretti C, et al. **Radiol Med (Torino)** 1996 Apr;91(4):477–80 (13 ref.) **(Ita)**

[Rhodococcus equi pneumonia in patients with HIV infection: report of 2 cases and review of the literature] Berna JD, et al. **Enferm Infecc Microbiol Clin** 1996 Mar; 14(3):177–80 (57 ref.) (Eng. Abstr.) **(Spa)**

RHODOPSIN

Langmuir-Blodgett films of photosensitive proteins. Pepe IM, et al. **J Photochem Photobiol B** 1996 May;33(3):191–200 (82 ref.)

METABOLISM

Shuttling between two protein conformations: the common mechanism for sensory transduction and ion transport. Spudich JL, et al. **Curr Opin Cell Biol** 1996 Aug;8(4):452–7 (47 ref.)

Is there a 'lock' for all agonist 'keys' in 7TM receptors? Schwartz TW, et al. **Trends Pharmacol Sci** 1996 Jun; 17(6):213–6 (37 ref.)

RHODOSPIRILLACEAE

CHEMISTRY

Purple bacterial antenna complexes. Fyfe PK, et al. **Curr Opin Struct Biol** 1996 Aug;6(4):467–72 (41 ref.)

RHODOTORULA

Central venous catheter infection with Rhodotorula minuta in a patient with AIDS taking suppressive doses of fluconazole. Goldani LZ, et al. **J Med Vet Mycol** 1995 Jul–Aug;33(4):267–70 (22 ref.)

GROWTH & DEVELOPMENT

High pressure influences on gene and protein expression. Bartlett DH, et al. **Res Microbiol** 1995 Oct;146(8):697–706 (63 ref.)

RHOMBENCEPHALIC SLEEP see **SLEEP, REM**

RHOMBENCEPHALON

[Rhombencephalic tissue in an ovarian teratoma with cerebellar foliation and maturation of the postnatal type] Fichera G. **Pathologica** 1995 Apr;87(2):203–10 (36 ref.) (Eng. Abstr.) **(Ita)**

EMBRYOLOGY

Genetic control of segmentation in the vertebrate hindbrain. Wilkinson DG. **Perspect Dev Neurobiol** 1995;3(1):29–38 (54 ref.)

RHONCHI see **RESPIRATORY SOUNDS**

RHUBARB

[Progress on research of mechanism of Rheum palmatum in delaying the chronic renal failure] Huang CL, et al. **Chung Kuo Chung Hsi I Chieh Ho Tsa Chih** 1995 Aug; 15(8):506–8 (22 ref.) **(Chi)**

RHUS DERMATITIS see **DERMATITIS, TOXICODENDRON**

RHYTHM METHOD

[Natural family planning] Freundl G. **Arch Gynecol Obstet** 1995;257(1–4):525–32 (11 ref.) **(Ger)**

RHYTHMICITY see **PERIODICITY**

RHYTIDECTOMY see **RHYTIDOPLASTY**

RHYTIDOPLASTY

ADVERSE EFFECTS

Parotid salivary fistula following rhytidectomy. Wolf K, et al. **Plast Reconstr Surg** 1996 Mar;97(3):641–2 (7 ref.)

METHODS

Surgical anatomy in endoscopic facial rejuvenation. Campiglio GL, et al. **Acta Chir Plast** 1996;38(1):3–10 (66 ref.)

A new concept in blepharoplasty. de la Plaza R, et al. **Aesthetic Plast Surg** 1996 May–Jun;20(3):221–33 (30 ref.)

Classification of facial rejuvenation techniques based on the subperiosteal approach and ancillary procedures. Ramirez OM. **Plast Reconstr Surg** 1996 Jan;97(1):45–55 (33 ref.)

RIB FRACTURES

COMPLICATIONS

Thoracic desmoid tumors: a rare evolution of rib fracture. Etiopathogenesis and therapeutic considerations. Wiel Marin A, et al. **G Chir** 1995 Aug–Sep;16(8–9):341–3 (12 ref.)

RIBAVIRIN

THERAPEUTIC USE

Summary: antiviral treatment of hepatitis C virus. Dusheiko GM. **Antiviral Res** 1996 Jan;29(1):77–82 (30 ref.)

Treatment options for chronic hepatitis C infection. James DG. **J Antimicrob Chemother** 1995 Oct;36(4):591–3 (19 ref.)

Future studies of combination therapy for chronic hepatitis C: optimizing response rates for each hepatitis C population. Main J. **J Hepatol** 1995;23 Suppl 2:32–5;

discussion 35-6 (18 ref.)
Reassessment of the indications for ribavirin therapy in respiratory syncytial virus infections. American Academy of Pediatrics Committee on Infectious Diseases. **Pediatrics** 1996 Jan;97(1):137-40 (28 ref.)

RIBOFLAVIN

BIOSYNTHESIS

Biosynthesis of riboflavin: structure and mechanism of lumazine synthase. Bacher A, et al. **Biochem Soc Trans** 1996 Feb;24(1):89-94 (28 ref.)

BLOOD

[Vitamin B2 (riboflavin)] Yasuda K, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:694-6 (13 ref.) **(Jpn)**

PHARMACOLOGY

Riboflavin-iron interactions with particular emphasis on the gastrointestinal tract. Powers HJ. **Proc Nutr Soc** 1995 Jul; 54(2):509-17 (45 ref.)

THERAPEUTIC USE

The therapy of respiratory chain encephalomyopathy: a critical review of the past and current perspective. Walker UA, et al. **Acta Neurol Scand** 1995 Oct;92(4):273-80 (77 ref.)

RIBONUCLEASE A see **RIBONUCLEASE, PANCREATIC**

RIBONUCLEASE H see **RIBONUCLEASE H, CALF THYMUS**

RIBONUCLEASE H, CALF THYMUS

METABOLISM

To cleave or not to cleave: ribozymes and antisense. Woolf TM. **Antisense Res Dev** 1995 Fall;5(3):227-32 (34 ref.)

RIBONUCLEASE N1 see **RIBONUCLEASE T1**

RIBONUCLEASE, PANCREATIC

CHEMISTRY

Bovine pancreatic ribonuclease A as a model of an enzyme with multiple substrate binding sites. Nogués MV, et al. **Biochim Biophys Acta** 1995 Nov 15;1253(1):16-24 (55 ref.)
[Three-dimensional structure and reaction mechanism of ribonuclease A] Nonaka T, et al. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1635-46 (62 ref.) **(Jpn)**

RIBONUCLEASE T1

[RNase T1-nucleotide interaction] Hakoshima T. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1627-34 (32 ref.) **(Jpn)**

RIBONUCLEASES

CHEMICAL SYNTHESIS

Sequence-specific and hydrolytic scission of DNA and RNA by lanthanide complex-oligoDNA hybrids. Komiyama M. **J Biochem (Tokyo)** 1995 Oct;118(4):665-70 (46 ref.)

RIBONUCLEIC ACID see **RNA**

RIBONUCLEOPROTEINS

CHEMISTRY

The unveiling of calreticulin--a clinically relevant tour of modern cell biology. Sontheimer RD, et al. **J Investig Med** 1995 Aug;43(4):362-70 (92 ref.)

IMMUNOLOGY

Ribonucleoprotein complexes as autoantigens. van Venrooij WJ, et al. **Curr Opin Immunol** 1995 Dec;7(6):819-24 (48 ref.)

PHYSIOLOGY

Ro/SS-A and La/SS-B: autoantigens in Sjögren's syndrome? Smeenk RJ. **Clin Rheumatol** 1995 Jul;14 Suppl 1:11-6 (53 ref.)
The role of the La autoantigen in internal initiation. Belsham GJ, et al. **Curr Top Microbiol Immunol** 1995;203:85-98 (57 ref.)
The unveiling of calreticulin--a clinically relevant tour of modern cell biology. Sontheimer RD, et al. **J Investig Med** 1995 Aug;43(4):362-70 (92 ref.)

RIBONUCLEOPROTEINS, SMALL NUCLEAR

METABOLISM

Small RNA chaperones for ribosome biogenesis. Steitz JA, et al. **Science** 1995 Dec 8;270(5242):1626-7 (16 ref.)

RIBONUCLEOPROTEINS, SMALL, U3 see **RIBONUCLEOPROTEINS, SMALL NUCLEAR**

RIBONUCLEOPROTEINS, SMALL, U4 see **RIBONUCLEOPROTEINS, SMALL, U4-U6**

RIBONUCLEOPROTEINS, SMALL, U4-U6

GENETICS

Yeast RNA polymerase III: transcription complexes and RNA synthesis. Geiduschek EP, et al. **Braz J Med Biol Res** 1995 Feb;28(2):147-59 (133 ref.)

RIBONUCLEOPROTEINS, SMALL, U6 see **RIBONUCLEOPROTEINS, SMALL, U4-U6**

RIBONUCLEOPROTEINS, SMALL, U7 see **RIBONUCLEOPROTEINS, SMALL NUCLEAR**

RIBONUCLEOSIDE DIPHOSPHATE REDUCTASE

ANTAGONISTS & INHIBITORS

Chemical and biological properties of cytotoxic alpha-(N)-heterocyclic carboxaldehyde thiosemicarbazones. Liu MC, et al. **Prog Med Chem** 1995; 32:1-35 (157 ref.)

RIBONUCLEOTIDE REDUCTASES

ANTAGONISTS & INHIBITORS

Ribonucleotide reductase inhibitors: new strategies for cancer chemotherapy. Nocentini G. **Crit Rev Oncol Hematol** 1996 Mar;22(2):89-126 (335 ref.)
Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Plunkett W, et al. **Semin Oncol** 1995 Aug; 22(4 Suppl 11):3-10 (26 ref.)
[The ribonucleotide reductase enzyme as a target for enzyme-directed chemotherapy effects of trimidox (3,4,5-trihydroxybenzohydroxamidoxim), a new inhibitor of ribonucleotide reductases] Findenig G, et al. **Wien Klin Wochenschr** 1995;107(22):694-7 (28 ref.) (Eng. Abstr.) **(Ger)**

BIOSYNTHESIS

Regulation of synthesis of ribonucleotide reductase and relationship to DNA replication in various systems. Greenberg GR, et al. **Prog Nucleic Acid Res Mol Biol** 1996; 53:345-95 (158 ref.)

CHEMISTRY

Mouse ribonucleotide reductase: from genes to proteins. Filatov D, et al. **Biochem Soc Trans** 1995 Nov;23(4):903-5 (24 ref.)

GENETICS

Mouse ribonucleotide reductase: from genes to proteins. Filatov D, et al. **Biochem Soc Trans** 1995 Nov;23(4):903-5 (24 ref.)

RIBONUCLEOTIDES

METABOLISM

Accumulation of purine catabolites in solid tumors exposed to therapeutic hyperthermia. Busse M, et al. **Experientia** 1996 May 15;52(5):469-73 (26 ref.)

RIBOSE-PHOSPHATE PYROPHOSPHOKINASE

CHEMISTRY

Mammalian phosphoribosyl-pyrophosphate synthetase. Tatibana M, et al. **Adv Enzyme Regul** 1995;35:229-49 (60 ref.)

RIBOSOMAL DNA see **DNA, RIBOSOMAL**

RIBOSOMAL FRAMESHIFTING see **FRAMESHIFTING, RIBOSOMAL**

RIBOSOMAL PROTEINS

METABOLISM

Protein recognition of a ribosomal RNA tertiary structure. Draper DE, et al. **Nucleic Acids Symp Ser** 1995;(33):5-7 (20 ref.)

RIBOSOMAL RNA see **RNA, RIBOSOMAL**

5S RIBOSOMAL RNA see **RNA, RIBOSOMAL, 5S**

16S RIBOSOMAL RNA see **RNA, RIBOSOMAL, 16S**

18S RIBOSOMAL RNA see **RNA, RIBOSOMAL, 18S**

RIBOSOMES

see related
DNA, RIBOSOMAL
RIBOSOMAL PROTEINS
RNA, RIBOSOMAL

CHEMISTRY

The suitability of a monofunctional reagent of an undecagold cluster for phasing data collected from the large ribosomal subunits from Bacillus stearothermophilus. Bartels H, et al. **Biopolymers** 1995;37(6):411-9 (19 ref.)
Ribosomes seen through a glass less darkly. Moore PB. **Structure** 1995 Sep 15;3(9):851-2 (4 ref.)

IMMUNOLOGY

[The role of some cellular components of bacterial parasites in determining the incidence of tuberculosis: studies on mycobacterial antigens, with special reference to mycobacterial immunoreactive ribosomal and secreted proteins] Yamada T, et al. **Kekkaku** 1995 Nov; 70(11):639-44 (40 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

Ribosome recycling by ribosome recycling factor (RRF)--an important but overlooked step of protein biosynthesis. Janosi L, et al. **Adv Biophys** 1996;32:121-201 (188 ref.)
Anatomy of the poliovirus internal ribosome entry site. Ehrenfeld E, et al. **Curr Top Microbiol Immunol** 1995; 203:65-83 (86 ref.)
Translation of encephalomyocarditis virus RNA by internal ribosomal entry. Hellen CU, et al. **Curr Top Microbiol Immunol** 1995;203:31-63 (178 ref.)
Structure and function of the hepatitis C virus internal ribosome entry site. Wang C, et al. **Curr Top Microbiol Immunol** 1995;203:99-115 (81 ref.)
Ribosome regulation by the nascent peptide. Lovett PS, et al. **Microbiol Rev** 1996 Jun;60(2):366-85 (148 ref.)
The large ribosomal subunit stalk as a regulatory element of the eukaryotic translational machinery. Ballesta JP, et al. **Prog Nucleic Acid Res Mol Biol** 1996;55:157-93 (119 ref.)
[Structure and function of 5S rRNA in ribosomes] Bogdanov AA, et al. **Mol Biol (Mosk)** 1995 Nov-Dec;29(6):1218-27 (56 ref.) **(Rus)**

PHYSIOLOGY

How and why ribosome? Burma DP. **Indian J Biochem Biophys** 1995 Dec;32(6):311-21 (76 ref.)
[Structural and functional analysis of the internal ribosome entry site within 5' noncoding region of hepatitis C virus RNA] Fukushi S, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:36-42 (17 ref.) **(Jpn)**

ULTRASTRUCTURE

How and why ribosome? Burma DP. **Indian J Biochem Biophys** 1995 Dec;32(6):311-21 (76 ref.)
The large ribosomal subunit stalk as a regulatory element of the eukaryotic translational machinery. Ballesta JP, et al. **Prog Nucleic Acid Res Mol Biol** 1996;55:157-93 (119 ref.)
Ribosome-[illegible]lla complexes in sinus histiocytes [letter] Eyden b. [illegible] et al. **Ultrastruct Pathol** 1995 Nov-Dec; 19(6):511-5 (65 ref.)

RIBOVIRIN see **RIBAVIRIN**

RIBOZYMES see **RNA, CATALYTIC**

RIBS

see related
TIETZE'S SYNDROME

[Extrapulmonary tuberculosis. An unusual case] Di Natale M, et al. **Minerva Med** 1995 Dec;86(12):555-7 (5 ref.) (Eng. Abstr.) **(Ita)**

ABNORMALITIES

[The cerebrocostomandibular syndrome] Casas Gómez J, et al. **An Esp Pediatr** 1996 Apr;44(4):369-72 (25 ref.) **(Spa)**

PATHOLOGY

Painless osteoid osteoma of the rib in an adult. A case report and a review of the literature. McDermott MB, et al. **Cancer** 1996 Apr 15;77(8):1442-9 (62 ref.)

RIBULOSE BIPHOSPHATE CARBOXYLASE-OXYGENASE see **RIBULOSEBIPHOSPHATE CARBOXYLASE**

RIBULOSE DIPHOSPHATE CARBOXYLASE see **RIBULOSEBIPHOSPHATE CARBOXYLASE**

RIBULOSEBIPHOSPHATE CARBOXYLASE

CHEMISTRY

Rubisco, an old challenge with new perspectives. Wildner GF, et al. **Z Naturforsch [C]** 1996 May-Jun;51(5-6):273-86 (63 ref.)

GENETICS

Rubisco rules fall; gene transfer triumphs. Palmer JD. **Bioessays** 1995 Dec;17(12):1005-8 (31 ref.)

METABOLISM

Rubisco, an old challenge with new perspectives. Wildner GF, et al. **Z Naturforsch [C]** 1996 May-Jun;51(5-6):273-86 (63 ref.)

RICE

Environmental fate of rice pesticides in California. Mabury SA, et al. **Rev Environ Contam Toxicol** 1996;147:71-117 (202 ref.)

GENETICS

The molecular biology of rice [comment] Shimamoto K. **Science** 1995 Dec 15;270(5243):1772-3 (13 ref.) Comment on: Science 1995 Dec 15;270(5243):1804-6.

QTL mapping in rice. McCouch SR, et al. **Trends Genet** 1995 Dec;11(12):482-7 (58 ref.)

RICKETS

COMPLICATIONS

Unusual cases of hyperparathyroidism [see comments] Vázquez-Quintana E, et al. **P R Health Sci J** 1995 Sep; 14(3):227-32 (8 ref.) Comment in: P R Health Sci J 1995 Sep;14(3):191-3.

ETIOLOGY

Nutritional aspects of metabolic bone disease in the newborn. Ryan S. **Arch Dis Child Fetal Neonatal Ed** 1996 Mar; 74(2):F145-8 (43 ref.)

RICKETS, HYPOPHOSPHATEMIC see **HYPOPHOSPHATEMIA, FAMILIAL**

RICKETS, RENAL see **RENAL OSTEODYSTROPHY**

RICKETS, VITAMIN D-RESISTANT see **HYPOPHOSPHATEMIA, FAMILIAL**

RICKETS, X-LINKED HYPOPHOSPHATEMIC see **HYPOPHOSPHATEMIA, FAMILIAL**

RICKETTSIA

PHYSIOLOGY

Rickettsial microbiology. Heymann WR. **Clin Dermatol** 1996 May-Jun;14(3):243-4 (17 ref.)

RICKETTSIA INFECTIONS

Rickettsial microbiology. Heymann WR. **Clin Dermatol** 1996 May-Jun;14(3):243-4 (17 ref.)

Other spotted fevers. Kaplan LI. **Clin Dermatol** 1996 May-Jun;14(3):259-67 (108 ref.)

DIAGNOSIS

Laboratory diagnosis of rickettsial diseases. Kostman JR. **Clin Dermatol** 1996 May-Jun;14(3):301-6 (58 ref.)

RICKETTSIA TSUTSUGAMUSHI

CLASSIFICATION

Classification of Rickettsia tsutsugamushi in a new genus, Orientia gen. nov., as Orientia tsutsugamushi comb. nov. Tamura A, et al. **Int J Syst Bacteriol** 1995 Jul;45(3):589-91 (55 ref.)

RICKETTSIACEAE

CLASSIFICATION

Classification of Rickettsia tsutsugamushi in a new genus, Orientia gen. nov., as Orientia tsutsugamushi comb. nov. Tamura A, et al. **Int J Syst Bacteriol** 1995 Jul;45(3):589-91 (55 ref.)

RICKETTSIACEAE INFECTIONS

Rickettsialpox. Heymann WR. **Clin Dermatol** 1996 May-Jun; 14(3):279-82 (16 ref.)

RICKETTSIALPOX see **RICKETTSIACEAE INFECTIONS**

RIDA see **SCRAPIE**

RIFABUTIN

ADVERSE EFFECTS

Rifabutin-associated uveitis. Tseng AL, et al. **Ann Pharmacother** 1995 Nov;29(11):1149-55 (45 ref.)

Mycobacterium avium complex infection, rifabutin, and uveitis--is there a connection? Nichols CW. **Clin Infect Dis** 1996 Apr;22 Suppl 1:S43-7; discussion S47-9 (21 ref.)

PHARMACOKINETICS

The clinical pharmacokinetics of rifabutin. Blaschke TF, et al. **Clin Infect Dis** 1996 Apr;22 Suppl 1:S15-21; discussion S21-2 (28 ref.)

PHARMACOLOGY

Rifabutin in the treatment of Mycobacterium avium complex infection: experience in Europe. Dautzenberg B. **Clin Infect Dis** 1996 Apr;22 Suppl 1:S33-6 (22 ref.)

Antimicrobial activity of rifabutin. Kunin CM. **Clin Infect Dis** 1996 Apr;22 Suppl 1:S3-13; discussion S13-4 (124 ref.)

Rifabutin prophylaxis for Mycobacterium avium complex infection in patients with AIDS. Siegal FP. **Clin Infect Dis** 1996 Apr;22 Suppl 1:S23-30; discussion S30-2 (38 ref.)

Rifamycin resistance in mycobacteria. Cole ST. **Res Microbiol** 1996 Jan-Feb;147(1-2):48-52 (43 ref.)

THERAPEUTIC USE

Potential role of rifabutin in prophylaxis for tuberculosis and infections due to multiple opportunistic pathogens. Chaisson RE. **Clin Infect Dis** 1996 Apr;22 Suppl 1:S61-6; discussion S66-9 (51 ref.)

Use of rifabutin in the treatment of pulmonary tuberculosis. Grassi C, et al. **Clin Infect Dis** 1996 Apr;22 Suppl 1:S50-4 (21 ref.)

Rifabutin therapy for disseminated Mycobacterium avium complex infection. Sullam PM. **Clin Infect Dis** 1996 Apr; 22 Suppl 1:S37-41; discussion S41-2 (41 ref.)

RIFAMPICIN see **RIFAMPIN**

RIFAMPIN

ADVERSE EFFECTS

[Two cases of therapy-related myelodysplastic syndrome] Takahashi A, et al. **Rinsho Ketsueki** 1996 Jan;37(1):53-9 (16 ref.) (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

Rifamycin resistance in mycobacteria. Cole ST. **Res Microbiol** 1996 Jan-Feb;147(1-2):48-52 (43 ref.)

THERAPEUTIC USE

Vancomycin, trimethoprim-sulfamethoxazole, and rifampin. Lundstrom TS, et al. **Infect Dis Clin North Am** 1995 Sep; 9(3):747-67 (91 ref.)

New World tegumentar leishmaniasis: chemotherapeutic activity of rifampicin in humans and experimental murine model. Do Valle TZ, et al. **Pathol Biol (Paris)** 1995 Sep; 43(7):618-21 (25 ref.)

RIFAMYCINS

BIOSYNTHESIS

Rifamycin SV and related ansamycins. Chiao JS, et al. **Biotechnology** 1995;28:477-98 (110 ref.)

Rifamycins: strain improvement program. Lal R, et al. **Crit Rev Microbiol** 1995;21(1):19-30 (42 ref.)

RIFLES see **FIREARMS**

RIFOMYCINS see **RIFAMYCINS**

RIGHT TO DIE

see related
SUICIDE, ASSISTED

Barriers to forgoing nutrition and hydration in nursing homes. Meisel A. **Am J Law Med** 1995;21(4):335-82 (274 ref.)

Redefining death in America, 1968. Stevens ML. **Caduceus** 1995 Winter;11(3):207-19 (41 ref.)

Terminating life-sustaining treatment of the demented. Callahan D. **Hastings Cent Rep** 1995 Nov-Dec;25(6):25-31 (11 ref.)

Living wills, durable powers of attorney for health care, and HIV infection. The need for statutory reform. Loue S. **J Leg Med** 1995 Dec;16(4):461-80 (96 ref.)

Euthanasia and the good life. Lemmens T. **Perspect Biol Med** 1995 Autumn;39(1):15-27 (25 ref.)

LEGISLATION & JURISPRUDENCE

Social work and end-of-life decisions: self-determination and the common good. Wesley CA. **Health Soc Work** 1996 May;21(2):115-21 (52 ref.)

Breathing life into the right to die: Oregon's Death with Dignity Act. Bushong SK, et al. **Issues Law Med** 1995 Winter;11(3):269-82 (102 ref.)

Physician-assisted suicide and euthanasia in the United States. Legal and ethical observations. Stone TH, et al. **J Leg Med** 1995 Dec;16(4):481-507 (194 ref.)

[Assisted dying--death on demand: borderline between medicine and law] Oehmichen M. **Z Gerontol Geriatr** 1995 Jul-Aug;28(4):273-8 (21 ref.) (Eng. Abstr.) **(Ger)**

RIGHT TO TREATMENT see **PATIENT ADVOCACY**

RIGHT VENTRICULAR DYSFUNCTION see **VENTRICULAR DYSFUNCTION, RIGHT**

RIGHT VENTRICULAR HYPERTROPHY see **HYPERTROPHY, RIGHT VENTRICULAR**

RILEY-DAY SYNDROME see **DYSAUTONOMIA, FAMILIAL**

RILEY VIRUS see **LACTATE DEHYDROGENASE VIRUS**

RINDERPEST

DIAGNOSIS

Recent developments in the diagnosis of rinderpest and peste des petits ruminants. Diallo A, et al. **Vet Microbiol** 1995 May;44(2-4):307-17 (36 ref.)

PREVENTION & CONTROL

Risk of introducing exotic disease through importation of animals and animal products. Metcalf HE, et al. **Rev Sci Tech** 1995 Dec;14(4):951-6 (12 ref.)

RING CHROMOSOMES

Small extra ring chromosome derived from chromosome 10p: clinical report and characterisation by FISH. Blennow E, et al. **J Med Genet** 1996 May;33(5):399-402 (30 ref.)

RING CONSTRICTIONS, INTRAUTERINE see **AMNIOTIC BAND SYNDROME**

RINGWORM see **TINEA**

RIOTS

see related
VIOLENCE

RISK ASSESSMENT

Screening for child abuse: problems and possibilities. Doueck HJ. **Appl Nurs Res** 1995 Nov;8(4):191-8 (53 ref.)

International harmonization of approaches to risk assessment: will resolution of scientific issues alone lead to success? Becking GC. **Drug Metab Rev** 1996 Feb-May; 28(1-2):269-83 (2 ref.)

Improving the science and art of risk assessment. Doull J. **Drug Metab Rev** 1996 Feb-May;28(1-2):1-7 (6 ref.)

Hazard evaluation in risk assessment: whatever happened to sound scientific judgment and weight of evidence? Doull J, et al. **Drug Metab Rev** 1996 Feb-May;28(1-2):285-99 (9 ref.)

Risk estimation--an overview: disease risk estimation based upon animal bioassays. Gaylor DW. **Drug Metab Rev** 1996 Feb-May;28(1-2):9-27 (39 ref.)

Biological markers and risk assessment. Goldstein BD. **Drug Metab Rev** 1996 Feb-May;28(1-2):225-33 (12 ref.)

Some thoughts about the use and communication of toxicology information. Kennedy GL Jr, et al. **Drug Metab Rev** 1996 Feb-May;28(1-2):235-43 (10 ref.)

Developmental toxicity risk assessment: consensus building, hypothesis formulation, and focused research. Kimmel CA. **Drug Metab Rev** 1996 Feb-May;28(1-2):85-103 (51 ref.)

Bioassay designs for validating biologically based mathematical models of carcinogenesis for risk assessment. Kodell RL. **Drug Metab Rev** 1996 Feb-May;28(1-2):219-23 (6 ref.)

Reducing uncertainty in risk assessment by using specific knowledge to replace default options. McClellan RO. **Drug Metab Rev** 1996 Feb-May;28(1-2):149-79 (64 ref.)

Risk proposals of the 103rd Congress. Paxman D. **Drug Metab Rev** 1996 Feb-May;28(1-2):245-67 (18 ref.)

A toxicologist's view of cancer risk assessment. Rozman KK, et al. **Drug Metab Rev** 1996 Feb-May;28(1-2):29-52 (27 ref.)

Making regulatory decisions across the food ingredient spectrum. Rulis AM. **Drug Metab Rev** 1996 Feb-May; 28(1-2):197-208 (8 ref.)

Noncancer risk assessment: reproductive toxicology. Schwetz BA. **Drug Metab Rev** 1996 Feb-May; 28(1-2):77-84 (11 ref.)

Evolution and current status of neurotoxicity risk assessment. Tilson HA. **Drug Metab Rev** 1996 Feb-May;28(1-2):121-39 (47 ref.)

Reality versus extrapolation: an academic perspective of cancer risk regulation. Waddell WJ. **Drug Metab Rev** 1996 Feb-May;28(1-2):181-95 (32 ref.)

Empirical and biologically based models for cancer risk assessment. Zielinski JM, et al. **Drug Metab Rev** 1996 Feb-May;28(1-2):53-75 (29 ref.)
Risk:benefit analysis of drugs in practice. The doctor, the patient and the licensing authority. **Drug Ther Bull** 1995 May;33(5):33-5 (7 ref.)
Risk assessment of recurrence of disease during supportive periodontal care. Epidemiological considerations. Ainamo J, et al. **J Clin Periodontol** 1996 Mar;23(3 Pt 2):232-9 (141 ref.)
An overview of caries risk assessment, and its potential utility. Moss ME, et al. **J Dent Educ** 1995 Oct;59(10):932-40 (42 ref.)
Defining neurotoxicity in a decision-making context. Tilson HA, et al. **Neurotoxicology** 1995 Summer;16(2):363-75 (49 ref.)
Unrealistic optimism about diet-related risks: implications for interventions. Raats MM, et al. **Proc Nutr Soc** 1996 Nov; 54(3):737-45 (36 ref.)
Benzoyl peroxide: review of experimental carcinogenesis and human safety data. Binder RL, et al.
Prog Clin Biol Res 1995;391:245-94 (168 ref.)
A decision tree approach for carcinogen risk assessment. Butterworth BE, et al. **Prog Clin Biol Res** 1995;391:49-70 (52 ref.)
Risk assessment for carcinogenesis promoting agents: need for a weight of all the evidence approach. Clayson DB. **Prog Clin Biol Res** 1995;391:359-67 (49 ref.)
Receptor-mediated carcinogenesis: the role of biological effect modeling for risk assessment of dioxin and tamoxifen. Demby KB, et al. **Prog Clin Biol Res** 1996;394:113-29 (57 ref.)
Liver tumor promotion: a process of natural selection. Jirtle RL. **Prog Clin Biol Res** 1995;391:149-59 (59 ref.)
Phenobarbital mouse liver tumors: implications of hepatic tumor promotion for cancer risk assessment. McClain RM. **Prog Clin Biol Res** 1995;391:325-36 (35 ref.)
The species specificity of dieldrin- or phenobarbital- induced hepatocarcinogenesis: case studies with implications for human health risk assessment. Stevenson DE, et al.
Prog Clin Biol Res 1995;391:337-45 (28 ref.)
Mechanistic considerations in risk assessment for epigenetic tumor-promoting carcinogens. Williams GM, et al.
Prog Clin Biol Res 1995;391:369-83 (69 ref.)
Holistic risk assessment: an emerging process for environmental decisions. Harvey T, et al.
Regul Toxicol Pharmacol 1995 Oct;22(2):110-7 (62 ref.)
Utilizing uncertainty factors in minimal risk levels derivation. Pohl HR, et al. **Regul Toxicol Pharmacol** 1995 Oct; 22(2):180-8 (52 ref.)
Chemical mixtures: current risk assessment methodologies and future directions. Seed J, et al.
Regul Toxicol Pharmacol 1995 Aug;22(1):76-94 (48 ref.)
Realistic risk assessment. Stöhrer G.
Regul Toxicol Pharmacol 1995 Oct;22(2):118-21 (26 ref.)
Risk analysis systems for veterinary biologicals: a regulator's tool box. Osborne CG, et al. **Rev Sci Tech** 1995 Dec; 14(4):925-35 (8 ref.)
Tissue dosimetry, pharmacokinetic modeling, and interspecies scaling factors. Andersen ME, et al.
Risk Anal 1995 Aug;15(4):533-7 (25 ref.)
Gender differences in risk perception: effects differ in stressed vs. non-stressed environments. Greenberg MR, et al.
Risk Anal 1995 Aug;15(4):503-11 (29 ref.)
Extrapolation of physiological parameters for physiologically based simulation models. Fiserova-Bergerova V.
Toxicol Lett 1995 Sep;79(1-3):77-86 (39 ref.)
Achieving credibility in risk assessment models. Kohn MC. **Toxicol Lett** 1995 Sep;79(1-3):107-14 (19 ref.)
Risk assessment and research: an essential link. Vandenberg JJ. **Toxicol Lett** 1995 Sep;79(1-3):17-22 (11 ref.)
Commentary. The uncontrolled variable in risk assessment: ad libitum overfed rodents--fat, facts and fiction. Keenan KP. **Toxicol Pathol** 1996 May-Jun;24(3):376-83 (57 ref.)
Incorporating biological information in quantitative risk assessment: an example with methylene chloride. Clewell HJ 3rd. **Toxicology** 1995 Sep 1;102(1-2):83-94 (33 ref.)
Cancer and non-cancer risk assessment: not so different if you consider mechanisms. Conolly RB. **Toxicology** 1995 Sep 1;102(1-2):179-88 (31 ref.)
The future of mechanistic research in risk assessment: where are we going and can we get there from here? Goddard MJ, et al. **Toxicology** 1995 Sep 1;102(1-2):53-70 (84 ref.)
Historical perspective on risk assessment in the federal government. Graham JD. **Toxicology** 1995 Sep 1; 102(1-2):29-52 (169 ref.)
Risk assessment and biological mechanisms: lessons learned, future opportunities. McClellan RO. **Toxicology** 1995 Sep 1;102(1-2):239-58 (48 ref.)
Assessing the risk assessment paradigm. Omenn GS.
Toxicology 1995 Sep 1;102(1-2):23-8 (24 ref.)
Risk assessment: toxicity from chemical exposure resulting from enhanced expression of CYP2E1. Raucy JL.
Toxicology 1995 Dec 28;105(2-3):217-24 (48 ref.)
Research to strengthen the scientific basis for health risk assessment: a survey of the context and rationale for mechanistically based methods and models. Sexton K, et al. **Toxicology** 1995 Sep 1;102(1-2):3-20 (62 ref.)
[Principles of evaluation of public health risk for environmental exposures] Bard D.
Rev Epidemiol Sante Publique 1995;43(5):423-31 (11 ref.) (Eng. Abstr.) **(Fre)**

RISK BEHAVIOR see RISK-TAKING

RISK FACTORS

[The concept of risk factors and flight certificate examination] Vlasov VV. **Aviakosm Ekolog Med** 1995;29(5):4-9 (60 ref.) (Eng. Abstr.) **(Rus)**

RISK MANAGEMENT

Managed health care. Managing the risks of laboratory testing in an integrated delivery system. Cooney MM.
Am J Clin Pathol 1995 Oct;104(4 Suppl 1):S50-3 (14 ref.)
Individual susceptibility to occupational toxicants: practical consequences for risk management. Norseth T.
Arch Toxicol Suppl 1996;18:367-78 (37 ref.)
Risk communication: a tool for behavior change. McCallum DB. **NIDA Res Monogr** 1995;155:65-89 (27 ref.)
Interindividual variations in susceptibility and sensitivity: linking risk assessment and risk management. Preston RJ.
Toxicology 1996 Jul 17;111(1-3):331-41 (42 ref.)
[Risk control in libraries] Bellante De Martiis G, et al.
Ann Ig 1996 Jan-Feb;8(1):35-46 (30 ref.) (Eng. Abstr.) **(Ita)**

ORGANIZATION & ADMINISTRATION

An introduction to risk adjustment. Iezzoni LI.
Am J Med Qual 1996 Spring;11(1):S8-11 (17 ref.)

RISK-TAKING

Effectiveness in adolescent health. Macfarlane A.
Acta Paediatr 1995 Oct;84(10):1089-93 (19 ref.)
Enabling approaches for HIV/AIDS prevention: can we modify the environment and minimize the risk? [editorial] Tawil O, et al. **AIDS** 1995 Dec;9(12):1299-306 (76 ref.)
Risk of HIV infection in psychiatrically ill patients. Grassi L. **AIDS Care** 1996 Feb;8(1):103-16 (79 ref.)
Health risk behaviors for Hispanic women. Torres S, et al.
Annu Rev Nurs Res 1995;13:293-319 (94 ref.)
Psychiatric patients and HIV infection: a new population at risk? Stefan MD, et al. **Br J Psychiatry** 1995 Dec; 167(6):721-7 (32 ref.)
Behavioral risk factors related to chronic diseases in ethnic minorities. Myers HF, et al. **Health Psychol** 1995 Dec; 14(7):613-21 (65 ref.)
Risk-taking and abusive behaviors among ethnic minorities. Yee BW, et al. **Health Psychol** 1995 Dec;14(7):622-31 (100 ref.)
Female drug abusers and the context of their HIV transmission risk behaviors. Allen K.
NIDA Res Monogr 1994;143:48-63 (14 ref.)
HIV risk in adolescents: the role of sexual activity and substance use behaviors. Boyer CB, et al.
NIDA Res Monogr 1994;143:135-54 (51 ref.)
Assessing the reliability and validity of self-reported risk behavior. Gibson DR, et al. **NIDA Res Monogr** 1994; 143:218-36 (13 ref.)
Future directions for studies on the context of HIV risk. Grace WC, et al. **NIDA Res Monogr** 1994;143:236-45 (6 ref.)
The context of risk: ethnographic contributions to the study of drug use and HIV. Koester SK. **NIDA Res Monogr** 1994; 143:202-17 (36 ref.)
HIV risk behaviors of heterosexual male drug users. Needle RH. **NIDA Res Monogr** 1994;143:5-8 (2 ref.)
Factors associated with sexual risk of AIDS in women. O'Leary A. **NIDA Res Monogr** 1994;143:64-81 (82 ref.)
Injection and sexual risk behaviors of male heterosexual injecting drug users. Stephens RC, et al.
NIDA Res Monogr 1994;143:9-25 (48 ref.)
Drug use and HIV risk among male sex workers: results of two samples in San Francisco. Waldorf D.
NIDA Res Monogr 1994;143:114-31 (18 ref.)
Anabolic steroid use and associated health risk behaviours. Middleman AB, et al. **Sports Med** 1996 Apr;21(4):251-5 (26 ref.)

RISPERIDONE

ADVERSE EFFECTS

Novel versus conventional antipsychotic drugs. Love RC.
Pharmacotherapy 1996 Jan-Feb;16(1 Pt 2):6-10 (24 ref.)

PHARMACOKINETICS

Pharmacokinetics of clozapine and risperidone: a review of recent literature. Byerly MJ, et al.
J Clin Psychopharmacol 1996 Apr;16(2):177-87 (78 ref.)

THERAPEUTIC USE

Clinical experience with risperidone. Marder SR.
J Clin Psychiatry 1996;57 Suppl 9:57-61 (36 ref.)
Risperidone and related 5HT2/D2 antagonists: a new type of antipsychotic agent? Megens AA, et al.
Prog Med Chem 1996;33:185-232 (113 ref.)
Risperidone: efficacy and safety. Umbricht D, et al.
Schizophr Bull 1995;21(4):593-606 (22 ref.)

RITTER DISEASE see STAPHYLOCOCCAL SCALDED SKIN SYNDROME

RNA

see related
REPETITIVE SEQUENCES, NUCLEIC ACID

The origin and early evolution of life: prebiotic chemistry, the pre-RNA world, and time. Lazcano A, et al. **Cell** 1996 Jun 14;85(6):793-8 (53 ref.)
Re-creating the RNA world. Hirao I, et al. **Curr Biol** 1995 Sep 1;5(9):1017-22 (50 ref.)
The search for missing links between self-replicating nucleic acids and the RNA world. James KD, et al.
Orig Life Evol Biosph 1995 Dec;25(6):515-30 (76 ref.)
[Stability prediction of active structures of nucleic acids] Sugimoto N. **Tanpakushitsu Kakusan Koso** 1994 Jul; 40(10):1548-57 (28 ref.) **(Jpn)**
[Structural motifs in interactions of nucleic acids] Takenaka A, et al. **Tanpakushitsu Kakusan Koso** 1994 Jul; 40(10):1527-39 (129 ref.) **(Jpn)**

ANALYSIS

RNA localization and the cytoskeleton in Drosophila oocytes. Pokrywka NJ. **Curr Top Dev Biol** 1995;31:139-66 (49 ref.)
Sequence-specific and hydrolytic scission of DNA and RNA by lanthanide complex-oligoDNA hybrids. Komiyama M.
J Biochem (Tokyo) 1995 Oct;118(4):665-70 (46 ref.)
Fluorescence in situ hybridization for the detection of DNA and RNA. Albertson DG, et al. **Methods Cell Biol** 1995; 48:339-64 (27 ref.)
In situ hybridization analysis of chick embryos in whole mount and tissue sections. Nieto MA, et al.
Methods Cell Biol 1996;51:219-35 (9 ref.)
Whole-mount in situ hybridization for the detection of RNA in Caenorhabditis elegans embryos. Seydoux G, et al.
Methods Cell Biol 1995;48:323-37 (19 ref.)

BIOSYNTHESIS

Nuclear ultrastructures associated with the RNA synthesis and processing. Raška I. **J Cell Biochem** 1995 Sep; 59(1):11-26 (46 ref.)
The role of p53 in regulating genomic stability when DNA and RNA synthesis are inhibited. Chernova OB, et al.
Trends Biochem Sci 1995 Oct;20(10):431-4 (49 ref.)

CHEMISTRY

Are engineered proteins getting competition from RNA? Breaker RR. **Curr Opin Biotechnol** 1996 Aug;7(4):442-8 (54 ref.)
Crystallization and structure determination of RNA. Lietzke SE, et al. **Curr Opin Struct Biol** 1995 Oct;5(5):645-9 (58 ref.)
Calorimetry of proteins and nucleic acids. Plum GE, et al.
Curr Opin Struct Biol 1995 Oct;5(5):682-90 (71 ref.)
RNA folding. Pyle AM, et al. **Curr Opin Struct Biol** 1995 Jun;5(3):303-10 (53 ref.)
Surface plasmon resonance and its use in biomolecular interaction analysis (BIA). Szabo A, et al.
Curr Opin Struct Biol 1995 Oct;5(5):699-705 (38 ref.)
RNA cleavage by small catalytic RNAs. Tuschl T, et al.
Curr Opin Struct Biol 1995 Jun;5(3):296-302 (53 ref.)
RNA recognition and cleavage by iron(II)-bleomycin. Battigello JM, et al. **Met Ions Biol Syst** 1996;33:593-617 (98 ref.)
Targeting of nucleic acids by iron complexes. Draganescu A, et al. **Met Ions Biol Syst** 1996;33:453-84 (92 ref.)
Zinc complexes as targeting agents for nucleic acids. Kimura E, et al. **Met Ions Biol Syst** 1996;33:29-52 (30 ref.)
Hydrolytic cleavage of RNA catalyzed by metal ion complexes. Morrow JR. **Met Ions Biol Syst** 1996;33:561-92 (116 ref.)
Porphyrin and metalloporphyrin interactions with nucleic acids. Pasternack RF, et al. **Met Ions Biol Syst** 1996; 33:367-97 (114 ref.)
Refinement of protein and nucleic acid structures. Westhof E, et al. **Methods Mol Biol** 1996;56:227-44 (39 ref.)
The importance of being modified: roles of modified nucleosides and Mg2+ in RNA structure and function. Agris PF. **Prog Nucleic Acid Res Mol Biol** 1996;53:79-129 (175 ref.)
Chemical and computer probing of RNA structure. Kolchanov NA, et al. **Prog Nucleic Acid Res Mol Biol** 1996;53:131-96 (193 ref.)

GENETICS

Fluorescence in situ hybridization: a brief review. Swiger RR, et al. **Environ Mol Mutagen** 1996;27(4):245-54 (69 ref.)
Nucleic acid fingerprinting by PCR-based methods: applications to problems in aging and mutagenesis. Welsh J, et al. **Mutat Res** 1995 Oct;338(1-6):215-29 (72 ref.)

METABOLISM

The nucleic acid ligand. A new tool for molecular recognition. McGown LB, et al. **Anal Chem** 1995 Nov 1; 67(21):663A-668A (28 ref.)
Protein-RNA recognition. Draper DE.
Annu Rev Biochem 1995;64:593-620 (183 ref.)
To cleave or not to cleave: ribozymes and antisense. Woolf TM. **Antisense Res Dev** 1995 Fall;5(3):227-32 (34 ref.)
Bovine pancreatic ribonuclease A as a model of an enzyme with multiple substrate binding sites. Nogués MV, et al.

Biochim Biophys Acta 1995 Nov 15;1253(1):16–24 (55 ref.)
Are engineered proteins getting competition from RNA? Breaker RR. **Curr Opin Biotechnol** 1996 Aug;7(4):442–8 (54 ref.)
RNA–protein complexes. Nagai K. **Curr Opin Struct Biol** 1996 Feb;6(1):53–61 (60 ref.)
Relationships between proteasomes and RNA. Schmid HP, et al. **Mol Biol Rep** 1995;21(1):43–7 (46 ref.)
The importance of being modified: roles of modified nucleosides and Mg2+ in RNA structure and function. Agris PF. **Prog Nucleic Acid Res Mol Biol** 1996;53:79–129 (175 ref.)
Nucleocytoplasmic transport. Görlich D, et al. **Science** 1996 Mar 15;271(5255):1513–8 (77 ref.)

PHYSIOLOGY

The developmental consequences of alternate splicing in sex determination and differentiation in Drosophila. MacDougall C, et al. **Dev Biol** 1995 Dec;172(2):353–76 (144 ref.)

RNA, ANTISENSE

Ribozyme mimics as catalytic antisense reagents. Bashkin JK, et al. **Appl Biochem Biotechnol** 1995 Jul–Sep;54(1–3):43–56 (21 ref.)
Depletion of nuclear poly(ADP-ribose) polymerase by antisense RNA expression: influence on genomic stability, chromatin organization, DNA repair, and DNA replication. Simbulan–Rosenthal CM, et al. **Prog Nucleic Acid Res Mol Biol** 1996;55:135–56 (68 ref.)
Antisense strategies in the treatment of hematological malignancies. Szakiel G. **Stem Cells** 1995 Dec;13 Suppl 3:88–92 (22 ref.)

ANALYSIS

[Antisense strategies in studies on the role of sugar chains in phenotype expression of neoplasms] Ugorski M. **Postepy Hig Med Dosw** 1995;49(1):77–84 (22 ref.) (Eng. Abstr.) **(Pol)**

GENETICS

Suppression of flavonoid flower pigmentation genes in Petunia hybrida by the introduction of antisense and sense genes. de Lange P, et al. **Curr Top Microbiol Immunol** 1995; 197:57–75 (88 ref.)
Sense and antisense inactivation of fruit ripening genes in tomato. Hamilton AJ, et al. **Curr Top Microbiol Immunol** 1995;197:77–89 (70 ref.)
A mechanism for beta-amyloid overproduction in Alzheimer's disease: precursor-independent generation of beta-amyloid via antisense RNA-primed mRNA synthesis. Volloch V. **FEBS Lett** 1996 Jul 22;390(2):124–8 (31 ref.)

RNA, BACTERIAL

ANALYSIS

Bacillus piliformis infection (Tyzzer's disease) in a patient infected with HIV-1: confirmation with 16S ribosomal RNA sequence analysis. Smith KJ, et al. **J Am Acad Dermatol** 1996 Feb;34(2 Pt 2):343–8 (18 ref.)

BIOSYNTHESIS

Control of rRNA transcription in Escherichia coli. Condon C, et al. **Microbiol Rev** 1995 Dec;59(4):623–45 (369 ref.)

GENETICS

RNA interactions in the regulation of transcription. von Hippel PH, et al. **Nucleic Acids Symp Ser** 1995;(33):1–4 (14 ref.)

METABOLISM

RNA interactions in the regulation of transcription. von Hippel PH, et al. **Nucleic Acids Symp Ser** 1995;(33):1–4 (14 ref.)

RNA-BINDING PROTEINS

CHEMISTRY

Structure and function of the rotavirus RNA-binding proteins. Patton JT. **J Gen Virol** 1995 Nov;76 (Pt 11):2633–44 (75 ref.)
Targeting of nucleic acids by iron complexes. Draganescu A, et al. **Met Ions Biol Syst** 1996;33:453–84 (92 ref.)

GENETICS

The superfamily of arginine/serine-rich splicing factors. Fu XD. **RNA** 1995 Sep;1(7):663–80 (160 ref.)
The molecular control mechanisms of meiosis in fission yeast. Yamamoto M. **Trends Biochem Sci** 1996 Jan;21(1):18–22 (48 ref.)
[Structure and function of FMR] Huang T, et al. **Sheng Li Ke Hsueh Chin Chan** 1995 Jul;26(3):218–22 (18 ref.) (Eng. Abstr.) **(Chi)**

METABOLISM

Masking of mRNA by Y-box proteins. Sommerville J, et al. **FASEB J** 1996 Mar;10(4):435–43 (64 ref.)
The PI/PTB domain: a new protein interaction domain involved in growth factor receptor signaling. Margolis B. **J Lab Clin Med** 1996 Sep;128(3):235–41 (66 ref.)
Double-stranded RNA binding proteins and their substrates. Bass BL. **Nucleic Acids Symp Ser** 1995;(33):13–5 (9 ref.)
[EBER-1 expression in salivary glands of Sjögren's syndrome] Nomura H, et al. **Nippon Rinsho** 1995 Oct; 53(10):2490–4 (22 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Iron–sulphur clusters as genetic regulatory switches: the bifunctional iron regulatory protein–1. Paraskeva E, et al. **FEBS Lett** 1996 Jun 24;389(1):40–3 (50 ref.)
Structure and function of the rotavirus RNA-binding proteins. Patton JT. **J Gen Virol** 1995 Nov;76 (Pt 11):2633–44 (75 ref.)
Molecular control of vertebrate iron metabolism: mRNA-based regulatory circuits operated by iron, nitric oxide, and oxidative stress. Hentze MW, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8175–82 (151 ref.)

RNA CAPS

PHYSIOLOGY

Cap–independent translation and internal initiation of translation in eukaryotic cellular mRNA molecules. Iizuka N, et al. **Curr Top Microbiol Immunol** 1995;203:155–77 (116 ref.)
Cap–dependent and cap–independent translation: operational distinctions and mechanistic interpretations. Jackson RJ, et al. **Curr Top Microbiol Immunol** 1995;203:1–29 (111 ref.)
Cap–independent translation of heat shock messenger RNAs. Rhoads RE, et al. **Curr Top Microbiol Immunol** 1995; 203:131–53 (108 ref.)
Cap–independent translation in adenovirus infected cells. Schneider RJ. **Curr Top Microbiol Immunol** 1995; 203:117–29 (61 ref.)
The influence of 5' and 3' end structures on pre–mRNA metabolism. Lewis JD, et al. **J Cell Sci Suppl** 1995;19:13–9 (66 ref.)

RNA, CATALYTIC

Application of ribozymes to cancer gene therapy. Kashani–Sabet M, et al. **Cancer Gene Ther** 1995 Sep; 2(3):213–23 (102 ref.)
[Structure and molecular design of ribozymes] Ohtsuka E, et al. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1400–7 (22 ref.) **(Jpn)**
[Directed molecular evolution of oligonucleotides] Terabe M. **Tanpakushitsu Kakusan Koso** 1996 Feb;41(2):166–9 (16 ref.) **(Jpn)**

CHEMISTRY

RNA cleavage by small catalytic RNAs. Tuschl T, et al. **Curr Opin Struct Biol** 1995 Jun;5(3):296–302 (53 ref.)
Hammerhead ribozyme engineering. Usman N, et al. **Curr Opin Struct Biol** 1996 Aug;6(4):527–33 (61 ref.)
Oligonucleotide–mediated modulation of mammalian gene expression. Scanlon KJ, et al. **FASEB J** 1995 Oct; 9(13):1288–96 (68 ref.)
Structure and function of the hammerhead ribozyme: an unfinished story. McKay DB. **RNA** 1996 May;2(5):395–403 (35 ref.)
Hammerhead ribozyme structure: U-turn for RNA structural biology. Doudna JA. **Structure** 1995 Aug 15;3(8):747–50 (20 ref.)
[Structural analysis of ribozymes] Uesugi S. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1494–501 (18 ref.) **(Jpn)**

GENETICS

Retrohoming: cDNA–mediated mobility of group II introns requires a catalytic RNA. Curcio MJ, et al. **Cell** 1996 Jan 12;84(1):9–12 (15 ref.)
RNase P--a 'Scarlet Pimpernel'. Kirsebom LA. **Mol Microbiol** 1995 Aug;17(3):411–20 (75 ref.)
Regulation of the hepatitis delta virus ribozymes: to cleave or not to cleave? Lazinski DW, et al. **RNA** 1995 May; 1(3):225–33 (70 ref.)

METABOLISM

To cleave or not to cleave: ribozymes and antisense. Woolf TM. **Antisense Res Dev** 1995 Fall;5(3):227–32 (34 ref.)
Ribozyme mimics as catalytic antisense reagents. Bashkin JK, et al. **Appl Biochem Biotechnol** 1995 Jul–Sep;54(1–3):43–56 (21 ref.)
Colocalizing ribozymes with substrate RNAs to increase their efficacy as gene inhibitors. Sullenger BA. **Appl Biochem Biotechnol** 1995 Jul–Sep;54(1–3):57–61 (28 ref.)
Hammerhead ribozyme engineering. Usman N, et al. **Curr Opin Struct Biol** 1996 Aug;6(4):527–33 (61 ref.)
Enzymes: chemistry and biochemistry. Jeffery J. **EXS** 1995; 73:79–104 (181 ref.)
Ribozymes: from mechanistic studies to applications in vivo. Ohkawa J, et al. **J Biochem (Tokyo)** 1995 Aug;118(2):251–8 (58 ref.)
Role of metal ions in ribozymes. Pyle AM. **Met Ions Biol Syst** 1996;32:479–520 (136 ref.)
RNase P--a 'Scarlet Pimpernel'. Kirsebom LA. **Mol Microbiol** 1995 Aug;17(3):411–20 (75 ref.)
How many different RNA enzymes. Karwan R. **Nucleic Acids Symp Ser** 1995;(33):103–5 (22 ref.)
Eukaryotic nuclear RNase P: structures and functions. Chamberlain JR, et al. **Prog Nucleic Acid Res Mol Biol** 1996;55:87–119 (145 ref.)
Structure and function of the hammerhead ribozyme: an unfinished story. McKay DB. **RNA** 1996 May;2(5):395–403 (35 ref.)

PHARMACOLOGY

Oligonucleotide modulation of multidrug resistance. Bouffard DY, et al. **Eur J Cancer** 1996 Jun;32A(6):1010–8 (111 ref.)
[Inhibition of HIV replication by ribozyme strategy] Ohkawa J, et al. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1421–9 (32 ref.) **(Jpn)**

THERAPEUTIC USE

Alternative approaches for the application of ribozymes as gene therapies for retroviral infections. Campbell TB, et al. **Adv Pharmacol** 1995;33:143–78 (146 ref.)
Ribozymes in gene therapy. Thompson JD, et al. **Nat Med** 1995 Mar;1(3):277–8 (11 ref.)
Therapeutic applications of ribozymes. Kijima H, et al. **Pharmacol Ther** 1995;68(2):247–67 (200 ref.)

RNA, CHLOROPLAST

GENETICS

RNA editing in plant organelles: a fertile field. Gray MW. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8157–9 (53 ref.)

RNA, CHROMOSOMAL see **RNA, NUCLEAR**

RNA-DEPENDENT DNA POLYMERASE see **RNA-DIRECTED DNA POLYMERASE**

RNA-DEPENDENT RNA POLYMERASE see **RNA REPLICASE**

RNA-DIRECTED DNA POLYMERASE

Introduction to quantitative reverse transcription polymerase chain reaction. Salomon RN. **Diagn Mol Pathol** 1995 Jun; 4(2):82–4 (8 ref.)
Quantitative RT-PCR for neuroendocrine studies. A minireview. Zamorano PL, et al. **Neuroendocrinology** 1996 May;63(5):397–407 (39 ref.)

BIOSYNTHESIS

Mechanisms of intron mobility. Belfort M, et al. **J Biol Chem** 1995 Dec 22;270(51):30237–40 (55 ref.)

CHEMISTRY

A model for DNA polymerase translocation: worm–like movement of DNA within the binding cleft. Wlassoff WA, et al. **FEBS Lett** 1996 Jul 15;390(1):6–9 (37 ref.)

DRUG EFFECTS

Non–nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of human immunodeficiency virus type 1 (HIV–1) infections: strategies to overcome drug resistance development. de Clercq E. **Med Res Rev** 1996 Mar;16(2):125–57 (180 ref.)

METABOLISM

Delavirdine mesylate, a potent non–nucleoside HIV–1 reverse transcriptase inhibitor. Freimuth WW. **Adv Exp Med Biol** 1996;394:279–89 (42 ref.)
Clinical experience with non–nucleoside reverse transcriptase inhibitors: L–697,661 and nevirapine. Kilby JM, et al. **Adv Exp Med Biol** 1996;394:291–8 (23 ref.)
HIV–1 virology. Simply Marvelous nuclear transport. Goldfarb DS. **Curr Biol** 1995 Jun 1;5(6):570–3 (19 ref.)
Non–nucleoside anti–HIV–1 reverse transcriptase inhibitors (NNRTIs): a chemical survey from lead compounds to selected drugs for clinical trials. Artico M. **Farmaco** 1996 May;51(5):305–31 (92 ref.)
A model for DNA polymerase translocation: worm–like movement of DNA within the binding cleft. Wlassoff WA, et al. **FEBS Lett** 1996 Jul 15;390(1):6–9 (37 ref.)

PHYSIOLOGY

Unusual reverse transcriptases. Singer MF. **J Biol Chem** 1995 Oct 20;270(42):24623–6 (58 ref.)

RNA, DOUBLE-STRANDED

GENETICS

Ribosomal frameshifting in yeast viruses. Dinman JD. **Yeast** 1995 Sep 30;11(12):1115–27 (60 ref.)

METABOLISM

Double-stranded RNA binding proteins and their substrates. Bass BL. **Nucleic Acids Symp Ser** 1995;(33):13-5 (9 ref.)

PHYSIOLOGY

When two strands are better than one: the mediators and modulators of the cellular responses to double-stranded RNA. Jacobs BL, et al. **Virology** 1996 May 15; 219(2):339-49 (173 ref.)

RNA EDITING

Mechanism and evolution of RNA editing in kinetoplastida. Arts GJ, et al. **Biochim Biophys Acta** 1996 Jun 3; 1307(1):39-54 (150 ref.)

RNA editing. An I for editing. Bass BL. **Curr Biol** 1995 Jun 1;5(6):598-600 (15 ref.)

The role of RNA editing in controlling glutamate receptor channel properties. Seeburg PH. **J Neurochem** 1996 Jan; 66(1):1-5 (38 ref.)

RNA editing in plant organelles: a fertile field. Gray MW. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8157-9 (53 ref.)

Trypanosome RNA editing: resolved [comment] Sollner-Webb B. **Science** 1996 Aug 30;273(5279):1182-3 (17 ref.) Comment on: Science 1996 Aug 30;273(5279):1189-95.

GENETICS

RNA editing: how a message is changed. Benne R. **Curr Opin Genet Dev** 1996 Apr;6(2):221-31 (99 ref.)

Apolipoprotein B mRNA editing protein: a tool for dissecting lipoprotein metabolism and a potential therapeutic gene for hypercholesterolemia. Chan L, et al. **Z Gastroenterol** 1996 Jun;34 Suppl 3:31-2 (16 ref.)

Reconstitution of apoB mRNA editing in liver by gene-transfer as a potential approach for the treatment of severe forms of polygenic hypercholesterolemia--an outline of the rationale. Greeve J, et al. **Z Gastroenterol** 1996 Jun;34 Suppl 3:27-30 (70 ref.)

RNA, FUNGAL

BIOSYNTHESIS

Yeast RNA polymerase III: transcription complexes and RNA synthesis. Geiduschek EP, et al. **Braz J Med Biol Res** 1995 Feb;28(2):147-59 (133 ref.)

CHEMISTRY

Secondary structure conservation of the U3 small nucleolar RNA introns in Saccharomyces. Brulé F, et al. **C R Acad Sci III** 1995 Dec;318(12):1197-206 (48 ref.)

GENETICS

The molecular control mechanisms of meiosis in fission yeast. Yamamoto M. **Trends Biochem Sci** 1996 Jan;21(1):18-22 (48 ref.)

METABOLISM

The pathway to maturity: processing of ribosomal RNA in Saccharomyces cerevisiae. Raué HA, et al. **Gene Expr** 1995; 5(1):71-7 (56 ref.)

Processing of pre-ribosomal RNA in Saccharomyces cerevisiae. Venema J, et al. **Yeast** 1995 Dec;11(16):1629-50 (142 ref.)

RNA, GUIDE

see related
RNA EDITING

METABOLISM

Trypanosome RNA editing: resolved [comment] Sollner-Webb B. **Science** 1996 Aug 30;273(5279):1182-3 (17 ref.) Comment on: Science 1996 Aug 30;273(5279):1189-95.

RNA, MESSENGER

Antisense oligodeoxynucleotides directed against the Na-Ca exchanger mRNA. Promising tools for studies on the cellular and molecular level. Niggli E, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:93-102 (33 ref.)

ANALYSIS

Acute leukemias expressing p210-and p 190-type bcr/abl mRNAs: report of two cases and review of the literature. Yamashita S, et al. **Acta Haematol** 1996;96(2):99-104 (23 ref.)

mRNA localisation during development. Micklem DR. **Dev Biol** 1995 Dec;172(2):377-95 (165 ref.)

Molecular Endocrinology of the oxytocin receptor. Kimura T, et al. **Endocr J** 1995 Oct;42(5):607-15 (62 ref.)

Detection of breast cancer micrometastases in lymph nodes by amplification of keratin 19 mRNA with reverse-transcriptase polymerase chain reaction. Noguchi S, et al. **Gan To Kagaku Ryoho** 1996 Mar;23 Suppl 1:50-5 (9 ref.)

Molecular pharmacology of the opioid receptors. Satoh M, et al. **Pharmacol Ther** 1995;68(3):343-64 (158 ref.)

[Messenger RNA of duodenal cholecystokinin: thanks to endoscopy... (editorial)] Chayvialle JA. **Gastroenterol Clin Biol** 1995 Aug-Sep;19(8-9):657-8 (13 ref.) **(Fre)**

[Quantitative PCR] Kawakami B, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):503-9 (16 ref.) **(Jpn)**

[Reverse transcriptase-polymerase chain reaction] Murakami Y. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):595-602 (12 ref.) **(Jpn)**

[Differential display analysis of mRNA] Nakagama H, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):580-4 (4 ref.) **(Jpn)**

BIOSYNTHESIS

Coronaviruses use discontinuous extension for synthesis of subgenome-length negative strands. Sawicki SG, et al. **Adv Exp Med Biol** 1995;380:499-506 (21 ref.)

Regulation of transcription of coronaviruses. van Marle G, et al. **Adv Exp Med Biol** 1995;380:507-10 (23 ref.)

Tissue-specific expression of rat neutral endopeptidase mRNAs. Li C, et al. **Ann N Y Acad Sci** 1996 Mar 22; 780:145-55 (10 ref.)

RNA editing. An I for editing. Bass BL. **Curr Biol** 1995 Jun 1;5(6):598-600 (15 ref.)

Trophic factor response to neuronal stimuli or injury. Isackson PJ. **Curr Opin Neurobiol** 1995 Jun;5(3):350-7 (75 ref.)

A mechanism for beta-amyloid overproduction in Alzheimer's disease: precursor-independent generation of beta-amyloid via antisense RNA-primed mRNA synthesis. Volloch V. **FEBS Lett** 1996 Jul 22;390(2):124-8 (31 ref.)

The formation of mRNA 3'-ends in plants. Wu L, et al. **Plant J** 1995 Sep;8(3):323-9 (35 ref.)

Glial fibrillary acidic protein mRNA and the development of gliosis in mice with chronic relapsing experimental allergic encephalomyelitis. Kothavale A, et al. **Prog Brain Res** 1995;105:305-10 (20 ref.)

CHEMISTRY

Strategies for RNA folding. Draper DE. **Trends Biochem Sci** 1996 Apr;21(4):145-9 (38 ref.)

GENETICS

Selenium and cellular immunity. Evidence that selenoproteins may be encoded in the +1 reading frame overlapping the human CD4, CD8, and HLA-DR genes. Taylor EW. **Biol Trace Elem Res** 1995 Aug-Sep;49(2-3):85-95 (37 ref.)

Estrogen regulated messenger RNAs in human breast cancer cells. May FE, et al. **Biomed Pharmacother** 1995; 49(9):400-14 (85 ref.)

A signaling pathway to translational control. Brown EJ, et al. **Cell** 1996 Aug 23;86(4):517-20 (20 ref.)

Use of non-radioactive probes for mRNA detection by in situ hybridization: interests and applications in the central nervous system. Le Moine C, et al. **Cell Mol Biol (Noisy-le-grand)** 1995 Nov;41(7):917-23 (37 ref.)

Transcription and masking of mRNA in germ cells: involvement of Y-box proteins. Sommerville J, et al. **Chromosoma** 1996 Apr;104(7):469-78 (66 ref.)

Initial splice-site recognition and pairing during pre-mRNA splicing. Reed R. **Curr Opin Genet Dev** 1996 Apr; 6(2):215-20 (47 ref.)

Cap-independent translation and internal initiation of translation in eukaryotic cellular mRNA molecules. Iizuka N, et al. **Curr Top Microbiol Immunol** 1995;203:155-77 (116 ref.)

Cap-independent translation of heat shock messenger RNAs. Rhoads RE, et al. **Curr Top Microbiol Immunol** 1995; 203:131-53 (108 ref.)

The polytene nucleus in morphological, cytochemical, and functional studies of messenger RNA transcription, processing, and transportation. Vázquez Nin GH, et al. **Eur J Histochem** 1996;40(1):7-16 (116 ref.)

A mechanism for beta-amyloid overproduction in Alzheimer's disease: precursor-independent generation of beta-amyloid via antisense RNA-primed mRNA synthesis. Volloch V. **FEBS Lett** 1996 Jul 22;390(2):124-8 (31 ref.)

Alternative splicing of the estrogen receptor primary transcript normally occurs in estrogen receptor positive tissues and cell lines. Pfeffer U, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1-6 Spec No):99-105 (37 ref.)

Neuropeptide messenger plasticity in the CNS neurons following axotomy. Palkovits M. **Mol Neurobiol** 1995 Apr-Jun;10(2-3):91-103 (48 ref.)

Internal initiation of translation in eukaryotes: the picornavirus paradigm and beyond. Jackson RJ, et al. **RNA** 1995 Dec;1(10):985-1000 (104 ref.)

Apolipoprotein B mRNA editing protein: a tool for dissecting lipoprotein metabolism and a potential therapeutic gene for hypercholesterolemia. Chan L, et al. **Z Gastroenterol** 1996 Jun;34 Suppl 3:31-2 (16 ref.)

Reconstitution of apoB mRNA editing in liver by gene-transfer as a potential approach for the treatment of severe forms of polygenic hypercholesterolemia--an outline of the rationale. Greeve J, et al. **Z Gastroenterol** 1996 Jun;34 Suppl 3:27-30 (70 ref.)

[Structural and functional analysis of the internal ribosome entry site within 5' noncoding region of hepatitis C virus RNA] Fukushi S, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:36-42 (17 ref.) **(Jpn)**

ISOLATION & PURIFICATION

[Isolation of mRNA 5'-end using oligo-capping] Suzuki Y, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):603-7 (0 ref.) **(Jpn)**

METABOLISM

Use of non-radioactive probes for mRNA detection by in situ hybridization: interests and applications in the central nervous system. Le Moine C, et al. **Cell Mol Biol (Noisy-le-grand)** 1995 Nov;41(7):917-23 (37 ref.)

Some physiological outcomes of renin gene studies. Morris BJ. **Clin Exp Pharmacol Physiol** 1995 Dec;22(12):966-75 (146 ref.)

Translational control. Awakening dormant mRNAs. Vassalli JD, et al. **Curr Biol** 1995 May 1;5(5):476-9 (23 ref.)

Stretch-induced parathyroid hormone-related peptide gene expression: implication in the regulation of myogenic tone. Noda M, et al. **Curr Opin Nephrol Hypertens** 1995 Sep; 4(5):383-7 (23 ref.)

Posttranscriptional regulation of gene expression in liver regeneration: role of mRNA stability. Kren BT, et al. **FASEB J** 1996 Apr;10(5):559-73 (93 ref.)

Masking of mRNA by Y-box proteins. Sommerville J, et al. **FASEB J** 1996 Mar;10(4):435-43 (64 ref.)

Flow-dependent regulation of gene expression in vascular endothelial cells. Ando J, et al. **Jpn Heart J** 1996 Jan; 37(1):19-32 (40 ref.)

mRNA stability in mammalian cells. Ross J. **Microbiol Rev** 1995 Sep;59(3):423-50 (395 ref.)

Glucose transporter gene expression: regulation of transcription and mRNA stability. McGowan KM, et al. **Pharmacol Ther** 1995 Jun;66(3):465-505 (287 ref.)

Molecular control of vertebrate iron metabolism: mRNA-based regulatory circuits operated by iron, nitric oxide, and oxidative stress. Hentze MW, et al. **Proc Natl Acad Sci U S A** 1996 Aug 6;93(16):8175-82 (151 ref.)

When cells stop making sense: effects of nonsense codons on RNA metabolism in vertebrate cells. Maquat LE. **RNA** 1995 Jul;1(5):453-65 (110 ref.)

The second catalytic step of pre-mRNA splicing. Umen JG, et al. **RNA** 1995 Nov;1(9):869-85 (131 ref.)

The shrewd grasp of RNA polymerase [comment] Landick R, et al. **Science** 1996 Jul 12;273(5272):202-3 (19 ref.) Comment on: Science 1996 Jul 12;273(5272):211-7.

Trypanosome RNA editing: resolved [comment] Sollner-Webb B. **Science** 1996 Aug 30;273(5279):1182-3 (17 ref.) Comment on: Science 1996 Aug 30;273(5279):1189-95.

AU-rich elements: characterization and importance in mRNA degradation. Chen CY, et al. **Trends Biochem Sci** 1995 Nov;20(11):465-70 (42 ref.)

mRNA 3' ends in focus. O'Hare K. **Trends Genet** 1995 Jul; 11(7):255-7 (19 ref.)

[Cytokine mRNA expression in the labial glands of patients with Sjögren's syndrome] Ohyama Y, et al. **Nippon Rinsho** 1995 Oct;53(10):2412-7 (13 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Estrogen receptor mRNA variants. Do they have a physiological role? Pfeffer U. **Ann N Y Acad Sci** 1996 Apr 30;784:304-13 (38 ref.)

Sorting of messenger RNAs in the cytoplasm: mRNA localization and the cytoskeleton. Hesketh JE. **Exp Cell Res** 1996 Jun 15;225(2):219-36 (123 ref.)

Compartmentalization of specific pre-mRNA metabolism: an emerging view. Moen PT Jr, et al. **Hum Mol Genet** 1995; 4 Spec No:1779-89 (80 ref.)

RNA, MESSENGER, EDITING see RNA EDITING

RNA, MESSENGER, POLYADENYLATED see RNA, MESSENGER

RNA, MESSENGER, PRECURSORS see RNA PRECURSORS

RNA, MESSENGER, SPLICING see RNA SPLICING

RNA, NEOPLASM

GENETICS

Estrogen regulated messenger RNAs in human breast cancer cells. May FE, et al. **Biomed Pharmacother** 1995; 49(9):400-14 (85 ref.)

Alternative splicing of the estrogen receptor primary transcript normally occurs in estrogen receptor positive tissues and cell lines. Pfeffer U, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1-6 Spec No):99-105 (37 ref.)

RNA, NON-POLYADENYLATED see RNA

RNA, NUCLEAR

METABOLISM

Eukaryotic nuclear RNase P: structures and functions. Chamberlain JR, et al. **Prog Nucleic Acid Res Mol Biol** 1996;55:87–119 (145 ref.)

RNA NUCLEOTIDYLTRANSFERASES

CHEMISTRY

Primase structure and function. Griep MA. **Indian J Biochem Biophys** 1995 Aug;32(4):171–8 (64 ref.)

RNA, POLYADENYLATED see RNA, MESSENGER

RNA POLYMERASE I

METABOLISM

Species specificity of transcription by RNA polymerase I. Heix J, et al. **Curr Opin Genet Dev** 1995 Oct;5(5):652–6 (26 ref.)

RNA POLYMERASE II

CHEMISTRY

Chromatin structure and RNA polymerase II connection: implications for transcription. Struhl K. **Cell** 1996 Jan 26; 84(2):179–82 (15 ref.)

METABOLISM

The unique C-terminal domain of RNA polymerase II and its role in transcription. Kang ME, et al. **Adv Enzymol Relat Areas Mol Biol** 1995;71:41–77 (98 ref.)

Transcriptional activation. A holistic view of the complex. Carey MF. **Curr Biol** 1995 Sep 1;5(9):1003–5 (19 ref.)

The RNA polymerase II elongation complex. Aso T, et al. **FASEB J** 1995 Nov;9(14):1419–28 (79 ref.)

Reversible phosphorylation of the C-terminal domain of RNA polymerase II. Dahmus ME. **J Biol Chem** 1996 Aug 9;271(32):19009–12 (56 ref.)

Transcription syndromes and the role of RNA polymerase II general transcription factors in human disease. Aso T, et al. **J Clin Invest** 1996 Apr 1;97(7):1561–9 (119 ref.)

Biochemistry meets genetics in the holoenzyme. Berk AJ. **Proc Natl Acad Sci U S A** 1995 Dec 19;92(26):11952–4 (45 ref.)

PHYSIOLOGY

Transcription: basal factors and activation. Ranish JA, et al. **Curr Opin Genet Dev** 1996 Apr;6(2):151–8 (77 ref.)

RNA POLYMERASE III

GENETICS

Yeast RNA polymerase III: transcription complexes and RNA synthesis. Geiduschek EP, et al. **Braz J Med Biol Res** 1995 Feb;28(2):147–59 (133 ref.)

Transcription of adenovirus RNA polymerase III genes. Pruzan R, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 1):201–26 (116 ref.)

RNA POLYMERASES

CHEMISTRY

Polymerase structures and function: variations on a theme? Joyce CM, et al. **J Bacteriol** 1995 Nov;177(22):6321–9 (47 ref.)

GENETICS

[Association of human hepatitis B virus (HBV) X protein and hRPB5, a subunit of RNA polymerases, and X transactivation] Murakami S. **Nippon Rinsho** 1995 Oct;53 Suppl:75–81 (21 ref.) **(Jpn)**

METABOLISM

Mitochondrial transcription initiation: promoter structures and RNA polymerases. Tracy RL, et al. **Curr Genet** 1995 Aug;28(3):205–16 (103 ref.)

Open complex formation by Escherichia coli RNA polymerase: the mechanism of polymerase-induced strand separation of double helical DNA. deHaseth PL, et al. **Mol Microbiol** 1995 Jun;16(5):817–24 (72 ref.)

Signal sensing by sigma 54-dependent regulators: derepression as a control mechanism. Shingler V. **Mol Microbiol** 1996 Feb;19(3):409–16 (51 ref.)

The shrewd grasp of RNA polymerase [comment] Landick R, et al. **Science** 1996 Jul 12;273(5272):202–3 (19 ref.) Comment on: Science 1996 Jul 12;273(5272):211–7.

RNA PRECURSORS

GENETICS

Initial splice-site recognition and pairing during pre-mRNA splicing. Reed R. **Curr Opin Genet Dev** 1996 Apr; 6(2):215–20 (47 ref.)

Finding splice sites within a wilderness of RNA. Black DL. **RNA** 1995 Oct;1(8):763–71 (132 ref.)

AT-AC introns: an ATtACk on dogma [comment] Mount SM. **Science** 1996 Mar 22;271(5256):1690–2 (12 ref.) Comment on: Science 1996 Mar 22;271(5256):1716–8.

METABOLISM

The pathway to maturity: processing of ribosomal RNA in Saccharomyces cerevisiae. Raué HA, et al. **Gene Expr** 1995; 5(1):71–7 (56 ref.)

The role of PRP8 protein in nuclear pre-mRNA splicing in yeast. Beggs JD, et al. **J Cell Sci Suppl** 1995;19:101–3 (47 ref.)

The influence of 5' and 3' end structures on pre-mRNA metabolism. Lewis JD, et al. **J Cell Sci Suppl** 1995;19:13–9 (66 ref.)

When cells stop making sense: effects of nonsense codons on RNA metabolism in vertebrate cells. Maquat LE. **RNA** 1995 Jul;1(5):453–65 (110 ref.)

The second catalytic step of pre-mRNA splicing. Umen JG, et al. **RNA** 1995 Nov;1(9):869–85 (131 ref.)

Trypanosome RNA editing: resolved [comment] Sollner-Webb B. **Science** 1996 Aug 30;273(5279):1182–3 (17 ref.) Comment on: Science 1996 Aug 30;273(5279):1189–95.

Small RNA chaperones for ribosome biogenesis. Steitz JA, et al. **Science** 1995 Dec 8;270(5242):1626–7 (16 ref.)

Small nucleolar RNAs guide ribosomal RNA methylation. Tollervey D. **Science** 1996 Aug 23;273(5278):1056–7 (13 ref.)

Processing of pre-ribosomal RNA in Saccharomyces cerevisiae. Venema J, et al. **Yeast** 1995 Dec;11(16):1629–50 (142 ref.)

PHYSIOLOGY

Compartmentalization of specific pre-mRNA metabolism: an emerging view. Moen PT Jr, et al. **Hum Mol Genet** 1995; 4 Spec No:1779–89 (80 ref.)

RNA PROBES

Use of non-radioactive probes for mRNA detection by in situ hybridization: interests and applications in the central nervous system. Le Moine C, et al. **Cell Mol Biol (Noisy-le-grand)** 1995 Nov;41(7):917–23 (37 ref.)

Northern analysis and nucleic acid probes. Sabelli PA, et al. **Methods Mol Biol** 1995;49:213–28 (32 ref.)

Chemical and computer probing of RNA structure. Kolchanov NA, et al. **Prog Nucleic Acid Res Mol Biol** 1996;53:131–96 (193 ref.)

RNA PROCESSING, POST-TRANSCRIPTIONAL

The nucleolus. Shaw PJ, et al. **Ann Rev Cell Dev Biol** 1995; 11:93–121 (202 ref.)

Post-transcriptional control of adenovirus gene expression. Imperiale MJ, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 2):139–71 (143 ref.)

The pathway to maturity: processing of ribosomal RNA in Saccharomyces cerevisiae. Raué HA, et al. **Gene Expr** 1995; 5(1):71–7 (56 ref.)

Nuclear ultrastructures associated with the RNA synthesis and processing. Raška I. **J Cell Biochem** 1995 Sep; 59(1):11–26 (46 ref.)

Small RNA chaperones for ribosome biogenesis. Steitz JA, et al. **Science** 1995 Dec 8;270(5242):1626–7 (16 ref.)

Processing of pre-ribosomal RNA in Saccharomyces cerevisiae. Venema J, et al. **Yeast** 1995 Dec;11(16):1629–50 (142 ref.)

GENETICS

The influence of 5' and 3' end structures on pre-mRNA metabolism. Lewis JD, et al. **J Cell Sci Suppl** 1995;19:13–9 (66 ref.)

RNA, PROTOZOAN

GENETICS

Molecular identification of nanoplanktonic protists based on small subunit ribosomal RNA gene sequences for ecological studies. Lim EL. **J Eukaryot Microbiol** 1996 Mar–Apr; 43(2):101–6 (47 ref.)

RNA REPLICASE

METABOLISM

Proteolytic processing of the arterivirus replicase. Snijder E, et al. **Adv Exp Med Biol** 1995;380:443–51 (28 ref.)

RNA, RIBOSOMAL

BIOSYNTHESIS

Control of rRNA transcription in Escherichia coli. Condon C, et al. **Microbiol Rev** 1995 Dec;59(4):623–45 (369 ref.)

Small RNA chaperones for ribosome biogenesis. Steitz JA, et al. **Science** 1995 Dec 8;270(5242):1626–7 (16 ref.)

CHEMISTRY

Protein recognition of a ribosomal RNA tertiary structure. Draper DE, et al. **Nucleic Acids Symp Ser** 1995;(33):5–7 (20 ref.)

Strategies for RNA folding. Draper DE. **Trends Biochem Sci** 1996 Apr;21(4):145–9 (38 ref.)

[Structure and function of ribosomal RNA] Endo Y. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1485–93 (29 ref.) **(Jpn)**

GENETICS

Molecular identification of nanoplanktonic protists based on small subunit ribosomal RNA gene sequences for ecological studies. Lim EL. **J Eukaryot Microbiol** 1996 Mar–Apr; 43(2):101–6 (47 ref.)

Archaeal ubiquity. Stein JL, et al. **Proc Natl Acad Sci U S A** 1996 Jun 25;93(13):6228–30 (13 ref.)

METABOLISM

The pathway to maturity: processing of ribosomal RNA in Saccharomyces cerevisiae. Raué HA, et al. **Gene Expr** 1995; 5(1):71–7 (56 ref.)

Small nucleolar RNAs guide ribosomal RNA methylation. Tollervey D. **Science** 1996 Aug 23;273(5278):1056–7 (13 ref.)

PHYSIOLOGY

[Structure and function of ribosomal RNA] Endo Y. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1485–93 (29 ref.) **(Jpn)**

RNA, RIBOSOMAL, PRECURSORS see RNA PRECURSORS

RNA, RIBOSOMAL, SELF-SPLICING see RNA, CATALYTIC

RNA, RIBOSOMAL, 5S

CHEMISTRY

Ribosomal 5S RNA: tertiary structure and interactions with proteins. Barciszewska MZ, et al. **Biol Rev Camb Philos Soc** 1996 Feb;71(1):1–25 (135 ref.)

[Structure and function of 5S rRNA in ribosomes] Bogdanov AA, et al. **Mol Biol (Mosk)** 1995 Nov–Dec;29(6):1218–27 (56 ref.) **(Rus)**

GENETICS

[Structure and properties of transcription IIIA from Xenopus laevis] Wyszko E, et al. **Postepy Biochem** 1995;41(2):102–9 (56 ref.) **(Pol)**

METABOLISM

Ribosomal 5S RNA: tertiary structure and interactions with proteins. Barciszewska MZ, et al. **Biol Rev Camb Philos Soc** 1996 Feb;71(1):1–25 (135 ref.)

[Structure and function of 5S rRNA in ribosomes] Bogdanov AA, et al. **Mol Biol (Mosk)** 1995 Nov–Dec;29(6):1218–27 (56 ref.) **(Rus)**

RNA, RIBOSOMAL, 16S

ANALYSIS

Bacillus piliformis infection (Tyzzer's disease) in a patient infected with HIV-1: confirmation with 16S ribosomal RNA sequence analysis. Smith KJ, et al. **J Am Acad Dermatol** 1996 Feb;34(2 Pt 2):343–8 (18 ref.)

GENETICS

Mutational analysis of 16S ribosomal RNA structure and function in Escherichia coli. Triman KL. **Adv Genet** 1995; 33:1–39 (144 ref.)

METABOLISM

Mutational analysis of 16S ribosomal RNA structure and function in Escherichia coli. Triman KL. **Adv Genet** 1995; 33:1–39 (144 ref.)

RNA, RIBOSOMAL, 18S

GENETICS

[Comparison of 18S ribosomal RNA genes in invertebrate phylogeny] Aleshin VV, et al. **Mol Biol (Mosk)** 1995 Nov–Dec;29(6):1408–26 (58 ref.) **(Rus)**

RNA RODENT VIRUSES see RNA VIRUSES

RNA SEQUENCE see BASE SEQUENCE

RNA, SMALL NUCLEAR

CHEMISTRY

Secondary structure conservation of the U3 small nucleolar RNA introns in Saccharomyces. Brulé F, et al. **C R Acad Sci III** 1995 Dec;318(12):1197–206 (48 ref.)

METABOLISM

The small nucleolar RNAs. Maxwell ES, et al. **Annu Rev Biochem** 1995;64:897–934 (196 ref.)

Small RNA chaperones for ribosome biogenesis. Steitz JA, et al. **Science** 1995 Dec 8;270(5242):1626–7 (16 ref.)

Small nucleolar RNAs guide ribosomal RNA methylation. Tollervey D. **Science** 1996 Aug 23;273(5278):1056–7 (13 ref.)

RNA, SMALL NUCLEAR, PRECURSORS see **RNA PRECURSORS**

RNA SPLICING

see related
RNA PRECURSORS

A new splicing variant in the frog heart sarcolemmal Na–Ca exchanger creates a putative ATP–binding site. Iwata T, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:37–45 (34 ref.)

RNA processing. Wilms' tumour—the splicing connection? Lamond AI. **Curr Biol** 1995 Aug 1;5(8):862–5 (10 ref.)

The role of PRP8 protein in nuclear pre–mRNA splicing in yeast. Beggs JD, et al. **J Cell Sci Suppl** 1995;19:101–5 (47 ref.)

Alternative splicing of the estrogen receptor primary transcript normally occurs in estrogen receptor positive tissues and cell lines. Pfeffer U, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1–6 Spec No):99–105 (37 ref.)

trans–splicing: an update. Nilsen TW. **Mol Biochem Parasitol** 1995 Jul;73(1–2):1–6 (35 ref.)

Finding splice sites within a wilderness of RNA. Black DL. **RNA** 1995 Oct;1(8):763–71 (132 ref.)

The superfamily of arginine/serine–rich splicing factors. Fu XD. **RNA** 1995 Sep;1(7):663–80 (160 ref.)

The second catalytic step of pre–mRNA splicing. Umen JG, et al. **RNA** 1995 Nov;1(9):869–85 (131 ref.)

AT–AC introns: an ATtACk on dogma [comment] Mount SM. **Science** 1996 Mar 22;271(5256):1690–2 (12 ref.) Comment on: Science 1996 Mar 22;271(5256):1716–8.

[The mechanism of pre–mRNA splicing] Tani T. **Seikagaku** 1995 Aug;67(8):1010–31 (92 ref.) **(Jpn)**

GENETICS

Initial splice–site recognition and pairing during pre–mRNA splicing. Reed R. **Curr Opin Genet Dev** 1996 Apr; 6(2):215–20 (47 ref.)

Molecular genetics of the glycophorin gene family, the antigens for MNSs blood groups: multiple gene rearrangements and modulation of splice site usage result in extensive diversification. Blumenfeld OO, et al. **Hum Mutat** 1995;6(3):199–209 (52 ref.)

The evolutionary conservation of the splicing apparatus between fission yeast and man. Wentz–Hunter K, et al. **Nucleic Acids Symp Ser** 1995;(33):226–8 (17 ref.)

PHYSIOLOGY

SR proteins and splicing control. Manley JL, et al. **Genes Dev** 1996 Jul 1;10(13):1569–79 (93 ref.)

Does the Wilms' tumour suppressor gene, WT1, play roles in both splicing and transcription? Charlieu JP, et al. **J Cell Sci Suppl** 1995;19:95–9 (20 ref.)

Alternatively spliced isoforms of the NMDAR1 receptor subunit. Zukin RS, et al. **Trends Neurosci** 1995 Jul; 18(7):306–13 (51 ref.)

RNA SPLICING, ALTERNATIVE see **ALTERNATIVE SPLICING**

RNA, TRANSFER

[tRNA identify—a view of Escherichia coli system] Hasegawa T. **Tanpakushitsu Kakusan Koso** 1994 Jul; 40(10):1474–84 (87 ref.) **(Jpn)**

[Mechanism of tRNA–recognition by aminoacyl–tRNA synthetases] Nureki S, et al. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1609–19 (37 ref.) **(Jpn)**

[Modified nucleosides of tRNA in decoding] Ueda T, et al. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1465–73 (17 ref.) **(Jpn)**

ANALYSIS

Molecular genetic approaches to identification, epidemiology and taxonomy of non–albicans Candida species. Sullivan DJ, et al. **J Med Microbiol** 1996 Jun;44(6):399–408 (109 ref.)

CHEMISTRY

RNA recognition and cleavage by iron(II)–bleomycin. Battigello JM, et al. **Met Ions Biol Syst** 1996;33:593–617 (98 ref.)

Trans–diammineplatinum(II): what makes it different from cis–DDP? Coordination chemistry of a neglected relative of cisplatin and its interaction with nucleic acids. Lippert B. **Met Ions Biol Syst** 1996;33:105–41 (153 ref.)

Usefulness of functional and structural solution data for the modeling of tRNA–like structures. Felden B, et al. **Pharm Acta Helv** 1996 Jun;71(1):3–9 (45 ref.)

Strategies for RNA folding. Draper DE. **Trends Biochem Sci** 1996 Apr;21(4):145–9 (38 ref.)

GENETICS

Compilation and classification of higher plant mitochondrial tRNA genes. Veronico P, et al. **Nucleic Acids Res** 1996 Jun 15;24(12):2199–203 (27 ref.)

Origin of genetic code: A needle in the haystack of tRNA sequences. Schimmel P. **Proc Natl Acad Sci U S A** 1996 May 14;93(10):4521–2 (17 ref.)

METABOLISM

The phosphofructokinase–uncharged tRNA interaction in metabolic and cell cycle control: an interpretive review. Rabinovitz M. **Nucleic Acids Symp Ser** 1995;(33):182–9 (53 ref.)

RNA, TRANSFER, GLU

METABOLISM

Glutamate transfer RNA: a cofactor for heme and chlorophyll biosynthesis. Madan Kumar A, et al. **Indian J Biochem Biophys** 1996 Feb;33(1):30–4 (31 ref.)

RNA, TRANSFER, PHE

CHEMISTRY

Nickel complexes as probes of guanine sites in nucleic acid folding. Burrows CJ, et al. **Met Ions Biol Syst** 1996; 33:537–60 (41 ref.)

RNA, TRANSFER, PRECURSORS see **RNA PRECURSORS**

RNA TUMOR VIRUSES see **RETROVIRIDAE**

RNA, VIRAL

Rhinovirus infection of the normal human airway. Gwaltney JM Jr. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 2):S36–9 (35 ref.)

Influenza viruses and cell membranes. Skehel JJ, et al. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 2):S13–5 (20 ref.)

ANALYSIS

Hepatitis C virus serum markers and liver disease in children with leukemia. Locasciulli A, et al. **Leuk Lymphoma** 1995 Apr;17(3–4):245–9 (22 ref.)

[Interactions between chronic viral hepatitis C and pregnancy] Grangé JD, et al. **Gastroenterol Clin Biol** 1995 May;19(5):520–4 (29 ref.) (Eng. Abstr.) **(Fre)**

[Histopathology of viral hepatitis C] Chevallier M, et al. **Pathol Biol (Paris)** 1995 Oct;43(8):703–8 (44 ref.) (Eng. Abstr.) **(Fre)**

[Hepatitis C virus. Virological diagnosis] Lunel F, et al. **Pathol Biol (Paris)** 1995 Oct;43(8):681–90 (42 ref.) (Eng. Abstr.) **(Fre)**

[Treatment of hepatitis C] Trepo C, et al. **Pathol Biol (Paris)** 1995 Oct;43(8):716–24 (58 ref.) (Eng. Abstr.) **(Fre)**

[HCV–RNA in liver of chronic hepatitis C—plus strand RNA and minus strand RNA] Endo H, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:623–8 (17 ref.) **(Jpn)**

[HCV–RNA in the circulating immune complexes] Hada H, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:143–9 (24 ref.) **(Jpn)**

[Quantitation of HCV–RNA by competitive–PCR] Kaneko S, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:281–6 (5 ref.) **(Jpn)**

[Method of detecting plus and minus strands of hepatitis C viral RNA by strand specific reverse transcription–polymerase chain reaction] Kawashima T, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:294–9 (11 ref.) **(Jpn)**

[Detection of HCV–RNA in liver by in situ hybridization] Yamada S, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:300–6 (29 ref.) **(Jpn)**

[Hepatitis A virus marker] Yotsuyanagi H, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:828–31 (7 ref.) **(Jpn)**

[Detection of Borna disease virus RNA by RT–PCR in PBMC] Nakaya T, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):700–4 (20 ref.) **(Jpn)**

BIOSYNTHESIS

Transcription, replication, recombination, and engineering of coronavirus genes. Lai MM. **Adv Exp Med Biol** 1995; 380:463–71 (29 ref.)

Coronaviruses use discontinuous extension for synthesis of subgenome–length negative strands. Sawicki SG, et al. **Adv Exp Med Biol** 1995;380:499–506 (21 ref.)

Regulation of transcription of coronaviruses. van Marle G, et al. **Adv Exp Med Biol** 1995;380:507–10 (23 ref.)

BLOOD

Measuring viral load in the clinical setting. Harrigan R. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995;10 Suppl 1:S34–40 (26 ref.)

HIV viral load markers in clinical practice. Saag MS, et al. **Nat Med** 1996 Jun;2(6):625–9 (33 ref.)

Viral counts count in HIV infection [see comments] Ho DD. **Science** 1996 May 24;272(5265):1124–5 (13 ref.) Comment in: Science 1996 May 24;272(5265):1167–70.

[Relation between histological findings by Scheuer's scores and serum levels of HCV–RNA, and HCV–genotype] Enomoto K, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:608–12 (16 ref.) **(Jpn)**

[Serum levels of HCV–RNA determined by branched DNA (bDNA) probe assay in chronic hepatitis C] Osada T, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:287–93 (13 ref.) **(Jpn)**

[Histological activity index score and levels of hepatitis C virus RNA in chronic hepatitis C] Takahashi M, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:602–7 (17 ref.) **(Jpn)**

CEREBROSPINAL FLUID

Rotavirus encephalitis: detection of the virus genomic RNA in the cerebrospinal fluid of a child. Yoshida A, et al. **Pediatr Infect Dis J** 1995 Oct;14(10):914–6 (19 ref.)

CHEMISTRY

Anatomy of the poliovirus internal ribosome entry site. Ehrenfeld E, et al. **Curr Top Microbiol Immunol** 1995; 203:65–83 (86 ref.)

Structure and function of the hepatitis C virus internal ribosome entry site. Wang C, et al. **Curr Top Microbiol Immunol** 1995;203:99–115 (81 ref.)

[Highly conserved secondary structures predicted in 5' noncoding region of HCV: a possible connection to viral replication] Katayama K, et al. **Nippon Rinsho** 1995 Sep; 53 Suppl:43–50 (19 ref.) **(Jpn)**

[Structure and function of RNA from closterovirus genomes] Agranovskaĭ AA. **Mol Biol (Mosk)** 1995 Nov–Dec; 29(6):1265–85 (121 ref.) **(Rus)**

GENETICS

Viruses in the RNA world. Rima BK. **Biochem Soc Trans** 1996 Feb;24(1):1–13 (26 ref.)

Translation of encephalomyocarditis virus RNA by internal ribosomal entry. Hellen CU, et al. **Curr Top Microbiol Immunol** 1995;203:31–63 (178 ref.)

Internal initiation of translation in eukaryotes: the picornavirus paradigm and beyond. Jackson RJ, et al. **RNA** 1995 Dec;1(10):985–1000 (104 ref.)

[Structural and functional analysis of the internal ribosome entry site within 5' noncoding region of hepatitis C virus RNA] Fukushi S, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:36–42 (17 ref.) **(Jpn)**

[Divergence and heterogeneity of HDV–RNA sequences in Japan] Imazeki F. **Nippon Rinsho** 1995 Oct;53 Suppl:752–8 (20 ref.) **(Jpn)**

[Structure and function of RNA from closterovirus genomes] Agranovskaĭ AA. **Mol Biol (Mosk)** 1995 Nov–Dec; 29(6):1265–85 (121 ref.) **(Rus)**

ISOLATION & PURIFICATION

[Biological diagnosis of hepatitis C virus infection. Role of serological and molecular tests] Pawlotsky JM, et al. **Gastroenterol Clin Biol** 1996 Mar;20(2):146–61 (186 ref.) **(Fre)**

METABOLISM

Colocalizing ribozymes with substrate RNAs to increase their efficacy as gene inhibitors. Sullenger BA. **Appl Biochem Biotechnol** 1995 Jul–Sep;54(1–3):57–61 (28 ref.)

Viruses in the RNA world. Rima BK. **Biochem Soc Trans** 1996 Feb;24(1):1–13 (26 ref.)

HIV–1 virology. Simply Marvelous nuclear transport. Goldfarb DS. **Curr Biol** 1995 Jun 1;5(6):570–3 (19 ref.)

[RNA ligands for HIV proteins] Iwai S. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1430–7 (64 ref.) **(Jpn)**

PHYSIOLOGY

Structure, function, and evolution of adenovirus virus–associated RNAs. Mathews MB. **Curr Top Microbiol Immunol** 1995;199 (Pt 2):173–87 (35 ref.)

When two strands are better than one: the mediators and modulators of the cellular responses to double–stranded RNA. Jacobs BL, et al. **Virology** 1996 May 15; 219(2):339–49 (173 ref.)

[Structure and function of hepatitis A virus RNA] Kuwabara Y. **Nippon Rinsho** 1995 Oct;53 Suppl:785–90 (16 ref.) **(Jpn)**

ULTRASTRUCTURE

[Structure and function of hepatitis A virus RNA] Kuwabara Y. **Nippon Rinsho** 1995 Oct;53 Suppl:785–90 (16 ref.) **(Jpn)**

RNA VIRUSES

DRUG EFFECTS

[Design of S-adenosylhomocystein hydrolase (SHAase) inhibitors as potent anti-RNA viral agents] Shuto S. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1261-7 (27 ref.) **(Jpn)**

ENZYMOLOGY

Proteolytic processing of the arterivirus replicase. Snijder E, et al. **Adv Exp Med Biol** 1995;380:443-51 (28 ref.)

GENETICS

Early events in virus-plant interactions. Maia IG, et al. **Braz J Med Biol Res** 1994 Nov;27(11):2521-32 (54 ref.)

Basic concepts in RNA virus evolution. Domingo E, et al. **FASEB J** 1996 Jun;10(8):859-64 (48 ref.)

Genetic manipulation of non-segmented negative-strand RNA viruses. Conzelmann KK. **J Gen Virol** 1996 Mar;77 (Pt 3):381-9 (68 ref.)

The potential exploitation of plant viral translational enhancers in biotechnology for increased gene expression. Turner R, et al. **Mol Biotechnol** 1995 Jun;3(3):225-36 (40 ref.)

Ribosomal frameshifting in yeast viruses. Dinman JD. **Yeast** 1995 Sep 30;11(12):1115-27 (60 ref.)

ISOLATION & PURIFICATION

[Procedures of viral identification in respiratory infections] Aspa J, et al. **Arch Bronconeumol** 1995 Nov;31(9):470-80 (132 ref.) **(Spa)**

PATHOGENICITY

Emerging viruses. Le Guenno B. **Sci Am** 1995 Oct; 273(4):56-64 (5 ref.)

PHYSIOLOGY

Viruses in the RNA world. Rima BK. **Biochem Soc Trans** 1996 Feb;24(1):1-13 (26 ref.)

Negative-strand virus M and retrovirus MA proteins: all in a family? Lenard J. **Virology** 1996 Feb 15;216(2):289-98 (116 ref.)

ULTRASTRUCTURE

Functional implications of protein-protein interactions in icosahedral viruses. Johnson JE. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):27-33 (21 ref.)

7S RNA see **RNA, SMALL NUCLEAR**

RNASE see **RIBONUCLEASES**

RNASE A see **RIBONUCLEASE, PANCREATIC**

RNASE H see **RIBONUCLEASE H, CALF THYMUS**

RNASE T1 see **RIBONUCLEASE T1**

RO 10-9359 see **ETRETINATE**

RO 15-1788 see **FLUMAZENIL**

ROBOTICS

Robotics and automated workstations for rapid response testing. Felder RA. **Am J Clin Pathol** 1995 Oct;104(4 Suppl 1):S26-32 (13 ref.)

[Laparoscopic technique--which developments are possible?] Voges U. **Urologe A** 1996 May;35(3):208-14 (6 ref.) (Eng. Abstr.) **(Ger)**

INSTRUMENTATION

Robots in operating theatres. Buckingham RA, et al. **BMJ** 1995 Dec 2;311(7018):1479-82 (22 ref.)

ROC ANALYSIS see **ROC CURVE**

ROC CURVE

[The ROC curve in the measurement of the diagnostic value of tests] Forsström JJ. **Duodecim** 1995;111(3):237-44 (41 ref.) **(Fin)**

ROCHALIMAEA see **BARTONELLA**

ROCHALIMAEA HENSELAE see **BARTONELLA HENSELAE**

ROCHALIMAEA INFECTIONS see **BARTONELLA INFECTIONS**

ROCKY MOUNTAIN SPOTTED FEVER

Rocky Mountain spotted fever. Silber JL. **Clin Dermatol** 1996 May-Jun;14(3):245-58 (121 ref.)

ROD-CONE DYSTROPHY see **RETINITIS PIGMENTOSA**

ROD OUTER SEGMENTS

METABOLISM

Turnover rate and number of Na(+)-Ca2+, K+ exchange sites in retinal photoreceptors. Rispoli G, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:346-55 (26 ref.)

Regulation of the bovine retinal rod Na-Ca+K exchanger. Schnetkamp PP, et al. **Ann N Y Acad Sci** 1996 Apr 15; 779:336-45 (24 ref.)

ROD PHOTORECEPTORS see **RODS (RETINA)**

RODENT CONTROL

see related
RODENTICIDES

RODENT DISEASES

GENETICS

Genetics of liver tumor susceptibility in mice. Dragani TA, et al. **Toxicol Lett** 1995 Dec;82-83:613-9 (36 ref.)

VIROLOGY

[Mouse hepatitis virus] Homberger FR. **Schweiz Arch Tierheilkd** 1996;138(4):183-8 (10 ref.) (Eng. Abstr.) **(Ger)**

RODENTIA

Ocular and orbital porcupine quills in the dog: a review and case series. Grahn BH, et al. **Can Vet J** 1995 Aug; 36(8):488-93 (24 ref.)

Use of rodent self-administration models to develop pharmacotherapies for cocaine abuse. Dworkin SI, et al. **NIDA Res Monogr** 1994;145:88-112 (65 ref.)

[Zoo-anthroponoses involving rodents: epidemiologic considerations] Rodhain F. **Bull Soc Pathol Exot** 1996; 89(1):5-11 (14 ref.) (Eng. Abstr.) **(Fre)**

ANATOMY & HISTOLOGY

Anatomy, development and lesion-induced plasticity of rodent corticospinal tract. Terashima T. **Neurosci Res** 1995 May;22(2):139-61 (180 ref.)

EMBRYOLOGY

Mammalian model systems for exploring cytoskeletal dynamics during fertilization. Navara CS, et al. **Curr Top Dev Biol** 1995;31:321-42 (54 ref.)

GENETICS

Human and rodent DNA sequence comparisons: a mosaic model of genomic evolution. Koop BF. **Trends Genet** 1995 Sep;11(9):367-71 (25 ref.)

PHYSIOLOGY

Changes in autonomic nervous system activity and consecutive hyperinsulinaemia: respective roles in the development of obesity in rodents. Pénicaud L, et al. **Diabetes Metab** 1996 Feb;22(1):15-24 (67 ref.)

RODENTICIDES

ADVERSE EFFECTS

Washington's experience and recommendations Re: Anticoagulant rodenticides. Morrissey B, et al. **Vet Hum Toxicol** 1995 Aug;37(4):362-3 (4 ref.)

RODS (RETINA)

METABOLISM

Calcium homeostasis in vertebrate retinal rod outer segments. Schnetkamp PP. **Cell Calcium** 1995 Oct;18(4):322-30 (54 ref.)

PHYSIOLOGY

Ca2+ flux in retinal rod and cone outer segments: differences in Ca2+ selectivity of the cGMP-gated ion channels and Ca2+ clearance rates. Korenbrot JI. **Cell Calcium** 1995 Oct;18(4):285-300 (75 ref.)

Rods, cones and calcium. McNaughton PA. **Cell Calcium** 1995 Oct;18(4):275-84 (66 ref.)

Beta wave of the scotopic (rod) electroretinogram as a measure of the activity of human on-bipolar cells. Hood DC, et al. **J Opt Soc Am A** 1996 Mar;13(3):623-33 (54 ref.)

RODS AND CONES

see related
RETINAL PIGMENTS

PHYSIOLOGY

How photons start vision. Baylor D. **Proc Natl Acad Sci U S A** 1996 Jan 23;93(2):560-5 (44 ref.)

ROENTGENOGRAPHY see **RADIOGRAPHY**

ROLE

Role, role enactment and the health care practitioner. Scott PA. **J Adv Nurs** 1995 Aug;22(2):323-8 (15 ref.)

The role of the testicles in male psychological development. Friedman RM. **J Am Psychoanal Assoc** 1996;44(1):201-53 (72 ref.)

Family caregiver role acquisition: role-making through situated interaction. Schumacher KL. **Sch Inq Nurs Pract** 1995 Fall;9(3):211-26; discussion 227-9 (76 ref.)

Asymmetrical role-taking: comparing battered and nonbattered women. Forte JA, et al. **Soc Work** 1996 Jan; 41(1):59-73 (56 ref.)

ROLE CONCEPT see **ROLE**

ROLE PLAYING

Role, role enactment and the health care practitioner. Scott PA. **J Adv Nurs** 1995 Aug;22(2):323-8 (15 ref.)

ROMANO-WARD SYNDROME see **LONG QT SYNDROME**

ROMBERG'S DISEASE see **FACIAL HEMIATROPHY**

ROOT CANAL FILLING MATERIALS

Trends in endodontic instruments and materials. Pantera EA Jr, et al. **N Y State Dent J** 1996 May;62(5):22-9 (13 ref.)

ROOT CANAL THERAPY

Factors to consider for predictable post and core build-ups of endodontically treated teeth. Part II: Clinical application of basic concepts. Manning KE, et al. **J Can Dent Assoc** 1995 Aug;61(8):696-701, 703, 705-7 (46 ref.)

Factors to consider for predictable post and core build-ups of endodontically treated teeth. Part I: Basic theoretical concepts. Manning KE, et al. **J Can Dent Assoc** 1995 Aug; 61(8):685-8, 690, 693-5 (40 ref.)

INSTRUMENTATION

Trends in endodontic instruments and materials. Pantera EA Jr, et al. **N Y State Dent J** 1996 May;62(5):22-9 (13 ref.)

ROOT CARIES

EPIDEMIOLOGY

The RCI revisited after 15 years: used, reinvented, modified, debated, and natural logged. Katz RV. **J Public Health Dent** 1996 Winter;56(1):28-34 (34 ref.)

ROOT RESORPTION

PATHOLOGY

Pre-eruptive resorption of dentin in the primary and permanent dentitions: case reports and literature review. Seow WK, et al. **Pediatr Dent** 1996 Jan-Feb;18(1):67-71 (24 ref.)

RORSCHACH TEST

An ego-psychological approach to the Rorschach. Frank G. **Psychol Rep** 1995 Dec;77(3 Pt 1):911-30 (110 ref.)

ROSA see **PLANTS, MEDICINAL**

ROSACEA see **ACNE ROSACEA**

ROSAI-DORFMAN DISEASE see **HISTIOCYTOSIS, SINUS**

ROSEOLA INFANTUM see **EXANTHEMA SUBITUM**

ROSS RIVER VIRUS

Mosquito-borne viruses and epidemic polyarthritis. Mackenzie JS, et al. **Med J Aust** 1996 Jan 15;164(2):90-3 (21 ref.)

ROTATIONAL ATHERECTOMY see **ATHERECTOMY, CORONARY**

ROTATOR CUFF

Rotator cuff disorders. Rodgers JA, et al. **Am Fam Physician** 1996 Jul;54(1):127-34 (29 ref.)

Arthroscopic treatment of rotator cuff disease. Gartsman GM. **J Shoulder Elbow Surg** 1995 May-Jun;4(3):228-41 (27 ref.)

ANATOMY & HISTOLOGY

The rotator cuff. Smith DS. **Curr Opin Neurol** 1995 Dec; 8(6):456-60 (10 ref.)

INJURIES

Arthroscopic rotator cuff repairs using suture anchors. Farrall LA. **AORN J** 1995 Nov;62(5):739–46, 748, 750; quiz 754, 756–8 (18 ref.)

Magnetic resonance imaging of impingement and rotator cuff tears. Stoller DW, et al. **Magn Reson Imaging Clin N Am** 1993 Sep;1(1):47–63 (61 ref.)

[Open surgical therapy of the rotator cuff] Habermeyer P. **Orthopade** 1995 Nov;24(6):512–28 (88 ref.) (Eng. Abstr.) **(Ger)**

[Arthroscopic treatment possibilities of the rotator cuff] Landsiedl F. **Orthopade** 1995 Nov;24(6):529–40 (80 ref.) (Eng. Abstr.) **(Ger)**

[Rupture of the rotator cuff] Povacz P, et al. **Wien Med Wochenschr** 1996;146(6–7):135–8 (16 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

Magnetic resonance imaging of impingement and rotator cuff disorders. A surgical perspective. Cuomo F, et al. **Magn Reson Imaging Clin N Am** 1993 Sep;1(1):65–76 (36 ref.)

Pathogenesis of rotator cuff disorders. Magnetic resonance imaging characteristics. Tyson LL, et al. **Magn Reson Imaging Clin N Am** 1993 Sep;1(1):37–46 (52 ref.)

SURGERY

Arthroscopic rotator cuff repairs using suture anchors. Farrall LA. **AORN J** 1995 Nov;62(5):739–46, 748, 750; quiz 754, 756–8 (18 ref.)

[Open surgical therapy of the rotator cuff] Habermeyer P. **Orthopade** 1995 Nov;24(6):512–28 (88 ref.) (Eng. Abstr.) **(Ger)**

[Arthroscopic treatment possibilities of the rotator cuff] Landsiedl F. **Orthopade** 1995 Nov;24(6):529–40 (80 ref.) (Eng. Abstr.) **(Ger)**

ROTAVIRUS

CHEMISTRY

Structure and function of the rotavirus RNA-binding proteins. Patton JT. **J Gen Virol** 1995 Nov;76 (Pt 11):2633–44 (75 ref.)

CLASSIFICATION

Review of G and P typing results from a global collection of rotavirus strains: implications for vaccine development. Gentsch JR, et al. **J Infect Dis** 1996 Sep;174 Suppl 1:S30–6 (65 ref.)

IMMUNOLOGY

Passive immunity against diarrhoea. Bogstedt AK, et al. **Acta Paediatr** 1996 Feb;85(2):125–8 (20 ref.)

Rotavirus vaccine: current status & future prospects. Naik TN, et al. **Indian J Med Res** 1996 Jul;104:76–85 (98 ref.)

The development of multivalent bovine rotavirus (strain WC3) reassortant vaccine for infants. Clark HF, et al. **J Infect Dis** 1996 Sep;174 Suppl 1:S73–80 (30 ref.)

Advances in molecular biology: impact on rotavirus vaccine development. Estes MK. **J Infect Dis** 1996 Sep;174 Suppl 1:S37–46 (117 ref.)

Molecular determinants of immunity and pathogenicity of rotavirus infection in the mouse model. Franco MA, et al. **J Infect Dis** 1996 Sep;174 Suppl 1:S47–50 (23 ref.)

Review of G and P typing results from a global collection of rotavirus strains: implications for vaccine development. Gentsch JR, et al. **J Infect Dis** 1996 Sep;174 Suppl 1:S30–6 (65 ref.)

Efficacy of a quadrivalent rhesus rotavirus–based human rotavirus vaccine aimed at preventing severe rotavirus diarrhea in infants and young children. Kapikian AZ, et al. **J Infect Dis** 1996 Sep;174 Suppl 1:S65–72 (39 ref.)

Host factors associated with protection against rotavirus disease: the skies are clearing. Offit PA. **J Infect Dis** 1996 Sep;174 Suppl 1:S59–64 (62 ref.)

Influence of breast-feeding and oral poliovirus vaccine on the immunogenicity and efficacy of rotavirus vaccines. Rennels MB. **J Infect Dis** 1996 Sep;174 Suppl 1:S107–11 (35 ref.)

Group A rotavirus veterinary vaccines. Saif LJ, et al. **J Infect Dis** 1996 Sep;174 Suppl 1:S98–106 (81 ref.)

Review of rotavirus vaccine trials in Finland. Vesikari T, et al. **J Infect Dis** 1996 Sep;174 Suppl 1:S81–7 (46 ref.)

Mechanisms of protection against rotavirus in humans and mice. Ward RL. **J Infect Dis** 1996 Sep;174 Suppl 1:S51–8 (92 ref.)

Human immunity to rotavirus. Molyneaux PJ. **J Med Microbiol** 1995 Dec;43(6):397–404 (94 ref.)

New lessons for rotavirus vaccines [comment] Glass RI, et al. **Science** 1996 Apr 5;272(5258):46–8 (14 ref.) Comment on: Science 1996 Apr 5;272(5258):101–4. Comment on: Science 1996 Apr 5;272(5258):104–7.

[Does vaccination prevent Rotavirus gastroenteritis? (editorial)] Vesikari T. **Duodecim** 1994;110(2):121–3 (15 ref.) **(Fin)**

ISOLATION & PURIFICATION

Rotavirus encephalitis: detection of the virus genomic RNA in the cerebrospinal fluid of a child. Yoshida A, et al. **Pediatr Infect Dis J** 1995 Oct;14(10):914–6 (19 ref.)

PATHOGENICITY

Molecular determinants of immunity and pathogenicity of rotavirus infection in the mouse model. Franco MA, et al. **J Infect Dis** 1996 Sep;174 Suppl 1:S47–50 (23 ref.)

Rotavirus pathogenicity. Burke B, et al. **Virology** 1996 Apr 15;218(2):299–305 (92 ref.)

ROTAVIRUS INFECTIONS

COMPLICATIONS

Rotavirus encephalitis: detection of the virus genomic RNA in the cerebrospinal fluid of a child. Yoshida A, et al. **Pediatr Infect Dis J** 1995 Oct;14(10):914–6 (19 ref.)

EPIDEMIOLOGY

[Adenoviruses from stool samples in hospital units. Comparison with main pathogens in gastroenteritis (rotavirus, Campylobacter, Salmonella)] Durepaire N, et al. **Pathol Biol (Paris)** 1995 Sep;43(7):601–10 (22 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Molecular determinants of immunity and pathogenicity of rotavirus infection in the mouse model. Franco MA, et al. **J Infect Dis** 1996 Sep;174 Suppl 1:S47–50 (23 ref.)

Host factors associated with protection against rotavirus disease: the skies are clearing. Offit PA. **J Infect Dis** 1996 Sep;174 Suppl 1:S59–64 (62 ref.)

Human immunity to rotavirus. Molyneaux PJ. **J Med Microbiol** 1995 Dec;43(6):397–404 (94 ref.)

PREVENTION & CONTROL

The development of multivalent bovine rotavirus (strain WC3) reassortant vaccine for infants. Clark HF, et al. **J Infect Dis** 1996 Sep;174 Suppl 1:S73–80 (30 ref.)

Advances in molecular biology: impact on rotavirus vaccine development. Estes MK. **J Infect Dis** 1996 Sep;174 Suppl 1:S37–46 (117 ref.)

Efficacy of a quadrivalent rhesus rotavirus–based human rotavirus vaccine aimed at preventing severe rotavirus diarrhea in infants and young children. Kapikian AZ, et al. **J Infect Dis** 1996 Sep;174 Suppl 1:S65–72 (39 ref.)

Influence of breast-feeding and oral poliovirus vaccine on the immunogenicity and efficacy of rotavirus vaccines. Rennels MB. **J Infect Dis** 1996 Sep;174 Suppl 1:S107–11 (35 ref.)

Review of rotavirus vaccine trials in Finland. Vesikari T, et al. **J Infect Dis** 1996 Sep;174 Suppl 1:S81–7 (46 ref.)

Mechanisms of protection against rotavirus in humans and mice. Ward RL. **J Infect Dis** 1996 Sep;174 Suppl 1:S51–8 (92 ref.)

New lessons for rotavirus vaccines [comment] Glass RI, et al. **Science** 1996 Apr 5;272(5258):46–8 (14 ref.) Comment on: Science 1996 Apr 5;272(5258):101–4. Comment on: Science 1996 Apr 5;272(5258):104–7.

[Does vaccination prevent Rotavirus gastroenteritis? (editorial)] Vesikari T. **Duodecim** 1994;110(2):121–3 (15 ref.) **(Fin)**

[A vaccine against diarrhea. Soon a reality in the fight against viral gastroenteritis in both developed and developing countries] Svensson L. **Lakartidningen** 1996 Jan 31; 93(5):353–8 (26 ref.) **(Swe)**

VETERINARY

Group A rotavirus veterinary vaccines. Saif LJ, et al. **J Infect Dis** 1996 Sep;174 Suppl 1:S98–106 (81 ref.)

VIROLOGY

Review of G and P typing results from a global collection of rotavirus strains: implications for vaccine development. Gentsch JR, et al. **J Infect Dis** 1996 Sep;174 Suppl 1:S30–6 (65 ref.)

ROTHMUND-THOMSON SYNDROME see **POIKILODERMA CONGENITALE**

ROUGHAGE see **DIETARY FIBER**

ROUND LIGAMENT

PATHOLOGY

Myolipoma of the round ligament: report of a case with a review of the English literature. Sonobe H, et al. **Virchows Arch** 1995;427(4):455–8 (24 ref.)

ROUSSY-LEVY SYNDROME see **CHARCOT-MARIE DISEASE**

ROUTINE DIAGNOSTIC TESTS see **DIAGNOSTIC TESTS, ROUTINE**

ROUX-EN-Y ANASTOMOSIS see **ANASTOMOSIS, ROUX-EN-Y**

ROUX-EN-Y DIVERSION see **ANASTOMOSIS, ROUX-EN-Y**

ROUX-EN-Y LOOP see **ANASTOMOSIS, ROUX-EN-Y**

ROWSON-PARR VIRUS see **FRIEND VIRUS**

ROYAL FREE DISEASE see **FATIGUE SYNDROME, CHRONIC**

RT7 ANTIGENS see **ANTIGENS, CD45**

RU-486 see **MIFEPRISTONE**

RUBBER

ADVERSE EFFECTS

Occupational asthma caused by natural rubber latex. Vandenplas O. **Eur Respir J** 1995 Nov;8(11):1957–65 (80 ref.)

Rubber latex in the air: an occupational and environmental cause of asthma? Hopkins J. **Food Chem Toxicol** 1995 Oct; 33(10):895–9 (23 ref.)

[Do employees in the rubber industry have an increased risk of laryngeal cancer?] Tisch M, et al. **HNO** 1995 Nov; 43(11):649–53 (24 ref.) (Eng. Abstr.) **(Ger)**

RUBBER SILICONE see **SILICONE ELASTOMERS**

RUBEFACIENTS see **IRRITANTS**

RUBELLA

[Yellow fever, measles, rubella] Yoshikawa Y. **Ryoikibetsu Shokogun Shirizu** 1995;(7):33–5 (9 ref.) **(Jpn)**

COMPLICATIONS

Acute hepatitis in an adult with acquired rubella infection. Arai M, et al. **J Gastroenterol** 1995 Aug;30(4):539–42 (14 ref.)

DIAGNOSIS

Almost extinct diseases: measles, mumps, rubella, and pertussis. Gold E. **Pediatr Rev** 1996 Apr;17(4):120–7 (7 ref.)

IMMUNOLOGY

Rubella immunity. Defining the level of protective antibody. Skendzel LP. **Am J Clin Pathol** 1996 Aug;106(2):170–4 (39 ref.)

PREVENTION & CONTROL

[Rubella and prospects for vaccine prophylaxis of it] Malinina Olu. **Tr Inst Im Pastera** 1992;67:116–21 (28 ref.) **(Rus)**

RUBELLA SYNDROME, CONGENITAL

DIAGNOSIS

[Cranial NMR in the late diagnosis of congenital rubella] Ruiz Pérez JJ, et al. **An Esp Pediatr** 1996 Jun;44(6):585–7 (20 ref.) **(Spa)**

RUBELLA VACCINE

ADVERSE EFFECTS

Case series analysis of adverse reactions to vaccines: a comparative evaluation. Farrington CP, et al. **Am J Epidemiol** 1996 Jun 1;143(11):1165–73 (18 ref.)

RUBEOLA see **MEASLES**

RUBIDIUM

PHARMACOKINETICS

Depolarization-induced 86Rb+ efflux in CHO cells expressing a recombinant potassium channel. Hu W, et al. **J Pharmacol Toxicol Methods** 1995 Sep;34(1):1–7 (83 ref.)

RUBINSTEIN-TAYBI SYNDROME

COMPLICATIONS

Glaucoma and findings simulating glaucoma in the Rubinstein–Taybi syndrome. Brei TJ, et al. **J Pediatr Ophthalmol Strabismus** 1995 Jul–Aug; 32(4):248–52 (56 ref.)

RUFFINI'S CORPUSCLES see **MECHANORECEPTORS**

RUGBY see **FOOTBALL**

RUMEN

CHEMISTRY

Prediction of ruminal volatile fatty acids and pH within the

RUMEN

net carbohydrate and protein system. Pitt RE, et al. **J Anim Sci** 1996 Jan;74(1):226–44 (126 ref.)

METABOLISM

Energy substrates for the rumen epithelium. Rémond D, et al. **Proc Nutr Soc** 1995 Mar;54(1):95–105 (53 ref.)

MICROBIOLOGY

Maximizing microbial protein synthesis in the rumen. Firkins JL. **J Nutr** 1996 Apr;126(4 Suppl):1347S–54S (71 ref.)

Ruminal microbial metabolism of peptides and amino acids. Wallace RJ. **J Nutr** 1996 Apr;126(4 Suppl):1326S–34S (79 ref.)

Reassessing the manipulation of protein synthesis by rumen microbes. Broudiscou L, et al. **Reprod Nutr Dev** 1995; 35(5):517–35 (144 ref.)

PARASITOLOGY

Effect of rumen protozoa on nitrogen utilization by ruminants. Jouany JP. **J Nutr** 1996 Apr;126(4 Suppl):1335S–46S (127 ref.)

PHYSIOLOGY

Transformations and effects of lipids in the rumen: three decades of research at Gent University. Demeyer DI, et al. **Arch Tierernahr** 1995;48(1–2):119–34 (41 ref.)

RUMINANTIA see RUMINANTS

RUMINANTS

Ruminant pestiviruses. Nettleton PF, et al. **Br Vet J** 1995 Nov–Dec;151(6):615–42 (130 ref.)

Reassessing the manipulation of protein synthesis by rumen microbes. Broudiscou L, et al. **Reprod Nutr Dev** 1995; 35(5):517–35 (144 ref.)

Orthopedic conditions of small ruminants. Llama, sheep, goat, and deer. Kaneps AJ. **Vet Clin North Am Food Anim Pract** 1996 Mar;12(1):211–31 (51 ref.)

CEREBROSPINAL FLUID

The collection and analysis of cerebrospinal fluid as an aid to diagnosis in ruminant neurological disease. Scott PR. **Br Vet J** 1995 Nov–Dec;151(6):603–14 (39 ref.)

GROWTH & DEVELOPMENT

Desirable characteristics of forage legumes for improving protein utilization in ruminants. Broderick GA. **J Anim Sci** 1995 Sep;73(9):2760–73 (60 ref.)

INJURIES

Fractures of the humerus. Rakestraw PC. **Vet Clin North Am Food Anim Pract** 1996 Mar;12(1):153–68 (31 ref.)

METABOLISM

Molecular evolution of ruminant lysozymes. Irwin DM. **EXS** 1996;75:347–61 (42 ref.)

Epithelial phosphate transport in ruminants, mechanisms and regulation. Shirazi-Beechey SP, et al. **Kidney Int** 1996 Apr; 49(4):992–6 (39 ref.)

Metabolic implications of ammonia production in the ruminant. Parker DS, et al. **Proc Nutr Soc** 1995 Jul; 54(2):549–63 (88 ref.)

Ingestion of sludge applied organic chemicals by animals. Fries GF. **Sci Total Environ** 1996 Jun 21;185(1–3):93–108 (112 ref.)

PHYSIOLOGY

Characteristics of plant cell walls affecting intake and digestibility of forages by ruminants. Jung HG, et al. **J Anim Sci** 1995 Sep;73(9):2774–90 (147 ref.)

Whole-body fuel selection in ruminants: nutrient supply and utilization by major tissues. Ortigues I, et al. **Proc Nutr Soc** 1995 Mar;54(1):235–51 (55 ref.)

Interferon, the oxytocin receptor and the maternal recognition of pregnancy in ruminants and non-ruminants: a comparative approach. Flint AP. **Reprod Fertil Dev** 1995; 7(3):313–8 (31 ref.)

Control of voluntary intake of precision-chopped silages by ruminants: a review. Dulphy JP, et al. **Reprod Nutr Dev** 1996;36(2):113–35 (144 ref.)

SURGERY

External skeletal fixation in ruminants. Anderson DE, et al. **Vet Clin North Am Food Anim Pract** 1996 Mar;12(1):117–52 (139 ref.)

Decision making in ruminant orthopedics. Fessler JF, et al. **Vet Clin North Am Food Anim Pract** 1996 Mar;12(1):1–18 (58 ref.)

Fracture biology, biomechanics, and internal fixation. Trostle SS, et al. **Vet Clin North Am Food Anim Pract** 1996 Mar; 12(1):19–46 (52 ref.)

VIROLOGY

Ruminant pestivirus infections in animals other than cattle and sheep. Løken T. **Vet Clin North Am Food Anim Pract** 1995 Nov; 11(3):597–614 (97 ref.)

RUNNING

An intermeniscal fibrous band in a recreational runner. Butler JP, et al. **Arthroscopy** 1995 Dec;11(6):735–7 (16 ref.)

[Atresia of the left coronary artery: a case in a marathon runner. Review of the literature] Bouchiat C, et al. **Arch Mal Coeur Vaiss** 1996 Apr;89(4):485–7 (10 ref.) (Eng. Abstr.) **(Fre)**

INJURIES

Biomechanics of iliotibial band friction syndrome in runners. Orchard JW, et al. **Am J Sports Med** 1996 May–Jun; 24(3):375–9 (26 ref.)

The diagnosis and management of plantar fasciitis. Quaschnick MS. **Nurse Pract** 1996 Apr;21(4):50–4, 60–3, quiz 64–5 (33 ref.)

Lower extremity injuries in runners. Helping athletic patients return to form. Wexler RK. **Postgrad Med** 1995 Oct; 98(4):185–7, 191–3 (29 ref.)

Overuse injuries of the lower extremity in runners. Rolf C. **Scand J Med Sci Sports** 1995 Aug;5(4):181–90 (105 ref.)

Common injuries in runners. Diagnosis, rehabilitation and prevention. Fredericson M. **Sports Med** 1996 Jan; 21(1):49–72 (137 ref.)

PHYSIOLOGY

Eccentric activation and muscle damage: biomechanical and physiological considerations during downhill running. Eston RG, et al. **Br J Sports Med** 1995 Jun;29(2):89–94 (53 ref.)

The study of kinematic transients in locomotion using the integrated kinematic sensor. Wu G, et al. **IEEE Trans Rehabil Eng** 1996 Sep;4(3):193–200 (18 ref.)

Maximal and submaximal oxygen uptake during running: how should body mass be accounted for? Svedenhag J. **Scand J Med Sci Sports** 1995 Aug;5(4):175–80 (33 ref.)

[Factors limiting performance in the triathlon] Margaritis I. **Can J Appl Physiol** 1996 Feb;21(1):1–15 (69 ref.) (Eng. Abstr.) **(Fre)**

RUNT DISEASE see GRAFT VS HOST DISEASE

RUPTURE, SPONTANEOUS

[Spontaneous hepatic rupture during pregnancy. Report of a case. Review of the literature] Villarreal Peral C, et al. **Ginecol Obstet Mex** 1995 Sep;63:395–7 (9 ref.) (Eng. Abstr.) **(Spa)**

RURAL HEALTH

see related
AGRICULTURAL WORKERS' DISEASES

Postgraduate training for rural family practice. Goals and opportunities. Rourke JT. **Can Fam Physician** 1996 Jun; 42:1133–8 (48 ref.)

Characteristics of cerebral gunshot injuries in the rural setting. Pikus HJ, et al. **Neurosurg Clin N Am** 1995 Oct; 6(4):611–20 (39 ref.)

Rural deprivation. Bonnar BC. **Occas Pap R Coll Gen Pract** 1995 Sep;(71):26–9 (21 ref.)

TRENDS

The virtual health economy: telemedicine and the supply of primary care physicians in rural America. McCarthy D. **Am J Law Med** 1995;21(1):111–30 (176 ref.)

RURAL HEALTH SERVICES

An ecological view of the rural environment: levels of influence on access to health care. Shreffler MJ. **ANS Adv Nurs Sci** 1996 Jun;18(4):48–59 (50 ref.)

Teamwork in rural practice. Cunningham WF, et al. **Occas Pap R Coll Gen Pract** 1995 Sep;(71):19–22 (45 ref.)

Health needs of rural residents. Watt IS. **Occas Pap R Coll Gen Pract** 1995 Sep;(71):5–9 (75 ref.)

ECONOMICS

Rural mental health coverage under health care reform. Shelton DA, et al. **Community Ment Health J** 1995 Dec; 31(6):539–52 (33 ref.)

MANPOWER

Human resource issues in rural mental health services. Merwin EI, et al. **Community Ment Health J** 1995 Dec; 31(6):525–37 (38 ref.)

ORGANIZATION & ADMINISTRATION

De facto mental health services in the rural south. Fox J, et al. **J Health Care Poor Underserved** 1995;6(4):434–68 (190 ref.)

Managed care: will the healthcare needs of rural citizens be met? Pierce SF, et al. **J Nurs Adm** 1996 Apr;26(4):28–32 (10 ref.)

HIV infection in rural communities. Sowell RL, et al. **Nurs Clin North Am** 1996 Mar;31(1):107–23 (73 ref.)

Rural general practice: international perspectives. Evans PR. **Occas Pap R Coll Gen Pract** 1995 Sep;(71):46–9 (20 ref.)

STANDARDS

Critical issues in reforming rural mental health service delivery. Blank MB, et al. **Community Ment Health J** 1995 Dec;31(6):511–24 (46 ref.)

TRENDS

An ecological view of the rural environment: levels of influence on access to health care. Shreffler MJ. **ANS Adv Nurs Sci** 1996 Jun;18(4):48–59 (50 ref.)

UTILIZATION

Critical issues in reforming rural mental health service delivery. Blank MB, et al. **Community Ment Health J** 1995 Dec;31(6):511–24 (46 ref.)

Local knowledge and rural mental health reform. Hill CE, et al. **Community Ment Health J** 1995 Dec;31(6):553–68 (48 ref.)

RURAL POPULATION

What is rurality? Rousseau N. **Occas Pap R Coll Gen Pract** 1995 Sep;(71):1–4 (39 ref.)

STATISTICS & NUMERICAL DATA

Explaining urban–rural variations in health: a review of interactions between individual and environment. Verheij RA. **Soc Sci Med** 1996 Mar;42(6):923–35 (73 ref.)

RUSSELL'S VIPER VENOM TIME see PROTHROMBIN TIME

RUTHENIUM

PHARMACOLOGY

Electron transfer in ruthenium-modified proteins. Bjerrum MJ, et al. **J Bioenerg Biomembr** 1995 Jun;27(3):295–302 (39 ref.)

RYANODINE

TOXICITY

Towards the development of ryanoid insecticides with low mammalian toxicity. Usherwood PN, et al. **Toxicol Lett** 1995 Dec;82–83:247–54 (13 ref.)

S PHASE

PHYSIOLOGY

Regulating S phase: CDKs, licensing and proteolysis. Wuarin J, et al. **Cell** 1996 Jun 14;85(6):785–7 (19 ref.)

DNA replication. Almost licensed. Ford C, et al. **Curr Biol** 1995 Sep 1;5(9):1009–12 (23 ref.)

SABIN VACCINE see POLIOVIRUS VACCINE, ORAL

SACCADES

[Saccadic latencies and unilateral spatial neglect caused by parietal lesions] Cochin JP, et al. **Rev Neurol (Paris)** 1996 Jan;152(1):32–7 (35 ref.) (Eng. Abstr.) **(Fre)**

SACCADIC EYE MOVEMENTS see SACCADES

SACCHARIDE-MEDIATED CELL ADHESION MOLECULES see CELL ADHESION MOLECULES

SACCHARIN

TOXICITY

Saccharin-induced bladder cancer in rats. Garland EM, et al. **Prog Clin Biol Res** 1995;391:237–43 (21 ref.)

SACCHAROMYCES

CYTOLOGY

Septin scaffolds and cleavage planes in Saccharomyces. Chant J. **Cell** 1996 Jan 26;84(2):187–90 (22 ref.)

GENETICS

Secondary structure conservation of the U3 small nucleolar RNA introns in Saccharomyces. Brulé F, et al. **C R Acad Sci III** 1995 Dec;318(12):1197–206 (48 ref.)

SACCHAROMYCES CEREVISIAE

Evidence for two prions in yeast: [URE3] and [PSI] Wickner RB, et al. **Curr Top Microbiol Immunol** 1996;207:147–60 (39 ref.)

CHEMISTRY

A heterodimeric transcriptional repressor becomes crystal clear [comment] Andrews BJ, et al. **Science** 1995 Oct 13; 270(5234):251–3 (18 ref.) Comment on: Science 1995 Oct

13;270(5234):262–9. Comment on: Science 1995 Oct 13;270(5234):262–9. Comment on: Science 1995 Oct 13;270(5234):290–3.

An overview of membrane transport proteins in Saccharomyces cerevisiae. Andre B. **Yeast** 1995 Dec; 11(16):1575–611 (258 ref.)

[Structure and functional similarity of yeast Sup35p and Ure2p proteins to mammalian prions] Kushnirov VV, et al. **Mol Biol (Mosk)** 1995 Jul–Aug;29(4):750–5 (27 ref.) (Eng. Abstr.) **(Rus)**

CYTOLOGY

G1 regulation and checkpoints operating around START in fission yeast. Woollard A, et al. **Bioessays** 1995 Jun; 17(6):481–90 (65 ref.)

Mother and daughter are doing fine: asymmetric cell division in yeast [comment] Amon A. **Cell** 1996 Mar 8;84(5):651–4 (20 ref.) Comment on: Cell 1996 Mar 8;84(5):687–97. Comment on: Cell 1996 Mar 8;84(5):699–709. Comment on: Cell 1996 Mar 8;84(5):711–22.

Cell division. Bud-site selection is only skin deep. Sanders SL, et al. **Curr Biol** 1995 Nov 1;5(11):1213–5 (25 ref.)

Development of cell polarity in budding yeast. Govindan B, et al. **J Exp Zool** 1995 Dec 1;273(5):401–24 (209 ref.)

Stationary phase in Saccharomyces cerevisiae. Werner-Washburne M, et al. **Mol Microbiol** 1996 Mar; 19(6):1159–66 (37 ref.)

Cell cycle arrest in response to DNA damage: lessons from yeast. Siede W. **Mutat Res** 1995 Sep;337(2):73–84 (100 ref.)

Cell shape determination: a pivotal role for Rho [comment] Bussey H. **Science** 1996 Apr 12;272(5259):224–5 (12 ref.) Comment on: Science 1996 Apr 12;272(5259):277–9. Comment on: Science 1996 Apr 12;272(5259):279–81.

DRUG EFFECTS

The heat shock and ethanol stress responses of yeast exhibit extensive similarity and functional overlap. Piper PW. **FEMS Microbiol Lett** 1995 Dec 15;134(2–3):121–7 (38 ref.)

ENZYMOLOGY

Proteasomes of the yeast S. cerevisiae: genes, structure and functions. Hilt W, et al. **Mol Biol Rep** 1995;21(1):3–10 (74 ref.)

Dynamics and organization of MAP kinase signal pathways. Errede B, et al. **Mol Reprod Dev** 1995 Dec;42(4):477–85 (19 ref.)

[Organelle specificity of yeast cell polyphosphatases] Kulaev IS, et al. **Biokhimiia** 1995 Sep;60(9):1396–402 (34 ref.) (Eng. Abstr.) **(Rus)**

GENETICS

Meiotic recombination: a mechanism for tracking and eliminating mutations? McKee BD. **Bioessays** 1996 May; 18(5):411–9 (72 ref.)

Yeast RNA polymerase III: transcription complexes and RNA synthesis. Geiduschek EP, et al. **Braz J Med Biol Res** 1995 Feb;28(2):147–59 (133 ref.)

Control of glycolytic gene expression in the budding yeast (Saccharomyces cerevisiae). Chambers A, et al. **Curr Genet** 1995 Dec;29(1):1–9 (100 ref.)

Molecular mechanisms of cell-type determination in budding yeast. Johnson AD. **Curr Opin Genet Dev** 1995 Oct; 5(5):552–8 (52 ref.)

The elusive centromere: sequence divergence and functional conservation. Sunkel CE, et al. **Curr Opin Genet Dev** 1995 Dec;5(6):756–67 (68 ref.)

Start-specific transcription in yeast. Breeden L. **Curr Top Microbiol Immunol** 1996;208:95–127 (112 ref.)

Complete nucleotide sequence of Saccharomyces cerevisiae chromosome X. Galibert F, et al. **EMBO J** 1996 May 1; 15(9):2031–49 (47 ref.)

Flavoprotein structure and mechanism. 8. Structure-function relations for old yellow enzyme. Karplus PA, et al. **FASEB J** 1995 Dec;9(15):1518–26 (39 ref.)

The pathway to maturity: processing of ribosomal RNA in Saccharomyces cerevisiae. Raué HA, et al. **Gene Expr** 1995; 5(1):71–7 (56 ref.)

The role of PRP8 protein in nuclear pre-mRNA splicing in yeast. Beggs JD, et al. **J Cell Sci Suppl** 1995;19:101–5 (47 ref.)

Stepwise assembly of initiation complexes at budding yeast replication origins during the cell cycle. Diffley JF, et al. **J Cell Sci Suppl** 1995;19:67–72 (25 ref.)

The regulation of euchromatin and heterochromatin by histones in yeast. Grunstein M, et al. **J Cell Sci Suppl** 1995; 19:29–36 (65 ref.)

Heterologous expression in yeast. Trueman LJ. **Methods Mol Biol** 1995;49:341–54 (18 ref.)

Sex and the single cell: meiosis in yeast. Roeder GS. **Proc Natl Acad Sci U S A** 1995 Nov 7;92(23):10450–6 (93 ref.)

Transcriptional coactivators in yeast and beyond. Guarente L. **Trends Biochem Sci** 1995 Dec;20(12):517–21 (54 ref.)

The initiation of DNA replication in the budding yeast cell division cycle. Diffley JF. **Yeast** 1995 Dec;11(16):1651–70 (163 ref.)

Genetically-modified brewing yeasts for the 21st century. Progress to date. Hammond JR. **Yeast** 1995 Dec; 11(16):1613–27 (82 ref.)

The chromosome ends of Saccharomyces cerevisiae. Louis EJ. **Yeast** 1995 Dec;11(16):1553–73 (157 ref.)

Review: compilation and characteristics of dedicated transcription factors in Saccharomyces cerevisiae. Svetlov VV, et al. **Yeast** 1995 Dec;11(15):1439–84 (70 ref.)

Review: the dominant flocculation genes of Saccharomyces cerevisiae constitute a new subtelomeric gene family. Teunissen AW, et al. **Yeast** 1995 Sep 15;11(11):1001–13 (57 ref.)

Processing of pre-ribosomal RNA in Saccharomyces cerevisiae. Venema J, et al. **Yeast** 1995 Dec;11(16):1629–50 (142 ref.)

[Prion-like cytoplasmic genetic determinants of the budding yeast: conformations and biological functions of protein] Ono B. **Tanpakushitsu Kakusan Koso** 1995 Nov; 40(15):2320–8 (49 ref.) **(Jpn)**

GROWTH & DEVELOPMENT

G1 regulation and checkpoints operating around START in fission yeast. Woollard A, et al. **Bioessays** 1995 Jun; 17(6):481–90 (65 ref.)

Molecular basis of cell integrity and morphogenesis in Saccharomyces cerevisiae. Cid VJ, et al. **Microbiol Rev** 1995 Sep;59(3):345–86 (463 ref.)

METABOLISM

Improving productivity of heterologous proteins in recombinant Saccharomyces cerevisiae fermentations. Vasavada A. **Adv Appl Microbiol** 1995;41:25–54 (182 ref.)

Methylglyoxal and regulation of its metabolism in microorganisms. Inoue Y, et al. **Adv Microb Physiol** 1995; 37:177–227 (310 ref.)

Receptor-mediated protein sorting to the vacuole in yeast: roles for a protein kinase, a lipid kinase and GTP-binding proteins. Stack JH, et al. **Ann Rev Cell Dev Biol** 1995; 11:1–33 (146 ref.)

Trehalose metabolism--new horizons in technological applications. Panek AD. **Braz J Med Biol Res** 1995 Feb; 28(2):169–81 (98 ref.)

Control of glycolytic gene expression in the budding yeast (Saccharomyces cerevisiae). Chambers A, et al. **Curr Genet** 1995 Dec;29(1):1–9 (100 ref.)

The heat shock and ethanol stress responses of yeast exhibit extensive similarity and functional overlap. Piper PW. **FEMS Microbiol Lett** 1995 Dec 15;134(2–3):121–7 (38 ref.)

Regulation of phospholipid biosynthesis in the yeast Saccharomyces cerevisiae. Carman GM, et al. **J Biol Chem** 1996 Jun 7;271(23):13293–6 (105 ref.)

Iron metabolism in eukaryotes: Mars and Venus at it again [comment] Kaplan J, et al. **Science** 1996 Mar 15; 271(5255):1510–2 (25 ref.) Comment on: Science 1996 Mar 15;271(5255):1552–7.

Post-translational protein translocation: not all hsc70s are created equal. Brodsky JL. **Trends Biochem Sci** 1996 Apr; 21(4):122–6 (40 ref.)

Genetically-modified brewing yeasts for the 21st century. Progress to date. Hammond JR. **Yeast** 1995 Dec; 11(16):1613–27 (82 ref.)

Review: compilation and characteristics of dedicated transcription factors in Saccharomyces cerevisiae. Svetlov VV, et al. **Yeast** 1995 Dec;11(15):1439–84 (70 ref.)

PHYSIOLOGY

Structure and function of kinetochores in budding yeast. Hyman AA, et al. **Ann Rev Cell Dev Biol** 1995;11:471–95 (97 ref.)

Silencing and heritable domains of gene expression. Loo S, et al. **Ann Rev Cell Dev Biol** 1995;11:519–48 (113 ref.)

Physiological implications of sterol biosynthesis in yeast. Parks LW, et al. **Annu Rev Microbiol** 1995;49:95–116 (121 ref.)

The TOR signalling pathway and growth control in yeast. Hall MN. **Biochem Soc Trans** 1996 Feb;24(1):234–9 (42 ref.)

A yeast transcription factor activating G1 cyclin expression has similarity to bacterial signal transduction proteins. Johnston LH, et al. **Biochem Soc Trans** 1996 Feb; 24(1):49–54 (26 ref.)

Stress signaling in yeast. Ruis H, et al. **Bioessays** 1995 Nov; 17(11):959–65 (74 ref.)

Plugging it in: signaling circuits and the yeast cell cycle. Wittenberg C, et al. **Curr Opin Cell Biol** 1996 Apr; 8(2):223–30 (55 ref.)

Molecular mechanisms of cell-type determination in budding yeast. Johnson AD. **Curr Opin Genet Dev** 1995 Oct; 5(5):552–8 (52 ref.)

The Saccharomyces cerevisiae kinetochore. Lechner J, et al. **FEBS Lett** 1996 Jun 24;389(1):70–4 (42 ref.)

VIROLOGY

Ribosomal frameshifting in yeast viruses. Dinman JD. **Yeast** 1995 Sep 30;11(12):1115–27 (60 ref.)

SACCULE AND UTRICLE

INNERVATION

Physiology of primary saccular afferents of goldfish: implications for Mauthner cell response. Fay RR. **Brain Behav Evol** 1995;46(3):141–50 (54 ref.)

PHYSIOPATHOLOGY

New diagnostic tests for the function of utricles, saccules and somatic graviceptors. Mittelstaedt H. **Acta Otolaryngol Suppl (Stockh)** 1995;520 Pt 1:188–93 (5 ref.)

SACRAL PLEXUS see LUMBOSACRAL PLEXUS

SACRAL REGION see SACROCOCCYGEAL REGION

SACROCOCCYGEAL REGION

Sacrococcygeal chordoma metastatic to the brain with review of the literature. Hall WA, et al. **J Neurooncol** 1995; 25(2):155–9 (16 ref.)

SACROILIAC JOINT

Recurrent subluxation of the sacroiliac joint: diagnosis and treatment. Lippitt Ab. **Bull Hosp Jt Dis** 1995;54(2):94–102 (29 ref.)

Sacroiliitis in sarcoidosis: case reports and review of the literature. Kötter I, et al. **Clin Rheumatol** 1995 Nov; 14(6):695–700 (29 ref.)

RADIOGRAPHY

[Computed tomography of the sacroiliac joints] Miquel A, et al. **Ann Radiol (Paris)** 1995;38(4):177–85 (28 ref.) **(Fre)**

SACRUM

Technique of sacral hernia repair. Kaplan LJ, et al. **Am Surg** 1996 Sep;62(9):762–4 (4 ref.)

[Familiar sacrococcygeal teratoma] Goto T, et al. **Nippon Rinsho** 1995 Nov;53(11):2779–85 (14 ref.) (Eng. Abstr.) **(Jpn)**

ABNORMALITIES

The Currarino syndrome--hereditary transmitted syndrome of anorectal, sacral and presacral anomalies. Case report and review of the literature. Köchling J, et al. **Eur J Pediatr Surg** 1996 Apr;6(2):114–9 (35 ref.)

MRI and radiographic findings in Currarino's triad. Pfluger T, et al. **Pediatr Radiol** 1996;26(8):524–7 (21 ref.)

[The caudal regression syndrome] Méndez Bustelo MJ, et al. **An Esp Pediatr** 1996 Apr;44(4):405–8 (23 ref.) **(Spa)**

INJURIES

Insufficiency fractures of the sacrum and os pubis. Peh WC, et al. **Br J Hosp Med** 1995 Jun 21–Jul 11;54(1):15–9 (20 ref.)

Stress fractures of the sacrum and lower extremity. Fanciullo JJ, et al. **Curr Opin Rheumatol** 1996 Mar;8(2):158–62 (26 ref.)

Lumbosacral fracture-subluxation associated with bilateral fractures of the first sacral pedicles: a case report and review of the literature. Shirado O, et al. **J Orthop Trauma** 1995;9(4):354–8 (28 ref.)

Vertical fracture of the central sacral canal: plane and simple. Hatem SF, et al. **J Trauma** 1996 Jan;40(1):138–40 (12 ref.)

PATHOLOGY

Malignant sacrococcygeal germ cell tumour in an adult. Smithers BM, et al. **Aust N Z J Surg** 1996 Mar;66(3):185–9 (25 ref.)

SURGERY

Urinary bladder dysfunction following anterior lumbosacral spine fusion: case report and review of the literature. Faraj AA, et al. **Eur Spine J** 1996;5(2):121–4 (11 ref.)

SAFETY

Tissue handling in suspected Creutzfeldt-Jakob disease (CJD) and other human spongiform encephalopathies (prion diseases). Budka H, et al. **Brain Pathol** 1995 Jul; 5(3):319–22 (20 ref.)

When a randomised controlled trial is needed to assess drug safety. The case of paediatric ibuprofen. Mitchell AA, et al. **Drug Saf** 1995 Jul;13(1):15–24 (21 ref.)

Safety in the presence of lightning. Holle RL, et al. **Semin Neurol** 1995 Dec;15(4):375–80 (9 ref.)

[The importance of the human factor in the medical support for flight safety] Lapa VV, et al. **Voen Med Zh** 1996 Apr; 317(4):41–4, 79 (16 ref.) (Eng. Abstr.) **(Rus)**

SAFETY, CONSUMER PRODUCT see CONSUMER PRODUCT SAFETY

SAFETY DEVICES see PROTECTIVE DEVICES

SAFETY, EQUIPMENT see EQUIPMENT SAFETY

SAFETY MANAGEMENT

The integrated model: implications for worksite health promotion and occupational health and safety practice. Baker E, et al. **Health Educ Q** 1996 May;23(2):175–90 (61 ref.)

SAFETY MANAGEMENT

METHODS

Formaldehyde disinfection in laboratories: limitations and hazards. Cheney JE, et al. **Br J Biomed Sci** 1995 Sep; 52(3):195–201 (53 ref.)

STANDARDS

Interdisciplinary "case studies" and training experts for primary prevention of environmentally-born health hazard. Dobrowolski JW. **Arch Toxicol Suppl** 1996;18:391–403 (16 ref.)

SAIDS see **SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME**

SALAAM SEIZURES see **SPASMS, INFANTILE**

SALAMANDERS see **URODELA**

SALARIES AND FRINGE BENEFITS

LEGISLATION & JURISPRUDENCE

Implications of negligent selection and retention of physicians in the age of ERISA. Dorros TA, et al. **Am J Law Med** 1995;21(4):383–418 (346 ref.)

SALBUTAMOL see **ALBUTEROL**

SALICYLATES

see related
ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL
CYCLOOXYGENASE INHIBITORS

BLOOD

[HPLC analysis of non-steroidal antirheumatic agents in biological material. I. Salicylates] Sochor J, et al. **Ceska Slov Farm** 1996 Feb;45(1):8–13 (54 ref.) (Eng. Abstr.) **(Cze)**

POISONING

Salicylate poisoning. Bari N. **JPMA J Pak Med Assoc** 1995 Jun;45(6):160–1 (17 ref.)

THERAPEUTIC USE

[Acetyl-salicylic acid and trifusal in the prevention of atherothrombotic stroke] Alvarez Sabin J. **Rev Neurol** 1995 Sep–Oct;23(123):1091–5 (36 ref.) **(Spa)**

SALICYLAZOSULFAPYRIDINE see **SULFASALAZINE**

SALICYLIC ACIDS

ADVERSE EFFECTS

Salicylism from topical salicylates: review of the literature. Brubacher JR, et al. **J Toxicol Clin Toxicol** 1996; 34(4):431–6 (31 ref.)

BLOOD

[Salicylic acid] Onouchi T, et al. **Nippon Rinsho** 1995 Feb; 53 Su Pt 1:1040–2 (13 ref.) **(Jpn)**

SALIENTIA see **ANURA**

SALINE see **SODIUM CHLORIDE**

SALINE SOLUTION, HYPERTONIC

ADMINISTRATION & DOSAGE

[Treatment of severe hypovolemia with hypertonic saline] Rask H, et al. **Ugeskr Laeger** 1996 Jan 29;158(5):584–9 (39 ref.) (Eng. Abstr.) **(Dan)**

THERAPEUTIC USE

Salt, starch, and water on the brain. Schell RM, et al. **J Neurosurg Anesthesiol** 1996 Apr;8(2):178–82 (56 ref.)

Hypertonic saline as a safe and efficacious treatment of intracranial hypertension. Zornow MH. **J Neurosurg Anesthesiol** 1996 Apr;8(2):175–7 (26 ref.)

Hypertonic volume therapy: feasibility in the prevention and treatment of multiple organ failure and sepsis. Monteiro Pacheco A Jr, et al. **Rev Paul Med** 1995 Nov–Dec; 113(6):1053–60 (53 ref.)

SALIVA

CHEMISTRY

Oral candidiasis, HIV, and saliva glucocorticoids. Enwonwu CO, et al. **Am J Pathol** 1996 Apr;148(4):1313–8 (68 ref.)

Biochemical composition of human saliva in relation to other mucosal fluids. Schenkels LC, et al. **Crit Rev Oral Biol Med** 1995;6(2):161–75 (165 ref.)

Application of saliva for drug monitoring. An in vivo model for transmembrane transport. Haeckel R, et al. **Eur J Clin Chem Clin Biochem** 1996 Mar;34(3):171–91 (179 ref.)

Effect of chronic stress associated with unemployment on salivary cortisol: overall cortisol levels, diurnal rhythm, and acute stress reactivity. Ockenfels MC, et al. **Psychosom Med** 1995 Sep–Oct;57(5):460–7 (61 ref.)

IMMUNOLOGY

Modifiers of the human mucosal immune system. Gleeson M, et al. **Immunol Cell Biol** 1995 Oct;73(5):397–404 (49 ref.)

[Salivary HIV antibodies. Review of current data and future prospectives] Polimeni A, et al. **Minerva Stomatol** 1995 Dec;44(12):583–90 (20 ref.) (Eng. Abstr.) **(Ita)**

METABOLISM

Saliva and growth factors: the fountain of youth resides in us all. Zelles T, et al. **J Dent Res** 1995 Dec;74(12):1826–32 (90 ref.)

MICROBIOLOGY

Does variability in salivary protein concentrations influence oral microbial ecology and oral health? Rudney JD. **Crit Rev Oral Biol Med** 1995;6(4):343–67 (249 ref.)

PHYSIOLOGY

Do salivary organic components play a protective role in health and disease of the esophageal mucosa? Sarosiek J, et al. **Digestion** 1995;56 Suppl 1:32–7 (34 ref.)

Carbonic anhydrase in the alimentary tract. Roles of the different isozymes and salivary factors in the maintenance of optimal conditions in the gastrointestinal canal. Parkkila S, et al. **Scand J Gastroenterol** 1996 Apr;31(4):305–17 (171 ref.)

SECRETION

[Inhibition of saliva secretion caused by antidepressive drugs; a risk for oral health] Peeters FP, et al. **Ned Tijdschr Geneeskd** 1996 Mar 9;140(10):533–6 (25 ref.) **(Dut)**

VIROLOGY

Risk of acquiring AIDS from salivary exchange through cardiopulmonary resuscitation courses and mouth-to-mouth resuscitation. Sun D, et al. **Semin Dermatol** 1995 Sep;14(3):205–11 (76 ref.)

SALIVARY DUCTS

PATHOLOGY

Intraoral salivary duct carcinoma: a clinicopathological study of four cases and review of the literature. Epivatianos A, et al. **Ann Dent** 1995 Summer–Fall;54(1–2):36–40 (21 ref.)

SALIVARY GLAND DISEASES

DIAGNOSIS

Imaging of the salivary glands. Weissman JL. **Semin Ultrasound CT MR** 1995 Dec;16(6):546–68 (28 ref.)

PATHOLOGY

Diagnostic difficulties in the interpretation of fine needle aspirates of salivary gland lesions: the problem revisited. Orell SR. **Cytopathology** 1995 Oct;6(5):285–300 (31 ref.)

[Adenomatoid hyperplasia of the minor salivary glands. Report of a clinical case] Tucci E, et al. **Minerva Stomatol** 1996 Jan–Feb;45(1–2):49–52 (9 ref.) (Eng. Abstr.) **(Ita)**

SALIVARY GLAND FISTULA

ETIOLOGY

Parotid salivary fistula following rhytidectomy. Wolf K, et al. **Plast Reconstr Surg** 1996 Mar;97(3):641–2 (7 ref.)

SALIVARY GLAND NEOPLASMS

CLASSIFICATION

Multiple tumours of the salivary glands—terminology and nomenclature. Seifert G, et al. **Eur J Cancer B Oral Oncol** 1996 Jan;32B(1):3–7 (105 ref.)

Classification of salivary gland tumours—a brief histopathological review. Simpson RH. **Histol Histopathol** 1995 Jul;10(3):737–46 (63 ref.)

Classification and differential diagnosis of clear and basal cell tumors of the salivary glands. Seifert G. **Semin Diagn Pathol** 1996 May;13(2):95–103 (47 ref.)

DIAGNOSIS

Basal cell (monomorphic) and minimally pleomorphic adenomas of the salivary glands. Distinction from the solid (anaplastic) type of adenoid cystic carcinoma in fine-needle aspiration. Stanley MW, et al. **Am J Clin Pathol** 1996 Jul; 106(1):35–41 (35 ref.)

Classification and differential diagnosis of clear and basal cell tumors of the salivary glands. Seifert G. **Semin Diagn Pathol** 1996 May;13(2):95–103 (47 ref.)

Imaging of the salivary glands. Weissman JL. **Semin Ultrasound CT MR** 1995 Dec;16(6):546–68 (28 ref.)

[Diagnosis and therapy of salivary gland tumors. II] Chilla R. **HNO** 1995 Nov;43(11):681–94 (24 ref.) **(Ger)**

[Diagnosis and therapy of salivary gland tumors. I] Chilla R. **HNO** 1995 Oct;43(10):627–33 (0 ref.) **(Ger)**

ETIOLOGY

New insights into the pathogenesis of Warthin's tumour. Gallo O. **Eur J Cancer B Oral Oncol** 1995 Jul;31B(4):211–5 (54 ref.)

Lymphoma in Sjögren's syndrome. From histopathology to molecular pathology. Jordan RC, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Mar;81(3):308–20 (70 ref.)

GENETICS

A mucoepidermoid carcinoma of minor salivary gland with t(11;19)(q21;p13.1) as the only karyotypic abnormality. El-Naggar AK, et al. **Cancer Genet Cytogenet** 1996 Mar; 87(1):29–33 (35 ref.)

PATHOLOGY

Intraoral salivary duct carcinoma: a clinicopathological study of four cases and review of the literature. Epivatianos A, et al. **Ann Dent** 1995 Summer–Fall;54(1–2):36–40 (21 ref.)

Diagnostic difficulties in the interpretation of fine needle aspirates of salivary gland lesions: the problem revisited. Orell SR. **Cytopathology** 1995 Oct;6(5):285–300 (31 ref.)

Salivary gland choristoma of the middle ear: report of a case and review of the literature. Hinni ML, et al. **Ear Nose Throat J** 1996 Jul;75(7):422–4 (17 ref.)

Classification of salivary gland tumours—a brief histopathological review. Simpson RH. **Histol Histopathol** 1995 Jul;10(3):737–46 (63 ref.)

Recurrent sialadenoma papilliferum of the buccal mucosa. Pimentel MT, et al. **J Laryngol Otol** 1995 Aug; 109(8):787–90 (29 ref.)

Simultaneous multifocal polymorphous low-grade adenocarcinoma. Report of two cases. Clayton JR, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1995 Jul;80(1):71–7 (31 ref.)

Basal cell adenocarcinoma of minor salivary and seromucous glands of the head and neck region. Fonseca I, et al. **Semin Diagn Pathol** 1996 May;13(2):128–37 (30 ref.)

[Hyalinizing clear cell carcinoma of the salivary glands] Seifert G, et al. **Pathologe** 1996 Mar;17(2):110–5 (26 ref.) (Eng. Abstr.) **(Ger)**

[Adenomatoid hyperplasia of the minor salivary glands. Report of a clinical case] Tucci E, et al. **Minerva Stomatol** 1996 Jan–Feb;45(1–2):49–52 (9 ref.) (Eng. Abstr.) **(Ita)**

PHYSIOPATHOLOGY

Salivary duct carcinoma. Clinicopathologic and immunohistochemical review of 26 cases. Lewis JE, et al. **Cancer** 1996 Jan 15;77(2):223–30 (35 ref.)

SALIVARY GLAND TUMOR, MIXED see **ADENOMA, PLEOMORPHIC**

SALIVARY GLAND VIRUS DISEASE see **CYTOMEGALOVIRUS INFECTIONS**

SALIVARY GLAND VIRUSES see **CYTOMEGALOVIRUS**

SALIVARY GLANDS

see related
SIALOGRAPHY

[Salivary gland heterotopia in the bone tissue of the mandible] Afanas'ev VV, et al. **Stomatologiia (Mosk)** 1995;74(2):69–70 (8 ref.) (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

Anethole dithiolethione: biochemical considerations. Christen MO. **Methods Enzymol** 1995;252:316–23 (40 ref.)

IMMUNOLOGY

[Aberrant expression of HLA-DR antigens on acinar and ductal epithelial cells of salivary glands in Sjögren's syndrome] Nakamura S, et al. **Nippon Rinsho** 1995 Oct; 53(10):2407–11 (16 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Salivary gland choristoma of the middle ear: report of a case and review of the literature. Hinni ML, et al. **Ear Nose Throat J** 1996 Jul;75(7):422–4 (17 ref.)

PHYSIOLOGY

Transgenic approaches to salivary gland research. Samuelson LC. **Annu Rev Physiol** 1996;58:209–29 (106 ref.)

VIROLOGY

[EBER-1 expression in salivary glands of Sjögren's syndrome] Nomura H, et al. **Nippon Rinsho** 1995 Oct; 53(10):2490–4 (22 ref.) (Eng. Abstr.) **(Jpn)**

[Detection of retrovirus in salivary glands of patients with

Sjögren's syndrome] Yamano S, et al. **Nippon Rinsho** 1995 Oct;53(10):2456–60 (21 ref.) (Eng. Abstr.) **(Jpn)**

[Expression of sequences homologous to HTLV-I pXIV gene in the labial salivary glands of Japanese patients with Sjögren's syndrome and pathogenesis] Yonaha-Nagato F, et al. **Nippon Rinsho** 1995 Oct;53(10):2473–8 (13 ref.) (Eng. Abstr.) **(Jpn)**

SALIVARY GLANDS, MINOR

PATHOLOGY

Simultaneous multifocal polymorphous low-grade adenocarcinoma. Report of two cases. Clayton JR, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1995 Jul;80(1):71–7 (31 ref.)

[An update on primary Gougerot-Sjögren's syndrome in 1995] Voisin MC. **Ann Pathol** 1996;16(1):11–9 (56 ref.) **(Fre)**

[Adenomatoid hyperplasia of the minor salivary glands. Report of a clinical case] Tucci E, et al. **Minerva Stomatol** 1996 Jan-Feb;45(1-2):49–52 (9 ref.) (Eng. Abstr.) **(Ita)**

SALIVARY PROTEINS

ANALYSIS

Does variability in salivary protein concentrations influence oral microbial ecology and oral health? Rudney JD. **Crit Rev Oral Biol Med** 1995;6(4):343–67 (249 ref.)

Biochemical composition of human saliva in relation to other mucosal fluids. Schenkels LC, et al. **Crit Rev Oral Biol Med** 1995;6(2):161–75 (165 ref.)

BIOSYNTHESIS

Saliva and growth factors: the fountain of youth resides in us all. Zelles T, et al. **J Dent Res** 1995 Dec;74(12):1826–32 (90 ref.)

CHEMISTRY

EP-GP and the lipocalin VEGh, two different human salivary 20-kDa proteins. Schenkels LC, et al. **J Dent Res** 1995 Sep;74(9):1543–50 (80 ref.)

PHYSIOLOGY

Salivary mucins: protective functions in relation to their diversity. Amerongen AV, et al. **Glycobiology** 1995 Dec; 5(8):733–40 (100 ref.)

SALIVATION

see related
SIALORRHEA
XEROSTOMIA

DRUG EFFECTS

[Decreased saliva secretion. A pharmacologic effect with sequelae for oral health] Foth H. **Med Monatsschr Pharm** 1995 Dec;18(12):350–7 (8 ref.) **(Ger)**

SALK VACCINE see **POLIOVIRUS VACCINE**

SALMO GAIRDNERI see **ONCORHYNCHUS MYKISS**

SALMONELLA

CLASSIFICATION

[Osteoarticular infections by Salmonella non-typhi] Ramos JM, et al. **Enferm Infecc Microbiol Clin** 1995 Aug-Sep; 13(7):406–10 (30 ref.) (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

Live Salmonella vaccines as a route towards oral immunisation. Everest P, et al. **Biologicals** 1995 Jun; 23(2):119–24 (48 ref.)

ISOLATION & PURIFICATION

Salmonella panama osteomyelitis in an otherwise healthy patient. A case report. van Cappelle HG, et al. **Clin Orthop** 1995 Dec;(321):235–8 (19 ref.)

Salmonellae and food safety. Tietjen M, et al. **Crit Rev Microbiol** 1995;21(1):53–83 (104 ref.)

Wiley Award Address. Evolution of methods for the detection of Salmonella in foods. Andrews WH. **J AOAC Int** 1996 Jan-Feb;79(1):4–12 (58 ref.)

Reptile-associated salmonellosis in New York State. Ackman DM, et al. **Pediatr Infect Dis J** 1995 Nov;14(11):955–9 (22 ref.)

METABOLISM

Iron supplying systems of Salmonella in diagnostics, epidemiology and infection. Kingsley R, et al. **FEMS Immunol Med Microbiol** 1995 Jul;11(4):257–64 (36 ref.)

PATHOGENICITY

Biology and clinical significance of virulence plasmids in Salmonella serovars. Guiney DG, et al. **Clin Infect Dis** 1995 Oct;21 Suppl 2:S146–51 (37 ref.)

Salmonellosis in horses [comment] Murray MJ. **J Am Vet Med Assoc** 1996 Aug 1;209(3):558–60 (10 ref.) Comment on: J Am Vet Med Assoc 1996 Aug 1;209(3):626–8. Comment on: J Am Vet Med Assoc 1996 Aug 1;209(3):629–31.

Growth-phase regulation of plasmid virulence genes in Salmonella. Guiney DG, et al. **Trends Microbiol** 1995 Jul; 3(7):275–9 (29 ref.)

PHYSIOLOGY

Current perspectives in salmonellosis [see comments] Lax AJ, et al. **Br Vet J** 1995 Jul-Aug;151(4):351–77 (230 ref.) Comment in: Br Vet J 1995 Jul-Aug;151(4):339–41.

Salmonellosis: a hundred years old and still going strong [editorial; comment] Wray C. **Br Vet J** 1995 Jul-Aug; 151(4):339–41 (10 ref.) Comment on: Br Vet J 1995 Jul-Aug;151(4):351–77.

ULTRASTRUCTURE

Salmonella fimbriae: novel antigens in the detection and control of salmonella infections. Thorns CJ. **Br Vet J** 1995 Nov-Dec;151(6):643–58 (82 ref.)

SALMONELLA ENTERITIDIS

Infectious endocarditis due to non-typhi Salmonella in patients infected with human immunodeficiency virus: report of two cases and review. Fernández Guerrero ML, et al. **Clin Infect Dis** 1996 May;22(5):853–5 (10 ref.)

SALMONELLA FOOD POISONING

PREVENTION & CONTROL

Salmonellae and food safety. Tietjen M, et al. **Crit Rev Microbiol** 1995;21(1):53–83 (104 ref.)

SALMONELLA INFECTIONS

Skull osteomyelitis due to Salmonella species: two case reports and review. Kamarulzaman A, et al. **Clin Infect Dis** 1996 Apr;22(4):638–41 (27 ref.)

Salmonella prosthetic valve endocarditis. Fukushima N, et al. **J Thorac Cardiovasc Surg** 1996 Sep;112(3):840–2 (5 ref.)

COMPLICATIONS

Infectious endocarditis due to non-typhi Salmonella in patients infected with human immunodeficiency virus: report of two cases and review. Fernández Guerrero ML, et al. **Clin Infect Dis** 1996 May;22(5):853–5 (10 ref.)

EPIDEMIOLOGY

[Osteoarticular infections by Salmonella non-typhi] Ramos JM, et al. **Enferm Infecc Microbiol Clin** 1995 Aug-Sep; 13(7):406–10 (30 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

Salmonella mycotic aneurysm of the aortic arch: case report and review. Meerkin D, et al. **Clin Infect Dis** 1995 Sep; 21(3):523–8 (32 ref.)

Reptile-associated salmonellosis in New York State. Ackman DM, et al. **Pediatr Infect Dis J** 1995 Nov;14(11):955–9 (22 ref.)

MICROBIOLOGY

Lung abscess due to nontyphoid Salmonella in an immunocompromised host. Case report with review of the literature. Ridha AG, et al. **Acta Clin Belg** 1996; 51(3):175–83 (41 ref.)

Infectious endocarditis due to non-typhi Salmonella in patients infected with human immunodeficiency virus: report of two cases and review. Fernández Guerrero ML, et al. **Clin Infect Dis** 1996 May;22(5):853–5 (10 ref.)

Salmonella panama osteomyelitis in an otherwise healthy patient. A case report. van Cappelle HG, et al. **Clin Orthop** 1995 Dec;(321):235–8 (19 ref.)

Iron supplying systems of Salmonella in diagnostics, epidemiology and infection. Kingsley R, et al. **FEMS Immunol Med Microbiol** 1995 Jul;11(4):257–64 (36 ref.)

SALMONELLA INFECTIONS, ANIMAL

Salmonellosis in horses [comment] Murray MJ. **J Am Vet Med Assoc** 1996 Aug 1;209(3):558–60 (10 ref.) Comment on: J Am Vet Med Assoc 1996 Aug 1;209(3):626–8. Comment on: J Am Vet Med Assoc 1996 Aug 1;209(3):629–31.

ETIOLOGY

Current perspectives in salmonellosis [see comments] Lax AJ, et al. **Br Vet J** 1995 Jul-Aug;151(4):351–77 (230 ref.) Comment in: Br Vet J 1995 Jul-Aug;151(4):339–41.

MICROBIOLOGY

Salmonellosis: a hundred years old and still going strong [editorial; comment] Wray C. **Br Vet J** 1995 Jul-Aug; 151(4):339–41 (10 ref.) Comment on: Br Vet J 1995 Jul-Aug;151(4):351–77.

SALMONELLA TYPHI

DRUG EFFECTS

Short course quinolone therapy of typhoid fever in developing countries. Limson BM. **Drugs** 1995;49 Suppl 2:136–8 (21 ref.)

SALMONELLA TYPHIMURIUM

Skull osteomyelitis due to Salmonella species: two case reports and review. Kamarulzaman A, et al. **Clin Infect Dis** 1996 Apr;22(4):638–41 (27 ref.)

Salmonella prosthetic valve endocarditis. Fukushima N, et al. **J Thorac Cardiovasc Surg** 1996 Sep;112(3):840–2 (5 ref.)

DRUG EFFECTS

Low pH adaptation and the acid tolerance response of Salmonella typhimurium. Foster JW. **Crit Rev Microbiol** 1995;21(4):215–37 (90 ref.)

Bacterial responses to host-defense peptides. Groisman EA. **Trends Microbiol** 1996 Apr;4(4):127–8; discussion 128–9 (17 ref.)

GENETICS

Optimization of the Salmonella/mammalian microsome assay for urine mutagenesis by experimental designs. De Méo M, et al. **Mutat Res** 1996 Jun;340(2-3):51–65 (50 ref.)

PATHOGENICITY

How Salmonella survive against the odds. Foster JW, et al. **Annu Rev Microbiol** 1995;49:145–74 (208 ref.)

PHYSIOLOGY

How Salmonella survive against the odds. Foster JW, et al. **Annu Rev Microbiol** 1995;49:145–74 (208 ref.)

Regulation of interaction between signaling protein CheY and flagellar motor during bacterial chemotaxis. Barak R, et al. **Curr Top Cell Regul** 1996;34:137–58 (156 ref.)

SALMONELLA TYPHOSA see **SALMONELLA TYPHI**

SALMONELLOSIS see **SALMONELLA INFECTIONS**

SALPINGITIS

DRUG THERAPY

[Antibiotics in gynecology. Treatment of acute infections] Judlin P. **Contracept Fertil Sex** 1996 May;24(5):353–8 (0 ref.) **(Fre)**

SALPINGOGRAPHY see **HYSTEROSALPINGOGRAPHY**

SALPINGOSTOMY

INSTRUMENTATION

[Possibilities and limits of endoscopic fallopian tube surgery] Korell M, et al. **Zentralbl Gynakol** 1995;117(12):663–9 (21 ref.) (Eng. Abstr.) **(Ger)**

METHODS

[Role of conservative therapy and medical treatment in ectopic pregnancy: literature review and clinical trial comparing medical treatment and conservative laparoscopic treatment] Fernandez H, et al. **Contracept Fertil Sex** 1996 Apr;24(4):297–302 (36 ref.) (Eng. Abstr.) **(Fre)**

SALTS

Role of peripheral angiotensin in salt appetite of the sodium-deplete rat. Thunhorst RL. **Neurosci Biobehav Rev** 1996;20(1):101–6 (33 ref.)

CHEMISTRY

Salt effects on nucleic acids. Sharp KA, et al. **Curr Opin Struct Biol** 1995 Jun;5(3):323–8 (35 ref.)

PHARMACOLOGY

The importance of calcium in the control of salt intake. Tordoff MG. **Neurosci Biobehav Rev** 1996;20(1):89–99 (104 ref.)

SALVAGE THERAPY

Recombinant alpha-interferon as treatment for chronic myelogenous leukemia in relapse after allogeneic bone marrow transplantation: a report from the Société Française de Greffe de Moelle. Pigneux A, et al. **Bone Marrow Transplant** 1995 Jun;15(6):819–24 (31 ref.)

[Salvage therapy for refractory testicular cancer] Kawai K,

SALVAGE THERAPY

et al. **Gan To Kagaku Ryoho** 1996 Aug;23(9):1129–35 (35 ref.) (Eng. Abstr.) **(Jpn)**

INSTRUMENTATION

The autoperfusion balloon catheter with special attention to its use as a bail–out device. Bonnier JJ. **Z Kardiol** 1995; 84 Suppl 2:79–82 (17 ref.)

METHODS

Can amputation be avoided in local recurrence after limb salvage for high grade osteosarcoma? A case report and a review of the literature. Babin SR, et al. **Int Orthop** 1995; 19(6):374–6 (10 ref.)

SAMPLE SIZE

Estimating sample sizes for binary, ordered categorical, and continuous outcomes in two group comparisons. Campbell MJ, et al. **BMJ** 1995 Oct 28;311(7013):1145–8 (28 ref.)

Planning and revising the sample size for a trial. Gould AL. **Stat Med** 1995 May 15–30;14(9–10):1039–51; discussion 1053–5 (15 ref.)

Formulae and tables for the determination of sample sizes and power in clinical trials for testing differences in proportions for the two–sample design: a review. Sahai H, et al. **Stat Med** 1996 Jan 15;15(1):1–21 (96 ref.)

Sample size determination in epidemiologic studies. Wickramaratne PJ. **Stat Methods Med Res** 1995 Dec; 4(4):311–37 (53 ref.)

SAMPLING STUDIES

Food sampling strategies for energy intake estimates. Holden JM. **Am J Clin Nutr** 1995 Nov;62(5 Suppl):1151S–1157S (31 ref.)

Overview of important design issues for a National Human Exposure Assessment Survey. Callahan MA, et al. **J Expo Anal Environ Epidemiol** 1995 Jul–Sep;5(3):257–82 (36 ref.)

Sampling homosexuals, bisexuals, gays, and lesbians for public health research: a review of the literature from 1990 to 1992. Sell RL, et al. **J Homosex** 1996;30(4):31–47 (19 ref.)

Correction for the design effect in school–based substance use and abuse prevention research: sample size requirements and analysis considerations. Dielman TE. **NIDA Res Monogr** 1994;139:115–25 (38 ref.)

SAND–DOLLAR see SEA URCHINS

SANDFLY FEVER see PHLEBOTOMUS FEVER

SANDHOFF DISEASE

DIAGNOSIS

[Adult form of GM2–gangliosidosis: a man and 2 sisters with hexosaminidase–A and –B deficiency (Sandhoff disease) and literature review] Schnorf H, et al. **Schweiz Med Wochenschr** 1996 May 4;126(18):757–64 (53 ref.) (Eng. Abstr.) **(Ger)**

GENETICS

[Recent advances in molecular genetics of GM2 gangliosidosis] Wakamatsu N. **Nippon Rinsho** 1995 Dec; 53(12):2988–93 (21 ref.) (Eng. Abstr.) **(Jpn)**

SAO PAULO TYPHUS see ROCKY MOUNTAIN SPOTTED FEVER

SAPHENOUS VEIN

TRANSPLANTATION

Antithrombotic therapy in patients with saphenous vein and internal mammary artery bypass grafts. Stein PD, et al. **Chest** 1995 Oct;108(4 Suppl):424S–430S (30 ref.)

Vein graft failure. Mills NL, et al. **Curr Opin Cardiol** 1995 Nov;10(6):562–8 (16 ref.)

The use of autologous saphenous vein grafts for isolated left anterior descending coronary artery revascularization. Pomar JL. **Eur Heart J** 1995 Jul;16 Suppl E:26–8 (20 ref.)

Arterial and venous conduits for coronary artery bypass. A current review. Cooper GJ, et al. **Eur J Cardiothorac Surg** 1996;10(2):129–40 (197 ref.)

Vein patch rupture: early complication of carotid endarterectomy. Blok JG, et al. **Eur J Surg** 1995 Jul; 161(7):519–21 (17 ref.)

Interposition vein cuffs [editorial] Harris P, et al. **Eur J Vasc Endovasc Surg** 1996 Apr;11(3):257–9 (11 ref.)

Interposition vein cuffs. Harris P, et al. **J Mal Vasc** 1996; 21 Suppl A:178–80 (11 ref.)

SAPONINS

Three autacoids—endogenous digitalis–like factor, clonidine–displacing substance, and quinidine–like immunoreactivity. Kölbel F, et al. **Sb Lek** 1995; 96(4):405–15 (65 ref.)

CHEMISTRY

Structural and immunological characterization of the vaccine adjuvant QS–21. Kensil CR, et al. **Pharm Biotechnol** 1995; 6:525–41 (41 ref.)

IMMUNOLOGY

Structural and immunological characterization of the vaccine adjuvant QS–21. Kensil CR, et al. **Pharm Biotechnol** 1995; 6:525–41 (41 ref.)

[Digoxin–like immunoreactive factors. Review of the literature] Ozzola G, et al. **Minerva Med** 1995 Nov; 86(11):475–80 (42 ref.) (Eng. Abstr.) **(Ita)**

PHARMACOLOGY

Lyme vaccine enhancement. N–terminal acylation of a protein antigen and inclusion of a saponin adjuvant. Coughlin RT, et al. **Pharm Biotechnol** 1995;6:719–35 (126 ref.)

Endogenous sodium pump inhibition: current status and therapeutic opportunities. Hollenberg NK, et al. **Prog Drug Res** 1996;46:9–42 (116 ref.)

THERAPEUTIC USE

[Phytotherapeutic aspects of diseases of the cardiovascular system. 5. Saponins and possibilities of their use in prevention and therapy] Purmová J, et al. **Ceska Slov Farm** 1995 Oct;44(5):246–51 (53 ref.) (Eng. Abstr.) **(Cze)**

SARCOCYSTIS

PATHOGENICITY

Current research on Sarcocystis species of domestic animals. Tenter AM. **Int J Parasitol** 1995 Nov;25(11):1311–30 (132 ref.)

PHYSIOLOGY

Current research on Sarcocystis species of domestic animals. Tenter AM. **Int J Parasitol** 1995 Nov;25(11):1311–30 (132 ref.)

SARCOCYSTOSIS

VETERINARY

Current research on Sarcocystis species of domestic animals. Tenter AM. **Int J Parasitol** 1995 Nov;25(11):1311–30 (132 ref.)

SARCOIDOSIS

Sarcoidosis. Peckham DG, et al. **Postgrad Med J** 1996 Apr; 72(846):196–200 (48 ref.)

Benign lymphoproliferative disorders. Shaffer S. **Semin Oncol Nurs** 1996 Feb;12(1):28–37 (44 ref.)

[Granulomatous tubulointerstitial nephritis—Wegener's granulomatosis, sarcoidosis] Yoshida M. **Nippon Rinsho** 1995 Aug;53(8):1974–80 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Sarcoidosis: diagnosis, clinical aspects, course and therapy] Ozerova LV. **Probl Tuberk** 1995;(4):51–4 (0 ref.) **(Rus)**

COMPLICATIONS

Unexpected sudden death in a young pregnant woman: unusual presentation of neurosarcoidosis. Maisel JA, et al. **Ann Emerg Med** 1996 Jul;28(1):94–7 (12 ref.)

Vitamin D, calcium, and sarcoidosis. Sharma OP. **Chest** 1996 Feb;109(2):535–9 (78 ref.)

Sacroiliitis in sarcoidosis: case reports and review of the literature. Kötter I, et al. **Clin Rheumatol** 1995 Nov; 14(6):695–700 (29 ref.)

Sarcoidosis and its ocular manifestations. Smith JA, et al. **Int Ophthalmol Clin** 1996 Winter;36(1):109–25 (77 ref.)

Acute sarcoid arthritis: a favourable outcome? A retrospective survey of 49 patients with review of the literature. Gran JT, et al. **Scand J Rheumatol** 1996; 25(2):70–3 (23 ref.)

[Systemic sarcoidosis with cutaneous lesions: literature review] Hubert A, et al. **Acta Clin Belg** 1995;50(4):207–13 (23 ref.) (Eng. Abstr.) **(Fre)**

[Digestive sites disclosing sarcoidosis] Chemlal K, et al. **Ann Med Interne (Paris)** 1996;147(2):103–6 (19 ref.) (Eng. Abstr.) **(Fre)**

[Cutaneous vasculitis in sarcoidosis. 2 cases and review of the literature (letter)] Sauvaget F, et al. **Ann Med Interne (Paris)** 1995;146(8):587–9 (10 ref.) **(Fre)**

[Cutaneous ulcerations in sarcoidosis] de La Blanchardière A, et al. **Rev Med Interne** 1995;16(12):927–9 (14 ref.) (Eng. Abstr.) **(Fre)**

[Hemoptysis in sarcoidosis. Apropos of 6 cases including 4 with fatal outcome] Lemay V, et al. **Rev Pneumol Clin** 1995;51(2):61–70 (45 ref.) (Eng. Abstr.) **(Fre)**

[Acute kidney failure in a recurrence of sarcoidosis at the height of summer] Wiemeyer A, et al. **Dtsch Med Wochenschr** 1996 Feb 9;121(6):165–8 (15 ref.) (Eng. Abstr.) **(Ger)**

[Cardiac sarcoidosis with myopathy and advanced A–V nodal block in a woman with a previous diagnosis of sarcoidosis] Sugo A, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Oct; 33(10):1111–8 (33 ref.) (Eng. Abstr.) **(Jpn)**

[Hepatic granuloma] Shiga J, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):420–2 (6 ref.) **(Jpn)**

DIAGNOSIS

Reversible esophageal motility disorder in a patient with sarcoidosis. Geissinger BW, et al. **Am J Gastroenterol** 1996 Jul;91(7):1423–6 (21 ref.)

Periarticular ankle sarcoidosis: a variant of Löfgren's syndrome. Mañá J, et al. **J Rheumatol** 1996 May;23(5):874–7 (21 ref.)

Differential diagnoses of bone marrow granuloma. Eid A, et al. **West J Med** 1996 Jun;164(6):510–5 (49 ref.)

[Sarcoidosis of the central nervous system: clinical and radiological polymorphism] de Sèze J, et al. **Rev Med Interne** 1996;17(6):482–7 (38 ref.) (Eng. Abstr.) **(Fre)**

[MRI aspect and course of supra–tentorial sarcoidosic lesions] Caparros–lefebvre D, et al. **Rev Neurol (Paris)** 1996 Mar; 152(3):196–201 (45 ref.) (Eng. Abstr.) **(Fre)**

[Prognosis of sarcoidosis] Müller–Quernheim J. **Versicherungsmedizin** 1995 Dec 1;47(6):216–21 (43 ref.) (Eng. Abstr.) **(Ger)**

[Splenic sarcoidosis. Review of the literature and description of a case studied with ultrasonography and computed tomography] Galuppo C, et al. **Radiol Med (Torino)** 1996 Jun;91(6):834–5 (4 ref.) **(Ita)**

[Intracranial mass as single manifestation of sarcoidosis] Rodríguez–Carballeira M, et al. **Rev Clin Esp** 1995 Nov; 195(11):765–8 (22 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

The riddle of sarcoidosis: have novel techniques brought any new insights as to the causative agent? [editorial] Eklund A, et al. **J Intern Med** 1996 Aug;240(2):59–62 (24 ref.)

IMMUNOLOGY

[Sarcoidosis: immunopathology and criteria of biological activity] Müller–Quernheim J, et al. **Rev Mal Respir** 1995; 12(6):525–31 (39 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Nodular lesions on fingertips. Diagnosis: cutaneous sarcoidosis. Di Landro A, et al. **Arch Dermatol** 1996 Apr; 132(4):460, 463 (9 ref.)

Sarcoidosis with skin manifestations—two case reports and review of literature. Siddiqi S, et al. **JPMA J Pak Med Assoc** 1995 Jun;45(6):162–4 (10 ref.)

[Sarcoidosis of the liver and intrahepatic biliary system] Tachibana T. **Ryoikibetsu Shokogun Shirizu** 1995;(8):333–6 (22 ref.) **(Jpn)**

RADIOGRAPHY

[The manifestation of subcutaneous sarcoidosis in the area of the breast] Ludwig K, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1995 Oct;163(4):356–7 (8 ref.) **(Ger)**

SARCOIDOSIS, PULMONARY

CHEMICALLY INDUCED

Sarcoidosis after interferon therapy for chronic active hepatitis C. Teragawa H, et al. **Intern Med** 1996 Jan; 35(1):19–23 (20 ref.)

COMPLICATIONS

[Sarcoidosis with pulmonary cavitation and calcification] Yokogawa K, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Nov; 33(11):1259–64 (27 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Pulmonary sarcoidosis: a mimic of respiratory infection. Blackmon GM, et al. **Semin Respir Infect** 1995 Sep; 10(3):176–86 (79 ref.)

EPIDEMIOLOGY

Pulmonary sarcoidosis: pathogenesis and population differences [see comments] Nagai S. **Intern Med** 1995 Sep; 34(9):833–8 (47 ref.) Comment in: Intern Med 1995 Sep;34(9):819.

ETIOLOGY

Pulmonary sarcoidosis: population differences and pathophysiology. Nagai S, et al. **South Med J** 1995 Oct; 88(10):1001–10 (85 ref.)

IMMUNOLOGY

The cytokine network in sarcoidosis. Müller–Quernheim J. **Eur Cytokine Netw** 1996 Jan–Mar;7(1):13–26 (142 ref.)

[Clinical and immunobiological observations on the inflammatory activity of sarcoidosis] Müller–Quernheim J. **Pneumologie** 1996 Jan;50(1):40–8 (101 ref.) **(Ger)**

PHYSIOPATHOLOGY

Pulmonary sarcoidosis: pathogenesis and population differences [see comments] Nagai S. **Intern Med** 1995 Sep; 34(9):833–8 (47 ref.) Comment in: Intern Med 1995 Sep;34(9):819.

RADIOGRAPHY

Evidence of expiratory CT scans of small-airway obstruction in sarcoidosis. Gleeson FV, et al. **AJR Am J Roentgenol** 1996 May;166(5):1052–4 (12 ref.)

SARCOLEMMA

CHEMISTRY

A new splicing variant in the frog heart sarcolemmal Na–Ca exchanger creates a putative ATP-binding site. Iwata T, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:37–45 (34 ref.)

METABOLISM

Na–Ca exchange studies in sarcolemmal skeletal muscle. Gonzalez-Serratos H, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:556–60 (11 ref.)

Kinetics and mechanism: modulation of ion transport in the cardiac sarcolemma sodium–calcium exchanger by protons, monovalent, ions, and temperature. Khananshvili D, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:217–35 (37 ref.)

PHYSIOLOGY

The role of the sarcolemma action potential in fatigue. Fuglevand AJ. **Adv Exp Med Biol** 1995;384:101–8 (56 ref.)

Mechanism of XIP in cardiac sarcolemmal vesicles. Hale CC. **Ann N Y Acad Sci** 1996 Apr 15;779:171–81 (7 ref.)

SARCOLYSINE see **MELPHALAN**

SARCOMA

Rhabdomyosarcoma and other soft tissue sarcomas of childhood. Pappo AS. **Curr Opin Oncol** 1995 Jul;7(4):361–6 (26 ref.)

Pediatric soft-tissue sarcomas. Conrad EU 3rd, et al. **Orthop Clin North Am** 1996 Jul;27(3):655–64 (94 ref.)

Breast sarcoma. Moore MP, et al. **Surg Clin North Am** 1996 Apr;76(2):383–92 (54 ref.)

[Sarcomatoid carcinoma] Fukuhara K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):504–6 (16 ref.) **(Jpn)**

[Primary hepatic sarcoma] Komatsu M, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):460–2 (8 ref.) **(Jpn)**

DIAGNOSIS

Soft tissue sarcomas: diagnosis, classification and prognostic factors. Fisher C. **Br J Plast Surg** 1996 Jan;49(1):27–33 (31 ref.)

Diagnosis and treatment of soft tissue sarcomas in adults. Dirix LY, et al. **Curr Opin Oncol** 1995 Jul;7(4):340–8 (72 ref.)

MR imaging of malignant soft-tissue tumors. Hanna SL, et al. **Magn Reson Imaging Clin N Am** 1995 Nov;3(4):629–50 (38 ref.)

DRUG THERAPY

The present state of the art in chemotherapy for soft tissue sarcomas in adults: the EORTC point of view. Verweij J, et al. **Crit Rev Oncol Hematol** 1995 Oct;20(3):193–201 (58 ref.)

Multidrug drug resistance in pediatric sarcomas. Chan HS, et al. **Hematol Oncol Clin North Am** 1995 Aug;9(4):889–908 (118 ref.)

Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas. Implications for decision making in the clinic. Demetri GD, et al. **Hematol Oncol Clin North Am** 1995 Aug;9(4):765–85 (123 ref.)

Adjuvant chemotherapy for soft tissue sarcomas. Mertens WC, et al. **Hematol Oncol Clin North Am** 1995 Aug; 9(4):801–15 (41 ref.)

New drugs for the treatment of sarcomas. van Oosterom AT, et al. **Hematol Oncol Clin North Am** 1995 Aug;9(4):909–25 (74 ref.)

Systemic adjuvant chemotherapy for soft tissue sarcomas. Zalupski MM, et al. **Hematol Oncol Clin North Am** 1995 Aug;9(4):787–800 (49 ref.)

Sarcomas: the role of adjuvant chemotherapy and a proposed new staging system. Baker LH, et al. **Monogr Pathol** 1996; 38:240–51 (49 ref.)

Ifosfamide in the treatment of soft tissue sarcomas. Connelly EF, et al. **Semin Oncol** 1996 Jun;23(3 Suppl 6):16–21 (21 ref.)

High-dose ifosfamide in the treatment of sarcomas of soft tissues and bone. Demetri GD. **Semin Oncol** 1996 Jun;23(3 Suppl 6):22–6 (19 ref.)

ETIOLOGY

Radiation-induced sarcoma of the breast. Mason RW, et al. **J Am Osteopath Assoc** 1996 Jun;96(6):368–70 (15 ref.)

Sarcomas in organ allograft recipients. Penn I. **Transplantation** 1995 Dec 27;60(12):1485–91 (48 ref.)

[Vertebral localizations of Paget disease] Chrétien J. **Ann Radiol (Paris)** 1995;38(4):169–76 (7 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Oncogenic role of "master" transcription factors in human leukemias and sarcomas: a developmental model. Look AT. **Adv Cancer Res** 1995;67:25–57 (162 ref.)

Primary intratesticular sarcoma. Immunohistochemical ultrastructural and DNA flow cytometric study of three cases with a review of the literature. Washecka RM, et al. **Cancer** 1996 Apr 15;77(8):1524–8 (26 ref.)

Cytogenetics and experimental models of sarcomas. Bridge JA. **Curr Opin Oncol** 1995 Jul;7(4):333–9 (49 ref.)

The emerging molecular genetics of sarcoma translocations. Ladanyi M. **Diagn Mol Pathol** 1995 Sep;4(3):162–73 (89 ref.)

Molecular biology of sarcomas. Gebhardt MC. **Orthop Clin North Am** 1996 Jul;27(3):421–9 (58 ref.)

METABOLISM

MDR1 gene expression: evaluation of its use as a molecular marker for prognosis and chemotherapy of bone and soft tissue sarcomas. Stein U, et al. **Eur J Cancer** 1996 Jan; 32A(1):86–92 (82 ref.)

MORTALITY

[Prognostic factors of bone and soft tissue sarcoma] Kawaguchi N, et al. **Gan To Kagaku Ryoho** 1996 Jul; 23(8):1093–8 (5 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Pseudosarcomatous myofibroblastic tumor of the urinary bladder in children: a study of 11 cases with review of the literature. An Intergroup Rhabdomyosarcoma Study. Hojo H, et al. **Am J Surg Pathol** 1995 Nov;19(11):1224–36 (43 ref.)

Soft tissue sarcomas in dermatology. Fish FS. **Dermatol Surg** 1996 Mar;22(3):268–73 (57 ref.)

The Met–HGF/SF autocrine signaling mechanism is involved in sarcomagenesis. Cortner J, et al. **EXS** 1995; 74:89–121 (101 ref.)

Undifferentiated embryonal sarcoma of the liver in childhood. Mistry RC, et al. **Indian J Cancer** 1995 Dec; 32(4):175–8 (11 ref.)

Sarcomas: the role of adjuvant chemotherapy and a proposed new staging system. Baker LH, et al. **Monogr Pathol** 1996; 38:240–51 (49 ref.)

[Review and prospects of pathology of soft tissue tumors in China] Yang G, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1995 Aug;24(4):245–7 (19 ref.) **(Chi)**

PHYSIOPATHOLOGY

The Met–HGF/SF autocrine signaling mechanism is involved in sarcomagenesis. Cortner J, et al. **EXS** 1995; 74:89–121 (101 ref.)

RADIOTHERAPY

Brachytherapy in sarcomas. Harrison LB, et al. **Hematol Oncol Clin North Am** 1995 Aug;9(4):747–63 (32 ref.)

Radiation as a therapeutic modality in sarcomas of the soft tissue. Suit H, et al. **Hematol Oncol Clin North Am** 1995 Aug;9(4):733–46 (44 ref.)

SECONDARY

Surgical treatment for pulmonary metastases from sarcoma. Putnam JB Jr, et al. **Hematol Oncol Clin North Am** 1995 Aug;9(4):869–87 (86 ref.)

[Chemotherapy of metastatic soft tissue sarcoma] Le Cesne A. **Presse Med** 1995 Sep 16;24(26):1214–20 (53 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Surgical management of primary soft tissue sarcoma. Beech DJ, et al. **Hematol Oncol Clin North Am** 1995 Aug; 9(4):707–18 (17 ref.)

Surgical management of primary bone sarcomas. Yasko AW, et al. **Hematol Oncol Clin North Am** 1995 Aug;9(4):719–31 (31 ref.)

The surgeon as a leader in cancer care: lessons learned from the study of soft tissue sarcoma. Brennan MF. **J Am Coll Surg** 1996 Jun;182(6):520–9 (35 ref.)

Soft-tissue sarcoma of the extremities. MR appearance of post-treatment changes and local recurrences. Varma DG, et al. **Magn Reson Imaging Clin N Am** 1995 Nov; 3(4):695–712 (59 ref.)

[Surgery of soft tissue sarcoma (with the exception of the retroperitoneum)] Stöckle E, et al. **Ann Chir** 1996; 50(3):263–75 (85 ref.) (Eng. Abstr.) **(Fre)**

[Prognostic factors of survival in infiltrating urothelial bladder carcinoma. A retrospective study of 158 patients treated by radical cystectomy] Thieblemont C, et al. **Bull Cancer (Paris)** 1996 Feb;83(2):139–46 (35 ref.) (Eng. Abstr.) **(Fre)**

[Tumor of the gastrointestinal autonomic nervous system (GAN-tumor or plexus sarcoma)] Flückiger R, et al. **Chirurg** 1996 Apr;67(4):371–9 (20 ref.) (Eng. Abstr.) **(Ger)**

[Surgical therapy of soft tissue sarcomas II. Sarcomas of the extremities and their surgical resection] Karakousis CP. **Chirurg** 1995 Oct;66(10):1006–15 (9 ref.) (Eng. Abstr.) **(Ger)**

[Surgical therapy of soft tissue sarcoma. I. General principles and resections of the trunk] Karakousis CP. **Chirurg** 1995 Sep;66(9):905–13 (17 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Soft tissue and bone sarcomas. Santoro A, et al. **Cancer Chemother Biol Response Modif** 1996;16:617–24 (36 ref.)

Limb-sparing therapy for soft tissue sarcomas. Pollock RE. **Curr Opin Gen Surg** 1994;:224–9 (13 ref.)

Diagnosis and treatment of soft tissue sarcomas in adults. Dirix LY, et al. **Curr Opin Oncol** 1995 Jul;7(4):340–8 (72 ref.)

Soft tissue sarcoma—messages from completed randomized trials. Gortzak E, et al. **Eur J Surg Oncol** 1995 Oct; 21(5):469–71 (25 ref.)

Soft tissue sarcomas—what is currently being done. Issels RD. **Eur J Surg Oncol** 1995 Oct;21(5):471–4 (12 ref.)

Soft tissue sarcoma therapy: prospects for future studies. Lejeune FJ, et al. **Eur J Surg Oncol** 1995 Oct;21(5):474–7 (19 ref.)

Preoperative therapy for soft tissue sarcoma. Eilber F, et al. **Hematol Oncol Clin North Am** 1995 Aug;9(4):817–23 (22 ref.)

Soft-tissue sarcomas. Cheng EY, et al. **Instr Course Lect** 1996;45:461–71 (101 ref.)

Soft tissue sarcomas. Herzog CE. **Pediatr Dent** 1995 Jul–Aug; 17(4):259–62 (10 ref.)

[Locally developed sarcoma of the thoracic wall] Bui NB, et al. **Bull Cancer (Paris)** 1996 May;83(5):335–43 (40 ref.) (Eng. Abstr.) **(Fre)**

ULTRASTRUCTURE

Primary intratesticular sarcoma. Immunohistochemical ultrastructural and DNA flow cytometric study of three cases with a review of the literature. Washecka RM, et al. **Cancer** 1996 Apr 15;77(8):1524–8 (26 ref.)

VETERINARY

Aggressive, undifferentiated sarcoma with widespread metastasis in a six-month-old Neopolitan mastiff. Sanders NA, et al. **J Am Anim Hosp Assoc** 1996 Mar–Apr; 32(2):97–101 (18 ref.)

Soft-tissue sarcomas. Thrall DE, et al. **Semin Vet Med Surg (Small Anim)** 1995 Aug;10(3):173–9 (45 ref.)

SARCOMA, ALVEOLAR SOFT PART

PATHOLOGY

Alveolar soft-part sarcoma of the female genital tract: a report of nine cases and review of the literature. Nielsen GP, et al. **Int J Gynecol Pathol** 1995 Oct;14(4):283–92 (30 ref.)

Alveolar soft-part sarcoma of the oral cavity: report of a case and review of the literature. Marker P, et al. **J Oral Maxillofac Surg** 1995 Oct;53(10):1203–8 (22 ref.)

SECONDARY

Successful treatment for solitary brain metastasis from alveolar soft part sarcoma. Wang CH, et al. **J Neurooncol** 1995;25(2):161–6 (31 ref.)

SURGERY

Successful treatment for solitary brain metastasis from alveolar soft part sarcoma. Wang CH, et al. **J Neurooncol** 1995;25(2):161–6 (31 ref.)

SARCOMA, CLEAR CELL

PATHOLOGY

Carcinoma of the tongue in a long-term survivor of clear cell sarcoma of the kidney. Ferbend P, et al. **Pediatr Pathol Lab Med** 1995 Mar–Apr;15(2):327–32 (22 ref.)

SURGERY

[Clear-cell sarcoma of the tendons and aponeuroses] Popkhristova E, et al. **Khirurgiia (Sofiia)** 1995;48(2):44–7 (23 ref.) **(Bul)**

SARCOMA, ENGELBRETH-HOLM-SWARM see **SARCOMA, EXPERIMENTAL**

SARCOMA, EPITHELIOID see **SARCOMA**

SARCOMA, EWING'S

Ewing's sarcoma. Vlasak R, et al. **Orthop Clin North Am** 1996 Jul;27(3):591–603 (51 ref.)

Cancer of bone in children. Jaffe N. **Pediatr Dent** 1995 Jul–Aug;17(4):263–7 (56 ref.)

SARCOMA, EWING'S

DIAGNOSIS

Ewing's sarcoma and extracranial peripheral neuroectodermal tumors. Granowetter L. **Curr Opin Oncol** 1995 Jul;7(4):355–60 (43 ref.)

GENETICS

Gene rearrangements in Ewing's sarcoma. Denny CT. **Cancer Invest** 1996;14(1):83–8 (47 ref.)

The molecular pathology of small round-cell tumours—relevance to diagnosis, prognosis, and classification. McManus AP, et al. **J Pathol** 1996 Feb; 178(2):116–21 (80 ref.)

PATHOLOGY

Malignant bone tumors of childhood. Himelstein BP, et al. **Pediatr Clin North Am** 1996 Aug;43(4):967–84 (38 ref.)

[Pathology of Ewing sarcoma] Roessner A, et al. **Pathologe** 1996 Jan;17(1):6–17 (112 ref.) (Eng. Abstr.) **(Ger)**

RADIOTHERAPY

[Radiotherapy and Ewing tumor in children] Carrie C, et al. **Bull Cancer (Paris)** 1995 Jul;82(7):527–30 (28 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Extraosseous Ewing's sarcoma in the foot. Berliner RA, et al. **J Foot Ankle Surg** 1995 May–Jun;34(3):301–4 (6 ref.)

THERAPY

Ewing's sarcoma and extracranial peripheral neuroectodermal tumors. Granowetter L. **Curr Opin Oncol** 1995 Jul;7(4):355–60 (43 ref.)

SARCOMA, EXPERIMENTAL

PATHOLOGY

BK virus-induced osteosarcoma (Os515) as a model of human osteosarcoma. Sekiguchi M, et al. **Anticancer Res** 1996 Jul–Aug;16(4A):1835–42 (40 ref.)

SARCOMA, GERMINOBLASTIC see **LYMPHOMA**

SARCOMA, IMMUNOBLASTIC see **LYMPHOMA, LARGE-CELL, IMMUNOBLASTIC**

SARCOMA, JENSEN see **SARCOMA, EXPERIMENTAL**

SARCOMA, KAPOSI'S

Sexually transmissible agent and African Kaposi's sarcoma [editorial] Matondo P, et al. **Int J STD AIDS** 1996 Jan–Feb; 7(1):4–6 (35 ref.)

Kaposi's sarcoma: advances and perspectives. Schwartz RA. **J Am Acad Dermatol** 1996 May;34(5 Pt 1):804–14 (188 ref.)

The role of molecular techniques in the understanding of emerging infections. Sable CA, et al. **Mol Med Today** 1996 Mar;2(3):120–8 (43 ref.)

COMPLICATIONS

AIDS-associated malignancies. Krown SE. **Cancer Chemother Biol Response Modif** 1996;16:441–61 (141 ref.)

Kaposi's sarcoma in patients infected with human virus (HIV): an overview. Hermans P, et al. **Cell Mol Biol (Noisy-le-grand)** 1995 May;41(3):357–64 (43 ref.)

Renal transplantation exposes patients with previous Kaposi's sarcoma to a high risk of recurrence. Doutrelepont JM, et al. **Transplantation** 1996 Aug 27;62(4):463–6 (15 ref.)

[Kaposi sarcoma of the glans penis with meatal obstruction. Case report and literature review] John H, et al. **Swiss Surg** 1996;(3):134–6 (3 ref.) (Eng. Abstr.) **(Ger)**

DIAGNOSIS

Immunocytochemistry in the diagnosis of Kaposi's sarcoma and angiosarcoma. Orchard GE, et al. **Br J Biomed Sci** 1995 Mar;52(1):35–49 (145 ref.)

Kaposi's sarcoma. An Update. Zalla MJ. **Dermatol Surg** 1996 Mar;22(3):274–87 (154 ref.)

The lung in HIV infection: can pulmonary function testing help? Mitchell DM, et al. **Monaldi Arch Chest Dis** 1996 Jun;51(3):214–22 (30 ref.)

DRUG THERAPY

Liposomal doxorubicin (Doxil). Porche DJ. **J Assoc Nurses AIDS Care** 1996 Mar–Apr;7(2):55–9 (6 ref.)

[Interferons in the therapy of solid tumors] Tomao S, et al. **Clin Ter** 1995 Aug–Sep;146(8–9):491–502 (96 ref.) (Eng. Abstr.) **(Ita)**

EPIDEMIOLOGY

An integrated approach to the epidemiology of Kaposi's sarcoma. Jacobson LP, et al. **Curr Opin Oncol** 1995 Sep; 7(5):450–5 (71 ref.)

Kaposi's sarcoma. How can epidemiology help find the cause? Drotman DP, et al. **Dermatol Clin** 1995 Jul; 13(3):575–82 (27 ref.)

Epidemiology of classic Kaposi's sarcoma, with special reference to mediterranean population. Franceschi S, et al. **Tumori** 1995 Sep–Oct;81(5):308–14 (74 ref.)

[Kaposi sarcoma. An epidemiological perspective] Lecker S, et al. **Ugeskr Laeger** 1995 Sep 18;157(38):5232–6 (38 ref.) (Eng. Abstr.) **(Dan)**

ETIOLOGY

Charting a new course through the chaos of KS (Kaposi's sarcoma) [comment] Nickoloff BJ, et al. **Am J Pathol** 1996 May;148(5):1323–9 (82 ref.) Comment on: Am J Pathol 1996 May;148(5):1387–96.

Recent insights into the pathogenesis of Kaposi's sarcoma. Fife K, et al. **Br J Cancer** 1996 Jun;73(11):1317–22 (68 ref.)

AIDS. Viruses, cytokines and Kaposi's sarcoma. Ganem D. **Curr Biol** 1995 May 1;5(5):469–71 (17 ref.)

Kaposi's sarcoma. How can epidemiology help find the cause? Drotman DP, et al. **Dermatol Clin** 1995 Jul; 13(3):575–82 (27 ref.)

AIDS-associated Kaposi's sarcoma: a new perspective of its pathogenesis and treatment. Ensoli B, et al. **Proc Assoc Am Physicians** 1995 Apr;107(1):8–18 (90 ref.)

Epidemiology of classic Kaposi's sarcoma, with special reference to mediterranean population. Franceschi S, et al. **Tumori** 1995 Sep–Oct;81(5):308–14 (74 ref.)

[Oral lesions in Kaposi sarcoma: clinical and radiotherapeutic considerations] Barberis M, et al. **Minerva Stomatol** 1996 Jan–Feb;45(1–2):17–27 (62 ref.) (Eng. Abstr.) **(Ita)**

GENETICS

Familial Kaposi's sarcoma: case reports and review of the literature. Cottoni E, et al. **Acta Derm Venereol** 1996 Jan; 76(1):59–61 (30 ref.)

PATHOLOGY

[Disseminated Kaposi's sarcoma with hepatosplenic involvement in AIDS] González-López A, et al. **Med Clin (Barc)** 1996 Apr 27;106(16):622–3 (15 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

Treatment of Kaposi's sarcoma [editorial; comment] Tur E, et al. **Arch Dermatol** 1996 Mar;132(3):327–31 (57 ref.) Comment on: Arch Dermatol 1996 Mar;132(3):285–90.

Classic (non-AIDS-related) Kaposi's sarcoma in a Japanese patient, successfully treated with alpha-2b-interferon [letter] Shimizu S, et al. **Br J Dermatol** 1995 Aug; 133(2):332–4 (8 ref.)

Treatment strategies for epidemic Kaposi's sarcoma. Volm MD, et al. **Curr Opin Oncol** 1995 Sep;7(5):429–36 (76 ref.)

AIDS-related malignancies. Spittle MF. **J R Soc Med** 1996 Jan;89(1):35P–6P (0 ref.)

Managing HIV. Part 5: Treating secondary outcomes. 5.14 HIV and Kaposi's sarcoma. Millar JL, et al. **Med J Aust** 1996 May 6;164(9):539–42 (16 ref.)

AIDS-associated Kaposi's sarcoma: a new perspective of its pathogenesis and treatment. Ensoli B, et al. **Proc Assoc Am Physicians** 1995 Apr;107(1):8–18 (90 ref.)

[Local treatments of AIDS-related Kaposi disease] Saiag P, et al. **Ann Dermatol Venereol** 1995;122(8):551–7 (56 ref.) **(Fre)**

VIROLOGY

An integrated approach to the epidemiology of Kaposi's sarcoma. Jacobson LP, et al. **Curr Opin Oncol** 1995 Sep; 7(5):450–5 (71 ref.)

Human herpesvirus 8 in lymphoma and Kaposi's sarcoma: now the virus can be propagated. Weiss RA. **Nat Med** 1996 Mar;2(3):277–8 (16 ref.)

[Human herpesvirus 8] Agut H, et al. **Transfus Clin Biol** 1996; 3(1):51–6 (26 ref.) (Eng. Abstr.) **(Fre)**

SARCOMA, MAST-CELL

PATHOLOGY

Biology, classification and treatment of human mastocytosis. Valent P. **Wien Klin Wochenschr** 1996;108(13):385–97 (106 ref.)

SARCOMA, OSTEOGENIC see **OSTEOSARCOMA**

SARCOMA, RETICULUM-CELL see **LYMPHOMA, LARGE-CELL**

SARCOMA, SMALL CELL

PATHOLOGY

Recurrent intrapulmonary malignant small cell tumor of the thoracopulmonary region with metastasis to the oral cavity: review of literature and case report. Hicks MJ, et al. **Ultrastruct Pathol** 1995 Jul–Aug;19(4):297–303 (21 ref.)

SARCOMA, SOFT TISSUE see **SARCOMA**

SARCOMA, SPINDLE CELL see **SARCOMA**

SARCOMA, SYNOVIAL

PATHOLOGY

Synovial sarcoma of the pharynx. Ramamurthy L, et al. **J Laryngol Otol** 1995 Dec;109(12):1207–10 (19 ref.)

SARCOMERES

CHEMISTRY

The anatomy of a molecular giant: how the sarcomere cytoskeleton is assembled from immunoglobulin superfamily molecules. Fürst DO, et al. **J Mol Cell Cardiol** 1995 Apr;27(4):951–9 (76 ref.)

SARCOPLASMIC RETICULUM

ENZYMOLOGY

Structure-function relationships in the Ca(2+)-ATPase of sarcoplasmic reticulum studied by use of the substrate analogue CrATP and site-directed mutagenesis. Comparison with the Na+,K(+)-ATPase. Vilsen B. **Acta Physiol Scand Suppl** 1995;624:1–146 (255 ref.)

Structure-function relationships in the Ca(2+)-ATPase of sarcoplasmic reticulum: facts, speculations and questions for the future. Martonosi AN. **Biochim Biophys Acta** 1996 Jul 18;1275(1–2):111–7 (116 ref.)

METABOLISM

Ion channels in the sarcoplasmic reticulum of striated muscle. Dulhunty AF, et al. **Acta Physiol Scand** 1996 Mar; 156(3):375–85 (48 ref.)

Calcium uptake and release modulated by counter-ion conductances in the sarcoplasmic reticulum of skeletal muscle. Fink RH, et al. **Acta Physiol Scand** 1996 Mar; 156(3):387–96 (65 ref.)

Sarcoplasmic reticulum function during myocardial ischaemia and reperfusion. Mubagwa K. **Cardiovasc Res** 1995 Aug;30(2):166–75 (114 ref.)

Regulation of expression of cardiac sarcoplasmic reticulum proteins under pathophysiological conditions. Dillmann WH. **Mol Cell Biochem** 1996 Apr 12–26;157(1–2):125–8 (14 ref.)

PHYSIOLOGY

The roles of the sodium and calcium current in triggering calcium release from the sarcoplasmic reticulum. Cannell MB, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:443–50 (21 ref.)

Evidence that reverse Na-Ca exchange can trigger SR calcium release. Litwin S, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:451–63 (20 ref.)

Regulation of vascular tone: cross-talk between sarcoplasmic reticulum and plasmalemma. Daniel EE, et al. **Can J Physiol Pharmacol** 1995 May;73(5):551–7 (46 ref.)

SARCOSOMES see **MITOCHONDRIA, MUSCLE**

SARCOSPORIDIA see **SARCOCYSTIS**

SARCOSPORIDIOSIS see **SARCOCYSTOSIS**

SARKOLYSIN see **MELPHALAN**

SATELLITE COMMUNICATIONS

ORGANIZATION & ADMINISTRATION

Satellite-delivered continuing medical education in Europe. Geraghty JG, et al. **Postgrad Med J** 1996 Apr; 72(846):218–20 (0 ref.)

SATELLITE DNA see **DNA, SATELLITE**

SATELLITES, ARTIFICIAL see **SPACECRAFT**

SATIATION

PHYSIOLOGY

[The mechanisms of satiation] Resa Bienzobas JJ, et al. **Nutr Hosp** 1996 Mar–Apr;11(2):94–7 (76 ref.) (Eng. Abstr.) **(Spa)**

SATIETY RESPONSE

PHYSIOLOGY

[Regulation of food intake] Schusdziarra V. **Zentralbl Chir** 1996;121(5):354–7 (34 ref.) (Eng. Abstr.) **(Ger)**

SCABIES

Scabies. Molinaro MJ, et al. **Cutis** 1995 Dec;56(6):317–21 (49 ref.)

DRUG THERAPY

Scabies treatment: current considerations. Orkin M, et al. **Curr Probl Dermatol** 1996;24:151–6 (13 ref.)

Permethrin. Taplin D, et al. **Curr Probl Dermatol** 1996; 24:255–60 (12 ref.)
[Lindane] Surber C, et al. **Hautarzt** 1995 Aug;46(8):528–36 (100 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Scabies: what's new? Orkin M. **Curr Probl Dermatol** 1995; 22:105–11 (11 ref.)

SCALDED SKIN SYNDROME, NONSTAPHYLOCOCCAL see **EPIDERMAL NECROLYSIS, TOXIC**

SCALDED SKIN SYNDROME, STAPHYLOCOCCAL see **STAPHYLOCOCCAL SCALDED SKIN SYNDROME**

SCALENUS ANTICUS SYNDROME see **THORACIC OUTLET SYNDROME**

SCALP

INJURIES

Entire scalp replantation: case report and review of the literature. Arashiro K, et al. **J Reconstr Microsurg** 1995 Jul;11(4):245–50 (32 ref.)

INNERVATION

Occipital neuralgia manifesting as orofacial pain. Sulfaro MA, et al.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995 Dec;80(6):751–5 (22 ref.)

SURGERY

Entire scalp replantation: case report and review of the literature. Arashiro K, et al. **J Reconstr Microsurg** 1995 Jul;11(4):245–50 (32 ref.)

SCALP DERMATOSES

CHEMICALLY INDUCED

Aplasia cutis congenita after exposure to methimazole: a causal relationship? Vogt T, et al. **Br J Dermatol** 1995 Dec; 133(6):994–6 (23 ref.)

COMPLICATIONS

Pyoderma gangrenosum and cranial osteolysis: case report and review of the paediatric literature. Samlaska CP, et al. **Br J Dermatol** 1995 Dec;133(6):972–7 (61 ref.)

DIAGNOSIS

The itchy scalp and other pruritic curiosities. Bernhard JD. **Semin Dermatol** 1995 Dec;14(4):326–9 (27 ref.)

DRUG THERAPY

Permethrin. Taplin D, et al. **Curr Probl Dermatol** 1996; 24:255–60 (12 ref.)

EPIDEMIOLOGY

[The epidemiological significance of human lice in relation to the characteristics of their parasitism] Khudobin VV. **Voen Med Zh** 1995 Oct;(10):52–8, 80 (32 ref.) (Eng. Abstr.) **(Rus)**

ETIOLOGY

[Necrotic purpura of the head disclosing Churg–Strauss syndrome] Ly S, et al. **Ann Dermatol Venereol** 1995; 122(3):94–6 (17 ref.) (Eng. Abstr.) **(Fre)**
[Multiple gangrenous lesions of the scalp in a case of cranial arteritis] Tomasina C, et al. **Minerva Med** 1995 May; 86(5):233–5 (12 ref.) (Eng. Abstr.) **(Ita)**

PATHOLOGY

Problem sites: scalp, palm and sole, and nail. Larko O. **Dermatol Clin** 1995 Oct;13(4):771–7 (91 ref.)

SCANNING ELECTRON MICROSCOPY see **MICROSCOPY, ELECTRON, SCANNING**

SCANNING, RADIOISOTOPE see **RADIONUCLIDE IMAGING**

SCANNING TUNNELING MICROSCOPY see **MICROSCOPY, SCANNING TUNNELING**

SCAPULA

Childhood soft tissue chondroma: a case report. Pollock L, et al. **Pediatr Pathol Lab Med** 1995 May–Jun;15(3):437–41 (6 ref.)
[Periarthritis humeroscapularis—clinical diagnosis and analysis of the syndrome concept] Jerosch J.
Wien Med Wochenschr 1996;146(6–7):142 (22 ref.) (Eng. Abstr.) **(Ger)**

ABNORMALITIES

Orthopedic conditions of the cervical spine and shoulder. Epps HR, et al. **Pediatr Clin North Am** 1996 Aug; 43(4):919–31 (37 ref.)

INJURIES

The scapula: coracoid, acromial, and avulsion fractures. Goss TP. **Am J Orthop** 1996 Feb;25(2):106–15 (39 ref.)

INNERVATION

Suprascapular nerve entrapment by ganglion cysts: a report of six cases with arthroscopic findings and review of the literature. Fehrman DA, et al. **Arthroscopy** 1995 Dec; 11(6):727–34 (47 ref.)
[Atypical entrapment syndrome of the distal suprascapular nerve of the incisura scapulae. Case report and overview of the literature] Röhrich E, et al. **Nervenarzt** 1995 Aug; 66(8):638–42 (28 ref.) (Eng. Abstr.) **(Ger)**

RADIOGRAPHY

[The labrum glenoidale] Bernageau J. **Ann Radiol (Paris)** 1995;38(5):266–74 (22 ref.) (Eng. Abstr.) **(Fre)**

SCARPA'S GANGLION see **VESTIBULAR NERVE**

SCARS see **CICATRIX**

SCARS, HYPERTROPHIC see **CICATRIX, HYPERTROPHIC**

SCATTER FACTOR see **HEPATOCYTE GROWTH FACTOR**

SCATTERING, RADIATION

see related
NEPHELOMETRY AND TURBIDIMETRY

SCHAMBERG'S DISEASE see **PIGMENTATION DISORDERS**

SCHAUMANN'S DISEASE see **SARCOIDOSIS**

SCHEIE'S SYNDROME see **MUCOPOLYSACCHARIDOSIS I**

SCHISTOSOMA

see related
SCHISTOSOMICIDES

SCHISTOSOMA MANSONI

IMMUNOLOGY

Comparison of purified 12 kDa and recombinant 15 kDa Fasciola hepatica antigens related to a Schistosoma mansoni fatty acid binding protein. Hillyer GV.
Mem Inst Oswaldo Cruz 1995 Mar–Apr;90(2):249–53 (17 ref.)

SCHISTOSOMIASIS

see related
SCHISTOSOMICIDES

COMPLICATIONS

Molecular and genetic events in schistosomiasis-associated human bladder cancer: role of oncogenes and tumor suppressor genes. Badawi AF. **Cancer Lett** 1996 Aug 2; 105(2):123–38 (111 ref.)
Cytokine regulation of granuloma formation in schistosomiasis. Wynn TA, et al. **Curr Opin Immunol** 1995 Aug;7(4):505–11 (61 ref.)

DRUG THERAPY

Antischistosomal drugs: past, present ... and future? Cioli D, et al. **Pharmacol Ther** 1995;68(1):35–85 (340 ref.)

METABOLISM

Glycobiology of schistosomiasis. Cummings RD, et al. **FASEB J** 1996 Jun;10(8):838–48 (91 ref.)

PREVENTION & CONTROL

Control and research on schistosomiasis in China. Chen M. **Chin Med J (Engl)** 1995 Sep;108(9):643–6 (9 ref.)
Development of a vaccine strategy against human and bovine schistosomiasis. Background and update. Capron A, et al. **Mem Inst Oswaldo Cruz** 1995 Mar–Apr;90(2):235–40 (29 ref.)
Synthetic peptide vaccines for schistosomiasis. Harn DA, et al. **Pharm Biotechnol** 1995;6:891–905 (41 ref.)

ULTRASONOGRAPHY

Ultrasonography in schistosomiasis in Africa. Doehring-Schwerdtfeger E, et al.
Mem Inst Oswaldo Cruz 1995 Mar–Apr;90(2):141–5 (55 ref.)

SCHISTOSOMIASIS HAEMATOBIA

DIAGNOSIS

[Peritoneal and tubal Schistosoma haematobium bilharziasis. Two case reports] Ekoukou D, et al.
J Gynecol Obstet Biol Reprod (Paris) 1995;24(8):819–24 (20 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

[Bladder schistosomiasis: report of 2 new cases with different anatomoclinical features and review of the literature] Peinado Ibarra F, et al. **Actas Urol Esp** 1995 Oct; 19(9):724–8 (17 ref.) (Eng. Abstr.) **(Spa)**

SCHISTOSOMIASIS, INTESTINAL see **SCHISTOSOMIASIS MANSONI**

SCHISTOSOMIASIS JAPONICA

[Schistosomiasis japonica of the liver] Kawashima T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):97–9 (6 ref.) **(Jpn)**

PREVENTION & CONTROL

Control of parasitic diseases in China. Current status and prospects. Yu S. **Chin Med J (Engl)** 1996 Apr;109(4):259–65 (16 ref.)

SCHISTOSOMIASIS MANSONI

Acute human schistosomiasis mansoni. Rabello A.
Mem Inst Oswaldo Cruz 1995 Mar–Apr;90(2):277–80 (35 ref.)
[Schistosoma haematobium] Kawashima T, et al.
Ryoikibetsu Shokogun Shirizu 1995;(7):106–8 (5 ref.) **(Jpn)**

SCHISTOSOMIASIS, URINARY see **SCHISTOSOMIASIS HAEMATOBIA**

SCHISTOSOMICIDES

THERAPEUTIC USE

Oltipraz: clinical opportunities for cancer chemoprevention. p Kensler TW, et al. **J Cell Biochem Suppl** 1995;22:101–7 (38 ref.)
Oltipraz, a novel inhibitor of human immunodeficiency virus type 1 (HIV-1) replication. Prochaska HJ, et al.
J Cell Biochem Suppl 1995;22:117–25 (40 ref.)
Antischistosomal drugs: past, present ... and future? Cioli D, et al. **Pharmacol Ther** 1995;68(1):35–85 (340 ref.)

SCHIZOAFFECTIVE DISORDER see **PSYCHOTIC DISORDERS**

SCHIZOMYCETES see **BACTERIA**

SCHIZOPHRENIA

Schizophrenia: a new frontier in developmental neurobiology. Wolf SS, et al. **Isr J Med Sci** 1996 Jan; 32(1):51–5 (40 ref.)
Pieces of the schizophrenia puzzle fall into place. Andreasen NC. **Neuron** 1996 Apr;16(4):697–700 (15 ref.)
[The deconstructions of schizophrenia (I)] Moriyama K.
Seishin Shinkeigaku Zasshi 1995;97(5):309–25 (41 ref.) (Eng. Abstr.) **(Jpn)**

BLOOD

Pharmacokinetics of clozapine and risperidone: a review of recent literature. Byerly MJ, et al.
J Clin Psychopharmacol 1996 Apr;16(2):177–87 (78 ref.)

CHEMICALLY INDUCED

The phencyclidine–glutamate model of schizophrenia. Halberstadt AL. **Clin Neuropharmacol** 1995 Jun; 18(3):237–49 (108 ref.)
NMDA antagonists as neurotherapeutic drugs, psychotogens, neurotoxins, and research tools for studying schizophrenia. Olney JW, et al. **Neuropsychopharmacology** 1995 Dec; 13(4):335–45 (75 ref.)
A review of NMDA receptors and the phencyclidine model of schizophrenia. Thornberg SA, et al. **Pharmacotherapy** 1996 Jan–Feb;16(1):82–93 (122 ref.)
[Glutamatergic hypothesis of schizophrenia: psychoses induced by phencyclidine and cortical–subcortical imbalance] Krebs MO. **Encephale** 1995 Sep–Oct; 21(5):581–8 (52 ref.) (Eng. Abstr.) **(Fre)**

CLASSIFICATION

A case against subtyping in schizophrenia. Goldberg TE, et al. **Schizophr Res** 1995 Oct;17(2):147–52 (39 ref.)
[Deficit: the value and difficulty of defining the primary or secondary character of observed symptoms] Petit M, et al. **Encephale** 1996 Jun;22 Spec No 2:13–8 (20 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

What are the functional consequences of neurocognitive

deficits in schizophrenia? Green MF. **Am J Psychiatry** 1996 Mar;153(3):321–30 (73 ref.)
Selected quantitative EEG (QEEG) and event-related potential (ERP) variables as discriminators for positive and negative schizophrenia. Gerez M, et al. **Biol Psychiatry** 1995 Jul 1;38(1):34–49 (152 ref.)
In vivo magnetic resonance spectroscopy. Applications in psychiatry. Maier M. **Br J Psychiatry** 1995 Sep; 167(3):299–306 (44 ref.)
Negative symptoms and affective disturbance in schizophrenia and related disorders. Malla AK. **Can J Psychiatry** 1995 Sep;40(7 Suppl 2):S55–9 (49 ref.)
New diagnostic issues in schizophrenic disorders. Carpenter WT Jr, et al. **Clin Neurosci** 1995;3(2):57–63 (46 ref.)
Structural brain imaging in schizophrenia. Pfefferbaum A, et al. **Clin Neurosci** 1995;3(2):105–11 (82 ref.)
Insight in clinical psychiatry revisited. Marková IS, et al. **Compr Psychiatry** 1995 Sep–Oct;36(5):367–76 (37 ref.)
Are mental diseases brain diseases? The contribution of neuropathology to understanding of schizophrenic psychoses. Knable MB, et al. **Eur Arch Psychiatry Clin Neurosci** 1995;245(4–5):224–30 (78 ref.)
Demography of DSM-III borderline personality disorder (PD): a comparison with Axis II PDs, affective illness and schizophrenia convergent and discriminant validation. Taub JM. **Int J Neurosci** 1995 Jun;82(3–4):191–214 (96 ref.)
Medical disorders in the schizophrenic patient. Vieweg V, et al. **Int J Psychiatry Med** 1995;25(2):137–72 (179 ref.)
Studies of the course and outcome of schizophrenia in later life. Cohen CI. **Psychiatr Serv** 1995 Sep;46(9):877–9, 889 (24 ref.)
The neurosociology of schizophrenia: vulnerability and functional disability. Carter M, et al. **Psychiatry** 1995 Aug; 58(3):209–24 (55 ref.)
Behavioral and neuroimaging studies on schizophrenia in Japan. Shimazono Y, et al. **Psychiatry Clin Neurosci** 1995 Mar;49(1):3–11 (72 ref.)
The neuropsychology of schizophrenia: relations with clinical and neurobiological dimensions. Elliott R, et al. **Psychol Med** 1995 May;25(3):581–94 (85 ref.)
Prodromal symptoms vs. early warning signs and clinical action in schizophrenia. Bustillo J, et al. **Schizophr Bull** 1995;21(4):553–9 (25 ref.)
Prodromal symptoms and relapse prevention in schizophrenia. Herz MI, et al. **Schizophr Bull** 1995; 21(4):541–51 (40 ref.)
Psychosis and violence: the case for a content analysis of psychotic experience. Junginger J. **Schizophr Bull** 1996; 22(1):91–103 (50 ref.)
Prodromal symptoms of relapse in schizophrenia: a review. Norman RM, et al. **Schizophr Bull** 1995;21(4):527–39 (60 ref.)
Late-onset schizophrenia and late paraphrenia. Riecher-Rössler A, et al. **Schizophr Bull** 1995;21(3):345–54; discussion 355–6 (80 ref.)
Assessing cognitive function in schizophrenics and patients with Alzheimer's disease. Mohs RC. **Schizophr Res** 1995 Sep;17(1):115–21 (65 ref.)
Facial processing in schizophrenia and delusional misidentification: cognitive neuropsychiatric approaches. Phillips ML, et al. **Schizophr Res** 1995 Sep;17(1):109–14 (45 ref.)
[Stability of positive/negative symptoms in schizophrenia] Ribeyre JM, et al. **Encephale** 1996 Jun;22 Spec No 2:29–31 (11 ref.) (Eng. Abstr.) **(Fre)**
[Schizophrenia and quality of life—sex-specific aspects] Röder-Wanner UU, et al. **Fortschr Neurol Psychiatr** 1995 Oct;63(10):393–401 (115 ref.) (Eng. Abstr.) **(Ger)**
[The effect of psychosocial factors in schizophrenia. Theoretical and practical-therapeutic consequences] Ciompi L. **Schweiz Arch Neurol Psychiatr** 1995; 146(5):207–14 (53 ref.) (Eng. Abstr.) **(Ger)**
[Methods of measurement of social adjustment in schizophrenia] Załuska M. **Psychiatr Pol** 1995 Sep–Oct; 29(5):631–40 (26 ref.) (Eng. Abstr.) **(Pol)**

DRUG THERAPY

Schizophrenia: recent advances in psychopharmacology. Sharma T. **Br J Hosp Med** 1996 Feb 21–Mar 5;55(4):194–8 (21 ref.)
Effectiveness of clozapine in hospitalised people with chronic neuroleptic-resistant schizophrenia. Avnon M, et al. **Br J Psychiatry** 1995 Dec;167(6):760–4 (15 ref.)
Consent to neuroleptic medication for schizophrenia: clinical, ethical and legal issues. Brabbins C, et al. **Br J Psychiatry** 1996 May;168(5):540–4 (23 ref.)
The treatment of negative symptoms: pharmacological and methodological issues. Carpenter WT Jr. **Br J Psychiatry Suppl** 1996 May;(29):17–22 (45 ref.)
Understanding schizophrenia: the impact of novel antipsychotics. Remington G. **Can J Psychiatry** 1995 Sep; 40(7 Suppl 2):S29–32 (39 ref.)
Neuroleptic dosing and neuroleptic plasma levels in schizophrenia: determining the optimal regimen. Shriqui CL. **Can J Psychiatry** 1995 Sep;40(7 Suppl 2):S38–48 (77 ref.)
Management of suspected neuroleptic malignant syndrome. Velamoor VR, et al. **Can J Psychiatry** 1995 Nov; 40(9):545–50 (33 ref.)
The drug treatment of patients with schizophrenia. **Drug Ther Bull** 1995 Nov;33(11):81–6 (43 ref.)
Adverse effects of antipsychotic agents. Do newer agents offer advantages? Owens DG. **Drugs** 1996 Jun; 51(6):895–930 (195 ref.)
Dopamine agonists in schizophrenia: a review. Benkert O, et al. **Eur Neuropsychopharmacol** 1995;5 Suppl:43–53 (68 ref.)
Effects of neuroleptic medications on the cognition of patients with schizophrenia: a review of recent studies. Goldberg TE, et al. **J Clin Psychiatry** 1996;57 Suppl 9:62–5 (23 ref.)
Treatment-resistant schizophrenic patients. Kane JM. **J Clin Psychiatry** 1996;57 Suppl 9:35–40 (40 ref.)
Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia. Lieberman JA, et al. **J Clin Psychiatry** 1996;57 Suppl 9:5–9 (43 ref.)
Clinical experience with risperidone. Marder SR. **J Clin Psychiatry** 1996;57 Suppl 9:57–61 (36 ref.)
Clozapine-induced neuroleptic malignant syndrome: review and report of new cases. Sachdev P, et al. **J Clin Psychopharmacol** 1995 Oct;15(5):365–71 (29 ref.)
Schizophrenia. Kane JM. **N Engl J Med** 1996 Jan 4; 334(1):34–41 (97 ref.)
Novel versus conventional antipsychotic drugs. Love RC. **Pharmacotherapy** 1996 Jan–Feb;16(1 Pt 2):6–10 (24 ref.)
Dopamine receptors—the present state of research and perspectives. Wolfarth S, et al. **Pol J Pharmacol** 1995 May–Jun;47(3):207–18 (95 ref.)
Chronic schizophrenia. Options for pharmacologic management. Pary R, et al. **Postgrad Med** 1995 Nov; 98(5):163–4, 167–70, 173 (25 ref.)
Risperidone and related 5HT2/D2 antagonists: a new type of antipsychotic agent? Megens AA, et al. **Prog Med Chem** 1996;33:185–232 (113 ref.)
Clozapine: efficacy and safety. Buchanan RW. **Schizophr Bull** 1995;21(4):579–91 (80 ref.)
Conventional antipsychotic medications for schizophrenia. Dixon LB, et al. **Schizophr Bull** 1995;21(4):567–77 (40 ref.)
Schizophrenia, Alzheimer's disease, and anti-inflammatory agents. Oken RJ, et al. **Schizophr Bull** 1996;22(1):1–4 (24 ref.)
The epidemiology of drug-induced akathisia: Part I. Acute akathisia. Sachdev P. **Schizophr Bull** 1995;21(3):431–49 (130 ref.)
The epidemiology of drug-induced akathisia: Part II. Chronic, tardive, and withdrawal akathisias. Sachdev P. **Schizophr Bull** 1995;21(3):451–61 (70 ref.)
Weight gain associated with neuroleptic medication: a review. Stanton JM. **Schizophr Bull** 1995;21(3):463–72 (100 ref.)
Risperidone: efficacy and safety. Umbricht D, et al. **Schizophr Bull** 1995;21(4):593–606 (22 ref.)
Cognitive impairment as a target for pharmacological treatment in schizophrenia. Davidson M, et al. **Schizophr Res** 1995 Sep;17(1):123–9 (55 ref.)
The treatment of tardive dyskinesia. Raja M. **Schweiz Arch Neurol Psychiatr** 1996;147(1):13–8 (99 ref.)
[Dopamine D4-receptor variants, schizophrenia and clozapine therapy] Ewald HL, et al. **Ugeskr Laeger** 1996 Jun 17;158(25):3601–3 (17 ref.) (Eng. Abstr.) **(Dan)**
[Current aspects of the use of clozapine in the Châlons-sur-Marne Psychiatric Hospital: intestinal occlusion with clozapine] Théret L, et al. **Ann Med Psychol (Paris)** 1995 Aug–Sep;153(7):474–7 (24 ref.) (Eng. Abstr.) **(Fre)**
[Associated psychotropic drugs in deficit schizophrenia] Beaufils B. **Encephale** 1996 Jun;22 Spec No 2:41–3 (18 ref.) (Eng. Abstr.) **(Fre)**
[Methodological constraints in evaluating anti-deficit effects] Boyer P, et al. **Encephale** 1996 Jun;22 Spec No 2:25–7 (16 ref.) (Eng. Abstr.) **(Fre)**
[Tolerance of neuroleptics, deficit syndrome and cognitive functions] Kahn JP. **Encephale** 1996 Jun;22 Spec No 2:49–54 (35 ref.) (Eng. Abstr.) **(Fre)**
[Treatment of negative symptoms in schizophrenia by amisulpride. Review of the literature] Pélissolo A, et al. **Encephale** 1996 May–Jun;22(3):215–9 (25 ref.) (Eng. Abstr.) **(Fre)**
[The place of amisulpride in the atypical neuroleptic class] Perrault G, et al. **Encephale** 1996 Jun;22 Spec No 2:3–8 (12 ref.) (Eng. Abstr.) **(Fre)**
[Incidence of the deficit form in refractory schizophrenia] Samuelian JC. **Encephale** 1996 Jun;22 Spec No 2:19–23 (30 ref.) (Eng. Abstr.) **(Fre)**
[Profile of the action of neuroleptics in deficit schizophrenia] Vanelle JM. **Encephale** 1996 Jun;22 Spec No 2:33–9 (35 ref.) (Eng. Abstr.) **(Fre)**
[Schizophrenic deficit syndrome and neurologic tolerance] Verdoux H, et al. **Encephale** 1996 Jun;22 Spec No 2:45–7 (27 ref.) (Eng. Abstr.) **(Fre)**
[The "neuroleptic threshold"—a review of the literature] Abraham D, et al. **Psychiatr Prax** 1996 May;23(3):109–16 (42 ref.) (Eng. Abstr.) **(Ger)**
[Neuroleptics and nicotine] Erdmann R. **Psychiatr Prax** 1995 Nov;22(6):223–7 (34 ref.) (Eng. Abstr.) **(Ger)**
[Recent developments in antipsychotic medication] Möller HJ. **Schweiz Arch Neurol Psychiatr** 1995;146(5):230–9 (50 ref.) (Eng. Abstr.) **(Ger)**
[Schizophrenia combination therapy with neuroleptics and benzodiazepines] Ruzikowska A. **Psychiatr Pol** 1996 Jan–Feb;30(1):55–64 (23 ref.) (Eng. Abstr.) **(Pol)**

ECONOMICS

Economics of schizophrenia. Williams R, et al. **Can J Psychiatry** 1995 Sep;40(7 Suppl 2):S60–7 (24 ref.)
Schizophrenia: shifting the balance of care. Kavanagh S, et al. **Soc Psychiatry Psychiatr Epidemiol** 1995 Aug; 30(5):206–12 (78 ref.)

EPIDEMIOLOGY

Schizophrenia: recent epidemiologic issues. Jablensky A. **Epidemiol Rev** 1995;17(1):10–20 (95 ref.)
Time trends in schizophrenia: changes in obstetric risk factors with industrialization. Warner R. **Schizophr Bull** 1995; 21(3):483–500 (160 ref.)
[Sex differences in schizophrenia] Häfner H, et al. **Gynakologe** 1995 Dec;28(6):426–33 (14 ref.) **(Ger)**
[Schizophrenia and substance dependence] Uchtenhagen A. **Schweiz Arch Neurol Psychiatr** 1995;146(5):215–23 (80 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Neurodevelopmental abnormalities and schizophrenia. A family affair. Wyatt RJ. **Arch Gen Psychiatry** 1996 Jan; 53(1):11–5 (35 ref.)
Perinatal risk factors and schizophrenia: selective review and methodological concerns. McNeil TF. **Epidemiol Rev** 1995; 17(1):107–12 (46 ref.)
A theory of the evolutionary origins of psychosis. Crow TJ. **Eur Neuropsychopharmacol** 1995;5 Suppl:59–63 (20 ref.)
Neurobiological plausibility of prenatal nutritional deprivation as a risk factor for schizophrenia. Brown AS, et al. **J Nerv Ment Dis** 1996 Feb;184(2):71–85 (98 ref.)
Schizophrenia. Cannon M, et al. **J Neurol Neurosurg Psychiatry** 1996 Jun;60(6):604–13 (140 ref.)
The estrogen connection: the etiological relationship between diabetes, cancer, rheumatoid arthritis and psychiatric disorders. Holden RJ. **Med Hypotheses** 1995 Aug; 45(2):169–89 (162 ref.)
An enzyme/brain–barrier theory of psychiatric pathogenesis: unifying observations on phenylketonuria, autism, schizophrenia and postpartum psychosis. Seim AR, et al. **Med Hypotheses** 1995 Nov;45(5):498–502 (36 ref.)
The case for heterogeneity in the etiology of schizophrenia. Tsuang MT, et al. **Schizophr Res** 1995 Oct;17(2):161–75 (210 ref.)
[Psychological theories in relation to the development of schizophrenia] Brun B, et al. **Ugeskr Laeger** 1996 Jul 22; 158(30):4283–7 (20 ref.) (Eng. Abstr.) **(Dan)**
[Schizophrenia. Current biological theories on the etiology] Hyllested A. **Ugeskr Laeger** 1996 Jul 22;158(30):4273–7 (40 ref.) (Eng. Abstr.) **(Dan)**
[Pathogenesis of schizophrenia. Illustrated by anatomical, physiological and neuropsychological aspects of the brain] Nielsen JR. **Ugeskr Laeger** 1996 Jul 22;158(30):4278–82 (40 ref.) (Eng. Abstr.) **(Dan)**
[Possible implication of obstetric risk factors in the etiopathogenesis of schizophrenia] Verdoux H, et al. **Rev Fr Gynecol Obstet** 1995 Oct;90(10):417–22 (25 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Linkage results in schizophrenia [editorial] Baron M. **Am J Med Genet** 1996 Apr 9;67(2):121–3 (24 ref.)
Chromosomal locations and modes of action of genes of the retinoid (vitamin A) system support their involvement in the etiology of schizophrenia. Goodman AB. **Am J Med Genet** 1995 Aug 14;60(4):335–48 (216 ref.)
Reflections on the evidence for a vulnerability locus for schizophrenia on chromosome 6p24–22 [editorial] Kendler KS, et al. **Am J Med Genet** 1996 Apr 9;67(2):124–6 (27 ref.)
Genetic anticipation in schizophrenia: pro and con. Petronis A, et al. **Clin Neurosci** 1995;3(2):76–80 (39 ref.)
The dopamine D3 receptor and schizophrenia: pharmacological, anatomical and genetic approaches. Griffon N, et al. **Eur Neuropsychopharmacol** 1995;5 Suppl:3–9 (33 ref.)
Gene-environment interaction in schizophrenia: season-of-birth effect reveals etiologically different subgroups. Franzek E, et al. **Psychopathology** 1996; 29(1):14–26 (129 ref.)
The case for or against heterogeneity in the etiology of schizophrenia. The genetic evidence. Cardno AG, et al. **Schizophr Res** 1995 Oct;17(2):153–9 (70 ref.)
A continuum of psychosis, one human gene, and not much else—the case for homogeneity. Crow TJ. **Schizophr Res** 1995 Oct;17(2):135–45 (85 ref.)
Genetic heterogeneity of schizophrenia. Tsuang MT, et al. **Seishin Shinkeigaku Zasshi** 1995;97(7):485–501 (145 ref.)
[Anatomy and genetics of mental disorders. New findings in schizophrenia research] Wetterberg L. **Lakartidningen** 1996 May 22;93(21):2049–55 (20 ref.) **(Swe)**

IMMUNOLOGY

The macrophage-T-lymphocyte theory of schizophrenia: additional evidence. Smith RS, et al. **Med Hypotheses** 1995 Aug;45(2):135–41 (84 ref.)
[How are psychological processes, the neuroendocrine system and immune system integrated?] Kaschka WP. **Z Klin Psychol Psychopathol Psychother** 1996;44(3):280–9

(50 ref.) (Eng. Abstr.) **(Ger)**
[Psychoneuroimmunology: brain–immunity related medicine] Kaminiwa S, et al. **Seishin Shinkeigaku Zasshi** 1995; 97(8):567–74 (22 ref.) **(Jpn)**

METABOLISM

The role of serotonin in schizophrenia. Iqbal N, et al. **Eur Neuropsychopharmacol** 1995;5 Suppl:11–23 (140 ref.)
Neurotransmitter systems in schizophrenia. Reynolds GP. **Int Rev Neurobiol** 1995;38:305–39 (144 ref.)
The N–methyl–D–aspartate receptor and schizophrenia. Strous RD, et al. **Isr J Med Sci** 1996 May;32(5):275–81 (51 ref.)

PATHOLOGY

New morphological and neuropathological findings in schizophrenia: a neurodevelopmental perspective. Bunney BG, et al. **Clin Neurosci** 1995;3(2):81–8 (120 ref.)
Neurodevelopmental animal models of schizophrenia. Lillrank SM, et al. **Clin Neurosci** 1995;3(2):98–104 (88 ref.)
Can schizophrenia be localized? Trimble MR. **J Neuropsychiatry Clin Neurosci** 1991 Winter;3(1):89–94 (12 ref.)
Cognitive impairment in elderly schizophrenia: a dementia (still) lacking distinctive histopathology. Arnold SE, et al. **Schizophr Bull** 1996;22(1):5–9 (30 ref.)

PHYSIOPATHOLOGY

Serotonin–dopamine interaction and its relevance to schizophrenia. Kapur S, et al. **Am J Psychiatry** 1996 Apr; 153(4):466–76 (140 ref.)
The role of mesolimbic dopaminergic and retrohippocampal afferents to the nucleus accumbens in latent inhibition: implications for schizophrenia. Gray JA, et al. **Behav Brain Res** 1995 Nov;71(1–2):19–31 (80 ref.)
Dopamine receptors and schizophrenia. Reynolds GP. **Biochem Soc Trans** 1996 Feb;24(1):202–5 (35 ref.)
Aspects of oxidative metabolism in schizophrenia [editorial] Marchbanks RM, et al. **Br J Psychiatry** 1995 Sep; 167(3):293–8 (24 ref.)
The psychobiology of first–episode schizophrenia. Waring EM. **Can J Psychiatry** 1995 Sep;40(7 Suppl 2):S33–7 (51 ref.)
Gating and habituation deficits in the schizophrenia disorders. Braff DL, et al. **Clin Neurosci** 1995;3(2):131–9 (48 ref.)
Schizophrenia: a disconnection syndrome? Friston KJ, et al. **Clin Neurosci** 1995;3(2):89–97 (61 ref.)
Factors influencing treatment response and outcome of first–episode schizophrenia: implications for understanding the pathophysiology of schizophrenia. Lieberman JA, et al. **J Clin Psychiatry** 1996;57 Suppl 9:5–9 (43 ref.)
Expressed emotion and a hypothetical model of relapse in schizophrenia. Eva FJ, et al. **Med Hypotheses** 1995 Jul; 45(1):99–105 (65 ref.)
Schizophrenia, suicide and the serotonin story. Holden RJ. **Med Hypotheses** 1995 May;44(5):379–91 (85 ref.)
The macrophage–T–lymphocyte theory of schizophrenia: additional evidence. Smith RS, et al. **Med Hypotheses** 1995 Aug;45(2):135–41 (84 ref.)
Dopamine release in the nucleus accumbens: the perspective from aberrations of consciousness in schizophrenia. Gray JA. **Neuropsychologia** 1995 Sep;33(9):1143–53 (53 ref.)
New insights into the biology of schizophrenia through the mechanism of action of clozapine. Brunello N, et al. **Neuropsychopharmacology** 1995 Nov;13(3):177–213 (400 ref.)
Schizophrenia: a disease of heteromodal association cortex? Pearlson GD, et al. **Neuropsychopharmacology** 1996 Jan; 14(1):1–17 (172 ref.)
Relation between backward masking deficits and smooth pursuit dysfunction in schizophrenia? Allen JS. **Optom Vis Sci** 1995 Jul;72(7):493–501 (61 ref.)
The dopamine D4 receptor in schizophrenia: an update [editorial] Kerwin RW, et al. **Psychol Med** 1996 Mar; 26(2):221–7 (56 ref.)
The functional architecture of the prefrontal cortex and schizophrenia [editorial] Lewis DA, et al. **Psychol Med** 1995 Sep;25(5):887–94 (80 ref.)
Schizophrenia and psychostimulant abuse: a review and re–analysis of clinical evidence. LeDuc PA, et al. **Psychopharmacology (Berl)** 1995 Oct;121(4):407–27 (85 ref.)
Regional cerebral blood flow in schizophrenia and the local circuit neurons hypothesis. Bachneff SA. **Schizophr Bull** 1996;22(1):163–82 (160 ref.)
Neuropsychological and olfactory dysfunction in schizophrenia: relationship of frontal syndromes to syndromes of schizophrenia. Pantelis C, et al. **Schizophr Res** 1995 Sep;17(1):35–45 (75 ref.)
Cortical maldevelopment, anti–psychotic drugs, and schizophrenia: a search for common ground. Weinberger DR, et al. **Schizophr Res** 1995 Aug 1;16(2):87–110 (215 ref.)
Novel dopamine receptors half a decade later [see comments] Sokoloff P, et al. **Trends Pharmacol Sci** 1995 Aug; 16(8):270–5 (60 ref.) Comment in: Trends Pharmacol Sci 1995 Dec;16(12):406–8.
[Deficit schizophrenia: from pharmacology to clinical practice] Tassin JP. **Encephale** 1996 Jun;22 Spec No 2:9–12 (20 ref.) (Eng. Abstr.) **(Fre)**
[Neurobiology of schizophrenia] Henn FA. **Schweiz Arch Neurol Psychiatr** 1995;146(5):224–9 (25 ref.) (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

Maintenance therapy of persons with schizophrenia. Carpenter WT Jr. **J Clin Psychiatry** 1996;57 Suppl 9:10–8 (118 ref.)

RADIONUCLIDE IMAGING

Positron emission tomography studies of abnormal glucose metabolism in schizophrenic illness. Buchsbaum MS. **Clin Neurosci** 1995;3(2):122–30 (77 ref.)
Utilization of radioligands in schizophrenia research. Sedvall G, et al. **Clin Neurosci** 1995;3(2):112–21 (47 ref.)
PET imaging of neuroreceptors in schizophrenia. Sedvall G, et al. **Eur Neuropsychopharmacol** 1995;5 Suppl:25–30 (18 ref.)

REHABILITATION

Perspectives on treatment needs in schizophrenia. Meise U, et al. **Br J Psychiatry Suppl** 1996 May;(29):9–16 (110 ref.)
A biopsychosocial rationale for coerced community treatment in the management of schizophrenia. Geller JL. **Psychiatr Q** 1995 Fall;66(3):219–35 (58 ref.)
Maintenance treatment of schizophrenia: a review of dose reduction and family treatment strategies. Schooler NR, et al. **Psychiatr Q** 1995 Winter;66(4):279–92 (41 ref.)
Assertive community treatment: an update of randomized trials. Burns BJ, et al. **Psychiatr Serv** 1995 Jul;46(7):669–75 (46 ref.)
Refocusing the training of psychiatric rehabilitation staff. Corrigan PW, et al. **Psychiatr Serv** 1995 Nov;46(11):1172–7 (33 ref.)
Family interventions for schizophrenia. Dixon LB, et al. **Schizophr Bull** 1995;21(4):631–43 (45 ref.)
Vocational rehabilitation in schizophrenia. Lehman AF. **Schizophr Bull** 1995;21(4):645–56 (45 ref.)
Treatment outcomes in schizophrenia: implications for practice, policy, and research. Lehman AF, et al. **Schizophr Bull** 1995;21(4):669–75 (15 ref.)
Assertive community treatment and case management for schizophrenia. Scott JE, et al. **Schizophr Bull** 1995; 21(4):657–68 (56 ref.)
Psychological interventions for schizophrenia. Scott JE, et al. **Schizophr Bull** 1995;21(4):621–30 (42 ref.)
An economic evaluation of schizophrenia––1991. Wyatt RJ, et al. **Soc Psychiatry Psychiatr Epidemiol** 1995 Aug; 30(5):196–205 (49 ref.)
[A rehabilitation project for patients with schizophrenia] Ojanen M, et al. **Duodecim** 1994;110(15):1452–7 (9 ref.) **(Fin)**
[Neuropsychological analysis of schizophrenia–induced attention deficits––attempt at an overview] Gebauer W, et al. **Rehabilitation (Stuttg)** 1995 Aug;34(3):128–38 (85 ref.) (Eng. Abstr.) **(Ger)**
[Chronic mental illness: quality of life] Główczak M, et al. **Psychiatr Pol** 1996 May–Jun;30(3):368–79 (20 ref.) (Eng. Abstr.) **(Pol)**

THERAPY

Research update on the psychosocial treatment of schizophrenia. Penn DL, et al. **Am J Psychiatry** 1996 May; 153(5):607–17 (89 ref.)
Fitting the treatment to the patient: recent advances in the practice of electroconvulsive therapy. Frukacz A, et al. **Aust N Z J Psychiatry** 1995 Sep;29(3):484–91 (24 ref.)
Community care of patients with schizophrenia: the role of the primary health care team. King M, et al. **Br J Gen Pract** 1996 Apr;46(405):231–7 (89 ref.)
Informed consent in chronic schizophrenia? [editorial] Jones GH. **Br J Psychiatry** 1995 Nov;167(5):565–8 (10 ref.)
Orphans of the 'Real': I. Some modern and postmodern perspectives on the neurobiological and psychosocial dimensions of psychosis and other primitive mental disorders. Grotstein JS. **Bull Menninger Clin** 1995 Summer; 59(3):287–311 (115 ref.)
Orphans of the 'Real': II. The future of object relations theory in the treatment of the psychoses and other primitive mental disorders. Grotstein JS. **Bull Menninger Clin** 1995 Summer;59(3):312–32 (75 ref.)
Management of schizophrenia. Marder SR. **J Clin Psychiatry** 1996;57 Suppl 3:9–13; discussion 47 (36 ref.)
Convulsive therapy in schizophrenia? Fink M, et al. **Schizophr Bull** 1996;22(1):27–39 (105 ref.)
Adjunctive treatments in schizophrenia: pharmacotherapies and electroconvulsive therapy. Johns CA, et al. **Schizophr Bull** 1995;21(4):607–19 (85 ref.)
Schizophrenia: shifting the balance of care. Kavanagh S, et al. **Soc Psychiatry Psychiatr Epidemiol** 1995 Aug; 30(5):206–12 (78 ref.)

VIROLOGY

Retroviruses and schizophrenia revisited. O'Reilly RL, et al. **Am J Med Genet** 1996 Feb 16;67(1):19–24 (65 ref.)

SCHIZOPHRENIA, BORDERLINE see **SCHIZOTYPAL PERSONALITY DISORDER**

SCHIZOPHRENIA, LATENT see **SCHIZOTYPAL PERSONALITY DISORDER**

SCHIZOPHRENIA, PARANOID

[Magical thinking in healthy people and in schizophrenia] Jarosz M. **Psychiatr Pol** 1996 May–Jun;30(3):471–84 (25 ref.) (Eng. Abstr.) **(Pol)**

DRUG THERAPY

Tardive tourettism after exposure to neuroleptic therapy. Bharucha KJ, et al. **Mov Disord** 1995 Nov;10(6):791–3 (17 ref.)

SCHIZOPHRENIA, PSEUDONEUROTIC see **SCHIZOTYPAL PERSONALITY DISORDER**

SCHIZOPHRENIC DISORDERS see **SCHIZOPHRENIA**

SCHIZOPHRENIC PSYCHOLOGY

What are the functional consequences of neurocognitive deficits in schizophrenia? Green MF. **Am J Psychiatry** 1996 Mar;153(3):321–30 (73 ref.)
Schizophrenia: recent advances in psychopharmacology. Sharma T. **Br J Hosp Med** 1996 Feb 21–Mar 5;55(4):194–8 (21 ref.)
Consent to neuroleptic medication for schizophrenia: clinical, ethical and legal issues. Brabbins C, et al. **Br J Psychiatry** 1996 May;168(5):540–4 (23 ref.)
Informed consent in chronic schizophrenia? [editorial] Jones GH. **Br J Psychiatry** 1995 Nov;167(5):565–8 (10 ref.)
In vivo magnetic resonance spectroscopy. Applications in psychiatry. Maier M. **Br J Psychiatry** 1995 Sep; 167(3):299–306 (44 ref.)
Aspects of oxidative metabolism in schizophrenia [editorial] Marchbanks RM, et al. **Br J Psychiatry** 1995 Sep; 167(3):293–8 (24 ref.)
The treatment of negative symptoms: pharmacological and methodological issues. Carpenter WT Jr. **Br J Psychiatry Suppl** 1996 May;(29):17–22 (45 ref.)
Perspectives on treatment needs in schizophrenia. Meise U, et al. **Br J Psychiatry Suppl** 1996 May;(29):9–16 (110 ref.)
Orphans of the 'Real': II. The future of object relations theory in the treatment of the psychoses and other primitive mental disorders. Grotstein JS. **Bull Menninger Clin** 1995 Summer;59(3):312–32 (75 ref.)
Orphans of the 'Real': I. Some modern and postmodern perspectives on the neurobiological and psychosocial dimensions of psychosis and other primitive mental disorders. Grotstein JS. **Bull Menninger Clin** 1995 Summer; 59(3):287–311 (115 ref.)
Negative symptoms and affective disturbance in schizophrenia and related disorders. Malla AK. **Can J Psychiatry** 1995 Sep;40(7 Suppl 2):S55–9 (49 ref.)
Understanding schizophrenia: the impact of novel antipsychotics. Remington G. **Can J Psychiatry** 1995 Sep; 40(7 Suppl 2):S29–32 (39 ref.)
Neuroleptic dosing and neuroleptic plasma levels in schizophrenia: determining the optimal regimen. Shriqui CL. **Can J Psychiatry** 1995 Sep;40(7 Suppl 2):S38–48 (77 ref.)
The psychobiology of first–episode schizophrenia. Waring EM. **Can J Psychiatry** 1995 Sep;40(7 Suppl 2):S33–7 (51 ref.)
Economics of schizophrenia. Williams R, et al. **Can J Psychiatry** 1995 Sep;40(7 Suppl 2):S60–7 (24 ref.)
Insight in clinical psychiatry revisited. Marková IS, et al. **Compr Psychiatry** 1995 Sep–Oct;36(5):367–76 (37 ref.)
Schizophrenia: recent epidemiologic issues. Jablensky A. **Epidemiol Rev** 1995;17(1):10–20 (95 ref.)
Perinatal risk factors and schizophrenia: selective review and methodological concerns. McNeil TF. **Epidemiol Rev** 1995; 17(1):107–12 (46 ref.)
Medical disorders in the schizophrenic patient. Vieweg V, et al. **Int J Psychiatry Med** 1995;25(2):137–72 (179 ref.)
Effects of neuroleptic medications on the cognition of patients with schizophrenia: a review of recent studies. Goldberg TE, et al. **J Clin Psychiatry** 1996;57 Suppl 9:62–5 (23 ref.)
Pharmacokinetics of clozapine and risperidone: a review of recent literature. Byerly MJ, et al. **J Clin Psychopharmacol** 1996 Apr;16(2):177–87 (78 ref.)
Expressed emotion and a hypothetical model of relapse in schizophrenia. Eva FJ, et al. **Med Hypotheses** 1995 Jul; 45(1):99–105 (65 ref.)
Schizophrenia, suicide and the serotonin story. Holden RJ. **Med Hypotheses** 1995 May;44(5):379–91 (85 ref.)
Dopamine release in the nucleus accumbens: the perspective from aberrations of consciousness in schizophrenia. Gray JA. **Neuropsychologia** 1995 Sep;33(9):1143–53 (53 ref.)
A biopsychosocial rationale for coerced community treatment in the management of schizophrenia. Geller JL. **Psychiatr Q** 1995 Fall;66(3):219–35 (58 ref.)
Maintenance treatment of schizophrenia: a review of dose reduction and family treatment strategies. Schooler NR, et al. **Psychiatr Q** 1995 Winter;66(4):279–92 (41 ref.)
Assertive community treatment: an update of randomized trials. Burns BJ, et al. **Psychiatr Serv** 1995 Jul;46(7):669–75 (46 ref.)
Refocusing the training of psychiatric rehabilitation staff. Corrigan PW, et al. **Psychiatr Serv** 1995 Nov;46(11):1172–7 (33 ref.)
The neurosociology of schizophrenia: vulnerability and functional disability. Carter M, et al. **Psychiatry** 1995 Aug;

58(3):209–24 (55 ref.)
The neuropsychology of schizophrenia: relations with clinical and neurobiological dimensions. Elliott R, et al. **Psychol Med** 1995 May;25(3):581–94 (85 ref.)
The dopamine D4 receptor in schizophrenia: an update [editorial] Kerwin RW, et al. **Psychol Med** 1996 Mar; 26(2):221–7 (56 ref.)
Cognitive impairment in elderly schizophrenia: a dementia (still) lacking distinctive histopathology. Arnold SE, et al. **Schizophr Bull** 1996;22(1):5–9 (30 ref.)
Regional cerebral blood flow in schizophrenia and the local circuit neurons hypothesis. Bachneff SA. **Schizophr Bull** 1996;22(1):163–82 (160 ref.)
Clozapine: efficacy and safety. Buchanan RW. **Schizophr Bull** 1995;21(4):579–91 (80 ref.)
Prodromal symptoms vs. early warning signs and clinical action in schizophrenia. Bustillo J, et al. **Schizophr Bull** 1995;21(4):553–9 (25 ref.)
Conventional antipsychotic medications for schizophrenia. Dixon LB, et al. **Schizophr Bull** 1995;21(4):567–77 (40 ref.)
Family interventions for schizophrenia. Dixon LB, et al. **Schizophr Bull** 1995;21(4):631–43 (45 ref.)
Convulsive therapy in schizophrenia? Fink M, et al. **Schizophr Bull** 1996;22(1):27–39 (105 ref.)
Prodromal symptoms and relapse prevention in schizophrenia. Herz MI, et al. **Schizophr Bull** 1995; 21(4):541–51 (40 ref.)
Psychosis and violence: the case for a content analysis of psychotic experience. Junginger J. **Schizophr Bull** 1996; 22(1):91–103 (50 ref.)
Vocational rehabilitation in schizophrenia. Lehman AF. **Schizophr Bull** 1995;21(4):645–56 (45 ref.)
Treatment outcomes in schizophrenia: implications for practice, policy, and research. Lehman AF, et al. **Schizophr Bull** 1995;21(4):669–75 (15 ref.)
Prodromal symptoms of relapse in schizophrenia: a review. Norman RM, et al. **Schizophr Bull** 1995;21(4):527–39 (60 ref.)
Schizophrenia, Alzheimer's disease, and anti-inflammatory agents. Oken RJ, et al. **Schizophr Bull** 1996;22(1):1–4 (24 ref.)
Late-onset schizophrenia and late paraphrenia. Riecher-Rössler A, et al. **Schizophr Bull** 1995;21(3):345–54; discussion 355–6 (80 ref.)
Assertive community treatment and case management for schizophrenia. Scott JE, et al. **Schizophr Bull** 1995; 21(4):657–68 (56 ref.)
Psychological interventions for schizophrenia. Scott JE, et al. **Schizophr Bull** 1995;21(4):621–30 (42 ref.)
Risperidone: efficacy and safety. Umbricht D, et al. **Schizophr Bull** 1995;21(4):593–606 (22 ref.)
The case for or against heterogeneity in the etiology of schizophrenia. The genetic evidence. Cardno AG, et al. **Schizophr Res** 1995 Oct;17(2):153–9 (70 ref.)
Cognitive impairment as a target for pharmacological treatment in schizophrenia. Davidson M, et al. **Schizophr Res** 1995 Sep;17(1):123–9 (55 ref.)
A case against subtyping in schizophrenia. Goldberg TE, et al. **Schizophr Res** 1995 Oct;17(2):147–52 (39 ref.)
Assessing cognitive function in schizophrenics and patients with Alzheimer's disease. Mohs RC. **Schizophr Res** 1995 Sep;17(1):115–21 (65 ref.)
Neuropsychological and olfactory dysfunction in schizophrenia: relationship of frontal syndromes to syndromes of schizophrenia. Pantelis C, et al. **Schizophr Res** 1995 Sep;17(1):35–45 (75 ref.)
Facial processing in schizophrenia and delusional misidentification: cognitive neuropsychiatric approaches. Phillips ML, et al. **Schizophr Res** 1995 Sep;17(1):109–14 (45 ref.)
The case for heterogeneity in the etiology of schizophrenia. Tsuang MT, et al. **Schizophr Res** 1995 Oct;17(2):161–75 (210 ref.)
Cortical maldevelopment, anti-psychotic drugs, and schizophrenia: a search for common ground. Weinberger DR, et al. **Schizophr Res** 1995 Aug 1;16(2):87–110 (215 ref.)
[Psychological theories in relation to the development of schizophrenia] Brun B, et al. **Ugeskr Laeger** 1996 Jul 22; 158(30):4283–7 (20 ref.) (Eng. Abstr.) **(Dan)**
[Associated psychotropic drugs in deficit schizophrenia] Beaufils B. **Encephale** 1996 Jun;22 Spec No 2:41–3 (18 ref.) (Eng. Abstr.) **(Fre)**
[Methodological constraints in evaluating anti-deficit effects] Boyer P, et al. **Encephale** 1996 Jun;22 Spec No 2:25–7 (16 ref.) (Eng. Abstr.) **(Fre)**
[Tolerance of neuroleptics, deficit syndrome and cognitive functions] Kahn JP. **Encephale** 1996 Jun;22 Spec No 2:49–54 (35 ref.) (Eng. Abstr.) **(Fre)**
[Treatment of negative symptoms in schizophrenia by amisulpride. Review of the literature] Pélissolo A, et al. **Encephale** 1996 May–Jun;22(3):215–9 (25 ref.) (Eng. Abstr.) **(Fre)**
[The place of amisulpride in the atypical neuroleptic class] Perrault G, et al. **Encephale** 1996 Jun;22 Spec No 2:3–8 (12 ref.) (Eng. Abstr.) **(Fre)**
[Deficit: the value and difficulty of defining the primary or secondary character of observed symptoms] Petit M, et al. **Encephale** 1996 Jun;22 Spec No 2:13–8 (20 ref.) (Eng. Abstr.) **(Fre)**
[Stability of positive/negative symptoms in schizophrenia] Ribeyre JM, et al. **Encephale** 1996 Jun;22 Spec No 2:29–31 (11 ref.) (Eng. Abstr.) **(Fre)**
[Incidence of the deficit form in refractory schizophrenia] Samuelian JC. **Encephale** 1996 Jun;22 Spec No 2:19–23 (30 ref.) (Eng. Abstr.) **(Fre)**
[Deficit schizophrenia: from pharmacology to clinical practice] Tassin JP. **Encephale** 1996 Jun;22 Spec No 2:9–12 (20 ref.) (Eng. Abstr.) **(Fre)**
[Profile of the action of neuroleptics in deficit schizophrenia] Vanelle JM. **Encephale** 1996 Jun;22 Spec No 2:33–9 (35 ref.) (Eng. Abstr.) **(Fre)**
[Schizophrenic deficit syndrome and neurologic tolerance] Verdoux H, et al. **Encephale** 1996 Jun;22 Spec No 2:45–7 (27 ref.) (Eng. Abstr.) **(Fre)**
[Schizophrenia and quality of life—sex-specific aspects] Röder-Wanner UU, et al. **Fortschr Neurol Psychiatr** 1995 Oct;63(10):393–401 (115 ref.) (Eng. Abstr.) **(Ger)**
[Sex differences in schizophrenia] Häfner H, et al. **Gynakologe** 1995 Dec;28(6):426–33 (14 ref.) **(Ger)**
[The "neuroleptic threshold"—a review of the literature] Abraham D, et al. **Psychiatr Prax** 1996 May;23(3):109–16 (42 ref.) (Eng. Abstr.) **(Ger)**
[Neuroleptics and nicotine] Erdmann R. **Psychiatr Prax** 1995 Nov;22(6):223–7 (34 ref.) (Eng. Abstr.) **(Ger)**
[Neuropsychological analysis of schizophrenia-induced attention deficits—attempt at an overview] Gebauer W, et al. **Rehabilitation (Stuttg)** 1995 Aug;34(3):128–38 (85 ref.) (Eng. Abstr.) **(Ger)**
[The effect of psychosocial factors in schizophrenia. Theoretical and practical-therapeutic consequences] Ciompi L. **Schweiz Arch Neurol Psychiatr** 1995; 146(5):207–14 (53 ref.) (Eng. Abstr.) **(Ger)**
[Neurobiology of schizophrenia] Henn FA. **Schweiz Arch Neurol Psychiatr** 1995;146(5):224–9 (25 ref.) (Eng. Abstr.) **(Ger)**
[Recent developments in antipsychotic medication] Möller HJ. **Schweiz Arch Neurol Psychiatr** 1995;146(5):230–9 (50 ref.) (Eng. Abstr.) **(Ger)**
[Schizophrenia and substance dependence] Uchtenhagen A. **Schweiz Arch Neurol Psychiatr** 1995;146(5):215–23 (80 ref.) (Eng. Abstr.) **(Ger)**
[How are psychological processes, the neuroendocrine system and immune system integrated?] Kaschka WP. **Z Klin Psychol Psychopathol Psychother** 1996;44(3):280–9 (50 ref.) (Eng. Abstr.) **(Ger)**
[Changes in sequence of time in schizophrenia—from 'severance' to 'collapse' in flux of time] Oae H. **Seishin Shinkeigaku Zasshi** 1995;97(6):405–21 (18 ref.) **(Jpn)**
[Methods of measurement of social adjustment in schizophrenia] Załuska M. **Psychiatr Pol** 1995 Sep–Oct; 29(5):631–40 (26 ref.) (Eng. Abstr.) **(Pol)**
[Positive and negative symptoms of schizophrenia] Lagomarsino AJ. **Acta Psiquiatr Psicol Am Lat** 1995 May; 41(2):141–7 (19 ref.) (Eng. Abstr.) **(Spa)**

SCHIZOPHRENIFORM DISORDERS see **PSYCHOTIC DISORDERS**

SCHIZOSACCHAROMYCES

CLASSIFICATION

Phylogenesis of fission yeasts. Contradictions surrounding the origin of a century old genus. Sipiczki M. **Antonie Van Leeuwenhoek** 1995 Aug;68(2):119–49 (300 ref.)

CYTOLOGY

G1 regulation and checkpoints operating around START in fission yeast. Woollard A, et al. **Bioessays** 1995 Jun; 17(6):481–90 (65 ref.)
How fission yeast fission in the middle. Chang F, et al. **Cell** 1996 Jan 26;84(2):191–4 (20 ref.)
Cell cycle arrest in response to DNA damage: lessons from yeast. Siede W. **Mutat Res** 1995 Sep;337(2):73–84 (100 ref.)

GENETICS

The elusive centromere: sequence divergence and functional conservation. Sunkel CE, et al. **Curr Opin Genet Dev** 1995 Dec;5(6):756–67 (68 ref.)
Molecular biology of DNA repair in the fission yeast Schizosaccharomyces pombe. Lehmann AR. **Mutat Res** 1996 Aug 8;363(3):147–61 (102 ref.)
The evolutionary conservation of the splicing apparatus between fission yeast and man. Wentz-Hunter K, et al. **Nucleic Acids Symp Ser** 1995;(33):226–8 (17 ref.)
Elements of chromosome structure and function in fission yeast. Allshire RC. **Semin Cell Biol** 1995 Apr;6(2):55–64 (74 ref.)
DNA structure checkpoints in fission yeast. Carr AM. **Semin Cell Biol** 1995 Apr;6(2):65–72 (33 ref.)

GROWTH & DEVELOPMENT

G1 regulation and checkpoints operating around START in fission yeast. Woollard A, et al. **Bioessays** 1995 Jun; 17(6):481–90 (65 ref.)
The molecular control mechanisms of meiosis in fission yeast. Yamamoto M. **Trends Biochem Sci** 1996 Jan;21(1):18–22 (48 ref.)

METABOLISM

The evolutionary conservation of the splicing apparatus between fission yeast and man. Wentz-Hunter K, et al. **Nucleic Acids Symp Ser** 1995;(33):226–8 (17 ref.)
Cyclins of the fission yeast Schizosaccharomyces pombe. Fisher D, et al. **Semin Cell Biol** 1995 Apr;6(2):73–8 (38 ref.)

PHYSIOLOGY

Cell cycle control in fission yeast and mammals: identification of new regulatory mechanisms. Okayama H, et al. **Adv Cancer Res** 1996;69:17–62 (246 ref.)
Control of signal transduction and morphogenesis by Ras. Hughes DA. **Semin Cell Biol** 1995 Apr;6(2):89–94 (49 ref.)
Pheromone communication in the fission yeast Schizosaccharomyces pombe. Nielsen O, et al. **Semin Cell Biol** 1995 Apr;6(2):95–104 (105 ref.)
The control of septum formation and cytokinesis in fission yeast. Simanis V. **Semin Cell Biol** 1995 Apr;6(2):79–87 (43 ref.)

SCHIZOTYPAL PERSONALITY DISORDER

DIAGNOSIS

Prodromal symptoms vs. early warning signs and clinical action in schizophrenia. Bustillo J, et al. **Schizophr Bull** 1995;21(4):553–9 (25 ref.)
Prodromal symptoms and relapse prevention in schizophrenia. Herz MI, et al. **Schizophr Bull** 1995; 21(4):541–51 (40 ref.)
Prodromal symptoms of relapse in schizophrenia: a review. Norman RM, et al. **Schizophr Bull** 1995;21(4):527–39 (60 ref.)
[Precursors of schizophrenia in adolescence and youth] Gindikin VIa. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995;95(5):101–5 (106 ref.) **(Rus)**

SCHMIDT'S SYNDROME see **POLYENDOCRINOPATHIES, AUTOIMMUNE**

SCHOENLEIN-HENOCH PURPURA see **PURPURA, SCHOENLEIN-HENOCH**

SCHOLARSHIPS see **FELLOWSHIPS AND SCHOLARSHIPS**

SCHOOL ADMISSION CRITERIA

Measurement of intelligence: misplaced trust and the lure of prophecy [see comments] Slack WV. **MD Comput** 1995 Sep–Oct;12(5):363–72 (127 ref.) Comment in: MD Comput 1995 Sep–Oct;12(5):325–6, 329.

SCHOOL HEALTH SERVICES

In search of effective programs to address students' emotional distress and behavioral problems. Part II: Critique of school- and community-based programs. Wassef A, et al. **Adolescence** 1995 Winter;30(120):757–77 (29 ref.)
In search of effective programs to address students' emotional distress and behavioral problems. Part I: Defining the problem. Wassef A, et al. **Adolescence** 1995 Fall; 30(119):523–38 (22 ref.)
School-based health clinics in the mid-1990s. Klein JD, et al. **Curr Opin Pediatr** 1995 Aug;7(4):353–9 (31 ref.)
Control of infections in schools. McMillan JA. **Pediatr Rev** 1995 Aug;16(8):283–8; quiz 289 (19 ref.)

SCHOOL NURSING

ORGANIZATION & ADMINISTRATION

The child with HIV in day care and school. Gross EJ, et al. **Nurs Clin North Am** 1996 Mar;31(1):231–41 (24 ref.)

SCHOOLS

Outcomes for youths with serious emotional disturbance in secondary school and early adulthood. Wagner MM. **Future Child** 1995 Summer–Fall;5(2):90–112 (37 ref.)
Does breakfast make a difference in school? Pollitt E. **J Am Diet Assoc** 1995 Oct;95(10):1134–9 (24 ref.)
Correction for the design effect in school-based substance use and abuse prevention research: sample size requirements and analysis considerations. Dielman TE. **NIDA Res Monogr** 1994;139:115–25 (38 ref.)
The child with HIV in day care and school. Gross EJ, et al. **Nurs Clin North Am** 1996 Mar;31(1):231–41 (24 ref.)
Habitual physical activity and academic performance. Shephard RJ. **Nutr Rev** 1996 Apr;54(4 Pt 2):S32–6 (42 ref.)

ORGANIZATION & ADMINISTRATION

School readiness. Lewit EM, et al. **Future Child** 1995 Summer–Fall;5(2):128–39 (26 ref.)
The Tennessee study of class size in the early school grades. Mosteller F. **Future Child** 1995 Summer–Fall;5(2):113–27 (17 ref.)

SCHOOLS, MEDICAL

Medical schools, the social contract and population medicine:

McMaster revisited. Coulter ID, et al.
J Manipulative Physiol Ther 1995 Oct;18(8):554–8 (25 ref.)

ORGANIZATION & ADMINISTRATION

Community medicine: an urban model. Deuschle KW, et al. **J Community Health** 1995 Dec;20(6):459–72 (37 ref.)

SCHOOLS, NURSERY

see related
CHILD DAY CARE CENTERS

SCHOOLS, NURSING

ECONOMICS

The budget process in schools of nursing: a primer for the novice administrator. Starck PL, et al. **J Prof Nurs** 1996 Mar–Apr;12(2):69–75 (7 ref.)

SCHWANN CELLS

CHEMISTRY

Structure and function of peripheral nerve myelin proteins. Uyemura K, et al. **Prog Brain Res** 1995;105:311–8 (27 ref.)

IMMUNOLOGY

Immunology of the Schwann cell. Armati PJ, et al.
Baillieres Clin Neurol 1996 Mar;5(1):47–64 (87 ref.)

METABOLISM

Schwann cell tumors express characteristic patterns of CD44 splice variants. Sherman L, et al. **J Neurooncol** 1995 Dec; 26(3):171–84 (57 ref.)

PATHOLOGY

Schwann cells in neuroblastoma. Ambros IM, et al.
Eur J Cancer 1995;31A(4):429–34 (80 ref.)

PHYSIOLOGY

Immunology of the Schwann cell. Armati PJ, et al.
Baillieres Clin Neurol 1996 Mar;5(1):47–64 (87 ref.)

Schwann cells and the regrowth of axons in the mammalian CNS: a review of transplantation studies in the rat visual system. Harvey AR, et al. **Clin Exp Pharmacol Physiol** 1995 Aug;22(8):569–79 (77 ref.)

p75NTR: a receptor after all [see comments] Bothwell M. **Science** 1996 Apr 26;272(5261):506–7 (20 ref.) Comment in: Science 1996 Apr 26;272(5261):542–5.

SCHWANNOMA see **NEURILEMMOMA**

SCHWANNOMA, ACOUSTIC see **NEUROMA, ACOUSTIC**

SCHWANNOMA, ACOUSTIC, BILATERAL see **NEUROFIBROMATOSIS 2**

SCHWARTZ–BARTTER SYNDROME see **INAPPROPRIATE ADH SYNDROME**

SCHWARTZ–JAMPEL SYNDROME see **OSTEOCHONDRODYSPLASIAS**

SCIATIC NERVE

see related
SCIATICA

Radiographic diagnosis and surgical repair of a sciatic hernia: report of a case. Hayashi N, et al. **Surg Today** 1995; 25(12):1066–8 (11 ref.)

SCIATICA

Diagnosis and management of low back pain and sciatica. Wheeler AH. **Am Fam Physician** 1995 Oct;52(5):1333–41, 1347–8 (33 ref.)

DIAGNOSIS

[Lumbago–sciatica syndrome as the first manifestation of metastatic renal adenocarcinoma] Amat Cecilia M, et al. **Actas Urol Esp** 1996 Jan;20(1):54–8 (7 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

[Cyclic sciatica and extrauterine endometriosis] Jelk W, et al. **Schweiz Rundsch Med Prax** 1995 Nov 14;84(46):1349–55 (29 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Spinal nerve root compression. Garfin SR, et al. **Spine** 1995 Aug 15;20(16):1810–20 (72 ref.)

SCID see **SEVERE COMBINED IMMUNODEFICIENCY**

SCID-HU MICE see **MICE, SCID**

SCID MICE see **MICE, SCID**

SCIENCE

Freudian suspicion versus suspicion of Freud. Crews F. **Ann N Y Acad Sci** 1996 Jun 24;775:470–82 (58 ref.)

Antiscience trends in the rise of the "alternative medicine" movement. Sampson W. **Ann N Y Acad Sci** 1996 Jun 24; 775:188–97 (34 ref.)

Humanism and positivism in nursing: contradictions and conflicts. Playle JF. **J Adv Nurs** 1995 Nov;22(5):979–84 (46 ref.)

Poster presentation: an effective means of scientific communication. Harikrishnan KM, et al.
J Assoc Physicians India 1995 Aug;43(8):546–7 (4 ref.)

State of the science. Breastfeeding for mothers and low birth weight infants. Meier PP, et al. **Nurs Clin North Am** 1996 Jun;31(2):351–65 (69 ref.)

Myth, metaphor and hypothesis: how anthropomorphism defeats science. Sullivan LG.
Philos Trans R Soc Lond B Biol Sci 1995 Aug 29; 349(1328):215–8; discussion 219–24 (9 ref.)

Limits of natural science: brain research and computers. Stieve H. **Z Naturforsch [C]** 1995 May–Jun;50(5–6):317–36 (86 ref.)

SCIENTIFIC SOCIETIES see **SOCIETIES, SCIENTIFIC**

SCINTIGRAPHY see **RADIONUCLIDE IMAGING**

SCINTIGRAPHY, COMPUTED TOMOGRAPHIC see **TOMOGRAPHY, EMISSION-COMPUTED**

SCINTIPHOTOGRAPHY see **RADIONUCLIDE IMAGING**

SCLERA

see related
SCLEROSTOMY

SCLEREDEMA ADULTORUM

PATHOLOGY

Scleroedema in a child. Mitsuhashi Y, et al. **J Dermatol** 1996 Jul;23(7):495–8 (8 ref.)

SCLERITIS

Noninfectious necrotizing scleritis. Legmann A, et al.
Int Ophthalmol Clin 1996 Winter;36(1):73–80 (24 ref.)

DIAGNOSIS

[Scleritis and episcleritis. Diagnosis and therapy] Althaus C, et al. **Ophthalmologe** 1996 Apr;93(2):205–16 (13 ref.) **(Ger)**

ETIOLOGY

[Isolated ocular recurrence of relapsing polychondritis. Apropos of a case] Gatinel D, et al. **J Fr Ophtalmol** 1996; 19(2):153–7 (7 ref.) (Eng. Abstr.) **(Fre)**

SCLERODERMA, CIRCUMSCRIBED

Scleroderma in children. Uziel Y, et al.
Pediatr Clin North Am 1995 Oct;42(5):1171–203 (131 ref.)

CHEMICALLY INDUCED

[Exposure to solvents in scleroderma: disseminated circumscribed scleroderma (morphea) in a painter exposed to perchloroethylene] Hinnen U, et al.
Schweiz Med Wochenschr 1995 Dec 16;125(50):2433–7 (13 ref.) (Eng. Abstr.) **(Ger)**

CLASSIFICATION

Classification of morphea (localized scleroderma) [see comments] Peterson LS, et al. **Mayo Clin Proc** 1995 Nov; 70(11):1068–76 (86 ref.) Comment in: Mayo Clin Proc 1996 Mar;71(3):318.

ETIOLOGY

Cutaneous manifestations of selected rheumatologic diseases. Ostezan LB, et al. **Am Fam Physician** 1996 Apr; 53(5):1625–36 (14 ref.)

PATHOLOGY

The scleroatrophic syndrome of Huriez: a cancer-prone genodermatosis. Hamm H, et al. **Br J Dermatol** 1996 Mar; 134(3):512–8 (24 ref.)

Linear scleroderma in children. Eubanks LE, et al.
Int J Dermatol 1996 May;35(5):330–6 (29 ref.)

PHYSIOPATHOLOGY

[Localized scleroderma in children] Uziel Y, et al.
Harefuah 1996 Mar 1;130(5):349–52 (31 ref.) **(Heb)**

SCLERODERMA, DIFFUSE see **SCLERODERMA, SYSTEMIC**

SCLERODERMA, LOCALIZED see **SCLERODERMA, CIRCUMSCRIBED**

SCLERODERMA, SYSTEMIC

Scleroderma. Silman AJ. **Baillieres Clin Rheumatol** 1995 Aug; 9(3):471–82 (33 ref.)

The repertoire of T-cell receptors in systemic sclerosis. Yurovsky VV. **Crit Rev Immunol** 1995;15(2):155–65 (66 ref.)

Systemic sclerosis: current pathogenetic concepts and future prospects for targeted therapy [clinical conference] **Lancet** 1996 May 25;347(9013):1453–8 (33 ref.)

COMPLICATIONS

The coexistence of systemic sclerosis and rheumatoid arthritis in five patients. Clinical and immunogenetic features suggest a distinct entity. Horiki T, et al.
Arthritis Rheum 1996 Jan;39(1):152–6 (15 ref.)

Pulmonary vascular aspects of systemic sclerosis [editorial] Wallman LL, et al. **Aust N Z J Med** 1996 Apr;26(2):150–3 (20 ref.)

Improvement of scleredema associated with IgA multiple myeloma after chemotherapy. Pujol JA, et al.
Clin Exp Dermatol 1995 Mar;20(2):149–52 (19 ref.)

Raynaud's phenomenon and the vascular disease in scleroderma. Kahaleh MB. **Curr Opin Rheumatol** 1995 Nov; 7(6):529–34 (37 ref.)

Mandibular resorption due to systemic sclerosis. Case report of surgical correction of a secondary open bite deformity. Haers PE, et al. **Int J Oral Maxillofac Surg** 1995 Aug; 24(4):261–7 (44 ref.)

Scleroderma in children. Uziel Y, et al.
Pediatr Clin North Am 1995 Oct;42(5):1171–203 (131 ref.)

[Scleroderma and alveolar inflammation] Crestani B, et al. **Rev Mal Respir** 1996;13(1):15–20 (45 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

[Systemic scleroderma] Sollberg S, et al. **Hautarzt** 1995 Aug; 46(8):587–601; quiz 600–1 (15 ref.) **(Ger)**

DRUG THERAPY

Treatment of scleroderma. Gelber AC, et al.
Curr Opin Rheumatol 1995 Nov;7(6):551–9 (66 ref.)

ETIOLOGY

Cutaneous manifestations of selected rheumatologic diseases. Ostezan LB, et al. **Am Fam Physician** 1996 Apr; 53(5):1625–36 (14 ref.)

GENETICS

Molecular genetics of systemic sclerosis. Reveille JD.
Curr Opin Rheumatol 1995 Nov;7(6):522–8 (65 ref.)

Familial systemic sclerosis—a report of two cases in the same kindred. Wanchu A, et al. **J Assoc Physicians India** 1995 Sep;43(9):633–4 (8 ref.)

IMMUNOLOGY

Immunologic aspects of scleroderma. White B.
Curr Opin Rheumatol 1995 Nov;7(6):541–5 (32 ref.)

Anti-topoisomerase-I and clinical findings in systemic sclerosis (scleroderma). Shoenfeld Y, et al.
Isr J Med Sci 1996 Jul;32(7):537–42 (32 ref.)

Systemic sclerosis 'state of the art' 1995 [editorial] Black CM. **Scand J Rheumatol** 1995;24(4):194–6 (14 ref.)

METABOLISM

Connective tissue metabolism including cytokines in scleroderma. Postlethwaite AE. **Curr Opin Rheumatol** 1995 Nov;7(6):535–40 (41 ref.)

PHYSIOPATHOLOGY

Measuring disease activity and severity in scleroderma [editorial] Clements PJ. **Curr Opin Rheumatol** 1995 Nov; 7(6):517–21 (32 ref.)

Clinical aspects of systemic and localized scleroderma. van den Hoogen FH, et al. **Curr Opin Rheumatol** 1995 Nov; 7(6):546–50 (48 ref.)

[Raynaud phenomenon and scleroderma] Haustein UF.
Hautarzt 1996 May;47(5):336–40 (61 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

[A case of the successful treatment of true scleroderma kidney] Nikolaev AIu, et al. **Klin Med (Mosk)** 1995; 73(3):104–5 (6 ref.) **(Rus)**

[Modern therapy of scleroderma] Karadaglić D.
Vojnosanit Pregl 1995 Jul–Aug;52(4):389–94 (41 ref.) **(Ser)**

SCLEROMA, NASAL see **RHINOSCLEROMA**

SCLEROSING AGENTS see **SCLEROSING SOLUTIONS**

SCLEROSING SOLUTIONS

ADMINISTRATION & DOSAGE

[Current treatment strategy in malignant pleural effusion] Türler A, et al. **Wien Klin Wochenschr** 1996;108(9):255–61

SCLEROSING SOLUTIONS

(56 ref.) (Eng. Abstr.) **(Ger)**

SCLEROSIS, DISSEMINATED see **MULTIPLE SCLEROSIS**

SCLEROSIS, HEREDITARY SPINAL see **FRIEDREICH'S ATAXIA**

SCLEROSIS, PRESENILE see **DEMENTIA, PRESENILE**

SCLEROSIS, PROGRESSIVE SYSTEMIC see **SCLERODERMA, SYSTEMIC**

SCLEROSTOMY

METHODS

Is laser sclerostomy surgery ready for 'prime time'? [editorial] Higginbotham EJ. **Arch Ophthalmol** 1995 Oct; 113(10):1243–4 (22 ref.)

SCLEROTHERAPY

see related
SCLEROSING SOLUTIONS

Ambulatory phlebectomy compared to sclerotherapy for varicose and telangiectatic veins: indications and complications. Weiss RA, et al. **Adv Dermatol** 1996;11:3–16; discussion 17 (37 ref.)

Drug treatment of esophageal variceal bleeding: alternative or supplement to endoscopic therapy? Zoller WG, et al. **Endoscopy** 1995 Oct;27(8):616–21 (65 ref.)

New approaches to endoscopic therapy for hemostasis of upper GI bleed. Rauws EA, et al. **Scand J Gastroenterol Suppl** 1995;212:90–5 (66 ref.)

[Sclerotherapy and elastic ligation of hemorrhoids] Dodi G, et al. **Ann Ital Chir** 1995 Nov–Dec;66(6):769–73 (9 ref.) (Eng. Abstr.) **(Ita)**

[Endoscopic sclerotherapy of esophageal and gastric varicose veins in liver cirrhosis with portal hypertension] Bulanov KI, et al. **Klin Khir** 1995;(4):38–40 (49 ref.) **(Rus)**

METHODS

[Hemorrhage caused by rupture of gastroesophageal varices: should we dilate the liver or strangulate the varices? (editorial)]– Calès P. **Gastroenterol Clin Biol** 1995 Nov; 19(11):899–902 (34 ref.) **(Fre)**

[Emergency medical treatment of portal hypertension] Heresbach D, et al. **Presse Med** 1995 Sep 30;24(28):1311–4 (26 ref.) (Eng. Abstr.) **(Fre)**

SCLEROTINIA see **ASCOMYCETES**

SCOLIOSIS

Scoliosis and spine deformities. Padman R. **Del Med J** 1995 Oct;67(10):528–33 (0 ref.)

[Kyphoscoliosis: etiology, pathology, complications and treatment] Malawski S. **Chir Narzadow Ruchu Ortop Pol** 1995;60(4):269–74 (23 ref.) (Eng. Abstr.) **(Pol)**

CONGENITAL

Congenital spinal deformity. Winter RB, et al. **Instr Course Lect** 1996;45:117–27 (47 ref.)

DIAGNOSIS

Adolescent idiopathic scoliosis: an update [see comments] Skaggs DL, et al. **Am Fam Physician** 1996 May 15; 53(7):2327–35 (29 ref.) Comment in: Am Fam Physician 1996 May 15;53(7):2268–72.

Spinal deformity. Boachie-Adjei O, et al. **Pediatr Clin North Am** 1996 Aug;43(4):883–97 (33 ref.)

Syringomyelia and chiari malformation presenting as scoliosis in cystic fibrosis. Rusakow LS, et al. **Pediatr Pulmonol** 1995 May;19(5):317–8 (10 ref.)

[Advances in diagnosis and treatment of idiopathic scoliosis in children and adolescents] Nowakowski A. **Chir Narzadow Ruchu Ortop Pol** 1995;60(6):445–9 (41 ref.) (Eng. Abstr.) **(Pol)**

EPIDEMIOLOGY

Scoliosis in China. A general review. Liu SL, et al. **Clin Orthop** 1996 Feb;(323):113–8 (44 ref.)

ETIOLOGY

Scoliosis as the first sign of a cystic spinal cord lesion. Samuelsson L, et al. **Eur Spine J** 1995;4(5):284–90 (41 ref.)

Symptomatic spinal hemangiomas in association with cutaneous hemangiomas. A case report. Asumu TO, et al. **Spine** 1996 May 1;21(9):1082–4 (7 ref.)

[Syringomyelia, scoliosis and idiopathic Arnold–Chiari malformations: a common etiology] Royo-Salvador MB. **Rev Neurol** 1996 Aug;24(132):937–59 (119 ref.) (Eng. Abstr.) **(Spa)**

REHABILITATION

[Physical treatment methods in dysplastic scoliosis in children] Nenasheva TV, et al. **Vopr Kurortol Fizioter Lech Fiz Kult** 1995 Sep–Oct;(5):44–6 (58 ref.) **(Rus)**

THERAPY

Adolescent idiopathic scoliosis: an update [see comments] Skaggs DL, et al. **Am Fam Physician** 1996 May 15; 53(7):2327–35 (29 ref.) Comment in: Am Fam Physician 1996 May 15;53(7):2268–72.

[Present views on nonoperative treatment for idiopathic scoliosis] Nowakowski A, et al. **Chir Narzadow Ruchu Ortop Pol** 1996;61(1):23–31 (39 ref.) (Eng. Abstr.) **(Pol)**

[Advances in diagnosis and treatment of idiopathic scoliosis in children and adolescents] Nowakowski A. **Chir Narzadow Ruchu Ortop Pol** 1995;60(6):445–9 (41 ref.) (Eng. Abstr.) **(Pol)**

SCOPOLAMINE

ADMINISTRATION & DOSAGE

New potential uses for transdermal scopolamine (hyoscine). La Rovere MT, et al. **Drugs** 1995 Nov;50(5):769–76 (49 ref.)

THERAPEUTIC USE

New potential uses for transdermal scopolamine (hyoscine). La Rovere MT, et al. **Drugs** 1995 Nov;50(5):769–76 (49 ref.)

SCORBUTUS see **SCURVY**

SCORPION VENOMS

Scorpion envenomation [editorial] Sofer S. **Intensive Care Med** 1995 Aug;21(8):626–8 (20 ref.)

PHARMACOLOGY

Scorpion venoms: taking the sting out of lung disease. Rogers DF. **Thorax** 1996 May;51(5):546–8 (12 ref.)

POISONING

The scorpion envenoming syndrome. Ismail M. **Toxicon** 1995 Jul;33(7):825–58 (201 ref.)

SCORPIONS

[Scorpion stings in children. Saudi Arabian experience] el Aminn EO, et al. **Arch Pediatr** 1995 Aug;2(8):766–73 (64 ref.) (Eng. Abstr.) **(Fre)**

SCOTOMA

PHYSIOPATHOLOGY

Physiology of suppression in strabismic amblyopia. Harrad R, et al. **Br J Ophthalmol** 1996 Apr;80(4):373–7 (63 ref.)

Turning a blind eye to cortical receptive fields. Chapman B, et al. **Neuron** 1996 Jan;16(1):9–12 (13 ref.)

SCRAPIE

see related
PRIONS
PRPSC PROTEINS

EPIDEMIOLOGY

Scrapie: the risk of its introduction and effects on trade. MacDiarmid SC. **Aust Vet J** 1996 May;73(5):161–4 (21 ref.)

PATHOLOGY

The pathological changes in peripheral organs of scrapie-infected animals. Ye X, et al. **Histol Histopathol** 1995 Oct;10(4):995–1021 (118 ref.)

PHYSIOPATHOLOGY

The 'infective' process in scrapie and human spongiform encephalopathy disease. Adams DH. **Med Hypotheses** 1995 Aug;45(2):214–8 (37 ref.)

[Prion-type pathologies: from scrapie to prion-related dementias. On the borderline between veterinary and human pathology] Domich L. **Rev Neurol** 1996 Jul; 24(131):785–802 (250 ref.) **(Spa)**

TRANSMISSION

Scrapie: the risk of its introduction and effects on trade. MacDiarmid SC. **Aust Vet J** 1996 May;73(5):161–4 (21 ref.)

The myth of maternal transmission of spongiform encephalopathy [see comments] Ridley RM, et al. **BMJ** 1995 Oct 21;311(7012):1071–5; discussion 1075–6 (61 ref.) Comment in: BMJ 1996 Jan 20;312(7024):180. Comment in: BMJ 1996 Jan 20;312(7024):180–1.

Proposed link between transmissible spongiform encephalopathies of man and animals [see comments] Diringer H. **Lancet** 1995 Nov 4;346(8984):1208–10 (20 ref.) Comment in: Lancet 1996 Jan 6;347(8993):65–6.

VIROLOGY

Reflections on scrapie and related disorders, with consideration of the possibility of a viral aetiology. Darcel C. **Vet Res Commun** 1995;19(3):231–52 (130 ref.)

SCRAPIE AGENT see **PRPSC PROTEINS**

SCRAPIE AMYLOID PRECURSOR PROTEIN see **PRPC PROTEINS**

SCRAPIE PRP see **PRPSC PROTEINS**

SCROFULA see **TUBERCULOSIS, LYMPH NODE**

SCROTUM

Diagnostic imaging of patients with acute scrotal pain. Barloon TJ, et al. **Am Fam Physician** 1996 Apr; 53(5):1734–50 (17 ref.)

Crohn's disease complicating male genitourinary tract without overlying cutaneous involvement. Minocha A, et al. **Am J Gastroenterol** 1996 Jul;91(7):1463–4 (9 ref.)

Pneumoscrotum: an unusual complication of pulmonary resection. Raudat CW, et al. **J Am Osteopath Assoc** 1996 Jun;96(6):362–3 (16 ref.)

Bilateral giant abdominoscrotal hydroceles in childhood. Serels S, et al. **Urology** 1996 May;47(5):763–5 (15 ref.)

Cystic dysplasia of the testis: an unusual cause of a pediatric scrotal mass. Zaragoza MR, et al. **Urology** 1996 Feb; 47(2):244–7 (12 ref.)

[Inguinal and scrotal hernias in steers] Brouwers EA, et al. **Tijdschr Diergeneeskd** 1996 Jan 1;121(1):2–5 (20 ref.) (Eng. Abstr.) **(Dut)**

[Leiomyosarcoma of the scrotum: a case report] Ozeki S, et al. **Hinyokika Kiyo** 1996 Mar;42(3):229–31 (13 ref.) (Eng. Abstr.) **(Jpn)**

ABNORMALITIES

Penoscrotal transposition and associated anomalies: report of five new cases and review of the literature. Parida SK, et al. **Am J Med Genet** 1995 Oct 23;59(1):68–75 (35 ref.)

[Accessory scrotum with lipoma: a case report] Konya E, et al. **Hinyokika Kiyo** 1996 Mar;42(3):233–6 (28 ref.) (Eng. Abstr.) **(Jpn)**

INJURIES

[Injuries of the scrotum. Analysis of 25 cases] el Moussaoui A, et al. **J Urol (Paris)** 1996;102(2):88–91 (20 ref.) (Eng. Abstr.) **(Fre)**

[A gunshot wound of the penis and scrotum] Dmitriev DG, et al. **Urol Nefrol (Mosk)** 1996 Mar–Apr;(2):47 (6 ref.) **(Rus)**

PATHOLOGY

Massive primary lipoma of the scrotum. Greeley DJ Jr, et al. **Am Surg** 1995 Nov;61(11):954–5 (10 ref.)

PHYSIOLOGY

[Temperature and male fertility] Bujan L, et al. **Contracept Fertil Sex** 1996 Jun;24(6):429–38 (40 ref.) **(Fre)**

SURGERY

ABC of general surgery in children. Acute problems of the scrotum [see comments] Davenport M. **BMJ** 1996 Feb 17; 312(7028):435–7 (0 ref.) Comment in: BMJ 1996 May 25;312(7042):1358–9.

SCRUB TYPHUS

[Rickettsiosis] Hosoi H, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):109–11 (5 ref.) **(Jpn)**

EPIDEMIOLOGY

Current status of tsutsugamushi disease in Korea. Chang WH. **J Korean Med Sci** 1995 Aug;10(4):227–38 (63 ref.)

SCURVY

ETIOLOGY

Hyperglycemia-induced latent scurvy and atherosclerosis: the scorbutic-metaplasia hypothesis. Price KD, et al. **Med Hypotheses** 1996 Feb;46(2):119–29 (136 ref.)

SCYPHOZOA see **JELLYFISH**

SEA ANEMONE VENOMS see **CNIDARIAN VENOMS**

SEA-BLUE HISTIOCYTE SYNDROME

[Sea-blue histiocytosis] Uchiyama H, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):272–5 (21 ref.) **(Jpn)**

SEA LION SPUMAVIRUS see **SPUMAVIRUS**

SEA LIONS see **SEALS**

SEA URCHINS

Sea urchin granuloma of the nail apparatus: report of 2 cases.

Haneke E, et al. **Dermatology** 1996;192(2):140–2 (9 ref.)

EMBRYOLOGY

Histone phosphorylation during sea urchin development. Green GR, et al. **Semin Cell Biol** 1995 Aug;6(4):219–27 (43 ref.)

GENETICS

Modular cis-regulatory organization of developmentally expressed genes: two genes transcribed territorially in the sea urchin embryo, and additional examples. Kirchhamer CV, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3; 93(18):9322–8 (67 ref.)

PHYSIOLOGY

Beakers versus breakers: how fertilisation in the laboratory differs from fertilisation in nature. Mead KS, et al. **Zygote** 1995 May;3(2):95–9 (62 ref.)

SEAFOOD

Role of dietary fish protein in the regulation of plasma lipids. Jacques H, et al. **Can J Cardiol** 1995 Oct;11 Suppl G:63G–71G (45 ref.)

ANALYSIS

Biogenic amines in fish and shellfish. Rawles DD, et al. **Adv Food Nutr Res** 1996;39:329–65 (147 ref.)

POISONING

Sea monsters. Sodeman WA Jr. **Compr Ther** 1995 Nov; 21(11):668–72 (18 ref.)

STANDARDS

Value-added products from underutilized fish species. Venugopal V, et al. **Crit Rev Food Sci Nutr** 1995 Sep; 35(5):431–53 (160 ref.)

SEALS

An overview of exposure to, and effects of, petroleum oil and organochlorine pollution in grey seals (Halichoerus grypus). Jenssen BM. **Sci Total Environ** 1996 Jul 16; 186(1–2):109–18 (54 ref.)

IMMUNOLOGY

Contaminant-induced immunotoxicity in harbour seals: wildlife at risk? Ross P, et al. **Toxicology** 1996 Aug 16; 112(2):157–69 (91 ref.)

METABOLISM

Environmental pollutants in marine mammals from the Norwegian coast and Arctic. Skaare JU. **Sci Total Environ** 1996 Jul 16;186(1–2):25–7 (12 ref.)

SEASICKNESS see **MOTION SICKNESS**

SEASONAL AFFECTIVE DISORDER

THERAPY

Treatment of seasonal affective disorder: a review. Tam EM, et al. **Can J Psychiatry** 1995 Oct;40(8):457–66 (73 ref.)

[Phototherapy in psychiatry: clinical update and review of indications] Gross F, et al. **Encephale** 1996 Mar–Apr; 22(2):143–8 (37 ref.) (Eng. Abstr.) **(Fre)**

[Seasonal affective syndrome and phototherapy: theoretical concepts and clinical applications] Sartori S, et al. **Encephale** 1996 Jan–Feb;22(1):7–16 (59 ref.) (Eng. Abstr.) **(Fre)**

SEASONAL MOOD DISORDER see **SEASONAL AFFECTIVE DISORDER**

SEASONS

The economy of winter: phenotypic plasticity in behavior and brain structure. Jacobs LF. **Biol Bull** 1996 Aug; 191(1):92–100 (61 ref.)

Is there a seasonal variation in the incidence of gestational diabetes? Moses R, et al. **Diabet Med** 1995 Jul;12(7):563–5 (10 ref.)

Interpregnancy intervals, high maternal age and seasonal effects on the human sex ratio. James WH. **Hum Reprod** 1996 Jan;11(1):7–8 (14 ref.)

Chronobiological aspects of pulmonary thromboembolism. Manfredini R, et al. **Int J Cardiol** 1995 Nov 10;52(1):31–7 (98 ref.)

The influence of season, photoperiod, and pineal melatonin on immune function. Nelson RJ, et al. **J Pineal Res** 1995 Nov;19(4):149–65 (209 ref.)

Comparative studies on programmes for management of energy supply: torpor, pre-winter fattening and migration. Andrews JF. **Proc Nutr Soc** 1995 Mar;54(1):301–15 (33 ref.)

Gene–environment interaction in schizophrenia: season-of-birth effect reveals etiologically different subgroups. Franzek E, et al. **Psychopathology** 1996; 29(1):14–26 (129 ref.)

Timing of seasonal breeding in birds, with particular reference to New Zealand birds. Cockrem JF. **Reprod Fertil Dev** 1995;7(1):1–19 (72 ref.)

[Acute kidney failure in a recurrence of sarcoidosis at the height of summer] Wiemeyer A, et al. **Dtsch Med Wochenschr** 1996 Feb 9;121(6):165–8 (15 ref.) (Eng. Abstr.) **(Ger)**

SEAT BELTS

see related
AIR BAGS

ADVERSE EFFECTS

Lumbar compression fractures secondary to lap-belt use in children. Sturm PF, et al. **J Pediatr Orthop** 1995 Jul–Aug; 15(4):521–3 (27 ref.)

Traumatic lumbar hernia: a seat belt injury. McCarthy MC, et al. **J Trauma** 1996 Jan;40(1):121–2 (10 ref.)

SEAWATER

see related
GEOLOGIC SEDIMENTS
THALASSOTHERAPY

Field evaluations of marine oil spill bioremediation. Swannell RP, et al. **Microbiol Rev** 1996 Jun;60(2):342–65 (121 ref.)

Beakers versus breakers: how fertilisation in the laboratory differs from fertilisation in nature. Mead KS, et al. **Zygote** 1995 May;3(2):95–9 (62 ref.)

SEAWEED

see related
CARRAGEENAN

SEBACEOUS CYST see **EPIDERMAL CYST**

SEBACEOUS GLAND NEOPLASMS

[Muir–Torre syndrome] Yoshikawa R, et al. **Nippon Rinsho** 1995 Nov;53(11):2803–6 (11 ref.) (Eng. Abstr.) **(Jpn)**

CLASSIFICATION

A call for logic in the classification of adnexal neoplasms [editorial; comment] McCalmont TH. **Am J Dermatopathol** 1996 Apr;18(2):103–9 (50 ref.) Comment on: Am J Dermatopathol 1996 Apr;18(2):124–36.

PATHOLOGY

Sebomatricoma: a unifying term that encompasses all benign neoplasms with sebaceous differentiation. Sáchez Yus E, et al. **Am J Dermatopathol** 1995 Jun;17(3):213–21 (22 ref.)

Intraoral sebaceous carcinoma. Abuzeid M, et al. **J Laryngol Otol** 1996 May;110(5):500–2 (27 ref.)

SEBACEOUS GLANDS

DRUG EFFECTS

Retinoids and sebaceous gland activity. Geiger JM. **Dermatology** 1995;191(4):305–10 (52 ref.)

SEBORRHEA see **DERMATITIS, SEBORRHEIC**

SEBORRHEIC KERATOSIS see **KERATOSIS, SEBORRHEIC**

SECOND-GENERATION ANTIDEPRESSIVE AGENTS see **ANTIDEPRESSIVE AGENTS, SECOND-GENERATION**

SECOND-LOOK SURGERY see **REOPERATION**

SECOND MALIGNANCY see **NEOPLASMS, SECOND PRIMARY**

SECOND MESSENGER SYSTEMS

Amyotrophic lateral sclerosis. A multifactorial disease. Eisen AA. **Adv Neurol** 1995;68:121–34 (108 ref.)

Signal transduction of the gonadotropin releasing hormone (GnRH) receptor: cross-talk of calcium, protein kinase C (PKC), and arachidonic acid. Naor Z, et al. **Cell Mol Neurobiol** 1995 Oct;15(5):527–44 (142 ref.)

Phosphoinositide second messengers in olfaction. Bruch RC. **Comp Biochem Physiol B Biochem Mol Biol** 1996 Mar; 113(3):451–9 (95 ref.)

Sphingolipid metabolites: members of a new class of lipid second messengers. Spiegel S, et al. **J Membr Biol** 1995 Aug;146(3):225–37 (122 ref.)

Inositol trisphosphate and cyclic ADP ribose as long range messengers generating local subcellular calcium signals. Petersen OH. **J Physiol Paris** 1995;89(3):125–7 (16 ref.)

Clinically accessible cell signaling: second messengers in sepsis and trauma. Rehring TF, et al. **J Surg Res** 1996 Jan; 60(1):270–7 (37 ref.)

Signalling by cGMP-dependent protein kinases. Vaandrager AB, et al. **Mol Cell Biochem** 1996 Apr 12–26;157(1–2):23–30 (67 ref.)

Phosphoinositide-generated messengers in cardiac signal transduction. van Heugten HA, et al. **Mol Cell Biochem** 1996 Apr 12–26;157(1–2):5–14 (88 ref.)

Platelet-activating factor is a synapse messenger and a modulator of gene expression in the nervous system. Bazan NG, et al. **Neurochem Int** 1995 May;26(5):435–41 (72 ref.)

Molecular biology of the opioid receptors: structures, functions and distributions. Minami M, et al. **Neurosci Res** 1995 Sep;23(2):121–45 (164 ref.)

Metabolism of myo-inositol phosphates and the alternative pathway in generation of myo-inositol trisphosphate involved in calcium mobilization in plants. Biswas S, et al. **Subcell Biochem** 1996;26:287–316 (203 ref.)

Cyclic AMP, the reluctant messenger in plants. Bolwell GP. **Trends Biochem Sci** 1995 Dec;20(12):492–5 (43 ref.)

Second messenger signalling during hormone-induced Xenopus oocyte maturation. Cork RJ, et al. **Zygote** 1994 Nov;2(4):289–99 (101 ref.)

[Second messenger system and regulation of smooth muscle contractile activity in digestive tract] Zheng GH, et al. **Sheng Li Ko Hsueh Chin Chan** 1995 Oct;26(4):359–62 (7 ref.) **(Chi)**

[Free radicals as second messengers] Raes M, et al. **C R Seances Soc Biol Fil** 1995;189(3):355–66 (46 ref.) (Eng. Abstr.) **(Fre)**

DRUG EFFECTS

Second messenger systems as targets for new therapeutic agents: focus on selective phosphodiesterase inhibitors. Palacios JM, et al. **Farmaco** 1995 Dec;50(12):819–27 (81 ref.)

GENETICS

A combined genetic and biochemical approach to mammalian signal transduction. Della NG, et al. **Aust N Z J Med** 1995 Dec;25(6):845–51 (36 ref.)

Genetics of myo-inositol phosphate synthesis and accumulation. Raboy V, et al. **Subcell Biochem** 1996; 26:257–85 (161 ref.)

PHYSIOLOGY

Molecular mechanisms of toxicant-induced immunosuppression: role of second messengers. Holsapple MP, et al. **Annu Rev Pharmacol Toxicol** 1996;36:131–59 (112 ref.)

Glycerophosphoinositols as potential markers of ras-induced transformation and novel second messengers. Corda D, et al. **Anticancer Res** 1996 May–Jun;16(3B):1341–50 (86 ref.)

Second messenger pathways in the modulation of neurotransmitter release. Majewski HK, et al. **Aust N Z J Med** 1995 Dec;25(6):817–21 (28 ref.)

Platelet activation. Blockmans D, et al. **Blood Rev** 1995 Sep; 9(3):143–56 (124 ref.)

Generation of free radicals and messenger function. Carlson JC, et al. **Can J Appl Physiol** 1995 Sep;20(3):280–8 (47 ref.)

The inositol triphosphate receptor family. Joseph SK. **Cell Signal** 1996 Jan;8(1):1–7 (97 ref.)

Messenger functions of phosphatidic acid. English D, et al. **Chem Phys Lipids** 1996 May 24;80(1–2):117–32 (140 ref.)

Sphingoid bases and phospholipase D activation. Spiegel S, et al. **Chem Phys Lipids** 1996 May 24;80(1–2):27–36 (87 ref.)

Developmental signalling. Hendry IA, et al. **Clin Exp Pharmacol Physiol** 1995 Aug;22(8):563–8 (21 ref.)

Signal transduction through lipid second messengers. Spiegel S, et al. **Curr Opin Cell Biol** 1996 Apr;8(2):159–67 (82 ref.)

Dual second-messenger pathways in olfactory transduction. Ache BW, et al. **Curr Opin Neurobiol** 1995 Aug;5(4):461–6 (48 ref.)

Regulation of cellular calcium through signaling cross-talk involves an intricate interplay between the actions of receptors, G-proteins, and second messengers. Bygrave FL, et al. **FASEB J** 1995 Oct;9(13):1297–303 (62 ref.)

The use of the human neuroblastoma SH-SY5Y to study the effect of second messengers on noradrenaline release. Vaughan PF, et al. **Gen Pharmacol** 1995 Oct;26(6):1191–201 (62 ref.)

Nitric oxide: a new paradigm for second messengers. Kerwin JF Jr, et al. **J Med Chem** 1995 Oct 27;38(22):4343–62 (192 ref.)

Ceramide: a potential second messenger in the nervous system. Chao MV. **Mol Cell Neurosci** 1995 Apr;6(2):91–6 (55 ref.)

Regulation of endothelial permeability by second messengers. Siflinger-Birnboim A, et al. **New Horiz** 1996 Feb;4(1):87–98 (86 ref.)

Endothelin receptor subtypes and their role in transmembrane signaling mechanisms. Sokolovsky M. **Pharmacol Ther** 1995;68(3):435–71 (208 ref.)

Agonist-specific coupling of G-protein-coupled receptors to second-messenger systems. Evans PD, et al. **Prog Brain Res** 1995;106:259–68 (35 ref.)

Arachidonic acid and eicosanoids as targets and effectors in second messenger interactions. Di Marzo V. **Prostaglandins Leukot Essent Fatty Acids** 1995 Oct; 53(4):239–54 (183 ref.)

Phosphoinositide turnover and its role in plant signal transduction. Coté GG, et al. **Subcell Biochem** 1996; 26:317–43 (156 ref.)

Phosphoinositides and synaptic transmission. Hawthorne JN. **Subcell Biochem** 1996;26:43–57 (64 ref.)

Regulation of the actin cytoskeleton by inositol phospholipid

pathways. Kandzari DE, et al. **Subcell Biochem** 1996; 26:97–114 (91 ref.)
Control of the Ca2+ release induced by myo-inositol trisphosphate and the implication in signal transduction. Missiaen L, et al. **Subcell Biochem** 1996;26:59–95 (216 ref.)
[Current information on nitric oxide as a neuronal messenger] Haulică I, et al. **Rom J Physiol** 1994 Jan-Dec;31(1–4):3–12 (28 ref.) **(Fre)**
[Second messenger-mediated transcriptional regulation of neural genes and possible drug action sites] Higuchi H, et al. **Nippon Yakurigaku Zasshi** 1995 Dec;106(6):365–78 (50 ref.) (Eng. Abstr.) **(Jpn)**

SECOND NEOPLASM see **NEOPLASMS, SECOND PRIMARY**

SECOND OPINION see **REFERRAL AND CONSULTATION**

SECOND PRIMARY NEOPLASMS see **NEOPLASMS, SECOND PRIMARY**

SECRETIN

see related
GASTROINTESTINAL AGENTS

BLOOD

[Secretin] Miyachi Y. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:636–9 (14 ref.) **(Jpn)**

SECRETORY GRANULES see **CYTOPLASMIC GRANULES**

SECRETORY IGA see **IGA, SECRETORY**

SECRETORY PHASE see **MENSTRUAL CYCLE**

SECRETORY RATE

DRUG EFFECTS

[Mucosa of the gastric fundus and antisecretory agents (editorial)] Diébold MD, et al. **Ann Pathol** 1996;16(2):75–7 (17 ref.) **(Fre)**

SECURITY MEASURES

How safe is your ED? Keep NB, et al. **Am J Nurs** 1995 Sep;95(9):44–50; quiz 51 (5 ref.)
The impact of violence in the health care setting upon nursing education. Whitley GG, et al. **J Nurs Educ** 1996 May; 35(5):211–8 (46 ref.)
Security in pediatric emergency departments. Graham CJ, et al. **Pediatr Emerg Care** 1995 Aug;11(4):220–2 (9 ref.)

ORGANIZATION & ADMINISTRATION

Healthcare violence. A nursing administration perspective. Claravall L. **J Nurs Adm** 1996 Feb;26(2):41–6 (29 ref.)

SEDATION, CONSCIOUS see **CONSCIOUS SEDATION**

SEDATIVES see **HYPNOTICS AND SEDATIVES**

SEDATIVES, BARBITURATE

POISONING

Hemodiafiltration in pentobarbital poisoning. Bironneau E, et al. **Ren Fail** 1996 Mar;18(2):299–303 (11 ref.)

SEDATIVES, NONBARBITURATE

Optimal intravenous dosing strategies for sedatives and analgesics in the intensive care unit. Barr J, et al. **Crit Care Clin** 1995 Oct;11(4):827–47 (64 ref.)
Barbiturates, neuroleptics, and propofol for sedation. Lund N, et al. **Crit Care Clin** 1995 Oct;11(4):875–86 (38 ref.)
Drugs and sedation for colonoscopy. Phillips MS. **Prim Care** 1995 Sep;22(3):433–43 (33 ref.)

PHARMACOLOGY

Propofol. An overview of its pharmacology and a review of its clinical efficacy in intensive care sedation. Fulton B, et al. **Drugs** 1995 Oct;50(4):636–57 (205 ref.)

THERAPEUTIC USE

The management of alcohol withdrawal using chlormethiazole. Morgan MY. **Alcohol Alcohol** 1995 Nov; 30(6):771–4 (21 ref.)
Propofol. An overview of its pharmacology and a review of its clinical efficacy in intensive care sedation. Fulton B, et al. **Drugs** 1995 Oct;50(4):636–57 (205 ref.)
Perioperative use of propofol for cardiac surgery. Jain U. **J Clin Anesth** 1996 May;8(3 Suppl):61S–66S (81 ref.)
Benzodiazepines for insomnia in community-dwelling elderly: a review of benefit and risk. Grad RM. **J Fam Pract** 1995 Nov;41(5):473–81 (41 ref.)

SEDIMENTS, GEOLOGIC see **GEOLOGIC SEDIMENTS**

SEDIMENTS, MARINE see **GEOLOGIC SEDIMENTS**

SEEDLINGS see **PLANTS**

SEEDS

Cellular, biological, and physicochemical basis for the hard-to-cook defect in legume seeds. Liu K. **Crit Rev Food Sci Nutr** 1995 Jul;35(4):263–98 (156 ref.)

CYTOLOGY

A novel cell-ablation strategy for studying plant development. Goldberg RB, et al. **Philos Trans R Soc Lond B Biol Sci** 1995 Oct 30; 350(1331):5–17 (43 ref.)

EMBRYOLOGY

Pattern formation in the Arabidopsis embryo: a genetic perspective. Jürgens G, et al. **Philos Trans R Soc Lond B Biol Sci** 1995 Oct 30; 350(1331):19–25 (38 ref.)

ENZYMOLOGY

Structure-function features of flaxseed allene oxide synthase. Brash AR, et al. **J Lipid Mediat Cell Signal** 1995 Oct; 12(2–3):275–82 (26 ref.)

VIROLOGY

Seed transmission of plant viruses: a lesson in biological complexity. Maule AJ, et al. **Trends Microbiol** 1996 Apr; 4(4):153–8 (24 ref.)

SEGMENTATION STAGE, OVUM see **CLEAVAGE STAGE, OVUM**

SEIZURES

[Conversion nonepileptic seizures] Amir I, et al. **Harefuah** 1996 Feb 15;130(4):272–7 (37 ref.) **(Heb)**

CHEMICALLY INDUCED

The neuropsychiatric complications of corticosteroid therapy. Vincent FM. **Compr Ther** 1995 Sep;21(9):524–8 (22 ref.)
Drug-induced seizures in the elderly. Causative agents and optimal management. Franson KL, et al. **Drugs Aging** 1995 Jul;7(1):38–48 (78 ref.)
Kainic acid seizures in the rat. Sperk G. **Prog Neurobiol** 1994 Jan;42(1):1–32 (415 ref.)

CLASSIFICATION

Inhibitory mechanisms of epileptic seizure generation. Engel J Jr. **Adv Neurol** 1995;67:157–71 (52 ref.)
Drop attacks. Lee MS, et al. **Adv Neurol** 1995;67:41–52 (99 ref.)
Atonic phenomena and partial seizures. A reappraisal. So NK. **Adv Neurol** 1995;67:29–39 (33 ref.)
Office management of common neurologic problems. Moe PG. **Compr Ther** 1995 Sep;21(9):513–8 (16 ref.)
A clinical approach to the classification of seizures and epileptic syndromes. Mosewich RK, et al. **Mayo Clin Proc** 1996 Apr;71(4):405–14 (36 ref.)

COMPLICATIONS

Bilateral posterior fracture-dislocation of the shoulders: management by bilateral shoulder hemiarthroplasties. Page AE, et al. **J Orthop Trauma** 1995;9(6):526–9 (31 ref.)
[Psychiatric diseases and ictus] Aguilar M, et al. **Rev Neurol** 1995;23 Suppl 1:S113–22 (128 ref.) **(Spa)**
[Hepatic diseases and ictus] Chamorro A. **Rev Neurol** 1995; 23 Suppl 1:S95–8 (24 ref.) **(Spa)**
[Ictus and cutaneous vascular syndromes] Trejo Gabriel y Galán JM. **Rev Neurol** 1995;23 Suppl 1:S99–105 (46 ref.) **(Spa)**

DIAGNOSIS

Negative motor phenomena in generalized epilepsies. A study of atonic seizures. Andermann F, et al. **Adv Neurol** 1995; 67:9–28 (117 ref.)
Drop attacks. Lee MS, et al. **Adv Neurol** 1995;67:41–52 (99 ref.)
Atonic phenomena and partial seizures. A reappraisal. So NK. **Adv Neurol** 1995;67:29–39 (33 ref.)
Epileptic negative myoclonus. Tassinari CA, et al. **Adv Neurol** 1995;67:181–97 (40 ref.)
The place of the EEG and imaging in the management of seizures. Verity CM. **Arch Dis Child** 1995 Dec;73(6):557–62 (34 ref.)
Pseudoseizures: an update. Nash JL. **Compr Ther** 1995 Sep; 21(9):486–91 (29 ref.)
The case for a dissociative interpretation of pseudoepileptic seizures. Kuyk J, et al. **J Nerv Ment Dis** 1996 Aug; 184(8):468–74 (83 ref.)
Psychogenic nonepileptic seizures. Chabolla DR, et al. **Mayo Clin Proc** 1996 May;71(5):493–500 (64 ref.)

DRUG THERAPY

Clinical use of drugs useful in the treatment of atonic seizures. Bourgeois B. **Adv Neurol** 1995;67:361–7 (42 ref.)
Status epilepticus and acute repetitive seizures in children, adolescents, and young adults: etiology, outcome, and treatment. Mitchell WG. **Epilepsia** 1996;37 Suppl 1:S74–80 (53 ref.)
Managing patients who have seizure disorders: dental and medical issues. Sanders BJ, et al. **J Am Dent Assoc** 1995 Dec;126(12):1641–7 (18 ref.)
Excitatory amino acid antagonists and the anticonvulsive activity of conventional antiepileptic drugs. Kleinrok Z, et al. **Pol J Pharmacol** 1995 May-Jun;47(3):247–52 (47 ref.)

EPIDEMIOLOGY

Clinical profile of patients with epileptic and nonepileptic seizures. Devinsky O, et al. **Neurology** 1996 Jun; 46(6):1530–3 (29 ref.)

ETIOLOGY

Neurologic complications in critically ill patients. Wijdicks EF. **Anesth Analg** 1996 Aug;83(2):411–9 (60 ref.)
Pseudoseizures: an update. Nash JL. **Compr Ther** 1995 Sep; 21(9):486–91 (29 ref.)
Status epilepticus and acute repetitive seizures in children, adolescents, and young adults: etiology, outcome, and treatment. Mitchell WG. **Epilepsia** 1996;37 Suppl 1:S74–80 (53 ref.)
Psychogenic seizures. Lesser RP. **Neurology** 1996 Jun; 46(6):1499–507 (84 ref.)
[Cerebrovascular manifestations of gastrointestinal diseases] González JL, et al. **Rev Neurol** 1995;23 Suppl 1:S91–4 (43 ref.) **(Spa)**
[Ictus, pregnancy and contraception] Pareja A, et al. **Rev Neurol** 1995;23 Suppl 1:S87–90 (27 ref.) **(Spa)**

METABOLISM

D-1 receptors in neurology and psychiatry an overview. Bédard PJ. **Prog Neuropsychopharmacol Biol Psychiatry** 1995 Sep;19(5):713–26 (73 ref.)

PATHOLOGY

Pathology of seizure disorders. Kim JH. **Neuroimaging Clin N Am** 1995 Nov;5(4):527–45 (93 ref.)
Kainic acid seizures in the rat. Sperk G. **Prog Neurobiol** 1994 Jan;42(1):1–32 (415 ref.)

PHYSIOPATHOLOGY

Negative motor phenomena in generalized epilepsies. A study of atonic seizures. Andermann F, et al. **Adv Neurol** 1995; 67:9–28 (117 ref.)
Physiology of atonic seizures. Blume WT. **Adv Neurol** 1995; 67:173–9 (38 ref.)
Inhibitory mechanisms of epileptic seizure generation. Engel J Jr. **Adv Neurol** 1995;67:157–71 (52 ref.)
Psychogenic seizures and the supplementary sensorimotor area. Kanner AM. **Adv Neurol** 1996;70:461–6 (42 ref.)
Epileptic negative myoclonus. Tassinari CA, et al. **Adv Neurol** 1995;67:181–97 (40 ref.)
Invasive electroencephalography in the evaluation of supplementary motor area seizures. Van Ness PC. **Adv Neurol** 1996;70:319–40 (35 ref.)
The stress protein response and its potential relationship to prolonged seizure activity. Lowenstein DH. **Clin Neuropharmacol** 1995 Apr;18(2):148–58 (64 ref.)
Nonepileptic events. Gates JR, et al. **Semin Neurol** 1995 Jun; 15(2):167–74 (33 ref.)
Unusual seizure types. Swartz BE. **Semin Neurol** 1995 Jun; 15(2):151–7 (61 ref.)
[Neonatal seizures] Holmes GL. **Rev Neurol** 1995;23 Suppl 3:S280–4 (37 ref.) **(Spa)**

PSYCHOLOGY

Psychogenic nonepileptic seizures. Chabolla DR, et al. **Mayo Clin Proc** 1996 May;71(5):493–500 (64 ref.)

SURGERY

The evaluation and image-guided surgical treatment of the patient with a medically intractable seizure disorder. Roberts DW, et al. **Neurosurg Clin N Am** 1996 Apr; 7(2):215–27 (46 ref.)

THERAPY

Office management of common neurologic problems. Moe PG. **Compr Ther** 1995 Sep;21(9):513–8 (16 ref.)
Pseudoseizures: an update. Nash JL. **Compr Ther** 1995 Sep; 21(9):486–91 (29 ref.)

VETERINARY

Treatment of acute isoniazid overdose in dogs. Villar D, et al. **Vet Hum Toxicol** 1995 Oct;37(5):473–7 (50 ref.)
[Seizure disorders in the dog. 1. Clinical features and differential diagnosis] Fischer A. **Tierarztl Prax** 1995 Dec; 23(6):596–602 (30 ref.) (Eng. Abstr.) **(Ger)**
[Significance of electroencephalography for the diagnosis of seizures in dogs] Schütt-Mast I, et al. **Tierarztl Prax** 1996 Apr;24(2):129–36 (6 ref.) (Eng. Abstr.) **(Ger)**

SEIZURES, FEBRILE see **CONVULSIONS, FEBRILE**

E-SELECTIN

ANALYSIS

Cytokines, adhesion molecules (E-selectin and VCAM-1) and graft-versus-host disease. Lange A, et al. **Arch Immunol Ther Exp (Warsz)** 1995;43(2):99-105 (23 ref.)

METABOLISM

Studies on selectin-carbohydrate interactions. Jacob GS, et al. **Adv Exp Med Biol** 1995;376:283-90 (16 ref.)

PHYSIOLOGY

Creation and characterization of E-selectin- and VCAM-1-deficient mice. Kwee L, et al. **Ciba Found Symp** 1995;189:17-28; discussion 28-34, 77-8 (26 ref.)

L-SELECTIN

PHYSIOLOGY

Leukocyte and endothelial adhesion molecules in ischaemia/reperfusion injuries. Winn RK, et al. **Ciba Found Symp** 1995;189:63-71; discussion 72-6, 77-8 (52 ref.)

Mechanisms of the adult respiratory distress syndrome: selectins. Albert RK. **Thorax** 1995 Sep;50 Suppl 1:S49-52 (53 ref.)

P-SELECTIN

PHYSIOLOGY

P-selectin knockout: a mouse model for various human diseases. Wagner DD. **Ciba Found Symp** 1995;189:2-10; discussion 10-16, 77-8 (43 ref.)

Leukocyte and endothelial adhesion molecules in ischaemia/reperfusion injuries. Winn RK, et al. **Ciba Found Symp** 1995;189:63-71; discussion 72-6, 77-8 (52 ref.)

Platelet activation by polymorphonuclear leukocytes: role of cathepsin G and P-selectin. Cerletti C, et al. **Thromb Haemost** 1995 Jul;74(1):218-23 (82 ref.)

The molecular basis of platelet and endothelial cell interaction with neutrophils and monocytes: role of P-selectin and the P-selectin ligand, PSGL-1. Furie B, et al. **Thromb Haemost** 1995 Jul;74(1):224-7 (56 ref.)

[Platelet (P)-selectin: its basics and clinical implications] Handa M. **Rinsho Ketsueki** 1995 Jul;36(7):638-47 (81 ref.) **(Jpn)**

SELECTINS

BLOOD

[Circulating adhesion molecules and diseases] Ma L, et al. **Chung Hua Nei Ko Tsa Chih** 1995 Jun;34(6):416-9 (20 ref.) **(Chi)**

METABOLISM

Carbohydrate-protein interactions in vascular biology. Nelson RM, et al. **Ann Rev Cell Dev Biol** 1995;11:601-31 (185 ref.)

Selectin-carbohydrate interactions and the initiation of the inflammatory response. Lasky LA. **Annu Rev Biochem** 1995;64:113-39 (150 ref.)

PHYSIOLOGY

The role of cellular adhesion molecules in surgery. Breidahl AF, et al. **Aust N Z J Surg** 1995 Dec;65(12):838-47 (54 ref.)

Leukocyte adhesion molecules. Chapman PT, et al. **Br Med Bull** 1995 Apr;51(2):296-311 (80 ref.)

Lymphocyte migration. A new spin on lymphocyte homing. Mackay C. **Curr Biol** 1995 Jul 1;5(7):733-6 (30 ref.)

Integrins, selectins and CAMs--the 'glue of life'. Froese S, et al. **S Afr Med J** 1994 Nov;84(11):759-64 (27 ref.)

SELECTION (GENETICS)

Tinkering with the tinkerer: pollution versus evolution. Fox GA. **Environ Health Perspect** 1995 May;103 Suppl 4:93-100 (84 ref.)

Natural selection of PAH-degrading bacterial guilds at coal-tar disposal sites. Ghiorse WC, et al. **Environ Health Perspect** 1995 Jun;103 Suppl 5:107-11 (15 ref.)

A "minimal essential Mhc" and an "unrecognized Mhc": two extremes in selection for polymorphism. Kaufman J, et al. **Immunol Rev** 1995 Feb;143:63-88 (84 ref.)

MHC diversity and selection. Takahata N. **Immunol Rev** 1995 Feb;143:225-47 (43 ref.)

Animal selection and breeding techniques that create diseased populations and compromise welfare. Ott RS. **J Am Vet Med Assoc** 1996 Jun 15;208(12):1969-74 (48 ref.)

Liver tumor promotion: a process of natural selection. Jirtle RL. **Prog Clin Biol Res** 1995;391:149-59 (59 ref.)

[Regulatory selection as an alternative to the neutrality theory] Sukhodolets VV. **Genetika** 1995 Dec; 31(12):1589-97 (41 ref.) (Eng. Abstr.) **(Rus)**

SELECTION CRITERIA see **PATIENT SELECTION**

SELEGILINE

THERAPEUTIC USE

Moderate Parkinson's disease. Strategies for maximizing treatment. Silverstein PM. **Postgrad Med** 1996 Jan; 99(1):52-4, 61-3, 67-8, passim (21 ref.)

Canine pituitary-dependent hyperadrenocorticism: a spontaneous animal model for neurodegenerative disorders and their treatment with l-deprenyl. Bruyette DS, et al. **Prog Brain Res** 1995;106:207-15 (30 ref.)

Canine cognitive dysfunction as a model for human age-related cognitive decline, dementia and Alzheimer's disease: clinical presentation, cognitive testing, pathology and response to l-deprenyl therapy. Ruehl WW, et al. **Prog Brain Res** 1995;106:217-25 (32 ref.)

SELENIUM

ADMINISTRATION & DOSAGE

The necessity of selenium substitution in total parenteral nutrition and artificial alimentation. Gramm HJ, et al. **J Trace Elem Med Biol** 1995 Mar;9(1):1-12 (75 ref.)

ANALYSIS

[Selenium] Sakai T, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:858-61 (11 ref.) **(Jpn)**

DEFICIENCY

Selenium and cellular immunity. Evidence that selenoproteins may be encoded in the +1 reading frame overlapping the human CD4, CD8, and HLA-DR genes. Taylor EW. **Biol Trace Elem Res** 1995 Aug-Sep;49(2-3):85-95 (37 ref.)

[Progresses in endemiology in China, 1995] Wang Z, et al. **Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):764-5 (0 ref.) **(Chi)**

[Advances in pathology of 5 endemic diseases in China] Wang F, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1995 Aug;24(4):252-4 (20 ref.) **(Chi)**

[Endemic iodine deficiency in Hungary and possibilities of iodine substitution] Bogye G, et al. **Orv Hetil** 1996 Feb 11;137(6):287-90 (25 ref.) (Eng. Abstr.) **(Hun)**

METABOLISM

Selenium in human lactation. Sanz Alaejos M, et al. **Nutr Rev** 1995 Jun;53(6):159-66 (101 ref.)

PHARMACOLOGY

Modulatory effects of selenium and strontium salts on keratinocyte-derived inflammatory cytokines. Celerier P, et al. **Arch Dermatol Res** 1995;287(7):680-2 (11 ref.)

Effects of selenium and vitamin E on the immune responses of domestic animals. Finch JM, et al. **Res Vet Sci** 1996 Mar;60(2):97-106 (108 ref.)

PHYSIOLOGY

Thyroid hormone deiodinases--a selenoenzyme family acting as gate keepers to thyroid hormone action. Köhrle J. **Acta Med Austriaca** 1996;23(1-2):17-30 (134 ref.)

Selenium and fertility in animals and man--a review. Hansen JC, et al. **Acta Vet Scand** 1996;37(1):19-30 (81 ref.)

Vitamin E and selenium: contrasting and interacting nutritional determinants of host resistance to parasitic and viral infections. Levander OA, et al. **Proc Nutr Soc** 1995 Jul;54(2):475-87 (73 ref.)

THERAPEUTIC USE

Selenium: a quest for better understanding. Badmaev V, et al. **Altern Ther Health Med** 1996 Jul;2(4):59-62, 65-7 (87 ref.)

SELF see **EGO**

SELF ADMINISTRATION

In vivo analysis of the role of dopamine in stimulant and opiate self-administration. Gratton A. **J Psychiatry Neurosci** 1996 Jul;21(4):264-79 (120 ref.)

Patient education and guided self-management plans. Neville R. **Respir Med** 1996 Aug;90(7):385-6 (15 ref.)

SELF ASSESSMENT (PSYCHOLOGY)

An overview of self-reported outcome assessment in dental research. Reisine S. **J Dent Educ** 1996 Jun;60(6):488-93 (25 ref.)

Self-ratings of health: do they also predict change in functional ability? Idler EL, et al. **J Gerontol B Psychol Sci Soc Sci** 1995 Nov;50(6):S344-53 (49 ref.)

SELF CARE

Intermittent catheterisation: simple, safe, and effective but underused. Hunt GM, et al. **BMJ** 1996 Jan 13; 312(7023):103-7 (35 ref.)

Diabetes self-management education. Clement S. **Diabetes Care** 1995 Aug;18(8):1204-14 (114 ref.)

[What are the therapeutic consequences of evaluating hypertensive patients with 24-hour blood pressure monitors and blood pressure self-measurement?] Zweiker R, et al. **Wien Med Wochenschr** 1995;145(15-16):365-72 (74 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Helping patients live with asthma. Rachelefsky GS. **Hosp Pract (Off Ed)** 1995 Nov 15;30(11):51-6, 59-64 (14 ref.)

Hypnosis: teaching children self-regulation. Sugarman LI. **Pediatr Rev** 1996 Jan;17(1):5-11 (35 ref.)

SELF CARE (REHABILITATION) see **ACTIVITIES OF DAILY LIVING**

SELF CONCEPT

see related
BODY IMAGE

Transformative narratives: from victimic to agentic life plots. Polkinghorne DE. **Am J Occup Ther** 1996 Apr; 50(4):299-305 (34 ref.)

The destructiveness of perfectionism. Implications for the treatment of depression. Blatt SJ. **Am Psychol** 1995 Dec; 50(12):1003-20 (175 ref.)

Pattern integrations in young depressed women: Part I. Beeber LS. **Arch Psychiatr Nurs** 1996 Jun;10(3):151-6 (21 ref.)

Social and cognitive approaches to depression: towards a new synthesis. Champion LA, et al. **Br J Clin Psychol** 1995 Nov;34 (Pt 4):485-503 (96 ref.)

Cult membership as a source of self-cohesion: forensic implications. Feldmann TB, et al. **Bull Am Acad Psychiatry Law** 1995;23(2):239-48 (46 ref.)

Self-esteem and cancer: theory and research. Katz MR, et al. **Can J Psychiatry** 1995 Dec;40(10):608-15 (120 ref.)

Reproductive health: a rendezvous with human dignity. Diczfalusy E. **Contraception** 1995 Jul;52(1):1-12 (69 ref.)

Schema model of the self-concept. Stein KF. **Image J Nurs Sch** 1995 Fall;27(3):187-93 (60 ref.)

Theoretical and empirical considerations of resourcefulness. Zauszniewski JA. **Image J Nurs Sch** 1995 Fall;27(3):177-80 (31 ref.)

Embodiment and emplacement: identities, representation and landscape in Sun City retirement communities. Laws G. **Int J Aging Hum Dev** 1995;40(4):253-80 (60 ref.)

Causation and complexity: old lessons, new crusades [comment] Layng TV. **J Behav Ther Exp Psychiatry** 1995 Sep;26(3):249-58 (50 ref.) Comment on: J Behav Ther Exp Psychiatry 1995 Sep;26(3):179-90.

Multiple identities and the integration of personality. Gregg GS. **J Pers** 1995 Sep;63(3):617-41 (35 ref.)

Self-with-other representations and a taxonomy of motives: two approaches to studying persons. Ogilvie DM, et al. **J Pers** 1995 Sep;63(3):643-79 (80 ref.)

Seeing one's self: locating narrative memory in a framework of personality. Singer JA. **J Pers** 1995 Sep;63(3):429-57 (75 ref.)

Familial and ecological correlates of self-esteem in African American children. Walker K, et al. **New Dir Child Dev** 1995 Summer;(68):23-34 (70 ref.)

Self-esteem and obesity in children and adolescents: a literature review. French SA, et al. **Obes Res** 1995 Sep; 3(5):479-90 (74 ref.)

Self-efficacy in pediatric resuscitation: implications for education and performance. Maibach EW, et al. **Pediatrics** 1996 Jan;97(1):94-9 (33 ref.)

Issues in personality as diathesis for depression: the case of sociotropy-dependency and autonomy-self-criticism. Coyne JC, et al. **Psychol Bull** 1995 Nov;118(3):358-78 (125 ref.)

Relation of threatened egotism to violence and aggression: the dark side of high self-esteem. Baumeister RF, et al. **Psychol Rev** 1996 Jan;103(1):5-33 (175 ref.)

A closer look at self-image in male foster care adolescents. Lyman SB, et al. **Soc Work** 1996 Jan;41(1):85-96 (70 ref.)

[White walls for black holes: essay on graffiti psychopathology] Catheline-Antipoff N, et al. **Psychiatr Enfant** 1995;38(2):625-53 (16 ref.) (Eng. Abstr.) **(Fre)**

SELF-DESTRUCTIVE BEHAVIOR see **SELF-INJURIOUS BEHAVIOR**

SELF DETERMINATION see **FREEDOM**

SELF DISCLOSURE

Contrasting self-report screens for alcohol problems: a review. Maisto SA, et al. **Alcohol Clin Exp Res** 1995 Dec; 19(6):1510-6 (24 ref.)

Forming a consortium: a design for interagency collaboration in the delivery of service following the disclosure of incest. Peck JS, et al. **Fam Process** 1995 Sep;34(3):287-302 (53 ref.)

Interviewing the young child sexual abuse victim. Lewin L. **J Psychosoc Nurs Ment Health Serv** 1995 Jul;33(7):5-10 (26 ref.)

Assessing the reliability and validity of self-reported risk behavior. Gibson DR, et al. **NIDA Res Monogr** 1994;

SELF DISCLOSURE

143:218–36 (13 ref.)

SELF ESTEEM see **SELF CONCEPT**

SELF-EXAMINATION

Applying cognitive-social theory to health-protective behavior: breast self-examination in cancer screening. Miller SM, et al. **Psychol Bull** 1996 Jan;119(1):70–94 (263 ref.)

SELF-HELP GROUPS

Latinos and mutual support group: a case for considering culture. Simoni JM, et al. **Am J Orthopsychiatry** 1995 Jul; 65(3):440–5 (26 ref.)

[Significance of support groups in the integrated management of chronically ill patients] Rodríguez-Agudelo Y, et al. **Gac Med Mex** 1995 May–Jun;131(3):329–34 (20 ref.) (Eng. Abstr.) **(Spa)**

SELF-INJURIOUS BEHAVIOR

COMPLICATIONS

Self-induced pneumoparotitis. Goguen LA, et al. **Arch Otolaryngol Head Neck Surg** 1995 Dec;121(12):1426–9 (28 ref.)

DRUG THERAPY

Self-injurious behavior: pathophysiology and implications for treatment. Pies RW, et al. **J Clin Psychiatry** 1995 Dec; 56(12):580–8 (75 ref.)

The use of opiate antagonists for recurrent self-injurious behavior. Buzan RD, et al. **J Neuropsychiatry Clin Neurosci** 1995 Fall;7(4):437–44 (86 ref.)

ETIOLOGY

Dopamine, serotonin and tachykinin in self-injurious behavior. Sivam SP. **Life Sci** 1996 May 24;58(26):2367–75 (66 ref.)

PHYSIOPATHOLOGY

Self-injurious behavior: pathophysiology and implications for treatment. Pies RW, et al. **J Clin Psychiatry** 1995 Dec; 56(12):580–8 (75 ref.)

PREVENTION & CONTROL

Physical restraint procedures for managing challenging behaviours presented by mentally retarded adults and children. Harris J. **Res Dev Disabil** 1996 Mar–Apr; 17(2):99–134 (52 ref.)

PSYCHOLOGY

Experimental models for aggression and inventories for the assessment of aggressive and autoaggressive behavior. Netter P, et al. **Pharmacopsychiatry** 1995 Oct;28 Suppl 2:58–63 (21 ref.)

Outward and inward directed aggressiveness: the interaction between violence and suicidality. Plutchik R. **Pharmacopsychiatry** 1995 Oct;28 Suppl 2:47–57 (58 ref.)

[Self-injury behavior] Rechenberger I. **Gynakologe** 1995 Dec; 28(6):446–51 (13 ref.) **(Ger)**

THERAPY

Annotation: self-injurious behaviour in children with learning disabilities: recent advances in assessment and intervention. Oliver C. **J Child Psychol Psychiatry** 1995 Sep;36(6):909–27 (100 ref.)

SELF-INSTRUCTION PROGRAMS see **PROGRAMMED INSTRUCTION**

SELF-INSTRUCTION PROGRAMS, COMPUTERIZED see **COMPUTER-ASSISTED INSTRUCTION**

SELF-MONITORING, BLOOD GLUCOSE see **BLOOD GLUCOSE SELF-MONITORING**

SELF MUTILATION

ETIOLOGY

Male genital self-mutilation. Romilly CS, et al. **Br J Hosp Med** 1996 Apr 3–16;55(7):427–31 (24 ref.)

SELF PERCEPTION see **SELF CONCEPT**

SELF TOLERANCE

see related
AUTOIMMUNE DISEASES
CLONAL ANERGY
CLONAL DELETION

Development and evolutionary aspects of thymic T cell education to neuroendocrine self. Geenen V, et al. **Acta Haematol** 1996;95(3–4):263–7 (27 ref.)

Self-tolerance checkpoints in B lymphocyte development. Goodnow CC, et al. **Adv Immunol** 1995;59:279–368 (475 ref.)

Antigen receptor 'capacity' and the sensitivity of self-tolerance. Nemazee D. **Immunol Today** 1996 Jan; 17(1):25–9 (28 ref.)

Simple developmental programs of gene expression and cellular composition of lymphoid organs at the origin of natural tolerance. Coutinho A. **Res Immunol** 1995 May–Jun;146(4–5):321–32 (0 ref.)

Thoughtful cruises in oceans of peptides and T cells. Kourilsky P. **Res Immunol** 1995 May–Jun;146(4–5):309–20 (33 ref.)

Inhibitory effects of class I molecules on murine NK cells: speculations on function, specificity and self-tolerance. Raulet DH, et al. **Semin Immunol** 1995 Apr;7(2):103–7 (24 ref.)

Missing self recognition by natural killer cells in MHC class I transgenic mice. A 'receptor calibration' model for how effector cells adapt to self. Sentman CL, et al. **Semin Immunol** 1995 Apr;7(2):109–19 (45 ref.)

IMMUNOLOGY

Role of viruses in the loss of tolerance to self-antigens and in autoimmune diseases. von Herrath MG, et al. **Trends Microbiol** 1995 Nov;3(11):424–30 (61 ref.)

SELLA TURCICA

Gangliocytomas of the sellar region—a review. Puchner MJ, et al. **Exp Clin Endocrinol Diabetes** 1995;103(3):129–49 (115 ref.)

Intrasellar abscess following transsphenoidal surgery. Henegar MM, et al. **Surg Neurol** 1996 Feb;45(2):183–8 (24 ref.)

[Double localization of intracranial germinoma. Apropos of a case] Alifdal M, et al. **Neurochirurgie** 1995;41(6):424–8 (23 ref.) (Eng. Abstr.) **(Fre)**

[Sellar metastases simulating the Tolosa-Hunt syndrome] Aprile I, et al. **Radiol Med (Torino)** 1996 Mar;91(3):311–3 (9 ref.) **(Ita)**

SEMANTICS

The medicalization of race: scientific legitimization of a flawed social construct [see comments] Witzig R. **Ann Intern Med** 1996 Oct 15;125(8):675–9 (57 ref.) Comment in: Ann Intern Med 1996 Oct 15;125(8):688–9.

Terms of address: implications for nursing. Bowie I. **J Adv Nurs** 1996 Jan;23(1):113–9 (17 ref.)

Neuroanatomical correlates of category-specific semantic disorders: a critical survey. Gainotti G, et al. **Memory** 1995 Sep–Dec;3(3–4):247–64 (50 ref.)

Imagery, concreteness, emotionality, meaningfulness, and pleasantness of words. Campos A. **Percept Mot Skills** 1995 Jun;80(3 Pt 1):867–80 (50 ref.)

The emotional Stroop task and psychopathology. Williams JM, et al. **Psychol Bull** 1996 Jul;120(1):3–24 (95 ref.)

SEMEN

see related
SPERM BANKS
SPERMATOZOA

Hemospermia: diagnosis and management. Mulhall JP, et al. **Urology** 1995 Oct;46(4):463–7 (51 ref.)

[Hemospermia associated with a urogenital sinus cyst: diagnostic contribution of MRI. Report a case] Cinque T, et al. **Radiol Med (Torino)** 1995 Dec;90(6):840–2 (8 ref.) **(Ita)**

CHEMISTRY

Forensic applications of genetic polymorphisms detected in human body fluids (urine, semen and blood). Kishi K, et al. **Forensic Sci Int** 1996 Jun 28;80(1–2):89–97 (55 ref.)

CYTOLOGY

Seminal leukocytes: passengers, terrorists or good samaritans? Aitken RJ, et al. **Hum Reprod** 1995 Jul;10(7):1736–9 (30 ref.)

IMMUNOLOGY

Human seminal plasma anaphylaxis (HSPA): case report and literature review. Ebo DG, et al. **Allergy** 1995 Sep; 50(9):747–50 (30 ref.)

Immunosuppressive mechanisms in semen: implications for contraception. Kelly RW. **Hum Reprod** 1995 Jul; 10(7):1686–93 (137 ref.)

METABOLISM

Do environmental estrogens contribute to the decline in male reproductive health? Jensen TK, et al. **Clin Chem** 1995 Dec; 41(12 Pt 2):1896–901 (68 ref.)

MICROBIOLOGY

Epididymal histoplasmosis diagnosed by isolation of Histoplasma capsulatum from semen. Randhawa HS, et al. **Mycopathologia** 1995 Sep;131(3):173–7 (20 ref.)

PHYSIOLOGY

Declining semen quality and increasing incidence of abnormalities in male reproductive organs—fact or fiction? Giwercman A. **Hum Reprod** 1995 Oct;10 Suppl 1:158–64 (44 ref.)

Computer assisted semen analysis systems: sperm motility assessment. Irvine DS. **Hum Reprod** 1995 Oct;10 Suppl 1:53–9 (43 ref.)

SEMEN PRESERVATION

see related
SPERM BANKS

Strategies in frozen donor semen procreation. Le Lannou D, et al. **Hum Reprod** 1995 Jul;10(7):1765–74 (90 ref.)

METHODS

Reproductive issues for men with cancer: technology and nursing management. Sweet V, et al. **Oncol Nurs Forum** 1996 Jan–Feb;23(1):51–8 (53 ref.)

Recent developments and concepts in the cryopreservation of spermatozoa and the assessment of their post-thawing function. Watson PF. **Reprod Fertil Dev** 1995;7(4):871–91 (155 ref.)

[The creation of genetic cryobanks and the use of the methods of developmental biology as a means for preserving rare animal species. I. The cryopreservation of the sperm of wild mammals] Rott NN. **Ontogenez** 1995 Jul–Aug;26(4):270–81 (59 ref.) (Eng. Abstr.) **(Rus)**

SEMICARBAZIDES

CHEMISTRY

Stereochemistry and cofactor identity status of semicarbazide-sensitive amine oxidases. Palcic MM, et al. **Prog Brain Res** 1995;106:41–7 (28 ref.)

METABOLISM

Semicarbazide-sensitive amine oxidases: some biochemical properties and general considerations. Buffoni F. **Prog Brain Res** 1995;106:323–31 (62 ref.)

Some aspects of the pathophysiology of semicarbazide-sensitive amine oxidase enzymes. Callingham BA, et al. **Prog Brain Res** 1995;106:305–21 (109 ref.)

Substrate-specificity of mammalian tissue-bound semicarbazide-sensitive amine oxidase. Lyles GA. **Prog Brain Res** 1995;106:293–303 (82 ref.)

SEMICIRCULAR CANALS

ANATOMY & HISTOLOGY

Balance and equilibrium, I: The vestibule and semicircular canals. Swartz JD, et al. **AJNR Am J Neuroradiol** 1996 Jan;17(1):17–21 (12 ref.)

PHYSIOLOGY

The caloric stimulus: mechanisms of heat transfer [see comments] O'Neill G. **Br J Audiol** 1995 Apr;29(2):87–94 (21 ref.) Comment in: Br J Audiol 1995 Apr;29(2):83–6.

SEMICONDUCTORS

DNA on a chip. Ross DW. **Arch Pathol Lab Med** 1996 Jun; 120(6):604–5 (4 ref.)

SEMILUNAR CARTILAGES see **MENISCI, TIBIAL**

SEMILUNAR GANGLION see **TRIGEMINAL GANGLION**

SEMINAL PLASMA see **SEMEN**

SEMINAL VESICLES

Ectopic ureter opening into the seminal vesicle in an infant: a case report and review of the Japanese literature. Terai A, et al. **Int J Urol** 1995 May;2(2):128–31 (17 ref.)

Seminal vesicle abscess: a case report and review of literature. Pandey P, et al. **Scand J Urol Nephrol** 1995 Dec;29(4):521–4 (14 ref.)

[Cystadenoma of the seminal vesicles. A case report] D'Erme M, et al. **Radiol Med (Torino)** 1996 Mar;91(3):322–4 (8 ref.) **(Ita)**

ABNORMALITIES

A complex cystic dysplastic urogenital anomaly—an odd presentation. Singh G, et al. **Int Urol Nephrol** 1995; 27(6):687–90 (5 ref.)

CYTOLOGY

Dynamics of the seminal vesicle epithelium. Mata LR. **Int Rev Cytol** 1995;160:267–302 (150 ref.)

PATHOLOGY

[Malacoplakia of the prostate and seminal vesicle. Ultrastructural study and review of the literature] Sánchez Chapado M, et al. **Arch Esp Urol** 1995 Oct;48(8):775–8 (34 ref.) (Eng. Abstr.) **(Spa)**

SEMINIFEROUS EPITHELIUM

PATHOLOGY

Increased follicle stimulating hormone in infertile men. Is increased plasma FSH always due to damaged germinal epithelium? Martin-du-Pan RC, et al. **Hum Reprod** 1995 Aug;10(8):1940-5 (82 ref.)

SEMINIFEROUS TUBULES

CYTOLOGY

Peritubular myoid cells in the testis: their structure and function. Maekawa M, et al. **Arch Histol Cytol** 1996 Mar; 59(1):1-13 (110 ref.)

SEMINOMA

COMPLICATIONS

Testicular germ cell tumors in patients with human immunodeficiency virus infection. Hentrich MU, et al. **Cancer** 1996 May 15;77(10):2109-16 (55 ref.)

[A case of testicular tumor associated with the contralateral undescended testis] Ueda H, et al. **Hinyokika Kiyo** 1995 Dec;41(12):1015-8 (20 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

[Retroperitoneal seminoma. A case report and literature review] Troisfontaines E, et al. **Acta Urol Belg** 1996 Mar; 64(1):55-9 (24 ref.) (Eng. Abstr.) **(Fre)**

[Embryonal carcinoma and anaplastic seminoma of the testis: diagnostic difficulties] Vallat AV, et al. **Arch Anat Cytol Pathol** 1996;44(2-3):109-12 (10 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

Therapy-related acute promyelocytic leukemia with t(15;17)(q22;q12) following chemotherapy with drugs targeting DNA topoisomerase II. A report of two cases and a review of the literature [see comments] Hoffmann L, et al. **Ann Oncol** 1995 Oct;6(8):781-8 (32 ref.) Comment in: Ann Oncol 1995 Oct;6(8):751-3.

[A case of secondary leukemia in anaplastic seminoma patient treated with long-term chemotherapy] Kamai T, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 May;87(5):875-9 (12 ref.) (Eng. Abstr.) **(Jpn)**

ETIOLOGY

Testicular seminoma originating in an undescended testis in a renal allograft recipient. Modlin CS, et al. **Urology** 1996 Jul;48(1):145-8 (9 ref.)

[Cryptorchidism and testicular cancer] Pereira Arias JG, et al. **Arch Esp Urol** 1995 Nov;48(9):959-61 (12 ref.) (Eng. Abstr.) **(Spa)**

PATHOLOGY

[Double cancers of renal cell carcinoma and testicular seminoma: a case report] Nozawa M, et al. **Hinyokika Kiyo** 1995 Dec;41(12):999-1002 (17 ref.) (Eng. Abstr.) **(Jpn)**

RADIOTHERAPY

Pericardial angiosarcoma after mediastinal irradiation for seminoma. A case report and a review of the literature. Killion MJ, et al. **Cancer** 1996 Aug 15;78(4):912-7 (30 ref.)

THERAPY

Diagnosis and treatment of urological malignancy: the testes. Wilkins M, et al. **Br J Hosp Med** 1996 Feb 21-Mar 5; 55(4):199-203 (23 ref.)

[Treatment of stage-I seminoma. Critical review] Santini D, et al. **Minerva Urol Nefrol** 1995 Mar;47(1):31-8 (51 ref.) **(Ita)**

SEMIOCHEMICALS see **PHEROMONES**

SEMISYNTHETIC VACCINES see **VACCINES, SYNTHETIC**

SENDAI VIRUS see **PARAINFLUENZA VIRUS TYPE 1**

SENECIO

see related
PYRROLIZIDINE ALKALOIDS

SENECIO ALKALOIDS see **PYRROLIZIDINE ALKALOIDS**

SENESCENCE see **AGING**

SENESCENCE, CELLULAR see **CELL AGING**

SENILE OSTEOPOROSIS see **OSTEOPOROSIS**

SENNA

[The mechanism of action of sennosides] Lemli J. **Ann Gastroenterol Hepatol (Paris)** 1996 Mar-Apr; 32(2):109-12 (29 ref.) (Eng. Abstr.) **(Fre)**

[Mechanism of action of sennosides] Lemli J. **Bull Acad Natl Med** 1995 Nov;179(8):1605-11 (29 ref.) (Eng. Abstr.) **(Fre)**

SENSATION

see related
PERCEPTION

PHYSIOLOGY

Microsurgical reconstruction of sensory skin. Brunelli GA, et al. **Ann Acad Med Singapore** 1995 Jul;24(4 Suppl):108-12 (14 ref.)

Sensations and brain processes. Flohr H. **Behav Brain Res** 1995 Nov;71(1-2):157-61 (13 ref.)

Neurobiology of visceral afferent neurons: neuroanatomy, functions, organ regulations and sensations. Jänig W. **Biol Psychol** 1996 Jan 5;42(1-2):29-51 (105 ref.)

Paradoxical clinical consequences of peripheral nerve injury: a review of anatomical, neurophysiological and psychological mechanisms. McAllister RM, et al. **Br J Plast Surg** 1995 Sep;48(6):384-95 (159 ref.)

Mechanisms of oral sensation. Capra NF. **Dysphagia** 1995 Fall;10(4):235-47 (72 ref.)

Gastrointestinal sensation. Mechanisms and relation to functional gastrointestinal disorders. Camilleri M, et al. **Gastroenterol Clin North Am** 1996 Mar;25(1):247-58 (41 ref.)

Clinical neurophysiology of cortical sensorimotor function: yesterday, today, and tomorrow. Aminoff MJ. **J Clin Neurophysiol** 1996 May;13(3):219-26 (60 ref.)

Transfer of coded information from sensory to motor networks. Salinas E, et al. **J Neurosci** 1995 Oct; 15(10):6461-74 (80 ref.)

Perspectives on the role of afferent signals in control of motor neuroprostheses. Johnson KO, et al. **Med Eng Phys** 1995 Oct;17(7):481-96 (99 ref.)

On the origin of consciousness, a postulate and its corollary. Cabanac M. **Neurosci Biobehav Rev** 1996;20(1):33-40 (50 ref.)

Identifying patients with diabetes mellitus who are at risk for lower-extremity complications: use of Semmes-Weinstein monofilaments. Mueller MJ. **Phys Ther** 1996 Jan;76(1):68-71 (15 ref.)

Mechanosensation and the DEG/ENaC ion channels [comment] Corey DP, et al. **Science** 1996 Jul 19; 273(5273):323-4 (21 ref.) Comment on: Science 1996 Jul 19;273(5273):361-4.

[The perception of muscle loading and the role of locomotor and respiratory sensation] Breslav IS. **Fiziol Zh Im I M Sechenova** 1994 Dec;80(12):10-20 (69 ref.) **(Rus)**

[The neural mechanisms of the autonomic responses evoked by somatic sensory stimulation] Sato A. **Fiziol Zh Im I M Sechenova** 1995 Nov;81(11):56-69 (27 ref.) **(Rus)**

SENSATION DISORDERS

COMPLICATIONS

T-cell-mediated ganglionitis associated with acute sensory neuronopathy. Hainfellner JA, et al. **Ann Neurol** 1996 Apr; 39(4):543-7 (20 ref.)

DIAGNOSIS

Investigations of disorders of balance. Rudge P, et al. **J Neurol Neurosurg Psychiatry** 1995 Dec;59(6):568-78 (70 ref.)

DRUG THERAPY

Neurotrophic factors: ready to go? Schätzl HM. **Trends Neurosci** 1995 Nov;18(11):463-4 (19 ref.)

EPIDEMIOLOGY

An epidemic of optic neuropathy and painful sensory neuropathy in Cuba: clinical aspects. Thomas PK, et al. **J Neurol** 1995 Oct;242(10):629-38 (53 ref.)

ETIOLOGY

Peripheral neuropathy: an often-overlooked cause of falls in the elderly. Richardson JK, et al. **Postgrad Med** 1996 Jun;99(6):161-72 (20 ref.)

PHYSIOPATHOLOGY

Orofacial phantom pain: theory and phenomenology. Marbach JJ. **J Am Dent Assoc** 1996 Feb;127(2):221-9 (48 ref.)

Peripheral neuropathy: an often-overlooked cause of falls in the elderly. Richardson JK, et al. **Postgrad Med** 1996 Jun;99(6):161-72 (20 ref.)

SENSE ORGANS

see related
RECEPTORS, SENSORY

GROWTH & DEVELOPMENT

[Polyunsaturated fatty acids and cerebral-sensory development in infants (editorial)] Ghisolfi J. **Arch Pediatr** 1995 Sep;2(9):825-30 (15 ref.) **(Fre)**

PHYSIOPATHOLOGY

Structural changes after lightning strike, with special emphasis on special sense orifices as portals of entry. Andrews C. **Semin Neurol** 1995 Sep;15(3):296-303 (18 ref.)

SENSITIVITY AND SPECIFICITY

Sensitivity analysis in economic evaluation: a review of published studies. Briggs A, et al. **Health Econ** 1995 Sep-Oct;4(5):355-71 (109 ref.)

The discrepancy in discrepant analysis. Hadgu A. **Lancet** 1996 Aug 31;348(9027):592-3 (7 ref.)

SENSITIVITY, CONTACT see **DERMATITIS, CONTACT**

SENSITIZATION, IMMUNOLOGIC see **IMMUNIZATION**

SENSORY GANGLIA see **GANGLIA, SENSORY**

SENSORY MOTOR PERFORMANCE see **PSYCHOMOTOR PERFORMANCE**

SENSORY THRESHOLDS

PHYSIOLOGY

Encoding with bursting, subthreshold oscillations, and noise in mammalian cold receptors. Longtin A, et al. **Neural Comput** 1996 Feb 15;8(2):215-55 (75 ref.)

Perception, personality, and respiratory control in life-threatening asthma. Gibson GJ. **Thorax** 1995 Sep;50 Suppl 1:S2-4 (15 ref.)

SENTINEL HEALTH EVENT see **SENTINEL SURVEILLANCE**

SENTINEL SURVEILLANCE

Problems in interpreting HIV sentinel seroprevalence studies. Strickler H, et al. **Ann Epidemiol** 1995 Nov;5(6):447-54 (51 ref.)

Sentinel screening for human immunotoxicity. Descotes J, et al. **Arch Toxicol Suppl** 1996;18:29-33 (13 ref.)

SEOUL VIRUS see **HANTAVIRUS**

SEPSIS

Treatment of sepsis and septic shock: a review. Wiessner WH, et al. **Heart Lung** 1995 Sep-Oct;24(5):380-92; quiz 392-3 (126 ref.)

Sepsis during pregnancy. Simpson KR. **J Obstet Gynecol Neonatal Nurs** 1995 Jul-Aug;24(6):550-6 (26 ref.)

Nitric oxide, sepsis, and arginine metabolism. Kelly E, et al. **JPEN J Parenter Enteral Nutr** 1995 May-Jun; 19(3):234-8 (52 ref.)

[Sepsis: pending subject for the XXI century] Gómez-Jiménez J, et al. **Med Clin (Barc)** 1995 Sep 16; 105(8):304-7 (59 ref.) **(Spa)**

BLOOD

Alterations in cell signaling and related effector functions in T lymphocytes in burn/trauma/septic injuries [editorial] Sayeed MM. **Shock** 1996 Mar;5(3):157-66 (111 ref.)

COMPLICATIONS

Prognostic importance of vital organ dysfunction in sepsis. Suter PM, et al. **Contrib Nephrol** 1995;116:16-21 (36 ref.)

Sepsis or ischemia in experimental acute renal failure: what have we learned? Johnson JP, et al. **New Horiz** 1995 Nov; 3(4):608-14 (79 ref.)

[Fulminant rhabdomyolysis secondary to Streptococcus viridans sepsis] Pérez Navero JL, et al. **An Esp Pediatr** 1996 Mar;44(3):282-4 (20 ref.) **(Spa)**

DIAGNOSIS

[Interstitial pneumonia and sepsis due to a Pasteurella multocida infection] Schlichthaar H, et al. **Dtsch Med Wochenschr** 1995 Nov 17;120(46):1582-6 (19 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Impact of the resin blood culture medium on the treatment of critically ill patients. Levin PD, et al. **Crit Care Med** 1996 May;24(5):797-801 (24 ref.)

Is it time to reposition vasopressors and inotropes in sepsis? Rudis MI, et al. **Crit Care Med** 1996 Mar;24(3):525-37 (74 ref.)

Coagulation inhibitor substitution during sepsis. Fourrier F, et al. **Intensive Care Med** 1995 Nov;21 Suppl 2:S264-8 (34 ref.)

Why sepsis trials fail. Bone RC. **JAMA** 1996 Aug 21; 276(7):565-6 (28 ref.)

SEPSIS

ENZYMOLOGY

Regulation and function of inducible nitric oxide synthase during sepsis and acute inflammation. Wong JM, et al. **Adv Pharmacol** 1995;34:155–70 (68 ref.)

Nitric oxide synthases: regulation in disease. Wong GK, et al. **Nephrol Dial Transplant** 1996 Jan;11(1):215–20 (62 ref.)

ETIOLOGY

Pathogenesis of sepsis with central venous catheter use: alternate locus-related versus central venous catheter-related sepsis. Chathas MK, et al. **J Obstet Gynecol Neonatal Nurs** 1995 Oct;24(8):725–33 (27 ref.)

Evaluation of the abdomen in sepsis of unknown origin. McDowell RK, et al. **Radiol Clin North Am** 1996 Jan; 34(1):177–90 (58 ref.)

Catheter sepsis: the central venous line Achilles' heel. Wiener ES. **Semin Pediatr Surg** 1995 Nov;4(4):207–14 (56 ref.)

[Quality assurance of bacterial incidents associated with blood transfusion] Noël L. **Transfus Clin Biol** 1996; 3(1):35–42 (28 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

The immuno-inflammatory cascade. Galley HF, et al. **Br J Anaesth** 1996 Jul;77(1):11–6 (24 ref.)

Coagulation inhibitor substitution during sepsis. Fourrier F, et al. **Intensive Care Med** 1995 Nov;21 Suppl 2:S264–8 (34 ref.)

Is sepsis a mediator-inhibitor mismatch? Lamy M, et al. **Intensive Care Med** 1995 Nov;21 Suppl 2:S250–7 (55 ref.)

Time course of cytokine levels in sepsis. Thijs LG, et al. **Intensive Care Med** 1995 Nov;21 Suppl 2:S258–63 (31 ref.)

METABOLISM

Muscle protein metabolism during sepsis. Hasselgren PO. **Biochem Soc Trans** 1995 Nov;23(4):1019–25 (46 ref.)

MICROBIOLOGY

Candida albicans septic thrombosis of the right atrium is associated with a central venous catheter. Kentos A, et al. **Clin Infect Dis** 1995 Aug;21(2):440–2 (18 ref.)

Stenotrophomonas maltophilia: an unusual cause of biliary sepsis. Papadakis KA, et al. **Clin Infect Dis** 1995 Oct; 21(4):1032–4 (9 ref.)

Flavimonas oryzihabitans sepsis in children. Reed RP. **Clin Infect Dis** 1996 Apr;22(4):733–4 (10 ref.)

Impact of the resin blood culture medium on the treatment of critically ill patients. Levin PD, et al. **Crit Care Med** 1996 May;24(5):797–801 (24 ref.)

Burkholderia cepacia sepsis in neonates. Kahyaoglu O, et al. **Pediatr Infect Dis J** 1995 Sep;14(9):815–6 (9 ref.)

PHYSIOPATHOLOGY

Lung-liver interactions in sepsis and multiple organ failure syndrome. Matuschak GM. **Clin Chest Med** 1996 Mar; 17(1):83–98 (191 ref.)

Sepsis/septic shock: participation of the microcirculation: an abbreviated review [see comments] Hinshaw LB. **Crit Care Med** 1996 Jun;24(6):1072–8 (75 ref.) Comment in: Crit Care Med 1996 Jun;24(6):918.

The cellular response in sepsis. Pajkrt D, et al. **Curr Top Microbiol Immunol** 1996;216:119–32 (40 ref.)

Clinically accessible cell signaling: second messengers in sepsis and trauma. Rehring TF, et al. **J Surg Res** 1996 Jan; 60(1):270–7 (37 ref.)

How 'dry' must the septic patient be kept – potentially conflicting interests of lung and peripheral circulation? [editorial] Reinhart K. **Nephrol Dial Transplant** 1996 Jul; 11(7):1241–2 (12 ref.)

Calcium: a regulator of the inflammatory response in endotoxemia and sepsis. Hotchkiss RS, et al. **New Horiz** 1996 Feb;4(1):58–71 (70 ref.)

Sepsis and multiple organ dysfunction syndrome: a clinical-mechanistic overview. Livingston DH, et al. **New Horiz** 1995 May;3(2):257–66 (93 ref.)

Alterations in calcium signaling and cellular responses in septic injury. Sayeed MM. **New Horiz** 1996 Feb;4(1):72–86 (114 ref.)

[The physiopathology of sepsis. Current concepts] Bauer M. **Anaesthesist** 1996 Apr;45(4):312–22 (49 ref.) (Eng. Abstr.) **(Ger)**

PREVENTION & CONTROL

Manipulation of local and systemic host defence in the prevention of perioperative sepsis. Windsor AC, et al. **Br J Surg** 1995 Nov;82(11):1460–7 (128 ref.)

SURGERY

[Septic complications in emergency surgery: our experience and a review of the literature] Bianchi G, et al. **G Chir** 1995 Aug-Sep;16(8–9):345–51 (45 ref.) (Eng. Abstr.) **(Ita)**

THERAPY

Plasmapheresis in severe sepsis or septic shock. Stegmayr BG. **Blood Purif** 1996;14(1):94–101 (66 ref.)

Supplemental immune globulins in sepsis: a critical appraisal. Werdan K, et al. **Clin Exp Immunol** 1996 May;104 Suppl 1:83–90 (48 ref.)

Nutritional support of the septic patient. Wojnar MM, et al. **Crit Care Clin** 1995 Jul;11(3):717–33 (59 ref.)

Influence of different volume therapies and pentoxifylline infusion on circulating soluble adhesion molecules in critically ill patients. Boldt J, et al. **Crit Care Med** 1996 Mar;24(3):385–91 (39 ref.)

Endotoxin-based molecular strategies for the prevention and treatment of gram-negative sepsis and septic shock. Pollack M, et al. **Curr Top Microbiol Immunol** 1996;216:275–97 (185 ref.)

Bacteremia and sepsis. Ferguson KL, et al. **Emerg Med Clin North Am** 1996 Feb;14(1):185–95 (36 ref.)

Plasmapheresis in the therapy of septic disease. Reinke P. **Int J Artif Organs** 1996 Feb;19(2):127–8 (11 ref.)

New therapeutic approaches in sepsis: a critical review. Eidelman LA, et al. **Intensive Care Med** 1995 Nov;21 Suppl 2:S269–72 (18 ref.)

Pharmacologic treatment of neonatal sepsis: antimicrobial agents and immunotherapy. Cavaliere TA. **J Obstet Gynecol Neonatal Nurs** 1995 Sep;24(7):647–58 (77 ref.)

How 'dry' must the septic patient be kept – potentially conflicting interests of lung and peripheral circulation? [editorial] Reinhart K. **Nephrol Dial Transplant** 1996 Jul; 11(7):1241–2 (12 ref.)

Continuous hemofiltration as blood purification in sepsis. Bellomo R. **New Horiz** 1995 Nov;3(4):732–7 (30 ref.)

Hypertonic volume therapy: feasibility in the prevention and treatment of multiple organ failure and sepsis. Monteiro Pacheco A Jr, et al. **Rev Paul Med** 1995 Nov-Dec; 113(6):1053–60 (53 ref.)

Blood component and immunotherapy in neonatal sepsis. Sweetman RW, et al. **Transfus Med Rev** 1995 Jul;9(3):251–9 (47 ref.)

[Neonatal bacterial sepsis. II. New developments in treatment and prevention] Pecheva N. **Akush Ginekol (Sofiia)** 1994; 33(2):33–5 (52 ref.) **(Bul)**

[Cytokine inhibitors in intensive care] Villard J, et al. **Rev Mal Respir** 1995;12(4):335–42 (66 ref.) (Eng. Abstr.) **(Fre)**

[Emergency therapy of sepsis] Funada H. **Nippon Naika Gakkai Zasshi** 1995 Nov 10;84(11):1870–5 (6 ref.) **(Jpn)**

SEPSIS SYNDROME

see related

RESPIRATORY DISTRESS SYNDROME, ADULT

Infection, the gut and the development of the multiple organ dysfunction syndrome. Nieuwenhuijzen GA, et al. **Eur J Surg** 1996 Apr;162(4):259–73 (185 ref.)

[Cytokines during the perisurgical period] Kawamura T. **Masui** 1996 May;45(5):536–46 (29 ref.) (Eng. Abstr.) **(Jpn)**

[The inflammatory response syndrome] Bojić I. **Vojnosanit Pregl** 1994 Jul-Aug;51(4):314–20 (71 ref.) **(Scr)**

COMPLICATIONS

Sepsis and the systemic inflammatory response syndrome: neuromuscular manifestations. Bolton CF. **Crit Care Med** 1996 Aug;24(8):1408–16 (82 ref.)

DIAGNOSIS

[Sepsis grading should be defined. Staging may result in better monitoring] Sjölin J. **Lakartidningen** 1996 Mar 13; 93(11):995–8 (15 ref.) **(Swe)**

DRUG THERAPY

Is it time to reposition vasopressors and inotropes in sepsis? Rudis MI, et al. **Crit Care Med** 1996 Mar;24(3):525–37 (74 ref.)

[Analgesia and sedation on patients with sepsis syndrome] Adams HA. **Anaesthesist** 1995 Dec;44 Suppl 3:S573–9 (30 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Pathogenesis of sepsis syndrome: possible relevance of pore-forming bacterial toxins. Bhakdi S, et al. **Curr Top Microbiol Immunol** 1996;216:101–18 (64 ref.)

Tumor necrosis factor and the systemic inflammatory response syndrome. Brouckaert P, et al. **Curr Top Microbiol Immunol** 1996;216:167–87 (129 ref.)

Sepsis, SIRS, and MODS: what's in a name? Nathens AB, et al. **World J Surg** 1996 May;20(4):386–91 (46 ref.)

IMMUNOLOGY

Immunologic dissonance: a continuing evolution in our understanding of the systemic inflammatory response syndrome (SIRS) and the multiple organ dysfunction syndrome (MODS) [see comments] Bone RC. **Ann Intern Med** 1996 Oct 15;125(8):680–7 (101 ref.) Comment in: Ann Intern Med 1996 Oct 15;125(8):690–1.

Sepsis and cytokines: current status. Blackwell TS, et al. **Br J Anaesth** 1996 Jul;77(1):110–7 (72 ref.)

Malnutrition, injury, and the host immune response: nutrient substitution. Gallagher HJ, et al. **Curr Opin Gen Surg** 1993; :92–104 (116 ref.)

Update on the mechanisms of immune suppression of injury and immune modulation. Faist E, et al. **World J Surg** 1996 May;20(4):454–9 (32 ref.)

METABOLISM

Oxidative metabolism in sepsis and sepsis syndrome. Taylor DE, et al. **J Crit Care** 1995 Sep;10(3):122–35 (134 ref.)

PHYSIOPATHOLOGY

Splanchnic ischemia and gut mucosal injury in sepsis and the multiple organ dysfunction syndrome. Pastores SM, et al. **Am J Gastroenterol** 1996 Sep;91(9):1697–710 (145 ref.)

Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: what we do and do not know about cytokine regulation. Bone RC. **Crit Care Med** 1996 Jan;24(1):163–72 (87 ref.)

Nutrition and the gut mucosal barrier. Deitch EA. **Curr Opin Gen Surg** 1993;:85–91 (34 ref.)

Regulation of protein metabolism during stress. Matthews DE, et al. **Curr Opin Gen Surg** 1993;:72–7 (45 ref.)

Lipid fuel metabolism in health and disease. Miles JM. **Curr Opin Gen Surg** 1993;:78–84 (34 ref.)

Sepsis in the critically ill patient. Baker CC, et al. **Curr Probl Surg** 1995 Dec;32(12):1013–83 (341 ref.)

Neuromuscular complications of sepsis in children. Sheth RD, et al. **J Child Neurol** 1995 Sep;10(5):346–52 (73 ref.)

Potential roles for endothelins in systemic inflammatory response syndrome with a particular relationship to cytokines. Battistini B, et al. **Shock** 1996 Mar;5(3):167–83 (181 ref.)

MODS/SIRS: result of an overwhelming inflammatory response? Goris RJ. **World J Surg** 1996 May;20(4):418–21 (24 ref.)

Metabolism of sepsis and multiple organ failure. Michie HR. **World J Surg** 1996 May;20(4):460–4 (31 ref.)

Mediators of injury and inflammation. Schlag G, et al. **World J Surg** 1996 May;20(4):406–10 (45 ref.)

[Is sepsis and septic shock due to a global oxygen insufficiency? A review in 2 parts. 2: Sepsis and lactate] Ensinger H, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May; 31(4):205–15 (175 ref.) **(Ger)**

[Tumor necrosis factor--friend and enemy] Zabel P. **Pneumologie** 1996 Apr;50(4):293–302 (104 ref.) **(Ger)**

PREVENTION & CONTROL

Surgical infections: blocking the mediator cascade responsible for sepsis and septic shock. Fink MP. **Curr Opin Gen Surg** 1993;:19–25 (45 ref.)

THERAPY

Nutritional management and the multisystem organ failure/systemic inflammatory response syndrome in critically ill preterm neonates. Adan D, et al. **Crit Care Clin** 1995 Jul;11(3):751–84 (162 ref.)

New immunotherapies for sepsis. Young LS, et al. **Proc Assoc Am Physicians** 1995 Oct;107(3):361–4 (19 ref.)

Clinical trials of new and novel therapeutic agents. Baue AE, et al. **World J Surg** 1996 May;20(4):493–8 (42 ref.)

Potential strategies for inflammatory mediator manipulation: retrospect and prospect. Fisher CJ Jr, et al. **World J Surg** 1996 May;20(4):447–53 (89 ref.)

Animal models as the basis of pharmacologic intervention in trauma and sepsis patients. Redl H, et al. **World J Surg** 1996 May;20(4):487–92 (81 ref.)

Prevention and therapy of multiple organ failure. Vincent JL. **World J Surg** 1996 May;20(4):465–70 (29 ref.)

SEPTICEMIA

COMPLICATIONS

[Sepsis] Fukazawa T. **Ryoikibetsu Shokogun Shirizu** 1995; (8):403–6 (19 ref.) **(Jpn)**

DIAGNOSIS

[Septic abortion in Campylobacter jejuni infection] Abderhalden R, et al. **Geburtshilfe Frauenheilkd** 1995 Oct; 55(10):599–601 (14 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

[Treatment of severe infections: should one always administer an aminoglycoside?] Cometta A, et al. **Schweiz Med Wochenschr Suppl** 1996;76:28S–33S (30 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Central venous catheter-related infections: pathogenesis, predictors, and prevention. Hoppe B. **Heart Lung** 1995 Jul-Aug;24(4):333–9; quiz 339–41 (85 ref.)

The many guises of septicaemia. Baddeley P. **Practitioner** 1995 Oct;239(1555):617–9 (6 ref.)

Sepsis, SIRS, and MODS: what's in a name? Nathens AB, et al. **World J Surg** 1996 May;20(4):386–91 (46 ref.)

MICROBIOLOGY

[Septicemia and endocarditis related to transvenous pacing leads of pacemakers: surgical indications and results] Leprince P, et al. **Arch Mal Coeur Vaiss** 1995 Feb; 88(2):241–6 (20 ref.) (Eng. Abstr.) **(Fre)**

[Microbial safety of blood products] Höher PG. **Infusionsther Transfusionsmed** 1996 Feb;23(1):42–58 (183 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

[Is infection and septic shock caused by a global oxygen deficiency? An overview in 2 parts. I: Infection and correlation between DO2 and VO2] Ensinger H, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Apr; 31(3):132–42 (0 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Surgical considerations for hematogenous osteomyelitis. Loder BG, et al. **J Foot Ankle Surg** 1995 Jul–Aug; 34(4):347–53 (58 ref.)

THERAPY

Prevention and therapy of multiple organ failure. Vincent JL. **World J Surg** 1996 May;20(4):465–70 (29 ref.)

SEPTUM PELLUCIDUM

PHYSIOLOGY

A computational model of cholinergic disruption of septohippocampal activity in classical eyeblink conditioning. Myers CE, et al. **Neurobiol Learn Mem** 1996 Jul;66(1):51–66 (90 ref.)

SEQUENCE ANALYSIS

The protein kinase C and protein kinase C related gene families. Dekker LV, et al. **Curr Opin Struct Biol** 1995 Jun; 5(3):396–402 (35 ref.)

Characterization and modeling of membrane proteins using sequence analysis. Reithmeier RA. **Curr Opin Struct Biol** 1995 Aug;5(4):491–500 (79 ref.)

Macintosh sequence analysis software. DNAStar's LaserGene. Clewley JP. **Mol Biotechnol** 1995 Jun; 3(3):221–4 (13 ref.)

METHODS

Assigning amino acid sequences to 3-dimensional protein folds. Fischer D, et al. **FASEB J** 1996 Jan;10(1):126–36 (54 ref.)

STATISTICS & NUMERICAL DATA

Statistical significance of sequence patterns in proteins. Karlin S. **Curr Opin Struct Biol** 1995 Jun;5(3):360–71 (47 ref.)

SEQUENCE ANALYSIS, DNA

Direct DNA sequencing in the clinical laboratory [editorial; comment] Kant JA. **Clin Chem** 1995 Oct;41(10):1407–9 (26 ref.) Comment on: Clin Chem 1995 Oct;41(10):1461–6.

Positional cloning reaches maturity. Nelson DL. **Curr Opin Genet Dev** 1995 Jun;5(3):298–303 (32 ref.)

Genome sequencing projects. Schlessinger D. **Nat Med** 1995 Sep;1(9):866–8 (15 ref.)

The nematode Caenorhabditis elegans and its genome. Hodgkin J, et al. **Science** 1995 Oct 20;270(5235):410–4 (25 ref.)

[Gene expression analysis by random cDNA sequencing] Fujimoto N, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr; 41(5):708–14 (15 ref.) **(Jpn)**

[PCR and DNA sequencing] Saito M, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):522–30 (6 ref.) **(Jpn)**

METHODS

Emerging technologies for sequencing antisense oligonucleotides: capillary electrophoresis and mass spectrometry. Cohen AS, et al. **Adv Chromatogr** 1996; 36:127–62 (115 ref.)

An update and lessons from whole-genome sequencing projects. Jones SJ. **Curr Opin Genet Dev** 1995 Jun; 5(3):349–53 (35 ref.)

Genomic DNA sequencing methods. Favello A, et al. **Methods Cell Biol** 1995;48:551–69 (9 ref.)

Large-scale complementary DNA sequencing methods. Fulton LL, et al. **Methods Cell Biol** 1995;48:571–82 (10 ref.)

Two-dimensional DNA typing: A cost-effective way of analyzing complex mixtures of DNA fragments for sequence variations. Vijg J. **Mol Biotechnol** 1995 Dec; 4(3):275–95 (53 ref.)

[Origin of modern humans revealed by complete sequences of hominoid mitochondrial DNAs] Horai S. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):727–32 (20 ref.) **(Jpn)**

[Gamma exonuclease method] Ishida S, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):531–3 (7 ref.) **(Jpn)**

[Large scale analysis of C. elegans cDNA] Kohara Y. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):715–20 (6 ref.) **(Jpn)**

[Novel molecular technology for HIV detection and analysis] Tamatsukuri S, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):686–95 (36 ref.) **(Jpn)**

SEQUENCE DELETION

Mutations in the cartilage oligomeric matrix protein (COMP) gene in pseudoachondroplasia and multiple epiphyseal dysplasia. Cohn DH, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:188–94 (18 ref.)

Human DNA topoisomerase II: biochemistry and role in chemotherapy resistance (review). Withoff S, et al. **Anticancer Res** 1996 Jul–Aug;16(4A):1867–80 (184 ref.)

The emerging role of insertions and deletions in protein engineering. Shortle D, et al. **Curr Opin Biotechnol** 1995 Aug;6(4):387–93 (40 ref.)

GENETICS

Human aging is associated with stochastic somatic mutations of mitochondrial DNA. Kadenbach B, et al. **Mutat Res** 1995 Oct;338(1–6):161–72 (112 ref.)

SEQUENCE DETERMINATION see **SEQUENCE ANALYSIS**

SEQUENCE DETERMINATION, DNA see **SEQUENCE ANALYSIS, DNA**

SEQUENCE HOMOLOGY, AMINO ACID

Class II B Mhc motifs in an evolutionary perspective. Klein J, et al. **Immunol Rev** 1995 Feb;143:89–111 (53 ref.)

Analysis of TCR usage in human tumors: a new tool for assessing tumor-specific immune responses. Sensi M, et al. **Immunol Today** 1995 Dec;16(12):588–95 (64 ref.)

Plant homologues of components of MAPK (mitogen-activated protein kinase) signal pathways in yeast and animal cells. Nishihama R, et al. **Plant Cell Physiol** 1995 Jul;36(5):749–57 (100 ref.)

[PH domain: a new functional domain] Touhara K. **Nippon Yakurigaku Zasshi** 1995 Jul;106(1):1–9 (47 ref.) (Eng. Abstr.) **(Jpn)**

SEQUENCE HOMOLOGY, NUCLEIC ACID

Class II B Mhc motifs in an evolutionary perspective. Klein J, et al. **Immunol Rev** 1995 Feb;143:89–111 (53 ref.)

Human and rodent DNA sequence comparisons: a mosaic model of genomic evolution. Koop BF. **Trends Genet** 1995 Sep;11(9):367–71 (25 ref.)

SEQUENCE TAGGED SITES

[Analysis of STS (sequence tagged site): microsatellite marker] Miki T, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):618–22 (13 ref.) **(Jpn)**

SERIAL EXTRACTION

Straight talk about extraction and nonextraction: a differential diagnostic decision. Vaden JL, et al. **Am J Orthod Dentofacial Orthop** 1996 Apr;109(4):445–52 (23 ref.)

SERINE

DRUG EFFECTS

Aspirin—now we can see it. Allen KN. **Nat Med** 1995 Sep; 1(9):882–3 (13 ref.)

SERINE PHOSPHATE see **PHOSPHOSERINE**

SERINE PHOSPHOGLYCERIDES see **PHOSPHATIDYLSERINES**

SERINE PROTEASE INHIBITORS see **SERINE PROTEINASE INHIBITORS**

SERINE PROTEASES see **SERINE PROTEINASES**

SERINE PROTEINASE ANTAGONISTS see **SERINE PROTEINASE INHIBITORS**

SERINE PROTEINASE INHIBITORS

see related
SERPINS

ADVERSE EFFECTS

Mechanisms of hyperkalemia caused by nafamostat mesilate. Muto S, et al. **Gen Pharmacol** 1995 Dec;26(8):1627–32 (34 ref.)

CHEMICAL SYNTHESIS

[Synthetic inhibitors targeting serine and aspartic acid proteases] Reboud-Ravaux MC, et al. **J Pharm Belg** 1996 May–Jun;51(3):161–4 (44 ref.) (Eng. Abstr.) **(Fre)**

PHARMACOLOGY

Thrombin inhibitors as antithrombotic agents: the importance of rapid inhibition. Stone SR, et al. **J Enzym Inhib** 1995; 9(1):3–15 (56 ref.)

[Synthetic inhibitors targeting serine and aspartic acid proteases] Reboud-Ravaux MC, et al. **J Pharm Belg** 1996 May–Jun;51(3):161–4 (44 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

The role of thrombin and thrombin inhibitors in coronary angioplasty. Ali MN, et al. **Chest** 1995 Nov;108(5):1409–19 (78 ref.)

SERINE PROTEINASE INHIBITORS, ENDOGENOUS see **SERINE PROTEINASE INHIBITORS**

SERINE PROTEINASE INHIBITORS, EXOGENOUS see **SERINE PROTEINASE INHIBITORS**

SERINE PROTEINASES

CHEMISTRY

Oviductins possess chitinase- and mucin-like domains: a lead in the search for the biological function of these oviduct-specific ZP-associating glycoproteins. Malette B, et al. **Mol Reprod Dev** 1995 Jul;41(3):384–97 (145 ref.)

The picornaviral 3C proteinases: cysteine nucleophiles in serine proteinase folds. Malcolm BA. **Protein Sci** 1995 Aug; 4(8):1439–45 (65 ref.)

GENETICS

Antigenic and genetic heterogeneity among Haemophilus influenzae and Neisseria IgA1 proteases. Lomholt H, et al. **Adv Exp Med Biol** 1995;371A:599–603 (18 ref.)

[Expression and purification of hepatitis C virus serine proteinase] Shoji I, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:30–5 (18 ref.) **(Jpn)**

IMMUNOLOGY

PELs and the perforin and granzyme independent mechanism of CTL-mediated lysis. Berke G. **Immunol Rev** 1995 Aug; 146:21–31 (52 ref.)

Granzyme B plays a critical role in cytotoxic lymphocyte-induced apoptosis. Shresta S, et al. **Immunol Rev** 1995 Aug;146:211–21 (32 ref.)

Tryptase immunoreactive mast cell hyperplasia in bronchopulmonary dysplasia. Lyle RE, et al. **Pediatr Pulmonol** 1995 Jun;19(6):336–43 (39 ref.)

ISOLATION & PURIFICATION

[Expression and purification of hepatitis C virus serine proteinase] Shoji I, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:30–5 (18 ref.) **(Jpn)**

METABOLISM

Utilization of transgenic mice in the study of matrix degrading proteinases and their inhibitors. Khokha R, et al. **Cancer Metastasis Rev** 1995 Jun;14(2):97–111 (109 ref.)

[A new serine protease zymogen activated by components of the fungal cell wall] Muta T. **Seikagaku** 1995 Aug; 67(8):1032–6 (15 ref.) **(Jpn)**

PHYSIOLOGY

Chymase-dependent angiotensin II forming systems in humans. Urata H, et al. **Am J Hypertens** 1996 Mar; 9(3):277–84 (63 ref.)

Influenza viruses, cell enzymes, and pathogenicity. Rott R, et al. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 2):S16–9 (45 ref.)

Biological significance of IgA1 proteases in bacterial colonization and pathogenesis: critical evaluation of experimental evidence. Kilian M, et al. **APMIS** 1996 May; 104(5):321–38 (155 ref.)

Target cell apoptosis induced by cytotoxic T cells and natural killer cells involves synergy between the pore-forming protein, perforin, and the serine protease, granzyme B. Trapani JA. **Aust N Z J Med** 1995 Dec;25(6):793–9 (63 ref.)

Neutrophil-mediated platelet activation: a key role for serine proteinases. Renesto P, et al. **Gen Pharmacol** 1995 Sep; 26(5):905–10 (54 ref.)

The acylation stimulating protein-adipsin system. Cianflone K, et al. **Int J Obes Relat Metab Disord** 1995 May;19 Suppl 1:S34–8 (57 ref.)

Proprotein convertases and the pathophysiology of human diseases: prospective considerations. Chrétien M, et al. **Proc Assoc Am Physicians** 1995 Apr;107(1):47–66 (138 ref.)

Complement factor D, a novel serine protease. Volanakis JE, et al. **Protein Sci** 1996 Apr;5(4):553–64 (70 ref.)

SERINE-THREONINE PROTEIN KINASES see **PROTEIN-SERINE-THREONINE KINASES**

SEROMUCOID see **OROSOMUCOID**

SEROSITIS

ETIOLOGY

Unexplained effusions: association with allogeneic bone marrow transplantation and acute or chronic graft-versus-host disease. Seber A, et al.

SEROSITIS

Bone Marrow Transplant 1996 Feb;17(2):207–11 (28 ref.)

SEROTHERAPY see **IMMUNIZATION, PASSIVE**

SEROTONIN

see related
RECEPTORS, SEROTONIN
SEROTONIN AGENTS

ANALYSIS

Innervation of cerebral arteries by nerves containing 5-hydroxytryptamine and noradrenaline. Lincoln J. **Pharmacol Ther** 1995;68(3):473–501 (256 ref.)

[Serotonin] Saijoh K. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:527–30 (17 ref.) **(Jpn)**

[New concepts relating to histochemistry of the serotonergic neural systems of the raphe nucleus] Villar MJ. **Acta Psiquiatr Psicol Am Lat** 1994 Dec;40(4):293–300 (36 ref.) (Eng. Abstr.) **(Spa)**

BLOOD

Eating disorder and obsessive-compulsive disorder: neurochemical and phenomenological commonalities. Jarry JL, et al. **J Psychiatry Neurosci** 1996 Jan;21(1):36–48 (125 ref.)

[Current views on pathophysiology of migraine. Part III: Biochemical hypothesis. The role of blood platelets] Prusiński A, et al. **Neurol Neurochir Pol** 1995 Nov–Dec; 29(6):867–76 (26 ref.) (Eng. Abstr.) **(Pol)**

CEREBROSPINAL FLUID

Eating disorder and obsessive-compulsive disorder: neurochemical and phenomenological commonalities. Jarry JL, et al. **J Psychiatry Neurosci** 1996 Jan;21(1):36–48 (125 ref.)

METABOLISM

Tryptophan, 5-hydroxytryptamine and a possible explanation for central fatigue. Newsholme EA, et al. **Adv Exp Med Biol** 1995;384:315–20 (16 ref.)

Pathophysiology and management of the serotonin syndrome. Brown TM, et al. **Ann Pharmacother** 1996 May; 30(5):527–33 (61 ref.)

The role of serotonin in schizophrenia. Iqbal N, et al. **Eur Neuropsychopharmacol** 1995;5 Suppl:11–23 (140 ref.)

Serotonin: current understanding and the way forward. Dinan TG. **Int Clin Psychopharmacol** 1996 Mar;11 Suppl 1:19–21 (10 ref.)

Cerebrospinal fluid 5-hydroxyindolacetic acid and aggression: a critical reappraisal of the clinical data. Tuinier S, et al. **Int Clin Psychopharmacol** 1995 Sep;10(3):147–56 (82 ref.)

Is central hyperacusis a symptom of 5-hydroxytryptamine (5-HT) dysfunction? Marriage J, et al. **J Laryngol Otol** 1995 Oct;109(10):915–21 (73 ref.)

Neurochemical correlates of antiepileptic drugs in the genetically epilepsy-prone rat (GEPR). Dailey JW, et al. **Life Sci** 1995;58(4):259–66 (49 ref.)

Alpha-methyl-L-tryptophan as a tracer to study brain serotonergic system. Diksic M, et al. **Neurochem Res** 1995 Nov;20(11):1353–60 (51 ref.)

Prenatal cocaine produces biochemical and functional changes in brain serotonin systems in rat progeny. Battaglia G, et al. **NIDA Res Monogr** 1995;158:115–48 (56 ref.)

[Serotonin in neurology and psychiatry] van Kempen GM. **Ned Tijdschr Geneeskd** 1995 Oct 14;139(41):2084–8 (31 ref.) **(Dut)**

PHARMACOLOGY

5-hydroxytryptamine: considerations about discovery, receptor classification and relevance to medical research. Villalón CM, et al. **Arch Med Res** 1995 Winter;26(4):331–44 (128 ref.)

PHYSIOLOGY

Evolutionary ancient roles of serotonin: long-lasting regulation of activity and development. Turlejski K. **Acta Neurobiol Exp (Warsz)** 1996;56(2):619–36 (138 ref.)

Neuroendocrine mechanisms during reversible hypovolaemic shock in humans with emphasis on the histaminergic and serotonergic system. Matzen SH. **Acta Physiol Scand Suppl** 1995;628:1–31 (208 ref.)

Involvement of serotonin in clinical features of Parkinson's disease and complications of L-DOPA therapy. Melamed E, et al. **Adv Neurol** 1996;69:545–50 (47 ref.)

Serotonin syndrome [see comments] Mills KC. **Am Fam Physician** 1995 Oct;52(5):1475–82 (23 ref.) Comment in: Am Fam Physician 1995 Oct;52(5):1263, 1266, 1271.

Serotonin–dopamine interaction and its relevance to schizophrenia. Kapur S, et al. **Am J Psychiatry** 1996 Apr; 153(4):466–76 (140 ref.)

Cholecystokinin modulation of serotonergic control of feeding behavior. Cooper SJ. **Ann N Y Acad Sci** 1996 Mar 22;780:213–22 (49 ref.)

Mechanisms and functions of serotonin neuronal systems: opportunities for neuropeptide interactions. Fuller RW. **Ann N Y Acad Sci** 1996 Mar 22;780:176–84 (61 ref.)

Galanin and 5-HT1A receptor interactions as an integrative mechanism in 5-HT neurotransmission in the brain. Hedlund PB, et al. **Ann N Y Acad Sci** 1996 Mar 22; 780:193–212 (82 ref.)

Interactions and coexistence of neuropeptides and serotonin in spinal autonomic systems. Helke CJ, et al. **Ann N Y Acad Sci** 1996 Mar 22;780:185–92 (49 ref.)

Bombesin receptors in the brain. Woodruff GN, et al. **Ann N Y Acad Sci** 1996 Mar 22;780:223–43 (74 ref.)

5-hydroxytryptamine: considerations about discovery, receptor classification and relevance to medical research. Villalón CM, et al. **Arch Med Res** 1995 Winter;26(4):331–44 (128 ref.)

Ecstasy intoxication: an overlap between serotonin syndrome and neuroleptic malignant syndrome. Demirkiran M, et al. **Clin Neuropharmacol** 1996 Apr;19(2):157–64 (43 ref.)

Role of serotonin in the action of atypical antipsychotic drugs. Meltzer HY. **Clin Neurosci** 1995;3(2):64–75 (162 ref.)

Serotonin receptors. Genetic insights into serotonin function. Heath MJ, et al. **Curr Biol** 1995 Sep 1;5(9):997–9 (11 ref.)

Studies on the nature of the antagonistic actions of dopamine and 5-hydroxytryptamine in renal tissues. Soares-da-Silva P, et al. **Hypertens Res** 1995 Jun;18 Suppl 1:S47–51 (21 ref.)

Behavior therapy: endogenous serotonin therapy? Baer L. **J Clin Psychiatry** 1996;57 Suppl 6:33–5 (12 ref.)

Noradrenergic and serotonergic abnormalities in depression: stress-induced dysfunction? Dinan TG. **J Clin Psychiatry** 1996;57 Suppl 4:14–8 (43 ref.)

Social phobia: everyone's disorder? Jefferson JW. **J Clin Psychiatry** 1996;57 Suppl 6:28–32 (28 ref.)

Serotonin dysfunction disorders: a behavioral neurochemistry perspective. Petty F, et al. **J Clin Psychiatry** 1996;57 Suppl 8:11–6 (24 ref.)

Self-injurious behavior: pathophysiology and implications for treatment. Pies RW, et al. **J Clin Psychiatry** 1995 Dec; 56(12):580–8 (75 ref.)

OCD: where the serotonin selectivity story begins. Pigott TA. **J Clin Psychiatry** 1996;57 Suppl 6:11–20 (91 ref.)

Biologic markers and neurochemical correlates of agitation and psychosis in dementia. Kirby M, et al. **J Geriatr Psychiatry Neurol** 1995 Oct;8 Suppl 1:S2–7 (63 ref.)

Beyond specificity: effects of serotonin and serotonergic treatments on psychobiological dysfunction. Dubovsky SL, et al. **J Psychosom Res** 1995 May;39(4):429–44 (103 ref.)

Serotonin and the regulation of hypothalamic-pituitary-adrenal axis function. Dinan TG. **Life Sci** 1996;58(20):1683–94 (146 ref.)

Dopamine, serotonin and tachykinin in self-injurious behavior. Sivam SP. **Life Sci** 1996 May 24;58(26):2367–75 (66 ref.)

Schizophrenia, suicide and the serotonin story. Holden RJ. **Med Hypotheses** 1995 May;44(5):379–91 (85 ref.)

Mean genes. Hen R. **Neuron** 1996 Jan;16(1):17–21 (50 ref.)

Role of the serotonergic system in the forced swimming test. Borsini F. **Neurosci Biobehav Rev** 1995 Fall;19(3):377–95 (178 ref.)

Serotonergic modulation of cholinergic function in the central nervous system: cognitive implications. Cassel JC, et al. **Neuroscience** 1995 Nov;69(1):1–41 (261 ref.)

Neurobehavioral pharmacology of cocaine: role for serotonin in its locomotor and discriminative stimulus effects. Cunningham KA, et al. **NIDA Res Monogr** 1994;145:40–66 (95 ref.)

Serotonin, eating behavior, and fat intake. Blundell JE, et al. **Obes Res** 1995 Nov;3 Suppl 4:471S–476S (61 ref.)

Biological actions of drugs affecting serotonin and eating. Garattini S. **Obes Res** 1995 Nov;3 Suppl 4:463S–470S (65 ref.)

Serotonin mechanisms in chemotherapy-induced emesis in cancer patients. Cubeddu LX. **Oncology** 1996 Jun;53 Suppl 1:18–25 (34 ref.)

Role of 5-HT in stress, anxiety, and depression. Graeff FG, et al. **Pharmacol Biochem Behav** 1996 May;54(1):129–41 (112 ref.)

Psychopharmacology of central serotonergic systems. Baumgarten HG, et al. **Pharmacopsychiatry** 1995 Oct;28 Suppl 2:73–9 (42 ref.)

5-Hydroxytryptamine in the central nervous system. Chojnacka-Wójcik E. **Pol J Pharmacol** 1995 May–Jun; 47(3):219–35 (173 ref.)

The peptidergic innervation of spinal motoneurons via the bulbospinal 5-hydroxytryptamine pathway. Cullheim S, et al. **Prog Brain Res** 1995;104:21–40 (115 ref.)

Gene expression of serotonergic neurons in the central nervous system: molecular and developmental analysis. Joh TH, et al. **Prog Brain Res** 1995;105:43–52 (31 ref.)

Toward a unified theory of serotonin dysregulation in eating and related disorders. Brewerton TD. **Psychoneuroendocrinology** 1995;20(6):561–90 (160 ref.)

[Hypothalamic-pituitary stress hormones and serotonergic system in the brain] Yan J, et al. **Sheng Li Ko Hsueh Chin Chan** 1995 Oct;26(4):337–40 (8 ref.) **(Chi)**

[Serotonin and cardiovascular diseases] Reneman RS, et al. **Ned Tijdschr Geneeskd** 1995 Oct 14;139(41):2080–4 (55 ref.) **(Dut)**

[Role of biogenic amines (catecholamines, histamine, serotonin, etc.) in food intake] Tsujii S. **Nippon Rinsho** 1995 Jun;53 Suppl:33–9 (20 ref.) **(Jpn)**

[Pulmonary and pulmonary-related reflexes mediated by serotonin receptors in the peripheral nervous system] Yoshioka M. **Nippon Yakurigaku Zasshi** 1995 Nov; 106(5):311–20 (49 ref.) (Eng. Abstr.) **(Jpn)**

SECRETION

Brain serotonin, carbohydrate-craving, obesity and depression. Wurtman RJ, et al. **Obes Res** 1995 Nov;3 Suppl 4:477S–480S (34 ref.)

THERAPEUTIC USE

[New perspectives in the serotoninergic treatment for depression] Hamon M. **Therapie** 1995 Nov–Dec;50(6):505–9 (20 ref.) (Eng. Abstr.) **(Fre)**

[Pharmacotherapy of anxiety disorders] Bitter I. **Orv Hetil** 1995 Nov 5;136(45):2435–9 (19 ref.) (Eng. Abstr.) **(Hun)**

SEROTONIN ACETYLTRANSFERASE see **ARYLAMINE ACETYLTRANSFERASES**

SEROTONIN AGENTS

ADVERSE EFFECTS

The serotonin syndrome. Implicated drugs, pathophysiology and management. Sporer KA. **Drug Saf** 1995 Aug; 13(2):94–104 (127 ref.)

[The serotonin syndrome: review of the literature and description of an original study] Lejoyeux M, et al. **Encephale** 1995 Sep–Oct;21(5):537–43 (45 ref.) (Eng. Abstr.) **(Fre)**

PHARMACOLOGY

Serotonin syndrome [see comments] Mills KC. **Am Fam Physician** 1995 Oct;52(5):1475–82 (23 ref.) Comment in: Am Fam Physician 1995 Oct;52(5):1263, 1266, 1271.

Cerebral metabolic effects of serotonin drugs and neurotoxins. Freo U. **Life Sci** 1996;59(11):877–91 (109 ref.)

Biological actions of drugs affecting serotonin and eating. Garattini S. **Obes Res** 1995 Nov;3 Suppl 4:463S–470S (65 ref.)

POISONING

Ecstasy intoxication: an overlap between serotonin syndrome and neuroleptic malignant syndrome. Demirkiran M, et al. **Clin Neuropharmacol** 1996 Apr;19(2):157–64 (43 ref.)

SEROTONIN AGONISTS

METABOLISM

Neurochemical correlates of antiepileptic drugs in the genetically epilepsy-prone rat (GEPR). Dailey JW, et al. **Life Sci** 1995;58(4):259–66 (49 ref.)

PHARMACOLOGY

5-HT3 receptors: pharmacologic and therapeutic aspects. Gyermek L. **J Clin Pharmacol** 1995 Sep;35(9):845–55 (100 ref.)

Role of the serotonergic system in the forced swimming test. Borsini F. **Neurosci Biobehav Rev** 1995 Fall;19(3):377–95 (178 ref.)

5-HT1A receptor agonists: recent developments and controversial issues. De Vry J. **Psychopharmacology (Berl)** 1995 Sep;121(1):1–26 (132 ref.)

Central 5-HT4 receptors. Eglen RM, et al. **Trends Pharmacol Sci** 1995 Nov;16(11):391–8 (84 ref.)

[Serotonin and cardiovascular diseases] Reneman RS, et al. **Ned Tijdschr Geneeskd** 1995 Oct 14;139(41):2080–4 (55 ref.) **(Dut)**

THERAPEUTIC USE

Augmentation with buspirone: a review. Harvey KV, et al. **Ann Clin Psychiatry** 1995 Sep;7(3):143–7 (32 ref.)

Migraine and cluster headache—their management with sumatriptan: a critical review of the current clinical experience. Wilkinson M, et al. **Cephalalgia** 1995 Oct; 15(5):337–57 (166 ref.)

Acute treatment of migraine attacks. Ferrari MD, et al. **Curr Opin Neurol** 1995 Jun;8(3):237–42 (34 ref.)

Therapeutic potential of drugs with mixed 5-HT4 agonist/5-HT3 antagonist action in the control of emesis. Tonini M, et al. **Pharmacol Res** 1995 May;31(5):257–60 (30 ref.)

5-HT1A receptor agonists: recent developments and controversial issues. De Vry J. **Psychopharmacology (Berl)** 1995 Sep;121(1):1–26 (132 ref.)

[New perspectives in the serotoninergic treatment for depression] Hamon M. **Therapie** 1995 Nov–Dec;50(6):505–9 (20 ref.) (Eng. Abstr.) **(Fre)**

[Drug treatment of obesity] Yoshida T. **Nippon Rinsho** 1995 Jun;53 Suppl:481–6 (20 ref.) **(Jpn)**

[Treatment of the acute migraine attack] Titus F. **Rev Neurol** 1995;23 Suppl 2:S203–7 (49 ref.) **(Spa)**

SEROTONIN ANTAGONISTS

see related
SEROTONIN UPTAKE INHIBITORS

Granisetron: the second serotonin-receptor antagonist. Adams VR, et al. **Ann Pharmacother** 1995 Dec; 29(12):1240-51 (72 ref.)

ADMINISTRATION & DOSAGE

[Prevention and treatment of postoperative nausea and vomiting with 5-HT3-receptor blockers] Alon E, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May; 31(4):200-4 (47 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

Medications used to prevent migraine headaches and their potential ocular adverse effects. Doughty MJ, et al. **Optom Vis Sci** 1995 Dec;72(12):879-91 (176 ref.)

Novel versus conventional antipsychotic drugs. Love RC. **Pharmacotherapy** 1996 Jan-Feb;16(1 Pt 2):6-10 (24 ref.)

PHARMACOKINETICS

Ondansetron clinical pharmacokinetics. Roila F, et al. **Clin Pharmacokinet** 1995 Aug;29(2):95-109 (40 ref.)

PHARMACOLOGY

5-HT3 receptors: pharmacologic and therapeutic aspects. Gyermek L. **J Clin Pharmacol** 1995 Sep;35(9):845-55 (100 ref.)

Cerebral metabolic effects of serotonin drugs and neurotoxins. Freo U. **Life Sci** 1996;59(11):877-91 (109 ref.)

A pharmacologic profile of oral granisetron (Kytril tablets). Blower P. **Semin Oncol** 1995 Aug;22(4 Suppl 10):3-5 (13 ref.)

Central 5-HT4 receptors. Eglen RM, et al. **Trends Pharmacol Sci** 1995 Nov;16(11):391-8 (84 ref.)

THERAPEUTIC USE

Ondansetron use for smoking cessation. Cropp CD, et al. **Ann Pharmacother** 1995 Oct;29(10):1041-2 (9 ref.)

Role of 5-hydroxytryptamine3 (5-HT3) antagonists in the prevention of emesis caused by anticancer therapy. Karim F, et al. **Biochem Pharmacol** 1996 Sep 13;52(5):685-92 (64 ref.)

Progress in reducing nausea and emesis. Comparisons of ondansetron (Zofran), granisetron (Kytril), and tropisetron (Navoban). Morrow GR, et al. **Cancer** 1995 Aug 1; 76(3):343-57 (121 ref.)

A risk-benefit assessment of cisapride in the treatment of gastrointestinal disorders. Tack J, et al. **Drug Saf** 1995 Jun; 12(6):384-92 (103 ref.)

Mechanisms and management of nausea and emesis [editorial] Dicato M. **Oncology** 1996 Jun;53 Suppl 1:1-3 (16 ref.)

Management of cisplatin-induced delayed emesis. Hesketh P. **Oncology** 1996 Jun;53 Suppl 1:73-7 (14 ref.)

Antiemetic study methodology: recommendations for future studies. Olver IN. **Oncology** 1996 Jun;53 Suppl 1:96-101 (32 ref.)

Therapeutic potential of drugs with mixed 5-HT4 agonist/5-HT3 antagonist action in the control of emesis. Tonini M, et al. **Pharmacol Res** 1995 May;31(5):257-60 (30 ref.)

Prophylaxis with oral granisetron for acute emesis induced by moderately emetogenic chemotherapy. Hesketh P. **Semin Oncol** 1995 Aug;22(4 Suppl 10):19-23 (23 ref.)

[Efficacy of ondansetron in acute and delayed cisplatin-induced nausea and vomiting] Depierre A. **Bull Cancer (Paris)** 1996 Feb;83(2):147-53 (29 ref.) (Eng. Abstr.) **(Fre)**

[Anti-5-HT-3: a new group of antiemetics] Galindo JR. **Rev Clin Esp** 1996 Feb;196(2):119-24 (73 ref.) **(Spa)**

[Prophylactic treatment of chronic cluster headache] Alberca R. **Rev Neurol** 1995;23 Suppl 4:S530-4 (55 ref.) **(Spa)**

[Prophylactic treatment of episodic forms of cluster headache] Liaño H, et al. **Rev Neurol** 1995;23 Suppl 4:S525-9 (29 ref.) **(Spa)**

SEROTONIN BLOCKADERS see **SEROTONIN ANTAGONISTS**

SEROTONIN RECEPTOR AGONISTS see **SEROTONIN AGONISTS**

SEROTONIN RECEPTORS see **RECEPTORS, SEROTONIN**

SEROTONIN REUPTAKE INHIBITORS see **SEROTONIN UPTAKE INHIBITORS**

SEROTONIN UPTAKE INHIBITORS

see related
ANTIDEPRESSIVE AGENTS, SECOND-GENERATION

ADVERSE EFFECTS

Clinical implications of antidepressant drug effects on sexual function. Harvey KV, et al. **Ann Clin Psychiatry** 1995 Dec; 7(4):189-201 (107 ref.)

Pathophysiology and management of the serotonin syndrome. Brown TM, et al. **Ann Pharmacother** 1996 May; 30(5):527-33 (61 ref.)

Selective serotonin reuptake inhibitors and tricyclic antidepressants in combination. Interactions and therapeutic uses. Taylor D. **Br J Psychiatry** 1995 Nov; 167(5):575-80 (38 ref.)

Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotonin reuptake inhibitors: a review of spontaneous reports. Liu BA, et al. **Can Med Assoc J** 1996 Sep 1; 155(5):519-27 (50 ref.)

Does selectivity matter? Deakin JFW. **Int Clin Psychopharmacol** 1996 Mar;11 Suppl 1:13-7 (12 ref.)

The safety and tolerability of citalopram. Muldoon C. **Int Clin Psychopharmacol** 1996 Mar;11 Suppl 1:35-40 (17 ref.)

Cardiovascular safety in depressed patients: focus on venlafaxine. Feighner JP. **J Clin Psychiatry** 1995 Dec; 56(12):574-9 (44 ref.)

Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors. Skop BP, et al. **Psychosomatics** 1996 Jan-Feb;37(1):12-6 (41 ref.)

PHARMACOKINETICS

Overview of the pharmacokinetics of fluvoxamine. van Harten J. **Clin Pharmacokinet** 1995;29 Suppl 1:1-9 (49 ref.)

Pharmacology and pharmacokinetics of citalopram and other SSRIs. Baumann P. **Int Clin Psychopharmacol** 1996 Mar; 11 Suppl 1:5-11 (62 ref.)

PHARMACOLOGY

Drug interactions and the cytochrome P450 system. The role of cytochrome P450 1A2. Brøsen K. **Clin Pharmacokinet** 1995;29 Suppl 1:20-5 (20 ref.)

Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6. Ereshefsky L, et al. **Clin Pharmacokinet** 1995;29 Suppl 1:10-8; discussion 18-9 (38 ref.)

Managing selective serotonin reuptake inhibitor-drug interactions in clinical practice. Rosenbaum JR. **Clin Pharmacokinet** 1995;29 Suppl 1:53-9 (17 ref.)

Metabolism of drugs by cytochrome P450 3A isoforms. Implications for drug interactions in psychopharmacology. von Moltke LL, et al. **Clin Pharmacokinet** 1995;29 Suppl 1:33-43; discussion 43-4 (66 ref.)

Fluvoxamine. A review of global drug-drug interaction data. Wagner W, et al. **Clin Pharmacokinet** 1995;29 Suppl 1:26-31; discussion 31-2 (23 ref.)

Pharmacology and pharmacokinetics of citalopram and other SSRIs. Baumann P. **Int Clin Psychopharmacol** 1996 Mar; 11 Suppl 1:5-11 (62 ref.)

Are pharmacokinetic drug interactions with the SSRIs an issue? Brøsen K. **Int Clin Psychopharmacol** 1996 Mar;11 Suppl 1:23-7 (9 ref.)

Does selectivity matter? Deakin JFW. **Int Clin Psychopharmacol** 1996 Mar;11 Suppl 1:13-7 (12 ref.)

Serotonin: current understanding and the way forward. Dinan TG. **Int Clin Psychopharmacol** 1996 Mar;11 Suppl 1:19-21 (10 ref.)

Sertraline 50 mg daily: the optimal dose in the treatment of depression. Preskorn SH, et al. **Int Clin Psychopharmacol** 1995 Sep;10(3):129-41 (55 ref.)

Cytochrome P450 monooxygenases and interactions of psychotropic drugs: a five-year update. Shen WW. **Int J Psychiatry Med** 1995;25(3):277-90 (78 ref.)

Serotonin selective reuptake inhibitor drug interactions and the cytochrome P450 system. Ereshefsky L, et al. **J Clin Psychiatry** 1996;57 Suppl 8:17-24; discussion 25 (78 ref.)

Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors. Skop BP, et al. **Psychosomatics** 1996 Jan-Feb;37(1):12-6 (41 ref.)

[Serotonin uptake inhibitors] Jiménez MD, et al. **Rev Neurol** 1995;23 Suppl 2:S190-2 (42 ref.) **(Spa)**

THERAPEUTIC USE

Clinical implications of antidepressant drug effects on sexual function. Harvey KV, et al. **Ann Clin Psychiatry** 1995 Dec; 7(4):189-201 (107 ref.)

Neurally mediated syncope and serotonin reuptake inhibitors. Samoil D, et al. **Clin Auton Res** 1995 Oct;5(5):251-5 (45 ref.)

The pathogenesis and treatment of obsessive-compulsive disorder. Dolberg OT, et al. **Clin Neuropharmacol** 1996 Apr;19(2):129-47 (112 ref.)

Neuropsychiatry of obsessive-compulsive disorder in children and adolescents. March JS, et al. **Compr Ther** 1995 Sep;21(9):507-12 (71 ref.)

Selective serotonin reuptake inhibitors in obsessive-compulsive disorder. **Drug Ther Bull** 1995 Jun; 33(6):47-8 (21 ref.)

Obsessive-compulsive disorder in elderly patients. Jackson CW. **Drugs Aging** 1995 Dec;7(6):438-48 (108 ref.)

Scandinavian experience with citalopram in the elderly. Gottfries CG. **Int Clin Psychopharmacol** 1996 Mar;11 Suppl 1:41-4 (14 ref.)

The antidepressant efficacy of citalopram. Montgomery SA, et al. **Int Clin Psychopharmacol** 1996 Mar;11 Suppl 1:29-33 (9 ref.)

Serotonin selective reuptake inhibitors in child and adolescent psychopharmacology: a review of published experience. DeVane CL, et al. **J Clin Psychiatry** 1996 Feb;57(2):55-66 (103 ref.)

Use of serotonin selective reuptake inhibitors in geriatric depression. Newhouse PA. **J Clin Psychiatry** 1996;57 Suppl 5:12-22 (79 ref.)

OCD: where the serotonin selectivity story begins. Pigott TA. **J Clin Psychiatry** 1996;57 Suppl 6:11-20 (91 ref.)

Does intolerance or lack of response with fluoxetine predict the same will happen with sertraline? Zarate CA, et al. **J Clin Psychiatry** 1996 Feb;57(2):67-71 (23 ref.)

One foot on the bandwagon? [editorial] Pies R. **J Clin Psychopharmacol** 1995 Oct;15(5):303-5 (16 ref.)

Serotonin uptake inhibitors: uses in clinical therapy and in laboratory research. Fuller RW. **Prog Drug Res** 1995; 45:167-204 (280 ref.)

[Prophylaxis of migraine] Liaño H. **Rev Neurol** 1995;23 Suppl 2:S212-8 (21 ref.) **(Spa)**

SEROTYPING

METHODS

Uses and limitations of gonococcal serotyping [editorial] Ross JD. **Int J STD AIDS** 1996 Jan-Feb;7(1):14-8 (68 ref.)

SERPENTINE (MINERAL) see **ASBESTOS, SERPENTINE**

SERPENTINE ASBESTOS see **ASBESTOS, SERPENTINE**

SERPIN SUPERFAMILY see **SERPINS**

SERPINS

CHEMISTRY

The structural puzzle of how serpin serine proteinase inhibitors work. Wright HT. **Bioessays** 1996 Jun; 18(6):453-64 (74 ref.)

METABOLISM

The structural puzzle of how serpin serine proteinase inhibitors work. Wright HT. **Bioessays** 1996 Jun; 18(6):453-64 (74 ref.)

PHYSIOLOGY

Maspin: a tumor suppressing serpin. Sager R, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 1):51-64 (14 ref.)

[Serpins, a functionally important class of proteins: the paradigm of alpha-1-antitrypsin] Emmerich J. **Rev Med Interne** 1996;17(2):176-9 (27 ref.) **(Fre)**

SERTOLI CELL TUMOR

PATHOLOGY

Sclerosing Sertoli cell tumor of the testis: a distinct histological subtype. Anderson GA. **J Urol** 1995 Nov; 154(5):1756-8 (11 ref.)

SERTOLI CELLS

CHEMISTRY

[Paracrine regulation of Leydig cells] Lejeune H, et al. **Ann Endocrinol (Paris)** 1996;57(1):55-63 (38 ref.) (Eng. Abstr.) **(Fre)**

CYTOLOGY

The comparative cell biology of accessory somatic (or Sertoli) cells in the animal testis. Guraya SS. **Int Rev Cytol** 1995;160:163-220 (230 ref.)

METABOLISM

Molecular role of sulfated glycoprotein-1 (SGP-1/prosaposin) in Sertoli cells. Morales CR, et al. **Histol Histopathol** 1995 Oct;10(4):1023-34 (11 ref.)

PHYSIOLOGY

Inositol lipid-mediated signalling in response to endothelin and ATP in the mammalian testis. Rudge SA, et al. **Mol Cell Biochem** 1995 Aug-Sep;149-150:161-74 (86 ref.)

Interleukin-1, interleukin-6 and the germ cell-Sertoli cell cross-talk. Jégou B, et al. **Reprod Fertil Dev** 1995; 7(4):723-30 (68 ref.)

[Paracrine regulation of Leydig cells] Lejeune H, et al. **Ann Endocrinol (Paris)** 1996;57(1):55-63 (38 ref.) (Eng. Abstr.) **(Fre)**

SERTOLI-LEYDIG CELL TUMOR

METABOLISM

Expression of alpha-fetoprotein by ovarian Sertoli-Leydig cell tumors. Case report and review of the literature. Hammad A, et al. **Arch Pathol Lab Med** 1995 Nov; 119(11):1075-9 (29 ref.)

PATHOLOGY

Expression of alpha-fetoprotein by ovarian Sertoli-Leydig cell tumors. Case report and review of the literature.

SERTOLI-LEYDIG CELL TUMOR

Hammad A, et al. **Arch Pathol Lab Med** 1995 Nov; 119(11):1075-9 (29 ref.)

SERUM A RELATED PROTEIN see **AMYLOID PROTEIN SAA**

SERUM ALBUMIN

see related
RECEPTORS, ALBUMIN

ANALYSIS

[Glycated albumin] Tanaka K, et al. **Nippon Rinsho** 1995 Feb; 53 Su Pt 1:549-52 (22 ref.) **(Jpn)**

METABOLISM

[The potential attachment sites of hepatitis B virus to the hepatocyte—the pre-S(2) antigen and the receptor for polymerized human serum albumin of hepatitis B virus] Matsuura K, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:125-31 (25 ref.) **(Jpn)**

PHYSIOLOGY

The use of neutralizing antibodies to demonstrate the role of transforming growth factor-beta and Amadori-glycated albumin as mediators of experimental diabetic kidney disease. Ziyadeh FN, et al. **Contrib Nephrol** 1996; 118:188-94 (39 ref.)

[Clinical significance of the pre-S antigens and the binding activity of polymerized human serum albumin to the receptor on hepatitis B virus particles] Matsuura K, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:265-74 (26 ref.) **(Jpn)**

SERUM AMYLOID PROTEIN A see **AMYLOID PROTEIN SAA**

SERUM MARKERS see **BIOLOGICAL MARKERS**

SERUM PROTEINS see **BLOOD PROTEINS**

SERUM SIALOMUCIN see **OROSOMUCOID**

SERVICE, SOCIAL see **SOCIAL WORK**

SESAMOID BONES

SURGERY

Avascular necrosis of the hallucial sesamoids. Fleischli J, et al. **J Foot Ankle Surg** 1995 Jul-Aug;34(4):358-65 (34 ref.)

SESQUITERPENES

THERAPEUTIC USE

Artesunate. A review of its pharmacology and therapeutic efficacy in the treatment of malaria. Barradell LB, et al. **Drugs** 1995 Oct;50(4):714-41 (101 ref.)

Artemisinin and the antimalarial endoperoxides: from herbal remedy to targeted chemotherapy. Meshnick SR, et al. **Microbiol Rev** 1996 Jun;60(2):301-15 (189 ref.)

[The role of qinghaosu derivatives in the treatment of malaria in 1995] Ambroise-Thomas P. **Med Trop (Mars)** 1995;55(3 Suppl):18-20 (7 ref.) **(Fre)**

[Qinghao derivatives in the treatment of severe malaria (letter)] Danis M. **Med Trop (Mars)** 1995;55(4 Suppl):115 (8 ref.) **(Fre)**

SET (PSYCHOLOGY)

Set as a physiological determinant of behavior. Kostandov EA. **Neurosci Behav Physiol** 1996 Jan-Feb;26(1):80-7 (20 ref.)

SETARIA

GROWTH & DEVELOPMENT

Development of Dirofilaria and Setaria nematodes in Aedes albopictus. Cancrini G, et al. **Parassitologia** 1995 Dec; 37(2-3):141-5 (24 ref.)

SEVENTH-DAY ADVENTISTS see **CHRISTIANITY**

SEVERE COMBINED IMMUNODEFICIENCY

DIAGNOSIS

X-linked severe combined immunodeficiency disease and the gamma c receptor component: prospects for molecular diagnosis. Farner NL, et al. **Clin Diagn Lab Immunol** 1995 Sep;2(5):518-23 (63 ref.)

EMBRYOLOGY

In utero transplantation of fetal liver stem cells into human fetuses. Touraine JL. **J Hematother** 1996 Apr;5(2):195-9 (15 ref.)

GENETICS

The molecular basis of X-linked severe combined immunodeficiency: defective cytokine receptor signaling. Leonard WJ. **Annu Rev Med** 1996;47:229-39 (52 ref.)

X-linked severe combined immunodeficiency disease and the gamma c receptor component: prospects for molecular diagnosis. Farner NL, et al. **Clin Diagn Lab Immunol** 1995 Sep;2(5):518-23 (63 ref.)

Genetic studies in severe combined immunodeficiency. de Saint Basile G, et al. **Clin Immunol Immunopathol** 1995 Sep; 76(3 Pt 2):S165-7 (28 ref.)

Potential targets for autosomal SCID mutations. Taccioli GE, et al. **Curr Opin Immunol** 1995 Aug;7(4):436-40 (50 ref.)

Variability of clinical and immunological phenotype in immunodeficiency-centromeric instability-facial anomalies syndrome. Report of two new patients and review of the literature. Franceschini P, et al. **Eur J Pediatr** 1995 Oct; 154(10):840-6 (21 ref.)

Molecular defects in the bare lymphocyte syndrome and regulation of MHC class II genes. Reith W, et al. **Immunol Today** 1995 Nov;16(11):539-46 (61 ref.)

Dysfunctional cytokine receptor signaling in severe combined immunodeficiency. Leonard WJ. **J Investig Med** 1996 Aug;44(6):304-11 (66 ref.)

[Primary immunodeficiency syndrome as gene experiment of nature] Yata J. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Apr;18(2):133-7 (18 ref.) **(Jpn)**

IMMUNOLOGY

Assessment of engraftment and function of human tonsillar and blood mononuclear cells in immunodeficient mice. Albini B, et al. **Adv Exp Med Biol** 1995;371A:85-9 (28 ref.)

Autoimmunity. Insights provided by the SCID mouse model. Jorgensen C, et al. **Rev Rhum Engl Ed** 1995 Jul-Sep; 62(7-8):519-24 (38 ref.)

THERAPY

Steps toward gene therapy: 1. The initial trials. Blaese RM. **Hosp Pract (Off Ed)** 1995 Nov 15;30(11):33-40 (7 ref.)

SEVERE COMBINED IMMUNODEFICIENT MICE see **MICE, SCID**

SEVERITY OF ILLNESS INDEX

Knowing the score: using predictive scoring systems in clinical practice. Zollo MB, et al. **Am J Crit Care** 1996 Mar;5(2):147-51 (21 ref.)

1994 Consensus Conference on Acute GVHD Grading. Przepiorka D, et al. **Bone Marrow Transplant** 1995 Jun; 15(6):825-8 (11 ref.)

Methodological problems in comparing the severity of rheumatoid arthritis between populations. Ali-Gombe A, et al. **Br J Rheumatol** 1995 Aug;34(8):781-4 (27 ref.)

Symptom indices in bladder outlet obstruction. Hines JE. **Br J Urol** 1996 Apr;77(4):494-501 (57 ref.)

Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome [see comments] Marshall JC, et al. **Crit Care Med** 1995 Oct;23(10):1638-52 (40 ref.) Comment in: Crit Care Med 1995 Oct;23(10):1619-20. Comment in: Crit Care Med 1996 Jul;24(7):1272-3.

The outcomes movement and new measures of the severity of psoriasis. Mckenna KE, et al. **J Am Acad Dermatol** 1996 Mar;34(3):534-8 (47 ref.)

The case for a simple method of grading osteoarthritis severity at arthroscopy [editorial; comment] Marshall KW. **J Rheumatol** 1996 Apr;23(4):582-5 (24 ref.) Comment on: J Rheumatol 1996 Apr;23(4):698-706.

Assessment of radiographic abnormalities in rheumatoid arthritis: what have we accomplished and where should we go from here? Sharp JT. **J Rheumatol** 1995 Sep; 22(9):1787-91 (48 ref.)

Rheumatoid arthritis. Outcome measures. Paulus HE, et al. **Rheum Dis Clin North Am** 1995 Aug;21(3):605-18 (52 ref.)

[Assessment of disease activity in systemic lupus erythematosus] Kano S. **Ryumachi** 1996 Feb;36(1):69-81 (28 ref.) **(Jpn)**

[Use of a scoring index for evaluating disease activity of Leśniowski-Crohn disease and ulcerative colitis in children] Ryżko J, et al. **Pediatr Pol** 1995 Jul;70(7):585-9 (9 ref.) (Eng. Abstr.) **(Pol)**

SEWAGE

ANALYSIS

[Biodegradation of polycyclic aromatic hydrocarbons and its application to the bioremediation of contaminated soils and sludges] Ferrari MD. **Rev Argent Microbiol** 1996 Apr-Jun;28(2):83-98 (71 ref.) (Eng. Abstr.) **(Spa)**

CHEMISTRY

Ingestion of sludge applied organic chemicals by animals. Fries GF. **Sci Total Environ** 1996 Jun 21;185(1-3):93-108 (112 ref.)

Sources, behaviour and fate of organic contaminants during sewage treatment and in sewage sludges. Rogers HR. **Sci Total Environ** 1996 Jun 21;185(1-3):3-26 (141 ref.)

SEX

see related
LIBIDO
PSYCHOSEXUAL DEVELOPMENT

Barriers to help-seeking for change in drinking: a gender-focused review of the literature. Schober R, et al. **Addict Behav** 1996 Jan-Feb;21(1):81-92 (96 ref.)

Reproductive and sexual health: a research and developmental challenge. Mbizvo MT. **Cent Afr J Med** 1996 Mar;42(3):80-5 (35 ref.)

Age, gender, and muscular strength. Hurley BF. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:41-4 (50 ref.)

Hormones and sexual orientation: a questionable link. Banks A, et al. **J Homosex** 1995;28(3-4):247-68 (70 ref.)

Science and belief: psychobiological research on sexual orientation. Byne W. **J Homosex** 1995;28(3-4):303-44 (140 ref.)

The biology of homosexuality: sexual orientation or sexual preference? De Cecco JP, et al. **J Homosex** 1995; 28(1-2):1-27 (55 ref.)

Wilson's Panchreston: the inclusive fitness hypothesis of sociobiology re-examined. Dickemann M. **J Homosex** 1995; 28(1-2):147-83 (65 ref.)

Sexuality in the brain. Doell RG. **J Homosex** 1995; 28(3-4):345-54 (27 ref.)

Animals models for the development of human sexuality: a critical evaluation. Fausto-Sterling A. **J Homosex** 1995; 28(3-4):217-36 (50 ref.)

Dexterity and sexuality: is there a relationship? Hamill JA. **J Homosex** 1995;28(3-4):375-96 (60 ref.)

Brain research, gender and sexual orientation. Swaab DF, et al. **J Homosex** 1995;28(3-4):283-301 (65 ref.)

Biology of bisexuality: critique and observations. Van Wyk PH, et al. **J Homosex** 1995;28(3-4):357-73 (65 ref.)

SEX ATTRACTANTS

Control of tsetse flies (Diptera: Glossinidae) with the aid of attractants. Jordan AM. **J Am Mosq Control Assoc** 1995 Jun;11(2 Pt 2):249-55 (52 ref.)

BIOSYNTHESIS

Pheromone biosynthesis activating neuropeptides: functions and chemistry. Teal PE, et al. **Peptides** 1996;17(2):337-44 (69 ref.)

SEX BEHAVIOR

see related
SEXUAL PARTNERS

Enabling approaches for HIV/AIDS prevention: can we modify the environment and minimize the risk? [editorial] Tawil O, et al. **AIDS** 1995 Dec;9(12):1299-306 (76 ref.)

HIV sexual risk reduction interventions for women: a review. Wingood GM, et al. **Am J Prev Med** 1996 May-Jun; 12(3):209-17 (33 ref.)

Adolescent sexuality and its problems. Yang M. **Ann Acad Med Singapore** 1995 Sep;24(5):736-40 (40 ref.)

APA resource document: legal sanctions for mental health professional-patient sexual misconduct. Hoge SK, et al. **Bull Am Acad Psychiatry Law** 1995;23(3):433-48 (56 ref.)

Regulating pastoral counseling practice: the problem of sexual misconduct. Young JL, et al. **Bull Am Acad Psychiatry Law** 1995;23(3):421-32 (32 ref.)

The evolutionary tangle of aging, sex, and reproduction and an experimental approach to its molecular dissection. Roy AK, et al. **Exp Gerontol** 1996 Jan-Apr;31(1-2):83-94 (36 ref.)

Heterosexual HIV transmission. Mayer KH, et al. **Infect Agents Dis** 1995 Dec;4(4):273-84 (112 ref.)

Influence of menopause on sexuality. Bachmann GA. **Int J Fertil Menopausal Stud** 1995;40 Suppl 1:16-22 (35 ref.)

The third wave: HIV infection among heterosexuals in the United States and Europe [editorial] Haverkos HW, et al. **Int J STD AIDS** 1995 Jul-Aug;6(4):227-32 (62 ref.)

Development of vaginal microbicides for the prevention of heterosexual transmission of HIV. Pauwels R, et al. **J Acquir Immune Defic Syndr Hum Retrovirol** 1996 Mar 1;11(3):211-21 (70 ref.)

Reexamination of the paradigm of HIV risk reduction in adolescents. Earl DT. **J Am Osteopath Assoc** 1995 Dec; 95(12):725-8 (32 ref.)

Women's sexuality: behaviors, responses, and individual differences. Andersen BL, et al. **J Consult Clin Psychol** 1995 Dec;63(6):891-906 (130 ref.)

Increased attention to human sexuality can improve HIV-AIDS prevention efforts: key research issues and directions. Kelly JA, et al. **J Consult Clin Psychol** 1995 Dec;63(6):907-18 (120 ref.)

Sexuality and related issues in the preadolescent and adolescent female with epilepsy. Mims J. **J Neurosci Nurs** 1996 Apr;28(2):102-6 (34 ref.)

Sequelae of premature sexual life [comment] Creatsas G. **J R Soc Med** 1995 Jul;88(7):369-71 (12 ref.) Comment on: J R Soc Med 1995 Jul;88(7):384-8.

HIV risk in adolescents: the role of sexual activity and substance use behaviors. Boyer CB, et al. **NIDA Res Monogr** 1994;143:135-54 (51 ref.)

HIV/AIDS risks among male, heterosexual noninjecting

drug users who exchange crack for sex. Inciardi JA. **NIDA Res Monogr** 1994;143:26–40 (66 ref.)
HIV risk behaviors of heterosexual male drug users. Needle RH. **NIDA Res Monogr** 1994;143:5–8 (2 ref.)
Factors associated with sexual risk of AIDS in women. O'Leary A. **NIDA Res Monogr** 1994;143:64–81 (82 ref.)
Substance use and HIV-transmitting behaviors among gay and bisexual men. Ostrow DG. **NIDA Res Monogr** 1994; 143:88–113 (35 ref.)
Injection and sexual risk behaviors of male heterosexual injecting drug users. Stephens RC, et al. **NIDA Res Monogr** 1994;143:9–25 (48 ref.)
Pathways of influence on fifth and eighth graders' reports about having had sexual intercourse. Porter CP, et al. **Res Nurs Health** 1996 Jun;19(3):193–204 (55 ref.)
Heterosexual transmission of HTLV-I. Epidemiological aspects. Figueroa JP. **West Indian Med J** 1996 Mar; 45(1):4–8 (80 ref.)
[Female sexuality after menopause] Rachev E, et al. **Akush Ginekol (Sofiia)** 1995;34(3):60–2 (10 ref.) **(Bul)**
[In the name of Commission VII (Sexually transmissible diseases and AIDS). Heterosexual transmission of HIV in France] Montagnier L. **Bull Acad Natl Med** 1995 Jun; 179(6):1209–24 (22 ref.) **(Fre)**
[Aging and sexuality in the male] Tordjman G. **Contracept Fertil Sex** 1996 Jun;24(6):501–4 (14 ref.) (Eng. Abstr.) **(Fre)**
[AIDS-related knowledge and sex behavior: a review of Italian studies of young people] Aloisi MS, et al. **Ann Ig** 1995 Sep–Oct;7(5):349–58 (38 ref.) (Eng. Abstr.) **(Ita)**
[Biological aspects of sexual orientation: similar behavior in mice and men] Larsson K, et al. **Lakartidningen** 1996 May 29;93(22):2139–42 (30 ref.) **(Swe)**

DRUG EFFECTS

Policing "perversions": Depo-Provera and John Money's new sexual order. Tsang DC. **J Homosex** 1995;28(3–4):397–426 (110 ref.)

PHYSIOLOGY

Oxytocin and female sexuality. Anderson-Hunt M, et al. **Gynecol Obstet Invest** 1995;40(4):217–21 (40 ref.)
Science and belief: psychobiological research on sexual orientation. Byne W. **J Homosex** 1995;28(3–4):303–44 (140 ref.)
The biology of homosexuality: sexual orientation or sexual preference? De Cecco JP, et al. **J Homosex** 1995; 28(1–2):1–27 (55 ref.)
Sexuality in the brain. Doell RG. **J Homosex** 1995; 28(3–4):345–54 (27 ref.)
Homosexuality, biology, and ideology. Haumann G. **J Homosex** 1995;28(1–2):57–77 (90 ref.)
Brain research, gender and sexual orientation. Swaab DF, et al. **J Homosex** 1995;28(3–4):283–301 (65 ref.)
Cough, exertional, and sexual headaches: an analysis of 72 benign and symptomatic cases. Pascual J, et al. **Neurology** 1996 Jun;46(6):1520–4 (19 ref.)
Sexuality in the elderly. Kaiser FE. **Urol Clin North Am** 1996 Feb;23(1):99–109 (76 ref.)
Sexuality and aging. Schiavi RC, et al. **Urol Clin North Am** 1995 Nov;22(4):711–26 (126 ref.)
[Androgens and feminine behavior] Kerdelhue B, et al. **Contracept Fertil Sex** 1996 May;24(5):407–12 (28 ref.) (Eng. Abstr.) **(Fre)**

PSYCHOLOGY

Addictive sexual behavior. Myers WA. **Am J Psychother** 1995 Fall;49(4):473–83 (27 ref.)
Managing erotic feelings in the physician–patient relationship [see comments] Golden GA, et al. **Can Med Assoc J** 1995 Nov 1;153(9):1241–5 (52 ref.) Comment in: Can Med Assoc J 1996 Apr 15;154(8):1149; discussion 1150. Comment in: Can Med Assoc J 1996 Apr 15;154(8):1149–50.
Gender–power relations and safer sex negotiation. Taylor BM. **J Adv Nurs** 1995 Oct;22(4):687–93 (46 ref.)

SEX BEHAVIOR, ANIMAL

c-Fos expression as a tool to search for the neurobiological base of the sexual behaviour of males. Bialy M, et al. **Acta Neurobiol Exp (Warsz)** 1996;56(2):567–77 (52 ref.)
Intersexuality in pigs: clinical, physiological and practical considerations. Hunter RH, et al. **Acta Vet Scand** 1996; 37(1):1–12 (29 ref.)
[Biological aspects of sexual orientation: similar behavior in mice and men] Larsson K, et al. **Lakartidningen** 1996 May 29;93(22):2139–42 (30 ref.) **(Swe)**

DRUG EFFECTS

The sexually dimorphic medial preoptic nucleus of quail: a key brain area mediating steroid action on male sexual behavior. Panzica GC, et al. **Front Neuroendocrinol** 1996 Jan;17(1):51–125 (287 ref.)

PHYSIOLOGY

Voltammetric and microdialysis monitoring of brain monoamine neurotransmitter release during sociosexual interactions. Mas M, et al. **Behav Brain Res** 1995 Nov; 71(1–2):69–79 (62 ref.)
Actions of sex steroids on behaviours beyond reproductive reflexes. Priest CA, et al. **Ciba Found Symp** 1995;191:74–84; discussion 84–9 (69 ref.)
Prolactin release after mating and genitosensory stimulation in females. Erskine MS. **Endocr Rev** 1995 Aug;16(4):508–28 (222 ref.)
Frank A. Beach Award. Functional significance of steroid modulation of GABAergic neurotransmission: analysis at the behavioral, cellular, and molecular levels. McCarthy MM. **Horm Behav** 1995 Jun;29(2):131–40 (48 ref.)
Animals models for the development of human sexuality: a critical evaluation. Fausto-Sterling A. **J Homosex** 1995; 28(3–4):217–36 (50 ref.)
Effects of testosterone and its metabolites on aromatase-immunoreactive cells in the quail brain: relationship with the activation of male reproductive behavior. Balthazart J, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1–6 Spec No):185–200 (125 ref.)
Differential control of proceptive and receptive components of female rat sexual behavior by the preoptic area. Sakuma Y. **Jpn J Physiol** 1995;45(2):211–28 (103 ref.)
Sperm competition: evolutionary causes and consequences. Birkhead TR. **Reprod Fertil Dev** 1995;7(4):755–75 (216 ref.)

SEX CHARACTERISTICS

Euclidean distance matrix analysis: confidence intervals for form and growth differences. Lele S, et al. **Am J Phys Anthropol** 1995 Sep;98(1):73–86 (28 ref.)
Influence of sex on pain assessment and management. Nevin K. **Ann Emerg Med** 1996 Apr;27(4):424–6 (26 ref.)
Influence of sex on cytogenetic end points: evidence from a large human sample and review of the literature. Bonassi S, et al. **Cancer Epidemiol Biomarkers Prev** 1995 Sep; 4(6):671–9 (77 ref.)
Effect of age and sex on the induction and elicitation of allergic contact dermatitis. Kwangsukstith C, et al. **Contact Dermatitis** 1995 Nov;33(5):289–98 (85 ref.)
Sexual dimorphism of hypertension. Chen YF. **Curr Opin Nephrol Hypertens** 1996 Mar;5(2):181–5 (33 ref.)
Racial, ethnic and gender differences in response to medicines. Matthews HW. **Drug Metabol Drug Interact** 1995;12(2):77–91 (38 ref.)
Gender as a risk factor for adverse events to medications. Kando JC, et al. **Drugs** 1995 Jul;50(1):1–6 (52 ref.)
Trinucleotide repeat expansion and human disease. Hummerich H, et al. **Electrophoresis** 1995 Sep; 16(9):1698–704 (92 ref.)
Effects of sex hormones on oncogene expression in the vagina and on development of sexual dimorphism of the pelvis and anococcygeus muscle in the mouse. Iguchi T, et al. **Environ Health Perspect** 1995 Oct;103 Suppl 7:79–82 (34 ref.)
Gender differences in secretory activity of the human somatotropic (growth hormone) axis. Veldhuis JD. **Eur J Endocrinol** 1996 Mar;134(3):287–95 (114 ref.)
The sexually dimorphic medial preoptic nucleus of quail: a key brain area mediating steroid action on male sexual behavior. Panzica GC, et al. **Front Neuroendocrinol** 1996 Jan;17(1):51–125 (287 ref.)
Oxytocin and female sexuality. Anderson-Hunt M, et al. **Gynecol Obstet Invest** 1995;40(4):217–21 (40 ref.)
Sexually dimorphic spatial learning in meadow voles Microtus pennsylvanicus and deer mice Peromyscus maniculatus. Galea LA, et al. **J Exp Biol** 1996 Jan;199 (Pt 1):195–200 (29 ref.)
Science and belief: psychobiological research on sexual orientation. Byne W. **J Homosex** 1995;28(3–4):303–44 (140 ref.)
Brain research, gender and sexual orientation. Swaab DF, et al. **J Homosex** 1995;28(3–4):283–301 (65 ref.)
Regulation of sex-specific formation of oestrogen in brain development: endogenous inhibitors of aromatase. Hutchison JB, et al. **J Steroid Biochem Mol Biol** 1996 Jan; 56(1–6 Spec No):201–7 (37 ref.)
Brain damage and postoperative hyponatremia: the role of gender. Ayus JC, et al. **Neurology** 1996 Feb;46(2):323–8 (72 ref.)
Meiosis in Drosophila: seeing is believing. Orr-Weaver TL. **Proc Natl Acad Sci U S A** 1995 Nov 7;92(23):10443–9 (59 ref.)
Social control of cell size: males and females are different. Fernald RD. **Prog Brain Res** 1995;105:171–7 (23 ref.)
Gender differences in risk perception: effects differ in stressed vs. non-stressed environments. Greenberg MR, et al. **Risk Anal** 1995 Aug;15(4):503–11 (29 ref.)
[Medical prescription and consumption of psychotropic drugs: questions on the differences between men and women] Baumann M, et al. **Cah Sociol Demogr Med** 1996 Jan–Mar;36(1):63–78 (38 ref.) (Eng. Abstr.) **(Fre)**
[Androgens and feminine behavior] Kerdelhue B, et al. **Contracept Fertil Sex** 1996 May;24(5):407–12 (28 ref.) (Eng. Abstr.) **(Fre)**

SEX CHROMATIN

see related
SEX DETERMINATION

SEX CHROMOSOME ABNORMALITIES

Genetic control of X inactivation and processes leading to X-inactivation skewing [editorial; comment] Belmont JW. **Am J Hum Genet** 1996 Jun;58(6):1101–8 (77 ref.) Comment on: Am J Hum Genet 1996 Jun;58(6):1111–9.
Sex chromosome tetrasomy and pentasomy. Linden MG, et al. **Pediatrics** 1995 Oct;96(4 Pt 1):672–82 (58 ref.)
[Generalized angitis and recurrent infection associated hemophagocytic syndrome in a girl with XXX syndrome] Wada Y, et al. **Ryumachi** 1995 Jun;35(3):589–94 (11 ref.) (Eng. Abstr.) **(Jpn)**

EPIDEMIOLOGY

Incidence of congenital heart disease: II. Prenatal incidence. Hoffman JI. **Pediatr Cardiol** 1995 Jul–Aug;16(4):155–65 (79 ref.)

ETIOLOGY

Debate. Assisted reproductive techniques – are we avoiding the genetic issues? Baschat AA, et al. **Hum Reprod** 1996 May;11(5):926–8 (10 ref.)
The risk of chromosomal abnormalities following ICSI. Martin RH. **Hum Reprod** 1996 May;11(5):924–5 (12 ref.)
Is ICSI associated with risks of genetic disease? Implications for counselling, practice and research. Persson JW, et al. **Hum Reprod** 1996 May;11(5):921–4 (30 ref.)

GENETICS

The origin of numerical chromosome abnormalities. Jacobs PA, et al. **Adv Genet** 1995;33:101–33 (66 ref.)
Sex determination and its pathology in man. Schafer AJ. **Adv Genet** 1995;33:275–329 (288 ref.)
The molecular basis of X-linked severe combined immunodeficiency: defective cytokine receptor signaling. Leonard WJ. **Annu Rev Med** 1996;47:229–39 (52 ref.)
Adrenoleukodystrophy. Moser HW. **Curr Opin Neurol** 1995 Jun;8(3):221–6 (37 ref.)
CRASH syndrome: clinical spectrum of corpus callosum hypoplasia, retardation, adducted thumbs, spastic paraparesis and hydrocephalus due to mutations in one single gene, L1. Fransen E, et al. **Eur J Hum Genet** 1995; 3(5):273–84 (49 ref.)
Casey Holter Essay Prize. The pathogenesis of X-linked hydrocephalus. Jouet M. **Eur J Pediatr Surg** 1995 Dec;5 Suppl 1:5–7 (36 ref.)
Xp-duplications with and without sex reversal. Baumstark A, et al. **Hum Genet** 1996 Jan;97(1):79–86 (32 ref.)

SEX CHROMOSOMES

Is sex worth searching for? Witt M. **Arch Immunol Ther Exp (Warsz)** 1994;42(5–6):345–8 (31 ref.)
[Sex chromosomes: what are they for? (A new concept)] Geodakian VA. **Dokl Akad Nauk** 1996 Feb;346(4):565–9 (15 ref.) **(Rus)**

GENETICS

Intrauterine diagnosis of sex chromosome aneuploidy. Linden MG, et al. **Obstet Gynecol** 1996 Mar;87(3):468–75 (51 ref.)
[Genetic mechanism of human sex differentiation] Ectors FJ. **Rev Med Brux** 1995 Dec;16(6):404–10 (40 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Sex chromatin in lepidoptera. Traut W, et al. **Q Rev Biol** 1996 Jun;71(2):239–56 (71 ref.)

SEX CORD-STROMAL TUMOR

PATHOLOGY

New developments in sex cord-stromal and germ cell tumors of the ovary. Gordon MD, et al. **Clin Lab Med** 1995 Sep; 15(3):595–610 (50 ref.)

SEX COUNSELING

Vasectomy counseling. Haws JM, et al. **Am Fam Physician** 1995 Oct;52(5):1395–9 (18 ref.)

METHODS

Treatment of sexual dysfunctions by sex therapy and other approaches. Hawton K. **Br J Psychiatry** 1995 Sep; 167(3):307–14 (45 ref.)

SEX DETERMINATION

Sex determination and its pathology in man. Schafer AJ. **Adv Genet** 1995;33:275–329 (288 ref.)
Sex determination in Hymenoptera: a need for genetic and molecular studies. Beukeboom LW. **Bioessays** 1995 Sep; 17(9):813–7 (47 ref.)
The developmental consequences of alternate splicing in sex determination and differentiation in Drosophila. MacDougall C, et al. **Dev Biol** 1995 Dec;172(2):353–76 (144 ref.)
The role of estrogen in turtle sex determination and the effect

of PCBs. Crews D, et al. **Environ Health Perspect** 1995 Oct;103 Suppl 7:73–7 (19 ref.)

Organization versus activation: the role of endocrine-disrupting contaminants (EDCs) during embryonic development in wildlife. Guillette LJ Jr, et al. **Environ Health Perspect** 1995 Oct;103 Suppl 7:157–64 (81 ref.)

The genetic basis of murine and human sex determination: a review. McElreavey K, et al. **Heredity** 1995 Dec;75 (Pt 6):599–611 (82 ref.)

The molecular genetics of human sex determination. Wolf U. **J Mol Med** 1995 Jul;73(7):325–31 (55 ref.)

Hormonal and behavioral determinants of the secondary sex ratio. Martin JF. **Soc Biol** 1995 Fall-Winter;42(3–4):226–38 (41 ref.)

METHODS

Is sex worth searching for? Witt M. **Arch Immunol Ther Exp (Warsz)** 1994;42(5–6):345–8 (31 ref.)

The molecular biology of SRY and its role in sex determination in mammals. Koopman P. **Reprod Fertil Dev** 1995;7(4):713–22 (63 ref.)

SEX DEVIATIONS see **PARAPHILIAS**

SEX DIFFERENCES see **SEX CHARACTERISTICS**

SEX DIFFERENTIATION

Sex differentiation — gonadogenesis and novel genes. Nordqvist K. **Int J Dev Biol** 1995 Oct;39(5):727–36 (76 ref.)

Xp duplications and sex reversal. Zanaria E, et al. **Philos Trans R Soc Lond B Biol Sci** 1995 Nov 29; 350(1333):291–6 (28 ref.)

Sexual differentiation of the human hypothalamus in relation to gender and sexual orientation. Swaab DF, et al. **Trends Neurosci** 1995 Jun;18(6):264–70 (61 ref.)

[Genetics and endocrinology of male sex differentiation: application to molecular study of male pseudohermaphroditism] Sultan C, et al. **C R Seances Soc Biol Fil** 1995;189(5):713–40 (83 ref.) (Eng. Abstr.) **(Fre)**

[Sex differentiation and its anomalies] Zamboni G, et al. **Pediatr Med Chir** 1996 Jan–Feb;18(1):3–12 (41 ref.) (Eng. Abstr.) **(Ita)**

[Sex differentiation and Ad4BP] Morohashi K. **Seikagaku** 1995 Oct;67(10):1195–209 (56 ref.) **(Jpn)**

GENETICS

Sex determination and its pathology in man. Schafer AJ. **Adv Genet** 1995;33:275–329 (288 ref.)

The evolution of chromosomal sex determination and dosage compensation. Charlesworth B. **Curr Biol** 1996 Feb 1; 6(2):149–62 (113 ref.)

The new genetics and women. Mahowald MB, et al. **Milbank Q** 1996;74(2):239–83 (160 ref.)

[Genetic mechanism of human sex differentiation] Ectors FJ. **Rev Med Brux** 1995 Dec;16(6):404–10 (40 ref.) (Eng. Abstr.) **(Fre)**

[Progress in the knowledge on the genetic process of sexual differentiation in humans] López-López M, et al. **Rev Invest Clin** 1996 Mar–Apr;48(2):129–37 (75 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

Sexuality in the brain. Doell RG. **J Homosex** 1995; 28(3–4):345–54 (27 ref.)

Animals models for the development of human sexuality: a critical evaluation. Fausto-Sterling A. **J Homosex** 1995; 28(3–4):217–36 (50 ref.)

Biomedical concepts of homosexuality: folk belief in a white coat. Gooren LJ. **J Homosex** 1995;28(3–4):237–46 (16 ref.)

Biology of bisexuality: critique and observations. Van Wyk PH, et al. **J Homosex** 1995;28(3–4):357–73 (65 ref.)

[Anti-Mullerian hormone. Structure and role in sexual differentiation] Jarmińska-Jackowiak T, et al. **Ginekol Pol** 1995 Jan;66(1):51–8 (35 ref.) (Eng. Abstr.) **(Pol)**

SEX DIFFERENTIATION DISORDERS

see related

TRANSSEXUALISM

Ethical issues in children with genital ambiguity. Grant DB. **Br J Urol** 1995 Nov;76 Suppl 2:75–8 (13 ref.)

CLASSIFICATION

[Sex differentiation and its anomalies] Zamboni G, et al. **Pediatr Med Chir** 1996 Jan–Feb;18(1):3–12 (41 ref.) (Eng. Abstr.) **(Ita)**

DIAGNOSIS

Imaging children with ambiguous genitalia and intersex states. Wright NB, et al. **Clin Radiol** 1995 Dec;50(12):823–9 (38 ref.)

ETIOLOGY

[Steroidal sex hormones and insensitivity syndromes] Stárka L, et al. **Bratisl Lek Listy** 1995 Nov;96(11):600–4 (20 ref.) (Eng. Abstr.) **(Slo)**

GENETICS

Sex determination and its pathology in man. Schafer AJ. **Adv Genet** 1995;33:275–329 (288 ref.)

Disorders of sexual development. Zajac JD, et al. **Baillieres Clin Endocrinol Metab** 1995 Jul;9(3):555–79 (75 ref.)

Luteinizing hormone receptor mutations and sex differentiation. Themmen AP, et al. **Eur J Endocrinol** 1996 May;134(5):533–40 (60 ref.)

Defects of androgen receptor function: from sex reversal to motor neurone disease. MacLean HE, et al. **Mol Cell Endocrinol** 1995 Aug 11;112(2):133–41 (104 ref.)

[Genetics of sexual development and its disorders] Osipova GR. **Genetika** 1996 Feb;32(2):184–91 (84 ref.) (Eng. Abstr.) **(Rus)**

SEX DIMORPHISM see **SEX CHARACTERISTICS**

SEX DISORDERS

CHEMICALLY INDUCED

Antidepressant-induced orgasm disorder. Segraves RT. **J Sex Marital Ther** 1995 Fall;21(3):192–201 (81 ref.)

DIAGNOSIS

Assessment: neurological evaluation of male sexual dysfunction. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. **Neurology** 1995 Dec;45(12):2287–92 (77 ref.)

ETIOLOGY

The sexual sequelae of testicular cancer. van Basten JP, et al. **Cancer Treat Rev** 1995 Sep;21(5):479–95 (141 ref.)

[Treatment of erectile dysfunction in multiple sclerosis] Fernández O. **Rev Neurol** 1995 Mar–Apr;23(120):320–1 (16 ref.) **(Spa)**

GENETICS

Reproductive phenotpes of the progesterone receptor null mutant mouse. Lydon JP, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1–6 Spec No):67–77 (78 ref.)

NURSING

Addressing sexual dysfunction following radiation therapy for a gynecologic malignancy [published erratum appears in Oncol Nurs Forum 1995 Nov–Dec;22(10):1476] Cartwright-Alcarese F. **Oncol Nurs Forum** 1995 Sep; 22(8):1227–32 (27 ref.)

SEX EDUCATION

Meeting the needs of young adults. McCauley AP, et al. **Popul Rep J** 1995 Oct;(41):1–43 (595 ref.)

[Progresses in child health in China, 1995] Yie G. **Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):754–5 (0 ref.) **(Chi)**

SEX FACTORS

Sex-specific differences in coronary artery disease risk factors, evaluation, and treatment: have they been adequately evaluated? Fetters JK, et al. **Am Heart J** 1996 Apr;131(4):796–813 (190 ref.)

SEX HORMONE-BINDING GLOBULIN

ANALYSIS

[Sex hormone-binding globulin (SHBG)] Saito H, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:569–72 (23 ref.) **(Jpn)**

PHYSIOLOGY

Sex steroid binding protein is a negative modulator of estrogen-induced breast cancer cell growth. Frairia R, et al. **Ann N Y Acad Sci** 1996 Apr 30;784:362–9 (18 ref.)

Roles of estrogen and SHBG in prostate physiology. Farnsworth WE. **Prostate** 1996 Jan;28(1):17–23 (49 ref.)

SEX HORMONES

ADVERSE EFFECTS

[Drug induced obesity] Murakami T, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:425–9 (16 ref.) **(Jpn)**

BIOSYNTHESIS

The ontogeny of growth hormone, insulin-like growth factors and sex steroids: molecular aspects. Han VK. **Horm Res** 1996;45(1–2):61–6 (45 ref.)

CONTRAINDICATIONS

[Sex hormone substitution in hormone-dependent neoplasms—oil into the fire?] Kleeberg UR. **Med Klin** 1996 Apr 10;91(4):234–7 (38 ref.) **(Ger)**

GENETICS

Molecular biology in reproductive endocrinology. Layman LC. **Curr Opin Obstet Gynecol** 1995 Oct;7(5):328–39 (104 ref.)

IMMUNOLOGY

Immunomodulatory mechanisms mediated by sex hormones in rheumatoid arthritis. Cutolo M, et al. **Ann N Y Acad Sci** 1996 Apr 30;784:237–51 (75 ref.)

Synthetic hormone/growth factor subunit vaccine with application to antifertility and cancer. Snyder LL, et al. **Pharm Biotechnol** 1995;6:907–30 (145 ref.)

PHARMACOLOGY

Gonadotropin gene modulation by steroids and gonadotropin-releasing hormone. Shupnik MA. **Biol Reprod** 1996 Feb;54(2):279–86 (60 ref.)

Effects of sex hormones on oncogene expression in the vagina and on development of sexual dimorphism of the pelvis and anococcygeus muscle in the mouse. Iguchi T, et al. **Environ Health Perspect** 1995 Oct;103 Suppl 7:79–82 (34 ref.)

Regulation of transforming growth factor beta by sex steroids. Hering S, et al. **Horm Metab Res** 1995 Aug; 27(8):345–51 (87 ref.)

Gonadotrophin surge-inhibiting/attenuating factor governs luteinizing hormone secretion during the ovarian cycle: physiology and pathology. de Koning J. **Hum Reprod** 1995 Nov;10(11):2854–61 (86 ref.)

[Sex hormones, glycolipid metabolism, and atherogenesis] Sarubbi B, et al. **Minerva Med** 1995 Jun;86(6):265–73 (67 ref.) (Eng. Abstr.) **(Ita)**

PHYSIOLOGY

In vitro models for the effects of sex hormones on neurons. Lustig RH. **Ann N Y Acad Sci** 1996 Apr 30;784:370–80 (72 ref.)

Steroid control of higher brain function and behavior. Mortaud S, et al. **Behav Genet** 1996 Jul;26(4):367–72 (22 ref.)

Non-genomic mechanisms of action of steroid hormones. Baulieu EE, et al. **Ciba Found Symp** 1995;191:24–37; discussion 37–42 (66 ref.)

Sex steroids and the immune system. Fox HS. **Ciba Found Symp** 1995;191:203–11; discussion 211–7 (31 ref.)

Sex steroids, cytokines and the bone marrow: new concepts on the pathogenesis of osteoporosis. Manolagas SC, et al. **Ciba Found Symp** 1995;191:187–96; discussion 197–202 (45 ref.)

Actions of sex steroids on behaviours beyond reproductive reflexes. Priest CA, et al. **Ciba Found Symp** 1995;191:74–84; discussion 84–9 (69 ref.)

Steroidal regulation of cell cycle progression. Sutherland RL, et al. **Ciba Found Symp** 1995;191:218–28; discussion 228–34 (29 ref.)

Sex hormones, proto-oncogene expression and apoptosis: their effects on rheumatoid synovial tissue. Cutolo M, et al. **Clin Exp Rheumatol** 1996 Jan–Feb;14(1):87–94 (58 ref.)

The role of gonadal steroids in hypothalamic-pituitary-adrenal axis regulation. Young EA. **Crit Rev Neurobiol** 1995;9(4):371–81 (78 ref.)

Frank A. Beach Award. Functional significance of steroid modulation of GABAergic neurotransmission: analysis at the behavioral, cellular, and molecular levels. McCarthy MM. **Horm Behav** 1995 Jun;29(2):131–40 (48 ref.)

Growth hormone, growth factors and the gonad. Albanese A, et al. **Horm Res** 1995;44 Suppl 3:15–17 (25 ref.)

Sex steroids, growth hormone, insulin-like growth factor-1: neuroendocrine and metabolic regulation in puberty. Mauras N, et al. **Horm Res** 1996;45(1–2):74–80 (41 ref.)

The connective tissue diseases and the overall influence of gender. Lahita RG. **Int J Fertil Menopausal Stud** 1996 Mar–Apr;41(2):156–65 (121 ref.)

Hormones and sexual orientation: a questionable link. Banks A, et al. **J Homosex** 1995;28(3–4):247–68 (70 ref.)

Animals models for the development of human sexuality: a critical evaluation. Fausto-Sterling A. **J Homosex** 1995; 28(3–4):217–36 (50 ref.)

Biomedical concepts of homosexuality: folk belief in a white coat. Gooren LJ. **J Homosex** 1995;28(3–4):237–46 (16 ref.)

Biology of bisexuality: critique and observations. Van Wyk PH, et al. **J Homosex** 1995;28(3–4):357–73 (65 ref.)

Dual regulation of the epidermal growth factor family of growth factors in breast cancer by sex steroids and protein kinase C. Martinez-Lacaci I, et al. **J Steroid Biochem Mol Biol** 1996 Jan;57(1–2):1–11 (145 ref.)

Evidence that mammalian sex ratios at birth are partially controlled by parental hormone levels at the time of conception. James WH. **J Theor Biol** 1996 Jun 21; 180(4):271–86 (164 ref.)

Sex steroid hormones and macrophage function. Miller L, et al. **Life Sci** 1996;59(1):1–14 (186 ref.)

Hormones and cancer in humans. Key TJ. **Mutat Res** 1995 Dec;333(1–2):59–67 (85 ref.)

Endocrine-immunological homeostasis: the interrelationship between the immune system and sex steroids involves the

hypothalamo-pituitary-gonadal axis. Drača SR. **Panminerva Med** 1995 Jun;37(2):71-6 (45 ref.)

The nonhuman primate model of the relationship between gonadal steroids and coronary heart disease. Clarkson TB, et al. **Prog Cardiovasc Dis** 1995 Nov-Dec;38(3):189-98 (34 ref.)

Hormonal and genetic interactions in murine hepatocarcinogenesis. Poole TM, et al. **Prog Clin Biol Res** 1995;391:187-94 (24 ref.)

Hormonal and pregnancy relationships to rheumatoid arthritis: convergent effects with immunologic and microvascular systems. Masi AT, et al. **Semin Arthritis Rheum** 1995 Aug;25(1):1-27 (166 ref.)

[Sex hormone replacement following menopause--for all women? A plea for prevention using estrogens and gestagens] Nocke W. **Ther Umsch** 1995 Oct;52(10):693-704 (14 ref.) (Eng. Abstr.) **(Ger)**

[Pathogenesis of visceral fat accumulation] Keno Y, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:121-6 (20 ref.) **(Jpn)**

[Role of steroid hormone in adipocyte metabolism] Nagasaka Y, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:111-4 (9 ref.) **(Jpn)**

[Current concepts concerning the role of sex hormones and gonadotropins in the development of laryngeal cancer] Shadyev KhD, et al. **Vestn Ross Akad Med Nauk** 1995; (10):22-4 (30 ref.) **(Rus)**

THERAPEUTIC USE

Symptoms related to the menopause and sex steroid treatments. Bäckström T. **Ciba Found Symp** 1995; 191:171-80; discussion 180-6 (55 ref.)

SEX MATURATION

PHYSIOLOGY

[Cryptorchism--assessment from an andrologic viewpoint] Weidner W, et al. **Urologe A** 1996 Mar;35(2):111-4 (31 ref.) (Eng. Abstr.) **(Ger)**

SEX OFFENSES

Sexual and physical abuse and gastrointestinal illness. Review and recommendations [see comments] Drossman DA, et al. **Ann Intern Med** 1995 Nov 15;123(10):782-94 (99 ref.) Comment in: Ann Intern Med 1995 Nov 15;123(10):774-81. Comment in: Ann Intern Med 1996 Sep 1;125(5):426; discussion 426-7.

[Hormonal treatments for disorders of sexual conduct] Cordier B, et al. **Bull Acad Natl Med** 1996 Mar; 180(3):599-605; discussion 605-10 (15 ref.) (Eng. Abstr.) **(Fre)**

LEGISLATION & JURISPRUDENCE

In camera inspections of privileged records in sexual assault trials: balancing defendants' rights and state interests under Massachusetts's Bishop Test. Crowley EM. **Am J Law Med** 1995;21(1):131-64 (313 ref.)

[Some medico-psychological perspectives on sexual homicides. Three cases] Bénézech M. **Ann Med Psychol (Paris)** 1995 Oct;153(8):501-11 (22 ref.) (Eng. Abstr.) **(Fre)**

PSYCHOLOGY

Child and adolescent sex abuse perpetrators: a review of the research literature. Vizard E, et al. **J Child Psychol Psychiatry** 1995 Jul;36(5):731-56 (115 ref.)

Helping survivors of sexual abuse through labor. Burian J. **MCN Am J Matern Child Nurs** 1995 Sep-Oct;20(5):252-6 (14 ref.)

[Some medico-psychological perspectives on sexual homicides. Three cases] Bénézech M. **Ann Med Psychol (Paris)** 1995 Oct;153(8):501-11 (22 ref.) (Eng. Abstr.) **(Fre)**

SEX PHEROMONES see **SEX ATTRACTANTS**

SEX PREDETERMINATION see **SEX PRESELECTION**

SEX PREFERENCE see **SEX**

SEX PRESELECTION

New advances in sex preselection. Reubinoff BE, et al. **Fertil Steril** 1996 Sep;66(3):343-50 (86 ref.)

Sex preselection by flow cytometric separation of X and Y chromosome-bearing sperm based on DNA difference: a review. Johnson LA. **Reprod Fertil Dev** 1995;7(4):893-903 (47 ref.)

METHODS

Fluorescent PCR: a new technique for PGD of sex and single-gene defects. Findlay I, et al. **J Assist Reprod Genet** 1996 Feb;13(2):96-103 (28 ref.)

[A girl or a boy, as made to order] Niemi M. **Duodecim** 1994; 110(12):1124-30 (39 ref.) **(Fin)**

SEX RATIO

Prevalence, incidence and sex ratio of transsexualism. Landén M, et al. **Acta Psychiatr Scand** 1996 Apr;93(4):221-3 (18 ref.)

Genetic control of the secondary sex ratio. Bernstein ME. **Hum Reprod** 1995 Oct;10(10):2531-3 (26 ref.)

Follicular phase length, cycle day of conception and sex ratio of offspring. James WH. **Hum Reprod** 1995 Oct; 10(10):2529-31 (39 ref.)

Interpregnancy intervals, high maternal age and seasonal effects on the human sex ratio. James WH. **Hum Reprod** 1996 Jan;11(1):7-8 (14 ref.)

Genetic and non-genetic determinants of the human sex ratio at birth [editorial] James WH. **Hum Reprod** 1996 May; 11(5):939-40 (24 ref.)

Further concepts on regulators of the sex ratio in human offspring. Non-optimal maturation of oocytes and the sex ratio. Jongbloet PH, et al. **Hum Reprod** 1996 Jan;11(1):2-7 (60 ref.)

Differential implantation rates and variations in the sex ratio. Mittwoch U. **Hum Reprod** 1996 Jan;11(1):8-9 (14 ref.)

Evidence that mammalian sex ratios at birth are partially controlled by parental hormone levels at the time of conception. James WH. **J Theor Biol** 1996 Jun 21; 180(4):271-86 (164 ref.)

Hormonal and behavioral determinants of the secondary sex ratio. Martin JF. **Soc Biol** 1995 Fall-Winter;42(3-4):226-38 (41 ref.)

SEX REVERSAL, GONADAL

Campomelic dysplasia with XY sex reversal: diverse phenotypes resulting from mutations in a single gene. Schafer AJ, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:137-49 (46 ref.)

Xp-duplications with and without sex reversal. Baumstark A, et al. **Hum Genet** 1996 Jan;97(1):79-86 (32 ref.)

Xp duplications and sex reversal. Zanaria E, et al. **Philos Trans R Soc Lond B Biol Sci** 1995 Nov 29; 350(1333):291-6 (28 ref.)

SEX ROLE see **GENDER IDENTITY**

SEX SELECTION see **SEX PRESELECTION**

SEX STEROID-BINDING PROTEIN see **SEX HORMONE-BINDING GLOBULIN**

SEXISM see **PREJUDICE**

SEXOLOGY see **SEX**

SEXUAL ABUSE, CHILD see **CHILD ABUSE, SEXUAL**

SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL see **PSYCHOSEXUAL DYSFUNCTIONS**

SEXUAL HARASSMENT

Harassment of women physicians. Schiffman M, et al. **J Am Med Womens Assoc** 1995 Nov-Dec;50(6):207-11 (36 ref.)

LEGISLATION & JURISPRUDENCE

Sexual harassment in medical education: a review of the literature with comments from the law. Nora LM. **Acad Med** 1996 Jan;71(1 Suppl):S113-8 (54 ref.)

SEXUAL INTERCOURSE see **COITUS**

SEXUAL ORIENTATION see **SEX BEHAVIOR**

SEXUAL PARTNERS

[Effectiveness of condoms in the prevention of HIV infection in partners of seropositive subjects] Guillén Grima F, et al. **Med Clin (Barc)** 1995 Oct 28;105(14):541-8 (99 ref.) **(Spa)**

PSYCHOLOGY

Gender-power relations and safer sex negotiation. Taylor BM. **J Adv Nurs** 1995 Oct;22(4):687-93 (46 ref.)

SEXUALLY TRANSMITTED DISEASES

What's new in sexually transmitted diseases. Benson PM. **Adv Dermatol** 1996;11:85-103; discussion 104 (43 ref.)

Oral manifestations of selected sexually related conditions. Terezhalmy GT, et al. **Dermatol Clin** 1996 Apr; 14(2):303-17 (163 ref.)

STDs: Screening, therapy, and long-term implications for the adolescent patient. Bishop-Townsend V. **Int J Fertil Menopausal Stud** 1996 Mar-Apr;41(2):109-14 (41 ref.)

Sequelae of premature sexual life [comment] Creatsas G. **J R Soc Med** 1995 Jul;88(7):369-71 (12 ref.) Comment on: J R Soc Med 1995 Jul;88(7):384-8.

[Progresses in dermatology and venereology in China, 1995] Zhu T. **Chung Hua I Hsueh Tsa Chih** 1995 Dec; 75(12):763-4 (0 ref.) **(Chi)**

COMPLICATIONS

Cervical intraepithelial neoplasia, cervical cancer, and HPV. Holly EA. **Annu Rev Public Health** 1996;17:69-84 (96 ref.)

Managing HIV. Part 5: Treating secondary outcomes. 5.18 HIV and sexually transmitted diseases. Plummer DC, et al. **Med J Aust** 1996 May 20;164(10):608-11 (611 ref.)

DIAGNOSIS

Update on laboratory diagnosis of sexually transmitted diseases. Woods GL. **Clin Lab Med** 1995 Sep;15(3):665-84 (70 ref.)

Application of DNA-based technologies in the diagnosis of sexually transmitted diseases. Mårdh PA, et al. **Curr Probl Dermatol** 1996;24:174-83 (43 ref.)

Diagnosing sexually transmitted diseases in HIV-positive patients. Penneys NS. **Curr Probl Dermatol** 1996;24:77-81 (22 ref.)

DRUG THERAPY

Antimicrobial therapy of non-viral sexually transmitted diseases--an update. Chan RK. **Ann Acad Med Singapore** 1995 Jul;24(4):579-83 (33 ref.)

Azithromycin. Johnson RB. **Curr Probl Dermatol** 1996; 24:184-93 (30 ref.)

Treating sexually transmitted diseases in pregnancy. Vetter K. **Curr Probl Dermatol** 1996;24:164-73 (36 ref.)

Drugs for sexually transmitted diseases. **Med Lett Drugs Ther** 1995 Dec 22;37(964):117-22 (28 ref.)

EPIDEMIOLOGY

Sexually transmitted diseases in Australia: a decade of change. Epidemiology and surveillance. Mulhall BP, et al. **Ann Acad Med Singapore** 1995 Jul;24(4):569-78 (56 ref.)

Sexually transmitted diseases in South Africa. Pham-Kanter GB, et al. **Genitourin Med** 1996 Jun;72(3):160-71 (115 ref.)

Sexually transmitted diseases in developing countries. Mabey D. **Trans R Soc Trop Med Hyg** 1996 Mar-Apr;90(2):97-9 (7 ref.)

ETIOLOGY

Carcinoma of the male breast: a sexually transmitted disease? Amir H, et al. **East Afr Med J** 1996 Mar;73(3):187-90 (32 ref.)

MICROBIOLOGY

Chlamydia trachomatis infection update [see comments] Heath CB, et al. **Am Fam Physician** 1995 Oct;52(5):1455-62 (17 ref.) Comment in: Am Fam Physician 1996 Mar;53(4):1085.

PREVENTION & CONTROL

Contraception, unintended pregnancies, and sexually transmitted diseases: why isn't a simple solution possible? Cates W Jr. **Am J Epidemiol** 1996 Feb 15;143(4):311-8 (30 ref.)

Barriers to conception and disease. Donovan B. **Ann Acad Med Singapore** 1995 Jul;24(4):608-14 (73 ref.)

Preventing pelvic infection after abortion [editorial] Stevenson MM, et al. **Int J STD AIDS** 1995 Sep-Oct; 6(5):305-12 (61 ref.)

Adolescent condom use, the health belief model, and the prevention of sexually transmitted disease. Hiltabiddle SJ. **J Obstet Gynecol Neonatal Nurs** 1996 Jan;25(1):61-6 (36 ref.)

Sexually transmitted diseases: current and emerging concerns. Youngkin EQ. **J Obstet Gynecol Neonatal Nurs** 1995 Oct; 24(8):743-58 (62 ref.)

The diaphragm: barrier contraception has a new social role. Tagg PI. **Nurse Pract** 1995 Dec;20(12):36, 39-42 (24 ref.)

[Rape and sexually transmitted diseases] Pawlaczyk M. **Ginekol Pol** 1996 Apr;67(4):210-4 (20 ref.) (Eng. Abstr.) **(Pol)**

RADIOTHERAPY

Laser therapy. Küng EE. **Curr Probl Dermatol** 1996; 24:247-54 (20 ref.)

THERAPY

Sexual infections in the antenatal patient. Priestley C, et al. **Practitioner** 1995 Sep;239(1554):552-7 (6 ref.)

TRANSMISSION

Sexually transmitted diseases in animals: ecological and evolutionary implications. Lockhart AB, et al. **Biol Rev Camb Philos Soc** 1996 Aug;71(3):415-71 (302 ref.)

Women, contraception and STDs including HIV [editorial] Carlin EM, et al. **Int J STD AIDS** 1995 Nov-Dec; 6(6):373-86 (234 ref.)

Sexually transmissible agent and African Kaposi's sarcoma [editorial] Matondo P, et al. **Int J STD AIDS** 1996 Jan-Feb; 7(1):4-6 (35 ref.)

SEXUALLY TRANSMITTED DISEASES, BACTERIAL

DRUG THERAPY

Quinolones in sexually transmitted diseases. Global experience. Ridgway GL. **Drugs** 1995;49 Suppl 2:115-22 (46 ref.)

The use of fluoroquinolones in sexually transmitted diseases

in Southeast Asia. Sivayathorn A. **Drugs** 1995;49 Suppl 2:123–7 (23 ref.)

[Azithromycin and genital infections] Micoud M, et al. **Pathol Biol (Paris)** 1995 Jun;43(6):542–6 (19 ref.) (Eng. Abstr.) **(Fre)**

SEXUALLY TRANSMITTED DISEASES, VIRAL

EPIDEMIOLOGY

Human papillomavirus infection and associated disease in persons infected with human immunodeficiency virus. Vernon SD, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S121–4 (27 ref.)

PREVENTION & CONTROL

Behavioural interventions in the control of human immunodeficiency virus and other sexually transmitted diseases—a review. Wong ML. **Ann Acad Med Singapore** 1995 Jul;24(4):602–7 (36 ref.)

TRANSMISSION

Sexual, vertical and household transmission of hepatitis C. Caldwell SH, et al. **Va Med Q** 1995 Fall;122(4):270–4 (35 ref.)

SEZARY SYNDROME

DRUG THERAPY

Chemotherapy for mycosis fungoides and the Sézary syndrome. Rosen ST, et al. **Hematol Oncol Clin North Am** 1995 Oct;9(5):1109–16 (18 ref.)

SGOT see **ASPARTATE AMINOTRANSFERASE**

SGPT see **ALANINE AMINOTRANSFERASE**

SH DOMAINS see **SRC HOMOLOGY DOMAINS**

SH-REAGENTS see **SULFHYDRYL REAGENTS**

SHARED PARANOID DISORDER

DIAGNOSIS

Shared psychotic disorder: a critical review of the literature. Silveira JM, et al. **Can J Psychiatry** 1995 Sep;40(7):389–95 (61 ref.)

GENETICS

Folie simultanée in monozygotic twins. White TG. **Can J Psychiatry** 1995 Sep;40(7):418–20 (26 ref.)

PSYCHOLOGY

[Induced delusional disorder in childhood and adolescence] Zillessen KE, et al. **Z Kinder Jugendpsychiatr** 1996 Jun; 24(2):117–26 (43 ref.) **(Ger)**

SHARP SYNDROME see **MIXED CONNECTIVE TISSUE DISEASE**

SHEEHAN'S SYNDROME see **HYPOPITUITARISM**

SHEEP

Microbiology of fresh and restructured lamb meat: a review. al-Sheddy IA, et al. **Crit Rev Microbiol** 1995;21(1):31–52 (183 ref.)

EMBRYOLOGY

Hypothalamic pituitary adrenal function in the sheep fetus. Matthews SG, et al. **Reprod Fertil Dev** 1995;7(3):509–16 (52 ref.)

GENETICS

Transgenic sheep and wool growth: possibilities and current status. Powell BC, et al. **Reprod Fertil Dev** 1994;6(5):615–23 (28 ref.)

GROWTH & DEVELOPMENT

Impact of composition manipulation on lean lamb production in the United States. Beermann DH, et al. **J Anim Sci** 1995 Aug;73(8):2493–502 (37 ref.)

PARASITOLOGY

The prevalence of anthelmintic resistance in nematode parasites of sheep in southern Latin America: general overview. Waller PJ, et al. **Vet Parasitol** 1996 Apr; 62(3–4):181–7 (20 ref.)

PHYSIOLOGY

Oviduct during early pregnancy: hormonal regulation and interactions with the fertilized ovum. Murray MK, et al. **Microsc Res Tech** 1995 Aug 15;31(6):497–506 (49 ref.)

SHEEP DISEASES

Resistance and the control of sheep ectoparasites. Levot GW. **Int J Parasitol** 1995 Nov;25(11):1355–62 (35 ref.)

Costs of major parasites to the Australian livestock industries. McLeod RS. **Int J Parasitol** 1995 Nov;25(11):1363–7 (25 ref.)

Australian–Indonesian collaboration in veterinary arbovirology—a review. Daniels PW, et al. **Vet Microbiol** 1995 Sep;46(1–3):151–74 (108 ref.)

The prevalence of anthelmintic resistance in nematode parasites of sheep in southern Latin America: general overview. Waller PJ, et al. **Vet Parasitol** 1996 Apr; 62(3–4):181–7 (20 ref.)

DIAGNOSIS

The clinical differentiation of nervous and muscular locomotor disorders of sheep in Australia. Bourke CA. **Aust Vet J** 1995 Jun;72(6):228–34 (40 ref.)

DRUG THERAPY

Chemotherapy of human nematodes: learning from the problems in sheep. Coles GC. **J R Soc Med** 1995 Nov; 88(11):649P–651P (10 ref.)

ETIOLOGY

Impaired absorption of magnesium in the aetiology of grass tetany. Dua K, et al. **Br Vet J** 1995 Jul–Aug;151(4):413–26 (98 ref.)

VIROLOGY

Retroviral aetiopathogenesis of ovine pulmonary carcinoma: a critical appraisal [see comments] Hecht SJ, et al. **Br Vet J** 1996 Jul;152(4):395–409 (56 ref.) Comment in: Br Vet J 1996 Jul;152(4):369–72.

Characteristics of ovine and caprine lentivirus infections. Perk K. **Leukemia** 1995 Oct;9 Suppl 1:S98–100 (25 ref.)

SHELLFISH

see related
MUSSELS

Spoilage and shelf-life extension of fresh fish and shellfish. Ashie IN, et al. **Crit Rev Food Sci Nutr** 1996 Jan; 36(1–2):87–121 (246 ref.)

ANALYSIS

Biogenic amines in fish and shellfish. Rawles DD, et al. **Adv Food Nutr Res** 1996;39:329–65 (147 ref.)

MICROBIOLOGY

Shellfish-borne illnesses. A Hong Kong perspective. Chan TY. **Trop Geogr Med** 1995;47(6):305–7 (17 ref.)

POISONING

Shellfish-borne illnesses. A Hong Kong perspective. Chan TY. **Trop Geogr Med** 1995;47(6):305–7 (17 ref.)

SHELTERED WORKSHOPS

see related
EMPLOYMENT, SUPPORTED

SHERMAN ANTITRUST ACT see **ANTITRUST LAWS**

SHIGELLA

see related
DYSENTERY, BACILLARY

SHIGELLA FLEXNERI

GENETICS

Live attenuated Shigella flexneri mutants as vaccine candidates against shigellosis and vectors for antigen delivery. Phalipon A, et al. **Biologicals** 1995 Jun; 23(2):125–34 (54 ref.)

PATHOGENICITY

[Pathogenicity of Shigella flexneri and its regulation] Sasakawa C. **Nippon Saikingaku Zasshi** 1995 Jul; 50(3):623–36 (76 ref.) **(Jpn)**

PHYSIOLOGY

The cell biology of infection by intracellular bacterial pathogens. Theriot JA. **Ann Rev Cell Dev Biol** 1995; 11:213–39 (106 ref.)

SHIGELLA INFECTIONS see **DYSENTERY, BACILLARY**

SHIKIMIC ACID

METABOLISM

The biosynthesis of shikimate metabolites. Dewick PM. **Nat Prod Rep** 1995 Dec;12(6):579–607 (189 ref.)

SHINGLES see **HERPES ZOSTER**

SHIPS

Anticoagulant therapy in ischaemic heart disease in seafarers. Częstochowska E. **Bull Inst Marit Trop Med Gdynia** 1993–94;44–45(1–4):13–5 (10 ref.)

Transportation disasters—a review. Lundin T. **J Trauma Stress** 1995 Jul;8(3):381–9 (27 ref.)

Use of intravenous sedation for wisdom tooth surgery on aircraft carriers. Hooley JR, et al. **Mil Med** 1995 Aug; 160(8):398–400 (17 ref.)

STANDARDS

Aircraft and ship disinfection. Cancellotti FM. **Rev Sci Tech** 1995 Mar;14(1):177–89 (20 ref.)

SHOCK

BLOOD

Advances in the study on rheological behavior of leukocyte during severe shock. Zhao K. **Chin Med J (Engl)** 1996 Feb; 109(2):110–1 (8 ref.)

COMPLICATIONS

Pathogenesis and treatment of multiorgan failure dysfunction syndrome in shock. Ciesielski L, et al. **Rocz Akad Med Bialymst** 1995;40(1):13–24 (50 ref.)

[Circulatory shock. Extrapulmonary etiology of respiratory insufficiency] Vogelmeier C, et al. **Internist (Berl)** 1995 Aug;36(8):756–64 (39 ref.) **(Ger)**

[The liver in shock and acute heart failure] Sekiyama T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):341–4 (9 ref.) **(Jpn)**

DIAGNOSIS

Systemic capillary leak syndrome in a child. Foeldvari I, et al. **J Pediatr** 1995 Nov;127(5):739–41 (15 ref.)

DRUG THERAPY

The use of colloids in clinical practice. Cone A. **Br J Hosp Med** 1995 Aug 16–Sep 5;54(4):155–9 (20 ref.)

New advances in the pharmacologic approach to circulatory shock. Chernow B. **J Clin Anesth** 1996 May;8(3 Suppl):67S–69S (15 ref.)

[Pharmacological routes of administration in circulatory collapse] Kristensen BB, et al. **Ugeskr Laeger** 1995 Dec 4;157(49):6864–8 (35 ref.) (Eng. Abstr.) **(Dan)**

[Treatment of severe hypovolemia with hypertonic saline] Rask H, et al. **Ugeskr Laeger** 1996 Jan 29;158(5):584–9 (39 ref.) (Eng. Abstr.) **(Dan)**

IMMUNOLOGY

The mechanisms of host defense dysfunction following shock and trauma. Faist E. **Curr Top Microbiol Immunol** 1996; 216:259–74 (92 ref.)

METABOLISM

[Changes in the generation of free oxygen radicals in shock and their significance in the irreversibility of a pathological process] Oborin AN. **Klin Khir** 1995;(6):34–8 (59 ref.) **(Rus)**

PHYSIOPATHOLOGY

Neuroendocrine mechanisms during reversible hypovolaemic shock in humans with emphasis on the histaminergic and serotonergic system. Matzen SH. **Acta Physiol Scand Suppl** 1995;628:1–31 (208 ref.)

Triage of critically ill patients: an overview of interventions. Rady MY. **Emerg Med Clin North Am** 1996 Feb;14(1):13–33 (91 ref.)

Microcirculatory homeostasis 1930–1990: insight into microcirculatory readjustments provided by studies on the peripheral circulatory insufficiency of the shock syndrome. Zweifach BW. **Microcirculation** 1995 Sep;2(3):245–51 (44 ref.)

Pathophysiology of fluid translocation in hypovolemic state. Duda K. **Rocz Akad Med Bialymst** 1995;40(1):25–35 (46 ref.)

Polymorphonuclear leukocytes: their role as central cellular elements in shock pathogenesis. Simms HH. **Shock** 1995 Sep;4(3):225–31 (92 ref.)

Invasive and noninvasive monitoring for early recognition and treatment of shock in high-risk trauma and surgical patients. Asensio JA, et al. **Surg Clin North Am** 1996 Aug; 76(4):985–97 (25 ref.)

Priorities in the management of profound shock. Britt LD, et al. **Surg Clin North Am** 1996 Aug;76(4):645–60 (56 ref.)

The critical care of the severely injured patient—I. Assessing and improving oxygen delivery. Cornwell EE 3rd, et al. **Surg Clin North Am** 1996 Aug;76(4):959–69 (30 ref.)

[Progresses in pathophysiology in China, 1995] Jin H. **Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):777–8 (0 ref.) **(Chi)**

[What is new in shock research?] Kreimeier U, et al. **Chirurg** 1995 Nov;66(11):1029–39 (83 ref.) (Eng. Abstr.) **(Ger)**

[Neonatal characteristics in the physiopathology of shock] Tuo P, et al. **Pediatr Med Chir** 1995 May–Jun;17(3):209–11 (13 ref.) (Eng. Abstr.) **(Ita)**

THERAPY

Emergency fluid management for hypovolemia. Pflederer TA. **Postgrad Med** 1996 Sep;100(3):243–4, 247–8, 251–4 (17 ref.)

Hypertonic volume therapy: feasibility in the prevention and treatment of multiple organ failure and sepsis. Monteiro Pacheco A Jr, et al. **Rev Paul Med** 1995 Nov–Dec; 113(6):1053–60 (53 ref.)

[New developments in clinical therapy of shock] Walz M, et al. **Chirurg** 1995 Nov;66(11):1040–9 (59 ref.) (Eng. Abstr.) **(Ger)**

SHOCK, ANAPHYLACTIC see ANAPHYLAXIS

SHOCK, CARDIOGENIC

Cardiogenic shock. Moscucci M, et al. **Cardiol Clin** 1995 Aug; 13(3):391–406 (116 ref.)

DIAGNOSIS

Cardiovascular shock. Rodgers KG. **Emerg Med Clin North Am** 1995 Nov;13(4):793–810 (61 ref.)

DRUG THERAPY

[Emergency drug therapy of acute heart failure and cardiogenic shock] Inishi Y, et al. **Nippon Naika Gakkai Zasshi** 1995 Nov 10;84(11):1810–4 (5 ref.) **(Jpn)**

ETIOLOGY

Reversible cardiogenic shock in an angry woman—case report and review of the literature. Kovacs KA, et al. **Can J Cardiol** 1996 Jul;12(7):689–93 (52 ref.)

PHYSIOPATHOLOGY

[VO2 and DO2 during cardiogenic shock and infection] Beale R. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May;31(1 Suppl):S22–5 (19 ref.) **(Ger)**

THERAPY

Cardiovascular shock. Rodgers KG. **Emerg Med Clin North Am** 1995 Nov;13(4):793–810 (61 ref.)

An update on cardiogenic shock. Talley JD. **J Ark Med Soc** 1995 Dec;92(7):341–2 (6 ref.)

[Therapeutic options in cardiogenic shock] Alonso Francia C, et al. **Rev Esp Cardiol** 1995 Sep;48(9):573–80 (73 ref.) (Eng. Abstr.) **(Spa)**

SHOCK, ENDOTOXIC see SHOCK, SEPTIC

SHOCK, HEMORRHAGIC

COMPLICATIONS

Shock-associated right colon ischemia and necrosis. Ludwig KA, et al. **J Trauma** 1995 Dec;39(6):1171–4 (28 ref.)

PHYSIOPATHOLOGY

Hemorrhagic shock. Peitzman AB, et al. **Curr Probl Surg** 1995 Nov;32(11):925–1002 (268 ref.)

Calcium regulation and nonprotective properties of calcium in surgical ischemia. Shapiro MJ, et al. **New Horiz** 1996 Feb;4(1):134–8 (29 ref.)

The opioid/anti-opioid balance in shock: a new target for therapy in resuscitation. Bertolini A. **Resuscitation** 1995 Aug;30(1):29–42 (177 ref.)

[Microcirculation and oxygen supply to the liver in hemorrhagic shock and sepsis] Vollmar B. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Oct; 30 Suppl 1:S52–4 (21 ref.) **(Ger)**

[The peptidergic correction of hemorrhagic shock] Bastrikova NA, et al. **Usp Fiziol Nauk** 1996 Jan–Mar; 27(1):32–46 (100 ref.) (Eng. Abstr.) **(Rus)**

THERAPY

Suspended animation for delayed resuscitation. Bellamy R, et al. **Crit Care Med** 1996 Feb;24(2 Suppl):S24–47 (137 ref.)

Resuscitation from severe hemorrhage. Shoemaker WC, et al. **Crit Care Med** 1996 Feb;24(2 Suppl):S12–23 (76 ref.)

Fluid resuscitation in traumatic haemorrhage. Cutress R. **J Accid Emerg Med** 1995 Sep;12(3):165–72 (29 ref.)

The opioid/anti-opioid balance in shock: a new target for therapy in resuscitation. Bertolini A. **Resuscitation** 1995 Aug;30(1):29–42 (177 ref.)

VETERINARY

Transfusion therapy in emergency and critical care medicine. Kirby R. **Vet Clin North Am Small Anim Pract** 1995 Nov; 25(6):1365–86 (25 ref.)

SHOCK LUNG see RESPIRATORY DISTRESS SYNDROME, ADULT

SHOCK, SEPTIC

Toxic shock syndrome: an opportunity for nursing intervention [see comments] Creehan PA. **J Obstet Gynecol Neonatal Nurs** 1995 Jul–Aug;24(6):557–61 (14 ref.) Comment in: J Obstet Gynecol Neonatal Nurs 1996 Feb;25(2):119.

COMPLICATIONS

Multiple organ failure in septic shock. Thijs LG, et al. **Curr Top Microbiol Immunol** 1996;216:209–37 (220 ref.)

[Pulmonary manifestations in a case of toxic shock syndrome] Stoica R. **Pneumoftiziologia** 1995 Jan–Jun;44(1–2):63–6 (9 ref.) (Eng. Abstr.) **(Rum)**

DIAGNOSIS

Nonmenstrual toxic shock syndrome: new insights into diagnosis, pathogenesis, and treatment. Parsonnet J. **Curr Clin Top Infect Dis** 1996;16:1–20 (91 ref.)

[Sepsis grading should be defined. Staging may result in better monitoring] Sjölin J. **Lakartidningen** 1996 Mar 13; 93(11):995–8 (15 ref.) **(Swe)**

DRUG THERAPY

Prospects for management of peripheral vascular failure in septic shock [editorial; comment] Allen JD, et al. **Br J Anaesth** 1996 Feb;76(2):177–8 (29 ref.) Comment on: Br J Anaesth 1996 Feb;76(2):251–7.

Nitric oxide inhibition in the treatment of septic shock [editorial; comment] Hata JS, et al. **Crit Care Med** 1995 Oct;23(10):1621–4 (26 ref.) Comment on: Crit Care Med 1995 Oct;23(10):1711–21.

ENZYMOLOGY

Selective inhibition of the activity of inducible nitric oxide synthase in septic shock. Thiemermann C. **Prog Clin Biol Res** 1995;392:383–92 (26 ref.)

ETIOLOGY

Significance and pathogenesis of septic shock. Brandtzaeg P. **Curr Top Microbiol Immunol** 1996;216:15–37 (134 ref.)

Cytokines as mediators in the pathogenesis of septic shock. Dinarello CA. **Curr Top Microbiol Immunol** 1996; 216:133–65 (160 ref.)

Mediators: nitric oxide and other toxic oxygen species. Evans TJ, et al. **Curr Top Microbiol Immunol** 1996;216:189–207 (97 ref.)

Superantigen-mediated lethal shock: the functional state of ligand-reactive T cells. Heeg K, et al. **Curr Top Microbiol Immunol** 1996;216:83–100 (95 ref.)

Definition and pathogenesis of septic shock. Vincent JL. **Curr Top Microbiol Immunol** 1996;216:1–13 (41 ref.)

Novel insight into molecular mechanism of endotoxin shock: biochemical analysis of LPS receptor signaling in a cell-free system targeting NF-kappaB and regulation of cytokine production/action through beta2 integrin in vivo. Mukaida N, et al. **J Leukoc Biol** 1996 Feb;59(2):145–51 (42 ref.)

Toxic shock syndrome as a complication of orthopaedic surgery. Grimes J, et al. **J Pediatr Orthop** 1995 Sep–Oct; 15(5):666–71 (28 ref.)

Septic shock—the unravelling of molecular mechanisms. Camussi G, et al. **Nephrol Dial Transplant** 1995 Oct; 10(10):1808–13 (42 ref.)

Peritonitis biliaris: some aspects of its origin. Vomela J, et al. **Rocz Akad Med Bialymst** 1995;40(1):58–64 (24 ref.)

IMMUNOLOGY

Immunoregulatory mechanisms of T-cell-dependent shock induced by a bacterial superantigen in mice. Florquin S, et al. **Infect Immun** 1996 Sep;64(9):3443–5 (31 ref.)

Cytokine knockout mice: possible application in toxicological research. Ryffel B. **Toxicology** 1995 Dec 20;105(1):69–80 (55 ref.)

METABOLISM

Interleukin-1 receptors in the brain-endocrine-immune axis. Modulation by stress and infection. Takao T, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:372–85 (52 ref.)

Nitric oxide, myocardial failure and septic shock. Brady AJ. **Int J Cardiol** 1995 Jul;50(3):269–72 (32 ref.)

MICROBIOLOGY

Septic shock due to Pasteurella multocida subspecies multocida in a previously healthy woman [letter] Ruiz-Irastorza G, et al. **Clin Infect Dis** 1995 Jul;21(1):232–4 (13 ref.)

Toxic shock syndrome as a complication of breast prostheses. Poblete JV, et al. **Plast Reconstr Surg** 1995 Dec; 96(7):1702–8 (54 ref.)

[Meningococcal infectious-toxic shock: pathogenetic features and biochemical signs] Roslyi IM. **Patol Fiziol Eksp Ter** 1996 Jan–Mar;(1):39–43 (71 ref.) **(Rus)**

PHYSIOPATHOLOGY

Role of nitric oxide in the vascular dysfunction of septic shock. Rees DD. **Biochem Soc Trans** 1995 Nov; 23(4):1025–9 (38 ref.)

Sepsis/septic shock: participation of the microcirculation: an abbreviated review [see comments] Hinshaw LB. **Crit Care Med** 1996 Jun;24(6):1072–8 (75 ref.) Comment in: Crit Care Med 1996 Jun;24(6):918.

Calcium: a regulator of the inflammatory response in endotoxemia and sepsis. Hotchkiss RS, et al. **New Horiz** 1996 Feb;4(1):58–71 (70 ref.)

Regulation of cytokine gene expression: tumor necrosis factor, interleukin-1, and the emerging biology of cytokine receptors. Williams G, et al. **New Horiz** 1995 May; 3(2):276–87 (123 ref.)

Pathogenic effects of endotoxin. Zivot JB, et al. **New Horiz** 1995 May;3(2):267–75 (86 ref.)

Metabolism of sepsis and multiple organ failure. Michie HR. **World J Surg** 1996 May;20(4):460–4 (31 ref.)

[Recent data on the physiopathology of septic shock] Lissac J, et al. **Bull Acad Natl Med** 1995 Nov;179(8):1671–88 (46 ref.) (Eng. Abstr.) **(Fre)**

[Hemodynamic management of septic shock. From a global approach to a gastrointestinal approach] Teboul JL, et al. **Presse Med** 1996 Mar 30;25(11):549–54 (28 ref.) (Eng. Abstr.) **(Fre)**

[VO2 and DO2 during cardiogenic shock and infection] Beale R. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May;31(1 Suppl):S22–5 (19 ref.) **(Ger)**

[Is sepsis and septic shock due to a global oxygen insufficiency? A review in 2 parts. 2: Sepsis and lactate] Ensinger H, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May; 31(4):205–15 (175 ref.) **(Ger)**

[Is infection and septic shock caused by a global oxygen deficiency? An overview in 2 parts. 1: Infection and correlation between DO2 and VO2] Ensinger H, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Apr; 31(3):132–42 (0 ref.) (Eng. Abstr.) **(Ger)**

[Microcirculation and oxygen supply to the liver in hemorrhagic shock and sepsis] Vollmar B. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Oct; 30 Suppl 1:S52–4 (21 ref.) **(Ger)**

PREVENTION & CONTROL

Surgical infections: blocking the mediator cascade responsible for sepsis and septic shock. Fink MP. **Curr Opin Gen Surg** 1993;:19–25 (45 ref.)

[Protective properties of antibodies raised against conjugates of endotoxin core oligosaccharides with proteins] Jachymek W. **Postepy Hig Med Dosw** 1995;49(1):171–8 (6 ref.) (Eng. Abstr.) **(Pol)**

THERAPY

Plasmapheresis in severe sepsis or septic shock. Stegmayr BG. **Blood Purif** 1996;14(1):94–101 (66 ref.)

Nonmenstrual toxic shock syndrome: new insights into diagnosis, pathogenesis, and treatment. Parsonnet J. **Curr Clin Top Infect Dis** 1996;16:1–20 (91 ref.)

Anticytokine strategies for the treatment of septic shock: relevance of animal models. Heumann D, et al. **Curr Top Microbiol Immunol** 1996;216:299–311 (38 ref.)

Endotoxin-based molecular strategies for the prevention and treatment of gram-negative sepsis and septic shock. Pollack M, et al. **Curr Top Microbiol Immunol** 1996;216:275–97 (185 ref.)

Potential strategies for inflammatory mediator manipulation: retrospect and prospect. Fisher CJ Jr, et al. **World J Surg** 1996 May;20(4):447–53 (89 ref.)

Animal models as the basis of pharmacologic intervention in trauma and sepsis patients. Redl H, et al. **World J Surg** 1996 May;20(4):487–92 (81 ref.)

VETERINARY

Porcine TNF: a review. Pauli U. **Vet Immunol Immunopathol** 1995 Aug;47(3–4):187–201 (63 ref.)

SHOCK THERAPY, ELECTRIC see ELECTROCONVULSIVE THERAPY

SHOCK, TOXIC see SHOCK, SEPTIC

SHOCK, TRAUMATIC

ETIOLOGY

Spinal shock. Atkinson PP, et al. **Mayo Clin Proc** 1996 Apr; 71(4):384–9 (79 ref.)

IMMUNOLOGY

[Role of metabolic arachidonic acid cascade and prostaglandin E2 in the pathogenesis of immunodeficiency in traumatic shock and acute hemorrhage] Pavlovskii MP, et al. **Klin Khir** 1995;(4):35–8 (62 ref.) **(Ukr)**

PHYSIOPATHOLOGY

[Pathophysiology of shock] Bühren V. **Unfallchirurg** 1996 Mar;99(3):207–20 (7 ref.) **(Ger)**

THERAPY

Fluid resuscitation in traumatic haemorrhage. Cutress R. **J Accid Emerg Med** 1995 Sep;12(3):165–72 (29 ref.)

Acute spinal cord injury and neurogenic shock in pregnancy. Gilson GJ, et al. **Obstet Gynecol Surv** 1995 Jul;50(7):556–60 (11 ref.)

SHOCKWAVES, ULTRASONIC

SHOCKWAVES, ULTRASONIC see ULTRASONICS

SHORT BOWEL SYNDROME

Short bowel syndrome. Vanderhoof JA. **Clin Perinatol** 1996 Jun;23(2):377–86 (35 ref.)

The short-bowel syndrome. Nightingale JM. **Eur J Gastroenterol Hepatol** 1995 Jun;7(6):514–20 (60 ref.)

METABOLISM

[Short bowel syndrome (small bowel bypass and extensive small bowel resection)] Hosoda S, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):388–91 (18 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Short bowel syndrome in children. Vanderhoof JA. **Curr Opin Pediatr** 1995 Oct;7(5):560–8 (73 ref.)

[Intestinal adaptation in the short and ultrashort bowel syndrome. Nutritional support] Galiano Segovia MJ, et al. **An Esp Pediatr** 1996 Jun;44(6):605–8 (16 ref.) **(Spa)**

REHABILITATION

[Short-bowel syndrome] Koblitz DK. **Z Gastroenterol** 1996 Jun;34 Suppl 2:41–6 (71 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Management of the short gut syndrome. Berger DL, et al. **Adv Surg** 1996;29:43–57 (125 ref.)

Edgar J. Poth Memorial Lecture. Surgical aspects of the short-bowel syndrome. Thompson JS. **Am J Surg** 1995 Dec;170(6):532–6 (40 ref.)

Short bowel syndrome in children and small intestinal transplantation. Vanderhoof JA. **Pediatr Clin North Am** 1996 Apr;43(2):533–50 (84 ref.)

Intestinal transplantation: a clinical update. Ploeg RJ, et al. **Scand J Gastroenterol Suppl** 1995;212:79–89 (53 ref.)

THERAPY

Short bowel syndrome. Stringer MD, et al. **Arch Dis Child** 1995 Aug;73(2):170–3 (39 ref.)

SHORT-TERM PSYCHOTHERAPY see PSYCHOTHERAPY, BRIEF

SHOTGUNS see FIREARMS

SHOULDER

Function after amputation, arthrodesis, or arthroplasty for tumors about the shoulder. Kneisl JS. **J South Orthop Assoc** 1995 Fall;4(3):228–36 (36 ref.)

Medico-legal aspects of brachial plexus injury: the obstetrician's point of view. Jakobovits A. **Med Law** 1996; 15(1):175–82 (30 ref.)

[Neuralgic shoulder amyotrophy] Cranovsky C. **Schweiz Med Wochenschr** 1996 Jan 27;126(4):111–9 (40 ref.) (Eng. Abstr.) **(Ger)**

[Unclear pathomechanism behind neck-shoulder pain. Problem with insurance claim] Zetterberg C. **Lakartidningen** 1996 Feb 28;93(9):793–6 (68 ref.) **(Swe)**

INJURIES

[Tendon injuries/diseases of the shoulder joint] Resch H. **Sportverletz Sportschaden** 1996 Mar;10(1):A1–10 (0 ref.) **(Ger)**

SURGERY

Recent advances in shoulder surgery. Uhthoff HK. **Curr Opin Rheumatol** 1996 Mar;8(2):154–7 (35 ref.)

[Holmium-YAG laser in outlet impingement of the shoulder. Mid-term results] De Simoni C, et al. **Orthopade** 1996 Feb; 25(1):84–90 (51 ref.) (Eng. Abstr.) **(Ger)**

SHOULDER DISLOCATION

Anterior shoulder instability. Current review. Liu SH, et al. **Clin Orthop** 1996 Feb;(323):327–37 (83 ref.)

CLASSIFICATION

Atraumatic recurrent posterior shoulder subluxation: review of the literature and recommendations for treatment. Heller KD, et al. **Acta Orthop Belg** 1995;61(4):263–70 (36 ref.)

COMPLICATIONS

Axillary artery injuries secondary to anterior dislocation of the shoulder. Gates JD, et al. **J Trauma** 1995 Sep; 39(3):581–3 (17 ref.)

Dislocation of the shoulder and ipsilateral fracture of the humeral shaft: case reports and literature review. Kontakis GM, et al. **J Trauma** 1995 Nov;39(5):990–2 (18 ref.)

Anterior glenohumeral dislocation with ipsilateral humeral shaft fracture. Davick J, et al. **Orthopedics** 1995 Aug; 18(8):745–8 (6 ref.)

RADIOGRAPHY

Fracture-dislocation of the shoulder with intrathoracic displacement of the humeral head. Kaar TK, et al. **Injury** 1995 Nov;26(9):638–9 (4 ref.)

Intrathoracic fracture-dislocation of the humerus. Brogdon BG, et al. **Skeletal Radiol** 1995 Jul;24(5):383–5 (5 ref.)

SURGERY

Acute shoulder dislocation. Indications and techniques for operative management. Arciero RA, et al. **Clin Sports Med** 1995 Oct;14(4):937–53 (31 ref.)

Bilateral posterior fracture-dislocation of the shoulders: management by bilateral shoulder hemiarthroplasties. Page AE, et al. **J Orthop Trauma** 1995;9(6):526–9 (31 ref.)

[Critical considerations in arthroscopic stabilization of the unstable shoulder joint] Jerosch J. **Sportverletz Sportschaden** 1996 Mar;10(1):1–12 (93 ref.) (Eng. Abstr.) **(Ger)**

[Diagnosis and therapy of shoulder instability] Habermeyer P, et al. **Wien Med Wochenschr** 1996;146(6–7):149–54 (16 ref.) (Eng. Abstr.) **(Ger)**

SHOULDER FRACTURES

RADIOGRAPHY

Fracture-dislocation of the shoulder with intrathoracic displacement of the humeral head. Kaar TK, et al. **Injury** 1995 Nov;26(9):638–9 (4 ref.)

Intrathoracic fracture-dislocation of the humerus. Brogdon BG, et al. **Skeletal Radiol** 1995 Jul;24(5):383–5 (5 ref.)

[Frequent injuries of the shoulder joint] Gaudernak T. **Wien Med Wochenschr** 1996;146(6–7):130–4 (16 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Bilateral posterior fracture-dislocation of the shoulders: management by bilateral shoulder hemiarthroplasties. Page AE, et al. **J Orthop Trauma** 1995;9(6):526–9 (31 ref.)

SHOULDER-HAND SYNDROME see REFLEX SYMPATHETIC DYSTROPHY

SHOULDER JOINT

Shoulder pain: the role of diagnostic injections. Larson HM, et al. **Am Fam Physician** 1996 Apr;53(5):1637–47 (10 ref.)

Suprascapular nerve entrapment by ganglion cysts: a report of six cases with arthroscopic findings and review of the literature. Fehrman DA, et al. **Arthroscopy** 1995 Dec; 11(6):727–34 (47 ref.)

Shoulder instability in athletes. The Asian perspective. Chan KM, et al. **Clin Orthop** 1996 Feb;(323):106–12 (47 ref.)

MRI of the shoulder. Shankman S, et al. **Curr Probl Diagn Radiol** 1995 Nov-Dec;24(6):201–25 (46 ref.)

Chronic anterior glenohumeral instability. Walch G. **J Bone Joint Surg Br** 1996 Jul;78(4):670–7 (25 ref.)

Arthroscopic treatment of rotator cuff disease. Gartsman GM. **J Shoulder Elbow Surg** 1995 May-Jun;4(3):228–41 (27 ref.)

Glenohumeral instability. Friedman RJ, et al. **J South Orthop Assoc** 1995 Fall;4(3):182–99 (85 ref.)

Arthroscopic Bankart procedures for anterior shoulder instability. A review of the literature. el Akad AM, et al. **Knee Surg Sports Traumatol Arthrosc** 1993;1(2):113–22 (61 ref.)

Rapid destructive arthritis of the shoulder. Nguyen VD. **Skeletal Radiol** 1996 Feb;25(2):107–12 (44 ref.)

[Clinical examination of the shoulder and diagnostic maneuvers] Hallez R, et al. **Rev Med Brux** 1995 Jul-Aug; 16(4):164–7 (4 ref.) (Eng. Abstr.) **(Fre)**

[Role of conservative treatment in impingement syndromes of the shoulder] Hauzeur JP. **Rev Med Brux** 1995 Jul-Aug; 16(4):171–7 (40 ref.) (Eng. Abstr.) **(Fre)**

[Prognosis of shoulder calcifications after irrigation treatment and roentgen findings. A prospective study and literature review] Ludwig R, et al. **Schweiz Rundsch Med Prax** 1996 Apr 16;85(16):526–33 (18 ref.) (Eng. Abstr.) **(Ger)**

[The shoulder joint--diagnostic imaging] Imhof H, et al. **Wien Med Wochenschr** 1996;146(6–7):116–20 (24 ref.) (Eng. Abstr.) **(Ger)**

[Periarthritis humeroscapularis--clinical diagnosis and analysis of the syndrome concept] Jerosch J. **Wien Med Wochenschr** 1996;146(6–7):142 (22 ref.) (Eng. Abstr.) **(Ger)**

[Conservative therapy of shoulder pain] Tilscher H. **Wien Med Wochenschr** 1996;146(6–7):138–42 (4 ref.) (Eng. Abstr.) **(Ger)**

ANATOMY & HISTOLOGY

Imaging techniques, normal variations, and diagnostic pitfalls in shoulder magnetic resonance imaging. Mirowitz SA. **Magn Reson Imaging Clin N Am** 1993 Sep;1(1):19–36 (46 ref.)

Normal regional anatomy of the shoulder. Petersilge CA, et al. **Magn Reson Imaging Clin N Am** 1993 Sep;1(1):1–18 (34 ref.)

Magnetic resonance arthrography of the shoulder. Tirman PF, et al. **Magn Reson Imaging Clin N Am** 1993 Sep; 1(1):125–42 (48 ref.)

Magnetic resonance imaging of the shoulder: review. Feller JF, et al. **Semin Roentgenol** 1995 Jul;30(3):224–40 (64 ref.)

INJURIES

The clinical presentation of shoulder instability including on field management. Bahr R, et al. **Clin Sports Med** 1995 Oct;14(4):761–76 (26 ref.)

Revision instability surgery. Barron OA, et al. **Clin Sports Med** 1995 Oct;14(4):955–72 (44 ref.)

The conservative management of the unstable shoulder including rehabilitation. Dines DM, et al. **Clin Sports Med** 1995 Oct;14(4):797–816 (76 ref.)

Imaging of shoulder instability. Gusmer PB, et al. **Clin Sports Med** 1995 Oct;14(4):777–95 (26 ref.)

Shoulder instability in the overhand or throwing athlete. Kvitne RS, et al. **Clin Sports Med** 1995 Oct;14(4):917–35 (25 ref.)

The surgical treatment of posterior shoulder instability. Murrell GA, et al. **Clin Sports Med** 1995 Oct;14(4):903–15 (48 ref.)

The surgical treatment of anterior shoulder instability. Payne LZ, et al. **Clin Sports Med** 1995 Oct;14(4):863–83 (45 ref.)

Arthroscopic shoulder stabilization. Overview of indications, technique, and efficacy. Swenson TM, et al. **Clin Sports Med** 1995 Oct;14(4):841–62 (41 ref.)

Arthroscopic evaluation of the unstable shoulder. Wall MS, et al. **Clin Sports Med** 1995 Oct;14(4):817–39 (102 ref.)

Complications of shoulder instability surgery. Wall MS, et al. **Clin Sports Med** 1995 Oct;14(4):973–1000 (153 ref.)

Management of multidirectional instability. Yamaguchi K, et al. **Clin Sports Med** 1995 Oct;14(4):885–902 (40 ref.)

Superior glenoid lesions: a diagnostic and therapeutic challenge. D'Alessandro DF, et al. **J South Orthop Assoc** 1995 Fall;4(3):214–27 (35 ref.)

[Shoulder problems in leisure athletes: physical examination, diagnosis and therapy. Sensible procedures in daily practice] Vaeckenstedt J, et al. **Schweiz Med Wochenschr** 1996 Mar 16;126(11):447–56 (21 ref.) (Eng. Abstr.) **(Ger)**

[Frequent injuries of the shoulder joint] Gaudernak T. **Wien Med Wochenschr** 1996;146(6–7):130–4 (16 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

Magnetic resonance imaging of miscellaneous disorders of the shoulder. Deutsch AL, et al. **Magn Reson Imaging Clin N Am** 1993 Sep;1(1):171–83 (66 ref.)

Magnetic resonance imaging of arthritides affecting the shoulder. Ferraro FA, et al. **Magn Reson Imaging Clin N Am** 1993 Sep;1(1):157–70 (76 ref.)

Magnetic resonance imaging of the postoperative shoulder. Haygood TM, et al. **Magn Reson Imaging Clin N Am** 1993 Sep;1(1):143–55 (26 ref.)

Magnetic resonance imaging of glenohumeral instability. Rafii M, et al. **Magn Reson Imaging Clin N Am** 1993 Sep; 1(1):87–104 (68 ref.)

Magnetic resonance imaging of the biceps complex. van Leersum M, et al. **Magn Reson Imaging Clin N Am** 1993 Sep;1(1):77–86 (23 ref.)

PHYSIOLOGY

Glenohumeral stability. Biomechanical properties of passive and active stabilizers. Bigliani LU, et al. **Clin Orthop** 1996 Sep;(330):13–30 (79 ref.)

Glenohumeral joint stability. Selective cutting studies on the static capsular restraints. Curl LA, et al. **Clin Orthop** 1996 Sep;(330):54–65 (36 ref.)

Superior glenoid impingement. Current concepts. Jobe CM. **Clin Orthop** 1996 Sep;(330):98–107 (27 ref.)

[Measurement of glenohumeral joint translation with a dynamic shoulder model] Wülker N, et al. **Z Orthop Ihre Grenzgeb** 1996 Jan-Feb;134(1):67–72 (46 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

The arthroscopic treatment of anterior and multidirectional shoulder instability. McIntyre LF, et al. **Instr Course Lect** 1996;45:47–56 (72 ref.)

Arthroscopic transglenoid suture capsulorrhaphy for anterior shoulder instability. Rose DJ. **Instr Course Lect** 1996; 45:57–64 (54 ref.)

Complications of total shoulder-replacement arthroplasty. Wirth MA, et al. **J Bone Joint Surg Am** 1996 Apr; 78(4):603–16 (110 ref.)

Magnetic resonance imaging of the postoperative shoulder. Haygood TM, et al. **Magn Reson Imaging Clin N Am** 1993 Sep;1(1):143–55 (26 ref.)

[Arthrodesis of the shoulder joint] Reichelt A. **Orthopade** 1996 Apr;25(2):104–11 (61 ref.) (Eng. Abstr.) **(Ger)**

[Infection following shoulder and elbow arthroplasty. Diagnosis and therapy] Schwyzer HK, et al. **Orthopade** 1995 Aug;24(4):367–75 (44 ref.) (Eng. Abstr.) **(Ger)**

[Arthroscopy and arthroscopic surgery of the shoulder joint] Landsiedl F. **Wien Med Wochenschr** 1996;146(6–7):146–8 (18 ref.) (Eng. Abstr.) **(Ger)**

[Rheumatoid orthopedics and endoprosthetics of the shoulder joint] Schwägerl W, et al. **Wien Med Wochenschr** 1996; 146(6–7):124–9 (31 ref.) (Eng. Abstr.) **(Ger)**

[Arthroscopic shoulder surgery] Okamura K. **Hokkaido Igaku Zasshi** 1995 May;70(3):375–81 (11 ref.) (Eng. Abstr.) **(Jpn)**

ULTRASONOGRAPHY

[Ultrasound examination of the shoulder joint] Lick-Schiffer W. **Wien Med Wochenschr** 1996;146(6-7):121-3 (11 ref.) (Eng. Abstr.) **(Ger)**

SHREWS

PHYSIOLOGY

The functional organization of local circuits in visual cortex: insights from the study of tree shrew striate cortex. Fitzpatrick D. **Cereb Cortex** 1996 May-Jun;6(3):329-41 (76 ref.)

Experimental models for carcinogenesis in the house musk shrew, Suncus murinus, Insectivora. Tsubura A, et al. **Histol Histopathol** 1995 Oct;10(4):1047-55 (69 ref.)

SHUTTLE VECTORS see **GENETIC VECTORS**

SHY-DRAGER SYNDROME

Shy-Drager syndrome: recognition and management. Abyad A. **J Am Board Fam Pract** 1995 Jul-Aug;8(4):325-30 (32 ref.)

DIAGNOSIS

Failure of the autonomic nervous system. Mitsky V, et al. **Compr Ther** 1995 Sep;21(9):529-34 (8 ref.)

Multiple system atrophy. Quinn N, et al. **Curr Opin Neurol** 1995 Aug;8(4):323-6 (28 ref.)

SH1 DOMAIN see **SRC HOMOLOGY DOMAINS**

SH2 DOMAIN see **SRC HOMOLOGY DOMAINS**

SH3 DOMAIN see **SRC HOMOLOGY DOMAINS**

SIADH see **INAPPROPRIATE ADH SYNDROME**

SIALADENITIS

IMMUNOLOGY

[Expression of ductal Fas antigen in sialoadenitis of Sjögren's syndrome] Matsumura R, et al. **Nippon Rinsho** 1995 Oct; 53(10):2446-50 (13 ref.) (Eng. Abstr.) **(Jpn)**

SIALIC ACIDS

METABOLISM

Infantile sialic acid storage disease: a rare cause of cytoplasmic vacuolation in pediatric patients. Hale LP, et al. **Pediatr Pathol Lab Med** 1995 May-Jun;15(3):443-53 (18 ref.)

[Lysosomal membrane transport disorders--cystinosis and sialic acid storage disorders (Salla disease, ISSD)] Yano T, et al. **Nippon Rinsho** 1995 Dec;53(12):3068-71 (5 ref.) (Eng. Abstr.) **(Jpn)**

[CD22: a cell adhesion molecule that displays alpha 2-6-linked sialic acid-binding lectin activity] Hanasaki K. **Seikagaku** 1995 Aug;67(8):1040-7 (15 ref.) **(Jpn)**

PHYSIOLOGY

[Morphological analysis of NCAM-180 deficient mouse brain--polysialic acid moiety and neuronal migration] Ono K. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2188-96 (44 ref.) **(Jpn)**

SIALIDASE see **NEURAMINIDASE**

SIALOGLYCOPEPTIDES see **SIALOGLYCOPROTEINS**

SIALOGLYCOPROTEINS

see related
ASIALOGLYCOPROTEINS

Interleukin-1 receptor antagonist. Lennard AC. **Crit Rev Immunol** 1995;15(1):77-105 (179 ref.)

Interleukin-1 and interleukin-1 receptor antagonist. Dinarello CA. **Nutrition** 1995 Sep-Oct;11(5 Suppl):492-4 (17 ref.)

Interleukin-1 antagonists. Dower SK, et al. **Ther Immunol** 1994 Apr;1(2):113-22 (73 ref.)

BIOSYNTHESIS

Interleukin-1 and interleukin-1 receptor antagonist production during haemodialysis: which cytokine is a surrogate marker for dialysis-related complications? Dinarello CA. **Nephrol Dial Transplant** 1995;10 Suppl 3:25-8 (32 ref.)

IMMUNOLOGY

Unconventional B-cell antigens and human immune repertoires. Silverman GJ. **Ann N Y Acad Sci** 1995 Sep 29;764:342-55 (42 ref.)

METABOLISM

Osteopontin at mineralized tissue interfaces in bone, teeth, and osseointegrated implants: ultrastructural distribution and implications for mineralized tissue formation, turnover, and repair. McKee MD, et al. **Microsc Res Tech** 1996 Feb 1;33(2):141-64 (112 ref.)

PHYSIOLOGY

Role of two mineral-associated adhesion molecules, osteopontin and bone sialoprotein, during cementogenesis. MacNeil RL, et al. **Connect Tissue Res** 1995;33(1-3):1-7 (87 ref.)

[Role of hepatitis B virus surface antigen in HBV infection--function of human hepatic sialoglycoprotein as HBV receptor] Suzuki T, et al. **Nippon Rinsho** 1995 Oct; 53 Suppl:132-7 (28 ref.) **(Jpn)**

THERAPEUTIC USE

Anticytokine strategies for the treatment of septic shock: relevance of animal models. Heumann D, et al. **Curr Top Microbiol Immunol** 1996;216:299-311 (38 ref.)

New therapeutic approaches in sepsis: a critical review. Eidelman LA, et al. **Intensive Care Med** 1995 Nov;21 Suppl 2:S269-72 (18 ref.)

New immunotherapies for sepsis. Young LS, et al. **Proc Assoc Am Physicians** 1995 Oct;107(3):361-4 (19 ref.)

SIALOGRAPHY

Imaging of the salivary glands. Weissman JL. **Semin Ultrasound CT MR** 1995 Dec;16(6):546-68 (28 ref.)

SIALOMETAPLASIA, NECROTIZING

PATHOLOGY

Necrotizing sialometaplasia: literature review and case reports. Imbery TA, et al. **J Am Dent Assoc** 1996 Jul; 127(7):1087-92 (35 ref.)

SIALOPROTEINS see **SIALOGLYCOPROTEINS**

SIALORRHEA

ETIOLOGY

Sialorrhea and gastroesophageal reflux [see comments] Mandel L, et al. **J Am Dent Assoc** 1995 Nov; 126(11):1537-41 (40 ref.) Comment in: J Am Dent Assoc 1996 Jan;127(1):18, 20.

SIALYL SSEA-1 see **ANTIGENS, CD15**

SIALYLTRANSFERASES

CHEMISTRY

[Structural and functional analysis of sialyltransferases: the dawn of new age for glycobiology] Tsuji S. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(16):2436-45 (42 ref.) **(Jpn)**

PHYSIOLOGY

1994, the year of sialyltransferases. Harduin-Lepers A, et al. **Glycobiology** 1995 Dec;5(8):741-58 (170 ref.)

[Structural and functional analysis of sialyltransferases: the dawn of new age for glycobiology] Tsuji S. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(16):2436-45 (42 ref.) **(Jpn)**

SICCA SYNDROME see **SJOGREN'S SYNDROME**

SICK BUILDING SYNDROME

ABC of work related disorders. Building related illnesses. Appleby PH. **BMJ** 1996 Sep 14;313(7058):674-7 (0 ref.)

SICK ROLE

Health psychology: psychological factors and physical disease from the perspective of human psychoneuroimmunology. Cohen S, et al. **Annu Rev Psychol** 1996;47:113-42 (155 ref.)

An integrated behavioral medicine approach to improving care of patients with diabetes mellitus. Jenkins CD. **Behav Med** 1995 Summer;21(2):53-65; discussion 66-8 (19 ref.)

Insight and adherence to treatment in psychotic disorders. Kemp RA, et al. **Br J Hosp Med** 1995 Sep 6-19;54(5):222-7 (46 ref.)

Psychological interventions in infection with the human immunodeficiency virus. Catalan J. **Br J Psychiatry** 1995 Jul;167(1):104-11 (65 ref.)

Self-esteem and cancer: theory and research. Katz MR, et al. **Can J Psychiatry** 1995 Dec;40(10):608-15 (120 ref.)

Psychiatric illness and cardiovascular disease risk. Hayward C. **Epidemiol Rev** 1995;17(1):129-38 (138 ref.)

Why do people consult the doctor? Campbell SM, et al. **Fam Pract** 1996 Feb;13(1):75-83 (111 ref.)

Situational disease. Gannik DE. **Fam Pract** 1995 Jun; 12(2):202-6 (14 ref.)

Illness and family functioning: theoretical and practical considerations from the primary care point of view. Tansella CZ. **Fam Pract** 1995 Jun;12(2):214-20 (14 ref.)

Pathways linking affective disturbances and physical disorders. Cohen S, et al. **Health Psychol** 1995 Sep; 14(5):374-80 (50 ref.)

Anxiety in medically ill older patients: a review and update. Hocking LB, et al. **Int J Psychiatry Med** 1995;25(3):221-38 (74 ref.)

The difficult elderly patient: curable hostile depression or personality disorder? Monfort JC. **Int Psychogeriatr** 1995; 7 Suppl:95-111 (50 ref.)

The social body and the biomechanical body: can they coexist in nurse education? Brown C, et al. **J Adv Nurs** 1996 Apr; 23(4):651-6 (36 ref.)

Postmodernism, health and illness. Mitchell DP. **J Adv Nurs** 1996 Jan;23(1):201-5 (28 ref.)

Somatisation in children. Garralda ME. **J Child Psychol Psychiatry** 1996 Jan;37(1):13-33 (125 ref.)

Annotation: aspects of pain in children and adolescents. McGrath PJ. **J Child Psychol Psychiatry** 1995 Jul; 36(5):717-30 (50 ref.)

Family and parental functioning in cystic fibrosis. Ievers CE, et al. **J Dev Behav Pediatr** 1996 Feb;17(1):48-55 (45 ref.)

Hope: implications for neuroscience nursing. Fowler SB. **J Neurosci Nurs** 1995 Oct;27(5):298-304 (47 ref.)

'Functional overlay', and illness behaviour in chronic pain: distress or malingering? Conceptual difficulties in medico-legal assessment of personal injury claims. Main CJ, et al. **J Psychosom Res** 1995 Aug;39(6):737-53 (58 ref.)

Psychosocial burdens of dialysis treatment modalities: do they differ and does it matter? Reynolds JM, et al. **Perit Dial Int** 1996;16 Suppl 1:S548-50 (13 ref.)

Psychological aspects of non-cardiac chest pain. Serlie AW, et al. **Psychother Psychosom** 1995;64(2):62-73 (57 ref.)

Stigma, HIV and AIDS: an exploration and elaboration of a stigma trajectory. Alonzo AA, et al. **Soc Sci Med** 1995 Aug;41(3):303-15 (79 ref.)

Sociological dimensions of illness behavior. Mechanic D. **Soc Sci Med** 1995 Nov;41(9):1207-16 (54 ref.)

[Psycho-oncology in gynecology] **Arch Gynecol Obstet** 1995; 257(1-4):270-7 (28 ref.) **(Ger)**

[Oral disease epidemiologic illness indices and oral health measures--traditional concepts are supplemented by new socio-dental indicators] Strippel H. **Gesundheitswesen** 1996 Mar;58(3):162-8 (50 ref.) (Eng. Abstr.) **(Ger)**

[Quality of life in chronic inflammatory bowel diseases] Bregenzer N, et al. **Med Klin** 1996 Jun 15;91(6):396-401 (36 ref.) **(Ger)**

[Pain and pain perception in the elderly from the viewpoint of rheumatology] Nehen HG. **Z Gerontol Geriatr** 1995 Sep-Oct;28(5):335-8 (10 ref.) (Eng. Abstr.) **(Ger)**

[Pain and psychological disorders in the elderly] Wojnar J, et al. **Z Gerontol Geriatr** 1995 Sep-Oct;28(5):369-73 (22 ref.) (Eng. Abstr.) **(Ger)**

[Psychological aspects of neurotransplantation] Ellgring H. **Zentralbl Neurochir** 1995;56(4):168-72 (11 ref.) (Eng. Abstr.) **(Ger)**

SICK SINUS SYNDROME

THERAPY

Cost benefit analysis of single and dual chamber pacing for sick sinus syndrome and atrioventricular block. An economic sensitivity analysis of the literature [see comments] Sutton R, et al. **Eur Heart J** 1996 Apr; 17(4):574-82 (46 ref.) Comment in: Eur Heart J 1996 Apr;17(4):495-6.

SICKLE CELL TRAIT

COMPLICATIONS

Exertional collapse and sudden death associated with sickle cell trait. Kerle KK, et al. **Am Fam Physician** 1996 Jul; 54(1):237-40 (18 ref.)

SICKNESS IMPACT PROFILE

Functional measures in children with rheumatic diseases. Murray KJ, et al. **Pediatr Clin North Am** 1995 Oct; 42(5):1127-54 (79 ref.)

[Many chronic problems in CVA patients at home] Hochstenbach JB, et al. **Ned Tijdschr Geneeskd** 1996 Jun 1;140(22):1182-6 (34 ref.) (Eng. Abstr.) **(Dut)**

SIDEROPHILIN see **TRANSFERRIN**

SIDEROPHORES

CHEMISTRY

Siderophores: structure and function of microbial iron transport compounds. Neilands JB. **J Biol Chem** 1995 Nov 10;270(45):26723-6 (43 ref.)

METABOLISM

Gene regulation of siderophore-mediated iron acquisition in Pseudomonas: not only the Fur repressor. Venturi V, et al. **Mol Microbiol** 1995 Aug;17(4):603-10 (40 ref.)

PHYSIOLOGY

Siderophores: structure and function of microbial iron transport compounds. Neilands JB. **J Biol Chem** 1995 Nov 10;270(45):26723-6 (43 ref.)

SIDEROSIS

see related
HEMOSIDEROSIS

Abdominal iron deposition: metabolism, MR findings, and clinical importance. Siegelman ES, et al. **Radiology** 1996 Apr;199(1):13–22 (170 ref.)

DIAGNOSIS

[Diagnosis of hepatic siderosis] Turlin B, et al. **Ann Pathol** 1995;15(5):365–71 (40 ref.) **(Fre)**

SIDS see SUDDEN INFANT DEATH

SIGA see IGA, SECRETORY

SIGMA ELEMENT see SIGMA FACTOR

SIGMA FACTOR

ANTAGONISTS & INHIBITORS

Negative regulation of transcription by anti-sigma factors. Wolska KI. **Acta Microbiol Pol** 1996;45(1):7–17 (71 ref.)
The role of anti-sigma factors in gene regulation. Brown KL, et al. **Mol Microbiol** 1995 May;16(3):397–404 (49 ref.)

GENETICS

Sigma factor and sporulation genes in Clostridium. Sauer U, et al. **FEMS Microbiol Rev** 1995 Oct;17(3):331–40 (82 ref.)

METABOLISM

Signal sensing by sigma 54-dependent regulators: derepression as a control mechanism. Shingler V. **Mol Microbiol** 1996 Feb;19(3):409–16 (51 ref.)

SIGMA INITIATION FACTOR see SIGMA FACTOR

SIGMA RECEPTORS see RECEPTORS, SIGMA

SIGMA SUBUNIT see SIGMA FACTOR

SIGMOID

see related
SIGMOIDOSCOPY

BLOOD SUPPLY

Colonic ischemia reveals thromboangiitis obliterans (Buerger's disease). Sauvaget F, et al. **Gastroenterology** 1996 Mar;110(3):900–3 (12 ref.)

SIGMOID DISEASES

Giant diverticulum of the sigmoid colon. Naber A, et al. **Int J Colorectal Dis** 1995;10(3):169–72 (50 ref.)
Endometriosis as a cause of colonic obstruction. Valko GP, et al. **J Am Board Fam Pract** 1995 Nov–Dec;8(6):481–3 (8 ref.)

DIAGNOSIS

Giant sigmoid diverticulum: report of two cases and endoscopic recognition. Mehta DC, et al. **Am J Gastroenterol** 1996 Jun;91(6):1269–71 (11 ref.)
Abdominal actinomycosis. Cintron JR, et al. **Dis Colon Rectum** 1996 Jan;39(1):105–8 (10 ref.)
[Intestinal obstruction and pregnancy] Dufour P, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(3):297–300 (10 ref.) (Eng. Abstr.) **(Fre)**
[Acute sigmoid diverticulitis—current diagnosis] Gillessen A, et al. **Chirurg** 1995 Dec;66(12):1177–81 (22 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

[Pathogenesis and pathophysiology of sigmoid diverticulitis] Hoffmann P, et al. **Chirurg** 1995 Dec;66(12):1169–72 (30 ref.) (Eng. Abstr.) **(Ger)**

MICROBIOLOGY

Isolated sigmoid tuberculosis. Report of a case. Horvath KD, et al. **Dis Colon Rectum** 1995 Dec;38(12):1327–30 (8 ref.)

SURGERY

Abdominal actinomycosis. Cintron JR, et al. **Dis Colon Rectum** 1996 Jan;39(1):105–8 (10 ref.)
Laparoscopic treatment of a sigmoid perforation after colonoscopy. Case report and review of literature. Mehdi A, et al. **Surg Endosc** 1996 Jun;10(6):666–7 (19 ref.)
[Thoughts on the treatment of diverticular sigmoiditis. Apropos of 191 cases] Flament JB, et al. **Chirurgie** 1994–95; 120(11):43–8; discussion 48–9 (22 ref.) (Eng. Abstr.) **(Fre)**

SIGMOID NEOPLASMS

DIAGNOSIS

Pyogenic liver abscess: warning indicator of silent colonic cancer. Report of a case and review of the literature. Teitz S, et al. **Dis Colon Rectum** 1995 Nov;38(11):1220–3 (18 ref.)
[Non-Hodgkin's lymphoma of the large intestine in an HIV-positive hemophiliac. A report of a case with an unusual presentation] Gigoni R, et al. **Radiol Med (Torino)** 1995 Sep;90(3):326–8 (11 ref.) **(Ita)**

PATHOLOGY

Increased incidence of second primary malignancy in patients with carcinoid tumors: case report and literature review. Rivadeneira DE, et al. **J Natl Med Assoc** 1996 May; 88(5):310–2 (12 ref.)

SURGERY

Trocar site tumor recurrence after laparoscopic-assisted colectomy. Fodera M, et al. **J Laparoendosc Surg** 1995 Aug; 5(4):259–62 (12 ref.)

SIGMOIDOSCOPY

Prevention of colorectal cancer by screening flexible sigmoidoscopy: possible role of the primary care physician. Abbas Z, et al. **Scott Med J** 1995 Jun;40(3):67–9 (41 ref.)

ADVERSE EFFECTS

Complications of colonoscopy and flexible sigmoidoscopy. Waye JD, et al. **Gastrointest Endosc Clin N Am** 1996 Apr; 6(2):343–77 (138 ref.)

SIGNAL INTERPRETATION, COMPUTER-ASSISTED see SIGNAL PROCESSING, COMPUTER-ASSISTED

SIGNAL PATHWAYS see SIGNAL TRANSDUCTION

SIGNAL PEPTIDES

CHEMISTRY

Protein sorting signals: simple peptides with complex functions. von Heijne G. **EXS** 1995;73:67–76 (57 ref.)

METABOLISM

Entry and egress of varicella-zoster virus: role of mannose 6-phosphate, heparan sulfate proteoglycan, and signal sequences in targeting virions and viral glycoproteins. Zhu Z, et al. **Neurology** 1995 Dec;45(12 Suppl 8):S15–7 (9 ref.)

PHYSIOLOGY

Protein transport via amino-terminal targeting sequences: common themes in diverse systems. Rusch SL, et al. **Mol Membr Biol** 1995 Oct–Dec;12(4):295–307 (175 ref.)

SIGNAL PROCESSING, COMPUTER-ASSISTED

Wavelets in biomedical engineering. Akay M. **Ann Biomed Eng** 1995 Sep–Oct;23(5):531–42 (34 ref.)
Digital storage and transmission of cardiovascular images: what are the costs, benefits and timetable for conversion? Thomas JD, et al. **Heart** 1996 Jul;76(1):13–7 (13 ref.)
Signal-averaged electrocardiography. **J Am Coll Cardiol** 1996 Jan;27(1):238–49 (138 ref.)
The P wave signal-averaged ECG. Ehlert FA, et al. **J Electrocardiol** 1995;28 Suppl:33–8 (12 ref.)
The signal-averaged high-resolution ECG. Selvester RH. **J Electrocardiol** 1995;28 Suppl:216–25 (74 ref.)
A physiologic method for monitoring premature infants. Ludington-Hoe S, et al. **J Nurs Meas** 1995 Summer; 3(1):13–29 (16 ref.)
Standard operating procedure (SOP) for the registration and computer-supported evaluation of pharmaco-EEG data. Working Team "EEG in Phase I" of CIPS. Versavel M, et al. **Pharmacopsychiatry** 1995 Nov;28(6):245–8 (8 ref.)
Statistical approaches to human brain mapping by functional magnetic resonance imaging. Lange N. **Stat Med** 1996 Feb 28;15(4):389–428 (93 ref.)
Spectral analysis of clinical signals: an interface between medical statisticians and medical engineers. Campbell MJ. **Stat Methods Med Res** 1996 Mar;5(1):51–66 (54 ref.)
Molecular cytogenetics: unraveling of the genetic composition of individual cells by fluorescence in situ hybridization and digital imaging microscopy. Tanke HJ, et al. **World J Urol** 1995;13(3):138–42 (19 ref.)
[Simultaneous video radiography and "solid state" intraluminal pharyngeal manometry during barium swallow; video manometry] Olsson R, et al. **Radiologe** 1995 Oct;35(10):753–8 (46 ref.) (Eng. Abstr.) **(Ger)**
[Electrophysiologic diagnosis in erectile dysfunction] Jost WH, et al. **Urologe A** 1996 Mar;35(2):120–6 (32 ref.) (Eng. Abstr.) **(Ger)**
[An analysis of heart rate variability. Spectrum analysis methods and complex signal demodulation] Burguera Pérez M, et al. **Rev Esp Cardiol** 1995 Oct;48(10):650–9 (49 ref.) (Eng. Abstr.) **(Spa)**

INSTRUMENTATION

Magnetic resonance imaging and epilepsy: neurosurgical decision making. Fried I. **Magn Reson Imaging** 1995; 13(8):1163–70 (47 ref.)
[Methods of microcirculatory monitoring (laser Doppler flowmetry, photoplethysmography and computer-assisted venous occlusion plethysmography)] Christ F. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May; 31(1 Suppl):S37–43 (77 ref.) **(Ger)**
[In vivo registration of monophasic action potentials—new possible applications in clinical electrophysiology] Behrens S, et al. **Z Kardiol** 1996 May;85(5):326–33 (35 ref.) (Eng. Abstr.) **(Ger)**

SIGNAL PROCESSING, DIGITAL see SIGNAL PROCESSING, COMPUTER-ASSISTED

SIGNAL SEQUENCES, PEPTIDES see SIGNAL PEPTIDES

SIGNAL TRANSDUCTION

see related
ION CHANNELS
SECOND MESSENGER SYSTEMS

Nuclear inositol lipid cycle and differentiation. Cocco L, et al. **Adv Enzyme Regul** 1995;35:23–33 (31 ref.)
Compartmentalization of cyclic AMP phosphodiesterases, signalling 'crosstalk', desensitization and the phosphorylation of Gi-2 add cell specific personalization to the control of the levels of the second messenger cyclic AMP. Houslay MD. **Adv Enzyme Regul** 1995;35:303–38 (68 ref.)
Cell surface beta 1,4-galactosyltransferase. A signal transducing receptor? Dubois DH, et al. **Adv Exp Med Biol** 1995;376:105–14 (72 ref.)
The Janus protein tyrosine kinase family and its role in cytokine signaling. Ihle JN. **Adv Immunol** 1995;60:1–35 (230 ref.)
The common gamma-chain for multiple cytokine receptors. Sugamura K, et al. **Adv Immunol** 1995;59:225–77 (256 ref.)
Diverse signaling pathways in the cellular actions of insulin. Saltiel AR. **Am J Physiol** 1996 Mar;270(3 Pt 1):E375–85 (97 ref.)
BMP signaling in Drosophila embryogenesis. Arora K, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:80–97 (68 ref.)
Structural and functional properties of the TRK family of neurotrophin receptors. Barbacid M. **Ann N Y Acad Sci** 1995 Sep 7;766:442–58 (67 ref.)
Inositol trisphosphate and calcium signaling. Berridge MJ. **Ann N Y Acad Sci** 1995 Sep 7;766:31–43 (43 ref.)
Platelet-derived growth factor. Distinct signal transduction pathways associated with migration versus proliferation. Bornfeldt KE, et al. **Ann N Y Acad Sci** 1995 Sep 7; 766:416–30 (67 ref.)
Regulation of APP processing by intra- and intercellular signals. Buxbaum JD, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:327–31 (17 ref.)
Interaction of signaling and trafficking proteins with the carboxyterminus of the epidermal growth factor receptor. Carpenter G, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:44–51 (28 ref.)
Mechanism of insulin and IGF-1 receptor activation and signal transduction specificity. Receptor dimer cross-linking, bell-shaped curves, and sustained versus transient signaling. De Meyts P, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:388–401 (43 ref.)
Protein serine/threonine kinases of the MAPK cascade. Graves JD, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:320–43 (151 ref.)
Cytokine signal transduction through a homo- or heterodimer of gp130. Kishimoto T, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:224–34 (22 ref.)
Cellular signaling pathways and cytoskeletal organization. Kosik KS, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:114–20 (28 ref.)
Signal transduction interception as a novel approach to disease management. Levitzki A. **Ann N Y Acad Sci** 1995 Sep 7;766:363–8 (22 ref.)
Genetic dissection of the transducing subunits of the T-cell antigen receptor. Malissen B, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:173–81 (23 ref.)
Definition of signals for neuronal differentiation. Obermeier A, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:1–17 (55 ref.)
Coreceptors and adapter proteins in T-cell signaling. Ravichandran KS, et al. **Ann N Y Acad Sci** 1995 Sep 7; 766:117–33 (91 ref.)
Signaling pathways in skeletal formation: a role for BMP receptors. Rosen V, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:59–69 (45 ref.)
Signal transduction mediated by the T-cell antigen receptor. Samelson LE, et al. **Ann N Y Acad Sci** 1995 Sep 7; 766:157–72 (68 ref.)
Na-Ca exchange in Ca2+ signaling and neurohormone secretion. Secretory vesicle contributions in adrenal chromaffin cells. Schneider AS, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:356–65 (17 ref.)
Cell growth signal transduction is quantal. Smith KA. **Ann N Y Acad Sci** 1995 Sep 7;766:263–71 (27 ref.)
IL-2 signaling involves recruitment and activation of multiple protein tyrosine kinases by the IL-2 receptor. Taniguchi T, et al. **Ann N Y Acad Sci** 1995 Sep 7; 766:235–44 (22 ref.)
Retinoid signaling in vertebrate limb development. Thaller C, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:1–11 (58 ref.)
Thrombin and its receptor in growth control. Van Obberghen-Schilling E, et al. **Ann N Y Acad Sci** 1995 Sep

7;766:431–41 (85 ref.)
Molecular and genetic insights into T-cell antigen receptor signaling. Weiss A, et al. **Ann N Y Acad Sci** 1995 Sep 7; 766:149–56 (39 ref.)
Protein import into the nucleus: an integrated view. Hicks GR, et al. **Ann Rev Cell Dev Biol** 1995;11:155–88 (230 ref.)
Integrins: emerging paradigms of signal transduction. Schwartz MA, et al. **Ann Rev Cell Dev Biol** 1995;11:549–99 (402 ref.)
Metabolic coupling factors in pancreatic beta-cell signal transduction. Newgard CB, et al. **Annu Rev Biochem** 1995; 64:689–719 (161 ref.)
Mechano-reception in osteoblast-like cells. Jones D, et al. **Biochem Cell Biol** 1995 Jul–Aug;73(7–8):525–34 (80 ref.)
Signaling in new directions. Samiei HV. **Biochem Cell Biol** 1995 Mar–Apr;73(3–4):133–6 (12 ref.)
Can n-3 polyunsaturated fatty acids be used as immunomodulatory agents? Calder PC. **Biochem Soc Trans** 1996 Feb;24(1):211–20 (83 ref.)
The signal transduction pathway leading from the toll receptor to nuclear localization of dorsal transcription factor. Gay NJ, et al. **Biochem Soc Trans** 1996 Feb; 24(1):35–8 (26 ref.)
Rel signalling pathway and the melanotic tumour phenotype of Drosophila. Govind S. **Biochem Soc Trans** 1996 Feb; 24(1):39–44 (44 ref.)
The TOR signalling pathway and growth control in yeast. Hall MN. **Biochem Soc Trans** 1996 Feb;24(1):234–9 (42 ref.)
A yeast transcription factor activating G1 cyclin expression has similarity to bacterial signal transduction proteins. Johnston LH, et al. **Biochem Soc Trans** 1996 Feb; 24(1):49–54 (26 ref.)
E2F and the molecular mechanisms of early cell-cycle control. La Thangue NB. **Biochem Soc Trans** 1996 Feb; 24(1):54–9 (29 ref.)
The actions of cyclosporin A and FK506 on T-lymphocyte activation. Mattila PS. **Biochem Soc Trans** 1996 Feb; 24(1):45–9 (40 ref.)
Interleukin I receptors and signal transduction. O'Neill LA. **Biochem Soc Trans** 1996 Feb;24(1):207–11 (44 ref.)
Phosphoinositide 3-kinase and CD28-mediated T-cell co-stimulation. Ward SG. **Biochem Soc Trans** 1996 Feb; 24(1):240–5 (50 ref.)
Ceramide signalling and the immune response. Ballou LR, et al. **Biochim Biophys Acta** 1996 Jun 11;1301(3):273–87 (134 ref.)
Signalling and transport through the nuclear membrane. Csermely P, et al. **Biochim Biophys Acta** 1995 Dec 20; 1241(3):425–51 (512 ref.)
Platelet-activating factor receptor: gene expression and signal transduction. Izumi T, et al. **Biochim Biophys Acta** 1995 Dec 7;1259(3):317–33 (231 ref.)
Integrin-mediated signaling in normal and malignant cells: a role of protein tyrosine kinases. Malik RK, et al. **Biochim Biophys Acta** 1996 Jun 7;1287(2–3):73–6 (61 ref.)
Phosphoinositide-specific phospholipase C and mitogenic signaling. Noh DY, et al. **Biochim Biophys Acta** 1995 Dec 18;1242(2):99–113 (143 ref.)
Calcium signalling and cell proliferation. Berridge MJ. **Bioessays** 1995 Jun;17(6):491–500 (71 ref.)
Signal transduction in the cardiac k-receptor. Wong TM, et al. **Biol Signals** 1995 May–Jun;4(3):174–8 (18 ref.)
Nobel Lecture. Signal transduction: evolution of an idea. Rodbell M. **Biosci Rep** 1995 Jun;15(3):117–33 (64 ref.)
Role of integrins as signal transducing cell adhesion molecules in human cutaneous melanoma. Danen EH, et al. **Cancer Surv** 1995;24:43–65 (130 ref.)
Ion channels, oxygen sensation and signal transduction in pulmonary arterial smooth muscle. Kozlowski RZ. **Cardiovasc Res** 1995 Sep;30(3):318–25 (73 ref.)
Peptide-surface association: the case of PDZ and PTB domains. Harrison SC. **Cell** 1996 Aug 9;86(3):341–3 (17 ref.)
STATs: signal transducers and activators of transcription. Ihle JN. **Cell** 1996 Feb 9;84(3):331–4 (20 ref.)
The body language of cells: the intimate connection between cell adhesion and behavior. Klymkowsky MW, et al. **Cell** 1995 Oct 6;83(1):5–8 (25 ref.)
Immunophysiology: the immune system as a multifunctional physiological unit. Deschaux P, et al. **Cell Mol Biol Res** 1995;41(1):1–10 (89 ref.)
Cholecystokinin receptors. Boden P, et al. **Cell Mol Neurobiol** 1995 Oct;15(5):545–59 (64 ref.)
Galanin—a neuropeptide with inhibitory actions. Kask K, et al. **Cell Mol Neurobiol** 1995 Dec;15(6):653–73 (146 ref.)
Recent advances in molecular recognition and signal transduction of active peptides: receptors for opioid peptides. Kieffer BL. **Cell Mol Neurobiol** 1995 Dec; 15(6):615–35 (101 ref.)
Cholinergic signaling in the rat pineal gland. Laitinen JT, et al. **Cell Mol Neurobiol** 1995 Apr;15(2):177–92 (72 ref.)
Signal transduction of the gonadotropin releasing hormone (GnRH) receptor: cross-talk of calcium, protein kinase C (PKC), and arachidonic acid. Naor Z, et al. **Cell Mol Neurobiol** 1995 Oct;15(5):527–44 (142 ref.)
Molecular neurobiology and pharmacology of the vasopressin/oxytocin receptor family. Peter J, et al. **Cell Mol Neurobiol** 1995 Oct;15(5):573–95 (100 ref.)
Angiotensin II: biosynthesis, molecular recognition, and signal transduction. Riordan JF. **Cell Mol Neurobiol** 1995 Dec;15(6):637–51 (62 ref.)
Endothelin receptor heterogeneity, G-proteins, and signaling via cAMP and cGMP cascades. Sokolovsky M. **Cell Mol Neurobiol** 1995 Oct;15(5):561–71 (40 ref.)
Neurotensin receptors: binding properties, transduction pathways, and structure. Vincent JP. **Cell Mol Neurobiol** 1995 Oct;15(5):501–12 (71 ref.)
Regulation of multidrug resistance through the cAMP and EGF signalling pathways. Rohlff C, et al. **Cell Signal** 1995 Jul;7(5):431–43 (131 ref.)
Characterization of somatostatin receptor subtypes. Bruns C, et al. **Ciba Found Symp** 1995;190:89–101; discussion 101–10 (68 ref.)
Spiral calcium waves: implications for signalling. Camacho P, et al. **Ciba Found Symp** 1995;188:66–77; discussion 78–84 (45 ref.)
Calcium signalling during chemotaxis. Fay FS, et al. **Ciba Found Symp** 1995;188:121–35; discussion 136–40 (34 ref.)
Function and regulation of somatostatin receptor subtypes. Schonbrunn A, et al. **Ciba Found Symp** 1995;190:204–17; discussion 217–21 (47 ref.)
Signalling events in the anergy induction of T helper 1 cells. Sloan-Lancaster J, et al. **Ciba Found Symp** 1995;195:189–96; discussion 196–202 (33 ref.)
Transforming growth factor-beta signal transduction. Brand T, et al. **Circ Res** 1996 Feb;78(2):173–9 (35 ref.)
Epithelial–mesenchymal signaling during tooth development. Thesleff I, et al. **Connect Tissue Res** 1995;32(1–4):9–15 (53 ref.)
Alterations in gene expression and signal transductions in human melanocytes and melanoma cells. Yamanishi DT, et al. **Crit Rev Oncog** 1994;5(5):429–50 (143 ref.)
The role of phosphotyrosine signaling pathway in a parotid gland proliferation and function. Purushotham KR, et al. **Crit Rev Oral Biol Med** 1995;6(2):119–31 (113 ref.)
Photosynthesis. Regulation by redox signalling. Allen JF, et al. **Curr Biol** 1995 Aug 1;5(8):869–72 (14 ref.)
Intracellular signalling. Switching off signals. Imboden JB, et al. **Curr Biol** 1995 Jul 1;5(7):727–9 (12 ref.)
Transcriptional control by protein phosphorylation: signal transmission from the cell surface to the nucleus. Karin M, et al. **Curr Biol** 1995 Jul 1;5(7):747–57 (102 ref.)
Intracellular signalling. New directions for phosphatidylinositol transfer. Martin T. **Curr Biol** 1995 Sep 1;5(9):990–2 (13 ref.)
Developmental signaling. Vertebrate ligands for Notch. Nye JS, et al. **Curr Biol** 1995 Sep 1;5(9):966–9 (25 ref.)
Signal transduction through lipid second messengers. Spiegel S, et al. **Curr Opin Cell Biol** 1996 Apr;8(2):159–67 (82 ref.)
Shuttling between two protein conformations: the common mechanism for sensory transduction and ion transport. Spudich JL, et al. **Curr Opin Cell Biol** 1996 Aug;8(4):452–7 (47 ref.)
Molecular basis of mammalian egg activation. Schultz RM, et al. **Curr Top Dev Biol** 1995;30:21–62 (186 ref.)
Signal transduction as a therapeutic target. Alessandro R, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 3):167–88 (123 ref.)
Regulation of human B cell activation by follicular dendritic cell and T cell signals. Grouard G, et al. **Curr Top Microbiol Immunol** 1995;201:105–17 (55 ref.)
The structural basis of CD4-MHC class II interactions: coreceptor contributions to T cell receptor antigen recognition and oligomerization-dependent signal transduction. König R, et al. **Curr Top Microbiol Immunol** 1996;205:19–46 (93 ref.)
Protein kinase C-delta, an important signaling molecule in the platelet-derived growth factor beta receptor pathway. Li W, et al. **Curr Top Microbiol Immunol** 1996;211:55–65 (23 ref.)
CD4 and signal transduction. Ravichandran KS, et al. **Curr Top Microbiol Immunol** 1996;205:47–62 (97 ref.)
Signal transduction by the lymphocyte-specific tyrosine protein kinase p56lck. Weil R, et al. **Curr Top Microbiol Immunol** 1996;205:63–87 (141 ref.)
Role of environmental signals and transcriptional regulators in neural crest development. Groves AK, et al. **Dev Genet** 1996;18(1):64–72 (82 ref.)
Are the beta-cell signaling molecules malonyl-CoA and cystolic long-chain acyl-CoA implicated in multiple tissue defects of obesity and NIDDM? Prentki M, et al. **Diabetes** 1996 Mar;45(3):273–83 (163 ref.)
Pathogenesis of insulin resistance: modulation of the insulin signal at receptor level. Kellerer M, et al. **Diabetes Res Clin Pract** 1995 Aug;28 Suppl:S173–7 (36 ref.)
Peptide signaling in human placenta and membranes: autocrine, paracrine, and endocrine mechanisms. Petraglia F, et al. **Endocr Rev** 1996 Apr;17(2):156–86 (431 ref.)
Insulin signaling network — waiting for Copernicus [editorial; comment] Draznin B. **Endocrinology** 1996 Jul; 137(7):2647–8 (20 ref.) Comment on: Endocrinology 1996 Jul;137(7):2649–58.
New insights into pancreatic beta-cell metabolic signaling in insulin secretion. Prenki M. **Eur J Endocrinol** 1996 Mar; 134(3):272–86 (134 ref.)
Transduction of the chemotactic cAMP signal across the plasma membrane of Dictyostelium cells. Van Haastert PJ. **Experientia** 1995 Dec 18;51(12):1144–54 (72 ref.)
The Met-HGF/SF autocrine signaling mechanism is involved in sarcomagenesis. Cortner J, et al. **EXS** 1995; 74:89–121 (101 ref.)
Liver regeneration 3: Regulation of signal transduction during liver regeneration. Diehl AM, et al. **FASEB J** 1996 Feb;10(2):215–27 (77 ref.)
G protein-coupled receptors and signaling pathways regulating growth responses. Post GR, et al. **FASEB J** 1996 May;10(7):741–9 (137 ref.)
Mitogenic signal transduction in human breast cancer cells. Strobl JS, et al. **Gen Pharmacol** 1995 Dec;26(8):1643–9 (39 ref.)
Inositols do it all. Majerus PW. **Genes Dev** 1996 May 1; 10(9):1051–3 (11 ref.)
Significance of defective endothelial signal transduction in impaired endothelium-dependent relaxation in atherosclerosis. Shimokawa H, et al. **Gerontology** 1995;41 Suppl 1:28–33 (19 ref.)
Importance of tyrosine phosphorylation in angiotensin II type 1 receptor signaling. Schieffer B, et al. **Hypertension** 1996 Mar;27(3 Pt 2):476–80 (51 ref.)
Light signal transduction mediated by phytochromes: preliminary studies and possible approaches. Song PS, et al. **Indian J Biochem Biophys** 1996 Feb;33(1):1–19 (131 ref.)
Signal transduction in brown adipose tissue recruitment: noradrenaline and beyond. Cannon B, et al. **Int J Obes Relat Metab Disord** 1996 Mar;20 Suppl 3:S36–42 (37 ref.)
Calcium channel diversity in the cardiovascular system. Katz AM. **J Am Coll Cardiol** 1996 Aug;28(2):522–9 (65 ref.)
Sphingolipids: their role in intracellular signaling and renal growth [editorial] Shayman JA. **J Am Soc Nephrol** 1996 Feb;7(2):171–82 (106 ref.)
Functional role of glycosphingolipids in cell recognition and signaling. Hakomori S, et al. **J Biochem (Tokyo)** 1995 Dec; 118(6):1091–103 (123 ref.)
Cytokine receptor signalling through two novel families of transducer molecules: Janus kinases, and signal transducers and activators of transcription. Finidori J, et al. **J Endocrinol** 1995 Oct;147(1):11–23 (117 ref.)
Chemical signaling in ciliates. Luporini P, et al. **J Eukaryot Microbiol** 1995 May–Jun;42(3):208–12 (30 ref.)
Dysfunctional cytokine receptor signaling in severe combined immunodeficiency. Leonard WJ. **J Investig Med** 1996 Aug;44(6):304–11 (66 ref.)
Endotoxin signal transduction in macrophages. Sweet MJ, et al. **J Leukoc Biol** 1996 Jul;60(1):8–26 (304 ref.)
Intracellular receptors and signal transducers and activators of transcription superfamilies: novel targets for small-molecule drug discovery. Rosen J, et al. **J Med Chem** 1995 Dec 8;38(25):4855–74 (124 ref.)
Cryptocrine signaling in the thymus network and T cell education to neuroendocrine self-antigens. Geenen V, et al. **J Mol Med** 1995 Sep;73(9):449–55 (49 ref.)
IL-2 gene therapy of solid tumors: an approach for the prevention of signal transduction defects in T cells. Zier KS, et al. **J Mol Med** 1996 Mar;74(3):127–34 (78 ref.)
Hyaluronan: RHAMM mediated cell locomotion and signaling in tumorigenesis. Hall CL, et al. **J Neurooncol** 1995 Dec;26(3):221–9 (84 ref.)
Transduction and adaptation in sensory receptor cells. Torre V, et al. **J Neurosci** 1995 Dec;15(12):7757–68 (105 ref.)
Mediators of injury in neurotrauma: intracellular signal transduction and gene expression. Bazan NG, et al. **J Neurotrauma** 1995 Oct;12(5):791–814 (249 ref.)
Signalling synapse formation between identified neurons. Drapeau P, et al. **J Physiol Paris** 1995;89(3):115–23 (52 ref.)
Inositol trisphosphate and cyclic ADP ribose as long range messengers generating local subcellular calcium signals. Petersen OH. **J Physiol Paris** 1995;89(3):125–7 (16 ref.)
Clinically accessible cell signaling: second messengers in sepsis and trauma. Rehring TF, et al. **J Surg Res** 1996 Jan; 60(1):270–7 (37 ref.)
Apoptosis overview emphasizing the role of oxidative stress, DNA damage and signal-transduction pathways. Payne CM, et al. **Leuk Lymphoma** 1995 Sep;19(1–2):43–93 (720 ref.)
Lymphocytes and neutrophils as peripheral models to study the effect of beta-amyloid on cellular calcium signalling in Alzheimer's disease. Eckert A, et al. **Life Sci** 1996; 59(5–6):499–510 (47 ref.)
Altered oxidation and signal transduction systems in fibroblasts from Alzheimer patients. Gibson G, et al. **Life Sci** 1996;59(5–6):477–89 (81 ref.)
Calcium signals in T lymphocytes from old mice. Miller RA. **Life Sci** 1996;59(5–6):469–75 (22 ref.)
Role of the time factor in signaling specificity: application to mitogenic and metabolic signaling by the insulin and insulin-like growth factor-I receptor tyrosine kinases. De Meyts P, et al. **Metabolism** 1995 Oct;44(10 Suppl 4):2–11 (88 ref.)
Intracellular signaling by growth factors. Seedorf K. **Metabolism** 1995 Oct;44(10 Suppl 4):24–32 (89 ref.)
Transmembrane signaling and phosphoinositides. Cho MH, et al. **Methods Cell Biol** 1995;49:543–54 (50 ref.)
Induction of signal transduction pathways through promoter activation. Walden R, et al. **Methods Cell Biol** 1995; 49:455–69 (26 ref.)
The social behavior of myxobacteria. Muñoz-Dorado J, et al. **Microbiologia** 1995 Dec;11(4):429–38 (61 ref.)
Polyunsaturated fatty acids and signalling via phospholipase C-beta and A2 in myocardium. de Jonge HW, et al. **Mol Cell Biochem** 1996 Apr 12–26;157(1–2):199–210 (79 ref.)
Angiotensin II signalling pathways in cardiac fibroblasts: conventional versus novel mechanisms in mediating cardiac growth and function. Dostal DE, et al.

Mol Cell Biochem 1996 Apr 12–26;157(1–2):15–21 (66 ref.)
Regulation and functional significance of phospholipase D in myocardium. Eskildsen–Helmond YE, et al. **Mol Cell Biochem** 1996 Apr 12–26;157(1–2):39–48 (72 ref.)
Inositolpolyphosphates and their binding proteins—a short review. Huisamen B, et al. **Mol Cell Biochem** 1996 Apr 12–26;157(1–2):229–32 (29 ref.)
Regulation of G protein function: implications for heart disease. Meij JT. **Mol Cell Biochem** 1996 Apr 12–26; 157(1–2):31–8 (43 ref.)
Oxygen–radical/nitric oxide mediate calcium–dependent hormone action on cyclic GMP system: a novel concept in signal transduction mechanisms. Mittal CK. **Mol Cell Biochem** 1995 Aug–Sep;149–150:257–62 (37 ref.)
Mitogen–activated protein kinase (MAPK) in cardiac tissues. Page C, et al. **Mol Cell Biochem** 1996 Apr 12–26; 157(1–2):49–57 (39 ref.)
Phosphotransfer reactions as a means of G protein activation. Piacentini L, et al. **Mol Cell Biochem** 1996 Apr 12–26; 157(1–2):59–63 (45 ref.)
Signalling by protein kinase C isoforms in the heart. Pucéat M, et al. **Mol Cell Biochem** 1996 Apr 12–26;157(1–2):65–72 (72 ref.)
Signalling by cGMP–dependent protein kinases. Vaandrager AB, et al. **Mol Cell Biochem** 1996 Apr 12–26;157(1–2):23–30 (67 ref.)
Phosphoinositide–generated messengers in cardiac signal transduction. van Heugten HA, et al. **Mol Cell Biochem** 1996 Apr 12–26;157(1–2):5–14 (88 ref.)
Branched–chain fatty acids: the case for a novel form of cell–cell signalling during Myxococcus xanthus development. Downard J, et al. **Mol Microbiol** 1995 Apr; 16(2):171–5 (18 ref.)
The signal–transduction network for Pho regulation in Bacillus subtilis. Hulett FM. **Mol Microbiol** 1996 Mar; 19(5):933–9 (27 ref.)
Transcriptional regulation by MAP kinases. Davis RJ. **Mol Reprod Dev** 1995 Dec;42(4):459–67 (31 ref.)
Dynamics and organization of MAP kinase signal pathways. Errede B, et al. **Mol Reprod Dev** 1995 Dec;42(4):477–85 (19 ref.)
Activation mechanism and function of the MAP kinase cascade. Gotoh Y, et al. **Mol Reprod Dev** 1995 Dec; 42(4):486–92 (48 ref.)
Ras–related proteins in signal transduction and growth control. McCormick F. **Mol Reprod Dev** 1995 Dec; 42(4):500–6 (8 ref.)
Interactions between Ras and Raf: key regulatory proteins in cellular transformation. Marshall M. **Mol Reprod Dev** 1995 Dec;42(4):493–9 (24 ref.)
Mechanisms regulating Raf–1 activity in signal transduction pathways. Morrison DK. **Mol Reprod Dev** 1995 Dec; 42(4):507–14 (27 ref.)
Guanine nucleotide exchange factors: activators of Ras superfamily proteins. Overbeck AF, et al. **Mol Reprod Dev** 1995 Dec;42(4):468–76 (32 ref.)
Dissection of the Torso signal transduction pathway in Drosophila. Perrimon N, et al. **Mol Reprod Dev** 1995 Dec; 42(4):515–22 (29 ref.)
LET–23–mediated signal transduction during Caenorhabditis elegans development. Sternberg PW, et al. **Mol Reprod Dev** 1995 Dec;42(4):523–8 (35 ref.)
Tumor suppressor genes in the TGF–beta signaling pathway? Serra R, et al. **Nat Med** 1996 Apr;2(4):390–1 (15 ref.)
Cytokine receptor signalling. Ihle JN. **Nature** 1995 Oct 19; 377(6550):591–4 (93 ref.)
An evolutionary perspective on signaling in behavior and immunology. McKean KA, et al. **Naturwissenschaften** 1995 Nov;82(11):509–16 (74 ref.)
Cholinergic and purinergic signalling in outer hair cells of mammalian cochlea. Heilbronn E, et al. **Neurochem Int** 1995 Oct–Nov;27(4–5):301–11 (79 ref.)
Signal transduction in hair cells and its regulation by calcium. Jaramillo F. **Neuron** 1995 Dec;15(6):1227–30 (19 ref.)
The 5–HT1A receptor: signaling, desensitization, and gene transcription. Albert PR, et al. **Neuropsychopharmacology** 1996 Jan;14(1):19–25 (45 ref.)
Transducers of life and death: TNF receptor superfamily and associated proteins. Baker SJ, et al. **Oncogene** 1996 Jan 4; 12(1):1–9 (48 ref.)
ACTH–related peptides: receptors and signal transduction systems involved in their neurotrophic and neuroprotective actions. Hol EM, et al. **Peptides** 1995;16(5):979–93 (150 ref.)
Plant homologues of components of MAPK (mitogen–activated protein kinase) signal pathways in yeast and animal cells. Nishihama R, et al. **Plant Cell Physiol** 1995 Jul;36(5):749–57 (100 ref.)
How photons start vision. Baylor D. **Proc Natl Acad Sci U S A** 1996 Jan 23;93(2):560–5 (44 ref.)
The biology of vision of Drosophila. Zuker CS. **Proc Natl Acad Sci U S A** 1996 Jan 23;93(2):571–6 (52 ref.)
The JAK–STAT pathway: summary of initial studies and recent advances. Darnell JE Jr. **Recent Prog Horm Res** 1996;51:391–403; discussion 403–4 (75 ref.)
Protein tyrosine phosphatases: their roles in signal transduction. Dixon JE. **Recent Prog Horm Res** 1996; 51:405–14; discussion 415 (31 ref.)
Modulator and messenger functions of cyclic ADP–ribose in calcium signaling. Lee HC. **Recent Prog Horm Res** 1996; 51:355–88; discussion 389 (86 ref.)
Extracellular matrix signaling from the cellular membrane skeleton to the nuclear skeleton: a model of gene regulation. Lelièvre S, et al. **Recent Prog Horm Res** 1996;51:417–32 (54 ref.)
IGF–I receptor signalling: lessons from the somatotroph. Melmed S, et al. **Recent Prog Horm Res** 1996;51:189–215; discussion 215–6 (65 ref.)
Notch and Wingless signals collide [see comments] Blair SS. **Science** 1996 Mar 29;271(5257):1822–3 (16 ref.) Comment in: Science 1996 Mar 29;271(5257):1826–32.
p75NTR: a receptor after all [see comments] Bothwell M. **Science** 1996 Apr 26;272(5261):506–7 (20 ref.) Comment in: Science 1996 Apr 26;272(5261):542–5.
Gating by cyclic AMP: expanded role for an old signaling pathway. Iyengar R. **Science** 1996 Jan 26;271(5248):461–3 (17 ref.)
STATs find that hanging together can be stimulating [comment] Leung S, et al. **Science** 1996 Aug 9; 273(5276):750–1 (19 ref.) Comment on: Science 1996 Aug 9;273(5276):794–7.
Regulating cell proliferation: as easy as APC [comment] Peifer M. **Science** 1996 May 17;272(5264):974–5 (16 ref.) Comment on: Nature 1996 May 17;272(5264):1020–3. Comment on: Nature 1996 May 17;272(5264):1023–6.
Signal transduction through the IL–4 and insulin receptor families. Wang LM, et al. **Stem Cells (Dayt)** 1995 Jul; 13(4):360–8 (47 ref.)
Cell signalling by integrins and immunoglobulin receptors in primed neutrophils. Edwards SW. **Trends Biochem Sci** 1995 Sep;20(9):362–7 (34 ref.)
Recognition and specificity in protein tyrosine kinase–mediated signalling. Zhou S, et al. **Trends Biochem Sci** 1995 Nov;20(11):470–5 (46 ref.)
Understanding signal transduction during bacterial infection. Akerley BJ, et al. **Trends Microbiol** 1996 Apr;4(4):141–6 (39 ref.)
Transduction mechanisms for gonadotrophin–induced oocyte maturation in mammals. Mattioli M. **Zygote** 1994 Nov; 2(4):347–9 (10 ref.)
Signals that make you different: receptor–mediated signal transduction in early development. Saxe CL 3rd. **Zygote** 1994 Aug;2(3):179–83 (42 ref.)
[The classes, structures, functions and signaling transduction of cytokine receptors] Lu J. **Sheng Li Ko Hsueh Chin Chan** 1995 Oct;26(4):305–11 (20 ref.) (Eng. Abstr.) **(Chi)**
[Signal transduction systems of nerve growth cone: effects of anesthetics on the machinery] Saito S, et al. **Masui** 1995; 44 Suppl:S113–8 (15 ref.) **(Jpn)**
[Hormone signal transduction and G protein] Okajima F. **Nippon Naika Gakkai Zasshi** 1995 Nov 10;84(11):1926–33 (10 ref.) **(Jpn)**
[Receptors and its signal transduction pathway in the renal interstitial cells] Arima S, et al. **Nippon Rinsho** 1995 Aug; 53(8):1861–7 (16 ref.) (Eng. Abstr.) **(Jpn)**
[Role of essential trace elements in intracellular signal transduction mechanisms] Furukawa T. **Nippon Rinsho** 1996 Jan;54(1):26–32 (20 ref.) (Eng. Abstr.) **(Jpn)**
[Molecular and pharmacological studies on signal transduction in the brain] Yamamoto H. **Nippon Yakurigaku Zasshi** 1996 Jan;107(1):9–19 (49 ref.) (Eng. Abstr.) **(Jpn)**
[14–3–3; a novel protein family which regulates intracellular signaling] Ichimura T, et al. **Seikagaku** 1995 Sep; 67(9):1156–62 (27 ref.) **(Jpn)**
[Novel NAD(+)–cleavage enzymes possibly involved in signal transduction system] Katada T, et al. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(13):1900–11 (76 ref.) **(Jpn)**
[14–3–3 protein family: the structure and function in cell signaling pathway] Shinkai F, et al. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(4):313–26 (53 ref.) **(Jpn)**
[Receptor–mediated signal transduction] Murayama T. **Yakugaku Zasshi** 1996 Apr;116(4):309–22 (31 ref.) (Eng. Abstr.) **(Jpn)**

DRUG EFFECTS

Isolation and biological activities of signal transduction inhibitors from microorganisms and plants. Umezawa K. **Adv Enzyme Regul** 1995;35:43–53 (35 ref.)
Muscarinic signaling in the central nervous system. Recent developments and anesthetic implications. Durieux ME. **Anesthesiology** 1996 Jan;84(1):173–89 (171 ref.)
The Gerhard Zbinden Memorial Lecture. Alteration of cell signalling in chemical toxicity. Nicotera P. **Arch Toxicol Suppl** 1996;18:3–11 (46 ref.)
SH2 domain protein interaction and possibilities for pharmacological intervention. Beattie J. **Cell Signal** 1996 Feb;8(2):75–86 (87 ref.)
Molecular and cellular adaptations in signal transduction pathways following ethanol exposure. Fitzgerald LW, et al. **Clin Neurosci** 1995;3(3):165–73 (98 ref.)
Targeting signal transduction for disease therapy. Levitzki A. **Curr Opin Cell Biol** 1996 Apr;8(2):239–44 (54 ref.)
Anticancer drugs acting against signaling pathways. Powis G. **Curr Opin Oncol** 1995 Nov;7(6):554–9 (95 ref.)
Intervention in receptor tyrosine kinase–mediated pathways: recombinant antibody fusion proteins targeted to ErbB2. Wels W, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 3):113–28 (47 ref.)
Effects of aluminum on neuronal signal transduction: mechanisms underlying disruption of phosphoinositide hydrolysis. Shafer TJ, et al. **Gen Pharmacol** 1995 Sep; 26(5):889–95 (46 ref.)
Signal transduction by Ras–like GTPases: a potential target for anticancer drugs. Spaargaren M, et al. **Gene Expr** 1995; 4(6):345–56 (122 ref.)
Lipopolysaccharide signal transduction, regulation of tumor necrosis factor biosynthesis, and signaling by tumor necrosis factor itself. Beutler B, et al. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S1–8 (65 ref.)
Pharmacologic control of intracellular signaling pathways: from research to therapy. Hakim J. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S106–13 (64 ref.)
Calcium–cell cycle regulator, differentiator, killer, chemopreventor, and maybe, tumor promoter. Whitfield JF, et al. **J Cell Biochem Suppl** 1995;22:74–91 (38 ref.)
Novel aspects of GnRH–induced intracellular signaling and secretion in pituitary gonadotrophs. Stojilkovic SS, et al. **J Neuroendocrinol** 1995 Oct;7(10):739–57 (110 ref.)
Enhancement of nuclear receptor transcriptional signalling. Renkawitz R, et al. **J Steroid Biochem Mol Biol** 1996 Jan; 56(1–6 Spec No):39–45 (29 ref.)
Interferon response pathways—a paradigm for cytokine signalling? Müller M, et al. **J Viral Hepat** 1994;1(2):87–103 (150 ref.)
Signal transduction mechanisms of parathyroid hormone– and parathyroid hormone–related–peptide–stimulated osteoclast–like cell formation from hemopoietic blast cells. Sugimoto T, et al. **Miner Electrolyte Metab** 1995; 21(1–3):161–5 (22 ref.)
Mechanisms of action of immunosuppressive agents: cyclosporin A, FK506, and rapamycin. Bierer BE. **Proc Assoc Am Physicians** 1995 Apr;107(1):28–40 (135 ref.)
Modulators of signal transduction as cancer chemotherapeutic agents—novel mechanisms and toxicities. Gescher A. **Toxicol Lett** 1995 Dec;82–83:159–65 (19 ref.)
The ethylene signal transduction pathway in Arabidopsis: an emerging paradigm? Chang C. **Trends Biochem Sci** 1996 Apr;21(4):129–33 (35 ref.)

GENETICS

The molecular basis of X–linked severe combined immunodeficiency: defective cytokine receptor signaling. Leonard WJ. **Annu Rev Med** 1996;47:229–39 (52 ref.)
A combined genetic and biochemical approach to mammalian signal transduction. Della NG, et al. **Aust N Z J Med** 1995 Dec;25(6):845–51 (36 ref.)
Genetic approaches to defining signaling by the CML–associated tyrosine kinase BCR–ABL. Afar DE, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:589–94 (49 ref.)
Proto–oncogenes and plasticity in cell signaling. Bishop JM, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:165–71 (25 ref.)
Calcium regulation of gene expression in neurons: the mode of entry matters. Gallin WJ, et al. **Curr Opin Neurobiol** 1995 Jun;5(3):367–74 (61 ref.)
Genetic approaches to mechanosensory transduction. Kernan M, et al. **Curr Opin Neurobiol** 1995 Aug;5(4):443–8 (46 ref.)
Clinical relevance of defects in signalling pathways. Kraus JE, et al. **Curr Opin Neurobiol** 1995 Jun;5(3):358–66 (66 ref.)
The biological cascade leading to cardiac hypertrophy. Neyses L, et al. **Eur Heart J** 1995 Dec;16 Suppl N:8–11 (27 ref.)
Signal transduction in the control of phosphate–regulated genes of Escherichia coli. Wanner BL. **Kidney Int** 1996 Apr;49(4):964–7 (24 ref.)
Regulation of cellular proliferation effects on alteration of normal signaling pathways. Malkin D. **Med Pediatr Oncol Suppl** 1996;1:20–4 (25 ref.)
Molecular methods for isolation of signal transduction pathway mutants. Chory J, et al. **Methods Cell Biol** 1995; 49:441–54 (16 ref.)
The nuclear response to cAMP: role of transcription factor CREM. Lalli E, et al. **Philos Trans R Soc Lond B Biol Sci** 1996 Feb 29; 351(1336):201–9 (50 ref.)
New connections in the regulation of PEPCK gene expression by insulin. Sutherland C, et al. **Philos Trans R Soc Lond B Biol Sci** 1996 Feb 29; 351(1336):191–9 (100 ref.)
[Mutation of G proteins] Trüeb RM. **Hautarzt** 1995 Sep; 46(9):603–6 (15 ref.) (Eng. Abstr.) **(Ger)**
[Molecular adaptation of the heart to hypertension] Neyses L, et al. **Z Kardiol** 1995;84 Suppl 4:71–6 (21 ref.) (Eng. Abstr.) **(Ger)**
[Heterogeneity of GTPase–activating proteins for Ras in the regulation of Ras signal transduction pathway] Hattori S, et al. **Yakugaku Zasshi** 1996 Jan;116(1):21–38 (58 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Signal transduction by the B–cell antigen receptor. DeFranco AL, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:195–201 (26 ref.)
Signaling difference between class IgM and IgD antigen receptors. Kim KM, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:81–8 (45 ref.)
Protein tyrosine kinases in the initiation of antigen receptor

signaling. Bolen JB. **Curr Opin Immunol** 1995 Jun; 7(3):306–11 (54 ref.)
Cytokine receptor signaling mechanisms. Karnitz LM, et al. **Curr Opin Immunol** 1995 Jun;7(3):320–6 (60 ref.)
Upstream–downstream: CD28 cosignaling pathways and T cell function. Rudd CE. **Immunity** 1996 Jun;4(6):527–34 (71 ref.)
TNF-induced activation of NF-kappa B. Schütze S, et al. **Immunobiology** 1995 Jul;193(2–4):193–203 (52 ref.)
The one signal theory of B cell activation revisited: a role for surface immunoglobulin in regulating T-independent antibody responses? Mamchak AA, et al. **Immunol Cell Biol** 1995 Jun;73(3):266–71 (29 ref.)
Multisubunit receptors in the immune system and their association with the cytoskeleton: in search of functional significance. Caplan S, et al. **Immunol Res** 1995; 14(2):98–118 (150 ref.)
T-cell activation: integration of signals from the antigen receptor and costimulatory molecules. Robey E, et al. **Immunol Today** 1995 Jul;16(7):306–10 (29 ref.)
Preventing abnormalities in signal transduction of T cells in cancer: the promise of cytokine gene therapy. Zier K, et al. **Immunol Today** 1996 Jan;17(1):39–45 (62 ref.)
Costimulation in tolerance and autoimmunity. Guerder S, et al. **Int Rev Immunol** 1995;13(2):135–46 (49 ref.)
Tolerance sensitivity of immature-stage B cells: can developmentally regulated B cell antigen receptor (BCR) signal transduction play a role? Monroe JG. **J Immunol** 1996 Apr 15;156(8):2657–60 (38 ref.)
Signalling intermediates of CD28. Ben-Neriah Y, et al. **Res Immunol** 1995 Mar–Apr;146(3):154–8 (28 ref.)
The critical role of CD28 signalling in the prevention of human T-cell anergy. Boussiotis VA, et al. **Res Immunol** 1995 Mar–Apr;146(3):140–9 (72 ref.)
Mechanisms of CD28 signalling. Schneider H, et al. **Res Immunol** 1995 Mar–Apr;146(3):149–54 (59 ref.)
Molecular mechanism of T-cell activation: role of protein tyrosine kinases in antigen receptor-mediated signal transduction. Thome M, et al. **Res Immunol** 1995 May–Jun; 146(4–5):291–307 (104 ref.)
The two-signal model and 'self'-reactivity: are they really compatible? A reply to Faro & Carneiro. Cohn M. **Scand J Immunol** 1996 Jan;43(1):1–5; discussion 6–8 (8 ref.)
Hybrid resistance: 'negative' and 'positive' signaling of murine natural killer cells. Bennett M, et al. **Semin Immunol** 1995 Apr;7(2):121–7 (24 ref.)
The Janus protein tyrosine kinases in hematopoietic cytokine signaling. Ihle JN. **Semin Immunol** 1995 Aug;7(4):247–54 (57 ref.)
Positive and negative regulation of leukocyte activation by protein tyrosine phosphatases. Thomas ML. **Semin Immunol** 1995 Aug;7(4):279–88 (85 ref.)
The Syk/ZAP-70 protein tyrosine kinase connection to antigen receptor signalling processes. van Oers NS, et al. **Semin Immunol** 1995 Aug;7(4):227–36 (71 ref.)

PHYSIOLOGY

Recent insights into ligand binding, activation and signalling by integrin adhesion receptors. Garratt AN, et al. **Acta Anat (Basel)** 1995;154(1):34–45 (112 ref.)
Signaling by the cytokine receptor superfamily in normal and transformed hematopoietic cells. Ihle JN. **Adv Cancer Res** 1996;68:23–65 (263 ref.)
Multifunctional calcium and calmodulin-dependent kinase II in neuronal function and disease. Churn SB. **Adv Neuroimmunol** 1995;5(3):241–59 (141 ref.)
Interactions of human immunodeficiency virus type 1 transactivator of transcription protein with signal transduction pathways. Garza HH Jr, et al. **Adv Neuroimmunol** 1995;5(3):321–5 (27 ref.)
Subversion of intracellular signal transduction by herpes simplex virus type 1. Halford WP, et al. **Adv Neuroimmunol** 1995;5(3):327–34 (46 ref.)
Regulation of astrocyte cell biology by the cAMP/protein kinase A signaling pathway. Huneycutt BS, et al. **Adv Neuroimmunol** 1995;5(3):261–9 (45 ref.)
The role of adrenoceptor-mediated signals in the modulation of lymphocyte function. Sanders VM. **Adv Neuroimmunol** 1995;5(3):283–98 (112 ref.)
Glyceraldehyde-3-phosphate dehydrogenase: a target for nitric oxide signaling. Brüne B, et al. **Adv Pharmacol** 1995; 34:351–60 (30 ref.)
Nitric oxide and cGMP signaling. McDonald LJ, et al. **Adv Pharmacol** 1995;34:263–75 (49 ref.)
Cellular signals in alcohol-induced liver injury: a review. Lands WE. **Alcohol Clin Exp Res** 1995 Aug;19(4):928–38 (112 ref.)
Cytokine signaling in mesothelial cells: receptor expression closes the autocrine loop. Gerwin BI. **Am J Respir Cell Mol Biol** 1996 Jun;14(6):505–7 (27 ref.)
Muscarinic signaling in the central nervous system. Recent developments and anesthetic implications. Durieux ME. **Anesthesiology** 1996 Jan;84(1):173–89 (171 ref.)
Receptor–effector coupling dysfunctions in Alzheimer's disease. Fowler CJ, et al. **Ann N Y Acad Sci** 1996 Jun 15;786:294–304 (72 ref.)
Cellular and molecular mechanisms of cardiovascular aging. Molecular pharmacological implications. Miyamoto A, et al. **Ann N Y Acad Sci** 1996 Jun 15;786:283–93 (58 ref.)
How bacteria sense and swim. Blair DF. **Annu Rev Microbiol** 1995;49:489–522 (197 ref.)
Insulin signal transduction and the IRS proteins. Myers MG Jr, et al. **Annu Rev Pharmacol Toxicol** 1996;36:615–58 (234 ref.)
Defects in G protein–coupled signal transduction in human disease. Spiegel AM. **Annu Rev Physiol** 1996;58:143–70 (90 ref.)
Cytokines: sources, receptors and signalling. Barrett KE. **Baillieres Clin Gastroenterol** 1996 Mar;10(1):1–15 (60 ref.)
Modulation of actin dynamics during stress and physiological stimulation by a signaling pathway involving p38 MAP kinase and heat-shock protein 27. Landry J, et al. **Biochem Cell Biol** 1995 Sep–Oct;73(9–10):703–7 (42 ref.)
Using fluorescence to probe calcium signalling mechanisms. Bolsover S. **Biochem Soc Trans** 1995 Aug;23(3):627–9 (12 ref.)
Signalling in extracellular-matrix-mediated control of epithelial cell phenotype. Edwards G, et al. **Biochem Soc Trans** 1995 Aug;23(3):464–8 (39 ref.)
Dynamic protein acylation and the regulation of localization and function of signal-transducing proteins. Jackson CS, et al. **Biochem Soc Trans** 1995 Aug;23(3):568–71 (40 ref.)
Interaction of protein kinase C with RACK1, a receptor for activated C-kinase: a role in beta protein kinase C mediated signal transduction. Mochly-Rosen D, et al. **Biochem Soc Trans** 1995 Aug;23(3):596–600 (32 ref.)
Signal transduction at the blood–brain barrier. Staddon JM, et al. **Biochem Soc Trans** 1995 Aug;23(3):475–9 (47 ref.)
Signals for mesoderm induction. Roles of fibroblast growth factor (FGF)/mitogen-activated protein kinase (MAPK) pathway. Gotoh Y, et al. **Biochim Biophys Acta** 1996 Aug 8;1288(1):F1–7 (121 ref.)
Ubiquitin in signal transduction and cell transformation. Isaksson A, et al. **Biochim Biophys Acta** 1996 Aug 8; 1288(1):F21–9 (73 ref.)
Signalling to p53: where does it all start? Kastan MB. **Bioessays** 1996 Aug;18(8):617–9 (28 ref.)
Towards unraveling the complexity of T cell signal transduction. Zenner G, et al. **Bioessays** 1995 Nov; 17(11):967–75 (54 ref.)
Role of endocrine cell microvesicles in intercellular chemical transduction. Moriyama Y, et al. **Biol Chem Hoppe Seyler** 1996 Mar;377(3):155–65 (108 ref.)
Estrogen receptors: bioactivities and interactions with cell signaling pathways. Katzenellenbogen BS. **Biol Reprod** 1996 Feb;54(2):287–93 (74 ref.)
Proteins that smell: pheromone recognition and signal transduction. Prestwich GD. **Bioorg Med Chem** 1996 Mar; 4(3):505–13 (55 ref.)
The molecular dissection of Fc gamma receptor mediated phagocytosis. Indik ZK, et al. **Blood** 1995 Dec 15; 86(12):4389–99 (85 ref.)
Angiotensin II–mediated signal transduction events in vascular smooth muscle cells: kinases and phosphatases. Duff JL, et al. **Blood Press Suppl** 1995;2:55–60 (68 ref.)
Backpropagation of action potentials generated at ectopic axonal loci: hypothesis that axon terminals integrate local environmental signals. Pinault D. **Brain Res Brain Res Rev** 1995 Jul;21(1):42–92 (484 ref.)
Mechanotransduction and the functional response of bone to mechanical strain. Duncan RL, et al. **Calcif Tissue Int** 1995 Nov;57(5):344–58 (225 ref.)
The 1994 Upjohn Award Lecture. Molecular and genetic approaches to the study of signal transduction in the adrenal cortex. Schimmer BP. **Can J Physiol Pharmacol** 1995 Aug;73(8):1097–107 (83 ref.)
An overview of the interferon system: signal transduction and mechanisms of action. Kalvakolanu DV, et al. **Cancer Invest** 1996;14(1):25–53 (347 ref.)
Integrin mediated signal transduction in oncogenesis: an overview. Dedhar S. **Cancer Metastasis Rev** 1995 Sep; 14(3):165–72 (59 ref.)
Signalling mechanisms in the regulation of vascular cell migration. Abedi H, et al. **Cardiovasc Res** 1995 Oct; 30(4):544–56 (145 ref.)
Molecular signalling mechanisms controlling growth and function of cardiac fibroblasts. Booz GW, et al. **Cardiovasc Res** 1995 Oct;30(4):537–43 (57 ref.)
Signal transduction mechanisms controlling cardiac contractility and their alterations in chronic heart failure. Brodde OE, et al. **Cardiovasc Res** 1995 Oct;30(4):570–84 (214 ref.)
Free radicals and intracellular events associated with cerebrovascular spasm. Cook DA, et al. **Cardiovasc Res** 1995 Oct;30(4):493–500 (112 ref.)
Angiotensin II signal transduction and the mitogen-activated protein kinase pathway. Duff JL, et al. **Cardiovasc Res** 1995 Oct;30(4):511–7 (102 ref.)
Mechano-electrical feedback in ventricular myocardium. Franz MR. **Cardiovasc Res** 1996 Jul;32(1):15–24 (40 ref.)
Mitogen-responsive nuclear factors that mediate growth control signals in vascular myocytes. Gorski DH, et al. **Cardiovasc Res** 1995 Oct;30(4):585–92 (114 ref.)
Mechanosensitive connective tissue: potential influence on heart rhythm. Kohl P, et al. **Cardiovasc Res** 1996 Jul; 32(1):62–8 (63 ref.)
Mechanoelectric feedback (transduction) in heart: concepts and implications. Lab MJ. **Cardiovasc Res** 1996 Jul; 32(1):3–14 (146 ref.)
Cell cycle control mechanisms and their role in cardiac growth. McGill CJ, et al. **Cardiovasc Res** 1995 Oct; 30(4):557–69 (182 ref.)
The role of tyrosine phosphorylation in angiotensin II–mediated intracellular signalling. Marrero MB, et al. **Cardiovasc Res** 1995 Oct;30(4):530–6 (54 ref.)
Mechanoelectric feedback and atrial arrhythmias. Nazir SA, et al. **Cardiovasc Res** 1996 Jul;32(1):52–61 (92 ref.)
Effects of mechano–electrical feedback: potential arrhythmogenic influence in patients with congestive heart failure. Reiter MJ. **Cardiovasc Res** 1996 Jul;32(1):44–51 (44 ref.)
Autonomic receptor—effector coupling during post-natal development. Robinson RB. **Cardiovasc Res** 1996 Feb;31 Spec No:E68–76 (68 ref.)
Intracellular signalling through protein kinases in the heart. Sugden PH, et al. **Cardiovasc Res** 1995 Oct;30(4):478–92 (206 ref.)
Mechano–electric feedback in the human heart. Taggart P. **Cardiovasc Res** 1996 Jul;32(1):38–43 (41 ref.)
Phospholipase-A2–dependent signalling in the heart. Van Bilsen M, et al. **Cardiovasc Res** 1995 Oct;30(4):518–29 (125 ref.)
The elemental principles of calcium signaling. Bootman MD, et al. **Cell** 1995 Dec 1;83(5):675–8 (24 ref.)
Calcium ions as extracellular messengers. Brown EM, et al. **Cell** 1995 Dec 1;83(5):679–82 (20 ref.)
KSR: a novel player in the RAS pathway [comment] Downward J. **Cell** 1995 Dec 15;83(6):831–4 (17 ref.) Comment on: Cell 1995 Dec 15;83(6):879–88. Comment on: Cell 1995 Dec 15;83(6):889–901. Comment on: Cell 1995 Dec 15;83(6):903–13.
A license to kill. Fraser A, et al. **Cell** 1996 Jun 14;85(6):781–4 (21 ref.)
Cell–cell signaling, microtubules, and the loss of symmetry in the Drosophila oocyte. Lehmann R. **Cell** 1995 Nov 3; 83(3):353–6 (15 ref.)
The RXR heterodimers and orphan receptors. Mangelsdorf DJ, et al. **Cell** 1995 Dec 15;83(6):841–50 (80 ref.)
TGFbeta signaling: receptors, transducers, and Mad proteins. Massagué J. **Cell** 1996 Jun 28;85(7):947–50 (20 ref.)
Regulation of dynein-driven microtubule sliding by an axonemal kinase and phosphatase in Chlamydomonas flagella. Habermacher G, et al. **Cell Motil Cytoskeleton** 1995;32(2):106–9 (23 ref.)
Regulation of ciliary beat frequency by a dynein light chain. Hamasaki T, et al. **Cell Motil Cytoskeleton** 1995;32(2):121–4 (27 ref.)
Regulation of the Jak/STAT signalling pathway. Finbloom DS, et al. **Cell Signal** 1995 Nov;7(8):739–45 (49 ref.)
Protein tyrosine phosphorylation as a mechanism of signalling in mast cells and basophils. Hamawy MM, et al. **Cell Signal** 1995 Aug;7(6):535–44 (90 ref.)
The postsynaptic density: a subcellular anchor for signal transduction enzymes. Klauck TM, et al. **Cell Signal** 1995 Nov;7(8):747–57 (114 ref.)
Angiotensin II signalling events mediated by tyrosine phosphorylation. Marrero MB, et al. **Cell Signal** 1996 Jan; 8(1):21–6 (30 ref.)
Roles of protein-tyrosine phosphatases in growth factor signalling. Matozaki T, et al. **Cell Signal** 1996 Jan;8(1):13–9 (67 ref.)
The stoichiometry of expression of protein components of the stimulatory adenylyl cyclase cascade and the regulation of information transfer. Milligan G. **Cell Signal** 1996 Feb; 8(2):87–95 (81 ref.)
Modulation of Ca2+ channels by alpha 1A- and alpha 2A-adrenoceptors in vascular myocytes: involvement of different transduction pathways. Mironneau J, et al. **Cell Signal** 1995 Jul;7(5):471–9 (29 ref.)
Role of heterotrimeric G-proteins in epidermal growth factor signalling. Ramírez I, et al. **Cell Signal** 1995 May; 7(4):303–11 (123 ref.)
Pancreastatin action in the liver: dual coupling to different G proteins. Sánchez-Margalet V, et al. **Cell Signal** 1996 Jan;8(1):9–12 (53 ref.)
Phosphatidate phosphohydrolase and signal transduction. Brindley DN, et al. **Chem Phys Lipids** 1996 May 24; 80(1–2):45–57 (78 ref.)
The N-acylation–phosphodiesterase pathway and cell signalling. Schmid HH, et al. **Chem Phys Lipids** 1996 May 24;80(1–2):133–42 (64 ref.)
Calcium signalling during mammalian fertilization. Miyazaki S. **Ciba Found Symp** 1995;188:235–47; discussion 247–51 (42 ref.)
Subcellular organization of calcium signalling in hepatocytes and the intact liver. Thomas AP, et al. **Ciba Found Symp** 1995;188:18–35; discussion 35–49 (56 ref.)
Calcium signalling in cardiac muscle cells. Wier WG, et al. **Ciba Found Symp** 1995;188:146–60; discussion 160–4 (41 ref.)
Developmental signalling. Hendry IA, et al. **Clin Exp Pharmacol Physiol** 1995 Aug;22(8):563–8 (21 ref.)
Signalling pathways activated by endothelin stimulation of renal cells. Nord EP. **Clin Exp Pharmacol Physiol** 1996 Apr;23(4):331–6 (54 ref.)
Biochemical pathways of retinoid transport, metabolism, and signal transduction. Napoli JL. **Clin Immunol Immunopathol** 1996 Sep;80(3 Pt 2):S52–62 (62 ref.)
Molecular and genetic insights into the role of protein tyrosine kinases in T cell receptor signaling. Weiss A. **Clin Immunol Immunopathol** 1995 Sep;76(3 Pt 2):S158–62 (30 ref.)
Activation of Ras and other signaling pathways by receptor tyrosine kinases. Schlessinger J, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:173–9 (43 ref.)

Steroid hormone signalling system and fungi. Zakelj-Mavrič M, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1995 Dec;112(4):637–42 (69 ref.)

Cell polarity. The importance of being polar. Glotzer M, et al. **Curr Biol** 1995 Oct 1;5(10):1102–5 (21 ref.)

Morphogenetic signalling. Responses to hedgehog. Kalderon D. **Curr Biol** 1995 Jun 1;5(6):580–2 (15 ref.)

Adipocyte differentiation. When precursors are also regulators. MacDougald OA, et al. **Curr Biol** 1995 Jun 1; 5(6):618–21 (16 ref.)

Protein tyrosine phosphatases as adhesion receptors. Brady-Kalnay SM, et al. **Curr Opin Cell Biol** 1995 Oct; 7(5):650–7 (58 ref.)

The Dbl family of oncogenes. Cerione RA, et al. **Curr Opin Cell Biol** 1996 Apr;8(2):216–22 (46 ref.)

Inhibition of cell adhesion by anti-adhesive molecules. Chiquet-Ehrismann R. **Curr Opin Cell Biol** 1995 Oct; 7(5):715–9 (46 ref.)

The 70 kDa S6 kinase: regulation of a kinase with multiple roles in mitogenic signalling. Chou MM, et al. **Curr Opin Cell Biol** 1995 Dec;7(6):806–14 (72 ref.)

Recent advances in understanding signal transduction pathways in worms and flies. Duffy JB, et al. **Curr Opin Cell Biol** 1996 Apr;8(2):231–8 (44 ref.)

Signal transduction of beta-catenin. Gumbiner BM. **Curr Opin Cell Biol** 1995 Oct;7(5):634–40 (51 ref.)

Tight junctions, membrane-associated guanylate kinases and cell signaling. Kim SK. **Curr Opin Cell Biol** 1995 Oct; 7(5):641–9 (71 ref.)

Budding yeast morphogenesis: signalling, cytoskeleton and cell cycle. Kron SJ, et al. **Curr Opin Cell Biol** 1995 Dec; 7(6):845–55 (84 ref.)

Integrin-mediated signalling: regulation by protein tyrosine kinases and small GTP-binding proteins. Parsons JT. **Curr Opin Cell Biol** 1996 Apr;8(2):146–52 (47 ref.)

A hierarchy of ECM-mediated signalling regulates tissue-specific gene expression. Roskelley CD, et al. **Curr Opin Cell Biol** 1995 Oct;7(5):736–47 (117 ref.)

Receptor signalling and the regulation of endocytic membrane transport. Seaman MN, et al. **Curr Opin Cell Biol** 1996 Aug;8(4):549–56 (67 ref.)

Protein tyrosine phosphatases in signaling. Streuli M. **Curr Opin Cell Biol** 1996 Apr;8(2):182–8 (81 ref.)

Signaling via hetero-oligomeric complexes of type I and type II serine/threonine kinase receptors. ten Dijke P, et al. **Curr Opin Cell Biol** 1996 Apr;8(2):139–45 (58 ref.)

Plugging it in: signaling circuits and the yeast cell cycle. Wittenberg C, et al. **Curr Opin Cell Biol** 1996 Apr; 8(2):223–30 (55 ref.)

Integrin transmembrane signaling and cytoskeletal control. Yamada KM, et al. **Curr Opin Cell Biol** 1995 Oct;7(5):681–9 (84 ref.)

Signalling by hedgehog family proteins in Drosophila and vertebrate development. Ingham PW. **Curr Opin Genet Dev** 1995 Aug;5(4):492–8 (67 ref.)

Dual second-messenger pathways in olfactory transduction. Ache BW, et al. **Curr Opin Neurobiol** 1995 Aug;5(4):461–6 (48 ref.)

Molecular machinery of auditory and vestibular transduction. Gillespie PG. **Curr Opin Neurobiol** 1995 Aug;5(4):449–55 (62 ref.)

Ligand-independent hormone secretion. Laue L. **Curr Opin Pediatr** 1995 Aug;7(4):434–9 (47 ref.)

Portrait of a myristoyl switch protein. Ames JB, et al. **Curr Opin Struct Biol** 1996 Aug;6(4):432–8 (47 ref.)

Cytoskeleton, cellular signals, and cytoplasmic localization in Chaetopterus embryos. Eckberg WR, et al. **Curr Top Dev Biol** 1995;31:5–39 (100 ref.)

Signal transduction mechanisms in glial cells. Bhat NR. **Dev Neurosci** 1995;17(5–6):267–84 (162 ref.)

Cross talk between peptide growth factor and estrogen receptor signaling systems. Ignar-Trowbridge DM, et al. **Environ Health Perspect** 1995 Oct;103 Suppl 7:35–8 (34 ref.)

Transmembrane and intracellular signalling by interleukin-4: receptor dimerization and beyond. Duschl A, et al. **Eur Cytokine Netw** 1996 Jan-Mar;7(1):37–49 (122 ref.)

p21ras: an oncoprotein functioning in growth factor-induced signal transduction. Bos JL. **Eur J Cancer** 1995 Jul-Aug; 31A(7–8):1051–4 (29 ref.)

The Jak-STAT pathway: specific signal transduction from the cell membrane to the nucleus. Heim MH. **Eur J Clin Invest** 1996 Jan;26(1):1–12 (133 ref.)

Growth hormone receptor: structure and signal transduction. Postel-Vinay MC, et al. **Eur J Endocrinol** 1995 Dec; 133(6):654–9 (57 ref.)

The epidermal growth factor/transforming growth factor-alpha family and their receptors. Brown KD. **Eur J Gastroenterol Hepatol** 1995 Oct;7(10):914–22 (58 ref.)

Basic actions of transforming growth factor-alpha and related peptides. Coffey RJ, et al. **Eur J Gastroenterol Hepatol** 1995 Oct;7(10):923–7 (49 ref.)

TNF-alpha- and IFN-gamma-mediated signal transduction pathways: effects on glial cell gene expression and function. Benveniste EN, et al. **FASEB J** 1995 Dec;9(15):1577–84 (68 ref.)

G-protein-coupled receptors in HL-60 human leukemia cells. Klinker JF, et al. **Gen Pharmacol** 1996 Jan;27(1):33–54 (247 ref.)

Signal transduction and activation of gene transcription by interferons. Gilmour KC, et al. **Gene Expr** 1995;5(1):1–18 (145 ref.)

The signals and molecular pathways involved in implantation, a symbiotic interaction between blastocyst and endometrium involving adhesion and tissue invasion. Tabibzadeh S, et al. **Hum Reprod** 1995 Jun;10(6):1579–602 (200 ref.)

Interleukin-1 signal transduction. O'Neill LA. **Int J Clin Lab Res** 1995;25(4):169–77 (95 ref.)

Signal transduction pathways in oligodendrocytes: role of tumor necrosis factor-alpha. Soliven B, et al. **Int J Dev Neurosci** 1995 Jun-Jul;13(3–4):351–67 (143 ref.)

Membrane mechanisms and intracellular signalling in cell volume regulation. Hoffmann EK, et al. **Int Rev Cytol** 1995; 161:173–262 (500 ref.)

Developmental neurotransmitters. Signals for shaping neuronal circuitry. Redburn DA, et al. **Invest Ophthalmol Vis Sci** 1996 Jul;37(8):1479–82 (16 ref.)

Calcium signalling in bacteria. Norris V, et al. **J Bacteriol** 1996 Jul;178(13):3677–82 (88 ref.)

The focal adhesion kinase. Schaller MD. **J Endocrinol** 1996 Jul;150(1):1–7 (88 ref.)

The PI/PTB domain: a new protein interaction domain involved in growth factor receptor signaling. Margolis B. **J Lab Clin Med** 1996 Sep;128(3):235–41 (66 ref.)

Role of CSB/p38/RK stress response kinase in LPS and cytokine signaling mechanisms. Lee JC, et al. **J Leukoc Biol** 1996 Feb;59(2):152–7 (62 ref.)

Novel insight into molecular mechanism of endotoxin shock: biochemical analysis of LPS receptor signaling in a cell-free system targeting NF-kappaB and regulation of cytokine production/action through beta2 integrin in vivo. Mukaida N, et al. **J Leukoc Biol** 1996 Feb;59(2):145–51 (42 ref.)

Calcium and inositol trisphosphate receptors. Taylor CW, et al. **J Membr Biol** 1995 May;145(2):109–18 (108 ref.)

The role of RNA editing in controlling glutamate receptor channel properties. Seeburg PH. **J Neurochem** 1996 Jan; 66(1):1–5 (38 ref.)

Gp130, a shared signal transducing receptor component for hematopoietic and neuropoietic cytokines. Taga T. **J Neurochem** 1996 Jul;67(1):1–10 (90 ref.)

The insulin-like growth factor signaling system and ALS neurotrophic factor treatment strategies. Festoff BW, et al. **J Neurol Sci** 1995 May;129 Suppl:114–21 (60 ref.)

The Ernst Schering Poster Award. Intracellular traffic of steroid hormone receptors. Guiochon-Mantel A, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1–6 Spec No):3–9 (64 ref.)

Defects in signal transduction pathways in chronic B lymphocytic leukemia cells. Jabbar SA, et al. **Leuk Lymphoma** 1995 Jun;18(1–2):163–70 (52 ref.)

The role of intracellular signalling pathways regulating thymocyte and leukemic T cell apoptosis. Conroy LA, et al. **Leukemia** 1996 Sep;10(9):1422–35 (205 ref.)

Interleukin-1 signal transduction. Bankers-Fulbright JL, et al. **Life Sci** 1996;59(2):61–83 (237 ref.)

Adrenoceptors in SHR: alterations in binding characteristics and intracellular signal transduction pathways. Takata Y, et al. **Life Sci** 1996;58(2):91–106 (199 ref.)

Up-regulation of intracellular signalling pathways may play a central pathogenic role in hypertension, atherogenesis, insulin resistance, and cancer promotion—the 'PKC syndrome'. McCarty MF. **Med Hypotheses** 1996 Mar; 46(3):191–221 (402 ref.)

Reactive oxygen species and vascular signal transduction mechanisms. Wolin MS. **Microcirculation** 1996 Mar; 3(1):1–17 (131 ref.)

Degenerative and protective signaling mechanisms in the neurofibrillary pathology of AD. Mattson MP. **Neurobiol Aging** 1995 May-Jun;16(3):447–57; discussion 458–63 (99 ref.)

Networking with proline-directed protein kinases implicated in tau phosphorylation. Pelech SL. **Neurobiol Aging** 1995 May-Jun;16(3):247–56; discussion 257–61 (135 ref.)

A brief appraisal on some aspects of the receptor-receptor interaction. Agnati LF, et al. **Neurochem Int** 1995 Aug; 27(2):139–46 (43 ref.)

TRP is cracked but is CRAC TRP? Clapham DE. **Neuron** 1996 Jun;16(6):1069–72 (17 ref.)

Adrenergic receptor signal transduction and regulation. Hein L, et al. **Neuropharmacology** 1995 Apr;34(4):357–66 (78 ref.)

Alterations in calcium signaling and cellular responses in septic injury. Sayeed MM. **New Horiz** 1996 Feb;4(1):72–86 (114 ref.)

Transmembrane signaling in kidney health and disease. Hack N, et al. **Pediatr Nephrol** 1995 Aug;9(4):514–25 (126 ref.)

Receptor cell biology: receptor-mediated endocytosis. Schwartz AL. **Pediatr Res** 1995 Dec;38(6):835–43 (133 ref.)

Phytochrome signal-transduction: characterization of pathways and isolation of mutants. Barnes SA, et al. **Philos Trans R Soc Lond B Biol Sci** 1995 Oct 30; 350(1331):67–74 (20 ref.)

JAKs, STATs and signal transduction in response to the interferons and other cytokines. Briscoe J, et al. **Philos Trans R Soc Lond B Biol Sci** 1996 Feb 29; 351(1336):167–71 (12 ref.)

Signal-transduction pathways controlling light-regulated development in Arabidopsis. Chory J, et al. **Philos Trans R Soc Lond B Biol Sci** 1995 Oct 30; 350(1331):59–65 (62 ref.)

Feedback regulation of map kinase signal pathways. Errede B, et al. **Philos Trans R Soc Lond B Biol Sci** 1996 Feb 29;351(1336):143–8; discussion 148–9 (30 ref.)

Janus kinases in cytokine signalling. Ihle JN. **Philos Trans R Soc Lond B Biol Sci** 1996 Feb 29; 351(1336):159–66 (120 ref.)

The regulation of AP-1 activity by mitogen-activated protein kinases. Karin M. **Philos Trans R Soc Lond B Biol Sci** 1996 Feb 29; 351(1336):127–34 (60 ref.)

Phosphatidylinositol 3' kinase: one of the effectors of Ras. Rodriguez-Viciana P, et al. **Philos Trans R Soc Lond B Biol Sci** 1996 Feb 29; 351(1336):225–31; discussion 231–2 (50 ref.)

Interleukin 1 (IL1) and tumour necrosis factor (TNF) signal transduction. Saklatvala J, et al. **Philos Trans R Soc Lond B Biol Sci** 1996 Feb 29; 351(1336):151–7 (40 ref.)

A heterotrimeric GTPase-regulated isoform of PI3K and the regulation of its potential effectors. Stephens L, et al. **Philos Trans R Soc Lond B Biol Sci** 1996 Feb 29; 351(1336):211–5 (40 ref.)

The IRS-signalling system in insulin and cytokine action. White MF. **Philos Trans R Soc Lond B Biol Sci** 1996 Feb 29;351(1336):181–9 (80 ref.)

Reconstitution of novel signalling cascades responding to cellular stresses. Woodgett JR, et al. **Philos Trans R Soc Lond B Biol Sci** 1996 Feb 29; 351(1336):135–41; discussion 142 (50 ref.)

Multineuronal codes in retinal signaling. Meister M. **Proc Natl Acad Sci U S A** 1996 Jan 23;93(2):609–14 (32 ref.)

pH regulation and proton signalling by glial cells. Deitmer JW, et al. **Prog Neurobiol** 1996 Feb;48(2):73–103 (265 ref.)

Molecular mechanisms of gustatory transduction in frog taste cells. Sato T, et al. **Prog Neurobiol** 1995 Jun;46(2–3):239–87 (100 ref.)

Survival factors, intracellular signal transduction, and the activation of endonucleases in apoptosis. Eastman A. **Semin Cancer Biol** 1995 Feb;6(1):45–52 (69 ref.)

Regulation by tumour antigens defines a role for PP2A in signal transduction. Mumby M. **Semin Cancer Biol** 1995 Aug;6(4):229–37 (59 ref.)

Control of signal transduction and morphogenesis by Ras. Hughes DA. **Semin Cell Biol** 1995 Apr;6(2):89–94 (49 ref.)

Alterations in cell signaling and related effector functions in T lymphocytes in burn/trauma/septic injuries [editorial] Sayeed MM. **Shock** 1996 Mar;5(3):157–66 (111 ref.)

Switching to Rac and Rho. Block C, et al. **Structure** 1995 Dec 15;3(12):1281–4 (30 ref.)

Protein phosphorylation and signal transduction. Barik S. **Subcell Biochem** 1996;26:115–64 (182 ref.)

Platelet activation by polymorphonuclear leukocytes: role of cathepsin G and P-selectin. Cerletti C, et al. **Thromb Haemost** 1995 Jul;74(1):218–23 (82 ref.)

Platelet activation: signal transduction via membrane receptors. Clemetson KJ. **Thromb Haemost** 1995 Jul; 74(1):111–6 (57 ref.)

Molecular mechanisms of fibroblast growth factor-1 traffick, signaling and release. Maciag T, et al. **Thromb Haemost** 1995 Jul;74(1):411–4 (56 ref.)

Role of signalling and cytoskeletal rearrangements in the pathogenesis of Entamoeba histolytica. Guillén N. **Trends Microbiol** 1996 May;4(5):191–7 (47 ref.)

Retrograde signaling at GABAA-receptor synapses in the mammalian CNS. Alger BE, et al. **Trends Neurosci** 1995 Aug;18(8):333–40 (42 ref.)

Facilitation of Ca2+ current in excitable cells. Dolphin AC. **Trends Neurosci** 1996 Jan;19(1):35–43 (95 ref.)

A faster transduction mechanism for the cochlear amplifier? Kolston PJ. **Trends Neurosci** 1995 Oct;18(10):427–9 (21 ref.)

Protease-mediated signalling: new paradigms for cell regulation and drug development. Hollenberg MD. **Trends Pharmacol Sci** 1996 Jan;17(1):3–6 (28 ref.)

Novel dopamine receptors half a decade later [see comments] Sokoloff P, et al. **Trends Pharmacol Sci** 1995 Aug; 16(8):270–5 (60 ref.) Comment in: Trends Pharmacol Sci 1995 Dec;16(12):406–8.

Integrin signaling and matrix assembly. Ruoslahti E. **Tumour Biol** 1996;17(2):117–24 (44 ref.)

Signal transduction in ischemic preconditioning. Downey JM, et al. **Z Kardiol** 1995;84 Suppl 4:77–86 (68 ref.)

[Phospholipase D. New pathways of signal transduction] Höer A, et al. **Med Monatsschr Pharm** 1996 May; 19(5):122–31 (81 ref.) **(Ger)**

[The leukotriene signal pathway—a very promising point of entry for inhibitors in therapy of inflammatory diseases] Müller MJ. **Pharm Unserer Zeit** 1995 Sep;24(5):264–72 (53 ref.) **(Ger)**

[Role of signal transduction mechanisms in light-induced entrainment of biological clocks] Shibata S. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(16):2408–17 (46 ref.) **(Jpn)**

[Vagovagal regulation of the gastrointestinal tract: from signal conduction to performance response] Grundy D, et al. **Fiziol Zh Im I M Sechenova** 1995 Nov;81(11):104–11 (36 ref.) **(Rus)**

[The central effects of interoceptive signalization] Zakharzhevskii VB. **Fiziol Zh Im I M Sechenova** 1995 Sep; 81(9):1–12 (64 ref.) **(Rus)**

[Structure and functional properties of GTP-binding proteins of plasma membranes] Usatiuk SA, et al. **Ukr Biokhim Zh** 1995 Jan-Feb;67(1):14–25 (25 ref.) (Eng. Abstr.) **(Ukr)**

RADIATION EFFECTS

Light-induced signal transduction pathway involving inositol phosphates. Sopory SK, et al. **Subcell Biochem** 1996; 26:345-70 (117 ref.)

SILAGE

Control of voluntary intake of precision-chopped silages by ruminants: a review. Dulphy JP, et al.
Reprod Nutr Dev 1996;36(2):113-35 (144 ref.)

SILICA see SILICON DIOXIDE

SILICON

CHEMISTRY

Silica, silicon and silicones ... unraveling the mystery. Lane TH, et al. **Curr Top Microbiol Immunol** 1996;210:3-12 (12 ref.)

SILICON DIOXIDE

Use of cardiopulmonary bypass during bronchoscopy following sand aspiration. A case report. Mellema JD, et al. **Chest** 1995 Oct;108(4):1176-7 (6 ref.)

ADVERSE EFFECTS

Silica exposure and autoimmune diseases. Steenland K, et al. **Am J Ind Med** 1995 Nov;28(5):603-8 (24 ref.)
Silica-associated connective tissue disease. A study of 24 cases. Koeger AC, et al. **Medicine (Baltimore)** 1995 Sep; 74(5):221-37 (122 ref.)
Renal disease--another effect of silica exposure? [editorial; comment] Kallenberg CG. **Nephrol Dial Transplant** 1995; 10(7):1117-9 (25 ref.) Comment on: Nephrol Dial Transplant 1995;10(7):1162-5.
Exposure to crystalline silica and risk of lung cancer: the epidemiological evidence. Weill H, et al. **Thorax** 1996 Jan; 51(1):97-102 (48 ref.)

CHEMISTRY

Silica, silicon and silicones ... unraveling the mystery. Lane TH, et al. **Curr Top Microbiol Immunol** 1996;210:3-12 (12 ref.)

TOXICITY

Fibrogenic and other biological effects of silica. Allison AC. **Curr Top Microbiol Immunol** 1996;210:147-58 (43 ref.)

SILICONE ELASTOMERS

Silicone rubber splinting for athletic hand and wrist injuries. Canelón MF. **J Hand Ther** 1995 Oct-Dec;8(4):252-7 (43 ref.)

ADVERSE EFFECTS

The microscopic interaction between silicone and the surrounding tissues. Needelman L.
Clin Podiatr Med Surg 1995 Jul;12(3):415-23 (31 ref.)
Amyloidosis and silicone synovitis: updated classification, updated pathophysiology, and synovial articular abnormalities. Goldman AB, et al.
Radiol Clin North Am 1996 Mar;34(2):375-94, xi (73 ref.)

SILICONE OILS

The use of silicone oil for HIV-related retinal detachment [editorial; comment] Blumenkranz MS. **Arch Ophthalmol** 1995 Nov;113(11):1366-8 (14 ref.) Comment on: Arch Ophthalmol 1995 Nov;113(11):1401-9.
[Treatment of vitreoretinal proliferation in rhegmatogenous detachment and silicone oil tamponade] Berrod JP, et al. **J Fr Ophtalmol** 1996;19(2):97-105 (32 ref.) (Eng. Abstr.) **(Fre)**

ADVERSE EFFECTS

[Treatment with silicone oil in complicated retinal detachment. Anatomopathological test of 2 enucleated eyes] Bacin F, et al. **J Fr Ophtalmol** 1996;19(1):13-8 (25 ref.) (Eng. Abstr.) **(Fre)**

SILICONE RUBBER see SILICONE ELASTOMERS

SILICONES

Silica, silicon and silicones ... unraveling the mystery. Lane TH, et al. **Curr Top Microbiol Immunol** 1996;210:3-12 (12 ref.)
Breast cancer risk among women using silicone gel breast implants. Edelman DA, et al.
Int J Fertil Menopausal Stud 1995 Sep-Oct;40(5):274-80 (41 ref.)
-Possibilities and limits of imaging for evaluating breast implants- Tristant H. **Arch Gynecol Obstet** 1995;256 Suppl:S135-47 (31 ref.) **(Fre)**

ADVERSE EFFECTS

Injectable silicone: cause of facial nodules, cellulitis, ulceration, and migration. Rapaport MJ, et al.
Aesthetic Plast Surg 1996 May-Jun;20(3):267-76 (34 ref.)
Silicone thorax: a complication of tube thoracostomy in the presence of mammary implants. Rice DC, et al.
Ann Thorac Surg 1995 Nov;60(5):1417-9 (8 ref.)
Should breast-feeding by women with silicone implants be recommended? [letter] Jordan ME, et al.
Arch Pediatr Adolesc Med 1996 Aug;150(8):880-1 (27 ref.)
Silicone breast implants and connective-tissue diseases [editorial; comment] Valesini G, et al.
Clin Exp Rheumatol 1995 Jul-Aug;13(4):421-3 (18 ref.) Comment on: Clin Exp Rheumatol 1995 Jul-aug;13(4):521-3.
The evolution of FDA policy on silicone breast implants: a case study of politics, bureaucracy, and business in the process of decision-making. Palley HA.
Int J Health Serv 1995;25(4):573-91 (61 ref.)
Silicone breast implants: immunotoxic and epidemiologic issues [see comments] Yoshida SH, et al. **Life Sci** 1995 Mar 10;56(16):1299-310 (95 ref.) Comment in: Life Sci 1995;57(19):1737-40.
A critical assessment of the relationship between silicone breast implants and connective tissue diseases. Wong O. **Regul Toxicol Pharmacol** 1996 Feb;23(1 Pt 1):74-85 (60 ref.)
Immunologic and biologic markers for silicone. Vojdani A, et al. **Toxicol Ind Health** 1994 Jan-Apr;10(1-2):25-42 (92 ref.)
[Complications from silicone implants and other so-called inert materials] Faure M. **Ann Dermatol Venereol** 1995; 122(6-7):455-9 (54 ref.) **(Fre)**

SILICOPOLYACRYLATE CEMENT see GLASS IONOMER CEMENTS

SILICOSIS

COMPLICATIONS

Silica exposure and autoimmune diseases. Steenland K, et al. **Am J Ind Med** 1995 Nov;28(5):603-8 (24 ref.)

ETIOLOGY

Fibrogenic and other biological effects of silica. Allison AC. **Curr Top Microbiol Immunol** 1996;210:147-58 (43 ref.)
On the relationship between activation and breakdown of macrophages in the pathogenesis of silicosis (an overview). Privalova LI, et al. **Med Lav** 1995 Nov-Dec;86(6):511-21 (28 ref.)
Exposure to crystalline silica and risk of lung cancer: the epidemiological evidence. Weill H, et al. **Thorax** 1996 Jan; 51(1):97-102 (48 ref.)

SILKWORMS

METABOLISM

Production of recombinant hantavirus nucleocapsid protein expressed in silkworm larvae and its use as a diagnostic antigen in detecting antibodies in serum from infected rats. Yoshimatsu K, et al. **Lab Anim Sci** 1995 Dec;45(6):641-6 (8 ref.)

SILVER

TOXICITY

Toxicological aspects of topical silver pharmaceuticals. Hollinger MA. **Crit Rev Toxicol** 1996 May;26(3):255-60 (57 ref.)

SILVER COMPOUNDS

POISONING

Silver products for medical indications: risk-benefit assessment. Fung MC, et al. **J Toxicol Clin Toxicol** 1996; 34(1):119-26 (45 ref.)

SILVER NITRATE STAINING see SILVER STAINING

SILVER STAINING

[Analysis of PCR products using silver staining] Sugano K. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):491-3 (4 ref.) **(Jpn)**

SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME

Selected models of HIV-induced neurological disease. Narayan O, et al. **Curr Top Microbiol Immunol** 1995; 202:151-66 (61 ref.)

COMPLICATIONS

Neurobiology of simian and feline immunodeficiency virus infections. Gardner MB, et al.
Curr Top Microbiol Immunol 1995;202:135-50 (62 ref.)

PHYSIOPATHOLOGY

Simian immunodeficiency virus variants: threat of new lentiviruses. McClure HM, et al. **Am J Med Sci** 1996 Jan; 311(1):30-3 (46 ref.)

SIMIAN AIDS see SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME

SIMIAN FOAMY VIRUSES see SPUMAVIRUS

SIMIAN IMMUNODEFICIENCY VIRUSES see SIV

SIMIAN LENTIVIRUSES see SIV

SIMIAN T-LYMPHOTROPIC VIRUS TYPE III see SIV

SIMIAN SARCOMA VIRUS PROTEINS see ANTIGENS, POLYOMAVIRUS TRANSFORMING

SIMIAN VIRUS 40 see POLYOMAVIRUS MACACAE

SIMMONDS' DISEASE see HYPOPITUITARISM

SIMPLE REPETITIVE SEQUENCE see REPETITIVE SEQUENCES, NUCLEIC ACID

SIMPLEXVIRUS

DRUG EFFECTS

Antiviral drug resistance in herpes simplex virus. Coen DM. **Adv Exp Med Biol** 1996;394:49-57 (15 ref.)
Treatment of acyclovir-resistant herpes simplex and varicella zoster virus infections. Safrin S. **Adv Exp Med Biol** 1996; 394:59-66 (44 ref.)

GENETICS

Minireview: the herpes simplex virus amplicon--a versatile defective virus vector. Frenkel N, et al. **Gene Ther** 1994; 1 Suppl 1:S40-6 (44 ref.)
HSV as a gene transfer vector for the nervous system. Glorioso JC, et al. **Mol Biotechnol** 1995 Aug;4(1):87-99 (61 ref.)

IMMUNOLOGY

Immune reactions in corneal herpetic disease. You T, et al. **Int Ophthalmol Clin** 1996 Winter;36(1):31-9 (12 ref.)

ISOLATION & PURIFICATION

[A case of herpes simplex encephalitis requiring surgical management] Kasó G, et al. **Orv Hetil** 1996 Feb 11; 137(6):299-302 (23 ref.) (Eng. Abstr.) **(Hun)**
[Detection and analysis of human herpesvirus genomes by polymerase chain reaction] Aono T, et al.
Tanpakushitsu Kakusan Koso 1996 Apr;41(5):669-75 (24 ref.) **(Jpn)**

PHYSIOLOGY

Subversion of intracellular signal transduction by herpes simplex virus type 1. Halford WP, et al.
Adv Neuroimmunol 1995;5(3):327-34 (46 ref.)

RADIATION EFFECTS

UV radiation and mouse models of herpes simplex virus infection. Norval M, et al. **Photochem Photobiol** 1996 Aug; 64(2):242-5 (26 ref.)

SINCALIDE

see related
APPETITE DEPRESSANTS
GASTROINTESTINAL AGENTS

PHARMACOLOGY

Cholecystokinin modulation of serotonergic control of feeding behavior. Cooper SJ. **Ann N Y Acad Sci** 1996 Mar 22;780:213-22 (49 ref.)

PHYSIOLOGY

Cholecystokinin receptors. Boden P, et al.
Cell Mol Neurobiol 1995 Oct;15(5):545-59 (64 ref.)
Cholecystokinin octapeptide (CCK-8): a negative feedback control mechanism for opioid analgesia. Han JS.
Prog Brain Res 1995;105:263-71 (20 ref.)

SINCALIDE RECEPTORS see RECEPTORS, CHOLECYSTOKININ

SINGLE PARENT

Looking for 'fresh' food: diet and lone parents. Dowler E, et al. **Proc Nutr Soc** 1996 Nov;54(3):759-69 (22 ref.)

SINGLE-PARENT FAMILY see SINGLE PARENT

SINGLE-PHOTON ABSORPTIOMETRY see ABSORPTIOMETRY, PHOTON

SINGLE-PHOTON EMISSION-COMPUTED TOMOGRAPHY see TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON

SINGLE-STRANDED CONFORMATIONAL POLYMORPHISM see **POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL**

SINGLE-STRANDED DNA see **DNA, SINGLE-STRANDED**

SINGLE-STRANDED DNA BINDING PROTEINS see **DNA-BINDING PROTEINS**

SINOATRIAL BLOCK

ETIOLOGY

[Sinoatrial block caused by gastroesophageal reflux. The role of simultaneous 24 hr. esophageal pH-metry and Holter-ECG in the differential diagnosis of angina pectoris] Patai A, et al. **Orv Hetil** 1996 Mar 31;137(13):687-90 (38 ref.) (Eng. Abstr.) **(Hun)**

SINOATRIAL NODAL REENTRY TACHYCARDIA see **TACHYCARDIA, SINOATRIAL NODAL REENTRY**

SINOATRIAL NODE

ANATOMY & HISTOLOGY

[Vascularization of the sinus node in the Black African] Yangni-Angate H, et al. **West Afr J Med** 1995 Jul-Sep; 14(3):181-3 (6 ref.) (Eng. Abstr.) **(Fre)**

[Critical analysis of the clinical and surgical importance of the variations in the origin of the sinoatrial node artery of the human heart] Caetano AG, et al.
Rev Assoc Med Bras 1995 Mar-Apr;41(2):94-102 (88 ref.) (Eng. Abstr.) **(Por)**

DRUG EFFECTS

Heart rate reduction in the treatment of chronic stable angina pectoris: experiences with a sinus node inhibitor [editorial] Frishman WH, et al. **Am Heart J** 1996 Jan;131(1):204-10 (63 ref.)

PHYSIOPATHOLOGY

Atrial fibrillation: maintenance of sinus rhythm versus rate control. Sopher SM, et al. **Am J Cardiol** 1996 Jan 25; 77(3):24A-37A (128 ref.)

SINUS ARRHYTHMIA see **ARRHYTHMIA, SINUS**

SINUS OF VALSALVA

[The perforation of a right-coronary sinus of Valsalva aneurysm into the right atrium] Elsner M, et al.
Dtsch Med Wochenschr 1995 Dec 15;120(50):1728-33 (38 ref.) (Eng. Abstr.) **(Ger)**

[Giant isolated extracadiac unruptured aneurysm of the right coronary sinus of valsalva--a case report] Mizushima T, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Feb; 44(2):202-7 (17 ref.) (Eng. Abstr.) **(Jpn)**

SINUS TACHYCARDIA see **TACHYCARDIA, SINUS**

SINUS THROMBOSIS

COMPLICATIONS

Septic thrombophlebitis of major dural venous sinuses. Southwick FS. **Curr Clin Top Infect Dis** 1995;15:179-203 (161 ref.)

ETIOLOGY

Uncommon complications of odontogenic infections. Ferrera PC, et al. **Am J Emerg Med** 1996 May;14(3):317-22 (49 ref.)

Lateral sinus thrombosis associated with otitis media and mastoiditis in children. Garcia RD, et al.
Pediatr Infect Dis J 1995 Jul;14(7):617-23 (35 ref.)

SINUSITIS

Chronic sinusitis. Chester AC. **Am Fam Physician** 1996 Feb 15;53(3):877-87 (44 ref.)

Fungal sinusitis: an update. Morpeth JF, et al.
Ann Allergy Asthma Immunol 1996 Feb;76(2):128-39; quiz 139-40 (64 ref.)

Management of chronic sinusitis. Lockey RF.
Hosp Pract (Off Ed) 1996 Mar 15;31(3):141-6,149-5 (6 ref.)

Rhinitis and sinusitis: office management. Guarderas JC.
Mayo Clin Proc 1996 Sep;71(9):882-8 (8 ref.)

CHEMICALLY INDUCED

Phenomenology, pathogenesis, diagnosis and treatment of aspirin-sensitive rhinosinusitis. Schapowal AG, et al.
Acta Otorhinolaryngol Belg 1995;49(3):235-50 (0 ref.)

COMPLICATIONS

Sinusitis and asthma: associations, influences and principles of management. Halpern GM.
Allergol Immunopathol (Madr) 1995 Jul-Aug;23(4):171-81 (60 ref.)

Gastroesophageal reflux and sinusitis in asthma. Hamilos DL.
Clin Chest Med 1995 Dec;16(4):683-97 (61 ref.)

Aspergillus sinusitis in patients with AIDS: report of three cases and review. Teh W, et al. **Clin Infect Dis** 1995 Sep; 21(3):529-35 (46 ref.)

DIAGNOSIS

Cytomegalovirus sinusitis. A new manifestation of AIDS. Marks SC, et al. **Arch Otolaryngol Head Neck Surg** 1996 Jul;122(7):789-91 (11 ref.)

Recent trends in the diagnosis and treatment of sinusitis. Jorissen M. **Eur Radiol** 1996;6(2):170-6 (53 ref.)

The diagnosis of sinusitis. Salman SD. **J Med Liban** 1994; 42(4):184-9 (11 ref.)

A realistic view of sinusitis. Slack R. **Practitioner** 1996 Jan; 240(1558):54-7 (3 ref.)

Diagnostic imaging of fungal sinusitis: eleven new cases and literature review. Roithmann R, et al. **Rhinology** 1995 Jun; 33(2):104-10 (20 ref.)

[Churg-Strauss syndrome. A differential diagnosis in chronic polypoid sinusitis] Trittel C, et al. **Laryngorhinootologie** 1995 Sep;74(9):577-80 (23 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Rhinocerebral mucormycosis. Therapy with amphotericin B lipid complex. Strasser MD, et al. **Arch Intern Med** 1996 Feb 12;156(3):337-9 (21 ref.)

Medical treatment of sinusitis. Baroody FM.
J Med Liban 1994;42(4):190-5 (26 ref.)

Advances in the management of acute and chronic sinusitis. Sandler NA, et al. **J Oral Maxillofac Surg** 1996 Aug; 54(8):1005-13 (59 ref.)

ETIOLOGY

Management of sinusitis in the asthmatic patient. Senior BA, et al. **Ann Allergy Asthma Immunol** 1996 Jul;77(1):6-15; quiz 15-9 (47 ref.)

Cystic fibrosis and the sinonasal tract. Batsakis JG, et al. **Ann Otol Rhinol Laryngol** 1996 Apr;105(4):329-30 (9 ref.)

MICROBIOLOGY

The role of anaerobic bacteria in recurrent episodes of sinusitis and tonsillitis. Nord CE. **Clin Infect Dis** 1995 Jun; 20(6):1512-24 (107 ref.)

Fungal sinusitis. Spring PM, et al. **J La State Med Soc** 1995 Sep;147(9):395-8 (10 ref.)

Diagnostic imaging of fungal sinusitis: eleven new cases and literature review. Roithmann R, et al. **Rhinology** 1995 Jun; 33(2):104-10 (20 ref.)

SURGERY

Management of recurrent and chronic sinusitis in children. Arjmand EM, et al. **Am J Otolaryngol** 1995 Nov-Dec; 16(6):367-82 (56 ref.)

Sinusitis in patients with cystic fibrosis. Hui Y, et al.
Eur Arch Otorhinolaryngol 1995;252(4):191-6 (44 ref.)

Surgical treatment of sinusitis. Ramadan HH.
J Med Liban 1994;42(4):196-9 (16 ref.)

THERAPY

Management of sinusitis in the asthmatic patient. Senior BA, et al. **Ann Allergy Asthma Immunol** 1996 Jul;77(1):6-15; quiz 15-9 (47 ref.)

Management of sinusitis. Duncavage JA. **Compr Ther** 1996 Apr;22(4):211-6 (12 ref.)

Sinusitis in the aged. Optimal management strategies. Knutson JW, et al. **Drugs Aging** 1995 Oct;7(4):310-6 (24 ref.)

VIROLOGY

Cytomegalovirus as precipitating factor of acute bacterial sinusitis in an immunocompetent patient. A case report. Morre TD, et al. **Acta Otorhinolaryngol Belg** 1996; 50(1):37-40 (20 ref.)

SINUSITIS, MAXILLARY see **MAXILLARY SINUSITIS**

SINUSITIS, SPHENOID see **SPHENOID SINUSITIS**

SIPHONAPTERA see **FLEAS**

SIPPLE SYNDROME see **MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A**

SIPUNCULIDA see **NEMATODA**

SIRENOMELIA see **ECTROMELIA**

SIROGNATHOGRAPHY see **JAW RELATION RECORD**

SIS GENES see **ONCOGENES**

SISTER CHROMATID EXCHANGE

Influence of sex on cytogenetic end points: evidence from a large human sample and review of the literature. Bonassi S, et al. **Cancer Epidemiol Biomarkers Prev** 1995 Sep; 4(6):671-9 (77 ref.)

Sister chromatid exchanges (SCEs) and high frequency cells (HFCs) in human population studies: principles of their analysis. Lazutka JR. **Mutat Res** 1995 Oct;331(2):229-31 (12 ref.)

DRUG EFFECTS

Implications of arsenic genotoxicity for dose response of carcinogenic effects. Rudel R, et al.
Regul Toxicol Pharmacol 1996 Apr;23(2):87-105 (55 ref.)

SITE-DIRECTED MUTAGENESIS see **MUTAGENESIS, SITE-DIRECTED**

SITE MAPPING, RESTRICTION see **RESTRICTION MAPPING**

SITE-SPECIFIC MUTAGENESIS see **MUTAGENESIS, SITE-DIRECTED**

SITOSTEROLS

PHARMACOLOGY

[From cholesterol to oxysterols. Current data] Luu B.
C R Seances Soc Biol Fil 1995;189(5):827-37 (28 ref.) (Eng. Abstr.) **(Fre)**

SITUATIONAL ETHICS see **ETHICS**

SIV

GENETICS

Simian immunodeficiency virus variants: threat of new lentiviruses. McClure HM, et al. **Am J Med Sci** 1996 Jan; 311(1):30-3 (46 ref.)

Phylogeny and natural history of the primate lentiviruses, SIV and HIV. Hirsch VM, et al. **Curr Opin Genet Dev** 1995 Dec;5(6):798-806 (28 ref.)

IMMUNOLOGY

Neutralising epitopes of simian immunodeficiency virus envelope glycoprotein. Kent KA. **J Med Primatol** 1995 May;24(3):145-9 (41 ref.)

SIV-1 see **SIV**

SIV-2 see **SIV**

SIXTH DISEASE see **EXANTHEMA SUBITUM**

SJOGREN'S SYNDROME

Diagnostic criteria and immunopathogenesis of Sjögren's syndrome: implications for therapy. Kruize AA, et al.
Immunol Today 1995 Dec;16(12):557-9 (2 ref.)

[Investigations of various animal models for Sjögren's syndrome] Hayashi Y. **Nippon Rinsho** 1995 Oct; 53(10):2383-8 (20 ref.) (Eng. Abstr.) **(Jpn)**

CLASSIFICATION

Sjögren's syndrome. Manthorpe R, et al.
Baillieres Clin Rheumatol 1995 Aug;9(3):483-96 (53 ref.)

Classification of disease manifestations in primary Sjögren's syndrome: present status and a new proposal. Oxholm P, et al. **Clin Rheumatol** 1995 Jul;14 Suppl 1:3-7 (21 ref.)

Primary Sjögren's syndrome: the challenge for classification of disease manifestations [comment] Oxholm P, et al.
J Intern Med 1996 Jun;239(6):467-74 (38 ref.) Comment on: J Intern Med 1996 Jun;239(6):475-82.

[Clinical aspects and types of Sjögren's syndrome] Sugai S, et al. **Nippon Rinsho** 1995 Oct;53(10):2376-82 (12 ref.) (Eng. Abstr.) **(Jpn)**

[Isotypes and subtypes of anti-SS-A and/or SS-B antibodies in different subgroups of Sjögren's syndrome] Takaya M, et al. **Nippon Rinsho** 1995 Oct;53(10):2429-33 (17 ref.) (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

Central nervous system disease in primary Sjögren's syndrome. De Backer H, et al. **Acta Neurol Belg** 1995; 95(3):142-6 (36 ref.)

Human T-cell lymphotropic virus type 1-associated myelopathy, Sjögren syndrome, and lymphocytic pneumonitis. Kompoliti A, et al. **Arch Neurol** 1996 Sep; 53(9):940-2 (31 ref.)

Sjögren's syndrome. Fox RI. **Curr Opin Rheumatol** 1995 Sep; 7(5):409-16 (109 ref.)

Acute transverse myelopathy and cutaneous vasculopathy in primary Sjögren's syndrome. Lyu RK, et al.
Eur Neurol 1995;35(6):359-62 (24 ref.)

Polymyositis and Sjögren's syndrome associated with bronchiolitis obliterans organizing pneumonia. Imasaki T, et al. **Intern Med** 1996 Mar;35(3):231-5 (22 ref.)

Lymphoma in Sjögren's syndrome. From histopathology to molecular pathology. Jordan RC, et al.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996 Mar;81(3):308-20 (70 ref.)

Osteomalacia as a presenting manifestation of Sjögren's syndrome. Hajjaj-Hassouni N, et al.
Rev Rhum Engl Ed 1995 Jul-Sep;62(7-8):529-32 (30 ref.)

Clinicopathological factors relating malignant lymphoma with Sjögren's syndrome. Anaya JM, et al.

Semin Arthritis Rheum 1996 Apr;25(5):337–46 (71 ref.)
[Renal involvement in Sjögren's syndrome--interstitial nephritis and glomerulonephritis] Fujimoto T, et al. **Nippon Rinsho** 1995 Oct;53(10):2495–502 (29 ref.) (Eng. Abstr.) **(Jpn)**
[Primary biliary cirrhosis in patients with Sjögren's syndrome] Furuya T, et al. **Nippon Rinsho** 1995 Oct; 53(10):2536–9 (18 ref.) (Eng. Abstr.) **(Jpn)**
[Clinical and pathological features of Sjögren's syndrome associated with autoimmune thyroid diseases] Ichikawa Y, et al. **Nippon Rinsho** 1995 Oct;53(10):2545–50 (26 ref.) (Eng. Abstr.) **(Jpn)**
[Autoimmune liver disease complicating Sjögren's syndrome] Masaki N, et al. **Nippon Rinsho** 1995 Oct;53(10):2530–5 (11 ref.) (Eng. Abstr.) **(Jpn)**
[T cell receptor repertoire of infiltrating T cells in the interstitial nephritis of patients with Sjögren's syndrome] Murata H, et al. **Nippon Rinsho** 1995 Oct;53(10):2510–5 (19 ref.) (Eng. Abstr.) **(Jpn)**
[Sjögren's syndrome associated with non-Hodgkin's lymphoma] Nagai K. **Nippon Rinsho** 1995 Oct; 53(10):2574–9 (23 ref.) (Eng. Abstr.) **(Jpn)**
[Cutaneous manifestations of primary Sjögren's syndrome] Nishiyama S, et al. **Nippon Rinsho** 1995 Oct;53(10):2551–6 (11 ref.) (Eng. Abstr.) **(Jpn)**
[Neuro-psychiatric involvement in primary Sjögren's syndrome] Sagawa A, et al. **Nippon Rinsho** 1995 Oct; 53(10):2563–7 (13 ref.) (Eng. Abstr.) **(Jpn)**
[Pulmonary function abnormalities and respiratory manifestations in Sjögren's syndrome] Shima H. **Nippon Rinsho** 1995 Oct;53(10):2516–20 (20 ref.) (Eng. Abstr.) **(Jpn)**
[Lymphoproliferative disorders in patients with Sjögren's syndrome--Vg gene rearrangement and expression of bcl-2 protein] Sugai S, et al. **Nippon Rinsho** 1995 Oct; 53(10):2580–6 (15 ref.) (Eng. Abstr.) **(Jpn)**
[Atrophic gastritis in Sjögren's syndrome] Sugaya T, et al. **Nippon Rinsho** 1995 Oct;53(10):2540–4 (11 ref.) (Eng. Abstr.) **(Jpn)**
[Chronic pancreatitis and pancreatic dysfunction associated with Sjögren's syndrome] Sumii T, et al. **Nippon Rinsho** 1995 Oct;53(10):2525–9 (24 ref.) (Eng. Abstr.) **(Jpn)**
[Sensory ataxic neuropathy associated with Sjögren's syndrome] Yasuda T, et al. **Nippon Rinsho** 1995 Oct; 53(10):2568–73 (23 ref.) (Eng. Abstr.) **(Jpn)**
[A case of Sjögren's syndrome with an eyelid tumor, a so-termed pseudolymphoma of the iacrimal gland] Takeshita S, et al. **Ryumachi** 1996 Feb;36(1):43–9 (17 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Sjögren's syndrome. Manthorpe R, et al. **Baillieres Clin Rheumatol** 1995 Aug;9(3):483–96 (53 ref.)
Sjögren's syndrome. Rothschild BM. **Compr Ther** 1996 Jan; 22(1):39–43 (24 ref.)
[Classification criteria for Sjögren's syndrome--sensitivity and specificity of criteria of the Japanese Ministry of Health and Welfare (1977) and criteria of European community (1993)] Miyawaki S, et al. **Nippon Rinsho** 1995 Oct; 53(10):2371–5 (6 ref.) (Eng. Abstr.) **(Jpn)**
[The ocular manifestations in Felty's syndrome] Giuri S. **Oftalmologia** 1996 Jan–Mar;40(1):51–7 (28 ref.) (Eng. Abstr.) **(Rum)**

EPIDEMIOLOGY

[Epidemiology and pathogenesis of Sjögren's syndrome] Miyasaka N. **Nippon Rinsho** 1995 Oct;53(10):2367–70 (10 ref.) (Eng. Abstr.) **(Jpn)**

ETIOLOGY

Vth International Symposium on Sjögren's syndrome. Clinical aspects and therapy. Fox RI. **Clin Rheumatol** 1995 Jul;14 Suppl 1:17–9 (30 ref.)
Sjögren's syndrome--a house of cards. Isenberg D. **Clin Rheumatol** 1995 Jul;14 Suppl 1:8–10 (11 ref.)
Sjögren's syndrome. Fox RI. **Curr Opin Rheumatol** 1995 Sep; 7(5):409–16 (109 ref.)
The etiopathogenesis of Sjögren's syndrome. Price EJ, et al. **Semin Arthritis Rheum** 1995 Oct;25(2):117–33 (119 ref.)
Systemic lupus erythematosus diagnosed during interferon alfa therapy. Morris LF, et al. **South Med J** 1996 Aug; 89(8):810–4 (30 ref.)
[Extrahepatic manifestations related to hepatitis C virus] Opolon P, et al. **Pathol Biol (Paris)** 1995 Oct;43(8):709–15 (59 ref.) (Eng. Abstr.) **(Fre)**
[HTLV-I infection in primary Sjögren's syndrome--epidemiological, clinical and virological studies] Eguchi K, et al. **Nippon Rinsho** 1995 Oct; 53(10):2467–72 (20 ref.) (Eng. Abstr.) **(Jpn)**
[Possible involvement of Epstein-Barr virus in the pathogenesis of Sjögren's syndrome] Haruta J, et al. **Nippon Rinsho** 1995 Oct;53(10):2479–83 (18 ref.) (Eng. Abstr.) **(Jpn)**
[Analyses of T cell clonality in mice with autoimmune sialoadenitis] Masuko K. **Nippon Rinsho** 1995 Oct; 53(10):2401–6 (16 ref.) (Eng. Abstr.) **(Jpn)**
[Expression of sequences homologous to HTLV-I pXIV gene in the labial salivary glands of Japanese patients with Sjögren's syndrome and pathogenesis] Yonaha-Nagato F, et al. **Nippon Rinsho** 1995 Oct;53(10):2473–8 (13 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

IgA glycosylation and disease. Dueymes M, et al. **Adv Exp Med Biol** 1995;376:217–20 (18 ref.)
Autoimmune connective tissue disease, chronic polyarthritides and B cell expansion: risks and perspectives with immunosuppressive drugs. Ferraccioli GF, et al. **Clin Exp Rheumatol** 1996 Jan–Feb;14 Suppl 14:S71–80 (100 ref.)
B-cell lymphoproliferation in primary Sjögren's syndrome. Tzioufas AG. **Clin Exp Rheumatol** 1996 Jan–Feb;14 Suppl 14:S65–70 (41 ref.)
Sjögren's syndrome, mixed cryoglobulinaemia and the monoclonal gammopathies. Vitali C, et al. **Clin Exp Rheumatol** 1996 Jan–Feb;14 Suppl 14:S59–63 (44 ref.)
Ro/SS-A and La/SS-B: autoantigens in Sjögren's syndrome? Smeenk RJ. **Clin Rheumatol** 1995 Jul;14 Suppl 1:11–6 (53 ref.)
[Expression of ductal Fas antigen in sialoadenitis of Sjögren's syndrome] Matsumura R, et al. **Nippon Rinsho** 1995 Oct; 53(10):2446–50 (13 ref.) (Eng. Abstr.) **(Jpn)**
[Autoantibodies in patients with Sjögren's syndrome and their clinical significance] Miyawaki S. **Nippon Rinsho** 1995 Oct;53(10):2422–8 (11 ref.) (Eng. Abstr.) **(Jpn)**
[Aberrant expression of HLA-DR antigens on acinar and ductal epithelial cells of salivary glands in Sjögren's syndrome] Nakamura S, et al. **Nippon Rinsho** 1995 Oct; 53(10):2407–11 (16 ref.) (Eng. Abstr.) **(Jpn)**
[Molecular mechanism on Sjögren's syndrome] Sumida T, et al. **Nippon Rinsho** 1995 Oct;53(10):2395–400 (13 ref.) (Eng. Abstr.) **(Jpn)**
[Immunological study of tissue-infiltrating lymphocytes in Sjögren's syndrome: virus specific T cell response] Takeda A, et al. **Nippon Rinsho** 1995 Oct;53(10):2484–9 (22 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

[Production and role of B cell growth factor (BCGF) in Sjögren's syndrome] Goto Y, et al. **Nippon Rinsho** 1995 Oct;53(10):2418–21 (15 ref.) (Eng. Abstr.) **(Jpn)**
[EBER-1 expression in salivary glands of Sjögren's syndrome] Nomura H, et al. **Nippon Rinsho** 1995 Oct; 53(10):2490–4 (22 ref.) (Eng. Abstr.) **(Jpn)**
[Analysis of Fas and bcl-2 expression on peripheral blood lymphocytes from primary Sjögren's syndrome] Ohashi H, et al. **Nippon Rinsho** 1995 Oct;53(10):2451–5 (24 ref.) (Eng. Abstr.) **(Jpn)**
[Cytokine mRNA expression in the labial glands of patients with Sjögren's syndrome] Ohyama Y, et al. **Nippon Rinsho** 1995 Oct;53(10):2412–7 (13 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

[An update on primary Gougerot-Sjögren's syndrome in 1995] Voisin MC. **Ann Pathol** 1996;16(1):11–9 (56 ref.) **(Fre)**
[Immunohistochemical identification of infiltrating mononuclear cells in tubulointerstitial nephritis associated with Sjögren's syndrome] Matsumura R, et al. **Nippon Rinsho** 1995 Oct;53(10):2503–9 (11 ref.) (Eng. Abstr.) **(Jpn)**
[Sjögren's syndrome as a lymphoaggressive disorder; bcl-2 expression in lymphocytes infiltrated in salivary glands] Takeshita S, et al. **Nippon Rinsho** 1995 Oct;53(10):2440–5 (10 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

[Clinical feature and pathology of airway disease in Sjögren's syndrome] Ota T, et al. **Nippon Rinsho** 1995 Oct; 53(10):2521–4 (12 ref.) (Eng. Abstr.) **(Jpn)**

THERAPY

Vth International Symposium on Sjögren's syndrome. Clinical aspects and therapy. Fox RI. **Clin Rheumatol** 1995 Jul;14 Suppl 1:17–9 (30 ref.)
[Current status and problems in the treatment of patients with Sjögren's syndrome] Tojo T, et al. **Nippon Rinsho** 1995 Oct;53(10):2389–94 (17 ref.) (Eng. Abstr.) **(Jpn)**

VIROLOGY

[Detection of retrovirus in salivary glands of patients with Sjögren's syndrome] Yamano S, et al. **Nippon Rinsho** 1995 Oct;53(10):2456–60 (21 ref.) (Eng. Abstr.) **(Jpn)**

SKELETAL FIXATION see **FRACTURE FIXATION**

SKELETAL MUSCLE see **MUSCLE, SKELETAL**

SKELETAL MUSCLE RELAXANTS see **NEUROMUSCULAR AGENTS**

SKELETAL MUSCLE VENTRICLE see **CARDIOMYOPLASTY**

SKELETIN see **DESMIN**

SKELETON

see related
BONE AND BONES
MHox and vertebrate skeletogenesis: the long and the short of it. Brickell PM. **Bioessays** 1995 Sep;17(9):750–3 (31 ref.)

SKID ROW ALCOHOLICS see **HOMELESS PERSONS**

SKIING

[Ski racing and asthma (editorial)] Laitinen L. **Duodecim** 1994;110(19):1754–6 (21 ref.) **(Fin)**

INJURIES

Fractures of the lateral process of the talus: a clinical review. "Snowboarder's ankle". McCrory P, et al. **Clin J Sport Med** 1996 Apr;6(2):124–8 (13 ref.)

SKILLED NURSING FACILITIES

Depression in long-term care facilities. Masand PS. **Geriatrics** 1995 Oct;50 Suppl 1:S16–24 (43 ref.)
[Tuberculosis in aged persons residing in Quebec facilities: are screening and chemoprophylaxis indicated? (see comments)] Marchand RS, et al. **Can J Public Health** 1995 Jul–Aug;86(4):238–42 (55 ref.) (Eng. Abstr.) Comment in: Can J Public Health 1995 Jul–Aug;86(4):221–3. **(Fre)**

ORGANIZATION & ADMINISTRATION

The medical director in hospital-based transitional care units. Smith RL, et al. **Clin Geriatr Med** 1995 Aug;11(3):373–89 (11 ref.)

SKIN

see related
DERMATOLOGIC AGENTS
KERATINOCYTES
Microdialysis in human skin [editorial] Church MK, et al. **Clin Exp Allergy** 1995 Nov;25(11):1027–9 (19 ref.)
[Injected fat for correction of soft tissue defects] Shoshani O, et al. **Harefuah** 1995 Dec 1;129(11):489–93 (40 ref.) **(Heb)**

ABNORMALITIES

The clinical spectrum of naevus anaemicus and its association with port wine stains: report of 15 cases and a review of the literature. Katugampola GA, et al. **Br J Dermatol** 1996 Feb;134(2):292–5 (19 ref.)
Isolated collagenoma: a case report with a review of connective tissue nevi of the collagen type. Gautam RK, et al. **J Dermatol** 1996 Jul;23(7):476–8 (22 ref.)

ANATOMY & HISTOLOGY

Digital imaging in dermatology. Kenet RD. **Clin Dermatol** 1995 Jul–Aug;13(4):381–92 (50 ref.)
Mechanical resilience of skin: a function of blood supply and lymphatic drainage. Ryan TJ. **Clin Dermatol** 1995 Sep–Oct; 13(5):429–32 (22 ref.)
The interstitium, the connective tissue environment of the lymphatic, and angiogenesis in human skin. Ryan TJ, et al. **Clin Dermatol** 1995 Sep–Oct;13(5):451–8 (54 ref.)
Lymphatics and adipose tissue. Ryan TJ. **Clin Dermatol** 1995 Sep–Oct;13(5):493–8 (38 ref.)
[Comments on the suitability of swine skin as a biological model for human skin] Meyer W. **Hautarzt** 1996 Mar; 47(3):178–82 (65 ref.) (Eng. Abstr.) **(Ger)**

BLOOD SUPPLY

Diverse interactions of calcitonin gene related peptide and nitric oxide in the gastric and cutaneous microcirculation. Holzer P, et al. **Can J Physiol Pharmacol** 1995 Jul; 73(7):991–4 (37 ref.)
Evaluation of skin blood flow by laser Doppler flowmetry. Eun HC. **Clin Dermatol** 1995 Jul–Aug;13(4):337–47 (151 ref.)
The use of non-invasive vascular assessment in diabetic patients with foot lesions. Takolander R, et al. **Diabet Med** 1996;13 Suppl 1:S39–42 (30 ref.)
Microvascular aspects of diabetic foot disease. Tooke JE, et al. **Diabet Med** 1996;13 Suppl 1:S26–9 (14 ref.)
Reflex parasympathetic vasodilatation in facial skin. Izumi H. **Gen Pharmacol** 1995 Mar;26(2):237–44 (74 ref.)
Intravital capillaroscopy in patients with chronic venous insufficiency and lymphoedema: relevance to Daflon 500 mg. Bollinger A, et al. **Int J Microcirc Clin Exp** 1995;15 Suppl 1:41–4 (24 ref.)
Advances in microcirculation network evaluation: an update. Fagrell B. **Int J Microcirc Clin Exp** 1995;15 Suppl 1:34–40 (61 ref.)
Microcirculatory models of ischaemia-reperfusion in skin and striated muscle. Nolte D, et al. **Int J Microcirc Clin Exp** 1995;15 Suppl 1:9–16 (67 ref.)
Angiogenesis and the skin: a primer. Arbiser JL. **J Am Acad Dermatol** 1996 Mar;34(3):486–97 (116 ref.)
Cutaneous vasculitis. Gibson LE, et al. **Rheum Dis Clin North Am** 1995 Nov;21(4):1097–113 (50 ref.)
[The vascular bed of the skin. Integration site of endogenous

and exogenous stimuli] Heckmann M. **Hautarzt** 1996 Jun; 47(6):417–21 (37 ref.) (Eng. Abstr.) **(Ger)**

[Skin circulation—measurements with laser–doppler] Marszalek A. **Med Pr** 1996;47(4):411–8 (16 ref.) (Eng. Abstr.) **(Pol)**

[Current aspects of cutaneous angiitis] Ivanov OL. **Vestn Ross Akad Med Nauk** 1995;(10):7–10 (24 ref.) **(Rus)**

CHEMISTRY

Immunohistochemical parameters for the age estimation of human skin wounds. A review. Betz P. **Am J Forensic Med Pathol** 1995 Sep;16(3):203–9 (53 ref.)

Instrumental evaluation of cutaneous hydration. Berardesca E, et al. **Clin Dermatol** 1995 Jul–Aug;13(4):323–7 (43 ref.)

Quantitative evaluation of skin surface lipids. Clarys P, et al. **Clin Dermatol** 1995 Jul–Aug;13(4):307–21 (85 ref.)

Proopiomelanocortin, its derived peptides, and the skin. Wintzen M, et al. **J Invest Dermatol** 1996 Jan;106(1):3–10 (155 ref.)

CYTOLOGY

Cell stress and implications of the heat–shock response in skin. Charveron M, et al. **Cell Biol Toxicol** 1995 Aug; 11(3–4):161–5 (15 ref.)

Mouse mast cell cytokine production: rôle in cutaneous inflammatory and immunological responses. Galli SJ, et al. **Exp Dermatol** 1995 Aug;4(4 Pt 2):240–9 (73 ref.)

A fresh morphological and functional look at dermal dendritic cells. Nestle FO, et al. **J Cutan Pathol** 1995 Oct; 22(5):385–93 (71 ref.)

[The metabolism of radiolabelled GM1–ganglioside in cultured skin fibroblasts from controls and patients with GM1–gangliosidosis] Inui K. **Nippon Rinsho** 1995 Dec; 53(12):3102–4 (4 ref.) (Eng. Abstr.) **(Jpn)**

DRUG EFFECTS

Topical retinoids and cutaneous biology. Craven NM, et al. **Clin Exp Dermatol** 1996 Jan;21(1):1–10 (141 ref.)

Physiological and toxicological changes in the skin resulting from the action and interaction of metal ions. Lansdown AB. **Crit Rev Toxicol** 1995;25(5):397–462 (720 ref.)

Light scattering of human skin: a comparison between zinc (II)–phthalocyanine and photofrin II. Ochsner M. **J Photochem Photobiol B** 1996 Jan;32(1–2):3–9 (23 ref.)

Topical iontophoretic drug delivery: pathways, principles, factors, and skin irritation. Singh J, et al. **Med Res Rev** 1996 May;16(3):285–96 (88 ref.)

The pro–inflammatory and hyperplasiogenic action of interleukin–1 alpha in mouse skin. Fischer SM, et al. **Prog Clin Biol Res** 1995;391:161–77 (66 ref.)

[Retinoids] Piérard GE, et al. **Rev Med Liege** 1996 Jan; 51(1):142–4 (13 ref.) **(Fre)**

IMMUNOLOGY

The role of cytokines and neuroendocrine hormones in cutaneous immunity and inflammation. Luger TA, et al. **Allergy** 1995 Apr;50(4):292–302 (119 ref.)

Immunopathology of nonneoplastic skin disease: a brief review. Wick MR, et al. **Am J Clin Pathol** 1996 Apr; 105(4):417–29 (122 ref.)

The immunology of nickel–induced allergic contact dermatitis. Sosroseno W. **Asian Pac J Allergy Immunol** 1995 Dec;13(2):173–81 (95 ref.)

Role of basophils and mast cells in acute and late reactions in the skin. Charlesworth EN. **Chem Immunol** 1995; 62:84–107 (73 ref.)

Immune cell traffic from blood through the normal human skin to lymphatics. Olszewski WL, et al. **Clin Dermatol** 1995 Sep–Oct;13(5):473–83 (29 ref.)

Lymphatics and the processing of antigen. Ryan TJ, et al. **Clin Dermatol** 1995 Sep–Oct;13(5):485–92 (34 ref.)

Cutaneous defenses against dermatophytes and yeasts. Wagner DK, et al. **Clin Microbiol Rev** 1995 Jul;8(3):317–35 (284 ref.)

Immune response of the skin. Schmitt D. **Clin Rev Allergy Immunol** 1995 Fall;13(3):177–88 (42 ref.)

Interleukin–6 and the skin. Paquet P, et al. **Int Arch Allergy Immunol** 1996 Apr;109(4):308–17 (44 ref.)

Epidermal cytokines in allergic contact dermatitis. Kondo S, et al. **J Am Acad Dermatol** 1995 Nov;33(5 Pt 1):786–800 (194 ref.)

Immunity at the surface: homeostatic mechanisms of the skin immune system. Williams IR, et al. **Life Sci** 1996; 58(18):1485–507 (216 ref.)

The skin immune system in the course of HIV–1 infection. Henry M, et al. **Photochem Photobiol** 1996 Aug;64(2):275–9 (42 ref.)

The role of epidermal cytokines in the generation of cutaneous immune reactions and ultraviolet radiation–induced immune suppression. Ullrich SE. **Photochem Photobiol** 1995 Sep;62(3):389–401 (99 ref.)

Cytokine regulation of chemical sensitization. Kimber I, et al. **Toxicol Lett** 1995 Dec;82–83:491–6 (29 ref.)

[Langerhans cells and cutaneous immune reactions] Barták P, et al. **Cas Lek Cesk** 1996 Mar 20;135(6):170–3 (27 ref.) (Eng. Abstr.) **(Cze)**

[Skin as an immune organ] Simon JC. **Med Monatsschr Pharm** 1995 Nov;18(11):316–9 (10 ref.) **(Ger)**

INJURIES

Burning the largest immune organ. Allgöwer M, et al. **Burns** 1995;21 Suppl 1:S7–47 (222 ref.)

Growth factors in skin wound healing. Moulin V. **Eur J Cell Biol** 1995 Sep;68(1):1–7 (89 ref.)

Cuts and scrapes? Plasmin heals! Vassalli JD, et al. **Nat Med** 1996 Mar;2(3):284–5 (13 ref.)

[Massive avulsion of the genital skin in a man. Apropos a case and a review of treatment] Cavadas Rodríguez P. **Arch Esp Urol** 1995 Nov;48(9):952–4 (3 ref.) (Eng. Abstr.) **(Spa)**

INNERVATION

Itch and pain. Teofoli P, et al. **Int J Dermatol** 1996 Mar; 35(3):159–66 (98 ref.)

Modulation of Langerhans cell function by epidermal nerves. Asahina A, et al. **J Allergy Clin Immunol** 1995 Dec;96(6 Pt 2):1178–82 (32 ref.)

Plasticity of cutaneous primary afferent projections to the spinal dorsal horn. Wilson P, et al. **Prog Neurobiol** 1996 Feb;48(2):105–29 (240 ref.)

METABOLISM

Neuropeptides, nerve growth factor and eczema. Giannetti A. **Australas J Dermatol** 1996 May;37 Suppl 1:S1–3 (47 ref.)

Overexpression of human keratin 1b produces a distinct skin phenotype in transgenic mouse skin. Coulombe PA, et al. **Biochem Cell Biol** 1995 Sep–Oct;73(9–10):611–8 (42 ref.)

Alkaloids from frog skins: selective probes for ion channels and nicotinic receptors. Daly JW. **Braz J Med Biol Res** 1995 Oct;28(10):1033–42 (28 ref.)

Adhesion molecules in cutaneous inflammation. Barker JN. **Ciba Found Symp** 1995;189:91–101; discussion 101–6 (38 ref.)

Skin elastic fibres: regulation of human elastin promoter activity in transgenic mice. Uitto J, et al. **Ciba Found Symp** 1995;192:237–53; discussion 253–8 (49 ref.)

Lymph transport in the skin. Ikomi F, et al. **Clin Dermatol** 1995 Sep–Oct;13(5):419–27 (40 ref.)

Assessment of delipidization as an enhancing factor in percutaneous penetration. Menczel E. **Curr Probl Dermatol** 1995;22:189–94 (11 ref.)

The concept of the acid mantle of the skin: its relevance for the choice of skin cleansers. Schmid MH, et al. **Dermatology** 1995;191(4):276–80 (27 ref.)

Molecular mechanisms of retinoid actions in skin. Fisher GJ, et al. **FASEB J** 1996 Jul;10(9):1002–13 (87 ref.)

Iontophoresis for enhancing penetration of dermatologic and antiviral drugs. Gangarosa LP Sr, et al. **J Dermatol** 1995 Nov;22(11):865–75 (39 ref.)

Hypothesis: spermine may be an important epidermal antioxidant. Løvaas E. **Med Hypotheses** 1995 Jul; 45(1):59–67 (125 ref.)

MICROBIOLOGY

Detection of mycobacterial DNA in the skin. Etiologic insights and diagnostic perspectives. Degitz K. **Arch Dermatol** 1996 Jan;132(1):71–5 (58 ref.)

PATHOLOGY

Raimer's bands: case report with a review of solar elastosis. Stanford DG, et al. **Acta Derm Venereol** 1995 Sep; 75(5):372–4 (23 ref.)

Neuritic leprosy: further progression and significance. Mishra B, et al. **Acta Leprol** 1995;9(4):187–94 (28 ref.)

Immunopathology of nonneoplastic skin disease: a brief review. Wick MR, et al. **Am J Clin Pathol** 1996 Apr; 105(4):417–29 (122 ref.)

Immunohistochemical parameters for the age estimation of human skin wounds. A review. Betz P. **Am J Forensic Med Pathol** 1995 Sep;16(3):203–9 (53 ref.)

Skin necrosis following subcutaneous heparin injection. Mar AW, et al. **Australas J Dermatol** 1995 Nov;36(4):201–3 (14 ref.)

Ambulatory phlebectomy. A rare complication of local anesthetic: case report and literature review. Olivencia JA. **Dermatol Surg** 1996 Jan;22(1):53–5 (15 ref.)

Vesicle formation in dermatomyositis associated with gynecologic malignancies. Kubo M, et al. **J Am Acad Dermatol** 1996 Feb;34(2 Pt 2):391–4 (27 ref.)

Localized reactions to injected therapeutic materials. Part 2. Surgical agents. Morgan AM. **J Cutan Pathol** 1995 Aug; 22(4):289–303 (65 ref.)

How accurately can bruises be aged in abused children? Literature review and synthesis. Schwartz AJ, et al. **Pediatrics** 1996 Feb;97(2):254–7 (46 ref.)

Nodules and draining tracts. Beale KM. **Vet Clin North Am Small Anim Pract** 1995 Jul; 25(4):887–900 (50 ref.)

Systemic diseases with cutaneous manifestations. Merchant SR, et al. **Vet Clin North Am Small Anim Pract** 1995 Jul; 25(4):945–59 (56 ref.)

Exudative, crusting, and scaling dermatoses. Sousa CA. **Vet Clin North Am Small Anim Pract** 1995 Jul;25(4):813–31 (23 ref.)

[Inguinal mastocytosis with histiocytic infiltrate] Enginger V, et al. **Ann Dermatol Venereol** 1995;122(8):536–9 (14 ref.) (Eng. Abstr.) **(Fre)**

[The treatment of cutaneous radiation–induced fibrosis with pentoxifylline and vitamin E. An empirical report] Gottlöber P, et al. **Strahlenther Onkol** 1996 Jan;172(1):34–8 (13 ref.) (Eng. Abstr.) **(Ger)**

[Neurocutaneous syndromes with predominant vascular anomalies] Rodríguez–Barrionuevo AC. **Rev Neurol** 1996 Sep;24(133):1072–84 (121 ref.) **(Spa)**

PHYSIOLOGY

Keratins and the skin. Fuchs E. **Ann Rev Cell Dev Biol** 1995; 11:123–53 (171 ref.)

Bioengineering in dermatology: general aspects and perspectives. Andreassi L. **Clin Dermatol** 1995 Jul–Aug; 13(4):289–92 (48 ref.)

Measurement of skin pH and its significance in cutaneous diseases. Chikakane K, et al. **Clin Dermatol** 1995 Jul–Aug; 13(4):299–306 (61 ref.)

Evaluation of biomechanical properties of human skin. Edwards C, et al. **Clin Dermatol** 1995 Jul–Aug;13(4):375–80 (48 ref.)

New concepts in tissue repair: skin as an example. Meddahi A, et al. **Diabetes Metab** 1996 Jul;22(4):274–8 (28 ref.)

The renin–angiotensin–system in the skin. Evidence for its presence and possible functional implications. Steckelings UM, et al. **Exp Dermatol** 1995 Dec;4(6):329–34 (37 ref.)

Skin–nervous system interactions. Ansel JC, et al. **J Invest Dermatol** 1996 Jan;106(1):198–204 (188 ref.)

The skin: upholder of physiological homeostasis. A physiological and (bio) physical study program. Forslind B. **Thromb Res** 1995 Oct 1;80(1):1–22 (44 ref.)

[Recent data and current studies of epidermal Langerhans cells] Dezutter–Dambuyant C. **Pathol Biol (Paris)** 1995 Dec;43(10):841–7 (78 ref.) (Eng. Abstr.) **(Fre)**

[Significance of skin surface pH] Yosipovitch G, et al. **Harefuah** 1996 Apr 1;130(7):478–80 (30 ref.) **(Heb)**

[The clinico–physiological characteristics of biologically active points] Panasiuk IeM, et al. **Fiziol Zh** 1995 Jan–Apr; 41(1–2):117–21 (19 ref.) (Eng. Abstr.) **(Ukr)**

PHYSIOPATHOLOGY

Cell stress and implications of the heat–shock response in skin. Charveron M, et al. **Cell Biol Toxicol** 1995 Aug; 11(3–4):161–5 (15 ref.)

Atopic dermatitis: the skin as a window into the pathogenesis of chronic allergic diseases. Leung DY. **J Allergy Clin Immunol** 1995 Sep;96(3):302–18; quiz 319 (47 ref.)

Racial differences in skin pathophysiology. Berardesca E, et al. **J Am Acad Dermatol** 1996 Apr;34(4):667–72 (50 ref.)

Skin response to mechanical stress: adaptation rather than breakdown—a review of the literature. Sanders JE, et al. **J Rehabil Res Dev** 1995 Oct;32(3):214–26 (71 ref.)

[Use of cultured fibroblasts for restoration of skin in severe burns] Sarkisov DS, et al. **Biull Eksp Biol Med** 1995 Jun; 119(6):566–70 (28 ref.) **(Rus)**

RADIATION EFFECTS

Ultraviolet radiation and free radical damage to skin. Tyrrell RM. **Biochem Soc Symp** 1995;61:47–53 (33 ref.)

A role for neutrophil elastase in solar elastosis. Starcher B, et al. **Ciba Found Symp** 1995;192:338–46; discussion 346–7 (6 ref.)

Photoimmunology of lupus erythematosus and dermatomyositis: a speculative review. Sontheimer RD. **Photochem Photobiol** 1996 May;63(5):583–94 (155 ref.)

The role of epidermal cytokines in the generation of cutaneous immune reactions and ultraviolet radiation–induced immune suppression. Ullrich SE. **Photochem Photobiol** 1995 Sep;62(3):389–401 (99 ref.)

[Radiotherapy of cutaneous cervical–facial carcinomas] Tordiglione M, et al. **Acta Otorhinolaryngol Ital** 1995 Jun; 15(3):168–78; discussion 179 (18 ref.) (Eng. Abstr.) **(Ita)**

SURGERY

Laser skin resurfacing [editorial; comment] Hruza GJ, et al. **Arch Dermatol** 1996 Apr;132(4):451–5 (61 ref.) Comment on: Arch Dermatol 1996 Apr;132(4):395–402. Comment on: Arch Dermatol 1996 APR;132(4):425–8. Comment on: Arch Dermatol 1996 APR;132(4):469–71.

A comparison between Mohs micrographic surgery and wide surgical excision for the treatment of dermatofibrosarcoma protuberans. Gloster HM Jr, et al. **J Am Acad Dermatol** 1996 Jul;35(1):82–7 (37 ref.)

Localized reactions to injected therapeutic materials. Part 2. Surgical agents. Morgan AM. **J Cutan Pathol** 1995 Aug; 22(4):289–303 (65 ref.)

ULTRASONOGRAPHY

High–frequency sonography combined with image analysis: a noninvasive objective method for skin evaluation and description. Seidenari S. **Clin Dermatol** 1995 Jul–Aug; 13(4):349–59 (65 ref.)

SKIN ABSORPTION

Dermal exposure to environmental contaminants in the Great Lakes. Moody RP, et al. **Environ Health Perspect** 1995 Dec;103 Suppl 9:103–14 (88 ref.)

PHYSIOLOGY

Percutaneous absorption: physical chemistry meets the skin. Guy RH. **Curr Probl Dermatol** 1995;22:132–8 (11 ref.)
Assessment of delipidization as an enhancing factor in percutaneous penetration. Menczel E. **Curr Probl Dermatol** 1995;22:189–94 (11 ref.)

SKIN AGING

[Heliodermatitis or photo-induced skin aging] Leccia MT, et al. **Ann Dermatol Venereol** 1995;122(10):720–8 (89 ref.) **(Fre)**

DRUG EFFECTS

Tretinoin for sun-aged skin. **Drug Ther Bull** 1996 Jul; 34(7):55–6 (13 ref.)
Treatment of photoaged skin. Efficacy, tolerability and costs of available agents. Helander SD. **Drugs Aging** 1996 Jan; 8(1):12–6 (34 ref.)
[Hormone replacement treatment and skin aging] Vaillant L, et al. **Therapie** 1996 Jan-Feb;51(1):67–70 (20 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

A new concept in blepharoplasty. de la Plaza R, et al. **Aesthetic Plast Surg** 1996 May-Jun;20(3):221–33 (30 ref.)
Fibroelastolytic patterns of intrinsic skin aging: pseudoxanthoma-elasticum-like papillary dermal elastolysis and white fibrous papulosis of the neck. Rongioletti F, et al. **Dermatology** 1995;191(1):19–24 (32 ref.)

RADIATION EFFECTS

Sun exposure and skin disease. Taylor CR, et al. **Annu Rev Med** 1996;47:181–91 (40 ref.)
Open questions in photobiology. IV. Photoaging of the skin. Giacomoni PU, et al. **J Photochem Photobiol B** 1996 May; 33(3):267–72 (56 ref.)

SKIN APPENDAGE DISEASES

PATHOLOGY

Pathologic quiz case 1. Microcystic adnexal carcinoma (MAC). Hunt JT, et al. **Arch Otolaryngol Head Neck Surg** 1995 Dec;121(12):1430–3 (27 ref.)

SKIN CARE

The concept of the acid mantle of the skin: its relevance for the choice of skin cleansers. Schmid MH, et al. **Dermatology** 1995;191(4):276–80 (27 ref.)

SKIN DISEASES

see related

DERMATOLOGIC AGENTS

Paraneoplastic dermatopathology: cutaneous paraneoplastic syndromes. Cohen PR. **Adv Dermatol** 1996;11:215–52; discussion 253 (146 ref.)
Common dermatoses. Part II. Nanda VS. **Am J Obstet Gynecol** 1996 Apr;174(4):1273–8 (36 ref.)
Disability and handicap in dermatology. Finlay AY, et al. **Int J Dermatol** 1996 May;35(5):305–11 (60 ref.)
Genetic and acquired cutaneous disorders associated with internal malignancy. Loucas E, et al. **Int J Dermatol** 1995 Nov;34(11):749–58 (128 ref.)
Skin hazards of the marine aquarium industry. Tong DW. **Int J Dermatol** 1996 Mar;35(3):153–8 (43 ref.)
Cutaneous malacoplakia: a report of two cases and review of the literature. Lowitt MH, et al. **J Am Acad Dermatol** 1996 Feb;34(2 Pt 2):325–32 (37 ref.)
Calcifying disorders of the skin. Walsh JS, et al. **J Am Acad Dermatol** 1995 Nov;33(5 Pt 1):693–706; quiz 707–10 (116 ref.)
Dermatological problems in the athlete. Eiland G, et al. **J Orthop Sports Phys Ther** 1996 Jun;23(6):388–402 (32 ref.)
Management of cutaneous symptoms. Gallagher J. **Semin Oncol Nurs** 1995 Nov;11(4):239–47 (63 ref.)
[Progresses in dermatology and venereology in China, 1995] Zhu T. **Chung Hua I Hsueh Tsa Chih** 1995 Dec; 75(12):763–4 (0 ref.) **(Chi)**

CHEMICALLY INDUCED

Ambulatory phlebectomy. A rare complication of local anesthetic: case report and literature review. Olivencia JA. **Dermatol Surg** 1996 Jan;22(1):53–5 (15 ref.)
Drug-induced severe skin reactions. Incidence, management and prevention. Wolkenstein P, et al. **Drug Saf** 1995 Jul; 13(1):56–68 (82 ref.)

CLASSIFICATION

Proposal for a pathogenesis-based classification of tumoral calcinosis. Smack D, et al. **Int J Dermatol** 1996 Apr; 35(4):265–71 (77 ref.)

COMPLICATIONS

Ophthalmologic abnormalities in encephalocraniocutaneous lipomatosis. MacLaren MJ, et al. **Doc Ophthalmol** 1995; 90(1):87–98 (31 ref.)
Clinical aspects of cutaneous necrotizing vasculitis. Campanile G, et al. **Int Angiol** 1995 Jun;14(2):151–61 (72 ref.)
Cutaneous findings in the mentally retarded. Schepis C, et al. **Int J Dermatol** 1996 May;35(5):317–22 (48 ref.)

DIAGNOSIS

Bioengineering in dermatology: general aspects and perspectives. Andreassi L. **Clin Dermatol** 1995 Jul-Aug; 13(4):289–92 (48 ref.)
Measurement of skin pH and its significance in cutaneous diseases. Chikakane K, et al. **Clin Dermatol** 1995 Jul-Aug; 13(4):299–306 (61 ref.)
Thermography and the possibilities for its applications in clinical and experimental dermatology. Di Carlo A. **Clin Dermatol** 1995 Jul-Aug;13(4):329–36 (38 ref.)
Digital imaging in dermatology. Kenet RD. **Clin Dermatol** 1995 Jul-Aug;13(4):381–92 (50 ref.)
Selected topics in dermatology for the primary care physician. Bentz MA, et al. **Compr Ther** 1996 Mar; 22(3):135–43 (25 ref.)
Diagnosis of cutaneous vasculitis. Claudy AL. **Int Angiol** 1995 Jun;14(2):183–7 (16 ref.)
Significance of the anti-Ro (SS-A) antibody in evaluation of patients with cutaneous manifestations of a connective tissue disease. Provost TT, et al. **J Am Acad Dermatol** 1996 Aug;35(2 Pt 1):147–69; quiz 170–2 (213 ref.)
Immunohistochemistry in diagnostic dermatopathology. Wallace ML, et al. **J Am Acad Dermatol** 1996 Feb;34(2 Pt 1):163–83; quiz 184–6 (289 ref.)
HIV-related skin diseases. Tschachler E, et al. **Lancet** 1996 Sep 7;348(9028):659–63 (45 ref.)
Fever, convulsions and coma in scleromyxedema: a "dermato-neuro syndrome". River Y, et al. **Neurology** 1996 Jun;46(6):1778–9 (7 ref.)
[Cartilaginous tumors and other cutaneous lesions] Cribier B, et al. **Ann Dermatol Venereol** 1996;123(1):40–52 (80 ref.) **(Fre)**
[Fat necrosis in the newborn] Beneggi A, et al. **Pediatr Med Chir** 1995 May-Jun;17(3):281–2 (10 ref.) (Eng. Abstr.) **(Ita)**
[Cutaneous lesions and lung infiltrates after a trip to Thailand] Martínez-Fernández R, et al. **Rev Clin Esp** 1995 Oct; 195(10):721–2 (15 ref.) **(Spa)**

DRUG THERAPY

Newer antibiotics: a dermatologist's guide. Webster GF. **Adv Dermatol** 1996;11:105–15; discussion 116 (60 ref.)
Dermatology. Lowitt MH, et al. **BMJ** 1995 Dec 16; 311(7020):1615–7 (19 ref.)
Topical retinoids and cutaneous biology. Craven NM, et al. **Clin Exp Dermatol** 1996 Jan;21(1):1–10 (141 ref.)
Benefits and risks of intralesional corticosteroid injection in the treatment of dermatological diseases. Firooz A, et al. **Clin Exp Dermatol** 1995 Sep;20(5):363–70 (79 ref.)
Alpha hydroxy acids in skin care. Clark CP 3rd. **Clin Plast Surg** 1996 Jan;23(1):49–56 (48 ref.)
Topical corticosteroids in clinical practice: focus on fluticasone propionate. Piacquadio DJ. **Cutis** 1996 Feb;57(2 Suppl):4–9 (19 ref.)
Minimizing complications from systemic glucocorticosteroid use. Nesbitt LT Jr. **Dermatol Clin** 1995 Oct;13(4):925–39 (56 ref.)
Cytokine treatment of mast-cell-mediated skin diseases. Luger TA. **Exp Dermatol** 1995 Aug;4(4 Pt 2):277–80 (39 ref.)
Photodynamic therapy in dermatology. Frazier CC. **Int J Dermatol** 1996 May;35(5):312–6 (50 ref.)
Botulinum A exotoxin use in clinical dermatology. Carruthers A, et al. **J Am Acad Dermatol** 1996 May;34(5 Pt 1):788–97 (118 ref.)
Advances in topical therapy for skin diseases. Willsteed EM. **Med J Aust** 1996 Sep 2;165(5):274–9 (25 ref.)
Managing HIV. Part 5: Treating secondary outcomes. 5.1 HIV and skin disease. Wong D, et al. **Med J Aust** 1996 Mar 18;164(6):352–6 (9 ref.)
Possible association of liver damage with the use of Chinese herbal medicine for skin disease. Perharic L, et al. **Vet Hum Toxicol** 1995 Dec;37(6):562–6 (30 ref.)
[Antiseptics in skin diseases] Wolkenstein P, et al. **Ann Dermatol Venereol** 1996;123(5):343–8 (50 ref.) **(Fre)**
[Topical corticosteroids] Duchesneau J, et al. **Union Med Can** 1995 Mar;124(1):15–9 (15 ref.) **(Fre)**

ENZYMOLOGY

A role for neutrophil elastase in solar elastosis. Starcher B, et al. **Ciba Found Symp** 1995;192:338–46; discussion 346–7 (6 ref.)

EPIDEMIOLOGY

[Dermatology in the tropics] Tapia Collantes A. **Rev Med Panama** 1995 Sep;20(3):65–71 (26 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

Cutaneous paraneoplastic syndromes in solid tumors. Kurzrock R, et al. **Am J Med** 1995 Dec;99(6):662–71 (70 ref.)
Sun exposure and skin disease. Taylor CR, et al. **Annu Rev Med** 1996;47:181–91 (40 ref.)
Specific mucosal erosions in hypereosinophilic syndrome. Evidence for eosinophil protein deposition [see comments] Aractingi S, et al. **Arch Dermatol** 1996 May;132(5):535–41 (37 ref.) Comment in: Arch Dermatol 1996 May;132(5):583–5.
Metastatic Crohn's disease. Report of 3 cases with special reference to histopathologic findings. Hackzell-Bradley M, et al. **Arch Dermatol** 1996 Aug;132(8):928–32 (22 ref.)
Splenosis in exit gunshot wound [letter] Burvin R, et al. **Br J Dermatol** 1996 Jul;135(1):148–50 (12 ref.)
Cutaneous manifestations of non-HIV immunosuppression. Child FJ, et al. **Br J Hosp Med** 1995 Oct 18–31;54(8):395–9 (28 ref.)
Causes and clinical manifestations of lymphatic failure. Harwood CA, et al. **Clin Dermatol** 1995 Sep-Oct; 13(5):459–71 (84 ref.)
Environmental skin injuries in children. Duarte AM. **Curr Opin Pediatr** 1995 Aug;7(4):423–30 (33 ref.)
Cutaneous side effects associated with interferon-alpha therapy: a review. Chang LW, et al. **Cutis** 1995 Sep; 56(3):144 (14 ref.)
Fever and rash. Schlossberg D. **Infect Dis Clin North Am** 1996 Mar;10(1):101–10 (9 ref.)
Cryoglobulinemia: recent findings in cutaneous and extracutaneous manifestations. Davis MD, et al. **Int J Dermatol** 1996 Apr;35(4):240–8 (50 ref.)
Proposal for a pathogenesis-based classification of tumoral calcinosis. Smack D, et al. **Int J Dermatol** 1996 Apr; 35(4):265–71 (77 ref.)
Cutaneous manifestations and consequences of smoking. Smith JB, et al. **J Am Acad Dermatol** 1996 May;34(5 Pt 1):717–32; quiz 733–4 (311 ref.)
Clinical review 74: Dermatological manifestations of endocrine disorders. Thiboutot DM. **J Clin Endocrinol Metab** 1995 Oct;80(10):3082–7 (27 ref.)
Elemental mercury-induced skin granuloma: a case report and review of the literature. Bradberry SM, et al. **J Toxicol Clin Toxicol** 1996;34(2):209–16 (38 ref.)
Managing HIV. Part 5: Treating secondary outcomes. 5.1 HIV and skin disease. Wong D, et al. **Med J Aust** 1996 Mar 18;164(6):352–6 (9 ref.)
[Systemic sarcoidosis with cutaneous lesions: literature review] Hubert A, et al. **Acta Clin Belg** 1995;50(4):207–13 (23 ref.) (Eng. Abstr.) **(Fre)**
[Cutaneous immunoallergic reactions caused by vaccines] Barbaud A, et al. **Ann Dermatol Venereol** 1995; 122(3):129–38 (120 ref.) **(Fre)**
[Hyperimmunoglobulinemia D or periodic fever syndrome. Cutaneous manifestations in 3 cases] Cartier H, et al. **Ann Dermatol Venereol** 1996;123(5):314–21 (34 ref.) (Eng. Abstr.) **(Fre)**
[Dermatological manifestations of Alagille syndrome] Doutre MS, et al. **Gastroenterol Clin Biol** 1996 Mar;20(2):207–8 (7 ref.) **(Fre)**
[Dermatoses and winter sports] Letawe C, et al. **Rev Med Liege** 1995 Nov;50(11):477–9 (12 ref.) **(Fre)**
[Metal dermatoses I] Schwarz T, et al. **Hautarzt** 1996 Apr; 47(4):316–28; quiz 327–8 (10 ref.) **(Ger)**
[Cutaneous manifestations of primary Sjögren's syndrome] Nishiyama S, et al. **Nippon Rinsho** 1995 Oct;53(10):2551–6 (11 ref.) (Eng. Abstr.) **(Jpn)**
[Essential trace element and skin diseases] Yamada H, et al. **Nippon Rinsho** 1996 Jan;54(1):99–105 (21 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Keratins and the skin. Fuchs E. **Ann Rev Cell Dev Biol** 1995; 11:123–53 (171 ref.)
Keratins and skin disorders. Rao KS, et al. **Cell Biol Int** 1996 Apr;20(4):261–74 (100 ref.)
Piezogenic pedal papules in two family members. Gibney MD, et al. **Cutis** 1996 Apr;57(4):260–2 (12 ref.)
Gene analysis of human skin and skin diseases. Yamanishi K. **J Dermatol Sci** 1996 Mar;11(3):169–76 (40 ref.)
[Prenatal diagnosis of cutaneous genetic diseases by the study of fetal DNA] Hovnanian A, et al. **Ann Dermatol Venereol** 1995;122(4):173–85 (151 ref.) (Eng. Abstr.) **(Fre)**
[X-linked genodermatoses] Vabres P, et al. **Ann Dermatol Venereol** 1995;122(4):154–60 (33 ref.) (Eng. Abstr.) **(Fre)**
[Transgenic mice as models for skin diseases (see comments)] Sellheyer K. **Hautarzt** 1995 Nov;46(11):755–61 (30 ref.) (Eng. Abstr.) Comment in: Hautarzt 1996 Jun;47(6):475–6. **(Ger)**

IMMUNOLOGY

Immunopathology of nonneoplastic skin disease: a brief review. Wick MR, et al. **Am J Clin Pathol** 1996 Apr; 105(4):417–29 (122 ref.)
Dermatological presentation of disease associated with antineutrophil cytoplasmic antibodies: a report of two contrasting cases and a review of the literature. Irvine AD, et al. **Br J Dermatol** 1996 May;134(5):924–8 (30 ref.)
Protracted cutaneous disorders in association with low CD4+ lymphocyte counts. Kurwa HA, et al. **Br J Dermatol** 1995 Oct;133(4):625–9 (19 ref.)
St. John Dermatological Society Oration, 1994. Immune responses in leprosy, cytokines and new archetypes for dermatology. Rea TH. **Clin Exp Dermatol** 1995 Mar;

20(2):89–97 (48 ref.)
Superantigens. Saloga J, et al. **Exp Dermatol** 1996 Apr; 5(2):65–71 (109 ref.)
[Skin as an immune organ] Simon JC.
Med Monatsschr Pharm 1995 Nov;18(11):316–9 (10 ref.) **(Ger)**
[Skin manifestations of graft–versus–host reaction following bone marrow transplantation] Itin PH, et al.
Schweiz Med Wochenschr 1996 Mar 2;126(9):339–47 (41 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

Raimer's bands: case report with a review of solar elastosis. Stanford DG, et al. **Acta Derm Venereol** 1995 Sep; 75(5):372–4 (23 ref.)
Immunopathology of nonneoplastic skin disease: a brief review. Wick MR, et al. **Am J Clin Pathol** 1996 Apr; 105(4):417–29 (122 ref.)
Granulomatous slack skin. Report of a case and review of the literature. Balus L, et al. **Am J Dermatopathol** 1996 Apr;18(2):199–206 (28 ref.)
Sinus histiocytosis confined to the skin. Case report and review of the literature. Pérez A, et al.
Am J Dermatopathol 1995 Aug;17(4):384–8 (18 ref.)
Nodular lesions on fingertips. Diagnosis: cutaneous sarcoidosis. Di Landro A, et al. **Arch Dermatol** 1996 Apr; 132(4):460, 463 (9 ref.)
Alterations of intermediate filaments in various histopathological conditions. Cadrin M, et al.
Biochem Cell Biol 1995 Sep–Oct;73(9–10):627–34 (103 ref.)
Indeterminate cell histiocytosis—a clinicopathological entity with features of both X– and non–X histiocytosis. Sidoroff A, et al. **Br J Dermatol** 1996 Mar;134(3):525–32 (34 ref.)
T lymphocyte chemotaxis and skin diseases. Tan J, et al. **Exp Dermatol** 1995 Oct;4(5):281–90 (87 ref.)
Clinical review 74: Dermatological manifestations of endocrine disorders. Thiboutot DM.
J Clin Endocrinol Metab 1995 Oct;80(10):3082–7 (27 ref.)
Subcutaneous juvenile xanthogranuloma. Sánchez Yus E, et al. **J Cutan Pathol** 1995 Oct;22(5):460–5 (17 ref.)

PHYSIOPATHOLOGY

Defective cell–cell adhesion in the epidermis. Stanley JR. **Ciba Found Symp** 1995;189:107–20; discussion 120–3, 174–6 (64 ref.)
T lymphocyte chemotaxis and skin diseases. Tan J, et al. **Exp Dermatol** 1995 Oct;4(5):281–90 (87 ref.)
Skin response to mechanical stress: adaptation rather than breakdown—a review of the literature. Sanders JE, et al. **J Rehabil Res Dev** 1995 Oct;32(3):214–26 (71 ref.)
The latest fashions in skin disease. Carroll JM, et al.
Mol Med 1995 Jan;1(2):123–6 (29 ref.)

PSYCHOLOGY

Psychodermatology: an update. Gupta MA, et al.
J Am Acad Dermatol 1996 Jun;34(6):1030–46 (196 ref.)

RADIOGRAPHY

Assessment of abnormal lymph drainage for the diagnosis of lymphedema by isotopic lymphangiography and by indirect lymphography. Partsch H. **Clin Dermatol** 1995 Sep–Oct;13(5):445–50 (45 ref.)

RADIONUCLIDE IMAGING

Assessment of abnormal lymph drainage for the diagnosis of lymphedema by irotopic lymphangiography and by indirect lymphography. Partsch H. **Clin Dermatol** 1995 Sep–Oct;13(5):445–50 (45 ref.)

RADIOTHERAPY

Office radiotherapy in dermatology: a contemporary perspective. de Launey JW, et al. **Australas J Dermatol** 1996 May;37(2):71–7; quiz 78–9 (39 ref.)

REHABILITATION

[Indications for psychosomatically–oriented dermatologic rehabilitation] Wehrmann J. **Hautarzt** 1996 Apr;47(4):253–7 (34 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Local anesthetics. Skidmore RA, et al. **Dermatol Surg** 1996 Jun;22(6):511–22; quiz 523–4 (83 ref.)
[Laser therapy of the skin] Hohenleutner U, et al. **HNO** 1995 Sep;43(9):557–71 (64 ref.) **(Ger)**

THERAPY

Gene therapy for skin diseases. Vogel JC, et al.
Adv Dermatol 1996;11:383–98; discussion 399 (38 ref.)
Eruptive pyogenic granulomas: a successfully treated patient and review of the literature. Shah M, et al.
Br J Dermatol 1995 Nov;133(5):795–6 (27 ref.)
Managing lymphedema. Mortimer PS. **Clin Dermatol** 1995 Sep–Oct;13(5):499–505 (21 ref.)
Dermatologic uses of interferons. Berman B, et al.
Dermatol Clin 1995 Jul;13(3):699–711 (101 ref.)
Is phototherapy safe for HIV–infected individuals? Adams ML, et al. **Photochem Photobiol** 1996 Aug;64(2):234–7 (41 ref.)
[Dermatologic pain therapy. Selected clinical aspects] Ladner E, et al. **Hautarzt** 1995 Dec;46(12):892–906 (12 ref.) **(Ger)**

VETERINARY

Erosive and ulcerative skin disease. Angarano DW.
Vet Clin North Am Small Anim Pract 1995 Jul;25(4):871–85 (35 ref.)
Nodules and draining tracts. Beale KM.
Vet Clin North Am Small Anim Pract 1995 Jul; 25(4):887–900 (50 ref.)
Diagnostic procedures in feline dermatology. Noxon JO.
Vet Clin North Am Small Anim Pract 1995 Jul;25(4):779–99 (14 ref.)
Selected feline eosinophilic skin diseases. Power HT, et al.
Vet Clin North Am Small Anim Pract 1995 Jul;25(4):833–50 (30 ref.)
Immune mediated skin diseases. Rosser EJ Jr. **Vet Q** 1995 Apr;17 Suppl 1:S37–8 (0 ref.)
The skin in systemic disease. Rosser EJ Jr. **Vet Q** 1995 Apr; 17 Suppl 1:S38–9 (0 ref.)
Skin disorders in cats. Willemse A. **Vet Q** 1995 Apr;17 Suppl 1:S40–1 (8 ref.)
['Oat bumps' in horses. Differential diagnosis and nutritional aspects] Hallebeek AJ, et al. **Tijdschr Diergeneeskd** 1995 Oct 15;120(20):588–91 (30 ref.) (Eng. Abstr.) **(Dut)**

SKIN DISEASES, BACTERIAL

Unusual cutaneous mycobacterial diseases. Groves R.
Clin Dermatol 1995 May–Jun;13(3):257–63 (82 ref.)
Cutaneous infections with rapidly growing mycobacteria. Sastry V, et al. **Clin Dermatol** 1995 May–Jun;13(3):266–71 (55 ref.)
Mycocutaneous atypical mycobacterial infections in acquired immunodeficiency syndrome. Zanelli G, et al.
Clin Dermatol 1995 May–Jun;13(3):281–8 (68 ref.)
May Helicobacter pylori be important for dermatologists? Rebora A, et al. **Dermatology** 1995;191(1):6–8 (21 ref.)
Botryomycosis. Bonifaz A, et al. **Int J Dermatol** 1996 Jun; 35(6):381–8 (91 ref.)
Streptococcal infections of skin and soft tissues [see comments] Bisno AL, et al. **N Engl J Med** 1996 Jan 25; 334(4):240–5 (51 ref.) Comment in: N Engl J Med 1996 May 30;334(22):1478.

COMPLICATIONS

Cutaneous manifestations of opportunistic infections in patients infected with human immunodeficiency virus. Tappero JW, et al. **Clin Microbiol Rev** 1995 Jul;8(3):440–50 (68 ref.)

DIAGNOSIS

Cutaneous Mycobacterium chelonei presenting in an immunocompetent host: case report and review of the literature. Kelley LC, et al. **Cutis** 1995 Nov;56(5):293–5 (10 ref.)
Bacillus piliformis infection (Tyzzer's disease) in a patient infected with HIV–1: confirmation with 16S ribosomal RNA sequence analysis. Smith KJ, et al.
J Am Acad Dermatol 1996 Feb;34(2 Pt 2):343–8 (18 ref.)
A case of cutaneous anthrax. Natori N.
Tohoku J Exp Med 1995 Jul;176(3):187–90 (7 ref.)

MICROBIOLOGY

Primary cutaneous nocardiosis caused by Nocardia otitidiscaviarum: two cases and a review of the literature. Freland C, et al. **J Trop Med Hyg** 1995 Dec;98(6):395–403 (26 ref.)
Lymphocutaneous Nocardia brasiliensis infection: a case report and review. Seddon M, et al. **N Z Med J** 1995 Sep 22;108(1008):385–6 (08 ref.)

SKIN DISEASES, BULLOUS see **SKIN DISEASES, VESICULOBULLOUS**

SKIN DISEASES, FUNGAL see **DERMATOMYCOSES**

SKIN DISEASES, INFECTIOUS

Mycobacterium marinum. Gluckman SJ. **Clin Dermatol** 1995 May–Jun;13(3):273–6 (40 ref.)
Diseases caused by Mycobacterium scrofulaceum. Hautmann G, et al. **Clin Dermatol** 1995 May–Jun;13(3):277–80 (25 ref.)
Pediatric soft tissue infections. Minnick KE, et al.
Semin Pediatr Surg 1995 Nov;4(4):228–33 (26 ref.)

COMPLICATIONS

An approach to acute fever and rash (AFR) in the adult. Levin S, et al. **Curr Clin Top Infect Dis** 1995;15:19–75 (234 ref.)

DRUG THERAPY

[Treatment of commonly occurring skin infections] Hyry H, et al. **Duodecim** 1995;111(8):697–702 (15 ref.) **(Fin)**

EPIDEMIOLOGY

Epidemiologic review of pediatric and adult maxillofacial infections in hospitalized patients. Scutari P Jr, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Mar;81(3):270–4 (11 ref.)

ETIOLOGY

Identifying high risk patients for Staphylococcus aureus infections: skin and soft tissue infections. Trilla A, et al. **J Chemother** 1995 Jul;7 Suppl 3:37–43 (14 ref.)
Dermatological problems in the athlete. Eiland G, et al.
J Orthop Sports Phys Ther 1996 Jun;23(6):388–402 (32 ref.)

PATHOLOGY

Pathological twists in association with infectious agents and infestations of the skin. Kossard S.
Australas J Dermatol 1996 May;37 Suppl 1:S17–9 (10 ref.)

ULTRASONOGRAPHY

[Ultrasound skin findings in HIV infection by imaging with 7.5 MHz linear transducers] Bogner JR, et al.
Bildgebung 1995 Dec;62(4):281–6 (14 ref.) (Eng. Abstr.) **(Ger)**

SKIN DISEASES, PAPULOSQUAMOUS

PARASITOLOGY

Rosacea–like demodicosis in an HIV–positive child. Barrio J, et al. **Dermatology** 1996;192(2):143–5 (23 ref.)

PATHOLOGY

Fibroelastolytic patterns of intrinsic skin aging: pseudoxanthoma–elasticum–like papillary dermal elastolysis and white fibrous papulosis of the neck. Rongioletti F, et al. **Dermatology** 1995;191(1):19–24 (32 ref.)
Sarcoidosis with skin manifestations—two case reports and review of literature. Siddiqi S, et al.
JPMA J Pak Med Assoc 1995 Jun;45(6):162–4 (10 ref.)

THERAPY

Treatment of vulvar dermatoses. Zellis S, et al.
Semin Dermatol 1996 Mar;15(1):71–6 (26 ref.)

SKIN DISEASES, PARASITIC

see related
ECTOPARASITIC INFESTATIONS

SKIN DISEASES, STAPHYLOCOCCAL see **STAPHYLOCOCCAL SKIN INFECTIONS**

SKIN DISEASES, VASCULAR

Cutaneous vasculitis and cutaneous vasculopathies. Kelly RI.
Australas J Dermatol 1995 Aug;36(3):109–17; quiz 118–9 (73 ref.)
Extensive necrotizing livedo reticularis in a patient with chronic renal failure, hyperparathyroidism and coagulation disorder: regression after subtotal parathyroidectomy. Dereure O, et al. **Dermatology** 1996;192(2):167–70 (33 ref.)

COMPLICATIONS

An approach to acute fever and rash (AFR) in the adult. Levin S, et al. **Curr Clin Top Infect Dis** 1995;15:19–75 (234 ref.)
[Ictus and cutaneous vascular syndromes] Trejo Gabriel y Galán JM. **Rev Neurol** 1995;23 Suppl 1:S99–105 (46 ref.) **(Spa)**

DIAGNOSIS

Acro–angiodermatitis: review of the literature and report of a case. Rashkovsky I, et al. **Acta Derm Venereol** 1995 Nov; 75(6):475–8 (55 ref.)
[Idiopathic white atrophy and the primary antiphospholipid syndrome: a promise still unfulfilled (letter)] LLamas P, et al. **Rev Clin Esp** 1996 May;196(5):342–3 (10 ref.) **(Spa)**

ETIOLOGY

[Extrahepatic manifestations of hepatitis A virus infection] Maïga MY, et al. **Gastroenterol Clin Biol** 1996;20(4):346–52 (110 ref.) **(Fre)**

PATHOLOGY

Langerhans cells and vasculitis. Romagnoli P, et al.
Int Angiol 1995 Jun;14(2):113–8 (88 ref.)

PHYSIOPATHOLOGY

The role of regulatory peptides in the pathogenesis of cutaneous necrotizing vasculitis. Hautmann G, et al.
Int Angiol 1995 Jun;14(2):138–50 (104 ref.)
Cytokines, fibrinolysis and vasculitis. Teofoli P, et al.
Int Angiol 1995 Jun;14(2):125–9 (51 ref.)

SKIN DISEASES, VESICULAR see **SKIN DISEASES, VESICULOBULLOUS**

SKIN DISEASES, VESICULOBULLOUS

Vesiculobullous disease of the oral cavity. Zunt SL.

Dermatol Clin 1996 Apr;14(2):291-302 (50 ref.)

COMPLICATIONS

Vesicle formation in dermatomyositis associated with gynecologic malignancies. Kubo M, et al. **J Am Acad Dermatol** 1996 Feb;34(2 Pt 2):391-4 (27 ref.)

DIAGNOSIS

Advances in the diagnosis of subepidermal bullous diseases [editorial] Yancey KB, et al. **Arch Dermatol** 1996 Feb; 132(2):220-2 (30 ref.)

[Pancreatic lipase deficiency and linear IgA disease in childhood] Olivera Olmedo JE, et al. **An Esp Pediatr** 1996 Jan;44(1):73-5 (15 ref.) **(Spa)**

DRUG THERAPY

Management of acquired bullous skin diseases [see comments] Fine JD. **N Engl J Med** 1995 Nov 30;333(22):1475-84 (112 ref.) Comment in: N Engl J Med 1996 Mar 28;334(13):864-5. Comment in: N Engl J Med 1996 Mar 28;334(13):865.

ETIOLOGY

[Bullous eruptions induced by phototherapy] Jeanmougin M. **Ann Dermatol Venereol** 1995;122(3):124-8 (36 ref.) **(Fre)**

IMMUNOLOGY

Bullous skin diseases. Nousari HC, et al. **Curr Opin Immunol** 1995 Dec;7(6):844-52 (76 ref.)

Recent progress in studies on autoantigens for various autoimmune blistering skin diseases. Hashimoto T. **Keio J Med** 1995 Dec;44(4):115-23 (84 ref.)

MICROBIOLOGY

Neonatal Malassezia furfur pustulosis. Rapelanoro R, et al. **Arch Dermatol** 1996 Feb;132(2):190-3 (30 ref.)

PATHOLOGY

Henoch-Schonlein purpura presenting as hemorrhagic vesicles and bullae: case report and literature review. Wananukul S, et al. **Pediatr Dermatol** 1995 Dec;12(4):314-7 (17 ref.)

VIROLOGY

Viral exanthems in childhood. Hogan PA. **Australas J Dermatol** 1996 May;37 Suppl 1:S14-6 (8 ref.)

SKIN DISEASES, VIRAL

Advances in viral infections. Krafchik BR. **Adv Dermatol** 1996;11:155-76; discussion 177 (109 ref.)

[Skin manifestations related to hepatitis C viruses] Doutre MS, et al. **Rev Med Interne** 1995;16(9):666-72 (71 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

Cutaneous manifestations of opportunistic infections in patients infected with human immunodeficiency virus. Tappero JW, et al. **Clin Microbiol Rev** 1995 Jul;8(3):440-50 (68 ref.)

DRUG THERAPY

Antiviral agents in dermatology: current status and future prospects. Memar OM, et al. **Int J Dermatol** 1995 Sep; 34(9):597-606 (98 ref.)

Iontophoresis for enhancing penetration of dermatologic and antiviral drugs. Gangarosa LP Sr, et al. **J Dermatol** 1995 Nov;22(11):865-75 (39 ref.)

ETIOLOGY

Cutaneous reactions following herpes zoster infections: report of three cases and a review of the literature. Gibney MD, et al. **Br J Dermatol** 1996 Mar;134(3):504-9 (22 ref.)

[Gianotti-Crosti syndrome due to a mixed infection produced by the mumps virus and the parainfluenza virus type 2] Hergueta Lendínez R, et al. **An Esp Pediatr** 1996 Jan; 44(1):65-6 (17 ref.) **(Spa)**

VIROLOGY

Hepatitis C virus in dermatology. A review. Pawlotsky JM, et al. **Arch Dermatol** 1995 Oct;131(10):1185-93 (138 ref.)

SKIN FISTULA see **CUTANEOUS FISTULA**

SKIN NEOPLASMS

Clinical histopathological characteristics of basal cell carcinoma in Japanese patients. Kikuchi A, et al. **Arch Dermatol** 1996 Mar;132(3):320-4 (24 ref.)

Aggressive basal cell carcinoma of head and neck areas. Vico P, et al. **Eur J Surg Oncol** 1995 Oct;21(5):490-7 (25 ref.)

Epidemiology and clinical manifestations of cutaneous T-cell lymphoma. Koh HK, et al. **Hematol Oncol Clin North Am** 1995 Oct;9(5):943-60 (105 ref.)

Lentigo maligna and lentigo maligna melanoma. Cohen LM. **J Am Acad Dermatol** 1995 Dec;33(6):923-36; quiz 937-40 (225 ref.)

Kaposi's sarcoma: advances and perspectives. Schwartz RA. **J Am Acad Dermatol** 1996 May;34(5 Pt 1):804-14 (188 ref.)

Primary plasmacytoma of the skin. Tüting T, et al. **J Am Acad Dermatol** 1996 Feb;34(2 Pt 2):386-90 (29 ref.)

Basal cell carcinoma. Goldberg LH. **Lancet** 1996 Mar 9; 347(9002):663-7 (29 ref.)

Cutaneous T-cell lymphoma (mycosis fungoides) [see comments] Lorincz AL. **Lancet** 1996 Mar 30; 347(9005):871-6 (30 ref.) Comment in: Lancet 1996 Jul 13;348(9020):130-1.

Squamous cell carcinoma. Marks R. **Lancet** 1996 Mar 16; 347(9003):735-8 (30 ref.)

Melanoma. Rivers JK. **Lancet** 1996 Mar 23;347(9004):803-6 (39 ref.)

Malignant melanomas--how many have you missed? Kelly JW. **Med J Aust** 1996 Apr 1;164(7):431-6 (25 ref.)

The significance of birthmarks. Rogers M. **Med J Aust** 1996 May 20;164(10):618-23 (24 ref.)

Congenital glomangioma: case report and review of the world literature. Glick SA, et al. **Pediatr Dermatol** 1995 Sep;12(3):242-4 (11 ref.)

[Lymphoma with skin manifestations in HIV infection: 8 cases] Estève E, et al. **Ann Dermatol Venereol** 1995; 122(8):488-93 (40 ref.) (Eng. Abstr.) **(Fre)**

[Cutaneous localization of T-cell prolymphocytic leukemia] Thomas A, et al. **Ann Dermatol Venereol** 1995;122(8):526-9 (17 ref.) (Eng. Abstr.) **(Fre)**

[Multiple perifollicular fibroma] Yamamoto T, et al. **Nippon Rinsho** 1995 Nov;53(11):2759-63 (11 ref.) (Eng. Abstr.) **(Jpn)**

BLOOD SUPPLY

[Incident light microscopic characterization of vascular patterns in skin tumors] Kreusch J, et al. **Hautarzt** 1996 Apr;47(4):264-72 (21 ref.) (Eng. Abstr.) **(Ger)**

CHEMICALLY INDUCED

Arsenic in Dermatology. Maloney ME. **Dermatol Surg** 1996 Mar;22(3):301-4 (31 ref.)

Protein kinase C and skin tumor promotion. Marks F, et al. **Mutat Res** 1995 Dec;333(1-2):161-72 (100 ref.)

A transgenic mouse model (TG.AC) for skin carcinogenesis: inducible transgene expression as a second critical event. Hansen LA, et al. **Prog Clin Biol Res** 1995;391:223-35 (34 ref.)

Skin carcinogenesis: characteristics, mechanisms, and prevention. Slaga TJ, et al. **Prog Clin Biol Res** 1995; 391:1-20 (43 ref.)

Transgenic approaches to understanding the mechanisms of chemical carcinogenesis in mouse skin. Brown K, et al. **Toxicol Lett** 1995 Dec;82-83:123-30 (20 ref.)

[Cutaneous pseudolymphoma during treatment of rheumatoid polyarthritis with low-dose methotrexate] Delaporte E, et al. **Ann Dermatol Venereol** 1995;122(8):521-5 (33 ref.) (Eng. Abstr.) **(Fre)**

[Levodopa and malignant melanoma--case report and review of the literature. A contribution to causal relationship between levodopa and the development of malignant melanoma] Kleinhans M, et al. **Hautarzt** 1996 Jun; 47(6):432-7 (29 ref.) (Eng. Abstr.) **(Ger)**

CLASSIFICATION

What is a nevus? A proposed definition of a common medical term. Happle R. **Dermatology** 1995;191(1):1-5 (38 ref.)

COMPLICATIONS

The clinical spectrum of naevus anaemicus and its association with port wine stains: report of 15 cases and a review of the literature. Katugampola GA, et al. **Br J Dermatol** 1996 Feb;134(2):292-5 (19 ref.)

Subcutaneous T-cell lymphoma with associated hemophagocytic syndrome and terminal leukemic transformation. Romero LS, et al. **J Am Acad Dermatol** 1996 May;34(5 Pt 2):904-10 (22 ref.)

Hypopigmented mycosis fungoides in a white female. Amichai B, et al. **J Dermatol** 1996 Jun;23(6):425-6 (9 ref.)

[Desmoplastic and neurotropic subungueal melanoma] Rongioletti F, et al. **Ann Dermatol Venereol** 1995; 122(10):707-10 (20 ref.) (Eng. Abstr.) **(Fre)**

[Paraneoplastic retinopathy associated with cutaneous melanoma. An update apropos of a case] Rougier MB, et al. **J Fr Ophtalmol** 1995;18(5):396-403 (16 ref.) (Eng. Abstr.) **(Fre)**

CONGENITAL

Congenital subungual nevus in a black infant. Libow LF, et al. **Cutis** 1995 Sep;56(3):154-6 (17 ref.)

Congenital nevi. Schleicher SM, et al. **Int J Dermatol** 1995 Dec;34(12):825-9 (34 ref.)

Cutaneous angiosarcoma arising in the radiation site of a congenital hemangioma. Caldwell JB, et al. **J Am Acad Dermatol** 1995 Nov;33(5 Pt 2):865-70 (50 ref.)

DIAGNOSIS

Immunocytochemistry in the diagnosis of Kaposi's sarcoma and angiosarcoma. Orchard GE, et al. **Br J Biomed Sci** 1995 Mar;52(1):35-49 (145 ref.)

Amelanotic lentigo maligna melanoma: a diagnostic conundrum-- presentation of four new cases. Rahbari H, et al. **Cancer** 1996 May 15;77(10):2052-7 (15 ref.)

Selected topics in dermatology for the primary care physician. Bentz MA, et al. **Compr Ther** 1996 Mar; 22(3):135-43 (25 ref.)

Evaluation of cutaneous lymphomas. Breneman DL. **Compr Ther** 1996 Mar;22(3):169-74 (18 ref.)

Nonmelanoma skin cancer. Epstein JH. **Compr Ther** 1996 Mar;22(3):179-82 (17 ref.)

The current status of melanoma early detection and screening. Koh HK, et al. **Dermatol Clin** 1995 Jul; 13(3):623-34 (80 ref.)

Management of stage I malignant melanoma. Greenstein DS, et al. **Dermatol Surg** 1995 Nov;21(11):927-37; quiz 938-9 (96 ref.)

Merkel cell carcinoma. O'Connor WJ, et al. **Dermatol Surg** 1996 Mar;22(3):262-7 (21 ref.)

Kaposi's sarcoma. An Update. Zalla MJ. **Dermatol Surg** 1996 Mar;22(3):274-87 (154 ref.)

Skin cancer. Recognition and treatment. Marks R, et al. **Drugs** 1995 Jul;50(1):48-61 (46 ref.)

Symptomatic spinal hemangiomas in association with cutaneous hemangiomas. A case report. Asumu TO, et al. **Spine** 1996 May 1;21(9):1082-4 (7 ref.)

[After excision of primary melanoma should an initial evaluation be performed? Point of view of a French dermatologist] Bonerandi JJ. **Ann Dermatol Venereol** 1995; 122(5):289-91 (36 ref.) **(Fre)**

[Prognostic factors of stage I melanoma: non histological factors] Delaunay M. **Ann Dermatol Venereol** 1995; 122(5):267-75 (114 ref.) **(Fre)**

[Screening for and early diagnosis of cutaneous melanoma] Piérard GE, et al. **Rev Med Liege** 1995 Dec;50(12):525-9 (18 ref.) **(Fre)**

[Malignant melanoma of the skin] Simon JC, et al. **Fortschr Med** 1995 Oct 10;113(28):393-6 (18 ref.) (Eng. Abstr.) **(Ger)**

[Lymphedema-associated angiosarcoma (the Stewart-Treves syndrome) of the lower extremity: its MRT imaging] Gelmetti W, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Feb;164(2):168-70 (15 ref.) **(Ger)**

DRUG THERAPY

Combination chemotherapy for disseminated malignant melanoma. Abbott KL, et al. **Anticancer Drugs** 1995 Aug; 6(4):489-97 (74 ref.)

Photodynamic therapy of primary skin cancer: a review. Roberts DJ, et al. **Br J Plast Surg** 1995 Sep;48(6):360-70 (71 ref.)

Melanoma: chemotherapy. Lee SM, et al. **Br Med Bull** 1995 Jul;51(3):609-30 (151 ref.)

Systemic therapy of skin carcinoma. Kempf RA. **Cancer Treat Res** 1995;78:137-62 (122 ref.)

Photopheresis for the treatment of cutaneous T-cell lymphoma. Lim HW, et al. **Hematol Oncol Clin North Am** 1995 Oct;9(5):1117-26 (25 ref.)

Topical treatment of early cutaneous T-cell lymphoma. Ramsay DL, et al. **Hematol Oncol Clin North Am** 1995 Oct;9(5):1031-56 (84 ref.)

Adjuvant therapy for cutaneous melanoma. Nathan FE, et al. **Semin Oncol** 1995 Dec;22(6):647-61 (85 ref.)

EPIDEMIOLOGY

Cutaneous malignant melanoma and sun exposure. Recent developments in epidemiology. Katsambas A, et al. **Arch Dermatol** 1996 Apr;132(4):444-50 (62 ref.)

Epidemiology of malignant melanoma. Boyle P, et al. **Br Med Bull** 1995 Jul;51(3):523-47 (81 ref.)

Skin cancer. Armstrong BK, et al. **Dermatol Clin** 1995 Jul; 13(3):583-94 (89 ref.)

The epidemiology of acquired melanocytic nevi. A brief review. Gallagher RP, et al. **Dermatol Clin** 1995 Jul; 13(3):595-603 (49 ref.)

The epidemiology of skin cancer. Gloster HM Jr, et al. **Dermatol Surg** 1996 Mar;22(3):217-26 (159 ref.)

Primary gastric T-cell lymphoma with cutaneous involvement. A case report and review of the literature. Naghavi R, et al. **J Clin Gastroenterol** 1995 Dec;21(4):312-6 (17 ref.)

The epidemiology of non-melanoma skin cancer: who, why and what can we do about it. Marks R. **J Dermatol** 1995 Nov;22(11):853-7 (27 ref.)

Familial cutaneous melanoma. Lucchina LC, et al. **Melanoma Res** 1995 Dec;5(6):413-8 (29 ref.)

Risk factors for basal cell carcinoma: a case-control study. Maia M, et al. **Rev Saude Publica** 1995 Feb;29(1):27-37 (35 ref.)

[Are skin tumors on the increase?] Böni R, et al. **Schweiz Med Wochenschr** 1995 Sep 2;125(35):1619-24 (50 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Charting a new course through the chaos of KS (Kaposi's sarcoma) [comment] Nickoloff BJ, et al. **Am J Pathol** 1996 May;148(5):1323-9 (82 ref.) Comment on: Am J Pathol 1996 May;148(5):1387-96.

Low-grade dermal angiosarcoma of the breast following radiotherapy. Bolin DJ, et al. **Am Surg** 1996 Aug; 62(8):668-72 (19 ref.)

Sun exposure and skin disease. Taylor CR, et al. **Annu Rev Med** 1996;47:181–91 (40 ref.)

Prospectives for cutaneous malignant melanoma. Considerations of the precursor state and heritability. Clark WH, et al. **Br Med Bull** 1995 Jul;51(3):717–46 (104 ref.)

Transgenic approaches to the analysis of ras and p53 function in multistage carcinogenesis. Kemp CJ, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:427–34 (50 ref.)

Carcinogenesis of cutaneous malignancies. Buzzell RA. **Dermatol Surg** 1996 Mar;22(3):209–15 (103 ref.)

Porokeratosis and cutaneous malignancy. A review. Sasson M, et al. **Dermatol Surg** 1996 Apr;22(4):339–42 (30 ref.)

Squamous cell carcinoma complicating perianal hidradenitis suppurativa. Pérez-Diaz D, et al. **Int J Colorectal Dis** 1995; 10(4):225–8 (23 ref.)

Three cases of breast angiosarcomas after breast-conserving treatment for carcinoma [letter] Weber B, et al. **Radiother Oncol** 1995 Dec;37(3):250–2 (21 ref.)

Basal cell carcinoma due to radiotherapy for carcinoma of the cervix. Copas P, et al. **South Med J** 1995 Nov; 88(11):1161–2 (12 ref.)

[Ozone depletion--does the incidence of skin cancer increase? (editorial)] Jokela K, et al. **Duodecim** 1994; 110(19):1756–9 (20 ref.) **(Fin)**

[Eruptive nevus in the course of Lyell syndrome] Jullien D, et al. **Ann Dermatol Venereol** 1995;122(8):540–2 (14 ref.) (Eng. Abstr.) **(Fre)**

[Lymphomatoid papulosis] Dreno B. **Presse Med** 1995 Jun 24;24(23):1084–7 (13 ref.) (Eng. Abstr.) **(Fre)**

[Cancers of the skin, relations to ultraviolet rays] Robert C, et al. **Presse Med** 1995 Nov 11;24(34):1610–6 (33 ref.) (Eng. Abstr.) **(Fre)**

[Cutaneous photocarcinogenesis] Césarini JP. **Rev Med Interne** 1995;16 Suppl 3:344s–347s (28 ref.) **(Fre)**

GENETICS

Familial Kaposi's sarcoma: case reports and review of the literature. Cottoni E, et al. **Acta Derm Venereol** 1996 Jan; 76(1):59–61 (30 ref.)

Activated ras. Yet another player in melanoma? [comment] Herlyn M, et al. **Am J Pathol** 1996 Sep;149(3):739–44 (47 ref.) Comment on: Am J Pathol 1996 Sep;149(3):883–93.

Epidermodysplasia verruciformis as a model of human papillomavirus-induced genetic cancer of the skin. Majewski S, et al. **Arch Dermatol** 1995 Nov;131(11):1312–8 (62 ref.)

Transgenic mice and squamous multistage skin carcinogenesis. Brown K, et al. **Cancer Metastasis Rev** 1995 Jun;14(2):113–24 (112 ref.)

Recent advances in the molecular genetics of malignant melanoma. Haluska FG, et al. **Cancer Surv** 1995;25:277–92 (72 ref.)

T-cell receptor gene analysis in cutaneous T-cell lymphomas. Whittaker S. **Clin Exp Dermatol** 1996 Mar;21(2):81–7 (67 ref.)

Transgenic approaches to the analysis of ras and p53 function in multistage carcinogenesis. Kemp CJ, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:427–34 (50 ref.)

Genetic epidemiology of familial melanoma. Goldstein AM, et al. **Dermatol Clin** 1995 Jul;13(3):605–12 (68 ref.)

The CHILD nevus: a distinct skin disorder. Happle R, et al. **Dermatology** 1995;191(3):210–6 (64 ref.)

Familial cutaneous melanoma. Lucchina LC, et al. **Melanoma Res** 1995 Dec;5(6):413–8 (29 ref.)

Is human patched the gatekeeper of common skin cancers? [news; comment] Sidransky D. **Nat Genet** 1996 Sep; 14(1):7–8 (11 ref.) Comment on: Nat Genet 1996 Sep;14(1):78–81.

Uveal melanoma and familial atypical mole and melanoma (FAM-M) syndrome. Singh AD, et al. **Ophthalmic Genet** 1995 Jun;16(2):53–61 (32 ref.)

p53 gene mutations and photocarcinogenesis. Nataraj AJ, et al. **Photochem Photobiol** 1995 Aug;62(2):218–30 (140 ref.)

The Gorlin syndrome gene: a tumor suppressor active in basal cell carcinogenesis and embryonic development. Bale AE, et al. **Proc Assoc Am Physicians** 1995 Jul;107(2):253–7 (35 ref.)

Multistage skin carcinogenesis in transgenic mice. Greenhalgh DA, et al. **Proc Assoc Am Physicians** 1995 Jul;107(2):258–75 (112 ref.)

Genetic factors controlling responsiveness to skin tumor promotion in mice. DiGiovanni J. **Prog Clin Biol Res** 1995; 391:195–212 (61 ref.)

Cutaneous mosaicism. Savin JA. **QJM** 1996 Jul;89(7):489–91 (18 ref.)

[Multiple primary melanoma and familial melanoma. Risk evaluation and screening tests. How to evaluate the risk of developing a second melanoma? In what family? Should screening methods be implemented? Which ones and why?] Grange F. **Ann Dermatol Venereol** 1995;122(5):365–71 (50 ref.) **(Fre)**

[Transgenic mice as models for skin diseases (see comments)] Sellheyer K. **Hautarzt** 1995 Nov;46(11):755–61 (30 ref.) (Eng. Abstr.) Comment in: Hautarzt 1996 Jun;47(6):475–6. **(Ger)**

IMMUNOLOGY

Immunoregulatory events in the skin of patients with cutaneous T-cell lymphoma. Hansen ER. **Arch Dermatol** 1996 May;132(5):554–61 (107 ref.)

The immunopathogenesis of cutaneous T-cell lymphoma. Rook AH, et al. **Hematol Oncol Clin North Am** 1995 Oct; 9(5):997–1010 (51 ref.)

CD31 immunoreactivity in mesenchymal neoplasms of the skin and subcutis: report of 145 cases and review of putative immunohistologic markers of endothelial differentiation. DeYoung BR, et al. **J Cutan Pathol** 1995 Jun;22(3):215–22 (45 ref.)

[Future of malignant stage I melanoma. Immunology and immunotherapy] Nicolas JF, et al. **Ann Dermatol Venereol** 1995;122(5):324–35 (105 ref.) **(Fre)**

[Immunology of melanoma] Bröcker EB, et al. **Hautarzt** 1995 Nov;46(11):818–28 (20 ref.) **(Ger)**

[Adhesion molecules in dermato-oncology] Dommann SN. **Hautarzt** 1996 Mar;47(3):169–71 (16 ref.) (Eng. Abstr.) **(Ger)**

[Interleukin 7 in dermatology. Molecular, immunologic and preclinical aspects] Möller P, et al. **Hautarzt** 1995 Oct; 46(10):676–82 (84 ref.) (Eng. Abstr.) **(Ger)**

METABOLISM

Adhesion molecules in melanoma--more than just superglue? Mason MD, et al. **J R Soc Med** 1996 Jul;89(7):393–5 (13 ref.)

NURSING

Management of cutaneous symptoms. Gallagher J. **Semin Oncol Nurs** 1995 Nov;11(4):239–47 (63 ref.)

PATHOLOGY

Multinucleate cell angiohistiocytoma. A review and report of four cases. Cribier B, et al. **Acta Derm Venereol** 1995 Sep;75(5):337–9 (5 ref.)

Parenchymal-stromal interactions in neoplasia. Theoretical considerations and observations in melanocytic neoplasia. Clark WH Jr, et al. **Acta Oncol** 1995;34(6):749–57 (25 ref.)

Advances in the histologic diagnosis of cutaneous T-cell lymphoma. Shapiro PE. **Adv Dermatol** 1996;11:255–84; discussion 285 (53 ref.)

Spindle-cell lipoma of the skin. Duve S, et al. **Am J Dermatopathol** 1995 Oct;17(5):529–33 (24 ref.)

Rapidly progressive CD8-positive cutaneous T-cell lymphoma with tongue involvement. Quarterman MJ, et al. **Am J Dermatopathol** 1995 Jun;17(3):287–91 (31 ref.)

Clear cell dermatofibroma. Case report of an unusual fibrohistiocytic lesion. Zelger BW, et al. **Am J Surg Pathol** 1996 Apr;20(4):483–91 (23 ref.)

Extramammary Paget's disease: a report of three cases and review of the literature. Png JC, et al. **Ann Acad Med Singapore** 1995 Jul;24(4):636–9 (30 ref.)

Pathologic quiz case 1. Microcystic adnexal carcinoma (MAC). Hunt JT, et al. **Arch Otolaryngol Head Neck Surg** 1995 Dec;121(12):1430–3 (27 ref.)

Multiple cutaneous plexiform schwannomas. Report of a case and review of the literature with particular reference to the association with types 1 and 2 neurofibromatosis and schwannomatosis. Reith JD, et al. **Arch Pathol Lab Med** 1996 Apr;120(4):399–401 (22 ref.)

An update on pachydermodactyly and a report of three additional cases. Kopera D, et al. **Br J Dermatol** 1995 Sep; 133(3):433–7 (26 ref.)

Ectopic extramammary Paget's disease affecting the upper abdomen. Onishi Y, et al. **Br J Dermatol** 1996 May; 134(5):958–61 (18 ref.)

General lessons from cutaneous lymphoma [editorial] Slater DN. **Br J Hosp Med** 1995 Nov 1–14;54(9):426–8 (6 ref.)

Cutaneous melanoma: pathology, relevant prognostic indicators and progression. Slominski A, et al. **Br Med Bull** 1995 Jul;51(3):548–69 (76 ref.)

Porocarcinoma of the heel. A case report with unusual histologic features. D'Amato MS, et al. **Cancer** 1996 Aug 15;78(4):751–7 (27 ref.)

Role of integrins as signal transducing cell adhesion molecules in human cutaneous melanoma. Danen EH, et al. **Cancer Surv** 1995;24:43–65 (130 ref.)

Acquired tufted angioma frequently develops at sites other than the neck and upper trunk [letter] Ward KA, et al. **Clin Exp Dermatol** 1996 Jan;21(1):80 (8 ref.)

Leiomyosarcoma of the skin. Treatment of 34 cases. Bernstein SC, et al. **Dermatol Surg** 1996 Jul;22(7):631–5 (27 ref.)

The many faces of squamous cell carcinoma. Bernstein SC, et al. **Dermatol Surg** 1996 Mar;22(3):243–54 (99 ref.)

Metastasis. A primer for dermatologists. Brodland DG. **Dermatol Surg** 1996 Mar;22(3):228–33 (47 ref.)

Disseminated cutaneous Cryptococcus clinically mimicking basal cell carcinoma [letter] Murakawa GJ, et al. **Dermatol Surg** 1995 Nov;21(11):992–3 (8 ref.)

Malignant melanoma. Parker T, et al. **Dermatol Surg** 1996 Mar;22(3):234–40 (24 ref.)

Unusual cutaneous lymphomas. Perniciaro C. **Dermatol Surg** 1996 Mar;22(3):288–92 (21 ref.)

Basal cell carcinoma. Identification and treatment of the high-risk patient. Randle HW. **Dermatol Surg** 1996 Mar; 22(3):255–61 (44 ref.)

Stump the experts. Case. Granular-cell tumor [see comments] Skidmore RA, et al. **Dermatol Surg** 1995 Nov;21(11):925, 997–8 (17 ref.) Comment in: Dermatol Surg 1996 May;22(5):484.

Multiple malignant melanoma and squamous-cell carcinoma in a burn scar. Ikeda I, et al. **Dermatology** 1995; 191(4):328–32 (20 ref.)

Cellular neurothekeoma. Tomasini C, et al. **Dermatology** 1996;192(2):160–3 (15 ref.)

The role of clinical trials in assessing optimal treatment of cutaneous melanoma not extending beyond the regional nodes. Cascinelli N. **Eur J Surg Oncol** 1996 Apr;22(2):123–7 (49 ref.)

Pathology of cutaneous T-cell lymphoma. Burg G, et al. **Hematol Oncol Clin North Am** 1995 Oct;9(5):961–95 (80 ref.)

Prognosis and staging of cutaneous T-cell lymphoma. Foss FM, et al. **Hematol Oncol Clin North Am** 1995 Oct; 9(5):1011–9 (22 ref.)

Cutaneous ganglioneuromas: a case report and review of the literature. Hammond RR, et al. **Hum Pathol** 1996 Jul; 27(7):735–8 (13 ref.)

Linear basal cell carcinoma. da Silva MO, et al. **Int J Dermatol** 1995 Jul;34(7):488 (6 ref.)

Multiple tumors of the follicular infundibulum. Kolenik SA 3rd, et al. **Int J Dermatol** 1996 Apr;35(4):282–4 (11 ref.)

Metastatic merkel cell tumour to the bladder. Woo HH, et al. **Int Urol Nephrol** 1995;27(3):301–5 (13 ref.)

Perforating pilomatricoma. Alli N, et al. **J Am Acad Dermatol** 1996 Jul;35(1):116–8 (11 ref.)

Granulomatous slack skin: a possible precursor of Hodgkin's disease. DeGregorio R, et al. **J Am Acad Dermatol** 1995 Dec;33(6):1044–7 (22 ref.)

Widespread eruptive dermal and atypical melanocytic nevi in association with chronic myelocytic leukemia: case report and review of the literature. Richert S, et al. **J Am Acad Dermatol** 1996 Aug;35(2 Pt 2):326–9 (25 ref.)

Subcutaneous T-cell lymphoma with associated hemophagocytic syndrome and terminal leukemic transformation. Romero LS, et al. **J Am Acad Dermatol** 1996 May;34(5 Pt 2):904–10 (22 ref.)

Premalignant keratinocytic neoplasms. Schwartz RA. **J Am Acad Dermatol** 1996 Aug;35(2 Pt 1):223–42 (399 ref.)

Acquired multiple blue nevi on an extremity. Suchniak JM, et al. **J Am Acad Dermatol** 1995 Dec;33(6):1051–2 (10 ref.)

Neurotropic melanoma with prominent melanization. Barnhill RL, et al. **J Cutan Pathol** 1995 Oct;22(5):450–9 (44 ref.)

Approach to diagnostic image analysis of melanocytic tumors. Smolle J, et al. **J Cutan Pathol** 1995 Apr; 22(2):128–31 (25 ref.)

Desmoplastic melanoma of the hand: case reports and review of the literature. Chung KC, et al. **J Hand Surg [Am]** 1995 Sep;20(5):873–6 (10 ref.)

[When, how and which patients should be screened for second melanoma?] Dreno B. **Ann Dermatol Venereol** 1995; 122(5):310–4 (42 ref.) **(Fre)**

[Detection methods of local, regional and distant recurrences of melanoma] Sigal R. **Ann Dermatol Venereol** 1995; 122(5):279–84 (46 ref.) **(Fre)**

[What are the methods for the detection of recurrent melanoma? What is their value? Should they be implemented? Which ones and how often?] Truchetet F, et al. **Ann Dermatol Venereol** 1995;122(5):360–4 (27 ref.) **(Fre)**

[Primary cutaneous neuroendocrine carcinoma (Merkel tumor). Clinical and therapeutic update apropos of 4 cases] Bassereau G, et al. **Ann Otolaryngol Chir Cervicofac** 1995; 112(3):123–8 (39 ref.) (Eng. Abstr.) **(Fre)**

[Syringomatous carcinoma a propos of three cases with a review of the literature] Verdier-Sevrain S, et al. **Ann Pathol** 1995;15(4):280–4 (15 ref.) (Eng. Abstr.) **(Fre)**

[Melanoma developped on nevus of Ota without ocular melanosis. Apropos of an anatomo-clinical case] Reichert S, et al. **J Fr Ophtalmol** 1996;19(5):389–94 (23 ref.) (Eng. Abstr.) **(Fre)**

[Dendritic cells in dogs and cats: models of study in human pathology] Marchal T, et al. **Pathol Biol (Paris)** 1995 Dec; 43(10):910–20 (68 ref.) (Eng. Abstr.) **(Fre)**

[Extemporaneous histologic examination of cutaneous carcinoma of the face] Barrellier P, et al. **Rev Stomatol Chir Maxillofac** 1995;96(5):329–34 (20 ref.) (Eng. Abstr.) **(Fre)**

[Microcystic adnexal carcinoma of the skin. An underestimated tumor] Rank C, et al. **Hautarzt** 1996 Apr; 47(4):284–8 (31 ref.) (Eng. Abstr.) **(Ger)**

[Desmoplastic malignant melanoma. Clinical and histopathologic results of a study in 34 patients] Rütten A, et al. **Hautarzt** 1996 Jun;47(6):447–53 (41 ref.) (Eng. Abstr.) **(Ger)**

[Lymph node problem in cutaneous head and neck carcinomas] Spriano G, et al. **Acta Otorhinolaryngol Ital** 1995 Jun;15(3):159–62; discussion 163 (32 ref.) (Eng. Abstr.) **(Ita)**

[Blue nevus of the endocervix] Di Renzi F, et al. **Minerva Ginecol** 1995 Jul–Aug;47(7–8):331–4 (23 ref.) (Eng. Abstr.) **(Ita)**

[Reevaluation of precancerous lesions of the skin] Tsuchida T, et al. **Gan To Kagaku Ryoho** 1995 Dec;22(14):2062–6 (7 ref.) (Eng. Abstr.) **(Jpn)**

[Disseminated Kaposi's sarcoma with hepatosplenic involvement in AIDS] González-López A, et al. **Med Clin (Barc)** 1996 Apr 27;106(16):622–3 (15 ref.) (Eng. Abstr.) **(Spa)**

[Neurocutaneous syndromes with predominant vascular anomalies] Rodríguez-Barrionuevo AC. **Rev Neurol** 1996

Sep;24(133):1072–84 (121 ref.) **(Spa)**

PHYSIOPATHOLOGY

The paradoxical association of regression with a poor prognosis in melanoma contrasted with a good prognosis in keratoacanthoma. Prehn RT. **Cancer Res** 1996 Mar 1; 56(5):937–940 (43 ref.)

The role of growth factors in mouse skin tumor promotion and premalignant progression. Yuspa SH, et al. **Prog Clin Biol Res** 1995;391:39–48 (43 ref.)

PREVENTION & CONTROL

Prevention and early detection strategies for melanoma and skin cancer. Current status [editorial] Koh HK, et al. **Arch Dermatol** 1996 Apr;132(4):436–43 (88 ref.)

Melanoma prevention and early detection. MacKie RM. **Br Med Bull** 1995 Jul;51(3):570–83 (26 ref.)

Prevention and control of melanoma: the public health approach. Marks R. **CA Cancer J Clin** 1996 Jul–Aug; 46(4):199–216 (46 ref.)

Preventing skin cancer through behavior change. Implications for interventions. Rossi JS, et al. **Dermatol Clin** 1995 Jul;13(3):613–22 (103 ref.)

Risks and benefits of retinoids in the chemoprevention of cancer. de Palo G, et al. **Drug Saf** 1995 Oct;13(4):245–56 (80 ref.)

Controlled clinical trials with fenretinide in breast cancer, basal cell carcinoma and oral leukoplakia. De Palo G, et al. **J Cell Biochem Suppl** 1995;22:11–7 (16 ref.)

Screening for melanoma and options for its evaluation [see comment] Elwood JM. **J Med Screen** 1994 Jan;1(1):22–38 (83 ref.) Comment on: J Med Screen 1994 Jan;1(1):2.

Skin cancer screening. Brandt TP. **Med Clin North Am** 1996 Jan;80(1):99–114 (39 ref.)

DNA repair and cytokines in antimutagenesis and anticarcinogenesis. Yarosh DB, et al. **Mutat Res** 1996 Feb 19;350(1):255–60 (28 ref.)

RADIOTHERAPY

Ultraviolet radiation for treatment of cutaneous T-cell lymphoma. Herrmann JJ, et al. **Hematol Oncol Clin North Am** 1995 Oct;9(5):1077–88 (40 ref.)

Electron beam treatment for cutaneous T-cell lymphoma. Jones GW, et al. **Hematol Oncol Clin North Am** 1995 Oct; 9(5):1057–76 (44 ref.)

Cutaneous angiosarcoma arising in the radiation site of a congenital hemangioma. Caldwell JB, et al. **J Am Acad Dermatol** 1995 Nov;33(5 Pt 2):865–70 (50 ref.)

[Radiotherapy of cutaneous cervical-facial carcinomas] Tordiglione M, et al. **Acta Otorhinolaryngol Ital** 1995 Jun; 15(3):168–78; discussion 179 (18 ref.) (Eng. Abstr.) **(Ita)**

SECONDARY

Cutaneous metastasis from a parotid adenocarcinoma. Report of a case with immunohistochemical findings and review of the literature. Tok J, et al. **Am J Dermatopathol** 1995 Jun;17(3):303–6 (9 ref.)

The role of the integrin vitronectin receptor, alpha v beta 3 in melanoma metastasis. Nip J, et al. **Cancer Metastasis Rev** 1995 Sep;14(3):241–52 (101 ref.)

Skin metastases from a laryngeal carcinoma: report of a case. Debois JM. **Cutis** 1996 Apr;57(4):264–6 (14 ref.)

Cutaneous metastases from squamous cell carcinoma of the vulva. A case report and review of the literature. Tobias DH, et al. **Eur J Gynaecol Oncol** 1995;16(5):382–6 (8 ref.)

[Cutaneous metastases of melanoma localized on the cicatrix at the site of flap taking] Salmon-Ehr V, et al. **Ann Dermatol Venereol** 1996;123(3):194–5 (16 ref.) (Eng. Abstr.) **(Fre)**

[Skin metastases, unusual presentation of lung cancer] Jurado Gámez B, et al. **An Med Interna** 1995 Jul;12(7):346–8 (15 ref.) (Eng. Abstr.) **(Spa)**

[Retroperitoneal liposarcoma with lung, skin and pancreatic metastases] Alcalá Pedrajas JN, et al. **Arch Bronconeumol** 1996 Jun–Jul;32(6):313–5 (21 ref.) (Eng. Abstr.) **(Spa)**

[Skin metastasis from transitional cell carcinoma of the bladder] Alvarez Castelo LM, et al. **Arch Esp Urol** 1995 Sep;48(7):749–50 (9 ref.) (Eng. Abstr.) **(Spa)**

SURGERY

Management of patients with intermediate-thickness melanoma. Urist MM. **Annu Rev Med** 1996;47:211–7 (25 ref.)

A factual, not arbitrary, basis for choice of resection margins in melanoma. Piepkorn M, et al. **Arch Dermatol** 1996 Jul; 132(7):811–4 (50 ref.)

Cryosurgery of malignant and premalignant diseases of the skin: a simple approach. Sinclair RD, et al. **Australas J Dermatol** 1995 Aug;36(3):133–42 (60 ref.)

Surgical management of malignant melanoma. Ball AS, et al. **Br Med Bull** 1995 Jul;51(3):584–608 (117 ref.)

Surgical management of primary cutaneous melanoma. Urist MM. **CA Cancer J Clin** 1996 Jul–Aug;46(4):217–24 (40 ref.)

Surgical oncology and tumor immunology [editorial] Bland KI, et al. **Curr Opin Gen Surg** 1993;:299–302 (16 ref.)

The case for minimal margins and delayed regional node dissection for high-risk cutaneous melanoma. Cascinelli N, et al. **Curr Opin Gen Surg** 1993;:310–5 (31 ref.)

The case for wide local excision and regional node dissection for high-risk cutaneous melanoma. Karakousis CP. **Curr Opin Gen Surg** 1993;:303–9 (40 ref.)

A comparison between Mohs micrographic surgery and wide surgical excision for the treatment of dermatofibrosarcoma protuberans. Gloster HM Jr, et al. **J Am Acad Dermatol** 1996 Jul;35(1):82–7 (37 ref.)

Surgical management of melanoma. Whooley BP, et al. **Surg Oncol** 1995 Aug;4(4):187–95 (75 ref.)

[In a patient, surgically treated for isolated primary melanoma, what is the risk of recurrence? How to evaluate this risk?] Gautier MS. **Ann Dermatol Venereol** 1995; 122(5):336–48 (53 ref.) **(Fre)**

[Micrographic surgery. A current methodological assessment] Kopke LF, et al. **Hautarzt** 1995 Sep; 46(9):607–14 (52 ref.) (Eng. Abstr.) **(Ger)**

[Laser therapy of the skin] Hohenleutner U, et al. **HNO** 1995 Sep;43(9):557–71 (64 ref.) **(Ger)**

[Philosophy in reconstruction of the face] Faga A. **Acta Otorhinolaryngol Ital** 1995 Jun;15(3):164–6; discussion 167 (13 ref.) **(Ita)**

THERAPY

Treatment of Kaposi's sarcoma [editorial; comment] Tur E, et al. **Arch Dermatol** 1996 Mar;132(3):327–31 (57 ref.) Comment on: Arch Dermatol 1996 Mar;132(3):285–90.

Biological response modifiers in melanoma. Bridgewater JA, et al. **Br Med Bull** 1995 Jul;51(3):656–77 (88 ref.)

Vaccine therapy for malignant melanoma. Morton DL, et al. **CA Cancer J Clin** 1996 Jul–Aug;46(4):225–44 (80 ref.)

Basal cell carcinoma. Identification and treatment of the high-risk patient. Randle HW. **Dermatol Surg** 1996 Mar; 22(3):255–61 (44 ref.)

The role of clinical trials in assessing optimal treatment of cutaneous melanoma not extending beyond the regional nodes. Cascinelli N. **Eur J Surg Oncol** 1996 Apr;22(2):123–7 (49 ref.)

Open trials in cutaneous malignant melanoma. Rudenstam CM. **Eur J Surg Oncol** 1996 Apr;22(2):128–30 (8 ref.)

Melanoma: questions for the future. Thomas JM. **Eur J Surg Oncol** 1996 Apr;22(2):130–3 (28 ref.)

Experimental therapies in the treatment of cutaneous T-cell lymphoma. Foss FM, et al. **Hematol Oncol Clin North Am** 1995 Oct;9(5):1127–37 (47 ref.)

Interferon in the treatment of cutaneous T-cell lymphoma. Olsen EA, et al. **Hematol Oncol Clin North Am** 1995 Oct; 9(5):1089–107 (72 ref.)

Assessing clinical outcomes in cutaneous T-cell lymphoma. Zackheim HS, et al. **Hematol Oncol Clin North Am** 1995 Oct;9(5):1021–9 (9 ref.)

Favorable prognostic factors in recurrent and metastatic melanoma. Buzzell RA, et al. **J Am Acad Dermatol** 1996 May;34(5 Pt 1):798–803 (74 ref.)

Multimodal management of diffuse neonatal hemangiomatosis. Stratte EG, et al. **J Am Acad Dermatol** 1996 Feb;34(2 Pt 2):337–42 (36 ref.)

Systemic treatments for advanced cutaneous melanoma. Anderson CM, et al. **Oncology (Huntingt)** 1995 Nov; 9(11):1149–58; discussion 1163–4, 1167–8 (55 ref.)

[Consensus conference. Follow-up of patients surgically treated for stage I melanoma] **Ann Dermatol Venereol** 1995; 122(5):250–8 (13 ref.) **(Fre)**

[Are there specific follow-up modalities recommended in the treatment of stage I melanoma?] Fortier-Beaulieu M. **Ann Dermatol Venereol** 1995;122(5):372–7 (52 ref.) **(Fre)**

[After excision of primary stage I cutaneous melanoma, is an initial evaluation necessary?] Richard-Lallemand MA. **Ann Dermatol Venereol** 1995;122(5):349–59 (63 ref.) **(Fre)**

[What are expected improvements in the follow-up and treatment of stage I melanoma?] Thomas L. **Ann Dermatol Venereol** 1995;122(5):378–88 (243 ref.) **(Fre)**

ULTRASONOGRAPHY

[Ultrasound skin findings in HIV infection by imaging with 7.5 MHz linear transducers] Bogner JR, et al. **Bildgebung** 1995 Dec;62(4):281–6 (14 ref.) (Eng. Abstr.) **(Ger)**

VETERINARY

Green turtle fibropapillomatosis: challenges to assessing the role of environmental cofactors. Herbst LH, et al. **Environ Health Perspect** 1995 May;103 Suppl 4:27–30 (37 ref.)

Feline cutaneous and subcutaneous neoplasms. Fox LE. **Vet Clin North Am Small Anim Pract** 1995 Jul;25(4):961–79 (138 ref.)

VIROLOGY

No detection of HTLV-I proviral DNA in lesional skin biopsies from Swiss and German patients with cutaneous T-cell lymphoma. Böni R, et al. **Br J Dermatol** 1996 Feb; 134(2):282–4 (20 ref.)

SKIN PIGMENTATION

Prediction and non-invasive assessment of neonatal jaundice in the term healthy newborn infant. Knudsen A. **Acta Paediatr** 1996 Apr;85(4):393–7 (32 ref.)

PHYSIOLOGY

The physical basis of skin color and its evaluation. Kollias N. **Clin Dermatol** 1995 Jul–Aug;13(4):361–7 (19 ref.)

SKIN TESTS

[Cockroach allergy: a study of its prevalence using skin tests with commercial extracts] Cuesta C, et al. **Allergol Immunopathol (Madr)** 1995 Nov–Dec; 23(6):295–300 (34 ref.) (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Adverse reactions associated with skin testing and immunotherapy. Lockey RF. **Allergy Proc** 1995 Nov–Dec; 16(6):293–6 (11 ref.)

SKIN TRANSPLANTATION

see related
SURGICAL FLAPS

IMMUNOLOGY

The pharmacology of immunosuppressant drugs in skin transplant rejection in mice and other rodents. Gardner CR. **Gen Pharmacol** 1995 Mar;26(2):245–71 (217 ref.)

Overview of a 10-year experience on methods and compositions for inducing site-specific immunosuppression with topical immunosuppressants. Hewitt CW, et al. **Transplant Proc** 1996 Apr;28(2):922–3 (12 ref.)

INSTRUMENTATION

A review of skin meshers. Vandeput J, et al. **Burns** 1995 Aug;21(5):364–70 (21 ref.)

METHODS

Hypospadias repair: the two-stage alternative. Bracka A. **Br J Urol** 1995 Dec;76 Suppl 3:31–41 (13 ref.)

"Microleaps" in the progression of flaps and grafts. Hallock GG. **Clin Plast Surg** 1996 Jan;23(1):117–38 (87 ref.)

SKIN TUBERCULOSIS see TUBERCULOSIS, CUTANEOUS

SKIN ULCER

ETIOLOGY

[Ki-1 positive non-Hodgkin's lymphoma disclosed by mucocutaneous ulcerations and glomerulonephritis] Bellou A, et al. **Rev Med Interne** 1995;16(12):913–8 (26 ref.) (Eng. Abstr.) **(Fre)**

[Cutaneous ulcerations in sarcoidosis] de La Blanchardière A, et al. **Rev Med Interne** 1995;16(12):927–9 (14 ref.) (Eng. Abstr.) **(Fre)**

[Apical ulceration of the glans penis in hypervascularization syndrome. Sequelae of revascularization operation in erectile dysfunction] Hartwig R, et al. **Hautarzt** 1995 Nov; 46(11):808–10 (12 ref.) (Eng. Abstr.) **(Ger)**

MICROBIOLOGY

[Mycobacterium ulcerans cutaneous infections: Buruli ulcers] Josse R, et al. **Med Trop (Mars)** 1995;55(4):363–73 (114 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

[Multiple nodular ulcerated cutaneous lesions] de la Cruz Alvarez J, et al. **Rev Clin Esp** 1996 May;196(5):329–30 (6 ref.) **(Spa)**

SURGERY

Growth factors and comprehensive surgical care of diabetic wounds. Knighton DR, et al. **Curr Opin Gen Surg** 1993; :32–9 (42 ref.)

VETERINARY

Erosive and ulcerative skin disease. Angarano DW. **Vet Clin North Am Small Anim Pract** 1995 Jul;25(4):871–85 (35 ref.)

SKIN WRINKLING see SKIN AGING

SKINFOLD THICKNESS

[Skinfold thickness for analysis of body fat mass] Koda M, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:189–93 (21 ref.) **(Jpn)**

SKULL

see related
CEPHALOMETRY
CRANIOMETRY
CRANIOTOMY
INTRACRANIAL PRESSURE
TREPHINING

Pyoderma gangrenosum and cranial osteolysis: case report and review of the paediatric literature. Šamlaska CP, et

al. **Br J Dermatol** 1995 Dec;133(6):972–7 (61 ref.)
Skull osteomyelitis due to Salmonella species: two case reports and review. Kamarulzaman A, et al. **Clin Infect Dis** 1996 Apr;22(4):638–41 (27 ref.)

ABNORMALITIES

Abnormal craniofacial growth. Friede H. **Acta Odontol Scand** 1995 Jun;53(3):203–9 (53 ref.)
Midline craniofacial defects and morning glory disc anomaly. A distinct clinical entity. Leitch RJ, et al. **Acta Ophthalmol Scand Suppl** 1996;(219):16–9 (13 ref.)
Patient with craniosynostosis and marfanoid phenotype (Shprintzen–Goldberg syndrome) and cloverleaf skull. Saal HM, et al. **Am J Med Genet** 1995 Jul 17;57(4):573–8 (16 ref.)
Trisomy 1q42 –> qter in a sister and brother: further delineation of the "trisomy 1q42 –> qter syndrome". Verschuuren–Bemelmans CC, et al. **Am J Med Genet** 1995 Jul 31;58(1):83–6 (13 ref.)
Schinzel–Giedion syndrome: further delineation of the phenotype. Elliott AM, et al. **Clin Dysmorphol** 1996 Apr; 5(2):135–42 (18 ref.)
Molecular biology experimental strategies for craniofacial–oral–dental dysmorphology. Slavkin HC. **Connect Tissue Res** 1995;32(1–4):233–9 (62 ref.)
Ophthalmologic abnormalities in encephalocraniocutaneous lipomatosis. MacLaren MJ, et al. **Doc Ophthalmol** 1995; 90(1):87–98 (31 ref.)
Frontonasal dysplasia: analysis of 21 cases and literature review. Guion–Almeida ML, et al. **Int J Oral Maxillofac Surg** 1996 Apr;25(2):91–7 (62 ref.)
Anaesthesia and craniofacial surgery. Karapurkar SA, et al. **J Postgrad Med** 1994 Jan–Mar;40(1):3–6 (6 ref.)

ANATOMY & HISTOLOGY

Embryology and anatomy of the cranial base. Ricciardelli EJ. **Clin Plast Surg** 1995 Jul;22(3):361–72 (27 ref.)
[Cranial morphology of modern kyongsangnam-do Koreans] Takenaka M. **Kaibogaku Zasshi** 1995 Oct;70(5):419–21 (12 ref.) **(Jpn)**

EMBRYOLOGY

Human prenatal craniofacial development related to brain development under normal and pathologic conditions. Kjaer I. **Acta Odontol Scand** 1995 Jun;53(3):135–43 (69 ref.)
Prenatal craniofacial development: new insights on normal and abnormal mechanisms [corrected and republished article originally printed in Crit Rev Oral Biol Med 1995;6(1):25–79] Johnston MC, et al. **Crit Rev Oral Biol Med** 1995;6(4):368–422 (405 ref.)
Programmed cell death and cell transformation in craniofacial development. Shuler CF. **Crit Rev Oral Biol Med** 1995;6(3):202–17 (124 ref.)

GROWTH & DEVELOPMENT

Growth of the cranial vault: influence of intracranial and extracranial pressures. Huggare J, et al. **Acta Odontol Scand** 1995 Jun;53(3):192–5 (27 ref.)

PATHOLOGY

Base of skull, nasopharynx, and parapharyngeal space. Vogl TJ, et al. **Neuroimaging Clin N Am** 1996 May;6(2):357–78 (25 ref.)
[The magnetic resonance assessment of craniofacial fibrous dysplasia. The completion of the study with gadolinium administration and magnetic resonance angiography] Di Girolamo M, et al. **Radiol Med (Torino)** 1996 Mar; 91(3):313–6 (10 ref.) **(Ita)**

PHYSIOPATHOLOGY

Soft and hard tissue response to endosseous dental implants. Listgarten MA. **Anat Rec** 1996 Jun;245(2):410–25 (154 ref.)

RADIOGRAPHY

Diagnostic radiology of the cranial base. Abrahams JJ, et al. **Clin Plast Surg** 1995 Jul;22(3):373–405 (34 ref.)
Base of skull, nasopharynx, and parapharyngeal space. Vogl TJ, et al. **Neuroimaging Clin N Am** 1996 May;6(2):357–78 (25 ref.)

SURGERY

Some aspects of bone formation and remodeling pertinent to craniofacial development and reconstructive treatment. Vargervik K. **Acta Odontol Scand** 1995 Jun;53(3):167–73 (16 ref.)
Unilateral coronal synostosis (anterior plagiocephaly): current clinical perspectives. Posnick JC. **Ann Plast Surg** 1996 Apr;36(4):430–47 (97 ref.)
Posterior skull base transfacial approaches. Beals SP, et al. **Clin Plast Surg** 1995 Jul;22(3):491–511 (51 ref.)
Transorbital approaches to the cranial base. Bumpous J, et al. **Clin Plast Surg** 1995 Jul;22(3):461–81 (47 ref.)
Neurosurgical considerations of cranial base surgery. Chenelle AG, et al. **Clin Plast Surg** 1995 Jul;22(3):451–60 (13 ref.)
Transfacial approaches to the cranial base. Fearon JA, et al. **Clin Plast Surg** 1995 Jul;22(3):483–90 (20 ref.)
Soft tissue reconstructive choices for craniofacial reconstruction. Mustoe TA, et al. **Clin Plast Surg** 1995 Jul; 22(3):543–54 (41 ref.)
Complications of skull base surgery. Nguyen TT, et al. **Clin Plast Surg** 1995 Jul;22(3):573–80 (18 ref.)
Reconstruction of the cranial base. Spinelli HM, et al. **Clin Plast Surg** 1995 Jul;22(3):555–61 (30 ref.)
Skull base surgery: an emerging new specialty. Feghali JG. **J Med Liban** 1994;42(4):208–11 (4 ref.)
Anaesthesia and craniofacial surgery. Karapurkar SA, et al. **J Postgrad Med** 1994 Jan–Mar;40(1):3–6 (6 ref.)
Use of demineralized bone implants in orbital and craniofacial reconstruction and a review of the literature. Neigel JM, et al. **Ophthal Plast Reconstr Surg** 1996 Jun;12(2):108–20 (63 ref.)
[Advances in the understanding of the etiopathogenesis of non syndromic craniostenoses and therapeutic approaches] Czorny A, et al. **Ann Chir Plast Esthet** 1995 Dec; 40(6):657–65 (22 ref.) (Eng. Abstr.) **(Fre)**
[Craniofacial surgery] Lyberg T. **Tidsskr Nor Laegeforen** 1996 Jan 20;116(2):230–4 (22 ref.) (Eng. Abstr.) **(Nor)**
[Current principles of surgery of the base of the skull] Spallone A, et al. **Zh Vopr Neirokhir Im N N Burdenko** 1995 Oct–Dec; (4):31–3 (55 ref.) **(Rus)**

SKULL FRACTURES

DIAGNOSIS

Fracture of the occipital condyle: case report and review of the literature. Emery E, et al. **Eur Spine J** 1995; 4(3):191–3 (17 ref.)

ETIOLOGY

Spontaneous intrauterine linear skull fracture: a rare complication of spontaneous vaginal delivery. Heise RH, et al. **Obstet Gynecol** 1996 May;87(5 Pt 2):851–4 (15 ref.)

PHYSIOPATHOLOGY

An imaging-based computational and experimental study of skull fracture: finite element model development. Bandak FA, et al. **J Neurotrauma** 1995 Aug;12(4):679–88 (31 ref.)

RADIOGRAPHY

An imaging-based computational and experimental study of skull fracture: finite element model development. Bandak FA, et al. **J Neurotrauma** 1995 Aug;12(4):679–88 (31 ref.)

SURGERY

Acute traumatic posterior fossa subdural haematomas. Borzone M, et al. **Acta Neurochir (Wien)** 1995;135(1–2):32–7 (9 ref.)
Removal of asymptomatic bone plates used for orthognathic surgery and facial fractures. Alpert B, et al. **J Oral Maxillofac Surg** 1996 May;54(5):618–21 (41 ref.)
Retention of asymptomatic bone plates used for orthognathic surgery and facial fractures. Haug RH. **J Oral Maxillofac Surg** 1996 May;54(5):611–7 (90 ref.)

VETERINARY

Skull trauma and mandibular fractures. Smith MM, et al. **Vet Clin North Am Small Anim Pract** 1995 Sep; 25(5):1127–48 (47 ref.)

SKULL NEOPLASMS

Chondroid chordoma of the lateral skull base. Kaufman BA, et al. **Pediatr Neurosurg** 1995;23(3):159–65 (44 ref.)

CLASSIFICATION

Maxillofacial fibro-osseous lesions: classification and differential diagnosis. Slootweg PJ. **Semin Diagn Pathol** 1996 May;13(2):104–12 (22 ref.)

COMPLICATIONS

Concurrent osteochondroma of the mandibular condyle and ipsilateral cranial base resulting in temperomandibular joint ankylosis: report of a case and review of the literature. Karras SC, et al. **J Oral Maxillofac Surg** 1996 May; 54(5):640–6 (27 ref.)

DIAGNOSIS

Distinction of masses involving the sella and suprasellar space: specificity of imaging features. Donovan JL, et al. **AJR Am J Roentgenol** 1996 Sep;167(3):597–603 (69 ref.)
Gangliocytomas of the sellar region—a review. Puchner MJ, et al. **Exp Clin Endocrinol Diabetes** 1995;103(3):129–49 (115 ref.)
Base of skull, nasopharynx, and parapharyngeal space. Vogl TJ, et al. **Neuroimaging Clin N Am** 1996 May;6(2):357–78 (25 ref.)
Transcalvarial primary lymphoma of bone. A report of two cases. Paige ML, et al. **Neuroradiology** 1995 Aug; 37(6):456–8 (11 ref.)
Maxillofacial fibro-osseous lesions: classification and differential diagnosis. Slootweg PJ. **Semin Diagn Pathol** 1996 May;13(2):104–12 (22 ref.)
[Primary non-Hodgkin's lymphoma of the skull in an 11-year-old girl. Follow-up and review of the literature] Daldrup HE, et al. **Radiologe** 1996 Apr;36(4):354–9 (31 ref.) (Eng. Abstr.) **(Ger)**
[A case of cranial metastasis of hepatocellular carcinoma] Shibukawa M, et al. **No To Shinkei** 1995 Nov; 47(11):1087–91 (28 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Cartinoid tumor of the middle ear and mastoid. Himi T, et al. **Auris Nasus Larynx** 1995;22(2):128–33 (21 ref.)
Pathology of tumors of the cranial base. Ross DA, et al. **Clin Plast Surg** 1995 Jul;22(3):407–16 (43 ref.)
Primary non-Hodgkin's lymphoma of the temporal bone. Bockmühl U, et al. **Eur Arch Otorhinolaryngol** 1995; 252(6):376–8 (16 ref.)

RADIOGRAPHY

Imaging quiz case 2. Bilateral osteomas of the petrous temporal bones. Hamilton MM, et al. **Arch Otolaryngol Head Neck Surg** 1996 Jul;122(7):793, 795 (9 ref.)

SECONDARY

Medullary carcinoma of the thyroid metastatic to the temporal bone. Redleaf MI, et al. **J Laryngol Otol** 1995 Dec;109(12):1200–3 (15 ref.)
[En-plaque meningioma as a rare cause of an osteosclerotic bone tumor of the frontal bone] Steidle B, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1995 Oct;163(4):350–2 (10 ref.) **(Ger)**
[A rare case of cranial metastasis from hepatocellular carcinoma] Momoji J, et al. **No Shinkei Geka** 1995 Nov; 23(11):997–1002 (25 ref.) (Eng. Abstr.) **(Jpn)**

SURGERY

Dermoid cyst of the frontal bone away from the anterior fontanel. Fujimaki T, et al. **Childs Nerv Syst** 1995 Jul; 11(7):424–7 (19 ref.)
Neurofibromatosis of the skull base. Jackson IT. **Clin Plast Surg** 1995 Jul;22(3):513–30 (26 ref.)
Microsurgery for cranial base tumors. Thomson JG, et al. **Clin Plast Surg** 1995 Jul;22(3):563–72 (74 ref.)
[Long-term results of the surgical treatment of spheno-orbital osteomeningioma] Gaillard S, et al. **Neurochirurgie** 1995;41(6):391–7 (34 ref.) (Eng. Abstr.) **(Fre)**
[Chondrosarcoma of the skull base. Apropos of sphenotemporal localization and review of the literature] Roche PH, et al. **Neurochirurgie** 1995;41(5):353–8 (34 ref.) (Eng. Abstr.) **(Fre)**
[Craniofacial surgery] Lyberg T. **Tidsskr Nor Laegeforen** 1996 Jan 20;116(2):230–4 (22 ref.) (Eng. Abstr.) **(Nor)**

THERAPY

Gangliocytomas of the sellar region—a review. Puchner MJ, et al. **Exp Clin Endocrinol Diabetes** 1995;103(3):129–49 (115 ref.)
[Malignant tumors of the petrous bone. Apropos of 25 cases] Depondt J, et al. **Ann Otolaryngol Chir Cervicofac** 1995; 112(7):309–16 (11 ref.) (Eng. Abstr.) **(Fre)**

SLAUGHTERHOUSES see **ABATTOIRS**

SLEEP

see related
POLYSOMNOGRAPHY

Individual factors that influence sleep after cardiac surgery. Simpson T, et al. **Am J Crit Care** 1996 May;5(3):182–9; quiz 190–1 (31 ref.)
Influence of exercise on human sleep. O'Connor PJ, et al. **Exerc Sport Sci Rev** 1995;23:105–34 (187 ref.)
Nocturnal enuresis: a guide to evaluation and treatment. Tietjen DN, et al. **Mayo Clin Proc** 1996 Sep;71(9):857–62 (30 ref.)
A simple maneuver to provoke benign neonatal sleep myoclonus. Alfonso I, et al. **Pediatrics** 1995 Dec; 96(6):1161–3 (20 ref.)
[Position and sudden death of the infant (editorial)] Faure C. **Presse Med** 1995 Dec 16–23;24(39):1879–81 (14 ref.) (Eng. Abstr.) **(Fre)**

DRUG EFFECTS

Muramyl peptides and the functions of sleep. Brown R. **Behav Brain Res** 1995 Jul–Aug;69(1–2):85–90 (41 ref.)
Induction of sleep. Lemoine P, et al. **Sleep** 1996 Apr;19(3 Suppl):S1–6 (57 ref.)
[Sleep, depression and antidepressive treatments (2)] Arriaga F. **Acta Med Port** 1995 Mar;8(3):181–6 (73 ref.) (Eng. Abstr.) **(Por)**

IMMUNOLOGY

Sleep and the immune system. Moldofsky H. **Int J Immunopharmacol** 1995 Aug;17(8):649–54 (54 ref.)

PHYSIOLOGY

Evidence for a sleep-promoting influence of stress. Cespuglio R, et al. **Adv Neuroimmunol** 1995;5(2):145–54 (39 ref.)
The hypothalamic-pituitary-adrenocortical system and sleep in man. Friess E, et al. **Adv Neuroimmunol** 1995;5(2):111–25 (63 ref.)

Sleep regulation: interactions among cytokines and classical neurotransmitters. Grazia de Simoni M, et al. **Adv Neuroimmunol** 1995;5(2):189–200 (61 ref.)
Prostaglandins and sleep. Hayaishi O, et al. **Adv Neuroimmunol** 1995;5(2):211–6 (9 ref.)
Cytokines in sleep regulation. Krueger JM, et al. **Adv Neuroimmunol** 1995;5(2):171–88 (85 ref.)
Corticotropin–releasing hormone involvement in stressor–induced alterations in sleep and in the regulation of waking. Opp MR. **Adv Neuroimmunol** 1995;5(2):127–43 (100 ref.)
Influence of host defense activation on sleep in humans. Pollmächer T, et al. **Adv Neuroimmunol** 1995;5(2):155–69 (94 ref.)
Towards a molecular biology of the circadian clock and sleep of mammals. Shiromani PJ, et al. **Adv Neuroimmunol** 1995; 5(2):217–30 (89 ref.)
Energy conservation and sleep. Berger RJ, et al. **Behav Brain Res** 1995 Jul–Aug;69(1–2):65–73 (77 ref.)
Mind and consciousness during sleep. Bosinelli M. **Behav Brain Res** 1995 Jul–Aug;69(1–2):195–201 (53 ref.)
An integrative analysis to sleep functions. Cai ZJ. **Behav Brain Res** 1995 Jul–Aug;69(1–2):187–94 (95 ref.)
EEG slow waves and sleep spindles: windows on the sleeping brain. Dijk DJ. **Behav Brain Res** 1995 Jul–Aug; 69(1–2):109–16 (61 ref.)
The function of sleep is to regulate brain excitability in order to satisfy the requirements imposed by waking. Drucker–Colín R. **Behav Brain Res** 1995 Jul–Aug; 69(1–2):117–24 (18 ref.)
Possible mechanisms for reducing memory confusion during sleep. Gardner–Medwin AR, et al. **Behav Brain Res** 1995 Jul–Aug;69(1–2):167–75 (24 ref.)
The sequential hypothesis of the function of sleep. Giuditta A, et al. **Behav Brain Res** 1995 Jul–Aug;69(1–2):157–66 (91 ref.)
Sleep as neuronal detoxification and restitution. Inoué S, et al. **Behav Brain Res** 1995 Jul–Aug;69(1–2):91–6 (64 ref.)
Brain organization and sleep function. Krueger JM, et al. **Behav Brain Res** 1995 Jul–Aug;69(1–2):177–85 (44 ref.)
One possible function of sleep: to produce dreams. Mancia M. **Behav Brain Res** 1995 Jul–Aug;69(1–2):203–6 (22 ref.)
Sleep function(s) and cerebral metabolism. Maquet P. **Behav Brain Res** 1995 Jul–Aug;69(1–2):75–83 (79 ref.)
The function of sleep. Comments on the symposium and an attempt at synthesis. Moorcroft WH. **Behav Brain Res** 1995 Jul–Aug;69(1–2):207–10 (27 ref.)
Sleep for development or development for waking?—some speculations from a human perspective. Salzarulo P, et al. **Behav Brain Res** 1995 Jul–Aug;69(1–2):23–7 (32 ref.)
Sleep states and memory processes. Smith C. **Behav Brain Res** 1995 Jul–Aug;69(1–2):137–45 (82 ref.)
Is sleep fundamentally different between mammalian species? Tobler I. **Behav Brain Res** 1995 Jul–Aug;69(1–2):35–41 (55 ref.)
Sleep research in depressive illness: clinical implications—a tasting menu. Kupfer DJ. **Biol Psychiatry** 1995 Sep 15; 38(6):391–403 (38 ref.)
Neural networks. Sleep and memory. Sejnowski TJ. **Curr Biol** 1995 Aug 1;5(8):832–4 (14 ref.)
Obstructive lung disease and sleep. Jokic R, et al. **Med Clin North Am** 1996 Jul;80(4):821–50 (210 ref.)
Sleep, microbes and cytokines. Krueger JM, et al. **Neuroimmunomodulation** 1994 Mar–Apr;1(2):100–9 (121 ref.)
Neuronal activities underlying the electroencephalogram and evoked potentials of sleeping and waking: implications for information processing. Coenen AM. **Neurosci Biobehav Rev** 1995 Fall;19(3):447–63 (75 ref.)
Changes in circadian rhythms and sleep quality with aging: mechanisms and interventions. Myers BL, et al. **Neurosci Biobehav Rev** 1995 Winter;19(4):553–71 (318 ref.)
Effects of traffic noise on sleep: a review. Kawada T. **Nippon Eiseigaku Zasshi** 1995 Dec;50(5):932–8 (44 ref.)
Brain cooling across wake–sleep behavioral states in homeothermic species: an analysis of the underlying physiological mechanisms. Parmeggiani PL. **Rev Neurosci** 1995 Oct–Dec;6(4):353–63 (36 ref.)
Magnocellular nuclei of the basal forebrain: substrates of sleep and arousal regulation. Szymusiak R. **Sleep** 1995 Jul; 18(6):478–500 (181 ref.)
[Light therapy can restore a disturbed sleep/wake rhythm in dementia: but what is the basis of its efficacy?] Beullens J. **Tijdschr Gerontol Geriatr** 1995 Dec;26(6):264–9 (40 ref.) (Eng. Abstr.) **(Dut)**
[Sleep and intra–ictal epileptic electroencephalographic activities] Autret A. **Neurophysiol Clin** 1995;25(5):263–82 (111 ref.) (Eng. Abstr.) **(Fre)**
[Normal and pathological aspects of respiration during sleep] Duron B. **Rev Med Interne** 1996;17 Suppl 1:11S–14S (20 ref.) **(Fre)**
[Physiology and pathophysiology of sleep] Steiger A. **Schweiz Med Wochenschr** 1995 Dec 2;125(48):2338–45 (38 ref.) (Eng. Abstr.) **(Ger)**
[Relationship between sleeping position and sudden infant death syndrome] Eidelman A, et al. **Harefuah** 1995 Sep; 129(5–6):197–200 (38 ref.) **(Heb)**
[Sleep as an indicator of functional deviations in the body (based on materials of the XII Congress of the European Society of Sleep Research. May 22–27, 1994, Florence, Italy)] Kalshnikova EO. **Fiziol Cheloveka** 1996 Mar–Apr; 22(2):124–31 (61 ref.) **(Rus)**
[Neurological studies of sleep] Bové A. **Rev Neurol** 1995 Mar–Apr;23(120):318–9 (27 ref.) **(Spa)**

SLEEP APNEA SYNDROMES

Sleep apnea: is your patient at risk? National Heart, Lung, and Blood Institute Working Group on Sleep Apnea. **Am Fam Physician** 1996 Jan;53(1):247–53 (36 ref.)
Recognition of obstructive sleep apnea. Strohl KP, et al. **Am J Respir Crit Care Med** 1996 Aug;154(2 Pt 1):279–89 (182 ref.)
Central sleep apnoea, pathogenesis and treatment: an overview and perspective. De Backer WA. **Eur Respir J** 1995 Aug;8(8):1372–83 (119 ref.)
Manifestations and consequences of obstructive sleep apnoea. Peter JH, et al. **Eur Respir J** 1995 Sep;8(9):1572–83 (85 ref.)
Sleep apnea: underdiagnosed and undertreated. Phillips B. **Hosp Pract (Off Ed)** 1996 Mar 15;31(3):193–4,197,201–2 passim (10 ref.)
Emerging issues in sleep–disordered breathing. Olson LG, et al. **Med J Aust** 1996 Jul 15;165(2):107–10 (21 ref.)

COMPLICATIONS

Is obstructive sleep apnea a common cause of essential hypertension? [see comments] Silverberg DS, et al. **Isr J Med Sci** 1995 Sep;31(9):527–35 (87 ref.) Comment in: Isr J Med Sci 1995 Sep;31(9):561–2.
Hirschsprung's disease associated with Ondine's curse: a special subgroup? Nakahara S, et al. **J Pediatr Surg** 1995 Oct;30(10):1481–4 (23 ref.)
Sleep–related breathing disorders. 4. Consequences of sleep disordered breathing. Ferguson KA, et al. **Thorax** 1995 Sep; 50(9):998–1004 (108 ref.)
[Obstructive sleep apnea syndrome and cardiovascular diseases] Théolade R, et al. **Ann Cardiol Angeiol (Paris)** 1995 Nov;44(9):507–16 (63 ref.) (Eng. Abstr.) **(Fre)**
[Bradycardia in sleep–related respiratory disorders. Clinical relevance, pathogenesis and therapy] Koehler U, et al. **Dtsch Med Wochenschr** 1995 Oct 6;120(40):1369–73 (26 ref.) **(Ger)**
[Sleep apnea and cardiovascular risk] Schäfer H, et al. **Z Kardiol** 1995 Nov;84(11):871–84 (112 ref.) (Eng. Abstr.) **(Ger)**

DIAGNOSIS

Obstructive sleep apnea in infants and young children. Ward SL, et al. **J Clin Neurophysiol** 1996 May;13(3):198–207 (40 ref.)
Obstructive sleep apnea. Diagnosis and treatment. Man GC. **Med Clin North Am** 1996 Jul;80(4):803–20 (80 ref.)
Is sleep apnea syndrome in the elderly a specific entity? Lévy P, et al. **Sleep** 1996 Apr;19(3 Suppl):S29–38 (78 ref.)
Sleep–related breathing disorder . 3. How to reach a diagnosis in patients who may have the sleep apnoea/hypopnoea syndrome. Douglas NJ. **Thorax** 1995 Aug;50(8):883–6 (20 ref.)
Sleep–related breathing disorders. 6. Obstructive sleep apnoea syndrome in infants and children: established facts and unsettled issues. Gaultier C. **Thorax** 1995 Nov; 50(11):1204–10 (101 ref.)
[Sleep apnea syndrome and snoring: the ENT approach] Pasche P, et al. **Rev Med Suisse Romande** 1996 Feb; 116(2):89–100 (28 ref.) **(Fre)**
[Sleep apnea and chronic obstructive respiratory tract disease (COPD): diagnostic and therapeutic consequences] Schäfer H, et al. **Pneumologie** 1996 Apr;50(4):278–85 (73 ref.) **(Ger)**
[Diagnosis of obstructive sleep apnea syndrome. Consensus report from the Respiratory Insufficiency and Sleep Disorders Group] Barbé F, et al. **Arch Bronconeumol** 1995 Nov;31(9):460–2 (20 ref.) **(Spa)**

ETIOLOGY

Obstructive sleep apnea syndrome in children: an overview. Boudewyns AN, et al. **Acta Otorhinolaryngol Belg** 1995; 49(3):275–9 (15 ref.)
Upper airway shape: Is it important in the pathogenesis of obstructive sleep apnea? Leiter JC. **Am J Respir Crit Care Med** 1996 Mar;153(3):894–8 (38 ref.)
The laboratory assessment of daytime sleepiness in childhood. Kotagal S, et al. **J Clin Neurophysiol** 1996 May; 13(3):208–18 (50 ref.)
Massive osteolysis of the mandible with subsequent obstructive sleep apnea syndrome: a case report. Kayada Y, et al. **J Oral Maxillofac Surg** 1995 Dec;53(12):1463–5 (14 ref.)
Sleep apnoea and sympathetic nervous system activity: a review. Coy TV, et al. **J Sleep Res** 1996 Mar;5(1):42–50 (80 ref.)
Nocturnal hypoxaemia in patients with chronic obstructive pulmonary disease: who should be treated and how? Heijdra YF, et al. **Neth J Med** 1995 Dec;47(6):296–301 (30 ref.)
Chronic alveolar hypoventilation: a review for the clinician. Martin TJ, et al. **Sleep** 1995 Oct;18(8):617–34 (253 ref.)
[Medical ENT diagnosis and therapy of sleep–associated respiratory disorders with obstruction of the upper airways] Riechelmann H, et al. **Pneumologie** 1995 Oct;49(10):523–7 (33 ref.) **(Ger)**
[Iatrogenic respiratory and sleep disorders and snoring] Gugger M. **Schweiz Med Wochenschr** 1996 Apr 13; 126(15):632–6 (15 ref.) (Eng. Abstr.) **(Ger)**
[Respiratory function disturbance in obesity.] Taguchi O. **Nippon Rinsho** 1995 Jun;53 Suppl:343–8 (20 ref.) **(Jpa)**

PHYSIOPATHOLOGY

Sleep disorders. Bootzin RR, et al. **Compr Ther** 1995 Aug; 21(8):401–6 (16 ref.)
Pathophysiology of obstructive sleep apnoea [see comments] Deegan PC, et al. **Eur Respir J** 1995 Jul;8(7):1161–78 (215 ref.) Comment in: Eur Respir J 1995 Jul;8(7):1071–2.
Sleep–related breathing disorder.2. Pathophysiology of obstructive sleep apnoea. White DP. **Thorax** 1995 Jul; 50(7):797–804 (52 ref.)
[Cardiovascular effects of obstructive sleep apnea syndrome] Chen E, et al. **Chung Hua Nei Ko Tsa Chih** 1995 Jun; 34(6):420–2 (20 ref.) **(Chi)**
[Sleep–related apnea disorders and associated cardiovascular diseases] Konermann M, et al. **Med Klin** 1995 Aug 15; 90(8):480–5 (60 ref.) **(Ger)**
[Sleep apnea syndrome, arterial hypertension and cardiovascular risks] Russi EW, et al. **Schweiz Med Wochenschr** 1995 Nov 25;125(47):2267–72 (36 ref.) (Eng. Abstr.) **(Ger)**
[Snoring—a sociocultural phenomenon with medical significance (editorial)] Häusler R. **Schweiz Rundsch Med Prax** 1996 May 21;85(21):678–83 (39 ref.) **(Ger)**

SURGERY

Surgical management of obstructive sleep apnea. Tiner BD. **J Oral Maxillofac Surg** 1996 Sep;54(9):1109–14 (36 ref.)
Methodological and statistical problems in sleep apnea research: the literature on uvulopalatopharyngoplasty. Schechtman KB, et al. **Sleep** 1995 Oct;18(8):659–66 (44 ref.)
[Surgical treatment of obstructive sleep apnea by maxillary and mandibular osteotomy] Hochban W, et al. **Fortschr Kiefer Gesichtschir** 1995;40:65–72 (28 ref.) **(Ger)**
[The surgical treatment of obstructive sleep apnea syndrome] Cimino A, et al. **Acta Otorhinolaryngol Ital** 1995 Apr;15(2 Suppl 47):3–14 (58 ref.) (Eng. Abstr.) **(Ita)**

THERAPY

Treatment of obstructive sleep apnea. A review. Hudgel DW. **Chest** 1996 May;109(5):1346–58 (131 ref.)
Treatment of obstructive sleep apnea: the role of nasal continuous positive airway pressure. Patel SR, et al. **Cleve Clin J Med** 1996 Jan–Feb;63(1):12–5 (29 ref.)
Management of sleep apnoea syndrome. Liistro G, et al. **Eur Respir J** 1995 Oct;8(10):1751–5 (38 ref.)
Nonsurgical management of the obstructive sleep apnea patient. Thornton WK, et al. **J Oral Maxillofac Surg** 1996 Sep;54(9):1103–8 (29 ref.)
Obstructive sleep apnea. Diagnosis and treatment. Man GC. **Med Clin North Am** 1996 Jul;80(4):803–20 (80 ref.)
Obstructive sleep apnea. Strollo PJ Jr, et al. **N Engl J Med** 1996 Jan 11;334(2):99–104 (55 ref.)
Nocturnal hypoxaemia in patients with chronic obstructive pulmonary disease: who should be treated and how? Heijdra YF, et al. **Neth J Med** 1995 Dec;47(6):296–301 (30 ref.)
Oral appliances for the treatment of snoring and obstructive sleep apnea: a review. Schmidt–Nowara W, et al. **Sleep** 1995 Jul;18(6):501–10 (61 ref.)
Sleep–related breathing disorders. 5. Nasal continuous positive airway pressure treatment for obstructive sleep apnoea. Grunstein RR. **Thorax** 1995 Oct;50(10):1106–13 (56 ref.)
[Treatment of obstructive sleep apnea syndrome] Roche N, et al. **Ann Med Interne (Paris)** 1996;147(3):151–60 (109 ref.) (Eng. Abstr.) **(Fre)**
[Medical treatment of sleep apnea syndrome] Besse F. **Rev Med Suisse Romande** 1996 Feb;116(2):101–5 (17 ref.) **(Fre)**
[Sleep apnea syndrome and snoring: the ENT approach] Pasche P, et al. **Rev Med Suisse Romande** 1996 Feb; 116(2):89–100 (28 ref.) **(Fre)**

SLEEP DEPRIVATION

[Activated mechanisms of epilepsy during sleep and wakefulness] Arroyo Serrano S. **Rev Neurol** 1995 Nov–Dec;23(124):1280–3 (39 ref.) **(Spa)**
[Sleep and deprivation in the epilepsy diagnostic] Madoz P. **Rev Neurol** 1995 Nov–Dec;23(124):1271–9 (84 ref.) **(Spa)**

PHYSIOLOGY

Sleep deprivation and human immune function. Dinges DF, et al. **Adv Neuroimmunol** 1995;5(2):97–110 (34 ref.)
Functional consequences of sustained sleep deprivation in the rat. Everson CA. **Behav Brain Res** 1995 Jul–Aug; 69(1–2):43–54 (84 ref.)
Sleep deprivation in the rat by the disk–over–water method. Rechtschaffen A, et al. **Behav Brain Res** 1995 Jul–Aug; 69(1–2):55–63 (43 ref.)
[Humoral aspects of sleep deprivation] Ebert D, et al. **Fortschr Neurol Psychiatr** 1995 Nov;63(11):441–50 (60 ref.) (Eng. Abstr.) **(Ger)**

SLEEP DISORDERS

Sleep disturbances and exercise. Driver S, et al. **Sports Med** 1996 Jan;21(1):1-6 (36 ref.)
[Sleep disorders] Shiozawa Z. **Nippon Naika Gakkai Zasshi** 1995 Sep 10;84(9):1422-8 (20 ref.) **(Jpn)**

COMPLICATIONS

[Sleep disorders and their impact on society] Balan S. **Harefuah** 1995 Sep;129(5-6):204-6 (31 ref.) **(Heb)**

DIAGNOSIS

Office management of common neurologic problems. Moe PG. **Compr Ther** 1995 Sep;21(9):513-8 (16 ref.)
Diagnostic testing. Sleep disorders. Mahowald MW. **Neurol Clin** 1996 Feb;14(1):183-200 (86 ref.)
[Neurological studies of sleep] Bové A. **Rev Neurol** 1995 Mar-Apr;23(120):318-9 (27 ref.) **(Spa)**

DRUG THERAPY

Assessing the residual effects of hypnotics. Hindmarch I, et al. **Acta Psychiatr Belg** 1994 Mar-Apr;94(2):88-95 (24 ref.)
[Sleep disorders--diagnosis and treatment. Recommendations of the German Society of Sleep Research and Sleep Medicine] Bornkessel B. **Med Monatsschr Pharm** 1996 Apr; 19(4):106-9 (0 ref.) **(Ger)**
[Therapy of jet lag] Samel A, et al. **Wien Med Wochenschr** 1995;145(17-18):458-60 (21 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Individual factors that influence sleep after cardiac surgery. Simpson T, et al. **Am J Crit Care** 1996 May;5(3):182-9; quiz 190-1 (31 ref.)
Postoperative sleep disturbances: mechanisms and clinical implications. Rosenberg-Adamsen S, et al. **Br J Anaesth** 1996 Apr;76(4):552-9 (71 ref.)
The laboratory assessment of daytime sleepiness in childhood. Kotagal S, et al. **J Clin Neurophysiol** 1996 May; 13(3):208-18 (50 ref.)
Sleep-related breathing disorders. 7. Sleep and breathing problems in general medicine. Calverley PM. **Thorax** 1995 Dec;50(12):1311-6 (98 ref.)
[L-dopa-responsive dystonia: 2 familial cases of adult onset with sleep disorders] el Alaoui-Faris M, et al. **Rev Neurol (Paris)** 1995 May;151(5):347-9 (10 ref.) (Eng. Abstr.) **(Fre)**
[Sleep disorders in neurologic diseases] Schilling F. **Z Arztl Fortbild (Jena)** 1996 Apr;90(2):131-7 (46 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Sleep and the temporal lobe. Van Sweden B. **Acta Neurol Belg** 1996 Mar;96(1):19-30 (20 ref.)
Physiology of REM sleep, cataplexy, and sleep paralysis. Hishikawa Y, et al. **Adv Neurol** 1995;67:245-71 (125 ref.)
Studies of sleep in fibromyalgia; techniques, clinical significance, and future directions [editorial] Smythe HA. **Br J Rheumatol** 1995 Oct;34(10):897-9 (13 ref.)
Sleep disorders. Bootzin RR, et al. **Compr Ther** 1995 Aug; 21(8):401-6 (16 ref.)
Circadian rhythm sleep disorders: a brief review with special reference to long-term follow-up. Ohta T. **Nagoya J Med Sci** 1995 Dec;58(3-4):83-93 (30 ref.)
[Physiology and pathophysiology of sleep] Steiger A. **Schweiz Med Wochenschr** 1995 Dec 2;125(48):2338-45 (38 ref.) (Eng. Abstr.) **(Ger)**
[Chronobiological health of the circadian system: examples for disorders of the sleep-waking rhythm] Moog R. **Wien Med Wochenschr** 1995;145(17-18):452-3 (18 ref.) (Eng. Abstr.) **(Ger)**
[Cardiac diseases and sleep related breathing disorders] Shpirer I, et al. **Harefuah** 1996 Apr 15;130(8):551-4 (44 ref.) **(Heb)**

PSYCHOLOGY

Sleep research in depressive illness: clinical implications--a tasting menu. Kupfer DJ. **Biol Psychiatry** 1995 Sep 15; 38(6):391-403 (38 ref.)
Sleep-related spells associated with parasomnias and narcolepsy. Aldrich MS. **Semin Neurol** 1995 Jun; 15(2):194-202 (37 ref.)

REHABILITATION

Influence of exercise on human sleep. O'Connor PJ, et al. **Exerc Sport Sci Rev** 1995;23:105-34 (187 ref.)

THERAPY

Treatment of delayed sleep phase syndrome. Regestein QR, et al. **Gen Hosp Psychiatry** 1995 Sep;17(5):335-45 (69 ref.)
[Phytopharmaceutic drugs in treatment of sleep disorders] Nachtmann A, et al. **Internist (Berl)** 1996 Jul;37(7):743-9 (50 ref.) **(Ger)**
[Disorders of the circadian sleep-wake rhythm--diagnostic and therapeutic principles] Mayer G, et al. **Wien Med Wochenschr** 1995;145(17-18):423-30 (38 ref.) (Eng. Abstr.) **(Ger)**

SLEEP, REM

Interaction between sleep and growth hormone. Evaluated by manual polysomnography and automatic power spectrum analysis. Ström C. **Acta Neurol Scand** 1995 Oct; 92(4):281-96 (103 ref.)
Sleep-related violence: a medical and forensic challenge. Broughton RJ, et al. **Sleep** 1995 Nov;18(9):727-30 (42 ref.)
Forensic sleep medicine and nocturnal wandering. Guilleminault C, et al. **Sleep** 1995 Nov;18(9):721-3 (15 ref.)
Complex motor behavior arising during the sleep period: forensic science implications. Mahowald MW, et al. **Sleep** 1995 Nov;18(9):724-7 (26 ref.)
[Paradoxical sleep and memory processes in humans] Guerrien A. **Acta Psychiatr Belg** 1994 Mar-Apr;94(2):75-87 (43 ref.) (Eng. Abstr.) **(Fre)**
[Infantile epilepsy and sleep] Prats Viñas JM. **Rev Neurol** 1995 Nov-Dec;23(124):1284-6 (32 ref.) **(Spa)**

DRUG EFFECTS

[Interaction of sleep, epilepsy and antiepileptic drugs in an adult] Salas Puig J. **Rev Neurol** 1995 Nov-Dec; 23(124):1287-9 (10 ref.) **(Spa)**

PHYSIOLOGY

Physiology of REM sleep, cataplexy, and sleep paralysis. Hishikawa Y, et al. **Adv Neurol** 1995;67:245-71 (125 ref.)
REM sleep and neural nets. Crick F, et al. **Behav Brain Res** 1995 Jul-Aug;69(1-2):147-55 (17 ref.)
Observations on delta homeostasis, the one-stimulus model of NREM-REM alternation and the neurobiologic implications of experimental dream studies. Feinberg I, et al. **Behav Brain Res** 1995 Jul-Aug;69(1-2):97-108 (56 ref.)
Processing of learned information in paradoxical sleep: relevance for memory. Hennevin E, et al. **Behav Brain Res** 1995 Jul-Aug;69(1-2):125-35 (97 ref.)
A functional role for REM sleep in brain maturation. Marks GA, et al. **Behav Brain Res** 1995 Jul-Aug;69(1-2):1-11 (71 ref.)
The function of fetal/neonatal rapid eye movement sleep. Mirmiran M. **Behav Brain Res** 1995 Jul-Aug;69(1-2):13-22 (64 ref.)
Phylogeny and the function of REM sleep. Siegel JM. **Behav Brain Res** 1995 Jul-Aug;69(1-2):29-34 (42 ref.)
Serotonin receptors and their function in sleep, anxiety disorders and depression. Leonard BE. **Psychother Psychosom** 1996 Mar-Apr;65(2):66-75 (75 ref.)
Localized and lateralized cerebral glucose metabolism associated with eye movements during REM sleep and wakefulness: a positron emission tomography (PET) study. Hong CC, et al. **Sleep** 1995 Sep;18(7):570-80 (71 ref.)
Prolactin and rapid eye movement sleep regulation. Roky R, et al. **Sleep** 1995 Sep;18(7):536-42 (96 ref.)

SLEEP STAGES

Sleep stages, memory and learning. Dotto L. **Can Med Assoc J** 1996 Apr 15;154(8):1193-6 (12 ref.)
Treatment of delayed sleep phase syndrome. Regestein QR, et al. **Gen Hosp Psychiatry** 1995 Sep;17(5):335-45 (69 ref.)
[Shift work systems from the chronobiological viewpoint] Knauth P. **Wien Med Wochenschr** 1995;145(17-18):406-10 (31 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Normal sleep architecture in infants and children. Kahn A, et al. **J Clin Neurophysiol** 1996 May;13(3):184-97 (100 ref.)
Conscious and pre-conscious processes as seen from the standpoint of sleep-waking cycle neurophysiology. Paré D, et al. **Neuropsychologia** 1995 Sep;33(9):1155-68 (98 ref.)
[Ontogenesis of sleep-wakefulness regulation] Hinckel P, et al. **Psychother Psychosom Med Psychol** 1995 Nov; 45(11):367-72 (27 ref.) (Eng. Abstr.) **(Ger)**
[Concepts and models of sleep regulation] Achermann P, et al. **Wien Med Wochenschr** 1995;145(17-18):402-6 (40 ref.) (Eng. Abstr.) **(Ger)**
[Chronobiology of depression] Giedke H. **Wien Med Wochenschr** 1995;145(17-18):411-8 (108 ref.) (Eng. Abstr.) **(Ger)**
[Chronobiological health of the circadian system: examples for disorders of the sleep-waking rhythm] Moog R. **Wien Med Wochenschr** 1995;145(17-18):452-3 (18 ref.) (Eng. Abstr.) **(Ger)**
[The development of the active sleep phase in phylogeny and ontogeny] Aristakesian EA, et al. **Zh Evol Biokhim Fiziol** 1995 May-Jun;31(3):346-65 (85 ref.) **(Rus)**

SLEEP TERROR DISORDER see **SLEEP DISORDERS**

SLEEPWALKING see **SOMNAMBULISM**

SLIME BACTERIA see **MYXOCOCCALES**

SLIPPED DISK see **INTERVERTEBRAL DISK DISPLACEMENT**

SLOW ALPHA 2-MACROGLOBULINS see **ALPHA-MACROGLOBULINS**

SLOW-REACTING SUBSTANCES see **AUTACOIDS**

SLOW VIRUS DISEASES

see related
PRION DISEASES

SLUDGE see **SEWAGE**

SLUDGE, BILIARY see **BILE**

SLUMS see **POVERTY AREAS**

SMALL NUCLEAR RIBONUCLEOPROTEINS see **RIBONUCLEOPROTEINS, SMALL NUCLEAR**

SMALL NUCLEAR RIBONUCLEOPROTEINS, U3 see **RIBONUCLEOPROTEINS, SMALL NUCLEAR**

SMALL NUCLEAR RIBONUCLEOPROTEINS, U4 see **RIBONUCLEOPROTEINS, SMALL, U4-U6**

SMALL NUCLEAR RIBONUCLEOPROTEINS, U4-U6 see **RIBONUCLEOPROTEINS, SMALL, U4-U6**

SMALL NUCLEAR RIBONUCLEOPROTEINS, U6 see **RIBONUCLEOPROTEINS, SMALL, U4-U6**

SMALL NUCLEAR RIBONUCLEOPROTEINS, U7 see **RIBONUCLEOPROTEINS, SMALL NUCLEAR**

SMALL NUCLEAR RNA see **RNA, SMALL NUCLEAR**

SMALLPOX VIRUS see **VARIOLA VIRUS**

SMELL

see related
ANOSMIA
ODORS

Recent advances in the neuropsychology of human olfaction and anosmia. Sullivan TE, et al. **Brain Inj** 1995 Aug-Sep; 9(6):641-6 (22 ref.)
Contribution of activity coefficients of methylene homologues to odor and flavor detection thresholds. Yamanaka T. **Chem Senses** 1995 Aug;20(4):471-5 (19 ref.)
Phosphoinositide second messengers in olfaction. Bruch RC. **Comp Biochem Physiol B Biochem Mol Biol** 1996 Mar; 113(3):451-9 (95 ref.)

DRUG EFFECTS

The sweet, sweet smell of diacetyl. Smith DP. **Neuron** 1996 Mar;16(3):469-71 (15 ref.)

GENETICS

Molecular genetics of mammalian olfaction. Breer H, et al. **Behav Genet** 1996 May;26(3):209-19 (55 ref.)
The genetics of olfaction. Griff IC, et al. **Curr Opin Genet Dev** 1995 Oct;5(5):657-61 (49 ref.)
Spatial patterning and information coding in the olfactory system. Sullivan SL, et al. **Curr Opin Genet Dev** 1995 Aug; 5(4):516-23 (66 ref.)
The genetics of olfaction. Griff IC, et al. **Curr Opin Neurobiol** 1995 Aug;5(4):456-60 (49 ref.)

PHYSIOLOGY

Proteins that smell: pheromone recognition and signal transduction. Prestwich GD. **Bioorg Med Chem** 1996 Mar; 4(3):505-13 (55 ref.)
The olfactory and visual systems are closely related in Drosophila. Gaines P, et al. **Braz J Med Biol Res** 1995 Feb;28(2):161-7 (27 ref.)
Memory mechanisms. Photographic memory in flies. Goda Y. **Curr Biol** 1995 Aug 1;5(8):852-3 (11 ref.)
Dual second-messenger pathways in olfactory transduction. Ache BW, et al. **Curr Opin Neurobiol** 1995 Aug;5(4):461-6 (48 ref.)
Olfactory learning. Keverne EB. **Curr Opin Neurobiol** 1995 Aug;5(4):482-8 (34 ref.)
Odor images and tunes. Laurent G. **Neuron** 1996 Mar; 16(3):473-6 (25 ref.)
Regulation of nutrient intake in humans: a theory based on taste and smell. Poothullil JM. **Neurosci Biobehav Rev** 1995 Fall;19(3):407-12 (61 ref.)
Hyperolfaction and hyperemesis gravidarum: what is the relationship? Erick M. **Nutr Rev** 1995 Oct;53(10):289-95 (75 ref.)
The molecular logic of smell. Axel R. **Sci Am** 1995 Oct; 273(4):154-9 (5 ref.)
Second-order neurones and receptor mechanisms in visual- and olfactory-information processing. Nakanishi S. **Trends Neurosci** 1995 Aug;18(8):359-64 (50 ref.)
[The power of odors--pathogenic or unpleasant] Glück U. **Schweiz Med Wochenschr** 1996 Jun 1;126(22):958-66 (55 ref.) (Eng. Abstr.) **(Ger)**

SMOG

ADVERSE EFFECTS

Effects of smog on absenteeism in forestry workers. Moll Van Charante AW, et al. **Arch Environ Health** 1996 Jan-Feb;51(1):34-41 (39 ref.)

SMOKELESS TOBACCO see TOBACCO, SMOKELESS

SMOKING

see related
TOBACCO USE DISORDER

Cigarette smoking and clinically significant drug interactions. Schein JR. **Ann Pharmacother** 1995 Nov;29(11):1139–48 (88 ref.)

Beneficial effects of nicotine and cigarette smoking: the real, the possible and the spurious. Baron JA. **Br Med Bull** 1996 Jan;52(1):58–73 (135 ref.)

[Cigarette smoking in diabetes] Gefel D, et al. **Harefuah** 1996 Jan 1;130(1):37–40 (40 ref.) **(Heb)**

[Connection between smoking and reduced risk of ulcerative colitis. Does nicotine mediate a protective effect?] Nilsson A. **Lakartidningen** 1995 Dec 13;92(50):4788–92 (20 ref.) **(Swe)**

ADVERSE EFFECTS

Hemodynamic and vascular effects of active and passive smoking. Zhu BQ, et al. **Am Heart J** 1995 Dec; 130(6):1270–5 (80 ref.)

Nicotine addiction and treatment. Rose JE. **Annu Rev Med** 1996;47:493–507 (111 ref.)

Smoking and other health related behaviour in the social and environmental context. Logan S, et al. **Arch Dis Child** 1996 Feb;74(2):176–9 (46 ref.)

Children and smoking: the family circle. Charlton A. **Br Med Bull** 1996 Jan;52(1):90–107 (83 ref.)

Cancers weakly related to smoking. Doll R. **Br Med Bull** 1996 Jan;52(1):35–49 (63 ref.)

Product modification. Waller RE, et al. **Br Med Bull** 1996 Jan;52(1):193–205 (38 ref.)

The fetus as a passive smoker. Koren G. **Can Fam Physician** 1996 Jul;42:1301–3 (15 ref.)

Passive and active smoking. A problem for adults [editorial; comment] Glantz SA, et al. **Circulation** 1996 Aug 15; 94(4):596–8 (38 ref.) Comment on: Circulation 1996 Aug 15;94(4):614–21. Comment on: Circulation 1996 Aug 15;94(4):622–8.

Epidemiology of cancer by tobacco products and the significance of TSNA. Gupta PC, et al. **Crit Rev Toxicol** 1996;26(2):183–98 (81 ref.)

Recent studies on mechanisms of bioactivation and detoxification of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), a tobacco-specific lung carcinogen. Hecht SS. **Crit Rev Toxicol** 1996;26(2):163–81 (83 ref.)

The biological significance of tobacco-specific N-nitrosamines: smoking and adenocarcinoma of the lung. Hoffmann D, et al. **Crit Rev Toxicol** 1996;26(2):199–211 (76 ref.)

Endogenous formation of nitrosamines and oxidative DNA-damaging agents in tobacco users. Nair J, et al. **Crit Rev Toxicol** 1996;26(2):149–61 (55 ref.)

Tobacco use and its contribution to early cancer mortality with a special emphasis on cigarette smoking. Shopland DR. **Environ Health Perspect** 1995 Nov;103 Suppl 8:131–42 (77 ref.)

Cigarette smoking and the thyroid. Bartalena L, et al. **Eur J Endocrinol** 1995 Nov;133(5):507–12 (57 ref.)

Cutaneous manifestations and consequences of smoking. Smith JB, et al. **J Am Acad Dermatol** 1996 May;34(5 Pt 1):717–32; quiz 733–4 (311 ref.)

Haemorheological consequences of chronic cigarette smoking. Ernst E. **J Cardiovasc Risk** 1995 Oct;2(5):435–9 (70 ref.)

N-acetylcysteine (NAC) and glutathione (GSH): antioxidant and chemopreventive properties, with special reference to lung cancer. van Zandwijk N. **J Cell Biochem Suppl** 1995; 22:24–32 (48 ref.)

Smoking and low back pain: is the association real? Leboeuf-Yde C, et al. **J Manipulative Physiol Ther** 1995 Sep;18(7):457–63 (24 ref.)

Tobacco use and the periodontal patient. **J Periodontol** 1996 Jan;67(1):51–6 (97 ref.)

Cigarette smoking and cardiovascular disease. Jeremy JY, et al. **J R Soc Health** 1995 Oct;115(5):289–95 (62 ref.)

Cigarette smoking and health of the heart. Leone A. **J R Soc Health** 1995 Dec;115(6):354–5 (13 ref.)

Reduction of tobacco health hazards in continuing users: individual behavioral and public health approaches. Kozlowski LT. **J Subst Abuse** 1989;1(3):345–57 (50 ref.)

Stress, smoking, and the cardiovascular system. Pomerleau OF, et al. **J Subst Abuse** 1989;1(3):331–43 (50 ref.)

The adverse effects of tobacco smoking on reproduction and health: a review from the literature. Tuormaa TE. **Nutr Health** 1995;10(2):105–20 (155 ref.)

Lung cancer and CYP2D6 (the debrisoquine polymorphism): sources of heterogeneity in the proposed association. Caporaso N, et al. **Pharmacogenetics** 1995;5 Spec No:S129–34 (44 ref.)

Cardiovascular risk-factor reduction in elderly patients with cardiac disease. Williams MA. **Phys Ther** 1996 May; 76(5):469–80 (103 ref.)

Smoking and cardiovascular disease. Yarnell JW. **QJM** 1996 Jul;89(7):493–8 (83 ref.)

What causes cancer? Trichopoulos D, et al. **Sci Am** 1996 Sep;275(3):80–7 (0 ref.)

Dietary fish oil and airways obstruction. Britton J. **Thorax** 1995 Sep;50 Suppl 1:S11–5 (28 ref.)

[Is smoking during pregnancy a cause of premature delivery?] Wisborg K, et al. **Ugeskr Laeger** 1995 Nov 27; 157(48):6707–12 (32 ref.) (Eng. Abstr.) **(Dan)**

[Effect of smoking on the fetus and the child during pregnancy] Gueguen C, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(8):853–9 (63 ref.) (Eng. Abstr.) **(Fre)**

[Neuroleptics and nicotine] Erdmann R. **Psychiatr Prax** 1995 Nov;22(6):223–7 (34 ref.) (Eng. Abstr.) **(Ger)**

[Tumors as sequelae of smoking] Drings P. **Z Arztl Fortbild (Jena)** 1995 Oct;89(5):447–58 (69 ref.) (Eng. Abstr.) **(Ger)**

[Smoking and peripheral vascular disorders] Stammler F, et al. **Z Arztl Fortbild (Jena)** 1995 Oct;89(5):459–66 (12 ref.) (Eng. Abstr.) **(Ger)**

[Smoking and pregnancy] Wenderlein JM. **Z Arztl Fortbild (Jena)** 1995 Oct;89(5):467–71 (15 ref.) (Eng. Abstr.) **(Ger)**

[How does smoking affect blood pressure?] Omvik P. **Tidsskr Nor Laegeforen** 1996 Feb 20;116(5):621–4 (44 ref.) (Eng. Abstr.) **(Nor)**

[Increased activity of phagocytes in cigarette smokers—supposed connection with lung emphysema] Zięba M, et al. **Pneumonol Pol** 1990 Nov-Dec; 58(11-12):651–4 (23 ref.) **(Pol)**

[Toxic lesions of the optic nerve] Mozherenkov VP, et al. **Vestn Oftalmol** 1996 Jan-Mar;112(1):54–5 (32 ref.) **(Rus)**

[The pediatrician and cancer prevention. Dietetic factors and smoking] Ferris i Tortajada J, et al. **An Esp Pediatr** 1996 Jul;45(1):6–13 (51 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Pharmacological interventions for smoking cessation. Nardini S. **Monaldi Arch Chest Dis** 1996 Apr;51(2):161–3 (7 ref.)

EPIDEMIOLOGY

The changing epidemiology of smoking and lung cancer histology. Wynder EL, et al. **Environ Health Perspect** 1995 Nov;103 Suppl 8:143–8 (67 ref.)

Epidemiology of tobacco use and dependence. Giovino GA, et al. **Epidemiol Rev** 1995;17(1):48–65 (195 ref.)

Trends in smoking in Europe. Franceschi S, et al. **Eur J Cancer Prev** 1995 Aug;4(4):271–84 (9 ref.)

High-density lipoprotein-cholesterol: determining hygienic factors for intervention [published erratum appears in J Occup Environ Med 1995 Sep;37(9):1121] Anzalone DA, et al. **J Occup Environ Med** 1995 Jul;37(7):856–61 (32 ref.)

The role of UK tobacco advertising: no effect on the nation's health? Kinman BF, et al. **J R Soc Health** 1995 Oct; 115(5):296–302 (27 ref.)

The "protective" influence of cigarette smoking on Alzheimer's and Parkinson's diseases. Quagmire or opportunity for neuroepidemiology? Riggs JE. **Neurol Clin** 1996 May;14(2):353–8 (24 ref.)

[Depression and smoking] Aubin HJ, et al. **Encephale** 1996 Jan-Feb;22(1):17–22 (49 ref.) (Eng. Abstr.) **(Fre)**

[Tobacco and women] Jiménez Ruiz CA. **Arch Bronconeumol** 1996 May;32(5):242–50 (133 ref.) **(Spa)**

[Tobacco among young people (editorial)] Viejo Bañuelos JL. **Arch Bronconeumol** 1995 Dec;31(10):491–3 (24 ref.) **(Spa)**

[Evolution in consumption of and attitude towards tobacco towards physicians at the regional hospital "Reina Sofía," Córdoba] Mengual Luque P, et al. **Gac Sanit** 1996 Jan-Feb; 10(52):18–24 (32 ref.) (Eng. Abstr.) **(Spa)**

[Smoking in Santiago, 1993–94] Medina E, et al. **Rev Med Chil** 1995 May;123(5):652–8 (32 ref.) (Eng. Abstr.) **(Spa)**

HISTORY

Forty years on: a war to recognise and win. How the tobacco industry has survived the revelations on smoking and health. Pollock D. **Br Med Bull** 1996 Jan;52(1):174–82 (25 ref.)

IMMUNOLOGY

[The effect of smoking on the status of immunity and on antiprotease protection] Golub NI. **Ter Arkh** 1996; 68(1):64–7 (43 ref.) **(Rus)**

LEGISLATION & JURISPRUDENCE

Tobacco industry tactics. Sweda EL Jr, et al. **Br Med Bull** 1996 Jan;52(1):183–92 (23 ref.)

Maryland restricts workplace smoking. Patrick E. **Md Med J** 1995 Oct;44(10):800–4 (32 ref.)

METABOLISM

Smoking and plasma lipoprotein metabolism [editorial] Freeman DJ, et al. **Clin Sci (Colch)** 1995 Oct;89(4):333–42 (94 ref.)

PHYSIOPATHOLOGY

Hemodynamic and vascular effects of active and passive smoking. Zhu BQ, et al. **Am Heart J** 1995 Dec; 130(6):1270–5 (80 ref.)

Smoking and coronary artery disease. Tresch DD, et al. **Clin Geriatr Med** 1996 Feb;12(1):23–32 (58 ref.)

Sites, mechanisms, and structural characteristics of the brain's nicotine receptor. Abood LG, et al. **J Subst Abuse** 1989; 1(3):259–71 (50 ref.)

Differential effect of chronic nicotine treatment on nicotinic receptor numbers in various brain regions of mice. Collins AC, et al. **J Subst Abuse** 1989;1(3):273–86 (43 ref.)

Dose-related actions of nicotine on behavior and physiology: review and implications for replacement therapy for nicotine dependence. Henningfield JE, et al. **J Subst Abuse** 1989;1(3):301–17 (50 ref.)

[The effect of smoking and of smoking cessation on pathophysiological mechanisms of cardiovascular diseases] van den Berkmortel FW, et al. **Ned Tijdschr Geneeskd** 1996 Aug 24;140(34):1712–6 (47 ref.) **(Dut)**

PREVENTION & CONTROL

Smoking cessation interventions in chronic illness. Wewers ME, et al. **Annu Rev Nurs Res** 1996;14:75–93 (55 ref.)

Community-based approaches for the prevention of alcohol, tobacco, and other drug use. Aguirre-Molina M, et al. **Annu Rev Public Health** 1996;17:337–58 (121 ref.)

Tobacco control. Chapman S. **BMJ** 1996 Jul 13; 313(7049):97–100 (43 ref.)

Preventing children from smoking. How family physicians and pediatricians can help. Thomas RE, et al. **Can Fam Physician** 1995 Sep;41:1517–23 (50 ref.)

Maryland restricts workplace smoking. Patrick E. **Md Med J** 1995 Oct;44(10):800–4 (32 ref.)

Cancer prevention strategies for the future: risk identification and preventive intervention. Colditz GA, et al. **Milbank Q** 1995;73(4):621–51 (104 ref.)

Incorporating effective smoking prevention and cessation counseling into practice. Klein JD. **Pediatr Ann** 1995 Dec; 24(12):646–52 (31 ref.)

Young people and alcohol, drugs and tobacco. Anderson K. **WHO Reg Publ Eur Ser** 1995;66:1–83 (59 ref.)

[Patient counseling by the physician in smoking cessation—conditions and prerequisites] Stössel U. **Z Arztl Fortbild (Jena)** 1995 Oct;89(5):489–98 (40 ref.) (Eng. Abstr.) **(Ger)**

PSYCHOLOGY

Marketing adolescent tobacco addiction. Tye J, et al. **Md Med J** 1995 Oct;44(10):767–73 (29 ref.)

Non-pharmacological interventions for smoking cessation: their relative role in a stepwise approach. Nardini S. **Monaldi Arch Chest Dis** 1996 Apr;51(2):164–5 (9 ref.)

[Prevention of smoking from the psychological medicine perspective] Müller MJ, et al. **Z Arztl Fortbild (Jena)** 1995 Oct;89(5):473–88 (13 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

An analysis of the effectiveness of interventions intended to help people stop smoking. Law M, et al. **Arch Intern Med** 1995 Oct 9;155(18):1933–41 (131 ref.)

URINE

Optimization of the Salmonella/mammalian microsome assay for urine mutagenesis by experimental designs. De Méo M, et al. **Mutat Res** 1996 Jun;340(2-3):51–65 (50 ref.)

SMOKING CESSATION

Ondansetron use for smoking cessation. Cropp CD, et al. **Ann Pharmacother** 1995 Oct;29(10):1041–2 (9 ref.)

Nicotine addiction and treatment. Rose JE. **Annu Rev Med** 1996;47:493–507 (111 ref.)

Smoking cessation programmes targeted at black and minority ethnic communities. Farren C, et al. **Br J Cancer Suppl** 1996 Sep;29:S78–80 (17 ref.)

Is clonidine an effective smoking cessation therapy? Gourlay SG, et al. **Drugs** 1995 Aug;50(2):197–207 (83 ref.)

The Agency for Health Care Policy and Research Smoking Cessation Clinical Practice Guideline [see comments] **JAMA** 1996 Apr 24;275(16):1270–80 (68 ref.) Comment in: JAMA 1996 Aug 14;276(6):448.

Incorporating effective smoking prevention and cessation counseling into practice. Klein JD. **Pediatr Ann** 1995 Dec; 24(12):646–52 (31 ref.)

Smoking cessation: time for action. Jarvis MJ. **Thorax** 1995 Sep;50 Suppl 1:S22–4 (24 ref.)

[The effect of smoking and of smoking cessation on pathophysiological mechanisms of cardiovascular diseases] van den Berkmortel FW, et al. **Ned Tijdschr Geneeskd** 1996 Aug 24;140(34):1712–6 (47 ref.) **(Dut)**

[Patient counseling by the physician in smoking cessation—conditions and prerequisites] Stössel U. **Z Arztl Fortbild (Jena)** 1995 Oct;89(5):489–98 (40 ref.) (Eng. Abstr.) **(Ger)**

ECONOMICS

An analysis of the effectiveness of interventions intended to help people stop smoking. Law M, et al. **Arch Intern Med** 1995 Oct 9;155(18):1933–41 (131 ref.)

METHODS

Smoking cessation interventions in chronic illness. Wewers ME, et al. **Annu Rev Nurs Res** 1996;14:75–93 (55 ref.)

An analysis of the effectiveness of interventions intended to help people stop smoking. Law M, et al. **Arch Intern Med** 1995 Oct 9;155(18):1933–41 (131 ref.)

SMOKING CESSATION

Preventing children from smoking. How family physicians and pediatricians can help. Thomas RE, et al. **Can Fam Physician** 1995 Sep;41:1517–23 (50 ref.)
Advances in studies on acupuncture abstinence. Cui M. **J Tradit Chin Med** 1995 Dec;15(4):301–7, contd (32 ref.)
Advanced in studies on acupuncture abstinence. Cui M. **J Tradit Chin Med** 1996 Mar;16(1):65–9 concl (38 ref.)
Smoking cessation counseling in adults and children: the clinician's role. Adams JA. **Md Med J** 1995 Oct; 44(10):779–87 (26 ref.)
Pharmacological interventions for smoking cessation. Nardini S. **Monaldi Arch Chest Dis** 1996 Apr;51(2):161–3 (7 ref.)
Non-pharmacological interventions for smoking cessation: their relative role in a stepwise approach. Nardini S. **Monaldi Arch Chest Dis** 1996 Apr;51(2):164–5 (9 ref.)
Nicotine medications for smoking cessation. Henningfield JE. **N Engl J Med** 1995 Nov 2;333(18):1196–203 (101 ref.)
Tobacco use and cancer. A reappraisal. Vigneswaran N, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1995 Aug;80(2):178–82 (62 ref.)
Smoking cessation interventions for pregnant women: review and future directions. O'Campo P, et al. **Semin Perinatol** 1995 Aug;19(4):279–85 (37 ref.)
[Smoking cessation with the nicotine patch] Batra A, et al. **Z Arztl Fortbild (Jena)** 1995 Oct;89(5):505–9 (28 ref.) (Eng. Abstr.) **(Ger)**
[Smoking cessation with alternative methods] Stumpfe KD. **Z Arztl Fortbild (Jena)** 1995 Oct;89(5):511–4 (27 ref.) (Eng. Abstr.) **(Ger)**

PSYCHOLOGY

Smoking cessation leads to reduced stress, but why? Parrott AC. **Int J Addict** 1995 Sep;30(11):1509–16 (17 ref.)
Dose-related actions of nicotine on behavior and physiology: review and implications for replacement therapy for nicotine dependence. Henningfield JE, et al. **J Subst Abuse** 1989;1(3):301–17 (50 ref.)
[Prevention of smoking from the psychological medicine perspective] Müller MJ, et al. **Z Arztl Fortbild (Jena)** 1995 Oct;89(5):473–88 (13 ref.) (Eng. Abstr.) **(Ger)**

SMOKING, PASSIVE see **TOBACCO SMOKE POLLUTION**

SMOOTH MUSCLE TUMOR

PATHOLOGY

Smooth-muscle tumors of the vulva. A clinicopathological study of 25 cases and review of the literature. Nielsen GP, et al. **Am J Surg Pathol** 1996 Jul;20(7):779–93 (63 ref.)
Pathologic considerations of uterine smooth muscle tumors. Prayson RA, et al. **Obstet Gynecol Clin North Am** 1995 Dec;22(4):637–57 (69 ref.)

VETERINARY

Hypoglycemia in four dogs with smooth muscle tumors. Beaudry D, et al. **J Vet Intern Med** 1995 Nov–Dec; 9(6):415–8 (25 ref.)

SMS 201-995 see **OCTREOTIDE**

SNAILS

ANATOMY & HISTOLOGY

Identifiable Achatina giant neurones: their localizations in ganglia, axonal pathways and pharmacological features. Takeuchi H, et al. **Gen Pharmacol** 1996 Jan;27(1):3–32 (220 ref.)

PARASITOLOGY

Control and research on schistosomiasis in China. Chen M. **Chin Med J (Engl)** 1995 Sep;108(9):643–6 (9 ref.)

PHYSIOLOGY

Neural regeneration in gastropod molluscs. Moffett SB. **Prog Neurobiol** 1995 Jun;46(2–3):289–330 (275 ref.)

SNAKE BITES

see related
ANTIVENINS

DIAGNOSIS

The emerging syndrome of envenoming by the New Guinea small-eyed snake Micropechis ikaheka. Warrell DA, et al. **QJM** 1996 Jul;89(7):523–30 (19 ref.)

THERAPY

[Snake bites] Vincent JL, et al. **Rev Med Brux** 1995 Nov; 16(5):349–52 (12 ref.) (Eng. Abstr.) **(Fre)**

SNAKE ENVENOMATION see **SNAKE BITES**

SNAKE VENOMS

see related
ANTIVENINS

PHARMACOLOGY

Anticoagulant effects of Pseudechis australis (Australian king brown snake) venom on human blood: a computerized thromboelastography study. Dambisya YM, et al. **Toxicon** 1995 Oct;33(10):1378–82 (16 ref.)

SNAKES

see related
SNAKE BITES
SNAKE VENOMS

SNEDDON-CHAMPION SYNDROME see **SNEDDON SYNDROME**

SNEDDON SYNDROME

COMPLICATIONS

[Sneddon syndrome and mitral valve disease] Puisieux F, et al. **Ann Cardiol Angeiol (Paris)** 1996 Feb;45(2):64–7 (19 ref.) (Eng. Abstr.) **(Fre)**
[Ictus and cutaneous vascular syndromes] Trejo Gabriel y Galán JM. **Rev Neurol** 1995;23 Suppl 1:S99–105 (46 ref.) **(Spa)**

SNEDDON-WILKINSON DISEASE see **SKIN DISEASES, VESICULOBULLOUS**

SNORING

Snoring. Hoffstein V. **Chest** 1996 Jan;109(1):201–22 (176 ref.)

ETIOLOGY

[Iatrogenic respiratory and sleep disorders and snoring] Gugger M. **Schweiz Med Wochenschr** 1996 Apr 13; 126(15):632–6 (15 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Biomechanics of snoring. Huang L, et al. **Endeavour** 1995; 19(3):96–100 (10 ref.)
Snoring: a review and a reassessment. Cole P, et al. **J Otolaryngol** 1995 Oct;24(5):303–6 (18 ref.)
[Snoring—a sociocultural phenomenon with medical significance (editorial)] Häusler R. **Schweiz Rundsch Med Prax** 1996 May 21;85(21):678–83 (39 ref.) **(Ger)**

THERAPY

Oral appliances for the treatment of snoring and obstructive sleep apnea: a review. Schmidt-Nowara W, et al. **Sleep** 1995 Jul;18(6):501–10 (61 ref.)

SNRNP see **RIBONUCLEOPROTEINS, SMALL NUCLEAR**

U3 SNRNP see **RIBONUCLEOPROTEINS, SMALL NUCLEAR**

U4 SNRNP see **RIBONUCLEOPROTEINS, SMALL, U4-U6**

U4-U6 SNRNP see **RIBONUCLEOPROTEINS, SMALL, U4-U6**

U6 SNRNP see **RIBONUCLEOPROTEINS, SMALL, U4-U6**

U7 SNRNP see **RIBONUCLEOPROTEINS, SMALL NUCLEAR**

SNUFF see **TOBACCO, SMOKELESS**

SOCCER

INJURIES

Knee injury patterns among men and women in collegiate basketball and soccer. NCAA data and review of literature. Arendt E, et al. **Am J Sports Med** 1995 Nov–Dec; 23(6):694–701 (34 ref.)
[Acute isolated ventral dislocation of the head of the fibula] Kohler G, et al. **Unfallchirurg** 1996 Mar;99(3):221–2 (10 ref.) (Eng. Abstr.) **(Ger)**

SOCIAL ACCOUNTABILITY see **SOCIAL RESPONSIBILITY**

SOCIAL ADJUSTMENT

Stepfamilies and children's adjustment. Dunn J. **Arch Dis Child** 1995 Dec;73(6):487–9 (23 ref.)
Psychological and social aspects of burns. Partridge J, et al. **Burns** 1995 Sep;21(6):453–7 (22 ref.)
Psychological needs and the facilitation of integrative processes. Ryan RM. **J Pers** 1995 Sep;63(3):397–427 (115 ref.)
Psychosocial aspects of accidental injuries—an overview [see comments] Schnyder U, et al. **Langenbecks Arch Chir** 1996; 381(3):125–31 (67 ref.) Comment in: Langenbecks Arch Chir 1996;381(3):123–4.
Psychosocial burdens of dialysis treatment modalities: do they differ and does it matter? Reynolds JM, et al. **Perit Dial Int** 1996;16 Suppl 1:S548–50 (13 ref.)
The neurosociology of schizophrenia: vulnerability and functional disability. Carter M, et al. **Psychiatry** 1995 Aug; 58(3):209–24 (55 ref.)
Issues in personality as diathesis for depression: the case of sociotropy–dependency and autonomy–self-criticism. Coyne JC, et al. **Psychol Bull** 1995 Nov;118(3):358–78 (125 ref.)
The sociocognitive model of dissociative identity disorder: a reexamination of the evidence. Gleaves DH. **Psychol Bull** 1996 Jul;120(1):42–59 (150 ref.)
[25 years kidney replacement therapy in childhood and adolescence—success of somatic and psychosocial rehabilitation] Bulla M, et al. **Versicherungsmedizin** 1996 Jun 1;48(3):85–9 (56 ref.) (Eng. Abstr.) **(Ger)**
[Quality of attachment representation, social integration and use of social network resources in advanced age] Wensauer M, et al. **Z Gerontol Geriatr** 1995 Nov–Dec;28(6):444–56 (89 ref.) (Eng. Abstr.) **(Ger)**
[Methods of measurement of social adjustment in schizophrenia] Załuska M. **Psychiatr Pol** 1995 Sep–Oct; 29(5):631–40 (26 ref.) (Eng. Abstr.) **(Pol)**

SOCIAL BEHAVIOR

Evaluating psychotropic drugs in people with mental retardation: where are the social validity data? Poling A, et al. **Am J Ment Retard** 1995 Sep;100(2):193–200 (48 ref.)
Basic behavioral science research for mental health. Vulnerability and resilience. Basic Behavioral Science Task Force of the National Advisory Mental Health Council. **Am Psychol** 1996 Jan;51(1):22–8 (7 ref.)
Social and emotional self-regulation. Tucker DM, et al. **Ann N Y Acad Sci** 1995 Dec 15;769:213–39 (120 ref.)
The design and analysis of social-interaction research. Kenny DA. **Annu Rev Psychol** 1996;47:59–86 (40 ref.)
Links between growth hormone deficiency, adaptation and social phobia. Stabler B, et al. **Horm Res** 1996;45(1–2):30–3 (27 ref.)
Life event timing synchrony. Sorenson DL. **Image J Nurs Sch** 1995 Winter;27(4):297–300 (40 ref.)
Reformulation of deviance and labeling theory for nursing. Trexler JC. **Image J Nurs Sch** 1996 Summer;28(2):131–5 (39 ref.)
Brief report: developmental neurobiological aspects of autism. Voeller KK. **J Autism Dev Disord** 1996 Apr; 26(2):189–93 (9 ref.)
Causation and complexity: old lessons, new crusades [comment] Layng TV. **J Behav Ther Exp Psychiatry** 1995 Sep;26(3):249–58 (50 ref.) Comment on: J Behav Ther Exp Psychiatry 1995 Sep;26(3):179–90.
Behavioral and social consequences related to the consumption of different beverage types. Smart RG. **J Stud Alcohol** 1996 Jan;57(1):77–84 (60 ref.)
HIV risk in adolescents: the role of sexual activity and substance use behaviors. Boyer CB, et al. **NIDA Res Monogr** 1994;143:135–54 (51 ref.)
Ethical and legal issues in social network research: the real and the ideal. Woodhouse DE, et al. **NIDA Res Monogr** 1995;151:131–43 (11 ref.)
Social control of cell size: males and females are different. Fernald RD. **Prog Brain Res** 1995;105:171–7 (23 ref.)
Contingency detection and the contingent organization of behavior in interactions: implications for socioemotional development in infancy. Tarabulsy GM, et al. **Psychol Bull** 1996 Jul;120(1):25–41 (110 ref.)
Insight and psychosis: a social perspective. Johnson S, et al. **Psychol Med** 1995 May;25(3):515–20 (24 ref.)
The influence of hunting pressure on the social behavior of vertebrates. Verdade LM. **Rev Bras Biol** 1996 Feb; 56(1):1–13 (82 ref.)

SOCIAL BEHAVIOR DISORDERS

see related
ANTISOCIAL PERSONALITY DISORDER
In search of effective programs to address students' emotional distress and behavioral problems. Part I: Defining the problem. Wassef A, et al. **Adolescence** 1995 Fall; 30(119):523–38 (22 ref.)
Translating what we know about the context of antisocial behavior into a lower prevalence of such behavior. Biglan A. **J Appl Behav Anal** 1995 Winter;28(4):479–92 (90 ref.)

DRUG THERAPY

Diagnostic-based pharmacological treatment of behavior disorders in persons with developmental disabilities: a review and a decision-making typology. Sturmey P. **Res Dev Disabil** 1995 Jul–Aug;16(4):235–52 (45 ref.)

PSYCHOLOGY

Adolescent substance use disorder with conduct disorder and comorbid conditions. Crowley TJ, et al. **NIDA Res Monogr** 1995;156:49–111 (178 ref.)

REHABILITATION

Treatment methodology. Guiding of behaviour through redirection in brain injury rehabilitation. Yuen HK, et al. **Brain Inj** 1996 Mar;10(3):229–38 (15 ref.)

THERAPY

Physical restraint procedures for managing challenging behaviours presented by mentally retarded adults and children. Harris J. **Res Dev Disabil** 1996 Mar-Apr; 17(2):99-134 (52 ref.)

SOCIAL CHANGE

"Freedom's just another word": aboriginal youth and mental health. Hunter E. **Aust N Z J Psychiatry** 1995 Sep; 29(3):374-84 (64 ref.)

The irruption of new technologies: a new challenge for ergonomics and anthropotechnology. Wisner A. **J Hum Ergol (Tokyo)** 1995 Jun;24(1):45-55 (30 ref.)

[Does learning new knowledge and discarding old knowledge go too slowly?] Olesen F. **Nord Med** 1996 Apr; 111(4):119-22 (15 ref.) **(Dan)**

SOCIAL CLASS

Do socio-economic status, marital status and occupation influence the prevalence of Helicobacter pylori infection? Veldhuyzen van Zanten SJ. **Aliment Pharmacol Ther** 1995; 9 Suppl 2:41-4 (35 ref.)

Race, class, and environmental health: a review and systematization of the literature. Brown P. **Environ Res** 1995 Apr;69(1):15-30 (53 ref.)

Psychosocial factors and quality of life in obesity. Sarlio-Lähteenkorva S, et al. **Int J Obes Relat Metab Disord** 1995 Nov;19 Suppl 6:S1-5 (49 ref.)

Socio-economic aspects of obesity: causes or effects? Sørensen TI. **Int J Obes Relat Metab Disord** 1995 Nov; 19 Suppl 6:S6-8 (16 ref.)

The influence of social class on health status: American and British research on health inequalities. Fein O. **J Gen Intern Med** 1995 Oct;10(10):577-86 (69 ref.)

Social causes of low birth weight. Kogan MD. **J R Soc Med** 1995 Nov;88(11):611-5 (78 ref.)

Practice-building seminars in chiropractic: a Petit Bourgeois response to biomedical domination. Baer HA. **Med Anthropol Q** 1996 Mar;10(1):29-44 (45 ref.)

An update on incidence of FAS: FAS is not an equal opportunity birth defect. Abel EL. **Neurotoxicol Teratol** 1995 Jul-Aug;17(4):437-43 (80 ref.)

Socioeconomic factors and the development of allergy. Strachan D. **Toxicol Lett** 1996 Aug;86(2-3):199-203 (33 ref.)

[A brief review of the debate over social inequalities in health] Doz JF, et al. **Aten Primaria** 1996 May 31; 17(9):585-9 (40 ref.) **(Spa)**

SOCIAL CLUBS, THERAPEUTIC see SELF-HELP GROUPS

SOCIAL CONDITIONS

Smoking and other health related behaviour in the social and environmental context. Logan S, et al. **Arch Dis Child** 1996 Feb;74(2):176-9 (46 ref.)

Community, family, and the social good: the psychological dynamics of procedural justice and social identification. Tyler TR, et al. **Nebr Symp Motiv** 1995;42:53-91 (100 ref.)

SOCIAL CONFORMITY

Cult membership as a source of self-cohesion: forensic implications. Feldmann TB, et al. **Bull Am Acad Psychiatry Law** 1995;23(2):239-48 (46 ref.)

SOCIAL CONTROL, FORMAL

Constructing the symbolic complainant: police subculture and the nonenforcement of protection orders for battered women. Rigakos GS. **Violence Vict** 1995 Fall;10(3):227-47 (50 ref.)

SOCIAL DESIRABILITY

Mechanisms related to psychological well-being in older women with chronic illnesses: age and disease comparisons. Heidrich SM. **Res Nurs Health** 1996 Jun;19(3):225-35 (47 ref.)

SOCIAL DISCRIMINATION see PREJUDICE

SOCIAL ENVIRONMENT

see related
LIFE STYLE

The social construction of the human brain. Eisenberg L. **Am J Psychiatry** 1995 Nov;152(11):1563-75 (163 ref.)

Origins and early development of perception, action, and representation. Bertenthal BI. **Annu Rev Psychol** 1996; 47:431-59 (150 ref.)

Environmental psychology 1989-1994. Sundstrom E, et al. **Annu Rev Psychol** 1996;47:485-512 (255 ref.)

Impact of the social environment on blood pressure in women. Wielgosz AT. **Can J Cardiol** 1996 Jun;12 Suppl D:13D-15D (10 ref.)

Antisocial personality disorder: a biopsychosocial model. Paris J. **Can J Psychiatry** 1996 Mar;41(2):75-80 (70 ref.)

Children of alcoholic parents. A review. Steinhausen HC. **Eur Child Adolesc Psychiatry** 1995 Jul;4(3):143-52 (55 ref.)

Settings as an important dimension in health education/promotion policy, programs, and research. Mullen PD, et al. **Health Educ Q** 1995 Aug;22(3):329-45 (101 ref.)

Music, noise, and the human voice in the nurse-patient environment. Pope DS. **Image J Nurs Sch** 1995 Winter; 27(4):291-6 (51 ref.)

Improving the transition from basic efficacy research to effectiveness studies: methodological issues and procedures. Clarke GN. **J Consult Clin Psychol** 1995 Oct;63(5):718-25 (50 ref.)

Issues in the transportability of treatment: the case of anxiety disorders in youths. Kendall PC, et al. **J Consult Clin Psychol** 1995 Oct;63(5):702-8 (60 ref.)

Bridging the gap between laboratory and clinic in child and adolescent psychotherapy. Weisz JR, et al. **J Consult Clin Psychol** 1995 Oct;63(5):688-701 (70 ref.)

Social conditions as fundamental causes of disease. Link BG, et al. **J Health Soc Behav** 1995;Spec No:80-94 (90 ref.)

Psychosocial/cultural issues in medicine and psychiatry: treating African Americans. Carter JH. **J Natl Med Assoc** 1995 Dec;87(12):857-60 (18 ref.)

Psychosocial factors and pregnancy outcome: a review with emphasis on methodological issues. Paarlberg KM, et al. **J Psychosom Res** 1995 Jul;39(5):563-95 (136 ref.)

The social and cultural context of menopause. Kaufert PA. **Maturitas** 1996 Mar;23(2):169-80 (49 ref.)

Growing up in a socially toxic environment: life for children and families in the 1990s. Garbarino J. **Nebr Symp Motiv** 1995;42:1-20 (37 ref.)

How can eating behavior be regulated in the complex environments of free-living humans? De Castro JM. **Neurosci Biobehav Rev** 1996;20(1):119-31 (34 ref.)

The sociocognitive model of dissociative identity disorder: a reexamination of the evidence. Gleaves DH. **Psychol Bull** 1996 Jul;120(1):42-59 (150 ref.)

Social influences on bipolar affective disorders. Ramana R, et al. **Soc Psychiatry Psychiatr Epidemiol** 1995 Jul; 30(4):152-60 (55 ref.)

Environmental and health-related quality of life: conceptual and methodological similarities. Rogerson RJ. **Soc Sci Med** 1995 Nov;41(10):1373-82 (80 ref.)

Explaining urban-rural variations in health: a review of interactions between individual and environment. Verheij RA. **Soc Sci Med** 1996 Mar;42(6):923-35 (73 ref.)

The household context for women's health care decisions: impacts of U.K. policy changes. Young R. **Soc Sci Med** 1996 Mar;42(6):949-63 (92 ref.)

[The effect of psychosocial factors in schizophrenia. Theoretical and practical-therapeutic consequences] Ciompi L. **Schweiz Arch Neurol Psychiatr** 1995; 146(5):207-14 (53 ref.) (Eng. Abstr.) **(Ger)**

[Stress in the evolution of societies: a means for survival] Sudakov KV. **Zh Evol Biokhim Fiziol** 1995 Jul-Aug; 31(4):489-99 (51 ref.) **(Rus)**

SOCIAL IDENTIFICATION

Cult membership as a source of self-cohesion: forensic implications. Feldmann TB, et al. **Bull Am Acad Psychiatry Law** 1995;23(2):239-48 (46 ref.)

Gay and lesbian identity development: a social identity perspective. Cox S, et al. **J Homosex** 1996;30(4):1-30 (54 ref.)

Community, family, and the social good: the psychological dynamics of procedural justice and social identification. Tyler TR, et al. **Nebr Symp Motiv** 1995;42:53-91 (100 ref.)

Anthropology, HIV and contingent identities. Gatter PN. **Soc Sci Med** 1995 Dec;41(11):1523-33 (71 ref.)

SOCIAL INSURANCE see SOCIAL SECURITY

SOCIAL INTERACTION see INTERPERSONAL RELATIONS

SOCIAL ISOLATION

PSYCHOLOGY

Review: diogenes syndrome. Cooney C, et al. **Age Ageing** 1995 Sep;24(5):451-3 (14 ref.)

SOCIAL JUSTICE

see related
CIVIL RIGHTS
HUMAN RIGHTS

Age related distributive justice and claims on resources. Irwin S. **Br J Sociol** 1996 Mar;47(1):68-92 (44 ref.)

SOCIAL MEDICINE

Social theory, social action, and intervention research: implications for cancer prevention among Latinos. Flores ET, et al. **J Natl Cancer Inst Monogr** 1995;(18):101-8 (53 ref.)

[Social medicine] Wang J. **Chung Hua I Hsueh Tsa Chih** 1996 Jan;76(1):75-6 (0 ref.) **(Chi)**

SOCIAL MOBILITY

Psychosocial factors and quality of life in obesity. Sarlio-Lähteenkorva S, et al. **Int J Obes Relat Metab Disord** 1995 Nov;19 Suppl 6:S1-5 (49 ref.)

SOCIAL PERCEPTION

see related
STEREOTYPING

Environmental psychology 1989-1994. Sundstrom E, et al. **Annu Rev Psychol** 1996;47:485-512 (255 ref.)

Brief report: developmental neurobiological aspects of autism. Voeller KK. **J Autism Dev Disord** 1996 Apr; 26(2):189-93 (9 ref.)

SOCIAL POLICY see PUBLIC POLICY

SOCIAL PROBLEMS

see related
ALCOHOLISM
SUBSTANCE DEPENDENCE

Preventing violence in a structurally violent society: mission impossible. Gil DG. **Am J Orthopsychiatry** 1996 Jan; 66(1):77-84 (18 ref.)

Rape is a major public health issue. Schafran LH. **Am J Public Health** 1996 Jan;86(1):15-7 (13 ref.)

[Tobacco among young people (editorial)] Viejo Bañuelos JL. **Arch Bronconeumol** 1995 Dec;31(10):491-3 (24 ref.) **(Spa)**

[A brief review of the debate over social inequalities in health] Doz JF, et al. **Aten Primaria** 1996 May 31; 17(9):585-9 (40 ref.) **(Spa)**

SOCIAL PSYCHOLOGY see PSYCHOLOGY, SOCIAL

SOCIAL RESPONSIBILITY

The autopsy. Some ethical reflections on the obligations of pathologists, hospitals, families, and society. Pellegrino ED. **Arch Pathol Lab Med** 1996 Aug;120(8):739-42 (0 ref.)

The third age, the Third World and the third millennium. Diczfalusy E. **Contraception** 1996 Jan;53(1):1-7 (23 ref.)

Lifestyles of the risky and infamous. From managed care to managed lives. Morreim EH. **Hastings Cent Rep** 1995 Nov-Dec;25(6):5-12 (43 ref.)

Community, family, and the social good: the psychological dynamics of procedural justice and social identification. Tyler TR, et al. **Nebr Symp Motiv** 1995;42:53-91 (100 ref.)

SOCIAL SCIENCES

[The knowledge on health and the social sciences] Jarillo Soto EC, et al. **Rev Esp Salud Publica** 1995 May-Aug; 69(3-4):265-76 (51 ref.) (Eng. Abstr.) **(Spa)**

EDUCATION

Teaching the social sciences to undergraduate medical students. Benbassat J. **Isr J Med Sci** 1996 Mar-Apr; 32(3-4):217-21 (40 ref.)

SOCIAL SECURITY

LEGISLATION & JURISPRUDENCE

[Social legislative and structural deficits of ambulatory management of chronic psychiatric and handicapped patients] Rössler W, et al. **Nervenarzt** 1995 Nov; 66(11):802-10 (34 ref.) (Eng. Abstr.) **(Ger)**

TRENDS

Entitlements and the federal budget: facts, folklore, and future. Gist JR. **Milbank Q** 1996;74(3):327-59 (42 ref.)

SOCIAL SERVICE see SOCIAL WORK

SOCIAL SERVICE, PSYCHIATRIC see SOCIAL WORK, PSYCHIATRIC

SOCIAL SUPPORT

see related
SELF-HELP GROUPS

A vision for the future: toward a service system responsive to those with co-occurring addictive and mental disorders. Osher FC. **Am J Orthopsychiatry** 1996 Jan;66(1):71-6 (16 ref.)

Relationship of anxiety, stress, and psychosocial development to reproductive health [see comments] Lederman RP. **Behav Med** 1995 Fall;21(3):101-12 (110 ref.) Comment in: Behav Med 1995 Fall;21(3):123-9.

Supportive psychotherapy. The search for positive meanings. Holmes J. **Br J Psychiatry** 1995 Oct;167(4):439-45; discussion 446-7 (48 ref.)

Social support and adjustment to cancer: reconciling descriptive, correlational, and intervention research. Helgeson VS, et al. **Health Psychol** 1996 Mar;15(2):135-48 (80 ref.)

Gay men with AIDS and their families of origin: an analysis of social support. Kadushin G. **Health Soc Work** 1996 May;

21(2):141–9 (100 ref.)
Social support: some pragmatic implications for health care professionals. Keeling DI, et al. **J Adv Nurs** 1996 Jan; 23(1):76–81 (36 ref.)
Social support and the patient with cancer: a consideration of the literature. Krishnasamy M. **J Adv Nurs** 1996 Apr; 23(4):757–62 (29 ref.)
Assessing social support in patients with cardiac disease. McCauley KM. **J Cardiovasc Nurs** 1995 Oct;10(1):73–80 (28 ref.)
Stress, coping, and social support processes: where are we? What next? Thoits PA. **J Health Soc Behav** 1995;Spec No:53–79 (220 ref.)
Social networks and family violence in cross-cultural perspective. Korbin JE. **Nebr Symp Motiv** 1995;42:107–34 (92 ref.)
Family support for persons with dual disorders. Clark RE. **New Dir Ment Health Serv** 1996 Summer;(70):65–78 (54 ref.)
Promising social network research results and suggestions for a research agenda. Friedman SR. **NIDA Res Monogr** 1995;151:196–215 (28 ref.)
Network models for HIV outreach and prevention programs for drug users. Trotter RT II, et al. **NIDA Res Monogr** 1995;151:144–80 (31 ref.)
Perinatally transmitted HIV infection. Supporting the helpers. Burr CK. **Nurs Clin North Am** 1996 Mar; 31(1):243–51 (21 ref.)
Strategies to support families of children with end-stage renal failure. Watson AR. **Pediatr Nephrol** 1995 Oct;9(5):628–31 (22 ref.)
Psychosocial issues in breast cancer. Helping patients get the support they need. Williams TR, et al. **Postgrad Med** 1995 Oct;98(4):97–9, 103–4, 107–8 passim (2 ref.)
Social influences on food choice and dietary change: a sociological attitude. Murcott A. **Proc Nutr Soc** 1996 Nov; 54(3):729–35 (13 ref.)
The relationship between social support and physiological processes: a review with emphasis on underlying mechanisms and implications for health. Uchino BN, et al. **Psychol Bull** 1996 May;119(3):488–531 (276 ref.)
Psychological and sociological aspects of the thalassemias. Ratip S, et al. **Semin Hematol** 1996 Jan;33(1):53–65 (53 ref.)
Supportive palliative treatment, psychological care and the hospice movement in Hungary. Muszbek K, et al. **Support Care Cancer** 1996 Jan;4(1):7–9 (10 ref.)
[Social networks and social support as health resources] Vahtera J, et al. **Duodecim** 1994;110(11):1054–60 (40 ref.) **(Fin)**
[Systemic approach to families dealing with cancer diagnosis, its treatment and its prognosis] Bodart A, et al. **Acta Psychiatr Belg** 1996 Jan–Feb;96(1):30–57 (73 ref.) (Eng. Abstr.) **(Fre)**
[Quality of attachment representation, social integration and use of social network resources in advanced age] Wensauer M, et al. **Z Gerontol Geriatr** 1995 Nov–Dec;28(6):444–56 (89 ref.) (Eng. Abstr.) **(Ger)**
[Does social support have an impact on the prognosis in cancer?] Jacobsen EM, et al. **Tidsskr Nor Laegeforen** 1995 Oct 10;115(24):3022–5 (31 ref.) (Eng. Abstr.) **(Nor)**

SOCIAL VALUES

Postmodernism, health and illness. Mitchell DP. **J Adv Nurs** 1996 Jan;23(1):201–5 (28 ref.)
Homosexuality, biology, and ideology. Haumann G. **J Homosex** 1995;28(1–2):57–77 (90 ref.)
Policing "perversions": Depo-Provera and John Money's new sexual order. Tsang DC. **J Homosex** 1995;28(3–4):397–426 (110 ref.)
Justifying prenatal screening and genetic amniocentesis programs by cost-effectiveness analyses: a re-evaluation. Ganiats TG. **Med Decis Making** 1996 Jan–Mar;16(1):45–50 (61 ref.)
Community, family, and the social good: the psychological dynamics of procedural justice and social identification. Tyler TR, et al. **Nebr Symp Motiv** 1995;42:53–91 (100 ref.)
The contrary ideals of individualism and nursing value of care. Katims I. **Sch Inq Nurs Pract** 1995 Fall;9(3):231–40; discussion 241–4 (30 ref.)

SOCIAL WELFARE

Effects of welfare reform on teenage parents and their children. Aber JL, et al. **Future Child** 1995 Summer–Fall; 5(2):53–71 (60 ref.)

ECONOMICS

Age related distributive justice and claims on resources. Irwin S. **Br J Sociol** 1996 Mar;47(1):68–92 (44 ref.)

SOCIAL WORK

see related
COMMUNITY HEALTH SERVICES

Social work and end-of-life decisions: self-determination and the common good. Wesley CA. **Health Soc Work** 1996 May;21(2):115–21 (52 ref.)
Beneficence re-examined: protective intervention in mental health. Murdach AD. **Soc Work** 1996 Jan;41(1):26–32 (43 ref.)
Understanding the social needs of streetwalking prostitutes. Weiner A. **Soc Work** 1996 Jan;41(1):97–105 (12 ref.)
Families of young technology-dependent children and the social worker. Bradley RH, et al. **Soc Work Health Care** 1995;21(1):23–37 (41 ref.)
Educating African-Americans about cancer prevention and detection: a review of the literature. Lowe JI, et al. **Soc Work Health Care** 1995;21(4):17–36 (36 ref.)
Afro-American women living with HIV infection: special therapeutic interventions for a growing population. Williams JK. **Soc Work Health Care** 1995;21(2):41–53 (30 ref.)
[Social networks and social support as health resources] Vahtera J, et al. **Duodecim** 1994;110(11):1054–60 (40 ref.) **(Fin)**
[Functions of the social worker in a multi-professional team in inpatient psychosomatic rehabilitation] Mans EJ. **Rehabilitation (Stuttg)** 1996 May;35(2):119–25 (27 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Cancer pain management and the role of social work: barriers and interventions. Glajchen M, et al. **Health Soc Work** 1995 Aug;20(3):200–6 (35 ref.)
Decision-making situations in health care. Murdach AD. **Health Soc Work** 1995 Aug;20(3):187–91 (37 ref.)
Anticipatory grief and AIDS: strategies for intervening with caregivers. Walker RJ, et al. **Health Soc Work** 1996 Feb; 21(1):49–57 (43 ref.)
Treatment of adolescent substance abusers: issues for practice and research. Jenson JM, et al. **Soc Work Health Care** 1995; 21(2):1–18 (58 ref.)

ORGANIZATION & ADMINISTRATION

Problems with public health outreach. Azzarto J. **Soc Work Health Care** 1995;22(1):57–67 (20 ref.)

STANDARDS

Starting in the middle: social work and quality assurance. Cooper L. **Aust Clin Rev** 1991;11:82–6 (5 ref.)

TRENDS

Immunization among African American children: implications for social work. Copeland VC. **Health Soc Work** 1996 May;21(2):105–14 (70 ref.)

SOCIAL WORK, PSYCHIATRIC

[Are current views of handling and classification of psychiatric problems discouraging?] Riikonen E, et al. **Duodecim** 1994;110(3):347–59 (54 ref.) **(Fin)**

ORGANIZATION & ADMINISTRATION

Managing mental health: whose responsibility? Rose SJ, et al. **Health Soc Work** 1996 Feb;21(1):76–80 (28 ref.)

SOCIAL WORKERS see **SOCIAL WORK**

SOCIALIZATION

The effect of living in a nursing home on socialization in elderly people. Jacelon CS. **J Adv Nurs** 1995 Sep; 22(3):539–46 (25 ref.)
Socialization into the therapeutic community culture. Szalay L. **NIDA Res Monogr** 1994;144:54–79 (21 ref.)
Facial emotion recognition by persons with mental retardation: a review of the experimental literature. Rojahn J, et al. **Res Dev Disabil** 1995 Sep–Oct;16(5):393–414 (75 ref.)

SOCIALIZED MEDICINE see **STATE MEDICINE**

SOCIETIES

Position of the American Dietetic Association: food irradiation. **J Am Diet Assoc** 1996 Jan;96(1):69–72 (27 ref.)
Position of the American Dietetic Association: vitamin and mineral supplementation. **J Am Diet Assoc** 1996 Jan; 96(1):73–7 (53 ref.)
Position of the American Dietetic Association: oral health and nutrition. **J Am Diet Assoc** 1996 Feb;96(2):184–9 (55 ref.)
Position of the American Dietetic Association: biotechnology and the future of food. **J Am Diet Assoc** 1995 Dec; 95(12):1429–32 (29 ref.)
Position of The American Dietetic Association: nutrition services in managed care. Laramee SH. **J Am Diet Assoc** 1996 Apr;96(4):391–5 (55 ref.)

SOCIETIES, DENTAL

The role of the AADR in promoting research integrity: perspectives and consensus statements. Bebeau MJ, et al. **J Dent Res** 1996 Feb;75(2):856–60 (9 ref.)

SOCIETIES, MEDICAL

The new BPA classification. Crawshaw P. **Arch Dis Child** 1995 Dec;73(6):563–7 (6 ref.)
College of American Pathologists Conference XXVIII on alternate site testing. What must we now do? Howanitz PJ. **Arch Pathol Lab Med** 1995 Oct;119(10):979–83 (30 ref.)
Present status of radiation oncology in China. Second survey of Chinese Society of Radiation Oncology. Yin W, et al. **Chin Med J (Engl)** 1996 Feb;109(2):117–8 (2 ref.)
The World Hypertension League: goals and perspectives. Ganten D, et al. **Clin Exp Hypertens** 1995 Oct; 17(7):1079–89 (7 ref.)
Towards a high standard of surgical oncology throughout Europe. O'Higgins N. **Eur J Cancer** 1995;31A Suppl 6:S22–4 (4 ref.)
The future of artificial organs [editorial] Gurland HJ, et al. **Int J Artif Organs** 1995 Feb;18(2):64–8 (10 ref.)
Assessment: Clinical autonomic testing report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. **Neurology** 1996 Mar;46(3):873–80 (101 ref.)
Reproductive biology and the Australian Society for Reproductive Biology in the 21st century. Findlay JK. **Reprod Fertil Dev** 1995;7(5):1021–4 (0 ref.)
[Prevention of coronary disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension] Pyörälä K, et al. **Cardiologia** 1996 Feb;41(2):149–82 (192 ref.) **(Ita)**
[30-year progress of Japanese Medical Society of Alcohol and Drug Studies—present status and future of alcohol studies] Takase S. **Nihon Arukoru Yakubutsu Igakkai Zasshi** 1996 Feb; 31(1):54–66 (25 ref.) **(Jpn)**
[Comment by a surgeon on Japan Endocrine Society, its past and future] Uozumi T. **Nippon Naibunpi Gakkai Zasshi** 1995 Nov 20;71(7):1047–52 (0 ref.) (Eng. Abstr.) **(Jpn)**

TRENDS

[The future of the Japan Endocrine Society] Yoshida S. **Nippon Naibunpi Gakkai Zasshi** 1995 Nov 20;71(7):1053–8 (11 ref.) (Eng. Abstr.) **(Jpn)**

SOCIETIES, SCIENTIFIC

The role of the AADR in promoting research integrity: perspectives and consensus statements. Bebeau MJ, et al. **J Dent Res** 1996 Feb;75(2):856–60 (9 ref.)

ORGANIZATION & ADMINISTRATION

Developing a workshop to address unresolved research issues. Brandt BF. **J Toxicol Environ Health** 1996 Aug 30; 48(6):ix–xii (6 ref.)

SOCIOECONOMIC FACTORS

Towards a political economy of anorexia? Fine B. **Appetite** 1995 Jun;24(3):231–42 (28 ref.)
Work conditions as explanations for the relation between socioeconomic status, gender, and psychological disorders. Lennon MC. **Epidemiol Rev** 1995;17(1):120–7 (118 ref.)
Picture imperfect: hidden problems among Asian Pacific islander elderly. Tanjasiri SP, et al. **Gerontologist** 1995 Dec; 35(6):753–60 (65 ref.)
Macrosocial and environmental influences on minority health. Johnson KW, et al. **Health Psychol** 1995 Dec; 14(7):601–12 (115 ref.)

SOCIOECONOMIC STATUS see **SOCIAL CLASS**

SOCIOENVIRONMENTAL THERAPY

Brief report: the case for social and behavioral intervention research. Schreibman L. **J Autism Dev Disord** 1996 Apr; 26(2):247–50 (8 ref.)

SOCIOLOGY

see related
GROUP PROCESSES

Post-natal depression: the relevance of sociological approaches. Thurtle V. **J Adv Nurs** 1995 Sep;22(3):416–24 (43 ref.)
[The concept of reification in psychiatry and sociology] Morozov VM, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1996;96(1):112–4 (15 ref.) **(Rus)**

SOCIOLOGY, MEDICAL

The sense of coherence: an historical and future perspective. McCubbin HI, et al. **Isr J Med Sci** 1996 Mar–Apr; 32(3–4):170–8 (19 ref.)
Naming and framing: the social construction of diagnosis and illness. Brown P. **J Health Soc Behav** 1995;Spec No:34–52 (69 ref.)
Medical sociology and the study of severe mental illness: reflections on past accomplishments and directions for future research. Cook JA, et al. **J Health Soc Behav** 1995; Spec No:95–114 (170 ref.)
Through the lenses of organizational sociology: the role of organizational theory and research in conceptualizing and examining our health care system. Flood AB, et al. **J Health Soc Behav** 1995;Spec No:154–69 (95 ref.)
Professional dynamics and the changing nature of medical work. Hafferty FW, et al. **J Health Soc Behav** 1995;Spec No:132–53 (130 ref.)
Social conditions as fundamental causes of disease. Link BG,

et al. **J Health Soc Behav** 1995;Spec No:80–94 (90 ref.)
Health, illness, and healing in an uncertain era: challenges from and for medical sociology. Pescosolido BA, et al. **J Health Soc Behav** 1995;Spec No:5–33 (155 ref.)
Stress, coping, and social support processes: where are we? What next? Thoits PA. **J Health Soc Behav** 1995;Spec No:53–79 (220 ref.)

SOCIOPATHIC PERSONALITY see **ANTISOCIAL PERSONALITY DISORDER**

SODIUM

see related
HYPERNATREMIA
HYPONATREMIA
NATRIURESIS

ADVERSE EFFECTS

Exacerbation of congestive heart failure after administration of polyethylene glycol–electrolyte lavage solution. Granberry MC, et al. **Ann Pharmacother** 1995 Dec; 29(12):1232–35 (12 ref.)

BLOOD

From plasma [Na+] to diagnosis and treatment. Enqquist A. **Acta Anaesthesiol Scand Suppl** 1995;107:273–9 (35 ref.)
Na–Ca exchange in circulating blood cells. Gardner JP, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:502–14 (27 ref.)
[Sodium] Kinouchi T. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:748–52 (29 ref.) **(Jpn)**

METABOLISM

Sodium–calcium relationships and cardiac function during coronary bolus perfusion. Jynge P, et al.
Acta Radiol Suppl 1995;399:122–34 (74 ref.)
Na–Ca exchange and Ca fluxes during contraction and relaxation in mammalian ventricular muscle. Bers DM, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:430–42 (31 ref.)
The roles of the sodium and calcium current in triggering calcium release from the sarcoplasmic reticulum. Cannell MB, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:443–50 (21 ref.)
Action potential duration modulates calcium influx, Na(+)–Ca2+ exchange, and intracellular calcium release in rat ventricular myocytes. Clark RB, et al.
Ann N Y Acad Sci 1996 Apr 15;779:417–29 (51 ref.)
Release of catecholamines and enkephalin peptides induced by reversal of the Na(+)–Ca2+ exchanger in chromaffin cells. Duarte EP, et al. **Ann N Y Acad Sci** 1996 Apr 15; 779:391–4 (6 ref.)
Na–Ca exchange studies in sarcolemmal skeletal muscle. Gonzalez–Serratos H, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:556–60 (11 ref.)
Calcium in the cardiac diadic cleft. Implications for sodium–calcium exchange. Langer GA, et al.
Ann N Y Acad Sci 1996 Apr 15;779:408–16 (24 ref.)
The kidney sodium–calcium exchanger. Lytton J, et al.
Ann N Y Acad Sci 1996 Apr 15;779:58–72 (30 ref.)
Mutagenesis studies of the cardiac Na(+)–Ca2+ exchanger. Nicoll DA, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:86–92 (14 ref.)
Molecular regulation of the Na(+)–Ca2+ exchanger. Philipson KD, et al. **Ann N Y Acad Sci** 1996 Apr 15; 779:20–8 (15 ref.)
The structural basis of Na(+)–Ca2+ exchange activity. Rahamimoff H, et al. **Ann N Y Acad Sci** 1996 Apr 15; 779:29–36 (16 ref.)
Voltage dependence of Na–Ca exchange in barnacle muscle cells. I. Na–Na exchange activated by alpha–chymotrypsin. Rasgado–Flores H, et al. **Ann N Y Acad Sci** 1996 Apr 15; 779:236–48 (28 ref.)
Alterations in sodium metabolism as an etiological model for hypertension. Lijnen P. **Cardiovasc Drugs Ther** 1995 Jun; 9(3):377–99 (238 ref.)
The role of Na–Ca exchange current in the cardiac action potential. Janvier NC, et al. **Cardiovasc Res** 1996 Jul; 32(1):69–84 (74 ref.)
Sodium transport in endothelial cells—a brief review. Lau YT. **Chin J Physiol** 1995;38(3):139–45 (52 ref.)
Cell volume regulated transporters of compatible osmolytes. Kwon HM, et al. **Curr Opin Cell Biol** 1995 Aug;7(4):465–71 (48 ref.)
Molecular characterization of the epithelial Na–K–Cl cotransporter isoforms. Payne JA, et al.
Curr Opin Cell Biol 1995 Aug;7(4):493–503 (73 ref.)
Sodium cotransporters. Wright EM, et al.
Curr Opin Cell Biol 1996 Aug;8(4):468–73 (49 ref.)
Regulation of sodium transport. Aperia AC.
Curr Opin Nephrol Hypertens 1995 Sep;4(5):416–20 (36 ref.)
Facilitative glucose transport proteins and sodium–glucose co–transporters in the kidney. Hoffman BB, et al.
Curr Opin Nephrol Hypertens 1995 Sep;4(5):406–11 (52 ref.)
Sodium–calcium balance in coronary angiography and experimental experience with iodixanol. Jynge P.
Eur Radiol 1996;6 Suppl 2:S8–12 (19 ref.)
The stimulation of Na,K,Cl cotransport and of system A for neutral amino acid transport is a mechanism for cell volume increase during the cell cycle. Bussolati O, et al.
FASEB J 1996 Jun;10(8):920–6 (49 ref.)
Endogenous ouabain, sodium balance and blood pressure: a review and a hypothesis [see comments] Hamlyn JM, et al. **J Hypertens** 1996 Feb;14(2):151–67 (136 ref.) Comment in: J Hypertens 1996 Feb;14(2):169–71.
Endogenous ouabain, sodium balance and blood pressure [comment] Pidgeon GB, et al. **J Hypertens** 1996 Feb; 14(2):169–71 (28 ref.) Comment on: J Hypertens 1996 Feb;14(2):151–67.
Renal Na/Pi–cotransporters. Biber J, et al. **Kidney Int** 1996 Apr;49(4):981–5 (33 ref.)
Guanine nucleotide–dependent carboxymethylation: a pathway for aldosterone modulation of apical Na+ permeability in epithelia. Sariban–Sohraby S, et al.
Kidney Int 1995 Oct;48(4):965–9 (66 ref.)
The role of active Na+ transport by lung epithelium in the clearance of airspace fluid. O'Brodovich HM.
New Horiz 1995 May;3(2):240–7 (55 ref.)
[Electrolyte metabolism in renal tubules] Takahashi N, et al. **Nippon Rinsho** 1995 Aug;53(8):1868–72 (8 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Effect of hypoxaemia on water and sodium homeostatic hormones and renal function. Olsen NV.
Acta Anaesthesiol Scand Suppl 1995;107:165–70 (55 ref.)
The exchanger and cardiac hypertrophy. Menick DR, et al.
Ann N Y Acad Sci 1996 Apr 15;779:489–501 (18 ref.)
Prostaglandins and sodium handling in Lyon hypertensive rats. Sassard J, et al. **Clin Exp Pharmacol Physiol** 1995 Dec; 22(12):S423–5 (18 ref.)
Neuroendocrine regulation of sodium and volume following subarachnoid hemorrhage. Diringer MN.
Clin Neuropharmacol 1995 Apr;18(2):114–26 (64 ref.)
Sodium and water homeostasis. Trachtman H.
Pediatr Clin North Am 1995 Dec;42(6):1343–63 (64 ref.)

URINE

Renal sodium excretion and edematous disorders. Martin PY, et al. **Endocrinol Metab Clin North Am** 1995 Sep; 24(3):459–79 (114 ref.)

SODIUM BICARBONATE

PHARMACOLOGY

Sodium bicarbonate loading and the rules of racing [editorial; comment] Williams RB. **Br Vet J** 1995 Sep–Oct; 151(5):473–5 (6 ref.) Comment on: Br Vet J 1995 Sep–Oct;151(5):523–45.

SODIUM CHANNELS

see related
NA(+)–K(+)–EXCHANGING ATPASE

ANALYSIS

[Distribution of amiloride–sensitive sodium channel in epithelial tissue] Bonvalet JP, et al.
C R Seances Soc Biol Fil 1995;189(2):169–77 (14 ref.) (Eng. Abstr.) **(Fre)**

ANTAGONISTS & INHIBITORS

Neuroprotective use–dependent blockers of Na+ and Ca2+ channels controlling presynaptic release of glutamate. Goldin SM, et al. **Ann N Y Acad Sci** 1995 Sep 15;765:210–29 (59 ref.)

CHEMISTRY

Molecular pore structure of voltage–gated sodium and calcium channels. Heinemann SH, et al.
Braz J Med Biol Res 1994 Dec;27(12):2781–802 (54 ref.)

DRUG EFFECTS

Pharmacology of sodium and calcium channel modulation in neurons: implications for neuroprotection. Spedding M, et al. **Biochem Soc Trans** 1995 Aug;23(3):633–6 (50 ref.)
Pharmacological modulation of voltage–gated Na+ channels: a rational and effective strategy against ischemic brain damage. Urenjak J, et al. **Pharmacol Rev** 1996 Mar; 48(1):21–67 (670 ref.)
Sodium channels and GABAA receptor–channel complex as targets of environmental toxicants. Narahashi T, et al. **Toxicol Lett** 1995 Dec;82–83:239–45 (20 ref.)
Na+ channels as targets for neuroprotective drugs. Taylor CP, et al. **Trends Pharmacol Sci** 1995 Sep;16(9):309–16 (74 ref.)
[Distribution of amiloride–sensitive sodium channel in epithelial tissue] Bonvalet JP, et al.
C R Seances Soc Biol Fil 1995;189(2):169–77 (14 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Expression cloning of the epithelial sodium channel. Canessa CM, et al. **Kidney Int** 1995 Oct;48(4):950–5 (29 ref.)

METABOLISM

Persistent sodium current in mammalian central neurons. Crill WE. **Annu Rev Physiol** 1996;58:349–62 (77 ref.)
Regulation of sodium transport. Aperia AC.
Curr Opin Nephrol Hypertens 1995 Sep;4(5):416–20 (36 ref.)
Role of the actin cytoskeleton on epithelial Na+ channel regulation. Cantiello HF. **Kidney Int** 1995 Oct;48(4):970–84 (91 ref.)
Renal sodium channels: regulation and single channel properties. Eaton DC, et al. **Kidney Int** 1995 Oct; 48(4):941–9 (88 ref.)
Cross–talk between sodium and potassium channels in tight epithelia. Harvey BJ. **Kidney Int** 1995 Oct;48(4):1191–9 (100 ref.)
Sodium channels and non–selective cation channels in the cortical collecting duct. Korbmacher C, et al.
Nephrol Dial Transplant 1995;10(9):1546–50 (36 ref.)
The role of active Na+ transport by lung epithelium in the clearance of airspace fluid. O'Brodovich HM.
New Horiz 1995 May;3(2):240–7 (55 ref.)

PHYSIOLOGY

Alkaloids from frog skins: selective probes for ion channels and nicotinic receptors. Daly JW. **Braz J Med Biol Res** 1995 Oct;28(10):1033–42 (28 ref.)
Regulation of voltage–dependent sodium channels. Cukierman S. **J Membr Biol** 1996 Jun;151(3):203–14 (64 ref.)
Structure and function of voltage–dependent sodium channels: comparison of brain II and cardiac isoforms. Fozzard HA, et al. **Physiol Rev** 1996 Jul;76(3):887–926 (258 ref.)
Mechanosensation and the DEG/ENaC ion channels [comment] Corey DP, et al. **Science** 1996 Jul 19; 273(5273):323–4 (21 ref.) Comment on: Science 1996 Jul 19;273(5273):361–4.
[Developmental aspects of electrophysiology in cardiac muscle] Satoh H, et al. **Nippon Yakurigaku Zasshi** 1996 May;107(5):213–23 (38 ref.) (Eng. Abstr.) **(Jpn)**

SODIUM CHLORIDE

see related
DIET, SODIUM–RESTRICTED

ADVERSE EFFECTS

Salt intake: potential deleterious effects excluding blood pressure. Antonios TF, et al. **J Hum Hypertens** 1995 Jun; 9(6):511–5 (45 ref.)

METABOLISM

1994 Homer W. Smith Award. From flies to physiology—accidental findings along the trail of renal NaCl transport. Aronson PS. **J Am Soc Nephrol** 1995 Jun; 5(12):2001–13 (104 ref.)
Hypertension in African Americans: the role of sodium chloride and extracellular fluid volume. Weinberger MH. **Semin Nephrol** 1996 Mar;16(2):110–6 (49 ref.)

PHARMACOLOGY

Role of the kidney in the genesis of hypertension: aberrant renal response to excess salt intake. Kurokawa K.
Clin Exp Pharmacol Physiol 1995 Dec;22(12):S417–22 (23 ref.)
The influence of salinity on the toxicity of various classes of chemicals to aquatic biota. Hall LW Jr, et al.
Crit Rev Toxicol 1995;25(4):281–346 (100 ref.)
Salt and blood pressure revisited. Swales JD.
J Hum Hypertens 1995 Jun;9(6):517–21 (41 ref.)

SODIUM CHLORIDE, DIETARY

ADMINISTRATION & DOSAGE

Salt and public health—policies for dietary salt in the Nordic countries. Närhinen M, et al.
Scand J Prim Health Care 1995 Dec;13(4):300–6 (18 ref.)

ADVERSE EFFECTS

Deleterious effects of salt intake other than effects on blood pressure. Antonios TF, et al.
Clin Exp Pharmacol Physiol 1995 Mar;22(3):180–4 (43 ref.)
Role of dietary salt in hypertension. Haddy FJ, et al.
J Am Coll Nutr 1995 Oct;14(5):428–38 (147 ref.)
Salt—more adverse effects. Antonios TF, et al. **Lancet** 1996 Jul 27;348(9022):250–1 (27 ref.)
Salt and public health—policies for dietary salt in the Nordic countries. Närhinen M, et al.
Scand J Prim Health Care 1995 Dec;13(4):300–6 (18 ref.)

STANDARDS

Human requirements of iodine & safe use of iodised salt. Ranganathan S, et al. **Indian J Med Res** 1995 Nov; 102:227–32 (21 ref.)

SODIUM CHLORIDE SOLUTION, HYPERTONIC see **SALINE SOLUTION, HYPERTONIC**

SODIUM CROMOGLYCATE see **CROMOLYN SODIUM**

SODIUM, DIETARY

ADMINISTRATION & DOSAGE

Salt sensitivity of blood pressure in humans. Weinberger MH.

SODIUM, DIETARY

Hypertension 1996 Mar;27(3 Pt 2):481–90 (104 ref.)

ADVERSE EFFECTS

Salt intake as a determinant of cardiac hypertrophy. Beil AH, et al. **Blood Press Suppl** 1995;2:30–4 (47 ref.)
Renal neural mechanisms in salt-sensitive hypertension. DiBona GF. **Blood Press Suppl** 1995;2:81–7 (61 ref.)
Dietary salt and hypertension. Hatton DC, et al. **Curr Opin Nephrol Hypertens** 1996 Mar;5(2):166–9 (22 ref.)
Salt and left ventricular hypertrophy: what are the links? Langenfeld MR, et al. **J Hum Hypertens** 1995 Nov; 9(11):909–16 (78 ref.)
The potentiality and practicality of a 'salt-free' diet for the prevention and amelioration of human disorders. Leeming RA. **Med Hypotheses** 1996 Jan;46(1):45–51 (45 ref.)
Dietary salt and blood pressure [comment] Dyer AR, et al. **Nat Med** 1995 Oct;1(10):994–6 (18 ref.) Comment on: Nat Med 1995 Oct;1(10):1009–16.
Salt and hypertension: where things stand. Luft FC. **Nephrol Dial Transplant** 1995;10(9):1524–5 (11 ref.)

SODIUM DODECYL SULFATE

ADVERSE EFFECTS

The sodium lauryl sulfate model: an overview. Lee CH, et al. **Contact Dermatitis** 1995 Jul;33(1):1–7 (92 ref.)

SODIUM ETIDRONATE see **ETIDRONATE DISODIUM**

SODIUM FLUORIDE

ADMINISTRATION & DOSAGE

Fluoride therapy of type I osteoporosis. Devogelaer JP, et al. **Clin Rheumatol** 1995 Sep;14 Suppl 3:26–31 (57 ref.)

SODIUM-GLUCOSE TRANSPORT SYSTEM see **MONOSACCHARIDE TRANSPORT PROTEINS**

SODIUM GOLD THIOMALATE see **GOLD SODIUM THIOMALATE**

SODIUM-HYDROGEN ANTIPORTER

ANALYSIS

Physiologic and molecular aspects of the Na+/H+ exchangers in health and disease processes. Soleimani M, et al. **J Investig Med** 1995 Oct;43(5):419–30 (82 ref.)

METABOLISM

Alterations in sodium metabolism as an etiological model for hypertension. Lijnen P. **Cardiovasc Drugs Ther** 1995 Jun; 9(3):377–99 (238 ref.)
Sodium-proton exchange and primary hypertension. An update. Siffert W, et al. **Hypertension** 1995 Oct;26(4):649–55 (82 ref.)
Chronic regulation of the proximal tubular Na/H antiporter: from HCO3 to SRC [editorial] Alpern RJ, et al. **Kidney Int** 1995 Nov;48(5):1386–96 (113 ref.)
Regulation of the Na+/H+ exchanger isoform NHE1: role of phosphorylation. Bianchini L, et al. **Kidney Int** 1996 Apr; 49(4):1038–41 (33 ref.)

PHYSIOLOGY

Physiologic and molecular aspects of the Na+/H+ exchangers in health and disease processes. Soleimani M, et al. **J Investig Med** 1995 Oct;43(5):419–30 (82 ref.)

SODIUM HYPOCHLORITE

HIV-1 prevention: interdisciplinary studies on the efficacy of bleach and development of prevention protocols. McCoy CB, et al. **Arch Immunol Ther Exp (Warsz)** 1995;43(1):1–9 (31 ref.)

SODIUM LAURYL SULFATE see **SODIUM DODECYL SULFATE**

SODIUM NAFCILLIN see **NAFCILLIN**

SODIUM PERTECHNETATE TC 99M

DIAGNOSTIC USE

The use of 99Tcm-Technegas in the investigation of patients with pulmonary thromboembolism. James JM, et al. **Nucl Med Commun** 1995 Oct;16(10):802–10 (34 ref.)

SODIUM, POTASSIUM ADENOSINETRIPHOSPHATASE see **NA(+)-K(+)-EXCHANGING ATPASE**

SODIUM, POTASSIUM ATPASE see **NA(+)-K(+)-EXCHANGING ATPASE**

SODIUM-POTASSIUM PUMP see **NA(+)-K(+)-EXCHANGING ATPASE**

SODIUM PUMP see **NA(+)-K(+)-EXCHANGING ATPASE**

SODIUM VALPROATE see **VALPROIC ACID**

SOFT TISSUE INFECTIONS

see related
SKIN DISEASES, INFECTIOUS

Soft tissue tuberculosis: a series of 11 cases. Puttick MP, et al. **J Rheumatol** 1995 Jul;22(7):1321–5 (33 ref.)
Pediatric soft tissue infections. Minnick KE, et al. **Semin Pediatr Surg** 1995 Nov;4(4):228–33 (26 ref.)

COMPLICATIONS

[Infectious complications of drug addiction] de Marie S. **Ned Tijdschr Geneeskd** 1995 Dec 16;139(50):2618–22 (47 ref.) **(Dut)**

DIAGNOSIS

MR imaging of soft-tissue infection. Beltran J. **Magn Reson Imaging Clin N Am** 1995 Nov;3(4):743–51 (18 ref.)

DRUG THERAPY

Local antibacterial therapy for the management of orthopaedic infections. Pharmacokinetic considerations. Henry SL, et al. **Clin Pharmacokinet** 1995 Jul;29(1):36–45 (88 ref.)

ETIOLOGY

Identifying high risk patients for Staphylococcus aureus infections: skin and soft tissue infections. Trilla A, et al. **J Chemother** 1995 Jul;7 Suppl 3:37–43 (14 ref.)

MICROBIOLOGY

Localized soft-tissue infections with Mycobacterium avium/Mycobacterium intracellulare complex in immunocompetent patients: granulomatous tenosynovitis of the hand or wrist. Hellinger WC, et al. **Clin Infect Dis** 1995 Jul;21(1):65–9 (25 ref.)

RADIOGRAPHY

Infected third branchial cleft cyst: retropharyngeal extension to the superior mediastinum. Hewel K, et al. **Can Assoc Radiol J** 1996 Apr;47(2):111–3 (8 ref.)
CT evaluation of soft tissue and muscle infection and inflammation: a systematic compartmental approach. Beauchamp NJ Jr, et al. **Skeletal Radiol** 1995 Jul; 24(5):317–24 (8 ref.)

SOFT TISSUE INJURIES

Soft-tissue injuries of the wrist. Halikis MN, et al. **Clin Sports Med** 1996 Apr;15(2):235–59 (64 ref.)

DIAGNOSIS

Musculotendinous injury. Weatherall PT, et al. **Magn Reson Imaging Clin N Am** 1995 Nov;3(4):753–72 (73 ref.)

DRUG THERAPY

Pharmacological treatment of soft-tissue injuries. Buckwalter JA. **J Bone Joint Surg Am** 1995 Dec;77(12):1902–14 (186 ref.)

ETIOLOGY

Surgical management of soft tissue lesions associated with pelvic ring injury. Kottmeier SA, et al. **Clin Orthop** 1996 Aug;(329):46–53 (43 ref.)

PHYSIOPATHOLOGY

Soft and hard tissue response to endosseous dental implants. Listgarten MA. **Anat Rec** 1996 Jun;245(2):410–25 (154 ref.)

SURGERY

Surgical management of soft tissue lesions associated with pelvic ring injury. Kottmeier SA, et al. **Clin Orthop** 1996 Aug;(329):46–53 (43 ref.)
Advances in the management of musculoskeletal trauma. Lazarus MD, et al. **Curr Opin Gen Surg** 1993;:46–54 (26 ref.)
Lower limb salvage: microvascular reconstruction of post-traumatic soft tissue and skeletal defects. Tomaino MM. **Orthopedics** 1995 Jul;18(7):665–72 (68 ref.)
[Concept for the management of combined bone-soft tissue defects of the lower extremity] Amgwerd MG, et al. **Swiss Surg** 1995;(2):90–5 (30 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

[Hyperbaric oxygen therapy in chronic radiation injury of soft tissues] Kooijman R, et al. **Ned Tijdschr Geneeskd** 1996 Aug 17;140(33):1671–4 (43 ref.) **(Dut)**

VETERINARY

Soft tissue injuries of the tarsus. Dik KJ, et al. **Vet Clin North Am Equine Pract** 1995 Aug;11(2):235–47 (25 ref.)

SOFT TISSUE NEOPLASMS

Extraabdominal desmoid tumor. Pereyo NG, et al. **J Am Acad Dermatol** 1996 Feb;34(2 Pt 2):352–6 (37 ref.)
Myxoid liposarcoma of the ankle. Werd MB, et al. **J Foot Ankle Surg** 1995 Sep-Oct;34(5):465–74 (39 ref.)
Pediatric soft-tissue sarcomas. Conrad EU 3rd, et al. **Orthop Clin North Am** 1996 Jul;27(3):655–64 (94 ref.)

CONGENITAL

Congenital-infantile fibrosarcoma: magnetic resonance imaging findings. Lee MJ, et al. **Can Assoc Radiol J** 1996 Apr;47(2):121–5 (27 ref.)
Infantile haemangiopericytoma of the hand. Templeton PA, et al. **J Hand Surg [Br]** 1996 Feb;21(1):121–3 (8 ref.)
[The current controversy in the treatment of congenital fibrosarcoma. A case report] Ramos Diaz JC, et al. **An Esp Pediatr** 1996 Apr;44(4):367–8 (13 ref.) **(Spa)**

DIAGNOSIS

Soft tissue sarcomas: diagnosis, classification and prognostic factors. Fisher C. **Br J Plast Surg** 1996 Jan;49(1):27–33 (31 ref.)
Congenital-infantile fibrosarcoma: magnetic resonance imaging findings. Lee MJ, et al. **Can Assoc Radiol J** 1996 Apr;47(2):121–5 (27 ref.)
Extraosseous osteogenic sarcoma of the mediastinum occurring in a Chinese patient. Lin J, et al. **Clin Oncol (R Coll Radiol)** 1995;7(3):200–1 (10 ref.)
Evaluation, diagnosis, and classification of benign soft-tissue tumors. Frassica FJ, et al. **Instr Course Lect** 1996;45:447–60 (24 ref.)
Imaging of pedal soft tissue neoplasms. Levey DS, et al. **J Foot Ankle Surg** 1995 Jul-Aug;34(4):411–8 (23 ref.)
MR imaging techniques for soft-tissue lesions. Byers GE, et al. **Magn Reson Imaging Clin N Am** 1995 Nov;3(4):563–76 (53 ref.)
MR imaging of malignant soft-tissue tumors. Hanna SL, et al. **Magn Reson Imaging Clin N Am** 1995 Nov;3(4):629–50 (38 ref.)
MR imaging of soft-tissue masses. Mass-like lesions that simulate neoplasms. Jelinek J, et al. **Magn Reson Imaging Clin N Am** 1995 Nov;3(4):727–41 (58 ref.)
MR imaging of musculoskeletal tumors of the hand and wrist. Kransdorf MJ, et al. **Magn Reson Imaging Clin N Am** 1995 May;3(2):327–44 (105 ref.)
Surgical considerations in a diagnostic imaging evaluation of musculoskeletal masses. Moreau G, et al. **Magn Reson Imaging Clin N Am** 1995 Nov;3(4):577–90 (30 ref.)
MR spectroscopy of musculoskeletal soft-tissue tumors. Negendank WG. **Magn Reson Imaging Clin N Am** 1995 Nov;3(4):713–25 (53 ref.)
MR imaging of benign soft-tissue masses. Sundaram M, et al. **Magn Reson Imaging Clin N Am** 1995 Nov;3(4):609–27 (62 ref.)
Benign and malignant masses. MR imaging differentiation. Weatherall PT. **Magn Reson Imaging Clin N Am** 1995 Nov; 3(4):669–94 (84 ref.)
Benign soft-tissue lesions in children. Smith JT, et al. **Orthop Clin North Am** 1996 Jul;27(3):645–54 (26 ref.)
Fibrosarcoma of the thigh. Case report and literature review. Testini M, et al. **Panminerva Med** 1996 Mar;38(1):51–5 (14 ref.)
Soft tissue chondroma of the neck: a case report and review of the literature. Kamysz JW, et al. **Pediatr Radiol** 1996; 26(2):145–7 (14 ref.)
From the archives of the AFIP. Musculoskeletal angiomatous lesions: radiologic-pathologic correlation. Murphey MD, et al. **Radiographics** 1995 Jul;15(4):893–917 (84 ref.)
MRI of posterior knee masses. Butler MG, et al. **Skeletal Radiol** 1996 May;25(4):309–17 (11 ref.)
Cystic hygroma of the arm: a case report and review of the literature. Carpenter CT, et al. **Skeletal Radiol** 1996 Feb; 25(2):201–4 (8 ref.)
A case of juxta-articular myxoma of the knee. Daluiski A, et al. **Skeletal Radiol** 1995 Jul;24(5):389–91 (23 ref.)
Malignant melanoma of soft parts involving the head and neck region: review of literature and case report. Hicks MJ, et al. **Ultrastruct Pathol** 1995 Sep-Oct;19(5):395–400 (28 ref.)
[Desmoplastic small round cell tumors in adults: a new entity] Farhat F, et al. **Bull Cancer (Paris)** 1995 Aug;82(8):665–73 (39 ref.) (Eng. Abstr.) **(Fre)**
[Cat-scratch disease presenting as a pseudotumor. Imaging by x-ray computed tomography and MRI] Leblan I, et al. **J Radiol** 1995 Sep;76(9):601–4 (19 ref.) (Eng. Abstr.) **(Fre)**
[Diagnosis and therapy of malignant soft-tissue tumors] Tunn PU, et al. **Dtsch Med Wochenschr** 1996 Feb 9;121(6):175–8 (19 ref.) **(Ger)**
[Lymphedema-associated angiosarcoma (the Stewart-Treves syndrome) of the lower extremity: its MRT imaging] Gelmetti W, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Feb;164(2):168–70 (15 ref.) **(Ger)**
[Elastofibroma dorsi. A report of a case diagnosed with magnetic resonance] Bianchi M, et al. **Radiol Med (Torino)** 1996 Jan-Feb;91(1-2):128–30 (16 ref.) **(Ita)**

DRUG THERAPY

The present state of the art in chemotherapy for soft tissue sarcomas in adults: the EORTC point of view. Verweij J, et al. **Crit Rev Oncol Hematol** 1995 Oct;20(3):193–201 (58 ref.)

Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas. Implications for decision making in the clinic. Demetri GD, et al. **Hematol Oncol Clin North Am** 1995 Aug;9(4):765–85 (123 ref.)

Adjuvant chemotherapy for soft tissue sarcomas. Mertens WC, et al. **Hematol Oncol Clin North Am** 1995 Aug; 9(4):801–15 (41 ref.)

Systemic adjuvant chemotherapy for soft tissue sarcomas. Zalupski MM, et al. **Hematol Oncol Clin North Am** 1995 Aug;9(4):787–800 (49 ref.)

High-dose ifosfamide in the treatment of sarcomas of soft tissues and bone. Demetri GD. **Semin Oncol** 1996 Jun;23(3 Suppl 6):22–6 (19 ref.)

EPIDEMIOLOGY

Angiosarcoma. A report of 67 patients and a review of the literature. Mark RJ, et al. **Cancer** 1996 Jun 1;77(11):2400–6 (53 ref.)

ETIOLOGY

Lymphangiosarcoma following mastectomy. Stewart NJ, et al. **Clin Orthop** 1995 Nov;(320):135–41 (15 ref.)

GENETICS

Cytogenetics and molecular genetics of bone and soft tissue tumors. Mandahl N. **Adv Cancer Res** 1996;69:63–99 (143 ref.)

Hereditary presacral teratoma. Bryant P, et al. **Aust N Z J Surg** 1996 Jun;66(6):418–20 (15 ref.)

A new cytogenetic subgroup in tenosynovial giant cell tumors (nodular tenosynovitis) is characterized by involvement of 16q24. Dal Cin P, et al. **Cancer Genet Cytogenet** 1996 Mar;87(1):85–7 (5 ref.)

t(9;22)(q22–31;q11–12) is a consistent marker of extraskeletal myxoid chondrosarcoma: evaluation of three cases. Sciot R, et al. **Mod Pathol** 1995 Sep;8(7):765–8 (19 ref.)

Cytogenetics and molecular biology of soft tissue tumors. Fletcher JA. **Monogr Pathol** 1996;38:37–64 (126 ref.)

[Specific chromosome aberrations in human soft-tissue tumors and their diagnostic significance] Mrózek K, et al. **Pol Tyg Lek** 1995 Sep;50(36–39):85–9 (30 ref.) (Eng. Abstr.) **(Pol)**

METABOLISM

MDR1 gene expression: evaluation of its use as a molecular marker for prognosis and chemotherapy of bone and soft tissue sarcomas. Stein U, et al. **Eur J Cancer** 1996 Jan; 32A(1):86–92 (82 ref.)

MORTALITY

[Prognostic factors of bone and soft tissue sarcoma] Kawaguchi N, et al. **Gan To Kagaku Ryoho** 1996 Jul; 23(8):1093–8 (5 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Malignant fibrous histiocytoma of the head and neck. Case report. Zapater E, et al. **Bull Group Int Rech Sci Stomatol Odontol** 1995 Sep–Oct; 38(3–4):121–4 (17 ref.)

Magnetic resonance imaging and histopathologic appearances of benign soft-tissue masses of the foot. Logan PM, et al. **Can Assoc Radiol J** 1996 Feb;47(1):36–43 (9 ref.)

Fine needle aspiration (FNA) in the diagnosis of soft tissue tumours; a review of 22 years experience. Willén H, et al. **Cytopathology** 1995 Aug;6(4):236–47 (41 ref.)

Soft tissue sarcomas in dermatology. Fish FS. **Dermatol Surg** 1996 Mar;22(3):268–73 (57 ref.)

New entities, concepts, and questions in childhood tumor pathology. Harms D. **Gen Diagn Pathol** 1995 May; 141(1):1–14 (32 ref.)

Rhabdomyosarcoma of the hand. Two case reports and a review of the literature. Xarchas K, et al. **J Hand Surg [Br]** 1996 Jun;21(3):325–9 (11 ref.)

Immunohistochemistry in the differential diagnosis of soft tissue tumors. Brooks JS. **Monogr Pathol** 1996;38:65–128 (456 ref.)

Fibrohistiocytic tumors. Fisher C. **Monogr Pathol** 1996; 38:162–80 (82 ref.)

An approach to the diagnosis of soft tissue tumors. Kempson RL, et al. **Monogr Pathol** 1996;38:1–36 (71 ref.)

Childhood soft tissue chondroma: a case report. Pollock L, et al. **Pediatr Pathol Lab Med** 1995 May–Jun;15(3):437–41 (6 ref.)

Malignant fibrous histiocytoma: morphologic pattern or pathologic entity? Hollowood K, et al. **Semin Diagn Pathol** 1995 Aug;12(3):210–20 (58 ref.)

Hemangiopericytoma: histopathological pattern or clinicopathologic entity? Nappi O, et al. **Semin Diagn Pathol** 1995 Aug;12(3):221–32 (113 ref.)

Lipomatous tumours of soft tissues: an update. Mentzel T, et al. **Virchows Arch** 1995;427(4):353–63 (57 ref.)

Myolipoma of the round ligament: report of a case with a review of the English literature. Sonobe H, et al. **Virchows Arch** 1995;427(4):455–8 (24 ref.)

[Low malignancy myxofibrosarcoma versus low malignancy fibromyxoid sarcoma. Distinct entities with similar names but different clinical course] Mentzel T, et al. **Pathologe** 1996 Mar;17(2):116–21 (19 ref.) (Eng. Abstr.) **(Ger)**

RADIOTHERAPY

Brachytherapy in sarcomas. Harrison LB, et al. **Hematol Oncol Clin North Am** 1995 Aug;9(4):747–63 (32 ref.)

Radiation as a therapeutic modality in sarcomas of the soft tissue. Suit H, et al. **Hematol Oncol Clin North Am** 1995 Aug;9(4):733–46 (44 ref.)

Adult soft tissue sarcomas of the head and neck treated by radiation and surgery or radiation alone: patterns of failure and prognostic factors. Willers H, et al. **Int J Radiat Oncol Biol Phys** 1995 Oct 15;33(3):585–93 (26 ref.)

Current controversies in pediatric radiation oncology. Marcus RB Jr. **Orthop Clin North Am** 1996 Jul;27(3):551–7 (20 ref.)

SECONDARY

Heterotopic ossification in adenocarcinoma of the colon. Hui Y, et al. **Chin Med J (Engl)** 1995 Oct;108(10):798–800 (2 ref.)

[Chemotherapy of metastatic soft tissue sarcoma] Le Cesne A. **Presse Med** 1995 Sep 16;24(26):1214–20 (53 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Surgical management of primary soft tissue sarcoma. Beech DJ, et al. **Hematol Oncol Clin North Am** 1995 Aug; 9(4):707–18 (17 ref.)

Adult soft tissue sarcomas of the head and neck treated by radiation and surgery or radiation alone: patterns of failure and prognostic factors. Willers H, et al. **Int J Radiat Oncol Biol Phys** 1995 Oct 15;33(3):585–93 (26 ref.)

The surgeon as a leader in cancer care: lessons learned from the study of soft tissue sarcoma. Brennan MF. **J Am Coll Surg** 1996 Jun;182(6):520–9 (35 ref.)

Extraosseous Ewing's sarcoma in the foot. Berliner RA, et al. **J Foot Ankle Surg** 1995 May–Jun;34(3):301–4 (6 ref.)

Extradigital glomus tumour. Takei TR, et al. **J Hand Surg [Br]** 1995 Jun;20(3):409–12 (26 ref.)

Surgical considerations in a diagnostic imaging evaluation of musculoskeletal masses. Moreau G, et al. **Magn Reson Imaging Clin N Am** 1995 Nov;3(4):577–90 (30 ref.)

Soft-tissue sarcoma of the extremities. MR appearance of post-treatment changes and local recurrences. Varma DG, et al. **Magn Reson Imaging Clin N Am** 1995 Nov; 3(4):695–712 (59 ref.)

Fibrosarcoma of the thigh. Case report and literature review. Testini M, et al. **Panminerva Med** 1996 Mar;38(1):51–5 (14 ref.)

[Clear-cell sarcoma of the tendons and aponeuroses] Popkhristova E, et al. **Khirurgiia (Sofiia)** 1995;48(2):44–7 (23 ref.) **(Bul)**

[The role of microsurgery in the reconstruction of loss of substance of soft tissue in the maxillofacial region] Iriarte Ortabe JI, et al. **Acta Stomatol Belg** 1995 Mar;92(1):17–29 (142 ref.) (Eng. Abstr.) **(Fre)**

[Surgery of soft tissue sarcoma (with the exception of the retroperitoneum)] Stöckle E, et al. **Ann Chir** 1996; 50(3):263–75 (85 ref.) (Eng. Abstr.) **(Fre)**

[Malignant tumors in infancy and childhood] Daum R. **Chirurg** 1996 Jun;67(6):584–92 (18 ref.) (Eng. Abstr.) **(Ger)**

[Surgical therapy of soft tissue sarcomas II. Sarcomas of the extremities and their surgical resection] Karakousis CP. **Chirurg** 1995 Oct;66(10):1006–15 (9 ref.) (Eng. Abstr.) **(Ger)**

[Surgical therapy of soft tissue sarcoma. I. General principles and resections of the trunk] Karakousis CP. **Chirurg** 1995 Sep;66(9):905–13 (17 ref.) (Eng. Abstr.) **(Ger)**

[The current controversy in the treatment of congenital fibrosarcoma. A case report] Ramos Díaz JC, et al. **An Esp Pediatr** 1996 Apr;44(4):367–8 (13 ref.) **(Spa)**

THERAPY

Soft tissue and bone sarcomas. Santoro A, et al. **Cancer Chemother Biol Response Modif** 1996;16:617–24 (36 ref.)

Limb-sparing therapy for soft tissue sarcomas. Pollock RE. **Curr Opin Gen Surg** 1994;:224–9 (13 ref.)

Preoperative therapy for soft tissue sarcoma. Eilber F, et al. **Hematol Oncol Clin North Am** 1995 Aug;9(4):817–23 (22 ref.)

Soft-tissue sarcomas. Cheng EY, et al. **Instr Course Lect** 1996;45:461–71 (101 ref.)

[Locally developed sarcoma of the thoracic wall] Bui NB, et al. **Bull Cancer (Paris)** 1996 May;83(5):335–43 (40 ref.) (Eng. Abstr.) **(Fre)**

[The current therapeutic trends in rhabdomyosarcoma of the cervicofacial area. A review of the topic] Colella G, et al. **Minerva Stomatol** 1995 Jul–Aug;44(7–8):335–44 (37 ref.) (Eng. Abstr.) **(Ita)**

ULTRASONOGRAPHY

[Ultrasound skin findings in HIV infection by imaging with 7.5 MHz linear transducers] Bogner JR, et al. **Bildgebung** 1995 Dec;62(4):281–6 (14 ref.) (Eng. Abstr.) **(Ger)**

[Giant-cell tumor of the carpal tunnel, a color Doppler echographic study. A case report] Chiodi E, et al. **Radiol Med (Torino)** 1996 Jan–Feb;91(1–2):126–7 (9 ref.) **(Ita)**

VETERINARY

Aggressive, undifferentiated sarcoma with widespread metastasis in a six-month-old Neopolitan mastiff. Sanders NA, et al. **J Am Anim Hosp Assoc** 1996 Mar–Apr; 32(2):97–101 (18 ref.)

SOFTWARE

Acoustic quantification: a new tool for diagnostic echocardiography. Goens MB, et al. **Curr Opin Cardiol** 1996 Jan;11(1):52–60 (28 ref.)

Creation of a District Diabetes Register using the DIALOG system. Vaughan NJ, et al. **Diabet Med** 1996 Feb; 13(2):175–81 (12 ref.)

DIALOG: co-ordination of the annual review process through a District Diabetes Register linked to the FHSA database. Vaughan NJ, et al. **Diabet Med** 1996 Feb; 13(2):182–8 (11 ref.)

New developments in EPG3 software. Jones W, et al. **Eur J Disord Commun** 1995;30(2):183–92 (22 ref.)

Programs, databases, and expert systems for human geneticists--a survey. Fischer C, et al. **Hum Genet** 1996 Feb;97(2):129–37 (103 ref.)

Advances in computational image processing for microscopy. Carragher B, et al. **J Struct Biol** 1996 Jan–Feb;116(1):2–8 (35 ref.)

MRC image processing programs. Crowther RA, et al. **J Struct Biol** 1996 Jan–Feb;116(1):9–16 (31 ref.)

The micrograph data processing program. Smith PR, et al. **J Struct Biol** 1996 Jan–Feb;116(1):35–40 (28 ref.)

A new generation of the IMAGIC image processing system. van Heel M, et al. **J Struct Biol** 1996 Jan–Feb;116(1):17–24 (58 ref.)

Multiple ligand–ion solutions: a guide for solution preparation and computer program understanding. Schubert R. **J Vasc Res** 1996 Jan–Feb;33(1):86–98 (44 ref.)

Macintosh sequence analysis software. DNAStar's LaserGene. Clewley JP. **Mol Biotechnol** 1995 Jun; 3(3):221–4 (13 ref.)

Radiology systems architecture. Deibel SR, et al. **Radiol Clin North Am** 1996 May;34(3):681–96 (17 ref.)

Anatomy of the jaw, dentition, and related regions. Abrahams JJ, et al. **Semin Ultrasound CT MR** 1995 Dec;16(6):453–67 (13 ref.)

Dental implants and dental CT software programs. Abrahams JJ, et al. **Semin Ultrasound CT MR** 1995 Dec;16(6):468–86 (21 ref.)

Toxicity estimation by chemical substructure analysis: the TOX II program. Klopman G, et al. **Toxicol Lett** 1995 Sep;79(1–3):145–55 (14 ref.)

Frontiers for the coming millennium. Kahan BD. **Transplant Proc** 1996 Aug;28(4):2299–306 (31 ref.)

[Virtual reality in medicine] Völter S, et al. **Radiologe** 1995 Sep;35(9):563–8 (25 ref.) (Eng. Abstr.) **(Ger)**

[Problems on medical statistic processing--special reference to incorrect application] Kuritani N. **Nippon Seirigaku Zasshi** 1996;58(3):127–32 (0 ref.) **(Jpn)**

STANDARDS

Software standards and the laboratory information system. Aller RD. **Am J Clin Pathol** 1996 Apr;105(4 Suppl 1):S48–53 (15 ref.)

SOFTWARE ENGINEERING see **SOFTWARE**

SOFTWARE TOOLS see **SOFTWARE**

SOFTWARE VALIDATION

Software regression testing and quality assurance. Weilert M. **Am J Clin Pathol** 1996 Apr;105(4 Suppl 1):S10–6 (8 ref.)

Bibliography database managers. A comparative review. Nicoll LH, et al. **Comput Nurs** 1996 Jan–Feb;14(1):45–56 (3 ref.)

SOFTWARE VERIFICATION see **SOFTWARE VALIDATION**

SOIL MICROBIOLOGY

The regulation of methane oxidation in soil. Mancinelli RL. **Annu Rev Microbiol** 1995;49:581–605 (216 ref.)

Molecular site assessment and process monitoring in bioremediation and natural attenuation. off Sayler GS, et al. **Appl Biochem Biotechnol** 1995 Jul–Sep;54(1–3):277–90 (25 ref.)

Bioaugmentation as a soil bioremediation approach. Vogel TM. **Curr Opin Biotechnol** 1996 Jun;7(3):311–6 (60 ref.)

[Biodegradation of polycyclic aromatic hydrocarbons and its application to the bioremediation of contaminated soils

and sludges] Ferrari MD. **Rev Argent Microbiol** 1996 Apr-Jun;28(2):83-98 (71 ref.) (Eng. Abstr.) **(Spa)**

SOIL POLLUTANTS

Interactions of aniline with soil and groundwater at an industrial spill site. Kosson DS, et al. **Environ Health Perspect** 1995 Jun;103 Suppl 5:71-3 (13 ref.)

[Exposure of children to lead from contaminated soil] Jacobsen P. **Ugeskr Laeger** 1996 Mar 11;158(11):1499-502 (22 ref.) (Eng. Abstr.) **(Dan)**

[Regional and local problems of chemical environmental pollution and health of the population (review of the literature)] Revich BA, et al. **Med Tr Prom Ekol** 1995; (9):23-9 (12 ref.) **(Rus)**

ADMINISTRATION & DOSAGE

Ingestion of sludge applied organic chemicals by animals. Fries GF. **Sci Total Environ** 1996 Jun 21;185(1-3):93-108 (112 ref.)

ADVERSE EFFECTS

Chemistry, toxicology, and human health risk of cyanide compounds in soils at former manufactured gas plant sites. Shifrin NS, et al. **Regul Toxicol Pharmacol** 1996 Apr; 23(2):106-16 (50 ref.)

Chlorophenols in the terrestrial environment. Jensen J. **Rev Environ Contam Toxicol** 1996;146:25-51 (95 ref.)

Hazard to man and the environment posed by the use of urban waste compost: a review. Déportes I, et al. **Sci Total Environ** 1995 Nov 30;172(2-3):197-22 (182 ref.)

ANALYSIS

Influence of soil half-life on risk assessment of carcinogens. Borgert CJ, et al. **Regul Toxicol Pharmacol** 1995 Oct; 22(2):143-51 (24 ref.)

Persistent pesticides in Mexico. Albert LA. **Rev Environ Contam Toxicol** 1996;147:1-44 (85 ref.)

Validation of a methodology for modelling PCDD and PCDF intake via the foodchain. Eduljee GH, et al. **Sci Total Environ** 1996 Sep 9;187(3):211-29 (36 ref.)

METABOLISM

Bioaugmentation as a soil bioremediation approach. Vogel TM. **Curr Opin Biotechnol** 1996 Jun;7(3):311-6 (60 ref.)

Atrazine retention and transport in soils. Ma L, et al. **Rev Environ Contam Toxicol** 1996;145:129-73 (209 ref.)

[Biodegradation of polycyclic aromatic hydrocarbons and its application to the bioremediation of contaminated soils and sludges] Ferrari MD. **Rev Argent Microbiol** 1996 Apr-Jun;28(2):83-98 (71 ref.) (Eng. Abstr.) **(Spa)**

PHARMACOKINETICS

Ingestion of sludge applied organic chemicals by animals. Fries GF. **Sci Total Environ** 1996 Jun 21;185(1-3):93-108 (112 ref.)

TOXICITY

Influence of soil half-life on risk assessment of carcinogens. Borgert CJ, et al. **Regul Toxicol Pharmacol** 1995 Oct; 22(2):143-51 (24 ref.)

SOIL POLLUTANTS, RADIOACTIVE

ADVERSE EFFECTS

Uranium in the environment: occurrence, transfer, and biological effects. Ribera D, et al. **Rev Environ Contam Toxicol** 1996;146:53-89 (130 ref.)

SOLANUM TUBEROSUM see **POTATOES**

SOLAR AGING OF SKIN see **SKIN AGING**

SOLEUS MUSCLE see **MUSCLE, SKELETAL**

SOLITARY CYSTS see **BONE CYSTS**

SOLITARY NUCLEUS

DRUG EFFECTS

Neurochemical modulation of cardiovascular control in the nucleus tractus solitarius. Lawrence AJ, et al. **Prog Neurobiol** 1996 Jan;48(1):21-53 (500 ref.)

PHYSIOLOGY

Neurochemical modulation of cardiovascular control in the nucleus tractus solitarius. Lawrence AJ, et al. **Prog Neurobiol** 1996 Jan;48(1):21-53 (500 ref.)

SOLO PRACTICE see **PRIVATE PRACTICE**

SOLUTIONS

Multiple ligand-ion solutions: a guide for solution preparation and computer program understanding. Schubert R. **J Vasc Res** 1996 Jan-Feb;33(1):86-98 (44 ref.)

SOLVENTS

ADMINISTRATION & DOSAGE

Removal of superglue from the external ear using acetone: case report and literature review. Abadir WF, et al. **J Laryngol Otol** 1995 Dec;109(12):1219-21 (5 ref.)

ADVERSE EFFECTS

Auditory and vestibular functions after single or combined exposure to toluene: a review. Morata TC, et al. **Arch Toxicol** 1995;69(7):431-43 (106 ref.)

Respiratory effects of organic solvent exposure. Schenker MB, et al. **Tuber Lung Dis** 1996 Feb;77(1):4-18 (92 ref.)

[Multiple occupational exposure to solvents] Alessio L, et al. **G Ital Med Lav** 1994 Jan-Nov;16(1-6):37-42 (26 ref.) (Eng. Abstr.) **(Ita)**

[Relationship between exposure to environmental toxins and motor neuron disease: a case report] Vanacore N, et al. **Med Lav** 1995 Nov-Dec;86(6):522-33 (50 ref.) (Eng. Abstr.) **(Ita)**

CHEMISTRY

Role of hydration and water structure in biological and colloidal interactions. Israelachvili J, et al. **Nature** 1996 Jan 18;379(6562):219-25 (85 ref.)

METABOLISM

In situ bioremediation of chlorinated solvents. Semprini L. **Environ Health Perspect** 1995 Jun;103 Suppl 5:101-5 (17 ref.)

Alcohol dehydrogenase: multiplicity and relatedness in the solvent-producing clostridia. Chen JS. **FEMS Microbiol Rev** 1995 Oct;17(3):263-73 (44 ref.)

Solventogenic enzymes of Clostridium acetobutylicum: catalytic properties, genetic organization, and transcriptional regulation. Dürre P, et al. **FEMS Microbiol Rev** 1995 Oct;17(3):251-62 (90 ref.)

Molecular genetics and the initiation of solventogenesis in Clostridium beijerinckii (formerly Clostridium acetobutylicum) NCIMB 8052. Wilkinson SR, et al. **FEMS Microbiol Rev** 1995 Oct;17(3):275-85 (69 ref.)

POISONING

Hepatitis, rash and eosinophilia following trichloroethylene exposure: a case report and speculation on mechanistic similarity to halothane induced hepatitis. Bond GR. **J Toxicol Clin Toxicol** 1996;34(4):461-6 (11 ref.)

[Exposure to solvents in scleroderma: disseminated circumscribed scleroderma (morphea) in a painter exposed to perchloroethylene] Hinnen U, et al. **Schweiz Med Wochenschr** 1995 Dec 16;125(50):2433-7 (13 ref.) (Eng. Abstr.) **(Ger)**

SOMATIC CELL HYBRIDS see **HYBRID CELLS**

SOMATIC GENE THERAPY see **GENE THERAPY**

SOMATIZATION DISORDER see **SOMATOFORM DISORDERS**

SOMATOCRININ see **SOMATOTROPIN-RELEASING HORMONE**

SOMATOFORM DISORDERS

DIAGNOSIS

The primary care of patients who have bodily concerns. Blackwell B, et al. **Arch Fam Med** 1996 Sep;5(9):457-63 (65 ref.)

Musculoskeletal pain syndromes that affect adolescents. Szer IS. **Arch Pediatr Adolesc Med** 1996 Jul;150(7):740-7 (23 ref.)

Medical disorders in the schizophrenic patient. Vieweg V, et al. **Int J Psychiatry Med** 1995;25(2):137-72 (179 ref.)

Transcultural aspects of dissociative and somatoform disorders. Escobar JI. **Psychiatr Clin North Am** 1995 Sep; 18(3):555-69 (45 ref.)

[Masked depression] Verster GC, et al. **S Afr Med J** 1995 Aug;85(8):759-62 (24 ref.) (Eng. Abstr.) **(Afr)**

[Diagnosis and management of neurotic occupational disorders (before pension application)] Stevens A, et al. **Nervenarzt** 1995 Nov;66(11):811-9 (42 ref.) (Eng. Abstr.) **(Ger)**

[Anxiety disorders in the elderly--diagnostic problems and therapeutic prospects] Boerner RJ. **Z Gerontol Geriatr** 1995 Nov-Dec;28(6):435-43 (48 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Unexplained illness: the mind versus the environment [see comments] Radcliffe MJ, et al. **J R Soc Med** 1995 Dec; 88(12):678-9 (12 ref.) Comment in: J R Soc Med 1996 Mar;89(3):180. Comment in: J R Soc Med 1996 Apr;89(4):238.

IMMUNOLOGY

Health psychology: psychological factors and physical disease from the perspective of human psychoneuroimmunology. Cohen S, et al. **Annu Rev Psychol** 1996;47:113-42 (155 ref.)

PSYCHOLOGY

Dissociation, somatization, and affect dysregulation: the complexity of adaptation of trauma. van der Kolk BA, et al. **Am J Psychiatry** 1996 Jul;153(7 Suppl):83-93 (90 ref.)

The primary care of patients who have bodily concerns. Blackwell B, et al. **Arch Fam Med** 1996 Sep;5(9):457-63 (65 ref.)

Body dysmorphic disorder: an underestimated entity? [letter] Hanes KR. **Australas J Dermatol** 1995 Nov;36(4):227-8 (8 ref.)

Fibromyalgia syndrome and psychiatric disorder. Dunne FJ, et al. **Br J Hosp Med** 1995 Sep 6-19;54(5):194-7 (23 ref.)

Association between psychopathology and headache syndromes. Merikangas KR. **Curr Opin Neurol** 1995 Jun; 8(3):248-51 (19 ref.)

Pathways linking affective disturbances and physical disorders. Cohen S, et al. **Health Psychol** 1995 Sep; 14(5):374-80 (50 ref.)

Somatisation in children. Garralda ME. **J Child Psychol Psychiatry** 1996 Jan;37(1):13-33 (125 ref.)

Annotation: aspects of pain in children and adolescents. McGrath PJ. **J Child Psychol Psychiatry** 1995 Jul; 36(5):717-30 (50 ref.)

Psychology's role in the assessment of erectile dysfunction: historical precedents, current knowledge, and methods. Ackerman MD, et al. **J Consult Clin Psychol** 1995 Dec; 63(6):862-76 (185 ref.)

Somatization in Hispanics. Hulme PA. **J Psychosoc Nurs Ment Health Serv** 1996 Mar;34(3):33-7 (14 ref.)

Somatoform and personality disorders: syndromal comorbidity and overlapping developmental pathways [comment] Bass C, et al. **J Psychosom Res** 1995 May; 39(4):403-27 (99 ref.) Comment on: J Psychosom Res 1995 May;39(4):395-7.

'Functional overlay', and illness behaviour in chronic pain: distress or malingering? Conceptual difficulties in medico-legal assessment of personal injury claims. Main CJ, et al. **J Psychosom Res** 1995 Aug;39(6):737-53 (58 ref.)

Psychological aspects of non-cardiac chest pain. Serlie AW, et al. **Psychother Psychosom** 1995;64(2):62-73 (57 ref.)

[What is somatization?] Rooijmans HG, et al. **Ned Tijdschr Geneeskd** 1996 Jun 8;140(23):1217-20 (16 ref.) **(Dut)**

[Psycho-oncology in gynecology] **Arch Gynecol Obstet** 1995; 257(1-4):270-7 (28 ref.) **(Ger)**

[Sense and success of psychosomatic preparation for labor] Stauber M. **Arch Gynecol Obstet** 1995;257(1-4):129-35 (8 ref.) **(Ger)**

[Chronic fatigue syndrome--psychiatric aspects] Lemke MR. **Fortschr Neurol Psychiatr** 1996 Apr;64(4):132-41 (77 ref.) (Eng. Abstr.) **(Ger)**

[Psychiatric emergencies and crises in gynecology] Gaebel W, et al. **Gynakologe** 1995 Dec;28(6):403-11 (19 ref.) **(Ger)**

[Pain and psychological disorders in the elderly] Wojnar J, et al. **Z Gerontol Geriatr** 1995 Sep-Oct;28(5):369-73 (22 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

The efficacy of psychosocial treatments in primary care. A review of randomized clinical trials. Brown C, et al. **Gen Hosp Psychiatry** 1995 Nov;17(6):414-24 (43 ref.)

SOMATOMAMMOTROPIN, CHORIONIC see **PLACENTAL LACTOGEN**

SOMATOMAMMOTROPIN RECEPTORS see **RECEPTORS, SOMATOTROPIN**

SOMATOMEDIN-BINDING PROTEINS see **INSULIN-LIKE GROWTH-FACTOR-BINDING PROTEINS**

SOMATOMEDIN C see **INSULIN-LIKE GROWTH FACTOR I**

SOMATOMEDIN C RECEPTORS see **RECEPTORS, INSULIN-LIKE-GROWTH FACTOR I**

SOMATOMEDIN MSA see **INSULIN-LIKE GROWTH FACTOR II**

SOMATOMEDIN RECEPTORS see **RECEPTORS, SOMATOMEDIN**

SOMATOMEDINS

see related
RECEPTORS, SOMATOMEDIN

METABOLISM

Insulin-like growth factors and breast cancer. Lee AV, et al. **Biomed Pharmacother** 1995;49(9):415-21 (74 ref.)

Relations of hormones and growth factors at the crossroad of pathogenesis and pharmacotherapeutics. The case of diabetes mellitus [editorial] Mathé G. **Biomed Pharmacother** 1995;49(5):221-4 (38 ref.)

Insulin-like growth factors (IGFs) and IGF-I treatment in

the adolescent with insulin-dependent diabetes mellitus. Dunger DB, et al. **Metabolism** 1995 Oct;44(10 Suppl 4):119–23 (56 ref.)

PHARMACOLOGY

How neurotrophic factors protect brain against excitotoxicity. Cuevas Sanchez P. **Surg Neurol** 1996 Aug; 46(2):152–3 (15 ref.)

PHYSIOLOGY

Is the central nervous system a target for growth hormone and insulin-like growth factors? Han VK. **Acta Paediatr Suppl** 1995 Sep;411:3–8 (63 ref.)

The role of the insulin-like growth factor system in human cancer. Werner H, et al. **Adv Cancer Res** 1996;68:183–223 (184 ref.)

Gene-targeting and transgenic approaches to IGF and IGF binding protein function. Wood TL. **Am J Physiol** 1995 Oct;269(4 Pt 1):E613–22 (101 ref.)

Insulin-like growth factors and inflammatory bowel disease. Lund PK, et al. **Baillieres Clin Gastroenterol** 1996 Mar; 10(1):83–96 (77 ref.)

Peptide growth factors in the prostate as mediators of stromal epithelial interaction. Byrne RL, et al. **Br J Urol** 1996 May; 77(5):627–33 (65 ref.)

The ovarian insulin and insulin-like growth factor system with an emphasis on domestic animals. Spicer LJ, et al. **Domest Anim Endocrinol** 1995 Jul;12(3):223–45 (182 ref.)

Insulin-like growth factor-binding proteins (IGFBPs) and their regulatory dynamics. Kelley KM, et al. **Int J Biochem Cell Biol** 1996 Jun;28(6):619–37 (162 ref.)

Insulin-like growth factors (IGFs) and IGF-binding proteins in diabetic kidney disease. Phillip M, et al. **Isr J Med Sci** 1995 Dec;31(12):712–6 (66 ref.)

IGFs in the feedback control of GH secretion: Hypothalamic and/or pituitary action? [editorial] Ceda GP. **J Endocrinol Invest** 1995 Oct;18(9):734–7 (26 ref.)

The insulin-like growth factor signaling system and ALS neurotrophic factor treatment strategies. Festoff BW, et al. **J Neurol Sci** 1995 May;129 Suppl:114–21 (60 ref.)

Growth hormone, insulin-like growth factor and the kidney [editorial] Krieg RJ Jr, et al. **Kidney Int** 1995 Aug; 48(2):321–36 (259 ref.)

The insulin-like growth factor system in vascular smooth muscle: interaction with insulin and growth factors. Arnqvist HJ, et al. **Metabolism** 1995 Oct;44(10 Suppl 4):58–66 (102 ref.)

The role of growth hormone, insulin-like growth factors (IGFs), and IGF-binding proteins in experimental diabetic kidney disease. Flyvbjerg A, et al. **Metabolism** 1995 Oct; 44(10 Suppl 4):67–71 (62 ref.)

The insulin-like growth factors in critical illness: pathophysiology and therapeutic potential. Holly JM. **Proc Nutr Soc** 1995 Jul;54(2):591–9 (56 ref.)

The insulin-like growth factor system in the prostate. Peehl DM, et al. **World J Urol** 1995;13(5):306–11 (38 ref.)

THERAPEUTIC USE

The insulin-like growth factor signaling system and ALS neurotrophic factor treatment strategies. Festoff BW, et al. **J Neurol Sci** 1995 May;129 Suppl:114–21 (60 ref.)

The insulin-like growth factors in critical illness: pathophysiology and therapeutic potential. Holly JM. **Proc Nutr Soc** 1995 Jul;54(2):591–9 (56 ref.)

How neurotrophic factors protect brain against excitotoxicity. Cuevas Sanchez P. **Surg Neurol** 1996 Aug; 46(2):152–3 (15 ref.)

SOMATOSENSORY CORTEX

ANATOMY & HISTOLOGY

Functional magnetic resonance imaging and the supplementary sensorimotor area. Gadian DG, et al. **Adv Neurol** 1996;70:161–5 (20 ref.)

GROWTH & DEVELOPMENT

[The development of rat somatosensory (barrel) cortex visualized by optical recording] Kurotani T, et al. **Tanpakushitsu Kakusan Koso** 1996 May;41(6):758–65 (7 ref.) **(Jpn)**

INJURIES

Neurocognitive studies in patients with supplementary sensorimotor area lesions. Burton DB, et al. **Adv Neurol** 1996;70:249–61 (58 ref.)

PHYSIOLOGY

Generation of movement-related potentials and fields in the supplementary sensorimotor area and the primary motor area. Deecke L, et al. **Adv Neurol** 1996;70:127–46 (50 ref.)

Historical overview. Freund HJ. **Adv Neurol** 1996;70:17–27 (70 ref.)

Electrical stimulation of the supplementary sensorimotor area. Fried I. **Adv Neurol** 1996;70:177–85 (52 ref.)

Generation of movement-related potentials in the supplementary sensorimotor area. Hallett M, et al. **Adv Neurol** 1996;70:147–52 (20 ref.)

Generation of contingent negative variation in the supplementary sensorimotor area. Ikeda A, et al. **Adv Neurol** 1996;70:153–9 (44 ref.)

Cortical stimulation of the supplementary sensorimotor area. Lim SH, et al. **Adv Neurol** 1996;70:187–97 (56 ref.)

The supplementary sensorimotor area. An overview. Lüders HO. **Adv Neurol** 1996;70:1–16 (21 ref.)

Generation of movement-related potentials in the supplementary sensorimotor area. Shibasaki H, et al. **Adv Neurol** 1996;70:117–25 (45 ref.)

Electrical stimulation of the supplementary sensorimotor area. Sutherling WW, et al. **Adv Neurol** 1996;70:211–5 (17 ref.)

Corticospinal efferents of the supplementary sensorimotor area in relation to the primary motor area. Wise SP. **Adv Neurol** 1996;70:57–69 (62 ref.)

Evolutionary and comparative neurobiology of the supplementary sensorimotor area. Wise SP. **Adv Neurol** 1996;70:71–83 (133 ref.)

Layer I of primary sensory neocortex: where top-down converges upon bottom-up. Cauller L. **Behav Brain Res** 1995 Nov;71(1–2):163–70 (52 ref.)

Plasticity of adult sensorimotor representations. Donoghue JP. **Curr Opin Neurobiol** 1995 Dec;5(6):749–54 (54 ref.)

The formation of a cortical somatotopic map. Killackey HP, et al. **Trends Neurosci** 1995 Sep;18(9):402–7 (56 ref.)

PHYSIOPATHOLOGY

Dystonia and the supplementary sensorimotor area. Hallett M, et al. **Adv Neurol** 1996;70:471–6 (31 ref.)

Psychogenic seizures and the supplementary sensorimotor area. Kanner AM. **Adv Neurol** 1996;70:461–6 (42 ref.)

Supplementary sensorimotor area epilepsy in adults. King DW, et al. **Adv Neurol** 1996;70:285–91 (31 ref.)

Unusual features of supplementary sensorimotor area epilepsy: cyclic pattern, unusual sensory aura, startle sensitivity, anoxic encephalopathy, and spontaneous remission. Reutens DC, et al. **Adv Neurol** 1996;70:293–300 (22 ref.)

Comparative assessment of sensorimotor function using functional magnetic resonance imaging and electrophysiological methods. Puce A. **J Clin Neurophysiol** 1995 Sep;12(5):450–9 (55 ref.)

SURGERY

Space-occupying lesions of the sensori-motor region. Ebeling U, et al. **Adv Tech Stand Neurosurg** 1995;22:137–81 (106 ref.)

SOMATOSENSORY EVOKED POTENTIALS see **EVOKED POTENTIALS, SOMATOSENSORY**

SOMATOSTATIN

see related
RECEPTORS, SOMATOSTATIN

ANALOGS & DERIVATIVES

Somatostatin analogues and multiple receptors: possible physiological roles. Coy DH, et al. **Ciba Found Symp** 1995; 190:240–52; discussion 252–4 (20 ref.)

Remission of acromegaly caused by pituitary carcinoma after surgical excision of growth hormone-secreting metastasis detected by 111-indium pentetreotide scan. Greenman Y, et al. **J Clin Endocrinol Metab** 1996 Apr;81(4):1628–33 (29 ref.)

Angiopeptin: experimental and clinical studies of inhibition of myointimal proliferation. Foegh ML, et al. **Kidney Int Suppl** 1995 Dec;52:S18–22 (47 ref.)

Octreotide. Lamberts SW, et al. **N Engl J Med** 1996 Jan 25;334(4):246–54 (76 ref.)

Therapy of neuroendocrine tumors with radiolabeled MIBG and somatostatin analogues. Wiseman GA, et al. **Semin Nucl Med** 1995 Jul;25(3):272–8 (39 ref.)

[Somatostatin and its analogs in the treatment of gastrointestinal and liver diseases] Feu F, et al. **Gastroenterol Hepatol** 1996 Feb;19(2):68–77 (102 ref.) **(Spa)**

BLOOD

Somatostatin levels during infancy, pregnancy, and lactation: a review. Goldstein A, et al. **Peptides** 1995;16(7):1321–6 (63 ref.)

[Somatostatin] Saito H. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:288–93 (16 ref.) **(Jpn)**

GENETICS

Regulation of somatostatin gene transcription by cAMP. Montminy M, et al. **Ciba Found Symp** 1995;190:7–20; discussion 20–5 (30 ref.)

METABOLISM

Somatostatin in the retina. Larsen JN. **Acta Ophthalmol Scand Suppl** 1995;(218):1–24 (91 ref.)

Anatomical localization and regulation of somatostatin gene expression in the basal ganglia and its clinical implications. Chesselet MF, et al. **Ciba Found Symp** 1995;190:51–9; discussion 59–64 (47 ref.)

Somatostatin modulates voltage-dependent Ca2+ channels in GH3 cells via a specific G(o) splice variant. Kleuss C. **Ciba Found Symp** 1995;190:171–82; discussion 182–6 (38 ref.)

Processing and intracellular targeting of prosomatostatin-derived peptides: the role of mammalian endoproteases. Patel YC, et al. **Ciba Found Symp** 1995; 190:26–40; discussion 40–50 (50 ref.)

PHYSIOLOGY

Somatostatin. Reisine T. **Cell Mol Neurobiol** 1995 Dec; 15(6):597–614 (106 ref.)

Somatostatin and its receptor. Introduction. Reichlin S. **Ciba Found Symp** 1995;190:1–6 (38 ref.)

Neuropeptides in morphologically and functionally identified primary afferent neurons in dorsal root ganglia: substance P, CGRP and somatostatin. Lawson SN. **Prog Brain Res** 1995;104:161–73 (56 ref.)

SECRETION

Pancreatic somatostatin-secreting gangliocytic paraganglioma with lymph node metastases. Tomic S, et al. **Am J Gastroenterol** 1996 Mar;91(3):607–8 (12 ref.)

The somatostatin-gastrin link of Helicobacter pylori infection. Calam J. **Ann Med** 1995 Oct;27(5):569–73 (46 ref.)

THERAPEUTIC USE

Review article: the relative effectiveness of somatostatin and octreotide therapy in pancreatic disease [see comments] Jenkins SA, et al. **Aliment Pharmacol Ther** 1995 Aug; 9(4):349–61 (91 ref.) Comment in: Aliment Pharmacol Ther 1995 Oct;9(5):581–3.

[Emergency medical treatment of portal hypertension] Heresbach D, et al. **Presse Med** 1995 Sep 30;24(28):1311–4 (26 ref.) (Eng. Abstr.) **(Fre)**

[Gastroduodenal hemorrhages of peptic origin and the outlook for using somatostatin (Stilamin)] Smakov GM. **Vestn Khir Im I I Grek** 1995;154(3):120–3 (37 ref.) **(Rus)**

[Somatostatin and its analogs in the treatment of gastrointestinal and liver diseases] Feu F, et al. **Gastroenterol Hepatol** 1996 Feb;19(2):68–77 (102 ref.) **(Spa)**

SOMATOSTATIN RECEPTORS see **RECEPTORS, SOMATOSTATIN**

SOMATOSTATIN-14 see **SOMATOSTATIN**

SOMATOSTATINOMA

COMPLICATIONS

Somatostatinoma of the pancreas associated with von Hippel-Lindau disease. Maki M, et al. **Intern Med** 1995 Jul;34(7):661–5 (20 ref.)

[Pancreatic somatostatinoma and MEN 1. Apropos of a case. Review of the literature] Roy J, et al. **Ann Endocrinol (Paris)** 1996;57(1):71–6 (26 ref.) (Eng. Abstr.) **(Fre)**

SOMATOTROPIN

see related
RECEPTORS, SOMATOTROPIN

Growth hormone: its clinical relevance. Rijnberk A. **Vet Q** 1995 Apr;17 Suppl 1:S17–9 (11 ref.)

ADVERSE EFFECTS

Complications of growth hormone therapy in children. Blethen SL. **Curr Opin Pediatr** 1995 Aug;7(4):466–71 (62 ref.)

[Hypophyseal growth hormone and Creutzfeldt-Jakob disease in The Netherlands. Ad hoc Commission Creutzfeldt-Jakob-disease of the Dutch Growth Foundation] Rikken B, et al. **Ned Tijdschr Geneeskd** 1996 Jun 1;140(22):1163–5 (17 ref.) **(Dut)**

AGONISTS

[The diagnostic-therapeutic fundamentals of growth-hormone secretagogues (editorial)] Argente Oliver J, et al. **An Esp Pediatr** 1996 Jul;45(1):2–5 (36 ref.) **(Spa)**

ANALYSIS

[Growth hormone (GH, hGH)] Inoue K, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:267–70 (20 ref.) **(Jpn)**

BIOSYNTHESIS

Control of growth hormone synthesis. Tuggle CK, et al. **Domest Anim Endocrinol** 1996 Jan;13(1):1–33 (256 ref.)

The ontogeny of growth hormone, insulin-like growth factors and sex steroids: molecular aspects. Han VK. **Horm Res** 1996;45(1–2):61–6 (45 ref.)

New insights in the molecular mechanism of progestin-induced proliferation of mammary epithelium: induction of the local biosynthesis of growth hormone (GH) in the mammary glands of dogs, cats and humans. Mol JA, et al. **J Steroid Biochem Mol Biol** 1996 Jan; 57(1–2):67–71 (44 ref.)

SOMATOTROPIN

BLOOD

[The biological basis of suicidal behavior: neuroendocrine and psychophysiological approach to the role of catecholamines] Pitchot W, et al. **Acta Psychiatr Belg** 1995 Jul–Oct;95(4–5):210–33 (102 ref.) (Eng. Abstr.) **(Fre)**

[Growth hormone–binding protein] Takeda S, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:346–50 (27 ref.) **(Jpn)**

DEFICIENCY

Growth hormone deficiency in children treated for leukaemia. Leiper A. **Acta Paediatr Suppl** 1995 Sep; 411:41–4 (21 ref.)

Growth hormone deficiency in adults: a review. Meling TR, et al. **Am J Med Sci** 1996 Apr;311(4):153–66 (124 ref.)

Short stature and growth hormone deficiency. Hindmarsh PC, et al. **Clin Endocrinol (Oxf)** 1995 Aug;43(2):133–42 (35 ref.)

How short is too short? Sherman L, et al. **Compr Ther** 1995 Oct;21(10):610–5 (9 ref.)

Metabolic effects of GH: a rationale for continued GH treatment of GH-deficient adults after cessation of linear growth. Juul A, et al. **Horm Res** 1995;44 Suppl 3:64–72 (90 ref.)

Growth hormone deficiency and quality of life. McGauley G, et al. **Horm Res** 1996;45(1–2):34–7 (23 ref.)

Safety of growth hormone after treatment of a childhood malignancy. Ogilvy-Stuart AL. **Horm Res** 1995;44 Suppl 3:73–9 (39 ref.)

Growth, growth hormone and cognitive functions. Sartorio A, et al. **Horm Res** 1996;45(1–2):23–9 (61 ref.)

Links between growth hormone deficiency, adaptation and social phobia. Stabler B, et al. **Horm Res** 1996;45(1–2):30–3 (27 ref.)

Age-related endocrine deficiencies and fractures of the proximal femur. I implications of growth hormone deficiency in the elderly. Boonen S, et al. **J Endocrinol** 1996 Apr;149(1):7–12 (72 ref.)

Growth hormone deficiency in adults: a new indication for recombinant human growth hormone [editorial] Bengtsson BA. **J Intern Med** 1996 Apr;239(4):283–6 (26 ref.)

Defining growth hormone deficiency in adults. Ho KK, et al. **Metabolism** 1995 Oct;44(10 Suppl 4):91–6 (63 ref.)

Fuel metabolism in growth hormone–deficient adults. Jørgensen JO, et al. **Metabolism** 1995 Oct;44(10 Suppl 4):103–7 (33 ref.)

[Growth hormone deficiency and substitution in adults] de Boer H, et al. **Ned Tijdschr Geneeskd** 1996 Jul 13; 140(28):1441–5 (33 ref.) **(Dut)**

[Growth hormone therapy in childhood. Growth hormone therapy in small children without growth hormone deficiency] Butenandt O. **Fortschr Med** 1996 Jun 10; 114(16):201–4 (42 ref.) (Eng. Abstr.) **(Ger)**

[Growth hormone substitution in adulthood. Use of recombinant human GH—strict diagnostic criteria] Feldmeier H, et al. **Fortschr Med** 1996 Jun 10;114(16):205–9 (42 ref.) (Eng. Abstr.) **(Ger)**

METABOLISM

IGFs in the feedback control of GH secretion: Hypothalamic and/or pituitary action? [editorial] Ceda GP. **J Endocrinol Invest** 1995 Oct;18(9):734–7 (26 ref.)

Carbohydrate metabolism in primary growth hormone resistance (Laron syndrome) before and during insulin-like growth factor–I treatment. Laron Z, et al. **Metabolism** 1995 Oct;44(10 Suppl 4):113–8 (41 ref.)

Binding in the growth hormone receptor complex. Wells JA. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):1–6 (39 ref.)

[Growth hormone (GH) and insulin-like growth factor I (IGF-1) in nutritional status] Chevenne D, et al. **Ann Biol Clin (Paris)** 1995;53(10–11):527–38 (115 ref.) (Eng. Abstr.) **(Fre)**

PHARMACOLOGY

Effects of growth hormone on cerebral development: morphological studies. Noguchi T. **Horm Res** 1996; 45(1–2):5–17 (41 ref.)

Effects of growth hormone on phosphocalcium homeostasis and bone metabolism. Saggese G, et al. **Horm Res** 1995; 44 Suppl 3:55–63 (86 ref.)

Growth hormone and calcitriol as modifiers of bone formation in renal osteodystrophy. Salusky IB, et al. **Kidney Int** 1995 Sep;48(3):657–65 (107 ref.)

Metabolic effects of growth hormone in humans. Møller N, et al. **Metabolism** 1995 Oct;44(10 Suppl 4):33–6 (49 ref.)

Metabolic effects of growth hormone in children. Wollmann HA, et al. **Metabolism** 1995 Oct;44(10 Suppl 4):97–102 (84 ref.)

[Growth hormone and bone metabolism] Manten JW, et al. **Ned Tijdschr Geneeskd** 1996 May 18;140(20):1064–8 (37 ref.) **(Dut)**

[Growth hormone, a potential way to improve livestock productivity in Africa] Missohou A. **Dakar Med** 1994; 39(1):9–15 (58 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Is the central nervous system a target for growth hormone and insulin-like growth factors? Han VK. **Acta Paediatr Suppl** 1995 Sep;411:3–8 (63 ref.)

Molecular mechanism of growth hormone action. Carter-Su C, et al. **Annu Rev Physiol** 1996;58:187–207 (139 ref.)

Effects of growth hormone and insulin-like growth factor I on the immune system. Auernhammer CJ, et al. **Eur J Endocrinol** 1995 Dec;133(6):635–45 (137 ref.)

Growth hormone, growth factors and the gonad. Albanese A, et al. **Horm Res** 1995;44 Suppl 3:15–17 (25 ref.)

Aging and immune function: a possible role for growth hormone. Gelato MC. **Horm Res** 1996;45(1–2):46–9 (25 ref.)

Sex steroid regulation of growth hormone secretion and action. Ho KK, et al. **Horm Res** 1996;45(1–2):67–73 (53 ref.)

Role of growth hormone and sex steroids in achieving and maintaining normal bone mass. Holmes SJ, et al. **Horm Res** 1996;45(1–2):86–93 (96 ref.)

Growth hormone and fertility—clinical studies. Homburg R. **Horm Res** 1996;45(1–2):81–5 (27 ref.)

Influence of growth hormone and androgens on body composition in adults. Jørgensen JO, et al. **Horm Res** 1996; 45(1–2):94–8 (31 ref.)

Growth hormone, growth factors and hematopoiesis. Kelley KW, et al. **Horm Res** 1996;45(1–2):38–45 (91 ref.)

Sex steroids, growth hormone, insulin-like growth factor–1: neuroendocrine and metabolic regulation in puberty. Mauras N, et al. **Horm Res** 1996;45(1–2):74–80 (41 ref.)

Effects of growth hormone on cerebral development: morphological studies. Noguchi T. **Horm Res** 1996; 45(1–2):5–17 (41 ref.)

Growth hormone and its receptors in the central nervous system—location and functional significance. Nyberg F, et al. **Horm Res** 1996;45(1–2):18–22 (28 ref.)

Growth hormone and the immune response to bacterial infection. Saito H, et al. **Horm Res** 1996;45(1–2):50–4 (39 ref.)

Growth, growth hormone and cognitive functions. Sartorio A, et al. **Horm Res** 1996;45(1–2):23–9 (61 ref.)

Growth hormone axis in cushing's syndrome. Wajchenberg BL, et al. **Horm Res** 1996;45(1–2):99–107 (36 ref.)

Growth hormone, insulin-like growth factor and the kidney [editorial] Krieg RJ Jr, et al. **Kidney Int** 1995 Aug; 48(2):321–36 (259 ref.)

The role of growth hormone, insulin-like growth factors (IGFs), and IGF-binding proteins in experimental diabetic kidney disease. Flyvbjerg A, et al. **Metabolism** 1995 Oct; 44(10 Suppl 4):67–71 (62 ref.)

The role of growth hormone/insulin–like growth factors in adipocyte differentiation. Wabitsch M, et al. **Metabolism** 1995 Oct;44(10 Suppl 4):45–9 (58 ref.)

Cardiac performance: growth hormone enters the race. Saccà L, et al. **Nat Med** 1996 Jan;2(1):29–31 (16 ref.)

The role of the growth and lactogenic hormone family in immune function. Berczi I. **Neuroimmunomodulation** 1994 Jul–Aug;1(4):201–16 (182 ref.)

An analytical review of growth hormone studies in children after renal transplantation. Ingulli E, et al. **Pediatr Nephrol** 1995;9 Suppl:S61–5 (22 ref.)

Growth hormone and malnutrition in dialysis patients. Blake PG. **Perit Dial Int** 1995 Jul–Sep;15(6):210–6 (49 ref.)

Catabolic hormones and growth hormone resistance in acquired immunodeficiency syndrome and other catabolic states. Rodgers BD. **Proc Soc Exp Biol Med** 1996 Sep; 212(4):324–31 (106 ref.)

[Growth factors and cytokines as messengers of hormonal effects] Ilvesmäki V, et al. **Duodecim** 1994;110(10):949–57 (53 ref.) **(Fin)**

[Growth hormone receptor and binding protein: roles in cellular responsiveness to growth hormone] Maes M, et al. **Ann Endocrinol (Paris)** 1995;56(4):253–8 (47 ref.) (Eng. Abstr.) **(Fre)**

[Growth hormone—a pathogenetic factor in chronic congestive heart insufficiency?] Dreifuss PM. **Dtsch Med Wochenschr** 1996 Apr 12;121(15):492–6 (35 ref.) **(Ger)**

[Zinc and the growth hormone system] Ripa S, et al. **Minerva Med** 1996 Jan–Feb;87(1–2):25–31 (86 ref.) (Eng. Abstr.) **(Ita)**

RADIATION EFFECTS

[Endocrinological and auxological sequelae in the treatment of oncological–hematological diseases] Cacciari E, et al. **Minerva Pediatr** 1996 Mar;48(3):63–70 (61 ref.) **(Ita)**

SECRETION

Interaction between sleep and growth hormone. Evaluated by manual polysomnography and automatic power spectrum analysis. Aström C. **Acta Neurol Scand** 1995 Oct; 92(4):281–96 (103 ref.)

Growth hormone/insulin–like growth factor I axis in children treated for brain tumours: relationship to chemotherapy and nutrition. Rappaport R, et al. **Acta Paediatr Suppl** 1995 Sep;411:37–9; discussion 40 (19 ref.)

Growth hormone insensitivity syndrome (Laron syndrome): main characteristics and effects of IGF1 treatment. Carel JC, et al. **Diabetes Metab** 1996 Jul;22(4):251–6 (34 ref.)

Insulin therapy and GH-IGF-I axis disorders in diabetes: impact of glycaemic control and hepatic insulinization. Hanaire-Broutin H, et al. **Diabetes Metab** 1996 Jul; 22(4):245–50 (42 ref.)

Exploration of the somatotropic axis. Tauber M, et al. **Diabetes Metab** 1996 Jul;22(4):240–4 (6 ref.)

Growth hormone secretagogues. Clinical experience and therapeutic potential. Laron Z. **Drugs** 1995 Oct; 50(4):595–601 (48 ref.)

Involvement of brain catecholamines and acetylcholine in growth hormone hypersecretory states. Pathophysiological, diagnostic and therapeutic implications. Müller EE, et al. **Drugs** 1995 Nov; 50(5):805–37 (285 ref.)

Influence of thyroid hormones on the regulation of growth hormone secretion. Giustina A, et al. **Eur J Endocrinol** 1995 Dec;133(6):646–53 (52 ref.)

Gender differences in secretory activity of the human somatotropic (growth hormone) axis. Veldhuis JD. **Eur J Endocrinol** 1996 Mar;134(3):287–95 (114 ref.)

Natural course of growth hormone hypersecretion in insulin–dependent diabetes mellitus. Wurzburger MI, et al. **Med Hypotheses** 1996 Feb;46(2):145–9 (48 ref.)

Neuroendocrine regulation of growth hormone secretion. Thorner MO, et al. **Neurosci Biobehav Rev** 1995 Fall; 19(3):465–8 (41 ref.)

IGF–I receptor signalling: lessons from the somatotroph. Melmed S, et al. **Recent Prog Horm Res** 1996;51:189–215; discussion 215–6 (65 ref.)

Modulation of pulsatile GH release through a novel receptor in hypothalamus and pituitary gland. Smith RG, et al. **Recent Prog Horm Res** 1996;51:261–85; discussion 285–6 (59 ref.)

A new receptor for growth hormone–release peptide [comment] Conn PM, et al. **Science** 1996 Aug 16; 273(5277):923 (13 ref.) Comment on: Science 1996 Aug 16;273(5277):974–7.

[Growth hormone secretion and nutrition] de Lemos Silva GM, et al. **Arq Gastroenterol** 1994 Oct–Dec;31(4):159–72 (115 ref.) (Eng. Abstr.) **(Por)**

[The diagnostic–therapeutic fundamentals of growth–hormone secretagogues (editorial)] Argente Oliver J, et al. **An Esp Pediatr** 1996 Jul;45(1):2–5 (36 ref.) **(Spa)**

THERAPEUTIC USE

Recombinant human growth hormone (rhGH) in dialysis patients: update 1995. Fine RN. **Adv Perit Dial** 1995; 11:261–5 (15 ref.)

Recombinant human growth hormone for children with renal failure. Tönshoff B, et al. **Adv Ren Replace Ther** 1996 Jan; 3(1):37–47 (63 ref.)

Lack of effects of recombinant growth hormone on muscle function in patients requiring prolonged mechanical ventilation: a prospective, randomized, controlled study. Pichard C, et al. **Crit Care Med** 1996 Mar;24(3):403–13 (55 ref.)

Evaluation of recombinant human growth hormone for wound management. Rasmussen LH. **Dan Med Bull** 1995 Sep;42(4):358–70 (141 ref.)

Growth hormone and dysmorphic syndromes. Galasso C, et al. **Horm Res** 1995;44 Suppl 3:42–8 (73 ref.)

Role of growth hormone and sex steroids in achieving and maintaining normal bone mass. Holmes SJ, et al. **Horm Res** 1996;45(1–2):86–93 (96 ref.)

Growth hormone and fertility—clinical studies. Homburg R. **Horm Res** 1996;45(1–2):81–5 (27 ref.)

Metabolic effects of GH: a rationale for continued GH treatment of GH-deficient adults after cessation of linear growth. Juul A, et al. **Horm Res** 1995;44 Suppl 3:64–72 (90 ref.)

Safety of growth hormone after treatment of a childhood malignancy. Ogilvy-Stuart AL. **Horm Res** 1995;44 Suppl 3:73–9 (39 ref.)

Growth hormone therapy in Turner syndrome. Analysis of long–term results. Ranke MB. **Horm Res** 1995;44 Suppl 3:35–41 (60 ref.)

Growth hormone deficiency in adults: a new indication for recombinant human growth hormone [editorial] Bengtsson BA. **J Intern Med** 1996 Apr;239(4):283–6 (26 ref.)

Guidelines for the use of growth hormone in children with short stature. A report by the Drug and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society. **J Pediatr** 1995 Dec;127(6):857–67 (72 ref.)

Cardiac performance: growth hormone enters the race. Saccà L, et al. **Nat Med** 1996 Jan;2(1):29–31 (16 ref.)

New hormones in the therapeutic arsenal of chronic renal failure. Growth hormone and erythropoietin. Warady BA, et al. **Pediatr Clin North Am** 1995 Dec;42(6):1551–77 (124 ref.)

[Growth hormone therapy] Sipilä I. **Duodecim** 1994; 110(10):991–9 (28 ref.) **(Fin)**

[Treatment with growth hormone of children with short stature, borne with intrauterine growth retardation] Czernichow P. **Arch Pediatr** 1996;3 Suppl 1:194s–196s (5 ref.) **(Fre)**

[Growth hormone: who can benefit from it?] Schwarz HP. **Ther Umsch** 1995 Oct;52(10):678–81 (16 ref.) (Eng. Abstr.) **(Ger)**

SOMATOTROPIN RECEPTORS see **RECEPTORS, SOMATOTROPIN**

SOMATOTROPIN RELEASE-INHIBITING HORMONE see **SOMATOSTATIN**

SOMATOTROPIN-RELEASING FACTOR 44 see **SOMATOTROPIN-RELEASING HORMONE**

SOMATOTROPIN-RELEASING HORMONE

ADMINISTRATION & DOSAGE

[Optimization of treatment with biosynthetic growth hormone] Chaussain JL. **Arch Pediatr** 1996;3 Suppl 1:151s-153s (21 ref.) **(Fre)**

BLOOD

[Growth hormone-releasing hormone (GHRH)] Shintani Y, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:342-5 (16 ref.) **(Jpn)**

SOMATOTYPES

[Significance of somatometric analysis in medical research] Gubina-Vakulik GI. **Arkh Patol** 1995 Nov-Dec;57(6):77-9 (68 ref.) (Eng. Abstr.) **(Rus)**

SOMNAMBULISM

Forensic sleep medicine and nocturnal wandering. Guilleminault C, et al. **Sleep** 1995 Nov;18(9):721-3 (15 ref.)

DIAGNOSIS

Sleep disorders. Yousaf F, et al. **Br J Hosp Med** 1996 Mar 20-Apr 2;55(6):353-8 (21 ref.)

SOMNOGRAPHY see **POLYSOMNOGRAPHY**

SONICATION

Understanding physical inactivation processes: combined preservation opportunities using heat, ultrasound and pressure. Earnshaw RG, et al. **Int J Food Microbiol** 1995 Dec;28(2):197-219 (122 ref.)

SONOGRAPHY, TRANSCRANIAL DOPPLER see **ULTRASONOGRAPHY, DOPPLER, TRANSCRANIAL**

SORBITAN DERIVATIVES see **POLYSORBATES**

SORBITOL

BLOOD

[Sorbitol] Hayashi T. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:540-2 (11 ref.) **(Jpn)**

METABOLISM

Methods available to estimate the energy values of sugar alcohols. Ellwood KC. **Am J Clin Nutr** 1995 Nov;62(5 Suppl):1169S-1174S (38 ref.)

SORBITOL DEHYDROGENASE see **IDITOL DEHYDROGENASE**

SORE THROAT see **PHARYNGITIS**

SOS RESPONSE (GENETICS)

SOS-regulated proteins in translesion DNA synthesis and mutagenesis. Walker GC. **Trends Biochem Sci** 1995 Oct; 20(10):416-20 (50 ref.)

SOTALOL

THERAPEUTIC USE

Evolving role of sotalol in the management of ventricular tachyarrhythmias. O'Callaghan PA, et al. **Am J Cardiol** 1996 Aug 29;78(4A):54-60 (40 ref.)

SOUND

see related
ACOUSTIC STIMULATION
NOISE

Insect sound production: transduction mechanisms and impedance matching. Bennet-Clark HC. **Symp Soc Exp Biol** 1995;49:199-218 (33 ref.)

SOUND LOCALIZATION

see related
ECHOLOCATION

SOUTHERN BLOTTING see **BLOTTING, SOUTHERN**

SOY BEANS see **SOYBEANS**

SOYBEANS

[Role of soybean proteins in human nutrition (review)] Vysotskii VG, et al. **Vopr Pitan** 1995;(5):20-7 (45 ref.) (Eng. Abstr.) **(Rus)**

SP1 TRANSCRIPTION FACTOR see **TRANSCRIPTION FACTOR, SP1**

SP-K RECEPTORS see **RECEPTORS, NEUROKININ-2**

SP-P RECEPTORS see **RECEPTORS, NEUROKININ-1**

SPACE (ASTRONOMY) see **EXTRATERRESTRIAL ENVIRONMENT**

SPACE CRAFT see **SPACECRAFT**

SPACE EXPLORATION see **SPACE FLIGHT**

SPACE FLIGHT

see related
EXTRATERRESTRIAL ENVIRONMENT
SPACECRAFT

The hazards of reproduction in space. Sullivan R. **Acta Obstet Gynecol Scand** 1996 Apr;75(4):372-7 (72 ref.)

Response of the neuromuscular unit to spaceflight: what has been learned from the rat model. Roy RR, et al. **Exerc Sport Sci Rev** 1996;24:399-425 (72 ref.)

The study of the brain using PET and SPECT: implications for space and underwater neurology. Newberg AB, et al. **J Neurol Sci** 1996 Mar;136(1-2):1-9 (84 ref.)

[Immune function during space flights] Nakahara K. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Apr;19(2):119-27 (52 ref.) **(Jpn)**

[Stresses under conditions of a normal mode of life, during hypokinesia (simulating effects of weightlessness) and in space flights] Grigor'ev AI, et al. **Fiziol Cheloveka** 1996 Mar-Apr;22(2):10-9 (35 ref.) **(Rus)**

[External respiration and gas exchange in space flights] Baranov VM, et al. **Kosm Biol Aviakosm Med** 1991 Nov-Dec;25(6):4-8 (48 ref.) (Eng. Abstr.) **(Rus)**

SPACE MEDICINE see **AEROSPACE MEDICINE**

SPACE PERCEPTION

Unilateral spatial neglect due to a haemorrhagic contusion in the right frontal lobe. Maeshima S, et al. **J Neurol** 1995 Oct;242(10):613-7 (15 ref.)

[Saccadic latencies and unilateral spatial neglect caused by parietal lesions] Cochin JP, et al. **Rev Neurol (Paris)** 1996 Jan;152(1):32-7 (35 ref.) (Eng. Abstr.) **(Fre)**

[Perception in space. Visual aspects of space perception] Viader F. **Rev Neurol (Paris)** 1995 Aug-Sep; 151(8-9):466-73 (67 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Cortical mechanisms for visual perception of object motion and position in space. Battaglini PP, et al. **Behav Brain Res** 1996 Apr;76(1-2):143-54 (57 ref.)

Multiple mechanisms of visual-spatial attention: recent evidence from human electrophysiology. Luck SJ. **Behav Brain Res** 1995 Nov;71(1-2):113-23 (52 ref.)

Encoding of intention and spatial location in the posterior parietal cortex. Andersen RA. **Cereb Cortex** 1995 Sep-Oct; 5(5):457-69 (58 ref.)

Oculocentric spatial representation in parietal cortex. Colby CL, et al. **Cereb Cortex** 1995 Sep-Oct;5(5):470-81 (38 ref.)

Simulation of spatial learning in the Morris water maze by a neural network model of the hippocampal formation and nucleus accumbens. Brown MA, et al. **Hippocampus** 1995; 5(3):171-88 (73 ref.)

Do animals have cognitive maps? Bennett AT. **J Exp Biol** 1996 Jan;199 (Pt 1):219-24 (57 ref.)

Sexually dimorphic spatial learning in meadow voles Microtus pennsylvanicus and deer mice Peromyscus maniculatus. Galea LA, et al. **J Exp Biol** 1996 Jan;199 (Pt 1):195-200 (29 ref.)

Deciphering the hippocampal polyglot: the hippocampus as a path integration system. McNaughton BL, et al. **J Exp Biol** 1996 Jan;199 (Pt 1):173-85 (56 ref.)

The mental and the neural: psychological and neural studies of mental rotation and memory scanning. Georgopoulos AP, et al. **Neuropsychologia** 1995 Nov;33(11):1531-47 (25 ref.)

Eye movement and visual localization of objects in space. Skavenski AA. **Rev Oculomot Res** 1990;4:263-87 (110 ref.)

The role of eye movement in the detection of contrast and spatial detail. Steinman RM, et al. **Rev Oculomot Res** 1990; 4:115-212 (176 ref.)

[The self-organization of the brain as the integration of the processes of different spatial and time scales] Kozhedub RG. **Usp Fiziol Nauk** 1995 Oct-Dec;26(4):28-47 (75 ref.) (Eng. Abstr.) **(Rus)**

SPACE SIMULATION

see related
WEIGHTLESSNESS SIMULATION

SPACE-TIME CLUSTERING

see related
DISEASE OUTBREAKS

SPACECRAFT

Medical education by satellite: the EuroTransMed experience. Young HL. **J Audiov Media Med** 1995 Jun; 18(2):75-8 (0 ref.)

SPACER DNA see **DNA, RIBOSOMAL**

SPANISH AMERICANS see **HISPANIC AMERICANS**

SPARC GLYCOPROTEIN see **OSTEONECTIN**

SPASM

see related
MUSCLE CRAMP
MYOTONIA

CHEMICALLY INDUCED

[Masseter muscle spasm--approach to patient] Ben-Abraham R, et al. **Harefuah** 1995 Aug;129(3-4):135-8 (20 ref.) **(Heb)**

ETIOLOGY

Hamstring spasm in anterior cruciate ligament injuries. Frank CB, et al. **Arthroscopy** 1995 Aug;11(4):444-8 (19 ref.)

SURGERY

Recurrence of hemifacial spasm after microvascular decompression. Payner TD, et al. **Neurosurgery** 1996 Apr; 38(4):686-90; discussion 690-1 (28 ref.)

[Microsurgical vascular decompression in the treatment of facial hemispasm. A retrospective study of a series of 65 cases and review of the literature] Sindou M, et al. **Neurochirurgie** 1996;42(1):17-28 (40 ref.) (Eng. Abstr.) **(Fre)**

SPASM, ESOPHAGEAL see **ESOPHAGEAL SPASM, DIFFUSE**

SPASMOPHILIA see **TETANY**

SPASMS, INFANTILE

DIAGNOSIS

A simple maneuver to provoke benign neonatal sleep myoclonus. Alfonso I, et al. **Pediatrics** 1995 Dec; 96(6):1161-3 (20 ref.)

SPASMUS NUTANS see **SPASMS, INFANTILE**

SPASTIC DIPLEGIA see **CEREBRAL PALSY**

SPASTIC PARAPARESIS see **PARAPARESIS, TROPICAL SPASTIC**

SPASTIC PARAPLEGIA see **PARAPLEGIA**

SPASTIC PARAPLEGIA, HEREDITARY

GENETICS

Hereditary spastic paraplegia: advances in genetic research. Hereditary Spastic Paraplegia Working group. Fink JK, et al. **Neurology** 1996 Jun;46(6):1507-14 (46 ref.)

SPASTICITY, MUSCLE see **MUSCLE SPASTICITY**

SPATIAL BEHAVIOR

Embodiment and emplacement: identities, representation and landscape in Sun City retirement communities. Laws G. **Int J Aging Hum Dev** 1995;40(4):253-80 (60 ref.)

DRUG EFFECTS

Spatial cognition in humans: possible modulation by androgens and estrogens. Hampson E. **J Psychiatry Neurosci** 1995 Nov;20(5):397-404 (66 ref.)

SPEARMAN RANK CORRELATION COEFFICIENT see **STATISTICS, NONPARAMETRIC**

SPECIALISM

Veterinary medical specialization. Lothrop CD Jr. **Adv Vet Sci Comp Med** 1995;39:141-90 (40 ref.)

Preventive medicine: notes toward an agenda for change. Guidotti TL. **Am J Prev Med** 1996 May-Jun;12(3):165-71 (24 ref.)

Primary care: specialists or generalists. Gabriel SE. **Mayo Clin Proc** 1996 Apr;71(4):415-9 (62 ref.)

LEGISLATION & JURISPRUDENCE

Benefits and burdens: legal and ethical issues raised by veterinary specialization. Tannenbaum J. **Adv Vet Sci Comp Med** 1995;39:253-96 (31 ref.)

SPECIALTIES, MEDICAL

The role of the transfusion medicine consultant. Popovsky MA, et al. **Am J Clin Pathol** 1996 Jun;105(6):798-801 (12 ref.)

SPECIALTIES, MEDICAL

How should subspecialists be trained for clinical careers? McFadden D. **Am J Med** 1996 Jul;101(1):1–4 (12 ref.)
[Nursing home medicine, a new medical specialism] de Pijper NF, et al. **Ned Tijdschr Geneeskd** 1995 Sep 9;139(36):1820–3 (41 ref.) **(Dut)**
[Evolution and current status of certification of specialists in Mexico] Espinosa de los Reyes VM. **Gac Med Mex** 1995 Jan–Feb;131(1):72–82 (31 ref.) **(Spa)**

EDUCATION

Women's health and enhancing generalism in internal medicine. Hoffman E, et al. **J Gen Intern Med** 1995 Aug; 10(8):451–4 (59 ref.)
Challenges of the spine specialists. North American Spine Society Presidential Address. Minneapolis, Minnesota, October 1994. Lee C. **Spine** 1995 Aug 15;20(16):1749–52 (24 ref.)

MANPOWER

A physician workforce for the 21st century. Cooper RA. **Ann Thorac Surg** 1995 Nov;60(5):1541–6 (10 ref.)
Balancing primary versus specialty care [see comments] Shi L. **J R Soc Med** 1995 Aug;88(8):428–32 (62 ref.) Comment in: J R Soc Med 1995 Aug;88(8):425.

ORGANIZATION & ADMINISTRATION

Evidence based critical care medicine; what is it and what can it do for us? Evidence Based Medicine in Critical Care Group. Cook DJ, et al. **Crit Care Med** 1996 Feb;24(2):334–7 (46 ref.)

SPECIALTIES, SURGICAL

MANPOWER

A physician workforce for the 21st century. Cooper RA. **Ann Thorac Surg** 1995 Nov;60(5):1541–6 (10 ref.)

TRENDS

What's new in pediatric surgery. Harrison MR. **J Am Coll Surg** 1996 Feb;182(2):145–9 (40 ref.)
What's new in surgical oncology. Norton JA. **J Am Coll Surg** 1996 Feb;182(2):122–9 (43 ref.)

SPECIES SPECIFICITY

Strain as a determinant factor in the differential responsiveness of rats to chemicals. Kacew S, et al. **Toxicol Pathol** 1995 Nov–Dec;23(6):701–14; discussion 714–5 (95 ref.)

SPECIESISM see ANIMAL RIGHTS

SPECIFIC PATHOGEN-FREE ORGANISMS

[Procedures for health monitoring in a breeding facility for specific pathogen free mice and rats] Wyss–Spillmann SK, et al. **Schweiz Arch Tierheilkd** 1995;137(11):505–14 (39 ref.) (Eng. Abstr.) **(Ger)**

SPECIFICITY see SENSITIVITY AND SPECIFICITY

SPECIMEN HANDLING

Tissue handling in suspected Creutzfeldt–Jakob disease (CJD) and other human spongiform encephalopathies (prion diseases). Budka H, et al. **Brain Pathol** 1995 Jul; 5(3):319–22 (20 ref.)
General principles of specimen collection and transport. Wilson ML. **Clin Infect Dis** 1996 May;22(5):766–77 (59 ref.)
Osteosarcoma. Specimen management following primary chemotherapy. Raymond AK, et al. **Hematol Oncol Clin North Am** 1995 Aug;9(4):841–67 (70 ref.)
Scanning electron microscopy of bone: instrument, specimen, and issues. Boyde A, et al. **Microsc Res Tech** 1996 Feb 1;33(2):92–120 (131 ref.)
[Consensus report: tissue handling in suspected Creutzfeldt–Jakob disease and other spongiform encephalopathies (prion diseases) in the human.European Union Biomed–1 Concerted Action] Budka H, et al. **Pathologe** 1996 Mar;17(2):171–5 (16 ref.) (Eng. Abstr.) **(Ger)**

INSTRUMENTATION

CYTYC Corporation. Zahniser DJ, et al. **Acta Cytol** 1996 Jan–Feb;40(1):37–44 (12 ref.)

METHODS

Specimen collection and storage for diagnostic molecular pathology investigation. Farkas DH, et al. **Arch Pathol Lab Med** 1996 Jun;120(6):591–6 (50 ref.)
Mitochondrial disorders. Methods and specimen selection for diagnostic molecular pathology. Kiechle FL, et al. **Arch Pathol Lab Med** 1996 Jun;120(6):597–603 (89 ref.)
Handling of large brain specimens: the use of microwaves. A review. Marani E, et al. **Eur J Morphol** 1995 Apr; 33(2):158–64 (33 ref.)
[Handling of biological material before trace element determination] Caroli S, et al. **Ann Ist Super Sanita** 1995; 31(2):219–24 (15 ref.) (Eng. Abstr.) **(Ita)**
[Assessment of factors causing pre–analytic variabililty] Minoia C. **Ann Ist Super Sanita** 1995;31(2):225–32 (13 ref.) (Eng. Abstr.) **(Ita)**
[Collection of bone marrow fluid] Tsubaki K. **Rinsho Byori** 1995 Jul;Suppl 99:24–30 (17 ref.) **(Jpn)**

SPECT see TOMOGRAPHY, EMISSION–COMPUTED, SINGLE–PHOTON

SPECTRIN

Actin–binding proteins. 1: Spectrin super family. Hartwig JH. **Protein Profile** 1995;2(7):703–800 (1448 ref.)

CHEMISTRY

Actin–binding proteins 1: spectrin superfamily. Hartwig JH. **Protein Profile** 1994;1(7):706–78 (479 ref.)

SPECTROFLUOROMETRY see SPECTROMETRY, FLUORESCENCE

SPECTROMETRY, FLUORESCENCE

Capillary electrophoresis with wavelength–resolved fluorescence detection. Timperman AT, et al. **Analyst** 1996 May;121(5):45R–52R (65 ref.)
Fluorescence resonance energy transfer spectroscopy is a reliable "ruler" for measuring structural changes in proteins. Dispelling the problem of the unknown orientation factor. dos Remedios CG, et al. **J Struct Biol** 1995 Sep–Oct; 115(2):175–85 (48 ref.)

INSTRUMENTATION

[Instruments used for measurement of intracellular calcium ions] Miyakawa A. **Nippon Seirigaku Zasshi** 1995; 57(10):401–17 (18 ref.) **(Jpn)**

METHODS

Time–resolved emission spectroscopy as a tool to follow nucleic acid–protein interaction. Bhargava P, et al. **Indian J Biochem Biophys** 1995 Dec;32(6):322–8 (23 ref.)
Application of fluorescence spectroscopy for determining the structure and function of proteins. Jiskoot W, et al. **Pharm Biotechnol** 1995;7:1–63 (185 ref.)
[Optical measurement of intracellular calcium concentration] Konishi M, et al. **Nippon Seirigaku Zasshi** 1995;57(7):313–24 (23 ref.) **(Jpn)**

SPECTROMETRY, MASS see SPECTRUM ANALYSIS, MASS

SPECTROMETRY, MASS, FAST ATOM BOMBARDMENT

INSTRUMENTATION

Analytical instruments for stable isotopic tracers in mineral metabolism. Yergey AL. **J Nutr** 1996 Jan;126(1):355S–361S (59 ref.)

SPECTROMETRY, MASS–GAS CHROMATOGRAPHY see MASS FRAGMENTOGRAPHY

SPECTROMETRY, MASS, MATRIX–ASSISTED LASER DESORPTION–IONIZATION

Matrix–assisted laser desorption/ionization mass spectrometry (MALDI–MS). Stults JT. **Curr Opin Struct Biol** 1995 Oct;5(5):691–8 (120 ref.)
Matrix–assisted laser desorption/ionisation mass spectrometry of oligosaccharides and glycoconjugates. Harvey DJ. **J Chromatogr A** 1996 Jan 12;720(1–2):429–46 (64 ref.)

SPECTROMETRY, PARTICLE–INDUCED X–RAY EMISSION see SPECTROMETRY, X–RAY EMISSION

SPECTROMETRY, PROTON–INDUCED X–RAY EMISSION see SPECTROMETRY, X–RAY EMISSION

SPECTROMETRY, X–RAY EMISSION

X–ray Spectrometry. Török SB, et al. **Anal Chem** 1996 Jun 15;68(12):467R–485R (397 ref.)
[Two dimensional imaging and functional evaluation of trace elements on tissues and organs by x–ray spectroscopy] Futatsugi Y, et al. **Nippon Rinsho** 1996 Jan;54(1):192–201 (20 ref.) (Eng. Abstr.) **(Jpn)**
[Particle Induced X–ray Emission (PIXE) for analysis of trace elements in biological materials] Iwata Y. **Nippon Rinsho** 1996 Jan;54(1):221–7 (16 ref.) (Eng. Abstr.) **(Jpn)**

SPECTROMETRY, X–RAY EMISSION, ELECTRON MICROSCOPIC see ELECTRON PROBE MICROANALYSIS

SPECTROMETRY, X–RAY EMISSION, ELECTRON PROBE see ELECTRON PROBE MICROANALYSIS

SPECTROMETRY, X–RAY FLUORESCENCE see SPECTROMETRY, X–RAY EMISSION

SPECTROPHOTOMETRY, ATOMIC ABSORPTION

[Inductively coupled plasma atomic emission spectrometry and ICP mass spectrometry] Yoshinaga J. **Nippon Rinsho** 1996 Jan;54(1):202–6 (14 ref.) (Eng. Abstr.) **(Jpn)**

SPECTROPHOTOMETRY, INFRARED

Near infra–red spectroscopy [editorial] Harris DN. **Anaesthesia** 1995 Dec;50(12):1015–6 (19 ref.)
Near infrared spectroscopy in the diagnosis of Alzheimer's disease. Hock C, et al. **Ann N Y Acad Sci** 1996 Jan 17; 777:22–9 (20 ref.)
Near–infrared spectroscopy: theory and applications. Wahr JA, et al. **J Cardiothorac Vasc Anesth** 1996 Apr; 10(3):406–18 (96 ref.)
A new application for near–infrared spectroscopy: detection of delayed intracranial hematomas after head injury. Robertson CS, et al. **J Neurotrauma** 1995 Aug; 12(4):591–600 (64 ref.)

INSTRUMENTATION

Near infrared spectroscopy: methodological principles and clinical application in preterm infants. Bernert G, et al. **Wien Klin Wochenschr** 1995;107(19):569–73 (36 ref.)

METHODS

MRS and NIRS for muscle disease evaluation. Olsen NJ, et al. **Bull Rheum Dis** 1995 Aug;44(5):4–7 (10 ref.)

SPECTROPHOTOMETRY, ULTRAVIOLET

METHODS

[Caged compounds and measurement of calcium ion] Iino M. **Nippon Seirigaku Zasshi** 1996;58(1):7–13 (12 ref.) **(Jpn)**

SPECTROSCOPY see SPECTRUM ANALYSIS

SPECTROSCOPY, FOURIER TRANSFORM INFRARED

METHODS

Fourier transform infrared spectroscopy investigations of protein structure. Cooper EA, et al. **Pharm Biotechnol** 1995; 7:101–43 (114 ref.)

SPECTROSCOPY, INFRARED, FOURIER TRANSFORM see SPECTROSCOPY, FOURIER TRANSFORM INFRARED

SPECTROSCOPY, MAGNETIC RESONANCE see NUCLEAR MAGNETIC RESONANCE

SPECTROSCOPY, MASS see SPECTRUM ANALYSIS, MASS

SPECTROSCOPY, MASS, FAST ATOM BOMBARDMENT see SPECTROMETRY, MASS, FAST ATOM BOMBARDMENT

SPECTROSCOPY, MASS, MATRIX–ASSISTED LASER DESORPTION–IONIZATION see SPECTROMETRY, MASS, MATRIX–ASSISTED LASER DESORPTION–IONIZATION

SPECTROSCOPY, NUCLEAR MAGNETIC RESONANCE see NUCLEAR MAGNETIC RESONANCE

SPECTRUM ANALYSIS

METHODS

Dielectric relaxation spectroscopy and some applications in the pharmaceutical sciences. Smith G, et al. **J Pharm Sci** 1995 Sep;84(9):1029–44 (150 ref.)
[Handling of biological material before trace element determination] Caroli S, et al. **Ann Ist Super Sanita** 1995; 31(2):219–24 (15 ref.) (Eng. Abstr.) **(Ita)**

SPECTRUM ANALYSIS, MASS

Future prospects for the analysis of complex biological systems using micro–column liquid chromatography–electrospray tandem mass spectrometry. Yates JR 3rd, et al. **Analyst** 1996 Jul;121(7):65R–76R (66 ref.)
Analysis of trace elements in the central nerve tissues with inductively coupled plasma–mass spectrometry. Ejima A, et al. **Tohoku J Exp Med** 1996 Jan;178(1):1–10 (14 ref.)

[Inductively coupled plasma atomic emission spectrometry and ICP mass spectrometry] Yoshinaga J. **Nippon Rinsho** 1996 Jan;54(1):202–6 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Advanced mass spectrometry in biochemical sciences] Ohashi Y. **Seikagaku** 1995 Nov;67(11):1295–301 (14 ref.) **(Jpn)**

[Stable isotopes in biomedical diagnosis and research] Martínez JA, et al. **Rev Med Univ Navarra** 1995 Jul–Sep; 39(3):141–52 (118 ref.) (Eng. Abstr.) **(Spa)**

INSTRUMENTATION

Analytical instruments for stable isotopic tracers in mineral metabolism. Yergey AL. **J Nutr** 1996 Jan;126(1):355S–361S (59 ref.)

METHODS

Mass spectrometry. Burlingame AL, et al. **Anal Chem** 1996 Jun 15;68(12):599R–651R (1049 ref.)

Bioanalytical mass spectrometry: many flavors to choose [editorial] Loo JA. **Bioconjug Chem** 1995 Nov–Dec; 6(6):644–65 (262 ref.)

Mass spectrometric approaches for the identification of gel-separated proteins. Patterson SD, et al. **Electrophoresis** 1995 Oct;16(10):1791–814 (202 ref.)

Investigation of protein folding by mass spectrometry. Miranker A, et al. **FASEB J** 1996 Jan;10(1):93–101 (47 ref.)

Application of tandem mass spectrometry for the analysis of long-chain carboxylic acids. Kuksis A, et al. **J Chromatogr B Biomed Appl** 1995 Sep 15;671(1–2):35–70 (116 ref.)

Mass spectrometry in protein structural analysis. Roepstorff P. **Pharm Biotechnol** 1995;7:145–77 (79 ref.)

Weighing the evidence for structure: electrospray ionization mass spectrometry of proteins. Robinson CV, et al. **Structure** 1995 Sep 15;3(9):861–5 (19 ref.)

[Plasma-desorption mass spectrometry of natural compounds. 1. Basic properties of the method and its use for analyzing proteins and peptides] Reztsova NA, et al. **Bioorg Khim** 1996 Jan;22(1):3–13 (141 ref.) (Eng. Abstr.) **(Rus)**

SPECTRUM ANALYSIS, MASS-GAS CHROMATOGRAPHY see **MASS FRAGMENTOGRAPHY**

SPECTRUM ANALYSIS, RAMAN

[Structural analysis of nucleic acids by the use of Raman microscope] Ueda T, et al. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1540–7 (19 ref.) **(Jpn)**

SPEECH

see related
VERBAL BEHAVIOR

[Work and voice] Sala E. **Duodecim** 1995;111(6):554–9 (16 ref.) **(Fin)**

[The prosody of speech and wordless messages] Toivanen JH, et al. **Duodecim** 1995;111(7):606–10 (23 ref.) **(Fin)**

PHYSIOLOGY

Fatigue of jaw muscles and speech mechanisms. Miles TS, et al. **Adv Exp Med Biol** 1995;384:415–26 (55 ref.)

Cleft palate speech dissected: a review of current knowledge and analysis. Wyatt R, et al. **Br J Plast Surg** 1996 Apr; 49(3):143–9 (32 ref.)

The functional role of the adenoids in speech. Finkelstein Y, et al. **Int J Pediatr Otorhinolaryngol** 1996 Jan; 34(1–2):61–74 (73 ref.)

Neural control of vocalization: respiratory and emotional influences. Davis PJ, et al. **J Voice** 1996 Mar;10(1):23–38 (107 ref.)

SPEECH ACOUSTICS

New processing strategies in cochlear implantation. Wilson BS, et al. **Am J Otol** 1995 Sep;16(5):669–75 (23 ref.)

Feature, phoneme, syllable or word: how is speech mentally represented? Sendlmeier WF. **Phonetica** 1995;52(3):131–43 (30 ref.)

SPEECH, ALARYNGEAL

see related
LARYNX, ARTIFICIAL

Tracheoesophageal speech. Blom ED. **Semin Speech Lang** 1995 Aug;16(3):191–204 (6 ref.)

General principles of working to develop alaryngeal speech. McFarlane SC, et al. **Semin Speech Lang** 1995 Aug; 16(3):175–9 (3 ref.)

SPEECH ARTICULATION TESTS

Fluent speech, fast articulatory rate, and delayed auditory feedback: creating a crisis for a scientific revolution? Stuart A, et al. **Percept Mot Skills** 1996 Feb;82(1):211–8 (42 ref.)

SPEECH DISCRIMINATION see **SPEECH PERCEPTION**

SPEECH DISORDERS

see related
LANGUAGE DISORDERS

PSYCHOLOGY

[Children with speech disorders] Rantala SL. **Duodecim** 1995; 111(6):567–72 (12 ref.) **(Fin)**

REHABILITATION

[Technology for the diagnosis and rehabilitation of patients with dysphonia] Vilkman E, et al. **Duodecim** 1995; 111(6):549–53 (10 ref.) **(Fin)**

THERAPY

Influence of body position on breathing and its implications for the evaluation and treatment of speech and voice disorders. Hoit JD. **J Voice** 1995 Dec;9(4):341–7 (37 ref.)

General principles of working to develop alaryngeal speech. McFarlane SC, et al. **Semin Speech Lang** 1995 Aug; 16(3):175–9 (3 ref.)

SPEECH INTELLIGIBILITY

see related
SPEECH PRODUCTION MEASUREMENT

SPEECH PERCEPTION

The dispute concerning the benefits to be expected from cochlear implantation of young deaf children [letter] Lane H. **Am J Otol** 1995 May;16(3):393–9 (41 ref.)

New processing strategies in cochlear implantation. Wilson BS, et al. **Am J Otol** 1995 Sep;16(5):669–75 (23 ref.)

A restrictive theory of agrammatic comprehension. Grodzinsky Y. **Brain Lang** 1995 Jul;50(1):27–51 (62 ref.)

Agrammatism as evidence about grammar. Linebarger MC. **Brain Lang** 1995 Jul;50(1):52–91 (74 ref.)

Speech pattern audiometry for clinical use. Hazan V, et al. **Eur J Disord Commun** 1995;30(2):116–23 (15 ref.)

Eye movements as a window into real-time spoken language comprehension in natural contexts. Eberhard KM, et al. **J Psycholinguist Res** 1995 Nov;24(6):409–36 (44 ref.)

Tasks and timing in the perception of linguistic anomaly. Fodor JD, et al. **J Psycholinguist Res** 1996 Jan;25(1):25–57 (36 ref.)

Interference in short-term memory: the magical number two (or three) in sentence processing. Lewis RL. **J Psycholinguist Res** 1996 Jan;25(1):93–115 (80 ref.)

A prosody tutorial for investigators of auditory sentence processing. Shattuck-Hufnagel S, et al. **J Psycholinguist Res** 1996 Mar;25(2):193–247 (156 ref.)

Fluent speech, fast articulatory rate, and delayed auditory feedback: creating a crisis for a scientific revolution? Stuart A, et al. **Percept Mot Skills** 1996 Feb;82(1):211–8 (42 ref.)

Feature, phoneme, syllable or word: how is speech mentally represented? Sendlmeier WF. **Phonetica** 1995;52(3):131–43 (30 ref.)

True auditory hallucinations as a conversion symptom. Nakaya M. **Psychopathology** 1995;28(4):214–9 (14 ref.)

PHYSIOLOGY

Hebb's concept of cell assemblies and the psychophysiology of word processing. Pulvermüller F. **Psychophysiology** 1996 Jul;33(4):317–33 (145 ref.)

SPEECH PRODUCTION MEASUREMENT

METHODS

Laryngograph: speech pattern element tools for therapy, training and assessment. Fourcin A, et al. **Eur J Disord Commun** 1995;30(2):101–15 (0 ref.)

New developments in EPG3 software. Jones W, et al. **Eur J Disord Commun** 1995;30(2):183–92 (22 ref.)

SPEECH SOUNDS see **PHONETICS**

SPEECH SYNTHESIZERS see **COMMUNICATION AIDS FOR DISABLED**

SPEECH THERAPY

Speech and language therapy: does it work? Enderby P, et al. **BMJ** 1996 Jun 29;312(7047):1655–8 (34 ref.)

Laryngograph: speech pattern element tools for therapy, training and assessment. Fourcin A, et al. **Eur J Disord Commun** 1995;30(2):101–15 (0 ref.)

Parents as partners: including mothers and fathers in the treatment of children who stutter. Kelly EM. **J Commun Disord** 1995 Jun;28(2):93–105 (50 ref.)

SPERM see **SPERMATOZOA**

SPERM BANKS

ORGANIZATION & ADMINISTRATION

[The creation of genetic cryobanks and the use of the methods of developmental biology as a means for preserving rare animal species. I. The cryopreservation of the sperm of wild mammals] Rott NN. **Ontogenez** 1995 Jul–Aug;26(4):270–81 (59 ref.) (Eng. Abstr.) **(Rus)**

SPERM CAPACITATION

Methods for the assessment of capacitation. Barboni B. **Zygote** 1994 Nov;2(4):367–9 (8 ref.)

PHYSIOLOGY

Cellular biology of capacitation and the acrosome reaction. Fraser LR. **Hum Reprod** 1995 Oct;10 Suppl 1:22–30 (50 ref.)

SPERM COUNT

see related
OLIGOSPERMIA

METHODS

Methods for assessing sperm motility, morphology, and counts in the rat, rabbit, and dog: a consensus report. ILSI Risk Science Institute Expert Working Group on Sperm Evaluation. Seed J, et al. **Reprod Toxicol** 1996 May–Jun; 10(3):237–44 (30 ref.)

SPERM FLAGELLUM see **SPERM TAIL**

SPERM HEAD

ULTRASTRUCTURE

The nuclear status of human sperm cells. Dadoune JP. **Micron** 1995;26(4):323–45 (182 ref.)

SPERM MATURATION

PHYSIOLOGY

Role of the epididymis in mediating changes in the male gamete during maturation. Cooper TG. **Adv Exp Med Biol** 1995;377:87–101 (133 ref.)

Gonadotrophin control of testicular germ cell development. Weinbauer GF, et al. **Adv Exp Med Biol** 1995;377:55–65 (59 ref.)

The epididymis as protector of maturing spermatozoa. Hinton BT, et al. **Reprod Fertil Dev** 1995;7(4):731–45 (149 ref.)

SPERM MOTILITY

Computer assisted semen analysis systems: sperm motility assessment. Irvine DS. **Hum Reprod** 1995 Oct;10 Suppl 1:53–9 (43 ref.)

Situs inversus and ciliary abnormalities. What is the connection? Afzelius BA. **Int J Dev Biol** 1995 Oct; 39(5):839–44 (57 ref.)

Derivation and reliability of kinematic measures of sperm motion. Davis RO, et al. **Reprod Fertil Dev** 1995; 7(4):857–69 (54 ref.)

PHYSIOLOGY

Regulation of sperm motility at the axonemal level. Gagnon C. **Reprod Fertil Dev** 1995;7(4):847–55 (73 ref.)

Methods for assessing sperm motility, morphology, and counts in the rat, rabbit, and dog: a consensus report. ILSI Risk Science Institute Expert Working Group on Sperm Evaluation. Seed J, et al. **Reprod Toxicol** 1996 May–Jun; 10(3):237–44 (30 ref.)

SPERM NUMBER see **SPERM COUNT**

SPERM–OVUM INTERACTIONS

Mammalian fertilization: egg and sperm (glyco)proteins that support gamete adhesion. Wassarman PM. **Am J Reprod Immunol** 1995 Mar;33(3):253–8 (48 ref.)

Gamete and immune cell recognition revisited. Belton RJ Jr, et al. **Bioessays** 1995 Dec;17(12):1075–80 (61 ref.)

Sperm–egg recognition mechanisms in mammals. Wassarman PM, et al. **Curr Top Dev Biol** 1995;30:1–19 (70 ref.)

When is the post-coital test normal? A critical appraisal. Oei SG, et al. **Hum Reprod** 1995 Jul;10(7):1711–4 (20 ref.)

Contribution of the male factor to unexplained infertility: a review. Mackenna A. **Int J Androl** 1995 Jun;18 Suppl 1:58–61 (25 ref.)

Sperm competition: evolutionary causes and consequences. Birkhead TR. **Reprod Fertil Dev** 1995;7(4):755–75 (216 ref.)

Interactions between gametes leading to fertilization: the sperm's eye view. Storey BT. **Reprod Fertil Dev** 1995; 7(4):927–42 (144 ref.)

Cell–cell interactions and oocyte growth. Canipari R. **Zygote** 1994 Nov;2(4):343–5 (31 ref.)

Oocyte reaction to penetrating sperm. Galeati G. **Zygote** 1994 Nov;2(4):355–8 (38 ref.)

Sperm activation in species with external fertilisation. Tosti E. **Zygote** 1994 Nov;2(4):359–61 (23 ref.)

Fertility of mammalian spermatozoa: its development and relativity. Yanagimachi R. **Zygote** 1994 Nov;2(4):371–2 (13 ref.)

SPERM-OVUM INTERACTIONS

PHYSIOLOGY

Towards molecular mechanisms for gamete adhesion and fusion during mammalian fertilization. Wassarman PM. **Curr Opin Cell Biol** 1995 Oct;7(5):658–64 (76 ref.)

Molecular basis of mammalian egg activation. Schultz RM, et al. **Curr Top Dev Biol** 1995;30:21–62 (186 ref.)

New concepts in human sperm–zona pellucida interaction. Clark GF, et al. **Hum Reprod** 1995 Oct;10 Suppl 1:31–7 (36 ref.)

Synchronous multispecific spawning on coral reefs: potential for hybridization and roles of gamete recognition. Babcock R. **Reprod Fertil Dev** 1995;7(4):943–50 (74 ref.)

SPERM PENETRATION see **SPERM-OVUM INTERACTIONS**

SPERM PRESERVATION see **SEMEN PRESERVATION**

SPERM TAIL

PHYSIOLOGY

Situs inversus and ciliary abnormalities. What is the connection? Afzelius BA. **Int J Dev Biol** 1995 Oct; 39(5):839–44 (57 ref.)

SPERMATIC CORD

Spermatic cord hematoma: case report and literature review. McKenney MG, et al. **Am Surg** 1996 Sep;62(9):768–9 (13 ref.)

Malignant fibrous histiocytoma of the spermatic cord. Glazier DB, et al. **J Urol** 1996 Mar;155(3):955–7 (26 ref.)

BLOOD SUPPLY

[Opening of the left V. spermatica interna into the left V. suprarenalis] Risse JH, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1995 Oct;163(4):364–6 (9 ref.) **(Ger)**

PATHOLOGY

Leiomyosarcoma of the spermatic cord: report of two cases and review of the literature. Stein A, et al. **World J Urol** 1996;14(1):59–61 (12 ref.)

SPERMATIC CORD TORSION

THERAPY

ABC of Urology. Urological emergencies in general practice [see comments] Dawson C, et al. **BMJ** 1996 Mar 30; 312(7034):838–40 (0 ref.) Comment in: BMJ 1996 Jul 13;313(7049):112; discussion 112–3.

SPERMATIDS

Spermatids as male gametes. Ogura A, et al. **Reprod Fertil Dev** 1995;7(2):155–8; discussion 158–9 (16 ref.)

SPERMATOBLASTS see **SPERMATIDS**

SPERMATOCYTES

see related
SPERM MATURATION

SPERMATOGENESIS

Occupation- and exposure-related studies on human sperm. Lähdetie J. **J Occup Environ Med** 1995 Aug;37(8):922–30 (92 ref.)

Efficiency of spermatogenesis. Johnson L. **Microsc Res Tech** 1995 Dec 1;32(5):385–422 (218 ref.)

Macro, micro, and molecular research on spermatogenesis: the quest to understand its control. Kerr JB. **Microsc Res Tech** 1995 Dec 1;32(5):364–84 (116 ref.)

Spermatogenesis in nonmammalian vertebrates. Pudney J. **Microsc Res Tech** 1995 Dec 15;32(6):459–97 (216 ref.)

[Spermatogenesis in amphibians analyzed by culture systems] Abe S. **Tanpakushitsu Kakusan Koso** 1995 Oct; 40(13):1912–26 (40 ref.) **(Jpn)**

GENETICS

Translational control in spermatogenesis. Schäfer M, et al. **Dev Biol** 1995 Dec;172(2):344–52 (62 ref.)

Homeobox genes and male reproductive development. Lindsey S, et al. **J Assist Reprod Genet** 1996 Feb; 13(2):182–92 (49 ref.)

The potential of intracytoplasmic sperm injection (ICSI) to transmit genetic defects causing male infertility. de Kretser DM. **Reprod Fertil Dev** 1995;7(2):137–41; discussion 141–2 (36 ref.)

A model for understanding gene regulation during spermatogenesis: the mouse testis Pdha-2 promoter. Iannello RC, et al. **Reprod Fertil Dev** 1995;7(4):705–12 (51 ref.)

The azoospermia factor (AZF) of the human Y chromosome in Yq11: function and analysis in spermatogenesis. Vogt PH, et al. **Reprod Fertil Dev** 1995;7(4):685–93 (56 ref.)

Genetic control of mitosis, meiosis and cellular differentiation during mammalian spermatogenesis. Wolgemuth DJ, et al. **Reprod Fertil Dev** 1995;7(4):669–83 (141 ref.)

PHYSIOLOGY

Current aspects of autocrine and paracrine regulation of spermatogenesis. Jégou B, et al. **Adv Exp Med Biol** 1995; 377:67–86 (72 ref.)

Gonadotrophin control of testicular germ cell development. Weinbauer GF, et al. **Adv Exp Med Biol** 1995;377:55–65 (59 ref.)

Molecular and cellular events in spermatogenesis. Grootegoed JA, et al. **Hum Reprod** 1995 Oct;10 Suppl 1:10–4 (26 ref.)

The endocrine regulation of spermatogenesis: independent roles for testosterone and FSH. McLachlan RI, et al. **J Endocrinol** 1996 Jan;148(1):1–9 (62 ref.)

Developmental expression and possible role of perinuclear theca proteins in mammalian spermatozoa. Oko RJ. **Reprod Fertil Dev** 1995;7(4):777–97 (26 ref.)

SPERMATOZOA

see related
OLIGOSPERMIA
SPERM BANKS

Cell cycle factors in the human oocyte and the intracytoplasmic injection of spermatozoa. Edwards RG. **Reprod Fertil Dev** 1995;7(2):143–53 (86 ref.)

ABNORMALITIES

Strict criteria for the evaluation of human sperm morphology and its impact on assisted reproduction. Grow D, et al. **Andrologia** 1995 Nov–Dec;27(6):325–33 (47 ref.)

Intracytoplasmic sperm injection (ICSI): potential genetic concerns. Patrizio P. **Hum Reprod** 1995 Oct;10(10):2520–3 (26 ref.)

[Cytogenetic abnormalities in sperm: a risk factor for application of medical reproduction techniques?] Rosenbusch B, et al. **Geburtshilfe Frauenheilkd** 1995 Sep; 55(9):518–25 (40 ref.) (Eng. Abstr.) **(Ger)**

CYTOLOGY

Sex preselection by flow cytometric separation of X and Y chromosome–bearing sperm based on DNA difference: a review. Johnson LA. **Reprod Fertil Dev** 1995;7(4):893–903 (47 ref.)

Methods for assessing sperm motility, morphology, and counts in the rat, rabbit, and dog: a consensus report. ILSI Risk Science Institute Expert Working Group on Sperm Evaluation. Seed J, et al. **Reprod Toxicol** 1996 May–Jun; 10(3):237–44 (30 ref.)

DRUG EFFECTS

Cytogenetic damage measured in human sperm following cancer chemotherapy. Robbins WA. **Mutat Res** 1996 Aug 17;355(1–2):235–52 (109 ref.)

Ionic control of sperm function. Fraser LR. **Reprod Fertil Dev** 1995;7(4):905–25 (169 ref.)

IMMUNOLOGY

Sperm antigens and immunocontraception. Kerr LE. **Reprod Fertil Dev** 1995;7(4):825–30 (74 ref.)

Infertility due to antisperm antibodies. Ohl DA, et al. **Urology** 1995 Oct;46(4):591–602 (170 ref.)

[Immunologic reactions in the male and female reproductive system] Kasprzak M, et al. **Postepy Hig Med Dosw** 1995; 49(6):693–717 (47 ref.) (Eng. Abstr.) **(Pol)**

METABOLISM

Sperm, a source of estrogen. Hess RA, et al. **Environ Health Perspect** 1995 Oct;103 Suppl 7:59–62 (41 ref.)

Sperm-binding proteins. Foltz KR. **Int Rev Cytol** 1995; 163:249–303 (310 ref.)

Developmental expression and possible role of perinuclear theca proteins in mammalian spermatozoa. Oko RJ. **Reprod Fertil Dev** 1995;7(4):777–97 (26 ref.)

PHYSIOLOGY

Role of the epididymis in mediating changes in the male gamete during maturation. Cooper TG. **Adv Exp Med Biol** 1995;377:87–101 (133 ref.)

Strict criteria for the evaluation of human sperm morphology and its impact on assisted reproduction. Grow D, et al. **Andrologia** 1995 Nov–Dec;27(6):325–33 (47 ref.)

Impact of reactive oxygen species on spermatozoa: a balancing act between beneficial and detrimental effects. de Lamirande E, et al. **Hum Reprod** 1995 Oct;10 Suppl 1:15–21 (43 ref.)

Contribution of the male factor to unexplained infertility: a review. Mackenna A. **Int J Androl** 1995 Jun;18 Suppl 1:58–61 (25 ref.)

Functional motion changes during sperm transit to the site of fertilization and in-vitro applications: a review. Mbizvo MT. **Int J Androl** 1995 Jun;18 Suppl 1:1–6 (59 ref.)

Enhancement of sperm function for treatment of male infertility. Naz RK, et al. **J Androl** 1995 Sep–Oct; 16(5):384–8 (22 ref.)

Cytogenetics of human spermatozoa: what about the reproductive relevance of structural chromosome aberrations? Rosenbusch BE. **J Assist Reprod Genet** 1995 Jul;12(6):375–83 (53 ref.)

Male infertility: evaluation of human sperm function and its clinical application. Lenzi A. **J Endocrinol Invest** 1995 Jun; 18(6):468–83 (105 ref.)

Cell biology of nematode sperm. L'Hernault SW, et al. **Methods Cell Biol** 1995;48:273–301 (38 ref.)

Free radicals, lipid peroxidation and sperm function. Aitken RJ. **Reprod Fertil Dev** 1995;7(4):659–68 (62 ref.)

Sperm competition: evolutionary causes and consequences. Birkhead TR. **Reprod Fertil Dev** 1995;7(4):755–75 (216 ref.)

'Chauvinist genes' of male germ cells: gene expression during mouse spermatogenesis. Eddy EM. **Reprod Fertil Dev** 1995; 7(4):695–704 (80 ref.)

Interleukin-1, interleukin-6 and the germ cell–Sertoli cell cross-talk. Jégou B, et al. **Reprod Fertil Dev** 1995; 7(4):723–30 (68 ref.)

Recent developments and concepts in the cryopreservation of spermatozoa and the assessment of their post-thawing function. Watson PF. **Reprod Fertil Dev** 1995;7(4):871–91 (155 ref.)

Ovarian regulation of sperm progression in the fallopian tubes. Hunter RH. **Zygote** 1994 Nov;2(4):363–6 (22 ref.)

Sperm activation in species with external fertilisation. Tosti E. **Zygote** 1994 Nov;2(4):359–61 (23 ref.)

Fertility of mammalian spermatozoa: its development and relativity. Yanagimachi R. **Zygote** 1994 Nov;2(4):371–2 (13 ref.)

Stability of the mammalian sperm nucleus. Yanagimachi R. **Zygote** 1994 Nov;2(4):383–4 (15 ref.)

TRANSPLANTATION

[Risks of intracytoplasmatic sperm cell injection for offspring?] Hollanders JM, et al. **Ned Tijdschr Geneeskd** 1996 Jan 6;140(1):9–11 (20 ref.) **(Dut)**

ULTRASTRUCTURE

Computer-assisted sperm analysis systems: morphometric aspects. Kruger T. **Hum Reprod** 1995 Oct;10 Suppl 1:46–52 (28 ref.)

Micro-assisted fertilization and sperm chromosome abnormalities. Rosenbusch B, et al. **Hum Reprod** 1996 May; 11(5):928–30 (29 ref.)

Workshop report: clinical CASA—the quest for consensus. Mortimer D, et al. **Reprod Fertil Dev** 1995;7(4):951–9 (51 ref.)

The sperm centrosome during fertilization in mammals: implications for fertility and reproduction. Navara CS, et al. **Reprod Fertil Dev** 1995;7(4):747–54 (30 ref.)

Stability of the mammalian sperm nucleus. Yanagimachi R. **Zygote** 1994 Nov;2(4):383–4 (15 ref.)

SPERMINE

METABOLISM

Hypothesis: spermine may be an important epidermal antioxidant. Løvaas E. **Med Hypotheses** 1995 Jul; 45(1):59–67 (125 ref.)

SPHAEROPHORUS INFECTIONS see **FUSOBACTERIUM INFECTIONS**

SPHAEROPHORUS NECROPHORUS see **FUSOBACTERIUM NECROPHORUM**

SPHENOID BONE

[Long-term results of the surgical treatment of spheno-orbital osteomeningioma] Gaillard S, et al. **Neurochirurgie** 1995;41(6):391–7 (34 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Pterygoid hamulus bursitis: one cause of craniofacial pain. Shankland WE 2nd. **J Prosthet Dent** 1996 Feb;75(2):205–10 (26 ref.)

SURGERY

[Decompressive neurovascular nose and skull-base surgery in primary headache with a rhinogenic trigger] Bonaccorsi P. **Ital J Neurol Sci** 1995 Nov;16(8 Suppl):69–100 (104 ref.) (Eng. Abstr.) **(Ita)**

SPHENOID SINUS

[Primary lymphoma of the sphenoid sinus. Report of a case and review of the literature] Ferrario F, et al. **Ann Otolaryngol Chir Cervicofac** 1995;112(6):298–302 (44 ref.) (Eng. Abstr.) **(Fre)**

SPHENOID SINUSITIS

MICROBIOLOGY

Clusterlike headache. A case of sphenoidal aspergilloma. Zanchin G, et al. **Headache** 1995 Sep;35(8):494–7 (20 ref.)

Mucormycosis of the sphenoid sinus in an otherwise healthy patient. Case report and literature review. Del Valle Zapico A, et al. **J Laryngol Otol** 1996 May;110(5):471–3 (19 ref.)

SPHEROCYTOSIS, HEREDITARY

see related
ANEMIA, SIDEROBLASTIC

BLOOD

[Intrathoracic extramedullary hematopoiesis in a case of hereditary spherocytosis] Takahashi R, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Jan;34(1):71–5 (13 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Hereditary spherocytic anemia with deletion of the short arm of chromosome 8. Okamoto N, et al. **Am J Med Genet** 1995 Sep 11;58(3):225–9 (14 ref.)

SPHEROIDS

DRUG EFFECTS

Multicellular resistance: a new paradigm to explain aspects of acquired drug resistance of solid tumors. Kerbel RS, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:661–72 (79 ref.)

SPHINCTEROTOMY, ENDOSCOPIC

Effects of sphincterotomy on gallbladder physiology: a review. Targarona EM, et al. **Endoscopy** 1995 Jun; 27(5):388–91 (29 ref.)

[Endoscopic management of bile leakage following laparoscopic cholecystectomy] Lakatos L, et al. **Orv Hetil** 1996 Mar 17;137(11):569–75 (47 ref.) (Eng. Abstr.) **(Hun)**

ADVERSE EFFECTS

Complications related to diagnostic and therapeutic endoscopic retrograde cholangiopancreatography. Aliperti G. **Gastrointest Endosc Clin N Am** 1996 Apr;6(2):379–407 (220 ref.)

INSTRUMENTATION

Laparoscopic and endoscopic management of common bile duct stones. Pitcher DE, et al. **Curr Opin Gen Surg** 1994; :203–7 (17 ref.)

METHODS

Safe laparoendoscopic approach to biliary pancreatitis in older patients. McGrath MF, et al. **Arch Surg** 1996 Aug; 131(8):826–31; discussion 831–3 (21 ref.)

["500 consecutive cases of laparoscopic cholecystectomy". Argument for the association to endoscopic sphincterotomy: analysis] Lagrange M. **J Chir (Paris)** 1996 Apr;133(2):65–71 (13 ref.) (Eng. Abstr.) **(Fre)**

SPHINGOGLYCOLIPIDS see **GLYCOSPHINGOLIPIDS**

SPHINGOLIPIDOSES

[Sphingolipidosis and lipid storage diseases] Inui K. **Ryoikibetsu Shokogun Shirizu** 1995;(8):358–61 (13 ref.) **(Jpn)**

DIAGNOSIS

[Biochemical diagnosis and enzymic diagnosis of lysosomal diseases] Izumi T. **Nippon Rinsho** 1995 Dec;53(12):2915–20 (10 ref.) (Eng. Abstr.) **(Jpn)**

SPHINGOLIPIDS

METABOLISM

Evidence for disruption of sphingolipid metabolism as a contributing factor in the toxicity and carcinogenicity of fumonisins. Riley RT, et al. **Nat Toxins** 1996;4(1):3–15 (77 ref.)

PHYSIOLOGY

Sphingoid bases and phospholipase D activation. Spiegel S, et al. **Chem Phys Lipids** 1996 May 24;80(1–2):27–36 (87 ref.)

Sphingolipids: their role in intracellular signaling and renal growth [editorial] Shayman JA. **J Am Soc Nephrol** 1996 Feb;7(2):171–82 (106 ref.)

Sphingolipid metabolites: members of a new class of lipid second messengers. Spiegel S, et al. **J Membr Biol** 1995 Aug;146(3):225–37 (122 ref.)

SPHINGOMYELIN PHOSPHODIESTERASE

see related
NIEMANN-PICK DISEASE

SPHINGOSINE

PHYSIOLOGY

Sphingoid bases and phospholipase D activation. Spiegel S, et al. **Chem Phys Lipids** 1996 May 24;80(1–2):27–36 (87 ref.)

SPHYGMOMANOMETERS, CONTINUOUS see **BLOOD PRESSURE MONITORS**

SPICES

ANALYSIS

Saffron chemoprevention in biology and medicine: a review. Nair SC, et al. **Cancer Biother** 1995 Winter;10(4):257–64 (41 ref.)

SPIDER BITE see **ARACHNIDISM**

SPIDER MONKEY see **CEBIDAE**

SPIN LABELS

see related
ELECTRON SPIN RESONANCE SPECTROSCOPY

SPINA BIFIDA see **SPINAL DYSRAPHISM**

SPINA BIFIDA OCCULTA

DIAGNOSIS

Diastematomyelia in adults. Modern imaging and operative treatment. Prasad VS, et al. **Clin Imaging** 1995 Oct–Dec; 19(4):270–4 (28 ref.)

PATHOLOGY

Occult spinal dysraphism in the infant [see comments] Kriss VM, et al. **Clin Pediatr (Phila)** 1995 Dec;34(12):650–4 (26 ref.) Comment in: Clin Pediatr (Phila) 1995 Dec;34(12):655–6.

RADIOGRAPHY

[Diastematomyelia in a 6-month-old child] Trofimova TN, et al. **Zh Vopr Neirokhir Im N N Burdenko** 1995 Oct–Dec; (4):38–9 (12 ref.) **(Rus)**

ULTRASONOGRAPHY

Occult spinal dysraphism in the infant [see comments] Kriss VM, et al. **Clin Pediatr (Phila)** 1995 Dec;34(12):650–4 (26 ref.) Comment in: Clin Pediatr (Phila) 1995 Dec;34(12):655–6.

SPINAL BIFIDA, CLOSED see **SPINA BIFIDA OCCULTA**

SPINAL CANAL

[Spinal canal bleeding in hemophilia A] Morichika S, et al. **Rinsho Ketsueki** 1995 Jul;36(7):687–93 (16 ref.) (Eng. Abstr.) **(Jpn)**

RADIOGRAPHY

[Computed tomographic demonstration of intraspinal air after an infection with peptostreptococci] Lorenzen J, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Feb;164(2):173–5 (10 ref.) **(Ger)**

SPINAL CORD

see related
MOTOR NEURONS
MYELOGRAPHY

Epidural spinal cord stimulation in the treatment of limb threatening vasospasm—report of a case with a five-year follow-up. Lepantalo M, et al. **Eur J Vasc Endovasc Surg** 1996 Apr;11(3):368–70 (5 ref.)

BLOOD SUPPLY

Combined malformation of the Vein of Galen and of spinal vessels: endovascular embolization. Hammen A, et al. **Clin Neuropathol** 1995 Jul–Aug;14(4):233–6 (15 ref.)

Fibrocartilaginous embolism of the spinal cord: a clinical and pathogenetic reconsideration. Tosi L, et al. **J Neurol Neurosurg Psychiatry** 1996 Jan;60(1):55–60 (44 ref.)

[Modern methods for treating spinal cord diseases of ischemic and traumatic origin in the late period (a review of the literature)] Mikhailenko AA, et al. **Voen Med Zh** 1995 Dec; (12):31–6 (28 ref.) **(Rus)**

CHEMISTRY

Tachykinin receptors in the spinal cord. Routh VH, et al. **Prog Brain Res** 1995;104:93–108 (115 ref.)

CYTOLOGY

Peptidergic neurons in the vertebrate spinal cord: evolutionary trends. Brodin L, et al. **Prog Brain Res** 1995; 104:61–74 (119 ref.)

The peptidergic innervation of spinal motoneurons via the bulbospinal 5-hydroxytryptamine pathway. Cullheim S, et al. **Prog Brain Res** 1995;104:21–40 (115 ref.)

Organization of peptidergic neurons in the dorsal horn of the spinal cord: anatomical and functional correlates. Ribeiro-da-Silva A, et al. **Prog Brain Res** 1995;104:41–59 (77 ref.)

DRUG EFFECTS

Anesthetic actions within the spinal cord: contributions to the state of general anesthesia. Collins JG, et al. **Trends Neurosci** 1995 Dec;18(12):549–53 (42 ref.)

EMBRYOLOGY

Role of the subplate neurons in specification of neocortical areas. Woźniak W. **Folia Morphol (Warsz)** 1995;54(3):141–5 (26 ref.)

ENZYMOLOGY

Neuropeptide converting and processing enzymes in the spinal cord and cerebrospinal fluid. Persson S, et al. **Prog Brain Res** 1995;104:111–30 (195 ref.)

IMMUNOLOGY

Interpreting MHC class I expression and class I/class II reciprocity in the CNS: reconciling divergent findings. Lampson LA. **Microsc Res Tech** 1995 Nov 1;32(4):267–85 (101 ref.)

METABOLISM

Retinoic acid synthesis in the developing spinal cord. Dräger UC, et al. **Adv Exp Med Biol** 1995;372:185–92 (26 ref.)

Spinal opioid systems in inflammation. Stanfa L, et al. **Inflamm Res** 1995 Jun;44(6):231–41 (119 ref.)

Neurotrophic factors in central nervous system trauma. Mocchetti I, et al. **J Neurotrauma** 1995 Oct;12(5):853–70 (186 ref.)

Release of neuropeptides in the spinal cord. Duggan AW. **Prog Brain Res** 1995;104:197–223 (162 ref.)

Interaction of neuropeptides and excitatory amino acids in the rat superficial spinal dorsal horn. Randić M, et al. **Prog Brain Res** 1995;104:225–53 (306 ref.)

Regulation of spinal neuropeptide genes in a rat model of peripheral inflammation and hyperalgesia. Ruda MA, et al. **Prog Brain Res** 1995;104:349–65 (121 ref.)

Prostaglandin-induced neuropeptide release from spinal cord. Vasko MR. **Prog Brain Res** 1995;104:367–80 (80 ref.)

PATHOLOGY

Stage IE non-Hodgkin's lymphoma involving the dura: A clinicopathologic study of five cases. Miranda RN, et al. **Arch Pathol Lab Med** 1996 Mar;120(3):254–60 (20 ref.)

Magnetic resonance imaging and spectroscopy in multiple sclerosis. Miller DH. **Curr Opin Neurol** 1995 Jun;8(3):210–5 (44 ref.)

Spontaneous and induced remyelination in multiple sclerosis and the Theiler's virus model of central nervous system demyelination. Miller DJ, et al. **Microsc Res Tech** 1995 Oct 15;32(3):230–45 (119 ref.)

Multiple neuroepithelial tumors of different cell types—case report. Akai T, et al. **Neurol Med Chir (Tokyo)** 1995 Dec; 35(12):901–4 (9 ref.)

Hopkins syndrome: T2-weighted high intensity of anterior horn on spinal MR imaging. Arita J, et al. **Pediatr Neurol** 1995 Oct;13(3):263–5 (15 ref.)

Spinal cord and bone metastasizing renal tumor of childhood. Arrotegui JI, et al. **Rev Neurol** 1995 Nov–Dec; 23(124):1231–2 (15 ref.)

[Neuroimaging and pathology of the spinal cord in compressive cervical myelopathy] Kameyama T, et al. **Rinsho Byori** 1995 Sep;43(9):886–90 (4 ref.) (Eng. Abstr.) **(Jpn)**

[Two siblings of familial amyotrophic lateral sclerosis with multisystemic degeneration characterized by mild involvement of the middle root zone of the posterior column, Clarke's nuclei and spinocerebellar tract] Yoshida M, et al. **Rinsho Shinkeigaku** 1995 Jun;35(6):589–99 (27 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Evidence for a spinal stepping generator in man. Electrophysiological study. Bussel B, et al. **Acta Neurobiol Exp (Warsz)** 1996;56(1):465–8 (25 ref.)

Some spinal mechanisms of negative motor phenomena in humans. Ashby P. **Adv Neurol** 1995;67:305–20 (60 ref.)

Corticospinal efferents of the supplementary sensorimotor area in relation to the primary motor area. Wise SP. **Adv Neurol** 1996;70:57–69 (62 ref.)

A spinal circuitry simulator as a teaching tool for neuromuscular physiology. Maw S, et al. **Am J Physiol** 1996 Jun;270(6 Pt 3):S50–68 (25 ref.)

Interactions and coexistence of neuropeptides and serotonin in spinal autonomic systems. Helke CJ, et al. **Ann N Y Acad Sci** 1996 Mar 22;780:185–92 (49 ref.)

Structural organization of the synaptic connections of the spinal cord motor neurons of mammals. Motorina MV. **Neurosci Behav Physiol** 1995 Jul–Aug;25(4):273–89 (134 ref.)

Pharmacology of descending noradrenergic systems in relation to motor function. Ono H, et al. **Pharmacol Ther** 1995;68(1):105–12 (61 ref.)

Spinal cord tachykinins in the micturition reflex. Lecci A, et al. **Prog Brain Res** 1995;104:145–59 (93 ref.)

SPINAL CORD

Opioid receptors in the superficial layers of the rat spinal cord: functional implications in pain processing. Lombard MC, et al. **Prog Brain Res** 1995;104:77–92 (79 ref.)
Proto-oncogenes: basic concepts and stimulation induced changes in the spinal cord. Munglani R, et al. **Prog Brain Res** 1995;104:283–98 (114 ref.)
Electrophysiology of neuropeptides in the sensory spinal cord. Radhakrishnan V, et al. **Prog Brain Res** 1995; 104:175–95 (176 ref.)
Neuropeptides and spinal cord reflexes. Wiesenfeld-Hallin Z. **Prog Brain Res** 1995;104:271–82 (104 ref.)
The isolated mammalian spinal cord. Kerkut GA, et al. **Prog Neurobiol** 1995 May;46(1):1–48 (233 ref.)
Plasticity of cutaneous primary afferent projections to the spinal dorsal horn. Wilson P, et al. **Prog Neurobiol** 1996 Feb;48(2):105–29 (240 ref.)
Modular organization of motor behavior in the frog's spinal cord. Bizzi E, et al. **Trends Neurosci** 1995 Oct;18(10):442–6 (30 ref.)

PHYSIOPATHOLOGY

Spinal cord pharmacology of pain. Dickenson AH. **Br J Anaesth** 1995 Aug;75(2):193–200 (71 ref.)
Ventral spinal subdural hematoma—case report. Yamagami T, et al. **Neurol Med Chir (Tokyo)** 1995 Dec;35(12):896–900 (22 ref.)
Degeneration and regeneration of axons in the lesioned spinal cord. Schwab ME, et al. **Physiol Rev** 1996 Apr;76(2):319–70 (774 ref.)

SECRETION

Plasticity of calcitonin gene related peptide neurotransmission in the spinal cord during peripheral inflammation. Seybold VS, et al. **Can J Physiol Pharmacol** 1995 Jul;73(7):1007–14 (51 ref.)

SURGERY

CT-guided pain procedures for intractable pain in malignancy. Kanpolat Y, et al. **Acta Neurochir Suppl (Wien)** 1995;64:88–91 (24 ref.)
Spinal cord and nerve root monitoring in spine surgery and related procedures. Herdmann J, et al. **Spine** 1996 Apr 1; 21(7):879–85 (20 ref.)

VIROLOGY

Spread of MHV-JHM from nasal cavity to white matter of spinal cord. Transneuronal movement and involvement of astrocytes. Perlman S, et al. **Adv Exp Med Biol** 1995; 380:73–8 (21 ref.)

SPINAL CORD COMPRESSION

COMPLICATIONS

Cervical spinal stenosis with cord neurapraxia and transient quadriplegia. Torg JS. **Sports Med** 1995 Dec;20(6):429–34 (10 ref.)

DIAGNOSIS

Cervical spondylotic myelopathy. Cates JR, et al. **J Manipulative Physiol Ther** 1995 Sep;18(7):471–5 (23 ref.)

ETIOLOGY

Spinal cord compression: from laboratory to clinic. Siegal T. **Eur J Cancer** 1995 Oct;31A(11):1748–53 (37 ref.)
Diaphyseal aclasis with spinal cord compression. Report of two cases and review of the literature. Labram EK, et al. **J Neurosurg** 1996 Mar;84(3):518–21 (18 ref.)
Spinal cord compression by eosinophilic granuloma of the cervical spine. Case report and review of the literature. Scarpinati M, et al. **Neurosurg Rev** 1995;18(3):209–12 (34 ref.)

SURGERY

Anterior decompressive microsurgery and osteosynthesis for the treatment of multi-segmental cervical spondylosis. Pathophysiological considerations, surgical indication, results and complications: a survey. Seifert V. **Acta Neurochir (Wien)** 1995;135(3–4):105–21 (108 ref.)
Spinal epidural hematoma. Report of a case and review of the literature. Rainov NG, et al. **Neurosurg Rev** 1995; 18(1):53–60 (115 ref.)
Controversy in spine care. Is fusion necessary after anterior cervical discectomy? Sonntag VK, et al. **Spine** 1996 May 1;21(9):1111–3 (15 ref.)

SPINAL CORD DISEASES

[Clinical study of spinal cord diseases] Tashiro K. **Nippon Naika Gakkai Zasshi** 1996 Mar 10;85(3):384–8 (8 ref.) **(Jpn)**

CHEMICALLY INDUCED

Severe neurologic deficit after nitrous oxide anesthesia. Hadzic A, et al. **Anesthesiology** 1995 Oct;83(4):863–6 (14 ref.)

DIAGNOSIS

Myelopathy. Ross JS. **Neuroimaging Clin N Am** 1995 Aug; 5(3):367–84 (75 ref.)
Neurophysiological techniques in the evaluation of disorders of the spine. Schnitzler A, et al. **Zentralbl Neurochir** 1995; 56(3):117–27 (41 ref.)
[MRI diagnosis of spinal cord diseases] Yanagi T. **Nippon Naika Gakkai Zasshi** 1995 Sep 10;84(9):1588–93 (9 ref.) **(Jpn)**

ETIOLOGY

Spinal epidural abscess in hemodialysis patients: report of three cases and review of the literature. Obrador GT, et al. **Am J Kidney Dis** 1996 Jan;27(1):75–83 (34 ref.)
Intramedullary haemorrhage due to AVM located within the medulla oblongata in a three year old child. Case report. Maggi G, et al. **J Neurosurg Sci** 1994 Dec;38(4):255–8 (15 ref.)
Myelopathy associated with fibrocartilaginous emboli (FE): review and two suspected cases. McLean JM, et al. **Surg Neurol** 1995 Sep;44(3):228–34; discussion 234–5 (46 ref.)
[Iatrogenic spinal epidermoid tumors. A late complication of spinal puncture] Reina MA, et al. **Rev Esp Anestesiol Reanim** 1996 Apr;43(4):142–6 (84 ref.) (Eng. Abstr.) **(Spa)**

MICROBIOLOGY

Managing HIV. Part 5: Treating secondary outcomes. 5.5 HIV and opportunistic neurological infections. Jones PD, et al. **Med J Aust** 1996 Apr 1;164(7):418–21 (22 ref.)

PATHOLOGY

Pigmented villonodular synovitis of the spine: a clinical, radiological, and morphological study of 12 cases. Giannini C, et al. **J Neurosurg** 1996 Apr;84(4):592–7 (19 ref.)
Spinal epidural hematoma during anticoagulant therapy. A case report and review of the literature. Rodriguez y Baena R, et al. **J Neurosurg Sci** 1995 Mar;39(1):87–94 (90 ref.)
[Neuroimaging and pathology of the spinal cord in compressive cervical myelopathy] Kameyama T, et al. **Rinsho Byori** 1995 Sep;43(9):886–90 (4 ref.) (Eng. Abstr.) **(Jpn)**

RADIOGRAPHY

Pigmented villonodular synovitis of the spine: a clinical, radiological, and morphological study of 12 cases. Giannini C, et al. **J Neurosurg** 1996 Apr;84(4):592–7 (19 ref.)

THERAPY

Neurosurgical care of spinal epidural, subdural, and intramedullary abscesses and arachnoiditis. Martin RJ, et al. **Orthop Clin North Am** 1996 Jan;27(1):125–36 (72 ref.)
[Modern methods for treating spinal cord diseases of ischemic and traumatic origin in the late period (a review of the literature)] Mikhailenko AA, et al. **Voen Med Zh** 1995 Dec; (12):31–6 (28 ref.) **(Rus)**

SPINAL CORD INJURIES

Pregnancy in spinal cord injured women. Baker ER, et al. **Arch Phys Med Rehabil** 1996 May;77(5):501–7 (67 ref.)
Head and spine injuries in youth sports. Cantu RC. **Clin Sports Med** 1995 Jul;14(3):517–32 (31 ref.)
Neurotrauma and trauma systems. Pitts LH. **New Horiz** 1995 Aug;3(3):546–8 (13 ref.)
Delayed central cord syndrome after a handstand in a child: case report. Lee KS, et al. **Paraplegia** 1996 Mar;34(3):176–8 (25 ref.)
[A case report of vaginal delivery controlled by epidural anesthesia in a woman with high spinal cord injury] Kase H, et al. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Sep; 47(9):957–60 (14 ref.) **(Jpn)**

COMPLICATIONS

Outcomes of tendon transfer surgery and occupational therapy in a child with tetraplegia secondary to spinal cord injury. Mulcahey MJ, et al. **Am J Occup Ther** 1995 Jul-Aug;49(7):607–17 (45 ref.)
Depression following spinal cord injury. Elliott TR, et al. **Arch Phys Med Rehabil** 1996 Aug;77(8):816–23 (89 ref.)
Post-traumatic syringomyelia (cystic myelopathy): a prospective study of 449 patients with spinal cord injury. Schurch B, et al. **J Neurol Neurosurg Psychiatry** 1996 Jan; 60(1):61–7 (42 ref.)
Spinal shock. Atkinson PP, et al. **Mayo Clin Proc** 1996 Apr; 71(4):384–9 (79 ref.)
Clinical approach to erectile dysfunction in spinal cord injured men. A review of clinical and experimental data. Courtois FJ, et al. **Paraplegia** 1995 Nov;33(11):628–35 (60 ref.)
[Traumatic spinothoracic cerebrospinal fluid fistula] Löw R, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1995 Nov;163(5):454–6 (9 ref.) **(Ger)**
[Modern methods for treating spinal cord diseases of ischemic and traumatic origin in the late period (a review of the literature)] Mikhailenko AA, et al. **Voen Med Zh** 1995 Dec; (12):31–6 (28 ref.) **(Rus)**
[Trauma and thrombosis. High risk of embolism in patients with spinal cord injuries, hip fractures and leg fractures] Bergqvist D. **Lakartidningen** 1996 Jul 24;93(30–31):2653–4 (19 ref.) **(Swe)**

DIAGNOSIS

Neurophysiological techniques in the evaluation of disorders of the spine. Schnitzler A, et al. **Zentralbl Neurochir** 1995; 56(3):117–27 (41 ref.)

DRUG THERAPY

Clinical potential for the use of neuroprotective agents. A brief overview. Trembly B. **Ann N Y Acad Sci** 1995 Sep 15;765:1–20; discussion 26–7 (87 ref.)
Advances in neurotrauma. Wilberger J. **Curr Opin Gen Surg** 1993;:55–61 (40 ref.)
Lazaroids. CNS pharmacology and current research. Clark WM, et al. **Drugs** 1995 Dec;50(6):971–83 (64 ref.)
Pharmacological treatment of central nervous system trauma. Faden AI. **Pharmacol Toxicol** 1996 Jan;78(1):12–7 (62 ref.)
New pharmacologic approaches to acute spinal cord injury. Rhoney DH, et al. **Pharmacotherapy** 1996 May-Jun; 16(3):382–92 (82 ref.)
The opioid receptor antagonist naloxone influences the pathophysiology of spinal cord injury. Olsson Y, et al. **Prog Brain Res** 1995;104:381–99 (96 ref.)
[The physiopathology of acute spinal cord injury and a hope for a successful treatment] Harat M, et al. **Neurol Neurochir Pol** 1996 Jan–Feb;30(1):123–35 (22 ref.) (Eng. Abstr.) **(Pol)**

EPIDEMIOLOGY

Substance misuse in individuals with spinal cord injury. Radnitz CL, et al. **Int J Addict** 1995 Jul;30(9):1117–40 (50 ref.)
Prevalence of spinal cord injury: an international comparison. Blumer CE, et al. **Neuroepidemiology** 1995;14(5):258–68 (29 ref.)

ETIOLOGY

Central nervous system complications of lightning and electrical injuries. Cherington M. **Semin Neurol** 1995 Sep; 15(3):233–40 (107 ref.)

IMMUNOLOGY

Influence of dynorphin A antibodies on the formation of edema and cell changes in spinal cord trauma. Sharma HS, et al. **Prog Brain Res** 1995;104:401–16 (95 ref.)

METABOLISM

Cytoskeletal derangements following central nervous system injury: modulation by neurotrophic gene transfection. Hayes RL, et al. **J Neurotrauma** 1995 Oct;12(5):933–41 (58 ref.)
Neurotrophic factors in central nervous system trauma. Mocchetti I, et al. **J Neurotrauma** 1995 Oct;12(5):853–70 (186 ref.)
Molecular biology of CNS injury. Yakovlev AG, et al. **J Neurotrauma** 1995 Oct;12(5):767–77 (83 ref.)

NURSING

Meeting the challenge of the older trauma patient [published erratum appears in Am J Nurs 1996 Jun;96(6):17] Stamatos CA, et al. **Am J Nurs** 1996 May;96(5):40–7; quiz 48 (7 ref.)

PHYSIOPATHOLOGY

Locomotor capacities after complete and partial lesions of the spinal cord. Rossignol S, et al. **Acta Neurobiol Exp (Warsz)** 1996;56(1):449–63 (135 ref.)
Cell stress genes and acute CNS injury. McIntosh TK, et al. **Neuropathol Appl Neurobiol** 1995 Dec;21(6):477–9 (27 ref.)
Mechanisms underlying the recovery of lower urinary tract function following spinal cord injury. de Groat WC. **Paraplegia** 1995 Sep;33(9):493–505 (70 ref.)
Bone metabolism in spinal cord injured individuals and in others who have prolonged immobilisation. A review. Uebelhart D, et al. **Paraplegia** 1995 Nov;33(11):669–73 (42 ref.)
Degeneration and regeneration of axons in the lesioned spinal cord. Schwab ME, et al. **Physiol Rev** 1996 Apr;76(2):319–70 (774 ref.)
Urodynamics of spinal cord injury. Watanabe T, et al. **Urol Clin North Am** 1996 Aug;23(3):459–73 (53 ref.)
[The physiopathology of acute spinal cord injury and a hope for a successful treatment] Harat M, et al. **Neurol Neurochir Pol** 1996 Jan–Feb;30(1):123–35 (22 ref.) (Eng. Abstr.) **(Pol)**

PREVENTION & CONTROL

Spinal cord protection during surgical procedures on the descending thoracic and thoracoabdominal aorta: review of current techniques. Gharagozloo F, et al. **Chest** 1996 Mar;109(3):799–809 (98 ref.)

PSYCHOLOGY

Depression following spinal cord injury. Elliott TR, et al. **Arch Phys Med Rehabil** 1996 Aug;77(8):816–23 (89 ref.)

RADIOGRAPHY

An unusual location for heterotopic ossification: lumbar anterior longitudinal ligament. Czyrny JJ, et al. **J Spinal Cord Med** 1995 Jul;18(3):194–9 (32 ref.)

REHABILITATION

Neurolaw: towards a new medical jurisprudence. Taylor JS. **Brain Inj** 1995 Oct;9(7):745–51 (44 ref.)

Principles underlying functional electrical stimulation techniques. Jaeger RJ. **J Spinal Cord Med** 1996 Apr; 19(2):93–6 (38 ref.)

Spinal cord injury, exercise and quality of life. Noreau L, et al. **Sports Med** 1995 Oct;20(4):226–50 (171 ref.)

SURGERY

[Nerve transplantation in the central nervous system: a strategy for inducing nerve fiber regeneration in lesions of the brain and spinal cord] Gauthier P, et al. **Rev Neurol (Paris)** 1996 Feb;152(2):106–15 (62 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Initial stabilization and medical management of acute spinal cord injury. Fehlings MG, et al. **Am Fam Physician** 1996 Jul;54(1):155–62 (09 ref.)

Meeting the challenge of the older trauma patient [published erratum appears in Am J Nurs 1996 Jun;96(6):17] Stamatos CA, et al. **Am J Nurs** 1996 May;96(5):40–7; quiz 48 (7 ref.)

Functional and therapeutic benefits of electrical stimulation after spinal injury. Andrews BJ, et al. **Curr Opin Neurol** 1995 Dec;8(6):461–6 (56 ref.)

Spinal cord lesions. Biering-Sørensen F, et al. **Curr Opin Neurol** 1995 Dec;8(6):451–5 (47 ref.)

Pain associated with spinal cord injury. Siddall PJ, et al. **Curr Opin Neurol** 1995 Dec;8(6):447–50 (40 ref.)

Prospects for the treatment of spinal cord and peripheral nerve injury [editorial] Hems TE, et al. **J Bone Joint Surg Br** 1996 Mar;78(2):176–7 (18 ref.)

Acute spinal cord injury and neurogenic shock in pregnancy. Gilson GJ, et al. **Obstet Gynecol Surv** 1995 Jul;50(7):556–60 (11 ref.)

Early management after acute traumatic spinal cord injury. Holtz A. **Ups J Med Sci** 1995;100(2):93–123 (83 ref.)

[A review for the past 20 years in spine and spinal cord injuries] Otani K. **Nippon Seikeigeka Gakkai Zasshi** 1996 Apr;70(4):135–45 (7 ref.) **(Jpn)**

SPINAL CORD NEOPLASMS

Neuroblastoma and brain tumors in childhood. Ater JL. **Pediatr Dent** 1995 Jul–Aug;17(4):268–72 (19 ref.)

DIAGNOSIS

Scoliosis as the first sign of a cystic spinal cord lesion. Samuelsson L, et al. **Eur Spine J** 1995;4(5):284–90 (41 ref.)

EPIDEMIOLOGY

Intramedullary spinal cord germinoma. Matsuyama Y, et al. **Spine** 1995 Nov 1;20(21):2338–40 (8 ref.)

Meningioma in children: a report of nine cases and a review of the literature. Sheikh BY, et al. **Surg Neurol** 1996 Apr; 45(4):328–35 (71 ref.)

PATHOLOGY

Spinal extradural angiolipoma. Krishnan VB, et al. **Aust N Z J Surg** 1996 Mar;66(3):194–6 (13 ref.)

Mesenchymal chondrosarcoma: a clinicopathologic and flow cytometric study of 13 cases presenting in the central nervous system. Rushing EJ, et al. **Cancer** 1996 May 1; 77(9):1884–91 (36 ref.)

Sacrococcygeal chordoma metastatic to the brain with review of the literature. Hall WA, et al. **J Neurooncol** 1995; 25(2):155–9 (16 ref.)

Multiple neuroepithelial tumors of different cell types—case report. Akai T, et al. **Neurol Med Chir (Tokyo)** 1995 Dec; 35(12):901–4 (9 ref.)

SECONDARY

Spinal cord and bone metastasizing renal tumor of childhood. Arrotegui JI, et al. **Rev Neurol** 1995 Nov–Dec; 23(124):1231–2 (15 ref.)

SURGERY

Symptomatic cavernous malformations affecting the spine and spinal cord. Harrison MJ, et al. **Neurosurgery** 1995 Aug;37(2):195–204; discussion 204–5 (87 ref.)

Intramedullary spinal cord germinoma: case report and review of the literature. Itoh Y, et al. **Neurosurgery** 1996 Jan;38(1):187–90; discussion 190–1 (17 ref.)

[A case of thoracic meningioma presenting paraplegia at 4.5 years after removal of a falx meningioma] Suga T, et al. **No Shinkei Geka** 1996 Jun;24(6):567–72 (23 ref.) (Eng. Abstr.) **(Jpn)**

ULTRASTRUCTURE

Clear cell meningioma: report of a spinal case. Prinz M, et al. **Gen Diagn Pathol** 1996 Mar;141(3–4):261–7 (16 ref.)

SPINAL DISEASES

Back injuries in the young athlete. Gerbino PG 2nd, et al. **Clin Sports Med** 1995 Jul;14(3):571–90 (120 ref.)

Challenges of the spine specialists. North American Spine Society Presidential Address. Minneapolis, Minnesota, October 1994. Lee C. **Spine** 1995 Aug 15;20(16):1749–52 (24 ref.)

[Spontaneous spinal epidural hematoma: 2 cases] Robin C, et al. **Rev Neurol (Paris)** 1996 Feb;152(2):139–42 (10 ref.) (Eng. Abstr.) **(Fre)**

CHEMICALLY INDUCED

Prolonged treatment with oral retinoids in adults: no influence on the frequency and severity of spinal abnormalities. Van Dooren-Greebe RJ, et al. **Br J Dermatol** 1996 Jan;134(1):71–6 (30 ref.)

CLASSIFICATION

Overview and classification of spinal infections. Calderone RR, et al. **Orthop Clin North Am** 1996 Jan;27(1):1–8 (38 ref.)

COMPLICATIONS

Cervicogenic headache: a personal view. Pearce JM. **Cephalalgia** 1995 Dec;15(6):463–9 (39 ref.)

The osteoporotic spine. Lee YL, et al. **Clin Orthop** 1996 Feb; (323):91–7 (37 ref.)

[On alleged radicular pain in patients with lumbar intervertebral disc hernias] Styczyński T, et al. **Neurol Neurochir Pol** 1995 Sep–Oct;29(5):747–52 (20 ref.) (Eng. Abstr.) **(Pol)**

[A case of angiosarcoma of the pelvis associated with angiomatosis of the spine] Uribe Uribe NO, et al. **Rev Invest Clin** 1996 Jan–Feb;48(1):49–53 (9 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Idiopathic spinal epidural lipomatosis. Case report and review of literature. Sato M, et al. **Clin Orthop** 1995 Nov; (320):129–34 (11 ref.)

The use of radiographic imaging studies in the evaluation of patients who have degenerative disorders of the lumbar spine. Boden SD. **J Bone Joint Surg Am** 1996 Jan; 78(1):114–24 (128 ref.)

The diagnosis of infections of the spine by modern imaging techniques. Rothman SL. **Orthop Clin North Am** 1996 Jan; 27(1):15–31 (15 ref.)

Magnetic resonance imaging. Use in patients with low back or radicular pain. Herzog RJ, et al. **Spine** 1995 Aug 15; 20(16):1834–8 (31 ref.)

[Magnetic resonance imaging for lumbar disk pathology. incidence of false negatives (editorial)] Berthelot JM, et al. **Presse Med** 1995 Oct 7;24(29):1329–31 (26 ref.) (Eng. Abstr.) **(Fre)**

[Role of CT and MR in the assessment of lumbar degenerative disk disease] Gualdi GF, et al. **Clin Ter** 1995 Oct;146(10):635–48 (24 ref.) (Eng. Abstr.) **(Ita)**

ETIOLOGY

Posttraumatic spinal osteolysis in ankylosing spondylitis as part of pseudoarthrosis. A case report. Albertsen AM, et al. **Acta Radiol** 1996 Jan;37(1):98–100 (10 ref.)

Pathogenesis of spondylarthropathies. Persistent bacterial antigen, autoimmunity, or both? Sieper J, et al. **Arthritis Rheum** 1995 Nov;38(11):1547–54 (80 ref.)

Impaired haemostasis and regional anaesthesia. Stafford-Smith M. **Can J Anaesth** 1996 May;43(5 Pt 2):R129–41 (33 ref.) **(Eng, Fre)**

Vertebral collapse in childhood leukemia. Meehan PL, et al. **J Pediatr Orthop** 1995 Sep–Oct;15(5):592–5 (31 ref.)

Wound management in spinal infection. Rubayi S. **Orthop Clin North Am** 1996 Jan;27(1):137–53 (47 ref.)

GENETICS

Juvenile rheumatoid arthritis and spondyloarthropathies. Lindsley CB. **Curr Opin Rheumatol** 1995 Sep;7(5):425–9 (46 ref.)

IMMUNOLOGY

Juvenile rheumatoid arthritis and spondyloarthropathies. Lindsley CB. **Curr Opin Rheumatol** 1995 Sep;7(5):425–9 (46 ref.)

Spinal infections in the immunocompromised host. Broner FA, et al. **Orthop Clin North Am** 1996 Jan;27(1):37–46 (38 ref.)

MICROBIOLOGY

Mycobacterial and fungal infections of bone and joints. Meier JL, et al. **Curr Opin Rheumatol** 1995 Jul;7(4):329–36 (75 ref.)

Spinal epidural abscess caused by Brucella: case report. Paz JF, et al. **J Neurosurg Sci** 1994 Dec;38(4):245–9 (22 ref.)

Microbiology and antimicrobial therapy of spinal infections. Sapico FL. **Orthop Clin North Am** 1996 Jan;27(1):9–13 (22 ref.)

PHYSIOPATHOLOGY

Nutritional status in the patient with spinal infection. Klein JD, et al. **Orthop Clin North Am** 1996 Jan;27(1):33–6 (30 ref.)

RADIOGRAPHY

Acute neuroradiology: methods, indications and timing. Fagerlund MK. **Ann Med** 1995 Dec;27(6):657–62 (53 ref.)

[Computed tomographic demonstration of intraspinal air after an infection with peptostreptococci] Lorenzen J, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Feb;164(2):173–5 (10 ref.) **(Ger)**

REHABILITATION

Spine update. Functional restoration. Hazard RG. **Spine** 1995 Nov 1;20(21):2345–8 (20 ref.)

Spine rehabilitation. Secondary and tertiary nonoperative care. Mayer TG, et al. **Spine** 1995 Sep 15;20(18):2060–6 (45 ref.)

SURGERY

Image-guided spine surgery. Foley KT, et al. **Neurosurg Clin N Am** 1996 Apr;7(2):171–86 (7 ref.)

Use of tissue expanders for wound closure of spinal infections or dehiscence. Paonessa KJ, et al. **Orthop Clin North Am** 1996 Jan;27(1):155–70 (32 ref.)

Minimally invasive surgical techniques to treat spine infections. Parker LM, et al. **Orthop Clin North Am** 1996 Jan;27(1):183–99 (40 ref.)

The use of antibiotics for wound prophylaxis in spinal surgery. Rimoldi RL, et al. **Orthop Clin North Am** 1996 Jan;27(1):47–52 (33 ref.)

Biologic factors affecting spinal fusion and bone regeneration. Boden SD, et al. **Spine** 1995 Dec 15;20(24 Suppl):102S–112S (127 ref.)

Biologic enhancement of spinal fusion. Boden SD, et al. **Spine** 1995 Dec 15;20(24 Suppl):113S–123S (159 ref.)

The indications for lumbar spinal fusion with and without instrumentation. Hanley EN Jr. **Spine** 1995 Dec 15;20(24 Suppl):143S–153S (108 ref.)

[Analgesia after surgery of the spine in adults and adolescents] Bernard JM, et al. **Cah Anesthesiol** 1995; 43(6):557–64 (78 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Pyogenic vertebral osteomyelitis and postsurgical disc space infections. Ozuna RM, et al. **Orthop Clin North Am** 1996 Jan;27(1):87–94 (59 ref.)

Wound infections in reconstructive spine surgery. Theiss SM, et al. **Orthop Clin North Am** 1996 Jan;27(1):105–10 (23 ref.)

Biologic enhancement of spinal fusion. Boden SD, et al. **Spine** 1995 Dec 15;20(24 Suppl):113S–123S (159 ref.)

The treatment of degenerative lumbar disorders. A critical review of the literature. Zdeblick TA. **Spine** 1995 Dec 15; 20(24 Suppl):126S–137S (165 ref.)

[Manual medicine in otorhinolaryngology. Theoretical principles— clinical practice—principles of therapy and prevention] Seifert K. **Laryngorhinootologie** 1995 Oct; 74(10):583–90 (38 ref.) (Eng. Abstr.) **(Ger)**

SPINAL DYSRAPHISM

GENETICS

Mechanisms of mutant genes in spina bifida: a review of implications from animal models. George TM, et al. **Pediatr Neurosurg** 1995;23(5):236–45 (62 ref.)

PREVENTION & CONTROL

Issues in the prevention of spina bifida. Bower C, et al. **J R Soc Med** 1996 Aug;89(8):436–42 (90 ref.)

SPINAL FLUID PRESSURE see **CEREBROSPINAL FLUID PRESSURE**

SPINAL FRACTURES

COMPLICATIONS

Posttraumatic spinal osteolysis in ankylosing spondylitis as part of pseudoarthrosis. A case report. Albertsen AM, et al. **Acta Radiol** 1996 Jan;37(1):98–100 (10 ref.)

Lumbosacral fracture-subluxation associated with bilateral fractures of the first sacral pedicles: a case report and review of the literature. Shirado O, et al. **J Orthop Trauma** 1995;9(4):354–8 (28 ref.)

Vertical fracture of the central sacral canal: plane and simple. Hatem SF, et al. **J Trauma** 1996 Jan;40(1):138–40 (12 ref.)

Retroperitoneal pseudomeningocele complicated by meningitis following a lumbar burst fracture. A case report. Nairus JG, et al. **Spine** 1996 May 1;21(9):1090–3 (13 ref.)

DIAGNOSIS

Thoracolumbar burst fracture: evaluating stability. Petersilge CA, et al. **Semin Ultrasound CT MR** 1996 Apr;17(2):105–13 (40 ref.)

Imaging of cervical spine trauma. Tehranzadeh J, et al. **Semin Ultrasound CT MR** 1996 Apr;17(2):93–104 (51 ref.)

SPINAL FRACTURES

DRUG THERAPY

Drug therapy for vertebral fractures in osteoporosis: evidence that decreases in bone turnover and increases in bone mass both determine antifracture efficacy. **Riggs BL, et al. Bone** 1996 Mar;18(3 Suppl):197S–201S (26 ref.)

EPIDEMIOLOGY

Vertebral fracture epidemiology. **Wasnich RD. Bone** 1996 Mar;18(3 Suppl):179S–183S (24 ref.)

ETIOLOGY

What is a vertebral fracture? **Ziegler R, et al. Bone** 1996 Mar;18(3 Suppl):169S–177S (46 ref.)

The osteoporotic spine. **Lee YL, et al. Clin Orthop** 1996 Feb; (323):91–7 (37 ref.)

Stress fractures of the sacrum and lower extremity. **Fanciullo JJ, et al. Curr Opin Rheumatol** 1996 Mar;8(2):158–62 (26 ref.)

Lumbar compression fractures secondary to lap–belt use in children. **Sturm PF, et al. J Pediatr Orthop** 1995 Jul–Aug; 15(4):521–3 (27 ref.)

Odontoid fracture and C1–C2 subluxation in psoriatic cervical spondyloarthropathy. A case report. **Sosner J, et al. Spine** 1996 Feb 15;21(4):519–21 (6 ref.)

PHYSIOPATHOLOGY

Fractures of the odontoid process in small children: biomechanical analysis and report of three cases. **Blauth M, et al. Eur Spine J** 1996;5(1):63–70 (27 ref.)

PREVENTION & CONTROL

Present and future of osteoporosis therapy. **Seeman E, et al. Bone** 1995 Aug;17(2 Suppl):23S–29S (47 ref.)

Fluoride therapy of type I osteoporosis. **Devogelaer JP, et al. Clin Rheumatol** 1995 Sep;14 Suppl 3:26–31 (57 ref.)

PSYCHOLOGY

The clinical impact of vertebral fractures: quality of life in women with osteoporosis. **Gold DT. Bone** 1996 Mar;18(3 Suppl):185S–189S (29 ref.)

SURGERY

Thoracic fracture–dislocations without spinal cord injury: a case report and literature review. **Liljenqvist U, et al. Eur Spine J** 1995;4(4):252–6 (34 ref.)

Traumatic atlantoaxial rotatory subluxation and dislocation. **Moore KR, et al. Spine** 1995 Sep 1;20(17):1928–30 (10 ref.)

[Injuries of the cervical spine. Diagnosis and surgical treatment] **Illgner A, et al. Unfallchirurg** 1996 May; 99(5):351–67; quiz 367 (10 ref.) **(Ger)**

THERAPY

General management of vertebral fractures. **Rapado A. Bone** 1996 Mar;18(3 Suppl):191S–196S (48 ref.)

Cervical spine fractures. **Hughes SP. J R Coll Surg Edinb** 1995 Oct;40(5):337–41 (16 ref.)

The treatment of thoracolumbar fractures: one point of view. **Rea GL, et al. J Spinal Disord** 1995 Oct;8(5):368–82 (59 ref.)

ULTRASONOGRAPHY

Diagnostic value of ultrasound analysis and bone densitometry as predictors of vertebral deformity in postmenopausal women. **Gonnelli S, et al. Osteoporos Int** 1995;5(6):413–8 (40 ref.)

VETERINARY

Spinal fracture/luxation. **Kirby BM. Vet Clin North Am Small Anim Pract** 1995 Sep; 25(5):1149–74 (49 ref.)

SPINAL FUSION

Should backache be treated with spinal fusion? The case for spinal fusion is unproved [comment] **Wilson-MacDonald J. BMJ** 1996 Jan 6;312(7022):39–40 (10 ref.) Comment on: BMJ 1996 Jan 6;312(7022):38–9.

The use of bone allografts in the spine. **Buttermann GR, et al. Clin Orthop** 1996 Mar;(324):75–85 (53 ref.)

Biologic enhancement of spinal fusion. **Boden SD, et al. Spine** 1995 Dec 15;20(24 Suppl):113S–123S (159 ref.)

Biologic factors affecting spinal fusion and bone regeneration. **Boden SD, et al. Spine** 1995 Dec 15;20(24 Suppl):102S–112S (127 ref.)

Is fusion indicated for lumbar spinal disorders? **Sonntag VK, et al. Spine** 1995 Dec 15;20(24 Suppl):138S–142S (23 ref.)

ADVERSE EFFECTS

Urinary bladder dysfunction following anterior lumbosacral spine fusion: case report and review of the literature. **Faraj AA, et al. Eur Spine J** 1996;5(2):121–4 (11 ref.)

Perioperative risk factors for wound infections after lower back fusions. **Capen DA, et al. Orthop Clin North Am** 1996 Jan;27(1):83–6 (24 ref.)

Complications of posterior cervical plating. **Heller JG, et al. Spine** 1995 Nov 15;20(22):2442–8 (21 ref.)

INSTRUMENTATION

Anterior decompressive microsurgery and osteosynthesis for the treatment of multi-segmental cervical spondylosis. Pathophysiological considerations, surgical indication, results and complications: a survey. **Seifert V. Acta Neurochir (Wien)** 1995;135(3–4):105–21 (108 ref.)

Thoracic fracture–dislocations without spinal cord injury: a case report and literature review. **Liljenqvist U, et al. Eur Spine J** 1995;4(4):252–6 (34 ref.)

Occipitocervical fusion by Luque loop rod instrumentation in Down syndrome. **Higo M, et al. J Pediatr Orthop** 1995 Jul–Aug;15(4):539–42 (17 ref.)

Public citizen opposition to spinal implant fixation. **Yuan HA. J Spinal Disord** 1995 Oct;8(5):413–8 (17 ref.)

The indications for lumbar spinal fusion with and without instrumentation. **Hanley EN Jr. Spine** 1995 Dec 15;20(24 Suppl):143S–153S (108 ref.)

Internal fixation (pedicle screw fixation) for fusions of the lumbar spine. **Vaccaro AR, et al. Spine** 1995 Dec 15;20(24 Suppl):157S–165S (54 ref.)

METHODS

Instrumentational posterior fusion for atlanto–axial subluxation in a young child with Down's syndrome—case report. **Kohno M, et al. Neurol Med Chir (Tokyo)** 1995 Oct;35(10):753–8 (22 ref.)

Interbody, posterior, and combined lumbar fusions. **Fraser RD. Spine** 1995 Dec 15;20(24 Suppl):167S–177S (83 ref.)

Biomechanics of fusion and stabilization. **Goel VK, et al. Spine** 1995 Dec 15;20(24 Suppl):85S–99S (141 ref.)

The indications for lumbar spinal fusion with and without instrumentation. **Hanley EN Jr. Spine** 1995 Dec 15;20(24 Suppl):143S–153S (108 ref.)

Assessment of spinal fusion. Critical evaluation of imaging techniques. **Herzog RJ, et al. Spine** 1996 May 1; 21(9):1114–8 (5 ref.)

TRENDS

Controversy in spine care. Is fusion necessary after anterior cervical discectomy? **Sonntag VK, et al. Spine** 1996 May 1;21(9):1111–3 (15 ref.)

UTILIZATION

Lumbar spinal fusion. Surgical rates, costs, and complications. **Katz JN. Spine** 1995 Dec 15;20(24 Suppl):78S–83S (26 ref.)

SPINAL GANGLIA see **GANGLIA, SPINAL**

SPINAL INJURIES

DIAGNOSIS

What is the evidence for an organic lesion in whiplash injury? **Gargan MF. J Psychosom Res** 1995 Aug;39(6):777–81 (27 ref.)

PHYSIOPATHOLOGY

Biomechanics and classification of traumatic lesions of the spine. **Chirossel JP, et al. Adv Tech Stand Neurosurg** 1995; 22:55–135 (113 ref.)

SURGERY

[Injuries of the cervical spine. Diagnosis and surgical treatment] **Illgner A, et al. Unfallchirurg** 1996 May; 99(5):351–67; quiz 367 (10 ref.) **(Ger)**

THERAPY

Preliminary findings of analysis of chiropractic utilization and cost in the workers' compensation system of New South Wales, Australia. **Tuchin PJ, et al. J Manipulative Physiol Ther** 1995 Oct;18(8):503–11 (57 ref.)

Acute spinal injury [see comments] **Chiles BW 3rd, et al. N Engl J Med** 1996 Feb 22;334(8):514–20 (54 ref.) Comment in: N Engl J Med 1996 Jun 27;334(26):1747–8. Comment in: N Engl J Med 1996 Jun 27;334(26):1748.

[Stabilization of the spine in accident victims] **Meertens JH, et al. Ned Tijdschr Geneeskd** 1996 Aug 10;140(32):1635–9 (30 ref.) **(Dut)**

[A review for the past 20 years in spine and spinal cord injuries] **Otani K. Nippon Seikeigeka Gakkai Zasshi** 1996 Apr;70(4):135–45 (7 ref.) **(Jpn)**

VETERINARY

Spinal fracture/luxation. **Kirby BM. Vet Clin North Am Small Anim Pract** 1995 Sep; 25(5):1149–74 (49 ref.)

SPINAL MUSCULAR ATROPHY see **MUSCULAR ATROPHY, SPINAL**

SPINAL MUSCULAR ATROPHY, INFANTILE see **WERDNIG-HOFFMANN DISEASE**

SPINAL NEOPLASMS

COMPLICATIONS

Spinal cord compression: from laboratory to clinic. **Siegal T. Eur J Cancer** 1995 Oct;31A(11):1748–53 (37 ref.)

DIAGNOSIS

CT and MR imaging of vertebral osteoblastoma. A report of two cases. **Ozkal E, et al. Clin Imaging** 1996 Jan–Mar; 20(1):37–41 (13 ref.)

Chordoma of the lower cervical spine. **D'Haen B, et al. Clin Neurol Neurosurg** 1995 Aug;97(3):245–8 (20 ref.)

Cervical spine tumors. **Sevick RJ. Neuroimaging Clin N Am** 1995 Aug;5(3):385–400 (66 ref.)

Symptomatic spinal hemangiomas in association with cutaneous hemangiomas. A case report. **Asumu TO, et al. Spine** 1996 May 1;21(9):1082–4 (7 ref.)

[Vertebral osteosarcoma. Review of the literature apropos of a case] **Peyrade F, et al. Bull Cancer (Paris)** 1995 Jul; 82(7):551–6 (31 ref.) (Eng. Abstr.) **(Fre)**

[Spinal chloroma as the initial manifestation of the transformation of essential thrombocythemia into acute myeloid leukemia] **Stroszczynski C, et al. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Mar;164(3):261–3 (13 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Paget sarcoma of the cervical vertebrae: an autopsy case report and review of the literature. **Matsukuma S, et al. Pathol Int** 1995 Nov;45(11):885–9 (27 ref.)

[Vertebral localizations of Paget disease] **Chrétien J. Ann Radiol (Paris)** 1995;38(4):169–76 (7 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

[Familiar sacrococcygeal teratoma] **Goto T, et al. Nippon Rinsho** 1995 Nov;53(11):2779–85 (14 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Paget sarcoma of the cervical vertebrae: an autopsy case report and review of the literature. **Matsukuma S, et al. Pathol Int** 1995 Nov;45(11):885–9 (27 ref.)

[A rare case of chondroid chordoma of the cervical spine] **Sarrazin JL, et al. J Radiol** 1996 Feb;77(2):141–4 (13 ref.) (Eng. Abstr.) **(Fre)**

RADIOGRAPHY

Pictorial review: Imaging of primary osteosarcoma of the spine. **Green R, et al. Clin Radiol** 1996 May;51(5):325–9 (22 ref.)

RADIOTHERAPY

Radiotherapeutic management of spinal metastases. **Janjan NA. J Pain Symptom Manage** 1996 Jan;11(1):47–56 (31 ref.)

[Radiotherapy of cutaneous cervical–facial carcinomas] **Tordiglione M, et al. Acta Otorhinolaryngol Ital** 1995 Jun; 15(3):168–78; discussion 179 (18 ref.) (Eng. Abstr.) **(Ita)**

SECONDARY

Spinal cord compression: from laboratory to clinic. **Siegal T. Eur J Cancer** 1995 Oct;31A(11):1748–53 (37 ref.)

Radiotherapeutic management of spinal metastases. **Janjan NA. J Pain Symptom Manage** 1996 Jan;11(1):47–56 (31 ref.)

SURGERY

Technique of sacral hernia repair. **Kaplan LJ, et al. Am Surg** 1996 Sep;62(9):762–4 (4 ref.)

Open approaches to posterior mediastinal tumors and the spine. **Thurer RJ, et al. Chest Surg Clin N Am** 1996 Feb; 6(1):117–38 (42 ref.)

Symptomatic cavernous malformations affecting the spine and spinal cord. **Harrison MJ, et al. Neurosurgery** 1995 Aug;37(2):195–204; discussion 204–5 (87 ref.)

Surgical management of malignant tumors of the adult bony spine. **Cahill DW. South Med J** 1996 Jul;89(7):653–65 (73 ref.)

SPINAL NERVE ROOTS

see related
POLYRADICULITIS
RADICULITIS

Management of cervical radiculopathy. **van Gijn J, et al. Eur Neurol** 1995;35(6):309–20 (31 ref.)

A cervical dural arteriovenous fistula in a patient presenting with radiculopathy. Case report. **Kohno M, et al. J Neurosurg** 1996 Jan;84(1):119–23 (26 ref.)

Cervical radiculopathy. **Ruggieri PM. Neuroimaging Clin N Am** 1995 Aug;5(3):349–66 (63 ref.)

Cervical Radiculopathy. **Ahlgren BD, et al. Orthop Clin North Am** 1996 Apr;27(2):253–63 (30 ref.)

[Varicella–zoster–virus myelitis without herpes. An important differential diagnosis of the radicular syndrome] **Jacobs A, et al. Dtsch Med Wochenschr** 1996 Mar 15; 121(11):331–5 (25 ref.) (Eng. Abstr.) **(Ger)**

[Cyclic sciatica and extrauterine endometriosis] **Jelk W, et al. Schweiz Rundsch Med Prax** 1995 Nov 14;84(46):1349–55 (29 ref.) (Eng. Abstr.) **(Ger)**

INJURIES

Neurologic injuries in pelvic ring fractures. **Reilly MC, et**

al. **Clin Orthop** 1996 Aug;(329):28–36 (32 ref.)

PATHOLOGY

MR imaging of spinal nerve roots: techniques, enhancement patterns, and imaging findings. Georgy BA, et al. **AJR Am J Roentgenol** 1996 Jan;166(1):173–9 (36 ref.)

[Two siblings of familial amyotrophic lateral sclerosis with multisystemic degeneration characterized by mild involvement of the middle root zone of the posterior column, Clarke's nuclei and spinocerebellar tract] Yoshida M, et al. **Rinsho Shinkeigaku** 1995 Jun;35(6):589–99 (27 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOPATHOLOGY

Spinal nerve root compression. Garfin SR, et al. **Spine** 1995 Aug 15;20(16):1810–20 (72 ref.)

SURGERY

Spinal cord and nerve root monitoring in spine surgery and related procedures. Herdmann J, et al. **Spine** 1996 Apr 1; 21(7):879–85 (20 ref.)

SPINAL NERVES

Purely epithelioid schwannoma. Two case reports and a review of the literature. Artico M, et al. **Neurochirurgie** 1996;42(1):61–5 (20 ref.)

SURGERY

Characteristics of patients successfully treated for cervicogenic headache by surgical decompression of the second cervical root. Pikus HJ, et al. **Headache** 1995 Nov–Dec;35(10):621–9 (39 ref.)

SPINAL OSTEOPHYTOSIS

DIAGNOSIS

Cervical spondylotic myelopathy. Cates JR, et al. **J Manipulative Physiol Ther** 1995 Sep;18(7):471–5 (23 ref.)

SURGERY

Anterior decompressive microsurgery and osteosynthesis for the treatment of multi-segmental cervical spondylosis. Pathophysiological considerations, surgical indication, results and complications: a survey. Seifert V. **Acta Neurochir (Wien)** 1995;135(3–4):105–21 (108 ref.)

Controversy in spine care. Is fusion necessary after anterior cervical discectomy? Sonntag VK, et al. **Spine** 1996 May 1;21(9):1111–3 (15 ref.)

SPINAL PUNCTURE

ADVERSE EFFECTS

Propionibacterium acnes vertebral osteomyelitis following lumbar puncture: case report and review [letter] Abolnik IZ, et al. **Clin Infect Dis** 1995 Sep;21(3):694–5 (10 ref.)

[Iatrogenic spinal epidermoid tumors. A late complication of spinal puncture] Reina MA, et al. **Rev Esp Anestesiol Reanim** 1996 Apr;43(4):142–6 (84 ref.) (Eng. Abstr.) **(Spa)**

SPINAL ROOTS see **SPINAL NERVE ROOTS**

SPINAL STENOSIS

Lumbar spinal stenosis: a review. Palumbo MA, et al. **R I Med** 1995 Nov;78(11):321–3 (11 ref.)

COMPLICATIONS

Spinal nerve root compression. Garfin SR, et al. **Spine** 1995 Aug 15;20(16):1810–20 (72 ref.)

Cervical spinal stenosis with cord neurapraxia and transient quadriplegia. Torg JS. **Sports Med** 1995 Dec;20(6):429–34 (10 ref.)

SURGERY

Surgical results of lumbar spinal stenosis. Herno A. **Ann Chir Gynaecol Suppl** 1995;210:1–969 (235 ref.)

SPINDLE APPARATUS, MITOTIC see **MITOTIC SPINDLE APPARATUS**

SPINE

ABNORMALITIES

Scoliosis and spine deformities. Padman R. **Del Med J** 1995 Oct;67(10):528–33 (0 ref.)

[Cerebro-oculofacial dysplasia associated with vertebral changes] Munteanu G, et al. **Oftalmologia** 1995 Oct–Dec; 39(4):316–21 (10 ref.) (Eng. Abstr.) **(Rum)**

ANATOMY & HISTOLOGY

The vertebral column—a phylogenetic failure? A theory explaining the function and vulnerability of the human spine. Putz RL, et al. **Clin Anat** 1996;9(3):205–12 (22 ref.)

PHYSIOLOGY

Mechanical testing of the spine. An appraisal of methodology, results, and conclusions. Adams MA. **Spine** 1995 Oct 1; 20(19):2151–6 (20 ref.)

Biomechanics of fusion and stabilization. Goel VK, et al. **Spine** 1995 Dec 15;20(24 Suppl):85S–99S (141 ref.)

[Landing after jumps—wrong technique promotes spondylolysis] Recknagel S, et al. **Z Orthop Ihre Grenzgeb** 1996 May–Jun;134(3):214–8 (50 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Somatic dysfunction and the phenomenon of visceral disease simulation: a probable explanation for the apparent effectiveness of somatic therapy in patients presumed to be suffering from true visceral disease. Nansel D, et al. **J Manipulative Physiol Ther** 1995 Jul–Aug;18(6):379–97 (351 ref.)

RADIOGRAPHY

What is a vertebral fracture? Ziegler R, et al. **Bone** 1996 Mar;18(3 Suppl):169S–177S (46 ref.)

SURGERY

The use of bone allografts in the spine. Buttermann GR, et al. **Clin Orthop** 1996 Mar;(324):75–85 (53 ref.)

Classics in Spine. Surgery literature revisited. Bessette L, et al. **Spine** 1996 Feb 1;21(3):259–63 (13 ref.)

Spinal cord and nerve root monitoring in spine surgery and related procedures. Herdmann J, et al. **Spine** 1996 Apr 1; 21(7):879–85 (20 ref.)

SPINOCEREBELLAR ATAXIAS see **SPINOCEREBELLAR DEGENERATION**

SPINOCEREBELLAR DEGENERATION

CLASSIFICATION

The relationship of multiple system atrophy to sporadic olivopontocerebellar atrophy and other forms of idiopathic late-onset cerebellar atrophy. Gilman S, et al. **Neurology** 1996 May;46(5):1197–9 (40 ref.)

[Classification and diagnosis of degenerative ataxias] Klockgether T, et al. **Nervenarzt** 1995 Aug;66(8):571–81 (59 ref.) (Eng. Abstr.) **(Ger)**

DIAGNOSIS

[Informed consent to the patient with hereditary ataxia] Takayanagi T, et al. **No To Shinkei** 1996 May;48(5):437–42 (16 ref.) **(Jpn)**

[Behr's syndrome. A report of 2 siblings studied by MR] Pascual-Castroviejo I, et al. **An Esp Pediatr** 1996 Jun; 44(6):593–5 (11 ref.) **(Spa)**

ETIOLOGY

[Trace elements in spinocerebellar degeneration] Nakashima K. **Nippon Rinsho** 1996 Jan;54(1):129–33 (21 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Inherited ataxias. Harding AE. **Curr Opin Neurol** 1995 Aug; 8(4):306–9 (27 ref.)

Clinical aspects of hereditary ataxias. Subramony SH. **J Child Neurol** 1995 Sep;10(5):353–62 (108 ref.)

Analysis of the CAG repeat and gene product in spinocerebellar ataxia type 1. Zoghbi HY. **Proc Assoc Am Physicians** 1995 Jul;107(2):231–6 (21 ref.)

[Molecular genetics of hereditary spinocerebellar ataxia] Tsuji S. **No To Shinkei** 1995 Oct;47(10):955–61 (32 ref.) **(Jpn)**

PATHOLOGY

[Two siblings of familial amyotrophic lateral sclerosis with multisystemic degeneration characterized by mild involvement of the middle root zone of the posterior column, Clarke's nuclei and spinocerebellar tract] Yoshida M, et al. **Rinsho Shinkeigaku** 1995 Jun;35(6):589–99 (27 ref.) (Eng. Abstr.) **(Jpn)**

SPIRITUAL HEALING see **MENTAL HEALING**

SPIRO COMPOUNDS

PHARMACOLOGY

Modulation of pulsatile GH release through a novel receptor in hypothalamus and pituitary gland. Smith RG, et al. **Recent Prog Horm Res** 1996;51:261–85; discussion 285–6 (59 ref.)

SPIROCERCA see **THELAZIOIDEA**

SPIROCHAETALES

PATHOGENICITY

Swine dysentery: more unknown than known. ter Huurne AA, et al. **Vet Microbiol** 1995 Oct;46(4):347–60 (96 ref.)

SPIROCHAETALES INFECTIONS

PATHOLOGY

Human intestinal spirochetosis [editorial] De Brito T, et al. **Rev Soc Bras Med Trop** 1996 Jul–Aug;29(4):313–7 (25 ref.) **(Eng, Por)**

SPIROCHETE INFECTIONS see **SPIROCHAETALES INFECTIONS**

SPIROMETRY

[Diagnosis of bronchial asthma and chronic obstructive lung disease by the family physician. Ad hoc consensus group 'Diagnosis of asthma/chronic obstructive lung disease by the family physician' (see comments)] van Schayck CP. **Ned Tijdschr Geneeskd** 1995 Sep 30;139(39):1966–71 (22 ref.) Comment in: Ned Tijdschr Geneeskd 1995 Dec 2;139(48):2512–3. **(Dut)**

[Valuable methods for lung function measurements. Spirometry at ambulatory centers is excellent for early diagnosis] Larsson M. **Lakartidningen** 1995 Nov 22; 92(47):4427–30, 4435–7 (27 ref.) **(Swe)**

SPIRURIDA INFECTIONS

VETERINARY

Spirocerca lupi infection in the dog: aberrant migration. Harrus S, et al. **J Am Anim Hosp Assoc** 1996 Mar–Apr; 32(2):125–30 (29 ref.)

SPLANCHNIC CIRCULATION

The gastric tonometer. A valuable monitor of splanchnic perfusion? Trinder TJ, et al. **Anaesthesia** 1996 Feb; 51(2):161–70 (142 ref.)

Mesenteric ischaemia: a multidisciplinary approach. Bradbury AW, et al. **Br J Surg** 1995 Nov;82(11):1446–59 (224 ref.)

Preservation of the pelvic circulation during infrarenal aortic surgery. Connolly JE, et al. **Cardiovasc Surg** 1996 Feb; 4(1):65–70 (46 ref.)

DRUG EFFECTS

Effects of catecholamines on regional perfusion and oxygenation in critically ill patients. Meier-Hellmann A, et al. **Acta Anaesthesiol Scand Suppl** 1995;107:239–48 (106 ref.)

[Effects of sevoflurane on the area of the liver and spleen] Schindler E, et al. **Anaesthesist** 1996 Feb;45 Suppl 1:S29–31 (30 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Splanchnic ischemia and gut mucosal injury in sepsis and the multiple organ dysfunction syndrome. Pastores SM, et al. **Am J Gastroenterol** 1996 Sep;91(9):1697–710 (145 ref.)

Splanchnic ischaemia/reperfusion and multiple organ failure. Biffl WL, et al. **Br J Anaesth** 1996 Jul;77(1):59–70 (136 ref.)

Determinants of splanchnic blood flow. Takala J. **Br J Anaesth** 1996 Jul;77(1):50–8 (78 ref.)

SPLEEN

see related
SPLENECTOMY

[A case of intrapancreatic accessory spleen with epidermoid cyst] Kanemaki N, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Aug;92(8):1212–6 (12 ref.) **(Jpn)**

ABNORMALITIES

The pathogenesis of cryptorchidism and splenogonadal fusion: a new hypothesis. Cortes D, et al. **Br J Urol** 1996 Feb;77(2):285–90 (24 ref.)

Acute abdomen from pedicle torsion ectopic pelvic spleen. A case report and review of the literature. Pizzo A, et al. **Clin Exp Obstet Gynecol** 1996;23(1):37–8 (5 ref.)

Wandering spleen with torsion in a geriatric patient. Report of an unusual case with a brief review of the clinical picture and management. McFee RB, et al. **Dig Dis Sci** 1995 Dec; 40(12):2656–9 (13 ref.)

Traumatic rupture of a wandering spleen in a child: case report and literature review. Horwitz JR, et al. **J Trauma** 1996 Aug;41(2):348–50 (21 ref.)

Splenogonadal fusion. Balaji KC, et al. **J Urol** 1996 Aug;156(2 Pt 2):854–6 (20 ref.)

Splenogonadal fusion: report of 2 cases and review of the literature. Karaman MI, et al. **J Urol** 1996 Jan; 155(1):309–11 (20 ref.)

[Acute torsion of an accessory spleen] Chateil JF, et al. **J Radiol** 1996 Mar;77(3):209–11 (7 ref.) (Eng. Abstr.) **(Fre)**

[Polysplenia syndrome in adults. Report of an atypical case] Catalano O, et al. **Radiol Med (Torino)** 1995 Dec; 90(6):837–9 (20 ref.) **(Ita)**

SPLEEN

BLOOD SUPPLY

[Portal hypertension and splenic circulation] Romero Torres R. **Rev Gastroenterol Peru** 1995;15 Suppl 1:S110–7 (31 ref.) (Eng. Abstr.) **(Spa)**

CYTOLOGY

Hematopoietic reserve provided by spleen colony-forming units (CFU-S). Nečas E, et al. **Exp Hematol** 1995 Nov; 23(12):1242–6 (47 ref.)

[Splenic colony forming method] Suzuki K, et al. **Rinsho Byori** 1995 Jul;Suppl 99:136–8 (12 ref.) **(Jpn)**

[Functional morphology of the spleen] Jakubovský J, et al. **Bratisl Lek Listy** 1995 Dec;96(12):637–41 (26 ref.) (Eng. Abstr.) **(Slo)**

IMMUNOLOGY

In situ studies of the germinal center reaction. Kelsoe G. **Adv Immunol** 1995;60:267–88 (128 ref.)

The germinal center reaction. Kelsoe G. **Immunol Today** 1995 Jul;16(7):324–6 (24 ref.)

INJURIES

Management of upper abdominal solid organ injuries. Richardson JD, et al. **AORN J** 1996 May;63(5):907–16 (15 ref.)

Selective nonoperative management of liver and spleen injuries in neurologically impaired adult patients. Archer LP, et al. **Arch Surg** 1996 Mar;131(3):309–15 (57 ref.)

Nonoperative management of a splenic tear in a Jehovah's Witness with hemophilia. Zieg PM, et al. **J Trauma** 1996 Feb;40(2):299–301 (21 ref.)

Splenectomy complicating left nephrectomy [see comments] Cooper CS, et al. **J Urol** 1996 Jan;155(1):30–6 (46 ref.) Comment in: J Urol 1996 Jan;155(1):37.

Splenic Injuries in children after blunt abdominal trauma. Benya EC, et al. **Semin Ultrasound CT MR** 1996 Apr; 17(2):170–6 (31 ref.)

[Nonoperative treatment of blunt splenic injuries in adults] Stein M, et al. **Harefuah** 1996 Apr 1;130(7):495–9 (27 ref.) **(Heb)**

[Splenorrhaphy and partial splenectomy as an alternative to splenectomy in trauma—overview] Radonić V, et al. **Acta Chir Iugosl** 1990;37(2):239–49 (52 ref.) (Eng. Abstr.) **(Scr)**

PATHOLOGY

Clonal expansion of T cells and HIV genotypes in microdissected splenic white pulps indicates viral replication in situ and infiltration of HIV-specific cytotoxic T lymphocytes. Cheynier R, et al. **Adv Exp Med Biol** 1995; 374:173–82 (47 ref.)

[Clinical value of spleen autograft] Vercesi M, et al. **Minerva Chir** 1995 Jul-Aug;50(7–8):687–92 (24 ref.) (Eng. Abstr.) **(Ita)**

PHYSIOLOGY

[Functional morphology of the spleen] Jakubovský J, et al. **Bratisl Lek Listy** 1995 Dec;96(12):637–41 (26 ref.) (Eng. Abstr.) **(Slo)**

[Hemolytic anemia and kidney failure in a female splenectomy patient] Vargas Pabón M, et al. **Rev Clin Esp** 1996 May;196(5):335–6, 339 (10 ref.) **(Spa)**

SURGERY

[Splenorrhaphy and partial splenectomy as an alternative to splenectomy in trauma—overview] Radonić V, et al. **Acta Chir Iugosl** 1990;37(2):239–49 (52 ref.) (Eng. Abstr.) **(Scr)**

TRANSPLANTATION

[Clinical value of spleen autograft] Vercesi M, et al. **Minerva Chir** 1995 Jul-Aug;50(7–8):687–92 (24 ref.) (Eng. Abstr.) **(Ita)**

[Autotransplantation of splenic tissue] Zurnadzh'iants VA, et al. **Khirurgiia (Mosk)** 1996;(1):80–2 (46 ref.) **(Rus)**

VIROLOGY

[Dendritic cells of spleen and blood and HIV-1 infection] Hosmalin A. **Pathol Biol (Paris)** 1995 Dec;43(10):889–96 (54 ref.) (Eng. Abstr.) **(Fre)**

SPLENECTOMY

Splenectomy complicating left nephrectomy [see comments] Cooper CS, et al. **J Urol** 1996 Jan;155(1):30–6 (46 ref.) Comment in: J Urol 1996 Jan;155(1):37.

Postsplenectomy care. Strategies to decrease the risk of infection. Williams DN, et al. **Postgrad Med** 1996 Jul; 100(1):195–8, 201, 205 (15 ref.)

The management of patients with Cooley's anemia: transfusions and splenectomy. Piomelli S. **Semin Hematol** 1995 Oct;32(4):262–8 (43 ref.)

Laparoscopic splenectomy. Rege RV, et al. **Surg Clin North Am** 1996 Jun;76(3):459–68 (21 ref.)

ADVERSE EFFECTS

Guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen. Working Party of the British Committee for Standards in Haematology Clinical Haematology Task Force [see comments] **BMJ** 1996 Feb 17;312(7028):430–4 (53 ref.) Comment in: BMJ 1996 May 25;312(7042):1359–60; discussion 1361. Comment in: BMJ 1996 May 25;312(7042):1360. Comment in: BMJ 1996 May 25;312(7042):1360; discussion 1361. Comment in: BMJ 1996 May 25;312(7042):1360–1. Comment in: BMJ 1996 May 25;312(7042):1361.

Early postsplenectomy arthritis caused by penicillin-resistant Streptococcus pneumoniae. Merle-Melet M, et al. **Eur J Clin Microbiol Infect Dis** 1996 Feb;15(2):159–60 (7 ref.)

METHODS

[Laparoscopic splenectomy: comments on the surgical technic] Contini S, et al. **Acta Biomed Ateneo Parmense** 1995;66(1–2):27–33 (10 ref.) (Eng. Abstr.) **(Ita)**

SPLENIC ARTERY

Rapidly progressive destruction of the hip. Case report and review of the literature. Puylaert D, et al. **Acta Orthop Belg** 1995;61(4):312–4 (5 ref.)

Carotid-cavernous sinus fistula and aneurysmal rupture associated with fibromuscular dysplasia. A case report. Hirai T, et al. **Acta Radiol** 1996 Jan;37(1):49–51 (8 ref.)

[Experiences with the endovascular embolization therapy of aneurysms of the splanchnic arteries—a report on 13 cases] Kramann B, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1995 Nov;163(5):417–23 (35 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

[An autopsy case of segmental mediolytic arteritis (SMA) accompanied with microscopic polyarteritis nodosa] Ito MR, et al. **Ryumachi** 1995 Aug;35(4):693–8 (16 ref.) (Eng. Abstr.) **(Jpn)**

SURGERY

Splenic arteriovenous fistula. Brothers TE, et al. **Int Surg** 1995 Apr-Jun;80(2):189–94 (90 ref.)

SPLENIC DISEASES

see related
SPLENOSIS

DIAGNOSIS

Inflammatory pseudotumor of the spleen: a rare entity that may mimic hematopoietic malignancy. McHenry CR, et al. **Am Surg** 1995 Dec;61(12):1067–71 (23 ref.)

Wandering spleen with torsion in a geriatric patient. Report of an unusual case with a brief review of the clinical picture and management. McFee RB, et al. **Dig Dis Sci** 1995 Dec; 40(12):2656–9 (13 ref.)

Systemic cat scratch disease: hepatic and splenic involvement about 3 pediatric cases. Destuynder O, et al. **Eur J Pediatr Surg** 1995 Dec;5(6):365–8 (43 ref.)

Diagnostic problems in the spleen. Nazeer T, et al. **Pathol Annu** 1995;30 Pt 2:283–329 (188 ref.)

[Splenic sarcoidosis. Review of the literature and description of a case studied with ultrasonography and computed tomography] Galuppo C, et al. **Radiol Med (Torino)** 1996 Jun;91(6):834–5 (4 ref.) **(Ita)**

[The imaging diagnosis of a rare case of inflammatory pseudotumor of the spleen] Meduri S, et al. **Radiol Med (Torino)** 1996 Jan-Feb;91(1–2):143–5 (7 ref.) **(Ita)**

ETIOLOGY

Cryoglobulinemia: recent findings in cutaneous and extracutaneous manifestations. Davis MD, et al. **Int J Dermatol** 1996 Apr;35(4):240–8 (50 ref.)

Peliosis of the spleen: possible association with chronic renal failure and erythropoietin therapy. Lam KY, et al. **Postgrad Med J** 1995 Aug;71(838):493–6 (30 ref.)

PATHOLOGY

Necrobiotic xanthogranuloma with cardiac involvement. Umbert I, et al. **Br J Dermatol** 1995 Sep;133(3):438–43 (37 ref.)

Diagnostic problems in the spleen. Nazeer T, et al. **Pathol Annu** 1995;30 Pt 2:283–329 (188 ref.)

RADIOGRAPHY

[Acute torsion of an accessory spleen] Chateil JF, et al. **J Radiol** 1996 Mar;77(3):209–11 (7 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

[Splenic cyst. Review of the literature and report of 2 cases] de Melo VA, et al. **Rev Hosp Clin Fac Med Sao Paulo** 1995 Sep-Oct;50(5):289–93 (40 ref.) (Eng. Abstr.) **(Por)**

SPLENIC INFARCTION

ETIOLOGY

[A case of pancreatic pseudocyst with splenic infarction] Sugiyama H, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Apr;93(4):293–8 (16 ref.) **(Jpn)**

SPLENIC NEOPLASMS

DIAGNOSIS

[A case study of nonfunctioning islet cell tumor in patient with splenic tumor and increased AFP] Zeki S, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 May;93(5):382–7 (20 ref.) **(Jpn)**

SECONDARY

[Splenic metastases] Tiszlavicz L. **Orv Hetil** 1996 Feb 11; 137(6):295–8 (25 ref.) (Eng. Abstr.) **(Hun)**

[Disseminated Kaposi's sarcoma with hepatosplenic involvement in AIDS] González-López A, et al. **Med Clin (Barc)** 1996 Apr 27;106(16):622–3 (15 ref.) (Eng. Abstr.) **(Spa)**

SPLENIC RUPTURE

Traumatic rupture of a wandering spleen in a child: case report and literature review. Horwitz JR, et al. **J Trauma** 1996 Aug;41(2):348–50 (21 ref.)

COMPLICATIONS

Splenosis in exit gunshot wound [letter] Burvin R, et al. **Br J Dermatol** 1996 Jul;135(1):148–50 (12 ref.)

DIAGNOSIS

Rupture of the spleen as the initial manifestation of Wilson's disease. Ahmed A, et al. **Am J Gastroenterol** 1996 Jul; 91(7):1454–5 (11 ref.)

MORTALITY

Spontaneous rupture of the spleen. A fatal complication of pregnancy. McCormick GM 2nd, et al. **Am J Forensic Med Pathol** 1995 Jun;16(2):132–4 (15 ref.)

SPLENIC VEIN

Case report: bleeding gastric varices secondary to splenic vein thrombosis successfully treated by splenic artery embolization. McDermott VG, et al. **Br J Radiol** 1995 Aug; 68(812):928–30 (14 ref.)

ABNORMALITIES

Large spleno-caval shunt not accompanied by cirrhosis or encephalopathy. Mitsui H, et al. **J Gastroenterol** 1996 Apr; 31(2):278–83 (33 ref.)

SURGERY

Splenic arteriovenous fistula. Brothers TE, et al. **Int Surg** 1995 Apr-Jun;80(2):189–94 (90 ref.)

SPLENOMEGALY

ETIOLOGY

IGHG3 G and the pathogenesis of hyperreactive malarious splenomegaly. Kelly KM. **Med Hypotheses** 1996 Feb; 46(2):135–9 (48 ref.)

[A case of primary biliary cirrhosis presenting histopathological similarity to idiopathic portal hypertension with huge splenomegaly] Kasuga Y, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Oct;92(10):1776–81 (18 ref.) **(Jpn)**

[Splenomegalic liver cirrhosis] Itakura M, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):171–4 (15 ref.) **(Jpn)**

SPLENOPORTOGRAPHY see **PORTOGRAPHY**

SPLENOSIS

ETIOLOGY

Splenosis in exit gunshot wound [letter] Burvin R, et al. **Br J Dermatol** 1996 Jul;135(1):148–50 (12 ref.)

SPLICED LEADER PEPTIDES see **SIGNAL PEPTIDES**

SPLICEOSOMES

see related
RNA SPLICING

SPLICING, ALTERNATIVE see **ALTERNATIVE SPLICING**

SPLICING, RNA see **RNA SPLICING**

SPLINTS

see related
STENTS

Silicone rubber splinting for athletic hand and wrist injuries. Canelón MF. **J Hand Ther** 1995 Oct-Dec;8(4):252-7 (43 ref.)

Splints: mechanics versus convention [see comments] Fess EE. **J Hand Ther** 1995 Apr-Jun;8(2):124-30 (25 ref.) Comment in: J Hand Ther 1996 Jan-Mar;9(1):67-8.

Objective and subjective observations of low-temperature thermoplastic materials. Lee DB. **J Hand Ther** 1995 Apr-Jun;8(2):138-43 (7 ref.)

SPLIT GENES see **GENES**

SPONDYLARTHRITIS ANKYLOPOIETICA see **SPONDYLITIS, ANKYLOSING**

SPONDYLITIS

DIAGNOSIS

Inflammatory and infectious processes of the cervical spine. Ruiz A, et al. **Neuroimaging Clin N Am** 1995 Aug; 5(3):401-25 (80 ref.)

Neonatal group B streptococcal vertebral osteomyelitis. Barton LL, et al. **Pediatrics** 1996 Sep;98(3 Pt 1):459-61 (9 ref.)

[Radiologic diagnosis of infectious spondylitis] Wikström M, et al. **Rontgenpraxis** 1996 Apr;49(4):79-84 (30 ref.) **(Ger)**

DRUG THERAPY

[Use of methotrexate in spondylarthropathies. Review of the literature] Toussirot E, et al. **Rev Med Interne** 1996; 17(4):333-9 (40 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Propionibacterium acnes vertebral osteomyelitis following lumbar puncture: case report and review [letter] Abolnik IZ, et al. **Clin Infect Dis** 1995 Sep;21(3):694-5 (10 ref.)

[Significance of intestinal inflammation in the pathogenesis of spondylarthropathies] Mielants H, et al. **Verh K Acad Geneeskd Belg** 1996;58(2):93-116 (70 ref.) (Eng. Abstr.) **(Dut)**

IMMUNOLOGY

Role of HLA-B27 in spondyloarthropathies. Khare SD, et al. **Curr Top Microbiol Immunol** 1996;206:85-100 (77 ref.)

PHYSIOPATHOLOGY

[Prognostic factors in early inflammatory arthritis] Combe B. **Rev Med Interne** 1996;17(3):224-30 (67 ref.) (Eng. Abstr.) **(Fre)**

SPONDYLITIS, ANKYLOSING

Spondyloarthropathies of childhood. Cabral DA, et al. **Pediatr Clin North Am** 1995 Oct;42(5):1051-70 (73 ref.)

COMPLICATIONS

Posttraumatic spinal osteolysis in ankylosing spondylitis as part of pseudoarthrosis. A case report. Albertsen AM, et al. **Acta Radiol** 1996 Jan;37(1):98-100 (10 ref.)

Coexisting rheumatoid arthritis and ankylosing spondylitis discussion of 3 cases with review of the literature. Toussirot E, et al. **Clin Rheumatol** 1995 Sep;14(5):554-60 (27 ref.)

Systemic amyloidosis following ankylosing spondylitis associated with congestive heart failure. A case report. Fujito T, et al. **Jpn Heart J** 1995 Sep;36(5):681-8 (17 ref.)

Odontoid fracture and C1-C2 subluxation in psoriatic cervical spondyloarthropathy. A case report. Sosner J, et al. **Spine** 1996 Feb 15;21(4):519-21 (6 ref.)

[Osteoporosis in ankylosing spondylitis] Toussirot E, et al. **Presse Med** 1996 Apr 27;25(15):720-4 (32 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Paleopathology, its character and contribution to understanding and distinguishing among rheumatologic diseases: perspectives on rheumatoid arthritis and spondyloarthropathy. Rothschild BM. **Clin Exp Rheumatol** 1995 Sep-Oct;13(5):657-62 (31 ref.)

HLA-B27 and spondyloarthropathy: value for early diagnosis? Gran JT, et al. **J Med Genet** 1995 Jul; 32(7):497-501 (23 ref.)

Evaluation of destructive spondyloarthropathies in hemodialysis by computerized tomographic scan and magnetic resonance imaging. Flipo RM, et al. **J Rheumatol** 1996 May;23(5):869-73 (28 ref.)

Seronegative spondyloarthropathies. El-Khoury GY, et al. **Radiol Clin North Am** 1996 Mar;34(2):343-57, xi (56 ref.)

Juvenile spondyloarthropathies: clinical manifestations and medical imaging. Azouz EM, et al. **Skeletal Radiol** 1995 Aug;24(6):399-408 (64 ref.)

DRUG THERAPY

Epidemiologic, clinical, and therapeutic aspects of reactive arthritis and ankylosing spondylitis. Toivanen A, et al. **Curr Opin Rheumatol** 1995 Jul;7(4):279-83 (53 ref.)

[Use of methotrexate in spondylarthropathies. Review of the literature] Toussirot E, et al. **Rev Med Interne** 1996; 17(4):333-9 (40 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

The pathogenetic role of HLA-B27. Feltkamp TE, et al. **Immunol Today** 1996 Jan;17(1):5-7 (4 ref.)

IMMUNOLOGY

Etiopathogenesis of reactive arthritis and ankylosing spondylitis. Careless DJ, et al. **Curr Opin Rheumatol** 1995 Jul;7(4):290-8 (70 ref.)

Epidemiologic, clinical, and therapeutic aspects of reactive arthritis and ankylosing spondylitis. Toivanen A, et al. **Curr Opin Rheumatol** 1995 Jul;7(4):279-83 (53 ref.)

SPONDYLODISCITIS see **DISCITIS**

SPONDYLOEPIPHYSEAL DYSPLASIA see **OSTEOCHONDRODYSPLASIAS**

SPONDYLOLISTHESIS

DIAGNOSIS

Imaging of spondylolysis and spondylolisthesis. Hession PR, et al. **Eur Radiol** 1996;6(3):284-90 (22 ref.)

SURGERY

[Long-term results of the surgical treatment of spondylolisthesis using Schöllner's sacral plate] Halm H, et al. **Z Orthop Ihre Grenzgeb** 1996 May-Jun;134(3):219-25 (35 ref.) (Eng. Abstr.) **(Ger)**

SPONDYLOLYSIS

DIAGNOSIS

Imaging of spondylolysis and spondylolisthesis. Hession PR, et al. **Eur Radiol** 1996;6(3):284-90 (22 ref.)

PHYSIOPATHOLOGY

[Landing after jumps--wrong technique promotes spondylolysis] Recknagel S, et al. **Z Orthop Ihre Grenzgeb** 1996 May-Jun;134(3):214-8 (50 ref.) (Eng. Abstr.) **(Ger)**

RADIOGRAPHY

Cervical spondylolysis: three levels of simultaneous involvement. Yochum TR, et al. **J Manipulative Physiol Ther** 1995 Jul-Aug;18(6):411-5 (10 ref.)

SPONDYLOSIS see **SPINAL OSTEOPHYTOSIS**

SPONDYLOSIS DEFORMANS see **SPINAL OSTEOPHYTOSIS**

SPONGIFORM ENCEPHALOPATHIES, TRANSMISSIBLE see **PRION DISEASES**

SPONGIFORM ENCEPHALOPATHY, BOVINE see **ENCEPHALOPATHY, BOVINE SPONGIFORM**

SPONGURIDINE see **ARABINOFURANOSYLURACIL**

SPONGY DISEASE OF WHITE MATTER see **CANAVAN DISEASE**

SPORES, BACTERIAL

Chemotherapeutic tumour targeting using clostridial spores. Minton NP, et al. **FEMS Microbiol Rev** 1995 Oct; 17(3):357-64 (40 ref.)

PHYSIOLOGY

Mechanisms for the prevention of damage to DNA in spores of Bacillus species. Setlow P. **Annu Rev Microbiol** 1995; 49:29-54 (91 ref.)

SPOROTHRIX see **SPOROTRICHUM**

SPOROTRICHOSIS

A contemporary view of sporotrichosis. Winn RE. **Curr Top Med Mycol** 1995;6:73-94 (135 ref.)

DRUG THERAPY

Old and new therapies for sporotrichosis. Kauffman CA. **Clin Infect Dis** 1995 Oct;21(4):981-5 (63 ref.)

SPOROTRICHUM

A contemporary view of sporotrichosis. Winn RE. **Curr Top Med Mycol** 1995;6:73-94 (135 ref.)

SPORTS

see related
ATHLETIC INJURIES
DOPING IN SPORTS

Exercised-induced hematuria. Gambrell RC, et al. **Am Fam Physician** 1996 Feb 15;53(3):905-11 (28 ref.)

Triggers for sudden cardiac death in the athlete. Maron BJ. **Cardiol Clin** 1996 May;14(2):195-210 (97 ref.)

Sports and hemophilia: antagonist or protagonist. Buzzard BM. **Clin Orthop** 1996 Jul;(328):25-30 (29 ref.)

The young athlete with chronic disease. Small E, et al. **Clin Sports Med** 1995 Jul;14(3):709-26 (144 ref.)

Evaluation and recommendations for participation in athletics for children with heart disease. Kaminer SJ, et al. **Curr Opin Pediatr** 1995 Oct;7(5):595-600 (15 ref.)

Athletes and arrhythmias: clinical considerations and perspectives. Josephson ME, et al. **Eur Heart J** 1996 Apr; 17(4):498-505 (47 ref.)

Indicators of vitamin and mineral status in athletes' blood: a review. Fogelholm M. **Int J Sport Nutr** 1995 Dec; 5(4):267-84 (91 ref.)

Do athletes need more dietary protein and amino acids? Lemon PW. **Int J Sport Nutr** 1995 Jun;5 Suppl:S39-61 (91 ref.)

Dietary carbohydrate as an ergogenic aid for prolonged and brief competitions in sport. Walberg-Rankin J. **Int J Sport Nutr** 1995 Jun;5 Suppl:S13-28 (67 ref.)

Dermatological problems in the athlete. Eiland G, et al. **J Orthop Sports Phys Ther** 1996 Jun;23(6):388-402 (32 ref.)

Structural and non-structural disease underlying high-risk cardiac arrhythmias relevant to sports medicine. Rossi L. **J Sports Med Phys Fitness** 1995 Jun;35(2):79-86 (29 ref.)

The use of artificial intelligence in the analysis of sports performance: a review of applications in human gait analysis and future directions for sports biomechanics. Lapham AC, et al. **J Sports Sci** 1995 Jun;13(3):229-37 (38 ref.)

Relationship of muscular strength to jaw posture in sports dentistry. Gelb H, et al. **N Y State Dent J** 1995 Nov; 61(9):58-66 (0 ref.)

The preparticipation sports physical: are we dropping the ball? Cavanaugh RM Jr, et al. **Pediatrics** 1995 Dec; 96(6):1151-3 (25 ref.)

Arrhythmias induced by exercise in athletes and others. McGovern BA, et al. **S Afr Med J** 1996 Apr;86 Suppl 2:C78-82 (22 ref.)

Infectious and lymphocytic myocarditis: epidemiology and factors relevant to sports medicine. Friman G, et al. **Scand J Med Sci Sports** 1995 Oct;5(5):269-78 (97 ref.)

Sudden death and physical activity in athletes and nonathletes. Jensen-Urstad M. **Scand J Med Sci Sports** 1995 Oct;5(5):279-84 (46 ref.)

Gastrointestinal symptoms during exercise. The effect of fluid supplementation. Peters HP, et al. **Sports Med** 1995 Aug; 20(2):65-76 (76 ref.)

Gastro-oesophageal reflux and exercise. Important pathology to consider in the athletic population. Shawdon A. **Sports Med** 1995 Aug;20(2):109-16 (32 ref.)

[Cardiovascular evaluation in athletic children] Sluysmans T, et al. **Arch Pediatr** 1995 Nov;2(11):1101-15 (106 ref.) (Eng. Abstr.) **(Fre)**

[Dermatoses and winter sports] Letawe C, et al. **Rev Med Liege** 1995 Nov;50(11):477-9 (12 ref.) **(Fre)**

[Sports as a preventive and rehabilitational measure for the elderly] Dorner H. **Fortschr Med** 1996 May 30; 114(15):183-6 (25 ref.) (Eng. Abstr.) **(Ger)**

[Gynecologic problems in female athletes] Broso R, et al. **Minerva Ginecol** 1996 Mar;48(3):99-106 (33 ref.) (Eng. Abstr.) **(Ita)**

[A giant unifocal biliary cystadenoma: a chance finding in a young asymptomatic athlete] Busoni F, et al. **Radiol Med (Torino)** 1996 Apr;91(4):480-2 (12 ref.) **(Ita)**

[Iron: perspective on the athletic woman] Castillo MC, et al. **Sangre (Barc)** 1995 Jun;40(3):199-205 (82 ref.) **(Spa)**

PHYSIOLOGY

Exercise and bone mass in young and premenopausal women. Snow CM. **Bone** 1996 Jan;18(1 Suppl):51S-55S (30 ref.)

The athlete's heart: is big beautiful? Shephard RJ. **Br J Sports Med** 1996 Mar;30(1):5-10 (75 ref.)

Shoulder instability in athletes. The Asian perspective. Chan KM, et al. **Clin Orthop** 1996 Feb;(323):106-12 (47 ref.)

Physiology of growth and development. Its relationship to performance in the young athlete. Roemmich JN, et al. **Clin Sports Med** 1995 Jul;14(3):483-502 (79 ref.)

Integration of the physiological factors determining endurance performance ability. Coyle EF. **Exerc Sport Sci Rev** 1995;23:25-63 (67 ref.)

Factors associated with menstrual irregularities and decreased bone mineral density in female athletes. Fruth SJ, et al. **J Orthop Sports Phys Ther** 1995 Jul;22(1):26-38 (54 ref.)

Optimal physical performance in athletes: key roles of dopamine in a specific neurotransmitter/hormonal mechanism. Gilbert C. **Mech Ageing Dev** 1995 Oct 13; 84(2):83-102 (85 ref.)

Circadian variation in sports performance. Atkinson G, et al. **Sports Med** 1996 Apr;21(4):292-312 (122 ref.)

Monitoring overtraining in athletes. Recommendations. Hooper SL, et al. **Sports Med** 1995 Nov;20(5):321-7 (42 ref.)

SPORTS

Applied physiology of water-skiing. Leggett SH, et al. **Sports Med** 1996 Apr;21(4):262–76 (30 ref.)
Blood hormones as markers of training stress and overtraining. Urhausen A, et al. **Sports Med** 1995 Oct; 20(4):251–76 (233 ref.)
[Sports and nutrition] Mannhart C. **Schweiz Rundsch Med Prax** 1995 Sep 5;84(36):963–9 (45 ref.) (Eng. Abstr.) **(Ger)**
[Sports and rehabilitation in old age] Niederhauser HU. **Schweiz Rundsch Med Prax** 1995 Oct 31;84(44):1259–64 (30 ref.) (Eng. Abstr.) **(Ger)**
[Patients with lung diseases and sports] Villiger B. **Schweiz Rundsch Med Prax** 1995 Sep 5;84(36):953–62 (38 ref.) (Eng. Abstr.) **(Ger)**
[Landing after jumps—wrong technique promotes spondylolysis] Recknagel S, et al. **Z Orthop Ihre Grenzgeb** 1996 May–Jun;134(3):214–8 (50 ref.) (Eng. Abstr.) **(Ger)**

PSYCHOLOGY

More than just a game: research developments and issues in competitive anxiety in sport. Jones G. **Br J Psychol** 1995 Nov;86 (Pt 4):449–78 (190 ref.)
Cognitive behavioral strategies in athletic performance enhancement. Meyers AW, et al. **Prog Behav Modif** 1996; 30:137–64 (140 ref.)
Intrapersonal and interpersonal factors in athletic performance. Iso-Ahola SE. **Scand J Med Sci Sports** 1995 Aug;5(4):191–9 (20 ref.)

SPORTS MEDICINE

see related
ATHLETIC INJURIES
PROTECTIVE DEVICES

[Ski racing and asthma (editorial)] Laitinen L. **Duodecim** 1994;110(19):1754–6 (21 ref.) **(Fin)**

ORGANIZATION & ADMINISTRATION

Organizational and psychological consultation in collegiate sports medicine groups. Anderson MB, et al. **J Am Coll Health** 1995 Sep;44(2):63–9 (18 ref.)

SPOUSE ABUSE

Spousal abuse and violence against women: the significance of understanding attachment. Vazquez CI. **Ann N Y Acad Sci** 1996 Jun 18;789:119–28 (26 ref.)
[Violence towards pregnant women] Rasmussen KL, et al. **Ugeskr Laeger** 1996 Apr 22;158(17):2373–6 (35 ref.) (Eng. Abstr.) **(Dan)**

DIAGNOSIS

Domestic violence: a hidden problem for general practice. Richardson J, et al. **Br J Gen Pract** 1996 Apr; 46(405):239–42 (43 ref.)

LEGISLATION & JURISPRUDENCE

Stalking as a variant of domestic violence. Kurt JL. **Bull Am Acad Psychiatry Law** 1995;23(2):219–30 (26 ref.)

PREVENTION & CONTROL

The primary health care provider's role in sexual assault prevention. Holmes MM. **Womens Health Issues** 1995 Winter;5(4):224–32 (42 ref.)

PSYCHOLOGY

Constructing the symbolic complainant: police subculture and the nonenforcement of protection orders for battered women. Rigakos GS. **Violence Vict** 1995 Fall;10(3):227–47 (50 ref.)

STATISTICS & NUMERICAL DATA

Prevalence of domestic violence in the United States. Wilt S, et al. **J Am Med Womens Assoc** 1996 May–Jul; 51(3):77–82 (44 ref.)
Prevalence of violence against pregnant women. Gazmararian JA, et al. **JAMA** 1996 Jun 26;275(24):1915–20 (38 ref.)

SPOUSE CAREGIVERS see **CAREGIVERS**

SPOUSES

The parents of a severely dependent child. Keeley D, et al. **Practitioner** 1995 Sep;239(1554):505–8, 510, 512 (0 ref.)

PSYCHOLOGY

Impact of aborted sudden cardiac death on survivors and their spouses: the phenomenon of different reference points. Doolittle ND, et al. **Am J Crit Care** 1995 Sep;4(5):389–96 (24 ref.)
The couple and the psychotherapeutic group. Kretsch RA, et al. **Isr J Psychiatry Relat Sci** 1995;32(3):184–93 (18 ref.)
Psychological intervention with couples after mastectomy. Baider L. **Support Care Cancer** 1995 Jul;3(4):239–43 (43 ref.)

SPRAINS AND STRAINS

DIAGNOSIS

Current concepts in the diagnosis and treatment of ankle sprains. Kuwada GT. **Clin Podiatr Med Surg** 1995 Oct; 12(4):653–65 (39 ref.)
Evaluation and treatment of ankle sprains. Anderson SJ. **Compr Ther** 1996 Jan;22(1):30–8 (52 ref.)
[Ankle sprain—a harmless injury? (editorial)] Hintermann B. **Schweiz Rundsch Med Prax** 1996 Mar 26;85(13):396–8 (17 ref.) **(Ger)**

DRUG THERAPY

Topical nonsteroidal antiinflammatory drugs for acute soft tissue injuries. Heyneman CA. **Ann Pharmacother** 1995 Jul–Aug;29(7–8):780–2 (14 ref.)

RADIOGRAPHY

[Views necessary for the traumatic wrist] Zeitoun F, et al. **Ann Radiol (Paris)** 1995;38(5):255–65 (25 ref.) (Eng. Abstr.) **(Fre)**

SPRUE see **CELIAC DISEASE**

SPUMAVIRINAE see **SPUMAVIRUS**

SPUMAVIRUS

GENETICS

Regulation of expression and pathogenic potential of human foamy virus in vitro and in transgenic mice. Aguzzi A, et al. **Curr Top Microbiol Immunol** 1996;206:243–73 (123 ref.)

PATHOGENICITY

Regulation of expression and pathogenic potential of human foamy virus in vitro and in transgenic mice. Aguzzi A, et al. **Curr Top Microbiol Immunol** 1996;206:243–73 (123 ref.)

SPUTUM

CHEMISTRY

[Concentration of cephems in sputum from patients with pulmonary infection: relationship between MICs of pathogenic bacteria, levels of antibiotic and efficacy] Rikitomi N. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:1020–3 (10 ref.) **(Jpn)**

SECRETION

A case of pancreatic carcinoma causing massive bronchial fluid production and electrolyte abnormalities. Lembo T, et al. **Chest** 1995 Oct;108(4):1161–3 (8 ref.)

SQUALENE

CHEMICAL SYNTHESIS

MF59. Design and evaluation of a safe and potent adjuvant for human vaccines. Ott G, et al. **Pharm Biotechnol** 1995; 6:277–96 (36 ref.)

SQUALENE SYNTHETASE

ANTAGONISTS & INHIBITORS

Discovery, biosynthesis, and mechanism of action of the zaragozic acids: potent inhibitors of squalene synthase. Bergstrom JD, et al. **Annu Rev Microbiol** 1995;49:607–39 (80 ref.)
Squalene synthase inhibitors: their potential as hypocholesterolaemic agents. Watson NS, et al. **Prog Med Chem** 1996;33:331–78 (83 ref.)

SQUINT see **STRABISMUS**

SRC-FAMILY KINASES

The Src and Csk families of tyrosine protein kinases in hemopoietic cells. Chow LM, et al. **Semin Immunol** 1995 Aug;7(4):207–26 (222 ref.)
[Src family of protein-tyrosine kinases and their regulator tyrosine kinase, Csk] Okada M. **Seikagaku** 1996 Apr; 68(4):251–64 (94 ref.) **(Jpn)**

CHEMISTRY

Regulation, substrates and functions of src. Brown MT, et al. **Biochim Biophys Acta** 1996 Jun 7;1287(2–3):121–49 (393 ref.)

METABOLISM

The kinase-dependent function of Lck in T-cell activation requires an intact site for tyrosine autophosphorylation. Xu H, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:99–116 (46 ref.)
Regulation, substrates and functions of src. Brown MT, et al. **Biochim Biophys Acta** 1996 Jun 7;1287(2–3):121–49 (393 ref.)
Signal transduction by the lymphocyte-specific tyrosine protein kinase p56lck. Weil R, et al. **Curr Top Microbiol Immunol** 1996;205:63–87 (141 ref.)

PHYSIOLOGY

Knockouts of Src-family kinases: stiff bones, wimpy T cells, and bad memories. Lowell CA, et al. **Genes Dev** 1996 Aug 1;10(15):1845–57 (111 ref.)

SRC GENES see **GENES, SRC**

SRC HOMOLOGY DOMAINS

Regulation, substrates and functions of src. Brown MT, et al. **Biochim Biophys Acta** 1996 Jun 7;1287(2–3):121–49 (393 ref.)
SH2 domains: a question of independence. Wandless TJ. **Curr Biol** 1996 Feb 1;6(2):125–7 (13 ref.)
Why two heads are better. Mayer BJ. **Structure** 1995 Oct 15;3(10):977–80 (27 ref.)

DRUG EFFECTS

SH2 domain protein interaction and possibilities for pharmacological intervention. Beattie J. **Cell Signal** 1996 Feb;8(2):75–86 (87 ref.)

PHYSIOLOGY

The PI/PTB domain: a new protein interaction domain involved in growth factor receptor signaling. Margolis B. **J Lab Clin Med** 1996 Sep;128(3):235–41 (66 ref.)
SH2 and SH3 domains: potential targets for anti-cancer drug design. Smithgall TE. **J Pharmacol Toxicol Methods** 1995 Nov;34(3):125–32 (52 ref.)

SRC PROTO-ONCOGENE PROTEIN PP60 see **PROTO-ONCOGENE PROTEIN PP60(C-SRC)**

SRS-A RECEPTORS see **RECEPTORS, LEUKOTRIENE**

SSCP see **POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL**

SSEA-1 see **ANTIGENS, CD15**

SSEA-1 DETERMINANT see **ANTIGENS, CD15**

SSPE see **SUBACUTE SCLEROSING PANENCEPHALITIS**

STA-MCA BYPASS see **CEREBRAL REVASCULARIZATION**

STABILIZING AGENTS see **EXCIPIENTS**

STABLE FACTOR see **FACTOR VII**

STAFF WORKLOAD see **WORKLOAD**

STAGE-SPECIFIC EMBRYONIC ANTIGEN-1 see **ANTIGENS, CD15**

STAGGERER MICE see **MICE, NEUROLOGIC MUTANTS**

STAGING, NEOPLASM see **NEOPLASM STAGING**

STAINING

see related
DYES

STAINS see **DYES**

STAMMERING see **STUTTERING**

STANDARD PREPARATIONS see **REFERENCE STANDARDS**

STANDARDS, REFERENCE see **REFERENCE STANDARDS**

STANOLONE

BLOOD

[Clinical application of dihydrotestosterone (DHT) determination] Isurugi K. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:588–92 (15 ref.) **(Jpn)**

METABOLISM

Role of dihydrotestosterone in androgen action. Wilson JD. **Prostate Suppl** 1996;6:88–92 (32 ref.)

STAPEDECTOMY see **STAPES SURGERY**

STAPES SURGERY

METHODS

Long-term hearing results following stapedotomy.

Dornhoffer JL, et al. **Am J Otol** 1994 Sep;15(5):674–8 (14 ref.)

STAPHYLOCOCCAL INFECTIONS

see related
CROSS INFECTION

Remediable recurrent meningitis. Rajeshwari K, et al. **Indian Pediatr** 1995 Apr;32(4):491–6 (28 ref.)

The significance of nasal carriage of Staphylococcus aureus and the incidence of postoperative wound infection. Wenzel RP, et al. **J Hosp Infect** 1995 Sep;31(1):13–24 (52 ref.)

Toxic shock syndrome: an opportunity for nursing intervention [see comments] Creehan PA. **J Obstet Gynecol Neonatal Nurs** 1995 Jul–Aug;24(6):557–61 (14 ref.) Comment in: J Obstet Gynecol Neonatal Nurs 1996 Feb;25(2):119.

Necrotizing fasciitis originating from pinna perichondritis. Skorina J, et al. **Otolaryngol Head Neck Surg** 1995 Oct; 113(4):467–73 (33 ref.)

[A case report of mediastinitis due to methicillin resistant Staphylococcus aureus after total aortic arch replacement] Asano S, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Jun;44(6):814–9 (18 ref.) (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

Coronary artery obstruction caused by perivalvular abscess in aortic valve endocarditis. Schlaifer JD, et al. **Am Heart J** 1996 Feb;131(2):413–6 (8 ref.)

Recurrent chancriform pyoderma: report of a case with tongue lesions. Is Staphylococcus aureus implicated? Holmes SC, et al. **Br J Dermatol** 1995 Aug;133(2):326–7 (5 ref.)

A rare complication of aortic valve endocarditis: diagnosis with transesophageal echocardiography. Winslow TM, et al. **J Am Soc Echocardiogr** 1995 Jul–Aug;8(4):546–50 (25 ref.)

Vertebral bone destruction in sickle cell disease: infection, infarction or both. Kooy A, et al. **Neth J Med** 1996 Jun; 48(6):227–31 (11 ref.)

Intraperitoneal rupture of an infected urachal cyst: a rare cause of peritonitis in children. Ogbevoen JO, et al. **Pediatr Emerg Care** 1996 Feb;12(1):41–3 (19 ref.)

Toxic shock syndrome as a complication of breast prostheses. Poblete JV, et al. **Plast Reconstr Surg** 1995 Dec; 96(7):1702–8 (54 ref.)

Fragmentation hemolysis: an unusual indication for valve replacement in native valve infective endocarditis. Gradon JD, et al. **South Med J** 1996 Aug;89(8):818–20 (7 ref.)

[Prognostic factors of prosthetic valve endocarditis. Apropos of 122 cases] Witchitz S, et al. **Arch Mal Coeur Vaiss** 1996 Jun;89(6):671–7 (30 ref.) (Eng. Abstr.) **(Fre)**

[Primary acute osteomyelitis of the sternum associated with anterior mediastinitis] Tabib W, et al. **J Chir (Paris)** 1996 Jan;133(1):20–2 (10 ref.) (Eng. Abstr.) **(Fre)**

[Pulmonary manifestations in a case of toxic shock syndrome] Stoica R. **Pneumoftiziologia** 1995 Jan–Jun;44(1–2):63–6 (9 ref.) (Eng. Abstr.) **(Rum)**

DIAGNOSIS

Liver abscess secondary to intrahepatic perforation of the gallbladder, presenting as a liver mass. Bakalakos EA, et al. **Am J Gastroenterol** 1996 Aug;91(8):1644–6 (12 ref.)

Staphylococcus aureus peritonsillar abscess in an 11-week old infant. Akhtar MJ, et al. **J Laryngol Otol** 1996 Jan; 110(1):78–80 (22 ref.)

Primary sternal osteomyelitis. Heaton PA, et al. **Pediatr Infect Dis J** 1995 Aug;14(8):722–3 (6 ref.)

Seminal vesicle abscess: a case report and review of literature. Pandey P, et al. **Scand J Urol Nephrol** 1995 Dec;29(4):521–4 (14 ref.)

DRUG THERAPY

Multifocal metachronous epidural abscesses of the spine. A case report. Chow GH, et al. **Spine** 1996 May 1; 21(9):1094–7 (11 ref.)

[Treatment of commonly occurring skin infections] Hyry H, et al. **Duodecim** 1995;111(8):697–702 (15 ref.) **(Fin)**

[Aminoglycosides in the treatment of infectious endocarditis] Malinverni R. **Schweiz Med Wochenschr Suppl** 1996; 76:14S–20S (41 ref.) (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

The epidemiology of methicillin-resistant Staphylococcus aureus colonisation and infection. Doebbeling BN. **J Chemother** 1995 Jul;7 Suppl 3:99–103 (35 ref.)

ETIOLOGY

Liver abscess secondary to intrahepatic perforation of the gallbladder, presenting as a liver mass. Bakalakos EA, et al. **Am J Gastroenterol** 1996 Aug;91(8):1644–6 (12 ref.)

Spontaneous bacterial peritonitis in a patient with nephrogenic ascites during an episode of acute renal transplant rejection. Horn S, et al. **Am J Kidney Dis** 1996 Mar;27(3):441–3 (22 ref.)

Spinal epidural abscess in hemodialysis patients: report of three cases and review of the literature. Obrador GT, et al. **Am J Kidney Dis** 1996 Jan;27(1):75–83 (34 ref.)

Invasive staphylococcal infections complicating percutaneous transluminal coronary angioplasty: three cases and review. Cleveland KO, et al. **Clin Infect Dis** 1995 Jul;21(1):93–6 (17 ref.)

Staphylococcus aureus infections during peritoneal dialysis. Coles GA. **J Chemother** 1995 Jul;7 Suppl 3:67–70 (22 ref.)

Staphylococcus aureus colonisation and bacteraemia in persons infected with human immunodeficiency virus: a dynamic interaction with the host. Craven DE. **J Chemother** 1995 Jul;7 Suppl 3:19–28 (46 ref.)

Identifying the patient risk for Staphylococcus aureus bloodstream infections. Espersen F. **J Chemother** 1995 Jul; 7 Suppl 3:11–7 (41 ref.)

Postoperative wound infections: risk factors and role of Staphylococcus aureus nasal carriage. Perl TM, et al. **J Chemother** 1995 Jul;7 Suppl 3:29–35 (51 ref.)

Identifying high risk patients for Staphylococcus aureus infections: skin and soft tissue infections. Trilla A, et al. **J Chemother** 1995 Jul;7 Suppl 3:37–43 (14 ref.)

Clinical and molecular aspects of the pathogenesis of Staphylococcus aureus bone and joint infections. Cunningham R, et al. **J Med Microbiol** 1996 Mar; 44(3):157–64 (55 ref.)

Infected iliac pseudoaneurysm after uncomplicated percutaneous balloon angioplasty and (Palmaz) stent insertion: a case report and literature review. Weinberg DJ, et al. **J Vasc Surg** 1996 Jan;23(1):162–6 (17 ref.)

Cerebrospinal fluid shunt complications: an emergency medicine perspective. Key CB, et al. **Pediatr Emerg Care** 1995 Oct;11(5):265–73 (56 ref.)

Retroperitoneal pseudomeningocele complicated by meningitis following a lumbar burst fracture. A case report. Nairus JG, et al. **Spine** 1996 May 1;21(9):1090–3 (13 ref.)

[Pulmonary arteriovenous fistulae and brain abscesses: a report of 2 cases treated by embolization and a review of the literature] Ricci P, et al. **Radiol Med (Torino)** 1996 Apr; 91(4):497–501 (24 ref.) **(Ita)**

IMMUNOLOGY

[Staphylococcus aureus and the human immune system] Slobodníková L. **Epidemiol Mikrobiol Imunol** 1995 Sep; 44(3):130–8 (131 ref.) (Eng. Abstr.) **(Slo)**

MICROBIOLOGY

Chronic blepharitis: a review. Smith RE, et al. **CLAO J** 1995 Jul;21(3):200–7 (81 ref.)

Median nerve compression at the wrist due to intracarpal canal sepsis. Flynn JM, et al. **J Hand Surg [Am]** 1995 Sep; 20(5):864–7 (18 ref.)

[Methicillin-resistant Staphylococcus epidermidis] Vandenbroucke-Grauls CM. **Ned Tijdschr Geneeskd** 1996 Jan 20;140(3):138–41 (25 ref.) (Eng. Abstr.) **(Dut)**

[Acute lumbago: infectious traps] Bonny O, et al. **Rev Med Suisse Romande** 1996 May;116(5):399–403 (8 ref.) **(Fre)**

PATHOLOGY

Antibiotics and the expression of staphylococcal virulence. Gemmell CG. **J Antimicrob Chemother** 1995 Aug; 36(2):283–91 (54 ref.)

PREVENTION & CONTROL

Vancomycin-resistant Staphylococcus aureus: perspectives on measures needed for control. Edmond MB, et al. **Ann Intern Med** 1996 Feb 1;124(3):329–34 (53 ref.)

Strategies for controlling methicillin-resistant Staphylococcus aureus in hospitals. Boyce JM. **J Chemother** 1995 Jul;7 Suppl 3:81–5 (24 ref.)

Aspects of the epidemiology of MRSA in Europe. Cookson B. **J Chemother** 1995 Jul;7 Suppl 3:93–8 (15 ref.)

The prospects for developing a vaccine against Staphylococcus aureus. Lee JC. **Trends Microbiol** 1996 Apr;4(4):162–6 (30 ref.)

SURGERY

Surgical considerations for hematogenous osteomyelitis. Loder BG, et al. **J Foot Ankle Surg** 1995 Jul–Aug; 34(4):347–53 (58 ref.)

[Removal of infected pacemaker leads in the elderly under extracorporeal circulation: two case reports and review of Japanese literature] Sato M, et al. **Kyobu Geka** 1995 Nov; 48(12):1009–12 (11 ref.) (Eng. Abstr.) **(Jpn)**

ULTRASONOGRAPHY

Pacemaker lead infection: detection by multiplane transesophageal echocardiography. Tighe DA, et al. **Am Heart J** 1996 Mar;131(3):616–8 (8 ref.)

STAPHYLOCOCCAL NUCLEASE see **MICROCOCCAL NUCLEASE**

STAPHYLOCOCCAL PROTEIN A

ADVERSE EFFECTS

Adverse clinical effects of immune sorption with staphylococcal protein A columns. Huestis DW, et al. **Transfus Med Rev** 1996 Jan;10(1):62–70 (59 ref.)

IMMUNOLOGY

Unconventional B-cell antigens and human immune repertoires. Silverman GJ. **Ann N Y Acad Sci** 1995 Sep 29;764:342–55 (42 ref.)

Adverse clinical effects of immune sorption with staphylococcal protein A columns. Huestis DW, et al. **Transfus Med Rev** 1996 Jan;10(1):62–70 (59 ref.)

STAPHYLOCOCCAL SCALDED SKIN SYNDROME

Staphylococcal scalded skin syndrome. Gemmell CG. **J Med Microbiol** 1995 Nov;43(5):318–27 (77 ref.)

STAPHYLOCOCCAL SKIN INFECTIONS

DRUG THERAPY

Common bacterial pyodermas. Taking aim against the most likely pathogens. Carroll JA. **Postgrad Med** 1996 Sep; 100(3):311–3, 317–22 (22 ref.)

STAPHYLOCOCCAL VACCINES

The prospects for developing a vaccine against Staphylococcus aureus. Lee JC. **Trends Microbiol** 1996 Apr;4(4):162–6 (30 ref.)

STAPHYLOCOCCUS

DRUG EFFECTS

[Methicillin-resistant Staphylococci] Sidorenko SV. **Antibiot Khimioter** 1995 Nov–Dec;40(11–12):57–69 (79 ref.) **(Rus)**

ISOLATION & PURIFICATION

Neurologic evaluation of the patient with acute bacterial meningitis. Ashwal S. **Neurol Clin** 1995 Aug;13(3):549–77 (105 ref.)

PATHOGENICITY

Molecular aspects of bacterial colonization. Bisno AL. **Infect Control Hosp Epidemiol** 1995 Nov;16(11):648–57 (83 ref.)

Antibiotics and the expression of staphylococcal virulence. Gemmell CG. **J Antimicrob Chemother** 1995 Aug; 36(2):283–91 (54 ref.)

STAPHYLOCOCCUS AUREUS

Recurrent chancriform pyoderma: report of a case with tongue lesions. Is Staphylococcus aureus implicated? Holmes SC, et al. **Br J Dermatol** 1995 Aug;133(2):326–7 (5 ref.)

The significance of nasal carriage of Staphylococcus aureus and the incidence of postoperative wound infection. Wenzel RP, et al. **J Hosp Infect** 1995 Sep;31(1):13–24 (52 ref.)

Staphylococcal scalded skin syndrome. Gemmell CG. **J Med Microbiol** 1995 Nov;43(5):318–27 (77 ref.)

Fragmentation hemolysis: an unusual indication for valve replacement in native valve infective endocarditis. Gradon JD, et al. **South Med J** 1996 Aug;89(8):818–20 (7 ref.)

[Acute lumbago: infectious traps] Bonny O, et al. **Rev Med Suisse Romande** 1996 May;116(5):399–403 (8 ref.) **(Fre)**

DRUG EFFECTS

Vancomycin-resistant Staphylococcus aureus: perspectives on measures needed for control. Edmond MB, et al. **Ann Intern Med** 1996 Feb 1;124(3):329–34 (53 ref.)

Antimicrobial-resistant pathogens in the 1990s. Jacoby GA. **Annu Rev Med** 1996;47:169–79 (62 ref.)

Erythromycin-resistant Staphylococcus aureus in Denmark. Westh H. **APMIS Suppl** 1996;57:1–37 (126 ref.)

Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Craig WA. **Diagn Microbiol Infect Dis** 1995 May–Jun;22(1–2):89–96 (31 ref.)

Strategies for controlling methicillin-resistant Staphylococcus aureus in hospitals. Boyce JM. **J Chemother** 1995 Jul;7 Suppl 3:81–5 (24 ref.)

Aspects of the epidemiology of MRSA in Europe. Cookson B. **J Chemother** 1995 Jul;7 Suppl 3:93–8 (15 ref.)

The epidemiology of methicillin-resistant Staphylococcus aureus colonisation and infection. Doebbeling BN. **J Chemother** 1995 Jul;7 Suppl 3:99–103 (35 ref.)

[A case report of mediastinitis due to methicillin resistant Staphylococcus aureus after total aortic arch replacement] Asano S, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Jun;44(6):814–9 (18 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Molecular evolution of MRSA. Hiramatsu K. **Microbiol Immunol** 1995;39(8):531–43 (68 ref.)

STAPHYLOCOCCUS AUREUS

IMMUNOLOGY

Unconventional B-cell antigens and human immune repertoires. Silverman GJ. **Ann N Y Acad Sci** 1995 Sep 29;764:342–55 (42 ref.)

The prospects for developing a vaccine against Staphylococcus aureus. Lee JC. **Trends Microbiol** 1996 Apr;4(4):162–6 (30 ref.)

ISOLATION & PURIFICATION

Invasive staphylococcal infections complicating percutaneous transluminal coronary angioplasty: three cases and review. Cleveland KO, et al. **Clin Infect Dis** 1995 Jul;21(1):93–6 (17 ref.)

Postoperative wound infections: risk factors and role of Staphylococcus aureus nasal carriage. Perl TM, et al. **J Chemother** 1995 Jul;7 Suppl 3:29–35 (51 ref.)

METABOLISM

[Discovery of epidermal cell differentiation inhibitor (EDIN) produced by Staphylococcus aureus and studies on the mode of action of EDIN] Sugai M. **Nippon Saikingaku Zasshi** 1995 Oct;50(4):937–46 (43 ref.) **(Jpn)**

PATHOGENICITY

Clinical and molecular aspects of the pathogenesis of Staphylococcus aureus bone and joint infections. Cunningham R, et al. **J Med Microbiol** 1996 Mar; 44(3):157–64 (55 ref.)

The epidermolytic (exfoliative) toxins of Staphylococcus aureus. Bailey CJ, et al. **Med Microbiol Immunol (Berl)** 1995 Aug;184(2):53–61 (67 ref.)

[Staphylococcus aureus and the human immune system] Slobodníková L. **Epidemiol Mikrobiol Imunol** 1995 Sep; 44(3):130–8 (131 ref.) (Eng. Abstr.) **(Slo)**

STAPHYLOCOCCUS EPIDERMIDIS

Cerebrospinal fluid shunt complications: an emergency medicine perspective. Key CB, et al. **Pediatr Emerg Care** 1995 Oct;11(5):265–73 (56 ref.)

DRUG EFFECTS

[Methicillin-resistant Staphylococcus epidermidis] Vandenbroucke-Grauls CM. **Ned Tijdschr Geneeskd** 1996 Jan 20;140(3):138–41 (25 ref.) (Eng. Abstr.) **(Dut)**

STAPHYLOMYCIN see **VIRGINIAMYCIN**

STARCH

ADMINISTRATION & DOSAGE

Epidemiology of fibre, resistant starch and colorectal cancer. Kritchevsky D. **Eur J Cancer Prev** 1995 Oct;4(5):345–52 (65 ref.)

BIOSYNTHESIS

From glycogen to amylopectin: a model for the biogenesis of the plant starch granule. Ball S, et al. **Cell** 1996 Aug 9;86(3):349–52 (18 ref.)

CHEMISTRY

Nonconventional methods of modification of starch. Tomasik P, et al. **Adv Carbohydr Chem Biochem** 1995;51:243–320 (332 ref.)

METABOLISM

Contribution of fiber and resistant starch to metabolizable energy. Behall KM, et al. **Am J Clin Nutr** 1995 Nov;62(5 Suppl):1158S–1160S (35 ref.)

Amylolytic enzymes and products derived from starch: a review. Guzmán-Maldonado H, et al. **Crit Rev Food Sci Nutr** 1995 Sep;35(5):373–403 (190 ref.)

The impact of complex carbohydrates on energy balance. Livesey G. **Eur J Clin Nutr** 1995 Oct;49 Suppl 3:S89–96 (30 ref.)

THERAPEUTIC USE

Salt, starch, and water on the brain. Schell RM, et al. **J Neurosurg Anesthesiol** 1996 Apr;8(2):178–82 (56 ref.)

STARFISH

METABOLISM

Starfish maturation-promoting factor. Kishimoto T. **Trends Biochem Sci** 1996 Jan;21(1):35–7 (18 ref.)

STARTLE REACTION

PHYSIOLOGY

Physiology of startle phenomena. Brown P. **Adv Neurol** 1995; 67:273–87 (79 ref.)

Gating and habituation deficits in the schizophrenia disorders. Braff DL, et al. **Clin Neurosci** 1995;3(2):131–9 (48 ref.)

STARVATION

PHYSIOPATHOLOGY

Hypothalamic response to starvation: implications for the study of wasting disorders. Schwartz MW, et al. **Am J Physiol** 1995 Nov;269(5 Pt 2):R949–57 (83 ref.)

Protein synthesis in the heart in vivo, its measurement and patho-physiological alterations. Preedy VR, et al. **Int J Cardiol** 1995 Jun 30;50(2):95–106 (48 ref.)

Fuel selection by the kidney: adaptation to starvation. Baverel G, et al. **Proc Nutr Soc** 1995 Mar;54(1):197–212 (116 ref.)

Feeding, fasting and starvation: factors affecting fuel utilization. MacDonald IA, et al. **Proc Nutr Soc** 1995 Mar; 54(1):267–74 (29 ref.)

PSYCHOLOGY

Anorexia nervosa, self-starvation and the reward of stress. Bergh C, et al. **Nat Med** 1996 Jan;2(1):21–2 (13 ref.)

STASIS ULCER see **VARICOSE ULCER**

STATE HEALTH PLANNING, UNITED STATES see **HEALTH PLANNING**

STATE HEALTH PLANS

ECONOMICS

On the Oregon trail. Kitzhaber J, et al. **Br Med Bull** 1995 Oct;51(4):808–18 (0 ref.)

LEGISLATION & JURISPRUDENCE

Medicaid physician participation: patients, poverty, and physician self-interest. Watson SD. **Am J Law Med** 1995; 21(2–3):191–220 (232 ref.)

STATE MEDICINE

ECONOMICS

Rationing in the NHS: the dance of the seven veils–in reverse. Klein R, et al. **Br Med Bull** 1995 Oct;51(4):769–80 (24 ref.)

Why rationing is on the agenda. Maxwell RJ. **Br Med Bull** 1995 Oct;51(4):761–8 (14 ref.)

Help or hindrance? The role of economics in rationing health care. Maynard A, et al. **Br Med Bull** 1995 Oct;51(4):854–68 (31 ref.)

General practitioner fundholding: weighing the evidence [see comments] Petchey R. **Lancet** 1995 Oct 28; 346(8983):1139–42 (42 ref.) Comment in: Lancet 1995 Dec 23–30;346(8991–8992):1710–1.

ORGANIZATION & ADMINISTRATION

Sweden: no easy choices. Calltorp J. **Br Med Bull** 1995 Oct; 51(4):791–8 (7 ref.)

Can we do better? Maxwell RJ. **Br Med Bull** 1995 Oct; 51(4):941–8 (4 ref.)

The research basis of health care decision making. Ingram N. **J Adv Nurs** 1996 Apr;23(4):692–6 (18 ref.)

Simulation modelling for resource allocation and planning in the health sector. Lehaney B, et al. **J R Soc Health** 1995 Dec;115(6):382–5 (47 ref.)

Shifting boundaries in professional care. Hopkins A, et al. **J R Soc Med** 1996 Jul;89(7):364–71 (36 ref.)

Population-centered and patient-focused purchasing: the U.K. experience. Ham C. **Milbank Q** 1996;74(2):191–214 (58 ref.)

TRENDS

The household context for women's health care decisions: impacts of U.K. policy changes. Young R. **Soc Sci Med** 1996 Mar;42(6):949–63 (92 ref.)

STATE-OF-THE-ART REVIEW see **REVIEW LITERATURE**

STATEWIDE HEALTH COORDINATING COUNCILS see **HEALTH PLANNING COUNCILS**

STATISTICAL BIAS see **BIAS (EPIDEMIOLOGY)**

STATISTICAL MODELS see **MODELS, STATISTICAL**

STATISTICAL REGRESSION see **REGRESSION ANALYSIS**

STATISTICS

see related
BIBLIOMETRICS
META-ANALYSIS
MODELS, STATISTICAL
PSYCHOMETRICS

A statistics primer. Greenfield ML, et al. **Am J Sports Med** 1996 May-Jun;24(3):393–5 (9 ref.)

Issues in biomedical statistics: comparing means by computer-intensive tests. Ludbrook J. **Aust N Z J Surg** 1995 Nov;65(11):812–9 (26 ref.)

Statistics notes. Logarithms. Bland JM, et al. **BMJ** 1996 Mar 16;312(7032):700 (0 ref.)

A review of the statistical analysis used in papers published in Clinical Radiology and British Journal of Radiology. Goldin J, et al. **Clin Radiol** 1996 Jan;51(1):47–50 (33 ref.)

Cerebrospinal fluid 5-hydroxyindolacetic acid and aggression: a critical reappraisal of the clinical data. Tuinier S, et al. **Int Clin Psychopharmacol** 1995 Sep;10(3):147–56 (82 ref.)

Methodological and statistical problems in sleep apnea research: the literature on uvulopalatopharyngoplasty. Schechtman KB, et al. **Sleep** 1995 Oct;18(8):659–66 (44 ref.)

[The level of use of statistical data in articles in the Orvosi Hetilap] Vitrai J, et al. **Orv Hetil** 1996 Mar 3;137(9):465–72 (46 ref.) (Eng. Abstr.) **(Hun)**

[Clinical application of statistics] Morita S. **Masui** 1995;44 Suppl:S71–7 (0 ref.) **(Jpn)**

[Problems on medical statistic processing—special reference to incorrect application] Kuritani N. **Nippon Seirigaku Zasshi** 1996;58(3):127–32 (0 ref.) **(Jpn)**

[Problems in medical statistics] Kuriya N. **Nippon Seirigaku Zasshi** 1996;58(4):175–81 (0 ref.) **(Jpn)**

EDUCATION

A guide to clinical epidemiology for radiologists: Part II statistical analysis. Goldin J, et al. **Clin Radiol** 1996 May; 51(5):317–24 (68 ref.)

METHODS

Ways of measuring rates of recurrent events. Glynn RJ, et al. **BMJ** 1996 Feb 10;312(7027):364–7 (29 ref.)

STATISTICS, NONPARAMETRIC

Nonparametric analysis of statistic images from functional mapping experiments. Holmes AP, et al. **J Cereb Blood Flow Metab** 1996 Jan;16(1):7–22 (26 ref.)

The rough and ready jackknife. Resnick B. **Nurs Res** 1996 May-Jun;45(3):185–8 (19 ref.)

STATUS ASTHMATICUS

COMPLICATIONS

Occult, occult auto-PEEP in status asthmaticus [editorial; comment] Stewart TE, et al. **Crit Care Med** 1996 Mar; 24(3):379–80 (13 ref.) Comment on: Crit Care Med 1996 Mar;24(3):541–6.

STATUS DYSRAPHICUS see **SPINAL DYSRAPHISM**

STATUS EPILEPTICUS

[XIVth Consensus Conference in Intensive Care and Emergency Medicine. Management of status epilepticus (children-adults)] **Therapie** 1996 Jan-Feb;51(1):75–9 (0 ref.) **(Fre)**

CHEMICALLY INDUCED

Lithium-pilocarpine neurotoxicity: a potential model of status epilepticus. Kulkarni SK, et al. **Methods Find Exp Clin Pharmacol** 1995 Oct;17(8):551–67 (195 ref.)

DRUG THERAPY

Status epilepticus and acute repetitive seizures in children, adolescents, and young adults: etiology, outcome, and treatment. Mitchell WG. **Epilepsia** 1996;37 Suppl 1:S74–80 (53 ref.)

ETIOLOGY

Status epilepticus and acute repetitive seizures in children, adolescents, and young adults: etiology, outcome, and treatment. Mitchell WG. **Epilepsia** 1996;37 Suppl 1:S74–80 (53 ref.)

PHYSIOPATHOLOGY

Pathophysiology of status epilepticus. Fountain NB, et al. **J Clin Neurophysiol** 1995 Jul;12(4):326–42 (114 ref.)

Electroclinical features of status epilepticus. Treiman DM. **J Clin Neurophysiol** 1995 Jul;12(4):343–62 (125 ref.)

THERAPY

[XIV Consensus Conference on Intensive care and emergency medicine. Management of status epilepticus (children-adults). 23 June 1995, Le Kremlin-Bicêtre] **Ann Fr Anesth Reanim** 1996;15(1):106–9 (0 ref.) **(Fre)**

[Treatment of status epilepticus—1995] Goldberg-Stern H, et al. **Harefuah** 1996 Feb 15;130(4):278–9 (6 ref.) **(Heb)**

STAVUDINE

PHARMACOLOGY

Antiretroviral activity of stavudine (2',3'-didehydro-3'-deoxythymidine, D4T). Riddler SA, et al. **Antiviral Res** 1995 Jun;27(3):189–203 (48 ref.)

THERAPEUTIC USE

Stavudine (d4T, Zerit). Friedland G, et al.

Adv Exp Med Biol 1996;394:271–7 (21 ref.)

STEALING see THEFT

STEAM

The potential for use of steam at atmospheric pressure to decontaminate or sterilize parenteral filling lines incorporating barrier isolation technology. Lysfjord JP, et al. **PDA J Pharm Sci Technol** 1995 Sep–Oct;49(5):212–9 (17 ref.)

STEAROYL-COA DESATURASE

GENETICS

The regulation of stearoyl-CoA desaturase (SCD). Ntambi JM. **Prog Lipid Res** 1995;34(2):139–50 (130 ref.)

STEARYL-COA DESATURASE see STEAROYL-COA DESATURASE

STEATONECROSIS see FAT NECROSIS

STEATORRHEA see CELIAC DISEASE

STEEL FACTOR see STEM CELL FACTOR

STEELE-RICHARDSON-OLSZEWSKI SYNDROME see SUPRANUCLEAR PALSY, PROGRESSIVE

STEELHEAD see ONCORHYNCHUS MYKISS

STEELY HAIR SYNDROME see KINKY HAIR SYNDROME

STEIN-LEVENTHAL SYNDROME see POLYCYSTIC OVARY SYNDROME

STEINERT'S DISEASE see MYOTONIA ATROPHICA

STEM CELL ASSAY see COLONY-FORMING UNITS ASSAY

STEM CELL ASSAY, TUMOR see TUMOR STEM CELL ASSAY

STEM CELL FACTOR

METABOLISM

Structural aspects of receptor dimerization. c-kit as an example. Blechman JM, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:344–62 (79 ref.)

PHYSIOLOGY

Stem cell factor as a survival and growth factor in human normal and malignant hematopoiesis. Hassan HT, et al. **Acta Haematol** 1996;95(3–4):257–62 (50 ref.)

Biology and clinical potential of stem-cell factor. Glaspy J, et al. **Cancer Chemother Pharmacol** 1996;38 Suppl:S53–7 (33 ref.)

THERAPEUTIC USE

Biology and clinical potential of stem-cell factor. Glaspy J, et al. **Cancer Chemother Pharmacol** 1996;38 Suppl:S53–7 (33 ref.)

STEM CELL FACTOR RECEPTORS see PROTO-ONCOGENE PROTEINS C-KIT

STEM CELL TRANSPLANTATION see HEMATOPOIETIC STEM CELL TRANSPLANTATION

STEM CELLS

Systems for production of calves from cultured bovine embryonic cells. First NL, et al. **Reprod Fertil Dev** 1994; 6(5):553–62 (35 ref.)

Development and validation of swine embryonic stem cells: a review. Wheeler MB. **Reprod Fertil Dev** 1994;6(5):563–8 (59 ref.)

[Genetic screening for novel genes by insertional mutagenesis with gene trap method in ES cells] Araki K, et al. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2017–24 (17 ref.) **(Jpn)**

[Origin and Nature of the mammalian embryonic stem cell lines] Nakatsuji N. **Tanpakushitsu Kakusan Koso** 1995 Oct; 40(14):2008–12 (11 ref.) **(Jpn)**

CHEMISTRY

CD34 cell separation: from basic research to clinical applications. Nadali G, et al. **Int J Clin Lab Res** 1995; 25(3):121–7 (39 ref.)

A collection of cortical crescents: asymmetric protein localization in CNS precursor cells. Doe CQ, et al. **Neuron** 1995 Nov;15(5):991–5 (31 ref.)

CYTOLOGY

In vitro differentiation of embryonic stem cells. Keller GM. **Curr Opin Cell Biol** 1995 Dec;7(6):862–9 (50 ref.)

From rodent glial precursor cell to human glial neoplasia in the oligodendrocyte-type-2 astrocyte lineage. Noble M, et al. **Glia** 1995 Nov;15(3):222–30 (63 ref.)

A collection of cortical crescents: asymmetric protein localization in CNS precursor cells. Doe CQ, et al. **Neuron** 1995 Nov;15(5):991–5 (31 ref.)

New insights into the stem cells and the precursors of the gastric epithelium. Karam SM. **Nutrition** 1995 Sep–Oct; 11(5 Suppl):607–13 (27 ref.)

Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model. Bonkhoff H, et al. **Prostate** 1996 Feb;28(2):98–106 (52 ref.)

Strategies for the isolation and characterization of bovine embryonic stem cells. Cherny RA, et al. **Reprod Fertil Dev** 1994;6(5):569–75 (30 ref.)

Studies of in vitro differentiation with embryonic stem cells. Pedersen RA. **Reprod Fertil Dev** 1994;6(5):543–52 (139 ref.)

Regulation of differentiation pathway of skeletal mesenchymal cells in cell lines by transforming growth factor-beta superfamily. Yamaguchi A. **Semin Cell Biol** 1995 Jun;6(3):165–73 (53 ref.)

Neurones from stem cells? Svendsen CN, et al. **Trends Neurosci** 1995 Nov;18(11):465–7 (33 ref.)

Hepatic epithelial stem-like cells. Grisham JW. **Verh Dtsch Ges Pathol** 1995;79:47–54 (38 ref.)

Embryonic stem cells in farm animals. Galli C, et al. **Zygote** 1994 Nov;2(4):385–9 (47 ref.)

DRUG EFFECTS

Transforming growth factor-beta-3 is mitogenic for rat retinal progenitor cells in vitro. Anchan RM, et al. **J Neurobiol** 1995 Oct;28(2):133–45 (50 ref.)

IMMUNOLOGY

Molecular interactions in the activation of effector and precursor cytotoxic T lymphocytes. Mescher MF. **Immunol Rev** 1995 Aug;146:177–210 (108 ref.)

Does graft-versus-host disease attack epithelial stem cells? Sale GE. **Mol Med Today** 1996 Mar;2(3):114–9 (32 ref.)

[Molecular and biological features of human CD34+ Hematopoietic stem/progenitor cells] Xi YZ. **Sheng Li Ko Hsueh Chin Chan** 1995 Oct;26(4):317–23 (20 ref.) (Eng. Abstr.) **(Chi)**

[Expression of primitive stem cell antigens on the blast cells of patients with chronic myeloid leukemia] Baryshnikov Alu. **Vestn Ross Akad Med Nauk** 1996;(3):9–13 (53 ref.) (Eng. Abstr.) **(Rus)**

PATHOLOGY

The neuroepithelial stem cell concept: implications for neuro-oncology. Brüstle O, et al. **J Neurooncol** 1995; 24(1):57–9 (17 ref.)

Ductular reaction in the liver. Desmet V, et al. **Pathol Res Pract** 1995 Jul;191(6):513–24 (153 ref.)

Immortalized neural stem cells: insights into development; prospects for gene therapy and repair. Snyder EY. **Proc Assoc Am Physicians** 1995 Jul;107(2):195–204 (58 ref.)

PHYSIOLOGY

In vitro differentiation of murine embryonic stem cells. New approaches to old problems. Weiss MJ, et al. **J Clin Invest** 1996 Feb 1;97(3):591–5 (59 ref.)

Microchimerism, dendritic cell progenitors and transplantation tolerance. Thomson AW, et al. **Stem Cells (Dayt)** 1995 Nov;13(6):622–39 (119 ref.)

RADIATION EFFECTS

Implications of delayed reproductive cell death (lethal mutations/genomic instability) for the interpretation of tissue responses. Hendry JH, et al. **Int J Radiat Biol** 1995 Oct;68(4):363–7 (32 ref.)

Biomarkers for low-level exposure causing epigenetic responses in stem cells. Trosko JE. **Stem Cells (Dayt)** 1995 May;13 Suppl 1:231–9 (90 ref.)

STEM CELLS, ERYTHROID see ERYTHROID PROGENITOR CELLS

STEM CELLS, HEMATOPOIETIC see HEMATOPOIETIC STEM CELLS

STEM CELLS, NEOPLASTIC see TUMOR STEM CELLS

STENOCARDIA see ANGINA PECTORIS

STENTS

Endovascular stents and stented grafts for the treatment of aneurysms and other arterial lesions. Marin ML, et al. **Adv Surg** 1996;29:93–109 (50 ref.)

Acute stent thrombosis associated with exercise testing after successful percutaneous transluminal coronary angioplasty. Samuels B, et al. **Am Heart J** 1995 Nov;130(5):1120–2 (15 ref.)

Endoscopic stenting of gallbladder for symptomatic cholelithiasis in patients with end-stage liver disease awaiting orthotopic liver transplantation. Shrestha R, et al. **Am J Gastroenterol** 1996 Mar;91(3):595–8 (21 ref.)

Wire stent for tracheomalacia in a five-year-old girl. Bousamra M 2nd, et al. **Ann Thorac Surg** 1996 Apr; 61(4):1239–40 (8 ref.)

Endovascular stents in children under 1 year of age: acute impact and late results. Hatai Y, et al. **Br Heart J** 1995 Dec;74(6):689–95 (16 ref.)

Transjugular intrahepatic portasystemic stent-shunt in the treatment of variceal haemorrhage. Jalan R, et al. **Br J Surg** 1995 Sep;82(9):1158–64 (46 ref.)

The present status of endoluminal stented grafts for the treatment of aneurysms, traumatic injuries and arterial occlusions. Veith FJ, et al. **Cardiovasc Surg** 1996 Feb; 4(1):3–7 (30 ref.)

Expandable stents. Nesbitt JC, et al. **Chest Surg Clin N Am** 1996 May;6(2):305–28 (33 ref.)

Intracoronary stenting. From concept to custom. Ruygrok PN, et al. **Circulation** 1996 Sep 1;94(5):882–90 (49 ref.)

Airway stents. Present and future. Colt HG, et al. **Clin Chest Med** 1995 Sep;16(3):465–78 (96 ref.)

Intracoronary stents. Wong SC, et al. **Curr Opin Cardiol** 1995 Jul;10(4):404–11 (37 ref.)

Intravascular stents: current applications. Bailey SR, et al. **Curr Probl Cardiol** 1995 Sep;20(9):614–78 (191 ref.)

Biliary endoprostheses in elderly patients with endoscopically irretrievable common bile duct stones: report on 117 patients [see comments] Bergman JJ, et al. **Gastrointest Endosc** 1995 Sep;42(3):195–201 (24 ref.) Comment in: Gastrointest Endosc 1995 Sep;42(3):272–3.

Metal stents in the oesophagus. Sturgess RP, et al. **Gut** 1995 Nov;37(5):593–4 (8 ref.)

New devices in interventional cardiology: present and future. Beyar R. **Isr J Med Sci** 1996 Jul;32(7):515–25 (42 ref.)

Subacute stent thrombosis: evolving issues and current concepts. Mak KH, et al. **J Am Coll Cardiol** 1996 Feb; 27(2):494–503 (102 ref.)

Coronary artery stents. American College of Cardiology. Pepine CJ, et al. **J Am Coll Cardiol** 1996 Sep;28(3):782–94 (55 ref.)

Carotid angioplasty and stenting: is endovascular treatment for cerebrovascular disease justified [editorial] Bergeron P. **J Endovasc Surg** 1996 May;3(2):129–31 (12 ref.)

Indications for carotid artery stenting: a preview of the potential derived from early clinical experience [editorial] Diethrich EB. **J Endovasc Surg** 1996 May;3(2):132–9 (15 ref.)

Percutaneous techniques for endoluminal carotid interventions. Diethrich EB, et al. **J Endovasc Surg** 1996 May;3(2):182–202 (8 ref.)

Anesthesia for carotid stent procedures. Kharrazi MR. **J Endovasc Surg** 1996 May;3(2):211–6 (8 ref.)

Patient preparation and monitoring for carotid stenting: the operating room nurse's perspective. Plat S, et al. **J Endovasc Surg** 1996 May;3(2):224–7 (6 ref.)

Intravascular ultrasound assessment in carotid interventions. Reid DB, et al. **J Endovasc Surg** 1996 May;3(2):203–10 (9 ref.)

The transjugular intrahepatic portosystemic stent-shunt: a review of the literature and own experiences. Rössle M, et al. **J Gastroenterol Hepatol** 1996 Mar;11(3):293–8 (48 ref.)

Intravascular stenting of traumatic abdominal aortic dissection. Marty-Ané CH, et al. **J Vasc Surg** 1996 Jan; 23(1):156–61 (13 ref.)

Stenting of superior vena caval obstruction. Jackson JE, et al. **Thorax** 1995 Sep;50 Suppl 1:S31–6 (36 ref.)

Extracorporeal shock-wave lithotripsy of middle ureteral stones: are ureteral stents necessary? Nakada SY, et al. **Urology** 1995 Nov;46(5):649–52 (18 ref.)

Indications and results of arterial stents for occlusive disease. Ahn SS, et al. **World J Surg** 1996 Jul–Aug;20(6):644–8 (29 ref.)

Endovascular technology and its impact on the relationships among vascular surgeons, interventional radiologists, and other specialists. Veith FJ, et al. **World J Surg** 1996 Jul–Aug;20(6):687–91 (36 ref.)

Coronary stents. Sigwart U. **Z Kardiol** 1995;84 Suppl 2:65–77 (75 ref.)

[The double J catheter in the shock wave treatment of kidney calculi] Pilar Laguna M, et al. **Ann Urol (Paris)** 1995; 29(6–7):364–9 (20 ref.) (Eng. Abstr.) **(Fre)**

[Biliary and esophageal self-expandable stents] Dumas R, et al. **Gastroenterol Clin Biol** 1996;20(5 Pt 2):B145–51 (84 ref.) **(Fre)**

[Treatment of tumoral stenoses of the hepatic hilum (editorial)] Valette PJ. **Gastroenterol Clin Biol** 1995 Jun–Jul;19(6–7):561–3 (17 ref.) **(Fre)**

[Plastic prostheses or self-expanding stents—is there an ideal drainage? Pro metal] Hochberger J, et al. **Bildgebung** 1995 Oct;62 Suppl 2:59–63 (22 ref.) **(Ger)**

[Hepatobiliary stenting in malignant and benign stenosis—which approach is the best? Endoscopic approach] Jung M, et al. **Bildgebung** 1995 Oct;62 Suppl 2:47–52 (24 ref.) **(Ger)**

[Stenting or operation in malignant or benign stenoses: where are the limits?—from the viewpoint of the surgeon] Schoenberg MH, et al. **Bildgebung** 1995 Oct;62 Suppl 2:73–6 (13 ref.) **(Ger)**

[Plastic prostheses or self-expanding stents—is there an ideal drainage? Pro synthetics] Soehendra N, et al. **Bildgebung** 1995 Oct;62 Suppl 2:55–8 (23 ref.) **(Ger)**

[Endovascular reconstruction of infrarenal abdominal aortic aneurysm] Allenberg JR, et al. **Chirurg** 1995 Sep; 66(9):870–7 (24 ref.) (Eng. Abstr.) **(Ger)**

-Anticoagulation after intracoronary stent implantation-

Bode C, et al. **Herz** 1996 Feb;21(1):60–3 (21 ref.) (Eng. Abstr.) **(Ger)**

[Current strategies in patients with urinary diversion, 2: Upper urinary tract] Moll F. **Z Arztl Fortbild (Jena)** 1996 May;90(3):241–8 (22 ref.) (Eng. Abstr.) **(Ger)**

[Alternative methods in interventional therapy of coronary heart disease] Erbel R, et al. **Z Kardiol** 1995;84 Suppl 2:53–64 (72 ref.) (Eng. Abstr.) **(Ger)**

[Local drug administration systems, preclinical and clinical use: perspectives and limitations] Gonschior P, et al. **Z Kardiol** 1996 Mar;85(3):155–65 (59 ref.) (Eng. Abstr.) **(Ger)**

[Endoscopic management of benign strictures of the common bile duct] Orosz P, et al. **Orv Hetil** 1996 Feb 11; 137(6):291–4 (31 ref.) (Eng. Abstr.) **(Hun)**

[Recanalization of 2 suprahepatic veins with metal stents via a percutaneous transhepatic approach in a case of the Budd–Chiari syndrome] Castrucci M, et al. **Radiol Med (Torino)** 1996 Jan–Feb;91(1–2):148–52 (16 ref.) **(Ita)**

[The use of self-expanding stents in the recanalization of gastric antrum neoplastic obstructions. The experience of a case] Profili S, et al. **Radiol Med (Torino)** 1995 Sep; 90(3):330–3 (23 ref.) **(Ita)**

[Local thrombolysis and stents in deep venous thrombosis. A new endovascular therapeutic technique] Nyman U, et al. **Lakartidningen** 1996 Aug 7;93(32–33):2750–6 (27 ref.) **(Swe)**

ADVERSE EFFECTS

Subacute stent thrombosis and the anticoagulation controversy: changes in drug therapy, operator technique, and the impact of intravascular ultrasound. Moussa I, et al. **Am J Cardiol** 1996 Aug 14;78(3A):13–7 (35 ref.)

Prevention of biliary stent clogging: a clinical review. Libby ED, et al. **Am J Gastroenterol** 1996 Jul;91(7):1301–8 (59 ref.)

Infected iliac pseudoaneurysm after uncomplicated percutaneous balloon angioplasty and (Palmaz) stent insertion: a case report and literature review. Weinberg DJ, et al. **J Vasc Surg** 1996 Jan;23(1):162–6 (17 ref.)

[The evaluation of the acute recoil of the Palmaz–Schatz stent using echography. A case report] Maiello L, et al. **Cardiologia** 1996 Jun;41(6):559–62 (10 ref.) (Eng. Abstr.) **(Ita)**

STANDARDS

Role of polymers in improving the results of stenting in coronary arteries. Peng T, et al. **Biomaterials** 1996 Apr; 17(7):685–94 (90 ref.)

TRENDS

Stents for intracoronary placement: current status and future directions. Eeckhout E, et al. **J Am Coll Cardiol** 1996 Mar 15;27(4):757–65 (96 ref.)

STEP TEST see **EXERCISE TEST**

STEPFAMILY see **FAMILY**

STEP-PARENTS see **PARENTS**

STEREOISOMERS

The cost benefit ratio of enantiomeric drugs. Pifferi G, et al. **Eur J Drug Metab Pharmacokinet** 1995 Jan–Mar; 20(1):15–25 (51 ref.)

Stereochemical aspects of pharmacotherapy. Brocks DR, et al. **Pharmacotherapy** 1995 Sep–Oct;15(5):551–64 (72 ref.)

[Pharmacokinetic implications associated to the use of drugs as racemates or pure enantiomers] Speisky H, et al. **Rev Med Chil** 1995 Jul;123(7):884–91 (25 ref.) (Eng. Abstr.) **(Spa)**

STEREOPHOTOGRAMMETRY see **PHOTOGRAMMETRY**

STEREOPSIS see **DEPTH PERCEPTION**

STEREOSCOPIC VISION see **DEPTH PERCEPTION**

STEREOTACTIC RADIOSURGERY see **RADIOSURGERY**

STEREOTAXIC TECHNIQUES

see related
BRAIN MAPPING

Does stereotactic treatment for Parkinson's disease slow the progression of the disease? Narabayashi H. **Adv Neurol** 1996;69:557–62 (18 ref.)

Review article: the functions of the basal ganglia and the paradox of stereotaxic surgery in Parkinson's disease [letter; comment] Iansek R, et al. **Brain** 1995 Dec;118 (Pt 6):1613–7 (21 ref.) Comment on: Brain 1994 Aug;117 (Pt 4):877–97.

When can stereotactic core biopsy replace excisional biopsy?—A clinical perspective. Morrow M. **Breast Cancer Res Treat** 1995;36(1):1–9 (54 ref.)

Stereotactic technology in tumor surgery: concepts and principles. Roberts DW. **J Neurooncol** 1995;24(3):281–4 (19 ref.)

The role of stereotactic radiation therapy in the management of children with brain tumors. Lew CM, et al. **J Pediatr Oncol Nurs** 1995 Oct;12(4):212–22 (31 ref.)

ECONOMICS

[Gamma knife versus stereotactic linear accelerator. Utilization, clinical results and cost–benefit relations] Becker G, et al. **Radiologe** 1996 Apr;36(4):345–53 (30 ref.) (Eng. Abstr.) **(Ger)**

INSTRUMENTATION

CT-guided pain procedures for intractable pain in malignancy. Kanpolat Y, et al. **Acta Neurochir Suppl (Wien)** 1995;64:88–91 (24 ref.)

Microelectrode monitoring of cortical and subcortical structures during stereotactic surgery. Lozano AM, et al. **Acta Neurochir Suppl (Wien)** 1995;64:30–4 (19 ref.)

Magnetic resonance imaging and epilepsy: neurosurgical decision making. Fried I. **Magn Reson Imaging** 1995; 13(8):1163–70 (47 ref.)

A technique for interactive image-guided neurosurgical intervention in primary brain tumors. Maciunas RJ, et al. **Neurosurg Clin N Am** 1996 Apr;7(2):245–66 (111 ref.)

Image-guided surgery of epilepsy. Olivier A, et al. **Neurosurg Clin N Am** 1996 Apr;7(2):229–43 (23 ref.)

The evaluation and image-guided surgical treatment of the patient with a medically intractable seizure disorder. Roberts DW, et al. **Neurosurg Clin N Am** 1996 Apr; 7(2):215–27 (46 ref.)

[Neurosurgical methods in Parkinson disease] Alesch F. **Wien Med Wochenschr** 1995;145(13):305–9 (23 ref.) (Eng. Abstr.) **(Ger)**

STEREOTYPED BEHAVIOR

[Stereotypies] Campos-Castelló J. **Rev Neurol** 1995;23 Suppl 3:S363–7 (33 ref.) **(Spa)**

STEREOTYPING

Effects of ageism on individual and health care providers' responses to healthy aging. Grant LD. **Health Soc Work** 1996 Feb;21(1):9–15 (46 ref.)

Reformulation of deviance and labeling theory for nursing. Trexler JC. **Image J Nurs Sch** 1996 Summer;28(2):131–5 (39 ref.)

Stigma, labelling and psychiatric misdiagnosis: origins and outcomes. Witztum E, et al. **Med Law** 1995;14(7–8):659–69 (27 ref.)

Constructing the symbolic complainant: police subculture and the nonenforcement of protection orders for battered women. Rigakos GS. **Violence Vict** 1995 Fall;10(3):227–47 (50 ref.)

STERILITY see **INFERTILITY**

STERILITY, FEMALE see **INFERTILITY, FEMALE**

STERILITY, MALE see **INFERTILITY, MALE**

STERILIZATION

High-level disinfection or "sterilization" of endoscopes? Muscarella LF. **Infect Control Hosp Epidemiol** 1996 Mar; 17(3):183–7 (61 ref.)

Heat sterilization of glucose-containing fluids for peritoneal dialysis: biological consequences of chemical alterations. Wieslander AP, et al. **Perit Dial Int** 1995;15(7 Suppl):S52–9; discussion S59–60 (32 ref.)

Sterilization and disinfection of instruments and materials in the surgery unit and laboratory areas. Best M, et al. **Semin Dermatol** 1995 Sep;14(3):243–6 (14 ref.)

[Function of the bio-clean room for bone marrow transplantation] Yamayoshi T. **Rinsho Byori** 1995 Jul;Suppl 99:74–83 (22 ref.) **(Jpn)**

INSTRUMENTATION

The potential for use of steam at atmospheric pressure to decontaminate or sterilize parenteral filling lines incorporating barrier isolation technology. Lysfjord JP, et al. **PDA J Pharm Sci Technol** 1995 Sep–Oct;49(5):212–9 (17 ref.)

METHODS

Gas plasma sterilization—application of space-age technology. Crow S, et al. **Infect Control Hosp Epidemiol** 1995 Aug;16(8):483–7 (7 ref.)

A review of the effects of gamma radiation on pharmaceutical materials. Jacobs GP. **J Biomater Appl** 1995 Jul;10(1):59–96 (213 ref.)

Sterilization and reprocessing of materials and medical devices—reusability. Jayabalan M. **J Biomater Appl** 1995 Jul;10(1):97–112 (39 ref.)

Currently practised sterilization methods—some inadvertent consequences. Nair PD. **J Biomater Appl** 1995 Oct; 10(2):121–35 (40 ref.)

Advances in photochemical approaches for blood sterilization. Ben-Hur E, et al. **Photochem Photobiol** 1995 Sep;62(3):383–8 (81 ref.)

Microbiologic considerations. Disinfection and sterilization strategies and the potential for airborne transmission of bloodborne pathogens. Favero MS, et al. **Surg Clin North Am** 1995 Dec;75(6):1071–89 (40 ref.)

The photodecontamination of cellular blood components: mechanisms and use of photosensitization in transfusion medicine. Ben-Hur E, et al. **Transfus Med Rev** 1996 Jan; 10(1):15–22 (71 ref.)

[Gas sterilization with gas hydrogen peroxide: a new technology in the pharmaceutical industry] Manzati C. **Boll Chim Farm** 1995 Sep;134(8):413–33 (23 ref.) (Eng. Abstr.) **(Ita)**

STANDARDS

Sterilization, toxicity, biocompatibility and clinical applications of polylactic acid/polyglycolic acid copolymers. Athanasiou KA, et al. **Biomaterials** 1996 Jan; 17(2):93–102 (100 ref.)

STERILIZATION, SEXUAL

see related
PEST CONTROL, BIOLOGICAL

STERILIZATION, TUBAL

A review of safety, efficacy, pros and cons, and issues of puerperal tubal sterilization—an update. Chi IC, et al. **Adv Contracept** 1995 Sep;11(3):187–206 (97 ref.)

Hysteroscopic sterilization. Sciarra JJ, et al. **Obstet Gynecol Clin North Am** 1995 Sep;22(3):581–9 (20 ref.)

Multidisciplinary experience in the selection of patients for tubal sterilization. Barini R, et al. **Rev Paul Med** 1995 Jan–Feb;113(1):715–20 (8 ref.)

STERNOCOSTOCLAVICULAR HYPEROSTOSIS see **HYPEROSTOSIS, STERNOCOSTOCLAVICULAR**

STERNUM

Primary sternal osteomyelitis. Heaton PA, et al. **Pediatr Infect Dis J** 1995 Aug;14(8):722–3 (6 ref.)

[Primary acute osteomyelitis of the sternum associated with anterior mediastinitis] Tabib W, et al. **J Chir (Paris)** 1996 Jan;133(1):20–2 (10 ref.) (Eng. Abstr.) **(Fre)**

ABNORMALITIES

[Mento-sternal fistulae. Review of the literature. Apropos of 4 cases] Sfeir R, et al. **Ann Chir Plast Esthet** 1995 Apr; 40(2):176–81 (19 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

The combined cervical and partial sternotomy approach for thymectomy. LoCicero J 3rd. **Chest Surg Clin N Am** 1996 Feb;6(1):85–93 (2 ref.)

Extended transsternal thymectomy. Mulder DG. **Chest Surg Clin N Am** 1996 Feb;6(1):95–105 (7 ref.)

Transverse sternothoracotomy. Wright C. **Chest Surg Clin N Am** 1996 Feb;6(1):149–56 (7 ref.)

STEROID 11-HYDROXYLASE

see related
ADRENAL HYPERPLASIA, CONGENITAL

DEFICIENCY

[11-beta-hydroxylase deficiency and glucocorticoid-sensitive hyperaldosteronism] Merino Arribas JM, et al. **An Esp Pediatr** 1996 Jun;44(6):609–11 (12 ref.) **(Spa)**

STEROID 21-HYDROXYLASE

DEFICIENCY

[21-hydroxylase deficiency. Review of the biochemical characteristics and their diagnostic implications] Campos López-Carrión M, et al. **Rev Clin Esp** 1995 Aug; 195(8):571–7 (81 ref.) **(Spa)**

STEROID HYDROXYLASES

GENETICS

The CYP2A gene subfamily: species differences, regulation, catalytic activities and role in chemical carcinogenesis. Fernandez-Salguero P, et al. **Pharmacogenetics** 1995;5 Spec No:S123–8 (56 ref.)

Transcriptional regulation of the genes encoding the cytochrome P-450 steroid hydroxylases. Parker KL, et al. **Vitam Horm** 1995;51:339–70 (121 ref.)

METABOLISM

Recent progress in enzymology and molecular biology of enzymes involved in vitamin D metabolism. Okuda K, et al. **J Lipid Res** 1995 Aug;36(8):1641–52 (89 ref.)

STEROID ISOMERASES

DEFICIENCY

[Congenital disorders of the bile acid metabolism (3

beta-hydroxy-delta 5-steroid dehydrogenase/isomerase deficiency, delta 4-3-oxosteroid 5 beta-reductase deficiency, cerebrotendinous xanthomatosis, and peroxisomal disorders] Kondo KH, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):362-6 (23 ref.) **(Jpn)**

STEROID 11-MONOOXYGENASE see **STEROID 11-HYDROXYLASE**

STEROID 21-MONOOXYGENASE see **STEROID 21-HYDROXYLASE**

STEROID MONOOXYGENASES see **STEROID HYDROXYLASES**

STEROID RECEPTORS see **RECEPTORS, STEROID**

STEROIDAL ANTI-INFLAMMATORY AGENTS see **ANTI-INFLAMMATORY AGENTS, STEROIDAL**

STEROIDS

see related
RECEPTORS, STEROID

ADMINISTRATION & DOSAGE

Long-term gonadotropin-releasing hormone agonist therapy: the evolving issue of steroidal "add-back" paradigms. Adashi EY. **Keio J Med** 1995 Dec;44(4):124-32 (120 ref.)

ADVERSE EFFECTS

Cutaneous alternariosis in an immunocompromised patient. Chaidemenos GC, et al. **Cutis** 1995 Sep;56(3):145-50 (40 ref.)

Complications associated with epidural steroid injections. Abram SE, et al. **Reg Anesth** 1996 Mar-Apr;21(2):149-62 (134 ref.)

BIOSYNTHESIS

Endocrine, paracrine and autocrine regulation of testicular steroidogenesis. Huhtaniemi I, et al. **Adv Exp Med Biol** 1995;377:33-54 (145 ref.)

Placental steroid hormone synthesis: unique features and unanswered questions. Strauss JF 3rd, et al. **Biol Reprod** 1996 Feb;54(2):303-11 (73 ref.)

Routes and regulation of NADPH production in steroidogenic mitochondria. Hanukoglu I, et al. **Endocr Res** 1995 Feb-May;21(1-2):231-41 (46 ref.)

Perilipin: possible roles in structure and metabolism of intracellular neutral lipids in adipocytes and steroidogenic cells. Londos C, et al. **Int J Obes Relat Metab Disord** 1996 Mar;20 Suppl 3:S97-101 (13 ref.)

Mitochondrial specificity of the early steps in steroidogenesis. Miller WL. **J Steroid Biochem Mol Biol** 1995 Dec; 55(5-6):607-16 (114 ref.)

IMMUNOLOGY

The Ku autoantigen: cast in a new light. Robinson A. **Can Med Assoc J** 1996 Jun 15;154(12):1871-3 (8 ref.)

METABOLISM

A putative receptor for neurosteroids on the GABAA receptor complex: the pharmacological properties and therapeutic potential of epalons. Gee KW, et al. **Crit Rev Neurobiol** 1995;9(2-3):207-27 (102 ref.)

Steroid hormones. Membrane transporters of steroid hormones. Thompson EB. **Curr Biol** 1995 Jul 1;5(7):730-2 (12 ref.)

[Cell membrane targets and steroid hormones: the beginning or end of the dispute?] Sergeev PV, et al. **Biull Eksp Biol Med** 1995 Oct;120(10):342-8 (22 ref.) **(Rus)**

PHARMACOLOGY

Neurosteroids: synthesis and functions in the central and peripheral nervous systems. Schumacher M, et al. **Ciba Found Symp** 1995;191:90-106; discussion 106-12 (50 ref.)

Steroid hormone effects on neurons subserving behavior. Weeks JC, et al. **Curr Opin Neurobiol** 1995 Dec;5(6):809-15 (57 ref.)

Research and development of aminosteroid neuromuscular blocking agents: past and future. Marshall RJ, et al. **Eur J Anaesthesiol Suppl** 1995 Sep;11:5-10 (19 ref.)

The sexually dimorphic medial preoptic nucleus of quail: a key brain area mediating steroid action on male sexual behavior. Panzica GC, et al. **Front Neuroendocrinol** 1996 Jan;17(1):51-125 (287 ref.)

Neurosteroids and GABAA receptor function. Lambert JJ, et al. **Trends Pharmacol Sci** 1995 Sep;16(9):295-303 (52 ref.)

[Steroid modulation of GABA(A) receptors] Gniot-Szulżycka J, et al. **Postepy Hig Med Dosw** 1995; 49(3):409-24 (71 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOLOGY

Oestrogen-responsive finger protein suggests a transcriptional cascade of steroid hormone regulation. **Ciba Found Symp** 1995;191:43-51 (18 ref.)

Non-genomic mechanisms of action of steroid hormones. Baulieu EE, et al. **Ciba Found Symp** 1995;191:24-37; discussion 37-42 (66 ref.)

Sex steroids and the immune system. Fox HS. **Ciba Found Symp** 1995;191:203-11; discussion 211-7 (31 ref.)

Sex steroids, cytokines and the bone marrow: new concepts on the pathogenesis of osteoporosis. Manolagas SC, et al. **Ciba Found Symp** 1995;191:187-96; discussion 197-202 (45 ref.)

Actions of sex steroids on behaviours beyond reproductive reflexes. Priest CA, et al. **Ciba Found Symp** 1995;191:74-84; discussion 84-9 (69 ref.)

Steroidal regulation of cell cycle progression. Sutherland RL, et al. **Ciba Found Symp** 1995;191:218-28; discussion 228-34 (29 ref.)

Transcriptional control by steroid hormones: the role of chromatin. Truss M, et al. **Ciba Found Symp** 1995;191:7-17; discussion 17-23 (45 ref.)

Steroid hormone signalling system and fungi. Zakelj-Mavrič M, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1995 Dec;112(4):637-42 (69 ref.)

Neurosteroids: biosynthesis and function. Robel P, et al. **Crit Rev Neurobiol** 1995;9(4):383-94 (52 ref.)

Steroid hormone effects on neurons subserving behavior. Weeks JC, et al. **Curr Opin Neurobiol** 1995 Dec;5(6):809-15 (57 ref.)

Steroid hormones and adipose tissue [comment] Prins JB, et al. **Eur J Clin Invest** 1996 Apr;26(4):259-61 (24 ref.) Comment on: Eur J Clin Invest 1996 Apr;26(4):262-9.

Endocrine glia: roles of glial cells in the brain actions of steroid and thyroid hormones and in the regulation of hormone secretion. Garcia-Segura LM, et al. **Front Neuroendocrinol** 1996 Apr;17(2):180-211 (253 ref.)

Molecular basis of neuronal plasticity to gonadal steroids. Matsumoto A, et al. **Funct Neurol** 1995 Mar-Apr; 10(2):59-76 (137 ref.)

Sex steroid regulation of growth hormone secretion and action. Ho KK, et al. **Horm Res** 1996;45(1-2):67-73 (53 ref.)

Looking beyond the dogma of genomic steroid action: insights and facts of the 1990s. Wehling M. **J Mol Med** 1995 Sep;73(9):439-47 (88 ref.)

Neurosteroids: molecular mechanisms of action and psychopharmacological significance. Rupprecht R, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1-6 Spec No):163-8 (50 ref.)

Sex steroid hormones and macrophage function. Miller L, et al. **Life Sci** 1996;59(1):1-14 (186 ref.)

Roles of steroid hormones and their receptors in structural organization in the nervous system. Kawata M. **Neurosci Res** 1995 Dec;24(1):1-46 (655 ref.)

Molecular genetic studies confirm the role of brassinosteroids in plant growth and development. Clouse SD. **Plant J** 1996 Jul;10(1):1-8 (61 ref.)

Phosphorylation and steroid hormone action. Bai W, et al. **Vitam Horm** 1995;51:289-313 (115 ref.)

[Function of endogenous opioid peptides and sex steroids at the level of the central nervous system] Bidzińska B, et al. **Postepy Hig Med Dosw** 1995;49(4):523-30 (44 ref.) (Eng. Abstr.) **(Pol)**

THERAPEUTIC USE

Symptoms related to the menopause and sex steroid treatments. Bäckström T. **Ciba Found Symp** 1995; 191:171-80; discussion 180-6 (55 ref.)

The thrombocytopenic purpuras. Recognition and management. Gillis S. **Drugs** 1996 Jun;51(6):942-53 (104 ref.)

Steroid anesthetics: old compounds, new drugs. Sear JW. **J Clin Anesth** 1996 May;8(3 Suppl):91S-98S (70 ref.)

[Treatment of acute bronchiolitis in infants. Role of bronchodilators and steroids] Labbé A. **Arch Pediatr** 1996 Apr;3(4):383-9 (76 ref.) (Eng. Abstr.) **(Fre)**

[The use of steroids in asthmatic children] Meza Morales A, et al. **Rev Alerg Mex** 1995 Jul-Aug;42(4):74-7 (19 ref.) (Eng. Abstr.) **(Spa)**

[Prophylactic treatment of chronic cluster headache] Alberca R. **Rev Neurol** 1995;23 Suppl 4:S530-4 (55 ref.) **(Spa)**

TOXICITY

Steroids, hypertension and cardiac fibrosis. Funder JW. **Blood Press Suppl** 1995;2:39-42 (15 ref.)

STEROIDS, ANABOLIC see **ANABOLIC STEROIDS**

STEROIDS, HETEROCYCLIC

METABOLISM

Green light for steroid hormones [comment] Russell DW. **Science** 1996 Apr 19;272(5260):370-1 (7 ref.) Comment on: Science 1996 Apr 19;272(5260):398-401.

STEROLS

METABOLISM

Physiological implications of sterol biosynthesis in yeast. Parks LW, et al. **Annu Rev Microbiol** 1995;49:95-116 (121 ref.)

PHARMACOLOGY

Biological effects of oxysterols: current status. Guardiola F, et al. **Food Chem Toxicol** 1996 Feb;34(2):193-211 (215 ref.)

STEVENS-JOHNSON SYNDROME

COMPLICATIONS

Bronchiolitis obliterans in children with Stevens-Johnson syndrome: follow-up with high resolution CT. Kim MJ, et al. **Pediatr Radiol** 1996;26(1):22-5 (9 ref.)

ETIOLOGY

[Stevens-Johnson syndrome and toxic epidermal necrolysis; therapy policy in these life-threatening illnesses. Netherlands Work Group Toxic Epidermal Necrolysis] van der Meer JB. **Ned Tijdschr Geneeskd** 1996 Jul 27; 140(30):1538-43 (29 ref.) **(Dut)**

IMMUNOLOGY

Immunopathology of Stevens-Johnson syndrome. Guitart J. **Allergy Proc** 1995 Jul-Aug;16(4):163-4 (9 ref.)

PATHOLOGY

Immunopathology of Stevens-Johnson syndrome. Guitart J. **Allergy Proc** 1995 Jul-Aug;16(4):163-4 (9 ref.)

STICKLEBACKS see **FISHES**

STIFF-MAN SYNDROME

DRUG THERAPY

Stiff-person syndrome with anti-glutamic acid decarboxylase autoantibodies: complete remission of symptoms after intrathecal baclofen administration. Seitz RJ, et al. **J Neurol** 1995 Oct;242(10):618-22 (32 ref.)

IMMUNOLOGY

The clinical significance of an autoimmune response against glutamic acid decarboxylase. Ellis TM, et al. **Nat Med** 1996 Feb;2(2):148-53 (30 ref.)

THERAPY

[Marked clinical improvement by plasmapheresis in a patient with stiff-man syndrome: a case with a negative anti-GAD antibody] Nakamagoe K, et al. **Rinsho Shinkeigaku** 1995 Aug;35(8):897-900 (12 ref.) (Eng. Abstr.) **(Jpn)**

STIFLE

INJURIES

Stifle injuries in cattle. Ducharme NG. **Vet Clin North Am Food Anim Pract** 1996 Mar;12(1):59-84 (42 ref.)

STIGMATIZATION see **CHRISTIANITY**

STILBESTROL see **DIETHYLSTILBESTROL**

STILLBIRTH see **FETAL DEATH**

STILL'S DISEASE, ADULT-ONSET

BLOOD

[Adult-onset Still's disease] Dalzotto R, et al. **Rev Med Suisse Romande** 1996 Jun;116(6):459-62 (36 ref.) **(Fre)**

COMPLICATIONS

[Association of Takayasu's arteritis, pregnancy and Still's disease] Fignon A, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(7):747-50 (13 ref.) (Eng. Abstr.) **(Fre)**

[A case of adult onset Still's disease complicated with adult respiratory distress syndrome and disseminated intravascular coagulation] Yokoyama M, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1995 Apr;18(2):207-14 (31 ref.) (Eng. Abstr.) **(Jpn)**

STILL'S DISEASE, JUVENILE-ONSET see **ARTHRITIS, JUVENILE RHEUMATOID**

STIMULATION, ACOUSTIC see **ACOUSTIC STIMULATION**

STIMULATION, AUDITORY see **ACOUSTIC STIMULATION**

STIMULATION, CHEMICAL

see related
ENZYME INDUCTION

STIMULATION, ELECTRIC see **ELECTRIC STIMULATION**

STIMULATION, PHOTIC see **PHOTIC STIMULATION**

STINGS

STINGS see BITES AND STINGS

STIPPLED EPIPHYSES see CHONDRODYSPLASIA PUNCTATA

STLV-III see SIV

STOCKINGS, COMPRESSION see BANDAGES

STOCKINGS, ELASTIC see BANDAGES

STOICISM see PHILOSOPHY

STOMACH

see related
FUNDOPLICATION
GASTRECTOMY
GASTROSCOPY
GASTROSTOMY

Gastric bezoar following penetrating abdominal injury. Diagnosis and endoscopic therapy. Kaplan LJ, et al. **Surg Endosc** 1996 Jan;10(1):62–4 (16 ref.)

BLOOD SUPPLY

Wegener's granulomatosis complicated by arterial aneurysm. Aoki N, et al. **Intern Med** 1995 Aug;34(8):790–3 (14 ref.)

Systemic multiple aneurysms of the intracranial arteries and visceral arteries: case report. Fuse T, et al. **Surg Neurol** 1996 Sep;46(3):258–61; discussion 261–2 (13 ref.)

Arterial vasculature of the stomach and oncologic gastrectomies. Guadagni S, et al. **Surg Radiol Anat** 1995; 17(3):269–76 (40 ref.)

CYTOLOGY

New insights into the stem cells and the precursors of the gastric epithelium. Karam SM. **Nutrition** 1995 Sep–Oct; 11(5 Suppl):607–13 (27 ref.)

DRUG EFFECTS

Nonsteroidal anti-inflammatory drugs: gastroduodenal injury and beyond. Bernsdorff KR, et al. **Dig Dis** 1995 Jul–Aug; 13(4):251–66 (134 ref.)

[Helicobacter pylori, nonsteroidal anti-inflammatory agents and gastroduodenal changes] Teixeira AV. **Acta Med Port** 1995 Sep;8(9):517–21 (70 ref.) (Eng. Abstr.) **(Por)**

ENZYMOLOGY

[The physiological and pathologic role of human gastric lipase] Tomasik P. **Przegl Lek** 1995;52(6):323–5 (20 ref.) **(Pol)**

INJURIES

Corrosive injuries of the oesophagus and stomach: experience in management at a regional paediatric centre. Stiff G, et al. **Ann R Coll Surg Engl** 1996 Mar;78(2):119–23 (68 ref.)

INNERVATION

[Regulation of food intake] Schusdziarra V. **Zentralbl Chir** 1996;121(5):354–7 (34 ref.) (Eng. Abstr.) **(Ger)**

METABOLISM

Gastric intrinsic factor and its receptor. Nicolas JP, et al. **Baillieres Clin Haematol** 1995 Sep;8(3):515–31 (99 ref.)

[Nitric oxide and oxidative metabolism: heads or tails in inflammatory gastric disease] Esteban Carretero J, et al. **Rev Esp Enferm Dig** 1996 Jun;88(6):423–30 (90 ref.) **(Spa)**

PATHOLOGY

Biology of gastric cancer: gastritis–metaplasia–dysplasia sequence, role of H Pylori, and molecular correlates of tumor progression. Lynch P. **J Infus Chemother** 1995 Summer;5(3):93–6 (23 ref.)

The consequences of hypergastrinemia. Creutzfeldt W. **Yale J Biol Med** 1994 May–Aug;67(3–4):181–94 (63 ref.)

[How to look for Helicobacter pylori?] Mégraud F. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S38–S43 (35 ref.) **(Fre)**

[A case report: giant gastric leiomyosarcoma, showing pedunculated extragastric development] Inoue K, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Dec;92(12):1942–6 (19 ref.) **(Jpn)**

PHYSIOLOGY

Barrier function of the gastric mucus gel. Engel E, et al. **Am J Physiol** 1995 Dec;269(6 Pt 1):G994–9 (33 ref.)

Basic actions of transforming growth factor–alpha and related peptides. Coffey RJ, et al. **Eur J Gastroenterol Hepatol** 1995 Oct;7(10):923–7 (49 ref.)

Control of motor and secretory functions of the stomach by a portal glucose signal. Sakaguchi T. **Neurosci Biobehav Rev** 1995 Fall;19(3):469–78 (134 ref.)

Vagal regulation of acid secretion and gastrin release. Debas HT, et al. **Yale J Biol Med** 1994 May–Aug;67(3–4):145–51 (25 ref.)

The biology and physiology of the ECL cell. **Håkanson R**, et al. **Yale J Biol Med** 1994 May–Aug;67(3–4):123–34 (50 ref.)

PHYSIOPATHOLOGY

Clinical significance of gastric myoelectrical dysrhythmias. Chen JD, et al. **Dig Dis** 1995 Sep–Oct;13(5):275–90 (103 ref.)

RADIONUCLIDE IMAGING

Recent advances in gastric emptying scintigraphy. Urbain JL, et al. **Semin Nucl Med** 1995 Oct;25(4):318–25 (38 ref.)

SURGERY

Minimal access surgery—the renaissance of gastric surgery? McCloy R, et al. **Yale J Biol Med** 1994 May–Aug; 67(3–4):159–66 (38 ref.)

[Current technique of gastric plasties in esophageal surgery] Ségol P, et al. **Ann Chir** 1996;50(1):13–22 (24 ref.) **(Fre)**

STOMACH DILATATION

DIAGNOSIS

Acute gastric dilatation in Duchenne muscular dystrophy: a case report and review of the literature. Bensen ES, et al. **Arch Phys Med Rehabil** 1996 May;77(5):512–4 (19 ref.)

STOMACH DISEASES

[Diffuse gastric angiomatosis. A clinical case. Review of the literature] Germain MA, et al. **Chirurgie** 1996;121(1):11–4 (20 ref.) (Eng. Abstr.) **(Fre)**

[Cholecystogastric fistula, cholecystoenteric fistula] Souda S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):436–8 (8 ref.) **(Jpn)**

[Gastric phlegmon] Kurguzov OP, et al. **Khirurgiia (Mosk)** 1995;(6):52–5 (76 ref.) **(Rus)**

CHEMICALLY INDUCED

NSAID gastropathy. A new understanding. Roth SH. **Arch Intern Med** 1996 Aug 12–26;156(15):1623–8 (82 ref.)

CLASSIFICATION

Classification of gastric lesions associated with portal hypertension. Hashizume M, et al. **J Gastroenterol Hepatol** 1995 May–Jun;10(3):339–43 (20 ref.)

COMPLICATIONS

Gastric tuberculosis presenting with massive hematemesis in association with acute myeloid leukemia. Quantrill SJ, et al. **Am J Gastroenterol** 1996 Jun;91(6):1259–60 (11 ref.)

Gastroduodenal dyspepsia: a personal view integrating clinical, endoscopic, histological and management criteria. The spiro syndrome. DeLuca VA Jr. **Dig Dis** 1996 Jan–Feb;14(1):27–42 (37 ref.)

Gastric secretion and the pathogenesis of peptic ulcer in the Helicobacter pylori infection. Konturek PC, et al. **J Physiol Pharmacol** 1996 Mar;47(1):5–19 (80 ref.)

CONGENITAL

Gastroduodenal disorders associated with emesis in infants. Reyna TM, et al. **Semin Pediatr Surg** 1995 Aug;4(3):190–7 (38 ref.)

DIAGNOSIS

[Endoscopy of the upper gastrointestinal tract in HIV disease] Caca K, et al. **Bildgebung** 1995 Dec;62(4):244–51 (56 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Bismuth therapy for Helicobacter pylori infection. A review of five years experience at a university hospital in Norway. Berstad A, et al. **J Physiol Pharmacol** 1996 Mar;47(1):31–49 (45 ref.)

ETIOLOGY

[Gastric mucosal lesion and free radicals] Hiraishi H, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Nov; 92(11):1817–24 (39 ref.) **(Jpn)**

[A case of gastric cancer associated with esophageal–hiatus hernia presenting with upside down stomach] Satoh K, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Jan;93(1):26–9 (12 ref.) **(Jpn)**

[The gastropathy of portal hypertension] Piqué JM. **Med Clin (Barc)** 1995 Oct 14;105(12):470–5 (57 ref.) **(Spa)**

MICROBIOLOGY

Clinical expressions of Helicobacter pylori infection. Howden CW. **Am J Med** 1996 May 20;100(5A):27S–32S; discussion 32S–34S (48 ref.)

PATHOLOGY

Gastric gland heterotopia with extensive lymphoid stroma: a gastric lymphoepithelial cyst. Delvaux S, et al. **Am J Gastroenterol** 1996 Mar;91(3):599–601 (17 ref.)

[A case report of epithelioid smooth muscle tumor (leiomyoblastoma) of the stomach prolapsing into the duodenal bulbus] Takashima Y, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Nov; 92(11):1858–62 (16 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Helicobacter pylori infection and gastric motor dysfunction. Wingate DL. **J Physiol Pharmacol** 1996 Mar;47(1):21–9 (0 ref.)

VETERINARY

Diagnosis and treatment of gastric disease. Strombeck DR. **Vet Q** 1995 Apr;17 Suppl 1:S11–2 (0 ref.)

Abomasal displacement in the bovine—a review on character, occurrence, aetiology and pathogenesis. Geishauser T. **Zentralbl Veterinarmed A** 1995 Jun; 42(4):229–51 (253 ref.)

[Right displacement of the abomasum in cattle. 1. Pathogenesis, clinical course and prognosis] Kümper H. **Tierarztl Prax** 1995 Aug;23(4):351–9 (30 ref.) (Eng. Abstr.) **(Ger)**

STOMACH NEOPLASMS

Mechanisms and management of gastric cancer. A comparison between the Japanese and U.S. experiences. Onishi K, et al. **Cancer Nurs** 1996 Jun;19(3):187–96 (18 ref.)

Early detection and treatment of oesophageal and gastric cancer. The Rotterdam Oesophageal Tumour Study Group. Siersema PD, et al. **Neth J Med** 1995 Aug; 47(2):76–86 (69 ref.)

Gastric cancer. McCulloch P. **Postgrad Med J** 1996 Aug; 72(850):450–7 (73 ref.)

Carcinogenesis after remote peptic ulcer surgery: the long–term prognosis of partial gastrectomy. Tersmette AC, et al. **Scand J Gastroenterol Suppl** 1995;212:96–9 (49 ref.)

[Gastroenterologic progresses in China, 1995] Fan D, et al. **Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):716–7 (0 ref.) **(Chi)**

[Atopic stomach polyp as the cause of invagination of Meckel's diverticulum] Schütter FW, et al. **Chirurg** 1995 Oct;66(10):1016–8 (24 ref.) (Eng. Abstr.) **(Ger)**

[Gastric leiomyoblastoma: report of our case load] Canini T, et al. **Ann Ital Chir** 1995 May–Jun;66(3):329–34 (30 ref.) (Eng. Abstr.) **(Ita)**

[Appearance in 2 brothers of double primary neoplasms: right renal carcinoma and gastric adenocarcinoma] Casetta G, et al. **Minerva Urol Nefrol** 1995 Mar;47(1):49–51 (11 ref.) (Eng. Abstr.) **(Ita)**

[Gastric cancer in children: report of a case] Berrospi Espinoza F, et al. **Rev Gastroenterol Peru** 1995 Sep–Dec; 15(3):296–8 (16 ref.) (Eng. Abstr.) **(Spa)**

BLOOD

Marked elevation of plasma carcinoembryonic antigen and stomach carcinoma. Horie Y, et al. **Cancer** 1996 May 15; 77(10):1991–7 (21 ref.)

CHEMICALLY INDUCED

Fish models for environmental carcinogenesis: the rainbow trout. Bailey GS, et al. **Environ Health Perspect** 1996 Mar; 104 Suppl 1:5–21 (174 ref.)

CLASSIFICATION

[A new histological classification of cancers of the stomach] Paraf F. **Gastroenterol Clin Biol** 1995 Oct;19(10):858–60 (12 ref.) **(Fre)**

COMPLICATIONS

Hemoperitoneum secondary to exogastric leiomyosarcoma: a case report. Tsianos GB, et al. **Hepatogastroenterology** 1995 Nov–Dec;42(6):885–7 (10 ref.)

Glomerulonephritis associated with malignant diseases of non–renal origin. A report of three cases and a review of the literature. Wągrowska–Danilewicz M, et al. **Pol J Pathol** 1995;46(3):195–8 (20 ref.)

[A case of gastric cancer associated with esophageal–hiatus hernia presenting with upside down stomach] Satoh K, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Jan;93(1):26–9 (12 ref.) **(Jpn)**

[Watermelon stomach and gastric carcinoid tumor in a cirrhotic patient] Oliveira CV, et al. **Arq Gastroenterol** 1995 Apr–Jun;32(2):66–70 (34 ref.) (Eng. Abstr.) **(Por)**

DIAGNOSIS

Detection and management of advanced gastric cancer. Hohenberger P, et al. **Ann Oncol** 1996 Feb;7(2):197–203 (44 ref.)

Eight cases of gastric tumors with calcification. Ichiishi E, et al. **Intern Med** 1995 Oct;34(10):1038–42 (11 ref.)

Diagnosis and staging of gastric cancer. Halvorsen RA Jr, et al. **Semin Oncol** 1996 Jun;23(3):325–35 (30 ref.)

Gastric cancer and pernicious anemia appearing as pseudoachalasia. el–Newihi HM, et al. **South Med J** 1996 Sep;89(9):906–10 (30 ref.)

[Gastric carcinoid. A clinical case and review of the literature] Capece G, et al.

Minerva Gastroenterol Dietol 1996 Mar;42(1):45–9 (11 ref.) (Eng. Abstr.) **(Ita)**

DRUG THERAPY

Adjuvant therapy for resectable gastric adenocarcinoma: preoperative and postoperative chemotherapy trials. Leach SD, et al. **J Infus Chemother** 1995 Summer;5(3):104–11 (46 ref.)

The role of chemotherapy for metastatic gastric cancer. O'Brien ME, et al. **J Infus Chemother** 1995 Summer; 5(3):112–6 (45 ref.)

Interferon–induced acute renal failure: a case report and literature review. Horowitz R, et al. **Med Oncol** 1995 Mar; 12(1):55–7 (10 ref.)

Adjuvant therapy of gastric cancer: the Japanese experience. Fukushima M. **Semin Oncol** 1996 Jun;23(3):369–78 (52 ref.)

Adjuvant and neoadjuvant therapy for gastric cancer. Kelsen DP. **Semin Oncol** 1996 Jun;23(3):379–89 (48 ref.)

The treatment of advanced gastric cancer. Wils J. **Semin Oncol** 1996 Jun;23(3):397–406 (73 ref.)

[Photodynamic therapy for gastric cancer] Mimura S, et al. **Gan To Kagaku Ryoho** 1996 Jan;23(1):41–6 (5 ref.) (Eng. Abstr.) **(Jpn)**

[Survival and changes of clinical laboratory data in phase II study with 5'-DFUR] Taguchi T. **Gan To Kagaku Ryoho** 1996 Jul;23(8):1019–29 (31 ref.) (Eng. Abstr.) **(Jpn)**

[Adjuvant chemotherapy for advanced gastric cancer] Furukawa H, et al. **Nippon Geka Gakkai Zasshi** 1996 Apr; 97(4):312–6 (24 ref.) (Eng. Abstr.) **(Jpn)**

[Adjuvant chemotherapy of gastric cancer] Shparik IaV. **Klin Khir** 1995;(5):38–41 (36 ref.) **(Ukr)**

ENZYMOLOGY

[The locus of pepsinogen A: molecular biologic studies in the carcinogenesis of gastric cancer] Shumakov AR, et al. **Vopr Onkol** 1996;42(2):7–11 (50 ref.) **(Rus)**

EPIDEMIOLOGY

The relationship between gastric cancer frequency and the ratio of gastric to duodenal ulcer. Correa P, et al. **Aliment Pharmacol Ther** 1995;9 Suppl 2:13–9 (26 ref.)

Gastric premalignancy and cancer screening in high–risk patients. Yoshida S, et al. **Am J Gastroenterol** 1996 May; 91(5):839–43 (24 ref.)

Helicobacter pylori as a risk factor for cancer. Webb PM, et al. **Baillieres Clin Gastroenterol** 1995 Sep;9(3):563–82 (109 ref.)

Primary gastric T–cell lymphoma with cutaneous involvement. A case report and review of the literature. Naghavi R, et al. **J Clin Gastroenterol** 1995 Dec;21(4):312–6 (17 ref.)

Epidemiology of gastric cancer. Neugut AI, et al. **Semin Oncol** 1996 Jun;23(3):281–91 (90 ref.)

Epithelioid gastric stromal tumors (leiomyoblastomas): a study of fifty–five cases. Lee JS, et al. **Surgery** 1995 Oct; 118(4):653–60; discussion 660–1 (19 ref.)

[Stomach cancer: what's new? (editorial)] Faivre J, et al. **Gastroenterol Clin Biol** 1995 Oct;19(10):793–6 (22 ref.) **(Fre)**

ETIOLOGY

Helicobacter pylori, duodenal ulcer, gastric cancer: tunnel vision or blinders? Graham DY, et al. **Ann Med** 1995 Oct; 27(5):589–94 (27 ref.)

Peptic ulcers and gastric cancer. Mera SL. **Br J Biomed Sci** 1995 Dec;52(4):271–81 (59 ref.)

Biology of gastric cancer: gastritis–metaplasia–dysplasia sequence, role of H Pylori, and molecular correlates of tumor progression. Lynch P. **J Infus Chemother** 1995 Summer;5(3):93–6 (23 ref.)

Helicobacter pylori infection and gastric cancer. Goldstone AR, et al. **J Pathol** 1996 Jun;179(2):129–37 (117 ref.)

Helicobacter pylori and gastric neoplasia: evolving concepts. Bolin TD, et al. **Med J Aust** 1995 Sep 4;163(5):253–5 (18 ref.)

Bacteria in the aetio–pathogenesis of gastric cancer: a review. Houben GM, et al. **Scand J Gastroenterol Suppl** 1995; 212:13–8 (61 ref.)

[Should Helicobacter pylori be eradicated in a patient with chronic gastritis?] Bouché O. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S143–S153 (127 ref.) **(Fre)**

[Management of stomach ulcer except in emergency: surgical treatment] Lacaine F. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S81–S83 (16 ref.) **(Fre)**

[Neuropsychiatric symptoms in vitamin B12 deficiency and microcarcinoidosis. The complications of chronic atrophic gastritis] Ossege LM, et al. **Dtsch Med Wochenschr** 1996 Jun 7;121(23):758–62 (25 ref.) (Eng. Abstr.) **(Ger)**

[Primary gastric lymphoma of the MALT type. The current knowledge on its etiology, therapy and prognosis] Fischbach W, et al. **Strahlenther Onkol** 1995 Oct; 171(10):549–53 (16 ref.) (Eng. Abstr.) **(Ger)**

[Helicobacter pylori and gastric cancer] León–Barúa R, et al. **Rev Gastroenterol Peru** 1995;15 Suppl 1:S23–7 (38 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

Genetics of gastric cancer. Peddanna N, et al. **Anticancer Res** 1995 Sep–Oct;15(5B):2055–64 (115 ref.)

Nutritional intervention to prevent hereditary cancer. Taylor PR, et al. **J Natl Cancer Inst Monogr** 1995;(17):43–7 (19 ref.)

Molecular biological observations in gastric cancer. Tahara E, et al. **Semin Oncol** 1996 Jun;23(3):307–15 (54 ref.)

[Genetic alterations in stomach cancer] Tahara E, et al. **Nippon Geka Gakkai Zasshi** 1996 Apr;97(4):252–6 (23 ref.) (Eng. Abstr.) **(Jpn)**

MICROBIOLOGY

Helicobacter pylori infection and gastric cancer: usefulness of screening high risk groups. Buckley M, et al. **Acta Gastroenterol Belg** 1995 Sep–Dec;58(5–6):382–7 (34 ref.)

Gastric carcinoma: the Helicobacter pylori trail. Deltenre M, et al. **Acta Gastroenterol Belg** 1995 Mar–Apr; 58(2):193–200 (56 ref.)

The prevalence of Helicobacter pylori infection in gastric cancer. Forman D. **Aliment Pharmacol Ther** 1995;9 Suppl 2:71–6 (36 ref.)

Primary gastric lymphoma. Isaacson PG. **Br J Biomed Sci** 1995 Dec;52(4):291–6 (40 ref.)

Helicobacter pylori as a promoter of intestinal metaplasia and gastric cancer: an alluring hypothesis in search of evidence. Genta RM. **Eur J Gastroenterol Hepatol** 1995 Aug;7 Suppl 1:S25–30 (53 ref.)

Helicobacter pylori, gastric cancer and gastric epithelial kinetics: a review. Lynch DA, et al. **Eur J Gastroenterol Hepatol** 1995 Aug;7 Suppl 1:S17–23 (69 ref.)

H. pylori infection: its role in chronic gastritis, carcinoma and peptic ulcer. Pajares JM. **Hepatogastroenterology** 1995 Nov–Dec;42(6):827–41 (141 ref.)

The significance of Helicobacter pylori colonization of the stomach. Cilley RE, et al. **Semin Pediatr Surg** 1995 Nov; 4(4):221–7 (68 ref.)

[Helicobacter pylori and gastric cancer] Tanida N, et al. **Nippon Geka Gakkai Zasshi** 1996 Apr;97(4):257–62 (41 ref.) (Eng. Abstr.) **(Jpn)**

[Helicobacter pylori infection in peptic ulcer and gastric cancer diseases] Matsukura N, et al. **Nippon Ika Daigaku Zasshi** 1995 Aug;62(4):313–9 (22 ref.) **(Jpn)**

[Helicobacter pylori infection and the risk of gastric cancer] Zaremba–Woroniecka A, et al. **Pol Arch Med Wewn** 1995 Aug;94(2):164–72 (40 ref.) **(Pol)**

PATHOLOGY

Recent developments in our understanding of gastric lymphomas. Isaacson PG. **Am J Surg Pathol** 1996;20 Suppl 1:S1–7 (29 ref.)

Early gastric lymphoma: a clinicopathologic study of ten patients, literature review, and comparison with early gastric adenocarcinoma. Kitamura K, et al. **Cancer** 1996 Mar 1;77(5):850–7 (70 ref.)

Helicobacter pylori, gastric cancer and gastric epithelial kinetics: a review. Lynch DA, et al. **Eur J Gastroenterol Hepatol** 1995 Aug;7 Suppl 1:S17–23 (69 ref.)

Primary tumour staging of gastric and colorectal cancer. Bruneton JN, et al. **Eur Radiol** 1996;6(2):140–6 (45 ref.)

Synchronous adenocarcinoma and low grade B–cell lymphoma of mucosa associated lymphoid tissue (MALT) of the stomach. Wotherspoon AC, et al. **Histopathology** 1995 Oct;27(4):325–31 (45 ref.)

Tonsillar metastasis from adenocarcinoma of the stomach. Benito I, et al. **J Laryngol Otol** 1996 Mar;110(3):291–3 (15 ref.)

Early gastric cancer of adenosquamous carcinoma type: report of a case and review of literature. Yoshida K, et al. **Jpn J Clin Oncol** 1996 Aug;26(4):252–7 (21 ref.)

Endocrine tumours of the stomach. Bordi C. **Pathol Res Pract** 1995 May;191(4):373–80 (33 ref.)

Primary non–Hodgkin lymphoma of the gastric stump. Vanbockrijck M, et al. **Pathol Res Pract** 1995 Jul; 191(6):525–9 (18 ref.)

Primary gastric lymphoma. Lopez M, et al. **Riv Eur Sci Med Farmacol** 1994 Sep–Dec;16 Suppl 1:31–7 (41 ref.)

Signet ring cell carcinoma in hyperplastic polyp. Zea–Iriarte WL, et al. **Scand J Gastroenterol** 1995 Jun;30(6):604–8 (26 ref.)

The pathological sequence in the development of gastric cancer: I. Hattori T, et al. **Scand J Gastroenterol Suppl** 1996;214:34–5; discussion 40–3 (8 ref.)

Premalignant lesions of the stomach. Ho SB. **Semin Gastrointest Dis** 1996 Apr;7(2):61–73 (85 ref.)

Laparoscopy and laparoscopic ultrasound in the staging of gastric cancer. Conlon KC, et al. **Semin Oncol** 1996 Jun; 23(3):347–51 (22 ref.)

Invasion and metastases in gastric cancer: in vitro and in vivo models with clinical correlations. Schwartz GK. **Semin Oncol** 1996 Jun;23(3):316–24 (31 ref.)

Simultaneous gastric adenocarcinoma and MALT–type lymphoma in Helicobacter pylori infection. von Herbay A, et al. **Virchows Arch** 1995;427(4):445–50 (62 ref.)

Gastric carcinoma arising from a hyperplasiogenic polyp with a diameter of less than 2 centimeters. Gschwantler M, et al. **Z Gastroenterol** 1995 Oct;33(10):610–2 (15 ref.)

[Advances in pathology of several common seen tumors in China] Liu F, et al. **Chung Hua Ping Li Hsueh Tsa Chih** 1995 Aug;24(4):207–9 (20 ref.) **(Chi)**

[Place of celioscopy in the diagnosis of invasiveness of digestive cancers] Chambon JP, et al. **Ann Chir** 1995; 49(6):513–8 (25 ref.) (Eng. Abstr.) **(Fre)**

[Leiomyosarcoma of the stomach—clinical aspects, morphology and therapy] Peitgen K, et al. **Med Klin** 1996 Mar 15;91(3):123–30 (35 ref.) (Eng. Abstr.) **(Ger)**

[Primary non–Hodgkin lymphoma of the stomach—internal medicine aspects] Fischbach W. **Schweiz Rundsch Med Prax** 1995 Nov 28;84(48):1427–31 (18 ref.) (Eng. Abstr.) **(Ger)**

[Pathology and pathogenesis of extranodal lymphomas in the gastrointestinal tract] Müller–Hermelink HK, et al. **Schweiz Rundsch Med Prax** 1995 Nov 28;84(48):1416–22 (22 ref.) (Eng. Abstr.) **(Ger)**

[New concepts on precancerous lesions of the stomach] Mai M, et al. **Gan To Kagaku Ryoho** 1995 Dec;22(14):2029–37 (49 ref.) (Eng. Abstr.) **(Jpn)**

[Biological features determining the chemosensitivity of gastric cancer] Ichiyoshi Y, et al. **Hum Cell** 1995 Dec; 8(4):157–61 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Prophylaxis and treatment of peritoneal metastasis from gastric cancer] Kaibara N. **Nippon Geka Gakkai Zasshi** 1996 Apr;97(4):308–11 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Comparative study on biological difference between gastric cancer and colorectal cancer] Mai M, et al. **Nippon Geka Gakkai Zasshi** 1996 Apr;97(4):263–8 (24 ref.) (Eng. Abstr.) **(Jpn)**

[A case report: giant gastric leiomyosarcoma, showing pedunculated extragastric development] Inoue K, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Dec;92(12):1942–6 (19 ref.) **(Jpn)**

[A case of signet–ring cell gastric cancer appearing an elevated type] Takahashi N, et al. **Nippon Shokakibyo Gakkai Zasshi** 1996 Jan;93(1):30–3 (17 ref.) **(Jpn)**

[A case report of epithelioid smooth muscle tumor (leiomyoblastoma) of the stomach prolapsing into the duodenal bulbus] Takashima Y, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Nov; 92(11):1858–62 (16 ref.) **(Jpn)**

[Concepts related to the course of gastric cancer] Espejo Romero H, et al. **Rev Gastroenterol Peru** 1995;15 Suppl 1:S46–70 (32 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOPATHOLOGY

[Gastric lymphoma: natural history and classification] Ducreux M, et al. **Gastroenterol Clin Biol** 1996;20(5 Pt 2):B105–112 (52 ref.) **(Fre)**

PREVENTION & CONTROL

Nutritional intervention to prevent hereditary cancer. Taylor PR, et al. **J Natl Cancer Inst Monogr** 1995;(17):43–7 (19 ref.)

RADIOGRAPHY

[Diagnostic accuracy of computerized tomography. Preoperative staging of gastric cancer] Zompetta C, et al. **Clin Ter** 1995 Dec;146(12):825–41 (18 ref.) (Eng. Abstr.) **(Ita)**

[Gastric lymphoma: diagnostic radiology in the staging of the disease] Falappa PG, et al. **Riv Eur Sci Med Farmacol** 1994 Sep–Dec;16 Suppl 1:83–8 (8 ref.) (Eng. Abstr.) **(Ita)**

RADIOTHERAPY

The role of irradiation as a component of combined modality treatment for gastric cancer. Gunderson LL, et al. **J Infus Chemother** 1995 Summer;5(3):117–24 (50 ref.)

The role of radiation therapy in gastric cancer. Minsky BD. **Semin Oncol** 1996 Jun;23(3):390–6 (24 ref.)

[Radiotherapy of primary non–Hodgkin lymphoma of the stomach] Hartmann A, et al. **Schweiz Rundsch Med Prax** 1996 Jun 4;85(23):765–70 (45 ref.) (Eng. Abstr.) **(Ger)**

SECONDARY

[Value of surgical treatment in patients with gastrointestinal metastatic tumors] Wang Z, et al. **Chung Hua Wai Ko Tsa Chih** 1995 Sep;33(9):551–3 (6 ref.) (Eng. Abstr.) **(Chi)**

SURGERY

Surgical treatment of esophageal and gastric cancer. Kiss J. **Acta Med Hung** 1994;50(3–4):205–19 (51 ref.)

Oesophageal substitution. Isolauri J. **Ann Chir Gynaecol** 1995; 84(2):241–6 (30 ref.)

Extended lymph node dissection (D2 resection) should now be performed routinely in the curative surgical treatment of gastric carcinoma. Ravichandran D, et al. **Ann R Coll Surg Engl** 1995 Nov;77(6):431–6 (50 ref.)

Prognostic significance and surgical management of lymph node metastasis in gastric cancer. Noguchi M, et al. **Br J Surg** 1996 Feb;83(2):156–61 (62 ref.)

Progress in the management of gastric cancer. Karpeh MS Jr, et al. **Curr Opin Gen Surg** 1994;:125–30 (47 ref.)

Treatment of gastric cancer. Sugimachi K. **Curr Opin Gen Surg** 1993;:216–8 (33 ref.)

Detection of anastomotic recurrence by endoscopic ultrasonography. Lightdale CJ.
Gastrointest Endosc Clin N Am 1995 Jul;5(3):595–600 (20 ref.)

Adjuvant therapy for resectable gastric adenocarcinoma: preoperative and postoperative chemotherapy trials. Leach SD, et al. **J Infus Chemother** 1995 Summer;5(3):104–11 (46 ref.)

Surgical therapy for gastric cancer. Roder JD, et al.
J Infus Chemother 1995 Summer;5(3):97–103 (20 ref.)

Surgery for gastric cancer: the American view. Brennan MF, et al. **Semin Oncol** 1996 Jun;23(3):352–9 (31 ref.)

Adjuvant therapy of gastric cancer: the Japanese experience. Fukushima M. **Semin Oncol** 1996 Jun;23(3):369–78 (52 ref.)

Adjuvant and neoadjuvant therapy for gastric cancer. Kelsen DP. **Semin Oncol** 1996 Jun;23(3):379–89 (48 ref.)

Surgical treatment for gastric cancer: the Japanese approach. Maruyama K, et al. **Semin Oncol** 1996 Jun;23(3):360–8 (28 ref.)

Arterial vasculature of the stomach and oncologic gastrectomies. Guadagni S, et al. **Surg Radiol Anat** 1995; 17(3):269–76 (40 ref.)

[Value of surgical treatment in patients with gastrointestinal metastatic tumors] Wang Z, et al.
Chung Hua Wai Ko Tsa Chih 1995 Sep;33(9):551–3 (6 ref.) (Eng. Abstr.) **(Chi)**

[Prognostic value of extensive lymph node excision in curative resections of stomach cancers. Apropos of a series of 100 patients] Berthet B, et al. **Chirurgie** 1996; 121(2):108–12 (21 ref.) (Eng. Abstr.) **(Fre)**

[Lymphadenectomies in the surgery of stomach cancer] Cirenei A. **Chirurgie** 1994–95;120(12):66–9 (31 ref.) (Eng. Abstr.) **(Fre)**

[Differential surgical procedure in curative therapy of stomach carcinoma] Hermanek P. **Leber Magen Darm** 1996 Mar;26(2):64, 67–72 (41 ref.) (Eng. Abstr.) **(Ger)**

[Sequelae of stomach resection and gastrectomy and its consequences] Kirchner R. **Z Gastroenterol** 1996 Jun;34 Suppl 2:20–3 (18 ref.) **(Ger)**

[Endoscopic mucosal resection (EMR) for early gastric cancer] Hiki Y. **Nippon Geka Gakkai Zasshi** 1996 Apr; 97(4):273–8 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Clinico-pathological studies and problems on para-aortic lymph node dissection—D4 dissection] Kitamura M, et al. **Nippon Geka Gakkai Zasshi** 1996 Apr;97(4):302–7 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Vagus-saving D2 procedure for early gastric carcinoma] Miwa K, et al. **Nippon Geka Gakkai Zasshi** 1996 Apr; 97(4):286–90 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Laparoscopic surgery for early gastric cancer] Ohgami M, et al. **Nippon Geka Gakkai Zasshi** 1996 Apr;97(4):279–85 (25 ref.) (Eng. Abstr.) **(Jpn)**

[Pylorus-preserving gastrectomy for early gastric cancer] Sasaki I, et al. **Nippon Geka Gakkai Zasshi** 1996 Apr; 97(4):291–6 (22 ref.) (Eng. Abstr.) **(Jpn)**

[Modified surgery for early gastric cancer] Yoshino K, et al. **Nippon Geka Gakkai Zasshi** 1996 Apr;97(4):269–72 (9 ref.) (Eng. Abstr.) **(Jpn)**

[Resection of the posterior mediastinal gastric tube used in reconstruction after radical surgery for esophageal cancer—case reports] Hashimoto M, et al.
Nippon Kyobu Geka Gakkai Zasshi 1995 Jul;43(7):1016–22 (19 ref.) (Eng. Abstr.) **(Jpn)**

[Cancer of the gastric stump] Pinatel Lopasso F.
Rev Gastroenterol Peru 1996 Jan–Apr;16(1):57–63 (69 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

Adjuvant treatment in gastric cancer. Possibilities to take or to leave it. Taton G. **Acta Chir Belg** 1996 Apr; 96(2):59–61 (21 ref.)

Detection and management of advanced gastric cancer. Hohenberger P, et al. **Ann Oncol** 1996 Feb;7(2):197–203 (44 ref.)

Strategies to decrease the incidence of intra-abdominal recurrence in resectable gastric cancer. Averbach AM, et al. **Br J Surg** 1996 Jun;83(6):726–33 (103 ref.)

Upper gastrointestinal tumors. Ogawa M, et al.
Cancer Chemother Biol Response Modif 1996;16:487–94 (22 ref.)

Endoscopic intubation of oesophagogastric malignancy. Hill J, et al. **Eur J Gastroenterol Hepatol** 1995 Sep;7(9):815–6 (8 ref.)

Adjuvant therapy of upper gastrointestinal tract cancers. Kelsen DP. **Semin Oncol** 1995 Dec;22(6):582–99 (78 ref.)

[Management of a patient with gastric lymphoma] Ruskoné-Fourmestraux A. **Gastroenterol Clin Biol** 1996; 20(5 Pt 2):B113–9 (31 ref.) **(Fre)**

[Management of a patient with cancer of the cardia] Souquet JC. **Gastroenterol Clin Biol** 1996;20(5 Pt 2):B98–104 (67 ref.) **(Fre)**

[Perioperative therapy in esophageal and stomach carcinoma] Stahl M, et al. **Med Klin** 1996 Apr 12;91 Suppl 3:85–92 (38 ref.) **(Ger)**

[The use of self-expanding stents in the recanalization of gastric antrum neoplastic obstructions. The experience of a case] Profili S, et al. **Radiol Med (Torino)** 1995 Sep; 90(3):330–3 (23 ref.) **(Ita)**

[Presence and future in neoadjuvant chemotherapy against gastric cancer] Yonemura Y, et al.
Gan To Kagaku Ryoho 1995 Nov;22(13):1893–904 (21 ref.) (Eng. Abstr.) **(Jpn)**

[Therapy for the gastric cancer in the near future] Aoki T, et al. **Nippon Geka Gakkai Zasshi** 1996 Apr;97(4):317–22 (58 ref.) (Eng. Abstr.) **(Jpn)**

ULTRASONOGRAPHY

Endosonographic staging of gastric cancer: a review of literature results. Rösch T.
Gastrointest Endosc Clin N Am 1995 Jul;5(3):549–57 (54 ref.)

Endoscopic ultrasonography in gastric lymphoma. Caletti GC, et al. **Schweiz Med Wochenschr** 1996 May 11; 126(19):819–25 (40 ref.)

Endoscopic ultrasonography. Pollack BJ, et al.
Semin Oncol 1996 Jun;23(3):336–46 (83 ref.)

[The ultrasonic diagnosis of stomach cancer] Romanov VA, et al. **Vestn Rentgenol Radiol** 1996 Mar–Apr;(2):51–3 (34 ref.) **(Rus)**

STOMACH, RUMINANT

ENZYMOLOGY

Molecular evolution of ruminant lysozymes. Irwin DM.
EXS 1996;75:347–61 (42 ref.)

STOMACH RUPTURE

ETIOLOGY

[Gastric rupture secondary to barotrauma in the framework of a diving accident. Apropos of a case report and literature review] Vuilleumier H, et al. **Swiss Surg** 1995;(5):226–9 (8 ref.) (Eng. Abstr.) **(Fre)**

STOMACH ULCER

CHEMICALLY INDUCED

Non-steroidal anti-inflammatory drug-induced gastric damage in experimental animals: underlying pathological mechanisms. Trevethick MA, et al. **Gen Pharmacol** 1995 Nov;26(7):1455–9 (63 ref.)

['Stomach-friendly' NSAIDs: careful optimism? (see comments)] Lems WF, et al. **Ned Tijdschr Geneeskd** 1995 Nov 4;139(44):2232–5 (23 ref.) Comment in: Ned Tijdschr Geneeskd 1995 Dec 30;139(52):2757–8. **(Dut)**

COMPLICATIONS

Helicobacter pylori and complicated ulcer disease. Laine LA. **Am J Med** 1996 May 20;100(5A):52S–57S; discussion 57S–59S (47 ref.)

What should be done when initial endoscopic therapy for bleeding peptic ulcer fails? [editorial] Swain P.
Endoscopy 1995 May;27(4):321–8 (69 ref.)

Oesophago-vascular fistulae secondary to benign peptic ulcer disease: a rare cause of fatal haemorrhage. Kenny PJ, et al. **Eur J Vasc Endovasc Surg** 1995 Oct;10(3):370–1 (6 ref.)

[When should Helicobacter pylori be eradicated?] Buckley M, et al. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S95–S102 (80 ref.) **(Fre)**

[Stomach cancer: what's new? (editorial)] Faivre J, et al. **Gastroenterol Clin Biol** 1995 Oct;19(10):793–6 (22 ref.) **(Fre)**

[Pneumopericardium: a race against time! Case report and literature review] Alvarez L, et al. **Rev Med Brux** 1996 Jun;17(3):143–6 (15 ref.) (Eng. Abstr.) **(Fre)**

[Gastroduodenal hemorrhages of peptic origin and the outlook for using somatostatin (Stilamin)] Smakov GM. **Vestn Khir Im I I Grek** 1995;154(3):120–3 (37 ref.) **(Rus)**

DRUG THERAPY

Eradication of Helicobacter pylori infection. Hunt RH.
Am J Med 1996 May 20;100(5A):42S–50S; discussion 50S–51S (72 ref.)

Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review. Hopkins RJ, et al. **Gastroenterology** 1996 Apr; 110(4):1244–52 (48 ref.)

[Treatment of stomach ulcer] Hudziak H.
Gastroenterol Clin Biol 1996 Jan;20(1 Pt 2):S136–S142 (51 ref.) **(Fre)**

EPIDEMIOLOGY

The relationship between gastric cancer frequency and the ratio of gastric to duodenal ulcer. Correa P, et al.
Aliment Pharmacol Ther 1995;9 Suppl 2:13–9 (26 ref.)

[Consensus conference: "Ulcer and gastritis at the time of Helicobacter pylori". Why and how? (editorial)] Bigard MA, et al. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S1–S4 (17 ref.) **(Fre)**

[Helicobacter pylori, gastric acid secretion, ulcer disease and HIV infection] Blondon H, et al.
Gastroenterol Clin Biol 1996;20(3):248–53 (49 ref.) **(Fre)**

[Gastroduodenal ulcer disease and gastritis: general epidemiology, natural history and progression] Bommelaer G. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S5–S8 (45 ref.) **(Fre)**

[Role of Helicobacter pylori in the pathogenesis of ulcer disease and gastritis] Dorval ED.
Gastroenterol Clin Biol 1996 Jan;20(1 Pt 2):S22–S26 (62 ref.) **(Fre)**

ETIOLOGY

Giant gastric ulceration associated with antiphospholipid antibody syndrome. Kalman DR, et al.
Am J Gastroenterol 1996 Jun;91(6):1244–7 (19 ref.)

Helicobacter pylori and gastric cancer. Forman D.
Scand J Gastroenterol Suppl 1996;214:31–3; discussion 40–3 (14 ref.)

[Helicobacter pylori, nonsteroidal anti-inflammatory agents and gastroduodenal changes] Teixeira AV.
Acta Med Port 1995 Sep;8(9):517–21 (70 ref.) (Eng. Abstr.) **(Por)**

[Hypoxic factor and its significance in the onset of gastroduodenal diseases] Pogromov AP, et al.
Klin Med (Mosk) 1996;74(1):3–7 (117 ref.) **(Rus)**

MICROBIOLOGY

Helicobacter pylori in duodenal and gastric ulcer disease. Rauws EJ, et al. **Baillieres Clin Gastroenterol** 1995 Sep; 9(3):529–47 (119 ref.)

[Role of Helicobacter infection in the causes and mechanisms of gastroduodenal ulcer and chronic gastritis] Chamouard P. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S103–S110 (120 ref.) **(Fre)**

[Helicobacter pylori and its role in gastric and duodenal ulcers] Mach T. **Przegl Lek** 1995;52(7):365–7 (24 ref.) **(Pol)**

PATHOLOGY

[Chronic gastritis and gastroduodenal ulcers: anatomopathological aspects, course and progression] Fléjou JF. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S9–S13 (41 ref.) **(Fre)**

PHYSIOPATHOLOGY

Healing of experimental gastric ulcers. Interference by gastric acid. Halter F, et al. **Dig Dis Sci** 1995 Nov;40(11):2481–6 (23 ref.)

Histamine, histamine H2-receptor antagonists, gastric acid secretion and ulcers: an overview. Pattichis K, et al.
Drug Metabol Drug Interact 1995;12(1):1–36 (43 ref.)

Epidermal growth factor and transforming growth factor-alpha: role in protection and healing of gastric mucosal lesions. Konturek PC, et al.
Eur J Gastroenterol Hepatol 1995 Oct;7(10):933–7 (26 ref.)

Cellular and molecular mechanisms of gastric ulcer healing. Is the quality of mucosal scar affected by treatment? Tarnawski A, et al. **Scand J Gastroenterol Suppl** 1995; 210:9–14 (30 ref.)

[Role of acid secretion in the pathogenesis of duodenal ulcer] Mignon M, et al. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S14–S21 (105 ref.) **(Fre)**

[Gastric stress ulcers: the protective role of hormones of the hypothalamo-hypophyseal-adrenocortical system] Filaretova LP. **Fiziol Zh Im I M Sechenova** 1995 Mar; 81(3):50–60 (80 ref.) (Eng. Abstr.) **(Rus)**

PREVENTION & CONTROL

Diclofenac/misoprostol. A review of its pharmacology and therapeutic efficacy in painful inflammatory conditions. Davis R, et al. **Drugs Aging** 1995 Nov;7(5):372–93 (76 ref.)

Use of misoprostol in the elderly: is the expense justified? Stucki G, et al. **Drugs Aging** 1996 Feb;8(2):84–8 (24 ref.)

Rapid epithelial restitution in the stomach: an updated perspective. Lacy ER. **Scand J Gastroenterol Suppl** 1995; 210:6–8 (18 ref.)

[When to look for Helicobacter pylori?] Delchier JC.
Gastroenterol Clin Biol 1996 Jan;20(1 Pt 2):S34–S37 (32 ref.) **(Fre)**

SURGERY

[Management of stomach ulcer except in emergency: surgical treatment] Lacaine F. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S81–S83 (16 ref.) **(Fre)**

[Surgical hemostasis in recurrent peptic ulcer hemorrhage after endoscopic hemostasis—indications and results] Thon KP, et al. **Bildgebung** 1995 Oct;62 Suppl 2:22–8 (29 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

[Medical treatment of stomach ulcer except in emergency] Bretagne JF. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S73–S80 (68 ref.) **(Fre)**

[Possibilities and results of endoscopic hemostasis in peptic ulcer hemorrhage] Bode JC. **Bildgebung** 1995 Oct;62 Suppl 2:16–20 (29 ref.) **(Ger)**

[Fibrin sealing, a concept for early elective endoscopic therapy] Friedrichs O. **Wien Med Wochenschr** 1995; 145(14):313–8 (42 ref.) (Eng. Abstr.) **(Ger)**

ULTRASONOGRAPHY

Gastric ulcer: can endoscopic ultrasonography predict healing? Wakabayashi T, et al.
Gastrointest Endosc Clin N Am 1995 Jul;5(3):675–82 (8 ref.)

STOMATITIS

The symptom experience of mucositis, stomatitis, and

xerostomia. Dose AM. **Semin Oncol Nurs** 1995 Nov; 11(4):248–55 (59 ref.)

CHEMICALLY INDUCED

[Extramedullary toxicity in bone marrow transplantation using busulfan and cyclophosphamide conditioning] Pascual MJ, et al. **Sangre (Barc)** 1995 Jun;40(3):191–7 (31 ref.) (Eng. Abstr.) **(Spa)**

NURSING

An overview of the oral complications of adult patients with malignant haematological conditions who have undergone radiotherapy or chemotherapy. Coleman S. **J Adv Nurs** 1995 Dec;22(6):1085–91 (47 ref.)

STOMATITIS, APHTHOUS

Recurrent aphthous stomatitis. Rees TD, et al. **Dermatol Clin** 1996 Apr;14(2):243–56 (237 ref.)

Recurrent aphthous ulcers: a review of diagnosis and treatment. Woo SB, et al. **J Am Dent Assoc** 1996 Aug; 127(8):1202–13 (125 ref.)

DRUG THERAPY

Thalidomide for aphthous ulcers in patients infected with the human immunodeficiency virus. Weidle PJ. **Am J Health Syst Pharm** 1996 Feb 15;53(4):368, 371–2, 378 (12 ref.)

GENETICS

[Recurrent aphthous stomatitis: current etiopathogenetic and therapeutic concepts] Carrozzo M, et al. **Minerva Stomatol** 1995 Oct;44(10):467–75 (98 ref.) (Eng. Abstr.) **(Ita)**

NURSING

Recurrent aphthous stomatitis: primary care management. Petersen MJ, et al. **Nurse Pract** 1996 May;21(5):36–40, 42, 47 (32 ref.)

PHYSIOPATHOLOGY

Recurrent aphthous stomatitis. An update. Ship JA. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Feb;81(2):141–7 (69 ref.)

STOMATITIS, GANGRENOUS see **NOMA**

STOMATITIS, HERPETIC

VIROLOGY

Herpesvirus infections. Greenberg MS. **Dent Clin North Am** 1996 Apr;40(2):359–68 (40 ref.)

STOMATITIS, ULCERATIVE see **GINGIVITIS, NECROTIZING ULCERATIVE**

STOMATOGNATHIC DISEASES

[Dysfunctions of the masticatory system] Gola R, et al. **Rev Stomatol Chir Maxillofac** 1995;96(4):177–98 (29 ref.) **(Fre)**

THERAPY

Considerations in the management of maxillofacial infections in the pregnant patient. Lawrenz DR, et al. **J Oral Maxillofac Surg** 1996 Apr;54(4):474–85 (47 ref.)

ULTRASONOGRAPHY

[The ultrasonic diagnosis of soft-tissue diseases of the maxillofacial area] Vorob'ev IuI. **Stomatologiia (Mosk)** 1995;74(2):74–7 (29 ref.) **(Rus)**

STOMATOGNATHIC SYSTEM

ANATOMY & HISTOLOGY

[The role of the basic skeletal system in the stomatognathic apparatus. A critical review of the literature] Silvestri A, et al. **Minerva Stomatol** 1995 Jul–Aug;44(7–8):345–60 (15 ref.) (Eng. Abstr.) **(Ita)**

PHYSIOLOGY

[Standard electromyographic and kinesiographic parameters in a sample of healthy population] Manni A, et al. **Minerva Stomatol** 1995 Sep;44(9):411–9 (29 ref.) (Eng. Abstr.) **(Ita)**

STOMATOLOGY see **DENTISTRY**

STRABISMUS

Update on strabismus and amblyopia. Campos EC. **Acta Ophthalmol Scand** 1995;73 Suppl 214:17–24; discussion 24–5 (88 ref.)

Update on strabismus and amblyopia. Campos EC. **Acta Ophthalmol Scand Suppl** 1995;(214):17–24; discussion 24–5 (90 ref.)

DIAGNOSIS

Six signs in children with life-threatening implications. Tien DR. **R I Med** 1995 Dec;78(12):342–5 (6 ref.)

DRUG THERAPY

[Clinical application of botulinum toxin] Grandas F. **Neurologia** 1995 Jun–Jul;10(6):224–33 (141 ref.) **(Spa)**

PHYSIOPATHOLOGY

[Cyclic strabismus. Presentation of two new cases and critical review of the literature] Tapiero B, et al. **J Fr Ophtalmol** 1995;18(6–7):411–20 (50 ref.) (Eng. Abstr.) **(Fre)**

[Neural mechanisms in infantile esotropia—what is not functioning? (news)] Tychsen L, et al. **Klin Monatsbl Augenheilkd** 1996 Mar;208(3):aA4–12 (0 ref.) **(Ger)**

SURGERY

Prevention of vomiting after paediatric strabismus surgery: a systematic review using the numbers-needed-to-treat method. Tramèr M, et al. **Br J Anaesth** 1995 Nov; 75(5):556–61 (48 ref.)

Anaesthetic management of the Kenny-Caffey syndrome using the laryngeal mask. Janke EL, et al. **Paediatr Anaesth** 1996;6(3):235–8 (16 ref.)

THERAPY

The current use of botulinum toxin therapy in strabismus [editorial] Rosenbaum AL. **Arch Ophthalmol** 1996 Feb; 114(2):213–4 (6 ref.)

STRABISMUS, CONVERGENT see **ESOTROPIA**

STRAMONIUM

CHEMISTRY

Determination of datura alkaloids by using chromatographic techniques: a review. Papadoyannis IN. **Nat Toxins** 1995; 3(4):310–6; discussion 317 (17 ref.)

Anti-nutritional factors of Datura in feedstuffs. Piva G, et al. **Nat Toxins** 1995;3(4):238–41; discussion 242 (24 ref.)

STREET CHILDREN see **HOMELESS YOUTH**

STREET DRUGS

Epidemiology of illicit and abused drugs in the general population, emergency department drug-related episodes, and arrestees. Rouse BA. **Clin Chem** 1996 Aug;42(8 Pt 2):1330–6 (9 ref.)

Substance misuse in individuals with spinal cord injury. Radnitz CL, et al. **Int J Addict** 1995 Jul;30(9):1117–40 (50 ref.)

Financing strategies for drug abuse treatment programs. Zarkin GA, et al. **J Subst Abuse Treat** 1995 Nov–Dec; 12(6):385–99 (26 ref.)

A guide to non-opiate illicit drugs. Robson P. **Practitioner** 1996 Mar;240(1560):140–8 (8 ref.)

[Schizophrenia and substance dependence] Uchtenhagen A. **Schweiz Arch Neurol Psychiatr** 1995;146(5):215–23 (80 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

CNS effects and abuse liability of anabolic-androgenic steroids. Lukas SE. **Annu Rev Pharmacol Toxicol** 1996; 36:333–57 (125 ref.)

Stimulant-induced pulmonary toxicity. Albertson TE, et al. **Chest** 1995 Oct;108(4):1140–9 (134 ref.)

How to have a stroke at an early age: the effects of crack, cocaine and other illicit drugs. Blank-Reid C. **J Neurosci Nurs** 1996 Feb;28(1):19–27 (29 ref.)

ANALYSIS

Technical issues concerning hair analysis for drugs of abuse. Harkey MR. **NIDA Res Monogr** 1995;154:218–34 (34 ref.)

PHARMACOKINETICS

Application of saliva for drug monitoring. An in vivo model for transmembrane transport. Haeckel R, et al. **Eur J Clin Chem Clin Biochem** 1996 Mar;34(3):171–91 (179 ref.)

Pharmacokinetics and pharmacodynamics of maternal-fetal transport of drugs of abuse: a critical review. Melethil S. **NIDA Res Monogr** 1995;154:132–51 (48 ref.)

Placental permeability for drugs of abuse and their metabolites. Olsen GD. **NIDA Res Monogr** 1995;154:152–62 (45 ref.)

TOXICITY

Examination of developmental neurotoxicity by the use of tissue culture model systems. Heller A, et al. **Clin Exp Pharmacol Physiol** 1995 May;22(5):375–8 (29 ref.)

STREET PEOPLE see **HOMELESS PERSONS**

STREET YOUTH see **HOMELESS YOUTH**

STREETER SYNDROME see **AMNIOTIC BAND SYNDROME**

STREPTOCOCCAL INFECTIONS

Diagnosis and treatment of streptococcal sore throat. **Drug Ther Bull** 1995 Feb;33(2):9–12 (28 ref.)

Severe invasive group A streptococcal disease: clinical description and mechanisms of pathogenesis. Schlievert PM, et al. **J Lab Clin Med** 1996 Jan;127(1):13–22 (34 ref.)

Group B streptococcus during the perinatal period. Shermer RH. **J Obstet Gynecol Neonatal Nurs** 1995 Jul–Aug; 24(6):562–6 (21 ref.)

The role of molecular techniques in the understanding of emerging infections. Sable CA, et al. **Mol Med Today** 1996 Mar;2(3):120–8 (43 ref.)

Streptococcal infections of skin and soft tissues [see comments] Bisno AL, et al. **N Engl J Med** 1996 Jan 25; 334(4):240–5 (51 ref.) Comment in: N Engl J Med 1996 May 30;334(22):1478.

Necrotizing fasciitis originating from pinna perichondritis. Skorina J, et al. **Otolaryngol Head Neck Surg** 1995 Oct; 113(4):467–73 (33 ref.)

[Group A streptococcal infections—from follicular tonsillitis to the "flesh-eating bacteria" syndrome] Moses AE, et al. **Harefuah** 1995 Sep;129(5–6):200–4 (39 ref.) **(Heb)**

COMPLICATIONS

[Neurologic complications of infectious endocarditis] Gergaud JM, et al. **Ann Med Interne (Paris)** 1995; 146(6):413–8 (34 ref.) (Eng. Abstr.) **(Fre)**

[Fulminant rhabdomyolysis secondary to Streptococcus viridans sepsis] Pérez Navero JL, et al. **An Esp Pediatr** 1996 Mar;44(3):282–4 (20 ref.) **(Spa)**

DIAGNOSIS

Adult retropharyngeal abscess: a case report and review of the literature. Tannebaum RD. **J Emerg Med** 1996 Mar–Apr;14(2):147–58 (52 ref.)

Neonatal group B streptococcal vertebral osteomyelitis. Barton LL, et al. **Pediatrics** 1996 Sep;98(3 Pt 1):459–61 (9 ref.)

[Retropharyngeal abscess. A report of 3 cases] Vázquez Rueda F, et al. **An Esp Pediatr** 1996 Jul;45(1):82–4 (10 ref.) **(Spa)**

[Meningitis due to streptococcus viridans] Alba D, et al. **Rev Neurol** 1995 May–Jun;23(121):656–60 (87 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Penicillin tolerance and treatment failure in group A streptococcal pharyngotonsillitis. van Asselt GJ, et al. **Eur J Clin Microbiol Infect Dis** 1996 Feb;15(2):107–15 (66 ref.)

Common bacterial pyodermas. Taking aim against the most likely pathogens. Carroll JA. **Postgrad Med** 1996 Sep; 100(3):311–3, 317–22 (22 ref.)

Recurrent streptococcal pharyngitis. Using practical treatment options to interrupt the cycle. Ruoff GE. **Postgrad Med** 1996 Feb;99(2):211–4, 219–22 (19 ref.)

[Treatment of commonly occurring skin infections] Hyry H, et al. **Duodecim** 1995;111(8):697–702 (15 ref.) **(Fin)**

[Aminoglycosides in the treatment of infectious endocarditis] Malinverni R. **Schweiz Med Wochenschr Suppl** 1996; 76:14S–20S (41 ref.) (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

The reemergence of serious group A streptococcal infections and acute rheumatic fever. Bronze MS, et al. **Am J Med Sci** 1996 Jan;311(1):41–54 (92 ref.)

Recent epidemiology of group A streptococcal infections in North America and abroad: an overview. Kaplan EL. **Pediatrics** 1996 Jun;97(6 Pt 2):945–8 (25 ref.)

[Increased incidence of severe Streptococcus group A infections in Noway during the last 10 years. New outbreak 1993–94] Høiby EA, et al. **Tidsskr Nor Laegeforen** 1995 Oct 20;115(25):3131–6 (44 ref.) (Eng. Abstr.) **(Nor)**

ETIOLOGY

Nephrobronchial fistula and lung abscess resulting from nephrolithiasis and pyelonephritis. O'Brien JD, et al. **Chest** 1995 Oct;108(4):1166–8 (6 ref.)

Recent epidemiology of group A streptococcal infections in North America and abroad: an overview. Kaplan EL. **Pediatrics** 1996 Jun;97(6 Pt 2):945–8 (25 ref.)

Group A streptococcus—from basic science to clinical disease. Stevens DL. **West J Med** 1996 Jan;164(1):25–7 (23 ref.)

[Pulmonary arteriovenous fistulae and brain abscesses: a report of 2 cases treated by embolization and a review of the literature] Ricci P, et al. **Radiol Med (Torino)** 1996 Apr; 91(4):497–501 (24 ref.) **(Ita)**

[The current problems of streptococcal infection] Totolian AA, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Mar–Apr;(2):117–20 (32 ref.) **(Rus)**

[Streptococcus bovis in a surgical wound and a colonic neoplasm] Martínez Mas E, et al. **Gastroenterol Hepatol** 1995 Nov;18(9):474–6 (19 ref.) (Eng. Abstr.) **(Spa)**

STREPTOCOCCAL INFECTIONS

MICROBIOLOGY

Emerging resistance in Enterococcus spp. Heath CH, et al. **Med J Aust** 1996 Jan 15;164(2):116–20 (44 ref.)
Neurologic complications of systemic critical illness. Young GB. **Neurol Clin** 1995 Aug;13(3):645–58 (47 ref.)
Common bacterial pyodermas. Taking aim against the most likely pathogens. Carroll JA. **Postgrad Med** 1996 Sep; 100(3):311–3, 317–22 (22 ref.)
[Problems of resistance in Streptococcus pneumoniae] Meis JF, et al. **Ned Tijdschr Geneeskd** 1996 Jan 20;140(3):141–4 (25 ref.) (Eng. Abstr.) **(Dut)**

PREVENTION & CONTROL

Prevention of neonatal septicaemia due to group B streptococci. Adriaanse AH.
Baillieres Clin Obstet Gynaecol 1995 Sep;9(3):545–52 (33 ref.)
Antimicrobial resistance in Streptococcus pneumoniae: can immunization prevent its spread? Munford RS, et al.
J Investig Med 1994 Dec;42(4):613–21 (72 ref.)
Designer vaccines to prevent infections due to group B Streptococcus. Kasper DL. **Proc Assoc Am Physicians** 1995 Oct;107(3):369–73 (22 ref.)

TRANSMISSION

Group B streptococcal infections in newborn infants. Zach TL. **Compr Ther** 1995 Nov;21(11):673–7 (20 ref.)

STREPTOCOCCAL OK-432 see **PICIBANIL**

STREPTOCOCCAL PREPARATION OK-432 see **PICIBANIL**

STREPTOCOCCUS

ENZYMOLOGY

The streptokinase gene: allelic variation, genomic environment and expression control. Malke H, et al.
Dev Biol Stand 1995;85:183–93 (36 ref.)

GENETICS

The streptokinase gene: allelic variation, genomic environment and expression control. Malke H, et al.
Dev Biol Stand 1995;85:183–93 (36 ref.)

ISOLATION & PURIFICATION

Neurologic complications of systemic critical illness. Young GB. **Neurol Clin** 1995 Aug;13(3):645–58 (47 ref.)
Evaluation of penicillins, cephalosporins, and macrolides for therapy of streptococcal pharyngitis. Shulman ST.
Pediatrics 1996 Jun;97(6 Pt 2):955–9 (34 ref.)

STREPTOCOCCUS AGALACTIAE

Prevention of neonatal septicaemia due to group B streptococci. Adriaanse AH.
Baillieres Clin Obstet Gynaecol 1995 Sep;9(3):545–52 (33 ref.)
Group B streptococcal infections in newborn infants. Zach TL. **Compr Ther** 1995 Nov;21(11):673–7 (20 ref.)
Group B streptococcus during the perinatal period. Shermer RH. **J Obstet Gynecol Neonatal Nurs** 1995 Jul–Aug; 24(6):562–6 (21 ref.)
Neonatal group B streptococcal vertebral osteomyelitis. Barton LL, et al. **Pediatrics** 1996 Sep;98(3 Pt 1):459–61 (9 ref.)

GENETICS

Characterization of the capsular polysaccharide genes of group B streptococci. Rubens CE, et al.
Dev Biol Stand 1995;85:237–44 (31 ref.)

IMMUNOLOGY

Designer vaccines to prevent infections due to group B Streptococcus. Kasper DL. **Proc Assoc Am Physicians** 1995 Oct;107(3):369–73 (22 ref.)

STREPTOCOCCUS BOVIS

[Neurologic complications of infectious endocarditis] Gergaud JM, et al. **Ann Med Interne (Paris)** 1995; 146(6):413–8 (34 ref.) (Eng. Abstr.) **(Fre)**
[Streptococcus bovis in a surgical wound and a colonic neoplasm] Martínez Mas E, et al. **Gastroenterol Hepatol** 1995 Nov;18(9):474–6 (19 ref.) (Eng. Abstr.) **(Spa)**

STREPTOCOCCUS FAECALIS see **ENTEROCOCCUS FAECALIS**

STREPTOCOCCUS FAECIUM see **ENTEROCOCCUS FAECIUM**

STREPTOCOCCUS GROUP A see **STREPTOCOCCUS PYOGENES**

STREPTOCOCCUS GROUP B see **STREPTOCOCCUS AGALACTIAE**

STREPTOCOCCUS LACTIS see **LACTOCOCCUS LACTIS**

STREPTOCOCCUS MUTANS

GENETICS

Physical map of Streptococcus mutans GS-5 chromosome. Zuccon FM, et al. **Dev Biol Stand** 1995;85:403–7 (14 ref.)

PATHOGENICITY

Dental caries is a transmissible infectious disease: the Keyes and Fitzgerald revolution. Tanzer JM. **J Dent Res** 1995 Sep;74(9):1536–42 (38 ref.)

PHYSIOLOGY

Cariogenicity depends more on diet than the prevailing mutans streptococcal species. van Palenstein Helderman WH, et al. **J Dent Res** 1996 Jan;75(1):535–45 (115 ref.)

STREPTOCOCCUS PNEUMONIAE

see related
PNEUMOCOCCAL INFECTIONS

Penicillin and multiply antibiotic-resistant Streptococcus pneumoniae. Estrada B, et al. **Compr Ther** 1995 Nov; 21(11):658–62 (32 ref.)
Pneumococcal virulence factors and host immune responses to them. Watson DA, et al.
Eur J Clin Microbiol Infect Dis 1995 Jun;14(6):479–90 (87 ref.)

DRUG EFFECTS

Antimicrobial-resistant pathogens in the 1990s. Jacoby GA. **Annu Rev Med** 1996;47:169–79 (62 ref.)
The role of penicillin-binding proteins in penicillin resistance of Streptococcus pneumoniae. Hakenbeck R, et al.
Dev Biol Stand 1995;85:115–23 (35 ref.)
Early postsplenectomy arthritis caused by penicillin-resistant Streptococcus pneumoniae. Merle-Melet M, et al.
Eur J Clin Microbiol Infect Dis 1996 Feb;15(2):159–60 (7 ref.)
Antimicrobial resistance in Streptococcus pneumoniae: can immunization prevent its spread? Munford RS, et al.
J Investig Med 1994 Dec;42(4):613–21 (72 ref.)
Meningitis caused by Streptococcus pneumoniae showing high level resistance to penicillin. Wise KA, et al.
Pathology 1995 Apr;27(2):165–7 (35 ref.)
[Problems of resistance in Streptococcus pneumoniae] Meis JF, et al. **Ned Tijdschr Geneeskd** 1996 Jan 20;140(3):141–4 (25 ref.) (Eng. Abstr.) **(Dut)**
[Penicillin-resistant pneumococci are coming—are you prepared? (editorial)] Saxén H, et al. **Duodecim** 1994; 110(18):1669–71 (13 ref.) **(Fin)**
[Antibiotic resistance in pneumococci] Moreillon P, et al. **Schweiz Med Wochenschr** 1996 Feb 17;126(7):255–63 (30 ref.) (Eng. Abstr.) **(Fre)**
[Penicillin-resistant Streptococcus pneumoniae] Yamaguchi K. **Nippon Naika Gakkai Zasshi** 1996 Feb 10;85(2):292–6 (12 ref.) **(Jpa)**
[Meningitis due to cefotaxime-resistant Streptococcus pneumoniae] Martín Fontelos P, et al. **An Esp Pediatr** 1996 Apr;44(4):395–6 (24 ref.) **(Spa)**
[The therapeutic implications of pneumococcal penicillin resistance] Lior C, et al. **Aten Primaria** 1996 Jul–Aug; 18(3):136–45 (82 ref.) **(Spa)**
[Pneumococcus resistance. Reconsiderations on its empirical treatment] Pallarés M. **Rev Med Univ Navarra** 1995 Apr–Jun;40(2):90–2 (13 ref.) **(Spa)**

IMMUNOLOGY

The value of influenza and pneumococcal vaccines in the elderly. Monto AS, et al. **Drugs Aging** 1996 Jun;8(6):445–51 (35 ref.)
Pneumococcal conjugate vaccines. Eby R.
Pharm Biotechnol 1995;6:695–718 (140 ref.)

METABOLISM

The role of penicillin-binding proteins in penicillin resistance of Streptococcus pneumoniae. Hakenbeck R, et al.
Dev Biol Stand 1995;85:115–23 (35 ref.)

PATHOGENICITY

The molecular basis of pneumococcal infection: a hypothesis. Cundell D, et al. **Clin Infect Dis** 1995 Dec;21 Suppl 3:S204–11 (114 ref.)
Streptococcus pneumoniae: virulence factors, pathogenesis, and vaccines. AlonsoDeVelasco E, et al. **Microbiol Rev** 1995 Dec;59(4):591–603 (163 ref.)

STREPTOCOCCUS PNEUMONIAE INFECTIONS see **PNEUMOCOCCAL INFECTIONS**

STREPTOCOCCUS PYOGENES

The reemergence of serious group A streptococcal infections and acute rheumatic fever. Bronze MS, et al.
Am J Med Sci 1996 Jan;311(1):41–54 (92 ref.)
Severe invasive group A streptococcal disease: clinical description and mechanisms of pathogenesis. Schlievert PM, et al. **J Lab Clin Med** 1996 Jan;127(1):13–22 (34 ref.)
Common bacterial pyodermas. Taking aim against the most likely pathogens. Carroll JA. **Postgrad Med** 1996 Sep; 100(3):311–3, 317–22 (22 ref.)
Recurrent streptococcal pharyngitis. Using practical treatment options to interrupt the cycle. Ruoff GE.
Postgrad Med 1996 Feb;99(2):211–4, 219–22 (19 ref.)
Towards understanding the pathogenesis of rheumatic fever [editorial] Carapetis JR, et al. **Scand J Rheumatol** 1996; 25(3):127–31; discussion 132–3 (49 ref.)
[Group A streptococcal infections—from follicular tonsillitis to the "flesh-eating bacteria" syndrome] Moses AE, et al. **Harefuah** 1995 Sep;129(5–6):200–4 (39 ref.) **(Heb)**
[Increased incidence of severe Streptococcus group A infections in Noway during the last 10 years. New outbreak 1993–94] Høiby EA, et al. **Tidsskr Nor Laegeforen** 1995 Oct 20;115(25):3131–6 (44 ref.) (Eng. Abstr.) **(Nor)**
[The current problems of streptococcal infection] Totolian AA, et al. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Mar–Apr;(2):117–20 (32 ref.) **(Rus)**

CHEMISTRY

[Cellular constituents and extracellular proteins involved in the pathogenic capacity of Streptococcus group A] Alouf J, et al. **Ann Pharm Fr** 1996;54(2):49–59 (57 ref.) (Eng. Abstr.) **(Fre)**

DRUG EFFECTS

Penicillin tolerance and treatment failure in group A streptococcal pharyngotonsillitis. van Asselt GJ, et al.
Eur J Clin Microbiol Infect Dis 1996 Feb;15(2):107–15 (66 ref.)

GENETICS

Molecular analysis of Streptococcus pyogenes adhesion. Hanski E, et al. **Methods Enzymol** 1995;253:269–305 (49 ref.)

ISOLATION & PURIFICATION

Rapid identification of group A streptococcus as the cause of necrotizing fasciitis. Ault MJ, et al. **Ann Emerg Med** 1996 Aug;28(2):227–30 (16 ref.)

PATHOGENICITY

Molecular aspects of bacterial colonization. Bisno AL.
Infect Control Hosp Epidemiol 1995 Nov;16(11):648–57 (83 ref.)
Acute pharyngitis: etiology and diagnosis. Bisno AL.
Pediatrics 1996 Jun;97(6 Pt 2):949–54 (76 ref.)
Adherence to physicians' instructions as a factor in managing streptococcal pharyngitis. Dajani AS. **Pediatrics** 1996 Jun; 97(6 Pt 2):976–80 (21 ref.)
Antibiotic resistance: relationship to persistence of group A streptococci in the upper respiratory tract. Gerber MA.
Pediatrics 1996 Jun;97(6 Pt 2):971–5 (59 ref.)
Recent epidemiology of group A streptococcal infections in North America and abroad: an overview. Kaplan EL.
Pediatrics 1996 Jun;97(6 Pt 2):945–8 (25 ref.)
Group A streptococcus—from basic science to clinical disease. Stevens DL. **West J Med** 1996 Jan;164(1):25–7 (23 ref.)
[Cellular constituents and extracellular proteins involved in the pathogenic capacity of Streptococcus group A] Alouf J, et al. **Ann Pharm Fr** 1996;54(2):49–59 (57 ref.) (Eng. Abstr.) **(Fre)**

STREPTODORNASE see **DEOXYRIBONUCLEASE I**

STREPTOGRAMIN see **VIRGINIAMYCIN**

STREPTOKINASE

ADMINISTRATION & DOSAGE

[Thrombolysis of an extensive venous thrombosis of the lower body in an anomaly of the vena cava inferior] Rühlmann C, et al. **Dtsch Med Wochenschr** 1996 Feb 2; 121(5):124–8 (29 ref.) (Eng. Abstr.) **(Ger)**

ADVERSE EFFECTS

How safe is the readministration of streptokinase? Lee HS.
Drug Saf 1995 Aug;13(2):76–80 (27 ref.)
Does the potential for development of streptokinase antibodies change the risk-benefit ratio in older patients? Brügemann J, et al. **Drugs Aging** 1995 Aug;7(2):110–6 (32 ref.)

GENETICS

The streptokinase gene: allelic variation, genomic environment and expression control. Malke H, et al.
Dev Biol Stand 1995;85:183–93 (36 ref.)

IMMUNOLOGY

Does the potential for development of streptokinase antibodies change the risk-benefit ratio in older patients? Brügemann J, et al. **Drugs Aging** 1995 Aug;7(2):110–6 (32 ref.)

THERAPEUTIC USE

Interpreting results from thrombolytic megatrials: distinguishing fact from fiction. Brophy JM. **Can J Cardiol** 1996 Jan;12(1):89–92 (22 ref.)

Alteplase. A reappraisal of its pharmacology and therapeutic use in vascular disorders other than acute myocardial infarction. Wagstaff AJ, et al. **Drugs** 1995 Aug; 50(2):289–316 (185 ref.)

Comparison of "accelerated" tissue plasminogen activator with streptokinase for treatment of suspected myocardial infarction [see comments] Kellett J, et al. **Med Decis Making** 1995 Oct–Dec;15(4):297–310 (145 ref.) Comment in: Med Decis Making 1995 Oct–Dec;15(4):395–6.

[Thrombolysis (Consensus about post-myocardial infarction treatment)] **Arq Bras Cardiol** 1995 Mar;64(3):271–80 (65 ref.) **(Por)**

STREPTOLYSINS

METABOLISM

Staphylococcal alpha-toxin, streptolysin-O, and Escherichia coli hemolysin: prototypes of pore-forming bacterial cytolysins. Bhakdi S, et al. **Arch Microbiol** 1996 Feb; 165(2):73–9 (45 ref.)

TOXICITY

Pathogenesis of sepsis syndrome: possible relevance of pore-forming bacterial toxins. Bhakdi S, et al. **Curr Top Microbiol Immunol** 1996;216:101–18 (64 ref.)

STREPTOMYCES

Treatment of eumycetoma and actinomycetoma. Welsh O, et al. **Curr Top Med Mycol** 1995;6:47–71 (105 ref.)

CHEMISTRY

Isolation and biological activities of signal transduction inhibitors from microorganisms and plants. Umezawa K. **Adv Enzyme Regul** 1995;35:43–53 (35 ref.)

GENETICS

Genetics of antibiotic production in Streptomyces coelicolor A3(2), a model streptomycete. Hopwood DA, et al. **Biotechnology** 1995;28:65–102 (132 ref.)

Autoregulators. Horinouchi S, et al. **Biotechnology** 1995; 28:103–19 (47 ref.)

Thiopeptides. Strohl WR, et al. **Biotechnology** 1995;28:223–38 (50 ref.)

Bialaphos. Thompson CJ, et al. **Biotechnology** 1995; 28:197–222 (68 ref.)

[Initiation of DNA replication in Streptomyces; organizational comparison of the oriC region in prokaryotic organisms] Zakrzewska-Czerwińska J. **Postepy Hig Med Dosw** 1995;49(1):149–60 (43 ref.) (Eng. Abstr.) **(Pol)**

METABOLISM

Tetracyclines. Bëhal V, et al. **Biotechnology** 1995;28:359–84 (99 ref.)

Polyethers. Birch AW, et al. **Biotechnology** 1995;28:443–76 (100 ref.)

Rifamycin SV and related ansamycins. Chiao JS, et al. **Biotechnology** 1995;28:477–98 (110 ref.)

Genetics of antibiotic production in Streptomyces coelicolor A3(2), a model streptomycete. Hopwood DA, et al. **Biotechnology** 1995;28:65–102 (132 ref.)

Anthracyclines. Hutchinson CR. **Biotechnology** 1995; 28:331–57 (118 ref.)

Macrolides. Katz L, et al. **Biotechnology** 1995;28:385–420 (136 ref.)

Avermectins. MacNeil DJ. **Biotechnology** 1995;28:421–42 (59 ref.)

Streptomycin and related aminoglycosides. Piepersberg W. **Biotechnology** 1995;28:531–70 (179 ref.)

Thiopeptides. Strohl WR, et al. **Biotechnology** 1995;28:223–38 (50 ref.)

Bialaphos. Thompson CJ, et al. **Biotechnology** 1995; 28:197–222 (68 ref.)

Chloramphenicol. Vining LC, et al. **Biotechnology** 1995; 28:505–30 (80 ref.)

1995 Colworth Prize Lecture. The regulation of antibiotic production in Streptomyces coelicolor A3(2). Bibb M. **Microbiology** 1996 Jun;142 (Pt 6):1335–44 (117 ref.)

STREPTOMYCIN

BIOSYNTHESIS

Autoregulators. Horinouchi S, et al. **Biotechnology** 1995; 28:103–19 (47 ref.)

Streptomycin and related aminoglycosides. Piepersberg W. **Biotechnology** 1995;28:531–70 (179 ref.)

CHEMISTRY

Streptomycin and related aminoglycosides. Piepersberg W. **Biotechnology** 1995;28:531–70 (179 ref.)

PHARMACOLOGY

Ribosomal drug resistance in mycobacteria. Sander P, et al. **Res Microbiol** 1996 Jan–Feb;147(1–2):59–67 (73 ref.)

THERAPEUTIC USE

Current problems with tuberculosis treatment. Grosset J. **Res Microbiol** 1996 Jan–Feb;147(1–2):10–6 (32 ref.)

STREPTOZOCIN

ADMINISTRATION & DOSAGE

Effects of streptozotocin-induced diabetes on postpneumonectomy lung growth and connective tissue levels. Ofulue AF, et al. **Pediatr Pulmonol** 1995 Jun; 19(6):365–70 (29 ref.)

STREPTOZOCIN DIABETES see **DIABETES MELLITUS, EXPERIMENTAL**

STREPTOZOTOCIN see **STREPTOZOCIN**

STREPTOZOTOCIN DIABETES see **DIABETES MELLITUS, EXPERIMENTAL**

STRESS

see related

GENERAL ADAPTATION SYNDROME

The stress-activated protein kinases. A novel ERK subfamily responsive to cellular stress and inflammatory cytokines. Kyriakis JM, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:303–19 (48 ref.)

Molecular responses to drought and cold stress. Shinozaki K, et al. **Curr Opin Biotechnol** 1996 Apr;7(2):161–7 (64 ref.)

Cells, stress and EMFs. Smith O. **Nat Med** 1996 Jan;2(1):23–4 (13 ref.)

The stress response. Brown IR. **Neuropathol Appl Neurobiol** 1995 Dec;21(6):473–5 (5 ref.)

Regulatory mechanism of stress response in mammalian nervous system during cerebral ischaemia or after heat shock. Higashi T, et al. **Neuropathol Appl Neurobiol** 1995 Dec;21(6):480–3 (19 ref.)

Cell stress genes and neuronal protection. Latchman DS. **Neuropathol Appl Neurobiol** 1995 Dec;21(6):475–7 (24 ref.)

Stress ulcer prophylaxis. Do critically ill patients need it? DePriest JL. **Postgrad Med** 1995 Oct;98(4):159–61, 165–6, 168 (23 ref.)

Chronic stress--the key to parturition? McMillen IC, et al. **Reprod Fertil Dev** 1995;7(3):499–507 (50 ref.)

[Intense physical exercise—excessive strain on the immune system?] Eliakim A, et al. **Harefuah** 1995 Dec 1; 129(11):498–502 (44 ref.) **(Heb)**

[Stress echocardiography. Rise of a new method] Mathias Júnior W. **Arq Bras Cardiol** 1995 Apr;64(4):401–8 (43 ref.) **(Por)**

BLOOD

Blood hormones as markers of training stress and overtraining. Urhausen A, et al. **Sports Med** 1995 Oct; 20(4):251–76 (233 ref.)

COMPLICATIONS

Hypnotizability and traumatic experience: a diathesis-stress model of dissociative symptomatology. Butler LD, et al. **Am J Psychiatry** 1996 Jul;153(7 Suppl):42–63 (155 ref.)

A role for CRH and the sympathetic nervous system in stress-induced immunosuppression. Friedman EM, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:396–418 (125 ref.)

Overview of neuroimmune stress interactions. Implications for susceptibility to inflammatory disease. Sternberg EM, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:364–71 (53 ref.)

Prophylaxis for stress-related gastrointestinal hemorrhage: a cost effectiveness analysis. Ben-Menachem T, et al. **Crit Care Med** 1996 Feb;24(2):338–45 (59 ref.)

Causes and mechanisms of primary headaches: toward a bio-behavioral model. Buzzi MG, et al. **Ital J Neurol Sci** 1995 Nov;16(8 Suppl):15–9 (32 ref.)

Occupational injury and stress. Johnston JJ. **J Occup Environ Med** 1995 Oct;37(10):1199–203 (25 ref.)

Cancer and stress. Cholst S. **Med Hypotheses** 1996 Feb; 46(2):101–6 (14 ref.)

Stress bleeding prophylaxis in the ICU: obligate or obsolete? [editorial] Bonten MJ, et al. **Neth J Med** 1996 Jan;48(1):4–7 (24 ref.)

[Ultrasound of stress cholecystitis—diagnosis and differential diagnosis] Macheiner P, et al. **Z Gastroenterol** 1996 Jan; 34(1):21–6 (36 ref.) (Eng. Abstr.) **(Ger)**

[Gastroduodenal stress lesions and hemorrhages—pathogenesis, diagnosis, prevention and therapy] Gheorghiu T. **Zentralbl Chir** 1995;120(9):670–6 (32 ref.) (Eng. Abstr.) **(Ger)**

DIAGNOSIS

Clinical assessment of sympathetic responses to stress. Goldstein DS. **Ann N Y Acad Sci** 1995 Dec 29;771:570–93 (144 ref.)

ENZYMOLOGY

Both ATF-2 and c-Jun are phosphorylated by stress-activated protein kinases in response to UV irradiation. Wilhelm D, et al. **Immunobiology** 1995 Jul; 193(2–4):143–8 (22 ref.)

Role of CSB/p38/RK stress response kinase in LPS and cytokine signaling mechanisms. Lee JC, et al. **J Leukoc Biol** 1996 Feb;59(2):152–7 (62 ref.)

IMMUNOLOGY

Stress and the immune system in the etiology of anxiety and depression. Leonard BE, et al. **Pharmacol Biochem Behav** 1996 May;54(1):299–303 (74 ref.)

[Effect of menstrual cycle on the immune response to surgical stress] Lazzaretti MG, et al. **Minerva Ginecol** 1995 May; 47(5):197–205 (48 ref.) (Eng. Abstr.) **(Ita)**

METABOLISM

Substance P and stress-induced changes in macrophages. Chancellor-Freeland C, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:472–84 (39 ref.)

Aging is associated in the 344/N Fischer rat with decreased stress responsivity of central and peripheral catecholaminergic systems and impairment of the hypothalamic-pituitary-adrenal axis. Cizza G, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:491–511 (68 ref.)

Stress, aging, and memory. Involvement of peripheral catecholamines. Mabry TR, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:512–22 (53 ref.)

Interleukin-1 receptors in the brain-endocrine-immune axis. Modulation by stress and infection. Takao T, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:372–85 (52 ref.)

Adenosine: a prototherapeutic concept in neurodegeneration. von Lubitz DK, et al. **Ann N Y Acad Sci** 1995 Sep 15; 765:163–78; discussion 196–7 (123 ref.)

Downregulation of cellular metabolism during environmental stress: mechanisms and implications. Hand SC, et al. **Annu Rev Physiol** 1996;58:539–63 (165 ref.)

Serotonin: current understanding and the way forward. Dinan TG. **Int Clin Psychopharmacol** 1996 Mar;11 Suppl 1:19–21 (10 ref.)

The oxidative stress response. Camhi SL, et al. **New Horiz** 1995 May;3(2):170–82 (114 ref.)

[Mammalian small stress proteins and responses to stress] Kato K, et al. **Nihon Shinkei Seishin Yakurigaku Zasshi** 1996 Feb;16(1):1–9 (46 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Why stress is bad for your brain. Sapolsky RM. **Science** 1996 Aug 9;273(5276):749–50 (11 ref.)

PHYSIOPATHOLOGY

Evidence for a sleep-promoting influence of stress. Cespuglio R, et al. **Adv Neuroimmunol** 1995;5(2):145–54 (39 ref.)

Corticotropin-releasing hormone involvement in stressor-induced alterations in sleep and in the regulation of waking. Opp MR. **Adv Neuroimmunol** 1995;5(2):127–43 (100 ref.)

The renin angiotensin system and the stress response. Aguilera G, et al. **Ann N Y Acad Sci** 1995 Dec 29; 771:173–86 (41 ref.)

Central regulation of ACTH release in stress. Assenmacher I, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:41–54 (81 ref.)

Hypothalamic tachykinins. Mediators of stress responses? Culman J, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:204–18 (68 ref.)

The neural network that regulates energy balance is responsive to glucocorticoids and insulin and also regulates HPA axis responsivity at a site proximal to CRF neurons. Dallman MF, et al. **Ann N Y Acad Sci** 1995 Dec 29; 771:730–42 (43 ref.)

The role of CRF in behavioral aspects of stress. Heinrichs SC, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:92–104 (63 ref.)

The protective role of the hypothalamic-pituitary-adrenal axis against lethality produced by immune, infectious, and inflammatory stress. Kapcala LP, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:419–37 (87 ref.)

Definitions of stress and sympathetic neuronal responses. Kopin IJ. **Ann N Y Acad Sci** 1995 Dec 29;771:19–30 (6 ref.)

Sympathoadrenal system in stress. Interaction with the hypothalamic-pituitary-adrenocortical system. Kvetňanský R, et al. **Ann N Y Acad Sci** 1995 Dec 29; 771:131–58 (158 ref.)

Neuroactive steroid modulators of the stress response. Morrow AL, et al. **Ann N Y Acad Sci** 1995 Dec 29; 771:257–72 (78 ref.)

Stress, conditioning, and the temporal aspects of affective disorders. Post RM, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:677–96 (42 ref.)

Neuroendocrinology and pathophysiology of the stress system. Stratakis CA, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:1–18 (72 ref.)

Neuropeptide Y. A novel sympathetic stress hormone and more. Zukowska-Grojec Z. **Ann N Y Acad Sci** 1995 Dec 29;771:219–33 (42 ref.)

Pathophysiological basis of vulnerability to drug abuse: role of an interaction between stress, glucocorticoids, and dopaminergic neurons. Piazza PV, et al. **Annu Rev Pharmacol Toxicol** 1996;36:359–78 (117 ref.)

Modulation of actin dynamics during stress and physiological

stimulation by a signaling pathway involving p38 MAP kinase and heat-shock protein 27. Landry J, et al. **Biochem Cell Biol** 1995 Sep-Oct;73(9-10):703-7 (42 ref.)
Angiotensin II--an important stress hormone. Yang G, et al. **Biol Signals** 1996 Jan-Feb;5(1):1-8 (41 ref.)
Fifteenth Gaddum Memorial Lecture December 1994. Stress and the neuroendocrine-immune axis: the pivotal role of glucocorticoids and lipocortin 1. Buckingham JC. **Br J Pharmacol** 1996 May;118(1):1-19 (138 ref.)
On the mechanism and possible therapeutic application of delayed cardiac adaptation to stress. Szekeres L. **Can J Cardiol** 1996 Feb;12(2):177-85 (49 ref.)
Central tachykinins: mediators of defence reaction and stress reactions. Culman J, et al. **Can J Physiol Pharmacol** 1995 Jul;73(7):885-91 (54 ref.)
Management of nutrition in the critically ill patient. Kudsk KA, et al. **Curr Opin Gen Surg** 1994;:24-9 (15 ref.)
Regulation of protein metabolism during stress. Matthews DE, et al. **Curr Opin Gen Surg** 1993;:72-7 (45 ref.)
Lipid fuel metabolism in health and disease. Miles JM. **Curr Opin Gen Surg** 1993;:78-84 (34 ref.)
Exercise training and the cross-stressor adaptation hypothesis. Sothmann MS, et al. **Exerc Sport Sci Rev** 1996; 24:267-87 (89 ref.)
Steroids, stability and stress. de Kloet ER. **Front Neuroendocrinol** 1995 Oct;16(4):416-25 (41 ref.)
Interventions based on the possibility that oxidative stress contributes to sarcopenia. Weindruch R. **J Gerontol A Biol Sci Med Sci** 1995 Nov;50 Spec No:157-61 (54 ref.)
Age-related changes before and after imposition of hemodynamic stress in the mammalian heart. Isoyama S. **Life Sci** 1996;58(19):1601-14 (112 ref.)
Neuroendocrine dysrhythmias. Elks ML. **Med Hypotheses** 1995 May;44(5):319-24 (43 ref.)
Anorexia nervosa, self-starvation and the reward of stress. Bergh C, et al. **Nat Med** 1996 Jan;2(1):21-2 (13 ref.)
The heat-shock response. De Maio A. **New Horiz** 1995 May; 3(2):198-207 (96 ref.)
Heat shock and tissue protection. Perdrizet GA. **New Horiz** 1995 May;3(2):312-20 (46 ref.)
Induction of the stress response to prevent organ injury. Ribeiro SP, et al. **New Horiz** 1995 May;3(2):301-11 (107 ref.)
Stress and the immune system in the etiology of anxiety and depression. Leonard BE, et al. **Pharmacol Biochem Behav** 1996 May;54(1):299-303 (74 ref.)
Central noradrenergic neurones and stress. Stanford SC. **Pharmacol Ther** 1995;68(2):297-42 (360 ref.)
Stress and the brain: a paradoxical role for adrenal steroids. McEwen BS, et al. **Vitam Horm** 1995;51:371-402 (113 ref.)
[Regulation of corticotropic function in stressful situations] Paulmyer-Lacroix O, et al. **Ann Endocrinol (Paris)** 1995; 56(4):245-51 (36 ref.) (Eng. Abstr.) **(Fre)**
[Gastric stress ulcers: the protective role of hormones of the hypothalamo-hypophyseal-adrenocortical system] Filaretova LP. **Fiziol Zh Im I M Sechenova** 1995 Mar; 81(3):50-60 (80 ref.) (Eng. Abstr.) **(Rus)**

PREVENTION & CONTROL

Occupational stress intervention. Hurrell JJ Jr, et al. **Am J Ind Med** 1996 Apr;29(4):338-41 (23 ref.)

PSYCHOLOGY

A multidimensional model of the antecedents of stress and coping appraisals: an approach to studying patients' perceptions of post cardiac surgery pain and their coping strategies. Shih FJ, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1996 Apr; 12(4):202-15 (22 ref.)

THERAPY

The role of stress management in blood pressure control: why the promissory note has failed to deliver. Hunyor SN, et al. **J Hypertens** 1996 Apr;14(4):413-8 (55 ref.)

VETERINARY

The influence of petrochemicals and stress on the immune system of seabirds. Briggs KT, et al. **Regul Toxicol Pharmacol** 1996 Apr;23(2):145-55 (77 ref.)

STRESS DISORDERS, POST-TRAUMATIC

Battered woman syndrome: a conceptual analysis of its status vis-à-vis DSM IV mental disorders. Roth DL, et al. **Med Law** 1995;14(7-8):641-58 (39 ref.)
Post traumatic stress disorder: turning the tide without opening the floodgates. McCulloch M, et al. **Med Sci Law** 1995 Oct;35(4):287-93 (38 ref.)

DIAGNOSIS

Conflict between current knowledge about posttraumatic stress disorder and its original conceptual basis. Yehuda R, et al. **Am J Psychiatry** 1995 Dec;152(12):1705-13 (123 ref.)
The clinical boundaries of posttraumatic stress disorder. McGorry PD. **Aust N Z J Psychiatry** 1995 Sep; 29(3):385-93 (38 ref.)
Assessment of sexual abuse and trauma: clinical measures. Miller TW, et al. **Child Psychiatry Hum Dev** 1995 Fall; 26(1):3-10 (20 ref.)
Medico-legal aspects of road traffic accidents. Mayou R. **J Psychosom Res** 1995 Aug;39(6):789-98 (13 ref.)
Legal and medical aspects of liability for negligently occasioned nervous shock: a current perspective. Mendelson D. **J Psychosom Res** 1995 Aug;39(6):721-35 (81 ref.)
[Post-traumatic stress disorder] Ponteva M. **Duodecim** 1995; 111(9):875-82 (20 ref.) **(Fin)**
[Symptoms, diagnosis and therapy of post-traumatic stress disorder] Bengel J, et al. **Z Klin Psychol Psychopathol Psychother** 1996;44(2):129-49 (105 ref.) (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

Review of psychiatric epidemiologic research on disasters. Bromet E, et al. **Epidemiol Rev** 1995;17(1):113-9 (70 ref.)

ETIOLOGY

Liability for psychiatric illness [editorial] Wessely S. **J Psychosom Res** 1995 Aug;39(6):659-69 (35 ref.)

PHYSIOPATHOLOGY

Traumatic stress and pathological dissociation. Putnam FW. **Ann N Y Acad Sci** 1995 Dec 29;771:708-15 (62 ref.)
Functional neuroanatomical correlates of the effects of stress on memory. Bremner JD, et al. **J Trauma Stress** 1995 Oct; 8(4):527-53 (115 ref.)
Post-traumatic stress disorders; psychophysiological and medical aspects. Derevenco P, et al. **Rom J Physiol** 1993 Jul-Dec;30(3-4):199-206 (31 ref.)

PSYCHOLOGY

Dissociation, somatization, and affect dysregulation: the complexity of adaptation of trauma. van der Kolk BA, et al. **Am J Psychiatry** 1996 Jul;153(7 Suppl):83-93 (90 ref.)
Transportation disasters--a review. Lundin T. **J Trauma Stress** 1995 Jul;8(3):381-9 (27 ref.)
Dissociation and the fragmentary nature of traumatic memories: overview and exploratory study. van der Kolk BA, et al. **J Trauma Stress** 1995 Oct;8(4):505-25 (85 ref.)
Trauma, traumatic memory, and research: where do we go from here? Wolfe J. **J Trauma Stress** 1995 Oct;8(4):717-26 (5 ref.)
Psychosocial problems in refugee children exposed to war. McCloskey LA, et al. **Pediatrics** 1996 Mar;97(3):394-7 (36 ref.)
Alcohol abuse in individuals exposed to trauma: a critical review. Stewart SH. **Psychol Bull** 1996 Jul;120(1):83-112 (280 ref.)
Post-traumatic stress disorders; psychophysiological and medical aspects. Derevenco P, et al. **Rom J Physiol** 1993 Jul-Dec;30(3-4):199-206 (31 ref.)

THERAPY

Post-traumatic stress disorder--a scar for life. D'Souza D. **Br J Clin Pract** 1995 Nov-Dec;49(6):309-13 (54 ref.)
PTSD diagnosis and treatment for mental health clinicians. Friedman MJ. **Community Ment Health J** 1996 Apr; 32(2):173-89; discussion 191-3 (50 ref.)
The empirical status of the clinical application of eye movement desensitization and reprocessing. Lohr JM, et al. **J Behav Ther Exp Psychiatry** 1995 Dec;26(4):285-302 (67 ref.)
Posttraumatic stress disorder: conceptualization and treatment. Boudewyns PA. **Prog Behav Modif** 1996; 30:165-89 (150 ref.)

STRESS FRACTURES see **FRACTURES, STRESS**

STRESS, MECHANICAL

Platelets and shear stress. Kroll MH, et al. **Blood** 1996 Sep 1;88(5):1525-41 (186 ref.)
Mechanotransduction and the functional response of bone to mechanical strain. Duncan RL, et al. **Calcif Tissue Int** 1995 Nov;57(5):344-58 (225 ref.)
Skin response to mechanical stress: adaptation rather than breakdown--a review of the literature. Sanders JE, et al. **J Rehabil Res Dev** 1995 Oct;32(3):214-26 (71 ref.)
Interface mechanics in external prosthetics: review of interface stress measurement techniques. Sanders JE. **Med Biol Eng Comput** 1995 Jul;33(4):509-16 (41 ref.)
[Stress fractures in athletes and military recruits. An overview] Orava S, et al. **Orthopade** 1995 Sep;24(5):457-66 (51 ref.) (Eng. Abstr.) **(Ger)**
[Lesions of the growth plate caused by sports stress] Segesser B, et al. **Orthopade** 1995 Sep;24(5):446-56 (60 ref.) (Eng. Abstr.) **(Ger)**

STRESS, OXIDATIVE see **OXIDATIVE STRESS**

STRESS PROTEINS see **HEAT-SHOCK PROTEINS**

STRESS, PSYCHOLOGICAL

see related
LIFE CHANGE EVENTS
In search of effective programs to address students' emotional distress and behavioral problems. Part I: Defining the problem. Wassef A, et al. **Adolescence** 1995 Fall; 30(119):523-38 (22 ref.)
In search of effective programs to address students' emotional distress and behavioral problems. Part II: Critique of school- and community-based programs. Wassef A, et al. **Adolescence** 1995 Winter;30(120):757-77 (29 ref.)
Mental stress as a trigger of myocardial ischemia and infarction. Krantz DS, et al. **Cardiol Clin** 1996 May; 14(2):271-87 (75 ref.)
Stress, coping, and social support processes: where are we? What next? Thoits PA. **J Health Soc Behav** 1995;Spec No:53-79 (220 ref.)
Work group culture, stress, and hostility. Correlations with organizational outcomes. Seago JA. **J Nurs Adm** 1996 Jun; 26(6):39-47 (56 ref.)
[Therapists' coping with his own abilities] Joss R. **Schweiz Rundsch Med Prax** 1996 Jul 16;85(29-30):904-10 (25 ref.) (Eng. Abstr.) **(Ger)**
[Stresses under conditions of a normal mode of life, during hypokinesia (simulating effects of weightlessness) and in space flights] Grigor'ev AI, et al. **Fiziol Cheloveka** 1996 Mar-Apr;22(2):10-9 (35 ref.) **(Rus)**

COMPLICATIONS

Hypnotizability and traumatic experience: a diathesis-stress model of dissociative symptomatology. Butler LD, et al. **Am J Psychiatry** 1996 Jul;153(7 Suppl):42-63 (155 ref.)
Psychological stress and susceptibility to upper respiratory infections. Cohen S. **Am J Respir Crit Care Med** 1995 Oct; 152(4 Pt 2):S53-8 (43 ref.)
The practice of anaesthesia--a stressor for the middle-aged? Seeley HF. **Anaesthesia** 1996 Jun;51(6):571-4 (16 ref.)
Distress amenorrhea. Tolis G, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:660-4 (35 ref.)
Health psychology: psychological factors and physical disease from the perspective of human psychoneuroimmunology. Cohen S, et al. **Annu Rev Psychol** 1996;47:113-42 (155 ref.)
The primary care of patients who have bodily concerns. Blackwell B, et al. **Arch Fam Med** 1996 Sep;5(9):457-63 (65 ref.)
Relationship of anxiety, stress, and psychosocial development to reproductive health [see comments] Lederman RP. **Behav Med** 1995 Fall;21(3):101-12 (110 ref.) Comment in: Behav Med 1995 Fall;21(3):123-9.
Treatment strategies for anxiety, stress, and developmental conflict during reproduction [see comments] Lederman RP. **Behav Med** 1995 Fall;21(3):113-22 (69 ref.) Comment in: Behav Med 1996 Fall;21(3):123-9.
A model of pain and anxiety associated with acute stressors: distress in dental procedures. Litt MD. **Behav Res Ther** 1996 May-Jun;34(5-6):459-76 (100 ref.)
Hemoconcentration and stress: a review of physiological mechanisms and relevance for cardiovascular disease risk. Allen MT, et al. **Biol Psychol** 1995 Aug;41(1):1-27 (125 ref.)
Teacher stress research: problems and progress. Pithers RT. **Br J Educ Psychol** 1995 Dec;65 (Pt 4):387-92 (21 ref.)
Reversible cardiogenic shock in an angry woman--case report and review of the literature. Kovacs KA, et al. **Can J Cardiol** 1996 Jul;12(7):689-93 (52 ref.)
Stress, stigmatization and psychosomatic purpuras. Panconesi E, et al. **Int Angiol** 1995 Jun;14(2):130-7 (51 ref.)
Stress: clarification of a confused concept. Morse DR. **Int J Psychosom** 1995;42(1-4):4-24 (136 ref.)
Assessing the characteristics of patients with oral lichen planus. Burkhart NW, et al. **J Am Dent Assoc** 1996 May; 127(5):648, 651-2, 655-6 passim (42 ref.)
Assessment of the cardiovascular effects of stress. Engler MB, et al. **J Cardiovasc Nurs** 1995 Oct;10(1):51-63 (85 ref.)
Corticotropin-releasing factor (CRF) and stress-related reproductive failure: the brain as a state of the art or the ovary as a novel clue? Nappi RE, et al. **J Endocrinol Invest** 1995 Dec;18(11):872-80 (89 ref.)
Occupational stress and the law: some current issues for employers. Howard G. **J Psychosom Res** 1995 Aug; 39(6):707-19 (27 ref.)
Psychosocial factors and pregnancy outcome: a review with emphasis on methodological issues. Paarlberg KM, et al. **J Psychosom Res** 1995 Jul;39(5):563-95 (136 ref.)
Stress, smoking, and the cardiovascular system. Pomerleau OF, et al. **J Subst Abuse** 1989;1(3):331-43 (50 ref.)
Functional neuroanatomical correlates of the effects of stress on memory. Bremner JD, et al. **J Trauma Stress** 1995 Oct; 8(4):527-53 (115 ref.)
The relationship between stress and the development of breast cancer: a literature review. Bryla CM. **Oncol Nurs Forum** 1996 Apr;23(3):441-8 (50 ref.)
A cognitive science perspective on kindling and episode sensitization in recurrent affective disorder. Segal ZV, et al. **Psychol Med** 1996 Mar;26(2):371-80 (70 ref.)
[Current developments in psychoneuroimmunology and psycho-oncology] Müller N. **Geburtshilfe Frauenheilkd** 1996 Jun;56(6):M82-6 (34 ref.) **(Ger)**
[Burn-out syndrome] Klieser E, et al. **Med Monatsschr Pharm** 1996 Jan;19(1):17-20 (6 ref.) **(Ger)**
[How are psychological processes, the neuroendocrine system and immune system integrated?] Kaschka WP. **Z Klin Psychol Psychopathol Psychother** 1996;44(3):280-9 (50 ref.) (Eng. Abstr.) **(Ger)**

[Psychological stress and neuronal plasticity. An expanded model of the stress reaction process as the basis for understand central nervous system adaptation processes] Huether G, et al. **Z Psychosom Med Psychoanal** 1996; 42(2):107–27 (70 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Sociocultural and therapeutic perspectives on violence. Blue HC, et al. **Psychiatr Clin North Am** 1995 Sep;18(3):571–87 (103 ref.)

ETIOLOGY

Target-controlled infusions: stress free anesthesia? Kenny GN, et al. **J Clin Anesth** 1996 May;8(3 Suppl):15S–20S (46 ref.)

Genetic testing for cancer predisposition: behavioral science issues. Lerman C, et al. **J Natl Cancer Inst Monogr** 1995; (17):63–6 (27 ref.)

The parents of a severely dependent child. Keeley D, et al. **Practitioner** 1995 Sep;239(1554):505–8, 510, 512 (0 ref.)

[Health effects of unemployment] Korzeniewska M. **Med Pr** 1995;46(4):407–14 (34 ref.) (Eng. Abstr.) **(Pol)**

IMMUNOLOGY

Stress, immune function, and relationship to pregnancy outcome. Gennaro S, et al. **Nurs Clin North Am** 1996 Jun; 31(2):293–303 (69 ref.)

Psychobiologic reactivity to stress and childhood respiratory illnesses: results of two prospective studies. Boyce WT, et al. **Psychosom Med** 1995 Sep–Oct;57(5):411–22 (113 ref.)

[Stress and the immune system] Schedlowski M, et al. **Naturwissenschaften** 1996 May;83(5):214–20 (78 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

CRH overproduction in transgenic mice: behavioral and immune system modulation. Stenzel-Poore MP, et al. **Ann N Y Acad Sci** 1996 Mar 22;780:36–48 (70 ref.)

Noradrenergic and serotonergic abnormalities in depression: stress-induced dysfunction? Dinan TG. **J Clin Psychiatry** 1996;57 Suppl 4:14–8 (43 ref.)

Anorexia nervosa, self-starvation and the reward of stress. Bergh C, et al. **Nat Med** 1996 Jan;2(1):21–2 (13 ref.)

Stress, immune function, and relationship to pregnancy outcome. Gennaro S, et al. **Nurs Clin North Am** 1996 Jun; 31(2):293–303 (69 ref.)

The role of cardiovascular reactivity as a mediator of hypertension in African Americans. Falkner B. **Semin Nephrol** 1996 Mar;16(2):117–25 (52 ref.)

[Stress-protective role of the opioidergic system under conditions of military operations] Shanin VIu. **Fiziol Cheloveka** 1996 Mar–Apr;22(2):43–6 (11 ref.) **(Rus)**

[Stress and arterial hypertension] Iakobson GS, et al. **Patol Fiziol Eksp Ter** 1996 Jan–Mar;(1):30–4 (104 ref.) **(Rus)**

[Stress in the evolution of societies: a means for survival] Sudakov KV. **Zh Evol Biokhim Fiziol** 1995 Jul–Aug; 31(4):489–99 (51 ref.) **(Rus)**

PREVENTION & CONTROL

Caring for the lay caregiver. Ruppert RA. **Am J Nurs** 1996 Mar;96(3):40–5; quiz 46 (6 ref.)

[Stress management: individual differences and determination of situations (review of studies)] Makowska Z. **Med Pr** 1995;46(4):395–406 (31 ref.) (Eng. Abstr.) **(Pol)**

PSYCHOLOGY

Psychological processes in psychogenic voice disorder. Butcher P. **Eur J Disord Commun** 1995;30(4):467–74 (15 ref.)

Duodenal ulcer: the helicobacterization of a psychosomatic disease? Melmed RN, et al. **Isr J Med Sci** 1996 Mar–Apr; 32(3–4):211–6 (66 ref.)

Chronic illness and the family life-cycle. Newby NM. **J Adv Nurs** 1996 Apr;23(4):786–91 (29 ref.)

Evolution of parental stress and coping processes: a framework for critical care practice. LaMontagne LL, et al. **J Pediatr Nurs** 1995 Aug;10(4):212–8 (13 ref.)

Hardiness and stress: a critical review. Huang C. **Matern Child Nurs J** 1995 Jul–Sep;23(3):82–9 (36 ref.)

NGF regulatory role in stress and coping of rodents and humans. Alleva E, et al. **Pharmacol Biochem Behav** 1996 May;54(1):65–72 (110 ref.)

Recent developments in anxiety, stress, and depression. File SE. **Pharmacol Biochem Behav** 1996 May;54(1):3–12 (156 ref.)

Role of 5-HT in stress, anxiety, and depression. Graeff FG, et al. **Pharmacol Biochem Behav** 1996 May;54(1):129–41 (112 ref.)

Stress: a major variable in the psychopharmacologic response. Stanford SC. **Pharmacol Biochem Behav** 1996 May;54(1):211–7 (49 ref.)

Psychobiologic reactivity to stress and childhood respiratory illnesses: results of two prospective studies. Boyce WT, et al. **Psychosom Med** 1995 Sep–Oct;57(5):411–22 (113 ref.)

Stress, reactivity, and disease [editorial] Cohen S, et al. **Psychosom Med** 1995 Sep–Oct;57(5):423–6 (14 ref.)

Effect of chronic stress associated with unemployment on salivary cortisol: overall cortisol levels, diurnal rhythm, and acute stress reactivity. Ockenfels MC, et al. **Psychosom Med** 1995 Sep–Oct;57(5):460–7 (61 ref.)

[Stress and anxiety] González de Rivera y Revuelta JL. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1995 Nov–Dec;23(6):310–3 (33 ref.) (Eng. Abstr.) **(Spa)**

[Stress as a precipitating factor in migraine] Galiano L, et al. **Rev Neurol** 1995 Jul–Aug;23(122):830–2 (10 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

Relief of suffering: where the art and science of medicine meet. O'Brien ME. **Postgrad Med** 1996 Jun;99(6):189–92, 197–200, 206–8 (14 ref.)

Stress management for the cardiovascular patient: a look at current treatment and trends. Ulmer D. **Prog Cardiovasc Nurs** 1996 Winter;11(1):21–9 (31 ref.)

Sociocultural and therapeutic perspectives on violence. Blue HC, et al. **Psychiatr Clin North Am** 1995 Sep;18(3):571–87 (103 ref.)

STRESS TEST see **EXERCISE TEST**

STRESSFUL EVENTS see **LIFE CHANGE EVENTS**

STRETCH RECEPTORS see **MECHANORECEPTORS**

STRETCH RECEPTORS, ARTERIAL see **PRESSORECEPTORS**

STRETCH RECEPTORS, MUSCLE see **MUSCLE SPINDLES**

STRETCH RECEPTORS, VASCULAR see **PRESSORECEPTORS**

STRIATE CORTEX see **VISUAL CORTEX**

STRIATED BORDER see **MICROVILLI**

STRIDOR see **RESPIRATORY SOUNDS**

STROKE see **CEREBROVASCULAR DISORDERS**

STROKE VOLUME

The assessment of left ventricular function by echocardiography. Gillespie ND, et al. **Scott Med J** 1995 Oct;40(5):132–3 (19 ref.)

[Arrhythmogenic right ventricle: dysplasia or cardiomyopathy? Value of left ventricle ejection fraction] Fontaine G, et al. **Ann Cardiol Angeiol (Paris)** 1995 Sep; 44(7):321–31 (37 ref.) (Eng. Abstr.) **(Fre)**

[Coronary artery bypass grafting for a patient with left ventricular ejection fraction of 16%: a case report and review of the Japanese literature] Aiba M, et al. **Kyobu Geka** 1995 Sep;48(10):861–4 (10 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

[Continuous monitoring of minute cardiac volume] Jansen JR. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May;31(1 Suppl):S30–4 (26 ref.) **(Ger)**

STROMAL CELLS

IMMUNOLOGY

Thymocyte-stromal-cell interactions and T-cell selection. Owen JJ, et al. **Immunol Today** 1995 Jul;16(7):336–8 (9 ref.)

In-vitro models of stroma-dependent lymphopoiesis. Péault B. **Semin Immunol** 1995 Jun;7(3):169–75 (76 ref.)

PATHOLOGY

Cellular changes involved in conversion of normal to malignant breast: importance of the stromal reaction. Rønnov-Jessen L, et al. **Physiol Rev** 1996 Jan;76(1):69–125 (630 ref.)

Gastrointestinal stromal tumors—a recently defined entity. Literature data and personal case report. Laky D, et al. **Rom J Morphol Embryol** 1995 Jan–Jun;41(1–2):73–8 (20 ref.)

PHYSIOLOGY

Biology of bone marrow stroma. Clark BR, et al. **Ann N Y Acad Sci** 1995 Dec 29;770:70–8 (57 ref.)

Tumor-stromal cytokine interactions in ovarian neoplasms. Kacinski BM. **EXS** 1995;74:181–90 (59 ref.)

Regulation of scatter factor (hepatocyte growth factor) production by tumor-stroma interaction. Rosen EM, et al. **EXS** 1995;74:17–31 (51 ref.)

Stromal-epithelial interaction in type IV collagenase expression and activation: The role in cancer metastasis. Shi YE, et al. **EXS** 1995;74:215–34 (98 ref.)

STRONGYLOIDES

PHYSIOLOGY

Human strongyloidiasis. Grove DI. **Adv Parasitol** 1996; 38:251–309 (209 ref.)

STRONGYLOIDES STERCORALIS

Strongyloidiasis: new endoscopic findings. Choudhry U, et al. **Gastrointest Endosc** 1995 Aug;42(2):170–3 (20 ref.)

[Chronic recurrent subileus due to Strongyloides stercoralis infection under immunosuppressive therapy] Birck R, et al. **Dtsch Med Wochenschr** 1996 May 31;121(22):723–6 (17 ref.) (Eng. Abstr.) **(Ger)**

[Strongyloides stercoralis. Report of a case and review of the literature] Taranto NJ. **Acta Gastroenterol Latinoam** 1995;25(2):113–20 (48 ref.) (Eng. Abstr.) **(Spa)**

[Strongyloides stercoralis hyperinfection syndrome in a patient with human immunodeficiency virus (HIV) infection: report of a case and review of the literature] Del Carpio D, et al. **Rev Gastroenterol Peru** 1995 Sep–Dec; 15(3):290–5 (31 ref.) (Eng. Abstr.) **(Spa)**

STRONGYLOIDIASIS

[Strongyloides stercoralis. Report of a case and review of the literature] Taranto NJ. **Acta Gastroenterol Latinoam** 1995;25(2):113–20 (48 ref.) (Eng. Abstr.) **(Spa)**

COMPLICATIONS

[Chronic recurrent subileus due to Strongyloides stercoralis infection under immunosuppressive therapy] Birck R, et al. **Dtsch Med Wochenschr** 1996 May 31;121(22):723–6 (17 ref.) (Eng. Abstr.) **(Ger)**

[Strongyloides stercoralis hyperinfection syndrome in a patient with human immunodeficiency virus (HIV) infection: report of a case and review of the literature] Del Carpio D, et al. **Rev Gastroenterol Peru** 1995 Sep–Dec; 15(3):290–5 (31 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Strongyloidiasis: new endoscopic findings. Choudhry U, et al. **Gastrointest Endosc** 1995 Aug;42(2):170–3 (20 ref.)

Serodiagnosis of strongyloidiasis. The application and significance. Sato Y, et al. **Rev Inst Med Trop Sao Paulo** 1995 Jan–Feb;37(1):35–41 (30 ref.)

PARASITOLOGY

Human strongyloidiasis. Grove DI. **Adv Parasitol** 1996; 38:251–309 (209 ref.)

STRONTIUM

PHARMACOLOGY

Modulatory effects of selenium and strontium salts on keratinocyte-derived inflammatory cytokines. Celerier P, et al. **Arch Dermatol Res** 1995;287(7):680–2 (11 ref.)

STRONTIUM RADIOISOTOPES

ADVERSE EFFECTS

[The results of multiyear research on fish populations from reservoirs falling within the area of the Kyshtym accident (a review)] Fetisov AN. **Radiats Biol Radioecol** 1995 Sep–Oct;35(5):751–8 (19 ref.) (Eng. Abstr.) **(Rus)**

THERAPEUTIC USE

Strontium chloride Sr 89 for treating pain from metastatic bone disease. Nightengale B, et al. **Am J Health Syst Pharm** 1995 Oct 15;52(20):2189–95 (87 ref.)

Strontium-89 for treatment of painful bone metastasis from prostate cancer. Altman GB, et al. **Oncol Nurs Forum** 1996 Apr;23(3):523–7 (30 ref.)

G-STROPHANTHIN see **OUABAIN**

STRUCTURAL GENES see **GENES, STRUCTURAL**

STRUCTURE-ACTIVITY RELATIONSHIP

Thresholds of toxicological concern based on structure-activity relationships. Munro IC, et al. **Drug Metab Rev** 1996 Feb–May;28(1–2):209–17 (9 ref.)

Flavoprotein structure and mechanism. 8. Structure-function relations for old yellow enzyme. Karplus PA, et al. **FASEB J** 1995 Dec;9(15):1518–26 (39 ref.)

Predicting modes of toxic action from chemical structure: an overview. Bradbury SP. **SAR QSAR Environ Res** 1994; 2(1–2):89–104 (45 ref.)

Impact of biodegradation test methods on the development and applicability of biodegradation QSARs. Cowan CE, et al. **SAR QSAR Environ Res** 1996;5(1):37–49 (20 ref.)

A mechanistic approach to deriving quantitative structure-activity relationship models for microbial degradation of organic compounds. Damborský J. **SAR QSAR Environ Res** 1996;5(1):27–36 (57 ref.)

Descriptors and techniques for quantitative structure-biodegradability studies. Dearden JC. **SAR QSAR Environ Res** 1996;5(1):17–26 (40 ref.)

Implementation of the three-dimensional-pattern search problem on Hopfield-like neural networks. Feuilleaubois E, et al. **SAR QSAR Environ Res** 1993;1(2–3):97–114 (29

ref.)
U.S. EPA regulatory perspectives on the use of QSAR for new and existing chemical evaluations. Zeeman M, et al. **SAR QSAR Environ Res** 1995;3(3):179–201 (48 ref.)
Use of graph theoretic parameters in risk assessment of chemicals. Basak SC, et al. **Toxicol Lett** 1995 Sep; 79(1–3):239–50 (55 ref.)
Quantitative structure–activity relationships and ecological risk assessment: an overview of predictive aquatic toxicology research. Bradbury SP. **Toxicol Lett** 1995 Sep; 79(1–3):229–37 (40 ref.)
Summary and recommendations for session B: activity classification and structure–activity relationship modeling for human health risk assessment of toxic substances. Bristol DW. **Toxicol Lett** 1995 Sep;79(1–3):265–80 (10 ref.)
The expanding role of quantitative structure–activity relationships (QSAR) in toxicology. Hansch C, et al. **Toxicol Lett** 1995 Sep;79(1–3):45–53 (11 ref.)
Structure–activity relationships and computer–assisted analysis of respiratory sensitization potential. Karol MH, et al. **Toxicol Lett** 1996 Aug;86(2–3):187–91 (10 ref.)
Toxicity estimation by chemical substructure analysis: the TOX II program. Klopman G, et al. **Toxicol Lett** 1995 Sep;79(1–3):145–55 (14 ref.)
Perspectives on collaboration and infrastructure development: industry perspectives. Knaak JB. **Toxicol Lett** 1995 Sep;79(1–3):305–12 (32 ref.)
Threshold of estimated toxicity for regulation of indirect food additives. Matthews EJ, et al. **Toxicol Lett** 1995 Sep; 79(1–3):123–9 (26 ref.)
Role of computational chemistry in support of hazard identification (ID): mechanism–based SARs. Richard AM. **Toxicol Lett** 1995 Sep;79(1–3):115–22 (31 ref.)
Development of structure–activity relationship rules for predicting carcinogenic potential of chemicals. Woo YT, et al. **Toxicol Lett** 1995 Sep;79(1–3):219–28 (18 ref.)
3D–QSAR: a current perspective. Green SM, et al. **Trends Pharmacol Sci** 1995 Sep;16(9):285–91 (66 ref.)
[Structure and activity: the joining of two methods] Rodriguez LA. **J Pharm Belg** 1996 May–Jun;51(3):176–86 (9 ref.) (Eng. Abstr.) **(Fre)**

STRUCTURE, MOLECULAR see **MOLECULAR STRUCTURE**

STRUMA OVARII

PATHOLOGY

[Struma ovarii. A case report] Barhmi R, et al. **Rev Fr Gynecol Obstet** 1995 Dec;90(12):539–41 (10 ref.) (Eng. Abstr.) **(Fre)**
[Struma ovarii. Three malignant cases and one benign case] Gamoudi A, et al. **Rev Fr Gynecol Obstet** 1995 Dec; 90(12):542–7 (17 ref.) (Eng. Abstr.) **(Fre)**

STUDENT HEALTH SERVICES

Inconsistencies in the literature on collegiate adult children of alcoholics: factors to consider for African Americans. Rodney HE. **J Am Coll Health** 1996 Jul;45(1):19–25 (58 ref.)

ORGANIZATION & ADMINISTRATION

Organizational and psychological consultation in collegiate sports medicine groups. Anderson MB, et al. **J Am Coll Health** 1995 Sep;44(2):63–9 (18 ref.)
Nurse–managed primary care center. Newland JA, et al. **Nurs Clin North Am** 1996 Sep;31(3):471–86 (20 ref.)

STUDENT LOANS see **TRAINING SUPPORT**

STUDENT SELECTION see **SCHOOL ADMISSION CRITERIA**

STUDENTS

AIDS education for college students: review and proposal for a research–based curriculum. Mulvihill CK. **AIDS Educ Prev** 1996 Feb;8(1):11–25 (72 ref.)
Training in the management of critical obstetric problems: trainee's view. Mikkelsen B, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Mar;65(1):149–51 (9 ref.)
School readiness. Lewit EM, et al. **Future Child** 1995 Summer–Fall;5(2):128–39 (26 ref.)

PSYCHOLOGY

A study of the development of traits of entry–level occupational therapy students. Donohue MV. **Am J Occup Ther** 1995 Jul–Aug;49(7):703–9 (22 ref.)
Outcomes for youths with serious emotional disturbance in secondary school and early adulthood. Wagner MM. **Future Child** 1995 Summer–Fall;5(2):90–112 (37 ref.)

STUDENTS, MEDICAL

Narrowing the gap between rhetoric and the reality of medical ethics. Silverman DR. **Acad Med** 1996 Mar; 71(3):227–37 (109 ref.)

PSYCHOLOGY

Decline of U.S. medical student career choice of psychiatry and what to do about it. Sierles FS, et al. **Am J Psychiatry** 1995 Oct;152(10):1416–26 (127 ref.)

STUDENTS, NURSING

A research development program for minority honors students. Inouye J. **J Nurs Educ** 1995 Sep;34(6):268–71 (35 ref.)
The impact of violence in the health care setting upon nursing education. Whitley GG, et al. **J Nurs Educ** 1996 May; 35(5):211–8 (46 ref.)

PSYCHOLOGY

Critical thinking and intuitive nursing practice. Paul RW, et al. **J Adv Nurs** 1995 Jul;22(1):40–7 (5 ref.)
Inquiry based learning, nursing student attitudes and the HIV patient. Cerny JE, et al. **J Nurs Educ** 1996 May; 35(5):219–22 (24 ref.)
Empowerment of graduate nursing students: a dialogue toward change. Roberts SJ, et al. **J Prof Nurs** 1996 Jul–Aug;12(4):233–9 (25 ref.)

STUNNED MYOCARDIUM see **MYOCARDIAL STUNNING**

STURGE–WEBER SYNDROME

SURGERY

Hemispherectomy: a hemidecortication approach and review of 52 cases. Carson BS, et al. **J Neurosurg** 1996 Jun; 84(6):903–11 (59 ref.)

STUTTERING

DIAGNOSIS

The topography of beginning stuttering. Zebrowski PM. **J Commun Disord** 1995 Jun;28(2):75–91 (40 ref.)

DRUG THERAPY

[Possibilities of concomitant drug treatment of stuttering in childhood and adolescence] Marcus A, et al. **Z Kinder Jugenpsychiatr** 1995 Sep;23(3):182–94 (115 ref.) **(Ger)**

PSYCHOLOGY

Exploring the attitudes of adults who stutter. Watson JB. **J Commun Disord** 1995 Jun;28(2):143–64 (55 ref.)
Fluent speech, fast articulatory rate, and delayed auditory feedback: creating a crisis for a scientific revolution? Stuart A, et al. **Percept Mot Skills** 1996 Feb;82(1):211–8 (42 ref.)
[Stuttering] Grönroos M. **Duodecim** 1995;111(6):560–6 (24 ref.) **(Fin)**

THERAPY

Parents as partners: including mothers and fathers in the treatment of children who stutter. Kelly EM. **J Commun Disord** 1995 Jun;28(2):93–105 (50 ref.)
Parents' speech and children's stuttering: a critique of the literature. Nippold MA, et al. **J Speech Hear Res** 1995 Oct; 38(5):978–89 (57 ref.)

STYRENES

see related
POLYSTYRENES

SUBACUTE SCLEROSING PANENCEPHALITIS

DIAGNOSIS

[Serial changes of MRI and SPECT findings in a case of adult–onset SSPE] Kunika N, et al. **Rinsho Shinkeigaku** 1995 Nov;35(11):1214–20 (26 ref.) (Eng. Abstr.) **(Jpn)**

VIROLOGY

Measles virus infection of cerebral endothelial cells and effect on their adhesive properties. Cosby SL, et al. **Vet Microbiol** 1995 May;44(2–4):135–9 (21 ref.)

SUBARACHNOID HEMORRHAGE

COMPLICATIONS

Subarachnoid haemorrhage in ADPKD patients: how to recognize and how to manage? [editorial] Pirson Y, et al. **Nephrol Dial Transplant** 1996 Jul;11(7):1236–8 (10 ref.)
Traumatic occlusion of the anterior cerebral artery—case report. Ishibashi A, et al. **Neurol Med Chir (Tokyo)** 1995 Dec;35(12):882–5 (7 ref.)
Anticoagulation for prevention of cerebral infarcts following subarachnoid hemorrhage. Wang DZ, et al. **Surg Neurol** 1995 Sep;44(3):270–4 (22 ref.)
[Cerebral vasospasm following subarachnoid hemorrhage as studied from the mechanism of physiological smooth muscle contraction] Sakaki S, et al. **No Shinkei Geka** 1996 Jan;24(1):19–28 (34 ref.) **(Jpn)**

DIAGNOSIS

Neurophysiologic monitoring in the neuroscience intensive care unit. Jordan KG. **Neurol Clin** 1995 Aug;13(3):579–626 (95 ref.)

DRUG THERAPY

Clinical potential for the use of neuroprotective agents. A brief overview. Trembly B. **Ann N Y Acad Sci** 1995 Sep 15;765:1–20; discussion 26–7 (87 ref.)
Innovations in aneurysmal subarachnoid hemorrhage: intracisternal t–PA for the prevention of vasospasm. Bell TE, et al. **J Neurosci Nurs** 1996 Apr;28(2):107–13 (37 ref.)

ETIOLOGY

Subarachnoid haemorrhage and myths about saccular aneurysms. Weller RO. **J Clin Pathol** 1995 Dec; 48(12):1078–81 (29 ref.)
Management of aneurysmal subarachnoid hemorrhage. Miller J, et al. **Neurol Clin** 1995 Aug;13(3):451–78 (112 ref.)
A neurologist's reflections on boxing. III. Vascular injuries. Unterharnscheidt F. **Rev Neurol** 1995 Jul–Aug; 23(122):847–55 (27 ref.)
[Multiple dural arteriovenous shunts presenting as subarachnoid hemorrhage: a case report] Nimura K, et al. **No Shinkei Geka** 1995 Sep;23(9):819–24 (22 ref.) (Eng. Abstr.) **(Jpn)**
[Ictus, pregnancy and contraception] Pareja A, et al. **Rev Neurol** 1995;23 Suppl 1:S87–90 (27 ref.) **(Spa)**

PHYSIOPATHOLOGY

Neuroendocrine regulation of sodium and volume following subarachnoid hemorrhage. Diringer MN. **Clin Neuropharmacol** 1995 Apr;18(2):114–26 (64 ref.)
Complications of Swan–Ganz catheterization for hemodynamic monitoring in patients with subarachnoid hemorrhage. Rosenwasser RH, et al. **Neurosurgery** 1995 Nov;37(5):872–5; discussion 875–6 (21 ref.)
[Subarachnoid hemorrhage] Seiler RW, et al. **Ther Umsch** 1996 Jul;53(7):585–9 (14 ref.) (Eng. Abstr.) **(Ger)**

RADIOGRAPHY

Natural history of giant intracranial aneurysms and indications for intervention. Barrow DL, et al. **Clin Neurosurg** 1995;42:214–44 (106 ref.)

SURGERY

Perioperative management of aneurysmal subarachnoid hemorrhage: Part 1. Operative management. Guy J, et al. **Anesth Analg** 1995 Nov;81(5):1060–72 (154 ref.)
Perioperative management of aneurysmal subarachnoid hemorrhage: Part 2. Postoperative management. McGrath BJ, et al. **Anesth Analg** 1995 Dec;81(6):1295–302 (94 ref.)
Aneurysmal subarachnoid hemorrhage in a patient with bilateral A1 fenestrations associated with an azygos anterior cerebral artery. Case report and literature review. Friedlander RM, et al. **J Neurosurg** 1996 Apr;84(4):681–4 (33 ref.)
[Treatment of subarachnoid hemorrhage] Ohman J. **Duodecim** 1994;110(5):511–5 (27 ref.) **(Fin)**

THERAPY

[Management of subarachnoid hemorrhage] De Tribolet N. **Rev Med Suisse Romande** 1996 Aug;116(8):621–7 (29 ref.) **(Fre)**

SUBARACHNOID PRESSURE see **INTRACRANIAL PRESSURE**

SUBARACHNOID SPACE

PHYSIOPATHOLOGY

Spontaneous periodic hypothermia. Kloos RT. **Medicine (Baltimore)** 1995 Sep;74(5):268–80 (131 ref.)

SUBCELLULAR FRACTIONS

METABOLISM

Inositol trisphosphate and cyclic ADP ribose as long range messengers generating local subcellular calcium signals. Petersen OH. **J Physiol Paris** 1995;89(3):125–7 (16 ref.)

SUBCHONDRAL CYSTS see **BONE CYSTS**

SUBCLAVIAN ARTERY

ABNORMALITIES

Right aortic arch with aberrant left subclavian artery: aneurysmal dilatation causing symptomatic compression of the right main bronchus in an adult. Patiniotis TC, et al. **Aust N Z J Surg** 1995 Sep;65(9):690–2 (9 ref.)
Survival after aberrant right subclavian artery–esophageal fistula: case report and literature review. Miller RG, et al. **J Vasc Surg** 1996 Aug;24(2):271–5 (45 ref.)
Innominate artery enlargement in congenital arteriovenous

fistula with subsequent tracheal compression and stridor. Döhlemann C, et al. **Pediatr Cardiol** 1995 Nov-Dec; 16(6):287-90 (17 ref.)
[The surgical correction of the right aortic arch with aberrant left subclavian artery and left ligamentum arteriosum--a rare case from clinical practice] Baev B, et al. **Khirurgiia (Sofiia)** 1995;48(1):48-50 (14 ref.) (Eng. Abstr.) **(Bul)**

SURGERY

Late aneurysm after subclavian flap aortoplasty for coarctation of the aorta. Kino K, et al. **Ann Thorac Surg** 1996 Apr;61(4):1262-4 (8 ref.)
False aneurysm of the thyrocervical trunk: an unconventional surgical approach. Abrokwah J, et al. **Eur J Vasc Endovasc Surg** 1996 Apr;11(3):373-4 (4 ref.)
[The surgical correction of the right aortic arch with aberrant left subclavian artery and left ligamentum arteriosum--a rare case from clinical practice] Baev B, et al. **Khirurgiia (Sofiia)** 1995;48(1):48-50 (14 ref.) (Eng. Abstr.) **(Bul)**

SUBCLAVIAN VEIN

[Therapeutic attitude in postcatheterization symptomatic stenosis of the subclavian vein] Frikha I, et al. **Ann Cardiol Angeiol (Paris)** 1996 Mar;45(3):127-31 (39 ref.) (Eng. Abstr.) **(Fre)**

ABNORMALITIES

Innominate artery enlargement in congenital arteriovenous fistula with subsequent tracheal compression and stridor. Döhlemann C, et al. **Pediatr Cardiol** 1995 Nov-Dec; 16(6):287-90 (17 ref.)

SUBCONSCIOUS see **UNCONSCIOUS (PSYCHOLOGY)**

SUBCORNEAL PUSTULAR DERMATOSIS see **SKIN DISEASES, VESICULOBULLOUS**

SUBCUTANEOUS EMPHYSEMA

Subcutaneous emphysema. Samlaska CP, et al. **Adv Dermatol** 1996;11:117-51; discussion 152 (241 ref.)

ETIOLOGY

Nontraumatic subcutaneous emphysema in association with rectal carcinoma. Chow E, et al. **Can Assoc Radiol J** 1996 Apr;47(2):94-7 (12 ref.)
Pneumoscrotum: an unusual complication of pulmonary resection. Raudat CW, et al. **J Am Osteopath Assoc** 1996 Jun;96(6):362-3 (16 ref.)

SUBDURAL EMPYEMA see **EMPYEMA, SUBDURAL**

SUBICULUM see **HIPPOCAMPUS**

SUBLINGUAL GLAND NEOPLASMS

PATHOLOGY

Basal cell adenocarcinoma of the sublingual gland: report of a case. Mima T, et al. **J Oral Maxillofac Surg** 1996 Sep; 54(9):1121-3 (6 ref.)

SUBLINGUAL REGION see **MOUTH FLOOR**

SUBMANDIBULAR GLAND DISEASES

DIAGNOSIS

Sialadenosis of the salivary glands. Pape SA, et al. **Br J Plast Surg** 1995 Sep;48(6):419-22 (33 ref.)

SUBMANDIBULAR GLAND NEOPLASMS

PATHOLOGY

A case of submandibular teratoma. Mckiernan DC, et al. **J Laryngol Otol** 1995 Oct;109(10):992-4 (12 ref.)

SECONDARY

Submandibular gland metastasis of breast carcinoma: a case report and review of the literature. Vessecchia G, et al. **Virchows Arch** 1995;427(3):349-51 (25 ref.)

THERAPY

Case report: pleural encasement secondary to acinar adenocarcinoma of the submandibular gland. Hynes J, et al. **Br J Radiol** 1996 Mar;69(819):276-7 (12 ref.)

SUBSIDIES, EDUCATIONAL see **TRAINING SUPPORT**

SUBSIDIES, GOVERNMENT see **FINANCING, GOVERNMENT**

SUBSIDIES, RESEARCH see **RESEARCH SUPPORT**

SUBSTANCE ABUSE

see related
DRUG AND NARCOTIC CONTROL
STREET DRUGS

Analysis of drugs of abuse in biological fluids by liquid chromatography. Binder SR. **Adv Chromatogr** 1996; 36:201-71 (413 ref.)
Recurrent non-Q-wave myocardial infarction associated with toluene abuse. Hussain TF, et al. **Am Heart J** 1996 Mar;131(3):615-6 (6 ref.)
Cocaine-associated agitated delirium and the neuroleptic malignant syndrome. Wetli CV, et al. **Am J Emerg Med** 1996 Jul;14(4):425-8 (18 ref.)
Prenatally drug-exposed children in out-of-home care: are we looking at the whole picture? Franck EJ. **Child Welfare** 1996 Jan-Feb;75(1):19-34 (30 ref.)
The effects of family structure and family relations on adolescent marijuana use. Hoffmann JP. **Int J Addict** 1995 Aug;30(10):1207-41 (106 ref.)
Cocaine-associated myocardial infarction. Hollander JE. **J R Soc Med** 1996 Aug;89(8):443-7 (69 ref.)
The disease called addiction: emerging evidence in a 200-year debate. Meyer RE. **Lancet** 1996 Jan 20; 347(8995):162-6 (62 ref.)
Androgens in men--uses and abuses. Bagatell CJ, et al. **N Engl J Med** 1996 Mar 14;334(11):707-14 (91 ref.)
Schizophrenia and psychostimulant abuse: a review and re-analysis of clinical evidence. LeDuc PA, et al. **Psychopharmacology (Berl)** 1995 Oct;121(4):407-27 (85 ref.)
[Progresses in psychiatry in China, 1995] Zhang M, et al. **Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):725-6 (0 ref.) **(Chi)**
[Anabolic steroid abuse and mental disorder] Nakatani Y, et al. **Arukoru Kenkyuto Yakubutsu Ison** 1995 Oct; 30(5):333-47 (45 ref.) (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

Complications of laxative abuse. Baker EH, et al. **Annu Rev Med** 1996;47:127-34 (20 ref.)
Tuberculosis in drug users. Perlman DC, et al. **Clin Infect Dis** 1995 Nov;21(5):1253-64 (138 ref.)
Drugs of abuse and renal disease. Bakir AA, et al. **Curr Opin Nephrol Hypertens** 1996 Mar;5(2):122-6 (46 ref.)
Extreme methaemoglobinaemia secondary to recreational use of amyl nitrite. Edwards RJ, et al. **J Accid Emerg Med** 1995 Jun;12(2):138-42 (41 ref.)
Recent changes in the etiology of hearing disorders: perinatal drug exposure. Gerber SE, et al. **J Am Acad Audiol** 1995 Sep;6(5):371-7 (50 ref.)
Methamphetamine and driving impairment. Logan BK. **J Forensic Sci** 1996 May;41(3):457-64 (37 ref.)
Cocaine during pregnancy: a critical review of the literature. Offidani C, et al. **Minerva Ginecol** 1995 Sep;47(9):381-90 (40 ref.)
Cocaine-associated intracranial hemorrhage: absence of vasculitis in 14 cases. Aggarwal SK, et al. **Neurology** 1996 Jun;46(6):1741-3 (10 ref.)
Qualitative research methods in drug abuse and AIDS prevention research: an overview. Carlson RG, et al. **NIDA Res Monogr** 1995;157:6-26 (75 ref.)
Physical health problems associated with adolescent substance abuse. Kokotailo P. **NIDA Res Monogr** 1995; 156:112-29 (52 ref.)
AIDS, drugs, and the adolescent. Steel E. **NIDA Res Monogr** 1995;156:130-45 (34 ref.)
Drug use, AIDS, and ethnography: advanced ethnographic research methods exploring the HIV epidemic. Trotter RT 2nd. **NIDA Res Monogr** 1995;157:38-64 (10 ref.)
A guide to non-opiate illicit drugs. Robson P. **Practitioner** 1996 Mar;240(1560):140-8 (8 ref.)
Cocaine using during pregnancy and low birth weight: the impact of prenatal care and drug treatment. Chazotte C, et al. **Semin Perinatol** 1995 Aug;19(4):293-300 (40 ref.)

DIAGNOSIS

Identifying substance abuse in primary care. Haverkos HW, et al. **Am Fam Physician** 1995 Nov 15;52(7):2029-35 (24 ref.)
Psychoactive substance use in forensic psychiatry. Kermani EJ, et al. **Am J Drug Alcohol Abuse** 1996 Feb;22(1):1-27 (173 ref.)
Diagnosis and treatment of drug and alcohol abuse in women. Kaufman E. **Am J Obstet Gynecol** 1996 Jan;174(1 Pt 1):21-7 (27 ref.)
Issues in the assessment of personality disorder and substance abuse using the Millon Clinical Multiaxial Inventory (MCMI-II). Flynn PM, et al. **J Clin Psychol** 1995 May; 51(3):415-21 (24 ref.)
Current issues and future needs in the assessment of adolescent drug abuse. Winters KC, et al. **NIDA Res Monogr** 1995;156:146-71 (60 ref.)

DRUG THERAPY

Use of rodent self-administration models to develop pharmacotherapies for cocaine abuse. Dworkin SI, et al. **NIDA Res Monogr** 1994;145:88-112 (65 ref.)
Pharmacotherapy for adolescents with psychoactive substance use disorders. Kaminer Y. **NIDA Res Monogr** 1995;156:291-324 (101 ref.)

ECONOMICS

Estimating costs of mental health and substance abuse coverage. Frank RG, et al. **Health Aff (Millwood)** 1995 Fall;14(3):102-15 (17 ref.)
Financing strategies for drug abuse treatment programs. Zarkin GA, et al. **J Subst Abuse Treat** 1995 Nov-Dec; 12(6):385-99 (26 ref.)

EPIDEMIOLOGY

Epidemiology of illicit and abused drugs in the general population, emergency department drug-related episodes, and arrestees. Rouse BA. **Clin Chem** 1996 Aug;42(8 Pt 2):1330-6 (9 ref.)
Substance abuse and HIV pregnancy. Sprauve ME. **Clin Obstet Gynecol** 1996 Jun;39(2):316-32 (98 ref.)
Substance misuse in individuals with spinal cord injury. Radnitz CL, et al. **Int J Addict** 1995 Jul;30(9):1117-40 (50 ref.)
Drug use and HIV risk among gay and bisexual men: an overview. Battjes RJ. **NIDA Res Monogr** 1994;143:82-7 (4 ref.)
Co-morbidity and therapeutic community treatment. Jainchill N. **NIDA Res Monogr** 1994;144:209-31 (35 ref.)
Testing theory through developmental epidemiologically based prevention research. Kellam SG. **NIDA Res Monogr** 1994;139:37-57 (33 ref.)
Identifying high-risk youth: prevalence and patterns of adolescent drug abuse. Newcomb MD. **NIDA Res Monogr** 1995;156:7-38 (68 ref.)
HIV risk in drug-using adolescents. Smeriglio VL. **NIDA Res Monogr** 1994;143:132-4 (5 ref.)
Anabolic steroid use and associated health risk behaviours. Middleman AB, et al. **Sports Med** 1996 Apr;21(4):251-5 (26 ref.)
[Abuse of psychotropic drugs during driving] Lemoine P, et al. **Encephale** 1996 Jan-Feb;22(1):1-6 (39 ref.) (Eng. Abstr.) **(Fre)**
[MDMA--"ecstasy"] Keup W. **Med Monatsschr Pharm** 1996 Jan;19(1):2-5 (27 ref.) **(Ger)**

ETHNOLOGY

Drug prevention research with Hispanic populations: theoretical and methodological issues and a generic structural model. Castro FG, et al. **NIDA Res Monogr** 1994; 139:203-33 (51 ref.)
Drug abuse prevention research concerns in Asian and Pacific Islander populations. Kuramoto FH. **NIDA Res Monogr** 1994;139:249-72 (13 ref.)
Cultural competence in assessing Hispanic youths and families: challenges in the assessment of treatment needs and treatment evaluation for Hispanic drug-abusing adolescents. Kurtines WM, et al. **NIDA Res Monogr** 1995; 156:172-89 (30 ref.)
Drug prevention research with Native-American populations: some considerations. Powless Sage G. **NIDA Res Monogr** 1994;139:235-48 (18 ref.)

ETIOLOGY

Drugs and deprivation. Pearson G. **J R Soc Health** 1996 Apr;116(2):113-6 (40 ref.)

GENETICS

Genetics and primary prevention of drug and alcohol abuse. Tarter RE. **Int J Addict** 1995 Sep;30(11):1479-84 (14 ref.)

PATHOLOGY

The dopamine transporter. The cloned target site of parkinsonism-inducing toxins and of drugs of abuse. Pifl C, et al. **Adv Neurol** 1996;69:235-8 (9 ref.)

PHYSIOPATHOLOGY

Pathophysiological basis of vulnerability to drug abuse: role of an interaction between stress, glucocorticoids, and dopaminergic neurons. Piazza PV, et al. **Annu Rev Pharmacol Toxicol** 1996;36:359-78 (117 ref.)
Molecular and cellular aspects of nicotine abuse. Dani JA, et al. **Neuron** 1996 May;16(5):905-8 (25 ref.)

PREVENTION & CONTROL

Community-based approaches for the prevention of alcohol, tobacco, and other drug use. Aguirre-Molina M, et al. **Annu Rev Public Health** 1996;17:337-58 (121 ref.)
Evaluating government health and substance abuse programs for indigenous peoples: a comparative review. Gray D, et al. **Aust J Public Health** 1995 Dec;19(6):567-72 (62 ref.)
Drug use and human rights: privacy, vulnerability, disability, and human rights infringements. Gilmore N. **J Contemp Health Law Policy** 1996 Spring;12(2):355-447 (348 ref.)
The prevention of drug abuse--state of the art and directions for future actions. van Heeringen KC. **J Toxicol Clin Toxicol** 1995;33(6):575-9 (22 ref.)
Synthesis of behavioral science learnings about technology transfer. Backer TE, et al. **NIDA Res Monogr** 1995; 155:262-79 (2 ref.)
Issues in drug abuse prevention intervention research with African Americans. Beatty LA. **NIDA Res Monogr** 1994; 139:171-201 (68 ref.)
Reducing impediments to technology transfer in drug abuse

programming. Brown BS. **NIDA Res Monogr** 1995; 155:169–85 (38 ref.)

Drug prevention research with Hispanic populations: theoretical and methodological issues and a generic structural model. Castro FG, et al. **NIDA Res Monogr** 1994; 139:203–33 (51 ref.)

Prevention intervention research: focus and perspective. Cázares A. **NIDA Res Monogr** 1994;139:5–35 (47 ref.)

Some design, measurement, and analysis pitfalls in drug abuse prevention research and how to avoid them: let your model be your guide. Collins LM. **NIDA Res Monogr** 1994; 139:95–114 (26 ref.)

Organizational change as human process, not technique. Diamond MA. **NIDA Res Monogr** 1995;155:119–31 (10 ref.)

Correction for the design effect in school-based substance use and abuse prevention research: sample size requirements and analysis considerations. Dielman TE. **NIDA Res Monogr** 1994;139:115–25 (38 ref.)

Developing effective behavior change interventions: some lessons learned from behavioral research. Fishbein M. **NIDA Res Monogr** 1995;155:246–61 (27 ref.)

Technology transfer in the criminal justice field: implications for substance abuse. Gendreau P. **NIDA Res Monogr** 1995; 155:198–208 (35 ref.)

Hypothesis formulation and testing in substance use prevention research. Hansen WB. **NIDA Res Monogr** 1994; 139:59–74 (23 ref.)

Testing theory through developmental epidemiologically based prevention research. Kellam SG. **NIDA Res Monogr** 1994;139:37–57 (33 ref.)

Drug abuse prevention research concerns in Asian and Pacific Islander populations. Kuramoto FH. **NIDA Res Monogr** 1994;139:249–72 (13 ref.)

Transferring research findings on persuasion to improve drug abuse prevention programs. McGuire WJ. **NIDA Res Monogr** 1995;155:225–45 (8 ref.)

Target populations and interventions in prevention research: what is high risk? Pentz MA. **NIDA Res Monogr** 1994; 139:75–93 (32 ref.)

Creating strong attitudes: two routes to persuasion. Petty RE. **NIDA Res Monogr** 1995;155:209–24 (33 ref.)

Drug prevention research with Native-American populations: some considerations. Powless Sage G. **NIDA Res Monogr** 1994;139:235–48 (18 ref.)

Diffusion of drug abuse prevention programs: spontaneous diffusion, agenda setting, and reinvention. Rogers EM. **NIDA Res Monogr** 1995;155:90–105 (10 ref.)

A field-based dissemination component in a drug abuse research center. Sorensen JL, et al. **NIDA Res Monogr** 1995;155:186–97 (24 ref.)

Young people and alcohol, drugs and tobacco. Anderson K. **WHO Reg Publ Eur Ser** 1995;66:1–83 (59 ref.)

PSYCHOLOGY

Female drug abusers and the context of their HIV transmission risk behaviors. Allen K. **NIDA Res Monogr** 1994;143:48–63 (14 ref.)

Assessing and enhancing readiness for change: implications for technology transfer. Backer TE. **NIDA Res Monogr** 1995;155:21–41 (40 ref.)

HIV risk in adolescents: the role of sexual activity and substance use behaviors. Boyer CB, et al. **NIDA Res Monogr** 1994;143:135–54 (51 ref.)

Adolescent substance use disorder with conduct disorder and comorbid conditions. Crowley TJ, et al. **NIDA Res Monogr** 1995;156:49–111 (178 ref.)

The therapeutic community: toward a general theory and model. De Leon G. **NIDA Res Monogr** 1994;144:16–53 (24 ref.)

Developing effective behavior change interventions: some lessons learned from behavioral research. Fishbein M. **NIDA Res Monogr** 1995;155:246–61 (27 ref.)

Qualitative research considerations and other issues in the study of methamphetamine use among men who have sex with other men. Gorman EM, et al. **NIDA Res Monogr** 1995;157:156–81 (77 ref.)

HIV/AIDS risks among male, heterosexual noninjecting drug users who exchange crack for sex. Inciardi JA. **NIDA Res Monogr** 1994;143:26–40 (66 ref.)

Substance use and HIV-transmitting behaviors among gay and bisexual men. Ostrow DG. **NIDA Res Monogr** 1994; 143:88–113 (35 ref.)

Going nowhere fast: methamphetamine use and HIV infection. Rotheram-Borus MJ, et al. **NIDA Res Monogr** 1994;143:155–82 (33 ref.)

Using focus groups in drug abuse and HIV/AIDS research. Shedlin MG, et al. **NIDA Res Monogr** 1995;157:136–55 (13 ref.)

Socialization into the therapeutic community culture. Szalay L. **NIDA Res Monogr** 1994;144:54–79 (21 ref.)

Drug use, AIDS, and ethnography: advanced ethnographic research methods exploring the HIV epidemic. Trotter RT 2nd. **NIDA Res Monogr** 1995;157:38–64 (10 ref.)

Drug use and HIV risk among male sex workers: results of two samples in San Francisco. Waldorf D. **NIDA Res Monogr** 1994;143:114–31 (18 ref.)

Cultural aspects of substance abuse and alcoholism. Assessment and management. Westermeyer J. **Psychiatr Clin North Am** 1995 Sep;18(3):589–605 (68 ref.)

Risk factors for adolescent suicide and suicidal behavior: mental and substance abuse disorders, family environmental factors, and life stress. Brent DA. **Suicide Life Threat Behav** 1995;25 Suppl:52–63 (44 ref.)

REHABILITATION

Chemically dependent patients in recovery: roles for the family physician. Del Toro IM, et al. **Am Fam Physician** 1996 Apr;53(5):1667–81 (19 ref.)

Quality improvement and substance abuse: rethinking impaired provider policies. Corsino BV, et al. **Am J Med Qual** 1996 Summer;11(2):94–9 (21 ref.)

Buprenorphine as a pharmacotherapy for cocaine abuse: a review of the evidence. Compton PA, et al. **J Addict Dis** 1995;14(3):97–114 (56 ref.)

Clinical issues in therapeutic communities. Carroll JF. **NIDA Res Monogr** 1994;144:268–79 (9 ref.)

Client outcomes from therapeutic communities. Condelli WS, et al. **NIDA Res Monogr** 1994;144:80–98 (29 ref.)

Predictors of retention in therapeutic communities. Condelli WS. **NIDA Res Monogr** 1994;144:117–27 (22 ref.)

Skills training for pregnant and parenting adolescents. Hall JA. **NIDA Res Monogr** 1995;156:255–90 (70 ref.)

Therapeutic communities in corrections and work release: some clinical and policy considerations. Inciardi JA, et al. **NIDA Res Monogr** 1994;144:259–67 (3 ref.)

Therapeutic communities for adolescents. Jainchill N, et al. **NIDA Res Monogr** 1995;156:190–217 (19 ref.)

Retention in therapeutic communities: challenges for the nineties. Lewis BF, et al. **NIDA Res Monogr** 1994; 144:99–116 (45 ref.)

Adolescents in therapeutic communities: retention and posttreatment outcome. Pompi KF. **NIDA Res Monogr** 1994;144:128–61 (28 ref.)

Posttreatment services for chemically dependent adolescents. Spear SF, et al. **NIDA Res Monogr** 1995;156:341–64 (73 ref.)

Therapeutic communities: substance abuse treatment for women. Stevens SJ, et al. **NIDA Res Monogr** 1994; 144:162–80 (30 ref.)

Socialization into the therapeutic community culture. Szalay L. **NIDA Res Monogr** 1994;144:54–79 (21 ref.)

Therapeutic communities in prison. Wexler HK, et al. **NIDA Res Monogr** 1994;144:181–208 (40 ref.)

THERAPY

Diagnosis and treatment of drug and alcohol abuse in women. Kaufman E. **Am J Obstet Gynecol** 1996 Jan;174(1 Pt 1):21–7 (27 ref.)

Challenges in moving from a traditional therapeutic community to a women and children's TC model. Brown VB, et al. **J Psychoactive Drugs** 1996 Jan–Mar;28(1):39–46 (16 ref.)

Advances in studies on acupuncture abstinence. Cui M. **J Tradit Chin Med** 1995 Dec;15(4):301–7, contd (32 ref.)

Management of cocaine abuse and dependence. Mendelson JH, et al. **N Engl J Med** 1996 Apr 11;334(15):965–72 (122 ref.)

Reviewing the behavioral science knowledge base on technology transfer. Introduction. Backer TE, et al. **NIDA Res Monogr** 1995;155:1–20 (23 ref.)

Prevention intervention research: focus and perspective. Cázares A. **NIDA Res Monogr** 1994;139:5–35 (47 ref.)

Youth Evaluation Services (YES): assessment, systems of referral, and treatment effects. Del Boca FK, et al. **NIDA Res Monogr** 1995;156:325–40 (11 ref.)

The therapeutic community: toward a general theory and model. De Leon G. **NIDA Res Monogr** 1994;144:16–53 (24 ref.)

Service delivery strategies for treating high-risk youth: delinquents, homeless, runaways, and sexual minorities. Farrow JA. **NIDA Res Monogr** 1995;156:39–48 (23 ref.)

Cocaine self-administration research: treatment implications. Foltin RW, et al. **NIDA Res Monogr** 1994;145:139–62 (38 ref.)

Co-morbidity and therapeutic community treatment. Jainchill N. **NIDA Res Monogr** 1994;144:209–31 (35 ref.)

Collaboration and diversity in technology transfer. Kavanagh KH. **NIDA Res Monogr** 1995;155:42–64 (81 ref.)

Family-based treatment for adolescent drug use: state of the science. Liddle HA, et al. **NIDA Res Monogr** 1995; 156:218–54 (153 ref.)

HIV and therapeutic communities. McCusker J, et al. **NIDA Res Monogr** 1994;144:232–58 (128 ref.)

Advances in adolescent drug abuse treatment. Rahdert E, et al. **NIDA Res Monogr** 1995;156:1–6 (5 ref.)

Therapeutic communities and treatment research. Tims FM, et al. **NIDA Res Monogr** 1994;144:1–15 (19 ref.)

Ethnicity and psychotherapy. A component in the treatment of cocaine addiction in African Americans. Foulks EF, et al. **Psychiatr Clin North Am** 1995 Sep;18(3):607–20 (59 ref.)

Treatment of adolescent substance abusers: issues for practice and research. Jenson JM, et al. **Soc Work Health Care** 1995; 21(2):1–18 (58 ref.)

SUBSTANCE ABUSE, INTRAVENOUS

see related
NEEDLE-EXCHANGE PROGRAMS
NEEDLE SHARING

Rahnella aquatilis bacteremia in an HIV-infected intravenous drug abuser. Funke G, et al. **Diagn Microbiol Infect Dis** 1995 Jul;22(3):293–6 (8 ref.)

COMPLICATIONS

AIDS behind bars: preventing HIV spread among incarcerated drug injectors [editorial] Dolan K, et al. **AIDS** 1995 Aug;9(8):825–32 (72 ref.)

Endocarditis in injection drug users. DeWitt DE, et al. **Am Fam Physician** 1996 May 1;53(6):2045–9 (24 ref.)

Injection drug use and human immunodeficiency virus infection. Alcabes P, et al. **Clin Infect Dis** 1995 Jun; 20(6):1467–79 (168 ref.)

Pyomyositis in intravenous drug abusers: report of a unique case and review of the literature. Hsueh PR, et al. **Clin Infect Dis** 1996 May;22(5):858–60 (10 ref.)

Chronic intestinal ischemia caused by intravenous cocaine use: report of two cases and review of the literature. Myers SI, et al. **J Vasc Surg** 1996 Apr;23(4):724–9 (23 ref.)

Context of HIV risk behavior among female injecting drug users and female sexual partners of injecting drug users. Hartel D. **NIDA Res Monogr** 1994;143:41–7 (31 ref.)

Applying the methodology of participant observation to the study of injection-related HIV risks. Koester S. **NIDA Res Monogr** 1995;157:84–99 (31 ref.)

Network models for HIV outreach and prevention programs for drug users. Trotter RT II, et al. **NIDA Res Monogr** 1995;151:144–80 (31 ref.)

[What are the non transfusional modes of transmission of hepatitis C virus?] Serfaty L, et al. **Gastroenterol Clin Biol** 1995 May;19(5):525–33 (110 ref.) **(Fre)**

EPIDEMIOLOGY

HIV risk behaviors of heterosexual male drug users. Needle RH. **NIDA Res Monogr** 1994;143:5–8 (2 ref.)

Syringe-mediated drug sharing among injecting drug users: patterns, social context and implications for transmission of blood-borne pathogens. Grund JP, et al. **Soc Sci Med** 1996 Mar;42(5):691–703 (89 ref.)

PSYCHOLOGY

Promising social network research results and suggestions for a research agenda. Friedman SR. **NIDA Res Monogr** 1995;151:196–215 (28 ref.)

Assessing the reliability and validity of self-reported risk behavior. Gibson DR, et al. **NIDA Res Monogr** 1994; 143:218–36 (13 ref.)

Injection and sexual risk behaviors of male heterosexual injecting drug users. Stephens RC, et al. **NIDA Res Monogr** 1994;143:9–25 (48 ref.)

Network models for HIV outreach and prevention programs for drug users. Trotter RT II, et al. **NIDA Res Monogr** 1995;151:144–80 (31 ref.)

Ethical and legal issues in social network research: the real and the ideal. Woodhouse DE, et al. **NIDA Res Monogr** 1995;151:131–43 (11 ref.)

REHABILITATION

Regulating controversial programs for unpopular people: methadone maintenance and syringe exchange programs [see comments] Des Jarlais DC, et al. **Am J Public Health** 1995 Nov;85(11):1577–84 (39 ref.) Comment in: Am J Public Health 1995 Nov;85(11):1490–1.

Syringe exchange: HIV prevention, key findings, and future directions. Paone D, et al. **Int J Addict** 1995;30(12):1647–83 (320 ref.)

SUBSTANCE ABUSE TREATMENT CENTERS

Access to substance abuse treatment for homeless women of reproductive age. Wenzel SL, et al. **J Psychoactive Drugs** 1996 Jan–Mar;28(1):17–30 (110 ref.)

Are detoxification programmes effective? [see comments] Mattick RP, et al. **Lancet** 1996 Jan 13;347(8994):97–100 (45 ref.) Comment in: Lancet 1996 Mar 30;347(9005):904.

ECONOMICS

Financing strategies for drug abuse treatment programs. Zarkin GA, et al. **J Subst Abuse Treat** 1995 Nov–Dec; 12(6):385–99 (26 ref.)

ORGANIZATION & ADMINISTRATION

Challenges in moving from a traditional therapeutic community to a women and children's TC model. Brown VB, et al. **J Psychoactive Drugs** 1996 Jan–Mar;28(1):39–46 (16 ref.)

A field-based dissemination component in a drug abuse research center. Sorensen JL, et al. **NIDA Res Monogr** 1995;155:186–97 (24 ref.)

STANDARDS

Evaluating the effectiveness of addiction treatments: reasonable expectations, appropriate comparisons. McLellan AT, et al. **Milbank Q** 1996;74(1):51–85 (69 ref.)

TRENDS

Regulating controversial programs for unpopular people: methadone maintenance and syringe exchange programs [see comments] Des Jarlais DC, et al. **Am J Public Health** 1995 Nov;85(11):1577–84 (39 ref.)

Comment in: Am J Public Health 1995 Nov;85(11):1490-1.

SUBSTANCE DEPENDENCE

see related
STREET DRUGS

Common addictions. Geller A. **Clin Symp** 1996;48(1):2-32 (32 ref.)
Prenatal cocaine exposure. Consequences for child and family. Eyler FD, et al. **J Fla Med Assoc** 1995 Sep; 82(9):603-6 (52 ref.)
Caffeine dependence: fact or fiction? Strain EC, et al. **J R Soc Med** 1995 Aug;88(8):437-40 (26 ref.)
Addiction: brain mechanisms and their treatment implications [see comments] Nutt DJ. **Lancet** 1996 Jan 6;347(8993):31-6 (47 ref.) Comment in: Lancet 1995 Jan 6;347(8993):6.
Pharmacology of barbiturate tolerance/dependence: GABAA receptors and molecular aspects. Ito T, et al. **Life Sci** 1996;59(3):169-95 (176 ref.)
Drug addiction: the yin and yang of hedonic homeostasis. Koob GF. **Neuron** 1996 May;16(5):893-6 (25 ref.)
Under siege: The brain on opiates. Nestler EJ. **Neuron** 1996 May;16(5):897-900 (26 ref.)
Overview of the effects of abuse and drugs on pregnancy and offspring. Zuckerman B, et al. **NIDA Res Monogr** 1995; 149:16-38 (89 ref.)

COMPLICATIONS

Cardiac arrest in cocaine users. Karch SB. **Am J Emerg Med** 1996 Jan;14(1):79-81 (30 ref.)
How to have a stroke at an early age: the effects of crack, cocaine and other illicit drugs. Blank-Reid C. **J Neurosci Nurs** 1996 Feb;28(1):19-27 (29 ref.)
Lung disease induced by drug addiction [editorial] [see comments] Benson MK, et al. **Thorax** 1995 Nov; 50(11):1125-7 (36 ref.) Comment in: Thorax 1996 May;51(5):556.
[Cocaine abuse and mental disease] Glyngdal P. **Ugeskr Laeger** 1996 Aug 12;158(33):4638-42 (39 ref.) (Eng. Abstr.) **(Dan)**
[Infectious complications of drug addiction] de Marie S. **Ned Tijdschr Geneeskd** 1995 Dec 16;139(50):2618-22 (47 ref.) **(Dut)**
[Hepatitis C virus infection. Epidemiology] Bastie A, et al. **Pathol Biol (Paris)** 1995 Oct;43(8):674-80 (78 ref.) (Eng. Abstr.) **(Fre)**
[Cocaine abuse--with special reference to cerebrovascular complications] Lalouschek W, et al. **Wien Klin Wochenschr** 1995;107(17):516-21 (65 ref.) (Eng. Abstr.) **(Ger)**
[Acute myocardial infarction in young age and drug dependence. Review of the literature and personal experience] Massari FM, et al. **G Ital Cardiol** 1995 Oct; 25(10):1273-83 (44 ref.) (Eng. Abstr.) **(Ita)**

DRUG THERAPY

Pharmacology of nicotine: addiction and therapeutics. Benowitz NL. **Annu Rev Pharmacol Toxicol** 1996; 36:597-613 (93 ref.)
A review of the effects of dopaminergic agents on humans, animals, and drug-seeking behavior, and its implications for medication development.Focus on GBR 12909. Rothman RB, et al. **Mol Neurobiol** 1995 Aug-Dec; 11(1-3):1-19 (130 ref.)
Pharmacotherapy for adolescents with psychoactive substance use disorders. Kaminer Y. **NIDA Res Monogr** 1995;156:291-324 (101 ref.)
Neurobiological mechanisms underlying the acquisition and expression of incentive motivation by cocaine-associated stimuli: relationship to craving. Pert A. **NIDA Res Monogr** 1994;145:163-90 (70 ref.)

ECONOMICS

Estimating costs of mental health and substance abuse coverage. Frank RG, et al. **Health Aff (Millwood)** 1995 Fall;14(3):102-15 (17 ref.)
Financing strategies for drug abuse treatment programs. Zarkin GA, et al. **J Subst Abuse Treat** 1995 Nov-Dec; 12(6):385-99 (26 ref.)

EPIDEMIOLOGY

The epidemiology of psychiatric disorders and the de facto mental health care system. Norquist GS, et al. **Annu Rev Med** 1996;47:473-9 (29 ref.)
Crack cocaine abuse: an epidemic with many public health consequences. Cornish JW, et al. **Annu Rev Public Health** 1996;17:259-73 (54 ref.)
Substance misuse in individuals with spinal cord injury. Radnitz CL, et al. **Int J Addict** 1995 Jul;30(9):1117-40 (50 ref.)
[MDMA--"ecstasy"] Keup W. **Med Monatsschr Pharm** 1996 Jan;19(1):2-5 (27 ref.) **(Ger)**
[Schizophrenia and substance dependence] Uchtenhagen A. **Schweiz Arch Neurol Psychiatr** 1995;146(5):215-23 (80 ref.) (Eng. Abstr.) **(Ger)**
[Abuse of alcohol and central nervous system stimulants. A growing problem in developing countries] Eide AH, et al. **Lakartidningen** 1995 Nov 29;92(48):4569-71 (31 ref.) **(Swe)**

ETHNOLOGY

The context of risk: ethnographic contributions to the study of drug use and HIV. Koester SK. **NIDA Res Monogr** 1994; 143:202-17 (36 ref.)
Culture in treatment, culture as treatment. A critical appraisal of developments in addictions programs for indigenous North Americans and Australians. Brady M. **Soc Sci Med** 1995 Dec;41(11):1487-98 (78 ref.)

ETIOLOGY

Addiction to benzodiazepines--how common? [see comments] Piper A Jr. **Arch Fam Med** 1995 Nov; 4(11):964-70 (111 ref.) Comment in: Arch Fam Med 1996 Jul-Aug;5(7):383-4. Comment in: Arch Fam Med 1996 Jul-Aug;5(7):384.
[Etiology and pathogenesis of addiction] van den Brink W. **Ned Tijdschr Geneeskd** 1995 Dec 16;139(50):2606-10 (35 ref.) **(Dut)**

GENETICS

Pharmacogenetics of cocaine: a critical review. Morse AC, et al. **Pharmacogenetics** 1995 Aug;5(4):183-92 (80 ref.)

IMMUNOLOGY

A shot in the arm for cocaine addiction. Slusher BS, et al. **Nat Med** 1996 Jan;2(1):26-7 (13 ref.)

METABOLISM

A review of the effects of dopaminergic agents on humans, animals, and drug-seeking behavior, and its implications for medication development.Focus on GBR 12909. Rothman RB, et al. **Mol Neurobiol** 1995 Aug-Dec; 11(1-3):1-19 (130 ref.)

NURSING

Intervention model for substance-using women. Tiedje LB, et al. **Image J Nurs Sch** 1996 Summer;28(2):113-8 (69 ref.)

PHYSIOPATHOLOGY

Pathophysiological basis of vulnerability to drug abuse: role of an interaction between stress, glucocorticoids, and dopaminergic neurons. Piazza PV, et al. **Annu Rev Pharmacol Toxicol** 1996;36:359-78 (117 ref.)
In vivo analysis of the role of dopamine in stimulant and opiate self-administration. Gratton A. **J Psychiatry Neurosci** 1996 Jul;21(4):264-79 (120 ref.)

PREVENTION & CONTROL

Women at risk for infection: the woman who is chemically dependent. Kendig S. **J Obstet Gynecol Neonatal Nurs** 1995 Oct;24(8):776-81 (38 ref.)
A shot in the arm for cocaine addiction. Slusher BS, et al. **Nat Med** 1996 Jan;2(1):26-7 (13 ref.)

PSYCHOLOGY

The motivation of addiction. Bell DS. **Acta Neurochir (Wien)** 1995;132(4):185-91 (27 ref.)
Modulation of drug-induced sensitization processes by endogenous opioid systems. Spanagel R. **Behav Brain Res** 1995 Sep;70(1):37-49 (148 ref.)
From controlled drug intake to loss of control: the irreversible development of drug addiction in the rat. Wolffgramm J, et al. **Behav Brain Res** 1995 Sep;70(1):77-94 (70 ref.)
[The addictive behavior of servicemen under combat conditions] Litvintsev SV, et al. **Voen Med Zh** 1995 Nov; (11):39-43, 80 (29 ref.) (Eng. Abstr.) **(Rus)**

REHABILITATION

Elevated rates of early discontinuation from pharmacotherapy trials in alcoholics and drug abusers. Kranzler HR, et al. **Alcohol Clin Exp Res** 1996 Feb; 20(1):16-20 (20 ref.)
Therapeutic communities for addictions: a theoretical framework. De Leon G. **Int J Addict** 1995;30(12):1603-45 (42 ref.)
A model for pharmacological research-treatment of cocaine dependence. Montoya ID, et al. **J Subst Abuse Treat** 1995 Nov-Dec;12(6):415-21 (44 ref.)
Key ingredients to effective addictions treatment. Waltman D. **J Subst Abuse Treat** 1995 Nov-Dec;12(6):429-39 (50 ref.)
Crime, disorder and legal pressure as a result of addiction problems in The Netherlands. Wolters RD. **Med Law** 1995; 14(7-8):521-9 (28 ref.)
Posttreatment services for chemically dependent adolescents. Spear SF, et al. **NIDA Res Monogr** 1995;156:341-64 (73 ref.)
[Craving--an adequately defined concept?] Wetterling T, et al. **Fortschr Neurol Psychiatr** 1996 Apr;64(4):142-52 (136 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Practice guideline for the treatment of patients with nicotine dependence. American Psychiatric Association. **Am J Psychiatry** 1996 Oct;153(10 Suppl):1-31 (219 ref.)
Treatment needs of drug-addicted mothers. Integrated parenting psychotherapy interventions. Luthar SS, et al. **J Subst Abuse Treat** 1995 Sep-Oct;12(5):341-8 (64 ref.)
Are detoxification programmes effective? [see comments] Mattick RP, et al. **Lancet** 1996 Jan 13;347(8994):97-100 (45 ref.) Comment in: Lancet 1996 Mar 30;347(9005):904.
What is important in drug misuse treatment? [see comments] Seivewright NA, et al. **Lancet** 1996 Feb 10;347(8998):373-6 (31 ref.) Comment in: Lancet 1996 Mar 30;347(9005):904.
Evaluating the effectiveness of addiction treatments: reasonable expectations, appropriate comparisons. McLellan AT, et al. **Milbank Q** 1996;74(1):51-85 (69 ref.)
Management of cocaine abuse and dependence. Mendelson JH, et al. **N Engl J Med** 1996 Apr 11;334(15):965-72 (122 ref.)
Pharmacological and behavioral treatment of cocaine addiction: animal models. Carroll ME. **NIDA Res Monogr** 1994;145:113-30 (26 ref.)
The management of opioid and benzodiazepine dependence in infants, children, and adolescents. Yaster M, et al. **Pediatrics** 1996 Jul;98(1):135-40 (41 ref.)
Culture in treatment, culture as treatment. A critical appraisal of developments in addictions programs for indigenous North Americans and Australians. Brady M. **Soc Sci Med** 1995 Dec;41(11):1487-98 (78 ref.)

SUBSTANCE K RECEPTORS see **RECEPTORS, NEUROKININ-2**

SUBSTANCE P

see related
RECEPTORS, NEUROKININ-1

ANALOGS & DERIVATIVES

The 'septide-sensitive' tachykinin receptor: still an enigma. Glowinski J. **Trends Pharmacol Sci** 1995 Nov;16(11):365-7 (34 ref.)

BLOOD

[Substance P] Matsubayashi S, et al. **Nippon Rinsho** 1995 Mar; 53 Su Pt 2:631-5 (44 ref.) **(Jpn)**

METABOLISM

Substance P and stress-induced changes in macrophages. Chancellor-Freeland C, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:472-84 (39 ref.)

PHYSIOLOGY

Neuroimmunomodulation: classical and non-classical cellular activation. Agro A, et al. **Adv Neuroimmunol** 1995; 5(3):311-9 (57 ref.)
Hypothalamic tachykinins. Mediators of stress responses? Culman J, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:204-18 (68 ref.)
White mineral and substance P. Weber KT. **Cardiovasc Res** 1996 May;31(5):675-82 (51 ref.)
Substance P: a neurotransmitter of amacrine and ganglion cells in the vertebrate retina. Kolb H, et al. **Histol Histopathol** 1995 Oct;10(4):947-68 (127 ref.)
Neuropeptides in morphologically and functionally identified primary afferent neurons in dorsal root ganglia: substance P, CGRP and somatostatin. Lawson SN. **Prog Brain Res** 1995;104:161-73 (56 ref.)

SUBSTANCE P RECEPTORS see **RECEPTORS, NEUROKININ-1**

SUBSTANCE USE DISORDERS

COMPLICATIONS

The management of treatment resistance in depressed patients with substance use disorders. Nunes EV, et al. **Psychiatr Clin North Am** 1996 Jun;19(2):311-27 (92 ref.)
Medical complications of glue sniffing. Meadows R, et al. **South Med J** 1996 May;89(5):455-62 (93 ref.)

DIAGNOSIS

Assessing substance use disorder in persons with severe mental illness. Drake RE, et al. **New Dir Ment Health Serv** 1996 Summer;(70):3-17 (75 ref.)

EPIDEMIOLOGY

Co-occurring addictive and mental disorders among adolescents: prevalence research and future directions. Greenbaum PE, et al. **Am J Orthopsychiatry** 1996 Jan; 66(1):52-60 (33 ref.)

GENETICS

The D2 dopamine receptor gene as a determinant of reward deficiency syndrome. Blum K, et al. **J R Soc Med** 1996 Jul;89(7):396-400 (66 ref.)

PSYCHOLOGY

Women with co-occurring addictive and mental disorders: an emerging profile of vulnerability. Alexander MJ. **Am J Orthopsychiatry** 1996 Jan;66(1):61-70 (86 ref.)
A vision for the future: toward a service system responsive to those with co-occurring addictive and mental disorders.

SUBSTANCE USE DISORDERS

Osher FC. **Am J Orthopsychiatry** 1996 Jan;66(1):71–6 (16 ref.)

Adolescent substance use disorder with conduct disorder and comorbid conditions. Crowley TJ, et al. **NIDA Res Monogr** 1995;156:49–111 (178 ref.)

REHABILITATION

Ambulatory medical detoxification for alcohol. Abbott PJ, et al. **Am J Drug Alcohol Abuse** 1995 Nov;21(4):549–63 (30 ref.)

Treatment of co-occurring substance abuse and major mental illness. Carey KB. **New Dir Ment Health Serv** 1996 Summer;(70):19–31 (31 ref.)

Family support for persons with dual disorders. Clark RE. **New Dir Ment Health Serv** 1996 Summer;(70):65–78 (54 ref.)

Group treatment for dually diagnosed clients. Mueser KT, et al. **New Dir Ment Health Serv** 1996 Summer;(70):33–51 (35 ref.)

Housing for persons with co-occurring mental and addictive disorders. Osher FC, et al. **New Dir Ment Health Serv** 1996 Summer;(70):53–64 (37 ref.)

THERAPY

The course, treatment, and outcome of substance disorder in persons with severe mental illness. Drake RE, et al. **Am J Orthopsychiatry** 1996 Jan;66(1):42–51 (66 ref.)

Psychosocial treatment for drug abuse. Selected review and recommendations for national health care. Crits-Christoph P, et al. **Arch Gen Psychiatry** 1996 Aug;53(8):749–56 (54 ref.)

SUBSTANCE WITHDRAWAL, NEONATAL see **NEONATAL ABSTINENCE SYNDROME**

SUBSTANCE WITHDRAWAL SYNDROME

[Acute exacerbation by reactivation of HBV in steroid withdrawal therapy] Arase Y. **Nippon Rinsho** 1995 Oct;53 Suppl:522–6 (6 ref.) **(Jpn)**

[Pathogenic mechanism of fulminant hepatic failure in HBs Ag carrier after withdrawal of cytotoxic chemotherapy] Inoue K, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:467–72 (22 ref.) **(Jpn)**

DRUG THERAPY

Therapy of alcohol withdrawal syndrome in intensive care unit patients following trauma: results of a prospective, randomized trial. Spies CD, et al. **Crit Care Med** 1996 Mar; 24(3):414–22 (64 ref.)

Is clonidine an effective smoking cessation therapy? Gourlay SG, et al. **Drugs** 1995 Aug;50(2):197–207 (83 ref.)

The effects of NMDA receptor antagonists and nitric oxide synthase inhibitors on opioid tolerance and withdrawal. Medication development issues for opiate addiction. Herman BH, et al. **Neuropsychopharmacology** 1995 Dec; 13(4):269–93 (165 ref.)

Perspectives on the N-methyl-D-aspartate/nitric oxide cascade and opioid tolerance. Pasternak GW, et al. **Neuropsychopharmacology** 1995 Dec;13(4):309–13 (24 ref.)

Effects of noncompetitive N-methyl-D-aspartate receptor antagonists on opiate tolerance and physical dependence. Trujillo KA. **Neuropsychopharmacology** 1995 Dec; 13(4):301–7 (38 ref.)

Nitric oxide synthase inhibitors. Preclinical studies of potential use for treatment of opioid withdrawal. Vaupel DB, et al. **Neuropsychopharmacology** 1995 Dec; 13(4):315–22 (27 ref.)

Drugs that modify opioid tolerance, physical dependence, and abstinence symptoms: preclinical and clinical studies. Bhargava HN. **NIDA Res Monogr** 1995;147:53–83 (127 ref.)

Inhibitors of nitric oxide synthase and the opioid withdrawal syndrome. London ED, et al. **NIDA Res Monogr** 1995; 147:170–81 (26 ref.)

Neurobiological mechanisms underlying the acquisition and expression of incentive motivation by cocaine-associated stimuli: relationship to craving. Pert A. **NIDA Res Monogr** 1994;145:163–90 (70 ref.)

100 years of ibogaine: neurochemical and pharmacological actions of a putative anti-addictive drug. Popik P, et al. **Pharmacol Rev** 1995 Jun;47(2):235–53 (224 ref.)

Benzodiazepines for alcohol withdrawal in the elderly and in patients with liver disease. Peppers MP. **Pharmacotherapy** 1996 Jan-Feb;16(1):49–57 (49 ref.)

EPIDEMIOLOGY

The epidemiology of drug-induced akathisia: Part II. Chronic, tardive, and withdrawal akathisias. Sachdev P. **Schizophr Bull** 1995;21(3):451–61 (70 ref.)

ETIOLOGY

Discontinuation reactions following sertraline. Leiter FL, et al. **Biol Psychiatry** 1995 Nov 15;38(10):694–5 (7 ref.)

Parkinsonism in alcohol withdrawal: case report and review of the literature. Luijckx GJ, et al. **Clin Neurol Neurosurg** 1995 Nov;97(4):336–9 (18 ref.)

[Recurrent amiodarone lung toxicity after withdrawal of the drug and treatment with corticoids] Donado Uña JR, et al. **Arch Bronconeumol** 1995 Oct;31(8):426–8 (13 ref.) (Eng. Abstr.) **(Spa)**

METABOLISM

The role of the locus coeruleus and N-methyl-D-aspartic acid (NMDA) and AMPA receptors in opiate withdrawal. Rasmussen K. **Neuropsychopharmacology** 1995 Dec; 13(4):295–300 (165 ref.)

PHYSIOPATHOLOGY

Factors influencing the success of withdrawal of antihypertensive drug therapy. Jennings GL, et al. **Blood Press Suppl** 1995;2:99–107 (28 ref.)

Cocaine reward and cocaine craving: the role of dopamine in perspective. Wise RA. **NIDA Res Monogr** 1994; 145:191–206 (92 ref.)

PREVENTION & CONTROL

Azapirones: an alternative to benzodiazepines for anxiety. Cadieux RJ. **Am Fam Physician** 1996 May 15;53(7):2349–53 (23 ref.)

PSYCHOLOGY

Drugs that modify opioid tolerance, physical dependence, and abstinence symptoms: preclinical and clinical studies. Bhargava HN. **NIDA Res Monogr** 1995;147:53–83 (127 ref.)

[Craving—an adequately defined concept?] Wetterling T, et al. **Fortschr Neurol Psychiatr** 1996 Apr;64(4):142–52 (136 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Nicotine addiction and treatment. Rose JE. **Annu Rev Med** 1996;47:493–507 (111 ref.)

Are detoxification programmes effective? [see comments] Mattick RP, et al. **Lancet** 1996 Jan 13;347(8994):97–100 (45 ref.) Comment in: Lancet 1996 Mar 30;347(9005):904.

SUBSTANTIA NIGRA

DRUG EFFECTS

Human substantia nigra in vitro as a bioassay for neurotrophic molecules of clinical significance. Silani V, et al. **Adv Neurol** 1996;69:253–62 (31 ref.)

PATHOLOGY

Functional positron emission tomographic studies of striatal dopaminergic activity. Changes induced by drugs and nigrostriatal degeneration. Tedroff J, et al. **Adv Neurol** 1996;69:443–8 (31 ref.)

Dopamine-induced, genotoxic activation of programmed cell death. A role in nigrostriatal neuronal degeneration in Parkinson's disease? Ziv I, et al. **Adv Neurol** 1996;69:229–33 (26 ref.)

Grumose or foamy spheroid bodies involving astrocytes in the human brain. Arai N. **Neuropathol Appl Neurobiol** 1995 Jun;21(3):238–45 (27 ref.)

PHYSIOPATHOLOGY

The use of PET in Parkinson's disease. Shinotoh H, et al. **Brain Cogn** 1995 Aug;28(3):297–310 (67 ref.)

Multiple system atrophy. Quinn N, et al. **Curr Opin Neurol** 1995 Aug;8(4):323–6 (28 ref.)

Basic research in substantia nigra and ventral tegmental area: clinical implications. Stratta F, et al. **J Neural Transm Suppl** 1995;45:47–55 (65 ref.)

Endogenous control of epilepsy: the nigral inhibitory system. Depaulis A, et al. **Prog Neurobiol** 1994 Jan;42(1):33–52 (186 ref.)

RADIONUCLIDE IMAGING

Hemiatrophy, juvenile-onset exertional alternating leg paresis, hypotonia, and hemidystonia and adult-onset hemiparkinsonism: the spectrum of hemiparkinsonism-hemiatrophy syndrome. Lang AE. **Mov Disord** 1995 Jul;10(4):489–95 (32 ref.)

TRANSPLANTATION

[Neurotransplantation in Parkinson disease: experimental and clinical results of functional reconstruction of the dopaminergic system] Nikkhah G, et al. **Zentralbl Neurochir** 1995;56(4):153–60 (29 ref.) (Eng. Abstr.) **(Ger)**

SUBTALAR JOINT

INJURIES

Subtalar joint dislocations. Bohay DR, et al. **Foot Ankle Int** 1995 Dec;16(12):803–8 (16 ref.)

Traumatic talectomy without fracture: four case reports and review of the literature. Jaffe KA, et al. **Foot Ankle Int** 1995 Sep;16(9):583–7 (30 ref.)

PATHOLOGY

Accessory calcaneus: a case report and literature review. Krause JO, et al. **Foot Ankle Int** 1995 Oct;16(10):646–50 (11 ref.)

SURGERY

Traumatic talectomy without fracture: four case reports and review of the literature. Jaffe KA, et al. **Foot Ankle Int** 1995 Sep;16(9):583–7 (30 ref.)

Extraosseous Ewing's sarcoma in the foot. Berliner RA, et al. **J Foot Ankle Surg** 1995 May-Jun;34(3):301–4 (6 ref.)

SUBTILISINS

[A family of Kex2-like endoproteases involved in processing of precursors for biologically active peptides and proteins] Nakayama K. **Seikagaku** 1995 Aug;67(8):995–1009 (95 ref.) **(Jpn)**

METABOLISM

Proenkephalin-processing enzymes in chromaffin granules: model for neuropeptide biosynthesis. Hook VY, et al. **Ann N Y Acad Sci** 1996 Mar 22;780:121–33 (22 ref.)

The role of prohormone convertases in insulin biosynthesis: evidence for inherited defects in their action in man and experimental animals. Steiner DF, et al. **Diabetes Metab** 1996 Apr;22(2):94–104 (72 ref.)

Furin/PACE/SPC1: a convertase involved in exocytic and endocytic processing of precursor proteins. Denault JB, et al. **FEBS Lett** 1996 Jan 29;379(2):113–6 (46 ref.)

Proteolytic processing mechanisms in the biosynthesis of neuroendocrine peptides: the subtilisin-like proprotein convertases. Rouillé Y, et al. **Front Neuroendocrinol** 1995 Oct;16(4):322–61 (202 ref.)

PHYSIOLOGY

Implications of the subtilisin/kexin-like precursor convertases in the development and function of nervous tissues. Marcinkiewicz M, et al. **Acta Neurobiol Exp (Warsz)** 1996;56(1):287–98 (60 ref.)

Influenza viruses, cell enzymes, and pathogenicity. Rott R, et al. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 2):S16–9 (45 ref.)

SUBTRACTION ANGIOGRAPHY, DIGITAL see **ANGIOGRAPHY, DIGITAL SUBTRACTION**

SUBTROCHANTERIC FRACTURES see **HIP FRACTURES**

SUBVALVULAR STENOSIS, IDIOPATHIC HYPERTROPHIC see **CARDIOMYOPATHY, HYPERTROPHIC**

SUCCIMER

DIAGNOSTIC USE

A review of renal scarring in children. MacKenzie JR. **Nucl Med Commun** 1996 Mar;17(3):176–90 (44 ref.)

SUCCINATE DEHYDROGENASE

CHEMISTRY

A structural model for the membrane-integral domain of succinate: quinone oxidoreductases. Hägerhäll C, et al. **FEBS Lett** 1996 Jun 24;389(1):25–31 (59 ref.)

SUCCINIC OXIDASE see **SUCCINATE DEHYDROGENASE**

SUCCINYLCHOLINE

ADVERSE EFFECTS

Variants of malignant hyperthermia. Special problems for the paediatric anaesthesiologist. Rosenberg H, et al. **Paediatr Anaesth** 1996;6(2):87–93 (37 ref.)

[Heart arrest in children after intravenous injection of succinylcholine in the ENT operating room (see comments)] Schulte-Sasse U. **HNO** 1995 Nov;43(11):676–9 (29 ref.) (Eng. Abstr.) Comment in: Hosp Formul 1995 Nov;43(11):640–1. **(Ger)**

CONTRAINDICATIONS

Use of suxamethonium in children [editorial] [see comments] Hopkins PM. **Br J Anaesth** 1995 Dec;75(6):675–7 (23 ref.) Comment in: Br J Anaesth 1996 Jun;76(6):883; discussion 884. Comment in: Br J Anaesth 1996 Jun;76(6):883–4; discussion 884.

PHARMACOLOGY

[The effect of suxamethonium on intracranial pressure] Handberg G, et al. **Ugeskr Laeger** 1996 Apr 22; 158(17):2381–3 (17 ref.) (Eng. Abstr.) **(Dan)**

SUCCINYLDICHOLINE see **SUCCINYLCHOLINE**

SUCKING BEHAVIOR

PHYSIOLOGY

Oral motor function in the neonate. Lau C, et al. **Clin Perinatol** 1996 Jun;23(2):161–78 (65 ref.)

Neonatal sucking behaviors. Medoff-Cooper B, et al.

Image J Nurs Sch 1995 Fall;27(3):195–200 (60 ref.)

SUCRALFATE

THERAPEUTIC USE

Prophylaxis for stress-related gastrointestinal hemorrhage: a cost effectiveness analysis. Ben-Menachem T, et al. **Crit Care Med** 1996 Feb;24(2):338–45 (59 ref.)

Sucralfate: prophylaxis of mucosal damage during cancer therapy. Henriksson R, et al. **Scand J Gastroenterol Suppl** 1995;210:45–7 (29 ref.)

Sucralfate in Helicobacter pylori eradication strategies. Lam SK, et al. **Scand J Gastroenterol Suppl** 1995;210:89–91 (19 ref.)

[Treatment of stomach ulcer] Hudziak H. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S136–S142 (51 ref.) **(Fre)**

SUCRASE-ISOMALTASE COMPLEX

DEFICIENCY

Congenital sucrase-isomaltase deficiency. Treem WR. **J Pediatr Gastroenterol Nutr** 1995 Jul;21(1):1–14 (92 ref.)

GENETICS

Congenital sucrase-isomaltase deficiency. Treem WR. **J Pediatr Gastroenterol Nutr** 1995 Jul;21(1):1–14 (92 ref.)

SUCROSE

ADVERSE EFFECTS

Acute renal failure after administration of intravenous immunoglobulin: review of the literature and case report. Winward DB, et al. **Pharmacotherapy** 1995 Nov–Dec; 15(6):765–72 (33 ref.)

METABOLISM

Mechanisms in the glucansucrase synthesis of polysaccharides and oligosaccharides from sucrose. Robyt JF. **Adv Carbohydr Chem Biochem** 1995;51:133–68 (146 ref.)

Congenital sucrase-isomaltase deficiency. Treem WR. **J Pediatr Gastroenterol Nutr** 1995 Jul;21(1):1–14 (92 ref.)

PHARMACOLOGY

Effect of sucrose and sweeteners on appetite and energy intake. Blundell JE, et al. **Int J Obes Relat Metab Disord** 1996 Mar;20 Suppl 2:S12–7 (46 ref.)

SUCTION

METHODS

[Aspiration of the adnexal mass—is it reliable?] Lavie O, et al. **Harefuah** 1995 Dec 1;129(11):502–7 (45 ref.) **(Heb)**

SUCTION LIPECTOMY see **LIPECTOMY**

SUDDEN CARDIAC DEATH see **DEATH, SUDDEN, CARDIAC**

SUDDEN DEAFNESS see **DEAFNESS, SUDDEN**

SUDDEN INFANT DEATH

Sudden infant death syndrome—Part I: General features. Lazoff M, et al. **Acad Emerg Med** 1995 Oct;2(10):926–33 (101 ref.)

Sudden infant death syndrome—Part III: Emergency department approach. Lazoff M, et al. **Acad Emerg Med** 1995 Dec;2(12):1077–80 (24 ref.)

Child abuse, sudden infant death syndrome, and psychosocial development. Botash AS, et al. **Curr Opin Pediatr** 1996 Apr;8(2):195–200 (29 ref.)

[Sudden death] Grégoire JM. **Rev Med Brux** 1996 Jun; 17(3):107–13 (52 ref.) (Eng. Abstr.) **(Fre)**

EPIDEMIOLOGY

[Position and sudden death of the infant (editorial)] Faure C. **Presse Med** 1995 Dec 16–23;24(39):1879–81 (14 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Sudden infant death syndrome—Part II: Etiologic theories. Lazoff M, et al. **Acad Emerg Med** 1995 Nov;2(11):996–1000 (22 ref.)

Postnatal development of responses to airflow obstruction. Harding R, et al. **Clin Exp Pharmacol Physiol** 1995 Aug; 22(8):537–43 (33 ref.)

Influence of body temperature on responses to hypoxia and hypercapnia: implications for SIDS. Maskrey M. **Clin Exp Pharmacol Physiol** 1995 Aug;22(8):527–32 (60 ref.)

Sleeping position and sudden infant death syndrome: a review of the literature and the implications for infants in the United States. Bradshaw CM. **Indiana Med** 1996 Jan–Feb; 89(1):64–73 (0 ref.)

Minor inflammatory lesions and sudden infant death: cause, coincidence, or epiphenomena? Byard RW, et al. **Pediatr Pathol Lab Med** 1995 Sep–Oct;15(5):649–54 (16 ref.)

[Relationship between sleeping position and sudden infant death syndrome] Eidelman A, et al. **Harefuah** 1995 Sep; 129(5–6):197–200 (38 ref.) **(Heb)**

PATHOLOGY

Vagal nerve complex in normal development and sudden infant death syndrome. Becker LE, et al. **Can J Neurol Sci** 1996 Feb;23(1):24–33 (35 ref.)

Minor inflammatory lesions and sudden infant death: cause, coincidence, or epiphenomena? Byard RW, et al. **Pediatr Pathol Lab Med** 1995 Sep–Oct;15(5):649–54 (16 ref.)

PREVENTION & CONTROL

["Home monitoring" does not prevent crib death. Managing possibilities and results of new technology (see comments)] Rognum TO. **Tidsskr Nor Laegeforen** 1995 Sep 20; 115(22):2790–3 (21 ref.) (Eng. Abstr.) Comment in: Tidsskr Nor Laegeforen 1995 Nov 10;115(27):3419–20. **(Nor)**

SUDECK'S ATROPHY see **REFLEX SYMPATHETIC DYSTROPHY**

SUFENTANIL

[Clinical use of sufentanil] Toftegaard M, et al. **Ugeskr Laeger** 1996 Jun 10;158(24):3483–6 (33 ref.) **(Dan)**

PHARMACOLOGY

Recent developments in analgesia during labour. Kan RE, et al. **Drugs** 1995 Sep;50(3):417–22 (41 ref.)

SUFFOCATION see **ASPHYXIA**

SUGAR ALCOHOL DEHYDROGENASES

BLOOD

[Glyceraldehyde reductase] Kanno T. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:396–7 (2 ref.) **(Jpn)**

SUGAR ALCOHOL OXIDOREDUCTASES see **SUGAR ALCOHOL DEHYDROGENASES**

SUGAR ALCOHOLS

METABOLISM

Methods available to estimate the energy values of sugar alcohols. Ellwood KC. **Am J Clin Nutr** 1995 Nov;62(5 Suppl):1169S–1174S (38 ref.)

SUGAR SUBSTITUTES see **SWEETENING AGENTS**

SUGARS see **CARBOHYDRATES**

SUGGESTION

see related
PERSUASIVE COMMUNICATION

Hypnosis for pain and neuromuscular rehabilitation with multiple sclerosis: case summary, literature review, and analysis of outcomes. Dane JR. **Int J Clin Exp Hypn** 1996 Jul;44(3):208–31 (60 ref.)

Does hypnosis pose special risks for negative effects? A master class commentary. Lynn SJ, et al. **Int J Clin Exp Hypn** 1996 Jan;44(1):7–19 (60 ref.)

SUICIDE

Autopsy case report of a rare acute iatrogenic water intoxication with a review of the literature. Chen X, et al. **Forensic Sci Int** 1995 Nov 30;76(1):27–34 (28 ref.)

Penetrating gunshots to the head and lack of immediate incapacitation. II. Review of case reports. Karger B. **Int J Legal Med** 1995;108(3):117–26 (75 ref.)

AIDS and suicide. Kirchner JT. **J Fam Pract** 1995 Nov; 41(5):493–6 (19 ref.)

Combined homicide-suicides: a review. Felthous AR, et al. **J Forensic Sci** 1995 Sep;40(5):846–57 (40 ref.)

Schizophrenia, suicide and the serotonin story. Holden RJ. **Med Hypotheses** 1995 May;44(5):379–91 (85 ref.)

[Low concentration level of total serum cholesterol as a risk factor for suicidal and aggressive behavior] Ainiyet J, et al. **Psychiatr Pol** 1996 May–Jun;30(3):499–509 (31 ref.) (Eng. Abstr.) **(Pol)**

PREVENTION & CONTROL

Pathways to suicide prevention. Murphy BM, et al. **Br J Hosp Med** 1995 Jun 21–Jul 11;54(1):11–4 (18 ref.)

Preventing suicide in women and men. Lester D. **Crisis** 1995; 16(2):79–84 (33 ref.)

Research in adolescent suicide: implications for training, service delivery, and public policy. Brent DA, et al. **Suicide Life Threat Behav** 1995 Summer;25(2):222–30 (40 ref.)

[Design of a program to prevent adolescent suicide] González-Seijo JC, et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1994 May–Jun;22(3):100–8 (59 ref.) (Eng. Abstr.) **(Spa)**

PSYCHOLOGY

Fear of AIDS and suicide in Finland: a review. Aro AR, et al. **AIDS Care** 1995;7 Suppl 2:5187–97 (60 ref.)

Suicide and AIDS: problem identification during counselling. Miller R. **AIDS Care** 1995;7 Suppl 2:5199–205 (18 ref.)

Epidemiology of suicide among persons with AIDS. Starace F. **AIDS Care** 1995;7 Suppl 2:S123–8 (15 ref.)

The psychological autopsy: a useful tool for determining proximate causation in suicide cases. Jacobs D, et al. **Bull Am Acad Psychiatry Law** 1995;23(2):165–82 (53 ref.)

The typology of personality disorders—diagnostic problems and their relevance for suicidal behavior [see comments] Bronisch T. **Crisis** 1996;17(2):55–8 (28 ref.) Comment in: Crisis 1996;17(2):50.

Outward and inward directed aggressiveness: the interaction between violence and suicidality. Plutchik R. **Pharmacopsychiatry** 1995 Oct;28 Suppl 2:47–57 (58 ref.)

Risk factors for adolescent suicide and suicidal behavior: mental and substance abuse disorders, family environmental factors, and life stress. Brent DA. **Suicide Life Threat Behav** 1995;25 Suppl:52–63 (44 ref.)

Models of development: understanding risk in adolescence. Graber JA, et al. **Suicide Life Threat Behav** 1995;25 Suppl:18–25 (35 ref.)

[Depression and suicide] Isometsä E, et al. **Duodecim** 1994; 110(3):341–6 (50 ref.) **(Fin)**

STATISTICS & NUMERICAL DATA

Methodological issues relevant to epidemiologic investigations of suicidal behaviors of adolescents. Borges G, et al. **Epidemiol Rev** 1995;17(1):228–39 (86 ref.)

SUICIDE, ASSISTED

Two cases of lethal nitrazepam poisoning. Brødsgaard I, et al. **Am J Forensic Med Pathol** 1995 Jun;16(2):151–3 (7 ref.)

LEGISLATION & JURISPRUDENCE

The constitutional case against permitting physician-assisted suicide for competent adults with "terminal conditions". Bopp J Jr, et al. **Issues Law Med** 1995 Winter;11(3):239–68 (130 ref.)

Physician-assisted death in The Netherlands: impact on long-term care. Fenigsen R. **Issues Law Med** 1995 Winter; 11(3):283–97 (59 ref.)

The debate on assisted suicide—redefining morally appropriate care for people with intractable suffering. Reitman JS. **Issues Law Med** 1995 Winter;11(3):299–329 (118 ref.)

[Assisted dying—death on demand: borderline between medicine and law] Oehmichen M. **Z Gerontol Geriatr** 1995 Jul–Aug;28(4):273–8 (21 ref.) (Eng. Abstr.) **(Ger)**

PSYCHOLOGY

Patient requests for euthanasia and assisted suicide in terminal illness. The role of the psychiatrist. Block SD, et al. **Psychosomatics** 1995 Sep–Oct;36(5):445–57 (75 ref.)

SUICIDE, ATTEMPTED

[The biological basis of suicidal behavior: neuroendocrine and psychophysiological approach to the role of catecholamines] Pitchot W, et al. **Acta Psychiatr Belg** 1995 Jul–Oct;95(4–5):210–33 (102 ref.) (Eng. Abstr.) **(Fre)**

PSYCHOLOGY

Risk factors for adolescent suicide and suicidal behavior: mental and substance abuse disorders, family environmental factors, and life stress. Brent DA. **Suicide Life Threat Behav** 1995;25 Suppl:52–63 (44 ref.)

STATISTICS & NUMERICAL DATA

Methodological issues relevant to epidemiologic investigations of suicidal behaviors of adolescents. Borges G, et al. **Epidemiol Rev** 1995;17(1):228–39 (86 ref.)

SULFADIAZINE

ADVERSE EFFECTS

Sulfadiazine-associated nephrotoxicity in patients with the acquired immunodeficiency syndrome. Becker K, et al. **Medicine (Baltimore)** 1996 Jul;75(4):185–94 (56 ref.)

SULFAMETHOXAZOLE-TRIMETHOPRIM COMBINATION see **TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION**

SULFAMYL DIURETICS see **DIURETICS, SULFAMYL**

SULFANILAMIDES

BLOOD

[Sulfa drugs] Fukaya K. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:1017–9 (6 ref.) **(Jpn)**

SULFAPYRIDINE

PHARMACOLOGY

Sulphasalazine, sulphapyridine or 5-aminosalicylic acid—which is the active moiety in rheumatoid arthritis? Bird HA. **Br J Rheumatol** 1995 Nov;34 Suppl 2:16–9 (11 ref.)

SULFASALAZINE

PHARMACOLOGY

Sulphasalazine, sulphapyridine or 5-aminosalicylic acid—which is the active moiety in rheumatoid arthritis? Bird HA. **Br J Rheumatol** 1995 Nov;34 Suppl 2:16–9 (11 ref.)

The antirheumatic agents sulphasalazine and methotrexate share an anti-inflammatory mechanism. Cronstein BN. **Br J Rheumatol** 1995 Nov;34 Suppl 2:30–2 (20 ref.)

Sulphasalazine: mechanism of action in rheumatoid arthritis. Smedegård G, et al. **Br J Rheumatol** 1995 Nov;34 Suppl 2:7–15 (133 ref.)

The effects of sulphasalazine on male fertility. Marmor D. **Reprod Toxicol** 1995 May–Jun;9(3):219–23 (58 ref.)

THERAPEUTIC USE

The history of the use of sulphasalazine in rheumatology. Amos RS. **Br J Rheumatol** 1995 Nov;34 Suppl 2:2–6 (51 ref.)

Clinical efficacy of sulphasalazine—a review. Capell HA. **Br J Rheumatol** 1995 Nov;34 Suppl 2:35–9 (30 ref.)

How and when should combination therapy be used? The role of an anchor drug. Farr M, et al. **Br J Rheumatol** 1995 Nov;34 Suppl 2:100–3 (38 ref.)

Combining sulphasalazine and methotrexate in rheumatoid arthritis: early clinical impressions. Haagsma CJ, et al. **Br J Rheumatol** 1995 Nov;34 Suppl 2:104–8 (30 ref.)

Sulfasalazine. A review of its pharmacological properties and therapeutic efficacy in the treatment of rheumatoid arthritis [published erratum appears in Drugs 1995 Oct;50(4):625] Rains CP, et al. **Drugs** 1995 Jul;50(1):137–56 (134 ref.)

Disease-modifying antirheumatic drugs. Potential effects in older patients. Gardner G, et al. **Drugs Aging** 1995 Dec; 7(6):420–37 (43 ref.)

SULFATASES

DEFICIENCY

[Metachromatic leukodystrophy (MLD) and Multiple sulphatase deficiency (MSD)] Eto Y, et al. **Nippon Rinsho** 1995 Dec;53(12):2994–3003 (24 ref.) (Eng. Abstr.) **(Jpn)**

SULFATES

[Zinc sulfate turbidity test (ZTT)] Monna T, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:167–70 (7 ref.) **(Jpn)**

METABOLISM

Sulfate transport in chondrodysplasia. Hästbacka J, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:131–6 (29 ref.)

A family of chondrodysplasias caused by mutations in the diastrophic dysplasia sulfate transporter gene and associated with impaired sulfation of proteoglycans. Superti-Furga A, et al. **Ann N Y Acad Sci** 1996 Jun 8; 785:195–201 (26 ref.)

Role of sulfate in thyroid hormone sulfation [comment] Visser TJ. **Eur J Endocrinol** 1996 Jan;134(1):12–4 (26 ref.) Comment on: Eur J Endocrinol 1996 Jan;134(1):45–9.

From legumes to leukocytes: biological roles for sulfated carbohydrates. Hooper LV, et al. **FASEB J** 1996 Aug; 10(10):1137–46 (88 ref.)

Atomic basis of the exquisite specificity of phosphate and sulfate transport receptors. Quiocho FA. **Kidney Int** 1996 Apr;49(4):943–6 (14 ref.)

SULFATES, INORGANIC see **SULFATES**

SULFATIDOSIS see **LEUKODYSTROPHY, METACHROMATIC**

SULFATION FACTOR see **SOMATOMEDINS**

SULFHEMOGLOBIN

ANALYSIS

[Sulfhemoglobin] Ohba Y. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:183–5 (13 ref.) **(Jpn)**

SULFHYDRYL COMPOUNDS

CHEMISTRY

Thiyl radicals in biological systems: significant or trivial? Kalyanaraman B. **Biochem Soc Symp** 1995;61:55–63 (37 ref.)

METABOLISM

Reduced, oxidized and protein-bound forms of homocysteine and other aminothiols in plasma comprise the redox thiol status—a possible element of the extracellular antioxidant defense system. Ueland PM, et al. **J Nutr** 1996 Apr;126(4 Suppl):1281S–4S (28 ref.)

PHARMACOLOGY

Role of Fenton chemistry in thiol-induced toxicity and apoptosis. Held KD, et al. **Radiat Res** 1996 May; 145(5):542–53 (81 ref.)

NMDA receptor redox sites: are they targets for selective neuronal protection? [see comments] Gozlan H, et al. **Trends Pharmacol Sci** 1995 Nov;16(11):368–74 (80 ref.) Comment in: Trends Pharmacol Sci 1996 May;17(5):186–7; discussion 187–9.

THERAPEUTIC USE

Thiol compounds and organic nitrates. Boesgaard S. **Dan Med Bull** 1995 Nov;42(5):473–84 (117 ref.)

SULFHYDRYL COMPOUNDS ANTAGONISTS see **SULFHYDRYL REAGENTS**

SULFHYDRYL COMPOUNDS INHIBITORS see **SULFHYDRYL REAGENTS**

SULFHYDRYL REAGENTS

see related
ENZYME INHIBITORS

PHARMACOLOGY

NMDA receptor redox sites: are they targets for selective neuronal protection? [see comments] Gozlan H, et al. **Trends Pharmacol Sci** 1995 Nov;16(11):368–74 (80 ref.) Comment in: Trends Pharmacol Sci 1996 May;17(5):186–7; discussion 187–9.

TOXICITY

Is ingested inorganic arsenic a "threshold" carcinogen? Abernathy CO, et al. **Fundam Appl Toxicol** 1996 Feb; 29(2):168–75 (59 ref.)

SULFITES

ADVERSE EFFECTS

Sulfite sensitivity: significance in human health. Lester MR. **J Am Coll Nutr** 1995 Jun;14(3):229–32 (9 ref.)

TOXICITY

Biological and biochemical effects of air pollutants: synergistic effects of sulphite. Hippeli S, et al. **Biochem Soc Symp** 1995;61:153–61 (43 ref.)

SULFITES, INORGANIC see **SULFITES**

SULFOLOBUS

GENETICS

The Sulfolobus solfataricus P2 genome project. Charlebois RL, et al. **FEBS Lett** 1996 Jun 24;389(1):88–91 (21 ref.)

SULFONAMIDES

Loop diuretics: comparison of torsemide, furosemide, and bumetanide. Chen BP. **Conn Med** 1996 Jun;60(6):343–5 (6 ref.)

[Discovery and development of tamsulosin hydrochloride, a new alpha 1-adrenoceptor antagonist] Takenaka T, et al. **Yakugaku Zasshi** 1995 Oct;115(10):773–89 (42 ref.) (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

Torsemide: a new loop diuretic. Fowler SF, et al. **Am J Health Syst Pharm** 1995 Aug 15;52(16):1771–80; quiz 1814–5 (60 ref.)

Possible modes of action of nimesulide in controlling neutrophilic inflammation. Dallegri F, et al. **Arzneimittelforschung** 1995 Oct;45(10):1114–7 (36 ref.)

THERAPEUTIC USE

Torsemide: a new loop diuretic. Fowler SF, et al. **Am J Health Syst Pharm** 1995 Aug 15;52(16):1771–80; quiz 1814–5 (60 ref.)

Antibiotic resistance: relationship to persistence of group A streptococci in the upper respiratory tract. Gerber MA. **Pediatrics** 1996 Jun;97(6 Pt 2):971–5 (59 ref.)

SULFONYLDIANILINE see **DAPSONE**

SULFONYLUREA COMPOUNDS

PHARMACOLOGY

The beta-cell response to oral hypoglycemic agents. Cook DL. **Diabetes Res Clin Pract** 1995 Aug;28 Suppl:S81–9 (72 ref.)

Extrapancreatic effects of sulfonylurea drugs. **Kaku K**, et al. **Diabetes Res Clin Pract** 1995 Aug;28 Suppl:S105–8 (21 ref.)

The molecular interaction of sulfonylureas with beta-cell ATP-sensitive K(+)-channels. Kramer W, et al. **Diabetes Res Clin Pract** 1995 Aug;28 Suppl:S67–80 (25 ref.)

Extrapancreatic effects of sulfonylureas—a comparison between glimepiride and conventional sulfonylureas. Müller G, et al. **Diabetes Res Clin Pract** 1995 Aug;28 Suppl:S115–37 (109 ref.)

Potassium channels in the cardiovascular system. Pogátsa G. **Diabetes Res Clin Pract** 1995 Aug;28 Suppl:S91–8 (48 ref.)

Sulfonylurea receptors and mechanism of sulfonylurea action. Panten U, et al. **Exp Clin Endocrinol Diabetes** 1996; 104(1):1–9 (100 ref.)

POISONING

Hypoglycemia following inadvertent and factitious sulfonylurea overdosages. Klonoff DC, et al. **Diabetes Care** 1995 Apr;18(4):563–7 (55 ref.)

THERAPEUTIC USE

Clinical profile of glimepiride. Draeger E. **Diabetes Res Clin Pract** 1995 Aug;28 Suppl:S139–46 (7 ref.)

Sulphonylurea treatment of NIDDM patients with cardiovascular disease: a mixed blessing? Leibowitz G, et al. **Diabetologia** 1996 May;39(5):503–14 (140 ref.)

Oral hypoglycemic agents as an alternative therapy for gestational diabetes [editorial; comment] Hod M, et al. **Isr J Med Sci** 1995 Oct;31(10):640–3 (47 ref.) Comment on: Isr J Med Sci 1995 Oct;31(10):623–5.

SULFOTRANSFERASES

GENETICS

Molecular biology of steroid sulfotransferases. Luu-The V, et al. **Ann N Y Acad Sci** 1996 Apr 30;784:137–48 (73 ref.)

SULFOXIDES

METABOLISM

New disulfide bond-forming reactions for peptide and protein synthesis. Kiso Y, et al. **Braz J Med Biol Res** 1994 Dec;27(12):2733–44 (24 ref.)

PHARMACOLOGY

Review article: the continuing development of proton pump inhibitors with particular reference to pantoprazole. Huber R, et al. **Aliment Pharmacol Ther** 1995 Aug;9(4):363–78 (59 ref.)

Similarities and differences in the properties of substituted benzimidazoles: a comparison between pantoprazole and related compounds. Kromer W. **Digestion** 1995; 56(6):443–54 (90 ref.)

THERAPEUTIC USE

Review article: the continuing development of proton pump inhibitors with particular reference to pantoprazole. Huber R, et al. **Aliment Pharmacol Ther** 1995 Aug;9(4):363–78 (59 ref.)

SULFUR

METABOLISM

Iron–sulphur clusters as genetic regulatory switches: the bifunctional iron regulatory protein-1. Paraskeva E, et al. **FEBS Lett** 1996 Jun 24;389(1):40–3 (50 ref.)

Phenotypic variation in xenobiotic metabolism and adverse environmental response: focus on sulfur-dependent detoxification pathways. McFadden SA. **Toxicology** 1996 Jul 17;111(1–3):43–65 (145 ref.)

Cation radicals of organosulphur compounds. Glass RS. **Xenobiotica** 1995 Jul;25(7):637–51 (64 ref.)

SULFUR AMINO ACIDS see **AMINO ACIDS, SULFUR**

SULFUR DIOXIDE

Respiratory effects of air pollutants: experimental studies in humans [see comments] Sandström T. **Eur Respir J** 1995 Jun;8(6):976–95 (221 ref.) Comment in: Eur Respir J 1995 Jun;8(6):883–4.

POISONING

[Chronic obstructive bronchopneumopathy after acute inhalation of sulfur anhydride. Apropos of a case] Ramakers M, et al. **Rev Pneumol Clin** 1995;51(6):343–7 (31 ref.) (Eng. Abstr.) **(Fre)**

SULFUR MUSTARD see **MUSTARD GAS**

SULFURTRANSFERASES

[Mercaptopyruvate sulfurtransferase is a rhodanese family] Nagahara N, et al. **Seikagaku** 1996 Mar;68(3):197–201 (15 ref.) **(Jpn)**

SULINDAC

TOXICITY

The developmental toxicity of indomethacin and sulindac. Lione A, et al. **Reprod Toxicol** 1995 Jan–Feb;9(1):7–20 (111 ref.)

SULPIRIDE

ANALOGS & DERIVATIVES

[Treatment of negative symptoms in schizophrenia by amisulpride. Review of the literature] Pélissolo A, et al. **Encephale** 1996 May–Jun;22(3):215–9 (25 ref.) (Eng. Abstr.) **(Fre)**

[The place of amisulpride in the atypical neuroleptic class] Perrault G, et al. **Encephale** 1996 Jun;22 Spec No 2:3–8 (12 ref.) (Eng. Abstr.) **(Fre)**

SUMATRIPTAN

THERAPEUTIC USE

Migraine and cluster headache--their management with sumatriptan: a critical review of the current clinical experience. Wilkinson M, et al. **Cephalalgia** 1995 Oct; 15(5):337–57 (166 ref.)

Pharmacologic treatment of recurrent pediatric headache. Graf WD, et al. **Pediatr Ann** 1995 Sep;24(9):477–84 (27 ref.)

[Sumatriptan ++ in the treatment of migraine and cluster headache] Láinez JM, et al. **Rev Neurol** 1995;23 Suppl 2:S166–78 (127 ref.) **(Spa)**

[Treatment of the acute migraine attack] Titus F. **Rev Neurol** 1995;23 Suppl 2:S203–7 (49 ref.) **(Spa)**

[Symptomatic treatment of cluster headache] Titus F. **Rev Neurol** 1995;23 Suppl 4:S519–24 (46 ref.) **(Spa)**

SUNBURN

see related
SUNSCREENING AGENTS

PREVENTION & CONTROL

Sunscreens: the ounce of prevention. Wentzell JM. **Am Fam Physician** 1996 Apr;53(5):1713–33 (31 ref.)

SUNFLOWER see **HELIANTHUS**

SUNLIGHT

ADVERSE EFFECTS

Raimer's bands: case report with a review of solar elastosis. Stanford DG, et al. **Acta Derm Venereol** 1995 Sep; 75(5):372–4 (23 ref.)

Sun exposure and skin disease. Taylor CR, et al. **Annu Rev Med** 1996;47:181–91 (40 ref.)

Cutaneous malignant melanoma and sun exposure. Recent developments in epidemiology. Katsambas A, et al. **Arch Dermatol** 1996 Apr;132(4):444–50 (62 ref.)

Current concepts. Photoprotection. Kaminester LH. **Arch Fam Med** 1996 May;5(5):289–95 (135 ref.)

Plasma exchange therapy for solar urticaria. Collins P, et al. **Br J Dermatol** 1996 Jun;134(6):1093–7 (20 ref.)

Tretinoin for sun-aged skin. **Drug Ther Bull** 1996 Jul; 34(7):55–6 (13 ref.)

Recent developments in vision research: light damage in cataract. McCarty CA, et al. **Invest Ophthalmol Vis Sci** 1996 Aug;37(9):1720–3 (14 ref.)

Photosensitivity. Baker CS. **Med J Aust** 1996 Jul 15; 165(2):96–101 (17 ref.)

Epidemiological studies of sunlight and cataract: the critical factor of ultraviolet exposure geometry [see comments] Sliney DH. **Ophthalmic Epidemiol** 1994 Jun;1(2):107–19 (33 ref.) Comment in: Int J Food Sci Nutr 1994 Jun;1(2):63–5.

[Heliodermatitis or photo-induced skin aging] Leccia MT, et al. **Ann Dermatol Venereol** 1995;122(10):720–8 (89 ref.) **(Fre)**

SUNSCREENING AGENTS

Sunscreens: the ounce of prevention. Wentzell JM. **Am Fam Physician** 1996 Apr;53(5):1713–33 (31 ref.)

SUPERANTIGENS

see related
APOPTOSIS
CLONAL ANERGY
RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA

Superantigenic characteristics of mouse mammary tumor viruses play a critical role in susceptibility to infection in mice. Pucillo CE, et al. **Immunol Res** 1995;14(1):58–68 (62 ref.)

Superantigens in autoimmune disease. Youinou P, et al. **Rev Rhum Engl Ed** 1995 Oct;62(9):591–7 (35 ref.)

[Superantigens] Palkama T, et al. **Duodecim** 1994; 110(2):202–6 (22 ref.) **(Fin)**

CHEMISTRY

Superantigen engineering. Abrahmsén L. **Curr Opin Struct Biol** 1995 Aug;5(4):464–70 (45 ref.)

IMMUNOLOGY

Unconventional B-cell antigens and human immune repertoires. Silverman GJ. **Ann N Y Acad Sci** 1995 Sep 29;764:342–55 (42 ref.)

Superantigens in Kawasaki syndrome. Leung DY, et al. **Clin Immunol Immunopathol** 1995 Nov;77(2):119–26 (48 ref.)

Superantigens. Saloga J, et al. **Exp Dermatol** 1996 Apr; 5(2):65–71 (109 ref.)

B-cell superantigens: implications for selection of the human antibody repertoire. Zouali M. **Immunol Today** 1995 Aug; 16(8):399–405 (73 ref.)

Immunoregulatory mechanisms of T-cell-dependent shock induced by a bacterial superantigen in mice. Florquin S, et al. **Infect Immun** 1996 Sep;64(9):3443–5 (31 ref.)

Exposure to superantigens as an immunogenetic explanation of type I diabetes mini-epidemics. Trucco M, et al. **J Pediatr Endocrinol Metab** 1995 Jan–Mar;8(1):3–10 (41 ref.)

In vivo effects of superantigens. Blackman MA, et al. **Life Sci** 1995;57(19):1717–35 (198 ref.)

Superantigens and pseudosuperantigens of gram-positive cocci. Fleischer B, et al. **Med Microbiol Immunol (Berl)** 1995 May;184(1):1–8 (85 ref.)

Superantigens: structure and relevance to human disease. Johnson HM, et al. **Proc Soc Exp Biol Med** 1996 Jun; 212(2):99–109 (88 ref.)

Bacterial superantigens in human disease: structure, function and diversity. Ulrich RG, et al. **Trends Microbiol** 1995 Dec; 3(12):463–8 (51 ref.)

[Superantigens and immunological diseases] Sugawara S, et al. **Arerugi** 1996 May;45(5):435–41 (35 ref.) **(Jpn)**

PHARMACOLOGY

In vivo effects of superantigens. Blackman MA, et al. **Life Sci** 1995;57(19):1717–35 (198 ref.)

PHYSIOLOGY

Bacterial pyrogenic exotoxins as superantigens. Kotb M. **Clin Microbiol Rev** 1995 Jul;8(3):411–26 (292 ref.)

Superantigen-mediated lethal shock: the functional state of ligand-reactive T cells. Heeg K, et al. **Curr Top Microbiol Immunol** 1996;216:83–100 (95 ref.)

[Superantigens and their implication in autoimmune diseases] Meyer O. **Presse Med** 1995 Sep 2–9;24(25):1171–7 (28 ref.) (Eng. Abstr.) **(Fre)**

SUPERINFECTION

Acute exacerbation and superinfection in patients with chronic viral hepatitis. Liaw YF. **J Formos Med Assoc** 1995 Sep;94(9):521–8 (78 ref.)

VIROLOGY

[Superinfection of hepatitis viruses in fulminant hepatitis (type B)] Watanabe A, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:477–81 (26 ref.) **(Jpn)**

SUPERINVASION, MICROBIAL see **SUPERINFECTION**

SUPERIOR COLLICULUS

EMBRYOLOGY

Mechanisms and molecules controlling the development of retinal maps. Roskies A, et al. **Perspect Dev Neurobiol** 1995; 3(1):63–75 (122 ref.)

SUPERIOR VENA CAVA OBSTRUCTION see **SUPERIOR VENA CAVA SYNDROME**

SUPERIOR VENA CAVA SYNDROME

ETIOLOGY

Carcinoma of the uterine cervix presenting as superior vena cava syndrome: report of three cases and a review of literature. Biswal BM, et al. **J Obstet Gynaecol** 1995 Oct; 21(5):437–42 (13 ref.)

SURGERY

Stenting of superior vena caval obstruction. Jackson JE, et al. **Thorax** 1995 Sep;50 Suppl 1:S31–6 (36 ref.)

[Surgical vein reconstruction in patients with tumor invasiveness of the superior caval system. Retrospective study of 7 cases] Jeanfaivre T, et al. **J Chir (Paris)** 1996 Apr;133(2):61–4 (19 ref.) (Eng. Abstr.) **(Fre)**

SUPERIOR VENA CAVA THROMBOSIS see **SUPERIOR VENA CAVA SYNDROME**

SUPEROVULATION

In vitro fertilization, gamete intrafallopian transfer, and superovulation with intrauterine insemination: efficacy and potential health hazards on babies delivered. Dawood MY. **Am J Obstet Gynecol** 1996 Apr;174(4):1208–17 (26 ref.)

SUPEROXIDE DISMUTASE

BLOOD

[Mn-superoxide dismutase] Taniguchi N, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:386–8 (9 ref.) **(Jpn)**

DEFICIENCY

Familial amyotrophic lateral sclerosis/motor neurone disease (FALS): a review of current developments. de Belleroche J, et al. **J Med Genet** 1995 Nov;32(11):841–7 (65 ref.)

GENETICS

Copper/zinc superoxide dismutase mutations and free radical damage in amyotrophic lateral sclerosis. Hosler BA, et al. **Adv Neurol** 1995;68:41–6 (24 ref.)

Motor neuron disease caused by mutations in superoxide dismutase 1. Wong PC, et al. **Curr Opin Neurol** 1995 Aug; 8(4):294–301 (77 ref.)

METABOLISM

Superoxide radical and superoxide dismutases. Fridovich I. **Annu Rev Biochem** 1995;64:97–112 (259 ref.)

Neurotoxicity, drugs and abuse, and the CuZn-superoxide dismutase transgenic mice. Cadet JL, et al. **Mol Neurobiol** 1995 Aug–Dec;11(1–3):155–63 (49 ref.)

Novel copper superoxide dismutase mimics and damage mediated by O2.-. Athar M, et al. **Nutrition** 1995 Sep–Oct; 11(5 Suppl):559–63 (61 ref.)

PHYSIOLOGY

Superoxide dismutase in familial amyotrophic lateral sclerosis: models for gain of function. Brown RH Jr. **Curr Opin Neurobiol** 1995 Dec;5(6):841–6 (48 ref.)

THERAPEUTIC USE

[Late complications of radiotherapy. Radiofibrosis is reversible] Baillet F. **Bull Cancer Radiother** 1995; 82(2):113–9 (37 ref.) **(Fre)**

SUPEROXIDES

see related
RESPIRATORY BURST

METABOLISM

Reactions between nitric oxide, superoxide, and peroxynitrite: footprints of peroxynitrite in vivo. Crow JP, et al. **Adv Pharmacol** 1995;34:17–43 (74 ref.)

Superoxide radical and superoxide dismutases. Fridovich I. **Annu Rev Biochem** 1995;64:97–112 (259 ref.)

Superoxide anion and endothelial regulation of arterial tone. Katusic ZS. **Free Radic Biol Med** 1996;20(3):443–8 (52 ref.)

Structure of human phagocyte cytochrome b and its relationship to microbicidal superoxide production. Jesaitis AJ. **J Immunol** 1995 Oct 1;155(7):3286–8 (57 ref.)

Novel copper superoxide dismutase mimics and damage mediated by O2.-. Athar M, et al. **Nutrition** 1995 Sep–Oct; 11(5 Suppl):559–63 (61 ref.)

[Nonphosphorylating respiration as the mechanism preventing the formation of active forms of oxygen] Skulachev VP. **Mol Biol (Mosk)** 1995 Nov–Dec; 29(6):1199–209 (54 ref.) **(Rus)**

SUPINE POSITION

PHYSIOLOGY

[Complications of patient positioning] Staender S. **Swiss Surg** 1995;(3):152–5 (16 ref.) (Eng. Abstr.) **(Ger)**

SUPPORT GROUPS see **SELF-HELP GROUPS**

SUPPORTED EMPLOYMENT see **EMPLOYMENT, SUPPORTED**

SUPPOSITORIES

ADVERSE EFFECTS

[Ano-rectal and colonic complications of suppositories and enemas] de Parades V, et al. **Gastroenterol Clin Biol** 1996; 20(5):446–52 (118 ref.) **(Fre)**

SUPPRESSION, GENETIC

Molecular handles on adaptive mutation. Rosenberg SM, et al. **Mol Microbiol** 1995 Oct;18(2):185–9 (33 ref.)

SUPPRESSOR CELLS see **T-LYMPHOCYTES, SUPPRESSOR-EFFECTOR**

SUPPRESSOR-EFFECTOR T-LYMPHOCYTES see

SUPPRESSOR-EFFECTOR T-LYMPHOCYTES

T-LYMPHOCYTES, SUPPRESSOR-EFFECTOR

SUPPRESSOR FACTOR, T-CELL, GLIOBLASTOMA-DERIVED see **TRANSFORMING GROWTH FACTOR BETA**

SUPPRESSOR FACTORS, IMMUNOLOGIC

PHYSIOLOGY

Interleukin-10 and its implications for immunopathology. Goldman M, et al. **Adv Nephrol Necker Hosp** 1995;24:79-90 (71 ref.)

SUPPRESSOR MUTATION see **SUPPRESSION, GENETIC**

SUPPRESSOR T-CELL FACTORS see **SUPPRESSOR FACTORS, IMMUNOLOGIC**

SUPPRESSOR TRANSFER RNA see **RNA, TRANSFER**

SUPRACHIASMATIC NUCLEUS

PHYSIOLOGY

Light, immediate-early genes, and circadian rhythms. Kornhauser JM, et al. **Behav Genet** 1996 May;26(3):221-40 (120 ref.)

[The complex interaction of the hypothalamic suprachiasmatic nuclei with the epiphysis and corpus striatum--a functionally unified system for regulating circadian behavioral fluctuations] Arushanian EB. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1996 Jan-Feb; 46(1):15-22 (44 ref.) (Eng. Abstr.) **(Rus)**

SUPRANUCLEAR PALSY, PROGRESSIVE

DIAGNOSIS

Differential diagnosis and clinical diagnostic criteria of progressive supranuclear palsy. Valldeoriola F, et al. **Adv Neurol** 1996;69:405-12 (62 ref.)

Neuropsychological features of progressive supranuclear palsy. Grafman J, et al. **Brain Cogn** 1995 Aug;28(3):311-20 (43 ref.)

Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Litvan I, et al. **Neurology** 1996 Jul;47(1):1-9 (88 ref.)

EPIDEMIOLOGY

The epidemiology of progressive supranuclear palsy. Golbe LI. **Adv Neurol** 1996;69:25-31 (22 ref.)

GENETICS

Familial progressive supranuclear palsy. Description of a pedigree and review of the literature. de Yébenes JG, et al. **Brain** 1995 Oct;118 (Pt 5):1095-103 (39 ref.)

PATHOLOGY

[Neuropathology of corticobasal degeneration] Wakabayashi K, et al. **No To Shinkei** 1996 Jun;48(6):521-32 (88 ref.) **(Jpn)**

PSYCHOLOGY

The cognitive syndrome of progressive supranuclear palsy. Dubois B, et al. **Adv Neurol** 1996;69:399-403 (17 ref.)

SUPRAOPTIC NUCLEUS

SECRETION

Release of oxytocin within the supraoptic nucleus. Mechanisms, physiological significance and antisense targeting. Neumann I, et al. **Adv Exp Med Biol** 1995; 395:173-83 (44 ref.)

SUPRAPUBIC CYSTOSTOMY see **CYSTOSTOMY**

SUPRASELLAR CYST see **CRANIOPHARYNGIOMA**

SUPRATENTORIAL NEOPLASMS

Management of primary malignant brain tumours [editorial] Whittle IR. **J Neurol Neurosurg Psychiatry** 1996 Jan; 60(1):2-5 (50 ref.)

Intracranial supratentorial tumors: classification, clinical findings, surgical management. Di Rocco C, et al. **Rays** 1996 Jan-Mar;21(1):9-25 (92 ref.) **(Eng, Ita)**

Intraventricular supratentorial tumors in children. Tortori-Donati P, et al. **Rays** 1996 Jan-Mar;21(1):26-49 (35 ref.) **(Eng, Ita)**

DIAGNOSIS

Prognostic factors in low-grade supratentorial astrocytomas: a uni-multivariate statistical analysis in 76 surgically treated adult patients. Nicolato A, et al. **Surg Neurol** 1995 Sep; 44(3):208-21; discussion 221-3 (60 ref.)

SURGERY

The surgery of cavernomas both supra-tentorial and infra-tentorial. Houtteville JP. **Adv Tech Stand Neurosurg** 1995;22:185-259 (134 ref.)

Low-grade gliomas. Recht LD, et al. **Neurol Clin** 1995 Nov; 13(4):847-59 (75 ref.)

Prognostic factors in low-grade supratentorial astrocytomas: a uni-multivariate statistical analysis in 76 surgically treated adult patients. Nicolato A, et al. **Surg Neurol** 1995 Sep; 44(3):208-21; discussion 221-3 (60 ref.)

SURAMIN

ADVERSE EFFECTS

Cutaneous eruptions from suramin. A clinical and histopathologic study of 60 patients. Lowitt MH, et al. **Arch Dermatol** 1995 Oct;131(10):1147-53 (30 ref.)

SURFACE-ACTIVE AGENTS

see related
PULMONARY SURFACTANTS

Palmitoylcarnitine, a surface-active metabolite. Gofii FM, et al. **FEBS Lett** 1996 Jul 15;390(1):1-5 (45 ref.)

ADVERSE EFFECTS

Surfactants and experimental irritant contact dermatitis. Effendy I, et al. **Contact Dermatitis** 1995 Oct;33(4):217-25 (86 ref.)

ANALYSIS

Sources, behaviour and fate of organic contaminants during sewage treatment and in sewage sludges. Rogers HR. **Sci Total Environ** 1996 Jun 21;185(1-3):3-26 (141 ref.)

CHEMISTRY

[Neonatal pulmonary alveolar proteinosis and SP-B deficiency: pulmonary surfactant at the time of molecular pathology (editorial)] Lacaze-Masmonteil T, et al. **Arch Pediatr** 1996 Apr;3(4):309-12 (33 ref.) **(Fre)**

[Polyoxyethylene tensides as vesicle components. 2.] Nürnberg E, et al. **Pharm Unserer Zeit** 1995 Nov; 24(6):331-8 (17 ref.) **(Ger)**

METABOLISM

Production of rhamnolipid biosurfactants. Ochsner UA, et al. **Adv Biochem Eng Biotechnol** 1996;53:89-118 (70 ref.)

PHARMACOLOGY

Direct and indirect receptor-independent G-protein activation by cationic-amphiphilic substances. Studies with mast cells, HL-60 human leukemic cells and purified G-proteins. Klinker JF, et al. **Exp Dermatol** 1995 Aug;4(4 Pt 2):231-9 (53 ref.)

[Influence of surfactants on hemodynamics during neonatal respiratory distress syndrome] Pladys P, et al. **Arch Pediatr** 1996 Feb;3(2):156-63 (78 ref.) (Eng. Abstr.) **(Fre)**

THERAPEUTIC USE

Gut mucosa reconditioning with species-specific lactobacilli, surfactants, pseudomucus, and fibers--an invited review. Bengmark S, et al. **Biotechnol Ther** 1994-95;5(3-4):171-94 (149 ref.)

Natural vs synthetic surfactants in neonatal respiratory distress syndrome. Halliday HL. **Drugs** 1996 Feb; 51(2):226-37 (48 ref.)

TOXICITY

Design and construction of model stream ecosystems. Rodgers JH Jr, et al. **Ecotoxicol Environ Saf** 1996 Feb; 33(1):30-7 (21 ref.)

SURFACE ANTIGENS see **ANTIGENS, SURFACE**

SURFACE GLYCOPROTEINS see **MEMBRANE GLYCOPROTEINS**

SURFACE MARKERS, IMMUNOLOGICAL see **ANTIGENS, SURFACE**

SURFACE PROPERTIES

Logarithmic growth in surface adsorption. Nygren H. **Adv Colloid Interface Sci** 1995 Dec 1;62(2-3):137-59 (71 ref.)

SURFACE PROTEINS see **MEMBRANE PROTEINS**

SURFACTANTS see **SURFACE-ACTIVE AGENTS**

SURFACTANTS, PULMONARY see **PULMONARY SURFACTANTS**

SURGERY

The surgeon as a leader in cancer care: lessons learned from the study of soft tissue sarcoma. Brennan MF. **J Am Coll Surg** 1996 Jun;182(6):520-9 (35 ref.)

What's new in pediatric surgery. Filston HC. **Pediatrics** 1995 Oct;96(4 Pt 1):748-57 (82 ref.)

A surgeon with HIV. Cembrowicz S, et al. **Practitioner** 1996 Jan;240(1558):9-12 (2 ref.)

Three-dimensional imaging, surgical planning, and image-guided therapy. Vannier MW, et al. **Radiol Clin North Am** 1996 May;34(3):545-63 (131 ref.)

Managing the infectious waste of the surgery unit and laboratory. Hoeltge GA. **Semin Dermatol** 1995 Sep; 14(3):247-51 (9 ref.)

Dermatologic surgery personnel with AIDS. Resnik SS, et al. **Semin Dermatol** 1995 Sep;14(3):240-2 (22 ref.)

The potential role of simple dermatologic surgery techniques in transmitting HIV infection. Spencer J, et al. **Semin Dermatol** 1995 Sep;14(3):219-27 (43 ref.)

Human immunodeficiency virus and acquired immunodeficiency syndrome: recent developments and their implications for pediatric surgeons. Cooper A. **Semin Pediatr Surg** 1995 Nov;4(4):252-61 (88 ref.)

Randomized controlled trials in surgery: Issues and problems. McLeod RS, et al. **Surgery** 1996 May;119(5):483-6 (13 ref.)

EDUCATION

Basic surgical training. 4: American and British scenes compared. Ger R. **Clin Anat** 1996;9(3):173-4 (2 ref.)

Basic surgical training. 3: A view from Ireland. Monkhouse S. **Clin Anat** 1996;9(3):171-2 (0 ref.)

Basic surgical training. 1: Postgraduate surgical examinations in the UK and Ireland. Raftery AT. **Clin Anat** 1996; 9(3):163-6 (1 ref.)

Basic surgical training. 2: Interactions with the undergraduate medical curriculum. Willan P. **Clin Anat** 1996;9(3):167-70 (1 ref.)

Objectives to direct the training of emergency medicine residents on off-service rotations: Surgery, part 2. Rakowski RT, et al. **J Emerg Med** 1995 Nov-Dec; 13(6):823-9 (7 ref.)

Training and privileging for new procedures. Dent TL. **Surg Clin North Am** 1996 Jun;76(3):615-21 (28 ref.)

The influence of surgical training on the practice of surgery. Are changes necessary? Stone MD, et al. **Surg Clin North Am** 1996 Feb;76(1):1-10 (33 ref.)

LEGISLATION & JURISPRUDENCE

[General aspects of organ donation] Gubernatis G, et al. **Chirurg** 1996 Apr;67(4):300-9 (30 ref.) (Eng. Abstr.) **(Ger)**

ORGANIZATION & ADMINISTRATION

Improving postoperative care: the role of the surgeon in the high dependency unit. Coggins R, et al. **Ann R Coll Surg Engl** 1996 May;78(3 (Pt 1)):163-7 (29 ref.)

The influence of surgical training on the practice of surgery. Are changes necessary? Stone MD, et al. **Surg Clin North Am** 1996 Feb;76(1):1-10 (33 ref.)

SURGERY, COSMETIC see **SURGERY, PLASTIC**

SURGERY, ELECTIVE

ECONOMICS

"Routine" preoperative studies. Which studies in which patients? Marcello PW, et al. **Surg Clin North Am** 1996 Feb;76(1):11-23 (42 ref.)

SURGERY, ENDOSCOPIC

Surgical anatomy in endoscopic facial rejuvenation. Campiglio GL, et al. **Acta Chir Plast** 1996;38(1):3-10 (66 ref.)

Endoscopic vagotomy for duodenal ulcer disease: procedures and appraisal. Cuschieri A. **Adv Surg** 1996;29:291-302 (38 ref.)

Video-assisted thoracic surgery: the current state of the art. Kaiser LR, et al. **AJR Am J Roentgenol** 1995 Nov; 165(5):1111-7 (35 ref.)

An intermeniscal fibrous band in a recreational runner. Butler JP, et al. **Arthroscopy** 1995 Dec;11(6):735-7 (16 ref.)

Suprascapular nerve entrapment by ganglion cysts: a report of six cases with arthroscopic findings and review of the literature. Fehrman DA, et al. **Arthroscopy** 1995 Dec; 11(6):727-34 (47 ref.)

The use of fiberoptic endoscopy in anesthesia. Lee AC, et al. **Chest Surg Clin N Am** 1996 May;6(2):329-47 (45 ref.)

Rigid bronchoscopy. Miller JI Jr. **Chest Surg Clin N Am** 1996 May;6(2):161-7 (4 ref.)

Endoscopic management of benign airway stenosis. Mehta AC, et al. **Clin Chest Med** 1995 Sep;16(3):401-13 (29 ref.)

Arthroscopy of the elbow. Baker CL, et al. **Clin Sports Med** 1996 Apr;15(2):261-81 (32 ref.)

The role of arthroscopy in athletic injuries of the wrist. Savoie FH 3rd, et al. **Clin Sports Med** 1996 Apr; 15(2):219-33 (12 ref.)

The role of endoscopy in the management of the infertile

patient. Graebe RA. **Curr Opin Obstet Gynecol** 1995 Aug; 7(4):265–72 (26 ref.)

Endoscopic diagnosis and management of biliary complications following orthotopic liver transplantation. Gholson CF, et al. **Dig Dis Sci** 1996 Jun;41(6):1045–53 (49 ref.)

Palliative endoscopic therapy of rectal carcinoma. Dohmoto M, et al. **Eur J Cancer** 1996 Jan;32A(1):25–9 (45 ref.)

Pelvic masses and endoscopic surgery: diagnosis. Miralles RM. **Eur J Obstet Gynecol Reprod Biol** 1996 Mar; 65(1):75–9 (28 ref.)

The present state and future of endoscopic surgery. Popiela T. **Int Surg** 1995 Oct–Dec;80(4):341–52 (60 ref.)

Hysteroscopic diagnosis and operative therapy of submucous myoma. Corson SL. **Obstet Gynecol Clin North Am** 1995 Dec;22(4):739–55 (37 ref.)

Hysteroscopic endometrial ablation. Goldrath MH. **Obstet Gynecol Clin North Am** 1995 Sep;22(3):559–72 (44 ref.)

Hysteroscopic sterilization. Sciarra JJ, et al. **Obstet Gynecol Clin North Am** 1995 Sep;22(3):581–9 (20 ref.)

Functional endoscopic sinus surgery. Slack R, et al. **Practitioner** 1995 Oct;239(1555):591–5 (3 ref.)

New approaches to endoscopic therapy for hemostasis of upper GI bleed. Rauws EA, et al. **Scand J Gastroenterol Suppl** 1995;212:90–5 (66 ref.)

Can the morbidity of esophagectomy be reduced by the thoracoscopic approach? Gossot D, et al. **Surg Endosc** 1995 Oct;9(10):1113–5 (14 ref.)

[Rising and trends of endoscopic cosmetic plastic surgery] Zhong D, et al. **Chung Hua Cheng Hsing Shao Shang Wai Ko Tsa Chih** 1995 Nov;11(6):469–51 (13 ref.) **(Chi)**

[Endonasal treatment of iatrogenic or spontaneous cerebrospinal rhinorrhea of the anterior cranial fossa] Coiffier T, et al. **Ann Otolaryngol Chir Cervicofac** 1995; 112(8):367–73 (48 ref.) (Eng. Abstr.) **(Fre)**

[Endoscopic resection of a peri-stenotic fibrous callus of the urethra using Guillemin's method] Giannakopoulos X, et al. **J Urol (Paris)** 1995;101(2):81–7 (37 ref.) (Eng. Abstr.) **(Fre)**

[Principles, technics and indications of endopyelotomy] Gelet A, et al. **Prog Urol** 1995 Sep;5(4):596–604 (22 ref.) **(Fre)**

[Malignant triton tumor of the posterior mediastinum treated by thoracoscopic approach. Apropos of a case] Pons F, et al. **Rev Pneumol Clin** 1995;51(6):338–42 (29 ref.) (Eng. Abstr.) **(Fre)**

[Hysteroscopic surgery] Kimmig R. **Arch Gynecol Obstet** 1995;257(1–4):21–9 (53 ref.) **(Ger)**

[Endoscopic surgery and malpractice] Ulsenheimer K. **Arch Gynecol Obstet** 1995;257(1–4):29–36 (29 ref.) **(Ger)**

[The "Vienna School" of surgical gynecology as an important component of modern therapeutic concepts] Kölbl H. **Gynakol Geburtshilfliche Rundsch** 1995;35(3):139–41 (18 ref.) (Eng. Abstr.) **(Ger)**

[Advance of endoscopic surgery—practical technique by video and its replacement of conventional surgery] Fujimoto S, et al. **Hokkaido Igaku Zasshi** 1995 May; 70(3):357–8 (0 ref.) (Eng. Abstr.) **(Jpn)**

[Arthroscopic shoulder surgery] Okamura K. **Hokkaido Igaku Zasshi** 1995 May;70(3):375–81 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Thoracoscopic surgery, current indication and technique] Okushiba S, et al. **Hokkaido Igaku Zasshi** 1995 May; 70(3):371–4 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Endourology update] Shinno Y, et al. **Hokkaido Igaku Zasshi** 1995 May;70(3):391–6 (7 ref.) (Eng. Abstr.) **(Jpn)**

[Current advances and future direction of arthroscopic surgery for disorders in the knee joint] Yasuda K. **Hokkaido Igaku Zasshi** 1995 May;70(3):383–9 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Gynecologic endoscopic surgery] Yoshida H, et al. **Hokkaido Igaku Zasshi** 1995 May;70(3):397–400 (8 ref.) (Eng. Abstr.) **(Jpn)**

[A case of bilateral thoracoscopic partial resection for unilateral spontaneous pneumothorax] Kinugasa S, et al. **Kyobu Geka** 1995 Oct;48(11):978–81 (12 ref.) (Eng. Abstr.) **(Jpn)**

[Anesthetic management for endoscopic surgery] Kazama T. **Masui** 1995;44 Suppl:S83–92 (11 ref.) **(Jpn)**

[Endoscopic mucosal resection (EMR) for early gastric cancer] Hiki Y. **Nippon Geka Gakkai Zasshi** 1996 Apr; 97(4):273–8 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Application of thoracoscopy for diagnosis and therapy of respiratory tract diseases] Inui K. **Nippon Naika Gakkai Zasshi** 1995 Sep 10;84(9):1594–9 (18 ref.) **(Jpn)**

ADVERSE EFFECTS

Small bowel obstruction following endoscopic extraperitoneal-preperitoneal herniorrhaphy. Azurin DJ, et al. **J Laparoendosc Surg** 1995 Aug;5(4):263–6 (10 ref.)

Pitfalls of endoscopic carpal tunnel release. Einhorn N, et al. **Orthop Clin North Am** 1996 Apr;27(2):373–80 (74 ref.)

Abdominal wall metastasis following percutaneous endoscopic gastrostomy. Becker G, et al. **Support Care Cancer** 1995 Sep;3(5):313–6 (18 ref.)

[Anesthesia for celiosurgery] Schoeffler P, et al. **Ann Chir** 1995;49(10):878–80 (19 ref.) **(Fre)**

INSTRUMENTATION

The role of minimal-access surgery in esophageal disease. Pellegrini CA. **Curr Opin Gen Surg** 1994;:117–9 (22 ref.)

Power sources in endoscopic surgery. Sutton C. **Curr Opin Obstet Gynecol** 1995 Aug;7(4):248–56 (43 ref.)

Burr hole neuroendoscopic fenestration of quadrigeminal cistern arachnoid cyst: technical case report. Ruge JR, et al. **Neurosurgery** 1996 Apr;38(4):830–7 (32 ref.)

Power sources. Luciano AA. **Obstet Gynecol Clin North Am** 1995 Sep;22(3):423–43 (36 ref.)

[Minimal invasive surgery in childhood] Schier F. **Chirurg** 1996 Jun;67(6):593–603 (26 ref.) (Eng. Abstr.) **(Ger)**

[Critical considerations in arthroscopic stabilization of the unstable shoulder joint] Jerosch J. **Sportverletz Sportschaden** 1996 Mar;10(1):1–12 (93 ref.) (Eng. Abstr.) **(Ger)**

[Arthroscopic approaches to reconstruction of the cruciate ligament: refresher course] Kohn D. **Sportverletz Sportschaden** 1995 Dec;9(4):A31–42 (0 ref.) **(Ger)**

[Arthroscopy and arthroscopic surgery of the shoulder joint] Landsiedl F. **Wien Med Wochenschr** 1996;146(6–7):146–8 (18 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Laparoscopic and thoracoscopic antirefiux surgery. Roberts PJ, et al. **Ann Chir Gynaecol** 1995;84(2):130–7 (30 ref.)

Arthroscopic rotator cuff repairs using suture anchors. Farrall LA. **AORN J** 1995 Nov;62(5):739–46, 748, 750; quiz 754, 756–8 (18 ref.)

A multicenter prospective review of 640 endoscopic carpal tunnel releases using the transbursal and extrabursal chow techniques. Nagle DJ, et al. **Arthroscopy** 1996 Apr; 12(2):139–43 (12 ref.)

Videothoracoscopic operations for bullous lung disease. Jacques LF. **Chest Surg Clin N Am** 1995 Nov;5(4):751–63 (29 ref.)

Local surgical treatment of rectal cancer. Buess GF. **Eur J Cancer** 1995 Jul–Aug;31A(7–8):1233–7 (20 ref.)

Video-assisted thoracoscopic pulmonary surgery—current status and potential evolution. Walker WS, et al. **Eur J Cardiothorac Surg** 1996;10(3):161–7 (62 ref.)

The arthroscopic treatment of anterior and multidirectional shoulder instability. McIntyre LF, et al. **Instr Course Lect** 1996;45:47–56 (72 ref.)

Arthroscopic transglenoid suture capsulorrhaphy for anterior shoulder instability. Rose DJ. **Instr Course Lect** 1996; 45:57–64 (54 ref.)

Endotherapy for chronic pancreatitis. Kozarek RA, et al. **Int J Pancreatol** 1996 Apr;19(2):93–102 (43 ref.)

Endoscopic surgical treatment of primary oesophageal motility disorders. Patti MG, et al. **J R Coll Surg Edinb** 1996 Jun;41(3):137–42 (27 ref.)

Hysteroscopic metroplasty for septate uterus. Fedele L, et al. **Obstet Gynecol Clin North Am** 1995 Sep;22(3):473–89 (55 ref.)

Media and delivery systems. Marlow JL. **Obstet Gynecol Clin North Am** 1995 Sep;22(3):409–22 (55 ref.)

Pitfalls of endoscopic carpal tunnel release. Einhorn N, et al. **Orthop Clin North Am** 1996 Apr;27(2):373–80 (74 ref.)

Newer techniques of carpal tunnel release. Mirza MA, et al. **Orthop Clin North Am** 1996 Apr;27(2):355–71 (61 ref.)

Minimally invasive surgical techniques to treat spine infections. Parker LM, et al. **Orthop Clin North Am** 1996 Jan;27(1):183–99 (40 ref.)

Colonoscopic polypectomy: indication, technique, and therapeutic implications. Greene FL. **Semin Surg Oncol** 1995 Nov–Dec;11(6):416–22 (19 ref.)

[Hemorrhage caused by rupture of gastroesophageal varices: should we dilate the liver or strangulate the varices? (editorial)- Calès P. **Gastroenterol Clin Biol** 1995 Nov; 19(11):899–902 (34 ref.) **(Fre)**

[Techniques and indications of endoscopic treatment of esophago-gastric varices in 1995] Ramond MJ. **Gastroenterol Clin Biol** 1995 Nov;19(11):921–34 (130 ref.) **(Fre)**

[Endoscopic management of benign strictures of the common bile duct] Orosz P, et al. **Orv Hetil** 1996 Feb 11; 137(6):291–4 (31 ref.) (Eng. Abstr.) **(Hun)**

[Endoscopic resection of colorectal lesions—technique and indication] Kato M. **Hokkaido Igaku Zasshi** 1995 May; 70(3):365–9 (11 ref.) (Eng. Abstr.) **(Jpn)**

[Endoscopic treatment of gastrointestinal cancers—indication and limitation] Suzuki H, et al. **Nippon Rinsho** 1996 Jun; 54(6):1699–704 (12 ref.) (Eng. Abstr.) **(Jpn)**

REHABILITATION

Rehabilitation following arthroscopic meniscectomy. St-Pierre DM. **Sports Med** 1995 Nov;20(5):338–47 (147 ref.)

TRENDS

[Will surgical wounds and pain be history? (editorial)] Kivilaakso E. **Duodecim** 1995;111(4):293–6 (16 ref.) **(Fin)**

SURGERY, ESTHETIC see **SURGERY, PLASTIC**

SURGERY, LAPAROSCOPIC

Laparoscopic colon resection for cancer—a favorable view. Ota DM. **Adv Surg** 1996;29:141–53 (16 ref.)

New applications of laparoscopy in gastrointestinal surgery. Sackier JM. **Am Fam Physician** 1996 Jan;53(1):237–42 (18 ref.)

Complications of laparoscopic cholecystectomy. Jones DB, et al. **Annu Rev Med** 1996;47:31–44 (45 ref.)

Operative laparoscopy and the gynecologic oncologist. Commentary and review. Edraki B, et al. **Cancer** 1995 Nov 15;76(10 Suppl):1987–91 (29 ref.)

The role of laparoscopy in gynecologic oncology. Hatch KD, et al. **Cancer** 1995 Nov 15;76(10 Suppl):2113–6 (15 ref.)

Cardiopulmonary physiology and pathophysiology as a consequence of laparoscopic surgery. Sharma KC, et al. **Chest** 1996 Sep;110(3):810–5 (76 ref.)

For tubal pregnancy, surgical treatment is usually best. Gomel V. **Clin Obstet Gynecol** 1995 Jun;38(2):353–61 (48 ref.)

Minimally invasive treatment of urinary stress incontinence and laparoscopically directed repair of pelvic floor defects. Lyons TL. **Clin Obstet Gynecol** 1995 Jun;38(2):380–91 (42 ref.)

Laparoscopic surgery: does it have a role in the management of gynecologic malignancies? Montz FJ, et al. **Clin Obstet Gynecol** 1995 Jun;38(2):426–35 (34 ref.)

Laparoscopic hysterectomy: does it work?: a bicontinental review of the literature and clinical commentary. Munro MG, et al. **Clin Obstet Gynecol** 1995 Jun;38(2):401–25 (67 ref.)

Myomectomy: laparoscopy or laparotomy? Parker WH. **Clin Obstet Gynecol** 1995 Jun;38(2):392–400 (25 ref.)

The case for laparoscopic management of the adnexal mass. Parker WH. **Clin Obstet Gynecol** 1995 Jun;38(2):362–9 (32 ref.)

Laparoscopic surgery: a real step forward, or tempting simply because possible and new? [editorial] Bruhat MA, et al. **Curr Opin Obstet Gynecol** 1995 Aug;7(4):239–42 (48 ref.)

Laparoscopic management of ectopic pregnancy. Grainger DA, et al. **Curr Opin Obstet Gynecol** 1995 Aug;7(4):277–82 (58 ref.)

Laparoscopic lymphadenectomy. Melendez TD, et al. **Curr Opin Obstet Gynecol** 1995 Aug;7(4):307–10 (20 ref.)

Laparoscopic management of polycystic ovarian disease. Rose BI. **Curr Opin Obstet Gynecol** 1995 Aug;7(4):273–6 (30 ref.)

Laparoscopic oophorectomy. Russell JB. **Curr Opin Obstet Gynecol** 1995 Aug;7(4):295–8 (20 ref.)

Laparoscopic surgery for incontinence and genitourinary prolapse. Smith AR. **Curr Opin Obstet Gynecol** 1995 Oct; 7(5):397–9 (21 ref.)

Laparoscopic interventions in the gut: yesterday, today, and tomorrow. McMahon AJ, et al. **Dig Dis** 1996 Jan–Feb; 14(1):14–26 (164 ref.)

Respiratory changes during laparoscopic operations [see comments] Moehlenhof O, et al. **Endosc Surg Allied Technol** 1995 Aug;3(4):162–6 (42 ref.) Comment in: Endosc Surg Allied Technol 1995 Aug;3(4):154–5.

Helium insufflation in laparoscopic surgery. Naude GP, et al. **Endosc Surg Allied Technol** 1995 Aug;3(4):183–6 (28 ref.)

Uterine fibroids: place and modalities of laparoscopic treatment. Dubuisson JB, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Mar;65(1):91–4 (17 ref.)

Ectopic pregnancy and laparoscopy: review of 1197 patients treated by salpingectomy or salpingotomy. Maymon R, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Sep;62(1):61–7 (62 ref.)

Laparoscopy for nonpalpable testis in childhood: is inguinal exploration necessary when vas and vessels are not seen? Arnbjörnsson E, et al. **Eur J Pediatr Surg** 1996 Feb;6(1):7–9 (19 ref.)

Current controversies in laparoscopic colorectal surgery [editorial] Agachan F, et al. **G Chir** 1996 Mar;17(3):77–83 (67 ref.)

Technology assessment in laparoscopic general surgery and gastrointestinal endoscopy: science or convenience? Bouchard S, et al. **Gastroenterology** 1996 Mar;110(3):915–25 (110 ref.)

Laparoscopic surgical staging of ovarian cancer. Childers JM, et al. **Gynecol Oncol** 1995 Oct;59(1):25–33 (30 ref.)

The controversy of laparoscopic myomectomy. Dicker D, et al. **Hum Reprod** 1996 May;11(5):935–7 (8 ref.)

Laparoscopic myomectomy today. A good technique when correctly indicated. Dubuisson JB, et al. **Hum Reprod** 1996 May;11(5):934–5 (21 ref.)

Laparoscopic myomectomy today. Why, when and for whom? Nezhat F, et al. **Hum Reprod** 1996 May;11(5):933–4 (13 ref.)

Laparoscopic adrenalectomy [editorial; comment] Prinz RA. **J Am Coll Surg** 1996 Jul;183(1):71–3 (9 ref.) Comment on: J Am Coll Surg 1996 Jul;183(1):1–10.

Trocar site tumor recurrence after laparoscopic-assisted colectomy. Fodera M, et al. **J Laparoendosc Surg** 1995 Aug; 5(4):259–62 (12 ref.)

An overview of consumer-driven ambulatory surgery: operative laparoscopy. Geier WS. **Nurse Pract** 1995 Nov; 20(11 Pt 1):36, 46–51 (61 ref.)

Laparoscopic coagulation of myoma (myolysis). Goldfarb

HA. **Obstet Gynecol Clin North Am** 1995 Dec;22(4):807–19 (32 ref.)

Laparoscopic myomectomy. Reich H.
Obstet Gynecol Clin North Am 1995 Dec;22(4):757–80 (18 ref.)

Laparoscopic surgery for adrenal lesions. Brown JP, et al. **Semin Surg Oncol** 1996 Mar–Apr;12(2):96–9 (12 ref.)

Laparoscopic staging pelvic lymphadenectomy: extraperitoneal approach. Das S. **Semin Surg Oncol** 1996 Mar–Apr;12(2):134–8 (27 ref.)

Laparoscopic pelvic lymphadenectomy: transperitoneal approach. Gill IS. **Semin Surg Oncol** 1996 Mar–Apr; 12(2):126–33 (39 ref.)

Role of laparoscopy in the diagnosis and treatment of prostate cancer. Moore RG, et al. **Semin Surg Oncol** 1996 Mar–Apr; 12(2):139–44 (51 ref.)

Laparoscopic extirpation of renal cell cancer: feasibility, questions, and concerns. Nakada SY, et al.
Semin Surg Oncol 1996 Mar–Apr;12(2):100–12 (34 ref.)

Laparoscopic surgery for bladder carcinoma. Parra RO, et al. **Semin Surg Oncol** 1996 Mar–Apr;12(2):145–52 (38 ref.)

Laparoscopic approaches to transitional cell carcinomas of the upper urinary tract. Patel A, et al.
Semin Surg Oncol 1996 Mar–Apr;12(2):113–20 (12 ref.)

Pathophysiologic effects of prolonged laparoscopic operation. Wolf JS Jr. **Semin Surg Oncol** 1996 Mar–Apr; 12(2):86–95 (100 ref.)

Laparoscopic appendectomy and the management of gynecologic pathologic conditions found at laparoscopy for presumed appendicitis. Apelgren KN, et al.
Surg Clin North Am 1996 Jun;76(3):469–82 (47 ref.)

Laparoscopy for staging and palliation of gastrointestinal malignancy. Bogen GL, et al. **Surg Clin North Am** 1996 Jun;76(3):557–69 (56 ref.)

Laparoscopic management of peptic ulcer disease. Casas AT, et al. **Surg Clin North Am** 1996 Jun;76(3):515–22 (23 ref.)

Training and privileging for new procedures. Dent TL.
Surg Clin North Am 1996 Jun;76(3):615–21 (28 ref.)

Laparoscopic adrenalectomy. Gagner M.
Surg Clin North Am 1996 Jun;76(3):523–37 (25 ref.)

Laparoscopic management of achalasia. Oddsdóttir M.
Surg Clin North Am 1996 Jun;76(3):451–8 (38 ref.)

Endoscopic approaches to common bile duct injuries. Ponsky JL. **Surg Clin North Am** 1996 Jun;76(3):505–13 (11 ref.)

Laparoscopy in trauma. Poole GV, et al.
Surg Clin North Am 1996 Jun;76(3):547–56 (48 ref.)

Laparoscopic splenectomy. Rege RV, et al.
Surg Clin North Am 1996 Jun;76(3):459–68 (21 ref.)

Laparoscopic antireflux surgery. Richardson WS, et al.
Surg Clin North Am 1996 Jun;76(3):437–50 (48 ref.)

Laparoscopic colon resection. Schirmer BD.
Surg Clin North Am 1996 Jun;76(3):571–83 (32 ref.)

Laparoscopic herniorrhaphy. Swanstrom LL.
Surg Clin North Am 1996 Jun;76(3):483–91 (26 ref.)

The feasibility of safe laparoscopic treatment of hydatid cysts of the liver [letter; comment] Bickel A, et al.
Surg Endosc 1995 Aug;9(8):934–5 (6 ref.) Comment on: Surg Endosc 1994 Sep;8(9):1103–4.

Laparoscopic resection of a large hepatic tumor. Ferzli G, et al. **Surg Endosc** 1995 Jun;9(6):733–5 (9 ref.)

Peritoneal cystic mesothelioma treated with minimally invasive approach. Navarra G, et al. **Surg Endosc** 1996 Jan; 10(1):60–1 (23 ref.)

Laparoscopic surgery for intestinal obstruction. Reissman P, et al. **Surg Endosc** 1995 Aug;9(8):865–8 (19 ref.)

Laparoscopic treatment of Meckel's diverticulum. Obstruction and bleeding managed with minimal morbidity. Sanders LE. **Surg Endosc** 1995 Jun;9(6):724–7 (14 ref.)

Beyond access. Advanced exposure techniques and organ manipulation in endosurgery [editorial] Swanstrom LL.
Surg Endosc 1995 Nov;9(11):1165–8 (28 ref.)

Minimally invasive colectomy in elderly patients. Peters WR, et al. **Surg Laparosc Endosc** 1995 Dec;5(6):477–9 (15 ref.)

Minimal access surgery—the renaissance of gastric surgery? McCloy R, et al. **Yale J Biol Med** 1994 May–Aug; 67(3–4):159–66 (38 ref.)

[Progresses in general surgery in China, 1995] Huang Y.
Chung Hua I Hsueh Tsa Chih 1995 Dec;75(12):731–2 (0 ref.) **(Chi)**

–Gynecologic endoscopic surgery. What are the limits?– Janecek P. **Arch Gynecol Obstet** 1995;256 Suppl:S6–11 (17 ref.) **(Fre)**

[Vaginal hysterectomy. Role of laparoscopic preparation. Our experience] Martin J, et al. **Chirurgie** 1996;121(2):91–5 (17 ref.) (Eng. Abstr.) **(Fre)**

[Complete hysterectomy for benign pathology and laparoscopy: respective indications of laparoscopic preparation and an exclusively laparoscopic approach] Chapron C, et al. **Contracept Fertil Sex** 1995 Dec; 23(12):741–8 (76 ref.) (Eng. Abstr.) **(Fre)**

[Operative hysteroscopy in 1995. Equipment, technique, indications and results] Merviel P, et al.
Contracept Fertil Sex 1995 Sep;23(9):516–23 (90 ref.) **(Fre)**

[Cardiovascular function during laparoscopic interventions in surgery and gynecology] Berg K, et al.
Anasthesiol Intensivmed Notfallmed Schmerzther 1995 Nov; 30(7):446–50 (28 ref.) **(Ger)**

–Complications. Surgical endoscopy versus gynecologic minimal invasive surgery– Wallwiener D, et al.
Arch Gynecol Obstet 1995;256 Suppl:S21–31 (18 ref.) **(Ger)**

[Rectal prolapse—choice of procedure and minimal invasive possibilities] Köckerling F, et al. **Chirurg** 1996 May; 67(5):471–82 (38 ref.) (Eng. Abstr.) **(Ger)**

[Cardiovascular function during laparoscopies] Berg K, et al. **Dtsch Med Wochenschr** 1995 Nov 10;120(45):1561–7 (49 ref.) **(Ger)**

[Inguinal hernia operation: still or after all an open one? (editorial)] Feussner H, et al. **Dtsch Med Wochenschr** 1996 Jun 21;121(25–26):815–8 (35 ref.) **(Ger)**

[Endourology update] Shinno Y, et al.
Hokkaido Igaku Zasshi 1995 May;70(3):391–6 (7 ref.) (Eng. Abstr.) **(Jpn)**

[Gynecologic endoscopic surgery] Yoshida H, et al.
Hokkaido Igaku Zasshi 1995 May;70(3):397–400 (8 ref.) (Eng. Abstr.) **(Jpn)**

[Is inguinal hernia to be treated by laparoscopic surgery?] Arvidsson D, et al. **Lakartidningen** 1996 Aug 7; 93(32–33):2727–31 (16 ref.) **(Swe)**

ADVERSE EFFECTS

Laparoscopic colon resection for cancer—an unfavorable view. Bertagnolli MM, et al. **Adv Surg** 1996;29:155–64 (46 ref.)

Laparoscopic electrosurgical complications and their prevention. Tucker RD, et al. **AORN J** 1995 Jul;62(1):51–3, 55, 58–9 passim; quiz 74–7 (16 ref.)

Complications of gynecologic laparoscopic surgery. Querleu D, et al. **Curr Opin Obstet Gynecol** 1995 Aug;7(4):257–61 (18 ref.)

Abdominal wall metastasis and peritoneal carcinomatosis after laparoscopic-assisted colectomy for colon cancer. Jacquet P, et al. **Eur J Surg Oncol** 1995 Oct;21(5):568–70 (25 ref.)

Complications of laparoscopic general surgery. Callery MP, et al. **Gastrointest Endosc Clin N Am** 1996 Apr;6(2):423–44 (80 ref.)

Port site metastasis. An unresolved problem in laparoscopic surgery. A review. Martinez J, et al. **Int Surg** 1995 Oct–Dec;80(4):315–21 (106 ref.)

[Seed metastases following laparoscopic surgery for gastrointestinal malignancies] Nieveen van Dijkum EJ, et al. **Ned Tijdschr Geneeskd** 1996 Jul 6;140(27):1391–4 (50 ref.) **(Dut)**

[Granulomatous peritonitis after laparoscopic surgery of an ovarian dermoid cyst. Diagnosis, management, prevention, a case report] Huss M, et al.
J Gynecol Obstet Biol Reprod (Paris) 1996;25(4):365–72 (54 ref.) (Eng. Abstr.) **(Fre)**

[Bowel complications in gynecologic laparoscopic surgery and their immediate repair without laparotomy. Four cases] Renault B, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996; 25(4):360–4 (16 ref.) (Eng. Abstr.) **(Fre)**

CONTRAINDICATIONS

["Contra laparoscopy" position in treatment of testicular varicocele] Tauber R, et al. **Urologe A** 1996 May; 35(3):246–50 (41 ref.) (Eng. Abstr.) **(Ger)**

ECONOMICS

Results of Nissen fundoplication. A cost analysis. Hinder RA, et al. **Surg Endosc** 1995 Dec;9(12):1328–32 (20 ref.)

INSTRUMENTATION

Laparoscopic assistance at vaginal hysterectomy: a literature review. Rempen A. **Arch Gynecol Obstet** 1996;258(2):57–64 (52 ref.)

Laparoscopic inguinal herniorrhaphy. Fallas MJ, et al.
Curr Opin Gen Surg 1994;:198–202 (11 ref.)

Controversies regarding laparoscopic colectomy for malignant diseases. Ota DM, et al. **Curr Opin Gen Surg** 1994;:208–13 (22 ref.)

Laparoscopic antireflux repair and myotomy. Peters JH, et al. **Curr Opin Gen Surg** 1993;:170–9 (36 ref.)

Necrotizing fasciitis following laparoscopic surgery. Case report and review of the literature. Golshani S, et al.
Surg Endosc 1996 Jul;10(7):751–4 (20 ref.)

Review on laparoscopic hysterectomy. Deprest JA, et al. **Zentralbl Gynakol** 1995;117(12):641–51 (75 ref.)

[Pro and contra: pelviscopy and microsurgery of the fallopian tube] Semm K. **Arch Gynecol Obstet** 1995;257(1–4):302–10 (14 ref.) **(Ger)**

[Minimal invasive surgery in childhood] Schier F.
Chirurg 1996 Jun;67(6):593–603 (26 ref.) (Eng. Abstr.) **(Ger)**

[Introduction of laparoscopic surgery in extrauterine pregnancy] Rempen A. **Geburtshilfe Frauenheilkd** 1995 Jul; 55(7):357–64 (28 ref.) (Eng. Abstr.) **(Ger)**

[Complications of laparoscopic interventions in urology] Fahlenkamp D, et al. **Urologe A** 1996 May;35(3):238–45 (20 ref.) (Eng. Abstr.) **(Ger)**

[Current status of laparoscopic surgery in pediatric urology] Fuchs GJ, et al. **Urologe A** 1996 May;35(3):175–84 (62 ref.) (Eng. Abstr.) **(Ger)**

[Laparoscopic technique—which developments are possible?] Voges U. **Urologe A** 1996 May;35(3):208–14 (6 ref.) (Eng. Abstr.) **(Ger)**

[Differential concept on use of laparoscopic anti-reflux operations] Fuchs KH, et al. **Zentralbl Chir** 1996; 121(4):294–9; discussion 300–2 (32 ref.) (Eng. Abstr.) **(Ger)**

[Possibilities and limits of endoscopic fallopian tube surgery] Korell M, et al. **Zentralbl Gynakol** 1995;117(12):663–9 (21 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Laparoscopic and thoracoscopic antireflux surgery. Roberts PJ, et al. **Ann Chir Gynaecol** 1995;84(2):130–7 (30 ref.)

Laparoscopic excision of distal pancreas including insulinoma. Sussman LA, et al. **Aust N Z J Surg** 1996 Jun; 66(6):414–6 (15 ref.)

Electrosurgery: principles and safety issues. Odell RC.
Clin Obstet Gynecol 1995 Sep;38(3):610–21 (15 ref.)

Laparoscopic hysterectomy. Mage G, et al.
Curr Opin Obstet Gynecol 1995 Aug;7(4):283–9 (67 ref.)

Endoscopy or the surgical revolution for women [editorial] Manhes H, et al. **Curr Opin Obstet Gynecol** 1995 Aug; 7(4):243–7 (18 ref.)

Severe endometriosis and operative laparoscopy. Nezhat C, et al. **Curr Opin Obstet Gynecol** 1995 Aug;7(4):299–306 (55 ref.)

Lymph node dissection in gynaecologic malignancy: the role of laparoscopy. Montz FJ. **Endosc Surg Allied Technol** 1995 Apr–Jun;3(2–3):96–100 (33 ref.)

Correction of stress urinary incontinence: transperitoneal approach. Cadeddu JA, et al. **J Endourol** 1996 Jun; 10(3):241–5 (25 ref.)

Correction of genital prolapse. Liu CY, et al. **J Endourol** 1996 Jun;10(3):259–65 (32 ref.)

Laparoscopic colostomy for a gunshot wound to the rectum. Namias N, et al. **J Laparoendosc Surg** 1995 Aug;5(4):251–3 (17 ref.)

Gasless laparoscopic gastrostomy. Viani MP, et al.
J Laparoendosc Surg 1995 Aug;5(4):245–9 (9 ref.)

Laparoscopic fenestration of giant posterolateral liver cyst. Watson DI, et al. **J Laparoendosc Surg** 1995 Aug;5(4):255–7 (7 ref.)

Gasless laparoscopy. Martin IG, et al.
J R Coll Surg Edinb 1996 Apr;41(2):72–4 (31 ref.)

Role of laparoscopic techniques in colorectal cancer surgery. Milsom JW, et al. **Oncology (Huntingt)** 1995 May; 9(5):393–8; discussion 398–9, 403–4, 409 (23 ref.)

The difficult laparoscopy. Halpern NB.
Surg Clin North Am 1996 Jun;76(3):603–13 (19 ref.)

Laparoscopic treatment of a sigmoid perforation after colonoscopy. Case report and review of literature. Mehdi A, et al. **Surg Endosc** 1996 Jun;10(6):666–7 (19 ref.)

Techniques of partial hysterectomy: an overview. Phillips G, et al. **Zentralbl Gynakol** 1995;117(12):625–8 (24 ref.)

[Laparoscopy in gastroenterology] Ovaska J, et al.
Duodecim 1994;110(20):1875–80 (16 ref.) **(Fin)**

[Surgery of colorectal cancer by laparoscopic approach] Boulez J. **Ann Chir** 1996;50(3):219–30 (45 ref.) **(Fre)**

[Total hysterectomy for benign pathologies. Conventional celiosurgical technique] Chapron C, et al. **Ann Chir** 1995; 49(7):613–20 (39 ref.) (Eng. Abstr.) **(Fre)**

[Hydrosalpinx and sterility: indications for salpingectomy] Aubriot FX, et al. **Contracept Fertil Sex** 1995 Nov; 23(11):670–3 (36 ref.) **(Fre)**

[Total hysterectomy for benign pathologies: why is laparoscopy of value?] Chapron C, et al.
Contracept Fertil Sex 1995 Nov;23(11):688–93 (63 ref.) (Eng. Abstr.) **(Fre)**

[Radical laparoscopic surgery of ectopic pregnancy: results from a continuous series of 383 interventions] Dubuisson JB, et al. **Contracept Fertil Sex** 1996 Feb;24(2):140–6 (36 ref.) (Eng. Abstr.) **(Fre)**

[Role of conservative therapy and medical treatment in ectopic pregnancy: literature review and clinical trial comparing medical treatment and conservative laparoscopic treatment] Fernandez H, et al.
Contracept Fertil Sex 1996 Apr;24(4):297–302 (36 ref.) (Eng. Abstr.) **(Fre)**

[Adenomyosis: role of hysteroscopic treatment] Mergui JL, et al. **Contracept Fertil Sex** 1995 Oct;23(10):590–4 (64 ref.) **(Fre)**

[Frontiers of digestive surgery using laparoscopy (editorial)] Champault G. **Gastroenterol Clin Biol** 1996;20(4):353–6 (37 ref.) **(Fre)**

[Is celioscopic surgery for colorectal cancer currently justified?] Pélissier EP, et al. **Gastroenterol Clin Biol** 1996; 20(4):374–8 (38 ref.) **(Fre)**

[Total laparoscopic hysterectomy. Operative technique, results and indications] Chapron C, et al.
J Gynecol Obstet Biol Reprod (Paris) 1995;24(8):802–10 (37 ref.) (Eng. Abstr.) **(Fre)**

[Alternatives and access routes in hysterectomies. Are randomizations dangerous?] Cosson M, et al.
J Gynecol Obstet Biol Reprod (Paris) 1996;25(3):257–63 (15 ref.) (Eng. Abstr.) **(Fre)**

[Laparoscopic surgery of large uterine fibromas. Operative technique and results] Dubuisson JB, et al.
J Gynecol Obstet Biol Reprod (Paris) 1995;24(7):705–10 (22 ref.) (Eng. Abstr.) **(Fre)**

[Laparoscopic hysterectomy. A series of 318 consecutive cases] Masson FN, et al.
J Gynecol Obstet Biol Reprod (Paris) 1996;25(4):340–52 (36 ref.) (Eng. Abstr.) **(Fre)**

[Ultrasonic diagnosis and laparoscopic treatment of an ovarian pregnancy. A case report and review of the literature] Riethmuller D, et al.
J Gynecol Obstet Biol Reprod (Paris) 1996;25(4):378–83 (25 ref.) (Eng. Abstr.) **(Fre)**

[Indications for celioscopic surgery in children (editorial)] Heloury Y. **Presse Med** 1995 Oct 14;24(30):1374–5 (9 ref.) **(Fre)**

[Laparoscopic hysterectomy—the future is here and now] Ben-Rafael Z, et al. **Harefuah** 1996 Apr 15;130(8):542–5 (19 ref.) **(Heb)**

[Laparoscopic splenectomy: comments on the surgical technic] Contini S, et al. **Acta Biomed Ateneo Parmense** 1995;66(1–2):27–33 (10 ref.) (Eng. Abstr.) **(Ita)**

[Laparoscopic surgery for early gastric cancer] Ohgami M, et al. **Nippon Geka Gakkai Zasshi** 1996 Apr;97(4):279–85 (25 ref.) (Eng. Abstr.) **(Jpn)**

[Amputation of the rectum via laparoscopy] Vasilescu C, et al. **Chirurgia (Bucur)** 1995;44(3):55–8 (6 ref.) (Eng. Abstr.) **(Rum)**

[Laparoscopic nephrectomy in a patient with a parenchymatous form of nephrogenic hypertension] Troitskii OA, et al. **Urol Nefrol (Mosk)** 1996 Mar–Apr; (2):8–11 (9 ref.) (Eng. Abstr.) **(Rus)**

STANDARDS

Laparoscopy in surgical treatment of vaginal aplasia: laparoscopy-assisted colpopoiesis and perineal hysterectomy with colpopoiesis. Adamian LV, et al. **Int J Fertil Menopausal Stud** 1996 Jan–Feb;41(1):40–5 (10 ref.)

STATISTICS & NUMERICAL DATA

Reporting results of laparoscopic procedures. The state-wide registry approach. Deveney K. **Surg Clin North Am** 1996 Jun;76(3):623–30 (21 ref.)

TRENDS

[Digestive surgery using the celioscopic route. Prospects for the future] Périssat J. **Bull Acad Natl Med** 1996 Mar; 180(3):679–91; discussion 691–6 (30 ref.) (Eng. Abstr.) **(Fre)**

[The future of surgical gynecology: from dogma to science—from science to practice standard] Sevelda P. **Gynakol Geburtshilfliche Rundsch** 1995;35(3):149–52 (7 ref.) (Eng. Abstr.) **(Ger)**

[The future of laparoscopic surgery in urology] Coptcoat MJ, et al. **Urologe A** 1996 May;35(3):226–32 (37 ref.) (Eng. Abstr.) **(Ger)**

[Obese patients on the operating table. A laparoscopic technique is under way] Näslund I. **Lakartidningen** 1996 Feb 7;93(6):485–8 (15 ref.) **(Swe)**

SURGERY, LASER see **LASER SURGERY**

SURGERY, MAXILLOFACIAL see **SURGERY, ORAL**

SURGERY, MINIMALLY INVASIVE

Endovascular surgery—an overview. Denton MJ. **Aust Fam Physician** 1995 Sep;24(9):1657, 1660–3, 1665–7 (7 ref.)

New technology in urology: why assessment needs to be more scientific. Keoghane SR, et al. **Br J Urol** 1996 Jun; 77(6):771–5 (31 ref.)

Antibiotic prophylaxis and infection control measures in minimally invasive surgery. Wilson AP. **J Antimicrob Chemother** 1995 Jul;36(1):1–5 (36 ref.)

Peritoneal cystic mesothelioma treated with minimally invasive approach. Navarra G, et al. **Surg Endosc** 1996 Jan; 10(1):60–1 (23 ref.)

Beyond access. Advanced exposure techniques and organ manipulation in endosurgery [editorial] Swanstrom LL. **Surg Endosc** 1995 Nov;9(11):1165–8 (28 ref.)

Minimally invasive colectomy in elderly patients. Peters WR, et al. **Surg Laparosc Endosc** 1995 Dec;5(6):477–9 (15 ref.)

-Complications. Surgical endoscopy versus gynecologic minimal invasive surgery- Wallwiener D, et al. **Arch Gynecol Obstet** 1995;256 Suppl:S21–31 (18 ref.) **(Ger)**

INSTRUMENTATION

[Minimal invasive surgery in childhood] Schier F. **Chirurg** 1996 Jun;67(6):593–603 (26 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Minimally invasive neurosurgery. Rosenfeld JV. **Aust N Z J Surg** 1996 Aug;66(8):553–9 (75 ref.)

[Minimal invasive therapy of benign prostatic hyperplasia] Madersbacher S, et al. **Wien Med Wochenschr** 1996; 146(8):169–75 (31 ref.) (Eng. Abstr.) **(Ger)**

SURGERY, OFFICE see **AMBULATORY SURGERY**

SURGERY, OPERATIVE

see related
INTRAOPERATIVE COMPLICATIONS
OPERATING ROOMS
POSTOPERATIVE COMPLICATIONS
REOPERATION

The role of scintigraphic perfusion imaging for predicting ischemic cardiac events in noncardiac surgery. Gojer B, et al. **Am J Card Imaging** 1995 Jul;9(3):213–25 (78 ref.)

Pharmacodynamics of antimicrobial therapy in surgery. DiPiro JT, et al. **Am J Surg** 1996 Jun;171(6):615–22 (46 ref.)

Noncardiac surgery in the cardiac patient: what is the question? [see comments] Bodenheimer MM. **Ann Intern Med** 1996 Apr 15;124(8):763–6 (22 ref.) Comment in: Ann Intern Med 1996 Apr 15;124(8):767–72.

Screening for cardiac disease in patients having noncardiac surgery [comment] Fleisher LA, et al. **Ann Intern Med** 1996 Apr 15;124(8):767–72 (20 ref.) Comment on: Ann Intern Med 1996 Apr 15;124(8):763–6.

The role of cellular adhesion molecules in surgery. Breidahl AF, et al. **Aust N Z J Surg** 1995 Dec;65(12):838–47 (54 ref.)

Occupational health in surgery: risks extend beyond the operating room. Patz JA, et al. **Aust N Z J Surg** 1995 Sep; 65(9):627–9 (27 ref.)

Preoperative strategies to assess cardiac risk before noncardiac surgery. Younis LT, et al. **Clin Cardiol** 1995 Aug;18(8):447–54 (53 ref.)

Role of fibrin sealants in surgical procedures on patients with hemostatic disorders. Martinowitz U, et al. **Clin Orthop** 1996 Jul;(328):65–75 (76 ref.)

Hemostasis: a practical review of conservative and operative care. Shopnick RI, et al. **Clin Orthop** 1996 Jul;(328):34–8 (39 ref.)

Preoperative assessment and perioperative management of cardiac ischemic risk in noncardiac surgery. Coley CM, et al. **Curr Probl Cardiol** 1996 May;21(5):289–382 (325 ref.)

Perioperative management of the diabetic patient. Peters A, et al. **Exp Clin Endocrinol Diabetes** 1995;103(4):213–8 (27 ref.)

Perioperative management of the rheumatoid patient. Haynie RL, et al. **J Foot Ankle Surg** 1996 Mar–Apr;35(2):94–100 (74 ref.)

Impact of anesthetic management on the outcome of cardiac patients for non-cardiac surgery. Gabriel FS. **Middle East J Anesthesiol** 1996 Feb;13(4):385–93 (20 ref.)

Down's syndrome and anaesthesia. Mitchell V, et al. **Paediatr Anaesth** 1995;5(6):379–84 (49 ref.)

Perioperative management of rheumatoid arthritis. Areas of concern for primary care physicians. Lyssy KJ, et al. **Postgrad Med** 1996 Feb;99(2):191–4, 199–201, 205–6 (27 ref.)

Invasive and noninvasive monitoring for early recognition and treatment of shock in high-risk trauma and surgical patients. Asensio JA, et al. **Surg Clin North Am** 1996 Aug; 76(4):985–97 (25 ref.)

Observational studies as alternatives to randomized clinical trials in surgical clinical research. Hu X, et al. **Surgery** 1996 Apr;119(4):473–5 (6 ref.)

Prognosis in surgery: why they are determined, strategies for making them, and study design. Mahoney JE, et al. **Surgery** 1996 Sep;120(3):563–6 (21 ref.)

Measurement in surgical clinical research [editorial] Wright JG, et al. **Surgery** 1996 Mar;119(3):241–4 (27 ref.)

Practice guidelines in surgery. Wright JG, et al. **Surgery** 1996 Jun;119(6):706–9 (29 ref.)

[Which operations can be done without general anesthesia?] Tarkkila P, et al. **Duodecim** 1995;111(4):365–9 (5 ref.) **(Fin)**

[Perforations and porosity of surgical gloves. Frequency, mechanism, risk] Johanet H, et al. **Ann Chir** 1996; 50(4):352–5 (35 ref.) (Eng. Abstr.) **(Fre)**

[Perioperative artificial nutrition in planned surgery in adults. Consensus development conference. Saint-Mande, France, 16 December 1994] **Ann Fr Anesth Reanim** 1995;14 Suppl 2:1–136 (0 ref.) **(Fre)**

[Assessment of the nutritional status of the surgical patient] Dionigi P. **Chir Ital** 1994;46(6):7–10 (28 ref.) (Eng. Abstr.) **(Ita)**

[Effect of menstrual cycle on the immune response to surgical stress] Lazzaretti MG, et al. **Minerva Ginecol** 1995 May; 47(5):197–205 (48 ref.) (Eng. Abstr.) **(Ita)**

[The treatment and teaching aspects in the computerized management of the surgical emergency (editorial)] Bonomo M, et al. **Recenti Prog Med** 1996 May;87(5):229–36 (24 ref.) **(Ita)**

[Disseminated intravascular coagulation syndrome in surgical practice] Titova MI, et al. **Klin Med (Mosk)** 1995;73(4):20–4 (30 ref.) **(Rus)**

ADVERSE EFFECTS

Evaluating cardiac risk in noncardiac surgery patients. Bronson DL, et al. **Cleve Clin J Med** 1995 Nov–Dec; 62(6):391–400 (39 ref.)

Sepsis in the critically ill patient. Baker CC, et al. **Curr Probl Surg** 1995 Dec;32(12):1013–83 (341 ref.)

ECONOMICS

Quality assurance and medical outcomes in the era of cost containment. Campion FX, et al. **Surg Clin North Am** 1996 Feb;76(1):139–59 (35 ref.)

Technology and surgery. Dilemma of the gimmick, true advances, and cost effectiveness. Traverso LW. **Surg Clin North Am** 1996 Feb;76(1):129–38 (10 ref.)

METHODS

In the rheumatoid patient: surgery to the cervical spine. Casey AT, et al. **Br J Rheumatol** 1995 Nov;34(11):1079–86 (48 ref.)

PSYCHOLOGY

Psychological and hypnotic preparation for anesthesia and surgery: an individual differences perspective. Kessler R, et al. **Int J Clin Exp Hypn** 1996 Jul;44(3):189–207 (60 ref.)

STANDARDS

Consensus conference: Blood Management Surgical Practice Guidelines. Dallas, Texas, January 12–14, 1995. **Am J Surg** 1995 Dec;170(6A Suppl):1S–73S (0 ref.)

Quality assurance and medical outcomes in the era of cost containment. Campion FX, et al. **Surg Clin North Am** 1996 Feb;76(1):139–59 (35 ref.)

TRENDS

New trends in the surgery of gynaecological tumours. Szánthó A, et al. **Acta Med Hung** 1994;50(3–4):195–203 (21 ref.)

Preparation and use of fibrin glue in surgery. Silver FH, et al. **Biomaterials** 1995 Aug;16(12):891–903 (124 ref.)

Needle suspension procedures: past, present, and future. Trockman BA, et al. **J Endourol** 1996 Jun;10(3):217–20 (36 ref.)

SURGERY, ORAL

see related
DENTISTRY, OPERATIVE

The potential risks, complications, and prevention of deep vein thrombosis in oral and maxillofacial surgery patients. Solomon JM, et al. **J Oral Maxillofac Surg** 1995 Dec; 53(12):1441–7 (28 ref.)

METHODS

[Free antebrachial flap with radial pedicle. I. Theoretic considerations and indications in maxillofacial reconstruction] Iriacte Ortabe JI, et al. **Acta Stomatol Belg** 1995 Jun;92(2):57–73 (243 ref.) (Eng. Abstr.) **(Fre)**

SURGERY, ORAL, PREPROSTHETIC

Preprosthetic surgery for the edentulous patients. Costello BJ, et al. **Dent Clin North Am** 1996 Jan;40(1):19–38 (46 ref.)

Preprosthetic orthodontics. Diedrich P. **Fortschr Kieferorthop** 1996 Apr;57(2):102–16 (29 ref.) **(Eng, Ger)**

Perioperative angioedema in a patient on long-term angiotensin-converting enzyme (ACE)-inhibitor therapy. Ogbureke KU, et al. **J Oral Maxillofac Surg** 1996 Jul; 54(7):917–20 (18 ref.)

METHODS

[The use of hydroxyapatite for the surgical preparation of the oral cavity for prosthesis] Zuev VP, et al. **Stomatologiia (Mosk)** 1996;75(1):71–4 (69 ref.) **(Rus)**

SURGERY, ORTHOPEDIC see **ORTHOPEDICS**

SURGERY, OUTPATIENT see **AMBULATORY SURGERY**

SURGERY, PLASTIC

Cosmetic laser surgery. Alster TS. **Adv Dermatol** 1996; 11:51–80; discussion 81 (93 ref.)

Endoscopic browlift. Core GB, et al. **Clin Plast Surg** 1995 Oct;22(4):619–31 (16 ref.)

Endoscopic abdominoplasty with repair of diastasis recti and abdominal wall hernia. Core GB, et al. **Clin Plast Surg** 1995 Oct;22(4):707–22 (14 ref.)

Endoscopic forehead lift. Aesthetics and analysis. Daniel RK, et al. **Clin Plast Surg** 1995 Oct;22(4):605–18 (32 ref.)

Endoscopic techniques in aesthetic breast surgery. Augmentation, mastectomy, biopsy, capsulotomy, capsulorrhaphy, reduction, mastopexy, and reconstructive techniques. Eaves FF 3rd, et al. **Clin Plast Surg** 1995 Oct; 22(4):683–95 (32 ref.)

Endoscopic abdominoplasty, mastopexy, and breast reduction. Faria-Correa MA. **Clin Plast Surg** 1995 Oct; 22(4):723–45 (9 ref.)

Complications in endoscopic plastic surgery. Howard PS, et al. **Clin Plast Surg** 1995 Oct;22(4):791–6 (13 ref.)

Plastic surgery research. Lawrence WT, et al. **Clin Plast Surg** 1996 Jan;23(1):173–82 (81 ref.)

Endoscopic technique for free flap harvesting. Miller MJ, et al. **Clin Plast Surg** 1995 Oct;22(4):755–73 (20 ref.)

The biplanar endoscopically assisted forehead lift. Oslin B, et al. **Clin Plast Surg** 1995 Oct;22(4):633–8 (4 ref.)

Plastic surgery's plastics. Ousterhout DK, et al. **Clin Plast Surg** 1996 Jan;23(1):183–90 (46 ref.)

Lasers in aesthetic surgery. Rosenberg GJ, et al. **Clin Plast Surg** 1996 Jan;23(1):29–48 (60 ref.)

Pediatric plastic surgery. Sadove AM, et al. **Clin Plast Surg** 1996 Jan;23(1):139–55 (55 ref.)

Endoscopic harvest of the omental and jejunal free flaps. Saltz R. **Clin Plast Surg** 1995 Oct;22(4):747–54 (24 ref.)

Gene therapy for plastic and reconstructive surgery. Shenaq SM, et al. **Clin Plast Surg** 1996 Jan;23(1):157–71 (119 ref.)

The current status of expanded polytetrafluoroethylene

(Gore-Tex) in facial plastic surgery. Levine B, et al. **Ear Nose Throat J** 1995 Oct;74(10):681–2, 684 (17 ref.)
Recent advances in facial plastic and reconstructive surgery. Haddad NM. **J Med Liban** 1994;42(4):240–1 (14 ref.)
Head and neck reconstruction. Deschler DG, et al. **Neuroimaging Clin N Am** 1996 May;6(2):505–14 (38 ref.)
Growth factors in surgery. Rudkin GH, et al. **Plast Reconstr Surg** 1996 Feb;97(2):469–76 (90 ref.)
Rehabilitation of a child with partial unilateral cryptophthalmos and multiple congenital anomalies. Konrad H, et al. **Trans Am Ophthalmol Soc** 1995;93:219–40; discussion 241–4 (121 ref.)
[The greater omentum. Its role in reconstructive plastic surgery] Micheau P. **Ann Chir Plast Esthet** 1995 Apr; 40(2):192–207 (65 ref.) (Eng. Abstr.) **(Fre)**
[Role of plastic surgery in the treatment of breast cancer] Petit JY, et al. **Bull Acad Natl Med** 1996 Feb;180(2):317–28; discussion 328–31 (17 ref.) (Eng. Abstr.) **(Fre)**
[Philosophy in reconstruction of the face] Faga A. **Acta Otorhinolaryngol Ital** 1995 Jun;15(3):164–6; discussion 167 (13 ref.) **(Ita)**

HISTORY

[1984–1994: Ten years of skin flaps. Foreword] Cariou JL. **Ann Chir Plast Esthet** 1995 Oct;40(5):435–9 (105 ref.) **(Fre)**
[History and prehistory of skin flaps] Glicenstein J. **Ann Chir Plast Esthet** 1995 Oct;40(5):441–6 (45 ref.) **(Fre)**

INSTRUMENTATION

Instrumentation and setup for endoscopic plastic surgery. Eaves FF 3rd, et al. **Clin Plast Surg** 1995 Oct;22(4):591–603 (27 ref.)

METHODS

Soft tissue reconstructive choices for craniofacial reconstruction. Mustoe TA, et al. **Clin Plast Surg** 1995 Jul; 22(3):543–54 (41 ref.)
Reconstruction of the cranial base. Spinelli HM, et al. **Clin Plast Surg** 1995 Jul;22(3):555–61 (30 ref.)
Microsurgery for cranial base tumors. Thomson JG, et al. **Clin Plast Surg** 1995 Jul;22(3):563–72 (74 ref.)
Laparoscopy in surgical treatment of vaginal aplasia: laparoscopy-assisted colpopoiesis and perineal hysterectomy with colpopoiesis. Adamian LV, et al. **Int J Fertil Menopausal Stud** 1996 Jan–Feb;41(1):40–5 (10 ref.)
[Rising and trends of endoscopic cosmetic plastic surgery] Zhong D, et al. **Chung Hua Cheng Hsing Shao Shang Wai Ko Tsa Chih** 1995 Nov;11(6):469–51 (13 ref.) **(Chi)**
[1984–1994: Ten years of skin flaps. Development of transfer techniques. New methods of autoplasty described during this period] Martin D. **Ann Chir Plast Esthet** 1995 Oct; 40(5):527–82 (126 ref.) (Eng. Abstr.) **(Fre)**

TRENDS

What's new in aesthetic surgery. Baker TM, et al. **Clin Plast Surg** 1996 Jan;23(1):3–16 (28 ref.)
What's new in plastic surgery. Mackinnon SE. **J Am Coll Surg** 1996 Feb;182(2):150–61 (122 ref.)

SURGERY, REPEAT see **REOPERATION**

SURGICAL ANASTOMOSIS see **ANASTOMOSIS, SURGICAL**

SURGICAL BLOOD LOSS see **BLOOD LOSS, SURGICAL**

SURGICAL DIATHERMY see **ELECTROCOAGULATION**

SURGICAL EQUIPMENT

Development of an instrument for endoscopic nasal surgery. Hochberg J, et al. **Clin Plast Surg** 1995 Oct;22(4):781–4 (4 ref.)
[Computer-assisted surgery: assessment and perspectives] Demongeot J. **Chirurgie** 1994–95;120(11):19–25 (27 ref.) (Eng. Abstr.) **(Fre)**

TRENDS

Robots in operating theatres. Buckingham RA, et al. **BMJ** 1995 Dec 2;311(7018):1479–82 (22 ref.)

SURGICAL FLAPS

The use of the temporoparietal fascial flap in temporal bone reconstruction. Cheney ML, et al. **Am J Otol** 1996 Jan; 17(1):137–42 (11 ref.)
Endoscopic technique for free flap harvesting. Miller MJ, et al. **Clin Plast Surg** 1995 Oct;22(4):755–73 (20 ref.)
Endoscopic harvest of the omental and jejunal free flaps. Saltz R. **Clin Plast Surg** 1995 Oct;22(4):747–54 (24 ref.)
[Free antebrachial flap with radial pedicle. I. Theoretic considerations and indications in maxillofacial reconstruction] Iriacte Ortabe JI, et al. **Acta Stomatol Belg** 1995 Jun;92(2):57–73 (243 ref.) (Eng. Abstr.) **(Fre)**
[1984–1994: ten years of skin flaps. Improvements and conceptual developments. Development of vascular concepts, classification and clinical concepts] Cariou JL. **Ann Chir Plast Esthet** 1995 Oct;40(5):447–525 (234 ref.) (Eng. Abstr.) **(Fre)**
[1984–1994: Ten years of skin flaps. Foreword] Cariou JL. **Ann Chir Plast Esthet** 1995 Oct;40(5):435–9 (105 ref.) **(Fre)**
[1984–1994: Ten years of skin flaps. Development of transfer techniques. New methods of autoplasty described during this period] Martin D. **Ann Chir Plast Esthet** 1995 Oct; 40(5):527–82 (126 ref.) (Eng. Abstr.) **(Fre)**
[The greater omentum. Its role in reconstructive plastic surgery] Micheau P. **Ann Chir Plast Esthet** 1995 Apr; 40(2):192–207 (65 ref.) (Eng. Abstr.) **(Fre)**
[Current treatment of hypospadias] Mollard P, et al. **J Urol (Paris)** 1996;102(1):9–17 (35 ref.) (Eng. Abstr.) **(Fre)**
[Reconstructive surgery using the flaps pedicled by rectus abdominis muscle or deep inferior epigastric artery] Hyakusoku H. **Nippon Ika Daigaku Zasshi** 1995 Dec; 62(6):567–73 (22 ref.) **(Jpn)**

ADVERSE EFFECTS

Complications of free flap donor sites. Mahoney J. **Microsurgery** 1995;16(7):437–44 (78 ref.)

HISTORY

[History and prehistory of skin flaps] Glicenstein J. **Ann Chir Plast Esthet** 1995 Oct;40(5):441–6 (45 ref.) **(Fre)**

METHODS

Subcutaneous island pedicle flaps in difficult wound closures. Jacobson RG, et al. **Am Fam Physician** 1996 Sep 1; 54(3):939–41 (5 ref.)
Microsurgical reconstruction of sensory skin. Brunelli GA, et al. **Ann Acad Med Singapore** 1995 Jul;24(4 Suppl):108–12 (14 ref.)
Flap reconstruction in the upper limb. Ikuta Y, et al. **Ann Acad Med Singapore** 1995 Jul;24(4 Suppl):124–30 (10 ref.)
The role of microsurgery and free tissue transfer in the reconstruction of the paediatric upper extremity. Kay S, et al. **Ann Acad Med Singapore** 1995 Jul;24(4 Suppl):113–23 (50 ref.)
Late aneurysm after subclavian flap aortoplasty for coarctation of the aorta. Kino K, et al. **Ann Thorac Surg** 1996 Apr;61(4):1262–4 (8 ref.)
The current hype in hypospadiology. Duckett JW. **Br J Urol** 1995 Dec;76 Suppl 3:1–7 (34 ref.)
"Microleaps" in the progression of flaps and grafts. Hallock GG. **Clin Plast Surg** 1996 Jan;23(1):117–38 (87 ref.)
Update on management of chronic osteomyelitis: report of four cases. Fasika OM, et al. **East Afr Med J** 1995 Sep; 72(9):611–2 (9 ref.)
Recurrent melanoma of the hard palate treated by en bloc excision and reconstruction with an autologous palatal bone graft subjected to cryotherapy and a buccal mucosal flap. Rosales J, et al. **J Oral Maxillofac Surg** 1995 Oct; 53(10):1218–20 (16 ref.)
Wound management in spinal infection. Rubayi S. **Orthop Clin North Am** 1996 Jan;27(1):137–53 (47 ref.)
Prefabricated flaps: experimental and clinical review. Abbase EA, et al. **Plast Reconstr Surg** 1995 Oct;96(5):1218–25 (69 ref.)
[Antebrachial free flap with radial pedicle. II. Surgical technique] Iriarte Ortabe JI, et al. **Acta Stomatol Belg** 1995 Sep;92(3):105–23 (195 ref.) (Eng. Abstr.) **(Fre)**
[Surgical therapy of soft tissue sarcomas II. Sarcomas of the extremities and their surgical resection] Karakousis CP. **Chirurg** 1995 Oct;66(10):1006–15 (9 ref.) (Eng. Abstr.) **(Ger)**
[The musculus pectoralis major rib flap. Personal experiences with 7 cases] Koch A, et al. **Chirurg** 1996 Mar;67(3):273–7 (26 ref.) (Eng. Abstr.) **(Ger)**
[Therapy of osteomyelitis in the metacarpal region with local pedicle m. interosseus dorsalis II and III–flap–plasty. Anatomic principles and case report] Giunta R, et al. **Handchir Mikrochir Plast Chir** 1996 Mar;28(2):64–9 (28 ref.) (Eng. Abstr.) **(Ger)**
[Biomechanical changes in the hip, femur and knee joint after removal of a tensor fasciae latae flap] Lattermann C, et al. **Handchir Mikrochir Plast Chir** 1996 Mar;28(2):76–82 (33 ref.) (Eng. Abstr.) **(Ger)**
[Fascial and fasciocutaneous flaps for treatment of posterior and distal area of the lower leg and heel area] Kulesza T. **Chir Narzadow Ruchu Ortop Pol** 1996;61(1):67–72 (11 ref.) **(Pol)**

SURGICAL GLOVES see **GLOVES, SURGICAL**

SURGICAL INJURIES see **INTRAOPERATIVE COMPLICATIONS**

SURGICAL INSTRUMENTS

Sterilization and disinfection of instruments and materials in the surgery unit and laboratory areas. Best M, et al. **Semin Dermatol** 1995 Sep;14(3):243–6 (14 ref.)
Epidemiology of injuries by needles and other sharp instruments. Minimizing sharp injuries in gynecologic and obstetric operations. Lewis FR Jr, et al. **Surg Clin North Am** 1995 Dec;75(6):1105–21 (34 ref.)
[Questions about re-sterilization and reuse of sterile disposable devices] Petrás G, et al. **Orv Hetil** 1995 Oct 22;136(43):2339–42 (39 ref.) (Eng. Abstr.) **(Hun)**

STANDARDS

A surgeon's perspective of medical device regulation. Brantigan JW. **J Spinal Disord** 1995 Oct;8(5):396–412 (74 ref.)
[European regulations concerning medical devices] Savarino L, et al. **Minerva Med** 1995 Nov;86(11):481–93 (26 ref.) (Eng. Abstr.) **(Ita)**

SURGICAL MESH

Critical appraisal and current position of laparoscopic hernia repair. Macintyre IM, et al. **J R Coll Surg Edinb** 1995 Oct; 40(5):331–6 (59 ref.)
Polypropylene mesh closure after emergency laparotomy: morbidity and outcome. Brandt CP, et al. **Surgery** 1995 Oct;118(4):736–40; discussion 740–1 (17 ref.)

SURGICAL NURSING see **PERIOPERATIVE NURSING**

SURGICAL REPLANTATION see **REPLANTATION**

SURGICAL REVISION see **REOPERATION**

SURGICAL SCRUB see **HANDWASHING**

SURGICAL STAPLERS

Stapling instruments for intestinal anastomosis in colorectal surgery. Moran BJ. **Br J Surg** 1996 Jul;83(7):902–9 (76 ref.)

SURGICAL STAPLING

Progress in surgical techniques in renal graft plantation. Anastomosis with titanium staplers. Gao W. **Chin Med J (Engl)** 1996 Feb;109(2):130–1 (0 ref.)

METHODS

Single and double stapled anastomoses in rectal cancer surgery; a retrospective study on the safety of the technique and its indication. Chiarugi M, et al. **Acta Chir Belg** 1996 Feb;96(1):31–6 (30 ref.)
Colorectal stapled anastomoses. Experiences and results. Hansen O, et al. **Dis Colon Rectum** 1996 Jan;39(1):30–6 (39 ref.)

SURGICAL WOUND DEHISCENCE

ETIOLOGY

Sight-threatening complications after radial keratotomy [editorial; comment] McDonnell PJ. **Arch Ophthalmol** 1996 Feb;114(2):211–2 (5 ref.) Comment on: Arch Ophthalmol 1996 Feb;114(2):129–34.
Ruptured globes following radial and hexagonal keratotomy surgery [see comments] Vinger PF, et al. **Arch Ophthalmol** 1996 Feb;114(2):129–34 (51 ref.) Comment in: Arch Ophthalmol 1996 Feb;114(2):211–2.

PHYSIOPATHOLOGY

Cutaneous wound healing. An overview. Koopmann CF Jr. **Otolaryngol Clin North Am** 1995 Oct;28(5):835–45 (14 ref.)
[Pathophysiology of the abdominal wall] Klinge U, et al. **Chirurg** 1996 Mar;67(3):229–33 (12 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Use of tissue expanders for wound closure of spinal infections or dehiscence. Paonessa KJ, et al. **Orthop Clin North Am** 1996 Jan;27(1):155–70 (32 ref.)

SURGICAL WOUND INFECTION

Postoperative mediastinitis: classification and management. El Oakley RM, et al. **Ann Thorac Surg** 1996 Mar; 61(3):1030–6 (80 ref.)
The significance of nasal carriage of Staphylococcus aureus and the incidence of postoperative wound infection. Wenzel RP, et al. **J Hosp Infect** 1995 Sep;31(1):13–24 (52 ref.)

DIAGNOSIS

Candida infection of the arteriovenous fistula used for hemodialysis. Nguyen MH, et al. **Am J Kidney Dis** 1996 Apr;27(4):596–8 (8 ref.)
Aortic graft infection with mycoplasma (Ureaplasma urealyticum). Levi N, et al. **Eur J Vasc Endovasc Surg** 1995 Oct;10(3):374–5 (14 ref.)

DRUG THERAPY

Antibiotic-resistant enterococci and the changing face of surgical infections. de Vera ME, et al. **Arch Surg** 1996 Mar; 131(3):338–42 (59 ref.)
The role of cefotaxime in the treatment of surgical infections. Wittmann DH. **Diagn Microbiol Infect Dis** 1995 May–Jun;

22(1-2):173-82 (67 ref.)
The infected wound and its management. Bumpous JM, et al. **Otolaryngol Clin North Am** 1995 Oct;28(5):987-1001 (44 ref.)

EPIDEMIOLOGY

[Retrospective study of postoperative infectious morbidity following cesarean section] Di Lieto A, et al. **Minerva Ginecol** 1996 Mar;48(3):85-92 (45 ref.) (Eng. Abstr.) **(Ita)**

ETIOLOGY

Persistent postoperative wound infection with Pasteurella multocida: case report and literature review [letter] Cook PP. **Infection** 1995 Jul-Aug;23(4):252 (4 ref.)
Postoperative wound infections: risk factors and role of Staphylococcus aureus nasal carriage. Perl TM, et al. **J Chemother** 1995 Jul;7 Suppl 3:29-35 (51 ref.)
Perioperative risk factors for wound infections after lower back fusions. Capen DA, et al. **Orthop Clin North Am** 1996 Jan;27(1):83-6 (24 ref.)
[Streptococcus bovis in a surgical wound and a colonic neoplasm] Martínez Mas E, et al. **Gastroenterol Hepatol** 1995 Nov;18(9):474-6 (19 ref.) (Eng. Abstr.) **(Spa)**

MICROBIOLOGY

Antibiotic-resistant enterococci and the changing face of surgical infections. de Vera ME, et al. **Arch Surg** 1996 Mar; 131(3):338-42 (59 ref.)

PHYSIOPATHOLOGY

Clinically accessible cell signaling: second messengers in sepsis and trauma. Rehring TF, et al. **J Surg Res** 1996 Jan; 60(1):270-7 (37 ref.)
Cutaneous wound healing. An overview. Koopmann CF Jr. **Otolaryngol Clin North Am** 1995 Oct;28(5):835-45 (14 ref.)

PREVENTION & CONTROL

Prophylaxis in bowel surgery. Nichols RL, et al. **Curr Clin Top Infect Dis** 1995;15:76-96 (89 ref.)
Surgical infections: blocking the mediator cascade responsible for sepsis and septic shock. Fink MP. **Curr Opin Gen Surg** 1993;:19-25 (45 ref.)
Antibiotic prophylaxis and infection control measures in minimally invasive surgery. Wilson AP. **J Antimicrob Chemother** 1995 Jul;36(1):1-5 (36 ref.)
Risk factors for surgical infection. Leaper DJ. **J Hosp Infect** 1995 Jun;30 Suppl:127-39 (72 ref.)
Antimicrobial skin preparations for the maxillofacial region. Morgan JP 3rd, et al. **J Oral Maxillofac Surg** 1996 Jan; 54(1):89-94 (56 ref.)
Wound repair: from ritual practice to scientific discipline. Edlich RF, et al. **J Trauma** 1996 Feb;40(2):326-9 (39 ref.)
The use of antibiotics for wound prophylaxis in spinal surgery. Rimoldi RL, et al. **Orthop Clin North Am** 1996 Jan;27(1):47-52 (33 ref.)
Choice of wound dressings and ointments. Brown CD, et al. **Otolaryngol Clin North Am** 1995 Oct;28(5):1081-91 (52 ref.)
[Prophylactic and therapeutic use of antibiotics in trauma surgery (see comments] Hansis M, et al. **Unfallchirurg** 1996 May;99(5):316-22 (35 ref.) (Eng. Abstr.) Comment in: Unfallchirurg 1996 May;99(5):315. **(Ger)**
[Use of mini-septopal in trauma surgery of the hand. Experimental and clinical studies] Zimmer K. **Polim Med** 1996;26(1-2):3-57 (136 ref.) (Eng. Abstr.) **(Pol)**
[Prevention of wound infection in surgical treatment of alimentary-constitutional obesity] Okoemov MN, et al. **Khirurgiia (Mosk)** 1995;(6):47-50 (77 ref.) **(Rus)**

SURGERY

Growth factors and comprehensive surgical care of diabetic wounds. Knighton DR, et al. **Curr Opin Gen Surg** 1993; :32-9 (42 ref.)
Use of tissue expanders for wound closure of spinal infections or dehiscence. Paonessa KJ, et al. **Orthop Clin North Am** 1996 Jan;27(1):155-70 (32 ref.)
[Diagnosis and therapy of local infections after surgical management of proximal femoral fractures] Dávid A, et al. **Zentralbl Chir** 1995;120(11):887-92 (29 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Pyogenic vertebral osteomyelitis and postsurgical disc space infections. Ozuna RM, et al. **Orthop Clin North Am** 1996 Jan;27(1):87-94 (59 ref.)
Wound infections in reconstructive spine surgery. Theiss SM, et al. **Orthop Clin North Am** 1996 Jan;27(1):105-10 (23 ref.)

SURGICENTERS

STANDARDS

How to increase efficiency in the operating room. Kanich DG, et al. **Surg Clin North Am** 1996 Feb;76(1):161-73 (23 ref.)

SURROGATE MARKERS see **BIOLOGICAL MARKERS**

SURVEILLANCE, IMMUNOLOGIC see **IMMUNOLOGIC SURVEILLANCE**

SURVEY METHODS see **DATA COLLECTION**

SURVEYS see **DATA COLLECTION**

SURVIVAL

PHYSIOLOGY

Psychological first-aid: a practical aide-memoire. Leach J. **Aviat Space Environ Med** 1995 Jul;66(7):668-74 (22 ref.)
[Stress in the evolution of societies: a means for survival] Sudakov KV. **Zh Evol Biokhim Fiziol** 1995 Jul-Aug; 31(4):489-99 (51 ref.) **(Rus)**

PSYCHOLOGY

Psychological first-aid: a practical aide-memoire. Leach J. **Aviat Space Environ Med** 1995 Jul;66(7):668-74 (22 ref.)

SURVIVAL ANALYSIS

Adjusting survival curves for confounders: a review and a new method. Nieto FJ, et al. **Am J Epidemiol** 1996 May 15;143(10):1059-68 (25 ref.)

SURVIVAL RATE

TRENDS

The changing face of paediatric oncology. Foot AB. **Palliat Med** 1995 Jul;9(3):193-9 (19 ref.)

SURVIVORS

Late effects of treatment in long-term survivors of cancer. Schwartz CL. **Cancer Treat Rev** 1995 Jul;21(4):355-66 (45 ref.)
Late effects of cancer treatment in children. Ried H, et al. **Pediatr Dent** 1995 Jul-Aug;17(4):273-84 (117 ref.)
Long-term survivors of HIV-1 infection. Klein MR, et al. **Trends Microbiol** 1995 Oct;3(10):386-91 (53 ref.)

PSYCHOLOGY

Impact of aborted sudden cardiac death on survivors and their spouses: the phenomenon of different reference points. Doolittle ND, et al. **Am J Crit Care** 1995 Sep;4(5):389-96 (24 ref.)
Life-threatening situations: supporting the child survivor and the family. Davenport LB, et al. **J Pediatr Nurs** 1995 Aug; 10(4):219-23 (7 ref.)

SURVIVORSHIP see **SURVIVAL RATE**

SUSPENDING AGENTS see **EXCIPIENTS**

SUSTAINED-RELEASE PREPARATIONS see **DELAYED-ACTION PREPARATIONS**

SUTURE TECHNIQUES

A "bicycle-handlebar" type of incision for primary and secondary abdominoplasty. Baroudi R, et al. **Aesthetic Plast Surg** 1995 Jul-Aug;19(4):307-20 (27 ref.)
Methods and materials for wound closure. Reiter D. **Otolaryngol Clin North Am** 1995 Oct;28(5):1069-80 (64 ref.)
[Are there still indications for cerclage in 1995?] Dufour P, et al. **Rev Fr Gynecol Obstet** 1995 Oct;90(10):423-30 (26 ref.) (Eng. Abstr.) **(Fre)**

INSTRUMENTATION

Arthroscopic rotator cuff repairs using suture anchors. Farrall LA. **AORN J** 1995 Nov;62(5):739-46, 748, 750; quiz 754, 756-8 (18 ref.)

SUTURES

Methods and materials for wound closure. Reiter D. **Otolaryngol Clin North Am** 1995 Oct;28(5):1069-80 (64 ref.)
[The prevention of adhesion formation in surgical gynecology (the role of suture materials and barriers)] Mynbaev OA, et al. **Akush Ginekol (Mosk)** 1995;(5):37-40 (38 ref.) **(Rus)**
[Use of suture materials in gynecologic surgery] Durdević S, et al. **Med Pregl** 1995;48(3-4):91-4 (12 ref.) (Eng. Abstr.) **(Scr)**
[Biomaterials and hernia surgery. Rationale for using them] Amid PK, et al. **Rev Esp Enferm Dig** 1995 Aug;87(8):582-6 (30 ref.) (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

[Choledochal calculosis due to a suture thread] Lo Casto RM, et al. **Minerva Chir** 1996 Jan-Feb;51(1-2):63-5 (11 ref.) (Eng. Abstr.) **(Ita)**

SUXAMETHONIUM see **SUCCINYLCHOLINE**

SV40 T ANTIGENS see **ANTIGENS, POLYOMAVIRUS TRANSFORMING**

SV40 T PROTEINS see **ANTIGENS, POLYOMAVIRUS TRANSFORMING**

SV40 VIRUS see **POLYOMAVIRUS MACACAE**

SWALLOWING see **DEGLUTITION**

SWAN-GANZ CATHETERIZATION see **CATHETERIZATION, SWAN-GANZ**

SWEAT GLAND NEOPLASMS

CLASSIFICATION

A call for logic in the classification of adnexal neoplasms [editorial; comment] McCalmont TH. **Am J Dermatopathol** 1996 Apr;18(2):103-9 (50 ref.) Comment on: Am J Dermatopathol 1996 Apr;18(2):124-36.

PATHOLOGY

Porocarcinoma of the heel. A case report with unusual histologic features. D'Amato MS, et al. **Cancer** 1996 Aug 15;78(4):751-7 (27 ref.)

SURGERY

Metastatic clear cell eccrine hidradenocarcinoma of the vulva: survival after primary surgical resection. Massad LS, et al. **Gynecol Oncol** 1996 May;61(2):287-90 (17 ref.)

SWEATING

see related
CYSTIC FIBROSIS
HYPERHIDROSIS

SWEATING, GUSTATORY

ETIOLOGY

Frey's syndrome following fracture of the mandibular condyle: case report and literature review. Mellor TK, et al. **Injury** 1996 Jun;27(5):359-60 (19 ref.)

SWEETENING AGENTS

CHEMISTRY

Plant-derived triterpenoid sweetness inhibitors. Suttisri R, et al. **J Ethnopharmacol** 1995 Jun 23;47(1):9-26 (109 ref.)

METABOLISM

Methods available to estimate the energy values of sugar alcohols. Ellwood KC. **Am J Clin Nutr** 1995 Nov;62(5 Suppl):1169S-1174S (38 ref.)
Sugar substitutes: their energy values, bulk characteristics, and potential health benefits. Levin GV, et al. **Am J Clin Nutr** 1995 Nov;62(5 Suppl):1161S-1168S (38 ref.)
Issues and advances in the use of transgenic organisms for the production of thaumatin, the intensely sweet protein from Thaumatococcus danielli. Zemanek EC, et al. **Crit Rev Food Sci Nutr** 1995 Sep;35(5):455-66 (44 ref.)

PHARMACOLOGY

Effect of sucrose and sweeteners on appetite and energy intake. Blundell JE, et al. **Int J Obes Relat Metab Disord** 1996 Mar;20 Suppl 2:S12-7 (46 ref.)

SWEET'S SYNDROME

CHEMICALLY INDUCED

Sweet's syndrome in a patient with acute promyelocytic leukemia during treatment with all-trans retinoic acid. Shirono K, et al. **Int J Hematol** 1995 Oct;62(3):183-7 (16 ref.)
Trimethoprim-sulfamethoxazole-associated acute febrile neutrophilic dermatosis: case report and review of drug-induced Sweet's syndrome. Walker DC, et al. **J Am Acad Dermatol** 1996 May;34(5 Pt 2):918-23 (21 ref.)
Sweet's syndrome involoving the musculoskeletal system during treatment of promyelocytic leukemia with all-trans retinoic acid. Christ E, et al. **Leukemia** 1996 Apr; 10(4):731-4 (10 ref.)

COMPLICATIONS

Sweet's syndrome associated with Behçet's disease. Lee MS, et al. **Australas J Dermatol** 1996 May;37(2):99-101 (15 ref.)
[Extracutaneous manifestations of neutrophilic dermatosis] Rodot S, et al. **Ann Dermatol Venereol** 1996;123(2):129-34 (45 ref.) **(Fre)**

DIAGNOSIS

[The appearance of Sweet's syndrome during the transition from a myelodysplastic syndrome to erythroleukemia] Grüne S, et al. **Dtsch Med Wochenschr** 1996 Jul 26; 121(30):939-42 (18 ref.) (Eng. Abstr.) **(Ger)**

SWEET'S SYNDROME

ETIOLOGY

Sweet's syndrome associated with granulocyte colony-stimulating factor. Jain KK. **Cutis** 1996 Feb; 57(2):107–10 (26 ref.)

Sweet's syndrome after splenic irradiation for chronic myelogenous leukemia. Pertusi RM, et al. **J Am Osteopath Assoc** 1996 Jun;96(6):366–7 (8 ref.)

[Sweet syndrome associated with Crohn disease] Ly S, et al. **Rev Med Interne** 1995;16(12):931–3 (18 ref.) (Eng. Abstr.) **(Fre)**

[Sweet syndrome and Yersinia enterocolitica infection. 2 cases] Neau D, et al. **Rev Med Interne** 1995;16(12):919–22 (13 ref.) (Eng. Abstr.) **(Fre)**

SWIMMING

PHYSIOLOGY

Commentary on effects of anthropogenic and natural organic chemicals on development, swimming behavior, and reproduction of Daphnia, a key member of aquatic ecosystems. Dodson SI, et al. **Environ Health Perspect** 1995 May;103 Suppl 4:7–11 (60 ref.)

Dynamics of the vortex wakes of flying and swimming vertebrates. Rayner JM. **Symp Soc Exp Biol** 1995;49:131–55 (103 ref.)

[Factors limiting performance in the triathlon] Margaritis I. **Can J Appl Physiol** 1996 Feb;21(1):1–15 (69 ref.) (Eng. Abstr.) **(Fre)**

SWIMMING POOLS

Factors associated with respiratory problems in swimmers. Potts J. **Sports Med** 1996 Apr;21(4):256–61 (43 ref.)

SWINE

[Current status and challenges in the production of transgenic pigs] Nagashima H. **Tanpakushitsu Kakusan Koso** 1995 Oct; 40(14):2241–8 (16 ref.) **(Jpn)**

ABNORMALITIES

Intersexuality in pigs: clinical, physiological and practical considerations. Hunter RH, et al. **Acta Vet Scand** 1996; 37(1):1–12 (29 ref.)

ANATOMY & HISTOLOGY

[Comments on the suitability of swine skin as a biological model for human skin] Meyer W. **Hautarzt** 1996 Mar; 47(3):178–82 (65 ref.) (Eng. Abstr.) **(Ger)**

EMBRYOLOGY

Development and validation of swine embryonic stem cells: a review. Wheeler MB. **Reprod Fertil Dev** 1994;6(5):563–8 (59 ref.)

GENETICS

The generation of transgenic pigs as potential organ donors for humans. Cozzi E, et al. **Nat Med** 1995 Sep;1(9):964–6 (30 ref.)

GROWTH & DEVELOPMENT

Sarcoptic mange and production performance of swine: a review of the literature and studies of associations between mite infestation, growth rate and measures of mange severity in growing pigs. Davies PR. **Vet Parasitol** 1995 Dec;60(3–4):249–64 (51 ref.)

METABOLISM

Influence of dietary vitamin E on the oxidative stability and quality of pig meat. Buckley DJ, et al. **J Anim Sci** 1995 Oct;73(10):3122–30 (61 ref.)

PHYSIOLOGY

Development and regulation of porcine pancreatic function. Pierzynowski SG, et al. **Int J Pancreatol** 1995 Oct; 18(2):81–94 (101 ref.)

Follicular atresia in pigs: measurement and physiology. Guthrie HD, et al. **J Anim Sci** 1995 Sep;73(9):2834–44 (47 ref.)

Interferon, the oxytocin receptor and the maternal recognition of pregnancy in ruminants and non-ruminants: a comparative approach. Flint AP. **Reprod Fertil Dev** 1995; 7(3):313–8 (31 ref.)

Endocrine bases of lactational anoestrus in the sow. Quesnel H, et al. **Reprod Nutr Dev** 1995;35(4):395–414 (107 ref.)

[Growth hormone, a potential way to improve livestock productivity in Africa] Missohou A. **Dakar Med** 1994; 39(1):9–15 (58 ref.) (Eng. Abstr.) **(Fre)**

SWINE DISEASES

Sarcoptic mange and production performance of swine: a review of the literature and studies of associations between mite infestation, growth rate and measures of mange severity in growing pigs. Davies PR. **Vet Parasitol** 1995 Dec;60(3–4):249–64 (51 ref.)

[Significance of PRRS virus infections for respiratory tract infections in swine—a literature review] Beilage EG. **DTW Dtsch Tierarztl Wochenschr** 1995 Dec;102(12):457–69 (127 ref.) (Eng. Abstr.) **(Ger)**

DIAGNOSIS

Porcine reproductive and respiratory syndrome (PRRS): a review, with emphasis on pathological, virological and diagnostic aspects. Done SH, et al. **Br Vet J** 1996 Mar; 152(2):153–74 (142 ref.)

EPIDEMIOLOGY

Ruminant pestivirus infections in animals other than cattle and sheep. Løken T. **Vet Clin North Am Food Anim Pract** 1995 Nov; 11(3):597–614 (97 ref.)

METABOLISM

Porcine TNF: a review. Pauli U. **Vet Immunol Immunopathol** 1995 Aug;47(3–4):187–201 (63 ref.)

MICROBIOLOGY

Swine dysentery: more unknown than known. ter Huurne AA, et al. **Vet Microbiol** 1995 Oct;46(4):347–60 (96 ref.)

PHYSIOPATHOLOGY

Endotoxaemia: where do we go from here? [editorial; comment] Barton MH. **Br Vet J** 1995 Sep-Oct; 151(5):469–71 (4 ref.) Comment on: Br Vet J 1995 Sep-Oct;151(5):489–522.

Mediators and vascular effects in response to endotoxin [see comments] Olson NC, et al. **Br Vet J** 1995 Sep-Oct; 151(5):489–522 (152 ref.) Comment in: Br Vet J 1995 Sep-Oct;151(5):469–71.

PREVENTION & CONTROL

Group A rotavirus veterinary vaccines. Saif LJ, et al. **J Infect Dis** 1996 Sep;174 Suppl 1:S98–106 (81 ref.)

Disinfection of farrowing pens. Owen JM. **Rev Sci Tech** 1995 Jun;14(2):381–91 (18 ref.)

Swine dysentery: more unknown than known. ter Huurne AA, et al. **Vet Microbiol** 1995 Oct;46(4):347–60 (96 ref.)

Pseudorabies virus eradication by area-wide vaccination is feasible. Stegeman A. **Vet Q** 1995 Dec;17(4):150–6 (85 ref.)

TRANSMISSION

Interspecies transmission of influenza viruses. Webster RG, et al. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 2):S25–30 (27 ref.)

SWINE FEVER see **HOG CHOLERA**

SWINE HERPESVIRUS 1 see **HERPESVIRUS 1, SUID**

SWISS BLUE see **METHYLENE BLUE**

SWISS MICE see **MICE**

SWITCH GENES see **GENES, SWITCH**

SWITCHING COMPLEX see **GENES, SWITCH**

SYCOSIS see **FOLLICULITIS**

SYLVIAN VEIN see **CEREBRAL VEINS**

SYMBIOSIS

What makes nodulation signals host-plant specific? Schultze M, et al. **Trends Microbiol** 1995 Oct;3(10):370–2 (24 ref.)

PHYSIOLOGY

Genetics, physiology, and evolutionary relationships of the genus Buchnera: intracellular symbionts of aphids. Baumann P, et al. **Annu Rev Microbiol** 1995;49:55–94 (179 ref.)

Heme synthesis in the rhizobium-legume symbiosis: a palette for bacterial and eukaryotic pigments. O'Brian MR. **J Bacteriol** 1996 May;178(9):2471–8 (95 ref.)

SYMBIOTES see **RICKETTSIACEAE**

SYMBIOTIC RELATIONS (PSYCHOLOGY) see **OBJECT ATTACHMENT**

SYMBOLISM

Consciousness: perspectives from symbolic and connectionist AI. Bechtel W. **Neuropsychologia** 1995 Sep;33(9):1075–86 (37 ref.)

Constructing the symbolic complainant: police subculture and the nonenforcement of protection orders for battered women. Rigakos GS. **Violence Vict** 1995 Fall;10(3):227–47 (50 ref.)

SYMPATHECTOMY

[Transthoracic endoscopic sympathectomy—anesthetic aspects] Rozenberg B, et al. **Harefuah** 1996 Mar 15; 130(6):430–2 (21 ref.) **(Heb)**

METHODS

Thoracoscopic sympathectomy. Daniel TM. **Chest Surg Clin N Am** 1996 Feb;6(1):69–83 (10 ref.)

Surgery of the sympathetic nervous system. Lee BY, et al. **J Spinal Cord Med** 1996 Jan;19(1):20–6 (50 ref.)

[Upper thoracic sympathectomy by thoracoscopic approach. A method of choice for the treatment of palmar hyperhidrosis] Lévy I, et al. **Ann Chir** 1995;49(9):858–62 (35 ref.) (Eng. Abstr.) **(Fre)**

[Treatment of primary hyperhidrosis of the upper limbs by transthoracic endoscopic sympathectomy] Lesèche G, et al. **Presse Med** 1995 Nov 4;24(33):1569–73 (36 ref.) (Eng. Abstr.) **(Fre)**

SYMPATHECTOMY, CHEMICAL

The current use of botulinum toxin therapy in strabismus [editorial] Rosenbaum AL. **Arch Ophthalmol** 1996 Feb; 114(2):213–4 (6 ref.)

SYMPATHETIC-BLOCKING AGENTS see **SYMPATHOLYTICS**

SYMPATHETIC DENERVATION see **SYMPATHECTOMY**

SYMPATHETIC FIBERS see **ADRENERGIC FIBERS**

SYMPATHETIC GANGLIA see **GANGLIA, SYMPATHETIC**

SYMPATHETIC NERVE BLOCK see **AUTONOMIC NERVE BLOCK**

SYMPATHETIC NERVOUS SYSTEM

see related
CHROMAFFIN SYSTEM
SYMPATHECTOMY
SYMPATHOLYTICS
SYMPATHOMIMETICS

ANATOMY & HISTOLOGY

The sympathetic innervation of the eyes and face: a clinicoanatomic review. Watson C, et al. **Clin Anat** 1995; 8(4):262–72 (44 ref.)

METABOLISM

Clinical assessment of sympathetic responses to stress. Goldstein DS. **Ann N Y Acad Sci** 1995 Dec 29;771:570–93 (144 ref.)

PHYSIOLOGY

Pre-sympathetic neurones in the rostral ventrolateral medulla of the rat: electrophysiology, morphology and relationship to adjacent neuronal groups. Lipski J, et al. **Acta Neurobiol Exp (Warsz)** 1996;56(1):373–84 (44 ref.)

Sympathetic nervous system response to intake. Welle S. **Am J Clin Nutr** 1995 Nov;62(5 Suppl):1118S–1122S (46 ref.)

Sympathoadrenal system in stress. Interaction with the hypothalamic-pituitary-adrenocortical system. Kvetňanský R, et al. **Ann N Y Acad Sci** 1995 Dec 29; 771:131–58 (158 ref.)

Sympathetic nervous system—immune system interactions in young and old Fischer 344 rats. Madden KS, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:523–34 (36 ref.)

Sympathetic reflex regulation of the peripheral circulation in humans. Jacobsen TN. **Dan Med Bull** 1996 Apr; 43(2):126–40 (148 ref.)

How sympathetic tone maintains or alters arterial pressure. Julien C, et al. **Fundam Clin Pharmacol** 1995;9(4):343–9 (39 ref.)

Role for endogenous dopamine in modulating sympathetic-adrenal activity in humans. Mannelli M, et al. **Hypertens Res** 1995 Jun;18 Suppl 1:S79–86 (92 ref.)

Myocardial imaging of sympathetic nervous function by radiolabelled metaiodobenzylguanidine [editorial; comment] Nakagawa M. **Intern Med** 1996 Feb;35(2):85–6 (7 ref.) Comment on: Intern Med 1996 Feb;35(2):94–9.

Neural and endothelial control of the peripheral circulation—implications for anesthesia: Part I. Neural control of the peripheral vasculature. Ebert TJ, et al. **J Cardiothorac Vasc Anesth** 1996 Jan;10(1):147–58 (124 ref.)

Biochemical assessment of sympathetic activity and prejunctional modulation of noradrenaline release in humans [editorial] Hjemdahl P, et al. **J Hypertens** 1996 Feb;14(2):147–50 (28 ref.)

Noradrenaline and ATP: cotransmitters and neuromodulators. Burnstock G. **J Physiol Pharmacol** 1995 Dec;46(4):365–84 (195 ref.)

Bulbospinal catecholamine neurones and sympathetic pattern generation. Coote JH, et al. **J Physiol Pharmacol** 1995 Sep; 46(3):259–71 (50 ref.)

Sleep apnoea and sympathetic nervous system activity: a review. Coy TV, et al. **J Sleep Res** 1996 Mar;5(1):42–50 (80 ref.)

The hypothalamo-sympathetic nervous system modulates peripheral cellular immunity. Hori T, et al. **Neurobiology (Bp)** 1995;3(3–4):309–17 (30 ref.)

Geometry, kinetics and plasticity of release and clearance of ATP and noradrenaline as sympathetic cotransmitters: roles for the neurogenic contraction. Stjärne L, et al. **Prog Neurobiol** 1995 Sep;47(1):45–94 (145 ref.)
Central neural organization and control of sympathetic nervous system in mammals. Sun MK. **Prog Neurobiol** 1995 Oct;47(3):157–233 (1200 ref.)
[The participation of enteral mechanisms in the sympathetic-adrenal inhibition of gastric secretion] Trefilov AB. **Usp Fiziol Nauk** 1995 Jan–Mar;26(1):76–92 (79 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

A role for CRH and the sympathetic nervous system in stress-induced immunosuppression. Friedman EM, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:396–418 (125 ref.)
Sympathetic nervous system as a coronary risk factor in hypertension. Julius S, et al. **Cardiologia** 1996 Apr; 41(4):309–17 (85 ref.)
The evidence for a pathophysiologic significance of the sympathetic overactivity in hypertension. Julius S. **Clin Exp Hypertens** 1996 Apr–May;18(3–4):305–21 (65 ref.)
Oculocephalic sympathetic dysfunction in posttraumatic headaches. Khurana RK. **Headache** 1995 Nov–Dec; 35(10):614–20 (32 ref.)
Sympathetic nervous system: contribution to human hypertension and related cardiovascular diseases. Esler M. **J Cardiovasc Pharmacol** 1995;26 Suppl 2:S24–8 (32 ref.)
Role of catecholamines and sympathetic activation as a risk factor for coronary artery disease. Amadi A, et al. **J Cardiovasc Risk** 1995 Jun;2(3):222–8 (66 ref.)
Rationale for treatment of patients with chronic heart failure with adrenergic blockade. Sackner-Bernstein JD, et al. **JAMA** 1995 Nov 8;274(18):1462–7 (71 ref.)
Hypertension and associated metabolic abnormalities—the role of insulin resistance and the sympathoadrenal system. Reaven GM, et al. **N Engl J Med** 1996 Feb 8;334(6):374–81 (85 ref.)
[The sympathetic-adrenergic system in heart failure] Ungerer M, et al. **Dtsch Med Wochenschr** 1996 Feb 2;121(5):141–5 (60 ref.) **(Ger)**
[Sympathetic nervous system and endothelial function in heart failure] Binggeli C, et al. **Schweiz Rundsch Med Prax** 1996 Feb 20;85(8):234–44 (104 ref.) (Eng. Abstr.) **(Ger)**
[The role of the sympathetic nervous system in essential arterial hypertension and organ damage] Grassi G, et al. **Ann Ital Med Int** 1995 Oct;10 Suppl:115S–120S (46 ref.) (Eng. Abstr.) **(Ita)**
[Neurohormonal factors in heart failure. II] Cosín Aguilar J, et al. **Rev Esp Cardiol** 1996 May;49(5):317–27 (47 ref.) (Eng. Abstr.) **(Spa)**

SYMPATHETIC TRANSMITTER RELEASERS see **ADRENERGIC AGENTS**

SYMPATHINS see **CATECHOLAMINES**

SYMPATHOLYTICS

see related
ADRENERGIC AGENTS

DIAGNOSTIC USE

Myocardial imaging of sympathetic nervous function by radiolabelled metaiodobenzylguanidine [editorial; comment] Nakagawa M. **Intern Med** 1996 Feb;35(2):85–6 (7 ref.) Comment on: Intern Med 1996 Feb;35(2):94–9.
Cardiac studies with metaiodobenzylguanidine: a critique of methods and interpretation of results. Glowniak JV. **J Nucl Med** 1995 Nov;36(11):2133–7 (41 ref.)

SYMPATHOMIMETICS

see related
CARDIOTONIC AGENTS
CARDIOVASCULAR AGENTS
MONOAMINE OXIDASE INHIBITORS
RECEPTORS, ADRENERGIC

ADMINISTRATION & DOSAGE

[Self-administration of adrenaline aerosol in anaphylactic reactions after insect stings] Ackermann RW, et al. **Ugeskr Laeger** 1996 Aug 5;158(32):4497–9 (27 ref.) (Eng. Abstr.) **(Dan)**

DIAGNOSTIC USE

[Urinary incontinence in castrated female dogs. 2. Therapy] Blendinger C, et al. **Tierarztl Prax** 1995 Aug;23(4):402–6 (30 ref.) (Eng. Abstr.) **(Ger)**
[Echocardiography with pharmacological stress: dobutamine or dipyridamole?] Salustri A, et al. **G Ital Cardiol** 1996 Apr;26(4):447–53 (45 ref.) **(Ita)**

THERAPEUTIC USE

A rationale for the selection of nasal decongestants in lacrimal drainage surgery. Hosal BM, et al. **Ophthal Plast Reconstr Surg** 1995 Sep;11(3):215–20 (29 ref.)
Pharmacologic treatment of recurrent pediatric headache. Graf WD, et al. **Pediatr Ann** 1995 Sep;24(9):477–84 (27 ref.)

SYMPHYSIOTOMY

[What about partial subcutaneous symphysiotomy or Zarate's operation? Review of the literature] Manouana M, et al. **Rev Fr Gynecol Obstet** 1995 Jul–Sep;90(7–9):373–8 (26 ref.) (Eng. Abstr.) **(Fre)**

SYMPORT see **ION TRANSPORT**

SYNAPSES

see related
GAP JUNCTIONS
SYNAPTIC TRANSMISSION
SYNAPTOSOMES

DRUG EFFECTS

Regulation of postsynaptic responses by calcitonin gene related peptide and ATP at developing neuromuscular junctions. Lu B, et al. **Can J Physiol Pharmacol** 1995 Jul; 73(7):1050–6 (42 ref.)

METABOLISM

Synaptic targeting of glutamate receptors. Ehlers MD, et al. **Curr Opin Cell Biol** 1996 Aug;8(4):484–9 (54 ref.)
Tyrosine phosphorylation and synapse formation at the neuromuscular junction. Mei L, et al. **Life Sci** 1995; 57(16):1459–66 (114 ref.)

PHYSIOLOGY

Extracellular ATP as a neurotransmitter: its role in synaptic plasticity in the hippocampus. Wieraszko A. **Acta Neurobiol Exp (Warsz)** 1996;56(2):637–48 (85 ref.)
Synaptic structure and function: dynamic organization yields architectural precision. Burns ME, et al. **Cell** 1995 Oct 20; 83(2):187–94 (60 ref.)
Neuronal target recognition. Garrity PA, et al. **Cell** 1995 Oct 20;83(2):177–85 (70 ref.)
Tight junctions, membrane-associated guanylate kinases and cell signaling. Kim SK. **Curr Opin Cell Biol** 1995 Oct; 7(5):641–9 (71 ref.)
Synaptic plasticity: hippocampal LTP. Larkman AU, et al. **Curr Opin Neurobiol** 1995 Jun;5(3):324–34 (120 ref.)
Modulation of inhibitory synapses in the mammalian brain. Marty A, et al. **Curr Opin Neurobiol** 1995 Jun;5(3):335–41 (38 ref.)
Synaptic feed-backs mediated by potassium ions. Matyushkin DP, et al. **Gen Physiol Biophys** 1995 Oct;14(5):369–81 (45 ref.)
Long-term hippocampal slices: a model system for investigating synaptic mechanisms and pathologic processes. Bahr BA. **J Neurosci Res** 1995 Oct 15; 42(3):294–305 (96 ref.)
Long-term regulation of short-term plasticity: a postsynaptic influence on presynaptic transmitter release. Davis GW. **J Physiol Paris** 1995;89(1):33–41 (39 ref.)
Signalling synapse formation between identified neurons. Drapeau P, et al. **J Physiol Paris** 1995;89(3):115–23 (52 ref.)
Mechanisms of synaptogenesis in hippocampal neurons in primary culture. Matteoli M, et al. **J Physiol Paris** 1995; 89(1):51–5 (34 ref.)
Overexpression of choline acetyltransferase reconstitutes discrete acetylcholine release in some but not all synapse formation-defective neuroblastoma cells. Zhong ZG, et al. **J Physiol Paris** 1995;89(3):137–45 (40 ref.)
Ionotropic glutamate receptors. Their possible role in the expression of hippocampal synaptic plasticity. Asztély F, et al. **Mol Neurobiol** 1996 Feb;12(1):1–11 (122 ref.)
Neurotrophic factors and synaptic plasticity. Lo DC. **Neuron** 1995 Nov;15(5):979–81 (31 ref.)
Nicotinic receptors in the development and modulation of CNS synapses. Role LW, et al. **Neuron** 1996 Jun; 16(6):1077–85 (132 ref.)
Structural organization of the synaptic connections of the spinal cord motor neurons of mammals. Motorina MV. **Neurosci Behav Physiol** 1995 Jul–Aug;25(4):273–89 (134 ref.)
Agrin: toward a molecular understanding of synapse regeneration. Deyst KA, et al. **Neurosurgery** 1995 Jul; 37(1):71–7 (81 ref.)
Anatomy and electrophysiology of fast central synapses lead to a structural model for long-term potentiation. Edwards FA. **Physiol Rev** 1995 Oct;75(4):759–87 (200 ref.)
Emergence of order in visual system development. Shatz CJ. **Proc Natl Acad Sci U S A** 1996 Jan 23;93(2):602–8 (61 ref.)
Induction of non-catalytic TrkB neurotrophin receptors during lesion-induced synaptic rearrangement in the adult rat hippocampus. Beck KD, et al. **Prog Brain Res** 1995; 105:197–210 (80 ref.)
Plasticity of developing neuromuscular synapses. Dan Y, et al. **Prog Brain Res** 1995;105:211–5 (13 ref.)
Synaptic mechanisms of olfactory recognition memory. Kaba H, et al. **Rev Neurosci** 1995 Apr–Jun;6(2):125–41 (128 ref.)
Retrograde signaling at GABAA-receptor synapses in the mammalian CNS. Alger BE, et al. **Trends Neurosci** 1995 Aug;18(8):333–40 (42 ref.)
How multiple-synapse boutons could preserve input specificity during an interneuronal spread of LTP. Harris KM. **Trends Neurosci** 1995 Aug;18(8):365–9 (44 ref.)
[Synaptic reorganization in early childhood experience and learning processes: relevance for the development of psychological diseases] Braun K. **Z Klin Psychol Psychopathol Psychother** 1996;44(3):253–66 (60 ref.) (Eng. Abstr.) **(Ger)**
[The mechanisms of synaptic plasticity: the role of synaptic protein phosphorylation and gene expression] Godukhin OV, et al. **Usp Fiziol Nauk** 1995 Jul–Sep;26(3):41–56 (98 ref.) (Eng. Abstr.) **(Rus)**
[The evolution of the synapses in the vertebrate central nervous system (a topical paper)] Motorina MV. **Zh Evol Biokhim Fiziol** 1995 Jan–Feb;31(1):3–13 (68 ref.) (Eng. Abstr.) **(Rus)**

ULTRASTRUCTURE

Synaptic structure and function: dynamic organization yields architectural precision. Burns ME, et al. **Cell** 1995 Oct 20; 83(2):187–94 (60 ref.)
Methods for determining numbers of cells and synapses: a case for more uniform standards of review. Coggeshall RE, et al. **J Comp Neurol** 1996 Jan 1;364(1):6–15 (30 ref.)
Anatomy and electrophysiology of fast central synapses lead to a structural model for long-term potentiation. Edwards FA. **Physiol Rev** 1995 Oct;75(4):759–87 (200 ref.)
An analysis of contemporary morphological concepts of synaptic remodelling in the CNS: perforated synapses revisited. Jones DG, et al. **Rev Neurosci** 1995 Jul–Sep; 6(3):177–219 (174 ref.)

SYNAPTIC BOUTONS see **PRESYNAPTIC TERMINALS**

SYNAPTIC MEMBRANES

see related
SYNAPTOSOMES

METABOLISM

Bacterial neurotoxins—a thousand years later. Linial M. **Isr J Med Sci** 1995 Oct;31(10):591–5 (15 ref.)

PHYSIOLOGY

The membrane fusion machine and neurotransmitter release. Fesce R, et al. **Neurochem Int** 1996 Jan;28(1):15–21 (44 ref.)

SYNAPTIC POTENTIALS see **SYNAPTIC TRANSMISSION**

SYNAPTIC RECEPTORS see **RECEPTORS, NEUROTRANSMITTER**

SYNAPTIC TERMINALS see **PRESYNAPTIC TERMINALS**

SYNAPTIC TRANSMISSION

see related
GAP JUNCTIONS
NEUROTRANSMITTERS
SYNAPSES

Plasticity of calcitonin gene related peptide neurotransmission in the spinal cord during peripheral inflammation. Seybold VS, et al. **Can J Physiol Pharmacol** 1995 Jul;73(7):1007–14 (51 ref.)
Peptidergic transmission: from morphological correlates to functional implications. Zupanc GK. **Micron** 1996 Feb; 27(1):35–91 (630 ref.)
Involvement of nitric oxide in neuromuscular transmission in canine proximal colon. Shuttleworth CW, et al. **Proc Soc Exp Biol Med** 1996 Jan;211(1):16–23 (50 ref.)
In vivo assessment of neurotransmitter system in cardiovascular diseases. Clinical issues. Merlet P, et al. **Q J Nucl Med** 1996 Mar;40(1):108–20 (108 ref.)
Cracking the neuronal code. Ferster D, et al. **Science** 1995 Nov 3;270(5237):756–7 (20 ref.)
[Pathophysiology on the disorder of neuromuscular transmission defects] Sahashi K, et al. **Rinsho Byori** 1995 Sep;43(9):902–9 (15 ref.) (Eng. Abstr.) **(Jpn)**

DRUG EFFECTS

Vigabatrin: effect on brain GABA levels measured by nuclear magnetic resonance spectroscopy. Mattson RH, et al. **Acta Neurol Scand Suppl** 1995;162:27–30 (16 ref.)
Bacterial neurotoxins—a thousand years later. Linial M. **Isr J Med Sci** 1995 Oct;31(10):591–5 (15 ref.)
Adrenoceptors and serotonin receptor function: relevance to antidepressant mechanisms of action. Potter WZ. **J Clin Psychiatry** 1996;57 Suppl 4:4–8 (45 ref.)
Role of nitric oxide in central synaptic transmission: effects on neurotransmitter release. Kuriyama K, et al. **Jpn J Pharmacol** 1995 Sep;69(1):1–8 (50 ref.)
Modulation of NMDA and dopaminergic neurotransmissions by sigma ligands: possible implications for the treatment of psychiatric disorders. Debonnel G, et al. **Life Sci** 1996; 58(9):721–34 (179 ref.)
Pharmacology of cotransmission in the autonomic nervous system: integrative aspects on amines, neuropeptides, adenosine triphosphate, amino acids and nitric oxide.

Lundberg JM. **Pharmacol Rev** 1996 Mar;48(1):113–78 (975 ref.)

100 years of ibogaine: neurochemical and pharmacological actions of a putative anti-addictive drug. Popik P, et al. **Pharmacol Rev** 1995 Jun;47(2):235–53 (224 ref.)

Molecular mechanisms of neuromuscular blocking agents: is the increased understanding of importance to the practising anaesthetist? Aglan MY, et al. **Pharmacol Ther** 1995; 68(3):365–83 (76 ref.)

Cholinergic and vasoactive intestinal polypeptidergic innervation of the cerebral arteries. Dauphin F, et al. **Pharmacol Ther** 1995;67(3):385–417 (274 ref.)

A review of NMDA receptors and the phencyclidine model of schizophrenia. Thornberg SA, et al. **Pharmacotherapy** 1996 Jan–Feb;16(1):82–93 (122 ref.)

Serotonin uptake inhibitors: uses in clinical therapy and in laboratory research. Fuller RW. **Prog Drug Res** 1995; 45:167–204 (280 ref.)

[Delay in the effect of antidepressive agents: pharmacologic approach] Allain H, et al. **Encephale** 1995 Mar;21 Spec No 2:9–15 (39 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Monoamine modulation of the synaptic inhibition in the hippocampus. Bijak M. **Acta Neurobiol Exp (Warsz)** 1996; 56(1):385–95 (45 ref.)

Monosynaptic Ia pathways and motor behaviour of the cat distal forelimb. Filert M. **Acta Neurobiol Exp (Warsz)** 1996; 56(1):423–34 (29 ref.)

Synaptic vesicles and release of transmitters: new insights at the molecular level. Fried G. **Acta Physiol Scand** 1995 May;154(1):1–15 (80 ref.)

Aspects of the search for neural mechanisms of memory. Rosenzweig MR. **Annu Rev Psychol** 1996;47:1–32 (150 ref.)

Second messenger pathways in the modulation of neurotransmitter release. Majewski HK, et al. **Aust N Z J Med** 1995 Dec;25(6):817–21 (28 ref.)

Deciphering neuronal secretion: tools of the trade. Linial M, et al. **Biochim Biophys Acta** 1996 Jun 10;1286(2):117–52 (395 ref.)

Synaptic structure and function: dynamic organization yields architectural precision. Burns ME, et al. **Cell** 1995 Oct 20; 83(2):187–94 (60 ref.)

The postsynaptic density: a subcellular anchor for signal transduction enzymes. Klauck TM, et al. **Cell Signal** 1995 Nov;7(8):747–57 (114 ref.)

Synaptic transmission. Kinetics of synaptic–vesicle recycling. Betz WJ, et al. **Curr Biol** 1995 Oct 1;5(10):1098–101 (18 ref.)

A case for interstitial cells of Cajal as pacemakers and mediators of neurotransmission in the gastrointestinal tract. Sanders KM. **Gastroenterology** 1996 Aug;111(2):492–515 (154 ref.)

Frank A. Beach Award. Functional significance of steroid modulation of GABAergic neurotransmission: analysis at the behavioral, cellular, and molecular levels. McCarthy MM. **Horm Behav** 1995 Jun;29(2):131–40 (48 ref.)

The role of monoamine oxidase and catechol O-methyltransferase in dopaminergic neurotransmission. Napolitano A, et al. **J Neural Transm Suppl** 1995;45:35–45 (60 ref.)

Presynaptic facilitation revisited: state and time dependence. Byrne JH, et al. **J Neurosci** 1996 Jan 15;16(2):425–35 (132 ref.)

Genetic dissection of the molecular mechanisms of transmitter vesicle release during synaptic transmission. Broadie KS. **J Physiol Paris** 1995;89(2):59–70 (55 ref.)

Noradrenaline and ATP: cotransmitters and neuromodulators. Burnstock G. **J Physiol Pharmacol** 1995 Dec;46(4):365–84 (195 ref.)

Presynaptic GABAA receptors in vertebrate synapses. Xi ZX, et al. **Kurume Med J** 1996;43(2):115–22 (84 ref.)

Platelet-activating factor is a synapse messenger and a modulator of gene expression in the nervous system. Bazan NG, et al. **Neurochem Int** 1995 May;26(5):435–41 (72 ref.)

Activation by GABAb, reduction of the intracellular concentration of Ca++, and inhibition of protein kinases are possible mechanisms of the long-term posttetanic modification of the efficiency of inhibitory transmission in the new cortex. Sil'kis IG. **Neurosci Behav Physiol** 1996 Jan–Feb;26(1):88–97 (41 ref.)

Principles of rhythmic motor pattern generation. Marder E, et al. **Physiol Rev** 1996 Jul;76(3):687–717 (327 ref.)

The involvement of PKC and multifunctional CaM kinase II of the postsynaptic neuron in induction and maintenance of long-term potentiation. Feng TP. **Prog Brain Res** 1995; 105:55–63 (27 ref.)

Interaction of neuropeptides and excitatory amino acids in the rat superficial spinal dorsal horn. Randić M, et al. **Prog Brain Res** 1995;104:225–53 (306 ref.)

Neuronal calcium channels encoded by the alpha 1A subunit and their contribution to excitatory synaptic transmission in the CNS. Wheeler DB, et al. **Prog Brain Res** 1995; 105:65–78 (51 ref.)

The origin of Gaussian distributions of synaptic potentials. Bennett MR. **Prog Neurobiol** 1995 Jul;46(4):331–50 (81 ref.)

Chemical synaptic transmission in the cochlea. Puel JL. **Prog Neurobiol** 1995 Dec;47(6):449–76 (251 ref.)

Functions of ionotropic and metabotropic glutamate receptors in sensory transmission in the mammalian thalamus. Salt TE, et al. **Prog Neurobiol** 1996 Jan; 48(1):55–72 (220 ref.)

Presynaptic inhibition in humans. Stein RB. **Prog Neurobiol** 1995 Dec;47(6):533–44 (52 ref.)

Long-term depression: a learning-related type of synaptic plasticity in the mammalian central nervous system. Zhuo M, et al. **Rev Neurosci** 1995 Jul–Sep;6(3):259–77 (142 ref.)

Post-traumatic epilepsy and recovery of function from experimental brain damage: a review. Droogan J. **Seizure** 1995 Sep;4(3):163–7 (31 ref.)

Wiring, dysmorphogenesis and epilepsy: a hypothesis. Sisodiya SM. **Seizure** 1995 Sep;4(3):169–85 (89 ref.)

Phosphoinositides and synaptic transmission. Hawthorne JN. **Subcell Biochem** 1996;26:43–57 (64 ref.)

Metaplasticity: the plasticity of synaptic plasticity. Abraham WC, et al. **Trends Neurosci** 1996 Apr;19(4):126–30 (53 ref.)

Calcium-independent synaptic transmission: artifact or fact? Piccolino M, et al. **Trends Neurosci** 1996 Apr;19(4):120–5 (37 ref.)

Neurophysiological techniques in the evaluation of disorders of the spine. Schnitzler A, et al. **Zentralbl Neurochir** 1995; 56(3):117–27 (41 ref.)

[Memory and synaptic plasticity] Maitre M. **Ann Biol Clin (Paris)** 1996;54(2):49–66 (164 ref.) (Eng. Abstr.) **(Fre)**

[The dopamine transporter: characterization and physiopathologic implications] Thibaut F, et al. **Encephale** 1995 Nov–Dec;21(6):445–51 (35 ref.) (Eng. Abstr.) **(Fre)**

[Function-controlled neurosurgery. Neurophysiologic and neuropsychological monitoring during surgery of the nervous system] Schmid UD, et al. **Nervenarzt** 1995 Aug; 66(8):582–95 (84 ref.) (Eng. Abstr.) **(Ger)**

[The simultaneous activation of excitatory and inhibitory inputs as a condition for the induction of homo-, hetero- and associative long-term excitation depression] Sil'kis IG. **Zh Vysh Nerv Deiat Im I P Pavlova** 1995 Nov–Dec; 45(6):1151–66 (58 ref.) (Eng. Abstr.) **(Rus)**

RADIATION EFFECTS

Effects of picotesla flux electromagnetic fields on dopaminergic transmission in Tourette's syndrome. Sandyk R. **Int J Neurosci** 1996 Feb;84(1–4):187–94 (95 ref.)

SYNAPTIC VESICLES

CHEMISTRY

Synaptic vesicle proteins and regulated exocytosis. Elferink LA, et al. **Prog Brain Res** 1995;105:79–85 (42 ref.)

METABOLISM

Synaptic vesicles and release of transmitters: new insights at the molecular level. Fried G. **Acta Physiol Scand** 1995 May;154(1):1–15 (80 ref.)

Synaptic transmission. Kinetics of synaptic–vesicle recycling. Betz WJ, et al. **Curr Biol** 1995 Oct 1;5(10):1098–101 (18 ref.)

Genetic dissection of the molecular mechanisms of transmitter vesicle release during synaptic transmission. Broadie KS. **J Physiol Paris** 1995;89(2):59–70 (55 ref.)

A unifying hypothesis for acetylcholine release. Israël M, et al. **Neurochem Int** 1996 Jan;28(1):1–9 (88 ref.)

PHYSIOLOGY

SNAREs and the specificity of transport vesicle targeting. Bennett MK. **Curr Opin Cell Biol** 1995 Aug;7(4):581–6 (52 ref.)

The membrane fusion machine and neurotransmitter release. Fesce R, et al. **Neurochem Int** 1996 Jan;28(1):15–21 (44 ref.)

Synaptic like microvesicles: do they participate in regulated exocytosis? Llona I. **Neurochem Int** 1995 Sep;27(3):219–26 (82 ref.)

Molecular mechanisms in synaptic vesicle endocytosis and recycling. De Camilli P, et al. **Neuron** 1996 Mar;16(3):481–6 (46 ref.)

Synaptic vesicle biogenesis, docking, and fusion: a molecular description. Calakos N, et al. **Physiol Rev** 1996 Jan; 76(1):1–29 (420 ref.)

The transport of neurotransmitters into synaptic vesicles. Peter D, et al. **Prog Brain Res** 1995;105:273–81 (30 ref.)

SECRETION

Deciphering neuronal secretion: tools of the trade. Linial M, et al. **Biochim Biophys Acta** 1996 Jun 10;1286(2):117–52 (395 ref.)

SYNAPTONEMAL COMPLEX

GENETICS

Is the synaptonemal complex a disjunction machine? Maguire MP. **J Hered** 1995 Sep–Oct;86(5):330–40 (91 ref.)

SYNAPTOSOMES

METABOLISM

Is lead toxicosis a reflection of altered energy metabolism in brain synaptosomes? Rafałowska U, et al. **Acta Neurobiol Exp (Warsz)** 1996;56(2):611–7 (30 ref.)

Function and metabolism of brain synaptosomes in chronic renal failure. Smogorzewski M, et al. **Artif Organs** 1995 Aug;19(8):795–800 (55 ref.)

Cytosolic and mitochondrial calcium in synaptosomes during aging. Satrústegui J, et al. **Life Sci** 1996;59(5–6):429–34 (33 ref.)

SYNCHROTRONS

Intravenous coronary angiography with dichromography using synchrotron radiation. Hamm CW, et al. **Herz** 1996 Apr;21(2):127–31 (13 ref.)

SYNCOPE

Syncope in the pediatric patient: diagnosis, pathophysiology, and treatment. Feit LR. **Adv Pediatr** 1996;43:469–94 (60 ref.)

[Neurocardiogenic syncope] Zhao Y, et al. **Chung Hua Nei Ko Tsa Chih** 1995 Apr;34(4):277–9 (20 ref.) **(Chi)**

[Neural syncope--a current therapeutic problem] Dvořák R, et al. **Vnitr Lek** 1995 Dec;41(12):846–50 (31 ref.) (Eng. Abstr.) **(Cze)**

DIAGNOSIS

Convulsive syncope in the aviation environment. Voge VM, et al. **Aviat Space Environ Med** 1995 Dec;66(12):1198–204 (45 ref.)

Evaluating unexplained syncope with upright tilt testing [see comments] Kapoor WN. **Cleve Clin J Med** 1995 Sep–Oct; 62(5):305–10 (33 ref.) Comment in: Cleve Clin J Med 1995 Sep–Oct;62(5):339–41.

Tilt table testing for assessing syncope. American College of Cardiology. Benditt DG, et al. **J Am Coll Cardiol** 1996 Jul;28(1):263–75 (97 ref.)

Recognizing syncope: pitfalls and surprises. Lempert T. **J R Soc Med** 1996 Jul;89(7):372–5 (38 ref.)

[Guidelines on the diagnostic assessment of patients with syncope] Alboni P, et al. **G Ital Cardiol** 1995 Jul; 25(7):937–48 (81 ref.) **(Ita)**

DRUG THERAPY

Neurally mediated syncope and serotonin reuptake inhibitors. Samoil D, et al. **Clin Auton Res** 1995 Oct;5(5):251–5 (45 ref.)

ETIOLOGY

Can serial tilt testing be used to evaluate therapy in neurally mediated syncope? Morillo CA, et al. **Am J Cardiol** 1996 Mar 1;77(7):521–3 (34 ref.)

Neurocardiogenic syncope. Sutton R, et al. **Br J Hosp Med** 1996 Apr 3–16;55(7):411–4 (37 ref.)

Syncope in the emergency department. A cardiologist's perspective. Gilman JK. **Emerg Med Clin North Am** 1995 Nov;13(4):955–71 (25 ref.)

Syncope: diagnosis of cardiac and noncardiac causes. Farrehi PM, et al. **Geriatrics** 1995 Nov;50(11):24–30 (19 ref.)

The clinical spectrum of neurocardiogenic syncope. Sutton R, et al. **J Cardiovasc Electrophysiol** 1995 Jul;6(7):569–76 (66 ref.)

Clinical neuromythology XV. Feinting science: Neurocardiogenic syncope and collateral vasovagal confusion. Landau WM, et al. **Neurology** 1996 Mar; 46(3):609–18 (77 ref.)

Identifying the causes of syncope and palpitations. Burn S, et al. **Practitioner** 1995 Nov;239(1556):666–9 (3 ref.)

[Neurocardiogenic (or vasovagal) syncope] Cafagna D, et al. **Minerva Med** 1996 May;87(5):207–15 (80 ref.) (Eng. Abstr.) **(Ita)**

[Neurocardiogenic syncope: its pathogenesis, diagnosis and treatment] Freitas J, et al. **Rev Port Cardiol** 1996 Feb; 15(2):103–9, 99 (37 ref.) (Eng. Abstr.) **(Por)**

PHYSIOPATHOLOGY

Can serial tilt testing be used to evaluate therapy in neurally mediated syncope? Morillo CA, et al. **Am J Cardiol** 1996 Mar 1;77(7):521–3 (34 ref.)

Power spectral analysis of heart rate variability during upright tilt test: a comparison of patients with syncope and normal subjects. Boulos M, et al. **Cardiology** 1996 Jan–Feb; 87(1):28–32 (20 ref.)

Current trends in etiology, diagnosis, and management of neurocardiogenic syncope. Grubb BP, et al. **Curr Opin Cardiol** 1996 Jan;11(1):32–41 (68 ref.)

Breath-holding spells. Breningstall GN. **Pediatr Neurol** 1996 Feb;14(2):91–7 (35 ref.)

[Low cerebral output, transient ischemic attack and syncope] Berger JP. **Rev Med Suisse Romande** 1996 Aug; 116(8):597–604 (23 ref.) **(Fre)**

[Physiopathology of vasovagal syncope: review of the most endorsed theories and recent findings] Giuliani M, et al. **G Ital Cardiol** 1995 Jul;25(7):911–21 (79 ref.) (Eng. Abstr.) **(Ita)**

PREVENTION & CONTROL

Is there an effective pharmacological treatment in the prevention of vasovagal syncope? Sutton R. **Arch Mal Coeur Vaiss** 1996 Feb;89 Spec No 1:25–28 (42 ref.)

THERAPY

Cardiac pacing during neurocardiogenic (vasovagal) syncope. Sra JS, et al. **J Cardiovasc Electrophysiol** 1995 Sep;6(9):751–60 (45 ref.)

SYNCYTIUM see **GIANT CELLS**

SYNDACTYLY

"New" ectodermal dysplasia with mental retardation and syndactyly. Ilyina HG, et al. **Am J Med Genet** 1995 Sep 25;58(4):345–7 (15 ref.)

COMPLICATIONS

Fraser syndrome (cryptophthalmos [hidden eye]–syndactyly syndrome). Sarman G, et al. **J Perinatol** 1995 Nov–Dec; 15(6):503–6 (12 ref.)

GENETICS

Polysyndactyly and asymptomatic hypothalamic hamartoma in mother and son: a variant of Pallister–Hall syndrome. Löw M, et al. **Clin Genet** 1995 Oct;48(4):209–12 (15 ref.)

Filippi syndrome: a new case with skeletal abnormalities. Héron D, et al. **J Med Genet** 1995 Aug;32(8):659–61 (6 ref.)

SURGERY

Tissue expanders in syndactyly: a brief review. d'Arcangelo M, et al. **Acta Chir Plast** 1996;38(1):11–3 (18 ref.)

SYNDROME

Computer systems in dysmorphology. Evans CD. **Clin Dysmorphol** 1995 Jul;4(3):185–201 (34 ref.)

SYNDROME X

[Ischemic cardiopathy in women: the role of estrogens in the coronary vascular wall and in syndrome X] Gaxiola E, et al. **Arch Inst Cardiol Mex** 1995 Sep–Oct;65(5):461–7 (61 ref.) **(Spa)**

DIAGNOSIS

[Syndrome X—current level of knowledge] Stanek W, et al. **Pol Arch Med Wewn** 1995 Dec;94(6):544–50 (36 ref.) **(Pol)**

ETIOLOGY

[Obesity and syndrome X] Mukaida H, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:577–81 (15 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Angina pectoris and normal coronary arteriograms: clinical presentation and hemodynamic characteristics. Kaski JC, et al. **Am J Cardiol** 1995 Nov 2;76(13):35D–42D (48 ref.)

PREVENTION & CONTROL

Hormone replacement therapy and syndrome X. Collins P. **Br J Obstet Gynaecol** 1996 May;103 Suppl 13:68–71; discussion 71–2 (45 ref.)

SYNOSTOSIS

RADIOGRAPHY

[Fracture of the lunatotriquetrum bone in the triquetral part. Case report and review of the literature] Höcker K, et al. **Handchir Mikrochir Plast Chir** 1995 Sep;27(5):254–7 (45 ref.) (Eng. Abstr.) **(Ger)**

[Congenital humeroradial synostosis] Fernández Torrico J, et al. **An Esp Pediatr** 1996 Jun;44(6):612–4 (10 ref.) **(Spa)**

SURGERY

Congenital radioulnar synostosis. Surgical correction by derotational osteotomy. Castelló JR, et al. **Ann Chir Main Memb Super** 1996;15(1):11–7 (8 ref.)

SYNOVIA see **SYNOVIAL FLUID**

SYNOVIAL CHONDROMATOSIS see **CHONDROMATOSIS, SYNOVIAL**

SYNOVIAL CHONDROMETAPLASIA see **CHONDROMATOSIS, SYNOVIAL**

SYNOVIAL CYST

COMPLICATIONS

Suprascapular nerve entrapment by ganglion cysts: a report of six cases with arthroscopic findings and review of the literature. Fehrman DA, et al. **Arthroscopy** 1995 Dec; 11(6):727–34 (47 ref.)

PATHOLOGY

Inflammatory synovial cyst of the temporomandibular joint: a case report and review of the literature. Bonacci CE, et al. **J Oral Maxillofac Surg** 1996 Jun;54(6):769–73 (22 ref.)

RADIOGRAPHY

[Isolated punched-out lesions of the carpus and pain of the wrist] Dumontier C, et al. **Ann Radiol (Paris)** 1995; 38(5):287–92 (50 ref.) (Eng. Abstr.) **(Fre)**

SYNOVIAL FLUID

CHEMISTRY

The role of molecular markers to monitor disease, intervention and cartilage breakdown in osteoarthritis. Lohmander LS, et al. **Acta Orthop Scand Suppl** 1995 Oct; 266:84–7 (32 ref.)

Cartilage matrix molecules in serum and synovial fluid. Simkin PA, et al. **Curr Opin Rheumatol** 1995 Jul;7(4):346–51 (28 ref.)

METABOLISM

Synovial fluid lipids and apolipoproteins: a contemporary perspective. Prete PE, et al. **Biorheology** 1995 Jan–Feb; 32(1):1–16 (103 ref.)

Sex hormones, proto-oncogene expression and apoptosis: their effects on rheumatoid synovial tissue. Cutolo M, et al. **Clin Exp Rheumatol** 1996 Jan–Feb;14(1):87–94 (58 ref.)

SYNOVIAL MEMBRANE

Function, biochemistry, and metabolism of the normal synovial membrane of the temporomandibular joint: a review of the literature. Dijkgraaf LC, et al. **J Oral Maxillofac Surg** 1996 Jan;54(1):95–100 (25 ref.)

BLOOD SUPPLY

Synovial perfusion in the human knee: a methodologic analysis. Simkin PA, et al. **Semin Arthritis Rheum** 1995 Aug;25(1):56–66 (33 ref.)

CYTOLOGY

Structure of the normal synovial membrane of the temporomandibular joint: a review of the literature. Dijkgraaf LC, et al. **J Oral Maxillofac Surg** 1996 Mar; 54(3):332–8 (30 ref.)

[The cellular aspects of the development of synovial joints and articular cartilage] Archer CW, et al. **Ontogenez** 1995 Jul–Aug;26(4):259–69 (42 ref.) (Eng. Abstr.) **(Rus)**

DRUG EFFECTS

Innovative treatment approaches for rheumatoid arthritis. Non-surgical synovectomy. Cruz-Esteban C, et al. **Baillieres Clin Rheumatol** 1995 Nov;9(4):787–801 (76 ref.)

PATHOLOGY

Magnetic resonance imaging manifestations of synovial lesions of the ankle and foot. Bergman AG. **Magn Reson Imaging Clin N Am** 1994 Feb;2(1):131–8 (33 ref.)

Synovial lesions of the hand and wrist. Bergman AG. **Magn Reson Imaging Clin N Am** 1995 May;3(2):265–79 (31 ref.)

Magnetic resonance imaging in synovial disorders and arthropathy of the knee. White EM. **Magn Reson Imaging Clin N Am** 1994 Aug;2(3):451–61 (11 ref.)

Synovial hemangioma: imaging features in eight histologically proven cases, review of the literature, and differential diagnosis. Greenspan A, et al. **Skeletal Radiol** 1995 Nov;24(8):583–90 (32 ref.)

PHYSIOLOGY

Synovium and epithelia: barriers between self and non-self? Berthelot JM, et al. **Clin Exp Rheumatol** 1995 Jul–Aug; 13(4):517–9 (40 ref.)

RADIATION EFFECTS

Innovative treatment approaches for rheumatoid arthritis. Non-surgical synovectomy. Cruz-Esteban C, et al. **Baillieres Clin Rheumatol** 1995 Nov;9(4):787–801 (76 ref.)

SYNOVIAL OSTEOCHONDROMATOSIS see **CHONDROMATOSIS, SYNOVIAL**

SYNOVIOMA see **SARCOMA, SYNOVIAL**

SYNOVITIS

Why the "SAPHO" syndrome? [editorial] Kahn MF. **J Rheumatol** 1995 Nov;22(11):2017–9 (20 ref.)

CLASSIFICATION

Amyloidosis and silicone synovitis: updated classification, updated pathophysiology, and synovial articular abnormalities. Goldman AB, et al. **Radiol Clin North Am** 1996 Mar;34(2):375–94, xi (73 ref.)

COMPLICATIONS

Idiopathic eosinophilic synovitis. Case report and review of the literature. Atanes A, et al. **Scand J Rheumatol** 1996; 25(3):183–5 (13 ref.)

DIAGNOSIS

Synovial lesions of the hand and wrist. Bergman AG. **Magn Reson Imaging Clin N Am** 1995 May;3(2):265–79 (31 ref.)

[RS3PE syndrome. A new rheumatic inflammatory syndrome in advanced age] Pittau E, et al. **Clin Ter** 1995 Nov; 146(11):663–73 (35 ref.) (Eng. Abstr.) **(Ita)**

DRUG THERAPY

Innovative treatment approaches for rheumatoid arthritis. Non-surgical synovectomy. Cruz-Esteban C, et al. **Baillieres Clin Rheumatol** 1995 Nov;9(4):787–801 (76 ref.)

PATHOLOGY

Inflammatory synovial cyst of the temporomandibular joint: a case report and review of the literature. Bonacci CE, et al. **J Oral Maxillofac Surg** 1996 Jun;54(6):769–73 (22 ref.)

RADIOTHERAPY

Innovative treatment approaches for rheumatoid arthritis. Non-surgical synovectomy. Cruz-Esteban C, et al. **Baillieres Clin Rheumatol** 1995 Nov;9(4):787–801 (76 ref.)

VETERINARY

Joint structure, biochemistry and biochemical disequilibrium in synovitis and equine joint disease. Palmer JL, et al. **Equine Vet J** 1994 Jul;26(4):263–77 (131 ref.)

SYNOVITIS, PIGMENTED VILLONODULAR

DIAGNOSIS

MRI of giant cell tumor of the tendon sheath in the cervical spine. Bui-Mansfield LT, et al. **J Comput Assist Tomogr** 1996 Jan–Feb;20(1):113–5 (6 ref.)

Pigmented villonodular synovitis of the temporomandibular joint. Youssef RE, et al. **J Oral Maxillofac Surg** 1996 Feb; 54(2):224–7 (22 ref.)

Pigmented villonodular synovitis. Bravo SM, et al. **Radiol Clin North Am** 1996 Mar;34(2):311–26, x–xi (31 ref.)

PATHOLOGY

Pigmented villonodular synovitis of the spine: a clinical, radiological, and morphological study of 12 cases. Giannini C, et al. **J Neurosurg** 1996 Apr;84(4):592–7 (19 ref.)

RADIOGRAPHY

Pigmented villonodular synovitis of the spine: a clinical, radiological, and morphological study of 12 cases. Giannini C, et al. **J Neurosurg** 1996 Apr;84(4):592–7 (19 ref.)

SYNOVIUM see **SYNOVIAL MEMBRANE**

2-5A SYNTHETASE see **2',5'-OLIGOADENYLATE SYNTHETASE**

SYNTHETASES see **LIGASES**

SYNTHETIC VACCINES see **VACCINES, SYNTHETIC**

SYPHILIS

The diagnosis and treatment of infectious syphilis. Fiumara NJ. **Compr Ther** 1995 Nov;21(11):639–44 (11 ref.)

Syphilis and gonorrhea. Siegel MA. **Dent Clin North Am** 1996 Apr;40(2):369–83 (34 ref.)

Syphilis. A tale of twisted treponemes. Flores JL. **West J Med** 1995 Dec;163(6):552–9 (45 ref.)

[Early syphilitic hepatitis] Sakuma H, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):131–3 (20 ref.) **(Jpn)**

[Gummatous syphilis of the liver] Ponomarev AA. **Klin Med (Mosk)** 1995;73(5):20–3 (36 ref.) **(Rus)**

COMPLICATIONS

The moth-eaten alopecia of secondary syphilis. A histopathological study of 12 patients. Jordaan HF, et al. **Am J Dermatopathol** 1995 Apr;17(2):158–62 (16 ref.)

DIAGNOSIS

Modern diagnosis and management of acquired syphilis [see comments] Nandwani R. **Br J Hosp Med** 1996 Apr 3–16; 55(7):399–403 (20 ref.) Comment in: Br J Hosp Med 1996 Apr 3–16;55(7):386–7.

Laboratory diagnosis of syphilis. Meyer JC. **Curr Probl Dermatol** 1996;24:1–11 (41 ref.)

Are you sure it's syphilis? A review of false positive serology. Nandwani R, et al. **Int J STD AIDS** 1995 Jul–Aug; 6(4):241–8 (63 ref.)

SYPHILIS

EPIDEMIOLOGY

Syphilis makes a comeback [editorial] Drusin LM. **Int J STD AIDS** 1996 Jan-Feb;7(1):7-9 (33 ref.)

PREVENTION & CONTROL

Strategies for syphilis prevention in the 1990s. St Louis ME. **Sex Transm Dis** 1996 Jan-Feb;23(1):58-67 (47 ref.)

SYPHILIS, CARDIOVASCULAR

COMPLICATIONS

Surgical treatment of an aortopulmonary artery fistula complicating a syphilitic aortic aneurysm. Pessotto R, et al. **Cardiovasc Surg** 1995 Dec;3(6):707-10 (17 ref.)

SURGERY

Surgical treatment of an aortopulmonary artery fistula complicating a syphilitic aortic aneurysm. Pessotto R, et al. **Cardiovasc Surg** 1995 Dec;3(6):707-10 (17 ref.)

SYPHILIS, CONGENITAL

Congenital and acquired early childhood syphilis. Rubins S, et al. **Cutis** 1995 Sep;56(3):132-6 (47 ref.)

PREVENTION & CONTROL

Lues-lues: maternal and fetal considerations of syphilis. Ray JG. **Obstet Gynecol Surv** 1995 Dec;50(12):845-50 (30 ref.)

RADIOGRAPHY

Skeletal lesions in early congenital syphilis (a review of 86 cases). Ghadouane M, et al. **Rev Rhum Engl Ed** 1995 Jun; 62(6):433-7 (10 ref.)

SYPHILIS SERODIAGNOSIS

METHODS

Are you sure it's syphilis? A review of false positive serology. Nandwani R, et al. **Int J STD AIDS** 1995 Jul-Aug; 6(4):241-8 (63 ref.)

SYRINGADENOMA see **ADENOMA, SWEAT GLAND**

SYRINGE-EXCHANGE PROGRAMS see **NEEDLE-EXCHANGE PROGRAMS**

SYRINGE SHARING see **NEEDLE SHARING**

SYRINGES

Syringe-mediated drug sharing among injecting drug users: patterns, social context and implications for transmission of blood-borne pathogens. Grund JP, et al. **Soc Sci Med** 1996 Mar;42(5):691-703 (89 ref.)

SYRINGOMA, CHONDROID see **ADENOMA, PLEOMORPHIC**

SYRINGOMYELIA

COMPLICATIONS

Syringomyelia as a cause of body hypertrophy. Sudo K, et al. **Lancet** 1996 Jun 8;347(9015):1593-5 (30 ref.)

DIAGNOSIS

Scoliosis as the first sign of a cystic spinal cord lesion. Samuelsson L, et al. **Eur Spine J** 1995;4(5):284-90 (41 ref.)

Syringomyelia and chiari malformation presenting as scoliosis in cystic fibrosis. Rusakow LS, et al. **Pediatr Pulmonol** 1995 May;19(5):317-8 (10 ref.)

ETIOLOGY

Post-traumatic syringomyelia (cystic myelopathy): a prospective study of 449 patients with spinal cord injury. Schurch B, et al. **J Neurol Neurosurg Psychiatry** 1996 Jan; 60(1):61-7 (42 ref.)

[Pathogenesis and surgical treatment of syringomyelia] Abe T. **No Shinkei Geka** 1995 Sep;23(9):759-66 (42 ref.) **(Jpn)**

[Syringomyelia associated with tentorial meningioma] Sasaki J, et al. **No To Shinkei** 1995 Aug;47(8):795-8 (13 ref.) (Eng. Abstr.) **(Jpn)**

[Syringomyelia, scoliosis and idiopathic Arnold-Chiari malformations: a common etiology] Royo-Salvador MB. **Rev Neurol** 1996 Aug;24(132):937-59 (119 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

Familial syringomyelia: case report and review of the literature. Zakeri A, et al. **Surg Neurol** 1995 Jul;44(1):48-53 (29 ref.)

SURGERY

Surgical indication and results of foramen magnum decompression versus syringosubarachnoid shunting for syringomyelia associated with Chiari I malformation. Hida K, et al. **Neurosurgery** 1995 Oct;37(4):673-8; discussion 678-9 (33 ref.)

[Isolated idiopathic syringobulbia: case report and summary of the literature] Kombos T, et al. **Zentralbl Neurochir** 1996; 57(2):103-7 (29 ref.) (Eng. Abstr.) **(Ger)**

[Pathogenesis and surgical treatment of syringomyelia] Abe T. **No Shinkei Geka** 1995 Sep;23(9):759-66 (42 ref.) **(Jpn)**

SYSTEMATIC BIAS see **BIAS (EPIDEMIOLOGY)**

SYSTEMATICS see **CLASSIFICATION**

SYSTEMIC INFLAMMATORY RESPONSE SYNDROME see **SEPSIS SYNDROME**

SYSTEMS ANALYSIS

see related
TASK PERFORMANCE AND ANALYSIS

Closing the clinical laboratory testing loop with information technology. Connelly DP, et al. **Am J Clin Pathol** 1996 Apr;105(4 Suppl 1):S40-7 (23 ref.)

SYSTEMS INTEGRATION

Integrating instruments and the laboratory information system. Chou D. **Am J Clin Pathol** 1996 Apr;105(4 Suppl 1):S60-4 (10 ref.)

Using hub technology to facilitate information system integration in a health-care enterprise. Gendler SM, et al. **Am J Clin Pathol** 1996 Apr;105(4 Suppl 1):S25-32 (5 ref.)

The hospital information system--integrated patient records. Scherrer JR. **Comput Methods Programs Biomed** 1995 Sep-Oct;48(1-2):1-6 (17 ref.)

SYSTEMS THEORY

see related
MODELS, THEORETICAL
SYSTEMS ANALYSIS

The system-topics framework and the structural arrangement of systems within and around personality. Mayer JD. **J Pers** 1995 Sep;63(3):459-93 (93 ref.)

[With problem of applying modern systems theories in clinical practice] Manteufel A, et al. **Z Klin Psychol Psychopathol Psychother** 1995;43(4):325-47 (55 ref.) (Eng. Abstr.) **(Ger)**

[Temporal organization and information in biological systems] Romanov IuA. **Aviakosm Ekolog Med** 1995; 29(4):4-9 (44 ref.) (Eng. Abstr.) **(Rus)**

[The systems organization of the breeding behavior of the moose in its natural habitat] Bogomolova EM, et al. **Usp Fiziol Nauk** 1995 Oct-Dec;26(4):48-74 (47 ref.) (Eng. Abstr.) **(Rus)**

[The information principle in physiology: an analysis from the position of the general theory of functional systems] Sudakov KV. **Usp Fiziol Nauk** 1995 Oct-Dec;26(4):3-27 (79 ref.) (Eng. Abstr.) **(Rus)**

[The plasticity of systemic brain mechanisms] Sudakov KV. **Usp Fiziol Nauk** 1996 Apr-Jun;27(2):3-27 (91 ref.) (Eng. Abstr.) **(Rus)**

[Food-acquisition and avoidance behaviors: the role of immunomodulators in their systemic organization] Zhuravlev BV, et al. **Usp Fiziol Nauk** 1996 Apr-Jun; 27(2):90-106 (107 ref.) (Eng. Abstr.) **(Rus)**

[Motivation and reinforcement in the systemic mechanisms of behavior: the dynamic engrams of reinforcement] Sudakov KV. **Zh Vyssh Nerv Deiat Im I P Pavlova** 1995 Jul-Aug;45(4):627-37 (40 ref.) (Eng. Abstr.) **(Rus)**

SYSTOLIC CLICK-MURMUR SYNDROME see **MITRAL VALVE PROLAPSE**

3T3 CELLS

CYTOLOGY

The insulin/Ras pathway of adipocytic differentiation of 3T3 L1 cells: dissociation between Raf-1 kinase and the MAPK/RSK cascade. Porras A, et al. **Int J Obes Relat Metab Disord** 1996 Mar;20 Suppl 3:S43-51 (47 ref.)

T3 ANTIGENS see **ANTIGENS, CD3**

T3 RECEPTORS see **RECEPTORS, THYROID HORMONE**

T4 ANTIGENS, T-CELL see **ANTIGENS, CD4**

T4 CELLS see **CD4-POSITIVE T-LYMPHOCYTES**

T4 PHAGE see **BACTERIOPHAGE T4**

T4 RECEPTORS see **RECEPTORS, THYROID HORMONE**

T6 ANTIGENS see **ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE**

T8 ANTIGENS, T-CELL see **ANTIGENS, CD8**

T8 CELLS see **CD8-POSITIVE T-LYMPHOCYTES**

T11 ERYTHROCYTE-BINDING GLYCOPROTEIN see **ANTIGENS, CD2**

T-ALL see **LEUKEMIA, T-CELL, ACUTE**

T-CELL ACTIVATION ANTIGEN see **ANTIGENS, CD27**

T-CELL ANTIGEN RECEPTOR-CD3 COMPLEX see **RECEPTOR-CD3 COMPLEX, ANTIGEN, T-CELL**

T-CELL ANTIGEN RECEPTOR DELTA-CHAIN GENE REARRANGEMENT see **GENE REARRANGEMENT, DELTA-CHAIN T-CELL ANTIGEN RECEPTOR**

T-CELL DIFFERENTIATION ANTIGENS see **ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE**

T-CELL GENE REARRANGEMENT see **GENE REARRANGEMENT, T-LYMPHOCYTE**

T-CELL GROWTH FACTOR see **INTERLEUKIN-2**

T-CELL GROWTH FACTOR RECEPTORS see **RECEPTORS, INTERLEUKIN-2**

T-CELL LEUKEMIA see **LEUKEMIA, T-CELL**

T-CELL LEUKEMIA, ACUTE see **LEUKEMIA, T-CELL, ACUTE**

T-CELL LEUKEMIA, ADULT see **LEUKEMIA, T-CELL**

T-CELL LEUKEMIA-LYMPHOMA, ADULT see **LEUKEMIA-LYMPHOMA, T-CELL, ACUTE, HTLV-I-ASSOCIATED**

T-CELL LEUKEMIA-LYMPHOMA, HTLV-I-ASSOCIATED see **LEUKEMIA-LYMPHOMA, T-CELL, ACUTE, HTLV-I-ASSOCIATED**

T-CELL LEUKEMIA VIRUS I, HUMAN see **HTLV-I**

T-CELL LEUKEMIA VIRUS II, HUMAN see **HTLV-II**

T-CELL LEUKEMIA VIRUSES, HUMAN see **HTLV-BLV VIRUSES**

T-CELL LYMPHOMA see **LYMPHOMA, T-CELL**

T-CELL LYMPHOMA, CUTANEOUS see **LYMPHOMA, T-CELL, CUTANEOUS**

T-CELL LYMPHOMA, PERIPHERAL see **LYMPHOMA, T-CELL, PERIPHERAL**

T-CELL RECEPTORS see **RECEPTORS, ANTIGEN, T-CELL**

T-CELL RECEPTORS, ALPHA-BETA see **RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA**

T-CELL RECEPTORS ALPHA-CHAIN see **RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA**

T-CELL RECEPTORS BETA-CHAIN see **RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA**

T-CELL RECEPTORS DELTA-CHAIN see **RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA**

T-CELL RECEPTORS GAMMA-CHAIN see **RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA**

T-CELL RECEPTORS, GAMMA-DELTA see **RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA**

T-CELL REPLACING FACTOR see **INTERLEUKIN-5**

T-CELL SUBSETS see **T-LYMPHOCYTE SUBSETS**

T-CELL SUPPRESSIVE FACTORS see **SUPPRESSOR FACTORS, IMMUNOLOGIC**

T-CELLS see **T-LYMPHOCYTES**

T-CELLS, HELPER-INDUCER see **T-LYMPHOCYTES, HELPER-INDUCER**

T-CELLS, SUPPRESSOR-EFFECTOR see **T-LYMPHOCYTES, SUPPRESSOR-EFFECTOR**

T-INDEPENDENT ANTIGENS see **ANTIGENS, T-INDEPENDENT**

T-SUPPRESSOR FACTORS see **SUPPRESSOR FACTORS, IMMUNOLOGIC**

T VIRUS see **RETICULOENDOTHELIOSIS VIRUS, AVIAN**

TABLE SALT see **SODIUM CHLORIDE, DIETARY**

TABLETS

ADVERSE EFFECTS

A case of esophageal perforation due to a pill-induced ulcer successfully treated with conservative measures. Yamaoka K, et al. **Am J Gastroenterol** 1996 May;91(5):1044-5 (9 ref.)

TAC PEPTIDE see **RECEPTORS, INTERLEUKIN-2**

TAC P55 PEPTIDE see **RECEPTORS, INTERLEUKIN-2**

TACHYARRHYTHMIA see **TACHYCARDIA**

TACHYCARDIA

Wide complex tachycardia. Delbridge TR, et al. **Emerg Med Clin North Am** 1995 Nov;13(4):903-24 (64 ref.)

COMPLICATIONS

Ventricular tachyarrhythmias, myocardial ischemia, and sudden cardiac death in patients with hypertensive heart disease. Zehender M, et al. **Clin Cardiol** 1995 Jul; 18(7):377-83 (84 ref.)

DIAGNOSIS

Narrow complex tachycardias. Collier WW, et al. **Emerg Med Clin North Am** 1995 Nov;13(4):925-54 (99 ref.)

[The esophageal approach in rhythmology] Mabo P, et al. **Arch Mal Coeur Vaiss** 1995 Dec;88 Spec No 5:43-7 (29 ref.) (Eng. Abstr.) **(Fre)**

[Rhythm emergencies] Schläpfer J, et al. **Schweiz Rundsch Med Prax** 1995 Nov 7;84(45):1314-20 (11 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

The actions of talinolol, a beta 1-selective beta blocker, in cardiac arrhythmia and acute myocardial infarction. Assmann I. **Curr Med Res Opin** 1995;13(6):325-42 (43 ref.)

Narrow complex tachycardias. Collier WW, et al. **Emerg Med Clin North Am** 1995 Nov;13(4):925-54 (99 ref.)

PHYSIOPATHOLOGY

[Transient entrainment of tachycardia] Grolleau R, et al. **Arch Mal Coeur Vaiss** 1995 Dec;88 Spec No 5:63-70 (33 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

The present role of radiofrequency catheter ablation in the management of cardiac arrhythmias. Kay GN, et al. **Am J Med** 1996 Mar;100(3):344-56 (23 ref.)

Advances in catheter ablation. Stafford PJ, et al. **Br J Hosp Med** 1996 Jan 17-Feb 6;55(1-2):44-6 (34 ref.)

THERAPY

The revolution and evolution of prehospital cardiac care. Eisenberg MS, et al. **Arch Intern Med** 1996 Aug 12-26; 156(15):1611-9 (43 ref.)

The implantable cardiac defibrillator. Kamalvand K, et al. **Br J Hosp Med** 1996 Jan 17-Feb 6;55(1-2):37-41 (16 ref.)

Control of rapid heart rate in patients with atrial fibrillation: drugs or ablation? Brignole M, et al. **Pacing Clin Electrophysiol** 1996 Mar;19(3):348-56 (63 ref.)

TACHYCARDIA, ATRIOVENTRICULAR NODAL REENTRY

DIAGNOSIS

[Diagnosis and therapy of AV node reentry tachycardia] Willems S, et al. **Med Klin** 1996 Jun 15;91(6):372-9 (51 ref.) **(Ger)**

SURGERY

Localization of the origin of the atrioventricular junctional rhythm induced during selective ablation of slow-pathway conduction in patients with atrioventricular node reentrant tachycardia. Yu JC, et al. **Am Heart J** 1996 May; 131(5):937-46 (45 ref.)

Radiofrequency catheter ablation for AV nodal reentrant tachycardias (AVNRT). Shah DC, et al. **Indian Heart J** 1996 May-Jun;48(3):231-9 (37 ref.)

[Endocavitary ablation of nodal reentrant tachycardia] Jaïs P, et al. **Arch Mal Coeur Vaiss** 1996 Feb;89 Spec No 1:83-7 (32 ref.) (Eng. Abstr.) **(Fre)**

[Lausanne experience in radiofrequency percutaneous ablation of the slow pathway in nodal tachycardia] Menafoglio A, et al. **Schweiz Med Wochenschr** 1996 May 25;126(21):915-23 (45 ref.) (Eng. Abstr.) **(Fre)**

[High frequency current catheter ablation in treatment of supraventricular and atrioventricular tachycardia] Hindricks G, et al. **Z Kardiol** 1995;84 Suppl 2:103-21 (88 ref.) (Eng. Abstr.) **(Ger)**

TACHYCARDIA, AV NODAL REENTRANT see **TACHYCARDIA, ATRIOVENTRICULAR NODAL REENTRY**

TACHYCARDIA, ECTOPIC ATRIAL

SURGERY

[Radiofrequency ablation in permanent ectopic left atrial tachycardia] Schmitt C, et al. **Dtsch Med Wochenschr** 1995 Nov 10;120(45):1538-42 (13 ref.) (Eng. Abstr.) **(Ger)**

[High frequency current catheter ablation in treatment of supraventricular and atrioventricular tachycardia] Hindricks G, et al. **Z Kardiol** 1995;84 Suppl 2:103-21 (88 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

New approaches to treatment of atrial flutter and tachycardia. Lesh MD, et al. **J Cardiovasc Electrophysiol** 1996 Apr;7(4):368-81 (72 ref.)

TACHYCARDIA, ECTOPIC JUNCTIONAL

SURGERY

[Atrial insertion of accessory pathways in permanent reciprocating junctional tachycardia] Elbaz M, et al. **Arch Mal Coeur Vaiss** 1995 Oct;88(10):1399-405 (39 ref.) (Eng. Abstr.) **(Fre)**

[High frequency current catheter ablation in treatment of supraventricular and atrioventricular tachycardia] Hindricks G, et al. **Z Kardiol** 1995;84 Suppl 2:103-21 (88 ref.) (Eng. Abstr.) **(Ger)**

TACHYCARDIA, PAROXYSMAL

Paroxysmal atrial fibrillation. A common but neglected entity. Aboaf AP, et al. **Arch Intern Med** 1996 Feb 26; 156(4):362-7 (55 ref.)

Paroxysmal supraventricular tachycardias. Lowenstein SR, et al. **J Emerg Med** 1996 Jan-Feb;14(1):39-51 (48 ref.)

ETIOLOGY

[Atrial septal aneurysm. Report of two clinical cases and review of the literature] Perrotta S, et al. **Minerva Cardioangiol** 1995 Jul-Aug;43(7-8):339-43 (23 ref.) (Eng. Abstr.) **(Ita)**

PHYSIOPATHOLOGY

Electrophysiologic characteristics of human atrial muscle in paroxysmal atrial fibrillation. Hashiba K, et al. **Am Heart J** 1996 Apr;131(4):778-89 (77 ref.)

SURGERY

Catheter ablation for the treatment of paroxysmal supraventricular tachycardia. Naccarelli GV, et al. **J Cardiovasc Electrophysiol** 1995 Oct;6(10 Pt 2):951-61 (47 ref.)

[Permanent junctional reciprocating tachycardia: a little-known clinical entity curable with radiofrequency ablation] Menafoglio A, et al. **Schweiz Med Wochenschr** 1995 Oct 21;125(42):1980-8 (43 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Management of infants, children, and adolescents with paroxysmal supraventricular tachycardia. Kugler JD, et al. **J Pediatr** 1996 Sep;129(3):324-38 (59 ref.)

TACHYCARDIA, RECIPROCAL see **TACHYCARDIA, PAROXYSMAL**

TACHYCARDIA, SA NODAL REENTRANT see **TACHYCARDIA, SINOATRIAL NODAL REENTRY**

TACHYCARDIA, SINOATRIAL NODAL REENTRY

PHYSIOPATHOLOGY

Interatrial, internodal, and dual reentrant atrioventricular nodal pathways: an anatomical update of arrhythmogenic substrates. Rossi L. **Cardiologia** 1996 Feb;41(2):129-34 (25 ref.)

TACHYCARDIA, SINUS

DIAGNOSIS

Normal sinus heart rate: appropriate rate thresholds for sinus tachycardia and bradycardia. Spodick DH. **South Med J** 1996 Jul;89(7):666-7 (9 ref.)

TACHYCARDIA, SUPRAVENTRICULAR

Paroxysmal supraventricular tachycardias. Lowenstein SR, et al. **J Emerg Med** 1996 Jan-Feb;14(1):39-51 (48 ref.)

CHEMICALLY INDUCED

[Supraventricular tachycardia with wide QRS complexes during Vaughan-Williams class I anti-arrhythmic treatment. Diagnostic and therapeutic implications] Aouate P, et al. **Arch Mal Coeur Vaiss** 1995 Dec;88(12):1869-74 (27 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

Successful treatment of supraventricular tachycardia-induced cardiomyopathy with amiodarone: case report and review of literature. Chen RP, et al. **Can J Cardiol** 1995 Nov;11(10):918-22 (20 ref.)

Tachycardiomyopathy: mechanisms and clinical implications. Fenelon G, et al. **Pacing Clin Electrophysiol** 1996 Jan; 19(1):95-106 (76 ref.)

DIAGNOSIS

Bedside diagnosis of wide QRS tachycardia [editorial; comment] Barold SS. **Pacing Clin Electrophysiol** 1995 Dec; 18(12 Pt 1):2109-15 (79 ref.) Comment on: Pacing Clin Electrophysiol 1995 Dec;18(12 Pt 1):2194-208.

Wide-complex tachycardias. The importance of identifying the mechanism. Janeira LF. **Postgrad Med** 1996 Sep; 100(3):259-62, 265-6, 269-72 passim (20 ref.)

[Intrauterine diagnosis and therapy of fetal arrhythmias] Gembruch U, et al. **Gynakologe** 1995 Oct;28(5):329-45 (69 ref.) **(Ger)**

[Diagnostic electrophysiological studies] Fuhrer J. **Schweiz Rundsch Med Prax** 1996 Apr 30;85(18):584-94 (20 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

[Adenosine in the treatment of supraventricular arrhythmias] Lommi J, et al. **Duodecim** 1994;110(5):473-7 (27 ref.) **(Fin)**

[Pharma-clinics. How I treat... supraventricular tachycardia in children] Massin M. **Rev Med Liege** 1996 Mar; 51(3):210-3 (32 ref.) **(Fre)**

[Effects of adenosine on the heart—therapeutic and diagnostic possibilities] Stark U, et al. **Wien Klin Wochenschr** 1996;108(12):343-51 (61 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Wide-complex tachycardias. The importance of identifying the mechanism. Janeira LF. **Postgrad Med** 1996 Sep; 100(3):259-62, 265-6, 269-72 passim (20 ref.)

[Supraventricular tachycardias: mechanism, diagnosis and therapy] Osswald S, et al. **Schweiz Med Wochenschr** 1996 Jun 1;126(22):974-85 (42 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

Catheter ablation for the treatment of paroxysmal supraventricular tachycardia. Naccarelli GV, et al. **J Cardiovasc Electrophysiol** 1995 Oct;6(10 Pt 2):951-61 (47 ref.)

[Survival after His bundle ablation for supraventricular arrhythmia. A 10-years experience in 317 consecutive patients] Poquet F, et al. **Arch Mal Coeur Vaiss** 1995 Nov; 88(11):1593-600 (31 ref.) (Eng. Abstr.) **(Fre)**

[Catheter ablation and modulation of the atrioventricular junction; current aspects] Robert F, et al. **Arch Mal Coeur Vaiss** 1996 Feb;89 Spec No 1:65-73 (50 ref.) (Eng. Abstr.) **(Fre)**

[High frequency current catheter ablation in treatment of supraventricular and atrioventricular tachycardia] Hindricks G, et al. **Z Kardiol** 1995;84 Suppl 2:103-21 (88 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Management of infants, children, and adolescents with paroxysmal supraventricular tachycardia. Kugler JD, et al. **J Pediatr** 1996 Sep;129(3):324-38 (59 ref.)

[New indications for cardiac pacing] Davy JM, et al. **Arch Mal Coeur Vaiss** 1995 Dec;88 Spec No 5:55-62 (43 ref.) (Eng. Abstr.) **(Fre)**

[Cardiology update—I] Trappe HJ, et al. **Med Klin** 1996 Apr 1;91 Suppl 1:118-27 (172 ref.) **(Ger)**

[Treatment of supraventricular tachyarrhythmias: drugs or ablation?] Chimienti M, et al. **G Ital Cardiol** 1996 Feb; 26(2):213-26 (80 ref.) **(Ita)**

TACHYCARDIA, VENTRICULAR

Ventricular tachycardia: prevalence, mechanisms and approaches to diagnosis and management. Sra JS, et al. **Indian Heart J** 1995 May-Jun;47(3):215-22 (51 ref.)

CHEMICALLY INDUCED

Erythromycin-induced polymorphous ventricular tachycardia with normal QT interval. Chennareddy SB, et al. **Am Heart J** 1996 Sep;132(3):691-4 (11 ref.)

COMPLICATIONS

Tachycardiomyopathy: mechanisms and clinical implications. Fenelon G, et al. **Pacing Clin Electrophysiol** 1996 Jan; 19(1):95-106 (76 ref.)

[Prognostic factors after sustained ventricular fibrillation or tachycardia. A multivariate study apropos of 160 cases] Fleurant E, et al. **Arch Mal Coeur Vaiss** 1996 Apr; 89(4):435-44 (31 ref.) (Eng. Abstr.) **(Fre)**

[Ventricular tachycardia in non-ischemic heart disease] Murin J, et al. **Vnitr Lek** 1995 Jul;41(7):476–9 (17 ref.) (Eng. Abstr.) **(Slo)**

DIAGNOSIS

Role of electrophysiologic evaluation in patients with ventricular arrhythmias. Athill CA, et al. **Indian Heart J** 1996 Mar–Apr;48(2):179–85 (33 ref.)

Bedside diagnosis of wide QRS tachycardia [editorial; comment] Barold SS. **Pacing Clin Electrophysiol** 1995 Dec; 18(12 Pt 1):2109–15 (79 ref.) Comment on: Pacing Clin Electrophysiol 1995 Dec;18(12 Pt 1):2194–208.

Wide-complex tachycardias. The importance of identifying the mechanism. Janeira LF. **Postgrad Med** 1996 Sep; 100(3):259–62, 265–6, 269–72 passim (20 ref.)

Is a baseline electrophysiologic study mandatory for the management of patients with spontaneous, sustained, ventricular tachyarrhythmias? Mitchell LB, et al. **Prog Cardiovasc Dis** 1996 Mar–Apr;38(5):385–92 (30 ref.)

Signal-averaged electrocardiogram in chronic Chagas' heart disease. de Moraes AP, et al. **Rev Paul Med** 1995 Mar–Apr; 113(2):851–7 (26 ref.)

[Sustained ventricular tachycardia: an evaluation of long-term prognosis] Bellon C, et al. **Arch Mal Coeur Vaiss** 1995 Jul;88(7):1014–9 (20 ref.) (Eng. Abstr.) **(Fre)**

[Ventricular tachycardia in the normal heart] Jordaens L. **Arch Mal Coeur Vaiss** 1995 Dec;88 Spec No 5:19–25 (26 ref.) (Eng. Abstr.) **(Fre)**

[In vivo registration of monophasic action potentials—new possible applications in clinical electrophysiology] Behrens S, et al. **Z Kardiol** 1996 May;85(5):326–33 (35 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Evolving role of sotalol in the management of ventricular tachyarrhythmias. O'Callaghan PA, et al. **Am J Cardiol** 1996 Aug 29;78(4A):54–60 (40 ref.)

An overview of antiarrhythmic drug management of electrical storm. Kowey PR. **Can J Cardiol** 1996 Apr;12 Suppl B:3B–8B; discussion 27B–28B (15 ref.)

Parenteral antiarrhythmics for life-threatening ventricular arrhythmias. Filart RA, et al. **J Cardiovasc Electrophysiol** 1995 Oct;6(10 Pt 2):901–13 (70 ref.)

Parenteral antiarrhythmic drug therapy in ventricular tachycardia/ventricular fibrillation: evolving role of class III agents—focus on amiodarone. Scheinman MM. **J Cardiovasc Electrophysiol** 1995 Oct;6(10 Pt 2):914–9 (34 ref.)

[Pharma-clinics. How I treat.... Ventricular tachycardia in children] Massin M. **Rev Med Liege** 1996 Feb;51(2):147–9 (28 ref.) **(Fre)**

[Calcium antagonists in treatment of ventricular tachycardia] Melichercik J, et al. **Z Kardiol** 1996 May;85(5):319–25 (31 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Ventricular tachycardia in ischaemic heart disease: insights into the mechanisms from cardiac mapping and implications for patient management. Doig JC, et al. **Eur Heart J** 1995 Aug;16(8):1027–35 (71 ref.)

Management strategies in patients at high risk of sudden cardiac death following myocardial infarction. Sra J, et al. **Indian Heart J** 1995 Mar–Apr;47(2):158–62 (37 ref.)

Ventricular tachycardia after myocardial infarction: from arrhythmia surgery to catheter ablation. Stevenson WG. **J Cardiovasc Electrophysiol** 1995 Oct;6(10 Pt 2):942–50 (52 ref.)

Bundle branch reentry ventricular tachycardia. Tchou P, et al. **Pacing Clin Electrophysiol** 1995 Jul;18(7):1427–37 (22 ref.)

[Arrhythmogenic right ventricle: dysplasia or cardiomyopathy? Value of left ventricle ejection fraction] Fontaine G, et al. **Ann Cardiol Angeiol (Paris)** 1995 Sep; 44(7):321–31 (37 ref.) (Eng. Abstr.) **(Fre)**

MORTALITY

Electrocardiographic predictors in the ESVEM trial: unsustained ventricular tachycardia, heart period variability, and the signal-averaged electrocardiogram. Anderson KP, et al. **Prog Cardiovasc Dis** 1996 May–Jun; 38(6):463–88 (89 ref.)

PHYSIOPATHOLOGY

Ionic mechanisms of ischemia-related ventricular arrhythmias. Ducceschi V, et al. **Clin Cardiol** 1996 Apr; 19(4):325–31 (106 ref.)

Polymorphous ventricular tachycardia in the early stages of an evolving myocardial infarction. Birnbaum Y, et al. **J Basic Clin Physiol Pharmacol** 1993 Oct–Dec;4(4):347–56 (68 ref.)

Resetting and transient entrainment of ventricular tachycardia. Frazier DW, et al. **Pacing Clin Electrophysiol** 1995 Oct;18(10):1919–46 (70 ref.)

Wide-complex tachycardias. The importance of identifying the mechanism. Janeira LF. **Postgrad Med** 1996 Sep; 100(3):259–62, 265–6, 269–72 passim (20 ref.)

[Late ventricular potentials: significance, electrophysiology and clinical importance in coronary disease] Zimmermann M. **Schweiz Rundsch Med Prax** 1996 Apr 30;85(18):604–12 (51 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

Endothelial cells, nitric oxide and ischaemic preconditioning. Parratt JR, et al. **Basic Res Cardiol** 1996 Jan–Feb; 91(1):27–30 (14 ref.)

SURGERY

Surgical treatment of ventricular tachycardia. Indications and results. Pagé PL. **Arch Mal Coeur Vaiss** 1996 Feb;89 Spec No 1:115–21 (24 ref.)

Ventricular tachycardia after myocardial infarction: from arrhythmia surgery to catheter ablation. Stevenson WG. **J Cardiovasc Electrophysiol** 1995 Oct;6(10 Pt 2):942–50 (52 ref.)

[Value of mapping in surgical treatment of ventricular tachycardia] Lacroix D, et al. **Arch Mal Coeur Vaiss** 1996 Feb;89 Spec No 1:109–13 (20 ref.) (Eng. Abstr.) **(Fre)**

[High frequency current catheter ablation in ventricular tachycardia] Haverkamp W, et al. **Z Kardiol** 1995;84 Suppl 2:83–102 (138 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Evolution of the management of malignant ventricular tachyarrhythmias: the roles of drug therapy and implantable defibrillators [editorial] Kim SG. **Am Heart J** 1995 Nov;130(5):1144–50 (59 ref.)

Interactions between pharmacologic and nonpharmacologic antiarrhythmic therapy. Greene HL. **Am J Cardiol** 1996 Aug 29;78(4A):61–6 (49 ref.)

Antitachycardia pacing: an overview. Horwood L, et al. **Am J Crit Care** 1995 Sep;4(5):397–404 (10 ref.)

The current status of the implantable cardioverter defibrillator. Gillis AM. **Annu Rev Med** 1996;47:85–93 (20 ref.)

Implantable cardioverter-defibrillator: present and future indications. Block M, et al. **Arch Mal Coeur Vaiss** 1996 Feb;89 Spec No 1:141–7 (61 ref.)

Evaluation and treatment of nonsustained ventricular tachycardia. Wilber DJ. **Curr Opin Cardiol** 1996 Jan; 11(1):23–31 (28 ref.)

Future prospects of antiarrhythmic treatment based on experimental studies. Janse MJ. **Eur Heart J** 1995 Aug;16 Suppl G:2–6 (44 ref.)

Implantable defibrillators are preferable to pharmacologic therapy for patients with ventricular tachyarrhythmias: an antagonist's viewpoint. Anderson J. **Prog Cardiovasc Dis** 1996 Mar–Apr;38(5):393–400 (32 ref.)

Implanted cardioverter–defibrillators are preferable to drugs as primary therapy in sustained ventricular tachyarrhythmias. Saksena S, et al. **Prog Cardiovasc Dis** 1996 May–Jun;38(6):445–54 (51 ref.)

[Significance of initial defibrillation by paramedics] Mauer D, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1995 Aug; 30(5):303–6 (30 ref.) **(Ger)**

[Implantable defibrillators—current status of guidelines. Recognized and possible indications—prerequisites] Andresen D. **Fortschr Med** 1996 Apr 20;114(11):128–32 (0 ref.) (Eng. Abstr.) **(Ger)**

[Cardiology update—I] Trappe HJ, et al. **Med Klin** 1996 Apr 1;91 Suppl 1:118–27 (172 ref.) **(Ger)**

[How do you want to die? The therapeutic options in ventricular tachyarrhythmia at the end of the anti-arrhythmia drug era] Seipel L. **Z Kardiol** 1995 Oct; 84(10):787–90 (38 ref.) **(Ger)**

[Implantable cardioverter–defibrillator: prevention of sudden cardiac death and impact on survival in patients with malignant ventricular arrhythmias] Occhetta E, et al. **Cardiologia** 1995 Jun;40(6):419–25 (35 ref.) **(Ita)**

TACHYKININ RECEPTORS see **RECEPTORS, TACHYKININ**

TACHYKININS

see related
RECEPTORS, TACHYKININ

GENETICS

Transcriptional control of neuropeptide gene expression in sensory neurons, using the preprotachykinin-A gene as a model. Quinn JP, et al. **Can J Physiol Pharmacol** 1995 Jul; 73(7):957–62 (59 ref.)

PHYSIOLOGY

Hypothalamic tachykinins. Mediators of stress responses? Culman J, et al. **Ann N Y Acad Sci** 1995 Dec 29;771:204–18 (68 ref.)

Central tachykinins: mediators of defence reaction and stress reactions. Culman J, et al. **Can J Physiol Pharmacol** 1995 Jul;73(7):885–91 (54 ref.)

Tachykinins, sensory nerves, and asthma—an overview. Lundberg JM. **Can J Physiol Pharmacol** 1995 Jul; 73(7):908–14 (99 ref.)

Tachykinin peptides, receptors, and peptidases in airway disease. Piedimonte G. **Exp Lung Res** 1995 Nov–Dec; 21(6):809–34 (154 ref.)

The mammalian tachykinin receptors. Maggi CA. **Gen Pharmacol** 1995 Sep;26(5):911–44 (245 ref.)

Dopamine, serotonin and tachykinin in self-injurious behavior. Sivam SP. **Life Sci** 1996 May 24;58(26):2367–75 (66 ref.)

Spinal cord tachykinins in the micturition reflex. Lecci A, et al. **Prog Brain Res** 1995;104:145–59 (93 ref.)

[Neuropeptides and nasal mucosa: a general review and update] Duroux S, et al. **Rev Laryngol Otol Rhinol (Bord)** 1996;117(1):3–7 (38 ref.) (Eng. Abstr.) **(Fre)**

TACHYPHYLAXIS

GENETICS

Causes and problems of nonresponse or poor response to drugs. Salvà Lacombe P, et al. **Drugs** 1996 Apr; 51(4):552–70 (162 ref.)

TACHYPLEUS see **HORSESHOE CRABS**

TACRINE

PHARMACOLOGY

THA—historical aspects, review of pharmacological properties and therapeutic effects. Soares JC, et al. **Dementia** 1995 Jul–Aug;6(4):225–34 (73 ref.)

THERAPEUTIC USE

THA—historical aspects, review of pharmacological properties and therapeutic effects. Soares JC, et al. **Dementia** 1995 Jul–Aug;6(4):225–34 (73 ref.)

Alzheimer's disease: the role of tacrine therapy. Jogerst G. **Iowa Med** 1995 Oct;85(10):409–11 (0 ref.)

[New therapeutic prospects in Alzheimer disease] Rouhart F. **Rev Med Interne** 1995;16(11):860–3 (28 ref.) (Eng. Abstr.) **(Fre)**

[Dementias: present situation and future perspectives (III). Neurological, therapeutic, psychosocial aspects and patient care] Espert R, et al. **Rev Neurol** 1995 Jan–Feb; 23(119):86–95 (138 ref.) (Eng. Abstr.) **(Spa)**

[Pharmacological treatment of Alzheimer's disease: present situation and perspectives] Jané F. **Rev Neurol** 1995 Jan–Feb;23(119):103–7 (43 ref.) (Eng. Abstr.) **(Spa)**

TACROLIMUS

Tacrolimus: a new immuosuppressive agent [see comments] Kelly PA, et al. **Am J Health Syst Pharm** 1995 Jul 15; 52(14):1521–35 (118 ref.) Comment in: Am J Health Syst Pharm 1995 Jul 15;52(14):1569–71.

FK506 in solid organ transplantation. Fung JJ, et al. **Ther Drug Monit** 1995 Dec;17(6):592–5 (33 ref.)

ADVERSE EFFECTS

The role of calcium-channel antagonists in solid organ transplantation. Huntress JD, et al. **New Horiz** 1996 Feb; 4(1):129–33 (30 ref.)

CHEMISTRY

Receptor (immunophilin-binding) assay for immunosuppressive drugs. Soldin SJ. **Ther Drug Monit** 1995 Dec;17(6):574–6 (18 ref.)

METABOLISM

Drug interactions in transplantation. Seifeldin R. **Clin Ther** 1995 Nov–Dec;17(6):1043–61 (102 ref.)

PHARMACOKINETICS

Clinical pharmacokinetics of tacrolimus. Venkataramanan R, et al. **Clin Pharmacokinet** 1995 Dec;29(6):404–30 (146 ref.)

PHARMACOLOGY

Inhibition of T lymphocyte activation and apoptotic cell death by cyclosporin A and tacrolimus (FK506). Its relevance to therapy of HIV infection. Thomson AW, et al. **Adv Exp Med Biol** 1995;374:211–6 (46 ref.)

The actions of cyclosporin A and FK506 on T-lymphocyte activation. Mattila PS. **Biochem Soc Trans** 1996 Feb; 24(1):45–9 (40 ref.)

The mechanism of action of cyclosporin A and FK506. Ho S, et al. **Clin Immunol Immunopathol** 1996 Sep;80(3 Pt 2):S40–5 (31 ref.)

Molecular mechanisms of immunosuppression by cyclosporine, FK506, and rapamycin. Cardenas ME, et al. **Curr Opin Nephrol Hypertens** 1995 Nov;4(6):472–7 (83 ref.)

Mechanisms of action of immunosuppressive agents: cyclosporin A, FK506, and rapamycin. Bierer BE. **Proc Assoc Am Physicians** 1995 Apr;107(1):28–40 (135 ref.)

Mode of action of tacrolimus (FK506): molecular and cellular mechanisms. Thomson AW, et al. **Ther Drug Monit** 1995 Dec;17(6):584–91 (79 ref.)

THERAPEUTIC USE

Randomised trialomania? The multicentre liver transplant trials of tacrolimus [see comments] Starzl TE, et al. **Lancet** 1995 Nov 18;346(8986):1346–50 (28 ref.) Comment in: Lancet 1995 Nov 18;346(8986):1310–1.

Nitric oxide synthase, immunophilins and poly(ADP-ribose) synthetase: novel targets for the development of neuroprotective drugs. Zhang J, et al. **Neurol Res** 1995 Aug;17(4):285-8 (37 ref.)
Clinical use of tacrolimus (FK-506) in infants and children with renal transplants. Ellis D. **Pediatr Nephrol** 1995 Aug; 9(4):487-94 (45 ref.)
Analysis of tacrolimus (FK 506) in relation to therapeutic drug monitoring. Jusko WJ. **Ther Drug Monit** 1995 Dec; 17(6):596-601 (42 ref.)
Consensus document: therapeutic monitoring of tacrolimus (FK-506). Jusko WJ, et al. **Ther Drug Monit** 1995 Dec; 17(6):606-14 (55 ref.)
Therapeutic drug monitoring of tacrolimus in clinical transplantation. McMaster P, et al. **Ther Drug Monit** 1995 Dec;17(6):602-5 (8 ref.)
Clinical use of FK 506 in liver transplantation. Klintmalm GB. **Transplant Proc** 1996 Apr;28(2):974-6 (13 ref.)
[Tacrolimus (FK 506): an immunosuppression alternative in solid organ transplantation. (Part 2)] Díaz M, et al. **Rev Med Univ Navarra** 1995 Apr-Jun;40(2):93-108 (170 ref.) **(Spa)**

TOXICITY

Pancreatic and nephrotoxicity of immunomodulator compounds. Hammond TG, et al. **Toxicol Lett** 1995 Dec; 82-83:99-105 (17 ref.)

TAENIA

GROWTH & DEVELOPMENT

Cysticercosis. Sotelo J, et al. **Curr Clin Top Infect Dis** 1996; 16:240-59 (109 ref.)

PHYSIOLOGY

Detection, screening and community epidemiology of taeniid cestode zoonoses: cystic echinococcosis, alveolar echinococcosis and neurocysticercosis. Craig PS, et al. **Adv Parasitol** 1996;38:169-250 (365 ref.)

TAENIA INFECTIONS see **TAENIASIS**

TAENIARHYNCHUS see **TAENIA**

TAENIASIS

see related
CYSTICERCOSIS

EPIDEMIOLOGY

[The prevalence of Taenia solum taeniasis and cysticercosis] Bessonov AS. **Med Parazitol (Mosk)** 1995 Apr-Jun; (2):47-51 (43 ref.) **(Rus)**

TAIL

Chasing tails in ascidians: developmental insights into the origin and evolution of chordates. Satoh N, et al. **Trends Genet** 1995 Sep;11(9):354-9 (44 ref.)

TAKATSUKI'S SYNDROME see **POEMS SYNDROME**

TAKAYASU SYNDROME see **TAKAYASU'S ARTERITIS**

TAKAYASU'S ARTERITIS

Takayasu's arteritis. Kerr GS. **Rheum Dis Clin North Am** 1995 Nov;21(4):1041-58 (128 ref.)

COMPLICATIONS

Behçet's disease and Takayasu's disease in children. Martini A. **Curr Opin Rheumatol** 1995 Sep;7(5):449-54 (71 ref.)
[Association of Takayasu's arteritis, pregnancy and Still's disease] Fignon A, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(7):747-50 (13 ref.) (Eng. Abstr.) **(Fre)**
[Chronic ischemic ophthalmopathy in Takayasu-Onishi disease] Chercotă G, et al. **Oftalmologia** 1996 Jan-Mar; 40(1):39-44 (19 ref.) (Eng. Abstr.) **(Rum)**

THERAPY

Behçet's disease and Takayasu's disease in children. Martini A. **Curr Opin Rheumatol** 1995 Sep;7(5):449-54 (71 ref.)

TALIPES CAVUS see **FOOT DEFORMITIES**

TALIPES EQUINOVARUS see **CLUBFOOT**

TALOCALCANEAL JOINT see **SUBTALAR JOINT**

TALUS

ABNORMALITIES

Congenital vertical talus. Drennan JC. **Instr Course Lect** 1996;45:315-22 (34 ref.)

INJURIES

Fractures of the lateral process of the talus: a clinical review. "Snowboarder's ankle". McCrory P, et al. **Clin J Sport Med** 1996 Apr;6(2):124-8 (13 ref.)
Transchondral fractures of the talar dome. Cox HA, et al. **Clin Podiatr Med Surg** 1995 Oct;12(4):667-87 (64 ref.)
Traumatic talectomy without fracture: four case reports and review of the literature. Jaffe KA, et al. **Foot Ankle Int** 1995 Sep;16(9):583-7 (30 ref.)
Talar fracture/dislocation in the adolescent patient. Valentine BC 2nd, et al. **J Foot Ankle Surg** 1995 Jul-Aug;34(4):379-83 (11 ref.)

SURGERY

Traumatic talectomy without fracture: four case reports and review of the literature. Jaffe KA, et al. **Foot Ankle Int** 1995 Sep;16(9):583-7 (30 ref.)

TAMOXIFEN

The effect of tamoxifen on the endometrium. Barakat RR. **Oncology (Huntingt)** 1995 Feb;9(2):129-34; discussion 139-40, 142 (27 ref.)

ADVERSE EFFECTS

The effects of tamoxifen on the uterus. Ismail SM. **Curr Opin Obstet Gynecol** 1996 Feb;8(1):27-31 (22 ref.)
The effects of tamoxifen treatment on the endometrium. Daniel Y, et al. **Fertil Steril** 1996 Jun;65(6):1083-9 (94 ref.)
Uterine neoplasms in patients treated with tamoxifen. Silva EG, et al. **J Cell Biochem Suppl** 1995;23:179-83 (22 ref.)
Tamoxifen-associated eye disease. A review. Nayfield SG, et al. **J Clin Oncol** 1996 Mar;14(3):1018-26 (58 ref.)
The beneficial effect of the estrogen antagonist tamoxifen on experimental systemic lupus erythematosus [letter; comment] Thylan S. **J Rheumatol** 1995 Aug;22(8):1606-7 (11 ref.) Comment on: J Rheumatol 1994 Dec;21(12):2231-8.
Tamoxifen and endometrial cancer: from experiment to patient. Assikis VJ, et al. **Recent Results Cancer Res** 1996; 140:61-71 (41 ref.)
Tamoxifen--breast cancer preventive or human carcinogen? Clute E. **Toxicol Ind Health** 1995 Sep-Oct;11(5):503-10 (12 ref.)
[Medical adverse effects of chemoprevention: the example of tamoxifen] Sasco AJ, et al. **Bull Cancer (Paris)** 1995 Jul; 82 Suppl 3:186s-206s (116 ref.) (Eng. Abstr.) **(Fre)**
[Expansive uterine myoma during tamoxifen therapy. 11 cases] Le Bouëdec G, et al. **Presse Med** 1995 Nov 25; 24(36):1694-6 (18 ref.) (Eng. Abstr.) **(Fre)**
[Surveillance of patients treated with tamoxifen] Sananes S, et al. **Presse Med** 1996 Mar 23;25(10):499-502 (25 ref.) (Eng. Abstr.) **(Fre)**
[Gynecologic monitoring of tamoxifen treatment of breast cancer] Le Bouedec G, et al. **Rev Fr Gynecol Obstet** 1995 Jul-Sep;90(7-9):379-82 (30 ref.) **(Fre)**
-Tamoxifen and the endometrium: monitoring and evaluation of endometrial changes- Rageth JC, et al. **Arch Gynecol Obstet** 1995;256 Suppl:S122-7 (24 ref.) **(Ger)**

PHARMACOLOGY

Tamoxifen as an antioxidant and cardioprotectant. Wiseman H. **Biochem Soc Symp** 1995;61:209-19 (65 ref.)
Gynaecologic effects of tamoxifen. Kuo DY, et al. **Med Oncol** 1995 Jun;12(2):87-94 (79 ref.)
Chemoprevention of breast cancer by tamoxifen: risks and opportunities. Smith LL, et al. **Toxicol Lett** 1995 Dec; 82-83:181-6 (18 ref.)

THERAPEUTIC USE

Tamoxifen therapy--long-term results and complications. Moore MP, et al. **Adv Surg** 1996;29:263-9 (29 ref.)
An overview of considerations for the testing of tamoxifen as a preventive for breast cancer. Jordan VC. **Ann N Y Acad Sci** 1995 Sep 30;768:141-7 (47 ref.)
Possible mechanisms in the emergence of tamoxifen-resistant breast cancer. Tonetti DA, et al. **Anticancer Drugs** 1995 Aug;6(4):498-507 (87 ref.)
Alternate antiestrogens and approaches to the prevention of breast cancer. Jordan VC. **J Cell Biochem Suppl** 1995; 22:51-7 (51 ref.)
Tamoxifen's role in chemoprevention of breast cancer: an update. Nayfield SG. **J Cell Biochem Suppl** 1995;22:42-50 (63 ref.)
Targeted anti-estrogens to treat and prevent diseases in women. Tonetti DA, et al. **Mol Med Today** 1996 May; 2(5):218-23 (35 ref.)
Tamoxifen: teaching an old drug new tricks? Grainger DJ, et al. **Nat Med** 1996 Apr;2(4):381-5 (23 ref.)
Adjuvant systemic therapy for breast cancer. Issues for primary care physicians. Berkowitz LD, et al. **Postgrad Med** 1995 Oct;98(4):85-8, 91, 94 (2 ref.)
Adjuvant treatment of breast cancer. Akerley WL 3rd. **R I Med** 1995 Sep;78(9):250-3 (12 ref.)
[Is breast cancer prevention by tamoxifen possible?] Namer M, et al. **Bull Cancer (Paris)** 1995 Jul;82 Suppl 3:155s-167s (65 ref.) (Eng. Abstr.) **(Fre)**
[Surveillance of patients treated with tamoxifen] Sananes S, et al. **Presse Med** 1996 Mar 23;25(10):499-502 (25 ref.) (Eng. Abstr.) **(Fre)**
[Hormone replacement therapy in menopausal women previously treated for breast cancer (editorial)] This P. **Presse Med** 1996 Feb 3;25(4):141-4 (25 ref.) (Eng. Abstr.) **(Fre)**
-Results of ongoing breast cancer prevention studies- Jungi WF. **Arch Gynecol Obstet** 1995;256 Suppl:S116-21 (18 ref.) **(Ger)**
[Tamoxifen in male infertility. Analysis of a questionable therapy] Rolf C, et al. **Dtsch Med Wochenschr** 1996 Jan 5;121(1-2):33-9 (77 ref.) **(Ger)**
[Agonists-antagonists of estrogens, their potential use in prophylaxis and treatment of osteoporosis] Hoszowski K. **Pol Tyg Lek** 1995 Nov;50(44-47):41-2 (16 ref.) (Eng. Abstr.) **(Pol)**

TOXICITY

Enhancement of tumor growth by drugs with some common molecular actions. LaBella FS, et al. **Mol Carcinog** 1996 Jun;16(2):68-76 (91 ref.)
Receptor-mediated carcinogenesis: the role of biological effect modeling for risk assessment of dioxin and tamoxifen. Demby KB, et al. **Prog Clin Biol Res** 1996;394:113-29 (57 ref.)

TANDEM REPEAT see **REPETITIVE SEQUENCES, NUCLEIC ACID**

TANNINS

CHEMISTRY

Hydrolyzable tannins and related polyphenols. Okuda T, et al. **Fortschr Chem Org Naturst** 1995;66:1-117 (266 ref.)

TAPE RECORDING, VIDEO see **VIDEOTAPE RECORDING**

TAPETORETINAL DEGENERATION see **RETINITIS PIGMENTOSA**

TAPEWORM INFECTION see **CESTODE INFECTIONS**

TAPEWORMS see **CESTODA**

TAPIOCA see **CASSAVA**

TARGETED RADIOTHERAPY see **RADIOTHERAPY**

TARGETED TOXINS see **IMMUNOTOXINS**

TARS

THERAPEUTIC USE

Tars and anthralins. Silverman A, et al. **Dermatol Clin** 1995 Oct;13(4):817-33 (137 ref.)

TARSAL BONES

ABNORMALITIES

Tarsal coalitions. Drennan JC. **Instr Course Lect** 1996; 45:323-9 (42 ref.)

INJURIES

Midfoot fractures. Valkosky GJ, et al. **Clin Podiatr Med Surg** 1995 Oct;12(4):773-89 (44 ref.)

RADIOGRAPHY

[Tarsal metastases from breast carcinoma: a case report and review of the literature] Sandomenico F, et al. **Radiol Med (Torino)** 1996 Mar;91(3):306-8 (16 ref.) **(Ita)**

RADIONUCLIDE IMAGING

[Tarsal metastases from breast carcinoma: a case report and review of the literature] Sandomenico F, et al. **Radiol Med (Torino)** 1996 Mar;91(3):306-8 (16 ref.) **(Ita)**

SURGERY

[Hindfoot arthrodesis] Wülker N, et al. **Orthopade** 1996 Apr; 25(2):177-86 (57 ref.) (Eng. Abstr.) **(Ger)**

TARSAL JOINT

ABNORMALITIES

Tarsal coalition. Kulik SA Jr, et al. **Foot Ankle Int** 1996 May; 17(5):286-96 (63 ref.)

INJURIES

Lisfranc's fracture-dislocation. A literature review and case presentations of tarsometatarsal joint injuries. Felder-Johnson KL, et al. **Clin Podiatr Med Surg** 1995 Oct;12(4):565-602 (61 ref.)

TARSAL TUNNEL SYNDROME

Tarsal tunnel syndrome. Finkel JE. **Magn Reson Imaging Clin N Am** 1994 Feb;2(1):67-78 (23 ref.)

TARSUS

see related
TARSAL BONES

PATHOLOGY

Tarsal coalition. Kulik SA Jr, et al. **Foot Ankle Int** 1996 May; 17(5):286–96 (63 ref.)

TARSUS, ANIMAL

INJURIES

Soft tissue injuries of the tarsus. Dik KJ, et al. **Vet Clin North Am Equine Pract** 1995 Aug;11(2):235–47 (25 ref.)

TARSUS OSSEUS see **TARSUS**

TARTRATES

CHEMISTRY

Fenton chemistry: an introduction. Wardman P, et al. **Radiat Res** 1996 May;145(5):523–31 (73 ref.)

TARUI DISEASE see **GLYCOGEN STORAGE DISEASE TYPE VII**

TASK PERFORMANCE AND ANALYSIS

see related
WORKLOAD

Ergonomics for industrially developing countries: an alternative approach. Rubio CA. **J Hum Ergol (Tokyo)** 1995 Jun;24(1):119–23 (3 ref.)

TASTE

Biogenesis of flavour compounds in cheese. Fox PF, et al. **Adv Exp Med Biol** 1995;367:59–98 (302 ref.)

Improving the sensory characteristics of reduced-fat cheese. Mistry VV. **Adv Exp Med Biol** 1995;367:371–82 (19 ref.)

Contribution of lactic acid bacteria to cheese ripening. Steele JL. **Adv Exp Med Biol** 1995;367:209–20 (43 ref.)

Time–temperature effects on microbial, chemical and sensory changes during cooling and aging of cheddar cheese. Torres JA, et al. **Adv Exp Med Biol** 1995;367:123–59 (95 ref.)

Bitterness in cheese: a review. Habibi-Najafi MB, et al. **Crit Rev Food Sci Nutr** 1996 May;36(5):397–411 (98 ref.)

DRUG EFFECTS

Plant-derived triterpenoid sweetness inhibitors. Suttisri R, et al. **J Ethnopharmacol** 1995 Jun 23;47(1):9–26 (109 ref.)

GENETICS

Supertasting, earaches and head injury: genetics and pathology alter our taste worlds. Bartoshuk LM, et al. **Neurosci Biobehav Rev** 1996;20(1):79–87 (64 ref.)

PHYSIOLOGY

Energy intake and sensory properties of food. Drewnowski A. **Am J Clin Nutr** 1995 Nov;62(5 Suppl):1081S–1085S (38 ref.)

Supertasting, earaches and head injury: genetics and pathology alter our taste worlds. Bartoshuk LM, et al. **Neurosci Biobehav Rev** 1996;20(1):79–87 (64 ref.)

Regulation of nutrient intake in humans: a theory based on taste and smell. Poothullil JM. **Neurosci Biobehav Rev** 1995 Fall;19(3):407–12 (61 ref.)

Taste reception. Lindemann B. **Physiol Rev** 1996 Jul; 76(3):718–66 (575 ref.)

The frog taste disc: a prototype of the vertebrate gustatory organ. Osculati F, et al. **Prog Neurobiol** 1995 Jul; 46(4):351–99 (241 ref.)

Molecular mechanisms of gustatory transduction in frog taste cells. Sato T, et al. **Prog Neurobiol** 1995 Jun;46(2–3):239–87 (100 ref.)

Gustatory function in the parabrachial nuclei: implications from lesion studies in rats. Spector AC. **Rev Neurosci** 1995 Apr–Jun;6(2):143–75 (163 ref.)

[Taste sensor] Toko K. **Tanpakushitsu Kakusan Koso** 1995 Sep;40(12):1859–65 (10 ref.) **(Jpn)**

TASTE BUDS

Carbohydrate histochemistry of vertebrate taste organs. Witt M. **Prog Histochem Cytochem** 1996;30(4):1–168 (470 ref.)

PHYSIOLOGY

Taste reception. Lindemann B. **Physiol Rev** 1996 Jul; 76(3):718–66 (575 ref.)

The frog taste disc: a prototype of the vertebrate gustatory organ. Osculati F, et al. **Prog Neurobiol** 1995 Jul; 46(4):351–99 (241 ref.)

TASTE DISORDERS

ETIOLOGY

[Zinc-deficient disorders of sense organs—dark adaptation, taste and smell disorders] Tomita H. **Nippon Rinsho** 1996 Jan;54(1):141–7 (40 ref.) (Eng. Abstr.) **(Jpn)**

TASTE THRESHOLD

Contribution of activity coefficients of methylene homologues to odor and flavor detection thresholds. Yamanaka T. **Chem Senses** 1995 Aug;20(4):471–5 (19 ref.)

TAT GENE PRODUCTS see **GENE PRODUCTS, TAT**

TAT PROTEIN see **GENE PRODUCTS, TAT**

TATA BOX

The TATA box binding protein. Burley SK. **Curr Opin Struct Biol** 1996 Feb;6(1):69–75 (38 ref.)

TATTOOING

Colonic tattooing with India ink: benefits, risks, and alternatives. Nizam R, et al. **Am J Gastroenterol** 1996 Sep; 91(9):1804–8 (26 ref.)

TAU PROTEINS

CEREBROSPINAL FLUID

[Differential diagnosis and diagnostic markers of Alzheimer's disease] Takeda M. **Seishin Shinkeigaku Zasshi** 1995; 97(8):557–66 (4 ref.) **(Jpn)**

CHEMISTRY

Structure, microtubule interactions, and phosphorylation of tau protein. Mandelkow EM, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:96–106 (51 ref.)

On the structure of microtubules, tau, and paired helical filaments. Mandelkow E, et al. **Neurobiol Aging** 1995 May–Jun;16(3):347–54 (57 ref.)

Tau domains, phosphorylation, and interactions with microtubules. Mandelkow EM, et al. **Neurobiol Aging** 1995 May–Jun;16(3):355–62; discussion 362–3 (57 ref.)

IMMUNOLOGY

Neurodegenerative disorders with extensive tau pathology: a comparative study and review. Feany MB, et al. **Ann Neurol** 1996 Aug;40(2):139–48 (93 ref.)

METABOLISM

Regulation of tau phosphorylation in Alzheimer's disease. Lee VM. **Ann N Y Acad Sci** 1996 Jan 17;777:107–13 (37 ref.)

Disruption of the cytoskeleton in Alzheimer's disease. Lee VM. **Curr Opin Neurobiol** 1995 Oct;5(5):663–8 (43 ref.)

Phosphorylation of paired helical filament tau in Alzheimer's disease neurofibrillary lesions: focusing on phosphatases. Trojanowski JQ, et al. **FASEB J** 1995 Dec;9(15):1570–6 (77 ref.)

Mechanisms of neuronal polarity. Cid-Arregui A, et al. **Neurobiol Aging** 1995 May–Jun;16(3):239–43; discussion 243–6 (61 ref.)

Hyperphosphorylation of tau in PHF. Morishima-Kawashima M, et al. **Neurobiol Aging** 1995 May–Jun;16(3):365–71; discussion 371–80 (56 ref.)

Networking with proline-directed protein kinases implicated in tau phosphorylation. Pelech SL. **Neurobiol Aging** 1995 May–Jun;16(3):247–56; discussion 257–61 (135 ref.)

PHYSIOLOGY

Tau protein and the neurofibrillary pathology of Alzheimer's disease. Goedert M. **Ann N Y Acad Sci** 1996 Jan 17; 777:121–31 (26 ref.)

Structure, microtubule interactions, and phosphorylation of tau protein. Mandelkow EM, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:96–106 (51 ref.)

Functional organization of tau proteins during neuronal differentiation and development. Maccioni RB, et al. **Braz J Med Biol Res** 1995 Aug;28(8):827–41 (78 ref.)

New clues to Alzheimer's disease: unraveling the roles of amyloid and tau [comment] Yankner BA. **Nat Med** 1996 Aug;2(8):850–2 (22 ref.) Comment on: Nat Med 1996 Aug;2(8):864–70.

ULTRASTRUCTURE

On the structure of microtubules, tau, and paired helical filaments. Mandelkow E, et al. **Neurobiol Aging** 1995 May–Jun;16(3):347–54 (57 ref.)

TAURINE

ANALOGS & DERIVATIVES

Acamprosate in alcohol dependence: how does it work? Littleton J. **Addiction** 1995 Sep;90(9):1179–88 (42 ref.)

Acamprosate as an aid in the treatment of alcoholism. Chick J. **Alcohol Alcohol** 1995 Nov;30(6):785–7 (17 ref.)

PHARMACOLOGY

Complementary vascular-protective actions of magnesium and taurine: a rationale for magnesium taurate. McCarty MF. **Med Hypotheses** 1996 Feb;46(2):89–100 (136 ref.)

TAURINE CHENODEOXYCHOLATE see **TAUROCHENODEOXYCHOLIC ACID**

TAUROCHENODEOXYCHOLATE see **TAUROCHENODEOXYCHOLIC ACID**

TAUROCHENODEOXYCHOLIC ACID

METABOLISM

TUDCA and UDCA are incorporated into hepatocyte membranes: different sites, but similar effects. Leuschner U, et al. **Ital J Gastroenterol** 1995 Sep;27(7):376–7 (11 ref.)

TAX GENE PRODUCTS see **GENE PRODUCTS, TAX**

TAX GENES see **GENES, PX**

TAX PROTEIN see **GENE PRODUCTS, TAX**

TAXOL see **PACLITAXEL**

TAXONOMY see **CLASSIFICATION**

TAY-SACHS DISEASE

GENETICS

[Recent advances in molecular genetics of GM2 gangliosidosis] Wakamatsu N. **Nippon Rinsho** 1995 Dec; 53(12):2988–93 (21 ref.) (Eng. Abstr.) **(Jpn)**

METABOLISM

GM2 ganglioside and pyramidal neuron dendritogenesis. Walkley SU, et al. **Neurochem Res** 1995 Nov; 20(11):1287–99 (115 ref.)

PREVENTION & CONTROL

[Biochemical, molecular and social aspects of carrier screening for Tay-Sachs disease] Peleg L, et al. **Harefuah** 1995 Dec 1;129(11):475–80 (43 ref.) **(Heb)**

TAY-SACHS DISEASE GANGLIOSIDE see **G(M2) GANGLIOSIDE**

TC-DTPA see **TECHNETIUM TC 99M PENTETATE**

TC 99M-DTPA see **TECHNETIUM TC 99M PENTETATE**

99MTC-HEXAMIBI see **TECHNETIUM TC 99M SESTAMIBI**

TC 99M-PERTECHNETATE see **SODIUM PERTECHNETATE TC 99M**

99MTC-SESTAMIBI see **TECHNETIUM TC 99M SESTAMIBI**

TCDD RECEPTORS see **RECEPTORS, ARYL HYDROCARBON**

TCGF see **INTERLEUKIN-2**

TCR ALPHA-BETA see **RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA**

TCR-CD3 COMPLEX see **RECEPTOR-CD3 COMPLEX, ANTIGEN, T-CELL**

TCR GAMMA-DELTA see **RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA**

TEA

see related
THEOPHYLLINE

Oral cancer and precancer related to betel and miang chewing in Thailand: a review. Reichart PA. **J Oral Pathol Med** 1995 Jul;24(6):241–3 (17 ref.)

CHEMISTRY

Antimicrobial properties of tea (Camellia sinensis L.). Hamilton-Miller JM. **Antimicrob Agents Chemother** 1995 Nov;39(11):2375–7 (48 ref.)

Polyphenols as cancer chemopreventive agents. Stoner GD, et al. **J Cell Biochem Suppl** 1995;22:169–80 (87 ref.)

TEACHING

Interactive journals: an educational strategy to promote reflection. Tryssenaar J. **Am J Occup Ther** 1995 Jul–Aug; 49(7):695–702 (37 ref.)

Graphic format for teaching long-term control of systemic arterial pressure. Faber JJ. **Am J Physiol** 1996 Jun;270(6 Pt 3):S40–9 (22 ref.)

A spinal circuitry simulator as a teaching tool for

neuromuscular physiology. Maw S, et al. **Am J Physiol** 1996 Jun;270(6 Pt 3):S50–68 (25 ref.)
Teacher stress research: problems and progress. Pithers RT. **Br J Educ Psychol** 1995 Dec;65 (Pt 4):387–92 (21 ref.)
Training in the management of critical problems: teacher's view. van Geijn HP, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Mar;65(1):145–8 (10 ref.)
Annotation: contemporary approaches to the teaching of reading. Snowling MJ. **J Child Psychol Psychiatry** 1996 Feb;37(2):139–48 (40 ref.)
[Learning clinical medicine] Lifshitz A. **Gac Med Mex** 1995 Sep–Dec;131(5–6):571–6 (15 ref.) (Eng. Abstr.) **(Spa)**

METHODS

Teaching and learning in ambulatory care settings: a thematic review of the literature. Irby DM. **Acad Med** 1995 Oct; 70(10):898–931 (152 ref.)
Learning and teaching in dermatology. A practitioner's guide. Brodell RT, et al. **Arch Dermatol** 1996 Aug; 132(8):946–52 (85 ref.)
Teaching the social sciences to undergraduate medical students. Benbassat J. **Isr J Med Sci** 1996 Mar–Apr; 32(3–4):217–21 (40 ref.)
Journal writing as a mode of thinking for RN–BSN students: a leveled approach to learning to listen to self and others. Hodges HF. **J Nurs Educ** 1996 Mar;35(3):137–41 (20 ref.)
Morning report and work rounds: opportunities for teaching and learning. Schiffman FJ. **Trans Am Clin Climatol Assoc** 1995;107:275–86 (19 ref.)

STANDARDS

Evaluating teaching effectiveness. Kirschling JM, et al. **J Nurs Educ** 1995 Dec;34(9):401–10 (30 ref.)

TRENDS

The future of gross anatomy teaching. Malamed S, et al. **Clin Anat** 1995;8(4):294–6 (13 ref.)

TEACHING MATERIALS

see related
AUDIOVISUAL AIDS

STANDARDS

Readability of patient education materials: implications for clinical practice. Albright J, et al. **Appl Nurs Res** 1996 Aug; 9(3):139–43 (37 ref.)

TEAR GASES

POISONING

Delayed pulmonary edema and bronchospasm after accidental lacrimator exposure. Vaca FE, et al. **Am J Emerg Med** 1996 Jul;14(4):402–5 (32 ref.)

TEARS

SECRETION

[Analysis of the efficacy of the large mono-canalicular intubation stent in the treatment of lacrimation caused by congenital obstruction of the lacrimal ducts in infants] Ruban JM, et al. **J Fr Ophtalmol** 1995;18(5):377–83 (11 ref.) (Eng. Abstr.) **(Fre)**

TEARS, ARTIFICIAL see **OPHTHALMIC SOLUTIONS**

TEAS, HERBAL see **BEVERAGES**

TEAS, MEDICINAL see **BEVERAGES**

TECHNETIUM

see related
ORGANOTECHNETIUM COMPOUNDS

Is there life after technetium: what is the potential for developing new broad-based radionuclides? Srivastava SC. **Semin Nucl Med** 1996 Apr;26(2):119–31 (78 ref.)

DIAGNOSTIC USE

Radiolabelled peptides: now and the future. Thakur ML. **Nucl Med Commun** 1995 Sep;16(9):724–32 (41 ref.)
Use of polyclonal IgG in HIV infection and AIDS. Buscombe JR, et al. **Q J Nucl Med** 1995 Sep;39(3):212–20 (34 ref.)
[Study on technetium-99m in radiopharmaceuticals] Ding HJ, et al. **Kao Hsiung I Hsueh Ko Hsueh Tsa Chih** 1996 Mar;12(3):132–44 (43 ref.) (Eng. Abstr.) **(Chi)**

HISTORY

Technetium, the missing element. de Jonge FA, et al. **Eur J Nucl Med** 1996 Mar;23(3):336–44 (34 ref.)

TECHNETIUM COMPOUNDS

DIAGNOSTIC USE

Scintigraphy in the evaluation of arthropathy. Tumeh SS. **Radiol Clin North Am** 1996 Mar;34(2):215–31, ix (35 ref.)
[Bone scintigraphy and algodystrophy] Tondeur M, et al. **Rev Med Liege** 1995 Dec;50(12):510–6 (58 ref.) **(Fre)**

TECHNETIUM-DTPA see **TECHNETIUM TC 99M PENTETATE**

TECHNETIUM TC 99M PENTETATE

DIAGNOSTIC USE

Clinical studies of alveolar–capillary permeability using technetium-99m DTPA aerosol. Sundram FX. **Ann Nucl Med** 1995 Nov;9(4):171–8 (26 ref.)
A review of renal scarring in children. MacKenzie JR. **Nucl Med Commun** 1996 Mar;17(3):176–90 (44 ref.)
99mTc DTPA transfer/permeability in patients with HIV disease. O'Doherty MJ. **Q J Nucl Med** 1995 Sep; 39(3):231–42 (60 ref.)

TECHNETIUM TC 99M PERTECHNETATE see **SODIUM PERTECHNETATE TC 99M**

TECHNETIUM TC 99M SESTAMIBI

DIAGNOSTIC USE

Sestamibi parathyroid imaging. McBiles M, et al. **Semin Nucl Med** 1995 Jul;25(3):221–34 (62 ref.)
Applications of 99mTc-sestamibi in oncology. Maffioli L, et al. **Tumori** 1996 Jan–Feb;82(1):12–21 (59 ref.)
[Nuclear medical breast diagnosis—scintigraphy using 99mTc-sestamibi (editorial)] Hahn K. **Nuklearmedizin** 1996 Jun;35(3):4–6 (28 ref.) **(Ger)**
[Image diagnosis of heart diseases using new radioisotope compounds] Nishimural T. **Nippon Naika Gakkai Zasshi** 1995 Sep 10;84(9):1564–8 (8 ref.) **(Jpn)**

TECHNOLOGY

STANDARDS

Consumer concerns about modern technology in agriculture: considerations for undergraduate and graduate teaching. Weber GM, et al. **J Anim Sci** 1995 Sep;73(9):2727–32 (16 ref.)

TRENDS

Technology, deskilling, and nurses: the impact of the technologically changing environment. Rinard RG. **ANS Adv Nurs Sci** 1996 Jun;18(4):60–9 (49 ref.)

TECHNOLOGY ASSESSMENT, BIOMEDICAL

Cochlear implants: it's time to rethink [editorial] [see comments] House WF. **Am J Otol** 1994 Sep;15(5):573–87 (31 ref.) Comment in: Am J Otol 1995 Jan;16(1):118–9; discussion 119–20. Comment in: Am J Otol 1995 Jan;16(1):120–1; discussion 122–3. Comment in: Am J Otol 1995 Jan;16(1):121–2; discussion 122–3. Comment in: Am J Otol 1995 Jan;16(1):123–4. Comment in: Am J Otol 1995 May;16(3):399–402.
Technology assessment: a Canadian perspective. Byrick RJ. **Can J Anaesth** 1996 May;43(5 Pt 2):R108–15 (20 ref.) **(Eng, Fre)**
Technology assessment in laparoscopic general surgery and gastrointestinal endoscopy: science or convenience? Bouchard S, et al. **Gastroenterology** 1996 Mar;110(3):915–25 (110 ref.)
Bone densitometry: patients with end-stage renal disease. Erlichman M, et al. **Health Technol Assess** 1996 Mar; (8):1–27 (174 ref.)
Plethysmography: safety, effectiveness, and clinical utility in diagnosing vascular disease. Graham AA. **Health Technol Assess** 1996;(7):1–46 (182 ref.)
Autologous peripheral stem-cell transplantation. Handelsman H. **Health Technol Assess** 1995 Aug;(5):1–16 (196 ref.)
Simultaneous pancreas-kidney and sequential pancreas-after-kidney transplantation. Holohan TV. **Health Technol Assess** 1995 Aug;(4):1–53 (110 ref.)
Prostheses for primary total hip replacement. A critical appraisal of the literature. Cowley DE. **Int J Technol Assess Health Care** 1995 Fall;11(4):770–8 (34 ref.)
Transcutaneous electrical nerve stimulation (TENS): a technology assessment. Reeve J, et al. **Int J Technol Assess Health Care** 1996 Spring;12(2):299–324 (96 ref.)
Technology seduction: lost opportunities in child health? Stanley FJ, et al. **J Paediatr Child Health** 1995 Aug; 31(4):302–6 (26 ref.)
Assessment: Clinical autonomic testing report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. **Neurology** 1996 Mar;46(3):873–80 (101 ref.)
Assessment of brain SPECT. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. **Neurology** 1996 Jan;46(1):278–85 (27 ref.)
Automated lamellar keratoplasty. American Academy of Ophthalmology [see comments] **Ophthalmology** 1996 May; 103(5):852–61 (15 ref.) Comment in: **Ophthalmology** 1996 May;103(5):703–4.
Families of young technology-dependent children and the social worker. Bradley RH, et al. **Soc Work Health Care** 1995;21(1):23–37 (41 ref.)

ECONOMICS

The role of perspective in defining economic measures for the evaluation of medical technology. Davidoff AJ, et al. **Int J Technol Assess Health Care** 1996 Winter;12(1):9–21 (28 ref.)
Technology and surgery. Dilemma of the gimmick, true advances, and cost effectiveness. Traverso LW. **Surg Clin North Am** 1996 Feb;76(1):129–38 (10 ref.)

METHODS

A model for technology assessment as applied to closed loop infusion systems. Technology Assessment Task Force of the Society of Critical Care Medicine. Jastremski M, et al. **Crit Care Med** 1995 Oct;23(10):1745–55 (105 ref.)
Investing in health wisely. The role of needs-based technology assessment. Jamison DT, et al. **Int J Technol Assess Health Care** 1995 Fall;11(4):673–84 (6 ref.)
Health transition and needs-based technology planning and implementation. Sitthi-Amorn C. **Int J Technol Assess Health Care** 1995 Fall;11(4):663–72 (44 ref.)
Technology assessment. Old, new, and needs-based. Tugwell P, et al. **Int J Technol Assess Health Care** 1995 Fall; 11(4):650–62 (39 ref.)
Technology assessment methods for radiology systems. Langlotz CP, et al. **Radiol Clin North Am** 1996 May; 34(3):667–79 (35 ref.)
Tools of the trade: analyzing technology as object in nursing. Sandelowski M. **Sch Inq Nurs Pract** 1996 Spring;10(1):5–16; discussion 17–21 (79 ref.)

TECHNOLOGY, FOOD see **FOOD TECHNOLOGY**

TECHNOLOGY, MEDICAL

see related
DIAGNOSIS, LABORATORY

Technology and home care. Smith CE. **Annu Rev Nurs Res** 1995;13:137–67 (234 ref.)
Principles of development and design of microsystems. Wagner B. **Endosc Surg Allied Technol** 1995 Aug;3(4):204–9 (26 ref.)
The impact of the technological care environment on the nursing role. Pelletier D, et al. **Int J Technol Assess Health Care** 1996 Spring;12(2):358–66 (81 ref.)
Technology and the lifeworld of critical care nursing. Walters AJ. **J Adv Nurs** 1995 Aug;22(2):338–46 (26 ref.)
The application of engineering and technology in the management of diabetes. Claremont DJ. **J Med Eng Technol** 1995 Nov–Dec;19(6):205–10 (64 ref.)

ECONOMICS

How to evaluate and implement new technologies in an era of managed care and cost containment. Koch DD. **Clin Chem** 1996 May;42(5):797–802 (34 ref.)
The economics of reimbursement and technological change in cancer care [see comments] Kesteloot K. **Eur J Cancer** 1995;31A(9):1406–9 (22 ref.) Comment in: Eur J Cancer 1995;31A(9):1387.

METHODS

Magnetic resonance elastography. Muthupillai R, et al. **Nat Med** 1996 May;2(5):601–3 (16 ref.)

TRENDS

Technological trends in clinical laboratory science. Burtis CA. **Clin Biochem** 1995 Jun;28(3):213–9 (77 ref.)
Public health implications of emerging vaccine technologies. Lawrence DN, et al. **Pharm Biotechnol** 1995;6:43–60 (48 ref.)

TECHNOLOGY, PHARMACEUTICAL

Overview of the newer antibiotics. Lea AS. **Proc Annu Meet Med Sect Am Counc Life Insur** 1995; :109–17 (0 ref.)
Strategies for production of pharmaceutical proteins in milk. Wilmut I, et al. **Reprod Fertil Dev** 1994;6(5):625–30 (51 ref.)
The production of pharmaceutical proteins from the milk of transgenic animals. Houdebine LM. **Reprod Nutr Dev** 1995;35(6):609–17 (64 ref.)

METHODS

[The way to long-term ambient temperature stabilization of biologicals—freeze-drying and evaporative-drying with vitrification] Franks F, et al. **Tanpakushitsu Kakusan Koso** 1996 May;41(6):810–6 (13 ref.) **(Jpn)**

TECHNOLOGY, PHARMACEUTICAL

TRENDS

The Leon Golberg Memorial Lecture. Structural molecular biology and drug discovery. Blundell TL. **Food Chem Toxicol** 1995 Nov;33(11):979–85 (33 ref.)

TECHNOLOGY, RADIOLOGIC

Image acquisition. Sites, technologies, and approaches. Horii SC. **Radiol Clin North Am** 1996 May;34(3):469–94 (56 ref.)

[The physician–patient relationship and sophisticated modern technology] Wenz W. **Rontgenpraxis** 1995 Aug; 48(8):238–44 (21 ref.) **(Ger)**

[Imaging science and technology in diagnostic radiology: expectations in the second century of Roentgen's discography of X-rays] Doi K. **Nippon Igaku Hoshasen Gakkai Zasshi** 1995 Oct; 55(13):475–86 (42 ref.) (Eng. Abstr.) **(Jpn)**

EDUCATION

Postpositivist methodology and clinical education. Baird M. **Radiol Technol** 1995 Sep–Oct;67(1):15–23 (86 ref.)

METHODS

Invited review: computer aids for decision-making in diagnostic radiology—a literature review. Taylor P. **Br J Radiol** 1995 Sep;68(813):945–57 (55 ref.)

The current state of the art in three dimensional oncologic imaging: an overview. Kuszyk BS, et al. **Int J Radiat Oncol Biol Phys** 1995 Dec 1;33(5):1029–39 (79 ref.)

TRENDS

[An opinion regarding diagnostic radiology in new century] Kono M. **Nippon Igaku Hoshasen Gakkai Zasshi** 1995 Oct; 55(13):467–74 (9 ref.) (Eng. Abstr.) **(Jpn)**

TECHNOLOGY TRANSFER

The irruption of new technologies: a new challenge for ergonomics and anthropotechnology. Wisner A. **J Hum Ergol (Tokyo)** 1995 Jun;24(1):45–55 (30 ref.)

Reviewing the behavioral science knowledge base on technology transfer. Introduction. Backer TE, et al. **NIDA Res Monogr** 1995;155:1–20 (23 ref.)

Assessing and enhancing readiness for change: implications for technology transfer. Backer TE. **NIDA Res Monogr** 1995;155:21–41 (40 ref.)

Synthesis of behavioral science learnings about technology transfer. Backer TE, et al. **NIDA Res Monogr** 1995; 155:262–79 (2 ref.)

Reducing impediments to technology transfer in drug abuse programming. Brown BS. **NIDA Res Monogr** 1995; 155:169–85 (38 ref.)

Organizational change as human process, not technique. Diamond MA. **NIDA Res Monogr** 1995;155:119–31 (10 ref.)

Technology transfer in the criminal justice field: implications for substance abuse. Gendreau P. **NIDA Res Monogr** 1995; 155:198–208 (35 ref.)

Collaboration and diversity in technology transfer. Kavanagh KH. **NIDA Res Monogr** 1995;155:42–64 (81 ref.)

Transferring research findings on persuasion to improve drug abuse prevention programs. McGuire WJ. **NIDA Res Monogr** 1995;155:225–45 (8 ref.)

Technology transfer as collaborative learning. Tenkasi RV, et al. **NIDA Res Monogr** 1995;155:147–68 (53 ref.)

TECTUM MESENCEPHALI see CORPORA QUADRIGEMINA

TEDELPARIN

METABOLISM

Microfilament dynamics: regulation of actin polymerization by actin-fragmin kinase and phosphatases. Waelkens E, et al. **Adv Enzyme Regul** 1995;35:199–227 (60 ref.)

TEENAGE PREGNANCY see PREGNANCY IN ADOLESCENCE

TEFLON see POLYTETRAFLUOROETHYLENE

TEGAFUR

THERAPEUTIC USE

Clinical development of new fluoropyrimidines: a major improvement in colorectal cancer treatment? Colleoni M, et al. **Tumori** 1995 Sep–Oct;81(5):303–7 (44 ref.)

TEGMENTUM MESENCEPHALI

PATHOLOGY

Motor neuron disease with involvement of the pallido-luysio-nigral system and mesencephalic tegmentum. Kato S, et al. **Clin Neuropathol** 1995 Jul–Aug; 14(4):241–4 (15 ref.)

PHYSIOLOGY

The pedunculopontine tegmental nucleus: where the striatum meets the reticular formation. Inglis WL, et al. **Prog Neurobiol** 1995 Sep;47(1):1–29 (205 ref.)

TEICHOMYCIN see TEICOPLANIN

TEICOPLANIN

ADVERSE EFFECTS

A risk–benefit assessment of teicoplanin in the treatment of infections. de Lalla F, et al. **Drug Saf** 1995 Nov; 13(5):317–28 (74 ref.)

THERAPEUTIC USE

A risk–benefit assessment of teicoplanin in the treatment of infections. de Lalla F, et al. **Drug Saf** 1995 Nov; 13(5):317–28 (74 ref.)

The comparative efficacy and safety of teicoplanin and vancomycin. Wood MJ. **J Antimicrob Chemother** 1996 Feb; 37(2):209–22 (27 ref.)

TELANGIECTASIA, HEREDITARY HEMORRHAGIC

Hereditary hemorrhagic telangiectasia (Osler–Weber–Rendu disease): new insights in pathogenesis, complications, and treatment. Haitjema T, et al. **Arch Intern Med** 1996 Apr 8;156(7):714–9 (99 ref.)

[Hereditary hemorrhagic telangiectasia (HHT)] Suda T, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):288–90 (20 ref.) **(Jpn)**

COMPLICATIONS

[Ischemic cerebrovascular complications in Rendu–Osler disease: a case] Albucher JF, et al. **Rev Neurol (Paris)** 1996 Apr;152(4):283–7 (11 ref.) (Eng. Abstr.) **(Fre)**

[Ictus and cutaneous vascular syndromes] Trejo Gabriel y Galán JM. **Rev Neurol** 1995;23 Suppl 1:S99–105 (46 ref.) **(Spa)**

THERAPY

[A patient with Rendu–Osler–Weber disease and pulmonary arteriovenous malformations treated satisfactorily by embolization] Martín Díaz E, et al. **Arch Bronconeumol** 1996 Jun–Jul;32(6):307–9 (12 ref.) (Eng. Abstr.) **(Spa)**

TELANGIECTASIS

THERAPY

Ambulatory phlebectomy compared to sclerotherapy for varicose and telangiectatic veins: indications and complications. Weiss RA, et al. **Adv Dermatol** 1996;11:3–16; discussion 17 (37 ref.)

TELECOMMUNICATION NETWORKS see COMPUTER COMMUNICATION NETWORKS

TELECOMMUNICATIONS, SATELLITE see SATELLITE COMMUNICATIONS

TELEMEDICINE

Recent progress in digital image formatting and current trends in computers: their role in digital image storage and telemedicine. Commentary. Thomas JD. **Curr Opin Cardiol** 1995 Nov;10(6):615–8 (14 ref.)

Teleradiology and telemedicine. Goldberg MA. **Radiol Clin North Am** 1996 May;34(3):647–65 (101 ref.)

LEGISLATION & JURISPRUDENCE

The virtual health economy: telemedicine and the supply of primary care physicians in rural America. McCarthy D. **Am J Law Med** 1995;21(1):111–30 (176 ref.)

METHODS

The Internet and the pediatrician: should there be a connection? Fikar CR. **Clin Pediatr (Phila)** 1996 May; 35(5):229–35 (19 ref.)

ORGANIZATION & ADMINISTRATION

Telematics in healthcare. Beltrame F, et al. **Technol Health Care** 1996 Apr;4(1):3–8 (4 ref.)

TELEMETRY

see related
TELEMEDICINE

TELENCEPHALON

[Telencephalon-specific cell adhesion molecule, telencephalin] Yoshihara Y, et al. **Tanpakushitsu Kakusan Koso** 1996 May;41(6):766–74 (36 ref.) **(Jpn)**

TELEOLOGICAL ETHICS see ETHICS

TELEPATHOLOGY

How is telepathology being used to improve patient care? Weinberg DS. **Clin Chem** 1996 May;42(5):831–5 (20 ref.)

TELERADIOLOGY

Imaging system architectures for picture archiving and communication systems. Dwyer SJ 3rd. **Radiol Clin North Am** 1996 May;34(3):495–503 (43 ref.)

Teleradiology and telemedicine. Goldberg MA. **Radiol Clin North Am** 1996 May;34(3):647–65 (101 ref.)

Portable chest radiography techniques and teleradiology. MacMahon H, et al. **Radiol Clin North Am** 1996 Jan; 34(1):1–20 (53 ref.)

Teleradiology: the practice of radiology enters Cyberspace. Coons T. **Radiol Technol** 1995 Nov–Dec;67(2):125–40; quiz 141–4 (33 ref.)

LEGISLATION & JURISPRUDENCE

Medical–legal issues in teleradiology [see comments] Berger SB, et al. **AJR Am J Roentgenol** 1996 Mar;166(3):505–10 (36 ref.) Comment in: AJR Am J Roentgenol 1996 Mar;166(3):511–2.

TELEVISION

Television viewing as a cause of increasing obesity among children in the United States, 1986–1990. Gortmaker SL, et al. **Arch Pediatr Adolesc Med** 1996 Apr;150(4):356–62 (40 ref.)

Growing up in a socially toxic environment: life for children and families in the 1990s. Garbarino J. **Nebr Symp Motiv** 1995;42:1–20 (37 ref.)

[TV and sedentary life result in more overweight people] Sjöström L. **Lakartidningen** 1996 Jan 17;93(3):167–70 (37 ref.) **(Swe)**

TELOMERASE

[Cellular senescence, cancer and telomerase] Suzuki M, et al. **Tanpakushitsu Kakusan Koso** 1996 Mar;41(3):220–7 (24 ref.) **(Jpn)**

ANTAGONISTS & INHIBITORS

Telomeres, telomerase and cancer: is the magic bullet real? Sharma HW, et al. **Anticancer Res** 1996 Jan–Feb; 16(1):511–5 (32 ref.)

Do telomerase antagonists represent a novel anti-cancer strategy? [editorial] Parkinson EK. **Br J Cancer** 1996 Jan; 73(1):1–4 (47 ref.)

METABOLISM

Telomeres, telomerase and cancer: is the magic bullet real? Sharma HW, et al. **Anticancer Res** 1996 Jan–Feb; 16(1):511–5 (32 ref.)

Telomerase, cell immortality, and cancer. Harley CB, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:307–15 (72 ref.)

Telomeres and telomerase in human leukemias. Shay JW, et al. **Leukemia** 1996 Aug;10(8):1255–61 (59 ref.)

Telomere dynamics and telomerase activation in tumor progression: prospects for prognosis and therapy. Healy KC. **Oncol Res** 1995;7(3–4):121–30 (84 ref.)

[Telomerase] Ide T, et al. **Gan To Kagaku Ryoho** 1996 Feb; 23(3):247–56 (29 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

Endless quest. Holliday R. **Bioessays** 1996 Jan;18(1):3–5 (26 ref.)

TELOMERE

Endless quest. Holliday R. **Bioessays** 1996 Jan;18(1):3–5 (26 ref.)

Partial deletion 11q: report of a case with a large terminal deletion 11q21–qter without loss of telomeric sequences, and review of the literature. Hertz JM, et al. **Clin Genet** 1995 May;47(5):231–5 (19 ref.)

Models of initiation of replicative senescence by loss of telomeric DNA. Allsopp RC. **Exp Gerontol** 1996 Jan–Apr; 31(1–2):235–43 (47 ref.)

From telomere loss to p53 induction and activation of a DNA–damage pathway at senescence: the telomere loss/DNA damage model of cell aging. Vaziri H, et al. **Exp Gerontol** 1996 Jan–Apr;31(1–2):295–301 (42 ref.)

Telomeres and telomerase in human leukemias. Shay JW, et al. **Leukemia** 1996 Aug;10(8):1255–61 (59 ref.)

[Biochemical aspects of the telomere] Matsuura A, et al. **Seikagaku** 1996 Apr;68(4):295–9 (15 ref.) **(Jpn)**

[Structure of four-stranded telomeric DNA] Shida T. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1578–82 (27 ref.) **(Jpn)**

CHEMISTRY

Telomere structure and function. Rhodes D, et al. **Curr Opin Struct Biol** 1995 Jun;5(3):311–22 (83 ref.)

GENETICS

[Gene expression during replicative senescence] Ide T. **Tanpakushitsu Kakusan Koso** 1996 Mar;41(3):228–36 (57

ref.) (Jpn)

PHYSIOLOGY

Telomeres, telomerase and cancer: is the magic bullet real? Sharma HW, et al. **Anticancer Res** 1996 Jan-Feb; 16(1):511-5 (32 ref.)
Telomere dynamics and telomerase activation in tumor progression: prospects for prognosis and therapy. Healy KC. **Oncol Res** 1995;7(3-4):121-30 (84 ref.)
Telomeres: beginning to understand the end. Zakian VA. **Science** 1995 Dec 8;270(5242):1601-7 (147 ref.)

TEMPERAMENT

Trends in research on temperament. Bates JE, et al. **Psychiatr Serv** 1995 Jul;46(7):661-3 (21 ref.)

PHYSIOLOGY

The psychobiological regulation of social cooperation [comment] Cloninger CR. **Nat Med** 1995 Jul;1(7):623-5 (21 ref.) Comment on: Nat Med 1995 Jul;1(7):654-7.

TEMPERANCE

PSYCHOLOGY

Controlled drinking after 25 years: how important was the great debate? [editorial] Sobell MB, et al. **Addiction** 1995 Sep;90(9):1149-53; discussion 1157-77 (28 ref.)

TEMPERATURE

see related
BODY TEMPERATURE

Thermal aspects of vehicle comfort. Holmér I, et al. **Appl Human Sci** 1995 Jul;14(4):159-65 (19 ref.)
Role of membrane lipids in temperature acclimatization of carp. Buda C, et al. **Arch Tierernahr** 1996;49(1):61-2 (7 ref.)
On modeling changes in food and biosolids at and around their glass transition temperature range. Peleg M. **Crit Rev Food Sci Nutr** 1996 Jan;36(1-2):49-67 (37 ref.)
Fluid needs in hot and cold environments. Murray R. **Int J Sport Nutr** 1995 Jun;5 Suppl:S62-73 (51 ref.)
Vitamin retention in cook/chill and cook/hot-hold hospital food-services. Williams PG. **J Am Diet Assoc** 1996 May; 96(5):490-8; quiz 499-500 (78 ref.)
Recent developments and concepts in the cryopreservation of spermatozoa and the assessment of their post-thawing function. Watson PF. **Reprod Fertil Dev** 1995;7(4):871-91 (155 ref.)
[Cell cycle analysis of temperature sensitive mutants for cell growth] Nishimoto T. **Hum Cell** 1995 Sep;8(3):89-94 (20 ref.) (Eng. Abstr.) (Jpn)

TEMPLATES

What is the orientation of DNA polymerases on their templates? Hughes SH, et al. **J Virol** 1996 May; 70(5):2679-83 (34 ref.)

TEMPORAL ARTERIES

INJURIES

Traumatic pseudoaneurysm of the superficial temporal artery associated with facial nerve palsy. Lalak NJ, et al. **J Cardiovasc Surg (Torino)** 1996 Apr;37(2):119-23 (54 ref.)

PHYSIOPATHOLOGY

[Cerebrovascular diseases and non-infectious inflammatory arteriopathies] Vivancos F, et al. **Rev Neurol** 1995;23 Suppl 1:S22-32 (84 ref.) (Spa)

SURGERY

[Superficial temporal artery to superior cerebellar artery anastomosis via the presigmoid retrolabyrinthine transtentorial approach] Ito M, et al. **No Shinkei Geka** 1995 Oct;23(10):869-74 (20 ref.) (Jpn)

TEMPORAL ARTERITIS

see related
POLYMYALGIA RHEUMATICA

Polymyalgia rheumatica and giant cell arteritis. Cimmino MA, et al. **Baillieres Clin Rheumatol** 1995 Aug;9(3):515-27 (60 ref.)
Giant cell arteritis. Nordborg E, et al. **Rheum Dis Clin North Am** 1995 Nov;21(4):1013-26 (91 ref.)
[Giant cell arteritis. A study of 191 patients] Armona J, et al. **Med Clin (Barc)** 1995 Dec 2;105(19):734-7 (34 ref.) (Eng. Abstr.) (Spa)

COMPLICATIONS

Survival after aortic dissection in giant cell arteritis [letter] Richardson MP, et al. **Ann Rheum Dis** 1996 May; 55(5):332-3 (20 ref.)
Facial edema and giant cell arteritis. Plantin P, et al. **Rev Rhum Engl Ed** 1996 Feb;63(2):145-7 (13 ref.)
[Inflammatory pseudotumor of the intestine caused by necrotizing vasculitis in the course of Horton disease] Fontaney F, et al. **Gastroenterol Clin Biol** 1995 Nov; 19(11):940-3 (25 ref.) (Eng. Abstr.) (Fre)
[Multiple gangrenous lesions of the scalp in a case of cranial arteritis] Tomasina C, et al. **Minerva Med** 1995 May; 86(5):233-5 (12 ref.) (Eng. Abstr.) (Ita)

DIAGNOSIS

[An atypical presentation of a case of Horton's giant-cell arteritis] Grignetti M, et al. **Minerva Med** 1995 Dec; 86(12):551-3 (11 ref.) (Eng. Abstr.) (Ita)
[Non-giant cell temporal arteritis as a manifestation of Churg-Strauss syndrome. Presentation of a case and review of literature] Serrano-Castro PJ, et al. **Neurologia** 1996 Feb; 11(2):82-4 (16 ref.) (Eng. Abstr.) (Spa)

ETIOLOGY

The aetiopathogenesis of giant cell arteritis. Stevens RJ, et al. **Br J Rheumatol** 1995 Oct;34(10):960-5 (121 ref.)
[Primary AL-type amyloidosis disclosed by Horton disease] Tron AM, et al. **Rev Med Interne** 1995;16(11):850-3 (16 ref.) (Eng. Abstr.) (Fre)

IMMUNOLOGY

Giant cell arteritis as an antigen-driven disease. Weyand CM, et al. **Rheum Dis Clin North Am** 1995 Nov;21(4):1027-39 (43 ref.)

TEMPORAL BONE

see related
LABYRINTH

Fibrous dysplasia of the temporal bone: ten new cases demonstrating the spectrum of otologic sequelae. Megerian CA, et al. **Am J Otol** 1995 Jul;16(4):408-19 (49 ref.)
Medullary carcinoma of the thyroid metastatic to the temporal bone. Redleaf MI, et al. **J Laryngol Otol** 1995 Dec;109(12):1200-3 (15 ref.)

PATHOLOGY

Primary non-Hodgkin's lymphoma of the temporal bone. Bockmühl U, et al. **Eur Arch Otorhinolaryngol** 1995; 252(6):376-8 (16 ref.)
Low-grade papillary adenomatous tumors of the temporal bone: report of two cases and review of the literature. Lavoie M, et al. **Mod Pathol** 1995 Aug;8(6):603-8 (17 ref.)
Temporal bone imaging. Casselman JW. **Neuroimaging Clin N Am** 1996 May;6(2):265-89 (51 ref.)
Magnetic resonance imaging in the evaluation of Langerhans' cell histiocytosis of the temporal bone: case report. Angeli SI, et al. **Otolaryngol Head Neck Surg** 1996 Jan; 114(1):120-4 (25 ref.)

RADIATION EFFECTS

Effects of cranial irradiation on hearing acuity: a review of the literature. Sataloff RT, et al. **Am J Otol** 1994 Nov; 15(6):772-80 (28 ref.)

RADIOGRAPHY

Temporal bone imaging. Casselman JW. **Neuroimaging Clin N Am** 1996 May;6(2):265-89 (51 ref.)

SURGERY

The use of the temporoparietal fascial flap in temporal bone reconstruction. Cheney ML, et al. **Am J Otol** 1996 Jan; 17(1):137-42 (11 ref.)
[Using temporal bone artificial implantation for the fixation of external ear prosthesis] Chen X, et al. **Chung Hua Cheng Hsing Shao Shang Wai Ko Tsa Chih** 1995 Sep;11(5):379-81 (15 ref.) (Chi)

TEMPORAL LOBE

Neuropsychological aspects of frontotemporal degeneration. Neary D. **Ann N Y Acad Sci** 1995 Dec 15;769:15-22 (31 ref.)

ANATOMY & HISTOLOGY

Anatomy of the medial temporal lobe. Van Hoesen GW. **Magn Reson Imaging** 1995;13(8):1047-55 (54 ref.)

BLOOD SUPPLY

Isolated cerebral intraaxial varix. Kelly KJ, et al. **AJNR Am J Neuroradiol** 1995 Sep;16(8):1633-5 (10 ref.)

METABOLISM

[N-acetyl-aspartate abnormalities in internal-temporal epileptic foci using proton magnetic resonance spectroscopy] Giroud M, et al. **Rev Neurol (Paris)** 1995 Jun-Jul;151(6-7):404-9 (28 ref.) (Eng. Abstr.) (Fre)

PATHOLOGY

The new neuropathology of degenerative frontotemporal dementias. Jackson M, et al. **Acta Neuropathol (Berl)** 1996; 91(2):127-34 (38 ref.)
Frontotemporal dementia: a clinicopathological review of four postmortem studies. Hooten WM, et al. **J Neuropsychiatry Clin Neurosci** 1996 Winter;8(1):10-9 (65 ref.)

PHYSIOLOGY

Personality, emotions and the temporolimbic system: a neuropsychological approach. Beeckmans K, et al. **Acta Neurol Belg** 1996 Mar;96(1):35-42 (51 ref.)
The representation of shape in the temporal lobe. Gochin PM. **Behav Brain Res** 1996 Apr;76(1-2):99-116 (155 ref.)
Stimulus specific adaptation in inferior temporal and medial temporal cortex of the monkey. Ringo JL. **Behav Brain Res** 1996 Apr;76(1-2):191-7 (39 ref.)
Perception and memory: action and interaction. Eacott MJ, et al. **Crit Rev Neurobiol** 1995;9(4):311-20 (50 ref.)
The brain's visual world: representation of visual targets in cerebral cortex. Maunsell JH. **Science** 1995 Nov 3; 270(5237):764-9 (43 ref.)

PHYSIOPATHOLOGY

Sleep and the temporal lobe. Van Sweden B. **Acta Neurol Belg** 1996 Mar;96(1):19-30 (20 ref.)
Perception, learning and identification studied with reversible suppression of cortical visual areas in monkeys. Horel JA. **Behav Brain Res** 1996 Apr;76(1-2):199-214 (90 ref.)
The effects of visual cortex lesions on the perception of rotated shapes. Walsh V, et al. **Behav Brain Res** 1996 Apr; 76(1-2):127-42 (75 ref.)
Schizophrenia: a disconnection syndrome? Friston KJ, et al. **Clin Neurosci** 1995;3(2):89-97 (61 ref.)
Brief report: medial temporal lobe and autism: a putative animal model in primates. Bachevalier J. **J Autism Dev Disord** 1996 Apr;26(2):217-20 (5 ref.)
Application of high field spectroscopic imaging in the evaluation of temporal lobe epilepsy. Hetherington HP, et al. **Magn Reson Imaging** 1995;13(8):1175-80 (14 ref.)
Photosensitive temporal lobe epilepsy. Benbadis SR, et al. **Neurology** 1996 Jun;46(6):1540-2 (10 ref.)

SURGERY

MRI hippocampal volume and neuropsychology in epilepsy surgery. Trenerry MR, et al. **Magn Reson Imaging** 1995; 13(8):1125-32 (47 ref.)
Intracarotid amobarbital procedure. The Wada test. Trenerry MR, et al. **Neuroimaging Clin N Am** 1995 Nov;5(4):721-8 (41 ref.)
Arteriovenous malformation associated with a large cyst--case report. Hatashita S, et al. **Neurol Med Chir (Tokyo)** 1995 Jun;35(6):377-9 (8 ref.)
[Temporal lobectomy: indications and role in the surgery of epilepsy] Benbadis S, et al. **Rev Med Interne** 1995; 16(8):626-35 (40 ref.) (Eng. Abstr.) (Fre)

TEMPORAL MUSCLE

Hemangioma of the temporalis muscle: a case report and review of the literature. Lopez-Cedrun JL, et al. **J Oral Maxillofac Surg** 1996 Sep;54(9):1130-2 (15 ref.)

TEMPOROMANDIBULAR JOINT

see related
CENTRIC RELATION

ANATOMY & HISTOLOGY

Function, biochemistry, and metabolism of the normal synovial membrane of the temporomandibular joint: a review of the literature. Dijkgraaf LC, et al. **J Oral Maxillofac Surg** 1996 Jan;54(1):95-100 (25 ref.)
Structure of the normal synovial membrane of the temporomandibular joint: a review of the literature. Dijkgraaf LC, et al. **J Oral Maxillofac Surg** 1996 Mar; 54(3):332-8 (30 ref.)

INJURIES

Intracranial reduction of an intact mandibular condyle displaced into the middle cranial fossa. Sandler NA, et al. **J Oral Maxillofac Surg** 1996 Apr;54(4):506-10 (17 ref.)
Internal derangement and the accessory ligaments around the temporomandibular joint. Osborn JW. **J Oral Rehabil** 1995 Oct;22(10):731-40 (33 ref.)

PATHOLOGY

Current trends in temporomandibular joint imaging. Larheim TA. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1995 Nov;80(5):555-76 (176 ref.)

PHYSIOPATHOLOGY

Internal derangement and the accessory ligaments around the temporomandibular joint. Osborn JW. **J Oral Rehabil** 1995 Oct;22(10):731-40 (33 ref.)

TEMPOROMANDIBULAR JOINT DISEASES

Temporomandibular joint imaging. Payne M, et al. **Clin Radiol** 1996 Jan;51(1):1-10 (54 ref.)

TEMPOROMANDIBULAR JOINT DISEASES

DIAGNOSIS

Temporomandibular disorders. 1. Clinical evaluation. Dimitroulis G, et al. **Aust Dent J** 1995 Oct;40(5):301–5 (30 ref.)

Pigmented villonodular synovitis of the temporomandibular joint. Youssef RE, et al. **J Oral Maxillofac Surg** 1996 Feb; 54(2):224–7 (22 ref.)

Temporomandibular joint and dental imaging. Westesson PL. **Neuroimaging Clin N Am** 1996 May;6(2):333–55 (31 ref.)

Current trends in temporomandibular joint imaging. Larheim TA. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1995 Nov;80(5):555–76 (176 ref.)

Imaging of the temporomandibular joint. Rao VM. **Semin Ultrasound CT MR** 1995 Dec;16(6):513–26 (53 ref.)

EPIDEMIOLOGY

Prevalence of temporomandibular joint dysfunction (TMJD) in Chinese children and adolescents. A cross-sectional epidemiological study. Deng YM, et al. **Eur J Orthod** 1995 Aug;17(4):305–9 (31 ref.)

ETIOLOGY

Pathogenesis of degenerative joint disease in the human temporomandibular joint. Haskin CL, et al. **Crit Rev Oral Biol Med** 1995;6(3):248–77 (359 ref.)

Concurrent osteochondroma of the mandibular condyle and ipsilateral cranial base resulting in temperomandibular joint ankylosis: report of a case and review of the literature. Karras SC, et al. **J Oral Maxillofac Surg** 1996 May; 54(5):640–6 (27 ref.)

Molecular biology of temporomandibular joint disorders: proposed mechanisms of disease. Milam SB, et al. **J Oral Maxillofac Surg** 1995 Dec;53(12):1448–54 (96 ref.)

Meniscal disorders. Orbach S. **N Y State Dent J** 1996 Apr; 62(4):24–31 (0 ref.)

METABOLISM

The structure, biochemistry, and metabolism of osteoarthritic cartilage: a review of the literature. Dijkgraaf LC, et al. **J Oral Maxillofac Surg** 1995 Oct;53(10):1182–92 (36 ref.)

PATHOLOGY

Inflammatory synovial cyst of the temporomandibular joint: a case report and review of the literature. Bonacci CE, et al. **J Oral Maxillofac Surg** 1996 Jun;54(6):769–73 (22 ref.)

The structure, biochemistry, and metabolism of osteoarthritic cartilage: a review of the literature. Dijkgraaf LC, et al. **J Oral Maxillofac Surg** 1995 Oct;53(10):1182–92 (36 ref.)

PHYSIOPATHOLOGY

A re-evaluation of the importance of disc position in temporomandibular disorders. Dolwick MF, et al. **Aust Dent J** 1996 Jun;41(3):184–7 (46 ref.)

Internal derangement and the accessory ligaments around the temporomandibular joint. Osborn JW. **J Oral Rehabil** 1995 Oct;22(10):731–40 (33 ref.)

New definition for relating occlusion to varying conditions of the temporomandibular joint. Dawson PE. **J Prosthet Dent** 1995 Dec;74(6):619–27 (39 ref.)

SURGERY

Temporomandibular disorders. Part 3. Surgical treatment. Dimitroulis G, et al. **Aust Dent J** 1996 Feb;41(1):16–20 (21 ref.)

THERAPY

Temporomandibular disorders. 2. Non-surgical treatment. Dimitroulis G, et al. **Aust Dent J** 1995 Dec;40(6):372–6 (25 ref.)

TMJ arthrocentesis. A conservative surgical alternative. Stein JI. **N Y State Dent J** 1995 Nov;61(9):68–76 (23 ref.)

TEMPOROMANDIBULAR JOINT SYNDROME

COMPLICATIONS

Orbital pseudotumor: report of a case after treatment for temporomandibular joint dysfunction. Oliver AJ, et al. **J Oral Maxillofac Surg** 1995 Dec;53(12):1465–9 (20 ref.)

DIAGNOSIS

Imaging of the temporomandibular joint. Rao VM. **Semin Ultrasound CT MR** 1995 Dec;16(6):513–26 (53 ref.)

DRUG THERAPY

Identifying a neurobiologic basis for drug therapy in TMDs. Denucci DJ, et al. **J Am Dent Assoc** 1996 May; 127(5):581–93 (80 ref.)

PHYSIOPATHOLOGY

[Standard electromyographic and kinesiographic parameters in a sample of healthy population] Manni A, et al. **Minerva Stomatol** 1995 Sep;44(9):411–9 (29 ref.) (Eng. Abstr.) **(Ita)**

TENASCIN

BIOSYNTHESIS

Tenascin expression in nephrogenesis and in normal or pathologic glomerulus morphologic features and functional implications [editorial] Truong LD, et al. **Nephron** 1996; 72(4):499–506 (43 ref.)

PHYSIOLOGY

The complexity in regulating the expression of tenascins. Chiquet-Ehrismann R, et al. **Bioessays** 1995 Oct; 17(10):873–8 (65 ref.)

Tenascins, a growing family of extracellular matrix proteins. Chiquet-Ehrismann R. **Experientia** 1995 Sep 29; 51(9–10):853–62 (117 ref.)

Tenascin-C and the development of articular cartilage. Pacifici M. **Matrix Biol** 1995 Dec;14(9):689–98 (54 ref.)

TENASCIN-C see **TENASCIN**

TENDINITIS

DIAGNOSIS

[Tendon pathology of the hand and wrist] Favarger N. **Rev Med Suisse Romande** 1996 Mar;116(3):187–95 (13 ref.) **(Fre)**

DRUG THERAPY

Topical nonsteroidal antiinflammatory drugs for acute soft tissue injuries. Heyneman CA. **Ann Pharmacother** 1995 Jul–Aug;29(7–8):780–2 (14 ref.)

SURGERY

Arthroscopic treatment of rotator cuff disease. Gartsman GM. **J Shoulder Elbow Surg** 1995 May–Jun;4(3):228–41 (27 ref.)

Lower leg overuse injuries in athletes. Järvinen M. **Knee Surg Sports Traumatol Arthrosc** 1993;1(2):126–30 (33 ref.)

[Tendon injuries/diseases of the shoulder joint] Resch H. **Sportverletz Sportschaden** 1996 Mar;10(1):A1–10 (0 ref.) **(Ger)**

THERAPY

[Prognosis of shoulder calcifications after irrigation treatment and roentgen findings. A prospective study and literature review] Ludwig R, et al. **Schweiz Rundsch Med Prax** 1996 Apr 16;85(16):526–33 (18 ref.) (Eng. Abstr.) **(Ger)**

ULTRASONOGRAPHY

[Ultrasound examination of the shoulder joint] Lick-Schiffer W. **Wien Med Wochenschr** 1996;146(6–7):121–3 (11 ref.) (Eng. Abstr.) **(Ger)**

VETERINARY

Diagnosis and management of tendon disorders in cattle. Anderson DE, et al. **Vet Clin North Am Food Anim Pract** 1996 Mar;12(1):85–116 (111 ref.)

TENDON INJURIES

Tibialis posterior tendon dysfunction and peroneal tendon subluxation. Hutchinson BL, et al. **Clin Podiatr Med Surg** 1995 Oct;12(4):703–23 (92 ref.)

Muscle–tendon injuries in young athletes. Best TM. **Clin Sports Med** 1995 Jul;14(3):669–86 (75 ref.)

Chronic rupture of the posterior tibial tendon. Rosenberg ZS. **Magn Reson Imaging Clin N Am** 1994 Feb;2(1):79–87 (36 ref.)

DIAGNOSIS

Achilles tendon and miscellaneous tendon lesions. Chandnani VP, et al. **Magn Reson Imaging Clin N Am** 1994 Feb; 2(1):89–96 (21 ref.)

Musculotendinous injury. Weatherall PT, et al. **Magn Reson Imaging Clin N Am** 1995 Nov;3(4):753–72 (73 ref.)

ETIOLOGY

Exercise loading of tendons and the development of overuse injuries. A review of current literature. Archambault JM, et al. **Sports Med** 1995 Aug;20(2):77–89 (71 ref.)

NURSING

Arthroscopic rotator cuff repairs using suture anchors. Farrall LA. **AORN J** 1995 Nov;62(5):739–46, 748, 750; quiz 754, 756–8 (18 ref.)

PATHOLOGY

Boutonniere deformity. Coons MS, et al. **Hand Clin** 1995 Aug;11(3):387–402 (30 ref.)

PHYSIOPATHOLOGY

Role of collagen in soft connective tissue wound healing. Oryan A. **Transplant Proc** 1995 Oct;27(5):2759–61 (34 ref.)

REHABILITATION

Early motion after extensor tendon surgery. Crosby CA, et al. **Hand Clin** 1996 Feb;12(1):57–64 (37 ref.)

Early motion after flexor tendon surgery. Wang AW, et al. **Hand Clin** 1996 Feb;12(1):43–55 (47 ref.)

SURGERY

Arthroscopic rotator cuff repairs using suture anchors. Farrall LA. **AORN J** 1995 Nov;62(5):739–46, 748, 750; quiz 754, 756–8 (18 ref.)

Ipsilateral peroneus brevis tendon grafting in a complicated case of traumatic rupture of tibialis anterior tendon. Forst R, et al. **Foot Ankle Int** 1995 Jul;16(7):440–4 (33 ref.)

Acute injuries of the extensor tendons proximal to the metacarpophalangeal joints. Aulicino PL. **Hand Clin** 1995 Aug;11(3):403–10 (33 ref.)

Tendon transfer for rupture of the extensor pollicis longus. Gelb RI. **Hand Clin** 1995 Aug;11(3):411–22 (75 ref.)

Salvage of extensor tendon function with tenolysis and joint release. Uhl RL. **Hand Clin** 1995 Aug;11(3):461–70 (19 ref.)

[Rupture of the distal tendon of the biceps brachialis: apropos of 43 cases] Catonné Y, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1995;81(2):163–72 (17 ref.) (Eng. Abstr.) **(Fre)**

[Tendon injuries/diseases of the shoulder joint] Resch H. **Sportverletz Sportschaden** 1996 Mar;10(1):A1–10 (0 ref.) **(Ger)**

THERAPY

Extensor tendon injuries at the distal interphalangeal joint. Brzezienski MA, et al. **Hand Clin** 1995 Aug;11(3):373–86 (47 ref.)

VETERINARY

Tendon lacerations. Bertone AL. **Vet Clin North Am Equine Pract** 1995 Aug;11(2):293–314 (15 ref.)

Tendon, tendon sheath, and ligament injuries in the pastern. Dyson SJ, et al. **Vet Clin North Am Equine Pract** 1995 Aug;11(2):217–33 (19 ref.)

Diagnosis and management of tendon disorders in cattle. Anderson DE, et al. **Vet Clin North Am Food Anim Pract** 1996 Mar;12(1):85–116 (111 ref.)

TENDON TRANSFER

Outcomes of tendon transfer surgery and occupational therapy in a child with tetraplegia secondary to spinal cord injury. Mulcahey MJ, et al. **Am J Occup Ther** 1995 Jul–Aug;49(7):607–17 (45 ref.)

Tendon transfer for rupture of the extensor pollicis longus. Gelb RI. **Hand Clin** 1995 Aug;11(3):411–22 (75 ref.)

[The "gold standard" in cruciate ligament replacement] Benedetto KP. **Chirurg** 1995 Nov;66(11):1061–70 (57 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Functional hand surgery following tetraplegia. Waters RL, et al. **Arch Phys Med Rehabil** 1996 Jan;77(1):86–94 (48 ref.)

Application of biomechanics to tendon transfers. Hoard AS, et al. **J Hand Ther** 1995 Apr–Jun;8(2):115–23 (44 ref.)

TENDONS

Hamstring spasm in anterior cruciate ligament injuries. Frank CB, et al. **Arthroscopy** 1995 Aug;11(4):444–8 (19 ref.)

Extensor tendon ruptures in rheumatoid arthritis. Williamson SC, et al. **Hand Clin** 1995 Aug;11(3):449–59 (21 ref.)

Miscellaneous conditions of tendons, tendon sheaths, and ligaments. Dyson SJ, et al. **Vet Clin North Am Equine Pract** 1995 Aug;11(2):315–37 (57 ref.)

[Congenital disorders of the bile acid metabolism (3 beta-hydroxy-delta 5-steroid dehydrogenase/isomerase deficiency, delta 4-3-oxosteroid 5 beta-reductase deficiency, cerebrotendinous xanthomatosis, and peroxisomal disorders] Kondo KH, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):362–6 (23 ref.) **(Jpn)**

ABNORMALITIES

Diagnosis and management of tendon disorders in cattle. Anderson DE, et al. **Vet Clin North Am Food Anim Pract** 1996 Mar;12(1):85–116 (111 ref.)

PATHOLOGY

Achilles tendon and miscellaneous tendon lesions. Chandnani VP, et al. **Magn Reson Imaging Clin N Am** 1994 Feb; 2(1):89–96 (21 ref.)

PHYSIOLOGY

Exercise loading of tendons and the development of overuse injuries. A review of current literature. Archambault JM, et al. **Sports Med** 1995 Aug;20(2):77–89 (71 ref.)

SURGERY

Microsurgical reconstruction of the extensor system. Desai SS, et al. **Hand Clin** 1995 Aug;11(3):471–82 (43 ref.)
Salvage of extensor tendon function with tenolysis and joint release. Uhl RL. **Hand Clin** 1995 Aug;11(3):461–70 (19 ref.)
[Clear-cell sarcoma of the tendons and aponeuroses] Popkhristova E, et al. **Khirurgiia (Sofiia)** 1995;48(2):44–7 (23 ref.) **(Bul)**

TRANSPLANTATION

Graft selection in knee surgery. Current concepts. Safran MR. **Am J Knee Surg** 1995 Fall;8(4):168–80 (115 ref.)
Biologic incorporation of allograft anterior cruciate ligament replacements. Jackson DW, et al. **Clin Orthop** 1996 Mar; (324):126–33 (26 ref.)
Ipsilateral peroneus brevis tendon grafting in a complicated case of traumatic rupture of tibialis anterior tendon. Forst R, et al. **Foot Ankle Int** 1995 Jul;16(7):440–4 (33 ref.)

TENDONS, PARA-ARTICULAR

Irreducible fracture of the calcaneus due to flexor hallucis longus tendon interposition. Anglen JO, et al. **J Orthop Trauma** 1996;10(4):285–8 (4 ref.)
[Tendon pathology of the hand and wrist] Favarger N. **Rev Med Suisse Romande** 1996 Mar;116(3):187–95 (13 ref.) **(Fre)**

ANATOMY & HISTOLOGY

MR imaging of knee ligaments. Pope TL Jr. **J South Orthop Assoc** 1996 Spring;5(1):46–62 (73 ref.)

INJURIES

Compressive neuropathies and tendinopathies in the athletic elbow and wrist. Plancher KD, et al. **Clin Sports Med** 1996 Apr;15(2):331–71 (142 ref.)
Extensor tendon injuries at the distal interphalangeal joint. Brzezienski MA, et al. **Hand Clin** 1995 Aug;11(3):373–86 (47 ref.)
Boutonniere deformity. Coons MS, et al. **Hand Clin** 1995 Aug;11(3):387–402 (30 ref.)
[Results of orthopedic and surgical treatment of mallet finger by subcutaneous rupture of the extensor tendon. Apropos of a series of 216 cases] Foucher G, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1995;81(6):491–6 (43 ref.) (Eng. Abstr.) **(Fre)**

TENEBRIO

PHYSIOLOGY

Interactions between parasites and insects vectors. Hurd H. **Mem Inst Oswaldo Cruz** 1994;89 Suppl 2:27–30 (20 ref.)

TENNIS

INJURIES

Hypothenar hammer syndrome caused by playing tennis. Nakamura T, et al. **Eur J Vasc Endovasc Surg** 1996 Feb; 11(2):240–2 (8 ref.)

TENNIS ELBOW

DIAGNOSIS

Medial and lateral epicondylitis in the athlete. Plancher KD, et al. **Clin Sports Med** 1996 Apr;15(2):283–305 (52 ref.)

SURGERY

[Significance of the radial compression syndrome for the diagnosis and surgical therapy of so-called epicondylitis humeri radialis (Epic. hum. rad.)] Totkas D, et al. **Z Orthop Ihre Grenzgeb** 1995 Jul–Aug;133(4):317–22 (73 ref.) (Eng. Abstr.) **(Ger)**

TENOSYNOVITIS

DIAGNOSIS

[Tendon pathology of the hand and wrist] Favarger N. **Rev Med Suisse Romande** 1996 Mar;116(3):187–95 (13 ref.) **(Fre)**

GENETICS

A new cytogenetic subgroup in tenosynovial giant cell tumors (nodular tenosynovitis) is characterized by involvement of 16q24. Dal Cin P, et al. **Cancer Genet Cytogenet** 1996 Mar;87(1):85–7 (5 ref.)

MICROBIOLOGY

Localized soft-tissue infections with Mycobacterium avium/Mycobacterium intracellulare complex in immunocompetent patients: granulomatous tenosynovitis of the hand or wrist. Hellinger WC, et al. **Clin Infect Dis** 1995 Jul;21(1):65–9 (25 ref.)

VETERINARY

Infectious tenosynovitis. Bertone AL. **Vet Clin North Am Equine Pract** 1995 Aug;11(2):163–76 (24 ref.)
Aseptic tenosynovitis of the digital flexor tendon sheath, fetlock and pastern annular ligament constriction. Dik KJ, et al. **Vet Clin North Am Equine Pract** 1995 Aug; 11(2):151–62 (20 ref.)

TENS see TRANSCUTANEOUS ELECTRIC NERVE STIMULATION

TENSION HEADACHE

[The tension headache] Kolosova OA, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995;95(4):94–8 (45 ref.) **(Rus)**
[Tension headache] Guitera Calvo V, et al. **Rev Clin Esp** 1995 Sep;195(2 Spec No):31–5 (32 ref.) **(Spa)**

EPIDEMIOLOGY

Headache epidemiology. Emphasis on migraine. Silberstein SD, et al. **Neurol Clin** 1996 May;14(2):421–34 (75 ref.)

TENSION-TYPE HEADACHE see TENSION HEADACHE

TERATOGENS

see related
ABNORMALITIES, DRUG-INDUCED

Teratogen update: ergot and ergotamine. Raymond GV. **Teratology** 1995 May;51(5):344–7 (19 ref.)
[Isotretinoin (RoAccutane) embryopathy. A case report] Pilorget H, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(5):511–5 (14 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Biochemical toxicology of chemical teratogenesis. Wells PG, et al. **Crit Rev Biochem Mol Biol** 1996 Feb;31(1):1–40 (200 ref.)

PHARMACOKINETICS

Toxicity prediction from metabolic pathway modelling. Jackson RC. **Toxicology** 1995 Sep 1;102(1–2):197–205 (23 ref.)

PHARMACOLOGY

Retinoids as teratogens. Soprano DR, et al. **Annu Rev Nutr** 1995;15:111–32 (117 ref.)

TOXICITY

Immunoteratology: I. MHC involvement in the embryo response to teratogens in mice. Torchinsky A, et al. **Am J Reprod Immunol** 1995 Nov;34(5):288–98 (27 ref.)
Drug treatment in the perinatal period and the risk of functional teratogenicity. Benešová O. **Arch Toxicol Suppl** 1996;18:89–96 (9 ref.)
Introduction to functional teratology. Dencker L. **Arch Toxicol Suppl** 1996;18:51–6 (10 ref.)
Teratogenic effects of alcohol: current status of animal research and in vitro models. Guerri C. **Arch Toxicol Suppl** 1996;18:71–80 (55 ref.)
Receptor-selective retinoid agonists and teratogenic activity. Willhite CC, et al. **Drug Metab Rev** 1996 Feb–May; 28(1–2):105–19 (33 ref.)
The road to embryologically based dose-response models. Kavlock RJ, et al. **Environ Health Perspect** 1996 Mar;104 Suppl 1:107–21 (88 ref.)
Bendectin: review of the medical literature of a comprehensively studied human nonteratogen and the most prevalent tortogen-litigen. Brent RL. **Reprod Toxicol** 1995 Jul–Aug;9(4):337–49 (178 ref.)
The developmental toxicity of indomethacin and sulindac. Lione A, et al. **Reprod Toxicol** 1995 Jan–Feb;9(1):7–20 (111 ref.)
An evaluative process for assessing human reproductive and developmental toxicity of agents. Moore JA, et al. **Reprod Toxicol** 1995 Jan–Feb;9(1):61–95 (88 ref.)
Teratogen update: carcinogenesis and teratogenesis associated with exposure to diethylstilbestrol (DES) in utero. Mittendorf R. **Teratology** 1995 Jun;51(6):435–45 (45 ref.)
Agents that cause birth defects. Shepard TH. **Yonsei Med J** 1995 Nov;36(5):393–6 (13 ref.)

TERATOID TUMOR see TERATOMA

TERATOLOGY

Introduction to functional teratology. Dencker L. **Arch Toxicol Suppl** 1996;18:51–6 (10 ref.)

TERATOMA

Rhabdomyosarcoma arising in teratoma of the testis. Banfield GK, et al. **J R Army Med Corps** 1995 Oct;141(3):167–8 (5 ref.)
[Hepatic teratoma, malignant teratoma] Kobayashi Y, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):329–32 (17 ref.) **(Jpn)**

COMPLICATIONS

Non-immunological hydrops fetalis and intrapericardial teratoma: case report and review. Perez-Aytes A, et al. **Prenat Diagn** 1995 Sep;15(9):859–63 (20 ref.)
A child with an intra-abdominal testicular teratoma: a case report and review of prepubertal cryptorchid germ cell tumors. Brown IR, et al. **Urology** 1995 Dec;46(6):863–6 (27 ref.)

CONGENITAL

Congenital teratoid cyst of the floor of the mouth--a case report. Harada H, et al. **Int J Oral Maxillofac Surg** 1995 Oct;24(5):361–2 (6 ref.)
Perinatal management of nasopharyngeal teratoma. Marras T, et al. **J Otolaryngol** 1995 Oct;24(5):310–2 (10 ref.)
[Ultrasound diagnosis of epignathus in the 17th week of pregnancy. Case report and review of the literature] Brühwiler H, et al. **Ultraschall Med** 1995 Oct;16(5):238–40 (18 ref.) (Eng. Abstr.) **(Ger)**

GENETICS

Hereditary presacral teratoma. Bryant P, et al. **Aust N Z J Surg** 1996 Jun;66(6):418–20 (15 ref.)
[Familiar sacrococcygeal teratoma] Goto T, et al. **Nippon Rinsho** 1995 Nov;53(11):2779–85 (14 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Squamous cell carcinoma arising from mature cystic teratoma: a report of three cases. Bontis J, et al. **Eur J Gynaecol Oncol** 1996;17(1):49–52 (20 ref.)
Thyroid carcinoma originating in a teratoma of the ovary. Ferrer J, et al. **Eur J Gynaecol Oncol** 1995;16(5):396–402 (24 ref.)
A case of submandibular teratoma. Mckiernan DC, et al. **J Laryngol Otol** 1995 Oct;109(10):992–4 (12 ref.)
[Rhombencephalic tissue in an ovarian teratoma with cerebellar foliation and maturation of the postnatal type] Fichera G. **Pathologica** 1995 Apr;87(2):203–10 (36 ref.) (Eng. Abstr.) **(Ita)**

PHYSIOPATHOLOGY

The 1993 ISOBM Abbott Award Lecture. Isozymes, tumor markers and oncodevelopmental biology. Fishman WH. **Tumour Biol** 1995;16(6):394–402 (58 ref.)

SECONDARY

Metastatic testicular tumor requiring inferior vena cava resection. Mullen JC, et al. **Urology** 1996 Feb;47(2):263–5 (10 ref.)

SURGERY

Immature mediastinal teratoma in a 2 1/2 year old Chinese girl. Yim AP, et al. **Aust N Z J Surg** 1996 Jun;66(6):420–2 (4 ref.)
Metastatic testicular tumor requiring inferior vena cava resection. Mullen JC, et al. **Urology** 1996 Feb;47(2):263–5 (10 ref.)

THERAPY

Perinatal management of nasopharyngeal teratoma. Marras T, et al. **J Otolaryngol** 1995 Oct;24(5):310–2 (10 ref.)

ULTRASONOGRAPHY

[The antenatal diagnosis of sacrococcygeal teratoma] Dukovski A. **Akush Ginekol (Sofiia)** 1995;34(2):53–5 (6 ref.) (Eng. Abstr.) **(Bul)**

TERATOMA, CYSTIC see TERATOMA

TERATOMA, MATURE see TERATOMA

TERFENADINE

ADVERSE EFFECTS

Cardiac actions of antihistamines. Woosley RL. **Annu Rev Pharmacol Toxicol** 1996;36:233–52 (73 ref.)

PHARMACOLOGY

Of oocytes and runny noses [editorial; comment] Rosen MR. **Circulation** 1996 Aug 15;94(4):607–9 (20 ref.) Comment on: Circulation 1996 Aug 15;94(4):817–23.

TERMINAL ADDITION ENZYME see DNA NUCLEOTIDYLEXOTRANSFERASE

TERMINAL CARE

see related
HOSPICE CARE
LIFE SUPPORT CARE
PALLIATIVE CARE

Care at the twilight: ethics and end-of-life care. Doukas DJ, et al. **Am Fam Physician** 1995 Oct;52(5):1294–6, 1299 (12 ref.)
The constitutional case against permitting physician-assisted suicide for competent adults with "terminal conditions".

Bopp J Jr, et al. **Issues Law Med** 1995 Winter;11(3):239–68 (130 ref.)
Patient-induced dehydration—can it ever be therapeutic? Smith SA. **Oncol Nurs Forum** 1995 Nov–Dec; 22(10):1487–91 (20 ref.)
Rehydration in palliative and terminal care: if not—why not? Dunphy K, et al. **Palliat Med** 1995 Jul;9(3):221–8 (32 ref.)
[How can we help children during the terminal phase?] Astudillo W, et al. **Rev Med Univ Navarra** 1995 Jul–Sep; 39(3):173–9 (37 ref.) (Eng. Abstr.) **(Spa)**

ECONOMICS

Cost savings at the end of life. What do the data show? Emanuel EJ. **JAMA** 1996 Jun 26;275(24):1907–14 (42 ref.)

LEGISLATION & JURISPRUDENCE

Breathing life into the right to die: Oregon's Death with Dignity Act. Bushong SK, et al. **Issues Law Med** 1995 Winter;11(3):269–82 (102 ref.)
[Assisted dying—death on demand: borderline between medicine and law] Oehmichen M. **Z Gerontol Geriatr** 1995 Jul–Aug;28(4):273–8 (21 ref.) (Eng. Abstr.) **(Ger)**

METHODS

A dying child. Dawson SA. **Can Fam Physician** 1995 Sep; 41:1534–40 (27 ref.)
Supportive care. Markman M. **Cancer Chemother Biol Response Modif** 1996;16:644–54 (56 ref.)
Psychiatric symptom management in terminal care. Breitbart W, et al. **Clin Geriatr Med** 1996 May;12(2):329–47 (86 ref.)
Effective pain management in terminal care. Dahl JL. **Clin Geriatr Med** 1996 May;12(2):279–300 (92 ref.)
Nonpain symptom management in terminal care. Rousseau P. **Clin Geriatr Med** 1996 May;12(2):313–27 (52 ref.)
Nonpharmacologic pain management in terminal care. Urba SG. **Clin Geriatr Med** 1996 May;12(2):301–11 (37 ref.)
Terminal care for noncancer patients. von Gunten CF, et al. **Clin Geriatr Med** 1996 May;12(2):349–58 (32 ref.)
Advanced HIV disease in children. Czarniecki L. **Nurs Clin North Am** 1996 Mar;31(1):207–19 (16 ref.)

PSYCHOLOGY

Anticipatory grief and AIDS: strategies for intervening with caregivers. Walker RJ, et al. **Health Soc Work** 1996 Feb; 21(1):49–57 (43 ref.)
Patient requests for euthanasia and assisted suicide in terminal illness. The role of the psychiatrist. Block SD, et al. **Psychosomatics** 1995 Sep–Oct;36(5):445–57 (75 ref.)

STANDARDS

Terminating life-sustaining treatment of the demented. Callahan D. **Hastings Cent Rep** 1995 Nov–Dec;25(6):25–31 (11 ref.)
Comfort at the end of life: palliative care policy. Jett LG. **J Nurs Adm** 1995 Nov;25(11):55–60 (23 ref.)
Good care of the dying patient. Council on Scientific Affairs, American Medical Association. **JAMA** 1996 Feb 14; 275(6):474–8 (96 ref.)

TERMINAL DEOXYRIBONUCLEOTIDYLTRANSFERASE see **DNA NUCLEOTIDYLEXOTRANSFERASE**

TERMINAL REPEAT see **REPETITIVE SEQUENCES, NUCLEIC ACID**

TERMINALS, COMPUTER see **COMPUTER TERMINALS**

TERMINATOR CODON see **CODON, TERMINATOR**

TERMINATOR REGIONS (GENETICS)

[Translation termination in eukaryotes] Kiselev LL, et al. **Mol Biol (Mosk)** 1995 Nov–Dec;29(6):1286–93 (39 ref.) **(Rus)**

TERMINOLOGY see **NOMENCLATURE**

TERPENES

BLOOD

Pennyroyal toxicity: measurement of toxic metabolite levels in two cases and review of the literature. Anderson IB, et al. **Ann Intern Med** 1996 Apr 15;124(8):726–34 (46 ref.)

CHEMISTRY

Monoterpenoids. Grayson DH. **Nat Prod Rep** 1996 Jun; 13(3):195–225 (567 ref.)
Lophozozymus pictor toxin: a fluorescent structural isomer of palytoxin. Lau CO, et al. **Toxicon** 1995 Oct;33(10):1373–7 (18 ref.)

METABOLISM

Isoprenoid antibiotics. Cane DE. **Biotechnology** 1995; 28:633–55 (99 ref.)
The biosynthesis of C5–C20 terpenoid compounds. Dewick PM. **Nat Prod Rep** 1995 Oct;12(5):507–34 (170 ref.)

PHARMACOLOGY

Plant-derived triterpenoid sweetness inhibitors. Suttisri R, et al. **J Ethnopharmacol** 1995 Jun 23;47(1):9–26 (109 ref.)

TOXICITY

Limonene. Von Burg R. **J Appl Toxicol** 1995 Nov–Dec; 15(6):495–9 (65 ref.)

TERRITORIALITY

Agency and research team co-operation: an exploration of human territoriality. Ervin NE, et al. **J Adv Nurs** 1996 Apr;23(4):728–32 (11 ref.)

TERRORISM see **VIOLENCE**

TEST-TUBE FERTILIZATION see **FERTILIZATION IN VITRO**

TESTICULAR DISEASES

[Cystic ectasia of the rete testis: apropos of a case] Poddevin F, et al. **J Urol (Paris)** 1996;102(2):92–4 (10 ref.) (Eng. Abstr.) **(Fre)**

CHEMICALLY INDUCED

Occupation- and exposure-related studies on human sperm. Lähdetie J. **J Occup Environ Med** 1995 Aug;37(8):922–30 (92 ref.)

COMPLICATIONS

Testicular microlithiasis: a benign condition with a malignant association. Miller RL, et al. **J Clin Ultrasound** 1996 May; 24(4):197–202 (32 ref.)
Cystic dysplasia of the testis: an unusual cause of a pediatric scrotal mass. Zaragoza MR, et al. **Urology** 1996 Feb; 47(2):244–7 (12 ref.)

DIAGNOSIS

Epididymal histoplasmosis diagnosed by isolation of Histoplasma capsulatum from semen. Randhawa HS, et al. **Mycopathologia** 1995 Sep;131(3):173–7 (20 ref.)

PATHOLOGY

Testicular cysts: a case report and review of a recent Tripler experience. Gange SN, et al. **Hawaii Med J** 1995 Jul; 54(7):678–9 (15 ref.)
Cystic dysplasia of the testis: a report of three cases and review of the literature. Loo CK, et al. **Pediatr Pathol Lab Med** 1995 Nov–Dec;15(6):885–93 (9 ref.)

ULTRASONOGRAPHY

[Testicular microlithiasis. A pediatric case report] Orazi C, et al. **Radiol Med (Torino)** 1996 Jan–Feb;91(1–2):145–7 (27 ref.) **(Ita)**

TESTICULAR FEMINIZATION

DIAGNOSIS

[The testicular feminization syndrome] Kolparov G, et al. **Akush Ginekol (Sofiia)** 1995;34(3):58–60 (18 ref.) **(Bul)**

GENETICS

Human androgen insensitivity syndrome. Brown TR. **J Androl** 1995 Jul–Aug;16(4):299–303 (17 ref.)

TESTICULAR HORMONES

PHYSIOLOGY

[Anti-Mullerian hormone. Structure and role in sexual differentiation] Jarmińska-Jackowiak T, et al. **Ginekol Pol** 1995 Jan;66(1):51–8 (35 ref.) (Eng. Abstr.) **(Pol)**

TESTICULAR INTERSTITIAL CELLS see **LEYDIG CELLS**

TESTICULAR NEOPLASMS

ABC of urology. Urological malignancy—III: Renal and testicular carcinoma. Dawson C, et al. **BMJ** 1996 May 4; 312(7039):1146–8 (4 ref.)
Rhabdomyosarcoma arising in teratoma of the testis. Banfield GK, et al. **J R Army Med Corps** 1995 Oct;141(3):167–8 (5 ref.)
Adenocarcinoma of the rete testis. Sánchez-Chapado M, et al. **Urology** 1995 Oct;46(4):468–75 (48 ref.)

CHEMICALLY INDUCED

A review of drug-induced Leydig cell hyperplasia and neoplasia in the rat and some comparisons with man. Prentice DE, et al. **Hum Exp Toxicol** 1995 Jul;14(7):562–72 (98 ref.)

COMPLICATIONS

Testicular germ cell tumors in patients with human immunodeficiency virus infection. Hentrich MU, et al. **Cancer** 1996 May 15;77(10):2109–16 (55 ref.)
The sexual sequelae of testicular cancer. van Basten JP, et al. **Cancer Treat Rev** 1995 Sep;21(5):479–95 (141 ref.)
Testicular microlithiasis: a benign condition with a malignant association. Miller RL, et al. **J Clin Ultrasound** 1996 May; 24(4):197–202 (32 ref.)
Sudden death caused by testicular germ cell tumour. Dada MA, et al. **Med Sci Law** 1995 Oct;35(4):357–9 (12 ref.)
Leydig cell tumour in a man with human immunodeficiency virus. Sanchez-Chapado M, et al. **Scand J Urol Nephrol** 1995 Sep;29(3):357–60 (18 ref.)
A child with an intra-abdominal testicular teratoma: a case report and review of prepubertal cryptorchid germ cell tumors. Brown IR, et al. **Urology** 1995 Dec;46(6):863–6 (27 ref.)
A symptomatic testicular cyst in a patient with von Hippel-Lindau disease. Brown JA, et al. **Urology** 1996 Sep; 48(3):494–5 (9 ref.)
[Congenital adrenal hyperplasia and testicular hypertrophy] Dieckmann K, et al. **Arch Pediatr** 1995 Dec;2(12):1167–72 (20 ref.) (Eng. Abstr.) **(Fre)**
[Association between testicular germinal tumor and Hodgkin disease] Al-Aukla N, et al. **Bull Cancer (Paris)** 1995 Dec; 82(12):1072–5 (28 ref.) (Eng. Abstr.) **(Fre)**
[A case of testicular tumor associated with the contralateral undescended testis] Ueda H, et al. **Hinyokika Kiyo** 1995 Dec;41(12):1015–8 (20 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Cancer and male infertility. Meirow D, et al. **Hum Reprod** 1995 Aug;10(8):2017–22 (59 ref.)
A case of microscopic testicular tumour. Shoji N, et al. **Int Urol Nephrol** 1995;27(2):189–91 (5 ref.)
Testicular lymphoblastic leukemia/lymphoma. Gutjahr P, et al. **World J Urol** 1995;13(4):230–2 (5 ref.)
[Retroperitoneal seminoma. A case report and literature review] Troisfontaines E, et al. **Acta Urol Belg** 1996 Mar; 64(1):55–9 (24 ref.) (Eng. Abstr.) **(Fre)**
[Embryonal carcinoma and anaplastic seminoma of the testis: diagnostic difficulties] Vallat AV, et al. **Arch Anat Cytol Pathol** 1996;44(2–3):109–12 (10 ref.) (Eng. Abstr.) **(Fre)**
[Desmoplastic small round cell tumors in adults: a new entity] Farhat F, et al. **Bull Cancer (Paris)** 1995 Aug;82(8):665–73 (39 ref.) (Eng. Abstr.) **(Fre)**
[Focal infarction of the testis. Report of a case simulating a gonadal mass] Pellicé C Jr, et al. **Actas Urol Esp** 1995 Oct;19(9):716–20 (23 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Hematopoietic growth factors and treatment of testicular cancer: biological interactions, routine use and dose-intensive chemotherapy. Bokemeyer C, et al. **Ann Hematol** 1996 Jan;72(1):1–9 (62 ref.)
Therapy-related acute promyelocytic leukemia with t(15;17)(q22;q12) following chemotherapy with drugs targeting DNA topoisomerase II. A report of two cases and a review of the literature [see comments] Hoffmann L, et al. **Ann Oncol** 1995 Oct;6(8):781–8 (32 ref.) Comment in: Ann Oncol 1995 Oct;6(8):751–3.
The management and outcome of stage IAE nonHodgkin's lymphoma of the testis. Zietman AL, et al. **J Urol** 1996 Mar;155(3):943–6 (21 ref.)
Adjuvant chemotherapy for patients with stage II nonseminomatous testis cancer. Motzer RJ. **Semin Oncol** 1995 Dec;22(6):641–6 (33 ref.)
The role of ifosfamide in the treatment of testicular and urothelial malignancies. Roth BJ. **Semin Oncol** 1996 Jun; 23(3 Suppl 7):19–27 (83 ref.)
[Treatment of stage I non-seminomatous germ cell tumors of the testis] Droz JP. **Presse Med** 1995 Oct 28; 24(32):1501–3 (10 ref.) (Eng. Abstr.) **(Fre)**
[A case of secondary leukemia in anaplastic seminoma patient treated with long-term chemotherapy] Kamai T, et al. **Nippon Hinyokika Gakkai Zasshi** 1996 May;87(5):875–9 (12 ref.) (Eng. Abstr.) **(Jpn)**

EPIDEMIOLOGY

A Scottish national audit of current patterns of management for patients with testicular non-seminomatous germ-cell tumours. The Scottish Radiological Society and the Scottish Committee of the Royal College of Radiologists. Howard GC, et al. **Br J Cancer** 1995 Nov;72(5):1303–6 (17 ref.)
Epidemiology of testicular cancer. Buetow SA. **Epidemiol Rev** 1995;17(2):433–49 (154 ref.)
Malignant testicular neoplasms in immunosuppressed patients. Leibovitch I, et al. **J Urol** 1996 Jun;155(6):1938–42 (41 ref.)

ETIOLOGY

Epidemiology of testicular cancer. Buetow SA. **Epidemiol Rev** 1995;17(2):433–49 (154 ref.)
Hormonal factors in carcinogenesis of the prostate and testis in humans and in animal models. Bosland MC. **Prog Clin Biol Res** 1996;394:309–52 (225 ref.)
Testicular seminoma originating in an undescended testis in

a renal allograft recipient. Modlin CS, et al. **Urology** 1996 Jul;48(1):145–8 (9 ref.)
[Cryptorchidism and testicular cancer] Pereira Arias JG, et al. **Arch Esp Urol** 1995 Nov;48(9):959–61 (12 ref.) (Eng. Abstr.) **(Spa)**

GENETICS

Primary intratesticular sarcoma. Immunohistochemical ultrastructural and DNA flow cytometric study of three cases with a review of the literature. Washecka RM, et al. **Cancer** 1996 Apr 15;77(8):1524–8 (26 ref.)
Testicular cancer in father and son. Ishikawa K, et al. **Int J Urol** 1996 Jan;3(1):70–3 (11 ref.)
Molecular biology of testicular germ cell tumors: current status. Schmidt B, et al. **J Mol Med** 1995 Jul;73(7):355–67 (189 ref.)
Reviews of chromosome studies in urological tumors. III. Cytogenetics and genes in testicular tumors. Sandberg AA, et al. **J Urol** 1996 May;155(5):1531–56 (254 ref.)
[Correlation between p-53 expression and clinical resistance in testicular cancer] Hanna E, et al. **Orv Hetil** 1996 Jan 14;137(2):59–64 (26 ref.) (Eng. Abstr.) **(Hun)**
[Testicular cancer in father and son] Murayama T, et al. **Hinyokika Kiyo** 1995 Oct;41(10):809–12 (12 ref.) (Eng. Abstr.) **(Jpn)**

MORTALITY

A Scottish national mortality study assessing cause of death, quality of and variation in management of patients with testicular non-seminomatous germ-cell tumours. The Scottish Radiological Society and the Scottish Standing Committee of the Royal College of Radiologists. Howard GC, et al. **Br J Cancer** 1995 Nov;72(5):1307–11 (14 ref.)

PATHOLOGY

Torsion of intraabdominal testicular tumors. A case report. Hutcheson JC, et al. **Cancer** 1996 Jan 15;77(2):339–43 (40 ref.)
Sclerosing Sertoli cell tumor of the testis: a distinct histological subtype. Anderson GA. **J Urol** 1995 Nov; 154(5):1756–8 (11 ref.)
[Double cancers of renal cell carcinoma and testicular seminoma: a case report] Nozawa M, et al. **Hinyokika Kiyo** 1995 Dec;41(12):999–1002 (17 ref.) (Eng. Abstr.) **(Jpn)**

RADIOTHERAPY

The management and outcome of stage IAE nonHodgkin's lymphoma of the testis. Zietman AL, et al. **J Urol** 1996 Mar;155(3):943–6 (21 ref.)

SURGERY

Metastatic testicular tumor requiring inferior vena cava resection. Mullen JC, et al. **Urology** 1996 Feb;47(2):263–5 (10 ref.)

THERAPY

Diagnosis and treatment of urological malignancy: the testes. Wilkins M, et al. **Br J Hosp Med** 1996 Feb 21–Mar 5; 55(4):199–203 (23 ref.)
The role of adjuvant treatment in low-stage germ cell testicular tumors. Pizzocaro G, et al. **Eur Urol** 1995; 28(4):267–72 (28 ref.)
Paratesticular rhabdomyosarcoma. de Vries JD. **World J Urol** 1995;13(4):219–25 (31 ref.)
[Therapy of germ cell tumors. Model for interdisciplinary treatment approach] Schmoll HJ. **Med Klin** 1996 Apr 12; 91 Suppl 3:80–4 (41 ref.) **(Ger)**
[Pathogenesis, diagnosis and therapy of testicular tumors] Weissbach I, et al. **Urologe A** 1996 Mar;35(2):163–72 (11 ref.) **(Ger)**
[Treatment of stage-I seminoma. Critical review] Santini D, et al. **Minerva Urol Nefrol** 1995 Mar;47(1):31–8 (51 ref.) **(Ita)**
[Germ cell tumor] Kasai M, et al. **Gan To Kagaku Ryoho** 1995 Oct;22(12):1749–55 (19 ref.) (Eng. Abstr.) **(Jpn)**
[Salvage therapy for refractory testicular cancer] Kawai K, et al. **Gan To Kagaku Ryoho** 1996 Aug;23(9):1129–35 (35 ref.) (Eng. Abstr.) **(Jpn)**
[High-dose chemotherapy with autologous bone marrow transplantation or peripheral blood stem cell transplantation--testicular cancer] Miyanaga N, et al. **Gan To Kagaku Ryoho** 1995 Oct;22(12):1771–6 (16 ref.) (Eng. Abstr.) **(Jpn)**
[Current procedure for treating testicular germ-cell tumors] Tiuliandin SA, et al. **Urol Nefrol (Mosk)** 1995 Nov-Dec; (6):40–4 (15 ref.) (Eng. Abstr.) **(Rus)**

ULTRASTRUCTURE

Primary intratesticular sarcoma. Immunohistochemical ultrastructural and DNA flow cytometric study of three cases with a review of the literature. Washecka RM, et al. **Cancer** 1996 Apr 15;77(8):1524–8 (26 ref.)

VETERINARY

[Testicular tumors in dogs: a literature review] Peters MA, et al. **Tijdschr Diergeneeskd** 1996 Jan 15;121(2):36–8 (47 ref.) (Eng. Abstr.) **(Dut)**

TESTICULAR TORSION see **SPERMATIC CORD TORSION**

TESTING, BIOCOMPATIBLE MATERIALS see **MATERIALS TESTING**

TESTIS

see related
ORCHIECTOMY

Chronic testicular pain. A workup and treatment guide for the primary care physician. Baum N, et al. **Postgrad Med** 1995 Oct;98(4):151–3, 156–8 (16 ref.)

ABNORMALITIES

The pathogenesis of cryptorchidism and splenogonadal fusion: a new hypothesis. Cortes D, et al. **Br J Urol** 1996 Feb;77(2):285–90 (24 ref.)
Splenogonadal fusion. Balaji KC, et al. **J Urol** 1996 Aug;156(2 Pt 2):854–6 (20 ref.)
Splenogonadal fusion: report of 2 cases and review of the literature. Karaman MI, et al. **J Urol** 1996 Jan; 155(1):309–11 (20 ref.)
[Value of echography in a case of polyorchidism] Dibiane A, et al. **J Radiol** 1996 Jul;77(7):509–11 (14 ref.) (Eng. Abstr.) **(Fre)**
[An echotomographic study of a case of polyorchidism] Battaglia F, et al. **Radiol Med (Torino)** 1995 Sep; 90(3):329–30 (7 ref.) **(Ita)**

BLOOD SUPPLY

[Opening of the left V. spermatica interna into the left V. suprarenalis] Risse JH, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1995 Oct;163(4):364–6 (9 ref.) **(Ger)**
[Focal infarction of the testis. Report of a case simulating a gonadal mass] Pellicé C Jr, et al. **Actas Urol Esp** 1995 Oct;19(9):716–20 (23 ref.) (Eng. Abstr.) **(Spa)**

CYTOLOGY

The comparative cell biology of accessory somatic (or Sertoli) cells in the animal testis. Guraya SS. **Int Rev Cytol** 1995;160:163–220 (230 ref.)
Theory and practice of stereological techniques applied to the estimation of cell number and nuclear volume in the testis. Wreford NG. **Microsc Res Tech** 1995 Dec 1; 32(5):423–36 (48 ref.)
Gonadal cell apoptosis. Hsueh AJ, et al. **Recent Prog Horm Res** 1996;51:433–55; discussion 455–6 (66 ref.)

EMBRYOLOGY

Normal testicular descent and the aetiology of cryptorchidism. Hutson JM, et al. **Adv Anat Embryol Cell Biol** 1996;132:1–56 (174 ref.)
Sex differentiation -- gonadogenesis and novel genes. Nordqvist K. **Int J Dev Biol** 1995 Oct;39(5):727–36 (76 ref.)
Molecular aspects of the ontogeny of the pituitary-gonadal axis. Huhtaniemi I. **Reprod Fertil Dev** 1995;7(5):1025–35 (57 ref.)
The molecular biology of SRY and its role in sex determination in mammals. Koopman P. **Reprod Fertil Dev** 1995;7(4):713–22 (63 ref.)
Genes involved in testicular development and function. Lamb DJ. **World J Urol** 1995;13(5):277–84 (118 ref.)
[Genetics of sexual development and its disorders] Osipova GR. **Genetika** 1996 Feb;32(2):184–91 (84 ref.) (Eng. Abstr.) **(Rus)**

ENZYMOLOGY

Two novel metallopeptidases with a specificity for basic residues: functional properties, structure and cellular distribution. Foulon T, et al. **Ann N Y Acad Sci** 1996 Mar 22;780:106–20 (49 ref.)
Sperm, a source of estrogen. Hess RA, et al. **Environ Health Perspect** 1995 Oct;103 Suppl 7:59–62 (41 ref.)

INJURIES

[Injuries of the scrotum. Analysis of 25 cases] el Moussaoui A, et al. **J Urol (Paris)** 1996;102(2):88–91 (20 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Endocrine, paracrine and autocrine regulation of testicular steroidogenesis. Huhtaniemi I, et al. **Adv Exp Med Biol** 1995;377:33–54 (145 ref.)
Influence of etomoxir on the expression of several genes in liver, testis and heart. Hegardt FG, et al. **Gen Pharmacol** 1995 Sep;26(5):897–904 (33 ref.)
Molecular role of sulfated glycoprotein-1 (SGP-1/prosaposin) in Sertoli cells. Morales CR, et al. **Histol Histopathol** 1995 Oct;10(4):1023–34 (11 ref.)
Homeobox genes and male reproductive development. Lindsey S, et al. **J Assist Reprod Genet** 1996 Feb; 13(2):182–92 (49 ref.)
A model for understanding gene regulation during spermatogenesis: the mouse testis Pdha-2 promoter. Iannello RC, et al. **Reprod Fertil Dev** 1995;7(4):705–12 (51 ref.)

PATHOLOGY

Whither the investigation of male infertility? Is FSH measurement redundant and should all azoospermic patients have testicular biopsy? Wu FC. **Hum Reprod** 1995 Aug;10(8):1945–7 (25 ref.)
Cystic dysplasia of the testis: a report of three cases and review of the literature. Loo CK, et al. **Pediatr Pathol Lab Med** 1995 Nov-Dec;15(6):885–93 (9 ref.)

PHYSIOLOGY

Current aspects of autocrine and paracrine regulation of spermatogenesis. Jégou B, et al. **Adv Exp Med Biol** 1995; 377:67–86 (72 ref.)
Gonadotrophin control of testicular germ cell development. Weinbauer GF, et al. **Adv Exp Med Biol** 1995;377:55–65 (59 ref.)
Thyroid hormone and male gonadal function. Jannini EA, et al. **Endocr Rev** 1995 Aug;16(4):443–59 (226 ref.)
The role of the testicles in male psychological development. Friedman RM. **J Am Psychoanal Assoc** 1996;44(1):201–53 (72 ref.)
Inositol lipid-mediated signalling in response to endothelin and ATP in the mammalian testis. Rudge SA, et al. **Mol Cell Biochem** 1995 Aug-Sep;149-150:161–74 (86 ref.)
Genes involved in testicular development and function. Lamb DJ. **World J Urol** 1995;13(5):277–84 (118 ref.)

PHYSIOPATHOLOGY

Testicular heating and its possible contributions to male infertility: a review. Mieusset R, et al. **Int J Androl** 1995 Aug;18(4):169–84 (105 ref.)
[Effect of obesity on gonadal function in men] Minowada S. **Nippon Rinsho** 1995 Jun;53 Suppl:320–4 (14 ref.) **(Jpn)**

ULTRASTRUCTURE

Cell-cell interactions in the testis of teleosts and elasmobranchs. Loir M, et al. **Microsc Res Tech** 1995 Dec 15;32(6):533–52 (93 ref.)

TESTIS, UNDESCENDED see **CRYPTORCHIDISM**

TESTOSTERONE

Role of growth factors, steroid and peptide hormones in the regulation of human prostatic tumor growth. Motta M, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1-6 Spec No):107–11 (36 ref.)

ADMINISTRATION & DOSAGE

[Androgens in the treatment of women] Flöter A, et al. **Lakartidningen** 1996 Jan 3;93(1-2):52–5 (46 ref.) **(Swe)**

ANALYSIS

The determination of bio-available testosterone. Wheeler MJ. **Ann Clin Biochem** 1995 Jul;32 (Pt 4):345–57 (63 ref.)

BLOOD

Human androgen insensitivity syndrome. Brown TR. **J Androl** 1995 Jul-Aug;16(4):299–303 (17 ref.)
[Testosterone, free testosterone] Isurugi K. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:584–7 (10 ref.) **(Jpn)**

PHYSIOLOGY

Testosterone and risk factors for cardiovascular disease in men. Barrett-Connor EL. **Diabete Metab** 1995 Jun; 21(3):156–61 (41 ref.)
The endocrine regulation of spermatogenesis: independent roles for testosterone and FSH. McLachlan RI, et al. **J Endocrinol** 1996 Jan;148(1):1–9 (62 ref.)
Effects of testosterone and its metabolites on aromatase-immunoreactive cells in the quail brain: relationship with the activation of male reproductive behavior. Balthazart J, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1-6 Spec No):185–200 (125 ref.)

THERAPEUTIC USE

Treatment review. Testosterone (Testoderm). Porche DJ. **J Assoc Nurses AIDS Care** 1995 Jul-Aug;6(4):43–5 (3 ref.)

URINE

Methods for urinary testosterone analysis. Venturelli E, et al. **J Chromatogr B Biomed Appl** 1995 Sep 15; 671(1-2):363–80 (85 ref.)

TESTOSTERONE 5-ALPHA-REDUCTASE

ANTAGONISTS & INHIBITORS

The effect of finasteride on prostate specific antigen: review of available data. Guess HA, et al. **J Urol** 1996 Jan; 155(1):3–9 (33 ref.)

[Medical treatment of benign hypertrophy of the prostate] Bensadoun H. **Presse Med** 1995 Oct 28;24(32):1485-9 (16 ref.) (Eng. Abstr.) **(Fre)**

[The effect of 5-alpha-reductase inhibitors on benign prostatic hyperplasia] Djavan B, et al. **Wien Med Wochenschr** 1996;146(8):165-8 (21 ref.) (Eng. Abstr.) **(Ger)**

[Current drug therapy of benign prostatic hyperplasia] Schmidbauer CP, et al. **Wien Med Wochenschr** 1996; 146(8):161-4 (12 ref.) (Eng. Abstr.) **(Ger)**

TESTOSTERONE DEHYDROGENASES see **17-HYDROXYSTEROID DEHYDROGENASES**

TESTOSTERONE DELTA-4-5-ALPHA-REDUCTASE see **TESTOSTERONE 5-ALPHA-REDUCTASE**

TESTOSTERONE-ESTRADIOL BINDING GLOBULIN see **SEX HORMONE-BINDING GLOBULIN**

TESTOSTERONE PROPIONATE see **TESTOSTERONE**

TETANUS

DIAGNOSIS

Immunodiagnosis and immunotherapy of tetanus and botulinum neurotoxins. Middlebrook JL, et al. **Curr Top Microbiol Immunol** 1995;195:89-122 (179 ref.)

IMMUNOLOGY

Cellular immunology of tetanus toxoid. Corradin G, et al. **Curr Top Microbiol Immunol** 1995;195:77-87 (45 ref.)

PREVENTION & CONTROL

The present status of tetanus and tetanus vaccination. Galazka A, et al. **Curr Top Microbiol Immunol** 1995;195:31-53 (100 ref.)

THERAPY

Immunodiagnosis and immunotherapy of tetanus and botulinum neurotoxins. Middlebrook JL, et al. **Curr Top Microbiol Immunol** 1995;195:89-122 (179 ref.)

TETANUS TOXIN

Ecology of neurotoxigenic strains of clostridia. Popoff MR. **Curr Top Microbiol Immunol** 1995;195:1-29 (113 ref.)

Molecular aspects of tetanus and botulinum neurotoxin poisoning. Ahnert-Hilger G, et al. **Prog Neurobiol** 1995 May;46(1):83-96 (180 ref.)

ANALYSIS

The metallo-proteinase activity of tetanus and botulism neurotoxins. Rossetto O, et al. **J Physiol Paris** 1995; 89(1):43-50 (60 ref.)

GENETICS

Molecular genetics of clostridial neurotoxins. Minton NP. **Curr Top Microbiol Immunol** 1995;195:161-94 (83 ref.)

ISOLATION & PURIFICATION

Growth of clostridia and preparation of their neurotoxins. Shone CC, et al. **Curr Top Microbiol Immunol** 1995; 195:143-60 (56 ref.)

METABOLISM

Neurospecific binding, internalization, and retrograde axonal transport. Halpern JL, et al. **Curr Top Microbiol Immunol** 1995;195:221-41 (147 ref.)

Quantal neurotransmitter release and the clostridial neurotoxins' targets. Poulain B, et al. **Curr Top Microbiol Immunol** 1995;195:243-55 (77 ref.)

Intracellular targets and metalloprotease activity of tetanus and botulism neurotoxins. Schiavo G, et al. **Curr Top Microbiol Immunol** 1995;195:257-74 (90 ref.)

Bacterial neurotoxins--a thousand years later. Linial M. **Isr J Med Sci** 1995 Oct;31(10):591-5 (15 ref.)

TOXICITY

The mechanism of action of tetanus and botulinum neurotoxins. Montecucco C, et al. **Arch Toxicol Suppl** 1996; 18:342-54 (66 ref.)

TETANUS TOXOID

The present status of tetanus and tetanus vaccination. Galazka A, et al. **Curr Top Microbiol Immunol** 1995;195:31-53 (100 ref.)

IMMUNOLOGY

Cellular immunology of tetanus toxoid. Corradin G, et al. **Curr Top Microbiol Immunol** 1995;195:77-87 (45 ref.)

TETANUS VACCINE see **TETANUS TOXOID**

TETANY

VETERINARY

Impaired absorption of magnesium in the aetiology of grass tetany. Dua K, et al. **Br Vet J** 1995 Jul-Aug;151(4):413-26 (98 ref.)

TETHERED CORD SYNDROME see **SPINA BIFIDA OCCULTA**

TETRACEMATE see **EDETIC ACID**

TETRACHLORODIBENZODIOXIN

ADVERSE EFFECTS

Induced gene transcription: implications for biomarkers. Sewall CH, et al. **Clin Chem** 1995 Dec;41(12 Pt 2):1829-34 (59 ref.)

Quantitative risk assessment and the limitations of the linearized multistage model. Lovell DP, et al. **Hum Exp Toxicol** 1996 Feb;15(2):87-104 (50 ref.)

ANALOGS & DERIVATIVES

Sources of PCDD/PCDF and impact on the environment. Fiedler H. **Chemosphere** 1996 Jan;32(1):55-64 (17 ref.)

Biomarkers for Great Lakes priority contaminants: halogenated aromatic hydrocarbons. Feeley MM. **Environ Health Perspect** 1995 Dec;103 Suppl 9:7-16 (106 ref.)

Reliability of the determinations of polychlorinated contaminants (biphenyls, dioxins, furans). Horwitz W, et al. **J AOAC Int** 1996 May-Jun;79(3):589-621 (55 ref.)

Validation of a methodology for modelling PCDD and PCDF intake via the foodchain. Eduljee GH, et al. **Sci Total Environ** 1996 Sep 9;187(3):211-29 (36 ref.)

ANALYSIS

Comparisons of estimated human body burdens of dioxinlike chemicals and TCDD body burdens in experimentally exposed animals. DeVito MJ, et al. **Environ Health Perspect** 1995 Sep;103(9):820-31 (113 ref.)

TOXICITY

Immunological effects of chlorinated dibenzo-p-dioxins. Kerkvliet NI. **Environ Health Perspect** 1995 Dec;103 Suppl 9:47-53 (85 ref.)

Receptor-mediated events and the evaluation of the Environmental Protection Agency (EPA) of dioxin risks. Sewall CH, et al. **Mutat Res** 1995 Dec;333(1-2):111-22 (54 ref.)

Modulation of gene expression and endocrine response pathways by 2,3,7,8-tetrachlorodibenzo-p-dioxin and related compounds. Safe SH. **Pharmacol Ther** 1995; 67(2):247-81 (369 ref.)

Developmental effects of dioxins and related endocrine disrupting chemicals. Birnbaum LS. **Toxicol Lett** 1995 Dec; 82-83:743-50 (60 ref.)

Chlorinated hydrocarbons: estrogens and antiestrogens. Safe S, et al. **Toxicol Lett** 1995 Dec;82-83:731-6 (30 ref.)

Review of the interaction between TCDD and glucocorticoids in embryonic palate. Abbott BD. **Toxicology** 1995 Dec 28;105(2-3):365-73 (86 ref.)

TETRACHLOROETHYLENE

METABOLISM

Reductive dechlorination of tetrachloroethene by a high rate anaerobic microbial consortium. Zinder SH, et al. **Environ Health Perspect** 1995 Jun;103 Suppl 5:5-7 (12 ref.)

POISONING

[Exposure to solvents in scleroderma: disseminated circumscribed scleroderma (morphea) in a painter exposed to perchloroethylene] Hinnen U, et al. **Schweiz Med Wochenschr** 1995 Dec 16;125(50):2433-7 (13 ref.) (Eng. Abstr.) **(Ger)**

TETRACYCLINE

PHARMACOLOGY

Diverse strategies for tetracycline-regulated inducible gene expression [see comments] Shockett PE, et al. **Proc Natl Acad Sci U S A** 1996 May 28;93(11):5173-6 (38 ref.) Comment in: Proc Natl Acad Sci U S A 1996 May 28;93(11):5185-90.

THERAPEUTIC USE

Antibiotic resistance: relationship to persistence of group A streptococci in the upper respiratory tract. Gerber MA. **Pediatrics** 1996 Jun;97(6 Pt 2):971-5 (59 ref.)

TETRACYCLINE ANTIBIOTICS see **ANTIBIOTICS, TETRACYCLINE**

TETRACYCLINE RESISTANCE

Tetracyclines: antibiotic action, uptake, and resistance mechanisms. Schnappinger D, et al. **Arch Microbiol** 1996 Jun;165(6):359-69 (119 ref.)

Surveillance of antibiotic resistance in Neisseria gonorrhoeae and implications for the therapy of gonorrhoea [editorial] Tapsall JW. **Int J STD AIDS** 1995 Jul-Aug;6(4):233-6 (24 ref.)

Clinical significance of bacterial resistance to tetracyclines in the treatment of periodontal diseases. Greenstein G. **J Periodontol** 1995 Nov;66(11):925-32 (72 ref.)

TETRACYCLINES

ADVERSE EFFECTS

Toxic effects and drug interactions of antimycobacterial therapy. Chan-Tompkins NH. **Clin Dermatol** 1995 May-Jun;13(3):223-33 (99 ref.)

BIOSYNTHESIS

Tetracyclines. Běhal V, et al. **Biotechnology** 1995;28:359-84 (99 ref.)

[Possible role of threonine metabolism in tetracycline biosynthesis] Mironov VA, et al. **Antibiot Khimioter** 1995 Mar;40(3):52-6 (29 ref.) (Eng. Abstr.) **(Rus)**

CHEMISTRY

Tetracyclines. Běhal V, et al. **Biotechnology** 1995;28:359-84 (99 ref.)

PHARMACOLOGY

Tetracyclines: antibiotic action, uptake, and resistance mechanisms. Schnappinger D, et al. **Arch Microbiol** 1996 Jun;165(6):359-69 (119 ref.)

TETRADECANOIC ACIDS see **MYRISTIC ACIDS**

TETRADECANOYLPHORBOL ACETATE

PHARMACOLOGY

New insights into the regulation of ICAM-1 gene expression. Ohh M, et al. **Leuk Lymphoma** 1996 Jan;20(3-4):223-8 (43 ref.)

TETRAETHYLTHIURAM DISULFIDE see **DISULFIRAM**

TETRAGASTRIN

see related
GASTROINTESTINAL AGENTS

TETRAGASTRIN RECEPTORS see **RECEPTORS, CHOLECYSTOKININ**

TETRAHYDRO-1,4-OXAZINES see **MORPHOLINES**

TETRAHYDROAMINOACRIDINE see **TACRINE**

TETRAHYDROCANNABINOL

ANALOGS & DERIVATIVES

Development of HU-211 as a neuroprotectant for ischemic brain damage. Biegon A, et al. **Neurol Res** 1995 Aug; 17(4):275-80 (27 ref.)

PHARMACOLOGY

Role of cyclic AMP in the actions of cannabinoid receptors. Childers SR, et al. **Biochem Pharmacol** 1996 Sep 27; 52(6):819-27 (68 ref.)

TETRAHYDROFOLATE DEHYDROGENASE

CHEMISTRY

Eukaryotic dihydrofolate reductase. Blakley RL. **Adv Enzymol Relat Areas Mol Biol** 1995;70:23-102 (102 ref.)

Origins of replication and the nuclear matrix: the DHFR domain as a paradigm. Dijkwel PA, et al. **Int Rev Cytol** 1995;162A:455-84 (180 ref.)

GENETICS

Transcriptional regulation of the dihydrofolate reductase gene. Slansky JE, et al. **Bioessays** 1996 Jan;18(1):55-62 (64 ref.)

METABOLISM

Eukaryotic dihydrofolate reductase. Blakley RL. **Adv Enzymol Relat Areas Mol Biol** 1995;70:23-102 (102 ref.)

Brodimoprim, a new bacterial dihydrofolate reductase inhibitor: a minireview. Periti P. **J Chemother** 1995 Jun; 7(3):221-3 (22 ref.)

TETRAHYMENA

PHYSIOLOGY

Multifunctional proteins in Tetrahymena: 14-nm filament protein/citrate synthase and translation elongation factor-1 alpha. Numata O. **Int Rev Cytol** 1996;164:1-35 (126 ref.)

TETRAHYMENA PYRIFORMIS

DRUG EFFECTS

Structure-toxicity relationships for phenols to Tetrahymena pyriformis. Cronin MT, et al. **Chemosphere** 1996 Apr; 32(8):1453-68 (36 ref.)

L-3,5,3',5'-TETRAIODOTHYRONINE see **LEVOTHYROXINE**

TETRALOGY OF FALLOT

COMPLICATIONS

Acinetobacter endocarditis in children: a case report and review of the literature. Malik AS. **Infection** 1995 Sep-Oct; 23(5):306-8 (18 ref.)

SURGERY

Repeated repair of tetralogy of Fallot. Report of 11 cases and review of the literature. Abramov D, et al. **Scand J Thorac Cardiovasc Surg** 1995;29(3):111-3 (13 ref.)

THERAPY

[Percutaneous pulmonary valvuloplasty in neonates and infants with tetralogy of Fallot] Godart F, et al. **Arch Mal Coeur Vaiss** 1996 May;89(5):533-9 (30 ref.) (Eng. Abstr.) **(Fre)**

ULTRASONOGRAPHY

[A 63-year-old man with uncorrected tetralogy of Fallot] Hoffmann A, et al. **Z Kardiol** 1995 Dec;84(12):1039-42 (22 ref.) (Eng. Abstr.) **(Ger)**

TETRAMETHYL ACRIDINE DIAMINE see **ACRIDINE ORANGE**

L-TETRAMISOLE see **LEVAMISOLE**

TETRANUCLEOTIDE REPEATS see **MICROSATELLITE REPEATS**

TETRAPLEGIA see **QUADRIPLEGIA**

TETRAZOLES

Discovery of losartan, the first angiotensin II receptor antagonist. Timmermans PB, et al. **J Hum Hypertens** 1995 Nov;9 Suppl 5:S3-18 (199 ref.)

Angiotensin receptor antagonists: focus on losartan. Johnston CI. **Lancet** 1995 Nov 25;346(8987):1403-7 (36 ref.)

[Selective type III phosphodiesterase inhibitor as an antithrombotic agent] Kimura Y. **Nippon Yakurigaku Zasshi** 1995 Sep;106(3):205-16 (39 ref.) (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

Angiotensin II antagonists: a new class of antihypertensive agent. Waeber B, et al. **Br J Clin Pract** 1996 Jul-Aug; 50(5):265-8 (35 ref.)

Angiotensin II receptor antagonism: losartan - sites and mechanisms of action. Triggle DJ. **Clin Ther** 1995 Nov-Dec;17(6):1005-30 (132 ref.)

Effect of angiotensin II blockade on cardiac hypertrophy and remodelling: a review. Dahlöf B. **J Hum Hypertens** 1995 Nov;9 Suppl 5:S37-44 (84 ref.)

[Antagonists of angiotensin II receptor] Karasek D, et al. **Postepy Hig Med Dosw** 1996;50(1):21-32 (64 ref.) (Eng. Abstr.) **(Pol)**

THERAPEUTIC USE

Angiotensin II receptor antagonists in heart failure: rationale and design of the evaluation of losartan in the elderly (ELITE) trial. Pitt B, et al. **Cardiovasc Drugs Ther** 1995 Oct;9(5):693-700 (80 ref.)

The future role of losartan. Hansson L. **J Hum Hypertens** 1995 Nov;9 Suppl 5:S55-8 (24 ref.)

[Losartan and the LIFE-study. Antihypertensive treatment with AT1-receptor antagonist] Kjeldsen SE, et al. **Tidsskr Nor Laegeforen** 1996 Feb 10;116(4):504-7 (25 ref.) (Eng. Abstr.) **(Nor)**

TEXTBOOKS, PROGRAMMED see **PROGRAMMED INSTRUCTION**

TEXTILE INDUSTRY

[A syndrome caused by separating rags in textile industry: a new clinical entity?] Fioravanti A, et al. **Minerva Med** 1995 Nov;86(11):467-4 (25 ref.) (Eng. Abstr.) **(Ita)**

METHODS

The development of advanced cellulosic fibres. Woodings CR. **Int J Biol Macromol** 1995 Dec;17(6):305-9 (31 ref.)

TEXTILES

ADVERSE EFFECTS

Textile dermatitis: an update. (I). Resins, additives and fibers. Hatch KL, et al. **Contact Dermatitis** 1995 Jun;32(6):319-26 (34 ref.)

TFE see **POLYTETRAFLUOROETHYLENE**

TGF-ALPHA see **TRANSFORMING GROWTH FACTOR ALPHA**

TGF-ALPHA RECEPTORS see **RECEPTORS, EPIDERMAL GROWTH FACTOR-UROGASTRONE**

TGF-BETA see **TRANSFORMING GROWTH FACTOR BETA**

TGF-BETA RECEPTORS see **RECEPTORS, TRANSFORMING GROWTH FACTOR BETA**

TH1 CELLS

The ontogeny of class-regulation of CD4+ T lymphocyte populations. Carneiro J, et al. **Int Immunol** 1995 Aug; 7(8):1265-77 (37 ref.)

IMMUNOLOGY

The role of Th1 and Th2 cells for mucosal IgA responses. Yamamoto M, et al. **Ann N Y Acad Sci** 1996 Feb 13; 778:64-71 (39 ref.)

Reversal of polarized T helper 1 and T helper 2 cell populations in murine leishmaniasis. Coffman RL, et al. **Ciba Found Symp** 1995;195:20-5; discussion 25-33 (30 ref.)

Signalling events in the anergy induction of T helper 1 cells. Sloan-Lancaster J, et al. **Ciba Found Symp** 1995;195:189-96; discussion 196-202 (33 ref.)

The Th1/Th2 balance in autoimmunity. Charlton B, et al. **Curr Opin Immunol** 1995 Dec;7(6):793-8 (51 ref.)

Cytokines and transplantation: Th1/Th2 regulation of the immune response to solid organ transplants in the adult. Dallman MJ. **Curr Opin Immunol** 1995 Oct;7(5):632-8 (54 ref.)

Peptide modulation of allergen-specific immune responses. Hoyne GF, et al. **Curr Opin Immunol** 1995 Dec;7(6):757-61 (41 ref.)

Graft-versus-host disease and the Th1/Th2 paradigm. Krenger W, et al. **Immunol Res** 1996;15(1):50-73 (172 ref.)

Fas-mediated cytotoxicity--a new immunoregulatory and pathogenic function of Th1 CD4+ T cells. Yagita H, et al. **Immunol Rev** 1995 Aug;146:223-39 (71 ref.)

Th1 and Th2 subsets: paradigms lost? Kelso A. **Immunol Today** 1995 Aug;16(8):374-9 (41 ref.)

The role of IL-12 in the induction of organ-specific autoimmune diseases. Trembleau S, et al. **Immunol Today** 1995 Aug;16(8):383-6 (51 ref.)

Biology of human TH1 and TH2 cells. Romagnani S. **J Clin Immunol** 1995 May;15(3):121-9 (77 ref.)

Characteristics of the T lymphocytes involved in experimental allergic encephalomyelitis. Kalman B, et al. **J Neuroimmunol** 1995 Sep;61(2):107-16 (101 ref.)

[The IgA immune system for mucosal vaccine: role of levels one and two Th2 cytokine producing T cells] Shimaoka M, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Feb; 19(1):114-8 (15 ref.) **(Jpn)**

METABOLISM

Dendritic cells from different tissues induce production of different T cell cytokine profiles. Everson MP, et al. **J Leukoc Biol** 1996 Apr;59(4):494-8 (31 ref.)

PHYSIOLOGY

Th1 and Th2 in human diseases. Romagnani S. **Clin Immunol Immunopathol** 1996 Sep;80(3 Pt 1):225-35 (103 ref.)

TH2 CELLS

The ontogeny of class-regulation of CD4+ T lymphocyte populations. Carneiro J, et al. **Int Immunol** 1995 Aug; 7(8):1265-77 (37 ref.)

IMMUNOLOGY

The one-two of T helper cells: does interferon-gamma knock out the Th2 hypothesis for asthma? [comment] Holtzman MJ, et al. **Am J Respir Cell Mol Biol** 1996 Apr;14(4):316-8 (24 ref.) Comment on: Am J Respir Cell Mol Biol 1996 Apr;14(4):319-26.

The role of Th1 and Th2 cells for mucosal IgA responses. Yamamoto M, et al. **Ann N Y Acad Sci** 1996 Feb 13; 778:64-71 (39 ref.)

Reversal of polarized T helper 1 and T helper 2 cell populations in murine leishmaniasis. Coffman RL, et al. **Ciba Found Symp** 1995;195:20-5; discussion 25-33 (30 ref.)

Role for CD30 antigen in human T helper 2-type responses. Romagnani S. **Ciba Found Symp** 1995;195:55-62; discussion 62-7 (43 ref.)

Cytokines and transplantation: Th1/Th2 regulation of the immune response to solid organ transplants in the adult. Dallman MJ. **Curr Opin Immunol** 1995 Oct;7(5):632-8 (54 ref.)

Antagonizing the differentiation and functions of human T helper type 2 cells. de Vries JE, et al. **Curr Opin Immunol** 1995 Dec;7(6):771-8 (63 ref.)

Induction of Th2 responses in infectious diseases. Pearce EJ, et al. **Curr Opin Immunol** 1995 Aug;7(4):497-504 (67 ref.)

Atopic allergy and other hypersensitivities editorial overview: technological advances and new insights into pathogenesis prelude novel therapeutic strategies [editorial] Romagnani S. **Curr Opin Immunol** 1995 Dec;7(6):745-50 (62 ref.)

Graft-versus-host disease and the Th1/Th2 paradigm. Krenger W, et al. **Immunol Res** 1996;15(1):50-73 (172 ref.)

Th1 and Th2 subsets: paradigms lost? Kelso A. **Immunol Today** 1995 Aug;16(8):374-9 (41 ref.)

Biology of human TH1 and TH2 cells. Romagnani S. **J Clin Immunol** 1995 May;15(3):121-9 (77 ref.)

Does exposure to UV radiation induce a shift to a Th-2-like immune reaction? Ullrich SE. **Photochem Photobiol** 1996 Aug;64(2):254-8 (41 ref.)

[The IgA immune system for mucosal vaccine: role of levels one and two Th2 cytokine producing T cells] Shimaoka M, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Feb; 19(1):114-8 (15 ref.) **(Jpn)**

METABOLISM

Role and modulation of T-cell cytokines in allergy. Daser A, et al. **Curr Opin Immunol** 1995 Dec;7(6):762-70 (61 ref.)

Antagonizing the differentiation and functions of human T helper type 2 cells. de Vries JE, et al. **Curr Opin Immunol** 1995 Dec;7(6):771-8 (63 ref.)

Dendritic cells from different tissues induce production of different T cell cytokine profiles. Everson MP, et al. **J Leukoc Biol** 1996 Apr;59(4):494-8 (31 ref.)

PHYSIOLOGY

Mercury: god of Th2 cells? [editorial; comment] Mathieson PW. **Clin Exp Immunol** 1995 Nov;102(2):229-30 (26 ref.) Comment on: Clin Exp Immunol 1995 Nov;102(2):297-307.

Th1 and Th2 in human diseases. Romagnani S. **Clin Immunol Immunopathol** 1996 Sep;80(3 Pt 1):225-35 (103 ref.)

RADIATION EFFECTS

Does exposure to UV radiation induce a shift to a Th-2-like immune reaction? Ullrich SE. **Photochem Photobiol** 1996 Aug;64(2):254-8 (41 ref.)

THALAMIC DISEASES

COMPLICATIONS

Understanding central post-stroke pain. Segatore M. **J Neurosci Nurs** 1996 Feb;28(1):28-35 (74 ref.)

PHYSIOPATHOLOGY

Thalamic tremor: case reports and implications of the tremor-generating mechanism. Miwa H, et al. **Neurology** 1996 Jan;46(1):75-9 (26 ref.)

THALAMIC NUCLEI

PHYSIOLOGY

On the neurophysiology of consciousness: I. An overview. Bogen JE. **Conscious Cogn** 1995 Mar;4(1):52-62 (70 ref.)

On the neurophysiology of consciousness: Part II. Constraining the semantic problem [see comments] Bogen JE. **Conscious Cogn** 1995 Jun;4(2):137-58 (100 ref.) Comment in: Conscious Cogn 1995 Jun;4(2):159-62. Comment in: Conscious Cogn 1995 Jun;4(2):163-6. Comment in: Conscious Cogn 1995 Jun;4(2):167-71. Comment in: Conscious Cogn 1995 Jun;4(2):172-93.

Thalamic contributions to attention and consciousness [comment] Newman J. **Conscious Cogn** 1995 Jun; 4(2):172-93 (65 ref.) Comment on: Conscious Cogn 1995 Jun;4(2):137-58.

[The roles of thalamic nucleus submedius in nociception and pain modulation] Tang JS, et al. **Sheng Li Ko Hsueh Chin Chan** 1995 Oct;26(4):312-6 (20 ref.) (Eng. Abstr.) **(Chi)**

THALAMOSTRIATE VEIN see **CEREBRAL VEINS**

THALAMUS

ANATOMY & HISTOLOGY

Anatomical evidence concerning the role of the thalamus in corticocortical communication: a brief review. Guillery RW. **J Anat** 1995 Dec;187 (Pt 3):583-92 (69 ref.)

CHEMISTRY

Functions of ionotropic and metabotropic glutamate receptors in sensory transmission in the mammalian

THALAMUS

thalamus. Salt TE, et al. **Prog Neurobiol** 1996 Jan; 48(1):55–72 (220 ref.)

PATHOLOGY

Vertical gaze paralysis and intermittent unresponsiveness in a patient with a thalamomesencephalic stroke. Beversdorf DQ, et al. **J Neuroophthalmol** 1995 Dec;15(4):230–5 (21 ref.)

PHYSIOLOGY

A model of the dynamics of prefrontal cortico–thalamo–basal ganglionic loops in verbal response selection tasks. Gullapalli V, et al. **Ann N Y Acad Sci** 1995 Dec 15; 769:375–80 (22 ref.)

The dorsal thalamus of jawed vertebrates: a comparative viewpoint. Butler AB. **Brain Behav Evol** 1995; 46(4–5):209–23 (115 ref.)

The evolution of isocortex. Kaas JH. **Brain Behav Evol** 1995; 46(4–5):187–96 (52 ref.)

The thalamus of reptiles and mammals: similarities and differences. Pritz MB. **Brain Behav Evol** 1995; 46(4–5):197–208 (54 ref.)

The role of the cerebello–thalamo–cortical pathway in skilled movement. Horne MK, et al. **Prog Neurobiol** 1995 Jun; 46(2–3):199–213 (150 ref.)

How do thalamic axons find their way to the cortex? Molnár Z, et al. **Trends Neurosci** 1995 Sep;18(9):389–97 (54 ref.)

[Clinical application of functional mapping; the present state of the art and its future prospects: (series 5) functional mapping of the human thalamus] Ohye C. **No Shinkei Geka** 1996 Jun;24(6):501–6 (22 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Primary (idiopathic) generalized epilepsy and underlying mechanisms. Niedermeyer E. **Clin Electroencephalogr** 1996 Jan;27(1):1–21 (147 ref.)

THALASSEMIA

Thalassemia in pregnancy. Kilpatrick SJ, et al. **Clin Obstet Gynecol** 1995 Sep;38(3):485–96 (62 ref.)

Thalassemia—a global public health problem. Weatherall DJ, et al. **Nat Med** 1996 Aug;2(8):847–9 (22 ref.)

[Thalassemia, heading for Sweden. A new patient group at Swedish pediatric clinics] Sandström L, et al. **Lakartidningen** 1996 Jan 3;93(1–2):26–30 (15 ref.) **(Swe)**

DIAGNOSIS

Advances in the prenatal and molecular diagnosis of the hemoglobinopathies and thalassemias. Embury SH. **Hemoglobin** 1995 Sep;19(5):237–61 (125 ref.)

GENETICS

Current status of thalassemia and the sickle cell syndromes in Greece. Loukopoulos D. **Semin Hematol** 1996 Jan; 33(1):76–86 (63 ref.)

IMMUNOLOGY

Production of monoclonal and polyclonal antibodies against various haemoglobins for the detection of thalassaemias. Gan YY, et al. **Ann Acad Med Singapore** 1996 Jan; 25(1):75–8 (20 ref.)

PHYSIOPATHOLOGY

Advances in the pathophysiology and treatment of thalassemia. Rund D, et al. **Crit Rev Oncol Hematol** 1995 Oct;20(3):237–54 (151 ref.)

PSYCHOLOGY

Psychological and sociological aspects of the thalassemias. Ratip S, et al. **Semin Hematol** 1996 Jan;33(1):53–65 (53 ref.)

THERAPY

Mucormycosis after bone marrow transplantation: report of four cases in thalassemia and review of the literature. Gaziev D, et al. **Bone Marrow Transplant** 1996 Mar; 17(3):409–14 (34 ref.)

Advances in the pathophysiology and treatment of thalassemia. Rund D, et al. **Crit Rev Oncol Hematol** 1995 Oct;20(3):237–54 (151 ref.)

Transfusion-dependent thalassemia: viral complications (epidemiology and follow-up). de Montalembert M, et al. **Semin Hematol** 1995 Oct;32(4):280–7 (46 ref.)

Chelation therapy in beta-thalassemia: the benefits and limitations of desferrioxamine. Giardina PJ, et al. **Semin Hematol** 1995 Oct;32(4):304–12 (93 ref.)

Management of thalassemias: growth and development, hormone substitution, vitamin supplementation, and vaccination. Kattamis CA, et al. **Semin Hematol** 1995 Oct; 32(4):269–79 (46 ref.)

Bone marrow transplantation in thalassemia. Lucarelli G, et al. **Semin Hematol** 1995 Oct;32(4):297–303 (26 ref.)

THALASSEMIA-ALPHA see **ALPHA-THALASSEMIA**

THALASSEMIA MAJOR see **BETA-THALASSEMIA**

THALASSEMIA MINOR see **BETA-THALASSEMIA**

THALASSOTHERAPY

TRENDS

[Thalassotherapy: its current therapeutic influence] San Martin Bacaicoa J. **An R Acad Nac Med (Madr)** 1995; 112(2):347–79 (51 ref.) **(Spa)**

THALIDOMIDE

THERAPEUTIC USE

Thalidomide in diseases associated with human immunodeficiency virus infection. Minor JR, et al. **Am J Health Syst Pharm** 1996 Feb 15;53(4):429–31 (14 ref.)

Thalidomide for aphthous ulcers in patients infected with the human immunodeficiency virus. Weidle PJ. **Am J Health Syst Pharm** 1996 Feb 15;53(4):368, 371–2, 378 (12 ref.)

Thalidomide: rationale for renewed use in immunological disorders. Schuler U, et al. **Drug Saf** 1995 Jun;12(6):364–9 (61 ref.)

THALLIUM

DIAGNOSTIC USE

Preliminary experience with thallous chloride T1 201–labeled single-photon emission computed tomography scanning in head and neck cancer. Gregor RT, et al. **Arch Otolaryngol Head Neck Surg** 1996 May;122(5):509–14 (25 ref.)

THALLIUM RADIOISOTOPES

DIAGNOSTIC USE

Preliminary experience with thallous chloride T1 201–labeled single-photon emission computed tomography scanning in head and neck cancer. Gregor RT, et al. **Arch Otolaryngol Head Neck Surg** 1996 May;122(5):509–14 (25 ref.)

Thallium imaging in management of post-revascularization patients. Alazraki P, et al. **Q J Nucl Med** 1996 Mar; 40(1):85–90 (26 ref.)

THANATOLOGY

see related
DEATH

THC see **TETRAHYDROCANNABINOL**

THEA see **TEA**

THECA CELL TUMOR see **THECOMA**

THECOMA

PATHOLOGY

Luteinized thecoma with sclerosing peritonitis. Werness BA. **Arch Pathol Lab Med** 1996 Mar;120(3):303–6 (9 ref.)

THEFT

PSYCHOLOGY

Military shoplifting. Lande G. **Mil Med** 1995 Aug; 160(8):404–7 (28 ref.)

THEILERIA

GENETICS

Influence of host and parasite genotypes on immunological control of Theileria parasites. Morrison WI. **Parasitology** 1996;112 Suppl:S53–66 (89 ref.)

PATHOGENICITY

Review of Australian species of Theileria, with special reference to Theileria buffeli of cattle. Stewart NP, et al. **Trop Anim Health Prod** 1996 Feb;28(1):81–90 (63 ref.)

THEILERIASIS

ETIOLOGY

Review of Australian species of Theileria, with special reference to Theileria buffeli of cattle. Stewart NP, et al. **Trop Anim Health Prod** 1996 Feb;28(1):81–90 (63 ref.)

GENETICS

Influence of host and parasite genotypes on immunological control of Theileria parasites. Morrison WI. **Parasitology** 1996;112 Suppl:S53–66 (89 ref.)

PREVENTION & CONTROL

Appropriate strategies for the control or eradication of ticks and tick-borne diseases. Wilson A. **Ann N Y Acad Sci** 1996 Jul 23;791:54–63 (21 ref.)

THEILER'S MURINE ENCEPHALOMYELITIS VIRUS see **POLIOVIRUSES, MURINE**

THELAZIA see **THELAZIOIDEA**

THELAZIOIDEA

PHYSIOLOGY

Spirocerca lupi infection in the dog: aberrant migration. Harrus S, et al. **J Am Anim Hosp Assoc** 1996 Mar–Apr; 32(2):125–30 (29 ref.)

THEOLOGY see **RELIGION**

THEOPHYLLINE

ADMINISTRATION & DOSAGE

Prolongation of ECT-induced seizures with theophylline [letter] Stewart JT. **J Am Geriatr Soc** 1996 Apr;44(4):475 (9 ref.)

ADVERSE EFFECTS

Influenza vaccine may enhance theophylline toxicity. A case report and review of the literature. Hamdy RC, et al. **J Tenn Med Assoc** 1995 Dec;88(12):463–4 (12 ref.)

BLOOD

[Theophylline] Nishihara K. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:966–9 (9 ref.) **(Jpn)**

PHARMACOLOGY

The role of theophylline in the treatment of asthma [editorial] Kamada AK, et al. **Ann Allergy Asthma Immunol** 1996 Jul; 77(1):1–3 (47 ref.)

PDE isoenzymes as targets for anti-asthma drugs. Schudt C, et al. **Eur Respir J** 1995 Jul;8(7):1179–83 (18 ref.)

Pharmacokinetic interactions related to the chemical structures of fluoroquinolones. Mizuki Y, et al. **J Antimicrob Chemother** 1996 May;37 Suppl A:41–55 (46 ref.)

POISONING

[Encephalopathy, convulsions and hypopotassemia in theophylline poisoning: a case analysis] Suárez Ortega S, et al. **Arch Bronconeumol** 1995 Aug–Sep;31(7):368–70 (23 ref.) (Eng. Abstr.) **(Spa)**

THERAPEUTIC USE

Theophylline and selective phosphodiesterase inhibitors as anti-inflammatory drugs in the treatment of bronchial asthma. Banner KH, et al. **Eur Respir J** 1995 Jun; 8(6):996–1000 (50 ref.)

Two new roles for theophylline in the asthmatic? [see comments] Jenne JW. **J Asthma** 1995;32(2):89–95 (56 ref.) Comment in: J Asthma 1995;32(2):85–7.

Theophylline in asthma. Weinberger M, et al. **N Engl J Med** 1996 May 23;334(21):1380–8 (100 ref.)

THERAPEUTIC COMMUNITY

Therapeutic communities for addictions: a theoretical framework. De Leon G. **Int J Addict** 1995;30(12):1603–45 (42 ref.)

Challenges in moving from a traditional therapeutic community to a women and children's TC model. Brown VB, et al. **J Psychoactive Drugs** 1996 Jan–Mar;28(1):39–46 (16 ref.)

Clinical issues in therapeutic communities. Carroll JF. **NIDA Res Monogr** 1994;144:268–79 (9 ref.)

Client outcomes from therapeutic communities. Condelli WS, et al. **NIDA Res Monogr** 1994;144:80–98 (29 ref.)

Predictors of retention in therapeutic communities. Condelli WS. **NIDA Res Monogr** 1994;144:117–27 (22 ref.)

The therapeutic community: toward a general theory and model. De Leon G. **NIDA Res Monogr** 1994;144:16–53 (24 ref.)

Therapeutic communities in corrections and work release: some clinical and policy considerations. Inciardi JA, et al. **NIDA Res Monogr** 1994;144:259–67 (3 ref.)

Co-morbidity and therapeutic community treatment. Jainchill N. **NIDA Res Monogr** 1994;144:209–31 (35 ref.)

Therapeutic communities for adolescents. Jainchill N, et al. **NIDA Res Monogr** 1995;156:190–217 (19 ref.)

Retention in therapeutic communities: challenges for the nineties. Lewis BF, et al. **NIDA Res Monogr** 1994; 144:99–116 (45 ref.)

HIV and therapeutic communities. McCusker J, et al. **NIDA Res Monogr** 1994;144:232–58 (128 ref.)

Adolescents in therapeutic communities: retention and posttreatment outcome. Pompi KF. **NIDA Res Monogr** 1994;144:128–61 (28 ref.)

Therapeutic communities: substance abuse treatment for women. Stevens SJ, et al. **NIDA Res Monogr** 1994; 144:162–80 (30 ref.)

Socialization into the therapeutic community culture. Szalay L. **NIDA Res Monogr** 1994;144:54–79 (21 ref.)

Therapeutic communities and treatment research. Tims FM, et al. **NIDA Res Monogr** 1994;144:1–15 (19 ref.)

Therapeutic communities in prison. Wexler HK, et al. **NIDA Res Monogr** 1994;144:181–208 (40 ref.)

THERAPEUTIC CULTS see **ALTERNATIVE MEDICINE**

THERAPEUTIC RADIOLOGY see **RADIATION ONCOLOGY**

THERAPEUTICS

Signal transduction interception as a novel approach to disease management. Levitzki A. **Ann N Y Acad Sci** 1995 Sep 7;766:363–8 (22 ref.)

[Ethical decisions in medical treatment] Jorke D. **Med Klin** 1996 Apr 10;91(4):238–42 (45 ref.) **(Ger)**

[How to read a scientific article? 5. How to choose a treatment?] Demichelis B, et al. **G Ital Cardiol** 1995 Oct; 25(10):1339–50 (55 ref.) **(Ita)**

PSYCHOLOGY

Determinants and consequences of children's coping in the medical setting: conceptualization, review, and critique. Rudolph KD, et al. **Psychol Bull** 1995 Nov;118(3):328–57 (130 ref.)

THERAPY, COMPUTER-ASSISTED

Three-dimensional imaging, surgical planning, and image-guided therapy. Vannier MW, et al. **Radiol Clin North Am** 1996 May;34(3):545–63 (131 ref.)

[The treatment and teaching aspects in the computerized management of the surgical emergency (editorial)] Bonomo M, et al. **Recenti Prog Med** 1996 May;87(5):229–36 (24 ref.) **(Ita)**

[Use of fuzzy set theory in therapy] Bogdanik T. **Pol Arch Med Wewn** 1995 Feb;93(2):149–54 (13 ref.) **(Pol)**

METHODS

[Computer-assisted surgery: assessment and perspectives] Demongeot J. **Chirurgie** 1994–95;120(11):19–25 (27 ref.) (Eng. Abstr.) **(Fre)**

THERAPY, HOME INFUSION see **HOME INFUSION THERAPY**

THERMOCOAGULATION see **ELECTROCOAGULATION**

THERMODILUTION

INSTRUMENTATION

The thermodilution method for the clinical assessment of cardiac output. Jansen JR. **Intensive Care Med** 1995 Aug; 21(8):691–7 (44 ref.)

THERMODYNAMICS

Salt-nucleic acid interactions. Anderson CF, et al. **Annu Rev Phys Chem** 1995;46:657–700 (63 ref.)

Principles of protein-protein recognition from structure to thermodynamics. Janin J. **Biochimie** 1995;77(7–8):497–505 (43 ref.)

Computational methods to predict binding free energy in ligand-receptor complexes. Murcko A, et al. **J Med Chem** 1995 Dec 22;38(26):4953–67 (90 ref.)

Strategies for RNA folding. Draper DE. **Trends Biochem Sci** 1996 Apr;21(4):145–9 (38 ref.)

[Thermodynamics of biophysical system: basics of network thermodynamics] Imai Y. **Nippon Seirigaku Zasshi** 1996; 58(3):133–41 (16 ref.) **(Jpn)**

THERMOELECTRIC POWER PLANTS see **POWER PLANTS**

THERMOGRAPHY

Thermography and the possibilities for its applications in clinical and experimental dermatology. Di Carlo A. **Clin Dermatol** 1995 Jul–Aug;13(4):329–36 (38 ref.)

METHODS

Transurethral microwave thermotherapy: an evolving technology in the treatment of benign prostatic enlargement [see comments] de Wildt MJ, et al. **Br J Urol** 1995 Nov;76(5):531–8 (47 ref.) Comment in: Br J Urol 1996 May;77(5):764.

THERMOLUMINESCENT DOSIMETRY

METHODS

[Use of low temperature methods with optically stimulated luminescence for measuring ionizing radiation doses] Jankowski J, et al. **Med Pr** 1996;47(3):293–302 (7 ref.) (Eng. Abstr.) **(Pol)**

THERMORECEPTORS

see related
BODY TEMPERATURE REGULATION

PHYSIOLOGY

Encoding with bursting, subthreshold oscillations, and noise in mammalian cold receptors. Longtin A, et al. **Neural Comput** 1996 Feb 15;8(2):215–55 (75 ref.)

THERMOREGULATION see **BODY TEMPERATURE REGULATION**

THERMOTHERAPY see **HYPERTHERMIA, INDUCED**

THIAMAZOLE see **METHIMAZOLE**

THIAMINE

BIOSYNTHESIS

The biosynthesis and degradation of thiamin (vitamin B1). Begley TP. **Nat Prod Rep** 1996 Jun;13(3):177–85 (103 ref.)

BLOOD

[Vitamin B1 (thiamin)] Hashizume N. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:691–3 (7 ref.) **(Jpn)**

METABOLISM

Alterations of thiamine phosphorylation and of thiamine-dependent enzymes in Alzheimer's disease. Héroux M, et al. **Metab Brain Dis** 1996 Mar;11(1):81–8 (35 ref.)

The biosynthesis and degradation of thiamin (vitamin B1). Begley TP. **Nat Prod Rep** 1996 Jun;13(3):177–85 (103 ref.)

THERAPEUTIC USE

The therapy of respiratory chain encephalomyopathy: a critical review of the past and current perspective. Walker UA, et al. **Acta Neurol Scand** 1995 Oct;92(4):273–80 (77 ref.)

Is there a role for thiamine supplementation in the management of heart failure? [editorial] Leslie D, et al. **Am Heart J** 1996 Jun;131(6):1248–50 (18 ref.)

THIAMINE DEFICIENCY

DRUG THERAPY

Is there a role for thiamine supplementation in the management of heart failure? [editorial] Leslie D, et al. **Am Heart J** 1996 Jun;131(6):1248–50 (18 ref.)

PATHOLOGY

Neuropathology of thiamine deficiency disorders. Kril JJ. **Metab Brain Dis** 1996 Mar;11(1):9–17 (42 ref.)

Neuropathology of thiamine deficiency: an update on the comparative analysis of human disorders and experimental models. Langlais PJ, et al. **Metab Brain Dis** 1996 Mar; 11(1):19–37 (88 ref.)

PHYSIOPATHOLOGY

The blood-brain barrier and selective vulnerability in experimental thiamine-deficiency encephalopathy in the mouse. Harata N, et al. **Metab Brain Dis** 1996 Mar; 11(1):55–69 (78 ref.)

PSYCHOLOGY

Neuropathology of thiamine deficiency disorders. Kril JJ. **Metab Brain Dis** 1996 Mar;11(1):9–17 (42 ref.)

THIAZIDE DIURETICS see **DIURETICS, THIAZIDE**

THIAZINES

ADVERSE EFFECTS

Review of clinical trials and benefit/risk ratio of meloxicam. Barner A. **Scand J Rheumatol Suppl** 1996;102:29–37 (15 ref.)

PHARMACOKINETICS

A review of the clinical pharmacokinetics of meloxicam. Türck D, et al. **Br J Rheumatol** 1996 Apr;35 Suppl 1:13–6 (28 ref.)

PHARMACOLOGY

Pharmacology of meloxicam, a new non-steroidal anti-inflammatory drug with an improved safety profile through preferential inhibition of COX-2. Engelhardt G. **Br J Rheumatol** 1996 Apr;35 Suppl 1:4–12 (69 ref.)

THIAZOLES

ADVERSE EFFECTS

Review of clinical trials and benefit/risk ratio of meloxicam. Barner A. **Scand J Rheumatol Suppl** 1996;102:29–37 (15 ref.)

PHARMACOKINETICS

A review of the clinical pharmacokinetics of meloxicam. Türck D, et al. **Br J Rheumatol** 1996 Apr;35 Suppl 1:13–6 (28 ref.)

PHARMACOLOGY

Pharmacology of meloxicam, a new non-steroidal anti-inflammatory drug with an improved safety profile through preferential inhibition of COX-2. Engelhardt G. **Br J Rheumatol** 1996 Apr;35 Suppl 1:4–12 (69 ref.)

Ebrotidine. Patel SS, et al. **Drugs** 1996 Jun;51(6):974–80; discussion 981 (41 ref.)

THERAPEUTIC USE

Ebrotidine. Patel SS, et al. **Drugs** 1996 Jun;51(6):974–80; discussion 981 (41 ref.)

Attenuation of hypertension by insulin-sensitizing agents. Kotchen TA. **Hypertension** 1996 Aug;28(2):219–23 (79 ref.)

THIENAMYCINS

ADMINISTRATION & DOSAGE

[Multicenter comparative study of meropenem vs. imipenem in the intramuscular treatment of hospital infections of the urinary tract] Tallarigo C, et al. **Minerva Urol Nefrol** 1995 Sep;47(3):147–56 (16 ref.) (Eng. Abstr.) **(Ita)**

PHARMACOLOGY

Meropenem. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Wiseman LR, et al. **Drugs** 1995 Jul;50(1):73–101 (195 ref.)

Meropenem: a microbiological overview. Edwards JR. **J Antimicrob Chemother** 1995 Jul;36 Suppl A:1–17 (73 ref.)

THERAPEUTIC USE

Meropenem—an advantageous antibiotic? **Drug Ther Bull** 1996 Jul;34(7):53–5 (23 ref.)

The newer cephalosporins. Aztreonam and imipenem. Ennis DM, et al. **Infect Dis Clin North Am** 1995 Sep;9(3):687–713 (123 ref.)

[Carbapenems in pediatrics] Aujard Y. **Arch Pediatr** 1996;3 Suppl 1:298s–301s (10 ref.) **(Fre)**

THIGH

see related
FEMUR

Biomechanics of iliotibial band friction syndrome in runners. Orchard JW, et al. **Am J Sports Med** 1996 May–Jun; 24(3):375–9 (26 ref.)

The role of quadriceps exercise in the treatment of patellofemoral pain syndrome. Callaghan MJ, et al. **Sports Med** 1996 May;21(5):384–91 (55 ref.)

THIMEROSAL

ADVERSE EFFECTS

[Source and clinical significance of allergy for thiomersal, an organic mercury compound] van 't Veen AJ, et al. **Ned Tijdschr Geneeskd** 1996 Feb 10;140(6):297–300 (31 ref.) **(Dut)**

THIN SECTIONING see **MICROTOMY**

THINKING

The assessment of unwanted intrusive thoughts: a review and critique of the literature. Clark DA, et al. **Behav Res Ther** 1995 Nov;33(8):967–76 (60 ref.)

Correcting faulty appraisals of obsessional thoughts. Freeston MH, et al. **Behav Res Ther** 1996 May–Jun;34(5–6):433–46 (52 ref.)

Reflective practice: reviewing the issues and refocusing the debate. Clarke B, et al. **Int J Nurs Stud** 1996 Apr; 33(2):171–80 (24 ref.)

[Magical thinking in healthy people and in schizophrenia] Jarosz M. **Psychiatr Pol** 1996 May–Jun;30(3):471–84 (25 ref.) (Eng. Abstr.) **(Pol)**

THINNESS

DIAGNOSIS

[Guidelines for body weight in adults] Kataoka K. **Nippon Rinsho** 1995 Jun;53 Suppl:141–6 (19 ref.) **(Jpn)**

THIO-TEPA see **THIOTEPA**

THIOBACILLUS

METABOLISM

Molecular aspects of the electron transfer system which participates in the oxidation of ferrous ion by Thiobacillus ferrooxidans. Yamanaka T, et al. **FEMS Microbiol Rev** 1995 Dec;17(4):401–13 (50 ref.)

THIOCARBAMATES

PHARMACOLOGY

Mobilizers of stored cadmium. Bláha K, et al. **Arch Toxicol Suppl** 1996;18:195–201 (24 ref.)

THIOCYANATES

PHARMACOLOGY

Role of goitrogens in iodine deficiency disorders & brain development. Rao PS, et al. **Indian J Med Res** 1995 Nov; 102:223–6 (16 ref.)

THIOL PROTEINASES see **CYSTEINE PROTEINASES**

THIOL REAGENTS see **SULFHYDRYL REAGENTS**

THIOLESTER HYDROLASES

METABOLISM

[Role of glyoxalases and methylglyoxal in cell proliferation and differentiation] Piskorska D, et al. **Postepy Hig Med Dosw** 1995;49(3):433–44 (56 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOLOGY

Advances in glyoxalase research. Glyoxalase expression in malignancy, anti-proliferative effects of methylglyoxal, glyoxalase I inhibitor diesters and S-D-lactoylglutathione, and methylglyoxal-modified protein binding and endocytosis by the advanced glycation endproduct receptor. Thornalley PJ. **Crit Rev Oncol Hematol** 1995 Aug;20(1–2):99–128 (225 ref.)

THIOLS see **SULFHYDRYL COMPOUNDS**

THIOMERSAL see **THIMEROSAL**

THIOMERSALATE see **THIMEROSAL**

THIONUCLEOTIDES

Antitumor effects of antisense phosphorothioate c-myc oligodeoxynucleotides: a question of mechanism [editorial; comment] Stein C.A.. **J Natl Cancer Inst** 1996 Apr 3; 88(7):391–3 (9 ref.) Comment on: J Natl Cancer Inst 1996 Apr 3;88(7):419–29.

PHARMACOLOGY

Prospects for the therapeutic use of antigene oligonucleotides. Maher LJ 3rd. **Cancer Invest** 1996; 14(1):66–82 (165 ref.)

Antisense oligodeoxynucleotides as clinical therapeutic agents. Tonkinson JL, et al. **Cancer Invest** 1996;14(1):54–65 (103 ref.)

THERAPEUTIC USE

Progress in antisense therapeutics. Crooke ST. **Hematol Pathol** 1995;9(2):59–72 (69 ref.)

TOXICITY

Antisense phosphorothioate oligodeoxynucleotides: introductory concepts and possible molecular mechanisms of toxicity. Zon G. **Toxicol Lett** 1995 Dec;82–83:419–24 (23 ref.)

THIOPHENES

THERAPEUTIC USE

Matrix metalloproteinase inhibition: a review of anti-tumour activity. Brown PD, et al. **Ann Oncol** 1995 Dec; 6(10):967–74 (48 ref.)

Thymidylate synthase inhibition, a dead end? [editorial] Herrmann R. **Eur J Cancer** 1995 Nov;31A(12):1919–20 (7 ref.)

ZD1694 (Tomudex): a new thymidylate synthase inhibitor with activity in colorectal cancer. Jackman AL, et al. **Eur J Cancer** 1995 Jul–Aug;31A(7–8):1277–82 (30 ref.)

THIOPHOSPHAMIDE see **THIOTEPA**

THIOREDOXIN

METABOLISM

Thioredoxin and control of F0F1: function and distribution. Mills JD, et al. **Biochem Soc Trans** 1995 Nov;23(4):775–80 (35 ref.)

THIOREDOXIN REDUCTASE (NADPH)

METABOLISM

Mechanism and structure of thioredoxin reductase from Escherichia coli. Williams CH Jr. **FASEB J** 1995 Oct; 9(13):1267–76 (47 ref.)

THIOSEMICARBAZONES

CHEMISTRY

Chemical and biological properties of cytotoxic alpha-(N)-heterocyclic carboxaldehyde thiosemicarbazones. Liu MC, et al. **Prog Med Chem** 1995; 32:1–35 (157 ref.)

THIOSULFATE CYANIDE TRANSSULPHURASE see **THIOSULFATE SULFURTRANSFERASE**

THIOSULFATE SULFURTRANSFERASE

[Mercaptopyruvate sulfurtransferase is a rhodanese family] Nagahara N, et al. **Seikagaku** 1996 Mar;68(3):197–201 (15 ref.) **(Jpn)**

THIOSULFATES

DIAGNOSTIC USE

[Sodium thiosulfate clearance] Nagase S, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:1078–81 (9 ref.) **(Jpn)**

THIOTEPA

ADVERSE EFFECTS

Intravesical thiotepa-induced eosinophilic cystitis. Choe JM, et al. **Urology** 1995 Nov;46(5):729–31 (15 ref.)

THIOUREA

ANALOGS & DERIVATIVES

International safety assessment of pesticides: dithiocarbamate pesticides, ETU, and PTU—a review and update. Vettorazzi G, et al. **Teratog Carcinog Mutagen** 1995–96; 15(6):313–37 (88 ref.)

THIRD-NERVE PALSY see **OCULOMOTOR NERVE PARALYSIS**

THIRD-NERVE PARALYSIS see **OCULOMOTOR NERVE PARALYSIS**

THIRD-WORLD COUNTRIES see **DEVELOPING COUNTRIES**

THIRST

see related
WATER DEPRIVATION

THOMSEN'S DISEASE see **MYOTONIA CONGENITA**

THORACIC ARTERIES

Coronary-pulmonary steal syndrome. Najm HK, et al. **Ann Thorac Surg** 1996 Jul;62(1):264–5 (7 ref.)

PHYSIOPATHOLOGY

Flow reserve capacity of left internal thoracic artery 23 years after Vineberg procedure. Nasu M, et al. **Ann Thorac Surg** 1996 Apr;61(4):1242–4 (5 ref.)

THORACIC CYST see **MEDIASTINAL CYST**

THORACIC DISEASES

CHEMICALLY INDUCED

[Destructive paraffinoma of the breast and thoracic wall caused by paraffin injection for mammary increase. Apropos of 3 cases with review of the literature] Zekri A, et al. **Ann Chir Plast Esthet** 1996 Feb;41(1):90–3 (7 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

[Application of thoracoscopy for diagnosis and therapy of thoracic diseases] Hida W. **Nippon Naika Gakkai Zasshi** 1995 Aug 10;84(8):1338–43 (11 ref.) **(Jpn)**

RADIOGRAPHY

Intrathoracic lymphoproliferative disorders and lymphoma. Murray KA, et al. **Curr Probl Diagn Radiol** 1996 May-Jun; 25(3):78–106 (133 ref.)

A radiologic update on medical diseases of the newborn chest. Cleveland RH. **Pediatr Radiol** 1995;25(8):631–7 (17 ref.)

SURGERY

[Thoracoscopic surgery, current indication and technique] Okushiba S, et al. **Hokkaido Igaku Zasshi** 1995 May; 70(3):371–4 (10 ref.) (Eng. Abstr.) **(Jpn)**

THERAPY

[Application of thoracoscopy for diagnosis and therapy of thoracic diseases] Hida W. **Nippon Naika Gakkai Zasshi** 1995 Aug 10;84(8):1338–43 (11 ref.) **(Jpn)**

ULTRASONOGRAPHY

[Transthoracic ultrasound in pneumology] Mathis G. **Pneumologie** 1995 Dec;49(12):667–73 (51 ref.) **(Ger)**

THORACIC DUCT

INJURIES

Thoracic duct injury in penetrating neck trauma. Whiteford MH, et al. **Am Surg** 1995 Dec;61(12):1072–5 (63 ref.)

SURGERY

Early thoracic duct ligation for postoperative chylothorax. Sieczka EM, et al. **J Surg Oncol** 1996 Jan;61(1):56–60 (27 ref.)

THORACIC INJURIES

COMPLICATIONS

Mitral valve injury after blunt chest trauma. McDonald ML, et al. **Ann Thorac Surg** 1996 Mar;61(3):1024–9 (43 ref.)

Silicone thorax: a complication of tube thoracostomy in the presence of mammary implants. Rice DC, et al. **Ann Thorac Surg** 1995 Nov;60(5):1417–9 (8 ref.)

Traumatic pneumatoceles in an infant: case report and review of the literature. Schimpl G, et al. **Eur J Pediatr Surg** 1996 Apr;6(2):104–6 (14 ref.)

Tension pneumopericardium following blunt injury. Capizzi PJ, et al. **J Trauma** 1995 Oct;39(4):775–80 (80 ref.)

[Acute mitral valve insufficiency] Acar J. **Ann Cardiol Angeiol (Paris)** 1995 Dec;44(10):561–6 (22 ref.) (Eng. Abstr.) **(Fre)**

[Traumatic tricuspid insufficiency] Vayre F, et al. **Arch Mal Coeur Vaiss** 1996 Apr;89(4):459–63 (30 ref.) (Eng. Abstr.) **(Fre)**

[Parietal problems in thoracic injuries by gunshot] Houdelette P. **J Chir (Paris)** 1996 Apr;133(2):82–90 (23 ref.) (Eng. Abstr.) **(Fre)**

[Traumatic spinothoracic cerebrospinal fluid fistula] Löw R, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1995 Nov;163(5):454–6 (9 ref.) **(Ger)**

DIAGNOSIS

Cardiac and mediastinal trauma. Rosenthal MA, et al. **Emerg Med Clin North Am** 1995 Nov;13(4):887–902 (78 ref.)

ETIOLOGY

Fracture-dislocation of the shoulder with intrathoracic displacement of the humeral head. Kaar TK, et al. **Injury** 1995 Nov;26(9):638–9 (4 ref.)

NURSING

Meeting the challenge of chest trauma. Laskowski-Jones L. **Am J Nurs** 1995 Sep;95(9):22–9; quiz 30 (13 ref.)

RADIOGRAPHY

Selected topics in chest trauma. Groskin SA. **Semin Ultrasound CT MR** 1996 Apr;17(2):119–41 (97 ref.)

CT in blunt chest trauma: pulmonary, tracheobronchial, and diaphragmatic injuries. Kang EY, et al. **Semin Ultrasound CT MR** 1996 Apr;17(2):114–8 (39 ref.)

SURGERY

Complex thoracic injuries. Richardson JD, et al. **Surg Clin North Am** 1996 Aug;76(4):725–48 (57 ref.)

[Surgery in childhood at the hospital for basic and routine general management] Willital GH. **Chirurg** 1996 Jun; 67(6):567–75 (28 ref.) (Eng. Abstr.) **(Ger)**

[Traumatic hemothorax treated by video-assisted thoracoscopic surgery] Freixinet J, et al. **Arch Bronconeumol** 1995 Oct;31(8):424–5 (10 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

Evaluation of intrapleural analgesia in the management of blunt traumatic chest wall pain: a clinical trial. Short K, et al. **Am Surg** 1996 Jun;62(6):488–93 (50 ref.)

VETERINARY

Management of fracture-associated thoracic trauma. Cockshutt JR. **Vet Clin North Am Small Anim Pract** 1995 Sep;25(5):1031–46 (53 ref.)

THORACIC NEOPLASMS

DIAGNOSIS

[A report of an intrathoracic case of hibernoma] Ninov B, et al. **Khirurgiia (Sofiia)** 1994;47(3):41–4 (23 ref.) (Eng. Abstr.) **(Bul)**

[Intrathoracic lipoma in children. Apropos of a case (letter)] Hoeffel JC, et al. **Ann Med Interne (Paris)** 1996;147(1):66–8 (33 ref.) **(Fre)**

ETIOLOGY

Thoracic desmoid tumors: a rare evolution of rib fracture. Etiopathogenesis and therapeutic considerations. Wiel Marin A, et al. **G Chir** 1995 Aug–Sep;16(8–9):341–3 (12 ref.)

RADIOGRAPHY

A lump in the chest. A common problem in an unusual setting [clinical conference] Patel V, et al. **BMJ** 1995 Dec 2; 311(7018):1491–4 (38 ref.)

Intrathoracic lymphoproliferative disorders and lymphoma. Murray KA, et al. **Curr Probl Diagn Radiol** 1996 May–Jun; 25(3):78–106 (133 ref.)

Normal and abnormal vascular structures that simulate neoplasms on chest radiographs: clues to the diagnosis. Cole TJ, et al. **Radiographics** 1995 Jul;15(4):867–91 (23 ref.)

Primitive neuroectodermal tumour of the chest wall (Askin tumour): CT and roentgenographic findings in a 51-year-old male. Miller JA, et al. **Respir Med** 1995 Nov; 89(10):705–8 (7 ref.)

SURGERY

The role of video-assisted thoracic surgery in thoracic oncological practice [see comments] Landreneau RJ, et al. **Cancer Invest** 1995;13(5):526–39 (60 ref.) Comment in: Cancer Invest 1995;13(5):551–2.

[Surgical therapy of soft tissue sarcoma. I. General principles and resections of the trunk] Karakousis CP. **Chirurg** 1995 Sep;66(9):905–13 (17 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Endobronchial treatment modalities in thoracic oncology [see comments] Baas P, et al. **Ann Oncol** 1995 Jul;6(6):523–31 (85 ref.) Comment in: Ann Oncol 1995 Nov;6(9):951–2.

[Locally developed sarcoma of the thoracic wall] Bui NB, et al. **Bull Cancer (Paris)** 1996 May;83(5):335–43 (40 ref.) (Eng. Abstr.) **(Fre)**

ULTRASONOGRAPHY

[Transthoracic ultrasound in pneumology] Mathis G. **Pneumologie** 1995 Dec;49(12):667–73 (51 ref.) **(Ger)**

VETERINARY

Radiation therapy of thoracic and abdominal tumors. LaRue SM, et al. **Semin Vet Med Surg (Small Anim)** 1995 Aug; 10(3):190–6 (32 ref.)

THORACIC NERVES

SURGERY

[Treatment of primary hyperhidrosis of the upper limbs by transthoracic endoscopic sympathectomy] Lesèche G, et al. **Presse Med** 1995 Nov 4;24(33):1569–73 (36 ref.) (Eng. Abstr.) **(Fre)**

THORACIC OUTLET SYNDROME

Thoracic outlet compression syndrome. Atasoy E. **Orthop Clin North Am** 1996 Apr;27(2):265–303 (58 ref.)

Historical perspectives and anatomic considerations. Thoracic outlet syndrome. Roos DB. **Semin Thorac Cardiovasc Surg** 1996 Apr;8(2):183–9 (26 ref.)

COMPLICATIONS

Congenital clavicular pseudoarthrosis associated with vascular thoracic outlet syndrome: case presentation and review of the literature. Hahn K, et al. **Cathet Cardiovasc Diagn** 1995 Aug;35(4):321–7 (30 ref.)

DIAGNOSIS

Evaluation of the patient with thoracic outlet syndrome. Mackinnon SE, et al. **Semin Thorac Cardiovasc Surg** 1996 Apr;8(2):190–200 (46 ref.)

[TOS (thoracic outlet syndrome)—a functional disease?] Lindgren KA. **Duodecim** 1994;110(12):1131–9 (41 ref.) **(Fin)**

[The superior thoracic outlet compression syndrome: a report of a case in childhood with complete cervical rib] Nedbal M, et al. **Pediatr Med Chir** 1995 May–Jun;17(3):261–3 (22 ref.) (Eng. Abstr.) **(Ita)**

[Diagnosis of the upper thoracic outlet syndrome] Maciejczak A, et al. **Neurol Neurochir Pol** 1995 Jul–Aug;29(4):577–89 (20 ref.) (Eng. Abstr.) **(Pol)**

[The vertebro-thoracic syndrome] Henriques M, et al. **Acta Med Port** 1995 Mar;8(3):169–71 (8 ref.) (Eng. Abstr.) **(Por)**

PHYSIOPATHOLOGY

Thoracic outlet syndrome: a current overview. Mackinnon SE, et al. **Semin Thorac Cardiovasc Surg** 1996 Apr; 8(2):176–82 (32 ref.)

SURGERY

Results of the surgical treatment for thoracic outlet syndrome. Sanders RJ. **Semin Thorac Cardiovasc Surg** 1996 Apr;8(2):221–8 (29 ref.)

[Thoracic outlet syndrome (TOS). Its limitations and indications for surgical treatment] Bonnard C. **Rev Med Suisse Romande** 1996 Mar;116(3):161–9 (27 ref.) **(Fre)**

THERAPY

[TOS (thoracic outlet syndrome)—a functional disease?] Lindgren KA. **Duodecim** 1994;110(12):1131–9 (41 ref.) **(Fin)**

THORACIC RADIOGRAPHY

Accuracy and efficacy of chest radiography in the intensive care unit. Henschke CI, et al. **Radiol Clin North Am** 1996 Jan;34(1):21–31 (50 ref.)

METHODS

Portable chest radiography techniques and teleradiology. MacMahon H, et al. **Radiol Clin North Am** 1996 Jan; 34(1):1–20 (53 ref.)

VETERINARY

Basic principles of thoracic radiography. Wolvekamp WT. **Vet Q** 1995 Apr;17 Suppl 1:S31–2 (0 ref.)

THORACIC SURGERY

Video-assisted thoracic surgery: the current state of the art. Kaiser LR, et al. **AJR Am J Roentgenol** 1995 Nov; 165(5):1111–7 (35 ref.)

Inhaled nitric oxide: therapeutic applications in cardiothoracic surgery. Fullerton DA, et al. **Ann Thorac Surg** 1996 Jun;61(6):1856–64 (56 ref.)

The use of fiberoptic endoscopy in anesthesia. Lee AC, et al. **Chest Surg Clin N Am** 1996 May;6(2):329–47 (45 ref.)

Perioperative fluid management for thoracic surgery: the puzzle of postpneumonectomy pulmonary edema. Slinger PD. **J Cardiothorac Vasc Anesth** 1995 Aug;9(4):442–51 (52 ref.)

Noncardiac thoracic surgical procedures. Definitions, indications, and postoperative radiology. Bhalla M. **Radiol Clin North Am** 1996 Jan;34(1):137–55 (28 ref.)

[Progresses in thoracic surgery in China, 1995] Li Z. **Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):733–4 (0 ref.) **(Chi)**

METHODS

The role of video-assisted thoracic surgery in thoracic oncological practice [see comments] Landreneau RJ, et al. **Cancer Invest** 1995;13(5):526–39 (60 ref.) Comment in: Cancer Invest 1995;13(5):551–2.

[New techniques in thoracic surgery. II] Andreassian B. **Presse Med** 1995 Jul 1–8;24(24):1127–32 (32 ref.) (Eng. Abstr.) **(Fre)**

[New techniques in thoracic surgery. I] Andreassian B. **Presse Med** 1995 Jun 24;24(23):1078–83 (53 ref.) (Eng. Abstr.) **(Fre)**

ORGANIZATION & ADMINISTRATION

Optimizing cardiothoracic surgery information for a managed care environment. Denton TA, et al. **Ann Thorac Surg** 1995 Nov;60(5):1522–5 (22 ref.)

STANDARDS

Quality initiatives and the power of the database: what they are and how they run. Grover FL, et al. **Ann Thorac Surg** 1995 Nov;60(5):1514–21 (15 ref.)

Quality initiatives and the power of the database: where we stand. Kouchoukos NT. **Ann Thorac Surg** 1995 Nov; 60(5):1526–9 (13 ref.)

Think before you prep: defining the terms of change in American healthcare. Tanenbaum SJ. **Ann Thorac Surg** 1995 Nov;60(5):1530–3 (12 ref.)

TRENDS

What's new in general thoracic surgery. Miller JI Jr. **J Am Coll Surg** 1996 Feb;182(2):162–9 (25 ref.)

THORACIC VERTEBRAE

Fibrocartilaginous embolism of the spinal cord: a clinical and pathogenetic reconsideration. Tosi L, et al. **J Neurol Neurosurg Psychiatry** 1996 Jan;60(1):55–60 (44 ref.)

ABNORMALITIES

Thoracic and lumbar meningocele in neurofibromatosis type 1. Report of two cases and review of the literature. Rainov NG, et al. **Neurosurg Rev** 1995;18(2):127–34 (47 ref.)

INJURIES

Posttraumatic spinal osteolysis in ankylosing spondylitis as part of pseudoarthrosis. A case report. Albertsen AM, et al. **Acta Radiol** 1996 Jan;37(1):98–100 (10 ref.)

Thoracic fracture-dislocations without spinal cord injury: a case report and literature review. Liljenqvist U, et al. **Eur Spine J** 1995;4(4):252–6 (34 ref.)

The treatment of thoracolumbar fractures: one point of view. Rea GL, et al. **J Spinal Disord** 1995 Oct;8(5):368–82 (59 ref.)

Thoracolumbar burst fracture: evaluating stability. Petersilge CA, et al. **Semin Ultrasound CT MR** 1996 Apr;17(2):105–13 (40 ref.)

MICROBIOLOGY

Torulopsis glabrata spinal osteomyelitis involving two contiguous vertebrae. A case report. Curran MP, et al. **Spine** 1996 Apr 1;21(7):866–70 (8 ref.)

PATHOLOGY

Monostotic fibrous dysplasia of the thoracic spine. A case report. Przybylski GJ, et al. **Spine** 1996 Apr 1;21(7):860–5 (28 ref.)

RADIOGRAPHY

Symptomatic spinal hemangiomas in association with cutaneous hemangiomas. A case report. Asumu TO, et al. **Spine** 1996 May 1;21(9):1082–4 (7 ref.)

[Vertebral localizations of Paget disease] Chrétien J. **Ann Radiol (Paris)** 1995;38(4):169–76 (7 ref.) (Eng. Abstr.) **(Fre)**

[Vertebral vacuum phenomena] Hamzé B, et al. **Ann Radiol (Paris)** 1995;38(4):186–91 (17 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Fracture of the iliac crest following bone grafting: a case report and literature review. Friend KD, et al. **Bull Hosp Jt Dis** 1995;54(1):49–51 (8 ref.)

THORACOSCOPY

The documentation of thoracic endoscopy. Prakash UB, et al. **Chest Surg Clin N Am** 1996 May;6(2):193–203 (27 ref.)

Thoracoscopy in the diagnosis and treatment of spontaneous pneumothorax. Boutin C, et al. **Clin Chest Med** 1995 Sep; 16(3):497–503 (30 ref.)

Thoracoscopic management of malignant pleural effusions. Colt HG. **Clin Chest Med** 1995 Sep;16(3):505–18 (108 ref.)

Medical thoracoscopy. Technical details. Mathur PN, et al. **Clin Chest Med** 1995 Sep;16(3):479–86 (27 ref.)

Medical thoracoscopy. Role in pleural and lung diseases. Mathur PN, et al. **Clin Chest Med** 1995 Sep;16(3):487–96 (85 ref.)

Diagnosing the indeterminate pulmonary nodule: percutaneous biopsy versus thoracoscopy. Mitruka S, et al. **Surgery** 1995 Oct;118(4):676–84 (25 ref.)

[Thoracoscopic surgery, current indication and technique] Okushiba S, et al. **Hokkaido Igaku Zasshi** 1995 May; 70(3):371–4 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Application of thoracoscopy for diagnosis and therapy of thoracic diseases] Hida W. **Nippon Naika Gakkai Zasshi** 1995 Aug 10;84(8):1338–43 (11 ref.) **(Jpn)**

[Application of thoracoscopy for diagnosis and therapy of respiratory tract diseases] Inui K. **Nippon Naika Gakkai Zasshi** 1995 Sep 10;84(9):1594–9 (18 ref.) **(Jpn)**

ADVERSE EFFECTS

Port site recurrences after laparoscopic and thoracoscopic procedures in malignancy. Johnstone PA, et al. **J Clin Oncol** 1996 Jun;14(6):1950–6 (38 ref.)

METHODS

Role of thoracoscopy (VATS) in pleural and pulmonary pathology. Van Schil P, et al. **Acta Chir Belg** 1996 Feb; 96(1):23–7 (28 ref.)

Laparoscopic and thoracoscopic antireflux surgery. Roberts PJ, et al. **Ann Chir Gynaecol** 1995;84(2):130–7 (30 ref.)

Video-assisted thoracoscopic pulmonary surgery—current status and potential evolution. Walker WS, et al. **Eur J Cardiothorac Surg** 1996;10(3):161–7 (62 ref.)

[Upper thoracic sympathectomy by thoracoscopic approach. A method of choice for the treatment of palmar hyperhidrosis] Lévy I, et al. **Ann Chir** 1995;49(9):858–62 (35 ref.) (Eng. Abstr.) **(Fre)**

[New techniques in thoracic surgery. II] Andreassian B. **Presse Med** 1995 Jul 1–8;24(24):1127–32 (32 ref.) (Eng. Abstr.) **(Fre)**

[Traumatic hemothorax treated by video-assisted thoracoscopic surgery] Freixinet J, et al. **Arch Bronconeumol** 1995 Oct;31(8):424–5 (10 ref.) (Eng. Abstr.) **(Spa)**

THORACOSTOMY

Treatment of complicated pleural fluid collections with image-guided drainage and intracavitary urokinase [see comments] Moulton JS, et al. **Chest** 1995 Nov; 108(5):1252–9 (20 ref.) Comment in: Chest 1995 Nov;108(5):1190–1.

THORACOTOMY

Effect of bullectomy on diaphragm strength. Travaline JM, et al. **Am J Respir Crit Care Med** 1995 Nov;152(5 Pt 1):1697–701 (25 ref.)

Con: unreliable benefit after thoracotomy—epidural is a better choice [comment] Riegler FX.
J Cardiothorac Vasc Anesth 1996 Apr;10(3):429–31 (20 ref.)
Comment on: J Cardiothorac Vasc Anesth 1996 Apr;10(3):425–8.

ADVERSE EFFECTS

Herniation of the lung following video-assisted minithoracotomy. van den Brink WA, et al.
Surg Endosc 1995 Jun;9(6):706–8 (10 ref.)

METHODS

'Emergency room' thoracotomy: is it ever justified? Roxburgh JC. **Ann R Coll Surg Engl** 1996 Jul;78(4):327–30 (14 ref.)

Transverse sternothoracotomy. Wright C.
Chest Surg Clin N Am 1996 Feb;6(1):149–56 (7 ref.)

THORAX

see related
THORACIC RADIOGRAPHY
THORACIC SURGERY
THORACOSCOPY
THORACOSTOMY
THORACOTOMY

Chest percussion. Yernault JC, et al. **Eur Respir J** 1995 Oct; 8(10):1756–60 (33 ref.)

Tissue inhomogeneity in the thorax: implications for 3-D treatment planning. Ten Haken RK, et al.
Front Radiat Ther Oncol 1996;29:180–7 (15 ref.)

Pro: intrapleural anesthesia is useful for thoracic analgesia [see comments] McIlvaine WB.
J Cardiothorac Vasc Anesth 1996 Apr;10(3):425–8 (41 ref.)
Comment in: J Cardiothorac Vasc Anesth 1996 Apr;10(3):429–31.

ABNORMALITIES

Congenital chest wall deformities. Shamberger RC.
Curr Probl Surg 1996 Jun;33(6):469–542 (162 ref.)

The fetal thorax: noncardiac chest anomalies. Sohaey R, et al. **Semin Ultrasound CT MR** 1996 Feb;17(1):34–50 (64 ref.)

BLOOD SUPPLY

Magnetic resonance angiography of systemic thoracic and abdominal veins. Hartnell GG.
Magn Reson Imaging Clin N Am 1993 Dec;1(2):281–94 (49 ref.)

Phase-contrast magnetic resonance angiography in the abdomen and thorax. Yuasa Y.
Magn Reson Imaging Clin N Am 1993 Dec;1(2):327–38 (25 ref.)

INNERVATION

Thoracoscopic sympathectomy. Daniel TM.
Chest Surg Clin N Am 1996 Feb;6(1):69–83 (10 ref.)

PHYSIOLOGY

Acoustic properties of the normal chest. Dalmay F, et al.
Eur Respir J 1995 Oct;8(10):1761–9 (68 ref.)

THORIUM DIOXIDE

ADVERSE EFFECTS

[Liver injury due to thorotrast] Ukida M.
Ryoikibetsu Shokogun Shirizu 1995;(8):52–4 (6 ref.) **(Jpn)**

[Liver neoplasms due to Thorotrast] Ukida M.
Ryoikibetsu Shokogun Shirizu 1995;(7):501–3 (19 ref.) **(Jpn)**

THORIUM OXIDE see **THORIUM DIOXIDE**

THORNAPPLE see **STRAMONIUM**

THREONINE

ADVERSE EFFECTS

Ethanol- and threonine-induced hypertension in rats: a common mechanism. Vasdev S, et al. **Can J Cardiol** 1995 Oct;11(9):807–15 (56 ref.)

BIOSYNTHESIS

Construction of L-lysine-, L-threonine-, and L-isoleucine-overproducing strains of Corynebacterium glutamicum. Sahm H, et al. **Ann N Y Acad Sci** 1996 May 15;782:25–39 (34 ref.)

METABOLISM

[Possible role of threonine metabolism in tetracycline biosynthesis] Mironov VA, et al. **Antibiot Khimioter** 1995 Mar;40(3):52–6 (29 ref.) (Eng. Abstr.) **(Rus)**

THREONINE PHOSPHATE see **PHOSPHOTHREONINE**

THRESHOLD LIMIT VALUES see **MAXIMUM PERMISSIBLE EXPOSURE LEVEL**

THROAT see **PHARYNX**

THROMBASE see **THROMBIN**

THROMBECTOMY

see related
EMBOLECTOMY

[Percutaneous local thrombolytic therapy and thrombectomy in occlusion of extremity arteries] Schneider E, et al.
Internist (Berl) 1996 Jun;37(6):607–12 (23 ref.) **(Ger)**

METHODS

[Percutaneous transluminal hydrodynamic thrombectomy—the initial results] Höpfner W, et al.
Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1996 Feb;164(2):141–5 (14 ref.) (Eng. Abstr.) **(Ger)**

[Surgical treatment of deep venous thrombosis—indications, possibilities and limitations in venous thrombectomy] Kniemeyer HW, et al. **Ther Umsch** 1996 Apr;53(4):277–83 (23 ref.) (Eng. Abstr.) **(Ger)**

THROMBELASTOGRAPHY

[Thrombelastography] Nakamura K. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:137–40 (8 ref.) **(Jpn)**

THROMBIN

see related
HEMOSTATICS

ANTAGONISTS & INHIBITORS

Thrombin active site inhibitors. Das J, et al.
Bioorg Med Chem 1995 Aug;3(8):999–1007 (57 ref.)

Challenges in the development of orally bioavailable thrombin active site inhibitors. Kimball SD.
Blood Coagul Fibrinolysis 1995 Sep;6(6):511–9 (98 ref.)

New directions in anticoagulant and antiplatelet treatment [editorial] Simoons ML, et al. **Br Heart J** 1995 Oct; 74(4):337–40 (33 ref.)

Thrombin inhibitors in acute myocardial infarction. Cannon CP. **Cardiol Clin** 1995 Aug;13(3):421–33 (73 ref.)

New thrombin inhibiting strategies for coronary artery disease. Shah PK, et al. **Indian Heart J** 1995 Jul–Aug; 47(4):381–6 (41 ref.)

Thrombin inhibitors as antithrombotic agents: the importance of rapid inhibition. Stone SR, et al. **J Enzym Inhib** 1995; 9(1):3–15 (56 ref.)

BIOSYNTHESIS

Thrombin generation in plasma: its assessment via the endogenous thrombin potential [published erratum appears in Thromb Haemost 1995 Nov;74(5):1388] Hemker HC, et al. **Thromb Haemost** 1995 Jul;74(1):134–8 (22 ref.)

Thrombin generation in myocardial infarction and hypercholesterolemia: effects of aspirin. Szczeklik A.
Thromb Haemost 1995 Jul;74(1):77–80 (34 ref.)

CHEMISTRY

Thrombin active site inhibitors. Das J, et al.
Bioorg Med Chem 1995 Aug;3(8):999–1007 (57 ref.)

METABOLISM

Thrombin specificity. Guillin MC, et al. **Thromb Haemost** 1995 Jul;74(1):129–33 (56 ref.)

Insight into the mechanism of action of heparin cofactor II. Tollefsen DM. **Thromb Haemost** 1995 Nov;74(5):1209–14 (64 ref.)

PHARMACOLOGY

Vascular endothelial cell activation and permeability responses to thrombin. Garcia JG, et al.
Blood Coagul Fibrinolysis 1995 Oct;6(7):609–26 (129 ref.)

PHYSIOLOGY

Thrombin and its receptor in growth control. Van Obberghen-Schilling E, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:431–41 (85 ref.)

The role of thrombin and thrombin inhibitors in coronary angioplasty. Ali MN, et al. **Chest** 1995 Nov;108(5):1409–19 (78 ref.)

Thrombin and proliferation of vascular smooth muscle cells. Fager G. **Circ Res** 1995 Oct;77(4):645–50 (73 ref.)

Thrombin functions and antithrombotic intervention. Fenton JW 2nd. **Thromb Haemost** 1995 Jul;74(1):493–8 (63 ref.)

Role of platelets, thrombin, integrin IIb-IIIa, fibronectin and von Willebrand factor on tumor adhesion in vitro and metastasis in vivo. Nierodzik ML, et al.
Thromb Haemost 1995 Jul;74(1):282–90 (67 ref.)

THROMBIN RECEPTORS see **RECEPTORS, THROMBIN**

THROMBOANGIITIS OBLITERANS

COMPLICATIONS

Colonic ischemia reveals thromboangiitis obliterans (Buerger's disease). Sauvaget F, et al. **Gastroenterology** 1996 Mar;110(3):900–3 (12 ref.)

[Buerger's disease disclosed by a perforation in the digestive system. Apropos of a case and review of the literature] Nyuyen TB, et al. **Rev Med Interne** 1996;17(1):70–5 (30 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

[Thrombosis in the small branches of the superior mesenteric artery in the early stages of essential thrombocythemia] Adorján T, et al. **Orv Hetil** 1996 Mar 10;137(10):527–9 (28 ref.) (Eng. Abstr.) **(Hun)**

ETIOLOGY

[Smoking and peripheral vascular disorders] Stammler F, et al. **Z Arztl Fortbild (Jena)** 1995 Oct;89(5):459–66 (12 ref.) (Eng. Abstr.) **(Ger)**

THROMBOCYTES see **BLOOD PLATELETS**

THROMBOCYTHEMIA see **THROMBOCYTOSIS**

THROMBOCYTHEMIA, ESSENTIAL see **THROMBOCYTHEMIA, HEMORRHAGIC**

THROMBOCYTHEMIA, HEMORRHAGIC

[Chronic myeloproliferative diseases. New knowledge about well known diseases] Aulitzky WE, et al.
Dtsch Med Wochenschr 1996 May 3;121(18):600–4 (42 ref.) (Eng. Abstr.) **(Ger)**

DIAGNOSIS

[Giant platelet syndrome] Jantunen E, et al. **Duodecim** 1994; 110(8):793–801 (33 ref.) **(Fin)**

[Thrombosis in the small branches of the superior mesenteric artery in the early stages of essential thrombocythemia] Adorján T, et al. **Orv Hetil** 1996 Mar 10;137(10):527–9 (28 ref.) (Eng. Abstr.) **(Hun)**

THERAPY

Treatment of essential thrombocythemia during pregnancy with interferon-alpha. Delage R, et al. **Obstet Gynecol** 1996 May;87(5 Pt 2):814–7 (15 ref.)

THROMBOCYTHEMIA, IDIOPATHIC see **THROMBOCYTHEMIA, HEMORRHAGIC**

THROMBOCYTHEMIA, PRIMARY see **THROMBOCYTHEMIA, HEMORRHAGIC**

THROMBOCYTOPATHY see **BLOOD PLATELET DISORDERS**

THROMBOCYTOPENIA

Fetal and neonatal thrombocytopenia. Udom-Rice I, et al.
Blood Rev 1995 Jun;9(2):57–64 (60 ref.)

Management of the obstetric patient with thrombocytopenia. Sullivan CA, et al. **Clin Obstet Gynecol** 1995 Sep; 38(3):521–34 (39 ref.)

Perinatal thrombocytopenia. Burrows RF, et al.
Clin Perinatol 1995 Sep;22(3):779–801 (79 ref.)

[Prenatal alloimmune thrombocytopenia] Peled Y, et al.
Harefuah 1995 Jun 15;128(12):781–4 (47 ref.) **(Heb)**

CHEMICALLY INDUCED

Heparin-associated thrombocytopenia: an update. Fondu P.
Acta Clin Belg 1995;50(6):343–57 (63 ref.)

Thrombolysis to treat arterial thrombotic complications of heparin-induced thrombocytopenia. Calligaro KD, et al.
Ann Vasc Surg 1995 Jul;9(4):397–400 (8 ref.)

The problem of thrombocytopenia and its management. Newland AC. **Anticancer Drugs** 1995 Oct;6 Suppl 5:65–73 (76 ref.)

Skin necrosis following subcutaneous heparin injection. Mar AW, et al. **Australas J Dermatol** 1995 Nov;36(4):201–3 (14 ref.)

Heparin induced thrombocytopenia. Dryjski M, et al.
Eur J Vasc Endovasc Surg 1996 Apr;11(3):260–9 (143 ref.)

[Expert discussion group and consensus conference on behalf of the Drug Committee of German Medical Community and Saarland Federal Medical Group 12 May 1995. Agreement on practical procedures for rapid, safe diagnosis and therapy of "white clot" syndrome. Blandfort R.
Chirurg 1995 Nov;66(11):Suppl 262–4 (0 ref.) **(Ger)**

COMPLICATIONS

Thrombolysis to treat arterial thrombotic complications of heparin-induced thrombocytopenia. Calligaro KD, et al.
Ann Vasc Surg 1995 Jul;9(4):397–400 (8 ref.)

[Thrombocytopenia with absence of the radius in a 24-year-old woman] Fortuna AM, et al. **Sangre (Barc)** 1995

Jun;40(3):223–5 (13 ref.) (Eng. Abstr.) **(Spa)**

CONGENITAL

Fetal neonatal thrombocytopenia. Bussel JB. **Thromb Haemost** 1995 Jul;74(1):426–8 (11 ref.)

DIAGNOSIS

Efficient diagnosis of thrombocytopenia. Goldstein KH, et al. **Am Fam Physician** 1996 Feb 15;53(3):915–20 (10 ref.)

Review: Postoperative thrombocytopenia: with etiologic, diagnostic, and therapeutic consideration. Chang JC. **Am J Med Sci** 1996 Feb;311(2):96–105 (84 ref.)

Thrombocytopenia in the neonate. Homans A. **Pediatr Clin North Am** 1996 Jun;43(3):737–56 (77 ref.)

[Diagnosis and therapy of fetal alloimmune thrombocytopenia] Marzusch K, et al. **Geburtshilfe Frauenheilkd** 1995 Oct;55(10):587–91 (29 ref.) (Eng. Abstr.) **(Ger)**

[Spinal chloroma as the initial manifestation of the transformation of essential thrombocythemia into acute myeloid leukemia] Stroszczynski C, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Mar;164(3):261–3 (13 ref.) (Eng. Abstr.) **(Ger)**

[Hematologic causes of vascular diseases of the central nervous system] Arboix A, et al. **Rev Neurol** 1995;23 Suppl 1:S41–9 (62 ref.) **(Spa)**

DRUG THERAPY

The thrombocytopenia of cancer. Prospects for effective cytokine therapy. Kaushansky K. **Hematol Oncol Clin North Am** 1996 Apr;10(2):431–55 (167 ref.)

ETIOLOGY

Interferon or hepatitis C virus induced autoimmune aplastic anemia and severe thrombocytopenia? A case report. Siciliano R, et al. **Ann Ital Med Int** 1995 Jul–Sep; 10(3):193–4 (10 ref.)

Thrombocytopenia in the antiphospholipid syndrome. Galli M, et al. **Br J Haematol** 1996 Apr;93(1):1–5 (50 ref.)

Thrombocytopenia in patients infected with human immunodeficiency virus: treatment update. Glatt AE, et al. **Clin Infect Dis** 1995 Aug;21(2):415–23 (92 ref.)

The thrombocytopenia of cancer. Prospects for effective cytokine therapy. Kaushansky K. **Hematol Oncol Clin North Am** 1996 Apr;10(2):431–55 (167 ref.)

Evans' syndrome, myelofibrosis and systemic lupus erythematosus: role of procollagens in myelofibrosis. Ramakrishna R, et al. **Pathology** 1995 Jul;27(3):255–9 (23 ref.)

[Transfusion–refractory thrombocytopenia during chemotherapy: pathogenesis, frequency and treatment] Helleberg C, et al. **Ugeskr Laeger** 1995 Sep 11; 157(37):5082–6 (40 ref.) (Eng. Abstr.) **(Dan)**

[Anti–platelet antibody and severe thrombocytopenia during interferon–alpha therapy for chronic active hepatitis C] Tanaka Y, et al. **Nihon Rinsho Meneki Gakkai Kaishi** 1996 Apr;19(2):150–6 (17 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Hereditary thrombocytopenias in childhood. Najean Y, et al. **Semin Thromb Hemost** 1995;21(3):294–304 (73 ref.)

IMMUNOLOGY

Leukophagocytosis in human parvovirus B19–induced transient bicytopenia in a healthy child. Wakamoto H, et al. **Acta Paediatr Jpn** 1996 Jun;38(3):278–81 (19 ref.)

PATHOLOGY

[Cloning of thrombopoietin and its physiologic role in megakaryocytopoiesis and thrombopoiesis] Miyazaki H. **Rinsho Ketsueki** 1996 Jan;37(1):1–6 (19 ref.) **(Jpn)**

PREVENTION & CONTROL

Amifostine and chemotherapy–related thrombocytopenia. Budd GT. **Semin Oncol** 1996 Aug;23(4 Suppl 8):49–52 (31 ref.)

SURGERY

The effect of thymectomy on myasthenia gravis, thrombocytopenia, and granulocytopenia associated with thymoma: report of a case. Kobayashi M, et al. **Surg Today** 1995;25(12):1061–5 (14 ref.)

THERAPY

The problem of thrombocytopenia and its management. Newland AC. **Anticancer Drugs** 1995 Oct;6 Suppl 5:65–73 (76 ref.)

Is interleukin 3 active in anticancer drug–induced thrombocytopenia? Newland AC. **Cancer Chemother Pharmacol** 1996;38 Suppl:S83–8 (46 ref.)

Effect of interleukin 11 on normal and pathological thrombopoiesis. Teramura M, et al. **Cancer Chemother Pharmacol** 1996;38 Suppl:S99–102 (27 ref.)

Platelet transfusion therapy for medical and surgical patients. Hussein MA, et al. **Cleve Clin J Med** 1996 Jul–Aug; 63(4):245–50 (44 ref.)

Thrombocytopenia in patients infected with human immunodeficiency virus: treatment update. Glatt AE, et al. **Clin Infect Dis** 1995 Aug;21(2):415–23 (92 ref.)

Platelet transfusion and alternatives to transfusion in patients with malignancy. Vaickus L, et al. **Stem Cells (Dayt)** 1995 Nov;13(6):588–96 (86 ref.)

[The interferon alfa–2a treatment of the severe form of the Kasabach–Merritt syndrome with neonatal onset] González de Dios J, et al. **An Esp Pediatr** 1996 Feb;44(2):179–83 (67 ref.) **(Spa)**

VIROLOGY

Glomerulonephritis, thrombocytopenia, and autoimmune neutropenia probably induced by a virus–like illness: case report and review of the literature. Mackey JR, et al. **Nephron** 1995;71(4):454–8 (33 ref.)

THROMBOCYTOSIS

Thrombocytosis in childhood. Sutor AH. **Semin Thromb Hemost** 1995;21(3):330–9 (69 ref.)

[Pregnancy in essential thrombocythemia. Manifestation time and risk for mother and child] Zahner J, et al. **Dtsch Med Wochenschr** 1995 Nov 3;120(44):1517–23 (55 ref.) **(Ger)**

COMPLICATIONS

Leukemia with megakaryocytic differentiation following essential thrombocythemia and myelofibrosis. Case report and review of the literature. Patiño–Sarcinelli F, et al. **Acta Haematol** 1996;95(2):122–8 (53 ref.)

Multiple myeloma following essential thrombocythemia. Cobo F, et al. **Leuk Lymphoma** 1995 Dec;20(1–2):177–9 (16 ref.)

DIAGNOSIS

[Essential thrombocythemia] Urbańczyk J. **Pol Arch Med Wewn** 1995 May;93(5):401–4 (19 ref.) **(Pol)**

ETIOLOGY

Primary thrombocythemia: a current perspective. Mughal TI. **Stem Cells (Dayt)** 1995 Jul;13(4):355–9 (33 ref.)

THERAPY

Successful treatment of essential thrombocythemia in a pregnancy with recombinant interferon–alpha 2a. Milano V, et al. **J Matern Fetal Med** 1996 Mar–Apr;5(2):74–8 (30 ref.)

The role of alpha–interferon in essential thrombocythaemia, polycythaemia vera and myelofibrosis with myeloid metaplasia (MMM): a concise update. Sacchi S. **Leuk Lymphoma** 1995 Sep;19(1–2):13–20 (86 ref.)

[Essential thrombocythemia] Urbańczyk J. **Pol Arch Med Wewn** 1995 May;93(5):401–4 (19 ref.) **(Pol)**

THROMBOELASTOGRAPHY see **THROMBELASTOGRAPHY**

THROMBOEMBOLISM

Deep venous thrombosis and pulmonary embolism. Brown HL, et al. **Clin Obstet Gynecol** 1996 Mar;39(1):87–100 (70 ref.)

BLOOD

Hypercoagulability, intraglomerular coagulation, and thromboembolism in nephrotic syndrome [editorial] Sagripanti A, et al. **Nephron** 1995;70(3):271–81 (118 ref.)

Developmental hemostasis: relevance to thromboembolic complications in pediatric patients. Andrew M. **Thromb Haemost** 1995 Jul;74(1):415–25 (141 ref.)

CHEMICALLY INDUCED

The pill. The controversy continues. Lidegaard O, et al. **Acta Obstet Gynecol Scand** 1996 Feb;75(2):93–7 (10 ref.)

[Risk of thromboembolism and oral contraceptives] Lê MG. **Contracept Fertil Sex** 1996 May;24(5):378–83 (7 ref.) (Eng. Abstr.) **(Fre)**

[Thromboembolism and ovarian hyperstimulation] Hocke C, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(7):691–6 (30 ref.) (Eng. Abstr.) **(Fre)**

[A new generation of oral contraceptives and venous thromboembolic diseases: unexpected results!] Scarabin PY. **Rev Epidemiol Sante Publique** 1996 Apr;44(2):188–9 (7 ref.) **(Fre)**

COMPLICATIONS

Congenital clavicular pseudoarthrosis associated with vascular thoracic outlet syndrome: case presentation and review of the literature. Hahn K, et al. **Cathet Cardiovasc Diagn** 1995 Aug;35(4):321–7 (30 ref.)

Hemorrhagic complications of thrombolytic therapy in the treatment of myocardial infarction and venous thromboembolism. Levine MN, et al. **Chest** 1995 Oct;108(4 Suppl):291S–301S (86 ref.)

DIAGNOSIS

[Activated factor VII as a new cardiovascular risk factor of atherothrombotic disease] Kario K, et al. **Rinsho Byori** 1995 Dec;43(12):1201–8 (28 ref.) (Eng. Abstr.) **(Jpn)**

[Postappendectomy vascular complications in childhood] Díez García R, et al. **An Esp Pediatr** 1996 Mar;44(3):270–2 (19 ref.) **(Spa)**

DRUG THERAPY

Thrombolysis in extremital arteries—indications and methods. Wellander E, et al. **Ann Chir Gynaecol** 1995; 84(4):341–8 (74 ref.)

Antithrombotic therapy for venous thromboembolic disease. Hyers TM, et al. **Chest** 1995 Oct;108(4 Suppl):335S–351S (232 ref.)

Alteplase. A reappraisal of its pharmacology and therapeutic use in vascular disorders other than acute myocardial infarction. Wagstaff AJ, et al. **Drugs** 1995 Aug; 50(2):289–316 (185 ref.)

Contemporary use of and future roles for heparin in antithrombotic therapy. Gibaldi M, et al. **J Clin Pharmacol** 1995 Nov;35(11):1031–45 (67 ref.)

Use of thrombolytics for the treatment of thromboembolic disease during pregnancy. Turrentine MA, et al. **Obstet Gynecol Surv** 1995 Jul;50(7):534–41 (52 ref.)

Heparin therapy: current regimens and principles of monitoring. Berry BR, et al. **Postgrad Med** 1996 Jun; 99(6):64–6, 69–76 (19 ref.)

Thrombolytic therapy: overview of results in major vascular occlusions. Marder VJ. **Thromb Haemost** 1995 Jul; 74(1):101–5 (60 ref.)

[Duration of antivitamin K therapy in venous thromboembolic disease] Ferrari E, et al. **Arch Mal Coeur Vaiss** 1995 Dec;88(12):1891–4 (24 ref.) (Eng. Abstr.) **(Fre)**

[The treatment of deep venous thrombosis with low–molecular–weight heparin] Samama MM, et al. **Rev Med Brux** 1995 Jul–Aug;16(4):304–9 (30 ref.) (Eng. Abstr.) **(Fre)**

[Prevention and treatment of thrombosis in pregnancy] Winkler UH, et al. **Geburtshilfe Frauenheilkd** 1996 Jun; 56(6):301–12 (83 ref.) (Eng. Abstr.) **(Ger)**

–Anticoagulant drugs– Gulba DC. **Herz** 1996 Feb; 21(1):12–27 (164 ref.) (Eng. Abstr.) **(Ger)**

[Anticoagulation in patients with atrial fibrillation] Mügge A. **Herz** 1996 Feb;21(1):28–36 (60 ref.) (Eng. Abstr.) **(Ger)**

[Biochemical, pharmacologic and clinical properties of new thrombolytic agents] Gulba DC. **Internist (Berl)** 1996 Jun; 37(6):552–66 (21 ref.) **(Ger)**

[Fibrinolytic agents—who benefits when?] Weichert W, et al. **Ther Umsch** 1995 Oct;52(10):652–60 (35 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Intracardiac thrombi: frequency, location, etiology, and complications: a morphologic review—Part V. Waller BF, et al. **Clin Cardiol** 1995 Dec;18(12):731–4 (17 ref.)

Thromboembolic complications in patients with pelvic trauma. Montgomery KD, et al. **Clin Orthop** 1996 Aug; (329):68–87 (94 ref.)

Intracardiac thrombosis: patient–related and device–related factors. Horstkotte D, et al. **J Heart Valve Dis** 1995 Mar; 4(2):114–20 (70 ref.)

Spontaneous arterial thrombosis associated with nephrotic syndrome: case report and review of the literature. Khatri VP, et al. **Nephron** 1995;71(1):95–7 (11 ref.)

Hypercoagulability, intraglomerular coagulation, and thromboembolism in nephrotic syndrome [editorial] Sagripanti A, et al. **Nephron** 1995;70(3):271–81 (118 ref.)

The investigation of a patient with unexpected venous thrombosis. Wilde JT. **Postgrad Med J** 1995 Dec; 71(842):720–4 (35 ref.)

Risk of thromboembolism in new onset or transient atrial fibrillation. Stoddard MF. **Prog Cardiovasc Dis** 1996 Jul–Aug;39(1):69–80 (67 ref.)

Hemostasis in childhood acute lymphoblastic leukemia: coagulopathy induced by disease and treatment. Mitchell LG, et al. **Semin Thromb Hemost** 1995;21(4):390–401 (80 ref.)

Is prosthetic valve thrombogenicity related to design or material? Edmunds LH Jr. **Tex Heart Inst J** 1996;23(1):24–7 (20 ref.)

[Right atrial thrombosis; an unusual late complication of the Fontan procedure. Apropos of a case] Soyer R, et al. **Arch Mal Coeur Vaiss** 1995 Mar;88(3):391–5 (14 ref.) (Eng. Abstr.) **(Fre)**

[Pulmonary cancer and recurrent arterial and venous thromboses] Auvray E, et al. **Rev Pneumol Clin** 1996; 52(3):188–91 (16 ref.) (Eng. Abstr.) **(Fre)**

[Trauma and thrombosis. High risk of embolism in patients with spinal cord injuries, hip fractures and leg fractures] Bergovist D. **Lakartidningen** 1996 Jul 24;93(30–31):2653–4 (19 ref.) **(Swe)**

GENETICS

Thrombophilia: the discovery of activated protein C resistance. Dahlbäck B. **Adv Genet** 1995;33:135–75 (114 ref.)

Resistance to activated protein C due to mutated factor V

as a novel cause of inherited thrombophilia. De Stefano V, et al. **Haematologica** 1995 Jul-Aug;80(4):344-56 (99 ref.)
Molecular genetics of human antithrombin deficiency. Perry DJ, et al. **Hum Mutat** 1996;7(1):7-22 (119 ref.)
[Resistance to activated protein C. A common genetic risk factor in venous thrombosis] Berntorp E, et al. **Lakartidningen** 1995 Sep 27;92(39):3587-90 (27 ref.) **(Swe)**

PHYSIOPATHOLOGY

[Recent morphofunctional findings on the left atrium: their relations to thromboembolic risk] Zeppellini R, et al. **G Ital Cardiol** 1995 Aug;25(8):1055-65 (57 ref.) (Eng. Abstr.) **(Ita)**

PREVENTION & CONTROL

Prevention of thromboembolic events in valvular heart disease. Gohlke-Bärwolf C, et al. **Acta Cardiol** 1996; 51(2):129-42 (37 ref.)
The need for highly purified products to treat hemophilia B. Scharrer I. **Acta Haematol** 1995;94 Suppl 1:2-7 (44 ref.)
Clinical applications of new antithrombotic agents. Beijering RJ, et al. **Ann Hematol** 1996 Apr;72(4):177-83 (52 ref.)
ABC of atrial fibrillation. Antithrombotic treatment for atrial fibrillation. Lip GY, et al. **BMJ** 1996 Jan 6;312(7022):45-9 (0 ref.)
Prevention of postoperative venous thromboembolism. Bullingham A, et al. **Br J Anaesth** 1995 Nov;75(5):622-30 (85 ref.)
Warfarin and aspirin as thromboprophylaxis in atrial fibrillation. Lip GY, et al. **Br J Clin Pharmacol** 1996 May; 41(5):369-79 (83 ref.)
Prevention of venous thromboembolism. Clagett GP, et al. **Chest** 1995 Oct;108(4 Suppl):312S-334S (312 ref.)
Atrial fibrillation: steering a management course between thromboembolism and proarrhythmic risk. Campbell RW. **Eur Heart J** 1995 Aug;16 Suppl G:28-31 (56 ref.)
Guidelines for prevention of thromboembolic events in valvular heart disease. Study Group of the Working Group on Valvular Heart Disease of the European Society of Cardiology. Gohlke-Bärwolf C, et al. **Eur Heart J** 1995 Oct;16(10):1320-30 (165 ref.)
Anticoagulation and pregnancy. Oakley CM. **Eur Heart J** 1995 Oct;16(10):1317-9 (22 ref.)
Prevention of venous thromboembolic risk in non-surgical patients. Bergmann JF, et al. **Haemostasis** 1996;26 Suppl 2:16-23 (16 ref.)
Optimization of oral anticoagulation for patients with mechanical heart valve prostheses. Piper C, et al. **J Heart Valve Dis** 1995 Mar;4(2):127-37 (83 ref.)
Management of atrial fibrillation in adults: prevention of thromboembolism and symptomatic treatment. Blackshear JL, et al. **Mayo Clin Proc** 1996 Feb;71(2):150-60 (65 ref.)
Prevention of postoperative venous thromboembolism [editorial; comment] Chong BH. **Med J Aust** 1996 Jun 3; 164(11):646-7 (13 ref.) Comment on: Med J Aust 1996 Jun 3;164(11):652-4, 656.
The risks and benefits of antithrombotic therapy in chronic atrial fibrillation. Hankey GJ, et al. **Med J Aust** 1996 May 20;164(10):624-6 (16 ref.)
Management of venous thromboembolic (VTE) disease--Part I: Prevention. Kayser SR. **Prog Cardiovasc Nurs** 1995 Fall;10(4):31-6 (18 ref.)
Thromboembolism in chronic Chagas' heart disease. Braga JC, et al. **Rev Paul Med** 1995 Mar-Apr;113(2):862-6 (29 ref.)
[Analysis of the individual quality of an oral anticoagulant using the ratio F1+2/INR] Bruhn HD, et al. **Dtsch Med Wochenschr** 1995 Oct 20;120(42):1441-4 (10 ref.) **(Ger)**
[Recommendations for prevention of thromboembolism in heart valve diseases. Working Group on Valvular Heart Disease, European Society of Cardiology] Gohlke-Bärwolf C, et al. **Z Kardiol** 1995 Dec;84(12):1018-32 (168 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Venous thromboembolism during pregnancy. Toglia MR, et al. **N Engl J Med** 1996 Jul 11;335(2):108-14 (70 ref.)
Interventional procedures in the intensive care unit patient. Mewissen MW, et al. **Radiol Clin North Am** 1996 Jan; 34(1):157-76 (110 ref.)
Preclinical management of thromboembolic disorders. Schreiber W, et al. **Semin Thromb Hemost** 1996;22(1):3-13 (96 ref.)
[Catheterization therapy of thromboembolic arterial occlusions of the lower extremities] Staněk F, et al. **Cas Lek Cesk** 1995 Aug 2;134(15):471-3 (28 ref.) (Eng. Abstr.) **(Cze)**
[APC resistance: pathogenesis, diagnosis, prevalence and importance of a new thrombosis risk factor] Wankmüller H, et al. **Med Klin** 1996 May 15;91(5):308-12, 324 (49 ref.) **(Ger)**

ULTRASONOGRAPHY

[The main indications for transesophageal echocardiography] Lesbre JP. **Ann Cardiol Angeiol (Paris)** 1995 Dec; 44(10):547-51 (21 ref.) (Eng. Abstr.) **(Fre)**
[Spontaneous intracardiac contrast and embolic risk] Lardoux H, et al. **Arch Mal Coeur Vaiss** 1996 Apr;89(4):451-7 (33 ref.) (Eng. Abstr.) **(Fre)**

THROMBOENDARTERECTOMY see **ENDARTERECTOMY**

THROMBOLYSIN see **PLASMIN**

THROMBOLYSIS, THERAPEUTIC see **THROMBOLYTIC THERAPY**

THROMBOLYTIC AGENTS see **FIBRINOLYTIC AGENTS**

THROMBOLYTIC THERAPY

Thrombolytic therapy in peripheral vascular disease. Ouriel K. **Adv Surg** 1996;29:191-206 (53 ref.)
Relation between systemic anticoagulation as determined by activated partial thromboplastin time and heparin measurements and in-hospital clinical events in unstable angina and non-Q wave myocardiaL infarction. Thrombolysis in Myocardial Ischemia III B Investigators. Becker RC, et al. **Am Heart J** 1996 Mar;131(3):421-33 (66 ref.)
Management of acute myocardial infarction: evaluating the past, practicing in the present, elaborating the future. Glogar D, et al. **Am Heart J** 1996 Aug;132(2 Pt 2 Su):465-70; discussion 496-502 (68 ref.)
Thrombolysis for acute Budd-Chiari syndrome: case report and literature review. Raju GS, et al. **Am J Gastroenterol** 1996 Jun;91(6):1262-3 (11 ref.)
Use of tissue type plasminogen activator in neonates: case reports and review of the literature. Smets K, et al. **Am J Perinatol** 1996 May;13(4):217-22 (21 ref.)
Clinical science review: current aspects of thrombolytic therapy in women with acute myocardial infarction. Hussain KM, et al. **Angiology** 1996 Jan;47(1):23-33 (83 ref.)
Thrombolysis to treat arterial thrombotic complications of heparin-induced thrombocytopenia. Calligaro KD, et al. **Ann Vasc Surg** 1995 Jul;9(4):397-400 (8 ref.)
Safety profile of thrombolytic drugs. Maggioni AP, et al. **Arq Bras Cardiol** 1995 Jul;65(1):87-90 (11 ref.)
Thrombolytic therapy of acute myocardial infarction. de Bono DP. **Baillieres Clin Haematol** 1995 Jun;8(2):403-12 (36 ref.)
Thrombolytic therapy of non-cardiac disorders. Verstraete M. **Baillieres Clin Haematol** 1995 Jun;8(2):413-24 (58 ref.)
Interventional neuroradiology. Pelz DM. **Baillieres Clin Neurol** 1995 Aug;4(2):297-315 (60 ref.)
New directions in anticoagulant and antiplatelet treatment [editorial] Simoons ML, et al. **Br Heart J** 1995 Oct; 74(4):337-40 (33 ref.)
Warfarin and aspirin as thromboprophylaxis in atrial fibrillation. Lip GY, et al. **Br J Clin Pharmacol** 1996 May; 41(5):369-79 (83 ref.)
Practical implications of circadian variations in thrombolytic and antithrombotic activities. Kurnik PB. **Cardiol Clin** 1996 May;14(2):251-62 (31 ref.)
Risk-benefit of thrombolysis. Simoons ML. **Cardiol Clin** 1995 Aug;13(3):339-45 (28 ref.)
Selecting a thrombolytic agent. White HD. **Cardiol Clin** 1995 Aug;13(3):347-54 (54 ref.)
Aggressive interventional treatment of acute myocardial infarction. Lessons from the animal laboratory applied to the catheterization suite. Feld S, et al. **Cardiology** 1995; 86(5):365-73 (65 ref.)
Peripheral thrombolysis: state of the art. Earnshaw JJ, et al. **Cardiovasc Surg** 1995 Aug;3(4):357-67 (28 ref.)
4th American College of Chest Physicians Consensus Conference on Antithrombotic Therapy. Tucson, Arizona, April 1995. Proceedings. **Chest** 1995 Oct;108(4 Suppl):225S-522S (0 ref.)
Coronary thrombolysis. Cairns JA, et al. **Chest** 1995 Oct; 108(4 Suppl):401S-423S (141 ref.)
Antithrombotic therapy for venous thromboembolic disease. Hyers TM, et al. **Chest** 1995 Oct;108(4 Suppl):335S-351S (232 ref.)
Thrombolytic therapy of left-sided prosthetic valve thrombosis. Koller PT, et al. **Chest** 1995 Dec;108(6):1683-9 (21 ref.)
Antithrombotic therapy in atrial fibrillation. Laupacis A, et al. **Chest** 1995 Oct;108(4 Suppl):352S-359S (52 ref.)
Treatment of complicated pleural fluid collections with image-guided drainage and intracavitary urokinase [see comments] Moulton JS, et al. **Chest** 1995 Nov; 108(5):1252-9 (20 ref.) Comment in: Chest 1995 Nov;108(5):1190-1.
Thrombolytic intervention of acute myocardial infarction in the 1990s. Hu D. **Chin Med J (Engl)** 1996 Feb;109(2):107-8 (0 ref.)
Fibrin-selective thrombolytic therapy for acute myocardial infarction. Collen D. **Circulation** 1996 Mar 1;93(5):857-65 (90 ref.)
Thrombolysis in ischemic stroke: double or quits? [editorial] van Gijn J. **Circulation** 1996 May 1;93(9):1616-7 (21 ref.)
The role of prolonged thrombolytic infusions and transesophageal echocardiography in thrombosed prosthetic heart valves: case report and review of the literature. Puleo JA, et al. **Clin Cardiol** 1995 Nov; 18(11):679-84 (50 ref.)
Left ventricular function following thrombolytic therapy for myocardial infarction. French JK, et al. **Clin Exp Pharmacol Physiol** 1995 Mar;22(3):173-9 (46 ref.)
Augmentation of thrombolysis with antiplatelet drugs. Coller BS. **Coron Artery Dis** 1995 Dec;6(12):911-4 (14 ref.)
Inhibitors of platelet glycoprotein IIb/IIIa as augmenters of thrombolysis. Eccleston D, et al. **Coron Artery Dis** 1995 Dec;6(12):947-55 (67 ref.)
Adjunctive therapy in coronary thrombolysis: prostaglandins, nitrates and calcium antagonists. Fitzgerald D. **Coron Artery Dis** 1995 Dec;6(12):940-6 (69 ref.)
Antiplatelet effects of fibrinolytic agents: a potential contributor to the hemostatic defect after thrombolysis. Kamat SG, et al. **Coron Artery Dis** 1995 Dec;6(12):930-5 (55 ref.)
Platelet activation by fibrinolytic agents: a potential mechanism for resistance to thrombolysis and reocclusion after successful thrombolysis. Leopold JA, et al. **Coron Artery Dis** 1995 Dec;6(12):923-9 (60 ref.)
Aspirin augmentation of the efficacy of thrombolysis. O'Donnell CJ, et al. **Coron Artery Dis** 1995 Dec;6(12):936-9 (23 ref.)
The role of coronary angiography after thrombolysis. Aguirre FV, et al. **Curr Opin Cardiol** 1995 Jul;10(4):381-8 (58 ref.)
Antiplatelet, antithrombotic, and lytic therapy for unstable angina, and the appropriate role of revascularization. de Feyter PJ, et al. **Curr Opin Cardiol** 1995 Jul;10(4):389-98 (36 ref.)
The importance of early patency after acute myocardial infarction. Grover A, et al. **Curr Opin Cardiol** 1995 Jul; 10(4):361-6 (29 ref.)
Thrombolysis in the era of the randomized trials. Zahger D, et al. **Curr Opin Cardiol** 1995 Jul;10(4):372-80 (84 ref.)
Optimising thrombolytic therapy in elderly patients with acute myocardial infarction. Verstraete M, et al. **Drugs Aging** 1996 Jan;8(1):17-22 (32 ref.)
Thrombolytic therapy. Young GP, et al. **Emerg Med Clin North Am** 1995 Nov;13(4):735-58 (124 ref.)
Remodelling of the coronary arteries after thrombolysis. Davies GJ. **Eur Heart J** 1995 Aug;16 Suppl I:31-2 (12 ref.)
Time as a factor in thrombolytic therapy. Julian DG. **Int J Cardiol** 1995 Aug;49 Suppl:S17-9 (15 ref.)
From the experimental myocardial infarction to the clinical acute myocardial infarction: limitations of thrombolytic therapy. Marzilli M. **Int J Cardiol** 1995 Aug;49 Suppl:S71-5 (30 ref.)
Reocclusion: the flip side of coronary thrombolysis. Verheugt FW, et al. **J Am Coll Cardiol** 1996 Mar 15;27(4):766-73 (62 ref.)
Contemporary use of and future roles for heparin in antithrombotic therapy. Gibaldi M, et al. **J Clin Pharmacol** 1995 Nov;35(11):1031-45 (67 ref.)
Thrombolytic therapy in 1995. Mahanonda N. **J Med Assoc Thai** 1995 Jun;78(6):314-21 (56 ref.)
Thrombolytic therapy for brain attack. Macabasco AC, et al. **J Neurosci Nurs** 1995 Jun;27(3):138-49; quiz 150-1 (24 ref.)
Fibrinolytic mechanism, biochemistry, and preclinical pharmacology of recombinant prourokinase. Credo RB, et al. **J Vasc Interv Radiol** 1995 Nov-Dec;6(6 Pt 2 Su):8S-18S (59 ref.)
Thrombolysis, flow, and vessel wall interactions. Grabowski EF. **J Vasc Interv Radiol** 1995 Nov-Dec;6(6 Pt 2 Su):25S-29S (37 ref.)
Surgery versus thrombolytic therapy in the management of peripheral arterial occlusions. Ouriel K. **J Vasc Interv Radiol** 1995 Nov-Dec;6(6 Pt 2 Su):48S-54S (42 ref.)
Thrombolytic therapy for obstruction of mechanical prosthetic valves. Hurrell DG, et al. **Mayo Clin Proc** 1996 Jun;71(6):605-13 (64 ref.)
The risks and benefits of antithrombotic therapy in chronic atrial fibrillation. Hankey GJ, et al. **Med J Aust** 1996 May 20;164(10):624-6 (16 ref.)
ISIS 4: clinical controversy regarding magnesium infusion, thrombolytic therapy, and acute myocardial infarction. Seelig MS. **Nutr Rev** 1995 Sep;53(9):261-4 (52 ref.)
Pulmonary embolism--the role of thrombolytic therapy in its management. More RS, et al. **Postgrad Med J** 1996 Mar; 72(845):157-61 (50 ref.)
A practical guide to thrombolysis. Gordon I. **Practitioner** 1995 Nov;239(1556):676-8 (10 ref.)
The role of thrombolysis in the management of acute arterial occlusions of the lower limb. Browning NG, et al. **S Afr J Surg** 1995 Dec;33(4):170-4 (52 ref.)
Thrombolytic therapy in acute myocardial infarction. Huber K, et al. **Semin Thromb Hemost** 1996;22(1):15-26 (115 ref.)
Thrombolytic therapy in acute lower limb ischemia. Pilger E. **Semin Thromb Hemost** 1996;22(1):61-7 (48 ref.)
Molecular basis of fibrinolysis, as relevant for thrombolytic therapy. Collen D, et al. **Thromb Haemost** 1995 Jul; 74(1):167-71 (40 ref.)
Thrombolytic therapy: overview of results in major vascular occlusions. Marder VJ. **Thromb Haemost** 1995 Jul; 74(1):101-5 (60 ref.)
The fibrinolytic system: from Petri dishes to genetic engineering. Verstraete M. **Thromb Haemost** 1995 Jul; 74(1):25-35 (108 ref.)
Angioplasty or thrombolysis for acute infarction? Reeder GS. **Z Kardiol** 1995;84 Suppl 2:1-4 (14 ref.)
[Catheterization therapy of thromboembolic arterial occlusions of the lower extremities] Staněk F, et al.

Cas Lek Cesk 1995 Aug 2;134(15):471–3 (28 ref.) (Eng. Abstr.) **(Cze)**

[Effects of thrombolysis on platelets and coagulation] Helft G, et al. **Ann Cardiol Angeiol (Paris)** 1995 Sep;44(7):354–60 (34 ref.) (Eng. Abstr.) **(Fre)**

[Thrombolysis after 75 years of age: benefits, risks, indications] Tabone X, et al. **Arch Mal Coeur Vaiss** 1995 Feb;88(2):255–60 (21 ref.) (Eng. Abstr.) **(Fre)**

[Indications of coronary angioplasty after thrombolysis] Vahanian A, et al. **Arch Mal Coeur Vaiss** 1995 Aug;88 Spec No 3:19–24 (30 ref.) (Eng. Abstr.) **(Fre)**

[Thrombolytic therapy in arterial disorders other than myocardial infarction] Verstraete M.
Arch Mal Coeur Vaiss 1996 Jan;89(1):77–82 (47 ref.) (Eng. Abstr.) **(Fre)**

[Thrombolytic therapy of acute myocardial infarction] Verstraete M. **Arch Mal Coeur Vaiss** 1995 Dec; 88(12):1883–9 (58 ref.) (Eng. Abstr.) **(Fre)**

[Fibrinolysis of deep venous thrombosis on implantable perfusion devices. Apropos of a consecutive series of 57 cases of thrombosis and 32 cases of fibrinolysis] Pucheu A, et al. **Bull Cancer (Paris)** 1996 Apr;83(4):293–9 (33 ref.) (Eng. Abstr.) **(Fre)**

[Acute carotid occlusion: thrombolytic treatment] Maiza D, et al. **J Mal Vasc** 1996;21 Suppl A:83–9 (10 ref.) (Eng. Abstr.) **(Fre)**

[Myocardial infarction and revascularization. Current indications] Grollier G, et al. **Rev Med Interne** 1995; 16(9):673–83 (62 ref.) (Eng. Abstr.) **(Fre)**

[The value of preclinical thrombolysis in acute myocardial infarct] Arntz HR.
Anasthesiol Intensivmed Notfallmed Schmerzther 1995 Aug; 30(5):299–302 (25 ref.) **(Ger)**

[Thrombolysis of an extensive venous thrombosis of the lower body in an anomaly of the vena cava inferior] Rühlmann C, et al. **Dtsch Med Wochenschr** 1996 Feb 2; 121(5):124–8 (29 ref.) (Eng. Abstr.) **(Ger)**

[Thrombolysis in stroke] Diener HC, et al.
Internist (Berl) 1996 Jun;37(6):613–8 (26 ref.) **(Ger)**

[Thrombolytic therapy of renal artery embolism. An expanded case report with review of the literature] Gulba DC, et al. **Internist (Berl)** 1996 Jun;37(6):623–7 (51 ref.) **(Ger)**

[Biochemical, pharmacologic and clinical properties of new thrombolytic agents] Gulba DC. **Internist (Berl)** 1996 Jun; 37(6):552–66 (21 ref.) **(Ger)**

[Postoperative thrombolytic therapy] Kolben M, et al.
Internist (Berl) 1996 Jun;37(6):619–22 (27 ref.) **(Ger)**

[Symptomatic therapy refractory myocardial ischemia in coronary heart disease. Chronic intermittent urokinase therapy and invasive therapeutic measures] Leschke M, et al. **Internist (Berl)** 1996 Jun;37(6):597–606 (50 ref.) **(Ger)**

[Thrombolytic therapy of acute pulmonary embolism] Pilger E, et al. **Internist (Berl)** 1996 Jun;37(6):574–84 (56 ref.) **(Ger)**

[Percutaneous local thrombolytic therapy and thrombectomy in occlusion of extremity arteries] Schneider E, et al.
Internist (Berl) 1996 Jun;37(6):607–12 (23 ref.) **(Ger)**

[Antithrombotic therapy in cerebrovascular disorders] Dahl T, et al. **Tidsskr Nor Laegeforen** 1995 Sep 30; 115(23):2909–12 (50 ref.) (Eng. Abstr.) **(Nor)**

[Thrombolysis (Consensus about post-myocardial infarction treatment)] **Arq Bras Cardiol** 1995 Mar;64(3):271–80 (65 ref.) **(Por)**

[Evaluation of a standard electrocardiogram in acute myocardial infarct and therapy with thrombolysis] Kuchárová L, et al. **Vnitr Lek** 1995 Dec;41(12):836–41 (43 ref.) (Eng. Abstr.) **(Slo)**

[Thrombolytic treatment in acute myocardial infarction in the aged: arguments in favor] Alonso-Orcajo N, et al.
Rev Esp Cardiol 1995 Sep;48(9):589–93 (43 ref.) **(Spa)**

[Thrombolytic treatment in acute myocardial infarction in the aged: arguments against] Pabón Osuna P, et al.
Rev Esp Cardiol 1995 Sep;48(9):581–8 (36 ref.) **(Spa)**

ADVERSE EFFECTS

Hemorrhagic complications of thrombolytic therapy in the treatment of myocardial infarction and venous thromboembolism. Levine MN, et al. **Chest** 1995 Oct;108(4 Suppl):291S–301S (86 ref.)

[Complications of thrombolytic therapy in pulmonary embolism] Meneveau N, et al. **Arch Mal Coeur Vaiss** 1995 Nov;88(11 Suppl):1769–76 (42 ref.) (Eng. Abstr.) **(Fre)**

[Contemporary opinions on the use of aspirin, heparin and thrombolytic therapy in unstable angina pectoris--pathogenetic findings versus results of many clinical tests] Popiel M, et al. **Przegl Lek** 1996;53(1):33–40 (40 ref.) (Eng. Abstr.) **(Pol)**

ECONOMICS

Clinical and economic lessons from studies of coronary thrombolysis. Mark DB. **J Vasc Interv Radiol** 1995 Nov-Dec;6(6 Pt 2 Su):94S–101S (27 ref.)

INSTRUMENTATION

Technical determinants of success in catheter-directed thrombolysis for peripheral arterial occlusions. Kandarpa K. **J Vasc Interv Radiol** 1995 Nov-Dec;6(6 Pt 2 Su):55S–61S (54 ref.)

METHODS

The results of arterial thrombolysis. Kroese AJ, et al.
Ann Chir Gynaecol 1995;84(4):350–3 (17 ref.)

Thrombolysis in extremital arteries--indications and methods. Wellander E, et al. **Ann Chir Gynaecol** 1995; 84(4):341–8 (74 ref.)

New thrombolytic agents and strategies. Collen D, et al.
Baillieres Clin Haematol 1995 Jun;8(2):425–35 (50 ref.)

Restenosis--an open file. Gottsauner-Wolf M, et al.
Clin Cardiol 1996 May;19(5):347–56 (118 ref.)

Thrombolytic therapy for acute arterial occlusion. Ouriel K.
Curr Opin Gen Surg 1994;:257–64 (39 ref.)

Guidelines for general practitioners administering thrombolytics. Rawles J. **Drugs** 1995 Oct;50(4):615–25 (45 ref.)

The promise of new genetically engineered plasminogen activators. Cutler D, et al. **J Vasc Interv Radiol** 1995 Nov-Dec;6(6 Pt 2 Su):3S–7S (16 ref.)

Drug variables in thrombolytic therapy. Meyerovitz MF.
J Vasc Interv Radiol 1995 Nov-Dec;6(6 Pt 2 Su):62S–65S (34 ref.)

Acute myocardial infarction. A guide for North Carolina doctors. Williams ML, et al. **N C Med J** 1995 Aug; 56(8):390–7 (39 ref.)

The management of acute myocardial infarction. Saltissi S, et al. **Postgrad Med J** 1995 Sep;71(839):534–41 (28 ref.)

Lower limb intraarterial thrombolysis as an adjunct to the management of arterial and graft occlusions. Braithwaite BD, et al. **World J Surg** 1996 Jul-Aug;20(6):649–54 (38 ref.)

[Therapeutic strategies in acute myocardial infarction. Results of STIM 93 registry] Monassier JP, et al.
Arch Mal Coeur Vaiss 1996 Mar;89(3):281–9 (35 ref.) (Eng. Abstr.) **(Fre)**

[Thrombolysis in acute myocardial infarct] Heintzen MP, et al. **Internist (Berl)** 1996 Jun;37(6):585–96 (80 ref.) **(Ger)**

[Thrombolytic therapy of venous thromboses] Heinz M, et al. **Internist (Berl)** 1996 Jun;37(6):567–73 (38 ref.) **(Ger)**

[Thrombolysis of myocardial infarction--state of the art] Erne P. **Schweiz Rundsch Med Prax** 1995 Oct 17; 84(42):1194–201 (72 ref.) (Eng. Abstr.) **(Ger)**

[Treatment possibilities for extensive pulmonary embolism as an alternative to the Trendelenburg operation] Sárosi I, et al. **Orv Hetil** 1995 Nov 19;136(47):2553–9 (51 ref.) (Eng. Abstr.) **(Hun)**

[Urokinase in a premature infant: its use in a case of right atrial thrombosis secondary to catheterization of the umbilical vein] Colnaghi C, et al. **Pediatr Med Chir** 1995 May-Jun;17(3):275–7 (10 ref.) (Eng. Abstr.) **(Ita)**

[Local thrombolysis and stents in deep venous thrombosis. A new endovascular therapeutic technique] Nyman U, et al. **Lakartidningen** 1996 Aug 7;93(32–33):2750–6 (27 ref.) **(Swe)**

[Antithrombotic treatment in connection with PTCA. New substances and regimes are coming] Scherstén F, et al.
Lakartidningen 1996 Jun 26;93(26–27):2499–502 (29 ref.) **(Swe)**

NURSING

Heparin as adjunctive therapy to coronary thrombolysis in acute myocardial infarction. Bowlby H, et al.
Heart Lung 1995 Jul-Aug;24(4):292–304; quiz 304–6 (112 ref.)

STANDARDS

Guidelines for general practitioners administering thrombolytics. Rawles J. **Drugs** 1995 Oct;50(4):615–25 (45 ref.)

Primary angioplasty and thrombolysis for acute myocardial infarction: an evidence summary [see comments] Lieu TA, et al. **J Am Coll Cardiol** 1996 Mar 1;27(3):737–50 (76 ref.) Comment in: J Am Coll Cardiol 1996 Mar 1;27(3):736.

TRENDS

Thrombolytic and antithrombotic treatment in myocardial infarction: main achievements and future perspectives. Agnelli G. **Int J Cardiol** 1995 Aug;49 Suppl:S77–87 (60 ref.)

Thrombolytic therapy: future issues. Samama MM, et al.
Thromb Haemost 1995 Jul;74(1):106–10 (46 ref.)

Advances in antithrombotic therapy: novel agents. Turpie AG, et al. **Thromb Haemost** 1995 Jul;74(1):565–71 (63 ref.)

[The new frontier of antithrombotic therapy: ASA + warfarin, the ideal solution?] Cimminiello C, et al.
G Ital Cardiol 1995 Sep;25(9):1187–93 (36 ref.) (Eng. Abstr.) **(Ita)**

THROMBOMODULIN

ANALYSIS

[Thrombomodulin (TM)] Sakuragawa N. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:132–6 (20 ref.) **(Jpn)**

THROMBOPENIA see **THROMBOCYTOPENIA**

THROMBOPHLEBITIS

see related
VENA CAVA FILTERS

Deep vein thrombosis. Tyrrell MR, et al.
Br J Clin Pract 1995 Sep-Oct;49(5):252–6 (77 ref.)

Phlegmasia caerulea dolens and venous gangrene. Perkins JM, et al. **Br J Surg** 1996 Jan;83(1):19–23 (62 ref.)

Calf deep venous thrombosis: a review of the literature. Giannoukas AD, et al. **Eur J Vasc Endovasc Surg** 1995 Nov;10(4):398–404 (87 ref.)

Mondor's disease. Pugh CM, et al. **J Natl Med Assoc** 1996 Jun;88(6):359–63 (27 ref.)

Clinical diagnosis and management of the patient with deep venous thromboembolism and acute pulmonary embolism. Eftychiou V. **Nurse Pract** 1996 Mar;21(3):50–2, 58, 61–2, passim, quiz 69–71 (34 ref.)

BLOOD

[Contribution of the hemostasis laboratory in the diagnosis of deep venous thrombosis] Demarmels Biasiutti F, et al.
Ther Umsch 1996 Apr;53(4):265–71 (24 ref.) (Eng. Abstr.) **(Ger)**

CHEMICALLY INDUCED

[Significance of hereditary thrombophilia for risk of thrombosis with oral contraceptives] Bauersachs R, et al.
Zentralbl Gynakol 1996;118(5):262–70 (53 ref.) (Eng. Abstr.) **(Ger)**

COMPLICATIONS

Diagnosis of pulmonary embolism [editorial] Hyers TM.
Thorax 1995 Sep;50(9):930–2 (13 ref.)

DIAGNOSIS

D-dimer testing and acute venous thromboembolism. A shortcut to accurate diagnosis? Becker DM, et al.
Arch Intern Med 1996 May 13;156(9):939–46 (46 ref.)

Diagnosis of deep vein thrombosis. Douketis JD, et al.
Can Fam Physician 1996 Mar;42:497–503 (35 ref.)

Septic thrombophlebitis of the portal vein (pylephlebitis): diagnosis and management in the modern era. Plemmons RM, et al. **Clin Infect Dis** 1995 Nov;21(5):1114–20 (32 ref.)

Duplex scanning for deep vein thrombosis: has it replaced both phlebography and noninvasive testing? Douglas MG, et al. **Semin Vasc Surg** 1996 Mar;9(1):3–12 (24 ref.)

[Current methods in the diagnosis of deep venous thrombosis of the lower limbs] Cappeliez O, et al. **Rev Med Brux** 1996 Jun;17(3):127–31 (19 ref.) (Eng. Abstr.) **(Fre)**

[Varicose veins and migrating thrombophlebitis] Leu AJ, et al. **Dtsch Med Wochenschr** 1996 Apr 19;121(16):527–31 (30 ref.) **(Ger)**

[Assessment of deep venous thrombosis] Z'Brun A, et al.
Ther Umsch 1996 Apr;53(4):258–64 (24 ref.) (Eng. Abstr.) **(Ger)**

[Pseudothrombophlebitis due to an expansive popliteal cyst associated with Reiter's syndrome] Mangiafico RA, et al.
Minerva Med 1995 Sep;86(9):391–4 (14 ref.) (Eng. Abstr.) **(Ita)**

DRUG THERAPY

Septic thrombophlebitis of the portal vein (pylephlebitis): diagnosis and management in the modern era. Plemmons RM, et al. **Clin Infect Dis** 1995 Nov;21(5):1114–20 (32 ref.)

Pharmacological properties of hirudin and its derivatives. Potential clinical advantages over heparin. Monreal M, et al. **Drugs Aging** 1996 Mar;8(3):171–82 (52 ref.)

Low-molecular-weight heparins and new strategies for the treatment of patients with established venous thrombosis. Baglin TP. **Haemostasis** 1996;26 Suppl 2:10–5 (19 ref.)

Low molecular weight heparins in the initial treatment of deep vein thrombosis. Volteas SK, et al. **Int Angiol** 1996 Mar;15(1):67–74 (46 ref.)

Oral anticoagulant therapy: practical aspects of management. Brigden ML. **Postgrad Med** 1996 Jun;99(6):81–4, 87–9, 93–4 passim (22 ref.)

Anticoagulant therapy for deep vein thrombosis: its proper application. Rohrer MJ, et al. **Semin Vasc Surg** 1996 Mar; 9(1):13–20 (38 ref.)

Oral anticoagulant treatment with and without aspirin. Altman R, et al. **Thromb Haemost** 1995 Jul;74(1):506–10 (37 ref.)

Treatment of a patient with an undefined hypercoagulable state with long-term low-molecular-weight heparin. Dobie SA, et al. **West J Med** 1996 Apr;164(4):350–3 (6 ref.)

[Thrombolysis of an extensive venous thrombosis of the lower body in an anomaly of the vena cava inferior] Rühlmann C, et al. **Dtsch Med Wochenschr** 1996 Feb 2; 121(5):124–8 (29 ref.) (Eng. Abstr.) **(Ger)**

[Thrombolytic therapy of venous thromboses] Heinz M, et al. **Internist (Berl)** 1996 Jun;37(6):567–73 (38 ref.) **(Ger)**

[Drug therapy of deep venous thrombosis] Bounameaux H.
Ther Umsch 1996 Apr;53(4):272–6 (16 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Resistance to activated protein C, the FV:Q506 allele, and venous thrombosis. Dahlbäck B, et al. **Ann Hematol** 1996 Apr;72(4):166–76 (152 ref.)

Thrombotic complications of varicose veins. A literature review of the role of superficial venous thrombosis. Guex JJ. **Dermatol Surg** 1996 Apr;22(4):378–82 (39 ref.)

The potential risks, complications, and prevention of deep vein thrombosis in oral and maxillofacial surgery patients. Solomon JM, et al. **J Oral Maxillofac Surg** 1995 Dec; 53(12):1441–7 (28 ref.)
Homocysteine—an atherogenic and a thrombogenic factor? Ubbink JB. **Nutr Rev** 1995 Nov;53(11):323–5 (18 ref.)
The investigation of a patient with unexpected venous thrombosis. Wilde JT. **Postgrad Med J** 1995 Dec; 71(842):720–4 (35 ref.)
Central venous catheter related thrombosis. Lowell JA, et al. **Surg Oncol Clin N Am** 1995 Jul;4(3):479–92 (68 ref.)
Resistance to activated protein C and factor V Leiden as risk factors for venous thrombosis. Bertina RM, et al. **Thromb Haemost** 1995 Jul;74(1):449–53 (53 ref.)
New molecular insights into the genetics of thrombophilia. Resistance to activated protein C caused by Arg506 to Gln mutation in factor V as a pathogenic risk factor for venous thrombosis. Dahlbäck B. **Thromb Haemost** 1995 Jul; 74(1):139–48 (112 ref.)
Resistance to activate protein C, the Arg506 to Gln mutation in the factor V gene, and venous thrombosis. Functional tests and DNA–based assays, pros and cons [see comments] Dahlbäck B. **Thromb Haemost** 1995 May;73(5):739–42 (33 ref.) Comment in: Thromb Haemost 1995 Nov;74(5):1380–1.
Cancer and thrombosis: from Phlegmasia alba dolens to transgenic mice. Donati MB. **Thromb Haemost** 1995 Jul; 74(1):278–81 (32 ref.)
Iliac vein compression as an anatomical cause of thrombophilia: Cockett's syndrome revisited. Verhaeghe R. **Thromb Haemost** 1995 Dec;74(6):1398–401 (24 ref.)
[Role of the hemostasis laboratory in the etiologic approach to deep vein thrombosis] De Maistre E, et al. **J Mal Vasc** 1996;21(1):1–6 (19 ref.) (Eng. Abstr.) **(Fre)**
[Pseudophlebitis disclosing nodular and focal myositis (letter)] Cardon T, et al. **Rev Med Interne** 1996;17(1):91–2 (17 ref.) **(Fre)**

GENETICS

[A new cause of hereditary venous thrombosis: activated protein C resistance] Trossaërt M, et al. **Ann Cardiol Angeiol (Paris)** 1995 Oct;44(8):438–42 (7 ref.) **(Fre)**
[Association of dysfibrinogenemia and thrombosis. Apropos of a family (Fibrinogen Melun) and review of the literature] Bentolila S, et al. **Ann Med Interne (Paris)** 1995; 146(8):575–80 (32 ref.) (Eng. Abstr.) **(Fre)**
[Point mutation G—>A nucleotide 1691 factor V gene as a cause of developing thrombotic complications in a family with plasma resistance to activated protein C] Lew Andowski KL, et al. **Pol Arch Med Wewn** 1996 May; 95(5):464–70 (11 ref.) (Eng. Abstr.) **(Pol)**
[Resistance to activated protein C. A common genetic risk factor in venous thrombosis] Berntorp E, et al. **Lakartidningen** 1995 Sep 27;92(39):3587–90 (27 ref.) **(Swe)**

PATHOLOGY

Angiomyolipoma of the kidney with extension into the inferior vena cava. Hibi H, et al. **Int J Urol** 1995 Nov; 2(5):332–5 (14 ref.)
[Thrombosis and phlebitis of superficial veins. Differential histopathologic diagnosis] Leu HJ. **Pathologe** 1995 Nov; 16(6):386–90 (9 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

[Experimental models of venous thrombosis] Azougagh Oualane F, et al. **Ann Cardiol Angeiol (Paris)** 1995 Jun–Aug; 44(6):288–98 (27 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

Thrombosis and embolism. Horn EH. **Baillieres Clin Obstet Gynaecol** 1995 Sep;9(3):595–618 (95 ref.)
Anticoagulants in pregnancy. Oakley CM. **Br Heart J** 1995 Aug;74(2):107–11 (54 ref.)
Prevention of venous thromboembolic risk in non–surgical patients. Bergmann JF, et al. **Haemostasis** 1996;26 Suppl 2:16–23 (16 ref.)
The role of low–molecular–weight heparins in the prevention of venous thrombosis in surgery with special reference to enoxaparin. Haas S. **Haemostasis** 1996;26 Suppl 2:39–48 (21 ref.)
Prevention of postoperative venous thromboembolism [editorial; comment] Chong BH. **Med J Aust** 1996 Jun 3; 164(11):646–7 (13 ref.) Comment on: Med J Aust 1996 Jun 3;164(11):652–4, 656.
Heparin therapy: current regimens and principles of monitoring. Berry BR, et al. **Postgrad Med** 1996 Jun; 99(6):64–6, 69–76 (19 ref.)
Management of venous thromboembolic (VTE) disease—Part I: Prevention. Kayser SR. **Prog Cardiovasc Nurs** 1995 Fall;10(4):31–6 (18 ref.)
[Preventive treatment alternatives for deep–vein thromboembolism after total joint replacement] Velan G, et al. **Harefuah** 1995 Sep;129(5–6):211–4 (44 ref.) **(Heb)**

SURGERY

[Surgical treatment of deep venous thrombosis—indications, possibilities and limitations in venous thrombectomy] Kniemeyer HW, et al. **Ther Umsch** 1996 Apr;53(4):277–83 (23 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Modern day treatment of acute deep venous thrombosis. Comerota AJ. **Aust N Z J Surg** 1995 Nov;65(11):773–9 (39 ref.)
Vena cava filters: available devices and current practices. Cooper JM, et al. **Mt Sinai J Med** 1996 May–Sep; 63(3–4):273–81 (54 ref.)
Current indications for caval interruption: should they be liberalized in view of improving technology? Greenfield LJ, et al. **Semin Vasc Surg** 1996 Mar;9(1):50–8 (32 ref.)
Caval interruption methods: comparison of options. Whitehill TA. **Semin Vasc Surg** 1996 Mar;9(1):59–69 (90 ref.)
[Local thrombolysis and stents in deep venous thrombosis. A new endovascular therapeutic technique] Nyman U, et al. **Lakartidningen** 1996 Aug 7;93(32–33):2750–6 (27 ref.) **(Swe)**

THROMBOPLASTIN

see related
HEMOSTATICS

Tissue factor: then and now. Nemerson Y. **Thromb Haemost** 1995 Jul;74(1):180–4 (29 ref.)

ANALYSIS

[Tissue factor (TF)] Sakuragawa N. **Nippon Rinsho** 1995 Mar; 53 Su Pt 2:154–6 (20 ref.) **(Jpn)**

ANTAGONISTS & INHIBITORS

Tissue factor pathway inhibitor. Broze GJ Jr. **Thromb Haemost** 1995 Jul;74(1):90–3 (50 ref.)

BIOSYNTHESIS

Pentoxifylline: a potential treatment for thrombosis associated with abnormal tissue factor expression by monocytes and endothelial cells. de Prost D. **J Cardiovasc Pharmacol** 1995; 25 Suppl 2:S114–8 (41 ref.)
Endothelial cell function, including tissue factor expression, under flow conditions. Grabowski EF, et al. **Thromb Haemost** 1995 Jul;74(1):123–8 (51 ref.)
Sites of tissue factor pathway inhibitor (TFPI) and tissue factor expression under physiologic and pathologic conditions. On behalf of the Subcommittee on Tissue factor Pathway Inhibitor (TFPI) of the Scientific and Standardization Committee of the ISTH. Osterud B, et al. **Thromb Haemost** 1995 May;73(5):873–5 (50 ref.)
Tissue factor expression in human leukocytes and tumor cells. Rickles FR, et al. **Thromb Haemost** 1995 Jul;74(1):391–5 (45 ref.)

CHEMISTRY

Initiation of blood coagulation: the tissue factor/factor VIIa complex. Kirchhofer D, et al. **Curr Opin Biotechnol** 1996 Aug;7(4):386–91 (46 ref.)

METABOLISM

Tissue factor modulation of factor VIIa activity: use in measuring trace levels of factor VIIa in plasma. Morrissey JH. **Thromb Haemost** 1995 Jul;74(1):185–8 (64 ref.)

PHYSIOLOGY

Initiation of blood coagulation: the tissue factor/factor VIIa complex. Kirchhofer D, et al. **Curr Opin Biotechnol** 1996 Aug;7(4):386–91 (46 ref.)
The tissue factor pathway: how it has become a "prima ballerina". Rapaport SI, et al. **Thromb Haemost** 1995 Jul; 74(1):7–17 (147 ref.)
Cell biology of tissue factor, the principal initiator of blood coagulation. Camerer E, et al. **Thromb Res** 1996 Jan 1; 81(1):1–41 (294 ref.)

STANDARDS

Calibration of thromboplastins. Finney DJ. **Proc R Soc Lond B Biol Sci** 1995 Oct 23;262(1363):71–5 (18 ref.)

THROMBOPLASTIN TIME, PARTIAL see **PARTIAL THROMBOPLASTIN TIME**

THROMBOPLASTINOGEN see **FACTOR VIII**

THROMBOPOIETIN

[Cloning of thrombopoietin and its physiologic role in megakaryocytopoiesis and thrombopoiesis] Miyazaki H. **Rinsho Ketsueki** 1996 Jan;37(1):1–6 (19 ref.) **(Jpn)**

BIOSYNTHESIS

[Thrombopoietin produced molecularly–biologically] von dem Borne AE, et al. **Ned Tijdschr Geneeskd** 1995 Sep 23;139(38):1922–7 (27 ref.) **(Dut)**

HISTORY

[The discovery of thrombopoietin] Boiron M. **Pathol Biol (Paris)** 1995 Sep;43(7):636–8 (9 ref.) **(Fre)**

METABOLISM

c–mpl, the thrombopoietin receptor. Vainchenker W, et al. **Thromb Haemost** 1995 Jul;74(1):526–8 (15 ref.)

PHARMACOLOGY

Thrombopoietin induces tyrosine phosphorylation of Stat3 and Stat5 in human blood platelets. Miyakawa Y, et al. **Blood** 1996 Jan 15;87(2):439–46 (36 ref.)
Thrombopoietin: biological and preclinical properties. Kaushansky K. **Leukemia** 1996 Apr;10 Suppl 1:S46–8 (20 ref.)

PHYSIOLOGY

Biologic effects of thrombopoietin, the Mpl ligand, and its therapeutic potential. Papayannopoulou T. **Cancer Chemother Pharmacol** 1996;38 Suppl:S69–73 (32 ref.)
Thrombopoietin: expression of its receptor MPL and proliferative effects on leukemic cells. Drexler HG, et al. **Leukemia** 1996 Sep;10(9):1405–21 (136 ref.)
Thrombopoietin: biological and preclinical properties. Kaushansky K. **Leukemia** 1996 Apr;10 Suppl 1:S46–8 (20 ref.)
The physiologic role and therapeutic potential of the Mpl–ligand in thrombopoiesis. Hunt P. **Stem Cells** 1995 Nov;13(6):579–87 (66 ref.)
Megakaryocytopoiesis: the state of the art. Gewirtz AM. **Thromb Haemost** 1995 Jul;74(1):204–9 (86 ref.)
Thrombopoietin: the primary regulator of megakaryocyte and platelet production. Kaushansky K. **Thromb Haemost** 1995 Jul;74(1):521–5 (43 ref.)

THERAPEUTIC USE

Biologic effects of thrombopoietin, the Mpl ligand, and its therapeutic potential. Papayannopoulou T. **Cancer Chemother Pharmacol** 1996;38 Suppl:S69–73 (32 ref.)

THROMBOSIS

see related
THROMBECTOMY

Intracardiac thrombi: frequency, location, etiology, and complications: a morphologic review—Part I. Waller BF, et al. **Clin Cardiol** 1995 Aug;18(8):477–9 (13 ref.)
[Hemorrhoidal thrombosis and perianal hematoma: diagnosis and treatment] Delaini GG, et al. **Ann Ital Chir** 1995 Nov–Dec;66(6):783–5 (8 ref.) (Eng. Abstr.) **(Ita)**
[Portal vein thrombosis] Kajikawa M, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):239–42 (24 ref.) **(Jpn)**

BLOOD

The role of lipoprotein(a) in atherogenesis and thrombosis. Hajjar KA, et al. **Annu Rev Med** 1996;47:423–42 (137 ref.)
Platelet activation mechanisms and markers in arterial thrombosis. Wu KK. **J Intern Med** 1996 Jan;239(1):17–34 (110 ref.)
Thrombophilia: some recent advances in understanding. James CM. **J R Nav Med Serv** 1995 Winter;81(3):203–6 (15 ref.)
The role of von Willebrand factor and fibrinogen in the initiation of platelet adhesion to thrombogenic surfaces. Ruggeri ZM. **Thromb Haemost** 1995 Jul;74(1):460–3 (45 ref.)
Plasminogen activator inhibitor 1 (PAI–1) in plasma: its role in thrombotic disease. Wiman B. **Thromb Haemost** 1995 Jul;74(1):71–6 (65 ref.)
[Activation of blood coagulation in extracorporeal circulation] Nowak G. **Wien Klin Wochenschr Suppl** 1996; 1:9–14 (28 ref.) **(Ger)**
[Activated coagulation factors in various thrombotic diseases] Komiyama Y, et al. **Rinsho Byori** 1995 Dec;43(12):1195–200 (19 ref.) (Eng. Abstr.) **(Jpn)**

CHEMICALLY INDUCED

High–purity factor IX concentrates for treatment of hemophilia B: relative purity and thrombogenic potential. Limentani SA, et al. **Acta Haematol** 1995;94 Suppl 1:12–7 (24 ref.)
In vivo models of thrombogenic potential: usefulness and limitations. MacGregor I, et al. **Acta Haematol** 1995;94 Suppl 1:18–23; discussion 24 (25 ref.)
Contrast media effects on hemostatic and thrombotic parameters. Possible consequences for practical techniques and prophylactic measures. Stormorken H, et al. **Acta Radiol Suppl** 1995;399:173–81 (67 ref.)
Oral contraceptives and thrombotic diseases: impact of new epidemiological studies [editorial] Lidegaard O, et al. **Contraception** 1996 Mar;53(3):135–9 (13 ref.)
[APC (activated protein C) resistance and oral contraceptives] Kreis I, et al. **Geburtshilfe Frauenheilkd** 1996 May;56(5):231–3 (21 ref.) (Eng. Abstr.) **(Ger)**

COMPLICATIONS

Fistula between duodenum and portal vein caused by peptic ulcer disease and complicated by hemorrhage and portal vein thrombosis. Soares MA, et al. **Am J Gastroenterol** 1996 Jul;91(7):1462–3 (7 ref.)

Case report: bleeding gastric varices secondary to splenic vein thrombosis successfully treated by splenic artery embolization. McDermott VG, et al. **Br J Radiol** 1995 Aug; 68(812):928–30 (14 ref.)

Serial changes of left atrial thrombus in mitral stenosis: transesophageal echocardiographic studies in candidates for balloon mitral commissurotomy. Hase M, et al. **Can J Cardiol** 1996 Mar;12(3):278–84 (28 ref.)

The contribution of thrombosis to the clinical expression of coronary atherosclerosis. Davies MJ. **Thromb Res** 1996 Apr 1;82(1):1–32 (137 ref.)

[Thrombosis in the small branches of the superior mesenteric artery in the early stages of essential thrombocythemia] Adorján T, et al. **Orv Hetil** 1996 Mar 10;137(10):527–9 (28 ref.) (Eng. Abstr.) **(Hun)**

CONGENITAL

Neonatal thrombosis: are we doing the right studies? Roy M, et al. **Semin Thromb Hemost** 1995;21(3):313–6 (30 ref.)

DIAGNOSIS

Thrombosis and hemostasis testing at the point of care. Oberhardt BJ. **Am J Clin Pathol** 1995 Oct;104(4 Suppl 1):S72–8 (19 ref.)

Malignant vascular disease of the kidney: nature of the lesions, mediators of disease progression, and the case for bilateral nephrectomy. Ruggenenti P, et al. **Am J Kidney Dis** 1996 Apr;27(4):459–75 (123 ref.)

[Contribution of laboratory tests and venous investigations in the diagnosis of pulmonary embolism] Perrier A, et al. **Arch Mal Coeur Vaiss** 1995 Nov;88(11 Suppl):1699–707 (48 ref.) (Eng. Abstr.) **(Fre)**

[Left atrial free floating thrombus without mitral valve disease. Review of the literature apropos of a case] Trémeau G, et al. **Arch Mal Coeur Vaiss** 1996 Jan;89(1):99–102 (10 ref.) (Eng. Abstr.) **(Fre)**

[Role of magnetic resonance imaging in cerebral venous thrombosis] Bousser MG. **J Mal Vasc** 1995;20(3):189–93 (21 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

Use of tissue type plasminogen activator in neonates: case reports and review of the literature. Smets K, et al. **Am J Perinatol** 1996 May;13(4):217–22 (21 ref.)

Thrombosis and the pharmacology of antithrombotic agents. Haines ST, et al. **Ann Pharmacother** 1995 Sep;29(9):892–905 (105 ref.)

Thrombolysis to treat arterial thrombotic complications of heparin-induced thrombocytopenia. Calligaro KD, et al. **Ann Vasc Surg** 1995 Jul;9(4):397–400 (8 ref.)

Peripheral thrombolysis: state of the art. Earnshaw JJ, et al. **Cardiovasc Surg** 1995 Aug;3(4):357–67 (28 ref.)

4th American College of Chest Physicians Consensus Conference on Antithrombotic Therapy. Tucson, Arizona, April 1995. Proceedings. **Chest** 1995 Oct;108(4 Suppl):225S–522S (0 ref.)

Therapeutic use of n-3 fatty acids for vascular disease and thrombosis. Goodnight SH, et al. **Chest** 1995 Oct;108(4 Suppl):302S–304S (36 ref.)

Thrombolytic therapy of left-sided prosthetic valve thrombosis. Koller PT, et al. **Chest** 1995 Dec;108(6):1683–9 (21 ref.)

Blockade of platelet GPIIb/IIIa receptors as an antithrombotic strategy. Coller BS. **Circulation** 1995 Nov 1;92(9):2373–80 (76 ref.)

The role of prolonged thrombolytic infusions and transesophageal echocardiography in thrombosed prosthetic heart valves: case report and review of the literature. Puleo JA, et al. **Clin Cardiol** 1995 Nov; 18(11):679–84 (50 ref.)

Antithrombotic therapy. Schubert PJ, et al. **Compr Ther** 1995 Jul;21(7):344–50 (32 ref.)

Pentoxifylline: a potential treatment for thrombosis associated with abnormal tissue factor expression by monocytes and endothelial cells. de Prost D. **J Cardiovasc Pharmacol** 1995; 25 Suppl 2:S114–8 (41 ref.)

Thrombolytic therapy for obstruction of mechanical prosthetic valves. Hurrell DG, et al. **Mayo Clin Proc** 1996 Jun;71(6):605–13 (64 ref.)

New developments in acute anticoagulation therapy: what improvements over traditional heparin are on the horizon? Carter CJ. **Postgrad Med** 1996 Jun;99(6):129–36 (22 ref.)

Thrombin functions and antithrombotic intervention. Fenton JW 2nd. **Thromb Haemost** 1995 Jul;74(1):493–8 (63 ref.)

Antiplatelet therapy with aspirin: from clinical trials to practice. Goodnight SH. **Thromb Haemost** 1995 Jul; 74(1):401–5 (64 ref.)

Antithrombotic benefits and hemorrhagic risks of direct thrombin antagonists. Harker LA, et al. **Thromb Haemost** 1995 Jul;74(1):464–72 (80 ref.)

Mechanism of action and thrombolytic potential of staphylokinase. Lijnen HR. **Verh K Acad Geneeskd Belg** 1995;57(4):303–14 (32 ref.)

Lower limb intraarterial thrombolysis as an adjunct to the management of arterial and graft occlusions. Braithwaite BD, et al. **World J Surg** 1996 Jul–Aug;20(6):649–54 (38 ref.)

[Fibrinolysis of deep venous thrombosis on implantable perfusion devices. Apropos of a consecutive series of 57 cases of thrombosis and 32 cases of fibrinolysis] Pucheu A, et al. **Bull Cancer (Paris)** 1996 Apr;83(4):293–9 (33 ref.) (Eng. Abstr.) **(Fre)**

[Deep venous thrombosis of the upper limbs. Literature review. Apropos of a case of Paget-Schrötter syndrome] Defraigne JO, et al. **Rev Med Liege** 1995 Aug;50(8):336–46 (58 ref.) **(Fre)**

-New aspects in antithrombotic therapy--platelet inhibitors- Terres W, et al. **Herz** 1996 Feb;21(1):1–11 (89 ref.) (Eng. Abstr.) **(Ger)**

[Urokinase in a premature infant: its use in a case of right atrial thrombosis secondary to catheterization of the umbilical vein] Colnaghi C, et al. **Pediatr Med Chir** 1995 May-Jun;17(3):275–7 (10 ref.) (Eng. Abstr.) **(Ita)**

[Oral anticoagulants treatment of thrombosis] Matsuda T. **Nippon Naika Gakkai Zasshi** 1995 Sep 10;84(9):1523–7 (2 ref.) **(Jpn)**

[Thrombophilia characterized by resistance to anticoagulants with indirect action] Barkagan ZS, et al. **Ter Arkh** 1995; 67(7):50–2 (8 ref.) (Eng. Abstr.) **(Rus)**

EPIDEMIOLOGY

Oral contraceptives and thrombotic diseases: impact of new epidemiological studies [editorial] Lidegaard O, et al. **Contraception** 1996 Mar;53(3):135–9 (13 ref.)

Antiphospholipid antibodies and thrombosis: assessment of the potential risk for thrombosis. Salem HH. **Lupus** 1996 Apr;5(2):163–6 (24 ref.)

[Epidemiology of pulmonary embolism] Ferrari E, et al. **Arch Mal Coeur Vaiss** 1995 Nov;88(11 Suppl):1687–91 (34 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Inferior vena cava thrombosis following percutaneous filter insertion: an unusual cause of haemodynamic compromise. Hainaut P, et al. **Acta Clin Belg** 1995;50(4):231–7 (21 ref.)

Subacute stent thrombosis and the anticoagulation controversy: changes in drug therapy, operator technique, and the impact of intravascular ultrasound. Moussa I, et al. **Am J Cardiol** 1996 Aug 14;78(3A):13–7 (35 ref.)

Portal and mesenteric thrombosis in protein S (pS) deficiency. Zigrossi P, et al. **Am J Gastroenterol** 1996 Jan;91(1):163–5 (11 ref.)

Renal infarction and thrombosis of the infrarenal aorta in a 35-year-old man with primary antiphospholipid syndrome. Poux JM, et al. **Am J Kidney Dis** 1996 May; 27(5):721–5 (20 ref.)

Conservative management strategy for pancreatitis-associated mesenteric venous thrombosis. Krummen DM, et al. **Am Surg** 1996 Jun;62(6):432–4 (12 ref.)

Prosthetic valve thrombosis: a case report and review of the literature. Goh PP, et al. **Ann Acad Med Singapore** 1996 Jan;25(1):147–51 (28 ref.)

Thrombogenesis. Nielsen JD. **Ann Chir Gynaecol** 1995; 84(4):327–34 (83 ref.)

Thrombophilia and the surgeon. Rhodes EG. **Ann R Coll Surg Engl** 1996 Jul;78(4):331–5 (33 ref.)

Bleeding and thrombosis in myeloproliferative disorders: mechanisms and treatment. Landolfi R, et al. **Crit Rev Oncol Hematol** 1995 Oct;20(3):203–22 (200 ref.)

Fourth-degree burn induced thrombosis of the femoral artery and vein. De Santis F, et al. **Eur J Vasc Endovasc Surg** 1996 Apr;11(3):378–80 (9 ref.)

Superior mesenteric artery thrombosis in a patient with the antiphospholipid syndrome. England RJ, et al. **Eur J Vasc Endovasc Surg** 1995 Oct;10(3):372–3 (4 ref.)

Thrombotic microangiopathies associated with drugs and bone marrow transplantation. Moake JL, et al. **Hematol Oncol Clin North Am** 1996 Apr;10(2):485–97 (66 ref.)

Prosthetic valve thrombosis. Horstkotte D, et al. **J Heart Valve Dis** 1995 Mar;4(2):141–53 (115 ref.)

Homocysteine and hemostasis: pathogenic mechanisms predisposing to thrombosis. Harpel PC, et al. **J Nutr** 1996 Apr;126(4 Suppl):1285S–9S (33 ref.)

Major vascular injury from high-pressure water jet. Harvey RL, et al. **J Trauma** 1996 Jan;40(1):165–7 (15 ref.)

Vertebrobasilar thrombosis associated with nonpenetrating cervical spine trauma. Prabhu V, et al. **J Trauma** 1996 Jan; 40(1):130–7 (59 ref.)

Posttraumatic inferior vena caval thrombosis: case report and review of the literature. Takeuchi M, et al. **J Trauma** 1995 Sep;39(3):605–8 (10 ref.)

Deep venous thrombosis with pulmonary embolus after selective embolization of an internal iliac artery aneurysm. Su WT, et al. **J Vasc Surg** 1996 Jan;23(1):152–5 (13 ref.)

Does atrial fibrillation confer a hypercoagulable state? Lip GY. **Lancet** 1995 Nov 18;346(8986):1313–4 (16 ref.)

Progressive thrombosis after treatment of diffuse large cell non-Hodgkin's lymphoma and concomitant lupus anticoagulant. Keung YK, et al. **Leuk Lymphoma** 1996 Jan; 20(3–4):341–5 (22 ref.)

Evolving concepts in the pathogenesis and treatment of arterial thrombosis. Chesebro JH, et al. **Mt Sinai J Med** 1995 Sep;62(4):275–86 (58 ref.)

Hemostatic complications in renal disorders of the young. Andrew M, et al. **Pediatr Nephrol** 1996 Feb;10(1):88–99 (135 ref.)

A neurologist's reflections on boxing. III. Vascular injuries. Unterharnscheidt F. **Rev Neurol** 1995 Jul–Aug; 23(122):847–55 (27 ref.)

Activated protein C resistance: molecular mechanisms. Griffin JH, et al. **Thromb Haemost** 1995 Jul;74(1):444–8 (35 ref.)

[Thrombosis of the superior mesenteric artery and Behçet's syndrome] Mercié P, et al. **Rev Med Interne** 1996; 17(6):470–3 (16 ref.) (Eng. Abstr.) **(Fre)**

[Thrombotic microangiopathies in HIV infection: 4 cases] Ninin E, et al. **Rev Med Interne** 1996;17(3):238–42 (16 ref.) (Eng. Abstr.) **(Fre)**

[Hyperhomocysteinemia as a risk factor in atherosclerotic and thrombotic vascular processes] Sela B. **Harefuah** 1995 Nov 15;129(10):407–12 (35 ref.) **(Heb)**

[A new cause of thrombophilia (editorial; comment)] Mannucci PM. **Ann Ital Med Int** 1996 Jan–Mar;11(1):5–7 (11 ref.) Comment on: Ann Ital Med Int 1996 Jan–Mar;11(1):33–8. **(Ita)**

[Neutrophilic leukocytes, thrombotic risk factors in vascular diseases] Berti F. **Cardiologia** 1996 Feb;41(2):107–16 (95 ref.) **(Ita)**

[A case report of a left atrial ball thrombus at 16 years after mitral valve replacement] Iida M, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Apr;44(4):539–44 (28 ref.) (Eng. Abstr.) **(Jpn)**

[Hematologic disturbances in patients with nonhematologic neoplasms. II. Thrombosis, bleedings and leukemoid reaction] Kwiatkowski A, et al. **Przegl Lek** 1995; 52(8):410–2 (11 ref.) **(Pol)**

[Trauma and thrombosis. High risk of embolism in patients with spinal cord injuries, hip fractures and leg fractures] Bergqvist D. **Lakartidningen** 1996 Jul 24;93(30–31):2653–4 (19 ref.) **(Swe)**

GENETICS

Thrombophilia: the discovery of activated protein C resistance. Dahlbäck B. **Adv Genet** 1995;33:135–75 (114 ref.)

Inherited thrombophilia: pathogenesis, clinical syndromes, and management. De Stefano V, et al. **Blood** 1996 May 1;87(9):3531–44 (138 ref.)

[Activated protein C resistance: role in venous and arterial thrombosis] Emmerich J, et al. **Arch Mal Coeur Vaiss** 1996 Jun;89(6):741–5 (31 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Antiphospholipid antibodies and thrombosis: assessment of the potential risk for thrombosis. Salem HH. **Lupus** 1996 Apr;5(2):163–6 (24 ref.)

METABOLISM

Fibrin D-dimer: a useful clinical marker of thrombogenesis? [editorial] Lip GY, et al. **Clin Sci (Colch)** 1995 Sep; 89(3):205–14 (115 ref.)

Pentoxifylline: a potential treatment for thrombosis associated with abnormal tissue factor expression by monocytes and endothelial cells. de Prost D. **J Cardiovasc Pharmacol** 1995; 25 Suppl 2:S114–8 (41 ref.)

PATHOLOGY

Thrombosis of the deep venous drainage of the brain in adults. Analysis of seven cases with review of the literature. Crawford SC, et al. **Arch Neurol** 1995 Nov;52(11):1101–8 (23 ref.)

Intracardiac thrombi: frequency, location, etiology, and complications: a morphologic review--Part II. Waller BF, et al. **Clin Cardiol** 1995 Sep;18(9):530–4 (29 ref.)

Intracardiac thrombi: frequency, location, etiology, and complications: a morphologic review--Part IV. Waller BF, et al. **Clin Cardiol** 1995 Nov;18(11):669–74 (44 ref.)

Thrombosis and inflammation as multicellular processes: significance of cell-cell interactions. Marcus AJ, et al. **Thromb Haemost** 1995 Jul;74(1):213–7 (54 ref.)

[Cardiac thrombosis in myocardial infarct] Perdigão C. **Rev Port Cardiol** 1996 Mar;15(3):233–51 (93 ref.) **(Por)**

PHYSIOPATHOLOGY

Thrombosis and the pharmacology of antithrombotic agents. Haines ST, et al. **Ann Pharmacother** 1995 Sep;29(9):892–905 (105 ref.)

Role of endothelium in thrombosis and hemostasis. Wu KK, et al. **Annu Rev Med** 1996;47:315–31 (50 ref.)

Platelet activation by fibrinolytic agents: a potential mechanism for resistance to thrombolysis and reocclusion after successful thrombolysis. Leopold JA, et al. **Coron Artery Dis** 1995 Dec;6(12):923–9 (60 ref.)

Cytokines and thrombosis. Dosquet C, et al. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S13–9 (65 ref.)

Activated protein C resistance and thrombosis. Nichols WL, et al. **Mayo Clin Proc** 1996 Sep;71(9):897–8 (6 ref.)

Endothelial cell function, including tissue factor expression, under flow conditions. Grabowski EF, et al. **Thromb Haemost** 1995 Jul;74(1):123–8 (51 ref.)

PREVENTION & CONTROL

Antiplatelet therapy. Schafer AI. **Am J Med** 1996 Aug; 101(2):199–209 (105 ref.)

Is deep vein thrombosis surveillance warranted in high-risk trauma patients? Piotrowski JJ, et al. **Am J Surg** 1996 Aug; 172(2):210–3 (9 ref.)

Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation [see comments] Blackshear JL, et al. **Ann Thorac Surg** 1996 Feb;61(2):755–9 (59 ref.)

Comment in: Ann Thorac Surg 1996 Feb;61(2):515.
Antiplatelet therapy and the prevention of thrombosis. Rodgers A, et al. **Aust N Z J Med** 1996 Apr;26(2):210–5 (19 ref.)
Anti-platelet monoclonal antibodies for the prevention of arterial thrombosis: experience with ReoPro, a monoclonal antibody directed against the platelet GPIIb/IIIa receptor. Weisman HF, et al. **Biochem Soc Trans** 1995 Nov; 23(4):1051–7 (25 ref.)
Rationalizing antithrombotic management for patients with prosthetic heart valves [editorial] Butchart EG. **J Heart Valve Dis** 1995 Mar;4(2):106–13 (62 ref.)
New developments in acute anticoagulation therapy: what improvements over traditional heparin are on the horizon? Carter CJ. **Postgrad Med** 1996 Jun;99(6):129–36 (22 ref.)
Current status of anticoagulation and thrombosis-related issues in mechanical valves. Gray RJ. **Tex Heart Inst J** 1996;23(1):36–41 (34 ref.)
Management of patients with hereditary defects predisposing to thrombosis including pregnant women. Bauer KA. **Thromb Haemost** 1995 Jul;74(1):94–100 (93 ref.)
Inhibition of intravascular thrombosis and vascular smooth muscle cell proliferation by gene therapy. Flugelman MY. **Thromb Haemost** 1995 Jul;74(1):406–10 (35 ref.)
Clinical trials of primary and secondary prevention of thrombosis and restenosis. Vermylen J. **Thromb Haemost** 1995 Jul;74(1):377–81 (54 ref.)
[Dyslipidemia, lipid lowering drugs and thrombosis] Ambrosi P, et al. **Arch Mal Coeur Vaiss** 1995 Nov;88(11):1641–5 (31 ref.) (Eng. Abstr.) **(Fre)**
[Indications of partial interruption of the inferior vena cava in pulmonary embolism] Schleich JM, et al. **Arch Mal Coeur Vaiss** 1995 Nov;88(11 Suppl):1785–91 (45 ref.) (Eng. Abstr.) **(Fre)**
[Inhibition of integrin function prevents restenosis following vascular injury] Matsuno H, et al. **Nippon Yakurigaku Zasshi** 1995 Sep;106(3):143–55 (47 ref.) (Eng. Abstr.) **(Jpn)**

RADIOGRAPHY

[Deep venous thrombosis of the upper limbs. Literature review. Apropos of a case of Paget-Schrötter syndrome] Defraigne JO, et al. **Rev Med Liege** 1995 Aug;50(8):336–46 (58 ref.) **(Fre)**

SURGERY

Malignant vascular disease of the kidney: nature of the lesions, mediators of disease progression, and the case for bilateral nephrectomy. Ruggenenti P, et al. **Am J Kidney Dis** 1996 Apr;27(4):459–75 (123 ref.)

THERAPY

The results of arterial thrombolysis. Kroese AJ, et al. **Ann Chir Gynaecol** 1995;84(4):350–3 (17 ref.)
Bleeding and thrombosis in myeloproliferative disorders: mechanisms and treatment. Landolfi R, et al. **Crit Rev Oncol Hematol** 1995 Oct;20(3):203–22 (200 ref.)
Evolving concepts in the pathogenesis and treatment of arterial thrombosis. Chesebro JH, et al. **Mt Sinai J Med** 1995 Sep;62(4):275–86 (58 ref.)
[Percutaneous local thrombolytic therapy and thrombectomy in occlusion of extremity arteries] Schneider E, et al. **Internist (Berl)** 1996 Jun;37(6):607–12 (23 ref.) **(Ger)**
[Deep venous thrombosis and the prevention of a pulmonary embolism with temporary caval filters: the experience in 2 pediatric cases] Patti G, et al. **Pediatr Med Chir** 1995 May–Jun;17(3):265–9 (10 ref.) (Eng. Abstr.) **(Ita)**

ULTRASONOGRAPHY

Usefulness of multiplane transesophageal echocardiography in differentiating left atrial appendage thrombus from pectinate muscles. Orsinelli DA, et al. **Am Heart J** 1996 Mar;131(3):622–3 (8 ref.)
Intraportal tumor thrombus of gallbladder carcinoma: detection with intravascular ultrasonography. Kaneko T, et al. **Am J Gastroenterol** 1996 Jun;91(6):1268–9 (8 ref.)
The role of prolonged thrombolytic infusions and transesophageal echocardiography in thrombosed prosthetic heart valves: case report and review of the literature. Puleo JA, et al. **Clin Cardiol** 1995 Nov; 18(11):679–84 (50 ref.)
[Pulmonary embolism and thrombi of the right heart] Chapoutot L, et al. **Arch Mal Coeur Vaiss** 1995 Nov;88(11 Suppl):1723–8 (35 ref.) (Eng. Abstr.) **(Fre)**

THROMBOSIS, CORONARY see **CORONARY THROMBOSIS**

THROMBOSIS, RETINAL VEIN see **RETINAL VEIN OCCLUSION**

THROMBOSIS, VENOUS see **THROMBOPHLEBITIS**

THROMBOSPONDIN RECEPTORS see **ANTIGENS, CD36**

THROMBOTEST see **PROTHROMBIN TIME**

THROMBOXANE A SYNTHASE see **THROMBOXANE SYNTHETASE**

THROMBOXANE A2

ANTAGONISTS & INHIBITORS

[Anti-allergic agent therapy of asthma] Fujimura M. **Nippon Naika Gakkai Zasshi** 1996 Feb 10;85(2):216–21 (5 ref.) **(Jpn)**

METABOLISM

Thromboxane A2 receptors. Halushka PV, et al. **J Lipid Mediat Cell Signal** 1995 Oct;12(2–3):361–78 (114 ref.)

THROMBOXANE A2 RECEPTORS see **RECEPTORS, THROMBOXANE**

THROMBOXANE B2

ANALYSIS

[Thromboxane B2 (TXB2)] Mito Y. **Nippon Rinsho** 1995 Mar; 53 Su Pt 2:716–20 (17 ref.) **(Jpn)**

THROMBOXANE RECEPTORS see **RECEPTORS, THROMBOXANE**

THROMBOXANE SYNTHETASE

METABOLISM

Prostacyclin and thromboxane synthases. Tanabe T, et al. **J Lipid Mediat Cell Signal** 1995 Oct;12(2–3):243–55 (67 ref.)

THROMBOXANES

see related
RECEPTORS, THROMBOXANE

ANTAGONISTS & INHIBITORS

Antiplatelet drugs. A comparative review. Schrör K. **Drugs** 1995 Jul;50(1):7–28 (189 ref.)

PHYSIOLOGY

Eicosanoids and renal allograft rejection. Wardle EN. **Nephron** 1995;70(2):151–4 (48 ref.)

THROMBUS see **THROMBOSIS**

THRUSH see **CANDIDIASIS, ORAL**

THUMB

Desmoplastic melanoma of the hand: case reports and review of the literature. Chung KC, et al. **J Hand Surg [Am]** 1995 Sep;20(5):873–6 (10 ref.)

BLOOD SUPPLY

Pulse oximetry for preoperative vascular assessment in a thumb near-amputation [see comments] Schumer E, et al. **J Emerg Med** 1995 Nov–Dec;13(6):753–5 (20 ref.)
Comment in: J Emerg Med 1995 Nov–Dec;13(6):815–6.

INJURIES

Toe-to-hand transfer. Current concepts, techniques, and research. Wei FC, et al. **Clin Plast Surg** 1996 Jan; 23(1):103–16 (64 ref.)
Pulse oximetry for preoperative vascular assessment in a thumb near-amputation [see comments] Schumer E, et al. **J Emerg Med** 1995 Nov–Dec;13(6):753–5 (20 ref.)
Comment in: J Emerg Med 1995 Nov–Dec;13(6):815–6.
Plea to save the great toe in total thumb reconstruction. Foucher G, et al. **Microsurgery** 1995;16(6):373–6 (23 ref.)

INNERVATION

[Anterior interosseus syndrome from the surgical viewpoint] Axmann HD, et al. **Nervenarzt** 1995 Aug;66(8):610–3 (44 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

MR imaging of the metacarpophalangeal joints. Masson JA, et al. **Magn Reson Imaging Clin N Am** 1995 May; 3(2):313–25 (54 ref.)

PHYSIOLOGY

Thumb movements, motions, and moments. Hollister A, et al. **J Hand Ther** 1995 Apr–Jun;8(2):106–14 (8 ref.)

SURGERY

Surgical treatment for osteoarthritis at the base of the thumb. Kuschner SH, et al. **Am J Orthop** 1996 Feb;25(2):91–100 (73 ref.)
Pulse oximetry for preoperative vascular assessment in a thumb near-amputation [see comments] Schumer E, et al. **J Emerg Med** 1995 Nov–Dec;13(6):753–5 (20 ref.)
Comment in: J Emerg Med 1995 Nov–Dec;13(6):815–6.
Plea to save the great toe in total thumb reconstruction. Foucher G, et al. **Microsurgery** 1995;16(6):373–6 (23 ref.)

THYME see **HERBS**

THYMECTOMY

Long-term outcome and quality of life after thymectomy for myasthenia gravis. Busch C, et al. **Ann Surg** 1996 Aug; 224(2):225–32 (22 ref.)
The effect of thymectomy on myasthenia gravis, thrombocytopenia, and granulocytopenia associated with thymoma: report of a case. Kobayashi M, et al. **Surg Today** 1995;25(12):1061–5 (14 ref.)

METHODS

Transcervical thymectomy. Ferguson MK. **Chest Surg Clin N Am** 1996 Feb;6(1):105–15 (24 ref.)
The combined cervical and partial sternotomy approach for thymectomy. LoCicero J 3rd. **Chest Surg Clin N Am** 1996 Feb;6(1):85–93 (2 ref.)
Extended transsternal thymectomy. Mulder DG. **Chest Surg Clin N Am** 1996 Feb;6(1):95–105 (7 ref.)

THYMIC CYST see **MEDIASTINAL CYST**

THYMIC GROUP VIRUSES see **HERPESVIRIDAE**

THYMIDINE

METABOLISM

[Comparison of 2 techniques for measuring lymphocyte proliferation: tritiated methyl-thymidine incorporation and propidium iodide fluorometry] Brohee D, et al. **Rev Med Brux** 1995 Nov;16(5):368–71 (10 ref.) (Eng. Abstr.) **(Fre)**

THYMIDINE KINASE

GENETICS

Gene therapy against cancer and HIV infection using the gene encoding herpes simplex virus thymidine kinase. Caruso M. **Mol Med Today** 1996 May;2(5):212–7 (37 ref.)
Transcriptional activation of thymidine kinase, a marker for cell cycle control. Dou QP, et al. **Prog Nucleic Acid Res Mol Biol** 1996;53:197–217 (92 ref.)
[Using the thymidine kinase gene in therapy of solid tumors] Wicke I, et al. **Internist (Berl)** 1996 Apr;37(4):369–73 (15 ref.) **(Ger)**
[Suicide genes for gene therapy] Suzuki S, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2720–6 (24 ref.) **(Jpn)**

METABOLISM

Mammalian deoxyribonucleoside kinases. Arnér ES, et al. **Pharmacol Ther** 1995;67(2):155–86 (241 ref.)

THYMIDINE PHOSPHATASE see **5'-NUCLEOTIDASE**

THYMIDINE PHOSPHORYLASE

METABOLISM

[Angiogenesis and enzymatic activity of thymidine phosphorylase] Haraguchi M, et al. **Seikagaku** 1996 Feb; 68(2):143–7 (21 ref.) **(Jpn)**

THYMIDYLATE SYNTHETASE

ANTAGONISTS & INHIBITORS

Folate-based thymidylate synthase inhibitors as anticancer drugs. Jackman AL, et al. **Ann Oncol** 1995 Nov;6(9):871–81 (84 ref.)
Thymidylate synthase inhibition, a dead end? [editorial] Herrmann R. **Eur J Cancer** 1995 Nov;31A(12):1919–20 (7 ref.)
ZD1694 (Tomudex): a new thymidylate synthase inhibitor with activity in colorectal cancer. Jackman AL, et al. **Eur J Cancer** 1995 Jul–Aug;31A(7–8):1277–82 (30 ref.)
Thymidylate synthase and drug resistance. Peters GJ, et al. **Eur J Cancer** 1995 Jul–Aug;31A(7–8):1299–305 (41 ref.)
Inhibitors of thymine nucleotide biosynthesis: antimetabolites that provoke genetic change via primary non-DNA targets. Kunz BA. **Mutat Res** 1996 Aug 17;355(1–2):129–40 (135 ref.)

METABOLISM

The catalytic mechanism and structure of thymidylate synthase. Carreras CW, et al. **Annu Rev Biochem** 1995; 64:721–62 (193 ref.)
[Factors of the therapeutic effectiveness of 5-fluorouracil] Manziuk LV, et al. **Vopr Onkol** 1996;42(2):31–6 (33 ref.) **(Rus)**

THYMINE DIMERS see **PYRIMIDINE DIMERS**

THYMOANALEPTICS see **ANTIDEPRESSIVE AGENTS**

THYMOL

[Thymol turbidity test (TTT)] Monna T, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:163–6 (11 ref.) **(Jpn)**

THYMOLEPTICS see ANTIDEPRESSIVE AGENTS

THYMOMA

COMPLICATIONS

Nephrotic syndrome, malignant thymoma, and myasthenia gravis. Case report and review of the literature. Jayasena SD, et al. **Am J Nephrol** 1995;15(4):361–3 (8 ref.)

[A case of thymoma in an elderly patient associated with myasthenia gravis] Mukaida T, et al. **Kyobu Geka** 1996 Apr; 49(4):274–7 (12 ref.) (Eng. Abstr.) **(Jpn)**

RADIOGRAPHY

Thymic carcinoma: case reports and review. Quagliano PV. **J Thorac Imaging** 1996 Winter;11(1):66–74 (65 ref.)

SURGERY

Thoracoscopic resection of mediastinal tumors and the thymus. Kaiser LR. **Chest Surg Clin N Am** 1996 Feb; 6(1):41–52 (7 ref.)

The effect of thymectomy on myasthenia gravis, thrombocytopenia, and granulocytopenia associated with thymoma: report of a case. Kobayashi M, et al. **Surg Today** 1995;25(12):1061–5 (14 ref.)

[Mediastinal malignant tumor resection and superior vena cava revascularization. Resection of invasive thymoma with growth into the superior vena cava and right atrium using cardiopulmonary bypass] **Nippon Kyobu Geka Gakkai Zasshi** 1995 May;43(5):717–9 (4 ref.) **(Jpn)**

THERAPY

Treatment of pediatric malignant thymoma: long-term remission in a 14-year-old boy with EBV-associated thymic carcinoma by aggressive, combined modality treatment. Niehues T, et al. **Med Pediatr Oncol** 1996 Jun; 26(6):419–24 (37 ref.)

THYMOSIN

ANALOGS & DERIVATIVES

Prothymosin alpha: in search of a function. Smith MR. **Leuk Lymphoma** 1995 Jul;18(3–4):209–14 (41 ref.)

THYMOTAXIN see BETA 2-MICROGLOBULIN

THYMUS-DEPENDENT LYMPHOCYTES see T-LYMPHOCYTES

THYMUS GLAND

see related
THYMECTOMY

Transcription factors that control development of the thymic microenvironment. Boehm T, et al. **Immunol Today** 1995 Dec;16(12):555–6 (20 ref.)

The role of the thymus during T-lymphocyte development in vitro. Anderson G, et al. **Semin Immunol** 1995 Jun; 7(3):177–83 (49 ref.)

CYTOLOGY

Developmental regulation of alpha beta T cell antigen receptor assembly in immature CD4+CD8+ thymocytes. Kearse KP, et al. **Bioessays** 1995 Dec;17(12):1049–54 (41 ref.)

The thymic nurse cell complex: an in vitro model for extracellular matrix-mediated intrathymic T cell migration. Villa-Verde DM, et al. **Braz J Med Biol Res** 1995 Aug; 28(8):907–12 (35 ref.)

Chicken thymic nurse cells: an overview. Rieker T, et al. **Dev Comp Immunol** 1995 Jul–Aug;19(4):281–9 (33 ref.)

Hemopoiesis in the thymus. Kendall MD. **Dev Immunol** 1995; 4(3):157–68 (107 ref.)

The molecular jury: deciding whether immature thymocytes should live or die [comment] Vukmanović S. **J Exp Med** 1996 Aug 1;184(2):305–9 (60 ref.) Comment on: J Exp Med 1996 Aug 1;184(2):531–7.

From thymic lineages back to hematopoietic stem cells, sometimes using homing receptors. Weissman IL. **J Immunol** 1996 Mar 15;156(6):2019–25 (114 ref.)

The role of intracellular signalling pathways regulating thymocyte and leukemic T cell apoptosis. Conroy LA, et al. **Leukemia** 1996 Sep;10(9):1422–35 (205 ref.)

EMBRYOLOGY

Winner of the Theodore E. Woodward Award: c-Myb and the coordinate regulation of thymic genes. Hutton JJ, et al. **Trans Am Clin Climatol Assoc** 1995;107:115–24 (39 ref.)

[Role of IL-7 on early thymocyte development] Tian L, et al. **Sheng Li Ko Hsueh Chin Chan** 1995 Jul;26(3):249–52 (13 ref.) **(Chi)**

IMMUNOLOGY

Development and evolutionary aspects of thymic T cell education to neuroendocrine self. Geenen V, et al. **Acta Haematol** 1996;95(3–4):263–7 (27 ref.)

Pathways from hematopoietic stem cells to thymocytes. Rodewald HR. **Curr Opin Immunol** 1995 Apr;7(2):176–87 (83 ref.)

Intrathymic and extrathymic clonal deletion of T cells. Sprent J, et al. **Curr Opin Immunol** 1995 Apr;7(2):196–205 (118 ref.)

Chicken thymic nurse cells: an overview. Rieker T, et al. **Dev Comp Immunol** 1995 Jul–Aug;19(4):281–9 (33 ref.)

Receptors and signals in early thymic selection. Levelt CN, et al. **Immunity** 1995 Dec;3(6):667–72 (68 ref.)

Extrathymic and thymic origin of murine IEL: are most IEL in euthymic mice derived from the thymus? Lin T, et al. **Immunol Cell Biol** 1995 Oct;73(5):469–73 (25 ref.)

Antigen-presenting function of the TL antigen and mouse CD1 molecules. Cheroutre H, et al. **Immunol Rev** 1995 Oct;147:31–52 (73 ref.)

Thymocyte-stromal-cell interactions and T-cell selection. Owen JJ, et al. **Immunol Today** 1995 Jul;16(7):336–8 (9 ref.)

Central tolerance of T cells. Sprent J. **Int Rev Immunol** 1995; 13(2):95–105 (85 ref.)

Cryptocrine signaling in the thymus network and T cell education to neuroendocrine self-antigens. Geenen V, et al. **J Mol Med** 1995 Sep;73(9):449–55 (49 ref.)

Microbial parasites versus developing T cells: an evolutionary 'arms race' with implications for the timing of thymic involution and HIV pathogenesis. Turke PW. **Thymus** 1994–95;24(1):29–40 (52 ref.)

PATHOLOGY

Pathology of the thymus: changes induced by xenobiotics and gene targeting. Schuurman HJ, et al. **APMIS** 1995 Jul–Aug;103(7–8):481–500 (110 ref.)

The thymus and the pathogenesis of myasthenia gravis. Levinson AI, et al. **Clin Immunol Immunopathol** 1996 Jan; 78(1):1–5 (46 ref.)

RADIATION EFFECTS

[Endocrine function of the thymus and ionizing radiation] Grinevich IuA, et al. **Radiats Biol Radioecol** 1995 May–Jun; 35(3):391–404 (126 ref.) (Eng. Abstr.) **(Rus)**

[Disordered thymus function and endocrine control as one of the bases for the development of a late postradiation immunodeficiency (a review of the literature)] Savina NP, et al. **Radiats Biol Radioecol** 1995 Jul–Aug;35(4):463–80 (155 ref.) (Eng. Abstr.) **(Rus)**

RADIOGRAPHY

Abnormalities of the thymus. Freundlich IM, et al. **J Thorac Imaging** 1996 Winter;11(1):58–65 (12 ref.)

SURGERY

Transcervical thymectomy. Ferguson MK. **Chest Surg Clin N Am** 1996 Feb;6(1):105–15 (24 ref.)

TRANSPLANTATION

HIV-1-associated pathology in hemato-lymphoid organs and the experimental evaluation in the SCID-hu mouse. Kaneshima H. **Int J Hematol** 1996 Jun;63(4):253–64 (89 ref.)

THYMUS HYPERPLASIA

CHEMICALLY INDUCED

[Thymus hyperplasia following chemotherapy] Cumin I, et al. **Presse Med** 1996 Feb 24;25(7):291–2 (13 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Case report: true massive thymic hyperplasia [see comments] Obaro RO. **Clin Radiol** 1996 Jan;51(1):62–4 (8 ref.) Comment in: Clin Radiol 1996 Jul;51(7):526–7.

THYMUS-INDEPENDENT ANTIGENS see ANTIGENS, T-INDEPENDENT

THYMUS NEOPLASMS

Thymolipoma—a rare mediastinal tumour—report of two cases and review of literature. Sirpal YM, et al. **Indian J Cancer** 1995 Mar;32(1):23–6 (17 ref.)

COMPLICATIONS

Nephrotic syndrome, malignant thymoma, and myasthenia gravis. Case report and review of the literature. Jayasena SD, et al. **Am J Nephrol** 1995;15(4):361–3 (8 ref.)

[A case of thymoma in an elderly patient associated with myasthenia gravis] Mukaida T, et al. **Kyobu Geka** 1996 Apr; 49(4):274–7 (12 ref.) (Eng. Abstr.) **(Jpn)**

EPIDEMIOLOGY

Thymus-related liposarcoma: report of a case and review of the literature. Sekine Y, et al. **Surg Today** 1996; 26(3):203–7 (21 ref.)

METABOLISM

[A case of ACTH-producing thymic carcinoid tumor with Cushing syndrome] Nishimura H, et al. **Kyobu Geka** 1996 Feb;49(2):99–104 (20 ref.) (Eng. Abstr.) **(Jpn)**

RADIOGRAPHY

Abnormalities of the thymus. Freundlich IM, et al. **J Thorac Imaging** 1996 Winter;11(1):58–65 (12 ref.)

Thymic carcinoma: case reports and review. Quagliano PV. **J Thorac Imaging** 1996 Winter;11(1):66–74 (65 ref.)

SURGERY

Thoracoscopic resection of mediastinal tumors and the thymus. Kaiser LR. **Chest Surg Clin N Am** 1996 Feb; 6(1):41–52 (7 ref.)

The effect of thymectomy on myasthenia gravis, thrombocytopenia, and granulocytopenia associated with thymoma: report of a case. Kobayashi M, et al. **Surg Today** 1995;25(12):1061–5 (14 ref.)

[Mediastinal malignant tumor resection and superior vena cava revascularization. Resection of invasive thymoma with growth into the superior vena cava and right atrium using cardiopulmonary bypass] **Nippon Kyobu Geka Gakkai Zasshi** 1995 May;43(5):717–9 (4 ref.) **(Jpn)**

THERAPY

Treatment of pediatric malignant thymoma: long-term remission in a 14-year-old boy with EBV-associated thymic carcinoma by aggressive, combined modality treatment. Niehues T, et al. **Med Pediatr Oncol** 1996 Jun; 26(6):419–24 (37 ref.)

THYROCALCITONIN see CALCITONIN

THYROGLOBULIN

BLOOD

Current status and performance goals for serum thyroglobulin assays. Spencer CA, et al. **Clin Chem** 1996 Jan;42(1):164–73 (54 ref.)

Thyroglobulin measurement. Techniques, clinical benefits, and pitfalls. Spencer CA, et al. **Endocrinol Metab Clin North Am** 1995 Dec;24(4):841–63 (76 ref.)

[Thyroglobulin (Tg)] Nishikawa M, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:380–3 (18 ref.) **(Jpn)**

GENETICS

Molecular genetics of hereditary thyroid diseases due to a defect in the thyroglobulin or thyroperoxidase synthesis. Targovnik HM, et al. **Braz J Med Biol Res** 1994 Dec; 27(12):2745–57 (31 ref.)

IMMUNOLOGY

Analytical and clinical performance goals for testing autoantibodies to thyroperoxidase, thyroglobulin, and thyrotropin receptor. Feldt-Rasmussen U. **Clin Chem** 1996 Jan;42(1):160–3 (20 ref.)

[Thyroglobulin antibodies] Kobayashi I. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:410–3 (10 ref.) **(Jpn)**

METABOLISM

The type-1 repeats of thyroglobulin regulate thyroglobulin degradation and T3, T4 release in thyrocytes. Molina F, et al. **FEBS Lett** 1996 Aug 12;391(3):229–31 (25 ref.)

THYROGLOSSAL CYST

COMPLICATIONS

Concurrent papillary and squamous carcinoma in a thyroglossal duct cyst: a case report [see comments] Kwan WB, et al. **Can J Surg** 1996 Aug;39(4):328–32 (20 ref.) Comment in: Can J Surg 1996 Aug;39(4):263–4. Comment in: Can J Surg 1996 Aug;39(4):340.

Squamous cell carcinoma in thyroglossal duct cyst. Deshpande A, et al. **J Laryngol Otol** 1995 Oct; 109(10):1001–4 (13 ref.)

DIAGNOSIS

Ectopic thyroid tissue presenting as a midline neck mass. Damiano A, et al. **Int J Pediatr Otorhinolaryngol** 1996 Jan; 34(1–2):141–8 (12 ref.)

PATHOLOGY

Papillary carcinoma arising in a thyroglossal duct cyst: a case report and literature review. Hilger AW, et al. **J Laryngol Otol** 1995 Nov;109(11):1124–7 (15 ref.)

[Papillary carcinoma on the site of a thyroglossal duct cyst: report of a case] Essakalli HL, et al. **Rev Laryngol Otol Rhinol (Bord)** 1995;116(3):213–6 (19 ref.) (Eng. Abstr.) **(Fre)**

[Papillary carcinoma arising in thyroglossal duct cyst: a case report and review of the literature] Sorrenti G, et al. **Acta Otorhinolaryngol Ital** 1995 Dec;15(6):460–4 (40 ref.) (Eng. Abstr.) **(Ita)**

THYROID ANTAGONISTS see ANTITHYROID AGENTS

THYROID CRISIS

DIAGNOSIS

[Thyrotoxic crisis. Pitfalls in diagnosis--intensive therapy] Hehrmann R. **Fortschr Med** 1996 Apr 10;114(10):114-7 (18 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

[Emergency drug therapy of thyroid disease] Tsushima T. **Nippon Naika Gakkai Zasshi** 1995 Nov 10;84(11):1848-51 (0 ref.) **(Jpn)**

THYROID DISEASES

Thyroid disease during pregnancy. Bishnoi A, et al. **Am Fam Physician** 1996 Jan;53(1):215-20 (19 ref.)

Thyroid dysfunction: an adolescent gynecologic perspective. Styne DM. **Curr Opin Obstet Gynecol** 1995 Oct;7(5):367-70 (13 ref.)

Subclinical thyroid disease. Elte JW, et al. **Postgrad Med J** 1996 Mar;72(845):141-6 (68 ref.)

Advances in the management of patients with thyroid disease. Dworkin HJ, et al. **Semin Nucl Med** 1995 Jul;25(3):205-20 (128 ref.)

CHEMICALLY INDUCED

Drug-induced thyroid disorders. Gittoes NJ, et al. **Drug Saf** 1995 Jul;13(1):46-55 (63 ref.)

COMPLICATIONS

Clinical associations between thyroid and liver diseases. Huang MJ, et al. **J Gastroenterol Hepatol** 1995 May-Jun; 10(3):344-50 (70 ref.)

[Liver dysfunction in endocrine disorders (thyroid diseases)] Kanamori A, et al. **Ryofukibetsu Shokogun Shiriza** 1995; (8):396-9 (13 ref.) **(Jpn)**

DIAGNOSIS

Interpreting thyroid tests. Costa AJ. **Am Fam Physician** 1995 Dec;52(8):2325-30 (19 ref.)

Evaluation of patients with mildly abnormal thyroid function tests. Pittman JG. **Am Fam Physician** 1996 Sep 1; 54(3):961-6 (19 ref.)

Guidelines for diagnosis and monitoring of thyroid disease: nonthyroidal illness. Stockigt JR. **Clin Chem** 1996 Jan; 42(1):188-92 (39 ref.)

An update on diagnostic methods in the investigation of diseases of the thyroid. Reinhardt MJ, et al. **Eur J Nucl Med** 1996 May;23(5):587-94 (58 ref.)

Primary care diagnosis of thyroid disease. Behnia M, et al. **Hosp Pract (Off Ed)** 1996 Jun 15;31(6):121-6, 131-4 (0 ref.)

Parathyroid and thyroid imaging. Yousem DM. **Neuroimaging Clin N Am** 1996 May;6(2):435-59 (96 ref.)

Thyroid and parathyroid imaging. Hopkins CR, et al. **Semin Ultrasound CT MR** 1995 Aug;16(4):279-95 (76 ref.)

[Thyroid amyloidosis diagnosed by echo-guided needle aspiration with a fine needle] Gimondo P, et al. **Radiol Med (Torino)** 1996 Mar;91(3):316-8 (6 ref.) **(Ita)**

[Recent progress in the diagnosis of thyroid diseases] Akamizu T. **Rinsho Byori** 1995 Nov;43(11):1115-9 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Postgravid health care and laboratory tests] Hidaka Y, et al. **Rinsho Byori** 1995 Nov;43(11):1101-7 (14 ref.) (Eng. Abstr.) **(Jpn)**

DRUG THERAPY

[Topics on diagnosis and therapy of thyroid diseases] Shishiba Y. **Nippon Naika Gakkai Zasshi** 1996 Mar 10;85(3):377-8 (0 ref.) **(Jpn)**

EPIDEMIOLOGY

[Thyroid disease among women in reproductive and non-reproductive age] Lizcano F, et al. **Rev Med Univ Navarra** 1995 Apr-Jun;40(2):85-9 (25 ref.) **(Spa)**

ETIOLOGY

TSH receptor and disease. Tonacchera M, et al. **Clin Endocrinol (Oxf)** 1996 Jun;44(6):621-33 (106 ref.)

Cigarette smoking and the thyroid. Bartalena L, et al. **Eur J Endocrinol** 1995 Nov;133(5):507-12 (57 ref.)

GENETICS

The TSH receptor and thyroid diseases. Paschke R, et al. **Baillieres Clin Endocrinol Metab** 1996 Jan;10(1):9-27 (93 ref.)

Molecular studies on thyrotropin (TSH) receptor and anti-TSH receptor antibodies. Akamizu T, et al. **Endocr J** 1995 Oct;42(5):617-27 (46 ref.)

TSH receptor and LH receptor, 1995. Kosugi S, et al. **Endocr J** 1995 Oct;42(5):587-606 (95 ref.)

[Molecular endocrinology of thyroid diseases] Meier CA. **Schweiz Med Wochenschr** 1995 Dec 9;125(49):2367-78 (64 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

[Does a clinician need autoimmune assays of the thyroid gland?] Välimäki MJ. **Duodecim** 1994;110(10):969-73 (14 ref.) **(Fin)**

METABOLISM

[Thyroid and AIDS] Bonnyns M, et al. **Rev Med Brux** 1995 Nov;16(5):361-3 (16 ref.) (Eng. Abstr.) **(Fre)**

[Molecular biology of thyroid diseases] Nagy E, et al. **Orv Hetil** 1996 Mar 17;137(11):563-8 (44 ref.) (Eng. Abstr.) **(Hun)**

PATHOLOGY

Histological changes mimicking papillary carcinoma following fine needle aspiration of the thyroid gland. Lopez JI, et al. **Arch Anat Cytol Pathol** 1996;44(2-3):98-100 (11 ref.)

Langerhans cell histiocytosis of the thyroid: a series of seven cases and a review of the literature. Thompson LD, et al. **Mod Pathol** 1996 Feb;9(2):145-9 (37 ref.)

[Puncture cytologic diagnosis of thyroid diseases: potentialities and limitations of the method] Malor NN, et al. **Arkh Patol** 1996 Mar-Apr;58(2):74-8 (52 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

[Cardiopulmonary involvement in thyroid gland diseases] Hellermann J, et al. **Pneumologie** 1996 May;50(5):375-80 (48 ref.) (Eng. Abstr.) **(Ger)**

SURGERY

[Analysis of complications of thyroid surgery: recurrent paralysis et hypoparathyroidism. On a series of 588 cases] Debry C, et al. **Ann Otolaryngol Chir Cervicofac** 1995; 112(5):211-7 (11 ref.) (Eng. Abstr.) **(Fre)**

[Thyroid surgery: risks and complications. Apropos of 134 cases] Duclos JY, et al. **Rev Laryngol Otol Rhinol (Bord)** 1995;116(3):199-207 (25 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Management of thyroid optic neuropathy. Lucarelli MJ, et al. **Int Ophthalmol Clin** 1996 Winter;36(1):179-93 (56 ref.)

[Endocrinology update. II] Burgstaller M, et al. **Med Klin** 1996 Apr 10;91(4):207-17 (171 ref.) **(Ger)**

[Endocrinology update--II] Burgstaller M, et al. **Med Klin** 1996 Apr 1;91 Suppl 1:34-44 (171 ref.) **(Ger)**

ULTRASONOGRAPHY

[The use of color Doppler sonography in the diagnosis of thyroid pathology] Angelillis L, et al. **Minerva Endocrinol** 1995 Dec;20(4):225-32 (44 ref.) (Eng. Abstr.) **(Ita)**

THYROID FUNCTION TESTS

Effects of iodine on thyroid function. Braverman LE, et al. **Acta Med Austriaca** 1996;23(1-2):4-9 (71 ref.)

Disturbances of thyroid function tests by drugs. Wenzel KW. **Acta Med Austriaca** 1996;23(1-2):57-60 (32 ref.)

Interpreting thyroid tests. Costa AJ. **Am Fam Physician** 1995 Dec;52(8):2325-30 (19 ref.)

Evaluation of thyroid status in patients with thyrotoxicosis. Braverman LE. **Clin Chem** 1996 Jan;42(1):174-8 (24 ref.)

Preanalytical considerations in testing thyroid function [see comments] Keffer JH. **Clin Chem** 1996 Jan;42(1):125-34 (140 ref.) Comment in: Clin Chem 1996 Jul;42(7):1124.

Compound W: a potential marker in maternal serum for assessing fetal thyroid function. Wu SY, et al. **Compr Ther** 1995 Oct;21(10):594-6 (17 ref.)

THYROID GLAND

see related
STRUMA OVARII
THYROIDECTOMY

Ectopic thyroid tissue presenting as a midline neck mass. Damiano A, et al. **Int J Pediatr Otorhinolaryngol** 1996 Jan; 34(1-2):141-8 (12 ref.)

[Ectopic lingual thyroid. Apropos of 3 cases] Maurice N, et al. **Ann Otolaryngol Chir Cervicofac** 1995;112(8):399-405 (24 ref.) (Eng. Abstr.) **(Fre)**

BLOOD SUPPLY

True aneurysm of the inferior thyroid artery. Case report and review of the literature. Raso AM, et al. **J Cardiovasc Surg (Torino)** 1995 Oct;36(5):493-5 (8 ref.)

CYTOLOGY

Evaluation of the role of mammalian thyroid parafollicular cells. Sawicki B. **Acta Histochem** 1995 Oct;97(4):389-99 (74 ref.)

Extracellular calcium sensitivity and voltage-dependent calcium channels in C cells. Raue F, et al. **Endocr Rev** 1995 Dec;16(6):752-64 (122 ref.)

DRUG EFFECTS

Effects of iodine on thyroid function. Braverman LE, et al. **Acta Med Austriaca** 1996;23(1-2):4-9 (71 ref.)

Evidence that iodolactones are the mediators of growth inhibition by iodine on the thyroid. Gärtner R, et al. **Acta Med Austriaca** 1996;23(1-2):47-51 (34 ref.)

Drugs and thyroid function. Surks MI, et al. **N Engl J Med** 1995 Dec 21;333(25):1688-94 (94 ref.)

IMMUNOLOGY

[Microsomal antibodies] Kobayashi I. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:414-7 (10 ref.) **(Jpn)**

METABOLISM

Thyrotropin-dependent transforming growth factor beta expression in thyroid gland [comment] Roger PP. **Eur J Endocrinol** 1996 Mar;134(3):269-71 (16 ref.) Comment on: Eur J Endocrinol 1996 Mar;134(3):373-8.

The type-1 repeats of thyroglobulin regulate thyroglobulin degradation and T3, T4 release in thyrocytes. Molina F, et al. **FEBS Lett** 1996 Aug 12;391(3):229-31 (25 ref.)

[Endemic iodine deficiency in Hungary and possibilities of iodine substitution] Bogye G, et al. **Orv Hetil** 1996 Feb 11;137(6):287-90 (25 ref.) (Eng. Abstr.) **(Hun)**

PATHOLOGY

Histological changes mimicking papillary carcinoma following fine needle aspiration of the thyroid gland. Lopez JI, et al. **Arch Anat Cytol Pathol** 1996;44(2-3):98-100 (11 ref.)

Mechanisms of nonneoplastic endocrine hyperplasia--a changing concept: a review focused on the thyroid gland. Studer H, et al. **Endocr Rev** 1995 Aug;16(4):411-26 (212 ref.)

[Techniques for thyroid imaging] Hermans J. **Ann Endocrinol (Paris)** 1995;56(5):495-506 (31 ref.) (Eng. Abstr.) **(Fre)**

[Non-neoplastic hypercalcitoninemia. Pathological anatomy] Saint-André JP, et al. **Ann Endocrinol (Paris)** 1996; 57(1):23-6 (14 ref.) (Eng. Abstr.) **(Fre)**

[Thyroid amyloidosis diagnosed by echo-guided needle aspiration with a fine needle] Gimondo P, et al. **Radiol Med (Torino)** 1996 Mar;91(3):316-8 (6 ref.) **(Ita)**

PHYSIOLOGY

Thermogenesis and thyroid function. Freake HC, et al. **Annu Rev Nutr** 1995;15:263-91 (161 ref.)

Nutritional and hormonal regulation of thyroid hormone deiodinases. Larsen PR, et al. **Annu Rev Nutr** 1995; 15:323-52 (149 ref.)

Physiological variations in thyroid hormones: physiological and pathophysiological considerations. Fisher DA. **Clin Chem** 1996 Jan;42(1):135-9 (24 ref.)

Cytokines and the endocrine system. II. Roles in substrate metabolism, modulation of thyroidal and pancreatic endocrine cell functions and autoimmune endocrine diseases. Mandrup-Poulsen T, et al. **Eur J Endocrinol** 1996 Jan;134(1):21-30 (174 ref.)

Central insulin may up-regulate thyroid activity by suppressing neuropeptide Y release in the paraventricular nucleus. McCarty MF. **Med Hypotheses** 1995 Aug; 45(2):193-9 (114 ref.)

Hypothalamic-pituitary-thyroid axis and the immune system. Pawlikowski M, et al. **Neuroimmunomodulation** 1994 May-Jun;1(3):149-52 (56 ref.)

PHYSIOPATHOLOGY

The aging thyroid. Mariotti S, et al. **Endocr Rev** 1995 Dec; 16(6):686-715 (403 ref.)

Cigarette smoking and the thyroid. Bartalena L, et al. **Eur J Endocrinol** 1995 Nov;133(5):507-12 (57 ref.)

[Endocrine function (pituitary, thyroid, adrenal gland) of obesity] Ogino Y, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:316-9 (13 ref.) **(Jpn)**

SECRETION

Evaluation of the role of mammalian thyroid parafollicular cells. Sawicki B. **Acta Histochem** 1995 Oct;97(4):389-99 (74 ref.)

ULTRASONOGRAPHY

[Thyroid amyloidosis diagnosed by echo-guided needle aspiration with a fine needle] Gimondo P, et al. **Radiol Med (Torino)** 1996 Mar;91(3):316-8 (6 ref.) **(Ita)**

THYROID HORMONE RECEPTORS see **RECEPTORS, THYROID HORMONE**

THYROID HORMONE RESISTANCE SYNDROME

see related
EUTHYROID SICK SYNDROMES

DIAGNOSIS

[Resistance to thyroid hormone] Härkönen M. **Duodecim** 1994;110(21):2009-11 (11 ref.) **(Fin)**

ETIOLOGY

Syndrome of resistance to thyroid hormone: insights into thyroid hormone action. Kopp P, et al. **Proc Soc Exp Biol Med** 1996 Jan;211(1):49-61 (73 ref.)

THYROID HORMONES

see related
HYPERTHYROIDISM
HYPOTHYROIDISM
RECEPTORS, THYROID HORMONE
THYROGLOBULIN

BLOOD

Evaluation of patients with mildly abnormal thyroid function tests. Pittman JG. **Am Fam Physician** 1996 Sep 1; 54(3):961–6 (19 ref.)
Physiological variations in thyroid hormones: physiological and pathophysiological considerations. Fisher DA. **Clin Chem** 1996 Jan;42(1):135–9 (24 ref.)

METABOLISM

Thyroid hormone deiodinases—a selenoenzyme family acting as gate keepers to thyroid hormone action. Köhrle J. **Acta Med Austriaca** 1996;23(1–2):17–30 (134 ref.)
Pathways of thyroid hormone metabolism. Visser TJ. **Acta Med Austriaca** 1996;23(1–2):10–6 (83 ref.)
Drug-induced thyroid disorders. Gittoes NJ, et al. **Drug Saf** 1995 Jul;13(1):46–55 (63 ref.)
Role of sulfate in thyroid hormone sulfation [comment] Visser TJ. **Eur J Endocrinol** 1996 Jan;134(1):12–4 (26 ref.) Comment on: Eur J Endocrinol 1996 Jan;134(1):45–9.
Thyroid hormone metabolism during development. Polk DH. **Reprod Fertil Dev** 1995;7(3):469–77 (44 ref.)
[Endemic iodine deficiency in Hungary and possibilities of iodine substitution] Bogye G, et al. **Orv Hetil** 1996 Feb 11;137(6):287–90 (25 ref.) (Eng. Abstr.) **(Hun)**

PHARMACOKINETICS

Hormone delivery systems to the brain–transthyretin. Schreiber G, et al. **Exp Clin Endocrinol Diabetes** 1995; 103(2):75–80 (51 ref.)

PHARMACOLOGY

Thyroid hormone and male gonadal function. Jannini EA, et al. **Endocr Rev** 1995 Aug;16(4):443–59 (226 ref.)
Syndrome of resistance to thyroid hormone: insights into thyroid hormone action. Kopp P, et al. **Proc Soc Exp Biol Med** 1996 Jan;211(1):49–61 (73 ref.)

PHYSIOLOGY

Effects of thyroid hormones on contractility and cation transport in skeletal muscle. Everts ME. **Acta Physiol Scand** 1996 Mar;156(3):325–33 (65 ref.)
Thyroid hormones and brain development. Bernal J, et al. **Eur J Endocrinol** 1995 Oct;133(4):390–8 (68 ref.)
Influence of thyroid hormones on the regulation of growth hormone secretion. Giustina A, et al. **Eur J Endocrinol** 1995 Dec;133(6):646–53 (52 ref.)
Thyroid hormone: modulation of muscle structure, function, and adaptive responses to mechanical loading. Caiozzo VJ, et al. **Exerc Sport Sci Rev** 1996;24:321–61 (159 ref.)
Endocrine glia: roles of glial cells in the brain actions of steroid and thyroid hormones and in the regulation of hormone secretion. Garcia-Segura LM, et al. **Front Neuroendocrinol** 1996 Apr;17(2):180–211 (253 ref.)
The Nutrition Society 1994 Silver Medal Lecture. Pregnancy, parturition and neonatal development: interactions between nutrition and thyroid hormones. Symonds ME. **Proc Nutr Soc** 1995 Jul;54(2):329–43 (97 ref.)
Thyroid hormone control of thermogenesis and energy balance. Silva JE. **Thyroid** 1995 Dec;5(6):481–92 (99 ref.)

THERAPEUTIC USE

Thyroid hormone therapy in cardiovascular disease. Klemperer JD, et al. **Prog Cardiovasc Dis** 1996 Jan–Feb; 38(4):329–36 (69 ref.)
Does thyroid hormone have a role as adjunctive therapy in depression? Jackson IM. **Thyroid** 1996 Feb;6(1):63–7 (41 ref.)
Thyroid hormone treatment of depression. Joffe RT, et al. **Thyroid** 1995 Jun;5(3):235–9 (33 ref.)

THYROID NEOPLASMS

Papillary thyroid carcinoma. Etiology, assessment, and therapy. Ain KB. **Endocrinol Metab Clin North Am** 1995 Dec;24(4):711–60 (350 ref.)
Follicular thyroid cancer. Grebe SK, et al. **Endocrinol Metab Clin North Am** 1995 Dec;24(4):761–801 (184 ref.)
Management of papillary thyroid cancer. Vassilopoulou-Sellin R. **Oncology (Huntingt)** 1995 Feb; 9(2):145–51; discussion 151–2, 154, 157 (50 ref.)
Medullary thyroid carcinoma: recent advances and management update. Marsh DJ, et al. **Thyroid** 1995 Oct; 5(5):407–24 (188 ref.)

BLOOD

[Hypercalcitoninemia in conditions other than medullary cancers of the thyroid] Niccoli P, et al. **Ann Endocrinol (Paris)** 1996;57(1):15–21 (53 ref.) (Eng. Abstr.) **(Fre)**

CHEMICALLY INDUCED

Mechanistic considerations for the relevance of animal data on thyroid neoplasia to human risk assessment. McClain RM. **Mutat Res** 1995 Dec;333(1–2):131–42 (69 ref.)
Mechanisms of chemically induced thyroid follicular carcinogenesis. Kanno J, et al. **Prog Clin Biol Res** 1996; 394:353–98 (176 ref.)

COMPLICATIONS

Squamous cell carcinoma in thyroglossal duct cyst. Deshpande A, et al. **J Laryngol Otol** 1995 Oct; 109(10):1001–4 (13 ref.)
[Basedow disease following metastatic thyroid cancer] Le Pommelet C, et al. **Presse Med** 1996 Apr 20;25(14):671–3 (20 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Optimal laboratory testing for diagnosis and monitoring of thyroid nodules, goiter, and thyroid cancer. Ladenson PW. **Clin Chem** 1996 Jan;42(1):183–7 (27 ref.)
Preoperative endocrine tumor localization utilizing a cost-effective approach. Leight GS Jr, et al. **Curr Opin Gen Surg** 1993;:108–14 (19 ref.)
Diagnostic problems in medullary carcinoma of the thyroid. Bussolati G, et al. **Pathol Res Pract** 1995 May;191(4):332–44 (64 ref.)
Diagnostic problems in differentiated carcinomas of the thyroid. Fonseca E, et al. **Pathol Res Pract** 1995 May; 191(4):318–31 (53 ref.)
[Thyroid cancer, its diagnosis and surgical treatment] Abdeluakhab M, et al. **Khirurgiia (Sofiia)** 1995;48(2):39–43 (0 ref.) **(Bul)**
[Cushing's syndrome associated with a metastatic medullary carcinoma of the thyroid. A report of 2 cases and a review of the literature] Martinez Diaz-Guerra G, et al. **Rev Clin Esp** 1995 Dec;195(12):849–52 (63 ref.) (Eng. Abstr.) **(Spa)**

EPIDEMIOLOGY

[Thyroid cancer—its prevalence, carcinogenic factors, classifications of the cancer, types, variants amd prognostic factors] Abdeluakhab M, et al. **Khirurgiia (Sofiia)** 1995; 48(2):32–8 (0 ref.) **(Bul)**
[Medullary cancer of the thyroid gland in France in 1995] Modigliani E. **Ann Endocrinol (Paris)** 1996;57(1):3–7 (14 ref.) (Eng. Abstr.) **(Fre)**
[Malignant thyroid tumors in Hungary: morbidity and mortality] Esik O, et al. **Orv Hetil** 1996 Apr 28; 137(17):905–11 (33 ref.) (Eng. Abstr.) **(Hun)**

ETIOLOGY

Changing concepts in the pathogenesis and management of thyroid carcinoma. Gagel RF, et al. **CA Cancer J Clin** 1996 Sep–Oct;46(5):261–83 (128 ref.)
Mechanisms and pathogenesis of thyroid cancer in animals and man. Williams ED. **Mutat Res** 1995 Dec; 333(1–2):123–9 (28 ref.)

GENETICS

Activating mutations of the TSH receptor gene cause thyroid diseases. Vassart G, et al. **Ann Endocrinol (Paris)** 1996; 57(1):50–4 (31 ref.)
RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma. Cote GJ, et al. **Baillieres Clin Endocrinol Metab** 1995 Jul; 9(3):609–30 (64 ref.)
Oncogenic activation of the ret protooncogene in thyroid cancer. Takahashi M. **Crit Rev Oncog** 1995;6(1):35–46 (96 ref.)
Genetics of follicular thyroid cancer. Farid NR, et al. **Endocrinol Metab Clin North Am** 1995 Dec;24(4):865–83 (87 ref.)
Molecular defects in thyroid carcinomas: role of the RET oncogene in thyroid neoplastic transformation. Santoro M, et al. **Eur J Endocrinol** 1995 Nov;133(5):513–22 (114 ref.)
Molecular analysis of mutations in thyroid tumors with TGGE. Simon D, et al. **Exp Clin Endocrinol Diabetes** 1995; 103(5):275–9 (36 ref.)
RET gene and its implications for cancer. Goodfellow PJ, et al. **J Natl Cancer Inst** 1995 Oct 18;87(20):1515–23 (71 ref.)
Recent advances in cytometry, cytogenetics and molecular genetics of thyroid tumours and tumour-like lesions. Soares P, et al. **Pathol Res Pract** 1995 May;191(4):304–17 (141 ref.)
Genetics of non-medullary thyroid cancer. Houlston RS, et al. **QJM** 1995 Oct;88(10):685–93 (93 ref.)
[Analysis of the RET gene and medullary cancer of the thyroid. Contribution to the diagnosis and treatment] Schuffenecker I, et al. **Ann Endocrinol (Paris)** 1996; 57(1):9–14 (27 ref.) (Eng. Abstr.) **(Fre)**
[Expression of the MDR1 gene in five human cell lines of medullary thyroid cancer and reversion of the resistance to doxorubicine by ciclosporin A and verapamil] Massart C, et al. **Bull Cancer (Paris)** 1996 Jan;83(1):39–45 (32 ref.) (Eng. Abstr.) **(Fre)**
[The direct gene test in familial medullary thyroid gland carcinoma and in MEN syndromes. Detection of mutations in the ret proto-oncogene saves screening studies] Stuhrmann M. **Fortschr Med** 1995 Dec 20;113(35–36):503–6 (23 ref.) (Eng. Abstr.) **(Ger)**
[Familial occurrence of thyroid tumors] Kameyama K, et al. **Nippon Rinsho** 1995 Nov;53(11):2697–701 (21 ref.) (Eng. Abstr.) **(Jpn)**
[Multiple endocrine neoplasia type 2A, type 2B and familial medullary thyroid carcinoma syndrome] Obara T, et al. **Nippon Rinsho** 1995 Nov;53(11):2708–15 (19 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

The immune response to papillary thyroid cancer [editorial; comment] Baker JR Jr. **J Clin Endocrinol Metab** 1995 Dec; 80(12):3419–20 (15 ref.) Comment on: J Clin Endocrinol Metab 1995 Dec;80(12):3421–4.

METABOLISM

[Molecular biology of thyroid diseases] Nagy E, et al. **Orv Hetil** 1996 Mar 17;137(11):563–8 (44 ref.) (Eng. Abstr.) **(Hun)**

MORTALITY

[Survival potentials of patients with papillary carcinoma of the thyroid gland in Hungary] Esik O, et al. **Orv Hetil** 1996 May 19;137(20):1067–78 (50 ref.) (Eng. Abstr.) **(Hun)**
[From Hiroshima to Chernobyl. Increasing number of late fatal cases of cancer] Drottz-Sjöberg BM, et al. **Lakartidningen** 1995 Nov 1;92(44):4100–2, 4105 (18 ref.) **(Swe)**

PATHOLOGY

Hyalinizing trabecular adenoma of the thyroid—morphology and differential diagnosis. Schmid KW, et al. **Acta Med Austriaca** 1996;23(1–2):65–8 (23 ref.)
Composite follicular variant of papillary carcinoma and mucoepidermoid carcinoma of the thyroid. Report of a case and review of the literature. Miranda RN, et al. **Am J Surg Pathol** 1995 Oct;19(10):1209–15 (23 ref.)
Medullary carcinoma of the thyroid: subtypes and current management. Randolph GW. **Compr Ther** 1996 Apr; 22(4):203–10 (30 ref.)
Histologic, flow cytometric, and genetic criteria in endocrine surgery. Flynn SD, et al. **Curr Opin Gen Surg** 1993;:115–20 (45 ref.)
Fine needle aspiration (FNA)-induced necrosis of tumours of the thyroid. Ramp U, et al. **Cytopathology** 1995 Aug; 6(4):248–54 (13 ref.)
Primary mucoepidermoid carcinoma of the thyroid gland: a report of six cases and a review of the literature of a follicular epithelial-derived tumor. Wenig BM, et al. **Hum Pathol** 1995 Oct;26(10):1099–108 (44 ref.)
Papillary carcinoma arising in a thyroglossal duct cyst: a case report and literature review. Hilger AW, et al. **J Laryngol Otol** 1995 Nov;109(11):1124–7 (15 ref.)
Medullary carcinoma of the thyroid metastatic to the temporal bone. Redleaf MI, et al. **J Laryngol Otol** 1995 Dec;109(12):1200–3 (15 ref.)
Controversies in the diagnosis and management of thyroid cancer. Thomas MJ. **J Otolaryngol** 1996 Feb;25(1):20–2 (11 ref.)
Papillary carcinoma of the thyroid gland with fibromatosis-like stroma: a case report and review of the literature. Mizukami Y, et al. **Mod Pathol** 1995 May; 8(4):366–70 (4 ref.)
Diagnostic problems in differentiated carcinomas of the thyroid. Fonseca E, et al. **Pathol Res Pract** 1995 May; 191(4):318–31 (53 ref.)
Papillary thyroid cancer: a pediatric perspective. Flannery TK, et al. **Pediatrics** 1996 Sep;98(3 Pt 1):464–6 (23 ref.)
[Retrospect and prospect of endocrinological pathology] Tan Y. **Chung Hua Ping Li Hsueh Tsa Chih** 1995 Aug; 24(4):239–41 (21 ref.) **(Chi)**
[Current anatomopathological aspects of differentiated thyroid cancers of follicular (vesicular) origin: value and necessity of a common language] Franc B. **Ann Chir** 1995; 49(10):909–21 (65 ref.) (Eng. Abstr.) **(Fre)**
[Detection of residual lesions and metastases of medullary thyroid cancer] Murat A. **Ann Endocrinol (Paris)** 1996; 57(1):27–32 (33 ref.) (Eng. Abstr.) **(Fre)**
[Primary angiosarcoma of the thyroid. Presentation of a case (epithelioid type) and nosological problems] Bisceglia M, et al. **Pathologica** 1995 Apr;87(2):154–61 (49 ref.) (Eng. Abstr.) **(Ita)**
[Puncture cytologic diagnosis of thyroid diseases: potentialities and limitations of the method] Malor NN, et al. **Arkh Patol** 1996 Mar–Apr;58(2):74–8 (52 ref.) (Eng. Abstr.) **(Rus)**

RADIOGRAPHY

[Radiological criteria for laryngeal tumors and cervical metastases] Melchor Diaz MA, et al. **Acta Otorrinolaringol Esp** 1996 Jan–Feb;47(1):1–7 (17 ref.) (Eng. Abstr.) **(Spa)**
[A woman with a unilateral adrenal mass. The adrenal metastasis of a medullary carcinoma of the thyroid] Maroto P, et al. **Rev Clin Esp** 1995 Dec;195(12):847–8 (5 ref.) **(Spa)**

THYROID NEOPLASMS

RADIOTHERAPY

Chronic myeloid leukaemia following 131I treatment for thyroid carcinoma: a report of two cases and review of the literature. Shimon I, et al. **Clin Endocrinol (Oxf)** 1995 Nov;43(5):651–4 (21 ref.)

Radioiodine therapy for thyroid cancer. Sweeney DC, et al. **Endocrinol Metab Clin North Am** 1995 Dec;24(4):803–39 (127 ref.)

Radiation protection issues associated with nuclear medicine out-patients [see comments] Thomson WH, et al. **Nucl Med Commun** 1995 Nov;16(11):879–92 (43 ref.) Comment in: Nucl Med Commun 1995 Nov;16(11):877–8.

[Indications for percutaneous radiotherapy in carcinoma of the thyroid gland. Freiburg consensus] Reinhardt M, et al. **Radiologe** 1995 Aug;35(8):535–9 (32 ref.) (Eng. Abstr.) **(Ger)**

SECONDARY

[A case of solitary metastasis from renal cell carcinoma to the thyroid gland] Muramoto M, et al. **Hinyokika Kiyo** 1996 Feb;42(2):123–5 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Radiological criteria for laryngeal tumors and cervical metastases] Melchor Diaz MA, et al. **Acta Otorrinolaringol Esp** 1996 Jan–Feb;47(1):1–7 (17 ref.) (Eng. Abstr.) **(Spa)**

SURGERY

Changing concepts in the pathogenesis and management of thyroid carcinoma. Gagel RF, et al. **CA Cancer J Clin** 1996 Sep–Oct;46(5):261–83 (128 ref.)

Concurrent papillary and squamous carcinoma in a thyroglossal duct cyst: a case report [see comments] Kwan WB, et al. **Can J Surg** 1996 Aug;39(4):328–32 (20 ref.) Comment in: Can J Surg 1996 Aug;39(4):263–4. Comment in: Can J Surg 1996 Aug;39(4):340.

The role of total thyroidectomy in the management of differentiated thyroid cancer. Stephenson BM, et al. **Curr Opin Gen Surg** 1994;:53–9 (61 ref.)

Management considerations in Hürthle cell carcinoma. Azadian A, et al. **Surgery** 1995 Oct;118(4):711–4; discussion 714–5 (23 ref.)

Optimal surgery for papillary thyroid carcinoma. Udelsman R, et al. **World J Surg** 1996 Jan;20(1):88–93 (65 ref.)

[Thyroid cancer, its diagnosis and surgical treatment] Abdeluakhab M, et al. **Khirurgiia (Sofiia)** 1995;48(2):39–43 (0 ref.) **(Bul)**

[Oncocytic cancers of the thyroid. Hürthle cell cancers] Janser JC, et al. **Chirurgie** 1996;121(1):28–36 (40 ref.) (Eng. Abstr.) **(Fre)**

[Prospective therapy study in differentiated thyroid carcinoma] Gemsenjäger E, et al. **Schweiz Med Wochenschr** 1995 Nov 18;125(46):2226–36 (41 ref.) (Eng. Abstr.) **(Ger)**

[Thyroid carcinoma in hyperthyroid syndromes] Ragni F, et al. **G Chir** 1996 Apr;17(4):158–65 (26 ref.) (Eng. Abstr.) **(Ita)**

THERAPY

Thyroid cancer: a review of treatment and follow-up. Vini L, et al. **Ann Nucl Med** 1996 Feb;10(1):1–7 (58 ref.)

Recent advances in the treatment of thyroid carcinoma [editorial] Wells SA Jr. **CA Cancer J Clin** 1996 Sep–Oct; 46(5):258–60 (16 ref.)

[Role of non surgical therapeutics in the treatment of patients with medullary cancer of the thyroid] Guliana JM. **Ann Endocrinol (Paris)** 1996;57(1):33–40 (41 ref.) (Eng. Abstr.) **(Fre)**

THYROID NODULE

see related
GOITER, NODULAR

Evaluation and management of the solid thyroid nodule. Burch HB. **Endocrinol Metab Clin North Am** 1995 Dec; 24(4):663–710 (349 ref.)

DIAGNOSIS

Controversies in the management of cold, hot, and occult thyroid nodules. Giuffrida D, et al. **Am J Med** 1995 Dec; 99(6):642–50 (81 ref.)

Optimal laboratory testing for diagnosis and monitoring of thyroid nodules, goiter, and thyroid cancer. Ladenson PW. **Clin Chem** 1996 Jan;42(1):183–7 (27 ref.)

Thyroid nodules and nodular thyroids: a clinical overview. Daniels GH. **Compr Ther** 1996 Apr;22(4):239–50 (99 ref.)

[Overzealous evaluation of the thyroid nodule] Sobel R, et al. **Harefuah** 1996 Mar 1;130(5):346–8 (9 ref.) **(Heb)**

THERAPY

Controversies in the management of cold, hot, and occult thyroid nodules. Giuffrida D, et al. **Am J Med** 1995 Dec; 99(6):642–50 (81 ref.)

THYROID PEROXIDASE see **IODIDE PEROXIDASE**

THYROID-STIMULATING HORMONE see **THYROTROPIN**

THYROID-STIMULATING HORMONE, ALPHA SUBUNIT see **GLYCOPROTEIN HORMONES, ALPHA SUBUNIT**

THYROID STIMULATING HORMONE RECEPTORS see **RECEPTORS, THYROTROPIN**

THYROID STORM see **THYROID CRISIS**

THYROIDECTOMY

ADVERSE EFFECTS

[Analysis of complications of thyroid surgery: recurrent paralysis et hypoparathyroidism. On a series of 588 cases] Debry C, et al. **Ann Otolaryngol Chir Cervicofac** 1995; 112(5):211–7 (11 ref.) (Eng. Abstr.) **(Fre)**

METHODS

The role of total thyroidectomy in the management of differentiated thyroid cancer. Stephenson BM, et al. **Curr Opin Gen Surg** 1994;:53–9 (61 ref.)

Optimal surgery for papillary thyroid carcinoma. Udelsman R, et al. **World J Surg** 1996 Jan;20(1):88–93 (65 ref.)

THYROIDITIS

ULTRASONOGRAPHY

Definite distinction between thyroidal inflammatory conditions and other soft tissue inflammations of the neck using ultrasound. Klima G, et al. **Acta Med Austriaca** 1996; 23(1–2):80–2 (9 ref.)

VETERINARY

Thyroiditis—a model canine autoimmune disease. Happ GM. **Adv Vet Sci Comp Med** 1995;39:97–139 (216 ref.)

THYROIDITIS, AUTOIMMUNE

Chronic autoimmune thyroiditis. Dayan CM, et al. **N Engl J Med** 1996 Jul 11;335(2):99–107 (117 ref.)

COMPLICATIONS

Acquired von Willebrand's disease: a rare manifestation of postpartum thyroiditis. Aylesworth CA, et al. **Am J Hematol** 1995 Nov;50(3):217–9 (10 ref.)

[Clinical and pathological features of Sjögren's syndrome associated with autoimmune thyroid diseases] Ichikawa Y, et al. **Nippon Rinsho** 1995 Oct;53(10):2545–50 (26 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

[Normocytic anemia and hypercholesterolemia as the manifestation of a variant of Hashimoto's thyroiditis] Buitrago Ramírez F, et al. **An Esp Pediatr** 1996 Jul; 45(1):76–8 (10 ref.) **(Spa)**

ETIOLOGY

[Extrahepatic manifestations related to hepatitis C virus] Opolon P, et al. **Pathol Biol (Paris)** 1995 Oct;43(8):709–15 (59 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

Tolerance induction as a therapeutic strategy for the control of autoimmune endocrine disease in mouse models. Parish NM, et al. **Immunol Rev** 1995 Apr;144:269–300 (103 ref.)

THERAPY

Tolerance induction as a therapeutic strategy for the control of autoimmune endocrine disease in mouse models. Parish NM, et al. **Immunol Rev** 1995 Apr;144:269–300 (103 ref.)

THYROIDITIS, CHRONIC see **THYROIDITIS, AUTOIMMUNE**

THYROIDITIS, INFECTIOUS see **THYROIDITIS, SUPPURATIVE**

THYROIDITIS, LYMPHOCYTIC see **THYROIDITIS, AUTOIMMUNE**

THYROIDITIS, LYMPHOMATOUS see **THYROIDITIS, AUTOIMMUNE**

THYROIDITIS, SUPPURATIVE

DIAGNOSIS

HIV-related Pneumocystis carinii thyroiditis: a unique case and literature review. Danahey DG, et al. **Otolaryngol Head Neck Surg** 1996 Jan;114(1):158–61 (15 ref.)

THYROLIBERIN see **PROTIRELIN**

THYROLIBERIN RECEPTORS see **RECEPTORS, THYROTROPIN-RELEASING HORMONE**

THYRONINES

BLOOD

[Monoiodothyronine (T1)] Takeshita A, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:387–9 (7 ref.) **(Jpn)**

METABOLISM

The type-1 repeats of thyroglobulin regulate thyroglobulin degradation and T3, T4 release in thyrocytes. Molina F, et al. **FEBS Lett** 1996 Aug 12;391(3):229–31 (25 ref.)

THYROTOXIC CRISIS see **THYROID CRISIS**

THYROTOXIC STORM see **THYROID CRISIS**

THYROTOXICOSIS

DIAGNOSIS

Diagnosis and management of thyrotoxicosis. Hennessey JV. **Am Fam Physician** 1996 Sep 15;54(4):1315–24 (37 ref.)

Thyrotoxic periodic paralysis associated with hypokalemia and hypophosphatemia. Norris KC, et al. **Am J Kidney Dis** 1996 Aug;28(2):270–3 (28 ref.)

Hypokalaemic periodic paralysis associated with thyrotoxicosis. Agarwal AK, et al. **J Indian Med Assoc** 1995 Sep;93(9):359–60, 358 (21 ref.)

PHYSIOPATHOLOGY

Evaluation of thyroid status in patients with thyrotoxicosis. Braverman LE. **Clin Chem** 1996 Jan;42(1):174–8 (24 ref.)

RADIOTHERAPY

Radiation protection issues associated with nuclear medicine out-patients [see comments] Thomson WH, et al. **Nucl Med Commun** 1995 Nov;16(11):879–92 (43 ref.) Comment in: Nucl Med Commun 1995 Nov;16(11):877–8.

THERAPY

Diagnosis and management of thyrotoxicosis. Hennessey JV. **Am Fam Physician** 1996 Sep 15;54(4):1315–24 (37 ref.)

THYROTROPIN

see related
RECEPTORS, THYROTROPIN

BLOOD

Current status and performance goals for serum thyrotropin (TSH) assays. Spencer CA, et al. **Clin Chem** 1996 Jan; 42(1):140–5 (40 ref.)

[Thyroid stimulating hormone (TSH)] Bando H, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:294–9 (12 ref.) **(Jpn)**

PHARMACOLOGY

Resistance to thyrotropin and other abnormalities of the thyrotropin receptor. Refetoff S, et al. **Recent Prog Horm Res** 1996;51:97–120; discussion 120–2 (67 ref.)

Thyrotropic action of human chorionic gonadotropin. Yoshimura M, et al. **Thyroid** 1995 Oct;5(5):425–34 (62 ref.)

PHYSIOLOGY

Thyrotropin-dependent transforming growth factor beta expression in thyroid gland [comment] Roger PP. **Eur J Endocrinol** 1996 Mar;134(3):269–71 (16 ref.) Comment on: Eur J Endocrinol 1996 Mar;134(3):373–8.

SECRETION

Thyrotropin-secreting pituitary tumors in hyper- and hypothyroidism. Beck-Peccoz P, et al. **Acta Med Austriaca** 1996;23(1–2):41–6 (45 ref.)

[Secretion of thyrotropin during states of wakefulness and sleep. Physiological data and clinical applications] Goichot B, et al. **Presse Med** 1996 Jun 15;25(21):980–4 (25 ref.) (Eng. Abstr.) **(Fre)**

[Hyperthyroxinemia in nonsuppressed TSH. Its differential diagnosis and therapy] Feldkamp J, et al. **Dtsch Med Wochenschr** 1995 Sep 29;120(39):1323–6 (15 ref.) **(Ger)**

THYROTROPIN ALPHA SUBUNIT see **GLYCOPROTEIN HORMONES, ALPHA SUBUNIT**

THYROTROPIN RECEPTORS see **RECEPTORS, THYROTROPIN**

THYROTROPIN-RELEASING HORMONE see **PROTIRELIN**

THYROTROPIN RELEASING HORMONE RECEPTORS see **RECEPTORS, THYROTROPIN-RELEASING HORMONE**

THYROXINE

see related
HYPERTHYROXINEMIA
RECEPTORS, THYROID HORMONE

BLOOD

Diagnosis of thyroid hormone transport protein anomalies: an overview. Langsteger W. **Acta Med Austriaca** 1996; 23(1-2):31-40 (140 ref.)
Analytical performance of free and total thyroxine assays. Nelson JC, et al. **Clin Chem** 1996 Jan;42(1):146-54 (50 ref.)
[Free thyroxin (FT4)] Nagayama Y, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:376-9 (12 ref.) **(Jpn)**
[Total thyroxine (T4)] Yokoyama N, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:372-5 (8 ref.) **(Jpn)**
[T3 uptake (T3U)] Zeki K, et al. **Nippon Rinsho** 1995 Mar; 53 Su Pt 2:369-71 (8 ref.) **(Jpn)**

METABOLISM

The type-1 repeats of thyroglobulin regulate thyroglobulin degradation and T3, T4 release in thyrocytes. Molina F, et al. **FEBS Lett** 1996 Aug 12;391(3):229-31 (25 ref.)
Drugs and thyroid function. Surks MI, et al.
N Engl J Med 1995 Dec 21;333(25):1688-94 (94 ref.)

THERAPEUTIC USE

A therapeutic controversy. Thyroid hormone treatment: when and what? Oppenheimer JH, et al.
J Clin Endocrinol Metab 1995 Oct;80(10):2873-83 (112 ref.)
Antenatal diagnosis and treatment of fetal goitrous hypothyroidism: case report and review of the literature. Abuhamad AZ, et al. **Ultrasound Obstet Gynecol** 1995 Nov; 6(5):368-71 (27 ref.)

L-THYROXINE see **LEVOTHYROXINE**

THYROXINE-BINDING GLOBULIN see **THYROXINE-BINDING PROTEINS**

THYROXINE-BINDING PREALBUMIN see **THYROXINE-BINDING PROTEINS**

THYROXINE-BINDING PROTEINS

ANALYSIS

[Thyroxine binding globulin (TBG)] Fujihira T, et al.
Nippon Rinsho 1995 Mar;53 Su Pt 2:384-6 (7 ref.) **(Jpn)**
[Thyroxine binding capacity (TBC)] Natori Y, et al.
Nippon Rinsho 1995 Mar;53 Su Pt 2:418-20 (15 ref.) **(Jpn)**

GENETICS

Diagnosis of thyroid hormone transport protein anomalies: an overview. Langsteger W. **Acta Med Austriaca** 1996; 23(1-2):31-40 (140 ref.)
Gene amplification as a cause for inherited thyroxine-binding globulin excess? [editorial; comment] Robbins J.
J Clin Endocrinol Metab 1995 Dec;80(12):3425-6 (23 ref.)
Comment on: J Clin Endocrinol Metab 1995 Dec;80(12):3758-62.

METABOLISM

Gene amplification as a cause for inherited thyroxine-binding globulin excess? [editorial; comment] Robbins J.
J Clin Endocrinol Metab 1995 Dec;80(12):3425-6 (23 ref.)
Comment on: J Clin Endocrinol Metab 1995 Dec;80(12):3758-62.

THYROXINE 5'-DEIODINASE see **IODIDE PEROXIDASE**

THYROXINE 5'-MONODEIODINASE see **IODIDE PEROXIDASE**

THYROXINE RECEPTORS see **RECEPTORS, THYROID HORMONE**

TIBIA

Anaplastic large cell Ki-1 lymphoma: primary bone presentation in an elderly man. Wang JC, et al.
Acta Haematol 1996;96(1):45-9 (20 ref.)
Biomechanics of iliotibial band friction syndrome in runners. Orchard JW, et al. **Am J Sports Med** 1996 May-Jun; 24(3):375-9 (26 ref.)
Caso quiz. Tibia vara caused by focal fibrocartilaginous dysplasia. Marchiodi L, et al. **Chir Organi Mov** 1995 Oct-Dec;80(4):453-6 (9 ref.) **(Eng, Ita)**
Neonatal osteofibrous dysplasia: report of two cases. Hindman BW, et al. **Pediatr Radiol** 1996;26(4):303-6 (14 ref.)

ABNORMALITIES

Absence/hypoplasia of tibia, polydactyly, retrocerebellar arachnoid cyst, and other anomalies: an autosomal recessive disorder. Holmes LB, et al. **J Med Genet** 1995 Nov; 32(11):896-900 (29 ref.)

INJURIES

Ipsilateral peroneus brevis tendon grafting in a complicated case of traumatic rupture of tibialis anterior tendon. Forst R, et al. **Foot Ankle Int** 1995 Jul;16(7):440-4 (33 ref.)

PATHOLOGY

Periosteal ganglion: a report of three new cases including MRI findings and a review of the literature. Okada K, et al. **Skeletal Radiol** 1996 Feb;25(2):153-7 (14 ref.)
[Comparative histomorphometry of subchondral bone density and articular cartilage thickness in the tibial head in early human arthritis] Böhringer ME, et al.
Z Orthop Ihre Grenzgeb 1995 Jul-Aug;133(4):291-302 (61 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Skeletal adaptations to mechanical usage: results from tibial loading studies in rats. Forwood MR, et al. **Bone** 1995 Oct; 17(4 Suppl):197S-205S (56 ref.)

SURGERY

Subcutaneous pretibial cyst formation associated with anterior cruciate ligament allografts: a report of four cases and literature review. Victoroff BN, et al. **Arthroscopy** 1995 Aug;11(4):486-94 (25 ref.)
Desmoplastic fibroma of the bone. A report of two patients, review of the literature, and therapeutic implications. Böhm P, et al. **Cancer** 1996 Sep 1;78(5):1011-23 (97 ref.)
Thermal necrosis after tibial reaming for intramedullary nail fixation. A report of three cases. Leunig M, et al.
J Bone Joint Surg Br 1996 Jul;78(4):584-7 (26 ref.)
Tibiofibular arthrodesis for malunion of the talocrural joint. Loder BG, et al. **J Foot Ankle Surg** 1995 May-Jun; 34(3):283-8 (8 ref.)
Endoprosthetic bone reconstruction following malignant tumor resection in skeletally immature patients. Ward WG, et al. **Orthop Clin North Am** 1996 Jul;27(3):493-502 (43 ref.)
[Stabilization of interligamentous valgus procedure in tibial head osteotomy using staples] Zügel N, et al.
Z Orthop Ihre Grenzgeb 1995 Sep-Oct;133(5):437-41 (31 ref.) (Eng. Abstr.) **(Ger)**

TIBIAL ARTERIES

True infrapopliteal artery aneurysms: report of two cases and literature review. Mönig SP, et al. **J Vasc Surg** 1996 Aug; 24(2):276-8 (20 ref.)

TIBIAL FRACTURES

The Tillaux fracture. Duchesneau S, et al.
J Foot Ankle Surg 1996 Mar-Apr;35(2):127-33; discussion 189 (24 ref.)
A review of open tibia fractures in children. Kreder HJ, et al. **J Pediatr Orthop** 1995 Jul-Aug;15(4):482-8 (19 ref.)

CLASSIFICATION

Are type IIIC lower extremity injuries an indication for primary amputation. Quirke TE, et al. **J Trauma** 1996 Jun; 40(6):992-6 (45 ref.)

NURSING

Surgical treatment of patients with open tibial fractures. Brown C, et al. **AORN J** 1996 May;63(5):875-81, 885-96; quiz 899-906 (31 ref.)

SURGERY

Surgical treatment of patients with open tibial fractures. Brown C, et al. **AORN J** 1996 May;63(5):875-81, 885-96; quiz 899-906 (31 ref.)
Arteriovenous fistulae complicating orthopaedic procedures. Ward AS, et al. **Aust N Z J Surg** 1995 Dec;65(12):905-7 (20 ref.)
Intramedullary nailing after external fixation of the tibia. Tornetta P 3rd, et al. **Bull Hosp Jt Dis** 1995;54(1):5-13 (31 ref.)
The rationales of interlocking nailing of the femur, tibia, and humerus. Brumback RJ. **Clin Orthop** 1996 Mar; (324):292-320 (142 ref.)
Are type IIIC lower extremity injuries an indication for primary amputation. Quirke TE, et al. **J Trauma** 1996 Jun; 40(6):992-6 (45 ref.)
Tibial plateau fractures: the arthroscopic option. Bobic V, et al. **Knee Surg Sports Traumatol Arthrosc** 1993; 1(3-4):239-42 (23 ref.)
Lower limb salvage: microvascular reconstruction of post-traumatic soft tissue and skeletal defects. Tomaino MM. **Orthopedics** 1995 Jul;18(7):665-72 (68 ref.)
[Secondary internal osteosynthesis after external fixation for recent or old open fracture of the lower limb] Bernat M, et al. **Rev Chir Orthop Reparatrice Appar Mot** 1996; 82(2):137-44 (18 ref.) (Eng. Abstr.) **(Fre)**
[Intramedullary nailing of lower leg fractures with minimal soft tissue injuries] Ruchholtz S, et al. **Orthopade** 1996 Jun; 25(3):197-206 (49 ref.) (Eng. Abstr.) **(Ger)**
[Local complications of intramedullary nailing] Strecker W, et al. **Orthopade** 1996 Jun;25(3):274-91 (59 ref.) (Eng. Abstr.) **(Ger)**
[Borderline indications for locked intramedullary nailing of femur and tibia] Vécsei V, et al. **Orthopade** 1996 Jun; 25(3):234-46 (66 ref.) (Eng. Abstr.) **(Ger)**

VETERINARY

Treatment of fractures of the tibia and radius-ulna by external coaptation. Adams SB, et al.
Vet Clin North Am Food Anim Pract 1996 Mar;12(1):181-98 (15 ref.)

TIBIAL MENISCI see **MENISCI, TIBIAL**

TIBIAL NERVE

see related
TARSAL TUNNEL SYNDROME

INJURIES

Nerve allotransplantation following severe tibial nerve injury. Case report. Mackinnon SE. **J Neurosurg** 1996 Apr; 84(4):671-6 (67 ref.)

PHYSIOLOGY

Somatosensory evoked potentials in acute neurological decompression illness. Murrison A, et al. **J Neurol** 1995 Oct;242(10):669-76 (22 ref.)

TIC

PHYSIOPATHOLOGY

[Tics: clinical spectrum] Calderón R. **Rev Neurol** 1995;23 Suppl 3:S355-8 (17 ref.) **(Spa)**

TIC DOULOUREUX see **TRIGEMINAL NEURALGIA**

TICK-BORNE DISEASES

[The tick--a disease carrier we have to learn to live with. "New" diseases require further research] Asbrink E, et al.
Lakartidningen 1996 Jul 24;93(30-31):2662-7 (29 ref.) **(Swe)**

EPIDEMIOLOGY

Does Lyme disease occur in the south?: a survey of emerging tick-borne infections in the region. Barbour AG.
Am J Med Sci 1996 Jan;311(1):34-40 (66 ref.)

PREVENTION & CONTROL

Appropriate strategies for the control or eradication of ticks and tick-borne diseases. Wilson A. **Ann N Y Acad Sci** 1996 Jul 23;791:54-63 (21 ref.)

TRANSMISSION

General framework for comparative quantitative studies on transmission of tick-borne diseases using Lyme borreliosis in Europe as an example. Randolph SE, et al.
J Med Entomol 1995 Nov;32(6):765-77 (70 ref.)

VETERINARY

Strategies to interrupt the development of Anaplasma marginale in its tick vector. The effect of bovine-derived antibodies. Kocan KM, et al. **Ann N Y Acad Sci** 1996 Jul 23;791:157-65 (57 ref.)

TICK CONTROL

[The tick--a disease carrier we have to learn to live with. "New" diseases require further research] Asbrink E, et al.
Lakartidningen 1996 Jul 24;93(30-31):2662-7 (29 ref.) **(Swe)**

METHODS

Appropriate strategies for the control or eradication of ticks and tick-borne diseases. Wilson A. **Ann N Y Acad Sci** 1996 Jul 23;791:54-63 (21 ref.)

TICK INFESTATIONS

IMMUNOLOGY

Host immunity to ticks. Wikel SK. **Annu Rev Entomol** 1996; 41:1-22 (127 ref.)

VETERINARY

Recent acquisitions on tick and tick-borne disease resistance in N'dama (Bos taurus) and Gobra zebu (Bos indicus) cattle. Mattioli RC, et al. **Parassitologia** 1995 Apr;37(1):63-7 (40 ref.)

TICKS

Progress and priorities in research on heartwater. Uilenberg G. **Ann N Y Acad Sci** 1996 Jul 23;791:1-16 (105 ref.)
Appropriate strategies for the control or eradication of ticks and tick-borne diseases. Wilson A. **Ann N Y Acad Sci** 1996 Jul 23;791:54-63 (21 ref.)
Evolution of ticks. Klompen JS, et al. **Annu Rev Entomol** 1996;41:141-61 (62 ref.)

TICKS

Recent acquisitions on tick and tick-borne disease resistance in N'dama (Bos taurus) and Gobra zebu (Bos indicus) cattle. Mattioli RC, et al. **Parassitologia** 1995 Apr;37(1):63–7 (40 ref.)

[The role of ticks in the epidemiology of Lyme borreliosis] Wegner Z, et al. **Przegl Epidemiol** 1995;49(3):245–50 (33 ref.) (Eng. Abstr.) **(Pol)**

[The tick—a disease carrier we have to learn to live with. "New" diseases require further research] Asbrink E, et al. **Lakartidningen** 1996 Jul 24;93(30–31):2662–7 (29 ref.) **(Swe)**

IMMUNOLOGY

Host immunity to ticks. Wikel SK. **Annu Rev Entomol** 1996; 41:1–22 (127 ref.)

MICROBIOLOGY

Strategies to interrupt the development of Anaplasma marginale in its tick vector. The effect of bovine-derived antibodies. Kocan KM, et al. **Ann N Y Acad Sci** 1996 Jul 23;791:157–65 (57 ref.)

PARASITOLOGY

[Ticks (Ixodidae) in zoonotic propagation of piroplasma Babesia micorti and Babesia divergens] Siński E, et al. **Wiad Parazytol** 1995;41(3):321–7 (13 ref.) (Eng. Abstr.) **(Pol)**

PHYSIOLOGY

Physiological age of ixodid ticks: aspects of its determination and application. Uspensky I. **J Med Entomol** 1995 Nov; 32(6):751–64 (97 ref.)

TICLOPIDINE

Ticlopidine. A review of its pharmacology, clinical efficacy and tolerability in the prevention of cerebral ischaemia and stroke. Noble S, et al. **Drugs Aging** 1996 Mar;8(3):214–32 (125 ref.)

ADVERSE EFFECTS

Severe aplastic anemia induced by ticlopidine: report of a case. Su CC, et al. **J Formos Med Assoc** 1995 Nov; 94(11):689–91 (8 ref.)

[Adverse hematologic effects of ticlopidine (letter)] Lesesve JF, et al. **Therapie** 1995 Sep–Oct;50(5):468–70 (11 ref.) **(Fre)**

THERAPEUTIC USE

[Ticlopidine in coronary artery diseases] Porter T, et al. **Harefuah** 1995 Nov 15;129(10):427–30 (26 ref.) **(Heb)**

TIETZE'S SYNDROME

[Reflexions on the Tietze syndrome. Clinical contribution] Pappalardo A, et al. **Clin Ter** 1995 Nov;146(11):675–82 (32 ref.) (Eng. Abstr.) **(Ita)**

TIGHT JUNCTIONS

PHYSIOLOGY

Tight junctions and the molecular basis for regulation of paracellular permeability. Anderson JM, et al. **Am J Physiol** 1995 Oct;269(4 Pt 1):G467–75 (63 ref.)

Regulation of tight-junction permeability during nutrient absorption across the intestinal epithelium. Ballard ST, et al. **Annu Rev Nutr** 1995;15:35–55 (105 ref.)

Zonula occludens (ZO)-1 and ZO-2: membrane-associated guanylate kinase homologues (MAGuKs) of the tight junction. Anderson JM, et al. **Biochem Soc Trans** 1995 Aug; 23(3):470–5 (45 ref.)

Tight junctions, membrane-associated guanylate kinases and cell signaling. Kim SK. **Curr Opin Cell Biol** 1995 Oct; 7(5):641–9 (71 ref.)

TILT-TABLE TEST

Can serial tilt testing be used to evaluate therapy in neurally mediated syncope? Morillo CA, et al. **Am J Cardiol** 1996 Mar 1;77(7):521–3 (34 ref.)

Tilt table testing for assessing syncope. American College of Cardiology. Benditt DG, et al. **J Am Coll Cardiol** 1996 Jul;28(1):263–75 (97 ref.)

INSTRUMENTATION

New diagnostic tests for the function of utricles, saccules and somatic graviceptors. Mittelstaedt H. **Acta Otolaryngol Suppl (Stockh)** 1995;520 Pt 1:188–93 (5 ref.)

METHODS

Evaluating unexplained syncope with upright tilt testing [see comments] Kapoor WN. **Cleve Clin J Med** 1995 Sep–Oct; 62(5):305–10 (33 ref.) Comment in: Cleve Clin J Med 1995 Sep–Oct;62(5):339–41.

TIME PERCEPTION

[Perspectives and time as relevant phenomena in the psychopathology of obsessive-compulsive neuroses] Kraus MR, et al. **Z Klin Psychol Psychopathol Psychother** 1995; 43(4):348–54 (33 ref.) (Eng. Abstr.) **(Ger)**

[Changes in sequence of time in schizophrenia—from 'severance' to 'collapse' in flux of time] Oae H. **Seishin Shinkeigaku Zasshi** 1995;97(6):405–21 (18 ref.) **(Jpn)**

PHYSIOLOGY

[The self-organization of the brain as the integration of the processes of different spatial and time scales] Kozhedub RG. **Usp Fiziol Nauk** 1995 Oct–Dec;26(4):28–47 (75 ref.) (Eng. Abstr.) **(Rus)**

TIMED-RELEASE PREPARATIONS see **DELAYED-ACTION PREPARATIONS**

TIMOLOL

PHARMACOLOGY

Topical beta-adrenergic antagonists and quinidine. A risky interaction [editorial] Higginbotham EJ. **Arch Ophthalmol** 1996 Jun;114(6):745–6 (7 ref.)

TINEA

Tinea of the skin, hair and nails. Wargon O. **Med J Aust** 1996 May 6;164(9):552–6 (23 ref.)

TINEA CAPITIS

DRUG THERAPY

Management of scalp ringworm. **Drug Ther Bull** 1996 Jan; 34(1):5–6 (15 ref.)

EPIDEMIOLOGY

Tinea capitis in adults. Gianni C, et al. **Mycoses** 1995 Jul–Aug;38(7–8):329–31 (16 ref.)

PARASITOLOGY

Tinea capitis caused by Trichophyton rubrum. Anstey A, et al. **Br J Dermatol** 1996 Jul;135(1):113–5 (25 ref.)

TINEA UNGUIUM see **ONYCHOMYCOSIS**

TINEA VERSICOLOR

Tinea versicolor. Silva-Lizama E. **Int J Dermatol** 1995 Sep; 34(9):611–7 (73 ref.)

DRUG THERAPY

Diagnosis and treatment of tinea versicolor. Savin R. **J Fam Pract** 1996 Aug;43(2):127–32 (25 ref.)

TINNITUS

[Tinnitus—etiology, diagnosis and treatment] Arnesen AR, et al. **Tidsskr Nor Laegeforen** 1996 Jun 30;116(17):2009–12 (13 ref.) (Eng. Abstr.) **(Nor)**

COMPLICATIONS

Cogan's syndrome: ophthalmic, audiovestibular, and systemic manifestations and therapy. Chynn EW, et al. **Int Ophthalmol Clin** 1996 Winter;36(1):61–72 (46 ref.)

DIAGNOSIS

Tinnitus and otoacoustic emissions. Ceranic BJ, et al. **Clin Otolaryngol** 1995 Jun;20(3):192–200 (89 ref.)

DRUG THERAPY

Misoprostol for tinnitus. Crinnion CL, et al. **Ann Pharmacother** 1995 Jul–Aug;29(7–8):782–4 (13 ref.)

REHABILITATION

Neurophysiological approach to tinnitus patients. Jastreboff PJ, et al. **Am J Otol** 1996 Mar;17(2):236–40 (38 ref.)

THERAPY

Approaches to tinnitus management. Ong TJ. **Scott Med J** 1994 Oct;39(5):131–4 (23 ref.)

TISSUE ADHESIVES

see related
BONE CEMENTS

[Adhesive substances in medicine—history, present status and perspectives] Puls M. **Cesk Fysiol** 1996 Mar;45(1):29–35 (42 ref.) (Eng. Abstr.) **(Cze)**

[Fibrin glue—an effective hemostatic-adhesive system] Balint B, et al. **Vojnosanit Pregl** 1995 Sep–Oct;52(5):477–82 (33 ref.) **(Ser)**

THERAPEUTIC USE

Fibrin sealant in surgery of patients with a hemorrhagic diathesis. Martinowitz U, et al. **Thromb Haemost** 1995 Jul; 74(1):486–92 (81 ref.)

Fibrin sealant in the United States: clinical use at the University of Virginia. Spotnitz WD. **Thromb Haemost** 1995 Jul;74(1):482–5 (54 ref.)

[Selective embolization with an adhesive fluid of complicated aneurysms of the hepatic artery: 3 cases] Cotroneo AR, et al. **Radiol Med (Torino)** 1996 Apr;91(4):492–6 (21 ref.) **(Ita)**

TISSUE BANKS

Bone allograft banking in South Australia. Campbell DG, et al. **Aust N Z J Surg** 1995 Dec;65(12):865–9 (43 ref.)

[Tissue banks] Aho AJ, et al. **Duodecim** 1995;111(7):599–605 (36 ref.) **(Fin)**

STANDARDS

Fetal tissue banking: standards and regulatory issues. Newman-Gage H. **J Hematother** 1996 Apr;5(2):189–93 (16 ref.)

UTILIZATION

[Utilization of bone marrow donor bank] Kodera Y. **Rinsho Byori** 1995 Jul;Suppl 99:66–73 (2 ref.) **(Jpn)**

TISSUE COMPATIBILITY see **HISTOCOMPATIBILITY**

TISSUE CULTURE

see related
CELL LINE
CELLS, CULTURED
CELLS, IMMOBILIZED
CLONE CELLS
TUMOR CELLS, CULTURED

The significance of cultivating cells and hemopoietic tissue from tunicates. Cooper EL, et al. **Adv Exp Med Biol** 1995; 371A:321–5 (21 ref.)

Acquisition and use of human in vitro liver preparations. Guillouzo A. **Cell Biol Toxicol** 1995 Aug;11(3–4):141–5 (17 ref.)

Culture and microsurgical manipulation of the early avian embryo. Selleck MA. **Methods Cell Biol** 1996;51:1–21 (55 ref.)

[Tissue engineering: artificial tissue replacement containing vital components] Sittinger M. **Laryngorhinootologie** 1995 Nov;74(11):695–9 (33 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Advances in PCR-based detection of mycoplasmas contaminating cell cultures. Rawadi G, et al. **PCR Methods Appl** 1995 Feb;4(4):199–208 (70 ref.)

TISSUE DISTRIBUTION

PHYSIOLOGY

Prediction of in vivo drug disposition from in vitro data based on physiological pharmacokinetics. Iwatsubo T, et al. **Biopharm Drug Dispos** 1996 May;17(4):273–310 (123 ref.)

TISSUE DONORS

Renal failure in a living-related kidney donor: case report and review of the literature. Said R, et al. **Am J Nephrol** 1996;16(4):334–8 (30 ref.)

Who are the donors in organ donation? The family's perspective in mandated choice. Klassen AC, et al. **Ann Intern Med** 1996 Jul 1;125(1):70–3 (14 ref.)

Multiple bone marrow infusions to enhance acceptance of allografts from the same donor. Ricordi C, et al. **Ann N Y Acad Sci** 1995 Dec 29;770:345–50 (23 ref.)

Bone allograft banking in South Australia. Campbell DG, et al. **Aust N Z J Surg** 1995 Dec;65(12):865–9 (43 ref.)

Bone marrow transplantation for chronic myeloid leukemia with volunteer unrelated donors using ex vivo or in vivo T-cell depletion: major prognostic impact of HLA class I identity between donor and recipient. Spencer A, et al. **Blood** 1995 Nov 1;86(9):3590–7 (40 ref.)

Marrow transplantation from unrelated volunteer donors. Anasetti C, et al. **Cancer Treat Res** 1995;76:137–68 (45 ref.)

Bone marrow transplantation from volunteer unrelated donors. Goulden NJ, et al. **Cancer Treat Rev** 1995 Jul; 21(4):325–53 (143 ref.)

Infectious disease transmission through cell, tissue, and organ transplantation: reducing the risk through donor selection. Eastlund T. **Cell Transplant** 1995 Sep–Oct;4(5):455–77 (223 ref.)

Nonheart-beating donors: the Maastricht experience. Daemen JW, et al. **Clin Transpl** 1994;:303–16 (59 ref.)

Transplantation of corneal tissue from donors with diseases of the central nervous system [see comments] Hogan RN, et al. **Cornea** 1995 Nov;14(6):547–53 (67 ref.) Comment in: Cornea 1995 Nov;14(6):545–6.

Clinical approaches to increasing uterine receptivity during human implantation. Edwards RG. **Hum Reprod** 1995 Dec; 10 Suppl 2:60–6 (26 ref.)

Should donors have the right to decide who receives their gametes? Pennings G. **Hum Reprod** 1995 Oct; 10(10):2736–40 (24 ref.)

Outcome following organ removal from poisoned donors in brain death status: a report of 12 cases and review of the literature. Hantson P, et al. **J Toxicol Clin Toxicol** 1995; 33(6):709–12 (8 ref.)
The clinical and ethical implications of hepatitis C for organ transplantation in Australia. Kerridge IH, et al. **Med J Aust** 1996 Sep 2;165(5):282–5 (49 ref.)
The generation of transgenic pigs as potential organ donors for humans. Cozzi E, et al. **Nat Med** 1995 Sep;1(9):964–6 (30 ref.)
Hypertension and the kidney: new insights from results of renal transplantation studies. Rettig R, et al. **Nephrol Dial Transplant** 1995 Oct;10 Suppl 9:9–16 (45 ref.)
Nutritional and metabolic considerations of the adult liver transplant candidate and organ donor. Driscoll DF, et al. **Nutrition** 1995 May–Jun;11(3):255–63 (85 ref.)
Hepatitis C infection in cadaver organ donors: strategies to reduce transmission of infection and prevent organ waste. Pereira BJ, et al. **Pediatr Nephrol** 1995;9 Suppl:S23–8 (41 ref.)
Testing tissue donors [editorial] Lumley SP, et al. **Transfus Med** 1995 Sep;5(3):167–70 (17 ref.)
Multiple organ harvesting: evolution of surgical technique—personal experience. Alfani D, et al. **Transplant Proc** 1996 Feb;28(1):152–4 (20 ref.)
Overview of imaging in living related donor hepatic transplantation. Cheng YF, et al. **Transplant Proc** 1996 Aug; 28(4):2412–4 (19 ref.)
Strategies for tolerance induction: potential applications in living donor liver transplantation. Emond JC, et al. **Transplant Proc** 1996 Aug;28(4):2371–4 (25 ref.)
Current progress in chimerism and donor-specific tolerance. Jankowski RA, et al. **Transplant Proc** 1996 Aug; 28(4):2071–4 (39 ref.)
Anesthesia for living related donor liver transplantation. Jawan B, et al. **Transplant Proc** 1996 Aug;28(4):2409–11 (39 ref.)
Ethical issues in living related donor liver transplantation. Strong RW, et al. **Transplant Proc** 1996 Aug;28(4):2366–9 (21 ref.)
Current ethical issues in organ transplantation. McGeown MG. **Ulster Med J** 1994 Apr;63(1):32–43 (21 ref.)
[Use of related live donors in renal transplantation] Broyer M. **Presse Med** 1996 Jun 1;25(19):891–9 (32 ref.) (Eng. Abstr.) **(Fre)**
[Cadaver donor nephrectomy. Surgical technique in the context of multi-organ donation] Benoit G, et al. **Prog Urol** 1996 Feb;6(1):114–22 (48 ref.) (Eng. Abstr.) **(Fre)**
[Liver transplantation: results with living donors] Gertsch P. **Ther Umsch** 1995 Sep;52(9):585–9 (23 ref.) (Eng. Abstr.) **(Fre)**
[Tests for donors of blood and bone marrow] Taniwaki K, et al. **Rinsho Byori** 1995 Jul;Suppl 99:102–10 (10 ref.) **(Jpn)**
[Answers to human organ procurement: donations, research, and prevention] Garrafa V. **Rev Assoc Med Bras** 1995 Jan–Feb;41(1):67–76 (59 ref.) **(Por)**

CLASSIFICATION

[Problems with donor–recipient matching in kidney and bone marrow transplantation] Nowakowska B. **Postepy Hig Med Dosw** 1995;49(1):107–15 (11 ref.) (Eng. Abstr.) **(Pol)**

LEGISLATION & JURISPRUDENCE

Ethical and policy issues in human fetal tissue transplants. Vawter DE, et al. **Cell Transplant** 1995 Sep–Oct; 4(5):479–82 (4 ref.)
Ethical and legal issues in human embryo donation [see comments] Robertson JA. **Fertil Steril** 1995 Nov; 64(5):885–94 (25 ref.) Comment in: Fertil Steril 1996 Jun;65(6):1262–3.
Organ donation consanguinity or universality. Kishore RR. **Med Law** 1996;15(1):93–104 (15 ref.)
[General aspects of organ donation] Gubernatis G, et al. **Chirurg** 1996 Apr;67(4):300–9 (30 ref.) (Eng. Abstr.) **(Ger)**
[Legal aspects of neurotransplantation] Wolfslast G. **Zentralbl Neurochir** 1995;56(4):210–4 (35 ref.) (Eng. Abstr.) **(Ger)**

STATISTICS & NUMERICAL DATA

The factors influencing organ donation: a review of the research. Gibson V. **J Adv Nurs** 1996 Feb;23(2):353–6 (26 ref.)

SUPPLY & DISTRIBUTION

Presumed consent: the solution to the critical organ donor shortage? Futterman LG. **Am J Crit Care** 1995 Sep; 4(5):383–8 (78 ref.)
Kidney transplantation from asystolic donors. Nicholson M. **Br J Hosp Med** 1996 Jan 17–Feb 6;55(1–2):51–6 (19 ref.)
Expanding the donor pool: use of marginal donors for solid organ transplantation. Alexander JW, et al. **Clin Transplant** 1996 Feb;10(1 Pt 1):1–19 (113 ref.)
Xenotransplantation: a possible solution to the shortage of donor organs. Bach FH, et al. **Transplant Proc** 1996 Feb; 28(1):416–7 (9 ref.)

TISSUE EMBEDDING

Colloidal gold post-embedding immunocytochemistry. Bendayan M. **Prog Histochem Cytochem** 1995;29(4):1–159 (465 ref.)

TISSUE EXPANDERS

Use of tissue expanders for wound closure of spinal infections or dehiscence. Paonessa KJ, et al. **Orthop Clin North Am** 1996 Jan;27(1):155–70 (32 ref.)

TISSUE EXPANSION

Tissue expanders in syndactyly: a brief review. d'Arcangelo M, et al. **Acta Chir Plast** 1996;38(1):11–3 (18 ref.)

METHODS

Palatal mucoperiosteal expansion as an adjunct to palatal fistula repair: case report and review of the literature. Van Damme PA, et al. **Cleft Palate Craniofac J** 1996 May; 33(3):255–7 (10 ref.)

TISSUE FACTOR see **THROMBOPLASTIN**

TISSUE FIXATION

METHODS

Handling of large brain specimens: the use of microwaves. A review. Marani E, et al. **Eur J Morphol** 1995 Apr; 33(2):158–64 (33 ref.)

TISSUE PRESERVATION

METHODS

Use of cryopreserved bone marrow in unrelated allogeneic transplantation. Stockschläder M, et al. **Bone Marrow Transplant** 1996 Feb;17(2):197–9 (18 ref.)
[Tissue banks] Aho AJ, et al. **Duodecim** 1995;111(7):599–605 (36 ref.) **(Fin)**
[Preservation of hematopoietic stem cells] Nakamura H, et al. **Rinsho Byori** 1995 Jul;Suppl 99:44–53 (14 ref.) **(Jpn)**

TISSUE PROCUREMENT see **ORGAN PROCUREMENT**

TISSUE STAINS see **DYES**

TISSUE THROMBOPLASTIN see **THROMBOPLASTIN**

TISSUE TRANSPLANTATION

see related
TISSUE DONORS
TISSUE PRESERVATION
TRANSPLANTATION IMMUNOLOGY

Experience with augmentation cystoplasty. A review. Mast P, et al. **Paraplegia** 1995 Oct;33(10):560–4 (25 ref.)

PATHOLOGY

[Tissue engineering: artificial tissue replacement containing vital components] Sittinger M. **Laryngorhinootologie** 1995 Nov;74(11):695–9 (33 ref.) (Eng. Abstr.) **(Ger)**

STANDARDS

Infectious disease transmission through cell, tissue, and organ transplantation: reducing the risk through donor selection. Eastlund T. **Cell Transplant** 1995 Sep–Oct;4(5):455–77 (223 ref.)

TRENDS

[Homologous transplantation of a limb (compound tissue): perspective for the future] Ferreira LM, et al. **Rev Assoc Med Bras** 1995 Mar–Apr;41(2):151–7 (73 ref.) **(Por)**

TISSUE-TYPE PLASMINOGEN ACTIVATOR see **ALTEPLASE**

TISSUE TYPING see **HISTOCOMPATIBILITY TESTING**

TITANIUM

Dental implants and dental CT software programs. Abrahams JJ, et al. **Semin Ultrasound CT MR** 1995 Dec;16(6):468–86 (21 ref.)
[15 years experience with the Ti-6Al-7Nb alloy for joint prostheses] Semlitsch M, et al. **Biomed Tech (Berl)** 1995 Dec;40(12):347–55 (38 ref.) (Eng. Abstr.) **(Ger)**

TITRATION see **TITRIMETRY**

TITRIMETRY

METHODS

[Improving on the Japanese pharmacopeia—on assays and determinations] Ishibashi M. **Eisei Shikenjo Hokoku** 1995; (113):137–9 (4 ref.) (Eng. Abstr.) **(Jpn)**

TLV see **MAXIMUM PERMISSIBLE EXPOSURE LEVEL**

TMJ SYNDROME see **TEMPOROMANDIBULAR JOINT SYNDROME**

TN ELEMENTS see **DNA INSERTION ELEMENTS**

TNF-ALPHA see **TUMOR NECROSIS FACTOR**

TNF-BETA see **LYMPHOTOXIN**

TNF RECEPTORS see **RECEPTORS, TUMOR NECROSIS FACTOR**

TOAD, FIRE-BELLIED see **ANURA**

TOADS AND FROGS see **ANURA**

TOADS, TRUE see **BUFONIDAE**

TOBACCO

see related
NICOTINE
SMOKING
TOBACCO USE DISORDER

Tobacco control. Chapman S. **BMJ** 1996 Jul 13; 313(7049):97–100 (43 ref.)
Forty years on: a war to recognise and win. How the tobacco industry has survived the revelations on smoking and health. Pollock D. **Br Med Bull** 1996 Jan;52(1):174–82 (25 ref.)
Tobacco industry tactics. Sweda EL Jr, et al. **Br Med Bull** 1996 Jan;52(1):183–92 (23 ref.)
Product modification. Waller RE, et al. **Br Med Bull** 1996 Jan;52(1):193–205 (38 ref.)
Oral white lesions with special reference to precancerous and tobacco- related lesions: conclusions of an international symposium held in Uppsala, Sweden, May 18–21 1994. International Collaborative Group on Oral White Lesions. Axéll T, et al. **J Oral Pathol Med** 1996 Feb;25(2):49–54 (3 ref.)
The role of UK tobacco advertising: no effect on the nation's health? Kinman BF, et al. **J R Soc Health** 1995 Oct; 115(5):296–302 (27 ref.)

CHEMISTRY

Synthesis of tobacco-specific N-nitrosamines and their metabolites and results of related bioassays. Amin S, et al. **Crit Rev Toxicol** 1996;26(2):139–47 (32 ref.)
Formation and analysis of tobacco-specific N-nitrosamines. Brunnemann KD, et al. **Crit Rev Toxicol** 1996;26(2):121–37 (43 ref.)
Recombinant aequorin methods for intracellular calcium measurement in plants. Knight H, et al. **Methods Cell Biol** 1995;49:201–16 (29 ref.)

GENETICS

Bioproduction of human enzymes in transgenic tobacco. Cramer CL, et al. **Ann N Y Acad Sci** 1996 May 25; 792:62–71 (50 ref.)
Co-suppression of beta-1,3-glucanase genes in Nicotiana tabacum. de Carvalho Niebel F, et al. **Curr Top Microbiol Immunol** 1995;197:91–103 (39 ref.)
trans-inactivation of homologous sequences in Nicotiana tabacum. Matzke AJ, et al. **Curr Top Microbiol Immunol** 1995;197:1–14 (30 ref.)
Leaf disk transformation using Agrobacterium tumefaciens-expression of heterologous genes in tobacco. Gallois P, et al. **Methods Mol Biol** 1995;49:39–48 (32 ref.)

TOBACCO DEPENDENCE see **TOBACCO USE DISORDER**

TOBACCO HORNWORM see **MANDUCA**

TOBACCO MOSAIC VIRUS

[Tobacco shining mosaic virus] Watanabe Y. **Tanpakushitsu Kakusan Koso** 1996 May;41(6):786–92 (9 ref.) **(Jpn)**

TOBACCO SMOKE POLLUTION

Hemodynamic and vascular effects of active and passive smoking. Zhu BQ, et al. **Am Heart J** 1995 Dec; 130(6):1270–5 (80 ref.)

ADVERSE EFFECTS

Passive smoking and lung cancer. Reynolds P, et al. **Ann Med** 1995 Dec;27(6):633–40 (50 ref.)
Passive smoking and cardiovascular risk. Kritz H, et al. **Arch Intern Med** 1995 Oct 9;155(18):1942–8 (53 ref.)
Environmental tobacco smoke. Law MR, et al. **Br Med Bull** 1996 Jan;52(1):22–34 (66 ref.)
The fetus as a passive smoker. Koren G. **Can Fam Physician** 1996 Jul;42:1301–3 (15 ref.)
Passive and active smoking. A problem for adults [editorial; comment] Glantz SA, et al. **Circulation** 1996 Aug 15; 94(4):596–8 (38 ref.) Comment on: Circulation 1996 Aug 15;94(4):614–21. Comment on: Circulation 1996 Aug

15;94(4):622–8.
Empirical and biologically based models for cancer risk assessment. Zielinski JM, et al. **Drug Metab Rev** 1996 Feb–May;28(1–2):53–75 (29 ref.)
Molecular toxicology endpoints in rodent inhalation studies. Brown BG, et al. **Exp Toxicol Pathol** 1995 May; 47(2–3):183–91 (29 ref.)
Passive smoking. Lejeune HB, et al. **J La State Med Soc** 1995 Oct;147(10):444–7 (17 ref.)
Cigarette smoking and health of the heart. Leone A. **J R Soc Health** 1995 Dec;115(6):354–5 (13 ref.)
Secondary tobacco smoke and preventive and protective measures. Hicks JN. **Laryngoscope** 1995 Dec;105(12 Pt 1):1287–9 (17 ref.)
Diet as a confounder of the association between air pollution and female lung cancer: Hong Kong studies on exposures to environmental tobacco smoke, incense, and cooking fumes as examples. Koo LC, et al. **Lung Cancer** 1996 Mar; 14 Suppl 1:S47–61 (21 ref.)
Involuntary smoking and the health of children. Samet JM. **Md Med J** 1995 Oct;44(10):774–8 (24 ref.)
Children's passive and prenatal exposure to cigarette smoke. Byrd RS, et al. **Pediatr Ann** 1995 Dec;24(12):640–2, 644–5 (37 ref.)
[Effect of smoking on the fetus and the child during pregnancy] Gueguen C, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(8):853–9 (63 ref.) (Eng. Abstr.) **(Fre)**
[Health damages from passive smoking] Sanner T, et al. **Tidsskr Nor Laegeforen** 1996 Feb 20;116(5):617–20 (23 ref.) (Eng. Abstr.) **(Nor)**

LEGISLATION & JURISPRUDENCE

Maryland restricts workplace smoking. Patrick E. **Md Med J** 1995 Oct;44(10):800–4 (32 ref.)

PREVENTION & CONTROL

Secondary tobacco smoke and preventive and protective measures. Hicks JN. **Laryngoscope** 1995 Dec;105(12 Pt 1):1287–9 (17 ref.)
Maryland restricts workplace smoking. Patrick E. **Md Med J** 1995 Oct;44(10):800–4 (32 ref.)

TOBACCO, SMOKELESS

Smokeless tobacco: epidemiology, health effects and cessation strategies [see comments] Spangler JG, et al. **Am Fam Physician** 1995 Oct;52(5):1421–30, 1433–4 (36 ref.) Comment in: Am Fam Physician 1995 Oct;52(5):1271–2, 1274.
Tobacco use and cancer. A reappraisal. Vigneswaran N, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1995 Aug;80(2):178–82 (62 ref.)

ADVERSE EFFECTS

Epidemiology of cancer by tobacco products and the significance of TSNA. Gupta PC, et al. **Crit Rev Toxicol** 1996;26(2):183–98 (81 ref.)
[Health hazards when using snuff] Steen T. **Tidsskr Nor Laegeforen** 1996 Feb 20;116(5):625–7 (41 ref.) (Eng. Abstr.) **(Nor)**

TOBACCO USE DISORDER

see related
SMOKING CESSATION

Smokeless tobacco: epidemiology, health effects and cessation strategies [see comments] Spangler JG, et al. **Am Fam Physician** 1995 Oct;52(5):1421–30, 1433–4 (36 ref.) Comment in: Am Fam Physician 1995 Oct;52(5):1271–2, 1274.
Common addictions. Geller A. **Clin Symp** 1996;48(1):2–32 (32 ref.)

PSYCHOLOGY

Marketing adolescent tobacco addiction. Tye J, et al. **Md Med J** 1995 Oct;44(10):767–73 (29 ref.)

TOBRAMYCIN

THERAPEUTIC USE

The place of tobramycin in lower respiratory tract infections (LRTI). Gialdroni Grassi G. **J Chemother** 1995 Aug; 7(4):344–54 (80 ref.)

TOCODYNAMOMETRY see **UTERINE MONITORING**

TOCOGRAPHY see **UTERINE MONITORING**

TOCOLYSIS

Prevention of preterm birth. Owen P, et al. **Baillieres Clin Obstet Gynaecol** 1995 Sep;9(3):465–79 (96 ref.)

ADVERSE EFFECTS

Acute pseudo-obstruction of the colon (Ogilvie's syndrome) resulting from combination tocolytic therapy. Pecha RE, et al. **Am J Gastroenterol** 1996 Jun;91(6):1265–6 (13 ref.)
Risks and complications of tocolysis. Hill WC. **Clin Obstet Gynecol** 1995 Dec;38(4):725–45 (133 ref.)

METHODS

[Therapy of threatened premature labor] Spätling L. **Arch Gynecol Obstet** 1995;257(1–4):458–62 (13 ref.) **(Ger)**

TOCOLYTIC AGENTS

Advances in the design of selective antagonists, potential tocolytics, and radioiodinated ligands for oxytocin receptors. Manning M, et al. **Adv Exp Med Biol** 1995; 395:559–83 (111 ref.)

ADVERSE EFFECTS

Risks and complications of tocolysis. Hill WC. **Clin Obstet Gynecol** 1995 Dec;38(4):725–45 (133 ref.)

THERAPEUTIC USE

Potential use of oxytocin and vasopressin V1a antagonists in the treatment of preterm labour and primary dysmenorrhoea. Akerlund M, et al. **Adv Exp Med Biol** 1995; 395:595–600 (32 ref.)
Progress in the development of oxytocin antagonists for use in preterm labor. Pettibone DJ, et al. **Adv Exp Med Biol** 1995;395:601–12 (49 ref.)
Beta-adrenergic agonists. Boyle JG. **Clin Obstet Gynecol** 1995 Dec;38(4):688–96 (36 ref.)
Indomethacin. Gordon MC, et al. **Clin Obstet Gynecol** 1995 Dec;38(4):697–705 (23 ref.)
Magnesium sulfate. Gordon MC, et al. **Clin Obstet Gynecol** 1995 Dec;38(4):706–12 (25 ref.)
Calcium channel blockers. Ray D, et al. **Clin Obstet Gynecol** 1995 Dec;38(4):713–21 (40 ref.)
Atosiban. Shubert PJ. **Clin Obstet Gynecol** 1995 Dec; 38(4):722–4 (12 ref.)
Delayed interval delivery after intrauterine infection and immature birth of twin 1—a case report and literature review. de Jong MW, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Nov;63(1):91–4 (29 ref.)
[Tocolytic drugs] Thoulon JM. **Contracept Fertil Sex** 1996 Feb;24(2):111–6 (30 ref.) **(Fre)**
[Drug treatment of threatened premature labor] Savey L, et al. **Rev Fr Gynecol Obstet** 1995 May–Jun; 90(5–6):297–301 (20 ref.) (Eng. Abstr.) **(Fre)**

TOCOLYTIC THERAPY see **TOCOLYSIS**

TOCOPHEROL see **VITAMIN E**

TOES

Clawtoe deformity following vascularized fibula graft. Bohay DR, et al. **Foot Ankle Int** 1995 Oct;16(10):607–9 (10 ref.)

ABNORMALITIES

[Epilepsy and psychomotor retardation in a child with aplasia cutis and brachydactyly (Adams–Oliver syndrome)] Verdú Pérez A, et al. **An Esp Pediatr** 1996 Mar;44(3):289–91 (15 ref.) **(Spa)**

PATHOLOGY

Wegener's granulomatosis with gangrene of toes. Handa R, et al. **Scand J Rheumatol** 1996;25(2):103–4 (6 ref.)

TRANSPLANTATION

The role of microsurgery and free tissue transfer in the reconstruction of the paediatric upper extremity. Kay S, et al. **Ann Acad Med Singapore** 1995 Jul;24(4 Suppl):113–23 (50 ref.)
Toe-to-hand transfer. Current concepts, techniques, and research. Wei FC, et al. **Clin Plast Surg** 1996 Jan; 23(1):103–16 (64 ref.)
Plea to save the great toe in total thumb reconstruction. Foucher G, et al. **Microsurgery** 1995;16(6):373–6 (23 ref.)

TOKEN ECONOMY

Use of a token economy with seriously mentally ill patients: criticisms and misconceptions. Corrigan PW. **Psychiatr Serv** 1995 Dec;46(12):1258–63 (52 ref.)

TOKEN REINFORCEMENT see **TOKEN ECONOMY**

TOLMETIN

ANALOGS & DERIVATIVES

The analgesic efficacy of ketorolac for acute pain. Catapano MS. **J Emerg Med** 1996 Jan–Feb;14(1):67–75 (101 ref.)

TOLOSA–HUNT SYNDROME see **OPHTHALMOPLEGIA**

TOLUENE

ADVERSE EFFECTS

Recurrent non-Q-wave myocardial infarction associated with toluene abuse. Hussain TF, et al. **Am Heart J** 1996 Mar;131(3):615–6 (6 ref.)
Auditory and vestibular functions after single or combined exposure to toluene: a review. Morata TC, et al. **Arch Toxicol** 1995;69(7):431–43 (106 ref.)
[Chemical hepatitis (halothane, toluene)] Shiomi S, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):49–51 (17 ref.) **(Jpn)**

METABOLISM

Physiological attributes of microbial BTEX degradation in oxygen-limited environments. Olsen RH, et al. **Environ Health Perspect** 1995 Jun;103 Suppl 5:49–51 (7 ref.)

TOMATOES

GENETICS

Sense and antisense inactivation of fruit ripening genes in tomato. Hamilton AJ, et al. **Curr Top Microbiol Immunol** 1995;197:77–89 (70 ref.)
Cf9 and Avr9, two major players in the gene–for–gene game. de Wit PJ. **Trends Microbiol** 1995 Jul;3(7):251–2 (15 ref.)

TOMODENSITOMETRY see **TOMOGRAPHY, X-RAY COMPUTED**

TOMOGRAPHY

METHODS

[Ultrasonic tomography in the diagnosis of pararectal metastases of rectal cancers] Tsyb AF, et al. **Vopr Onkol** 1996;42(2):95–100 (47 ref.) **(Rus)**

STATISTICS & NUMERICAL DATA

Data processing techniques for serial EIT spectroscopy images: a review of some preliminary results. Smallwood RH, et al. **Physiol Meas** 1995 Aug;16(3 Suppl A):A129–42 (37 ref.)

TOMOGRAPHY, COMPUTED, SCANNERS see **TOMOGRAPHY SCANNERS, X-RAY COMPUTED**

TOMOGRAPHY, EMISSION-COMPUTED

Fluorodopa PET scanning in Parkinson's disease. Snow BJ. **Adv Neurol** 1996;69:449–57 (73 ref.)
FDG uptake within regionally stunned myocardium. McFalls EO, et al. **Am J Card Imaging** 1995 Oct;9(4):269–74 (30 ref.)
Human rehearsal processes and the frontal lobes: PET evidence. Awh E, et al. **Ann N Y Acad Sci** 1995 Dec 15; 769:97–117 (37 ref.)
Functional imaging patterns in Alzheimer's disease. Relationships to neurobiology. Jagust WJ. **Ann N Y Acad Sci** 1996 Jan 17;777:30–6 (20 ref.)
Clinical and neuroimaging features of familial Alzheimer's disease. Rossor MN, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:49–56 (18 ref.)
Imaging pain in humans. Berman J. **Br J Anaesth** 1995 Aug; 75(2):209–16 (40 ref.)
Noun and verb retrieval by normal subjects. Studies with PET. Warburton E, et al. **Brain** 1996 Feb;119 (Pt 1):159–79 (85 ref.)
The use of PET in Parkinson's disease. Shinotoh H, et al. **Brain Cogn** 1995 Aug;28(3):297–310 (67 ref.)
Positron emission tomography studies of abnormal glucose metabolism in schizophrenic illness. Buchsbaum MS. **Clin Neurosci** 1995;3(2):122–30 (77 ref.)
Utilization of radioligands in schizophrenia research. Sedvall G, et al. **Clin Neurosci** 1995;3(2):112–21 (47 ref.)
Positron emission tomography: a new investigational area for cancer research. Wells P, et al. **Clin Oncol (R Coll Radiol)** 1996;8(1):7–14 (48 ref.)
The current status of clinical PET imaging. Cook GJ, et al. **Clin Radiol** 1996 Sep;51(9):603–13 (108 ref.)
Does positron emission tomography contribute to the management of clinical cardiac problems? Camici PG, et al. **Eur Heart J** 1996 Feb;17(2):174–81 (70 ref.)
The impact of myocardial blood flow quantitation with PET on the understanding of cardiac diseases. Camici PG, et al. **Eur Heart J** 1996 Jan;17(1):25–34 (95 ref.)
Can positron emission tomography (PET) be used to detect subclinical response to cancer therapy? The EC PET Oncology Concerted Action and the EORTC PET Study Group. Price P, et al. **Eur J Cancer** 1995 Nov; 31A(12):1924–7 (14 ref.)
Radioligands for brain 5–HT2 receptor imaging in vivo: why do we need them? [editorial] Busatto GF. **Eur J Nucl Med** 1996 Aug;23(8):867–70 (36 ref.)
The imaging science of positron emission tomography. Jones T. **Eur J Nucl Med** 1996 Jul;23(7):807–13 (26 ref.)
Pulmonary studies using positron emission tomography. Rhodes CG, et al. **Eur Respir J** 1995 Jun;8(6):1001–17 (80

ref.)
PET studies of the striatal dopaminergic system in Parkinson's disease (PD). Piccini P, et al. **J Neural Transm Suppl** 1995;45:123–31 (57 ref.)
Distinctive serial magnetic resonance changes in a young woman with rapidly evolved neurocysticercosis, with positron emission tomography results. Nagayama M, et al. **J Neuroimaging** 1996 Jul;6(3):198–201 (15 ref.)
The study of the brain using PET and SPECT: implications for space and underwater neurology. Newberg AB, et al. **J Neurol Sci** 1996 Mar;136(1–2):1–9 (84 ref.)
Fluorine-18-fluorodeoxyglucose PET to determine regional cerebral glucose utilization: a re-examination. Schmidt KC, et al. **J Nucl Med** 1996 Feb;37(2):394–9 (42 ref.)
Clinical applications: MRI, SPECT, and PET. Spencer SS, et al. **Magn Reson Imaging** 1995;13(8):1119–24 (34 ref.)
Hemiatrophy, juvenile-onset exertional alternating leg paresis, hypotonia, and hemidystonia and adult-onset hemiparkinsonism: the spectrum of hemiparkinsonism-hemiatrophy syndrome. Lang AE. **Mov Disord** 1995 Jul;10(4):489–95 (32 ref.)
Use of positron emission tomography for the evaluation of epilepsy. DeCarli C, et al. **Neuroimaging Clin N Am** 1995 Nov;5(4):623–45 (134 ref.)
Localized and lateralized cerebral glucose metabolism associated with eye movements during REM sleep and wakefulness: a positron emission tomography (PET) study. Hong CC, et al. **Sleep** 1995 Sep;18(7):570–80 (71 ref.)
[Positron-emission tomography: role of 18F-fluorodeoxyglucose (18FDG) imaging in oncology] Lagrange JL, et al. **Bull Cancer (Paris)** 1995 Aug; 82(8):611–22 (118 ref.) (Eng. Abstr.) **(Fre)**
[Positron-emission tomography in akinetic rigidity syndrome] Goldman S. **Rev Med Brux** 1995 Dec; 16(6):399–403 (35 ref.) (Eng. Abstr.) **(Fre)**
[Study of functional neuro-anatomy of perception using positron emission tomography] Baron JC. **Rev Neurol (Paris)** 1995 Aug–Sep;151(8–9):511–7 (58 ref.) (Eng. Abstr.) **(Fre)**
[Contribution of position emission tomography in a case of Marchiafava Bignami disease: Morel's laminar sclerosis?] Logak M, et al. **Rev Neurol (Paris)** 1996 Jan;152(1):47–50 (10 ref.) (Eng. Abstr.) **(Fre)**
[Nuclear cardiology: techniques of metabolic evaluation] Parodi O, et al. **G Ital Cardiol** 1995 Dec;25(12):1675–8 (10 ref.) **(Ita)**
[Cancer diagnosis with positron emission tomography (PET)] Kubota K. **Kaku Igaku** 1996 Feb;33(2):207–12 (22 ref.) (Eng. Abstr.) **(Jpn)**
[Nuclear medicine for evaluation of brain function] Yonekura Y. **Kaku Igaku** 1995 Dec;32(12):1375–9 (16 ref.) (Eng. Abstr.) **(Jpn)**
[Positron-emission tomographic studies of the brain in parkinsonism patients] Berezhkova LV. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995;95(6):93–7 (43 ref.) **(Rus)**
[Neuroimaging techniques in the Gilles de la Tourette syndrome] Lampreave JL, et al. **Rev Neurol** 1996 Aug; 24(132):921–5 (39 ref.) (Eng. Abstr.) **(Spa)**

INSTRUMENTATION

Specifying dual-detector gamma cameras and associated computer systems. Tindale WB. **Nucl Med Commun** 1995 Jul;16(7):534–8 (4 ref.)

METHODS

Diagnosis of coronary artery disease in women: roles of three dimensional imaging with magnetic resonance or positron emission tomography. Patterson RE, et al. **Am J Card Imaging** 1996 Jan;10(1):78–88 (86 ref.)
A conceptual overview and critique of functional neuroimaging techniques in humans: I. MRI/FMRI and PET. Aine CJ. **Crit Rev Neurobiol** 1995;9(2–3):229–309 (312 ref.)
Neurochemical imaging of the brain in health and disease. Biegon A. **Isr J Med Sci** 1996 May;32(5):271–5 (34 ref.)

STATISTICS & NUMERICAL DATA

Nonparametric analysis of statistic images from functional mapping experiments. Holmes AP, et al. **J Cereb Blood Flow Metab** 1996 Jan;16(1):7–22 (26 ref.)

TRENDS

Imaging and staging of small-cell lung cancer: is there a future role for octreotide scintigraphy? Stokkel MP, et al. **Br J Clin Pract** 1995 Sep–Oct;49(5):235–8 (41 ref.)
Positron emission tomography: present and future. Heiss WD. **Technol Health Care** 1996 Apr;4(1):15–29 (60 ref.)

TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON

Functional imaging patterns in Alzheimer's disease. Relationships to neurobiology. Jagust WJ. **Ann N Y Acad Sci** 1996 Jan 17;777:30–6 (20 ref.)
Preliminary experience with thallous chloride T1 201-labeled single-photon emission computed tomography scanning in head and neck cancer. Gregor RT, et al. **Arch Otolaryngol Head Neck Surg** 1996 May;122(5):509–14 (25 ref.)
Imaging pain in humans. Berman J. **Br J Anaesth** 1995 Aug; 75(2):209–16 (40 ref.)
Radioligands for brain 5-HT2 receptor imaging in vivo: why do we need them? [editorial] Busatto GF. **Eur J Nucl Med** 1996 Aug;23(8):867–70 (36 ref.)
Brain SPECT imaging of neuropsychiatric disorders. Krausz Y, et al. **Eur J Radiol** 1996 Feb;21(3):183–7 (39 ref.)
The study of the brain using PET and SPECT: implications for space and underwater neurology. Newberg AB, et al. **J Neurol Sci** 1996 Mar;136(1–2):1–9 (84 ref.)
Clinical applications: MRI, SPECT, and PET. Spencer SS, et al. **Magn Reson Imaging** 1995;13(8):1119–24 (34 ref.)
Single photon emission computed tomography. Mullan BP, et al. **Neuroimaging Clin N Am** 1995 Nov;5(4):647–73 (154 ref.)
Assessment of brain SPECT. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. **Neurology** 1996 Jan;46(1):278–85 (27 ref.)
Behavioral and neuroimaging studies on schizophrenia in Japan. Shimazono Y, et al. **Psychiatry Clin Neurosci** 1995 Mar;49(1):3–11 (72 ref.)
[Neurological applications of single photon emission tomoscintigraphy] Stievenart JL, et al. **Rev Neurol (Paris)** 1995 Nov;151(11):619–33 (139 ref.) (Eng. Abstr.) **(Fre)**
[Frontal type dementia and amyotrophic lateral sclerosis. 3 cases with (HmPAO Tc99m) single-photon emission tomography study] Vercelletto M, et al. **Rev Neurol (Paris)** 1995 Nov;151(11):640–7 (43 ref.) (Eng. Abstr.) **(Fre)**
[Stress echocardiography versus myocardial scintigraphy: comparative value in coronary heart disease] Silber S. **Herz** 1996 Apr;21(2):136–41 (68 ref.) **(Ger)**
[Nuclear medicine for evaluation of brain function] Yonekura Y. **Kaku Igaku** 1995 Dec;32(12):1375–9 (16 ref.) (Eng. Abstr.) **(Jpn)**
[Neuroimaging techniques in the Gilles de la Tourette syndrome] Lampreave JL, et al. **Rev Neurol** 1996 Aug; 24(132):921–5 (39 ref.) (Eng. Abstr.) **(Spa)**
[Pictures of the psyche. Imaging the highest functions of the brain: consciousness, language, emotions, is now possible] Ingvar DH. **Lakartidningen** 1995 Dec 20;92(51–52):4885–9 (20 ref.) **(Swe)**
[SPECT. An important clinical method for brain function studies] Wikkelsø C, et al. **Lakartidningen** 1996 Jul 10; 93(28–29):2585–91 (78 ref.) **(Swe)**

METHODS

Review article: quantitative leucocyte scanning in the assessment of inflammatory bowel disease activity and its response to therapy. Weldon MJ, et al. **Aliment Pharmacol Ther** 1996 Apr;10(2):123–32 (70 ref.)
Neurochemical imaging of the brain in health and disease. Biegon A. **Isr J Med Sci** 1996 May;32(5):271–5 (34 ref.)
D2-receptor imaging with [123I]IBZM and single photon emission tomography in psychiatry: a survey of current status. Schlösser R, et al. **J Neural Transm Gen Sect** 1995; 99(1–3):173–85 (52 ref.)
Attenuation compensation for cardiac single-photon emission computed tomographic imaging: Part 2. Attenuation compensation algorithms. King MA, et al. **J Nucl Cardiol** 1996 Jan–Feb;3(1):55–64 (66 ref.)
[The use of SPECT with 201Tl in the evaluation of brain tumors] Prat-Acín R, et al. **Rev Neurol** 1996 Aug; 24(132):909–13 (34 ref.) (Eng. Abstr.) **(Spa)**

TOMOGRAPHY, NMR see **MAGNETIC RESONANCE IMAGING**

TOMOGRAPHY, POSITRON-EMISSION see **TOMOGRAPHY, EMISSION-COMPUTED**

TOMOGRAPHY, PROTON SPIN see **MAGNETIC RESONANCE IMAGING**

TOMOGRAPHY, RADIONUCLIDE-COMPUTED see **TOMOGRAPHY, EMISSION-COMPUTED**

TOMOGRAPHY SCANNERS, X-RAY COMPUTED

see related
RADIOGRAPHIC IMAGE ENHANCEMENT

[Spiral scanners: principles and clinical prospects] Buthiau D, et al. **Rev Med Interne** 1996;17(3):243–54 (58 ref.) (Eng. Abstr.) **(Fre)**

TOMOGRAPHY, SINGLE-PHOTON, EMISSION-COMPUTED see **TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON**

TOMOGRAPHY, TRANSMISSION COMPUTED see **TOMOGRAPHY, X-RAY COMPUTED**

TOMOGRAPHY, ULTRASONIC see **ULTRASONOGRAPHY**

TOMOGRAPHY, X-RAY COMPUTED

Crowned dens syndrome: a manifestation of hydroxy-apatite rheumatism. Malca SA, et al. **Acta Neurochir (Wien)** 1995; 135(3–4):126–30 (21 ref.)
CT features of ulcerative colitis and Crohn's disease. Gore RM, et al. **AJR Am J Roentgenol** 1996 Jul;167(1):3–15 (86 ref.)
Hepatic metastases from granulosa cell tumor of the ovary: CT and sonographic findings. Neste MG, et al. **AJR Am J Roentgenol** 1996 May;166(5):1122–4 (8 ref.)
Clostridial infection of the abdomen: CT findings in two successfully treated patients. Spencer JA, et al. **AJR Am J Roentgenol** 1996 May;166(5):1094–6 (8 ref.)
CT angiography [see comments] Zeman RK, et al. **AJR Am J Roentgenol** 1995 Nov;165(5):1079–88 (65 ref.) Comment in: AJR Am J Roentgenol 1996 May;166(5):1227–9.
Diagnostic imaging in the evaluation of blunt abdominal trauma. Barloon TJ, et al. **Am Fam Physician** 1996 Jul; 54(1):205–9 (20 ref.)
Computed tomography--guided aspiration of a ganglion cyst of the anterior cruciate ligament: a case report. Campagnolo DI, et al. **Arch Phys Med Rehabil** 1996 Jul; 77(7):732–3 (22 ref.)
Interventional radiology in the treatment of blunt liver trauma: case report with review of literature. Harms J, et al. **Bildgebung** 1996 Mar;63(1):51–4 (22 ref.)
Perspectives of pQCT technology associated to biomechanical studies in skeletal research employing rat models. Ferretti JL. **Bone** 1995 Oct;17(4 Suppl):353S–364S (48 ref.)
Imaging of intestinal obstruction. Traill ZC, et al. **Br J Hosp Med** 1996 Mar 6–19;55(5):267–71 (20 ref.)
Dermoid cyst of the ovary: computed tomography diagnosis of an unusual case. Garant M, et al. **Can Assoc Radiol J** 1996 Apr;47(2):107–10 (9 ref.)
Diastematomyelia in adults. Modern imaging and operative treatment. Prasad VS, et al. **Clin Imaging** 1995 Oct–Dec; 19(4):270–4 (28 ref.)
CT scan as an important diagnostic tool in the initial phase of diffuse bilateral renal cortical necrosis. Kim HJ, et al. **Clin Nephrol** 1996 Feb;45(2):125–30 (24 ref.)
Imaging of small cell carcinoma of the oesophagus. Fenlon HM, et al. **Clin Radiol** 1995 Sep;50(9):634–8 (33 ref.)
The role of radiology in the investigation and management of patients with haemoptysis. Marshall TJ, et al. **Clin Radiol** 1996 Jun;51(6):391–400 (66 ref.)
CT manifestations of pulmonary aspergillosis. Logan PM, et al. **Crit Rev Diagn Imaging** 1996 Feb;37(1):1–37 (43 ref.)
CT of the pulmonary hilum: evaluation with thin-section ultrafast CT. Murata K, et al. **Crit Rev Diagn Imaging** 1996 Feb;37(1):39–77 (57 ref.)
Primary staging of urinary bladder carcinoma: the role of MRI and a comparison with CT. Barentsz JO, et al. **Eur Radiol** 1996;6(2):129–33 (49 ref.)
Optimizing joint-imaging: (CT)-arthrography. Obermann WR. **Eur Radiol** 1996;6(3):275–83 (8 ref.)
CT during arterial portography. Soyer P. **Eur Radiol** 1996; 6(3):349–57 (69 ref.)
The CT-simulation 3-D treatment planning process. Michalski JM, et al. **Front Radiat Ther Oncol** 1996;29:43–56 (10 ref.)
The current state of the art in three dimensional oncologic imaging: an overview. Kuszyk BS, et al. **Int J Radiat Oncol Biol Phys** 1995 Dec 1;33(5):1029–39 (79 ref.)
Computer tomography and magnetic resonance imaging in the evaluation of bladder cancer. Husband JE. **J Belge Radiol** 1995 Dec;78(6):350–5 (33 ref.)
Osteoma of the internal auditory canal: case report. Coakley DJ, et al. **J Laryngol Otol** 1996 Feb;110(2):158–60 (10 ref.)
An imaging-based computational and experimental study of skull fracture: finite element model development. Bandak FA, et al. **J Neurotrauma** 1995 Aug;12(4):679–88 (31 ref.)
Anatomic distribution and histopathologic patterns in diffuse lung disease: correlation with HRCT. Colby TV, et al. **J Thorac Imaging** 1996 Winter;11(1):1–26 (51 ref.)
Electron beam computed tomography and coronary artery disease: scanning for coronary artery calcification. Rumberger JA, et al. **Mayo Clin Proc** 1996 Apr; 71(4):369–77 (30 ref.)
Imaging of pleural diseases. Maffessanti M, et al. **Monaldi Arch Chest Dis** 1996 Apr;51(2):138–44 (22 ref.)
Temporal bone imaging. Casselman JW. **Neuroimaging Clin N Am** 1996 May;6(2):265–89 (51 ref.)
Imaging of the larynx. Castelijns JA, et al. **Neuroimaging Clin N Am** 1996 May;6(2):401–15 (68 ref.)
Computed tomography and myelography in the evaluation of cervical degenerative disease. Russell EJ. **Neuroimaging Clin N Am** 1995 Aug;5(3):329–48 (83 ref.)
Oral cavity, oropharynx, and salivary glands. Sigal R. **Neuroimaging Clin N Am** 1996 May;6(2):379–400 (44 ref.)
Imaging of cervical lymphadenopathy. van den Brekel MW, et al. **Neuroimaging Clin N Am** 1996 May;6(2):417–34 (137 ref.)
Base of skull, nasopharynx, and parapharyngeal space. Vogl TJ, et al. **Neuroimaging Clin N Am** 1996 May;6(2):357–78 (25 ref.)
The role of computed tomography and magnetic resonance imaging in planning for conservation laryngeal surgery. Weinstein GS, et al. **Neuroimaging Clin N Am** 1996 May;

6(2):497–504 (25 ref.)
Temporomandibular joint and dental imaging. Westesson PL. **Neuroimaging Clin N Am** 1996 May;6(2):333–55 (31 ref.)
CT of a peripatetic intracranial foreign body. Bearcroft PW, et al. **Neuroradiology** 1995 Oct;37(7):542–4 (16 ref.)
Calcification of cervical ganglia: case report. Casolin AL, et al. **Neuroradiology** 1995 Aug;37(6):468–70 (19 ref.)
Pneumocephalus due to nasopharyngeal carcinoma: case report. Kiu MC, et al. **Neuroradiology** 1996 Jan;38(1):70–2 (24 ref.)
Delayed post-traumatic epidural hematoma. A review. Domenicucci M, et al. **Neurosurg Rev** 1995;18(2):109–22 (51 ref.)
Early onset bilateral calcifications and epilepsy. Nunes ML, et al. **Pediatr Neurol** 1995 Jul;13(1):80–2 (11 ref.)
Bronchiolitis obliterans in children with Stevens-Johnson syndrome: follow-up with high resolution CT. Kim MJ, et al. **Pediatr Radiol** 1996;26(1):22–5 (9 ref.)
Behavioral and neuroimaging studies on schizophrenia in Japan. Shimazono Y, et al. **Psychiatry Clin Neurosci** 1995 Mar;49(1):3–11 (72 ref.)
CT of the pediatric gastrointestinal tract. Auringer ST, et al. **Radiol Clin North Am** 1996 Jul;34(4):701–15 (38 ref.)
Congestive heart failure and adult respiratory distress syndrome. New insights using computed tomography. Goodman LR. **Radiol Clin North Am** 1996 Jan;34(1):33–46 (30 ref.)
CT scan of mesentery-omentum peritoneum. Sivit CJ. **Radiol Clin North Am** 1996 Jul;34(4):863–84 (58 ref.)
Pulmonary thromboembolism: recent developments in diagnosis with CT and MR imaging. Gefter WB, et al. **Radiology** 1995 Dec;197(3):561–74 (102 ref.)
Airways and lung: correlation of CT with fiberoptic bronchoscopy. Naidich DP, et al. **Radiology** 1995 Oct; 197(1):1–12 (98 ref.)
Carcinoma of the pancreatic head area. Diagnostic imaging: computed tomography. Brizi MG, et al. **Rays** 1995 Jul–Sep; 20(3):249–68 (47 ref.) **(Eng, Ita)**
Primitive neuroectodermal tumour of the chest wall (Askin tumour): CT and roentgenographic findings in a 51-year-old male. Miller JA, et al. **Respir Med** 1995 Nov; 89(10):705–8 (7 ref.)
Epiploic appendicitis: ultrasound and CT characteristics. Rutten MJ, et al.
Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1996 Mar;164(3):264–5 (6 ref.)
Computed tomography imaging of focal hepatic lesions. Jacobs JE, et al. **Semin Roentgenol** 1995 Oct;30(4):308–23 (48 ref.)
Computed tomography evaluation of colorectal carcinoma. Scharling ES, et al. **Semin Roentgenol** 1996 Apr; 31(2):142–53 (69 ref.)
Lesions of the jaws. DelBalso AM.
Semin Ultrasound CT MR 1995 Dec;16(6):487–512 (42 ref.)
Identification and evaluation of centrilobular opacities on high-resolution CT. Gruden JF, et al.
Semin Ultrasound CT MR 1995 Oct;16(5):435–49 (30 ref.)
CT of pulmonary metastases with pathological correlation. Hirakata K, et al. **Semin Ultrasound CT MR** 1995 Oct; 16(5):379–94 (63 ref.)
CT of pulmonary tuberculosis. Im JG, et al.
Semin Ultrasound CT MR 1995 Oct;16(5):420–34 (35 ref.)
CT in blunt chest trauma: pulmonary, tracheobronchial, and diaphragmatic injuries. Kang EY, et al.
Semin Ultrasound CT MR 1996 Apr;17(2):114–8 (39 ref.)
Oral cavity: anatomy and pathology. Laine FJ, et al.
Semin Ultrasound CT MR 1995 Dec;16(6):527–45 (40 ref.)
Bronchiectasis: CT/clinical correlations. McGuinness G, et al. **Semin Ultrasound CT MR** 1995 Oct;16(5):395–419 (63 ref.)
Imaging of the temporomandibular joint. Rao VM.
Semin Ultrasound CT MR 1995 Dec;16(6):513–26 (53 ref.)
CT of abdominal and pelvic trauma. Roberts JL.
Semin Ultrasound CT MR 1996 Apr;17(2):142–69 (71 ref.)
CT of the lungs in patients with pulmonary emphysema. Stern EJ, et al. **Semin Ultrasound CT MR** 1995 Oct; 16(5):345–52 (43 ref.)
Imaging of the salivary glands. Weissman JL.
Semin Ultrasound CT MR 1995 Dec;16(6):546–68 (28 ref.)
Acute lung disease in the immunocompromised host: differential diagnosis at high-resolution CT. Worthy S, et al. **Semin Ultrasound CT MR** 1995 Oct;16(5):353–60 (24 ref.)
CT evaluation of soft tissue and muscle infection and inflammation: a systematic compartmental approach. Beauchamp NJ Jr, et al. **Skeletal Radiol** 1995 Jul; 24(5):317–24 (8 ref.)
CT/MRI of musculoskeletal complications of AIDS. Wyatt SH, et al. **Skeletal Radiol** 1995 Oct;24(7):481–8 (21 ref.)
[Magnetic resonance or computerized tomography for imaging of the brain?] Suoranta H, et al. **Duodecim** 1994; 110(16):1540–7 (9 ref.) **(Fin)**
[Computed tomography of the sacroiliac joints] Miquel A, et al. **Ann Radiol (Paris)** 1995;38(4):177–85 (28 ref.) **(Fre)**
[What can be expected from x-ray computed tomography in gastrointestinal diseases?] Bruel JM, et al.
Gastroenterol Clin Biol 1996;20(5 Pt 2):B140–4 (27 ref.) **(Fre)**
[Cerebral toxoplasmosis. Neuroradiologic diagnosis and prognostic monitoring] Martin-Duverneuil N, et al.
J Neuroradiol 1995 Sep;22(3):196–203 (28 ref.) (Eng. Abstr.) **(Fre)**
[Cat-scratch disease presenting as a pseudotumor. Imaging by x-ray computed tomography and MRI] Leblan I, et al. **J Radiol** 1995 Sep;76(9):601–4 (19 ref.) (Eng. Abstr.) **(Fre)**
[Hypersensitivity pneumopathies: x-ray computed tomographic aspects] Moysan P, et al. **J Radiol** 1995 Jul; 76(7):435–40 (27 ref.) (Eng. Abstr.) **(Fre)**
[Spiral scanning angiography of pulmonary embolism] Rémy J, et al. **J Radiol** 1996 May;77(5):325–38 (60 ref.) **(Fre)**
[Patchy changes in white matter in cranial computerized and magnetic resonance tomography—significance for (differential) diagnosis of dementia of the Alzheimer type and vascular dementia] Stoppe G, et al.
Fortschr Neurol Psychiatr 1995 Nov;63(11):425–40 (150 ref.) (Eng. Abstr.) **(Ger)**
[Modern radiologic diagnosis for the ENT physician] Dammann F, et al. **HNO** 1995 Oct;43(10):590–5 (17 ref.) (Eng. Abstr.) **(Ger)**
[Modern neuroradiologic diagnosis and interventional strategies for the ENT physician] Hofmann E, et al.
HNO 1995 Oct;43(10):584–9 (29 ref.) (Eng. Abstr.) **(Ger)**
[Neuroradiology in ophthalmology. 1] Müller-Forell W, et al. **Ophthalmologe** 1995 Aug;92(4):595–614 (0 ref.) **(Ger)**
[Computerized tomography of malignancies of the oral cavity, the oropharynx and hypopharynx and invasiveness] Helmberger R, et al. **Radiologe** 1996 Mar;36(3):193–8 (19 ref.) (Eng. Abstr.) **(Ger)**
[Neuroradiologic findings in arterial cerebral ischemia] Jansen O, et al. **Radiologe** 1995 Nov;35(11):779–90 (33 ref.) (Eng. Abstr.) **(Ger)**
[Fournier's gangrene in a woman in computed tomography] Lehmann KJ, et al.
Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1995 Nov;163(5):446–8 (15 ref.) **(Ger)**
[Computed tomographic demonstration of intraspinal air after an infection with peptostreptococci] Lorenzen J, et al.
Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1996 Feb;164(2):173–5 (10 ref.) **(Ger)**
[Computed tomography in acute rhabdomyolysis] Steidle B, et al.
Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1995 Oct;163(4):353–5 (10 ref.) **(Ger)**
[The shoulder joint—diagnostic imaging] Imhof H, et al.
Wien Med Wochenschr 1996;146(6–7):116–20 (24 ref.) (Eng. Abstr.) **(Ger)**
[Role of CT and MR in the assessment of lumbar degenerative disk disease] Gualdi GF, et al. **Clin Ter** 1995 Oct;146(10):635–48 (24 ref.) (Eng. Abstr.) **(Ita)**
[Diagnostic accuracy of computerized tomography. Preoperative staging of gastric cancer] Zompetta C, et al. **Clin Ter** 1995 Dec;146(12):825–41 (18 ref.) (Eng. Abstr.) **(Ita)**
[Appendiceal mucocele: diagnosis by echography, spiral computed tomography and magnetic resonance] Bertolotto M, et al. **Radiol Med (Torino)** 1995 Dec;90(6):829–32 (6 ref.) **(Ita)**
[Giant myelolipoma of the adrenals. A report of 3 cases studied by CT and a review of the literature] Catalano O, et al. **Radiol Med (Torino)** 1995 Dec;90(6):842–6 (53 ref.) **(Ita)**
[The Mounier-Kuhn syndrome (tracheobronchomegaly). The diagnostic role of computed tomography] Villani PC, et al. **Radiol Med (Torino)** 1995 Sep;90(3):313–6 (16 ref.) **(Ita)**
[Early diagnosis of hepatocellular carcinoma using computed tomography and magnetic resonance imaging] Moriyama N. **Nippon Naika Gakkai Zasshi** 1995 Dec 10; 84(12):1997–2002 (4 ref.) **(Jpn)**
[The measurement of fat distribution by computed tomography] Nakamura T, et al. **Nippon Rinsho** 1995 Jun; 53 Suppl:209–14 (10 ref.) **(Jpn)**
[Pseudostone of the gallbladder] Kubota Y, et al.
Ryoikibetsu Shokogun Shirizu 1996;(9):415–7 (3 ref.) **(Jpn)**
[Computed tomography of pneumoconiosis] Zhang X, et al.
Sangyo Eiseigaku Zasshi 1995 Sep;37(5):321–8 (77 ref.) (Eng. Abstr.) **(Jpn)**
[Contrast media for computerized and magnetic resonance tomography. Basic principles] Rinck PA, et al.
Vestn Rentgenol Radiol 1995 Nov-Dec;(6):52–9 (22 ref.) (Eng. Abstr.) **(Rus)**
[Radiological criteria for laryngeal tumors and cervical metastases] Melchor Díaz MA, et al.
Acta Otorrinolaringol Esp 1996 Jan–Feb;47(1):1–7 (17 ref.) (Eng. Abstr.) **(Spa)**
[Localized tracheobronchial amyloidosis. The usefulness of computed tomography] Sánchez Antuña A, et al.
Arch Bronconeumol 1995 Dec;31(10):540–2 (23 ref.) (Eng. Abstr.) **(Spa)**

INSTRUMENTATION

Helical CT cholangiography. Stockberger SM, et al.
Abdom Imaging 1996 Mar–Apr;21(2):98–104 (17 ref.)
Non-invasive visualization of coronary arteries with and without calcification by electron beam computed tomography. Schmermund A, et al. **Herz** 1996 Apr; 21(2):118–26 (49 ref.)
Image-guided spine surgery. Foley KT, et al.
Neurosurg Clin N Am 1996 Apr;7(2):171–86 (7 ref.)
Dental implants and dental CT software programs. Abrahams JJ, et al. **Semin Ultrasound CT MR** 1995 Dec;16(6):468–86 (21 ref.)
Anatomy of the jaw, dentition, and related regions. Abrahams JJ, et al. **Semin Ultrasound CT MR** 1995 Dec;16(6):453–67 (13 ref.)
[Coronary arteries and coronary artery bypass in CT: options, limitations and perspectives] Steiner P. **Aktuelle Radiol** 1995 Sep;5(5):283–9 (28 ref.) (Eng. Abstr.) **(Ger)**
[clinical application of multiplanar and 3D reconstruction of spiral CT in diagnosis of acetabulum fractures] Stroszczynski C, et al. **Aktuelle Radiol** 1996 Mar;6(2):91–5 (23 ref.) (Eng. Abstr.) **(Ger)**
[Radiation dosage of various CT techniques in diagnostic lung imaging] Heinz-Peer G, et al. **Radiologe** 1996 Jun; 36(6):470–4 (18 ref.) (Eng. Abstr.) **(Ger)**
[Spiral CT in chronic lung thromboembolism] Kontrus M, et al. **Radiologe** 1996 Jun;36(6):496–502 (27 ref.) (Eng. Abstr.) **(Ger)**
[Spiral CT of the lung. Technique, findings, value] Prokop M, et al. **Radiologe** 1996 Jun;36(6):457–69 (42 ref.) (Eng. Abstr.) **(Ger)**

METHODS

Castleman's disease of the lung: radiographic, high-resolution CT, and pathologic findings. Barrie JR, et al.
AJR Am J Roentgenol 1996 May;166(5):1055–6 (8 ref.)
Evidence of expiratory CT scans of small-airway obstruction in sarcoidosis. Gleeson FV, et al.
AJR Am J Roentgenol 1996 May;166(5):1052–4 (12 ref.)
Ultrafast computed tomography for detection of coronary artery calcification. Fusman B, et al.
Am J Card Imaging 1995 Jul;9(3):206–12 (43 ref.)
Are there gender differences regarding coronary artery calcification. Kung S, et al. **Am J Card Imaging** 1996 Jan; 10(1):72–7 (60 ref.)
Quantitative computed tomography (QCT) of the lumbar spine and appendicular skeleton. Glüer CC, et al.
Eur J Radiol 1995 Sep;20(3):173–8 (55 ref.)
Spiral CT angiography—can we forget about arteriography to diagnose renal artery stenosis? [editorial] Olbricht CJ, et al. **Nephrol Dial Transplant** 1996 Jul;11(7):1227–31 (28 ref.)
Current techniques in three-dimensional CT simulation and radiation treatment planning. Stephenson JA, et al.
Oncology (Huntingt) 1995 Nov;9(11):1225–32, 1235; discussion 1235–40 (26 ref.)
Invited article: helical/spiral CT scanning: a pediatric radiology perspective. White KS. **Pediatr Radiol** 1996; 26(1):5–14 (27 ref.)
CT scan of bowel trauma in the pediatric patient. Cox TD, et al. **Radiol Clin North Am** 1996 Jul;34(4):807–18 (23 ref.)
Thin-section CT, emphysema, air trapping, and airway obstruction [editorial; comment] Müller NL, et al.
Radiology 1996 Jun;199(3):621–2 (22 ref.) Comment on: Radiology 1996 Jun;199(3):825–9.
Skeletal 3-D CT: advantages of volume rendering over surface rendering. Kuszyk BS, et al. **Skeletal Radiol** 1996 Apr;25(3):207–14 (16 ref.)
[3-dimensional imaging—new computerized tomography technique] Suramo I, et al. **Duodecim** 1994;110(19):1776–80 (13 ref.) **(Fin)**
[Analysis of texture in medical imaging. Review of the literature] Rolland Y, et al. **Ann Radiol (Paris)** 1995; 38(6):315–47 (102 ref.) (Eng. Abstr.) **(Fre)**
[Factors of image quality in spiral x-ray computed tomography] Ernst O, et al. **J Radiol** 1995 Dec; 76(12):1069–74 (13 ref.) (Eng. Abstr.) **(Fre)**
[Value of imaging in asthma] Paganin F, et al.
Rev Pneumol Clin 1996;52(2):88–96 (36 ref.) (Eng. Abstr.) **(Fre)**
[Contrast medium administration in spiral computed tomography: the results of a consensus conference. Institute for Radiodiagnosis, Regensburg] Feuerbach S, et al.
Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1996 Feb;164(2):158–65 (23 ref.) (Eng. Abstr.) **(Ger)**
[Possibilities of spiral-CT for diagnosis of focal liver lesions] Helmberger H, et al. **Rontgenpraxis** 1996 Mar;49(3):49–54 (35 ref.) **(Ger)**
[High-resolution computerized tomography of the lungs: bases, findings, indications] Hauser M, et al.
Schweiz Med Wochenschr 1996 Mar 9;126(10):398–408 (52 ref.) (Eng. Abstr.) **(Ger)**
[High resolution CT in the evaluation of pulmonary parenchymal diseases] Pirolli FM, et al. **Clin Ter** 1995 Nov; 146(11):747–57 (20 ref.) (Eng. Abstr.) **(Ita)**
[Three-dimensional image diagnosis of neoplasms] Moriyama N. **Nippon Naika Gakkai Zasshi** 1996 Mar 10;85(3):333–6 (7 ref.) **(Jpn)**
[Early diagnosis of pancreatic carcinoma and utility of helical CT] Ichikawa T, et al. **Nippon Rinsho** 1995 Nov; 53(11):2868–73 (11 ref.) (Eng. Abstr.) **(Jpn)**
[3D-CT of the central nervous system] Machida T.
No To Shinkei 1996 Jul;48(7):607–12 (8 ref.) **(Jpn)**
[What does high-resolution CAT contribute in the study of diffuse interstitial diseases? (editorial)] Agustí C, et al.
Arch Bronconeumol 1995 Aug–Sep;31(7):311–3 (24 ref.) **(Spa)**

TOMOGRAPHY, X-RAY COMPUTED, SCANNERS see **TOMOGRAPHY SCANNERS, X-RAY COMPUTED**

TONGUE

INJURIES

Posttraumatic macroglossia complicated by hyaluronidase injection. Dort JC. **Otolaryngol Head Neck Surg** 1996 Feb; 114(2):308–9 (9 ref.)

SURGERY

[The surgical treatment of obstructive sleep apnea syndrome] Cimino A, et al. **Acta Otorhinolaryngol Ital** 1995 Apr;15(2 Suppl 47):3–14 (58 ref.) (Eng. Abstr.) **(Ita)**

TRANSPLANTATION

[The use of tongue flaps for oral tissue repair] Robben C, et al. **Acta Stomatol Belg** 1995 Dec;92(4):171–84 (28 ref.) (Eng. Abstr.) **(Dut)**

TONGUE DISEASES

CHEMICALLY INDUCED

Perioperative angioedema in a patient on long–term angiotensin–converting enzyme (ACE)–inhibitor therapy. Ogbureke KU, et al. **J Oral Maxillofac Surg** 1996 Jul; 54(7):917–20 (18 ref.)

DIAGNOSIS

[Choristoma of the gastric mucosa: report of a case] Fernandes M, et al. **Rev Laryngol Otol Rhinol (Bord)** 1995; 116(5):347–9 (09 ref.) (Eng. Abstr.) **(Fre)**

MICROBIOLOGY

Recurrent chancriform pyoderma: report of a case with tongue lesions. Is Staphylococcus aureus implicated? Holmes SC, et al. **Br J Dermatol** 1995 Aug;133(2):326–7 (5 ref.)

PATHOLOGY

Ulcerative eosinophilic granuloma: a report of five new cases. Movassaghi K, et al. **Br J Oral Maxillofac Surg** 1996 Feb; 34(1):115–7 (12 ref.)

Conditions peculiar to the tongue. McNally MA, et al. **Dermatol Clin** 1996 Apr;14(2):257–72 (34 ref.)

Osseous choristoma of the tongue. Wei Cheong Ngeow, et al. **J Nihon Univ Sch Dent** 1996 Mar;38(1):49–51 (3 ref.)

TONGUE, FISSURED

see related
MELKERSSON–ROSENTHAL SYNDROME

TONGUE, GEOGRAPHIC see **GLOSSITIS, BENIGN MIGRATORY**

TONGUE NEOPLASMS

Cancer of the tongue [see comments] Leong IT, et al. **J Can Dent Assoc** 1995 Sep;61(9):792–6 (28 ref.) Comment in: J Can Dent Assoc 1995 Nov;61(11):922, 944.

[Ectopic lingual thyroid. Apropos of 3 cases] Maurice N, et al. **Ann Otolaryngol Chir Cervicofac** 1995;112(8):399–405 (24 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Giant neurofibroma of the tongue. Sahota JS, et al. **Int J Pediatr Otorhinolaryngol** 1996 Jan;34(1–2):153–7 (10 ref.)

PATHOLOGY

Rapidly progressive CD8–positive cutaneous T–cell lymphoma with tongue involvement. Quarterman MJ, et al. **Am J Dermatopathol** 1995 Jun;17(3):287–91 (31 ref.)

Hodgkin's disease primarily involving Waldeyer's ring. Case report and review of the literature. Dunphy CH, et al. **Arch Pathol Lab Med** 1996 Mar;120(3):285–7 (10 ref.)

Liposarcoma of the base of tongue and tonsillar fossa: A possibly underdiagnosed neoplasm. Saddik M, et al. **Arch Pathol Lab Med** 1996 Mar;120(3):292–5 (23 ref.)

Management of a carcinoma of the tongue during pregnancy: report of case. Lasaridis N, et al. **J Oral Maxillofac Surg** 1996 Feb;54(2):221–4 (16 ref.)

Ancient schwannoma of the oral floor and ventricular portion of the tongue: a case report and review of the literature. Nakayama H, et al. **Jpn J Clin Oncol** 1996 Jun;26(3):185–8 (15 ref.)

Osteogenic sarcoma of the tongue. Case report and review of the literature. Loyzaga JM, et al. **Pathol Res Pract** 1996 Jan;192(1):75–8; discussion 79–80 (9 ref.)

Carcinoma of the tongue in a long–term survivor of clear cell sarcoma of the kidney. Ferbend P, et al. **Pediatr Pathol Lab Med** 1995 Mar–Apr;15(2):327–32 (22 ref.)

Squamous cell carcinoma of the tongue in a child with Fanconi anemia: a case report and review of the literature. Somers GR, et al. **Pediatr Pathol Lab Med** 1995 Jul–Aug; 15(4):597–607 (62 ref.)

RADIOTHERAPY

[ORL brachytherapy. Brachytherapy of epidermoid carcinoma of the oral cavity] Haie–Meder C, et al. **Bull Cancer Radiother** 1995;82(2):186–90 (42 ref.) **(Fre)**

[ORL brachytherapy. Focus on brachytherapy for squamous cell carcinoma of the oral cavity and pharynx] Mazeron JJ. **Bull Cancer Radiother** 1995;82(2):179–85 (68 ref.) **(Fre)**

[Time factor and curietherapy: the example of epidermoid carcinoma of the mobile tongue] Mazeron JJ, et al. **Bull Cancer Radiother** 1990;77(1):15–22 (34 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

[Retrospective study of 136 cases of epidermoid carcinoma of the base of the tongue treated at the Alexis Vautrin Centre 1978–1992] Hoffstetter S, et al. **Bull Cancer Radiother** 1996;83(2):90–6 (11 ref.) (Eng. Abstr.) **(Fre)**

TONOFILAMENTS see **INTERMEDIATE FILAMENTS**

TONOMETRY

Non–contact tonometry. Moseley MJ. **Ophthalmic Physiol Opt** 1995 Sep;15 Suppl 2:S35–7 (32 ref.)

VETERINARY

The role of tonometry in the clinical management of the glaucomas in companion animals. Gelatt KN. **Vet Q** 1995 Apr;17 Suppl 1:S45 (0 ref.)

TONSIL

see related
TONSILLECTOMY

[Peritonsillar abscess. Emergency tonsillectomy?] Marchal F, et al. **Ann Otolaryngol Chir Cervicofac** 1995;112(8):393–8 (26 ref.) (Eng. Abstr.) **(Fre)**

CYTOLOGY

Assessment of engraftment and function of human tonsillar and blood mononuclear cells in immunodeficient mice. Albini B, et al. **Adv Exp Med Biol** 1995;371A:85–9 (28 ref.)

DRUG EFFECTS

[Effect of the molecular structure of azithromycin on pharmacokinetics and the antimicrobial activity] Pechère JC. **Pathol Biol (Paris)** 1995 Jun;43(6):483–7 (8 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Obstructive sleep apnea syndrome in children: an overview. Boudewyns AN, et al. **Acta Otorhinolaryngol Belg** 1995; 49(3):275–9 (15 ref.)

Lymphoid changes of the nasopharyngeal and palatine tonsils that are indicative of human immunodeficiency virus infection. A clinicopathologic study of 12 cases. Wenig BM, et al. **Am J Surg Pathol** 1996 May;20(5):572–87 (76 ref.)

Giant primary amyloidoma of the tonsil. López Amado M, et al. **J Laryngol Otol** 1996 Jun;110(6):613–5 (20 ref.)

Adenotonsillar disease. Zalzal GH. **J Med Liban** 1994; 42(4):230–4 (18 ref.)

TONSIL, PALATINE see **TONSIL**

TONSILLAR NEOPLASMS

PATHOLOGY

Hodgkin's disease primarily involving Waldeyer's ring. Case report and review of the literature. Dunphy CH, et al. **Arch Pathol Lab Med** 1996 Mar;120(3):285–7 (10 ref.)

Liposarcoma of the base of tongue and tonsillar fossa: A possibly underdiagnosed neoplasm. Saddik M, et al. **Arch Pathol Lab Med** 1996 Mar;120(3):292–5 (23 ref.)

Tonsillar lipoma: a case report. Harada H, et al. **J Laryngol Otol** 1995 Jul;109(7):662–4 (7 ref.)

Hairy polyp of the tonsil. Mitchell TE, et al. **J Laryngol Otol** 1996 Jan;110(1):101–3 (16 ref.)

RADIOTHERAPY

[Place of iridium 192 implantation in irradiation of T1–T2 squamous cell carcinoma of the velopharyngeal arch] Mazeron JJ, et al. **Bull Cancer Radiother** 1996;83(1):47–53 (43 ref.) (Eng. Abstr.) **(Fre)**

[Value of the combination of external radiotherapy and curietherapy in carcinoma of the velo–tonsillar region. Statistical study of a series of 361 patients] Pernot M, et al. **Bull Cancer Radiother** 1996;83(1):40–6 (32 ref.) (Eng. Abstr.) **(Fre)**

SECONDARY

Tonsillar metastasis from adenocarcinoma of the stomach. Benito I, et al. **J Laryngol Otol** 1996 Mar;110(3):291–3 (15 ref.)

TONSILLECTOMY

Pain after tonsillectomy. Husband AD, et al. **Clin Otolaryngol** 1996 Apr;21(2):99–101 (44 ref.)

[Peritonsillar abscess. Emergency tonsillectomy?] Marchal F, et al. **Ann Otolaryngol Chir Cervicofac** 1995;112(8):393–8 (26 ref.) (Eng. Abstr.) **(Fre)**

ADVERSE EFFECTS

[Hemorrhagic complications of ORL surgery] Boisson–Bertrand D, et al. **Cah Anesthesiol** 1995; 43(5):489–95 (48 ref.) **(Fre)**

TONSILLITIS

[The role of focal infection in the pathogenesis and present–day approaches to therapeutic policy in chronic tonsillitis] Pal'chun VT, et al. **Vestn Otorinolaringol** 1995 Sep–Oct;(5):5–12 (0 ref.) **(Rus)**

DIAGNOSIS

Tuberculous tonsillitis. Celik O, et al. **J Otolaryngol** 1995 Oct;24(5):307–9 (14 ref.)

[Pharyngo–tonsillitis: Current clinical, bacteriological, serological and therapeutic aspects] Sternon J, et al. **Rev Med Brux** 1995 Nov;16(5):344–8 (12 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

Penicillin tolerance and treatment failure in group A streptococcal pharyngotonsillitis. van Asselt GJ, et al. **Eur J Clin Microbiol Infect Dis** 1996 Feb;15(2):107–15 (66 ref.)

MICROBIOLOGY

The role of anaerobic bacteria in recurrent episodes of sinusitis and tonsillitis. Nord CE. **Clin Infect Dis** 1995 Jun; 20(6):1512–24 (107 ref.)

Tuberculous tonsillitis. Celik O, et al. **J Otolaryngol** 1995 Oct;24(5):307–9 (14 ref.)

TOOTH

see related
DENTITION
MALOCCLUSION
MASTICATION
ODONTOGENESIS

CHEMISTRY

Relating tooth and blood lead levels in children. Rabinowitz MB. **Bull Environ Contam Toxicol** 1995 Dec;55(6):853–7 (14 ref.)

Molecular biological studies on teeth, and inquests. Yamamoto K. **Forensic Sci Int** 1996 Jun 28;80(1–2):79–87 (21 ref.)

CYTOLOGY

Tooth crown morphogenesis and cytodifferentiations: candid questions and critical comments. Ruch JV. **Connect Tissue Res** 1995;32(1–4):1–8 (84 ref.)

DRUG EFFECTS

Tetracyclines and calcified tissues. van der Bijl P, et al. **Ann Dent** 1995 Summer–Fall;54(1–2):69–72 (46 ref.)

EMBRYOLOGY

Application of immunocytochemistry for detection of proliferating cell populations during tooth development. Casasco A. **Anat Rec** 1996 Jun;245(2):162–73 (146 ref.)

Structure and organization of odontoblasts. Sasaki T, et al. **Anat Rec** 1996 Jun;245(2):235–49 (98 ref.)

Evolution in tooth developmental biology: of morphology and molecules. Slavkin HC, et al. **Anat Rec** 1996 Jun; 245(2):131–50 (166 ref.)

Molecular mechanisms of cell and tissue interactions during early tooth development. Thesleff I, et al. **Anat Rec** 1996 Jun;245(2):151–61 (68 ref.)

INNERVATION

Comparison of functional characteristics of intradental A– and C–nerve fibres in dental pain. Ngassapa DN. **East Afr Med J** 1996 Mar;73(3):207–9 (30 ref.)

METABOLISM

Osteopontin at mineralized tissue interfaces in bone, teeth, and osseointegrated implants: ultrastructural distribution and implications for mineralized tissue formation, turnover, and repair. McKee MD, et al. **Microsc Res Tech** 1996 Feb 1;33(2):141–64 (112 ref.)

PHYSIOLOGY

Rigid–body kinematics and single–tooth displacements. Nikolai RJ. **Am J Orthod Dentofacial Orthop** 1996 Jul; 110(1):88–92 (4 ref.)

[Electrical tooth stimulation and somatosensory evoked potential] Umino M. **Kokubyo Gakkai Zasshi** 1996 Jun; 63(2):287–95 (36 ref.) **(Jpn)**

RADIATION EFFECTS

The effects of laser irradiation of the dental tissues—a review. Love RM. **N Z Dent J** 1995 Dec;91(406):134–7 (26 ref.)

ULTRASTRUCTURE

Structural relationship between the primary crystal formations and the matrix macromolecules in different hard tissues. Discussion of a general principle. Höhling HJ, et al. **Connect Tissue Res** 1995;33(1–3):171–8 (59 ref.)

TOOTH ABNORMALITIES

[Mice carrying null mutations of the homeotic genes Hoxa10 and Msx1] Satokata I, et al. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2134–43 (50 ref.) **(Jpn)**

EPIDEMIOLOGY

Survey of anomalies in primary teeth and their correlation with the permanent dentition. Whittington BR, et al. **N Z Dent J** 1996 Mar;92(407):4–8 (40 ref.)

Dens evaginatus of anterior teeth. Literature review and radiographic survey of 15,000 teeth. Dankner E, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Apr;81(4):472–5 (47 ref.)

GENETICS

Microdontia with severe microcephaly and short stature in two brothers: osteodysplastic primordial dwarfism with dental findings. Lin HJ, et al. **Am J Med Genet** 1995 Aug 28;58(2):136–42 (4 ref.)

Molecular biology experimental strategies for craniofacial–oral–dental dysmorphology. Slavkin HC. **Connect Tissue Res** 1995;32(1–4):233–9 (62 ref.)

[Incidence of structural disorders of teeth in hereditary epidermolysis bullosa] Gábris K, et al. **Fogorv Sz** 1996 Jan; 89(1):7–10 (25 ref.) (Eng. Abstr.) **(Hun)**

SURGERY

Autotransplantation in cleidocranial dysplasia: case report with 5-year follow-up. Halazonetis J, et al. **J Oral Maxillofac Surg** 1995 Dec;53(12):1472–5 (10 ref.)

TOOTH ABRASION

[Micro-abrasions of enamel: an alternative to the elimination of superficial demineralization and decalcification] Tudts M, et al. **Rev Belge Med Dent** 1996;51(3):54–71 (55 ref.) (Eng. Abstr.) **(Fre)**

EPIDEMIOLOGY

The tooth wear index: a flawed epidemiological tool in an ageing population group. Donachie MA, et al. **Community Dent Oral Epidemiol** 1996 Apr;24(2):152–8 (28 ref.)

ETIOLOGY

Stress-induced cervical lesions: review of advances in the past 10 years. Lee WC, et al. **J Prosthet Dent** 1996 May; 75(5):487–94 (65 ref.)

THERAPY

Stress-induced cervical lesions: review of advances in the past 10 years. Lee WC, et al. **J Prosthet Dent** 1996 May; 75(5):487–94 (65 ref.)

TOOTH APEX see **TOOTH ROOT**

TOOTH, ARTIFICIAL

see related
ACRYLIC RESINS

TOOTH BLEACHING

Hydrogen peroxide: a review of its use in dentistry. Marshall MV, et al. **J Periodontol** 1995 Sep;66(9):786–96 (100 ref.)

TOOTH CALCIFICATION

Ultrastructural organic–inorganic relationships in calcified tissues: cartilage and bone vs. enamel. Bonucci E. **Connect Tissue Res** 1995;33(1–3):157–62 (67 ref.)

Dentin mineralization and the role of odontoblasts in calcium transport. Linde A. **Connect Tissue Res** 1995;33(1–3):163–70 (46 ref.)

Enamel mineralization and the role of ameloblasts in calcium transport. Takano Y. **Connect Tissue Res** 1995; 33(1–3):127–37 (74 ref.)

PHYSIOLOGY

Recent observations on enamel crystal formation during mammalian amelogenesis. Aoba T. **Anat Rec** 1996 Jun; 245(2):208–18 (74 ref.)

TOOTH CROWDING see **MALOCCLUSION**

TOOTH, DECIDUOUS

Description and epidemiology of nursing caries. Milnes AR. **J Public Health Dent** 1996 Winter;56(1):38–50 (59 ref.)

ABNORMALITIES

Survey of anomalies in primary teeth and their correlation with the permanent dentition. Whittington BR, et al. **N Z Dent J** 1996 Mar;92(407):4–8 (40 ref.)

Talon cusp affecting the primary maxillary central incisors in two sets of female twins: report of two cases. Liu JF, et al. **Pediatr Dent** 1995 Sep–Oct;17(5):362–4 (16 ref.)

INJURIES

Anterior tooth trauma in the primary dentition: incidence, classification, treatment methods, and sequelae: a review of the literature. Fried I, et al. **ASDC J Dent Child** 1995 Jul–Aug;62(4):256–61 (27 ref.)

Traumatic injuries in the preschool child. Harding AM, et al. **Dent Clin North Am** 1995 Oct;39(4):817–35 (37 ref.)

PATHOLOGY

A clinical and histopathological study of radicular cysts associated with primary molars. Mass E, et al. **J Oral Pathol Med** 1995 Nov;24(10):458–61 (9 ref.)

Pre-eruptive resorption of dentin in the primary and permanent dentitions: case reports and literature review. Seow WK, et al. **Pediatr Dent** 1996 Jan–Feb;18(1):67–71 (24 ref.)

TOOTH DEMINERALIZATION

see related
DENTAL CARIES

TOOTH DISCOLORATION

THERAPY

[Micro-abrasions of enamel: an alternative to the elimination of superficial demineralization and decalcification] Tudts M, et al. **Rev Belge Med Dent** 1996;51(3):54–71 (55 ref.) (Eng. Abstr.) **(Fre)**

VETERINARY

[Veterinary dentistry (12). Discoloration of teeth in companion an:mals] van Foreest AW. **Tijdschr Diergeneeskd** 1996 Jun 1;121(11):316–22 (18 ref.) (Eng. Abstr.) **(Dut)**

TOOTH DISEASES

CHEMICALLY INDUCED

Review article. The rat incisor in toxicologic pathology. Kuijpers MH, et al. **Toxicol Pathol** 1996 May–Jun; 24(3):346–60 (28 ref.)

ETIOLOGY

Anorexia and bulimia nervosa (the eating disorders): conditions of interest to the dental practitioner. Robb ND, et al. **J Dent** 1996 Jan–Mar;24(1–2):7–16 (77 ref.)

GENETICS

Genetics in oral–facial growth and diseases. Nakata M. **Int Dent J** 1995 Aug;45(4):227–44 (39 ref.)

PATHOLOGY

Review article. The rat incisor in toxicologic pathology. Kuijpers MH, et al. **Toxicol Pathol** 1996 May–Jun; 24(3):346–60 (28 ref.)

Dental dysplasia in rats and mice. Losco PE. **Toxicol Pathol** 1995 Nov–Dec;23(6):677–88 (36 ref.)

PREVENTION & CONTROL

Preventive dentistry and the family physician. Clark MM, et al. **Am Fam Physician** 1996 Feb 1;53(2):619–26, 631–2 (30 ref.)

RADIOGRAPHY

The use of panoramic radiology in dental practice. Rushton VE, et al. **J Dent** 1996 May;24(3):185–201 (167 ref.)

VETERINARY

Dental dysplasia in rats and mice. Losco PE. **Toxicol Pathol** 1995 Nov–Dec;23(6):677–88 (36 ref.)

An update in dentistry. van Foreest AW. **Vet Q** 1995 Apr; 17 Suppl 1:S8–9 (0 ref.)

TOOTH EROSION

EPIDEMIOLOGY

The tooth wear index: a flawed epidemiological tool in an ageing population group. Donachie MA, et al. **Community Dent Oral Epidemiol** 1996 Apr;24(2):152–8 (28 ref.)

ETIOLOGY

The relationship between gastro–oesophageal reflux disease and dental erosion. Bartlett DW, et al. **J Oral Rehabil** 1996 May;23(5):289–97 (48 ref.)

TOOTH ERUPTION

Bone surface morphology reflects local skeletal metabolism. Marks SC Jr, et al. **Microsc Res Tech** 1996 Feb 1; 33(2):121–7 (23 ref.)

PHYSIOLOGY

Tooth eruption: theories and facts. Marks SC Jr, et al. **Anat Rec** 1996 Jun;245(2):374–93 (100 ref.)

The mechanism of tooth eruption. Kardos TB. **Br Dent J** 1996 Aug 10;181(3):91–5 (70 ref.)

The basic and applied biology of tooth eruption. Marks SC Jr. **Connect Tissue Res** 1995;32(1–4):149–57 (84 ref.)

TOOTH ERUPTION, ECTOPIC

COMPLICATIONS

Intranasal tooth in a patient with a cleft lip and alveolus. Yeung KH, et al. **Cleft Palate Craniofac J** 1996 Mar; 33(2):157–9 (30 ref.)

DIAGNOSIS

The nasal tooth. Case report. Nastri AL, et al. **Aust Dent J** 1996 Jun;41(3):176–7 (7 ref.)

TOOTH EXTRACTION

An analysis of bacteremias during dental extractions. A double-blind, placebo-controlled study of chlorhexidine. Lockhart PB. **Arch Intern Med** 1996 Mar 11;156(5):513–20 (67 ref.)

Surgical management of patients on warfarin sodium. Beirne OR, et al. **J Oral Maxillofac Surg** 1996 Sep;54(9):1115–8 (18 ref.)

Use of oral premedicants in pediatric dental population. Krost BG, et al. **N Y State Dent J** 1996 Jan;62(1):40–3 (8 ref.)

[Extraction in orthodontics: when and why?] Bousaba S, et al. **Rev Belge Med Dent** 1995;50(2):53–65 (32 ref.) (Eng. Abstr.) **(Fre)**

[The decision to extract in orthodontics] Limme M. **Rev Belge Med Dent** 1995;50(2):40–52 (10 ref.) (Eng. Abstr.) **(Fre)**

ADVERSE EFFECTS

Lingual nerve damage during lower third molar removal: a comparison of two surgical methods. Robinson PP, et al. **Br Dent J** 1996 Jun 22;180(12):456–61 (29 ref.)

METHODS

[Severe complications after surgical removal of wisdom teeth] Locher MC, et al. **Fortschr Kiefer Gesichtschir** 1995; 40:123–8 (55 ref.) (Eng. Abstr.) **(Ger)**

VETERINARY

Endodontics of dogs and cats: an alternative to extraction. Clarke DE. **Aust Vet J** 1995 Oct;72(10):383–9 (57 ref.)

TOOTH GERM

see related
ODONTOGENESIS

PHYSIOLOGY

Epithelial–mesenchymal signaling during tooth development. Thesleff I, et al. **Connect Tissue Res** 1995;32(1–4):9–15 (53 ref.)

TOOTH, IMPACTED

ETIOLOGY

The impacted maxillary canine: I. Review of concepts. Kuftinec MM, et al. **ASDC J Dent Child** 1995 Sep–Oct; 62(5):317–24 (42 ref.)

SURGERY

[Should we or should we not extract impacted teeth?] Lechien P. **Rev Belge Med Dent** 1995;50(2):29–39 (16 ref.) (Eng. Abstr.) **(Fre)**

[Severe complications after surgical removal of wisdom teeth] Locher MC, et al. **Fortschr Kiefer Gesichtschir** 1995; 40:123–8 (55 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

The impacted maxillary canine: II. Clinical approaches and solutions. Kuftinec MM, et al. **ASDC J Dent Child** 1995 Sep–Oct;62(5):325–34 (37 ref.)

TOOTH INJURIES

Anterior tooth trauma in the primary dentition: incidence, classification, treatment methods, and sequelae: a review of the literature. Fried I, et al. **ASDC J Dent Child** 1995

Jul-Aug;62(4):256-61 (27 ref.)

THERAPY

Traumatic injuries in the preschool child. **Harding AM, et al. Dent Clin North Am** 1995 Oct;39(4):817-35 (37 ref.)
Management of trauma in the child and adolescent. **Camp JH. Pediatr Dent** 1995 Sep-Oct;17(5):379-86 (12 ref.)

TOOTH MOVEMENT, MINOR

INSTRUMENTATION

A clinical report for distalizing maxillary molars by using super-elastic wires. **Basdra EK, et al. Fortschr Kieferorthop** 1996 Apr;57(2):118-23 (6 ref.) **(Eng, Ger)**

METHODS

A possible mechanism of action of repelling, molar distalizing magnets. Part I. **Blechman AM, et al. Am J Orthod Dentofacial Orthop** 1995 Oct;108(4):428-31 (18 ref.)
Rigid-body kinematics and single-tooth displacements. **Nikolai RJ. Am J Orthod Dentofacial Orthop** 1996 Jul; 110(1):88-92 (4 ref.)

TOOTH ROOT

see related
ROOT RESORPTION

Stress-induced cervical lesions: review of advances in the past 10 years. **Lee WC, et al. J Prosthet Dent** 1996 May; 75(5):487-94 (65 ref.)

RADIOGRAPHY

[The reliability of apical x-ray pictures in the diagnosis of mandibular bone lesions. A review of the literature and in-vitro study] **Briseño Marroquin B, et al. Schweiz Monatsschr Zahnmed** 1995;105(9):1142-8 (38 ref.) (Eng. Abstr.) **(Ger)**

TOOTH, SUPERNUMERARY

DIAGNOSIS

The nasal tooth. Case report. **Nastri AL, et al. Aust Dent J** 1996 Jun;41(3):176-7 (7 ref.)

TOOTH SUPPORTING STRUCTURES see PERIODONTIUM

TOOTH, UNERUPTED

see related
TOOTH, IMPACTED

TRANSPLANTATION

Autotransplantation in cleidocranial dysplasia: case report with 5-year follow-up. **Halazonetis J, et al. J Oral Maxillofac Surg** 1995 Dec;53(12):1472-5 (10 ref.)

TOOTH, WISDOM see MOLAR, THIRD

TOOTHACHE

Orofacial phantom pain: theory and phenomenology. **Marbach JJ. J Am Dent Assoc** 1996 Feb;127(2):221-9 (48 ref.)

PSYCHOLOGY

A model of pain and anxiety associated with acute stressors: distress in dental procedures. **Litt MD. Behav Res Ther** 1996 May-Jun;34(5-6):459-76 (100 ref.)

TOOTHBRUSHING

[Mechanical and chemical plaque control] **Schiffner U. Schweiz Monatsschr Zahnmed** 1995;105(12):1576-85 (41 ref.) **(Ger, Fre)**

TOOTHPASTE

The role of fluoride toothpastes in the prevention of dental caries. **Bowen WH. J R Soc Med** 1995 Sep;88(9):505-7 (16 ref.)

ADVERSE EFFECTS

Contact allergens in toothpastes and a review of their hypersensitivity. **Sainio EL, et al. Contact Dermatitis** 1995 Aug;33(2):100-5 (74 ref.)

TOPECTOMY see PSYCHOSURGERY

TOPOGRAPHIC BRAIN MAPPING see BRAIN MAPPING

TORNADOES see NATURAL DISASTERS

TORP see OSSICULAR REPLACEMENT PROSTHESIS

TORSADES DE POINTES

Torsades de pointes and long QT syndromes. **Janeira LF. Am Fam Physician** 1995 Oct;52(5):1447-53 (36 ref.)

CHEMICALLY INDUCED

Cardiac actions of antihistamines. **Woosley RL. Annu Rev Pharmacol Toxicol** 1996;36:233-52 (73 ref.)
The association between intravenous haloperidol and Torsades de Pointes. Three cases and a literature review. **Hunt N, et al. Psychosomatics** 1995 Nov-Dec;36(6):541-9 (55 ref.)

PATHOLOGY

Role of M cells in acquired long QT syndrome, U waves, and torsade de pointes. **Antzelevitch C, et al. J Electrocardiol** 1995;28 Suppl:131-8 (44 ref.)

TORSION DYSTONIA see DYSTONIA MUSCULORUM DEFORMANS

TORTICOLLIS

DIAGNOSIS

[Benign paroxysmal torticollis in infancy] **Oliván Gonzalvo G. An Esp Pediatr** 1996 Jun;44(6):615-6 (8 ref.) **(Spa)**

ETIOLOGY

Pseudotumor of infancy and congenital muscular torticollis. **Porter SB, et al. Am Fam Physician** 1995 Nov 1; 52(6):1731-6 (19 ref.)

PHYSIOPATHOLOGY

Cervical dystonia (spasmodic torticollis). Some aspects of the natural history. **Van Zandijcke M. Acta Neurol Belg** 1995 Dec;95(4):210-5 (39 ref.)
Orthopedic conditions of the cervical spine and shoulder. **Epps HR, et al. Pediatr Clin North Am** 1996 Aug; 43(4):919-31 (37 ref.)

TORTURE

[Identification of victims of violence and torture: the practitioner's role] **Subilia L, et al. Schweiz Med Wochenschr** 1996 Jul 27;126(30):1291-6 (20 ref.) (Eng. Abstr.) **(Fre)**

TORULA see CRYPTOCOCCUS

TORULOPSIS see CANDIDA

TORULOSIS see CRYPTOCOCCOSIS

TOTAL BODY IRRADIATION see WHOLE-BODY IRRADIATION

TOTAL PARENTERAL NUTRITION see PARENTERAL NUTRITION, TOTAL

TOTAL QUALITY MANAGEMENT

Quality improvement and substance abuse: rethinking impaired provider policies. **Corsino BV, et al. Am J Med Qual** 1996 Summer;11(2):94-9 (21 ref.)
The quality of cervical cancer screening: a primary care perspective. **Curtis P, et al. Am J Med Qual** 1996 Spring; 11(1):11-7 (49 ref.)
Total quality management: field of dreams? [see comments] **Bigelow B, et al. Health Care Manage Rev** 1995 Fall; 20(4):15-25; discussion 28-9, 30-33 (127 ref.) Comment in: Health Care Manage Rev 1996 Winter;21(1):93-4.
Can educational accreditation drive interdisciplinary learning in the health professions? **Gelmon SB. Jt Comm J Qual Improv** 1996 Mar;22(3):213-22 (27 ref.)
Accepting the Galvin challenge: increasing efficiency and productivity in health professions education. **Neuhauser D, et al. Jt Comm J Qual Improv** 1996 Mar;22(3):223-27 (1 ref.)
[Company Wide Quality Control (total quality): methodological principles and intervention techniques for step-by-step improvement] **Corbara F, et al. G Ital Cardiol** 1996 Jan;26(1):61-72 (8 ref.) (Eng. Abstr.) **(Ita)**

METHODS

Strategic service quality management for health care. **Anderson EA, et al. Am J Med Qual** 1996 Spring; 11(1):3-10 (48 ref.)
Ten tools of continuous quality improvement: a review and case example of hospital discharge. **Ziegenfuss JT JR, et al. Am J Med Qual** 1995 Winter;10(4):213-20 (8 ref.)
Implementing TQM in the health care sector. **Motwani J, et al. Health Care Manage Rev** 1996 Winter;21(1):73-82 (44 ref.)
Critical care medicine: opportunities and strategies for improvement. **Cohen IL, et al. Jt Comm J Qual Improv** 1996 Feb;22(2):85-103 (97 ref.)

ORGANIZATION & ADMINISTRATION

Quality in residency training: toward a broader, multidimensional definition. **Elliott RL, et al. Acad Med** 1996 Mar;71(3):243-7 (15 ref.)
Total quality management and the medical director. **Schnelle JF. Clin Geriatr Med** 1995 Aug;11(3):433-48 (21 ref.)
Linking quality improvement with primary health care. **Sukati NA. Int Nurs Rev** 1995 Jul-Aug;42(4):109-14, 124 (36 ref.)
Improving nursing practice, education, and research. **Fagin CM. J Nurs Adm** 1996 Mar;26(3):30-7 (12 ref.)
Performance measurement: integrating quality management and activity-based cost management. **McKeon T. J Nurs Adm** 1996 Apr;26(4):45-51 (8 ref.)
Managed care and total quality management: a necessary integration. **Phoon J, et al. J Nurs Care Qual** 1996 Jan; 10(2):25-32 (22 ref.)
How to increase efficiency in the operating room. **Kanich DG, et al. Surg Clin North Am** 1996 Feb;76(1):161-73 (23 ref.)
Cost effectiveness in the intensive care unit. **Kirton OC, et al. Surg Clin North Am** 1996 Feb;76(1):175-200 (54 ref.)

TOURETTE SYNDROME

CHEMICALLY INDUCED

Tardive tourettism after exposure to neuroleptic therapy. **Bharucha KJ, et al. Mov Disord** 1995 Nov;10(6):791-3 (17 ref.)

DIAGNOSIS

[Neuroimaging techniques in the Gilles de la Tourette syndrome] **Lampreave JL, et al. Rev Neurol** 1996 Aug; 24(132):921-5 (39 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Clinical management of Tourette's syndrome and associated disorders. **Sandor P. Can J Psychiatry** 1995 Dec; 40(10):577-83 (58 ref.)
Psychopharmacology in child and adolescent psychiatry: a review of the past seven years. Part I. **Campbell M, et al. J Am Acad Child Adolesc Psychiatry** 1995 Sep; 34(9):1124-32 (132 ref.)
Considerations of natural history and pathophysiology in the psychopharmacology of Tourette's syndrome. **Peterson BS. J Clin Psychiatry** 1996;57 Suppl 9:24-34 (82 ref.)

PHYSIOPATHOLOGY

Effects of picotesla flux electromagnetic fields on dopaminergic transmission in Tourette's syndrome. **Sandyk R. Int J Neurosci** 1996 Feb;84(1-4):187-94 (95 ref.)
Considerations of natural history and pathophysiology in the psychopharmacology of Tourette's syndrome. **Peterson BS. J Clin Psychiatry** 1996;57 Suppl 9:24-34 (82 ref.)

PSYCHOLOGY

Executive functions and developmental psychopathology. **Pennington BF, et al. J Child Psychol Psychiatry** 1996 Jan; 37(1):51-87 (225 ref.)

TOURETTE'S DISORDER see TOURETTE SYNDROME

TOURNIQUET PAIN TEST see PAIN MEASUREMENT

TOURNIQUETS

Surgical hemostasis by pneumatic ankle tourniquet during 3027 podiatric operations. **Derner R, et al. J Foot Ankle Surg** 1995 May-Jun;34(3):236-46 (87 ref.)
[Do we still need a blood-free field?] **Sarkar MR. Unfallchirurg** 1996 May;99(5):374-8 (40 ref.) **(Ger)**

TOXEMIA

METABOLISM

[Endotoxemia and carbonhydrate metabolism] **Zhai Z, et al. Chung Hua Cheng Hsing Shao Shang Wai Ko Tsa Chih** 1996 Jan;12(1):62-5 (21 ref.) **(Chi)**

VETERINARY

Endotoxaemia: where do we go from here? [editorial; comment] **Barton MH. Br Vet J** 1995 Sep-Oct; 151(5):469-71 (4 ref.) Comment on: Br Vet J 1995 Sep-Oct;151(5):489-522.
Mediators and vascular effects in response to endotoxin [see comments] **Olson NC, et al. Br Vet J** 1995 Sep-Oct; 151(5):489-522 (152 ref.) Comment in: Br Vet J 1995 Sep-Oct;151(5):469-71.

TOXIC SHOCK SYNDROME see SHOCK, SEPTIC

TOXIC SUBSTANCES, ENVIRONMENTAL see HAZARDOUS SUBSTANCES

TOXICITY TESTS

Immunotoxicity of PCBs (Aroclors) in relation to Great Lakes. **Tryphonas H. Environ Health Perspect** 1995 Dec;

103 Suppl 9:35–46 (97 ref.)
Use of mechanistic and pharmacokinetic data for risk assessment at the National Institute of Environmental Health Sciences (NIEHS). Schwetz BA. **Toxicol Lett** 1995 Sep;79(1–3):29–32 (0 ref.)
Strain as a determinant factor in the differential responsiveness of rats to chemicals. Kacew S, et al. **Toxicol Pathol** 1995 Nov–Dec;23(6):701–14; discussion 714–5 (95 ref.)

METHODS

Alternative method of assessing toxicity. Atterwill CK. **Methods Mol Biol** 1995;43:1–9 (8 ref.)
Immune function assays. Nicklin S. **Methods Mol Biol** 1995; 43:245–56 (10 ref.)
Chemical mixtures: current risk assessment methodologies and future directions. Seed J, et al. **Regul Toxicol Pharmacol** 1995 Aug;22(1):76–94 (48 ref.)
Reproductive toxicity testing of therapeutic biotechnology agents. Henck JW, et al. **Teratology** 1996 Mar;53(3):185–95 (34 ref.)
Predictive testing for respiratory sensitization in the mouse. Kimber I, et al. **Toxicol Lett** 1996 Aug;86(2–3):193–8 (31 ref.)
Predictive testing for respiratory sensitisation. Pauluhn J. **Toxicol Lett** 1996 Aug;86(2–3):177–85 (17 ref.)
[A new method for evaluating acute toxicity intragastrically for classification of chemical substances] Rydzyński K, et al. **Med Pr** 1995;46(4):369–83 (29 ref.) (Eng. Abstr.) **(Pol)**
[Prospects of the use of a quantitative functional–morphological method in the evaluation of toxicity of chemical substances] Popuchiyev VV. **Med Tr Prom Ekol** 1995;(12):24–7 (10 ref.) (Eng. Abstr.) **(Rus)**

STANDARDS

Neurotoxicity modeling for risk assessment. Kodell RL, et al. **Regul Toxicol Pharmacol** 1995 Aug;22(1):24–9 (10 ref.)

TOXICODENDRON

see related
DERMATITIS, TOXICODENDRON

TOXICODENDRON DERMATITIS see **DERMATITIS, TOXICODENDRON**

TOXICOKINETICS see **PHARMACOKINETICS**

TOXICOLOGY

see related
POISONS

Interest and limits of human tissue and cell use in pharmacotoxicology. Potier M, et al. **Cell Biol Toxicol** 1995 Aug;11(3–4):133–9 (30 ref.)
Role of the clinical toxicologist in court. Chamberlain RT. **Clin Chem** 1996 Aug;42(8 Pt 2):1337–41 (29 ref.)
Trace element food toxicology: an old and ever–growing discipline. Ybañez N, et al. **Crit Rev Food Sci Nutr** 1996 Apr;36(4):299–320 (87 ref.)
Modifying toxicokinetics with antidotes. Baud FJ, et al. **Toxicol Lett** 1995 Dec;82–83:785–93 (20 ref.)
Understanding mechanisms of inhaled toxicants: implications for replacing default factors with chemical–specific data. Bogdanffy MS, et al. **Toxicol Lett** 1995 Dec;82–83:919–32 (46 ref.)
Receptor–mediated toxicity. Gustafsson JA. **Toxicol Lett** 1995 Dec;82–83:465–70 (24 ref.)
The expanding role of quantitative structure–activity relationships (QSAR) in toxicology. Hansch C, et al. **Toxicol Lett** 1995 Sep;79(1–3):45–53 (11 ref.)
Perspectives on collaboration and infrastructure development: industry perspectives. Knaak JB. **Toxicol Lett** 1995 Sep;79(1–3):305–12 (32 ref.)
Program development in military toxicology laboratories. Mattie DR, et al. **Toxicol Lett** 1995 Sep;79(1–3):291–5 (1 ref.)
Injury and repair as opposing forces in risk assessment. Mehendale HM. **Toxicol Lett** 1995 Dec;82–83:891–9 (43 ref.)
Perspectives on collaboration and infrastructure development among government, academia, and industry. O'Flaherty EJ. **Toxicol Lett** 1995 Sep;79(1–3):297–8 (0 ref.)
NIEHS perspectives on collaboration among government, academia, and industry. Olden K. **Toxicol Lett** 1995 Sep; 79(1–3):287–9 (0 ref.)
The hazards of synthetic (anthropogenic) chemicals. Silbergeld EK. **Toxicol Lett** 1995 Dec;82–83:835–41 (29 ref.)
The use of physiologically–based pharmacokinetic/pharmacodynamic dosimetry models for chemical mixtures. Yang RS, et al. **Toxicol Lett** 1995 Dec; 82–83:497–504 (21 ref.)
Risk assessment and biological mechanisms: lessons learned, future opportunities. McClellan RO. **Toxicology** 1995 Sep 1;102(1–2):239–58 (48 ref.)
Assessing the risk assessment paradigm. Omenn GS. **Toxicology** 1995 Sep 1;102(1–2):23–8 (24 ref.)
[Molecular pharmacological and toxicological studies of drug–metabolizing enzymes] Kato R. **Yakugaku Zasshi** 1995 Sep;115(9):661–80 (94 ref.) (Eng. Abstr.) **(Jpn)**

LEGISLATION & JURISPRUDENCE

Historical perspective on risk assessment in the federal government. Graham JD. **Toxicology** 1995 Sep 1; 102(1–2):29–52 (169 ref.)

METHODS

Hazard evaluation in risk assessment: whatever happened to sound scientific judgment and weight of evidence? Doull J, et al. **Drug Metab Rev** 1996 Feb–May;28(1–2):285–99 (9 ref.)
Comparative methods of toxicity testing. Consensus document following an International Life Sciences Institute–ILSI Europe Workshop held in May 1995. Huggett AC, et al. **Food Chem Toxicol** 1996 Feb; 34(2):183–92 (34 ref.)
New molecular endpoints and methods for routine toxicity testing. MacGregor JT, et al. **Fundam Appl Toxicol** 1995 Jul;26(2):156–73 (76 ref.)
Precision–cut tissue slices: applications in pharmacology and toxicology. Parrish AR, et al. **Life Sci** 1995;57(21):1887–901 (151 ref.)
Measurements of environmental lead contamination and human exposure. Flegal AR, et al. **Rev Environ Contam Toxicol** 1995;143:1–45 (231 ref.)
Development of physiologically based pharmacokinetic and physiologically based pharmacodynamic models for applications in toxicology and risk assessment. Andersen ME. **Toxicol Lett** 1995 Sep;79(1–3):35–44 (38 ref.)
The future of mechanistic research in risk assessment: where are we going and can we get there from here? Goddard MJ, et al. **Toxicology** 1995 Sep 1;102(1–2):53–70 (84 ref.)
[Potential and limitations of neutron activation analysis methods for measuring elements of toxicological and environmental interest] Gallorini M. **Ann Ist Super Sanita** 1995;31(2):239–44 (10 ref.) (Eng. Abstr.) **(Ita)**

STANDARDS

Biomarkers in epidemiology. Grandjean P. **Clin Chem** 1995 Dec;41(12 Pt 2):1800–3 (13 ref.)
Improving the science and art of risk assessment. Doull J. **Drug Metab Rev** 1996 Feb–May;28(1–2):1–7 (6 ref.)
Harmonization of animal clinical pathology testing in toxicity and safety studies. The Joint Scientific Committee for International Harmonization of Clinical Pathology Testing. Weingand K, et al. **Fundam Appl Toxicol** 1996 Feb; 29(2):198–201 (26 ref.)
Commentary. The uncontrolled variable in risk assessment: ad libitum overfed rodents—fat, facts and fiction. Keenan KP. **Toxicol Pathol** 1996 May–Jun;24(3):376–83 (57 ref.)
Peer review in toxicologic pathology. Ward JM, et al. **Toxicol Pathol** 1995 Mar–Apr;23(2):226–34 (26 ref.)

TRENDS

Acquisition and use of human in vitro liver preparations. Guillouzo A. **Cell Biol Toxicol** 1995 Aug;11(3–4):141–5 (17 ref.)
Extrapolating the future: research trends in modeling. Menzel DB. **Toxicol Lett** 1995 Sep;79(1–3):299–303 (8 ref.)
A toxicologic pathologist's view of apoptosis or I used to call it necrobiosis, but now I'm singing the apoptosis blues [see comments] Levin S. **Toxicol Pathol** 1995 Jul–Aug; 23(4):533–9 (34 ref.) Comment in: Toxicol Pathol 1995 Sep–Oct;23(5):617–21.

TOXIN–ANTIBODY CONJUGATES see **IMMUNOTOXINS**

TOXIN–ANTIBODY HYBRIDS see **IMMUNOTOXINS**

TOXIN CARRIERS see **IMMUNOTOXINS**

TOXIN CONJUGATES see **IMMUNOTOXINS**

TOXINS

see related
ANTITOXINS

ADVERSE EFFECTS

Sentinel screening for human immunotoxicity. Descotes J, et al. **Arch Toxicol Suppl** 1996;18:29–33 (13 ref.)
Specific factors leading to interindividual variability in response to occupational toxicants. Goergens HW. **Arch Toxicol Suppl** 1996;18:357–61 (28 ref.)
Assessment of immunotoxic effects in humans. Descotes J, et al. **Clin Chem** 1995 Dec;41(12 Pt 2):1870–3 (36 ref.)

CHEMISTRY

Middle molecules: toxicity and removal by hemodialysis and related strategies. Vanholder R, et al. **Artif Organs** 1995 Nov;19(11):1120–5 (46 ref.)

IMMUNOLOGY

Antibodies proposed as therapeutic agents. Bismuth C, et al. **Arch Toxicol Suppl** 1996;18:321–32 (39 ref.)

ISOLATION & PURIFICATION

[Removal of toxic substances from the body as a method for normalization of the functioning of the immune system] Lebedev KA, et al. **Fiziol Cheloveka** 1995 Sep–Oct; 21(5):131–43 (22 ref.) **(Rus)**
[Current status of the plasmapheresis problem] Kalinin NN. **Gematol Transfuziol** 1995 Mar–Apr;40(2):46–8 (12 ref.) **(Rus)**

PHARMACOKINETICS

[The role of dialysis membranes in elimination of uremic toxins] Grzeszczak W, et al. **Przegl Lek** 1996;53(5):439–42 (27 ref.) **(Pol)**

PHARMACOLOGY

Potential role of environmental genotoxic agents in diabetes mellitus and neurodegenerative diseases. Eizirik DL, et al. **Biochem Pharmacol** 1996 Jun 28;51(12):1585–91 (92 ref.)
Molecular biology and evolution of resistance of toxicants. Taylor M, et al. **Mol Biol Evol** 1996 Jul;13(6):719–34 (141 ref.)

TOXICITY

The Gerhard Zbinden Memorial Lecture. Alteration of cell signalling in chemical toxicity. Nicotera P. **Arch Toxicol Suppl** 1996;18:3–11 (46 ref.)
Toxicological data needed for safety evaluation and regulation on inherent plant toxins. Speijers GJ. **Nat Toxins** 1995;3(4):222–6; discussion 242 (9 ref.)
Function and activation of the transcription factor NF–kappa B in the response to toxins and pathogens. Schmitz ML. **Toxicol Lett** 1995 Dec;82–83:407–11 (19 ref.)

TOXINS, CHIMERIC see **IMMUNOTOXINS**

TOXINS, DEACTIVATED see **TOXOIDS**

TOXINS, TARGETED see **IMMUNOTOXINS**

TOXOCARA CANIS

[Hepatic toxocariasis] Ishibashi H, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):48–50 (20 ref.) **(Jpn)**
[Visceral larva migrans: a mixed form of presentation in an adult. The clinical and laboratory aspects] Barra LA, et al. **Rev Soc Bras Med Trop** 1996 Jul–Aug;29(4):373–6 (18 ref.) (Eng. Abstr.) **(Por)**

TOXOIDS

GENETICS

Genetic detoxification of bacterial toxins: a new approach to vaccine development. Rappuoli R, et al. **Int Arch Allergy Immunol** 1995 Dec;108(4):327–33 (39 ref.)

TOXOPLASMA

DRUG EFFECTS

[New pathogens and mode of action of azithromycin: Toxoplasma gondii] Derouin F. **Pathol Biol (Paris)** 1995 Jun;43(6):561–4 (25 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Induction and regulation of host cell–mediated immunity by Toxoplasma gondii. Sher A, et al. **Ciba Found Symp** 1995; 195:95–104; discussion 104–9 (36 ref.)

PHYSIOLOGY

Intracellular survival of protozoan parasites with special reference to Leishmania spp., Toxoplasma gondii and Trypanosoma cruzi. Mauël J. **Adv Parasitol** 1996;38:1–51 (250 ref.)
Reactivation toxoplasmic retinochoroiditis in patients undergoing bone marrow transplantation: is there a role for chemoprophylaxis? Peacock JE Jr, et al. **Bone Marrow Transplant** 1995 Jun;15(6):983–7 (23 ref.)
Molecular genetic strategies in Toxoplasma gondii: close in on a successful invader. Soldati D. **FEBS Lett** 1996 Jun 24;389(1):80–3 (37 ref.)
A ubiquitous intracellular parasite: the cellular biology of Toxoplasma gondii. Smith JE. **Int J Parasitol** 1995 Nov; 25(11):1301–9 (88 ref.)

TOXOPLASMA GONDII see **TOXOPLASMA**

TOXOPLASMA GONDII INFECTION see **TOXOPLASMOSIS**

TOXOPLASMOSIS

[Toxoplasmosis of the liver] Kume H, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):93–5 (9 ref.) **(Jpn)**

BLOOD

[Ultrasonic signs of fetal toxoplasmosis. Review of the literature] Abboud P, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(7):733–8 (17

ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

[Extracerebral toxoplasmosis in immunodepressed subjects. Case report of a case of pulmonary toxoplasmosis in an HIV-positive patient and literature review] Kamm W, et al. **Rev Med Suisse Romande** 1996 May;116(5):385–90 (23 ref.) **(Fre)**

DRUG THERAPY

Therapeutic approaches for AIDS-related toxoplasmosis [see comments] Behbahani R, et al. **Ann Pharmacother** 1995 Jul–Aug;29(7–8):760–8 (52 ref.) Comment in: Ann Pharmacother 1995 Dec;29(12):1303–4.

Atovaquone. A review of its pharmacological properties and therapeutic efficacy in opportunistic infections. Spencer CM, et al. **Drugs** 1995 Jul;50(1):176–96 (64 ref.)

[New pathogens and mode of action of azithromycin: Toxoplasma gondii] Derouin F. **Pathol Biol (Paris)** 1995 Jun;43(6):561–4 (25 ref.) (Eng. Abstr.) **(Fre)**

EPIDEMIOLOGY

Duodenal and hepatic toxoplasmosis in a patient with HIV infection: review of the literature. Bonacini M, et al. **Am J Gastroenterol** 1996 Sep;91(9):1838–40 (13 ref.)

ETIOLOGY

[Toxoplasmosis as a risk factor in pregnant women after renal transplantation] Ejmocka-Ambroziak A, et al. **Wiad Lek** 1994 Sep;47(17–18):700–1 (9 ref.) (Eng. Abstr.) **(Pol)**

IMMUNOLOGY

Induction and regulation of host cell-mediated immunity by Toxoplasma gondii. Sher A, et al. **Ciba Found Symp** 1995; 195:95–104; discussion 104–9 (36 ref.)

PREVENTION & CONTROL

Preventive care in obstetrics: toxoplasmosis, cytomegalovirus, and hepatitis B. Ledger WJ. **J Matern Fetal Med** 1996 May–Jun;5(3):100–5 (26 ref.)

THERAPY

The potential role of azithromycin in the treatment of prophylaxis of toxoplasmosis. Chang HR. **Int J STD AIDS** 1996;7 Suppl 1:18–22 (34 ref.)

TOXOPLASMOSIS, ANIMAL

[Experimental models of toxoplasmosis. Pharmacological applications] Derouin F, et al. **Parasite** 1995 Sep; 2(3):243–56 (85 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

[New pathogens and mode of action of azithromycin: Toxoplasma gondii] Derouin F. **Pathol Biol (Paris)** 1995 Jun;43(6):561–4 (25 ref.) (Eng. Abstr.) **(Fre)**

TOXOPLASMOSIS, CEREBRAL

DIAGNOSIS

Radiologic and laboratory evaluation of enhancing brain lesions in patients with AIDS. Johnson MD, et al. **Compr Ther** 1995 Nov;21(11):645–52 (45 ref.)

Neurologic opportunistic infections. Clifford DB. **Curr Opin Neurol** 1995 Jun;8(3):175–8 (32 ref.)

[Cerebral toxoplasmosis. Neuroradiologic diagnosis and prognostic monitoring] Martin-Duverneuil N, et al. **J Neuroradiol** 1995 Sep;22(3):196–203 (28 ref.) (Eng. Abstr.) **(Fre)**

[Magnetic resonance in AIDS-related encephalopathy] Gualdi GF, et al. **Clin Ter** 1995 Dec;146(12):843–56 (42 ref.) (Eng. Abstr.) **(Ita)**

[Applications of the polymerase chain reaction (PCR) to the diagnosis of central nervous system infections] Querol JM, et al. **An Med Interna** 1996 May;13(5):235–8 (20 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

[New pathogens and mode of action of azithromycin: Toxoplasma gondii] Derouin F. **Pathol Biol (Paris)** 1995 Jun;43(6):561–4 (25 ref.) (Eng. Abstr.) **(Fre)**

[Clarithromycin combined with pyrimethamine in cerebral toxoplasmosis--a report of 2 cases] Dalston MO, et al. **Rev Soc Bras Med Trop** 1995 Oct–Dec;28(4):409–13 (11 ref.) (Eng. Abstr.) **(Por)**

PREVENTION & CONTROL

Preventing toxoplasmic encephalitis in persons infected with human immunodeficiency virus. Richards FO Jr, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S49–56 (44 ref.)

TOXOPLASMOSIS, CONGENITAL

DIAGNOSIS

Diagnosis and treatment of congenital toxoplasmosis. Boyer KM. **Adv Pediatr Infect Dis** 1996;11:449–67 (51 ref.)

Teratogen update: congenital toxoplasmosis. Lynfield R, et al. **Teratology** 1995 Sep;52(3):176–80 (22 ref.)

DRUG THERAPY

Diagnosis and treatment of congenital toxoplasmosis. Boyer KM. **Adv Pediatr Infect Dis** 1996;11:449–67 (51 ref.)

PREVENTION & CONTROL

-Screening for toxoplasmosis in pregnancy- Extermann P. **Arch Gynecol Obstet** 1995;256 Suppl:S170–2 (10 ref.) **(Fre)**

-Toxoplasmosis in pregnancy: arguments in favor of systematic screening in Switzerland- Hohlfeld P. **Arch Gynecol Obstet** 1995;256 Suppl:S165–9 (26 ref.) **(Fre)**

THERAPY

Teratogen update: congenital toxoplasmosis. Lynfield R, et al. **Teratology** 1995 Sep;52(3):176–80 (22 ref.)

ULTRASONOGRAPHY

[Ultrasonic signs of fetal toxoplasmosis. Review of the literature] Abboud P, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(7):733–8 (17 ref.) (Eng. Abstr.) **(Fre)**

TOXOPLASMOSIS, OCULAR

COMPLICATIONS

Ocular toxoplasmosis: toxoplasmic retinochoroiditis. Tabbara KF. **Int Ophthalmol Clin** 1995 Spring;35(2):15–29 (29 ref.)

ETIOLOGY

Reactivation toxoplasmic retinochoroiditis in patients undergoing bone marrow transplantation: is there a role for chemoprophylaxis? Peacock JE Jr, et al. **Bone Marrow Transplant** 1995 Jun;15(6):983–7 (23 ref.)

TOYS see **PLAY AND PLAYTHINGS**

TP53 GENES see **GENES, P53**

TP53 PROTEIN see **PROTEIN P53**

TP RECEPTORS see **RECEPTORS, THROMBOXANE**

TPN DIAPHORASE see **NADPH DEHYDROGENASE**

TR ALPHA see **RECEPTORS, THYROID HORMONE**

TR BETA see **RECEPTORS, THYROID HORMONE**

TRABECULAR MESHWORK

ANATOMY & HISTOLOGY

Morphology of the aqueous outflow pathway. Gong H, et al. **Microsc Res Tech** 1996 Mar 1;33(4):336–67 (76 ref.)

METABOLISM

The extracellular matrix and its modulation in the trabecular meshwork. Yue BY. **Surv Ophthalmol** 1996 Mar–Apr; 40(5):379–90 (146 ref.)

[Trabecular meshwork and elastin] Segawa K. **Nippon Ganka Gakkai Zasshi** 1995 Dec;99(12):1291–302 (51 ref.) (Eng. Abstr.) **(Jpn)**

TRABECULECTOMY

Trabeculectomy with intraoperative sponge 5-fluorouracil. Mora JS, et al. **Ophthalmology** 1996 Jun;103(6):963–70 (28 ref.)

ADVERSE EFFECTS

[Is trabeculectomy without danger in case of threatened fixation?] Grunewald F, et al. **J Fr Ophtalmol** 1996; 19(4):253–8 (18 ref.) (Eng. Abstr.) **(Fre)**

METHODS

[Long-term reduction of intraocular pressure by goniotrepanation or laser trabeculoplasty] Funk J, et al. **Klin Monatsbl Augenheilkd** 1995 Oct;207(4):215–23 (38 ref.) (Eng. Abstr.) **(Ger)**

TRABECULOPLASTY see **TRABECULECTOMY**

TRACE ELEMENTS

see related
MICRONUTRIENTS

[Metal dermatoses I] Schwarz T, et al. **Hautarzt** 1996 Apr; 47(4):316–28; quiz 327–8 (10 ref.) **(Ger)**

[Zinc--update of an essential trace element] Rimbach G, et al. **Z Ernahrungswiss** 1996 Jun;35(2):123–42 (211 ref.) (Eng. Abstr.) **(Ger)**

[Renal disease and trace elements] Marumo F, et al. **Nippon Rinsho** 1996 Jan;54(1):93–8 (7 ref.) (Eng. Abstr.) **(Jpn)**

[Trace elements in spinocerebellar degeneration] Nakashima K. **Nippon Rinsho** 1996 Jan;54(1):129–33 (21 ref.) (Eng. Abstr.) **(Jpn)**

[Inherited neurological disease--relationship between an essential trace elements and Wilson/Menkes disease] Ozawa M, et al. **Nippon Rinsho** 1996 Jan;54(1):117–22 (18 ref.) (Eng. Abstr.) **(Jpn)**

[Overview--suppression effect of essential trace elements on arteriosclerotic development and it's mechanism] Saito N. **Nippon Rinsho** 1996 Jan;54(1):59–66 (21 ref.) (Eng. Abstr.) **(Jpn)**

[Essential trace element and skin diseases] Yamada H, et al. **Nippon Rinsho** 1996 Jan;54(1):99–105 (21 ref.) (Eng. Abstr.) **(Jpn)**

[Amyotrophic lateral sclerosis--causative role of trace elements] Yase Y. **Nippon Rinsho** 1996 Jan;54(1):123–8 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Alzheimer's disease and trace elements] Yoshida H, et al. **Nippon Rinsho** 1996 Jan;54(1):111–6 (20 ref.) (Eng. Abstr.) **(Jpn)**

ADMINISTRATION & DOSAGE

Micronutrients in critical illness. Demling RH, et al. **Crit Care Clin** 1995 Jul;11(3):651–73 (40 ref.)

[Trace elements in long-term total parenteral nutrition] Itokawa Y. **Nippon Rinsho** 1996 Jan;54(1):172–8 (20 ref.) (Eng. Abstr.) **(Jpn)**

ANALYSIS

Trace element food toxicology: an old and ever-growing discipline. Ybañez N, et al. **Crit Rev Food Sci Nutr** 1996 Apr;36(4):299–320 (87 ref.)

Bioavailability of micronutrients in a fibre-rich diet, especially related to minerals. Frølich W. **Eur J Clin Nutr** 1995 Oct;49 Suppl 3:S116–22 (44 ref.)

Risk assessment of essential trace elements: new approaches to setting recommended dietary allowances and safety limits. Mertz W. **Nutr Rev** 1995 Jul;53(7):179–85 (38 ref.)

Analysis of trace elements in the central nerve tissues with inductively coupled plasma-mass spectrometry. Ejima A, et al. **Tohoku J Exp Med** 1996 Jan;178(1):1–10 (14 ref.)

[Handling of biological material before trace element determination] Caroli S, et al. **Ann Ist Super Sanita** 1995; 31(2):219–24 (15 ref.) (Eng. Abstr.) **(Ita)**

[Potential and limitations of neutron activation analysis methods for measuring elements of toxicological and environmental interest] Gallorini M. **Ann Ist Super Sanita** 1995;31(2):239–44 (10 ref.) (Eng. Abstr.) **(Ita)**

[Instrumental analysis of trace elements] Mattiello G, et al. **Ann Ist Super Sanita** 1995;31(2):233–7 (10 ref.) (Eng. Abstr.) **(Ita)**

[Assessment of factors causing pre-analytic variability] Minoia C. **Ann Ist Super Sanita** 1995;31(2):225–32 (13 ref.) (Eng. Abstr.) **(Ita)**

[Two dimensional imaging and functional evaluation of trace elements on tissues and organs by x-ray spectroscopy] Futatsugi Y, et al. **Nippon Rinsho** 1996 Jan;54(1):192–201 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Particle Induced X-ray Emission (PIXE) for analysis of trace elements in biological materials] Iwata Y. **Nippon Rinsho** 1996 Jan;54(1):221–7 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Neutron activation analysis of biological samples] Ohta A, et al. **Nippon Rinsho** 1996 Jan;54(1):207–14 (7 ref.) (Eng. Abstr.) **(Jpn)**

[Problems related to trace element determination in biological materials] Okamoto K. **Nippon Rinsho** 1996 Jan; 54(1):186–91 (6 ref.) (Eng. Abstr.) **(Jpn)**

[Flameless atomic absorption spectrometry for analysis of trace elements in biological materials] Watanabe M. **Nippon Rinsho** 1996 Jan;54(1):228–32 (7 ref.) (Eng. Abstr.) **(Jpn)**

[Inductively coupled plasma atomic emission spectrometry and ICP mass spectrometry] Yoshinaga J. **Nippon Rinsho** 1996 Jan;54(1):202–6 (14 ref.) (Eng. Abstr.) **(Jpn)**

BLOOD

Storage and preservation of blood and urine for trace element analysis. A review. Subramanian KS. **Biol Trace Elem Res** 1995 Aug–Sep;49(2–3):187–210 (96 ref.)

[Concentrations of essential trace elements in blood and introduction of analytical techniques] Chiba M. **Nippon Rinsho** 1996 Jan;54(1):179–85 (4 ref.) (Eng. Abstr.) **(Jpn)**

[Reversed-phase high-performance liquid chromatograph--application to serum aluminium monitoring] Hoshino H, et al. **Nippon Rinsho** 1996 Jan; 54(1):215–20 (9 ref.) (Eng. Abstr.) **(Jpn)**

DEFICIENCY

[Zinc-deficient disorders of sense organs--dark adaptation, taste and smell disorders] Tomita H. **Nippon Rinsho** 1996 Jan;54(1):141–7 (40 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSTIC USE

[Methods and clinical significance of an oral tolerance test of essential trace element, especially an oral zinc tolerance

test] Arakawa Y, et al. **Nippon Rinsho** 1996 Jan; 54(1):162–71 (35 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Nutrition and immunity with emphasis on infection and autoimmune disease. Harbige LS. **Nutr Health** 1996; 10(4):285–312 (136 ref.)

METABOLISM

Bioavailability of micronutrients in a fibre-rich diet, especially related to minerals. Frølich W. **Eur J Clin Nutr** 1995 Oct;49 Suppl 3:S116–22 (44 ref.)

Trace elements in renal failure: are they clinically important? [editorial] Gallieni M, et al. **Nephrol Dial Transplant** 1996 Jul;11(7):1232–5 (38 ref.)

[Dynamics of essential trace elements in the body—the mechanism of absorption, transport, storage and excretion] Saito T, et al. **Nippon Rinsho** 1996 Jan;54(1):12–6 (11 ref.) (Eng. Abstr.) **(Jpn)**

PHYSIOLOGY

[Trace elements: biological role and nutritional aspects for humans] Ingrao G, et al. **Ann Ist Super Sanita** 1995; 31(2):275–81 (32 ref.) (Eng. Abstr.) **(Ita)**

[Trace elements as activation factors of enzymes: characteristic enzymes and their activation mechanisms] Esaki N, et al. **Nippon Rinsho** 1996 Jan;54(1):17–25 (18 ref.) (Eng. Abstr.) **(Jpn)**

[Role of essential trace elements in intracellular signal transduction mechanisms] Furukawa T. **Nippon Rinsho** 1996 Jan;54(1):26–32 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Trace elements and blood pressure regulation] Ito Y, et al. **Nippon Rinsho** 1996 Jan;54(1):106–10 (28 ref.) (Eng. Abstr.) **(Jpn)**

[Role of essential trace elements in the disturbance of carbohydrate metabolism] Kimura K. **Nippon Rinsho** 1996 Jan;54(1):79–84 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Essential trace elements and immunity] Kodama H. **Nippon Rinsho** 1996 Jan;54(1):46–51 (21 ref.) (Eng. Abstr.) **(Jpn)**

[Trace elements: mechanistic aspects of anticarcinogenic action] Koyama H. **Nippon Rinsho** 1996 Jan;54(1):52–8 (22 ref.) (Eng. Abstr.) **(Jpn)**

[The role of trace elements concerning to disorders of lipid metabolism] Miyake N. **Nippon Rinsho** 1996 Jan;54(1):73–8 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Role of trace elements on metallothionein gene expression] Ohta H. **Nippon Rinsho** 1996 Jan;54(1):40–5 (23 ref.) (Eng. Abstr.) **(Jpn)**

[Effects of essential trace elements on bone turnover—in relation to the osteoporosis] Okano T. **Nippon Rinsho** 1996 Jan;54(1):148–54 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Role of essential trace elements on sexual function and its disorder] Shinohara A, et al. **Nippon Rinsho** 1996 Jan; 54(1):155–61 (20 ref.) (Eng. Abstr.) **(Jpn)**

[Liver diseases and essential trace elements] Suzuki K, et al. **Nippon Rinsho** 1996 Jan;54(1):85–92 (18 ref.) (Eng. Abstr.) **(Jpn)**

[Trace elements and their physiological roles] Wada O, et al. **Nippon Rinsho** 1996 Jan;54(1):5–11 (12 ref.) (Eng. Abstr.) **(Jpn)**

STANDARDS

Risk assessment of essential trace elements: new approaches to setting recommended dietary allowances and safety limits. Mertz W. **Nutr Rev** 1995 Jul;53(7):179–85 (38 ref.)

[Reference values for trace elements in biological fluids] Apostoli P. **Ann Ist Super Sanita** 1995;31(2):261–74 (30 ref.) (Eng. Abstr.) **(Ita)**

[Reference materials and trace element analysis] Gallorini M, et al. **Ann Ist Super Sanita** 1995;31(2):255–9 (11 ref.) (Eng. Abstr.) **(Ita)**

[Quality control for trace elements in occupational and environmental medicine] Morisi G, et al. **Ann Ist Super Sanita** 1995;31(2):245–54 (8 ref.) (Eng. Abstr.) **(Ita)**

THERAPEUTIC USE

Trace elements in parenteral micronutrition. Leung FY. **Clin Biochem** 1995 Dec;28(6):561–6 (76 ref.)

URINE

Storage and preservation of blood and urine for trace element analysis. A review. Subramanian KS. **Biol Trace Elem Res** 1995 Aug-Sep;49(2–3):187–210 (96 ref.)

TRACHEA

see related
ANESTHESIA, INTRATRACHEAL
INTUBATION, INTRATRACHEAL
TRACHEOSTOMY
TRACHEOTOMY

ABNORMALITIES

Prenatal sonographic diagnosis of upper airway obstruction: a challenge that can be achieved. Golan-Porat N, et al. **J Laryngol Otol** 1996 Jun;110(6):583–5 (16 ref.)

Congenital tracheal cartilaginous sleeve. Lin SY, et al. **Laryngoscope** 1995 Nov;105(11):1213–9 (17 ref.)

Multiple pulmonary chondrohamartomas in trachea, bronchi and lung parenchyma. Review of the literature. Domínguez H, et al. **Respir Med** 1996 Feb;90(2):111–4 (17 ref.)

ANATOMY & HISTOLOGY

Anatomy of the larynx, trachea, and bronchi. Armstrong WB, et al. **Otolaryngol Clin North Am** 1995 Aug;28(4):685–99 (24 ref.)

ENZYMOLOGY

The role of HMT (histamine N-methyltransferase) in airways: a review. Okinaga S, et al. **Methods Find Exp Clin Pharmacol** 1995 Nov;17 Suppl C:16–20 (52 ref.)

INJURIES

CT in blunt chest trauma: pulmonary, tracheobronchial, and diaphragmatic injuries. Kang EY, et al. **Semin Ultrasound CT MR** 1996 Apr;17(2):114–8 (39 ref.)

[Tracheal rupture secondary to intubation or tracheostomy] Varela G, et al. **Arch Bronconeumol** 1995 Oct;31(8):421–3 (11 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

Anatomy of the larynx, trachea, and bronchi. Armstrong WB, et al. **Otolaryngol Clin North Am** 1995 Aug;28(4):685–99 (24 ref.)

RADIOGRAPHY

Radiology of the central airways. Worrell JA. **Otolaryngol Clin North Am** 1995 Aug;28(4):701–20 (23 ref.)

SURGERY

An overview of treatment options for lower airway obstruction. Wanamaker JR, et al. **Otolaryngol Clin North Am** 1995 Aug;28(4):751–70 (52 ref.)

TRACHEAL CYST see **MEDIASTINAL CYST**

TRACHEAL DISEASES

COMPLICATIONS

Laryngeal squamous carcinoma associated with longstanding localised amyloidosis. A case report. Navani SS, et al. **Indian J Cancer** 1995 Mar;32(1):43–5 (7 ref.)

DIAGNOSIS

Tracheobronchopathia osteochondroplastica. Report of a young man with severe disease and retrospective review of 18 cases. Vilkman S, et al. **Respiration** 1995;62(3):151–4 (13 ref.)

ETIOLOGY

[Tracheobronchial complications of assisted ventilation in children] Denoyelle F, et al. **Rev Mal Respir** 1996 Jul; 13(3):259–64 (34 ref.) (Eng. Abstr.) **(Fre)**

[Complications of tracheotomy (editorial)] Viau F. **Rev Mal Respir** 1996;13(2):89–92 (19 ref.) **(Fre)**

[Clinical feature and pathology of airway disease in Sjögren's syndrome] Ota T, et al. **Nippon Rinsho** 1995 Oct; 53(10):2521–4 (12 ref.) (Eng. Abstr.) **(Jpn)**

RADIOGRAPHY

[Localized tracheobronchial amyloidosis. The usefulness of computed tomography] Sánchez Antuña A, et al. **Arch Bronconeumol** 1995 Dec;31(10):540–2 (23 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

Wire stent for tracheomalacia in a five-year-old girl. Bousamra M 2nd, et al. **Ann Thorac Surg** 1996 Apr; 61(4):1239–40 (8 ref.)

Cryotherapy for tracheobronchial disorders. Maiwand MO, et al. **Clin Chest Med** 1995 Sep;16(3):427–43 (57 ref.)

TRACHEAL NEOPLASMS

Primary tracheal non-Hodgkin's lymphoma. A case report and review of the literature. Fidias P, et al. **Cancer** 1996 Jun 1;77(11):2332–8 (38 ref.)

COMPLICATIONS

Endoscopic management of acute respiratory failure related to tracheobronchial malignancies. Ninane V. **Support Care Cancer** 1995 Nov;3(6):418–21 (40 ref.)

PATHOLOGY

[Double-primary cancer of the lung and trachea] Kishiro I, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Feb; 34(2):216–9 (13 ref.) (Eng. Abstr.) **(Jpn)**

RADIOGRAPHY

Radiology of the central airways. Worrell JA. **Otolaryngol Clin North Am** 1995 Aug;28(4):701–20 (23 ref.)

[Radiological criteria for laryngeal tumors and cervical metastases] Melchor Díaz MA, et al. **Acta Otorrinolaringol Esp** 1996 Jan–Feb;47(1):1–7 (17 ref.) (Eng. Abstr.) **(Spa)**

SECONDARY

[Radiological criter... for laryngeal tumors and cervical metastases] Melchor Díaz MA, et al. **Acta Otorrinolaringol Esp** 1996 Jan–Feb;47(1):1–7 (17 ref.) (Eng. Abstr.) **(Spa)**

SURGERY

[Current state of tracheal replacement] Mönig SP, et al. **Dtsch Med Wochenschr** 1996 May 17;121(20):670–4 (92 ref.) **(Ger)**

TRACHEAL STENOSIS

DIAGNOSIS

Diagnosis and management of pediatric tracheal stenosis. Rimell FL, et al. **Otolaryngol Clin North Am** 1995 Aug; 28(4):809–27 (57 ref.)

ETIOLOGY

Innominate artery enlargement in congenital arteriovenous fistula with subsequent tracheal compression and stridor. Döhlemann C, et al. **Pediatr Cardiol** 1995 Nov–Dec; 16(6):287–90 (17 ref.)

SURGERY

Augmentation techniques in laryngotracheal reconstruction. Eliachar I, et al. **Acta Otorhinolaryngol Belg** 1995; 49(4):397–406 (43 ref.)

Laser bronchoscopy. Ramser ER, et al. **Clin Chest Med** 1995 Sep;16(3):415–26 (66 ref.)

Laser treatment of lower airway stenosis. Coleman JA Jr, et al. **Otolaryngol Clin North Am** 1995 Aug;28(4):771–83 (8 ref.)

Open surgical techniques for laryngotracheal stenosis. Duncavage JA, et al. **Otolaryngol Clin North Am** 1995 Aug; 28(4):785–95 (18 ref.)

Operative evaluation of airway obstruction. Gardner GM, et al. **Otolaryngol Clin North Am** 1995 Aug;28(4):737–50 (12 ref.)

Diagnosis and management of pediatric tracheal stenosis. Rimell FL, et al. **Otolaryngol Clin North Am** 1995 Aug; 28(4):809–27 (57 ref.)

An overview of treatment options for lower airway obstruction. Wanamaker JR, et al. **Otolaryngol Clin North Am** 1995 Aug;28(4):751–70 (52 ref.)

THERAPY

Expandable stents. Nesbitt JC, et al. **Chest Surg Clin N Am** 1996 May;6(2):305–28 (33 ref.)

Airway stents. Present and future. Colt HG, et al. **Clin Chest Med** 1995 Sep;16(3):465–78 (96 ref.)

Endoscopic management of benign airway stenosis. Mehta AC, et al. **Clin Chest Med** 1995 Sep;16(3):401–13 (29 ref.)

TRACHEITIS

Acute laryngotracheitis. Sinha V, et al. **Indian Pediatr** 1995 Jul;32(7):821–5 (17 ref.)

TRACHEOBRONCHOMEGALY

RADIOGRAPHY

[The Mounier-Kuhn syndrome (tracheobronchomegaly). The diagnostic role of computed tomography] Villani PC, et al. **Radiol Med (Torino)** 1995 Sep;90(3):313–6 (16 ref.) **(Ita)**

TRACHEOESOPHAGEAL FISTULA

DIAGNOSIS

[The MMT syndrome (microcephaly, mesobrachyphalangy and tracheoesophageal fistula). The first case described in Spain and a review of the literature] Martínez-Frías ML, et al. **An Esp Pediatr** 1996 Jul;45(1):87–9 (7 ref.) **(Spa)**

TRACHEOSTOMY

An overview of treatment options for lower airway obstruction. Wanamaker JR, et al. **Otolaryngol Clin North Am** 1995 Aug;28(4):751–70 (52 ref.)

ADVERSE EFFECTS

Subglottic air pressure: a key component of swallowing efficiency. Eibling DE, et al. **Ann Otol Rhinol Laryngol** 1996 Apr;105(4):253–8 (19 ref.)

[Tracheal rupture secondary to intubation or tracheostomy] Varela G, et al. **Arch Bronconeumol** 1995 Oct;31(8):421–3 (11 ref.) (Eng. Abstr.) **(Spa)**

METHODS

Percutaneous dilational tracheostomy: report of 356 cases. Hill BB, et al. **J Trauma** 1996 Aug;41(2):238–43; discussion

243-4 (41 ref.)

UTILIZATION

Changing indications for tracheostomy in maxillofacial trauma. Taicher S, et al. **J Oral Maxillofac Surg** 1996 Mar; 54(3):292-5; discussion 295-6 (21 ref.)

TRACHEOTOMY

Management of upper airway obstruction: intubation vs tracheotomy. Bu Saba NY, et al. **J Med Liban** 1994; 42(4):235-9 (18 ref.)

ADVERSE EFFECTS

[Complications of tracheotomy (editorial)] Viau F. **Rev Mal Respir** 1996;13(2):89-92 (19 ref.) **(Fre)**

TRACHOMA

PREVENTION & CONTROL

Developments for a global approach to trachoma control. Thylefors B, et al. **Rev Int Trach Pathol Ocul Trop Subtrop Sante Publique** 1994;71:63-7, 69-77 (27 ref.) **(Eng, Fre)**

Preventive strategies for trachoma control. West SK. **Rev Int Trach Pathol Ocul Trop Subtrop Sante Publique** 1994;71:23-33, 39-46 (35 ref.) **(Eng, Fre)**

TRACK AND FIELD

see related
RUNNING

TRADE UNIONS see LABOR UNIONS

TRADEMARKS see PATENTS

TRADITIONAL MEDICINE, AFRICAN see MEDICINE, AFRICAN TRADITIONAL

TRADITIONAL MEDICINE, CHINESE see MEDICINE, CHINESE TRADITIONAL

TRADITIONAL MEDICINE, ORIENTAL see MEDICINE, ORIENTAL TRADITIONAL

TRAINING PROGRAMS see EDUCATION

TRAINING SUPPORT

STANDARDS

Pharmaceutical industry support for continuing medical education programs: a review of current ethical guidelines. Rosner F. **Mt Sinai J Med** 1995 Nov;62(6):427-30 (21 ref.)

TRAMADOL

PHARMACOKINETICS

Pharmacokinetics, efficacy, and safety of analgesia with a focus on tramadol HCl. Gibson TP. **Am J Med** 1996 Jul 31;101(1A):47S-53S (30 ref.)

PHARMACOLOGY

A novel approach to the pharmacology of analgesics. Raffa RB. **Am J Med** 1996 Jul 31;101(1A):40S-46S (33 ref.)

TRANQUILIZING AGENTS

see related
HYPNOTICS AND SEDATIVES

ADVERSE EFFECTS

Five-year multicenter retrospective review of cyclobenzaprine toxicity. Spiller HA, et al. **J Emerg Med** 1995 Nov-Dec;13(6):781-5 (14 ref.)

PHARMACOLOGY

The road to tranquility: the search for selective anti-anxiety agents. Estes JW. **Synapse** 1995 Sep;21(1):10-20 (69 ref.)

THERAPEUTIC USE

Lithium therapy: limitations and alternatives in the treatment of bipolar disorders. Calabrese JR, et al. **Ann Clin Psychiatry** 1995 Jun;7(2):103-12 (80 ref.)

Psychopharmacology in child and adolescent psychiatry: a review of the past seven years. Part II. Campbell M, et al. **J Am Acad Child Adolesc Psychiatry** 1995 Oct; 34(10):1262-72 (138 ref.)

The road to tranquility: the search for selective anti-anxiety agents. Estes JW. **Synapse** 1995 Sep;21(1):10-20 (69 ref.)

[Prophylactic treatment of episodic forms of cluster headache] Liaño H, et al. **Rev Neurol** 1995;23 Suppl 4:S525-9 (29 ref.) **(Spa)**

TRANQUILIZING AGENTS, MAJOR see ANTIPSYCHOTIC AGENTS

TRANQUILIZING AGENTS, MINOR see ANTI-ANXIETY AGENTS

TRANS-ACTING FACTORS see TRANS-ACTIVATORS

TRANS-ACTING TRANSCRIPTION FACTOR, HIV see GENE PRODUCTS, TAT

TRANS-ACTIVATION (GENETICS)

Transcriptional activation. A holistic view of the complex. Carey MF. **Curr Biol** 1995 Sep 1;5(9):1003-5 (19 ref.)

Mechanisms of transcription activation by nuclear receptors: studies on the human glucocorticoid receptor tau 1 transactivation domain. McEwan IJ, et al. **Mutat Res** 1995 Dec;333(1-2):15-22 (43 ref.)

Transcriptional activation of thymidine kinase, a marker for cell cycle control. Dou QP, et al. **Prog Nucleic Acid Res Mol Biol** 1996;53:197-217 (92 ref.)

STATs find that hanging together can be stimulating [comment] Leung S, et al. **Science** 1996 Aug 9; 273(5276):750-1 (19 ref.) Comment on: Science 1996 Aug 9;273(5276):794-7.

[Transactivation function of X gene-cellular gene fusion product or 3' truncated pre S2/S gene cellular gene fusion product from integrated hepatitis B virus DNA] Mita E, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:89-93 (15 ref.) **(Jpn)**

[Association of human hepatitis B virus (HBV) X protein and hRPB5, a subunit of RNA polymerases, and X transactivation] Murakami S. **Nippon Rinsho** 1995 Oct;53 Suppl:75-81 (21 ref.) **(Jpn)**

[Transactivation function of HBV X protein and tumor suppressor gene p53] Takada S. **Nippon Rinsho** 1995 Oct; 53 Suppl:82-8 (33 ref.) **(Jpn)**

DRUG EFFECTS

Role of protein kinase C and cyclic AMP/protein kinase A in high glucose-stimulated transcriptional activation of collagen alpha 1 (IV) in glomerular mesangial cells. Ziyadeh FN, et al. **J Diabetes Complications** 1995 Oct-Dec; 9(4):255-61 (35 ref.)

GENETICS

New understanding of the molecular mechanism of receptor-mediated genomic actions of the vitamin D hormone. Haussler MR, et al. **Bone** 1995 Aug;17(2 Suppl):33S-38S (30 ref.)

Transcription: basal factors and activation. Ranish JA, et al. **Curr Opin Genet Dev** 1996 Apr;6(2):151-8 (77 ref.)

IMMUNOLOGY

Activation of NF-kappa B by the Tax protein of HTLV-1. Munoz E, et al. **Immunobiology** 1995 Jul;193(2-4):128-36 (54 ref.)

PHYSIOLOGY

Chromatin structure and RNA polymerase II connection: implications for transcription. Struhl K. **Cell** 1996 Jan 26; 84(2):179-82 (15 ref.)

Regulation of transcription by E2F1/DP1. Martin K, et al. **J Cell Sci Suppl** 1995;19:91-4 (35 ref.)

Stress-induced transcriptional activation. Mager WH, et al. **Microbiol Rev** 1995 Sep;59(3):506-31 (232 ref.)

A new role for lactoferrin: DNA binding and transcription activation. Fleet JC. **Nutr Rev** 1995 Aug;53(8):226-7 (7 ref.)

TRANS-ACTIVATOR PROTEIN, HIV see GENE PRODUCTS, REV

TRANS-ACTIVATOR PROTEIN P40(TAX) see GENE PRODUCTS, TAX

TRANS-ACTIVATOR PROTEIN P40(X) see GENE PRODUCTS, TAX

TRANS-ACTIVATORS

Biochemistry and functions of hepatitis B virus X protein. Koike K, et al. **Intervirology** 1995;38(1-2):89-99 (76 ref.)

The JAK-STAT pathway: summary of initial studies and recent advances. Darnell JE Jr. **Recent Prog Horm Res** 1996;51:391-403; discussion 403-4 (75 ref.)

Transcriptional coactivators in yeast and beyond. Guarente L. **Trends Biochem Sci** 1995 Dec;20(12):517-21 (54 ref.)

BIOSYNTHESIS

Complementation cloning of mammalian transcriptional regulators: the example of MHC class II gene regulators. Steimle V, et al. **Curr Opin Genet Dev** 1995 Oct;5(5):646-51 (53 ref.)

GENETICS

Variation in the core and X genes of hepatitis B virus. Carman WF. **Intervirology** 1995;38(1-2):75-88 (96 ref.)

Hepatitis B virus HBx gene and hepatocarcinogenesis. Koike K. **Intervirology** 1995;38(3-4):134-42 (49 ref.)

[Mutations in X region gene] Honda A, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:58-64 (22 ref.) **(Jpn)**

[Probable implication of mutations of the X open reading frame in the onset of fulminant hepatitis B] Kaneko M, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:463-6 (14 ref.) **(Jpn)**

[Molecular mechanism of HBV hepatocarcinogenesis] Koike K. **Nippon Rinsho** 1995 Oct;53 Suppl:65-74 (37 ref.) **(Jpn)**

[Transactivation function of X gene-cellular gene fusion product or 3' truncated pre S2/S gene cellular gene fusion product from integrated hepatitis B virus DNA] Mita E, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:89-93 (15 ref.) **(Jpn)**

[Inhibition of HBx gene expression by antisense oligonucleotide] Moriya K, et al. **Nippon Rinsho** 1995 Oct; 53 Suppl:111-4 (9 ref.) **(Jpn)**

[Association of human hepatitis B virus (HBV) X protein and hRPB5, a subunit of RNA polymerases, and X transactivation] Murakami S. **Nippon Rinsho** 1995 Oct;53 Suppl:75-81 (21 ref.) **(Jpn)**

[Transactivation function of HBV X protein and tumor suppressor gene p53] Takada S. **Nippon Rinsho** 1995 Oct; 53 Suppl:82-8 (33 ref.) **(Jpn)**

METABOLISM

Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Schindler C, et al. **Annu Rev Biochem** 1995;64:621-51 (145 ref.)

Thrombopoietin induces tyrosine phosphorylation of Stat3 and Stat5 in human blood platelets. Miyakawa Y, et al. **Blood** 1996 Jan 15;87(2):439-46 (36 ref.)

STATs: signal transducers and activators of transcription. Ihle JN. **Cell** 1996 Feb 9;84(3):331-4 (20 ref.)

Reflections on STAT3, STAT5, and STAT6 as fat STATs. Darnell JE Jr. **Proc Natl Acad Sci U S A** 1996 Jun 25; 93(13):6221-4 (45 ref.)

STATs find that hanging together can be stimulating [comment] Leung S, et al. **Science** 1996 Aug 9; 273(5276):750-1 (19 ref.) Comment on: Science 1996 Aug 9;273(5276):794-7.

PHYSIOLOGY

Lymphopoiesis. Transcription factors controlling B-cell development. Desiderio S. **Curr Biol** 1995 Jun 1;5(6):605-8 (20 ref.)

The role of brahma and related proteins in transcription and development. Tamkun JW. **Curr Opin Genet Dev** 1995 Aug; 5(4):473-7 (51 ref.)

The Jak-STAT pathway: specific signal transduction from the cell membrane to the nucleus. Heim MH. **Eur J Clin Invest** 1996 Jan;26(1):1-12 (133 ref.)

Biochemistry and functions of hepatitis B virus X protein. Koike K, et al. **Intervirology** 1995;38(1-2):89-99 (76 ref.)

TRANSACTIONAL ANALYSIS

Environmental psychology 1989-1994. Sundstrom E, et al. **Annu Rev Psychol** 1996;47:485-512 (255 ref.)

TRANSACTIVATION see TRANS-ACTIVATION (GENETICS)

TRANSAMINASES see AMINOTRANSFERASES

TRANSCOBALAMIN II see TRANSCOBALAMINS

TRANSCOBALAMINS

METABOLISM

Transcobalamin II and the membrane receptor for the transcobalamin II-cobalamin complex. Rothenberg SP, et al. **Baillieres Clin Haematol** 1995 Sep;8(3):499-514 (100 ref.)

TRANSCORTIN

ANALYSIS

[Corticosteroid-binding globulin (CBG): measurement and its clinical implication] Hirai A, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:495-8 (29 ref.) **(Jpn)**

TRANSCRIPTASES see RNA POLYMERASES

TRANSCRIPTION FACTOR AP-1

see related
PROTO-ONCOGENE PROTEINS C-FOS
PROTO-ONCOGENE PROTEINS C-JUN

METABOLISM

Antioxidant and redox regulation of gene transcription. Sen CK, et al. **FASEB J** 1996 May;10(7):709-20 (94 ref.)

PHYSIOLOGY

Redox signalling by transcription factors NF-kappa B and AP-1 in lymphocytes. Schulze-Osthoff K, et al. **Biochem Pharmacol** 1995 Sep 7;50(6):735-41 (69 ref.)

The glucocorticoid receptor synergizes with Jun homodimers to activate AP-1-regulated promoters lacking GR binding sites. Teurich S, et al. **Chem Senses** 1995 Apr;20(2):251-5 (17 ref.)

AP-1 transcription factor complexes in CNS disorders and

development. Pennypacker KR. **J Fla Med Assoc** 1995 Aug;82(8):551–4 (26 ref.)

Defects in signal transduction pathways in chronic B lymphocytic leukemia cells. Jabbar SA, et al. **Leuk Lymphoma** 1995 Jun;18(1–2):163–70 (52 ref.)

The regulation of AP-1 activity by mitogen-activated protein kinases. Karin M. **Philos Trans R Soc Lond B Biol Sci** 1996 Feb 29; 351(1336):127–34 (60 ref.)

TRANSCRIPTION FACTOR NF-KB see **NF-KAPPA B**

TRANSCRIPTION FACTOR, SP1

GENETICS

Expression of human monoamine oxidase (MAO) A gene controlled by transcription factor Sp1. Shih JC, et al. **Prog Brain Res** 1995;106:49–56 (36 ref.)

TRANSCRIPTION FACTORS

see related

TRANS-ACTIVATORS

Co-activators and co-repressors: mediators of gene activation by nuclear hormone receptors. Meier CA. **Eur J Endocrinol** 1996 Feb;134(2):158–9 (5 ref.)

Phylogenetic, structural and functional analyses of the LacI–GalR family of bacterial transcription factors. Nguyen CC, et al. **FEBS Lett** 1995 Dec 18;377(2):98–102 (23 ref.)

The nuclear factor IL-4 (NF-IL4). Köhler I, et al. **Immunobiology** 1995 Jul;193(2–4):273–80 (23 ref.)

The C/EBP family of transcription factors. Wedel A, et al. **Immunobiology** 1995 Jul;193(2–4):171–85 (100 ref.)

Transcription factors. 1: bZIP proteins. Hurst HC. **Protein Profile** 1994;1(2):123–68 (471 ref.)

[Mechanism of gene expression—basic transcription factor and starting mechanism of genetic transcription] Kitajima S. **Fukuoka Igaku Zasshi** 1995 Dec;86(12):432–6 (2 ref.) **(Jpn)**

[Regulation of gene expression through phosphorylation of transcription factors] Hagiwara M. **Seikagaku** 1995 Dec; 67(12):1388–91 (11 ref.) **(Jpn)**

[Recent developments in studies on transcription factors—role of TFIID in transcriptional activation] Hisatake K. **Seikagaku** 1996 Apr;68(4):285–9 (16 ref.) **(Jpn)**

[Regulation of neural differentiation by HES helix-loop-helix transcription factors] Kageyama R. **Seikagaku** 1995 Sep; 67(9):1093–114 (71 ref.) **(Jpn)**

[Sex differentiation and Ad4BP] Morohashi K. **Seikagaku** 1995 Oct;67(10):1195–209 (56 ref.) **(Jpn)**

[Structure and function of PAS proteins] Sogawa K. **Seikagaku** 1995 Nov;67(11):1283–7 (14 ref.) **(Jpn)**

[Stereochemical basis of DNA super-structure formation by transcription factors] Suzuki M. **Tanpakushitsu Kakusan Koso** 1996 Feb;41(2):105–18 (21 ref.) **(Jpn)**

ANALYSIS

Does the Wilms' tumour suppressor gene, WT1, play roles in both splicing and transcription? Charlieu JP, et al. **J Cell Sci Suppl** 1995;19:95–9 (20 ref.)

ANTAGONISTS & INHIBITORS

The actions of cyclosporin A and FK506 on T-lymphocyte activation. Mattila PS. **Biochem Soc Trans** 1996 Feb; 24(1):45–9 (40 ref.)

BIOSYNTHESIS

A new subclass of helix-loop-helix transcription factors expressed in paraxial mesoderm and chondrogenic cell lineages. Olson EN, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:108–18 (30 ref.)

Heat shock transcription factors: structure and regulation. Wu C. **Ann Rev Cell Dev Biol** 1995;11:441–69 (157 ref.)

New perspectives on eye evolution. Halder G, et al. **Curr Opin Genet Dev** 1995 Oct;5(5):602–9 (68 ref.)

Complementation cloning of mammalian transcriptional regulators: the example of MHC class II gene regulators. Steimle V, et al. **Curr Opin Genet Dev** 1995 Oct;5(5):646–51 (53 ref.)

CHEMISTRY

DNA conformation and its changes upon binding transcription factors. Suzuki M, et al. **Adv Biophys** 1996; 32:53–72 (47 ref.)

Heat shock transcription factors: structure and regulation. Wu C. **Ann Rev Cell Dev Biol** 1995;11:441–69 (157 ref.)

Introduction to the E2F family: protein structure and gene regulation. Slansky JE, et al. **Curr Top Microbiol Immunol** 1996;208:1–30 (122 ref.)

Structural alterations in the transcription factor PEBP2/CBF linked to four different types of leukemia. Ito Y. **J Cancer Res Clin Oncol** 1996;122(5):266–74 (46 ref.)

Transcription factors 3: nuclear receptors. Groenemeyer H, et al. **Protein Profile** 1995;2(11):1173–308 (3351 ref.)

Transcription factors 2: helix-loop-helix. Littlewood TD, et al. **Protein Profile** 1994;1(6):635–709 (1097 ref.)

Transcription factor IIA: a structure with multiple functions [comment] Jacobson RH, et al. **Science** 1996 May 10; 272(5263):827–8 (11 ref.) Comment on: Science 1996 May 10;272(5263):830–6.

hSRY: molecular gender bender. Bramham J, et al. **Structure** 1995 Jul 15;3(7):631–3 (19 ref.)

[Structure determination of transcription factors] Shirakawa M. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1598–608 (54 ref.) **(Jpn)**

CLASSIFICATION

Transcription factor families: muscling in on the myogenic program. Ludolph DC, et al. **FASEB J** 1995 Dec; 9(15):1595–604 (65 ref.)

DRUG EFFECTS

Transcription factors as drug targets: opportunities for therapeutic selectivity. Butt TR, et al. **Gene Expr** 1995; 4(6):319–36 (137 ref.)

PPAR: a mediator of peroxisome proliferator action. Green S. **Mutat Res** 1995 Dec;333(1–2):101–9 (65 ref.)

GENETICS

PAX and HOX in neoplasia. Stuart ET, et al. **Adv Genet** 1995;33:255–74 (92 ref.)

The proteolipid protein gene: double, double, ... and trouble [editorial] Hodes ME, et al. **Am J Hum Genet** 1996 Jul; 59(1):12–5 (27 ref.)

Pax genes and skeletal development. Balling R, et al. **Ann N Y Acad Sci** 1996 Jun 8;785:27–33 (29 ref.)

A role for immediate-early transcription factors in learning and memory. Dragunow M. **Behav Genet** 1996 May; 26(3):293–9 (55 ref.)

BRCA1, a gene involved in inherited predisposition to breast and ovarian cancer. Feunteun J, et al. **Biochim Biophys Acta** 1996 Mar 18;1242(3):177–80 (42 ref.)

The TEL gene and human leukemia. Golub TR, et al. **Biochim Biophys Acta** 1996 Aug 8;1288(1):M7–10 (27 ref.)

MHox and vertebrate skeletogenesis: the long and the short of it. Brickell PM. **Bioessays** 1995 Sep;17(9):750–3 (31 ref.)

Contacts in context: promoter specificity and macromolecular interactions in transcription. Goodrich JA, et al. **Cell** 1996 Mar 22;84(6):825–30 (32 ref.)

Know your neighbors: three phenotypes in null mutants of the myogenic bHLH gene MRF4. Olson EN, et al. **Cell** 1996 Apr 5;85(1):1–4 (20 ref.)

X chromosome inactivation, XIST, and pursuit of the X-inactivation center. Willard HF. **Cell** 1996 Jul 12; 86(1):5–7 (14 ref.)

Transcriptional control and the regulation of endocrine genes. Zajac JD, et al. **Clin Exp Pharmacol Physiol** 1995 Dec;22(12):935–43 (68 ref.)

BCL-6 and the molecular pathogenesis of B-cell lymphoma. Dalla-Favera R, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:117–23 (49 ref.)

Regulation of mammalian neural development by helix-loop-helix transcription factors. Kageyama R, et al. **Crit Rev Neurobiol** 1995;9(2–3):177–88 (84 ref.)

The hepatocyte nuclear factor-3/forkhead transcription regulatory family in development, inflammation, and neoplasia. Hromas R, et al. **Crit Rev Oncol Hematol** 1995 Aug;20(1–2):129–40 (64 ref.)

RNA processing. Wilms' tumour—the splicing connection? Lamond AI. **Curr Biol** 1995 Aug 1;5(8):862–5 (10 ref.)

Muscle development. Making Drosophila muscle. Taylor MV. **Curr Biol** 1995 Jul 1;5(7):740–2 (14 ref.)

Involvement of the TEL gene in hematologic malignancy by diverse molecular genetic mechanisms. Golub TR, et al. **Curr Top Microbiol Immunol** 1996;211:279–88 (21 ref.)

Introduction to the E2F family: protein structure and gene regulation. Slansky JE, et al. **Curr Top Microbiol Immunol** 1996;208:1–30 (122 ref.)

Developmental role of transcription factor isoforms generated by alternative splicing. López AJ. **Dev Biol** 1995 Dec;172(2):396–411 (118 ref.)

Retinoic acid regulatory pathways, chromosomal translocations, and acute promyelocytic leukemia. Chen Z, et al. **Genes Chromosomes Cancer** 1996 Mar;15(3):147–56 (123 ref.)

Inherited breast and ovarian cancer. Szabo CI, et al. **Hum Mol Genet** 1995;4 Spec No:1811–7 (64 ref.)

Transcription-factor mutations and disease. Latchman DS. **N Engl J Med** 1996 Jan 4;334(1):28–33 (43 ref.)

Hox genes and the evolution of diverse body plans. Akam M. **Philos Trans R Soc Lond B Biol Sci** 1995 Sep 29; 349(1329):313–9 (52 ref.)

Immediate early genes (IEGs) encoding for inducible transcription factors (ITFs) and neuropeptides in the nervous system: functional network for long-term plasticity and pain. Herdegen T, et al. **Prog Brain Res** 1995; 104:299–321 (184 ref.)

Kainate-induced changes in gene expression in the rat hippocampus. Pennypacker KR, et al. **Prog Brain Res** 1995; 105:105–16 (64 ref.)

Molecular biology of breast cancer: integration of cellular and molecular concepts into therapeutic strategies. Konstadoulakis MM, et al. **R I Med** 1995 Sep;78(9):257–60 (67 ref.)

The gene responsible for adrenal hypoplasia congenita, DAX-1, encodes a nuclear hormone receptor that defines a new class within the superfamily. Burris TP, et al. **Recent Prog Horm Res** 1996;51:241–59; discussion 259–60 (94 ref.)

Gene fusions encoding chimaeric transcription factors in solid tumours. Sorensen PH, et al. **Semin Cancer Biol** 1996 Feb; 7(1):3–14 (100 ref.)

Mutations of the BRCA1 gene in human cancer. Xu CF, et al. **Semin Cancer Biol** 1996 Feb;7(1):33–40 (63 ref.)

Interplay between nucleosomes and transcription factors at the yeast PHO5 promoter. Svaren J, et al. **Semin Cell Biol** 1995 Aug;6(4):177–83 (52 ref.)

Transcription factors in renal development: the WT1 and Pax-2 story. Dressler GR. **Semin Nephrol** 1995 Jul; 15(4):263–71 (86 ref.)

Xenobiotic receptor knockout mice. Gonzalez FJ, et al. **Toxicol Lett** 1995 Dec;82–83:117–21 (11 ref.)

Finding prospective partners in the library: the two-hybrid system and phage display find a match. Allen JB, et al. **Trends Biochem Sci** 1995 Dec;20(12):511–6 (50 ref.)

Insight into the microphthalmia gene. Moore KJ. **Trends Genet** 1995 Nov;11(11):442–8 (41 ref.)

Review: compilation and characteristics of dedicated transcription factors in Saccharomyces cerevisiae. Svetlov VV, et al. **Yeast** 1995 Dec;11(15):1439–84 (70 ref.)

Transcription factors of T and B lymphocytes—basic research and clinical perspectives for gastroenterology. Neurath MF, et al. **Z Gastroenterol** 1996 Feb;34(2):138–50 (138 ref.)

[Transcription factors of the PEA3 group in mammary cancer] Monté D, et al. **Ann Endocrinol (Paris)** 1995; 56(5):547–51 (8 ref.) (Eng. Abstr.) **(Fre)**

[Does the c-ets 1 oncogene participate in the regulation of tumor angiogenesis?] Vandenbunder B, et al. **Arch Inst Pasteur Tunis** 1994 Jul–Oct;71(3–4):493–509 (56 ref.) (Eng. Abstr.) **(Fre)**

[Several transcription factors participate in the functioning of the alpha-fetoprotein gene promoter] Bois-Joyeux B, et al. **Bull Cancer (Paris)** 1995 Jul;82(7):541–50 (51 ref.) (Eng. Abstr.) **(Fre)**

[Molecular adaptation of the heart to hypertension] Neyses L, et al. **Z Kardiol** 1995;84 Suppl 4:71–6 (21 ref.) (Eng. Abstr.) **(Ger)**

[Cardiac gene expression after brief coronary occlusion] Zimmermann R, et al. **Z Kardiol** 1995;84 Suppl 4:159–65 (23 ref.) (Eng. Abstr.) **(Ger)**

[Targeted ablation of transcription factor genes] Kondoh H. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(14):2126–33 (30 ref.) **(Jpn)**

[Inducible regulatable promoter—ionizing radiation-inducible promoter EGR-1] Ohno T. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2624–30 (25 ref.) **(Jpn)**

[Structure and properties of transcription IIIA from Xenopus laevis] Wyszko E, et al. **Postepy Biochem** 1995;41(2):102–9 (56 ref.) **(Pol)**

ISOLATION & PURIFICATION

Molecular biology of retinal ganglion cells. Xiang M, et al. **Proc Natl Acad Sci U S A** 1996 Jan 23;93(2):596–601 (41 ref.)

METABOLISM

DNA conformation and its changes upon binding transcription factors. Suzuki M, et al. **Adv Biophys** 1996; 32:53–72 (47 ref.)

Oncogenic role of "master" transcription factors in human leukemias and sarcomas: a developmental model. Look AT. **Adv Cancer Res** 1995;67:25–57 (162 ref.)

Transcription factors responsive to cAMP. Sassone-Corsi P. **Ann Rev Cell Dev Biol** 1995;11:355–77 (73 ref.)

Common themes in assembly and function of eukaryotic transcription complexes. Zawel L, et al. **Annu Rev Biochem** 1995;64:533–61 (230 ref.)

Leucine-responsive regulatory protein: a global regulator of gene expression in E. coli. Newman EB, et al. **Annu Rev Microbiol** 1995;49:747–75 (122 ref.)

Multiple steps in the regulation of transcription-factor level and activity. Calkhoven CF, et al. **Biochem J** 1996 Jul 15; 317 (Pt 2):329–42 (269 ref.)

The signal transduction pathway leading from the toll receptor to nuclear localization of dorsal transcription factor. Gay NJ, et al. **Biochem Soc Trans** 1996 Feb; 24(1):35–8 (26 ref.)

A yeast transcription factor activating G1 cyclin expression has similarity to bacterial signal transduction proteins. Johnston LH, et al. **Biochem Soc Trans** 1996 Feb; 24(1):49–54 (26 ref.)

E2F and the molecular mechanisms of early cell-cycle control. La Thangue NB. **Biochem Soc Trans** 1996 Feb; 24(1):54–9 (29 ref.)

Brain POU-er. Sharp ZD, et al. **Bioessays** 1996 May; 18(5):347–50 (23 ref.)

The Max transcription factor network: involvement of Mad in differentiation and an approach to identification of target genes. Hurlin PJ, et al. **Cold Spring Harb Symp Quant Biol** 1994;59:109–16 (42 ref.)

Phosphorylation of transcription factors and control of the cell cycle. Boulikas T. **Crit Rev Eukaryot Gene Expr** 1995; 5(1):1–77 (524 ref.)

The Ets family of proteins: weak modulators of gene expression in quest for transcriptional partners. Crepieux P, et al. **Crit Rev Oncog** 1994;5(6):615–38 (192 ref.)

Transcriptional regulation. Flipping the Myc switch. Bernards R. **Curr Biol** 1995 Aug 1;5(8):859–61 (13 ref.)
The role of BSAP (Pax–5) in B–cell development. Busslinger M, et al. **Curr Opin Genet Dev** 1995 Oct;5(5):595–601 (53 ref.)
C/EBP alpha: a critical regulator of genes governing integrative metabolic processes. Darlington GJ, et al. **Curr Opin Genet Dev** 1995 Oct;5(5):565–70 (37 ref.)
Molecular mechanisms of cell–type determination in budding yeast. Johnson AD. **Curr Opin Genet Dev** 1995 Oct; 5(5):552–8 (52 ref.)
DNA excision repair and transcription: implications for genome evolution. Sullivan DT. **Curr Opin Genet Dev** 1995 Dec;5(6):786–91 (55 ref.)
Start–specific transcription in yeast. Breeden L. **Curr Top Microbiol Immunol** 1996;208:95–127 (112 ref.)
Regulatory interactions among E2Fs and cell cycle control proteins. Cobrinik D. **Curr Top Microbiol Immunol** 1996; 208:31–61 (146 ref.)
Use of the E2F transcription factor by DNA tumor virus regulatory proteins. Cress WD, et al. **Curr Top Microbiol Immunol** 1996;208:63–78 (112 ref.)
Conclusions and future directions. Farnham PJ. **Curr Top Microbiol Immunol** 1996;208:129–37 (21 ref.)
Transcriptional regulation by the t(8;21) fusion protein, AML–1/ETO. Hiebert SW, et al. **Curr Top Microbiol Immunol** 1996;211:253–8 (19 ref.)
Regulation of muscle differentiation by the MEF2 family of MADS box transcription factors. Olson EN, et al. **Dev Biol** 1995 Nov;172(1):2–14 (102 ref.)
Role of environmental signals and transcriptional regulators in neural crest development. Groves AK, et al. **Dev Genet** 1996;18(1):64–72 (82 ref.)
The RNA polymerase II elongation complex. Aso T, et al. **FASEB J** 1995 Nov;9(14):1419–28 (79 ref.)
Masking of mRNA by Y–box proteins. Sommerville J, et al. **FASEB J** 1996 Mar;10(4):435–43 (64 ref.)
Rel/NF–kappa B/I kappa B family: intimate tales of association and dissociation. Verma IM, et al. **Genes Dev** 1995 Nov 15;9(22):2723–35 (114 ref.)
Regulation of transcription by E2F1/DP1. Martin K, et al. **J Cell Sci Suppl** 1995;19:91–4 (35 ref.)
Transcription syndromes and the role of RNA polymerase II general transcription factors in human disease. Aso T, et al. **J Clin Invest** 1996 Apr 1;97(7):1561–9 (119 ref.)
Endotoxin signal transduction in macrophages. Sweet MJ, et al. **J Leukoc Biol** 1996 Jul;60(1):8–26 (304 ref.)
Intracellular receptors and signal transducers and activators of transcription superfamilies: novel targets for small–molecule drug discovery. Rosen J, et al. **J Med Chem** 1995 Dec 8;38(25):4855–74 (124 ref.)
Interaction of steroid hormone receptors with transcription factors involves chromatin remodelling. Beato M, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1–6 Spec No):47–59 (144 ref.)
Polyunsaturated fatty acid regulation of hepatic gene transcription. Clarke SD, et al. **Lipids** 1996 Mar;31 Suppl:S7–11 (50 ref.)
Signal sensing by sigma 54–dependent regulators: derepression as a control mechanism. Shingler V. **Mol Microbiol** 1996 Feb;19(3):409–16 (51 ref.)
Retinoid receptors in human lung cancer and breast cancer. Zhang XK, et al. **Mutat Res** 1996 Feb 19;350(1):267–77 (87 ref.)
Pharmacological regulation of transcription factor binding. Pennypacker KR. **Pharmacology** 1995 Jun;51(1):1–12 (125 ref.)
A dynamic assembly of diverse transcription factors integrates activation and cell–type information for interleukin 2 gene regulation. Rothenberg EV, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9358–65 (87 ref.)
DNA recognition code of transcription factors. Suzuki M, et al. **Protein Eng** 1995 Apr;8(4):319–28 (101 ref.)
Transcription factors 3: nuclear receptors. Gronemeyer H, et al. **Protein Profile** 1995;2(11):1173–308 (3351 ref.)
Transcription factors 2: helix–loop–helix. Littlewood TD, et al. **Protein Profile** 1994;1(6):635–709 (1097 ref.)
Transcription factor IIA: a structure with multiple functions [comment] Jacobson RH, et al. **Science** 1996 May 10; 272(5263):827–8 (11 ref.) Comment on: Science 1996 May 10;272(5263):830–6.
Intercalation, DNA kinking, and the control of transcription. Werner MH, et al. **Science** 1996 Feb 9;271(5250):778–84 (54 ref.)
Histone deacetylase: a regulator of transcription [comment] Wolffe AP. **Science** 1996 Apr 19;272(5260):371–2 (16 ref.) Comment on: Science 1996 Apr 19;272(5260):408–11.
Review: compilation and characteristics of dedicated transcription factors in Saccharomyces cerevisiae. Svetlov VV, et al. **Yeast** 1995 Dec;11(15):1439–84 (70 ref.)
[Interaction of Oct–proteins with DNA] Stepchenko AG, et al. **Mol Biol (Mosk)** 1996 May–Jun;30(3):503–13 (46 ref.) **(Rus)**

PHYSIOLOGY

Towards understanding of the role of transcription factors in learning processes. Kaczmarek L. **Acta Biochim Pol** 1995;42(2):221–6 (59 ref.)
Transcription factors and pattern formation in the developing lung. Cardoso WV. **Am J Physiol** 1995 Oct;269(4 Pt 1):L429–42 (185 ref.)
The role of the Opaque2 transcriptional factor in the regulation of protein accumulation and amino acid metabolism in maize seeds. Yunes JA, et al. **An Acad Bras Cienc** 1994;66 Su 1 (Pt 2):227–37; quiz 237–8 (60 ref.)
Activation of immediate early genes by vestibular stimulation. Kaufman GD. **Ann N Y Acad Sci** 1996 Jun 19;781:437–442 (12 ref.)
CAK in TFIIH: crucial connection or confounding coincidence? Fisher RP, et al. **Biochim Biophys Acta** 1996 Aug 8;1288(1):O7–10 (51 ref.)
Mammalian nucleotide excision repair. Ma L, et al. **Biochim Biophys Acta** 1995 Dec 18;1242(2):137–63 (261 ref.)
The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation. Schoonjans K, et al. **Biochim Biophys Acta** 1996 Jul 26;1302(2):93–109 (259 ref.)
Lens development and crystallin gene expression: many roles for Pax–6. Cvekl A, et al. **Bioessays** 1996 Aug;18(8):621–30 (72 ref.)
Cooperation between transcription factors regulates liver development. Aran A, et al. **Biol Neonate** 1995;67(6):387–96 (46 ref.)
The transcriptional control of hematopoiesis. Shivdasani RA, et al. **Blood** 1996 May 15;87(10):4025–39 (175 ref.)
The role of inducible transcription factors in apoptotic nerve cell death. Dragunow M, et al. **Brain Res Brain Res Rev** 1995 Jul;21(1):1–28 (374 ref.)
Yeast RNA polymerase III: transcription complexes and RNA synthesis. Geiduschek EP, et al. **Braz J Med Biol Res** 1995 Feb;28(2):147–59 (133 ref.)
The RXR heterodimers and orphan receptors. Mangelsdorf DJ, et al. **Cell** 1995 Dec 15;83(6):841–50 (80 ref.)
Regulation of the Jak/STAT signalling pathway. Finbloom DS, et al. **Cell Signal** 1995 Nov;7(8):739–45 (49 ref.)
Dopamine regulation of transcription factor–target interactions in rat striatum. Hyman SE, et al. **Chem Senses** 1995 Apr;20(2):257–60 (24 ref.)
Transcription and masking of mRNA in germ cells: involvement of Y–box proteins. Sommerville J, et al. **Chromosoma** 1996 Apr;104(7):469–78 (66 ref.)
Oestrogen–responsive finger protein suggests a transcriptional cascade of steroid hormone regulation. **Ciba Found Symp** 1995;191:43–51 (18 ref.)
Transcription factors. Barnes PJ, et al. **Clin Exp Allergy** 1995 Nov;25 Suppl 2:46–9 (27 ref.)
The role of brahma and related proteins in transcription and development. Tamkun JW. **Curr Opin Genet Dev** 1995 Aug; 5(4):473–7 (51 ref.)
Regulation of adipocyte gene expression and differentiation by peroxisome proliferator activated receptor gamma. Tontonoz P, et al. **Curr Opin Genet Dev** 1995 Oct; 5(5):571–6 (51 ref.)
The TATA box binding protein. Burley SK. **Curr Opin Struct Biol** 1996 Feb;6(1):69–75 (38 ref.)
The cellular effects of E2F overexpression. Adams PD, et al. **Curr Top Microbiol Immunol** 1996;208:79–93 (94 ref.)
A role for STAT family transcription factors in myeloid differentiation. Barahmand–pour F, et al. **Curr Top Microbiol Immunol** 1996;211:121–8 (25 ref.)
Regulation of immature myeloid cell differentiation by PEBP2/CBF, Myb, C/EBP and Ets family members. Friedman AD. **Curr Top Microbiol Immunol** 1996; 211:149–57 (45 ref.)
Pathogenetic role of the PML1RAR alpha fusion protein in acute promyelocytic leukemia. Grignani F, et al. **Curr Top Microbiol Immunol** 1996;211:269–78 (52 ref.)
Hematopoietic transcriptional regulation by the myeloid zinc finger gene, MZF–1. Hromas R, et al. **Curr Top Microbiol Immunol** 1996;211:159–64 (15 ref.)
Function of PU.1 (Spi–1), C/EBP, and AML1 in early myelopoiesis: regulation of multiple myeloid CSF receptor promoters. Zhang DE, et al. **Curr Top Microbiol Immunol** 1996;211:137–47 (61 ref.)
The potential roles of nm23 in cancer metastasis and cellular differentiation. MacDonald NJ, et al. **Eur J Cancer** 1995 Jul–Aug;31A(7–8):1096–100 (30 ref.)
Liver–enriched transcription factors and hepatocyte differentiation. Cereghini S. **FASEB J** 1996 Feb; 10(2):267–82 (101 ref.)
Archaeal transcription factors and their role in transcription initiation. Thomm M. **FEMS Microbiol Rev** 1996 May; 18(2–3):159–71 (64 ref.)
Repression and activation by multiprotein complexes that alter chromatin structure. Kingston RE, et al. **Genes Dev** 1996 Apr 15;10(8):905–20 (145 ref.)
Transcription factors and inflammatory disease. Barnes PJ. **Hosp Pract (Off Ed)** 1996 Jun 15;31(6):93–100, 105–6 (0 ref.)
The interplay between lymphoid–specific and ubiquitous transcription factors controls the expression of interleukin 2 gene in T lymphocytes. Avots A, et al. **Immunobiology** 1995 Jul;193(2–4):254–8 (20 ref.)
NF–Y, IRF–2, and C/EBP proteins are involved in regulation of human IL–4 gene expression. Li–Weber M, et al. **Immunobiology** 1995 Jul;193(2–4):263–7 (9 ref.)
The inducible transcription factor NF–AT plays an important role in the activation of the murine interleukin–4 promoter. Schneider G, et al. **Immunobiology** 1995 Jul; 193(2–4):268–72 (14 ref.)
The NF–jun transcription factor in the hematopoietic response to mitogenic signals. Sott C, et al. **Immunobiology** 1995 Jul;193(2–4):149–54 (16 ref.)
Molecular principles of Oct2–mediated gene activation in B cells. Wirth T, et al. **Immunobiology** 1995 Jul; 193(2–4):161–70 (45 ref.)
Transcription factors that control development of the thymic microenvironment. Boehm T, et al. **Immunol Today** 1995 Dec;16(12):555–6 (20 ref.)
BSAP: a key regulator of B–cell development and differentiation. Neurath MF, et al. **Immunol Today** 1995 Dec;16(12):564–9 (22 ref.)
The possibility of active form of vitamins A and D as suppressors on adipocyte development via ligand–dependent transcriptional regulators. Kawada T, et al. **Int J Obes Relat Metab Disord** 1996 Mar;20 Suppl 3:S52–7 (22 ref.)
Regulation of the interferon system and cell growth by the IRF transcription factors. Taniguchi T, et al. **J Cancer Res Clin Oncol** 1995;121(9–10):516–20 (34 ref.)
The role of early growth response gene 1 (egr–1) in regulation of the immune response. McMahon SB, et al. **J Leukoc Biol** 1996 Aug;60(2):159–66 (101 ref.)
The role of transcription factors in the pituitary expression of the glycoprotein hormone alpha–subunit gene. Aylwin SJ, et al. **J Mol Endocrinol** 1995 Dec;15(3):221–31 (82 ref.)
Chicken ovalbumin upstream promoter–transcription factors and their regulation. Qiu Y, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1–6 Spec No):81–5 (30 ref.)
Enhancement of nuclear receptor transcriptional signalling. Renkawitz R, et al. **J Steroid Biochem Mol Biol** 1996 Jan; 56(1–6 Spec No):39–45 (29 ref.)
Transcription antitermination: the lambda paradigm updated. Friedman DI, et al. **Mol Microbiol** 1995 Oct;18(2):191–200 (70 ref.)
Genetic mechanisms of early neurogenesis in Drosophila melanogaster. Campos–Ortega JA. **Mol Neurobiol** 1995 Apr–Jun;10(2–3):75–89 (97 ref.)
Mechanisms for species differences in receptor–mediated carcinogenesis. Barrett JC. **Mutat Res** 1995 Dec; 333(1–2):189–202 (111 ref.)
Molecular enhancement of memory formation. Carew TJ. **Neuron** 1996 Jan;16(1):5–8 (24 ref.)
JAKs, STATs and signal transduction in response to the interferons and other cytokines. Briscoe J, et al. **Philos Trans R Soc Lond B Biol Sci** 1996 Feb 29; 351(1336):167–71 (12 ref.)
Transcription factors 2: helix–loop–helix. Littlewood TD, et al. **Protein Profile** 1995;2(6):621–702 (1294 ref.)
Mechanisms of gene activation [comment] Buratowski S. **Science** 1995 Dec 15;270(5243):1773–4 (7 ref.) Comment on: Science 1995 Dec 15;270(5243):1825–8.
A new turn (or two) for twist [comment] Michelson AM. **Science** 1996 Jun 7;272(5267):1449–50 (15 ref.) Comment on: Science 1996 Jun 7;272(5267):1476–80. Comment on: Science 1996 Jun 7;272(5267):1481–4.
Pheromone communication in the fission yeast Schizosaccharomyces pombe. Nielsen O, et al. **Semin Cell Biol** 1995 Apr;6(2):95–104 (105 ref.)
Receptor–mediated toxicity. Gustafsson JA. **Toxicol Lett** 1995 Dec;82–83:465–70 (24 ref.)
Receptors as tools for understanding the toxicity of retinoids. Levin AA. **Toxicol Lett** 1995 Dec;82–83:91–7 (57 ref.)
The relationship between the flamenco gene and gypsy in Drosophila: how to tame a retrovirus. Bucheton A. **Trends Genet** 1995 Sep;11(9):349–53 (40 ref.)
[Toward the treatment of obesity: role of PPAR gamma in adipogenesis] Motojima K. **Tanpakushitsu Kakusan Koso** 1995 Oct;40(13):1936–41 (32 ref.) **(Jpn)**

TRANSCRIPTION, GENETIC

see related
GENE PRODUCTS, REV
GENE PRODUCTS, TAT
GENE PRODUCTS, TAX
GENES, PX
GENES, REV
TRANS–ACTIVATORS
TRANSCRIPTION FACTORS

c–Fos expression as a tool to search for the neurobiological base of the sexual behaviour of males. Bialy M, et al. **Acta Neurobiol Exp (Warsz)** 1996;56(2):567–77 (52 ref.)
Oncogenic role of "master" transcription factors in human leukemias and sarcomas: a developmental model. Look AT. **Adv Cancer Res** 1995;67:25–57 (162 ref.)
The unique C–terminal domain of RNA polymerase II and its role in transcription. Kang ME, et al. **Adv Enzymol Relat Areas Mol Biol** 1995;71:41–77 (98 ref.)
Transcription, replication, recombination, and engineering of coronavirus genes. Lai MM. **Adv Exp Med Biol** 1995; 380:463–71 (29 ref.)
Coronaviruses use discontinuous extension for synthesis of subgenome–length negative strands. Sawicki SG, et al. **Adv Exp Med Biol** 1995;380:499–506 (21 ref.)
Regulation of transcription of coronaviruses. van Marle G, et al. **Adv Exp Med Biol** 1995;380:507–10 (23 ref.)
Differential display RT–PCR for identifying novel gene expression in the lung. Sunday ME. **Am J Physiol** 1995 Sep;269(3 Pt 1):L273–84 (72 ref.)
Tissue–specific expression of rat neutral endopeptidase mRNAs. Li C, et al. **Ann N Y Acad Sci** 1996 Mar 22;

780:145–55 (10 ref.)
Transcription factors responsive to cAMP. Sassone-Corsi P. **Ann Rev Cell Dev Biol** 1995;11:355–77 (73 ref.)
The nucleolus. Shaw PJ, et al. **Ann Rev Cell Dev Biol** 1995; 11:93–121 (202 ref.)
Multiple steps in the regulation of transcription-factor level and activity. Calkhoven CF, et al. **Biochem J** 1996 Jul 15; 317 (Pt 2):329–42 (269 ref.)
E2F and the molecular mechanisms of early cell-cycle control. La Thangue NB. **Biochem Soc Trans** 1996 Feb; 24(1):54–9 (29 ref.)
Transcriptional silencing of homeotic genes in Drosophila. Bienz M, et al. **Bioessays** 1995 Sep;17(9):775–84 (71 ref.)
Transcriptional regulation of the dihydrofolate reductase gene. Slansky JE, et al. **Bioessays** 1996 Jan;18(1):55–62 (64 ref.)
The transcriptional control of hematopoiesis. Shivdasani RA, et al. **Blood** 1996 May 15;87(10):4025–39 (175 ref.)
Regulation of ribosomal DNA transcription during neonatal cardiomyocyte hypertrophy. Hannan RD, et al. **Cardiovasc Res** 1995 Oct;30(4):501–10 (135 ref.)
Transcription and masking of mRNA in germ cells: involvement of Y-box proteins. Sommerville J, et al. **Chromosoma** 1996 Apr;104(7):469–78 (66 ref.)
Oestrogen-responsive finger protein suggests a transcriptional cascade of steroid hormone regulation. **Ciba Found Symp** 1995;191:43–51 (18 ref.)
Regulation of somatostatin gene transcription by cAMP. Montminy M, et al. **Ciba Found Symp** 1995;190:7–20; discussion 20–5 (30 ref.)
Transcriptional control by steroid hormones: the role of chromatin. Truss M, et al. **Ciba Found Symp** 1995;191:7–17; discussion 17–23 (45 ref.)
Advanced glycosylation end products modulate transcriptional regulations on mesangial cells. Iehara N, et al. **Contrib Nephrol** 1996;118:141–6 (13 ref.)
The Ets family of proteins: weak modulators of gene expression in quest for transcriptional partners. Crepieux P, et al. **Crit Rev Oncog** 1994;5(6):615–38 (192 ref.)
Transcriptional regulation. Flipping the Myc switch. Bernards R. **Curr Biol** 1995 Aug 1;5(8):859–61 (13 ref.)
Mitochondrial transcription initiation: promoter structures and RNA polymerases. Tracy RL, et al. **Curr Genet** 1995 Aug;28(3):205–16 (103 ref.)
Species specificity of transcription by RNA polymerase I. Heix J, et al. **Curr Opin Genet Dev** 1995 Oct;5(5):652–6 (26 ref.)
DNA excision repair and transcription: implications for genome evolution. Sullivan DT. **Curr Opin Genet Dev** 1995 Dec;5(6):786–91 (55 ref.)
Regulation of adipocyte gene expression and differentiation by peroxisome proliferator activated receptor gamma. Tontonoz P, et al. **Curr Opin Genet Dev** 1995 Oct; 5(5):571–6 (51 ref.)
Transcriptional regulation of the IL-2 gene. Jain J, et al. **Curr Opin Immunol** 1995 Jun;7(3):333–42 (112 ref.)
Start-specific transcription in yeast. Breeden L. **Curr Top Microbiol Immunol** 1996;208:95–127 (112 ref.)
Transcriptionally targeted gene therapy. Hart IR. **Curr Top Microbiol Immunol** 1996;213 (Pt 3):19–25 (28 ref.)
Hematopoietic transcriptional regulation by the myeloid zinc finger gene, MZF-1. Hromas R, et al. **Curr Top Microbiol Immunol** 1996;211:159–64 (15 ref.)
Transcriptional modulation by the adenovirus E1A gene. Jones N. **Curr Top Microbiol Immunol** 1995;199 (Pt 3):59–80 (118 ref.)
Adenovirus E1A: transcription regulation and alteration of cell growth control. Nevins JR. **Curr Top Microbiol Immunol** 1995;199 (Pt 3):25–32 (39 ref.)
Transcription of adenovirus RNA polymerase III genes. Pruzan R, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 1):201–26 (116 ref.)
E3 transcription unit of adenovirus. Wold WS, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 1):237–74 (196 ref.)
Developmental roles for chromatin and chromosomal structure. Patterton D, et al. **Dev Biol** 1996 Jan 10; 173(1):2–13 (140 ref.)
Translational control in spermatogenesis. Schäfer M, et al. **Dev Biol** 1995 Dec;172(2):344–52 (62 ref.)
The RNA polymerase II elongation complex. Aso T, et al. **FASEB J** 1995 Nov;9(14):1419–28 (79 ref.)
Chromatin and transcription. Edmondson DG, et al. **FASEB J** 1996 Aug;10(10):1173–82 (59 ref.)
The fibronectin gene as a model for splicing and transcription studies. Kornblihtt AR, et al. **FASEB J** 1996 Feb; 10(2):248–57 (76 ref.)
Posttranscriptional regulation of gene expression in liver regeneration: role of mRNA stability. Kren BT, et al. **FASEB J** 1996 Apr;10(5):559–73 (93 ref.)
Antioxidant and redox regulation of gene transcription. Sen CK, et al. **FASEB J** 1996 May;10(7):709–20 (94 ref.)
Liver regeneration 4: transcriptional control of liver regeneration. Taub R. **FASEB J** 1996 Mar;10(4):413–27 (95 ref.)
Cytochromes P450 5: induction of cytochrome P4501A1: a model for analyzing mammalian gene transcription. Whitlock JP Jr, et al. **FASEB J** 1996 Jun;10(8):809–18 (44 ref.)
Archaeal transcription factors and their role in transcription initiation. Thomm M. **FEMS Microbiol Rev** 1996 May; 18(2-3):159–71 (64 ref.)
Mechanisms for inducible control of angiotensinogen gene transcription. Brasier AR, et al. **Hypertension** 1996 Mar; 27(3 Pt 2):465–75 (108 ref.)
Transcriptional regulation of the genes involved in lipoprotein transport. The role of proximal promoters and long-range regulatory elements and factors in apolipoprotein gene regulation. Kardassis D, et al. **Hypertension** 1996 Apr;27(4):980–1008 (116 ref.)
Mechanisms of transcriptional synergism of eukaryotic genes. The interferon-beta paradigm. Thanos D. **Hypertension** 1996 Apr;27(4):1025–9 (25 ref.)
Scaffold/matrix-attached regions: structural properties creating transcriptionally active loci. Bode J, et al. **Int Rev Cytol** 1995;162A:389–454 (230 ref.)
Contributions of nuclear architecture to transcriptional control. Stein GS, et al. **Int Rev Cytol** 1995;162A:251–78 (196 ref.)
On the structure of replication and transcription factories. Hughes TA, et al. **J Cell Sci Suppl** 1995;19:59–65 (64 ref.)
Polyunsaturated fatty acid regulation of hepatic gene transcription. Clarke SD, et al. **Lipids** 1996 Mar;31 Suppl:S7–11 (50 ref.)
Techniques for analyzing transcription and translation. Krause M. **Methods Cell Biol** 1995;48:513–29 (52 ref.)
Transcription and translation. Krause M. **Methods Cell Biol** 1995;48:483–512 (149 ref.)
In vitro transcription of class II promoters in higher plants. Cooke R, et al. **Methods Mol Biol** 1995;49:271–89 (19 ref.)
Control of rRNA transcription in Escherichia coli. Condon C, et al. **Microbiol Rev** 1995 Dec;59(4):623–45 (369 ref.)
Necessary but not sufficient: the role of glucocorticoids in the acidosis-induced increase in levels of mRNAs encoding proteins of the ATP-dependent proteolytic pathway in rat muscle. Price SR, et al. **Miner Electrolyte Metab** 1996; 22(1-3):72–5 (14 ref.)
Transcription antitermination: the lambda paradigm updated. Friedman DI, et al. **Mol Microbiol** 1995 Oct;18(2):191–200 (70 ref.)
Transcriptional regulation of bioluminescence genes from Vibrio fischeri. Sitnikov DM, et al. **Mol Microbiol** 1995 Sep;17(5):801–12 (84 ref.)
Transcriptional regulation by MAP kinases. Davis RJ. **Mol Reprod Dev** 1995 Dec;42(4):459–67 (31 ref.)
The 5-HT1A receptor: signaling, desensitization, and gene transcription. Albert PR, et al. **Neuropsychopharmacology** 1996 Jan;14(1):19–25 (45 ref.)
Transcriptional control of osteoblast growth and differentiation. Stein GS, et al. **Physiol Rev** 1996 Apr; 76(2):593–629 (461 ref.)
S1-nuclease-sensitive DNA structures contribute to transcriptional regulation of the human PDGF A-chain. Wang ZY, et al. **Prog Nucleic Acid Res Mol Biol** 1996; 55:227–44 (110 ref.)
Transcriptional control of cell phenotypes in the neuroendocrine system. Rosenfeld MG, et al. **Recent Prog Horm Res** 1996;51:217–38; discussion 238–9 (98 ref.)
Depolarization-transcription coupling in excitable cells. Schmidt J. **Rev Physiol Biochem Pharmacol** 1996; 127:251–79 (158 ref.)
Transcription factor IIA: a structure with multiple functions [comment] Jacobson RH, et al. **Science** 1996 May 10; 272(5263):827–8 (11 ref.) Comment on: Science 1996 May 10;272(5263):830–6.
Intercalation, DNA kinking, and the control of transcription. Werner MH, et al. **Science** 1996 Feb 9;271(5250):778–84 (54 ref.)
Histone deacetylase: a regulator of transcription [comment] Wolffe AP. **Science** 1996 Apr 19;272(5260):371–2 (16 ref.) Comment on: Science 1996 Apr 19;272(5260):408–11.
Transcriptional coactivators in yeast and beyond. Guarente L. **Trends Biochem Sci** 1995 Dec;20(12):517–21 (54 ref.)
Nucleotide excision repair and the link with transcription. Lehmann AR. **Trends Biochem Sci** 1995 Oct;20(10):402–5 (29 ref.)
Action at a distance: DNA-looping and initiation of transcription. Rippe K, et al. **Trends Biochem Sci** 1995 Dec; 20(12):500–6 (39 ref.)
Transcription: new insights from studies on Archaea. Baumann P, et al. **Trends Genet** 1995 Jul;11(7):279–83 (43 ref.)
Propagating memory of transcriptional states. Paro R. **Trends Genet** 1995 Aug;11(8):295–7 (17 ref.)
Transcriptional regulation: lessons from the human neurotropic polyomavirus, JCV. Raj GV, et al. **Virology** 1995 Nov 10;213(2):283–91 (79 ref.)
Transcriptional regulation of the genes encoding the cytochrome P-450 steroid hydroxylases. Parker KL, et al. **Vitam Horm** 1995;51:339–70 (121 ref.)
[Mechanism of gene expression--basic transcription factor and starting mechanism of genetic transcription] Kitajima S. **Fukuoka Igaku Zasshi** 1995 Dec;86(12):432–6 (2 ref.) **(Jpn)**
[Transcriptional machinery and its regulatory elements of HBV genome] Nishizono A, et al. **Nippon Rinsho** 1995 Oct; 53 Suppl:28–34 (30 ref.) **(Jpn)**
[Second messenger-mediated transcriptional regulation of neural genes and possible drug action sites] Higuchi H, et al. **Nippon Yakurigaku Zasshi** 1995 Dec;106(6):365–78 (50 ref.) (Eng. Abstr.) **(Jpn)**
[Human alpha-fetoprotein transcriptional regulatory regions: application to gene therapy] Tamaoki T, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2613–7 (25 ref.) **(Jpn)**

DRUG EFFECTS

The actions of cyclosporin A and FK506 on T-lymphocyte activation. Mattila PS. **Biochem Soc Trans** 1996 Feb; 24(1):45–9 (40 ref.)
Induced gene transcription: implications for biomarkers. Sewall CH, et al. **Clin Chem** 1995 Dec;41(12 Pt 2):1829–34 (59 ref.)
Polyunsaturated fatty acid regulation of hepatic gene transcription. Clarke SD, et al. **J Nutr** 1996 Apr;126(4 Suppl):1105S–9S (52 ref.)
Enhancement of nuclear receptor transcriptional signalling. Renkawitz R, et al. **J Steroid Biochem Mol Biol** 1996 Jan; 56(1-6 Spec No):39–45 (29 ref.)
cAMP-dependent regulation of gene transcription by cAMP response element-binding protein and cAMP response element modulator. Habener JF, et al. **Vitam Horm** 1995; 51:1–57 (196 ref.)

GENETICS

Gene expression in the intestine: the effect of dietary nucleotides. LeLeiko NS, et al. **Adv Pediatr** 1995;42:145–69 (65 ref.)
Regulation of gene transcription in respiratory epithelial cells. Whitsett JA, et al. **Am J Respir Cell Mol Biol** 1996 Feb; 14(2):118–20 (25 ref.)
Contacts in context: promoter specificity and macromolecular interactions in transcription. Goodrich JA, et al. **Cell** 1996 Mar 22;84(6):825–30 (32 ref.)
Targeting chromatin disruption: Transcription regulators that acetylate histones. Wolffe AP, et al. **Cell** 1996 Mar 22; 84(6):817–9 (15 ref.)
DNA repair and transcription. Bhatia PK, et al. **Curr Opin Genet Dev** 1996 Apr;6(2):146–50 (60 ref.)
Transcription: basal factors and activation. Ranish JA, et al. **Curr Opin Genet Dev** 1996 Apr;6(2):151–8 (77 ref.)
Silencing is golden: negative regulation in the control of neuronal gene transcription. Schoenherr CJ, et al. **Curr Opin Neurobiol** 1995 Oct;5(5):566–71 (48 ref.)
Role of kinases in HTLV-I transformation. Xu X, et al. **J Investig Med** 1996 Apr;44(4):113–23 (169 ref.)
Identification and characterization of transcriptional regulatory elements of the human aromatase cytochrome P450 gene (CYP19). Toda K, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1-6 Spec No):151–9 (22 ref.)
Mechanisms of mutant genes in spina bifida: a review of implications from animal models. George TM, et al. **Pediatr Neurosurg** 1995;23(5):236–45 (62 ref.)
Glucose transporter gene expression: regulation of transcription and mRNA stability. McGowan KM, et al. **Pharmacol Ther** 1995 Jun;66(3):465–505 (287 ref.)
Drosophila chromatin and transcription. Becker PB. **Semin Cell Biol** 1995 Aug;6(4):185–90 (50 ref.)
The HMG-14/-17 chromosomal protein family: architectural elements that enhance transcription from chromatin templates. Bustin M, et al. **Semin Cell Biol** 1995 Aug; 6(4):247–55 (39 ref.)
Chromatin and transcriptional activity in early Xenopus development. Landsberger N, et al. **Semin Cell Biol** 1995 Aug;6(4):191–9 (65 ref.)

IMMUNOLOGY

Influence of redox status of lymphocytes and monocytes on HIV transcription and replication. Gougerot-Pocidalo MA, et al. **Immunobiology** 1995 Jul;193(2-4):204–9 (27 ref.)
Transcriptional regulation of the tumor necrosis factor alpha gene. Jongeneel CV. **Immunobiology** 1995 Jul; 193(2-4):210–6 (23 ref.)
The cis-acting elements controlling mouse IL-2R alpha transcription. Nabholz M, et al. **Immunobiology** 1995 Jul; 193(2-4):259–62 (4 ref.)
Transcriptional regulation of the human T cell receptor delta gene. Redondo JM, et al. **Immunobiology** 1995 Jul; 193(2-4):288–92 (14 ref.)
Transcriptional regulation of the human intercellular adhesion molecule-1 gene: a short overview. Stratowa C, et al. **Immunobiology** 1995 Jul;193(2-4):293–304 (37 ref.)

PHYSIOLOGY

Negative regulation of transcription by anti-sigma factors. Wolska KI. **Acta Microbiol Pol** 1996;45(1):7–17 (71 ref.)
Chromatin structure and transcriptional activity of MAG gene. Konat GW. **Acta Neurobiol Exp (Warsz)** 1996; 56(1):281–5 (25 ref.)
Transcription of the human neuronal nitric oxide synthase gene in the central nervous system is mediated by multiple promoters. Young AP, et al. **Adv Pharmacol** 1995;34:91–112 (51 ref.)
Control of transcription by steroid hormones. Beato M, et al. **Ann N Y Acad Sci** 1996 Apr 30;784:93–123 (266 ref.)
Intestine-specific gene transcription. Traber PG, et al. **Annu Rev Physiol** 1996;58:275–97 (106 ref.)
xRB as a modulator of transcription. Sellers WR, et al. **Biochim Biophys Acta** 1996 Aug 8;1288(1):M1–5 (77 ref.)
Specificity mechanisms in the control of transcription. von

Hippel PH, et al. **Biophys Chem** 1996 Apr 16;59(3):231–46 (56 ref.)
From transcript to protein. Dreyfuss G, et al. **Cell** 1996 Jun 28;85(7):963–72 (80 ref.)
Transcriptional control by protein phosphorylation: signal transmission from the cell surface to the nucleus. Karin M, et al. **Curr Biol** 1995 Jul 1;5(7):747–57 (102 ref.)
Regulation of transcription by MAP kinase cascades. Treisman R. **Curr Opin Cell Biol** 1996 Apr;8(2):205–15 (95 ref.)
Multiple SWItches to turn on chromatin? Peterson CL. **Curr Opin Genet Dev** 1996 Apr;6(2):171–5 (36 ref.)
The role of brahma and related proteins in transcription and development. Tamkun JW. **Curr Opin Genet Dev** 1995 Aug; 5(4):473–7 (51 ref.)
The role of CcpA transcriptional regulator in carbon metabolism in Bacillus subtilis. Henkin TM. **FEMS Microbiol Lett** 1996 Jan 1;135(1):9–15 (35 ref.)
Signal transduction and activation of gene transcription by interferons. Gilmour KC, et al. **Gene Expr** 1995;5(1):1–18 (145 ref.)
Does the Wilms' tumour suppressor gene, WT1, play roles in both splicing and transcription? Charlieu JP, et al. **J Cell Sci Suppl** 1995;19:95–9 (20 ref.)
Interaction of steroid hormone receptors with transcription factors involves chromatin remodelling. Beato M, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1–6 Spec No):47–59 (144 ref.)
Regulation of human immunodeficiency virus type 1 and cytokine gene expression in myeloid cells by NF-kappa B/Rel transcription factors. Roulston A, et al. **Microbiol Rev** 1995 Sep;59(3):481–505 (481 ref.)
The role of anti-sigma factors in gene regulation. Brown KL, et al. **Mol Microbiol** 1995 May;16(3):397–404 (49 ref.)

TRANSCRIPTIONAL ACTIVATION see **TRANS-ACTIVATION (GENETICS)**

TRANSCRIPTIONAL REGULATORY ELEMENTS see **GENES, REGULATOR**

TRANSCULTURAL NURSING

Nursing, humanism and transcultural theory: the 'bracketing-out' of reality. Mulholland J. **J Adv Nurs** 1995 Sep;22(3):442–9 (43 ref.)
Transcultural nursing: a perspective derived from Jean-Paul Sartre. Rajan MF. **J Adv Nurs** 1995 Sep;22(3):450–5 (20 ref.)
Cultural diversity: a nursing concept not yet reliably defined. Habayeb GL. **Nurs Outlook** 1995 Sep–Oct;43(5):224–7 (45 ref.)

EDUCATION

Towards an individualized client's care: implication for education. The transcultural approach. Abdullah SN. **J Adv Nurs** 1995 Oct;22(4):715–20 (36 ref.)
A critique of multiculturalism in heath care: the challenge for nurse education. Culley L. **J Adv Nurs** 1996 Mar; 23(3):564–70 (42 ref.)

METHODS

Cultural aspects of pain in childbearing women. Weber SE. **J Obstet Gynecol Neonatal Nurs** 1996 Jan;25(1):67–72 (20 ref.)

TRANSCULTURAL STUDIES see **CROSS-CULTURAL COMPARISON**

TRANSCUTANEOUS ELECTRIC NERVE STIMULATION

Transcutaneous electrical nerve stimulation (TENS): a technology assessment. Reeve J, et al. **Int J Technol Assess Health Care** 1996 Spring;12(2):299–324 (96 ref.)
[Highlights in the subject of low frequency-high intensity TENS (review)] Galletti SP, et al. **Minerva Stomatol** 1995 Sep;44(9):421–9 (41 ref.) (Eng. Abstr.) **(Ita)**

UTILIZATION

Clinical and experimental evaluation of cranial TENS in the U.S.: a review. Taylor DN. **Acupunct Electrother Res** 1995 Apr–Jul;20(2):117–32 (45 ref.)

TRANSDERMAL ELECTROSTIMULATION see **TRANSCUTANEOUS ELECTRIC NERVE STIMULATION**

TRANSDUCERS, PRESSURE

Intracranial pressure monitoring techniques. Ghajar J. **New Horiz** 1995 Aug;3(3):395–9 (42 ref.)

TRENDS

Transducers for foot pressure measurement: survey of recent developments. Cobb J, et al. **Med Biol Eng Comput** 1995 Jul;33(4):525–32 (44 ref.)

TRANSESOPHAGEAL ECHOCARDIOGRAPHY see **ECHOCARDIOGRAPHY, TRANSESOPHAGEAL**

TRANSFECTION

see related
ELECTROPORATION

Sodium-calcium exchange and calcium homeostasis in transfected Chinese hamster ovary cells. Reeves JP, et al. **Ann N Y Acad Sci** 1996 Apr 15;779:73–85 (27 ref.)
The impact of cytokines on high dose chemotherapy followed by transplantation of purified and ex vivo expanded peripheral blood stem cells: achieving a state of minimal residual disease for tumor immunotherapy with cytokine gene transfected cells [editorial] Mertelsmann R. **Eur Cytokine Netw** 1995 Mar–Apr;6(2):79–82 (12 ref.)
P53-mediated radioresistance does not correlate with metastatic potential in tumorigenic rat embryo cell lines following oncogene transfection. Bristow RG, et al. **Int J Radiat Oncol Biol Phys** 1996 Jan 15;34(2):341–55 (81 ref.)
The mechanism of somatic hypermutation studied with transgenic and transfected target genes. Storb U, et al. **Semin Immunol** 1996 Jun;8(3):131–40 (55 ref.)
In situ cytokine gene transfection using vaccinia virus vectors. Lattime EC, et al. **Semin Oncol** 1996 Feb; 23(1):88–100 (98 ref.)

METHODS

Use of plasmid DNA for direct gene transfer and immunization. Davis HL, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:21–9 (29 ref.)
Improved cationic lipid formulations for in vivo gene therapy. Felgner PL, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:126–39 (51 ref.)
Gene transfer and amplification in CHO cells. Efficient methods for maximizing specific productivity and assessment of genetic consequences. Wurm FM, et al. **Ann N Y Acad Sci** 1996 May 15;782:70–8 (25 ref.)
Adenovirus-augmented, receptor-mediated gene delivery and some solutions to the common toxicity problems. Cotten M. **Curr Top Microbiol Immunol** 1995;199 (Pt 3):283–95 (70 ref.)

TRANSFER RNA see **RNA, TRANSFER**

TRANSFER RNA, GLU see **RNA, TRANSFER, GLU**

TRANSFER RNA, PHE see **RNA, TRANSFER, PHE**

TRANSFERASES

METABOLISM

Asparagine-linked glycosylation: specificity and function of oligosaccharyl transferase. Imperiali B, et al. **Bioorg Med Chem** 1995 Dec;3(12):1565–78 (86 ref.)
Protein prenyltransferases. Casey PJ, et al. **J Biol Chem** 1996 Mar 8;271(10):5289–92 (78 ref.)

PHYSIOLOGY

Biochemistry, molecular biology, and genetics of the oligosaccharyltransferase. Silberstein S, et al. **FASEB J** 1996 Jun;10(8):849–58 (69 ref.)
Role of translocases in the generation of phosphatidylserine asymmetry. Diaz C, et al. **J Membr Biol** 1996 May; 151(1):1–9 (99 ref.)

TRANSFERENCE (PSYCHOLOGY)

A self psychologist in couplesland: multisubjective approach to transference and countertransference-like phenomena in marital relationships. Livingston MS. **Fam Process** 1995 Dec;34(4):427–39 (26 ref.)
The transference and the zone of proximal development. Wilson A, et al. **J Am Psychoanal Assoc** 1996;44(1):167–200 (51 ref.)
[Reflections on transference, countertransference, session frequency and the analytic process] Holder A. **Psychiatr Enfant** 1995;38(2):603–23 (5 ref.) (Eng. Abstr.) **(Fre)**
[Remembering in the transference--on the interdisciplinary dialogue between psychoanalysis and biological memory research] Leuzinger-Bohleber M. **Psychother Psychosom Med Psychol** 1996 Jun;46(6):217–27 (53 ref.) (Eng. Abstr.) **(Ger)**

TRANSFERRIN

see related
RECEPTORS, TRANSFERRIN

ANALOGS & DERIVATIVES

Gamma-glutamyltranspeptidase and carbohydrate deficient transferrin: alternative measures of excessive alcohol consumption. Litten RZ, et al. **Alcohol Clin Exp Res** 1995 Dec;19(6):1541–6 (37 ref.)

ANALYSIS

[Total iron binding capacity (TIBC), unsaturated iron binding capacity (UIBC)] Sakurada K, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:812–4 (7 ref.) **(Jpn)**
[Transferrin] Yamaguchi T, et al. **Nippon Rinsho** 1995 Feb; 53 Su Pt 1:227–9 (6 ref.) **(Jpn)**

PHYSIOLOGY

Mechanisms of iron uptake by mammalian cells. Qian ZM, et al. **Biochim Biophys Acta** 1995 Nov 30;1269(3):205–14 (109 ref.)
Iron and infection: new developments and their implications. Ward CG, et al. **J Trauma** 1996 Aug;41(2):356–64 (83 ref.)

TRANSFERRIN RECEPTORS see **RECEPTORS, TRANSFERRIN**

TRANSFORMATION, BACTERIAL

Is thermophily a transferrable property in bacteria? Lindsay JA. **Crit Rev Microbiol** 1995;21(3):165–74 (55 ref.)

TRANSFORMATION, GENETIC

see related
DNA, RECOMBINANT

In vitro transformation by hepatitis B virus DNA. Schaefer S, et al. **Intervirology** 1995;38(3–4):143–54 (112 ref.)
DNA transformation. Mello C, et al. **Methods Cell Biol** 1995; 48:451–82 (45 ref.)
Medfly transformed--official! [comment] Ashburner M. **Science** 1995 Dec 22;270(5244):1941–2 (11 ref.) Comment on: Science 1995 Dec 22;270(5244):2002–5. Comment on: Science 1995 Dec 22;270(5244):2005–8.

TRANSFORMING GENES see **ONCOGENES**

TRANSFORMING GROWTH FACTOR ALPHA

ANTAGONISTS & INHIBITORS

Role of growth factors, steroid and peptide hormones in the regulation of human prostatic tumor growth. Motta M, et al. **J Steroid Biochem Mol Biol** 1996 Jan;56(1–6 Spec No):107–11 (36 ref.)

DRUG EFFECTS

[New approaches to antitumor therapy: the use of preparations acting on processes regulated by epidermal and/or alpha-transforming growth factors] Kushlinskii NE, et al. **Eksp Klin Farmakol** 1996 Jan–Feb;59(1):74–80 (64 ref.) **(Rus)**

PHARMACOLOGY

Endocrine and paracrine negative regulators of adipose differentiation. Serrero G, et al. **Int J Obes Relat Metab Disord** 1996 Mar;20 Suppl 3:S58–64 (33 ref.)

PHYSIOLOGY

Transforming growth factor-alpha. Gangarosa LM, et al. **Baillieres Clin Gastroenterol** 1996 Mar;10(1):49–63 (54 ref.)
Peptide growth factors in the prostate as mediators of stromal epithelial interaction. Byrne RL, et al. **Br J Urol** 1996 May; 77(5):627–33 (65 ref.)
Basic actions of transforming growth factor-alpha and related peptides. Coffey RJ, et al. **Eur J Gastroenterol Hepatol** 1995 Oct;7(10):923–7 (49 ref.)
Epidermal growth factor and transforming growth factor-alpha actions on the gut. Goodlad RA, et al. **Eur J Gastroenterol Hepatol** 1995 Oct;7(10):928–32 (29 ref.)
Epidermal growth factor and transforming growth factor-alpha: role in protection and healing of gastric mucosal lesions. Konturek PC, et al. **Eur J Gastroenterol Hepatol** 1995 Oct;7(10):933–7 (26 ref.)
The role of growth factors in mouse skin tumor promotion and premalignant progression. Yuspa SH, et al. **Prog Clin Biol Res** 1995;391:39–48 (43 ref.)
Epidermal growth factor-related peptides and the epidermal growth factor receptor in normal and malignant prostate. Sherwood ER, et al. **World J Urol** 1995;13(5):290–6 (65 ref.)
[Transforming growth factor (TGF)] Kasai S, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:822–5 (12 ref.) **(Jpn)**

TRANSFORMING GROWTH FACTOR ALPHA RECEPTORS see **RECEPTORS, EPIDERMAL GROWTH FACTOR-UROGASTRONE**

TRANSFORMING GROWTH FACTOR BETA

Bone morphogenetic protein-2: biology and applications. Riley EH, et al. **Clin Orthop** 1996 Mar;(324):39–46 (70 ref.)
[Transforming growth factor-beta and its receptors] Miyazono K. **Nippon Yakurigaku Zasshi** 1996 Mar; 107(3):133–40 (28 ref.) (Eng. Abstr.) **(Jpn)**

ANALYSIS

Factor VIII concentrates and the immune system--laboratory investigations. Wadhwa M, et al.

Blood Coagul Fibrinolysis 1995 Jul;6 Suppl 2:S65–79 (73 ref.)

BIOSYNTHESIS

Transforming growth factor beta: relevance to radiotherapy. Parker CC, et al. **Clin Oncol (R Coll Radiol)** 1995;7(3):160–1 (19 ref.)

Immunoregulatory and fibrogenic activities of cyclosporine: a unifying hypothesis based on transforming growth factor–beta expression. Khanna A, et al. **Transplant Proc** 1996 Aug;28(4):2015–8 (38 ref.)

CHEMISTRY

Structure and activation of the large latent transforming growth factor–beta complex. Nunes I, et al. **Int J Obes Relat Metab Disord** 1996 Mar;20 Suppl 3:S4–8 (45 ref.)

DEFICIENCY

Transforming growth factor–beta1–deficient mice: identification of isoform–specific activities in vivo. Letterio JJ, et al. **J Leukoc Biol** 1996 Jun;59(6):769–74 (52 ref.)

DRUG EFFECTS

Negative selection in hepatic tumor promotion in relation to cancer risk assessment. Andersen ME, et al. **Toxicology** 1995 Sep 1;102(1–2):223–37 (82 ref.)

GENETICS

Regulation of transforming growth factor beta by sex steroids. Hering S, et al. **Horm Metab Res** 1995 Aug; 27(8):345–51 (87 ref.)

IMMUNOLOGY

The immunoregulatory roles of transforming growth factor beta. Sosroseno W, et al. **Br J Biomed Sci** 1995 Jun; 52(2):142–8 (111 ref.)

METABOLISM

Poly(alpha–hydroxy acids): carriers for bone morphogenetic proteins. Hollinger JO, et al. **Biomaterials** 1996 Jan; 17(2):187–94 (101 ref.)

Thyrotropin–dependent transforming growth factor beta expression in thyroid gland [comment] Roger PP. **Eur J Endocrinol** 1996 Mar;134(3):269–71 (16 ref.) Comment on: Eur J Endocrinol 1996 Mar;134(3):373–8.

Structure and activation of the large latent transforming growth factor–beta complex. Nunes I, et al. **Int J Obes Relat Metab Disord** 1996 Mar;20 Suppl 3:S4–8 (45 ref.)

Tumor suppressor genes in the TGF–beta signaling pathway? Serra R, et al. **Nat Med** 1996 Apr;2(4):390–1 (15 ref.)

PHARMACOLOGY

Elimination of transformed cells by normal cells: a novel concept for the control of carcinogenesis. Bauer G. **Histol Histopathol** 1996 Jan;11(1):237–55 (152 ref.)

Transforming growth factor–beta–3 is mitogenic for rat retinal progenitor cells in vitro. Anchan RM, et al. **J Neurobiol** 1995 Oct;28(2):133–45 (50 ref.)

Transforming growth factor–beta s in mammary tumorigenesis: promoters or antipromoters? Wakefield LM, et al. **Prog Clin Biol Res** 1995;391:133–48 (56 ref.)

Regulation of differentiation pathway of skeletal mesenchymal cells in cell lines by transforming growth factor–beta superfamily. Yamaguchi A. **Semin Cell Biol** 1995 Jun;6(3):165–73 (53 ref.)

How neurotrophic factors protect brain against excitotoxicity. Cuevas Sanchez P. **Surg Neurol** 1996 Aug; 46(2):152–3 (15 ref.)

Immunoregulatory and fibrogenic activities of cyclosporine: a unifying hypothesis based on transforming growth factor–beta expression. Khanna A, et al. **Transplant Proc** 1996 Aug;28(4):2015–8 (38 ref.)

PHYSIOLOGY

Transforming growth factor–beta in GI neoplasia, wound healing and immune response. Pignatelli M, et al. **Baillieres Clin Gastroenterol** 1996 Mar;10(1):65–81 (110 ref.)

Negative regulation of cell growth by TGF beta. Polyak K. **Biochim Biophys Acta** 1996 Mar 18;1242(3):185–99 (244 ref.)

Signaling by the transforming growth factor–beta receptors. Yingling JM, et al. **Biochim Biophys Acta** 1995 Dec 18; 1242(2):115–36 (119 ref.)

A pivotal role for TGF–beta in atherogenesis? Grainger DJ, et al. **Biol Rev Camb Philos Soc** 1995 Nov;70(4):571–96 (108 ref.)

Transforming growth factor–beta 1 and the development of vascular hypertrophy in hypertension. Agrotis A, et al. **Blood Press Suppl** 1995;2:43–8 (43 ref.)

Peptide growth factors in the prostate as mediators of stromal epithelial interaction. Byrne RL, et al. **Br J Urol** 1996 May; 77(5):627–33 (65 ref.)

Transforming growth factor beta and cancer. Nørgaard P, et al. **Cancer Treat Rev** 1995 Jul;21(4):367–403 (313 ref.)

TGFbeta signaling: receptors, transducers, and Mad proteins. Massagué J. **Cell** 1996 Jun 28;85(7):947–50 (20 ref.)

Transforming growth factor–beta signal transduction. Brand T, et al. **Circ Res** 1996 Feb;78(2):173–9 (35 ref.)

The use of neutralizing antibodies to demonstrate the role of transforming growth factor–beta and Amadori–glycated albumin as mediators of experimental diabetic kidney disease. Ziyadeh FN, et al. **Contrib Nephrol** 1996; 118:188–94 (39 ref.)

Hyperglycemia and diabetic kidney disease. The case for transforming growth factor–beta as a key mediator. Sharma K, et al. **Diabetes** 1995 Oct;44(10):1139–46 (124 ref.)

Transforming growth factor–beta 1: a lesion–associated cytokine of the nervous system. Kiefer R, et al. **Int J Dev Neurosci** 1995 Jun–Jul;13(3–4):331–9 (54 ref.)

Neural functions of the transforming growth factors beta. Krieglstein K, et al. **Int J Dev Neurosci** 1995 Jun–Jul; 13(3–4):301–15 (126 ref.)

Role of transforming growth factor–beta in diabetic glomerulosclerosis and renal hypertrophy. Ziyadeh FN, et al. **Kidney Int Suppl** 1995 Sep;51:S34–6 (34 ref.)

TGF–beta and megakaryocytes in the pathogenesis of myelofibrosis in myeloproliferative disorders. Martyré MC. **Leuk Lymphoma** 1995 Dec;20(1–2):39–44 (58 ref.)

TGF–beta: receptors and cell cycle arrest. Saltis J. **Mol Cell Endocrinol** 1996 Feb 5;116(2):227–32 (61 ref.)

Many roads lead to atheroma [comment] Hayden MR, et al. **Nat Med** 1995 Jan;1(1):22–3 (18 ref.) Comment on: Nat Med 1995 Jan;1(1):74–9.

The role of TGF–beta in growth inhibition of peritoneal mesothelial cells in high–glucose dialysate. Kumano K, et al. **Perit Dial Int** 1995;15(7 Suppl):S93–5 (18 ref.)

The role of growth factors in mouse skin tumor promotion and premalignant progression. Yuspa SH, et al. **Prog Clin Biol Res** 1995;391:39–48 (43 ref.)

[TGF–beta: usage in nephrology] Quirin N, et al. **Nephrologie** 1996;17(4):227–35 (91 ref.) (Eng. Abstr.) **(Fre)**

[Transforming growth factor (TGF)] Kasai S, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:822–5 (12 ref.) **(Jpn)**

THERAPEUTIC USE

How neurotrophic factors protect brain against excitotoxicity. Cuevas Sanchez P. **Surg Neurol** 1996 Aug; 46(2):152–3 (15 ref.)

TRANSFORMING GROWTH FACTOR BETA RECEPTORS see **RECEPTORS, TRANSFORMING GROWTH FACTOR BETA**

TRANSFORMING GROWTH FACTORS

METABOLISM

Pattern formation. Gurken meets torpedo for the first time. Gavis ER. **Curr Biol** 1995 Nov 1;5(11):1252–4 (14 ref.)

PHYSIOLOGY

Growth factors and ulcerative gastrointestinal disease. Playford RJ, et al. **Baillieres Clin Gastroenterol** 1996 Mar; 10(1):135–49 (60 ref.)

TRANSFORMING REGION see **BASE SEQUENCE**

TRANSGENES

see related
ANIMALS, TRANSGENIC

Transgenetics and gene targeting in studies of prion diseases. Scott MR, et al. **Curr Top Microbiol Immunol** 1996; 207:95–123 (134 ref.)

Transgenic targeting of neuroendocrine peptide genes in the hypothalamic–pituitary axis. Waschek JA. **Mol Neurobiol** 1995 Apr–Jun;10(2–3):205–17 (50 ref.)

Use of transgenic mouse models for studying somatic mutations in aging. Martus HJ, et al. **Mutat Res** 1995 Oct; 338(1–6):203–13 (46 ref.)

The mechanism of somatic hypermutation studied with transgenic and transfected target genes. Storb U, et al. **Semin Immunol** 1996 Jun;8(3):131–40 (55 ref.)

Characterization of the cis–acting elements required for somatic hypermutation of murine antibody V genes using conventional transgenic and transgene homologous recombination approaches. Tumas–Brundage K, et al. **Semin Immunol** 1996 Jun;8(3):141–50 (68 ref.)

Regulation and expression of transgenes in fish -- a review. Iyengar A, et al. **Transgenic Res** 1996 May;5(3):147–66 (101 ref.)

DRUG EFFECTS

Of mice and mutants: target size and sensitivity. Skopek TR. **Mutat Res** 1995 Oct;331(2):225–8 (7 ref.)

GENETICS

The mammary gland as a bioreactor: factors regulating the efficient expression of milk protein–based transgenes. Rosen JM, et al. **Am J Clin Nutr** 1996 Apr;63(4):627S–32S (53 ref.)

TRANSGENIC ANIMALS see **ANIMALS, TRANSGENIC**

TRANSGENIC MICE see **MICE, TRANSGENIC**

TRANSGENIC PLANTS see **PLANTS, TRANSGENIC**

TRANSIENT ISCHEMIC ATTACK see **CEREBRAL ISCHEMIA, TRANSIENT**

TRANSIENTS AND MIGRANTS

see related
HOMELESS PERSONS

TRANSKETOLASE

BLOOD

[Erythrocyte transketolase] Yasuda K, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:258–61 (10 ref.) **(Jpn)**

TRANSLATING

Working effectively with interpreters in the primary care setting. Poss JE, et al. **Nurse Pract** 1995 Dec;20(12):43–7 (9 ref.)

TRANSLATION, GENETIC

p53 and translational control. Ewen ME, et al. **Biochim Biophys Acta** 1996 Mar 18;1242(3):181–4 (48 ref.)

Effects of rare codon clusters on high–level expression of heterologous proteins in Escherichia coli. Kane JF. **Curr Opin Biotechnol** 1995 Oct;6(5):494–500 (26 ref.)

The role of the La autoantigen in internal initiation. Belsham GJ, et al. **Curr Top Microbiol Immunol** 1995;203:85–98 (57 ref.)

Translation of encephalomyocarditis virus RNA by internal ribosomal entry. Hellen CU, et al. **Curr Top Microbiol Immunol** 1995;203:31–63 (178 ref.)

Cap–independent translation and internal initiation of translation in eukaryotic cellular mRNA molecules. Iizuka N, et al. **Curr Top Microbiol Immunol** 1995;203:155–77 (116 ref.)

Cap–dependent and cap–independent translation: operational distinctions and mechanistic interpretations. Jackson RJ, et al. **Curr Top Microbiol Immunol** 1995;203:1–29 (111 ref.)

Cap–independent translation of heat shock messenger RNAs. Rhoads RE, et al. **Curr Top Microbiol Immunol** 1995; 203:131–53 (108 ref.)

Cap–independent translation in adenovirus infected cells. Schneider RJ. **Curr Top Microbiol Immunol** 1995; 203:117–29 (61 ref.)

Structure and function of the hepatitis C virus internal ribosome entry site. Wang C, et al. **Curr Top Microbiol Immunol** 1995;203:99–115 (81 ref.)

Translational control of eukaryotic gene expression. Role of the guanine nucleotide exchange factor and chain initiation factor–2. Singh LP, et al. **Enzyme Protein** 1994–95; 48(2):61–80 (101 ref.)

Initiation of protein synthesis in eukaryotic cells. Pain VM. **Eur J Biochem** 1996 Mar 15;236(3):747–71 (372 ref.)

Translational research on hereditary colon, breast, and ovarian cancers. Li FP. **J Natl Cancer Inst Monogr** 1995; (17):1–4 (26 ref.)

Interpreting cDNA sequences: some insights from studies on translation. Kozak M. **Mamm Genome** 1996 Aug; 7(8):563–74 (258 ref.)

Transcription and translation. Krause M. **Methods Cell Biol** 1995;48:483–512 (149 ref.)

Techniques for analyzing transcription and translation. Krause M. **Methods Cell Biol** 1995;48:513–29 (52 ref.)

The large ribosomal subunit stalk as a regulatory element of the eukaryotic translational machinery. Ballesta JP, et al. **Prog Nucleic Acid Res Mol Biol** 1996;55:157–93 (119 ref.)

Effects of the ferritin open reading frame on translational induction by iron. Mascotti DP, et al. **Prog Nucleic Acid Res Mol Biol** 1996;55:121–34 (82 ref.)

Internal initiation of translation in eukaryotes: the picornavirus paradigm and beyond. Jackson RJ, et al. **RNA** 1995 Dec;1(10):985–1000 (104 ref.)

Post–translational modification of poly(ADP–ribose) polymerase induced by DNA strand breaks. Lindahl T, et al. **Trends Biochem Sci** 1995 Oct;20(10):405–11 (46 ref.)

The end in sight: terminating translation in eukaryotes. Stansfield I, et al. **Trends Biochem Sci** 1995 Dec; 20(12):489–91 (17 ref.)

[Translation termination in eukaryotes] Kiselev LL, et al. **Mol Biol (Mosk)** 1995 Nov–Dec;29(6):1286–93 (39 ref.) **(Rus)**

DRUG EFFECTS

Translation–targeted therapeutics for viral diseases. Harford JB. **Gene Expr** 1995;4(6):357–67 (59 ref.)

PHYSIOLOGY

Regulation of iron metabolism: translational effects mediated by iron, heme, and cytokines. Mascotti DP, et al. **Annu Rev Nutr** 1995;15:239–61 (143 ref.)

Translational control. Awakening dormant mRNAs. Vassalli JD, et al. **Curr Biol** 1995 May 1;5(5):476–9 (23 ref.)

TRANSLOCATION (GENETICS)

Oncogenic role of "master" transcription factors in human leukemias and sarcomas: a developmental model. Look AT. **Adv Cancer Res** 1995;67:25–57 (162 ref.)

Detection of a subtle rearrangement of chromosome 22 using molecular techniques. Biesecker LG, et al. **Am J Med Genet** 1995 Sep 25;58(4):389–94 (15 ref.)

Detection of minimal residual disease in hematopoietic tissues. Sharp JG, et al. **Ann N Y Acad Sci** 1995 Dec 29; 770:242–61 (89 ref.)

Therapy-related acute promyelocytic leukemia with t(15;17)(q22;q12) following chemotherapy with drugs targeting DNA topoisomerase II. A report of two cases and a review of the literature [see comments] Hoffmann L, et al. **Ann Oncol** 1995 Oct;6(8):781–8 (32 ref.) Comment in: Ann Oncol 1995 Oct;6(8):751–3.

Therapy-related acute leukemia associated with t(11q23) after primary acute myeloid leukemia with t(8;21): a report of two cases [letter] Roulston D, et al. **Blood** 1995 Nov 1;86(9):3613–4 (7 ref.)

Further evidence for the clonal nature of the idiopathic hypereosinophilic syndrome: complete haematological and cytogenetic remission induced by interferon-alpha in a case with a unique chromosomal abnormality. Malbrain ML, et al. **Br J Haematol** 1996 Jan;92(1):176–83 (55 ref.)

Translocation (Y;1)(q12;q12) in hematologic malignancies. Report on two new cases, FISH characterization, and review of the literature. Michaux L, et al. **Cancer Genet Cytogenet** 1996 Jan;86(1):35–8 (13 ref.)

A mucoepidermoid carcinoma of minor salivary gland with t(11;19)(q21;p13.1) as the only karyotypic abnormality. El-Naggar AK, et al. **Cancer Genet Cytogenet** 1996 Mar; 87(1):29–33 (35 ref.)

der(1;15)(q10;10): a nonrandom chromosomal abnormality of myeloid neoplasia. Wong KF, et al. **Cancer Genet Cytogenet** 1995 Sep;83(2):144–7 (12 ref.)

DNA helicases: new breeds of translocating motors and molecular pumps. West SC. **Cell** 1996 Jul 26;86(2):177–80 (13 ref.)

Molecular characterization of trisomic segment 3p24.1—>3pter: a case with review of the literature. Conte RA, et al. **Clin Genet** 1995 Jul;48(1):49–53 (37 ref.)

Acute non-lymphoblastic leukaemia with t(16;21): case report with a review of the literature. Hiyoshi M, et al. **Clin Lab Haematol** 1995 Sep;17(3):243–6 (15 ref.)

The role of chromosome translocations in T cell acute leukemia. Hwang LY, et al. **Curr Opin Immunol** 1995 Oct; 7(5):659–64 (54 ref.)

Transcriptional regulation by the t(8;21) fusion protein, AML-1/ETO. Hiebert SW, et al. **Curr Top Microbiol Immunol** 1996;211:253–8 (19 ref.)

Retinoic acid regulatory pathways, chromosomal translocations, and acute promyelocytic leukemia. Chen Z, et al. **Genes Chromosomes Cancer** 1996 Mar;15(3):147–56 (123 ref.)

Distinct Xp11.2 breakpoints in two renal cell carcinomas exhibiting X;autosome translocations. Dijkhuizen T, et al. **Genes Chromosomes Cancer** 1995 Sep;14(1):43–50 (20 ref.)

Bone and brain involvement in a case of diffuse large B cell lymphoma associated with t(2;3)(p12;q27). Utsumi S, et al. **Int J Hematol** 1995 Dec;62(4):247–52 (16 ref.)

Hypomelanosis of Ito and X;autosome translocations: a unifying hypothesis. Hatchwell E. **J Med Genet** 1996 Mar; 33(3):177–83 (61 ref.)

t(2;5) translocations in anaplastic large cell lymphomas and Hodgkin's disease [editorial; comment] Herbst H. **J Pathol** 1996 Feb;178(2):113–5 (22 ref.) Comment on: J Pathol 1996 Feb;178(2):128–32.

Myelodysplastic syndrome with t(5;12)(q31;p12–p13) and eosinophilia: a pediatric case with review of literature. Pellier I, et al. **J Pediatr Hematol Oncol** 1996 Aug; 18(3):285–8 (19 ref.)

Detection of chromosomal translocations in leukemia-lymphoma cells by polymerase chain reaction. Drexler HG, et al. **Leuk Lymphoma** 1995 Nov; 19(5–6):359–80 (278 ref.)

t(9;22)(q22–31;q11–12) is a consistent marker of extraskeletal myxoid chondrosarcoma: evaluation of three cases. Sciot R, et al. **Mod Pathol** 1995 Sep;8(7):765–8 (19 ref.)

Gene fusions encoding chimaeric transcription factors in solid tumours. Sorensen PH, et al. **Semin Cancer Biol** 1996 Feb; 7(1):3–14 (100 ref.)

[Human familial autosomal reciprocal translocations] Cohen O, et al. **Ann Genet** 1995;38(4):177–86 (37 ref.) (Eng. Abstr.) **(Fre)**

[Fluorescent in-situ hybridization technique (FISH) in the diagnosis of Philadelphia translocation in chronic myeloid leukemia] Martinet D, et al. **Schweiz Med Wochenschr** 1996 May 18;126(20):855–63 (30 ref.) (Eng. Abstr.) **(Fre)**

[Chromosomal translocation and molecular characteristics in hematological malignancies] Inokuchi K. **Nippon Ika Daigaku Zasshi** 1996 Jun;63(3):175–80 (23 ref.) **(Jpn)**

[Therapy-related leukemia with t(8;21) initially diagnosed as MDS (RAEB in T)] Hanamura A, et al. **Rinsho Ketsueki** 1995 Aug;36(8):755–61 (15 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Uniparental isodisomy of chromosome 14 in two cases: an abnormal child and a normal adult. Papenhausen PR, et al. **Am J Med Genet** 1995 Nov 20;59(3):271–5 (30 ref.)

The emerging molecular genetics of sarcoma translocations. Ladanyi M. **Diagn Mol Pathol** 1995 Sep;4(3):162–73 (89 ref.)

A new myeloproliferative disorder associated with chromosomal translocations involving 8p11: a review [see comments] Macdonald D, et al. **Leukemia** 1995 Oct; 9(10):1628–30 (30 ref.) Comment in: Leukemia 1996 Jul;10(7):1252–3.

TRANSLOCATION, BACTERIAL see **BACTERIAL TRANSLOCATION**

TRANSLOCATION, CHROMOSOMAL see **TRANSLOCATION (GENETICS)**

TRANSLUMINAL CORONARY BALLOON DILATATION see **ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY**

TRANSMEMBRANE POTENTIALS see **MEMBRANE POTENTIALS**

TRANSMISSIBLE DEMENTIAS see **PRION DISEASES**

TRANSMISSION, DENTIST-PATIENT see **DISEASE TRANSMISSION, PROFESSIONAL-TO-PATIENT**

TRANSMISSION ELECTRON MICROSCOPY see **MICROSCOPY, ELECTRON**

TRANSMISSION, HEALTH CARE WORKER-PATIENT see **DISEASE TRANSMISSION, PROFESSIONAL-TO-PATIENT**

TRANSMISSION, HORIZONTAL see **DISEASE TRANSMISSION, HORIZONTAL**

TRANSMISSION, PATIENT-TO-PROFESSIONAL see **DISEASE TRANSMISSION, PATIENT-TO-PROFESSIONAL**

TRANSMISSION, PHYSICIAN-PATIENT see **DISEASE TRANSMISSION, PROFESSIONAL-TO-PATIENT**

TRANSMISSION, PROFESSIONAL-TO-PATIENT see **DISEASE TRANSMISSION, PROFESSIONAL-TO-PATIENT**

TRANSMISSION, VERTICAL see **DISEASE TRANSMISSION, VERTICAL**

TRANSMITTER UPTAKE INHIBITORS, NEURONAL see **NEUROTRANSMITTER UPTAKE INHIBITORS**

TRANSMITTERS, BIOGENIC AMINE see **BIOGENIC AMINE NEUROTRANSMITTERS**

TRANSPHOSPHORYLASES see **PHOSPHOTRANSFERASES**

TRANSPLACENTAL EXPOSURE see **MATERNAL-FETAL EXCHANGE**

TRANSPLANT REJECTION see **GRAFT REJECTION**

TRANSPLANTATION

see related
HISTOCOMPATIBILITY TESTING
NEOPLASM TRANSPLANTATION
ORGAN TRANSPLANTATION
TISSUE TRANSPLANTATION
TRANSPLANTATION CHIMERA

Multiple organ harvesting: evolution of surgical technique—personal experience. Alfani D, et al. **Transplant Proc** 1996 Feb;28(1):152–4 (20 ref.)

Recurrent cytomegalovirus disease in solid-organ transplant recipients. Falagas ME, et al. **Transplant Proc** 1995 Oct; 27(5 Suppl 1):34–7 (23 ref.)

Risk factors and pathogenesis of posttransplant lymphoproliferative disorders. Ho M. **Transplant Proc** 1995 Oct;27(5 Suppl 1):38–40 (36 ref.)

Prophylactic cytomegalovirus management strategies. Martin M. **Transplant Proc** 1995 Oct;27(5 Suppl 1):23–7 (30 ref.)

Transplant information transfer and analysis in cyberspace. Merion RM. **Transplant Proc** 1996 Aug;28(4):2026–8 (3 ref.)

Role of immunoglobulins and new antivirals in treatment of cytomegalovirus infection. Paya CV. **Transplant Proc** 1995 Oct;27(5 Suppl 1):28–30 (21 ref.)

Neoplasia: an example of plasticity of the immune response. Penn I. **Transplant Proc** 1996 Aug;28(4):2089–93 (29 ref.)

[Free oxygen radicals during transplantation surgery] Bolbjerg ML, et al. **Ugeskr Laeger** 1995 Oct 16; 157(42):5841–5 (40 ref.) (Eng. Abstr.) **(Dan)**

[Rheumatic manifestations of transplant recipients] Levy G, et al. **Harefuah** 1996 Apr 15;130(8):546–8 (23 ref.) **(Heb)**

[Answers to human organ procurement: donations, research, and prevention] Garrafa V. **Rev Assoc Med Bras** 1995 Jan-Feb;41(1):67–76 (59 ref.) **(Por)**

[Prevention of cytomegalovirus in organ transplantation] Aguado JM. **Rev Clin Esp** 1996 Apr;196(4):240–7 (118 ref.) **(Spa)**

ADVERSE EFFECTS

Bacterial complications of transplantation: diagnosis and treatment. Donnelly JP. **J Antimicrob Chemother** 1995 Oct; 36 Suppl B:59–72 (65 ref.)

Viral complications after transplantation. Griffiths PD. **J Antimicrob Chemother** 1995 Oct;36 Suppl B:91–106 (74 ref.)

Important interactions of drugs with immunosuppressive agents used in transplant recipients. Lake KD, et al. **J Antimicrob Chemother** 1995 Oct;36 Suppl B:11–22 (115 ref.)

Fungal complications of transplantation: diagnosis, treatment and prevention. Warnock DW. **J Antimicrob Chemother** 1995 Oct;36 Suppl B:73–90 (105 ref.)

ECONOMICS

The economics of transplantation. Gould FK, et al. **J Antimicrob Chemother** 1995 Oct;36 Suppl B:135–40 (17 ref.)

HISTORY

The immunological background to transplantation. Haeney M. **J Antimicrob Chemother** 1995 Oct;36 Suppl B:1–9 (9 ref.)

INSTRUMENTATION

Implantable biohybrid artificial organs. Colton CK. **Cell Transplant** 1995 Jul-Aug;4(4):415–36 (72 ref.)

LEGISLATION & JURISPRUDENCE

Ethical and legal aspects, and the history of organ transplantation in Turkey. Haberal M, et al. **Transplant Proc** 1996 Feb;28(1):382–3 (12 ref.)

METHODS

Cytomegalovirus prophylaxis in solid organ transplant recipients. Patel R, et al. **Transplantation** 1996 May 15; 61(9):1279–89 (58 ref.)

PATHOLOGY

Angiopeptin: experimental and clinical studies of inhibition of myointimal proliferation. Foegh ML, et al. **Kidney Int Suppl** 1995 Dec;52:S18–22 (47 ref.)

Allograft vascular disease: comparison of heart and other grafted organs. Radio S, et al. **Transplant Proc** 1996 Feb; 28(1):496–9 (34 ref.)

STANDARDS

Ethical and legal aspects, and the history of organ transplantation in Turkey. Haberal M, et al. **Transplant Proc** 1996 Feb;28(1):382–3 (12 ref.)

TRENDS

Neural transplantation for Huntington's disease: experimental rationale and recommendations for clinical trials. Shannon KM, et al. **Cell Transplant** 1996 Mar-Apr;5(2):339–52 (107 ref.)

What's new in transplantation. Burdick JF. **J Am Coll Surg** 1996 Feb;182(2):170–6 (52 ref.)

Frontiers for the coming millennium. Kahan BD. **Transplant Proc** 1996 Aug;28(4):2299–306 (31 ref.)

TRANSPLANTATION, ALLOGENEIC see **TRANSPLANTATION, HOMOLOGOUS**

TRANSPLANTATION, AUTOLOGOUS

Renal autotransplantation after horseshoe kidney injury: a case report and literature review. Murphy JT, et al. **J Trauma** 1996 May;40(5):840–4 (28 ref.)

METHODS

Biology of ACL reconstructions: what happens to the graft? Arnoczky SP. **Instr Course Lect** 1996;45:229–33 (52 ref.)

Anterior cruciate ligament: injuries and treatment. Larson RV, et al. **Instr Course Lect** 1996;45:235–43 (47 ref.)

[1984–1994: Ten years of skin flaps. Development of transfer techniques. New methods of autoplasty described during this period] Martin D. **Ann Chir Plast Esthet** 1995 Oct; 40(5):527–82 (126 ref.) (Eng. Abstr.) **(Fre)**

TRANSPLANTATION, BONE see **BONE TRANSPLANTATION**

TRANSPLANTATION, BONE MARROW see **BONE MARROW TRANSPLANTATION**

TRANSPLANTATION, BRAIN TISSUE see **BRAIN TISSUE TRANSPLANTATION**

TRANSPLANTATION, CARDIAC see **HEART TRANSPLANTATION**

TRANSPLANTATION CHIMERA

see related
ANIMALS, TRANSGENIC

Microchimerism, dendritic cell progenitors and transplantation tolerance. Thomson AW, et al. **Stem Cells (Dayt)** 1995 Nov;13(6):622–39 (119 ref.)

IMMUNOLOGY

Chimerism after organ transplantation: is there any clinical significance? Burlingham WJ. **Clin Transplant** 1996 Feb; 10(1 Pt 2):110–7 (51 ref.)

The changing immunology of organ transplantation. Starzl TE, et al. **Hosp Pract (Off Ed)** 1995 Oct 15;30(10):31–4, 37–42 (11 ref.)

The human immune system in hu-PBL-SCID mice. Tary-Lehmann M, et al. **Immunol Today** 1995 Nov; 16(11):529–33 (34 ref.)

PHYSIOLOGY

[Dynamic bone marrow take and lymphohematopoietic chimerism following allogeneic bone marrow transplantation] Demidova IA, et al. **Ter Arkh** 1995; 67(8):74–80 (90 ref.) **(Rus)**

TRANSPLANTATION, CORNEAL see **CORNEAL TRANSPLANTATION**

TRANSPLANTATION, FETAL TISSUE see **FETAL TISSUE TRANSPLANTATION**

TRANSPLANTATION, HEART see **HEART TRANSPLANTATION**

TRANSPLANTATION, HEART-LUNG see **HEART-LUNG TRANSPLANTATION**

TRANSPLANTATION, HEMATOPOIETIC STEM CELL see **HEMATOPOIETIC STEM CELL TRANSPLANTATION**

TRANSPLANTATION, HEPATIC see **LIVER TRANSPLANTATION**

TRANSPLANTATION, HETEROLOGOUS

Assessment of engraftment and function of human tonsillar and blood mononuclear cells in immunodeficient mice. Albini B, et al. **Adv Exp Med Biol** 1995;371A:85–9 (28 ref.)

HIV-1-associated pathology in hemato-lymphoid organs and the experimental evaluation in the SCID-hu mouse. Kaneshima H. **Int J Hematol** 1996 Jun;63(4):253–64 (89 ref.)

Xenotransplantation. Kemp E. **J Intern Med** 1996 Apr; 239(4):287–97 (50 ref.)

Does xenogeneic demineralized bone matrix have clinical utility as a bone graft substitute? Block JE, et al. **Med Hypotheses** 1995 Jul;45(1):27–32 (60 ref.)

Quail-chick transplantations. Le Douarin N, et al. **Methods Cell Biol** 1996;51:23–59 (105 ref.)

Barriers to xenotransplantation [see comments] Bach FH, et al. **Nat Med** 1995 Sep;1(9):869–73 (38 ref.) Comment in: Nat Med 1995 Nov;1(11):1100.

The generation of transgenic pigs as potential organ donors for humans. Cozzi E, et al. **Nat Med** 1995 Sep;1(9):964–6 (30 ref.)

Xenograft rejection--molecular mechanisms and therapeutic implications. Magee JC, et al. **Ther Immunol** 1994 Jan; 1(1):45–58 (123 ref.)

Xenotransplantation: a possible solution to the shortage of donor organs. Bach FH, et al. **Transplant Proc** 1996 Feb; 28(1):416–7 (9 ref.)

ADVERSE EFFECTS

Xenotransplantation at a crossroads: prevention versus progress. Allan JS. **Nat Med** 1996 Jan;2(1):18–21 (19 ref.)

IMMUNOLOGY

Pathogenesis and mechanisms of graft rejection in concordant xenotransplantation with special reference to hamster-to-rat cardiac transplantation. Steinbrüchel DA. **APMIS Suppl** 1996;58:5–45 (281 ref.)

Genetic engineering of endothelial cells to ameliorate xenograft rejection. Bach FH, et al. **Clin Transplant** 1996 Feb;10(1 Pt 2):124–7 (19 ref.)

Immunological tolerance to xenogeneic grafts induced by cyclophosphamide in adult animals. Chernyakhovskaya IYu, et al. **Folia Biol (Praha)** 1994;40(6):371–80 (33 ref.)

Complement inhibitory therapeutics and xenotransplantation. Ryan US. **Nat Med** 1995 Sep;1(9):967–8 (19 ref.)

Tolerance and xenograft survival. Sachs DH, et al. **Nat Med** 1995 Sep;1(9):969 (6 ref.)

Xenoreactive natural antibodies in the world of natural antibodies: typical or unique? Parker W, et al. **Transpl Immunol** 1995 Sep;3(3):181–91 (88 ref.)

15-Deoxyspergualin in experimental transplant models: a review. Kaufman DB. **Transplant Proc** 1996 Apr; 28(2):868–70 (31 ref.)

[Xenotransplantation] White DJ, et al. **Chirurg** 1996 Apr; 67(4):324–30 (44 ref.) (Eng. Abstr.) **(Ger)**

METHODS

[Fundamental problems of xenograft] Hammer C. **Ann Chir** 1995;49(6):519–24; discussion 524–6 (12 ref.) **(Fre)**

TRENDS

Use of mammalian liver cells for artificial liver support. Jauregui HO, et al. **Cell Transplant** 1996 May-Jun; 5(3):353–67 (130 ref.)

The emergence of xenotransplantation. Fryer JP, et al. **Transpl Immunol** 1995 Mar;3(1):21–31 (98 ref.)

The potential of xenotransplants. Bollinger RR. **Transplant Proc** 1996 Aug;28(4):2024–5 (9 ref.)

TRANSPLANTATION, HETEROTOPIC

IMMUNOLOGY

Local cellular immunology of experimental transplant vascular sclerosis. Orosz CG. **Clin Transplant** 1996 Feb;10(1 Pt 2):100–3 (21 ref.)

PHYSIOLOGY

Molecular strategies for clinical xenotransplantation in cardiothoracic surgery. Hoopes CW, et al. **Semin Thorac Cardiovasc Surg** 1996 Apr;8(2):156–74 (131 ref.)

TRANSPLANTATION, HOMOLOGOUS

Immunobiology and immunopharmacology of organ allograft rejection. Suthanthiran M, et al. **J Clin Immunol** 1995 Jul; 15(4):161–71 (87 ref.)

[Immunologic tolerance of fetal allograft] Deneys V, et al. **Presse Med** 1995 Nov 18;24(35):1651–7 (31 ref.) (Eng. Abstr.) **(Fre)**

[Homologous graft transplantation] Kitamura S, et al. **Kyobu Geka** 1996 Jan;49(1):65–72 (100 ref.) **(Jpn)**

ADVERSE EFFECTS

Transmission of disease through transplantation of musculoskeletal allografts. Tomford WW. **J Bone Joint Surg Am** 1995 Nov;77(11):1742–54 (164 ref.)

IMMUNOLOGY

Contribution of class I HLA-A2 antigen in immune reactions. Komlos L, et al. **Med Hypotheses** 1995 Jul;45(1):54–8 (41 ref.)

Transmembrane signaling requirements of T cells: implications for regulation of alloimmunity. Suthanthiran M. **Transplant Proc** 1995 Oct;27(5 Suppl 1):5–7 (25 ref.)

METHODS

Biology of ACL reconstructions: what happens to the graft? Arnoczky SP. **Instr Course Lect** 1996;45:229–33 (52 ref.)

PATHOLOGY

Post-transplant hypertension and chronic renal allograft failure. Paul LC, et al. **Kidney Int Suppl** 1995 Dec;52:S34–7 (25 ref.)

The Banff classification of renal allograft pathology: where do we go from here? Racusen L, et al. **Transplant Proc** 1996 Feb;28(1):486–8 (22 ref.)

Report of the Third Banff Conference on Allograft Pathology (July 20–24, 1995) on classification and lesion scoring in renal allograft pathology. Solez K, et al. **Transplant Proc** 1996 Feb;28(1):441–4 (51 ref.)

TRANSPLANTATION IMMUNOLOGY

see related
HISTOCOMPATIBILITY TESTING
IMMUNOSUPPRESSION

Endothelin in organ transplantation. Watschinger B, et al. **Am J Kidney Dis** 1996 Jan;27(1):151–61 (127 ref.)

Human herpesvirus-6 in transplantation: an emerging pathogen. Singh N, et al. **Ann Intern Med** 1996 Jun 15; 124(12):1065–71 (58 ref.)

The bidirectional paradigm of transplant immunology. Starzl TE, et al. **Ann N Y Acad Sci** 1995 Dec 29;770:165–76 (32 ref.)

Immunobiology of cellular transplantation. Gill RG, et al. **Cell Transplant** 1995 Jul-Aug;4(4):361–70 (90 ref.)

The two-way paradigm of transplantation immunology. Rao AS, et al. **Clin Immunol Immunopathol** 1996 Sep;80(3 Pt 2):S46–51 (30 ref.)

The immune response: the afferent arm. Czitrom AA. **Clin Orthop** 1996 May;(326):11–24 (115 ref.)

Human leukocyte antigen system and the immune response to it. Nelson KA. **Clin Orthop** 1996 May;(326):35–42 (53 ref.)

Effect of crossmatching on outcome in organ transplantation. Wang-Rodriguez J, et al. **Crit Rev Clin Lab Sci** 1995; 32(4):345–76 (194 ref.)

Transplantation immunology. Ball ST, et al. **Curr Opin Nephrol Hypertens** 1995 Nov;4(6):465–71 (72 ref.)

Detection of alloantibodies by flow cytometry: relevance to clinical transplantation. Scornik JC. **Cytometry** 1995 Dec 15;22(4):259–63 (37 ref.)

Immunobiology of transplantation. Sykes M. **FASEB J** 1996 May;10(7):721–30 (68 ref.)

The immunological background to transplantation. Haeney M. **J Antimicrob Chemother** 1995 Oct;36 Suppl B:1–9 (9 ref.)

Introducing graft-versus-leukemia into autologous stem cell transplantation. Klingemann HG. **J Hematother** 1995 Aug; 4(4):261–7 (71 ref.)

Unraveling immune privilege [comment] Streilein JW. **Science** 1995 Nov 17;270(5239):1158–9 (19 ref.) Comment on: Science 1995 Nov 17;270(5239):1189–92.

Chimerism and thoracic organ transplantation. Gammie JS, et al. **Semin Thorac Cardiovasc Surg** 1996 Apr;8(2):149–55 (45 ref.)

Xenobiotics, chimerism and the induction of tolerance following organ transplantation. Delaney CP, et al. **Ther Immunol** 1994 Jun;1(3):153–64 (118 ref.)

Brequinar sodium. Cramer DV. **Transplant Proc** 1996 Apr; 28(2):960–3 (20 ref.)

Renovascular elements of the cyclosporine injury. Curtis JJ. **Transplant Proc** 1996 Aug;28(4):2094–6 (18 ref.)

Developments in immunosuppressive therapy. Daar AS. **Transplant Proc** 1995 Oct;27(5):2671–5 (5 ref.)

Current progress in chimerism and donor-specific tolerance. Jankowski RA, et al. **Transplant Proc** 1996 Aug; 28(4):2071–4 (39 ref.)

Immunosuppression with the vitamin D analogue MC 1288 in experimental transplantation. Johnsson C, et al. **Transplant Proc** 1996 Apr;28(2):888–91 (35 ref.)

Cyclosporine pharmacology. Lee JI, et al. **Transplant Proc** 1996 Aug;28(4):2156–8 (20 ref.)

New strategies of immune modulation by DNA viruses. McFadden G, et al. **Transplant Proc** 1996 Aug;28(4):2085–8 (32 ref.)

Minimizing the toxicity of antilymphocyte antibody therapy. Pascual M, et al. **Transplant Proc** 1996 Aug;28(4):2113–4 (15 ref.)

Antiviral antibodies in transplantation. Snydman DR. **Transplant Proc** 1995 Oct;27(5 Suppl 1):10–2 (22 ref.)

An overview of the first decade of cyclosporine. Stiller CR. **Transplant Proc** 1996 Aug;28(4):2005–12 (3 ref.)

Can graft endothelial cells initiate a host anti-graft immune response? Pober JS, et al. **Transplantation** 1996 Feb 15; 61(3):343–9 (72 ref.)

DRUG EFFECTS

Immunosuppressants: cellular and molecular mechanisms of action. Suthanthiran M, et al. **Am J Kidney Dis** 1996 Aug; 28(2):159–72 (109 ref.)

Overview of immunosuppressive therapy in organ transplantation. MacGregor MS, et al. **Br J Hosp Med** 1995 Sep 20–Oct 3;54(6):276–84 (32 ref.)

[Perspectives of immunosuppressive therapy] Meuer S, et al. **Chirurg** 1996 Apr;67(4):310–7 (53 ref.) (Eng. Abstr.) **(Ger)**

IMMUNOLOGY

The changing immunology of organ transplantation. Starzl TE, et al. **Hosp Pract (Off Ed)** 1995 Oct 15;30(10):31–4, 37–42 (11 ref.)

Role of heat shock proteins in heart transplant rejection. Liu K, et al. **J Heart Lung Transplant** 1996 Mar;15(3):222–8 (71 ref.)

Alloantigen processing and presentation. Tambur AR, et al. **J Heart Lung Transplant** 1995 Nov-Dec;14(6 Pt 1):1031–7 (49 ref.)

TRANSPLANTATION, ISLETS OF LANGERHANS see **ISLETS OF LANGERHANS TRANSPLANTATION**

TRANSPLANTATION, ISOGENEIC

[Renal transplantation from related live donors. Results and survival] Hajri M, et al. **Ann Urol (Paris)** 1995;29(3):186–92 (17 ref.) (Eng. Abstr.) **(Fre)**

TRANSPLANTATION, KIDNEY see **KIDNEY TRANSPLANTATION**

TRANSPLANTATION, LIVER see **LIVER TRANSPLANTATION**

TRANSPLANTATION, LUNG see **LUNG TRANSPLANTATION**

TRANSPLANTATION, ORGAN see **ORGAN TRANSPLANTATION**

TRANSPLANTATION, PANCREAS see **PANCREAS TRANSPLANTATION**

TRANSPLANTATION, PANCREATIC ISLETS see **ISLETS OF LANGERHANS TRANSPLANTATION**

TRANSPLANTATION, RENAL see **KIDNEY TRANSPLANTATION**

TRANSPLANTATION, SKIN see **SKIN**

TRANSPLANTATION

TRANSPLANTATION, SYNGENEIC see **TRANSPLANTATION, ISOGENEIC**

TRANSPLANTATION, TISSUE see **TISSUE TRANSPLANTATION**

TRANSPORT, BIOLOGICAL see **BIOLOGICAL TRANSPORT**

TRANSPORT OF WOUNDED AND SICK see **TRANSPORTATION OF PATIENTS**

TRANSPORT PROTEINS see **CARRIER PROTEINS**

TRANSPORTATION

The importation of the black rhinoceros (Diceros bicornis) from Zimbabwe into Australia. Kelly JD, et al. **Aust Vet J** 1995 Oct;72(10):369–74 (10 ref.)

Caring for Older People. Public transport. Roper TA, et al. **BMJ** 1996 Aug 17;313(7054):415–8 (0 ref.)

Lightning and transportation. Cherington M. **Semin Neurol** 1995 Dec;15(4):362–6 (47 ref.)

A review of post transport mortality among younger calves. Knowles TG. **Vet Rec** 1995 Oct 14;137(16):406–7 (17 ref.)

LEGISLATION & JURISPRUDENCE

Quarantine requirements for the importation of black rhinoceros from Zimbabwe into Australia. Doyle KA, et al. **Aust Vet J** 1995 Oct;72(10):364–8 (4 ref.)

STANDARDS

Scrapie: the risk of its introduction and effects on trade. MacDiarmid SC. **Aust Vet J** 1996 May;73(5):161–4 (21 ref.)

TRANSPORTATION OF PATIENTS

[Primary care and transportation of patients with neural trauma] Glerup OK, et al. **Ugeskr Laeger** 1996 Jun 3; 158(23):3295–301 (33 ref.) (Eng. Abstr.) **(Dan)**

[Transport of critically ill patients] Ben Abraham R, et al. **Harefuah** 1996 Apr 1;130(7):474–8 (14 ref.) **(Heb)**

TRANSPOSABLE ELEMENTS see **DNA INSERTION ELEMENTS**

TRANSPOSITION OF GREAT VESSELS

SURGERY

Arterial switch operation: myocardial ischemia reversed by internal mammary artery graft. Merlo M, et al. **Ann Thorac Surg** 1996 Aug;62(2):586–8 (12 ref.)

Surgical repair of d-transposition with aortopulmonary window: a case report. Marangi D, et al. **J Thorac Cardiovasc Surg** 1996 Mar;111(3):671–2 (9 ref.)

Congenitally corrected transposition of the great arteries: ventricle to pulmonary artery connection strategies. Bove EL. **Semin Thorac Cardiovasc Surg** 1995 Jul;7(3):139–44 (19 ref.)

[Double outlet left ventricle: a rare and unusual cardiopathy. Apropos of 7 new cases] Gouton M, et al. **Arch Mal Coeur Vaiss** 1996 May;89(5):553–9 (10 ref.) (Eng. Abstr.) **(Fre)**

TRANSPOSONS see **DNA INSERTION ELEMENTS**

TRANSSEXUALISM

Legal recognition of transsexuals in Australia. Finlay H. **J Contemp Health Law Policy** 1996 Spring;12(2):503–33 (95 ref.)

DIAGNOSIS

Further insights into transsexualism. Becker D, et al. **Psychopathology** 1996;29(1):1–6 (17 ref.)

EPIDEMIOLOGY

Prevalence, incidence and sex ratio of transsexualism. Landén M, et al. **Acta Psychiatr Scand** 1996 Apr;93(4):221–3 (18 ref.)

PSYCHOLOGY

Further insights into transsexualism. Becker D, et al. **Psychopathology** 1996;29(1):1–6 (17 ref.)

[Transsexual wish and and cis-sexual defense] Sigusch V. **Psyche (Stuttg)** 1995 Sep–Oct;49(9–10):811–37 (75 ref.) (Eng. Abstr.) **(Ger)**

TRANSTHYRETIN see **PREALBUMIN**

TRANSUDATES see **EXUDATES AND TRANSUDATES**

TRAUMA see **WOUNDS AND INJURIES**

TRAUMA CENTERS

ECONOMICS

Cost effectiveness in trauma care. Elliott DC, et al. **Surg Clin North Am** 1996 Feb;76(1):47–62 (101 ref.)

ORGANIZATION & ADMINISTRATION

Neurotrauma and trauma systems. Pitts LH. **New Horiz** 1995 Aug;3(3):546–8 (13 ref.)

TRAUMA DISORDERS, CUMULATIVE see **REPETITION STRAIN INJURY**

TRAUMA, MULTIPLE see **MULTIPLE TRAUMA**

TRAUMA SEVERITY INDICES

The injury severity score—importance and uses. Linn S. **Ann Epidemiol** 1995 Nov;5(6):440–6 (64 ref.)

Measurement of disability after multiple injuries: the functional independence measure. Clinical review. Hetherington H, et al. **Eur J Surg** 1995 Aug;161(8):549–55 (60 ref.)

[A review of injury classification in traumatology. A Swedish model needs to be set up soon] Andrén-Sandberg A. **Lakartidningen** 1996 Aug 28;93(34):2860–1 (30 ref.) **(Swe)**

TRAUMA UNITS see **TRAUMA CENTERS**

TRAUMATOLOGY

see related
WOUNDS AND INJURIES

Ultrasound, what every trauma surgeon should know [see comments] Rozycki GS, et al. **J Trauma** 1996 Jan;40(1):1–4 (23 ref.) Comment in: J Trauma 1996 Aug;41(2):368–70.

EDUCATION

Advanced trauma life support. Gwinnutt CL, et al. **Eur J Anaesthesiol** 1996 Mar;13(2):95–101 (27 ref.)

TRENDS

What's new in trauma and burns. Flint L. **J Am Coll Surg** 1996 Feb;182(2):177–84 (68 ref.)

Wound repair: from ritual practice to scientific discipline. Edlich RF, et al. **J Trauma** 1996 Feb;40(2):326–9 (39 ref.)

TRAVEL

Preventing hepatitis A infections in travelers to endemic areas. Koff RS. **Am J Trop Med Hyg** 1995 Dec;53(6):586–90 (29 ref.)

Arboviruses causing neurological disorders in the central nervous system. Dobler G. **Arch Virol Suppl** 1996;11:33–40 (18 ref.)

Emerging and reemerging of filoviruses. Feldmann H, et al. **Arch Virol Suppl** 1996;11:77–100 (93 ref.)

Arboviruses as imported disease agents: the need for increased awareness. Gubler DJ. **Arch Virol Suppl** 1996; 11:21–32 (29 ref.)

Significance of imported hepatitis B virus infections. Jilg W. **Arch Virol Suppl** 1996;11:181–3 (10 ref.)

Relative importance of the enterically transmitted human hepatitis viruses type A and E as a cause of foreign travel associated hepatitis. Langer BC, et al. **Arch Virol Suppl** 1996;11:171–9 (25 ref.)

Vector-borne viral diseases in Sweden—a short review. Niklasson B, et al. **Arch Virol Suppl** 1996;11:49–55 (37 ref.)

Imported vector- and rodent-borne virus infections—an introduction. Schwarz TF. **Arch Virol Suppl** 1996;11:3–11 (49 ref.)

Evaluating fever in travellers returning from tropical countries. Humar A, et al. **BMJ** 1996 Apr 13; 312(7036):953–6 (25 ref.)

Caring for Older People. Public transport. Roper TA, et al. **BMJ** 1996 Aug 17;313(7054):415–8 (0 ref.)

Travel statement on jet lag. Paulson E. **Can Med Assoc J** 1996 Jul 1;155(1):61–6 (17 ref.) **(Eng, Fre)**

Selections from current literature: the traveller to high altitude. Fahrenwald R. **Fam Pract** 1995 Jun;12(2):237–41 (0 ref.)

Air travel induced meningitis following vestibular schwannoma (acoustic neuroma) surgery. Callanan V, et al. **J Laryngol Otol** 1996 Mar;110(3):258–60 (18 ref.)

An imported case of hepatic unilocular hydatid disease. Chai JY, et al. **Korean J Parasitol** 1995 Jun;33(2):125–30 (26 ref.)

Children and international travel: immunizations. Barnett ED, et al. **Pediatr Infect Dis J** 1995 Nov;14(11):982–92 (67 ref.)

Diarrhoea in the returned traveller. Ellis C. **Practitioner** 1996 Mar;240(1560):188–92 (4 ref.)

Cyclospora in patients with traveller's diarrhea. Gascon J, et al. **Scand J Infect Dis** 1995;27(5):511–4 (18 ref.)

[Epidemiology, physiopathology and treatment of travellers' diarrhea] Bouchaud O, et al. **Ann Med Interne (Paris)** 1995; 146(6):431–7 (62 ref.) **(Fre)**

[Contaminated fish and pork] Perret JL, et al. **Med Trop (Mars)** 1996;56(1):25–7 (0 ref.) **(Fre)**

[Therapy of jet lag] Samel A, et al. **Wien Med Wochenschr** 1995;145(17–18):458–60 (21 ref.) (Eng. Abstr.) **(Ger)**

[Japanese encephalitis—implications for travelers to the Far East] Shapira I, et al. **Harefuah** 1996 Mar 15;130(6):406–8 (36 ref.) **(Heb)**

[The lung and trips by plane] Ibáñez Cuerda MD, et al. **Arch Bronconeumol** 1995 Dec;31(10):526–33 (65 ref.) **(Spa)**

[Cutaneous lesions and lung infiltrates after a trip to Thailand] Martínez-Fernández R, et al. **Rev Clin Esp** 1995 Oct; 195(10):721–2 (15 ref.) **(Spa)**

TREACHER COLLINS SYNDROME see **MANDIBULOFACIAL DYSOSTOSIS**

TREADMILL TEST see **EXERCISE TEST**

TREATMENT COSTS see **HEALTH CARE COSTS**

TREATMENT EFFECTIVENESS see **TREATMENT OUTCOME**

TREATMENT FAILURE

Sites of failure and times to failure in carcinoma of the vulva treated conservatively: a Gynecologic Oncology Group study. Stehman FB, et al. **Am J Obstet Gynecol** 1996 Apr; 174(4):1128–32; discussion 1132–3 (5 ref.)

TREATMENT FUTILITY see **MEDICAL FUTILITY**

TREATMENT OUTCOME

Prevention. How much harm? How much benefit? 1. Influence of reporting methods on perception of benefits [see comments] Marshall KG. **Can Med Assoc J** 1996 May 15;154(10):1493–9 (56 ref.) Comment in: Can Med Assoc J 1996 May 15;154(10):1510–2.

Assessing clinical outcomes in cutaneous T-cell lymphoma. Zackheim HS, et al. **Hematol Oncol Clin North Am** 1995 Oct;9(5):1021–9 (9 ref.)

Demonstrating effectiveness—the concept of numbers-needed-to-treat. Wiffen PJ, et al. **J Clin Pharm Ther** 1996 Feb;21(1):23–7 (10 ref.)

The Injury Severity Score is unable to differentiate between poor care and severe injury. Rutledge R. **J Trauma** 1996 Jun;40(6):944–50 (36 ref.)

The person-trade-off approach to valuing health care programs [see comments] Nord E. **Med Decis Making** 1995 Jul-Sep;15(3):201–8 (32 ref.) Comment in: Med Decis Making 1995 Jul-Sep;15(3):287–8.

Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Harrell FE Jr, et al. **Stat Med** 1996 Feb 28;15(4):361–87 (72 ref.)

TREATMENT PROTOCOLS see **CLINICAL PROTOCOLS**

TREATMENT REFUSAL

see related
PATIENT DROPOUTS

Patient decision making. The missing ingredient in compliance research. Donovan JL. **Int J Technol Assess Health Care** 1995 Summer; 11(3):443–55 (46 ref.)

When dialysis becomes worse than death [editorial; comment] Sessa A. **Nephrol Dial Transplant** 1995;10(7):1128–30 (24 ref.) Comment on: Nephrol Dial Transplant 1995;10(7):1142–4.

Patient-induced dehydration—can it ever be therapeutic? Smith SA. **Oncol Nurs Forum** 1995 Nov-Dec; 22(10):1487–91 (20 ref.)

[Demand for the stopping of chronic hemodialysis. Apropos of 1 case] Lassaunière JM, et al. **Nephrologie** 1996; 17(4):237–41 (23 ref.) (Eng. Abstr.) **(Fre)**

LEGISLATION & JURISPRUDENCE

Working with noncompliant and abusive dialysis patients: practical strategies based on ethics and the law. Johnson CC, et al. **Adv Ren Replace Ther** 1996 Jan;3(1):77–86 (40 ref.)

The maternal-fetal rights dilemma: honoring a woman's choice of medical care during pregnancy. Arch RR. **J Contemp Health Law Policy** 1996 Spring;12(2):637–73 (255 ref.)

Consent to medical treatment by older children in English & Scottish law. Bissett-Johnson A, et al. **J Contemp Health Law Policy** 1996 Spring;12(2):449–73 (117 ref.)

A visitation with informed consent and refusal. Hirsh HL. **Leg Med** 1995;:147–203 (131 ref.)

TREHALOSE

METABOLISM

Trehalose metabolism—new horizons in technological applications. Panek AD. **Braz J Med Biol Res** 1995 Feb; 28(2):169–81 (98 ref.)

The regulation of trehalose metabolism in insects. Becker

TREHALOSE

A, et al. **Experientia** 1996 May 15;52(5):433–9 (54 ref.)

TREMATODA

ISOLATION & PURIFICATION

Studies on the helminth parasites of birds from Egypt: 1–trematoda and cestoda. Ashour AA, et al. **J Egypt Soc Parasitol** 1996 Apr;26(1):207–16 (24 ref.)

[Trematode parasites of Italian bats] Ricci M. **Parassitologia** 1995 Dec;37(2–3):199–214 (32 ref.) (Eng. Abstr.) **(Ita)**

TREMATODE INFECTIONS

VETERINARY

Studies on the helminth parasites of birds from Egypt: 1–trematoda and cestoda. Ashour AA, et al. **J Egypt Soc Parasitol** 1996 Apr;26(1):207–16 (24 ref.)

[Trematode parasites of Italian bats] Ricci M. **Parassitologia** 1995 Dec;37(2–3):199–214 (32 ref.) (Eng. Abstr.) **(Ita)**

TREMOR

Essential tremor and related disorders. Wills AJ. **Br J Hosp Med** 1995 Jun 21–Jul 11;54(1):21–6 (24 ref.)

CHEMICALLY INDUCED

[The serotonin syndrome: review of the literature and description of an original study] Lejoyeux M, et al. **Encephale** 1995 Sep–Oct;21(5):537–43 (45 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Essential tremor and its variants. Britton TC. **Curr Opin Neurol** 1995 Aug;8(4):314–9 (60 ref.)

DRUG THERAPY

Clonazepam–sensitive intermittent dystonic tremor. Davis TL, et al. **South Med J** 1995 Oct;88(10):1069–71 (16 ref.)

EPIDEMIOLOGY

How familial is familial tremor? The genetic epidemiology of essential tremor. Louis ED, et al. **Neurology** 1996 May; 46(5):1200–5 (71 ref.)

ETIOLOGY

The role of aging in the clinical expression of essential tremor. Elble RJ. **Exp Gerontol** 1995 May–Aug;30(3–4):337–47 (43 ref.)

Tremor as the result of shunt obstruction: four patients with cysticercosis and secondary parkinsonism: report of four cases. Keane JR. **Neurosurgery** 1995 Sep;37(3):520–2 (3 ref.)

[Most frequent causes for hand tremor in clinical practice] Málly J. **Orv Hetil** 1995 Oct 8;136(41):2211–6 (53 ref.) (Eng. Abstr.) **(Hun)**

[A case of portal–systemic encephalopathy with slowly progressive, non–flapping tremor] Oue Y, et al. **Rinsho Shinkeigaku** 1995 Aug;35(8):889–92 (20 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

How familial is familial tremor? The genetic epidemiology of essential tremor. Louis ED, et al. **Neurology** 1996 May; 46(5):1200–5 (71 ref.)

PHYSIOPATHOLOGY

Thalamic tremor: case reports and implications of the tremor–generating mechanism. Miwa H, et al. **Neurology** 1996 Jan;46(1):75–9 (26 ref.)

[Tremor and ataxia] Dueñas DA. **Rev Neurol** 1995;23 Suppl 3:S349–54 (41 ref.) **(Spa)**

TRENCH FEVER

Q fever and trench fever. Gluckman SJ. **Clin Dermatol** 1996 May–Jun;14(3):283–7 (36 ref.)

TRENCH MOUTH see **GINGIVITIS, NECROTIZING ULCERATIVE**

TREPHINING

INSTRUMENTATION

Burr hole neuroendoscopic fenestration of quadrigeminal cistern arachnoid cyst: technical case report. Ruge JR, et al. **Neurosurgery** 1996 Apr;38(4):830–7 (32 ref.)

TREPONEMA

PHYSIOLOGY

Aspects of adherence of oral spirochetes. Thomas DD. **Crit Rev Oral Biol Med** 1996;7(1):4–11 (48 ref.)

TREPONEMA PALLIDUM

CHEMISTRY

Treponema pallidum and the quest for outer membrane proteins. Radolf JD. **Mol Microbiol** 1995 Jun;16(6):1067–73 (60 ref.)

TRETINOIN

see related
RECEPTORS, RETINOIC ACID

ADMINISTRATION & DOSAGE

Prevention of cervical intraepithelial neoplasia and cervical cancer. Meyskens FL Jr, et al. **Am J Clin Nutr** 1995 Dec; 62(6 Suppl):1417S–1419S (24 ref.)

ADVERSE EFFECTS

All–trans–retinoic acid and pseudotumor cerebri in a young adult with acute promyelocytic leukemia: a possible disease association. Visani G, et al. **Haematologica** 1996 Mar–Apr; 81(2):152–4 (12 ref.)

Sweet's syndrome in a patient with acute promyelocytic leukemia during treatment with all–trans retinoic acid. Shirono K, et al. **Int J Hematol** 1995 Oct;62(3):183–7 (16 ref.)

Induction of retinoid resistance by all–trans retinoic acid in acute promyelocytic leukemia after remission. Cornic M, et al. **Leuk Lymphoma** 1995 Jul;18(3–4):249–57 (108 ref.)

Sweet's syndrome involoving the musculoskeletal system during treatment of promyelocytic leukemia with all–trans retinoic acid. Christ E, et al. **Leukemia** 1996 Apr; 10(4):731–4 (10 ref.)

ANALOGS & DERIVATIVES

Bioactivities of N–(4–hydroxyphenyl) retinamide and retinoyl beta–glucuronide. Formelli F, et al. **FASEB J** 1996 Jul;10(9):1014–24 (109 ref.)

METABOLISM

Retinoic acid synthesis in the developing spinal cord. Dräger UC, et al. **Adv Exp Med Biol** 1995;372:185–92 (26 ref.)

Retinoic acid synthesizing enzymes in the embryonic and adult vertebrate. McCaffery P, et al. **Adv Exp Med Biol** 1995;372:173–83 (45 ref.)

Retinoids and Hox genes. Marshall H, et al. **FASEB J** 1996 Jul;10(9):969–78 (62 ref.)

Retinoic acid biosynthesis and metabolism. Napoli JL. **FASEB J** 1996 Jul;10(9):993–1001 (43 ref.)

Retinoic acid and pattern formation in vertebrates. Conlon RA. **Trends Genet** 1995 Aug;11(8):314–9 (53 ref.)

[The participation of retinoic acid in embryonic and postembryonic development] Maden M. **Ontogenez** 1995 Nov–Dec;26(6):419–29 (57 ref.) (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

Retinoids and their receptors in modulation of differentiation, development, and prevention of head and neck cancers. Lotan R. **Anticancer Res** 1996 Jul–Aug;16(4C):2415–9 (45 ref.)

Modulation of B–cell immunoglobulin synthesis by retinoic acid. Ballow M, et al. **Clin Immunol Immunopathol** 1996 Sep;80(3 Pt 2):S73–81 (37 ref.)

Tretinoin. A review of its pharmacodynamic and pharmacokinetic properties and use in the management of acute promyelocytic leukaemia. Gillis JC, et al. **Drugs** 1995 Nov;50(5):897–923 (160 ref.)

Gene expression and neuroblastoma cell differentiation in response to retinoic acid: differential effects of 9–cis and all–trans retinoic acid. Redfern CP, et al. **Eur J Cancer** 1995;31A(4):486–94 (73 ref.)

All–trans retinoic acid (ATRA) and the regulation of adhesion molecules in acute myeloid leukemia. Di Noto R, et al. **Leuk Lymphoma** 1996 Apr;21(3–4):201–9 (74 ref.)

Retinoid receptors in human lung cancer and breast cancer. Zhang XK, et al. **Mutat Res** 1996 Feb 19;350(1):267–77 (87 ref.)

A regulatory pathway of thermogenesis in brown fat through retinoic acid. Wolf G. **Nutr Rev** 1995 Aug;53(8):230–1 (4 ref.)

Retinoic acid and pattern formation in vertebrates. Conlon RA. **Trends Genet** 1995 Aug;11(8):314–9 (53 ref.)

THERAPEUTIC USE

Pathogenesis and management of acute promyelocytic leukemia. Warrell RP Jr. **Annu Rev Med** 1996;47:555–65 (44 ref.)

Differentiation therapy of acute promyelocytic leukemia: clinical and molecular features [see comments] Miller WH Jr. **Cancer Invest** 1996;14(2):142–50 (65 ref.) Comment in: Cancer Invest 1996;14(2):182–3.

Differentiation therapy of acute promyelocytic leukemia. Chen Z. **Chin Med J (Engl)** 1996 Mar;109(3):179–82 (9 ref.)

Tretinoin for sun–aged skin. **Drug Ther Bull** 1996 Jul; 34(7):55–6 (13 ref.)

Tretinoin. A review of its pharmacodynamic and pharmacokinetic properties and use in the management of acute promyelocytic leukaemia. Gillis JC, et al. **Drugs** 1995 Nov;50(5):897–923 (160 ref.)

Treatment of photoaged skin. Efficacy, tolerability and costs of available agents. Helander SD. **Drugs Aging** 1996 Jan; 8(1):12–6 (34 ref.)

Retinoid differentiation therapy in promyelocytic leukemia. Chomienne C, et al. **FASEB J** 1996 Jul;10(9):1025–30 (67 ref.)

Retinoic acid regulatory pathways, chromosomal translocations, and acute promyelocytic leukemia. Chen Z, et al. **Genes Chromosomes Cancer** 1996 Mar;15(3):147–56 (123 ref.)

Acute promyelocytic leukemia: retinoic acid response and resistance. Early E, et al. **J Investig Med** 1995 Aug; 43(4):337–44 (108 ref.)

Differentiating therapy in acute myeloid leukemia. Tallman MS. **Leukemia** 1996 Aug;10(8):1262–8 (62 ref.)

Differentiating therapy in acute myeloid leukemia. Tallman MS. **Leukemia** 1996 Jun;10 Suppl 2:s33–8 (62 ref.)

Differentiating therapy with all–trans retinoic acid in acute myeloid leukemia. Tallman MS. **Leukemia** 1996 Apr;10 Suppl 1:S12–5 (28 ref.)

[Retinoids and acute promyelocytic leukemia. A therapeutic revolution] Hermanne JP, et al. **Rev Med Liege** 1996 Mar; 51(3):217–23 (23 ref.) **(Fre)**

[Differentiation therapy of leukemia] Ono R. **Nippon Naika Gakkai Zasshi** 1995 Sep 10;84(9):1574–8 (8 ref.) **(Jpn)**

[Clinical pharmacology of all–trans retinoic acid (ATRA)] Robak T. **Acta Haematol Pol** 1995;26(3):269–77 (34 ref.) (Eng. Abstr.) **(Pol)**

TRH RECEPTORS see **RECEPTORS, THYROTROPIN–RELEASING HORMONE**

TRIACYLGLYCEROL LIPASE see **LIPASE**

TRIACYLGLYCEROLS see **TRIGLYCERIDES**

TRIAGE

Acute–phase mental health consequences of disasters: implications for triage and emergency medical services [see comments] Burkle FM Jr. **Ann Emerg Med** 1996 Aug; 28(2):119–28 (78 ref.) Comment in: Ann Emerg Med 1996 Aug;28(2):220–2.

Management of unique clinical entities in disaster medicine. Gans L, et al. **Emerg Med Clin North Am** 1996 May; 14(2):301–26 (104 ref.)

[A review of injury classification in traumatology. A Swedish model needs to be set up soon] Andrén–Sandberg A. **Lakartidningen** 1996 Aug 28;93(34):2860–1 (30 ref.) **(Swe)**

METHODS

Triage: techniques and applications in decision making. Kennedy K, et al. **Ann Emerg Med** 1996 Aug;28(2):136–44 (74 ref.)

Military penetrating craniocerebral injuries. Applications to civilian triage and management. George ED, et al. **Neurosurg Clin N Am** 1995 Oct;6(4):753–9 (101 ref.)

TRIAL OF LABOR

see related
CESAREAN SECTION
DELIVERY

Cervical ripening and labor induction after previous cesarean delivery. Chez RA. **Clin Obstet Gynecol** 1995 Jun; 38(2):287–92 (45 ref.)

TRIAMCINOLONE

ADMINISTRATION & DOSAGE

The delivery of aerosolized steroids from MDIs with nozzle extensions: quantitative laboratory evaluation of a method to improve aerosol delivery to intubated patients. Hess D, et al. **Intensive Care Med** 1995 Nov;21(11):945–51 (36 ref.)

THERAPEUTIC USE

Contact allergy to topical corticosteroids and systemic contact dermatitis from prednisolone with tolerance of triamcinolone. Bircher AJ, et al. **Acta Derm Venereol** 1995 Nov;75(6):490–3 (38 ref.)

TRIAZINES

THERAPEUTIC USE

Potential use of gabapentin and lamotrigine. Cory PR, et al. **Ann Pharmacother** 1995 Nov;29(11):1160–1 (10 ref.)

Lamotrigine. An update of its pharmacology and therapeutic use in epilepsy. Fitton A, et al. **Drugs** 1995 Oct; 50(4):691–713 (175 ref.)

Lamotrigine. Messenheimer JA. **Epilepsia** 1995;36 Suppl 2:S87–94 (64 ref.)

[Resistance to chemotherapy in cancers of the kidney and therapeutic perspectives] Oudard S, et al. **J Urol (Paris)** 1995;101(3):122–4 (25 ref.) (Eng. Abstr.) **(Fre)**

[Advances in the diagnostic and treatment of infantile epilepsy] Legido A. **Rev Neurol** 1996 Jun;24(130):688–93 (25 ref.) **(Spa)**

TRIAZIQUONE

CHEMISTRY

Trenimon: structure and reactivity of a versatile chemical agent. Rademacher P, et al. **Mutat Res** 1995 Nov; 340(1):37–49 (76 ref.)

TRIAZOLES

ADVERSE EFFECTS

The safety profile of nefazodone. Robinson DS, et al. **J Clin Psychiatry** 1996;57 Suppl 2:31–8 (20 ref.)

CHEMICAL SYNTHESIS

[New fluorogenic dienophile: synthesis, reaction with vitamin D, vitamin A and microcystins, and application to fluorometric assays] Shimizu M, et al. **Yakugaku Zasshi** 1995 Aug;115(8):584–602 (67 ref.) (Eng. Abstr.) **(Jpn)**

PHARMACOLOGY

Activation of the phospholipase/cyclooxygenase cascade in the rabbit cornea by platelet-activating factor is challenged by PAF receptor antagonists. Hurst JS, et al. **J Ocul Pharmacol Ther** 1995 Fall;11(3):329–37 (39 ref.)

Dapiprazole's effect upon accommodative recovery: is it due entirely to changes in depth of field? Molinari JF, et al. **Optom Vis Sci** 1995 Aug;72(8):552–6 (18 ref.)

THERAPEUTIC USE

Nefazodone: a new antidepressant. Ellingrod VL, et al. **Am J Health Syst Pharm** 1995 Dec 15;52(24):2799–812 (54 ref.)

Nefazodone and venlafaxine: two new agents for the treatment of depression. Goldberg RJ. **J Fam Pract** 1995 Dec;41(6):591–4 (19 ref.)

New antidepressants. Kupecz D. **Nurse Pract** 1995 Sep; 20(9):64–7 (18 ref.)

TRIBAVIRIN see **RIBAVIRIN**

TRIBUTYRINASE see **LIPASE**

TRICARBOXYLIC ACIDS

PHARMACOLOGY

Discovery, biosynthesis, and mechanism of action of the zaragozic acids: potent inhibitors of squalene synthase. Bergstrom JD, et al. **Annu Rev Microbiol** 1995;49:607–39 (80 ref.)

TRICHINA SPIRALIS see **TRICHINELLA SPIRALIS**

TRICHINELLA SPIRALIS

IMMUNOLOGY

[Phosphocholine antigens in muscle larvae of Trichinella spiralis] Bitkowska E. **Wiad Parazytol** 1996;42(1):57–63 (37 ref.) (Eng. Abstr.) **(Pol)**

TRICHINELLIASIS see **TRICHINOSIS**

TRICHINOSIS

DIAGNOSIS

Clinical aspects of infection with Trichinella spp. Capó V, et al. **Clin Microbiol Rev** 1996 Jan;9(1):47–54 (106 ref.)

[Phosphocholine antigens in muscle larvae of Trichinella spiralis] Bitkowska E. **Wiad Parazytol** 1996;42(1):57–63 (37 ref.) (Eng. Abstr.) **(Pol)**

EPIDEMIOLOGY

Clinical aspects of infection with Trichinella spp. Capó V, et al. **Clin Microbiol Rev** 1996 Jan;9(1):47–54 (106 ref.)

TRICHLOROETHYLENE

ADVERSE EFFECTS

Cancer in relation to occupational exposure to trichloroethylene. Weiss NS. **Occup Environ Med** 1996 Jan; 53(1):1–5 (27 ref.)

Trichloroethylene—a review of the literature from a health effects perspective. Gist GL, et al. **Toxicol Ind Health** 1995 May-Jun;11(3):253–307 (470 ref.)

Evaluating human variability in chemical risk assessment: hazard identification and dose-response assessment for noncancer oral toxicity of trichloroethylene. Barton HA, et al. **Toxicology** 1996 Jul 17;111(1–3):271–87 (83 ref.)

POISONING

Hepatitis, rash and eosinophilia following trichloroethylene exposure: a case report and speculation on mechanistic similarity to halothane induced hepatitis. Bond GR. **J Toxicol Clin Toxicol** 1996;34(4):461–6 (11 ref.)

TOXICITY

Genetic toxicology of trichloroethylene (TCE). Fahrig R, et al. **Mutat Res** 1995 Nov;340(1):1–36 (126 ref.)

TRICHOBEZOARS see **BEZOARS**

TRICHOCEPHALIASIS see **TRICHURIASIS**

TRICHODERMA

ENZYMOLOGY

Safety evaluation of beta-glucanase derived from Trichoderma reesei: summary of toxicological data. Coenen TM, et al. **Food Chem Toxicol** 1995 Oct;33(10):859–66 (24 ref.)

GENETICS

Production of recombinant proteins in the filamentous fungus Trichoderma reesei. Keränen S, et al. **Curr Opin Biotechnol** 1995 Oct;6(5):534–7 (30 ref.)

TRICHOMONAS

see related
ANTITRICHOMONAL AGENTS

TRICHOMONAS INFECTIONS

see related
ANTITRICHOMONAL AGENTS

TRICHOMONAS VAGINITIS

DRUG THERAPY

Metronidazole: utilization in the obstetric and gynecologic patient. Schwebke JR. **Sex Transm Dis** 1995 Nov-Dec; 22(6):370–6 (84 ref.)

IMMUNOLOGY

Use of an animal model of trichomoniasis as a basis for understanding this disease in women. Corbeil LB. **Clin Infect Dis** 1995 Oct;21 Suppl 2:S158–61 (29 ref.)

PARASITOLOGY

Use of an animal model of trichomoniasis as a basis for understanding this disease in women. Corbeil LB. **Clin Infect Dis** 1995 Oct;21 Suppl 2:S158–61 (29 ref.)

TRICHOPHYTON

ISOLATION & PURIFICATION

Tinea capitis caused by Trichophyton rubrum. Anstey A, et al. **Br J Dermatol** 1996 Jul;135(1):113–5 (25 ref.)

TRICHOPHYTOSIS see **TINEA**

TRICHOTHECENE EPOXIDES see **TRICHOTHECENES**

TRICHOTHECENES

TOXICITY

Toxicology of deoxynivalenol (vomitoxin). Rotter BA, et al. **J Toxicol Environ Health** 1996 May;48(1):1–34 (244 ref.)

TRICHOTILLOMANIA

DIAGNOSIS

The characterization and treatment of trichotillomania. Christenson GA, et al. **J Clin Psychiatry** 1996;57 Suppl 8:42–7; discussion 48–9 (59 ref.)

THERAPY

The characterization and treatment of trichotillomania. Christenson GA, et al. **J Clin Psychiatry** 1996;57 Suppl 8:42–7; discussion 48–9 (59 ref.)

TRICHURIASIS

DIAGNOSIS

A case of Trichuris trichiura infection diagnosed by colonoscopy. Yoshida M, et al. **Am J Gastroenterol** 1996 Jan;91(1):161–2 (7 ref.)

TRICUSPID ATRESIA

see related
FONTAN PROCEDURE

TRICUSPID INCOMPETENCE see **TRICUSPID VALVE INSUFFICIENCY**

TRICUSPID REGURGITATION see **TRICUSPID VALVE INSUFFICIENCY**

TRICUSPID VALVE

Fragmentation hemolysis: an unusual indication for valve replacement in native valve infective endocarditis. Gradon JD, et al. **South Med J** 1996 Aug;89(8):818–20 (7 ref.)

EMBRYOLOGY

[The embryogenesis of the atrioventricular valves] Berishvili II, et al. **Morfologiia** 1996;109(1):106–9 (34 ref.) **(Rus)**

INJURIES

Traumatic tricuspid insufficiency: a case followed for 32 years, with a note on early sources. FitzGibbon GM, et al. **Can J Cardiol** 1996 Mar;12(3):289–94 (19 ref.)

[Traumatic tricuspid regurgitation: a case report and a review of operated cases in Japan] Yamada T, et al. **Kyobu Geka** 1996 Feb;49(2):146–50 (21 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Tricuspid valve endocarditis with large vegetations in a non-drug addict without underlying cardiac disease. Iwama T, et al. **Intern Med** 1996 Mar;35(3):203–6 (20 ref.)

SURGERY

Excision of papillary fibroelastoma arising from the septal leaflet of the tricuspid valve. Lee CC, et al. **J Card Surg** 1995 Sep;10(5):589–91 (11 ref.)

TRICUSPID VALVE INCOMPETENCE see **TRICUSPID VALVE INSUFFICIENCY**

TRICUSPID VALVE INSUFFICIENCY

CONGENITAL

[A surgical case report of isolated congenital tricuspid valve insufficiency] Yokoyama S, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Jul;43(7):1063–8 (14 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Aspects of tricuspid valve disease, heart failure and the "restriction-dilatation syndrome". Barlow JB. **Rev Port Cardiol** 1995 Dec;14(12):991–1004 (43 ref.)

ETIOLOGY

Traumatic tricuspid insufficiency: a case followed for 32 years, with a note on early sources. FitzGibbon GM, et al. **Can J Cardiol** 1996 Mar;12(3):289–94 (19 ref.)

Complete heart block and severe tricuspid regurgitation after radiotherapy. Case report and review of the literature [see comments] Knight CJ, et al. **Chest** 1995 Dec;108(6):1748–51 (26 ref.) Comment in: Chest 1996 Aug;110(2):580–1.

Tricuspid insufficiency after intracardiac migration of a Greenfield filter: case report and review of the literature. James KV, et al. **J Vasc Surg** 1996 Sep;24(3):494–8 (21 ref.)

[Traumatic tricuspid insufficiency] Vayre F, et al. **Arch Mal Coeur Vaiss** 1996 Apr;89(4):459–63 (30 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

[Traumatic tricuspid regurgitation: a case report and a review of operated cases in Japan] Yamada T, et al. **Kyobu Geka** 1996 Feb;49(2):146–50 (21 ref.) (Eng. Abstr.) **(Jpn)**

[A surgical case report of isolated congenital tricuspid valve insufficiency] Yokoyama S, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Jul;43(7):1063–8 (14 ref.) (Eng. Abstr.) **(Jpn)**

TRICUSPID VALVE STENOSIS

DIAGNOSIS

Aspects of tricuspid valve disease, heart failure and the "restriction-dilatation syndrome". Barlow JB. **Rev Port Cardiol** 1995 Dec;14(12):991–1004 (43 ref.)

ETIOLOGY

[Loculated pericardial effusion leading to functional tricuspid stenosis in a case of rheumatoid arthritis] Galli CA, et al. **Cardiologia** 1995 Sep;40(9):685–8 (11 ref.) (Eng. Abstr.) **(Ita)**

TRICYCLIC ANTIDEPRESSIVE AGENTS see **ANTIDEPRESSIVE AGENTS, TRICYCLIC**

TRIETHYLENETHIOPHOSPHORAMIDE see **THIOTEPA**

TRIGEMINAL GANGLION

PHYSIOPATHOLOGY

[Trigeminal neuralgia: role of neurogenic ectopic activity in the trigeminal ganglion] Rappaport ZH, et al. **Harefuah** 1995 Aug;129(3–4):116–22 (39 ref.) **(Heb)**

TRIGEMINAL NERVE

see related
TRIGEMINAL NEURALGIA

Neurinoma of the trigeminal root and atypical trigeminal neuralgia: case report and review of the literature. Tancioni F, et al. **Surg Neurol** 1995 Jul;44(1):36–42 (29 ref.)

[Raeder's syndrome (the paratrigeminal syndrome): its etiology related to carotid artery dissection. A case report] Monti L, et al. **Radiol Med (Torino)** 1996 Apr;91(4):473–5 (16 ref.) **(Ita)**

BLOOD SUPPLY

Deficient habituation of evoked cortical potentials in migraine: a link between brain biology, behavior and trigeminovascular activation? Schoenen J. **Biomed Pharmacother** 1996;50(2):71–8 (78 ref.)

PATHOLOGY

Trigeminal neuropathy: evaluation with MR imaging. Majoie CB, et al. **Radiographics** 1995 Jul;15(4):795–811 (33 ref.)

PHYSIOPATHOLOGY

[Decompressive neurovascular nose and skull-base surgery in primary headache with a rhinogenic trigger] Bonaccorsi P. **Ital J Neurol Sci** 1995 Nov;16(8 Suppl):69–100 (104 ref.) (Eng. Abstr.) **(Ita)**

[Trigemino-vegetative physiopathology in the central dysnociceptive biorhythms in primary headache] Passàli D, et al. **Ital J Neurol Sci** 1995 Nov;16(8 Suppl):41–5 (14 ref.) (Eng. Abstr.) **(Ita)**

[Atypical forms of cluster headache] Navarro A, et al. **Rev Neurol** 1995;23 Suppl 4:S540–3 (36 ref.) **(Spa)**

SURGERY

CT-guided pain procedures for intractable pain in malignancy. Kanpolat Y, et al. **Acta Neurochir Suppl (Wien)** 1995;64:88–91 (24 ref.)

Postsurgical development of dural arteriovenous malformations after transpetrosal and transtentorial operations: case report. Sasaki T, et al. **Neurosurgery** 1995 Oct;37(4):820–4; discussion 824–5 (14 ref.)

TRIGEMINAL NEURALGIA

Neurinoma of the trigeminal root and atypical trigeminal neuralgia: case report and review of the literature. Tancioni F, et al. **Surg Neurol** 1995 Jul;44(1):36–42 (29 ref.)

DIAGNOSIS

Trigeminal neuralgia versus atypical facial pain. A review of the literature and case report. Türp JC, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Apr;81(4):424–32 (73 ref.)

Trigeminal neuropathy: evaluation with MR imaging. Majoie CB, et al. **Radiographics** 1995 Jul;15(4):795–811 (33 ref.)

PHYSIOPATHOLOGY

[Trigeminal neuralgia: role of neurogenic ectopic activity in the trigeminal ganglion] Rappaport ZH, et al. **Harefuah** 1995 Aug;129(3–4):116–22 (39 ref.) **(Heb)**

TRIGEMINAL NUCLEUS, SPINAL

Anatomy and physiology of headache. Bogduk N. **Biomed Pharmacother** 1995;49(10):435–45 (47 ref.)

TRIGGER POINTS, MYOFASCIAL see **MYOFASCIAL PAIN SYNDROMES**

TRIGLYCERIDE LIPASE see **LIPASE**

TRIGLYCERIDES

ANALYSIS

Methods for the analysis of triacylglycerols. Ruiz-Gutiérrez V, et al. **J Chromatogr B Biomed Appl** 1995 Sep 15; 671(1–2):133–68 (327 ref.)

BLOOD

Nutritional regulation of lipoprotein lipase. Olivecrona T, et al. **Can J Cardiol** 1995 Oct;11 Suppl G:73G–78G (31 ref.)

Metabolic aspects of the treatment of hypertension. Lithell H. **J Hypertens Suppl** 1995 Aug;13(2):S77–80 (29 ref.)

Postprandial triacylglycerolaemia—nutritional implications. Roche HM, et al. **Prog Lipid Res** 1995;34(3):249–66 (110 ref.)

Mutations affecting human lipoprotein lipase gene. Antikainen M, et al. **Z Gastroenterol** 1996 Jun;34 Suppl 3:59–61 (20 ref.)

Cellular metabolism of triglyceride-rich lipoproteins: role of heparan sulfate, lipoprotein lipase and lipoprotein receptors. Sehayek E, et al. **Z Gastroenterol** 1996 Jun;34 Suppl 3:110–2 (16 ref.)

[Triglyceride] Shibuya Y, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:606–10 (20 ref.) **(Jpn)**

CHEMISTRY

The role of stereospecific saturated fatty acid positions on lipid nutrition. Decker EA. **Nutr Rev** 1996 Apr;54(4 Pt 1):108–10 (18 ref.)

METABOLISM

The role of insulin in the control of hepatic fatty acid and glycerolipid metabolism assessed by studies in vivo. Zammit VA. **Braz J Med Biol Res** 1995 Oct;28(10):1027–31 (24 ref.)

Smoking and plasma lipoprotein metabolism [editorial] Freeman DJ, et al. **Clin Sci (Colch)** 1995 Oct;89(4):333–42 (94 ref.)

Triglycerides and coronary risk. Shepherd J, et al. **Isr J Med Sci** 1996 Jun;32(6):345–55 (38 ref.)

[Role of catecholamines in adipocyte metabolism] Nagasaka Y, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:106–10 (13 ref.) **(Jpn)**

[Role of cholesterol esters in triglyceride transport] Titov VN. **Biokhimiia** 1995 Sep;60(9):1371–81 (40 ref.) (Eng. Abstr.) **(Rus)**

[Cholesterol turnover in triglyceride transport and effect of probucol] Titov VN. **Vopr Med Khim** 1995 Sep–Oct; 41(5):2–8 (80 ref.) **(Rus)**

TRIIODOBENZOIC ACIDS

Visipaque--a step forward. A historical review. Almen T. **Acta Radiol Suppl** 1995;399:2–18 (48 ref.)

ADVERSE EFFECTS

Main results of the first comparative clinical studies on Visipaque. Grynne BH, et al. **Acta Radiol Suppl** 1995; 399:265–70 (23 ref.)

TOXICITY

Sodium-calcium balance in coronary angiography and experimental experience with iodixanol. Jynge P. **Eur Radiol** 1996;6 Suppl 2:S8–12 (19 ref.)

TRIIODOTHYRONINE

see related
RECEPTORS, THYROID HORMONE

BLOOD

Diagnosis of thyroid hormone transport protein anomalies: an overview. Langsteger W. **Acta Med Austriaca** 1996; 23(1–2):31–40 (140 ref.)

Clinical usage recommendations and analytic performance goals for total and free triiodothyronine measurements. Klee GG. **Clin Chem** 1996 Jan;42(1):155–9 (38 ref.)

[Total triiodothyronine (total T3)] Ochi Y, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:356–9 (12 ref.) **(Jpn)**

[Free T3 (FT3)] Ochi Y, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:360–3 (10 ref.) **(Jpn)**

[T3 uptake (T3U)] Zeki K, et al. **Nippon Rinsho** 1995 Mar; 53 Su Pt 2:369–71 (8 ref.) **(Jpn)**

METABOLISM

Drugs and thyroid function. Surks MI, et al. **N Engl J Med** 1995 Dec 21;333(25):1688–94 (94 ref.)

PHARMACOLOGY

Enhancement of erythroid colony growth by triiodothyronine in cell cultures from bone marrow of normal and anemic rats with chronic renal failure. Malgor LA, et al. **Acta Physiol Pharmacol Ther Latinoam** 1995; 45(2):79–86 (40 ref.)

PHYSIOLOGY

T3 or not T3--the slings and arrows of outrageous TR function [editorial; comment] Chin WW, et al. **Endocrinology** 1996 Feb;137(2):387–8 (23 ref.) Comment on: Endocrinology 1996 Feb;137(2):390–9.

THERAPEUTIC USE

A therapeutic controversy. Thyroid hormone treatment: when and what? Oppenheimer JH, et al. **J Clin Endocrinol Metab** 1995 Oct;80(10):2873–83 (112 ref.)

3,3',5'-TRIIODOTHYRONINE see **TRIIODOTHYRONINE, REVERSE**

TRIIODOTHYRONINE RECEPTORS see **RECEPTORS, THYROID HORMONE**

TRIIODOTHYRONINE, REVERSE

BLOOD

[Reverse T3 (rT3)] Ochi Y, et al. **Nippon Rinsho** 1995 Mar; 53 Su Pt 2:364–8 (19 ref.) **(Jpn)**

TRIMESTER, FIRST see **PREGNANCY TRIMESTER, FIRST**

TRIMETHOPRIM

ANALOGS & DERIVATIVES

Brodimoprim, a new bacterial dihydrofolate reductase inhibitor: a minireview. Periti P. **J Chemother** 1995 Jun; 7(3):221–3 (22 ref.)

TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION

ADVERSE EFFECTS

Trimethoprim-sulfamethoxazole-associated acute febrile neutrophilic dermatosis: case report and review of drug-induced Sweet's syndrome. Walker DC, et al. **J Am Acad Dermatol** 1996 May;34(5 Pt 2):918–23 (21 ref.)

[Intolerance to trimethoprim-sulfamethoxazole in Pneumocystis carinii pneumonia in AIDS. Search for predictive factors] Pinzani V, et al. **Ann Med Interne (Paris)** 1995;146(7):505–9 (25 ref.) (Eng. Abstr.) **(Fre)**

[Cotrimoxazole induced dermatitis and curative treatment of AIDS pneumocystosis] Caumes E. **Rev Mal Respir** 1996; 13(2):101–6 (45 ref.) (Eng. Abstr.) **(Fre)**

[Trimethoprim-sulfamethoxazole-induced cholestatic hepatitis. Clinico-immunological demonstration of its allergic origin] Cario E, et al. **Dtsch Med Wochenschr** 1996 Feb 2;121(5):129–32 (10 ref.) (Eng. Abstr.) **(Ger)**

PHARMACOLOGY

[In vitro susceptibility of Pasteurella and related bacteria to five orally administered antibiotics] Lion C, et al. **Pathol Biol (Paris)** 1996 May;44(5):341–6 (13 ref.) (Eng. Abstr.) **(Fre)**

THERAPEUTIC USE

Cotrimoxazole. Rationale for re-examining its indications for use. Howe RA, et al. **Drug Saf** 1996 Apr;14(4):213–8 (35 ref.)

Vancomycin, trimethoprim-sulfamethoxazole, and rifampin. Lundstrom TS, et al. **Infect Dis Clin North Am** 1995 Sep; 9(3):747–67 (91 ref.)

TRIMETHYLTIN COMPOUNDS

TOXICITY

How does trimethyltin affect the brain: facts and hypotheses. Koczyk D. **Acta Neurobiol Exp (Warsz)** 1996;56(2):587–96 (85 ref.)

TRINUCLEOTIDE REPEATS

Huntington's disease. Their loss is our gain? Feero W, et al. **Curr Biol** 1995 Nov 1;5(11):1229–31 (17 ref.)

Trinucleotide repeat expansion and human disease. Hummerich H, et al. **Electrophoresis** 1995 Sep; 16(9):1698–704 (92 ref.)

FMR1 triplet arrays: paying the price for perfection. Hirst MC. **J Med Genet** 1995 Oct;32(10):761–3 (16 ref.)

The expanding world of trinucleotide repeats [comment] Warren ST. **Science** 1996 Mar 8;271(5254):1374–5 (7 ref.) Comment on: Science 1996 Mar 8;271(5254):1423–7.

[A new mechanism of mutation in man: expansion of trinucleotide repeats] Illarioshkin SN, et al. **Genetika** 1995 Nov;31(11):1478–89 (108 ref.) (Eng. Abstr.) **(Rus)**

GENETICS

Trinucleotide instability: a repeating theme in human inherited disorders. Gusella JF, et al. **Annu Rev Med** 1996; 47:201–9 (18 ref.)

Spinal and bulbar muscular atrophy: a trinucleotide-repeat expansion neurodegenerative disease. Brooks BP, et al. **Trends Neurosci** 1995 Oct;18(10):459–61 (25 ref.)

[Triplet repeat disorders] Yamada M. **Tanpakushitsu Kakusan Koso** 1996 Apr;41(5):643–51 (54 ref.) **(Jpn)**

TRIOLEIN

THERAPEUTIC USE

Adrenoleukodystrophy: molecular genetics, pathology, and Lorenzo's oil. Moser HW, et al. **Brain Pathol** 1995 Jul; 5(3):259–66 (72 ref.)

Komrower Lecture. Adrenoleukodystrophy: natural history, treatment and outcome. Moser HW. **J Inherit Metab Dis** 1995;18(4):435–47 (47 ref.)

TRIOSEPHOSPHATE DEHYDROGENASE see **GLYCERALDEHYDEPHOSPHATE DEHYDROGENASE**

TRIOSEPHOSPHATE ISOMERASE

see related
ANEMIA, HEMOLYTIC, CONGENITAL NONSPHEROCYTIC

TRIPHOSPHOPYRIDINE NUCLEOTIDE see NADP

TRIPLE-SYMPTOM COMPLEX see BEHCET'S SYNDROME

TRIPLET REPEATS see TRINUCLEOTIDE REPEATS

TRISACCHARIDES

ADMINISTRATION & DOSAGE

[Acarbose, a glucosidase inhibitor: a new therapeutic principle in diabetes mellitus] Hermansen K, et al. **Ugeskr Laeger** 1996 Apr 29;158(18):2564–8 (33 ref.) **(Dan)**

[Acarbose in therapy of diabetes] Mehnert H. **Internist (Berl)** 1995 Dec;36(12):1190–5 (21 ref.) **(Ger)**

PHARMACOLOGY

The mechanism of alpha-glucosidase inhibition in the management of diabetes. Bischoff H. **Clin Invest Med** 1995 Aug;18(4):303–11 (31 ref.)

THERAPEUTIC USE

Clinical experience with acarbose as first line therapy in NIDDM. Fölsch UR. **Clin Invest Med** 1995 Aug; 18(4):312–7 (28 ref.)

TRISOMY

Cytogenetic and molecular analysis in trisomy 12p. Allen TL, et al. **Am J Med Genet** 1996 May 3;63(1):250–6 (33 ref.)

Transient leukemia with trisomy 21: description of a case and review of the literature. Bhatt S, et al. **Am J Med Genet** 1995 Sep 25;58(4):310–4 (23 ref.)

Mosaic vs. nonmosaic trisomy 9: report of a liveborn infant evaluated by fluorescence in situ hybridization and review of the literature. Cantú ES, et al. **Am J Med Genet** 1996 Apr 24;62(4):330–5 (39 ref.)

Clinical and molecular cytogenetic observations in three cases of "trisomy 12p syndrome". Rauch A, et al. **Am J Med Genet** 1996 May 3;63(1):243–9 (26 ref.)

Trisomy 1q42 —> qter in a sister and brother: further delineation of the "trisomy 1q42 —> qter syndrome". Verschuuren-Bemelmans CC, et al. **Am J Med Genet** 1995 Jul 31;58(1):83–6 (13 ref.)

Risk of fetal mosaicism when placental mosaicism is diagnosed by chorionic villus sampling. Phillips OP, et al. **Am J Obstet Gynecol** 1996 Mar;174(3):850–5 (24 ref.)

Trisomy 8 and 20 in desmoid tumors and breast cancer: more than a casual coincidence? [letter; comment] Rohen G, et al. **Cancer Genet Cytogenet** 1996 Jan;86(1):92 (9 ref.) Comment on: Cancer Genet Cytogenet 1995 Feb;79(2):139–43.

Aspects of the neoplasms observed in patients with constitutional autosomal trisomy. Satge D, et al. **Cancer Genet Cytogenet** 1996 Mar;87(1):63–70 (164 ref.)

Trisomy 15 in hematological malignancies: six cases and review of the literature. Smith SR, et al. **Cancer Genet Cytogenet** 1996 Jul 1;89(1):27–30 (19 ref.)

Molecular characterization of trisomic segment 3p24.1—>3pter: a case with review of the literature. Conte RA, et al. **Clin Genet** 1995 Jul;48(1):49–53 (37 ref.)

A distinct phenotype associated with partial trisomy 10q due to proximal direct duplication 10q11 —> q223? van Buggenhout G, et al. **Genet Couns** 1996;7(1):53–9 (14 ref.)

Philadelphia chromosome-negative cells with trisomy 8 after busulfan and interferon treatment of Ph1-positive chronic myelogenous leukemia. Izumi T, et al. **Int J Hematol** 1996 Jul;64(1):73–7 (17 ref.)

Preliminary characterization of the central nervous system in partial trisomy 16 mice. Holtzman DM, et al. **Prog Clin Biol Res** 1995;393:227–40 (32 ref.)

Fetal exomphalos and chromosomal defects: relationship to maternal age and gestation. Snijders RJ, et al. **Ultrasound Obstet Gynecol** 1995 Oct;6(4):250–5 (30 ref.)

DIAGNOSIS

Prenatal diagnosis of trisomy 9. Six cases and a review of the literature. Saura R, et al. **Prenat Diagn** 1995 Jul; 15(7):609–14 (25 ref.)

TRISOMY 21 see DOWN SYNDROME

TRITERPENES

ISOLATION & PURIFICATION

[Advances in the study of the chemical constituents of gardenia] Wang G, et al. **Chung Kuo Chung Yao Tsa Chih** 1996 Feb;21(2):67–9, 72 (34 ref.) **(Chi)**

PHARMACOLOGY

Pharmacology of oleanolic acid and ursolic acid. Liu J. **J Ethnopharmacol** 1995 Dec 1;49(2):57–68 (91 ref.)

TRITHIOANETHOL see ANETHOLE TRITHIONE

TRITHIOPARAMETHOXYPHENYLPROPENE see ANETHOLE TRITHIONE

TRITICUM see WHEAT

TRITONS see POLYETHYLENE GLYCOLS

TRNA see RNA, TRANSFER

TRNAGLU see RNA, TRANSFER, GLU

TRNAPHE see RNA, TRANSFER, PHE

TROCHANTER see FEMUR

TROCHANTERIC FRACTURES see HIP FRACTURES

TROPHIC FACTOR RECEPTORS see RECEPTORS, GROWTH FACTOR

TROPHOBLAST

IMMUNOLOGY

T-helper 1-type immunity to trophoblast: evidence for a new immunological mechanism for recurrent abortion in women. Hill JA. **Hum Reprod** 1995 Dec;10 Suppl 2:114–20 (75 ref.)

[Adhesion molecules and trophoblastic invasion] Loke YW, et al. **Contracept Fertil Sex** 1995 Sep;23(9):573–5 (40 ref.) (Eng. Abstr.) **(Fre)**

[Trophoblastic interferons and embryonal immune tolerance] Martal J, et al. **Contracept Fertil Sex** 1995 Sep;23(9):562–72 (163 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Materno-fetal immunobiology in normal pregnancy and its possible failure in recurrent spontaneous abortion? Vince GS, et al. **Hum Reprod** 1995 Dec;10 Suppl 2:107–13 (50 ref.)

PHYSIOLOGY

Not trophoblast alone: a review of the contribution of the fetal microvasculature to transplacental exchange. Firth JA, et al. **Placenta** 1996 Mar-Apr;17(2-3):89–96 (64 ref.)

Angiotensin II and its different receptor subtypes in placenta and fetal membranes. Kalenga MK, et al. **Placenta** 1996 Mar-Apr;17(2-3):103–110 (50 ref.)

[Regulation of the expression of HLA class I genes in human trophoblasts] Le Bouteiller P. **Pathol Biol (Paris)** 1995 Sep; 43(7):628–35 (53 ref.) (Eng. Abstr.) **(Fre)**

TROPHOBLASTIC NEOPLASMS

Placental site trophoblastic tumor: three case reports and literature review. Denny LA, et al. **Gynecol Oncol** 1995 Nov;59(2):300–3 (15 ref.)

Gestational trophoblastic diseases: current trends and perspectives. Wang TH, et al. **J Formos Med Assoc** 1995 Aug;94(8):449–57 (71 ref.)

DIAGNOSIS

Gestational trophoblastic diseases. Lage JM, et al. **Curr Opin Obstet Gynecol** 1996 Feb;8(1):79–82 (26 ref.)

DRUG THERAPY

Gestational trophoblastic disease. Berkowitz RS, et al. **Cancer** 1995 Nov 15;76(10 Suppl):2079–85 (81 ref.)

PATHOLOGY

Gestational trophoblastic disease. New approaches to diagnosis. Lage JM, et al. **Clin Lab Med** 1995 Sep; 15(3):631–64 (50 ref.)

[Recent advances in gynecological pathology in China] Huang S. **Chung Hua Ping Li Hsueh Tsa Chih** 1995 Aug; 24(4):228–31 (20 ref.) **(Chi)**

THERAPY

Current views on the management of trophoblastic tumors. Tham KF, et al. **Int J Gynaecol Obstet** 1995 Jul;49 Suppl:S77–89 (48 ref.)

[Valuable lessons obtained from clinical experience of trophoblastic diseases] Tomoda Y. **Nippon Sanka Fujinka Gakkai Zasshi** 1995 Aug;47(8):701–9 (9 ref.) **(Jpn)**

TROPHOBLASTIC TUMOR see TROPHOBLASTIC NEOPLASMS

TROPHOBLASTIC TUMOR, PLACENTAL SITE

Recurrent placental site trophoblastic tumor of the uterus: clinical, pathologic, ultrastructural, and DNA fingerprint study. Kodama S, et al. **Gynecol Oncol** 1996 Jan;60(1):89–93 (20 ref.)

[Non-trophoblastic tumors of the placenta] Dukovski A. **Akush Ginekol (Sofiia)** 1994;33(2):40–3 (28 ref.) **(Bul)**

PATHOLOGY

[Placental site trophoblastic tumor] Rosati R, et al. **Rev Chil Obstet Ginecol** 1995;60(1):46–50 (16 ref.) (Eng. Abstr.) **(Spa)**

TROPICAL CLIMATE

Viral respiratory infections and their role as public health problem in tropical countries (review). Karaivanova GM. **Afr J Med Med Sci** 1995 Mar;24(1):1–7 (72 ref.)

Tropical neuropathies. Román GC. **Baillieres Clin Neurol** 1995 Nov;4(3):469–87 (63 ref.)

Dermatophagoides siboney and Blomia tropicalis—dust mites of subtropical and tropical areas [editorial] van Hage-Hamsten M. **Clin Exp Allergy** 1995 Oct;25(10):905–7 (25 ref.)

[Tropical reactive arthritis] Jeandel P. **Med Trop (Mars)** 1995; 55(4):325–8 (0 ref.) **(Fre)**

[The importance of tropical animal hygiene for indigenous animal production] Böhnel H. **Berl Munch Tierarztl Wochenschr** 1995 Dec;108(12):443–6 (6 ref.) (Eng. Abstr.) **(Ger)**

TROPICAL MEDICINE

Consensus statement from the International Workshop on Types of Diabetes Peculiar to the Tropics, 17–19 October 1995, in Cuttack, India. **Acta Diabetol** 1996 Mar;33(1):62–4 (0 ref.)

Carbohydrate tolerance in patients with tropical ataxic neuropathy—A human model of chronic cyanide intoxication. Famuyiwa OO, et al. **Afr J Med Med Sci** 1995 Jun;24(2):151–7 (28 ref.)

Adverse effects of chemotherapeutic agents used in tropical medicine. Cook GC. **Drug Saf** 1995 Jul;13(1):31–45 (142 ref.)

The Centre for Tropical Veterinary Medicine (CTVM) pulling its weight in the field of draught animal research. Pearson RA, et al. **Trop Anim Health Prod** 1996 Feb; 28(1):49–59 (40 ref.)

Microbiological research at the Centre for Tropical Veterinary Medicine (CTVM). Scott GR. **Trop Anim Health Prod** 1996 Feb;28(1):40–8 (24 ref.)

[What are the rules?] Zwart D. **Tijdschr Diergeneeskd** 1995 Sep 15;120(18):536–42 (55 ref.) **(Dut)**

[How to do blood transfusions in the tropical environment?] Aubert M, et al. **Med Trop (Mars)** 1996;56(1):28–32 (9 ref.) **(Fre)**

[The importance of tropical animal hygiene for indigenous animal production] Böhnel H. **Berl Munch Tierarztl Wochenschr** 1995 Dec;108(12):443–6 (6 ref.) (Eng. Abstr.) **(Ger)**

[Dermatology in the tropics] Tapia Collantes A. **Rev Med Panama** 1995 Sep;20(3):65–71 (26 ref.) (Eng. Abstr.) **(Spa)**

TROPICAL SPASTIC PARAPARESIS see PARAPARESIS, TROPICAL SPASTIC

TROPOELASTIN

METABOLISM

The 67 kDa spliced variant of beta-galactosidase serves as a reusable protective chaperone for tropoelastin. Hinek A. **Ciba Found Symp** 1995;192:185–91; discussion 191–6 (30 ref.)

TROPONIN

BLOOD

The case for cardiac troponin T: marker for effective risk stratification of patients with acute cardiac ischemia. Alonsozana GL, et al. **Clin Chem** 1996 May;42(5):803–8 (51 ref.)

New biochemical markers for myocardial cell injury. Hamm CW, et al. **Curr Opin Cardiol** 1995 Jul;10(4):355–60 (42 ref.)

[Troponin—current possibility for the diagnosis of myocardial infarction (editorial)] Partanen J. **Duodecim** 1994;110(18):1673–5 (16 ref.) **(Fin)**

[Troponin T] Nishimura H, et al. **Nippon Rinsho** 1995 Feb; 53 Su Pt 1:246–7 (4 ref.) **(Jpn)**

GENETICS

Familial hypertrophic cardiomyopathy: a genetic model of cardiac hypertrophy. Watkins H, et al. **Hum Mol Genet** 1995;4 Spec No:1721–7 (59 ref.)

METABOLISM

Troponin C - troponin I interactions and molecular signalling in cardiac myofilaments. Solaro RJ. **Adv Exp Med Biol** 1995;382:109–15 (24 ref.)

Regulation of phospholamban and troponin-I phosphorylation in the intact rat cardiomyocytes by adrenergic and cholinergic stimuli: roles of cyclic nucleotides, calcium, protein kinases and phosphatases and depolarization. Sulakhe PV, et al. **Mol Cell Biochem** 1995 Aug-Sep;149-150:103–26 (96 ref.)

TROUT, RAINBOW see ONCORHYNCHUS MYKISS

TROUT, REDBAND see **ONCORHYNCHUS MYKISS**

TRS-ART GENE PROTEIN, HIV see **GENE PRODUCTS, REV**

TRS-ART GENES see **GENES, REV**

TRUNCAL VAGOTOMY see **VAGOTOMY, TRUNCAL**

TRUSSES

Trusses in the management of hernia today. Cheek CM, et al. **Br J Surg** 1995 Dec;82(12):1611-3 (23 ref.)

TRUTH DISCLOSURE

Pre-operative information in mastoidectomy: what about the facial nerve and hearing loss? Wormald PJ. **J Laryngol Otol** 1996 Jan;110(1):10-2 (8 ref.)

Delayed reporting of the rape victim. Burgess AW, et al. **J Psychosoc Nurs Ment Health Serv** 1995 Sep;33(9):21-9 (14 ref.)

The disclosure of the diagnosis of cancer. Carnes JW, et al. **Med Clin North Am** 1996 Jan;80(1):145-51 (10 ref.)

Discussing the diagnosis and prognosis with cancer patients. Bennett M, et al. **Postgrad Med J** 1996 Jan;72(843):25-9 (14 ref.)

Your child is brain dead. Blair AW, et al. **Postgrad Med J** 1996 Mar;72(845):137-40 (33 ref.)

A surgeon with HIV. Cembrowicz S, et al. **Practitioner** 1996 Jan;240(1558):9-12 (2 ref.)

[Recommendations for patient education in poor prognosis. Australian Consensus Document] Bornkessel B. **Med Monatsschr Pharm** 1996 May;19(5):143-5 (0 ref.) **(Ger)**

[To disclose to the patients the diagnosis and information about the likely course of amyotrophic lateral sclerosis] Hayashi H. **No To Shinkei** 1996 May;48(5):409-15 (22 ref.) **(Jpn)**

[Some problems in giving notice of the name of a disease: with special reference to Alzheimer's disease and vascular dementia] Hirai S. **No To Shinkei** 1996 May;48(5):431-5 (3 ref.) **(Jpn)**

[Information giving in Parkinson's disease] Kuzuhara S. **No To Shinkei** 1996 May;48(5):417-23 (10 ref.) **(Jpn)**

TRYPANOCIDAL AGENTS

THERAPEUTIC USE

Etiological treatment of acute and chronic Chagas' heart disease. Fragata Filho AA, et al. **Rev Paul Med** 1995 Mar-Apr;113(2):867-72 (11 ref.)

TRYPANOSOMA

see related
TRYPANOCIDAL AGENTS

CYTOLOGY

Mitosis and genome partition in trypanosomes. Solari AJ. **Biocell** 1995 Aug;19(2):65-84 (77 ref.)

TRYPANOSOMA BRUCEI see **TRYPANOSOMA BRUCEI BRUCEI**

TRYPANOSOMA BRUCEI BRUCEI

METABOLISM

Regulation and control of compartmentalized glycolysis in bloodstream form Trypanosoma brucei. Bakker BM, et al. **J Bioenerg Biomembr** 1995 Oct;27(5):513-25 (63 ref.)

TRYPANOSOMA CRUZI

Plant metabolites active against Trypanosoma cruzi. Sepúlveda-Boza S, et al. **Planta Med** 1996 Apr;62(2):98-105 (63 ref.)

IMMUNOLOGY

[Role of cytokines in resistance and pathology in Trypanosoma cruzi infection] Laucella SA, et al. **Rev Argent Microbiol** 1996 Apr-Jun;28(2):99-109 (81 ref.) (Eng. Abstr.) **(Spa)**

PATHOGENICITY

Cellular microbiology emerging. Cossart P, et al. **Science** 1996 Jan 19;271(5247):315-6 (22 ref.)

[Chagas disease. Importance of the parasite in the pathogenesis of the cardiac chronic disease] Higuchi ML. **Arq Bras Cardiol** 1995 Mar;64(3):251-4 (46 ref.) **(Por)**

PHYSIOLOGY

Intracellular survival of protozoan parasites with special reference to Leishmania spp., Toxoplasma gondii and Trypanosoma cruzi. Mauël J. **Adv Parasitol** 1996;38:1-51 (250 ref.)

TRYPANOSOMATIDAE see **TRYPANOSOMATINA**

TRYPANOSOMATINA

GENETICS

The structure and replication of kinetoplast DNA. Shapiro TA, et al. **Annu Rev Microbiol** 1995;49:117-43 (126 ref.)

Trypanosome RNA editing: resolved [comment] Sollner-Webb B. **Science** 1996 Aug 30;273(5279):1182-3 (17 ref.) Comment on: Science 1996 Aug 30;273(5279):1189-95.

METABOLISM

Galactofuranose-containing glycoconjugates in trypanosomatids. de Lederkremer RM, et al. **Glycobiology** 1995 Sep;5(6):547-52 (42 ref.)

TRYPANOSOMIASIS

see related
TRYPANOCIDAL AGENTS

TRYPANOSOMIASIS, AFRICAN

BLOOD

Regulation and control of compartmentalized glycolysis in bloodstream form Trypanosoma brucei. Bakker BM, et al. **J Bioenerg Biomembr** 1995 Oct;27(5):513-25 (63 ref.)

IMMUNOLOGY

[Immunology and immunopathology of African trypanosomiasis] Vincendeau P, et al. **Med Trop (Mars)** 1996;56(1):73-8 (56 ref.) (Eng. Abstr.) **(Fre)**

TRYPANOSOMIASIS, CARDIOVASCULAR see **CHAGAS CARDIOMYOPATHY**

TRYPANOSOMIASIS, SOUTH AMERICAN see **CHAGAS DISEASE**

TRYPSIN

BLOOD

[Serum trypsin] Hayakawa T, et al. **Nippon Rinsho** 1995 Feb; 53 Su Pt 1:314-6 (8 ref.) **(Jpn)**

METABOLISM

Trypsin inhibition: a potential cause of cobalamin deficiency common to the pathogenesis of Alzheimer-type dementia and AIDS dementia complex? McCaddon A, et al. **Med Hypotheses** 1995 Aug;45(2):200-4 (49 ref.)

TRYPSIN INHIBITOR, ALPHA 1-ANTITRYPSIN see **ALPHA 1-ANTITRYPSIN**

TRYPSIN INHIBITOR, KAZAL PANCREATIC

BLOOD

[Pancreatic secretory trypsin inhibitor (PSTI)] Ogawa M. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:317-22 (18 ref.) **(Jpn)**

TRYPSIN INHIBITOR, KUNITZ, PANCREATIC see **APROTININ**

TRYPSIN INHIBITORS

Trypsin inhibition: a potential cause of cobalamin deficiency common to the pathogenesis of Alzheimer-type dementia and AIDS dementia complex? McCaddon A, et al. **Med Hypotheses** 1995 Aug;45(2):200-4 (49 ref.)

PHARMACOLOGY

The inter-alpha-inhibitor family: from structure to regulation. Salier JP, et al. **Biochem J** 1996 Apr 1;315 (Pt 1):1-9 (68 ref.)

TRYPTAMINE RECEPTORS see **RECEPTORS, SEROTONIN**

TRYPTAMINES

see related
RECEPTORS, SEROTONIN

TRYPTOPHAN

see related
EOSINOPHILIA-MYALGIA SYNDROME

ADVERSE EFFECTS

Epidemiology of potential association between L-tryptophan ingestion and eosinophilia-myalgia syndrome. Daniels SR, et al. **J Clin Epidemiol** 1995 Dec;48(12):1413-27; discussion 1429-40 (64 ref.)

ANALOGS & DERIVATIVES

Biogenesis of novel quinone coenzymes. Tanizawa K. **J Biochem (Tokyo)** 1995 Oct;118(4):671-8 (52 ref.)

Alpha-methyl-L-tryptophan as a tracer to study brain serotonergic system. Diksic M, et al. **Neurochem Res** 1995 Nov;20(11):1353-60 (51 ref.)

METABOLISM

Tryptophan, 5-hydroxytryptamine and a possible explanation for central fatigue. Newsholme EA, et al. **Adv Exp Med Biol** 1995;384:315-20 (16 ref.)

Cation-pi interactions in chemistry and biology: a new view of benzene, Phe, Tyr, and Trp. Dougherty DA. **Science** 1996 Jan 12;271(5246):163-8 (66 ref.)

TRYPTOPHAN HYDROXYLASE

PHYSIOLOGY

Structure and function of the aromatic amino acid hydroxylases. Hufton SE, et al. **Biochem J** 1995 Oct 15; 311 (Pt 2):353-66 (223 ref.)

TRYPTOPHAN MONOOXYGENASE see **TRYPTOPHAN HYDROXYLASE**

TSETSE FLIES

Control of tsetse flies (Diptera: Glossinidae) with the aid of attractants. Jordan AM. **J Am Mosq Control Assoc** 1995 Jun;11(2 Pt 2):249-55 (52 ref.)

TSH see **THYROTROPIN**

TSH, ALPHA SUBUNIT see **GLYCOPROTEIN HORMONES, ALPHA SUBUNIT**

TSH RECEPTORS see **RECEPTORS, THYROTROPIN**

TSUTSUGAMUSHI DISEASE see **SCRUB TYPHUS**

TUBAL EMBRYO TRANSFER see **EMBRYO TRANSFER**

TUBAL LIGATION see **STERILIZATION, TUBAL**

TUBE FEEDING see **ENTERAL NUTRITION**

TUBE ILEOSTOMY see **ILEOSTOMY**

TUBERCULIN TEST

STATISTICS & NUMERICAL DATA

Interpretation of the tuberculin skin test. Rose DN, et al. **J Gen Intern Med** 1995 Nov;10(11):635-42 (35 ref.)

TUBERCULIN-TYPE HYPERSENSITIVITY see **HYPERSENSITIVITY, DELAYED**

TUBERCULOID BACILLUS see **MYCOBACTERIUM, ATYPICAL**

TUBERCULOID INFECTIONS see **MYCOBACTERIUM INFECTIONS, ATYPICAL**

TUBERCULOMA, INTRACRANIAL

Central nervous system tuberculosis: medical management and surgical indications. Gropper MR, et al. **Surg Neurol** 1995 Oct;44(4):378-84; discussion 384-5 (33 ref.)

TUBERCULOSIS

see related
ANTITUBERCULAR AGENTS
TUBERCULIN TEST

Tuberculosis infection and disease in children. Sass P. **Am Fam Physician** 1996 May 1;53(6):2087-94 (27 ref.)

The reemergence of mycobacterial infections. Fry DE. **Arch Surg** 1996 Jan;131(1):14-7 (27 ref.)

Tuberculosis: a re-emerging problem for health care workers. Bagg J. **Br Dent J** 1996 May 25;180(10):376-81 (47 ref.)

Tuberculosis in the elderly. Epidemiology and optimal management. Davies PD. **Drugs Aging** 1996 Jun;8(6):436-44 (31 ref.)

Tuberculous psoas abscess. Harrigan RA, et al. **J Emerg Med** 1995 Jul-Aug;13(4):493-8 (32 ref.)

Tuberculosis 2000. Davies PD, et al. **J R Soc Med** 1996 Aug; 89(8):431-5 (23 ref.)

Soft tissue tuberculosis: a series of 11 cases. Puttick MP, et al. **J Rheumatol** 1995 Jul;22(7):1321-5 (33 ref.)

Pediatric TB in the 1990s. Ott MJ, et al. **MCN Am J Matern Child Nurs** 1995 Jan-Feb;20(1):16-20 (36 ref.)

[Progresses in the study on tuberculosis in China, 1995] Wang Z. **Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):728-9 (0 ref.) **(Chi)**

[Tuberculosis semper viva] Kubín M. **Cas Lek Cesk** 1996 Jan 17;135(2):39-42 (26 ref.) (Eng. Abstr.) **(Cze)**

[Tuberculosis of the gallbladder] Ikai M, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):219-21 (10 ref.) **(Jpn)**

[Current concepts on the course of pregnancies complicated by tuberculosis] Ambriz-Lopez R, et al. **Ginecol Obstet Mex** 1996 Jun;64:272-7 (30 ref.) (Eng. Abstr.) **(Spa)**

COMPLICATIONS

Tuberculosis-associated haemophagocytic syndrome: a report of two cases and a review of the literature. Undar L, et al. **Acta Haematol** 1996;96(2):73-8 (36 ref.)

Tuberculosis in patients with chronic renal failure in China. Zhang X. **Chin Med J (Engl)** 1996 Feb;109(2):115-7 (0 ref.)

Vertebral bone destruction in sickle cell disease: infection, infarction or both. Kooy A, et al. **Neth J Med** 1996 Jun; 48(6):227-31 (11 ref.)

DIAGNOSIS

Primary esophageal tuberculosis: a case report and 1996 update [letter] Trehan AK. **Am J Gastroenterol** 1996 Jun; 91(6):1286-7 (10 ref.)

Molecular biology in medicine: laboratory diagnosis of tuberculosis. Ling ML. **Ann Acad Med Singapore** 1996 Jan; 25(1):94-7 (26 ref.)

Pitfalls in contact tracing and early diagnosis of childhood tuberculosis. Clark JE, et al. **BMJ** 1996 Jul 27; 313(7051):221-2 (6 ref.)

New technology in the diagnosis of tuberculosis. Marshall BG, et al. **Br J Hosp Med** 1996 Apr 17-30;55(8):491-34 (25 ref.)

Interpretation of the tuberculin skin test. Rose DN, et al. **J Gen Intern Med** 1995 Nov;10(11):635-42 (35 ref.)

Tuberculosis: diagnosis and treatment of resurgent disease. Strull GE, et al. **J Oral Maxillofac Surg** 1995 Nov; 53(11):1334-40 (23 ref.)

Tuberculous tonsillitis. Celik O, et al. **J Otolaryngol** 1995 Oct;24(5):307-9 (14 ref.)

Tuberculosis: the resurgence of our most lethal infectious disease--a review. Cremin BJ. **Pediatr Radiol** 1995; 25(8):620-6 (128 ref.)

[Bacteriological diagnosis of tuberculosis: current hieratic classification of methods] Carbonnelle B, et al. **Rev Med Interne** 1995;16(7):518-23 (45 ref.) (Eng. Abstr.) **(Fre)**

[The application of molecular biology to the diagnosis of mycobacteriosis] Koga H. **Kekkaku** 1995 Oct;70(10):601-6 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Genetic methods of diagnosing tuberculosis] Krychniak-Soszka A. **Pneumonol Alergol Pol** 1996; 64(1-2):102-5 (32 ref.) **(Pol)**

[The influence of HIV infection on development of tuberculosis] Kwiatkowska S. **Pol Arch Med Wewn** 1995 May;93(5):421-6 (39 ref.) **(Pol)**

DRUG THERAPY

Short course chemotherapy in childhood tuberculosis [editorial] Chopra K. **Indian Pediatr** 1995 Jun;32(6):625-8 (10 ref.)

Tuberculosis: diagnosis and treatment of resurgent disease. Strull GE, et al. **J Oral Maxillofac Surg** 1995 Nov; 53(11):1334-40 (23 ref.)

Antimycobacterial quinolones: a comparative analysis of structure-activity and structure-cytotoxicity relationships. Klopman G, et al. **Res Microbiol** 1996 Jan-Feb; 147(1-2):86-96 (32 ref.)

The chemotherapy of tuberculosis--from the past to the future. Collazos J, et al. **Respir Med** 1995 Aug;89(7):463-9 (68 ref.)

[Azithromycin and Mycobacterium avium infection] Perronne C. **Pathol Biol (Paris)** 1995 Jun;43(6):565-7 (12 ref.) (Eng. Abstr.) **(Fre)**

[Therapy and prognosis of tuberculosis] Fischer B, et al. **Versicherungsmedizin** 1995 Dec 1;47(6):212-6 (12 ref.) (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

Esophageal tuberculosis [letter] Jiménez FJ, et al. **Am J Gastroenterol** 1996 Apr;91(4):826-7 (10 ref.)

Mycobacterial disease of the head and neck: current perspective. Cleary KR, et al. **Ann Otol Rhinol Laryngol** 1995 Oct;104(10 Pt 1):830-3 (22 ref.)

Inner-city tuberculosis in the USA. McGowan JE Jr, et al. **J Hosp Infect** 1995 Jun;30 Suppl:282-95 (65 ref.)

The need for epidemic intelligence. Bloch AB, et al. **Public Health Rep** 1996 Jan-Feb;111(1):26-31; discussion 32-3 (57 ref.)

Epidemiology of Mycobacterium bovis infection in animals and humans, with particular reference to Africa. Cosivi O, et al. **Rev Sci Tech** 1995 Sep;14(3):733-46 (63 ref.)

The epidemiology of Mycobacterium bovis infections in animals and man: a review. O'Reilly LM, et al. **Tuber Lung Dis** 1995 Aug;76 Suppl 1:1-46 (362 ref.)

[Tuberculosis in low prevalence countries. Back to the future?] Pedersen JT, et al. **Ugeskr Laeger** 1995 Dec 4; 157(49):6859-63 (39 ref.) (Eng. Abstr.) **(Dan)**

[Tuberculosis in Switzerland in 1996: prevention and treatment] Zellweger JP. **Schweiz Med Wochenschr** 1996 Jun 22;126(25):1112-8 (38 ref.) (Eng. Abstr.) **(Fre)**

[The mode of infection of tuberculosis--analysis using molecular epidemiologic methods] Abe C. **Kekkaku** 1995 Nov;70(11):645-50 (32 ref.) (Eng. Abstr.) **(Jpn)**

[Tuberculosis as a global emergency] Kochi A. **Kekkaku** 1996 Apr;71(4):319-27 (0 ref.) **(Jpn)**

[Recent trend of tuberculosis] Shimokata K. **Nippon Naika Gakkai Zasshi** 1995 Sep 10;84(9):1600-4 (9 ref.) **(Jpn)**

ETIOLOGY

Tuberculous brain abscess should be considered in HIV/AIDS patients [letter] Velasco-Martínez JJ, et al. **AIDS** 1995 Oct;9(10):1197-9 (16 ref.)

Tuberculosis in heart transplant recipients. Muñoz P, et al. **Clin Infect Dis** 1995 Aug;21(2):398-402 (36 ref.)

Pathogenesis of experimental tuberculosis in animal models. McMurray DN, et al. **Curr Top Microbiol Immunol** 1996; 215:157-79 (104 ref.)

Mycobacterium tuberculosis--an emerging pathogen? Hopewell PC. **West J Med** 1996 Jan;164(1):33-5 (12 ref.)

HISTORY

Tuberculosis: why "the white plague"? Weisse AB. **Perspect Biol Med** 1995 Autumn;39(1):132-8 (15 ref.)

IMMUNOLOGY

The protective immune response to Mycobacterium tuberculosis. Cooper AM, et al. **Curr Opin Immunol** 1995 Aug;7(4):512-6 (53 ref.)

Immune responses in animal models. Orme IM. **Curr Top Microbiol Immunol** 1996;215:181-96 (62 ref.)

The Koch phenomenon and the immunopathology of tuberculosis. Rook GA, et al. **Curr Top Microbiol Immunol** 1996;215:239-62 (112 ref.)

Functional T cell subsets in mycobacterial and listerial infections: lessons from other intracellular pathogens. Szalay G, et al. **Curr Top Microbiol Immunol** 1996; 215:283-302 (102 ref.)

Mechanisms of anergy in tuberculosis. Toossi Z, et al. **Curr Top Microbiol Immunol** 1996;215:221-38 (99 ref.)

[Variations in the degree of protection conferred by BCG: role and implications for heterologous immunity] Moren A. **Rev Epidemiol Sante Publique** 1996 Jun;44(3):290-2 (4 ref.) **(Fre)**

[The mechanism of induction and expression of protective immunity with special reference to the role of cytokines] Mitsuyama M. **Kekkaku** 1995 Nov;70(11):651-7 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Some problems concerning local cellular immunity in tuberculosis] Shimokata K. **Kekkaku** 1995 Oct; 70(10):595-600 (9 ref.) (Eng. Abstr.) **(Jpn)**

[The influence of HIV infection on development of tuberculosis] Kwiatkowska S. **Pol Arch Med Wewn** 1995 May;93(5):421-6 (39 ref.) **(Pol)**

MICROBIOLOGY

Mycobacterial disease of the head and neck: current perspective. Cleary KR, et al. **Ann Otol Rhinol Laryngol** 1995 Oct;104(10 Pt 1):830-3 (22 ref.)

NURSING

Tuberculosis: what nurses need to know to help control the epidemic. Grimes DE, et al. **Nurs Outlook** 1995 Jul-Aug; 43(4):164-73 (20 ref.)

PATHOLOGY

The Koch phenomenon and the immunopathology of tuberculosis. Rook GA, et al. **Curr Top Microbiol Immunol** 1996;215:239-62 (112 ref.)

PREVENTION & CONTROL

New vaccines against tuberculosis. Silva CL. **Braz J Med Biol Res** 1995 Aug;28(8):843-51 (33 ref.)

Advancement of tuberculosis control and research in China. Yan B. **Chin Med J (Engl)** 1995 Aug;108(8):563-6 (11 ref.)

Prophylaxis for tuberculosis in Europe--ongoing research. Carosi G, et al. **Clin Infect Dis** 1996 Apr;22 Suppl 1:S55-60 (31 ref.)

Potential role of rifabutin in prophylaxis for tuberculosis and infections due to multiple opportunistic pathogens. Chaisson RE. **Clin Infect Dis** 1996 Apr;22 Suppl 1:S61-6; discussion S66-9 (51 ref.)

BCG against tuberculosis: 1996. Lenner R. **Conn Med** 1996 Jun;60(6):329-34 (67 ref.)

BCG immunization: review of past experience, current use, and future prospects. Brewer TF, et al. **Curr Clin Top Infect Dis** 1995;15:253-70 (94 ref.)

The protective immune response to Mycobacterium tuberculosis. Cooper AM, et al. **Curr Opin Immunol** 1995 Aug;7(4):512-6 (53 ref.)

BCG vaccination in the control of tuberculosis. Huebner RE. **Curr Top Microbiol Immunol** 1996;215:263-82 (103 ref.)

Tuberculosis. Phelan JA, et al. **Dent Clin North Am** 1996 Apr;40(2):327-41 (35 ref.)

Prevention and management of tuberculosis in HIV positive patients living in countries with a low prevalence of Mycobacterium tuberculosis. Brook MG, et al. **Genitourin Med** 1996 Apr;72(2):89-92 (34 ref.)

Hospital-acquired tuberculosis. deWit D. **Med J Aust** 1995 Oct 16;163(8):428-31 (43 ref.)

Tuberculosis: what nurses need to know to help control the epidemic. Grimes DE, et al. **Nurs Outlook** 1995 Jul-Aug; 43(4):164-73 (20 ref.)

Perspectives for the control of tuberculosis. Rosen H, et al. **Ther Immunol** 1995 Apr;2(2):105-13 (74 ref.)

Animal models of protective immunity in tuberculosis to evaluate candidate vaccines. Griffin JF, et al. **Trends Microbiol** 1995 Nov;3(11):418-24 (50 ref.)

Prospects for new vaccines against tuberculosis. Orme IM. **Trends Microbiol** 1995 Oct;3(10):401-4 (27 ref.)

BCG vaccination against tuberculosis: past disappointments and future hopes. Roche PW, et al. **Trends Microbiol** 1995 Oct;3(10):397-401 (34 ref.)

International union against tuberculosis and lung disease (IUATLD): initiatives in non-tuberculous lung disease. Becklake MR. **Tuber Lung Dis** 1995 Dec;76(6):493-504 (82 ref.)

[Tuberculosis in aged persons residing in Quebec facilities: are screening and chemoprophylaxis indicated? (see comments)] Marchand RS, et al. **Can J Public Health** 1995 Jul-Aug;86(4):238-42 (55 ref.) (Eng. Abstr.) Comment in: Can J Public Health 1995 Jul-Aug;86(4):221-3. **(Fre)**

[Variations in the degree of protection conferred by BCG: role and implications for heterologous immunity] Moren A. **Rev Epidemiol Sante Publique** 1996 Jun;44(3):290-2 (4 ref.) **(Fre)**

[Immunization against tuberculosis: new vaccination strategies or is there an alternative to BCG?] Kaufman SH. **Immun Infekt** 1995 Aug;23(4):119-24 (24 ref.) (Eng. Abstr.) **(Ger)**

RADIOGRAPHY

The resurgence of TB and its implications for radiology. Newman J. **Radiol Technol** 1996 May-Jun;67(5):379-96; quiz 397-400 (95 ref.)

TRANSMISSION

Community-based outbreaks of tuberculosis. Raffalli J, et al. **Arch Intern Med** 1996 May 27;156(10):1053-60 (83 ref.)

Tuberculosis. Phelan JA, et al. **Dent Clin North Am** 1996 Apr;40(2):327-41 (35 ref.)

Mycobactericidal testing of disinfectants: an update. Sattar SA, et al. **J Hosp Infect** 1995 Jun;30 Suppl:372-82 (37 ref.)

Hospital-acquired tuberculosis. deWit D. **Med J Aust** 1995 Oct 16;163(8):428-31 (43 ref.)

The zoonotic importance of Mycobacterium bovis. Moda G, et al. **Tuber Lung Dis** 1996 Apr;77(2):103-8 (33 ref.)

VETERINARY

The epidemiology of Mycobacterium bovis infections in animals and man: a review. O'Reilly LM, et al. **Tuber Lung Dis** 1995 Aug;76 Suppl 1:1-46 (362 ref.)

Feline tuberculosis: a literature review and discussion of 19 cases caused by an unusual mycobacterial variant. Gunn-Moore DA, et al. **Vet Rec** 1996 Jan 20;138(3):53-8 (38 ref.)

TUBERCULOSIS, BOVINE

EPIDEMIOLOGY

Epidemiology of Mycobacterium bovis infection in animals and humans, with particular reference to Africa. Cosivi O, et al. **Rev Sci Tech** 1995 Sep;14(3):733-46 (63 ref.)

TUBERCULOSIS, CUTANEOUS

Cutaneous tuberculosis. MacGregor RR. **Clin Dermatol** 1995 May-Jun;13(3):245-55 (45 ref.)

DIAGNOSIS

Detection of mycobacterial DNA in the skin. Etiologic insights and diagnostic perspectives. Degitz K. **Arch Dermatol** 1996 Jan;132(1):71-5 (58 ref.)

ETIOLOGY

Bilateral inguinal scrofuloderma during steroid therapy in a patient with bullous pemphigoid. Kawabata E, et al. **J Dermatol** 1995 Aug;22(8):582-6 (22 ref.)

TUBERCULOSIS, DRUG-RESISTANT see **TUBERCULOSIS, MULTIDRUG-RESISTANT**

TUBERCULOSIS, GASTROINTESTINAL

COMPLICATIONS

Massive rectal bleeding from colonic tuberculosis. Monkemuller KE, et al. **Am J Gastroenterol** 1996 Jul; 91(7):1439-41 (22 ref.)

Gastric tuberculosis presenting with massive hematemesis in association with acute myeloid leukemia. Quantrill SJ, et al. **Am J Gastroenterol** 1996 Jun;91(6):1259-60 (11 ref.)

Pulmonary acremonium abscesses and gastrointestinal tuberculosis manifested as massive upper gastrointestinal bleeding. Miró O, et al. **Nephrol Dial Transplant** 1995; 10(8):1444-6 (17 ref.)

TUBERCULOSIS, GASTROINTESTINAL

DIAGNOSIS

Gastrointestinal tuberculosis in renal transplantation: a case report and review. Ahsan N, et al. **Clin Transplant** 1995 Aug;9(4):349–52 (19 ref.)

Isolated sigmoid tuberculosis. Report of a case. Horvath KD, et al. **Dis Colon Rectum** 1995 Dec;38(12):1327–30 (8 ref.)

Does Crohn's disease need differentiation from tuberculosis? Jayanthi V, et al. **J Gastroenterol Hepatol** 1996 Feb; 11(2):183–6 (42 ref.)

TUBERCULOSIS, HEPATIC

[Tuberculosis and tuberculoma of the liver] Goto H, et al. **Ryofukibetsu Shokogun Shiriza** 1995;(7):79–81 (9 ref.) **(Jpn)**

TUBERCULOSIS, LYMPH NODE

DIAGNOSIS

Tuberculous inguinal lymphadenitis. Challapalli M, et al. **Pediatr Infect Dis J** 1995 Aug;14(8):723–4 (5 ref.)

[Problems in the diagnosis and therapy of lymph node tuberculosis in HIV-negative patients] Canova CR, et al. **Schweiz Med Wochenschr** 1995 Dec 26;125(51–52):2511–7 (24 ref.) (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

Mycobacterial disease of the head and neck: current perspective. Cleary KR, et al. **Ann Otol Rhinol Laryngol** 1995 Oct;104(10 Pt 1):830–3 (22 ref.)

ETIOLOGY

Bilateral inguinal scrofuloderma during steroid therapy in a patient with bullous pemphigoid. Kawabata E, et al. **J Dermatol** 1995 Aug;22(8):582–6 (22 ref.)

MICROBIOLOGY

Mycobacterial disease of the head and neck: current perspective. Cleary KR, et al. **Ann Otol Rhinol Laryngol** 1995 Oct;104(10 Pt 1):830–3 (22 ref.)

TUBERCULOSIS, MALE GENITAL

COMPLICATIONS

[Tuberculous prostatic abscess in a patient with AIDS] Duarte Ojeda JM, et al. **Actas Urol Esp** 1995 Sep; 19(8):655–61 (22 ref.) (Eng. Abstr.) **(Spa)**

TUBERCULOSIS, MENINGEAL

Central nervous system tuberculosis: medical management and surgical indications. Gropper MR, et al. **Surg Neurol** 1995 Oct;44(4):378–84; discussion 384–5 (33 ref.)

COMPLICATIONS

[Cerebrovascular manifestations of infectious diseases] Martínez Vázquez F, et al. **Rev Neurol** 1995;23 Suppl 1:S11–21 (88 ref.) **(Spa)**

DIAGNOSIS

Serological diagnosis of tuberculosis. Bothamley GH. **Eur Respir J Suppl** 1995 Sep;20:676s–688s (114 ref.)

[Applications of the polymerase chain reaction (PCR) to the diagnosis of central nervous system infections] Querol JM, et al. **An Med Interna** 1996 May;13(5):235–8 (20 ref.) (Eng. Abstr.) **(Spa)**

SURGERY

Intramedullary spinal cord abscess: case report. Tacconi L, et al. **Neurosurgery** 1995 Oct;37(4):817–9 (25 ref.)

TUBERCULOSIS, MILIARY

THERAPY

[Percutaneous catheter drainage of an unusually extensive tuberculous hypostatic abscess] Freund M, et al. **Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr** 1996 Jul;165(1):96–8 (11 ref.) **(Ger)**

TUBERCULOSIS, MULTIDRUG-RESISTANT

Multidrug-resistant tuberculosis. Lee SK, et al. **Ann Acad Med Singapore** 1995 May;24(3):442–6 (23 ref.)

Drug-resistant tuberculosis: mechanisms and management. Hayward CM, et al. **Br J Hosp Med** 1995 Nov 15–Dec 12;54(10):494–500 (24 ref.)

[Multidrug-resistant tuberculosis] Bouvet E. **Presse Med** 1996 Mar 2–9;25(8):393–8 (25 ref.) (Eng. Abstr.) **(Fre)**

[Multidrug-resistant tuberculosis. Epidemiology, treatment, prevention and diagnostic research] Perronne C, et al. **Rev Med Interne** 1995;16(7):547–52 (30 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

[Diagnosis of tuberculosis] Rüsch-Gerdes S. **Internist (Berl)** 1995 Oct;36(10):957–60 (20 ref.) **(Ger)**

DRUG THERAPY

The good news and the bad news about multidrug-resistant tuberculosis [editorial] Castro KG, et al. **Clin Infect Dis** 1995 Nov;21(5):1265–6 (16 ref.)

Drug-resistant tuberculosis. **Drug Ther Bull** 1995 Apr; 33(4):28–9 (25 ref.)

Drug resistance in Mycobacterium tuberculosis. Cole ST, et al. **Eur Respir J Suppl** 1995 Sep;20:701s–713s (116 ref.)

New drugs for tuberculosis. Grassi C, et al. **Eur Respir J Suppl** 1995 Sep;20:714s–718s (73 ref.)

Multi drug resistant tuberculosis. Dey AB, et al. **Trop Gastroenterol** 1995 Apr–Jun;16(2):92–100 (39 ref.)

[Renaissance of tuberculosis?] Meyer FJ, et al. **Internist (Berl)** 1995 Dec;36(12):1162–73 (80 ref.) **(Ger)**

[The problem of resistance in the treatment of Mycobacterium infections: new experimental results and combinations for the treatment of tuberculosis and leprosy] Seydel JK, et al. **Pharm Unserer Zeit** 1995 Nov; 24(6):313–23 (14 ref.) **(Ger)**

EPIDEMIOLOGY

Drug-resistant tuberculosis in the 1990s [see comments] Yew WW, et al. **Eur Respir J** 1995 Jul;8(7):1184–92 (103 ref.) Comment in: Eur Respir J 1995 Jul;8(7):1073–5.

"Tuberculosis". Aoki M. **J Epidemiol** 1996 Aug;6(3 Suppl):S75–9 (7 ref.)

Tuberculosis in London: a review, and an account of the work of the London Consultants in Communicable Disease Control Group Working Party. McEvoy M, et al. **J Hosp Infect** 1995 Jun;30 Suppl:296–305 (23 ref.)

The need for epidemic intelligence. Bloch AB, et al. **Public Health Rep** 1996 Jan–Feb;111(1):26–31; discussion 32–3 (57 ref.)

Escalating threat from tuberculosis: the third epidemic. Malin AS, et al. **Thorax** 1995 Sep;50 Suppl 1:S37–42 (38 ref.)

MICROBIOLOGY

Mycobacterial dormancy [editorial] Gangadharam PR. **Tuber Lung Dis** 1995 Dec;76(6):477–9 (24 ref.)

PREVENTION & CONTROL

Institutional control measures for tuberculosis in the era of multiple drug resistance. ACCP/ATS Consensus Conference. American College of Chest Physicians and the American Thoracic Society. **Chest** 1995 Dec; 108(6):1690–710 (143 ref.)

Multidrug-resistant tuberculosis: prevention is better than cure. Gilbert GL. **Med J Aust** 1996 Jan 15;164(2):121–4 (42 ref.)

Multidrug-resistant tuberculosis in the USA: the end of the beginning [editorial; comment] Nolan CM. **Tuber Lung Dis** 1996 Aug;77(4):293–4 (25 ref.) Comment on: Tuber Lung Dis 1996 Aug;77(4):315–21.

TUBERCULOSIS, OCULAR

Intraocular tuberculosis. Clinicopathologic study of five cases. Biswas J, et al. **Retina** 1995;15(6):461–8 (22 ref.)

TUBERCULOSIS, OSTEOARTICULAR

Mycobacterial and fungal infections of bone and joints. Meier JL, et al. **Curr Opin Rheumatol** 1995 Jul;7(4):329–36 (75 ref.)

Tuberculosis of bones and joints. Watts HG, et al. **J Bone Joint Surg Am** 1996 Feb;78(2):288–98 (92 ref.)

DIAGNOSIS

Prosthetic joint infection due to Mycobacterium tuberculosis: report of three cases. Tokumoto JI, et al. **Clin Infect Dis** 1995 Jul;21(1):134–6 (14 ref.)

[Extrapulmonary tuberculosis. An unusual case] Di Natale M, et al. **Minerva Med** 1995 Dec;86(12):555–7 (5 ref.) (Eng. Abstr.) **(Ita)**

SURGERY

Periprosthetic infections due to Mycobacterium tuberculosis in patients with no prior history of tuberculosis. Spinner RJ, et al. **J Arthroplasty** 1996 Feb;11(2):217–22 (46 ref.)

TUBERCULOSIS, PERITONEAL

ULTRASONOGRAPHY

[Diagnosis of a retroperitoneal BCG abscess in an infant. Case report and review of the literature] Stegmann J. **Ultraschall Med** 1996 Feb;17(1):27–30 (21 ref.) (Eng. Abstr.) **(Ger)**

TUBERCULOSIS, PULMONARY

see related

PNEUMONECTOMY

Drug-resistant tuberculosis: mechanisms and management. Hayward CM, et al. **Br J Hosp Med** 1995 Nov 15–Dec 12;54(10):494–500 (24 ref.)

Tuberculosis research—the way forward [editorial] Beyers AD, et al. **S Afr Med J** 1996 Jan;86(1):30–3 (24 ref.)

[From first symptom to diagnosis and from diagnosis to treatment of tuberculosis: still a long delay] Gulbaran Z, et al. **Rev Pneumol Clin** 1996;52(1):20–5 (23 ref.) (Eng. Abstr.) **(Fre)**

[Clinical comparison of pulmonary tuberculosis with pulmonary M. avium complex disease] Suzuki K. **Kekkaku** 1995 Nov;70(11):659–63 (4 ref.) (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

Surgical treatment of complications 45 years after extraperiosteal pneumonolysis and plombage using acrylic resin balls for cavitary pulmonary tuberculosis. Thomas GE, et al. **Chest** 1995 Oct;108(4):1163–4 (8 ref.)

Tuberculosis in drug users. Perlman DC, et al. **Clin Infect Dis** 1995 Nov;21(5):1253–64 (138 ref.)

Tuberculosis in patients infected with human immunodeficiency virus: perspective on the past decade. Shafer RW, et al. **Clin Infect Dis** 1996 Apr;22(4):683–704 (324 ref.)

Clinical problem solving in geriatric medicine: an older man with a pleural effusion. Berg J, et al. **J Am Geriatr Soc** 1996 Sep;44(9):1093–7 (41 ref.)

Anergy, AIDS and tuberculosis. Hegde HR. **Med Hypotheses** 1995 Nov;45(5):433–40 (48 ref.)

[Pulmonary infection due to Mycobacterium szulgai associated with multiple bullous disease of the lung] Mori K, et al. **Kekkaku** 1995 Sep;70(9):511–6 (12 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Outpatient management of tuberculosis [see comments] McColloster P, et al. **Am Fam Physician** 1996 Apr; 53(5):1579–94 (12 ref.) Comment in: Am Fam Physician 1996 Apr;53(5):1511–2.

New technology in the diagnosis of tuberculosis. Marshall BG, et al. **Br J Hosp Med** 1996 Apr 17–30;55(8):491–34 (25 ref.)

Quality standard for the identification and treatment of persons coinfected with human immunodeficiency virus and Mycobacterium tuberculosis. Phair JP, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S130–1 (4 ref.)

Diagnostic mycobacteriology laboratory practices. Shinnick TM, et al. **Clin Infect Dis** 1995 Aug;21(2):291–9 (56 ref.)

Tuberculosis in pregnancy: interactions, diagnosis, and management. Miller KS, et al. **Clin Obstet Gynecol** 1996 Mar;39(1):120–42 (87 ref.)

Serological diagnosis of tuberculosis. Bothamley GH. **Eur Respir J Suppl** 1995 Sep;20:676s–688s (114 ref.)

Molecular diagnosis of tuberculosis. Richeldi L, et al. **Eur Respir J Suppl** 1995 Sep;20:689s–700s (95 ref.)

Clinical problem solving in geriatric medicine: an older man with a pleural effusion. Berg J, et al. **J Am Geriatr Soc** 1996 Sep;44(9):1093–7 (41 ref.)

The lung in HIV infection: can pulmonary function testing help? Mitchell DM, et al. **Monaldi Arch Chest Dis** 1996 Jun;51(3):214–22 (30 ref.)

[Clinical aspects and therapy of ubiquitous mycobacterioses] Fätkenheuer G, et al. **Internist (Berl)** 1995 Oct; 36(10):987–94 (52 ref.) **(Ger)**

[Clinical aspects and therapy of tuberculosis] Höffken G, et al. **Internist (Berl)** 1995 Oct;36(10):961–9 (61 ref.) **(Ger)**

[Diagnosis of tuberculosis] Rüsch-Gerdes S. **Internist (Berl)** 1995 Oct;36(10):957–60 (20 ref.) **(Ger)**

[Pediatric tuberculosis in Germany. Current recommendations for diagnosis, prevention and therapy] Magdorf K, et al. **Med Klin** 1995 Oct 15;90(10):585–93 (54 ref.) **(Ger)**

[Molecular biological methods in the mycobacteriological laboratory—was 1995 a year of progress, problems or both?] Böttger EC, et al. **Pneumologie** 1995 Dec; 49(12):664–6 (19 ref.) **(Ger)**

[Mycobacteria and mycobacterioses] Böttger EC. **Pneumologie** 1995 Dec;49 Suppl 3:636–42 (18 ref.) (Eng. Abstr.) **(Ger)**

[Current status and diagnostic value of nucleic acid amplification and conventional methods in laboratory diagnosis of tuberculosis] Küchler R. **Pneumologie** 1996 Apr;50(4):323–6 (19 ref.) **(Ger)**

[Serologic and chromatographic methods of diagnosing tuberculosis] Krychniak-Soszka A. **Pneumonol Alergol Pol** 1996;64(1–2):106–10 (17 ref.) **(Pol)**

DRUG THERAPY

Outpatient management of tuberculosis [see comments] McColloster P, et al. **Am Fam Physician** 1996 Apr; 53(5):1579–94 (12 ref.) Comment in: Am Fam Physician 1996 Apr;53(5):1511–2.

The good news and the bad news about multidrug-resistant tuberculosis [editorial] Castro KG, et al. **Clin Infect Dis** 1995 Nov;21(5):1265–6 (16 ref.)

Use of rifabutin in the treatment of pulmonary tuberculosis. Grassi C, et al. **Clin Infect Dis** 1996 Apr;22 Suppl 1:S50–4 (21 ref.)

Quality standard for the identification and treatment of persons coinfected with human immunodeficiency virus and Mycobacterium tuberculosis. Phair JP, et al.

Clin Infect Dis 1995 Aug;21 Suppl 1:S130-1 (4 ref.)
Tuberculosis in pregnancy: interactions, diagnosis, and management. Miller KS, et al. **Clin Obstet Gynecol** 1996 Mar;39(1):120-42 (87 ref.)
Drug resistance in Mycobacterium tuberculosis. Cole ST, et al. **Eur Respir J Suppl** 1995 Sep;20:701s-713s (116 ref.)
New drugs for tuberculosis. Grassi C, et al. **Eur Respir J Suppl** 1995 Sep;20:714s-718s (73 ref.)
Present-day management of pulmonary tuberculosis. Kundu AK, et al. **J Indian Med Assoc** 1995 Apr;93(4):144-8 (2 ref.)
[Renaissance of tuberculosis?] Meyer FJ, et al. **Internist (Berl)** 1995 Dec;36(12):1162-73 (80 ref.) **(Ger)**
[Therapeutic approaches in diseases caused by mycobacteria] Urbanczik R. **Pneumologie** 1995 Dec;49 Suppl 3:649-52 (32 ref.) (Eng. Abstr.) **(Ger)**
[Therapy and prognosis of tuberculosis] Fischer B, et al. **Versicherungsmedizin** 1995 Dec 1;47(6):212-6 (12 ref.) (Eng. Abstr.) **(Ger)**

EPIDEMIOLOGY

Tuberculosis as an opportunistic disease in persons infected with human immunodeficiency virus. Castro KG. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S66-71 (71 ref.)
Drug-resistant tuberculosis in the 1990s [see comments] Yew WW, et al. **Eur Respir J** 1995 Jul;8(7):1184-92 (103 ref.) Comment in: Eur Respir J 1995 Jul;8(7):1073-5.
Epidemiology of tuberculosis in Europe. Rieder HL. **Eur Respir J Suppl** 1995 Sep;20:620s-632s (157 ref.)
Epidemiology of tuberculosis by DNA fingerprinting. van Soolingen D, et al. **Eur Respir J Suppl** 1995 Sep; 20:649s-656s (58 ref.)
"Tuberculosis". Aoki M. **J Epidemiol** 1996 Aug;6(3 Suppl):S75-9 (7 ref.)
Tuberculosis: current implications and management in obstetrics. Robinson CA, et al. **Obstet Gynecol Surv** 1996 Feb;51(2):115-24 (52 ref.)
Tuberculosis and HIV infection worldwide. Murray JF. **Pneumologie** 1995 Dec;49 Suppl 3:653-6 (22 ref.)
Current problems with tuberculosis treatment. Grosset J. **Res Microbiol** 1996 Jan-Feb;147(1-2):10-6 (32 ref.)
[Tuberculosis in France: how can the current epidemic be stopped? Conference of Experts on Tuberculosis, 15 December 1994, Paris] Bégué P, et al. **Rev Mal Respir** 1995; 12 Suppl 3:R132-57 (73 ref.) **(Fre)**
[HIV infection and tuberculosis] Brodt HR. **Internist (Berl)** 1995 Oct;36(10):970-9 (63 ref.) **(Ger)**
[Epidemiology of tuberculosis] Schlegel J, et al. **Internist (Berl)** 1995 Oct;36(10):951-6 (9 ref.) **(Ger)**
[Does AIDS influence the epidemiology of tuberculosis?] Ferlinz R, et al. **Pneumologie** 1995 Aug;49(8):449-54 (7 ref.) **(Ger)**
[Childhood tuberculosis in Spain (editorial)] Alcaide Megías J, et al. **Arch Bronconeumol** 1995 Oct;31(8):375-7 (31 ref.) **(Spa)**

ETIOLOGY

[Two complications of bullous emphysema. Apropos of a case] Guichenez P, et al. **Rev Pneumol Clin** 1995; 51(4):250-2 (14 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Functions of T-cell subsets and cytokines in mycobacterial infections. Munk ME, et al. **Eur Respir J Suppl** 1995 Sep; 20:668s-675s (91 ref.)
The role of T-cell subsets in Mycobacterium tuberculosis infection. Boom WH. **Infect Agents Dis** 1996 Mar; 5(2):73-81 (68 ref.)
Immunosuppression in tuberculosis. Ellner JJ. **Infect Agents Dis** 1996 Mar;5(2):62-72 (30 ref.)
Pulmonary immune response to Mycobacterium tuberculosis and human immunodeficiency virus. Rich EA. **Infect Agents Dis** 1996 Mar;5(2):108-18 (61 ref.)
Cytokine circuits in tuberculosis. Toossi Z. **Infect Agents Dis** 1996 Mar;5(2):98-107 (94 ref.)
Regulation of the human immune response in tuberculosis. Tsuyuguchi I. **Infect Agents Dis** 1996 Mar;5(2):82-97 (57 ref.)
Immunopathology of tuberculosis: roles of macrophages and monocytes. Fenton MJ, et al. **Infect Immun** 1996 Mar; 64(3):683-90 (95 ref.)
Anergy, AIDS and tuberculosis. Hegde HR. **Med Hypotheses** 1995 Nov;45(5):433-40 (48 ref.)
Infection, evolution and autoimmunity: a hypothesis. Jones DE, et al. **QJM** 1995 Dec;88(12):919-25 (56 ref.)
[Immunology of tuberculosis] Kaufmann SH. **Pneumologie** 1995 Dec;49 Suppl 3:643-8 (23 ref.) (Eng. Abstr.) **(Ger)**
[Macrophages and lymphocytes in immune reactions during the course of tuberculosis] Dubaniewicz A, et al. **Pneumonol Alergol Pol** 1995;63(7-8):469-73 (29 ref.) **(Pol)**

MICROBIOLOGY

Reactivation and exogenous reinfection: their relative roles in the pathogenesis of tuberculosis. Le HQ, et al. **Curr Clin Top Infect Dis** 1996;16:260-76 (67 ref.)
New approaches to identification of antigens of Mycobacterium tuberculosis. Wallis RS. **Infect Agents Dis** 1996 Mar;5(2):119-25 (70 ref.)

PREVENTION & CONTROL

Preventive therapy for tuberculosis in HIV infection: the promise and the reality [editorial] O'Brien RJ, et al. **AIDS** 1995 Jul;9(7):665-73 (83 ref.)
Nosocomial tuberculosis: new progress in control and prevention. McGowan JE Jr. **Clin Infect Dis** 1995 Sep; 21(3):489-505 (153 ref.)
Vaccination against tuberculosis. Lowrie DB, et al. **Int Arch Allergy Immunol** 1995 Dec;108(4):309-12 (25 ref.)
Tuberculosis: current implications and management in obstetrics. Robinson CA, et al. **Obstet Gynecol Surv** 1996 Feb;51(2):115-24 (52 ref.)
Tuberculosis control in South Africa--time for a new paradigm? [editorial] Wilkinson D, et al. **S Afr Med J** 1996 Jan;86(1):33-5 (19 ref.)
Use of BCG in high prevalence areas for HIV. Felten MK, et al. **Trop Med Parasitol** 1995 Jun;46(2):69-71 (30 ref.)

RADIOGRAPHY

CT of pulmonary tuberculosis. Im JG, et al. **Semin Ultrasound CT MR** 1995 Oct;16(5):420-34 (35 ref.)
The typically 'atypical' radiographic presentation of tuberculosis in advanced HIV disease [editorial] Daley CL. **Tuber Lung Dis** 1995 Dec;76(6):475-6 (18 ref.)
[Standard radiological characteristics of thoracic sites of tuberculosis in patients with AIDS in a Tunisian population] Tiouiri H, et al. **Rev Pneumol Clin** 1995; 51(6):321-4 (12 ref.) (Eng. Abstr.) **(Fre)**

RADIOTHERAPY

[Use of low-intensity lasers in tuberculosis] Kul'chavenia EV. **Probl Tuberk** 1995;(4):19-21 (38 ref.) **(Rus)**

SURGERY

Pulmonary artery reconstruction for tuberculosis. Cohen AS, et al. **Ann Thorac Surg** 1996 Apr;61(4):1257-9 (7 ref.)
Primary Epstein-Barr virus-related non-Hodgkin's lymphoma of the pleural cavity following long-standing tuberculous empyema. Molinie V, et al. **Arch Pathol Lab Med** 1996 Mar;120(3):288-91 (18 ref.)

TUBERCULOSIS, RENAL

ETIOLOGY

Tuberculosis in renal transplant units [editorial] Drobniewski FA, et al. **Nephrol Dial Transplant** 1996 May;11(5):768-70 (13 ref.)

TUBERCULOSIS, SPINAL

[Current aspects of spinal tuberculosis. Apropos of 10 cases] Souidi A, et al. **Rev Pneumol Clin** 1996;52(1):15-9 (36 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

Severe kyphotic deformity in tuberculosis of the spine. Tuli SM. **Int Orthop** 1995;19(5):327-31 (24 ref.)

DIAGNOSIS

Tuberculosis of the spine. Boachie-Adjei O, et al. **Orthop Clin North Am** 1996 Jan;27(1):95-103 (49 ref.)

RADIOGRAPHY

Tuberculosis of the cervical spine. Lukhele M. **S Afr Med J** 1996 May;86(5):553-6 (8 ref.)

SURGERY

Intramedullary spinal cord abscess: case report. Tacconi L, et al. **Neurosurgery** 1995 Oct;37(4):817-9 (25 ref.)

THERAPY

Tuberculosis of the spine. Boachie-Adjei O, et al. **Orthop Clin North Am** 1996 Jan;27(1):95-103 (49 ref.)

TUBERCULOSIS, UROGENITAL

DRUG THERAPY

[The therapeutic aspects of urogenital tuberculosis. Apropos of 86 cases] Bennani S, et al. **Prog Urol** 1995 Sep; 5(4):556-67 (73 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

[The therapeutic aspects of urogenital tuberculosis. Apropos of 86 cases] Bennani S, et al. **Prog Urol** 1995 Sep; 5(4):556-67 (73 ref.) (Eng. Abstr.) **(Fre)**

TUBERCULOSIS VACCINES see **BCG VACCINE**

TUBERCULOSTATIC AGENTS see **ANTITUBERCULAR AGENTS**

TUBEROUS SCLEROSIS

COMPLICATIONS

Tuberous sclerosis with a brain tumor. Chaudhary D, et al. **Indian Pediatr** 1995 Feb;32(2):235-8 (13 ref.)
[Neurocutaneous disorders with achromic spots. Tuberous sclerosis of Bourneville. Diagnostic criteria and follow-up protocol] Prats-Viñas JM. **Rev Neurol** 1996 Sep; 24(133):1056-9 (7 ref.) **(Spa)**

DIAGNOSIS

Familial bilateral periventricular nodular heterotopia mimics tuberous sclerosis. Jardine PE, et al. **Arch Dis Child** 1996 Mar;74(3):244-6 (13 ref.)
[Neurocutaneous disorders with achromic spots. Tuberous sclerosis of Bourneville. Diagnostic criteria and follow-up protocol] Prats-Viñas JM. **Rev Neurol** 1996 Sep; 24(133):1056-9 (7 ref.) **(Spa)**

PHYSIOPATHOLOGY

Lymphangioleiomyomatosis and tuberous sclerosis: where is the border? [editorial] Bonetti F, et al. **Eur Respir J** 1996 Mar;9(3):399-401 (19 ref.)

ULTRASONOGRAPHY

[Prenatal diagnosis of Bourneville-Pringle disease (cerebral tuberous sclerosis)] Stümpflen-Mauser I, et al. **Ultraschall Med** 1996 Feb;17(1):34-7 (16 ref.) (Eng. Abstr.) **(Ger)**

TUBULIN

Evolution of a dynamic cytoskeleton. Mitchison TJ. **Philos Trans R Soc Lond B Biol Sci** 1995 Sep 29; 349(1329):299-304 (18 ref.)

BIOSYNTHESIS

Tubulin expression and axonal transport in injured and regenerating neurons in the adult mammalian central nervous system. Fournier AE, et al. **Biochem Cell Biol** 1995 Sep-Oct;73(9-10):659-64 (39 ref.)
Production and utilization of detyrosinated tubulin in developing Artemia larvae: evidence for a tubulin-reactive carboxypeptidase. Xiang H, et al. **Biochem Cell Biol** 1995 Sep-Oct;73(9-10):673-85 (82 ref.)

CHEMISTRY

A new point of view on the problem of G-protein aggregation. Assembly-disassembly of tubulin as an oscillation process. Tulub AA, et al. **Biochem Mol Biol Int** 1995 Jul;36(3):475-82 (20 ref.)
Identification of two new members of the tubulin family. Burns RG. **Cell Motil Cytoskeleton** 1995;31(4):255-8 (10 ref.)

DRUG EFFECTS

Antimitotic natural products and their interactions with tubulin. Hamel E. **Med Res Rev** 1996 Mar;16(2):207-31 (143 ref.)
Paclitaxel: a unique tubulin interacting anticancer agent. Vyas DM, et al. **Prog Med Chem** 1995;32:289-337 (301 ref.)

METABOLISM

Effects of taxol on the polymerization and posttranslational modification of class III beta-tubulin in P19 embryonal carcinoma cells. Laferrière NB, et al. **Biochem Cell Biol** 1995 Sep-Oct;73(9-10):687-94 (36 ref.)
Chaperonin-mediated folding of actin and tubulin. Lewis SA, et al. **J Cell Biol** 1996 Jan;132(1-2):1-4 (32 ref.)

TUBULOINTERSTITIAL NEPHRITIS see **NEPHRITIS, INTERSTITIAL**

TULAREMIA

EPIDEMIOLOGY

[Tularemia occurs in the whole country. A good year for rodents prepares the ground for an epidemic] Bäck E. **Lakartidningen** 1995 Oct 11;92(41):3790-3 (14 ref.) **(Swe)**

MICROBIOLOGY

[Francisella tularensis persistence in the body of highly sensitive animals] Shlygina KN. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Mar-Apr; (2):110-2 (34 ref.) **(Rus)**

TUMESCENCE, PENILE see **PENILE ERECTION**

TUMOR ANTIBODIES see **ANTIBODIES, NEOPLASM**

TUMOR ANTIGENS see **ANTIGENS, NEOPLASM**

TUMOR-ASSOCIATED CARBOHYDRATE ANTIGENS see **ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE**

TUMOR AUTOCRINE MOTILITY FACTOR see **AUTOCRINE MOTILITY FACTOR**

TUMOR CELLS, CULTURED

see related
DRUG SCREENING ASSAYS, ANTITUMOR

The SKM-1 leukemic cell line established from a patient with progression to myelomonocytic leukemia in myelodysplastic syndrome (MDS)–contribution to better understanding of MDS. Nakagawa T, et al. **Leuk Lymphoma** 1995 Apr;17(3–4):335–9 (63 ref.)

DRUG EFFECTS

Structure–activity–relationship studies on modulators of the multidrug transporter P-glycoprotein—an overview. Ecker G, et al. **Wien Klin Wochenschr** 1995;107(22):681–6 (51 ref.)

[Combined effect of Paclitaxel and ionizing radiation. Experimental data of in-vitro and in-vivo models] Rübe C, et al. **Strahlenther Onkol** 1996 May;172 Suppl 1:2–5 (30 ref.) **(Ger)**

[The ribonucleotide reductase enzyme as a target for enzyme-directed chemotherapy effects of trimidox (3,4,5-trihydroxybenzohydroxamidoxim), a new inhibitor of ribonucleotide reductases] Findenig G, et al. **Wien Klin Wochenschr** 1995;107(22):694–7 (28 ref.) (Eng. Abstr.) **(Ger)**

PATHOLOGY

The development of a functionally relevant cell culture model of progressive human breast cancer. Weaver VM, et al. **Semin Cancer Biol** 1995 Jun;6(3):175–84 (56 ref.)

PHYSIOLOGY

Hepatocyte growth factor in lung morphogenesis and tumor invasion: role as a mediator in epithelium–mesenchyme and tumor–stroma interactions. Matsumoto K, et al. **Cancer Chemother Pharmacol** 1996;38 Suppl:S42–7 (36 ref.)

RADIATION EFFECTS

[Combined effect of Paclitaxel and ionizing radiation. Experimental data of in-vitro and in-vivo models] Rübe C, et al. **Strahlenther Onkol** 1996 May;172 Suppl 1:2–5 (30 ref.) **(Ger)**

TUMOR CELLS, EMBOLIC see **NEOPLASM CIRCULATING CELLS**

TUMOR-DERIVED ACTIVATED CELLS see **LYMPHOCYTES, TUMOR-INFILTRATING**

TUMOR ESCAPE

see related
ANTIGENIC MODULATION
IMMUNE TOLERANCE

TUMOR-INFILTRATING LYMPHOCYTES see **LYMPHOCYTES, TUMOR-INFILTRATING**

TUMOR INITIATORS see **CARCINOGENS**

TUMOR LYSIS SYNDROME

see related
TUMOR NECROSIS FACTOR

[The tumor lysis syndrome] Barreiro G, et al. **Rev Clin Esp** 1996 May;196(5):310–2 (41 ref.) **(Spa)**

ETIOLOGY

Tumor lysis syndrome induced by fludarabine monophosphate: a case report [letter] Nakhoul F, et al. **Eur J Haematol** 1996 Apr;56(4):254–5 (12 ref.)

TUMOR MARKERS, BIOCHEMICAL see **TUMOR MARKERS, BIOLOGICAL**

TUMOR MARKERS, BIOLOGICAL

Evidence from cancer intervention and biomarker studies and the development of biochemical markers. Bowen PE, et al. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1403S–1409S (54 ref.)

Can molecular markers now be used for early diagnosis of malignancy? Duffy MJ. **Clin Chem** 1995 Oct;41(10):1410–3 (38 ref.)

Tumor antigens in astrocytic gliomas. Kurpad SN, et al. **Glia** 1995 Nov;15(3):244–56 (105 ref.)

Statistical considerations and modeling of clinical utility of tumor markers. George SL. **Hematol Oncol Clin North Am** 1994 Jun;8(3):457–70 (45 ref.)

Tumor markers for breast cancer. Current utilities and future prospects. Hayes DF. **Hematol Oncol Clin North Am** 1994 Jun;8(3):485–506 (114 ref.)

Intermediate cancer biomarkers and their use in beta-carotene studies in humans. Gerster H. **Int J Vitam Nutr Res** 1996;66(1):3–18 (83 ref.)

Prostatic intraepithelial neoplasia and other changes during promotion and progression. Pretlow TG, et al. **Pathol Res Pract** 1995 Sep;191(9):842–9 (49 ref.)

Characteristics of invasive bladder cancers: histological and molecular markers. Liebert M, et al. **Semin Urol Oncol** 1996 May;14(2):62–72 (136 ref.)

Biologic indicators of exposure: are markers associated with oncogenesis useful as biologic markers of effect? Ziegler BL, et al. **Stem Cells (Dayt)** 1995 May;13 Suppl 1:326–38 (151 ref.)

[Contribution of biology to the therapeutic decision: cancer of the breast in 1995] Chinot O, et al. **Bull Cancer Radiother** 1995;82(2):225–37 (62 ref.) **(Fre)**

[Application of tumor marker for immunotargeting therapy of cancer] Yamaguchi T, et al. **Nippon Rinsho** 1996 Jun; 54(6):1674–9 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Prospects of early immunocytochemical diagnosis in periampullary tumors (a review of foreign literature)] Kubyshkin VA, et al. **Khirurgiia (Mosk)** 1995;(6):50–2 (42 ref.) **(Rus)**

[Angiogenesis—a marker for metastases] Sköldenberg E, et al. **Lakartidningen** 1996 May 8;93(19):1853–5 (24 ref.) **(Swe)**

ANALYSIS

Molecular analysis of premalignant and carcinoma in situ lesions of the human breast. Steeg PS, et al. **Am J Pathol** 1996 Sep;149(3):733–8 (49 ref.)

Oncogene products and other diagnostic markers in human breast cancer patients. Treatment effects and their significance. Dowsett M, et al. **Ann N Y Acad Sci** 1996 Apr 30;784:403–11 (11 ref.)

Dynamic use of tumor markers, rationale-clinical applications and pitfalls. Gion M, et al. **Anticancer Res** 1996 Jul–Aug;16(4B):2279–84 (61 ref.)

Tumor markers as targets for selective diagnostic and therapeutic procedures. Roselli M, et al. **Anticancer Res** 1996 Jul–Aug;16(4B):2187–92 (59 ref.)

Clinical applications of urinary gonadotropin peptides (UGP) in gynecologic oncology. Schwartz PE, et al. **Anticancer Res** 1996 Jul–Aug;16(4B):2135–9 (35 ref.)

A simple mucus test for cancer screening. Shamsuddin AM. **Anticancer Res** 1996 Jul–Aug;16(4B):2193–9 (57 ref.)

Tumour markers: from laboratory to clinical use. Torre GC, et al. **Anticancer Res** 1996 Jul–Aug;16(4B):2215–9 (16 ref.)

College of American Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors. Report of the Colorectal Cancer Working Group. Fielding LP, et al. **Arch Pathol Lab Med** 1995 Dec;119(12):1115–21 (58 ref.)

College of American Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors. Report of the Prostate Cancer Working Group. Grignon DJ, et al. **Arch Pathol Lab Med** 1995 Dec;119(12):1122–6 (79 ref.)

College of American Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors. Summary. Members of the Cancer Committee. Henson DE, et al. **Arch Pathol Lab Med** 1995 Dec;119(12):1109–12 (10 ref.)

Growth factors: potential for the management of solid epithelial tumours. Jankowski JA. **Baillieres Clin Gastroenterol** 1996 Mar;10(1):165–79 (64 ref.)

Breast cancer: the search for new prognostic markers. Davis AR. **Br J Biomed Sci** 1996 Jun;53(2):157–61 (20 ref.)

Immunocytochemistry in the diagnosis of Kaposi's sarcoma and angiosarcoma. Orchard GE, et al. **Br J Biomed Sci** 1995 Mar;52(1):35–49 (145 ref.)

Immunohistochemical markers in uterine tumour diagnostics. Danihel L, et al. **Bratisl Lek Listy** 1995 Jul;96(7):353–60 (43 ref.) **(Eng, Slo)**

Chemoprevention trials and surrogate end point biomarkers in the cervix. Mitchell MF, et al. **Cancer** 1995 Nov 15;76(10 Suppl):1956–77 (227 ref.)

Diagnosis and reversal of multidrug resistance in paediatric cancers. Chan HS, et al. **Eur J Cancer** 1996 Jun; 32A(6):1051–61 (153 ref.)

Prognostic value of plasminogen activators and their inhibitors in colorectal cancer. Verspaget HW, et al. **Eur J Cancer** 1995 Jul–Aug;31A(7–8):1105–9 (28 ref.)

Hereditary and environmental risk factors; clinical and laboratory risk matters for head and neck, especially oral, cancer and precancer. Johnson NW, et al. **Eur J Cancer Prev** 1996 Feb;5(1):5–17 (139 ref.)

Molecular and biological factors in the prognosis of non-small cell lung cancer. Kanters SD, et al. **Eur Respir J** 1995 Aug;8(8):1389–97 (89 ref.)

Proliferation markers. Iatropoulos MJ, et al. **Exp Toxicol Pathol** 1996 Feb;48(2–3):175–81 (31 ref.)

Interference by human antibodies with tumor marker assays. Reinsberg J. **Hybridoma** 1995 Apr;14(2):205–8 (30 ref.)

The immunodiagnosis of Hodgkin's disease [editorial] Carbone A, et al. **Int J Biol Markers** 1996 Jan–Mar; 11(1):1–5 (36 ref.)

Correlation between pS2 protein positivity, steroid receptor status and other prognostic factors in breast cancer. Racca S, et al. **Int J Biol Markers** 1995 Apr–Jun;10(2):87–93 (35 ref.)

Potential criteria for cohort selection in chemoprevention trials of uterine adenocarcinoma. Baker VV. **J Cell Biochem Suppl** 1995;23:184–8 (32 ref.)

Biomarkers in the ovary. Berchuck A. **J Cell Biochem Suppl** 1995;23:223–6 (20 ref.)

Biomarkers in the endometrium. Berchuck A. **J Cell Biochem Suppl** 1995;23:174–8 (32 ref.)

A phase II chemoprevention trial design to identify surrogate endpoint biomarkers in breast cancer. Dhingra K. **J Cell Biochem Suppl** 1995;23:19–24 (27 ref.)

Strategies for phase II cancer chemoprevention trials: cervix, endometrium, and ovary. Kelloff GJ, et al. **J Cell Biochem Suppl** 1995;23:1–9 (51 ref.)

Surrogate endpoint biomarkers for cervical cancer chemopreventive trials. Ruffin MT 4th, et al. **J Cell Biochem Suppl** 1995;23:113–24 (98 ref.)

Role of the pathologist in biomarker studies. Wilkinson EJ, et al. **J Cell Biochem Suppl** 1995;23:10–8 (29 ref.)

Anti-Thomsen-Friedenreich (T) antibody and its application to human breast carcinoma: where are we after 20 years? [editorial; comment] McCarty KS Jr. **J Immunol Methods** 1995 Dec 27;188(2):171–3 (7 ref.) Comment on: J Immunol Methods 1995 Dec 27;188(2):175–85.

CD44: physiological expression of distinct isoforms as evidence for organ-specific metastasis formation. Zöller M. **J Mol Med** 1995 Sep;73(9):425–38 (265 ref.)

Immunohistochemistry in the differential diagnosis of soft tissue tumors. Brooks JS. **Monogr Pathol** 1996;38:65–128 (456 ref.)

Proliferation markers as a tool in oncological neuropathology. Tauš V. **Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove** 1995;38(4):145–65 (144 ref.)

Radioimmunoguided Surgery system improves survival for patients with recurrent colorectal cancer. Bertsch DJ, et al. **Surgery** 1995 Oct;118(4):634–8; discussion 638–9 (9 ref.)

New prognostic factors in resectable non-small cell lung cancer. Smit EF, et al. **Thorax** 1996 Jun;51(6):638–46 (95 ref.)

The 1993 ISOBM Abbott Award Lecture. Isozymes, tumor markers and oncodevelopmental biology. Fishman WH. **Tumour Biol** 1995;16(6):394–402 (58 ref.)

[Primary angiosarcoma of the thyroid. Presentation of a case (epithelioid type) and nosological problems] Bisceglia M, et al. **Pathologica** 1995 Apr;87(2):154–61 (49 ref.) (Eng. Abstr.) **(Ita)**

[Clinical implication of tumor marker expressions suggesting biological characters of m...gnancies] Ariyoshi Y, et al. **Nippon Rinsho** 1996 Jun;54(6):1568–73 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Role of tumor marker in the presymptomatic diagnosis of hereditary malignant tumors] Baba S, et al. **Nippon Rinsho** 1996 Jun;54(6):1597–603 (13 ref.) (Eng. Abstr.) **(Jpn)**

[Usefulness and limitation of serum tumor markers in diagnosis of lung cancer] Fukuda M, et al. **Nippon Rinsho** 1996 Jun;54(6):1610–5 (13 ref.) (Eng. Abstr.) **(Jpn)**

[Selection of drugs for chemotherapy based on drug resistance marker] Fukumoto H, et al. **Nippon Rinsho** 1996 Jun;54(6):1680–4 (28 ref.) (Eng. Abstr.) **(Jpn)**

[Expression of EGF receptor subfamily in tumor] Gamou S, et al. **Nippon Rinsho** 1996 Jun;54(6):1521–8 (29 ref.) (Eng. Abstr.) **(Jpn)**

[Biological function of cancer-associated carbohydrate antigens] Kannagi R. **Nippon Rinsho** 1996 Jun;54(6):1551–9 (33 ref.) (Eng. Abstr.) **(Jpn)**

[Gynecologic malignancies] Kato H. **Nippon Rinsho** 1996 Jun;54(6):1637–41 (12 ref.) (Eng. Abstr.) **(Jpn)**

[Current advancement of assay of tumor markers and the perspective in future] Kawamura T. **Nippon Rinsho** 1996 Jun;54(6):1642–8 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Clinical application of oncogene and antioncogene as a tumor marker] Kondo H, et al. **Nippon Rinsho** 1996 Jun; 54(6):1494–8 (7 ref.) (Eng. Abstr.) **(Jpn)**

[Tumor markers in urological malignancies] Kuriyama M. **Nippon Rinsho** 1996 Jun;54(6):1631–6 (23 ref.) (Eng. Abstr.) **(Jpn)**

[Molecular microheterogeneity of tumor marker substances and its significance of biological recognition] Kuwabara M, et al. **Nippon Rinsho** 1996 Jun;54(6):1580–6 (17 ref.) (Eng. Abstr.) **(Jpn)**

[Enzyme immunoassay (EIA) as an assay system of tumor markers] Kuwabara M, et al. **Nippon Rinsho** 1995 Sep; 53(9):2256–61 (17 ref.) (Eng. Abstr.) **(Jpn)**

[How to determine the best combination assay by several tumor markers?] Matsunaga T, et al. **Nippon Rinsho** 1996 Jun;54(6):1654–8 (5 ref.) (Eng. Abstr.) **(Jpn)**

[Historical aspect and present status of tumor marker studies] Matsuoka Y. **Nippon Rinsho** 1996 Jun;54(6):1479–85 (5 ref.) **(Jpn)**

[Sensitivity and specificity of tumor markers in cancer diagnosis] Motoo Y, et al. **Nippon Rinsho** 1996 Jun; 54(6):1587–91 (14 ref.) (Eng. Abstr.) **(Jpn)**

[Leukocyte surface antigen] Nakahara K. **Nippon Rinsho** 1996 Jun;54(6):1536–41 (8 ref.) (Eng. Abstr.) **(Jpn)**

[Applications of tumor markers to the screening of endometrial and ovarian cancers] Nozawa S, et al. **Nippon Rinsho** 1996 Jun;54(6):1665–73 (19 ref.) (Eng. Abstr.) **(Jpn)**

[Peptide hormone] Ohnami S, et al. **Nippon Rinsho** 1996 Jun; 54(6):1510–4 (15 ref.) (Eng. Abstr.) **(Jpn)**

[Isoenzyme] Ohta H, et al. **Nippon Rinsho** 1996 Jun; 54(6):1505–9 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Tumor markers in lymphoproliferative disorders] Ohtsu T. **Nippon Rinsho** 1996 Jun;54(6):1621–5 (16 ref.) (Eng. Abstr.) **(Jpn)**

[Viral tumor markers] Ohtsuru A, et al. **Nippon Rinsho** 1996 Jun;54(6):1529–35 (18 ref.) (Eng. Abstr.) **(Jpn)**

[Amines and pteridines] Shimpo K, et al. **Nippon Rinsho** 1996

Jun;54(6):1515–20 (22 ref.) (Eng. Abstr.) **(Jpn)**
[Tumor markers: neoplasmas in digestive organs] Takami H, et al. **Nippon Rinsho** 1996 Jun;54(6):1616–20 (5 ref.) (Eng. Abstr.) **(Jpn)**
[Organ specificity of tumor markers and its application for clinical diagnosis] Watanabe N. **Nippon Rinsho** 1996 Jun; 54(6):1592–6 (6 ref.) (Eng. Abstr.) **(Jpn)**
[Detection of tumor markers by genetic diagnostic methods and its clinical application] Yamamoto H, et al. **Nippon Rinsho** 1996 Jun;54(6):1574–9 (19 ref.) (Eng. Abstr.) **(Jpn)**
[Assessment of response to chemotherapy by tumor marker in solid neoplasms] Yoshimoto M, et al. **Nippon Rinsho** 1996 Jun;54(6):1685–9 (12 ref.) (Eng. Abstr.) **(Jpn)**
[Gallbladder carcinoma producing CEA, AFP, CA19–9, sialyl SSEA and CSF] Tanigawa N. **Ryoikibetsu Shokogun Shirizu** 1996;(9):237–9 (7 ref.) **(Jpn)**
[Glutathione S-transferase as a metabolic biomarker for predisposition to lung neoplasms induced by chemical carcinogens] Lutz W, et al. **Med Pr** 1995;46(5):497–503 (14 ref.) (Eng. Abstr.) **(Pol)**
[Cyfra 21-1—new marker for lung cancer] Luczak E, et al. **Pneumonol Alergol Pol** 1996;64(1–2):96–101 (19 ref.) (Eng. Abstr.) **(Pol)**
[The clinical prospects for the study of epidermal growth factor receptors in human tumors] Kushpinskiĭ NE, et al. **Klin Lab Diagn** 1996 Jan–Feb;(1):9–12 (20 ref.) **(Rus)**

ANTAGONISTS & INHIBITORS

Butyrate and markers of neoplastic change in the colon. Johnson IT. **Eur J Cancer Prev** 1995 Oct;4(5):365–71 (64 ref.)

BIOSYNTHESIS

Early metastasis of human solid tumours: expression of cell adhesion molecules. Pantel K, et al. **Ciba Found Symp** 1995; 189:157–70; discussion 170–3, 174–6 (62 ref.)
The role of CD44 splice variants in human metastatic cancer. Sleeman J, et al. **Ciba Found Symp** 1995;189:142–51; discussion 151–6, 174–6 (43 ref.)
[Alpha-fetoprotein producing hepatocellular carcinoma, AT-III producing hepatocellular carcinoma] Nakamura K, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):265–8 (11 ref.) **(Jpn)**

BLOOD

Tumor markers in breast cancer follow-up: a potentially useful parameter still awaiting definitive assessment. Forza Operativa Nazionale sul Carcinoma Mammario (FONCaM). Gion M, et al. **Ann Oncol** 1995;6 Suppl 2:31–5 (24 ref.)
Does the assessment of serum markers in patients with lung cancer aid in the clinical decision making process? Ebert W, et al. **Anticancer Res** 1996 Jul–Aug;16(4B):2161–8 (27 ref.)
Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection. Berek JS, et al. **Cancer** 1995 Nov 15;76(10 Suppl):2092–6 (25 ref.)
Ovarian cancer screening. van Nagell JR Jr, et al. **Cancer** 1995 Nov 15;76(10 Suppl):2086–91 (27 ref.)
The use of prognostic markers in surgery for colorectal cancer. Northover J. **Eur J Cancer** 1995 Jul–Aug; 31A(7–8):1207–9 (36 ref.)
Glycoforms of serum alpha 1-acid glycoprotein as markers of inflammation and cancer. Mackiewicz A, et al. **Glycoconj J** 1995 Jun;12(3):241–7 (43 ref.)
The use of serologic tumor markers in gastrointestinal malignancies. Posner MR, et al. **Hematol Oncol Clin North Am** 1994 Jun;8(3):533–53 (87 ref.)
Tumor markers in the diagnosis, monitoring and therapy of pancreatic cancer: state of the art. Plebani M, et al. **Int J Biol Markers** 1995 Oct–Dec;10(4):189–99 (95 ref.)
Tumor markers. An update. Pamies RJ, et al. **Med Clin North Am** 1996 Jan;80(1):185–99 (81 ref.)
The c-erbB transmembrane growth factor receptors as serum biomarkers in human cancer studies. Brandt-Rauf PW. **Mutat Res** 1995 Dec;333(1–2):203–8 (25 ref.)
How to integrate serum tumor markers into clinical oncologic practice. van Dalen A. **Nutrition** 1995 Sep–Oct;11(5 Suppl):489–91 (21 ref.)
Serum (circulating) tumor markers for breast cancer. Hayes DF. **Recent Results Cancer Res** 1996;140:101–13 (52 ref.)
Clinical applications of serum markers for lung cancer. Ferrigno D, et al. **Respir Med** 1995 Oct;89(9):587–97 (158 ref.)
[Screening of undifferentiated carcinoma of the nasopharynx] Sasco AJ. **Bull Cancer (Paris)** 1996 May;83(5):344–51 (70 ref.) (Eng. Abstr.) **(Fre)**
[Early diagnosis of hepatocellular carcinoma by serum AFP and PIVKA-II analysis] Aoyagi Y, et al. **Nippon Naika Gakkai Zasshi** 1995 Dec 10;84(12):2003–7 (5 ref.) **(Jpn)**
[Cut-off values and grey-zone of tumor markers in blood] Takagi Y, et al. **Nippon Rinsho** 1996 Jun;54(6):1649–53 (5 ref.) (Eng. Abstr.) **(Jpn)**
[The role of serum markers in diagnosis and treatment monitoring in patients with lung cancer] Jassem E, et al. **Przegl Lek** 1995;52(8):392–4 (22 ref.) **(Pol)**
[Tumor markers in gynecology] Alekseeva ML, et al. **Akush Ginekol (Mosk)** 1995;(5):35–7 (30 ref.) **(Rus)**
[Clinical usefulness of the new criteria based on the serum quantification of prostate-specific antigen in the early diagnosis of prostatic cancer (editorial)] Morote Robles J. **Actas Urol Esp** 1996 Jan;20(1):1–12 (71 ref.) **(Spa)**

CHEMISTRY

The use of tumor markers in germ cell malignancies. Bosl GJ, et al. **Hematol Oncol Clin North Am** 1994 Jun; 8(3):573–87 (86 ref.)
Use of tumor markers in lung cancer. Strauss GM, et al. **Hematol Oncol Clin North Am** 1994 Jun;8(3):507–32 (109 ref.)
Altered glycoprotein sugar-chain structures as possible diagnostic and prognostic markers in malignant tumors. Yoshida K, et al. **Int J Urol** 1995 Nov;2(5):281–7 (53 ref.)
[Molecular microheterogeneity of tumor marker substances and its significance of biological recognition] Kuwabara M, et al. **Nippon Rinsho** 1996 Jun;54(6):1580–6 (17 ref.) (Eng. Abstr.) **(Jpn)**

CLASSIFICATION

Classification of tumor markers. Suresh MR. **Anticancer Res** 1996 Jul–Aug;16(4B):2273–7 (15 ref.)
[Definition and classification of tumor marker] Ishii M. **Nippon Rinsho** 1996 Jun;54(6):1473–8 (7 ref.) **(Jpn)**

GENETICS

Biomarkers: a molecular approach to cancer epidemiology. Shi CY, et al. **Ann Acad Med Singapore** 1996 Jan; 25(1):49–54 (41 ref.)
Molecular genetic tumor markers in the early diagnosis and screening of non-small-cell lung cancer. Jacobson DR, et al. **Ann Oncol** 1995;6 Suppl 3:S3–8 (44 ref.)
Detection of chromosomal translocations in leukemia-lymphoma cells by polymerase chain reaction. Drexler HG, et al. **Leuk Lymphoma** 1995 Nov; 19(5–6):359–80 (278 ref.)
[Regulation of tumor marker gene expression] Sakai M, et al. **Nippon Rinsho** 1996 Jun;54(6):1560–7 (26 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

[Serum tumor markers in the diagnosis of cancer of unknown primary site] Cohen AD, et al. **Harefuah** 1995 Oct; 129(7–8):279–82 (31 ref.) **(Heb)**

METABOLISM

Some tumor cell protein kinases activated by receptors as markers, including elastin receptors. Parsons DF. **Cancer Invest** 1995;13(6):629–36 (61 ref.)
MDR1 gene expression: evaluation of its use as a molecular marker for prognosis and chemotherapy of bone and soft tissue sarcomas. Stein U, et al. **Eur J Cancer** 1996 Jan; 32A(1):86–92 (82 ref.)
Cathepsin D and breast cancer [see comments] Westley BR, et al. **Eur J Cancer** 1996 Jan;32A(1):15–24 (78 ref.) Comment in: Eur J Cancer 1996 Jan;32A(1):7–8.
p53 overexpression in head and neck squamous cell carcinoma: review of the literature. Raybaud-Diogène H, et al. **Eur J Cancer B Oral Oncol** 1996 May;32B(3):143–9 (66 ref.)
Marker rhythms for cancer chronotherapy. From laboratory animals to human beings. Focan C. **In Vivo** 1995 Jul–Aug; 9(4):283–98 (113 ref.)
Nuclear p53 overexpression is an independent prognostic parameter in node-negative non-small cell lung carcinoma. Dalquen P, et al. **J Pathol** 1996 Jan;178(1):53–8 (41 ref.)
Tumor-induced changes in host metabolism: a possible marker of neoplastic disease. Rossi Fanelli F, et al. **Nutrition** 1995 Sep–Oct;11(5 Suppl):595–600 (56 ref.)
Intermediate biomarkers in the colorectal tumor progression. Risio M, et al. **Tumori** 1995 May–Jun;81(3 Suppl):16–8 (19 ref.)

URINE

Beta-core fragment (beta-core/UGF/UGP), a tumor marker: a 7-year report. Cole LA, et al. **Gynecol Oncol** 1996 Feb;60(2):264–70 (38 ref.)

TUMOR NECROSIS FACTOR

Tumor necrosis factors: developments during the last decade. Aggarwal BB, et al. **Eur Cytokine Netw** 1996 Apr–Jun; 7(2):93–124 (334 ref.)

ANALYSIS

Tumor necrosis factor-alpha and the failing human heart. Oral H, et al. **Clin Cardiol** 1995 Sep;18(9 Suppl 4):IV20–7 (71 ref.)
[Tumor necrosis factor (TNF)] Watanabe N. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:767–70 (15 ref.) **(Jpn)**

ANTAGONISTS & INHIBITORS

Anti-cytokine therapy in rheumatoid arthritis. Elliott MJ, et al. **Baillieres Clin Rheumatol** 1995 Nov;9(4):633–52 (81 ref.)
Anticytokine strategies for the treatment of septic shock: relevance of animal models. Heumann D, et al. **Curr Top Microbiol Immunol** 1996;216:299–311 (38 ref.)
Multiple sclerosis: TNF revisited, with promise [comment] Raine CS. **Nat Med** 1995 Mar;1(3):211–4 (28 ref.) Comment on: Nat Med 1995 Mar;1(3):244–8.

BIOSYNTHESIS

Inhibition of lipopolysaccharide-induced TNF-alpha production by semisynthetic polymyxin-B conjugated dextran. Coyne CP, et al. **Biotechnol Ther** 1994–95; 5(3–4):137–62 (108 ref.)
Tumor necrosis factor in glomerular injury. Ardaillou R, et al. **Contrib Nephrol** 1996;118:59–67 (30 ref.)
Lipopolysaccharide signal transduction, regulation of tumor necrosis factor biosynthesis, and signaling by tumor necrosis factor itself. Beutler B, et al. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S1–8 (65 ref.)
n-3 polyunsaturated fatty acids and human cytokine synthesis. Endres S. **Lipids** 1996 Mar;31 Suppl:S239–42 (19 ref.)
Controlling the production of interleukin-1 and tumor necrosis factor in disease. Dinarello CA. **Nutrition** 1995 Sep–Oct;11(5 Suppl):695–7 (18 ref.)
[Regulation of interleukin 6 (IL-6) and TNF-alpha through lactoferrin in mice] Machnicki M. **Postepy Hig Med Dosw** 1995;49(1):53–7 (4 ref.) (Eng. Abstr.) **(Pol)**

GENETICS

Transcriptional regulation of the tumor necrosis factor alpha gene. Jongeneel CV. **Immunobiology** 1995 Jul; 193(2–4):210–6 (23 ref.)
Genetics of tumour necrosis factor-alpha in autoimmune, infectious, and neoplastic diseases. Wilson AG, et al. **J Inflamm** 1995;45(1):1–12 (114 ref.)
Genetics of tumour necrosis factor in systemic lupus erythematosus [editorial] Wilson AG, et al. **Lupus** 1996 Apr;5(2):87–8 (29 ref.)
Regulation of cytokine gene expression: tumor necrosis factor, interleukin-1, and the emerging biology of cytokine receptors. Williams G, et al. **New Horiz** 1995 May; 3(2):276–87 (123 ref.)
Porcine TNF: a review. Pauli U. **Vet Immunol Immunopathol** 1995 Aug;47(3–4):187–201 (63 ref.)
[Gene therapy of cancer using TNF gene] Sato Y, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2694–9 (30 ref.) **(Jpn)**

IMMUNOLOGY

TNF alpha is an effective therapeutic target for rheumatoid arthritis. Feldmann M, et al. **Ann N Y Acad Sci** 1995 Sep 7;766:272–8 (20 ref.)
Monoclonal anti-TNF alpha antibody as a probe of pathogenesis and therapy of rheumatoid disease. Maini RN, et al. **Immunol Rev** 1995 Apr;144:195–223 (112 ref.)
New therapeutic approaches in sepsis: a critical review. Eidelman LA, et al. **Intensive Care Med** 1995 Nov;21 Suppl 2:S269–72 (18 ref.)
Time course of cytokine levels in sepsis. Thijs LG, et al. **Intensive Care Med** 1995 Nov;21 Suppl 2:S258–63 (31 ref.)
TNF and AIDS: two sides of the same coin? Pallarés-Trujillo J, et al. **Med Res Rev** 1995 Nov;15(6):533–46 (128 ref.)
[Tumor necrosis factor and underlying infection] Hazout A. **Contracept Fertil Sex** 1995 Oct;23(10):631–4 (9 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

A study on tumor necrosis factor, tumor necrosis factor receptors, and nitric oxide in human fetal glial cultures. St. Pierre BA, et al. **Adv Pharmacol** 1995;34:415–38 (94 ref.)
Grain dust, endotoxin, and airflow obstruction. Schwartz DA. **Chest** 1996 Mar;109(3 Suppl):57S–63S (51 ref.)
Thalidomide: rationale for renewed use in immunological disorders. Schuler U, et al. **Drug Saf** 1995 Jun;12(6):364–9 (61 ref.)

PHARMACOLOGY

Neutral mediation of food aversions and anorexia induced by tumor necrosis factor and tumors. Bernstein IL. **Neurosci Biobehav Rev** 1996;20(1):177–81 (27 ref.)
Stimulation of phospholipase A2 expression in rat cultured astrocytes by LPS, TNF alpha and IL-1 beta. Sun GY, et al. **Prog Brain Res** 1995;105:231–8 (27 ref.)
[Recent data and current studies of epidermal Langerhans cells] Dezutter-Dambuyant C. **Pathol Biol (Paris)** 1995 Dec;43(10):841–7 (78 ref.) (Eng. Abstr.) **(Fre)**
[In vitro differenciation and functions of dendritic cells obtained from CD34+ hematopoietic progenitors] Dubois B, et al. **Pathol Biol (Paris)** 1995 Dec;43(10):829–40 (88 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Involvement of tumor necrosis factor-alpha in the pathogenesis of experimental and human glomerulonephritis. Ortiz A, et al. **Adv Nephrol Necker Hosp** 1995;24:53–77 (139 ref.)

TUMOR NECROSIS FACTOR

Brain injury and inflammation. A putative role of TNF alpha. Arvin B, et al. **Ann N Y Acad Sci** 1995 Sep 15;765:62–71; discussion 98–9 (67 ref.)
Intracellular signalling mechanisms of interleukin 1 and tumour necrosis factor: possible targets for therapy. Saklatvala J. **Br Med Bull** 1995 Apr;51(2):402–18 (69 ref.)
Tumour necrosis factor alpha: a potential mediator of asthma. Shah A, et al. **Clin Exp Allergy** 1995 Nov;25(11):1038–44 (59 ref.)
Tumor necrosis factor and the systemic inflammatory response syndrome. Brouckaert P, et al. **Curr Top Microbiol Immunol** 1996;216:167–87 (129 ref.)
Modulation of insulin receptor signaling. Potential mechanisms of a cross talk between bradykinin and the insulin receptor. Häring HU, et al. **Diabetes** 1996 Jan;45 Suppl 1:S115–9 (35 ref.)
Mechanisms of action of the tumor necrosis factor and lymphotoxin ligand–receptor system. Warzocha K, et al. **Eur Cytokine Netw** 1995 Mar–Apr;6(2):83–96 (143 ref.)
TNF–alpha– and IFN–gamma–mediated signal transduction pathways: effects on glial cell gene expression and function. Benveniste EN, et al. **FASEB J** 1995 Dec;9(15):1577–84 (68 ref.)
Tumor necrosis factor alpha increases expression of adenovirus E3 proteins. Deryckere F, et al. **Immunobiology** 1995 Jul;193(2–4):186–92 (16 ref.)
TNF–induced activation of NF–kappa B. Schütze S, et al. **Immunobiology** 1995 Jul;193(2–4):193–203 (52 ref.)
Signal transduction pathways in oligodendrocytes: role of tumor necrosis factor–alpha. Soliven B, et al. **Int J Dev Neurosci** 1995 Jun–Jul;13(3–4):351–67 (143 ref.)
Lipopolysaccharide signal transduction, regulation of tumor necrosis factor biosynthesis, and signaling by tumor necrosis factor itself. Beutler B, et al. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S1–8 (65 ref.)
Dissection of the pathologies induced by transmembrane and wild–type tumor necrosis factor in transgenic mice. Probert L, et al. **J Leukoc Biol** 1996 Apr;59(4):518–25 (93 ref.)
Tumor necrosis factor in renal injury. Baud L, et al. **Miner Electrolyte Metab** 1995;21(4–5):336–41 (55 ref.)
The tumor necrosis factor ligand and receptor families. Bazzoni F, et al. **N Engl J Med** 1996 Jun 27;334(26):1717–25 (80 ref.)
Interleukin 1 (IL1) and tumour necrosis factor (TNF) signal transduction. Saklatvala J, et al. **Philos Trans R Soc Lond B Biol Sci** 1996 Feb 29; 351(1336):151–7 (40 ref.)
[Tumor necrosis factor—friend and enemy] Zabel P. **Pneumologie** 1996 Apr;50(4):293–302 (104 ref.) **(Ger)**

SECRETION

Mechanisms regulating cytokine release from peritoneal macrophages during continuous ambulatory peritoneal dialysis. Fieren MW. **Blood Purif** 1996;14(2):179–87 (60 ref.)

THERAPEUTIC USE

Improve the DNA recombination protein drugs. Lu S. **Chin Med J (Engl)** 1996 Mar;109(3):191–2 (0 ref.)
p55 and p75 tumor necrosis factor receptor expression on human glioblastoma cells. Kato T, et al. **Neurol Med Chir (Tokyo)** 1995 Aug;35(8):567–74 (30 ref.)
[Clinical importance of tumor necrosis factor] Blokhin BM, et al. **Gematol Transfuziol** 1995 Sep–Oct;40(5):34–5 (23 ref.) **(Rus)**

TUMOR NECROSIS FACTOR–ALPHA see **TUMOR NECROSIS FACTOR**

TUMOR NECROSIS FACTOR–BETA see **LYMPHOTOXIN**

TUMOR NECROSIS FACTOR RECEPTORS see **RECEPTORS, TUMOR NECROSIS FACTOR**

TUMOR PROMOTERS see **CARCINOGENS**

TUMOR SPHEROIDS see **SPHEROIDS**

TUMOR STAGING see **NEOPLASM STAGING**

TUMOR STEM CELL ASSAY

The clonogenic precursor cell in multiple myeloma. Bakkus MH, et al. **Leuk Lymphoma** 1995 Jul;18(3–4):221–9 (79 ref.)

TUMOR STEM CELLS

CYTOLOGY

From rodent glial precursor cell to human glial neoplasia in the oligodendrocyte–type–2 astrocyte lineage. Noble M, et al. **Glia** 1995 Nov;15(3):222–30 (63 ref.)

DRUG EFFECTS

Selective elimination of malignant stem cells using photosensitizers followed by light treatment. Levy JG, et al. **Stem Cells (Dayt)** 1995 Jul;13(4):336–43 (28 ref.)

PATHOLOGY

Which progenitor is the target cell in the development of acute promyelocytic leukemia? Takatsuki H, et al. **Leuk Lymphoma** 1995 Apr;17(3–4):251–4 (29 ref.)

PHYSIOLOGY

Screening for clonal genetic alterations. Sidransky D. **Eur J Cancer** 1995 Jul–Aug;31A(7–8):1127–9 (23 ref.)

RADIATION EFFECTS

Selective elimination of malignant stem cells using photosensitizers followed by light treatment. Levy JG, et al. **Stem Cells (Dayt)** 1995 Jul;13(4):336–43 (28 ref.)

ULTRASTRUCTURE

Detection of chromosomal translocations in leukemia–lymphoma cells by polymerase chain reaction. Drexler HG, et al. **Leuk Lymphoma** 1995 Nov; 19(5–6):359–80 (278 ref.)

TUMOR SUPPRESSOR GENES see **GENES, SUPPRESSOR, TUMOR**

TUMOR VIRUS INFECTIONS

Viral infections in the immunocompetent patient. Miller CS. **Dermatol Clin** 1996 Apr;14(2):225–41 (206 ref.)
Post–transplant lymphoproliferative disorder. Basgoz N, et al. **Infect Dis Clin North Am** 1995 Dec;9(4):901–23 (69 ref.)
Hepatitis C virus as a causative agent of hepatocellular carcinoma. Shimotohno K. **Intervirology** 1995; 38(3–4):162–9 (55 ref.)
[Progresses in orodentofacial surgery in China, 1995] Qiu W. **Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):759–60 (0 ref.) **(Chi)**
[Molecular biology of human papilloma virus infection of the female genital tract] Davidson B, et al. **Harefuah** 1995 Nov 15;129(10):417–20 (37 ref.) **(Heb)**
[An experimental model for gene therapy of murine retroviral leukemias] Aizaki K, et al. **Tanpakushitsu Kakusan Koso** 1995 Dec;40(17):2679–85 (19 ref.) **(Jpn)**
[Virus as an etiological factor of cancer in human beings] Dalen A. **Tidsskr Nor Laegeforen** 1995 Oct 30; 115(26):3263–5 (27 ref.) (Eng. Abstr.) **(Nor)**
[Current concepts on human papillomavirus infection] Garfias Cano R, et al. **Ginecol Obstet Mex** 1995 Dec; 63:509–13 (36 ref.) (Eng. Abstr.) **(Spa)**
[Molecular bases of papillomavirus and polyomavirus carcinogenesis] Taja–Chayeb L, et al. **Salud Publica Mex** 1996 Jan–Feb;38(1):47–57 (40 ref.) (Eng. Abstr.) **(Spa)**

COMPLICATIONS

AIDS–related non–Hodgkin's lymphomas: molecular genetics, viral infection and cytokine deregulation. Gaidano G, et al. **Acta Haematol** 1996;95(3–4):193–8 (32 ref.)
Human papillomaviruses, cervical cancer and the developing world. Birley HD. **Ann Trop Med Parasitol** 1995 Oct; 89(5):453–63 (69 ref.)
Cervical intraepithelial neoplasia, cervical cancer, and HPV. Holly EA. **Annu Rev Public Health** 1996;17:69–84 (96 ref.)
The role of Epstein–Barr virus in Hodgkin's disease from different geographical areas. Weinreb M, et al. **Arch Dis Child** 1996 Jan;74(1):27–31 (34 ref.)
Primary adrenal leiomyosarcoma in a man with acquired immunodeficiency syndrome (AIDS). Further evidence for an increase in smooth muscle tumors related to Epstein–Barr infection in AIDS. Zetler PJ, et al. **Arch Pathol Lab Med** 1995 Dec;119(12):1164–7 (19 ref.)
Epstein–Barr virus–related localized hepatic lymphoproliferative disorders after liver transplantation. Raymond E, et al. **Cancer** 1995 Oct 15;76(8):1344–51 (36 ref.)
Human papillomaviruses in gynecological cancer. Duggan MA. **Curr Opin Obstet Gynecol** 1996 Feb;8(1):56–62 (41 ref.)
The pathology of vulvar neoplasia. Lininger RA, et al. **Curr Opin Obstet Gynecol** 1996 Feb;8(1):63–8 (28 ref.)
Human papillomavirus–associated malignancies in HIV–positive men and women. Palefsky J. **Curr Opin Oncol** 1995 Sep;7(5):437–41 (46 ref.)
Cervical intraepithelial neoplasia. Crum CP, et al. **J Cell Biochem Suppl** 1995;23:71–9 (44 ref.)
The molecular biology of cervical cancer. Münger K. **J Cell Biochem Suppl** 1995;23:55–60 (36 ref.)
Human papillomavirus type 18: association with poor prognosis in early stage cervical cancer [see comments] Burger RA, et al. **J Natl Cancer Inst** 1996 Oct 2; 88(19):1361–8 (42 ref.) Comment in: J Natl Cancer Inst 1996 Oct 2;88(19):1331–2.
Hemophagocytic syndrome in Epstein–Barr virus–associated T–lymphoproliferative disorders: disease spectrum, pathogenesis, and management. Su IJ, et al. **Leuk Lymphoma** 1995 Nov;19(5–6):401–6 (407 ref.)
Human papillomaviruses: their clinical significance in the management of cervical carcinoma [see comments] Hines JF, et al. **Oncology (Huntingt)** 1995 Apr;9(4):279–85; discussion 286–8, 291 (50 ref.) Comment in: Oncology (Huntingt) 1995 Aug;9(8):702.
[Primary non–Hodgkin's lymphomas of the liver in human immunodeficiency virus infected patients. Three cases] Brugière O, et al. **Gastroenterol Clin Biol** 1996;20(3):307–11 (18 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Human papillomavirus infections. Rüdlinger R, et al. **Curr Probl Dermatol** 1996;24:67–76 (24 ref.)
Clinical aspects of genito–anal papillomavirus infection with a focus on when and how to investigate. von Krogh G. **Curr Probl Dermatol** 1996;24:140–50 (42 ref.)

EPIDEMIOLOGY

Human papillomavirus infection and associated disease in persons infected with human immunodeficiency virus. Vernon SD, et al. **Clin Infect Dis** 1995 Aug;21 Suppl 1:S121–4 (27 ref.)
Epidemiology of human papillomaviruses. Vittorio CC, et al. **Dermatol Clin** 1995 Jul;13(3):561–74 (165 ref.)

ETIOLOGY

The epidemiology of cervical carcinogenesis. Schiffman MH, et al. **Cancer** 1995 Nov 15;76(10 Suppl):1888–901 (165 ref.)
Human papilloma virus infection of the vulva. Beutner KR. **Semin Dermatol** 1996 Mar;15(1):2–7 (63 ref.)
[Human papilloma virus infection and renal transplantation. Two personally observed cases and a review of the literature] Lefebvre G, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(6):600–3 (20 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Epidermodysplasia verruciformis as a model of human papillomavirus–induced genetic cancer of the skin. Majewski S, et al. **Arch Dermatol** 1995 Nov;131(11):1312–8 (62 ref.)
MMTV–induced mutations in mouse mammary tumors: their potential relevance to human breast cancer. Callahan R. **Breast Cancer Res Treat** 1996;39(1):33–44 (82 ref.)
Molecular biology of cervical cancer and its precursors. Park TW, et al. **Cancer** 1995 Nov 15;76(10 Suppl):1902–13 (90 ref.)
Molecular analysis and characterization of two myeloid leukemia inducing murine retroviruses. Rassart E, et al. **Curr Top Microbiol Immunol** 1996;211:201–10 (36 ref.)
[Cellular and molecular pathogenesis of cancer of the cervix] Monsonego J. **Contracept Fertil Sex** 1995 Dec; 23(12):731–40 (63 ref.) (Eng. Abstr.) **(Fre)**

IMMUNOLOGY

Immunity to human papillomavirus–associated cervical neoplasia. Stern PL. **Adv Cancer Res** 1996;69:175–211 (187 ref.)
Immune intervention against virus–associated human cancers. Rickinson AB. **Ann Oncol** 1995;6 Suppl 1:69–71 (20 ref.)
Selective mechanisms utilized by persistent and oncogenic viruses to interfere with antigen processing and presentation. Ehrlich R. **Immunol Res** 1995;14(2):77–97 (165 ref.)
Immune regulation in Epstein–Barr virus–associated diseases. Khanna R, et al. **Microbiol Rev** 1995 Sep;59(3):387–405 (265 ref.)

PATHOLOGY

Progressive multifocal leukoencephalopathy: a review of the pathology and pathogenesis. Aksamit AJ Jr. **Microsc Res Tech** 1995 Nov 1;32(4):302–11 (39 ref.)
Human polyoma virus infection of renal allografts: histopathologic diagnosis, clinical significance, and literature review. Pappo O, et al. **Mod Pathol** 1996 Feb; 9(2):105–9 (23 ref.)
[Cellular and molecular pathogenesis of cancer of the cervix] Monsonego J. **Contracept Fertil Sex** 1995 Dec; 23(12):731–40 (63 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

Strategies involved in developing an effective vaccine for EBV–associated diseases. Moss DJ, et al. **Adv Cancer Res** 1996;69:213–45 (201 ref.)
Tumor vaccine design: concepts, mechanisms, and efficacy testing. Schirrmacher V. **Int Arch Allergy Immunol** 1995 Dec;108(4):340–4 (25 ref.)
Prospects for a vaccine against human papillomavirus. Hines JF, et al. **Obstet Gynecol** 1995 Nov;86(5):860–6 (30 ref.)

THERAPY

Human papillomavirus infection: treatment options for warts [see comments] Miller DM, et al. **Am Fam Physician** 1996 Jan;53(1):135–43, 148–50 (30 ref.) Comment in: Am Fam Physician 1996 Jul;54(1):59, 62.
Interferons. Gross G. **Curr Probl Dermatol** 1996;24:233–46 (59 ref.)
Treatment of pediatric malignant thymoma: long–term remission in a 14–year–old boy with EBV–associated thymic carcinoma by aggressive, combined modality treatment. Niehues T, et al. **Med Pediatr Oncol** 1996 Jun; 26(6):419–24 (37 ref.)

TRANSMISSION

Genital oncogenic human papillomavirus infection: a short review on the mode of transmission. Tay SK. **Ann Acad Med Singapore** 1995 Jul;24(4):598–601 (39 ref.)
Perinatal acquisition of cervical cancer–associated

papillomaviruses. Cason J. **Br J Obstet Gynaecol** 1996 Sep; 103(9):853–8 (66 ref.)

VETERINARY

Lymphoid leukosis viruses, their recognition as 'persistent' viruses and comparisons with certain other retroviruses of veterinary importance. Darcel C. **Vet Res Commun** 1996; 20(1):83–108 (112 ref.)

VIROLOGY

Mammary tumors induced by polyomavirus. Fluck MM, et al. **Breast Cancer Res Treat** 1996;39(1):45–56 (49 ref.)

Pathobiology of human papillomavirus. Prasad CJ. **Clin Lab Med** 1995 Sep;15(3):685–704 (81 ref.)

Roots and perspectives of contemporary papillomavirus research. zur Hausen H. **J Cancer Res Clin Oncol** 1996; 122(1):3–13 (133 ref.)

Epstein–Barr virus (EBV) in extranodal T–cell non–Hodgkin's lymphomas (T–NHL). Identification of nasal T–NHL as a distinct clinicopathological entity associated with EBV. Kanavaros P, et al. **Leuk Lymphoma** 1995 Jun;18(1–2):27–34 (86 ref.)

College health providers' knowledge, attitudes, and management practices of genital HPV infection. Linnehan MJ, et al. **Nurse Pract** 1996 May;21(5):122–4, 127–9 (55 ref.)

[Association of Chlamydia trachomatis and human papilloma virus as predisposing factors in cervical intraepithelial neoplasia] González Sánchez JL, et al. **Ginecol Obstet Mex** 1995 Oct;63:422–6 (30 ref.) (Eng. Abstr.) **(Spa)**

[P53 protein and human papillomavirus oncogenes in carcinogenesis of the uterine cervix] Toledo–Cuevas EM, et al. **Rev Invest Clin** 1996 Jan–Feb;48(1):59–68 (42 ref.) (Eng. Abstr.) **(Spa)**

TUMOR VIRUSES see **ONCOGENIC VIRUSES**

TUMORICIDAL ACTIVITY, IMMUNOLOGIC see **CYTOTOXICITY, IMMUNOLOGIC**

TUMORIGENICITY TESTS see **CARCINOGENICITY TESTS**

TUMORS see **NEOPLASMS**

TUNA

METABOLISM

Structural basis for oxygen delivery: muscle capillaries and manifolds in tuna red muscle. Mathieu–Costello O, et al. **Comp Biochem Physiol A Physiol** 1996 Jan;113(1):25–31 (37 ref.)

TUNGSTEN

METABOLISM

Tungsten in biological systems. Kletzin A, et al. **FEMS Microbiol Rev** 1996 Mar;18(1):5–63 (346 ref.)

TUNICA INTIMA

DRUG EFFECTS

Oestradiol inhibition of vascular myointimal proliferation following immune, chemical and mechanical injury. Foegh ML, et al. **Ciba Found Symp** 1995;191:139–45; discussion 145–9 (19 ref.)

METABOLISM

Structure of cholesterol–containing particles accumulating in atherosclerotic lesions and the mechanisms of their derivation. Hoff HF, et al. **Curr Opin Lipidol** 1995 Oct; 6(5):317–25 (91 ref.)

PATHOLOGY

Mechanisms and prevention of restenosis: from experimental models to clinical practice. Bauters C, et al. **Cardiovasc Res** 1996 Jun;31(6):835–46 (181 ref.)

Uremic small–artery disease with medial calcification and intimal hyperplasia (so–called calciphylaxis): a complication of chronic renal failure and benefit from parathyroidectomy. Hafner J, et al. **J Am Acad Dermatol** 1995 Dec;33(6):954–62 (61 ref.)

The prognostic significance of intimal proliferation in cardiac allograft vasculopathy: a paradigm shift. Mehra MR, et al. **J Heart Lung Transplant** 1995 Nov–Dec;14(6 Pt 2):S207–11 (20 ref.)

Prevention of late lumen loss after coronary angioplasty by photodynamic therapy: role of activated neutrophils. Sluiter W, et al. **Mol Cell Biochem** 1996 Apr 12–26; 157(1–2):233–8 (44 ref.)

[Experimental approaches for gene therapy modification of vascular remodeling] von der Leyen HE, et al. **Z Kardiol** 1995 Oct;84(10):791–7 (62 ref.) (Eng. Abstr.) **(Ger)**

TUNICA INTIMA VASORUM see **TUNICA INTIMA**

TUNICA MEDIA

PATHOLOGY

Uremic small–artery disease with medial calcification and intimal hyperplasia (so–called calciphylaxis): a complication of chronic renal failure and benefit from parathyroidectomy. Hafner J, et al. **J Am Acad Dermatol** 1995 Dec;33(6):954–62 (61 ref.)

TUNICATA see **UROCHORDATA**

TURBIDIMETRY see **NEPHELOMETRY AND TURBIDIMETRY**

TURBINATES

SURGERY

Effect of partial middle turbinectomy on nasal airflow and resistance. Cook PR, et al. **Otolaryngol Head Neck Surg** 1995 Oct;113(4):413–9 (32 ref.)

[Comparative study of most recent surgical techniques for the treatment of the hypertrophy of inferior turbinates] Passali D, et al. **Acta Otorhinolaryngol Ital** 1995 Jun; 15(3):219–28 (78 ref.) (Eng. Abstr.) **(Ita)**

TURNER'S SYNDROME

DRUG THERAPY

Growth hormone therapy in Turner syndrome. Analysis of long–term results. Ranke MB. **Horm Res** 1995;44 Suppl 3:35–41 (60 ref.)

[Inducing feminization in Turner syndrome (editorial)] Bost M. **Arch Pediatr** 1995 Nov;2(11):1035–7 (12 ref.) **(Fre)**

PSYCHOLOGY

Psychological characteristics of Turner syndrome. el Abd S, et al. **J Child Psychol Psychiatry** 1995 Oct;36(7):1109–25 (60 ref.)

TURNER'S SYNDROME, MALE see **NOONAN SYNDROME**

TURTLES

Green turtle fibropapillomatosis: challenges to assessing the role of environmental cofactors. Herbst LH, et al. **Environ Health Perspect** 1995 May;103 Suppl 4:27–30 (37 ref.)

PHYSIOLOGY

The role of estrogen in turtle sex determination and the effect of PCBs. Crews D, et al. **Environ Health Perspect** 1995 Oct;103 Suppl 7:73–7 (19 ref.)

TWEENS see **POLYSORBATES**

TWENTY–FOUR HOUR RHYTHM see **CIRCADIAN RHYTHM**

TWIN STUDIES

Twins and twinning [editorial] Hall JG. **Am J Med Genet** 1996 Jan 22;61(3):202–4 (41 ref.)

Twin studies in insulin dependent diabetes and other autoimmune diseases. Rowe RE, et al. **Diabetes Metab Rev** 1995 Jul;11(2):121–35 (85 ref.)

Review of the contribution of twin studies in the search for non–genetic causes of multiple sclerosis. James WH. **Neuroepidemiology** 1996;15(3):132–41 (35 ref.)

TWIN TRANSFUSION see **FETOFETAL TRANSFUSION**

TWIN TRANSFUSION SYNDROME see **FETOFETAL TRANSFUSION**

TWINS

see related
DISEASES IN TWINS

Intrapartum management of multiple gestations. Houlihan C, et al. **Clin Perinatol** 1996 Mar;23(1):91–116 (92 ref.)

Delayed interval delivery after intrauterine infection and immature birth of twin 1—a case report and literature review. de Jong MW, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Nov;63(1):91–4 (29 ref.)

Placental pathology casebook. Liveborn twin of an extramembranous pregnancy. Baergen RN, et al. **J Perinatol** 1995 Nov–Dec;15(6):510–3 (7 ref.)

PSYCHOLOGY

[The question of cognitive activity in twins] Bak F. **Acta Genet Med Gemellol (Roma)** 1994;43(3–4):193–206 (30 ref.) **(Fre)**

TWINS, CONJOINED

Rachipagus conjoined twins: they really do occur! Spencer R. **Teratology** 1995 Dec;52(6):346–56 (30 ref.)

SURGERY

Separation of conjoined twins. Wirt SW, et al. **AORN J** 1995 Oct;62(4):527–40, 543–5; quiz 546–50 (25 ref.)

Conjoined twins in Zambia. Nath S, et al. **J R Coll Surg Edinb** 1996 Aug;41(4):250–4 (14 ref.)

TWINS, DIZYGOTIC

Umbilical veins in dichorionic twins. A morpho–functional assessment. Cester N, et al. **Clin Exp Obstet Gynecol** 1995; 22(3):183–97 (34 ref.)

TWINS, FRATERNAL see **TWINS, DIZYGOTIC**

TWINS, IDENTICAL see **TWINS, MONOZYGOTIC**

TWINS, MONOZYGOTIC

MZ female twins discordant for X–linked diseases: a review. Tiberio G. **Acta Genet Med Gemellol (Roma)** 1994; 43(3–4):207–14 (28 ref.)

Monozygotic twins discordant for the Russell–Silver syndrome. Bailey W, et al. **Am J Med Genet** 1995 Aug 28;58(2):101–5 (3 ref.)

Simultaneous acute appendicitis in monozygotic twins: coincidence or genetic? Gurbuz AT, et al. **Am Surg** 1996 May;62(5):407–8 (6 ref.)

Monoamniotic twin pregnancies. Review of the literature, and a case report with vaginal delivery. Dubecq F, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Jun;66(2):183–6 (15 ref.)

Pitfalls in the diagnosis of nonconjoined monoamniotic twins. Strohbehn K, et al. **J Perinatol** 1995 Nov–Dec;15(6):484–93 (56 ref.)

GENETICS

Some causes of genotypic and phenotypic discordance in monozygotic twin pairs. Machin GA. **Am J Med Genet** 1996 Jan 22;61(3):216–28 (145 ref.)

TWO–PARAMETER MODELS see **MODELS, STATISTICAL**

TY1 TRANSPOSON see **DNA INSERTION ELEMENTS**

TYMPANIC CAVITY see **EAR, MIDDLE**

TYMPANIC MEMBRANE

see related
MYRINGOPLASTY
TYMPANOPLASTY

INJURIES

Tympanic membrane wound healing. An overview. Gladstone HB, et al. **Otolaryngol Clin North Am** 1995 Oct; 28(5):913–32 (111 ref.)

SURGERY

Chronic otitis media after tympanostomy tube placement caused by Mycobacterium abscessus: a new clinical entity? Franklin DJ, et al. **Am J Otol** 1994 May;15(3):313–20 (21 ref.)

TYMPANIC MEMBRANE PERFORATION

ETIOLOGY

Lightning injury of the tympanic membrane. Gordon MA, et al. **Am J Otol** 1995 May;16(3):373–6 (7 ref.)

SURGERY

Lightning injury of the tympanic membrane. Gordon MA, et al. **Am J Otol** 1995 May;16(3):373–6 (7 ref.)

TYMPANIC MEMBRANE RUPTURE see **TYMPANIC MEMBRANE PERFORATION**

TYMPANOPLASTY

see related
MYRINGOPLASTY

Mechanical and acoustic analysis of middle ear reconstruction. Rosowski JJ, et al. **Am J Otol** 1995 Jul; 16(4):486–97 (56 ref.)

METHODS

[Modern aspects of tympanoplasty. An overview] Helms J. **Laryngorhinootologie** 1995 Aug;74(8):465–7 (14 ref.) (Eng. Abstr.) **(Ger)**

TYMPANOSTOMY TUBE INSERTION see **MIDDLE EAR VENTILATION**

TYMPANUM see **EAR, MIDDLE**

TYPE A PERSONALITY

Thalasselis syndrome and genetic theories on keratoconus. Thalasselis A. **J Am Optom Assoc** 1995 Aug;66(8):495–9 (64 ref.)

TYPE C ONCOVIRUSES see **RETROVIRIDAE**

TYPE I HYPERSENSITIVITY see **HYPERSENSITIVITY, IMMEDIATE**

TYPE IV HYPERSENSITIVITY see **HYPERSENSITIVITY, DELAYED**

TYPHOID

DRUG THERAPY

Short course quinolone therapy of typhoid fever in developing countries. Limson BM. **Drugs** 1995;49 Suppl 2:136–8 (21 ref.)

The new quinolones in the treatment of diarrhoea and typhoid fever. Waiz A. **Drugs** 1995;49 Suppl 2:132–5 (54 ref.)

TYPHOID–PARATYPHOID VACCINES

IMMUNOLOGY

A new typhoid vaccine composed of the Vi capsular polysaccharide. Plotkin SA, et al. **Arch Intern Med** 1995 Nov 27;155(21):2293–9 (70 ref.)

TYPHUS see **TYPHUS, EPIDEMIC LOUSE-BORNE**

TYPHUS, ABDOMINAL see **TYPHOID**

TYPHUS, EPIDEMIC LOUSE-BORNE

The typhus group. Baxter JD. **Clin Dermatol** 1996 May–Jun; 14(3):271–8 (36 ref.)

TYPHUS, SAO PAULO see **ROCKY MOUNTAIN SPOTTED FEVER**

TYPHUS, SCRUB see **SCRUB TYPHUS**

TYPING, BACTERIAL see **BACTERIAL TYPING TECHNIQUES**

TYPING, FUNGAL see **MYCOLOGICAL TYPING TECHNIQUES**

TYPOLOGY see **SOMATOTYPES**

TYROSINASE see **MONOPHENOL MONOOXYGENASE**

TYROSINE

ANALOGS & DERIVATIVES

Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective. Tcheng JE. **Am J Cardiol** 1996 Aug 14; 78(3A):35–40 (27 ref.)

Preparative purification of tyrosinamide N-linked oligosaccharides. Rice KG, et al. **J Chromatogr A** 1996 Jan 12;720(1–2):235–49 (34 ref.)

Stearyl tyrosine. An organic equivalent of aluminum-based immunoadjuvants. Penney C. **Pharm Biotechnol** 1995; 6:611–24 (26 ref.)

ANALYSIS

Production and utilization of detyrosinated tubulin in developing Artemia larvae: evidence for a tubulin-reactive carboxypeptidase. Xiang H, et al. **Biochem Cell Biol** 1995 Sep–Oct;73(9–10):673–85 (82 ref.)

BIOSYNTHESIS

Thrombopoietin induces tyrosine phosphorylation of Stat3 and Stat5 in human blood platelets. Miyakawa Y, et al. **Blood** 1996 Jan 15;87(2):439–46 (36 ref.)

BLOOD

[Inborn errors of amino acid metabolism] Owada M. **Ryoikibetsu Shokogun Shirizu** 1995;(8):352–7 (23 ref.) **(Jpn)**

CHEMISTRY

Copper amine oxidase: a novel use for a tyrosine [comment] Fontecave M, et al. **Structure** 1995 Nov 15;3(11):1127–9 (22 ref.) Comment on: Structure 1995 Nov 15;3(11):1171–84.

METABOLISM

Protein tyrosine phosphorylation and estradiol action. Auricchio F, et al. **Ann N Y Acad Sci** 1996 Apr 30; 784:149–72 (41 ref.)

The role of tyrosine phosphorylation in angiotensin II-mediated intracellular signalling. Marrero MB, et al. **Cardiovasc Res** 1995 Oct;30(4):530–6 (54 ref.)

Protein tyrosine phosphorylation as a mechanism of signalling in mast cells and basophils. Hamawy MM, et al. **Cell Signal** 1995 Aug;7(6):535–44 (90 ref.)

Involvement of tyrosine phosphorylation in endothelial adhesion molecule induction. Weber C. **Immunol Res** 1996; 15(1):30–7 (42 ref.)

Tyrosinaemia—treatment and outcome. Kvittingen EA. **J Inherit Metab Dis** 1995;18(4):375–9 (16 ref.)

Tyrosine phosphorylation and synapse formation at the neuromuscular junction. Mei L, et al. **Life Sci** 1995; 57(16):1459–66 (114 ref.)

Cation-pi interactions in chemistry and biology: a new view of benzene, Phe, Tyr, and Trp. Dougherty DA. **Science** 1996 Jan 12;271(5246):163–8 (66 ref.)

PHYSIOLOGY

Modulation of biological tyrosine reactions by tyrosine phosphorylation. Gmeiner BM, et al. **Wien Klin Wochenschr** 1995;107(22):687–9 (12 ref.)

TYROSINE HYDROXYLASE see **TYROSINE 3-MONOOXYGENASE**

TYROSINE 3-MONOOXYGENASE

CHEMISTRY

Tyrosine hydroxylase. Kaufman S. **Adv Enzymol Relat Areas Mol Biol** 1995;70:103–220 (328 ref.)

METABOLISM

Tyrosine hydroxylase. Kaufman S. **Adv Enzymol Relat Areas Mol Biol** 1995;70:103–220 (328 ref.)

Intricate regulation of tyrosine hydroxylase activity and gene expression. Kumer SC, et al. **J Neurochem** 1996 Aug; 67(2):443–62 (112 ref.)

PHYSIOLOGY

Structure and function of the aromatic amino acid hydroxylases. Hufton SE, et al. **Biochem J** 1995 Oct 15; 311 (Pt 2):353–66 (223 ref.)

TYROSINE PHOSPHATASE see **PROTEIN-TYROSINE-PHOSPHATASE**

TYROSINE PROTEIN KINASE see **PROTEIN-TYROSINE KINASE**

TYROSINE-SPECIFIC PROTEIN KINASE see **PROTEIN-TYROSINE KINASE**

TYROSYL PHOSPHOPROTEIN PHOSPHATASE see **PROTEIN-TYROSINE-PHOSPHATASE**

U1 SMALL NUCLEAR RNA see **RNA, SMALL NUCLEAR**

U2 SMALL NUCLEAR RNA see **RNA, SMALL NUCLEAR**

U3 SMALL NUCLEAR RIBONUCLEOPROTEINS see **RIBONUCLEOPROTEINS, SMALL NUCLEAR**

U3 SMALL NUCLEAR RNA see **RNA, SMALL NUCLEAR**

U4 SMALL NUCLEAR RIBONUCLEOPROTEINS see **RIBONUCLEOPROTEINS, SMALL, U4-U6**

U4 SMALL NUCLEAR RNA see **RNA, SMALL NUCLEAR**

U4-U6 SMALL NUCLEAR RIBONUCLEOPROTEINS see **RIBONUCLEOPROTEINS, SMALL, U4-U6**

U5 SMALL NUCLEAR RNA see **RNA, SMALL NUCLEAR**

U6 SMALL NUCLEAR RIBONUCLEOPROTEINS see **RIBONUCLEOPROTEINS, SMALL, U4-U6**

U6 SMALL NUCLEAR RNA see **RNA, SMALL NUCLEAR**

U7 SMALL NUCLEAR RIBONUCLEOPROTEINS see **RIBONUCLEOPROTEINS, SMALL NUCLEAR**

U7 SMALL NUCLEAR RNA see **RNA, SMALL NUCLEAR**

UBIQUINOL-CYTOCHROME-C REDUCTASE

CHEMISTRY

A compilation of mutations located in the cytochrome b subunit of the bacterial and mitochondrial bc1 complex. Brasseur G, et al. **Biochim Biophys Acta** 1996 Jul 18; 1275(1–2):61–9 (45 ref.)

Functional implications of the structure of the 'Rieske' iron-sulfur protein of bovine heart mitochondrial cytochrome bc1 complex. Link TA, et al. **Biochim Biophys Acta** 1996 Jul 18;1275(1–2):54–60 (45 ref.)

Crystallization and preliminary structure of beef heart mitochondrial cytochrome-bc1 complex. Yu CA, et al. **Biochim Biophys Acta** 1996 Jul 18;1275(1–2):47–53 (52 ref.)

Bifurcated ubihydroquinone oxidation in the cytochrome bc1 complex by proton-gated charge transfer. Brandt U. **FEBS Lett** 1996 May 27;387(1):1–6 (38 ref.)

METABOLISM

Energy conservation by bifurcated electron-transfer in the cytochrome-bc1 complex. Brandt U. **Biochim Biophys Acta** 1996 Jul 18;1275(1–2):41–6 (35 ref.)

UBIQUINONE

BLOOD

[Ubiquinone (CoQ)] Ito K, et al. **Nippon Rinsho** 1995 Feb; 53 Su Pt 1:745–7 (14 ref.) **(Jpn)**

THERAPEUTIC USE

The therapy of respiratory chain encephalomyopathy: a critical review of the past and current perspective. Walker UA, et al. **Acta Neurol Scand** 1995 Oct;92(4):273–80 (77 ref.)

[Is ubiquinone worth noticing? (editorial)] Alho H. **Duodecim** 1994;110(4):369–71 (18 ref.) **(Fin)**

UBIQUINONE REDUCTASE see **NAD(P)H DEHYDROGENASE (QUINONE)**

UBIQUITIN

BIOSYNTHESIS

[Inclusion body myositis] Serratrice G. **Presse Med** 1996 Jun 15;25(21):985–8 (23 ref.) (Eng. Abstr.) **(Fre)**

BLOOD

Necessary but not sufficient: the role of glucocorticoids in the acidosis-induced increase in levels of mRNAs encoding proteins of the ATP-dependent proteolytic pathway in rat muscle. Price SR, et al. **Miner Electrolyte Metab** 1996; 22(1–3):72–5 (14 ref.)

METABOLISM

Roles of ubiquitinylation in proteolysis and cellular regulation. Wilkinson KD. **Annu Rev Nutr** 1995;15:161–89 (136 ref.)

Cell cycle. The only way out of mitosis. Glotzer M. **Curr Biol** 1995 Sep 1;5(9):970–2 (26 ref.)

Proteolysis. The proteasome: a protein-degrading organelle? Rubin DM, et al. **Curr Biol** 1995 Aug 1;5(8):854–8 (32 ref.)

The ubiquitin-dependent proteolytic pathway in skeletal muscle: its role in pathological states. Argilés JM, et al. **Trends Pharmacol Sci** 1996 Jun;17(6):223–6 (40 ref.)

PHYSIOLOGY

Roles of ubiquitinylation in proteolysis and cellular regulation. Wilkinson KD. **Annu Rev Nutr** 1995;15:161–89 (136 ref.)

Ubiquitin in signal transduction and cell transformation. Isaksson A, et al. **Biochim Biophys Acta** 1996 Aug 8; 1288(1):F21–9 (73 ref.)

Protein degradation or regulation: Ub the judge. Hochstrasser M. **Cell** 1996 Mar 22;84(6):813–5 (15 ref.)

UDDER see **MAMMAE**

UDP GALACTOSE ACETYLGLUCOSAMINE GALACTOSYLTRANSFERASE see **N-ACETYLLACTOSAMINE SYNTHASE**

UDP GALACTOSE EPIMERASE see **URIDINE DIPHOSPHATE GLUCOSE EPIMERASE**

UDP GALACTOSE PYROPHOSPHORYLASE see **GALACTOSEPHOSPHATE URIDYLYLTRANSFERASE**

UDP GLUCOSE EPIMERASE see **URIDINE DIPHOSPHATE GLUCOSE EPIMERASE**

UDP GLUCURONOSYLTRANSFERASE see **GLUCURONOSYLTRANSFERASE**

ULCER

see related
CORNEAL ULCER
PEPTIC ULCER
SKIN ULCER

Endoscopic management of ulcer disease. Fleischer D. **Yale J Biol Med** 1994 May–Aug;67(3–4):167–72 (37 ref.)

COMPLICATIONS

Umbilical cord ulceration as a cause of hypoxic-ischemic encephalopathy: report of a case and review of the literature. Khurana A, et al. **J Perinatol** 1995 Sep–Oct; 15(5):423–5 (21 ref.)

ULCER, APHTHOUS see **STOMATITIS, APHTHOUS**

ULNA

Gamekeeper's thumb: ulnar collateral ligament injury. Richard JR. **Am Fam Physician** 1996 Apr;53(5):1775–81 (12 ref.)

Periostitis of the upper extremity: a report of 2 cases and literature review. Meese MA, et al. **Clin Orthop** 1996 Mar; (324):222–6 (17 ref.)

Chronic disorders of the forearm. Richards RR. **J Bone Joint Surg Am** 1996 Jun;78(6):916–30 (143 ref.)

[Extrapulmonary tuberculosis. An unusual case] Di Natale M, et al. **Minerva Med** 1995 Dec;86(12):555–7 (5 ref.) (Eng. Abstr.) **(Ita)**

ABNORMALITIES

Congenital radioulnar synostosis. Surgical correction by derotational osteotomy. Castelló JR, et al. **Ann Chir Main Memb Super** 1996;15(1):11–7 (8 ref.)

Bilateral ulnar agenesis: case report and review of the literature. Bozner P, et al. **Pediatr Pathol Lab Med** 1995 Nov–Dec;15(6):895–913 (84 ref.)

GROWTH & DEVELOPMENT

Traumatic ulnar physeal arrest after distal forearm fractures in children. Ray TD, et al. **J Pediatr Orthop** 1996 Mar–Apr; 16(2):195–200 (15 ref.)

INJURIES

Acute dislocations of the distal radioulnar joint. Bruckner JD, et al. **Instr Course Lect** 1996;45:27–36 (96 ref.)

Traumatic plastic deformity of an adult forearm: case report and literature review. Simonian PT, et al. **J Orthop Trauma** 1996;10(3):213–5 (12 ref.)

ULNA FRACTURES

REHABILITATION

Current management of fractures of distal radius and ulna. Williams RL, et al. **Br J Hosp Med** 1996 Mar 20–Apr 2; 55(6):320–8 (60 ref.)

SURGERY

[Fractures of the distal humerus and proximal forearm] Dorow C, et al. **Unfallchirurg** 1996 Jun;99(6):440–9 (10 ref.) **(Ger)**

VETERINARY

Treatment of fractures of the tibia and radius–ulna by external coaptation. Adams SB, et al. **Vet Clin North Am Food Anim Pract** 1996 Mar;12(1):181–98 (15 ref.)

ULNAR ARTERY

Aneurysms of the digital artery: a review and report of three cases. Yajima H, et al. **Microsurgery** 1995;16(8):566–70 (19 ref.)

INJURIES

Hypothenar hammer syndrome caused by playing tennis. Nakamura T, et al. **Eur J Vasc Endovasc Surg** 1996 Feb; 11(2):240–2 (8 ref.)

ULNAR NERVE

ANATOMY & HISTOLOGY

Ulnar nerve anatomy and compression. Khoo D, et al. **Orthop Clin North Am** 1996 Apr;27(2):317–38 (70 ref.)

ULNAR NERVE COMPRESSION see **ULNAR NERVE COMPRESSION SYNDROME**

ULNAR NERVE COMPRESSION SYNDROME

Ulnar nerve anatomy and compression. Khoo D, et al. **Orthop Clin North Am** 1996 Apr;27(2):317–38 (70 ref.)

DIAGNOSIS

General principles and use of electrodiagnostic studies in carpal and cubital tunnel syndromes. With special attention to pitfalls and interpretation. Hilburn JW. **Hand Clin** 1996 May;12(2):205–21 (64 ref.)

ETIOLOGY

Ulnar nerve compression at the elbow caused by a prominent medial head of the triceps and an anconeus epitrochlearis muscle. O'Hara JJ, et al. **J Hand Surg [Br]** 1996 Feb; 21(1):133–5 (5 ref.)

ULNAR NERVE ENTRAPMENT see **ULNAR NERVE COMPRESSION SYNDROME**

ULTIMOBRANCHIAL BODY

see related
CALCITONIN

ULTRAFILTRATION

see related
HEMOFILTRATION

METHODS

Ultrafiltration membranes in biotechnology. Ghose TK. **Hindustan Antibiot Bull** 1994 Aug–Nov;36(3–4):173–90 (26 ref.)

ULTRAMICROTOMY see **MICROTOMY**

ULTRASONIC DIAGNOSIS see **ULTRASONOGRAPHY**

ULTRASONIC IMAGING see **ULTRASONOGRAPHY**

ULTRASONIC LITHOTRIPSY see **LITHOTRIPSY**

ULTRASONIC THERAPY

Application of focused ultrasound for the stimulation of neural structures. Gavrilov LR, et al. **Ultrasound Med Biol** 1996;22(2):179–92 (50 ref.)

METHODS

Review article: high intensity focused ultrasound—potential for cancer treatment. Hill CR, et al. **Br J Radiol** 1995 Dec; 68(816):1296–1303 (44 ref.)

ULTRASONICS

An ultrasonic time-of-flight system for hand movement measurement. Berners AC, et al. **Physiol Meas** 1995 Nov; 16(4):203–11 (13 ref.)

ULTRASONOGRAPHY

Intraoperative ultrasonography. Reading CC. **Abdom Imaging** 1996 Jan–Feb;21(1):21–9 (62 ref.)

The use of ultrasonography in the labor and delivery suite. Benito CW, et al. **Clin Perinatol** 1996 Mar;23(1):117–39 (87 ref.)

Quantitative ultrasound. Fuerst T, et al. **Eur J Radiol** 1995 Sep;20(3):188–92 (46 ref.)

Ultrasound, what every trauma surgeon should know [see comments] Rozycki GS, et al. **J Trauma** 1996 Jan;40(1):1–4 (23 ref.) Comment in: J Trauma 1996 Aug;41(2):368–70.

[Diagnostic ultrasound imaging in municipal health care centers (editorial)] Kunnamo I. **Duodecim** 1994; 110(21):1971–3 (11 ref.) **(Fin)**

[Value of ultrasound in diagnosis of acute appendicitis] Zoller WG, et al. **Bildgebung** 1996 Jun;63(2):78–82 (38 ref.) (Eng. Abstr.) **(Ger)**

[1995 literature review: ultrasound and roentgen diagnosis of gallbladder, bile ducts and pancreas] Brambs HJ, et al. **Rontgenpraxis** 1996 Apr;49(4):94–9 (31 ref.) **(Ger)**

INSTRUMENTATION

Practical application of ultrasound biomicroscopy. Pavlin CJ. **Can J Ophthalmol** 1995 Jun;30(4):225–9 (44 ref.)

[Ultrasound skin findings in HIV infection by imaging with 7.5 MHz linear transducers] Bogner JR, et al. **Bildgebung** 1995 Dec;62(4):281–6 (14 ref.) (Eng. Abstr.) **(Ger)**

[Current proctology—modern functional diagnosis] Feifel G, et al. **Chirurg** 1996 Mar;67(3):205–12 (33 ref.) (Eng. Abstr.) **(Ger)**

[Recommendations of the Urogynecology Study Group on ultrasound of the lower urinary tract within the scope of functional urogynecologic diagnosis] Schär G, et al. **Gynakol Geburtshilfliche Rundsch** 1996;36(1):33–6 (20 ref.) **(Ger)**

[Basic principles of vaginal ultrasound] Bernaschek G. **Gynakologe** 1995 Aug;28(4):220–4 (11 ref.) **(Ger)**

[Transvaginal 3 D ultrasound in gynecology] Merz E, et al. **Gynakologe** 1995 Aug;28(4):270–5 (9 ref.) **(Ger)**

METHODS

Why do we need contrast agents for ultrasound? Cosgrove D. **Clin Radiol** 1996 Feb;51 Suppl 1:1–4 (20 ref.)

Endoscopic ultrasound—current applications. McLean A, et al. **Clin Radiol** 1996 Feb;51(2):83–98 (103 ref.)

Endoscopic ultrasonography in gastric lymphoma. Caletti GC, et al. **Schweiz Med Wochenschr** 1996 May 11; 126(19):819–25 (40 ref.)

Three-dimensional ultrasound. Kavic MS. **Surg Endosc** 1996 Jan;10(1):74–6 (7 ref.)

[Analysis of texture in medical imaging. Review of the literature] Rolland Y, et al. **Ann Radiol (Paris)** 1995; 38(6):315–47 (102 ref.) (Eng. Abstr.) **(Fre)**

[Extraordinary success of ultrasonography] Gharbi HA, et al. **Arch Pediatr** 1996;3 Suppl 1:217s–219s (10 ref.) **(Fre)**

[The role of ultrasonography in the diagnosis and staging of gastroenteric lymphoma] Rapaccini GL, et al. **Riv Eur Sci Med Farmacol** 1994 Sep–Dec;16 Suppl 1:75–81 (17 ref.) (Eng. Abstr.) **(Ita)**

TRENDS

Ultrasound: present and future. Pourcelot L, et al. **Technol Health Care** 1996 Apr;4(1):31–6 (0 ref.)

VETERINARY

Diagnostic ultrasound in veterinary practice: How safe is it? Horder MM, et al. **Aust Vet J** 1996 Jan;73(1):10–5 (76 ref.)

[Sonographic possibilities in emergency medicine] Gerwing M, et al. **Berl Munch Tierarztl Wochenschr** 1996 Apr; 109(4):123–9 (37 ref.) (Eng. Abstr.) **(Ger)**

ULTRASONOGRAPHY, COLOR DOPPLER see **ULTRASONOGRAPHY, DOPPLER, COLOR**

ULTRASONOGRAPHY, DOPPLER

The current status of Doppler sonography in obstetrics. Alfirevic Z, et al. **Curr Opin Obstet Gynecol** 1996 Apr; 8(2):114–8 (38 ref.)

Intra-uterine growth retardation. Holmes RP, et al. **Curr Opin Obstet Gynecol** 1996 Apr;8(2):148–54 (51 ref.)

Cerebrovascular assessment of the high-risk patient: the role of transcranial Doppler ultrasound. Doblar DD. **J Cardiothorac Vasc Anesth** 1996 Jan;10(1):3–14 (116 ref.)

The role of neuromonitoring in cardiovascular surgery. Edmonds HL Jr, et al. **J Cardiothorac Vasc Anesth** 1996 Jan;10(1):15–23 (51 ref.)

Current topic: in vivo investigation of the placental circulations by Doppler echography [see comments] Jauniaux E, et al. **Placenta** 1995 Jun;16(4):323–31 (52 ref.) Comment in: Placenta 1995 Jun;16(4):333–4.

Fetal ductus arteriosus—how far may it bend? Brezinka C. **Ultrasound Obstet Gynecol** 1995 Jul;6(1):6–7 (19 ref.)

[Diagnostic and clinical value of Doppler ultrasound in obstetrics] Gonser M, et al. **Geburtshilfe Frauenheilkd** 1995 Nov;55(11):605–15 (127 ref.) (Eng. Abstr.) **(Ger)**

[Assessment of deep venous thrombosis] Z'Brun A, et al. **Ther Umsch** 1996 Apr;53(4):258–64 (24 ref.) (Eng. Abstr.) **(Ger)**

INSTRUMENTATION

[Transvaginal Doppler/color Doppler in gynecologic diagnosis] Voigt HJ. **Gynakologe** 1995 Aug;28(4):254–61 (45 ref.) **(Ger)**

ULTRASONOGRAPHY, DOPPLER, COLOR

Controversies in assessment of ovarian tumors with transvaginal color Doppler ultrasound. Tekay A, et al. **Acta Obstet Gynecol Scand** 1996 Apr;75(4):316–29 (89 ref.)

Colour Doppler energy (power) mode ultrasound. MacSweeney JE, et al. **Clin Radiol** 1996 Jun;51(6):387–90 (21 ref.)

Penile vascular assessment using color duplex sonography in men with Peyronie's disease. Levine LA, et al. **J Urol** 1996 Apr;155(4):1270–3 (21 ref.)

Orbital sonography in children. Ramji FG, et al. **Pediatr Radiol** 1996;26(4):245–58 (70 ref.)

Color Doppler sonography of the thoracic inlet veins. Nazarian GK, et al. **Radiographics** 1995 Nov;15(6):1357–71 (10 ref.)

Color Doppler ultrasound imaging of the eye and orbit. Williamson TH, et al. **Surv Ophthalmol** 1996 Jan–Feb; 40(4):255–67 (69 ref.)

Prenatal diagnosis of cerebral arteriovenous malformation using color Doppler ultrasonography: case report and review of the literature. Sepulveda W, et al. **Ultrasound Obstet Gynecol** 1995 Oct;6(4):282–6 (30 ref.)

[Transcranial Doppler and color duplex ultrasound. Familiar and new uses] Baumgartner RW, et al. **Ultraschall Med** 1996 Apr;17(2):50–4 (50 ref.) (Eng. Abstr.) **(Ger)**

[Ultrasound diagnosis, follow-up and therapy of cystic degeneration of the adventitia. 2 case reports and review of the literature] Schäberle W, et al. **Ultraschall Med** 1996 Jun;17(3):131–7 (39 ref.) (Eng. Abstr.) **(Ger)**

[Assessing of ovarian physiology and pathology with color Doppler imaging] Tibi Y, et al. **Harefuah** 1995 Dec 1; 129(11):485–8 (38 ref.) **(Heb)**

[Angiogenesis of gynecologic tumors studied with color Doppler] Kurjak A, et al. **Lijec Vjesn** 1995 May–Jun; 117(5–6):139–45 (88 ref.) (Eng. Abstr.) **(Scr)**

INSTRUMENTATION

[Transvaginal Doppler/color Doppler in gynecologic diagnosis] Voigt HJ. **Gynakologe** 1995 Aug;28(4):254–61 (45 ref.) **(Ger)**

ULTRASONOGRAPHY, DOPPLER, DUPLEX

Reevaluation of duplex criteria for diagnosis of high-grade carotid artery stenosis: when do we need angiography and when can we operate without angiography? Karacagil S, et al. **Int Angiol** 1995 Dec;14(4):410–4 (14 ref.)

[Duplex sonography in tumor diagnosis] Karasch T, et al. **Dtsch Med Wochenschr** 1996 Jul 5;121(27):876–84 (51 ref.) **(Ger)**

STANDARDS

Angiographic and duplex grading of internal carotid stenosis: can we overcome the confusion? Nicolaides AN, et al. **J Endovasc Surg** 1996 May;3(2):158–65 (32 ref.)

ULTRASONOGRAPHY, DOPPLER, TRANSCRANIAL

Transcranial Doppler ultrasound for cerebral perfusion. Jørgensen LG. **Acta Physiol Scand Suppl** 1995;625:1–44 (215 ref.)

Intracranial pressure and cerebral arterial flow velocity indices in childhood hydrocephalus: current review. Goh D, et al. **Childs Nerv Syst** 1995 Jul;11(7):392–6 (25 ref.)

Value of transcranial Doppler indices in predicting raised ICP in infantile hydrocephalus. A study with review of the literature. Hanlo PW, et al. **Childs Nerv Syst** 1995 Oct; 11(10):595–603 (45 ref.)

High-intensity transient signals: evolution or revolution in understanding cerebral embolism? [editorial] Hennerici M. **Eur Neurol** 1995;35(5):249–53 (42 ref.)

Transcranial Doppler ultrasonography: what is its role in cardiac and vascular surgical patients? Kahn RA, et al. **J Cardiothorac Vasc Anerth** 1995 Oct;9(5):589–97 (71 ref.)

Transcranial Doppler measurements. Newell DW. **New Horiz** 1995 Aug;3(3):423–30 (69 ref.)

[Detection of cardiac embolism by transcranial Doppler] Pettelot G, et al. **Ann Cardiol Angeiol (Paris)** 1996 Jan; 45(1):34–8 (19 ref.) (Eng. Abstr.) **(Fre)**

[Circulating cerebral microembolisms. Detection with transcranial Doppler ultrasound] Thiel A, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 Apr; 31(3):127–31 (41 ref.) (Eng. Abstr.) **(Ger)**

[The significance of so-called "high-intensity transient signals" (HITS) during transcranial Doppler sonography] Sliwka U, et al. **Dtsch Med Wochenschr** 1995 Dec 1; 120(48):1667–70 (28 ref.) **(Ger)**

[Transcranial Doppler and color duplex ultrasound. Familiar and new uses] Baumgartner RW, et al. **Ultraschall Med** 1996 Apr;17(2):50–4 (50 ref.) (Eng. Abstr.) **(Ger)**

[Investigation of cerebrovascular reactivity using transcranial doppler ultrasonography] Sapieja W. **Neurol Neurochir Pol** 1995 Jul–Aug;29(4):591–5 (24 ref.) (Eng. Abstr.) **(Pol)**

METHODS

[Cerebrovascular ultrasound diagnosis] Baumgartner RW, et al. **Ther Umsch** 1996 Jul;53(7):528–34 (44 ref.) (Eng. Abstr.) **(Ger)**

ULTRASONOGRAPHY, DUPLEX DOPPLER see **ULTRASONOGRAPHY, DOPPLER, DUPLEX**

ULTRASONOGRAPHY, FETAL see **ULTRASONOGRAPHY, PRENATAL**

ULTRASONOGRAPHY, INTERVENTIONAL

What have we learned from in vitro intravascular ultrasound? [editorial] Gussenhoven EJ, et al. **Am Heart J** 1996 Sep; 132(3):702–10 (48 ref.)

Role of echocardiography in perioperative management of patients undergoing open heart surgery. Joffe II, et al. **Am Heart J** 1996 Jan;131(1):162–76 (130 ref.)

Subacute stent thrombosis and the anticoagulation controversy: changes in drug therapy, operator technique, and the impact of intravascular ultrasound. Moussa I, et al. **Am J Cardiol** 1996 Aug 14;78(3A):13–7 (35 ref.)

Intraportal tumor thrombus of gallbladder carcinoma: detection with intravascular ultrasonography. Kaneko T, et al. **Am J Gastroenterol** 1996 Jun;91(6):1268–9 (8 ref.)

Understanding intravascular ultrasound. Strimike C. **Am J Nurs** 1996 Jun;96(6):40–3; quiz 44 (11 ref.)

Intravascular ultrasound imaging of peripheral arteries as an adjunct to balloon angioplasty and atherectomy. Korogi Y, et al. **Cardiovasc Intervent Radiol** 1996 Jan–Feb;19(1):1–9 (39 ref.)

Assessment of transplant arteriopathy by intracoronary two-dimensional ultrasound imaging and coronary flow velocity. Wolford T, et al. **Cathet Cardiovasc Diagn** 1995 Aug;35(4):335–42 (35 ref.)

Assessing the physiologic significance of coronary artery disease: role of Doppler methodology. Schlaifer JD, et al. **Clin Cardiol** 1996 Mar;19(3):172–8 (38 ref.)

Intravascular ultrasound: clinical applications. Jain A, et al. **Indian Heart J** 1995 Mar–Apr;47(2):151–7 (75 ref.)

Demonstration of cystic adventitial disease by intravascular ultrasound imaging. Koppensteiner R, et al. **J Vasc Surg** 1996 Mar;23(3):534–6 (9 ref.)

Laparoscopy and laparoscopic ultrasound in the staging of gastric cancer. Conlon KC, et al. **Semin Oncol** 1996 Jun; 23(3):347–51 (22 ref.)

Endoscopic ultrasonography. Pollack BJ, et al. **Semin Oncol** 1996 Jun;23(3):336–46 (83 ref.)

[The role of ultrasonic endoscopy in the examination of post-obstetrical anal incontinence] Roseau G. **Contracept Fertil Sex** 1995 Dec;23(12):752–7 (28 ref.) (Eng. Abstr.) **(Fre)**

[Intravascular echography: a new approach to the pathophysiologic assessment of atherosclerotic lesions] Marsico F. G **Ital Cardiol** 1995 Dec;25(12):1649–51 (16 ref.) **(Ita)**

INSTRUMENTATION

Usefulness of endoscopic ultrasonography in the diagnosis of choledocholithiasis. Palazzo L, et al. **Abdom Imaging** 1996 Mar–Apr;21(2):93–7 (51 ref.)

Intracoronary Doppler flow velocity measurements for the evaluation and treatment of coronary artery disease. Bach RG, et al. **Curr Opin Cardiol** 1995 Jul;10(4):434–42 (35 ref.)

Intravascular ultrasound for evaluation of coronary arteries. Görge G, et al. **Herz** 1996 Apr;21(2):78–89 (82 ref.)

Three-dimensional reconstruction of coronary arteries with intravascular ultrasound. von Birgelen C, et al. **Herz** 1995 Aug;20(4):277–89 (85 ref.)

METHODS

Three-dimensional intracoronary ultrasound imaging. Methodology and clinical relevance for the assessment of coronary arteries and bypass grafts. Von Birgelen C, et al. **J Cardiovasc Surg (Torino)** 1996 Apr;37(2):129–39 (100 ref.)

[Intracoronary ultrasound: scientific aspects and clinical possibilities] Rickenbacher P, et al. **Schweiz Rundsch Med Prax** 1996 Mar 12;85(11):320–8 (153 ref.) (Eng. Abstr.) **(Ger)**

TRENDS

[The future and forseeable of intravascular echographic technics] Balbarini A. **Cardiologia** 1996 Jun;41(6):501–4 (42 ref.) **(Ita)**

ULTRASONOGRAPHY, INTRAVASCULAR see **ULTRASONOGRAPHY, INTERVENTIONAL**

ULTRASONOGRAPHY, MAMMARY

Sonographic evaluation of benign and malignant breast lesions. Kelly KM. **Crit Rev Diagn Imaging** 1996 Apr; 37(2):79–161 (72 ref.)

Breast ultrasound. Ueno E. **Gan To Kagaku Ryoho** 1996 Mar; 23 Suppl 1:14–23 (18 ref.)

The current role of ultrasonography in breast imaging. Jackson VP. **Radiol Clin North Am** 1995 Nov;33(6):1161–70 (70 ref.)

ULTRASONOGRAPHY, PRENATAL

Prenatal diagnosis of a choledochal cyst: a case report and review of the literature. Benhidjeb T, et al. **Am J Perinatol** 1996 May;13(4):207–10 (20 ref.)

Prenatal sonographic diagnosis of Treacher Collins syndrome: a case and review of the literature. Cohen J, et al. **Am J Perinatol** 1995 Nov;12(6):416–9 (23 ref.)

Comprehensive ultrasound examination in a private perinatal practice. Ott WJ, et al. **Am J Perinatol** 1995 Nov; 12(6):385–91 (14 ref.)

Ethical issues of diagnosis in utero. Perrotti M, et al. **Br J Urol** 1995 Nov;76 Suppl 2:79–83 (37 ref.)

The use of ultrasonography in the labor and delivery suite. Benito CW, et al. **Clin Perinatol** 1996 Mar;23(1):117–39 (87 ref.)

Ultrasound features of normal early pregnancy development. Jurkovic D, et al. **Curr Opin Obstet Gynecol** 1995 Dec; 7(6):493–504 (55 ref.)

The spectrum of first-trimester ultrasound findings. Sohaey R, et al. **Curr Probl Diagn Radiol** 1996 Mar–Apr; 25(2):54–75 (93 ref.)

Extra-lobar pulmonary sequestration with prenatal diagnosis. A report of 5 cases and review of the literature. Plattner V, et al. **Eur J Pediatr Surg** 1995 Aug;5(4):235–7 (16 ref.)

A case of varix dilatation of the umbilical vein and review of the literature. Babay ZA, et al. **Fetal Diagn Ther** 1996 May–Jun;11(3):221–3 (10 ref.)

Routine obstetric ultrasound. Skupski DW, et al. **Int J Gynaecol Obstet** 1995 Sep;50(3):233–42 (35 ref.)

Prenatal sonographic diagnosis of upper airway obstruction: a challenge that can be achieved. Golan-Porat N, et al. **J Laryngol Otol** 1996 Jun;110(6):583–5 (16 ref.)

Prenatally diagnosed choledochal cysts: observation or early surgery? Lugo-Vicente HL. **J Pediatr Surg** 1995 Sep; 30(9):1288–90 (24 ref.)

Antenatal diagnosis of renal tract anomalies: has it increased the sum of human happiness? Malone PS. **J R Soc Med** 1996 Mar;89(3):155P–8P (45 ref.)

Prenatal ultrasonographic assessment of the ductus arteriosus: a review. Sherer DM, et al. **Obstet Gynecol** 1996 Apr; 87(4):630–7 (50 ref.)

Ultrasound screening for fetal abnormalities [see comments] Chitty LS. **Prenat Diagn** 1995 Dec;15(13):1241–57 (74 ref.) Comment in: Prenat Diagn 1995 Dec;15(13):1209–13.

Areas of increased echogenicity in the fetal abdomen: diagnosis and significance. Rypens FF, et al. **Radiographics** 1995 Nov;15(6):1329–44; discussion 1344–5 (58 ref.)

Sonography of the placenta with emphasis on pathological correlation. Harris RD, et al. **Semin Ultrasound CT MR** 1996 Feb;17(1):66–89 (39 ref.)

The fetal heart: a practical sonographic approach. Sohaey R, et al. **Semin Ultrasound CT MR** 1996 Feb;17(1):15–33 (36 ref.)

First-trimester ultrasound: the essentials. Sohaey R, et al. **Semin Ultrasound CT MR** 1996 Feb;17(1):2–14 (64 ref.)

The fetal thorax: noncardiac chest anomalies. Sohaey R, et al. **Semin Ultrasound CT MR** 1996 Feb;17(1):34–50 (64 ref.)

Fetal gastrointestinal anomalies. Sohaey R, et al. **Semin Ultrasound CT MR** 1996 Feb;17(1):51–65 (64 ref.)

Antenatal diagnosis and treatment of fetal goitrous hypothyroidism: case report and review of the literature. Abuhamad AZ, et al. **Ultrasound Obstet Gynecol** 1995 Nov; 6(5):368–71 (27 ref.)

The art of ultrasound in obstetrics: from abstraction to hyper-realism [editorial] Achiron R. **Ultrasound Obstet Gynecol** 1995 Jul;6(1):1–3 (9 ref.)

Fetal ductus arteriosus—how far may it bend? Brezinka C. **Ultrasound Obstet Gynecol** 1995 Jul;6(1):6–7 (19 ref.)

The significance of echogenic areas in the fetal abdomen. Carroll SG, et al. **Ultrasound Obstet Gynecol** 1996 Apr; 7(4):293–8 (58 ref.)

Fetal structural disorders—the large series are emerging [comment] Eik-Nes SH. **Ultrasound Obstet Gynecol** 1995 Jun;5(6):364–5 (10 ref.) Comment on: Ultrasound Obstet Gynecol 1995 Jun;5(6):366–71. Comment on: Ultrasound Obstet Gynecol 1995 Jun;5(6):372–80.

The length of human pregnancy as calculated by ultrasonographic measurement of the fetal biparietal diameter. Kieler H, et al. **Ultrasound Obstet Gynecol** 1995 Nov;6(5):353–7 (26 ref.)

Antenatal diagnosis and management of meconium peritonitis: a case report and review of the literature. Konje JC, et al. **Ultrasound Obstet Gynecol** 1995 Jul;6(1):66–9 (13 ref.)

Single umbilical artery: a clinical enigma in modern prenatal diagnosis. Persutte WH, et al. **Ultrasound Obstet Gynecol** 1995 Sep;6(3):216–29 (56 ref.)

IRONFAN—a sonographic window into the natural history of fetal anomalies. International Registry of the Onset of Fetal Anomalies [editorial] Rottem S. **Ultrasound Obstet Gynecol** 1995 Jun;5(6):361–3 (6 ref.)

Is ultrasound unsound? A review of epidemiological studies of human exposure to ultrasound. Salvesen KA, et al. **Ultrasound Obstet Gynecol** 1995 Oct;6(4):293–8 (26 ref.)

Prenatal diagnosis of cerebral arteriovenous malformation using color Doppler ultrasonography: case report and review of the literature. Sepulveda W, et al. **Ultrasound Obstet Gynecol** 1995 Oct;6(4):282–6 (30 ref.)

Resolving fetal hyperechogenic lung lesions: an unresolved issue [see comments] Sepulveda W, et al. **Ultrasound Obstet Gynecol** 1995 Jul;6(1):4–5 (26 ref.) Comment in: Ultrasound Obstet Gynecol 1995 Nov;6(5):372–3.

Fetal exomphalos and chromosomal defects: relationship to maternal age and gestation. Snijders RJ, et al. **Ultrasound Obstet Gynecol** 1995 Oct;6(4):250–5 (30 ref.)

First-trimester ultrasound screening for chromosomal defects. Snijders RJ, et al. **Ultrasound Obstet Gynecol** 1996 Mar;7(3):216–26 (58 ref.)

[The antenatal diagnosis of sacrococcygeal teratoma] Dukovski A. **Akush Ginekol (Sofiia)** 1995;34(2):53–5 (6 ref.) (Eng. Abstr.) **(Bul)**

[Ultrasonic signs of fetal toxoplasmosis. Review of the literature] Abboud P, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(7):733–8 (17 ref.) (Eng. Abstr.) **(Fre)**

[Prolonged pregnancy. Review of the literature] Boisselier P, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995; 24(7):739–46 (52 ref.) (Eng. Abstr.) **(Fre)**

[Uterine velocimetry and vascular pregnancy pathologies prevented with low-dose aspirin] Haddad B, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(4):396–404 (51 ref.) (Eng. Abstr.) **(Fre)**

[Prenatal diagnosis of three caudal regression syndromes associated with maternal diabetes] Houfflin V, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(4):389–95 (40 ref.) (Eng. Abstr.) **(Fre)**

[Ultrasonic diagnosis and laparoscopic treatment of an ovarian pregnancy. A case report and review of the literature] Riethmuller D, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(4):378–83 (25 ref.) (Eng. Abstr.) **(Fre)**

[Amniocentesis and single choroid plexus cyst. Current status] Morales-Roselló J, et al. **Rev Fr Gynecol Obstet** 1995 Oct;90(10):412–6 (30 ref.) (Eng. Abstr.) **(Fre)**

[Diagnostic and clinical value of Doppler ultrasound in obstetrics] Gonser M, et al. **Geburtshilfe Frauenheilkd** 1995 Nov;55(11):605–15 (127 ref.) (Eng. Abstr.) **(Ger)**

[Diagnostic-therapeutic concept in abnormalities of the abdominal wall and diaphragm] Terinde R, et al. **Gynakologe** 1995 Oct;28(5):368–83 (84 ref.) **(Ger)**

[Diagnostic-therapeutic concept in abnormalities of the kidneys and efferent urinary tract] Tutschek B, et al. **Gynakologe** 1995 Oct;28(5):356–67 (59 ref.) **(Ger)**

[Diagnostic-therapeutic concept in hydrocephalus] Voigt HJ. **Gynakologe** 1995 Oct;28(5):346–55 (27 ref.) **(Ger)**

[Ultrasound diagnosis of epignathus in the 17th week of pregnancy. Case report and review of the literature] Brühwiler H, et al. **Ultraschall Med** 1995 Oct;16(5):238–40 (18 ref.) (Eng. Abstr.) **(Ger)**

[Prenatal diagnosis of Bourneville-Pringle disease (cerebral tuberous sclerosis)] Stümpflen-Mauser I, et al. **Ultraschall Med** 1996 Feb;17(1):34–7 (16 ref.) (Eng. Abstr.) **(Ger)**

[Prenatal diagnosis of left cardiac abnormality] Hajdú J, et al. **Orv Hetil** 1995 Oct 22;136(43):2333–7 (22 ref.) (Eng. Abstr.) **(Hun)**

[Blood circulation in retarded and normal offspring of hypertonic pregnant women] Jakobovits A, et al. **Orv Hetil** 1996 Apr 14;137(15):793–7 (46 ref.) (Eng. Abstr.)

(Hun)

[An analysis of the causes for the occurrence of Down's syndrome and the current approaches to its prevention at the stage of mass prenatal ultrasonic and immunobiochemical screening of pregnant women] Veropotvelian NP, et al. **Tsitol Genet** 1995 Sep–Oct; 29(5):82–92 (71 ref.) (Eng. Abstr.) **(Rus)**

[Polyhydramnios and its relationship with congenital malformations: ultrasonographic diagnosis] Gaxiola Castro R, et al. **Ginecol Obstet Mex** 1995 Dec;63:505–8 (12 ref.) (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

[A review of epidemiologic studies on ultrasound during pregnancy] Vogel E. **Ultraschall Med** 1996 Feb;17(1):2–6 (36 ref.) (Eng. Abstr.) **(Ger)**

INSTRUMENTATION

[Potential 3-dimensional (3D-)ultrasound in the diagnosis of fetal abnormalities] Steiner H. **Gynakologe** 1995 Oct; 28(5):315–20 (31 ref.) **(Ger)**

[Use of 3D ultrasound technique in prenatal diagnosis] Merz E. **Ultraschall Med** 1995 Aug;16(4):154–61 (28 ref.) (Eng. Abstr.) **(Ger)**

STANDARDS

Guessing the weight of the baby [comment] Hall MH. **Br J Obstet Gynaecol** 1996 Aug;103(8):734–6 (24 ref.) Comment on: Br J Obstet Gynaecol 1996 Aug;103(8):747–54.

UTILIZATION

Use of ultrasonography in the home care of high-risk childbearing women. Stringer M. **Nurs Clin North Am** 1996 Jun;31(2):305–12 (17 ref.)

[The use of Doppler-ultrasound in obstetrics] Skajaa K, et al. **Ugeskr Laeger** 1996 Feb 19;158(8):1055–61 (40 ref.) (Eng. Abstr.) **(Dan)**

ULTRASONOGRAPHY, TRANSCRANIAL DOPPLER see **ULTRASONOGRAPHY, DOPPLER, TRANSCRANIAL**

ULTRASOUND, INTERVENTIONAL see **ULTRASONOGRAPHY, INTERVENTIONAL**

ULTRAVIOLET RAYS

Ultraviolet radiation and free radical damage to skin. Tyrrell RM. **Biochem Soc Symp** 1995;61:47–53 (33 ref.)

A role for neutrophil elastase in solar elastosis. Starcher B, et al. **Ciba Found Symp** 1995;192:338–46; discussion 346–7 (6 ref.)

UV and nucleic acids. Douki T, et al. **EXS** 1995;73:173–97 (126 ref.)

Both ATF-2 and c-Jun are phosphorylated by stress-activated protein kinases in response to UV irradiation. Wilhelm D, et al. **Immunobiology** 1995 Jul; 193(2–4):143–8 (22 ref.)

Recent developments in vision research: light damage in cataract. McCarty CA, et al. **Invest Ophthalmol Vis Sci** 1996 Aug;37(9):1720–3 (14 ref.)

Open questions in photobiology. IV. Photoaging of the skin. Giacomoni PU, et al. **J Photochem Photobiol B** 1996 May; 33(3):267–72 (56 ref.)

DNA UVB dosimeters. Regan JD, et al. **J Photochem Photobiol B** 1995 Nov;31(1–2):57–61 (19 ref.)

Mechanisms of ultraviolet light-induced pigmentation. Gilchrest BA, et al. **Photochem Photobiol** 1996 Jan; 63(1):1–10 (110 ref.)

[Photosensitivity] Granlund H. **Duodecim** 1995;111(5):457–65 (19 ref.) **(Fin)**

[The biomedical effects of ultraviolet radiation and their mechanisms] Strzhizhovskii AD. **Usp Fiziol Nauk** 1995 Oct–Dec;26(4):98–112 (129 ref.) (Eng. Abstr.) **(Rus)**

ADVERSE EFFECTS

Risk assessment for the harmful effects of UVB radiation on the immunological resistance to infectious diseases. Van Loveren H, et al. **Arch Toxicol Suppl** 1996;18:21–8 (19 ref.)

Nonmelanoma skin cancer. Epstein JH. **Compr Ther** 1996 Mar;22(3):179–82 (17 ref.)

The effects of near ultraviolet radiation on the toxic effects of polycyclic aromatic hydrocarbons in animals and plants: a review. Arfsten DP, et al. **Ecotoxicol Environ Saf** 1996 Feb;33(1):1–24 (109 ref.)

Bactericidal UV-C lamp misuse [letter] [corrected] [published erratum appears in Isr J Med Sci 1995 Nov;31(11):701] Zamir E. **Isr J Med Sci** 1995 Sep;31(9):578 (5 ref.)

Keratinocyte-derived cytokines and UVB-induced immunosuppression. Kondo S, et al. **J Dermatol** 1995 Nov; 22(11):888–93 (45 ref.)

UVB-dependent modulation of epidermal cytokine network: roles in UVB-induced depletion of Langerhans cells and dendritic epidermal T cells. Takashima A. **J Dermatol** 1995 Nov;22(11):876–87 (100 ref.)

The ozone hole. Lehmann P. **Med J Aust** 1995 Dec 4–18; 163(11–12):576–8 (7 ref.)

DNA repair and cytokines in antimutagenesis and anticarcinogenesis. Yarosh DB, et al. **Mutat Res** 1996 Feb 19;350(1):255–60 (28 ref.)

Solar ultraviolet radiation and ocular disease: a review of the epidemiological and experimental evidence. Dolin PJ, et al. **Ophthalmic Epidemiol** 1994 Dec;1(3):155–64 (79 ref.)

Methodological considerations for future epidemiological studies of solar ultraviolet radiation and eye disease. Dolin PJ. **Ophthalmic Epidemiol** 1994 Dec;1(3):165–70 (16 ref.)

Epidemiological studies of sunlight and cataract: the critical factor of ultraviolet exposure geometry [see comments] Sliney DH. **Ophthalmic Epidemiol** 1994 Jun;1(2):107–19 (33 ref.) Comment in: Int J Food Sci Nutr 1994 Jun;1(2):63–5.

p53 gene mutations and photocarcinogenesis. Nataraj AJ, et al. **Photochem Photobiol** 1995 Aug;62(2):218–30 (140 ref.)

The role of urocanic acid in UV-induced immunosuppression: recent advances (1992–1994). Norval M, et al. **Photochem Photobiol** 1995 Aug;62(2):209–17 (64 ref.)

UV radiation and mouse models of herpes simplex virus infection. Norval M, et al. **Photochem Photobiol** 1996 Aug; 64(2):242–5 (26 ref.)

Does exposure to UV radiation induce a shift to a Th-2-like immune reaction? Ullrich SE. **Photochem Photobiol** 1996 Aug;64(2):254–8 (41 ref.)

The role of epidermal cytokines in the generation of cutaneous immune reactions and ultraviolet radiation-induced immune suppression. Ullrich SE. **Photochem Photobiol** 1995 Sep;62(3):389–401 (99 ref.)

Medical UV exposures and HIV activation. Zmudzka BZ, et al. **Photochem Photobiol** 1996 Aug;64(2):246–53 (62 ref.)

[Cancers of the skin, relations to ultraviolet rays] Robert C, et al. **Presse Med** 1995 Nov 11;24(34):1610–6 (33 ref.) (Eng. Abstr.) **(Fre)**

[Cutaneous photocarcinogenesis] Césarini JP. **Rev Med Interne** 1995;16 Suppl 3:344s–347s (28 ref.) **(Fre)**

[Natural ultraviolet radiation as a human risk factor (review)] Strzhizhovskii AD. **Radiats Biol Radioecol** 1996 Mar–Apr; 36(2):299–309 (51 ref.) (Eng. Abstr.) **(Rus)**

ULTRAVIOLET SPECTROPHOTOMETRY see **SPECTROPHOTOMETRY, ULTRAVIOLET**

ULTRAVIOLET THERAPY

see related
PHOTOCHEMOTHERAPY

Phototherapy. Abel EA. **Dermatol Clin** 1995 Oct;13(4):841–9 (44 ref.)

Ultraviolet radiation for treatment of cutaneous T-cell lymphoma. Herrmann JJ, et al. **Hematol Oncol Clin North Am** 1995 Oct;9(5):1077–88 (40 ref.)

UMBILICAL ARTERIES

ABNORMALITIES

Single umbilical artery: a clinical enigma in modern prenatal diagnosis. Persutte WH, et al. **Ultrasound Obstet Gynecol** 1995 Sep;6(3):216–29 (56 ref.)

[Single umbilical artery] Pirhonen J. **Duodecim** 1994; 110(21):1987–92 (32 ref.) **(Fin)**

[Prognostic value of a single umbilical artery. 87 cases] Blache G, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995; 24(5):522–8 (34 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Umbilical artery Doppler velocimetry: clinical utility in high-risk pregnancies. Divon MY. **Am J Obstet Gynecol** 1996 Jan;174(1 Pt 1):10–4 (36 ref.)

ULTRASONOGRAPHY

Single umbilical artery: a clinical enigma in modern prenatal diagnosis. Persutte WH, et al. **Ultrasound Obstet Gynecol** 1995 Sep;6(3):216–29 (56 ref.)

UMBILICAL CORD

Umbilical cord ulceration as a cause of hypoxic-ischemic encephalopathy: report of a case and review of the literature. Khurana A, et al. **J Perinatol** 1995 Sep–Oct; 15(5):423–5 (21 ref.)

ULTRASONOGRAPHY

A case of varix dilatation of the umbilical vein and review of the literature. Babay ZA, et al. **Fetal Diagn Ther** 1996 May–Jun;11(3):221–3 (10 ref.)

UMBILICAL CORD BLOOD see **FETAL BLOOD**

UMBILICAL CYST see **URACHAL CYST**

UMBILICAL HERNIA see **HERNIA, UMBILICAL**

UMBILICAL VEINS

[Urokinase in a premature infant: its use in a case of right atrial thrombosis secondary to catheterization of the umbilical vein] Colnaghi C, et al. **Pediatr Med Chir** 1995 May–Jun;17(3):275–7 (10 ref.) (Eng. Abstr.) **(Ita)**

ANATOMY & HISTOLOGY

Umbilical veins in dichorionic twins. A morpho-functional assessment. Cester N, et al. **Clin Exp Obstet Gynecol** 1995; 22(3):183–97 (34 ref.)

ULTRASONOGRAPHY

A case of varix dilatation of the umbilical vein and review of the literature. Babay ZA, et al. **Fetal Diagn Ther** 1996 May–Jun;11(3):221–3 (10 ref.)

UMBILICUS

[Imaging of connective tissue formations of the sub-umbilical anterior abdominal wall] Roy C, et al. **Ann Radiol (Paris)** 1995;38(7–8):389–95 (20 ref.) (Eng. Abstr.) **(Fre)**

UMBRELLA FILTERS see **VENA CAVA FILTERS**

UMP see **URIDINE MONOPHOSPHATE**

UNCOMPENSATED CARE

see related
MEDICALLY UNINSURED

UNCONSCIOUS (PSYCHOLOGY)

Process dissociation, single-process theories, and recognition memory. Ratcliff R, et al. **J Exp Psychol Gen** 1995 Dec; 124(4):352–74 (41 ref.)

[The evolution of the concept of archetypes in Jungian psychology] Pérez Urdaniz A, et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1995 Sep–Oct;23(5):262–5 (25 ref.) (Eng. Abstr.) **(Spa)**

UNCONSCIOUSNESS

see related
SYNCOPE

ETIOLOGY

Neurologic complications in critically ill patients. Wijdicks EF. **Anesth Analg** 1996 Aug;83(2):411–9 (60 ref.)

Penetrating injuries in the Vietnam war. Traumatic unconsciousness, epilepsy, and psychosocial outcome. Salazar AM, et al. **Neurosurg Clin N Am** 1995 Oct; 6(4):715–26 (34 ref.)

UNCOUPLING AGENTS

see related
IONOPHORES

UNDER-DEVELOPED COUNTRIES see **DEVELOPING COUNTRIES**

UNDULANT FEVER see **BRUCELLOSIS**

UNEMPLOYMENT

Health and unemployment. Dooley D, et al. **Annu Rev Public Health** 1996;17:449–65 (112 ref.)

Effect of chronic stress associated with unemployment on salivary cortisol: overall cortisol levels, diurnal rhythm, and acute stress reactivity. Ockenfels MC, et al. **Psychosom Med** 1995 Sep–Oct;57(5):460–7 (61 ref.)

PSYCHOLOGY

[Health effects of unemployment] Korzeniewska M. **Med Pr** 1995;46(4):407–14 (34 ref.) (Eng. Abstr.) **(Pol)**

UNIFIED MEDICAL LANGUAGE SYSTEM

see related
NOMENCLATURE

UNIPOLAR DEPRESSION see **DEPRESSIVE DISORDER**

UNIPORT see **ION TRANSPORT**

UNITED STATES DEPARTMENT OF AGRICULTURE

Present systems and future needs for risk assessment of biologicals in the United States of America: the perspective of the regulator. Espeseth DA. **Rev Sci Tech** 1995 Dec; 14(4):1143–55 (3 ref.)

UNITED STATES DEPARTMENT OF VETERANS AFFAIRS

HISTORY

The evolution of American Medical Association policies concerning health care of veterans. Kendall JW. **Mil Med** 1995 Oct;160(10):518–21 (10 ref.)

UNITED STATES ENVIRONMENTAL PROTECTION AGENCY

U.S. EPA regulatory perspectives on the use of QSAR for new and existing chemical evaluations. Zeeman M, et al. **SAR QSAR Environ Res** 1995;3(3):179-201 (48 ref.)

The new chemicals process at the Environmental Protection Agency (EPA): structure-activity relationships for hazard identification and risk assessment. Wagner WM, et al. **Toxicol Lett** 1995 Sep;79(1-3):67-73 (3 ref.)

UNITED STATES FOOD AND DRUG ADMINISTRATION

Ventricular fibrillation, automatic external defibrillators, and the United States Food and Drug Administration: confrontation without comprehension. Cummins RO, et al. **Ann Emerg Med** 1995 Nov;26(5):621-31; discussion 632-4 (95 ref.)

Cell transplantation and Federal regulation. Noguchi PD. **Cell Transplant** 1995 Jul-Aug;4(4):411-4 (4 ref.)

Food and Drug Administration (FDA)'s impact on laboratory performance: FDA's perspective. Gutman S. **Clin Chem** 1996 May;42(5):786-9 (5 ref.)

LEGISLATION & JURISPRUDENCE

Human protection against non-genotoxic carcinogens in the US without the Delaney Clause. Weisburger JH. **Exp Toxicol Pathol** 1996 Feb;48(2-3):201-8 (41 ref.)

Risk assessment of carcinogens in food with special consideration of non-genotoxic carcinogens. Scientific arguments for use of risk assessment and for changing the Delaney Clause specifically. Williams GM, et al. **Exp Toxicol Pathol** 1996 Feb;48(2-3):209-15 (21 ref.)

The evolution of FDA policy on silicone breast implants: a case study of politics, bureaucracy, and business in the process of decision-making. Palley HA. **Int J Health Serv** 1995;25(4):573-91 (61 ref.)

UNITED STATES NATIONAL INSTITUTES OF HEALTH see **NATIONAL INSTITUTES OF HEALTH (U.S.)**

UNITED STATES OCCUPATIONAL SAFETY AND HEALTH ADMINISTRATION

STANDARDS

The origin and development of the asbestos Threshold Limit Value: scientific indifference and corporate influence. Egilman DS, et al. **Int J Health Serv** 1995;25(4):667-96 (98 ref.)

UNITED STATES VETERANS ADMINISTRATION see **UNITED STATES DEPARTMENT OF VETERANS AFFAIRS**

UNIVERSAL PRECAUTIONS

Infection control. Miller CH. **Dent Clin North Am** 1996 Apr; 40(2):437-56 (38 ref.)

A work-systems analysis of compliance with universal precautions among health care workers. DeJoy DM, et al. **Health Educ Q** 1996 May;23(2):159-74 (80 ref.)

Compliance with handwashing and barrier precautions. Larson E, et al. **J Hosp Infect** 1995 Jun;30 Suppl:88-106 (81 ref.)

Are universal precautions realistic? Gerberding JL, et al. **Surg Clin North Am** 1995 Dec;75(6):1091-104 (23 ref.)

LEGISLATION & JURISPRUDENCE

Legal considerations in infectious diseases and dentistry. Burris S. **Dent Clin North Am** 1996 Apr;40(2):425-35 (62 ref.)

UNIVERSITIES

AIDS education for college students: review and proposal for a research-based curriculum. Mulvihill CK. **AIDS Educ Prev** 1996 Feb;8(1):11-25 (72 ref.)

UNIVERSITY HEALTH SERVICES see **STUDENT HEALTH SERVICES**

UNIVERSITY MEDICAL CENTERS see **ACADEMIC MEDICAL CENTERS**

UNKNOWN PRIMARY TUMORS see **NEOPLASMS, UNKNOWN PRIMARY**

UNSATURATED DIETARY FATS see **DIETARY FATS, UNSATURATED**

UP-REGULATION (PHYSIOLOGY)

see related
DOWN-REGULATION (PHYSIOLOGY)

DRUG EFFECTS

[Modulation of integrin alpha-v-beta-1 expression on human tumor cells by leukemia inhibitory factor (LIF) and oncostatin M (OSM)] Heymann D, et al. **Bull Cancer (Paris)** 1996 Jan;83(1):13-21 (41 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Up-regulation of intracellular signalling pathways may play a central pathogenic role in hypertension, atherogenesis, insulin resistance, and cancer promotion--the 'PKC syndrome'. McCarty MF. **Med Hypotheses** 1996 Mar; 46(3):191-221 (402 ref.)

UPHILL TRANSPORT see **BIOLOGICAL TRANSPORT, ACTIVE**

UPPER EXTREMITY see **ARM**

UPPER RESPIRATORY INFECTIONS see **RESPIRATORY TRACT INFECTIONS**

UPREGULATION see **UP-REGULATION (PHYSIOLOGY)**

URACHAL CYST

COMPLICATIONS

Intraperitoneal rupture of an infected urachal cyst: a rare cause of peritonitis in children. Ogbevoen JO, et al. **Pediatr Emerg Care** 1996 Feb;12(1):41-3 (19 ref.)

DIAGNOSIS

[Urachal cyst. A case report and review of the literature] Cudazzo E, et al. **Minerva Chir** 1996 Jan-Feb;51(1-2):77-82 (16 ref.) (Eng. Abstr.) **(Ita)**

URACHUS

Mixed adenocarcinoma and neuroendocrine carcinoma arising in the urachus. A case report and review of the literature. Munichor M, et al. **Eur Urol** 1995;28(4):345-7 (22 ref.)

[Urachal adenocarcinoma associated with urothelial tumor of the bladder. Report of a case] Payen E, et al. **Prog Urol** 1996 Apr;6(2):288-91 (13 ref.) (Eng. Abstr.) **(Fre)**

URACIL

CHEMISTRY

AU-rich elements: characterization and importance in mRNA degradation. Chen CY, et al. **Trends Biochem Sci** 1995 Nov;20(11):465-70 (42 ref.)

METABOLISM

Uracil metabolism--UMP synthesis from orotic acid or uridine and conversion of uracil to beta-alanine: enzymes and cDNAs. Traut TW, et al. **Prog Nucleic Acid Res Mol Biol** 1996;53:1-78 (273 ref.)

THERAPEUTIC USE

Clinical development of new fluoropyrimidines: a major improvement in colorectal cancer treatment? Colleoni M, et al. **Tumori** 1995 Sep-Oct;81(5):303-7 (44 ref.)

URACIL ARABINOFURANOSIDE see **ARABINOFURANOSYLURACIL**

URACIL ARABINOSIDE see **ARABINOFURANOSYLURACIL**

URALENIC ACID see **GLYCYRRHETINIC ACID**

URANIUM

The yellowed archives of yellowcake. Silver K. **Public Health Rep** 1996 Mar-Apr;111(2):116-27 (55 ref.)

ADVERSE EFFECTS

Uranium in the environment: occurrence, transfer, and biological effects. Ribera D, et al. **Rev Environ Contam Toxicol** 1996;146:53-89 (130 ref.)

PHARMACOKINETICS

PBK modeling for metals. Examples with lead, uranium, and chromium. O'Flaherty EJ. **Toxicol Lett** 1995 Dec; 82-83:367-72 (6 ref.)

URANIUM COMPOUNDS

ADVERSE EFFECTS

Empirical and biologically based models for cancer risk assessment. Zielinski JM, et al. **Drug Metab Rev** 1996 Feb-May;28(1-2):53-75 (29 ref.)

URBAN HEALTH

Healthy Cities: toward worldwide health promotion. Flynn BC. **Annu Rev Public Health** 1996;17:299-309 (59 ref.)

Cervical cancer survival in a high risk urban population. Thoms WW, et al. **Cancer** 1995 Dec 15;76(12):2518-23 (26 ref.)

Evaluation of a possible association of urban air toxics and asthma. Leikauf GD, et al. **Environ Health Perspect** 1995 Sep;103 Suppl 6:253-71 (179 ref.)

Environmental risk factors of childhood asthma in urban centers. Malveaux FJ, et al. **Environ Health Perspect** 1995 Sep;103 Suppl 6:59-62 (30 ref.)

The effects of poverty environments on elders' subjective well-being: a conceptual model. Brown V. **Gerontologist** 1995 Aug;35(4):541-8 (48 ref.)

Epidemiologic aspects of infective endocarditis in an urban population. A 5-year prospective study. Hogevik H, et al. **Medicine (Baltimore)** 1995 Nov;74(6):324-39 (69 ref.)

The Jeremiah Metzger Lecture on the climate of cities. Bondurant S. **Trans Am Clin Climatol Assoc** 1995; 107:189-212 (32 ref.)

[The City and Health--an analysis of recent (socio-) historical literature] Labisch A. **Zentralbl Hyg Umweltmed** 1995 Apr;197(1-3):111-33 (96 ref.) (Eng. Abstr.) **(Ger)**

STATISTICS & NUMERICAL DATA

Gunshot wounds to the head in an urban setting. Krieger MD, et al. **Neurosurg Clin N Am** 1995 Oct;6(4):605-10 (28 ref.)

URBAN HEALTH SERVICES

Urban search and rescue. Barbera JA, et al. **Emerg Med Clin North Am** 1996 May;14(2):399-412 (76 ref.)

ORGANIZATION & ADMINISTRATION

Community medicine: an urban model. Deuschle KW, et al. **J Community Health** 1995 Dec;20(6):459-72 (37 ref.)

URBAN HOSPITALS see **HOSPITALS, URBAN**

URBAN POPULATION

Inner-city tuberculosis in the USA. McGowan JE Jr, et al. **J Hosp Infect** 1995 Jun;30 Suppl:282-95 (65 ref.)

STATISTICS & NUMERICAL DATA

Syringe-mediated drug sharing among injecting drug users: patterns, social context and implications for transmission of blood-borne pathogens. Grund JP, et al. **Soc Sci Med** 1996 Mar;42(5):691-703 (89 ref.)

Explaining urban-rural variations in health: a review of interactions between individual and environment. Verheij RA. **Soc Sci Med** 1996 Mar;42(6):923-35 (73 ref.)

URBAN RENEWAL

see related
HOUSING

UREA

see related
BLOOD UREA NITROGEN

ANALYSIS

The urea breath test: a non-invasive clinical tool for detecting Helicobacter pylori infection. Perri F, et al. **Ital J Gastroenterol** 1995 Mar;27(2):55-63 (77 ref.)

On-line monitoring of the delivery of the hemodialysis prescription. Keshaviah PR, et al. **Pediatr Nephrol** 1995;9 Suppl:S2-8 (23 ref.)

BLOOD

Hemodialysis vascular access: effect on urea kinetics and the dialysis prescription. Butterly DW, et al. **Am J Nephrol** 1996;16(1):45-51 (32 ref.)

Serum creatinine and urea: make the most of these simple test. Isles CG, et al. **Br J Hosp Med** 1996 Apr 17-30; 55(8):513-6 (3 ref.)

Urea monitoring in the dialysis patient. Panzetta G. **Int J Artif Organs** 1995 Sep;18(9):530-3 (24 ref.)

METABOLISM

Urea cycle disorders: diagnosis, pathophysiology, and therapy. Brusilow SW, et al. **Adv Pediatr** 1996;43:127-70 (59 ref.)

The significance of protein intake and catabolism. Flanigan MJ, et al. **Adv Ren Replace Ther** 1995 Oct;2(4):330-40 (62 ref.)

Dialysate-based kinetic modeling. Garred LJ. **Adv Ren Replace Ther** 1995 Oct;2(4):305-18 (35 ref.)

Brain swelling after dialysis: old urea or new osmoles? Silver SM, et al. **Am J Kidney Dis** 1996 Jul;28(1):1-13 (49 ref.)

Quantifying hemodialysis. Depner TA. **Am J Nephrol** 1996; 16(1):17-28 (78 ref.)

Simplified approaches to calculate Kt/V. It's time for agreement. Movilli E. **Nephrol Dial Transplant** 1996 Jan; 11(1):24-7 (31 ref.)

Urea recycling: an aid to the excretion of potassium during

antidiuresis. Halperin ML, et al. **Nephron** 1996;72(4):507–11 (32 ref.)
Answers to all your questions about peritoneal urea clearance and nutrition in CAPD patients [editorial] Blake PG, et al. **Perit Dial Int** 1996 May–Jun;16(3):248–51 (25 ref.)
Salvage of urea–nitrogen and protein requirements. Jackson AA. **Proc Nutr Soc** 1995 Jul;54(2):535–47 (38 ref.)
Urea transport and Kidd blood groups. Cartron JP, et al. **Transfus Clin Biol** 1995;2(4):309–15 (24 ref.)

PHARMACOKINETICS

Thoughts about judging dialysis treatment: mathematics and measurements, mirrors in the mind. Lowrie EG. **Semin Nephrol** 1996 May;16(3):242–62 (86 ref.)

UREAPLASMA INFECTIONS

DIAGNOSIS

Aortic graft infection with mycoplasma (Ureaplasma urealyticum). Levi N, et al. **Eur J Vasc Endovasc Surg** 1995 Oct;10(3):374–5 (14 ref.)

DRUG THERAPY

Nongonococcal urethritis. Nickel P, et al. **Curr Probl Dermatol** 1996;24:97–104 (34 ref.)

UREAPLASMA UREALYTICUM

Nongonococcal urethritis. Nickel P, et al. **Curr Probl Dermatol** 1996;24:97–104 (34 ref.)
Aortic graft infection with mycoplasma (Ureaplasma urealyticum). Levi N, et al. **Eur J Vasc Endovasc Surg** 1995 Oct;10(3):374–5 (14 ref.)

UREASE

[Helicobacter pylori urease] Nagata K, et al. **Nippon Saikingaku Zasshi** 1995 Oct;50(4):961–70 (60 ref.) **(Jpn)**

GENETICS

Molecular biology of microbial ureases. Mobley HL, et al. **Microbiol Rev** 1995 Sep;59(3):451–80 (307 ref.)

PHYSIOLOGY

Molecular biology of microbial ureases. Mobley HL, et al. **Microbiol Rev** 1995 Sep;59(3):451–80 (307 ref.)

UREMIA

The immune system in uremia and during its treatment. Haag–Weber M, et al. **New Horiz** 1995 Nov;3(4):669–79 (172 ref.)

BLOOD

Urea monitoring in the dialysis patient. Panzetta G. **Int J Artif Organs** 1995 Sep;18(9):530–3 (24 ref.)
Non–invasive circulating indicators of bone metabolism in uraemic patients: can they replace bone biopsy? [editorial] Schmidt–Gayk H, et al. **Nephrol Dial Transplant** 1996 Mar; 11(3):415–8 (8 ref.)

COMPLICATIONS

Reduced cardiac ischaemia tolerance in uraemia – what is the role of structural abnormalities of the heart? [editorial] Amann K, et al. **Nephrol Dial Transplant** 1996 Jul; 11(7):1238–41 (24 ref.)
Watermelon stomach. An unusual cause of recurrent upper GI tract bleeding in the uraemic patient: efficient treatment with oestrogen–progesterone therapy. Hermans C, et al. **Nephrol Dial Transplant** 1996 May;11(5):871–4 (29 ref.)
Influence of uraemia and haemodialysis on host defence and infection. Vanholder R, et al. **Nephrol Dial Transplant** 1996 Apr;11(4):593–8 (69 ref.)
1–alpha–Hydroxyvitamin D3 derivatives in the treatment of renal bone diseases: justification and optimal modalities of administration. Fournier A, et al. **Nephron** 1995; 71(3):254–83 (194 ref.)
Uremic pruritus. Ståhle–Bäckdahl M. **Semin Dermatol** 1995 Dec;14(4):297–301 (43 ref.)
Effects of uremia on growth in children. Hanna JD, et al. **Semin Nephrol** 1996 May;16(3):230–41 (79 ref.)
The heart in uremia. Massry SG, et al. **Semin Nephrol** 1996 May;16(3):214–21 (65 ref.)
[Uremic pruritus. Pathophysiologic and therapeutic concepts] Mettang T, et al. **Dtsch Med Wochenschr** 1996 Aug 16; 121(33):1025–31 (66 ref.) **(Ger)**
[Therapy of idiopathic and uremic restless legs syndrome] Trenkwalder C, et al. **Nervenarzt** 1996 Apr;67(4):265–76 (79 ref.) (Eng. Abstr.) **(Ger)**
[Prevention and treatment of uremic autonomic neuropathy] Rozentryt P, et al. **Postepy Hig Med Dosw** 1995; 49(6):767–82 (97 ref.) (Eng. Abstr.) **(Pol)**
[Uremic autonomic neuropathy—pathogenesis, diagnostic methods] Rozentryt P, et al. **Postepy Hig Med Dosw** 1995; 49(5):671–89 (101 ref.) (Eng. Abstr.) **(Pol)**

DRUG THERAPY

Arterial hypertension in uraemic patients treated with erythropoietin [editorial] Kokot F, et al. **Nephron** 1995; 71(2):127–32 (52 ref.)

ETIOLOGY

Uremic small–artery disease with medial calcification and intimal hyperplasia (so–called calciphylaxis): a complication of chronic renal failure and benefit from parathyroidectomy. Hafner J, et al. **J Am Acad Dermatol** 1995 Dec;33(6):954–62 (61 ref.)
Metabolic acidosis as a uremic toxin. Bailey JL, et al. **Semin Nephrol** 1996 May;16(3):160–6 (37 ref.)
Glomerular protein trafficking and progression of renal disease to terminal uremia. Benigni A, et al. **Semin Nephrol** 1996 May;16(3):151–9 (85 ref.)

IMMUNOLOGY

Dysfunction of polymorphonuclear leukocytes in uremia. Haag–Weber M, et al. **Semin Nephrol** 1996 May; 16(3):192–201 (123 ref.)

METABOLISM

Uremic acidosis and protein metabolism. Mitch WE. **Curr Opin Nephrol Hypertens** 1995 Nov;4(6):488–92 (41 ref.)
Metabolic acidosis stimulates protein metabolism in uremia. Mitch WE. **Miner Electrolyte Metab** 1996;22(1–3):62–5 (20 ref.)
Nutrition and dialysis adequacy. Schreiber MJ Jr. **Perit Dial Int** 1995;15(5 Suppl):S39–49 (81 ref.)
Activities of nitric oxide in normal physiology and uremia. Blantz RC, et al. **Semin Nephrol** 1996 May;16(3):144–50 (38 ref.)

MORTALITY

Causes of death in autosomal dominant polycystic kidney disease. Fick GM, et al. **J Am Soc Nephrol** 1995 Jun; 5(12):2048–56 (81 ref.)

PHYSIOPATHOLOGY

The role of the parathyroid glands in the uremic syndrome. Ritz E, et al. **Am J Kidney Dis** 1995 Nov;26(5):808–13 (53 ref.)
[Function of the autonomic nervous system in uremia] Rozentryt P, et al. **Postepy Hig Med Dosw** 1995; 49(4):551–61 (100 ref.) (Eng. Abstr.) **(Pol)**

PREVENTION & CONTROL

Azotemia control by extracorporeal therapy in patients with acute renal failure. Macias WL, et al. **New Horiz** 1995 Nov; 3(4):688–98 (62 ref.)

SURGERY

The patient with type II diabetes and uraemia—to transplant or not to transplant [editorial] Hirschl MM. **Nephrol Dial Transplant** 1995;10(9):1515–6 (7 ref.)

THERAPY

Treatment of acute renal failure in intensive care patients. Böhler J. **Int J Artif Organs** 1996 Feb;19(2):108–10 (8 ref.)
The management of uraemia in the elderly: treatment choices. Mignon F, et al. **Nephrol Dial Transplant** 1995;10 Suppl 6:55–9 (17 ref.)
Nutritional status in children receiving chronic peritoneal dialysis. Canepa A, et al. **Perit Dial Int** 1996;16 Suppl 1:S526–31 (37 ref.)
Integration of peritoneal dialysis in active uremia treatment. Ronco C, et al. **Perit Dial Int** 1996;16 Suppl 1:S393–7 (8 ref.)
[The role of dialysis membranes in elimination of uremic toxins] Grzeszczak W, et al. **Przegl Lek** 1996;53(5):439–42 (27 ref.) **(Pol)**

UREOHYDROLASES

[Gene technology to overproduce the enzymes useful as diagnostic reagents] Sugiyama M, et al. **Rinsho Byori** 1995 Aug;43(8):765–71 (8 ref.) (Eng. Abstr.) **(Jpn)**

URETER

see related
URETEROSCOPY
URETEROSTOMY

Ectopic ureter opening into the seminal vesicle in an infant: a case report and review of the Japanese literature. Terai A, et al. **Int J Urol** 1995 May;2(2):128–31 (17 ref.)
Ureteric injuries. Clinical and experimental studies. Cormio L. **Scand J Urol Nephrol Suppl** 1995;171:1–66 (210 ref.)

ABNORMALITIES

A complex cystic dysplastic urogenital anomaly—an odd presentation. Singh G, et al. **Int Urol Nephrol** 1995; 27(6):687–90 (5 ref.)
Segmental multicystic kidney and ipsilateral duplication anomalies. Corrales JG, et al. **J Urol** 1996 Apr; 155(4):1398–401 (24 ref.)
Inverted Y duplication of the ureter with associated ureterocele and bladder outlet obstruction. Regan TC, et al. **J Urol** 1996 Feb;155(2):642 (3 ref.)
Ureteral triplication, occasionally an isolated anomaly. Singh G, et al. **Urol Int** 1996;56(2):117–8 (4 ref.)
[Ectopic ureter in prostatic urethra. Unusual discovery in an adult] Prieto Ugidos N, et al. **Arch Esp Urol** 1995 Oct; 48(8):843–6 (11 ref.) (Eng. Abstr.) **(Spa)**

EMBRYOLOGY

Inductive interactions between the mesenchyme and the ureteric bud. Davies JA, et al. **Exp Nephrol** 1996 Mar–Apr; 4(2):77–85 (82 ref.)

PHYSIOLOGY

Calcitonin gene related peptide as inhibitory neurotransmitter in the ureter. Maggi CA, et al. **Can J Physiol Pharmacol** 1995 Jul;73(7):986–90 (21 ref.)
Inductive interactions between the mesenchyme and the ureteric bud. Davies JA, et al. **Exp Nephrol** 1996 Mar–Apr; 4(2):77–85 (82 ref.)

SURGERY

Initial experience with retroperitoneoscopic nephroureterectomy: use of a double–balloon technique. Gill IS, et al. **Urology** 1995 Nov;46(5):747–50 (22 ref.)

URETERAL CALCULI

THERAPY

Extracorporeal shock–wave lithotripsy of middle ureteral stones: are ureteral stents necessary? Nakada SY, et al. **Urology** 1995 Nov;46(5):649–52 (18 ref.)
[Treatment of renal and ureteral lithiasis] Doré B. **Presse Med** 1995 Oct 28;24(32):1495–7 (17 ref.) (Eng. Abstr.) **(Fre)**
[Extracorporeal lithotripsy in the treatment of upper urinary tract lithiasis] Guillonneau B, et al. **Presse Med** 1995 Dec 2;24(37):1743–6 (25 ref.) (Eng. Abstr.) **(Fre)**
[Flexible ureterorenoscopy: a method for minimally invasive diagnosis and therapy in the upper urinary tract] Fuchs GJ. **Wien Med Wochenschr** 1995;145(11–12):267–73 (22 ref.) (Eng. Abstr.) **(Ger)**
[The small urinary calculus: natural course and current treatment concepts] Hübner WA, et al. **Wien Med Wochenschr** 1995;145(11–12):276–9 (23 ref.) (Eng. Abstr.) **(Ger)**
[Current status of percutaneous calculus therapy] Kaldenbach U, et al. **Wien Med Wochenschr** 1995;145(11–12):260–7 (62 ref.) (Eng. Abstr.) **(Ger)**
[Strategy changes in the treatment of ureteral lithiasis and nephritic colic] González Enguita C, et al. **Actas Urol Esp** 1996 Apr;20(4):351–60 (35 ref.) (Eng. Abstr.) **(Spa)**
[Current treatment of ureteral lithiasis] Reina Ruiz C, et al. **Actas Urol Esp** 1995 Nov–Dec;19(10):742–54 (43 ref.) (Eng. Abstr.) **(Spa)**

URETERAL DISEASES

Ureteric injuries. Clinical and experimental studies. Cormio L. **Scand J Urol Nephrol Suppl** 1995;171:1–66 (210 ref.)
Ureteroarterial fistula: case report and review of the literature. Batter SJ, et al. **Urology** 1996 Sep;48(3):481–9 (35 ref.)

COMPLICATIONS

Renal colic. Cordell WH. **Ann Emerg Med** 1996 Apr; 27(4):451–3 (11 ref.)

DIAGNOSIS

[A case of localized amyloidosis of the ureter] Awakura Y, et al. **Hinyokika Kiyo** 1996 Feb;42(2):135–8 (8 ref.) (Eng. Abstr.) **(Jpn)**
[Cystic pyeloureteritis. A review of the literature in the period of 1946–1994 and a report of a new case] Romero Pérez P, et al. **Actas Urol Esp** 1995 Mar;19(3):252–7 (20 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

Buckshot colic: case report and review of the literature [see comments] Fildes JJ, et al. **J Trauma** 1995 Dec;39(6):1181–4 (27 ref.) Comment in: J Trauma 1996 Jun;40(6):1054.
[Ureteral stenoses and fistulas after kidney transplantation] Hajri M, et al. **Ann Urol (Paris)** 1995;29(3):177–85 (32 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

[Pseudocystic ureteritis. Apropos of a case] Joual A, et al. **Ann Urol (Paris)** 1995;29(5):284–6 (7 ref.) (Eng. Abstr.) **(Fre)**

RADIOGRAPHY

Ureteric pseudo–diverticula—its implications and a review of the literature on various ureteric diverticula. Tan TH. **Singapore Med J** 1995 Dec;36(6):682–3 (11 ref.)
Ureteral pseudodiverticulosis: the case for the retrograde urogram. Socher SA, et al. **Urology** 1996 Jun;47(6):924–7 (13 ref.)

URETERAL NEOPLASMS

[Fibroepithelial polyps of the ureter and the kidney pelvis. Report of 3 cases] Robert M, et al. **Prog Urol** 1996 Apr; 6(2):282–7 (31 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Primary leiomyosarcoma of the ureter. Griffin JH, et al. **J Surg Oncol** 1996 Jun;62(2):148–52 (15 ref.)

PATHOLOGY

Nephrogenic adenoma of the urinary tract: a review of the microscopic appearance of 80 cases with emphasis on unusual features. Oliva E, et al. **Mod Pathol** 1995 Sep; 8(7):722–30 (27 ref.)

[Transitional cell carcinoma of the ureter and cyclophosphamide: apropos of a case] Ponsot Y, et al. **Prog Urol** 1995 Sep;5(4):578–9 (8 ref.) (Eng. Abstr.) **(Fre)**

SECONDARY

[Metachronous metastasis in ureteral stump secondary to ipsilateral renal adenocarcinoma] Pereira Arias JG, et al. **Arch Esp Urol** 1995 Sep;48(7):746–8 (9 ref.) (Eng. Abstr.) **(Spa)**

SURGERY

Fibroepithelial polyps of the renal pelvis: report of two cases and review of the literature. Fernández Aceñero MJ, et al. **Minerva Urol Nefrol** 1995 Sep;47(3):133–6 (10 ref.)

Laparoscopic approaches to transitional cell carcinomas of the upper urinary tract. Patel A, et al. **Semin Surg Oncol** 1996 Mar–Apr;12(2):113–20 (12 ref.)

[Definitive endourological treatment in urothelial tumors of the upper urinary tract] Rodríguez Rodríguez R, et al. **Arch Esp Urol** 1995 Nov;48(9):937–43 (41 ref.) (Eng. Abstr.) **(Spa)**

URETERAL OBSTRUCTION

Urinary tract obstruction in children. Peters CA. **J Urol** 1995 Nov;154(5):1874–83; discussion 1883–4 (101 ref.)

[Obstructive and reflux nephropathy] Orikasa S, et al. **Nippon Rinsho** 1995 Aug;53(8):2019–26 (18 ref.) (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

Rapidly reversible acute renal failure from ureteral obstruction in pregnancy. Jena M, et al. **Am J Kidney Dis** 1996 Sep;28(3):457–60 (22 ref.)

ETIOLOGY

[Ureteral stenoses and fistulas after kidney transplantation] Hajri M, et al. **Ann Urol (Paris)** 1995;29(3):177–85 (32 ref.) (Eng. Abstr.) **(Fre)**

[Ureteral obstruction in the kidney transplant patient] Vennarecci G, et al. **Minerva Urol Nefrol** 1995 Jun; 47(2):59–64 (9 ref.) (Eng. Abstr.) **(Ita)**

SURGERY

[Pediatric ureteral ureteral outlet obstruction and obstructive megaureter: observation or operation?] Goepel M, et al. **Urologe A** 1996 Mar;35(2):91–6 (31 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

[Flexible ureterorenoscopy: a method for minimally invasive diagnosis and therapy in the upper urinary tract] Fuchs GJ. **Wien Med Wochenschr** 1995;145(11–12):267–73 (22 ref.) (Eng. Abstr.) **(Ger)**

URETEROCELE

COMPLICATIONS

Inverted Y duplication of the ureter with associated ureterocele and bladder outlet obstruction. Regan TC, et al. **J Urol** 1996 Feb;155(2):642 (3 ref.)

URETEROLITHIASIS see **URETERAL CALCULI**

URETEROSCOPY

[Principles, technics and indications of endopyelotomy] Gelet A, et al. **Prog Urol** 1995 Sep;5(4):596–604 (22 ref.) **(Fre)**

[Endourology update] Shinno Y, et al. **Hokkaido Igaku Zasshi** 1995 May;70(3):391–6 (7 ref.) (Eng. Abstr.) **(Jpn)**

METHODS

[Technics of ureteral endoscopic access] Iglesias Prieto JI, et al. **Arch Esp Urol** 1995 Oct;48(8):813–21 (30 ref.) (Eng. Abstr.) **(Spa)**

URETEROSTOMY

ADVERSE EFFECTS

[Intravesical foreign body caused arising from ureterostomy protective resin–gum] Oliver Llinares FJ, et al. **Arch Esp Urol** 1995 Oct;48(8):847–8 (6 ref.) (Eng. Abstr.) **(Spa)**

METHODS

[Lich–Gregoir ureteroneocystostomy: experience of a North–American pediatric center] Leblanc B, et al. **Ann Chir** 1995;49(8):685–8 (17 ref.) (Eng. Abstr.) **(Fre)**

URETHANE

see related
POLYURETHANES

ANALOGS & DERIVATIVES

Urethane–protected alpha–amino acid N–carboxyanhydrides and peptide synthesis. Fuller WD, et al. **Biopolymers** 1996; 40(2):183–205 (56 ref.)

URETHRA

ABNORMALITIES

Posterior urethral valves. Dinneen MD, et al. **Br J Urol** 1996 Aug;78(2):275–81 (79 ref.)

Complete duplication of the bladder and urethra: a case report and review of the literature. Ciftci AO, et al. **J Pediatr Surg** 1995 Nov;30(11):1605–6 (10 ref.)

Posterior urethral valves in patients with Down syndrome. Kupferman JC, et al. **Pediatr Nephrol** 1996 Apr;10(2):143–6 (35 ref.)

Congenital posterior urethral perineal fistulae: a unique form of urethral duplication. Wagner JR, et al. **Urology** 1996 Aug;48(2):277–80 (12 ref.)

[Ectopic ureter in prostatic urethra. Unusual discovery in an adult] Prieto Ugidos N, et al. **Arch Esp Urol** 1995 Oct; 48(8):843–6 (11 ref.) (Eng. Abstr.) **(Spa)**

ANATOMY & HISTOLOGY

The significance of smooth and striated muscles in the sphincter function of the urethra in healthy women. Thind P. **Neurourol Urodyn** 1995;14(6):585–618 (289 ref.)

Functional anatomy of the organs of micturition. Elbadawi A. **Urol Clin North Am** 1996 May;23(2):177–210 (255 ref.)

ENZYMOLOGY

Nitric oxide synthase and the lower urinary tract: possible implications for physiology and pathophysiology. Andersson KE, et al. **Scand J Urol Nephrol Suppl** 1995; 175:43–53 (102 ref.)

INJURIES

[Endoscopic resection of a peri–stenotic fibrous callus of the urethra using Guillemin's method] Giannakopoulos X, et al. **J Urol (Paris)** 1995;101(2):81–7 (37 ref.) (Eng. Abstr.) **(Fre)**

INNERVATION

Neurophysiology of micturition and continence. Chai TC, et al. **Urol Clin North Am** 1996 May;23(2):221–36 (142 ref.)

PATHOLOGY

Anatomic goals in the correction of female stress urinary incontinence. Mostwin JL, et al. **J Endourol** 1996 Jun; 10(3):207–12 (29 ref.)

PHYSIOLOGY

The significance of smooth and striated muscles in the sphincter function of the urethra in healthy women. Thind P. **Neurourol Urodyn** 1995;14(6):585–618 (289 ref.)

Videourodynamic studies. McGuire EJ, et al. **Urol Clin North Am** 1996 May;23(2):309–21 (13 ref.)

Micturitional urethral pressure profilometry. Sullivan MP, et al. **Urol Clin North Am** 1996 May;23(2):263–78 (25 ref.)

PHYSIOPATHOLOGY

Leak–point pressures. McGuire EJ, et al. **Urol Clin North Am** 1996 May;23(2):253–62 (12 ref.)

Detrusor–sphincter dyssynergia. Barsanti JA, et al. **Vet Clin North Am Small Anim Pract** 1996 Mar; 26(2):327–38 (32 ref.)

SURGERY

Hypospadias repair: current principles and procedures. Mouriquand PD, et al. **Br J Urol** 1995 Dec;76 Suppl 3:9–22 (40 ref.)

Transpubic urethroplasty in children: report of 10 cases with review of the literature. Senocak ME, et al. **J Pediatr Surg** 1995 Sep;30(9):1319–24 (20 ref.)

[Prevention using quinolones in transurethral surgery] Gasser TC. **Ann Urol (Paris)** 1996;30(3):124–8 (30 ref.) (Eng. Abstr.) **(Fre)**

[Simplified vesico–urethral anastomosis after radical retropubic prostatectomy for cancer. A preliminary comparative study] Doré B, et al. **J Urol (Paris)** 1995; 101(3):113–21 (31 ref.) (Eng. Abstr.) **(Fre)**

ULTRASONOGRAPHY

Imaging of the lower urinary tract. Koelbl H, et al. **Curr Opin Obstet Gynecol** 1995 Oct;7(5):382–5 (18 ref.)

URETHRAL DISEASES

COMPLICATIONS

[Apropos of a case of nephrogenic adenoma in a urethral diverticulum in a woman] Materne R, et al. **Acta Urol Belg** 1995 Dec;63(4):13–8 (59 ref.) (Eng. Abstr.) **(Fre)**

CONGENITAL

Congenital urethrocutaneous fistula: a case report and literature review, with a nomenclature proposal. Karnak I, et al. **J Pediatr Surg** 1995 Oct;30(10):1504–5 (7 ref.)

DIAGNOSIS

Urethral prolapse: an often misdiagnosed cause of urogenital bleeding in girls. Anveden–Hertzberg L, et al. **Pediatr Emerg Care** 1995 Aug;11(4):212–4 (25 ref.)

DRUG THERAPY

Management of rectourethral fistulas in Crohn's disease. Santoro GA, et al. **Int J Colorectal Dis** 1995;10(4):183–8 (47 ref.)

ETIOLOGY

[A case of urethral diverticulum in a male paraplegic patient] Kawakami T, et al. **Hinyokika Kiyo** 1995 Nov; 41(11):887–90 (8 ref.) (Eng. Abstr.) **(Jpn)**

SURGERY

[Mucous prolapse of the urethra] Pouya M, et al. **Acta Urol Belg** 1995 Dec;63(4):23–9 (17 ref.) (Eng. Abstr.) **(Fre)**

[Urethral parameatal cysts. Report of two cases and review of the literature] Di Cello V, et al. **Minerva Urol Nefrol** 1995 Sep;47(3):137–9 (6 ref.) (Eng. Abstr.) **(Ita)**

URETHRAL NEOPLASMS

Primary non–Hodgkin's lymphoma of the male urethra. A case report and review of the literature. Hofmockel G, et al. **Urol Int** 1995;55(3):177–80 (26 ref.)

COMPLICATIONS

[Apropos of a case of nephrogenic adenoma in a urethral diverticulum in a woman] Materne R, et al. **Acta Urol Belg** 1995 Dec;63(4):13–8 (59 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Paraganglioma of the prostatic urethra. A report of three cases and a review of the literature. Boyle M, et al. **Br J Urol** 1996 Mar;77(3):445–8 (16 ref.)

The histogenesis of clear cell adenocarcinoma of the lower urinary tract. Case series and review of the literature. Drew PA, et al. **Hum Pathol** 1996 Mar;27(3):248–52 (32 ref.)

Nephrogenic adenoma of the urinary tract: a review of the microscopic appearance of 80 cases with emphasis on unusual features. Oliva E, et al. **Mod Pathol** 1995 Sep; 8(7):722–30 (27 ref.)

[Inverted papilloma of the female urethra] Viguri Díaz A, et al. **Arch Esp Urol** 1995 Nov;48(9):954–6 (8 ref.) (Eng. Abstr.) **(Spa)**

RADIOTHERAPY

Long–term disease–free survival after plasmacytoma of the urethra: a case report and review of the literature. Mordkin RM, et al. **Urology** 1996 Jul;48(1):149–50 (7 ref.)

SECONDARY

Current methods of assessing and treating carcinoma in situ of the bladder with or without involvement of the prostatic urethra. Kurth KH, et al. **Int J Urol** 1995 Jun;2 Suppl 2:8–22 (124 ref.)

SURGERY

Fibroepithelial polyps of the renal pelvis: report of two cases and review of the literature. Fernández Aceñero MJ, et al. **Minerva Urol Nefrol** 1995 Sep;47(3):133–6 (10 ref.)

URETHRAL OBSTRUCTION

ABC of urology. Bladder outflow obstruction. Dawson C, et al. **BMJ** 1996 Mar 23;312(7033):767–70 (0 ref.)

COMPLICATIONS

Posterior urethral valves in patients with Down syndrome. Kupferman JC, et al. **Pediatr Nephrol** 1996 Apr;10(2):143–6

(35 ref.)

DIAGNOSIS

Bio-acoustic signals from stenotic tube flow: state of the art and perspectives for future methodological development. Ask P, et al. **Med Biol Eng Comput** 1995 Sep;33(5):669-75 (29 ref.)

ETIOLOGY

[Kaposi sarcoma of the glans penis with meatal obstruction. Case report and literature review] John H, et al. **Swiss Surg** 1996;(3):134-6 (3 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOPATHOLOGY

Physiological principles for surgical correction of detrusor dysfunction. Blaivas JG, et al. **J Endourol** 1996 Jun; 10(3):213-6 (42 ref.)

Effects of ureteral obstruction on renal growth. Chevalier RL. **Semin Nephrol** 1995 Jul;15(4):353-60 (73 ref.)

VETERINARY

Pathophysiology of urethral obstruction. Bartges JW, et al. **Vet Clin North Am Small Anim Pract** 1996 Mar; 26(2):255-64 (18 ref.)

Feline urethral plugs. Etiology and pathophysiology. Osborne CA, et al. **Vet Clin North Am Small Anim Pract** 1996 Mar; 26(2):233-53 (15 ref.)

URETHRAL STENOSIS see **URETHRAL STRICTURE**

URETHRAL STRICTURE

[Urethral stenosis. Conceptual review and classification] Romero Pérez P, et al. **Actas Urol Esp** 1995 May; 19(5):345-55 (39 ref.) (Eng. Abstr.) **(Spa)**

CONGENITAL

Congenital bulbar urethral strictures occurring in three brothers. Donnellan SM, et al. **Aust N Z J Surg** 1996 Jun; 66(6):423-4 (12 ref.)

SURGERY

Transpubic urethroplasty in children: report of 10 cases with review of the literature. Senocak ME, et al. **J Pediatr Surg** 1995 Sep;30(9):1319-24 (20 ref.)

[Endoscopic resection of a peri-stenotic fibrous callus of the urethra using Guillemin's method] Giannakopoulos X, et al. **J Urol (Paris)** 1995;101(2):81-7 (37 ref.) (Eng. Abstr.) **(Fre)**

URETHRITIS

DRUG THERAPY

Nongonococcal urethritis. Nickel P, et al. **Curr Probl Dermatol** 1996;24:97-104 (34 ref.)

URIC ACID

BLOOD

Hyperuricemia and xanthine oxidase in preeclampsia, revisited. Many A, et al. **Am J Obstet Gynecol** 1996 Jan; 174(1 Pt 1):288-91 (60 ref.)

Abnormal serum uric acid levels in children. Wilcox WD. **J Pediatr** 1996 Jun;128(6):731-41 (112 ref.)

Acute renal failure with hyperuricemia as initial presentation of leukemia in children. Larsen G, et al. **J Pediatr Hematol Oncol** 1996 May;18(2):191-4 (16 ref.)

[Hyperuricemia] Gröbner W, et al. **Internist (Berl)** 1995 Dec; 36(12):1207-21 (13 ref.) **(Ger)**

[Hyperuricemia] Gröbner W, et al. **Urologe A** 1996 May; 35(3):263-77 (13 ref.) **(Ger)**

[Obesity and the related diseases: gout] Akaoka Y, et al. **Nippon Naika Gakkai Zasshi** 1995 Aug 10;84(8):1262-6 (6 ref.) **(Jpn)**

[Uric acid] Nishioka K. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:469-72 (4 ref.) **(Jpn)**

[Hyperuric acidemia and obesity] Yamanouchi T, et al. **Nippon Rinsho** 1995 Jun;53 Suppl:310-5 (13 ref.) **(Jpn)**

METABOLISM

On the significance of brain extracellular uric acid detected with in-vivo monitoring techniques: a review. O'Neill RD, et al. **Behav Brain Res** 1995 Nov;71(1-2):33-49 (254 ref.)

Gout, uric acid metabolism, and crystal-induced inflammation. Weinberger A. **Curr Opin Rheumatol** 1995 Jul;7(4):359-63 (49 ref.)

[Renal diseases in disturbance of urate metabolism] Tofuku Y. **Nippon Rinsho** 1995 Aug;53(8):1988-94 (22 ref.) (Eng. Abstr.) **(Jpn)**

URIDINE

METABOLISM

Uracil metabolism--UMP synthesis from orotic acid or uridine and conversion of uracil to beta-alanine: enzymes and cDNAs. Traut TW, et al. **Prog Nucleic Acid Res Mol Biol** 1996;53:1-78 (273 ref.)

URIDINE DIPHOSPHATE GLUCOSE EPIMERASE

PHYSIOLOGY

The Leloir pathway: a mechanistic imperative for three enzymes to change the stereochemical configuration of a single carbon in galactose. Frey PA. **FASEB J** 1996 Mar; 10(4):461-70 (40 ref.)

URIDINE MONOPHOSPHATE

BIOSYNTHESIS

Uracil metabolism--UMP synthesis from orotic acid or uridine and conversion of uracil to beta-alanine: enzymes and cDNAs. Traut TW, et al. **Prog Nucleic Acid Res Mol Biol** 1996;53:1-78 (273 ref.)

METABOLISM

Trypanosome RNA editing: resolved [comment] Sollner-Webb B. **Science** 1996 Aug 30;273(5279):1182-3 (17 ref.) Comment on: Science 1996 Aug 30;273(5279):1189-95.

URIDYLATE 5'-NUCLEOTIDASE see **5'-NUCLEOTIDASE**

URIDYLIC ACID see **URIDINE MONOPHOSPHATE**

URINALYSIS

Urinalysis. When--and when not--to order. Misdraji J, et al. **Postgrad Med** 1996 Jul;100(1):173-6, 181-2, 185-8 passim (15 ref.)

URINARY CALCULI

ABC of urology. Urinary stone disease. Dawson C, et al. **BMJ** 1996 May 11;312(7040):1219-21 (0 ref.)

COMPLICATIONS

Urinary bladder carcinogenesis: implications for risk assessment. Rodent Bladder Carcinogenesis Working Group. **Food Chem Toxicol** 1995 Sep;33(9):797-802 (32 ref.)

Effects of stones and other physical factors on the induction of rodent bladder cancer. Clayson DB, et al. **Food Chem Toxicol** 1995 Sep;33(9):771-84 (142 ref.)

ETIOLOGY

The influence of diet on urinary stone disease. Parivar F, et al. **J Urol** 1996 Feb;155(2):432-40 (139 ref.)

Experimental calcium oxalate nephrolithiasis and the formation of human urinary stones. Khan SR. **Scanning Microsc** 1995 Mar;9(1):89-100; discussion 100-1 (79 ref.)

[Role of glycosaminoglycans relating to formation of urolithiasis] Nishio S. **Nippon Hinyokika Gakkai Zasshi** 1995 Nov;86(11):1597-609 (99 ref.) **(Jpn)**

METABOLISM

[Metabolic investigation of calcium oxalate urinary lithiasis. Indicators of lithogenic risk: modalities, applications and perspectives] Robert M. **Prog Urol** 1996 Feb;6(1):44-51 (84 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

Prevention of recurrent calcium stones: a rational approach. Tomson CR. **Br J Urol** 1995 Oct;76(4):419-24 (45 ref.)

[The dilemma of metaphylaxis of urinary calculi] Zechner O. **Wien Med Wochenschr** 1995;145(11-12):279-82 (6 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Pediatric urolithiasis: medical and surgical management. Cohen TD, et al. **Urology** 1996 Mar;47(3):292-303 (135 ref.)

[Current status and future developments in noninvasive treatment of urinary calculi with extracorporeal shockwave lithotripsy (ESWL)] Hofbauer J, et al. **Wien Med Wochenschr** 1995;145(11-12):254-8 (52 ref.) (Eng. Abstr.) **(Ger)**

[Urolithiasis in children] Türk C, et al. **Wien Med Wochenschr** 1995;145(11-12):258-60 (11 ref.) (Eng. Abstr.) **(Ger)**

URINE

Crystalluria: a neglected aspect of urinary sediment analysis. Fogazzi GB. **Nephrol Dial Transplant** 1996 Feb; 11(2):379-87 (56 ref.)

VETERINARY

Feline urolithiasis. Etiology and pathophysiology. Osborne CA, et al. **Vet Clin North Am Small Anim Pract** 1996 Mar; 26(2):217-32 (37 ref.)

Feline crystalluria. Detection and interpretation. Osborne CA, et al. **Vet Clin North Am Small Anim Pract** 1996 Mar; 26(2):369-91 (3 ref.)

Urolith analysis. Submission, methods, and interpretation. Ulrich LK, et al. **Vet Clin North Am Small Anim Pract** 1996 Mar;26(2):393-400 (5 ref.)

URINARY CATHETERIZATION

Bladder instillations and bladder washouts in the management of catheterized patients. Getliffe KA. **J Adv Nurs** 1996 Mar; 23(3):548-54 (49 ref.)

[Bladder dysfunctions in encephalomyelitis disseminata--drug and interventional therapeutic options] Zwergel U, et al. **Fortschr Neurol Psychiatr** 1995 Dec; 63(12):495-503 (125 ref.) (Eng. Abstr.) **(Ger)**

[Urinary tract infections in patients with non-indwelling catheter (I). Risk factors, pathogenesis, etiology, and clinical course] Ignacio Barrasa Villar J, et al. **Med Clin (Barc)** 1996 May 11;106(18):704-10 (80 ref.) **(Spa)**

ADVERSE EFFECTS

[Bacteriuria caused by bladder catheters; value of various preventive measures] Geenen RW, et al. **Ned Tijdschr Geneeskd** 1996 Apr 27;140(17):918-22 (27 ref.) **(Dut)**

[Urinary infections in patients with non-permanent bladder catheter (and II): diagnosis, treatment, prevention and research aspects] Barrasa Villar JI, et al. **Med Clin (Barc)** 1996 Apr 13;106(14):548-54 (67 ref.) **(Spa)**

INSTRUMENTATION

[The double J catheter in the shock wave treatment of kidney calculi] Pilar Laguna M, et al. **Ann Urol (Paris)** 1995; 29(6-7):364-9 (20 ref.) (Eng. Abstr.) **(Fre)**

METHODS

Intermittent catheterisation: simple, safe, and effective but underused. Hunt GM, et al. **BMJ** 1996 Jan 13; 312(7023):103-7 (35 ref.)

VETERINARY

Urolith analysis. Submission, methods, and interpretation. Ulrich LK, et al. **Vet Clin North Am Small Anim Pract** 1996 Mar;26(2):393-400 (5 ref.)

URINARY DIVERSION

Which patients are suitable for continent diversion or bladder substitution following cystectomy or other definitive local treatment? Skinner DG, et al. **Int J Urol** 1995 Jun;2 Suppl 2:105-12 (105 ref.)

[Current practice and controversies in urinary diversion--the selection of the operation method of urinary diversion and postoperative care] Okajima E, et al. **Hinyokika Kiyo** 1995 Nov;41(11):899-901 (10 ref.) (Eng. Abstr.) **(Jpn)**

ADVERSE EFFECTS

[Endourologic treatment of uretero-ileal stenosis] del Hoyo Campos J, et al. **Arch Esp Urol** 1995 Sep;48(7):735-40 (23 ref.) (Eng. Abstr.) **(Spa)**

INSTRUMENTATION

[Current strategies in patients with urinary diversion, 2: Upper urinary tract] Moll F. **Z Arztl Fortbild (Jena)** 1996 May;90(3):241-8 (22 ref.) (Eng. Abstr.) **(Ger)**

METHODS

The prosthetic bladder. Gürpinar T, et al. **World J Urol** 1996; 14(1):47-52 (22 ref.)

The use of neobladders in women undergoing cystectomy for transitional-cell cancer. Stenzl A, et al. **World J Urol** 1996;14(1):15-21 (37 ref.)

URINARY FISTULA

Nephrobronchocutaneous fistula. Aly SA, et al. **Ulster Med J** 1994 Apr;63(1):116-8 (5 ref.)

Ureteroarterial fistula: case report and review of the literature. Batter SJ, et al. **Urology** 1996 Sep;48(3):481-9 (35 ref.)

CONGENITAL

Congenital urethrocutaneous fistula: a case report and literature review, with a nomenclature proposal. Karnak I, et al. **J Pediatr Surg** 1995 Oct;30(10):1504-5 (7 ref.)

DRUG THERAPY

Management of rectourethral fistulas in Crohn's disease. Santoro GA, et al. **Int J Colorectal Dis** 1995;10(4):183-8 (47 ref.)

ETIOLOGY

Nephrobronchial fistula and lung abscess resulting from nephrolithiasis and pyelonephritis. O'Brien JD, et al. **Chest** 1995 Oct;108(4):1166-8 (6 ref.)

[Ureteral stenoses and fistulas after kidney transplantation] Hajri M, et al. **Ann Urol (Paris)** 1995;29(3):177-85 (32 ref.) (Eng. Abstr.) **(Fre)**

URINARY INCONTINENCE

ABC of urology. Urinary incontinence and urinary infection. Dawson C, et al. **BMJ** 1996 Apr 13;312(7036):961–4 (0 ref.)
Quality of life and urinary incontinence. Kelleher CJ, et al. **Curr Opin Obstet Gynecol** 1995 Oct;7(5):404–8 (26 ref.)
Urinary incontinence in the elderly population. Chutka DS, et al. **Mayo Clin Proc** 1996 Jan;71(1):93–101 (51 ref.)
Urinary incontinence. Basic types and their management in older patients. Yim PS, et al. **Postgrad Med** 1996 May; 99(5):137–40, 143–4, 149–50 (14 ref.)
Geriatric incontinence. Resnick NM. **Urol Clin North Am** 1996 Feb;23(1):55–74 (110 ref.)
Urge incontinence. Swami SK, et al. **Urol Clin North Am** 1996 Aug;23(3):417–25 (57 ref.)

COMPLICATIONS

[Treatment of micturition disorders in multiple sclerosis] Bagunyà-Durich J. **Neurologia** 1996 May;11(5):182–91 (30 ref.) **(Spa)**

EPIDEMIOLOGY

[Epidemiology — cost] **Prog Urol** 1995 Nov;5(5):747–53 (39 ref.) **(Fre)**

ETIOLOGY

Agenesis of bladder associated with multiple organ anomalies. Sarica K, et al. **Int Urol Nephrol** 1995; 27(6):697–703 (10 ref.)
Interpreting the effect of common medical conditions on voiding dysfunction in the elderly. DuBeau CE. **Urol Clin North Am** 1996 Feb;23(1):11–8 (52 ref.)
Postprostatectomy incontinence. Haab F, et al. **Urol Clin North Am** 1996 Aug;23(3):447–57 (70 ref.)
[Urinary incontinence of bladder origin — bladder instability] **Prog Urol** 1995 Nov;5(5):773–87 (124 ref.) **(Fre)**
[Effect of pregnancy and delivery on genuine stress incontinence] Zilberman B, et al. **Harefuah** 1995 Jul; 129(1–2):43–6 (21 ref.) **(Heb)**

PHYSIOPATHOLOGY

Matrix changes in the bladder associated with normal aging. Shapiro E, et al. **Adv Exp Med Biol** 1995;385:187–90; discussion 223–8 (23 ref.)
Physiological principles for surgical correction of detrusor dysfunction. Blaivas JG, et al. **J Endourol** 1996 Jun; 10(3):212–6 (42 ref.)
Leak-point pressures. McGuire EJ, et al. **Urol Clin North Am** 1996 May;23(2):253–62 (12 ref.)
[Mechanisms of continence and incontinence. Nosologic profiles] **Prog Urol** 1995 Nov;5(5):755–72 (67 ref.) **(Fre)**
[Pro: a critical contribution to better understanding of possible functional disorders of the genital, bladder and pelvic floor system] Schüssler B. **Arch Gynecol Obstet** 1995; 257(1–4):359–62 (14 ref.) **(Ger)**

PSYCHOLOGY

Psychosocial issues in geriatric urology: problems in treatment and treatment seeking. Umlauf MG, et al. **Urol Clin North Am** 1996 Feb;23(1):127–36 (35 ref.)

REHABILITATION

Physical therapy as an effective change agent in the treatment of patients with urinary incontinence. McCandless S, et al. **J Miss State Med Assoc** 1995 Sep;36(9):271–4 (18 ref.)
Prevention and treatment of incontinence after radical prostatectomy. Milam DF, et al. **Semin Urol Oncol** 1995 Aug;13(3):224–37 (50 ref.)

SURGERY

Experience with augmentation cystoplasty. A review. Mast P, et al. **Paraplegia** 1995 Oct;33(10):560–4 (25 ref.)
[Pelvic floor insufficiency as an interdisciplinary responsibility] Hansen H. **Chirurg** 1996 May;67(5):498–504 (14 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Nursing assessment and management strategies for urinary incontinence. Ravalli R, et al. **J Endourol** 1996 Jun; 10(3):297–300 (14 ref.)
[Electric stimulation—hope for patients with urinary incontinence] Franek A, et al. **Pol Tyg Lek** 1996 Feb; 51(6–9):109–12 (40 ref.) **(Pol)**

VETERINARY

[Urinary incontinence in castrated female dogs. 2. Therapy] Blendinger C, et al. **Tierarztl Prax** 1995 Aug;23(4):402–6 (30 ref.) (Eng. Abstr.) **(Ger)**

URINARY INCONTINENCE, STRESS

Stress incontinence: new alternatives. McGuire EJ. **Int J Fertil Menopausal Stud** 1996 Mar–Apr;41(2):142–7 (27 ref.)
[Urinary incontinence of urethral origin. Stress urinary incontinence] **Prog Urol** 1995 Nov;5(5):789–849 (378 ref.) **(Fre)**

DIAGNOSIS

Proper diagnosis: a must before surgery for stress incontinence. McGuire EJ, et al. **J Endourol** 1996 Jun; 10(3):201–5 (26 ref.)
Diagnosis of stress urinary incontinence. An overview. Dupont MC, et al. **Urol Clin North Am** 1996 Aug; 23(3):407–15 (6 ref.)

ETIOLOGY

Mixed urinary incontinence secondary to lead poisoning. Crewalk JA, et al. **J Urol** 1996 Jun;155(6):2029 (3 ref.)
Female stress urinary incontinence due to intrinsic sphincteric deficiency: recognition and management. Haab F, et al. **J Urol** 1996 Jul;156(1):3–17 (222 ref.)
Pelvic organ prolapse and stress urinary incontinence. Rush CB, et al. **Med Clin North Am** 1995 Nov;79(6):1473–9 (16 ref.)
[Apropos of a case of nephrogenic adenoma in a urethral diverticulum in a woman] Materne R, et al. **Acta Urol Belg** 1995 Dec;63(4):13–8 (59 ref.) (Eng. Abstr.) **(Fre)**
[Female urology: new advances in 1995] Chassagne S, et al. **J Urol (Paris)** 1996;102(1):33–9 (32 ref.) **(Fre)**

PREVENTION & CONTROL

Protecting the pelvic floor: obstetric management to prevent incontinence and pelvic organ prolapse. Handa VL, et al. **Obstet Gynecol** 1996 Sep;88(3):470–8 (46 ref.)

SURGERY

Minimally invasive treatment of urinary stress incontinence and laparoscopically directed repair of pelvic floor defects. Lyons TL. **Clin Obstet Gynecol** 1995 Jun;38(2):380–91 (42 ref.)
Complications of urogynaecological surgery. Neale R. **Curr Opin Obstet Gynecol** 1995 Oct;7(5):400–3 (21 ref.)
Laparoscopic surgery for incontinence and genitourinary prolapse. Smith AR. **Curr Opin Obstet Gynecol** 1995 Oct; 7(5):397–9 (21 ref.)
Correction of stress urinary incontinence: transperitoneal approach. Cadeddu JA, et al. **J Endourol** 1996 Jun; 10(3):241–5 (25 ref.)
Anatomic goals in the correction of female stress urinary incontinence. Mostwin JL, et al. **J Endourol** 1996 Jun; 10(3):207–12 (29 ref.)
Needle suspension procedures: past, present, and future. Trockman BA, et al. **J Endourol** 1996 Jun;10(3):217–20 (36 ref.)
Outcome of sling cystourethropexy in the pediatric population: a critical review. Pérez LM, et al. **J Urol** 1996 Aug;156(2 Pt 2):642–6 (26 ref.)
Which is the most appropriate operation for genuine stress incontinence (GSI)? Ng KW. **Singapore Med J** 1995 Dec; 36(6):590–6 (82 ref.)
[The vaginal route in the treatment of stress urinary incontinence] Lobel B, et al. **Prog Urol** 1995 Dec; 5(6):1012–21 (8 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Injectables in the treatment of female stress incontinence. Appell RA. **Curr Opin Obstet Gynecol** 1995 Oct;7(5):393–6 (32 ref.)
Conservative management of incontinence. Wilson D, et al. **Curr Opin Obstet Gynecol** 1995 Oct;7(5):386–92 (41 ref.)
Rationale and treatment results with bioinjectables. Burney TL, et al. **J Endourol** 1996 Jun;10(3):273–7 (29 ref.)
Introl bladder neck support prosthesis: a nonsurgical urethropexy. Davila GW. **J Endourol** 1996 Jun;10(3):293–6 (7 ref.)

URINARY RESERVOIRS, CONTINENT

Experience with augmentation cystoplasty. A review. Mast P, et al. **Paraplegia** 1995 Oct;33(10):560–4 (25 ref.)
Bladder preservation and continent urinary diversion in T3b transitional cell carcinoma of the bladder. Cespedes RD, et al. **Semin Urol Oncol** 1996 May;14(2):103–11 (56 ref.)
[Current practice and controversies in urinary diversion—the selection of the operation method of urinary diversion and postoperative care] Okajima E, et al. **Hinyokika Kiyo** 1995 Nov;41(11):899–901 (10 ref.) (Eng. Abstr.) **(Jpn)**

INSTRUMENTATION

[Current strategies in patients with urinary diversion, 2: Upper urinary tract] Moll F. **Z Arztl Fortbild (Jena)** 1996 May;90(3):241–8 (22 ref.) (Eng. Abstr.) **(Ger)**

URINARY RETENTION

see related
URINARY CATHETERIZATION

ETIOLOGY

[Effects of anesthesia on postoperative micturition and urinary retention] Pertek JP, et al. **Ann Fr Anesth Reanim** 1995;14(4):340–51 (44 ref.) (Eng. Abstr.) **(Fre)**
[Obstructive uropathy secondary to genitourinary prolapse] Pereira Arias JG, et al. **Actas Urol Esp** 1995 Mar; 19(3):247–50 (9 ref.) (Eng. Abstr.) **(Spa)**
[Acute urinary retention secondary to an imperforate hymen with hematocolpos] Gatius Tonda C, et al. **An Esp Pediatr** 1996 Apr;44(4):381–2 (8 ref.) **(Spa)**

URINARY TRACT

ABNORMALITIES

What can we infer from findings in subgroups? [editorial; comment] Hatch M. **Epidemiology** 1995 Sep;6(5):473–5 (4 ref.) Comment on: Epidemiology 1995 Sep;6(5):485–9.
Antenatal diagnosis of renal tract anomalies: has it increased the sum of human happiness? Malone PS. **J R Soc Med** 1996 Mar;89(3):155P–8P (45 ref.)

ANATOMY & HISTOLOGY

Applied anatomy and physiology of the feline lower urinary tract. Fletcher TF. **Vet Clin North Am Small Anim Pract** 1996 Mar; 26(2):181–96 (40 ref.)

EMBRYOLOGY

Fetal lower urinary tract physiology: in vivo studies. Mevorach RA, et al. **Adv Exp Med Biol** 1995;385:85–91; discussion 131–9 (9 ref.)

GROWTH & DEVELOPMENT

Developmental physiology—overview. de Groat WC. **Adv Exp Med Biol** 1995;385:81–3; discussion 131–9 (5 ref.)

INJURIES

Urologic injuries in pelvic ring disruptions. Watnik NF, et al. **Clin Orthop** 1996 Aug;(329):37–45 (38 ref.)
Management of complex urologic injuries. Skinner EC, et al. **Surg Clin North Am** 1996 Aug;76(4):861–78 (36 ref.)
Healing responses of the lower urinary tract. Degner DA, et al. **Vet Clin North Am Small Anim Pract** 1996 Mar; 26(2):197–206 (41 ref.)

PATHOLOGY

Diagnostic imaging of the feline lower urinary tract. Johnston GR, et al. **Vet Clin North Am Small Anim Pract** 1996 Mar; 26(2):401–15 (9 ref.)

PHYSIOLOGY

Developmental physiology—overview. de Groat WC. **Adv Exp Med Biol** 1995;385:81–3; discussion 131–9 (5 ref.)
Fetal lower urinary tract physiology: in vivo studies. Mevorach RA, et al. **Adv Exp Med Biol** 1995;385:85–91; discussion 131–9 (9 ref.)
Urine storage mechanisms. Vaughan CW, et al. **Prog Neurobiol** 1995 Jun;46(2–3):215–37 (225 ref.)
Healing responses of the lower urinary tract. Degner DA, et al. **Vet Clin North Am Small Anim Pract** 1996 Mar; 26(2):197–206 (41 ref.)
Applied anatomy and physiology of the feline lower urinary tract. Fletcher TF. **Vet Clin North Am Small Anim Pract** 1996 Mar; 26(2):181–96 (40 ref.)
[Role of nitric oxide (no) in urology] Yoshida M, et al. **Nippon Hinyokika Gakkai Zasshi** 1995 Dec; 86(12):1691–710 (140 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Mechanisms underlying the recovery of lower urinary tract function following spinal cord injury. de Groat WC. **Paraplegia** 1995 Sep;33(9):493–505 (70 ref.)

RADIATION EFFECTS

Damage to the urinary tract secondary to irradiation. Fichtner J, et al. **World J Urol** 1995;13(4):240–2 (23 ref.)

SURGERY

Urinary tract reconstruction in children undergoing renal transplantation. Ewalt DH, et al. **Adv Ren Replace Ther** 1996 Jan;3(1):69–76 (19 ref.)

URINARY TRACT DISEASES see **UROLOGIC DISEASES**

URINARY TRACT INFECTIONS

see related
ANTI-INFECTIVE AGENTS, URINARY

ABC of urology. Urinary incontinence and urinary infection. Dawson C, et al. **BMJ** 1996 Apr 13;312(7036):961–4 (0 ref.)
Genitourinary infection in older women. Sale PG. **J Obstet Gynecol Neonatal Nurs** 1995 Oct;24(8):769–75 (26 ref.)
Urinary tract infections. Ang BS. **Singapore Med J** 1995 Jun; 36(3):314–7 (33 ref.)

COMPLICATIONS

A review of renal scarring in children. MacKenzie JR. **Nucl Med Commun** 1996 Mar;17(3):176–90 (44 ref.)
[Endoscopic resection of a peri-stenotic fibrous callus of the urethra using Guillemin's method] Giannakopoulos X, et

al. **J Urol (Paris)** 1995;101(2):81–7 (37 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Urinary tract infections in infants and children. Nash MA, et al. **Adv Pediatr Infect Dis** 1996;11:403–48 (187 ref.)
Review: urinary tract infection in elderly people—time to review management? Gray RP, et al. **Age Ageing** 1995 Jul; 24(4):341–5 (45 ref.)
Urinary tract infection [editorial] Mehta KP. **Indian Pediatr** 1996 Mar;33(3):173–6 (14 ref.)
Common genitourinary infections. Freeman SB. **J Obstet Gynecol Neonatal Nurs** 1995 Oct;24(8):735–42 (26 ref.)
Urinary tract infections. Old and new concepts. Hellerstein S. **Pediatr Clin North Am** 1995 Dec;42(6):1433–57 (93 ref.)
[Renal and urinary tract leishmaniasis. A disease to keep in mind] Romero Maroto J, et al. **Actas Urol Esp** 1995 Nov–Dec;19(10):789–94 (25 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

Urinary tract infections in elderly women. Nygaard IE, et al. **Am Fam Physician** 1996 Jan;53(1):175–82 (29 ref.)
Oral cephalosporins: clinical results in urinary tract infections. Giamarellou H. **Antibiot Chemother** 1995; 47:145–59 (46 ref.)
Treatment of urinary tract infections. Korman TM, et al. **Aust Fam Physician** 1995 Dec;24(12):2205–11 (5 ref.)
Fungal urinary tract infections in the elderly: treatment guidelines. Jacobs LG. **Drugs Aging** 1996 Feb;8(2):89–96 (32 ref.)
[Treatment of urinary tract infection in children] Brun P, et al. **Arch Pediatr** 1996 Jan;3(1):81–4 (8 ref.) (Eng. Abstr.) **(Fre)**
[Urinary infections and the role of quinolones] Rutschmann O. **Rev Med Suisse Romande** 1996 May;116(5):405–8 (34 ref.) **(Fre)**
[Multicenter comparative study of meropenem vs. imipenem in the intramuscular treatment of hospital infections of the urinary tract] Tallarigo C, et al. **Minerva Urol Nefrol** 1995 Sep;47(3):147–56 (16 ref.) (Eng. Abstr.) **(Ita)**

ETIOLOGY

Transurethral laser therapy and urinary tract infections. Miller J, et al. **Ann Urol (Paris)** 1996;30(3):131–8 (38 ref.)
The association of urinary tract infection with a recent pelvic examination in women. Tiemstra JD, et al. **Arch Fam Med** 1996 Jun;5(6):357–60 (18 ref.)
Urinary tract infection. Gulati S, et al. **Indian Pediatr** 1996 Mar;33(3):211–7 (20 ref.)
[Urinary tract infections—causes, differential diagnosis and treatment] Papstein C, et al. **Z Arztl Fortbild (Jena)** 1996 May;90(3):179–85 (18 ref.) (Eng. Abstr.) **(Ger)**
[Urinary infections in patients with non-permanent bladder catheter (and II): diagnosis, treatment, prevention and research aspects] Barrasa Villar JI, et al. **Med Clin (Barc)** 1996 Apr 13;106(14):548–54 (67 ref.) **(Spa)**
[Urinary tract infections in patients with non-indwelling catheter (I). Risk factors, pathogenesis, etiology, and clinical course] Ignacio Barrasa Villar J, et al. **Med Clin (Barc)** 1996 May 11;106(18):704–10 (80 ref.) **(Spa)**

MICROBIOLOGY

Swarming and pathogenicity of Proteus mirabilis in the urinary tract. Mobley HL, et al. **Trends Microbiol** 1995 Jul;3(7):280–4 (36 ref.)
[Urinary infections: specific aspects] Andreu A. **Enferm Infecc Microbiol Clin** 1995 Nov;13(9):527–31 (31 ref.) **(Spa)**

PATHOLOGY

A review of renal scarring in children. MacKenzie JR. **Nucl Med Commun** 1996 Mar;17(3):176–90 (44 ref.)

PREVENTION & CONTROL

Oral fleroxacin prophylaxis in transurethral surgery. Gasser TC, et al. **J Urol** 1996 Jul;156(1):146–8 (27 ref.)
Neonatal circumcision: an end to the controversy? Roberts JA. **South Med J** 1996 Feb;89(2):167–71 (37 ref.)
[Prevention using quinolones in transurethral surgery] Gasser TC. **Ann Urol (Paris)** 1996;30(3):124–8 (30 ref.) (Eng. Abstr.) **(Fre)**
[Primary vesico-ureteral reflux. Current data and perspectives (editorial)] Lottmann H, et al. **Presse Med** 1996 Feb 10;25(5):185–7 (8 ref.) (Eng. Abstr.) **(Fre)**
[Mucosal immunity with implications for use in developing a new generation of vaccines] Osek J, et al. **Postepy Hig Med Dosw** 1995;49(4):469–86 (62 ref.) (Eng. Abstr.) **(Pol)**

RADIOGRAPHY

[Hip dislocation and urinary tract. Two trends in pediatric radiology] Jorulf H, et al. **Lakartidningen** 1995 Nov 29; 92(48):4563–6 (20 ref.) **(Swe)**

THERAPY

Treatment of community-acquired urinary tract infections. Perdue BE, et al. **Am Pharm** 1995 Dec;NS35(12):37–45 (51 ref.)
Biotherapeutic agents. A neglected modality for the treatment and prevention of selected intestinal and vaginal infections [see comments] Elmer GW, et al. **JAMA** 1996 Mar 20;275(11):870–6 (81 ref.) Comment in: JAMA 1996 Jul 3;276(1):29–30.
Urinary tract infections. Old and new concepts. Hellerstein S. **Pediatr Clin North Am** 1995 Dec;42(6):1433–57 (93 ref.)

VETERINARY

Viral infections of the feline urinary tract. Kruger JM, et al. **Vet Clin North Am Small Anim Pract** 1996 Mar; 26(2):281–96 (77 ref.)
Bacterial urinary tract infections. Lees GE. **Vet Clin North Am Small Anim Pract** 1996 Mar; 26(2):297–304 (12 ref.)
Biologic behavior of feline lower urinary tract diseases. Lulich JP, et al. **Vet Clin North Am Small Anim Pract** 1996 Mar;26(2):207–15 (13 ref.)
Fungal infections of the feline lower urinary tract. Lulich JP, et al. **Vet Clin North Am Small Anim Pract** 1996 Mar; 26(2):309–15 (10 ref.)
Overview of diagnosis of feline lower urinary tract disorders. Lulich JP, et al. **Vet Clin North Am Small Anim Pract** 1996 Mar;26(2):339–52 (3 ref.)

URINATION

DRUG EFFECTS

[Effects of anesthesia on postoperative micturition and urinary retention] Pertek JP, et al. **Ann Fr Anesth Reanim** 1995;14(4):340–51 (44 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Neuronal circuitry of the lower urinary tract; central and peripheral neuronal control of the micturition cycle. Kinder MV, et al. **Anat Embryol (Berl)** 1995 Sep;192(3):195–209 (55 ref.)
Clinical evaluation of voiding symptoms and uroflowmetry in elderly men. A prospective study. Jørgensen JB. **Dan Med Bull** 1995 Jun;42(3):244–56 (113 ref.)
The significance of smooth and striated muscles in the sphincter function of the urethra in healthy women. Thind P. **Neurourol Urodyn** 1995;14(6):585–618 (289 ref.)
Spinal cord tachykinins in the micturition reflex. Lecci A, et al. **Prog Brain Res** 1995;104:145–59 (93 ref.)
Urine storage mechanisms. Vaughan CW, et al. **Prog Neurobiol** 1995 Jun;46(2–3):215–37 (225 ref.)
Nitric oxide synthase and the lower urinary tract: possible implications for physiology and pathophysiology. Andersson KE, et al. **Scand J Urol Nephrol Suppl** 1995; 175:43–53 (102 ref.)
Factors that modulate the initiation of micturition. Levin RM, et al. **Scand J Urol Nephrol Suppl** 1995;175:3–10 (56 ref.)
Suprapontine influences on the micturition reflex. Torrens M. **Scand J Urol Nephrol Suppl** 1995;175:11–3 (24 ref.)
Neurophysiology of micturition and continence. Chai TC, et al. **Urol Clin North Am** 1996 May;23(2):221–36 (142 ref.)
Cystometry. Dmochowski R. **Urol Clin North Am** 1996 May; 23(2):243–52 (51 ref.)
Functional anatomy of the organs of micturition. Elbadawi A. **Urol Clin North Am** 1996 May;23(2):177–210 (255 ref.)
Pressure-flow studies of micturition. Griffiths DJ. **Urol Clin North Am** 1996 May;23(2):279–97 (29 ref.)
Uroflowmetry. Jørgensen JB, et al. **Urol Clin North Am** 1996 May;23(2):237–42 (73 ref.)
Electromyography of the perineal floor. Siroky MB. **Urol Clin North Am** 1996 May;23(2):299–307 (16 ref.)
Micturitional urethral pressure profilometry. Sullivan MP, et al. **Urol Clin North Am** 1996 May;23(2):263–78 (25 ref.)
Smooth-muscle physiology. Zimmern PE, et al. **Urol Clin North Am** 1996 May;23(2):211–9 (45 ref.)

URINATION DISORDERS

Pediatric neurourology. Ewalt DH, et al. **Urol Clin North Am** 1996 Aug;23(3):501–9 (42 ref.)
[Urination disorders] Hattori T. **Nippon Naika Gakkai Zasshi** 1995 Sep 10;84(9):1438–41 (4 ref.) **(Jpn)**
[Uncoordinated urinary syndrome. New aspects of an old problem] Rapariz M, et al. **Actas Urol Esp** 1995 Apr; 19(4):261–80 (36 ref.) (Eng. Abstr.) **(Spa)**

CHEMICALLY INDUCED

Poisoning from "Spanish fly" (cantharidin). Karras DJ, et al. **Am J Emerg Med** 1996 Sep;14(5):478–83 (17 ref.)

DIAGNOSIS

The nocturnal polyuria syndrome (NPS). Asplund R. **Gen Pharmacol** 1995 Oct;26(6):1203–9 (29 ref.)
Ambulatory urodynamics: extramural testing of the lower and upper urinary tract by Holter monitoring of cystometrogram, uroflowmetry, and renal pelvic pressures. van Waalwijk van Doorn ES, et al. **Urol Clin North Am** 1996 Aug;23(3):345–71 (32 ref.)
Evoked potential testing. Vodušek DB. **Urol Clin North Am** 1996 Aug;23(3):427–46 (83 ref.)

DRUG THERAPY

Hormonal and non-hormonal interventions for menopausal symptoms. Coope J. **Maturitas** 1996 Mar;23(2):159–68 (73 ref.)

ETIOLOGY

Urinary bladder dysfunction following anterior lumbosacral spine fusion: case report and review of the literature. Faraj AA, et al. **Eur Spine J** 1996;5(2):121–4 (11 ref.)
Effects of cerebrovascular accident on micturition. Burney TL, et al. **Urol Clin North Am** 1996 Aug;23(3):483–90 (33 ref.)

PHYSIOPATHOLOGY

Clinical evaluation of voiding symptoms and uroflowmetry in elderly men. A prospective study. Jørgensen JB. **Dan Med Bull** 1995 Jun;42(3):244–56 (113 ref.)
The nocturnal polyuria syndrome (NPS). Asplund R. **Gen Pharmacol** 1995 Oct;26(6):1203–9 (29 ref.)
Factors that modulate the initiation of micturition. Levin RM, et al. **Scand J Urol Nephrol Suppl** 1995;175:3–10 (56 ref.)

THERAPY

Psychological approaches to the management of sensory urgency and idiopathic detrusor instability. Hunt J. **Br J Urol** 1996 Mar;77(3):339–41 (37 ref.)
[Bladder dysfunctions in encephalomyelitis disseminata—drug and interventional therapeutic options] Zwergel U, et al. **Fortschr Neurol Psychiatr** 1995 Dec; 63(12):495–503 (125 ref.) (Eng. Abstr.) **(Ger)**

VETERINARY

Detrusor-sphincter dyssynergia. Barsanti JA, et al. **Vet Clin North Am Small Anim Pract** 1996 Mar; 26(2):327–38 (32 ref.)
Overview of diagnosis of feline lower urinary tract disorders. Lulich JP, et al. **Vet Clin North Am Small Anim Pract** 1996 Mar;26(2):339–52 (3 ref.)

URINE

see related
ALBUMINURIA
ALKAPTONURIA
BACTERIURIA
CYSTINURIA
GLYCOSURIA
HEMATURIA
MAPLE SYRUP URINE DISEASE
PHENYLKETONURIA
POLYURIA
PROTEINURIA

CHEMISTRY

Role of urinary physiology and chemistry in bladder carcinogenesis. Cohen SM. **Food Chem Toxicol** 1995 Sep; 33(9):715–30 (110 ref.)
Species comparison of the content and composition of urinary proteins. Hard GC. **Food Chem Toxicol** 1995 Sep; 33(9):731–46 (173 ref.)
Forensic applications of genetic polymorphisms detected in human body fluids (urine, semen and blood). Kishi K, et al. **Forensic Sci Int** 1996 Jun 28;80(1–2):89–97 (55 ref.)
Practical guide to diagnosis and differential diagnosis of ARF in the ICU. Druml W, et al. **Int J Artif Organs** 1996 Feb; 19(2):87–9 (3 ref.)
Measurement of the influence of diet on feline urinary pH. Allen TA. **Vet Clin North Am Small Anim Pract** 1996 Mar; 26(2):363–8 (6 ref.)
Feline crystalluria. Detection and interpretation. Osborne CA, et al. **Vet Clin North Am Small Anim Pract** 1996 Mar; 26(2):369–91 (3 ref.)

CYTOLOGY

Evaluation of asymptomatic microhematuria. Fracchia JA, et al. **Urology** 1995 Oct;46(4):484–9 (23 ref.)

PHYSIOLOGY

Role of urinary physiology and chemistry in bladder carcinogenesis. Cohen SM. **Food Chem Toxicol** 1995 Sep; 33(9):715–30 (110 ref.)

URINE CONCENTRATING ABILITY see **KIDNEY CONCENTRATING ABILITY**

UROBILINOGEN

URINE

[Urinary urobilinogen] Adachi Y, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:141–3 (6 ref.) **(Jpn)**

UROCANIC ACID

UROCANIC ACID

METABOLISM

The role of urocanic acid in UV-induced immunosuppression: recent advances (1992-1994). Norval M, et al. **Photochem Photobiol** 1995 Aug;62(2):209-17 (64 ref.)

UROCHORDATA

CHEMISTRY

Vanadium in ascidians and the chemistry of tunichromes. Smith MJ, et al. **Met Ions Biol Syst** 1995;31:423-90 (361 ref.)

CYTOLOGY

The significance of cultivating cells and hemopoietic tissue from tunicates. Cooper EL, et al. **Adv Exp Med Biol** 1995; 371A:321-5 (21 ref.)

Cellular and molecular characterization of transdifferentiation in the process of morphallaxis of budding tunicates. Kawamura K, et al. **Semin Cell Biol** 1995 Jun;6(3):117-26 (67 ref.)

EMBRYOLOGY

An intrinsic genetic program for autonomous differentiation of muscle cells in the ascidian embryo. Satoh N, et al. **Proc Natl Acad Sci U S A** 1996 Sep 3;93(18):9315-21 (48 ref.)

GROWTH & DEVELOPMENT

Development and evolution of an egg cytoskeletal domain in ascidians. Jeffery WR. **Curr Top Dev Biol** 1995;31:243-76 (77 ref.)

Chasing tails in ascidians: developmental insights into the origin and evolution of chordates. Satoh N, et al. **Trends Genet** 1995 Sep;11(9):354-9 (44 ref.)

METABOLISM

Vanadium transport in animal systems. Kustin K, et al. **Met Ions Biol Syst** 1995;31:511-42 (88 ref.)

URODELA

ANATOMY & HISTOLOGY

Amphibian parathyroids: morphological and functional aspects. Srivastav AK, et al. **Microsc Res Tech** 1995 Oct 1;32(2):79-90 (113 ref.)

PHYSIOLOGY

[The urodelean retina as a model for studying the retinal regeneration potentials of other vertebrates] Grigorian EN. **Ontogenez** 1996 May-Jun;27(3):173-85 (117 ref.) (Eng. Abstr.) **(Rus)**

URODYNAMICS

Ambulatory urodynamics. Bristow SE, et al. **Br J Urol** 1996 Mar;77(3):333-8 (30 ref.)

Ambulatory urodynamics. van Waalwijk van Doorn ES, et al. **Curr Opin Obstet Gynecol** 1995 Oct;7(5):378-81 (14 ref.)

Investigation of the neurogenic bladder. Fowler CJ. **J Neurol Neurosurg Psychiatry** 1996 Jan;60(1):6-13 (52 ref.)

Urodynamics and multiple sclerosis. Hinson JL, et al. **Urol Clin North Am** 1996 Aug;23(3):475-81 (46 ref.)

Ambulatory urodynamics: extramural testing of the lower and upper urinary tract by Holter monitoring of cystometrogram, uroflowmetry, and renal pelvic pressures. van Waalwijk van Doorn ES, et al. **Urol Clin North Am** 1996 Aug;23(3):345-71 (32 ref.)

Urodynamics of spinal cord injury. Watanabe T, et al. **Urol Clin North Am** 1996 Aug;23(3):459-73 (53 ref.)

PHYSIOLOGY

Ambulatory urodynamic monitoring [see comments] Heslington K, et al. **Br J Obstet Gynaecol** 1996 May; 103(5):393-9 (49 ref.) Comment in: Br J Obstet Gynaecol 1996 May;103(5):xxi.

Neurophysiology of micturition and continence. Chai TC, et al. **Urol Clin North Am** 1996 May;23(2):221-36 (142 ref.)

Functional anatomy of the organs of micturition. Elbadawi A. **Urol Clin North Am** 1996 May;23(2):177-210 (255 ref.)

Pressure-flow studies of micturition. Griffiths DJ. **Urol Clin North Am** 1996 May;23(2):279-97 (29 ref.)

Uroflowmetry. Jørgensen JB, et al. **Urol Clin North Am** 1996 May;23(2):237-42 (73 ref.)

Leak-point pressures. McGuire EJ, et al. **Urol Clin North Am** 1996 May;23(2):253-62 (12 ref.)

Videourodynamic studies. McGuire EJ, et al. **Urol Clin North Am** 1996 May;23(2):309-21 (13 ref.)

Electromyography of the perineal floor. Siroky MB. **Urol Clin North Am** 1996 May;23(2):299-307 (16 ref.)

Micturitional urethral pressure profilometry. Sullivan MP, et al. **Urol Clin North Am** 1996 May;23(2):263-78 (25 ref.)

UROGASTRONE see **EPIDERMAL GROWTH FACTOR-UROGASTRONE**

UROGASTRONE RECEPTORS see **RECEPTORS, EPIDERMAL GROWTH FACTOR-UROGASTRONE**

UROGENITAL DISEASES

ABC of urology. Common paediatric problems. Dawson C, et al. **BMJ** 1996 May 18;312(7041):1291-4 (2 ref.)

Medical and surgical strategies for treating urogynecological disorders. Samsioe G. **Int J Fertil Menopausal Stud** 1996 Mar-Apr;41(2):136-41 (22 ref.)

COMPLICATIONS

The role of urogenital tract infections in the etiology of preterm birth: a review. Martius J, et al. **Arch Gynecol Obstet** 1996;258(1):1-19 (166 ref.)

Racial disparities in preterm births. The role of urogenital infections [see comments] Fiscella K. **Public Health Rep** 1996 Mar-Apr;111(2):104-13 (15 ref.) Comment in: Public Health Rep 1996 Mar-Apr;111(2):114-5.

EPIDEMIOLOGY

The prevalence of urogenital symptoms in postmenopausal women. Stenberg A, et al. **Maturitas** 1995 Dec;22 Suppl:S17-S20 (22 ref.)

ETIOLOGY

A complex cystic dysplastic urogenital anomaly--an odd presentation. Singh G, et al. **Int Urol Nephrol** 1995; 27(6):687-90 (5 ref.)

Environment and the genitourinary tract. Droller MJ. **Otolaryngol Head Neck Surg** 1996 Feb;114(2):248-52 (37 ref.)

RADIOTHERAPY

[Low-intensity laser therapy in urology] Kul'chavenia EV. **Urol Nefrol (Mosk)** 1996 Jan-Feb;(1):41-4 (95 ref.) **(Rus)**

SURGERY

Severe endometriosis and operative laparoscopy. Nezhat C, et al. **Curr Opin Obstet Gynecol** 1995 Aug;7(4):299-306 (55 ref.)

[Complications of laparoscopic interventions in urology] Fahlenkamp D, et al. **Urologe A** 1996 May;35(3):238-45 (20 ref.) (Eng. Abstr.) **(Ger)**

[Urologic geriatrics] Steffens J, et al. **Urologe A** 1995 Nov; 34(6):499-509 (9 ref.) **(Ger)**

[Laparoscopic technique--which developments are possible?] Voges U. **Urologe A** 1996 May;35(3):208-14 (6 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

[What is new in pediatric urology?] Ringert RH. **Urologe A** 1996 Mar;35(2):87-90 (9 ref.) **(Ger)**

ULTRASONOGRAPHY

Ethical issues of diagnosis in utero. Perrotti M, et al. **Br J Urol** 1995 Nov;76 Suppl 2:79-83 (37 ref.)

[Recommendations of the Urogynecology Study Group on ultrasound of the lower urinary tract within the scope of functional urogynecologic diagnosis] Schär G, et al. **Gynakol Geburtshilfliche Rundsch** 1996;36(1):33-6 (20 ref.) **(Ger)**

UROGENITAL NEOPLASMS

[Muir-Torre syndrome] Yoshikawa R, et al. **Nippon Rinsho** 1995 Nov;53(11):2803-6 (11 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

[Paraneoplastic syndromes] Kaboth U, et al. **Urologe A** 1995 Sep;34(5):431-6 (0 ref.) **(Ger)**

EPIDEMIOLOGY

[Multiple primary neoplasia in a urologic setting. Clinical review and tentative etiopathogenetic profile] Marino G, et al. **Minerva Urol Nefrol** 1995 Jun;47(2):71-6 (18 ref.) (Eng. Abstr.) **(Ita)**

GENETICS

[Molecular prognostic markers for urogenital cancers] Kubota Y. **Gan To Kagaku Ryoho** 1996 Jul;23(8):997-1003 (32 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Molecular staging of genitourinary malignancies. Katz AE, et al. **Urology** 1996 Jun;47(6):948-58 (86 ref.)

SURGERY

[Complications of laparoscopic interventions in urology] Fahlenkamp D, et al. **Urologe A** 1996 May;35(3):238-45 (20 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

[Preoperative chemotherapy in genitourinary cancer] Kawai K, et al. **Gan To Kagaku Ryoho** 1995 Nov;22(13):1912-7 (24 ref.) (Eng. Abstr.) **(Jpn)**

UROGENITAL SYSTEM

ABNORMALITIES

[Diagnostic-therapeutic concept in abnormalities of the kidneys and efferent urinary tract] Tutschek B, et al. **Gynakologe** 1995 Oct;28(5):356-67 (59 ref.) **(Ger)**

[What is new in pediatric urology?] Ringert RH. **Urologe A** 1996 Mar;35(2):87-90 (9 ref.) **(Ger)**

INJURIES

[Urogenital injuries caused by projectiles. Data on recent conflicts and the North-American civilian experience] Houdelette P. **J Chir (Paris)** 1995 Oct;132(10):375-81 (19 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Activation of the androgen receptor by polypeptide growth factors and cellular regulators. Culig Z, et al. **World J Urol** 1995;13(5):285-9 (43 ref.)

UROKINASE

The urokinase/urokinase-receptor system and cancer invasion. Conese M, et al. **Baillieres Clin Haematol** 1995 Jun;8(2):365-89 (237 ref.)

Urokinase-type plasminogen activator (uPA) and its receptor (CD87): a new target in tumor invasion and metastasis. Schmitt M, et al. **J Obstet Gynaecol** 1995 Apr;21(2):151-65 (60 ref.)

ADMINISTRATION & DOSAGE

Thrombolysis for acute Budd-Chiari syndrome: case report and literature review. Raju GS, et al. **Am J Gastroenterol** 1996 Jun;91(6):1262-3 (11 ref.)

[Thrombolysis of an extensive venous thrombosis of the lower body in an anomaly of the vena cava inferior] Rühlmann C, et al. **Dtsch Med Wochenschr** 1996 Feb 2; 121(5):124-8 (29 ref.) (Eng. Abstr.) **(Ger)**

[Urokinase in a premature infant: its use in a case of right atrial thrombosis secondary to catheterization of the umbilical vein] Colnaghi C, et al. **Pediatr Med Chir** 1995 May-Jun;17(3):275-7 (10 ref.) (Eng. Abstr.) **(Ita)**

ANALYSIS

Fibrinolysis components as prognostic markers in breast cancer and colorectal carcinoma. Gandolfo GM, et al. **Anticancer Res** 1996 Jul-Aug;16(4B):2155-9 (37 ref.)

METABOLISM

Targeting plant toxins to the urokinase and alpha 2-macroglobulin receptors. Cavallaro U, et al. **Semin Cancer Biol** 1995 Oct;6(5):269-78 (60 ref.)

PHARMACOLOGY

Fibrinolytic mechanism, biochemistry, and preclinical pharmacology of recombinant prourokinase. Credo RB, et al. **J Vasc Interv Radiol** 1995 Nov-Dec;6(6 Pt 2 Su):8S-18S (59 ref.)

PHYSIOLOGY

Effect of antisense inhibition of Urokinase receptor on malignancy. Ossowski L. **Curr Top Microbiol Immunol** 1996;213 (Pt 3):101-12 (71 ref.)

THERAPEUTIC USE

Treatment of complicated pleural fluid collections with image-guided drainage and intracavitary urokinase [see comments] Moulton JS, et al. **Chest** 1995 Nov; 108(5):1252-9 (20 ref.) Comment in: Chest 1995 Nov;108(5):1190-1.

UROKINASE-TYPE PLASMINOGEN ACTIVATOR see **UROKINASE**

UROLITHIASIS see **URINARY CALCULI**

UROLOGIC DISEASES

Hemospermia: diagnosis and management. Mulhall JP, et al. **Urology** 1995 Oct;46(4):463-7 (51 ref.)

[Why and how to measure the quality of life? Questions to be asked by the urologist] Lukacs B. **Presse Med** 1995 Oct 28;24(32):1514-8 (16 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

Pediatric renal transplantation into the abnormal urinary tract. Churchill BM, et al. **Pediatr Nephrol** 1996 Feb; 10(1):113-20 (17 ref.)

CONGENITAL

Congenital nephropathies and uropathies. Becker N, et al. **Pediatr Clin North Am** 1995 Dec;42(6):1319-41 (45 ref.)

DIAGNOSIS

ABC of urology. Urological evaluation. Dawson C, et al.

BMJ 1996 Mar 16;312(7032):695–8 (0 ref.)
Ambulatory urodynamics. Bristow SE, et al. **Br J Urol** 1996 Mar;77(3):333–8 (30 ref.)
Evaluation of asymptomatic microhematuria. Fracchia JA, et al. **Urology** 1995 Oct;46(4):484–9 (23 ref.)

EPIDEMIOLOGY

Epidemiology of urinary symptoms in the geriatric population. Fultz NH, et al. **Urol Clin North Am** 1996 Feb; 23(1):1–10 (68 ref.)

ETIOLOGY

Lower urinary tract dysfunction in pregnancy: a review. Mikhail MS, et al. **Obstet Gynecol Surv** 1995 Sep; 50(9):675–83 (99 ref.)

GENETICS

Ethical issues and molecular biology in urology. Neal DE. **Br J Urol** 1995 Nov;76 Suppl 2:65–70 (15 ref.)
Molecular advances in pediatric urology. Pressler LB, et al. **Urology** 1995 Dec;46(6):888–98 (115 ref.)

SURGERY

Laparoscopy in urology: present status, controversies, and future directions. Matsuda T, et al. **Int J Urol** 1996 Mar; 3(2):83–97 (211 ref.)
Oral fleroxacin prophylaxis in transurethral surgery. Gasser TC, et al. **J Urol** 1996 Jul;156(1):146–8 (27 ref.)
Aspirin, a silent risk factor in urology. Zhu JP, et al. **Scand J Urol Nephrol** 1995 Dec;29(4):369–74 (64 ref.)
[Progresses in urology in China, 1995] Guo Y. **Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):735–6 (0 ref.) **(Chi)**
[The future of laparoscopic surgery in urology] Coptcoat MJ, et al. **Urologe A** 1996 May;35(3):226–32 (37 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

ABC of urology. Introduction to urology. Dawson C, et al. **BMJ** 1996 Mar 9;312(7031):623–5 (0 ref.)
Urologic care in long-term facilities. Pranikoff K. **Urol Clin North Am** 1996 Feb;23(1):137–46 (111 ref.)
[Percutaneous surgical interventions and extracorporeal lithotripsy in the treatment of the urological complications after a kidney transplant] Urenkov SB, et al. **Urol Nefrol (Mosk)** 1995 Jul–Aug;(4):45–9 (122 ref.) **(Rus)**

ULTRASONOGRAPHY

[Potential of ultrasonography in urologic diagnostic algorithms] Mayayo Dehesa T, et al. **Arch Esp Urol** 1995 Sep;48(7):665–77; discussion 678 (35 ref.) (Eng. Abstr.) **(Spa)**

URINE

Urinalysis. When—and when not—to order. Misdraji J, et al. **Postgrad Med** 1996 Jul;100(1):173–6, 181–2, 185–8 passim (15 ref.)

VETERINARY

Diagnostic imaging of the feline lower urinary tract. Johnston GR, et al. **Vet Clin North Am Small Anim Pract** 1996 Mar; 26(2):401–15 (9 ref.)
Cystocentesis. Diagnostic and therapeutic considerations. Kruger JM, et al. **Vet Clin North Am Small Anim Pract** 1996 Mar; 26(2):353–61 (14 ref.)
Inherited and congenital diseases of the feline lower urinary tract. Kruger JM, et al. **Vet Clin North Am Small Anim Pract** 1996 Mar; 26(2):265–79 (45 ref.)
Biologic behavior of feline lower urinary tract diseases. Lulich JP, et al. **Vet Clin North Am Small Anim Pract** 1996 Mar;26(2):207–15 (13 ref.)
Overview of diagnosis of feline lower urinary tract disorders. Lulich JP, et al. **Vet Clin North Am Small Anim Pract** 1996 Mar;26(2):339–52 (3 ref.)
Feline lower urinary tract disorders. Definition of terms and concepts. Osborne CA, et al. **Vet Clin North Am Small Anim Pract** 1996 Mar; 26(2):169–79 (16 ref.)

UROLOGIC NEOPLASMS

Mixed adenocarcinoma and neuroendocrine carcinoma arising in the urachus. A case report and review of the literature. Munichor M, et al. **Eur Urol** 1995;28(4):345–7 (22 ref.)
[Urothelial inverted papilloma] Rodríguez-Rubio FI, et al. **Actas Urol Esp** 1995 Sep;19(8):611–9 (49 ref.) (Eng. Abstr.) **(Spa)**

BLOOD SUPPLY

Angiogenesis in urological malignancy. O'Brien TS, et al. **Br J Urol** 1995 Dec;76(6):675–82 (42 ref.)

DIAGNOSIS

[Tumor markers in urological malignancies] Kuriyama M. **Nippon Rinsho** 1996 Jun;54(6):1631–6 (23 ref.) (Eng. Abstr.) **(Jpn)**

ETIOLOGY

Urinary bladder carcinogenesis: a working group approach to risk assessment. Neumann DA, et al. **Food Chem Toxicol** 1995 Sep;33(9):701–4 (17 ref.)

PATHOLOGY

Epithelial tumours of the lower urinary tract in humans and rodents. Oyasu R. **Food Chem Toxicol** 1995 Sep; 33(9):747–55 (64 ref.)

THERAPY

The management of urological malignancies during pregnancy. Loughlin KR. **Br J Urol** 1995 Nov;76(5):639–44 (60 ref.)

UROLOGY

see related
UROLOGIC DISEASES

ABC of urology. Introduction to urology. Dawson C, et al. **BMJ** 1996 Mar 9;312(7031):623–5 (0 ref.)

METHODS

Computer modeling in urology. Kattan MW, et al. **Urology** 1996 Jan;47(1):14–21 (33 ref.)

TRENDS

New technology in urology: why assessment needs to be more scientific. Keoghane SR, et al. **Br J Urol** 1996 Jun; 77(6):771–5 (31 ref.)
Diagnostic and therapeutic approach to moderate and severe male subfertility in 1995. Comhaire F, et al. **Hum Reprod** 1995 Oct;10 Suppl 1:144–50 (40 ref.)
Male subfertility: concepts in 1995. Yovich JL, et al. **Hum Reprod** 1995 Oct;10 Suppl 1:3–9 (43 ref.)
What's new in urology. Flanigan RC. **J Am Coll Surg** 1996 Feb;182(2):185–90 (38 ref.)

UROPORPHYRINOGEN CARBOXY-LYASE see **UROPORPHYRINOGEN DECARBOXYLASE**

UROPORPHYRINOGEN DECARBOXYLASE

GENETICS

Uroporphyrinogen decarboxylase. Elder GH, et al. **J Bioenerg Biomembr** 1995 Apr;27(2):207–14 (87 ref.)

METABOLISM

Uroporphyrinogen decarboxylase. Elder GH, et al. **J Bioenerg Biomembr** 1995 Apr;27(2):207–14 (87 ref.)

UROPORPHYRINOGEN I SYNTHASE see **PORPHOBILINOGEN DEAMINASE**

UROPORPHYRINOGEN III COSYNTHETASE see **UROPORPHYRINOGEN III SYNTHASE**

UROPORPHYRINOGEN III SYNTHASE

CHEMISTRY

Porphobilinogen deaminase and uroporphyrinogen III synthase: structure, molecular biology, and mechanism. Shoolingin-Jordan PM. **J Bioenerg Biomembr** 1995 Apr; 27(2):181–95 (111 ref.)

UROPORPHYRINOGEN ISOMERASE see **UROPORPHYRINOGEN III SYNTHASE**

UROTENSINS

PHYSIOLOGY

Distribution and molecular forms of urotensin II and its role in cardiovascular regulation in vertebrates. Conlon JM, et al. **J Exp Zool** 1996 Jun 1–15;275(2–3):226–38 (92 ref.)

URSODEOXYCHOLIC ACID

METABOLISM

TUDCA and UDCA are incorporated into hepatocyte membranes: different sites, but similar effects. Leuschner U, et al. **Ital J Gastroenterol** 1995 Sep;27(7):376–7 (11 ref.)

PHARMACOKINETICS

Clinical pharmacokinetics of therapeutic bile acids. Crosignani A, et al. **Clin Pharmacokinet** 1996 May; 30(5):333–58 (156 ref.)
Intestinal absorption of bile acids: effect of ursodeoxycholic acid treatment. Stiehl A. **Ital J Gastroenterol** 1995 May; 27(4):193–5 (31 ref.)

THERAPEUTIC USE

Drug-induced vanishing bile duct syndrome: response to ursodiol. O'Brien CB, et al. **Am J Gastroenterol** 1996 Jul; 91(7):1456–7 (10 ref.)
Temporary resolution of obstructive jaundice during ursodeoxycholic acid therapy in a patient with primary sclerosing cholangitis and a dominant biliary stricture. Fracchia M, et al. **Ital J Gastroenterol** 1995 Oct–Nov; 27(8):430–5 (38 ref.)
[Bile acids in liver diseases—current indications] Stiehl A. **Ther Umsch** 1995 Oct;52(10):682–6 (29 ref.) (Eng. Abstr.) **(Ger)**
[Primary biliary cirrhosis and ursodeoxycholic acid therapy] Makino I. **Nippon Naika Gakkai Zasshi** 1996 Mar 10; 85(3):399–403 (10 ref.) **(Jpn)**
[Ursodeoxycholic acid: an alternative in the treatment of chronic cholestasis] Parés A, et al. **Gastroenterol Hepatol** 1996 Feb;19(2):58–67 (110 ref.) **(Spa)**

URTICARIA

Urticaria and angioedema: a clinical spectrum. Charlesworth EN. **Ann Allergy Asthma Immunol** 1996 Jun;76(6):484–95; quiz 495–9 (90 ref.)
Urticaria. The diagnostic challenge of hives. Sveum RJ. **Postgrad Med** 1996 Aug;100(2):77–8, 81–4 (4 ref.)

CHEMICALLY INDUCED

Cefotiam-induced contact urticaria syndrome: an occupational condition in Japanese nurses. Shimizu S, et al. **Dermatology** 1996;192(2):174–6 (19 ref.)

COMPLICATIONS

[The Schnitzler syndrome as a cause of recurrent fever of unknown origin] Winckelmann G, et al. **Dtsch Med Wochenschr** 1996 Jul 5;121(27):860–4 (14 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Update on urticaria and angioedema (hives). Fox RW. **Allergy Proc** 1995 Nov–Dec;16(6):289–92 (20 ref.)
[Non-sedative antihistaminics in the treatment of chronic urticaria] Negro JM, et al. **Allergol Immunopathol (Madr)** 1995 May–Jun;23(3):137–44 (45 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

Urticarial vasculitis. O'Donnell B, et al. **Int Angiol** 1995 Jun; 14(2):166–74 (74 ref.)
Interleukin-3-induced urticaria-like eruption. Bridges AG, et al. **J Am Acad Dermatol** 1996 Jun;34(6):1076–8 (19 ref.)

THERAPY

Plasma exchange therapy for solar urticaria. Collins P, et al. **Br J Dermatol** 1996 Jun;134(6):1093–7 (20 ref.)

URTICARIA, GIANT see **ANGIONEUROTIC EDEMA**

URTICARIA PIGMENTOSA

DIAGNOSIS

[Systemic mastocytosis: a case with diffuse bone involvement] Biarese V, et al. **Minerva Med** 1996 Jan–Feb;87(1–2):33–9 (16 ref.) (Eng. Abstr.) **(Ita)**

USER-COMPUTER INTERFACE

Using hub technology to facilitate information system integration in a health-care enterprise. Gendler SM, et al. **Am J Clin Pathol** 1996 Apr;105(4 Suppl 1):S25–32 (5 ref.)
Bridging theory and practice: cognitive science and medical informatics. Patel VL, et al. **Medinfo** 1995;8 Pt 2:1278–82 (26 ref.)
Medicine in virtual environments. Dumay AC. **Technol Health Care** 1995 Oct;3(2):75–89 (87 ref.)
A graphical interface for searching the human genome. Adler D. **Trends Genet** 1995 Oct;11(10):416–7 (0 ref.)
[Virtual reality in medicine] Völter S, et al. **Radiologe** 1995 Sep;35(9):563–8 (25 ref.) (Eng. Abstr.) **(Ger)**

USTILAGO

GENETICS

Control of mating and development in Ustilago maydis. Kahmann R, et al. **Curr Opin Genet Dev** 1995 Oct; 5(5):559–64 (31 ref.)

PHYSIOLOGY

Control of mating and development in Ustilago maydis. Kahmann R, et al. **Curr Opin Genet Dev** 1995 Oct; 5(5):559–64 (31 ref.)

UTERINE CONTRACTION

see related
CARDIOTOCOGRAPHY
LABOR, PREMATURE

UTERINE CONTRACTION

OXYTOCICS
TOCOLYTIC AGENTS
UTERINE MONITORING

Current status of home uterine activity monitoring. Iams JD. **Clin Obstet Gynecol** 1995 Dec;38(4):771–9 (35 ref.)

Intrapartum use of fetal heart rate monitoring, contraction monitoring, and amnioinfusion. Cusick W, et al. **Clin Perinatol** 1995 Dec;22(4):875–906 (130 ref.)

PHYSIOLOGY

Parturition: activation of stimulatory pathways or loss of uterine quiescence? López Bernal A, et al. **Adv Exp Med Biol** 1995;395:435–51 (107 ref.)

Regulation of the switch from myometrial contractures to contractions in late pregnancy: studies in the pregnant sheep and monkey. Nathanielsz PW, et al. **Reprod Fertil Dev** 1995;7(3):595–602 (42 ref.)

UTERINE DISEASES

Inflammatory pseudotumor of the uterus: a case report. Kargi HA, et al. **Tumori** 1995 Nov–Dec;81(6):454–6 (8 ref.)

[Advances in the research on the pathogenesis, diagnosis and treatment of uterine adenomyosis] Zhou YF, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1995 Aug;30(8):502–5 (32 ref.) **(Chi)**

[Progresses in gynecology in China, 1995] Lang J. **Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):747–8 (0 ref.) **(Chi)**

DIAGNOSIS

Magnetic resonance imaging of the uterus. Kier R. **Magn Reson Imaging Clin N Am** 1994 May;2(2):189–210 (54 ref.)

Hysteroscopy and hysterography. Barbot J. **Obstet Gynecol Clin North Am** 1995 Sep;22(3):591–603 (10 ref.)

Intrauterine adhesions. March CM. **Obstet Gynecol Clin North Am** 1995 Sep;22(3):491–505 (58 ref.)

Office hysteroscopy. Siegler AM. **Obstet Gynecol Clin North Am** 1995 Sep;22(3):457–71 (34 ref.)

Endometrial cytology by direct sampling. Its value and limitations in the diagnosis of endometrial lesions. Nguyen GK, et al. **Pathol Annu** 1995;30 Pt 2:179–202 (42 ref.)

ETIOLOGY

Etiology of and therapeutic approach to synechia uteri. Schenker JG. **Eur J Obstet Gynecol Reprod Biol** 1996 Mar; 65(1):109–13 (20 ref.)

Postoperative uterine granulomata following endometrial resection. Smart PJ, et al. **Pathology** 1995 Apr;27(2):209–11 (14 ref.)

[Uterine inversion] Gerber S. **Rev Med Suisse Romande** 1996 Apr;116(4):277–83 (26 ref.) **(Fre)**

PATHOLOGY

Outpatient endometrial assessment. Read MD. **Br J Hosp Med** 1995 Aug 16–Sep 5;54(4):150–3 (45 ref.)

Endometrial cytology by direct sampling. Its value and limitations in the diagnosis of endometrial lesions. Nguyen GK, et al. **Pathol Annu** 1995;30 Pt 2:179–202 (42 ref.)

Postoperative uterine granulomata following endometrial resection. Smart PJ, et al. **Pathology** 1995 Apr;27(2):209–11 (14 ref.)

RADIOGRAPHY

Hysteroscopy and hysterography. Barbot J. **Obstet Gynecol Clin North Am** 1995 Sep;22(3):591–603 (10 ref.)

SURGERY

Hysterectomy in a Danish cohort. Prevalence, incidence and socio–demographic characteristics. Settnes A, et al. **Acta Obstet Gynecol Scand** 1996 Mar;75(3):274–80 (35 ref.)

Endometrial resection. Holt EM, et al. **Baillieres Clin Obstet Gynaecol** 1995 Jun;9(2):279–97 (38 ref.)

Endoscopy or the surgical revolution for women [editorial] Manhes H, et al. **Curr Opin Obstet Gynecol** 1995 Aug; 7(4):243–7 (18 ref.)

Intrauterine adhesions. March CM. **Obstet Gynecol Clin North Am** 1995 Sep;22(3):491–505 (58 ref.)

Review on laparoscopic hysterectomy. Deprest JA, et al. **Zentralbl Gynakol** 1995;117(12):641–51 (75 ref.)

[Total hysterectomy for benign pathologies. Conventional celiosurgical technique] Chapron C, et al. **Ann Chir** 1995; 49(7):613–20 (39 ref.) (Eng. Abstr.) **(Fre)**

[Total hysterectomy for benign pathologies: why is laparoscopy of value?] Chapron C, et al. **Contracept Fertil Sex** 1995 Nov;23(11):688–93 (63 ref.) (Eng. Abstr.) **(Fre)**

[Laparoscopic hysterectomy. A series of 318 consecutive cases] Masson FN, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(4):340–52 (36 ref.) (Eng. Abstr.) **(Fre)**

[Uterine inversion] Gerber S. **Rev Med Suisse Romande** 1996 Apr;116(4):277–83 (26 ref.) **(Fre)**

[Hysteroscopic surgery] Kimmig R. **Arch Gynecol Obstet** 1995;257(1–4):21–9 (53 ref.) **(Ger)**

THERAPY

Etiology of and therapeutic approach to synechia uteri. Schenker JG. **Eur J Obstet Gynecol Reprod Biol** 1996 Mar; 65(1):109–13 (20 ref.)

ULTRASONOGRAPHY

[Uterine diagnosis] Weber G, et al. **Gynakologe** 1995 Aug; 28(4):225–32 (35 ref.) **(Ger)**

UTERINE ENDOSCOPY see **HYSTEROSCOPY**

UTERINE HEMORRHAGE

see related
MENORRHAGIA

Serious haemorrhage during delivery. Ravina JH. **Eur J Obstet Gynecol Reprod Biol** 1996 Mar;65(1):137–40 (17 ref.)

Abnormal uterine bleeding. Jennings JC. **Med Clin North Am** 1995 Nov;79(6):1357–76 (87 ref.)

CHEMICALLY INDUCED

Hormone replacement therapy: aspects of bleeding problems and compliance. Samsioe G. **Int J Fertil Menopausal Stud** 1996 Jan–Feb;41(1):11–5 (20 ref.)

COMPLICATIONS

Treatment of menorrhagia due to dysfunctional uterine bleeding. Rosenfeld JA. **Am Fam Physician** 1996 Jan; 53(1):165–72 (24 ref.)

ETIOLOGY

Zonary placenta. Steemers NY, et al. **Int J Gynaecol Obstet** 1995 Dec;51(3):251–3 (3 ref.)

PATHOLOGY

Outpatient endometrial biopsy: the pipelle. Youssif SN, et al. **Br J Hosp Med** 1995 Sep 6–19;54(5):198–201 (23 ref.)

SURGERY

Endometrial ablation: indications and preliminary diagnostic hysteroscopy. Taylor PJ, et al. **Baillieres Clin Obstet Gynaecol** 1995 Jun;9(2):251–60 (18 ref.)

THERAPY

Transfusion therapy in pregnancy. Naef RW 3rd, et al. **Clin Obstet Gynecol** 1995 Sep;38(3):547–57 (29 ref.)

Place of emergency arterial embolisation in obstetric haemorrhage about 16 personal cases. Merland JJ, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Mar;65(1):141–3 (20 ref.)

UTERINE INVERSION see **UTERINE DISEASES**

UTERINE MONITORING

Current status of home uterine activity monitoring. Iams JD. **Clin Obstet Gynecol** 1995 Dec;38(4):771–9 (35 ref.)

UTERINE MUSCLE see **MYOMETRIUM**

UTERINE NEOPLASMS

Placental site trophoblastic tumor: three case reports and literature review. Denny LA, et al. **Gynecol Oncol** 1995 Nov;59(2):300–3 (15 ref.)

Recurrent placental site trophoblastic tumor of the uterus: clinical, pathologic, ultrastructural, and DNA fingerprint study. Kodama S, et al. **Gynecol Oncol** 1996 Jan;60(1):89–93 (20 ref.)

Gestational trophoblastic diseases: current trends and perspectives. Wang TH, et al. **J Formos Med Assoc** 1995 Aug;94(8):449–57 (71 ref.)

The myomatous erythrocytosis syndrome: a review. LevGur M, et al. **Obstet Gynecol** 1995 Dec;86(6):1026–30 (38 ref.)

[Non–trophoblastic tumors of the placenta] Dukovski A. **Akush Ginekol (Sofiia)** 1994;33(2):40–3 (28 ref.) **(Bul)**

COMPLICATIONS

Myomas and pregnancy. Phelan JP. **Obstet Gynecol Clin North Am** 1995 Dec;22(4):801–5 (28 ref.)

Myomata uteri and infertility. Wallach EE, et al. **Obstet Gynecol Clin North Am** 1995 Dec;22(4):791–9 (32 ref.)

DIAGNOSIS

Immunohistochemical markers in uterine tumour diagnostics. Danihel L, et al. **Bratisl Lek Listy** 1995 Jul;96(7):353–60 (43 ref.) **(Eng, Slo)**

Gestational trophoblastic diseases. Lage JM, et al. **Curr Opin Obstet Gynecol** 1996 Feb;8(1):79–82 (26 ref.)

Hysteroscopic diagnosis and operative therapy of submucous myoma. Corson SL. **Obstet Gynecol Clin North Am** 1995 Dec;22(4):739–55 (37 ref.)

Uterine fibroids. Diagnosis and indications for treatment. Hutchins FL Jr. **Obstet Gynecol Clin North Am** 1995 Dec; 22(4):659–65 (12 ref.)

Ultrasonography and magnetic resonance imaging of uterine fibroids. Mayer DP, et al. **Obstet Gynecol Clin North Am** 1995 Dec;22(4):667–725 (91 ref.)

[Treatment of uterine fibromas] Amiel C, et al. **Ann Chir** 1996;50(1):40–50 (79 ref.) (Eng. Abstr.) **(Fre)**

[Choriocarcinoma] Wierzchniewska A, et al. **Ginekol Pol** 1995 Sep;66(9):537–40 (23 ref.) (Eng. Abstr.) **(Pol)**

DRUG THERAPY

Gestational trophoblastic disease. Berkowitz RS, et al. **Cancer** 1995 Nov 15;76(10 Suppl):2079–85 (81 ref.)

Treatment of fibromas. Jourdain O, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Jun;66(2):99–107 (99 ref.)

ECONOMICS

Medical and socioeconomic impact of uterine fibroids. Greenberg MD, et al. **Obstet Gynecol Clin North Am** 1995 Dec;22(4):625–36 (40 ref.)

ETIOLOGY

[Relation between progesterone and pathogenesis of uterine leiomyomas] Yang Y, et al. **Chung Hua Fu Chan Ko Tsa Chih** 1996 Mar;31(3):184–5 (13 ref.) **(Chi)**

GENETICS

Flow cytometric and clinicopathologic study of 197 hydatidiform moles with special reference to the significance of cytometric aneuploidy and literature review. Fukunaga M, et al. **Cytometry** 1995 Jun 15;22(2):135–8 (21 ref.)

[Evaluation of prognostic factors in gynecological cancer examined by molecular biological study] Nagai N. **Gan To Kagaku Ryoho** 1996 Jul;23(8):1004–9 (27 ref.) (Eng. Abstr.) **(Jpn)**

[Familial ovarian cancer, uterine cancer] Fushiki H, et al. **Nippon Rinsho** 1995 Nov;53(11):2769–72 (20 ref.) (Eng. Abstr.) **(Jpn)**

PATHOLOGY

Gestational trophoblastic disease. New approaches to diagnosis. Lage JM, et al. **Clin Lab Med** 1995 Sep; 15(3):631–64 (50 ref.)

Myometrial and stromal lesions of the uterus. Smoot JS, et al. **Clin Lab Med** 1995 Sep;15(3):545–73 (66 ref.)

MR imaging of the female pelvis. Mayo–Smith WW, et al. **Clin Radiol** 1995 Oct;50(10):667–76 (57 ref.)

Choriocarcinoma presenting as a breast lump. Fowler CA, et al. **Eur J Surg Oncol** 1995 Oct;21(5):576–8 (14 ref.)

Two unusual presentations of müllerian adenosarcoma: case reports, literature review, and treatment considerations. Gollard R, et al. **Gynecol Oncol** 1995 Dec;59(3):412–22 (26 ref.)

Myxoid leiomyosarcoma of the uterus with unusual malignant histologic pattern—a case report. Schneider D, et al. **Gynecol Oncol** 1995 Oct;59(1):156–8 (7 ref.)

Atypical polypoid adenomyomas of the uterus. Fukunaga M, et al. **Histopathology** 1995 Jul;27(1):35–42 (18 ref.)

Pathologic considerations of uterine smooth muscle tumors. Prayson RA, et al. **Obstet Gynecol Clin North Am** 1995 Dec;22(4):637–57 (69 ref.)

[Recent advances in gynecological pathology in China] Huang S. **Chung Hua Ping Li Hsueh Tsa Chih** 1995 Aug; 24(4):228–31 (20 ref.) **(Chi)**

[Case of benign metastaxsizing leiomyoma of the lungs] Nishida T, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1996 Feb;44(2):182–7 (23 ref.) (Eng. Abstr.) **(Jpn)**

[Placental site trophoblastic tumor] Rosati R, et al. **Rev Chil Obstet Ginecol** 1995;60(1):46–50 (16 ref.) (Eng. Abstr.) **(Spa)**

PREVENTION & CONTROL

Potential criteria for cohort selection in chemoprevention trials of uterine adenocarcinoma. Baker VV. **J Cell Biochem Suppl** 1995;23:184–8 (32 ref.)

SECONDARY

[Expansive uterine myoma during tamoxifen therapy. 11 cases] Le Bouëdec G, et al. **Presse Med** 1995 Nov 25; 24(36):1694–6 (18 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Hysterectomy in a Danish cohort. Prevalence, incidence and socio–demographic characteristics. Settnes A, et al. **Acta Obstet Gynecol Scand** 1996 Mar;75(3):274–80 (35 ref.)

Myomectomy: laparoscopy or laparotomy? Parker WH. **Clin Obstet Gynecol** 1995 Jun;38(2):392–400 (25 ref.)

Uterine fibroids: place and modalities of laparoscopic treatment. Dubuisson JB, et al. **Eur J Obstet Gynecol Reprod Biol** 1996 Mar;65(1):91–4 (17 ref.)

Treatment of fibromas. Jourdain O, et al.

Eur J Obstet Gynecol Reprod Biol 1996 Jun;66(2):99–107 (99 ref.)
The controversy of laparoscopic myomectomy. Dicker D, et al. **Hum Reprod** 1996 May;11(5):935–7 (8 ref.)
Laparoscopic myomectomy today. A good technique when correctly indicated. Dubuisson JB, et al. **Hum Reprod** 1996 May;11(5):934–5 (21 ref.)
Laparoscopic myomectomy today. Why, when and for whom? Nezhat F, et al. **Hum Reprod** 1996 May;11(5):933–4 (13 ref.)
Hysteroscopic diagnosis and operative therapy of submucous myoma. Corson SL. **Obstet Gynecol Clin North Am** 1995 Dec;22(4):739–55 (37 ref.)
Laparoscopic coagulation of myoma (myolysis). Goldfarb HA. **Obstet Gynecol Clin North Am** 1995 Dec;22(4):807–19 (32 ref.)
Abdominal myomectomy as a treatment for symptomatic uterine fibroids. Hutchins FL Jr. **Obstet Gynecol Clin North Am** 1995 Dec;22(4):781–9 (28 ref.)
Laparoscopic myomectomy. Reich H. **Obstet Gynecol Clin North Am** 1995 Dec;22(4):757–80 (18 ref.)
Necrotizing fasciitis following laparoscopic surgery. Case report and review of the literature. Golshani S, et al. **Surg Endosc** 1996 Jul;10(7):751–4 (20 ref.)
Review on laparoscopic hysterectomy. Deprest JA, et al. **Zentralbl Gynakol** 1995;117(12):641–51 (75 ref.)
[Laparoscopic surgery of large uterine fibromas. Operative technique and results] Dubuisson JB, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(7):705–10 (22 ref.) (Eng. Abstr.) **(Fre)**
[Hysteroscopic surgery] Kimmig R. **Arch Gynecol Obstet** 1995;257(1–4):21–9 (53 ref.) **(Ger)**
[Indications for hysterectomy--a time for re-evaluation] Lerner A, et al. **Harefuah** 1996 Mar 15;130(6):400–3 (25 ref.) **(Heb)**
[Uterine myomectomy in the treatment of infertility] Reroń A. **Ginekol Pol** 1995 Feb;66(2):108–11 (24 ref.) (Eng. Abstr.) **(Pol)**
[Heterologous adenosarcoma of the Müllerian ducts in adolescence. Presentation of clinical case and review of the literature] Juárez Azpilcueta A, et al. **Ginecol Obstet Mex** 1995 Sep;63:398–400 (15 ref.) (Eng. Abstr.) **(Spa)**

THERAPY

Current views on the management of trophoblastic tumors. Tham KF, et al. **Int J Gynaecol Obstet** 1995 Jul;49 Suppl:S77–89 (48 ref.)
Medical management of uterine fibromyomata. Davis KM, et al. **Obstet Gynecol Clin North Am** 1995 Dec;22(4):727–38 (44 ref.)
[Choriocarcinoma] Wierzchniewska A, et al. **Ginekol Pol** 1995 Sep;66(9):537–40 (23 ref.) (Eng. Abstr.) **(Pol)**

ULTRASONOGRAPHY

Transvaginal color Doppler and pelvic tumor vascularity: lessons learned and future challenges. Kurjak A, et al. **Ultrasound Obstet Gynecol** 1995 Aug;6(2):145–59 (38 ref.)
[Uterine diagnosis] Weber G, et al. **Gynakologe** 1995 Aug; 28(4):225–32 (35 ref.) **(Ger)**
[Ultrasound studies in afterloading therapy of uterine malignancy] Günter HH, et al. **Ultraschall Med** 1995 Aug; 16(4):162–6 (20 ref.) (Eng. Abstr.) **(Ger)**

VETERINARY

Cellular and molecular mechanisms of cancers of the uterus in animals. McLachlan JA, et al. **Prog Clin Biol Res** 1996; 394:175–82 (46 ref.)

UTERINE PERFORATION

ETIOLOGY

[Uterine perforation and localization of an IUD in the bladder associated with bladder calculosis. Report of a case and review of the literature] Reyes-Acevedo J, et al. **Ginecol Obstet Mex** 1995 Oct;63:407–9 (13 ref.) (Eng. Abstr.) **(Spa)**

UTERINE PROLAPSE

COMPLICATIONS

[Female urology: new advances in 1995] Chassagne S, et al. **J Urol (Paris)** 1996;102(1):33–9 (32 ref.) **(Fre)**
[Obstructive uropathy secondary to genitourinary prolapse] Pereira Arias JG, et al. **Actas Urol Esp** 1995 Mar; 19(3):247–50 (9 ref.) (Eng. Abstr.) **(Spa)**

CONGENITAL

Management of genital prolapse in neonates and young women. de Mola JR, et al. **Obstet Gynecol Surv** 1996 Apr; 51(4):253–60 (25 ref.)

PHYSIOPATHOLOGY

[Pro: a critical contribution to better understanding of possible functional disorders of the genital, bladder and pelvic floor system] Schüssler B. **Arch Gynecol Obstet** 1995; 257(1–4):359–62 (14 ref.) **(Ger)**

PREVENTION & CONTROL

Protecting the pelvic floor: obstetric management to prevent incontinence and pelvic organ prolapse. Handa VL, et al. **Obstet Gynecol** 1996 Sep;88(3):470–8 (46 ref.)

SURGERY

Laparoscopic surgery for incontinence and genitourinary prolapse. Smith AR. **Curr Opin Obstet Gynecol** 1995 Oct; 7(5):397–9 (21 ref.)
Transvaginal correction of pelvic prolapse. Albo M, et al. **J Endourol** 1996 Jun;10(3):231–9 (21 ref.)
Correction of genital prolapse. Liu CY, et al. **J Endourol** 1996 Jun;10(3):259–65 (32 ref.)
[Pelvic floor insufficiency as an interdisciplinary responsibility] Hansen H. **Chirurg** 1996 May;67(5):498–504 (14 ref.) (Eng. Abstr.) **(Ger)**

UTERINE RUPTURE

CHEMICALLY INDUCED

[Uterine rupture during induced abortion with prostaglandins in the second trimester] Zieger W, et al. **Geburtshilfe Frauenheilkd** 1995 Oct;55(10):592–8 (43 ref.) (Eng. Abstr.) **(Ger)**

ETIOLOGY

Uterine rupture with fetal death following blunt trauma. Harrison SD, et al. **AJR Am J Roentgenol** 1995 Dec; 165(6):1452 (9 ref.)
Midtrimester uterine rupture. A case report. Levrant SG, et al. **J Reprod Med** 1996 Mar;41(3):186–90 (28 ref.)
[Obstetrical complications of adenomyosis. Literature review and two case reports] Bensaid F, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(4):416–8 (5 ref.) (Eng. Abstr.) **(Fre)**

PREVENTION & CONTROL

[Uterine rupture: literature review and Genevan experience (1980–1994)] Valiton-Crusi A. **Rev Med Suisse Romande** 1996 Apr;116(4):273–6 (26 ref.) **(Fre)**

UTERINE STIMULANTS see **OXYTOCICS**

UTEROPLACENTAL CIRCULATION

Current topic: in vivo investigation of the placental circulations by Doppler echography [see comments] Jauniaux E, et al. **Placenta** 1995 Jun;16(4):323–31 (52 ref.) Comment in: Placenta 1995 Jun;16(4):333–4.

UTEROVERDINE see **BILIVERDINE**

UTERUS

see related
HYSTERECTOMY
HYSTEROSALPINGOGRAPHY
HYSTEROSCOPY

ABNORMALITIES

Hernia uteri (correction of: uterus) inguinale associated with unilateral renal agenesis. Keating JP, et al. **Aust N Z J Surg** 1995 Sep;65(9):688–90 (10 ref.)
Congenital uterine malformations. Woodward PJ, et al. **Curr Probl Diagn Radiol** 1995 Sep–Oct;24(5):178–97 (51 ref.)
Hysteroscopic metroplasty for septate uterus. Fedele L, et al. **Obstet Gynecol Clin North Am** 1995 Sep;22(3):473–89 (55 ref.)
[Uterine malformations and infertility] Brun JL. **Contracept Fertil Sex** 1996 May;24(5):343–6 (35 ref.) **(Fre)**
[Gynecological malformations. Classification and contribution of different imaging methods] Maubon A, et al. **J Radiol** 1996 Jul;77(7):465–75 (32 ref.) **(Fre)**
[Uterine malformations. Diagnosis, prognosis and treatment] Brun JL, et al. **Presse Med** 1995 Nov 18;24(35):1658–62 (25 ref.) (Eng. Abstr.) **(Fre)**

ANATOMY & HISTOLOGY

Magnetic resonance imaging of the uterus. Kier R. **Magn Reson Imaging Clin N Am** 1994 May;2(2):189–210 (54 ref.)

BLOOD SUPPLY

Vasoactive peptides and uterine vessels. Stjernquist M, et al. **Gynecol Endocrinol** 1995 Jun;9(2):165–76 (77 ref.)
Current topic: in vivo investigation of the placental circulations by Doppler echography [see comments] Jauniaux E, et al. **Placenta** 1995 Jun;16(4):323–31 (52 ref.) Comment in: Placenta 1995 Jun;16(4):333–4.
Interrelationships between the renin angiotensin system and uteroplacental blood flow--a recent perspective. Binder ND, et al. **Reprod Fertil Dev** 1995;7(6):1437–42 (55 ref.)
[Uterine velocimetry and vascular pregnancy pathologies prevented with low-dose aspirin] Haddad B, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1996;25(4):396–404 (51 ref.) (Eng. Abstr.) **(Fre)**

DRUG EFFECTS

The effects of tamoxifen on the uterus. Ismail SM. **Curr Opin Obstet Gynecol** 1996 Feb;8(1):27–31 (22 ref.)
The effects of ovulation induction with gonadotrophins on the ovary and uterus and implications for assisted reproduction. Balen A. **Hum Reprod** 1995 Sep;10(9):2233–7 (55 ref.)
Ovulation induction. Effects of ovulation induction with gonadotrophins on the ovary and uterus and their implications for assisted reproduction. Rojas FJ. **Hum Reprod** 1995 Sep;10(9):2219–24 (47 ref.)
[Azithromycin: tissue pharmacology] Bergogne-Bérézin E. **Pathol Biol (Paris)** 1995 Jun;43(6):498–504 (29 ref.) (Eng. Abstr.) **(Fre)**
[Effect of the molecular structure of azithromycin on pharmacokinetics and the antimicrobial activity] Pechère JC. **Pathol Biol (Paris)** 1995 Jun;43(6):483–7 (8 ref.) (Eng. Abstr.) **(Fre)**

METABOLISM

Regulation of utero-placental prorenin. Poisner AM. **Adv Exp Med Biol** 1995;377:411–26 (96 ref.)

PATHOLOGY

Myometrial and stromal lesions of the uterus. Smoot JS, et al. **Clin Lab Med** 1995 Sep;15(3):545–73 (66 ref.)

PHYSIOLOGY

Clinical approaches to increasing uterine receptivity during human implantation. Edwards RG. **Hum Reprod** 1995 Dec; 10 Suppl 2:60–6 (26 ref.)
Effects of aging on the female reproductive system. Pellicer A, et al. **Hum Reprod** 1995 Dec;10 Suppl 2:77–83 (37 ref.)
Secretory type II phospholipase A2 and the generation of intrauterine signals. Rice GE. **Reprod Fertil Dev** 1995; 7(6):1471–9 (99 ref.)

SURGERY

Myomectomy: laparoscopy or laparotomy? Parker WH. **Clin Obstet Gynecol** 1995 Jun;38(2):392–400 (25 ref.)
Hysteroscopic metroplasty for septate uterus. Fedele L, et al. **Obstet Gynecol Clin North Am** 1995 Sep;22(3):473–89 (55 ref.)

UTILITARIANISM see **ETHICS**

UTILIZATION REVIEW

see related
INSURANCE CLAIM REVIEW
Physical restraint use in the hospital setting: unresolved issues and directions for research. Mion LC, et al. **Milbank Q** 1996;74(3):411–33 (80 ref.)

METHODS

Evaluation of appropriateness of paediatric admission. Werneke U, et al. **Arch Dis Child** 1996 Mar;74(3):268–73 (24 ref.)

ORGANIZATION & ADMINISTRATION

The design and analysis of hospital utilization studies. Ash A. **Int J Qual Health Care** 1995 Sep;7(3):245–52 (18 ref.)
Appropriateness of hospital use: an overview of Italian studies. Fellin G, et al. **Int J Qual Health Care** 1995 Sep; 7(3):219–25 (12 ref.)
A European project assessing the appropriateness of hospital utilization: background, objectives and preliminary results. The Project Steering Group and the Coordinating Center. Liberati A, et al. **Int J Qual Health Care** 1995 Sep; 7(3):187–99 (111 ref.)
An overview of Spanish studies on appropriateness of hospital use. Lorenzo S, et al. **Int J Qual Health Care** 1995 Sep;7(3):213–8 (28 ref.)
Appropriateness of hospital use in the United Kingdom: a review of activity in the field. O'Neill D, et al. **Int J Qual Health Care** 1995 Sep;7(3):239–44 (22 ref.)
The evolution of hospital utilization review methods in the United States. Restuccia JD. **Int J Qual Health Care** 1995 Sep;7(3):253–60 (19 ref.)
Medical appropriateness of hospital utilization: an overview of the Swiss experience. Santos-Eggimann B, et al. **Int J Qual Health Care** 1995 Sep;7(3):227–32 (24 ref.)
Appropriateness in patient care: a new conceptual framework. Sharpe VA, et al. **Milbank Q** 1996;74(1):115–38 (80 ref.)

STATISTICS & NUMERICAL DATA

Ten tools of continuous quality improvement: a review and case example of hospital discharge. Ziegenfuss JT JR, et al. **Am J Med Qual** 1995 Winter;10(4):213–20 (8 ref.)

UTILIZATION REVIEW, DRUG see **DRUG UTILIZATION REVIEW**

UTRICLE see **SACCULE AND UTRICLE**

UVEAL DISEASES

UVEAL DISEASES

SURGERY

The Bowman Lecture. Naumann GO. **Eye** 1995;9 (Pt 4):395–421 (227 ref.)

UVEAL NEOPLASMS

EPIDEMIOLOGY

["Melanoma 92". epidemiological study of uveal melanoma in France] Vidal JL, et al. **J Fr Ophtalmol** 1995; 18(8–9):520–8 (39 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Uveal melanoma and familial atypical mole and melanoma (FAM-M) syndrome. Singh AD, et al. **Ophthalmic Genet** 1995 Jun;16(2):53–61 (32 ref.)

UVEITIS

CHEMICALLY INDUCED

Rifabutin-associated uveitis. Tseng AL, et al. **Ann Pharmacother** 1995 Nov;29(11):1149–55 (45 ref.)

Mycobacterium avium complex infection, rifabutin, and uveitis—is there a connection? Nichols CW. **Clin Infect Dis** 1996 Apr;22 Suppl 1:S43–7; discussion S47–9 (21 ref.)

ETIOLOGY

Intraocular lens implantation in patients with juvenile rheumatoid arthritis-associated uveitis: an unresolved management issue [editorial; comment] Holland GN. **Am J Ophthalmol** 1996 Aug;122(2):255–7 (10 ref.) Comment on: Am J Ophthalmol 1996 Aug;122(2):161–70.

[Uveitis: late complication of undiagnosed Whipple disease] Wechsler B, et al. **Rev Med Interne** 1995;16(9):687–90 (30 ref.) (Eng. Abstr.) **(Fre)**

[Differential internal medicine diagnosis of uveitis] Benning K, et al. **Med Klin** 1995 Nov 15;90(11):645–52 (37 ref.) **(Ger)**

IMMUNOLOGY

Intraocular inflammatory disease (uveitis) and the use of oral tolerance: a status report. Nussenblatt RB, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:325–37 (23 ref.)

[Contribution of immunologic mechanisms in endogenous uveitis] Kubicka A. **Klin Oczna** 1995 Mar–Apr;97(3–4):90–2 (20 ref.) (Eng. Abstr.) **(Pol)**

PREVENTION & CONTROL

Intraocular inflammatory disease (uveitis) and the use of oral tolerance: a status report. Nussenblatt RB, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:325–37 (23 ref.)

THERAPY

The use of oral tolerance as a therapy for ocular autoimmunity. Rizzo LV. **Braz J Med Biol Res** 1995 Aug; 28(8):931–6 (23 ref.)

VETERINARY

Uveitis in dogs and cats: guidelines for the practitioner. Goodhead AD. **J S Afr Vet Assoc** 1996 Mar;67(1):12–9 (22 ref.)

VIROLOGY

Human T-lymphotropic virus type 1 and its ocular manifestations. Mochizuki M. **Int Ophthalmol Clin** 1995 Spring;35(2):107–20 (28 ref.)

UVEITIS, ANTERIOR

ETIOLOGY

The pathogenetic role of HLA-B27. Feltkamp TE, et al. **Immunol Today** 1996 Jan;17(1):5–7 (4 ref.)

IMMUNOLOGY

Clinical features and associated systemic diseases of HLA-B27 uveitis. Tay-Kearney ML, et al. **Am J Ophthalmol** 1996 Jan;121(1):47–56 (36 ref.)

UVEITIS, POSTERIOR

COMPLICATIONS

The subretinal fibrosis and uveitis syndrome. Kaiser PK, et al. **Int Ophthalmol Clin** 1996 Winter;36(1):145–52 (19 ref.)

Cataract extraction in patients with chronic posterior uveitis. Tabbara KF, et al. **Int Ophthalmol Clin** 1995 Spring; 35(2):121–31 (19 ref.)

ETIOLOGY

Posterior uveitis in the acquired immunodeficiency syndrome. McCluskey PJ, et al. **Int Ophthalmol Clin** 1995 Spring;35(2):1–14 (20 ref.)

UVEITIS, SYMPATHETIC see **OPHTHALMIA, SYMPATHETIC**

UVEOMENINGOENCEPHALITIC SYNDROME

COMPLICATIONS

Vogt-Koyanagi-Harada syndrome. Rao NA, et al. **Int Ophthalmol Clin** 1995 Spring;35(2):69–86 (30 ref.)

UVOMORULIN see **CADHERINS**

UVULA

SURGERY

Methodological and statistical problems in sleep apnea research: the literature on uvulopalatopharyngoplasty. Schechtman KB, et al. **Sleep** 1995 Oct;18(8):659–66 (44 ref.)

[The surgical treatment of obstructive sleep apnea syndrome] Cimino A, et al. **Acta Otorhinolaryngol Ital** 1995 Apr;15(2 Suppl 47):3–14 (58 ref.) (Eng. Abstr.) **(Ita)**

V1 RECEPTORS see **RECEPTORS, VASOPRESSIN**

V2 RECEPTORS see **RECEPTORS, VASOPRESSIN**

V-ABL GENES see **GENES, ABL**

V-ERBA PROTEINS see **ONCOGENE PROTEINS V-ERBA**

V-FOS GENES see **GENES, FOS**

V-FOS PROTEINS see **ONCOGENE PROTEINS V-FOS**

V-HA-RAS GENES see **GENES, RAS**

V-JUN PROTEIN see **ONCOGENE PROTEIN P65(GAG-JUN)**

V-KI-RAS GENES see **GENES, RAS**

V-MYC GENES see **GENES, MYC**

V-ONC PROTEINS see **ONCOGENE PROTEINS, VIRAL**

V-SRC GENES see **GENES, SRC**

VACCINATION

Preventing hepatitis A infections in travelers to endemic areas. Koff RS. **Am J Trop Med Hyg** 1995 Dec;53(6):586–90 (29 ref.)

Vaccination policies and practices [see comments] Henderson DA. **Aust J Public Health** 1995 Dec;19(6):634–8 (5 ref.) Comment in: Aust J Public Health 1995 Dec;19(6):545–6.

Tumor cells engineered to produce cytokines or cofactors as cellular vaccines: do animal studies really support clinical trials? Colombo MP, et al. **Cancer Immunol Immunother** 1995 Nov;41(5):265–70 (66 ref.)

BCG against tuberculosis: 1996. Lenner R. **Conn Med** 1996 Jun;60(6):329–34 (67 ref.)

Yellow fever: an emerging threat for Kenya and other east African countries. Sanders EJ, et al. **East Afr Med J** 1996 Jan;73(1):10–2 (21 ref.)

Global aspects of vaccination. Ada G. **Int Arch Allergy Immunol** 1995 Dec;108(4):304–8 (13 ref.)

Influenza vaccines. Brede HD. **Int Arch Allergy Immunol** 1995 Dec;108(4):318–20 (2 ref.)

Vaccination for birth control. Dirnhofer S, et al. **Int Arch Allergy Immunol** 1995 Dec;108(4):350–4 (36 ref.)

Vaccination against tuberculosis. Lowrie DB, et al. **Int Arch Allergy Immunol** 1995 Dec;108(4):309–12 (25 ref.)

Vaccines to prevent and treat autoimmune diseases. Mor F, et al. **Int Arch Allergy Immunol** 1995 Dec;108(4):345–9 (42 ref.)

Progress on vaccination against Haemonchus contortus. Newton SE. **Int J Parasitol** 1995 Nov;25(11):1281–9 (35 ref.)

Anaesthesia and recently vaccinated children. van der Walt JH, et al. **Paediatr Anaesth** 1996;6(2):135–41 (18 ref.)

Vaccination update. Hib, hepatitis, polio, varicella, influenza, pneumococcal and meningococcal disease. Vetter RT, et al. **Postgrad Med** 1995 Nov;98(5):141–4, 146, 149–50 (28 ref.)

Vaccination update. Diphtheria, tetanus, pertussis, mumps, rubella, measles. Vetter RT, et al. **Postgrad Med** 1995 Oct; 98(4):133–7, 141–2, 144–5 passim (30 ref.)

DNA-mediated immunization: prospects for hepatitis B vaccination. Michel ML. **Res Virol** 1995 Jul–Aug; 146(4):261–5 (28 ref.)

Vaccines in the prevention of viral pneumonia. Betts RF. **Semin Respir Infect** 1995 Dec;10(4):282–7 (34 ref.)

Antigens recognized on human tumors by cytolytic T lymphocytes: towards vaccination? Coulie PG. **Stem Cells (Dayt)** 1995 Jul;13(4):393–403 (65 ref.)

[Current status of the prevention and treatment of measles] Zi WL. **Chung Hua Liu Hsing Ping Hsueh Tsa Chih** 1996 Apr;17(2):111–2 (7 ref.) **(Chi)**

[Cancer vaccines: scientific bases and clinical developments] Bellet D. **Bull Cancer (Paris)** 1995 Nov;82(11):899–909 (49 ref.) (Eng. Abstr.) **(Fre)**

[Active vaccinations in multiple sclerosis] Flachenecker P, et al. **Dtsch Med Wochenschr** 1995 Nov 3;120(44):1513–6 (40 ref.) **(Ger)**

[In utero vaccination to prevent neonatal infections] Lubin D, et al. **Harefuah** 1995 Jun 1;128(11):711–4 (40 ref.) **(Heb)**

[Effect of vaccination on the risk of hepatitis B infection in hospital personnel] Mihály I, et al. **Orv Hetil** 1996 Mar 31;137(13):681–5 (36 ref.) (Eng. Abstr.) **(Hun)**

[Vaccination of the elderly (editorial)] Cruz Jentoft AJ. **Rev Clin Esp** 1995 Sep;195(9):595–7 (30 ref.) **(Spa)**

ADVERSE EFFECTS

[Vaccination failures. III. Postvaccinal complications and immunization schedules. Immunoprophylaxis in dogs and cats] Overgaauw PA. **Tijdschr Diergeneeskd** 1996 Feb 15; 121(4):101–5 (60 ref.) **(Dut)**

CONTRAINDICATIONS

Are there restrictions to vaccinating a child who has recovered from hemolytic uremic syndrome? Kaplan BS. **Pediatr Nephrol** 1996 Apr;10(2):138 (7 ref.)

LEGISLATION & JURISPRUDENCE

Obtaining marketing authorization for nucleic acid vaccines in the European Union. Cichutek K. **Ann N Y Acad Sci** 1995 Nov 27;772:178–85 (15 ref.)

Regulatory issues in the use of DNA vaccines. Minor PD. **Ann N Y Acad Sci** 1995 Nov 27;772:170–7 (29 ref.)

Regulatory considerations in vaccine design. Davenport LW. **Pharm Biotechnol** 1995;6:81–96 (7 ref.)

METHODS

Protective efficacy of intramuscular immunization with naked DNA. Donnelly JJ, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:40–6 (26 ref.)

DNA vectors. Precedents and safety. Hilleman MR. **Ann N Y Acad Sci** 1995 Nov 27;772:1–14 (52 ref.)

Overview of DNA vaccines. Liu MA. **Ann N Y Acad Sci** 1995 Nov 27;772:15–20 (28 ref.)

Potential DNA vaccine integration into host cell genome. Nichols WW, et al. **Ann N Y Acad Sci** 1995 Nov 27; 772:30–9 (8 ref.)

Immunological properties of bacterial DNA. Pisetsky DS, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:152–63 (33 ref.)

DNA-mediated immunization to the hepatitis B surface antigen. Activation and entrainment of the immune response. Whalen RG, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:64–76 (31 ref.)

Vaccination in the immunocompromised person. Grabowsky M, et al. **Bull Rheum Dis** 1995 Dec;44(8):3–6 (9 ref.)

Strategy for vaccination against hepatitis B in areas with high endemicity: focus on Korea. Ahn YO. **Gut** 1996;38 Suppl 2:S63–6 (16 ref.)

Developing new hepatitis B immunisation strategies. Zuckerman AJ. **Gut** 1996;38 Suppl 2:S60–2 (6 ref.)

Tumor vaccination. Mallmann P. **Hybridoma** 1995 Apr; 14(2):187–90 (19 ref.)

Hepatitis B immunization in adolescents. Lawrence MH, et al. **J Adolesc Health** 1995 Oct;17(4):234–43 (126 ref.)

Novel vaccine approaches. Ertl HC, et al. **J Immunol** 1996 May 15;156(10):3579–82 (46 ref.)

STANDARDS

Influenza vaccination in the elderly. Morgan R, et al. **Postgrad Med J** 1996 Jun;72(848):339–42 (30 ref.)

STATISTICS & NUMERICAL DATA

Immunization among African American children: implications for social work. Copeland VC. **Health Soc Work** 1996 May;21(2):105–14 (70 ref.)

TRENDS

Novel vaccine approaches. Ertl HC, et al. **J Immunol** 1996 May 15;156(10):3579–82 (46 ref.)

VETERINARY

DNA immunization with bovine herpesvirus-1 genes. Babiuk LA, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:47–63 (56 ref.)

The interference by maternally-derived antibody with active immunization of farm animals against foot-and-mouth disease. Kitching RP, et al. **Br Vet J** 1995 Jul–Aug; 151(4):379–89 (40 ref.)

Advances in feline health research: impact of recent developments in vaccinology on feline welfare. Richards JR. **J Am Vet Med Assoc** 1996 Feb 15;208(4):505–10 (30 ref.)

Control of bovine viral diarrhea infection by use of vaccination. Bolin SR. **Vet Clin North Am Food Anim Pract** 1995 Nov;11(3):615–25 (74 ref.)

Pseudorabies virus eradication by area-wide vaccination is feasible. Stegeman A. **Vet Q** 1995 Dec;17(4):150–6 (85 ref.)

[Vaccination in practice. II. Immunoprophylaxis in dogs and cats] Overgaauw PA. **Tijdschr Diergeneeskd** 1996 Feb 15; 121(4):95–101 (0 ref.) **(Dut)**

[Vaccination failures. III. Postvaccinal complications and immunization schedules. Immunoprophylaxis in dogs and cats] Overgaauw PA. **Tijdschr Diergeneeskd** 1996 Feb 15; 121(4):101–5 (60 ref.) **(Dut)**

[Vaccination strategies for contagious bovine pleuropneumonia in Africa] Sylla D, et al. **Rev Sci Tech** 1995 Sep;14(3):577–92 (8 ref.) (Eng. Abstr.) **(Fre)**

[Infectious coryza: review of diagnostic methods and vaccines] Blackall PJ, et al. **Rev Argent Microbiol** 1995 Jul–Sep;27(3):156–74 (62 ref.) **(Spa)**

VACCINATION ENCEPHALITIS see **ENCEPHALOMYELITIS, ACUTE DISSEMINATED**

VACCINE THERAPY see **IMMUNOTHERAPY, ACTIVE**

VACCINES

Idiotype manipulation in disease management. Kohler H, et al. **Adv Exp Med Biol** 1995;383:117–22 (38 ref.)

Targeting the zona pellucida for immunocontraception: a minireview. Tesarik J. **Hum Reprod** 1995 Dec;10 Suppl 2:132–9 (35 ref.)

Vaccines to prevent and treat autoimmune diseases. Mor F, et al. **Int Arch Allergy Immunol** 1995 Dec;108(4):345–9 (42 ref.)

Clinical considerations in vaccine trials with special reference to candidate HIV vaccines. Fast PE, et al. **Pharm Biotechnol** 1995;6:97–134 (255 ref.)

Laboratory empiricism, clinical design, and social value. The rough road toward vaccine development. Francis DP. **Pharm Biotechnol** 1995;6:135–9 (9 ref.)

Nanoparticles as adjuvants for vaccines. Kreuter J. **Pharm Biotechnol** 1995;6:463–72 (32 ref.)

A compendium of vaccine adjuvants and excipients. Vogel FR, et al. **Pharm Biotechnol** 1995;6:141–228 (284 ref.)

[Advances in the research on nucleic acid vaccines] Lu F, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1995 Sep; 29(5):303–4 (20 ref.) **(Chi)**

ADMINISTRATION & DOSAGE

Liposomal vaccines. Green S, et al. **Adv Exp Med Biol** 1995; 383:83–92 (27 ref.)

Vaccine adjuvancy: a new potential area of development for GM–CSF. Taglietti M. **Adv Exp Med Biol** 1995;378:565–9 (22 ref.)

Cholera toxin B subunit as transmucosal carrier–delivery and immunomodulating system for induction of antiinfectious and antipathological immunity. Czerkinsky C, et al. **Ann N Y Acad Sci** 1996 Feb 13;778:185–93 (32 ref.)

Optimal delivery of vaccines: clinical pharmacokinetic considerations. Gizurarson S. **Clin Pharmacokinet** 1996 Jan; 30(1):1–15 (85 ref.)

Design and production of single–immunization vaccines using polylactide polyglycolide microsphere systems. Cleland JL. **Pharm Biotechnol** 1995;6:439–62 (57 ref.)

Liposomal presentation of antigens for human vaccines. Glück R. **Pharm Biotechnol** 1995;6:325–45 (142 ref.)

Polymer microspheres for vaccine delivery. Hanes J, et al. **Pharm Biotechnol** 1995;6:389–412 (76 ref.)

Lipid matrix–based vaccines for mucosal and systemic immunization. Mannino RJ, et al. **Pharm Biotechnol** 1995; 6:363–87 (59 ref.)

Water–soluble phosphazene polymers for parenteral and mucosal vaccine delivery. Payne LG, et al. **Pharm Biotechnol** 1995;6:473–93 (15 ref.)

Liposome design and vaccine development. Pietrobon PJ. **Pharm Biotechnol** 1995;6:347–61 (145 ref.)

Vehicles for oral immunization. Santiago N, et al. **Pharm Biotechnol** 1995;6:413–38 (160 ref.)

ADVERSE EFFECTS

An update on vaccine safety. Zimmerman RK, et al. **Am Fam Physician** 1996 Jul;54(1):185–93 (43 ref.)

Preclinical safety assessment considerations in vaccine development. Bussiere JL, et al. **Pharm Biotechnol** 1995; 6:61–79 (87 ref.)

[Cutaneous immunoallergic reactions caused by vaccines] Barbaud A, et al. **Ann Dermatol Venereol** 1995; 122(3):129–38 (120 ref.) **(Fre)**

GENETICS

Use of plant viruses for delivery of vaccine epitopes. Beachy RN, et al. **Ann N Y Acad Sci** 1996 May 25;792:43–9 (16 ref.)

IMMUNOLOGY

Vaccination for birth control. Dirnhofer S, et al. **Int Arch Allergy Immunol** 1995 Dec;108(4):350–4 (36 ref.)

Development of a vaccine strategy against human and bovine schistosomiasis. Background and update. Capron A, et al. **Mem Inst Oswaldo Cruz** 1995 Mar–Apr;90(2):235–40 (29 ref.)

A new approach to vaccine adjuvants. Immunopotentiation by intracellular T–helper–like signals transmitted by loxoribine. Goodman MG. **Pharm Biotechnol** 1995; 6:581–609 (73 ref.)

Vaccine research and development for the prevention of filarial nematode infections. Grieve RB, et al. **Pharm Biotechnol** 1995;6:737–68 (250 ref.)

Lipid matrix–based vaccines for mucosal and systemic immunization. Mannino RJ, et al. **Pharm Biotechnol** 1995; 6:363–87 (59 ref.)

Mutant ras epitopes as targets for cancer vaccines. Abrams SI, et al. **Semin Oncol** 1996 Feb;23(1):118–34 (79 ref.)

ISOLATION & PURIFICATION

Induction of specific immunity at mucosal surfaces: prospects for vaccine development. Czerkinsky C, et al. **Adv Exp Med Biol** 1995;371B:1409–16 (21 ref.)

PHARMACOKINETICS

Optimal delivery of vaccines: clinical pharmacokinetic considerations. Gizurarson S. **Clin Pharmacokinet** 1996 Jan; 30(1):1–15 (85 ref.)

PHARMACOLOGY

Heat shock protein–peptide complexes for use in vaccines. Heike M, et al. **J Leukoc Biol** 1996 Aug;60(2):153–8 (75 ref.)

Adjuvants for human vaccines—current status, problems and future prospects. Gupta RK, et al. **Vaccine** 1995 Oct; 13(14):1263–76 (123 ref.)

STANDARDS

Regulatory considerations in vaccine design. Davenport LW. **Pharm Biotechnol** 1995;6:81–96 (7 ref.)

Application of risk assessment to veterinary biologicals: the perspective of the animal health industry. Folkers C, et al. **Rev Sci Tech** 1995 Dec;14(4):1207–16 (5 ref.)

Biologicals: test procedures available to assess components and products, with limitations. Lee AM. **Rev Sci Tech** 1995 Dec;14(4):1073–82 (11 ref.)

Risk of introducing exotic disease through importation of animals and animal products. Metcalf HE, et al. **Rev Sci Tech** 1995 Dec;14(4):951–6 (12 ref.)

Regulatory framework and requirements for managing risks associated with veterinary biological products in Africa: present systems and future needs. Sylla D, et al. **Rev Sci Tech** 1995 Dec;14(4):1171–84 (18 ref.)

VACCINES, ATTENUATED

Efficacy, immunogenicity, safety, and use of live attenuated chickenpox vaccine. Krause PR, et al. **J Pediatr** 1995 Oct; 127(4):518–25 (39 ref.)

Varicella vaccine [editorial] Ellis RW. **Vaccine** 1995; 13(15):1387–8 (21 ref.)

THERAPEUTIC USE

Development of live attenuated varicella vaccine. Gershon AA. **Proc Assoc Am Physicians** 1995 Oct;107(3):365–8 (31 ref.)

VACCINES, CONJUGATE

THERAPEUTIC USE

[Protective properties of antibodies raised against conjugates of endotoxin core oligosaccharides with proteins] Jachymek W. **Postepy Hig Med Dosw** 1995;49(1):171–8 (6 ref.) (Eng. Abstr.) **(Pol)**

VACCINES, INACTIVATED

Hepatitis A vaccine. Bader TF. **Am J Gastroenterol** 1996 Feb;91(2):217–22 (41 ref.)

[Inactivated antihepatitis A vaccine] Escolar M, et al. **Rev Med Univ Navarra** 1995 Apr–Jun;40(2):110–4 (14 ref.) **(Spa)**

VACCINES, KILLED see **VACCINES, INACTIVATED**

VACCINES, RECOMBINANT see **VACCINES, SYNTHETIC**

VACCINES, SYNTHETIC

The development and use of T cell receptor peptide vaccines. Brostoff S. **Adv Exp Med Biol** 1995;383:249–54 (18 ref.)

Vaccines in the treatment of cancer. Baltz JK. **Am J Health Syst Pharm** 1995 Nov 15;52(22):2574–85; quiz 2594–5 (37 ref.)

DNA immunization with bovine herpesvirus–1 genes. Babiuk LA, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:47–63 (56 ref.)

Adenovirus and adeno–associated virus as vectors for gene therapy. Berns KI, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:95–104 (48 ref.)

Obtaining marketing authorization for nucleic acid vaccines in the European Union. Cichutek K. **Ann N Y Acad Sci** 1995 Nov 27;772:178–85 (15 ref.)

Assuring the safety and efficacy of DNA vaccines. Griffiths E. **Ann N Y Acad Sci** 1995 Nov 27;772:164–9 (10 ref.)

DNA vectors. Precedents and safety. Hilleman MR. **Ann N Y Acad Sci** 1995 Nov 27;772:1–14 (52 ref.)

Nucleic acid malaria vaccines. Current status and potential. Hoffman SL, et al. **Ann N Y Acad Sci** 1995 Nov 27; 772:88–94 (11 ref.)

Overview of DNA vaccines. Liu MA. **Ann N Y Acad Sci** 1995 Nov 27;772:15–20 (28 ref.)

Potential DNA vaccine integration into host cell genome. Nichols WW, et al. **Ann N Y Acad Sci** 1995 Nov 27; 772:30–9 (8 ref.)

A genetic approach to idiotypic vaccination for B cell lymphoma. Stevenson FK, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:212–26 (23 ref.)

DNA–mediated immunization to the hepatitis B surface antigen. Activation and entrainment of the immune response. Whalen RG, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:64–76 (31 ref.)

Influenza virus vectors. García–Sastre A, et al. **Biologicals** 1995 Jun;23(2):171–8 (40 ref.)

Poxvirus–based vectors as vaccine candidates. Pincus S, et al. **Biologicals** 1995 Jun;23(2):159–64 (31 ref.)

Animal models of human–derived cancer vaccines. Herlyn D, et al. **Cell Biophys** 1995 Aug;27(1):15–30 (56 ref.)

Idiotypic DNA vaccines against B–cell lymphoma. Stevenson FK, et al. **Immunol Rev** 1995 Jun;145:211–28 (40 ref.)

Efficacy, immunogenicity, safety, and use of live attenuated chickenpox vaccine. Krause PR, et al. **J Pediatr** 1995 Oct; 127(4):518–25 (39 ref.)

Cytokine–containing liposomes as adjuvants for subunit vaccines. Lachman LB, et al. **Pharm Biotechnol** 1995; 6:659–71 (37 ref.)

Public health implications of emerging vaccine technologies. Lawrence DN, et al. **Pharm Biotechnol** 1995;6:43–60 (48 ref.)

Genetically altered herpesviruses as vaccines. Young PL, et al. **Vet Microbiol** 1995 Sep;46(1–3):175–9 (20 ref.)

Immune response to synthetic peptides representing antigenic sites on the glycoprotein of infectious hematopoietic necrosis virus. Emmenegger E, et al. **Vet Res** 1995; 26(5–6):374–8 (21 ref.)

[Progress in the development of vaccines against Aujeszky's disease] Mettenleiter TC. **Tierarztl Prax** 1995 Dec; 23(6):570–4 (22 ref.) (Eng. Abstr.) **(Ger)**

ADMINISTRATION & DOSAGE

New and safe "oral" live vaccines based on lactobacillus. Claassen E, et al. **Adv Exp Med Biol** 1995;371B:1553–8 (23 ref.)

Protective efficacy of intramuscular immunization with naked DNA. Donnelly JJ, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:40–6 (26 ref.)

ADVERSE EFFECTS

Risk potential of the chromosomal insertion of foreign DNA. Kurth R. **Ann N Y Acad Sci** 1995 Nov 27;772:140–51 (25 ref.)

BIOSYNTHESIS

Molecular bases for the construction of artificial immunogens and vaccines based on synthetic polyions. Khaitov RM. **Allergy Proc** 1995 Sep–Oct;16(5):255–60 (14 ref.)

Use of macromolecular assemblies as expression systems for peptides and synthetic vaccines. Lomonossoff GP, et al. **Curr Opin Struct Biol** 1996 Apr;6(2):176–82 (66 ref.)

CHEMISTRY

Development of vaccines based on formulations containing nonionic block copolymers. Brey RN. **Pharm Biotechnol** 1995;6:297–311 (52 ref.)

Design of experimental synthetic peptide immunogens for prevention of HIV–1 and HTLV–I retroviral infections. Hart MK, et al. **Pharm Biotechnol** 1995;6:821–45 (175 ref.)

GENETICS

BCG as a vector for the construction of multivalent recombinant vaccines. Gicquel B. **Biologicals** 1995 Jun; 23(2):113–8 (34 ref.)

The use of picornaviruses as vectors for the engineering of live recombinant vaccines. Girard M, et al. **Biologicals** 1995 Jun;23(2):165–9 (32 ref.)

Recombinant adenoviruses as vaccines. Randrianarison–Jewtoukoff V, et al. **Biologicals** 1995 Jun; 23(2):145–57 (82 ref.)

From virus to vaccine: developments using the simple eukaryote, Dictyostelium discoideum. Emslie KR, et al. **Trends Microbiol** 1995 Dec;3(12):476–9 (23 ref.)

IMMUNOLOGY

The use of multiple antigen peptides in the analysis and induction of protective immune responses against infectious diseases. Nardin EH, et al. **Adv Immunol** 1995;60:105–49 (135 ref.)

Molecular bases for the construction of artificial immunogens and vaccines based on synthetic polyions. Khaitov RM. **Allergy Proc** 1995 Sep–Oct;16(5):255–60 (14 ref.)

Immunological properties of bacterial DNA. Pisetsky DS, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:152–63 (33 ref.)

The polymorphic epithelial mucin: potential as an immunogen for a cancer vaccine. Graham RA, et al. **Cancer Immunol Immunother** 1996 Feb;42(2):71–80 (61 ref.)

Synthetic recombinant vaccines against viral agents. Arnon A, et al. **Int Arch Allergy Immunol** 1995 Dec;108(4):321–6 (48 ref.)

VACCINES, SYNTHETIC

Design of experimental synthetic peptide immunogens for prevention of HIV-1 and HTLV-I retroviral infections. Hart MK, et al. **Pharm Biotechnol** 1995;6:821-45 (175 ref.)
The MAP system. A flexible and unambiguous vaccine design of branched peptides. Nardelli B, et al. **Pharm Biotechnol** 1995;6:803-19 (57 ref.)
Immunological and formulation design considerations for subunit vaccines. Newman MJ, et al. **Pharm Biotechnol** 1995;6:1-42 (290 ref.)
Synthetic hormone/growth factor subunit vaccine with application to antifertility and cancer. Snyder LL, et al. **Pharm Biotechnol** 1995;6:907-30 (145 ref.)
Sperm antigens and immunocontraception. Kerr LE. **Reprod Fertil Dev** 1995;7(4):825-30 (74 ref.)
Adenovirus vectors as recombinant viral vaccines. Imler JL. **Vaccine** 1995 Sep;13(13):1143-51 (72 ref.)
[Efficacy of acellular pertussis vaccines] Wirsing von König CH, et al. **Immun Infekt** 1995 Aug;23(4):125-9 (15 ref.) (Eng. Abstr.) **(Ger)**

ISOLATION & PURIFICATION

New and safe "oral" live vaccines based on lactobacillus. Claassen E, et al. **Adv Exp Med Biol** 1995;371B:1553-8 (23 ref.)
Human tumour antigens recognized by T-cells: perspectives for new cancer vaccines. Van den Eynde B, et al. **Biochem Soc Trans** 1995 Aug;23(3):681-6 (38 ref.)

PHARMACOLOGY

The polymorphic epithelial mucin: potential as an immunogen for a cancer vaccine. Graham RA, et al. **Cancer Immunol Immunother** 1996 Feb;42(2):71-80 (61 ref.)
DNA vaccines: what can we expect? Siegrist CA, et al. **Infect Agents Dis** 1996 Jan;5(1):55-9 (19 ref.)

STANDARDS

Regulatory issues in the use of DNA vaccines. Minor PD. **Ann N Y Acad Sci** 1995 Nov 27;772:170-7 (29 ref.)
Environmental safety assessment of vaccines derived from biotechnology. Pastoret PP, et al. **Rev Sci Tech** 1995 Dec; 14(4):963-77 (40 ref.)

THERAPEUTIC USE

Retroviral vectors for HIV immunotherapy. Warner JF, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:105-16 (36 ref.)
Non-replicating expression vectors: applications in vaccine development and gene therapy. Limbach KJ, et al. **Epidemiol Infect** 1996 Jun;116(3):241-56 (87 ref.)
Synthetic peptide vaccines for schistosomiasis. Harn DA, et al. **Pharm Biotechnol** 1995;6:891-905 (41 ref.)
Designer vaccines to prevent infections due to group B Streptococcus. Kasper DL. **Proc Assoc Am Physicians** 1995 Oct;107(3):369-73 (22 ref.)

VACCINIA VIRUS

GENETICS

In situ cytokine gene transfection using vaccinia virus vectors. Lattime EC, et al. **Semin Oncol** 1996 Feb; 23(1):88-100 (98 ref.)
Functional organization of variola major and vaccinia virus genomes. Shchelkunov SN. **Virus Genes** 1995;10(1):53-71 (261 ref.)
[Analyses of cellular immune mechanism in chronic hepatitis C using recombinant vaccinia virus expression system] Nishizono A, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:179-85 (19 ref.) **(Jpn)**
[Expression of the proteins encoded by the hepatitis C viral genome by vaccinia virus expression system] Tanaka T, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:85-90 (16 ref.) **(Jpn)**

VACUOLATING AGENT see **POLYOMAVIRUS MACACAE**

VACUOLES

METABOLISM

Receptor-mediated protein sorting to the vacuole in yeast: roles for a protein kinase, a lipid kinase and GTP-binding proteins. Stack JH, et al. **Ann Rev Cell Dev Biol** 1995; 11:1-33 (146 ref.)
Protein transport to the yeast vacuole. Horazdovsky BF, et al. **Curr Opin Cell Biol** 1995 Aug;7(4):544-51 (71 ref.)

MICROBIOLOGY

The varied lifestyles of intracellular pathogens within eukaryotic vacuolar compartments. Garcia-del Portillo F, et al. **Trends Microbiol** 1995 Oct;3(10):373-80 (69 ref.)

PARASITOLOGY

The varied lifestyles of intracellular pathogens within eukaryotic vacuolar compartments. Garcia-del Portillo F, et al. **Trends Microbiol** 1995 Oct;3(10):373-80 (69 ref.)

PATHOLOGY

Infantile sialic acid storage disease: a rare cause of cytoplasmic vacuolation in pediatric patients. Hale LP, et al. **Pediatr Pathol Lab Med** 1995 May-Jun;15(3):443-53 (18 ref.)

PHYSIOLOGY

Protein targeting to the plant vacuole--a historical perspective. Dombrowski JE, et al. **Braz J Med Biol Res** 1996 Apr;29(4):413-30 (221 ref.)
Vacuolar biogenesis in yeast: sorting out the sorting proteins. Conibear E, et al. **Cell** 1995 Nov 17;83(4):513-6 (17 ref.)

VACUUM EXTRACTION, OBSTETRICAL

Vacuum-assisted delivery. Williams MC. **Clin Perinatol** 1995 Dec;22(4):933-52 (77 ref.)

ADVERSE EFFECTS

Choice and instrumental delivery. Drife JO. **Br J Obstet Gynaecol** 1996 Jul;103(7):608-11 (38 ref.)

VAGAL BODY see **AORTIC BODIES**

VAGINA

see related
COLPOSCOPY

Transvaginal ultrasonography in nonpregnant and postmenopausal women. Weissman AM, et al. **Am Fam Physician** 1996 May 1;53(6):2065-72 (23 ref.)

ABNORMALITIES

Laparoscopy in surgical treatment of vaginal aplasia: laparoscopy-assisted colpopoiesis and perineal hysterectomy with colpopoiesis. Adamian LV, et al. **Int J Fertil Menopausal Stud** 1996 Jan-Feb;41(1):40-5 (10 ref.)

ANATOMY & HISTOLOGY

A morphologist's approach to the vagina--age-related changes and estrogen sensitivity. Forsberg JG. **Maturitas** 1995 Dec;22 Suppl:S7-S15 (82 ref.)

DRUG EFFECTS

Effects of sex hormones on oncogene expression in the vagina and on development of sexual dimorphism of the pelvis and anococcygeus muscle in the mouse. Iguchi T, et al. **Environ Health Perspect** 1995 Oct;103 Suppl 7:79-82 (34 ref.)

MICROBIOLOGY

[Causes and consequences of an unbalanced vaginal ecosystem] Kunz J. **Schweiz Rundsch Med Prax** 1995 Nov 28;84(48):1405-15 (79 ref.) (Eng. Abstr.) **(Ger)**
[Bacterial flora of the vagina and the effect of endogenous and exogenous factors on its changes] Bulanda M, et al. **Ginekol Pol** 1996 Jan;67(1):28-33 (19 ref.) (Eng. Abstr.) **(Pol)**

PATHOLOGY

Anatomic goals in the correction of female stress urinary incontinence. Mostwin JL, et al. **J Endourol** 1996 Jun; 10(3):207-12 (29 ref.)
Effectiveness of vaginal Papanicolaou smear screening after total hysterectomy for benign disease. Fetters MD, et al. **JAMA** 1996 Mar 27;275(12):940-7 (90 ref.)

PHYSIOLOGY

[Vaginal environment. The vaginal climate and its variations] Nicoli JM, et al. **Rev Fr Gynecol Obstet** 1995 Nov; 90(11):471-80 (8 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Recurrent squamous cell carcinoma in a rectus abdominis neovagina. Carlson JW, et al. **Gynecol Oncol** 1995 Oct; 59(1):159-61 (17 ref.)
Laparoscopy in surgical treatment of vaginal aplasia: laparoscopy-assisted colpopoiesis and perineal hysterectomy with colpopoiesis. Adamian LV, et al. **Int J Fertil Menopausal Stud** 1996 Jan-Feb;41(1):40-5 (10 ref.)

VAGINAL BIRTH AFTER CESAREAN

Cervical ripening and labor induction after previous cesarean delivery. Chez RA. **Clin Obstet Gynecol** 1995 Jun; 38(2):287-92 (45 ref.)
Vaginal birth after cesarean delivery. Martins ME. **Clin Perinatol** 1996 Mar;23(1):141-53 (43 ref.)
Vaginal birth after cesarean section: current opinion. Weinstein D, et al. **Int J Gynaecol Obstet** 1996 Apr; 53(1):1-10 (52 ref.)
[Is induced labor justified in cases of scarred uterus, breech presentation and multiple pregnancy?] Schaal JP, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24 Suppl 1:57-61 (39 ref.) **(Fre)**

VAGINAL DISEASES

ETIOLOGY

Urethral prolapse: an often misdiagnosed cause of urogenital bleeding in girls. Anveden-Hertzberg L, et al. **Pediatr Emerg Care** 1995 Aug;11(4):212-4 (25 ref.)

VAGINAL FISTULA

ETIOLOGY

Genital fistulas secondary to diverticular disease of the colon: a review. Tancer ML, et al. **Obstet Gynecol Surv** 1996 Jan; 51(1):67-73 (67 ref.)

VAGINAL NEOPLASMS

Recurrent squamous cell carcinoma in a rectus abdominis neovagina. Carlson JW, et al. **Gynecol Oncol** 1995 Oct; 59(1):159-61 (17 ref.)

DIAGNOSIS

[Pseudosarcoma botryoides during pregnancy] Lasso de la Vega J, et al. **Rev Med Panama** 1995 Jan-May;20(1-2):45-9 (8 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

Effectiveness of vaginal Papanicolaou smear screening after total hysterectomy for benign disease. Fetters MD, et al. **JAMA** 1996 Mar 27;275(12):940-7 (90 ref.)

PATHOLOGY

Angiomyofibroblastoma of the vulva and vagina. Nielsen GP, et al. **Mod Pathol** 1996 Mar;9(3):284-91 (25 ref.)

THERAPY

Treatment of vaginal recurrence in endometrial cancer. A review. Møller LA, et al. **Acta Obstet Gynecol Scand** 1996 Jan;75(1):1-7 (45 ref.)

VAGINAL PROLAPSE see **UTERINE PROLAPSE**

VAGINAL SMEARS

Cervical intraepithelial neoplasia: false negative smears. Allen SM. **Br J Biomed Sci** 1996 Jun;53(2):152-6 (36 ref.)
Every woman with an abnormal cervical smear should be referred for treatment: debate. Flannelly G, et al. **Clin Obstet Gynecol** 1995 Sep;38(3):585-91 (20 ref.)
Cervical neoplasia: are adjunctive tests to cervical cytology worthwhile? Greenberg MD, et al. **Clin Obstet Gynecol** 1995 Sep;38(3):600-9 (24 ref.)
Every woman with an abnormal cervical smear should not be referred for colposcopy: debate. Prendiville W, et al. **Clin Obstet Gynecol** 1995 Sep;38(3):592-9 (16 ref.)
Radiation treatment effects in cervical cytology. Powers CN. **Diagn Cytopathol** 1995 Jul;13(1):75-80 (18 ref.)
Cytologic screening for cervix cancer: each year or each 3 years? Dubois G. **Eur J Obstet Gynecol Reprod Biol** 1996 Mar;65(1):57-9 (14 ref.)
The Papanicolaou smear: its value and limitations. Lieu D. **J Fam Pract** 1996 Apr;42(4):391-9 (40 ref.)
Effectiveness of vaginal Papanicolaou smear screening after total hysterectomy for benign disease. Fetters MD, et al. **JAMA** 1996 Mar 27;275(12):940-7 (90 ref.)
The abnormal Papanicolaou smear. McIntyre-Seltman K. **Med Clin North Am** 1995 Nov;79(6):1427-42 (49 ref.)
Screening for cervical cancer. Guidozzi F. **Obstet Gynecol Surv** 1996 Apr;51(4):247-52 (46 ref.)
[The cytological screening problems in cancer of the cervix uteri] Khristova L. **Akush Ginekol (Sofiia)** 1994;33(2):39-40 (14 ref.) **(Bul)**
[Role of the general physician in a screening strategy for cancer of the cervix uteri] Boüüaert C, et al. **Rev Med Liege** 1995 Dec;50(12):517-24 (37 ref.) **(Fre)**

INSTRUMENTATION

Neuromedical Systems, Inc. Mango LJ. **Acta Cytol** 1996 Jan-Feb;40(1):53-9 (25 ref.)
NeoPath, Inc. NeoPath AutoPap 300 Automatic Pap Screener System. Patten SF Jr, et al. **Acta Cytol** 1996 Jan-Feb;40(1):45-52 (12 ref.)
CYTYC Corporation. Zahniser DJ, et al. **Acta Cytol** 1996 Jan-Feb;40(1):37-44 (12 ref.)

METHODS

The minimally abnormal Papanicolaou smear. Brotzman GL, et al. **Am Fam Physician** 1996 Mar;53(4):1154-62 (39 ref.)
Impact of variation in endocervical specimen collection and testing techniques on frequency of false-positive and false-negative Chlamydia detection results. Kellogg JA. **Am J Clin Pathol** 1995 Nov;104(5):554-9 (65 ref.)
Endometrial cytology by direct sampling. Its value and limitations in the diagnosis of endometrial lesions. Nguyen GK, et al. **Pathol Annu** 1995;30 Pt 2:179-202 (42 ref.)

STANDARDS

Impact of variation in endocervical specimen collection and testing techniques on frequency of false-positive and

false-negative Chlamydia detection results. Kellogg JA. **Am J Clin Pathol** 1995 Nov;104(5):554–9 (65 ref.)
The quality of cervical cancer screening: a primary care perspective. Curtis P, et al. **Am J Med Qual** 1996 Spring; 11(1):11–7 (49 ref.)

VAGINITIS

Genitourinary infection in older women. Sale PG. **J Obstet Gynecol Neonatal Nurs** 1995 Oct;24(8):769–75 (26 ref.)
Office gynecology for the primary care physician, part I: vaginitis, the Papanicolaou smear, contraception, and postmenopausal estrogen replacement. Reife CM. **Med Clin North Am** 1996 Mar;80(2):299–319 (63 ref.)

DIAGNOSIS

Common genitourinary infections. Freeman SB. **J Obstet Gynecol Neonatal Nurs** 1995 Oct;24(8):735–42 (26 ref.)

VAGINITIS, BACTERIAL see **VAGINOSIS, BACTERIAL**

VAGINITIS, NONSPECIFIC see **VAGINOSIS, BACTERIAL**

VAGINOSIS, BACTERIAL

[Bacterial vaginosis II. Related pathology and therapy] Oyarzún E, et al. **Rev Chil Obstet Ginecol** 1995;60(2):135–42 (43 ref.) **(Spa)**
[Bacterial vaginosis. I: history, microbiology, and diagnosis] Oyarzún E, et al. **Rev Chil Obstet Ginecol** 1995;60(1):51–62 (50 ref.) **(Spa)**

COMPLICATIONS

Role of bacterial vaginosis in pelvic inflammatory disease. Sweet RL. **Clin Infect Dis** 1995 Jun;20 Suppl 2:S271–5 (46 ref.)

DIAGNOSIS

Bacterial vaginosis. Martius J. **Curr Probl Dermatol** 1996; 24:34–9 (17 ref.)

DRUG THERAPY

Adjunctive care of preterm labor—the use of antibiotics. Lewis R, et al. **Clin Obstet Gynecol** 1995 Dec;38(4):755–70 (69 ref.)
Bacterial vaginosis. Martius J. **Curr Probl Dermatol** 1996; 24:105–9 (35 ref.)
Secnidazole. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic use in the management of protozoal infections and bacterial vaginosis. Gillis JC, et al. **Drugs** 1996 Apr;51(4):621–38 (56 ref.)
Metronidazole: utilization in the obstetric and gynecologic patient. Schwebke JR. **Sex Transm Dis** 1995 Nov–Dec; 22(6):370–6 (84 ref.)

THERAPY

Bacterial vaginosis: the case for treatment. O'Dowd T. **Practitioner** 1995 Sep;239(1554):538–41 (11 ref.)

VAGOTOMY

Endoscopic vagotomy for duodenal ulcer disease: procedures and appraisal. Cuschieri A. **Adv Surg** 1996;29:291–302 (38 ref.)
Dragstedt, gastric acid and duodenal ulcer. Hobsley M. **Yale J Biol Med** 1994 May–Aug;67(3–4):173–80 (42 ref.)
Minimal access surgery—the renaissance of gastric surgery? McCloy R, et al. **Yale J Biol Med** 1994 May–Aug; 67(3–4):159–66 (38 ref.)
Therapeutic applications of vagotomy. Olbe L. **Yale J Biol Med** 1994 May–Aug;67(3–4):153–7 (13 ref.)

VAGOTOMY, PARIETAL CELL see **VAGOTOMY, PROXIMAL GASTRIC**

VAGOTOMY, PROXIMAL GASTRIC

Should the 1996 citation for Zollinger–Ellison syndrome read: "Acid-reducing surgery in, aggressive resection out"? [editorial; comment] Jensen RT. **Am J Gastroenterol** 1996 Jun;91(6):1067–70 (43 ref.) Comment on: Am J Gastroenterol 1996 Jun;91(6):1104–11.
Laparoscopic management of peptic ulcer disease. Casas AT, et al. **Surg Clin North Am** 1996 Jun;76(3):515–22 (23 ref.)

METHODS

[Management of stomach ulcer except in emergency: surgical treatment] Lacaine F. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S81–S83 (16 ref.) **(Fre)**
[Management of duodenal ulcer except in emergency: surgical treatment] Michot F, et al. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S64–S72 (87 ref.) **(Fre)**

VAGOTOMY, SELECTIVE PROXIMAL see **VAGOTOMY, PROXIMAL GASTRIC**

VAGOTOMY, TRUNCAL

METHODS

[Management of duodenal ulcer except in emergency: surgical treatment] Michot F, et al. **Gastroenterol Clin Biol** 1996 Jan;20(1 Pt 2):S64–S72 (87 ref.) **(Fre)**

VAGUS NERVE

see related
VAGOTOMY
Functioning glomus vagale tumor: report of case. Guiral H, et al. **J Oral Maxillofac Surg** 1996 Feb;54(2):227–30 (12 ref.)
[Vagus-saving D2 procedure for early gastric carcinoma] Miwa K, et al. **Nippon Geka Gakkai Zasshi** 1996 Apr; 97(4):286–90 (11 ref.) (Eng. Abstr.) **(Jpn)**
[Mediastinal schwannoma originating from the intrathoracic vagal nerve—a case report and review of the literature] Ohtaki A, et al. **Nippon Kyobu Geka Gakkai Zasshi** 1995 Sep;43(9):1675–9 (19 ref.) (Eng. Abstr.) **(Jpn)**
[Therapy of epilepsy with stimulation of the vagus nerve] Tomović M. **Vojnosanit Pregl** 1994 Mar–Apr;51(2):143–6 (25 ref.) **(Scr)**

DRUG EFFECTS

New potential uses for transdermal scopolamine (hyoscine). La Rovere MT, et al. **Drugs** 1995 Nov;50(5):769–76 (49 ref.)

PHYSIOLOGY

Vagal nerve complex in normal development and sudden infant death syndrome. Becker LE, et al. **Can J Neurol Sci** 1996 Feb;23(1):24–33 (35 ref.)
Vagal control of digestion: modulation by central neural and peripheral endocrine factors. Rogers RC, et al. **Neurosci Biobehav Rev** 1996;20(1):57–66 (91 ref.)
Sub-diaphragmatic vagal afferent integration of meal-related gastrointestinal signals. Schwartz GJ, et al. **Neurosci Biobehav Rev** 1996;20(1):47–56 (31 ref.)
Vagal regulation of acid secretion and gastrin release. Debas HT, et al. **Yale J Biol Med** 1994 May–Aug;67(3–4):145–51 (25 ref.)
[Regulation of food intake] Schusdziarra V. **Zentralbl Chir** 1996;121(5):354–7 (34 ref.) (Eng. Abstr.) **(Ger)**
[Vagovagal regulation of the gastrointestinal tract: from signal conduction to performance response] Grundy D, et al. **Fiziol Zh Im I M Sechenova** 1995 Nov;81(11):104–11 (36 ref.) **(Rus)**

PHYSIOPATHOLOGY

Is there an effective pharmacological treatment in the prevention of vasovagal syncope? Sutton R. **Arch Mal Coeur Vaiss** 1996 Feb;89 Spec No 1:25–28 (42 ref.)

VALIDITY OF RESULTS see **REPRODUCIBILITY OF RESULTS**

VALINE

ANALOGS & DERIVATIVES

Valacyclovir HCl (Valtrex): an acyclovir prodrug with improved pharmacokinetics and better efficacy for treatment of zoster. Smiley ML, et al. **Adv Exp Med Biol** 1996;394:33–9 (23 ref.)
Valacyclovir: a review of its antiviral activity, pharmacokinetic properties, and clinical efficacy. Beutner KR. **Antiviral Res** 1995 Dec;28(4):281–90 (29 ref.)
Aciclovir and its l-valyl ester, valaciclovir. Smiley ML, et al. **Curr Probl Dermatol** 1996;24:209–18 (56 ref.)

VALINOMYCIN

CHEMISTRY

Molecular structure and mechanisms of action of cyclic and linear ion transport antibiotics. Duax WL, et al. **Biopolymers** 1996;40(1):141–55 (44 ref.)

VALPROIC ACID

ADVERSE EFFECTS

Pancreatitis with normal serum amylase associated with sodium valproate: a case report. Otusbo S, et al. **Brain Dev** 1995 May–Jun;17(3):219–21 (7 ref.)
[Acute pancreatitis caused by valproic acid: apropos a case] Bahamonde Carrasco A, et al. **Gastroenterol Hepatol** 1996 May;19(5):253–4 (21 ref.) (Eng. Abstr.) **(Spa)**

BLOOD

[Valproic acid] Kohda Y. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:918–20 (10 ref.) **(Jpn)**

PHARMACOLOGY

Interactions of valproic acid with carbamazepine and its metabolites' concentrations, concentrations ratios, and level/dose ratios in epileptic children. Liu H, et al. **Clin Neuropharmacol** 1995 Feb;18(1):1–12 (34 ref.)

THERAPEUTIC USE

Predictors of response to mood stabilizers. Calabrese JR, et al. **J Clin Psychopharmacol** 1996 Apr;16(2 Suppl 1):24S–31S (88 ref.)
The emerging role of valproate in bipolar disorder and other psychiatric disorders. Guay DR. **Pharmacotherapy** 1995 Sep–Oct;15(5):631–47 (146 ref.)

VALSALVA'S MANEUVER

Myelopathy associated with fibrocartilaginous emboli (FE): review and two suspected cases. McLean JM, et al. **Surg Neurol** 1995 Sep;44(3):228–34; discussion 234–5 (46 ref.)

VAN BOGAERT'S LEUKOENCEPHALITIS see **SUBACUTE SCLEROSING PANENCEPHALITIS**

VANADATES

METABOLISM

Interaction of vanadates with biogenic ligands. Crans DC. **Met Ions Biol Syst** 1995;31:147–209 (209 ref.)

PHARMACOLOGY

Use of vanadate-induced photocleavage for detecting phosphate binding sites in proteins. Muhlrad A, et al. **Met Ions Biol Syst** 1995;31:211–30 (65 ref.)
Vanadium compounds as insulin mimics. Orvig C, et al. **Met Ions Biol Syst** 1995;31:575–94 (126 ref.)
Stimulation of enzyme activity by oxovanadium complexes. Stankiewicz PJ, et al. **Met Ions Biol Syst** 1995;31:249–85 (158 ref.)
Inhibition of phosphate-metabolizing enzymes by oxovanadium(V) complexes. Stankiewicz PJ, et al. **Met Ions Biol Syst** 1995;31:287–324 (169 ref.)

VANADIUM

BLOOD

A critical review on normal concentrations of vanadium in human blood, serum, and urine. Sabbioni E, et al. **Sci Total Environ** 1996 Sep 20;188(1):49–58 (63 ref.)

CHEMISTRY

The vanadyl ion: molecular structure of coordinating ligands by electron paramagnetic resonance and electron nuclear double resonance spectroscopy. Makinen MW, et al. **Met Ions Biol Syst** 1995;31:89–127 (80 ref.)
Solution properties of vanadium(III) with regard to biological systems. Meier R, et al. **Met Ions Biol Syst** 1995; 31:45–88 (110 ref.)
Vanadium in ascidians and the chemistry of tunichromes. Smith MJ, et al. **Met Ions Biol Syst** 1995;31:423–90 (361 ref.)

METABOLISM

Vanadium-protein interactions. Chasteen ND. **Met Ions Biol Syst** 1995;31:231–47 (68 ref.)
Vanadium transport in animal systems. Kustin K, et al. **Met Ions Biol Syst** 1995;31:511–42 (88 ref.)

PHYSIOLOGY

Vanadium nitrogenases of Azotobacter. Eady RR. **Met Ions Biol Syst** 1995;31:363–405 (106 ref.)
Vanadium in mammalian physiology and nutrition. Nielsen FH. **Met Ions Biol Syst** 1995;31:543–73 (144 ref.)
Inorganic considerations on the function of vanadium in biological systems. Rehder D. **Met Ions Biol Syst** 1995; 31:1–43 (154 ref.)
Vanadium-dependent haloperoxidases. Vilter H. **Met Ions Biol Syst** 1995;31:325–62 (192 ref.)
The role of vanadium in the management of diabetes. Brichard SM, et al. **Trends Pharmacol Sci** 1995 Aug; 16(8):265–70 (60 ref.)

TOXICITY

Vanadium: a review of the reproductive and developmental toxicity. Domingo JL. **Reprod Toxicol** 1996 May–Jun; 10(3):175–82 (61 ref.)

URINE

A critical review on normal concentrations of vanadium in human blood, serum, and urine. Sabbioni E, et al. **Sci Total Environ** 1996 Sep 20;188(1):49–58 (63 ref.)

VANADIUM COMPOUNDS

THERAPEUTIC USE

Antitumor activity of vanadium compounds. Djordjevic C.

VANADIUM COMPOUNDS

Met Ions Biol Syst 1995;31:595–616 (89 ref.)

VANADYL see **VANADATES**

VANCOMYCIN

ADVERSE EFFECTS

Diarrhea associated with parenteral vancomycin therapy [letter] Schenfeld LA, et al. **Clin Infect Dis** 1995 Jun; 20(6):1578–9 (5 ref.)

BLOOD

[Vancomycin] Furuta I, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:1028–30 (6 ref.) **(Jpn)**

PHARMACOLOGY

Pharmacodynamics of antimicrobial therapy in surgery. DiPiro JT, et al. **Am J Surg** 1996 Jun;171(6):615–22 (46 ref.)

Vancomycin–resistant Staphylococcus aureus: perspectives on measures needed for control. Edmond MB, et al. **Ann Intern Med** 1996 Feb 1;124(3):329–34 (53 ref.)

Emerging resistance in Enterococcus spp. Heath CH, et al. **Med J Aust** 1996 Jan 15;164(2):116–20 (44 ref.)

THERAPEUTIC USE

Pharmacodynamics of antimicrobial therapy in surgery. DiPiro JT, et al. **Am J Surg** 1996 Jun;171(6):615–22 (46 ref.)

Controversies in endophthalmitis prevention. The risk for emerging resistance to vancomycin [editorial; comment] Alfonso EC, et al. **Arch Ophthalmol** 1995 Nov; 113(11):1369–70 (15 ref.) Comment on: Arch Ophthalmol 1995 Nov;113(11):1353–4.

Antimicrobial resistance patterns in long term geriatric care. Implications for drug therapy. Mao CA, et al. **Drugs Aging** 1996 Mar;8(3):162–70 (66 ref.)

Vancomycin, trimethoprim–sulfamethoxazole, and rifampin. Lundstrom TS, et al. **Infect Dis Clin North Am** 1995 Sep; 9(3):747–67 (91 ref.)

Vancomycin administration and monitoring reappraisal. Saunders NJ. **J Antimicrob Chemother** 1995 Aug; 36(2):279–82 (32 ref.)

The comparative efficacy and safety of teicoplanin and vancomycin. Wood MJ. **J Antimicrob Chemother** 1996 Feb; 37(2):209–22 (27 ref.)

VANILMANDELIC ACID

ANALYSIS

[Vanillylmandelic acid (VMA)] Inoue J, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:524–6 (9 ref.) **(Jpn)**

URINE

Screening for neuroblastoma: a review of the evidence [see comments] Chamberlain J. **J Med Screen** 1994 Jul; 1(3):169–75 (37 ref.) Comment in: J Med Screen 1994 Jul;1(3):141–2.

VANYLGLYCOL see **METHOXYHYDROXYPHENYLGLYCOL**

VAPORIZATION see **VOLATILIZATION**

VAPORIZATION, LASER see **LASER SURGERY**

VAPORIZERS see **NEBULIZERS AND VAPORIZERS**

VARIABLE NUMBER OF TANDEM REPEATS

see related
DNA FINGERPRINTING

Uniparental isodisomy of chromosome 14 in two cases: an abnormal child and a normal adult. Papenhausen PR, et al. **Am J Med Genet** 1995 Nov 20;59(3):271–5 (30 ref.)

Single-cell analysis of unstable genes. Daniels R, et al. **J Assist Reprod Genet** 1996 Feb;13(2):163–9 (28 ref.)

DNA fingerprinting and forensic medicine. Boonsaeng V. **Southeast Asian J Trop Med Public Health** 1995;26 Suppl 1:296–300 (26 ref.)

VARIABLE REGION, IG see **IMMUNOGLOBULIN VARIABLE REGION**

VARIATION, ANTIGENIC see **ANTIGENIC VARIATION**

VARIATION (GENETICS)

Control and function of complex-type oligosaccharide synthesis. Novel variants of the lacNAc pathway. Van den Eijnden DH, et al. **Adv Exp Med Biol** 1995;376:47–52 (26 ref.)

Using oligonucleotide probe arrays to access genetic diversity. Lipshutz RJ, et al. **Biotechniques** 1995 Sep; 19(3):442–7 (16 ref.)

The genetic origin of responses to drugs. Waring RH, et al. **Br Med Bull** 1995 Apr;51(2):449–61 (30 ref.)

Glial transplants: an in vivo analysis of extrinsic and intrinsic determinants of dysmyelination in genetic variants. Lachapelle F. **Brain Pathol** 1995 Jul;5(3):289–99 (103 ref.)

Genetic variation of apolipoprotein B can produce both low and high levels of apoB–containing lipoproteins in plasma. Schonfeld G. **Can J Cardiol** 1995 Oct;11 Suppl G:86G–92G (79 ref.)

Apolipoprotein E polymorphism and dietary plasma cholesterol response. Tikkanen M, et al. **Can J Cardiol** 1995 Oct;11 Suppl G:93G–96G (25 ref.)

Nucleotide excision repair: variations associated with cancer development and speciation. Cleaver JE, et al. **Cancer Surv** 1995;25:125–42 (76 ref.)

Quantitative genetics. Loci with large effects. Keightley PD. **Curr Biol** 1995 May 1;5(5):485–7 (7 ref.)

The elusive centromere: sequence divergence and functional conservation. Sunkel CE, et al. **Curr Opin Genet Dev** 1995 Dec;5(6):756–67 (68 ref.)

Polymerase chain reaction–based assays for the characterisation of plant genetic resources. Powell W, et al. **Electrophoresis** 1995 Sep;16(9):1726–30 (36 ref.)

Variability in gene expression and tumor formation within genetically homogeneous animal populations in bioassays. Wolff GL. **Fundam Appl Toxicol** 1996 Feb;29(2):176–84 (30 ref.)

The unique structures of protozoan myoglobin and yeast hemoglobin: an evolutionary diversity. Shikama K, et al. **Int J Biochem Cell Biol** 1995 Nov;27(11):1107–15 (35 ref.)

Molecular identification of nanoplanktonic protists based on small subunit ribosomal RNA gene sequences for ecological studies. Lim EL. **J Eukaryot Microbiol** 1996 Mar–Apr; 43(2):101–6 (47 ref.)

Hepatitis C virus variants and the role of genotyping. Smith DB, et al. **J Hepatol** 1995;23 Suppl 2:26–31 (31 ref.)

CD44: physiological expression of distinct isoforms as evidence for organ–specific metastasis formation. Zöller M. **J Mol Med** 1995 Sep;73(9):425–38 (265 ref.)

Involvement of CD44 and its variant isoforms in membrane–cytoskeleton interaction, cell adhesion and tumor metastasis. Bourrguignon LY, et al. **J Neurooncol** 1995 Dec;26(3):201–8 (44 ref.)

Schwann cell tumors express characteristic patterns of CD44 splice variants. Sherman L, et al. **J Neurooncol** 1995 Dec; 26(3):171–84 (57 ref.)

Molecular basis for a geographic variation of varicella–zoster virus recognized by a peptide antibody. Kinchington PR, et al. **Neurology** 1995 Dec;45(12 Suppl 8):S13–4 (7 ref.)

Genetic variation of CNS receptors—a new perspective for pharmacogenetics. Propping P, et al. **Pharmacogenetics** 1995 Oct;5(5):318–25 (75 ref.)

Use of physiologically based pharmacokinetic modeling to investigate individual versus population risk. Clewell HJ 3rd, et al. **Toxicology** 1996 Jul 17;111(1–3):315–29 (107 ref.)

Human interindividual variability in susceptibility to toxic effects: from annoying detail to a central determinant of risk. Hattis D. **Toxicology** 1996 Jul 17;111(1–3):5–14 (37 ref.)

Interindividual variations in susceptibility and sensitivity: linking risk assessment and risk management. Preston RJ. **Toxicology** 1996 Jul 17;111(1–3):331–41 (42 ref.)

The genetic basis of quantitative variation: numbers of sensory bristles of Drosophila melanogaster as a model system. Mackay TF. **Trends Genet** 1995 Dec;11(12):464–70 (35 ref.)

Running the gamut of retroviral variation. Wain–Hobson S. **Trends Microbiol** 1996 Apr;4(4):135–41 (48 ref.)

[Intraspecific genetic diversity: monitoring and principles of conservation] Altukhov IuP. **Genetika** 1995 Oct; 31(10):1333–57 (110 ref.) (Eng. Abstr.) **(Rus)**

GENETICS

Generation of MHC class II diversity by intra– and intergenic recombination. Andersson L, et al. **Immunol Rev** 1995 Feb; 143:5–12 (19 ref.)

[Role of genetic epidemiology in the study of infectious diseases. The example of malaria] Garcia A, et al. **Med Trop (Mars)** 1995;55(4 Suppl):14–8 (39 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Unraveling chemosensory diversity. Buck LB. **Cell** 1995 Nov 3;83(3):349–52 (17 ref.)

VARICELLA see **CHICKENPOX**

VARICELLA-ZOSTER VIRUS see **HERPESVIRUS 3, HUMAN**

VARICES see **VARICOSE VEINS**

VARICOCELE

COMPLICATIONS

Debate on the pros and cons of varicocele treatment—in favour of varicocele treatment. Hargreave TB. **Hum Reprod** 1995 Oct;10 Suppl 1:151–7 (28 ref.)

[Surgical cure of varicocele and male infertility: for or against?] Adjiman M. **Contracept Fertil Sex** 1996 Jun; 24(6):439–41 (16 ref.) **(Fre)**

[Surgical cure of varicocele and male infertility: for or against?] Amar E. **Contracept Fertil Sex** 1996 Jun; 24(6):442–3 (7 ref.) **(Fre)**

ETIOLOGY

Varicocele as a presenting feature of Wilms' tumor. Monroe K, et al. **Pediatr Emerg Care** 1995 Oct;11(5):300–1 (7 ref.)

SURGERY

[Surgical cure of varicocele and male infertility: for or against?] Adjiman M. **Contracept Fertil Sex** 1996 Jun; 24(6):439–41 (16 ref.) **(Fre)**

[Surgical cure of varicocele and male infertility: for or against?] Amar E. **Contracept Fertil Sex** 1996 Jun; 24(6):442–3 (7 ref.) **(Fre)**

[Current status of laparoscopic surgery in pediatric urology] Fuchs GJ, et al. **Urologe A** 1996 May;35(3):175–84 (62 ref.) (Eng. Abstr.) **(Ger)**

["Contra laparoscopy" position in treatment of testicular varicocele] Tauber R, et al. **Urologe A** 1996 May; 35(3):246–50 (41 ref.) (Eng. Abstr.) **(Ger)**

[Surgical management of varicocele in childhood. A new modified surgical technique] Campobasso P. **Minerva Urol Nefrol** 1995 Sep;47(3):141–6 (54 ref.) (Eng. Abstr.) **(Ita)**

THERAPY

Debate on the pros and cons of varicocele treatment—in favour of varicocele treatment. Hargreave TB. **Hum Reprod** 1995 Oct;10 Suppl 1:151–7 (28 ref.)

VARICOSE ULCER

DRUG THERAPY

Pharmacologic treatment of venous leg ulcers. Dormandy JA. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S61–5 (29 ref.)

NURSING

Living with a venous leg ulcer: a descriptive study of patients' experiences. Walshe C. **J Adv Nurs** 1995 Dec; 22(6):1092–100 (38 ref.)

PSYCHOLOGY

Living with a venous leg ulcer: a descriptive study of patients' experiences. Walshe C. **J Adv Nurs** 1995 Dec; 22(6):1092–100 (38 ref.)

SURGERY

Congenitally absent inferior vena cava presenting in adulthood with venous stasis and ulceration: a surgically treated case. Dougherty MJ, et al. **J Vasc Surg** 1996 Jan; 23(1):141–6 (17 ref.)

THERAPY

Management of venous leg ulcers. Hafner J, et al. **Vasa** 1996; 25(2):161–7 (49 ref.)

[Treatment of ulcus cruris. What is the role of wound dressings?] Sedlarik KM. **Med Monatsschr Pharm** 1995 Dec;18(12):358–62 (21 ref.) **(Ger)**

VARICOSE VEINS

see related
ESOPHAGEAL AND GASTRIC VARICES
SCLEROSING SOLUTIONS
SCLEROTHERAPY

CLASSIFICATION

Classification and grading of chronic venous disease in the lower limbs—a consensus statement. Organized by Straub Foundation with the cooperation of the American Venous Forum at the 6th annual meeting, February 22–25, 1994, Maui, Hawaii. Beebe HG, et al. **Vasa** 1995;24(4):313–8 (44 ref.)

COMPLICATIONS

Thrombotic complications of varicose veins. A literature review of the role of superficial venous thrombosis. Guex JJ. **Dermatol Surg** 1996 Apr;22(4):378–82 (39 ref.)

Jejunal phlebectasia presenting with massive gastrointestinal hemorrhage. Mejia EM, et al. **J Clin Gastroenterol** 1996 Apr;22(3):215–7 (7 ref.)

DIAGNOSIS

Isolated cerebral intraaxial varix. Kelly KJ, et al. **AJNR Am J Neuroradiol** 1995 Sep;16(8):1633–5 (10 ref.)

[Varicose veins and migrating thrombophlebitis] Leu AJ, et al. **Dtsch Med Wochenschr** 1996 Apr 19;121(16):527–31 (30 ref.) **(Ger)**

METABOLISM

[Role of glycosoaminoglycans in venous disease. Mode of action of some flavonoid drugs] Drubaix I, et al. **Pathol Biol (Paris)** 1995 May;43(5):461–70 (37 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

[Multiple bronchial varices] Otsuka T, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1996 Mar; 34(3):327–30 (10 ref.) (Eng. Abstr.) **(Jpn)**

SURGERY

Ambulatory phlebectomy. A rare complication of local anesthetic: case report and literature review. Olivencia JA. **Dermatol Surg** 1996 Jan;22(1):53–5 (15 ref.)

[Chronic venous insufficiency] Hauer G, et al. **Chirurg** 1996 May;67(5):505–14 (42 ref.) (Eng. Abstr.) **(Ger)**

[Recurrent bleeding from colonic varices in portal hypertension. The successful prevention of recurrence by the implantation of a transjugular intrahepatic stent-shunt (TIPS)] Allgaier HP, et al. **Dtsch Med Wochenschr** 1995 Dec 22;120(51–52):1773–6 (2? ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Ambulatory phlebectomy compared to sclerotherapy for varicose and telangiectatic veins: indications and complications. Weiss RA, et al. **Adv Dermatol** 1996;11:3–16; discussion 17 (37 ref.)

[Ambulatory therapy in varicose veins] Eichlisberger R, et al. **Ther Umsch** 1996 Apr;53(4):295–303 (24 ref.) (Eng. Abstr.) **(Ger)**

VARIOLA VIRUS

GENETICS

Functional organization of variola major and vaccinia virus genomes. Shchelkunov SN. **Virus Genes** 1995;10(1):53–71 (261 ref.)

VAS DEFERENS

see related
VASECTOMY
VASOVASOSTOMY

ABNORMALITIES

[Molecular basis of cystic fibrosis and congenital bilateral agenesis of vas deferens] Bienvenu T, et al. **Contracept Fertil Sex** 1996 Jun;24(6):495–500 (31 ref.) (Eng. Abstr.) **(Fre)**

VASA NERVORUM

Vasculitic neuropathy. Fathers E, et al. **Br J Hosp Med** 1996 May 15–Jun 4;55(10):643–7 (28 ref.)

VASCULAR ACCESS PORTS see **CATHETERS, INDWELLING**

VASCULAR-ASSIST DEVICES see **HEART-ASSIST DEVICES**

VASCULAR CAPACITANCE

see related
VASCULAR RESISTANCE

VASCULAR CELL ADHESION MOLECULE-1

ANALYSIS

Cytokines, adhesion molecules (E-selectin and VCAM-1) and graft-versus-host disease. Lange A, et al. **Arch Immunol Ther Exp (Warsz)** 1995;43(2):99–105 (23 ref.)

[Function and regulation of adhesion molecules in CTLs induction of chronic hepatitis B—expression of ICAM-1 and VCAM-1 in liver tissues] Doi T. **Nippon Rinsho** 1995 Oct;53 Suppl:180–4 (19 ref.) **(Jpn)**

BIOSYNTHESIS

Involvement of tyrosine phosphorylation in endothelial adhesion molecule induction. Weber C. **Immunol Res** 1996; 15(1):30–7 (42 ref.)

METABOLISM

Mechanisms of VCAM-1 and fibronectin binding to integrin alpha 4 beta 1: implications for integrin function and rational drug design. Humphries MJ, et al. **Ciba Found Symp** 1995;189:177–91; discussion 191–9 (43 ref.)

PHYSIOLOGY

Creation and characterization of E-selectin- and VCAM-1-deficient mice. Kwee L, et al. **Ciba Found Symp** 1995;189:17–28; discussion 28–34, 77–8 (26 ref.)

CD 105 and angiogenesis [editorial] Kumar P, et al. **J Pathol** 1996 Apr;178(4):363–6 (42 ref.)

VASCULAR DEMENTIA see **DEMENTIA, VASCULAR**

VASCULAR DISEASES

CHEMICALLY INDUCED

[Vascular disorders following chemotherapy] van der Lelie J, et al. **Ned Tijdschr Geneeskd** 1995 Nov 11;139(45):2296–9 (24 ref.) **(Dut)**

[Drug-induced iatrogenic arterial diseases] Cacoub P, et al. **Rev Med Interne** 1995;16(11):827–32 (34 ref.) (Eng. Abstr.) **(Fre)**

CLASSIFICATION

Classification and grading of chronic venous disease in the lower limbs: a consensus statement. American Venous Forum [editorial] Myers KA. **Aust N Z J Surg** 1995 Nov; 65(11):769–72 (44 ref.)

COMPLICATIONS

Vascular abdominal emergencies. Walker JS, et al. **Emerg Med Clin North Am** 1996 Aug;14(3):571–92 (85 ref.)

Peripheral ulcerative keratitis in the collagen vascular diseases. Gregory JK, et al. **Int Ophthalmol Clin** 1996 Winter;36(1):21–30 (37 ref.)

DIAGNOSIS

Review: Binswanger's disease, leukoaraiosis and dementia [letter; comment] Hasan M, et al. **Age Ageing** 1995 Sep; 24(5):454 (4 ref.) Comment on: Age Ageing 1994 Jan;23(1):75–81.

Diagnosis of vascular trauma. Modrall JG, et al. **Ann Vasc Surg** 1995 Jul;9(4):415–21 (61 ref.)

Classification and grading of chronic venous disease in the lower limbs: a consensus statement. American Venous Forum [editorial] Myers KA. **Aust N Z J Surg** 1995 Nov; 65(11):769–72 (44 ref.)

Plethysmography: safety, effectiveness, and clinical utility in diagnosing vascular disease. Graham AA. **Health Technol Assess** 1996;(7):1–46 (182 ref.)

MR angiography of the hand and wrist. Rofsky NM. **Magn Reson Imaging Clin N Am** 1995 May;3(2):345–59 (31 ref.)

Identification of endothelial cell-surface proteins as targets for diagnosis and treatment of disease. Jacobson BS, et al. **Nat Med** 1996 Apr;2(4):482–4 (22 ref.)

Visualization of microcirculatory disorders in haemorrhagic fever with renal syndrome. Sirotin BZ, et al. **Nephrol Dial Transplant** 1996 Apr;11(4):721–2 (6 ref.)

Collagen vascular diseases. Corley DE, et al. **Semin Respir Infect** 1995 Jun;10(2):78–85 (18 ref.)

Vascular imaging before, during, and after endovascular repair. White RA, et al. **World J Surg** 1996 Jul–Aug; 20(6):622–9 (42 ref.)

[Clinical picture of vibration syndrome and diagnostic principles] Iżycki J. **Med Pr** 1996;47(3):277–83 (17 ref.) (Eng. Abstr.) **(Pol)**

DRUG THERAPY

Thrombolytic therapy of non-cardiac disorders. Verstraete M. **Baillieres Clin Haematol** 1995 Jun;8(2):413–24 (58 ref.)

Treatment of vascular disease with local drug delivery systems. Makkar RR, et al. **Cardiologia** 1995 Sep; 40(9):651–7 (47 ref.)

Therapeutic use of n-3 fatty acids for vascular disease and thrombosis. Goodnight SH, et al. **Chest** 1995 Oct;108(4 Suppl):302S–304S (36 ref.)

Inhalational nitric oxide in pulmonary parenchymal and vascular disease. Cornfield DN, et al. **J Lab Clin Med** 1996 Jun;127(6):530–9 (64 ref.)

Thrombolytic therapy in 1995. Mahanonda N. **J Med Assoc Thai** 1995 Jun;78(6):314–21 (56 ref.)

EPIDEMIOLOGY

Vascular holism: the epidemiology of vascular disease. Barnes RW. **Ann Vasc Surg** 1995 Nov;9(6):576–82 (36 ref.)

ETIOLOGY

Pathology and pathogenesis of vascular injury in systemic lupus erythematosus. Interactions of inflammatory cells and activated endothelium. Belmont HM, et al. **Arthritis Rheum** 1996 Jan;39(1):9–22 (147 ref.)

Diagnosis of cancer-associated vascular disorders. Naschitz JE, et al. **Cancer** 1996 May 1;77(9):1759–67 (110 ref.)

Ehlers-Danlos type IV syndrome. A review from a vascular surgical point of view. Bergqvist D. **Eur J Surg** 1996 Mar; 162(3):163–70 (101 ref.)

Neuro-ophthalmology and systemic disease—Part I. An annual review (1994). Newman NJ. **J Neuroophthalmol** 1995 Jun;15(2):109–21 (136 ref.)

Cardiovascular effects of environmental chemicals. Taylor AE. **Otolaryngol Head Neck Surg** 1996 Feb;114(2):209–11 (26 ref.)

[Nervous microangiopathy and POEMS syndrome] Maillot F, et al. **Rev Med Interne** 1995;16(12):934–7 (12 ref.) (Eng. Abstr.) **(Fre)**

[Neutrophilic leukocytes, thrombotic risk factors in vascular diseases] Berti F. **Cardiologia** 1996 Feb;41(2):107–16 (95 ref.) **(Ita)**

GENETICS

Inherited diseases of the vasculature. Shovlin CL, et al. **Annu Rev Physiol** 1996;58:483–507 (174 ref.)

Genetics and the metabolic syndrome. Bouchard C. **Int J Obes Relat Metab Disord** 1995 May;19 Suppl 1:S52–9 (43 ref.)

Molecular genetic insights into cardiovascular disease. Keating MT, et al. **Science** 1996 May 3;272(5262):681–5 (33 ref.)

IMMUNOLOGY

Local cellular immunology of experimental transplant vascular sclerosis. Orosz CG. **Clin Transplant** 1996 Feb;10(1 Pt 2):100–3 (21 ref.)

METABOLISM

Oxygen radical-nitric oxide reactions in vascular diseases. Freeman BA, et al. **Adv Pharmacol** 1995;34:45–69 (81 ref.)

Parathyroid hormone-related peptide and models of vascular disease: its expression and action in vascular smooth muscle cells. Nishizawa Y, et al. **Miner Electrolyte Metab** 1995; 21(1–3):152–6 (36 ref.)

The role of nitric oxide and other endothelium-derived vasoactive substances in vascular disease. Cohen RA. **Prog Cardiovasc Dis** 1995 Sep–Oct;38(2):105–28 (294 ref.)

Amino acid metabolism and the vascular endothelium: regulation and disease implications [editorial] Pan M, et al. **Shock** 1995 Aug;4(2):79–88 (96 ref.)

[Measurement of biological parameters of endothelial origin: value in human pathology] Sampol J, et al. **Ann Biol Clin (Paris)** 1995;53(6):329–38 (108 ref.) (Eng. Abstr.) **(Fre)**

MORTALITY

Chronic and degenerative disease: major causes of morbidity and death. Doll R. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1301S–1305S (15 ref.)

PATHOLOGY

Pathology and pathogenesis of vascular injury in systemic lupus erythematosus. Interactions of inflammatory cells and activated endothelium. Belmont HM, et al. **Arthritis Rheum** 1996 Jan;39(1):9–22 (147 ref.)

Selected vascular lesions of the placenta. Gersell DJ. **Clin Lab Med** 1995 Sep;15(3):611–29 (73 ref.)

Allograft vascular disease: comparison of heart and other grafted organs. Radio S, et al. **Transplant Proc** 1996 Feb; 28(1):496–9 (34 ref.)

PHYSIOPATHOLOGY

Modulation of vasoconstriction by endothelium-derived nitric oxide: the influence of vascular disease. Woodman OL. **Clin Exp Pharmacol Physiol** 1995 Sep;22(9):585–93 (97 ref.)

Mechanics of the arterial wall: review and directions. Humphrey JD. **Crit Rev Biomed Eng** 1995;23(1–2):1–162 (512 ref.)

Superoxide anion and endothelial regulation of arterial tone. Katusic ZS. **Free Radic Biol Med** 1996;20(3):443–8 (52 ref.)

Sick vessel syndrome: vascular changes in hypertension and atherosclerosis. Heistad DD, et al. **J Hum Hypertens** 1995 Jun;9(6):449–53 (38 ref.)

Look who's talking—intracellular communication in chronic vascular disease [editorial] Haller H. **Nephrol Dial Transplant** 1995;10(9):1500–1 (15 ref.)

RADIOGRAPHY

Normal and abnormal vascular structures that simulate neoplasms on chest radiographs: clues to the diagnosis. Cole TJ, et al. **Radiographics** 1995 Jul;15(4):867–91 (23 ref.)

Arteriography and interventional therapy for diseases of the hand. Loring LA, et al. **Radiographics** 1995 Nov; 15(6):1299–310 (25 ref.)

SURGERY

Vascular surgery at the crossroads [editorial] Lepäntalo M, et al. **Ann Chir Gynaecol** 1995;84(4):325–6 (8 ref.)

Endovascular surgery—an overview. Denton MJ. **Aust Fam Physician** 1995 Sep;24(9):1657, 1660–3, 1665–7 (7 ref.)

[Venous allografts for salvage of lower limbs: hope and reality] Van Damme H, et al. **Rev Med Liege** 1995 Oct; 50(10):433–42 (72 ref.) **(Fre)**

[Vascular surgery methods for elderly patients. Elective interventions with reduced risk are possible] Raithel D. **Fortschr Med** 1995 Oct 20;113(29):409–12 (8 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Identification of endothelial cell-surface proteins as targets for diagnosis and treatment of disease. Jacobson BS, et al. Nat Med 1996 Apr;2(4):482–4 (22 ref.)

Arteriography and interventional therapy for diseases of the hand. Loring LA, et al. **Radiographics** 1995 Nov; 15(6):1299–310 (25 ref.)

ULTRASONOGRAPHY

Demonstration of cystic adventitial disease by intravascular

VASCULAR DISEASES

ultrasound imaging. Koppensteiner R, et al. **J Vasc Surg** 1996 Mar;23(3):534–6 (9 ref.)

VASCULAR DISEASES, PERIPHERAL see **PERIPHERAL VASCULAR DISEASES**

VASCULAR ENDOTHELIUM see **ENDOTHELIUM, VASCULAR**

VASCULAR GRAFT OCCLUSION see **GRAFT OCCLUSION, VASCULAR**

VASCULAR HEADACHE

ETIOLOGY

Causes and mechanisms of primary headaches: toward a bio-behavioral model. Buzzi MG, et al. **Ital J Neurol Sci** 1995 Nov;16(8 Suppl):15–9 (32 ref.)

PREVENTION & CONTROL

[Decompressive neurovascular nose and skull-base surgery in primary headache with a rhinogenic trigger] Bonaccorsi P. **Ital J Neurol Sci** 1995 Nov;16(8 Suppl):69–100 (104 ref.) (Eng. Abstr.) **(Ita)**

VASCULAR INTIMA see **TUNICA INTIMA**

VASCULAR MEDIA see **TUNICA MEDIA**

VASCULAR NEOPLASMS

Leiomyosarcoma of the superior vena cava. Spaggiari L, et al. **Ann Thorac Surg** 1996 Jul;62(1):274–6 (8 ref.)

Primary leiomyosarcoma of the abdominal aorta. Malone MD, et al. **J Vasc Surg** 1996 Sep;24(3):487–93 (36 ref.)

IMMUNOLOGY

CD31 immunoreactivity in mesenchymal neoplasms of the skin and subcutis: report of 145 cases and review of putative immunohistologic markers of endothelial differentiation. DeYoung BR, et al. **J Cutan Pathol** 1995 Jun;22(3):215–22 (45 ref.)

PATHOLOGY

Endovascular papillary angioendothelioma-like tumour associated with lymphoedema. Fukunaga M, et al. **Histopathology** 1995 Sep;27(3):243–9 (16 ref.)

Vascular tumors: an update with emphasis on the diagnosis of angiosarcoma and borderline vascular neoplasms. Fletcher CD. **Monogr Pathol** 1996;38:181–206 (42 ref.)

[Intravascular malignant lymphoma (ex-malignant angioendotheliosis). 3 cases] Demolombe-Ragué S, et al. **Presse Med** 1995 Nov 25;24(36):1689–93 (10 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

[Surgical vein reconstruction in patients with tumor invasiveness of the superior caval system. Retrospective study of 7 cases] Jeanfaivre T, et al. **J Chir (Paris)** 1996 Apr;133(2):61–4 (19 ref.) (Eng. Abstr.) **(Fre)**

[Surgical therapy of leiomyosarcoma of the inferior vena cava] Zieren J, et al. **Zentralbl Chir** 1995;120(8):641–9 (105 ref.) (Eng. Abstr.) **(Ger)**

VASCULAR PATENCY

see related
GRAFT OCCLUSION, VASCULAR

PHYSIOLOGY

The importance of early patency after acute myocardial infarction. Grover A, et al. **Curr Opin Cardiol** 1995 Jul; 10(4):361–6 (29 ref.)

VASCULAR PERMEABILITY see **CAPILLARY PERMEABILITY**

VASCULAR PROSTHESIS see **BLOOD VESSEL PROSTHESIS**

VASCULAR RESISTANCE

Resistance vessel growth and remodelling: cause or consequence in cardiovascular disease. Mulvany MJ. **J Hum Hypertens** 1995 Jun;9(6):479–85 (43 ref.)

[Arterial hypertension and vascular resistance] Krzesinski JM, et al. **Rev Med Liege** 1995 Sep;50(9):365–72 (41 ref.) **(Fre)**

PHYSIOLOGY

Arterial compliance in hypertension and diabetes mellitus. McVeigh GE. **Am J Nephrol** 1996;16(3):217–22 (52 ref.)

Evaluation of arterial compliance in humans. Giannattasio C, et al. **Clin Exp Hypertens** 1996 Apr–May;18(3–4):347–62 (23 ref.)

[Hypertension and hemorheology] Klein W, et al. **Wien Med Wochenschr** 1995;145(15–16):355–7 (22 ref.) (Eng. Abstr.) **(Ger)**

VASCULAR SMOOTH MUSCLE see **MUSCLE, SMOOTH, VASCULAR**

VASCULAR SURGERY

Ambulatory phlebectomy compared to sclerotherapy for varicose and telangiectatic veins: indications and complications. Weiss RA, et al. **Adv Dermatol** 1996;11:3–16; discussion 17 (37 ref.)

Penile revascularization: an overview. Shah RS, et al. **Ann Acad Med Singapore** 1995 Sep;24(5):749–54 (39 ref.)

Vascular surgery at the crossroads [editorial] Lepäntalo M, et al. **Ann Chir Gynaecol** 1995;84(4):325–6 (8 ref.)

Endothelial cell injury in cardiovascular surgery. Verrier ED, et al. **Ann Thorac Surg** 1996 Sep;62(3):915–22 (69 ref.)

Angioscopy in vascular surgery: the state of the art. Pevec WC. **Ann Vasc Surg** 1996 Jan;10(1):66–75 (71 ref.)

Endovascular surgery—an overview. Denton MJ. **Aust Fam Physician** 1995 Sep;24(9):1657, 1660–3, 1665–7 (7 ref.)

Anaesthesia for major vascular surgery. Beattie C. **Can J Anaesth** 1996 May;43(5 Pt 2):R3–13 (5 ref.) **(Eng, Fre)**

Lower extremity arterial reconstruction in patients with diabetes mellitus. Estes JM, et al. **Diabet Med** 1996;13 Suppl 1:S43–7 (17 ref.)

New concepts of the renin-angiotensin system—implications for vascular and endovascular surgery. O'Donohoe MK, et al. **Eur J Vasc Endovasc Surg** 1996 May;11(4):393–401 (117 ref.)

Intraoperative blood salvage (IOBS) in cardiac and vascular surgery. Valbonesi M, et al. **Int J Artif Organs** 1995 Mar; 18(3):130–5 (19 ref.)

Transcranial Doppler ultrasonography: what is its role in cardiac and vascular surgical patients? Kahn RA, et al. **J Cardiothorac Vasc Anesth** 1995 Oct;9(5):589–97 (71 ref.)

Lower limb salvage: microvascular reconstruction of post-traumatic soft tissue and skeletal defects. Tomaino MM. **Orthopedics** 1995 Jul;18(7):665–72 (68 ref.)

METHODS

Endovascular surgery. Ferguson JM, et al. **J R Coll Surg Edinb** 1996 Aug;41(4):223–31 (68 ref.)

[Blood salvage: decisive progress in vascular surgery] Patra P, et al. **J Mal Vasc** 1996;21 Suppl A:13–21 (86 ref.) (Eng. Abstr.) **(Fre)**

TRENDS

What's new in vascular surgery. Ernst CB. **J Am Coll Surg** 1996 Feb;182(2):191–200 (69 ref.)

VASCULITIS

Cutaneous vasculitis and cutaneous vasculopathies. Kelly RI. **Australas J Dermatol** 1995 Aug;36(3):109–17; quiz 118–9 (73 ref.)

Vasculitis. Watts RA, et al. **Baillieres Clin Rheumatol** 1995 Aug;9(3):529–54 (88 ref.)

Vasculitis. Puett DW. **Bull Rheum Dis** 1995 Nov;44(7):4–8 (11 ref.)

Childhood systemic lupus erythematosus, vasculitis, and rheumatic fever and neonatal lupus. Pelkonen P. **Curr Opin Rheumatol** 1995 Sep;7(5):430–6 (62 ref.)

Vasculitis. Smith JG Jr. **J Dermatol** 1995 Nov;22(11):812–22 (30 ref.)

Vasculitis in children. Athreya BH. **Pediatr Clin North Am** 1995 Oct;42(5):1239–61 (58 ref.)

Vasculitis of the central nervous system. Calabrese LH. **Rheum Dis Clin North Am** 1995 Nov;21(4):1059–76 (89 ref.)

Cutaneous vasculitis. Gibson LE, et al. **Rheum Dis Clin North Am** 1995 Nov;21(4):1097–113 (50 ref.)

Polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome. Clinical aspects and treatment. Lhote F, et al. **Rheum Dis Clin North Am** 1995 Nov; 21(4):911–47 (132 ref.)

[Primary angiitis of the central nervous system] Abu-Shakra M, et al. **Harefuah** 1996 Jan 1;130(1):26–9 (24 ref.) **(Heb)**

[Current aspects of cutaneous angiitis] Ivanov OL. **Vestn Ross Akad Med Nauk** 1995;(10):7–10 (24 ref.) **(Rus)**

[Systemic vasculitis] Mitrović D, et al. **Vojnosanit Pregl** 1994 Jan-Feb;51(1):47–53 (8 ref.) **(Ser)**

CHEMICALLY INDUCED

Cocaine-associated cerebral vasculitis. Merkel PA, et al. **Semin Arthritis Rheum** 1995 Dec;25(3):172–83 (82 ref.)

CLASSIFICATION

Antineutrophil cytoplasmic antibodies in the classification of vasculitis. Niles JL. **Annu Rev Med** 1996;47:303–13 (32 ref.)

Working classification of vasculitis. Ghersetich I, et al. **Int Angiol** 1995 Jun;14(2):101–6 (50 ref.)

Classification of vasculitides. A survey. Leu HJ. **Vasa** 1995; 24(4):319–24 (27 ref.)

[Autoantibodies against neutrophil cytoplasm and their significance in the classification of systemic vasculitis] Fijalkowska-Morawska J, et al. **Przegl Lek** 1995; 52(6):318–22 (20 ref.) (Eng. Abstr.) **(Pol)**

COMPLICATIONS

Primary angiitis of the central nervous system associated with Hodgkin's disease. Yuen RW, et al. **Arch Pathol Lab Med** 1996 Jun;120(6):573–6 (22 ref.)

Necrotizing herpes zoster mimicking relapse of vasculitis in angioimmunoblastic lymphadenopathy with dysproteinaemia. Böni R, et al. **Br J Dermatol** 1995 Dec; 133(6):978–82 (29 ref.)

Vasculitic neuropathy. Fathers E, et al. **Br J Hosp Med** 1996 May 15–Jun 4;55(10):643–7 (28 ref.)

Multifocal stenosing ulcerations of the small intestine revealing vasculitis associated with C2 deficiency. Perlemuter G, et al. **Gastroenterology** 1996 May; 110(5):1628–32 (23 ref.)

Clinical aspects of cutaneous necrotizing vasculitis. Campanile G, et al. **Int Angiol** 1995 Jun;14(2):151–61 (72 ref.)

Cogan's syndrome: ophthalmic, audiovestibular, and systemic manifestations and therapy. Chynn EW, et al. **Int Ophthalmol Clin** 1996 Winter;36(1):61–72 (46 ref.)

Vasculitis associated with connective tissue disorders. Bacon PA, et al. **Rheum Dis Clin North Am** 1995 Nov; 21(4):1077–96 (107 ref.)

Gastrointestinal manifestations of collagen-vascular diseases. Bassel K, et al. **Semin Gastrointest Dis** 1995 Oct;6(4):228–40 (124 ref.)

[Collagen diseases and vasculitis] Takasaki Y. **Ryoikibetsu Shokogun Shirizu** 1995;(8):329–32 (19 ref.) **(Jpn)**

[Cerebrovascular diseases and non-infectious inflammatory arteriopathies] Vivancos F, et al. **Rev Neurol** 1995;23 Suppl 1:S22–32 (84 ref.) **(Spa)**

DIAGNOSIS

Vasculitis: diagnosis and therapy. Hunder G. **Am J Med** 1996 Feb 26;100(2A):37S–45S (29 ref.)

The clinical utility of ANCA positivity [editorial] Edgar JD. **Ann Rheum Dis** 1996 Aug;55(8):494–6 (37 ref.)

Vasculitic neuropathy. Said G. **Baillieres Clin Neurol** 1995 Nov;4(3):489–503 (67 ref.)

Diagnosis of cutaneous vasculitis. Claudy AL. **Int Angiol** 1995 Jun;14(2):183–7 (16 ref.)

Vasculitis in children and adolescents. Dillon MJ, et al. **Rheum Dis Clin North Am** 1995 Nov;21(4):1115–36 (124 ref.)

Granulomatous vasculitis. Hammar SP. **Semin Respir Infect** 1995 Jun;10(2):107–20 (47 ref.)

[The forms and diagnosis of vasculitis] Andrassy K, et al. **Dtsch Med Wochenschr** 1996 Jul 26;121(30):945–8 (13 ref.) **(Ger)**

[Vasculitis] Berlit P. **Ther Umsch** 1996 Jul;53(7):559–67 (36 ref.) (Eng. Abstr.) **(Ger)**

[Vasculitis—new etiopathogenic and clinical aspects] Górnaś P, et al. **Pol Arch Med Wewn** 1995 Jan;93(1):81–7 (45 ref.) **(Pol)**

[Approach to the diagnosis and therapy of vascular neuropathy] Hernández MA, et al. **Rev Neurol** 1995 Sep-Oct;23(123):1008–12 (40 ref.) (Eng. Abstr.) **(Spa)**

DRUG THERAPY

[The therapy of vasculitis] Andrassy K, et al. **Dtsch Med Wochenschr** 1996 Aug 2;121(31–32):985–7 (14 ref.) **(Ger)**

[Immunosuppressive therapy of vasculitis: current aspects and perspectives] Giacomelli R, et al. **Recenti Prog Med** 1996 Mar;87(3):124–34 (74 ref.) (Eng. Abstr.) **(Ita)**

[Approach to the diagnosis and therapy of vascular neuropathy] Hernández MA, et al. **Rev Neurol** 1995 Sep-Oct;23(123):1008–12 (40 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

The central role of the endothelium in the pathogenesis of vasculitides. Lombardi A, et al. **Int Angiol** 1995 Jun; 14(2):175–82 (92 ref.)

Pathogenic mechanisms of vessel damage in vasculitis syndromes. Sundy JS, et al. **Rheum Dis Clin North Am** 1995 Nov;21(4):861–81 (101 ref.)

Vasculitides in hairy cell leukemia. Hasler P, et al. **Semin Arthritis Rheum** 1995 Oct;25(2):134–42 (48 ref.)

[Generalized angitis and recurrent infection associated hemophagocytic syndrome in a girl with XXX syndrome] Wada Y, et al. **Ryumachi** 1995 Jun;35(3):589–94 (11 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

Antineutrophil cytoplasmic autoantibodies (ANCA) associated vasculitides—immunologic and clinical aspects. Schulz JI. **Bratisl Lek Listy** 1995 Oct;96(10):520–2 (20 ref.)

Antineutrophil cytoplasmic autoantibody testing in vasculitides. Gross WL. **Rheum Dis Clin North Am** 1995 Nov;21(4):987–1011 (182 ref.)

Anti-neutrophil cytoplasmic antibodies in primary small vessel vasculitides. Wiik AS. **Scand J Rheumatol** 1996; 25(2):65–9 (35 ref.)

Antineutrophil cytoplasmic antibodies: major autoantigens, pathophysiology, and disease associations. Schultz DR, et al. **Semin Arthritis Rheum** 1995 Dec;25(3):143–59 (120 ref.)

[Vasculitis—new etiopathogenic and clinical aspects] Górnaś P, et al. **Pol Arch Med Wewn** 1995 Jan;93(1):81–7 (45 ref.)

(Pol)

[The immunological approach to systemic and pulmonary vasculitis] Ancochea Bermúdez J. **Arch Bronconeumol** 1995 Aug-Sep;31(7):350-61 (103 ref.) **(Spa)**

PATHOLOGY

Langerhans cells and vasculitis. Romagnoli P, et al. **Int Angiol** 1995 Jun;14(2):113-8 (88 ref.)

Primary angiitis of the central nervous system associated with cerebral amyloid angiopathy: report of two cases and review of the literature. Fountain NB, et al. **Neurology** 1996 Jan;46(1):190-7 (39 ref.)

Histopathologic specificity of systemic vasculitis. Lie JT. **Rheum Dis Clin North Am** 1995 Nov;21(4):883-909 (72 ref.)

Pathogenic mechanisms of vessel damage in vasculitis syndromes. Sundy JS, et al. **Rheum Dis Clin North Am** 1995 Nov;21(4):861-81 (101 ref.)

PHYSIOPATHOLOGY

The role of regulatory peptides in the pathogenesis of cutaneous necrotizing vasculitis. Hautmann G, et al. **Int Angiol** 1995 Jun;14(2):138-50 (104 ref.)

Cytokines, fibrinolysis and vasculitis. Teofoli P, et al. **Int Angiol** 1995 Jun;14(2):125-9 (51 ref.)

[Cerebrovascular diseases and non-infectious inflammatory arteriopathies] Vivancos F, et al. **Rev Neurol** 1995;23 Suppl 1:S22-32 (84 ref.) **(Spa)**

THERAPY

New treatment strategies for systemic vasculitis: the role of intravenous immune globulin therapy. Lockwood CM. **Clin Exp Immunol** 1996 May;104 Suppl 1:77-82 (48 ref.)

Therapeutic guidelines in vasculitis. Stadler R, et al. **Int Angiol** 1995 Jun;14(2):188-96 (85 ref.)

Treatment of systemic and renal-limited vasculitic disorders with pooled human intravenous immune globulin. Jordan SC. **J Clin Immunol** 1995 Nov;15(6 Suppl):76S-85S (40 ref.)

Vasculitis in children and adolescents. Dillon MJ, et al. **Rheum Dis Clin North Am** 1995 Nov;21(4):1115-36 (124 ref.)

VASCULITIS, ALLERGIC CUTANEOUS

CHEMICALLY INDUCED

Acute febrile toxic reaction in patients with refractory rheumatoid arthritis who are receiving combined therapy with methotrexate and azathioprine. Blanco R, et al. **Arthritis Rheum** 1996 Jun;39(6):1016-20 (19 ref.)

ETIOLOGY

[Cutaneous vasculitis in sarcoidosis. 2 cases and review of the literature (letter)] Sauvaget F, et al. **Ann Med Interne (Paris)** 1995;146(8):587-9 (10 ref.) **(Fre)**

VASCULITIS, CHURG-STRAUSS see **CHURG-STRAUSS SYNDROME**

VASCULITIS, HEMORRHAGIC see **PURPURA, SCHOENLEIN-HENOCH**

VASCULITIS, HYPERSENSITIVITY

DIAGNOSIS

[Leukocytoclastic vasculitis as the form of presentation of hepatocarcinoma] Sánchez-Angulo JI, et al. **Gastroenterol Hepatol** 1996 May;19(5):255-8 (35 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

Urticarial vasculitis. O'Donnell B, et al. **Int Angiol** 1995 Jun; 14(2):166-74 (74 ref.)

VASCULITIS, LEUKOCYTOCLASTIC see **VASCULITIS, HYPERSENSITIVITY**

VASECTOMY

Vasectomy counseling. Haws JM, et al. **Am Fam Physician** 1995 Oct;52(5):1395-9 (18 ref.)

STANDARDS

Ethical issues in male sterilization in developing countries. Rizvi SA, et al. **Br J Urol** 1995 Nov;76 Suppl 2:103-5 (18 ref.)

VASECTOMY REVERSAL see **VASOVASOSTOMY**

VASOACTIVE AGONISTS see **VASOCONSTRICTOR AGENTS**

VASOACTIVE ANTAGONISTS see **VASODILATOR AGENTS**

VASOACTIVE INTESTINAL PEPTIDE

see related
GASTROINTESTINAL AGENTS
RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE
VASODILATOR AGENTS

ANTAGONISTS & INHIBITORS

A VIP hybrid antagonist: from developmental neurobiology to clinical applications. Gozes I, et al. **Cell Mol Neurobiol** 1995 Dec;15(6):675-87 (74 ref.)

BIOSYNTHESIS

[A case report of the VIP producing tumor with liver metastasis presenting WDHA syndrome] Inoue S, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Aug;92(8):1217-22 (13 ref.) **(Jpn)**

BLOOD

[Vasoactive intestinal polypeptide (VIP)] Yamaguchi K, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:626-30 (12 ref.) **(Jpn)**

PHARMACOLOGY

Roles of peptides and other substances in cotransmission from vascular autonomic and sensory neurons. Morris JL, et al. **Can J Physiol Pharmacol** 1995 May;73(5):521-32 (123 ref.)

PHYSIOLOGY

A VIP hybrid antagonist: from developmental neurobiology to clinical applications. Gozes I, et al. **Cell Mol Neurobiol** 1995 Dec;15(6):675-87 (74 ref.)

VIP as a cell-growth and differentiation neuromodulator role in neurodevelopment. Muller JM, et al. **Mol Neurobiol** 1995 Apr-Jun;10(2-3):115-34 (126 ref.)

Photic information coded by vasoactive intestinal polypeptide and neuropeptide Y. Shinohara K, et al. **Neurosci Biobehav Rev** 1995 Fall;19(3):349-52 (16 ref.)

Cholinergic and vasoactive intestinal polypeptidergic innervation of the cerebral arteries. Dauphin F, et al. **Pharmacol Ther** 1995;67(3):385-417 (274 ref.)

VASOACTIVE INTESTINAL PEPTIDE RECEPTORS see **RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE**

VASOCONSTRICTION

see related
VASOCONSTRICTOR AGENTS

Coronary vasomotion of the stunned myocardium. Mandinov L, et al. **Basic Res Cardiol** 1995 Jul-Aug;90(4):288-90 (11 ref.)

Mechanisms of abnormal vasoreactivity in persistent pulmonary hypertension of the newborn infant. Abman SH, et al. **J Perinatol** 1996 Mar-Apr;16(2 Pt 2 Su):S18-23 (44 ref.)

DRUG EFFECTS

Vasodilatative and vasoconstrictive effects of angiography contrast media. Karstoft J, et al. **Acta Radiol Suppl** 1995; 399:164-9 (41 ref.)

Calcium blockage in pulmonary hypertension and hypoxic vasoconstriction. Neely CF, et al. **New Horiz** 1996 Feb; 4(1):99-106 (74 ref.)

PHYSIOLOGY

Evidence in vivo for induction of cardiovascular growth processes by vasoconstrictor systems. Adams MA, et al. **Blood Press Suppl** 1995;2:61-7 (64 ref.)

Ion channels, oxygen sensation and signal transduction in pulmonary arterial smooth muscle. Kozlowski RZ. **Cardiovasc Res** 1995 Sep;30(3):318-25 (73 ref.)

Peptides as neurotransmitters in vascular autonomic neurons. Morris JL. **Clin Exp Pharmacol Physiol** 1995 Nov; 22(11):792-802 (119 ref.)

Modulation of vasoconstriction by endothelium-derived nitric oxide: the influence of vascular disease. Woodman OL. **Clin Exp Pharmacol Physiol** 1995 Sep;22(9):585-93 (97 ref.)

Clinical aspects of hypoxic pulmonary vasoconstriction. Leach RM, et al. **Exp Physiol** 1995 Sep;80(5):865-75 (29 ref.)

The role of the endothelium in hypoxic pulmonary vasoconstriction. Ward JP, et al. **Exp Physiol** 1995 Sep; 80(5):793-801 (24 ref.)

How vessels narrow. Schwartz SM. **Z Kardiol** 1995;84 Suppl 4:129-35 (58 ref.)

[Endothelin--a cardiovascular regulatory peptide. II. Outline of its pathophysiologic activity] Lisý O. **Cesk Fysiol** 1995 Sep;44(3):152-7 (45 ref.) (Eng. Abstr.) **(Cze)**

[Endothelin--a cardiovascular regulatory peptide. I. Physiologic activity] Lisý O. **Cesk Fysiol** 1995 Sep; 44(3):147-51 (32 ref.) (Eng. Abstr.) **(Cze)**

[Hypoxic pulmonary vasoconstriction] Theissen IL, et al. **Anaesthesist** 1996 Jul;45(7):643-52 (137 ref.) (Eng. Abstr.) **(Ger)**

VASOCONSTRICTOR AGENTS

Clinical review 79: Angiotensin II: an insulin-sensitizing vasoactive hormone? Morris AD, et al. **J Clin Endocrinol Metab** 1996 Apr;81(4):1303-6 (40 ref.)

ADVERSE EFFECTS

Ambulatory phlebectomy. A rare complication of local anesthetic: case report and literature review. Olivencia JA. **Dermatol Surg** 1996 Jan;22(1):53-5 (15 ref.)

Teratogen update: ergot and ergotamine. Raymond GV. **Teratology** 1995 May;51(5):344-7 (19 ref.)

METABOLISM

Chymase-dependent angiotensin II forming systems in humans. Urata H, et al. **Am J Hypertens** 1996 Mar; 9(3):277-84 (63 ref.)

PHARMACOLOGY

Pharmacological blood-brain barrier modification for selective drug delivery. Cloughesy TF, et al. **J Neurooncol** 1995 Nov;26(2):125-32 (39 ref.)

THERAPEUTIC USE

Is it time to reposition vasopressors and inotropes in sepsis? Rudis MI, et al. **Crit Care Med** 1996 Mar;24(3):525-37 (74 ref.)

Acute treatment of migraine attacks. Ferrari MD, et al. **Curr Opin Neurol** 1995 Jun;8(3):237-42 (34 ref.)

Vasoactive drugs and the importance of renal perfusion pressure. Bersten AD, et al. **New Horiz** 1995 Nov; 3(4):650-61 (94 ref.)

Pharmacologic treatment of recurrent pediatric headache. Graf WD, et al. **Pediatr Ann** 1995 Sep;24(9):477-84 (27 ref.)

Pharmacological therapy for portal hypertension: rationale and results. Burroughs AK, et al. **Semin Gastrointest Dis** 1995 Jul;6(3):148-64 (148 ref.)

[Prophylactic treatment of chronic cluster headache] Alberca R. **Rev Neurol** 1995;23 Suppl 4:S530-4 (55 ref.) **(Spa)**

[Prophylactic treatment of episodic forms of cluster headache] Liaño H, et al. **Rev Neurol** 1995;23 Suppl 4:S525-9 (29 ref.) **(Spa)**

[Symptomatic treatment of cluster headache] Titus F. **Rev Neurol** 1995;23 Suppl 4:S519-24 (46 ref.) **(Spa)**

[Treatment of the acute migraine attack] Titus F. **Rev Neurol** 1995;23 Suppl 2:S203-7 (49 ref.) **(Spa)**

VASOCONSTRICTOR AGENTS, NASAL see **NASAL DECONGESTANTS**

VASODILATION

see related
VASODILATOR AGENTS

Cardiovascular actions of insulin: are they important in long-term blood pressure regulation? Hall JE, et al. **Clin Exp Pharmacol Physiol** 1995 Oct;22(10):689-700 (89 ref.)

Significance of defective endothelial signal transduction in impaired endothelium-dependent relaxation in atherosclerosis. Shimokawa H, et al. **Gerontology** 1995;41 Suppl 1:28-33 (19 ref.)

Mechanisms of abnormal vasoreactivity in persistent pulmonary hypertension of the newborn infant. Abman SH, et al. **J Perinatol** 1996 Mar-Apr;16(2 Pt 2 Su):S18-23 (44 ref.)

[Liver cirrhosis and cardiovascular system] Ponte E, et al. **Minerva Med** 1996 Jun;87(6):299-310 (80 ref.) (Eng. Abstr.) **(Ita)**

DRUG EFFECTS

Vasodilatative and vasoconstrictive effects of angiography contrast media. Karstoft J, et al. **Acta Radiol Suppl** 1995; 399:164-9 (41 ref.)

Effects of iodinated contrast media on peripheral blood flow. Pugh ND, et al. **Acta Radiol Suppl** 1995;399:155-63 (64 ref.)

Disparate effects of antihypertensive drugs on large artery distensibility and compliance in hypertension. Van Bortel LM, et al. **Am J Cardiol** 1995 Nov 24;76(15):46E-49E (24 ref.)

PHYSIOLOGY

Endothelium-dependent hyperpolarization. Beyond nitric oxide and cyclic GMP. Cohen RA, et al. **Circulation** 1995 Dec 1;92(11):3337-49 (211 ref.)

Reflex parasympathetic vasodilatation in facial skin. Izumi H. **Gen Pharmacol** 1995 Mar;26(2):237-44 (74 ref.)

Nitroxidergic nerves and hypertension. Toda N. **Hypertens Res** 1995 Mar;18(1):19-26 (68 ref.)

Large artery function and alterations in hypertension. London GM. **J Hypertens Suppl** 1995 Aug;13(2):S35-8 (23 ref.)

Effects of exercise training on endothelium-dependent peripheral vascular responsiveness. Delp MD. **Med Sci Sports Exerc** 1995 Aug;27(8):1152-7 (38 ref.)

Endothelium-mediated control of coronary vascular tone after chronic exercise training. Laughlin MH. **Med Sci Sports Exerc** 1995 Aug;27(8):1135-44 (34 ref.)

Nitric oxide production and NO synthase gene expression contribute to vascular regulation during exercise. Shen W, et al. **Med Sci Sports Exerc** 1995 Aug;27(8):1125-34 (75 ref.)

VASODILATOR AGENTS

Inhaled vasodilator therapy in acute lung injury: first, do NO harm? [editorial] Brett SJ, et al. **Thorax** 1995 Aug; 50(8):821–3 (4 ref.)

ADMINISTRATION & DOSAGE

[Controlled clinical studies of tolerance development and dosing problems in nitrate therapy] Abshagen U. **Herz** 1996 Jun;21 Suppl 1:23–30 (18 ref.) (Eng. Abstr.) **(Ger)**

[Use of nitrates in coronary heart disease including acute myocardial infarct] Auch-Schwelk W. **Herz** 1996 Jun;21 Suppl 1:31–4 (34 ref.) (Eng. Abstr.) **(Ger)**

[The usefulness of inhaled nitric oxide in the treatment of pulmonary hypertension in the postoperative period of cardiac surgery in infancy] de Lucas García N, et al. **An Esp Pediatr** 1996 Apr;44(4):373–6 (27 ref.) **(Spa)**

[Long-term results of the treatment with intracavernous injection of vasoactive drugs] Rodríguez Vela L, et al. **Arch Esp Urol** 1996 Apr;49(3):257–69 (25 ref.) (Eng. Abstr.) **(Spa)**

ADVERSE EFFECTS

Canalicular cholestasis due to amiodarone toxicity. A definite diagnosis obtained by electron microscopy. Macarri G, et al. **Ital J Gastroenterol** 1995 Oct–Nov;27(8):436–8 (18 ref.)

BLOOD

[Drug of nitrate and nitrite] Iida K. **Nippon Rinsho** 1995 Feb; 53 Su Pt 1:986–8 (17 ref.) **(Jpn)**

DIAGNOSTIC USE

Nuclear cardiology studies—principles for stress modality selection. Underwood R. **Br J Clin Pract Symp Suppl** 1995 Nov;82:10–2 (9 ref.)

[Pharmacologic tests in cardiac decompensation] Perini G, et al. **G Ital Cardiol** 1995 Dec;25(12):1635–41 (25 ref.) **(Ita)**

[Echocardiography with pharmacological stress: dobutamine or dipyridamole?] Salustri A, et al. **G Ital Cardiol** 1996 Apr;26(4):447–53 (45 ref.) **(Ita)**

PHARMACOKINETICS

The nifedipine gastrointestinal therapeutic system (GITS). Evaluation of pharmaceutical, pharmacokinetic and pharmacological properties. Grundy JS, et al. **Clin Pharmacokinet** 1996 Jan;30(1):28–51 (131 ref.)

PHARMACOLOGY

The nifedipine gastrointestinal therapeutic system (GITS). Evaluation of pharmaceutical, pharmacokinetic and pharmacological properties. Grundy JS, et al. **Clin Pharmacokinet** 1996 Jan;30(1):28–51 (131 ref.)

Carvedilol, a novel vasodilating beta-blocker with the potential for cardiovascular organ protection. Feuerstein GZ, et al. **Eur Heart J** 1996 Apr;17 Suppl B:24–9 (24 ref.)

Molecular mechanisms and therapeutic strategies related to nitric oxide. Moncada S, et al. **FASEB J** 1995 Oct; 9(13):1319–30 (126 ref.)

The effects of chronic hypoxia on the pharmacological responsiveness of the pulmonary artery. Karamsetty VS, et al. **Pharmacol Ther** 1995;68(2):233–46 (110 ref.)

[Adrenomedullin] Zeng Z. **Chung Hua Nei Ko Tsa Chih** 1995 Sep;34(9):635–7 (14 ref.) **(Chi)**

[Pharmacology of nitrates and other NO donors] Dendorfer A. **Herz** 1996 Jun;21 Suppl 1:38–49 (54 ref.) (Eng. Abstr.) **(Ger)**

[Vasodilators and renal function in cirrhosis] Albillos A, et al. **Gastroenterol Hepatol** 1995 Nov;18(9):488–92 (46 ref.) **(Spa)**

THERAPEUTIC USE

Inhaled nitric oxide therapy for persistent pulmonary hypertension of the newborn. Fineman JR, et al. **Acta Paediatr Jpn** 1995 Aug;37(4):425–30 (41 ref.)

Beneficial actions of nitrates in cardiovascular disease. Abrams J. **Am J Cardiol** 1996 May 30;77(13):31C–7C (29 ref.)

Nitric oxide and nitrovasodilators: similarities, differences, and interactions. Kelly RA, et al. **Am J Cardiol** 1996 May 30;77(13):2C–7C (70 ref.)

Treatment of pulmonary hypertension in patients with chronic obstructive pulmonary disease: position of vasodilators with special focus on urapidil. Adnot S, et al. **Blood Press** 1995;Suppl 3:47–57 (43 ref.)

Myocardial protection in the occlusion/reperfusion dog model: the role of ischemic necrosis vs reperfusion injury. Chagas AC, et al. **Braz J Med Biol Res** 1995 Sep; 28(9):951–9 (40 ref.)

The pharmacological treatment of Menière's disease. Brookes GB. **Clin Otolaryngol** 1996 Feb;21(1):3–11 (78 ref.)

Nicorandil for angina. **Drug Ther Bull** 1995 Dec;33(12):89–92 (26 ref.)

Celiprolol. An evaluation of its pharmacological properties and clinical efficacy in the management of hypertension and angina pectoris. Dunn CJ, et al. **Drugs Aging** 1995 Nov; 7(5):394–411 (111 ref.)

Pentoxifylline (oxpentifylline). A review of its therapeutic efficacy in the management of peripheral vascular and cerebrovascular disorders. Frampton JE, et al. **Drugs Aging** 1995 Dec;7(6):480–503 (150 ref.)

Racing horses, nitroglycerin and exercise induced pulmonary haemorrhage (EIPH) [editorial; comment] Harkins JD, et al. **Equine Vet J** 1995 Jul;27(4):240–1 (12 ref.) Comment on: Equine Vet J 1995 Jul;27(4):275–9.

Pentoxifylline and critical leg ischemia. Colgan MP, et al. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S58–60 (19 ref.)

Pentoxifylline: a potential treatment for thrombosis associated with abnormal tissue factor expression by monocytes and endothelial cells. de Prost D. **J Cardiovasc Pharmacol** 1995; 25 Suppl 2:S114–8 (41 ref.)

Prevention studies with pentoxifylline: new clinical projects. Eugène-Jolchine I, et al. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S143–6 (29 ref.)

Pentoxifylline and intermittent claudication: review of clinical trials and cost-effectiveness analyses. Gillings DB. **J Cardiovasc Pharmacol** 1995;25 Suppl 2:S44–50 (20 ref.)

Tissue protection by anti-ischemic drugs. Nolte D, et al. **Minerva Cardioangiol** 1995 Nov–Dec;43(11–12):485–91 (59 ref.)

Vasoactive drugs and the importance of renal perfusion pressure. Bersten AD, et al. **New Horiz** 1995 Nov; 3(4):650–61 (94 ref.)

Pharmacological therapy for portal hypertension: rationale and results. Burroughs AK, et al. **Semin Gastrointest Dis** 1995 Jul;6(3):148–64 (148 ref.)

[Characteristics of angina pectoris therapy with nitrates] Silber S. **Herz** 1996 Jun;21 Suppl 1:4–22 (331 ref.) (Eng. Abstr.) **(Ger)**

[The role of nitrates in therapy of heart failure] Strasser RH. **Herz** 1996 Jun;21 Suppl 1:35–7 (36 ref.) (Eng. Abstr.) **(Ger)**

[Effects of adenosine on the heart—therapeutic and diagnostic possibilities] Stark U, et al. **Wien Klin Wochenschr** 1996;108(12):343–51 (61 ref.) (Eng. Abstr.) **(Ger)**

[Magnesium sulfate in acute myocardial infarction] Balli E, et al. **G Ital Cardiol** 1995 Nov;25(11):1425–32 (33 ref.) (Eng. Abstr.) **(Ita)**

VASOMOTOR SYSTEM

see related
BAROREFLEX
MUSCLE, SMOOTH, VASCULAR
VASOCONSTRICTOR AGENTS
VASODILATOR AGENTS

DRUG EFFECTS

Hormonal and non-hormonal interventions for menopausal symptoms. Coope J. **Maturitas** 1996 Mar;23(2):159–68 (73 ref.)

PHYSIOLOGY

Temporal chaos in the microcirculation. Griffith TM. **Cardiovasc Res** 1996 Mar;31(3):342–58 (108 ref.)

Estrogen, progesterone, and vascular reactivity: potential cellular mechanisms. White MM, et al. **Endocr Rev** 1995 Dec;16(6):739–51 (172 ref.)

[The vasomotor effects of neuropeptides] Polenov SA, et al. **Fiziol Zh Im I M Sechenova** 1995 Jun;81(6):29–47 (84 ref.) **(Rus)**

PHYSIOPATHOLOGY

Hemodynamic and vascular effects of active and passive smoking. Zhu BQ, et al. **Am Heart J** 1995 Dec; 130(6):1270–5 (80 ref.)

Control of vascular reactivity. McCormack DG. **New Horiz** 1995 May;3(2):248–56 (83 ref.)

[The role of coronary vasomotoricity in ischemic cardiopathy: fluctuating preconceptions (editorial)] Maseri A, et al. **Cardiologia** 1996 Jan;41(1):19–30 (132 ref.) **(Ita)**

VASOPRESSIN, ARGININE see **ARGIPRESSIN**

VASOPRESSIN, DEAMINO ARGININE see **DESMOPRESSIN**

VASOPRESSIN, ISOLEUCYL see **VASOTOCIN**

VASOPRESSIN, NON-MAMMALIAN see **VASOTOCIN**

VASOPRESSIN RECEPTORS see **RECEPTORS, VASOPRESSIN**

VASOPRESSINS

see related
INAPPROPRIATE ADH SYNDROME
RECEPTORS, VASOPRESSIN

ADVERSE EFFECTS

[A case of rhabdomyolysis with administration of intravenous vasopressin] Hino A, et al. **Rinsho Shinkeigaku** 1995 Aug; 35(8):911–3 (10 ref.) (Eng. Abstr.) **(Jpn)**

BLOOD

[Vasopressin (anti-diuretic hormone: ADH)] Tokinaga K, et al. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:304–7 (9 ref.) **(Jpn)**

GENETICS

Vasopressin and oxytocin: molecular biology and evolution of the peptide hormones and their receptors. Mohr E, et al. **Vitam Horm** 1995;51:235–66 (137 ref.)

METABOLISM

The nocturnal polyuria syndrome (NPS). Asplund R. **Gen Pharmacol** 1995 Oct;26(6):1203–9 (29 ref.)

PHARMACOLOGY

Molecular pharmacology of V1a vasopressin receptors. Howl J, et al. **Gen Pharmacol** 1995 Oct;26(6):1143–52 (72 ref.)

Molecular mechanisms for the regulation of water transport in amphibian epithelia by antidiuretic hormone. Jo I, et al. **Kidney Int** 1995 Oct;48(4):1088–96 (113 ref.)

PHYSIOLOGY

Molecular neurobiology and pharmacology of the vasopressin/oxytocin receptor family. Peter J, et al. **Cell Mol Neurobiol** 1995 Oct;15(5):573–95 (100 ref.)

[Water and chloride channels and urine concentrating system] Marumo F. **Nippon Naika Gakkai Zasshi** 1995 Dec 10; 84(12):2080–4 (12 ref.) **(Jpn)**

[Water-electrolyte imbalance and posterior pituitary gland hormone] Yoshida S. **Nippon Naika Gakkai Zasshi** 1995 Sep 10;84(9):1388–95 (20 ref.) **(Jpn)**

VASOPRESSOR AGENTS see **VASOCONSTRICTOR AGENTS**

VASOSTOMY see **VASOVASOSTOMY**

VASOTOCIN

ANALOGS & DERIVATIVES

Atosiban. Shubert PJ. **Clin Obstet Gynecol** 1995 Dec; 38(4):722–4 (12 ref.)

[Water homeostasis in amphibia: vasotocin and hydrins] Acher R. **C R Seances Soc Biol Fil** 1995;189(2):199–214 (59 ref.) (Eng. Abstr.) **(Fre)**

GENETICS

Structure and organization of the isotocin and vasotocin genes from teleosts. Venkatesh B, et al. **Adv Exp Med Biol** 1995;395:629–38 (24 ref.)

METABOLISM

[Water homeostasis in amphibia: vasotocin and hydrins] Acher R. **C R Seances Soc Biol Fil** 1995;189(2):199–214 (59 ref.) (Eng. Abstr.) **(Fre)**

VASOVASOSTOMY

METHODS

Microscopic vasovasostomy: current practice and future trends. Donovan JF Jr. **Microsurgery** 1995;16(5):325–32 (63 ref.)

VATER'S AMPULLA

see related
CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE
SPHINCTEROTOMY, ENDOSCOPIC

Periampullary tumours: report of two cases. Kassa E. **East Afr Med J** 1996 May;73(5):333–5 (17 ref.)

Vater's papilla and periampullary area villous adenoma: personal experience about nine cases and review of the literature. Motton G, et al. **Hepatogastroenterology** 1996 Mar–Apr;43(8):448–55 (77 ref.)

Metastatic renal cell carcinoma to ampulla of Vater: an unusual lesion amenable to surgical resection. Leslie KA, et al. **Surgery** 1996 Mar;119(3):349–51 (14 ref.)

[Neurofibromatosis (von Recklinghausen disease) and carcinoid tumor in Vater's ampulla] Simon L, et al. **Orv Hetil** 1995 Oct 15;136(42):2287–92 (34 ref.) (Eng. Abstr.) **(Hun)**

[Prospects of early immunocytochemical diagnosis in periampullary tumors (a review of foreign literature)] Kubyshkin VA, et al. **Khirurgiia (Mosk)** 1995;(6):50–2 (42 ref.) **(Rus)**

[Digestive hemorrhage due to duodenal angiodysplasia in the periampullary area] Pamplona J, et al. **Gastroenterol Hepatol** 1996 May;19(5):250–2 (22 ref.) (Eng. Abstr.) **(Spa)**

[Adenoma of Vater's ampulla without clinical or analytical expression (letter)] Moreira VF, et al. **Rev Clin Esp** 1996 May;196(5):343–4 (11 ref.) **(Spa)**

SURGERY

Is local excision of pT1-ampullary carcinomas justified? Klein P, et al. **Eur J Surg Oncol** 1996 Aug;22(4):366–71 (24 ref.)

[Carcinoid of the major duodenal papilla] Kalotov E, et al.

Khirurgiia (Sofiia) 1995;48(4):55–9 (11 ref.) (Bul)

VCAM-1 see VASCULAR CELL ADHESION MOLECULE-1

VECTORCARDIOGRAPHY

[Electrophysiologic approach to the diagnosis of left ventricular hypertrophy] de Micheli A, et al. Arch Inst Cardiol Mex 1995 Jul–Aug;65(4):365–74 (12 ref.) (Spa)

[Electrophysiological approach to the diagnosis of uncomplicated and complicated left ventricular blocks] de Micheli A, et al. Arch Inst Cardiol Mex 1996 Jan–Feb; 66(1):70–82 (27 ref.) (Spa)

VECTORS, GENETIC see GENETIC VECTORS

VEGETABLE OILS see PLANT OILS

VEGETABLES

What accounts for the association of vegetables and fruits with lower incidence of cancers and coronary heart disease? [editorial; comment] Omenn GS. Ann Epidemiol 1995 Jul;5(4):333–5 (12 ref.) Comment on: Ann Epidemiol 1995 Jul;5(4):255–60. Comment on: Ann Epidemiol 1995 Jul;5(4):261–9.

Effects of processing on dietary fibre in vegetables. Nyman M. Eur J Clin Nutr 1995 Oct;49 Suppl 3:S215–8 (22 ref.)

Chemoprevention of colon cancer by minor dietary constituents and their synthetic analogues. Reddy BS. Prev Med 1996 Jan–Feb;25(1):48–50 (13 ref.)

STANDARDS

Diet, nutrition & cancer—the Indian scenario. Krishnaswamy K, et al. Indian J Med Res 1995 Nov;102:200–9 (70 ref.)

VEGETARIANISM

Vegetarian diet components, protein and blood pressure: which nutrients are important? Beilin LJ, et al. Clin Exp Pharmacol Physiol 1995 Mar;22(3):195–8 (48 ref.)

Iodine in the diet: perspectives for vegans. Lightowler HJ, et al. J R Soc Health 1996 Feb;116(1):14–20 (43 ref.)

The medical costs attributable to meat consumption [see comments] Barnard ND, et al. Prev Med 1995 Nov; 24(6):646–55 (105 ref.) Comment in: Prev Med 1995 Nov;24(6):565–7.

VEGETATIVE STATE, PERSISTENT see PERSISTENT VEGETATIVE STATE

VEHICLE EMISSIONS

ADVERSE EFFECTS

Diesel engine exhaust and lung cancer: an unproven association. Muscat JE, et al. Environ Health Perspect 1995 Sep;103(9):812–8 (77 ref.)

[Advances in the study on biological effects of diesel exhaust] Lu Y, et al. Chung Hua Yu Fang I Hsueh Tsa Chih 1995 Sep;29(5):305–6 (15 ref.) (Chi)

TOXICITY

Mutagenic nitroarenes, diesel emissions, particulate-induced mutations and cancer: an essay on cancer-causation by a moving target. Rosenkranz HS. Mutat Res 1996 Feb; 367(2):65–72 (85 ref.)

VEHICLES

Vehicles for oral immunization. Santiago N, et al. Pharm Biotechnol 1995;6:413–38 (160 ref.)

CHEMISTRY

[Lipid vehicles for the parenteral administration of drugs (1): emulsions] Bermejo Vicedo T, et al. Nutr Hosp 1996 Jan–Feb;11(1):7–16 (49 ref.) (Eng. Abstr.) (Spa)

VEHICLES, MOTOR see MOTOR VEHICLES

VEILED CELLS see DENDRITIC CELLS

VEILLONELLA

Veillonella infections in children. Brook I. J Clin Microbiol 1996 May;34(5):1283–5 (21 ref.)

VEIN OF GALEN see CEREBRAL VEINS

VEINS

DRUG EFFECTS

Comparison of the effect of dopamine in primate arteries and veins. Okamura T, et al. Hypertens Res 1995 Jun;18 Suppl 1:S35–7 (19 ref.)

INJURIES

Peripheral vascular injury. Flynn TC. Curr Opin Gen Surg 1994;:30–4 (41 ref.)

Venous injuries: military versus civilian experience. Ierardi RP, et al. Mil Med 1995 Aug;160(8):396–8 (25 ref.)

INNERVATION

The role of the autonomic nerves in the control of nasal circulation. Lung MA. Biol Signals 1995 May–Jun; 4(3):179–85 (33 ref.)

PATHOLOGY

Venous disease and tumors. Knopp EA. Magn Reson Imaging Clin N Am 1995 Aug;3(3):509–28 (22 ref.)

Venography of the extremities and pelvis. Spritzer CE. Magn Reson Imaging Clin N Am 1993 Dec;1(2):239–51 (28 ref.)

TRANSPLANTATION

Techniques and strategies using arm veins. Andros G. Semin Vasc Surg 1995 Sep;8(3):179–87 (28 ref.)

Preoperative assessment of alternative veins. Salles-Cunha SX, et al. Semin Vasc Surg 1995 Sep;8(3):172–8 (21 ref.)

[Venous allografts for salvage of lower limbs: hope and reality] Van Damme H, et al. Rev Med Liege 1995 Oct; 50(10):433–42 (72 ref.) (Fre)

ULTRASONOGRAPHY

Color Doppler sonography of the thoracic inlet veins. Nazarian GK, et al. Radiographics 1995 Nov;15(6):1357–71 (10 ref.)

VELOCIMETRY see RHEOLOGY

VELOCIMETRY, LASER-DOPPLER see LASER-DOPPLER FLOWMETRY

VELOPHARYNGEAL INSUFFICIENCY

see related
SPEECH DISORDERS

The functional role of the adenoids in speech. Finkelstein Y, et al. Int J Pediatr Otorhinolaryngol 1996 Jan; 34(1–2):61–74 (73 ref.)

VELUM PALATINUM see PALATE, SOFT

VENA CAVA FILTERS

Vena cava filters: available devices and current practices. Cooper JM, et al. Mt Sinai J Med 1996 May–Sep; 63(3–4):273–81 (54 ref.)

Current indications for caval interruption: should they be liberalized in view of improving technology? Greenfield LJ, et al. Semin Vasc Surg 1996 Mar;9(1):50–8 (32 ref.)

Caval interruption methods: comparison of options. Whitehill TA. Semin Vasc Surg 1996 Mar;9(1):59–69 (90 ref.)

[Indications of partial interruption of the inferior vena cava in pulmonary embolism] Schleich JM, et al. Arch Mal Coeur Vaiss 1995 Nov;88(11 Suppl):1785–91 (45 ref.) (Eng. Abstr.) (Fre)

[Pulmonary embolism prophylaxis with vena cava filters] Obergassel L, et al. Dtsch Med Wochenschr 1996 Aug 23; 121(34–35):1060–5 (52 ref.) (Ger)

[Deep venous thrombosis and the prevention of a pulmonary embolism with temporary caval filters: the experience in 2 pediatric cases] Patti G, et al. Pediatr Med Chir 1995 May–Jun;17(3):265–9 (10 ref.) (Eng. Abstr.) (Ita)

ADVERSE EFFECTS

Complications of inferior vena cava filters. Ray CE Jr, et al. Abdom Imaging 1996 Jul–Aug;21(4):368–74 (57 ref.)

Inferior vena cava thrombosis following percutaneous filter insertion: an unusual cause of haemodynamic compromise. Hainaut P, et al. Acta Clin Belg 1995;50(4):231–7 (21 ref.)

Tricuspid insufficiency after intracardiac migration of a Greenfield filter: case report and review of the literature. James KV, et al. J Vasc Surg 1996 Sep;24(3):494–8 (21 ref.)

VENA CAVA, INFERIOR

Inferior vena cava thrombosis following percutaneous filter insertion: an unusual cause of haemodynamic compromise. Hainaut P, et al. Acta Clin Belg 1995;50(4):231–7 (21 ref.)

Use of tissue type plasminogen activator in neonates: case reports and review of the literature. Smets K, et al. Am J Perinatol 1996 May;13(4):217–22 (21 ref.)

Obstruction of the hepatic veins or suprahepatic inferior vena cava. Valla D, et al. Dig Dis 1996 Mar–Apr;14(2):99–118 (182 ref.)

Posttraumatic inferior vena caval thrombosis: case report and review of the literature. Takeuchi M, et al. J Trauma 1995 Sep;39(3):605–8 (10 ref.)

Duodenocaval fistula complicating peptic ulcer disease: case report and review of the literature. Miller CA, et al. Surgery 1996 Jun;119(6):718–9 (14 ref.)

[Deep venous thrombosis and the prevention of a pulmonary embolism with temporary caval filters: the experience in 2 pediatric cases] Patti G, et al. Pediatr Med Chir 1995 May–Jun;17(3):265–9 (10 ref.) (Eng. Abstr.) (Ita)

[Recanalization of 2 suprahepatic veins with metal stents via a percutaneous transhepatic approach in a case of the Budd–Chiari syndrome] Castrucci M, et al. Radiol Med (Torino) 1996 Jan–Feb;91(1–2):148–52 (16 ref.) (Ita)

[Postappendectomy vascular complications in childhood] Díez García R, et al. An Esp Pediatr 1996 Mar;44(3):270–2 (19 ref.) (Spa)

[Percutaneous transluminal angioplasty of the vena cava inferior] Ledesma Velasco M, et al. Arch Inst Cardiol Mex 1995 May–Jun;65(3):255–9 (7 ref.) (Eng. Abstr.) (Spa)

ABNORMALITIES

Congenital absence of portal venous system associated with a large inferior mesenteric-caval shunt: a case report. Komatsu S, et al. Hepatogastroenterology 1995 Jul; 42(3):286–90 (17 ref.)

Congenitally absent inferior vena cava presenting in adulthood with venous stasis and ulceration: a surgically treated case. Dougherty MJ, et al. J Vasc Surg 1996 Jan; 23(1):141–6 (17 ref.)

Combined membranous obstruction and saccular aneurysm of the inferior vena cava. Augustin N, et al. Thorac Cardiovasc Surg 1995 Aug;43(4):223–6 (30 ref.)

[Thrombolysis of an extensive venous thrombosis of the lower body in an anomaly of the vena cava inferior] Rühlmann C, et al. Dtsch Med Wochenschr 1996 Feb 2; 121(5):124–8 (29 ref.) (Eng. Abstr.) (Ger)

INJURIES

[Atrio-caval shunt in injury to the suprahepatic vena cava. Apropos of a case and review of the literature] Orsoni P, et al. J Chir (Paris) 1995 Nov;132(11):438–41 (24 ref.) (Eng. Abstr.) (Fre)

PATHOLOGY

Angiomyolipoma of the kidney with extension into the inferior vena cava. Hibi H, et al. Int J Urol 1995 Nov; 2(5):332–5 (14 ref.)

SURGERY

Aortocaval fistula treated by aortic exclusion. Woolley DS, et al. J Vasc Surg 1995 Nov;22(5):639–42 (27 ref.)

Metastatic testicular tumor requiring inferior vena cava resection. Mullen JC, et al. Urology 1996 Feb;47(2):263–5 (10 ref.)

[Surgical therapy of leiomyosarcoma of the inferior vena cava] Zieren J, et al. Zentralbl Chir 1995;120(8):641–9 (105 ref.) (Eng. Abstr.) (Ger)

VENA CAVA, SUPERIOR

see related
SUPERIOR VENA CAVA SYNDROME

Leiomyosarcoma of the superior vena cava. Spaggiari L, et al. Ann Thorac Surg 1996 Jul;62(1):274–6 (8 ref.)

ABNORMALITIES

Coronary sinus ostial atresia with persistent left superior vena cava. Santoscoy R, et al. Ann Thorac Surg 1996 Mar; 61(3):879–82 (20 ref.)

Large spleno-caval shunt not accompanied by cirrhosis or encephalopathy. Mitsui H, et al. J Gastroenterol 1996 Apr; 31(2):278–83 (33 ref.)

[The integrated imaging of a rare case of partial anomalous pulmonary venous connections] Midiri M, et al. Radiol Med (Torino) 1995 Sep;90(3):320–3 (10 ref.) (Ita)

SURGERY

Late conduit occlusion after modified Fontan procedure with classic Glenn shunt. Koutlas TC, et al. Ann Thorac Surg 1996 Jul;62(1):258–61; discussion 261–2 (8 ref.)

[Mediastinal malignant tumor resection and superior vena cava revascularization. Resection of invasive thymoma with growth into the superior vena cava and right atrium using cardiopulmonary bypass] Nippon Kyobu Geka Gakkai Zasshi 1995 May;43(5):717–9 (4 ref.) (Jpn)

VENAE CAVAE

ABNORMALITIES

[Late manifestation of congenital intrahepatic portacaval shunt in a healthy liver] Kerleau JM, et al. Rev Med Interne 1995;16(8):616–8 (7 ref.) (Eng. Abstr.) (Fre)

VENEREAL DISEASES see SEXUALLY TRANSMITTED DISEASES

VENEREAL DISEASES, BACTERIAL see SEXUALLY TRANSMITTED DISEASES, BACTERIAL

VENEREAL DISEASES, VIRAL see SEXUALLY TRANSMITTED DISEASES, VIRAL

VENEREAL WARTS see CONDYLOMATA ACUMINATA

VENEREOLOGY

see related
SEXUALLY TRANSMITTED DISEASES

VENESECTION see **PHLEBOTOMY**

VENIPUNCTURE see **PHLEBOTOMY**

VENO-OCCLUSIVE DISEASE, HEPATIC see **HEPATIC VENO-OCCLUSIVE DISEASE**

VENO-OCCLUSIVE DISEASE, PULMONARY see **PULMONARY VENO-OCCLUSIVE DISEASE**

VENOMS

see related
ANTIVENINS

CHEMISTRY

Bioactive peptides from lizard venoms. Raufman JP. **Regul Pept** 1996 Jan 16;61(1):1–18 (165 ref.)

VENOUS CATHETERIZATION, CENTRAL see **CATHETERIZATION, CENTRAL VENOUS**

VENOUS CATHETERIZATION, PERIPHERAL see **CATHETERIZATION, PERIPHERAL**

VENOUS INSUFFICIENCY

Chronic venous insufficiency. Miller WL. **Curr Opin Cardiol** 1995 Sep;10(5):543–8 (24 ref.)

CLASSIFICATION

Diagnosis of chronic venous disease of the lower extremities: the "CEAP" classification [see comments] Kistner RL, et al. **Mayo Clin Proc** 1996 Apr;71(4):338–45 (6 ref.) Comment in: Mayo Clin Proc 1996 Apr;71(4):422–3.

Classification and grading of chronic venous disease in the lower limbs--a consensus statement. Organized by Straub Foundation with the cooperation of the American Venous Forum at the 6th annual meeting, February 22–25, 1994, Maui, Hawaii. Beebe HG, et al. **Vasa** 1995;24(4):313–8 (44 ref.)

COMPLICATIONS

Iliac vein compression as an anatomical cause of thrombophilia: Cockett's syndrome revisited. Verhaeghe R. **Thromb Haemost** 1995 Dec;74(6):1398–401 (24 ref.)

DIAGNOSIS

Diagnosis of chronic venous disease of the lower extremities: the "CEAP" classification [see comments] Kistner RL, et al. **Mayo Clin Proc** 1996 Apr;71(4):338–45 (6 ref.) Comment in: Mayo Clin Proc 1996 Apr;71(4):422–3.

PATHOLOGY

Intravital capillaroscopy in patients with chronic venous insufficiency and lymphoedema: relevance to Daflon 500 mg. Bollinger A, et al. **Int J Microcirc Clin Exp** 1995;15 Suppl 1:41–4 (24 ref.)

SURGERY

Congenitally absent inferior vena cava presenting in adulthood with venous stasis and ulceration: a surgically treated case. Dougherty MJ, et al. **J Vasc Surg** 1996 Jan; 23(1):141–6 (17 ref.)

[Chronic venous insufficiency] Hauer G, et al. **Chirurg** 1996 May;67(5):505–14 (42 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Leech therapy in digital replantation. Golden MA, et al. **AORN J** 1995 Sep;62(3):364–6, 369, 371–2, passim (0 ref.)

VENOUS LEAKAGE, PENILE see **IMPOTENCE, VASCULOGENIC**

VENOUS THROMBOSIS see **THROMBOPHLEBITIS**

VENOUS ULCER see **VARICOSE ULCER**

VENOVENOUS HEMOFILTRATION see **HEMOFILTRATION**

VENTILATION, HIGH-FREQUENCY see **HIGH-FREQUENCY VENTILATION**

VENTILATION, HIGH FREQUENCY JET see **HIGH-FREQUENCY JET VENTILATION**

VENTILATION, INTERMITTENT POSITIVE-PRESSURE see **INTERMITTENT POSITIVE-PRESSURE VENTILATION**

VENTILATION, MECHANICAL see **RESPIRATION, ARTIFICIAL**

VENTILATION, MIDDLE EAR see **MIDDLE EAR VENTILATION**

VENTILATION-PERFUSION RATIO

Ventilation/perfusion: from the bench to the patient. Hlastala MP. **Cardiologia** 1996 May;41(5):405–15 (10 ref.)

VENTILATION TESTS see **RESPIRATORY FUNCTION TESTS**

VENTILATOR WEANING

Neuromuscular complications in the ICU: the spectrum of critical illness-related conditions causing muscular weakness and weaning failure. Hund EF. **J Neurol Sci** 1996 Mar;136(1–2):10–6 (75 ref.)

VENTILATORS, MECHANICAL

CLASSIFICATION

[Invasive ventilation. Classification, technique and clinical experiences with BiPAP/APRV (Biphasic Positive Airway Pressure/Airway Pressure Release Ventilation)] Antonsen K, et al. **Ugeskr Laeger** 1996 Jan 22;158(4):413–9 (23 ref.) (Eng. Abstr.) **(Dan)**

VENTILATORS, PULMONARY see **VENTILATORS, MECHANICAL**

VENTILATORY MUSCLES see **RESPIRATORY MUSCLES**

VENTRAL HERNIA see **HERNIA, VENTRAL**

VENTRAL ROOTS see **SPINAL NERVE ROOTS**

VENTRAL TEGMENTAL AREA

PHYSIOPATHOLOGY

Basic research in substantia nigra and ventral tegmental area: clinical implications. Stratta F, et al. **J Neural Transm Suppl** 1995;45:47–55 (65 ref.)

VENTRICLE-ASSIST DEVICE see **HEART-ASSIST DEVICES**

VENTRICULAR DYSFUNCTION

Ventricular remodeling. Maisch B. **Cardiology** 1996;87 Suppl 1:2–10 (22 ref.)

DRUG THERAPY

Propafenone: an effective agent for the management of supraventricular arrhythmias. Grant AO. **J Cardiovasc Electrophysiol** 1996 Apr;7(4):353–64 (74 ref.)

Current perspectives on beta-receptor antagonists in the treatment of symptomatic ventricular dysfunction. Adams KF Jr. **Pharmacotherapy** 1996 Mar-Apr;16(2 Pt 2):69S–77S (46 ref.)

Is there a role for digoxin in patients with systolic dysfunction? Williamson KM. **Pharmacotherapy** 1996 Mar-Apr;16(2 Pt 2):37S–42S (27 ref.)

PATHOLOGY

Ventricular remodeling in global ischemia. Anversa P, et al. **Cardioscience** 1995 Jun;6(2):89–100 (59 ref.)

Cellular basis of ventricular remodeling after myocardial infarction in rats. Olivetti G, et al. **Cardioscience** 1995 Jun; 6(2):101–6 (29 ref.)

PHYSIOPATHOLOGY

Evidence favoring the hypothesis that ventricular arrhythmias have prognostic significance in left ventricular hypertrophy secondary to systemic hypertension. Almendral J, et al. **Am J Cardiol** 1995 Nov 2; 76(13):60D–63D (27 ref.)

Electrophysiologic changes in ischemic ventricular myocardium: I. Influence of ionic, metabolic, and energetic changes. Cascio WE, et al. **J Cardiovasc Electrophysiol** 1995 Nov;6(11):1039–62 (165 ref.)

VENTRICULAR DYSFUNCTION, LEFT

"Hibernating" myocardium: asleep or part dead? [editorial] Armstrong WF. **J Am Coll Cardiol** 1996 Aug;28(2):530–5 (43 ref.)

[Correlation between the persistence of ST elevation and left ventricular aneurysm in the post-infarction period] Hamani A, et al. **Ann Cardiol Angeiol (Paris)** 1995 Sep;44(7):361–4 (22 ref.) (Eng. Abstr.) **(Fre)**

COMPLICATIONS

Drug therapy versus implantation of a cardiac defibrillator for the treatment of malignant arrhythmias in left ventricular dysfunction [editorial] Mannino MM, et al. **Am Heart J** 1996 Jun;131(6):1251–9 (44 ref.)

Congestive heart failure due to hypertensive ventricular diastolic dysfunction. Iriarte MM, et al. **Am J Cardiol** 1995 Nov 2;76(13):43D–47D (20 ref.)

Left ventricular hypertrophy and diastolic dysfunction: their relation to coronary heart disease. Störk T, et al. **Cardiovasc Drugs Ther** 1995 Aug;9 Suppl 3:533–7 (33 ref.)

Ventricular tachyarrhythmias, myocardial ischemia, and sudden cardiac death in patients with hypertensive heart disease. Zehender M, et al. **Clin Cardiol** 1995 Jul; 18(7):377–83 (84 ref.)

[Congestive heart failure associated with ischemic cardiopathy] da Silva MA. **Arq Bras Cardiol** 1995 Apr; 64(4):347–54 (42 ref.) **(Por)**

DIAGNOSIS

Management of heart failure. Mair FS. **Am Fam Physician** 1996 Jul;54(1):245–54, 258–60 (40 ref.)

Clinical assessment of regional function: strengths and limitations. Quiñones MA. **Coron Artery Dis** 1995 Aug; 6(8):625–8 (7 ref.)

Myocardial viability. Hendel RC, et al. **Curr Probl Cardiol** 1996 Mar;21(3):145–221 (260 ref.)

Assessing myocardial viability to help select patients for revascularization to improve left ventricular dysfunction due to coronary artery disease. Patterson RE, et al. **Semin Thorac Cardiovasc Surg** 1995 Oct;7(4):214–26 (61 ref.)

DRUG THERAPY

Current controversies with ACE inhibitor treatment in heart failure. Visser FC, et al. **Cardiology** 1996;87 Suppl 1:23–8 (21 ref.)

The use of angiotensin converting enzyme inhibitors in asymptomatic patients with left ventricular dysfunction after myocardial infarction. Bazunga M. **Conn Med** 1995 Nov;59(11):663–6 (39 ref.)

Angiotensin converting enzyme inhibition in asymptomatic left ventricular systolic dysfunction and early heart failure. Konstam MA. **Eur Heart J** 1995 Dec;16 Suppl N:59–64 (44 ref.)

Angiotensin-converting enzyme inhibitors in left ventricular dysfunction. Linn WD. **Pharmacotherapy** 1996 Mar-Apr; 16(2 Pt 2):50S–58S (48 ref.)

EPIDEMIOLOGY

[Management of patients with sustained ventricular arrhythmia: anti-arrhythmia agents or defibrillator?] Cappato R, et al. **Cardiologia** 1996 Feb;41(2):95–105 (75 ref.) **(Ita)**

ETIOLOGY

Systolic ventricular dysfunction and heart failure due to coronary microangiopathy in hypertensive heart disease. Vogt M, et al. **Am J Cardiol** 1995 Nov 2;76(13):48D–53D (34 ref.)

Left ventricular dysfunction and heart failure. Mechanistic and therapeutic distinctions. Cohn JN. **Clin Exp Hypertens** 1996 Apr-May;18(3–4):559–68 (29 ref.)

Left ventricular remodelling after acute myocardial infarction--solved and unsolved issues. Bassand JP. **Eur Heart J** 1995 Aug;16 Suppl I:58–63 (53 ref.)

The relationship of left ventricular geometry and hypertrophy to left ventricular function in valvular heart disease. Carabello BA. **J Heart Valve Dis** 1995 Oct;4 Suppl 2:S132–8; discussion S138–9 (39 ref.)

Left ventricular function in aortic stenosis: a clinical review. Roger VL. **J Heart Valve Dis** 1995 Oct;4 Suppl 2:S230–5 (49 ref.)

Tachycardiomyopathy: mechanisms and clinical implications. Fenelon G, et al. **Pacing Clin Electrophysiol** 1996 Jan; 19(1):95–106 (76 ref.)

PHYSIOPATHOLOGY

Incomplete, delayed functional recovery late after reperfusion following acute myocardial infarction: "maimed myocardium" [editorial] Boden WE, et al. **Am Heart J** 1995 Oct;130(4):922–32 (60 ref.)

Left ventricular hypertrophy regression as a process with variable biological implications. Simko F. **Can J Cardiol** 1996 May;12(5):507–13 (89 ref.)

Critical review of heart failure: the role of left ventricular remodeling in the therapeutic response. Cohn JN. **Clin Cardiol** 1995 Sep;18(9 Suppl 4):IV4–12 (21 ref.)

Changes in neurohumoral systems during the development of congestive heart failure: impact on cardiovascular and renal function. Elsner D. **Eur Heart J** 1995 Dec;16 Suppl N:52–8 (37 ref.)

Rationale for treatment of patients with chronic heart failure with adrenergic blockade. Sackner-Bernstein JD, et al. **JAMA** 1995 Nov 8;274(18):1462–7 (71 ref.)

The apical ventricular lesion in Chagas' heart disease. Nogueira EA, et al. **Rev Paul Med** 1995 Mar-Apr; 113(2):785–90 (31 ref.)

[Diastolic dysfunction of the left ventricle as a cause of heart failure: a clinical problem] Muntinga HJ, et al. **Ned Tijdschr Geneeskd** 1995 Oct 7;139(40):2023–8 (30 ref.) **(Dut)**

[From left hypertrophy to heart insufficiency: hemodynamic and clinical findings] Sütsch G, et al. **Schweiz Rundsch Med Prax** 1996 Feb 20;85(8):218–26 (75 ref.) (Eng. Abstr.) **(Ger)**

[Renin-angiotensin-aldosterone system and left ventricular

diastolic dysfunction] Witkowska M.
Pol Arch Med Wewn 1995 Sep;94(3):259–65 (32 ref.) **(Pol)**

PREVENTION & CONTROL

Myocardial infarction: when and how should we initiate treatment with ACE inhibitors? GISSI-3 Investigators. Latini R, et al. **Cardiology** 1996;87 Suppl 1:16–22 (22 ref.)

SURGERY

Assessing myocardial viability to help select patients for revascularization to improve left ventricular dysfunction due to coronary artery disease. Patterson RE, et al. **Semin Thorac Cardiovasc Surg** 1995 Oct;7(4):214–26 (61 ref.)

THERAPY

Management of heart failure. Mair FS.
Am Fam Physician 1996 Jul;54(1):245–54, 258–60 (40 ref.)
[Management of patients with sustained ventricular arrhythmia: anti-arrhythmia agents or defibrillator?] Cappato R, et al. **Cardiologia** 1996 Feb;41(2):95–105 (75 ref.) **(Ita)**

ULTRASONOGRAPHY

Newer Doppler measures of left ventricular diastolic function. Pai RG, et al. **Clin Cardiol** 1996 Apr;19(4):277–88 (68 ref.)
Analysis of left ventricular systolic function. Schiller NB, et al. **Heart** 1996 Jun;75(6 Suppl 2):17–26 (42 ref.)
Analysis of left ventricular diastolic function. Yamamoto K, et al. **Heart** 1996 Jun;75(6 Suppl 2):27–35 (61 ref.)
A practical guide to assessment of ventricular diastolic function using Doppler echocardiography. Cohen GI, et al. **J Am Coll Cardiol** 1996 Jun;27(7):1753–60 (77 ref.)
The assessment of left ventricular function by echocardiography. Gillespie ND, et al. **Scott Med J** 1995 Oct;40(5):132–3 (19 ref.)
[Evaluation of systolic and diastolic left ventricular function by echocardiography] Haertel JC. **Arq Bras Cardiol** 1995 Apr;64(4):391–400 (45 ref.) **(Por)**

VENTRICULAR DYSFUNCTION, RIGHT

Right ventricular dysfunction after acute pulmonary embolism: pathophysiologic factors, detection, and therapeutic implications. Lualdi JC, et al. **Am Heart J** 1995 Dec;130(6):1276–82 (49 ref.)

COMPLICATIONS

[Outcome of arrhythmogenic right ventricular dysplasia. Apropos of 4 cases] Fontaine G, et al.
Arch Mal Coeur Vaiss 1995 Jul;88(7):973–9 (12 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

MR imaging of pulmonary hypertension and right ventricular dysfunction. Boxt LM.
Magn Reson Imaging Clin N Am 1996 May;4(2):307–25 (94 ref.)

ETIOLOGY

Double outlet right ventricle with restrictive ventricular septal defect. Sardana R, et al. **Indian Heart J** 1996 Jan–Feb;48(1):59–60 (10 ref.)

PATHOLOGY

Endomyocardial biopsy in arrhythmogenic right ventricular cardiomyopathy [editorial] Angelini A, et al.
Am Heart J 1996 Jul;132(1 Pt 1):203–6 (35 ref.)
[Significance of lymphoplasmocytic infiltration in arrhythmogenic right ventricular dysplasia. Apropos of 3 own cases and review of the literature] Fontaliran F, et al. **Arch Mal Coeur Vaiss** 1995 Jul;88(7):1021–8 (32 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

Right-to-left flow through a patent foramen ovale in acute right ventricular infarction. Two case reports and a proposal for management. Amsel BJ, et al. **Chest** 1995 Nov;108(5):1468–71 (23 ref.)
[Special anesthesia care in heart transplantation. The management of right ventricular failure] Gómez-Arnau J, et al. **Rev Esp Cardiol** 1995;48 Suppl 7:60–4 (22 ref.) (Eng. Abstr.) **(Spa)**

VENTRICULAR ECTOPIC BEATS see **VENTRICULAR PREMATURE COMPLEXES**

VENTRICULAR EJECTION FRACTION see **STROKE VOLUME**

VENTRICULAR END-DIASTOLIC VOLUME see **STROKE VOLUME**

VENTRICULAR END-SYSTOLIC VOLUME see **STROKE VOLUME**

VENTRICULAR FIBRILLATION

CHEMICALLY INDUCED

Reducing arrhythmogenic effects in the isolated heart enriching roentgen contrast media with electrolytes. Survey and present state. Besjakov J, et al.
Acta Radiol Suppl 1995;399:115–21 (53 ref.)
A review of coronary arteriography- and contrast media-induced ventricular fibrillation. Morris TW.
Acta Radiol Suppl 1995;399:100–4 (49 ref.)

COMPLICATIONS

[Prognostic factors after sustained ventricular fibrillation or tachycardia. A multivariate study apropos of 160 cases] Fleurant E, et al. **Arch Mal Coeur Vaiss** 1996 Apr;89(4):435–44 (31 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

Is a baseline electrophysiologic study mandatory for the management of patients with spontaneous, sustained, ventricular tachyarrhythmias? Mitchell LB, et al.
Prog Cardiovasc Dis 1996 Mar–Apr;38(5):385–92 (30 ref.)
[In vivo registration of monophasic action potentials—new possible applications in clinical electrophysiology] Behrens S, et al. **Z Kardiol** 1996 May;85(5):326–33 (35 ref.) (Eng. Abstr.) **(Ger)**

DRUG THERAPY

Evolving role of sotalol in the management of ventricular tachyarrhythmias. O'Callaghan PA, et al. **Am J Cardiol** 1996 Aug 29;78(4A):54–60 (40 ref.)
An overview of antiarrhythmic drug management of electrical storm. Kowey PR. **Can J Cardiol** 1996 Apr;12 Suppl B:3B–8B; discussion 27B–28B (15 ref.)
Parenteral antiarrhythmics for life-threatening ventricular arrhythmias. Filart RA, et al.
J Cardiovasc Electrophysiol 1995 Oct;6(10 Pt 2):901–13 (70 ref.)
Parenteral antiarrhythmic drug therapy in ventricular tachycardia/ventricular fibrillation: evolving role of class III agents—focus on amiodarone. Scheinman MM.
J Cardiovasc Electrophysiol 1995 Oct;6(10 Pt 2):914–9 (34 ref.)

METABOLISM

The role of catecholamines on intercellular coupling, myocardial cell synchronization and self ventricular defibrillation. Manoach M, et al. **Mol Cell Biochem** 1995 Jun 7–21;147(1–2):181–5 (63 ref.)

PHYSIOPATHOLOGY

The hibernator heart—nature's model of resistance to ventricular fibrillation. Johansson BW. **Cardiovasc Res** 1996 May;31(5):826–32 (39 ref.)
Electrocardiographic and clinical precursors of ventricular fibrillation: chain of events. Bayés-Genís A, et al.
J Cardiovasc Electrophysiol 1995 May;6(5):410–7 (47 ref.)

PREVENTION & CONTROL

Anions, membrane resistance and ventricular fibrillation. Curtis MJ, et al. **J Basic Clin Physiol Pharmacol** 1994 Jan–Mar;5(1):19–26 (24 ref.)
How can we facilitate spontaneous termination of ventricular fibrillation and prevent sudden cardiac death? A working hypothesis. Manoach M, et al.
J Cardiovasc Electrophysiol 1995 Jul;6(7):584–9 (58 ref.)

THERAPY

Interactions between pharmacologic and nonpharmacologic antiarrhythmic therapy. Greene HL. **Am J Cardiol** 1996 Aug 29;78(4A):61–6 (49 ref.)
Ventricular fibrillation, automatic external defibrillators, and the United States Food and Drug Administration: confrontation without comprehension. Cummins RO, et al. **Ann Emerg Med** 1995 Nov;26(5):621–31; discussion 632–4 (95 ref.)
Implantable cardioverter-defibrillator: present and future indications. Block M, et al. **Arch Mal Coeur Vaiss** 1996 Feb;89 Spec No 1:141–7 (61 ref.)
The implantable cardiac defibrillator. Kamalvand K, et al. **Br J Hosp Med** 1996 Jan 17–Feb 6;55(1–2):37–41 (16 ref.)
Implantable defibrillators are preferable to pharmacologic therapy for patients with ventricular tachyarrhythmias: an antagonist's viewpoint. Anderson J. **Prog Cardiovasc Dis** 1996 Mar–Apr;38(5):393–400 (32 ref.)
[Sudden cardiac death and immediate defibrillation by trained lay persons] Theissen K. **Dtsch Med Wochenschr** 1996 Apr 12;121(15):463–4 (18 ref.) **(Ger)**
[Implantable defibrillators—current status of guidelines. Recognized and possible indications—prerequisites] Andresen D. **Fortschr Med** 1996 Apr 20;114(11):128–32 (0 ref.) (Eng. Abstr.) **(Ger)**
[Automated implantable cardioverter/defibrillators. Indications for implantation and clinical results] Ulbricht LJ, et al. **Z Kardiol** 1995;84 Suppl 2:127–36 (96 ref.) (Eng. Abstr.) **(Ger)**

VENTRICULAR FUNCTION

see related

HEART FUNCTION TESTS

Ventricular performance curves revisited. Kolev N, et al.
Eur J Anaesthesiol 1995 Sep;12(5):445–9 (13 ref.)
Role of M cells in acquired long QT syndrome, U waves, and torsade de pointes. Antzelevitch C, et al.
J Electrocardiol 1995;28 Suppl:131–8 (44 ref.)
Clinical aspects of cardiac memory revisited. Elizari MV, et al. **J Electrocardiol** 1995;28 Suppl:148–55 (25 ref.)
[A paradoxical intraventricular gradient in a patient with atypical hypertrophic myocardiopathy] Penas Lado M, et al. **Rev Esp Cardiol** 1995 Oct;48(10):686–9 (10 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

Stretch-induced modifications of myocardial performance: from ventricular function to cellular and molecular mechanisms. Crozatier B. **Cardiovasc Res** 1996 Jul;32(1):25–37 (143 ref.)
Echocardiographic and other noninvasive measurements of cardiac hemodynamics and ventricular function. Pai RG, et al. **Curr Probl Cardiol** 1995 Oct;20(10):681–770 (241 ref.)
Ventricular function in Chagas' heart disease. Maciel BC, et al. **Rev Paul Med** 1995 Mar–Apr;113(2):814–20 (43 ref.)

VENTRICULAR FUNCTION, LEFT

Echocardiography assessment of left ventricular function in the critically ill. McLean AS. **Anaesth Intensive Care** 1996 Feb;24(1):60–5 (40 ref.)
A practical guide to assessment of ventricular diastolic function using Doppler echocardiography. Cohen GI, et al. **J Am Coll Cardiol** 1996 Jun;27(7):1753–60 (77 ref.)
Ongoing clinical trials of angiotensin-converting enzyme inhibitors for treatment of coronary artery disease in patients with preserved left ventricular function. Pepine CJ. **J Am Coll Cardiol** 1996 Apr;27(5):1048–52 (14 ref.)
The relationship of left ventricular geometry and hypertrophy to left ventricular function in valvular heart disease. Carabello BA. **J Heart Valve Dis** 1995 Oct;4 Suppl 2:S132–8; discussion S138–9 (39 ref.)
The effect of left ventricular function on the echocardiographic assessment of heart valve disease. Chambers J. **J Heart Valve Dis** 1995 Oct;4 Suppl 2:S145–52; discussion S152–3 (55 ref.)
Left ventricular function in mitral valve disease. Oakley CM. **J Heart Valve Dis** 1995 Oct;4 Suppl 2:S236–40; discussion S240–1 (28 ref.)
Left ventricular function in valvular heart disease: invasive and non-invasive assessment of left ventricular function. Shah PM. **J Heart Valve Dis** 1995 Oct;4 Suppl 2:S140–3; discussion S143–4 (27 ref.)
The assessment of left ventricular function by echocardiography. Gillespie ND, et al. **Scott Med J** 1995 Oct;40(5):132–3 (19 ref.)
[Left ventricular diastolic function assessment by transthoracic Doppler echocardiography] Poulsen SH, et al. **Ugeskr Laeger** 1996 Aug 12;158(33):4631–7 (33 ref.) (Eng. Abstr.) **(Dan)**
[Left ventricular remodeling and its role following myocardial infarction (editorial)] Uusimaa P, et al.
Duodecim 1994;110(23–24):2179, 2181–2 (17 ref.) **(Fin)**
[Continuous ambulatory measurement of left ventricular function by an isotopic method] Millaire A.
Arch Mal Coeur Vaiss 1995 Oct;88(10):1453–63 (30 ref.) (Eng. Abstr.) **(Fre)**
[Coronary artery bypass grafting for a patient with left ventricular ejection fraction of 16%: a case report and review of the Japanese literature] Aiba M, et al.
Kyobu Geka 1995 Sep;48(10):861–4 (10 ref.) (Eng. Abstr.) **(Jpn)**

DRUG EFFECTS

Circulatory effects of desflurane. Coriat P. **Anaesthesia** 1995 Oct;50 Suppl:18–21 (19 ref.)
Left ventricular function following thrombolytic therapy for myocardial infarction. French JK, et al.
Clin Exp Pharmacol Physiol 1995 Mar;22(3):173–9 (46 ref.)
Drug differences between ACE inhibitors in experimental settings and clinical practice. Voors AA, et al.
J Cardiovasc Risk 1995 Oct;2(5):413–22 (105 ref.)

PHYSIOLOGY

Congestive heart failure with normal left ventricular systolic function. Clinical approaches to the diagnosis and treatment of diastolic heart failure. Vasan RS, et al.
Arch Intern Med 1996 Jan 22;156(2):146–57 (184 ref.)
Left-ventricular diastolic function and hypertension. Graettinger WF, et al. **Cardiol Clin** 1995 Nov;13(4):559–67 (57 ref.)
Adrenergic control of the force-frequency relation. Ross J Jr, et al. **Circulation** 1995 Oct 15;92(8):2327–32 (48 ref.)
Left ventricular function following thrombolytic therapy for myocardial infarction. French JK, et al.
Clin Exp Pharmacol Physiol 1995 Mar;22(3):173–9 (46 ref.)
Torsional deformation of the left ventricle. Yun KL, et al.
J Heart Valve Dis 1995 Oct;4 Suppl 2:S214–20; discussion S220–2 (42 ref.)
[Diagnosis of coronary heart disease using echocardiography

VENTRICULAR FUNCTION, LEFT

3D reconstructions. Diagnosis of global and regional left ventricular function] Buck T, et al. **Herz** 1995 Aug; 20(4):252–62 (57 ref.) (Eng. Abstr.) **(Ger)**

[Trans-thoracic 3D echocardiography reconstruction for left ventricular volume determination] Kupferwasser I, et al. **Herz** 1995 Aug;20(4):243–51 (53 ref.) (Eng. Abstr.) **(Ger)**

[Evaluation of systolic and diastolic left ventricular function by echocardiography] Haertel JC. **Arq Bras Cardiol** 1995 Apr;64(4):391–400 (45 ref.) **(Por)**

VENTRICULAR HYPERTROPHY, LEFT see **HYPERTROPHY, LEFT VENTRICULAR**

VENTRICULAR HYPERTROPHY, RIGHT see **HYPERTROPHY, RIGHT VENTRICULAR**

VENTRICULAR INFLOW OBSTRUCTION see **VENTRICULAR OUTFLOW OBSTRUCTION**

VENTRICULAR OUTFLOW OBSTRUCTION

DIAGNOSIS

[A double ventricular obstruction in a case of hypertrophic cardiomyopathy] Giordano G, et al. **Cardiologia** 1995 Aug; 40(8):611–3 (7 ref.) (Eng. Abstr.) **(Ita)**

VENTRICULAR OUTFLOW OBSTRUCTION, LEFT see **VENTRICULAR OUTFLOW OBSTRUCTION**

VENTRICULAR OUTFLOW OBSTRUCTION, RIGHT see **VENTRICULAR OUTFLOW OBSTRUCTION**

VENTRICULAR PREMATURE COMPLEXES

[Management of the patient with ventricular extrasystole] Inama G, et al. **G Ital Cardiol** 1995 Dec;25(12):1653–8 (20 ref.) **(Ita)**

DIAGNOSIS

[Supraventricular cardiac arrhythmia and fenestrated aneurysm of the interatrial septum in a newborn infant] Armengol Rofes AJ, et al. **An Esp Pediatr** 1996 Jan; 44(1):63–4 (7 ref.) **(Spa)**

ETIOLOGY

[Ventricular extrasystole with R-on-T phenomenon in long-term ECG--prognostic relevance, subsequent diagnosis and therapeutic consequences?] Grimm W. **Internist (Berl)** 1995 Aug;36(8):847–50 (12 ref.) **(Ger)**

VENTRICULAR PRESSURE

Gender differences in older patients with pressure-overload hypertrophy of the left ventricle. Aurigemma GP, et al. **Cardiology** 1995;86(4):310–7 (29 ref.)

VENTRICULAR SEPTAL DEFECTS see **HEART SEPTAL DEFECTS, VENTRICULAR**

VENTRICULAR SEPTAL PERFORATION see **VENTRICULAR SEPTAL RUPTURE**

VENTRICULAR SEPTAL RUPTURE

ETIOLOGY

A rare complication of aortic valve endocarditis: diagnosis with transesophageal echocardiography. Winslow TM, et al. **J Am Soc Echocardiogr** 1995 Jul-Aug;8(4):546–50 (25 ref.)

[Left ventricular rupture following aortic and mitral valve replacement in a patient with osteogenesis imperfecta: a case report] Ichikawa H, et al. **Kyobu Geka** 1996 Apr; 49(4):294–6 (13 ref.) (Eng. Abstr.) **(Jpn)**

SURGERY

[Left free wall rupture complicating acute myocardial infarction--a case report of surgical success by a new modified method] Imura H, et al.
Nippon Kyobu Geka Gakkai Zasshi 1996 Apr;44(4):511–5 (14 ref.) (Eng. Abstr.) **(Jpn)**

ULTRASONOGRAPHY

A rare complication of aortic valve endocarditis: diagnosis with transesophageal echocardiography. Winslow TM, et al. **J Am Soc Echocardiogr** 1995 Jul-Aug;8(4):546–50 (25 ref.)

VENTRICULOCISTERNOSTOMY see **VENTRICULOSTOMY**

VENTRICULOGRAPHY, RADIONUCLIDE see **RADIONUCLIDE VENTRICULOGRAPHY**

VENTRICULOPERITONEAL SHUNT

Tremor as the result of shunt obstruction: four patients with cysticercosis and secondary parkinsonism: report of four cases. Keane JR. **Neurosurgery** 1995 Sep;37(3):520–2 (3 ref.)

ADVERSE EFFECTS

Radiological case of the month. Shunt migration into the thorax. Huang PP, et al. **Arch Pediatr Adolesc Med** 1996 Mar;150(3):323–4 (13 ref.)

Peritoneal implantation of meningeal melanosis via ventriculoperitoneal shunt: a case report and review of the literature. Gattuso P, et al. **Diagn Cytopathol** 1995 Oct; 13(3):257–9 (19 ref.)

[Anal migration of ventriculo-peritoneal shunt catheter. Apropos of 3 cases] Sami A, et al. **Neurochirurgie** 1995; 41(4):315–8 (25 ref.) (Eng. Abstr.) **(Fre)**

VENTRICULOSTOMY

INSTRUMENTATION

Intracerebroventricular administration of morphine for control of irreducible cancer pain. Lazorthes YR, et al. **Neurosurgery** 1995 Sep;37(3):422–8; discussion 428–9 (26 ref.)

VERAPAMIL

PHARMACOLOGY

[Expression of the MDR1 gene in five human cell lines of medullary thyroid cancer and reversion of the resistance to doxorubicine by ciclosporin A and verapamil] Massart C, et al. **Bull Cancer (Paris)** 1996 Jan;83(1):39–45 (32 ref.) (Eng. Abstr.) **(Fre)**

POISONING

Massive overdose of sustained-release verapamil: a case report and review of literature. Ashraf M, et al.
Am J Med Sci 1995 Dec;310(6):258–63 (35 ref.)

THERAPEUTIC USE

Anti-ischemic intervention as prognosis improvement in patients with coronary artery disease, with special focus on verapamil. Jespersen CM. **Am J Cardiol** 1996 Jun 20; 77(16):32D–36D (64 ref.)

A chronotherapeutic approach to the management of hypertension. White WB. **Am J Hypertens** 1996 Apr;9(4 Pt 3):29S–33S (27 ref.)

Myocardial protection in the occlusion/reperfusion dog model: the role of ischemic necrosis vs reperfusion injury. Chagas AC, et al. **Braz J Med Biol Res** 1995 Sep; 28(9):951–9 (40 ref.)

Anti-ischaemic intervention with verapamil in patients recovering from acute myocardial infarction. Jespersen CM. **Eur Heart J** 1995 Aug;16 Suppl H:13–7 (24 ref.)

VERBAL BEHAVIOR

see related
LANGUAGE DISORDERS
SPEECH DISORDERS

Higher-order behavior classes: contingencies, beliefs, and verbal behavior [comment] Catania AC.
J Behav Ther Exp Psychiatry 1995 Sep;26(3):191–200 (60 ref.) Comment on: J Behav Ther Exp Psychiatry 1995 Sep;26(3):179–90.

Parents' speech and children's stuttering: a critique of the literature. Nippold MA, et al. **J Speech Hear Res** 1995 Oct; 38(5):978–89 (57 ref.)

Fluent speech, fast articulatory rate, and delayed auditory feedback: creating a crisis for a scientific revolution? Stuart A, et al. **Percept Mot Skills** 1996 Feb;82(1):211–8 (42 ref.)

[The discourse as the practice component. (The study of Foucault's theory of objects of discourse, represented in psychopathology)] Díaz Marsa M.
Actas Luso Esp Neurol Psiquiatr Cienc Afines 1995 Sep-Oct;23(5):266–72 (53 ref.) (Eng. Abstr.) **(Spa)**

PHYSIOLOGY

A model of the dynamics of prefrontal cortico-thalamo-basal ganglionic loops in verbal response selection tasks. Gullapalli V, et al. **Ann N Y Acad Sci** 1995 Dec 15; 769:375–80 (22 ref.)

VERBAL LEARNING

see related
LANGUAGE DISORDERS

The California Verbal Learning Test: psychometric characteristics and clinical application. Elwood RW.
Neuropsychol Rev 1995 Sep;5(3):173–201 (122 ref.)

Cognitive components of picture naming. Johnson CJ, et al. **Psychol Bull** 1996 Jul;120(1):113–39 (310 ref.)

PHYSIOLOGY

Neuroanatomical correlates of category-specific semantic disorders: a critical survey. Gainotti G, et al. **Memory** 1995 Sep-Dec;3(3-4):247–64 (50 ref.)

VERMIFUGES see **ANTHELMINTICS**

VERNER-MORRISON SYNDROME see **VIPOMA**

VERRUCA see **WARTS**

VERRUGA PERUANA see **BARTONELLA INFECTIONS**

VERTEBRAL ANKYLOSING HYPEROSTOSIS see **HYPEROSTOSIS, DIFFUSE IDIOPATHIC SKELETAL**

VERTEBRAL ARTERY

Dissection of the internal carotid and vertebral arteries: imaging features. Provenzale JM.
AJR Am J Roentgenol 1995 Nov;165(5):1099–104 (53 ref.)

[Dissection of the carotid artery and vertebral artery--diagnosis and therapy] Sperling W, et al.
Fortschr Neurol Psychiatr 1996 Apr;64(4):153–60 (37 ref.) (Eng. Abstr.) **(Ger)**

[Spontaneous dissection of the left vertebral artery in a young woman. A report and the diagnostic considerations of a case] La Brocca A, et al. **Minerva Med** 1996 Jan-Feb; 87(1-2):41–4 (23 ref.) (Eng. Abstr.) **(Ita)**

INJURIES

Endovascular surgical approach to intracranial vascular diseases. Higashida RT, et al. **J Endovasc Surg** 1996 May; 3(2):146–57 (57 ref.)

The management of penetrating vascular injuries. Day JD, et al. **Neurosurg Clin N Am** 1995 Oct;6(4):799–808 (59 ref.)

PHYSIOPATHOLOGY

Proximal ligation of large distal posterior inferior cerebellar artery aneurysm. Yamaguchi N, et al.
Neurol Med Chir (Tokyo) 1996 Jan;36(1):31–5 (20 ref.)

SURGERY

Proximal ligation of large distal posterior inferior cerebellar artery aneurysm. Yamaguchi N, et al.
Neurol Med Chir (Tokyo) 1996 Jan;36(1):31–5 (20 ref.)

VERTEBRAL ARTERY INSUFFICIENCY see **VERTEBROBASILAR INSUFFICIENCY**

VERTEBRATES

Evolutionary pressures in the spread and persistence of infectious agents in vertebrate populations. Anderson RM.
Parasitology 1995;111 Suppl:S15–31 (69 ref.)

The influence of hunting pressure on the social behavior of vertebrates. Verdade LM. **Rev Bras Biol** 1996 Feb; 56(1):1–13 (82 ref.)

[The interrelationships of ixodid ticks (Ixodidae) with the causative agents of transmissible vertebrate infections] Balashov IuS. **Parazitologiia** 1995 Sep-Oct;29(5):337–52 (90 ref.) (Eng. Abstr.) **(Rus)**

ANATOMY & HISTOLOGY

Inductive signals. Revolving vertebrates. Jones CM, et al. **Curr Biol** 1995 Jun 1;5(6):574–6 (16 ref.)

Developmental evolution of metazoan bodyplans: the fossil evidence. Valentine JW, et al. **Dev Biol** 1996 Feb 1; 173(2):373–81 (88 ref.)

The pineal gland: structural and functional diversity. Shedpure M, et al. **Indian J Exp Biol** 1995 Sep;33(9):625–40 (80 ref.)

Evolution of myosin filament arrangements in vertebrate skeletal muscle. Luther PK, et al. **J Morphol** 1996 Sep; 229(3):325–35 (28 ref.)

EMBRYOLOGY

Somite differentiation. Sonic signals somites. Bumcrot DA, et al. **Curr Biol** 1995 Jun 1;5(6):612–4 (13 ref.)

Mapping vertebrate embryos. Tam PP, et al. **Curr Biol** 1996 Feb 1;6(2):104–6 (7 ref.)

Determination events in the nervous system of the vertebrate embryo. Bally-Cuif L, et al. **Curr Opin Genet Dev** 1995 Aug;5(4):450–8 (70 ref.)

Homeobox genes in vertebrate gastrulation. Boncinelli E, et al. **Curr Opin Genet Dev** 1995 Oct;5(5):619–27 (58 ref.)

Signalling by hedgehog family proteins in Drosophila and vertebrate development. Ingham PW.
Curr Opin Genet Dev 1995 Aug;5(4):492–8 (67 ref.)

Vertebrate limb development. Tickle C.
Curr Opin Genet Dev 1995 Aug;5(4):478–84 (31 ref.)

Heterochrony and the phylotypic period. Richardson MK. **Dev Biol** 1995 Dec;172(2):412–21 (86 ref.)

Vertebrate gastrulation and axial patterning: editorial overview, Part 2. Magnuson T, et al. **Dev Genet** 1995; 17(2):103–6 (43 ref.)

Invertebrate versus vertebrate neurogenesis: variations on the same theme? Salzberg A, et al. **Dev Genet** 1996;18(1):1–10 (128 ref.)

Evolutionary developmental biology of the tetrapod limb. Hinchliffe JR. **Dev Suppl** 1994;:163–8 (115 ref.)

Bone morphogenetic proteins: multifunctional regulators of vertebrate development. Hogan BL. **Genes Dev** 1996 Jul 1;10(13):1580–94 (160 ref.)

Developmental biology of the vertebrate heart. Icardo JM.

J Exp Zool 1996 Jun 1-15;275(2-3):144-61 (175 ref.)
Patterning of the vertebrate neural crest. Bronner-Fraser M. Perspect Dev Neurobiol 1995;3(1):53-62 (47 ref.)
Regionalization of the forebrain from neural plate to neural tube. Papalopulu N. Perspect Dev Neurobiol 1995; 3(1):39-52 (125 ref.)
Mechanisms and molecules controlling the development of retinal maps. Roskies A, et al. Perspect Dev Neurobiol 1995; 3(1):63-75 (122 ref.)
Genetic control of segmentation in the vertebrate hindbrain. Wilkinson DG. Perspect Dev Neurobiol 1995;3(1):29-38 (54 ref.)
Retinoic acid and pattern formation in vertebrates. Conlon RA. Trends Genet 1995 Aug;11(8):314-9 (53 ref.)
Induction and patterning of the vertebrate nervous system. Kelly OG, et al. Trends Genet 1995 Jul;11(7):273-8 (62 ref.)
[HN7-3/fork head (winged-helix) transcription factor family in dorso-ventral pattern formation of vertebrate embryos] Sasaki H. Seikagaku 1995 Oct;67(10):1218-21 (15 ref.) (Jpn)

GENETICS

MHox and vertebrate skeletogenesis: the long and the short of it. Brickell PM. Bioessays 1995 Sep;17(9):750-3 (31 ref.)
Homeobox genes in vertebrate gastrulation. Boncinelli E, et al. Curr Opin Genet Dev 1995 Oct;5(5):619-27 (58 ref.)
Vertebrate Hox genes and proliferation: an alternative pathway to homeosis? Duboule D. Curr Opin Genet Dev 1995 Aug;5(4):525-8 (17 ref.)
Hox genes and chordate evolution. Holland PW, et al. Dev Biol 1996 Feb 1;173(2):382-95 (75 ref.)
The origin of vertebrate limbs. Coates MI. Dev Suppl 1994; :169-80 (116 ref.)
A class act: conservation of homeodomain protein functions. Manak JR, et al. Dev Suppl 1994;:61-77 (230 ref.)
Isolation and characterization of vertebrate lysozyme genes. Irwin DM, et al. EXS 1996;75:225-41 (71 ref.)
Studies of DNA methylation in animals. Bird A, et al. J Cell Sci Suppl 1995;19:37-9 (23 ref.)
Concerted evolution of repetitive DNA sequences in eukaryotes. Elder JF Jr, et al. Q Rev Biol 1995 Sep; 70(3):297-320 (146 ref.)
When cells stop making sense: effects of nonsense codons on RNA metabolism in vertebrate cells. Maquat LE. RNA 1995 Jul;1(5):453-65 (110 ref.)
Retinoic acid and pattern formation in vertebrates. Conlon RA. Trends Genet 1995 Aug;11(8):314-9 (53 ref.)

GROWTH & DEVELOPMENT

Programmed cell death in development. Sanders EJ, et al. Int Rev Cytol 1995;163:105-73 (410 ref.)

IMMUNOLOGY

Peptides as weapons against microorganisms in the chemical defense system of vertebrates. Nicolas P, et al. Annu Rev Microbiol 1995;49:277-304 (116 ref.)
Evolution and developmental regulation of the major histocompatibility complex. Salter-Cid L, et al. Crit Rev Immunol 1995;15(1):31-75 (389 ref.)
New insights into V(D)J recombination and its role in the evolution of the immune system. Thompson CB. Immunity 1995 Nov;3(5):531-9 (104 ref.)
IgY: clues to the origins of modern antibodies. Warr GW, et al. Immunol Today 1995 Aug;16(8):392-8 (42 ref.)

METABOLISM

Retinoic acid synthesizing enzymes in the embryonic and adult vertebrate. McCaffery P, et al. Adv Exp Med Biol 1995;372:173-83 (45 ref.)
Presynaptic GABAA receptors in vertebrate synapses. Xi ZX, et al. Kurume Med J 1996;43(2):115-22 (84 ref.)
Peptidergic neurons in the vertebrate spinal cord: evolutionary trends. Brodin L, et al. Prog Brain Res 1995; 104:61-74 (119 ref.)

PARASITOLOGY

The genus Hepatozoon (Apicomplexa: Adeleina). Smith TG. J Parasitol 1996 Aug;82(4):565-85 (118 ref.)

PHYSIOLOGY

Regeneration in the vertebrate central nervous system: phylogeny, ontogeny, and mechanisms. Larner AJ, et al. Biol Rev Camb Philos Soc 1995 Nov;70(4):597-619 (159 ref.)
The dorsal thalamus of jawed vertebrates: a comparative viewpoint. Butler AB. Brain Behav Evol 1995; 46(4-5):209-23 (115 ref.)
Neurotransmitter organization and connectivity of the basal ganglia in vertebrates: implications for the evolution of basal ganglia. Medina L, et al. Brain Behav Evol 1995; 46(4-5):235-58 (214 ref.)
A segmental morphological paradigm for understanding vertebrate forebrains. Puelles L. Brain Behav Evol 1995; 46(4-5):319-37 (145 ref.)
Molecular genetic analysis of circadian rhythms in vertebrates and invertebrates. Sehgal A. Curr Opin Neurobiol 1995 Dec;5(6):824-31 (73 ref.)
Ras target proteins in eukaryotic cells. Marshall MS. FASEB J 1995 Oct;9(13):1311-8 (78 ref.)
The relevance of cell microenvironments for the appearance of lympho-haemopoietic tissues in primitive vertebrates. Zapata AG, et al. Histol Histopathol 1995 Jul;10(3):761-78 (82 ref.)
Comparative aspects of regulation and function of the adrenal complex in different groups of vertebrates. Hanke W, et al. Horm Metab Res 1995 Sep;27(9):389-97 (29 ref.)
The pineal gland: structural and functional diversity. Shedpure M, et al. Indian J Exp Biol 1995 Sep;33(9):625-40 (80 ref.)
Gravity, blood circulation, and the adaptation of form and function in lower vertebrates. Lillywhite HB. J Exp Zool 1996 Jun 1-15;275(2-3):217-25 (37 ref.)
Epilogue: comparative cardiovascular biology of lower vertebrates. Muñoz-Chápuli R, et al. J Exp Zool 1996 Jun 1-15;275(2-3):249-51 (16 ref.)
Hypothalamic integration of body fluid regulation. Denton DA, et al. Proc Natl Acad Sci U S A 1996 Jul 9; 93(14):7397-404 (80 ref.)
Dynamics of the vortex wakes of flying and swimming vertebrates. Rayner JM. Symp Soc Exp Biol 1995;49:131-55 (103 ref.)
[Morphologic adaptation of the vertebrate eye to the environment] Puzzolo D. Arch Ital Anat Embriol 1994 Oct-Dec;99(4):17-100 (250 ref.) (Ita)
[Cell sources, regulatory factors and gene expression in the regeneration of the crystalline lens and retina in vertebrate animals] Mitashov VI. Izv Akad Nauk Ser Biol 1996 May-Jun;(3):298-318 (183 ref.) (Eng. Abstr.) (Rus)
[The urodelean retina as a model for studying the retinal regeneration potentials of other vertebrates] Grigorian EN. Ontogenez 1996 May-Jun;27(3):173-85 (117 ref.) (Eng. Abstr.) (Rus)
[A morphofunctional analysis of the nuclear apparatus of the nonapeptidergic neurosecretory cells in the vertebrate hypothalamus] Polenov AL, et al. Tsitologiia 1996; 38(1):28-38 (55 ref.) (Eng. Abstr.) (Rus)
[The evolution of the synapses in the vertebrate central nervous system (a topical paper)] Motorina MV. Zh Evol Biokhim Fiziol 1995 Jan-Feb;31(1):3-13 (68 ref.) (Eng. Abstr.) (Rus)

VERTEBROBASILAR INSUFFICIENCY

DIAGNOSIS

[Dissection of the carotid artery and vertebral artery--diagnosis and therapy] Sperling W, et al. Fortschr Neurol Psychiatr 1996 Apr;64(4):153-60 (37 ref.) (Eng. Abstr.) (Ger)

ETIOLOGY

Vertebrobasilar thrombosis associated with nonpenetrating cervical spine trauma. Prabhu V, et al. J Trauma 1996 Jan; 40(1):130-7 (59 ref.)

PATHOLOGY

Anatomy of segmental duplication in the human basilar artery. Possible site of aneurysm formation. De Caro R, et al. Clin Neuropathol 1995 Nov-Dec;14(6):303-9 (35 ref.)

VERTICAL TRANSMISSION see DISEASE TRANSMISSION, VERTICAL

VERTICILLIUM see HYPHOMYCETES

VERTIGO

Benign paroxysmal positional vertigo: the canalith repositioning procedure. Bernard ME, et al. Am Fam Physician 1996 Jun;53(8):2613-6, 2621 (05 ref.)

CHEMICALLY INDUCED

Antivertigo medications and drug-induced vertigo. A pharmacological review. Rascol O, et al. Drugs 1995 Nov; 50(5):777-91 (112 ref.)

COMPLICATIONS

Benign paroxysmal positional vertigo. Gordon N. Br J Clin Pract 1996 Jun;50(4):208-10 (17 ref.)
Cogan's syndrome: ophthalmic, audiovestibular, and systemic manifestations and therapy. Chynn EW, et al. Int Ophthalmol Clin 1996 Winter;36(1):61-72 (46 ref.)

DIAGNOSIS

Office management of common neurologic problems. Moe PG. Compr Ther 1995 Sep;21(9):513-8 (16 ref.)
Recent advances in clinical neurotology. Baloh RW, et al. J Vestib Res 1995 Jul-Aug;5(4):231-52 (97 ref.)

DRUG THERAPY

Antivertigo medications and drug-induced vertigo. A pharmacological review. Rascol O, et al. Drugs 1995 Nov; 50(5):777-91 (112 ref.)

ETIOLOGY

Phobic postural vertigo. Brandt T. Neurology 1996 Jun; 46(6):1515-9 (31 ref.)
[Vertigo. The most frequent forms] Brandt T. Internist (Berl) 1995 Nov;36(11):1105-13 (16 ref.) (Ger)

PHYSIOPATHOLOGY

[Benign paroxysmal positional vertigo] Wolf M. Harefuah 1995 Dec 1;129(11):494-8 (42 ref.) (Heb)

SURGERY

[Vestibular nerve section for medically uncontrollable vertigo with Menière's disease] Kohmura E, et al. No Shinkei Geka 1995 Sep;23(9):767-72 (18 ref.) (Jpn)

THERAPY

Benign paroxysmal positional vertigo: analysis of 44 cases treated by the canalith repositioning procedure of Epley. Weider DJ, et al. Am J Otol 1994 May;15(3):321-6 (44 ref.)
Office management of common neurologic problems. Moe PG. Compr Ther 1995 Sep;21(9):513-8 (16 ref.)

VERTIGO, AURAL see MENIERE'S DISEASE

VERY-LOW-DENSITY LIPOPROTEINS see LIPOPROTEINS, VLDL

VESICAL CALCULI see BLADDER CALCULI

VESICAL FISTULA see BLADDER FISTULA

VESICANTS see IRRITANTS

VESICATION see BLISTER

VESICO-URETERAL REFLUX

[Obstructive and reflux nephropathy] Orikasa S, et al. Nippon Rinsho 1995 Aug;53(8):2019-26 (18 ref.) (Eng. Abstr.) (Jpn)

DIAGNOSIS

The current status of screening for vesicoureteral reflux. Noe HN. Pediatr Nephrol 1995 Oct;9(5):638-41 (16 ref.)

PHYSIOPATHOLOGY

[Vesico-ureteral reflux; causes, diagnosis and treatment] Scholtmeijer RJ. Ned Tijdschr Geneeskd 1995 Nov 11; 139(45):2299-302 (16 ref.) (Dut)

PREVENTION & CONTROL

[Primary vesico-ureteral reflux. Current data and perspectives (editorial)] Lottmann H, et al. Presse Med 1996 Feb 10;25(5):185-7 (8 ref.) (Eng. Abstr.) (Fre)

SURGERY

Initial experience with retroperitoneoscopic nephroureterectomy: use of a double-balloon technique. Gill IS, et al. Urology 1995 Nov;46(5):747-50 (22 ref.)
[Lich-Gregoir ureteroneocystostomy: experience of a North-American pediatric center] Leblanc B, et al. Ann Chir 1995;49(8):685-8 (17 ref.) (Eng. Abstr.) (Fre)
[Current status of laparoscopic surgery in pediatric urology] Fuchs GJ, et al. Urologe A 1996 May;35(3):175-84 (62 ref.) (Eng. Abstr.) (Ger)

THERAPY

[Endoscopic treatment of vesicoureterorenal reflux in the child] Frey P. Urologe A 1996 Mar;35(2):97-103 (26 ref.) (Eng. Abstr.) (Ger)

VESICOSTOMY see CYSTOSTOMY

VESICOVAGINAL FISTULA

EPIDEMIOLOGY

[Epidemiologic and therapeutic features of urogenital fistulae in Guinea (Conakry)] Guirassy S, et al. Prog Urol 1995 Nov;5(5):684-9 (21 ref.) (Eng. Abstr.) (Fre)

THERAPY

[Epidemiologic and therapeutic features of urogenital fistulae in Guinea (Conakry)] Guirassy S, et al. Prog Urol 1995 Nov;5(5):684-9 (21 ref.) (Eng. Abstr.) (Fre)

VESICULAR SKIN DISEASES see SKIN DISEASES, VESICULOBULLOUS

VESICULOBULLOUS SKIN DISEASES see SKIN DISEASES, VESICULOBULLOUS

VESPID VENOMS see WASP VENOMS

VESTIBULAR APPARATUS see VESTIBULE

VESTIBULAR AQUEDUCT

Large vestibular aqueduct syndrome with massive endolymphatic sacs. Reussner LA, et al. Otolaryngol Head Neck Surg 1995 Nov;113(5):606-10 (14 ref.)

VESTIBULAR DISEASES

VESTIBULAR DISEASES

DIAGNOSIS

Neurotology. Baloh RW, et al. **Neurol Clin** 1996 Feb; 14(1):85–101 (22 ref.)

Assessment: electronystagmography. Report of the Therapeutics and Technology Assessment Subcommittee. **Neurology** 1996 Jun;46(6):1763–6 (9 ref.)

Large vestibular aqueduct syndrome with massive endolymphatic sacs. Reussner LA, et al. **Otolaryngol Head Neck Surg** 1995 Nov;113(5):606–10 (14 ref.)

ETIOLOGY

Preservation of auditory and vestibular function after surgical removal of bilateral vestibular schwannomas in a patient with neurofibromatosis type 2. Black FO, et al. **Am J Otol** 1995 Jul;16(4):431–43 (51 ref.)

Audiovestibular complications of non-otological surgery. Mahoney CF, et al. **Clin Otolaryngol** 1995 Dec;20(6):510–6 (53 ref.)

VESTIBULAR FUNCTION TESTS

Investigations of disorders of balance. Rudge P, et al. **J Neurol Neurosurg Psychiatry** 1995 Dec;59(6):568–78 (70 ref.)

INSTRUMENTATION

New diagnostic tests for the function of utricles, saccules and somatic graviceptors. Mittelstaedt H. **Acta Otolaryngol Suppl (Stockh)** 1995;520 Pt 1:188–93 (5 ref.)

VESTIBULAR HAIR CELLS see **HAIR CELLS, VESTIBULAR**

VESTIBULAR NERVE

The choice of approach in surgery for acoustic neuromas (vestibular schwannomas). Thomsen J, et al. **Tokai J Exp Clin Med** 1994 Dec;19(3–6):93–101 (18 ref.)

SURGERY

[Vestibular nerve section for medically uncontrollable vertigo with Menière's disease] Kohmura E, et al. **No Shinkei Geka** 1995 Sep;23(9):767–72 (18 ref.) **(Jpn)**

VESTIBULE

ANATOMY & HISTOLOGY

Balance and equilibrium, I: The vestibule and semicircular canals. Swartz JD, et al. **AJNR Am J Neuroradiol** 1996 Jan;17(1):17–21 (12 ref.)

DRUG EFFECTS

Auditory and vestibular functions after single or combined exposure to toluene: a review. Morata TC, et al. **Arch Toxicol** 1995;69(7):431–43 (106 ref.)

EMBRYOLOGY

Development of second-order vestibular projections in the chicken embryo. Glover JC. **Ann N Y Acad Sci** 1996 Jun 19;781:13–20 (12 ref.)

PHYSIOLOGY

Evidence of somatic graviception from new and classical investigations. Mittelstaedt H. **Acta Otolaryngol Suppl (Stockh)** 1995;520 Pt 1:186–7 (5 ref.)

Activation of immediate early genes by vestibular stimulation. Kaufman GD. **Ann N Y Acad Sci** 1996 Jun 19;781:437–442 (12 ref.)

Adaptation in the oculomotor response to caloric irrigation and the merits of bithermal stimulation [see comments] Barnes G. **Br J Audiol** 1995 Apr;29(2):95–106 (22 ref.) Comment in: Br J Audiol 1995 Apr;29(2):83–6.

Comparison of assessment of caloric nystagmus by observation of duration and by electronystagmographic measurement of slow-phase velocity [see comments] Luxon L. **Br J Audiol** 1995 Apr;29(2):107–15 (29 ref.) Comment in: Br J Audiol 1995 Apr;29(2):83–6.

The caloric stimulus: mechanisms of heat transfer [see comments] O'Neill G. **Br J Audiol** 1995 Apr;29(2):87–94 (21 ref.) Comment in: Br J Audiol 1995 Apr;29(2):83–6.

Molecular machinery of auditory and vestibular transduction. Gillespie PG. **Curr Opin Neurobiol** 1995 Aug;5(4):449–55 (62 ref.)

'Vestibular compensation': neural plasticity and its relations to functional recovery after labyrinthine lesions in frogs and other vertebrates. Dieringer N. **Prog Neurobiol** 1995 Jun;46(2–3):97–129 (225 ref.)

VESTIBULOCOCHLEAR NERVE see **ACOUSTIC NERVE**

VETERANS

Access to and patterns of use of oral health care among elderly veterans. Gilbert GH. **Med Care** 1995 Nov;33(11 Suppl):NS78–89 (58 ref.)

Functionally dependent veterans. Issues related to providing and improving their oral health care. Henry RG. **Med Care** 1995 Nov;33(11 Suppl):NS143–63 (82 ref.)

PSYCHOLOGY

Critical interaction therapy: couples therapy in combat-related posttraumatic stress disorder. Johnson DR, et al. **Fam Process** 1995 Dec;34(4):401–12 (16 ref.)

STATISTICS & NUMERICAL DATA

Research issues related to the oral health status of aging veterans. Gibson G, et al. **Med Care** 1995 Nov;33(11 Suppl):NS45–56 (46 ref.)

VETERANS ADMINISTRATION (U.S.) see **UNITED STATES DEPARTMENT OF VETERANS AFFAIRS**

VETERANS HOSPITALS see **HOSPITALS, VETERANS**

VETERINARIANS

Eastern barred bandicoot recovery: the role of the veterinarian in the management of endangered species. Seebeck J, et al. **Aust Vet J** 1996 Mar;73(3):81–3 (21 ref.)

VETERINARY CLINICS see **HOSPITALS, ANIMAL**

VETERINARY HOSPITALS see **HOSPITALS, ANIMAL**

VETERINARY MEDICINE

see related
ANIMAL DISEASES

Overview: bridging basic science and clinical medicine. Dodds WJ. **Adv Vet Sci Comp Med** 1995;39:1–28 (91 ref.)

Veterinary medical specialization. Lothrop CD Jr. **Adv Vet Sci Comp Med** 1995;39:141–90 (40 ref.)

Benefits and burdens: legal and ethical issues raised by veterinary specialization. Tannenbaum J. **Adv Vet Sci Comp Med** 1995;39:253–96 (31 ref.)

Registration of veterinary products in Argentina. Butler E, et al. **Rev Sci Tech** 1995 Dec;14(4):1121–31 (4 ref.) **(Eng, Spa)**

Models used in Australia in risk assessments for veterinary biologicals. Doyle KA. **Rev Sci Tech** 1995 Dec; 14(4):1021–42 (27 ref.)

Application of risk assessment to veterinary biologicals: the perspective of the animal health industry. Folkers C, et al. **Rev Sci Tech** 1995 Dec;14(4):1207–16 (5 ref.)

Models of risk assessments for biologicals or related products in the European Union. Moos M. **Rev Sci Tech** 1995 Dec; 14(4):1009–20 (6 ref.)

Risk analysis in the manufacture of veterinary biologicals. Moreau Y. **Rev Sci Tech** 1995 Dec;14(4):937–50 (10 ref.)

Risk analysis systems for veterinary biologicals: a regulator's tool box. Osborne CG, et al. **Rev Sci Tech** 1995 Dec; 14(4):925–35 (8 ref.)

Risk analysis methods and techniques for veterinary biologicals used in Australia. Owusu J. **Rev Sci Tech** 1995 Dec;14(4):1083–96 (9 ref.)

Risk analysis for the importation of veterinary biologicals into the United States of America. Roth HJ, et al. **Rev Sci Tech** 1995 Dec;14(4):1061–72 (6 ref.)

Risk analysis for veterinary biologicals released into the environment. Silva SV, et al. **Rev Sci Tech** 1995 Dec; 14(4):1043–59 (16 ref.)

Wildlife, people and development: veterinary contributions to wildlife health and resource management in Africa. Kock MD. **Trop Anim Health Prod** 1996 Feb;28(1):68–80 (28 ref.)

The Centre for Tropical Veterinary Medicine (CTVM) pulling its weight in the field of draught animal research. Pearson RA, et al. **Trop Anim Health Prod** 1996 Feb; 28(1):49–59 (40 ref.)

Microbiological research at the Centre for Tropical Veterinary Medicine (CTVM). Scott GR. **Trop Anim Health Prod** 1996 Feb;28(1):40–8 (24 ref.)

Australian–Indonesian collaboration in veterinary arbovirology—a review. Daniels PW, et al. **Vet Microbiol** 1995 Sep;46(1–3):151–74 (108 ref.)

[What are the rules?] Zwart D. **Tijdschr Diergeneeskd** 1995 Sep 15;120(18):536–42 (55 ref.) **(Dut)**

[The importance of tropical animal hygiene for indigenous animal production] Böhnel H. **Berl Munch Tierarztl Wochenschr** 1995 Dec;108(12):443–6 (6 ref.) (Eng. Abstr.) **(Ger)**

ECONOMICS

Changing the way we practice: how to thrive and not just survive in veterinary medicine. Becker M. **Vet Q** 1995 Apr; 17 Suppl 1:S49–50 (0 ref.)

ORGANIZATION & ADMINISTRATION

Group decision making. Palazzolo C. **J Am Vet Med Assoc** 1996 Aug 1;209(3):566–9 (11 ref.)

[The organization of veterinary services in African animal husbandry systems: chances for the exchange of interdisciplinary learning processes] Kirk M. **Berl Munch Tierarztl Wochenschr** 1995 Dec;108(12):447–50 (16 ref.) (Eng. Abstr.) **(Ger)**

STANDARDS

Standards for veterinary clinical trials. Boothe DM, et al. **Adv Vet Sci Comp Med** 1995;39:191–252 (46 ref.)

Recommended biocontainment features for research and diagnostic facilities where animal pathogens are used. First International Veterinary Biosafety Workshop. Barbeito MS, et al. **Rev Sci Tech** 1995 Sep;14(3):873–87 (8 ref.)

Risk assessment related to veterinary biologicals: specific issues in developing nations. Ward DE. **Rev Sci Tech** 1995 Dec;14(4):991–1007 (35 ref.)

TRENDS

ICNV 1966 to ICTV 1994: the contribution of veterinary virology. Fenner F. **Vet Microbiol** 1995 Sep;46(1–3):3–13 (27 ref.)

[Sonographic possibilities in emergency medicine] Gerwing M, et al. **Berl Munch Tierarztl Wochenschr** 1996 Apr; 109(4):123–9 (37 ref.) (Eng. Abstr.) **(Ger)**

VIBRATION

ADVERSE EFFECTS

ABC of work related disorders. Occupational hearing loss and vibration induced disorders. Jones CM. **BMJ** 1996 Jul 27;313(7051):223–6 (0 ref.)

[Clinical picture of vibration syndrome and diagnostic principles] Iżycki J. **Med Pr** 1996;47(3):277–83 (17 ref.) (Eng. Abstr.) **(Pol)**

THERAPEUTIC USE

Adjunctive ventilation with tracheal gas insufflation—good vibrations? [editorial; comment] Marini JJ. **Crit Care Med** 1996 Mar;24(3):375–8 (27 ref.) Comment on: Crit Care Med 1996 Mar;24(3):451–7.

VIBRIO

ENZYMOLOGY

Predicted structure and possible ionmotive mechanism of the sodium-linked NADH-ubiquinone oxidoreductase of Vibrio alginolyticus. Rich PR, et al. **FEBS Lett** 1995 Nov 13;375(1–2):5–10 (42 ref.)

GENETICS

Transcriptional regulation of bioluminesence genes from Vibrio fischeri. Sitnikov DM, et al. **Mol Microbiol** 1995 Sep;17(5):801–12 (84 ref.)

METABOLISM

Transcriptional regulation of bioluminesence genes from Vibrio fischeri. Sitnikov DM, et al. **Mol Microbiol** 1995 Sep;17(5):801–12 (84 ref.)

Biochemistry of bacterial bioluminescence. Tu SC, et al. **Photochem Photobiol** 1995 Oct;62(4):615–24 (106 ref.)

PATHOGENICITY

Winner of the Theodore E. Woodward Clinical Award. Monster of the Chesapeake Bay—Vibrio vulnificus. Calia FM. **Trans Am Clin Climatol Assoc** 1994;106:49–56; discussion 56–7 (31 ref.)

PHYSIOLOGY

The viable but non-culturable state in the human pathogen Vibrio vulnificus. Oliver JD. **FEMS Microbiol Lett** 1995 Nov 15;133(3):203–8 (22 ref.)

VIBRIO CHOLERAE

see related
CHOLERA TOXIN

CLASSIFICATION

[Epidemic of cholera due to a new serogroup Vibrio cholerae O139 Bengal] Shimada T, et al. **Nippon Saikingaku Zasshi** 1995 Oct;50(4):1005–17 (70 ref.) **(Jpn)**

GENETICS

Epidemiology & molecular biology of Vibrio cholerae O139 Bengal. Albert MJ. **Indian J Med Res** 1996 Jul;104:14–27 (53 ref.)

Molecular insights into the evolution & epidemiology of Vibrio cholerae. Nair GB. **Indian J Med Res** 1996 Jul; 104:5–13 (73 ref.)

METABOLISM

[Adhesins from Vibrio cholerae: phenotypic analysis and genetic control of synthesis] Smirnova NI. **Mol Gen Mikrobiol Virusol** 1995 Jul–Sep;(3):18–26 (80 ref.) (Eng. Abstr.) **(Rus)**

PATHOGENICITY

Adherence & colonization properties of Vibrio cholerae & diarrhoeagenic Escherichia coli. Ghose AC.

Indian J Med Res 1996 Jul;104:38–51 (160 ref.)

PHYSIOLOGY

An ace up the sleeve of the cholera bacterium. Richardson SH, et al. **Nat Med** 1996 Aug;2(8):853–5 (8 ref.)

VIBRIO COMMA see **VIBRIO CHOLERAE**

VIBRIO FETUS see **CAMPYLOBACTER FETUS**

VIBRIO INFECTIONS

DIAGNOSIS

Lower extremity manifestations of Vibrio vulnificus infection. Laughlin TJ, et al. **J Foot Ankle Surg** 1995 Jul–Aug;34(4):354–7 (19 ref.)

VIBRIONACEAE

ISOLATION & PURIFICATION

Plesiomonas shigelloides septicemia: case report and literature review. Lee AC, et al. **Pediatr Hematol Oncol** 1996 May–Jun;13(3):265–9 (23 ref.)

METABOLISM

Biochemistry of bacterial bioluminescence. Tu SC, et al. **Photochem Photobiol** 1995 Oct;62(4):615–24 (106 ref.)

VIDARABINE

ANALOGS & DERIVATIVES

[Fludarabine in the treatment of chronic lymphocytic leukemia and other lymphoproliferative disorders] Pawelski S. **Acta Haematol Pol** 1995;26(3):263–8 (32 ref.) (Eng. Abstr.) **(Pol)**

VIDARABINE MONOPHOSPHATE see **VIDARABINE PHOSPHATE**

VIDARABINE PHOSPHATE

ANALOGS & DERIVATIVES

Tumor lysis syndrome induced by fludarabine monophosphate: a case report [letter] Nakhoul F, et al. **Eur J Haematol** 1996 Apr;56(4):254–5 (12 ref.)

VIDEO DISPLAY TERMINALS see **COMPUTER TERMINALS**

VIDEO MICROSCOPY see **MICROSCOPY, VIDEO**

VIDEO RECORDING

Video-assisted thoracic surgery: the current state of the art. Kaiser LR, et al. **AJR Am J Roentgenol** 1995 Nov; 165(5):1111–7 (35 ref.)

Videothoracoscopic operations for bullous lung disease. Jacques LF. **Chest Surg Clin N Am** 1995 Nov;5(4):751–63 (29 ref.)

Time-lapse cinephotomicrography, videography, and videomicrography of the avian blastoderm. Bortier H, et al. **Methods Cell Biol** 1996;51:331–54 (18 ref.)

Videourodynamic studies. McGuire EJ, et al. **Urol Clin North Am** 1996 May;23(2):309–21 (13 ref.)

[Traumatic hemothorax treated by video-assisted thoracoscopic surgery] Freixinet J, et al. **Arch Bronconeumol** 1995 Oct;31(8):424–5 (10 ref.) (Eng. Abstr.) **(Spa)**

INSTRUMENTATION

[Simultaneous video radiography and "solid state" intraluminal pharyngeal manometry during barium swallow; video manometry] Olsson R, et al. **Radiologe** 1995 Oct;35(10):753–8 (46 ref.) (Eng. Abstr.) **(Ger)**

[Videocinematography of swallowing. Indications, methodology and findings] Pokieser P, et al. **Radiologe** 1995 Oct;35(10):703–11 (9 ref.) (Eng. Abstr.) **(Ger)**

[Laparoscopic technique--which developments are possible?] Voges U. **Urologe A** 1996 May;35(3):208–14 (6 ref.) (Eng. Abstr.) **(Ger)**

VIDEOMICROSCOPY see **MICROSCOPY, VIDEO**

VIDEOTAPE RECORDING

[Advance of endoscopic surgery--practical technique by video and its replacement of conventional surgery] Fujimoto S, et al. **Hokkaido Igaku Zasshi** 1995 May; 70(3):357–8 (0 ref.) (Eng. Abstr.) **(Jpn)**

VIDINE see **CHOLINE**

VIGILANCE, CORTICAL see **AROUSAL**

VILLAGE HEALTH WORKER see **COMMUNITY HEALTH AIDES**

VINBLASTINE

ANALOGS & DERIVATIVES

Vinorelbine: a new antineoplastic drug for the treatment of non-small-cell lung cancer. Jones SF, et al. **Ann Pharmacother** 1996 May;30(5):501–6 (29 ref.)

Vinorelbine: an overview. Johnson SA, et al. **Cancer Treat Rev** 1996 Mar;22(2):127–42 (88 ref.)

Current status of vinorelbine for breast cancer. Smith GA. **Oncology (Huntingt)** 1995 Aug;9(8):767–73; discussion 774, 776, 779 (41 ref.)

Update: vinorelbine (navelbine) in non-small cell lung cancer. Crawford J. **Semin Oncol** 1996 Apr;23(2 Suppl 5):2–7 (24 ref.)

VINCA ALKALOIDS

ADMINISTRATION & DOSAGE

Errors involving pediatric patients receiving chemotherapy: a literature review. Trinkle R, et al. **Med Pediatr Oncol** 1996 May;26(5):344–51 (47 ref.)

PHARMACOLOGY

[Pharmacology of Catharanthus alkaloids] Levêque D, et al. **Bull Cancer (Paris)** 1996 Mar;83(3):176–86 (90 ref.) (Eng. Abstr.) **(Fre)**

VINCALEUKOBLASTINE see **VINBLASTINE**

VINCENT'S INFECTION see **GINGIVITIS, NECROTIZING ULCERATIVE**

VINCRISTINE

PHARMACOLOGY

The comparative clinical pharmacology of vincristine and vindesine: does vindesine offer any advantage in clinical use? Joel S. **Cancer Treat Rev** 1996 Nov;21(6):513–25 (75 ref.)

VINDESINE

PHARMACOLOGY

The comparative clinical pharmacology of vincristine and vindesine: does vindesine offer any advantage in clinical use? Joel S. **Cancer Treat Rev** 1996 Nov;21(6):513–25 (75 ref.)

THERAPEUTIC USE

The role of vindesine in oncology--recommendations after 10 years' experience. Dancey J, et al. **Anticancer Drugs** 1995 Oct;6(5):625–36 (122 ref.)

Progress in preclinical and clinical studies for the development of new anticancer drugs in Japan, with emphasis on taxanes. Saijo N, et al. **Cancer Chemother Pharmacol** 1996;38 Suppl:S11–5 (21 ref.)

VINYL CHLORIDE

TOXICITY

Quantitative cancer assessment for vinyl chloride: indications of early-life sensitivity. Cogliano VJ, et al. **Toxicology** 1996 Jul 17;111(1–3):21–8 (11 ref.)

VINYL CHLORIDE POLYMER see **POLYVINYL CHLORIDE**

VIOLENCE

see related
BATTERED WOMEN

Cultural-societal roots of violence. The examples of genocidal violence and of contemporary youth violence in the United States. Staub E. **Am Psychol** 1996 Feb; 51(2):117–32 (122 ref.)

Spousal abuse and violence against women: the significance of understanding attachment. Vazquez CI. **Ann N Y Acad Sci** 1996 Jun 18;789:119–28 (26 ref.)

Pervasive media violence. Schooler C, et al. **Annu Rev Public Health** 1996;17:275–98 (216 ref.)

Violence, crime, and mental illness. How strong a link? [editorial] Marzuk PM. **Arch Gen Psychiatry** 1996 Jun; 53(6):481–6 (51 ref.)

Violence in the health care environment. Gregg CM, et al. **Arch Otolaryngol Head Neck Surg** 1996 Jan;122(1):11–6 (19 ref.)

Violence among children and adolescents and the role of the pediatrician. Dukarm CP, et al. **Bull N Y Acad Med** 1995 Summer;72(1):5–15 (38 ref.)

Violence as a public health issue. Satcher D. **Bull N Y Acad Med** 1995 Summer;72(1):46–56 (30 ref.)

Risk-taking and abusive behaviors among ethnic minorities. Yee BW, et al. **Health Psychol** 1995 Dec;14(7):622–31 (100 ref.)

Violence: the scientific medical perspective. Pincus JH. **Isr J Med Sci** 1996 Jul;32(7):511–4 (24 ref.)

The impact of violence in the health care setting upon nursing education. Whitley GG, et al. **J Nurs Educ** 1996 May; 35(5):211–8 (46 ref.)

Growing up in a socially toxic environment: life for children and families in the 1990s. Garbarino J. **Nebr Symp Motiv** 1995;42:1–20 (37 ref.)

The perspectives of violent street gang injuries. Hutson HR, et al. **Neurosurg Clin N Am** 1995 Oct;6(4):621–8 (38 ref.)

Outward and inward directed aggressiveness: the interaction between violence and suicidality. Plutchik R. **Pharmacopsychiatry** 1995 Oct;28 Suppl 2:47–57 (58 ref.)

Sociocultural and therapeutic perspectives on violence. Blue HC, et al. **Psychiatr Clin North Am** 1995 Sep;18(3):571–87 (103 ref.)

Sleep-related violence: a medical and forensic challenge. Broughton RJ, et al. **Sleep** 1995 Nov;18(9):727–30 (42 ref.)

Aggressive behavior in childhood and early adolescence: an ecological-developmental perspective on youth violence. Fraser MW. **Soc Work** 1996 Jul;41(4):347–61 (120 ref.)

[Violence towards pregnant women] Rasmussen KL, et al. **Ugeskr Laeger** 1996 Apr 22;158(17):2373–6 (35 ref.) (Eng. Abstr.) **(Dan)**

[Threats and physical violence at work] Laakkonen A, et al. **Duodecim** 1994;110(16):1510–6 (33 ref.) **(Fin)**

[Dangers and therapist obligations: Canadian perspective] Melançon G, et al. **Can J Psychiatry** 1995 Oct;40(8):474–8 (18 ref.) (Eng. Abstr.) **(Fre)**

[Identification of victims of violence and torture: the practitioner's role] Subilia L, et al. **Schweiz Med Wochenschr** 1996 Jul 27;126(30):1291–6 (20 ref.) (Eng. Abstr.) **(Fre)**

[Epilepsy and delinquent behavior] Arías Horcajadas F, et al. **Actas Luso Esp Neurol Psiquiatr Cienc Afines** 1995 Sep–Oct;23(5):235–40 (33 ref.) (Eng. Abstr.) **(Spa)**

PREVENTION & CONTROL

How safe is your ED? Keep NB, et al. **Am J Nurs** 1995 Sep;95(9):44–50; quiz 51 (5 ref.)

Preventing violence in a structurally violent society: mission impossible. Gil DG. **Am J Orthopsychiatry** 1996 Jan; 66(1):77–84 (18 ref.)

Preventing injuries from violence towards women [editorial] Davidson LL. **Am J Public Health** 1996 Jan;86(1):12–4 (24 ref.)

Firearm violence among youth: public health strategies for prevention. Powell EC, et al. **Ann Emerg Med** 1996 Aug; 28(2):204–12 (83 ref.)

Violence in children: the scope for prevention. Graham P. **Arch Dis Child** 1996 Mar;74(3):185–7 (23 ref.)

Healthcare violence. A nursing administration perspective. Claravall L. **J Nurs Adm** 1996 Feb;26(2):41–6 (29 ref.)

PSYCHOLOGY

Violence in children: the scope for prevention. Graham P. **Arch Dis Child** 1996 Mar;74(3):185–7 (23 ref.)

Dementia and guns [see comments] Mendez MF. **J Am Geriatr Soc** 1996 Apr;44(4):409–10 (10 ref.) Comment in: J Am Geriatr Soc 1996 Apr;44(4):467–9.

Relation of threatened egotism to violence and aggression: the dark side of high self-esteem. Baumeister RF, et al. **Psychol Rev** 1996 Jan;103(1):5–33 (175 ref.)

Psychosis and violence: the case for a content analysis of psychotic experience. Junginger J. **Schizophr Bull** 1996; 22(1):91–103 (50 ref.)

Male and female sexual victimization in dating relationships: gender differences in coercion techniques and outcomes. Waldner-Haugrud LK, et al. **Violence Vict** 1995 Fall; 10(3):203–15 (23 ref.)

[Violence--an element of the psychiatric profession] Cahn T. **Schweiz Arch Neurol Psychiatr** 1995;146(3):109–14 (25 ref.) (Eng. Abstr.) **(Ger)**

STATISTICS & NUMERICAL DATA

Evidence bearing on mental illness as a possible cause of violent behavior. Link BG, et al. **Epidemiol Rev** 1995; 17(1):172–81 (51 ref.)

Aggression against doctors: a review. Hobbs FD, et al. **J R Soc Med** 1996 Feb;89(2):69–72 (38 ref.)

[Epidemiology of violence in psychiatry] Ferrero F, et al. **Schweiz Arch Neurol Psychiatr** 1995;146(3):121–5 (28 ref.) (Eng. Abstr.) **(Fre)**

VIP see **VASOACTIVE INTESTINAL PEPTIDE**

VIP RECEPTORS see **RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE**

VIPERIDAE

[Snake bites] Vincent JL, et al. **Rev Med Brux** 1995 Nov; 16(5):349–52 (12 ref.) (Eng. Abstr.) **(Fre)**

VIPERINAE see **VIPERIDAE**

VIPOMA

DIAGNOSIS

[Metastasizing pancreatic vipoma. Its diagnosis and therapy with the somatostatin analog octreotide] Scheffold N, et al. **Dtsch Med Wochenschr** 1995 Oct 27;120(43):1463–7 (21 ref.) (Eng. Abstr.) **(Ger)**

VIPOMA

DRUG THERAPY

[Metastasizing pancreatic vipoma. Its diagnosis and therapy with the somatostatin analog octreotide] Scheffold N, et al. **Dtsch Med Wochenschr** 1995 Oct 27;120(43):1463–7 (21 ref.) (Eng. Abstr.) **(Ger)**

METABOLISM

[A case report of the VIP producing tumor with liver metastasis presenting WDHA syndrome] Inoue S, et al. **Nippon Shokakibyo Gakkai Zasshi** 1995 Aug;92(8):1217–22 (13 ref.) **(Jpn)**

VIRAL ANTIBODIES see **ANTIBODIES, VIRAL**

VIRAL ANTIGENS see **ANTIGENS, VIRAL**

VIRAL COAT PROTEINS see **CAPSID**

VIRAL CONJUNCTIVITIS see **CONJUNCTIVITIS, VIRAL**

VIRAL CORE PROTEINS

ANALYSIS

[Analysis of the mechanisms relating the localization of HCV core protein and hepatic injury—an immunohistochemical study] Masumoto T, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:174–8 (15 ref.) **(Jpn)**

CHEMISTRY

First glimpses at structure-function relationships of the nucleocapsid protein of retroviruses. Darlix JL, et al. **J Mol Biol** 1995 Dec 8;254(4):523–37 (140 ref.)

GENETICS

[Mutations in precore and core nucleotide sequence of hepatitis B virus correlated with fulminant and severe hepatitis] Ehata T, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:457–62 (10 ref.) **(Jpn)**

[Precore/core mutation and clinical course of chronic hepatitis B virus infection from the view point of asymptomatic carriers] Fujiwara K, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:401–5 (20 ref.) **(Jpn)**

[Changes in precore and core region of hepatitis B virus during the course of chronic hepatitis B virus carriers] Hamasaki K, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:411–4 (9 ref.) **(Jpn)**

[Nucleotide mutations in the precore and core region of hepatitis B virus] Karasawa T, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:52–7 (20 ref.) **(Jpn)**

[PCR-based genotyping with genotype-specific primers derived from the C gene of HCV genome] Okamoto H. **Nippon Rinsho** 1995 Sep;53 Suppl:312–20 (26 ref.) **(Jpn)**

IMMUNOLOGY

[Epitopes of hepatitis B virus nucleocapsid protein] Ehata T, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:148–54 (17 ref.) **(Jpn)**

[HCV core specific CTL and epitope] Kita H, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:156–62 (19 ref.) **(Jpn)**

[Serodiagnosis of HCV infection by means of HCV core antibodies (CP-9 Ab, CP-10 Ab)] Nagai K, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:224–9 (17 ref.) **(Jpn)**

[Quantitative assay of anti-HCV core antibody with JCC-2 ELISA: anti-HCV core IgG antibody] Nakashima T, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:247–52 (19 ref.) **(Jpn)**

[Antibodies generated against hepatitis C virus (HCV) core antigen: IgM and IgA antibody against HCV core] Sato S, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:253–9 (16 ref.) **(Jpn)**

[An assay system for ARIMA14 antibody] Sho Y, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:236–40 (14 ref.) **(Jpn)**

[Linear B cell epitopes located on core and NS3 regions of HCV] Ueda S. **Nippon Rinsho** 1995 Sep;53 Suppl:123–8 (21 ref.) **(Jpn)**

PHYSIOLOGY

First glimpses at structure-function relationships of the nucleocapsid protein of retroviruses. Darlix JL, et al. **J Mol Biol** 1995 Dec 8;254(4):523–37 (140 ref.)

ULTRASTRUCTURE

Computer modeling of prototypic and aberrant nucleocapsids of varicella-zoster virus. Grose C, et al. **Virology** 1995 Dec 20;214(2):321–9 (24 ref.)

URINE

Beta-core fragment (beta-core/UGF/UGP), a tumor marker: a 7-year report. Cole LA, et al. **Gynecol Oncol** 1996 Feb;60(2):264–70 (38 ref.)

VIRAL DNA see **DNA, VIRAL**

VIRAL ENCEPHALITIS see **ENCEPHALITIS, VIRAL**

VIRAL ENVELOPE PROTEINS

Pseudotyped retroviral vectors for studies of human gene therapy. Friedmann T, et al. **Nat Med** 1995 Mar;1(3):275–7 (29 ref.)

CHEMISTRY

Viral envelope glycoproteins swing into action. Stuart D, et al. **Structure** 1995 Jul 15;3(7):645–8 (27 ref.)

GENETICS

[Current status of the study on hepatitis C virus envelope region gene and its vaccine] Li Q, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1995 Nov; 29(6):363–5 (18 ref.) **(Chi)**

[Viral escape from humoral immune system by mutations in hypervariable region of HCV envelope protein and mechanism of persistent viral infection] Kato N, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:129–35 (13 ref.) **(Jpn)**

[Genetic heterogeneity and variability of hepatitis C virus and hypervariable regions] Kato N, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:64–70 (17 ref.) **(Jpn)**

[Processing of hepatitis C virus envelope proteins] Matsuura Y, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:51–6 (17 ref.) **(Jpn)**

IMMUNOLOGY

Human studies in the development of human immunodeficiency virus vaccines. Dolin R. **J Infect Dis** 1995 Nov;172(5):1175–83 (91 ref.)

[Hypervariable region specific formation of immune complexes in a plasma with quasispecies of hepatitis C virus] Hijikata M, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:150–5 (19 ref.) **(Jpn)**

METABOLISM

Entry and egress of varicella-zoster virus: role of mannose 6-phosphate, heparan sulfate proteoglycan, and signal sequences in targeting virions and viral glycoproteins. Zhu Z, et al. **Neurology** 1995 Dec;45(12 Suppl 8):S15–7 (9 ref.)

PHYSIOLOGY

Site directed mutagenesis of the murine coronavirus spike protein. Effects on fusion. Bos EC, et al. **Adv Exp Med Biol** 1995;380:283–6 (14 ref.)

VIRAL EYE INFECTIONS see **EYE INFECTIONS, VIRAL**

VIRAL FUSION GLYCOPROTEINS see **VIRAL FUSION PROTEINS**

VIRAL FUSION PROTEINS

GENETICS

Deletion mutants in human cytomegalovirus glycoprotein US9 are impaired in cell-cell transmission and in altering tight junctions of polarized human retinal pigment epithelial cells. Pereira L, et al. **Scand J Infect Dis Suppl** 1995;99:82–7 (42 ref.)

[Transactivation function of X gene-cellular gene fusion product or 3' truncated pre S2/S gene cellular gene fusion product from integrated hepatitis B virus DNA] Mita E, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:89–93 (15 ref.) **(Jpn)**

VIRAL GAG PROTEINS see **GENE PRODUCTS, GAG**

VIRAL GENE EXPRESSION REGULATION see **GENE EXPRESSION REGULATION, VIRAL**

VIRAL GENE PRODUCTS see **VIRAL PROTEINS**

VIRAL GENE PROTEINS see **VIRAL PROTEINS**

VIRAL GENES see **GENES, VIRAL**

VIRAL GENOME see **GENOME, VIRAL**

VIRAL HEPATITIS VACCINES

Hepatitis A vaccine. Bader TF. **Am J Gastroenterol** 1996 Feb;91(2):217–22 (41 ref.)

[Current status of the study on hepatitis C virus envelope region gene and its vaccine] Li Q, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1995 Nov; 29(6):363–5 (18 ref.) **(Chi)**

[Hepatitis A vaccine] Ring-Larsen H. **Ugeskr Laeger** 1995 Dec 11;157(50):7024–7 (26 ref.) **(Dan)**

[Development of hepatitis C virus vaccine] Matsuura Y, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:112–6 (18 ref.) **(Jpn)**

[Approaches to development of hepatitis A vaccine and unresolved issues] Odoh K. **Nippon Rinsho** 1995 Oct;53 Suppl:878–83 (18 ref.) **(Jpn)**

[Inactivated antihepatitis A vaccine] Escolar M, et al. **Rev Med Univ Navarra** 1995 Apr-Jun;40(2):110–4 (14 ref.) **(Spa)**

ADMINISTRATION & DOSAGE

Prevention of hepatitis A virus infection. Moyer L, et al. **Am Fam Physician** 1996 Jul;54(1):107–14 (27 ref.)

Preventing hepatitis A infections in travelers to endemic areas. Koff RS. **Am J Trop Med Hyg** 1995 Dec;53(6):586–90 (29 ref.)

[Hepatitis A vaccine] Ring-Larsen H. **Ugeskr Laeger** 1995 Dec 11;157(50):7024–7 (26 ref.) **(Dan)**

[Efficacy of immune serum globulin and hepatitis A vaccine with special reference to anti-HA antibody titers] Fujiyama S. **Nippon Rinsho** 1995 Oct;53 Suppl:884–91 (17 ref.) **(Jpn)**

[Vaccination against hepatitis A gives protection fast. Combination with gamma-globulin is probably unnecessary] Iwarson S. **Lakartidningen** 1996 May 22; 93(21):2045–6 (9 ref.) **(Swe)**

IMMUNOLOGY

Hepatitis A and B vaccines in children. Lieberman JM, et al. **Adv Pediatr Infect Dis** 1996;11:333–63 (131 ref.)

Hepatitis vaccines. Katkov WN. **Med Clin North Am** 1996 Sep;80(5):1189–200 (89 ref.)

THERAPEUTIC USE

[For whom is the hepatitis A vaccination in 1995? (editorial)] Buisson Y. **Gastroenterol Clin Biol** 1995 Oct;19(10):745–6 (18 ref.) **(Fre)**

VIRAL INSERTIONAL MUTAGENESIS see **MUTAGENESIS, INSERTIONAL**

VIRAL INTERFERENCE

see related
INTERFERONS

VIRAL M PROTEINS see **VIRAL MATRIX PROTEINS**

VIRAL MARKERS see **BIOLOGICAL MARKERS**

VIRAL MATRIX PROTEINS

BLOOD

The cytomegalovirus antigenemia assay: a plea for standardization. The TH, et al. **Scand J Infect Dis Suppl** 1995;99:25–9 (31 ref.)

METABOLISM

Influenza virus M2 protein and haemagglutinin conformation changes during intracellular transport. Ciampor F, et al. **Acta Virol** 1995 Jun;39(3):171–81 (41 ref.)

PHYSIOLOGY

Role of Epstein-Barr virus gene latent membrane protein in nasopharyngeal carcinoma. Nicholson LJ, et al. **Trends Microbiol** 1996 Apr;4(4):132–3 (21 ref.)

Negative-strand virus M and retrovirus MA proteins: all in a family? Lenard J. **Virology** 1996 Feb 15;216(2):289–98 (116 ref.)

VIRAL NONSTRUCTURAL PROTEINS

GENETICS

[Genotyping of hepatitis C virus by polymerase chain reaction with a mixed primer set derived from nucleotide sequences of NS5 region] Chayama K. **Nippon Rinsho** 1995 Sep;53 Suppl:321–5 (14 ref.) **(Jpn)**

IMMUNOLOGY

[C8-2 (NS5) antibody and epitope analysis] Nozaki C, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:230–5 (11 ref.) **(Jpn)**

[Induction of cytotoxic T cells specific for HCV-NS5 and cytokine] Shirai M, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:163–9 (17 ref.) **(Jpn)**

[Linear B cell epitopes located on core and NS3 regions of HCV] Ueda S. **Nippon Rinsho** 1995 Sep;53 Suppl:123–8 (21 ref.) **(Jpn)**

[Specific antibody assay for genotyping of hepatitis C virus] Yasui K, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:260–5 (13 ref.) **(Jpn)**

METABOLISM

Minute virus of mice cis-acting sequences required for genome replication and the role of the trans-acting viral protein, NS-1. Astell CR, et al. **Prog Nucleic Acid Res Mol Biol** 1996;55:245–85 (116 ref.)

VIRAL ONCOGENE PROTEINS see **ONCOGENE PROTEINS, VIRAL**

VIRAL PACKAGING see **VIRUS ASSEMBLY**

VIRAL PROTEINS

Proteins of bovine leukemia virus and human T-cell leukemia viruses. Hrušková-Heidingsfeldová O. **Folia Biol (Praha)** 1995;41(5):201–12 (66 ref.)

[RNA ligands for HIV proteins] Iwai S. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1430–7 (64 ref.) **(Jpn)**

ANALYSIS

Molecular diagnosis of nasopharyngeal carcinoma: a review. Gan YY, et al. **Ann Acad Med Singapore** 1996 Jan; 25(1):71–4 (32 ref.)

Immunohistochemical detection of hepatitis C virus-related proteins in liver tissue. Sansonno D, et al. **Clin Exp Rheumatol** 1995 Nov–Dec;13 Suppl 13:S29–32 (15 ref.)

BIOSYNTHESIS

Production of recombinant hantavirus nucleocapsid protein expressed in silkworm larvae and its use as a diagnostic antigen in detecting antibodies in serum from infected rats. Yoshimatsu K, et al. **Lab Anim Sci** 1995 Dec;45(6):641–6 (8 ref.)

CHEMICAL SYNTHESIS

[Chemical synthesis of nucleopeptide] Ueno Y, et al. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1342–8 (20 ref.) **(Jpn)**

CHEMISTRY

Structure and function of the rotavirus RNA-binding proteins. Patton JT. **J Gen Virol** 1995 Nov;76 (Pt 11):2633–44 (75 ref.)

Functional implications of protein-protein interactions in icosahedral viruses. Johnson JE. **Proc Natl Acad Sci U S A** 1996 Jan 9;93(1):27–33 (21 ref.)

GENETICS

Transcription of adenovirus RNA polymerase III genes. Pruzan R, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 1):201–26 (116 ref.)

[Expression of HCV proteins by using recombinant baculoviruses] Aizaki H, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:80–4 (16 ref.) **(Jpn)**

IMMUNOLOGY

DNA immunization with bovine herpesvirus-1 genes. Babiuk LA, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:47–63 (56 ref.)

Viral evasion of cytokine-mediated host defense mechanisms. Gribaudo G, et al. **G Batteriol Virol Immunol** 1994 Jan–Dec;86(1–12):3–10 (41 ref.)

Cytokine gene regulation by viral gene products. Geist LJ, et al. **J Lab Clin Med** 1995 Dec;126(6):517–20 (40 ref.)

Immune response to synthetic peptides representing antigenic sites on the glycoprotein of infectious hematopoietic necrosis virus. Emmenegger E, et al. **Vet Res** 1995; 26(5–6):374–8 (21 ref.)

[Molecular mimicry between LKM 1-autoantigen and HCV-polyproteins] Miyakawa H, et al. **Nippon Rinsho** 1995 Sep;53 Suppl:885–91 (20 ref.) **(Jpn)**

METABOLISM

Viral lipoproteins: the role of myristoylation. Harper DR, et al. **Biochem Soc Trans** 1995 Aug;23(3):553–7 (49 ref.)

Sequence determinants of folding and stability for the P22 Arc repressor dimer. Sauer RT, et al. **FASEB J** 1996 Jan; 10(1):42–8 (21 ref.)

Single-stranded DNA binding protein encoded by the filamentous bacteriophage M13: structural and functional characteristics. Stassen AP, et al. **Mol Biol Rep** 1994–95; 20(3):109–27 (101 ref.)

Entry and egress of varicella-zoster virus: role of mannose 6-phosphate, heparan sulfate proteoglycan, and signal sequences in targeting virions and viral glycoproteins. Zhu Z, et al. **Neurology** 1995 Dec;45(12 Suppl 8):S15–7 (9 ref.)

[Phosphorylation of proteins as a factor for regulating viral infection] Bukrinskaia AG. **Mol Biol (Mosk)** 1996 May–Jun; 30(3):514–7 (32 ref.) **(Rus)**

PHYSIOLOGY

Potential roles of apoptosis in viral pathogenesis. Collins M. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 2):S20–4 (63 ref.)

Molecular mechanisms of protein-mediated membrane fusion. Hughson FM. **Curr Opin Struct Biol** 1995 Aug; 5(4):507–13 (60 ref.)

Functional similarity between adenovirus E1B 19-kDa protein and proteins encoded by Bcl-2 proto-oncogene and Epstein-Barr virus BHRF1 gene. Subramanian T, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 1):153–61 (52 ref.)

Potyviral HC-Pro: a multifunctional protein. Maia IG, et al. **J Gen Virol** 1996 Jul;77 (Pt 7):1335–41 (51 ref.)

The role of anti-sigma factors in gene regulation. Brown KL, et al. **Mol Microbiol** 1995 May;16(3):397–404 (49 ref.)

[Mosaic proteins] Zak I. **Postepy Biochem** 1995;41(2):120–30 (81 ref.) **(Pol)**

VIRAL REGULATORY PROTEINS

METABOLISM

Use of the E2F transcription factor by DNA tumor virus regulatory proteins. Cress WD, et al. **Curr Top Microbiol Immunol** 1996;208:63–78 (112 ref.)

PHYSIOLOGY

HIV accessory proteins: emerging therapeutic targets. Miller RH, et al. **Mol Med** 1995 Jul;1(5):479–85 (11 ref.)

VIRAL RNA see **RNA, VIRAL**

VIRAL SHEDDING see **VIRUS SHEDDING**

VIRAL STRUCTURAL GENES see **GENES, STRUCTURAL, VIRAL**

VIRAL STRUCTURAL PROTEINS

Adenovirus fiber. Chroboczek J, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 1):163–200 (125 ref.)

CHEMISTRY

Viruses. Liljas L. **Curr Opin Struct Biol** 1996 Apr;6(2):151–6 (40 ref.)

Structure of the receptor binding domain of adenovirus type 5 fiber protein. Xia D, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 1):39–46 (17 ref.)

PHYSIOLOGY

Role of adenovirus structural components in the regulation of adenovirus infection. Russell WC, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 1):81–98 (78 ref.)

VIRAL TAIL PROTEINS

METABOLISM

Thermolabile folding intermediates: inclusion body precursors and chaperonin substrates. King J, et al. **FASEB J** 1996 Jan;10(1):57–66 (63 ref.)

VIRAL TRANSFORMING PROTEINS see **ONCOGENE PROTEINS, VIRAL**

VIRAL VACCINES

Papillomavirus vaccines: current status and future prospects. Schiller JT, et al. **Adv Dermatol** 1996;11:355–80; discussion 381 (96 ref.)

Development of protection against coronavirus induced diseases. A review. Enjuanes L, et al. **Adv Exp Med Biol** 1995;380:197–211 (108 ref.)

Varicella vaccine: rationale and indications for use. Zimmerman RK. **Am Fam Physician** 1996 Feb 1; 53(2):647–51, 654 (18 ref.)

Varicella vaccine [editorial] Moffitt JE, et al. **Ann Allergy Asthma Immunol** 1996 May;76(5):381–3 (29 ref.)

DNA immunization with bovine herpesvirus-1 genes. Babiuk LA, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:47–63 (56 ref.)

Immunization in adults in the 1990s. Gardner P, et al. **Curr Clin Top Infect Dis** 1995;15:271–300 (115 ref.)

Advances in molecular biology: impact on rotavirus vaccine development. Estes MK. **J Infect Dis** 1996 Sep;174 Suppl 1:S37–46 (117 ref.)

Efficacy of a quadrivalent rhesus rotavirus-based human rotavirus vaccine aimed at preventing severe rotavirus diarrhea in infants and young children. Kapikian AZ, et al. **J Infect Dis** 1996 Sep;174 Suppl 1:S65–72 (39 ref.)

Host factors associated with protection against rotavirus disease: the skies are clearing. Offit PA. **J Infect Dis** 1996 Sep;174 Suppl 1:S59–64 (62 ref.)

Group A rotavirus veterinary vaccines. Saif LJ, et al. **J Infect Dis** 1996 Sep;174 Suppl 1:S98–106 (81 ref.)

Review of rotavirus vaccine trials in Finland. Vesikari T, et al. **J Infect Dis** 1996 Sep;174 Suppl 1:S81–7 (46 ref.)

DNA vaccines. McDonnell WM, et al. **N Engl J Med** 1996 Jan 4;334(1):42–5 (0 ref.)

Prospects for a vaccine against human papillomavirus. Hines JF, et al. **Obstet Gynecol** 1995 Nov;86(5):860–6 (30 ref.)

New lessons for rotavirus vaccines [comment] Glass RI, et al. **Science** 1996 Apr 5;272(5258):46–8 (14 ref.) Comment on: Science 1996 Apr 5;272(5258):101–4. Comment on: Science 1996 Apr 5;272(5258):104–7.

Varicella vaccine [editorial] Ellis RW. **Vaccine** 1995; 13(15):1387–8 (21 ref.)

Control of bovine viral diarrhea infection by use of vaccination. Bolin SR. **Vet Clin North Am Food Anim Pract** 1995 Nov;11(3):615–25 (74 ref.)

Genetically altered herpesviruses as vaccines. Young PL, et al. **Vet Microbiol** 1995 Sep;46(1–3):175–9 (20 ref.)

Immune response to synthetic peptides representing antigenic sites on the glycoprotein of infectious hematopoietic necrosis virus. Emmenegger E, et al. **Vet Res** 1995; 26(5–6):374–8 (21 ref.)

[Does vaccination prevent Rotavirus gastroenteritis? (editorial)] Vesikari T. **Duodecim** 1994;110(2):121–3 (15 ref.) **(Fin)**

[Vaccination against feline retrovirus infections] Horzinek MC. **Tierarztl Prax** 1996 Apr;24(2):197–202 (16 ref.) (Eng. Abstr.) **(Ger)**

[Progress in the development of vaccines against Aujeszky's disease] Mettenleiter TC. **Tierarztl Prax** 1995 Dec; 23(6):570–4 (22 ref.) (Eng. Abstr.) **(Ger)**

ADMINISTRATION & DOSAGE

Protective efficacy of intramuscular immunization with naked DNA. Donnelly JJ, et al. **Ann N Y Acad Sci** 1995 Nov 27;772:40–6 (26 ref.)

Hepatitis E: an overview. Mast EE, et al. **Annu Rev Med** 1996;47:257–66 (55 ref.)

Retrovirus and retrotransposon particles as antigen presentation and delivery systems. Adams SE, et al. **Pharm Biotechnol** 1995;6:769–86 (63 ref.)

Pseudorabies virus eradication by area-wide vaccination is feasible. Stegeman A. **Vet Q** 1995 Dec;17(4):150–6 (85 ref.)

[Penetration of neurotropic viruses into the central nervous system after airborne mode of transmission] Ryzhikov AB, et al. **Vopr Virusol** 1995 Jul–Aug;40(4):146–50 (51 ref.) **(Rus)**

ADVERSE EFFECTS

Pathogenesis of respiratory syncytial virus vaccine-augmented pathology. Graham BS. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 2):S63–6 (48 ref.)

[After vaccination for tick-borne encephalitis must onset of neurologic disorders be expected?] Hofmann H. **Wien Klin Wochenschr** 1995;107(17):509–15 (17 ref.) (Eng. Abstr.) **(Ger)**

CHEMISTRY

Viral vaccines and residual cellular DNA. Horaud F. **Biologicals** 1995 Sep;23(3):225–8 (17 ref.)

CLASSIFICATION

[Immunity—technical aspects of vaccines. I. Immunoprophylaxis in dogs and cats] Overgaauw PA. **Tijdschr Diergeneeskd** 1996 Feb 15;121(4):90–5 (0 ref.) (Eng. Abstr.) **(Dut)**

GENETICS

Nucleic acid vaccines. Vogel FR, et al. **Clin Microbiol Rev** 1995 Jul;8(3):406–10 (32 ref.)

From virus to vaccine: developments using the simple eukaryote, Dictyostelium discoideum. Emslie KR, et al. **Trends Microbiol** 1995 Dec;3(12):476–9 (23 ref.)

Antigenic variants in a plaque-isolate of foot-and-mouth disease virus: implications for vaccine production. Piatti P, et al. **Vaccine** 1995;13(8):781–4 (23 ref.)

IMMUNOLOGY

Strategies involved in developing an effective vaccine for EBV-associated diseases. Moss DJ, et al. **Adv Cancer Res** 1996;69:213–45 (201 ref.)

Principles of cytotoxic T lymphocyte induction and recognition. Whitton JL, et al. **Curr Top Microbiol Immunol** 1995;202:247–59 (42 ref.)

Rotavirus vaccine: current status & future prospects. Naik TN, et al. **Indian J Med Res** 1996 Jul;104:76–85 (98 ref.)

Synthetic recombinant vaccines against viral agents. Arnon A, et al. **Int Arch Allergy Immunol** 1995 Dec;108(4):321–6 (48 ref.)

Tumor vaccine design: concepts, mechanisms, and efficacy testing. Schirrmacher V. **Int Arch Allergy Immunol** 1995 Dec;108(4):340–4 (25 ref.)

The development of multivalent bovine rotavirus (strain WC3) reassortant vaccine for infants. Clark HF, et al. **J Infect Dis** 1996 Sep;174 Suppl 1:S73–80 (30 ref.)

Molecular determinants of immunity and pathogenicity of rotavirus infection in the mouse model. Franco MA, et al. **J Infect Dis** 1996 Sep;174 Suppl 1:S47–50 (23 ref.)

Review of G and P typing results from a global collection of rotavirus strains: implications for vaccine development. Gentsch JR, et al. **J Infect Dis** 1996 Sep;174 Suppl 1:S30–6 (65 ref.)

Influence of breast-feeding and oral poliovirus vaccine on the immunogenicity and efficacy of rotavirus vaccines. Rennels MB. **J Infect Dis** 1996 Sep;174 Suppl 1:S107–11 (35 ref.)

Mechanisms of protection against rotavirus in humans and mice. Ward RL. **J Infect Dis** 1996 Sep;174 Suppl 1:S51–8 (92 ref.)

A novel generation of viral vaccines based on the ISCOM matrix. Rimmelzwaan GF, et al. **Pharm Biotechnol** 1995; 6:543–58 (101 ref.)

Adenovirus vectors as recombinant viral vaccines. Imler JL. **Vaccine** 1995 Sep;13(13):1143–51 (72 ref.)

[Anti-idiotypic antibodies as vaccinal and diagnostic preparations in viral infections] Tarasishin LA. **Mikrobiol Z** 1996 Jan–Feb;58(1):97–105 (30 ref.) (Eng. Abstr.) **(Rus)**

VIRAL VACCINES

[The prospects for the development of viral vaccines] Bektimirov TA, et al. **Voen Med Zh** 1995 Jul;(7):45–8 (14 ref.) **(Rus)**

[Immobilized preparations in virology and vaccinology] Mikhallov VV, et al. **Vopr Virusol** 1995 Sep–Oct; 40(5):194–7 (33 ref.) **(Rus)**

STANDARDS

Quantitative risk analysis applied to innocuity and potency tests on the oil–adjuvanted vaccine against foot and mouth disease in Argentina. Cané BG, et al. **Rev Sci Tech** 1995 Dec;14(4):1097–119 (5 ref.) **(Eng, Spa)**

SUPPLY & DISTRIBUTION

[New vaccines. What can we expect in the coming years?] Bjune G, et al. **Tidsskr Nor Laegeforen** 1995 Oct 10; 115(24):3032–4 (20 ref.) (Eng. Abstr.) **(Nor)**

[A vaccine against diarrhea. Soon a reality in the fight against viral gastroenteritis in both developed and developing countries] Svensson L. **Lakartidningen** 1996 Jan 31; 93(5):353–8 (26 ref.) **(Swe)**

THERAPEUTIC USE

Therapeutic immunization for recurrent herpes simplex virus infections. McKenzie R, et al. **Adv Exp Med Biol** 1996; 394:67–83 (91 ref.)

Non–replicating expression vectors: applications in vaccine development and gene therapy. Limbach KJ, et al. **Epidemiol Infect** 1996 Jun;116(3):241–56 (87 ref.)

Can virus therapy of human cancer be improved by apoptosis induction? [published erratum appears in Med Hypotheses 1995 Sep;45(3):316] Sinkovics JG, et al. **Med Hypotheses** 1995 May;44(5):359–68 (72 ref.)

The varicella vaccine. An evolving mosaic of information. Zannolli R, et al. **Panminerva Med** 1996 Mar;38(1):28–32 (31 ref.)

Development of live attenuated varicella vaccine. Gershon AA. **Proc Assoc Am Physicians** 1995 Oct;107(3):365–8 (31 ref.)

[Immunoprophylaxis of respiratory syncytial (RS–viral) infection: results and prospects] Leshchinskaia NP. **Tr Inst Im Pastera** 1992;67:74–85 (33 ref.) **(Rus)**

[Rubella and prospects for vaccine prophylaxis of it] Malinina OIu. **Tr Inst Im Pastera** 1992;67:116–21 (28 ref.) **(Rus)**

VIREMIA

DIAGNOSIS

Fatal enterovirus type 71 infection: rapid detection and diagnostic pitfalls. Landry ML, et al. **Pediatr Infect Dis J** 1995 Dec;14(12):1095–100 (16 ref.)

DRUG THERAPY

Viral dynamics of HIV: implications for drug development and therapeutic strategies. Havlir DV, et al. **Ann Intern Med** 1996 Jun 1;124(11):984–94 (112 ref.)

PREVENTION & CONTROL

Improved safety from plasma derivatives: purification and viral elimination characteristics of mononine. Feldman F, et al. **Acta Haematol** 1995;94 Suppl 1:25–32; discussion 33–4 (13 ref.)

VIROLOGY

Measuring viral load in the clinical setting. Harrigan R. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995;10 Suppl 1:S34–40 (26 ref.)

Viral counts count in HIV infection [see comments] Ho DD. **Science** 1996 May 24;272(5265):1124–5 (13 ref.) Comment in: Science 1996 May 24;272(5265):1167–70.

VIRGINIAMYCIN

Quinupristin/dalfopristin (RP 59500): a new streptogramin antibiotic. Chant C, et al. **Ann Pharmacother** 1995 Oct; 29(10):1022–7 (30 ref.)

PHARMACOLOGY

[In vitro susceptibility of Pasteurella and related bacteria to five orally administered antibiotics] Lion C, et al. **Pathol Biol (Paris)** 1996 May;44(5):341–6 (13 ref.) (Eng. Abstr.) **(Fre)**

VIRGINIAMYCIN FACTOR M1 see **VIRGINIAMYCIN**

VIRGINIAMYCIN FACTOR S1 see **VIRGINIAMYCIN**

VIRILISM

COMPLICATIONS

Recurrent maternal virilization during pregnancy associated with polycystic ovarian syndrome: a case report and review of the literature. Ben–Chetrit A, et al. **Hum Reprod** 1995 Nov;10(11):3057–60 (34 ref.)

VIRION

METABOLISM

Entry and egress of varicella–zoster virus: role of mannose 6–phosphate, heparan sulfate proteoglycan, and signal sequences in targeting virions and viral glycoproteins. Zhu Z, et al. **Neurology** 1995 Dec;45(12 Suppl 8):S15–7 (9 ref.)

ULTRASTRUCTURE

Tubulovesicular structures (TVS): virus–like particles specific for all subacute spongiform virus encephalopathies—what are they really? Liberski PP. **Arch Immunol Ther Exp (Warsz)** 1994;42(2):89–93 (18 ref.)

VIROLOGY

Virology research and virulent human pandemics. Mims CA. **Epidemiol Infect** 1995 Dec;115(3):377–86 (49 ref.)

METHODS

Quantitative molecular methods in virology. Clementi M, et al. **Arch Virol** 1995;140(9):1523–39 (107 ref.)

PCR and non–isotopic labeling techniques for plant virus detection. Fenby NS, et al. **Cell Mol Biol (Noisy–le–grand)** 1995 Jul;41(5):639–52 (94 ref.)

VIRULENCE

The evolution of virulence: a unifying link between parasitology and ecology. Ewald PW. **J Parasitol** 1995 Oct; 81(5):659–69 (71 ref.)

Triggering bacterial virulence [comment] Cotter PA, et al. **Science** 1996 Aug 30;273(5279):1183–4 (15 ref.) Comment on: Science 1996 Aug 30;273(5279):1231–3. Comment on: Science 1996 Aug 30;273(5279):1234–6.

GENETICS

Molecular genetic approaches for the study of virulence in both pathogenic bacteria and fungi. Hensel M, et al. **Microbiology** 1996 May;142 (Pt 5):1049–58 (52 ref.)

A role for bacteriophages in the evolution and transfer of bacterial virulence determinants. Cheetham BF, et al. **Mol Microbiol** 1995 Oct;18(2):201–8 (85 ref.)

VIRUS ACTIVATION

[Pathogenic mechanism of Sendai virus—virus activation and germination polarity by host proteases] Tashiro M. **Uirusu** 1995 Jun;45(1):76–80 (12 ref.) **(Jpn)**

RADIATION EFFECTS

Medical UV exposures and HIV activation. Zmudzka BZ, et al. **Photochem Photobiol** 1996 Aug;64(2):246–53 (62 ref.)

VIRUS ASSEMBLY

The use of hydrostatic pressure as a tool to study viruses and other macromolecular assemblages. Silva JL, et al. **Curr Opin Struct Biol** 1996 Apr;6(2):166–75 (79 ref.)

Virus assembly. D'Halluin JC. **Curr Top Microbiol Immunol** 1995;199 (Pt 1):47–66 (145 ref.)

Selective encapsidation of adenovirus DNA. Schmid SI, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 1):67–80 (45 ref.)

Virus DNA packaging: the strategy used by phage lambda. Catalano CE, et al. **Mol Microbiol** 1995 Jun;16(6):1075–86 (87 ref.)

Molecular recognition in the assembly of the segmented reovirus genome. Joklik WK, et al. **Prog Nucleic Acid Res Mol Biol** 1996;53:249–81 (188 ref.)

Orbivirus structure and assembly. Roy P. **Virology** 1996 Feb 1;216(1):1–11 (60 ref.)

PHYSIOLOGY

DNA packaging and cutting by phage terminases: control in phage T4 by a synaptic mechanism. Black LW. **Bioessays** 1995 Dec;17(12):1025–30 (55 ref.)

Comparison of packaging strategy in retroviruses and pararetroviruses. Mesnard JM, et al. **Virology** 1995 Oct 20; 213(1):1–6 (62 ref.)

VIRUS DISEASES

see related

ANTIVIRAL AGENTS

Viral respiratory infections in the community: epidemiology, agents, and interventions. Monto AS. **Am J Med** 1995 Dec 29;99(6B):24S–27S (14 ref.)

The clinical impact of human respiratory virus infections. Denny FW Jr. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 2):S4–12 (40 ref.)

Immunizations, animal–induced injuries and disease, neonatal jaundice, and viral infections. Gerson WT. **Curr Opin Pediatr** 1995 Aug;7(4):477–86 (73 ref.)

Nurses: at special risk. Jackson MM, et al. **J Obstet Gynecol Neonatal Nurs** 1995 Jul–Aug;24(6):533–40 (37 ref.)

Viral infections of the newborn. Strodtbeck F. **J Obstet Gynecol Neonatal Nurs** 1995 Sep;24(7):659–67 (21 ref.)

Can virus therapy of human cancer be improved by apoptosis induction? [published erratum appears in Med Hypotheses 1995 Sep;45(3):316] Sinkovics JG, et al. **Med Hypotheses** 1995 May;44(5):359–68 (72 ref.)

Anaesthesia in children with viral respiratory tract infections. Van der Walt J. **Paediatr Anaesth** 1995;5(4):257–62 (25 ref.)

[Clinical aspects, diagnosis and treatment of intrauterine infections] Simakova MG, et al. **Akush Ginekol (Mosk)** 1995;(4):7–10 (54 ref.) **(Rus)**

BLOOD

Infectious hazards associated with blood transfusion. Hurley DR. **Adverse Drug React Toxicol Rev** 1995 Autumn; 14(3):157–74 (69 ref.)

COMPLICATIONS

Why do viruses make infants wheeze? Balfour–Lynn IM. **Arch Dis Child** 1996 Mar;74(3):251–9 (101 ref.)

Viruses and cryoglobulinemia. Galli M. **Clin Exp Rheumatol** 1995 Nov–Dec;13 Suppl 13:S63–70 (66 ref.)

Infections, idiotypes and SLE [editorial; comment] George J, et al. **Lupus** 1995 Oct;4(5):333–5 (40 ref.) Comment on: Lupus 1995 Oct;4(5):339–47.

Infectious gastroenterocolitides in children: an update on emerging pathogens. Sherman PM, et al. **Pediatr Clin North Am** 1996 Apr;43(2):391–407 (114 ref.)

[Giant cell hepatitis with virus associated hemophagocytic syndrome] Onuki M, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):520–2 (18 ref.) **(Jpn)**

[Postviral fatigue syndrome] Haukenes G, et al. **Tidsskr Nor Laegeforen** 1995 Oct 10;115(24):3017–22 (36 ref.) (Eng. Abstr.) **(Nor)**

[The role of viral respiratory tract infections on pathogenesis of bronchial asthma. I. Clinical and experimental investigations] Kroczyńska–Bednarek J, et al. **Pneumonol Alergol Pol** 1995;63(9–10):566–9 (35 ref.) **(Pol)**

[Early identification of respiratory viruses in asthmatic children] Morfin Maciel BM, et al. **Rev Alerg Mex** 1996 Mar–Apr;43(2):45–8 (22 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

Quantitative molecular methods in virology. Clementi M, et al. **Arch Virol** 1995;140(9):1523–39 (107 ref.)

[Exanthema in children] Winterberg DH. **Ned Tijdschr Geneeskd** 1996 Jul 20;140(29):1494–9 (14 ref.) **(Dut)**

[ELISA for diagnosis of infections by viruses] Yoshihara N. **Nippon Rinsho** 1995 Sep;53(9):2277–82 (12 ref.) (Eng. Abstr.) **(Jpn)**

[Anti–idiotypic antibodies as vaccinal and diagnostic preparations in viral infections] Tarasishin LA. **Mikrobiol Z** 1996 Jan–Feb;58(1):97–105 (30 ref.) (Eng. Abstr.) **(Rus)**

[Clinical virology in pediatrics (editorial)] Xairó Mimó D, et al. **An Esp Pediatr** 1996 Mar;44(3):191–6 (7 ref.) **(Spa)**

DRUG THERAPY

Antiviral resistance in clinical practice. Kimberlin DW, et al. **Antiviral Res** 1995 Apr;26(4):423–38 (64 ref.)

Translation–targeted therapeutics for viral diseases. Harford JB. **Gene Expr** 1995;4(6):357–67 (59 ref.)

EPIDEMIOLOGY

Viral respiratory infections and their role as public health problem in tropical countries (review). Karaivanova GM. **Afr J Med Med Sci** 1995 Mar;24(1):1–7 (72 ref.)

Vector–borne viral diseases in Sweden—a short review. Niklasson B, et al. **Arch Virol Suppl** 1996;11:49–55 (37 ref.)

[The epidemiological characteristics of acute intestinal infections in wartime] Kartsev AD. **Voen Med Zh** 1996 May;317(5):40–3 (24 ref.) **(Rus)**

ETIOLOGY

Foodborne and waterborne illness in children. Rivera–Matos IR, et al. **Adv Pediatr Infect Dis** 1996;11:101–34 (112 ref.)

Infectious risk of plasma donations: relationship to safety of intravenous immune globulins. Dodd RY. **Clin Exp Immunol** 1996 May;104 Suppl 1:31–4 (25 ref.)

Infection in the bone marrow transplant recipient. Walter EA, et al. **Infect Dis Clin North Am** 1995 Dec;9(4):823–47 (133 ref.)

Viral complications after transplantation. Griffiths PD. **J Antimicrob Chemother** 1995 Oct;36 Suppl B:91–106 (74 ref.)

Emerging viruses. Le Guenno B. **Sci Am** 1995 Oct; 273(4):56–64 (5 ref.)

Astrovirus gastroenteritis. Blacklow NR, et al. **Trans Am Clin Climatol Assoc** 1994;106:58–66; discussion 66–8 (31 ref.)

[Pathogenesis of infections—a complex interplay between microbes and the immune defence] Haug CJ, et al. **Tidsskr Nor Laegeforen** 1995 Oct 30;115(26):3254–8 (25 ref.) (Eng. Abstr.) **(Nor)**

[The etiology and pathogenesis of intrauterine infection] Durova AA, et al. **Akush Ginekol (Mosk)** 1995;(6):9–12 (59 ref.) **(Rus)**

GENETICS

Viral mutations, TCR antagonism and escape from the immune response. Franco A, et al. **Curr Opin Immunol** 1995 Aug;7(4):524–31 (62 ref.)

DNA vaccines. McDonnell WM, et al. **N Engl J Med** 1996 Jan 4;334(1):42–5 (0 ref.)

IMMUNOLOGY

Viral myocarditis: are we dealing with an autoimmune phenomenon? Finkelstein Y, et al. **Ann Med Interne (Paris)** 1995;146(5):322–4 (28 ref.)

Evasion of immunologic defenses and emerging viral threats. Herndon RM. **Arch Neurol** 1996 Jan;53(1):23–7 (18 ref.)

Viral mutations, TCR antagonism and escape from the immune response. Franco A, et al. **Curr Opin Immunol** 1995 Aug;7(4):524–31 (62 ref.)

Principles of cytotoxic T lymphocyte induction and recognition. Whitton JL, et al. **Curr Top Microbiol Immunol** 1995;202:247–59 (42 ref.)

Vitamin A and retinoids in antiviral responses. Ross AC, et al. **FASEB J** 1996 Jul;10(9):979–85 (53 ref.)

Viral evasion of cytokine-mediated host defense mechanisms. Gribaudo G, et al. **G Batteriol Virol Immunol** 1994 Jan–Dec;86(1–12):3–10 (41 ref.)

Actions of cytokines on the immune response and viral interactions: an overview. Peters M. **Hepatology** 1996 Apr; 23(4):909–16 (79 ref.)

Immunoglobulin gene usage in the human anti-pathogen response. Newkirk MM, et al. **Infect Agents Dis** 1995 Sep; 4(3):153–60 (59 ref.)

Human regulator of complement activation (RCA) gene family proteins and their relationship to microbial infection. Seya T. **Microbiol Immunol** 1995;39(5):295–305 (82 ref.)

Immunology taught by viruses [see comments] Zinkernagel RM. **Science** 1996 Jan 12;271(5246):173–8 (51 ref.) Comment in: Science 1996 May 3;272(5262):634–5.

Viral immunopathology. Introduction. Zinkernagel RM, et al. **Springer Semin Immunopathol** 1995;17(2–3):119–20 (0 ref.)

The viral-autoimmunity relationship. Cohen AD, et al. **Viral Immunol** 1995;8(1):1–9 (83 ref.)

[The role of cytokines in viral infections] Cavallo R, et al. **G Batteriol Virol Immunol** 1994 Jan–Dec;86(1–12):65–78 (44 ref.) (Eng. Abstr.) **(Ita)**

[New immunopathogenetic aspects of infectious diseases] Müller F, et al. **Tidsskr Nor Laegeforen** 1995 Oct 30; 115(26):3259–62 (33 ref.) (Eng. Abstr.) **(Nor)**

[Role of viral respiratory tract infections on the pathogenesis of bronchial asthma. II. Effect on the immune system] Kroczyńska-Bednarek J, et al. **Pneumonol Alergol Pol** 1995; 63(9–10):570–6 (40 ref.) **(Pol)**

[The mechanism of the development of nonspecific immunosuppression in viral infections] Zheleznikova GF. **Zh Mikrobiol Epidemiol Immunobiol** 1995 Sep–Oct; (5):122–4 (15 ref.) **(Rus)**

METABOLISM

[Phosphorylation of proteins as a factor for regulating viral infection] Bukrinskaia AG. **Mol Biol (Mosk)** 1996 May–Jun; 30(3):514–7 (32 ref.) **(Rus)**

PATHOLOGY

Infections of the eyelid, lacrimal system, conjunctiva, and cornea. Durand M, et al. **Curr Clin Top Infect Dis** 1996; 16:125–50 (150 ref.)

PREVENTION & CONTROL

Recombinant adenoviruses as vaccines. Randrianarison-Jewtoukoff V, et al. **Biologicals** 1995 Jun; 23(2):145–57 (82 ref.)

Antiviral antibodies in transplantation. Snydman DR. **Transplant Proc** 1995 Oct;27(5 Suppl 1):10–2 (22 ref.)

[Communicable diseases in Norway. Epidemiological status and future challenge for prevention of the most important diseases] Lystad A, et al. **Tidsskr Nor Laegeforen** 1995 Sep 30;115(23):2899–903 (29 ref.) (Eng. Abstr.) **(Nor)**

[Possibilities and etiologic problems in prophylaxis of human virus infections] Kantoch M, et al. **Postepy Hig Med Dosw** 1995;49(3):309–41 (173 ref.) (Eng. Abstr.) **(Pol)**

[Anti-idiotypic antibodies as vaccinal and diagnostic preparations in viral infections] Tarasishin LA. **Mikrobiol Z** 1996 Jan–Feb;58(1):97–105 (30 ref.) (Eng. Abstr.) **(Rus)**

THERAPY

Return to the past: the case for antibody-based therapies in infectious diseases. Casadevall A, et al. **Clin Infect Dis** 1995 Jul;21(1):150–61 (181 ref.)

Non-replicating expression vectors: applications in vaccine development and gene therapy. Limbach KJ, et al. **Epidemiol Infect** 1996 Jun;116(3):241–56 (87 ref.)

TRANSMISSION

Emerging viral infections. Johnson RT. **Arch Neurol** 1996 Jan;53(1):18–22 (29 ref.)

Vector-borne viral diseases in Sweden—a short review. Niklasson B, et al. **Arch Virol Suppl** 1996;11:49–55 (37 ref.)

Imported vector- and rodent-borne virus infections—an introduction. Schwarz TF. **Arch Virol Suppl** 1996;11:3–11 (49 ref.)

Virology research and virulent human pandemics. Mims CA. **Epidemiol Infect** 1995 Dec;115(3):377–86 (49 ref.)

Transmission of disease through transplantation of musculoskeletal allografts. Tomford WW. **J Bone Joint Surg Am** 1995 Nov;77(11):1742–54 (164 ref.)

Viral hazards to and from health care workers. Jeffries DJ. **J Hosp Infect** 1995 Jun;30 Suppl:140–55 (96 ref.)

Xenotransplantation at a crossroads: prevention versus progress. Allan JS. **Nat Med** 1996 Jan;2(1):18–21 (19 ref.)

"Childhood" viruses as a cause of pneumonia in adults. Yang E, et al. **Semin Respir Infect** 1995 Dec;10(4):232–43 (40 ref.)

Virally inactivated fresh frozen plasma. Williamson LM, et al. **Vox Sang** 1995;69(3):159–65 (45 ref.)

[The interrelationships of ixodid ticks (Ixodidae) with the causative agents of transmissible vertebrate infections] Balashov IuS. **Parazitologiia** 1995 Sep–Oct;29(5):337–52 (90 ref.) (Eng. Abstr.) **(Rus)**

[Penetration of neurotropic viruses into the central nervous system after airborne mode of transmission] Ryzhikov AB, et al. **Vopr Virusol** 1995 Jul–Aug;40(4):146–50 (51 ref.) **(Rus)**

VETERINARY

The role of dipterous insects in the mechanical transmission of animal viruses. Carn VM. **Br Vet J** 1996 Jul; 152(4):377–93 (55 ref.)

Clinical application of interferons in large animal medicine. Moore BR. **J Am Vet Med Assoc** 1996 May 15; 208(10):1711–5 (50 ref.)

Inactivation of viruses in liquid manure. Haas B, et al. **Rev Sci Tech** 1995 Jun;14(2):435–45 (28 ref.)

Viral infections of the feline urinary tract. Kruger JM, et al. **Vet Clin North Am Small Anim Pract** 1996 Mar; 26(2):281–96 (77 ref.)

ICNV 1966 to ICTV 1994: the contribution of veterinary virology. Fenner F. **Vet Microbiol** 1995 Sep;46(1–3):3–13 (27 ref.)

[Diagnosis of contagious diseases in animals using PCR] Hofmann MA, et al. **Schweiz Arch Tierheilkd** 1995; 137(12):531–6 (9 ref.) (Eng. Abstr.) **(Ger)**

VIROLOGY

Potential roles of apoptosis in viral pathogenesis. Collins M. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 2):S20–4 (63 ref.)

Glomerulonephritis, thrombocytopenia, and autoimmune neutropenia probably induced by a virus-like illness: case report and review of the literature. Mackey JR, et al. **Nephron** 1995;71(4):454–8 (33 ref.)

Multiple viral pathogenicity: another paradigm in medical research? Sotelo J. **Perspect Biol Med** 1996 Summer; 39(4):507–13 (20 ref.)

[New opportunistic pathogens in AIDS] Morillon M. **Med Trop (Mars)** 1996;56(1):17–20 (20 ref.) **(Fre)**

[Virus-associated arthritis (see comments)] Saal JG. **Z Rheumatol** 1995 Nov–Dec;54(6):391–404 (148 ref.) (Eng. Abstr.) Comment in: Z Rheumatol 1995 Nov–Dec;54(6):389–90. **(Ger)**

VIRUS INDUCTION see **VIRUS ACTIVATION**

VIRUS INHIBITORS

GENETICS

Mx transgenic mice--animal models of health. Arnheiter H, et al. **Curr Top Microbiol Immunol** 1996;206:119–47 (88 ref.)

IMMUNOLOGY

Interferons, Mx genes, and resistance to influenza virus. Horisberger MA. **Am J Respir Crit Care Med** 1995 Oct; 152(4 Pt 2):S67–71 (56 ref.)

VIRUS INTEGRATION

see related
PROVIRUSES

Risk potential of the chromosomal insertion of foreign DNA. Kurth R. **Ann N Y Acad Sci** 1995 Nov 27;772:140–51 (25 ref.)

Potential DNA vaccine integration into host cell genome. Nichols WW, et al. **Ann N Y Acad Sci** 1995 Nov 27; 772:30–9 (8 ref.)

The mechanism of adenovirus DNA integration: studies in a cell-free system. Fechteler K, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 2):109–37 (122 ref.)

Retroviral insertional mutagenesis in murine promonocytic leukemias: c-myb and Mmi1. Wolff L, et al. **Curr Top Microbiol Immunol** 1996;211:191–9 (33 ref.)

Retroviral integrase, putting the pieces together. Andrake MD, et al. **J Biol Chem** 1996 Aug 16;271(33):19633–6 (59 ref.)

Primary adult T cell leukemia of bone: two patients with primary bone lesion showing monoclonal integration of HTLV-I proviral DNA. Takemoto S, et al. **Leukemia** 1996 Feb;10(2):333–7 (24 ref.)

VIRUS LATENCY

see related
VIRUS ACTIVATION

Cytomegalovirus latency and latency-specific transcription in hematopoietic progenitors. Kondo K, et al. **Scand J Infect Dis Suppl** 1995;99:63–7 (24 ref.)

PHYSIOLOGY

Epstein-Barr virus and the B cell: that's all it takes. Thorley-Lawson DA, et al. **Trends Microbiol** 1996 May; 4(5):204–8 (27 ref.)

VIRUS PARTICLE see **VIRION**

VIRUS PEPLOMER PROTEINS see **VIRAL ENVELOPE PROTEINS**

VIRUS RECEPTORS see **RECEPTORS, VIRUS**

VIRUS REPLICATION

Clonal expansion of T cells and HIV genotypes in microdissected splenic white pulps indicates viral replication in situ and infiltration of HIV-specific cytotoxic T lymphocytes. Cheynier R, et al. **Adv Exp Med Biol** 1995; 374:173–82 (47 ref.)

Cyclophilin and gag in HIV-1 replication and pathogenesis. Franke EK, et al. **Adv Exp Med Biol** 1995;374:217–28 (122 ref.)

Transcription, replication, recombination, and engineering of coronavirus genes. Lai MM. **Adv Exp Med Biol** 1995; 380:463–71 (29 ref.)

Regulation of macrophage activation and HIV replication. Montaner LJ, et al. **Adv Exp Med Biol** 1995;374:47–56 (69 ref.)

Coronaviruses use discontinuous extension for synthesis of subgenome-length negative strands. Sawicki SG, et al. **Adv Exp Med Biol** 1995;380:499–506 (21 ref.)

Molecular basis of cell cycle dependent HIV-1 replication. Implications for control of virus burden. Stevenson M, et al. **Adv Exp Med Biol** 1995;374:33–45 (56 ref.)

The role of the cell cycle in HIV-1 infection. Zack JA. **Adv Exp Med Biol** 1995;374:27–31 (26 ref.)

Nuclear organization of replication and gene expression in adenovirus-infected cells. Bridge E, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 1):99–117 (86 ref.)

Molecular interactions during adenovirus DNA replication. Hay RT, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 2):31–48 (114 ref.)

Expression, nuclear transport, and phosphorylation of adenovirus DNA replication proteins. Ramachandra M, et al. **Curr Top Microbiol Immunol** 1995;199 (Pt 2):50–88 (262 ref.)

Adenovirus DNA replication. Van der Vliet PC. **Curr Top Microbiol Immunol** 1995;199 (Pt 2):1–30 (147 ref.)

Homologous recombination in the replicative cycle of adenovirus and its relationship to DNA replication. Young CS. **Curr Top Microbiol Immunol** 1995;199 (Pt 2):89–108 (75 ref.)

Replication of hepatitis C virus: catching it in the act [editorial; comment] Branch AD. **Hepatology** 1996 Feb; 23(2):372–5 (40 ref.) Comment on: Hepatology 1996 Feb;23(2):205–9.

The nuclear matrix and virus function. Deppert W, et al. **Int Rev Cytol** 1995;162A:485–537 (92 ref.)

New perspectives on HIV pathogenesis. Viral replication is continuous throughout the course of disease. **J Assoc Nurses AIDS Care** 1995 Jul–Aug;6(4):26–7 (7 ref.)

Replication of baculovirus DNA. Kool M, et al. **J Gen Virol** 1995 Sep;76 (Pt 9):2103–18 (150 ref.)

Gene transfer using replication-defective retroviral and adenoviral vectors. Leber SM, et al. **Methods Cell Biol** 1996;51:161–83 (42 ref.)

Manipulating gene expression with replication-competent retroviruses. Morgan BA, et al. **Methods Cell Biol** 1996; 51:185–218 (25 ref.)

Cytomegalovirus latency and latency-specific transcription in hematopoietic progenitors. Kondo K, et al. **Scand J Infect Dis Suppl** 1995;99:63–7 (24 ref.)

[Hepatitis B virus-specific DNA polymerase activity as a sensitive marker of viral replication] Matsuura K, et al. **Nippon Rinsho** 1995 Oct;53 Suppl:275–83 (19 ref.) **(Jpn)**

[Eukaryotic DNA replication: analysis of reconstitution of SV40 DNA replication] Waga S. **Seikagaku** 1995 Sep; 67(9):1142–8 (19 ref.) **(Jpn)**

DRUG EFFECTS

Sorivudine: a potent inhibitor of varicella zoster virus replication. Whitley RJ. **Adv Exp Med Biol** 1996;394:41–4 (11 ref.)

Oltipraz, a novel inhibitor of human immunodeficiency virus type 1 (HIV-1) replication. Prochaska HJ, et al. **J Cell Biochem Suppl** 1995;22:117–25 (40 ref.)

Approaches to the development of novel inhibitors of

VIRUS REPLICATION

hepatitis C virus replication. Clarke BE. **J Viral Hepat** 1995;2(1):1–8 (40 ref.)
[Inhibition of HIV replication by ribozyme strategy] Ohkawa J, et al. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1421–9 (32 ref.) **(Jpn)**
[Nucleosides and related compounds which act as inhibitors against replication of HIV-1] Tanaka H, et al. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1250–60 (27 ref.) **(Jpn)**

IMMUNOLOGY

Apoptosis during HIV infection. A cytopathic effect of HIV or an important host-defense mechanism against viruses in general? Martin SJ, et al. **Adv Exp Med Biol** 1995; 374:129–38 (46 ref.)
The immunology of primary HIV infection: which immune responses control HIV replication? Safrit JT, et al. **Curr Opin Immunol** 1995 Aug;7(4):456–61 (36 ref.)
Influence of redox status of lymphocytes and monocytes on HIV transcription and replication. Gougerot-Pocidalo MA, et al. **Immunobiology** 1995 Jul;193(2–4):204–9 (27 ref.)

PHYSIOLOGY

Rhinoviruses and cells: molecular aspects. Rowlands DJ. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 2):S31–5 (41 ref.)
HIV interactions with cells of the nervous system. Dubois-Dalcq M, et al. **Curr Opin Neurobiol** 1995 Oct; 5(5):647–55 (65 ref.)
Dendritic cells and the replication of HIV-1. Cameron P, et al. **J Leukoc Biol** 1996 Feb;59(2):158–71 (194 ref.)
Pathophysiology of hepatitis C virus infection. Camps J, et al. **Pathol Biol (Paris)** 1995 Oct;43(8):691–702 (104 ref.)
[Epithelial dendritic cells and HIV-1 infection in vivo and in vitro] Dezutter-Dambuyant C, et al. **Pathol Biol (Paris)** 1995 Dec;43(10):882–8 (71 ref.) (Eng. Abstr.) **(Fre)**
[Hepatitis B virus replication and fulminant hepatitis: special reference to genomic variants] Kamimura T. **Nippon Rinsho** 1995 Oct;53 Suppl:473–6 (8 ref.) **(Jpn)**
[Highly conserved secondary structures predicted in 5' noncoding region of HCV: a possible connection to viral replication] Katayama K, et al. **Nippon Rinsho** 1995 Sep; 53 Suppl:43–50 (19 ref.) **(Jpn)**

VIRUS SHEDDING

DRUG EFFECTS

Subclinical shedding of HSV: its potential for reduction by antiviral therapy. Corey L, et al. **Adv Exp Med Biol** 1996; 394:11–6 (7 ref.)

VIRUSES

see related
ANTIVIRAL AGENTS
RECEPTORS, VIRUS

Environmental virology: from detection of virus in sewage and water by isolation to identification by molecular biology—a trip of over 50 years. Metcalf TG, et al. **Annu Rev Microbiol** 1995;49:461–87 (146 ref.)
[The structure and function of spherical viruses] Morimoto Y. **Seikagaku** 1995 Oct;67(10):1236–40 (15 ref.) **(Jpn)**

CHEMISTRY

Viruses. Liljas L. **Curr Opin Struct Biol** 1996 Apr;6(2):151–6 (40 ref.)
The science of macromolecular crystallization. McPherson A, et al. **Structure** 1995 Aug 15;3(8):759–68 (90 ref.)

CLASSIFICATION

Evolutionary aspects, and taxonomic definition of viruses together with mobile extrachromosomal elements of relative autonomy into a special highest rank taxon (a review). Berencsi G, et al. **Acta Microbiol Immunol Hung** 1995;42(2):141–53 (154 ref.)
ICNV 1966 to ICTV 1994: the contribution of veterinary virology. Fenner F. **Vet Microbiol** 1995 Sep;46(1–3):3–13 (27 ref.)
Molecular biology of fish viruses: a review. Bernard J, et al. **Vet Res** 1995;26(5–6):341–51 (65 ref.)

DRUG EFFECTS

Molecular mechanisms of antiviral resistance. Kimberlin DW, et al. **Antiviral Res** 1995 Apr;26(4):369–401 (79 ref.)
Modes of action of disinfectants. Maris P. **Rev Sci Tech** 1995 Mar;14(1):47–55 (24 ref.)

GENETICS

Viral vectors in gene therapy. Smith AE. **Annu Rev Microbiol** 1995;49:807–38 (150 ref.)
Molecular mechanisms of antiviral resistance. Kimberlin DW, et al. **Antiviral Res** 1995 Apr;26(4):369–401 (79 ref.)
Antagonists or altruists: do viral mutants modulate T-cell responses? Davenport MP. **Immunol Today** 1995 Sep; 16(9):432–6 (30 ref.)
The variety of human virus evolution. Fitch WM. **Mol Phylogenet Evol** 1996 Feb;5(1):247–58 (15 ref.)
Virus-vectored immunocontraception for control of wild rabbits: identification of target antigens and construction of recombinant viruses. Holland MK, et al. **Reprod Fertil Dev** 1994;6(5):631–42 (61 ref.)
Molecular biology of fish viruses: a review. Bernard J, et al. **Vet Res** 1995;26(5–6):341–51 (65 ref.)
[Diagnosis of contagious diseases in animals using PCR] Hofmann MA, et al. **Schweiz Arch Tierheilkd** 1995; 137(12):531–6 (9 ref.) (Eng. Abstr.) **(Ger)**
[Regulation of gene expression by antisense molecule] Matsukura M. **Tanpakushitsu Kakusan Koso** 1994 Jul; 40(10):1378–82 (20 ref.) **(Jpn)**

GROWTH & DEVELOPMENT

Inactivation of viruses in liquid manure. Haas B, et al. **Rev Sci Tech** 1995 Jun;14(2):435–45 (28 ref.)

IMMUNOLOGY

Cytotoxic T cell effector and memory function in viral immunity. Doherty PC. **Curr Top Microbiol Immunol** 1996; 206:1–14 (108 ref.)
Viral evasion of cytokine-mediated host defense mechanisms. Gribaudo G, et al. **G Batteriol Virol Immunol** 1994 Jan-Dec;86(1–12):3–10 (41 ref.)
Antagonists or altruists: do viral mutants modulate T-cell responses? Davenport MP. **Immunol Today** 1995 Sep; 16(9):432–6 (30 ref.)
Viruses, cytokines, antigens, and autoimmunity. Gianani R, et al. **Proc Natl Acad Sci U S A** 1996 Mar 19;93(6):2257–9 (43 ref.)
Virus escape from immune control: mechanisms of persistence within the host. Paroli M, et al. **Res Virol** 1995 Jul-Aug;146(4):267–71 (27 ref.)
Immunology taught by viruses [see comments] Zinkernagel RM. **Science** 1996 Jan 12;271(5246):173–8 (51 ref.) Comment in: Science 1996 May 3;272(5262):634–5.
Viral immunopathology. Introduction. Zinkernagel RM, et al. **Springer Semin Immunopathol** 1995;17(2–3):119–20 (0 ref.)

ISOLATION & PURIFICATION

A new look at viruses in type 1 diabetes. Yoon JW. **Diabetes Metab Rev** 1995 Jul;11(2):83–107 (194 ref.)
Virally inactivated fresh frozen plasma. Williamson LM, et al. **Vox Sang** 1995;69(3):159–65 (45 ref.)

METABOLISM

Microbial recognition of target-cell glycoconjugates. Karlsson KA. **Curr Opin Struct Biol** 1995 Oct;5(5):622–35 (74 ref.)

PATHOGENICITY

Acute pharyngitis: etiology and diagnosis. Bisno AL. **Pediatrics** 1996 Jun;97(6 Pt 2):949–54 (76 ref.)
Multiple viral pathogenicity: another paradigm in medical research? Sotelo J. **Perspect Biol Med** 1996 Summer; 39(4):507–13 (20 ref.)
Role of viruses in the loss of tolerance to self-antigens and in autoimmune diseases. von Herrath MG, et al. **Trends Microbiol** 1995 Nov;3(11):424–30 (61 ref.)

PHYSIOLOGY

Penetration of solutes, viruses, and cells across the blood-brain barrier. Brightman MW, et al. **Curr Top Microbiol Immunol** 1995;202:63–78 (56 ref.)
Virus entry and release in polarized epithelial cells. Compans RW. **Curr Top Microbiol Immunol** 1995;202:209–19 (54 ref.)
Virus-neuron-cytotoxic T lymphocyte interactions. Rall GF, et al. **Curr Top Microbiol Immunol** 1995;202:261–73 (33 ref.)
Strategies used by viruses to evade the immune response. Paroli M, et al. **Ital J Gastroenterol** 1995 Apr;27(3):133–6 (33 ref.)

ULTRASTRUCTURE

Ab initio phase determination and phase extension using non-crystallographic symmetry. Rossmann MG. **Curr Opin Struct Biol** 1995 Oct;5(5):650–5 (51 ref.)
Virus crystallography. Fry E, et al. **Methods Mol Biol** 1996; 56:319–63 (160 ref.)

VISCERA

Visceral pain. McMahon SB, et al. **Br J Anaesth** 1995 Aug; 75(2):132–44 (114 ref.)

INJURIES

Visceral injury. Porter JM, et al. **Curr Opin Gen Surg** 1993; :62–8 (31 ref.)

INNERVATION

Neurobiology of visceral afferent neurons: neuroanatomy, functions, organ regulations and sensations. Jänig W. **Biol Psychol** 1996 Jan 5;42(1–2):29–51 (105 ref.)
Interoception. Vaitl D. **Biol Psychol** 1996 Jan 5;42(1–2):1–27 (100 ref.)

PARASITOLOGY

Visceral leishmaniasis emerging as an important opportunistic infection in HIV-infected persons living in areas nonendemic for Leishmania donovani. Albrecht H, et al. **Arch Pathol Lab Med** 1996 Feb;120(2):189–98 (53 ref.)

SURGERY

[Liver transplantation as school for visceral surgery—experiences for perioperative management] Neuhaus P, et al. **Chirurg** 1996 Apr;67(4):341–7 (31 ref.) (Eng. Abstr.) **(Ger)**

VISCERAL AFFERENTS

PHYSIOLOGY

Neurobiology of visceral afferent neurons: neuroanatomy, functions, organ regulations and sensations. Jänig W. **Biol Psychol** 1996 Jan 5;42(1–2):29–51 (105 ref.)
[The chemical structure of the peripheral autonomic (visceral) reflex] Nozdrachev AD. **Usp Fiziol Nauk** 1996 Apr-Jun;27(2):28–60 (74 ref.) (Eng. Abstr.) **(Rus)**

PHYSIOPATHOLOGY

Somatic dysfunction and the phenomenon of visceral disease simulation: a probable explanation for the apparent effectiveness of somatic therapy in patients presumed to be suffering from true visceral disease. Nansel D, et al. **J Manipulative Physiol Ther** 1995 Jul-Aug;18(6):379–97 (351 ref.)

VISCERAL MYOPATHY see **INTESTINAL PSEUDO-OBSTRUCTION**

VISCOSITY

see related
BLOOD VISCOSITY

VISION

see related
VISUAL PERCEPTION

The importance and state of medical and public health research related to vision in Australia. McCarty CA, et al. **Aust N Z J Ophthalmol** 1996 Feb;24(1):3–5 (8 ref.)
Recovery of vision following transsphenoidal surgery for pituitary adenomas. Powell M. **Br J Neurosurg** 1995; 9(3):367–73 (7 ref.)
Too good to be true? New technologies and surgical procedures for better vision. Perlman EM. **R I Med** 1995 Dec;78(12):359–62 (3 ref.)
[Perception in space. Visual aspects of space perception] Viader F. **Rev Neurol (Paris)** 1995 Aug-Sep; 151(8–9):466–73 (67 ref.) (Eng. Abstr.) **(Fre)**

DRUG EFFECTS

Electrophysiology of the visual system: from neuroscience to human neuropharmacology. Sannita WG. **Neuropsychobiology** 1995;32(4):208–13 (44 ref.)

PHYSIOLOGY

Indocyanine green angiography. Can it help preserve the vision of our patients? [editorial; comment] Bressler NM, et al. **Arch Ophthalmol** 1996 Jun;114(6):747–9 (30 ref.) Comment on: Arch Ophthalmol 1996 Jun;114(6):693–7.
Frontal lobe mechanisms subserving vision-for-action versus vision-for-perception. Boussaoud D, et al. **Behav Brain Res** 1995 Dec 14;72(1–2):1–15 (145 ref.)
Neural mechanisms for stimulus selection in cortical areas of the macaque subserving object vision. Chelazzi L. **Behav Brain Res** 1995 Nov;71(1–2):125–34 (84 ref.)
Multiple mechanisms of visual-spatial attention: recent evidence from human electrophysiology. Luck SJ. **Behav Brain Res** 1995 Nov;71(1–2):113–23 (52 ref.)
A review of simultaneous visual discrimination as a method of training octopuses. Boal JG. **Biol Rev Camb Philos Soc** 1996 May;71(2):157–90 (66 ref.)
The olfactory and visual systems are closely related in Drosophila. Gaines P, et al. **Braz J Med Biol Res** 1995 Feb;28(2):161–7 (27 ref.)
The sources of visual information to the primate frontal lobe: a novel role for the superior parietal lobule. Caminiti R, et al. **Cereb Cortex** 1996 May-Jun;6(3):319–28 (102 ref.)
Wiring up the visual system. Beazley LD, et al. **Clin Exp Pharmacol Physiol** 1995 Aug;22(8):550–8 (53 ref.)
Schwann cells and the regrowth of axons in the mammalian CNS: a review of transplantation studies in the rat visual system. Harvey AR, et al. **Clin Exp Pharmacol Physiol** 1995 Aug;22(8):569–79 (77 ref.)
Vision: filling in and pop out. Derrington A. **Curr Biol** 1996 Feb 1;6(2):141–3 (7 ref.)
Dyslexia. Reading between the laminae. Walsh V. **Curr Biol** 1995 Nov 1;5(11):1216–7 (10 ref.)
Parallel versus serial processing: new vistas on the distributed organization of the visual system. Bullier J, et al. **Curr Opin Neurobiol** 1995 Aug;5(4):497–503 (70 ref.)
Age-related changes in visual function and visual organs of rats. Kiyosawa I. **Exp Anim** 1996 Apr;45(2):103–14 (34 ref.)
Drosophila in vision research. The Friedenwald Lecture. Pak WL. **Invest Ophthalmol Vis Sci** 1995 Nov;36(12):2340–57 (137 ref.)
Vision in dogs. Miller PE, et al. **J Am Vet Med Assoc** 1995

Dec 15;207(12):1623–34 (68 ref.)
Electrophysiology of the visual system: from neuroscience to human neuropharmacology. Sannita WG. **Neuropsychobiology** 1995;32(4):208–13 (44 ref.)
How photons start vision. Baylor D. **Proc Natl Acad Sci U S A** 1996 Jan 23;93(2):560–5 (44 ref.)
Emergence of order in visual system development. Shatz CJ. **Proc Natl Acad Sci U S A** 1996 Jan 23;93(2):602–8 (61 ref.)
The biology of vision of Drosophila. Zuker CS. **Proc Natl Acad Sci U S A** 1996 Jan 23;93(2):571–6 (52 ref.)
Separating colour and luminance information in the visual system. Kingdom FA, et al. **Spat Vis** 1995;9(2):191–219 (77 ref.)
'My most true mind thus makes mine eye untrue'. Albright TD. **Trends Neurosci** 1995 Aug;18(8):331–3 (10 ref.)
Second-order neurones and receptor mechanisms in visual- and olfactory-information processing. Nakanishi S. **Trends Neurosci** 1995 Aug;18(8):359–64 (50 ref.)
[Anatomo-physiological bases of residual vision following lesion to the primary visual area. Contribution to electrophysiological approach in monkeys] Girard P. **Rev Neurol (Paris)** 1995 Aug–Sep;151(8–9):457–65 (30 ref.) (Eng. Abstr.) **(Fre)**
[The effect of painful dazzle on the perception process] Janosik E. **Med Pr** 1996;47(2):175–81 (16 ref.) (Eng. Abstr.) **(Pol)**
[The epiphysis in the visual analyzer system] Arushanian EB, et al. **Usp Fiziol Nauk** 1995 Jul–Sep;26(3):25–40 (98 ref.) (Eng. Abstr.) **(Rus)**

VISION, BINOCULAR

[Visual and sensory results of surgical treatment of cataract in children. Apropos of 135 cases] Lesueur L, et al. **J Fr Ophtalmol** 1995;18(11):667–77 (28 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOLOGY

Binocular eye movements and the perception of depth. Collewijn H, et al. **Rev Oculomot Res** 1990;4:213–61 (169 ref.)

VISION DISORDERS

Understanding cortical visual impairment in children. Baker-Nobles L, et al. **Am J Occup Ther** 1995 Oct; 49(9):899–903 (12 ref.)

CHEMICALLY INDUCED

Medications used to prevent migraine headaches and their potential ocular adverse effects. Doughty MJ, et al. **Optom Vis Sci** 1995 Dec;72(12):879–91 (176 ref.)

COMPLICATIONS

Occupational therapy and the person with diabetes and vision impairment. Cate Y, et al. **Am J Occup Ther** 1995 Oct; 49(9):905–11 (31 ref.)
Charles Bonnet syndrome: an early marker for dementia? [see comments] Pliskin NH, et al. **J Am Geriatr Soc** 1996 Sep;44(9):1055–61 (43 ref.) Comment in: J Am Geriatr Soc 1996 Sep;44(9):1128–9.

DIAGNOSIS

Screening for ocular dysfunction in children: approaching a common program. Lennerstrand G, et al. **Acta Ophthalmol Scand Suppl** 1995;(214):26–38; discussion 39–40 (88 ref.)
Advances in neuroimaging of the visual pathways. Davis PC, et al. **Am J Ophthalmol** 1996 Jun;121(6):690–705 (37 ref.)
Clinical alternative for reducing the time needed to perform automated threshold perimetry. Fingeret M. **J Am Optom Assoc** 1995 Nov;66(11):699–705 (14 ref.)
Investigation of visual loss: neuro-ophthalmology from a neurologist's perspective. Lueck CJ. **J Neurol Neurosurg Psychiatry** 1996 Mar;60(3):275–80 (48 ref.)
The Glenn A. Fry Award Lecture. Early losses of visual function in glaucoma. Johnson CA. **Optom Vis Sci** 1995 Jun;72(6):359–70 (67 ref.)
[Neuroradiology in ophthalmology. 1] Müller-Forell W, et al. **Ophthalmologe** 1995 Aug;92(4):595–614 (0 ref.) **(Ger)**
[Behr's syndrome. A report of 2 siblings studied by MR] Pascual-Castroviejo I, et al. **An Esp Pediatr** 1996 Jun; 44(6):593–5 (11 ref.) **(Spa)**

EPIDEMIOLOGY

Methods for a population-based study of eye disease: the Melbourne Visual Impairment Project. Livingston PM, et al. **Ophthalmic Epidemiol** 1994 Dec;1(3):139–48 (32 ref.)

ETIOLOGY

The eye in systemic disease. Stanbury RM, et al. **Br J Hosp Med** 1996 Jan 17–Feb 6;55(1–2):19–26 (16 ref.)
Investigation of visual loss: neuro-ophthalmology from a neurologist's perspective. Lueck CJ. **J Neurol Neurosurg Psychiatry** 1996 Mar;60(3):275–80 (48 ref.)
Alzheimer's disease and the eye. Armstrong RA, et al. **Ophthalmic Physiol Opt** 1996 Mar;16 Suppl 1:S2–8 (32 ref.)
[Vision disorders in inflammatory-rheumatic diseases] Bernauer W. **Ther Umsch** 1996 Jan;53(1):58–67 (16 ref.) (Eng. Abstr.) **(Ger)**
[Why are AIDS patients frequently visually impaired?] Fabricius EM. **Ther Umsch** 1996 Jan;53(1):49–57 (13 ref.) (Eng. Abstr.) **(Ger)**
[Vision disorders to vascular dysregulation] Flammer F, et al. **Ther Umsch** 1996 Jan;53(1):37–42 (20 ref.) (Eng. Abstr.) **(Ger)**
[Vision disorders in retrochiasmatic lesions of the visual pathways] Huber A. **Ther Umsch** 1996 Jan;53(1):31–6 (15 ref.) (Eng. Abstr.) **(Ger)**
[Zinc-deficient disorders of sense organs—dark adaptation, taste and smell disorders] Tomita H. **Nippon Rinsho** 1996 Jan;54(1):141–7 (40 ref.) (Eng. Abstr.) **(Jpn)**

PREVENTION & CONTROL

Low vision: physician screening helps to improve patient function. Castor TD, et al. **Geriatrics** 1995 Dec;50(12):51–2, 55–7; quiz 58–9 (5 ref.)
Eyeglass MEDRETE: practical considerations (a user's guide). Dreher RJ, et al. **Mil Med** 1996 Jun;161(6):334–8 (4 ref.)

VISION, LOW see **VISION, SUBNORMAL**

VISION, MONOCULAR

Success of monovision in presbyopes: review of the literature and potential applications to refractive surgery. Jain S, et al. **Surv Ophthalmol** 1996 May–Jun;40(6):491–9 (67 ref.)

VISION SCREENING

Screening for ocular dysfunction in children: approaching a common program. Lennerstrand G, et al. **Acta Ophthalmol Scand Suppl** 1995;(214):26–38; discussion 39–40 (88 ref.)

METHODS

Low vision: physician screening helps to improve patient function. Castor TD, et al. **Geriatrics** 1995 Dec;50(12):51–2, 55–7; quiz 58–9 (5 ref.)

VISION, SUBNORMAL

PHYSIOPATHOLOGY

Luminance and chromatic contrast effects on reading and object recognition in low vision: a review of the literature. Eperjesi F, et al. **Ophthalmic Physiol Opt** 1995 Nov; 15(6):561–8 (20 ref.)

VISION TESTS

METHODS

Newer visual function tests in the evaluation of glaucoma. Stewart WC, et al. **Surv Ophthalmol** 1995 Sep–Oct; 40(2):119–35 (186 ref.)

VISITING NURSES see **COMMUNITY HEALTH NURSING**

VISNA

Selected models of HIV-induced neurological disease. Narayan O, et al. **Curr Top Microbiol Immunol** 1995; 202:151–66 (61 ref.)

VIROLOGY

Early events in infection of lymphoid tissue by a lentivirus, maedi-visna. Blacklaws B, et al. **Trends Microbiol** 1995 Nov;3(11):434–40 (48 ref.)

VISNA-MAEDI VIRUS

IMMUNOLOGY

Early events in infection of lymphoid tissue by a lentivirus, maedi-visna. Blacklaws B, et al. **Trends Microbiol** 1995 Nov;3(11):434–40 (48 ref.)

VISNA VIRUS see **VISNA-MAEDI VIRUS**

VISUAL ACUITY

see related
FORM PERCEPTION
REFRACTION, OCULAR
REFRACTIVE ERRORS

Vernier acuity and aging. Lakshminarayanan V, et al. **Int Ophthalmol** 1995;19(2):109–15 (61 ref.)
[Visual and sensory results of surgical treatment of cataract in children. Apropos of 135 cases] Lesueur L, et al. **J Fr Ophtalmol** 1995;18(11):667–77 (28 ref.) (Eng. Abstr.) **(Fre)**

VISUAL AIDS see **AUDIOVISUAL AIDS**

VISUAL ANALOGUE PAIN SCALE see **PAIN MEASUREMENT**

VISUAL CONTRAST SENSITIVITY see **CONTRAST SENSITIVITY**

VISUAL CORTEX

ANATOMY & HISTOLOGY

Anatomical substrates for early stages in cortical processing of visual information in the macaque monkey. Levitt JB, et al. **Behav Brain Res** 1996 Apr;76(1–2):5–19 (119 ref.)

CYTOLOGY

Cellular aspects of callosal connections and their development. Innocenti GM, et al. **Neuropsychologia** 1995 Aug;33(8):961–87 (99 ref.)

PHYSIOLOGY

Cortical mechanisms for visual perception of object motion and position in space. Battaglini PP, et al. **Behav Brain Res** 1996 Apr;76(1–2):143–54 (57 ref.)
Interareal synchronization in the visual cortex. Bressler SL. **Behav Brain Res** 1996 Apr;76(1–2):37–49 (167 ref.)
Neural mechanisms for stimulus selection in cortical areas of the macaque subserving object vision. Chelazzi L. **Behav Brain Res** 1995 Nov;71(1–2):125–34 (84 ref.)
Plasticity following neonatal visual cortex damage in cats. Spear PD. **Can J Physiol Pharmacol** 1995 Sep;73(9):1389–97 (40 ref.)
The functional organization of local circuits in visual cortex: insights from the study of tree shrew striate cortex. Fitzpatrick D. **Cereb Cortex** 1996 May–Jun;6(3):329–41 (76 ref.)
Human visual cortex. Progress and puzzles. Kaas JH. **Curr Biol** 1995 Oct 1;5(10):1126–8 (12 ref.)
Parallel versus serial processing: new vistas on the distributed organization of the visual system. Bullier J, et al. **Curr Opin Neurobiol** 1995 Aug;5(4):497–503 (70 ref.)
Orientation in visual cortex: a simple mechanism emerges. Das A. **Neuron** 1996 Mar;16(3):477–80 (23 ref.)
Electrophysiology of the visual system: from neuroscience to human neuropharmacology. Sannita WG. **Neuropsychobiology** 1995;32(4):208–13 (44 ref.)
Functional MRI: are we all moving towards artifactual conclusions? Or fMRI fact or fancy? Weisskoff RM. **NMR Biomed** 1995 May;8(3):101–3 (10 ref.)
Involvement of nerve growth factor in visual cortex plasticity. Gu Q. **Rev Neurosci** 1995 Oct–Dec;6(4):329–51 (259 ref.)
The brain's visual world: representation of visual targets in cerebral cortex. Maunsell JH. **Science** 1995 Nov 3; 270(5237):764–9 (43 ref.)
Functional brain imaging studies of cortical mechanisms for memory. Ungerleider LG. **Science** 1995 Nov 3; 270(5237):769–75 (94 ref.)
Behind the optic nerve: an inside view of the primate visual system. Van Essen DC. **Trans Am Ophthalmol Soc** 1995; 93:123–33 (2 ref.)
Theory meets experiment: correlated neural activity helps determine ocular dominance column periodicity. Goodhill GJ, et al. **Trends Neurosci** 1995 Oct;18(10):437–9 (38 ref.)
[Role of cortical motor areas in voluntary movements] Kurata K. **No To Shinkei** 1995 Dec;47(12):1135–42 (35 ref.) **(Jpn)**

PHYSIOPATHOLOGY

Understanding cortical visual impairment in children. Baker-Nobles L, et al. **Am J Occup Ther** 1995 Oct; 49(9):899–903 (12 ref.)
The effects of visual cortex lesions on the perception of rotated shapes. Walsh V, et al. **Behav Brain Res** 1996 Apr; 76(1–2):127–42 (75 ref.)
Turning a blind eye to cortical receptive fields. Chapman B, et al. **Neuron** 1996 Jan;16(1):9–12 (13 ref.)
[Anatomo-physiological bases of residual vision following lesion to the primary visual area. Contribution to electrophysiological approach in monkeys] Girard P. **Rev Neurol (Paris)** 1995 Aug–Sep;151(8–9):457–65 (30 ref.) (Eng. Abstr.) **(Fre)**
[Neural mechanisms in infantile esotropia—what is not functioning? (news)] Tychsen L, et al. **Klin Monatsbl Augenheilkd** 1996 Mar;208(3):aA4–12 (0 ref.) **(Ger)**

VISUAL EVOKED RESPONSE see **EVOKED POTENTIALS, VISUAL**

VISUAL FIELDS

see related
PERIMETRY

Dapiprazole's effect upon accommodative recovery: is it due entirely to changes in depth of field? Molinari JF, et al. **Optom Vis Sci** 1995 Aug;72(8):552–6 (18 ref.)
[Is trabeculectomy without danger in case of threatened fixation?] Grunewald F, et al. **J Fr Ophtalmol** 1996; 19(4):253–8 (18 ref.) (Eng. Abstr.) **(Fre)**

VISUAL FIELDS

PHYSIOLOGY

The relationship between visual field size and electroretinogram amplitude in retinitis pigmentosa. Sandberg MA, et al. **Invest Ophthalmol Vis Sci** 1996 Jul; 37(8):1693–8 (10 ref.)

The Glenn A. Fry Award Lecture. Early losses of visual function in glaucoma. Johnson CA. **Optom Vis Sci** 1995 Jun;72(6):359–70 (67 ref.)

Receptive-field dynamics in the central visual pathways. DeAngelis GC, et al. **Trends Neurosci** 1995 Oct; 18(10):451–8 (60 ref.)

VISUAL MOTOR COORDINATION see **PSYCHOMOTOR PERFORMANCE**

VISUAL PATHWAYS

Rods, cones and calcium. McNaughton PA. **Cell Calcium** 1995 Oct;18(4):275–84 (66 ref.)

The magnocellular deficit hypothesis in dyslexia: a review of reported evidence. Greatrex JC, et al. **Ophthalmic Physiol Opt** 1995 Sep;15(5):501–6 (40 ref.)

ANATOMY & HISTOLOGY

Anatomical substrates for early stages in cortical processing of visual information in the macaque monkey. Levitt JB, et al. **Behav Brain Res** 1996 Apr;76(1–2):5–19 (119 ref.)

BLOOD SUPPLY

Stereotactic radiosurgery for postgeniculate visual pathway arteriovenous malformations. Pollock BE, et al. **J Neurosurg** 1996 Mar;84(3):437–41 (29 ref.)

EMBRYOLOGY

Development of second-order vestibular projections in the chicken embryo. Glover JC. **Ann N Y Acad Sci** 1996 Jun 19;781:13–20 (12 ref.)

Mechanisms and molecules controlling the development of retinal maps. Roskies A, et al. **Perspect Dev Neurobiol** 1995; 3(1):63–75 (122 ref.)

GROWTH & DEVELOPMENT

Development and plasticity of the neural circuitry underlying visual recognition memory. Webster MJ, et al. **Can J Physiol Pharmacol** 1995 Sep;73(9):1364–71 (37 ref.)

PATHOLOGY

Advances in neuroimaging of the visual pathways. Davis PC, et al. **Am J Ophthalmol** 1996 Jun;121(6):693–705 (37 ref.)

PHYSIOLOGY

Interareal synchronization in the visual cortex. Bressler SL. **Behav Brain Res** 1996 Apr;76(1–2):37–49 (167 ref.)

Wiring up the visual system. Beazley LD, et al. **Clin Exp Pharmacol Physiol** 1995 Aug;22(8):550–8 (53 ref.)

Path integration in mammals and its interaction with visual landmarks. Etienne AS, et al. **J Exp Biol** 1996 Jan;199 (Pt 1):201–9 (49 ref.)

Computations on metric maps in mammals: getting oriented and choosing a multi-destination route. Gallistel CR, et al. **J Exp Biol** 1996 Jan;199 (Pt 1):211–7 (47 ref.)

Deciphering the hippocampal polyglot: the hippocampus as a path integration system. McNaughton BL, et al. **J Exp Biol** 1996 Jan;199 (Pt 1):173–85 (56 ref.)

TRP is cracked but is CRAC TRP? Clapham DE. **Neuron** 1996 Jun;16(6):1069–72 (17 ref.)

The brain's visual world: representation of visual targets in cerebral cortex. Maunsell JH. **Science** 1995 Nov 3; 270(5237):764–9 (43 ref.)

Behind the optic nerve: an inside view of the primate visual system. Van Essen DC. **Trans Am Ophthalmol Soc** 1995; 93:123–33 (2 ref.)

Receptive-field dynamics in the central visual pathways. DeAngelis GC, et al. **Trends Neurosci** 1995 Oct; 18(10):451–8 (60 ref.)

PHYSIOPATHOLOGY

[Vision disorders in retrochiasmatic lesions of the visual pathways] Huber A. **Ther Umsch** 1996 Jan;53(1):31–6 (15 ref.) (Eng. Abstr.) **(Ger)**

VISUAL PERCEPTION

Is there a sex difference in human laterality? II. An exhaustive survey of visual laterality studies from six neuropsychology journals. Hiscock M, et al. **J Clin Exp Neuropsychol** 1995 Aug;17(4):590–610 (60 ref.)

Inverse-intensity effect in duration of visible persistence. Di Lollo V, et al. **Psychol Bull** 1995 Sep;118(2):223–37 (100 ref.)

The brain's visual world: representation of visual targets in cerebral cortex. Maunsell JH. **Science** 1995 Nov 3; 270(5237):764–9 (43 ref.)

[Acoustic and optical perceptual disorders in depressive diseases—an overview of results from experimental studies] Kallert TW. **Schweiz Arch Neurol Psychiatr** 1996; 147(1):4–11 (61 ref.) (Eng. Abstr.) **(Ger)**

PHYSIOLOGY

Hemispheric asymmetry for visual information processing. Hellige JB. **Acta Neurobiol Exp (Warsz)** 1996;56(1):485–97 (66 ref.)

Anatomical substrates for early stages in cortical processing of visual information in the macaque monkey. Levitt JB, et al. **Behav Brain Res** 1996 Apr;76(1–2):5–19 (119 ref.)

Task dependency of visual processing in the human visual system. Orban GA, et al. **Behav Brain Res** 1996 Apr; 76(1–2):215–23 (41 ref.)

On the specificity of neurons and visual areas. Schiller PH. **Behav Brain Res** 1996 Apr;76(1–2):21–35 (83 ref.)

Visual perception and phenomenal consciousness. Stoerig P, et al. **Behav Brain Res** 1995 Nov;71(1–2):147–56 (69 ref.)

Development and plasticity of the neural circuitry underlying visual recognition memory. Webster MJ, et al. **Can J Physiol Pharmacol** 1995 Sep;73(9):1364–71 (37 ref.)

The sources of visual information to the primate frontal lobe: a novel role for the superior parietal lobule. Caminiti R, et al. **Cereb Cortex** 1996 May–Jun;6(3):319–28 (102 ref.)

Vision: filling in and pop out. Derrington A. **Curr Biol** 1996 Feb 1;6(2):141–3 (7 ref.)

Path integration in mammals and its interaction with visual landmarks. Etienne AS, et al. **J Exp Biol** 1996 Jan;199 (Pt 1):201–9 (49 ref.)

Turning a blind eye to cortical receptive fields. Chapman B, et al. **Neuron** 1996 Jan;16(1):9–12 (13 ref.)

Visual integration in the split brain. Corballis MC. **Neuropsychologia** 1995 Aug;33(8):937–59 (78 ref.)

Cerebral correlates of visual awareness. Milner AD. **Neuropsychologia** 1995 Sep;33(9):1117–30 (84 ref.)

Multineuronal codes in retinal signaling. Meister M. **Proc Natl Acad Sci U S A** 1996 Jan 23;93(2):609–14 (32 ref.)

The role of visual and cognitive processes in the control of eye movement. Kowler E. **Rev Oculomot Res** 1990; 4:1–70 (255 ref.)

Comparison of perception in the moving and stationary eye. Sperling G. **Rev Oculomot Res** 1990;4:307–51 (120 ref.)

Eye movements in visual search: cognitive, perceptual and motor control aspects. Viviani P. **Rev Oculomot Res** 1990; 4:353–93 (235 ref.)

[The effect of painful dazzle on the perception process] Janosik E. **Med Pr** 1996;47(2):175–81 (16 ref.) (Eng. Abstr.) **(Pol)**

[Development of visual perception in early childhood] Farber DA, et al. **Fiziol Cheloveka** 1995 Sep–Oct;21(5):162–71 (92 ref.) **(Rus)**

[The epiphysis in the visual analyzer system] Arushanian EB, et al. **Usp Fiziol Nauk** 1995 Jul–Sep;26(3):25–40 (98 ref.) (Eng. Abstr.) **(Rus)**

[The specific features of the work of the visual mechanisms in the right and left hemispheres of the human brain] Krol' VM. **Zh Vysh Nerv Deiat Im I P Pavlova** 1995 Nov–Dec; 45(6):1075–84 (35 ref.) (Eng. Abstr.) **(Rus)**

VISUAL PURPLE see **RHODOPSIN**

VISUAL STIMULATION see **PHOTIC STIMULATION**

VITAL STATISTICS

[A practical approach to health information in Spain] Mirón Canelo JA, et al. **Rev Clin Esp** 1996 Mar;196(3):174–8 (57 ref.) **(Spa)**

VITAMIN A

ADMINISTRATION & DOSAGE

Interdependence of vitamin A and iron: an important association for programmes of anaemia control. Bloem MW. **Proc Nutr Soc** 1995 Jul;54(2):501–8 (39 ref.)

ANALOGS & DERIVATIVES

[Retinyl palmitate] Moriwaki H, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:681–3 (11 ref.) **(Jpn)**

ANALYSIS

Breast-milk vitamin A as an indicator of the vitamin A status of women and infants. Stoltzfus RJ, et al. **Bull World Health Organ** 1995;73(5):703–11 (44 ref.)

[New fluorogenic dienophile: synthesis, reaction with vitamin D, vitamin A and microcystins, and application to fluorometric assays] Shimizu M, et al. **Yakugaku Zasshi** 1995 Aug;115(8):584–602 (67 ref.) (Eng. Abstr.) **(Jpn)**

BLOOD

[Vitamin A (retinoids)] Moriwaki H, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:688–90 (4 ref.) **(Jpn)**

GENETICS

Chromosomal locations and modes of action of genes of the retinoid (vitamin A) system support their involvement in the etiology of schizophrenia. Goodman AB. **Am J Med Genet** 1995 Aug 14;60(4):335–48 (216 ref.)

PHARMACOLOGY

The possibility of active form of vitamins A and D as suppressors on adipocyte development via ligand-dependent transcriptional regulators. Kawada T, et al. **Int J Obes Relat Metab Disord** 1996 Mar;20 Suppl 3:S52–7 (22 ref.)

Benefits and liabilities of vitamin A and carotenoids. Olson JA. **J Nutr** 1996 Apr;126(4 Suppl):1208S–12S (30 ref.)

Activity profiles of antimutagens: in vitro and in vivo data. Waters MD, et al. **Mutat Res** 1996 Feb 19;350(1):109–29 (117 ref.)

PHYSIOLOGY

Retinoic acid and retinoic acid receptors in development. Sucov HM, et al. **Mol Neurobiol** 1995 Apr–Jun; 10(2–3):169–84 (113 ref.)

[The significance of vitamin A for the immune system (review)] Kolb E. **Berl Munch Tierarztl Wochenschr** 1995 Oct;108(10):385–90 (45 ref.) (Eng. Abstr.) **(Ger)**

THERAPEUTIC USE

The contribution of vitamin A to public health. Underwood BA, et al. **FASEB J** 1996 Jul;10(9):1040–8 (57 ref.)

[Vitamin A derivatives and prevention of bronchial cancers] Thiberville L, et al. **Rev Mal Respir** 1996;13(2):193–5 (19 ref.) **(Fre)**

VITAMIN A ACID see **TRETINOIN**

VITAMIN A ALDEHYDE see **RETINALDEHYDE**

VITAMIN A DEFICIENCY

see related
XEROPHTHALMIA

[Subclinical vitamin A deficiency—health implications in children] Hershkovitz E, et al. **Harefuah** 1995 Dec 15; 129(12):591–5 (45 ref.) **(Heb)**

DRUG THERAPY

The contribution of vitamin A to public health. Underwood BA, et al. **FASEB J** 1996 Jul;10(9):1040–8 (57 ref.)

VIROLOGY

Vitamin A and retinoids in antiviral responses. Ross AC, et al. **FASEB J** 1996 Jul;10(9):979–85 (53 ref.)

VITAMIN B 1 see **THIAMINE**

VITAMIN B 2 see **RIBOFLAVIN**

VITAMIN B 6 see **PYRIDOXINE**

VITAMIN B 12

BLOOD

Blood folic acid and vitamin B12 in relation to neural tube defects. Wald NJ, et al. **Br J Obstet Gynaecol** 1996 Apr; 103(4):319–24 (16 ref.)

[Vitamin B12] Uchiyama Y. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:704–8 (17 ref.) **(Jpn)**

METABOLISM

Malabsorption of food cobalamin. Carmel R. **Baillieres Clin Haematol** 1995 Sep;8(3):639–55 (67 ref.)

Inherited errors of cobalamin metabolism and their management. Linnell JC, et al. **Baillieres Clin Haematol** 1995 Sep;8(3):567–601 (154 ref.)

An update of vitamin B12 metabolism and deficiency states. Swain R. **J Fam Pract** 1995 Dec;41(6):595–600 (41 ref.)

PHYSIOLOGY

Vitamin B12 in health and disease: part I—inherited disorders of function, absorption, and transport. Kapadia CR. **Gastroenterologist** 1995 Dec;3(4):329–44 (89 ref.)

THERAPEUTIC USE

Screening the older population for cobalamin (vitamin B12) deficiency. Stabler SP. **J Am Geriatr Soc** 1995 Nov; 43(11):1290–7 (47 ref.)

VITAMIN B 12-BINDING PROTEINS see **TRANSCOBALAMINS**

VITAMIN B 12 DEFICIENCY

COMPLICATIONS

Review: cobalamin deficiency and mental impairment in elderly people. van Goor L, et al. **Age Ageing** 1995 Nov; 24(6):536–42 (80 ref.)

Neurological complications of acquired cobalamin deficiency: clinical aspects. Savage DG, et al. **Baillieres Clin Haematol** 1995 Sep;8(3):657–78 (114 ref.)

[Neuropsychiatric symptoms in vitamin B12 deficiency and microcarcinoidosis. The complications of chronic atrophic gastritis] Ossege LM, et al. **Dtsch Med Wochenschr** 1996 Jun 7;121(23):758–62 (25 ref.) (Eng. Abstr.) **(Ger)**

DIAGNOSIS

Screening the older population for cobalamin (vitamin B12)

deficiency. Stabler SP. **J Am Geriatr Soc** 1995 Nov; 43(11):1290–7 (47 ref.)
An update of vitamin B12 metabolism and deficiency states. Swain R. **J Fam Pract** 1995 Dec;41(6):595–600 (41 ref.)

GENETICS

Vitamin B12 in health and disease: part I—inherited disorders of function, absorption, and transport. Kapadia CR. **Gastroenterologist** 1995 Dec;3(4):329–44 (89 ref.)

METABOLISM

Metabolite assays in cobalamin and folate deficiency. Green R. **Baillieres Clin Haematol** 1995 Sep;8(3):533–66 (161 ref.)
The biochemical basis of the neuropathy in cobalamin deficiency. Weir DG, et al. **Baillieres Clin Haematol** 1995 Sep;8(3):479–97 (103 ref.)
High prevalence of cobalamin deficiency in the elderly. Allen RH, et al. **Trans Am Clin Climatol Assoc** 1995;107:37–45; discussion 45–7 (14 ref.)

PATHOLOGY

Morphology, biology and biochemistry of cobalamin- and folate-deficient bone marrow cells. Wickramasinghe SN. **Baillieres Clin Haematol** 1995 Sep;8(3):441–59 (70 ref.)

PHYSIOPATHOLOGY

Cobalamin and folate deficiency in the elderly. Matthews JH. **Baillieres Clin Haematol** 1995 Sep;8(3):679–97 (96 ref.)
Trypsin inhibition: a potential cause of cobalamin deficiency common to the pathogenesis of Alzheimer-type dementia and AIDS dementia complex? McCaddon A, et al. **Med Hypotheses** 1995 Aug;45(2):200–4 (49 ref.)

PREVENTION & CONTROL

Vitamin B12 deficiency and the fortification of food with folic acid. Bower C, et al. **Eur J Clin Nutr** 1995 Nov; 49(11):787–93 (34 ref.)

VITAMIN B DEFICIENCY

BLOOD

[P-methylmalonate and P-homocysteine: metabolic markers of vitamin deficiencies. Background, validity and applications] Rasmussen K. **Ugeskr Laeger** 1996 Jul 1; 158(27):3913–8 (40 ref.) (Eng. Abstr.) **(Dan)**

METABOLISM

Carnitine in neonatal nutrition. Borum PR. **J Child Neurol** 1995 Nov;10 Suppl 2:S25–31 (51 ref.)
Carnitine deficiency in epilepsy: Risk factors and treatment. Coulter DL. **J Child Neurol** 1995 Nov;10 Suppl 2:S32–9 (90 ref.)
Carnitine in human immunodeficiency virus type 1 infection/acquired immune deficiency syndrome. Mintz M. **J Child Neurol** 1995 Nov;10 Suppl 2:S40–4 (50 ref.)
Primary and secondary carnitine deficiency syndromes. Pons R, et al. **J Child Neurol** 1995 Nov;10 Suppl 2:S8–24 (149 ref.)

VITAMIN B T see **CARNITINE**

VITAMIN C see **ASCORBIC ACID**

VITAMIN D

see related
RECEPTORS, CALCITRIOL

ADMINISTRATION & DOSAGE

The role of vitamin D and calcium supplementation in the prevention of osteoporotic fractures in the elderly. Compston JE. **Clin Endocrinol (Oxf)** 1995 Oct; 43(4):393–405 (146 ref.)
Role of calcium and vitamin D in the prevention and the treatment of postmenopausal osteoporosis: an overview. Kaufman JM. **Clin Rheumatol** 1995 Sep;14 Suppl 3:9–13 (46 ref.)
Optimum route of administration of vitamin D in renal failure. Sweny P. **Nephrol Dial Transplant** 1995;10 Suppl 4:29–32; discussion 37–43 (37 ref.)

ANALOGS & DERIVATIVES

[Vitamin D and its metabolites] Masuda S, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:712–5 (11 ref.) **(Jpn)**

ANALYSIS

[New fluorogenic dienophile: synthesis, reaction with vitamin D, vitamin A and microcystins, and application to fluorometric assays] Shimizu M, et al. **Yakugaku Zasshi** 1995 Aug;115(8):584–602 (67 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Recent advances in the molecular biology of vitamin D action. Darwish HM, et al. **Prog Nucleic Acid Res Mol Biol** 1996;53:321–44 (181 ref.)

METABOLISM

Altered vitamin D metabolism and receptor interaction with the target genes in renal failure: calcitriol receptor interaction with its target gene in renal failure. Hsu CH, et al. **Curr Opin Nephrol Hypertens** 1995 Jul;4(4):302–6 (36 ref.)
Defects in the synthesis and metabolism of vitamin D. Holick MF. **Exp Clin Endocrinol Diabetes** 1995;103(4):219–27 (49 ref.)
Vitamin D sites and mechanisms of action: a histochemical perspective. Reflections on the utility of autoradiography and cytopharmacology for drug targeting. Stumpf WE. **Histochem Cell Biol** 1995 Dec;104(6):417–27 (68 ref.)
Recent progress in enzymology and molecular biology of enzymes involved in vitamin D metabolism. Okuda K, et al. **J Lipid Res** 1995 Aug;36(8):1641–52 (89 ref.)
[Vitamin D and osteoporosis] Ljunghall S, et al. **Nord Med** 1995;110(10):253–7 (11 ref.) (Eng. Abstr.) **(Swe)**

PHARMACOLOGY

The possibility of active form of vitamins A and D as suppressors on adipocyte development via ligand-dependent transcriptional regulators. Kawada T, et al. **Int J Obes Relat Metab Disord** 1996 Mar;20 Suppl 3:S52–7 (22 ref.)

PHYSIOLOGY

New understanding of the molecular mechanism of receptor-mediated genomic actions of the vitamin D hormone. Haussler MR, et al. **Bone** 1995 Aug;17(2 Suppl):33S–38S (30 ref.)
The vitamin D Endocrine system: manipulation of structure-function relationships to provide opportunities for development of new cancer chemopreventive and immunosuppressive agents. Norman AW. **J Cell Biochem Suppl** 1995;22:218–25 (39 ref.)
Vitamin D and bone health. Holick MF. **J Nutr** 1996 Apr; 126(4 Suppl):1159S–64S (33 ref.)
Recent advances in the molecular biology of vitamin D action. Darwish HM, et al. **Prog Nucleic Acid Res Mol Biol** 1996;53:321–44 (181 ref.)
[Vitamin D and osteoporosis] Hoszowski K. **Pol Tyg Lek** 1995 Nov;50(44–47):53–5 (29 ref.) (Eng. Abstr.) **(Pol)**

THERAPEUTIC USE

Calcium and vitamin D: possible protective agents against colorectal cancer? Kleibeuker JH, et al. **Eur J Cancer** 1995 Jul–Aug;31A(7–8):1081–4 (33 ref.)
Current and future nonhormonal approaches to the treatment of osteoporosis. Bilezikian JP. **Int J Fertil Menopausal Stud** 1996 Mar–Apr;41(2):148–55 (45 ref.)
Calcium and the prevention of colon cancer. Lipkin M, et al. **J Cell Biochem Suppl** 1995;22:65–73 (54 ref.)
The need to treat predialysis patients. Hamdy NA. **Nephrol Dial Transplant** 1995;10 Suppl 4:19–22; discussion 37–43 (25 ref.)
Vitamin D in the treatment of osteoporosis revisited. Fujita T. **Proc Soc Exp Biol Med** 1996 Jun;212(2):110–5 (76 ref.)

VITAMIN D 3 see **CHOLECALCIFEROL**

VITAMIN D 3 RECEPTORS see **RECEPTORS, CALCITRIOL**

VITAMIN D-BINDING GLOBULIN see **VITAMIN D-BINDING PROTEIN**

VITAMIN D-BINDING PROTEIN

BLOOD

[Vitamin D-binding protein (Gc-globulin)] Masuda S, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:742–4 (13 ref.) **(Jpn)**

GENETICS

German population data on the loci low-density-lipoprotein receptor, glycophorin A, hemoglobin gamma G, D7S8 and group-specific component. Huckenbeck W, et al. **Anthropol Anz** 1995 Sep;53(3):193–8 (14 ref.)

METABOLISM

Molecular recognition in vitamin D-binding protein. Ray R. **Proc Soc Exp Biol Med** 1996 Sep;212(4):305–12 (55 ref.)

VITAMIN D DEFICIENCY

see related
RICKETS

COMPLICATIONS

The role of vitamin D and calcium supplementation in the prevention of osteoporotic fractures in the elderly. Compston JE. **Clin Endocrinol (Oxf)** 1995 Oct; 43(4):393–405 (146 ref.)

METABOLISM

Age-related endocrine deficiencies and fractures of the proximal femur. II implications of vitamin D deficiency in the elderly. Boonen S, et al. **J Endocrinol** 1996 Apr; 149(1):13–7 (57 ref.)

VITAMIN D RECEPTORS see **RECEPTORS, CALCITRIOL**

VITAMIN DEFICIENCY see **AVITAMINOSIS**

VITAMIN E

ADMINISTRATION & DOSAGE

Considerations of the scientific substantiation for antioxidant vitamins and beta-carotene in disease prevention. Blumberg JB. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1521S–1526S (59 ref.)
Evidence from cancer intervention and biomarker studies and the development of biochemical markers. Bowen PE, et al. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1403S–1409S (54 ref.)
Antioxidants in oral cancer prevention. Garewal H. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1410S–1416S (54 ref.)
Antioxidant vitamin-cardiovascular disease hypothesis is still promising, but still unproven: the need for randomized trials. Hennekens CH, et al. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1377S–1380S (26 ref.)
Evidence for protection against age-related macular degeneration by carotenoids and antioxidant vitamins. Snodderly DM. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1448S–1461S (153 ref.)
Epidemiologic evidence for vitamin E in prevention of cardiovascular disease. Stampfer MJ, et al. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1365S–1369S (27 ref.)
Relations among aging, antioxidant status, and cataract. Taylor A, et al. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1439S–1447S (80 ref.)
A review of dietary vitamin E supplementation for improvement of beef quality. Liu Q, et al. **J Anim Sci** 1995 Oct;73(10):3131–40 (81 ref.)
[Antioxidative vitamins and cataracts in the elderly] Heseker H. **Z Ernahrungswiss** 1995 Sep;34(3):167–76 (68 ref.) (Eng. Abstr.) **(Ger)**
[Can vitamin E prevent development of coronary heart disease?] Nguyen KN, et al. **Tidsskr Nor Laegeforen** 1996 Mar 30;116(9):1109–13 (61 ref.) (Eng. Abstr.) **(Nor)**

ADVERSE EFFECTS

Safety of antioxidant vitamins and beta-carotene. Diplock AT. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1510S–1516S (56 ref.)

ANALYSIS

Influence of dietary fatty acid composition and vitamin E on fatty acids and alpha-tocopherol in carp (Cyprinus carpio L.). Schwarz FJ. **Arch Tierernahr** 1996;49(1):63–71 (37 ref.)

BLOOD

[Determination of serum or plasma alpha-tocopherol by high performance liquid chromatography: optimization of operative models] Jezequel-Cuer M, et al. **Ann Biol Clin (Paris)** 1995;53(6):343–52 (34 ref.) (Eng. Abstr.) **(Fre)**
[Vitamin E (tocopherol)] Kitagawa M, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:716–21 (13 ref.) **(Jpn)**

PHARMACOLOGY

Antioxidants and immune response in aged persons: overview of present evidence. Meydani SN, et al. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1462S–1476S (146 ref.)
Vitamins E and C, beta-carotene, and other carotenoids as antioxidants. Sies H, et al. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1315S–1321S (87 ref.)
Coantioxidants make alpha-tocopherol an efficient antioxidant for low-density lipoprotein. Thomas SR, et al. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1357S–1364S (66 ref.)
Vitamin E: beyond antioxidant function. Traber MG, et al. **Am J Clin Nutr** 1995 Dec;62(6 Suppl):1501S–1509S (91 ref.)
Influence of dietary fatty acid composition and vitamin E on fatty acids and alpha-tocopherol in carp (Cyprinus carpio L.). Schwarz FJ. **Arch Tierernahr** 1996;49(1):63–71 (37 ref.)
Vitamin E and aging immune response. Meydani SN, et al. **Clin Geriatr Med** 1995 Nov;11(4):567–76 (52 ref.)
Influence of dietary vitamin E on the oxidative stability and quality of pig meat. Buckley DJ, et al. **J Anim Sci** 1995 Oct;73(10):3122–30 (61 ref.)
The dual roles of nutrients as antioxidants and prooxidants: their effects on tumor cell growth. Schwartz JL. **J Nutr** 1996 Apr;126(4 Suppl):1221S–7S (42 ref.)
Effects of selenium and vitamin E on the immune responses

VITAMIN E

of domestic animals. Finch JM, et al. **Res Vet Sci** 1996 Mar;60(2):97–106 (108 ref.)

Antioxidant agents and colorectal carcinogenesis: role of beta-carotene, vitamin E and vitamin C. Pappalardo G, et al. **Tumori** 1996 Jan-Feb;82(1):6–11 (88 ref.)

PHYSIOLOGY

The antioxidant vitamins and cardiovascular disease. A critical review of epidemiologic and clinical trial data [see comments] Jha P, et al. **Ann Intern Med** 1995 Dec 1; 123(11):860–72 (55 ref.) Comment in: Ann Intern Med 1995 Dec 1;123(11):887.

Effect of vitamin E, vitamin C and beta-carotene on LDL oxidation and atherosclerosis. Jialal I, et al. **Can J Cardiol** 1995 Oct;11 Suppl G:97G–103G (97 ref.)

Update on the biological characteristics of the antioxidant micronutrients: vitamin C, vitamin E, and the carotenoids. Rock CL, et al. **J Am Diet Assoc** 1996 Jul;96(7):693–702; quiz 703–4 (128 ref.)

The importance of vitamin E in reducing cardiovascular risk. Abbey M. **Nutr Rev** 1995 Sep;53(9 Pt 2):S28–32 (44 ref.)

Vitamin E and selenium: contrasting and interacting nutritional determinants of host resistance to parasitic and viral infections. Levander OA, et al. **Proc Nutr Soc** 1995 Jul;54(2):475–87 (73 ref.)

Vitamin E status and response to exercise training. Tiidus PM, et al. **Sports Med** 1995 Jul;20(1):12–23 (101 ref.)

THERAPEUTIC USE

Epidemiologic studies of antioxidants and cancer in humans. Flagg EW, et al. **J Am Coll Nutr** 1995 Oct;14(5):419–27 (88 ref.)

[The treatment of cutaneous radiation-induced fibrosis with pentoxifylline and vitamin E. An empirical report] Gottlöber P, et al. **Strahlenther Onkol** 1996 Jan;172(1):34–8 (13 ref.) (Eng. Abstr.) **(Ger)**

VITAMIN G see **RIBOFLAVIN**

VITAMIN H see **BIOTIN**

VITAMIN K

ADMINISTRATION & DOSAGE

Prenatal exposure to phenytoin, facial development, and a possible role for vitamin K. Howe AM, et al. **Am J Med Genet** 1995 Sep 11;58(3):238–44 (52 ref.)

[Should benefit-risk ratio of the intramuscular vitamin K be reevaluated in newborn infants? (editorial)] Autret E, et al. **Arch Pediatr** 1996 May;3(5):415–8 (25 ref.) **(Fre)**

ANTAGONISTS & INHIBITORS

[Duration of antivitamin K therapy in venous thromboembolic disease] Ferrari E, et al. **Arch Mal Coeur Vaiss** 1995 Dec;88(12):1891–4 (24 ref.) (Eng. Abstr.) **(Fre)**

BLOOD

[Vitamin K] Shirahata A. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:722–5 (9 ref.) **(Jpn)**

METABOLISM

Transport of vitamin K to bone in humans. Kohlmeier M, et al. **J Nutr** 1996 Apr;126(4 Suppl):1192S–6S (28 ref.)

Chemistry, nutritional sources, tissue distribution and metabolism of vitamin K with special reference to bone health. Shearer MJ, et al. **J Nutr** 1996 Apr;126(4 Suppl):1181S–6S (25 ref.)

Vitamin K and energy transduction: a base strength amplification mechanism [see comments] Dowd P, et al. **Science** 1995 Sep 22;269(5231):1684–91 (39 ref.) Comment in: Science 1995 Nov 24;270(5240):1285.

PHARMACOLOGY

The mechanism of action of vitamin K. Dowd P, et al. **Annu Rev Nutr** 1995;15:419–40 (91 ref.)

Effects of vitamin K on bone mass and bone metabolism. Vermeer C, et al. **J Nutr** 1996 Apr;126(4 Suppl):1187S–91S (42 ref.)

PHYSIOLOGY

The importance of menaquinones in human nutrition. Suttie JW. **Annu Rev Nutr** 1995;15:399–417 (80 ref.)

Role of vitamin K in bone metabolism. Vermeer C, et al. **Annu Rev Nutr** 1995;15:1–22 (102 ref.)

Antenatal drugs affecting vitamin K status of the fetus and the newborn. Astedt B. **Semin Thromb Hemost** 1995; 21(4):364–70 (84 ref.)

THERAPEUTIC USE

The therapy of respiratory chain encephalomyopathy: a critical review of the past and current perspective. Walker UA, et al. **Acta Neurol Scand** 1995 Oct;92(4):273–80 (77 ref.)

VITAMIN K 1 see **PHYTONADIONE**

VITAMIN K DEFICIENCY

Vitamin K deficiency and hemorrhage in infancy. Greer FR. **Clin Perinatol** 1995 Sep;22(3):759–77 (80 ref.)

CHEMICALLY INDUCED

Antenatal drugs affecting vitamin K status of the fetus and the newborn. Astedt B. **Semin Thromb Hemost** 1995; 21(4):364–70 (84 ref.)

PHYSIOPATHOLOGY

Observations on vitamin K deficiency in the fetus and newborn: has nature made a mistake? Israels LG, et al. **Semin Thromb Hemost** 1995;21(4):357–63 (36 ref.)

Vitamin K deficiency bleeding in infants and children. Sutor AH. **Semin Thromb Hemost** 1995;21(3):317–29 (94 ref.)

VITAMIN K-DEPENDENT BONE PROTEIN see **OSTEOCALCIN**

VITAMIN K-DEPENDENT PROTEIN S see **PROTEIN S**

VITAMIN K REDUCTASE see **NAD(P)H DEHYDROGENASE (QUINONE)**

VITAMIN M see **FOLIC ACID**

VITAMIN P COMPLEX see **BIOFLAVONOIDS**

VITAMIN PP see **NIACINAMIDE**

VITAMINS

The requirement for vitamins in aging and age-associated degenerative conditions. Blumberg J. **Bibl Nutr Dieta** 1995; (52):108–15 (44 ref.)

Nitrosamines and vitamins. Reed PI. **Bibl Nutr Dieta** 1995; (52):30–42 (63 ref.)

Dietary antioxidants in disease prevention. Gordon M. **Nat Prod Rep** 1996 Aug;13(4):265–73 (130 ref.)

ADMINISTRATION & DOSAGE

Vitamin intake in Great Britain: association with mortality rates for coronary heart disease. Ashwell M, et al. **Bibl Nutr Dieta** 1995;(52):128–36 (9 ref.)

Criteria and scientific basis for RDA (PRI). Philip W, et al. **Bibl Nutr Dieta** 1995;(52):146–57 (20 ref.)

Micronutrients, antioxidants and risk of cancer. Schorah CJ. **Bibl Nutr Dieta** 1995;(52):92–107 (101 ref.)

Micronutrients in critical illness. Demling RH, et al. **Crit Care Clin** 1995 Jul;11(3):651–73 (40 ref.)

Position of the American Dietetic Association: vitamin and mineral supplementation. **J Am Diet Assoc** 1996 Jan; 96(1):73–7 (53 ref.)

Vitamin and mineral supplements as nutritional aids to exercise performance and health. Armstrong LE, et al. **Nutr Rev** 1996 Apr;54(4 Pt 2):S149–58 (126 ref.)

ADVERSE EFFECTS

Safety of antioxidant vitamins. Meyers DG, et al. **Arch Intern Med** 1996 May 13;156(9):925–35 (208 ref.)

[Vitamins and metals: possible hazards for humans] Ballmer PE. **Schweiz Med Wochenschr** 1996 Apr 13;126(15):607–11 (16 ref.) (Eng. Abstr.) **(Ger)**

ANTAGONISTS & INHIBITORS

[Is oxythiamine an antivitamin?] Vinogradov VV, et al. **Biokhimiia** 1995 Oct;60(10):1564–74 (107 ref.) (Eng. Abstr.) **(Rus)**

BLOOD

Plasma concentrations of cytokines, their soluble receptors, and antioxidant vitamins can predict the development of multiple organ failure in patients at risk. Borrelli E, et al. **Crit Care Med** 1996 Mar;24(3):392–7 (38 ref.)

Indicators of vitamin and mineral status in athletes' blood: a review. Fogelholm M. **Int J Sport Nutr** 1995 Dec; 5(4):267–84 (91 ref.)

IMMUNOLOGY

Nutrition and immunity with emphasis on infection and autoimmune disease. Harbige LS. **Nutr Health** 1996; 10(4):285–312 (136 ref.)

METABOLISM

Vitamin retention in cook/chill and cook/hot-hold hospital food-services. Williams PG. **J Am Diet Assoc** 1996 May; 96(5):490–8; quiz 499–500 (78 ref.)

Intestinal absorption of water-soluble vitamins. Rose RC. **Proc Soc Exp Biol Med** 1996 Jul;212(3):191–8 (49 ref.)

[Vitamins with antioxidant action and rheumatic diseases (a review)] Lobareva LS, et al. **Vopr Pitan** 1995;(4):24–9 (71 ref.) (Eng. Abstr.) **(Rus)**

PHARMACOLOGY

How 'safe' are antioxidant vitamins? Garewal HS, et al. **Drug Saf** 1995 Jul;13(1):8–14 (57 ref.)

Nutrient antioxidants in the pathogenesis and prevention of cervical dysplasias and cancer. Romney SL, et al. **J Cell Biochem Suppl** 1995;23:96–103 (45 ref.)

Vitamins as homocysteine-lowering agents. Brattström L. **J Nutr** 1996 Apr;126(4 Suppl):1276S–80S (48 ref.)

Homocysteine, vitamins and arterial occlusive disease: an overview. Rosenberg IH. **J Nutr** 1996 Apr;126(4 Suppl):1235S–7S (26 ref.)

PHYSIOLOGY

Vitamins in the maintenance of optimum immune functions and in the prevention of phagocyte-mediated tissue damage and carcinogenesis. Anderson R, et al. **Bibl Nutr Dieta** 1995;(52):66–74 (34 ref.)

Cardiovascular disease and vitamins. Concurrent correction of 'suboptimal' plasma antioxidant levels may, as important part of 'optimal' nutrition, help to prevent early stages of cardiovascular disease and cancer, respectively. Gey KF. **Bibl Nutr Dieta** 1995;(52):75–91 (58 ref.)

Iron and vitamins. Hallberg L. **Bibl Nutr Dieta** 1995;(52):20–9 (39 ref.)

[Vitamins as radioprotectors of normal cells] Konopacka M. **Postepy Hig Med Dosw** 1996;50(2):145–56 (67 ref.) (Eng. Abstr.) **(Pol)**

STANDARDS

Periconceptional vitamin supplementation to prevent neural tube defects: how can we do it? Mills JL, et al. **Eur J Obstet Gynecol Reprod Biol** 1995 Jul;61(1):49–55 (21 ref.)

THERAPEUTIC USE

The therapy of respiratory chain encephalomyopathy: a critical review of the past and current perspective. Walker UA, et al. **Acta Neurol Scand** 1995 Oct;92(4):273–80 (77 ref.)

Cardiovascular disease and vitamins. Concurrent correction of 'suboptimal' plasma antioxidant levels may, as important part of 'optimal' nutrition, help to prevent early stages of cardiovascular disease and cancer, respectively. Gey KF. **Bibl Nutr Dieta** 1995;(52):75–91 (58 ref.)

Pharmacologic prevention of colonic neoplasms. Effects of calcium, vitamins, omega fatty acids, and nonsteroidal anti-inflammatory drugs. Eastwood GL. **Dig Dis** 1996 Mar-Apr;14(2):119–28 (124 ref.)

The politics of nutrition in North America. Levenstein HA. **Neurosci Biobehav Rev** 1996;20(1):75–8 (14 ref.)

[Prevention of second primary cancer with vitamin supplementation in patients treated for head and neck cancers] Bairati I, et al. **Bull Cancer Radiother** 1996; 83(1):12–6 (37 ref.) (Eng. Abstr.) **(Fre)**

VITELLOGENESIS

PHYSIOLOGY

Vitellogenesis as a biomarker for estrogenic contamination of the aquatic environment. Sumpter JP, et al. **Environ Health Perspect** 1995 Oct;103 Suppl 7:173–8 (39 ref.)

VITILIGO

DRUG THERAPY

Current treatment of vitiligo in China. Shao C, et al. **Chin Med J (Engl)** 1995 Sep;108(9):647–9 (10 ref.)

ETIOLOGY

Melanoma and vitiligo: immunology's Grecian urn. Berd D, et al. **Cancer Immunol Immunother** 1996 Jun;42(5):263–7 (56 ref.)

VITRECTOMY

The endophthalmitis vitrectomy study [editorial; comment] [see comments] Forster RK. **Arch Ophthalmol** 1995 Dec; 113(12):1555–7 (6 ref.) Comment on: Arch Ophthalmol 1995 Dec;113(12):1479–96. Comment in: Arch Ophthalmol 1996 Aug;114(8):1025; discussion 1026–7. Comment in: Arch Ophthalmol 1996 Aug;114(8):1029–30; discussion 1028–9.

[Surgical treatment of diabetic retinopathy] Gribomont AC. **Bull Soc Belge Ophtalmol** 1995;256:105–12 (50 ref.) (Eng. Abstr.) **(Fre)**

[Surgical treatment by vitrectomy and autologous serum of 36 idiopathic macular holes] Monin C, et al. **J Fr Ophtalmol** 1996;19(5):341–8 (39 ref.) (Eng. Abstr.) **(Fre)**

[The indications for vitrectomy in retinal detachment] Nicoară S. **Oftalmologia** 1995 Oct-Dec;39(4):362–7 (10 ref.) (Eng. Abstr.) **(Rum)**

INSTRUMENTATION

[Development of pars plana vitrectomy. My personal contribution] Machemer R. **Klin Monatsbl Augenheilkd** 1995 Sep;207(3):147–61 (103 ref.) **(Ger)**

VITREORETINOPATHY, PROLIFERATIVE

[Bioactive substances in the regulation of vitreoretinal proliferation] Balashova LM. **Vestn Oftalmol** 1995 Jul-Sep; 111(3):31-3 (57 ref.) **(Rus)**

PATHOLOGY

Proliferative vitreoretinopathy: pathobiology, surgical management, and adjunctive treatment. Charteris DG. **Br J Ophthalmol** 1995 Oct;79(10):953-60 (160 ref.)

PREVENTION & CONTROL

Proliferative vitreoretinopathy [editorial; comment] Leaver PK. **Br J Ophthalmol** 1995 Oct;79(10):871-2 (44 ref.) Comment on: Br J Ophthalmol 1995 Oct;79(10):874-7.

SURGERY

Proliferative vitreoretinopathy: pathobiology, surgical management, and adjunctive treatment. Charteris DG. **Br J Ophthalmol** 1995 Oct;79(10):953-60 (160 ref.)

[Treatment of vitreoretinal proliferation in rhegmatogenous detachment and silicone oil tamponade] Berrod JP, et al. **J Fr Ophtalmol** 1996;19(2):97-105 (32 ref.) (Eng. Abstr.) **(Fre)**

VITREOUS BODY

see related
VITRECTOMY

Vitreoretinal emergencies. Reichel E. **Am Fam Physician** 1995 Oct;52(5):1415-9 (16 ref.)

ABNORMALITIES

[Persistence of the primordial vitreous body and buphthalmos] Cernea P, et al. **Oftalmologia** 1995 Oct-Dec; 39(4):338-42 (8 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Diabetic vitreopathy [editorial; comment] Sebag J. **Ophthalmology** 1996 Feb;103(2):205-6 (5 ref.) Comment on: Ophthalmology 1996 Feb;103(2):315-22. Comment on: Ophthalmology 1996 FEB;103(2):323-8.

Vitreous amyloidosis in familial amyloidotic polyneuropathy. Report of a case with the Val30Met transthyretin mutation. Ciulla TA, et al. **Surv Ophthalmol** 1995 Nov-Dec; 40(3):197-206 (123 ref.)

Ocular amyloidosis, with special reference to the hereditary forms with vitreous involvement. Sandgren O. **Surv Ophthalmol** 1995 Nov-Dec;40(3):173-96 (261 ref.)

[Changes in vitreous structure caused by oxygen free radicals] Ueno N. **Nippon Ganka Gakkai Zasshi** 1995 Dec; 99(12):1342-60 (90 ref.) (Eng. Abstr.) **(Jpn)**

VITREOUS HEMORRHAGE

COMPLICATIONS

Severe occlusive retinal periphlebitis with vitreous hemorrhage in multiple sclerosis. Ronzani M, et al. **Ger J Ophthalmol** 1995 Nov;4(6):328-31 (15 ref.)

Diabetic vitreopathy [editorial; comment] Sebag J. **Ophthalmology** 1996 Feb;103(2):205-6 (5 ref.) Comment on: Ophthalmology 1996 Feb;103(2):315-22. Comment on: Ophthalmology 1996 FEB;103(2):323-8.

VITRONECTIN

BLOOD

[Vitronectin] Yamanaka H, et al. **Nippon Rinsho** 1995 Feb; 53 Su Pt 1:251-3 (13 ref.) **(Jpn)**

METABOLISM

The PAI-1/vitronectin interaction: two cats in a bag? Deng G, et al. **Thromb Haemost** 1995 Jul;74(1):66-70 (47 ref.)

PHYSIOLOGY

The versatility of adhesion receptor ligands in haemostasis: morpho-regulatory functions of vitronectin. Hess S, et al. **Thromb Haemost** 1995 Jul;74(1):258-65 (115 ref.)

VIVISECTION

see related
ANIMAL WELFARE

VMW65 PROTEIN see **HERPES SIMPLEX VIRUS PROTEIN VMW65**

VNTR see **VARIABLE NUMBER OF TANDEM REPEATS**

VNTR LOCI see **VARIABLE NUMBER OF TANDEM REPEATS**

VNTR REGION see **VARIABLE NUMBER OF TANDEM REPEATS**

VNTR SEQUENCES see **VARIABLE NUMBER OF TANDEM REPEATS**

VOCABULARY

A reverse length effect in dysphasic naming: when elephant is easier than ant. Best W. **Cortex** 1995 Dec;31(4):637-52 (50 ref.)

VOCAL CORD PARALYSIS

ETIOLOGY

[Analysis of complications of thyroid surgery: recurrent paralysis et hypoparathyroidism. On a series of 588 cases] Debry C, et al. **Ann Otolaryngol Chir Cervicofac** 1995; 112(5):211-7 (11 ref.) (Eng. Abstr.) **(Fre)**

[Left vocal cord paralysis in cytomegalovirus multifocal neuropathy in a patient with HIV infection] de La Blanchardiere A, et al. **Presse Med** 1996 Jan 27;25(3):106-7 (7 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Anatomic considerations in the surgical treatment of unilateral laryngeal paralysis. Hoffman HT, et al. **Head Neck** 1996 Mar-Apr;18(2):174-87 (90 ref.)

Unilateral vocal fold paralysis: a review of the current methods of surgical rehabilitation. Harries ML. **J Laryngol Otol** 1996 Feb;110(2):111-6 (57 ref.)

VOCAL CORDS

Two new otolaryngologic findings in child abuse. Drake AF, et al. **Arch Otolaryngol Head Neck Surg** 1995 Dec; 121(12):1417-20 (11 ref.)

SURGERY

CO2 laser posterior transverse cordotomy for isolated type IV posterior glottic stenosis. Gaboriau H, et al. **Am J Otolaryngol** 1995 Sep-Oct;16(5):350-3 (20 ref.)

VOCAL FOLD see **VOCAL CORDS**

VOCALIZATION, ANIMAL

Aggression, anxiety and vocalizations in animals: GABAA and 5-HT anxiolytics. Miczek KA, et al. **Psychopharmacology (Berl)** 1995 Sep;121(1):38-56 (161 ref.)

PHYSIOLOGY

Behavioral learning. The illuminated songbird. Mooney R. **Curr Biol** 1995 Jun 1;5(6):609-11 (611 ref.)

The King Solomon Lectures in Neuroethology. A white canary on Mount Acropolis. Nottebohm F. **J Comp Physiol [A]** 1996 Aug;179(2):149-56 (57 ref.)

VOCATIONAL REHABILITATION see **REHABILITATION, VOCATIONAL**

VOCATIONS see **OCCUPATIONS**

VOGT-KOYANAGI-HARADA SYNDROME see **UVEOMENINGOENCEPHALITIC SYNDROME**

VOICE

Music, noise, and the human voice in the nurse-patient environment. Pope DS. **Image J Nurs Sch** 1995 Winter; 27(4):291-6 (51 ref.)

G. Paul Moore Lecture. Rational thought: the impact of voice science upon voice care. Sataloff RT. **J Voice** 1995 Sep;9(3):215-34 (166 ref.)

Expression of emotion in voice and music. Scherer KR. **J Voice** 1995 Sep;9(3):235-48 (89 ref.)

[Work and voice] Sala E. **Duodecim** 1995;111(6):554-9 (16 ref.) **(Fin)**

VOICE DISORDERS

CHEMICALLY INDUCED

[Dysphonia produced by corticoid inhalation: truth or myth?] Bonet Agusti M, et al. **Arch Bronconeumol** 1995 Oct; 31(8):415-7 (10 ref.) (Eng. Abstr.) **(Spa)**

REHABILITATION

[Technology for the diagnosis and rehabilitation of patients with dysphonia] Vilkman E, et al. **Duodecim** 1995; 111(6):549-53 (10 ref.) **(Fin)**

SURGERY

Phonosurgery. Kieff DA, et al. **Compr Ther** 1996 Apr; 22(4):222-30 (33 ref.)

[Basic principles for indications in phonosurgery] Friedrich G. **Laryngorhinootologie** 1995 Nov;74(11):663-5 (24 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Medical problems of professional voice users. Mitchell SA. **Compr Ther** 1996 Apr;22(4):231-8 (40 ref.)

Influence of body position on breathing and its implications for the evaluation and treatment of speech and voice disorders. Hoit JD. **J Voice** 1995 Dec;9(4):341-7 (37 ref.)

VOICE PROSTHESIS see **LARYNX, ARTIFICIAL**

VOLATILIZATION

[The way to long-term ambient temperature stabilization of biologicals--freeze-drying and evaporative-drying with vitrification] Franks F, et al. **Tanpakushitsu Kakusan Koso** 1996 May;41(6):810-6 (13 ref.) **(Jpn)**

VOLES see **MICROTINAE**

VOLKMANN CONTRACTURE see **COMPARTMENT SYNDROMES**

VOLTAGE-CLAMP TECHNIQUES see **PATCH-CLAMP TECHNIQUES**

VOLVULUS see **INTESTINAL OBSTRUCTION**

VOMER see **NASAL SEPTUM**

VOMITING

see related
ANTIEMETICS

Emesis and anti-emesis. Naylor RJ, et al. **Cancer Surv** 1994; 21:117-35 (138 ref.)

The cyclic vomiting syndrome described. Fleisher DR. **J Pediatr Gastroenterol Nutr** 1995;21 Suppl 1:S1-5 (7 ref.)

Cyclic vomiting: the pattern and syndrome paradigm. Li BU. **J Pediatr Gastroenterol Nutr** 1995;21 Suppl 1:S6-10 (11 ref.)

Nausea, vomiting, and retching: the management of the symptom experience. Rhodes VA, et al. **Semin Oncol Nurs** 1995 Nov;11(4):256-65 (32 ref.)

CHEMICALLY INDUCED

Serotonin mechanisms in chemotherapy-induced emesis in cancer patients. Cubeddu LX. **Oncology** 1996 Jun;53 Suppl 1:18-25 (34 ref.)

Mechanisms and management of nausea and emesis [editorial] Dicato M. **Oncology** 1996 Jun;53 Suppl 1:1-3 (16 ref.)

Pathophysiology, severity, pattern, and risk factors for carboplatin-induced emesis. du Bois A, et al. **Oncology** 1996 Jun;53 Suppl 1:46-50 (29 ref.)

Management of cisplatin-induced delayed emesis. Hesketh P. **Oncology** 1996 Jun;53 Suppl 1:73-7 (14 ref.)

The severity and pattern of emesis following different cytotoxic agents. Martin M. **Oncology** 1996 Jun;53 Suppl 1:26-31 (16 ref.)

Management of other non-cisplatin-induced emesis. Schmoll HJ, et al. **Oncology** 1996 Jun;53 Suppl 1:51-5 (24 ref.)

Optimal control of cyclophosphamide-induced emesis. Stewart A. **Oncology** 1996 Jun;53 Suppl 1:32-8 (38 ref.)

Optimal control of acute cisplatin-induced emesis. Verweij J, et al. **Oncology** 1996 Jun;53 Suppl 1:56-64 (80 ref.)

COMPLICATIONS

The relationship between cyclic vomiting syndrome and abdominal migraine. Symon DN, et al. **J Pediatr Gastroenterol Nutr** 1995;21 Suppl 1:S42-3 (18 ref.)

DIAGNOSIS

Differential diagnosis of cyclic vomiting syndrome. Forbes D. **J Pediatr Gastroenterol Nutr** 1995;21 Suppl 1:S11-4 (42 ref.)

[A diabetic woman with a picture of temporospatial disorientation, nausea and vomiting] Urbano García J, et al. **Rev Clin Esp** 1996 May;196(5):333-4, 338 (6 ref.) **(Spa)**

DRUG THERAPY

Assessing the comparative clinical value of tropisetron. Olver IN. **Aust N Z J Med** 1995 Oct;25(5):523-7 (31 ref.)

Progress in reducing nausea and emesis. Comparisons of ondansetron (Zofran), granisetron (Kytril), and tropisetron (Navoban). Morrow GR, et al. **Cancer** 1995 Aug 1; 76(3):343-57 (121 ref.)

Ondansetron. Thavaraj V, et al. **Indian Pediatr** 1995 Aug; 32(8):898-901 (12 ref.)

Management of acute emesis. Singhal S, et al. **J Assoc Physicians India** 1995 Aug;43(8):560-2 (6 ref.)

Management of cyclic vomiting syndrome. Fleisher DR. **J Pediatr Gastroenterol Nutr** 1995;21 Suppl 1:S52-6 (20 ref.)

Economic impact of antiemesis. Grunberg SM. **Oncology (Huntingt)** 1995 Nov;9(11 Suppl):155-60 (16 ref.)

Therapeutic potential of drugs with mixed 5-HT4 agonist/5-HT3 antagonist action in the control of emesis. Tonini M, et al. **Pharmacol Res** 1995 May;31(5):257-60 (30 ref.)

[Prevention and treatment of postoperative nausea and vomiting with 5-HT3-receptor blockers] Alon E, et al. **Anasthesiol Intensivmed Notfallmed Schmerzther** 1996 May; 31(4):200-4 (47 ref.) (Eng. Abstr.) **(Ger)**

VOMITING

ETIOLOGY

Abdominal migraine as a cause of vomiting in children: a clinician's view. Bentley D, et al. **J Pediatr Gastroenterol Nutr** 1995;21 Suppl 1:S49–51 (15 ref.)

Metabolic etiologies of cyclic or recurrent vomiting. Korson M. **J Pediatr Gastroenterol Nutr** 1995;21 Suppl 1:S15–9 (11 ref.)

The role of the paraventricular system in the pathogenesis of cyclic vomiting. Pasricha PJ. **J Pediatr Gastroenterol Nutr** 1995;21 Suppl 1:S29–30 (26 ref.)

Towards understanding the aetiology and pathophysiology of the emetic reflex: novel approaches to antiemetic drugs. Bountra C, et al. **Oncology** 1996 Jun;53 Suppl 1:102–9 (17 ref.)

Mechanisms of chemotherapy/radiotherapy-induced emesis in animal models. Naylor RJ, et al. **Oncology** 1996 Jun;53 Suppl 1:8–17 (77 ref.)

Metabolic and infectious disorders associated with emesis in infants. Cohen R. **Semin Pediatr Surg** 1995 Aug;4(3):136–46 (46 ref.)

Disorders of the central and autonomic nervous systems as a cause for emesis in infants. Johns DW. **Semin Pediatr Surg** 1995 Aug;4(3):152–6 (37 ref.)

Pharyngeal and swallowing disorders in infants. Jolley SG, et al. **Semin Pediatr Surg** 1995 Aug;4(3):157–65 (38 ref.)

Gastroesophageal reflux disease as a cause for emesis in infants. Jolley SG. **Semin Pediatr Surg** 1995 Aug; 4(3):176–89 (48 ref.)

Emesis in infants as a consequence of feedings. Marshall CM, et al. **Semin Pediatr Surg** 1995 Aug;4(3):147–51 (31 ref.)

Esophageal disorders associated with emesis in infants and children. Myers NA. **Semin Pediatr Surg** 1995 Aug; 4(3):166–75 (25 ref.)

Gastroduodenal disorders associated with emesis in infants. Reyna TM, et al. **Semin Pediatr Surg** 1995 Aug;4(3):190–7 (38 ref.)

NURSING

Management of nausea and vomiting in children. Keller VE. **J Pediatr Nurs** 1995 Oct;10(5):280–6 (30 ref.)

PATHOLOGY

[A 27-year-old woman with abdominal pain, vomiting, dark urine and hyponatremia (clinical conference)] **Rev Clin Esp** 1995 Oct;195(10):726–36 (74 ref.) **(Spa)**

PHYSIOPATHOLOGY

Serotonergic mediation of vomiting. Gale JD. **J Pediatr Gastroenterol Nutr** 1995;21 Suppl 1:S22–8 (72 ref.)

The central control of vomiting. Meadows N. **J Pediatr Gastroenterol Nutr** 1995;21 Suppl 1:S20–1 (8 ref.)

Towards understanding the aetiology and pathophysiology of the emetic reflex: novel approaches to antiemetic drugs. Bountra C, et al. **Oncology** 1996 Jun;53 Suppl 1:102–9 (17 ref.)

Pathophysiology, severity, pattern, and risk factors for carboplatin-induced emesis. du Bois A, et al. **Oncology** 1996 Jun;53 Suppl 1:46–50 (29 ref.)

PREVENTION & CONTROL

Role of 5-hydroxytryptamine3 (5-HT3) antagonists in the prevention of emesis caused by anticancer therapy. Karim F, et al. **Biochem Pharmacol** 1996 Sep 13;52(5):685–92 (64 ref.)

Prevention of vomiting after paediatric strabismus surgery: a systematic review using the numbers-needed-to-treat method. Tramèr M, et al. **Br J Anaesth** 1995 Nov; 75(5):556–61 (48 ref.)

Prophylactic therapy in cyclic vomiting syndrome. Forbes D, et al. **J Pediatr Gastroenterol Nutr** 1995;21 Suppl 1:S57–9 (7 ref.)

Mechanisms and management of nausea and emesis [editorial] Dicato M. **Oncology** 1996 Jun;53 Suppl 1:1–3 (16 ref.)

Management of cisplatin-induced delayed emesis. Hesketh P. **Oncology** 1996 Jun;53 Suppl 1:73–7 (14 ref.)

Management of other non-cisplatin-induced emesis. Schmoll HJ, et al. **Oncology** 1996 Jun;53 Suppl 1:51–5 (24 ref.)

Optimal control of cyclophosphamide-induced emesis. Stewart A. **Oncology** 1996 Jun;53 Suppl 1:32–8 (38 ref.)

Optimal control of acute cisplatin-induced emesis. Verweij J, et al. **Oncology** 1996 Jun;53 Suppl 1:56–64 (80 ref.)

Preventing chemotherapy-induced nausea and vomiting: an update and a review of emesis. Ettinger DS. **Semin Oncol** 1995 Aug;22(4 Suppl 10):6–18 (109 ref.)

Prophylaxis with oral granisetron for acute emesis induced by moderately emetogenic chemotherapy. Hesketh P. **Semin Oncol** 1995 Aug;22(4 Suppl 10):19–23 (23 ref.)

[Efficacy of ondansetron in acute and delayed cisplatin-induced nausea and vomiting] Depierre A. **Bull Cancer (Paris)** 1996 Feb;83(2):147–53 (29 ref.) (Eng. Abstr.) **(Fre)**

[Optimal control by ondansetron of acute and prolonged emesis induced by chemotherapy without cisplatin] Harousseau JL. **Bull Cancer (Paris)** 1996 Jan;83(1):71–76 (27 ref.) (Eng. Abstr.) **(Fre)**

PSYCHOLOGY

Psychophysiologic treatment of cyclic vomiting. Magagna J. **J Pediatr Gastroenterol Nutr** 1995;21 Suppl 1:S31–6 (10 ref.)

SURGERY

ABC of general surgery in children. Surgically correctable causes of vomiting in infancy. Davenport M. **BMJ** 1996 Jan 27;312(7025):236–9 (0 ref.)

THERAPY

Psychophysiologic treatment of cyclic vomiting. Magagna J. **J Pediatr Gastroenterol Nutr** 1995;21 Suppl 1:S31–6 (10 ref.)

Can acupuncture have specific effects on health? A systematic review of acupuncture antiemesis trials. Vickers AJ. **J R Soc Med** 1996 Jun;89(6):303–11 (49 ref.)

VOMITING, ANTICIPATORY

PSYCHOLOGY

Models, mechanisms and management of anticipatory nausea and emesis. Morrow GR, et al. **Oncology** 1996 Jun;53 Suppl 1:4–7 (12 ref.)

THERAPY

Models, mechanisms and management of anticipatory nausea and emesis. Morrow GR, et al. **Oncology** 1996 Jun;53 Suppl 1:4–7 (12 ref.)

VON GIERKE'S DISEASE see **GLYCOGEN STORAGE DISEASE TYPE I**

VON HIPPEL-LINDAU DISEASE see **HIPPEL-LINDAU DISEASE**

VON WILLEBRAND FACTOR

Pathogenesis, clinical picture and treatment of von Willebrand's disease. Lethagen SR. **Ann Med** 1995 Dec; 27(6):641–51 (106 ref.)

ANALYSIS

von Willebrand factor and its relevance to cardiovascular disorders. Lip GY, et al. **Br Heart J** 1995 Dec;74(6):580–3 (28 ref.)

[von Willebrand factor (vWF)] Takahashi Y. **Nippon Rinsho** 1995 Mar;53 Su Pt 2:100–4 (11 ref.) **(Jpn)**

GENETICS

Molecular mechanism and classification of von Willebrand disease. Sadler JE, et al. **Thromb Haemost** 1995 Jul; 74(1):161–6 (61 ref.)

METABOLISM

Von Willebrand's disease and the mechanisms of platelet function. Ruggeri ZM. **Ciba Found Symp** 1995;189:35–45; discussion 45–50, 77–8 (37 ref.)

PHYSIOLOGY

von Willebrand factor: its function and its measurement in the laboratory. Fleming TG. **Br J Biomed Sci** 1995 Mar; 52(1):50–7 (34 ref.)

Role of platelets, thrombin, integrin IIb-IIIa, fibronectin and von Willebrand factor on tumor adhesion in vitro and metastasis in vivo. Nierodzik ML, et al. **Thromb Haemost** 1995 Jul;74(1):282–90 (67 ref.)

The role of von Willebrand factor and fibrinogen in the initiation of platelet adhesion to thrombogenic surfaces. Ruggeri ZM. **Thromb Haemost** 1995 Jul;74(1):460–3 (45 ref.)

VON WILLEBRAND'S DISEASE

Pathogenesis, clinical picture and treatment of von Willebrand's disease. Lethagen SR. **Ann Med** 1995 Dec; 27(6):641–51 (106 ref.)

CLASSIFICATION

Molecular mechanism and classification of von Willebrand disease. Sadler JE, et al. **Thromb Haemost** 1995 Jul; 74(1):161–6 (61 ref.)

COMPLICATIONS

Acquired von Willebrand's disease: a rare manifestation of postpartum thyroiditis. Aylesworth CA, et al. **Am J Hematol** 1995 Nov;50(3):217–9 (10 ref.)

DIAGNOSIS

[Giant platelet syndrome] Jantunen E, et al. **Duodecim** 1994; 110(8):793–801 (33 ref.) **(Fin)**

[Hematologic causes of vascular diseases of the central nervous system] Arboix A, et al. **Rev Neurol** 1995;23 Suppl 1:S41–9 (62 ref.) **(Spa)**

DRUG THERAPY

Current management of von Willebrand's disease. Castaman G, et al. **Drugs** 1995 Oct;50(4):602–14 (82 ref.)

GENETICS

von Willebrand disease in children and adolescents. Werner EJ. **Pediatr Clin North Am** 1996 Jun;43(3):683–707 (131 ref.)

Von Willebrand disease in childhood. Schneppenheim R, et al. **Semin Thromb Hemost** 1995;21(3):261–75 (155 ref.)

METABOLISM

Von Willebrand's disease and the mechanisms of platelet function. Ruggeri ZM. **Ciba Found Symp** 1995;189:35–45; discussion 45–50, 77–8 (37 ref.)

PATHOLOGY

Von Willebrand's disease and the mechanisms of platelet function. Ruggeri ZM. **Ciba Found Symp** 1995;189:35–45; discussion 45–50, 77–8 (37 ref.)

VP-16 see **ETOPOSIDE**

VP16 PROTEIN see **HERPES SIMPLEX VIRUS PROTEIN VMW65**

VP 16-213 see **ETOPOSIDE**

VULVA

PATHOLOGY

Update on the surgical pathology of the vulva. Johnson TL. **Clin Lab Med** 1995 Sep;15(3):455–92 (167 ref.)

SURGERY

Update on the surgical pathology of the vulva. Johnson TL. **Clin Lab Med** 1995 Sep;15(3):455–92 (167 ref.)

-Therapy of vulvar carcinoma in the early stages- Gitsch G. **Geburtshilfe Frauenheilkd** 1996 Feb;56(2):63–9 (66 ref.) (Eng. Abstr.) **(Ger)**

VIROLOGY

Herpesvirus infections of the vulva. Nader SN, et al. **Semin Dermatol** 1996 Mar;15(1):8–16 (75 ref.)

VULVAR DISEASES

ETIOLOGY

Vulvar pain syndrome: a review. Baggish MS, et al. **Obstet Gynecol Surv** 1995 Aug;50(8):618–27 (54 ref.)

Dermatitis of the vulva. Marren P, et al. **Semin Dermatol** 1996 Mar;15(1):36–41 (24 ref.)

Vulvar disease in the pediatric population. Ridley CM. **Semin Dermatol** 1996 Mar;15(1):29–35 (22 ref.)

PATHOLOGY

Differentiating normal and abnormal findings of the vulva. Apgar BS, et al. **Am Fam Physician** 1996 Mar;53(4):1171–80 (24 ref.)

Crohn's disease of the vulva. Vettraino IM, et al. **Am J Dermatopathol** 1995 Aug;17(4):410–3 (10 ref.)

Update on the surgical pathology of the vulva. Johnson TL. **Clin Lab Med** 1995 Sep;15(3):455–92 (167 ref.)

Vulvitis granulomatosa: a cryptogenic chronic inflammatory hypertrophy of vulvar labia related to cheilitis granulomatosa and Crohn's disease. Guerrieri C, et al. **Int J Gynecol Pathol** 1995 Oct;14(4):352–9 (62 ref.)

Multiple milia localized to the vulva. Kanekura T, et al. **J Dermatol** 1996 Jun;23(6):427–8 (18 ref.)

SURGERY

Surgical treatment of vulvar lichen sclerosus: a review. Abramov Y, et al. **Obstet Gynecol Surv** 1996 Mar; 51(3):193–9 (55 ref.)

THERAPY

Vulvar pain syndrome: a review. Baggish MS, et al. **Obstet Gynecol Surv** 1995 Aug;50(8):618–27 (54 ref.)

Tackling vulval problems. Colvin D, et al. **Practitioner** 1995 Sep;239(1554):547–50 (6 ref.)

Treatment of vulvar dermatoses. Zellis S, et al. **Semin Dermatol** 1996 Mar;15(1):71–6 (26 ref.)

VIROLOGY

Human papilloma virus infection of the vulva. Beutner KR. **Semin Dermatol** 1996 Mar;15(1):2–7 (63 ref.)

Herpesvirus infections of the vulva. Nader SN, et al. **Semin Dermatol** 1996 Mar;15(1):8–16 (75 ref.)

VULVAR NEOPLASMS

Vulval intraepithelial neoplasia [editorial] Jebakumar S, et al. **Int J STD AIDS** 1996 Jan-Feb;7(1):10–3 (45 ref.)

Malignant melanoma of the vulva: a review. Dunton CJ, et al. **Obstet Gynecol Surv** 1995 Oct;50(10):739–46 (43 ref.)

Vulvar squamous cell carcinoma. Ansink A.

Semin Dermatol 1996 Mar;15(1):51–9 (103 ref.)
Vulvar melanoma. Panizzon RG. **Semin Dermatol** 1996 Mar; 15(1):67–70 (20 ref.)

CHEMICALLY INDUCED

Postmenopausal estrogens and progestogens and the incidence of gynecologic cancer. Weiss NS, et al. **Maturitas** 1996 Mar;23(2):235–9 (43 ref.)

DIAGNOSIS

[Amelanotic nodular malignant melanoma of the vulva. Case report and review of the literature] Hofmann U, et al. **Hautarzt** 1995 Dec;46(12):850–3 (27 ref.) (Eng. Abstr.) **(Ger)**

[A peripheral neuroectodermal tumor of the vulva] Paredes E, et al. **Acta Med Port** 1995 Mar;8(3):161–3 (17 ref.) (Eng. Abstr.) **(Por)**

DRUG THERAPY

Prolonged continuous infusion cisplatin and 5-fluorouracil with radiation for locally advanced carcinoma of the vulva. Eifel PJ, et al. **Gynecol Oncol** 1995 Oct;59(1):51–6 (22 ref.)

ETIOLOGY

Paget's disease. Kürzl RG. **Semin Dermatol** 1996 Mar; 15(1):60–6 (62 ref.)
[The etiology of vulvar carcinoma--still an enigma] Bornstein J, et al. **Harefuah** 1995 Jun 15;128(12):793–7 (48 ref.) **(Heb)**

PATHOLOGY

Differentiating normal and abnormal findings of the vulva. Apgar BS, et al. **Am Fam Physician** 1996 Mar;53(4):1171–80 (24 ref.)
Smooth-muscle tumors of the vulva. A clinicopathological study of 25 cases and review of the literature. Nielsen GP, et al. **Am J Surg Pathol** 1996 Jul;20(7):779–93 (63 ref.)
Update on the surgical pathology of the vulva. Johnson TL. **Clin Lab Med** 1995 Sep;15(3):455–92 (167 ref.)
The pathology of vulvar neoplasia. Lininger RA, et al. **Curr Opin Obstet Gynecol** 1996 Feb;8(1):63–8 (28 ref.)
Prognostic factors in squamous cell cancer of the vulva and the implications for treatment. van der Velden J, et al. **Curr Opin Obstet Gynecol** 1996 Feb;8(1):3–7 (36 ref.)
Cutaneous metastases from squamous cell carcinoma of the vulva. A case report and review of the literature. Tobias DH, et al. **Eur J Gynaecol Oncol** 1995;16(5):382–6 (8 ref.)
Vulvar Merkel cell tumor with glandular and squamous differentiation. Scurry J, et al. **Gynecol Oncol** 1996 Aug; 62(2):292–7 (15 ref.)
Angiomyofibroblastoma of the vulva and vagina. Nielsen GP, et al. **Mod Pathol** 1996 Mar;9(3):284–91 (25 ref.)
Sebaceous carcinoma of the vulva. Kawamoto M, et al. **Pathol Int** 1995 Oct;45(10):767–73 (32 ref.)
Malignant rhabdoid tumor of the vulva: a case report and review of the literature. Lupi G, et al. **Tumori** 1996 Jan-Feb;82(1):93–5 (15 ref.)

RADIOTHERAPY

Prolonged continuous infusion cisplatin and 5-fluorouracil with radiation for locally advanced carcinoma of the vulva. Eifel PJ, et al. **Gynecol Oncol** 1995 Oct;59(1):51–6 (22 ref.)
[Role of radiotherapy in the combined treatment of invasive cancer of the vulva] Micheletti L, et al. **Minerva Ginecol** 1995 Oct;47(10):447–53 (42 ref.) (Eng. Abstr.) **(Ita)**

SURGERY

Adenoid cystic carcinoma of Bartholin's gland: a review of the literature and report of a patient. DePasquale SE, et al. **Gynecol Oncol** 1996 Apr;61(1):122–5 (32 ref.)
Metastatic clear cell eccrine hidradenocarcinoma of the vulva: survival after primary surgical resection. Massad LS, et al. **Gynecol Oncol** 1996 May;61(2):287–90 (17 ref.)
-Therapy of vulvar carcinoma in the early stages- Gitsch G. **Geburtshilfe Frauenheilkd** 1996 Feb;56(2):63–9 (66 ref.) (Eng. Abstr.) **(Ger)**
[Therapy of preinvasive vulvar neoplasia--standardized or individual?] Schnürch HG, et al. **Zentralbl Gynakol** 1996; 118(6):345–9 (30 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Sites of failure and times to failure in carcinoma of the vulva treated conservatively: a Gynecologic Oncology Group study. Stehman FB, et al. **Am J Obstet Gynecol** 1996 Apr; 174(4):1128–32; discussion 1132–3 (5 ref.)
Controversies in the management of vulvar carcinoma. Cavanagh D, et al. **Br J Obstet Gynaecol** 1996 Apr; 103(4):293–300 (37 ref.)
Management of vulvar cancer. Homesley HD. **Cancer** 1995 Nov 15;76(10 Suppl):2159–70 (57 ref.)

VIROLOGY

Bilateral primary ovarian squamous cell carcinoma associated with human papilloma virus infection and vulvar and cervical intraepithelial neoplasia. A case report with review of the literature. Mai KT, et al. **Am J Surg Pathol** 1996 Jun;20(6):767–72 (23 ref.)
HIV-related primary non-Hodgkin's lymphoma of the vulva. Kaplan EJ, et al. **Gynecol Oncol** 1996 Apr;61(1):131–8 (41 ref.)
[A Buschke and Lowenstein tumor in a female patient] Reichenbach I, et al. **J Gynecol Obstet Biol Reprod (Paris)** 1995;24(5):491–5 (16 ref.) (Eng. Abstr.) **(Fre)**

VULVITIS

DIAGNOSIS

Common genitourinary infections. Freeman SB. **J Obstet Gynecol Neonatal Nurs** 1995 Oct;24(8):735–42 (26 ref.)

PATHOLOGY

Vulvitis granulomatosa: a cryptogenic chronic inflammatory hypertrophy of vulvar labia related to cheilitis granulomatosa and Crohn's disease. Guerrieri C, et al. **Int J Gynecol Pathol** 1995 Oct;14(4):352–9 (62 ref.)

VULVOVAGINITIS

ETIOLOGY

Paediatric vulvovaginitis. O'Brien TJ. **Australas J Dermatol** 1995 Nov;36(4):216–8 (17 ref.)

VZ VIRUS see HERPESVIRUS 3, HUMAN

WAARDENBURG'S SYNDROME

GENETICS

Mutations in PAX3 that cause Waardenburg syndrome type I: ten new mutations and review of the literature. Baldwin CT, et al. **Am J Med Genet** 1995 Aug 28;58(2):115–22 (16 ref.)

WAGES see SALARIES AND FRINGE BENEFITS

WAIST-HIP RATIO see BODY CONSTITUTION

WAITING LISTS

The UNOS OPTN waiting list: 1988 to 1994. United Network for Organ Sharing. Organ Procurement and Transplantation Network. Guo TJ, et al. **Clin Transpl** 1994; :69–86 (6 ref.)
[Screening of patients waiting for kidney transplantation] Járay J, et al. **Orv Hetil** 1995 Nov 12;136(46):2501–5 (40 ref.) (Eng. Abstr.) **(Hun)**

WAKEFULNESS

see related
INSOMNIA

Localized and lateralized cerebral glucose metabolism associated with eye movements during REM sleep and wakefulness: a positron emission tomography (PET) study. Hong CC, et al. **Sleep** 1995 Sep;18(7):570–80 (71 ref.)
[Activated mechanisms of epilepsy during sleep and wakefulness] Arroyo Serrano S. **Rev Neurol** 1995 Nov-Dec;23(124):1280–3 (39 ref.) **(Spa)**

PHYSIOLOGY

The function of sleep is to regulate brain excitability in order to satisfy the requirements imposed by waking. Drucker-Colin R. **Behav Brain Res** 1995 Jul-Aug; 69(1-2):117–24 (18 ref.)
Sleep for development or development for waking?--some speculations from a human perspective. Salzarulo P, et al. **Behav Brain Res** 1995 Jul-Aug;69(1-2):23–7 (32 ref.)
The laboratory assessment of daytime sleepiness in childhood. Kotagal S, et al. **J Clin Neurophysiol** 1996 May; 13(3):208–18 (50 ref.)
Conscious and pre-conscious processes as seen from the standpoint of sleep-waking cycle neurophysiology. Paré D, et al. **Neuropsychologia** 1995 Sep;33(9):1155–68 (98 ref.)
Neuronal activities underlying the electroencephalogram and evoked potentials of sleeping and waking: implications for information processing. Coenen AM. **Neurosci Biobehav Rev** 1995 Fall;19(3):447–63 (75 ref.)
Brain cooling across wake-sleep behavioral states in homeothermic species: an analysis of the underlying physiological mechanisms. Parmeggiani PL. **Rev Neurosci** 1995 Oct-Dec;6(4):353–63 (36 ref.)
[Light therapy can restore a disturbed sleep/wake rhythm in dementia: but what is the basis of its efficacy?] Beullens J. **Tijdschr Gerontol Geriatr** 1995 Dec;26(6):264–9 (40 ref.) (Eng. Abstr.) **(Dut)**
[Is the animal in hibernal sleep awake?] Canguilhem B, et al. **Neurophysiol Clin** 1996;26(1):1–7 (20 ref.) (Eng. Abstr.) **(Fre)**
[Ontogenesis of sleep-wakefulness regulation] Hinckel P, et al. **Psychother Psychosom Med Psychol** 1995 Nov; 45(11):367–72 (27 ref.) (Eng. Abstr.) **(Ger)**
[Chronobiological health of the circadian system: examples for disorders of the sleep-waking rhythm] Moog R. **Wien Med Wochenschr** 1995;145(17-18):452–3 (18 ref.) (Eng. Abstr.) **(Ger)**

WALDENSTROM'S MACROGLOBULINEMIA

COMPLICATIONS

Role of plasmapheresis in thrombocytopenic purpura associated with Waldenström's macroglobulinemia. Patel TC, et al. **Mayo Clin Proc** 1996 Jun;71(6):597–600 (14 ref.)

EPIDEMIOLOGY

The incidence and epidemiology of plasma cell neoplasms. Bergsagel D. **Stem Cells (Dayt)** 1995 Aug;13 Suppl 2:1–9 (56 ref.)

ETIOLOGY

Systemic lupus erythematosus diagnosed during interferon alfa therapy. Morris LF, et al. **South Med J** 1996 Aug; 89(8):810–4 (30 ref.)

GENETICS

[Primary macroglobulinemia with t(11;18) (q21;q21)] Hirase N, et al. **Rinsho Ketsueki** 1996 Apr;37(4):340–5 (17 ref.) (Eng. Abstr.) **(Jpn)**

WALKING

Prognosis for ambulation in cerebral palsy. Sala DA, et al. **Dev Med Child Neurol** 1995 Nov;37(11):1020–6 (9 ref.)

PHYSIOLOGY

The study of kinematic transients in locomotion using the integrated kinematic sensor. Wu G, et al. **IEEE Trans Rehabil Eng** 1996 Sep;4(3):193–200 (18 ref.)
Exercise performance of lower-extremity amputees. Ward KH, et al. **Sports Med** 1995 Oct;20(4):207–14 (50 ref.)

PSYCHOLOGY

Psychosocial factors in childhood pedestrian injury: a matched case-control study. Kid's 'n Cars Team. Christoffel KK, et al. **Pediatrics** 1996 Jan;97(1):33–42 (49 ref.)

STATISTICS & NUMERICAL DATA

Psychosocial factors in childhood pedestrian injury: a matched case-control study. Kid's 'n Cars Team. Christoffel KK, et al. **Pediatrics** 1996 Jan;97(1):33–42 (49 ref.)

WALLERIAN DEGENERATION

Wallerian degeneration in peripheral nerve disease. Griffin JW, et al. **Baillieres Clin Neurol** 1996 Mar;5(1):65–75 (99 ref.)
[Degeneration and regeneration of the peripheral nervous system with aging] Verdú E, et al. **Rev Neurol** 1995 May-Jun;23(121):648–55 (98 ref.) (Eng. Abstr.) **(Spa)**

WANGIELLA see EXOPHIALA

WAR

see related
COMBAT DISORDERS

Antipersonnel mines: the global epidemic. Chaloner EJ, et al. **Ann R Coll Surg Engl** 1996 Jan;78(1):1–4 (37 ref.)
Injuries due to antipersonnel land mines in Sri Lanka. Goonetilleke G. **Ceylon Med J** 1995 Dec;40(4):141–5 (8 ref.)
The impact of infectious diseases on the health of U.S. troops deployed to the Persian Gulf during operations Desert Shield and Desert Storm. Hyams KC, et al. **Clin Infect Dis** 1995 Jun;20(6):1497–504 (69 ref.)
Suspended animation for delayed resuscitation. Bellamy R, et al. **Crit Care Med** 1996 Feb;24(2 Suppl):S24–47 (137 ref.)
The effects of weapons: surgical challenge and medical dilemma. Coupland RM. **J R Coll Surg Edinb** 1996 Apr; 41(2):65–71 (6 ref.)
Environmental health issues in prisoner of war camps. Korte DV, et al. **Mil Med** 1995 Oct;160(10):483–6 (24 ref.)
Military penetrating craniocerebral injuries. Applications to civilian triage and management. George ED, et al. **Neurosurg Clin N Am** 1995 Oct;6(4):753–9 (101 ref.)
Penetrating injuries in the Vietnam war. Traumatic unconsciousness, epilepsy, and psychosocial outcome. Salazar AM, et al. **Neurosurg Clin N Am** 1995 Oct; 6(4):715–26 (34 ref.)
Medical care of women deployed during Desert Storm. Lyon DS. **South Med J** 1996 Feb;89(2):172–6 (6 ref.)
[The epidemiological characteristics of acute intestinal infections in wartime] Kartsev AD. **Voen Med Zh** 1996 May;317(5):40–3 (24 ref.) **(Rus)**
[The addictive behavior of servicemen under combat conditions] Litvintsev SV, et al. **Voen Med Zh** 1995 Nov; (11):39–43, 80 (29 ref.) (Eng. Abstr.) **(Rus)**
[Principles of surgical treatment of war injuries of the peripheral nerves] Roganović Z, et al. **Vojnosanit Pregl** 1995 Sep-Oct;52(5):483–7 (52 ref.) **(Scr)**

HISTORY

[The etiology of Leningrad blockade-related hypertension] Klebanov IuA. **Klin Med (Mosk)** 1995;73(3):18–21 (38 ref.)

(Rus)

WAR NEUROSES see COMBAT DISORDERS

WARFARIN

ADMINISTRATION & DOSAGE

Surgical management of patients on warfarin sodium. Beirne OR, et al. **J Oral Maxillofac Surg** 1996 Sep;54(9):1115–8 (18 ref.)

International Normalized Ratio (INR): an improved way to monitor oral anticoagulant therapy. Oertel LB. **Nurse Pract** 1995 Sep;20(9):15–6, 21–2 (12 ref.)

[Oral anticoagulants treatment of thrombosis] Matsuda T. **Nippon Naika Gakkai Zasshi** 1995 Sep 10;84(9):1523–7 (2 ref.) (Jpn)

ADVERSE EFFECTS

Spermatic cord hematoma: case report and literature review. McKenney MG, et al. **Am Surg** 1996 Sep;62(9):768–9 (13 ref.)

Adverse interactions between warfarin and nonsteroidal antiinflammatory drugs: mechanisms, clinical significance, and avoidance [see comments] Chan TY. **Ann Pharmacother** 1995 Dec;29(12):1274–83 (89 ref.) Comment in: Ann Pharmacother 1995 Dec;29(12):1289–91.

Warfarin–induced changes in procoagulant and anticoagulant proteins. Stirling Y. **Blood Coagul Fibrinolysis** 1995 Jul; 6(5):361–73 (115 ref.)

ANTAGONISTS & INHIBITORS

Oral vitamin K1: an option to reduce warfarin's activity. Harrell CC, et al. **Ann Pharmacother** 1995 Dec; 29(12):1228–32 (26 ref.)

BLOOD

International Normalized Ratio (INR): an improved way to monitor oral anticoagulant therapy. Oertel LB. **Nurse Pract** 1995 Sep;20(9):15–6, 21–2 (12 ref.)

THERAPEUTIC USE

ABC of atrial fibrillation. Antithrombotic treatment for atrial fibrillation. Lip GY, et al. **BMJ** 1996 Jan 6;312(7022):45–9 (0 ref.)

Warfarin and aspirin as thromboprophylaxis in atrial fibrillation. Lip GY, et al. **Br J Clin Pharmacol** 1996 May; 41(5):369–79 (83 ref.)

Antithrombotic therapy in atrial fibrillation. Turpie AG, et al. **Can Fam Physician** 1996 Jul;42:1341–5 (16 ref.)

Anticoagulation: risks and benefits in atrial fibrillation. Fiore LD. **Geriatrics** 1996 Jun;51(6):22–4, 27–8, 31 (37 ref.)

Outpatient anticoagulation issues for the primary care physician. Spandorfer JM, et al. **Med Clin North Am** 1996 Mar;80(2):475–91 (79 ref.)

Oral anticoagulant therapy: practical aspects of management. Brigden ML. **Postgrad Med** 1996 Jun;99(6):81–4, 87–9, 93–4 passim (22 ref.)

Anticoagulant therapy for deep vein thrombosis: its proper application. Rohrer MJ, et al. **Semin Vasc Surg** 1996 Mar; 9(1):13–20 (38 ref.)

The role of coumadin and aspirin in atrial fibrillation. Hutter AM Jr. **Trans Am Clin Climatol Assoc** 1995;107:79–85; discussion 85–6 (17 ref.)

[The new frontier of antithrombotic therapy: ASA + warfarin, the ideal solution?] Cimminiello C, et al. **G Ital Cardiol** 1995 Sep;25(9):1187–93 (36 ref.) (Eng. Abstr.) (Ita)

[Atrial fibrillation due to non–valvular causes: indications for antithrombotic therapy] Codinach Huix P. **Med Clin (Barc)** 1996 Apr 20;106(15):586–9 (25 ref.) (Spa)

WART–HOG DISEASE VIRUS see AFRICAN SWINE FEVER VIRUS

WARTHIN TUMOR see ADENOLYMPHOMA

WARTS

EPIDEMIOLOGY

The descriptive epidemiology of warts in the community. Kilkenny M, et al. **Australas J Dermatol** 1996 May; 37(2):80–6 (40 ref.)

ETIOLOGY

Oral verruca vulgaris in a bone marrow transplant patient: a case report and review of literature. Barasch A, et al. **Eur J Cancer B Oral Oncol** 1996 Mar;32B(2):137–9 (13 ref.)

THERAPY

Nongenital warts: when is treatment warranted? Landow K. **Postgrad Med** 1996 Mar;99(3):245–9 (16 ref.)

WARTS, GENITAL see CONDYLOMATA ACUMINATA

WARTS, VENEREAL see CONDYLOMATA ACUMINATA

WASP VENOMS

ADVERSE EFFECTS

Allergy to bee and wasp venom. Gelder C, et al. **Br J Hosp Med** 1996 Mar 20–Apr 2;55(6):349–52 (30 ref.)

THERAPEUTIC USE

Venom immunotherapy: tolerance to a 3–day protocol of rush–immunotherapy. Díez Gómez ML, et al. **Allergol Immunopathol (Madr)** 1995 Nov–Dec;23(6):277–84 (40 ref.)

WASPS

Venom immunotherapy: tolerance to a 3–day protocol of rush–immunotherapy. Díez Gómez ML, et al. **Allergol Immunopathol (Madr)** 1995 Nov–Dec;23(6):277–84 (40 ref.)

WASTE DISPOSAL, MEDICAL see MEDICAL WASTE DISPOSAL

WASTE DISPOSAL, SOLID see REFUSE DISPOSAL

WASTE MANAGEMENT

Collection of domestic waste. Review of occupational health problems and their possible causes. Poulsen OM, et al. **Sci Total Environ** 1995 Aug 18;170(1–2):1–19 (83 ref.)

WATER

see related
BODY WATER
FRESH WATER
MINERAL WATERS
SEAWATER

Birth under water—to breathe or not to breathe. Johnson P. **Br J Obstet Gynaecol** 1996 Mar;103(3):202–8 (37 ref.)

Water activity, water glass dynamics, and the control of microbiological growth in foods. Chirife J, et al. **Crit Rev Food Sci Nutr** 1996 May;36(5):465–513 (151 ref.)

Molecular responses to drought and cold stress. Shinozaki K, et al. **Curr Opin Biotechnol** 1996 Apr;7(2):161–7 (64 ref.)

ADVERSE EFFECTS

Major vascular injury from high–pressure water jet. Harvey RL, et al. **J Trauma** 1996 Jan;40(1):165–7 (15 ref.)

Aquagenic pruritus. du Peloux Menagé H, et al. **Semin Dermatol** 1995 Dec;14(4):313–6 (40 ref.)

CHEMISTRY

Micro–osmosis in gels, cells and enzymes. Wiggins PM. **Cell Biochem Funct** 1995 Sep;13(3):165–72 (54 ref.)

Role of hydration and water structure in biological and colloidal interactions. Israelachvili J, et al. **Nature** 1996 Jan 18;379(6562):219–25 (85 ref.)

METABOLISM

The role of cellular hydration in the regulation of cell function. Häussinger D. **Biochem J** 1996 Feb 1;313 (Pt 3):697–710 (170 ref.)

Osmotic effects of water compartments in protein polymers. Lew VL, et al. **Cell Biochem Funct** 1995 Sep;13(3):173–6 (15 ref.)

Diffusional water permeability of mammalian red blood cells. Benga G, et al. **Comp Biochem Physiol B Biochem Mol Biol** 1995 Dec; 112(4):653–9 (54 ref.)

Water channels. Fushimi K, et al. **Curr Opin Nephrol Hypertens** 1995 Sep;4(5):392–7 (37 ref.)

Doubly labelled water measurement of total energy expenditure. Ritz P, et al. **Diabete Metab** 1995 Oct; 21(4):241–51 (68 ref.)

Modeling organic chemical fate in aquatic systems: significance of bioaccumulation and relevant time–space scales. Thomann RV. **Environ Health Perspect** 1995 Jun; 103 Suppl 5:53–7 (15 ref.)

Molecular mechanisms for passive and active transport of water. Zeuthen T. **Int Rev Cytol** 1995;160:99–161 (290 ref.)

Molecular mechanisms for the regulation of water transport in amphibian epithelia by antidiuretic hormone. Jo I, et al. **Kidney Int** 1995 Oct;48(4):1088–96 (113 ref.)

The aquaporin family of water channels in kidney. Nielsen S, et al. **Kidney Int** 1995 Oct;48(4):1057–68 (83 ref.)

Water channels in the kidney collecting duct. Sasaki S, et al. **Kidney Int** 1995 Oct;48(4):1082–7 (43 ref.)

PHYSIOLOGY

Neuroendocrine regulation of sodium and volume following subarachnoid hemorrhage. Diringer MN. **Clin Neuropharmacol** 1995 Apr;18(2):114–26 (64 ref.)

Sodium and water homeostasis. Trachtman H. **Pediatr Clin North Am** 1995 Dec;42(6):1343–63 (64 ref.)

WATER BUFFALOES see BUFFALOES

WATER CONSUMPTION see DRINKING

WATER DEPRIVATION

[The recent trend in preoperative fasting] Kawasaki J, et al. **Masui** 1995 Aug;44(8):1154–8 (31 ref.) (Eng. Abstr.) (Jpn)

WATER–ELECTROLYTE BALANCE

see related
FLUID THERAPY
OSMOLAR CONCENTRATION
REHYDRATION SOLUTIONS
WATER–ELECTROLYTE IMBALANCE

Osmoadaptation in bacteria. Galinski EA. **Adv Microb Physiol** 1995;37:272–328 (265 ref.)

Fluid needs in hot and cold environments. Murray R. **Int J Sport Nutr** 1995 Jun;5 Suppl:S62–73 (51 ref.)

Hypothalamic integration of body fluid regulation. Denton DA, et al. **Proc Natl Acad Sci U S A** 1996 Jul 9; 93(14):7397–404 (80 ref.)

[Which problems arise in the hydration of elderly persons?] Mutsers A. **Rev Med Liege** 1996 Mar;51(3):249–53 (25 ref.) (Fre)

[Regulation of cell function by level of hydration] Häussinger D. **Naturwissenschaften** 1996 Jun;83(6):264–71 (39 ref.) (Eng. Abstr.) (Ger)

PHYSIOLOGY

Salt and water homeostasis: uroguanylin is a circulating peptide hormone with natriuretic activity. Forte LR, et al. **Am J Kidney Dis** 1996 Aug;28(2):296–304 (35 ref.)

Pathophysiology of the aquaporin water channels. King LS, et al. **Annu Rev Physiol** 1996;58:619–48 (159 ref.)

Aldosterone and its mechanism of action: more questions than answers. Fuller PJ. **Aust N Z J Med** 1995 Dec;25(6):800–7 (57 ref.)

Cell volume regulated transporters of compatible osmolytes. Kwon HM, et al. **Curr Opin Cell Biol** 1995 Aug;7(4):465–71 (48 ref.)

Endogenous ouabain, sodium balance and blood pressure: a review and a hypothesis [see comments] Hamlyn JM, et al. **J Hypertens** 1996 Feb;14(2):151–67 (136 ref.) Comment in: J Hypertens 1996 Feb;14(2):169–71.

Endogenous ouabain, sodium balance and blood pressure [comment] Pidgeon GB, et al. **J Hypertens** 1996 Feb; 14(2):169–71 (28 ref.) Comment on: J Hypertens 1996 Feb;14(2):151–67.

How 'dry' must the septic patient be kept – potentially conflicting interests of lung and peripheral circulation? [editorial] Reinhart K. **Nephrol Dial Transplant** 1996 Jul; 11(7):1241–2 (12 ref.)

Fluid balance for optimal performance. Gisolfi CV. **Nutr Rev** 1996 Apr;54(4 Pt 2):S159–68 (86 ref.)

Pulse reverse osmosis: a new theory in the maintenance of fluid balance. Prior FG, et al. **Perfusion** 1995 May; 10(3):159–70 (19 ref.)

Optimal use of glucose polymer (icodextrin) in peritoneal dialysis. Mistry CD, et al. **Perit Dial Int** 1996;16 Suppl 1:S104–8 (23 ref.)

Peritoneal equilibration in children. Morgenstern BZ. **Perit Dial Int** 1996;16 Suppl 1:S532–9 (43 ref.)

Aquaporin water channels in the kidney: localization and regulation. Nielsen S. **Perit Dial Int** 1996;16 Suppl 1:S25–7 (46 ref.)

Theoretical analysis of osmotic agents in peritoneal dialysis. What size is an ideal osmotic agent? Rippe B, et al. **Perit Dial Int** 1996;16 Suppl 1:S97–103 (18 ref.)

[The physiology of the kidney and water–salt metabolism: the basic research trends in Russia] Ivanova LN. **Usp Fiziol Nauk** 1995 Jul–Sep;26(3):3–13 (74 ref.) (Eng. Abstr.) (Rus)

WATER–ELECTROLYTE IMBALANCE

see related
FLUID THERAPY
REHYDRATION SOLUTIONS

[Water–electrolyte imbalance and posterior pituitary gland hormone] Yoshida S. **Nippon Naika Gakkai Zasshi** 1995 Sep 10;84(9):1388–95 (20 ref.) (Jpn)

CHEMICALLY INDUCED

Renal and electrolyte complications associated with antibiotic therapy. Kasama R, et al. **Am Fam Physician** 1996 Jan; 53(1):227–32 (23 ref.)

Complications of laxative abuse. Baker EH, et al. **Annu Rev Med** 1996;47:127–34 (20 ref.)

ETIOLOGY

A case of pancreatic carcinoma causing massive bronchial fluid production and electrolyte abnormalities. Lembo T, et al. **Chest** 1995 Oct;108(4):1161–3 (8 ref.)

Electrolyte fluxes in the gut and oral rehydration solutions. Acra SA, et al. **Pediatr Clin North Am** 1996 Apr; 43(2):433–49 (64 ref.)

The refeeding syndrome: an approach to understanding its complications and preventing its occurrence. Brooks MJ, et al. **Pharmacotherapy** 1995 Nov–Dec;15(6):713–26 (76 ref.)

NURSING

Assessing fluid and electrolyte balance in elders. O'Donnell ME. **Am J Nurs** 1995 Nov;95(11):40–5; quiz 46 (11 ref.)

PHYSIOPATHOLOGY

Disorders of body fluid balance: a new look into the mechanisms of disease. Plante GE, et al. **Can J Cardiol** 1995 Oct;11(9):788–802 (89 ref.)

Electrolyte fluxes in the gut and oral rehydration solutions. Acra SA, et al. **Pediatr Clin North Am** 1996 Apr; 43(2):433–49 (64 ref.)

Pathophysiology of fluid translocation in hypovolemic state. Duda K. **Rocz Akad Med Bialymst** 1995;40(1):25–35 (46 ref.)

THERAPY

Management of fluid imbalance. Eckart J, et al. **Int J Artif Organs** 1996 Feb;19(2):106–7 (16 ref.)

Emergency fluid management for hypovolemia. Pfiederer TA. **Postgrad Med** 1996 Sep;100(3):243–4, 247–8, 251–4 (17 ref.)

[Emergency therapy of acute kidney failure and water-electrolyte imbalance] Ando K, et al. **Nippon Naika Gakkai Zasshi** 1995 Nov 10;84(11):1852–7 (6 ref.) **(Jpn)**

WATER INTAKE see **DRINKING**

WATER INTOXICATION

see related
WATER-ELECTROLYTE IMBALANCE

PATHOLOGY

Autopsy case report of a rare acute iatrogenic water intoxication with a review of the literature. Chen X, et al. **Forensic Sci Int** 1995 Nov 30;76(1):27–34 (28 ref.)

WATER MICROBIOLOGY

Foodborne and waterborne illness in children. Rivera-Matos IR, et al. **Adv Pediatr Infect Dis** 1996;11:101–34 (112 ref.)

Microbiology to 10,500 meters in the deep sea. Yayanos AA. **Annu Rev Microbiol** 1995;49:777–805 (170 ref.)

Biofilm and the dental office. Shearer BG. **J Am Dent Assoc** 1996 Feb;127(2):181–9 (49 ref.)

Dental unit water contamination. Peters E, et al. **J Can Dent Assoc** 1996 Jun;62(6):492–5 (41 ref.)

Winner of the Theodore E. Woodward Clinical Award. Monster of the Chesapeake Bay—Vibrio vulnificus. Calia FM. **Trans Am Clin Climatol Assoc** 1994;106:49–56; discussion 56–7 (31 ref.)

[Cyanobacteria, their toxins and health risks] Thébault l, et al. **Med Trop (Mars)** 1995;55(4):375–80 (43 ref.) (Eng. Abstr.) **(Fre)**

[Bacterial regrowth in water-supply networks and the health and hygiene aspects] Aulicino FA, et al. **Ann Ig** 1994 Jul-Dec;6(4–6):861–6 (28 ref.) (Eng. Abstr.) **(Ita)**

[Hypersensitivity pneumonitis caused by a home humidifier] Hagiwara S, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Sep; 33(9):1024–9 (10 ref.) (Eng. Abstr.) **(Jpn)**

WATER MOVEMENTS

Gravitational effects of the period of high tides and the new moon on lunacy. Myers DE. **J Emerg Med** 1995 Jul–Aug; 13(4):529–32 (24 ref.)

WATER POLLUTANTS

Interactions of aniline with soil and groundwater at an industrial spill site. Kosson DS, et al. **Environ Health Perspect** 1995 Jun;103 Suppl 5:71–3 (13 ref.)

ANALYSIS

Monitoring of herbicide pollution in water by capillary electrophoresis. Dinelli G, et al. **J Chromatogr A** 1996 May 10;733(1–2):337–47 (60 ref.)

TOXICITY

Quantitative structure-activity relationships and ecological risk assessment: an overview of predictive aquatic toxicology research. Bradbury SP. **Toxicol Lett** 1995 Sep; 79(1–3):279–37 (40 ref.)

WATER POLLUTANTS, CHEMICAL

[Chlorination and ozonation of contaminants in water environment and role of free radicals] Hamada A. **Yakugaku Zasshi** 1995 Oct;115(10):790–804 (52 ref.) (Eng. Abstr.) **(Jpn)**

[Regional and local problems of chemical environmental pollution and health of the population (review of the literature)] Revich BA, et al. **Med Tr Prom Ekol** 1995; (9):23–9 (12 ref.) **(Rus)**

ADVERSE EFFECTS

A review of factors affecting productivity of bald eagles in the Great Lakes region: implications for recovery. Bowerman WW, et al. **Environ Health Perspect** 1995 May; 103 Suppl 4:51–9 (58 ref.)

The reproductive toxicology of Great Lakes contaminants. Foster WG. **Environ Health Perspect** 1995 Dec;103 Suppl 9:63–9 (85 ref.)

Drinking water and cancer. Morris RD. **Environ Health Perspect** 1995 Nov;103 Suppl 8:225–31 (47 ref.)

Vitellogenesis as a biomarker for estrogenic contamination of the aquatic environment. Sumpter JP, et al. **Environ Health Perspect** 1995 Oct;103 Suppl 7:173–8 (39 ref.)

Health implications of nitrate and nitrite in drinking water: an update on methemoglobinemia occurrence and reproductive and developmental toxicity. Fan AM, et al. **Regul Toxicol Pharmacol** 1996 Feb;23(1 Pt 1):35–43 (54 ref.)

Chlorophenols in the terrestrial environment. Jensen J. **Rev Environ Contam Toxicol** 1996;146:25–51 (95 ref.)

Health implications for Faroe islanders of heavy metals and PCBs from pilot whales. Weihe P, et al. **Sci Total Environ** 1996 Jul 16;186(1–2):141–8 (37 ref.)

ANALYSIS

Plants and animals as biomonitors of heavy metal level in the aquatic ecosystem of the river Danube. Oertel N. **Arch Toxicol Suppl** 1996;18:404–16 (23 ref.)

Biomarkers for Great Lakes priority contaminants: halogenated aromatic hydrocarbons. Feeley MM. **Environ Health Perspect** 1995 Dec;103 Suppl 9:7–16 (106 ref.)

Current developments in the analysis of water pollution by polychlorinated biphenyls. Font G, et al. **J Chromatogr A** 1996 May 10;733(1–2):449–71 (154 ref.)

Copper regulatory level in drinking-water as proposed by Sidhu et al. Fitzgerald DJ. **Regul Toxicol Pharmacol** 1996 Apr;23(2):173–5 (9 ref.)

Persistent pesticides in Mexico. Albert LA. **Rev Environ Contam Toxicol** 1996;147:1–44 (85 ref.)

METABOLISM

Modeling organic chemical fate in aquatic systems: significance of bioaccumulation and relevant time-space scales. Thomann RV. **Environ Health Perspect** 1995 Jun; 103 Suppl 5:53–7 (15 ref.)

PHARMACOKINETICS

Dermal exposure to environmental contaminants in the Great Lakes. Moody RP, et al. **Environ Health Perspect** 1995 Dec;103 Suppl 9:103–14 (88 ref.)

Epidemiological analysis of persistent organochlorine contaminants in cetaceans. Colborn T, et al. **Rev Environ Contam Toxicol** 1996;146:91–172 (247 ref.)

Bioaccumulation of polycyclic aromatic hydrocarbons by marine organisms. Meador JP, et al. **Rev Environ Contam Toxicol** 1995;143:79–165 (320 ref.)

POISONING

An overview of exposure to, and effects of, petroleum oil and organochlorine pollution in grey seals (Halichoerus grypus). Jenssen BM. **Sci Total Environ** 1996 Jul 16; 186(1–2):109–18 (54 ref.)

TOXICITY

Foodborne and waterborne illness in children. Rivera-Matos IR, et al. **Adv Pediatr Infect Dis** 1996;11:101–34 (112 ref.)

The influence of salinity on the toxicity of various classes of chemicals to aquatic biota. Hall LW Jr, et al. **Crit Rev Toxicol** 1995;25(4):281–346 (100 ref.)

Narcosis due to environmental pollutants in aquatic organisms: residue-based toxicity, mechanisms, and membrane burdens. van Wezel AP, et al. **Crit Rev Toxicol** 1995;25(3):255–79 (94 ref.)

Design and construction of model stream ecosystems. Rodgers JH Jr, et al. **Ecotoxicol Environ Saf** 1996 Feb; 33(1):30–7 (21 ref.)

Immunotoxicity of heavy metals in relation to Great Lakes. Bernier J, et al. **Environ Health Perspect** 1995 Dec;103 Suppl 9:23–34 (145 ref.)

Pesticide-induced immunotoxicity: are Great Lakes residents at risk? Thomas PT. **Environ Health Perspect** 1995 Dec; 103 Suppl 9:55–61 (78 ref.)

Immunotoxicity of PCBs (Aroclors) in relation to Great Lakes. Tryphonas H. **Environ Health Perspect** 1995 Dec; 103 Suppl 9:35–46 (97 ref.)

The influence of petrochemicals and stress on the immune system of seabirds. Briggs KT, et al. **Regul Toxicol Pharmacol** 1996 Apr;23(2):145–55 (77 ref.)

Predicting modes of toxic action from chemical structure: an overview. Bradbury SP. **SAR QSAR Environ Res** 1994; 2(1–2):89–104 (45 ref.)

The application of structure-activity relationships (SARs) in the aquatic toxicity evaluation of discrete organic chemicals. Clements RG, et al. **SAR QSAR Environ Res** 1995;3(3):203–15 (25 ref.)

Feminized responses in fish to environmental estrogens. Sumpter JP. **Toxicol Lett** 1995 Dec;82–83:737–42 (18 ref.)

Contaminant-induced immunotoxicity in harbour seals: wildlife at risk? Ross P, et al. **Toxicology** 1996 Aug 16; 112(2):157–69 (91 ref.)

WATER POLLUTANTS, RADIOACTIVE

ADVERSE EFFECTS

Uranium in the environment: occurrence, transfer, and biological effects. Ribera D, et al. **Rev Environ Contam Toxicol** 1996;146:53–89 (130 ref.)

WATER POLLUTION

LEGISLATION & JURISPRUDENCE

Public health and regulatory considerations of the Safe Drinking Water Act. Raucher RS. **Annu Rev Public Health** 1996;17:179–202 (20 ref.)

PREVENTION & CONTROL

Public health and regulatory considerations of the Safe Drinking Water Act. Raucher RS. **Annu Rev Public Health** 1996;17:179–202 (20 ref.)

WATER POLLUTION, CHEMICAL

Field evaluations of marine oil spill bioremediation. Swannell RP, et al. **Microbiol Rev** 1996 Jun;60(2):342–65 (121 ref.)

ADVERSE EFFECTS

Factors associated with respiratory problems in swimmers. Potts J. **Sports Med** 1996 Apr;21(4):256–61 (43 ref.)

PREVENTION & CONTROL

[The fluorosis problem in Senegal: data evaluation and presentation of a new method for defluoridating the water supply] Pontié M, et al. **Sante** 1996 Jan–Feb;6(1):27–36 (44 ref.) (Eng. Abstr.) **(Fre)**

WATER POLLUTION, RADIOACTIVE

ADVERSE EFFECTS

[The results of multiyear research on fish populations from reservoirs falling within the area of the Kyshtym accident (a review)] Fetisov AN. **Radiats Biol Radioecol** 1995 Sep–Oct;35(5):751–8 (19 ref.) (Eng. Abstr.) **(Rus)**

[The sequelae of the Kyshtym and Chernobyl accidents for hydrobionts] Polikarpov GG, et al. **Radiats Biol Radioecol** 1995 Jul–Aug;35(4):536–49 (79 ref.) (Eng. Abstr.) **(Rus)**

WATER PURIFICATION

Biofilm and the dental office. Shearer BG. **J Am Dent Assoc** 1996 Feb;127(2):181–9 (49 ref.)

[Chlorination and ozonation of contaminants in water environment and role of free radicals] Hamada A. **Yakugaku Zasshi** 1995 Oct;115(10):790–804 (52 ref.) (Eng. Abstr.) **(Jpn)**

METHODS

Water treatment for hemodialysis. Ismail N, et al. **Am J Nephrol** 1996;16(1):60–72 (86 ref.)

[The fluorosis problem in Senegal: data evaluation and presentation of a new method for defluoridating the water supply] Pontié M, et al. **Sante** 1996 Jan–Feb;6(1):27–36 (44 ref.) (Eng. Abstr.) **(Fre)**

[Methods of drinking water conservation in autonomous objects (review)] Avchinnikov AV, et al. **Gig Sanit** 1996 Mar–Apr;(2):9–13 (59 ref.) (Eng. Abstr.) **(Rus)**

WATER SUPPLY

see related
WATER PURIFICATION

Drinking water and cancer. Morris RD. **Environ Health Perspect** 1995 Nov;103 Suppl 8:225–31 (47 ref.)

Monitoring of herbicide pollution in water by capillary electrophoresis. Dinelli G, et al. **J Chromatogr A** 1996 May 10;733(1–2):337–47 (60 ref.)

[Bacterial regrowth in water-supply networks and the health and hygiene aspects] Aulicino FA, et al. **Ann Ig** 1994 Jul-Dec;6(4–6):861–6 (28 ref.) (Eng. Abstr.) **(Ita)**

[The effect of economic activities altering water resources on the parasitological situation] Artamoshin AS, et al. **Med Parazitol (Mosk)** 1995 Apr–Jun;(2):51–7 (50 ref.) (Eng. Abstr.) **(Rus)**

ANALYSIS

Copper regulatory level in drinking-water as proposed by Sidhu et al. Fitzgerald DJ. **Regul Toxicol Pharmacol** 1996 Apr;23(2):173–5 (9 ref.)

LEGISLATION & JURISPRUDENCE

Public health and regulatory considerations of the Safe Drinking Water Act. Raucher RS. **Annu Rev Public Health** 1996;17:179–202 (20 ref.)

WATER SUPPLY

STANDARDS

Public health and regulatory considerations of the Safe Drinking Water Act. Raucher RS.
Annu Rev Public Health 1996;17:179–202 (20 ref.)
[Methods of drinking water conservation in autonomous objects (review)] Avchinnikov AV, et al. **Gig Sanit** 1996 Mar–Apr;(2):9–13 (39 ref.) (Eng. Abstr.) **(Rus)**

WATERY DIARRHEA SYNDROME see **VIPOMA**

WATERY DIARRHEA WITH HYPOKALEMIC ALKALOSIS see **VIPOMA**

WAXES

see related
CERUMEN

ADVERSE EFFECTS

Adverse effects of bone wax in surgery of the orbit. Katz SE, et al. **Ophthal Plast Reconstr Surg** 1996 Jun;12(2):121–6 (15 ref.)

ANALYSIS

Plant wax components: a new approach to estimating intake and diet composition in herbivores. Dove H, et al.
J Nutr 1996 Jan;126(1):13–26 (62 ref.)

WDHA see **VIPOMA**

WDHH see **VIPOMA**

WEANING

Infant nutrition. Part 2: Weaning–1 year. Lambert EJ, et al. **Br J Hosp Med** 1995 Oct 4–17;54(7):327–30 (5 ref.)
Transition to breast/bottle feedings: the premature infant. Lemons PK, et al. **J Am Coll Nutr** 1996 Apr;15(2):126–35 (34 ref.)
Dietary fiber in weaning foods of young children. Agostoni C, et al. **Pediatrics** 1995 Nov;96(5 Pt 2):1002–5 (42 ref.)

WEATHER

Acknowledging the weather–health link. Bart JL, et al.
Can Med Assoc J 1995 Oct 1;153(7):941–4 (30 ref.)

WEAVER MICE see **MICE, NEUROLOGIC MUTANTS**

WEBER–CHRISTIAN DISEASE see **PANNICULITIS, NODULAR NONSUPPURATIVE**

WEDGE PRESSURE see **PULMONARY WEDGE PRESSURE**

WEGENER'S GRANULOMATOSIS

Wegener's granulomatosis. Duna GF, et al.
Rheum Dis Clin North Am 1995 Nov;21(4):949–86 (270 ref.)
[Wegener granulomatosis. Anatomoclinical study. Review of the literature] Pinède L, et al. **Ann Med Interne (Paris)** 1995;146(5):339–64 (236 ref.) **(Fre)**
[Granulomatous tubulointerstitial nephritis—Wegener's granulomatosis, sarcoidosis] Yoshida M. **Nippon Rinsho** 1995 Aug;53(8):1974–80 (20 ref.) (Eng. Abstr.) **(Jpn)**

COMPLICATIONS

Wegener's granulomatosis complicated by arterial aneurysm. Aoki N, et al. **Intern Med** 1995 Aug;34(8):790–3 (14 ref.)
Wegener's granulomatosis with gangrene of toes. Handa R, et al. **Scand J Rheumatol** 1996;25(2):103–4 (6 ref.)
[Wegener's granulomatosis, with successive lung and orbit involvement, occurring 14 and 4 years before systemic symptoms as well as renal and sinusal sites (letter)] Girard–Madoux MH, et al. **Ann Med Interne (Paris)** 1995; 146(8):598–600 (16 ref.) **(Fre)**

DIAGNOSIS

Recurrent Wegener's granulomatosis: a case report and review. Piercey S, et al. **Ann Allergy Asthma Immunol** 1996 Apr;76(4):317–20 (7 ref.)
The clinical utility of ANCA positivity [editorial] Edgar JD. **Ann Rheum Dis** 1996 Aug;55(8):494–6 (37 ref.)
[ANCA–associated vasculitis (Wegener's granulomatosis, Churg–Strauss syndrome, microscopic polyangiitis). 2. Diagnostic procedure (see comments) de Groot K, et al. **Z Rheumatol** 1995 Sep–Oct;54(5):291–302 (59 ref.) (Eng. Abstr.) Comment in: Z Rheumatol 1995 Sep–Oct;54(5):277–8. **(Ger)**

IMMUNOLOGY

[ANCA–associated vasculitis (Wegener's granulomatosis, Churg–Strauss syndrome, microscopic polyangiitis). 1. Systemic aspects, pathogenesis and clinical aspects (see comments)] Gross WL, et al. **Z Rheumatol** 1995 Sep–Oct; 54(5):279–90 (22 ref.) (Eng. Abstr.) Comment in: Z Rheumatol 1995 Sep–Oct;54(5):277–8. **(Ger)**

RADIOGRAPHY

[Wegener's granulomatosis: clinical, radiological and diagnostic characteristics. Apropos of a case] Polus M, et al. **Acta Clin Belg** 1995;50(5):291–6 (18 ref.) (Eng. Abstr.) **(Fre)**

THERAPY

[ANCA–associated vasculitis (Wegener's granulomatosis, Churg–Strauss syndrome, microscopic polyangiitis). 3. Therapeutic procedure (see comments)] Reinhold–Keller E, et al. **Z Rheumatol** 1995 Sep–Oct;54(5):303–9 (30 ref.) (Eng. Abstr.) Comment in: Z Rheumatol 1995 Sep–Oct;54(5):277–8. **(Ger)**

WEIGHT GAIN

see related
OBESITY

A critique of the new recommendations for weight gain in pregnancy. Johnson JW, et al. **Am J Obstet Gynecol** 1996 Jan;174(1 Pt 1):254–8 (25 ref.)
"Weight cycling" and mortality: how do the epidemiologists explain the role of intentional weight loss? Williamson DF. **J Am Coll Nutr** 1996 Feb;15(1):6–13 (23 ref.)
Physical inactivity and metabolic factors as predictors of weight gain. Saris WH. **Nutr Rev** 1996 Apr;54(4 Pt 2):S110–5 (28 ref.)
Dietary intake and physical activity as "predictors" of weight gain in observational, prospective studies of adults. Williamson DF. **Nutr Rev** 1996 Apr;54(4 Pt 2):S101–9 (15 ref.)

DRUG EFFECTS

Drugs that cause weight gain. Fernstrom MH. **Obes Res** 1995 Nov;3 Suppl 4:435S–439S (18 ref.)
Weight gain associated with neuroleptic medication: a review. Stanton JM. **Schizophr Bull** 1995;21(3):463–72 (100 ref.)

PHYSIOLOGY

Is weight cycling detrimental to health? A review of the literature in humans. Muls E, et al.
Int J Obes Relat Metab Disord 1995 Sep;19 Suppl 3:S46–50 (48 ref.)
Weight change in the postpartum period. A review of the literature. Crowell DT. **J Nurse Midwifery** 1995 Sep–Oct; 40(5):418–23 (37 ref.)
The Weight–Control Information Network: a project of the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health. **Nutr Rev** 1995 Aug;53(8):232–3 (0 ref.)
Influence of altered body weight on energy expenditure. Kinney JM. **Nutr Rev** 1995 Sep;53(9):265–8 (14 ref.)
Susceptibility to development of central adiposity among populations. Fujimoto WY, et al. **Obes Res** 1995 Sep;3 Suppl 2:179S–186S (28 ref.)
Changing diet and exercise behaviors in individuals at risk for weight gain. Wing RR. **Obes Res** 1995 Sep;3 Suppl 2:277s–282s (28 ref.)

WEIGHT LIFTING

Reversing sarcopenia: how weight training can build strength and vitality. Evans WJ. **Geriatrics** 1996 May;51(5):46–7, 51–3; quiz 54 (18 ref.)

INJURIES

Volar dislocation of the lunate in a weight lifter. Miller SJ, et al. **Orthopedics** 1996 Jan;19(1):61–3 (17 ref.)

WEIGHT LOSS

see related
THINNESS

Psychosocial consequences of weight reduction: how much weight loss is enough? Wadden TA, et al.
Am J Clin Nutr 1996 Mar;63(3 Suppl):461S–465S (48 ref.)
"Weight cycling" and mortality: how do the epidemiologists explain the role of intentional weight loss? Williamson DF. **J Am Coll Nutr** 1996 Feb;15(1):6–13 (23 ref.)
Recent progress in the studies on weight reduction by acupuncture and moxibustion. Liu Z, et al.
J Tradit Chin Med 1995 Sep;15(3):224–30 (42 ref.)
Is weight loss hazardous? Lee IM, et al. **Nutr Rev** 1996 Apr; 54(4 Pt 2):S116–24 (51 ref.)
Clinical applications of diet and physical activity in weight loss. Wood PD. **Nutr Rev** 1996 Apr;54(4 Pt 2):S131–5 (29 ref.)
Preventing relapse in weight control: a discussion of cognitive and behavioral strategies. Turner LW, et al.
Psychol Rep 1995 Oct;77(2):651–6 (25 ref.)
[Effects of one–week inpatient weight reduction program for obese persons] Ogawa K, et al. **Nippon Rinsho** 1995 Jun; 53 Suppl:501–8 (11 ref.) **(Jpn)**

DRUG EFFECTS

Chromium and other insulin sensitizers may enhance glucagon secretion: implications for hypoglycemia and weight control. McCarty MF. **Med Hypotheses** 1996 Feb; 46(2):77–80 (35 ref.)

PHYSIOLOGY

Is weight cycling detrimental to health? A review of the literature in humans. Muls E, et al.
Int J Obes Relat Metab Disord 1995 Sep;19 Suppl 3:S46–50 (48 ref.)
Exercise for weight loss: what are the facts? Zelasko CJ. **J Am Diet Assoc** 1995 Dec;95(12):1414–7 (22 ref.)
Weight change in the postpartum period. A review of the literature. Crowell DT. **J Nurse Midwifery** 1995 Sep–Oct; 40(5):418–23 (37 ref.)
The Weight–Control Information Network: a project of the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health. **Nutr Rev** 1995 Aug;53(8):232–3 (0 ref.)
Influence of altered body weight on energy expenditure. Kinney JM. **Nutr Rev** 1995 Sep;53(9):265–8 (14 ref.)
Effect of degree of weight loss on health benefits. Blackburn G. **Obes Res** 1995 Sep;3 Suppl 2:211s–216s (48 ref.)

WEIGHT REDUCTION see **WEIGHT LOSS**

WEIGHTLESSNESS SIMULATION

[Stresses under conditions of a normal mode of life, during hypokinesia (simulating effects of weightlessness) and in space flights] Grigor'ev AI, et al. **Fiziol Cheloveka** 1996 Mar–Apr;22(2):10–9 (35 ref.) **(Rus)**

WEIL'S DISEASE

[Leptospirosis, Weil's disease] Sakurai Y.
Ryoikibetsu Shokogun Shirizu 1995;(7):115–7 (11 ref.) **(Jpn)**

WELLNESS PROGRAMS see **HEALTH PROMOTION**

WERDNIG–HOFFMANN DISEASE

GENETICS

[Molecular genetic diagnosis and deletion analysis in Type I–III spinal muscular atrophy] Spiegel R, et al.
Schweiz Med Wochenschr 1996 May 25;126(21):907–14 (30 ref.) (Eng. Abstr.) **(Ger)**

WERLHOF'S DISEASE see **PURPURA, THROMBOCYTOPENIC, IDIOPATHIC**

WERMER SYNDROME see **MULTIPLE ENDOCRINE NEOPLASIA TYPE 1**

WERNER'S SYNDROME

DRUG THERAPY

Potential for pharmacological intervention in Werner syndrome. Murano S. **Drugs Aging** 1995 Dec;7(6):449–58 (57 ref.)

GENETICS

[Positional cloning of the genes for progeroid syndromes] Miki T, et al. **Tanpakushitsu Kakusan Koso** 1996 Mar; 41(3):245–54 (41 ref.) **(Jpn)**

WERNICKE AREA see **TEMPORAL LOBE**

WERNICKE'S ENCEPHALOPATHY

[Wernicke's encephalopathy] Andersson JE.
Ugeskr Laeger 1996 Feb 12;158(7):898–901 (40 ref.) (Eng. Abstr.) **(Dan)**

DIAGNOSIS

[Wernicke's encephalopathy: report of a case with obstructive pyloric syndrome] Oliveira HA, et al.
Arq Neuropsiquiatr 1995 Sep;53(3–A):488–93 (24 ref.) (Eng. Abstr.) **(Por)**

PATHOLOGY

Neuronal cell death in Wernicke's encephalopathy: pathophysiologic mechanisms and implications for PET imaging. Leong DK, et al. **Metab Brain Dis** 1996 Mar; 11(1):71–9 (58 ref.)

WEST SYNDROME see **SPASMS, INFANTILE**

WESTERN BLOTTING see **BLOTTING, WESTERN**

WESTERN IMMUNOBLOTTING see **BLOTTING, WESTERN**

WET LUNG see **PULMONARY EDEMA**

WHALES

Intestinal adenocarcinomas in two beluga whales (Delphinapterus leucas) from the estuary of the St. Lawrence River. Martineau D, et al. **Can Vet J** 1995 Sep; 36(9):563–5 (14 ref.)

METABOLISM

Environmental pollutants in marine mammals from the Norwegian coast and Arctic. Skaare JU.
Sci Total Environ 1996 Jul 16;186(1-2):25-7 (12 ref.)
Health implications for Faroe islanders of heavy metals and PCBs from pilot whales. Weihe P, et al.
Sci Total Environ 1996 Jul 16;186(1-2):141-8 (37 ref.)

PHYSIOLOGY

Possible mechanisms of action of environmental contaminants on St. Lawrence beluga whales (Delphinapterus leucas). De Guise S, et al. **Environ Health Perspect** 1995 May;103 Suppl 4:73-7 (78 ref.)

WHEAT

[Food fortification with emphasis on the addition of micronutrients to wheat flour] Arroyave G.
Arch Latinoam Nutr 1993 Sep;43(3):186-90 (16 ref.) (Eng. Abstr.) **(Spa)**

WHEELCHAIRS

STANDARDS

Could changes in the wheelchair delivery system improve safety? [see comments] Kirby RL, et al.
Can Med Assoc J 1995 Dec 1;153(11):1585-91 (40 ref.)
Comment in: Can Med Assoc J 1996 Mar 15;154(6):762, 764.

WHEEZING see RESPIRATORY SOUNDS

WHIPLASH INJURIES

COMPLICATIONS

Oculocephalic sympathetic dysfunction in posttraumatic headaches. Khurana RK. **Headache** 1995 Nov-Dec; 35(10):614-20 (32 ref.)
Spine update. Impaired cognitive functioning after whiplash injury of the cervical spine. Radanov BP, et al. **Spine** 1996 Feb 1;21(3):392-7 (26 ref.)

DIAGNOSIS

What is the evidence for an organic lesion in whiplash injury? Gargan MF. **J Psychosom Res** 1995 Aug;39(6):777-81 (27 ref.)
Long-term outcome after whiplash injury. A 2-year follow-up considering features of injury mechanism and somatic, radiologic, and psychosocial findings. Radanov BP, et al. **Medicine (Baltimore)** 1995 Sep;74(5):281-97 (61 ref.)
[Clinical aspects and neurologic expert assessment in sequelae of whiplash injury to the cervical spine] Jenzer G.
Nervenarzt 1995 Oct;66(10):730-5 (30 ref.) (Eng. Abstr.) **(Ger)**
[Whiplash injury--a valid diagnosis (editorial)] Sahar A.
Harefuah 1996 Apr 1;130(7):463-5 (19 ref.) **(Heb)**

ETIOLOGY

[Management of patients with simple cervical distortions] Foletti G, et al. **Presse Med** 1995 Nov 11;24(34):1617-20 (24 ref.) (Eng. Abstr.) **(Fre)**

PHYSIOPATHOLOGY

Oculocephalic sympathetic dysfunction in posttraumatic headaches. Khurana RK. **Headache** 1995 Nov-Dec; 35(10):614-20 (32 ref.)
[Whiplash injury--a valid diagnosis (editorial)] Sahar A.
Harefuah 1996 Apr 1;130(7):463-5 (19 ref.) **(Heb)**

WHIPPLE'S DISEASE

Human models: Whipple's disease, coeliac disease and jejunoileal bypass. Utsinger PD, et al.
Baillieres Clin Rheumatol 1996 Feb;10(1):77-103 (129 ref.)
Whipple's disease. Fantry GT, et al. **Dig Dis** 1995 Mar-Apr; 13(2):108-18 (62 ref.)
[Whipple's disease: an entity to keep in mind] Gisbert JP, et al. **Rev Clin Esp** 1995 Sep;195(9):627-32 (74 ref.) **(Spa)**

COMPLICATIONS

[Uveitis: late complication of undiagnosed Whipple disease] Wechsler B, et al. **Rev Med Interne** 1995;16(9):687-90 (30 ref.) (Eng. Abstr.) **(Fre)**
[Neurologic manifestations of Whipple disease] Alba D, et al. **An Med Interna** 1995 Oct;12(10):508-12 (92 ref.) (Eng. Abstr.) **(Spa)**

DIAGNOSIS

[Whipple's disease] Asakura H.
Ryoikibetsu Shokogun Shirizu 1995;(8):280-3 (11 ref.) **(Jpn)**
[Abdominal pseudotumor and Whipple's disease] Guilera M, et al. **Gastroenterol Hepatol** 1996 May;19(5):247-9 (16 ref.) (Eng. Abstr.) **(Spa)**

ETIOLOGY

[Whipple's disease: more on the identity of its etiological agent (editorial)] Ponte C, et al. **Rev Clin Esp** 1995 Sep; 195(9):598-9 (19 ref.) **(Spa)**

WHITE BLOOD CELL COUNT see LEUKOCYTE COUNT

WHITE BLOOD CELL TRANSFUSION see LEUKOCYTE TRANSFUSION

WHITE BLOOD CELLS see LEUKOCYTES

WHITE SPOTS see DENTAL CARIES

WHITES

see related
CAUCASOID RACE

Pediatric injury hospitalization in Hispanic children and non-Hispanic white children in southern California. Aagran PF, et al. **Arch Pediatr Adolesc Med** 1996 Apr; 150(4):400-6 (41 ref.)
Ethnic differences in stroke: black-white differences in the United States population. SECORDS Investigators. Southeastern Consortium on Racial Differences in Stroke. Gaines K, et al. **Neuroepidemiology** 1995;14(5):209-39 (194 ref.)

STATISTICS & NUMERICAL DATA

Racial differences in health: not just black and white, but shades of gray. Lillie-Blanton M, et al.
Annu Rev Public Health 1996;17:411-48 (52 ref.)
Differences in cancer incidence, mortality, and survival between African Americans and whites. Walker B, et al. **Environ Health Perspect** 1995 Nov;103 Suppl 8:275-81 (64 ref.)
Framing the debate: can prenatal care help to reduce the black-white disparity in infant mortality? Rowley DL.
J Am Med Wom Assoc 1995 Sep-Oct;50(5):187-93 (119 ref.)
Separate black and white infant mortality models: differences in the importance of structural variables. Bird ST.
Soc Sci Med 1995 Dec;41(11):1507-12 (37 ref.)

WHOLE BLOOD COAGULATION TIME

Activated clotting time versus activated partial thromboplastin time for therapeutic monitoring of heparin [see comments] Simko RJ, et al. **Ann Pharmacother** 1995 Oct;29(10):1015-21; quiz 1061 (36 ref.) Comment in: Ann Pharmacother 1995 Oct;29(10):1045-6.

WHOLE-BODY IRRADIATION

Preparative regimens: chemotherapy versus chemoradiotherapy. A historical perspective. Santos GW.
Ann N Y Acad Sci 1995 Dec 29;770:1-7 (38 ref.)

ADVERSE EFFECTS

[Therapeutic approaches of hematopoietic syndrome following accidental total whole body irradiation] Thierry D, et al. **Bull Cancer (Paris)** 1996 May;83(5):361-70 (40 ref.) (Eng. Abstr.) **(Fre)**
[Oro-dental manifestations of leukemia in children] Nikoui M, et al. **J Can Dent Assoc** 1996 May;62(5):443-6, 449-50 (41 ref.) (Eng. Abstr.) **(Fre)**

WHOLE-CELL RECORDING see PATCH-CLAMP TECHNIQUES

WHOOPING COUGH

see related
PERTUSSIS VACCINE

DIAGNOSIS

Almost extinct diseases: measles, mumps, rubella, and pertussis. Gold E. **Pediatr Rev** 1996 Apr;17(4):120-7 (7 ref.)
The modern face of whooping cough. Jenkinson D.
Practitioner 1995 Oct;239(1555):620-1 (5 ref.)

PREVENTION & CONTROL

Acellular pertussis vaccines: a turning point in infant and adolescent vaccination. Rappuoli R. **Infect Agents Dis** 1996 Jan;5(1):21-8 (51 ref.)
Control of whooping cough in New Zealand; slow progress [see comments] Lennon D, et al. **N Z Med J** 1995 Dec 8;108(1013):495-7 (37 ref.) Comment in: N Z Med J 1996 Mar 8;109(1017):84. Comment in: N Z Med J 1996 Mar 22;109(1018):107-8.
[Efficacy of acellular pertussis vaccines] Wirsing von König CH, et al. **Immun Infekt** 1995 Aug;23(4):125-9 (15 ref.) (Eng. Abstr.) **(Ger)**

WIFE ABUSE see SPOUSE ABUSE

WILCOX TEST see STATISTICS, NONPARAMETRIC

WILCOXON RANK TEST see STATISTICS, NONPARAMETRIC

WILLIAMS-BEUREN SYNDROME see WILLIAMS SYNDROME

WILLIAMS SYNDROME

COMPLICATIONS

Stroke in Williams syndrome. Wollack JB, et al. **Stroke** 1996 Jan;27(1):143-6 (20 ref.)

DIAGNOSIS

[Williams-Beuren syndrome: diagnosis and ocular manifestations] Offret H, et al. **J Fr Ophtalmol** 1995; 18(11):699-702 (13 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Surgical treatment of diffuse supravalvular aortic stenosis. Folliguet TA, et al. **Ann Thorac Surg** 1996 Apr;61(4):1251-3 (4 ref.)

WILLIS' CIRCLE see CIRCLE OF WILLIS

WILMS' TUMOR see NEPHROBLASTOMA

WILMS' TUMOR GENES see GENES, WILMS' TUMOR

WILSON'S DISEASE see HEPATOLENTICULAR DEGENERATION

WINE

Alcohol consumption and coronary heart disease: good habits may be more important than just good wine [see comments] Rimm EB. **Am J Epidemiol** 1996 Jun 1;143(11):1094-8; discussion 1099 (39 ref.) Comment in: Am J Epidemiol 1996 Jun 1;143(1):1089-93.
[A wine pitcher, cause of lead poisoning] Jouglard J, et al. **Presse Med** 1996 Feb 17;25(6):243-6 (8 ref.) (Eng. Abstr.) **(Fre)**

ADVERSE EFFECTS

Wine and headache. Jarisch R, et al.
Int Arch Allergy Immunol 1996 May;110(1):7-12 (45 ref.)

WING

PHYSIOLOGY

Unsteady aerodynamics of insect flight. Ellington CP.
Symp Soc Exp Biol 1995;49:109-29 (74 ref.)

WIRSUNG'S DUCT see PANCREATIC DUCTS

WISKOTT-ALDRICH SYNDROME

BLOOD

Defects in Wiskott-Aldrich syndrome blood cells. Remold-O'Donnell E, et al. **Blood** 1996 Apr 1; 87(7):2621-31 (118 ref.)

GENETICS

Wiskott-Aldrich syndrome. al Mulhim I. **Indian Pediatr** 1995 Nov;32(11):1224-8 (20 ref.)

WITHDRAWAL SYMPTOMS see SUBSTANCE WITHDRAWAL SYNDROME

WITTENBORN SCALES see PSYCHIATRIC STATUS RATING SCALES

WIVES see SPOUSES

WOLFF-PARKINSON-WHITE SYNDROME

DIAGNOSIS

[The esophageal approach in rhythmology] Mabo P, et al. **Arch Mal Coeur Vaiss** 1995 Dec;88 Spec No 5:43-7 (29 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

Wolff-Parkinson-White syndrome and radiofrequency ablation. Lai N, et al. **J Fam Pract** 1995 Nov;41(5):497-500 (19 ref.)
[Surgery for WPW syndrome with concomitant CABG: a case report] Ueda T, et al. **Kyobu Geka** 1996 Apr; 49(4):331-3 (5 ref.) (Eng. Abstr.) **(Jpn)**

WOLFFIAN DUCT

An ovarian tumor of probable Wolffian origin with hormonal function. Inoue H, et al. **Gynecol Oncol** 1995 Nov; 59(2):304-8 (11 ref.)

WOLFRAM see TUNGSTEN

WOLMAN DISEASE

[Acid lipase deficiency: Wolman disease and cholesteryl ester storage disease] Tanaka A. **Nippon Rinsho** 1995 Dec; 53(12):3004–8 (10 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSIS

Wolman's disease. Uniyal KJ, et al. **Indian Pediatr** 1995 Feb; 32(2):232–5 (9 ref.)

GENETICS

ACAT/CEH and ACEH/LAL: two key enzymes in hepatic cellular cholesterol homeostasis and their involvement in genetic disorders. Schmitz G, et al. **Z Gastroenterol** 1996 Jun;34 Suppl 3:68–72 (19 ref.)

WOMEN

Mental health problems of homeless women and differences across subgroups. Robertson MJ, et al. **Annu Rev Public Health** 1996;17:311–36 (74 ref.)

Cancer among special populations: women, ethnic minorities, and the poor. Haynes A. **Environ Health Perspect** 1995 Nov;103 Suppl 8:319–20 (10 ref.)

PSYCHOLOGY

Women's mental health: the new national focus. Blumenthal SJ. **Ann N Y Acad Sci** 1996 Jun 18;789:1–16 (55 ref.)

Women, work, and family: mental health issues. Denmark F, et al. **Ann N Y Acad Sci** 1996 Jun 18;789:101–17 (46 ref.)

Hispanic wome.. and mental health. Gil RM. **Ann N Y Acad Sci** 1996 Jun 18;789:147–59 (53 ref.)

African-American women: considering diverse identities and societal barriers in psychotherapy. Greene B. **Ann N Y Acad Sci** 1996 Jun 18;789:191–209 (30 ref.)

Spousal abuse and violence against women: the significance of understanding attachment. Vazquez CI. **Ann N Y Acad Sci** 1996 Jun 18;789:119–28 (26 ref.)

An analysis of altruism: a concept of caring. Smith A. **J Adv Nurs** 1995 Oct;22(4):785–90 (22 ref.)

Female drug abusers and the context of their HIV transmission risk behaviors. Allen K. **NIDA Res Monogr** 1994;143:48–63 (14 ref.)

Context of HIV risk behavior among female injecting drug users and female sexual partners of injecting drug users. Hartel D. **NIDA Res Monogr** 1994;143:41–7 (31 ref.)

Therapeutic communities: substance abuse treatment for women. Stevens SJ, et al. **NIDA Res Monogr** 1994; 144:162–80 (30 ref.)

Women's compliance with cardiac rehabilitation programs. Ginzel AR. **Prog Cardiovasc Nurs** 1996 Winter;11(1):30–5 (38 ref.)

[Women and capital offense] Räsänen P, et al. **Duodecim** 1994; 110(4):403–6 (31 ref.) **(Fin)**

WOMEN, ABUSED see **BATTERED WOMEN**

WOMEN, BATTERED see **BATTERED WOMEN**

WOMEN PHYSICIANS see **PHYSICIANS, WOMEN**

WOMEN, WORKING

Women's work and women's health. Hatch MC. **Epidemiol Prev** 1996 Apr–Sep;20(2–3):176–9 (19 ref.)

The pregnant worker: how much is too much? Assessing safe activity levels. Feinberg JS, et al. **Hawaii Med J** 1996 May;55(5):85–6 (15 ref.)

Employment-related physical activity and pregnancy outcome. Berkowitz GS. **J Am Med Wom Assoc** 1995 Sep–Oct;50(5):167–9, 174 (33 ref.)

[European study of working mothers and congenital malformations] Candela S, et al. **Epidemiol Prev** 1996 Apr–Sep;20(2–3):183–5 (17 ref.) **(Ita)**

PSYCHOLOGY

Management of conflict: do nurses/women handle it differently? Valentine PE. **J Adv Nurs** 1995 Jul;22(1):142–9 (77 ref.)

WOMEN'S HEALTH

HIV sexual risk reduction interventions for women: a review. Wingood GM, et al. **Am J Prev Med** 1996 May–Jun; 12(3):209–17 (33 ref.)

More on women and the prevention of HIV infection [editorial; comment] Stein ZA. **Am J Public Health** 1995 Nov;85(11):1485–8 (44 ref.) Comment on: Am J Public Health 1995 Nov;85(11):1514–20. Comment on: Am J Public Health 1995 Nov;85(11):1521–5. Comment on: Am J Public Health 1995 Nov;85(11):1526–30.

Women's health as a priority. **Am Pharm** 1995 Sep;NS35(9 Suppl):S1–11; quiz S12–3 (47 ref.)

Women's mental health: the new national focus. Blumenthal SJ. **Ann N Y Acad Sci** 1996 Jun 18;789:1–16 (55 ref.)

Hispanic women and mental health. Gil RM. **Ann N Y Acad Sci** 1996 Jun 18;789:147–59 (53 ref.)

African-American women: considering diverse identities and societal barriers in psychotherapy. Greene B. **Ann N Y Acad Sci** 1996 Jun 18;789:191–209 (30 ref.)

Health risk behaviors for Hispanic women. Torres S, et al. **Annu Rev Nurs Res** 1995;13:293–319 (94 ref.)

Population and women's reproductive health: an international perspective. Miller K, et al. **Annu Rev Public Health** 1996; 17:359–82 (79 ref.)

Historical and analytical overview of policy issues affecting women living with AIDS: a blueprint for learning from our past. Cooper EB. **Bull N Y Acad Med** 1995 Summer; 72(1 Suppl):283–99 (59 ref.)

Women, hormones and blood pressure. Khaw KT. **Can J Cardiol** 1996 Jun;12 Suppl D:9D–12D (16 ref.)

Hypertension in women. Robitaille NM. **Can J Cardiol** 1996 Jun;12 Suppl D:6D–8D (17 ref.)

Impact of the social environment on blood pressure in women. Wielgosz AT. **Can J Cardiol** 1996 Jun;12 Suppl D:13D–15D (10 ref.)

Reproductive and sexual health: a research and developmental challenge. Mbizvo MT. **Cent Afr J Med** 1996 Mar;42(3):80–5 (35 ref.)

Reproductive health: a rendezvous with human dignity. Diczfalusy E. **Contraception** 1995 Jul;52(1):1–12 (69 ref.)

Women's work and women's health. Hatch MC. **Epidemiol Prev** 1996 Apr–Sep;20(2–3):176–9 (19 ref.)

Epidemiology of menstruation and its relevance to women's health. Harlow SD, et al. **Epidemiol Rev** 1995;17(2):265–86 (220 ref.)

Cervical cancer: how often—and why—to screen older women. Mandelblatt JS, et al. **Geriatrics** 1996 Jun; 51(6):45–8; quiz 49 (33 ref.)

Gender bias in the diagnosis and treatment of coronary artery disease. Beery TA. **Heart Lung** 1995 Nov–Dec;24(6):427–35 (64 ref.)

Contraception for women with health problems. Corson SL. **Int J Fertil Menopausal Stud** 1996 Mar–Apr;41(2):77–84 (28 ref.)

Gender differences in cardiovascular outcomes. Hartz RS. **Int J Fertil Menopausal Stud** 1996 Mar–Apr;41(2):101–8 (37 ref.)

Principal cancers among women: breast, lung and colorectal. Rozenberg S, et al. **Int J Fertil Menopausal Stud** 1996 Mar–Apr;41(2):166–71 (33 ref.)

The perimenopause: a critical time in a woman's life. Sulak PJ. **Int J Fertil Menopausal Stud** 1996 Mar–Apr;41(2):85–9 (18 ref.)

Diabetes mellitus: its impact on women. Wishner KL. **Int J Fertil Menopausal Stud** 1996 Mar–Apr;41(2):177–86 (99 ref.)

The women's health agenda: evolution of hormone replacement therapy as treatment and prophylaxis for coronary artery disease. King KM, et al. **J Adv Nurs** 1996 May;23(5):984–91 (39 ref.)

An analysis of altruism: a concept of caring. Smith A. **J Adv Nurs** 1995 Oct;22(4):785–90 (22 ref.)

Abortion: the antithesis of womanhood? Timpson J. **J Adv Nurs** 1996 Apr;23(4):776–85 (121 ref.)

Prenatal care and public policy: lessons for promoting women's health. Hughes DC, et al. **J Am Med Wom Assoc** 1995 Sep–Oct;50(5):156–9, 163 (32 ref.)

Family planning: an essential component of prenatal care. Klerman LV, et al. **J Am Med Wom Assoc** 1995 Sep–Oct; 50(5):147–51 (31 ref.)

Women's health and enhancing generalism in internal medicine. Hoffman E, et al. **J Gen Intern Med** 1995 Aug; 10(8):451–4 (59 ref.)

Feminist research. Torkelson DJ. **J Neurosci Nurs** 1996 Apr; 28(2):121–4 (31 ref.)

Women at risk for infection: the woman who is chemically dependent. Kendig S. **J Obstet Gynecol Neonatal Nurs** 1995 Oct;24(8):776–81 (38 ref.)

The impact of recent advances in microbiology and immunology on perinatal and women's health care. Munro CL. **J Obstet Gynecol Neonatal Nurs** 1995 Jul–Aug; 24(6):525–31 (32 ref.)

Access to substance abuse treatment for homeless women of reproductive age. Wenzel SL, et al. **J Psychoactive Drugs** 1996 Jan–Mar;28(1):17–30 (110 ref.)

Well-being, symptoms and the menopausal transition. Dennerstein L. **Maturitas** 1996 Mar;23(2):147–57 (51 ref.)

The new genetics and women. Mahowald MB, et al. **Milbank Q** 1996;74(2):239–83 (160 ref.)

Women living with HIV infection. Abercrombie PD. **Nurs Clin North Am** 1996 Mar;31(1):97–106 (56 ref.)

Women's health. The role of advanced practice nurses in the 21st century. Spatz DL. **Nurs Clin North Am** 1996 Jun; 31(2):269–77 (16 ref.)

An analysis of the women's health movement and its impact on the delivery of health care within the United States. Geary MS. **Nurse Pract** 1995 Nov;20(11 Pt 1):24, 27–8, 30–1, passim (45 ref.)

Screening, health promotion, and prevention in women. Bowman MA, et al. **Prim Care** 1995 Dec;22(4):661–77 (98 ref.)

The women's health initiative: will it resolve the issues? Michels KB, et al. **Recent Results Cancer Res** 1996; 140:295–305 (53 ref.)

Health concerns of artistic women gymnasts. O'Connor PJ, et al. **Sports Med** 1996 May;21(5):321–5 (37 ref.)

Women's health in a changing world. A continuous challenge. Varkevisser CM. **Trop Geogr Med** 1995; 47(5):186–92 (23 ref.)

[The work environment and the health risk for women in Italy: the results and prospects of epidemiological research] Pirastu R, et al. **Epidemiol Prev** 1996 Apr–Sep; 20(2–3):180–2 (10 ref.) **(Ita)**

[Education and women's health: reflections from a gender perspective] Campero-Cuenca L. **Salud Publica Mex** 1996 May–Jun;38(3):217–22 (48 ref.) (Eng. Abstr.) **(Spa)**

WOMEN'S HEALTH SERVICES

An analysis of the women's health movement and its impact on the delivery of health care within the United States. Geary MS. **Nurse Pract** 1995 Nov;20(11 Pt 1):24, 27–8, 30–1, passim (45 ref.)

Medical care of women deployed during Desert Storm. Lyon DS. **South Med J** 1996 Feb;89(2):172–6 (6 ref.)

ORGANIZATION & ADMINISTRATION

Certified nurse midwives: over twenty years of military service. Davis LJ. **Mil Med** 1995 Aug;160(8):401–4 (20 ref.)

TRENDS

[Advances in the study of industrial women's hygiene in China] Bao Y, et al. **Chung Hua Yu Fang I Hsueh Tsa Chih** 1995 Sep;29(5):301–2 (20 ref.) **(Chi)**

WOMEN'S LIBERATION see **WOMEN'S RIGHTS**

WOMEN'S RIGHTS

The third step: Freud, the feminists, and postmodernism. Dimen M. **Am J Psychoanal** 1995 Dec;55(4):303–19; discussion 321–30 (31 ref.)

Feminism and nursing. Chinn PL. **Annu Rev Nurs Res** 1995; 13:267–89 (110 ref.)

Intervention model for substance-using women. Tiedje LB, et al. **Image J Nurs Sch** 1996 Summer;28(2):113–8 (69 ref.)

Grounded theory as feminist research methodology. Keddy B, et al. **J Adv Nurs** 1996 Mar;23(3):448–53 (30 ref.)

Feminist research: its relevance to nursing. Sigsworth J. **J Adv Nurs** 1995 Nov;22(5):896–9 (18 ref.)

Abortion: the antithesis of womanhood? Timpson J. **J Adv Nurs** 1996 Apr;23(4):776–85 (121 ref.)

Implementing feminist perspectives in clinical care. Howe EG. **J Clin Ethics** 1996 Spring;7(1):2–12 (40 ref.)

The maternal-fetal rights dilemma: honoring a woman's choice of medical care during pregnancy. Arch RR. **J Contemp Health Law Policy** 1996 Spring;12(2):637–73 (255 ref.)

Feminist research. Torkelson DJ. **J Neurosci Nurs** 1996 Apr; 28(2):121–4 (31 ref.)

WOOD

Wood dust. **IARC Monogr Eval Carcinog Risks Hum** 1995; 62:35–215 (383 ref.)

WOODCHUCK HEPATITIS VIRUS see **HEPATITIS VIRUS, WOODCHUCK**

WOODCHUCKS see **MARMOTA**

WOOL

ECONOMICS

Prospects for expanded mohair and cashmere production and processing in the United States of America. Lupton CJ. **J Anim Sci** 1996 May;74(5):1164–72 (18 ref.)

GROWTH & DEVELOPMENT

Transgenic sheep and wool growth: possibilities and current status. Powell BC, et al. **Reprod Fertil Dev** 1994;6(5):615–23 (28 ref.)

WOOLLY MONKEY see **CEBIDAE**

WORK

see related
EMPLOYMENT

Alternative medicine in the workplace. Lippin RA. **Altern Ther Health Med** 1996 Jan;2(1):47–51 (28 ref.)

Occupational conditions and workers' sense of community: variations by gender and race. Lambert SJ, et al. **Am J Community Psychol** 1995 Apr;23(2):151–79 (78 ref.)

Women, work, and family: mental health issues. Denmark F, et al. **Ann N Y Acad Sci** 1996 Jun 18;789:101–17 (46 ref.)

Factors relating to return to work after burn injury. Wrigley M, et al. **J Burn Care Rehabil** 1995 Jul–Aug;16(4):445–50; discussion 444 (19 ref.)

Functional restoration. Returning patients with chronic low back pain to work—revolution or fad? Teasell RW, et al. **Spine** 1996 Apr 1;21(7):844–7 (17 ref.)

WORK CAPACITY EVALUATION

The injured worker: assessing "return-to-work" status. Mazanec DJ. **Cleve Clin J Med** 1996 May–Jun;63(3):166–71 (27 ref.)

[Management and monitoring of transient work incapacity. Is the primary care model effective?] Alberquilla Menéndez-Asenjo A, et al. **Aten Primaria** 1996 Jan; 17(1):40–6 (33 ref.) (Eng. Abstr.) **(Spa)**

WORK OF BREATHING

Wasted efforts and dyssynchrony: is the patient-ventilator battle back? [editorial; comment] Rossi A, et al. **Intensive Care Med** 1995 Nov;21(11):867–70 (24 ref.) Comment on: Intensive Care Med 1995 Nov;21(11):871–9.

PHYSIOLOGY

Ascites and its effects upon respiratory muscle loading and work of breathing. Rosado M, et al. **Crit Care Med** 1996 Mar;24(3):538–40 (22 ref.)

WORK SATISFACTION see JOB SATISFACTION

WORK SCHEDULE TOLERANCE

Female noise exposure, shift work, and reproduction. Nurminen T. **J Occup Environ Med** 1995 Aug;37(8):945–50 (31 ref.)

Working conditions, maternity legislation, and preterm birth. Berkowitz GS, et al. **Semin Perinatol** 1995 Aug;19(4):272–8 (40 ref.)

[Shift work systems from the chronobiological viewpoint] Knauth P. **Wien Med Wochenschr** 1995;145(17–18):406–10 (31 ref.) (Eng. Abstr.) **(Ger)**

WORKERS' COMPENSATION

see related
DISABILITY EVALUATION

Economic compensation for hearing loss. Dobie RA. **Occup Med** 1995 Jul–Aug;10(3):663–8 (22 ref.)

ECONOMICS

Preliminary findings of analysis of chiropractic utilization and cost in the workers' compensation system of New South Wales, Australia. Tuchin PJ, et al. **J Manipulative Physiol Ther** 1995 Oct;18(8):503–11 (57 ref.)

LEGISLATION & JURISPRUDENCE

[Occupational asthma: definition—epidemiology—etiologic substances—prognosis—prevention—diagnosis—expert assessment aspects] Merget R, et al. **Pneumologie** 1996 May; 50(5):356–63 (83 ref.) **(Ger)**

WORKING WOMEN see WOMEN, WORKING

WORKLOAD

Work conditions as explanations for the relation between socioeconomic status, gender, and psychological disorders. Lennon MC. **Epidemiol Rev** 1995;17(1):120–7 (118 ref.)

Physical workload and the aging worker: a review of the literature. de Zwart BC, et al. **Int Arch Occup Environ Health** 1995;68(1):1–12 (123 ref.)

Pediatric emergency medicine fellow clinical work requirements. Wiley JF 2nd, et al. **Pediatr Emerg Care** 1995 Dec;11(6):381–8 (13 ref.)

LEGISLATION & JURISPRUDENCE

Occupational stress and the law: some current issues for employers. Howard G. **J Psychosom Res** 1995 Aug; 39(6):707–19 (27 ref.)

PSYCHOLOGY

Psychophysiology and adaptive automation. Byrne EA, et al. **Biol Psychol** 1996 Feb 5;42(3):249–68 (75 ref.)

WORKMEN'S COMPENSATION see WORKERS' COMPENSATION

WORKPLACE

Cancer and the workplace [see comments] Stellman JM, et al. **CA Cancer J Clin** 1996 Mar–Apr;46(2):70–92 (64 ref.) Comment in: CA Cancer J Clin 1996 Jul–Aug;46(4):255–6.

The integrated model: implications for worksite health promotion and occupational health and safety practice. Baker E, et al. **Health Educ Q** 1996 May;23(2):175–90 (61 ref.)

Worksite health programs: working together to advance employee health. Heaney CA, et al. **Health Educ Q** 1996 May;23(2):133–6 (18 ref.)

The ecology of work and health: research and policy directions for the promotion of employee health. Stokols D, et al. **Health Educ Q** 1996 May;23(2):137–58 (162 ref.)

A basic framework of working environment control for occupational health in Japan. Koshi S. **Ind Health** 1996; 34(3):149–65 (5 ref.)

Strategy of biological monitoring and setting of biological threshold limits (BAT values) in Germany [see comments] Lehnert G, et al. **Isr J Med Sci** 1995 Sep;31(9):549–57 (23 ref.) Comment in: Isr J Med Sci 1995 Sep;31(9):563–4.

Participatory ergonomics that builds on local solutions. Kogi K. **J Hum Ergol (Tokyo)** 1995 Jun;24(1):37–45 (17 ref.)

The development and state of health and safety in the workplace in west Africa: perspectives from Nigeria. Asuzu MC. **West Afr J Med** 1996 Jan–Mar;15(1):36–44 (19 ref.)

[Threats and physical violence at work] Laakkonen A, et al. **Duodecim** 1994;110(16):1510–6 (33 ref.) **(Fin)**

[Work and voice] Sala E. **Duodecim** 1995;111(6):554–9 (16 ref.) **(Fin)**

WORLD HEALTH

Intake of carbohydrate and its components—international comparisons, trends over time, and effects of changing to low-fat diets. Stephen AM, et al. **Am J Clin Nutr** 1995 Oct;62(4):851S–867S (378 ref.)

Heterologous antisera and antivenins are essential biologicals: perspectives on a worldwide crisis. Wilde H, et al. **Ann Intern Med** 1996 Aug 1;125(3):233–6 (22 ref.)

Healthy Cities: toward worldwide health promotion. Flynn BC. **Annu Rev Public Health** 1996;17:299–309 (59 ref.)

Population and women's reproductive health: an international perspective. Miller K, et al. **Annu Rev Public Health** 1996; 17:359–82 (79 ref.)

Public health aspects of ophthalmic disease: introduction. Sommer A. **Annu Rev Public Health** 1996;17:115–9 (26 ref.)

Vaccination policies and practices [see comments] Henderson DA. **Aust J Public Health** 1995 Dec;19(6):634–8 (5 ref.) Comment in: Aust J Public Health 1995 Dec;19(6):545–6.

Number of people with glaucoma worldwide [see comments] Quigley HA. **Br J Ophthalmol** 1996 May;80(5):389–93 (54 ref.) Comment in: Br J Ophthalmol 1996 May;80(5):385–7.

Modern treatment of haemophilia. Berntorp E, et al. **Bull World Health Organ** 1995;73(5):691–701 (45 ref.)

Reproductive and sexual health: a research and developmental challenge. Mbizvo MT. **Cent Afr J Med** 1996 Mar;42(3):80–5 (35 ref.)

Intestinal worms: our turn to turn. de Silva HJ, et al. **Ceylon Med J** 1995 Dec;40(4):134–6 (11 ref.)

Preventing diabetes mellitus; the epidemiological basis. Fernando D. **Ceylon Med J** 1995 Dec;40(4):136–8 (26 ref.)

The contribution of vitamin A to public health. Underwood BA, et al. **FASEB J** 1996 Jul;10(9):1040–8 (57 ref.)

Patterns and predictability in emerging infections. Morse SS. **Hosp Pract (Off Ed)** 1996 Apr 15;31(4):85–91, 96–101, 104 passim (11 ref.)

Human rights and medical practice, including reference to the joint Oslo statements of September 1993 and March 1994. Alderslade R. **J Public Health Med** 1995 Sep; 17(3):335–42 (7 ref.)

Malaria, the submerged disease. Olliaro P, et al. **JAMA** 1996 Jan 17;275(3):230–3 (54 ref.)

Differences in the care of ESRD patients worldwide: required resources and future outlook. Chugh KS, et al. **Kidney Int Suppl** 1995 Aug;50:S7–13 (38 ref.)

Evolution of complex disasters. Burkholder BT, et al. **Lancet** 1995 Oct 14;346(8981):1012–5 (21 ref.)

Global burden of the HIV pandemic [see comments] Quinn TC. **Lancet** 1996 Jul 13;348(9020):99–106 (50 ref.) Comment in: Lancet 1996 Aug 17;348(9025):480–1.

The emergence of "emerging diseases": a lesson in holistic epidemiology. Kilbourne ED. **Mt Sinai J Med** 1996 May–Sep;63(3–4):159–66 (31 ref.)

Overview of perinatally transmitted HIV infection. Boland M. **Nurs Clin North Am** 1996 Mar;31(1):155–64 (36 ref.)

Global distribution and continuing spread of Aedes albopictus. Knudsen AB. **Parassitologia** 1995 Dec; 37(2–3):91–7 (44 ref.)

Meeting the needs of young adults. McCauley AP, et al. **Popul Rep J** 1995 Oct;(41):1–43 (595 ref.)

Exposure to environmental chemicals relevant for respiratory hypersensitivity: global aspects. Schwela D. **Toxicol Lett** 1996 Aug;86(2–3):131–42 (13 ref.)

Population growth in the 21st century: cause for crisis or celebration? Cleland J. **Trop Med Int Health** 1996 Feb; 1(1):15–26 (22 ref.)

Healthy aging and the quality of life. Darnton-Hill I. **World Health Forum** 1995;16(4):335–43; discussion 344–72 (13 ref.)

[Kaposi sarcoma. An epidemiological perspective] Lecker S, et al. **Ugeskr Laeger** 1995 Sep 18;157(38):5232–6 (38 ref.) (Eng. Abstr.) **(Dan)**

[Tuberculosis as a global emergency] Kochi A. **Kekkaku** 1996 Apr;71(4):319–27 (0 ref.) **(Jpn)**

[International collaboration for health] Umenai T. **Nippon Koshu Eisei Zasshi** 1996 Apr;43(4):263–6 (9 ref.) **(Jpn)**

[The end of antibiotics? Increasing bacterial resistance in global and Norwegian perspective] Jensenius M, et al. **Tidsskr Nor Laegeforen** 1995 Nov 10;115(27):3382–6 (52 ref.) (Eng. Abstr.) **(Nor)**

[World cholera pandemics as mono- and polycyclic phenomena] Arutiunov Iul. **Zh Mikrobiol Epidemiol Immunobiol** 1996 Mar–Apr; (2):113–7 (26 ref.) **(Rus)**

[Two different HIV types are known. The differences may explain mechanisms of the infection] Andersson S, et al. **Lakartidningen** 1996 Jun 5;93(23):2230, 2235–6 (37 ref.) **(Swe)**

WORLD HEALTH ORGANIZATION

Development of the World Health Organization Guidelines on Cancer Pain Relief and Palliative Care in Children. McGrath PA. **J Pain Symptom Manage** 1996 Aug; 12(2):87–92 (12 ref.)

The World Health Organization Cancer Pain and Palliative Care Program. Past, present, and future. Stjernswärd J, et al. **J Pain Symptom Manage** 1996 Aug;12(2):65–72 (31 ref.)

The role of qualitative research in the Global Programme on AIDS at the World Health Organization. O'Reilly KR. **NIDA Res Monogr** 1995;157:27–37 (17 ref.)

WORM DISKS see OPTICAL STORAGE DEVICES

WOUND HEALING

see related
CICATRIX

Healing of experimentally created defects: a review. Aaboe M, et al. **Br J Oral Maxillofac Surg** 1995 Oct;33(5):312–8 (130 ref.)

A healed ulcer: what now? Walsh CH. **Diabet Med** 1996;13 Suppl 1:S58–60 (16 ref.)

Effects of early motion on healing of musculoskeletal tissues. Buckwalter JA. **Hand Clin** 1996 Feb;12(1):13–24 (81 ref.)

[Tumor implantation in cicatrization sites following surgery for digestive cancers] Jacquet P, et al. **J Chir (Paris)** 1996 Jun;133(4):175–82 (63 ref.) (Eng. Abstr.) **(Fre)**

[Tissue regeneration processes in the bovine mammary gland] Michel G, et al. **Tierarztl Prax** 1996 Jun;24(3):223–7 (11 ref.) (Eng. Abstr.) **(Ger)**

[The cicatrization of corneal wounds] Spineanu L. **Oftalmologia** 1995 Oct–Dec;39(4):356–60 (6 ref.) (Eng. Abstr.) **(Rum)**

DRUG EFFECTS

Toxicological aspects of topical silver pharmaceuticals. Hollinger MA. **Crit Rev Toxicol** 1996 May;26(3):255–60 (57 ref.)

The use of antioxidants in healing. Martin A. **Dermatol Surg** 1996 Feb;22(2):156–60 (30 ref.)

The potential role of growth and differentiation factors in periodontal regeneration. **J Periodontol** 1996 May; 67(5):545–53 (128 ref.)

Choice of wound dressings and ointments. Brown CD, et al. **Otolaryngol Clin North Am** 1995 Oct;28(5):1081–91 (52 ref.)

The infected wound and its management. Bumpous JM, et al. **Otolaryngol Clin North Am** 1995 Oct;28(5):987–1001 (44 ref.)

[Influence of colloidal bismuth subcitrate, metronidazole, and amoxycillin on Helicobacter pylori and gastroduodenal ulcer healing] Quintero M, et al. **G E N** 1995 Apr–Jun; 49(2):116–22 (21 ref.) (Eng. Abstr.) **(Spa)**

IMMUNOLOGY

Immunohistochemical parameters for the age estimation of human skin wounds. A review. Betz P. **Am J Forensic Med Pathol** 1995 Sep;16(3):203–9 (53 ref.)

Immune involvement in wound healing. Barbul A, et al. **Otolaryngol Clin North Am** 1995 Oct;28(5):955–68 (94 ref.)

PHYSIOLOGY

Transforming growth factor-beta in GI neoplasia, wound healing and immune response. Pignatelli M, et al. **Baillieres Clin Gastroenterol** 1996 Mar;10(1):65–81 (110 ref.)

Microfilament organization and wound repair in retinal pigment epithelium. Kalnins VI, et al. **Biochem Cell Biol** 1995 Sep–Oct;73(9–10):709–22 (97 ref.)

Mucosal healing and adaptation in the small intestine. Basson MD. **Curr Opin Gen Surg** 1994;:138–46 (62 ref.)

Growth factors and comprehensive surgical care of diabetic wounds. Knighton DR, et al. **Curr Opin Gen Surg** 1993; :32–9 (42 ref.)

SPARC and the extracellular matrix: implications for cancer and wound repair. Reed MJ, et al. **Curr Top Microbiol Immunol** 1996;213 (Pt 1):81–94 (66 ref.)

New concepts in tissue repair: skin as an example. Meddahi A, et al. **Diabetes Metab** 1996 Jul;22(4):274–8 (28 ref.)

Post-infarction myocardial remodelling: why does it happen? Francis GS, et al. **Eur Heart J** 1995 Dec;16 Suppl N:31–6 (41 ref.)

Growth factors in skin wound healing. Moulin V. **Eur J Cell Biol** 1995 Sep;68(1):1–7 (89 ref.)

Epidermal growth factor and transforming growth factor-alpha: role in protection and healing of gastric mucosal lesions. Konturek PC, et al. **Eur J Gastroenterol Hepatol** 1995 Oct;7(10):933–7 (26 ref.)

The effects of ageing on cutaneous wound healing in mammals. Ashcroft GS, et al. **J Anat** 1995 Aug;187 (Pt 1):1–26 (287 ref.)

The role of cytokines in wound healing. Slavin J. **J Pathol** 1996 Jan;178(1):5–10 (50 ref.)

The role of growth factors in wound healing. Greenhalgh DG. **J Trauma** 1996 Jul;41(1):159–67 (133 ref.)

Cuts and scrapes? Plasmin heals! Vassalli JD, et al. **Nat Med** 1996 Mar;2(3):284–5 (13 ref.)

Burns and wound management. Ahrenholz DH, et al. **Otolaryngol Clin North Am** 1995 Oct;28(5):1039–55 (45 ref.)

Respiratory mucosa wound healing and its management. An overview. Dohar JE, et al. **Otolaryngol Clin North Am** 1995

WOUND HEALING

Oct;28(5):897–912 (28 ref.)
Tympanic membrane wound healing. An overview. Gladstone HB, et al. **Otolaryngol Clin North Am** 1995 Oct; 28(5):913–32 (111 ref.)
Wound healing after laser surgery. Hendrick DA, et al. **Otolaryngol Clin North Am** 1995 Oct;28(5):969–86 (89 ref.)
Growth factors in wound healing. Hom DB. **Otolaryngol Clin North Am** 1995 Oct;28(5):933–53 (96 ref.)
Cutaneous wound healing. An overview. Koopmann CF Jr. **Otolaryngol Clin North Am** 1995 Oct;28(5):835–45 (14 ref.)
Methods and materials for wound closure. Reiter D. **Otolaryngol Clin North Am** 1995 Oct;28(5):1069–80 (64 ref.)
Management of scar contractures, hypertrophic scars, and keloids. Sherris DA, et al. **Otolaryngol Clin North Am** 1995 Oct;28(5):1057–68 (29 ref.)
Cartilage wound healing. An overview. Silver FH, et al. **Otolaryngol Clin North Am** 1995 Oct;28(5):847–64 (81 ref.)
Facial bone wound healing. An overview. Szachowicz EH. **Otolaryngol Clin North Am** 1995 Oct;28(5):865–80 (35 ref.)
Scar formation: the spectral nature of fetal and adult wound repair. Ferguson MW, et al. **Plast Reconstr Surg** 1996 Apr; 97(4):854–60 (42 ref.)
Wound healing: the role of the macrophage and other immune cells. DiPietro LA. **Shock** 1995 Oct;4(4):233–40 (72 ref.)
Role of collagen in soft connective tissue wound healing. Oryan A. **Transplant Proc** 1995 Oct;27(5):2759–61 (34 ref.)
Healing responses of the lower urinary tract. Degner DA, et al. **Vet Clin North Am Small Anim Pract** 1996 Mar; 26(2):197–206 (41 ref.)
Recombinant bone morphogenetic proteins: novel substances for enhancing bone healing. Kirker-Head CA. **Vet Surg** 1995 Sep–Oct;24(5):408–19 (80 ref.)
[Biomechanical changes in the hip, femur and knee joint after removal of a tensor fasciae latae flap] Lattermann C, et al. **Handchir Mikrochir Plast Chir** 1996 Mar;28(2):76–82 (33 ref.) (Eng. Abstr.) **(Ger)**

RADIATION EFFECTS

Irradiated bone and its management. Costantino PD, et al. **Otolaryngol Clin North Am** 1995 Oct;28(5):1021–38 (29 ref.)
Irradiated soft tissue and its management. Hom DB, et al. **Otolaryngol Clin North Am** 1995 Oct;28(5):1003–19 (47 ref.)
[Effect of low-intensity laser radiation on the metabolic and restorative processes of the body] Briskin BS, et al. **Klin Med (Mosk)** 1996;74(1):54–5 (08 ref.) **(Rus)**

WOUND INFECTION

DRUG THERAPY

Antibiotic therapy in diabetic foot infection. van der Meer JW, et al. **Diabet Med** 1996;13 Suppl 1:S48–51 (19 ref.)

ETIOLOGY

Simian bites and bacterial infection. Goldstein EJ, et al. **Clin Infect Dis** 1995 Jun;20(6):1551–2 (14 ref.)

IMMUNOLOGY

Immune involvement in wound healing. Barbul A, et al. **Otolaryngol Clin North Am** 1995 Oct;28(5):955–68 (94 ref.)

PREVENTION & CONTROL

Comparison of intravenous and oral antibiotic therapy in the treatment of fractures caused by low-velocity gunshots. A prospective, randomized study of infection rates. Knapp TP, et al. **J Bone Joint Surg Am** 1996 Aug;78(8):1167–71 (35 ref.)

THERAPY

Wound management in spinal infection. Rubayi S. **Orthop Clin North Am** 1996 Jan;27(1):137–53 (47 ref.)

WOUNDS AND INJURIES

see related
FIRST AID
TRANSPORTATION OF PATIENTS

Trauma management in the 21st century. Baue AE, et al. **Shock** 1995 Nov;4(5):384–8 (21 ref.)

BLOOD

Alterations in cell signaling and related effector functions in T lymphocytes in burn/trauma/septic injuries [editorial] Sayeed MM. **Shock** 1996 Mar;5(3):157–66 (111 ref.)
[Traumatic emergencies and hemostasis] Samama CM. **Cah Anesthesiol** 1995;43(5):479–82 (23 ref.) (Eng. Abstr.) **(Fre)**

CLASSIFICATION

The injury severity score—importance and uses. Linn S. **Ann Epidemiol** 1995 Nov;5(6):440–6 (64 ref.)
The Injury Severity Score is unable to differentiate between poor care and severe injury. Rutledge R. **J Trauma** 1996 Jun;40(6):944–50 (36 ref.)
[A review of injury classification in traumatology. A Swedish model needs to be set up soon] Andrén-Sandberg A. **Lakartidningen** 1996 Aug 28;93(34):2860–1 (30 ref.) **(Swe)**

COMPLICATIONS

Is deep vein thrombosis surveillance warranted in high-risk trauma patients? Piotrowski JJ, et al. **Am J Surg** 1996 Aug; 172(2):210–3 (9 ref.)
Trauma and bacterial translocation [see comments] Saadia R. **Br J Surg** 1995 Sep;82(9):1243–4 (18 ref.) Comment in: Br J Surg 1996 Feb;83(2):282–3. Comment in: Br J Surg 1996 Feb;83(2):283.
Priorities in the management of profound shock. Britt LD, et al. **Surg Clin North Am** 1996 Aug;76(4):645–60 (56 ref.)
The aetiologies of epilepsy in tropical Africa. Adamolekun B. **Trop Geogr Med** 1995;47(3):115–7 (29 ref.)
[Traumatic myositis ossificans. Posttraumatic non-neoplastic heterotopic ossification] Jacobsen S. **Ugeskr Laeger** 1995 Sep 25;157(39):5385–8 (35 ref.) (Eng. Abstr.) **(Dan)**
[Mechanical trauma as a cause of cancer—a continuing dispute] Cohen AD, et al. **Harefuah** 1995 Jun 1; 128(11):715–8 (36 ref.) **(Heb)**
[Liver failure after severe trauma] Omori Y, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(7):252–5 (20 ref.) **(Jpn)**

DIAGNOSIS

The injured worker: assessing "return-to-work" status. Mazanec DJ. **Cleve Clin J Med** 1996 May–Jun;63(3):166–71 (27 ref.)
Medico-legal aspects of road traffic accidents. Mayou R. **J Psychosom Res** 1995 Aug;39(6):789–98 (13 ref.)

DRUG THERAPY

Evaluation of recombinant human growth hormone for wound management. Rasmussen LH. **Dan Med Bull** 1995 Sep;42(4):358–70 (141 ref.)

ECONOMICS

Economic dimensions of slip and fall injuries. Englander F, et al. **J Forensic Sci** 1996 Sep;41(5):733–46 (42 ref.)

EPIDEMIOLOGY

Pediatric injury hospitalization in Hispanic children and non-Hispanic white children in southern California. Aagran PF, et al. **Arch Pediatr Adolesc Med** 1996 Apr; 150(4):400–6 (41 ref.)
Biomechanical epidemiology: a new approach to injury control research. Winston FK, et al. **J Trauma** 1996 May; 40(5):820–4 (32 ref.)
Injuries to women in the United States: an overview. Schnitzer PG, et al. **Women Health** 1995;23(1):9–27 (51 ref.)

ETIOLOGY

Falls in community-dwelling older persons. King MB, et al. **J Am Geriatr Soc** 1995 Oct;43(10):1146–54 (97 ref.)
Occupational injury and stress. Johnston JJ. **J Occup Environ Med** 1995 Oct;37(10):1199–203 (25 ref.)

IMMUNOLOGY

Malnutrition, injury, and the host immune response: nutrient substitution. Gallagher HJ, et al. **Curr Opin Gen Surg** 1993; :92–104 (116 ref.)
The mechanisms of host defense dysfunction following shock and trauma. Faist E. **Curr Top Microbiol Immunol** 1996; 216:259–74 (92 ref.)
Trauma-induced suppression of antigen presentation and expression of major histocompatibility class II antigen complex in leukocytes [editorial] Ayala A, et al. **Shock** 1996 Feb;5(2):79–90 (140 ref.)

METABOLISM

Metabolic responses of the critically ill patient. Kinney JM. **Crit Care Clin** 1995 Jul;11(3):569–85 (66 ref.)

MORTALITY

Prevention of traumatic deaths to children in the United States: how far have we come and where do we need to go? Rivara FP, et al. **Pediatrics** 1996 Jun;97(6 Pt 1):791–7 (58 ref.)

PHYSIOPATHOLOGY

Regulation of protein metabolism during stress. Matthews DE, et al. **Curr Opin Gen Surg** 1993;:72–7 (45 ref.)
Clinically accessible cell signaling: second messengers in sepsis and trauma. Rehring TF, et al. **J Surg Res** 1996 Jan; 60(1):270–7 (37 ref.)
Invasive and noninvasive monitoring for early recognition and treatment of shock in high-risk trauma and surgical patients. Asensio JA, et al. **Surg Clin North Am** 1996 Aug; 76(4):985–97 (25 ref.)

PREVENTION & CONTROL

On the prevention of accidents and injuries. A comparative analysis of conceptual frameworks. Andersson R, et al. **Accid Anal Prev** 1995 Dec;27(6):757–68 (30 ref.)
Preventing injuries from violence towards women [editorial] Davidson LL. **Am J Public Health** 1996 Jan;86(1):12–4 (24 ref.)
Developmental and behavioral issues in childhood injury prevention. Rivara FP. **J Dev Behav Pediatr** 1995 Oct; 16(5):362–70 (79 ref.)
Research on injury prevention: time for an international agenda? Stone DH. **J Epidemiol Community Health** 1996 Apr;50(2):127–30 (25 ref.)
Economic dimensions of slip and fall injuries. Englander F, et al. **J Forensic Sci** 1996 Sep;41(5):733–46 (42 ref.)
Childhood injury: significance and prevention strategies. Crawley T. **J Pediatr Nurs** 1996 Aug;11(4):225–32 (33 ref.)
Biomechanical epidemiology: a new approach to injury control research. Winston FK, et al. **J Trauma** 1996 May; 40(5):820–4 (32 ref.)
Prevention of traumatic deaths to children in the United States: how far have we come and where do we need to go? Rivara FP, et al. **Pediatrics** 1996 Jun;97(6 Pt 1):791–7 (58 ref.)

SURGERY

Wound repair: from ritual practice to scientific discipline. Edlich RF, et al. **J Trauma** 1996 Feb;40(2):326–9 (39 ref.)
[Progresses in traumatology in China, 1995] Wang Z. **Chung Hua I Hsueh Tsa Chih** 1995 Dec;75(12):743–4 (0 ref.) **(Chi)**
[The child with minor trauma. Does observation of fasting times reduce the risk of aspiration?] Kraus GB, et al. **Anaesthesist** 1996 May;45(5):420–7 (71 ref.) (Eng. Abstr.) **(Ger)**
[Prophylactic and therapeutic use of antibiotics in trauma surgery (see comments] Hansis M, et al. **Unfallchirurg** 1996 May;99(5):316–22 (35 ref.) (Eng. Abstr.) Comment in: Unfallchirurg 1996 May;99(5):315. **(Ger)**
[Trauma in the last trimester of pregnancy] Prokop A, et al. **Unfallchirurg** 1996 Jun;99(6):450–3 (11 ref.) (Eng. Abstr.) **(Ger)**
[Do we still need a blood-free field?] Sarkar MR. **Unfallchirurg** 1996 May;99(5):374–8 (40 ref.) **(Ger)**
[Violence against the elderly from the trauma surgery viewpoint] Witthohn A, et al. **Z Gerontol Geriatr** 1996 May–Jun;29(3):206–9 (22 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Fluid resuscitation of the trauma patient: how much is enough? Hamiliton SM, et al. **Can J Surg** 1996 Feb; 39(1):11–6 (39 ref.)
Suspended animation for delayed resuscitation. Bellamy R, et al. **Crit Care Med** 1996 Feb;24(2 Suppl):S24–47 (137 ref.)
Trauma systems, shock, and resuscitation. Fallon WF. **Curr Opin Gen Surg** 1993;:40–5 (24 ref.)
Management of unique clinical entities in disaster medicine. Gans L, et al. **Emerg Med Clin North Am** 1996 May; 14(2):301–26 (104 ref.)
Advanced trauma life support. Gwinnutt CL, et al. **Eur J Anaesthesiol** 1996 Mar;13(2):95–101 (27 ref.)
The Injury Severity Score is unable to differentiate between poor care and severe injury. Rutledge R. **J Trauma** 1996 Jun;40(6):944–50 (36 ref.)
Ethical decision making in managing trauma. Ratzan SC. **Neurosurg Clin N Am** 1995 Oct;6(4):809–16 (12 ref.)
The critical care of the severely injured patient—II. Pulmonary and renal support. Belzberg H, et al. **Surg Clin North Am** 1996 Aug;76(4):971–83 (38 ref.)
[Artificial nutrition in the injured patient] Enrichens F, et al. **Chir Ital** 1994;46(6):49–53 (22 ref.) (Eng. Abstr.) **(Ita)**

VETERINARY

Anesthetic management of the trauma patient. Cuvelliez S, et al. **Vet Clin North Am Small Anim Pract** 1995 Sep; 25(5):1073–92 (42 ref.)
Traumatic joint luxations in small animals. McLaughlin RM Jr. **Vet Clin North Am Small Anim Pract** 1995 Sep; 25(5):1175–96 (28 ref.)
General management considerations for the trauma patient. Payne JT. **Vet Clin North Am Small Anim Pract** 1995 Sep; 25(5):1015–29 (6 ref.)
Skull trauma and mandibular fractures. Smith MM, et al. **Vet Clin North Am Small Anim Pract** 1995 Sep; 25(5):1127–48 (47 ref.)

WOUNDS, GUNSHOT

Gunshot wounds to the foot and ankle. Sergi AR, et al. **Clin Podiatr Med Surg** 1995 Oct;12(4):689–702 (41 ref.)
Penetrating gunshots to the head and lack of immediate incapacitation. II. Review of case reports. Karger B. **Int J Legal Med** 1995;108(3):117–26 (75 ref.)
Shotgun slug injuries: case report and literature review. Gestring ML, et al. **J Trauma** 1996 Apr;40(4):650–3 (23 ref.)
Shotgun wounds and pellet emboli: case reports and review of the literature. Yoshioka H, et al. **J Trauma** 1995 Sep; 39(3):596–601 (33 ref.)
The perspectives of violent street gang injuries. Hutson HR, et al. **Neurosurg Clin N Am** 1995 Oct;6(4):621–8 (38 ref.)
Gunshot wounds to the head in an urban setting. Krieger MD, et al. **Neurosurg Clin N Am** 1995 Oct;6(4):605–10 (28 ref.)
Characteristics of cerebral gunshot injuries in the rural setting. Pikus HJ, et al. **Neurosurg Clin N Am** 1995 Oct; 6(4):611–20 (39 ref.)
Multivariate analysis and prediction of outcome following penetrating head injury. Polin RS, et al.

Neurosurg Clin N Am 1995 Oct;6(4):689–99 (25 ref.)

Penetrating injuries in the Vietnam war. Traumatic unconsciousness, epilepsy, and psychosocial outcome. Salazar AM, et al. **Neurosurg Clin N Am** 1995 Oct; 6(4):715–26 (34 ref.)

COMPLICATIONS

Splenosis in exit gunshot wound [letter] Burvin R, et al. **Br J Dermatol** 1996 Jul;135(1):148–50 (12 ref.)

Gunshot cholecystitis. Petersen JM, et al. **J Clin Gastroenterol** 1995 Dec;21(4):320–2 (17 ref.)

Neuralgia–like symptoms in a patient with an airgun pellet in the ethmoid sinus: a case report. Donald PJ, et al. **J Laryngol Otol** 1995 Jul;109(7):646–9 (19 ref.)

Carotid artery pseudoaneurysm and pellet embolism to the middle cerebral artery following a shotgun wound of the neck. Cogbill TH, et al. **J Trauma** 1995 Oct;39(4):763–7 (16 ref.)

Hypopituitarism secondary to transfacial gunshot wound. D'Angelica M, et al. **J Trauma** 1995 Oct;39(4):768–71 (12 ref.)

Buckshot colic: case report and review of the literature [see comments] Fildes JJ, et al. **J Trauma** 1995 Dec;39(6):1181–4 (27 ref.) Comment in: J Trauma 1996 Jun;40(6):1054.

Paradoxical bullet embolism: case report and literature review. Schurr M, et al. **J Trauma** 1996 Jun;40(6):1034–6 (11 ref.)

Management of traumatic aneurysms caused by high–velocity missile head wounds. Aarabi B. **Neurosurg Clin N Am** 1995 Oct;6(4):775–97 (263 ref.)

Gastric bezoar following penetrating abdominal injury. Diagnosis and endoscopic therapy. Kaplan LJ, et al. **Surg Endosc** 1996 Jan;10(1):62–4 (16 ref.)

Traumatic pyeloduodenal fistula: a case report and review of the literature. Ginsberg DA, et al. **Urology** 1996 Apr; 47(4):588–91 (20 ref.)

[Parietal problems in thoracic injuries by gunshot] Houdelette P. **J Chir (Paris)** 1996 Apr;133(2):82–90 (23 ref.) (Eng. Abstr.) **(Fre)**

DRUG THERAPY

Comparison of intravenous and oral antibiotic therapy in the treatment of fractures caused by low–velocity gunshots. A prospective, randomized study of infection rates. Knapp TP, et al. **J Bone Joint Surg Am** 1996 Aug;78(8):1167–71 (35 ref.)

ETIOLOGY

Gunshot wound review. Fackler ML. **Ann Emerg Med** 1996 Aug;28(2):194–203 (59 ref.)

PHYSIOPATHOLOGY

Penetrating gunshots to the head and lack of immediate incapacitation. I. Wound ballistics and mechanisms of incapacitation. Karger B. **Int J Legal Med** 1995; 108(2):53–61 (90 ref.)

Penetrating gunshots to the head and lack of immediate incapacitation. II. Review of case reports. Karger B. **Int J Legal Med** 1995;108(3):117–26 (75 ref.)

Patients with Glasgow Coma Scale scores 3, 4, 5 after gunshot wounds to the brain. Kaufman HH, et al. **Neurosurg Clin N Am** 1995 Oct;6(4):701–14 (63 ref.)

PREVENTION & CONTROL

Incorporating gun safety into clinical practice. Camosy PA. **Am Fam Physician** 1996 Sep 1;54(3):971–5, 977–8 (16 ref.)

RADIOGRAPHY

CT of a peripatetic intracranial foreign body. Bearcroft PW, et al. **Neuroradiology** 1995 Oct;37(7):542–4 (16 ref.)

The radiologic evaluation of craniocerebral missile injuries. Kim PE, et al. **Neurosurg Clin N Am** 1995 Oct;6(4):669–87 (85 ref.)

SURGERY

Management of penetrating war wounds. Teh J. **Aust Fam Physician** 1995 Dec;24(12):2186–90 (0 ref.)

Laparoscopic colostomy for a gunshot wound to the rectum. Namias N, et al. **J Laparoendosc Surg** 1995 Aug;5(4):251–3 (17 ref.)

Venous injuries: military versus civilian experience. Ierardi RP, et al. **Mil Med** 1995 Aug;160(8):396–8 (25 ref.)

Military penetrating craniocerebral injuries. Applications to civilian triage and management. George ED, et al. **Neurosurg Clin N Am** 1995 Oct;6(4):753–9 (101 ref.)

[Urogenital injuries caused by projectiles. Data on recent conflicts and the North–American civilian experience] Houdelette P. **J Chir (Paris)** 1995 Oct;132(10):375–81 (19 ref.) (Eng. Abstr.) **(Fre)**

[A gunshot wound of the penis and scrotum] Dmitriev DG, et al. **Urol Nefrol (Mosk)** 1996 Mar–Apr;(2):47 (6 ref.) **(Rus)**

THERAPY

Care and variations in the care of patients with gunshot wounds to the brain. Kaufman HH. **Neurosurg Clin N Am** 1995 Oct;6(4):727–39 (91 ref.)

VETERINARY

Gunshot injuries: pathophysiology and treatments. Bebchuk TN, et al. **Vet Clin North Am Small Anim Pract** 1995 Sep; 25(5):1111–26 (33 ref.)

WOUNDS, MULTIPLE see **MULTIPLE TRAUMA**

WOUNDS, NONPENETRATING

Blunt myocardial injury [see comments] Feghali NT, et al. **Chest** 1995 Dec;108(6):1673–7 (35 ref.) Comment in: Chest 1996 May;109(5):1413–4.

Blunt gallbladder injuries: presentation of twenty–two cases with review of the literature. Sharma O. **J Trauma** 1995 Sep;39(3):576–80 (51 ref.)

Blunt trauma to the abdomen. Haller JA Jr. **Pediatr Rev** 1996 Jan;17(1):29–31 (8 ref.)

COMPLICATIONS

Uterine rupture with fetal death following blunt trauma. Harrison SD, et al. **AJR Am J Roentgenol** 1995 Dec; 165(6):1452 (9 ref.)

Pharyngo–esophageal perforation due to blunt trauma. Polsky S, et al. **Am Surg** 1995 Nov;61(11):994–6 (11 ref.)

Mitral valve injury after blunt chest trauma. McDonald ML, et al. **Ann Thorac Surg** 1996 Mar;61(3):1024–9 (43 ref.)

Silicone thorax: a complication of tube thoracostomy in the presence of mammary implants. Rice DC, et al. **Ann Thorac Surg** 1995 Nov;60(5):1417–9 (8 ref.)

Ruptured globes following radial and hexagonal keratotomy surgery [see comments] Vinger PF, et al. **Arch Ophthalmol** 1996 Feb;114(2):129–34 (51 ref.) Comment in: Arch Ophthalmol 1996 Feb;114(2):211–2.

ABC of urology. Urological trauma and bladder reconstruction. Dawson C, et al. **BMJ** 1996 May 25; 312(7042):1352–4 (5 ref.)

Acute ascites with blunt cardiac rupture. Dagenais F, et al. **Can J Cardiol** 1996 Jan;12(1):86–8 (12 ref.)

Traumatic pneumatoceles in an infant: case report and review of the literature. Schimpl G, et al. **Eur J Pediatr Surg** 1996 Apr;6(2):104–6 (14 ref.)

The effect of associated injuries, blood loss, and oxygen debt on death and disability in blunt traumatic brain injury: the need for early physiologic predictors of severity. Siegel JH. **J Neurotrauma** 1995 Aug;12(4):579–90 (18 ref.)

Tension pneumopericardium following blunt injury. Capizzi PJ, et al. **J Trauma** 1995 Oct;39(4):775–80 (80 ref.)

Traumatic lumbar hernia: a seat belt injury. McCarthy MC, et al. **J Trauma** 1996 Jan;40(1):121–2 (10 ref.)

Vertebrobasilar thrombosis associated with nonpenetrating cervical spine trauma. Prabhu V, et al. **J Trauma** 1996 Jan; 40(1):130–7 (59 ref.)

Renal artery pseudoaneurysm after blunt abdominal trauma: case report and literature review. Swana HS, et al. **J Trauma** 1996 Mar;40(3):459–61 (15 ref.)

Posttraumatic inferior vena caval thrombosis: case report and review of the literature. Takeuchi M, et al. **J Trauma** 1995 Sep;39(3):605–8 (10 ref.)

Intra–abdominal injury with handlebar hernia: case report and literature review. Yarbrough DR 3rd. **J Trauma** 1996 Jan;40(1):116–8 (21 ref.)

Intravascular stenting of traumatic abdominal aortic dissection. Marty–Ané CH, et al. **J Vasc Surg** 1996 Jan; 23(1):156–61 (13 ref.)

Splenic Injuries in children after blunt abdominal trauma. Benya EC, et al. **Semin Ultrasound CT MR** 1996 Apr; 17(2):170–6 (31 ref.)

Diagnosis of pancreatic injury after blunt abdominal trauma. Lane MJ, et al. **Semin Ultrasound CT MR** 1996 Apr; 17(2):177–82 (29 ref.)

[Traumatic tricuspid regurgitation: a case report and a review of operated cases in Japan] Yamada T, et al. **Kyobu Geka** 1996 Feb;49(2):146–50 (21 ref.) (Eng. Abstr.) **(Jpn)**

[Traumatic aortic valve insufficiency] Nascimento J, et al. **Rev Port Cardiol** 1996 Feb;15(2):147–52, 101 (17 ref.) (Eng. Abstr.) **(Por)**

DIAGNOSIS

Blunt abdominal injuries. Diagnostic peritoneal lavage, ultrasonography and computed tomography scanning. Chiquito PE. **Injury** 1996 Mar;27(2):117–24 (92 ref.)

Perforation in hypopharynx and deep cervical emphysema caused by blunt external trauma. Kiukaanniemi H, et al. **Mil Med** 1995 Sep;160(9):479–81 (5 ref.)

[A report of 6 cases of traumatic ruptures of the duodenum] Bălan B, et al. **Chirurgia (Bucur)** 1995;44(1):8–14 (0 ref.) **(Rum)**

ETIOLOGY

A review of intestinal injury from blunt abdominal trauma. Munns J, et al. **Aust N Z J Surg** 1995 Dec;65(12):857–60 (15 ref.)

Motor–scooter handlebar syndrome: blunt traumatic injury of the femoral artery. Baker WE, et al. **J Trauma** 1996 Jun;40(6):1017–20 (18 ref.)

METABOLISM

The effect of associated injuries, blood loss, and oxygen debt on death and disability in blunt traumatic brain injury: the need for early physiologic predictors of severity. Siegel JH. **J Neurotrauma** 1995 Aug;12(4):579–90 (18 ref.)

PHYSIOPATHOLOGY

Selective nonoperative management of liver and spleen injuries in neurologically impaired adult patients. Archer LP, et al. **Arch Surg** 1996 Mar;131(3):309–15 (57 ref.)

Blunt abdominal trauma. Boulanger BR, et al. **Emerg Med Clin North Am** 1996 Feb;14(1):151–71 (89 ref.)

RADIOGRAPHY

Radiologic management of abdominal trauma in pregnancy. Goldman SM, et al. **AJR Am J Roentgenol** 1996 Apr; 166(4):763–7 (33 ref.)

Diagnostic imaging in the evaluation of blunt abdominal trauma. Barloon TJ, et al. **Am Fam Physician** 1996 Jul; 54(1):205–9 (20 ref.)

CT in blunt chest trauma: pulmonary, tracheobronchial, and diaphragmatic injuries. Kang EY, et al. **Semin Ultrasound CT MR** 1996 Apr;17(2):114–8 (39 ref.)

CT of abdominal and pelvic trauma. Roberts JL. **Semin Ultrasound CT MR** 1996 Apr;17(2):142–69 (71 ref.)

SURGERY

Visceral injury. Porter JM, et al. **Curr Opin Gen Surg** 1993; :62–8 (31 ref.)

Traumatic injury to the azygous vein: case report. Butler DA, et al. **J Trauma** 1995 Oct;39(4):761–2 (10 ref.)

Evolution in the management of duodenal injuries. Carrillo EH, et al. **J Trauma** 1996 Jun;40(6):1037–45; discussion 1045–6 (55 ref.)

Successful repair of left ventricular rupture caused by blunt trauma: a case report. Aida H, et al. **Surgery** 1995 Nov; 118(5):907–8 (11 ref.)

[Surgery in childhood at the hospital for basic and routine general management] Willital GH. **Chirurg** 1996 Jun; 67(6):567–75 (28 ref.) (Eng. Abstr.) **(Ger)**

[Anterior interosseus syndrome from the surgical viewpoint] Axmann HD, et al. **Nervenarzt** 1995 Aug;66(8):610–3 (44 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Initial management of auricular trauma. Lee D, et al. **Am Fam Physician** 1996 May 15;53(7):2339–44 (20 ref.)

Evaluation of intrapleural analgesia in the management of blunt traumatic chest wall pain: a clinical trial. Short K, et al. **Am Surg** 1996 Jun;62(6):488–93 (50 ref.)

Selective nonoperative management of liver and spleen injuries in neurologically impaired adult patients. Archer LP, et al. **Arch Surg** 1996 Mar;131(3):309–15 (57 ref.)

Interventional radiology in the treatment of blunt liver trauma: case report with review of literature. Harms J, et al. **Bildgebung** 1996 Mar;63(1):51–4 (22 ref.)

Nonoperative management of a splenic tear in a Jehovah's Witness with hemophilia. Zieg PM, et al. **J Trauma** 1996 Feb;40(2):299–301 (21 ref.)

Complex hepatic injuries. Pachter HL, et al. **Surg Clin North Am** 1996 Aug;76(4):763–82 (66 ref.)

[Nonoperative treatment of blunt splenic injuries in adults] Stein M, et al. **Harefuah** 1996 Apr 1;130(7):495–9 (27 ref.) **(Heb)**

ULTRASONOGRAPHY

Ultrasonography for the initial evaluation of blunt abdominal trauma: A review of prospective trials. Pearl WS, et al. **Ann Emerg Med** 1996 Mar;27(3):353–61 (36 ref.)

WOUNDS, PENETRATING

Thoracic duct injury in penetrating neck trauma. Whiteford MH, et al. **Am Surg** 1995 Dec;61(12):1072–5 (63 ref.)

COMPLICATIONS

Acute repair of aorta–innominate vein fistulas. Roye GD, et al. **J Trauma** 1995 Oct;39(4):753–6 (12 ref.)

[Parietal problems in thoracic injuries by gunshot] Houdelette P. **J Chir (Paris)** 1996 Apr;133(2):82–90 (23 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

[Blunt and penetrating abdominal trauma. Patient assessment algorithm and principles for management] Ertel W, et al. **Unfallchirurg** 1996 Apr;99(4):288–303 (28 ref.) **(Ger)**

DRUG THERAPY

Options for cerebral protection after penetrating head injury. Rabb CH. **Neurosurg Clin N Am** 1995 Oct;6(4):643–56 (207 ref.)

EPIDEMIOLOGY

Epidemiology of injuries by needles and other sharp instruments. Minimizing sharp injuries in gynecologic and obstetric operations. Lewis FR Jr, et al. **Surg Clin North Am** 1995 Dec;75(6):1105–21 (34 ref.)

ETIOLOGY

Major vascular injury from high–pressure water jet. Harvey RL, et al. **J Trauma** 1996 Jan;40(1):165–7 (15 ref.)

WOUNDS, PENETRATING

PHYSIOPATHOLOGY

Cerebral hemodynamic disturbances following penetrating craniocerebral injury and their influence on outcome. Kordestani RK, et al. **Neurosurg Clin N Am** 1995 Oct; 6(4):657–67 (68 ref.)

Options for cerebral protection after penetrating head injury. Rabb CH. **Neurosurg Clin N Am** 1995 Oct;6(4):643–56 (207 ref.)

PREVENTION & CONTROL

The relationship of episiotomy to third and fourth degree lacerations. Golden WE, et al. **J Ark Med Soc** 1996 Feb; 92(9):447–8 (15 ref.)

Injury prevention in anesthesiology. Berry AJ. **Surg Clin North Am** 1995 Dec;75(6):1123–32 (21 ref.)

SURGERY

'Emergency room' thoracotomy: is it ever justified? Roxburgh JC. **Ann R Coll Surg Engl** 1996 Jul;78(4):327–30 (14 ref.)

Non-surgical trauma to the extrahepatic biliary tract. Parks RW, et al. **Br J Surg** 1995 Oct;82(10):1303–10 (127 ref.)

Visceral injury. Porter JM, et al. **Curr Opin Gen Surg** 1993; :62–8 (31 ref.)

Techniques to reduce the discomfort of paediatric laceration repair. Roberts PA, et al. **Med J Aust** 1996 Jan 1; 164(1):32–5 (37 ref.)

Penetrating cardiac injuries. Asensio JA, et al. **Surg Clin North Am** 1996 Aug;76(4):685–724 (119 ref.)

Complex problems in penetrating neck trauma. Demetriades D, et al. **Surg Clin North Am** 1996 Aug;76(4):661–83 (96 ref.)

Penetrating maxillofacial trauma--a case report. Arotiba TG. **West Afr J Med** 1995 Jul-Sep;14(3):186–8 (5 ref.)

[Therapy of osteomyelitis in the metacarpal region with local pedicle m. interosseus dorsalis II and III-flap-plasty. Anatomic principles and case report] Giunta R, et al. **Handchir Mikrochir Plast Chir** 1996 Mar;28(2):64–9 (28 ref.) (Eng. Abstr.) **(Ger)**

THERAPY

Initial management of auricular trauma. Lee D, et al. **Am Fam Physician** 1996 May 15;53(7):2339–44 (20 ref.)

The management of penetrating vascular injuries. Day JD, et al. **Neurosurg Clin N Am** 1995 Oct;6(4):799–808 (59 ref.)

The prehospital and emergency department management of penetrating head injuries. Eckstein M. **Neurosurg Clin N Am** 1995 Oct;6(4):741–51 (80 ref.)

Planning for pediatric laceration repairs. Brokaw A, et al. **Nurse Pract** 1996 Mar;21(3):42, 45, 49 (3 ref.)

VETERINARY

Management of penetrating joint injuries. Lewis DD. **Vet Clin North Am Small Anim Pract** 1995 Sep; 25(5):1197–223 (107 ref.)

WOUNDS, STAB

COMPLICATIONS

Traumatic fistula between the left anterior descending coronary artery and a left ventricular pseudoaneurysm. Haapanen YT, et al. **Cardiovasc Intervent Radiol** 1996 Jul-Aug;19(4):272–4 (11 ref.)

Clostridial meningitis as a result of craniocerebral arrow injury. Neal G, et al. **J Trauma** 1996 Mar;40(3):476–80 (23 ref.)

SURGERY

Cardiopulmonary bypass for resuscitation after penetrating cardiac trauma. Karmy-Jones R, et al. **Ann Thorac Surg** 1996 Apr;61(4):1244–5 (5 ref.)

WPW SYNDROME see **WOLFF-PARKINSON-WHITE SYNDROME**

WR-2721 see **AMIFOSTINE**

WRIST

MR imaging of musculoskeletal tumors of the hand and wrist. Kransdorf MJ, et al. **Magn Reson Imaging Clin N Am** 1995 May;3(2):327–44 (105 ref.)

ANATOMY & HISTOLOGY

Anatomy of the extensor mechanism of the hand and wrist. Wehbé MA. **Hand Clin** 1995 Aug;11(3):361–6 (13 ref.)

Normal anatomy of the hand and wrist. Prendergast N, et al. **Magn Reson Imaging Clin N Am** 1995 May;3(2):197–212 (33 ref.)

MR imaging of normal and injured wrist ligaments. Smith DK. **Magn Reson Imaging Clin N Am** 1995 May;3(2):229–48 (63 ref.)

MR imaging of the triangular fibrocartilage complex. Totterman SM, et al. **Magn Reson Imaging Clin N Am** 1995 May;3(2):213–28 (24 ref.)

BLOOD SUPPLY

MR angiography of the hand and wrist. Rofsky NM. **Magn Reson Imaging Clin N Am** 1995 May;3(2):345–59 (31 ref.)

PATHOLOGY

Synovial lesions of the hand and wrist. Bergman AG. **Magn Reson Imaging Clin N Am** 1995 May;3(2):265–79 (31 ref.)

PHYSIOLOGY

Extensor physiology in the hand and wrist. Thompson ST, et al. **Hand Clin** 1995 Aug;11(3):367–71 (16 ref.)

SURGERY

Clinical applications of MR imaging in hand and wrist surgery. Rettig ME, et al. **Magn Reson Imaging Clin N Am** 1995 May;3(2):361–8 (18 ref.)

WRIST INJURIES

Soft-tissue injuries of the wrist. Halikis MN, et al. **Clin Sports Med** 1996 Apr;15(2):235–59 (64 ref.)

COMPLICATIONS

Recurrent locking of the wrist due to dorsal midcarpal subluxation. Craigen MA. **J Bone Joint Surg Br** 1996 Jul; 78(4):664–6 (5 ref.)

[Post-traumatic psoriatic arthritis. 2 cases] Thomachot B, et al. **Presse Med** 1996 Jan 6-13;25(1):21–4 (13 ref.) (Eng. Abstr.) **(Fre)**

DIAGNOSIS

The immature athlete. Common injuries and overuse syndromes of the elbow and wrist. Gill TJ 4th, et al. **Clin Sports Med** 1996 Apr;15(2):401–23 (49 ref.)

Bony injuries of the wrist, forearm, and elbow. Griggs SM, et al. **Clin Sports Med** 1996 Apr;15(2):373–400 (114 ref.)

Compressive neuropathies and tendinopathies in the athletic elbow and wrist. Plancher KD, et al. **Clin Sports Med** 1996 Apr;15(2):331–71 (142 ref.)

The role of arthroscopy in athletic injuries of the wrist. Savoie FH 3rd, et al. **Clin Sports Med** 1996 Apr; 15(2):219–33 (12 ref.)

Unusual problems of the athlete's elbow, forearm, and wrist. Shaffer B, et al. **Clin Sports Med** 1996 Apr;15(2):425–38 (11 ref.)

Acute dislocations of the distal radioulnar joint. Bruckner JD, et al. **Instr Course Lect** 1996;45:27–36 (96 ref.)

MR imaging of normal and injured wrist ligaments. Smith DK. **Magn Reson Imaging Clin N Am** 1995 May;3(2):229–48 (63 ref.)

MR imaging of the triangular fibrocartilage complex. Totterman SM, et al. **Magn Reson Imaging Clin N Am** 1995 May;3(2):213–28 (24 ref.)

ETIOLOGY

Volar dislocation of the lunate in a weight lifter. Miller SJ, et al. **Orthopedics** 1996 Jan;19(1):61–3 (17 ref.)

[A syndrome caused by separating rags in textile industry: a new clinical entity?] Fioravanti A, et al. **Minerva Med** 1995 Nov;86(11):467–4 (25 ref.) (Eng. Abstr.) **(Ita)**

RADIOGRAPHY

Dislocation of the distal radioulnar joint associated with a transstyloid radiocarpal fracture dislocation. A case report and review of the literature. Stoffelen D, et al. **Acta Orthop Belg** 1996 Mar;62(1):52–5 (7 ref.)

[Views necessary for the traumatic wrist] Zeitoun F, et al. **Ann Radiol (Paris)** 1995;38(5):255–65 (25 ref.) (Eng. Abstr.) **(Fre)**

REHABILITATION

Early motion after flexor tendon surgery. Wang AW, et al. **Hand Clin** 1996 Feb;12(1):43–55 (47 ref.)

Silicone rubber splinting for athletic hand and wrist injuries. Canelón MF. **J Hand Ther** 1995 Oct-Dec;8(4):252–7 (43 ref.)

THERAPY

Volar transscaphoid perilunate fracture dislocation: case report and review. Hayeems EB, et al. **J Trauma** 1996 Jun; 40(6):1031–3 (14 ref.)

WRIST JOINT

Carpal instability. Ruby LK. **Instr Course Lect** 1996;45:3–13 (44 ref.)

Evaluation and treatment of the rheumatoid wrist. Terrono AL, et al. **Instr Course Lect** 1996;45:15–26 (64 ref.)

Recurrent locking of the wrist due to dorsal midcarpal subluxation. Craigen MA. **J Bone Joint Surg Br** 1996 Jul; 78(4):664–6 (5 ref.)

Synovial osteochondromatosis of the distal radioulnar joint: ultrasound diagnosis. Leekam RN, et al. **J Clin Ultrasound** 1996 May;24(4):207–8 (10 ref.)

ANATOMY & HISTOLOGY

MR imaging of normal and injured wrist ligaments. Smith DK. **Magn Reson Imaging Clin N Am** 1995 May;3(2):229–48 (63 ref.)

MR imaging of the triangular fibrocartilage complex. Totterman SM, et al. **Magn Reson Imaging Clin N Am** 1995 May;3(2):213–28 (24 ref.)

PATHOLOGY

Synovial lesions of the hand and wrist. Bergman AG. **Magn Reson Imaging Clin N Am** 1995 May;3(2):265–79 (31 ref.)

Synovial hemangioma: imaging features in eight histologically proven cases, review of the literature, and differential diagnosis. Greenspan A, et al. **Skeletal Radiol** 1995 Nov;24(8):583–90 (32 ref.)

PHYSIOPATHOLOGY

Complex carpal dislocation. Irwin LR, et al. **J Hand Surg [Br]** 1995 Dec;20(6):746–9 (15 ref.)

RADIOGRAPHY

[Arthrography of the wrist joint] Tian G, et al. **Chung Hua Wai Ko Tsa Chih** 1995 Jul;33(7):441–4 (29 ref.) **(Chi)**

[Isolated punched-out lesions of the carpus and pain of the wrist] Dumontier C, et al. **Ann Radiol (Paris)** 1995; 38(5):287–92 (50 ref.) (Eng. Abstr.) **(Fre)**

SURGERY

[Arthrodesis of the wrist in arthritis] Knopp W, et al. **Orthopade** 1996 Apr;25(2):121–5 (23 ref.) (Eng. Abstr.) **(Ger)**

WRITING

Journal writing as a mode of thinking for RN-BSN students: a leveled approach to learning to listen to self and others. Hodges HF. **J Nurs Educ** 1996 Mar;35(3):137–41 (20 ref.)

[White walls for black holes: essay on graffiti psychopathology] Catheline-Antipoff N, et al. **Psychiatr Enfant** 1995;38(2):625–53 (16 ref.) (Eng. Abstr.) **(Fre)**

[Writing and reading scientific texts] Kuss E, et al. **Geburtshilfe Frauenheilkd** 1995 Jul;55(7):414–24 (85 ref.) **(Ger)**

WRONGFUL BIRTH see **WRONGFUL LIFE**

WRONGFUL LIFE

'Wrongful conception', 'wrongful birth' and 'wrongful life': the first South African cases. Strauss SA. **Med Law** 1996; 15(1):161–73 (15 ref.)

WRYNECK see **TORTICOLLIS**

WUCHERERIA BANCROFTI

[Role of ivermectin in the prophylaxis of lymphatic filariasis] Cartel JL, et al. **Med Trop (Mars)** 1995;55(3 Suppl):30–3 (26 ref.) **(Fre)**

X CHROMOSOME

MZ female twins discordant for X-linked diseases: a review. Tiberio G. **Acta Genet Med Gemellol (Roma)** 1994; 43(3–4):207–14 (28 ref.)

Menkes and Wilson diseases. Monaco AP, et al. **Adv Genet** 1995;33:233–53 (91 ref.)

Sex determination and its pathology in man. Schafer AJ. **Adv Genet** 1995;33:275–329 (288 ref.)

Molecular and cellular aspects of X-linked agammaglobulinemia. Sideras P, et al. **Adv Immunol** 1995; 59:135–223 (445 ref.)

Genetic control of X inactivation and processes leading to X-inactivation skewing [editorial; comment] Belmont JW. **Am J Hum Genet** 1996 Jun;58(6):1101–8 (77 ref.) Comment on: Am J Hum Genet 1996 Jun;58(6):1111–9.

Juberg-Marsidi syndrome: report of an additional case. Tsukahara M, et al. **Am J Med Genet** 1995 Sep 25; 58(4):353–5 (7 ref.)

The molecular basis of X-linked severe combined immunodeficiency: defective cytokine receptor signaling. Leonard WJ. **Annu Rev Med** 1996;47:229–39 (52 ref.)

Dietary management of X-linked adrenoleukodystrophy. Moser HW, et al. **Annu Rev Nutr** 1995;15:379–97 (77 ref.)

Defects in Wiskott-Aldrich syndrome blood cells. Remold-O'Donnell E, et al. **Blood** 1996 Apr 1; 87(7):2621–31 (118 ref.)

Isodicentric (X)(q13) in haematological malignancies: presentation of five new cases, application of fluorescence in situ hybridization (FISH) and review of the literature. Dierlamm J, et al. **Br J Haematol** 1995 Dec;91(4):885–91 (23 ref.)

X-linked severe combined immunodeficiency disease and the gamma c receptor component: prospects for molecular diagnosis. Farner NL, et al. **Clin Diagn Lab Immunol** 1995 Sep;2(5):518–23 (63 ref.)

Application of linked markers for genetic diagnosis of Alport

syndrome. Barker DF, et al. **Contrib Nephrol** 1996; 117:29–45 (33 ref.)
Adrenoleukodystrophy. Moser HW. **Curr Opin Neurol** 1995 Jun;8(3):221–6 (37 ref.)
Complete nucleotide sequence of Saccharomyces cerevisiae chromosome X. Galibert F, et al. **EMBO J** 1996 May 1; 15(9):2031–49 (47 ref.)
CRASH syndrome: clinical spectrum of corpus callosum hypoplasia, retardation, adducted thumbs, spastic paraparesis and hydrocephalus due to mutations in one single gene, L1. Fransen E, et al. **Eur J Hum Genet** 1995; 3(5):273–84 (49 ref.)
Casey Holter Essay Prize. The pathogenesis of X-linked hydrocephalus. Jouet M. **Eur J Pediatr Surg** 1995 Dec;5 Suppl 1:5–7 (36 ref.)
Distinct Xp11.2 breakpoints in two renal cell carcinomas exhibiting X;autosome translocations. Dijkhuizen T, et al. **Genes Chromosomes Cancer** 1995 Sep;14(1):43–50 (20 ref.)
Xp-duplications with and without sex reversal. Baumstark A, et al. **Hum Genet** 1996 Jan;97(1):79–86 (32 ref.)
Norrie disease and MAO genes: nearest neighbors. Chen ZY, et al. **Hum Mol Genet** 1995;4 Spec No:1729–37 (100 ref.)
Syndromal mental retardation due to mutations in a regulator of gene expression. Gibbons RJ, et al. **Hum Mol Genet** 1995;4 Spec No:1705–9 (24 ref.)
BTKbase: a database of XLA-causing mutations. International Study Group. Vihinen M, et al. **Immunol Today** 1995 Oct;16(10):460–5 (39 ref.)
Hypomelanosis of Ito and X;autosome translocations: a unifying hypothesis. Hatchwell E. **J Med Genet** 1996 Mar; 33(3):177–83 (61 ref.)
The alpha-thalassemia/mental retardation syndromes. Gibbons RJ, et al. **Medicine (Baltimore)** 1996 Mar; 75(2):45–52 (32 ref.)
X-linked recessive bulbospinal neuronopathy (SBMA). Sobue G. **Nagoya J Med Sci** 1995 Dec;58(3–4):95–106 (41 ref.)
X-linked lymphoproliferative disease: twenty-five years after the discovery. Seemayer TA, et al. **Pediatr Res** 1995 Oct; 38(4):471–8 (67 ref.)
Sex chromosome tetrasomy and pentasomy. Linden MG, et al. **Pediatrics** 1995 Oct;96(4 Pt 1):672–82 (58 ref.)
The expanded trinucleotide repeat in Kennedy's disease. Fischbeck KH. **Proc Assoc Am Physicians** 1995 Jul; 107(2):228–30 (9 ref.)
Chromosome manipulation: a systematic approach toward understanding human chromosome structure and function [comment] Willard HF. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):6847–50 (28 ref.) Comment on: Proc Natl Acad Sci U S A 1996 Jul 9;93(14):7125–30.
The gene responsible for adrenal hypoplasia congenita, DAX-1, encodes a nuclear hormone receptor that defines a new class within the superfamily. Burris TP, et al. **Recent Prog Horm Res** 1996;51:241–59; discussion 259–60 (94 ref.)
Sex preselection by flow cytometric separation of X and Y chromosome-bearing sperm based on DNA difference: a review. Johnson LA. **Reprod Fertil Dev** 1995;7(4):893–903 (47 ref.)
Fragile X syndrome and other dynamic mutation diseases. Sutherland GR, et al. **Southeast Asian J Trop Med Public Health** 1995;26 Suppl 1:77–85 (41 ref.)
[The human genome—chromosome X. Focus on Xq28] Sedláček Z. **Cas Lek Cesk** 1995 Dec 6;134(23):760–6 (97 ref.) (Eng. Abstr.) **(Cze)**
[X-linked genodermatoses] Vabres P, et al. **Ann Dermatol Venereol** 1995;122(4):154–60 (33 ref.) (Eng. Abstr.) **(Fre)**
[A family with X-linked hydrocephalus resulting from mutations in the neural cell adhesion molecule L1] Maruta K, et al. **Rinsho Shinkeigaku** 1996 Mar;36(3):462–6 (16 ref.) (Eng. Abstr.) **(Jpn)**
[Generalized angitis and recurrent infection associated hemophagocytic syndrome in a girl with XXX syndrome] Wada Y, et al. **Ryumachi** 1995 Jun;35(3):589–94 (11 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Mutations in the X-linked and autosomal recessive forms of chronic granulomatous disease. Roos D, et al. **Blood** 1996 Mar 1;87(5):1663–81 (151 ref.)
Understanding enamel formation from mutations causing X-linked amelogenesis imperfecta. Lagerström-Fermér M, et al. **Connect Tissue Res** 1995;32(1–4):241–6 (40 ref.)
The myotubular myopathies: differential diagnosis of the X linked recessive, autosomal dominant, and autosomal recessive forms and present state of DNA studies. Wallgren-Pettersson C, et al. **J Med Genet** 1995 Sep; 32(9):673–9 (56 ref.)
Sex chromosome aneuploidy and aging. Stone JF, et al. **Mutat Res** 1995 Oct;338(1–6):107–13 (51 ref.)
Xp duplications and sex reversal. Zanaria E, et al. **Philos Trans R Soc Lond B Biol Sci** 1995 Nov 29; 350(1333):291–6 (28 ref.)
Equality for X chromosomes [see comments] Kelley RL, et al. **Science** 1995 Dec 8;270(5242):1607–10 (49 ref.) Comment in: Science 1996 May 24;272(5265):1190–1.
[Molecular genetic research on Duchenne-Becker myodystrophy. The correlation of the severity of the disease with the type of deletion] Badalian LO, et al. **Zh Nevropatol Psikhiatr Im S S Korsakova** 1995;95(6):90–2 (35 ref.) **(Rus)**

ULTRASTRUCTURE

An angiomyoma with t(X;10)(q22;q23.2). Sonobe H, et al. **Cancer Genet Cytogenet** 1996 Aug;90(1):54–6 (17 ref.)
X chromosome inactivation, XIST, and pursuit of the X-inactivation center. Willard HF. **Cell** 1996 Jul 12; 86(1):5–7 (14 ref.)

X INACTIVATION see **DOSAGE COMPENSATION (GENETICS)**

X-LINKED LYMPHOPROLIFERATIVE SYNDROME see **LYMPHOPROLIFERATIVE DISORDERS**

X-RAY ABSORPTIOMETRY, DUAL-ENERGY see **DENSITOMETRY, X-RAY**

X-RAY CRYSTALLOGRAPHY see **CRYSTALLOGRAPHY, X-RAY**

X-RAY DEPARTMENTS see **RADIOLOGY DEPARTMENT, HOSPITAL**

X-RAY, DIAGNOSTIC see **RADIOGRAPHY**

X-RAY DIFFRACTION

Crystallographic methods and protocols. Introduction. Sanderson MR. **Methods Mol Biol** 1996;56:1–21 (70 ref.)

X-RAY EMISSION SPECTROMETRY see **SPECTROMETRY, X-RAY EMISSION**

X-RAY EMISSION SPECTROMETRY, ELECTRON MICROSCOPIC see **ELECTRON PROBE MICROANALYSIS**

X-RAY EMISSION SPECTROMETRY, ELECTRON PROBE see **ELECTRON PROBE MICROANALYSIS**

X-RAY EMISSION SPECTROSCOPY see **SPECTROMETRY, X-RAY EMISSION**

X-RAY FLUORESCENCE SPECTROMETRY see **SPECTROMETRY, X-RAY EMISSION**

X-RAY INFORMATION SYSTEMS see **RADIOLOGY INFORMATION SYSTEMS**

X-RAY MICROANALYSIS, ELECTRON MICROSCOPIC see **ELECTRON PROBE MICROANALYSIS**

X-RAY MICROANALYSIS, ELECTRON PROBE see **ELECTRON PROBE MICROANALYSIS**

X-RAY TOMOGRAPHY, COMPUTED see **TOMOGRAPHY, X-RAY COMPUTED**

X SYNDROME see **SYNDROME X**

XANTHINE DEHYDROGENASE

ANTAGONISTS & INHIBITORS

Role of xanthine oxidase and its inhibitor in hypoxia: reoxygenation injury. Saugstad OD. **Pediatrics** 1996 Jul; 98(1):103–7 (83 ref.)

PHYSIOLOGY

Role of xanthine oxidase and its inhibitor in hypoxia: reoxygenation injury. Saugstad OD. **Pediatrics** 1996 Jul; 98(1):103–7 (83 ref.)

XANTHINE OXIDASE

ANTAGONISTS & INHIBITORS

Role of xanthine oxidase and its inhibitor in hypoxia: reoxygenation injury. Saugstad OD. **Pediatrics** 1996 Jul; 98(1):103–7 (83 ref.)

CHEMISTRY

Recent studies on xanthine oxidase and related enzymes. Bray RC, et al. **Biochem Soc Trans** 1996 Feb;24(1):99–105 (41 ref.)

METABOLISM

Hyperuricemia and xanthine oxidase in preeclampsia, revisited. Many A, et al. **Am J Obstet Gynecol** 1996 Jan; 174(1 Pt 1):288–91 (60 ref.)
Recent studies on xanthine oxidase and related enzymes. Bray RC, et al. **Biochem Soc Trans** 1996 Feb;24(1):99–105 (41 ref.)

PHYSIOLOGY

Role of xanthine oxidase and its inhibitor in hypoxia: reoxygenation injury. Saugstad OD. **Pediatrics** 1996 Jul; 98(1):103–7 (83 ref.)

XANTHINES

ANALYSIS

[Oxypurine] Kono N. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:506–9 (15 ref.) **(Jpn)**

PHARMACOLOGY

Stimulation of Na+, K(+)-pump activity in skeletal muscle by methylxanthines: evidence and proposed mechanisms. Lindinger MI, et al. **Acta Physiol Scand** 1996 Mar; 156(3):347–53 (45 ref.)
Immunomodulatory actions of xanthines and isoenzyme selective phosphodiesterase inhibitors. Banner KH, et al. **Monaldi Arch Chest Dis** 1995 Aug;50(4):286–92 (96 ref.)
[Recent adenosine antagonists] Suzuki F, et al. **Tanpakushitsu Kakusan Koso** 1994 Jul;40(10):1277–92 (73 ref.) **(Jpn)**

THERAPEUTIC USE

HWA 285 (propentofylline)—a new compound for the treatment of both vascular dementia and dementia of the Alzheimer type. Rother M, et al. **Ann N Y Acad Sci** 1996 Jan 17;777:404–9 (23 ref.)

XANTHOGRANULOMA, JUVENILE

CONGENITAL

[Juvenile xanthogranuloma: a congenital giant form] Labbé L, et al. **Ann Dermatol Venereol** 1995;122(10):678–81 (20 ref.) (Eng. Abstr.) **(Fre)**

PATHOLOGY

Subcutaneous juvenile xanthogranuloma. Sánchez Yus E, et al. **J Cutan Pathol** 1995 Oct;22(5):460–5 (17 ref.)
Juvenile xanthogranuloma: forms of systemic disease and their clinical implications. Freyer DR, et al. **J Pediatr** 1996 Aug;129(2):227–37 (49 ref.)
Intraoral juvenile xanthogranuloma. A case report and literature review. Kwan CY, et al. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod** 1996 Apr;81(4):450–3 (19 ref.)

PREVENTION & CONTROL

The risk intraocular juvenile xanthogranuloma: survey of current practices and assessment of risk. Chang MW, et al. **J Am Acad Dermatol** 1996 Mar;34(3):445–9 (26 ref.)

XANTHOGRANULOMATOUS PYELONEPHRITIS see **PYELONEPHRITIS, XANTHOGRANULOMATOUS**

XANTHOMA DISSEMINATUM see **HISTIOCYTOSIS, NON-LANGERHANS-CELL**

XANTHOMA, JUVENILE see **XANTHOGRANULOMA, JUVENILE**

XANTHOMATOSIS

[Xanthogranulomatous cholecystitis] Iwamoto S, et al. **Ryoikibetsu Shokogun Shirizu** 1996;(9):196–8 (10 ref.) **(Jpn)**

DIAGNOSIS

[Fibroxanthogranulomatous inflammation] Kitamra T. **Ryoikibetsu Shokogun Shirizu** 1996;(9):290–1 (8 ref.) **(Jpn)**

METABOLISM

[Congenital disorders of the bile acid metabolism (3 beta-hydroxy-delta 5-steroid dehydrogenase/isomerase deficiency, delta 4-3-oxosteroid 5 beta-reductase deficiency, cerebrotendinous xanthomatosis, and peroxisomal disorders] Kondo KH, et al. **Ryoikibetsu Shokogun Shirizu** 1995;(8):362–6 (23 ref.) **(Jpn)**

PATHOLOGY

Necrobiotic xanthogranuloma with cardiac involvement. Umbert I, et al. **Br J Dermatol** 1995 Sep;133(3):438–43 (37 ref.)
Verruciform xanthoma. Case report and literature review. Huang JS, et al. **J Periodontol** 1996 Feb;67(2):162–5 (13 ref.)
[Xanthelasma palpebrarum] Kemler MA, et al. **Ned Tijdschr Geneeskd** 1996 May 11;140(19):1014–7 (38 ref.) **(Dut)**

XANTHOMATOSIS, FAMILIAL see **WOLMAN DISEASE**

XANTHOMATOSIS, WOLMAN'S see **WOLMAN DISEASE**

XANTHOMONAS

Resistant nosocomial gram-negative bacillary pathogens: Acinetobacter baumannii, Xanthomonas maltophilia, and Pseudomonas cepacia. Fang FC, et al. **Curr Clin Top Infect Dis** 1996;16:52–83 (363 ref.)

XANTHOMONAS

[Hospital pneumonia due to Xanthomonas maltophilia and AIDS (letter)] Sitges M, et al. **Arch Bronconeumol** 1996 May;32(5):259–60 (6 ref.) **(Spa)**

DRUG EFFECTS

The emergence of epidemic, multiple-antibiotic-resistant Stenotrophomonas (Xanthomonas) maltophilia and Burkholderia (Pseudomonas) cepacia. Spencer RC. **J Hosp Infect** 1995 Jun;30 Suppl:453–64 (105 ref.)

XENOANTIGENS see **ANTIGENS, HETEROPHILE**

XENOBIOTICS

Evaluating the impact of exposure to environmental contaminants on human health. Silkworth JB, et al. **Clin Chem** 1996 Aug;42(8 Pt 2):1345–9 (34 ref.)

ADVERSE EFFECTS

Neuropsychiatric and somatic characteristics of young adults with and without self-reported chemical odor intolerance and chemical sensitivity. Bell IR, et al. **Arch Environ Health** 1996 Jan–Feb;51(1):9–21 (114 ref.)

Site specific drug and xenobiotic induced renal toxicity. Hawksworth GM, et al. **Arch Toxicol Suppl** 1996;18:184–92 (19 ref.)

Manifestations of chemically induced liver damage. Batt AM, et al. **Clin Chem** 1995 Dec;41(12 Pt 2):1882–7 (40 ref.)

Thresholds of toxicological concern based on structure-activity relationships. Munro IC, et al. **Drug Metab Rev** 1996 Feb–May;28(1–2):209–17 (9 ref.)

Commentary on effects of anthropogenic and natural organic chemicals on development, swimming behavior, and reproduction of Daphnia, a key member of aquatic ecosystems. Dodson SI, et al. **Environ Health Perspect** 1995 May;103 Suppl 4:7–11 (60 ref.)

Genotoxicology and risk assessment in the era of the human genome project. Vorce RL, et al. **J Toxicol Clin Toxicol** 1996;34(5):521–3 (10 ref.)

The effects of exposure to "synthetic" chemicals on human health: a review. VanDoren PM. **Risk Anal** 1996 Jun; 16(3):367–76 (57 ref.)

Toxicological consequences of multiple chemical interactions: a primer. Calabrese EJ. **Toxicology** 1995 Dec 28;105(2–3):121–35 (81 ref.)

Isobolographic analysis of interactions: an update on applications and utility. Gessner PK. **Toxicology** 1995 Dec 28;105(2–3):161–79 (33 ref.)

Risk assessment: toxicity from chemical exposure resulting from enhanced expression of CYP2E1. Raucy JL. **Toxicology** 1995 Dec 28;105(2–3):217–24 (48 ref.)

[The role of genetically determined acetylation of drugs and xenobiotics in pathogenesis of neoplastic diseases] Niewiński P, et al. **Postepy Hig Med Dosw** 1996; 50(2):131–43 (50 ref.) (Eng. Abstr.) **(Pol)**

CHEMISTRY

Physiologically-based pharmacokinetic modeling and bioactivation of xenobiotics. Clewell HJ 3rd, et al. **Toxicol Ind Health** 1994 Jan–Apr;10(1–2):1–24 (55 ref.)

IMMUNOLOGY

Predictive molecular and genetic toxicology. Application to the detection of sensitizing potential of xenobiotics. Garrigue JL, et al. **Clin Rev Allergy Immunol** 1995 Fall; 13(3):189–200 (38 ref.)

Cytochromes P450 and drug toxicity. Immunological consequences. Mansuy D. **Clin Rev Allergy Immunol** 1995 Fall;13(3):201–9 (12 ref.)

METABOLISM

Manipulations of catabolic genes for the degradation and detoxification of xenobiotics. Lal R, et al. **Adv Appl Microbiol** 1995;41:55–95 (181 ref.)

The molecular biology of xenobiotic enzymes and the predisposition to idiopathic Parkinson's disease. Ho SL, et al. **Adv Neurol** 1996;69:53–60 (36 ref.)

Molecular genetics of cytochrome P450 IID. Anomalies of drug metabolism. Jacqz-Aigrain E, et al. **Clin Rev Allergy Immunol** 1995 Fall;13(3):211–21 (50 ref.)

Biochemical toxicology of chemical teratogenesis. Wells PG, et al. **Crit Rev Biochem Mol Biol** 1996 Feb;31(1):1–40 (200 ref.)

Xenobiotic metabolism in brain. Ravindranath V, et al. **Drug Metab Rev** 1995;27(3):419–48 (117 ref.)

Using biomarkers of genetic susceptibility to enhance the study of cancer etiology. Rothman N, et al. **Environ Health Perspect** 1995 Nov;103 Suppl 8:291–5 (74 ref.)

Specificity of human UDP-glucuronosyltransferases and xenobiotic glucuronidation. Burchell B, et al. **Life Sci** 1995; 57(20):1819–31 (64 ref.)

Enzymes and transport systems involved in the formation and disposition of glutathione S-conjugates. Role in bioactivation and detoxication mechanisms of xenobiotics. Commandeur JN, et al. **Pharmacol Rev** 1995 Jun; 47(2):271–330 (596 ref.)

Cell systems for use in studies on the relationship between foreign compound metabolism and toxicity. Oesch F, et al. **Pharmacol Toxicol** 1995 May;76(5):325–7 (16 ref.)

Xenobiotic lipids: the inclusion of xenobiotic compounds in pathways of lipid biosynthesis. Dodds PF. **Prog Lipid Res** 1995;34(3):219–47 (209 ref.)

Xenobiotic metabolism in brain. Ravindranath V, et al. **Toxicol Lett** 1995 Dec;82–83:633–8 (19 ref.)

An introduction to drug disposition: the basic principles of absorption, distribution, metabolism, and excretion. Caldwell J, et al. **Toxicol Pathol** 1995 Mar–Apr; 23(2):102–14 (78 ref.)

[Role of human cytochrome P-450 enzymes in the metabolism of xenobiotics] Monostory K, et al. **Acta Pharm Hung** 1995 Sep;65(5):147–56 (94 ref.) (Eng. Abstr.) **(Hun)**

PHARMACOKINETICS

Scaling basic toxicokinetic parameters from rat to man. Bachmann K, et al. **Environ Health Perspect** 1996 Apr; 104(4):400–7 (148 ref.)

Phase III elimination: another two-edge sword [editorial] Vore M. **Environ Health Perspect** 1994 May;102(5):422–3 (9 ref.)

Recent advances in carrier-mediated hepatic uptake and biliary excretion of xenobiotics. Yamazaki M, et al. **Pharm Res** 1996 Apr;13(4):497–513 (77 ref.)

Assessment of hepatic function with xenobiotics. Reichen J. **Semin Liver Dis** 1995 Aug;15(3):189–201 (212 ref.)

Observations on vitamin K deficiency in the fetus and newborn: has nature made a mistake? Israels LG, et al. **Semin Thromb Hemost** 1995;21(4):357–63 (36 ref.)

Physiologically-based pharmacokinetic modeling and bioactivation of xenobiotics. Clewell HJ 3rd, et al. **Toxicol Ind Health** 1994 Jan–Apr;10(1–2):1–24 (55 ref.)

Physiologically based pharmacokinetic (PB–PK) models in the study of the disposition and biological effects of xenobiotics and drugs. Andersen ME. **Toxicol Lett** 1995 Dec;82–83:341–8 (23 ref.)

Variability in glutathione-dependent detoxication in vivo and its relevance to detoxication of chemical mixtures. Jones DP, et al. **Toxicology** 1995 Dec 28;105(2–3):267–74 (40 ref.)

Phenotypic variation in xenobiotic metabolism and adverse environmental response: focus on sulfur-dependent detoxification pathways. McFadden SA. **Toxicology** 1996 Jul 17;111(1–3):43–65 (145 ref.)

PHARMACOLOGY

Polymorphic forms of the Ah receptor and induction of the CYP1A1 gene. Fujii-Kuriyama Y, et al. **Pharmacogenetics** 1995;5 Spec No:S149–53 (30 ref.)

Mechanisms of action of new immunosuppressive drugs. Morris RE. **Ther Drug Monit** 1995 Dec;17(6):564–9 (10 ref.)

TOXICITY

Pathology of the thymus: changes induced by xenobiotics and gene targeting. Schuurman HJ, et al. **APMIS** 1995 Jul–Aug;103(7–8):481–500 (110 ref.)

Methods for studying renal toxicity. Kruidering M, et al. **Arch Toxicol Suppl** 1996;18:173–83 (38 ref.)

Predictive molecular and genetic toxicology. Application to the detection of sensitizing potential of xenobiotics. Garrigue JL, et al. **Clin Rev Allergy Immunol** 1995 Fall; 13(3):189–200 (38 ref.)

Cytochromes P450 and drug toxicity. Immunological consequences. Mansuy D. **Clin Rev Allergy Immunol** 1995 Fall;13(3):201–9 (12 ref.)

Biotransformation and membrane transport in nephrotoxicity. Dekant W, et al. **Crit Rev Toxicol** 1996 May;26(3):309–34 (203 ref.)

Scaling basic toxicokinetic parameters from rat to man. Bachmann K, et al. **Environ Health Perspect** 1996 Apr; 104(4):400–7 (148 ref.)

Lung injury: cell-specific bioactivation/deactivation of circulating pneumotoxins. Dinsdale D. **Int J Exp Pathol** 1995 Dec;76(6):393–401 (71 ref.)

Renal handling of drugs and amino acids after impairment of kidney or liver function—influences of maturity and protective treatment. Fleck C, et al. **Pharmacol Ther** 1995; 67(1):53–77 (341 ref.)

Cell systems for use in studies on the relationship between foreign compound metabolism and toxicity. Oesch F, et al. **Pharmacol Toxicol** 1995 May;76(5):325–7 (16 ref.)

Measures of cell replication in risk/safety assessment of xenobiotic-induced, nongenotoxic carcinogenesis. Jones HB, et al. **Regul Toxicol Pharmacol** 1996 Apr;23(2):117–27 (103 ref.)

Predicting modes of toxic action from chemical structure: an overview. Bradbury SP. **SAR QSAR Environ Res** 1994; 2(1–2):89–104 (45 ref.)

Role of proinflammatory cytokines in a toxic response: application of cytokine knockout mice in toxicological research. Ryffel B. **Toxicol Lett** 1995 Dec;82–83:477–82 (33 ref.)

Toxicological consequences of multiple chemical interactions: a primer. Calabrese EJ. **Toxicology** 1995 Dec 28;105(2–3):121–35 (81 ref.)

Hematotoxic interactions: occurrence, mechanisms and predictability. Krishnan K, et al. **Toxicology** 1995 Dec 28; 105(2–3):355–64 (43 ref.)

Toxicodynamics of low level toxicant interactions of biological significance: inhibition of tissue repair. Mehendale HM. **Toxicology** 1995 Dec 28;105(2–3):251–66 (95 ref.)

XENOGRAFT see **TRANSPLANTATION, HETEROLOGOUS**

XENOGRAFT BIOPROSTHESIS see **BIOPROSTHESIS**

XENOGRAFT DRESSINGS see **BIOLOGICAL DRESSINGS**

XENON

[The narcotic properties of xenon and the prospects for its use in anesthesiology] Damir EA, et al. **Anesteziol Reanimatol** 1996 Jan–Feb;(1):71–5 (88 ref.) **(Rus)**

XENOPUS

EMBRYOLOGY

Specifying the dorsoanterior axis in frogs: 70 years since Spemann and Mangold. Elinson RP, et al. **Curr Top Dev Biol** 1995;30:253–85 (166 ref.)

Axis formation during amphibian oogenesis: reevaluating the role of the cytoskeleton. Gard DL. **Curr Top Dev Biol** 1995; 30:215–52 (122 ref.)

Cortical cytoskeleton of the Xenopus oocyte, egg, and early embryo. Larabell CA. **Curr Top Dev Biol** 1995;31:433–53 (72 ref.)

mRNA localisation during development. Micklem DR. **Dev Biol** 1995 Dec;172(2):377–95 (165 ref.)

Chromatin and transcriptional activity in early Xenopus development. Landsberger N, et al. **Semin Cell Biol** 1995 Aug;6(4):191–9 (65 ref.)

GENETICS

Chromatin and transcriptional activity in early Xenopus development. Landsberger N, et al. **Semin Cell Biol** 1995 Aug;6(4):191–9 (65 ref.)

METABOLISM

Activation mechanism and function of the MAP kinase cascade. Gotoh Y, et al. **Mol Reprod Dev** 1995 Dec; 42(4):486–92 (48 ref.)

XENOPUS LAEVIS

EMBRYOLOGY

GTP-binding proteins and early embryogenesis in Xenopus. Paquereau L, et al. **Cell Signal** 1995 May;7(4):295–302 (71 ref.)

Confocal immunofluorescence microscopy of microtubules, microtubule-associated proteins, and microtubule-organizing centers during amphibian oogenesis and early development. Gard DL, et al. **Curr Top Dev Biol** 1995;31:383–431 (137 ref.)

Intermediate filament organization, reorganization, and function in the clawed frog Xenopus. Klymkowsky MW. **Curr Top Dev Biol** 1995;31:455–86 (140 ref.)

Apoptosis of larval cells during amphibian metamorphosis. Ishizuya-Oka A. **Microsc Res Tech** 1996 Jun 15; 34(3):228–35 (73 ref.)

[Pattern formation in the early embryogenesis of the clawed toad] Mglinets VA. **Ontogenez** 1995 Jul–Aug;26(4):282–92 (72 ref.) (Eng. Abstr.) **(Rus)**

[The morphological criteria and proposed mechanisms of cortical contractility in oocytes of the clawed toad] Riabova LV, et al. **Ontogenez** 1996 May–Jun;27(3):165–72 (14 ref.) (Eng. Abstr.) **(Rus)**

GENETICS

Xenopus oocytes as a heterologous expression system. Theodoulou FL, et al. **Methods Mol Biol** 1995;49:317–40 (48 ref.)

[Structure and properties of transcription IIIA from Xenopus laevis] Wyszko E, et al. **Postepy Biochem** 1995;41(2):102–9 (56 ref.) **(Pol)**

METABOLISM

The inositol trisphosphate receptor of Xenopus oocytes. Parys JB, et al. **Cell Calcium** 1995 Nov;18(5):353–63 (89 ref.)

PARASITOLOGY

Parasitic disease in amphibians: control by the regulation of worm burdens. Tinsley RC. **Parasitology** 1995;111 Suppl:S153–78 (62 ref.)

PHYSIOLOGY

Apoptosis of larval cells during amphibian metamorphosis. Ishizuya-Oka A. **Microsc Res Tech** 1996 Jun 15; 34(3):228–35 (73 ref.)

XENOTRANSPLANTATION see **TRANSPLANTATION, HETEROLOGOUS**

XERODERMA see **ICHTHYOSIS**

XERODERMA PIGMENTOSUM

[Xeroderma pigmentosum] Ueda M, et al. **Nippon Rinsho** 1995 Nov;53(11):2815–20 (16 ref.) (Eng. Abstr.) **(Jpn)**

GENETICS

Xeroderma pigmentosum and molecular cloning of DNA repair genes. Boulikas T. **Anticancer Res** 1996 Mar–Apr; 16(2):693–708 (161 ref.)

XEROPHTHALMIA

DIAGNOSIS

Treatment of dry eye by blocking the lacrimal canaliculi. Murube J, et al. **Surv Ophthalmol** 1996 May–Jun; 40(6):463–80 (109 ref.)

SURGERY

Treatment of dry eye by blocking the lacrimal canaliculi. Murube J, et al. **Surv Ophthalmol** 1996 May–Jun; 40(6):463–80 (109 ref.)

XEROSTOMIA

The symptom experience of mucositis, stomatitis, and xerostomia. Dose AM. **Semin Oncol Nurs** 1995 Nov; 11(4):248–55 (59 ref.)

CHEMICALLY INDUCED

[Decreased saliva secretion. A pharmacologic effect with sequelae for oral health] Foth H. **Med Monatsschr Pharm** 1995 Dec;18(12):350–7 (8 ref.) **(Ger)**

DIAGNOSIS

Xerostomia: diagnosis and management. Greenspan D. **Oncology (Huntingt)** 1996 Mar;10(3 Suppl):7–11 (25 ref.)

NURSING

A nursing perspective on radiation–induced xerostomia. Iwamoto RR. **Oncology (Huntingt)** 1996 Mar;10(3 Suppl):12–5 (42 ref.)

THERAPY

Xerostomia: diagnosis and management. Greenspan D. **Oncology (Huntingt)** 1996 Mar;10(3 Suppl):7–11 (25 ref.)

XIPHOPHORUS see **CYPRINODONTIFORMES**

XIPHOSURA see **HORSESHOE CRABS**

XYLENES

METABOLISM

Physiological attributes of microbial BTEX degradation in oxygen–limited environments. Olsen RH, et al. **Environ Health Perspect** 1995 Jun;103 Suppl 5:49–51 (7 ref.)

XYLITOL

BLOOD

[Xylitol] Kizaki Z, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:557–60 (13 ref.) **(Jpn)**

XYLOBIASES see **XYLOSIDASES**

XYLOSIDASES

CHEMISTRY

Biochemistry and genetics of microbial xylanases. Jeffries TW. **Curr Opin Biotechnol** 1996 Jun;7(3):337–42 (51 ref.)

GENETICS

Biochemistry and genetics of microbial xylanases. Jeffries TW. **Curr Opin Biotechnol** 1996 Jun;7(3):337–42 (51 ref.)

METABOLISM

Cellulose hydrolysis by bacteria and fungi. Tomme P, et al. **Adv Microb Physiol** 1995;37:1–81 (367 ref.)

Evidence for lysozyme–type mechanism of hydrolysis in xylanases. Dupont C, et al. **EXS** 1996;75:411–23 (32 ref.)

Y CHROMOSOME

Sex determination and its pathology in man. Schafer AJ. **Adv Genet** 1995;33:275–329 (288 ref.)

Translocation (Y;1)(q12;q12) in hematologic malignancies. Report on two new cases, FISH characterization, and review of the literature. Michaux L, et al. **Cancer Genet Cytogenet** 1996 Jan;86(1):35–8 (13 ref.)

Human evolution. Y–chromosome clues to human ancestry. Brookfield JF. **Curr Biol** 1995 Oct 1;5(10):1114–5 (9 ref.)

Sex chromosome tetrasomy and pentasomy. Linden MG, et al. **Pediatrics** 1995 Oct;96(4 Pt 1):672–82 (58 ref.)

Chromosome manipulation: a systematic approach toward understanding human chromosome structure and function [comment] Willard HF. **Proc Natl Acad Sci U S A** 1996 Jul 9;93(14):6847–50 (28 ref.) Comment on: Proc Natl Acad Sci U S A 1996 Jul 9;93(14):7125–30.

Sex preselection by flow cytometric separation of X and Y chromosome–bearing sperm based on DNA difference: a review. Johnson LA. **Reprod Fertil Dev** 1995;7(4):893–903 (47 ref.)

The azoospermia factor (AZF) of the human Y chromosome in Yq11: function and analysis in spermatogenesis. Vogt PH, et al. **Reprod Fertil Dev** 1995;7(4):685–93 (56 ref.)

Fathers and sons: the Y chromosome and human evolution. Jobling MA, et al. **Trends Genet** 1995 Nov;11(11):449–56 (33 ref.)

[Genetics of sexual development and its disorders] Osipova GR. **Genetika** 1996 Feb;32(2):184–91 (84 ref.) (Eng. Abstr.) **(Rus)**

GENETICS

Clinical features of nine males with molecularly defined deletions of the Y chromosome long arm. Salo P, et al. **J Med Genet** 1995 Sep;32(9):711–5 (37 ref.)

Sex chromosome aneuploidy and aging. Stone JF, et al. **Mutat Res** 1995 Oct;338(1–6):107–13 (51 ref.)

IMMUNOLOGY

The Yaa gene model of systemic lupus erythematosus. Izui S, et al. **Immunol Rev** 1995 Apr;144:137–56 (62 ref.)

YAC see **CHROMOSOMES, YEAST ARTIFICIAL**

YAWNING

DRUG EFFECTS

Yawning behavior for preclinical drug evaluation. Furukawa T. **Methods Find Exp Clin Pharmacol** 1996 Mar; 18(2):141–55 (81 ref.)

YEAST ARTIFICIAL CHROMOSOMES see **CHROMOSOMES, YEAST ARTIFICIAL**

YEAST, BAKER'S see **SACCHAROMYCES CEREVISIAE**

YEAST, BREWER'S see **SACCHAROMYCES CEREVISIAE**

YEAST, FISSION see **SCHIZOSACCHAROMYCES**

YEASTS

Cutaneous defenses against dermatophytes and yeasts. Wagner DK, et al. **Clin Microbiol Rev** 1995 Jul;8(3):317–35 (284 ref.)

CHEMISTRY

Cell wall polysaccharides of pathogenic yeasts. Fukazawa Y, et al. **Curr Top Med Mycol** 1995;6:189–219 (166 ref.)

CLASSIFICATION

Epidemiology of fungal infections: the promise of molecular typing. Pfaller MA. **Clin Infect Dis** 1995 Jun;20(6):1535–9 (61 ref.)

CYTOLOGY

Budding yeast morphogenesis: signalling, cytoskeleton and cell cycle. Kron SJ, et al. **Curr Opin Cell Biol** 1995 Dec; 7(6):845–55 (84 ref.)

DRUG EFFECTS

[Rational use of antimycotics against yeast infections] Hof H, et al. **Immun Infekt** 1995 Dec;23(6):209–15 (29 ref.) (Eng. Abstr.) **(Ger)**

ENZYMOLOGY

Review: biosynthesis and function of yeast vacuolar proteases. Van Den Hazel HB, et al. **Yeast** 1996 Jan; 12(1):1–16 (110 ref.)

GENETICS

Replication origins in eukaryotes. Donovan S, et al. **Curr Opin Genet Dev** 1996 Apr;6(2):203–7 (45 ref.)

Linear DNA plasmids of yeasts. Fukuhara H. **FEMS Microbiol Lett** 1995 Aug 15;131(1):1–9 (32 ref.)

Interplay between nucleosomes and transcription factors at the yeast PHO5 promoter. Svaren J, et al. **Semin Cell Biol** 1995 Aug;6(4):177–83 (52 ref.)

Genetically engineered yeast cells and their applications. Pompon D, et al. **Toxicol Lett** 1995 Dec;82–83:815–22 (14 ref.)

ISOLATION & PURIFICATION

New and emerging yeast pathogens. Hazen KC. **Clin Microbiol Rev** 1995 Oct;8(4):462–78 (168 ref.)

METABOLISM

Mitogen and stress response pathways: MAP kinase cascades and phosphatase regulation in mammals and yeast. Waskiewicz AJ, et al. **Curr Opin Cell Biol** 1995 Dec; 7(6):798–805 (79 ref.)

Yeast motor proteins. Streiblová E, et al. **Folia Microbiol (Praha)** 1995;40(6):571–82 (59 ref.)

Review: methylotrophic yeasts as factories for the production of foreign proteins. Faber KN, et al. **Yeast** 1995 Nov; 11(14):1331–44 (111 ref.)

PATHOGENICITY

Cell wall polysaccharides of pathogenic yeasts. Fukazawa Y, et al. **Curr Top Med Mycol** 1995;6:189–219 (166 ref.)

PHYSIOLOGY

Vacuolar biogenesis in yeast: sorting out the sorting proteins. Conibear E, et al. **Cell** 1995 Nov 17;83(4):513–6 (17 ref.)

Generation of cell polarity in yeast. Chant J. **Curr Opin Cell Biol** 1996 Aug;8(4):557–65 (56 ref.)

YELLOW FEVER

[Yellow fever, measles, rubella] Yoshikawa Y. **Ryoikibetsu Shokogun Shirizu** 1995;(7):33–5 (9 ref.) **(Jpn)**

EPIDEMIOLOGY

Yellow fever: an emerging threat for Kenya and other east African countries. Sanders EJ, et al. **East Afr Med J** 1996 Jan;73(1):10–2 (21 ref.)

What is the potential for future outbreaks of chikungunya, dengue and yellow fever in southern Africa? [editorial] Jupp PG, et al. **S Afr Med J** 1996 Jan;86(1):35–7 (20 ref.)

PREVENTION & CONTROL

Yellow fever: an emerging threat for Kenya and other east African countries. Sanders EJ, et al. **East Afr Med J** 1996 Jan;73(1):10–2 (21 ref.)

YELLOW JACKETS see **WASPS**

YELLOW MARROW see **BONE MARROW**

YERSINIA

GENETICS

Environmental modulation of gene expression and pathogenesis in Yersinia. Straley SC, et al. **Trends Microbiol** 1995 Aug;3(8):310–7 (56 ref.)

[Comparative genetics of representatives of the genus Yersinia and evolution of their pathogenicity] Anisimov PI, et al. **Genetika** 1996 Mar;32(3):325–30 (36 ref.) (Eng. Abstr.) **(Rus)**

[Molecular genetic aspects of invasive and antiphagocytic properties of pathogenic Yersinia] Kukleva LM, et al. **Mol Gen Mikrobiol Virusol** 1996 Jan–Mar;(1):11–6 (95 ref.) **(Rus)**

PATHOGENICITY

Triggering bacterial virulence [comment] Cotter PA, et al. **Science** 1996 Aug 30;273(5279):1183–4 (15 ref.) Comment on: Science 1996 Aug 30;273(5279):1231–3. Comment on: Science 1996 Aug 30;273(5279):1234–6.

Environmental modulation of gene expression and pathogenesis in Yersinia. Straley SC, et al. **Trends Microbiol** 1995 Aug;3(8):310–7 (56 ref.)

YERSINIA ENTEROCOLITICA

Transfusion reaction due to Yersinia enterocolitica and review of other reported cases. Beresford AM. **Pathology** 1995 Apr;27(2):133–5 (19 ref.)

[Yersinia enterocolitica: a cause of acute intestinal intussusception] Barthod F, et al. **Presse Med** 1996 Apr 20;25(14):668–70 (13 ref.) (Eng. Abstr.) **(Fre)**

[Sweet syndrome and Yersinia enterocolitica infection. 2 cases] Neau D, et al. **Rev Med Interne** 1995;16(12):919–22 (13 ref.) (Eng. Abstr.) **(Fre)**

ISOLATION & PURIFICATION

Multiple hepatic abscesses due to Yersinia enterocolitica. Strungs I, et al. **Pathology** 1995 Oct;27(4):374–7 (14 ref.)

YERSINIA INFECTIONS

see related
ARTHRITIS, REACTIVE

COMPLICATIONS

[Yersinia enterocolitica: a cause of acute intestinal intussusception] Barthod F, et al. **Presse Med** 1996 Apr 20;25(14):668–70 (13 ref.) (Eng. Abstr.) **(Fre)**

[Sweet syndrome and Yersinia enterocolitica infection. 2 cases] Neau D, et al. **Rev Med Interne** 1995;16(12):919–22 (13 ref.) (Eng. Abstr.) **(Fre)**

EPIDEMIOLOGY

[Yersinia infections] Hoogkamp–Korstanje JA. **Ned Tijdschr Geneeskd** 1996 Jan 20;140(3):128–30 (18 ref.) (Eng. Abstr.) **(Dut)**

YERSINIA INFECTIONS

TRANSMISSION

Transfusion reaction due to Yersinia enterocolitica and review of other reported cases. Beresford AM. **Pathology** 1995 Apr;27(2):133–5 (19 ref.)

YERSINIA PESTIS

IMMUNOLOGY

Relationship between virulence and immunity as revealed in recent studies of the F1 capsule of Yersinia pestis. Friedlander AM, et al. **Clin Infect Dis** 1995 Oct;21 Suppl 2:S178–81 (28 ref.)

ISOLATION & PURIFICATION

[Shibasaburo Kitasato's discovery of plague bacillus and its historical background—on the occasion of the centennial anniversary] Nakase Y. **Nippon Saikingaku Zasshi** 1995 Jul; 50(3):637–50 (53 ref.) **(Jpn)**

METABOLISM

[The biochemical aspects of the pathogenicity of the causative agent of plague] Naumov AV, et al. **Med Parazitol (Mosk)** 1995 Oct–Dec;(4):17–22 (54 ref.) **(Rus)**

PATHOGENICITY

Relationship between virulence and immunity as revealed in recent studies of the F1 capsule of Yersinia pestis. Friedlander AM, et al. **Clin Infect Dis** 1995 Oct;21 Suppl 2:S178–81 (28 ref.)

[Pathogenicity of Yersinia pestis: microbiological and molecular aspect] Wake A. **Nippon Saikingaku Zasshi** 1995 Jul;50(3):651–69 (41 ref.) **(Jpn)**

[The biochemical aspects of the pathogenicity of the causative agent of plague] Naumov AV, et al. **Med Parazitol (Mosk)** 1995 Oct–Dec;(4):17–22 (54 ref.) **(Rus)**

YERSINIA PSEUDOTUBERCULOSIS

IMMUNOLOGY

[Hypersensitivity pneumonitis caused by a home humidifier] Hagiwara S, et al. **Nippon Kyobu Shikkan Gakkai Zasshi** 1995 Sep; 33(9):1024–9 (10 ref.) (Eng. Abstr.) **(Jpn)**

YERSINIA PSEUDOTUBERCULOSIS INFECTIONS

ETIOLOGY

Report of four cases of Yersinia pseudotuberculosis septicemia and a literature review. Ljungberg P, et al. **Eur J Clin Microbiol Infect Dis** 1995 Sep;14(9):804–10 (31 ref.)

YOHIMBINE

ANALOGS & DERIVATIVES

Pathophysiology of postischemic hypoxia and cerebral protection: implications of the almitrine and raubasine combination. Chan P. **Eur Neurol** 1995;35 Suppl 1:23–7 (41 ref.)

Quantitative electroencephalography in aging brain and cerebrovascular disease: the effects of almitrine–raubasine. Sebban C. **Eur Neurol** 1995;35 Suppl 1:37–42 (16 ref.)

THERAPEUTIC USE

Pathophysiology of postischemic hypoxia and cerebral protection: implications of the almitrine and raubasine combination. Chan P. **Eur Neurol** 1995;35 Suppl 1:23–7 (41 ref.)

YOLK PROTEINS see EGG PROTEINS

YOLK SAC

CYTOLOGY

Role of yolk sac endodermal cells with special reference to the fetal macrophage differentiation. Yamashita A. **J Leukoc Biol** 1996 Feb;59(2):139–44 (26 ref.)

PHYSIOLOGY

The temporary anatomical structures prominent in the first trimester may be fulfilling exchange functions assigned to the placenta in the second and third trimester. Docherty SM, et al. **Hum Reprod** 1996 Jun;11(6):1157–61 (38 ref.)

YOLK SAC TUMOR see ENDODERMAL SINUS TUMOR

YOUTH see ADOLESCENCE

YTTRIUM RADIOISOTOPES

THERAPEUTIC USE

Review of five consecutive studies of radiolabeled immunoglobulin therapy in Hodgkin's disease. Vriesendorp HM, et al. **Cancer Res** 1995 Dec 1;55(23 Suppl):5888s–5892s (15 ref.)

Z-DNA see DNA

ZALCITABINE

THERAPEUTIC USE

ddC (zalcitabine). Skowron G. **Adv Exp Med Biol** 1996; 394:257–69 (49 ref.)

Studies of zidovudine in combination with didanosine and zalcitabine. Jablonowski H. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995;10 Suppl 1:S52–6 (17 ref.)

ZEA see CORN

ZEBRAFISH

The zebrafish: heritable disorders in transparent embryos. Driever W, et al. **J Clin Invest** 1996 Apr 15;97(8):1788–94 (67 ref.)

ANATOMY & HISTOLOGY

[Results and conclusions from 328 radical operations of rectal carcinoma by one surgeon. Comparative anatomic studies with Brachydanio rerio and Latimeria chalumnae] Stelzner F. **Chirurg** 1995 Dec;66(12):1230–8 (22 ref.) (Eng. Abstr.) **(Ger)**

EMBRYOLOGY

Transparent things: cell fates and cell movements during early embryogenesis of zebrafish. Solnica-Krezel L, et al. **Bioessays** 1995 Nov;17(11):931–9 (59 ref.)

Cardiovascular morphogenesis in zebrafish. Weinstein BM, et al. **Cardiovasc Res** 1996 Feb;31 Spec No:E17–24 (39 ref.)

Axis formation in zebrafish. Driever W. **Curr Opin Genet Dev** 1995 Oct;5(5):610–8 (81 ref.)

Lateral specification of cell fate during vertebrate development. Raible DW, et al. **Curr Opin Genet Dev** 1995 Aug;5(4):444–9 (54 ref.)

Fate maps of the zebrafish embryo. Woo K, et al. **Curr Opin Genet Dev** 1995 Aug;5(4):439–43 (26 ref.)

PHYSIOLOGY

Introducing genes into zebrafish. Gaiano N, et al. **Biochim Biophys Acta** 1996 Aug 8;1288(1):O11–4 (43 ref.)

ZELLWEGER SYNDROME

[Zellweger syndrome] Suzuki Y. **Ryoikibetsu Shokogun Shirizu** 1995;(7):544–6 (10 ref.) **(Jpn)**

GENETICS

Zellweger syndrome: first reported case in Thailand and literature review. Jaruratanasirikul S, et al. **Southeast Asian J Trop Med Public Health** 1995;26 Suppl 1:47–51 (12 ref.)

ZENKER'S DIVERTICULUM

Zenker's diverticulum: reappraisal. Watemberg S, et al. **Am J Gastroenterol** 1996 Aug;91(8):1494–8 (75 ref.)

ZHONG YI XUE see MEDICINE, CHINESE TRADITIONAL

ZIDOVUDINE

ADVERSE EFFECTS

Recombinant erythropoietin for zidovudine-induced anemia in AIDS. Kuehl AK, et al. **Ann Pharmacother** 1995 Jul–Aug;29(7–8):778–9 (15 ref.)

METABOLISM

Metabolism of Zidovudine. Veal GJ, et al. **Gen Pharmacol** 1995 Nov;26(7):1469–75 (54 ref.)

THERAPEUTIC USE

Zidovudine: anno 1995. Danner SA. **Adv Exp Med Biol** 1996; 394:225–43 (114 ref.)

Prophylaxis for occupational exposure to HIV. Gerberding JL. **Ann Intern Med** 1996 Sep 15;125(6):497–501 (31 ref.)

Zidovudine therapy in HIV infection: which patients should be treated and when. Barry MG, et al. **Br J Clin Pharmacol** 1995 Aug;40(2):107–10 (39 ref.)

The role of antiretroviral therapy in the management of HIV infection in women. Mofenson LM. **Clin Obstet Gynecol** 1996 Jun;39(2):361–85 (113 ref.)

Guidelines for the use of zidovudine in pregnant women with HIV infection. De Santis M, et al. **Drugs** 1995 Jul;50(1):43–7 (34 ref.)

Ups and downs—and ups in the antiviral therapy of HIV infection. Weller IV, et al. **Genitourin Med** 1996 Feb; 72(1):2–5 (24 ref.)

Studies of zidovudine in combination with didanosine and zalcitabine. Jablonowski H. **J Acquir Immune Defic Syndr Hum Retrovirol** 1995;10 Suppl 1:S52–6 (17 ref.)

ZINC

Zinc complexes as targeting agents for nucleic acids. Kimura E, et al. **Met Ions Biol Syst** 1996;33:29–52 (30 ref.)

[Zinc—update of an essential trace element] Rimbach G, et al. **Z Ernahrungswiss** 1996 Jun;35(2):123–42 (211 ref.) (Eng. Abstr.) **(Ger)**

ADMINISTRATION & DOSAGE

Zinc and human health. Aggett PJ, et al. **Nutr Rev** 1995 Sep;53(9 Pt 2):S16–22 (39 ref.)

ANALYSIS

Zinc status of Indian children. Bhaskaram P, et al. **Indian J Med Res** 1995 Nov;102:210–5 (13 ref.)

[Zinc] Wada O, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:819–22 (4 ref.) **(Jpn)**

CHEMISTRY

Structural features of a superfamily of zinc-endopeptidases: the metzincins. Stöcker W, et al. **Curr Opin Struct Biol** 1995 Jun;5(3):383–90 (47 ref.)

DEFICIENCY

Clinical and laboratory assessment of zinc deficiency in Dutch children. A review. Van Wouwe JP. **Biol Trace Elem Res** 1995 Aug–Sep;49(2–3):211–25 (68 ref.)

Zinc deficiency [editorial] Bhaskaram P. **Indian Pediatr** 1995 Nov;32(11):1153–6 (15 ref.)

The treatment of zinc deficiency is an immunotherapy [editorial] Hadden JW. **Int J Immunopharmacol** 1995 Sep; 17(9):697–701 (37 ref.)

Zinc deficiency in women, infants and children. Prasad AS. **J Am Coll Nutr** 1996 Apr;15(2):113–20 (65 ref.)

Zinc and the elderly. Ripa S, et al. **Minerva Med** 1995 Jun; 86(6):275–8 (58 ref.)

[Zinc deficiency in children] Naveh Y. **Harefuah** 1995 Jun 1;128(11):728–32 (66 ref.) **(Heb)**

[Zinc and diabetes mellitus] Ripa S, et al. **Minerva Med** 1995 Oct;86(10):415–21 (101 ref.) (Eng. Abstr.) **(Ita)**

[Zinc-deficient disorders of sense organs—dark adaptation, taste and smell disorders] Tomita H. **Nippon Rinsho** 1996 Jan;54(1):141–7 (40 ref.) (Eng. Abstr.) **(Jpn)**

DIAGNOSTIC USE

[Methods and clinical significance of an oral tolerance test of essential trace element, especially an oral zinc tolerance test] Arakawa Y, et al. **Nippon Rinsho** 1996 Jan; 54(1):162–71 (35 ref.) (Eng. Abstr.) **(Jpn)**

IMMUNOLOGY

The treatment of zinc deficiency is an immunotherapy [editorial] Hadden JW. **Int J Immunopharmacol** 1995 Sep; 17(9):697–701 (37 ref.)

METABOLISM

Copper/zinc superoxide dismutase mutations and free radical damage in amyotrophic lateral sclerosis. Hosler BA, et al. **Adv Neurol** 1995;68:41–6 (24 ref.)

Zinc metallochemistry in biochemistry. Vallee BL, et al. **EXS** 1995;73:259–77 (66 ref.)

Metal-responsive gene regulation and the zinc metalloregulatory model. Suhy DA, et al. **Met Ions Biol Syst** 1996;32:557–78 (49 ref.)

Copper and zinc metabolism in health and disease: speciation and interactions. Bremner I, et al. **Proc Nutr Soc** 1995 Jul; 54(2):489–99 (60 ref.)

Iron–zinc and calcium–Fe interactions in relation to Zn and Fe absorption. Fairweather-Tait SJ. **Proc Nutr Soc** 1995 Jul;54(2):465–73 (41 ref.)

PHARMACOLOGY

Endocrine interaction between zinc and prolactin. An interpretative review. Brandão-Neto J, et al. **Biol Trace Elem Res** 1995 Aug–Sep;49(2–3):139–49 (57 ref.)

beta-Alanyl-L-histidinato zinc and bone resorption. Yamaguchi M. **Gen Pharmacol** 1995 Oct;26(6):1179–83 (27 ref.)

PHYSIOLOGY

Zinc, human diseases and aging. Fabris N, et al. **Aging (Milano)** 1995 Apr;7(2):77–93 (172 ref.)

Behaviour of zinc in physical exercise: a special reference to immunity and fatigue. Cordova A, et al. **Neurosci Biobehav Rev** 1995 Fall;19(3):439–45 (101 ref.)

[Zinc and the growth hormone system] Ripa S, et al. **Minerva Med** 1996 Jan–Feb;87(1–2):25–31 (86 ref.) (Eng. Abstr.) **(Ita)**

STANDARDS

Micronutrients (magnesium, zinc, and copper): are mineral supplements needed for athletes? Lukaski HC. **Int J Sport Nutr** 1995 Jun;5 Suppl:S74–83 (37 ref.)

ZINC COMPOUNDS

[Zinc sulfate turbidity test (ZTT)] Monna T, et al. **Nippon Rinsho** 1995 Feb;53 Su Pt 1:167–70 (7 ref.) **(Jpn)**

PHARMACOLOGY

beta-Alanyl-L-histidinato zinc and bone resorption. Yamaguchi M. **Gen Pharmacol** 1995 Oct;26(6):1179–83 (27 ref.)

ZINC FINGERS

Oestrogen-responsive finger protein suggests a transcriptional cascade of steroid hormone regulation. **Ciba Found Symp** 1995;191:43–51 (18 ref.)

Designing DNA-binding proteins on the surface of filamentous phage. Choo Y, et al. **Curr Opin Biotechnol** 1995 Aug;6(4):431–6 (23 ref.)

Hematopoietic transcriptional regulation by the myeloid zinc finger gene, MZF-1. Hromas R, et al. **Curr Top Microbiol Immunol** 1996;211:159–64 (15 ref.)

Molecular analysis of Evi1, a zinc finger oncogene involved in myeloid leukemia. Lopingco MC, et al. **Curr Top Microbiol Immunol** 1996;211:211–22 (63 ref.)

NMR structural studies on the zinc finger domains of nuclear hormone receptors. Knegtel RM, et al. **EXS** 1995;73:279–95 (30 ref.)

Metal replacement in DNA-binding zinc finger proteins and its relevance to mutagenicity and carcinogenicity through free radical generation. Sarkar B. **Nutrition** 1995 Sep–Oct; 11(5 Suppl):646–9 (17 ref.)

The enigma of LIM domains. Gill GN. **Structure** 1995 Dec 15;3(12):1285–9 (31 ref.)

ZZ and TAZ: new putative zinc fingers in dystrophin and other proteins. Ponting CP, et al. **Trends Biochem Sci** 1996 Jan;21(1):11–13 (20 ref.)

[Conversion of zinc finger protein to artificial site-specific nuclease: application to chromosome mapping and sequencing] Nagaoka M, et al. **Nippon Rinsho** 1995 Oct; 53(10):2589–96 (10 ref.) (Eng. Abstr.) **(Jpn)**

[Negative repressor THZif-1 of protooncogene c-myc] Yokoyama K, et al. **Nippon Rinsho** 1995 Nov; 53(11):2827–36 (13 ref.) (Eng. Abstr.) **(Jpn)**

[Design of a novel Zn finger-based DNA cutter] Kuwahara J, et al. **Tanpakushitsu Kakusan Koso** 1994 Jul; 40(10):1457–64 (21 ref.) **(Jpn)**

ZINOSTATIN

TOXICITY

DNA damage and mutagenesis by radiomimetic DNA-cleaving agents: bleomycin, neocarzinostatin and other enediynes. Povirk LF. **Mutat Res** 1996 Aug 17; 355(1-2):71–89 (125 ref.)

ZOLLINGER-ELLISON SYNDROME

see related
MULTIPLE ENDOCRINE NEOPLASIA TYPE 1

DIAGNOSIS

Zollinger-Ellison syndrome: diagnosis and management. Fass R, et al. **Hosp Pract (Off Ed)** 1995 Nov 15;30(11):73–6, 79–80 (13 ref.)

SURGERY

Should the 1996 citation for Zollinger-Ellison syndrome read: "Acid-reducing surgery in, aggressive resection out"? [editorial; comment] Jensen RT. **Am J Gastroenterol** 1996 Jun;91(6):1067–70 (43 ref.) Comment on: Am J Gastroenterol 1996 Jun;91(6):1104–11.

The place for curative surgical procedures in the treatment of sporadic and familial Zollinger-Ellison syndrome. Delcore R, et al. **Curr Opin Gen Surg** 1994;:69–76 (119 ref.)

Recent advances in the localization and surgical management of duodenal gastrinomas. Lawton GP, et al. **Curr Opin Gen Surg** 1994;:131–7 (50 ref.)

[Progress in pancreatic endocrine tumor surgery: with special reference to the Zollinger-Ellison syndrome] Imamura M. **Nippon Shokakibyo Gakkai Zasshi** 1995 Dec;92(12):1905–10 (10 ref.) **(Jpn)**

THERAPY

Zollinger-Ellison syndrome: diagnosis and management. Fass R, et al. **Hosp Pract (Off Ed)** 1995 Nov 15;30(11):73–6, 79–80 (13 ref.)

Zollinger-Ellison syndrome: past, present and future controversies. Jensen RT. **Yale J Biol Med** 1994 May-Aug; 67(3-4):195–214 (108 ref.)

ZONA see HERPES ZOSTER

ZONA GLOMERULOSA

PHYSIOLOGY

Diacylglycerol production, Ca2+ influx, and protein kinase C activation in sustained cellular responses. Rasmussen H, et al. **Endocr Rev** 1995 Oct;16(5):649–81 (268 ref.)

ZONA PELLUCIDA

IMMUNOLOGY

Targeting the zona pellucida for immunocontraception: a minireview. Tesarik J. **Hum Reprod** 1995 Dec;10 Suppl 2:132–9 (35 ref.)

PHYSIOLOGY

The equine embryonic capsule: practical implications of recent research. Oriol JG. **Equine Vet J** 1994 May; 26(3):184–6 (34 ref.)

New concepts in human sperm-zona pellucida interaction. Clark GF, et al. **Hum Reprod** 1995 Oct;10 Suppl 1:31–7 (36 ref.)

ZONE THERAPY see MASSAGE

ZOOLOGY

see related
ANIMALS

ZOONOSES

see related
DISEASE RESERVOIRS

Patterns and predictability in emerging infections. Morse SS. **Hosp Pract (Off Ed)** 1996 Apr 15;31(4):85–91, 96–101, 104 passim (11 ref.)

Population medicine and infectious diseases. Hoskins JD. **J Am Vet Med Assoc** 1996 Feb 15;208(4):510–2 (7 ref.)

Emerging bacterial zoonotic and vector-borne diseases. Ecological and epidemiological factors. Walker DH, et al. **JAMA** 1996 Feb 14;275(6):463–9 (92 ref.)

Introduction: ecological impact of parasitism on wildlife host populations. Grenfell BT, et al. **Parasitology** 1995;111 Suppl:S3–14 (185 ref.)

The zoonotic importance of Mycobacterium bovis. Moda G, et al. **Tuber Lung Dis** 1996 Apr;77(2):103–8 (33 ref.)

Feline dermatophytosis. Recent advances and recommendations for therapy. Moriello KA, et al. **Vet Clin North Am Small Anim Pract** 1995 Jul;25(4):901–21 (49 ref.)

[Domestic animals and pets as sources of infection] Vuento R. **Duodecim** 1994;110(6):555–66 (34 ref.) **(Fin)**

EPIDEMIOLOGY

Zoonotic diseases in Canada: an interdisciplinary challenge. Hamilton J. **Can Med Assoc J** 1996 Aug 15;155(4):413–8 (17 ref.)

[Zoo-anthroponoses involving rodents: epidemiologic considerations] Rodhain F. **Bull Soc Pathol Exot** 1996; 89(1):5–11 (14 ref.) (Eng. Abstr.) **(Fre)**

ETIOLOGY

Rare, new and emerging helminth zoonoses. Smyth JD. **Adv Parasitol** 1995;36:1–45 (180 ref.)

TRANSMISSION

Interspecies transmission of influenza viruses. Webster RG, et al. **Am J Respir Crit Care Med** 1995 Oct;152(4 Pt 2):S25–30 (27 ref.)

ZOOPHAGINAE see VIRUSES

ZOSTER see HERPES ZOSTER

ZUCLOMIFENE see CLOMIPHENE

ZYGOMATIC FRACTURES

[Zygomatic-orbito-malar fractures. Apropos of 85 cases] Ait Benhamou C, et al. **Rev Laryngol Otol Rhinol (Bord)** 1996; 117(1):15–7 (18 ref.) (Eng. Abstr.) **(Fre)**

ZYGOMYCOSIS see MUCORMYCOSIS

ZYGOMYCOTINA

ISOLATION & PURIFICATION

Mixed intranasal infection caused by Fusarium solani and a zygomycete in a leukaemic patient. Lopes JO, et al. **Mycoses** 1995 Jul-Aug;38(7-8):281–4 (26 ref.)

ZYGOTE

DRUG EFFECTS

Important biological variables that can influence the degree of chemical-induced aneuploidy in mammalian oocyte and zygotes. Mailhes JB. **Mutat Res** 1995 Oct;339(3):155–76 (144 ref.)

PHYSIOLOGY

Oviduct during early pregnancy: hormonal regulation and interactions with the fertilized ovum. Murray MK, et al. **Microsc Res Tech** 1995 Aug 15;31(6):497–506 (49 ref.)

Role of chromatin structure in zygotic gene activation in the mammalian embryo. Schultz RM, et al. **Semin Cell Biol** 1995 Aug;6(4):201–8 (52 ref.)

ZYMOGENS see ENZYME PRECURSORS

ISBN 0-16-048940-7

90000

9 780160 489402